id|nct_id|intervention_type|name|description
45443979|NCT01199211|Other|Exercise training, women, marathon|Prospective study with no intervention in women who have volunteered to run a full marathon or a half-marathon. Each subject will serve as own control. Each subject will be studies at 3 stages: baseline, after at least 12 weeks of training for the marathon (we will not provide training), 6 weeks after running the marathon.
45443980|NCT05667987|Drug|Intravenous lidocaine administration|General anesthesia with intravenous lidocaine administration
45443981|NCT03844737|Device|VisuXL®|Treatment of discomfort forms of the ocular surface, in professional water-polo athletes exposed to pool water for prolonged periods.
45443982|NCT01201239|Drug|raltegravir|RAL 400 mg twice daily plus OBT (optimized background therapy) for 48 weeks
45443983|NCT01199367|Drug|KW-2450 in combination with lapatinib and letrozole|Three subjects will be assigned to each of 4 sequential cohorts. Dose escalation may proceed once at least 3 subjects have completed 30 days of study treatment. Subjects who withdraw prior to completing Day 30 for reasons other than DLT will be replaced. If a DLT is observed, additional subjects may be enrolled so that up to 6 subjects are enrolled at that dose level.
45443984|NCT03840213|Behavioral|Filling a questionnaire and interviewDescription|"The questionnaire focuses on the dietary practices of patients treated with chemotherapy. It consists of 35 questions, completing an average of 20 minutes.~Interviews will be conducted with patients who have changed their diet since the beginning of their treatment in order to further develop the results of the quantitative survey."
45443985|NCT01203735|Drug|Valproic acid|800mg per day for entire period of RT
45443986|NCT04029753|Behavioral|Walk out from operating room|After the surgery of laparoscopic radical gastrectomy, patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb.
45443987|NCT03966417|Other|Exercise training|Continuous exercise training 2 times per week for a period of 12 weeks.
45443988|NCT01203813|Other|Electronic Decision Support|"Physicians randomized to the intervention will receive:~Electronic alerts during office visits for patients with chronic kidney disease~Opportunity to enroll their patients with chronic kidney disease in a self management support outreach program"
45443989|NCT01203969|Procedure|Single port laparoscopic surgery|laparoscopic surgery in which all the instrument was entered into the abdominal cavity through the single port in the umbilicus
45443990|NCT01203969|Procedure|Conventional laparoscopic surgery|laparoscopic surgery in which each of the instrument were entered into the abdominal cavity through the multiple port in multiple quadrants of abdomen
45443991|NCT03842631|Drug|Timolol Maleate 0.5% Oph Soln|External use of 0.5% Timolol Maleate Drops for all patients in different depths of IH lesion.
45443992|NCT03841227|Device|Active-tDCS|Active home-based tDCS applied at home. 5 days a week for 4 weeks.
45443993|NCT03841227|Device|Sham-tDCS|Sham home-based tDCS applied at home. 5 days a week for 4 weeks.
45443994|NCT03300050|Biological|cH8/1N1 LAIV|"Live-attenuated influenza virus vaccine (LAIV) expressing chimeric hemagglutinin (HA) with the H8 head and H1 stalk and neuraminidase (NA) subtype 1 (N1) (cH8/1N1):~HA head, A/mallard/Sweden/24/2002 (H8N4); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1) containing the backbone of the cold-adapted/temperature sensitive of the Russian LAIV A/Leningrad/134/17/1957 (Len17 IDCDCRG46D).~Administered intranasally as drops at a dose of 10⁷·⁵ (plus or minus ⁰·⁵) 50% egg infectious dose (EID50), formulated in a total volume of 0.5 mL sterile saline (0.25 mL per nostril)."
45443995|NCT03300050|Biological|AS03-adjuvanted cH5/1N1 IIV|"Chimeric H5 head with H1 stalk plus N1 (cH5/1N1) split virion inactivated influenza virus vaccine (IIV) plus AS03 adjuvant: HA head, A/Vietnam/1203/2004 (H5N1); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1).~Administered intramuscularly at a dose of 15 μg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS)."
45443996|NCT03300050|Biological|cH5/1N1 IIV|"Chimeric H5 head with H1 stalk plus N1 (cH5/1N1) split virion inactivated influenza virus vaccine (IIV):~HA head, A/Vietnam/1203/2004 (H5N1); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1).~Administered intramuscularly at a dose of 15 μg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS)."
45443997|NCT03300050|Biological|AS03-adjuvanted cH8/1N1 IIV|"Chimeric H8 head with H1 stalk plus N1 (cH8/1N1) inactivated influenza vaccine plus AS03 adjuvant: HA head, A/mallard/Sweden/24/2002 (H8N4); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1).~Administered intramuscularly at a dose of 15 μg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS)."
45443998|NCT03300050|Biological|Normal saline|Administered intranasally as 0.25 mL nasal drops per nostril
45443999|NCT03300050|Biological|Phosphate buffered saline (PBS)|Administered intramuscularly as 0.5 mL injection
45444000|NCT03842787|Other|Biological analysis|"Biological and research analysis:~Quantification of ficolin-3, anti-ficolin-3 antibodies, ficolin-2, anti-ficolin-2 antibodies~Purification of patients' antibodies (anti-ficolin-3 and -2)~Evaluation of effects of anti-ficolin-3 and anti-ficolin-2 purified antibodies Investigation of ficolin-3 and ficolin-2 deposition in renal biopsy"
45452099|NCT01583933|Device|Hawley retainer|subjects in this arm will have the retainer for 24 hours a day for 6 months. During food intake they won´t have this device.
45599354|NCT02299765|Drug|Gefitinib|patients in arm A will be given gefitinib as target therapy
45599355|NCT02299765|Drug|gemcitabine|patients in arm A will be given gemcitabine chemotherapy
45599356|NCT02299765|Drug|carboplatin|patients in arm A will be given carboplatin chemotherapy
45599357|NCT03112395|Device|Pio Medical Device|The Pio device combines the technologies of pulse modulated magnetic fields and light emission locally applied to the wound area.
46073585|NCT02824536|Drug|10-1074|Intravenous Infusion of 10-1074
46073586|NCT02824536|Drug|Placebo|Intravenous Infusion of Sterile Saline (NaCl 0.9%)
46073587|NCT00831129|Drug|Rosiglitazone|4 mg daily
46073588|NCT00831129|Drug|Placebo Rosiglitazone|1 tab daily
46073589|NCT00831129|Drug|Simvastatin|40 mg daily
46073590|NCT00637962|Biological|HIV glycoprotein CN54gp140 (vaccine)|vaginal immunisation with 100ug CN54gp140 antigen in gel on 9 occasions in one menstrual cycle
45444001|NCT03841071|Other|ROM/CFS intervention|The intervention (ROM/CFS) includes self-reported measures for adaptation to life with an ostomy and health-related quality of life, as well as patient satisfaction recorded by the clinical feedback system. The measures are electronically assessed before each clinical consultation at 3, 6, and 12 months after surgery, and annually thereafter. The scores are instantly analysed and graphically presented for use during the consultation and the patient and stoma care nurse can discuss the findings.
45444002|NCT05669781|Drug|Metoclopramide 10mg|Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively
45444003|NCT05669781|Combination Product|Gum and metoclopramide|Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively and one stick of sugar-free gum (over 15minutes) 8 hourly till either the first flatus or feces was passed
45444004|NCT05669781|Other|Gum|One stick of sugar-free gum (over 15minutes) 8 hourly till either the first flatus or feces was passed
45444005|NCT05669781|Other|Control|10ml of sterile water intravenously 8hourly for the first 72hours post-operatively
45444006|NCT05118867|Behavioral|iPREPARED|iPREPARED is a mobile health technology that can be accessed via the web, tablet, or phone. It contains a preparatory video that outlines what to expect during the hospitalization. Instructional videos and examples are provided for the patient and their recovery partner to use to do their own reorientation, distraction techniques, physical activity, and sleep hygiene.
45444007|NCT01202331|Drug|mass treatment with oral azithromycin|For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. Nasopharyngeal swabs will be collected in each community from 15 randomly selected children among the 60 participants under age 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
45444008|NCT04346511|Other|Acupuncture|Patients will have six, 0.25*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal.
45444009|NCT01201551|Drug|Brimonidine|Week1, day2: 1 eyedrop/right eye Week2, day1: 1 eyedrop/left eye Week2, day2: 1 eyedrop/left eye
45444010|NCT01201551|Drug|Latanoprost|Week1, day1: 1 eyedrop/right eye Week1, day2: 1 eyedrop/right eye Week2, day2: 1 eyedrop/left eye
45444011|NCT01201551|Drug|Placebo|Week1, day1: 1 eyedrop/left eye Week1, day2: 2 eyedrops/left eye Week2, day1: 1 eyedrop/right eye Week2, day2: 2 eyedrops/right eye
45444012|NCT03838809|Device|surface electromyography-biofeedback|Two electrodes were putted on the motor point of the extensor muscle of the hand and the foot. The positive electrode was placed on the distal zone of the hand or the foot, while the negative electrode was placed on the proximal zone.
45444013|NCT03838419|Radiation|intraoperative radiotherapy|IORT with 21 Gy prescribed to the 90% isodose line
45444014|NCT03838419|Radiation|whole breast irradiation|hypofractionated WBI Total dose 40.05 Gy (15 x 2.67 Gy)
45444015|NCT01204125|Drug|paclitaxel|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
45444016|NCT01204125|Drug|Iniparib (SAR2405550 -BSI-201)|"Pharmaceutical form : solution for infusion~Route of administration :Intravenous"
45444017|NCT03074240|Procedure|TAPB Group|Subjects allocated to the TAPB group will be monitored for instances of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia will be compared.
45754758|NCT01908725|Drug|Lamazym|ERT, i.v. infusions weekly
45754759|NCT00580333|Drug|cisplatin|Preoperatively: Given intravenously on day one of the treatment cycle (once every 3 weeks) for four cycles
45754760|NCT00580333|Drug|bevacizumab|Preoperatively: Given intravenously on day 1 of the treatment cycle (once every three weeks) for three cycles Postoperatively: Intravenously for four 2-week cycles (once every two weeks) and after the 8 weeks (study doctor will determine course of treatment) for an additional four 2-week cycles with or with out paclitaxel
45754761|NCT00580333|Drug|doxorubicin|Postoperative: Given intravenously for four 2-week cycles
45754762|NCT00580333|Drug|cyclophosphamide|Postoperative: Given intravenously for four two-week cycles
45754763|NCT00580333|Drug|paclitaxel|Postoperative: 8 weeks after postoperative chemotherapy regimen (study doctor will determine course of treatment) paclitaxel for four 2-week cycles (once every two weeks)
45754764|NCT05622617|Drug|no intervention|no intervention
45754765|NCT05013541|Other|No intervention|Observational study, standard record of need to void during cystometry
45754766|NCT00509171|Device|Reamer Irrigator Aspirator|Use of standard reamer vs reamer irrigator-aspirator during IM nailing of tibial shaft fractures
45754767|NCT05622539|Combination Product|CONVENTIONAL ACUTE STROKE MANAGEMENT|Conventional treatment for acute stroke patients, with or without reperfusion treatments
45754768|NCT00580645|Drug|varenicline|2mg/day or 1mg/day with 1-week medication lead-in period.
45754769|NCT00580645|Drug|placebo|placebo
45934844|NCT00041210|Drug|ABVD regimen|
45444018|NCT03074240|Procedure|RSB Group|Subjects allocated to the RSB group will be monitored for instances of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia will be compared.
45599358|NCT02299843|Procedure|RALPPS|Using radiofrequency ablation assisted ALPPS（RALPPS）instead of in-situ split of liver to form a coagulation band in stage I.Habib 4X was used in RFA.
45444019|NCT03074240|Procedure|conversion to general anesthesia|For those who do not respond to TAPB or RSB to allow for completion of the intended procedure.
45444020|NCT05276882|Other|Hypnosis|"It will be an individualized hypnosis session of Ericksonian type. It consists in going through 3 phases: induction, dissociation, suggestion.~The principle is to focus the patient's attention by talking to her or by surprising her, or by making her do an incongruous gesture which will make her focus on a restricted idea. She will reduce her field of consciousness and concentrate. This is where her work will begin, allowing her unconscious to function in order to find her solutions. At this moment, she is particularly receptive to suggestions and the hypnotherapist accompanies and guides her thoughts and her associations of ideas on therapeutic paths. He provokes a unique personal work which aims to promote healing."
45444021|NCT05276882|Other|pre-surgery consultation|"Dialogue with the patient to clarify her expectations.~Answers to the patient's questions~Precision on the organization of the hospitalization if necessary~Information on the postoperative period with postural advice to facilitate the first getting up with less discomfort, and postures promoting rest in the postoperative period~Information on relaxation techniques and their interest (abdominal breathing)"
45804002|NCT05719454|Device|CNT testing|The effect of CNT on blood pressure will be obtained throughout the year long follow up period.
45444022|NCT03725085|Drug|Mucinex™ extended-release (SE)|2 tablets of Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)
45804003|NCT01349192|Drug|Rifampin|Adult Dose: 300mg twice daily for 14 days. Pediatric Dose: <40kg : 15mg/kg daily for 14 days divided every 12 hours.
45599359|NCT02299843|Procedure|ALPPS|Treat the hepatocellular carcinoma with ALPPS.
45599360|NCT03510559|Drug|Forearm Nerve Block|Blockade of the arm below the elbow using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
45599361|NCT03510559|Drug|Brachial Plexus Block|Blockade of the entire arm using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
45804186|NCT04825795|Drug|DPP4-inhibitor|Prescription of DPP4-inhibitor during the period between the two coronary CT scan
45599362|NCT04003311|Device|Comprehensive Primary Micro Stem|Patients that have been implanted with the Comprehensive Primary Micro Stem to repair shoulder malfunction/disease.
45599363|NCT04003311|Device|Comprehensive Anatomic Versa-Dial Titanium Humeral Head|Patients that have been implanted with the Comprehensive Anatomic Versa-Dial Titanium Humeral head to repair shoulder malfunction/disease.
45599364|NCT04702997|Drug|Bardoxolone methyl oral capsule|Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status
45599365|NCT04702997|Drug|Placebo oral capsule|Capsule containing an inert placebo
45599366|NCT04771923|Drug|Tranexamic acid|Topical instillation of tranexamic acid up to 3x. If bleeding is not controlled patients crossover to adrenaline.
45599367|NCT04771923|Drug|Adrenaline|Topical instillation of adrenaline up to 3x. If bleeding is not controlled patients crossover to tranexamic acid.
45934845|NCT00041210|Drug|Stanford V regimen|
45444023|NCT03638024|Diagnostic Test|Maternal plasma cell free fetal DNA levels|Measurement Maternal plasma cell free fetal DNA levels in both groups (study and control groups)
45444024|NCT03755804|Drug|bendamustine|Given intravenously (IV)
45444025|NCT03755804|Drug|Etoposide|Given intravenously (IV)
45599368|NCT02306941|Behavioral|Internet-delivered CBT|The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, adapted for adolescents with FAP/FD and their parents. Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
45754770|NCT04941469|Device|Specifically optimized off-the-counter foot orthosis (Medical grade foot orthosis)|"The study device is a specifically optimized off-the-counter foot orthosis modified by an additional wedging added onto the original Formthotics (Original Dual Hard) with standard arch fill reduction to achieve a foot orthosis that is tailored for the management of mechanical foot pains in the Subtle Cavus foot type. The original Formthotics (Original Dual Hard) is currently in use and is considered a Class A medical device according to the Health Science Authority of Singapore risk classification system. At the moment, the original Formthotics (Original Dual Hard) is also available in the retail market, abeit, without assessment guided optimisations for specific feet types."
45754771|NCT04941469|Device|Plain off-the-counter foot orthosis (Medical grade foot orthosis)|The control device for this study would be the plain original Formthotics (Original Dual Hard).
45754772|NCT00580957|Drug|Blocked|Trimethaphan 4 mg/min IV will be infused for the duration of the study. L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance
45934846|NCT00041210|Drug|dacarbazine|
45599369|NCT04718415|Drug|sintilimab, paclitaxel, carboplatin|Patients receive sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 - 4 courses in the absence of disease progression or unacceptable toxicity.
45934847|NCT00041210|Drug|doxorubicin hydrochloride|
45444026|NCT03755804|Drug|Doxorubicin|Given intravenously (IV)
45444027|NCT03755804|Drug|Bleomycin|Given intravenously (IV)
45444028|NCT03755804|Drug|Vincristine|Given intravenously (IV)
45444029|NCT03755804|Drug|Vinblastine|Given intravenously (IV)
45444030|NCT03755804|Drug|Prednisone|Given orally (PO)
45444031|NCT03755804|Drug|Filgrastim|Given subcutaneously (SQ) or IV
45444032|NCT03755804|Drug|Brentuximab Vedotin|Given intravenously (IV)
45444033|NCT03755804|Drug|Cyclophosphamide|Given intravenously (IV)
45444034|NCT03755804|Drug|DTIC|Given intravenously (IV)
45599370|NCT04718415|Procedure|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
45599371|NCT04631549|Drug|SHR3680|SHR3680, PO, single dose
45599372|NCT02303275|Behavioral|Lifestyle Change|"Intervention: Lifestyles Change Program (LCP)~The LCP is a 12-week multi-disciplinary program that incorporates a holistic approach to chronic disease management, which will be tailored to our study population, patients with chronic heart failure. The core of the LCP includes:~Clinician, Dietician, Exercise physiologist, Counselor, Nurse Case Manager Medical oversight by board-certified Cardiologist, Exercise prescription, Stress management classes (yoga, meditation, guided imagery), Group support, lifestyle change lectures, body composition analyses, grocery store tour, cooking classes, Music Wellness, and resiliency classes."
45599373|NCT02303275|Behavioral|Lifestyle Change|The lifestyle change program consists of classes conducted three times a week for 12 weeks at the Scripps Center for Integrative Medicine. Each day participants will spend about four to five hours in a variety of classes such as monitored exercise, group support, mindful-yoga and meditation, vegetarian cooking classes, music-centered wellness, mind-body lectures, and resiliency training.
45652924|NCT05095389|Device|ADRCs|Administration of Autologous Adipose Derived Regenerative Cells into the Diabetic Foot Ulcer
45754773|NCT00580957|Drug|Intact|Saline IV infusion to simulate trimethaphan infusion in active arm Insulin clamp will be done to determine insulin resistance
45652925|NCT05095389|Other|standard care|standard care
45754774|NCT00581347|Other|outreach services|Tracking/reminder/recall/home visit strategy.
45934848|NCT00041210|Drug|etoposide|
45599374|NCT02307019|Other|Program on specific prevention of health|The intervention will be centered in provide effective tools to manage each situation presented while a caregiver cares for patients poststroke with upper limb apraxia. Moreover, the workshops will be focused on the balance between the assistance provided by the caregiver and the improvement and the increase the autonomy and independence of the patients. Finally, we will provide skills and strategies to the caregiver for enhancing the environment adaptation of the patients.
45599375|NCT02307019|Other|Program on general prevention of health|The general health educative program will consist in an educational workshop for caregivers where they are taught the habitual guidelines to caring for patients in situation of dependency.
45444035|NCT03755804|Other|Quality of Life Measurements|Quality of Life measurements may be done in low-risk cycles 1 and 2 BEABOVP, intermediate-risk cycles 1, 2 and 3 BEABOVP and high-risk cycles 1 and 2 AEPA and cycles 1, 2, 3, and 4 CAPDac. QOL may be done at year 1, 2 and 5 for all risk groups.
45599376|NCT04616573|Device|OMNI® Surgical System|Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System
45599377|NCT04616573|Device|iStent inject|Trabecular meshwork implantation
45599378|NCT02300155|Drug|Pregvit®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing -twice daily for '35 mg' group
45599379|NCT02300155|Drug|Orifer F®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing-once daily for '60 mg' group
45599380|NCT04598321|Drug|Talazoparib Oral Capsule|An orally available PARP inhibitor for the treatment of advanced breast cancer with germline BRCA mutations.
45599381|NCT03510403|Device|nastent™|Snorer and OSA patients (mild or moderate OSA) use the nasal airway stent for sleeping, each night for 1 month.
45599382|NCT02234765|Other|Primary Care-based management|Patients will be diagnosed and follow-up in Primary Care.
45599383|NCT02234765|Other|Standard management|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
45599384|NCT03513133|Behavioral|working memory training|Hierarchical cognitive training of the different components of working memory according to Baddeley model; 15 tasks are used addressing: the phonological loop (8 tasks), the visuospatial sketchpad (4 tasks) and the central executive 3 tasks). Task are given in a hierarchical order, according to each individual patient's deficits and improvement.
45599385|NCT05254899|Drug|Anti-PD-1 monoclonal antibody|200mg iv on Day 1 of each 14-day cycle for 3 cycles in induction treatment; 200mg iv on Day 1,15, 29 during RT treatment
45599386|NCT05254899|Drug|Pegaspargase|3000 U/m2 im on Day 2 of each 14-day cycle for 3 cycles in induction treatment
45754775|NCT04387903|Procedure|Surgical re-interventionafter pancreaticoduodenectomy|Mandatory surgical management of complications after pancreatico-duodenectomy through peritoneal lavage, draiange, repair of fistula, completion pancreatectomy, control of bleeding, bowel resection, and feeding jejunostomy.
45754776|NCT00509249|Biological|ziv-aflibercept|Given IV
45754777|NCT00509249|Other|laboratory biomarker analysis|Correlative studies
45754778|NCT00509249|Other|pharmacological study|Correlative studies
45444036|NCT03755804|Radiation|Radiotherapy|Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy for all risk groups. Radiotherapy will be administered after completion of all chemotherapy upon hematologic count recovery.
45444037|NCT03838185|Drug|J147|Single oral dose of J147
45599387|NCT05254899|Drug|Gemcitabine|1g/m2 iv on Day 2 of each 14-day cycle for 3 cycles in induction treatment
45599388|NCT05254899|Drug|Oxaliplatin|1g/m2 iv on Day 2 of each 14-day cycle for 3 cycles in induction treatment
45599389|NCT05254899|Radiation|Involved site radiotherapy|Involved site radiotherapy according to the ILROG guideline with primary tumor dose of 50-56Gy 14-28 days after inductive therapy
45599390|NCT02307097|Procedure|Cognitive-Behavioural Bibliotherapy|
45599391|NCT02307097|Procedure|Cognitive-Behavioural Therapy|
45599392|NCT02307097|Other|WAIT|
45599393|NCT03148509|Drug|risperidone|DA receptor-mediated drugs
45599394|NCT03148509|Drug|aripiprazole|DA receptor-mediated drugs
45599395|NCT03148509|Drug|bupropion|DA receptor-mediated drugs
45599396|NCT03148431|Drug|LY3002815|Administered IV
45599397|NCT03148431|Drug|Placebo|Administered IV
45599398|NCT04464343|Other|no intervention|This is an observation study, with no intervention
45599399|NCT02039271|Other|Music therapy|This will include 30 minutes before and after ambulation on post-op days 1 and 2. This will be contingent on when the participant had surgery the day prior and when they are ready and able to begin ambulating. Participants in the intervention group will do a VAS prior to listening to music and then afterward while those in the control group will do a VAS prior to and after each ambulation. Participants will be ambulating twice a day, in the AM and PM so the intervention will be given twice a day.
45754779|NCT00624013|Drug|sertraline|50 mg up to 100 mg daily for 6 months
45754780|NCT00624013|Drug|Placebo|50 mg up to 100 mg daily for 6 months
45444038|NCT03838185|Drug|Placebo|Single oral dose of corn oil
45754781|NCT02121041|Drug|Amlodipine|Amlodipine 5 mg or 10 mg
45754782|NCT02121041|Drug|Chlorthalidone|Chlorthalidone 12.5 mg or 25 mg
45754783|NCT02121041|Drug|Losartan|Losartan 50 mg or 100 mg
45754784|NCT00509873|Drug|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
45444039|NCT05282199|Other|INSPIRATORY MUSCLE TRAINING|In the group of post-COVID-19 patients in which reduced endurance and inspiratory muscle power are identified, inspiratory muscle training (IMT) will be performed with a load equivalent to 50% of MIP (assessed weekly) for eight weeks.
45444040|NCT01566825|Drug|Amitriptyline|amitriptyline 25 mg at 9:30 pm, day 10, and 50 mg at 1:30 am, day 11
45444041|NCT01566825|Drug|Placebo|placebo(white 8 mm Lichtenstein®) at 9:30 pm, day 10, and at 1:30 am, day 11
45452100|NCT01584011|Other|taste measurement|Taste measurements with Electrogustometry and Filter paper test before and after surgery until one year after surgery
45452101|NCT01584011|Other|Symptom questionnaire|Answering a symptom questionnaire before and after surgery until one year after surgery
45452102|NCT01584011|Behavioral|Quality of life questionnaire|Answering a quality of life questionnaire before and one year after surgery
45599400|NCT03507283|Procedure|Double head pterygia excision and repair|Complete excision of the pterygia was done. A free conjunctival autograft was obtained. The graft was divided vertically into two parts then secured into conjunctival defects.
45599401|NCT05254665|Drug|Docetaxel Polymeric Micelles for Injection|Docetaxel polymeric micelles，usage and quantity of Docetaxel polymeric micelles follows the clinical study proctol，not published.
45754785|NCT00509873|Drug|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
45754786|NCT02133781|Biological|Fluzone® 2009-2010 Formula|This vaccine is given intramuscularly
45754787|NCT02133781|Biological|FluMist® 2009-2010 Formula|This vaccine is given intranasally
45754788|NCT01855451|Drug|Cetuximab|
45754789|NCT01855451|Radiation|RT (70 Gy in 35 fractions)|
45754790|NCT01855451|Drug|Cisplatin|
45754791|NCT02134951|Drug|Ketamine|intravenous infusion of saline solution with ketamine
45754792|NCT02134951|Drug|Normal saline|Normal saline will be used for placebo in this group
45804004|NCT01349192|Drug|Trimethoprim/Sulfamethoxazole|Adult Dose: 320/1600 orally twice daily for 14 days. Pediatric Dose: <40 kg : 8mg/kg trimethoprim / 40 mg/kg sulfamethoxazole twice a day for 14 days.
45911001|NCT02002156|Biological|NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®|This group will receive no BCG but will receive all routine vaccinations.
45599402|NCT03513055|Other|nurse inject premixed insulin|nurse inject premixed insulin，coaching in the injection technique
45599403|NCT03148353|Procedure|Subacromial injection|"Modified ultrasound guided corticosteroid subacromial injection~Standardized ultrasound guided corticosteroid subacromial injection"
45599404|NCT05254587|Device|IOLMASTER 700 TK|4 different intraocular lens (IOL) calculation methods (Haigis TK, ASCRS calculator, Barrett Ture K Classic K, Barrett True K TK) will be performed using the preoperative biometry data.
45599405|NCT03512977|Procedure|sphenopalatine ganglion block|the intervention will be performed on sitting position. Lidocaine 2% viscous (0.5ml) will be apply on cotton swab sticks and one will be gently inserted into nostril, along the floor of the nose. Stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab stick will be left undisturbed for 20 minutes.
45452103|NCT01584011|Other|Nerve sample|Collect nerve samples from patients undergoing surgery because of vestibular schwannoma, chronic otitis media or cholesteatoma where the nerve cant be saved during planned operation.
45599406|NCT03512977|Drug|conservative treatment|Conservative treatments are iv hydration, analgesic agents, caffeine or theophylline
45599407|NCT03148119|Drug|QRH-882260 Heptapeptide|topical spray; fluorescently-labeled peptide composed of a 7-amino acid sequence [Gln-Arg-His-Lys-Pro-Arg-Glu] attached via a 5 amino acid linker [Gly-Gly-Gly-Ser-Lys] to a near-infrared fluorophore, Cy5. The complete peptide sequence is written as: Gln-Arg-His-Lys-Pro-Arg-Glu-Gly-Gly-Gly-Ser-Lys(Cy5)-NH2, and is abbreviated as: QRHKPRE-GGGSK-(Cy5)-NH2.
45599408|NCT03148119|Device|Scanning Fiber Endoscope|Endoscope used for providing the light via laser to image the area of interest in the colon after the QRH has been sprayed and rinsed.
45599409|NCT03132727|Other|Pharyngo laryngeal MRI|"Patients will be outgoing a pharyngolaryngeal MRI, with injection of gadolinium, in addition to the CT imaging. They will have this MRI in case of doubt about cartilage invasion. It will be realised during the time between the CT imaging and the day of surgery.~Device : gadolinium-based MRI contrast agent This will be realized according to the standard procedure."
45599410|NCT02336919|Behavioral|Txt2Prevent|A 60-day text messaging program called Txt2Prevent (see description in the arm description).
45599411|NCT03512899|Procedure|Right internal jugular access.|Implantation using percutaneous puncture.
45599412|NCT03512899|Procedure|Left internal jugular access.|Implantation using percutaneous puncture.
45599413|NCT03512899|Procedure|Right axillary vein access.|Implantation using percutaneous puncture.
45652926|NCT05095389|Other|Placebo|placebo
45754793|NCT00510497|Biological|Autologous HIV-1 ApB DC Vaccine|Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption
45754794|NCT03029780|Biological|Opdivo|Specified dose on specified days
45754795|NCT03029780|Biological|Yervoy|Specified dose on specified days
45754796|NCT00624559|Drug|celecoxib (Celebrex)|Celecoxib (Celebrex) was administered at 100 mg, twice per day for each day of sodium diet
45754797|NCT00624559|Other|Placebo|Placebo pill taken twice per day on each day of the diet
45754798|NCT00510809|Drug|Policosanol|Policosanol 20 mg daily
45754799|NCT00510809|Other|Placebo|Placebo daily
45754800|NCT00510809|Drug|Policosanol Plus Already In Use Statin Therapy|Policosanol 20 mg daily Statin Therapy
45754801|NCT02776982|Procedure|Confocal endomicroscopy|Confocal endomicroscopy will be performed during clinically indicated endoscopy.
45754802|NCT02776982|Procedure|Mucosal impedance|Mucosal impedance will be performed at the time of clinically indicated endoscopy.
45754803|NCT02776982|Procedure|Research biopsies|Research biopsies will be obtained during clinically indicated endoscopy.
45754804|NCT02776982|Procedure|Bravo ambulatory pH monitor|Bravo ambulatory pH capsule will be placed during clinically indicated endoscopy.
45754805|NCT00625729|Biological|aldesleukin|Day 0-14, 10 million international units, 3 times per week for 6 doses
45754806|NCT00625729|Biological|allogeneic natural killer cells|Day 0 infusion of cells (1.5-8 x 10^7 cells/kg).
45754807|NCT00625729|Biological|rituximab|Administered Day -8, day -1, day +6 and day +13, intravenously (IV) 357 mg/m^2
45754808|NCT00625729|Drug|cyclophosphamide|60 mg/kg intravenous (IV) on Day -5.
45754809|NCT00625729|Drug|fludarabine phosphate|Day -6 through day -2, 25 mg/m^2 intravenous (IV)
45452104|NCT01097135|Drug|Duraprep Surgical Solution|
45754810|NCT02335502|Device|Implantation with the commercially available Axium neurostimulator|
45754811|NCT00581971|Drug|celecoxib|400mg bid starting 1 week before radiotherapy and taken through radiotherapy.
45754812|NCT00581971|Drug|Carboplatin|IV, AUC 2.0, weekly for weeks 1 through 7
45754813|NCT00581971|Drug|Paclitaxel|IV 30 mg/m2, weekly for weeks 1 through 7
45754814|NCT00581971|Radiation|Radiation Therapy|70.2Gy, at 1.8Gy qd, Monday through Friday
45754815|NCT03029234|Drug|Dexamethasone|20 mg intravenous (IV) or oral dexamethasone on days 1, 2, 8, 9, 15, 16, 22, and 23 in 28-day cycles.
45754816|NCT03029234|Drug|Carfilzomib|Infusion of IV carfilzomib on days 1, 2, 8, 9, 15 and 16 in each 28-day cycle.
45754817|NCT01670318|Device|platinum chromium everolimus-eluting stent (PROMUS Element by Boston Scientific, Massachusetts)|
45444042|NCT02940392|Device|Rezum System|"The Rezūm System is designed to treat patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death.~The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure."
45444043|NCT04306809|Behavioral|Internet-delivered ACT for PTSD and chronic pain|The participants will go through an active internet-based ACT treatment focused on education about PTSD, value-based exposure for the traumatic memory and avoided situations, and behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 3 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
45599414|NCT03512899|Procedure|Left axillary vein access.|Implantation using percutaneous puncture.
45599415|NCT02349009|Drug|C-82 Topical Gel, 1%|active
45754818|NCT03155828|Device|CPAP|Women with diagnosed obstructive sleep apnea will be treated using continuous positive airway pressure as per standard of care.
45599416|NCT02349009|Drug|C-82 Topical Gel, Placebo|placebo
45599417|NCT03507205|Device|Biomatrix; Biomatrix Flex; Nobori|Biodegradable polymer-coated biolimus-eluting stents
45599418|NCT03507205|Device|Xience Prime|Durable polymer-coated everolimus-eluting stents
45599419|NCT03507205|Device|Xience V/Promus; Cypher|Durable polymer-coated everolimus-eluting stents; Sirolimus-eluting stents
45599420|NCT03507205|Device|DP-ZES-RI|Durable polymer-coated zotarolimus-eluting stents
45599421|NCT03507205|Device|Endeavor; Resolute|Durable polymer-coated zotarolimus-eluting stents
45599422|NCT03507439|Device|VitalPatch Biosensor|Patients will receive the VitalPatch Biosensor system at 5 monitoring periods
45754819|NCT03155204|Drug|tiotropium pMDI|inhalation
45754820|NCT03111992|Drug|PDR001|Anti-PD1 antibody
45754821|NCT03111992|Drug|CJM112|Anti-IL-17A antibody
45754822|NCT03111992|Drug|LCL161|Oral small molecule SMAC-mimetic
45754823|NCT00626431|Drug|Leuprolide acetate - Formulation A|Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation A, 45 mg 6 month depot, 24 weeks apart.
45754824|NCT00626431|Drug|Leuprolide acetate - Formulation B|Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation B, 45 mg 6 month depot, 24 weeks apart.
45754825|NCT01670474|Drug|rt-PA (2mg/2mL) actilysis|At the first catheter dysfunction (Qb < 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. All catheters analyzed (fmDLC, polyDLC and siDLC) will be locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions: i.e. fmDLC, polyDLC amd siDLC.
45444044|NCT03559010|Drug|Norgestrel 0.075 mg tablets|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 16 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet."
45444045|NCT03298412|Drug|Blinatumomab|Blinatumomab is administered as a continuous IV infusion.
45444046|NCT03297398|Drug|Group-1 (15mg, OPK-88004)|15mg, OPK-88004
45444047|NCT03297398|Drug|Group-2 (25 mg,OPK-88004)|25 mg,OPK-88004
45444048|NCT03297398|Other|Placebo|Placebo
45444049|NCT04698902|Device|Intracoronary lithotripsy|Intracoronary lithotripsy involves the use of sonic pressure waves generated from emitters enclosed within a balloon delivery system. The generated sonic waves act to fracture calcium within the coronary artery wall.
45599423|NCT03507439|Device|DynaPort Move Monitor|Patients will receive the DynaPort Move Monitor (belt) at 2 monitoring periods
45754826|NCT01670474|Drug|rt-PA|At the first catheter dysfunction (Qb < 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed in this study (i.e. fmDLC, polyDLC, siDLC) will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions.
45754827|NCT03155360|Other|Non interventional study|Non interventional study
45754828|NCT00582205|Drug|Paclitaxel, Cisplatin IP|Paclitaxel 135 mg/m2 IV (3-hr infusion) on Day 1, Cisplatin 50 mg/m2 IP on Days 1 and 8, Repeat every 3 weeks for 6 cycles
45754829|NCT05630612|Drug|Sparsentan|6 weeks of treatment with sparsentan or irbesartan. This will be administered in a double-blind fashion.
45754830|NCT04717453|Other|No Intervention|No Intervention
45754831|NCT00626743|Drug|SK3530 100mg, Placebo, Amlodipine|
45804187|NCT04825795|Drug|No DPP4-inhibitor|No prescription of DPP4-inhibitor during the period between the two coronary CT scan
45444050|NCT01202019|Other|Circuit Resistance Training (CRT)|CRT will occur 3 times per week for 26 weeks. Each session will last approximately 40-45 minutes and employ resistance training (weight lifting) and endurance activities (reciprocal arm exercise, Vita-Glide®, RehaMed International) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
45444051|NCT03293654|Drug|MB02|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
45444052|NCT03293654|Drug|US licenced Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
45444053|NCT03293654|Drug|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
45444054|NCT03312218|Behavioral|Spaced educational intervention|A spaced educational intervention will be provided to participants
45444055|NCT03930615|Drug|Letermovir|LET tablet or intravenous infusion at a total daily dose of 240 mg (when given with cyclosporin A) or 480 mg (when given alone).
45599424|NCT03510325|Drug|Olanzapine|Commonly used oral antipsychotics intervention therapy.
45599425|NCT03510325|Drug|Risperidone|Commonly used oral antipsychotics intervention therapy.
45599426|NCT03510325|Drug|Aripiprazole|Commonly used oral antipsychotics intervention therapy.
45599427|NCT03510325|Drug|Amisulpride|Commonly used oral antipsychotics intervention therapy.
45599428|NCT03510325|Drug|Paliperidone long-acting injection|long-acting injection
45599429|NCT02337075|Behavioral|PATH program|A brief education session, use of a wearable physical activity tracker, and physical activity mentoring by an Activity Mentor every 2 weeks.
45599430|NCT02337075|Device|Activity Mentor|
45599431|NCT03507127|Drug|Varenicline|Standard dosing: 0.5 mg/day on days 1-3, 0.5 mg twice daily (morning, evening) on days 4-7, then 1 mg twice daily to the end of the medication period.
45599432|NCT03507127|Drug|Placebo|Dosing schedule matched to active comparator: on tablet on days 1-3, one tablet twice daily (morning, evening) on days 4-7, then one tablet twice daily to the end of the medication period.
45599433|NCT02340351|Device|Auricular acupuncture|Auricular acupuncture according to the the NADA protocol includes the needling of five specific acupuncture points on both ears: point 51 (= Sympathetic point), point 55 (= Shen Men), point 95 (= Kidney point), point 97 (= Liver point) and point 101 (= Lung point). All points were acupunctured with fine sterile single use steel needles with the size of 0.25 x 20 millimetres. The needles were inserted about 2-3 millimetres, so that the needle point pierces the skin and is just positioned in the cartilage of the ear. They remained in position for 30 minutes.
45599434|NCT02340351|Procedure|Progressive muscle relaxation|Progressive muscle relaxation was carried out by the method of Bernstein and Borkovec. All participants were asked to close eyes while sitting comfortably. Each group session included 16 main exercises of consciously tensing and relaxing specific groups of muscles.
45599435|NCT02307409|Other|Sonoclot/TEG test|The Sonoclot/TEG test will be done at the study time points. Within 12 hours of presentation in the emergency department, at 72 hours, and at 7 days, or when the patient meets the study criteria for suspected or proven sepsis
45599436|NCT02336841|Other|Treatment as usual + Recovery MANTRA|Participants in this group will receive the guided self-help intervention including video-clips, a workbook, and guidance from peer mentors, and treatment as usual.
45599437|NCT02336841|Other|Treatment as usual + feedback|Participants in this group will receive treatment as usual and feedback on their eating disorder symptoms.
45599438|NCT03512821|Drug|Ursodiol 500 MG|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
45754832|NCT01670708|Behavioral|HOPE|HOPE Court Judge provides warning hearing; random drug testing; violation hearing and jail/other sanctions for failed drug test or failure to comply with other probation conditions.
45599439|NCT03512821|Drug|Urso Forte 500Mg Tablet|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
45599440|NCT02336529|Drug|Bupivacaine|
45599441|NCT02336529|Drug|NaCl|
45599442|NCT04658433|Dietary Supplement|300 mg of omega3-FA|The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.
45599443|NCT02307487|Drug|120 mg MMC in 90ml gel|120 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
45599444|NCT02307487|Drug|140 mg MMC in 90ml gel|140 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
45599445|NCT02307487|Drug|160 mg MMC in 90ml gel|160 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
45599446|NCT02307487|Drug|120 mg MMC in 60ml gel|120 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
45599447|NCT02307487|Drug|140 mg MMC in 60ml gel|140 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
45599448|NCT02307487|Drug|160 mg MMC in 60ml gel|160 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
45599449|NCT03148041|Other|health education program|"Intensive health education program for intervention group: 1.The introductory 30 minute Arabic lecture for increase level of the awareness of the participants regarding stroke. Lecture from the USA National Stroke Association, 2011, will be used. The lecture includes the following issues about stroke (1) definition; (2) signs and symptoms; (3) risk factors; (4) treatment; and (5) prevention.~2. Self-help materials will involve health education brochures regarding stroke and will be distributed for all participants at the time they are attending the lecture. The brochures which will be used for this study will be collected from the World Stroke Day 2016 Brochures, the Arabic version.~The routine care for control group: different lecture and brochures will be used"
45599450|NCT03510091|Behavioral|Counseling|A video will be shown to parents of patients ages 9-18 that review HPV transmission, relation to cancer, role of immunization, myths, side effects, series timing and need for completion. All parents or legal guardians of patients will be given the option to proceed with HPV vaccination, decline, or discuss further with their provider
45599451|NCT02349087|Device|Acute EEG with fast applicable EEG electrode|
45599452|NCT02307565|Drug|Midodrine|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
45599453|NCT02307565|Drug|Placebo|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
45599454|NCT02340429|Device|DE500 Digital Video Otoscope|
45599455|NCT02307643|Drug|MT-1303 Low dose|
45599456|NCT02307643|Drug|MT-1303 High dose|
45599457|NCT02348931|Device|Use of customized nasal brace (Nasella) for nose deformities|
45599458|NCT02348931|Procedure|corrective surgery|
45754833|NCT01670708|Behavioral|Probation as Usual|Probation officer supervises following standard protocols.
45444056|NCT03930615|Drug|Placebo|Placebo was administered as tablets matched to LET or as inactive (saline or dextrose) intravenous infusion.
45444057|NCT05276648|Diagnostic Test|CAM ICU test|CAM ICU for delirium
45599459|NCT05253885|Device|Smartphone use|"Smartphone addiction scale (short version) higher than 33~Smartphone users of 4-5 inches screen size smartphones, weighing 140-160 grams and dimensions less than 159*79*9 mm."
45599460|NCT02300389|Radiation|Hypofractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with hypofractionated dose of 7.5 Gy in two fractions (II phase) to the total dose of 61 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
45599461|NCT02300389|Radiation|Conventional Fractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with conventional fractionated dose of 2 Gy in 15 fractions (II phase) to the total dose of 76 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
45599462|NCT02348853|Behavioral|Healthy Weight for Living (HWL)|
45599463|NCT02348853|Behavioral|Current Best Practice (CBP)|
45599464|NCT02300467|Drug|NOV120401|5 to 45 mg/day PO for 5 consecutive days and 2 days off
45599465|NCT04477551|Procedure|Diode laser (device) with scaling and root planing|Combined use of diode laser device and scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
45444058|NCT05276648|Diagnostic Test|MOCA test|MOCA for cognitif disfonction
45599466|NCT04477551|Procedure|Conventional scaling and root planing|Use of scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
45599467|NCT03510013|Procedure|1-1-8 wash-in|wash-in phase during start of low flow anesthesia
45599468|NCT03510013|Drug|Sevoflurane|Drug used for wash-in protocol
45754834|NCT03154190|Other|Best Practice|Receive usual care
45444059|NCT05276648|Diagnostic Test|brief pain test|BRİEF PAİN for chronic pain
45444060|NCT05276648|Diagnostic Test|VAS scale|VAS scale for acute pain
45444061|NCT03655340|Drug|Alprolix|Extended half-life factor IX product
45444062|NCT03838029|Drug|Propranolol and etodolac|A perioperative combined drug regimen
45599469|NCT05253729|Device|Focused ESWT|F-ESWT (dose 0.01-0.15 mJ/mm2, frequency 4-5 Hz, 1500 shocks) was applied perpendicular to the palmar side of the wrist which was done once a week for a total of three sessions plus conservative treatment.
45599470|NCT05253729|Behavioral|Control|Participants in the control group received only conservative treatment including disease education, advice about proper posture and activity, night wrist splint and nerve gliding exercise.
45599471|NCT03512665|Dietary Supplement|Full dose supplement|A 7ml vial composed of a mixture of pine, macadamia and pomegranate oils.
45599472|NCT03512665|Dietary Supplement|Low dose Supplement|A 7 mL vial composed of a mixture containing 50% study supplement (Pine, macadamia and pomegranate oils) and 50% sunflower oil.
45599473|NCT03512665|Other|Control Oil|A 7ml vial composed of sunflower oil with appearance and organoleptic properties similar to those of the supplement provided in the intervention groups.
45599474|NCT02340507|Other|Rice and bread (high GI)|Rice is a high glycaemic index glutinous rice. Bread is a high glycaemic index white bread.
45599475|NCT02340507|Other|Rice and bread (low GI)|Rice is a low glycaemic index parboiled basmati rice. Bread is a low glycaemic index multigrain bread.
45599476|NCT02307721|Drug|Intranasal naloxone|Administer 0,1 ml 8 mg/ml naloxone intranasally, dose = 0,8 mg naloxone
45599477|NCT02307721|Drug|Intramuscular naloxone|Administer 2 mL, dose intramuscular naloxone 0,8 mg
45599478|NCT02307721|Drug|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone. After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4. In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.
45599479|NCT02307721|Device|Aptar Unidose|This is the spray device chosen, and its function in this setting (spray up side down) will be assessed by weighing the device before and after administration.
45599480|NCT02348541|Device|CollaGUARD|
45599481|NCT03506815|Drug|Rivaroxaban 10 MG|Rivaroxaban 10mg po daily x 90 (+/- 3 days)
45444063|NCT03838029|Other|Placebo|Placebo
45444064|NCT03842397|Device|Kephalios Device 1|The Kephalios Device 1 is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of the Kephalios Device 1 is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3
45444065|NCT04708340|Drug|Rejuveinix (RJX) Active Comparator|Active drug comprised of: ascorbic acid, magnesium sulfate heptahydrate, cyanocobalamin, thiamine, riboflavin 5' phosphate, niacinamide, pyridoxine, calcium d-pantothenate, and sodium bicarbonate.
45444066|NCT04708340|Drug|Placebo Comparator|0.9% Sodium Chloride in Water for Injection a.k.a. Normal Saline for injection
45599482|NCT02348697|Biological|NOVOCART 3D|Autologous Chondrocyte Implantation
45599483|NCT03509935|Other|Intervention Ultrasound Group|"Protocol:~US 4 pulmonary quadrants in each hemithorax: anterior and lateral, upper and lower regions (figure 1)~US inferior vena cava, collaborative index or distensibility according to the patient's conditions, in spontaneous or controlled ventilation, respectively.~Cardiac US: subjective evaluation of contractility in normal, discreetly reduced or severely reduced."
45599484|NCT05227677|Other|GA guided anti-diabetic therapy adjustment|The GA concentration will be measured at 4-week intervals in both groups. The anti-diabetic treatment regimen will be strengthened when GA value is higher than 16% at 4 weeks.
45599485|NCT05227677|Other|current guidelines to adjust treatment|The GA concentration will be measured at 4-week intervals. Investigators will be not aware of the GA value and rely on the current guidelines to adjust treatment.
45599486|NCT02336061|Behavioral|Evaluation of gender differences on the psychosocial and economic impact.|
45599487|NCT03506737|Other|Conventional exercise protocol|Breathing exercises and global active exercises of the upper and lower limbs while in the upright seated position
45599488|NCT03506737|Other|Cycle ergometer exercise protocol|Stationary cycle ergometer exercise while in the upright seated position for 20 minutes. The protocol will be performed intermittently with 5 periods; each period consists of 3 minutes of cycling followed by 1-minute of rest.
45599489|NCT02442973|Procedure|Control group (CG): standard practice|Standard practice group
45754835|NCT03154190|Other|Laboratory Biomarker Analysis|Correlative studies
45754836|NCT03154190|Procedure|Supportive Care|Undergo health care coach support
45754837|NCT03154190|Other|Survey Administration|Ancillary studies
45754838|NCT00582361|Procedure|Standard Wound Dressing|Group A patients will have a standard dressing applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
45599490|NCT02442973|Procedure|Ultrasound group (UG):|"SpineView3D™ anatomical scouting approach"
45599491|NCT02442973|Device|Accuro SpineView3D™|subject will be scanned with 'Accuro SpineView3D
45599492|NCT02348463|Drug|Clindamycin-2-phosphate|how many women will deliver before the 37th week of gestation
45599493|NCT03512509|Other|Low glycaemic potato|The Carisma potato variety is used as the low glycaemic index potato.
45599494|NCT03512509|Other|High glycaemic potato|The Arizona potato variety is used as the high glycaemic index potato.
45599495|NCT02340273|Device|Therapeutic ultrasound|Patients receive therapeutic ultrasound daily for 4 hours of continuous therapy at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
45599496|NCT02340273|Device|Placebo therapeutic ultrasound|"Patients receive sham therapeutic ultrasound daily for 4 hours."
45599497|NCT02300623|Drug|Antiretroviral therapy plus Interleukin-2|Daily s.c. IL-2: 750,000 UI/m2/day for 6 months
45599498|NCT02300623|Drug|Antiretroviral therapy alone|Standard antiretroviral therapy
45599499|NCT02336217|Other|Experimental Group instructions for glucose management via App|The Experimental Group receives individually calculated instructions for glucose management management via the App.
45599500|NCT02336217|Other|Placebo Comparator general instructions|The Placebo Comparator Group receives general instructions but not the complete management algorithm
45599501|NCT04463953|Drug|Zanubrutinib,Ixazomib and Dexamethasone|Zanubrutinib, 160mg orally, twice a day; Ixazomib, 4 mg orally, day 1, 8, 15; Dexamethasone, 20mg orally, days 1, 8, 15；Ixazomib and dexamethasone every 4 weeks of a cycle, with induction of 6 cycles, and then maintain every 12 weeks, up to 6 cycles (96 cycles in total). Zanubrutinib is taken orally twice a day for up to 96 cycles, with a reduction in the last ID cycle. ZID regimen will continue 6 cycles after reaching the maximum response after introduction section.
45599502|NCT02340039|Dietary Supplement|Polyphenols|Drinks will be delivered in random order at 3 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
45599503|NCT02336295|Other|Food Frequency Questionnaires|filling a Food Frequency Questionnaires
45599504|NCT02307955|Device|firefly|
45599505|NCT02307955|Other|Standard of care|
45599506|NCT03147963|Drug|Docetaxel|Docetaxel will be given until progression or patient intolerance
45599507|NCT03512431|Diagnostic Test|Micro sampling|Compare finger prick micro samples with venous blood samples for measuring whole blood tacrolimus concentrations
45599508|NCT02348307|Drug|FYU-981, (Oral single dosing)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
45599509|NCT02348307|Drug|Placebo, (Oral single dosing)|Subjects randomized to the placebo arm receive placebo.
45599510|NCT02303509|Drug|UCB5857 Part 1|"Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 1 mg, 5 mg, 10 mg or 15 mg~Route of administration: Oral"
45444067|NCT05282433|Drug|Surufatinib|Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
45444068|NCT01204281|Other|Mechanical ventilation mode (PAV+ vs. ACV)|Compare two ventilatory modes in the acute phase of illness
45444069|NCT04204629|Drug|HIP1601 40mg|Single dosing of HIP1601 40mg, PO
45754839|NCT00582361|Device|VAC|Group B patients will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
45444070|NCT03292640|Drug|DFD-03 (0.1% tazarotene) Lotion|DFD-03 Lotion (0.1% tazarotene) - twice daily application
45444071|NCT03292640|Drug|DFD-03 (0% tazarotene) Lotion (Placebo)|DFD-03 Vehicle Lotion (0% tazarotene) - twice daily application
45599511|NCT02303509|Drug|UCB5857 Part 2|"Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 5 mg, 8 mg, 15 mg~Route of administration: Oral"
45599512|NCT02303509|Other|Placebo|"Active substance: Placebo~Pharmaceutical form: Capsule~Concentration: Avicel PH 102, 50 mg~Route of administration: Oral"
45599513|NCT02340117|Genetic|SGT-53|The dose of SGT-53 will be 3.6 mg DNA/infusion. If necessary, the dose of SGT-53 can be de-escalated to 2.4 mg, 1.2 mg or 0.6 mg DNA per infusion in the event that increased toxicity probably or definitely related to SGT-53 is observed with the combination.
45599514|NCT02340117|Drug|nab-paclitaxel|The dose of nab-paclitaxel will be 125 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7. If increased toxicities related to administration of nab-paclitaxel is observed, the dose of nab-paclitaxel can be reduced to 100 or 75 mg/m² when appropriate.
45599515|NCT02340117|Drug|Gemcitabine|The dose of gemcitabine will be 1000 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7, after the administration of nab-paclitaxel. If increased toxicities related to administration of gemcitabine is observed, the dose of gemcitabine can be reduced to 800 or 600 mg/m² when appropriate.
45599516|NCT02300701|Drug|Xolair|According to manufacturer's instructions
45599517|NCT02300701|Drug|Placebo|Placebo
45599518|NCT02336139|Drug|Sofosbuvir (SOF)/GS-5816|12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose
45754840|NCT01670786|Procedure|pleurodesis|Comparison of two dosages of iodopovidone as an agent for pleurodesis in malignant pleural effusion
45754841|NCT05701592|Procedure|DB-PCLR|DB-PCLR with reconstruction of both PCL bundles: anterolateral and posteromedial bundle will be performed.
45754842|NCT00582517|Device|Compass Universal Hinge External Fixator|Application of the Compass Knee Hinge adds approximately 30 minutes to the surgical time. After the apparatus has been in place for the appropriate amount of time (6-8 weeks), it is removed either in the clinical setting, or in the one-day surgery area of UAB Highlands.
45754843|NCT00582517|Procedure|Non-invasive External Knee Brace|For Group A patients, an external knee brace (several brands available and no one brace specified for this study) will be placed on the leg following surgical repair of the knee dislocation.
45754844|NCT03155048|Drug|oral estrogen replacement therapy|oral estradiol group for endometrial preparation
45444072|NCT01204359|Radiation|Iodine 131|iodine 131，185、370、555mBq，6 months
45444073|NCT01567215|Procedure|silver nitrate|Application 1 - 2 times a week for 3 - 4 weeks
45444074|NCT01567215|Drug|Steroids|Dermovate creme group IV steroid. Application 2 times a day for 3 weeks or less if the granuloma disappears.
45444075|NCT01567215|Procedure|alcohol|Alcohol swabs 82% ethanol. Application 6 - 8 times a day, each time the parents change the diaper. Treatment for 3 weeks or less if the granuloma disappears.
45444076|NCT02871141|Procedure|electroconvulsive therapy|electroconvulsive therapy
45444077|NCT02871141|Drug|Antidepressant|Antidepressant
45444078|NCT01202487|Drug|LET - Lidocaine Epinephrine Tetracaine|One time application of 3 cc of Lidocaine Epinephrine Tetracaine Solution at least 45 minutes prior to laceration repair
45444079|NCT03882411|Behavioral|Electronic shared decision making (eSDM) tool|The web application includes depression screening, behavioral activation, and a patient preference driven treatment selection decision aid. Treatment options will include medications, cardiac rehab/exercise program, and therapy. In addition to education, providers will receive a patient preference report in real time with options for coordination of care
45444080|NCT03841461|Other|International Physical Activity Questionnaire-Short Form|IPAQ has been developed to obtain valid and comparable information about the level of physical activity based on individual reports on daily physical activity in the international arena. This form consists of 7 questions; provides information about time spent in walking, moderate and violent activities, and time spent sitting. The calculation of the total score of the short form includes total of duration and frequency whom walking, moderate activity and severe activity. The energy required for the activities is calculated by the MET-minute score.Standard MET values for these activities has been established. These; Walking = 3.3 MET;Moderate Severe Physical Activity = 4.0 MET;Severe Physical Activity = 8.0 MET;Seating = 1.5 MET.Classification is based on the numerical data obtained.Accordingly,there are 3 activity levels: Inactive,minimal active and very active.
45444081|NCT03841461|Other|The Pittsburgh Sleep Quality Index|It is a scale that provides information about the sleep quality of the individuals and the type and severity of the sleep disorder in the last month. It consists of 24 questions, 19 of which are evaluated. The PSQI consists of 1 total score and 7 sub-dimensions (subjective sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disturbance, sleep medication use, daytime dysfunction). Each item in the scale has a value between 0 (no distress) and 3 (serious distress). The sum of the scores related to the seven sub-dimensions gives the total PSQI score. The score of each sub-dimension ranges from 0 to 3. The total PSQI score ranged from 0 to 21. While the sleep quality of the patients with a total score of 5 and below is considered as 'good'; >5 refers to poor sleep quality.
45444082|NCT03841461|Other|The Fatigue Severity Scale|Each question on this scale, which is composed of Likert type questions: 1.I strongly disagree 2.I do not agree 3.No tend to disagree 4. Indefinitely. The score of the scale, which consists of 9 questions, varies between 9-63. People are asked to mark the appropriate options for each question taking into account their status in the last 1 month period.
45599519|NCT02300779|Dietary Supplement|Low-residue diet|"Subjects will be instructed by members of the research team to follow a low-residue diet for 4 days.~Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.~Fasting will be required from 2 hours after the bowel cleansing is complete. Their usual treatment for diabetes (whether insulin or an oral agent) will be adjusted."
45444083|NCT03841461|Other|General Information Form|A form, which is prepared by us, including the purpose of the study, demographic information, daily working hours and assignment durations.
45444084|NCT03852381|Device|Spinal Cord Stimulation|Paresthesia-based SCS(PB-SCS), with stimulating frequencies between 30 to 80 Hz that confer a tingling sensation. Three different paresthesia-free SCS (PF-SCS) modes that use frequencies in the range of 400-10,000 Hz include Burst, High Frequency stimulation at 1.2 kHz and High Density stimulation at 400 Hz.
45444085|NCT02696109|Behavioral|Treatment As Usual|Participants in the TAU arm will be assigned to standard care at our partnering mental health agency. These clients are free to attend one-on-one counseling or any other services available at the clinic or elsewhere to address mental health challenges.
45444086|NCT02696109|Behavioral|Cornerstone|Participants in the experimental arm will be assigned a Transition Facilitator, a clinician with whom the client will meet one-on-one, and will be asked to attend once-a-week groups with other transition age youth. The groups will focus on issues relevant to successful transition to independent adulthood including stress and anger management and healthy relationships.
45444087|NCT03292406|Drug|Placebo|Non active ingredients of CD11301
45444088|NCT03292406|Drug|CD11301 0.03%|Topical Gel
45444089|NCT03292406|Drug|CD11301 0.06%|Topical Gel
45444090|NCT01201707|Procedure|Angioplasty|In this procedure, a small catheter (tube) that is approximately the size of a piece of spaghetti is introduced into the vein that is narrowed based on the findings of the venogram. This catheter has a small balloon on it. That balloon is inflated across the narrowing within the vein with the goal of increasing the diameter of that vein and improving flow within that vein.
45444091|NCT01201707|Other|Observation|Patients in this arm will be diagnosed with CCSVI based on venography but will receive no intervention. They will be followed in the same manner as patients treated with angioplasty.
45599520|NCT02300779|Dietary Supplement|Usual care|"Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by a liquid-only diet for an additional day.~Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.~Fasting will be required from 2 hours after the bowel cleansing is complete. No modifications in their usual treatment will be made."
45599521|NCT02340195|Drug|Idalopirdine (Lu AE58054) 60 mg|encapsulated film-coated tablets for oral use once daily for 10 days
45599522|NCT02300857|Behavioral|Low carbohydrate diet|Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein
45444092|NCT01204437|Drug|Epirubicin, Cyclophosphamide|4 cycles of chemotherapy with epirubicin plus cyclophosphamide (EC) on day 1 q22
45444093|NCT01204437|Drug|Cyclophosphamide, Methotrexate, 5 FU|6 cycles CMF on days 1 and 8 q29 Cyclophosphamide (500mg/qm), Methotrexate (40 mg/qm), 5 FU (600mg/qm)
45599523|NCT02300857|Behavioral|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
45599524|NCT02300857|Behavioral|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
45599525|NCT02339961|Radiation|Ultrasound radiation|Recording Doppler ultrasound noninvasively from the right chest wall
45599526|NCT04464733|Drug|HRS9950|Group A to Group E: dose 1-dose 5, single dose Group F: dose 2, multiple doses Group C-: dose 3 food effect Group G to Group J: dose 2-dose4, multiple doses
45599527|NCT04464733|Drug|Placebo|Group A to Group J
45599528|NCT02335827|Procedure|irreversible electroporation|Percutaneous (CT-guided and/or US-guided) or open IRE with voltage in level B for renal tumors
45754845|NCT03155048|Drug|Estradiol transdermal patch|transdermal estradiol group for endometrial preparation
45754846|NCT01661647|Device|3D knee kinematic assessment under local anesthesia|3D knee kinematic assessment under local anesthesia
45934849|NCT00041210|Drug|mechlorethamine hydrochloride|
45934850|NCT00041210|Drug|prednisone|
45444094|NCT01204437|Drug|Capecitabine, Nab-Paclitaxel|6 cycles of weekly nab-paclitaxel 100 mg/m2 on days 1, 8, 15 q22 with a week of rest every 6 weeks in combination with capecitabine 2000 mg/m2, days 1 - 14 orally, divided into 2 daily doses every 3 weeks for 6 cycles
45444095|NCT01201941|Other|e-Chasqui|"The laboratory component of the PIH-EMR, termed e-Chasqui, permits web-based entry of culture and DST results at all regional and central laboratories performing these tests. In addition, the system includes applications to assess quality control, generate aggregate reports, notify health centers of new results or contaminated samples, and track enrolled patients and the status of pending laboratory tests."
45599529|NCT04465045|Procedure|Laparoscopy-hysteroscopy|Under general anesthesia, we start by a first look in laparoscopy, to look for endometriosis mainly, tubal infertility, ovarian cysts or any abnormalities that may not have been suspected on the first exam. Then we check tubal patency after a look at the uterine cavity by hysteroscopy. Then we treat everything possible to treat to improve fertility, spontaneous or with ART.
45444096|NCT02633241|Drug|Dexmedetomidine bolus and high infusion-Propofol|First, the investigators will administer dexmedetomidine 1mcg/kg over 5 minutes. Next, the investigators will begin an infusion at 1mcg/kg/hour. At the 5 minute point, propofol will be given (2-3mg/kg bolus followed by 100mcg/kg/min infusion). The attending clinician will determine whether or not the child is in an adequate state to begin the MRI scan. If the sedative effect of the dexmedetomidine-propofol does not produce a sufficiently sedated state within 10 minutes, a repeat bolus of propofol 2mg/kg will be administered. The dose of Dexmedetomidine will not be changed. The dose will be repeated if the child is not adequately sedated in 2 more minutes. At this time infusion rate of propofol will be increased to 200 mcg/kg/minute. If the child is not sedated in 5 more minutes, the outcome will be recorded as a technique failure and sedation will continue at the discretion of the anesthesiologist.
45444097|NCT02633241|Drug|Dexmedetomidine bolus and low infusion-Propofol|First, the investigators will administer dexmedetomidine 1mcg/kg over 5 minutes. Next, the investigators will begin an infusion at 0.5mcg/kg/hour. At the 5 minute point, propofol will be given (2-3mg/kg bolus followed by 100mcg/kg/min infusion). The attending clinician will determine whether or not the child is in an adequate state to begin the MRI scan. If the sedative effect of the dexmedetomidine-propofol does not produce a sufficiently sedated state within 10 minutes, a repeat bolus of propofol 2mg/kg will be administered. The dose of Dexmedetomidine will not be changed. The dose will be repeated if the child is not adequately sedated in 2 more minutes. At this time infusion rate of propofol will be increased to 200 mcg/kg/minute. If the child is not sedated in 5 more minutes, the outcome will be recorded as a technique failure and sedation will continue at the discretion of the anesthesiologist.
45444098|NCT02633241|Drug|Dexmedetomidine bolus only - Propofol|First, the investigators will begin by administering dexmedetomidine 1mcg/kg over 5 minutes. When this is completed, they will administer propofol 2-3mg/kg titrated bolus followed by 100mcg/kg/min infusion which can also be titrated up or down to a maximum of 300mcg/kg/min to keep the blood pressure and heart rate within 30% of baseline levels.
45444099|NCT03292016|Drug|APL-130277|APL-130277 sublingual thin film
45444100|NCT03292016|Drug|APO-go|Subcutaneous APO-go
45444101|NCT03292016|Drug|Apokyn|Subcutaneous APOKYN
45444102|NCT03836313|Device|iovera°|"Cryoneurolysis treatment using the iovera° device targeting the anterior femoral cutaneous nerve (AFCN) and the infrapatellar branch of the saphenous nerve (ISN) will occur approximately 4 weeks before surgery by a trained member of the study staff. Treatment will occur in clinic using suggested anatomical markings to target appropriate the AFCN and infrapatellar branch of the saphenous nerve (ISN) of the operative knee.~The iovera° device contains three 27- gauge needles, all 6.9mm in length which will indent the subjects' skin and be inserted under the subcutaneous fat about 7 mm. Lidocaine will be used for superficial anesthetic at the treatment site before the needles puncture the patient's skin.There are a total of 9 iovera° cooling cycles. Treatment will be performed unilaterally and will be guided by visualization and palpation of anatomical landmarks."
45444103|NCT05669391|Diagnostic Test|Genomic analysis of antidepressants|Genomic analysis of all antidepressants. Tris EDTA anticoagulation and salting out were used to extract DNA. OD 260/280 was between 1.6-1.8 and the concentration was greater than 50 ng/ μ L。 Using the PCR gene chip detection method and the Asian Screening Array (ASA) chip detection technology of Illumina Company (this chip is the first whole genome SNP chip designed based on the whole genome sequencing data of 9000+East Asian populations, which contains 750000 markers, with 85% of the effective loci), we can obtain the genetic information of polymorphic loci related to the individual differences of drug effects of subjects.
45444104|NCT01206075|Drug|Mozobil|Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
45444105|NCT01206075|Drug|Mozobil|Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
45444106|NCT01206075|Drug|Mozobil|Up to sixteen patients (splenectomized and non-splenectomized) who were not previously mobilized will receive Mozobil at 240µg/kg for one to three days, followed by one to three leukaphereses.
45444107|NCT03637946|Other|Device: SHOFU beautifil II LS|Restorative system FL-Bond II (self-etching adhesive system)/ beautifil II (composite restorative) were used following manufacturer's instructions
45444108|NCT05669235|Diagnostic Test|Questionnaires|A series of questionnaires will be carried out that assess both respiratory problems, depression and strength.
45652927|NCT04790747|Drug|CAR-T cells|Each subject receives sequential radiotherapy and CAR-T cells by intravenous infusion
45444109|NCT03290300|Device|Vivaer Stylus|Previous nasal obstruction treatment with the Aerin Medical Vivaer Stylus
45652928|NCT03068221|Other|anaerobic exercise|assessing anaerobic exercise status
45444110|NCT03829527|Behavioral|Psychotherapy|Psychological intervention combining a standardized treatment manual with a smartphone application
45444111|NCT03835377|Other|Iron-biofortified beans|Iron-biofortified beans (Phaseolus vulgaris L MIB465)
45444112|NCT03835377|Other|Control beans|Control beans (Phaseolus vulgaris L Jamapa variety), identical in color and size
45444113|NCT03289676|Combination Product|Storytelling Narrative Intervention|"In the first phase, three sections of a video, each for 5-7 minutes will be produced by Star story tellers who are eloquent and have authentic personal experiences of quitting smoking. Participants who receive 8-weekly 30-minute cessation counseling sessions along with NRT are randomly assigned to watch either the smoking cessation video or attention-control video of women taking about their HIV infection."
45444114|NCT03834831|Dietary Supplement|Coenzyme Q10|Coenzyme Q10
45444115|NCT03834831|Dietary Supplement|Selenium|Selenium
45444116|NCT01206153|Drug|metformin|
45444117|NCT01298271|Drug|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
45444118|NCT03840681|Other|Augmentation|non invasive technique to increase bone width and eliminate need for second surgery
45444119|NCT03536858|Behavioral|COACH (Communicating about Choices in Transplantation)|COACH is a behavioral communication intervention designed specifically for ESRD patients pursuing kidney transplantation. The COACH program consists of four modules: 1) Kidney transplant options, 2) Discussing your transplant options, 3) Requesting living donation, and 4) Maintaining positive relationships. The content and teaching strategies were guided by the concepts of social cognitive theory as well as principles of adult learning and communication skill acquisition. We believe that patients will transfer these skills to other patients at the hemodialysis clinic who are on their shift.
45444120|NCT03840759|Other|inpatient geriatric consultation team|For the intervention group, a geriatric physician was consulted and recommendations were made by the geriatric consultant after a complete CGA.
45444121|NCT05281965|Drug|Retinoic acid|Retinoic acid oral
45444122|NCT04251884|Procedure|Local anesthetic (ropivacaine)|Patients randomized in the treatment arm will receive a sonography-guided pudendal nerve block
45444123|NCT01202799|Drug|2% w/w diclofenac sodium topical gel|2% w/w diclofenac sodium topical gel
45444124|NCT01202799|Drug|1.5% w/w diclofenac sodium topical solution|1.5% w/w diclofenac sodium topical solution
45444125|NCT01202799|Drug|75 mg diclofenac sodium delayed release tablet|75 mg diclofenac sodium delayed release tablet
45444126|NCT03637868|Drug|Eribulin|Patients will receive eribulin 1.4 mg/m² administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
45444127|NCT03829605|Other|Measurement of hydrogen sulfide|Hydrogen sulfide will be measured by ELISA and correlated with nitric oxide and hyperglycemia
45444128|NCT03287804|Biological|AUTO2|"AUTO2 (APRIL CAR T Cells) Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 15 x 10⁶ to 350 x 10⁶ APRIL CAR T Cells.~Following Phase 2 dose determination patients will be treated with selected dose of APRIL CAR T Cells"
45444129|NCT03834207|Device|Use of the C3-Cloud IT system|Patients who are recruited to the intervention arm will use the C3-Cloud system during the pilot study.
45444130|NCT01298505|Drug|PF-03654764 2.5mg plus fexofenadine 60mg|PF-03654764 2.5mg plus fexofenadine 60mg twice daily for 7 days
45444131|NCT01298505|Drug|PF-03654764 5mg plus fexofenadine 60mg|PF-03654764 5mg plus fexofenadine 60mg twice daily for 7 days
45444132|NCT01298505|Drug|placebo|placebo given twice daily for 7 days
45444133|NCT01204593|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day at bedtime
45444134|NCT01204593|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: three times a day, preferably just before the meal
45444135|NCT03286400|Device|CTAG Device with ACTIVE CONTROL|Intent to treat with the CTAG Device with ACTIVE CONTROL in the treatment of aortic diseases as part of routine clinical practice.
45444136|NCT01298583|Behavioral|ankle tracking training|one group will use the ankle for tracking, the other group will use the ankle for simple movement
45444137|NCT02019303|Procedure|FNA and Core biopsy|Both procedures will be performed on the same lymph node
45444138|NCT05669469|Procedure|Bariatric surgery|1) gastric pouch creation, 2) creation of biliopancreatic limb, 3) jejunojejunostomy creation, and 4) creation of gastrojejunostomy.
45444139|NCT03310970|Drug|Lidocaine 5% patch|Each subject will wear three generic Lidocaine 5% topical patches for 12 hours.
45444140|NCT03310970|Drug|Lidocaine hydrochloride|Each subject will receive a dose of 0.5 mg/kg intravenously over a period of 5 minutes.
45444141|NCT03310970|Drug|Lidoderm 5% patch|Each subject will wear three Lidoderm® topical patches for 12 hours.
45599530|NCT04421703|Behavioral|Med-South Lifestyle Program|The Med-South Lifestyle Program is an evidence-based behavior change intervention that translates the PREDIMED (Mediterranean) dietary pattern for a Southeastern US population and includes support for increased physical activity.
45599531|NCT02300935|Drug|trametinib|
45599532|NCT02300935|Drug|nab-paclitaxel|
45599533|NCT02339805|Other|next generation sequencing|DNA from plasma, peripheral blood mononuclear cell and bone marrow will be sequenced by NGS for a panel of 34 genes.
45599534|NCT02339805|Device|Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)|tumor Assessment tool during the study
45599535|NCT02301013|Procedure|Urinary incontience surgery|Surgery for stress or mixed urinary incontience
45444142|NCT03833505|Other|Bitestrip|The parents of the patients were asked to complete a survey that included questions about the demographic data, medical history of the patient, clinical findings of E. For diagnosis of sleep bruxism, a single-use BiteStrip® device (Up2dent, Inc.), including an electromyographic electrode, small display screen and lithium cell, was used to record the increased electromyographic activity of the masticatory muscles during sleep and bruxism, other harmful oral habits, family life and habits.
45444143|NCT01298817|Dietary Supplement|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). The soy used in Medifast products is Solae SUPRO® water-washed soy protein isolate. Depending on seasonal variations, soy MR products contain approximately 1.5-3.0 milligrams of soy isoflavones for every 1 gram of soy protein. Thus, participants in the soy treatment arm will consume at least 28 g/soy protein and 42-108 mg/isoflavones per day.
45444144|NCT01298817|Dietary Supplement|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). This group will receive the non soy supplements.
45444145|NCT03828981|Procedure|fast-track recovery program|"Pre-operative: fast-track management counseling, fast-track educational video,tobacco cessation, daily physical activity, light meal 6 hours and clear liquids up to 2 hours before surgery, no bowel preparation, a warm blanket, medication.~Intra-operative: vaginal wound infiltrative anesthesia, early remove of urine catheter.~Post-operative: early oral intake liquids and food, early mobilization, avoiding opioids by use of pregabaline for postoperative pain."
45444146|NCT01312688|Other|Early Goal Directed Hemodynamic Therapy in Sepsis|Early Goal Directed Hemodynamic Therapy according to the SSC guidelines
45599536|NCT02301013|Drug|300 cc saline|
45754847|NCT03155126|Other|Fluid resuscitation|Patients in the saline group were resuscitated with saline, patients in the other group were resuscitated with acetated Ringer's sodium
45444147|NCT05275322|Behavioral|Unified Protocol|The Unified Protocol for transdiagnostic treatment of EDs (hereinafter UP) is a transdiagnostic treatment based on emotional regulation published in 2011 by David H. Barlow et al. (Barlow et al., 2011). It consists of eight treatment modules, with five of them being central (mindfulness, cognitive flexibility, countering emotional behaviors, tolerating physical sensations, and emotional exposure).
45444148|NCT01204827|Device|13C Methacetin Breath Test (BreathID)|
45444149|NCT01775709|Device|PE tube with Duckbill Valve|PE tube with Duckbill Valve
45444150|NCT03427814|Drug|pamiparib|60 mg PO BID
45444151|NCT03427814|Drug|Placebo|60 mg PO BID
45599537|NCT03511885|Other|There is no intervention|
45599538|NCT03147729|Radiation|Radiofrequency non ablation|Use of radiofrequency
45599539|NCT02301091|Procedure|TACE|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
45599540|NCT02301091|Procedure|RFA|For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
45599541|NCT02301091|Drug|pirarubicin,mitomycin and lobaplatin|They were cytotoxic drugs used in the TACE procedure.
45599542|NCT02335593|Dietary Supplement|Zinc Sulphate|Zinc Sulphate Hard Gel capsules 110mg
45444152|NCT01770717|Other|Spatial Frequency Domain Imaging|Assessment of Pressure Ulcer Formation using Spatial Frequency Domain Imaging
45599543|NCT02335593|Other|Corn Starch filled Hard Gel Capsules|Corn Starch filled Hard Gel Capsules
45599544|NCT02335593|Drug|Epoetin alfa 2000-4000 IU solution for injection|Epoetin alfa 2000-4000 IU solution for injection
45599545|NCT02335593|Drug|Iron Hydroxide Saccharate Complex Solution for injection|Iron Hydroxide Saccharate Complex Solution for injection
45599546|NCT03511807|Other|Electrical|"For the electrical stimulation:~An electrode will be inserted into the ear canal which will be stimulated."
45599547|NCT03511807|Other|Acoustic|"For the acoustic stimulation:~A typical sound will be presented for 6 minutes. Loudness is reported for 4 minutes after the stimulus offset to measure the presence and duration of the residual inhibition. If a successful acoustic stimulus is found, the subject will be given a series of sound files to listen to on a digital music player (CD or MP3 player) and will be asked to listen to each sound file (5 minute duration) and record their tinnitus loudness/annoyance during and after each sound stimulation. For some subjects, the investigators will use music on a digital music player (MP3 player) to see if music listening and music exercises will help reduce the intensity or annoyance level of the tinnitus (using the same surveys). These music-based exercises will involve training in recognition of musical intervals (e.g., octaves, fifths, and thirds)."
45599548|NCT02339727|Dietary Supplement|Preterm infants formula|The group 1 of children will receive a preterm infants formula supplemented with DHA and ARA with a relationship omega 6/omega 3 = 2/1 during the first 3 months of life. And group 2 will receive other Preterm infants formula very similar, but with a ratio of DHA and AA=1/1 also during the first 3 months of life.
45599549|NCT02335515|Device|Soctec|Gastroretentive Drug Delivery System
45599550|NCT03511651|Procedure|PEEP|Two PEEP levels will be used during mechanical ventilation.
45599551|NCT03511573|Procedure|bariatric and other laparoscopic surgery|We have obtained liver samples during laparoscopic surgical procedures in the majority of cases. The majority of laparoscopic procedures were sleeve gastrectomies performed for morbid obesity as a primary restrictive procedure; in 5 cases the liver biopsies were performed during laparoscopic cholecystectomies.
45754848|NCT00513461|Drug|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given PO
45754849|NCT00513461|Other|placebo|Given PO
45599552|NCT02339649|Procedure|Blood Sample|Blood Sample
45599553|NCT02339649|Behavioral|Neurocognitive Assessment|Neurocognitive Assessment
45599554|NCT02339649|Other|Resting State EEG|10-20 Minutes of Resting State EEG
45599555|NCT02339649|Procedure|Lumbar Puncture|Lumbar Puncture
45444153|NCT01680237|Behavioral|Cognitive behavior therapy|Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises as well as identification and correction of maladaptive thoughts about anxiety and its consequences.
45599556|NCT02339649|Other|MRI|60 Minutes MRI
45444154|NCT01680237|Behavioral|Exposure in-vivo|Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises.
45599557|NCT03511495|Diagnostic Test|Galilei Corneal Topographer|A series of five measurements via the Galilei corneal topographer of each keratoconic eye in quick succession
45599558|NCT02339337|Other|Abbreviation of treatment duration|
45599559|NCT02301247|Behavioral|Memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
45599560|NCT02301247|Behavioral|Placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
45599561|NCT02339259|Other|Observation|
45444155|NCT03840603|Diagnostic Test|Film Array RP2 Assay guided|Nasopharyngeal swab sample collected from subjects with a suspected LRTI for the Film Array RP2 assay plus a blood sample for the PCT assay.
45599562|NCT02308267|Other|Lung explants|Lung explants from end-stage CF, which were obtained for a reason independent from the study in the Paris (Prof Burgel) and Leuven (Prof Dupont) centres will be analysed for pIgR and IgA expression as well as for Pseudomonas aeruginosa colonization. Some lung explants from control patients will also be obtained from the Leuven centre.
45599563|NCT02308267|Other|Sputum, nasal fluid and serum|Sputum, nasal (fluid) and serum samples from CF patients and controls patients will be collected (Leuven, Paris, Torino, Verona and Saint-Luc Brussels) for S-IgA and microbiological assays. Spontaneous sputum will be collected, while nasal fluid will be sampled through nasal lavage. Control subjects will consist of COPD patients and healthy subjects (smokers or not).
45599564|NCT02308267|Procedure|Bronchoscopy|Endobronchial biopsies (EBB) and broncho-alveolar lavage (BAL) will be sampled at the KULeuven centre (Prof Dupont) in some CF patients (homozygous for the DF508 mutation) and colonized or not with Pseudomonas aeruginosa and who must have a general anaesthesia for a reason independent from the study. In these patients, a bronchial endoscopy will be performed during narcosis to take EBB (n=8) and BAL (2x50mL). If possible, nasal and rectal biopsies will also be performed in some patients. Samples will be assessed for pIgR and IgA expression and for primary broncho-epithelial cultures (carried out at the UCL centre, Pr Pilette). Control subjects will be patients without CF and without evidence of lung disease and who are undergoing narcosis for an independent reason at the KULeuven centre.
45599565|NCT03105219|Drug|Ivabradine|Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.
45599566|NCT03105219|Other|Sham Comparator|Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).
45599567|NCT02308345|Other|Pre-chemotherapy visit summary Video|
45444156|NCT05663541|Diagnostic Test|Lower extremity position test|Assessing proprioception of the lower extremity of individuals multiple sclerosis
45444157|NCT03832959|Device|EnsoETM|The EnsoETM is a device with a esophageal probe that can provide temperature adjustment
45444158|NCT01206543|Other|Intraoperative imaging using 1.5T MRI|Intraoperative imaging and determination of degree of resection / complete tumor removal
45444159|NCT05281419|Other|Intralesional triamcinolone injection|Injecting 40mg triamcinolone into the abscess cavity through the aspiration needle or drainage tube every 1 week
45599568|NCT03105141|Device|Remote ischemic conditioning|"Remote ischemic conditioning is composed of 5 cycles of 5-min bilateral upper limb ischemia intervened by 5-min reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to a given pressure followed by deflation, twice daily for 12 months.~Two different magnitude of limb ischemia pressure will be set: 200 mmHg and 40 mmHg above systolic pressure (60 patients for each).~Optimal inflating pressure will be determined based on the results."
45754850|NCT00513461|Other|laboratory biomarker analysis|Correlative studies
45444160|NCT05281419|Other|No intralesional triamcinolone injection|No intralesional triamcinolone injection
45444161|NCT01485471|Device|Diffuse optical spectroscopy imaging|ear exam imaging
45444162|NCT03285308|Drug|Placebo|Placebo injected subcutaneously twice daily.
45754851|NCT00513461|Other|immunoenzyme technique|Correlative studies
45754852|NCT00513461|Other|high performance liquid chromatography|Correlative studies
45934851|NCT00041210|Drug|vinblastine sulfate|
45599569|NCT03105141|Device|Remote ischemic conditioning|"Remote ischemic conditioning is composed of a given cycle of 5-min bilateral upper limb ischemia intervened by 5-min reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, twice daily for 12 months.~The number of cycles of limb ischemia will be set as: 4, 5 and 6 (60 patients for each).~Optimal cycles for application will be determined based on the results."
45599570|NCT03105141|Device|Remote ischemic conditioning|"Remote ischemic conditioning is composed of 5 cycles of a given duration of bilateral upper limb ischemia intervened by reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, twice daily for 12 months.~The duration of each cycle for limb ischemia will be set as: 4, 5 and 6-min (60 patients for each).~Ischemia duration algorithm will be determined based on the results."
45599571|NCT03105141|Device|Remote ischemic conditioning|"Remote ischemic conditioning is composed of 5 cycles of 5-min bilateral upper limb ischemia intervened by reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, once or twice daily for 12 months.~The method for application will be set as: once daily for 12 months and twice daily for 12 months (60 patients for each)."
45599572|NCT02308423|Radiation|XR of shoulder|Radiologic examination: Axial view, Axillary view and Anterior posterior view- to evaluate the level of osteoarthritis by Kellgren Lawrence score and Samilson score.
45599573|NCT03506659|Device|SUDO-SCAN Device|Sudo-scan is a machine with 2 palets for hands and 2 palets for foots. The patient has to put his 2 hands and 2 foots on the machine. The machine do the measures during 2 minutes.
45599574|NCT03105453|Other|3 Sampling points|When entering the in-vitro fertilization/intracytoplasmatic sperm injection 4 samples will be harvested: a rectal swab, a cervical swab, a vaginal swab and an intra-uterine sample using an empty embryo catheter. After the ovarian stimulation treatment, the same patients will be sampled two more times: once at the moment of oocyte retrieval (rectal, cervical, vaginal and intra-uterine samples) and again just before the embryo transfer (at this stage, the embryo culture medium will be harvested, as well as an intra-uterine sample using the tip of an empty embryo inner catheter before the embryo transfer and a rectal sample)
45599575|NCT02339493|Other|Computer Electronic Alert|A computer program that will issue an on-screen electronic alert notifying the responsible provider that his or her patient is high-risk for stroke due to AF or atrial flutter and that the patient is not ordered to receive anticoagulant therapy. The alert will provide options for anticoagulation for stroke prevention in AF as well as additional information in the form of suggested reading.
45599576|NCT02339103|Other|Warmed IV fluids|1 Liter of warmed IV fluids at 42 degrees celsius
45599577|NCT02339103|Other|Warmed perfusion pads|Neoprene perfusion pads placed on the palms and soles to rewarm through focusing on the arteriovenous anastomoses
45599578|NCT03512587|Procedure|Personalized quantum sonotherapy|Quantum sonotherapy is an alternative non-pharmacological treatment that effects a molecular reorganization that occurs after the sound stimulus. The audible words and their waves have the ability to generate vibrations and stimulate the psycho-neuro-endocrine chain, independent of the semantic meaning of the words. It is an alternative therapy that uses non-musical sound waves.
45599579|NCT03512587|Procedure|Placebo|Headphones will be place in patients without playing quantum sonotherapy
45599580|NCT03506503|Procedure|Nanofat grafting|hair loss area will be treated by processed autologous Nanofat grafting
45599581|NCT02308813|Other|Braking and functionality|
45599582|NCT02332317|Behavioral|Palliative rehabilitation|12-week individually customized, specialized palliative rehabilitation program
45599583|NCT02308891|Drug|lactated Ringer's solution (vigorous hydration arm)|"Initial bolus of lactated Ringer's solution at 10mL/kg over 1 hour prior to ERCP~Intravenous lactated Ringer's solution at a rate of 3mL/kg/h during the procedure and continued for 8 hours.~At the end of ERCP, post-procedure bolus of lactated Ringer's solution at 10mL/Kg over 1hour"
45754853|NCT00627367|Drug|Hydromorphone|Hydromorphone 1mg IV, followed by an optional dose of 1mg IV hydromorphone 15 minutes
45754854|NCT00627367|Drug|Nonprotocolized|An IV opioid the type and dose of which will be determined by the treating clinician
45754855|NCT01670864|Behavioral|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above messages. A special designed health education card, based on the health education model, will be also provided to the participants. Additional telephone follow-up counseling (reminder) at 1-week & 1-month will be made to the participants in this group.
45754856|NCT01670864|Behavioral|SMS intervention group|The text messages are divided into two groups which target to smokers who are ready to quit and those who are not ready to quit. For smokers who are ready to quit, messages would be focused on practical advice and emotional support. For smokers who are not ready to quit, messages would be focused on motivating the smokers to have quit attempt.
45754857|NCT04387981|Drug|[14C]-orvepitant|Oral solution of [14C]-orvepitant
45444163|NCT03285308|Drug|Relamorelin|Relamorelin 10 micrograms (μg) injected subcutaneously twice daily.
45444164|NCT01298973|Drug|Viscoat|One group will receive Viscoat for incision closure
45444165|NCT01298973|Drug|Saline|One group will receive Saline to irrigate the wound
45444166|NCT03831867|Other|Pilates|The intervention program consisted in the realization of exercises of the Pilates Method. The duration of the program was 32 weeks, with a frequency of two weekly sessions and a duration per intervention of 10 minutes. During this time the experimental group developed the intervention program with the Pilates Method.
45444167|NCT03831399|Dietary Supplement|Leucine|Administration 6 g/day of leucine at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks
45444168|NCT03831399|Dietary Supplement|Placebo|Administration 6 g/day of lactose at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks
45444169|NCT01206699|Drug|corticoid (altim® 1.5 ml)|Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)
45444170|NCT01206699|Drug|physiological solution (1.5 ml)|Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)
45444171|NCT04427072|Drug|Capmatinib|400mg of capmatinib tablets administered orally twice daily
45444172|NCT04427072|Drug|Docetaxel|Docetaxel 75 mg/m2 by intravenous infusion every 21 days
45599584|NCT02308891|Drug|lactated Ringer's solution (standard hydration arm)|- Patients will receive lactated Ringer's solution at the start of the ERCP and the fluids will be administered at a rate of 1.5ml/kg/h during the procedure and for 8hours after ERCP.
45444173|NCT03537651|Drug|TEZ/IVA|Fixed-dose combination tablet for oral administration.
45444174|NCT03537651|Drug|IVA|Tablet for oral administration.
45599585|NCT02308891|Device|endoscopic retrograde cholangiopancreatography (ERCP)|endoscopic retrograde cholangiopancreatography
45599586|NCT02332083|Device|SR-WBV|Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
45599587|NCT02332083|Device|Exergame|Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
45599588|NCT02332083|Other|SR-WBV|Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1
45599589|NCT02332083|Device|Aktiv Tramp|Participants will undergo a training program set from the 5 to 8 week, three times a week over 4 minutes.
45444175|NCT03525327|Other|Line Dance Class|"Line or party dances to be taught will include:~Electric Slide (Mainland USA)Hukilau (Hawaii)Cupid Shuffle (Mainland USA)Poco Poco (Philippines)Cha Cha Slide (Mainland USA)Tush Push (Mainland USA)Trojan Crawl (Mainland USA)Wobble (Mainland USA)Goyang Maumere (Indonesia)"
45599590|NCT02308969|Drug|LSD|100ug per os, single dose
45599591|NCT02308969|Drug|Placebo|Capsules containing mannitol looking identical to LSD
45599592|NCT02338947|Procedure|Off-pump coronary-artery bypass grafting|Surgical access to the heart will be gained through a median sternotomy in all of the patients. In order to reduce the risk of bleeding and transfusions, an absorbable hemostat will be used in the sternal bone marrow. An automatic autotransfusion system will be used to recovery of red blood cells in all patients. Off-pump surgery will be performed with the use of heart stabilizers. Patients will be heparinized with 250 IU/kg intravenously to achieve activated clotting time >200s. The proximal anastomosis will be performed according to our guidelines. The distal anastomosis will be constructed with the help of mechanical stabilizers and cardiac positioner. Intracoronary shunts will be used routinely.
45754858|NCT03154892|Procedure|Intracameral injection|Intracameral Conbercept injection for the treatment of NVG
45754859|NCT03154892|Procedure|Intravitreal injection|Intravitreal Conbercept injection for the treatment of NVG
45934852|NCT00041210|Drug|vincristine sulfate|
45444176|NCT03523923|Behavioral|Collaborative Care|"Up to 12 phone sessions over 16 weeks from Collaborative Care Manager (CCM).~Session 1: Establish rapport, perform structured clinical assessment explain the rationale and parameters of the intervention, provide brief education on pain and together with the participant create an overall treatment plan and detailed follow-up plan.~Sessions 2-12 Components:~Care Management Weekly monitoring of response to treatment using standardized measures.~Collaborative Medical Management: Optimized management of problem areas. Medication recommendations will follow evidence-based treatment algorithms with consultation of supervisors.~Psychosocial Treatment: Evidence based, focus on pain self-management skills/education, initially on foundational skills including: (1) pain education; (2) relaxation skills training; (3) behavioral activation and goal setting; 4) importance of physical activity and (5) motivational interviewing to promote adherence to healthcare and goals."
45444177|NCT01299051|Behavioral|Steps to Health|"Steps to Health (STH): The STH curriculum is a 12-month educational program targeting obese employees for healthy lifestyle changes for weight loss. The program includes:~Face-to-face visit with counselor during Month 1 to set specific health goals.~Telephone counseling at 6 and 12 months, coupled with biometric feedback sessions.~Monthly generic health education materials sent via e-mail.~Incentives (up to 1,000 STH dollars [$100]) to take part in the program assessments."
45444178|NCT01299051|Behavioral|Steps to Health Plus!|"The STH+ intervention is an intensive 12-month behavioral intervention targeting obese employees. It is stage-based and works with the participant at his/her level of readiness to change using counseling based on motivational interviewing. STH+ includes:~Face-to-face visit with counselor at Month 1~Meeting with exercise physiologist in Month 2~Monthly counseling sessions (in-person in Months 3, 6, 9 and 12, others via telephone)~Meeting with exercise physiologist during Month 5~Quarterly biometric feedback (Months 3, 6, 9, and 12)~Incentives (up to 1,000 STH dollars [$100]) to take part in the program assessments."
45444179|NCT01206855|Device|MIST Therapy|Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
45444180|NCT01206855|Other|Standard Postoperative Incision Care|Incision cleansing, topical creams, and dressing as needed
45444181|NCT01203111|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day in the evening at bedtime
45444182|NCT01203111|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day, 0 to 15 minutes before the main meal
45444183|NCT02722941|Drug|Panobinostat|Maintenance therapy dosing as outlined in Cohorts A and B.
45444184|NCT03420339|Drug|Stimulant|The stimulants used must meet FDA dosage guidelines for age.
45444185|NCT01297179|Drug|Mirabegron|Oral
45444186|NCT01297179|Drug|Minidril|Oral
45444187|NCT01297179|Drug|Placebo|Oral
45452105|NCT01097213|Drug|Ethanol|Intravenous infusion of 6% ethanol in half-normal saline for approximately 1 hour: The dosage is controlled by a physiologically-based pharmacokinetic (PBPK) model of alcohol distribution and elimination, developed by O'Connor and his associates at the Indiana Alcohol Research Center (IARC) (Ramchandani et al, 1999). PBPK Parameters that determine the dosage and frequency of the infusion for a specific individual are estimated by means of morphometric variables (age, height, weight and gender).
45452106|NCT01097213|Drug|Placebo - half-normal saline|Intravenous infusion of half-normal saline for approximately 1 hour: The dosage is equal to the infusion dosage estimated by the PBPK model of alcohol distribution and elimination (Ramchandani et al., 1999) for the drug - ethanol condition.
45452107|NCT01093079|Procedure|Laparoscopic partial nephrectomy|Laparoscopic partial nephrectomy
45452108|NCT01093079|Procedure|Open partial nephrectomy|Open partial nephrectomy
45452109|NCT00154102|Drug|Cetuximab|Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Number of Cycles: until progression or unacceptable toxicity develops
45599593|NCT02338947|Procedure|On-pump coronary-artery bypass grafting|Surgical access to the heart will be gained through a median sternotomy in all of the patients. On-pump surgery will be performed in normothermia, with the use of aortic cross-clamping and cold cardioplegic arrest. Patients will be heparinized with 500 IU/kg to achieve an activated clotting time >480 s. Heparin will be neutralized with 1:1 protamine sulfate. The automatic autotransfusion system will be used just in massive blood loss to recovery the red blood cells. Surgical techniques will be performed according to our guidelines.
45599594|NCT02309203|Device|FRED|Flow Re-Direction Endoluminal Device
45599595|NCT02309281|Drug|aflibercept 2mg|Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
45599596|NCT02335281|Procedure|FMT|Standardized FMT once
45599597|NCT02335281|Drug|Mesalazine|2g Po perday
45599598|NCT02309437|Drug|Oxycodone|Use oxycodone to treat patients with mild pain caused by radiation mucositis.
45599599|NCT02309437|Drug|Oxycodone|Use oxycodone to treat patients with moderate/severe pain caused by radiation mucositis.
45599600|NCT02335359|Drug|tranexamic acid diluted in 100 ml of saline solution (loading dose)|
45444188|NCT03830775|Procedure|Platelet-rich plasma (PRP)|"PRP is obtained from obtaining an autologous blood sample, which is then condensed in a small commercial centrifuge to isolate a concentrated sample of platelets and growth factors. This sample contains high concentrations of Platelet-derived growth factors (PDGF), transforming growth factors β (TGFβ), insulin-like growth factor-1 (IGF1), and vascular endothelial growth factor-1 (VEGF) all of which aid in healing of soft tissues. (Padilla) The blood sample is autologous, the concentration is prepared in the clinic, and the complications of the injection are no greater than any other injection given in the clinic.~All patients will have a blood sample prepared for PRP. The patient will then be blinded and half will randomly be assigned to PRP injection (2cc) and half will be randomly assigned to placebo (2cc of 0.9% sterile saline)"
45444189|NCT01207089|Drug|AZD8329|AZD8329 Oral Solution 20mg/ml
45444190|NCT01207089|Drug|Placebo|Placebo AZD8329 Oral Solution
45599601|NCT02335359|Drug|tranexamic acid undiluted (continous infusion)|
45599602|NCT02335359|Drug|Placebo|Saline
45599603|NCT02338869|Behavioral|Dialogue-based psychosocial rehabilitation|
45599604|NCT02338791|Device|Manual Mobilization|Stabilization of the glenoid fossa with movement of the humerus using varying degrees of force as applied by a physical therapist. Subject is positioned with the shoulder in 55 degrees of abduction and 30 degrees of horizontal adduction. Manual force is applied by a physical therapist on the proximal humeral head moving the humeral head posterior, inferior or lateral (distraction). An ultrasound transducer placed over the anterior shoulder joint provides imaging of the humeral head and the glenoid fossa. This manual intervention is repeated three times in each direction on each arm.
45599605|NCT03511261|Drug|10% Curcumin mucoadhesive gel|Group 1 10%of mucoadhesive gel for topical application two times per day.
45599606|NCT03511261|Drug|Curcumin capsules 500mg|Group 2 curcumin 500 mg capsules for oral intake two times per day
45599607|NCT03511261|Drug|5% curcumin mucoadhesive gel + Curcumin capsules 250 mg|Group 3 5% curcumin mucoadhesive gel topical application two times per day + curcumin 250 mg capsules for oral intake two times per day
45599608|NCT03511261|Drug|Placebo capsule|Group 4 placebo capsules for oral intake two times per day
45934853|NCT00041210|Radiation|radiation therapy|
45934854|NCT00209872|Drug|Gabapentin|
45444191|NCT01205139|Drug|TMC435|150 mg capsule once daily for 7 days
45444192|NCT01205139|Drug|TDF|300 mg tablet once daily for 7 days
45444193|NCT01205139|Drug|TMC435 + TDF|150 mg TMC435 capsule + 300 mg TDF tablet, once daily for 7 days
45444194|NCT01205139|Drug|TMC435 + TMC278|150 mg TMC435 capsule + 25 mg TMC278 tablet, once daily for 11 days
45444195|NCT01205139|Drug|TMC278|25 mg tablet once daily for 11 days
45444196|NCT01205139|Drug|TMC435|150 mg capsule once daily for 11 days
45444197|NCT01205217|Drug|Lapatinib|Lapatinib 1000 mg orally once daily continuously
45444198|NCT01205217|Drug|Trastuzumab|Part II (Week 13-24) Trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV Day 1 of each week
45444199|NCT01205217|Drug|Epirubicin|Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days
45444200|NCT01205217|Drug|Cyclophosphamide|Part I (Week 1-12) Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days
45444201|NCT01205217|Drug|Paclitaxel|Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week
45934855|NCT00209872|Drug|Lidocaine|
45444202|NCT01203267|Drug|Paclitaxel, Carboplatin|Paclitaxel 80 mg/m2, carboplatin AUC of 2 mg/min/ml, given on days 1, 8 and 15 of a 28-day cycle.
45444203|NCT01299363|Behavioral|Dilator use|Women randomized to vaginal dilators will be given instructions to perform exercises with vaginal dilators from postoperative weeks 4 to 8
45444204|NCT01205295|Other|Cognitive behavioural therapy|Cognitive behavioural therapy Psychologist Preoperative Efficacy of treatment
45444205|NCT03826953|Other|Nurse Led Allergy Clinic|Project to investigate if it is feasible to establish a nurse-led primary care-based allergy clinic intervention in NHS Lothian, and to understand the acceptability and estimate the impact of this service on improving access and outcomes in patients with allergic conditions.WE will undertake a mixed-methods longitudinal evaluation of the community-based nurse-led allergy clinic.
45599609|NCT04125069|Procedure|Coronary Artery Bypass Graft (CABG)|Mitochondrial function will be studied on cardiac tissue collected intraoperatively at the time of placement of the ECC cannulas by the surgeon. Fragments from auricle dissection of the right atrium of the patient will be requalified as sample residues, and will be used immediately by the surgeon to measure mitochondrial respiration (measurement of oxygen consumption by oxygenation and permeability test of the external mitochondrial membrane by the addition of cytochrome C in the oxygen chamber).
45599610|NCT03509701|Diagnostic Test|VZV-specific antibody response from blood|Check VZV-specific antibody response, VZV specific T-cell mediated immune response by IFN-γ ELISPOT assay from blood, and real-time PCR results from saliva
45599611|NCT03933735|Drug|TNB-383B|Intravenous (IV) Injection
45599612|NCT03511183|Drug|XELIRI + bevacizumab|Irinotecan，200mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle
45599613|NCT03511183|Drug|XELOX + bevacizumab|Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle
45599614|NCT03922035|Other|Best Practice|Receive standard peri-/post-transplant supportive care
45599615|NCT03922035|Drug|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
45599616|NCT02303587|Drug|methylprednisolone|
45599617|NCT03916419|Device|ViewRay MR-Linear Accelerator|-Radiation will be delivered by this machine
45599618|NCT03916419|Radiation|Radiation therapy|-60Gy in 15 fractions
45599619|NCT03916419|Drug|Paclitaxel|-50 mg/m^2 intravenous
45444206|NCT05666427|Behavioral|Pelvic floor muscle training combined with stabilization exercises|While people are doing stabilization exercises, they will also work the pelvic floor muscles. Practices will be combined with breathing.
45444207|NCT05666427|Behavioral|Pelvic floor muscle training|Exercises that activate the pelvic floor muscles to strengthen and increase endurance.
45444208|NCT01299441|Device|ECOM ETT|Intubation with ECOM endotracheal tube (ETT)
45444209|NCT01299519|Behavioral|Weight Maintenance|Subjects in the weight maintenance arm will maintain a steady body weight (plus or minus 2% of initial body weight) for six months.
45444210|NCT01299519|Behavioral|Weight Loss|Half of the subjects in the weight loss arm will lose 5% of their weight through a low-calorie diet, and half will also lose 10% and 15% body weight.
45444211|NCT01207245|Other|Tobramycin time of administration|Random allocation to time of day of administration of tobramycin
45444212|NCT01297413|Biological|Allogeneic adult mesenchymal bone marrow stem cells|Patients will receive intravenously one dose of 0.5-1.5 million cells per kg of allogeneic adult mesenchymal bone marrow stem cells
45444213|NCT01297569|Drug|Ranibizumab|
45444214|NCT01203345|Drug|IVIG|The infants received their first dose of study drug within 24 hours of randomization.
45444215|NCT01203345|Drug|Placebo|An equal volume of 5 percent albumin solution
45444216|NCT01299597|Drug|Atorvastatin|20mg single dose given alone and coadministered with SB649868 on day 8 and 12 of the 14-day repeat dose period.
45444217|NCT01299597|Drug|Simvastatin|10mg single dose given alone and coadministered with SB649868 on day 12 and 14 of the 14-day repeat dose period.
45444218|NCT01299597|Drug|SB649868|20mg daily given for 14 days.
45911002|NCT02002169|Other|Shower Technique Protocol|Video and educational pamphlets of the STP will be used to assist in training participants randomized to this intervention. The participant must successfully demonstrate the STP on a training mannequin and be deemed by the study coordinator as ready to independently and correctly perform it before proceeding.
45444219|NCT03723915|Biological|Pembrolizumab|Given IV
45444220|NCT03723915|Biological|Wild-type Reovirus|Given pelareorep IV
45599620|NCT03916419|Drug|Carboplatin AUC|-2 mg/mL/min intravenous over 30 minutes
45599621|NCT03916419|Biological|Durvalumab|-10 mg/kg
45599622|NCT02301325|Behavioral|Smoking research cigarettes with or without NRT|
45599623|NCT02303665|Other|The dual therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
45444221|NCT01205373|Drug|BI 671800|High dose oral drinking solution
45444222|NCT01207323|Drug|MEHD7945A|MEHD7945A will be administered as specified in the individual arms.
45444223|NCT01205607|Device|ITPR -5 mm Hg then -9 mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 & -9 mm Hg
45599624|NCT02303665|Other|The triple therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
45444224|NCT01205607|Device|ITPR -9 & then -5mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 & -9 mm Hg
45444225|NCT05662293|Other|Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part)|Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part). The assessment will be done via mail, letter or phone
45599625|NCT03914703|Procedure|EZ Pass Suture Passer|Instruments used to help with rotator cuff or ACL repair
45934856|NCT00209872|Drug|S-ketamine|
45934857|NCT00209872|Procedure|Epidural analgesia|
45599626|NCT02301481|Radiation|SIB-IMRT|45.1Gy and 40.04Gy in 22 fractions using intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) to primary tumor
45599627|NCT02301481|Drug|S-1|40mg/m2, orally twice daily every weekday concurrently with radiotherapy treatment
45599628|NCT02301481|Procedure|Surgery|Surgery, preferred D2 lymphadenectomy
45599629|NCT02301481|Drug|SOX|SOX (S-1: 40~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
45444226|NCT05662293|Other|Data collection: Quality of Life (QoL) Questionnaire (prospective part)|"Data collection: Quality of Life (QoL) Questionnaire (prospective part). The questionnaire EQ-5D-5L questionnaire will be used to assess quality of life."
45444227|NCT05662293|Other|Data collection (retrospective study)|Anonymized search and review of patients electronic health records of the University Hospital of Basel for patients with a reduced LVEF and a concomitant (±1year or after any observation of a reduced LVEF in imaging) diagnosis of arrhythmia known to be causing AiCM.
45599630|NCT03901053|Device|Reaktiv AFO|This device is a carbon fiber ankle foot orthosis (brace) that contacts the foot and lower leg. It consists of a foot plate that is designed to protect the foot, a carbon fiber strut on the back that stores and returns energy, and a cuff that goes below the knee. It has a custom geometry and alignment that is specific to the individual.
45599631|NCT03901053|Device|PhatBrace AFO|Although lighter and thinner than the Reaktiv it has a similar overall design. The posterior strut is typically longer and the footplate is thinner, more compliant and less customized. Further, the device is formed into a single piece.
45599632|NCT02301559|Behavioral|Pilates exercises|Pilates exercises with emphasis on pelvic region
45599633|NCT03107871|Drug|Valganciclovir|Valganciclovir is supplied as a powder for reconstitution into an oral solution. The reconstituted solution formulation comprises the following excipients: Povidone K30, fumaric acid, sodium benzoate, saccharin sodium, mannitol, flavor, and purified water.
45599634|NCT03107871|Drug|Simple Syrup|Simple Syrup contains sucrose 85% weight by volume, purified water, and methyl paraben as a preservative along with natural preservatives. It will be flavored to match the flavor of valganciclovir.
45599635|NCT02301637|Device|Eeva™ Test|The Eeva System is indicated to provide adjunctive information on events occurring during the first two days of development that may predict further development to the blastocyst stage on Day 5 of development. This adjunctive information aids in the selection of embryo(s) for transfer on Day 3 when, following morphological assessment on Day 3, there are multiple embryos deemed suitable for transfer or freezing.
45599636|NCT03506035|Diagnostic Test|Research new biomarker for RA|Analyze T and B cell response against new citrullinated peptides
45599637|NCT02309749|Other|CAP|
45599638|NCT03509623|Diagnostic Test|Blood sampling through direct peripheral venous puncture|Fasting blood samples will be collected 10-15 minutes before the first intravitreal injection of aflibercept and at 7 and 30 days post-injection using a 19-gauge needle under minimum stasis. Blood coagulation parameters will be evaluated.
45599639|NCT03064113|Drug|Placebo|
45599640|NCT03064113|Drug|TD-4208 700 μg|
45444228|NCT05662293|Other|Data collection (prospective study database)|Data collection on alcohol consumption, family history, rhythm disorder, hospitalizations, cardiac assessments, adverse events at baseline, 6 months, 1 year, 2 years and 5 years.
45444229|NCT01297647|Procedure|urodynamic examination|"Standard urodynamic investigation according to the ICS standard, Good urodynamic practice.Following insertion of 8 F transurethral catheter, retrograde filling of the bladder (20 mL/min) with body warm saline.~Current recording of pabd. , pves and pdet., subsequently pressure flow study. Additionally imaging with fluoroscopy to detect possible vesico ureteral renal reflux."
45444230|NCT03840057|Drug|Azithromycin Injection|Azithromycin, a semi-synthetic macrolide antibiotic derived from erythromycin. The role of azithromycin as a prokinetic agent was first reported in a retrospective cohort study, which showed azithromycin to be equivalent to erythromycin in accelerating gastric emptying in patients with gastroparesis. The aim of this intervention arm is to evaluate the effectiveness of azithromycin as a prokinetic agent in the management of UGIB.
45444231|NCT03840057|Drug|Metoclopramide Injectable Solution|Metoclopramide, a 5-HT4 agonist and a dopamine D2-receptor antagonist, is approved for short-term treatment of gastroparesis. The use of metoclopramide as a prokinetic agent in the setting of UGIB has been previously studied, but the number of subject involved was too low to adequately power the studies. The aim of this intervention arm is to further evaluate the effectiveness of metoclopramide as a prokinetic agent in the management of UGIB.
45444232|NCT03840057|Drug|Sodium chloride 0.9%|Normal saline is used as a placebo control.
45599641|NCT03064113|Drug|TD-4208 350 μg|
45599642|NCT03064113|Drug|Ipratropium 500 μg|
45599643|NCT04464109|Procedure|Evisceration with orbital implantation|Evisceration will be performed. Alloplastic orbital implant will be inserted either posterior to the sclera or partly within the scleral canal.
45599644|NCT02309827|Drug|PF-06651600 or Placebo|PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.
45599645|NCT02301715|Drug|Oxytocin|OT spray will be performed by the research pharmacy at the University Regional Hospital Pharmacy of Besançon. The placebo contained all inactive ingredients except for the neuropeptide. Placebo and OT spray containers will be prepared to look identical and will be counterbalance to be randomly assigned by the pharmacy as well. Double blinding and randomization of patients in the two groups will also be carried out by the pharmacy service. Researchers, as well as participants, will be blinded to the content of the spray. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
45599646|NCT02301715|Drug|Placebo|The placebo contained all inactive ingredients except for the neuropeptide. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
45934858|NCT00073125|Drug|ABT-510/Thrombospondin-1 mimetic|
45599647|NCT02301871|Device|Dr. Gene's Health and Wellness|The device is used to perfom deep neck flexors muscles traning. These low load craniocervical flexion exercise are even in early stages of rehabilitation when pain or pathology might preclude high load exercises and thus gradually reduces the symptoms.
45754860|NCT00559013|Device|Staple line reinforcement|Placement of reinforcement material on circular anastomotic staple line for prevention of leak during and post surgery.
45599648|NCT02301871|Procedure|Muscle Energy Technique|MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.
45599649|NCT02301871|Procedure|Static stretching and Cervical non thrust manipulation|conventional treatment for 5 days per week for 2 weeks such as MHP (Moist Heat Pack) for 20 minutes, Static Stretching exercises for upper trapezius, levator scapulae and scalene muscle which is held for 10-30 seconds- repeated 3-5 times, Cervical spine non-thrust mobilization (Grade 3) was given to each segment from C2-C7 was oscillated for 10 repetitions, followed by a 10 seconds rest between segments, Cervical spine active ROM (Range of Motion) exercises with 10 repetitions- 2-3 times a day and Postural exercises were given as home programme.
45599650|NCT03053037|Procedure|final apical size instrumentation|root canal instrumentation to two different final preparation sizes
45599651|NCT03509545|Drug|CHF Patients: ER Torsemide 40 mg|ER Torsemide 40mg given once daily to CHF patients
45599652|NCT03509545|Drug|CHF Patients: Furosemide 40 mg|Stable CHF patients taking twice-daily 40 mg Furosemide
45599653|NCT03037671|Device|Continuous Glucose Monitor (CGM)|Participants will wear the continuous glucose monitor (GCM) device during the peri-HSCT period for the duration of their initial hospital admission. No intervention based on results.
45444233|NCT05623917|Behavioral|Tele-supervised diaphragmatic respiratory exercise|the group will contain 20 females. the females will receive tele-supervised Diaphragmatic Respiratory Exercise ( applied at the homes of the females two times per the day, at the morning and at the evening, twenty minutes for every time, the sessions will be applied daily for 3 months in all females).
45599654|NCT02301949|Drug|Thalidomide|Patients are randomly assigned to receive a second course of four-month treatment of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China). Medications are taken orally 25mg four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
45599655|NCT02301949|Other|Placebo|Patients are randomly assigned to receive placebo tablets (Pharmaceutical Co., Ltd. of ChangZhou, China) four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
45599656|NCT02338557|Device|motor relearning programme|MRP exercises for training of Wrist Extensors, Extension of wrist and holding objects, training of supination of forearm, opposition of thumb, cupping of hand and training of manipulation of the objects
45599657|NCT02338557|Device|MIRROR THERAPY|Mirror therapy in which patient was seated close to the table in front of mirror (35x35 cm). The involved hand was placed behind the mirror. : the practice consisted of intransitive exercises as Hand opening, Wrist extension and flexion, Forearm pronation and supination, Hand sliding on a flat surface. During the session patient were asked to try to do the same movement with the paretic hand while they were moving the non-paretic hand.In both the groups total treatment was given for 1 hour/day for 6 days/week
45444234|NCT01297725|Procedure|Blunt right, sharp left|Blunt fascial entry on the right side of the midline and sharp fascial entry on the left side of the midline.
45599658|NCT03510949|Device|Nasopharyngeal airway or laryngeal mask airway|Comparing the incidence of postoperative soar throat with the use of nasopharyngeal airway versus laryngeal mask airway
45599659|NCT02335203|Drug|Depot medroxyprogesterone acetate|One injection intragluteally of 400mg depot medroxyprogesterone acetate at the time of the patient's first visit with the Program in Womens' Oncology
45444235|NCT01297725|Procedure|Blunt left, sharp right|Blunt fascial entry on the left side of the midline and sharp fascial entry on the right side of the midline.
45444236|NCT01205841|Procedure|Ottawa Ankle and Foot Rules|As previously published
45444237|NCT01205841|Procedure|Buffalo Rule|As previously published
45599660|NCT02335203|Other|Placebo|One injection intragluteally of 1mL Normal Saline (0.9% Sodium Chloride) at the time of the patient's first visit with the Program in Womens' Oncology
45599661|NCT05159401|Procedure|prevention of respiratory failure|Positive dynamics during CT or X-ray examinations in the form of reduction of hypoventilation zones, straightening of lung tissue
45599662|NCT02335047|Other|Impaired passivity test|Description of the test: the subject lies in the supine position on an exercise mat with his/her feet together. The subject is told to let his/her arms rest loosely by his/her side (as if they were ropes) and to keep the head aligned with the back. The examiner pulls the subject into the sitting position by pulling on the subject's wrists, with passive flexion of the trunk until the hip joint is fully flexed..
45599663|NCT02303899|Drug|Gemcitabine|infusion drug
45599664|NCT02303899|Drug|Imatinib mesylate|oral drug
45599665|NCT02338635|Drug|Ursodeoxycholic Acid|Inhibition of ER stress (Ursodeoxycholic Acid)
45599666|NCT02334891|Other|Standard|Standard management
45599667|NCT03510871|Drug|nivolumab, ipilimumab|All enrolled subjects will receive nivolumab 3 mg/kg plus ipilimumab 1 mg/kg intravenously on day 1 of each cycle (every 3 weeks). Tumor assessment will be done after 6 weeks (2 cycles) and 12 weeks (4 cycles).
45599668|NCT02331771|Drug|Donepezil|Donepezil 5 mg once daily 2 days before ECT and continuing through the last ECT procedure.
45599669|NCT02331771|Drug|Placebo|Placebo capsule once daily 2 days before ECT and continuing through the last ECT procedure.
45599670|NCT02309905|Device|Telemedicine|Inmates of prisons having telemedicine after implementation of telemedicine
45599671|NCT02338401|Dietary Supplement|Omega-3 Complete|Fish Oil Capsules
45599672|NCT02338401|Dietary Supplement|Placebo Pill|Olive Oil Capsules
45444238|NCT01205841|Procedure|Ottawa Ankle and Foot Rules + application of a tuning fork to the distal fibula and tibia|As previously published
45444239|NCT01205841|Procedure|Thompson Test|As previously published
45599673|NCT02883387|Other|Preoperative CT angiography|Patients will receive a CT scan to map the blood vessels to be used during surgery for breast reconstruction
45599674|NCT02883387|Other|No Preoperative Imaging|No imaging will be done to map blood vessels prior to surgery
45599675|NCT02309983|Other|Electrical Stimulation|Electrical stimulation is a rehabilitative approach that generates muscle activity by alternating leg extension and flexion even in individuals who are unable to stand or step independently. Electrical stimulation will be applied to multiple muscles of the lower limb.
45754861|NCT03154736|Other|Interview|Individual interview and group interview Socio-economic questionnaire
45599676|NCT02309983|Other|Stand Retraining with Body Weight Support (BWS)|Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion.
45599677|NCT02334969|Drug|Naoxintong Capsule|This is Naoxintong capsule,which is composed of Huangqi,Chishao,Danshen,Danggui, Chuanxiong,Taoren,Honghua,Ruxiang,Moyao,Jixueteng,Niuxi,Guizhi,Sangzhi,Dilong,Quanxie,etal.
45599678|NCT02334969|Drug|Placebo|placebo capsule has the same as Naoxintong capsule in the appearance, shape,colour and content tinct.
45599679|NCT03505645|Procedure|Periarticular infiltration|"The injection will consist of the same drugs for all patients: 150mg levobupivacaine 0.25%, 10mg morphine; and 30mg ketorolac made up to a volume of 150ml with saline.~The difference between treatment groups is how the multimodal injection is administered: either by periarticular infiltration around the knee, or by simple intra-articular injection after the knee joint capsule has been closed.~Treatment group 1: Periarticular infiltration~Intra-operatively after bone cuts have been made and prior to implant cementation, the multimodal injection will be infiltrated around the knee at 6 specific sites:~Medial femoral condyle periosteum~Medial gutter~Lateral femoral condyle periosteum~Lateral gutter~Posteromedial capsule~Posterolateral capsule"
45599680|NCT03505645|Procedure|Intra-articular infiltration|"The injection will consist of the same drugs for all patients: 150mg levobupivacaine 0.25%, 10mg morphine; and 30mg ketorolac made up to a volume of 150ml with saline.~The difference between treatment groups is how the multimodal injection is administered: either by periarticular infiltration around the knee, or by simple intra-articular injection after the knee joint capsule has been closed.~After implant cementation and watertight joint capsular closure, the multimodal injection will be injected intra-articularly through the closed capsule."
45599681|NCT05230953|Biological|mRNA1273 vaccine|fourth dose of the mRNA1273 vaccine (50 microgram) adminstered IM
45599682|NCT03505567|Device|KOWA OCT Bi-µ|Non-contact, ultra-high resolution ophthalmic imaging system for fundus imaging and axial cross-sectional and three-dimensional imaging of retinal structures.
45599683|NCT03505567|Device|Optovue iVue 100|U.S. Food and Drug Administration (FDA) cleared and commercially available Optovue iVue 100
45599684|NCT02334501|Drug|Lansoprazole|
45599685|NCT02334501|Drug|Neratinib|
45599686|NCT02302027|Device|platinium IRC9LXO2AWQ|high flow concentrator delivering normobaric oxygen after extraction, 9 liter per minute dimensions: 46 * 67 * 36 cm
45599687|NCT02331927|Biological|Aflibercept|"Early marker-driven switch of antiangiogenic treatment (bevacizumab to aflibercept) maintaining the chemotherapy backbone until definite radiological progression.~compared to a conventional treatment approach of changing chemotherapy and antiangiogenic agent at time of radiologic progression."
45599688|NCT02302183|Device|FreeO2 v2.0 automatic adjustment|
45599689|NCT02302183|Device|FreeO2 v2.0 data collecting|
45599690|NCT04888000|Other|Educational Intervention|Professional development program provided to small groups of health care professionals in three different sessions over a period of one month with additional independent individual work to be completed between sessions.
45599691|NCT05157321|Device|Repetitive Transcranial Magnetic Stimulation|TMS device will deliver repetitive trains of magnetic pulses using Magstim Rapid 2 with angulated figure of eight shaped coil. The device comprised two-channel Neuro-EMG-MS digital system for determining the motor threshold of the patients that will be used for establishing the threshold intensity for stimulation. The figure of eight-shaped coil generated a magnetic field of up to 4 Tesla that penetrates the cranium, enters into the soft tissue of the brain and henceforth stimulates the motor neurons.
45599692|NCT05157321|Device|Sham Repetitive Transcranial Magnetic Stimulation|Sham Repetitive Transcranial Magnetic Stimulation
45599693|NCT02322190|Procedure|Extracorporeal Photopheresis (ECP)|Twice weekly for 1 month or Twice every other week for 2 months or Twice during one week per month for 4 months for a total of up to 7 months of treatment.
45599694|NCT02322190|Drug|Methoxsalen|Sterile solution used in conjunction with photopheresis procedure.
45599695|NCT05054127|Other|foiiow up patients|observational study
45599696|NCT02304055|Drug|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly iv.
45599697|NCT02304055|Drug|Oxytocin|100 women with atonic PPH will receive Oxytocin 5IU slowly iv.
45599698|NCT02331849|Device|High resolution manometry (HRM)|High resolution manometry of the esophagus
45911003|NCT02002169|Other|Standard CVC Care|Nuanced differences may be present at participating units; however, the key components of the intervention are 1) HD nurse delivery of CVC care 2) chlorhexidine or povidone cleansing 3) dry gauze dressing 4) standardized frequency. For both STP and control arms, participants whose HD centre uses polysporin triple ointment as part of standard CVC care will continue to have it applied as per program policy.
45599700|NCT02334579|Radiation|CyberKnife Stereotactic Radiosurgery|Five treatments given over about one week.
45599701|NCT05012865|Drug|avelumab|as provided in real world practice
45599702|NCT05012865|Drug|axitinib|as provided in real world practice
45934859|NCT00209911|Procedure|cardioversion|
45599703|NCT03505489|Procedure|Deep inhalation technique|Use of deep inhalations for administration of inhalant
45599704|NCT03505489|Procedure|Tidal breathing technique|Use of tidal breathing for administration of inhalant
45599705|NCT03505489|Drug|Methacholine|Methacholine direct bronchoconstrictor used for bronchoprovocation challenge
45599706|NCT03505489|Drug|Mannitol|Mannitol indirect bronchoconstrictor used for bronchoprovocation challenge
45599707|NCT02334657|Other|SF-36|postal questionnaire consisting a short-form health survey with 36 simple questions (SF-36)
45599708|NCT02310373|Other|Nicotine free hookah smoking|Subjects will smoke waterpipe in a controlled research environment
45934860|NCT00209950|Drug|Gaboxadol|
45599709|NCT02338323|Drug|Febuxostat|It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
45444240|NCT01205841|Procedure|Palpation of the fibula|Palpation of the fibula over its entire length.
45599710|NCT02338323|Drug|Benzbromarone|It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
45444241|NCT01205841|Procedure|Ottawa Ankle and Foot Rules + palpation of the cuboid bone|As previously published
45599711|NCT02311465|Other|Palliative Care|"Components of the palliative care service intervention are expected to include:~Establishment of a palliative care plan~Care coordination by palliative care team~Informational, patient friendly materials supporting Palliative Care~Communication by palliative care team to all providers and teams involved in patient's care~Systematic collection of information, including identification of surrogate or health care proxy and advance care planning~Questionnaires capturing health related quality of life at regular intervals throughout the intervention period"
45599712|NCT03112083|Dietary Supplement|Nutritional counseling A|Krill powder capsules
45599713|NCT03112083|Dietary Supplement|Nutritional counselling B|Placebo capsules
45599714|NCT03790683|Device|EnsoETM|Patients having major surgery will have the EnsoETM device placed after induction of general anesthesia. Addition of standard of care surface warming was specified as optional after first 7 patients.
45599715|NCT03790683|Device|Surface Warming|Forced air warming device will be placed on the patient according to standard practice.
45599716|NCT02310451|Biological|blood test|blood test to J0-M3-M6-M12
45599717|NCT02310529|Behavioral|Interpersonal Psychotherapy|"Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group).IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected.~Intervention will be delivered by trained clinical psychologists."
45599718|NCT02338167|Procedure|Blood sampling|A blood sample will be taken during a routine blood draw
45599719|NCT02304133|Other|Education|
45599720|NCT02321800|Drug|Cefiderocol|2000 mg intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
45599721|NCT02321800|Drug|Imipenem/cilastatin|1000 mg of each intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
45599722|NCT02310607|Other|Not an interventional study|Not an interventional study
45599723|NCT02310295|Device|Laser|focal macular laser therapy
45599724|NCT02310295|Drug|Bevacizumab|Intravitreal injection of Bevacizumab
45911004|NCT02002195|Drug|FOLFOX|Oxaliplatin 85 mg/m2 is given as a 2 hours intravenous infusion, concomitant to and S-leucovorin 200 mg/m2, and followed by 5-FU 2,400 mg/m2 as a 46 hours continuous infusion.
45444242|NCT01205841|Procedure|Ottawa Ankle and Foot Rules + palpation over the deltoid ligament|As previously published
45444243|NCT01205841|Procedure|Malleolar Zone Algorithm|As previously published
45444244|NCT01205841|Procedure|Low Risk Exam|As previously published
45444245|NCT01205841|Procedure|Bernese Ankle Rules|As previously published
45444246|NCT01205841|Procedure|Ottawa Ankle and Foot Rules + swelling of the distal fibula|As previously published
45444247|NCT03825627|Device|Transcranial Direct Current Stimulation|"Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp at F3 (active electrode, 4.4×4.4cm) and on the contralateral supraorbital area (reference electrode, 5.1×10.2cm).~Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton, Alberta, Canada). For each stimulation, the direct current is initially increased in a ramp-like fashion over 10 s until reaching 2 milliampere (mA) and will be similarly decreased at the end of stimulation.~In the active tDCS condition, stimulation will be maintained for 20 min; in the sham condition, it will be turned off after 15 s of stimulation, with a ramp-up/down of 10 s (i.e., 35 s total)."
45444248|NCT01205919|Behavioral|Internet-based guided self-help for tinnitus|Internet-based guided self-help for tinnitus: provided via Internet, duration of 10 weeks
45599725|NCT02310295|Drug|Triamcinolone Acetonide|Intravitreal injection of Triamcinolone Acetonide
45599726|NCT02310685|Other|Comprehensive e-health wellness program|"Participants randomized to this arm will have complete access to the myhealthcheckup website equipped with online tools including health assessments with coaching modules, educational material with quizzes, exercise challenges and motivational tips. The subject will meet with the pharmacist on 4 occasions (initial, 3, 6, 12 months) to update the cardiovascular risk profile, BP, weight, waist circumference and lipid profile. All interventions that were prespecified to be administered as part of the protocol, even if a particular intervention is not of interest."
45599727|NCT02338089|Drug|Oxytocin|Oxytocin, 100 micromolar solution
45599728|NCT02310841|Device|ANGELAA|Different control strategies with transfemoral prosthesis prototype ANGELAA, developed at the Sensory-Motor Systems Lab, ETH Zurich, not commercially available, only 1 device exists
45599729|NCT02338245|Drug|ASLAN001|ASLAN001 400mg BID
45599730|NCT02338245|Drug|Lapatinib|Lapatinib 1250mg QD
45599731|NCT02338245|Drug|Capecitabine|Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle
45599732|NCT02311543|Drug|TachoSil® patches|TachoSil® is a sterile, ready-to-use, absorbable surgical patch and consists of an equine collagen sponge coated with human fibrinogen and human thrombin.
45599733|NCT02332005|Drug|diepalrestat choline|aldose reductase inhibitor
45599734|NCT02332005|Drug|Placebo|Placebo
45652929|NCT05068271|Behavioral|Multi-Domain Exercise Program|The multi-domain exercise consisted of the main exercise (e.g., aerobic exercise, resistance exercise, flexibility training, and coordinative exercise), social interaction, and meditation. Participants are encouraged to engage in 150 min exercise per week consisting of one 90-min on-site session and multiple online sessions for 6 months.
45599735|NCT02311699|Behavioral|Intervention to reduce IPV and HIV|The Ethiopian traditional coffee ceremony will be used as an entry point for a community based intervention to provide information, change behaviour around IPV and improve gender equity and intra-couple relations. The coffee ceremony is a culturally established forum for community discussion and conflict resolution and an integral part of Ethiopian life. The intervention will involve regular coffee ceremonies, during which approximately 20 members of the community will participate in education and discussions centred on gender issues, sexuality, communication and conflict resolution, HIV/AIDS and its link with violence, as well as HIV/AIDS prevention. Each coffee ceremony will be moderated by a female or male facilitator trained in participatory learning, moderation, HIV/AIDS prevention, counselling, and gender issues. The intervention will involve 14 two-hour session per group of participants.
45599736|NCT02331693|Biological|anti-EGFR CAR T|
45599737|NCT02304211|Drug|Insulin|Insulin will be administered either into the radial artery (microdose intervention) or IV (systemic intervention).
45599738|NCT02311777|Drug|Pregabalin|Pregabalin will be given orally during preoperative period
45599739|NCT02311777|Drug|Ketamine|Ketamine will be given on the surgery day before the anesthesia induction
45599740|NCT02311777|Drug|Placebo|Placebo will be given orally during preoperative period
45599741|NCT03504865|Drug|Liposomal bupivacaine|Given at the end of the operation.
45599742|NCT03504865|Drug|Standard bupivacaine|Given at the end of the operation.
45599743|NCT03504865|Other|Placebo|Saline will be administered as the placebo and will be given at the end of the operation.
45599744|NCT02304289|Drug|Artesunate|Oral Artesunate once-daily for 14 days, dose-escalation
45599745|NCT02292784|Drug|Retosiban|This is a safety follow-up study of infants and children exposed to retosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
45599746|NCT02292784|Drug|Atosiban|This is a safety follow-up study of infants and children exposed to atosiban comparator during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
45599747|NCT02292784|Drug|Placebo|This is a safety follow-up study of infants and children exposed to matching placebo for retosiban/ atosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product
45599748|NCT02338011|Drug|Gefitinib|Gefitinib was given 250mg per day. Dose reduction was allowed for intolerable adverse effects such as rash(grade 4)、diarrhea(grade 3-4) or non hematological toxicity(grade 3-4) from 250mg per day to 250mg every other day then to 250mg every three days if needed.
45599749|NCT02338011|Radiation|WBRT|WBRT was delivered in 3.0 Gy fractions once per day 5 days per week to a total dose of 30Gy (10 fractions).
45599750|NCT02311855|Biological|Influenza vaccine|"Each participant will have a blood draw to measure the antibody titres influenza strains covered by the 2014-2015 influenza vaccine at three different time points:~Visit 1- Baseline/prior to vaccination Visit 2- 4-6 weeks post-vaccination Visit 3- end of influenza season (April-May)~At Visit 1, after the baseline blood draw, all participants will be vaccinated by Research staff in order to standardize the time from Baseline blood draw to vaccination. Participants aged 65 and older will be offered the extra strength version of the vaccine, which is usual care. Participants under the age of 65 will be given the usual strength vaccine. All patients will be given the intramuscular (IM) vaccine."
45599751|NCT02334189|Behavioral|Letter|Patients receive an information letter following an avoidable visit to the Emergency Department.
45599752|NCT04463407|Other|Educational talk about physical activity and nutritional recommendations before a critical period of fat gain in university students|An intervention was performed emulating a traditional nutritional session from a primary healthcare center (public health system). Traditionally, this session lasts around 20 minutes and includes a body composition measurement, nutritional assessment, and a brief educational talk about healthy eating. Just the intervention group received a series of healthy recommendations specially focused on the National Holiday.
45599753|NCT04463485|Procedure|Delayed Clamping|Umbilical cord clamping was delayed 60 seconds at the end of second stage of labor.
45444249|NCT01205919|Other|Internet discussion forum|Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
45599754|NCT02337855|Other|Placebo|Placebo: normal saline for parenteral administration. Group C. Group F, and Group I: single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113.
45911005|NCT02002195|Drug|Capecitabine|Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
45444250|NCT01297803|Drug|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before &after scleral flap dissection
45444251|NCT01297803|Drug|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before &after scleral flap dissection
45444252|NCT03248739|Device|Clear Bactiseal 'large' catheter (EVD)|Antibiotic-impregnated 'large' catheter (inner diameter 1.9 mm, outer diameter 3.4 mm)
45444253|NCT03248739|Device|Orange Bactiseal 'small' catheter (EVD)|Antibiotic-impregnated 'small' catheter (inner diameter 1.5 mm, outer diameter 3 mm)
45444254|NCT03178383|Behavioral|Project HEAL|Standard group churches will not be asked to, or provided special encouragement to technical assistance with, institutionalizing health promotion activities in their churches.
45444255|NCT03178383|Behavioral|Project HEAL 2.0|In this approach, rather than developing a separate health ministry, cancer activities could be integrated throughout existing church ministries (e.g. men's, women's, seniors).
45444256|NCT03824691|Drug|Cabozantinib|cabozantinib 40 mg orally once daily
45444257|NCT03824691|Drug|Durvalumab|1500 mg durvalumab (MEDI4736) IV infusion every 28 days
45444258|NCT01299831|Behavioral|72 hour fast|The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.
45444259|NCT01299831|Behavioral|control, 12 hour fast|The 12 hour fast will be used as a basic metabolic control
45444260|NCT01299831|Drug|Growth hormone|Genotropin bolus(0,005 mg/kg over 20 min.) will be administered at the beginning of the study day after a 12 hour fast.
45599755|NCT02337855|Biological|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel. Group A: single dose IM 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113. Group D: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113. Group G: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113.
45599756|NCT02337855|Biological|Sm-TSP-2/Alhydrogel/GLA-AF|Sm-TSP-2/Alhydrogel/GLA-AF. Group B: single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group E: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group H: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113.
45599757|NCT04463329|Procedure|conventional two-operator versus single operator using Jedi grip axillary brachial plexus blockage|on goup C, operator used the probe and needle with different hands while an assistant controlling the syringe to aspirate or inject local anesthetic. On Group J single operator controlled the probe with one hand while controlling the needle and the syringe on the other hand with the Jedi technique. The needle was held between the index finger and the middle phalanx of the middle finger, and the syringe was held with fingers 4 and 5, with the plunger part to the thumb in the palm.
45599758|NCT02309125|Procedure|immediate progressive loading using gingival formers|"Implant placement will be 1 mm subcrestally, and it will receive transmucosal healing using gingival former.~The gingival former will be replaced every 2 weeks by consequent larger size gingival former (at surgery time group A will receive 2 mm height gingival former which will be swapped by,3 mm, 4 mm and the last is 5 mm)."
45754862|NCT05622305|Behavioral|1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained public health nurses consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. We also provide a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD.
45754863|NCT00627679|Drug|Budesonide Inhalation Suspension|Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
45754864|NCT00627679|Drug|MAP0010 low dose|Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
45444261|NCT01299831|Drug|Olbetam|"The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.~During the last 12 hours of fasting and the study day lipolysis will be inhibited with one tablet of olbetam 250 mg every 4 hours."
45444262|NCT01205997|Drug|Fentanyl|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
45444263|NCT01205997|Drug|placebo(distilled water)|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
45444264|NCT01205997|Drug|magnesium sulphate|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
45934861|NCT00209989|Drug|Zarnestra|ZARNESTRA 100 bid (phase II recommended dose defined in phase I)will be administered continuously from one week prior to start of radiation therapy until the last day of radiation therapy.
45444265|NCT05622825|Biological|DC-CIK|To explore the therapeutic effect and safety of cryoablation combined with autologous DC-CIK (through hepatic artery infusion, HIA) for patients with advanced liver cancers
45444266|NCT05281575|Behavioral|Baby Friendly Spaces (BFS)|Designed to meet the unique needs of populations living in humanitarian contexts, BFS focus on two domains: psychosocial support that targets maternal wellbeing and childcare practices that target caregiver functioning to also address child wellbeing and development. In so doing, BFS strengthens mothers' internal resources and skills in caring for their children both in quantity (time spent caring for the child) and quality (responsiveness), to positively impact the health status and wellbeing of their children. In BFS, the following activities are delivered by trained psychosocial workers: counselling for infant and young child feeding practices; hygiene education and promotion; mother-child bonding activities that provide psychosocial stimulation essential for children at risk of, or experiencing, malnutrition; and provision of maternal psychosocial support (i.e. psychoeducation, stress management).
45452110|NCT00154102|Drug|FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)|Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops
45452111|NCT01280344|Drug|Saline Solution for Injection|Intravenous (IV)
45452112|NCT01280344|Drug|Ipamorelin|Intravenous (IV)
45599759|NCT02309125|Procedure|submerged healing|the implant placement will be 1 mm subcrestally, and it will receive unloaded healing.(submerged healing)
45599760|NCT02320396|Drug|Desloratadine 5 mg|Desloratadine 5 mg tablets
45599761|NCT02320396|Drug|Placebo|Placebo tablets
45599762|NCT02333955|Drug|GCS-100|3 mg GCS-100 IV push. All doses of study drug will be administered least once monthly for a total of 1 year with a follow-up 4 weeks after the last dose is administered.
45599763|NCT03509233|Other|Q-SRP|Quadrant scaling and root planing under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within four sessions in intervals of 1 week
45444267|NCT05281497|Behavioral|Health platform|Each participant was provided with a wearable device (a Heart Rate Smart Wristband, GSH405-B6, Golden Smart Home Technology Corporation). Each participant downloaded an app (WowGoHealth app) to connect with the health management platform (GSH AI health platform). Participants' exercise-related data, including number of steps walked, distance, consumed calories, and heart rate, were collected by the wearable devices. All participants were taught to record a dietary diary (taking photos of meals) using a smartphone application. All collected information was uploaded to the health management platform. For the intervention group, we encouraged exercise including an 18-minutes calisthenics made by the Health Promotion Administration, Ministry of Health and Welfare (https://www.youtube.com/watch?v=r3xJW-b2tZY).
45444268|NCT05281497|Behavioral|Social media|We built a LINE group to inspire the intervention group.
45599764|NCT03509233|Other|FMS|Full mouth scaling and rootplaning under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within 24 hours
45599765|NCT03509233|Other|FMD|Full mouth scaling and rootplaning under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within 24 hours with additional disinfection using 0.2% chlorhexidine (mouth rinsing and tonsil spray), subgingival application of 1% chlorhexidine gel and 2 months postoperative home care using chlorhexidine 0.2% (rinse and spray)
45599766|NCT03509233|Other|FMDP|FMD protocol (see FMD arm) with additional use of subgingival airpolishing (Air Flow, EMS) using Erythritol powder (Air-Flow Plus powder, EMS) for 20 seconds per tooth
45599767|NCT02334111|Behavioral|RESPECT-Plus|A RESPECT-Plus family specialist (FS) will deliver the intervention to subjects (mothers in treatment for opiate use disorder) recruited during their third trimester of pregnancy and randomized into the study's intervention arm post-delivery. During their infant's hospital stay, the FS will schedule a convenient time to meet the subjects (mothers) to educate them on infant soothing techniques. With permission from the mother, the FS will join the subjects during their infant's routine well-child visits at the pediatric primary site. Optional home visiting provides another meeting opportunity between the subjects and FS.
45599768|NCT02334033|Other|other|
45754865|NCT00627679|Drug|MAP0010 intermediate dose|Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
45754866|NCT00627679|Drug|MAP0010 high dose|Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
45444269|NCT05281497|Other|exercise including an 18-minutes calisthenics|exercise including an 18-minutes calisthenics
45444270|NCT03818997|Drug|DKN-01|Patient will receive DKN-01 300 mg IV every 2 weeks
45444271|NCT03818997|Drug|Atezolizumab|Patient will receive Atezolizumab 840 mg IV every 2 weeks until PD
45444272|NCT03818997|Drug|Paclitaxel|Patient will receive Paclitaxel 80 mg/m2 IV on day 1, 8 and 15 of a 28 day cycle until PD
45444273|NCT05623449|Other|Clinical examination|Current medications (only those prescribed to treat pain, anxiety and depression), non-drug treatment(s) prior to treatment in hypnosis as well as any ongoing treatment(s).
45444274|NCT05623449|Other|Anxiety and Depression Scale (HAD)|To screen for anxious and depressive symptoms
45444275|NCT05623449|Procedure|pain scale|Measurement of pain intensity
45444276|NCT05623449|Procedure|hypnosis consultation|5 hypnosis consultation
45444277|NCT05623449|Procedure|Maintenance|Qualitative assessment
45444278|NCT05623449|Other|Data collection|Age, sex, socio-professional category, level of education, comorbidities, date of diagnosis of chronic peripheral neuropathic pain, distance between home and hospital.
45444279|NCT03819075|Device|Lightwalker Laser (Fotona)|For the laser group we will use a Lightwalker Laser (Fotona) with a Er:YAG 2940 nm and Nd:YAG 1064 nm wavelengths units. The laser protocol will follow the instructions of the manufacturer (TwinLight protocol) and consists of degranulation of necrotic soft tissue and bone, implant surface disinfection and creating spot bleeding in bone with Er:YAG and deep disinfection and biomodulation with Nd:YAG.
45444280|NCT03819075|Other|standard|Granulation tissue elimination, mechanical instrumentation of the implant surface and curettage of intraosseous or supracrestally bone defects will be accomplished using plastic curets, under irrigation with sterile saline solution. Cotton pellets soaked in sterile saline solution will be use to clean debris and remains of removed tissue.
45599769|NCT02312089|Drug|Triptorelin|Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval
45599770|NCT02331459|Other|Multicomponent training intervention|"Intervention characteristics: 24weeks, 5days/week, 60min/session Day 1, 3 and 5 15 min (a) 40 min (b) 5 min (d) Day 2 and 4 15 min (a) 40 min (c) 5 min (d)~Legend:~min. =minutes a = Proprioception exercises, postural sway and dynamic balance, coordination and flexibility of the lumbo-pelvic area b = Aerobic training 65% maximal Heart rate c = Strength training arms and legs d = Stretching"
45652930|NCT05068271|Behavioral|Control Group|"The usual physical activity group, as the control group, is informed to maintain their lifestyles. In addition, participants are invited to attend one 60-min online educational course per week. The logs of physical activity behavior will be obtained from the participants once per month during the intervention period."
45754867|NCT03159884|Drug|Conbercept|
45754868|NCT00514709|Biological|DTaP-HB PRP~T Combined Vaccine|0.5 mL, Intramuscular (IM)
45754869|NCT00514709|Biological|DTaP-HB-PRP~T vaccine|0.5 mL, IM
45754870|NCT00514709|Biological|Oral Polio Vaccine|Oral co-administered with study vaccine.
45599771|NCT02331459|Other|Nutritional intervention|"Enrolled patients will receive nutritional information on optimal daily energy intake, ensuring at least a daily protein intake of 1 g. of by kg of weight.~Calcium plus vitamin D (total amount 1200 mg calcium plus 800 IU of vitamin D) Vitamin D will be provided if calcidiol (Cldl) blood levels are lower than 30 ng/ml.~Cldl 20-29 ng/dl it will provide calciferol 20.000 IU every 15 days (3 months) Cldl 10-19 ng/dl it will provide calciferol 20.000 IU every 10 days (3 months) Cldl 1-9 ng/dl it will provide calciferol 20.000 IU every 7 days (3 months)"
45599772|NCT02310997|Other|Umbilical Cord Blood Transplant|
45599773|NCT02310997|Drug|Cyclophosphamide|
45599774|NCT02310997|Radiation|Total body irradiation|
45599775|NCT02310997|Drug|Busulfan|
45599776|NCT02310997|Drug|Melphalan|
45599777|NCT02310997|Drug|Fludarabine|
45599778|NCT02337699|Device|Implantation with the commercially available Axium neurostimulator|
45599779|NCT02337699|Procedure|QST Testing|
45599780|NCT02337543|Drug|NEO6860|NEO6860 is an NCE acting as a TRPV1 antagonist
45599781|NCT02337543|Drug|Placebo|Placebo
45599782|NCT03505411|Dietary Supplement|melatonin supplementation|
45599783|NCT02292238|Drug|Benfotiamine|"To test whether increasing brain thiamine by administering 600 mg per day (300 mg/morning and 300 mg/evening) of benfotiamine for one year can slow cognitive decline in these patients as measured with the Alzheimer's Disease Assessment Scale (ADAS-COG).~To determine whether increasing brain thiamine availability with 600 mg (300 mg/morning and 300 mg/evening) per day of benfotiamine for one year can slow the decline in brain glucose metabolism in these patients as measured with Fluorodeoxyglucose Positron Emission Tomography(FGPET) in the posterior cingulate."
45599784|NCT03509155|Other|National portion & IYCF counseling|Eight or twelve pieces of Biscuits supplementation per day as serving size recommendation based on the requirement from Ministry of Health, accompanied by IYCF Counseling emphasizing on local food optimization. The difference in serving size recommendation will be evaluated to see the efficacy of Biscuits supplementation on wasting children age 6-23 months of age
45599785|NCT03509155|Other|Adjusted portion & local food counseling|four pieces of Biscuits supplementation per day as serving size recommendation, accompanied by IYCF Counseling. The difference in serving size recommendation will be evaluated to see the efficacy of Biscuits supplementation on wasting children age 6-23 months of age
45599786|NCT02772159|Drug|TD-4208|One dose each of treatments A: [14C] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: [14C] TD-4208 200 μg oral solution administered in a fasted state.
45599787|NCT02631447|Drug|LGX818|LGX818 450 mg p.o. od
45599788|NCT02631447|Drug|MEK162|MEK162 45 mg p.o. bid
45599789|NCT02631447|Drug|Nivolumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
45599790|NCT02631447|Drug|Ipilimumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
45599791|NCT03505333|Procedure|conventional suture|we use Liga-sure device for hysterectomy
45599792|NCT02311075|Biological|Blood samples|Blood samples will be performed at baseline and during endothelial stimulation by hand skin heating to quantify metabolites of NO, EETs, ET-1 and ROS
45599793|NCT02312167|Device|confocal laser endomicroscopy|probe-based and needle-based confocal laser endomicroscopy
45599794|NCT02333877|Other|Skinlink|suture using Skinlink
45599795|NCT02333877|Other|Nylon|conventional suture using nylon
45599796|NCT02337309|Drug|SF1126|SF1126 in IV form with be given to patients on this study.
45599797|NCT03504631|Other|No intervention|no intervention
45599798|NCT03867123|Drug|LAM561|Arm 1: Daily for 6 weeks. Arm 2: daily, two 28-day cycles
45599799|NCT03867123|Radiation|RT|In Arm 1: Fractionated focal irradiation of 1.8-2 Gy/fraction/day, 5 days/week, 6 weeks. Total dose up to 60 Gy
45599800|NCT03867123|Drug|TMZ|Arm 1: 75 mg/m2/day, daily, 6 weeks Arm 2: 200 mg/m2/day, daily the first 5 days of two 28-day cycles (in case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery)
45599801|NCT03504475|Drug|Paroxetine Hydrochloride Tablet 20 mg|A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.
45599802|NCT03504475|Drug|Paxil® 20 mg|Paxil® Tablet 20 mg will be used as a comparator drug for the bioequivalence study, manufactured by GlaxoSmithKline（Distributed by: Apotex Corp.）.
45599803|NCT02327247|Drug|Felodipine|Extended Release Tablets, 10mg
45599804|NCT02327247|Drug|PLENDIL®|Extended Release Tablets, 10mg
45599805|NCT03505255|Drug|Neostigmine|Neostigmine is a cholinesterase-inhibitor, which augments the concentration of acetylcholine (ACh) at the neuromuscular junction
45599806|NCT03505255|Other|Normal saline|Normal saline 0.9 % is given in the control group
45599807|NCT02333799|Drug|Bedaquiline|100mg tablets
45599808|NCT02333799|Drug|PA-824|200mg tablets
45599809|NCT02333799|Drug|Linezolid|Scored 600mg tablets
45599810|NCT02311231|Drug|bivalirudin|Will be administered as an intravenous bolus of 0.75 mg per kilogram, followed by an infusion of 1.75 mg per kilogram per hour). Bivalirudin will be administered alone or with a low dose of heparin up to 3000U heparin in lab or up to 5000 U given pre-hospital according to local practice.
45599811|NCT02311231|Drug|Heparin|Treatment with unfractionated Heparin 5000 IU/ml i.v. ,Leo Pharma, Sweden, (the control group). Heparin in the control group is administered as an intravenous or intra-arterial bolus according to local practice. A dose of 70-100 U/kg is recommended
45652931|NCT05181085|Drug|NST 6179|orally administered, fully synthetic medium chain fatty acid (MCFA) analogue
45652932|NCT05181085|Drug|Placebo|inactive analogue
46066496|NCT01635569|Behavioral|Group-based family cognitive-behavioural therapy|Baseline and post-12 sessions
45599812|NCT03508999|Drug|Metronidazole gel|The application of metronidazole gel is effective in the management of gingivitis in patients undergoing orthodontic therapy. Additionally, the constant reminder therapy at weekly interval would also lead to improvement in the oral hygiene.16 According to pertinent literature survey, none of the study has been conducted to compare the effectiveness of SMS reminders and use of anaerobic gel to reduce gingival inflammation.
45599813|NCT03508999|Other|SMS text reminder|Subjects will be provided biweekly reminder via 'SMS text reminder' in the form of text message reinforcing oral hygiene. Additionally, patients will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
45599814|NCT03508999|Other|Placebo gel|Group C will be subjects will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
45599815|NCT02333721|Procedure|D2 lymphadenectomy including No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
45599816|NCT02333721|Procedure|D2 lymphadenectomy excluding No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
45599817|NCT03505177|Dietary Supplement|Chitin-glucan fiber|4.5g per day of chitin-glucan during 3 weeks
45599818|NCT03105375|Drug|Single ascending dose of X842|Each subject in a the same cohort will be assigned to the same single dose of X842. The subjects in the subsequent cohort will be assigned to a single dose of X842 based on safety and efficacy data generated from the previous cohort.
45599819|NCT03105375|Drug|Multiple ascending dose of X842|Each subject in a the same cohort will be assigned to the same dose of X842 once daily for five days. The subjects in the subsequent cohort will be assigned to same dose of X842 once daily for five days based on safety and efficacy data generated from the previous cohort.
45599820|NCT03105375|Drug|Losec|Each subject in one cohort will be assigned to a standard dose of omeprazole once daily for five days.
45599821|NCT02304445|Procedure|Transarterial Chemoembolization (TACE)|TACE is a treatment modality where local delivery of an anti-neoplastic agent is performed through the feeding artery of the tumor followed by end embolization of the artery. The goal of TACE is to cause tumor necrosis and tumor control via acute arterial occlusion while preserving as much functional liver tissue as possible.
45599822|NCT02304445|Radiation|TACE+Stereotactic Body Radiotherapy|This intervention adds Stereotactic Body Radiation (SBRT) to TACE therapy. SBRT is the precise administration of large doses of radiotherapy delivered over 1-5 treatments to extra-cranial tumors.
45599823|NCT02316301|Drug|Long interval misoprostol|A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
45599824|NCT02316301|Drug|Short interval misoprostol|A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
45599825|NCT02333409|Procedure|Electroacupuncture|Electroacupuncture (EA) has been used as a part of Traditional Chinese Medicine (TCM) and the benefits and success of EA as a viable treatment option for acute and chronic pain of various origins have been well-recognised.electro-acupuncture (EA) is taken place as to give out the stimulation with fixed frequency, pulse width and current to acupuncture needle for further promotion of analgesics effects.
45599826|NCT03504319|Other|Exposure to high-fat smoothie|Both groups will drink the high-fat smoothie and the study team will observe how they respond metabolically in the subsequent four hours using metabolic analyzer and blood draws.
45599827|NCT03144609|Procedure|low PEEP|The control group consisted of obese patients mechanically ventilated by a standardized volume-controlled breathing mode with low respiratory volume without alveolar recruitment maneuver and using low values of PEEP up to 4 cm H2O.
45599828|NCT03144609|Procedure|ARM|The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with alveolar recruitment maneuver performed immediately after induction, followed every 30 minutes during the hemodynamic stable condition under operation.
45599829|NCT03144609|Procedure|high PEEP|The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with higher PEEP, provided that the upper limit of 40 cm H20 was not exceeded.
46066497|NCT01635569|Other|Waitlist|Baseline and post-12 sessions
45599830|NCT02312323|Device|Definitive 65 HPT contact lenses|
45599831|NCT02312323|Device|Definitive 65 contact lenses|
45599832|NCT02327091|Drug|alfacalcidol|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo
45599833|NCT02304523|Drug|CDFR0612|Preparation 500mL is a mixture of CDFR0612 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
45599834|NCT02304523|Drug|CDFR0613|Preparation 500mL is a mixture of CDFR0613 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
45599835|NCT02304523|Drug|Coolprep Powder|Preparation 500mL is a water solution of Coolprep Powder A and B. A total of 3L (Preparation 2L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
45599836|NCT02316535|Drug|Capecitabine|adjuvant chemotherapy;
45599837|NCT03105063|Diagnostic Test|ultrasound scan of the hip|validation of Ultrasound test as a tool for diagosing AIIS morphology
45599838|NCT03501823|Other|Photoacoustic tomography|A non-invasive, safe modality that relies on light and sound to generate images.
45599839|NCT03501745|Behavioral|WeChat|Through remote management and propaganda of intelligent mobile phone, the standard rate of blood pressure control and the change of renal function were observed.
45599840|NCT02333253|Drug|cetrotide|0.25 cetrotide S.c was added on when leading follicle reach >12 mm
45599841|NCT03501667|Other|Use of decision support tool|use of a decision support software during clinical assessment of a case
45599842|NCT03501667|Other|Use of UpToDate|Control group, participants using current literature prior to assessing a clinical case. Allowing 10 minutes to read on a topic during clinical care is an active intervention in the study participant fund of knowledge.
45599843|NCT02039661|Drug|Lidocaine Spray|These patients received 2 puff lidocaine spray
45599844|NCT02039661|Drug|Placebo|
45599845|NCT02312479|Device|Nyxoah SAT system|The Nyxoah SAT system is comprised of an implantable nerve stimulator implanted over one of the tongue muscles via a minimally invasive procedure. Stimulation of the Hypoglossal nerves causes the tongue muscles to contract, thus maintaining an open airway during sleep.
45599846|NCT02331537|Behavioral|Internet-based cognitive-behavior therapy|Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into seven modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
45599847|NCT02304679|Other|Pre-inclusion questionnaires|"(Month -2)~During this visit, the investigator will:~Validate the patient's inclusion and exclusion criteria;~Obtain informed consent from the patient;~Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~Prescribe 1 month of PDE5i treatment.~The next visit will be scheduled"
45599848|NCT02304679|Drug|1 month of PDE5i treatment|5 mg Tadalafil per day for 1 month
45599849|NCT02304679|Other|PDE5i follow-up questionnaires|"(Month -1)~During this visit the investigator will:~Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~Remind the patient that over the next 4 weeks he is not to take any treatments for his condition (wash-out period).~The next visit will be scheduled"
45599850|NCT02304679|Other|Inclusion questionnaires|"(Day 0)~During this visit the investigator will:~Verify inclusion and exclusion criteria, and proceed with final inclusion~Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~Randomize the patient at the end of the visit~The patient will go home with a calendar specifying the time and place of the various visits. The patient should have four weekly LIESWT or sham sessions within the next month. The first session may take place the same day and immediately after the present visit."
45599851|NCT02304679|Device|4 weekly LIESWT (Wave 1) with the RENOVA device|Following final inclusion, patients will have weekly LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
45599852|NCT02304679|Device|4 weekly sham LIESWT (Wave 1) with the RENOVA device|Following final inclusion, patients will have weekly sham LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
45599853|NCT02304679|Other|Follow-up questionnaires 1 month after Wave 1|"(Month 2)~During this visit the investigator will:~Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
45599854|NCT02304679|Other|Follow-up questionnaires 3 months after Wave 1|"(Month 4)~During this visit the investigator will:~Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~The patient should have four weekly LIESWT sessions within the next month. The first session may take place the same day and immediately after the present visit."
45754871|NCT01670942|Other|hypobaric chamber|We will use a large (26 tons) multi-place hyperbaric and hypobaric chamber at IMC in Murray, Utah (elevation 1500m or 4500ft, average ambient barometric pressure 645mm Hg). In the hypobaric study, the barometric pressure will be lowered to 554mm Hg (phase 1) or 471mm Hg (phase 2) over 20 minutes and held there for two hours.
45652933|NCT05195385|Procedure|Low-dose computed tomography of the chest|Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules
45754872|NCT03154814|Drug|ulinastatin|ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB
45754873|NCT03154814|Drug|control|conventional CPB was applied without ulinastatin treatment
45599855|NCT02304679|Device|8 bi-weekly LIESWT (Wave 2) with the RENOVA device|During the 5th month following final inclusion, all patients will have bi-weekly LIESWT sessions. These will occur twice per week for four consecutive weeks. Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
45444281|NCT03818841|Device|High-flow nasal cannula device|Patients will be randomly allocated to this treatment
45599856|NCT02304679|Other|Follow-up questionnaires 1 month after Wave 2|"(Month 6)~During this visit the investigator will:~Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
45599857|NCT02304679|Other|Questionnaires via postal mail|Eight, 11, and 14 months after final inclusion, corresponding to 3, 6 and 9 months following Wave 2, the IIEF, SEP2, SEP3, GAQ and EHS questionnaires will be sent to patients via postal mail.
45599858|NCT02304679|Other|Final follow-up questionnaires 12 months after Wave 2|"(Month 17)~During this visit the investigator will:~Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
45599859|NCT02326935|Biological|Autologous adipose derived mesenchymal cells|Autologous adipose derived mesenchymal cells, 150M cells deployed via two (2) treatments via intravenous injection.
45599860|NCT02331615|Device|neuroConn_CE_DC-STIMULATOR|right frontal anodal stimulation
45599861|NCT02331615|Device|neuroConn_CE_DC-STIMULATOR|left frontal anodal stimulation
45599862|NCT02331615|Device|SHAM|no meaningful stimulation will be given
45599863|NCT03503851|Device|MitraClip implantation|Device to approximate the mitral valve leaflets
45599864|NCT02326779|Drug|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) 100 mg OD for 3 years
45599865|NCT03503539|Procedure|Mini percutaneous nephrolithotomy|
45599866|NCT03503539|Procedure|Retrograde intrarenal surgery|
45599867|NCT02331303|Other|Radium-223 dichloride (Xofigo, BAY88-8223)|Xofigo was approved in the US and EU for the following indication: Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Xofigo is contraindicated in women who are or may become pregnant.
45599868|NCT02316925|Dietary Supplement|Setria glutathione supplement|500 mg/day capsule taken in the morning
45599869|NCT02316925|Dietary Supplement|Crystalline Cellulose|500 mg/day capsule taken in the morning
45599870|NCT03144375|Other|Medical optimization and education|Medical treatment and education about the sinusitis disease process prior to surgery as compared to baseline surgical and treatment counseling
45599871|NCT03144375|Procedure|Standard of Care sinus surgery|
45599872|NCT03508531|Procedure|ESP Block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 40 mL of bupivacaine/lidocaine mixture will be injected.
45444282|NCT03818841|Device|Non-rebreathing oxygen mask group|Patients will be randomly allocated to this treatment
45444283|NCT01203657|Behavioral|Tai Chi|Tai Chi classes, 60 minutes, 2x week
45444284|NCT03818919|Drug|Celecoxib|Post-Operative Non Opioid Pain Protocol
45599873|NCT03508531|Procedure|OSTAP block|The bilateral OSTAP will be performed at the end of the surgery. A total of 40 ml local anesthetic mixture (Bupivacaine and lidocaine) will be injected bilaterally with interfascial plane between the external oblique and transversus abdominis muscles
45599874|NCT03508531|Other|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
45599875|NCT02039895|Radiation|HITS|Helical irradiation of the total skin by helical tomotherapy
45599876|NCT02317081|Device|Axetis Inert Coronary Stents|de novo coronary artery stenosis in native vessels
45599877|NCT02331381|Device|Magnetic resonance imaging|
45444285|NCT03818919|Drug|Ketorolac|Post-Operative Non Opioid Pain Protocol
45444286|NCT03818919|Drug|Gabapentin|Post-Operative Non Opioid Pain Protocol
45444287|NCT03818919|Drug|Acetaminophen|Post-Operative Non Opioid Pain Protocol
45444288|NCT03818919|Drug|Diazepam|Post-Operative Non Opioid Pain Protocol
45444289|NCT03818919|Drug|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
45444290|NCT03822195|Procedure|Carotid endoarterectomy|Surgical removal of carotid bifurcation plaque and arterial repair (direct suture or patch)
45444291|NCT05622747|Other|Passive heating|1 h hot water immersion (to the clavicle, @40°C, rectal temperature ~38.5°C and <39°C)
45444292|NCT03821493|Drug|PF-06651600 10 mg tablets|"On Day 1 in Period 1, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered.~On Day 4 of Period 2, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered after itraconazole."
45754874|NCT00561431|Device|Standard dose of dialysis|Continuous Venovenous Hemodiafiltration (CVVHDF) effluent dose of 20 ml/kg/hr
45754875|NCT00561431|Device|High dose of dialysis|Continuous Venovenous Hemodiafiltration (CVVHDF) effluent rate 35 ml/kg/hr
45754876|NCT01671020|Drug|Fimasartan|Period 1 fisrt administration of fimasartan 60mg Period 2 second administration of fimasartan 30mg
45754877|NCT01671020|Drug|Fimasartan|Period 1 first administration of fimasartan 30mg Period 2 second administration of fimasartan 60mg
45754878|NCT03154970|Device|Craniocervical flexion training|The cervical stabilization will be performed with craniocervical flexion training with two weekly sessions for 6 weeks
45754879|NCT00515021|Drug|Eplerenone (Morning)|"Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 4 weeks at 100mg.~100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 100mg, by mouth, daily, in the evening x another 4 weeks."
45754880|NCT00515021|Drug|Eplerenone (Night-time)|Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg
45754881|NCT03159650|Device|intravascular ultrasonography|intravascular ultrasonography will be used during the study for the resolving proximal cap ambiguity of chronic total occlusion, facilitating re-entry into the true lumen after subintimal crossing and confirming distal true lumen guidewire position
45754882|NCT03159728|Behavioral|Educative intervention:|"In the induction of the new group members are present, including caregivers who start the program and those who coordinated.~In Module I: to strengthen the knowledge of the situation and the people involved in care.~In Module II: to strengthen the value in the caregiver through decision making, skill and social support to back it up.~In Module III: or end, after analyzing that uneasy caregiver, patience is reviewed through the meaning of family care and self."
45754883|NCT03159494|Other|High-Intensity Training|"8 times of Hit consisting of 3 minutes of Warm-up on an indoor bike followed by 10 intervals of 1 minute at 90% og HRmax interspersed of 1 minute of recovery.~As for the pilot study 6 times of training were completed"
45754884|NCT00515177|Behavioral|Mindfulness-Based Stress Reduction|The intervention is a standardized program of mindfulness training led by an instructor. 8 weekly 2.5 hours sessions provide information on stress, cognition and health and training in a variety of mindfulness techniques including gentle yoga, body scan and sitting meditations. The program includes homework and home practice of mindfulness.
45754885|NCT00515177|Drug|eszopiclone|"One 3 mg tablet of eszopiclone nightly for 8-weeks followed by 3-months of as needed use"
45754886|NCT03159806|Device|Microdialysis sampling|Insertion of CE-marked intravenous microdialysis catheter, use of CE-marked microdialysis pump to collect intravenous microdialysis samples
45754887|NCT00583375|Device|Augment® Bone Graft|Augment® Bone Graft
45444293|NCT03821493|Drug|Itraconazole Solution 200 mg|"Itraconazole 200 mg will be administered as 20 mL (10 mg/mL) oral solution once daily on Days 1-5 in Period 2.~On Day 4 of Period 2, co-administration of itraconazole 200 mg and PF-06651600 30 mg will occur. Itraconazole will be administered first followed by PF-06651600 tablets."
45444294|NCT05621265|Behavioral|Automated Text messaging|daily text message
45444295|NCT05346237|Behavioral|Quality of life questionnaire|Filling out questionnaires, measuring maximum phonation and diadochokinesis
45444296|NCT01301937|Drug|Meglumine antimoniate|"Meglumine antimoniate (Aventis, São Paulo, Brazil) is stored and ministered under actual conditions employed by the health services in Brazil. Each patient will be included in one of two treatment groups with meglumine antimoniate IM:~High continuous dose: 20 mg/kg/day for 30 continuous days.~Low continuous dose 5 mg/kg/day for up to 120 continuous days.~There will be no cross-over between the groups for the purpose of this study. The data from those patients who require permanent discontinuation of a scheme will be assessed in the group that were randomized, ie, by intention to treat~Arms: High continuous dose, Low continuous dose"
45444297|NCT03814551|Behavioral|Signage|Placement of signage discouraging consumption of beverages with added sugar
45754888|NCT00583375|Procedure|Standard of Care|Autologous Bone Graft
45444298|NCT01300299|Radiation|Stereotactic Body Radiation Therapy|12 Gray (Gy) x 4 fractions (48 Gy) will be delivered to peripherally located tumors (> 2 cm in all directions around the proximal bronchial tree and centrally located tumors (within <2 centimeters (cm) of proximal bronchial tree). Treatment should be given on consecutive days. There will be 4 or 5 treatments.
45444299|NCT03814395|Other|No intervention|This is an observational study without any intervention
45444300|NCT03818451|Dietary Supplement|Co-ultraPEALut (Glialia)|Co-ultraPEALut is administered to moderate traumatic brain injured patients for 180 days
45444301|NCT05623371|Behavioral|Training leaders in leading well-being and the psychosocial working environment|"The intervention comprises five training modules with practice in small groups in between. Training will take place over 5 months. The training will be received in groups of 20 and the training will be facilitated by 2 facilitators. Central themes of the training are:~Self-care and well-being of the manager and how to cope with stress as a manager.~Employee well-being and reducing risk-factors in the psychosocial working environment of employee mental health problems~Enhancing protective factors social social support and a healthy team climate~Responding to employees at risk and how to handle difficult conversations and procedures on return to work~Managing well-being in employees during organizational change and final reflections~The training will comprise video material and in person training of competencies and behaviors in group settings.~The waitlist control group will receive an offer of a webinar and written information."
45444302|NCT05623371|Behavioral|The offer of a webinar and written material|The offer of a webinar plus written material
45444303|NCT01300845|Procedure|Humidification|From randomization, oxygen therapy is humidified
45444304|NCT01300845|Procedure|No Humidification|oxygen therapy is never humidified
45444305|NCT05618223|Drug|Dapagliflozin|Dapagliflozin 10 mg once daily in addition to standard therapy
45754889|NCT04348760|Behavioral|Rotation Diet|Based on the food-specific IgG measurement and relative distribution, a personalized food profile was created for each subject identifying 1 to 3 relevant food groups/nutritional clusters. Subjects were then instructed to avoid the foods highlighted in their personal food profile in certain days of the week, and to assume them in 7 of the 21 meals of the week. No calorie restriction was imposed in the diet.
45934862|NCT00209989|Procedure|standard Radiation therapy|Radiotherapy will be focused on the initial tumour volume with a reasonable margin of safety (2 cm). A total dose of 60 Gray (Gy) will be given to the Clinical Target Volume
45934863|NCT00041249|Drug|brostallicin|
45444306|NCT03814473|Other|Diet|"Participants provided with a brochure providing a thorough description of the diet, ~8 example recipes for each meal (i.e. breakfast, lunch, dinner, and snacks) included as a sample menu, and guidance to assist in shopping and self-preparation of food for the prescribed diet and to improve adherence. Diet consisted of following the popular paleolithic diet"
45599878|NCT03503461|Other|exosomes analysis|Perform exosomes analysis in urine sample obtain from usual urine testing in both kidney transplant and control group.
45599879|NCT02312635|Drug|D-Cycloserine|Half of the participants will be randomly chosen to receive the medication D-cycloserine in addition to the working memory program, while the other group will receive an inactive pill (placebo).
45754890|NCT03078218|Diagnostic Test|Pulse oximetry|The tool evaluated will be the assumption of peripherical arterial oxygen saturation by pulse oximetry. The pulse oximetry will identify hypoxemic CCHD and hypoxemic non-cardiac disease before discharge.The test will be realised before 24 hours of life in a newborn aged at least of 35 weeks of gestation.
45444307|NCT05623293|Diagnostic Test|eye - Optcial coherence tomography|pre and postoperative
45599880|NCT02312635|Behavioral|Cogmed Working Memory Training|Both arms of the study will receive Cogmed working memory training for 6 weeks, M-F.
45599881|NCT03991533|Other|multiparametric MRI|preoperative multiparametric MRI
45444308|NCT03814629|Drug|Weifuchun|The treatment group（Weifuchun group）was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(vitamin group) was given vitamin tablets (0.2 g), 4 tablets each time, 3 times a day, and 1 hour after a meal.
45444309|NCT01585935|Drug|SMOFLIPID|target dose: 3g/kg/d
45599882|NCT03503383|Behavioral|Patient Health Questionnaire-9|PHQ-9 for assessing and monitoring depression severity
45599883|NCT03503383|Behavioral|Generalized Anxiety Disorder Scale (GAD-7)|to diagnose generalized anxiety disorder, the GAD-7 also proved to have good sensitivity and specificity as a screener for panic, social anxiety, and post-traumatic stress disorder
45599884|NCT03144453|Drug|Sugammadex Injectable Product|Patients receive sugammadex at the end of the surgery
45754891|NCT04664881|Device|SmartHeart Device|A body-worn device that allows an individual to immediately transmit a 12-lead ECG from anywhere and anytime, using a smartphone application to a physician's office, hospital or monitoring center where designated on-call staff interpret the ECG and make recommendations.
45754892|NCT03154502|Diagnostic Test|Urinary sodium excretion|Urinary sodium and potassium were measured using the Ion-Selective Electrode (ISE) indirect Na-K-Cl for Gen.2 (Roche Diagnostic, Switzerland).
45754893|NCT00628147|Device|Narrow band imaging colonoscope|Adult colonoscopes with narrow band imaging capabilities (XCF-H160AY2L and XCF-Q160W6L, Olympus Medical Systems Corporation, Hachioji, Japan). There is an automatic switch on the handle of the endoscope that allows the physician to instantly switch between narrow band imaging and standard full spectrum white light modes.
45754894|NCT01671254|Dietary Supplement|FishOil|
45754895|NCT01671254|Dietary Supplement|CBE75|
45444310|NCT01585935|Drug|INTRALIPID|target dose: 3g/kg/d
45599885|NCT03144453|Drug|Neostigmine, Atropine|Patients receive neostigmine+atropine at the end of the surgery
45754896|NCT01671254|Dietary Supplement|CBE150|
45444311|NCT05623215|Radiation|Radiographs of the knee for radiostereometric analysis (RSA)|RSA radiographs will be made 5 and 10 years after the total knee arthroplasty.
45444312|NCT01300377|Drug|Bupivacaine / Lidocaine|5cc 1% Lidocaine solution mixed with 5 cc 0.25% Bupivacaine solution administered locally to the surgical site at time of the surgical procedure. Administered once only.
45599886|NCT02317159|Drug|Imatinib|400mg imatinib qd PO
45599887|NCT02333175|Other|Specialist review|Specialist review with individually tailored treatment strategies suggested by specialist
45444313|NCT01300377|Drug|Lidocaine|10 cc 1% solution administered locally to the surgical site at time of surgical procedure. Administered once only.
45444314|NCT03814707|Drug|Topical application of 0.2% hyaluronic acid gel|Topical application of 0.2% hyaluronic acid gel will be placed immediately in palatal donor site after free gingival graft harvesting
45444315|NCT03814707|Biological|Platelet rich fibrin|Placement of Platelet rich fibrin in the palatal donor sie after free gingival graft harvesting and suturing by criss cross sutured then covered by periodontal pack.
45444316|NCT03818295|Drug|[14C]-praliciguat|10 mg praliciguat containing approximately 500 μCi of [14C]-praliciguat
45599888|NCT04463173|Drug|Anaprazole|single dose, oral administration 30 minutes after breakfast with high fat food.
45599889|NCT04463173|Drug|Anaprazole|single dose, oral administration before breakfast.
45599890|NCT02332941|Drug|Rituximab|The purpose of this study is to determine if treatment of Age Related Macular Degeneration (AMD) with a new medication,rituximab is effective.
45599891|NCT02333019|Behavioral|Let's Talk About Sex|Multimedia web site to build parental skills in communicating with their pre-adolescnet child sex and relationships, pregnancy prevention, and risk of sexually transmitted infections.
45599892|NCT02333019|Behavioral|Websites; preventing teen pregnancy|Two general web sites with information about preventing teen pregnancy
45599893|NCT03503227|Drug|prednisolone|daily oral low dose prednisolone (10 mg/day) :a glucocorticoid
45599894|NCT03503227|Drug|Acetyl Salicylic acid|daily oral low dose Acetylsalicylic acid (75 mg) : Antiplatelet agent
45599895|NCT02305069|Drug|Pioglitazone|Described elsewhere
45599896|NCT02305069|Drug|Insulin|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
45599897|NCT02305069|Drug|Octreotide|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
45599898|NCT02305069|Drug|Glucose|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
45754897|NCT01671254|Dietary Supplement|placebo|
45934864|NCT00210028|Drug|Tamoxifen|
45934865|NCT00210028|Drug|Zarnestra|
45599899|NCT02305069|Drug|Mixed Amino Acids|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
45599900|NCT02305069|Other|[2H5]phenylalanine|Administered to allow the determination of leg protein breakdown rates in study visits. Description of amount administered provided elsewhere.
45599901|NCT02305069|Other|[1-13C]leucine|Administered to allow the determination of muscle protein synthesis rates in study visits. Description of amount administered provided elsewhere.
45599902|NCT02331225|Other|No intervention given|There is no intervention for this study
45599903|NCT02330913|Procedure|Intracorporeal esophagojejunostomy|Under laparoscopic view, esophagojejunostomy was pereformed with 60mm linear stapler on right side of distal esophagus like as functional end-to-end fashion before esophageal and jejunal resection. Then, three procedures of esophageal resection, common entry hole closure and jejunal resection was performed with a single use of 60mm stapler. Also, jejunojejunostomy was also performed via already made staple entry hole.
45599904|NCT02312869|Other|No intervention|not applicable, observational study
45599905|NCT03418441|Other|Community-acquired CNS infections|Prospective observational registration of clinical characteristics and outcome
45599906|NCT02331069|Drug|Dextrose 5% (D5W)|0,1,2, and 3 week injection sessions consisting of injection of 2 ml of D5W into the D-T groove at the point of maximal pain at 1-2 cm depth, followed by subcutaneous injection of D5W at 4 cm intervals along the course of the PACN if tenderness is present.
45599907|NCT02331069|Other|Physical therapy|Three times weekly X 3 week sessions to include myofascial release, exercise, and one modality.
45599908|NCT03503149|Other|no intervention|observational study
45599909|NCT03144531|Behavioral|Sleep Intervention for Kids and Parents (SKIP)|Dyadic approach using self-efficacy theory to set goals, anticipate barriers, problem solve
45599910|NCT02312947|Device|coblation (COBLATION II surgery system ,CE8001-01)|comparison of two methods of operation : coblation and cold dissection
45599911|NCT02312947|Device|cold dissection adenoidectomy|comparison of two methods of operation : coblation and cold dissectionby currete
45599912|NCT02313025|Other|speech sound intervention|"An intervention that stimulates speech sound perception and production in four-year-olds.~Each day at preschool the children receive a 15 to 20 minutes intervention, for 12 weeks"
45599913|NCT02313025|Other|World-project|An intervention that stimulates vocabulary development in four-year-olds. Each day at preschool the children receive a 120 minutes intervention, for 10 weeks
45599914|NCT02332785|Other|Data Collection|Data collection of endoscopy procedure reports of participants with serrated polyps at MD Anderson Cancer Center in Houston, Texas.
45599915|NCT03501511|Behavioral|IDF modules|Patients in this arm will receive Pre-Ramadan education using IDF module for 4 weeks prior to Ramadan fasting
45599916|NCT03501511|Behavioral|Conversational Maps|Patients in this arm will receive Pre-Ramadan Education using Ramadan Fasting Diabetes conversation map for 4 weeks prior to Ramadan fasting
45599917|NCT03144297|Other|Lumbar puncture|diagnostic lumbar puncture
45599918|NCT03144297|Other|BOD POD (air-displacement plethysmography)|Assessment of body fat
45599919|NCT02317237|Procedure|Local anesthesia|Conscious sedation
45804005|NCT01349192|Drug|Minocycline|"only subjects greater or equal to 8 years of age, who are not able to tolerate TMP/SMX or whose screening MRSA is resistant to TMP/SMX should be prescribed minocycline.~Adult dose: 100 mg orally twice daily for 14 days Pediatric dose: < 50 kg : 2mg/kg orally twice daily for 14 days not to exceed 200mg per day."
45444317|NCT05623137|Device|Acu-TENS|A dual-channel TENS stimulator will be used (ECS300A; Neurotrac, Verity Medical LTD, Ireland). Electrodes will be placed over selected acupoints (i.e., bilateral Sanyinjiao (SP6), Neiguan (PC6), Shenmen (HT7), Hegu (LI4), Zusanli (ST36) and Quchi (LI11)) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
45444318|NCT05623137|Device|Sham Acu-TENS|A dual-channel TENS stimulator will be used (ITO Physiotherapy & Rehabilitation, Co, Ltd, Tokyo, Japan). Electrodes will be placed over selected acupoints (i.e., bilateral Sanyinjiao (SP6), Neiguan (PC6), Shenmen (HT7), Hegu (LI4), Zusanli (ST36) and Quchi (LI11)) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
45452113|NCT01269658|Drug|Azithromycin ophthalmic solution, 1%|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
45452114|NCT01269658|Drug|Vehicle|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
45452115|NCT02268604|Drug|BIIB 722 CL|
45452116|NCT02268604|Drug|Placebo|
45452117|NCT01263886|Drug|ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
45452118|NCT01263886|Drug|placebo|"Pharmaceutical form:solution~Route of administration: intravenous"
45599920|NCT02332473|Drug|Ypeginterferon alfa-2b|
45599921|NCT02332473|Drug|Granulocyte-macrophage colony stimulating factor|
45599922|NCT03501433|Dietary Supplement|Nicotinamide riboside chloride (Niagen)|250 mg capsules 2x/day for 7 days
45599923|NCT03501433|Dietary Supplement|Placebo|2x/day for 7 days
45599924|NCT02383251|Drug|Pazopanib|Pazopanib 600mg during the fist cycle. Then, if there is not heptic triuyble, the dose could be increased to 800mg
45599925|NCT02383251|Drug|Paclitaxel|Arm 1 : Paclitaxel 65mg/m² Arm 2: Paclitaxel 80mg/m²
45599926|NCT02317393|Other|K5-RGD PET|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
45599927|NCT02317393|Other|FDG|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
45599928|NCT02313103|Drug|lofexidine HCl|400 micrograms
45599929|NCT01959633|Drug|Vemurafenib|Vemurafenib 960 mg b.i.d. for each course of treatment lasting 28 days
45599930|NCT01959633|Drug|Peg-interferon|"In the Phase I are included 3 cohorts. Cohort 1) Peg-interferon 1 µg/Kg one time per week s.c. Cohort 2) Peg-interferon 2 µg/Kg one time per week s.c. Cohort 3) Peg-interferon 3 µg/Kg one time per week s.c. Interferon treatment should start after 15 days of Vemurafenib only~In the Phase II is included the cohort selected by phase I due to MTD and expanded at RD."
45599931|NCT01959633|Drug|Cobimetinib|Cobimetinib 60 mg o.d. (21 days on followed by 7 days off)
45599932|NCT02305147|Other|Clinical, biological and imaging followup|Assessment of motor and non motor signs every 12 months. Imaging and blood, cerebral fluid, stools and skin samples for identification of biomarkers of disease phenotype and progression.
45599933|NCT02326545|Behavioral|MindLight|MindLight is a video game that uses neurofeedback as part of game mechanics. Participants play for 5 hours total over 3 weeks. Measures taken pre, post, and 3-month follow-up.
45599934|NCT02326545|Behavioral|Online CBT|Five sessions of power point slides that cover primary concepts and homework of cognitive behavioral therapy. Adapted for children. Measures taken pre, post, and 3-month follow-up.
45599935|NCT02313181|Other|Early Limited Formula|10 milliliters (mL) Nutramigen fed to baby by syringe after each breastfeeding and discontinued at the start of mature milk production
45804006|NCT01349192|Drug|Mupirocin|1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 14 days.
45444319|NCT05623137|Other|SHP|SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. The sleep guide contains information on how much sleep is needed by every individual daily, factors that could affect sleep, and risk factors for sleep disorders. It also contains information on the types of sleep disorders, delayed sleep syndrome, insomnia-producing behavior that could affect sleep quality, and suggestions for inducing sleep. The participants will be instructed to read the guide after the baseline assessment (T0). Those instructions will be reinforced by the research practitioner after each treatment session, in order to maintain the healthy sleeping habits.
45599936|NCT02313181|Other|Standard Care|Continue exclusive breastfeeding unless otherwise directed by a health care provider
45599937|NCT02326389|Behavioral|Exercise|The exercise intervention is a 10-week program involving 40 minutes of aerobic exercise targeting 60-75% of maximum heart rate on 3 days each week, with an additional 5-minute stretching warm up and cool down.
45599938|NCT02326389|Behavioral|Cognitive Remediation|Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
45599939|NCT02313259|Other|Speed discrimination test|"The participant has to stare in the middle of two screens, i.e the reference screen and the test screen. Dots are moving from the center to the edge of the screens at different speeds. The participant is forced to determine if the dots of the test screen are moving faster or slower than the reference screen.~The test is designed in Psychtoolbox3. Data analyses performed using MATLAB. Two-alternative forced choice paradigm."
45599940|NCT02313259|Behavioral|Driving simulation|"25 km simulated car driving session. The participant is seated in the driver compartment of a real car featuring all the actual components (steering wheel, pedals regulating speed and brakes). He is instructed to respect road regulations as well as safety rules and must perform some driving manoeuvres, such has turning at intersections, stopping when necessary, passing another car, etc.~Software Drive 3.0 by Systems Technology Inc., Hawthorne, California, USA. Magnetic head tracker (Flock of Birds, Ascension Technology Corporation, Burlington, Vermont, USA).~A fixed-base driving simulator. 2 driving scenarios: a practice (10 minutes) and a main scenario including rural and urban sections (35 minutes)."
45804007|NCT01349192|Drug|chlorhexidine gluconate oral rinse|for subjects able to swish without swallowing. 0.12% chlorhexidine gluconate oral rinse twice daily for 14 days.
45444320|NCT03819699|Drug|Lu AF20513|Lu AF20513 suspension for injection
45444321|NCT03819699|Biological|booster vaccine|booster vaccine (Cohort 2) - to be administered as per national recommendations
45444322|NCT03817827|Other|Acupuncture|this group will receive Acupuncture for 30 minutes three times per week
45444323|NCT03817827|Dietary Supplement|Diet supplementary|Diet supplementary with soy product
45444324|NCT03814239|Other|protocol|In patients of Group Protocol , basal crystalloid infusion was started at 4 ml/kg/h right after general anesthesia induction and intubation. ClearSight System (Edwards Lifesciences Cop, Irvine, CA, USA) was used to measure stroke volume variation and cardiac output, continuously and noninvasively through finger- cuffed technology. If SVV was >15% rapid crystalloid bolus of 10ml/kg or 4ml/kg colloid bolus were administered until it reached a value of ≤15%. After two consecutive fluid boluses SVV remained >15%, administration of noradrenaline infusion was considered.
45444325|NCT03819621|Device|IRISS Medical Technologies mediGrid app|IRISS mediGrid is standalone software, loaded on a mobile electronic platform, which is intended to record and document ophthalmic and other bodily characteristics and to aid in the diagnosis of abnormalities.
45444326|NCT01300533|Drug|BIND-014|
45444327|NCT01300611|Drug|TXA127 300 mcg/kg/day|Injection, 300 mcg/kg/day for 28 days
45444328|NCT01300611|Drug|TXA127 1000 mcg/kg/day|Injection, 1000 mcg/kg/day for 28 days
45804008|NCT01349192|Drug|2% Chlorhexidine solution wipes|whole body wash solution wipes once daily for first 5 days.
45934866|NCT00069030|Biological|VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP|
45599941|NCT02326623|Other|distraction|distraction using an iPad with a selection of child-appropriate games
45599942|NCT02326623|Other|topical anesthetic cream|standard care is to use a topical anesthetic cream at the site of planning IV access
45599943|NCT02317471|Biological|autologous gp96 vaccination|"Vaccination of gp96 derived from autologous tumor tissue. Treatment will be started between 3-6 weeks after the surgery.~gp96 of 25ug in 1mL normal saline s.c. on days 1 of each cycle, up to a maximum of 10 doses (1 cycle= 7 days). 200-400mg cyclophosphamide i.v. 1-3 days before each gp96 infusion."
45599944|NCT02317471|Drug|Oxaliplatin+S-1|"Treatment will be start at the 5th week after the surgery.~S-1: 40~60mg bid，d1~14 q3W; oxaliplatin:130mg/m2，iv drip for 2h，d1,q3W 6 cycles."
45599945|NCT02332551|Device|NanoKnife|Irreversible electroporation (IRE) is a new, minima-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and the gallbladder .
45599946|NCT03501355|Device|Inspiratory muscle strength training|"Treatment group will receive inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 50% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 50% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
45599947|NCT03501355|Device|Inspiratory muscle endurance training|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 30% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
45599948|NCT02326077|Other|Ultrasound|Monitoring of the mechanism of labor
45599949|NCT02326077|Other|Acceptability of ultrasound monitoring of labor|Evaluation of the acceptability of intrapartum ultrasound monitoring - the rate of uptake ultrasound protocol during labor
45444329|NCT05323851|Behavioral|COVID-surg-SPIGC questionnaire|The questionnaire aimed to evaluate how the COVID-19 pandemic determined a shift in daily practice through a multidimensional assessment of surgical clinical care in three different time frames.
45754898|NCT04638283|Behavioral|Goal Attainment Scaling|Individual goals will be formulated and measured by Goal Attainment Scaling (GAS). GAS provides a method for quantifying the attainment of individualized goals, typically set in cognitive rehabilitation. Different levels of outcomes for each goal are operationalized in a five-point scale and given a numeric value. For each individual goal, minus two refers to the goal attainment much less than expected, minus one refers to a little less than expected, zero refers to expected outcome, plus one refers to a little bit better than expected and plus two refers to goal attainment much better than expected. The participants can establish as many goals as desired. Outcomes can be summed within different patient goals, as well as across patients to assess overall outcome of treatment outcomes.
45754899|NCT03154424|Procedure|External fixation in treatment the distal radius fracture|Compare two techniques
45754900|NCT04405310|Biological|Convalescent Plasma of patients with COVID-19|Convalescent Plasma from patients with covid-19 by Apheresis, the maximum plasma volume withdrawn per session should not exceed 600 mL, excluding the anticoagulant volume, or 16% of the total blood volume, in the absence of volumetric replacement.
45754901|NCT04405310|Other|placebo (hartmann plus albumine)|use of albumin 20% in 250cc of Hartmann solution
45754902|NCT01671410|Drug|oral morphine|Oral morphine for the treatment of neonatal abstinence syndrome
45754903|NCT01671410|Drug|sublingual buprenorphine|Sublingual buprenorphine for the treatment of neonatal abstinence syndrome
45754904|NCT01671566|Behavioral|Home based interval training|The participant in the intervention group will receive an individualized interval training program. The individualized adjustments in training load will be made from the results of the CPET-incremental and adjustments in training time from the results of the constant work rate 75% of peak work rate (Watt). The training will be home based and performed on a ergometer cycle 3 times a week for twelve weeks. During exercise they will wear a heart rate monitoring watch. The registered heart rate will be transferred to a webpage after the exercise session. Only the physiotherapist and participant have the access to this page. The physiotherapist and participant will have a weekly contact to promote compliance, provide feedback and if necessary adjust the training time or load. Progression in training load and time will be made when necessary to keep a relevant intensity.
45934867|NCT00210067|Drug|denufosol tetrasodium (INS37217) Intravitreal Injection|
45444330|NCT03817749|Dietary Supplement|Exogenous ketone monoester|Participants will consume 20g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.
45444331|NCT03817671|Other|5% O2|Culturing embryos in 5% O2 just after thawing and till embryo transfer
45444332|NCT03817671|Other|2% O2|Culturing embryos in 2% O2 just after thawing and till embryo transfer
45444333|NCT01301313|Drug|Levosimendan|Levosimendan 2.5 mg / ml ampoules. The drug will be administrated in continuous intravenous perfusion in a single dose of 0.1 - 0.2 micrograms/ kg / min for 24 hours.
45444334|NCT01301313|Drug|Conventional intensified inotropic treatment|Increasing the dose and / or the number of inotropes (dopamine and / or dobutamine and / or milrinone and / or adrenaline)
45444335|NCT04540575|Behavioral|NICU Acquires MOM|Mother receives 1) hospital-grade electric smart breast pump for home use at no charge to the mother while the infant is in the NICU and the mother continues to pump; 2) free pickup of expressed MOM from home to transport to NICU 2-3 times per week during weekdays as needed; 3) receives payment for opportunity costs of pumping and handling milk at $24.00/day for each day that the mother pumps during her infant's NICU stay
45444336|NCT04540575|Behavioral|Mother Provides MOM|Mother receives standard Rush NICU lactation care
45599950|NCT02326077|Other|Patients' experience regarding intrapartum ultrasound|The day after birth, consenting women are invited to take part in a questionnaire survey. Questionnaires contained no identifying information other than a code number and contains features regarding the patient's impression about the ultrasound monitoring scans during labor. The final questions concerned the willingness of having again another such protocol for labor monitoring in the future.
45599951|NCT02305225|Behavioral|Sleep Deprivation|
45599952|NCT03501199|Other|platelet-rich fibrin placement|filling the buccal gap with platelet-rich fibrin after immediate dental implant placement
45599953|NCT03501199|Other|xenogenic graft placement|filling the buccal gap with xenogenic graft after immediate dental implant placement
45599954|NCT03501199|Other|no extra material|filling the buccal gap with no material after immediate dental implant placement
45599955|NCT03501199|Procedure|tooth extraction|extraction of tooth which is unrestorable
45599956|NCT03501199|Procedure|immediate implant placement|putting dental implant into a socket which has been prepared with compatible drills
45599957|NCT03501199|Other|collagen membran placement|placing collagen membran on extraction socket after dental implant placement to cover all
45599958|NCT03501199|Procedure|raising flap|raising the buccal flap with two vertical incision to cover extraction socket for primary closure
45599959|NCT02332629|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
45599960|NCT02332629|Drug|Isotonic Sodium Chloride|Placebo
45599961|NCT02313337|Other|Oral administration|Premedicate--Oral administration of a mixture at preoperative 30 minutes: ketamine 3 mg/kg, midazolam 0.5 mg/kg and atropine 0.02 mg/kg, plus 50% glucose solution to 0.5ml /kg.
45754905|NCT02676752|Procedure|Medical Examination|Evaluation of secondary lymphedema and fibrosis (LEF) status
45599962|NCT02313337|Other|Intramuscular injection|Premedicate--At preoperative 30 minutes intramuscular injection of atropine 0.02 mg/kg, 5 minutes before entering the operation room, intramuscular injection of ketamine 5 mg/kg.
45599963|NCT02313337|Other|Rectal perfusion|Premedicate--At preoperative 30 minutes rectal infusion of midazolam 0.5mg/kg
45599964|NCT02313337|Other|Dripping nose|Premedicate--At preoperative 30 minutes dripping nose of Imidazole valium 0.2 mg/kg
45599965|NCT02313337|Drug|Anesthesia induction(midazolam,fentanyl,propofol,atracurium)|After entering the operation room ,all cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
45599966|NCT02313337|Procedure|Intubation|Intubation when the trachea-oesophageal fistula（TOF） value fell 15%, BIS value dropped to 40.
45599967|NCT02313337|Drug|Anesthesia maintenance(midazolam,fentanyl,propofol,atracurium)|All cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
45599968|NCT02305303|Procedure|Diary|A diary written prospectively during the ICU stay by the staff and relatives
45599969|NCT02330835|Behavioral|In the Drivers Seat|Multimedia student behavior management program for school bus drivers and school administrators
45599970|NCT02330835|Behavioral|School bus driver training videos|Basic bus driving safety videos
45754906|NCT02676752|Other|Questionnaire Administration|Completion of questionnaires
45444337|NCT03817359|Combination Product|Remifentanil-propofol mixture|Participants receive total intravenous anesthesia with remifentanil-propofol mixture by single TCI pump in intervention group. All TCI target concentration adjustments or extra bolus of propofol or remifentanil during operation were based on BIS and ANI monitor.
45599971|NCT04463563|Other|Physiological|Changes to carbon dioxide, oxygen flow, cardiac output, blood pressure, haemoglobin, surgical surveillance, depth of anaesthesia, patient position.
45599972|NCT02325999|Procedure|ESD AND LRLD|A new therapy for gastric cancer : Endoscopic Submucosal Dissection combine with Laparoscopic Regional Lymph node Dissection.
45599973|NCT04463017|Drug|HU6|HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
45754907|NCT02676752|Procedure|Shear Wave Elastography|Undergo ultrasound shear wave elastrography
45444338|NCT03281876|Biological|NTHi Mcat investigational vaccine (GSK3277511A)|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.
45444339|NCT03281876|Biological|Placebo|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.
45599974|NCT05078073|Device|Hyperbaric oxygen therapy|Patients with aGVHD treated with HBOT every two days
45599975|NCT03503071|Procedure|Cytoreductive surgery and intraperitoneal chemotherapy|Cytoreductive surgery and intraperitoneal chemotherapy for colorectal cancer or pseudomyxoma peritonei. Either early postoperative intraperitoneal chemotherapy (EPIC) or hyperthermic intraperitoneal chemotherapy (HIPEC) is used for intraperitoneal chemotherapy.
45599976|NCT04463095|Procedure|PER ORAL ENDOSCOPY MYOTOMY (POEM)|Peroral endoscopic myotomy (POEM)combines thelong-term efficacy of a myotomy with the benefits of an endoscopic, minimally invasive procedure.Other therapeutic options include endoscopic balloon dilatation and surgical myotomy. Endoscopic balloon dilatation is still widely performed because of its relative non-invasiveness and simplicity, but it has a relatively lower success rate and often requires multiple treatment sessions. Surgical myotomy has been thought to be the curative therapeutic choice for symptomatic achalasia. However, it requires skin incisions and additional anti-reflux surgical intervention.Unlike surgical myotomy, POEM preserves the anatomical integrity of the LES and possibly minimizes postoperative reflux.
45754908|NCT03159338|Biological|Platelet rich fibrin|Platelet rich fibrin will be prepared by taking 20 cc blood and centrifugation with 28000 rpm.
45754909|NCT03159338|Biological|Placebo|In control group , after spliting the osteotomy site before fixation a placebo gel will be placed
45754910|NCT00630253|Biological|Anti-Thymocyte Globulin|30 mg/kg/day will be administered after MP on days -6, -5, -4, -3 and -2.
45754911|NCT00630253|Drug|Cyclophosphamide|5 mg/kg is to be given as a 2 hour infusion, Days -6 through -3.
45754912|NCT00630253|Drug|Fludarabine|35 mg/m^2 intravenously (IV) on days -6 through -2.
45754913|NCT00630253|Procedure|Hematopoietic Stem Cell Transplantation|Bone marrow or umbilical cord blood infusion on day 0.
45444340|NCT03813849|Diagnostic Test|Sonographic examination of uterus after surgical evacuation|
45754914|NCT00630253|Drug|Methylprednisolone|Methylprednisolone (MP) 2 mg/kg/day intravenously every 24 hours will be given from day -6 until day -2 as a premedication for ATG.
45754915|NCT00630253|Drug|Filgrastim|5 mcg/kg per day intravenously (IV) continue until Absolute neutrophil count > or = 2.5 x 10^9/L
45599977|NCT02305459|Device|Yttrium-90 loaded SIR-Spheres microspheres|Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
45599978|NCT02305459|Behavioral|QLQ-C30 with HCC module|In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient.
45599979|NCT02330757|Drug|Estradiol valerate|Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is < 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
45599980|NCT02330757|Drug|Sequential Clomiphene citrate and Gonadotropin|Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle > 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
45599981|NCT03500965|Behavioral|text-only PWL|control condition (no image)
45599982|NCT03500965|Behavioral|graphic PWL|pictorial warning
45599983|NCT03500965|Behavioral|absolute risk|Percentage risk information for smoking-related diseases for smokers
45599984|NCT03500965|Behavioral|relative risk|Percentage risk information for smoking-related diseases for smokers and non-smokers
45599985|NCT03502993|Diagnostic Test|Validation of biomarker|
45444341|NCT03813927|Dietary Supplement|Vitamin D|Supplementation with tablet 170 μg Vitamin each day.
45444342|NCT03813927|Dietary Supplement|Placebo|Placebo with tablet 20 μg Vitamin each day.
45599986|NCT03502993|Other|Antibiotic prescription|
45599987|NCT03502993|Other|re-attendance at ED|
45599988|NCT03502993|Other|Hospitalisation|
45599989|NCT03502837|Other|emotional sound and neutral sound|"Neutral voice is a meaningless sound (namely the interjection ah) and the emotional stimuli were the same voice pronouncing the same word with an emotional prosody of happiness or sadness.The stimulus material consisted of positive and negative sound selected from the International Affective Digitalized Sounds (IADS) database.In order to identify experimental stimuli sets that were matched for ratings of arousal and valence between the two valence types,investigators used an algorithm to equate normative valence and arousal ratings for the selection of auditory stimuli."
45754916|NCT00630253|Drug|Cyclosporine|Cyclosporine IV over 2 hours or orally every 8-12 hours beginning on day -3 and continuing until day 100, followed by a taper.
45754917|NCT00630253|Drug|Mycophenolate Mofetil|Day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute GVHD. Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count [ANC] > 0.5 x 10^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours PO (to a maximum dose of 1 gram).
45754918|NCT03158948|Drug|MOTREM|Formulated LR12 peptide
45754919|NCT03158948|Drug|Placebo|placebo
45754920|NCT01671722|Drug|Montelukast sodium|Montelukast sodium tablets 10mg
45754921|NCT00584701|Drug|Risperidone|Dose will start at 0.5 mg and may be increased throughout the course of the study if no adverse events occur
45754922|NCT03158870|Procedure|Surgery complications|Assessment of the influence of surgeon-anesthesiologist collaboration on surgery complications during and up to 30 days after pheochromocytoma surgery.
45754923|NCT01671878|Other|Reference Glucose|
45754924|NCT01671878|Other|Test Food 1 (Cereal)|
45754925|NCT01671878|Other|Test Food 2 (Biscuit)|
45754926|NCT00630409|Drug|Gemcitabine|800 mg IV day 1 and 8
45444343|NCT03809091|Diagnostic Test|Whole genome sequencing|Whole genome sequencing of patients and their family will be performed. Among the variants detected by WGS, disease-causing variants will be analyzed by using segregation analysis.
45444344|NCT01302015|Biological|RNL-Vascostem®|
45599990|NCT03500887|Device|intragastric bag|
45754927|NCT00630409|Drug|Doxil|24 mg/m2 every 21 days IV
45754928|NCT01671956|Biological|Bertilimumab|IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
45754929|NCT01671956|Biological|Placebo|IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
45754930|NCT00630955|Drug|memantine|Memantine 20 mg once per day for 7 days
45754931|NCT00630955|Drug|Memantine|Memantine 40 mg once per day for 7 days
45754932|NCT00630955|Drug|Placebo|Placebo once per day for 7 days
45754933|NCT05701280|Device|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of the dentate nucleus area of the cerebellum plus motor rehabilitation to improve upper-extremity function.
45754934|NCT05701280|Other|Rehabilitation|Motor rehabilitation to improve upper-extremity function.
45754935|NCT00584857|Drug|Paclitaxel ,Carboplatin , Megesterol Acetate|Paclitaxel will be administered at an appropriate dose (175mg/m2) as a 3 hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate. Megesterol Acetate will be given orally four times a day at an anti-tumor dosage of 40 mg. This will be given for a total of 6 cycles over 18 weeks with the Megace continuing for 5 years as long as no evidence of recurrence is present.
45754936|NCT03153800|Biological|bronchial basal cells|Transplantation of autologous bronchial basal cells by fiberoptic bronchoscopy.
45934868|NCT00210145|Behavioral|Aesthetic care|
45934869|NCT00210223|Procedure|Radiofrequency|
45599991|NCT03500809|Procedure|Aqueous release of the wound|"Anaesthetic drop (tetracaine 1%) followed by povidone iodine 5% drop is instilled. After 5 minutes, a sterile 30 gauge needle tip is pressed on the posterior lip of the one of the existing cuts (paracentesis or main wound) from cataract surgery to release the fluid and consequently the pressure.~This will be performed under careful monitoring to avoid any undesirable shallowing of the anterior chamber of the eye."
45599992|NCT02305615|Other|Bevacizumab|Bevacizumab at a dose and schedule according to approved label and SmPC. The recommended dose of bevacizumab, administered as an intravenous infusion, is either 5 milligrams per kilogram (mg/kg) or 10 mg/kg of body weight given once every 2 weeks or 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks. Bevacizumab is always used in combination with chemotherapy for the treatment of participants with metastatic CRC. It is recommended that treatment be continued until progression of the underlying disease or until unacceptable toxicity.
45599993|NCT02305615|Combination Product|Chemotherapy|Fluoropyrimidine-based doublet chemotherapy (5-Fluorouracil [5-FU] or capecitabine plus oxaliplatin or irinotecan) as first-line treatment; and continued fluoropyrimidine treatment with or without treatment modification for oxaliplatin or irinotecan, as per treating physician discretion.
45444345|NCT03817047|Behavioral|Physical education|"Physical education (60 minutes): In addition to the ordinary PE-lessons. The pedagogical activities taught in this lesson should be in line with the curriculum of 9th grade and led by the PE-teacher. In the Don't worry - be happy intervention this class was also organized by the students. The students practiced their Be Happy-activities, or they introduced their class peers to their Be Happy-activity. A PE-teacher was present to support the students if necessary."
45444346|NCT03817047|Behavioral|Physical active learning|The curriculum of the subjects (i.e. maths, English, Norwegian) were taught in a physically active manner. The lesson should last 30 minutes and be led by the teacher of the current subject.
45599994|NCT02313415|Procedure|UC-MSCs therapy|Before considering whether patients meet the inclusion criteria, they are diagnosed as intrauterine adhesions with at least one unsuccessful hysteroscopic surgery. And after that there will be history taking, physical examination, ultrasound examination and hysteroscopy examination. If they agree to participate, they will receive separation of adhesions by hysteroscopy surgery and endometrial biopsies, then a collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity. The procedure was performed after taking 6 mg/day × 10 days Progynova, continuous administration of the same dosage Progynova for 30 days and 60mg of progesterone were injected on the 30th day post-operation. Postoperative observation including ultrasound examination once a month for 3 times and hysteroscopy after 3 months. The doctor will select an appropriate time for pregnancy and follow-up including requiring patients to do some unscheduled visits.
45599995|NCT02313493|Behavioral|Baby Triple P|
45599996|NCT02305693|Drug|Letrozole|
45599997|NCT02305693|Procedure|Laparoscopic ovarian drilling|
45599998|NCT02317861|Drug|RDEA3170|Oral Treatment
45599999|NCT02317861|Drug|Febuxostat|Oral Treatment
45600000|NCT02317861|Drug|Benzbromarone|Oral Treatment
45600001|NCT02317939|Other|instruction|online instruction tutorials at followup visits
45600002|NCT02317939|Other|standard baseline instruction|self-guidance at followup visits
45600003|NCT02318017|Drug|Methylphenidate|Before neurocognitive testing, Methylphenidate/Placebo will be given
45600004|NCT02318017|Drug|Placebo|
45600005|NCT02313727|Drug|Pamidronate|intravenous infusion of pamidronate 60 mg
45600006|NCT02313727|Other|Placebo (NaCl 0.9%)|intravenous infusion of NaCl 0.9% 500 ml
45600007|NCT02313805|Other|Checklist|The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are on the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
45600008|NCT03132493|Drug|Nivolumab 10 MG/ML|nivolumab 3 mg/kg as an intravenous infusion every 2 weeks until progression
45600009|NCT03508453|Biological|IC14|Monoclonal antibody against CD14
45754937|NCT00585013|Drug|Nitric Oxide|Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
45600010|NCT03508453|Other|Placebo|sterile normal saline for injection prepared to be identical to study drug
45600011|NCT02313883|Drug|PerioSept(r)|Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
45600012|NCT02313961|Other|Remote ischaemic conditioning|Remote ischaemic conditioning is induced by 3 cycles of manual inflation of a blood pressure cuff placed on the left lower limb to 200 mmHg for 5 minutes and then deflation to 0 mmHg for another 5 minutes.
45600013|NCT02318173|Device|Dilapan-S|Synthetic osmotic dilators Dilapan-S, Dilasoft for cervical ripening prior to induction of labor in women with unfavourable cervix
45600014|NCT03500653|Dietary Supplement|Curcumin|4 gr curcumin
45600015|NCT03500653|Dietary Supplement|Placebo|4 gr placebo
45600016|NCT02318251|Other|Involuntary muscle contractions|Physiotherapy program focusing on involuntary pelvic floor muscle fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day). This program includes the standard physiotherapy.
45754938|NCT01672034|Procedure|Laparoscopic gastric bypass surgery|
45600017|NCT02318251|Other|Voluntary muscle contractions|Physiotherapy program (physiotherapy standard program) focusing on voluntary fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day).
45754939|NCT01672112|Drug|Oxycodone|Oral Oxycodone 5mg 6hrly/prn
45754940|NCT01672112|Drug|Codeine|Oral Codeine 60mg 6hrly/prn
45754941|NCT00632281|Radiation|Stereotactic Body Radiation Therapy|Prescription dose: 48 Gy or 60 Gy RT
45754942|NCT05540366|Other|Physical therapy combined with aerobic exercise|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes aerobic exercise programme on a bike.
45600018|NCT02305927|Dietary Supplement|Vitamin D3 (cholecalciferol)|Supplements containing 3,000 IU vitamin D3 taken orally once per day by the mother starting from the second trimester until 12 months postpartum
45444347|NCT03817047|Behavioral|Physical activity|"Without a connection to any specific subject Physical activity should be performed as 30 minutes a week. There are no specific aims to be taught in this lesson, but physical activities that stimulates mastery, joy and well-being should be in focus."
45444348|NCT03817047|Behavioral|Be happy|The Be Happy classes were self-organized activity groups of at least three students, developed according to activity preferences across regular classes. The Be Happy groups practiced traditional sports and physical activities, lifestyle sports, dancing, out-door recreation, drama etc. - inside or outside school.
45444349|NCT01313546|Other|Stimulation of quariceps muscle|stimulation of quadriceps muscle through the stimulating catheter
45600019|NCT02305927|Other|Placebo|Placebo supplements taken orally once per day by the mother starting from the second trimester until 12 months postpartum
45754943|NCT05540366|Other|Physical Therapy|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the intervention group)
45754944|NCT00585637|Drug|Vitamin D|Taken orally every day for three months
45600020|NCT02318407|Drug|AMG 403|AMG 403 for the treatment of subjects with osteoarthritis
45600021|NCT02318407|Drug|Placebo|contains no active drug
45600022|NCT03500575|Device|photopheresis|• Treated group will receive ECP with Therakos online system. Each session consists in 1 treatment for 2 consecutive days. First session stars within 72 hours after transplantation followed by a session weekly for 3 time and 2 sessions for the next 2 months (6 sessions = 12 treatment)
45600023|NCT03500497|Diagnostic Test|RetHe measurement (Sysmex)|RetHe measurement is done from blood samples gained during standard patient care perioperatively
45600024|NCT02440009|Drug|Itraconazole|Oral itraconazole 200 mg BD for 6 months
45600025|NCT02440009|Drug|Glucocorticoids|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months.
45600026|NCT02318485|Biological|Limbal epithelial stem cell graft|
45600027|NCT02318563|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based)
45600028|NCT02318563|Drug|Placebo Solution|A matching oral solution containing no cannabidiol
45600029|NCT02314195|Drug|Selective serotonin re-uptake inhibitor|A medication of selective serotonin re-uptake inhibitor (SSRI) family, Behavioral. The type and dosage of the medication was decided by the treating psychiatrist.
45600030|NCT02314195|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for obsessive compulsive disorder carried out by a psychologist.
45600031|NCT02314195|Other|Music therapy|12 sessions of 30-minute individual-based receptive music therapy, supervised by the treating psychiatrist.
45600032|NCT02314273|Drug|rhIL-11|patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80000/mL
45600033|NCT03502525|Behavioral|Break the Cycle Intervention|The intervention uses motivational interviewing to enhance persons who inject drugs' (PWID) motivation and skills to avoid helping non-PWID transition to injecting. The intervention entails discussions with participants in 8 areas: the participant's first time injecting; the participant's exposures to situations where helping with non-PWIDs' first injections is an option, and the extent to which they helped; their behaviors that might encourage non-PWID to inject for the first time; the risks associated with injection drug use; role-playing in which participants develop behaviors and scripts for avoiding or refusing requests to initiate non-PWID into injection; role- playing talking with other PWID about not encouraging non-PWID to start injecting; imparting safer injection practices when helping with a first injection seems like the best option; and receiving training in and using naloxone to reverse overdoses.
45600034|NCT02314351|Drug|Metoclopramide 10 mg|Intravenous form of metoclopramide is in the same appearance with placebo
45600035|NCT02314351|Drug|Placebo|Intravenous form of metoclopramide is in the same appearance with placebo
45600036|NCT02314351|Drug|Fentanyl|Intravenous fentanyl (1 mcg/kg), if pain persists at 30th minute
45600037|NCT02314429|Device|Vaginal ring releasing lactic acid (racemic mixture)|
45600038|NCT02314507|Other|Gua sha|A smooth, rounded-edged Gua sha tool will be press-stroked into the flesh enough to contact the fascial layer start at the midline of the subject's back. A stroke line is typically 4 to 6 inches long. Press-stroking will be repeated in one direction until the petechiae raises on that stroke line, typically 8 to 12 strokes. Gua sha will then be continued at the next stroke line directly adjacent to the one before, until the area covered the lower one third of the back.
45600039|NCT02314507|Other|Hot pack|A hydrocollator pack will be used and it will be stored at 42-43oC in the hydrocollator. 6 layers of towel will be used to cover the hydrocollator pack when applying to the back of the subjects.
45600040|NCT02318641|Device|oximetry|Retinal oximetry will be performed with Oxymap.
45600041|NCT04464031|Other|electronic alert|The e-alert system was developed by the divisions of Nephrology and Information Management of Guangdong Provincial People's Hospital (Patent Application 201610001950.5). The alert system made a diagnosis of acute kidney injury according to Kidney Disease: Improving Global Outcomes criteria. Then, the doctor receives an alert of acute kidney injury.
45754945|NCT00585637|Dietary Supplement|Placebo|Placebo pill taken once daily for 3 month
45754946|NCT01670630|Procedure|Sheathed speculum examination|
45754947|NCT01670630|Procedure|Standard speculum examination|
45754948|NCT03158558|Behavioral|Accelerated, Multi-Couple Group CBCT for PTSD|Intensive weekend retreat version of cognitive-behavioral conjoint therapy for PTSD (Monson & Fredman, 2012)
45754949|NCT03158792|Drug|Enoxaparin 20Mg/0.2mL Prefilled Syringe|Enoxaparin 20mg subcutaneously once daily
45754950|NCT03158792|Drug|Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml|Enoxaparin 30mg subcutaneously once daily. Half of the graduated 60Mg/0.6Ml Inj Syringe is administered
45754951|NCT01798771|Procedure|Interventional arm|5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.
45754952|NCT01798771|Procedure|Control arm|5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.
45934870|NCT00041288|Biological|therapeutic allogeneic lymphocytes|
45754953|NCT03158480|Biological|DC-CIK immunotherapy|Cytokine-induced killer (CIK) cells are co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to condylomata acuminata patients
45754954|NCT05701202|Dietary Supplement|Super-Whey protein|2 different protein supplements (as above) will be given in a randomised crossover fashion to participants
45754955|NCT05701202|Dietary Supplement|Isonitrogenous whey protein|2 different protein supplements (as above) will be given in a randomised crossover fashion to participants
45600042|NCT03500185|Other|PFMT in group|Participants randomized to this group will perform the PFMT protocol in a group, with physiotherapeutic supervision, lasting 1 hour, in the Outpatient Clinic of Gynecology of Hospital of Clinics of Porto Alegre (HCPA), for a period of 3 months. You will also be instructed to perform exercises at home. After this period, they will be reassessed and will follow the same protocol for another 3 months now at home. After this period, they will be evaluated again.
45600043|NCT03500185|Other|PFMT at home|Randomized participants for this group will receive guidance on the home PFMT protocol on the day of the initial evaluation. They will be instructed to perform the exercises daily for a period of 3 months. After 3 months they will be re-evaluated and will follow the same protocol for another 3 months at home. After this period they will be evaluated again.
45600044|NCT02314585|Other|Exercise|Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
45600045|NCT02314585|Other|Education|Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
45754956|NCT00633919|Biological|SLITone(TM) Dermatophagoides mix|Sublingual immunotherapy with SLITone Dermatophagoides mix (200 STU) once daily for 2 years
45754957|NCT00633919|Biological|Placebo|Sublingual immunotherapy once daily for 2 years
45754958|NCT00633919|Drug|Salbutamol inhaler|200 µg per puff; a short acting beta2-agonist (please refer to the 'detailed description' for details on the use)
45754959|NCT00633919|Drug|Budesonide/formoterol inhaler|80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting beta2-agonist (please refer to the 'detailed description' for details on the use)
45754960|NCT00633919|Drug|Prednisone tablet|5 mg per tablet; oral corticosteroids (please refer to the 'detailed description' for details on the use)
45754961|NCT00633919|Drug|Desloratadine tablet|5 mg per tablet: anti-histamine (please refer to the 'detailed description' for details on the use)
45444350|NCT03817281|Device|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
45444351|NCT01560351|Device|rTMS|Two sessions of repeated Transcranial Magnetic Stimulation (real rTMS and sham rTMS) are planned for each participant, at interval of 4 weeks, in a random order.
45444352|NCT02819518|Biological|Pembrolizumab|IV infusion
45444353|NCT02819518|Drug|Nab-paclitaxel|IV infusion
45754962|NCT00633919|Drug|Budesonide nasal spray|64 µg per puff; inhaled corticosteroid (please refer to the 'detailed description' for details on the use)
45754963|NCT01672190|Other|Yoga Therapy Program|
45444354|NCT02819518|Drug|Paclitaxel|IV infusion
45444355|NCT02819518|Drug|Gemcitabine|IV infusion
45444356|NCT02819518|Drug|Carboplatin|IV infusion
45444357|NCT02819518|Drug|Normale Saline Solution|IV infusion
45444358|NCT03310580|Drug|AR-13324 Ophthalmic Solution 0.02%|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
45444359|NCT03310580|Drug|AR-13324 Ophthalmic Solution 0.04%|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
45444360|NCT03310580|Drug|AR-13324 Ophthalmic Solution Placebo|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
45444361|NCT04514991|Device|Foundation|Collagen-based, bone filling augmentation material used to stimulate bone formation in extraction sockets or bone defects in the alveolar ridge.
45444362|NCT03816969|Device|Self-pressurized air-Q with blocker|"It has a drain tube through which a suction tube is passed like the Air-QILA blocker, and Instead of the pilot balloon and inflating cuff, the air-Q SP with blocker incorporates a self-regulating periglottic cuff at the end of this tube , a communication orifice at the junction of the peri-glottic cuff and the airway tube.~This communication between two spaces enables the cuff to dynamically regulate intra-cuff pressure depending on airway pressure. This distinguishing feature of the air-Q SP may result in reduced risk for airway morbidities related to cuff hyperinflation"
45444363|NCT03816969|Device|Air-Q ILA blocker|A good seal will provide good ventilation, will guarantee the desired depth of anesthesia at lower gas flows and with lesser leaks to the esophagus, it will not cause rise in intragastric pressure thus preventing regurgitation However, When the cuff pressure is more than the mucosal perfusion pressure, it is likely to either cause postoperative pharyngo-laryngeal symptoms (sore throat, dysphagia, dysphonia) or cause local mucosal trauma and nerve injuries
45444364|NCT05275166|Behavioral|Induction of alcohol craving|Presentation of images that may induce craving for alcohol. Recording of brain activity
45444365|NCT05275166|Other|Questionnaires|Questionnaires related to alcohol, quality of life, anxiety and depression
45444366|NCT03817203|Other|Kinesio tape application|Kinesio tape application combined with pelvic floor exercises will be performed.Taping is carried out for 2 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
45444367|NCT03817203|Other|Sham tape application|Sham tape application combined with pelvic floor exercises will be performed.Sham taping is carried out for 2 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
45444368|NCT03816579|Other|PRO-A|30 g of beef protein will be consumed at each meal
45444369|NCT03816579|Other|PRO-B|30 g of complementary proteins will be consumed at each meal
45444370|NCT03816579|Other|PRO-C|30 g of complementary proteins will be consumed over 24 hours
45444371|NCT03781804|Drug|OPN-375|OPN-375, BID
45444372|NCT03638336|Device|ILY robotic flexible ureteroscopy|fragmentation of nephrolithiasis
45444373|NCT03813771|Drug|Benepali|Benepali will be adminstered subcutaneously at a dose of 50mg weekly and discontinued at the primary endpoint (24 weeks).
45934871|NCT00041288|Drug|cyclophosphamide|
45754964|NCT01672268|Other|cardiac computed tomography|cardiac computed tomography, Transcatheter Aortic Valve Implantation, safety and efficacy
45754965|NCT03158246|Drug|Generic Zoledronic Acid|Generic Zoledronic Acid (Yigu®) 5mg/100ml injection
45754966|NCT03158246|Drug|Original Zoledronic Acid|Original Zoledronic Acid (Aclasta®) 5mg/100ml injection
45754967|NCT03158246|Dietary Supplement|calcium|600mg/d calcium for oral daily
45754968|NCT03158246|Dietary Supplement|vitamin D|925IU/d vitamin D for oral daily
45754969|NCT03157856|Other|Fluorescence assessment|All subjects of the study are going to have a radical prostatectomy. The FEMTO-ST medical device is used on 3 fresh biopsies (2 healthy and 1 malignant) which will be prelevated from the resected prostate in order to determine the prostatic or non-prostatic nature of tissue.
45754970|NCT03157934|Other|not applicable (observational study)|Observational study without study related intervention
45754971|NCT00515411|Drug|Docetaxel, Leucovorin, Fluorouracil, Cisplatin|Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min)
45754972|NCT00515411|Drug|Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen|"Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17~* 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg~Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter."
45444374|NCT03813771|Drug|Sulfasalazine|Sulfasalazine will be added at follow up visits (T2T care) if the subject fails to achieve low disease activity,administered orally at a dose of 1g twice daily.
45444375|NCT03813771|Drug|Methotrexate|Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks.
45754973|NCT00515411|Drug|Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab|"Treatment for Her2 Positive Participants~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes."
45754974|NCT00586261|Drug|Pioglitazone|Pioglitazone 30 mg daily for 6 months
45754975|NCT00586261|Drug|Placebo|Placebo 30 mg daily for 6 months
45754976|NCT00586261|Drug|Nitroglycerin|0.4 mg sublingual nitroglycerin tablet was given to all patients without a contraindication to check the brachial reactivity.
45754977|NCT03157778|Other|Obese men|Biological measures before, just before, and after lunch, in obese men
45754978|NCT03157778|Other|Normal-weight men|Biological measures before, just before, and after lunch, in normal-weight men.
45754979|NCT03157622|Behavioral|Exposure in vivo|10 sessions based on an individualized fear hierarchy
45754980|NCT03157622|Behavioral|Cognitive Behavioural Psychotherapy|graded activity, relaxation techniques and cognitive interventions
45754981|NCT00634621|Drug|Hexaminolevulinate (Hexvix)|Each patient enrolled into the study will be infused with 50 mL of a 2 mg/mL Hexvix solution in the bladder using a catheter. Subsequently, after fluid retention by the patient in the bladder for one hour, the bladder will be emptied.
45754982|NCT03157700|Behavioral|REAL media curriculum|REAL media is a 5-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth substance use.
45754983|NCT02744989|Device|Neuroconn or Neuroelectric tDCS stimulator|Stimulation parameters were chosen in conformity with those for the treatment of schizophrenic symptoms (Brunelin et al, 2012), adapted according to the latest data from the literature and the tDCS operating stimulator. The experimental tDCS group will receive the ACTIVE stimulation with the following parameters: oscillatory Direct Current with high frequency random noise stimulation (hf-tRNS - 100 to 500 Hz), Intensity = 2 mA, offset = + 1 mA, seance duration = 20 minutes ramp up/ramp down 30 seconds. Total number of sessions = 10 (sessions twice daily for 5 days separated by at least 2 hours for 5 consecutive weekdays).
45754984|NCT02744989|Device|Sham tDCS|The control group will receive the SHAM stimulation (placebo) following the same regimen (i.e., twice daily sessions separated by at least 2 hours for 5 consecutive weekdays). Sham stimulation consists of a 20 minutes session including 40 seconds of active stimulation (same parameters as in the ACTIVE arm) at the beginning of the sessions, whatever the stimulator
45754985|NCT05699798|Other|Conservative Treatment (CT)|Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions.
45804009|NCT01349192|Behavioral|Environmental Decontamination|"wipe down high touch surfaces and medical equipment with surface disinfecting wipes daily for the first 21 days.~wash all linens and towels in hot water once weekly for three weeks."
45444376|NCT03813771|Drug|Hydroxychloroquine|Hydroxychloroquine will be added at follow up visits (T2T care) if the subject fails to achieve low diseaseactivity, administered at a dose of 200mg daily.
45934872|NCT00041288|Drug|cyclosporine|
45444377|NCT03401762|Behavioral|MCI|EMG-controlled game
45444378|NCT03401762|Behavioral|Sham MCI|Sham control game
45444379|NCT03813693|Other|towels impregnated with 2% chlorhexidine gluconate|"The first TICHG should be used on the neck, chest and abdomen; The second TICHG should be used on the right upper limb, start at the shoulder; The third TICHG was intended for the upper left limb; The fourth TICHG should be used on the neck and chest; The fifth TICHG was for the right lower limb; The sixth TICHG should be used on the lower left limb.~2) Time of application: use six TICHGs the night before surgery and the six remaining on the morning of surgery.~3) After the hygiene of each member, discard the TICHG. After use of TICHG, allow the product to dry on the skin. Do not use bath towels to dry yourself and wear clean clothes."
45444380|NCT03813693|Other|chlorhexidine gluconate 2% liquid|Spread the product on the skin during the bath and massage for 3 minutes, so that it is distributed equally to all parts of the body (except the face, hair and intimate area). Then rinse with water and dry with a clean, dry towel, and wear clean clothes.
45444381|NCT02036242|Drug|Sole local anesthetic|0.125% ropivacaine 10-15 ml every 1h during labor delivery
45444382|NCT02036242|Drug|Sufentanil (Opioid plus local anesthetic)|Sufentanil combined with 0.125% ropivacaine, 10-15 ml every 1h during labor delivery
45444383|NCT02036242|Drug|Ropivacaine|
45600046|NCT02314663|Device|"COMBINED STRATEGY"|"Participants in the intervention group will be supplied with: a) printed matter containing information on the disease and its management (this will be handed out at each of the follow-up visits); b) mobile-telephone text messages containing guideline summaries, reminders of forthcoming appointments and/or arrangements for making new appointments in the event of non-attendance (in the periods between visits); and, c) self-report cards to check compliance with recommendations (across the entire follow-up)."
45600047|NCT04463875|Dietary Supplement|magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10|Supplementation per os
45600048|NCT03500029|Radiation|Transcranial magnetic stimulation (TMS)|TMS treatment group is treated with TMS for 20-40 minutes a time, 5 times a week. The stimulation parameters were 20 Hz and 80% MT. Each stimulation continues for 2 seconds, and the interval time of stimulation is 58 seconds.
45600049|NCT03500029|Drug|antidepressants|Medication group is treated with anti-depression for 6 weeks. The drugs and their doses belong to the first-line treatment for depression in the current guideline .
45600050|NCT03508375|Biological|blood samples|blood samples
45600051|NCT02330991|Drug|Temozolomide|
45600052|NCT03502447|Device|TearCare|TearCare treatment includes an in-office 15 minute thermal treatment session where heat is delivered to the eyelids. This is immediately followed by manual clearing of the meibomian glands.
45600053|NCT03502447|Device|Warm Compress and Lid Massage|Subjects randomized to the Warm Compress and Lid Massage Group will be instructed to apply a moist, warm compress to their eyelids daily for 5 minutes and then perform lid massage.
45754986|NCT05699798|Other|Instrument-assisted Soft Tissue Mobilization (IASTM)|"IASTM was performed only on the neck and upper back muscles on the aching side using the sweep technique on the origo and insertion lines. A total of 6 sessions were applied, two sessions per week for 3 weeks.~Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions."
45754987|NCT05699798|Other|Extracorporeal Shock Wave Therapy (ESWT)|"ESWT therapy was applied on the muscle with active trigger point, at 1.5-2.0 bar pressure, at 10 Hz frequency, 2000 beats in each session, twice a week, in total 6 sessions.~Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions."
45754988|NCT00515723|Drug|risperidone|randomized to 12 week trial of risperidone.
46066498|NCT01622127|Device|Parietex ProGrip™|ProGrip™ mesh is a lightweight (40g/m2) monofilament polypropylene or polyester mesh with resorbable polylactic acid (PLA) micro-grips, which provide self-gripping properties during the first few months after implantation.
46066499|NCT01621594|Device|The Toshiba Aquilion ONE CT system|To test the diagnostic accuracy of low-radiation dose CT coronary angiography for detecting significant coronary artery stenosis and to determine the prognostic value of low-radiation dose CT coronary angiography for discriminating patient risk of death or major adverse cardiac events.
46066500|NCT03197922|Combination Product|MIE Treatment|"Appointments consist of a series of sitting routines (i.e., sits). Each sit consists of 10 min on the toilet, followed by 1 min of standing, then repeating the 10 min on the toilet 1 min off, for up to 32 cumulative minutes of sitting. The first sit occurs prior to the administration of any medication providing an opportunity for an independent continent bowel movement. If no continent bowel movement occurs, trained staff administer a dose of a liquid glycerin suppository, immediately followed by another sit to ensure any resulting bowel movement is continent. Glycerin suppositories are replaced by bisacodyl if 2 days pass without a continent bowel movement using the liquid glycerin suppository. Behavioral intervention consists of potent positive reinforcers when a continent bowel movement occurs. As independent continent bowel movements begin to occur, the need for the medical regimen diminishes, and is gradually faded out entirely."
46066501|NCT01613118|Drug|RE-021 (Sparsentan)|Oral, once-daily
46066502|NCT01613118|Drug|Irbesartan|Oral, once-daily
46066503|NCT01575808|Device|GP1101|Endovascular stent graft implantation
46066504|NCT01563341|Device|Deep brain stimulation|Study will be utilizing multiple brain electrodes simultaneously. The study will require at least two electrodes to be placed in one cerebral hemisphere (one for motor improvement and one for potential cognitive implications).
46073591|NCT00637962|Biological|Carbopol 974|vaginal immunisation with Carbopol 974 P 0.924%; benzyl alcohol 1.09%; sodium hydroxide 0.176%; and purified water 97.81%. alone on 9 occasions in one menstrual cycle
45444384|NCT05281107|Dietary Supplement|Placebo, 500 mg calcium|Berry flavoured sachet powder (500 mg calcium)
45600054|NCT02306083|Drug|Placebo three times a day|
45600055|NCT02306083|Drug|glucosamine sulfate 1500 mg three times a day|
45600056|NCT03502369|Procedure|Anterior Quadratus lamborum block|Local anaesthetic will be injected in the fascial plane between psoas major muscle and quadratus lumborum muscle.
45600057|NCT02318875|Dietary Supplement|Kritech administration|300mg/day (1 capsule) during 12 weeks; oral ingestion
45600058|NCT02318875|Other|Placebo adminstration|1 placebo capsule per day during 12 weeks; oral ingestion
45600059|NCT02318953|Device|Mobile app follow-up care|The mobile app follow-up care is an application that can be loaded on to a smartphone. It allows the patient to submit photos of their surgical site, VAS pain scores, and QoR9 scores. The information collected is transmitted to members of the surgical team (i.e. the primary surgeon) and used to monitor recovery over the first 30-days following surgery.
45600060|NCT02318953|Other|Conventional, in-person follow-up care|This includes a typical in-person visit with the operating surgeon at one- and four-weeks after surgery.
45600061|NCT04462939|Dietary Supplement|Elevit Breastfeeding & Postnatal Care|Multi-micronutrients, lutein and DHA soft gel capsules; one capsule daily, oral
45600062|NCT04462939|Drug|Placebo|No active ingredients except of 225 μg iodine; One capsule daily, oral
45444385|NCT05281107|Dietary Supplement|600 IU vitamin D + 500 mg calcium|Berry flavoured sachet powder (600 IU vitamin D + 500 mg calcium)
45600063|NCT03502291|Biological|Study one: LAIV + Inoculation|Pneumococci bacteria nasal inoculation following vaccination with LAIV and intramuscular placebo
45600064|NCT03502291|Biological|Study one: Placebo + Inoculation|Pneumococci bacteria nasal inoculation following vaccination QIV with nasal placebo spray
45600065|NCT03502291|Biological|Study two: Inoculation + LAIV|Pneumococci bacteria nasal inoculation prior to vaccination with LAIV and intramuscular placebo
45600066|NCT03502291|Biological|Study two: Inoculation + placebo|Pneumococci bacteria nasal inoculation prior to vaccination QIV with nasal placebo
45600067|NCT02306239|Drug|Terlipressin|
45600068|NCT02306239|Drug|Norepinephrine|
45600069|NCT02314741|Procedure|POEM Procedure|The procedure is performed under anesthesia.The procedure involves endoscopic electrosurgical dissection with an Olympus triangular tip knife.The myotomy is usually ~6cm long & averages 8-10cm. After the myotomy is performed the scope is withdrawn & inserted into the lumen to inspect the mucosa, ensure mucosal integrity & confirm easy passage of the endoscope through the LES consistent with an adequate myotomy. The mucosal entry site is usually 2-3cm long, & is closed with 5-10 endoscopic clips. Patients are hospitalized after procedure for observation.The patient is given IV-nutrition until post-operative day 1. An esophagram is obtained. If no loss of mucosal integrity or leak is noted, a liquid diet is started, which is continued for several days before initiating a solid diet.
45600070|NCT02319187|Drug|S1|S1 80mg to 120 mg per day on Days 1-14, every 21 days
45600071|NCT02319187|Drug|S-1|S1 80mg to 120 mg per day on Days 1-10, every 14 days;
45600072|NCT02319187|Drug|irinotecan|irinotecan 160mg/m2 d1, every 14 days
45754989|NCT00515723|Drug|olanzapine|randomized to 12 week trial of olanzapine.
45754990|NCT00515723|Drug|quetiapine|randomized to 12 week trial of quetiapine.
45754991|NCT00515723|Drug|ziprasidone|randomized to 12 week trial of ziprasidone.
45444386|NCT05281107|Dietary Supplement|1200 IU vitamin D + 500 mg calcium|Berry flavoured sachet powder (1200 IU vitamin D + 500 mg calcium)
45444387|NCT05281107|Dietary Supplement|4000 IU vitamin D + 500 mg calcium|Berry flavoured sachet powder (4000 IU vitamin D + 500 mg calcium)
45754992|NCT04405154|Biological|Camrelizumab|Administered as an intravenous (IV) infusion every 2 weeks (Q2W): 14 days prior to radiation, then Day 1 of radiation and then every 14 days for total 8 doses.
45754993|NCT04405154|Drug|Cisplatin|75-100 mg/m^2 administered as an IV infusion Q3W, for a total of 3 doses, at the same time as radiation: Day 1, Day 22, Day 43 of radiation.
45754994|NCT04405154|Radiation|IMRT or VMAT|66-70 Gy given in 33-35 fractions over 6-7 weeks.
45754995|NCT00586573|Drug|memantine hydrochloride|tablet, 5-20 mg, twice daily, by mouth, 12 weeks
45934873|NCT00041288|Drug|fludarabine phosphate|
45934874|NCT00041288|Drug|methotrexate|
45444388|NCT03415022|Behavioral|computer-based treatment|30 minute sessions of free viewing of faces and listening to music
45934875|NCT00041288|Drug|mycophenolate mofetil|
46073592|NCT02824380|Drug|DA-4001 H|5% minoxidil / high dose of finasteride
45444389|NCT05219331|Procedure|Ventriculoperitoneal shunt|Treatment oh hydrocephalus
45444390|NCT02816398|Device|Percutaneous creation of an arteriovenous fistula|Use of catheter system for percutaneous creation of an arteriovenous fistula
45444391|NCT03816501|Other|music|The preference of the patients will be listened to preoperatively through the headphones
45444392|NCT03816501|Other|no music|the patients will not be listened
45444393|NCT02036398|Device|Double J stent without nephrostomy|Double J stent only left at the end of the procedure without placement of a nephrostomy tube
45444394|NCT02036398|Device|nephrostomy tube and double J stent|Double J stent and nephrostomy tube left at end of procedure
45444395|NCT03461900|Other|Minifluid challenge|Pragmatic optimization fluid management protocol based on Mini-Fluid Challenge (MFC) in treating an acute circulatory failure. MFC consist of an infusion of 100 ml of colloid solution (4% human serum albumin) during 1 minute via a separate venous line. Before and after each MFC and depending on the hemodynamic device used, the attending physician will perform a first set of hemodynamic measurements, including cardiac index (CI) or cardiac output (CO); stroke volume (SV), indexed stroke volume (iSV) or velocity time index (VTI). If the variation in measurement is superior to 10%, the attending physician will infuse 400 ml of buffered crystalloid solution or saline solution. After an infusion of 500 ml, fluid responsiveness will be evaluated with CI or CO measurement. For non-responders, fluid challenge must be stopped and other therapeutics should be considered. For responder, another MFC should be consider if hemodynamic status is not stabilized.
45444396|NCT03461900|Other|Usual practice|Patients included in control group will be managed according to the last surviving sepsis recommendations edited in 2017.
45444397|NCT04384809|Biological|Leukocyte rich platelet rich plasma|Leukocyte rich platelet rich plasma will be obtained and prepared from a peripheral artery of the subject and then will be injected in the common extensor tendon
45600073|NCT02306317|Other|Standard procedure|FiO2 manually controlled by nursing
45600074|NCT02306317|Other|Experimental procedure|FiO2 manually controlled by parents, after training.
45600075|NCT02319265|Drug|Melatonin|Oral liquid
45600076|NCT02319343|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
45600077|NCT02319343|Drug|Isotonic Sodium Chloride|Placebo
45600078|NCT02314819|Drug|fruquintinib|fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
45600079|NCT02314819|Drug|placebo|fruquintinib placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
45600080|NCT02314897|Device|LV pacing|Left ventricular pacing lead implanted via the coronary sinus.
45600081|NCT02314897|Device|RV pacing|Conventional right ventricular pacing.
45600082|NCT03508141|Drug|Fibrinogen Concentrate|Experimental
45600083|NCT03508141|Drug|Cryoprecipitate|Comparator
45600084|NCT02314975|Device|AcceleDent vibrational device|Supplementary vibrational force with fixed appliances
45600085|NCT02314975|Device|Sham AcceleDent device|Supplementary sham-vibrational device with fixed appliances
45600086|NCT02314975|Other|Fixed appliance only|Fixed appliance treatment only
45600087|NCT02315053|Other|Low dose FDG PET/CT 5 x.|Multiple FDG PET/CT studies will be added to the normal diagnostic procedures as a part of this study, with the number of scans depending on the study stage, to a maximum of 6 per patient.
45754996|NCT05486234|Behavioral|modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias|Participants will undergo a baseline assessment before completing computerized tasks. During the baseline assessment, participants will be asked questions about alcohol and cannabis use. We will also ask questions about the way participants think about things, past life experiences related to substance use, and questions about how participants feel about reducing their substance use. Then, participants will complete a series computerized tasks where they will push and pull a joystick in response to images that are presented on a screen or where they will try to get a high score. During the computerized tasks, we will also be measuring brain activity using EEG. During the study, participants will also be asked to respond to questions about their health and behavior using an app on a smartphone or tablet using a secure program. Participants in the Treatment Group will then complete four sessions of the modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias.
45754997|NCT05486234|Behavioral|modified Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.|Participants will undergo a baseline assessment before completing computerized tasks. During the baseline assessment, participants will be asked questions about alcohol and cannabis use. We will also ask questions about the way participants think about things, past life experiences related to substance use, and questions about how participants feel about reducing their substance use. Then, participants will complete a series computerized tasks where they will push and pull a joystick in response to images that are presented on a screen or where they will try to get a high score. During the computerized tasks, we will also be measuring brain activity using EEG. During the study, participants will also be asked to respond to questions about their health and behavior using an app on a smartphone or tablet using a secure program. Participants in the Control Group will then complete four sessions of an Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.
45754998|NCT05622227|Diagnostic Test|Drug: 68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of breast cancer by PET/CT.
45754999|NCT05459246|Other|Virtual reality glasses|"Beginning 1 minute before the start of the procedure, the patients will be watched (30-45 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30-45 minutes)."
45600088|NCT02315209|Device|UHS, UPP, Comfort Plug|only Repairs with 3D Devices (UPP,UHS,Comfort Plug)
45600089|NCT02319421|Other|Alarm Reduction Script|The intervention will consist of a script to facilitate the discussion of the alarm data that will take place on weekday mornings. The script will be used by huddle participants as a structured outline to rapidly discuss the high alarm low acuity patients eligible for intervention. The patients who are identified will have further discussion on rounds to determine if there are appropriate ways to reduce the alarm rates of individual patients through the safe adjustment of physiologic monitor parameters.
45600090|NCT02319499|Dietary Supplement|Zinc Alone|Zn-alone group received 10 mg/day of elemental zinc (as zinc sulphate)
45600091|NCT02319499|Dietary Supplement|Iron and Zinc|Zn+Fe group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate)
45600092|NCT02319499|Dietary Supplement|Iron, Zinc and Vitamin A|Zn+Fe+vit.A group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate), plus 1,000 IU/day of vitamin A
45600093|NCT02319499|Other|Placebo|Placebo group received no minerals/vitamin
45600094|NCT03499639|Drug|Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet|"Patients with eGFR between 59-30ml/min: a co-formula of ombitasvir (OBV; 25mg)/ paritaprevir (PTV; 150mg)/ ritonavir (r; 100mg) (OBV/PTV/r) once-daily plus ribavirin (RIB) was given for 12 weeks. Dose adjustment of RIB was made as follow: If eGFR was 30-59 ml/min, an alternating dosing of 200 mg and 400 mg daily; if eGFR 15-30 ml/min, dosing was 200 mg once daily.~Patients on hemodialysis: a co-formula of OBV/PTV/r (25/150/100mg) once-daily plus RIB 200 mg 3 times/week, only in the days that they have their hemodialysis settings, 4 hours before the hemodialysis setting for 12 weeks."
45600095|NCT03499561|Diagnostic Test|urine analysis|Intervention is (urine analysis ): of a mid stream urine sample will be taken
45755000|NCT01799005|Dietary Supplement|Flavanol (410 mg)|
45755001|NCT01799005|Dietary Supplement|Control (no flavanols)|
45600096|NCT03502135|Drug|Tetracaine HCl and oxymetazoline HCl nasal spray|Two intranasal sprays of anesthetic. Each spray delivers 0.2 mL of solution containing 6 mg tetracaine hydrochloride and 0.1 mg of oxymetazoline hydrochloride
45600097|NCT02320747|Other|Tai Chi|
45600098|NCT02315287|Drug|Pioglitazone|Comparison of two different thiazolidinediones
45600099|NCT02315287|Drug|Lobeglitazone|Comparison of two different thiazolidinediones
45600100|NCT02319577|Drug|oral vinorelbine|Anti-neoplastic drug (PO chemotherapeutical agent, vinka alkaloid)
45600101|NCT02319577|Drug|Gefitinib|EGFR tyrosine kinase inhibitor
45600102|NCT03499405|Behavioral|Family Navigator Intervention|Caregivers will be paired with a culturally matched family navigator.
45755002|NCT00515879|Drug|D-cycloserine|50 mg
45755003|NCT00515879|Behavioral|Cognitive behavioral therapy (CBT)|CBT sessions aim to help participants become more comfortable with social situations.
45755004|NCT00515879|Drug|Placebo|Same dosage as active pill
45600103|NCT04462783|Other|Symptoms entered into the CovidX application|Participants are asked to enter symptoms into the CovidX application at least daily for 30 days. Additionally, they will enter demographic information and some survey information will be collected.
45600104|NCT02319655|Procedure|Air tamponade|Air tamponade
45600105|NCT02319655|Procedure|Balanced salt solution filling|BSS filling
45600106|NCT02319733|Device|Bioresorbable vascular scaffold|Implantation of Bioresorbable vascular scaffold in vulnerable plaques
45600107|NCT03501901|Diagnostic Test|Antibiotic susceptibility test|
45600108|NCT03132259|Drug|high dose dexmedethomidine|Dexmedethomidine continuous drip 0.5 mcg/kg/hr a
45600109|NCT03132259|Drug|low dose dexmedethomidine|Dexmedethomidine continuous drip 0.2 mcg/kg/hr
45600110|NCT02315677|Device|Nasal Intubation with nasal RAE endotracheal tube|A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the standard nasal RAE endotracheal tube with bevel facing leftward.
45600111|NCT02315677|Device|Nasal Intubation with Parker Flex-Tip endotracheal tube|A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the Parker Flex-Tip endotracheal tube with the bevel facing posteriorly.
45600112|NCT02315833|Drug|Acetium|Capsule for oral administration contains L-cysteine 100mg
45600113|NCT02315833|Drug|Placebo|A placebo capsule matching Acetium for oral administration.
45600114|NCT02315911|Procedure|ATE|surgical removal of adenoids and tonsils
45600115|NCT02315911|Procedure|APP|surgical removal of adenoids and tonsils and suturing of palatal pillars
45600116|NCT02316067|Other|Rehabilitation|The CHORDATA® Method (16 sessions; 50 minutes each; twice a week) consisted of three exercises: (1) anterior pendulum, with the patient seated on a chair, upper limb suspended by springs and straps, and actively moving the trunk forward; (2) posterior pendulum exercise, on a similar position as exercise (1) but now moving the trunk backwards and recruiting the abdominal wall muscles during a posterior pelvic tilt motion; and (3) stand-up and sit-down exercise, patient with knees fixed anteriorly, initiating the standing-up movement by pulling back and down the springs, trying to maintain the standing position for as long as possible, balancing the trunk and transferring the supporting force from the upper limbs to the lower limbs.
45600117|NCT02316145|Behavioral|Habilitation (Internet-based support and coaching)|Support and coaching with therapist (psychologist or educational therapist) by using chat and e-mail
45600118|NCT02319811|Procedure|Cryopreserved meniscus transplants|Lateral or medial cryopreserved meniscus transplants implanted into appropriately indicated patients.
45600119|NCT03499171|Drug|Citalopram 20mg|Citalopram is taken once a day as an add-on to PPI treatment (2x/d).
45600120|NCT03499171|Drug|Placebo Oral Tablet|Placebo is taken once a day as an add-on to PPI treatment (2x/d)
45600121|NCT02447419|Drug|Gefitinib|Gefitinib 250mg will be administered orally daily
45600122|NCT02319889|Radiation|Stereotactic Body Radiotherapy|Undergo SBRT
45600123|NCT02319889|Drug|Carboplatin|Given IV
45600124|NCT02319889|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
45600125|NCT03499093|Other|OES|"The first seven items of OES refer to face, facial profile, mouth, teeth alignment, teeth form, teeth color and gums. They are combined into an OES summary score ranging from 0 to 70. The eight item of OES is an overall impression item and is not included in the summary score.~Internal Consistency was determined using Cronbach's alpha and inter-item correlation for the OES scores (n=140).~Test-Retest Reliability was assessed using Intraclass Correlation Coefficient. Patients with prosthetic needs (n=20 PP-E subjects and n=15 PP-NE subjects) completed twice the OES-F at an interval of two weeks.~Convergent validity was assessed by comparing mean OES summary scores evaluated by participant of the esthetic group (PP-E, n=35) and by an expert group. Expert OES score were based on three photographs of each participant.~Discriminative validity was tested by comparing the OES summary scores using a one-way ANOVA and Scheffe post hoc test."
45600126|NCT03499015|Procedure|Balloon Eustachian Tuboplasty (BET)|A balloon catheter is used to dilate the cartilage part of the eustachian tube and is inserted through the nose to reach the opening of the tube, located in the nasopharynx.
45600127|NCT03498547|Procedure|caudal block|For the caudal block, sacral horns are palpated and sacral hiatus and epidural area will be determined at S4-S5 level through ulştrasonography. The 20 G adult caudal needle will then be placed to the caudal epidural space and 25 mL bupivacaine at a concentration of 0.5% will be applied in the prone Jack-Knife position with resistance loss.
45600128|NCT03498547|Procedure|saddle block|In the saddle block group hyperbaric bupivacaine at a dose of 7 mg will be given to the intrathecal space after a 25 G quincke spinal needle is inserted with ultrasonographyguidance between L4-L5 vertebral disc and clear cerebrospinal fluid is seen. The patient will be placed in sitting position for 5 minutes.
45755005|NCT03152942|Drug|Progesterone|Progesterone 400mg to be administered once daily for 34 weeks in the patients randomised to receive progesterone alone
45755006|NCT03152942|Drug|Aminophylline|Patients randomised to the combination arm to be administered aminophylline 225 mg to be taken once at night for 1 week and then if tolerated increased to 225 mg twice daily Progesterone 400mg to be administered once daily for 34 weeks.
45934876|NCT00041288|Drug|tacrolimus|
45444398|NCT04384809|Device|Percutaneous Tenotomy|Patients will undergo percutaneous tenotomy of the common extensor tendon using the Tenex tenotomy device
45600129|NCT03498937|Device|Active tDCS|10 active tDCS sessions (2 sessions/day for 5 days, 30 min each, 2 mA) applied to the dlPFC
45600130|NCT03498937|Device|Sham tDCS|10 sham tDCS sessions (2 sessions/day for 5 days, 30 min each, 0 mA) applied to the dlPFC
45600131|NCT04461613|Other|Original IPAQ followed by a revised one.|Comparing two questionnaires (a revised version and an original International Physical Activity Questionnaire short form) with an activity diary.
45600132|NCT04461613|Other|Revised IPAQ followed by an original one.|Comparing two questionnaires (a revised version and an original International Physical Activity Questionnaire short form) with an activity diary.
45600133|NCT04461769|Device|Transcranial Electrical Stimulation|Oscillating electrical current
45600134|NCT03494491|Dietary Supplement|Chitin-glucan|Second test day (D2), subjects will received 4.5g of chitine-glucan
45600135|NCT03494491|Dietary Supplement|Maltodextrin|First test day (D0), subjects will received 4.5g of maltodextrin.
45600136|NCT02324413|Drug|Clonidine|Comparison between placebo and 2 different concentrations of clonidine
45600137|NCT02324413|Drug|Placebo|
45600138|NCT03498703|Drug|Azathioprine Pill|Azathioprine increase pregnancy rate in cases with recurrent implantaion failure
45600139|NCT03498703|Drug|Placebo Oral Tablet|Placebo tablets
45934877|NCT00041288|Procedure|peripheral blood stem cell transplantation|
45600140|NCT03498469|Behavioral|Standardized reintegration package|Participants assigned to this comparison arm will receive a standardized reintegration package that includes individualized case management support and a reunification cash grant Individualized case management will consist of a caseworker-developed individualized care plan with routine caseworker visits at the household level. Home visitation will begin during the family assessment and preparation stages and continue throughout the 15-month post-reunification follow-up period. For the cash grant, the family of each enrolled child will receive a reunification cash grant in the Ugandan Shilling equivalent of $125, administered in two equal disbursements. It is designed to offset the cost of child care.
45600141|NCT03498469|Behavioral|Enhanced reintegration package|Participants assigned to this arm will receive an enhanced reintegration package that consists of the parenting program, individualized case management, and the reunification grant. will be delivered at the household level by project trained parenting facilitators. The program will consist of approximately 13 bi-weekly sessions, which will be delivered over the course of 7 months. The individualized case management and the reunification grant will be similar to those in the comparison arm.
45600142|NCT02324491|Drug|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks.
45755007|NCT03157544|Behavioral|multimodal non-pharmacological Pain Relief Kit|"Participants will be told: No two people have the same kind of pain and that pain management must be individualized to your pain. Thus, we want you to try the four modes of the non-pharmacological interventions included in the kit individually and in combination in order to determine what works best to relieve your pain~The Pain Relief kit will also include written instructions and materials for three behavioral techniques directed at maintaining compliance with the non-pharmacological interventions. During the review of the Pain Relief Kit with a member of the research staff participants will be informed about the recommended use of the three behavioral techniques including setting goals, working with a buddy and keeping a graph of your progress. This information will also be included in written form in the Pain Relief Kit."
45444399|NCT02812186|Procedure|Deep to Moderate NMB|"Rocuronium infusion will be paused and the Train of Four (TOF) monitor will be set to every 1-2 min. Once the patient has achieved a moderate NMB state (one to two twitches), the infusion of the muscle relaxant will be resumed at a low dose to maintain the patient at this level of blockade."
45444400|NCT02812186|Procedure|Moderate to Deep NMB|"Rocuronium infusion will be increased in increments of 0.1-0.2 mg/kg/hr. and the TOF monitor will be set to every 1-2 min. Once the patient has no twitches and a PTC of 0-1 (deep NMB) the infusion will be adjusted to maintain the patient at this level of NMB."
45444401|NCT02812186|Drug|Rocuronium|
45444402|NCT02811640|Other|Study Participants|IAP will be observed and measured with a hand held Stryker Pressure Monitor during laparoscopic surgery and compared to the standard IAP measurements obtained with the insufflator at the time of PD catheter insertion
45600143|NCT02324491|Drug|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 52 weeks.
45600144|NCT02320981|Diagnostic Test|Standard of Care esophagogastroduodenoscopy (EGD) with measurement of mucosal impedance|
45600145|NCT03494413|Diagnostic Test|Transpharyngeal Doppler sonography (TPS)|Usage of transpharyngeal Doppler to assess cerebral perfusion during cardiovascular surgery
45600146|NCT03494413|Diagnostic Test|Conventional colour-coded Duplex sonography (CDS)|Usage of conventional colour-coded Duplex sonography (CDS) to assess cerebral perfusion during cardiovascular surgery
45755008|NCT00586729|Device|Vashe|Antimicrobial irrigant
45755009|NCT00586729|Drug|Mafenide acetate|Antimicrobial solution
45934878|NCT00041288|Radiation|radiation therapy|
45600147|NCT03494257|Drug|Brinzolamide-Brimonidine fixed combination|Simbrinza 0.2%-1% Ophthalmic Suspension
45934879|NCT00210262|Behavioral|Feedback and Education|
45600148|NCT03132181|Drug|Empagliflozin|Patient will be treaded according to standard care but additionally take one tablet Empagliflozin per day
45600149|NCT03132181|Other|Placebo|Patient will be treaded according to standard care but additionally take one tablet placebo per day
45600150|NCT02320045|Drug|ITCA 650 (Exenatide in osmotic mini pump)|
46073593|NCT02824380|Drug|DA-4001 L|5% minoxidil / low dose of finasteride
45934880|NCT00073164|Drug|Divalproex Sodium Extended-Release Tablets|
45600151|NCT02320357|Drug|Treatment by clopidogrel|Peripheral blood will be obtained during the study
45934881|NCT00073164|Drug|Olanzapine|
45934882|NCT00073164|Drug|Risperidone|
45600152|NCT02320513|Other|Wearing activty monitoring device (Fitbit Flex)|
46073594|NCT00705861|Drug|Placebo|Placebo as a substitute of SK3530 100mg
46073595|NCT00705861|Drug|SK3530|SK3530 100mg
46073596|NCT00913341|Drug|Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)|
45600153|NCT02320513|Device|Fitbit Flex|
45600154|NCT03498235|Drug|Sevoflurane|In Team Sevoflurane,patients undergo sevoflurane.
45600155|NCT03498235|Drug|Propofol|In Team Propofol ,anesthesia is maintained with propofol
45600156|NCT02320591|Other|care management fee|for each Medicare beneficiary attributed to the practice, the practice received a monthly care management fee
45934883|NCT00210301|Drug|Provigil (modafinil)|
45934884|NCT00210340|Drug|intrathecal rituximab|
45934885|NCT00411541|Drug|vincristine|
46073597|NCT00913341|Drug|Alprazolam Tablets, 1 mg (The Upjohn Company)|
45600157|NCT02320591|Other|feedback reports|Each participating practice received quarterly reports showing the practice's trend in key outcomes during the pre-intervention and intervention periods. The risk adjusted average Medicare expenditures of their patients were also shown in relation to all of the other CPC practices in their region, and to those with a similar average risk profile. Unadjusted hospitalization rates and emergency room visits were also plotted over time and compared to those of other CPC practices in the region
45444403|NCT03310268|Other|0.454% Stannous fluoride (SnF2) and 0.072% sodium fluoride (NaF): 1450 ppm fluoride in total|Participants will be instructed to apply experimental dentifrice (containing 454% SnF2 and 0.072% NaF, 1450 ppm fluoride in total), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
45755010|NCT01672346|Procedure|PVAI followed by adenosine provocation|All patients will undergo PVAI and ablation of the posterior wall of the LA using an open-irrigated ablation catheter and under general anesthesia. After PV isolation is achieved, all will undergo PVAI followed by adenosine provocation test with 24 mg of adenosine to check for PV reconnection. Upon identification, additional RF energy would be used to ablate those sites (that were revealed by adenosine-provocation).
45755011|NCT01672424|Other|Ice Chips|11 ounces of ice chips given to the laboring parturient
45444404|NCT03310268|Other|1400 ppm fluoride as sodium monofluorophosphate (SMFP)|Participants will be instructed to apply negative control dentifrice (containing 1400 ppm fluoride as SMFP), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
45444405|NCT03310268|Other|Stannous Chloride (SnCl2) and 0.15% NaF: 1450 ppm fluoride in total|Participants will be instructed to apply positive control dentifrice (containing SnCl2 and 0.15% NaF, 1450 ppm fluoride in total), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
45444406|NCT01301469|Drug|6% HES 130/0.42 in plasma adapted Ringer's solution|60 g/l hydroxyethyl starch 130 dissolved in plasma adapted Ringer's solution (balanced solution)
45600158|NCT02320591|Other|technical assistance|CPC practices could ask for technical assistance on transformation activities from a regional learning faculty (RLF). The RLF also provided seminars and other learning activities, as well as provided a forum for participating practices to share lessons they had learned.
45600159|NCT02324803|Drug|pazopanib|continuous treatment of 800 mg pazopanib once daily until disease progression
45600160|NCT02324881|Behavioral|Telephone-Based Intervention|Use PSMA
45444407|NCT01301469|Drug|6% HES 130/0.4 in a saline solution|60 g/l Hydroxyethyl starch (HES) with a mean molecular weight of 130 kDalton which is dissolved in a saline solution
45600161|NCT02324881|Other|Questionnaire Administration|Ancillary studies
45600162|NCT03498157|Behavioral|Exercise|The exercise intervention is an at least 2 weeks lasting (till the day surgery is taking place) 5-times weekly resistance training intervention combined with aerobic exercise (mostly walking).
45600163|NCT03498157|Behavioral|Prehabilitation Education|Participate will receive a 2 hour group-based prehabilitation class which will be held at the Penn State Cancer Institute, Hershey
45600164|NCT02324959|Device|RehaCom|The computer-based neurorehabilitation program is intended for patients with acquired cognitive deficits after brain damage, e.g. after stroke. The RehaCom software has five different therapeutic groups aimed at restoration of attention, memory, executive functions, and visual field, respectively. Each group has one to four different modules to choose from for each therapy session. Only attention will be trained in this study.
45600165|NCT02324959|Device|Acupuncture|"The affected meridian group is treated by needling on Baihui (GV20|DU20) and Shenting (GV24|DU24) - both acupoints of the Governor Vessel. Baihui is 5 cun (1cun=3.33 cm) superior to the anterior hairline on the anterior median line (midpoint of the connecting line between the auricular apices)."
45755012|NCT01672424|Other|Protein Drink|Patients will receive 11 ounces of a protein shake which contains 30 grams of protein
45755013|NCT00635479|Device|VAC device|Vacuum Assisted Closure (VAC) device for surgical incision
45444408|NCT03805113|Device|Magnetotherapy device|Use of magnetotherapy device 15 consecutive working days in elegible patients with erosive hand osteoarthritis.
45444409|NCT03805113|Device|Placebo|Use of unplugged magnetotherapy device 15 consecutive working days in elegible patients with erosive hand osteoarthritis.
45444410|NCT05254730|Device|macro-micro tetrodes for intracranial recording|novel design of tetrode micro electrodes within the standard macro intracranial electrodes used clinically for identification of the epileptogenic zone
45755014|NCT00635479|Other|Gauze dressing|Gauze dressing for surgical incision
45755015|NCT00516503|Drug|baclofen/amitriptyline/ketamine gel|Applied topically
45755016|NCT00516503|Other|placebo|Applied topically
45600166|NCT02325037|Drug|GLPG1837 single ascending doses|Single dose, oral suspension
45600167|NCT02325037|Drug|Placebo single dose|Single dose, oral suspension matching placebo
45600168|NCT02325037|Drug|GLPG1837 multiple ascending doses|Multiple doses, daily for 14 days, oral suspension
45755017|NCT03157310|Drug|Gefitinib|Daily oral administration of 250 mg Gefitinib
45755018|NCT03157076|Device|Cardiac Resynchronization therapy device with Closed Loop Stimulation (CLS)|The feature CLS will be programmed ON or Off according to a randomization list after one month after baseline visit. One month later the alternate will be programmed.
45755019|NCT00587041|Dietary Supplement|Oxadrop|Oxadrop 1 packet daily plus 1 placebo capsule twice daily. Each gram of Oxadrop® contains 2x1011 bacteria (L. acidophilus, L. brevis, S. thermophilus, and B. infantis).
45755020|NCT00587041|Dietary Supplement|Agri-King Synbiotic (AKSB)|AKSB 1 capsule twice daily plus 1 placebo packet daily. AKSB contains Fructo-oligosaccharide; Enterococcus faecium (SF68); Saccharomyces cerevisiae subspecies Boulardi; and Saccharomyces cerevisiae
45755021|NCT00587041|Other|Placebo|1 placebo packet daily and 1 placebo capsule twice daily
45934886|NCT00411541|Drug|dexamethasone|
45934887|NCT00210379|Drug|rituximab|
45934888|NCT00210379|Drug|CHOP|
45934889|NCT00210379|Drug|intrathecal methotrexate|
45934890|NCT00210379|Procedure|radiotherapy|
45600169|NCT02325037|Drug|Placebo multiple doses|Multiple doses, daily for 14 days, oral suspension, matching placebo
45600170|NCT02320669|Drug|Triostat|Bolus of Triiodothyronine followed by infusion for 48 hours
45600171|NCT02320669|Drug|Placebo|Bolus of Placebo followed by infusion for 48 hours
45600172|NCT02565199|Device|rTMS over Premotor Cortex (Contralateral Hemisphere)|"Location of rTMS: premotor cortex~Frequency of rTMS: 0.1 Hz~Time of rTMS: 50 milliseconds before the onset of movement-related EMG~Device: MagStim Super Rapid 2 Transcranial Magnetic Stimulator"
45600173|NCT02565199|Device|rTMS over Premotor Cortex (Ipsilateral Hemisphere)|"Location of rTMS: premotor cortex~Frequency of rTMS: 0.1 Hz~Time of rTMS: 50 milliseconds before the onset of movement-related EMG~Device: Super Rapid 2 Transcranial Magnetic Stimulator"
45600174|NCT02565199|Device|rTMS (Control 1)|"Location of rTMS: premotor cortex~Frequency of rTMS: 0.1 Hz~Time of rTMS: 400 milliseconds after the onset of movement-related EMG~Device: Super Rapid 2 Transcranial Magnetic Stimulator"
45600175|NCT02565199|Device|rTMS (Control 2)|"Location of rTMS: somatosensory cortex~Frequency of rTMS: 0.1 Hz~Time of rTMS: 50 milliseconds before the onset of movement-related EMG~Device: Super Rapid 2 Transcranial Magnetic Stimulator"
45600176|NCT02565199|Device|rTMS (Control 3)|"Location of rTMS: premotor cortex~Frequency of rTMS: 0.1 Hz~Time of rTMS: 50 milliseconds before the onset of movement-related EMG~Device: Super Rapid 2 Transcranial Magnetic Stimulator with Sham Coil"
45600177|NCT02565199|Other|Motor Training|During motor training, participants will quickly extend their hand at a pace of one extension every 5 seconds (0.2Hz) in response to an auditory cue.
45600178|NCT02325193|Device|Minimed®640G system|Sensor augmented insulin therapy with and without use of Predictive low glucose management (PLGM)
45755022|NCT03157388|Drug|Combined Vancomycin and Gentamycin and Meropenem|"The following combined antibiotic regime will be administered for eradication of gut bacteria.~7 days combined antibiotic treatment, per oral route, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate and gentamycin 40 mg (Hexamycin®), solution and meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined in approximately 100 ml of apple juice."
45600179|NCT03498079|Diagnostic Test|3D ultrasound|3D ultrasound will be done to females complaining from primary infertility with mullerian anomalies
45600180|NCT02325271|Other|Frequent blood and urine sampling and blood pressure measurement|Blood and urine sampling for the determination of VEGF and biomarkers
45755023|NCT04387825|Drug|ADSVF application in the right hand|40 ml of fat was mixed with 2 ml of ADSVF and placed in 1-ml and 3-ml syringes. Using a 19-gauge blunt cannula (0.8 mm), 0.5 ml was applied to the radial and ulnar edge of each metacarpal phalangeal (MP) and interphalangeal (IP) joint in contact with each neurovascular digital pedicle and 3 ml was applied to each side of the metacarpal trapezius joint, together with 10 ml distributed subcutaneously throughout the palm of the hand and 10 ml evenly distributed on the back of the hand
45755024|NCT05698940|Procedure|Infundibultomy|Infundibultomy on one side of patient
45755025|NCT01672502|Behavioral|Sleep health education provided via a web-based program|All firefighters in the experimental group and controls will be asked to complete an approximately 30 minute education session. This education session will split into two modules, module 1: an introduction to the program along with basic sleeps hygiene information and module 2: standard training. Topics covered in module 2 will include basic sleep physiology, the causes and consequences of sleep disorders, and fatigue countermeasures. We will emphasize strategies to maximize sleep and reduce fatigue both on and off work.
45804188|NCT03225599|Other|Cranial Osteopathic Manipulative Medicine|"The hands will be placed on the head using the vault hold (bilateral thumbs are off the head, index fingers on the temporal bones, middle fingers on the sphenoid bones, ring fingers on the mastoid and the 5th fingers on the occipital bone). Diagnosis and treatment of restrictions palpated on the scalp will be made using this hand position"
45600181|NCT05129917|Dietary Supplement|Placebo|consume 1 sachet per day for 14 day
45600182|NCT05129917|Dietary Supplement|Gojinsen® drinks|consume 1 sachet per day for 14 day
45600183|NCT02321059|Device|Measurement of abdominal wall strength|Test-retest examination of the reliability of the Goodstrength trunk dynamometer
45600184|NCT03491761|Biological|PRP Treatment|PRP will be prepared using an Arthrex ACP® kit (a low-leukocyte Autologous Conditioned Plasma system). This is a single-spin system that concentrates platelets and separates red blood cells (RBCs) as well as white blood cells (WBCs) from the treatment product.
45600185|NCT03491761|Biological|HA Treatment|Euflexxa will be used for treatment. It will be prepared according to the package insert.
45600186|NCT04789213|Other|Liver Transplantation|Liver Transplantation
45600187|NCT04774003|Drug|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) in 0.5 mL solution. Subcutaneous administration at Day 1
45600188|NCT04774003|Drug|Placebo|Inclisiran sodium 0mg (equivalent to inclisiran 0 mg) in 1.5 mL solution. Subcutaneous administration at Day 1
45444411|NCT01303263|Behavioral|Educational Intervention|45-minute teaching session on healthcare costs, in which each resident reviewed an itemized hospital bill for a patient he/she had cared for, followed by an open-ended discussion about reducing unnecessary costs.
45600189|NCT04774003|Drug|300 mg inclisiran sodium (equivalent to 284 mg inclisiran)|300 mg inclisiran sodium (equivalent to 284 mg inclisiran) in 1.5 mL solution. Subcutaneous administration at Day 1
45600190|NCT03132103|Dietary Supplement|Oral Vitamin D3|
45600191|NCT03132103|Dietary Supplement|Placebo Oral Vitamin D3|
45600192|NCT03132103|Radiation|Solar simulated radiation (SSR)|
45600193|NCT03132103|Radiation|Placebo SSR|
45600194|NCT04706221|Device|CM-1500|Blood volume monitor CM-1500
45600195|NCT02321215|Other|Introductory Disease Education|This intervention will consist of two one-on-one education sessions, each lasting 30 minutes.
45755026|NCT01672502|Other|Sleep disorder detection and treatment|Firefighters in the intervention districts will complete a sleep disorders screening questionnaire. The questionnaire will focus on identifying individuals who show increased likelihood of suffering from obstructive sleep apnea, insomnia, shift work disorder, and restless legs syndrome using validated screening tools. Those assessed to be at high risk for one of these sleep disorders will be referred to a local AASM-accredited Clinical Sleep Disorders Service for evaluation and, if necessary, treatment. Diagnosis and treatment of sleep-related disorders will reduce the risk of fatigue-related accidents and improve the health and safety of affected individuals.
45755027|NCT01672502|Other|Optimization of Sleep in Fire Station|First, we will review and retrofit the sleeping quarters to provide a better environment for napping and sleep; light, noise, bed type, space, temperature, and location would all be considered and where possible, changes made to improve the sleeping environment. Secondly, we will work with management and union personnel to develop a 'sleep friendly' policy during the daytime, with specified protected times for naps during the day before the overnight work in order to reduce sleepiness during overnight work. Finally, we will upgrade the alerting systems, that is, we will work with management and union personnel to consider changing the policy that requires the sleeping areas of all stations to receive all alarm calls, even if that particular station is not required to attend the alarm.
45600196|NCT04635943|Drug|Ivermectin|One daily dose of NOXAL-Ivermectin Oral Solution (6 mg/mL) at 300mcg/kg for three (3) consecutive days. A weight-equivalence table will be used to determine each participant´s dose (number of oral drops/day).
45600197|NCT04635943|Drug|Placebo|The placebo presentation will be an oral drop solution undistinguishable from ivermectin, but without this device pharmaceutical ingredient.
45600198|NCT04398355|Combination Product|acupuncture|acupuncture
45600199|NCT04398355|Combination Product|Liu-Zi-Jue Gongfa|Liu-Zi-Jue Gongfa
45600200|NCT04344535|Biological|Convalescent Plasma|450-550 mL of plasma containing anti-SARS-CoV-2 antibody titer ideally > 1:320, but meeting minimum titer per FDA Guidelines for convalescent plasma.
45600201|NCT04344535|Biological|Standard Donor Plasma|450-550 mL of plasma with low titer to anti-SARS-CoV-2 antibodies
45600202|NCT04292275|Device|Biobeat Wrist Watch|Standard of care procedures and therapies for managing heart failure will be carried out according to each investigator's standard procedures. In addition, participants will be provided with a Biobeat wrist watch for continuous measurement and reporting of blood pressure data and with a smartphone to report weight.
45600203|NCT04292275|Other|Standard of Care|Standard of care procedures and therapies for managing heart failure will be carried out according to each investigator's standard procedures.
45600204|NCT04461847|Procedure|subcutaneous mastectomy|Operating subcutaneous mastectomy
45600205|NCT04461847|Procedure|endoscopic subcutaneous mastectomy|Operating endoscopic subcutaneous mastectomy
45600206|NCT04461925|Procedure|Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells|i/v infusions
45600207|NCT04461925|Drug|Antibiotics|per os
45600208|NCT04461925|Drug|Hormones|a moderate amount of dexamethasone i/v
45600209|NCT04461925|Drug|Anticoagulant Therapy|Sub-Q
45600210|NCT04461925|Device|Оxygen therapy|Оxygen therapy, mechanical ventilation and other supportive therapies
45600211|NCT02325583|Drug|30% Glucose|ORAL 30% GLUCOSE 0,5-2 ML
45600212|NCT02325583|Drug|Midazolam|INTRAVENOUS 0.1 MG/KG MIDAZOLAM
45600213|NCT02325661|Other|cognitive interviewing|"For the individual cognitive interviews we are using the two techniques to think aloud and the verbal probing. To think aloud means, that the patients are asked to express precisely what comes to their mind when reading the single questions. This means, the interviewer is interested in the line of thoughts, which arise when reading the question. Thereby, the problems which appear in the usually covert process of answering a question should be revealed. In a second step, we are using the verbal probing technique to identify possible misunderstandings of the questions or difficulties with single phrases. The interviewer asks further questions that target the patients' interpretation."
45600214|NCT03494101|Other|Blood samples|Blood samples will be collected and analyzed at different study time points
45600215|NCT03494101|Other|Stool samples|Stool samples will be collected and analyzed at different study time points
45600216|NCT03494101|Other|Clinical information|Clinical information will be collected at different study time points using questionnaires
45600217|NCT03494023|Diagnostic Test|Endoscopic ultrasound|Measurement of the common bile duct diameter
45600218|NCT03109561|Other|Resting State Indirect Calorimetry|The investigator will measure the amount of oxygen participants breathe in and the amount of carbon dioxide they breathe out using a portable unit. Participants will be asked wearing a loose-fitting face mask that measures oxygen intake and carbon dioxide output.
45755028|NCT02135653|Radiation|Radiotherapy|
45600219|NCT03109561|Genetic|ApoE|The investigator will conduct a genetic test on DNA isolated from from the participants blood. Participants will be asked to provide about 2 tablespoons.
45600220|NCT03109561|Diagnostic Test|Metabolism|To more accurately measure the amount of carbohydrates, fats and proteins that the participants bodies metabolize, participants will be asked to provide two urine samples (one at the beginning, and one at the end, of the study). The total amount of urine to be collected is approximately 4 teaspoons.
45600221|NCT03109561|Other|Cognitive Challenge|Participants will be asked to follow simple instructions that are displayed on computer screen.
45600222|NCT02321293|Dietary Supplement|CurcuVIVA™|80 mg PO daily for 8 weeks with an option to reduce the dose based on individual tolerability
45600223|NCT02321293|Drug|Tyrosine Kinase Inhibitor gefitinib (Iressa)|250 mg PO daily until progression
45600224|NCT02321293|Drug|Tyrosine Kinase Inhibitor erlotinib (Tarceva)|150 mg PO daily until progression
45600225|NCT03493867|Device|Vitaliti|Measurements recorded by the Vitaliti device will be compared to the recordings from the arterial catheter.
45600226|NCT04462549|Behavioral|Resource Facilitation|"RF involves working one on one with a brain injury specialist. This specialist is called a Resource Facilitator and works with clients to help set and achieve their own goals along with a team of professionals that specialize in this kind of injury. This may include brain injury education, family education, needs assessments, and service identification."
45600227|NCT02325817|Device|Drug-eluting balloon|Treat the side branch of bifurcation lesion with drug-eluting balloon
46066505|NCT01546753|Drug|Walnut Protein Powder|Blinded study product dosing begins with a 1-day oral desensitization protocol to walnut for subjects in the active arm. Starting at 0.1 mg protein and increasing to a maximum of 6 mg or until allergic symptoms develop. Subjects continue daily dosing of blinded OIT (walnut) with build-up every 2 weeks to a maximum daily dose of 1500mg at week 34, followed by 4 weeks of daily maintenance dosing. OFC to walnut and second tree nut occurs at week 38 then treatment is unblinded and open-label maintenance dosing occurs.
45755029|NCT02135653|Other|Eischens Yoga|
45755030|NCT05622149|Behavioral|Diet Only|Food tracking based on macronutrient goals.
45755031|NCT05622149|Behavioral|Training Only|Subjects completed 16 weeks of supervised resistance training
45755032|NCT05622149|Behavioral|Diet plus Training|Food tracking plus resistance training.
45444412|NCT02810392|Drug|Intranasal Insulin|Delivery is with the Vianase device, 20 IU twice daily for 3 weeks.
45444413|NCT02810392|Drug|Intranasal saline|Delivery is with the Vianase device, 0.5 cc of normal saline
45444414|NCT03816423|Other|video|Participants randomized to the intervention group, will wacth a pre-appointment video, followed by a routine prenatal care visit.
45444415|NCT03805035|Device|electroacupuncture|Group 2 (n=10) EA at ST36 and GB34;intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
45444416|NCT03805035|Drug|antihistamine(low dose) chlorpheniramine (Dexchlorpheniramine maleate)|Group 3 (n=10) EA at ST36 and GB34 plus chlorpheniramine (Dexchlorpheniramine maleate 2mg/tab, 1 tab);intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
45444417|NCT03805035|Drug|antihistamine(high dose) chlorpheniramine (Dexchlorpheniramine maleate)|Group 4 (n=10) EA at ST36 and GB34 plus chlorpheniramine (Dexchlorpheniramine maleate2mg/tab, 2 tabs);intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
45444418|NCT03805035|Device|acupuncture|Minimal needling at ST36 and GB34
45444419|NCT02815540|Procedure|12-Lead ECG|Subjects will be monitored while on cannabidiol with a 12-Lead ECG and/or Holter monitoring
45444420|NCT02815540|Drug|Cannabidiol|Subjects who are planning to take state dispensed medical cannabidiol, or are already taking state dispensed medical cannabidiol.
45444421|NCT03816267|Device|Nebulizer|Nebulization via mask
45444422|NCT03816267|Drug|Salbutamol|Delivery of appropriate dose according to weight
45444423|NCT03816267|Device|Metered dose inhaler and spacer|Medication will be delivered through inhaler and spacer
45444424|NCT03280550|Drug|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.
45600228|NCT02325817|Device|Uncoated ballloon|Treat the side branch of bifurcation lesion with uncoated balloon
45600229|NCT02325895|Other|Dried Plum|Three doses of dried plum (0 g, 50 g and 100g) were used as intervention.
45755033|NCT03156920|Drug|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
45755034|NCT03156920|Drug|Sumatriptan|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
46066506|NCT01546753|Drug|Oat Powder (placebo)|Blinded study product dosing begins with a one-day oral desensitization protocol with placebo (oat) powder. Subjects in the placebo group will undergo the same protocol as those in the active group with placebo OIT dosing. Unblinding to treatment assignment will occur after the 38 week oral food challenge. Placebo subjects will cross-over to active, open-label treatment with walnut powder after the 38 week oral food challenge. beginning with initial escalation day, through build-up and maintenance dosing per the same protocol sequence as noted for active, walnut powder. Subjects will complete an oral food challenge to walnut and the second tree nut at week 38 then will continue on long-term, open-label maintenance dosing until the end of study using same protocol design.
45755035|NCT05247385|Drug|Prasugrel|Compared platelet inhibition and adenosine levels at baseline and after 15 days
45755036|NCT05247385|Drug|Ticagrelor|Compared platelet inhibition and adenosine levels at baseline and after 15 days
45755037|NCT03156842|Drug|Fimasartan/Amlodipine, Rosuvastatin|"A fixed dose combination tablet of Fimasartan and Amlodipine and Rosuvastatin will be administrated once daily on treatment period."
45755038|NCT03156842|Drug|Fimasartan/Amlodipine|"A fixed dose combination tablet of Fimasartan and Amlodipine will be administrated once daily on treatment period."
45444425|NCT03280550|Drug|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
45600230|NCT03491605|Other|peripheral EBV-DNA load|No intervention
45600231|NCT02321371|Drug|Lactulose + Rifaximin|Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route
45600232|NCT02321371|Drug|Lactulose|Continuation of Lactulose therapy for further 48 hours.
45600233|NCT04002037|Drug|Triamcinolone Acetonide 40mg/mL|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
45600234|NCT04002037|Drug|Triamcinolone Acetonide 10mg/mL|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
45600235|NCT04002037|Drug|Dexamethasone 4 mg/ml|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
45755039|NCT03156842|Drug|Fimasartan, Rosuvastatin|"Fimasartan and Rosuvastatin will be administrated once daily on treatment period."
45755040|NCT01672580|Behavioral|exposure to vitamin use|"Seed individuals in village are given daily adult multivitamin, with training on use and general nutrition information, along with coupons to distribute to others in village"
45600236|NCT03931681|Drug|OKI-179|OKI-179 single agent
45600237|NCT05144425|Procedure|total knee arthroplasty with and without using pneumatic tourniquet|The randomization will be performed by a research fellow who will not be involved in patient care. All of the operations will be performed through the medial parapatellar approach by experienced knee surgeons. Drainage system will be used for 48 hours postoperative. In the tourniquet group, the tourniquet will be inflated to a pressure of systolic blood pressure plus 100 mm Hg and will be released after the joint capsule has been closed. hemostasis and then will be wrapped with elastic bandages. In the non-tourniquet group, the tourniquet will be wrapped around the thigh but will not be inflated during the surgery. The criterion for a blood transfusion will set as a hemoglobin (Hb) level of<8 g/dL or patient with symptomatic anemia.
45600238|NCT05143879|Dietary Supplement|Citrulline|3 g/day during 9 weeks
45600239|NCT05143879|Dietary Supplement|Nitrate|300 mg/day during 9 weeks
45600240|NCT05143879|Dietary Supplement|Nitrate plus Citrulline|3 g/day of citrulline and 300 mg/day of nitrate during 9 weeks
45755041|NCT01672580|Behavioral|exposure to water chlorination|"Seed individuals in village are given Clorox bleach for water purification, with training on use and general information on water hygiene, along with coupons to distribute to others in village"
45755042|NCT01672580|Behavioral|high in-degree|"Seed individuals for starting intervention are chosen on the basis of high (social network) in-degree"
45755043|NCT01672580|Behavioral|nominated by random|"Seed individuals for starting intervention are chosen on the basis of being named as a friend/alter of a randomly selected individual"
45444426|NCT02036554|Drug|Everolimus|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
45755044|NCT00636649|Drug|Escitalopram|10-20 mg
45755045|NCT00636649|Drug|Placebo|Placebo
45755046|NCT03156764|Other|Qp/Qs ratio monitoring|Op/Qs -monitor will be calculated using SpO2 and cerebral oximetry Op/Qs -blood will be calculated using ABGA and VBGA
45755047|NCT05061524|Drug|YH35324|Subcutaneous injection of YH35324
45755048|NCT05061524|Drug|Placebo|Subcutaneous injection of None of active ingredient
45444427|NCT02036554|Drug|Tacrolimus|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
45444428|NCT02036554|Drug|Mycophenolic acid|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
45755049|NCT05061524|Drug|Omalizumab|Subcutaneous injection of Omalizumab
45444429|NCT05577117|Drug|Dexmedetomidine|drugs are injected with induction of general anesthesia
45444430|NCT03813303|Drug|Midazolam|Administration of midazolam by anesthesiologist for sedation.
45444431|NCT03813303|Drug|Fentanyl|Administration of fentanyl by anesthesiologist for sedation.
45444432|NCT03813303|Drug|Propofol|Administration of propofol by anesthesiologist for sedation.
45444433|NCT03813381|Behavioral|Calorie and protein restriction diet|"Patient in intervention arm will be given individualized dietary advice on the basis of WCRF/AICR recommendations. The aim of healthy dietary advice will be the reduction of patient's total daily calorie intake up to 600 kcal below their energy requirements and 0.8g of protein/Kg body weight mostly form plant-origin food.~Patients, periodically, will meet the dietitian for a 45-minute nutritional counselling session and a trained nurse for a 15-minute health coaching session.~Each patient in the IA will be involved in at least three 4-hour cooking classes.~Patients in the IA, after a medical/cardiac evaluation to assure their physical ability for exercise, will attend Nordic walking sessions of moderate intensity two times per month during the 24 months of intervention."
45444434|NCT05562063|Drug|Sotagliflozin|Daily administration of sotagliflozin (2x200 mg, PO, OD) for 6 months.
45444435|NCT05562063|Drug|Placebo|Matching placebo for 6 months.
45600241|NCT05143879|Dietary Supplement|Placebo|3 g/day during 9 weeks
45600242|NCT05143411|Other|PRE-test|we are going to verify glucose levels before (pre) and after (post) the use of the mobile application.
45755050|NCT00636805|Drug|Palonosetron (Aloxi) and Dexamethasone|single i.v. , dose of palonosetron 0.25 mg, and 10mg dexamethasone infused over 15 min, administered 30 min before the first dose Irinotecan and Bevacizumab chemotherapy.
45755051|NCT03153254|Device|Test upper limb robot assisted therapy device|During 1 session of 1/2 hour.
45755052|NCT03153254|Device|Training with new upper limb robot assisted therapy device|During 2 to 5 sessions of 1/2 hour.
45755053|NCT05247151|Other|Oxytocin|Oxytocin nasal spray in a positive social setting.
45755054|NCT05247151|Other|Placebo|Placebo nasal spray in a positive social setting.
45755055|NCT03153098|Behavioral|Active Herts|Active Herts is a community physical activity intervention aimed at inactive adults aged 16 and over who have one or more risk factors for CVD and/or a mild to moderate mental health condition. The programme uses the latest evidence-based behaviour change techniques to target physical activity, wellbeing, and key drivers of behaviour from the COM-B model of behaviour change.
45755056|NCT02137447|Device|Negative Pressure treatment|
45804189|NCT05662202|Combination Product|BF-200 ALA and red light LED lamp|"Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (ALA-PDT, Ameluz®-PDT):~Topical application of up to 3 tubes BF-200 ALA on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing.~PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit."
45600243|NCT04462237|Procedure|Root coverage procedures|Treatment of multiple adjacent gingival recession using a coronally advanced flap
45600244|NCT05129839|Device|lightened and musical baby mobile|Before going to sleep in the infant's room in the intervention group, a lightened and musical baby mobile was used.
45600245|NCT05129761|Drug|Syrup Hydryllin|( Syrup Hydryllin & Hydryllin Sugar-Free (Diphenhydramine, Ammonium Chloride, Menthol, Aminophylline) and Syrup Hydryllin DM (Dextromethorphan & Diphenhydramine)
45600246|NCT03497611|Procedure|transcatheter valve implantation|aortic transcatheter valve implantation using Edwards SAPIEN 3 valve
45444436|NCT03400904|Other|Patients with brain injury and mechanical ventilation exposed to extubation/tracheostomy|Extubation and/or tracheostomy if applicable
45600247|NCT03493555|Behavioral|Peer Health Navigator for PrEP|Peer health systems navigator to improve adherence to PrEP
45600248|NCT03493477|Other|exposure will be abnormal skeletal jaw relations|Class II skeletal jaw relation or class III skeletal jaw relation based on lateral cephalometric radiograph
45600249|NCT03493399|Behavioral|Interference|"The principle of interference-based techniques is to move the resources allocated to the elaboration of intrusive desire thoughts to a competing task (e.g., clay modelling, competitive mental imagery, Tetris) in order to monopolize the resources underlying craving, thus preventing its elaboration and reducing its vividness and overwhelming nature. Several studies (Andrade, Pears, May, & Kavanagh, 2012; May, Andrade, Panabokke, & Kavanagh, 2010; Skorka-Brown, Andrade, Whalley, & May, 2015) have shown the efficacy of such techniques to reduce substance-related craving. Yet, data obtained on clinical samples remain scarce.~Due to the flexibility of the single case design towards each participant, the list of interference-based techniques that will be used in this study cannot be exhaustive. However, the following will be proposed to participants: Tetris (smartphone version), manipulation of a bunch of keys, manipulation of a fidget, mental imagery, reading and memorizing a text."
45600250|NCT03491449|Procedure|Group A|Maintaining a systolic blood pressure ≥ 140 and ≤ 160mm Hg for 72 hours.
45600251|NCT03491449|Procedure|Group B|Maintaining a systolic blood pressure <185mm Hg for 72 hours.
45600252|NCT03491371|Drug|Methylsulfonic apatinib|Anti-angiogenesis Tyrosine kinase inhibitor which specifically inhibits VEGFR-2.
45600253|NCT03546829|Drug|Vancomycin|125 mg, 4x daily for 5 weeks
45600254|NCT03546829|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Patients planned to undergo SBRT to a lung lesion will be randomized to either vancomycin for 1 week before RT and for 1 month after start of RT,
45600255|NCT04461223|Diagnostic Test|contrast-enhanced cardiac magnetic resonance imaging(MAGNETOM Aera 1.5T)|CMR T1 mapping, T2mapping, T2* mapping, LGE, ECV
45444437|NCT03804801|Dietary Supplement|Hibiscus Sabdariffa|The extract of the plant Hibiscus Sabdariffa, also known as sour or red tea
45755057|NCT02464904|Procedure|Cryotherapy|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). The procedure will involve 2 to 3 applications of cryospray on the location of the disease. After establishing cryofrost over a minimum of a 2 x 2 cm area, cryospray will continue for 15 to 20 seconds, allow a thaw period of 60 seconds followed by one to two repeats in the same location before proceeding onto the next location. We will treat a minimum of 6 x 6 cm area in aggregate. The freezing procedure will be video-recorded and freezing locations and time will be recorded. Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection.
45755058|NCT02464904|Other|Control|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection
45444438|NCT03637790|Drug|PF-04965842|single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842.
45444439|NCT03637790|Other|rifampin|In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842
45444440|NCT03816033|Procedure|Cryotherapy|Catheter ablation treatment for the treatment of the studied arrhythmias
45444441|NCT03816033|Procedure|radiofrequency catheter ablation|Catheter ablation treatment for the treatment of the studied arrhythmias
45444442|NCT03356132|Device|Silimed® Textured Silicone Gel-Filled Breast Implant|Women undergoing primary and secondary breast augmentation using Silimed® Textured Silicone Gel-Filled Breast Implant.
45600256|NCT03493321|Other|PRF with Theracal|using the PRF which is a new technique with an bioactive material which is the Theracal to evaluate its effect upon the radicular pulp tissue
45600257|NCT03491293|Behavioral|Behavioral Weight Loss + Text|Participants will attend weekly one hour classes on line. They will type their input and responses within the chat room. They will record their calorie and fat intake daily and weigh themselves daily. Interventionists will review the diaries weekly and provide feedback to reinforce or shape new behaviors and to identify high risk situations for problem solving.
45444443|NCT03356132|Device|Silimed® Polyurethane Foam Covered Silicone Gel-Filled Breast Implant|Women undergoing primary and secondary breast augmentation using Silimed® silicone gel-filled breast implants with polyurethane foam covered surface.
45755059|NCT05246995|Drug|IBI325+Sintilimab|IBI325 + sintilimab combination does-escalation Patients will receive IBI325 monotherapy on Cycle 1 Day 1 ,and then receive IBI325 and sintilimab combination until progressive disease, intolerability, or other reasons leading to treatment discontinuation
45600258|NCT03491293|Behavioral|Behavioral Weight Loss + Video|Participants will attend weekly one hour classes on line. They will have audio and video within the chat room, and will talk with their facilitator and classmates during their weekly meeting. They will record their calorie and fat intake daily and weigh themselves daily. Interventionists will review the diaries weekly and provide
45600259|NCT03497533|Biological|TriCAR-T-CD19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.5-1 x 10^6 CAR+ T cells/kg
45600260|NCT03284047|Drug|Botulinum toxin type A|Participants will be randomized to one of three botulinum toxin type A doses.
45600261|NCT02321605|Behavioral|e-BPS|"Participants are asked to write and imagine about a future in which they have reached all their goals and they have developed all their potentialities in four different domains: personal, professional, social and health domain.~They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero & Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform in which they can visualize all the content they had developed previously."
45600262|NCT02321605|Behavioral|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts.
45600263|NCT03493243|Other|Questionnaires|2-hour clinical observation
45600264|NCT05046847|Drug|TQB3811|TQB3811 is a second-generation TrkA inhibitor.
45600265|NCT02321683|Device|Taperloc|Femoral stem with electrochemical deposition of hydroxyapatite
45600266|NCT03493087|Dietary Supplement|Menakinon 7|Menakinon 7 - One tablet a day against vitamin K deficiency
45600267|NCT03493087|Dietary Supplement|Diet rich in vitamin K|Diet with large content of vegetables and dairy products
45600268|NCT03493009|Device|Pure-Vu System|The Pure-Vu System is Food and Drug Administration (FDA) approved device since September 22, 2016, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
45444444|NCT04576598|Other|Self-management program to increase physical activity levels|Information and Communication Technologies will be used to carry out various remote sessions. The sessions will address important issues to promote self-management of sedentary lifestyle by stroke survivors. Additionally, a peer support group will be created in order to improve adherence to the program.
45600269|NCT03490747|Behavioral|Physical activity referral scheme|An 18-week physical activity referral scheme co-developed by a local multidisciplinary stakeholder group. Behaviour change support underpinned by Self-Determination Theory (Ryan & Deci, 2000) will be provided by an exercise referral practitioner at weeks 1,4,8,12 and 18 to facilitate increased physical activity levels. Patients will be supported to develop a tailored programme of physical activity that may involve use of the fitness centre facilities (e.g. swimming, group classes, gymnasium use), participation in community-based initiatives, and changes to habitual physical activity. Focus on promoting patient autonomy and tailoring activities to patient's preferences and needs. Subsidised access to fitness centre facilities for first 12 weeks.
45600270|NCT03490747|Behavioral|Usual care exercise referral scheme|A comparative usual care exercise referral scheme that includes fitness centre based activities (e.g. swimming, group classes, gymnasium use). Patients meet an exercise referral practitioner at their induction (week 1) and week 12 (post scheme). Patients are typically prescribed a gym-based, 12-week programme. Subsidised access to fitness centre facilities for 12 weeks.
45600271|NCT03497377|Drug|18F-DCFPyL Injection|
45600272|NCT03497377|Drug|18F-NaF|
45600273|NCT03173521|Biological|AAV2/8.TBG.hARSB|"Adeno-associated viral vector serotype 8 with liver-specific thyroxinebinding globulin (TBG) promoter driving the expression of the human ARSB gene. Four dose levels are available:~Starting dose is 6x1011 gc of vector per kg of body weight;~High dose is 2x1012 gc of vector per kg of body weight and will be administered after at least two subjects at the starting dose have experienced no DLT;~Very high dose is 6x1012 vector per kg of body weight and will be administered after three subjects at the high dose have experienced no DLT;~Low dose is 2x1011 gc of vector per kg of body weight. Intermediate doses are also possible. The administration of the IMP will be performed into a peripheral vein. The IMP final volume to be injected is calculated based on the patient's weight (determined on the day of hospital admission), as 3 mL/kg."
45444445|NCT04576598|Other|Education information|Education on the importance of active lifestyle habits post-stroke.
45600274|NCT03136627|Drug|Tivozanib|Tivozanib (AV-951): Phase 1b study and Phase 2a study: Subjects will receive 1 dose of tivozanib daily for 21 days followed by a 7 day rest period (1 cycle = 4 weeks).
45600275|NCT03136627|Drug|Nivolumab|Nivolumab: Phase 1b study and Phase 2a study: All subjects will receive IV nivolumab 240 mg every 2 weeks administered over 1 hour.
45755060|NCT03153566|Biological|tuberculin|inject the mother wart with .3 ml tuberculin vaccine every 2 weeks
45755061|NCT03153566|Device|cryotherapy|10 sec 1 cycle into all genital warts
45755062|NCT01676246|Drug|100 mg flupirtine intravenous|Administration of 100 mg flupirtine intravenous (3 mg solution intravenously, 1 vial Kadadolon® inject)
45755063|NCT01676246|Drug|100 mg flupirtine per os|Administration of 100 mg flupirtine per os (1 capsule Kadadolon®)
45755064|NCT01676246|Drug|400 mg flupirtine per os|Administration of 400 mg flupirtine (1 Kadadolon® S long retard tablet)
45934891|NCT00210418|Dietary Supplement|Fortified food rations|The Fortified food rations were included in both arms, but targeted to all children 6-24 months of age in the 'preventive' arm and to malnourished children (WAZ <-2 Z-scores) in the 'recuperative arm. Food rations included Corn-Soy Blend, lentils, oil and wheat.
45755065|NCT01676246|Procedure|induce delayed onset of muscle soreness (DOMS)|"The DOMS exercise protocol consists of two sets of 50 concentric/eccentric contractions of the calf muscles of one leg with a rest of 5 min in-between. The exercise is performed 22-26 h prior to medication. For pain measurements, muscle pain is stimulated by standing on tiptoes of one leg for 30 s, which requires a constriction of the affected calf muscles. The other leg is lifted and the subjects are allowed to hold on to a table to keep their balance. The pain intensity during this stimulation is then rated by means of a 10 cm visual analogue scale (VAS). The VAS is extended from no pain to intolerable pain with a precision of 1 mm. The stimulation is repeated with the other leg. The sequence of the legs is chosen randomly."
45755066|NCT01676246|Procedure|electric pain measurement|"The method has been described to be sensitive to quantify analgesic opioid effects. Painful 5 Hz sine waves electrical stimuli (increase of intensity 0.2 mA/s, from 0 to 20 mA), which predominantly activate C-fibres, will be applied via two gold electrodes placed on the medial and lateral side of the distal phalangeal joint (middle finger of the left hand as default-testing site).~During testing, subjects keep a button continuously pressed until they find the pain intolerably and interrupt the current by releasing the button. The electrical current at which this occurred is defined as pain tolerance, the target parameter of this pain model. Each value of pain tolerance is the median of five subsequent measurements obtained at an interval of 1 min."
45755067|NCT04275830|Behavioral|Baseline Surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
45600276|NCT02489617|Other|Pathologic evaluation of excised tissue|Up to 3 months after excisional biopsy
45600277|NCT02922985|Drug|Intravenous acetominophen|One dose if 1 gram intravenous to be given pre-surgery
45600278|NCT02922985|Drug|Ketorolac, intramuscular|One dose of 60 mg Intramuscular to be given at time of skin closure
45600279|NCT02922985|Drug|Bupivacaine, subcutaneous|Inject 20 mL of 0.25% bupivacaine at the site of anticipated skin incision.
45600280|NCT02922985|Drug|Normal saline|Normal saline will be given intravenously, intra-muscularly, and subcutaneously in the same volume as the study drugs for the patients in the placebo group.
45600281|NCT02765191|Other|Plasma expansion with Ringer's Acetate|7,5 ml/kg mL Ringer's acetate during 5-10 minutes will be administered intravenously
45600282|NCT04881955|Drug|[14C]-Ecopipam|[14C]-Ecopipam
45600283|NCT03490591|Behavioral|Robot-assisted hand rehabilitation|Robot-assisted hand rehabilitation: 20 minute of warm-up exercise and 40 minute of robot-assisted hand exercise intervention. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task, robot-assisted task, and game task.
45600284|NCT03497299|Device|Active rTMS (20Hz)|Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
45600285|NCT03497299|Device|Sham rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
45600286|NCT02234843|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily or twice daily, as tablets
45600287|NCT02234843|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily, twice daily or three times daily, as oral suspension
45600288|NCT02234843|Drug|Standard of Care|"LMWH (low molecular weight heparin) or fondaparinux or vitamin K antagonist (VKA) therapy.~dose : as per standard of care"
45600289|NCT02740231|Drug|JTA-004 intra-articular injection|Each patient will undergo a single injection of JTA-004 into the knee joint
45600290|NCT02740231|Device|Reference product intra-articular injection|Each patient will undergo a single injection of Reference product into the knee joint
45600291|NCT02672215|Behavioral|Start to stand|web-based computer-tailored intervention including personalized feedback and tips on how to reduce and/or interrupt workplace sitting
45600292|NCT02672215|Behavioral|generic advice|general, non-tailored web-based generic advice with tips
45600293|NCT03492931|Drug|Ticagrelor|Patients will receive a single dose of ticagrelor
45600294|NCT04715191|Genetic|CARE T cells|"Three different dosing schedules will be evaluated. The following dose levels will be evaluated:~DL1: 1x10^8/m2 DL2: 3x10^8/m2 DL3: 1x10^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
45600295|NCT04715191|Drug|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.
45600296|NCT04715191|Drug|Fludara|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.
45444446|NCT03813069|Other|IR3535|The topical repellent IR3535 (3-[N-butyl-N-acetyl]-aminopropionic acid ethyl ester) only
45600297|NCT02234921|Drug|Cyclophosphamide|A single dose of cyclophosphamide, 300 mg/m2, will be administered intravenously 3 Days prior to the first vaccine.
45600298|NCT02234921|Biological|DRibble Vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19 and 22. Eight vaccinations will be administered. Week 1 and 4 vaccines will be administered by intranodal injections performed using ultrasound guidance.
45600299|NCT02234921|Biological|HPV Vaccinations|Patients will receive a dose of 0.5-mL CERVARIX at week 1 (Day 4) and week 7 by intramuscular injection at a site distant from the DRibble vaccine.
45600300|NCT02234921|Drug|Imiquimod|Imiquimod cream (5%, 250 mg) will be self-applied topically for 5 consecutive days by patients to a 4 x 5-cm outlined area of healthy extremity skin starting on the day of the second vaccine and again during each additional vaccine cycle.
45600301|NCT02321761|Drug|Amantadine hydrochloride|Drug dosages: day 0-14 no drug will be given Days 15-21 100 mg Days 22-28 200 mg Days 29-42 400 mg Days 43-56 200 day 57-70 no drug will be given
45600302|NCT03492853|Genetic|DNA extraction and sequencing|DNA extraction from peripheral blood and KASP sequencing
45755068|NCT04275830|Behavioral|Heart rate variability biofeedback|"Participants randomized to the intervention arm will receive exactly the same four digital stories via REDCap, a standardized HRV sensor and accompanying smart phone app, and a 30-minute HRVB training to use the biofeedback signals to generate a resonant frequency pattern of HRV (coherence) after collecting data at baseline in person. Participants will be given a take-home manual and specifically asked to practice their HRVB skills at home for 5 minutes prior to viewing stories once each week and upload a log of their time practiced to the cloud. The main purpose of adding HRVB practice as a priming experience (i.e., to teach participants to practice HRV prior to viewing stories) is to optimize results by focusing patients' and caregivers' skills and experience on HRV as a mechanism of improved emotion regulation, and then combine this achieved coherent pattern with DS intervention."
45600303|NCT02234999|Drug|CC-122|3mg [14C]-CC-122 will be administered as a single dose
45600304|NCT04674241|Drug|Dexmedetomidine|Ten minutes after anesthesia induction and endotracheal intubation, patients assigned to dexmedetomidine group were given a loading dose of dexmedetomidine 0.6 μg/kg over 10 minutes, followed by continuous infusion at a rate of 0.4 μg/kg/h until the start of dural closure.
45600305|NCT04674241|Drug|0.9% saline|0.9% saline is administered with the same volume at the same speed as the other group.
45600306|NCT02259569|Other|Pressure-controlled ventilation|
45755069|NCT04275830|Behavioral|Heart rate variability waitlist and Digital storytelling Control intervention|Four Digital Stories Intervention (4 patient stories about hematopoietic cell transplantation (HCT) over the course of 2 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each). The 4 digital stories patients produced contained the following content: (1) a leukemia patient expressed and controlled her depression and anxiety and described how she dealt with the intensive treatment and recovery through a positive attitude and active coping; (2) a mother of 3 children, who was experiencing severe pain due to MS, coped with HCT through family support and positive reframing; (3) a lymphoma patient coped with the HCT procedures by praying during the treatment; and (4) a father of young twins had a HCT twice, and his wife helped him cope with emotional distress through open communication and expressing emotions.Participants will receive a 30-minute HRVB training session at T2.
45755070|NCT03152864|Behavioral|Full Package|Individuals will be randomly allocated to receive the full HealthRhythms package (Rhythm Sensing, Rhythm Trending, and Rhythm Stabilization) program on their smartphones
45444447|NCT03813069|Other|Permethrin lower dose|A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children of 10-20 kg.
45444448|NCT03813069|Other|Permethrin higher dose|A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children more than 20 kg.
45444449|NCT03276026|Drug|Sugammadex|Sugammadex is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
45444450|NCT03276026|Drug|Neostigmine|Neostigmine is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
45444451|NCT03813225|Other|Bilateral serratus Intercostal plane Block|Will be performed by echo guided one puncture in the fifth costal arch with anterior axilary line, where the tip of the needle will be guided until it reaches a point above the external intercostal muscle, below the anterior serratus above the costal arch where they will be administered 21 ml of anesthesic mass, (20 ml of levobupivacaine 0.375 and 1 mg (2mg) of dexamethasone.)
45444452|NCT01303497|Drug|Paclitaxel|Day 1, 8 and 15 : Paclitaxel 90 mg/m², IV over 1h, during 6 cycles (1 cycle = 28 days)
45444453|NCT01303497|Drug|Bevacizumab|"Bevacizumab until progression or inacceptable toxicity :~During the cycles of chemotherapy : Day 1 and D15 : 10 mg/kg,IV~After 6 cycles of chemotherapy : 15 mg/kg, IV"
45444454|NCT05221424|Other|Patient Education|"The training program about hypertension prepared according to the Roy Adaptation Model was performed in a room in the cardiology outpatient clinic of a state hospital. The training content was shaped according to 4 (four) basic areas of the Roy Adaptation Model (physiological field, self-concept field, role function field and interdependence field). The training taught to each patient individually and interactively with the support of powerpoint presentation lasted for averagely 45-50 minutes. A Hypertension Training Booklet was prepared according to the Roy Adaptation Model in order to be used during the training and to strengthen the training."
45444455|NCT03816189|Diagnostic Test|Blood test|Patients in each group will have a blood sample (9x7 mL) for eosinophils isolation, study of activation markers on whole blood and serum biomarkers testing
45600307|NCT02259569|Other|Volume-controlled ventilation|
45600308|NCT04650295|Other|Household Remedy|If the participant experiences a muscle cramp one tablespoon (one sip) of the household product will be taken. The treatment phase of the study will be for 28 days.
45600309|NCT04650295|Other|Tap water|If the participant experiences a muscle cramp one tablespoon (one sip) of tap water will be taken. The treatment phase of the study will be for 28 days.
45600310|NCT02259647|Drug|Sorafenib 400mg twice daily + intravenous infusion ofVit K1|Sorafenib 400mg twice daily + intravenous infusion ofVit K1 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by oral Vitamin K1 20mg twice daily for 3month
45755071|NCT00517595|Drug|Pemetrexed and Gemcitabine plus Bevacizumab|Bevacizumab 10 mg/kg will be given intravenously according to weight. Pemetrexed 500 mg/m^2 and gemcitabine 1500 mg/m^2 will be given intravenously according to weight and height. All agents are administered every 2 weeks.
45600311|NCT02259647|Drug|Sorafenib 400 mg twice daily + Intravenousinfusion of placebo|Sorafenib 400 mg twice daily + Intravenousinfusion ofplacebo daily for 6 days, followed by oral placebo twice daily x 3month
45600312|NCT03490435|Diagnostic Test|Tests for diagnosis of intestinal parasitic diseases|"Feces testing:~fresh fecal samples will be used to preparing direct (saline and iodine wet) mounts using supplementary techniques (flotation, sedimentation), as well as temporary mounts (hematoxylin and trichrome staining). Other technique of fresh fecal samples examination will be ParaSys™~A non-preserved stool samples will be stored below -20°C. Defrosted fecal specimen will be subjected to enzyme-linked immunosorbent assays (ELISA) - Giardia antigen test (coproantigens)"
45444456|NCT03816189|Diagnostic Test|Skin biopsies|In patients who will accept, skin biopsies will be performed in damaged and apparently normal skin, excluding fingers, hands, feet and face (biopsies are facultative)
45755072|NCT02014844|Drug|aldoxorubicin|
45755073|NCT01672814|Drug|riboflavin ophthalmic solution|Administration of riboflavin every 2 minutes for 20 minutes
45444457|NCT01589523|Drug|Glycocholic Acid|10-15mg/kg body weight/day taken orally. Supplied as either liquid or 50mg capsules.
45600313|NCT02321839|Drug|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
45600314|NCT03490279|Dietary Supplement|Lactoferrin CRX|Patients will be asked to take lactoferrin CRX as already mentioned (blindly).
45600315|NCT03490279|Other|Placebo|Patients will be asked to take placebo as already mentioned (blindly).
45452119|NCT01233700|Behavioral|Motivational Interviewing|Standard motivational interviewing techniques will be applied to assist subjects to consider and work to resolve any remaining concerns, doubts, or ambivalence about their decision about donating an organ to someone else.
45452120|NCT01233700|Behavioral|Healthy Lifestyles Education|Educational information will be presented to subjects in didactic form on lifestyles issues of relevance to living donors.
45452121|NCT02267668|Behavioral|STEP|Physical therapists guide participants through novel set of assigned exercises
45600316|NCT02750345|Drug|Nitisinone|A single oral dose of Nitisinone 10 mg Tablet will be administered.
45600317|NCT02750345|Drug|Nitisinone Baked Tablet|A single oral dose of Nitisinone 10 mg Tablet (6 months @ 40°C/75% RH) will be administered.
45600318|NCT02750345|Drug|Orfadin|A single oral dose of Orfadin 10 mg hard capsule will be administered.
45600319|NCT02640625|Dietary Supplement|Probiotic compound|Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
45600320|NCT03131869|Other|Thickened Beverages Nectar|Thickened beverages in nectar consistency
45600321|NCT03131869|Other|Thickened Beverage Honey|Thickened beverages in honey consistency
45600322|NCT01329263|Other|Menthol to non-menthol|Switch from smoking menthol to non-menthol cigarettes.
45600323|NCT02474329|Other|Clinical assessment|During the 13 week follow-up, trained physiotherapists will perform a standardized clinical assessment, based on the PPMI protocol (www.ppmi-info.org) for every included patient. This assessment will last for 60 minutes, and it will be done once.
45452122|NCT02267668|Behavioral|Control|Participants self-guide through standard exercises
45600324|NCT02474329|Device|Fox Insight self-monitoring android app and falls detector|Patients will be asked to wear a smartwatch and a pendant movement sensor, both with triaxial accelerometers, during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.
45600325|NCT04392869|Behavioral|The CRAFT program (adapted due to COVID-19)|"The CRAFT program was created by P. Posadas, PhD (Posadas 2017). This program aims to cultivate positive emotions toward oneself and others, engaging socio-emotional processes and activating traits such as empathy, motivation and creativity. It has been previously implemented in other Higher Education Institutions (Rull et al 2019, Posadas 2018, 2019).~It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction) but it has been adapted and extended due to the situation caused by the COVID19 pandemic.~The resulting 12 week program is structured along the following topics: Consciousness, Relaxation-Breathing-Regulation, Mindfulness/Full Attention, Bliss, Transcendence, Communication as Connection, Mindfully, Consciously and Blissfully Living our Daily Lives, My Work of Art My Wonderful Craft Work Here and Now, Time and Energy Management, Passion and Compassion in the COVID context."
45755074|NCT01672814|Device|Vedera KXS Microwave System|The Vedera KXS dose will be based on the pre-treatment manifest refraction spherical equivalent (MRSE), to be administered one day prior to the CXL procedure.
45755075|NCT00638365|Biological|KB001|Single-dose, 3mg/kg or 10mg/kg dose administered intravenously
45755076|NCT00638365|Other|Placebo|Placebo single-dose administered intravenously
45755077|NCT04764890|Other|Electroacupuncture|Electroacupuncture in several point
45755078|NCT04764890|Other|Manual therapy|Manual therapy in the lower spine.
45755079|NCT00524225|Drug|Neumega (Oprelvekin, Interleukin 11, IL-11)|25 micrograms/kg by subcutaneous injection once daily for four days, followed by once daily on days 1-3 before and after elective surgery or dental procedure
45755080|NCT00669019|Drug|saracatinib|
45755081|NCT01673048|Procedure|3-Nail-ESIN in femoral shaft fractures|
45755082|NCT05560373|Drug|Huperzine A injection, operational treatment, the best basic treatment|intramuscular
45755083|NCT05560373|Other|operational treatment, the best basic treatment|other
45755084|NCT05560373|Drug|Huperzine A injection, interventional treatment, the best basic treatment|intramuscular
46066507|NCT01546753|Drug|Open-label Walnut Protein Powder|Open-label treatment phase begins after the 38 week oral food challenge with unblinding of treatment assignment. For those on active treatment, daily maintenance dosing occurs for up to a total of 298 weeks. For those on placebo treatment, cross-over to active, open-label treatment occurs using the same active treatment protocol. Placebo-crossover subjects will complete an oral food challenge to walnut and the second tree nut at week 38 of active therapy then continue on long-term, open-label maintenance dosing until the end of study using same protocol design. All subjects may reach a qualifying IgE to walnut/second tree nut early and will undergo an OFCs on and 4 weeks off OIT. All subjects will have OFCs on and 4 weeks off OIT at week 142 and at week 298, unless both walnut/second tree nut OFCs are passed at previous OFC prompting addition of these foods into the diet.
45755085|NCT05560373|Other|Interventional treatment, the best basic treatment|other
46066508|NCT01528982|Behavioral|Mindfulness|Subjects receive mindfulness training
45600326|NCT04392869|Behavioral|The MBSR program (adapted due to COVID-19)|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA.~It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction) but it has been adapted and extended due to the situation caused by the COVID19 pandemic.~The resulting 12 week program is structured along the following topics: The Underpinnings of MBSR, The Perception of Reality, Emotion Regulation, Understanding Stress: The Mind-Body Relation, Responding to Stress, Communication and Personal Relations, Daily Life Management, My Personal Plan: The First Week of the Rest of my Life, Time and Energy Management, Emotion Regulation in the COVID context."
45755086|NCT02140957|Behavioral|Educational Intervention|Parents of children in both intervention and control groups received standardized counseling on healthy nutrition based on Canadian Paediatric Society guidelines. In addition, during the same 9-month doctors visit, parents of infants allocated to the intervention group were given a sip cup (Avent Magic CupTM) and shown how to use it. A trained research assistant told intervention group parents the risks of continued bottle use. They were also instructed to limit daily milk consumption to 16 ounces. Parents were also counseled to discontinue bottle use in the next 1 week using a step-wise protocol described on a handout to be placed on their refrigerator. Parents of infants allocated to the control group did not receive this information.
45755087|NCT05560295|Procedure|Naser Al-Husban|uterine surgery
45755088|NCT04747574|Drug|EXO-CD24|The study active treatment is EXO-CD24 -exosomes (natural nano-sized vesicles secreted by human cells) that were engineered to overexpress CD24, aerosolized in normal saline for inhalation via a standard hospital-grade inhalation device, QD for 5 days.
45755089|NCT01676480|Behavioral|Endurance training|12 weeks of endurance training 3 times per week
45755090|NCT05560139|Device|a-tDCS|Transcranial direct current stimulation
45755091|NCT00670267|Drug|nadolol|Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.
45755092|NCT05621915|Drug|Nadroparin|Subcutaneous injection of nadroparin according to the ICU guidelines for thromboprophylaxis in ICU patients.
45755093|NCT01673204|Drug|Calcitriol|dosage of 0.5mcg administered orally once daily for 12 month
45755094|NCT01673204|Drug|Placebo|
45755095|NCT05621837|Other|MDSC quantification|Blood sample will be collected at baseline and during therapy, and, optionally, in case of disease progression (PD).
45755096|NCT04393298|Drug|UCB6114|Study participants will receive predefined doses of UCB6114 administered intravenously at pre-specified time points.
45755097|NCT04393298|Drug|trifluridine/tipiracil|Study participants will receive predefined doses of trifluridine/tipiracil (TFD/TPI) administered as film-coated tablets at pre-specified time points.
45755098|NCT04393298|Drug|mFOLFOX6|Study participants will receive predefined doses of oxaliplatin, Leucovorin and 5-fluorouracil as part of the mFOLFOX6 chemotherapy regimen administered as intravenous (iv) infusion at prespecified time points.
45755099|NCT00641563|Drug|Dexmedetomidine|Infusion of dexmedetomidine
45755100|NCT00641563|Drug|Midazolam|Midazolam infusion
45755101|NCT00641563|Drug|Remifentanil|Infusion of remifentanil
45755102|NCT05621759|Drug|Cyclophosphamide|Nitrogen mustard alkylating agent produced by Bristol-Myers Squibb.
45755103|NCT05621759|Drug|Abatacept|Calcineurin-inhibitor produced by Astellas.
45755104|NCT05621759|Drug|Tacrolimus|Selective T cell co-stimulation modulator produced by Bristol-Myers Squibb.
45755105|NCT02251262|Device|Whole-body 18FDG-PET-CT scan|18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
45755106|NCT00641641|Drug|Tenofovir + emtricitabine + raltegravir.|TDF 300mg once daily + FTC 200mg once daily + RAL 400mg twice daily.
45755107|NCT03152474|Drug|Solumedrol 20mg|Dosed Intravenous every 8 hrs.
45755108|NCT03152474|Drug|Vitamin A 100,000 IU|Dosed Intramuscular once daily
45755109|NCT03152474|Other|Placebo|Placebo dosed intravenous every 8 hrs. or Intramuscular once daily.
45755110|NCT00641797|Drug|Meclizine|medication administration 25mg PO one time
45755111|NCT00641797|Other|Epley Maneuver|Patient has vestibular rehabilitation utilizing the Epley Maneuver.
45755112|NCT00641797|Drug|Lorazepam|Lorazepam 1 - 5mg PO/IV prn
45755113|NCT00641797|Drug|Diphenhydramine|25 - 50mg PO/IV once prn
45755114|NCT00641797|Drug|Ondansetron|Ondansetron 4 - 8 mg PO/IV prn
45755115|NCT04333459|Biological|Hataan DNA Vaccine/Puumala DNA Vaccine|Vaccine compared in High and Lose Doses.
45755116|NCT00671515|Drug|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
45755117|NCT00671671|Drug|Small Molecule Agent (PF-868554)|Study drug will be administered 700mg BID in the fed state for three days.
45755118|NCT00671671|Drug|Small Molecule Agent (PF-868554)|Study drug will be given 450mg BID for a duration of 10 days.
45755119|NCT01893320|Drug|Vosaroxin|"Phase I Starting Dose: 90 mg/m2 by vein on Days 1 and 4 of each cycle.~Phase II Starting Dose: 70 mg/m2 by vein on Days 1 and 4 of each cycle, or maximum tolerated dose from Phase I."
45755120|NCT01893320|Drug|Decitabine|Phase I and II: 20 mg/m2 by vein daily for 5 consecutive days (Days 1 to 5).
45755121|NCT01799707|Behavioral|vision restoration training|visual stimuli repetitively presented to stimulate areas of residual vision. The training consists of luminance increment stimuli similar to perimetry and the task isa simple detection task (pressing a key whenever a target stimulus was detected).
45755122|NCT01799707|Behavioral|Discrimination Training|the stimulus is a line segment (bar) which is always presented within the central ±5° visual field in one of four possible random orientations: horizontal, vertical, oblique to the right or oblique to the left. If the patient has visual field defects in this central area, 80% of the stimuli are presented in the intact part of the training region. The task is to identify the orientation of the line segment and press, as fast as possible, one of 4 assigned buttons on the keyboard.
45600327|NCT03490123|Drug|R1-Total community treatment with azithromycin|At month 0, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
45600328|NCT03490123|Drug|R2-Total community treatment with azithromycin|At month 6, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
45600329|NCT03490123|Drug|R3-Total community treatment with azithromycin|At month 12, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
45600330|NCT03490123|Drug|R2-Total targeted treatment with azithromycin|At 6 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
45452123|NCT02268682|Other|Patient-Guided|"The Explore Transplant education program was designed to increase patient informed decision-making and knowledge and is based on the theoretical tenets of the Transtheoretical Model of Behavior Change. The program helps patients think about what might motivate them to pursue transplant, addresses commonly held concerns about transplant and involving a living donor, and shares real-life transplant stories of donors and recipients. The ET materials were written for patients with low health literacy. Already developed for the Explore Transplant program are brochures, videos, and factsheets. ET at Home is an expansion of the ET program. Newly designed postcards and text messages have added to the list of transplant education resources for this program."
45600331|NCT03490123|Drug|R3-Total targeted treatment with azithromycin|At 12 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
45600332|NCT02235233|Drug|Technetium Tc 99M Mebrofenin|Each subject will be injected with ~2.5 mCi of Technetium Tc 99M Mebrofenin
45600333|NCT02182687|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered in five total fractions, with at a minimum of one day between any two treatments. The entire treatment must be delivered within 15 total days.
45600334|NCT02182687|Procedure|Trans-Arterial Chemoembolization (TACE)|First day will be administered and a second TACE will be administered after 4 weeks and subsequently if imaging is showing disease progression. Following each TACE procedure all patients will remain in hospital for observation.
45600335|NCT02182687|Drug|Doxorubin|This procedure will be completed with 2 vials of drug eluting beads each loaded with 50 mg of Doxorubin.
45600336|NCT02235389|Drug|Alteplase (Actilyse)|
45600337|NCT02235389|Drug|Standard therapy|
45600338|NCT02235467|Behavioral|ABA parent training|A parent training based on Applied Behavior Analysis that is going to be delivered by video modeling in 21 weeks
45600339|NCT03489967|Other|Induced-hypoglycemia test|Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to induce hypoglycemia. Oral treatment (16g of carbohydrates or 32g of carbohydrates) will be given when plasma glucose levels are at the target threshold of < 3.0 mmol/L or 3.0-3.5 mmol/L. Hypoglycemia symptoms will be assessed every 10 minutes by the participant using a validated scale starting from the time of insulin bolus until hypoglycemia recovery. One hour after hypoglycemia recovery, a standardized meal will be given.
45600340|NCT02235545|Device|St. Jude Medical Optisure Lead|Patients implanted with St. Jude Medical Optisure Lead
45600341|NCT03489889|Drug|Ursodeoxycholic Acid 300mg tablet|Cross-over study: Ursodeoxycholic Acid 300mg tablet and after Ursodeoxycholic Acid 300mg capsule
45600342|NCT03489889|Drug|Ursodeoxycholic Acid 300mg capsule|Cross-over study: Ursodeoxycholic Acid 300mg capsule and after Ursodeoxycholic Acid 300mg tablet
45600343|NCT02235779|Other|Transbronchial lung cryobiopsy|
45755123|NCT00648115|Other|Basic Vocational Services|Vocational services
45755124|NCT00648115|Other|Self-Study|Veteran receives self-study resources
45755125|NCT00648115|Other|Group Program|Veteran participates in group vocational program
45755126|NCT01799785|Behavioral|Aerobic exercise|Aerobic exercise for 8 weeks (3 times per week, 30-60 minutes each session)
45755127|NCT01799785|Other|Usual Care|
45755128|NCT04273022|Other|Exercise|A single bout of standardized, moderate exercise
45755129|NCT04244396|Device|TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)|TactiCath SE is indicated for use in cardiac electrophysiological mapping (stimulation and recording), and, when used in conjunction with a radiofrequency generator, for cardiac ablation of supraventricular arrhythmias in the right and left atrium, including atrial fibrillation.
45755130|NCT04236908|Drug|NSAIDS|Naproxen 500mg by mouth twice a day as needed.
46066509|NCT01528982|Behavioral|Cognition|Subject receive cognitive training
46066510|NCT01334788|Other|sleep deprivation|Sleep restriction
45755131|NCT04236908|Device|Battlefield Acupuncture|"Battlefield Acupuncture in both ears (which includes the points cingulate gyrus, thalamus, omega-2, point zero and shen men).~Battlefield acupuncture utilizes up to 10 ASP acupuncture needles (5 in each ear). The Battlefield Acupuncture points include: cingulate gyrus, thalamus, omega-2, point zero, and shen men. The semi-permanent needles are left in place and typically stay in place for 2-7 days. Needles will usually fall out on their own, can be removed by the patient or the patient can call study staff and come in for removal if desired."
45600344|NCT04062383|Behavioral|Positive Psychology + Motivational Interviewing|For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
45600345|NCT01388491|Drug|desogestrel/ethinyl estradiol and ethinyl estradiol|
45600346|NCT01388491|Drug|desogestrel/ethinyl estradiol|
45600347|NCT02236169|Drug|Ipratropium bromide HFA-134a inhalation aerosol|
45755132|NCT04236908|Device|GV26 with manual tonification|"Acupuncture to include use of GV 26 with manual tonification (twisting or rotating the needle).~The protocol for using GV26 is as follows: With the patient in a seated position the acupuncturist places a 40mm needle in the acupuncture point GV26 (located on the philtrum, on the anterior midline, at the junction of the upper 1/3 and lower 2/3 of the distance from the nose to the margin of the upper lip). The acupuncturist then rapidly rotates the needle at the handle clockwise and counterclockwise (known as manual tonification) for 20-40 seconds at a time. The patient then stands up and assesses their pain. This will be performed up to 6 cycles. If a patient is unable to sit or stand, this may also be performed in a supine position with the patient attempting to sit or stand every 20-40 seconds."
45755133|NCT04157725|Drug|mild stimulation protocol: oral Clomiphene Citrate|Group A (mild stimulation protocol) will receive oral Clomiphene Citrate (Clomid®) 150 mg/day for 5 days (starting on the 2nd of menses), followed by FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting from the 6th day of the menstrual cycle. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.
45755134|NCT04157725|Drug|Conventional Stimulation Protocol: will receive FSH/HMG|Group B (conventional stimulation protocol) will receive FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting on the 2nd day of menses. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.
45600348|NCT02236169|Drug|Atrovent CFC inhalation aerosol|
45755135|NCT01673360|Device|Elevate PC|List of AMS prolapse products
45600349|NCT01352533|Procedure|Running polypropylene closure|Half of every wound will be closed with Standard of Care running polypropylene sutures
45600350|NCT01352533|Procedure|Tissue Adhesive (Derma-Bond)|Approximately half of wounds will be randomized to be closed with tissue adhesive.
45755136|NCT01673360|Device|Mini Arc Pro|List of AMS Urinary Incontinence devices
45755137|NCT01673360|Device|RetroArc|List of AMS Urinary Incontinence devices
45755138|NCT00672451|Dietary Supplement|rhubarb extract|titrate rhubarb extract titrated up to 6grams daily by mouth
45755139|NCT00672451|Dietary Supplement|placebo|placebo titrated up to 6 pills daily as patient tolerates
45755140|NCT05316350|Device|Electrocardiogram recording|ECG recording with investigational device
45755141|NCT05316350|Device|Electrocardiogram recording|ECG recording with reference device
45755142|NCT04095871|Other|Observational study|No intervention, patients record the time of CISC
45755143|NCT01673672|Biological|CYT003|7 subcutaneous injections, weekly/biweekly within 10 weeks
45755144|NCT01673672|Biological|Placebo|7 subcutaneous injections, weekly/biweekly within 10 weeks
46066511|NCT01334788|Other|Normal sleep|These are subjects who are randomized to sleep normally.
46066512|NCT01291420|Biological|autologous dendritic cell vaccination|4 biweekly intradermal DC injections of 10*10E6 DCs (500 µL) at 5 sites (100 µL/site) in the ventromedial regions of the upper arm approximately 5-10 cm of the regional lymph nodes
45600351|NCT01352533|Procedure|Subcuticular polyglactin-910 combined with tissue adhesive|Approximately half of the experimental wounds will be randomized to be closed with a combination of subcuticular polyglactin-910 and tissue adhesive.
45600352|NCT05101057|Device|SpinalogicTM Bone Graft Stimulator|The SpinalogicTM is a portable, battery-powered, microprocessor-controlled, non-invasive bone growth stimulator. The device is currently approved and commercially indicated as an adjunct electrical treatment to primary lumbar spinal fusion surgery for one or two levels.
45600353|NCT05099029|Biological|EV71 vaccine|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AI(OH)3] per dose) Two vaccinations at 28 days apart
45600354|NCT05099029|Biological|Placebo|Placebo ([ adjuvant 150 μg AI(OH)3] per dose) Two vaccinations at 28 days apart
45600355|NCT02749799|Drug|DFD-01 (betamethasone dipropionate) Spray, 0.05%|DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.
45600356|NCT03492697|Drug|PF-06882961 Immediate Release Tablet|Immediate Release Tablet
45600357|NCT03492697|Drug|PF-06882961 Controlled Release Tablet (long)|Controlled Release tablet (long)
45600358|NCT03492697|Drug|PF-06882961 Controlled Release Tablet (short)|Controlled Release tablet (short)
45755145|NCT03154112|Device|Measurement of oxygen consumption and caloric expenditure|This study will involve an ~1 hour, single point in time measurement of oxygen consumption, carbon dioxide production, resting energy expenditure, and respiratory quotient using two methods while patients are breathing an FiO2 of 40%. These measurements will be measured using the novel, responsive device and compared with gas collected simultaneously collected from a Douglas bag.
45600359|NCT03492697|Drug|PF-06882961 Immediate Release Solution|PF-06882961 Immediate Release solution
45600360|NCT02236247|Drug|ivabradine|5 mg oral twice daily
45600361|NCT02236247|Drug|Placebo|A placebo pill (identical to ivabradine) will be administered twice daily
45600362|NCT03492619|Behavioral|Intensive Intervention|an intervention focused on alleviating discouragement, food insecurity, and excess weight in women and targeted at the individual, family, and community levels
45600363|NCT03492619|Behavioral|Non-Intensive Intervention|Group sessions for healthy lifestyle
45600364|NCT03755219|Procedure|TEP|By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
45600365|NCT03755219|Procedure|TAPP|By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
45600366|NCT03492541|Other|Propylene glycol-based eye drops|Nano-emulsion ocular lubricant
45600367|NCT03492385|Drug|PB2452 Infusion|30 minute - 12 hour infusion
45600368|NCT03492385|Drug|Placebo - Sodium Chloride|30 minute - 12 hour infusion
45600369|NCT03492385|Drug|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo
45600370|NCT03492385|Drug|Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo and Ticagerlor 180 mg 24 hours following MEDI2452 (PB2452) or Placebo
45600371|NCT03736265|Drug|Carvedilol|Carvedilol is started at a dose of 6.25 mg once daily. After 1 week, this will increased to a dose of 12.5 mg once daily. Target dose of 12.5 mg once daily will be maintained if systolic blood pressure does not fall below 90 mm Hg and HR 50 beats per minute.
45600372|NCT04939363|Combination Product|Obinutuzumab with Ibrutinib and Venetoclax|"Obinutuzumab intravenous infusion:~Ibrutinib PO 560mg daily starting on cycle 1 day 1 for 12 cycles.~Venetoclax with an accelerated ramp-up and close inpatient Tumor Lysis Syndromes (TLS) monitoring starts on cycle 1 day 15 to the target dose of 400mg daily for a total of 12 cycles:"
45600373|NCT03625427|Dietary Supplement|Placebo|The placebo is olive oil, stripped of polyphenols, 70% oleic acid, administered as two 1-gram capsules per day. Packaged as single-serve packets containing 2 capsules for each daily dose.
45600374|NCT03625427|Dietary Supplement|Palmitoleic acid, 500 mg (Dose 1)|Palmitoleic acid (POA) 1 gram capsules containing 500 mg POA
45600375|NCT03625427|Dietary Supplement|Palmitoleic acid, 1,000 mg (Dose 2)|Palmitoleic acid (POA) taken as two 1 gram capsules each containing 500 mg POA
45600376|NCT02321917|Device|MECC system with rheoparin coating|MECC system for extracorporeal circulation equipped with rheoparin coating.
45600377|NCT02236325|Behavioral|DBT Brief Suicide Intervention|Participants assigned to the DBT Brief Suicide Intervention are presented with a selection of coping strategies selected from the Dialectical Behavior Therapy (DBT) skills training curriculum. The strategies are 1) mindfulness, 2) mindfulness of current emotions, 3) opposite-to-emotion action, 4) distraction, and 5) changing your body chemistry.
45600378|NCT02236325|Behavioral|Relaxation Training|Participants assigned to the Relaxation Training condition receive instruction in a sensory awareness practice and are guided through the practice by the therapist.
45600379|NCT02236403|Drug|Ivermectin 0.1% Metronidazole 1%|
45600380|NCT02236403|Other|None intervention|Volunteers with no signs of blepharitis and with eyelashes with no demodex. Symptoms and signs will be compared with experimental group
45755146|NCT04120766|Drug|Nicorandil|20 mg po qd
45755147|NCT04120766|Drug|Placebo|Matching tablet
45600381|NCT02236481|Drug|Anakinra|
45600382|NCT02236481|Drug|TNF alpha inhibitors|
45600383|NCT03491527|Procedure|Absolute isolation|Absolute isolation with rubber dam
45600384|NCT03491527|Procedure|Manipulation of the resin cement with MTA|Manipulation of the resin cement with MTA according to the manufacturer's recommendations.
45600385|NCT03491527|Procedure|Manipulation of the resin cement without MTA|Manipulation of the resin cement without MTA according to the manufacturer's recommendations.
45600386|NCT03491527|Procedure|Fiber Post cimentation|Insertion of the cement on the root canal and on post surface. Light-cured for 40 seconds on each surface.
45600387|NCT03491527|Procedure|Dental Prepare|Confection of a indirect crown prepare with diamand burs.
45600388|NCT03491527|Procedure|Dental impression|Dental impression whith silicone.
45600389|NCT03491527|Procedure|Crown cimentation|Insertion of the cement on the inner surface of the crown. Light-cured for 40 seconds on each surface.
45600390|NCT03491527|Procedure|Occlusal adjustment|Analysis of the occlusion with carbon paper.
45600391|NCT03253393|Device|Smart Touch Technology packaging|hioxifilcon A contact lens in Smart Touch Technology (hydrogel, no EDTA) midafilcon A contact lens in Smart Touch Technology (silicone hydrogel, with EDTA)
45600392|NCT03253393|Device|Conventional lens packaging|hioxifilcon A contact lens in conventional lens packaging (hydrogel, no EDTA) midafilcon A contact lens in conventional lens packaging (silicone hydrogel, with EDTA)
45600393|NCT03253393|Device|EDTA|hioxifilcon A contact lens in Smart Touch Technology (hydrogel, with EDTA) midafilcon A contact lens in Smart Touch Technology (silicone hydrogel, no EDTA)
45755148|NCT01673750|Other|Questionnaire|The primary outcome, characterizing body image among HIV infected adolescents, will be measured using a questionnaire administered to study participants through Audio Computer Assisted Self-Interview (ACASI) technology.
45755149|NCT04053062|Biological|LIGHT-PSMA-CART cells|LIGHT-PSMA-CART cells will be given IV at split doses
45911006|NCT02002234|Procedure|Hemicraniotomy|Hemicraniotomy involves removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank.
45755150|NCT03159416|Drug|Inclisiran|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
45755151|NCT00673075|Drug|Nebivolol|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily
45600394|NCT02261441|Other|Observational and noninterventional study|No specific recommendations will be provide to physicians about treatments. As a result, treatments of patients will be prescribed, modified or withdrawn according only to physicians´ judgment.
45600395|NCT03128671|Behavioral|FAVoR Intervention|The FAVoR intervention includes a set of 8 scripted recorded messages, no longer than 2 minutes long, includes subject's name, uses simple terms, and is written at a 5th grade reading level. Messages include information about the critical care environment, the visual and auditory stimuli to be expected, and the availability of providers and family.
45600396|NCT02261519|Drug|NaBen®|500 mg twice daily (1000 mg total)
45600397|NCT02261519|Other|Placebo|0 mg twice daily (0 mg total)
45600398|NCT02654327|Device|VV-ECCO2R to enable lower tidal volume mechanical ventilation|In the intervention arm a dual lumen catheter will be inserted into a central vein. VV-ECCO2R is commenced and managed as per study manual. Tidal volumes are then reduced on mechanical ventilation to enable lower tidal volume ventilation. Lower tidal volume facilitated by VV-ECCO2R will continue for a least 2 days up to a maximum of 7 days
45600399|NCT02934529|Drug|Irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min., day 1, q d15
45600400|NCT02934529|Drug|Folinic Acid|Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1, q d15
45600401|NCT02934529|Drug|5-FU|5-FU 400 mg/m² bolus day 1, q d15
45600402|NCT02934529|Drug|5-FU|5-FU 2400 mg/m² iv over 46 h day 1-2, q d15
45600403|NCT02934529|Drug|Cetuximab|cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) day 1 + 8
45600404|NCT02934529|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg BW iv over 30 to 90 minutes: day 1
45600405|NCT02934529|Drug|Capecitabine|Capecitabine 1250 mg/m2 2 x day p.o. day 1-14, q d15
45600406|NCT02934529|Drug|regorafenib|160 mg per day (day 1-21) (repeated on day 28)
45600407|NCT02934529|Drug|Irinotecan 125mg|Irinotecan 125 mg/m² iv, 60 - 90 min. weekly (D1, D8, D15, D22)
45600408|NCT02934529|Drug|Cetuximab wkly|Cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) weekly (D1, D8, D15, D22, D29, D36)
45600409|NCT02638805|Drug|ITCA 650 Osmotic Mini Pump 20/60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day
45600410|NCT02638805|Drug|ITCA 650 Osmotic Mini Pump 60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day
45600411|NCT02638805|Drug|Metformin|Stable dose for at least 3 months (at least 1000 mg/day)
45600412|NCT02638805|Drug|Liraglutide|Stable dose for at least 3 months (at least 1.2 mg/day)
45600413|NCT02261675|Drug|dexmedetomidine|children received intravenous infusion with a bolus dose dexmedetomidine and followed by a continuous infusion before induction. use sevoflurane for induction and a steady-state end-tidal sevoflurane concentration was maintained for at least 15 min before skin incision.
45600414|NCT02261753|Dietary Supplement|Classical ketogenic diet|A high fat low carbohydrate, low protein diet.
45600415|NCT02261831|Other|obese patients|collection of blood sampling and biopsies
45600416|NCT02261831|Other|diabetic patients|collection of blood sampling and biopsies
45600417|NCT02261831|Other|patients free of obesity and diabetes|collection of blood sampling and biopsies
45600418|NCT02261831|Other|patients free type 2 diabetes|collection of blood sampling and biopsies
45600419|NCT02261987|Other|Autogenic drainage (AD)|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
45600420|NCT02261987|Other|Resistive inspiratory manoeuvre (RIM)|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
45600421|NCT02261987|Other|Resistive inspiratory manoeuvre+autogenic drainage|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
45600422|NCT02262143|Drug|Rosuvastatin|Rosuvastatin 10 mg, qd, po
45600423|NCT02262143|Drug|Fenofibrate|Fenofibrate 160mg, qd, po
45600424|NCT02620553|Drug|Human Insulin|There is a study drug dose increase once during the study. The dose increase will occur 6 months after entering into the study. A total of 6 children will be included at each dose (3 children will not have received insulin prior to entering the study and 3 children will have received a lower dose of insulin for 6 months). Further dose increases or more frequent dose increases in individual children will not be performed during Pre-POINT. Escalation will occur in both treatment and placebo group so that participants and study investigators will remain blinded to treatment throughout the study. First dose (2.5 mg oral insulin/day) Second dose (7.5 mg oral insulin/day) Third dose (22.5 mg oral insulin/day) Fourth dose (67.5 mg oral insulin/day)
45600425|NCT02620553|Other|Oral Placebo|Oral Placebo is given orally daily
45600426|NCT04588727|Drug|AZD3366|In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort[s]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).
45600427|NCT04588727|Drug|Placebo|In Part A and Part B, subjects will be randomized to receive intravenous infusion of placebo (0.9% sodium chloride solution).
45600428|NCT04588727|Drug|Ticagrelor|In Part B, subjects will receive oral ticagrelor tablets.
45755152|NCT00673075|Drug|Carvedilol|Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily
45755153|NCT03159104|Drug|Tenoten for children|Oral administration.
45755154|NCT03159104|Drug|Placebo|Oral administration.
45755155|NCT02250014|Procedure|cryotherapy|Undergo cryotherapy
45755156|NCT02250014|Biological|sargramostim|Given subcutaneously
46066513|NCT00836537|Drug|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fed
46066514|NCT00836537|Drug|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fed
45600429|NCT04588727|Drug|acetylsalicylic acid (ASA)|In Part B, subjects will receive oral ASA chewable tablets.
45600430|NCT02262299|Drug|Pirfenidone|Receive tablets with pirfenidone
45755157|NCT00651625|Device|Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001|The RPD is a safety syringe device that is hypothesized to be safer, less painful, and more effective for patients undergoing a syringe and needle procedure (please see arm #1).
45755158|NCT00651625|Device|conventional syringe - BD Ref 309604|the conventional syringe or the RPD will be used for syringe and needle procedures performed by physicians.
45600431|NCT02262299|Drug|Placebo|Recieve tablets with placebo
45600432|NCT02608697|Drug|CAT-2054|
45600433|NCT02608697|Drug|Placebo|
45600434|NCT02608697|Drug|Atorvastatin|
45600435|NCT02262455|Drug|STM 434|STM 434 will be administered by IV injection. There are five planned dose levels, from 0.25mg/kg to 4mg/kg, which is dependent on the cohort (group) a participant is assigned to.
45600436|NCT02262455|Drug|Liposomal doxorubicin|Liposomal doxorubicin (40 mg/m2) will be administered once every 28 days by IV infusion prior to STM 434 for those participants enrolled in Part 3 of the trial. Liposomal doxorubicin will be administered for a maximum of 6 cycles (each cycle being 28 days).
45600437|NCT02262533|Drug|Apixaban|
45600438|NCT02262533|Drug|Atenolol|
45600439|NCT02262611|Drug|Micardis®|
45600440|NCT02262611|Drug|MicardisPlus®|
45600441|NCT02607683|Drug|XAF5 (concentration A: 0.1%)|
45600442|NCT02607683|Drug|XAF5 (concentration B: 0.035%)|
45600443|NCT02607683|Drug|Matching placebo|
45600444|NCT02600429|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into affected eye(s), five times a day for 4 weeks.
45600445|NCT02600429|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
45600446|NCT02262689|Drug|GSK2256294|GSK2256294 will be supplied as gelatin capsule to be administered orally with the unit dose 5 mg / dose level 15 mg
45600447|NCT02262689|Drug|Placebo|Matched Placebo will be supplied as gelatin capsule to be administered orally
45600448|NCT04476875|Other|Open Outpatient Clinic Programme|
45600449|NCT04476719|Drug|ATAFENOVIR 200 MG KAPSUL|A 200 mg capsule 0ral administration with 240 ml water
45600450|NCT04476719|Drug|ARBIDOL 100 MG KAPSUL|Two 100 mg capsules will be administrated with 240 ml water orally.
45600451|NCT04476563|Diagnostic Test|Obtaining biological samples|Biological samples (blood, urine, stool). Liver tissue will be obtained from ChILI group when clinically indicated
45600452|NCT04476485|Other|endocrine therapy|If the expression of sj-subway in the surgical wax block is eligible, it is recommended but not mandatory that patients follow the guidelines to choose the appropriate extended endocrine therapy. 1. For postmenopausal patients: Extend treatment with aromatase inhibitors 10 years: letrozole or anastrozole or exemestane. 2. For premenopausal patients: An initial 5 years tamoxifen treatment followed by additional 5 years extended tamoxifen treatment. Postmenopausals are treated with aromatase inhibitors 5 years. 3. For patients have completed ovarian function suppression plus initial 5-year aromatase inhibitor treatment: Menopausals: Aromatase inhibitors; Non-menopausals: 5 years of tamoxifen treatment or ovarian function suppression plus 5 years of aromatase inhibitor treatment. 4. For patients have completed ovarian function suppression plus initial 5-year tamoxifen treatment: Menopausals: Aromatase inhibitors for additional 5 years; Non-menopausals: Tamoxifen for additional 5 years.
45600453|NCT02262767|Drug|PF-06649751|Experimental Pfizer compound.
45600454|NCT02262767|Drug|Trimethobenzamide Hydrochloride|Trimethobenzamide Hydrochloride is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
45755159|NCT03156608|Device|Novii ECG/EKG System|External fetal heart rate monitoring
45755160|NCT03156608|Device|External fetal heart rate monitoring|External fetal heart rate monitoring
45755161|NCT04022096|Drug|Tegoprazan 25mg QD|Tegoprazan 25mg tablets will be orally administered, once daily, for up to 6 months.
45755162|NCT04022096|Drug|Lansoprazole 15mg QD|Lansoprazole 15mg capsules will be orally administered, once daily, for up to 6 months.
45600455|NCT02589275|Drug|TNX-102 SL Tablet 2.8 mg|TNX-102 SL 2.8 mg tablet taken daily at bedtime
45600456|NCT02262845|Device|The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers|Used to drain pancreatic ducts
45600457|NCT04476641|Other|CELL|inject the DC-CIK(dendritic cell activated and cytokine induced killer cell)
45600458|NCT02263001|Other|Auricular acupuncture|Auricular therapy for treatment of musculoskeletal pain
45600459|NCT02263001|Other|Usual Care|Usual care therapy consists of over-the-counter and prescribed pharmacotherapy
45600460|NCT02543567|Biological|Ad26.ZEBOV 5*10^10 viral particles (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 5*10^10 viral particles on Day 1
45600461|NCT02543567|Biological|Ad26.ZEBOV 2*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 2*10^10 viral particles on Day 1
45600462|NCT02543567|Biological|Ad26.ZEBOV 0.8*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 0.8*10^10 viral particles on Day 1
45600463|NCT02543567|Biological|MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]|MVA-BN-Filo- live replication incompetent vaccine, IM injection of 1*10^8 Infectious Unit [Inf. U.] once on Day 57
45600464|NCT02543567|Biological|MVA-BN-Filo 5*10^7 Inf. U.|MVA-BN-Filo- live replication incompetent vaccine, IM injection of 5*10^7 Inf. U. once on Day 57
45755163|NCT01673906|Drug|Diagnostic work up|Patients will undergo MDCT, PET and EUS. Every attempt will be made to achieve a pre-operative cytologic diagnosis of any primary lesion by EUS-FNA. All diagnostic tests (MDCT, PET, EUS) should be performed during a two month time span, in this fixed order. The nuclear medicine doctor will be blinded of findings of MDCT. The gastroenterologist will be blinded about the findings of MDCT and PET until he has completed the diagnostic EUS. For ethical reasons, the findings of MDCT and PET will be disclosed to her/him, while the patient is still sedated in the operating room, just before the FNA. The minimal technical requirement for the techniques, the requested levels of clinical competence of the operators and the procedure for critical revision of radiological and cytological and histological specimens are detailed in the protocol. For PET any 68Ga -labeled-octreotide analogue will be allowed. Before EUS, an extended-esophagogastroduodenoscopy (until the Treitz) until will be performed.
45600465|NCT02543567|Biological|Placebo|One 0.5 ml IM injection of 0.9% saline administered once on Day 1 and Day 57
45600466|NCT02515175|Biological|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
45600467|NCT02515175|Biological|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
45600468|NCT02515175|Drug|Placebo|0.9% Normal Saline
45600469|NCT02513303|Drug|Sirolimus|A single dose of sirolimus delivered locally
45600470|NCT02513303|Procedure|AV Fistula Surgery|AV Fistula Surgery
45600471|NCT02513303|Device|Sirolimus-eluting Collagen Implant (SeCI)|SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.
45600472|NCT02476019|Drug|ISIS-FGFR4RX|ISIS-FGFR4RX administered subcutaneously
45600473|NCT02476019|Drug|Placebo|Placebo administered subcutaneously
45600474|NCT01620515|Drug|NX-1207 2.5 mg|A single intraprostatic injection of NX-1207 2.5 mg followed by active surveillance.
45600475|NCT01620515|Drug|NX-1207 15 mg|A single intraprostatic injection of NX-1207 15 mg followed by active surveillance.
45600476|NCT01616303|Drug|Carboplatin|carboplatin (area under the curve (AUC) 6, administered intravenously in a single day for 6 cycles every three weeks [21 days])
45600477|NCT01616303|Drug|Paclitaxel|Paclitaxel (175 mg / square meter, intravenously over three hours in one day to be repeated for 6 cycles every three weeks [21 days])
45600478|NCT01616303|Biological|oregovomab|oregovomab (2 mg infused intravenously jointly during the 1st, 3rd and 5th chemotherapy cycle and 12 weeks after the 5th cycle).
45600479|NCT02263313|Other|EGO-COMBO group|Assess the safety and effectiveness of Combo stent
45600480|NCT01597349|Drug|FP01|Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.
45755164|NCT04014296|Behavioral|High Protein Diet|16 week group-based weight loss program with high protein diet. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed after 8 weeks. Non-responders will be randomized to either combine the HP diet with supervised resistance training counseling (2 days per week) or add a protein supplement.
45755165|NCT04014296|Behavioral|Resistance Training|16 week weight loss program with normal protein diet and resistance training counseling. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:20%:26%. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed after 8 weeks. Non-responders will be randomized to either combine resistance training with HP/protein supplement or add supervised sessions with a personal trainer (2 days per week) to the resistance training regimen.
45755166|NCT00673153|Drug|gemtuzumab ozogamicin|Given IV
45755167|NCT00673153|Drug|vorinostat|Given orally
45755168|NCT00673153|Other|laboratory biomarker analysis|Correlative studies
45755169|NCT00673855|Other|Lubricant Eye Drops FID 112903|Lubricant Eye Drops FID 112903 1 drop each eye 1 time
45755170|NCT00673855|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops
45755171|NCT03956576|Other|[Pyr]apelin-13|Peptide [Pyr]apelin-13 infusion
45755172|NCT00654511|Drug|Fentanyl|Fentanyl 1mcg/kg, Intravenous (IV)
45911007|NCT02002234|Procedure|Standard medical treatment|Standard medical treatment involves elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L.
45600481|NCT02263391|Behavioral|Opt-in or Opt-out testing|Study participants will be offered a health screening onsite.
45600482|NCT02263391|Behavioral|Focus Group|Study participants will be invited to participate in a focus group discussion.
45600483|NCT02263469|Biological|Replenine®-VF (High Purity Factor IX)|
45600484|NCT02263703|Biological|Quadrivalent HPV vaccine|Three 0.5 mL doses will be given at time 0, 2 months after the 1st dose and then 6 months after the initial dose. For kidney transplant recipients the first dose will be at least 6 months post-transplant.
45600485|NCT01590719|Drug|Placebo|Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
45600486|NCT01590719|Drug|Onartuzumab (MetMAb)|Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
45600487|NCT01590719|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 IV every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
45600488|NCT01590719|Drug|Folinic acid|Folinic acid 400 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
45600489|NCT01590719|Drug|Levofolinic acid|If folinic acid is unavailable: levofolinic acid 200 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
45600490|NCT01590719|Drug|5-Fluorouracil|5-Fluorouracil 400 mg/m2 IV followed by 2400 mg/m2 IV infusion every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
45600491|NCT01571297|Drug|RM-131|Double blind RM-131 will be studied with various doses and regimens from 10 to 100 μg for 35 days.
45600492|NCT01571297|Drug|Placebo|Placebo given subcutaneously for 35 days
45600493|NCT02263781|Procedure|Blood draw|Blood draw
45600494|NCT02263781|Procedure|muscle biopsy|Muscle biopsy during planned anesthesia/surgery
45600495|NCT01543919|Drug|PH-797804|0.25 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
45600496|NCT01543919|Drug|PH-797804|1 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
45600497|NCT01543919|Drug|PH-797804|3 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
45600498|NCT01543919|Drug|PH-797804|6 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
45600499|NCT01543919|Drug|PH-797804|10 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
45600500|NCT01543919|Drug|Placebo|Placebo oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
45755173|NCT00654511|Drug|Fentanyl|Fentanyl 2mcg/kg, Intravenous (IV)
45755174|NCT00654511|Drug|Dexmedetomidine|Dexmedetomidine, 2mcg/kg, Intravenous (IV)
45755175|NCT00654511|Drug|Dexmedetomidine|Dexmedetomidine, 4mcg/kg Intravenous (IV)
45600501|NCT02263859|Device|aura6000 System|The aura6000 System is intended to unilaterally stimulate the hypoglossal nerve which innervates the muscles of the tongue. The aura6000 System stimulates the hypoglossal nerve cyclically and continuously during sleep to maintain muscle tone of the tongue and upper airway during sleep. Stimulation is generated by a programmable, multi-current source, implantable neurostimulator (IPG) and delivered to the hypoglossal nerve by a lead with multi-contact cuff electrode (lead).
45600502|NCT01543451|Drug|Elsiglutide|24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
45600503|NCT01543451|Drug|Placebo|24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
45755176|NCT01670084|Drug|nilotinib|Given PO
45600504|NCT01536041|Drug|ONO-6950|200 mg QD, single dose
45600505|NCT01536041|Drug|ONO-6950|20 mg QD, single dose
45911008|NCT02002247|Drug|sodium selenite|All subjects will receive an IV bolus of 2000µg selenium within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of 2000µg selenium. Then on every further morning during ICU-stay, patients will receive an IV bolus of 1000µg selenium via central or peripheral venous access until death, discharge from ICU to the ward, or for a maximum of 10 days.
45600506|NCT01536041|Drug|Montelukast|10 mg Montelukast, QD single dose
45600507|NCT01536041|Drug|Placebo|Placebo to match ONO-6950 tablets or leukotriene receptor antagonist (LTRA) tablets dosed in a similar manner
45600508|NCT01534403|Biological|Epratuzumab|Epratuzumab 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles (ie, Weeks 0, 1, 2, 3, 12, 13, 14, 15, 24, 25, 26, 27, 36, 37, 38, 39, 48, 49, 50, 51, 60, 61, 62, 63, 72, 73, 74, 75, 84, 85, 86, and 87)
45600509|NCT01523171|Drug|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
45600510|NCT01522469|Drug|Crenolanib Besylate (CP-868,596-26)|Subjects will take crenolanib 200mg/m2/day divided in three doses daily (preferably every eight hours), taken orally at least 30 minutes pre or post meal until disease progression, death, or the patient discontinues treatment for adverse events, investigator's judgment, or other reasons. Patients who are able to proceed to allogeneic stem cell transplant will be able to resume crenolanib therapy post-transplant in an attempt to maintain remission.
45600511|NCT02263937|Procedure|Bilateral Nucleus Basalis Meynert DBS|Low frequency stimulation applied using standard Deep brain stimualtion hardware.
45600512|NCT02263937|Procedure|Sham Nucleus Basalis Meynert DBS|DBS system switched off.
45600513|NCT02264015|Drug|Cilobradine, low, film-coated tablets|
45600514|NCT02264015|Drug|Cilobradine, high, film-coated tablets|
45600515|NCT02264015|Drug|Placebo, film-coated tablets|
45600516|NCT02264015|Drug|Moxifloxacin, film-coated tablets|
45600517|NCT02264093|Drug|Propranolol|
45600518|NCT02264093|Drug|Talsaclidine|
45755177|NCT01670084|Biological|rituximab|Given IV
45755178|NCT01670084|Drug|cyclophosphamide|Given IV
45755179|NCT01670084|Drug|doxorubicin hydrochloride|Given IV
45755180|NCT01670084|Drug|vincristine sulfate|Given IV
45600519|NCT01516541|Other|Background care|Guidelines-based medical care
45600520|NCT01516541|Drug|Placebo|Matching dalcetrapib placebo orally daily
45600521|NCT01516541|Drug|dalcetrapib|600 mg orally daily
45600522|NCT01516307|Biological|OPT-822/OPT-821(30 μg/100 μg)|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37. OPT-822 and OPT-821 are combined at time of injection.
45600523|NCT01516307|Biological|Phosphate Buffer Saline (PBS)|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
45600524|NCT01516307|Drug|Cyclophosphamide|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
45600525|NCT01516073|Drug|Fluticasone Propionate|FP BID for 12 weeks
45600526|NCT01495247|Drug|BEZ235|Doses of oral BEZ235 (BID), supplied as 50mg, 200mg, 300mg or 400mg in SDS sachets, together with standard weekly paclitaxel at a fixed dose (80mg/m²) during 1h by i.v. in infusion.
45600527|NCT01495247|Drug|Paclitaxel|"The paclitaxel infusion will be given in the morning and directly thereafter the BEZ235 dose will be given.~BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established. The initial dose level for the first cohort will be 200mg (BID), and then based on the Bayesian model the dose may be escalated to 300mg, 400mg, 500mg or 600mg for the next cohorts."
45600528|NCT01495013|Drug|1mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
45600529|NCT01495013|Drug|2mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
45600530|NCT01495013|Drug|3mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
45600531|NCT01495013|Drug|4mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
45600532|NCT01495013|Drug|1mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
45600533|NCT01495013|Drug|2mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
45755181|NCT01670084|Drug|methotrexate|Given IV or IT
45755182|NCT01670084|Drug|cytarabine|Given IV or IT
45755183|NCT01670084|Drug|prednisone|Given PO
45755184|NCT01670084|Drug|mesna|Given IV
45755185|NCT01670084|Drug|dexamethasone|Given IV or PO
45755186|NCT01670084|Drug|leucovorin calcium|Given IV
45755187|NCT00674479|Drug|INCB018424|Starting dose: 25 mg by mouth (po) twice daily for 7 days each week for 4 weeks.
45755188|NCT01670162|Drug|Aflibercept|Intravitreal Injection 2mg/0.05mL Aflibercept
45755189|NCT04345783|Drug|Camrelizumab for injection, apatinib mesylate and tegio|Camrelizumab for injection: fixed dose of 200 mg, ivgtt for 30 minutes, given on D1, repeat for every 3 weeks; Apatinib mesylate: 250 mg, p.o, qd; Tegio capsule: p.o., bid, D1-14, repeat for every 21 days.
45755190|NCT04763954|Other|Rethink therapeutic game|The Rethink therapeutic game is a 7 levels online game developed and tested for children. Each level is based on a specific skill and its efficiency has been previously studies in children.
45755191|NCT02142361|Device|enfilcon A|Silicone hydrogel toric lenses.
45755192|NCT04764266|Diagnostic Test|Heparansulfate and Syndecan 1|Blood samples will be collected from the patient at 5 different time points. Three perfusate samples will be collected during normothermic machine perfusion (4,9ml each).
45600534|NCT01495013|Drug|3mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
45600535|NCT01495013|Drug|4mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
45755193|NCT01676636|Drug|Traditional Tablet|The traditional tablets will be swallowed with liquid. Each tablet will contain 500 mg of calcium (as calcium carbonate), thus participants will be asked to take 3 per day.. Participants will be asked to take the tablets with a liquid of their choosing with a meal. Traditional tablets will function as a control in this study, as they represent what is widely available on the market in Bangladesh.
45600536|NCT01495013|Drug|1mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
45600537|NCT01495013|Drug|2mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
45600538|NCT01495013|Drug|3mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
45600539|NCT01495013|Drug|4mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
45600540|NCT01495013|Drug|10mg Atorvastatin|1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
45600541|NCT01495013|Drug|20mg Atorvastatin|1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
45600542|NCT01491971|Drug|Degarelix|
45600543|NCT02264171|Drug|Tamsulosin HCl|
45600544|NCT02264171|Drug|Ketoconazole|
45600545|NCT02264327|Behavioral|Motivational Interviewing Simulator (SIM)|The interactive, case-based, multiplayer web-based game allows service providers to deepen their skills in Motivational Interviewing (MI), a widely recognized evidence-based practice that supports people to make positive behavior changes related to health, wellness, mental illness, and addiction.The SIM will have three arenas for play, so that users can practice more advanced MI skills and include: Single Player, Two Player, and Advanced Free play. The SIM is equipped with multiple story-lines and characters to keep learners engaged over time and to provide practice on diverse case scenarios, making the Sim relevant to a wide audience. Lastly the SIM will provide an opportunity for feedback from peers and MI experts.
45600546|NCT02264327|Behavioral|Motivational Interviewing eBook (eBook)|"The Phase I research team developed a 69-page eBook as a credible online comparator that presents information comparable to that included in the Sim, but without the interactive, role-playing, peer learning functionalities embodied in the Sim. Developed in Hyperlink Markup Language, the eBook presented MI skills, followed by transcripts of effective and not-effective samples of MI from the Sim itself. The e-Book includes the story-lines along with sample dialogue and expert feedback on MI skills."
45600547|NCT02264327|Behavioral|Motivational Interviewing Training (MI Training)|The training intervention consists of a free two-day standardized Motivational Interviewing (MI) training provided by experienced MI trainers.
45600548|NCT01488929|Drug|TC-5619|
45755194|NCT01676636|Drug|Chewable tablets|Chewable tablets are chewed in the absence of additional water. Each chewable tablet will contain 300 mg of calcium (as calcium carbonate), thus participants will be asked to take 5 per day. Participants will be asked to consume the chewable tablets with a meal.
45755195|NCT01676636|Drug|Unflavoured Powder|The unflavoured powder with suspension agent will be tasteless and consumed by either adding it to a semi-solid food or drink of one's choosing. Appropriate foods for mixing with the powder will be at the discretion of the participants. This vehicle was selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. A similar product is Sprinkles, a multiple micronutrient powder developed at SickKids by Dr. Zlotkin.
45755196|NCT01676636|Drug|Flavoured Powder|The flavoured powder with suspension agent will be consumed by adding it to clean water with a meal. This vehicle was also selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. Similar products include oral rehydration salts or artificial juice flavour crystals.
45600549|NCT01488929|Drug|Placebo|
45755197|NCT04404296|Device|25-gauge, bevel-tip, 20000 cut per minute pars plana vitrectomy|Pars plana vitrectomy using 25-gauge, bevel-tip, 20000 cut per minute vitrectomy probe
45755198|NCT00675259|Drug|bevacizumab|bevacizumab 10 mg/kg on days 1 and 15 administered every 28 days [1 cycle] for 5 cycles
45600550|NCT01486277|Drug|Quisinostat, 12 mg|Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).
45600551|NCT01481051|Drug|Latanoprost-PPDS|Sustained delivery for 12 weeks
45600552|NCT01480583|Drug|GRN1005|550 mg/m2 IV every 3 weeks
45600553|NCT01480583|Drug|Trastuzumab|2 mg/kg IV every week or 6 mg/kg IV every 3 weeks per investigator choice
45755199|NCT00675259|Drug|carboplatin|AUC 2 IV on days 1, 8, and 15
45600554|NCT01480583|Drug|18F-FLT|5 mCi of 18F-FLT IV during Screening and during Cycle 1
45600555|NCT04476407|Drug|benapenem|single-dose Benapenem 1.0mg(iv), 60min infusion
45600556|NCT04476407|Drug|benapenem|single-dose Benapenem 1.0mg(iv), 60min infusion
45600557|NCT04476407|Drug|benapenem|single-dose Benapenem 1.0mg(iv), 60min infusion
45600558|NCT03135587|Procedure|Loading level|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot with selected weight loading suit at 3.0km/h.
45600559|NCT01474421|Drug|AQW051|Patients will receive AQW051 in a high dose once daily orally for 28 days.
45600560|NCT01474421|Drug|AQW051|Patients will receive AQW051 in a low dose once daily orally for 28 days.
45600561|NCT01474421|Drug|Placebo|Patients will receive placebo once daily orally for 28 days.
45600562|NCT01470131|Drug|Masitinib|Masitinib 6 mg/kg/day
45600563|NCT01470131|Drug|Placebo|Matching placebo
45755200|NCT00675259|Drug|nab-paclitaxel|100 mg/M2 IV
45600564|NCT01470131|Drug|Bortezomib|Standard therapy (cycles of bortezomib)
45600565|NCT01470131|Drug|Dexamethasone|Standard therapy (cycles of dexamethasone)
45600566|NCT02264561|Other|Food|Active group
45600567|NCT02264561|Other|Food|Control group
45600568|NCT01464437|Drug|AMG 151|Drug: AMG 151 50 mg BID
45600569|NCT01464437|Drug|Placebo|Placebo
45600570|NCT01464437|Drug|Metformin|Subjects will remain on their metformin regimen throughout the study. The metformin dose must be ≥ 850 mg/day for at least 2 months immediately prior to randomization.
45755201|NCT00675259|Procedure|Surgery|lumpectomy or mastectomy along with axillary lymph node dissection approximately 4-5 weeks after completion of NCT.
45755202|NCT00675259|Drug|Adjuvant chemotherapy|All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab at 15 mg/kg IV every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
45600571|NCT01464437|Drug|AMG 151|Drug: AMG 151 100 mg BID
45600572|NCT01464437|Drug|AMG 151|Drug: AMG 151 200 mg BID
45600573|NCT01464437|Drug|AMG 151|Drug: AMG 151 100 mg QD
45600574|NCT01464437|Drug|AMG 151|Drug: AMG 151 200 mg QD
45600575|NCT01464437|Drug|AMG 151|Drug: AMG 151 400 mg QD
45600576|NCT02925338|Other|QOL questionaire|Health assessment questionnaire disability index for rheumatoid polyarthritis questionnaire
45600577|NCT02264717|Procedure|SPECT|Patients are randomized to either SPECT or Cardiac MRI
45600578|NCT02264717|Procedure|Cardiac MRI|Patients are randomized to either SPECT or Cardiac MR
45600579|NCT01461317|Drug|Etrolizumab|Participants will receive etrolizumab at a dose of 100 mg.
45600580|NCT01449071|Biological|Placebo|Placebo infusions at study weeks 0, 1, 2, and 3.
45600581|NCT01449071|Biological|Epratuzumab 400 mg|Epratuzumab 400 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
45600582|NCT01449071|Biological|Epratuzumab 1200 mg|Epratuzumab 1200 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
45600583|NCT01449071|Biological|Epratuzumab 100 mg|Epratuzumab 100 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
45755203|NCT01674218|Drug|Moxifloxacin|Moxifloxacin will be given orally to the following treatment groups, in combination with either PA-824 or PA-824 placebo: Treatment D: 400 mg + PA-824 placebo; Treatment E: 400 mg + PA-824 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
45600584|NCT01449071|Biological|Epratuzumab 600 mg|Epratuzumab 600 mg infusions at study weeks 0, 1, 2, and 3.
45600585|NCT01445795|Drug|200 mg INX-08189 Fasted|200 mg capsule INX-08189 fasted x7 days
45600586|NCT01445795|Drug|Placebo QD Fasted|Placebo capsule QD fasted x7 days
45600587|NCT01445795|Drug|100 mg INX-08189 QD|100 mg INX-08189 capsule QD x 7 days
45600588|NCT01445795|Drug|Placebo QD|Placebo capsule Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
45755204|NCT01674218|Drug|PA-824|PA-824 will be given orally to the following treatment groups, together with either moxifloxacin or moxifloxacin placebo: Treatment B: 400 mg + moxifloxacin placebo; Treatment C: 1000 mg + moxifloxacin placebo; Treatment E: 400 mg + moxifloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
45600589|NCT01445795|Drug|100 mg INX-08189 with low-fat meal|INX-08189 100 mg capsule, with low-fat meal QD for seven days
45600590|NCT01445795|Drug|Placebo with low-fat meal|Placebo capsule administered with a low-fat meal QD for seven days
45755205|NCT01674218|Other|Placebo|Placebo tablets to match Moxifloxacin or PA-824 will be given orally, in combination with either moxifloxacin or PA-824: Treatment A: PA-824 placebo + moxifloxacin placebo; Treatment B: PA-824 400 mg + moxifloxacin placebo; Treatment C: PA-824 1000 mg + moxifloxacin placebo Treatment D: PA-824 placebo + moxafloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
45600591|NCT01445795|Drug|100 mg INX-08189 BID Fasted|100 mg INX-08189 BID fasted x7 days
45600592|NCT01445795|Drug|Placebo BID Fasted|Placebo BID fasted x7 days
45600593|NCT01445795|Drug|ribavirin|
45600594|NCT04423328|Behavioral|acupressure|self-acupressure
45600595|NCT02264795|Drug|Lidocaine|Lidocaine 2% with epinephrine 5mcg/ml
45600596|NCT02264795|Drug|Placebo|0.9% Sodium Chloride Solution
45600597|NCT02264873|Drug|Decitabine|Dose escalation starting at 5 mg, and increasing by 2.5 mg to a Dose Level of 12.5 mg qd x 3 days.
45600598|NCT02264951|Dietary Supplement|Tributyrin|a triglyceride containing three C4-acids
45600599|NCT02264951|Dietary Supplement|C8-diet oil|a triglyceride containing 2 C8-fatty acids and one oleic acid at sn-2 position
45600600|NCT02264951|Dietary Supplement|Olive oil|a triglyceride containing mostly three oleic acids
45600601|NCT02264951|Dietary Supplement|Carrot|mainly water and glucose
45600602|NCT01438775|Drug|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
45600603|NCT02543528|Device|Investigational Lens 1|One fresh pair of Investigational Lens 1 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
45600604|NCT02543528|Device|Investigational Lens 2|One fresh pair of Investigational Lens 2 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
45600605|NCT02543528|Device|Investigational Lens 3|One fresh pair of Investigational Lens 3 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
45600606|NCT02543528|Device|etafilcon A (Reusable)|One fresh pair of etafilcon A (Reusable) contact lenses worn continuously in 6nights/7 days wear cycles for 6 months of total wear.
45600607|NCT02543528|Device|etafilcon A (1-Day)|2-week contact lens adaptation period wearing prior to randomization
45600608|NCT02265029|Other|Immediate spa treatment|spa treatment in rheumatology with sedative and antalgique techniques and mobilizing techniques (rehabilitation in pool)
45600609|NCT02265029|Other|Late spa treatment|spa treatment in rheumatology with sedative and antalgique techniques and mobilizing techniques (rehabilitation in pool)
45600610|NCT04458974|Device|Transcranial direct current stimulation|"The intervention consists in two-weeks treatment, 10 consecutive sessions of tDCS ( Monday to Friday) applied concurrently to neuropsychological rehabilitation.~The tDCS Multisite StratStim® 8-channel device (Neuroelectrics) will be used for tDCS stimulation. The duration of the stimulation will be 20 minutes at 2 mA. The tDCS will be applied with the cathode positioned in P3 (following the international 10/20 EEG system), and the return electrodes will be placed in C3, CP5, CP1, Pz, PO3, PO7, P7.~The sessions will last 1 hour."
45600611|NCT04458974|Procedure|Neuropsychological rehabilitation|"The neuropsychological rehabilitation protocol has been designed for the recovery of neglect symptomatology. Each session will consist on the performance of different cognitive stimulation tasks aimed at improving attention and visoperceptive abilities. The tasks will be applied through the NeuronUp neurorehabilitation platform in order to achieve maximum homogeneity and objectivity across patients.~The neuropsychological rehabilitation will last 30min (in 1h intervention session)."
45755206|NCT03860558|Other|Lifestyle Intervention|Participants will undergo a 12-week multidisciplinary program for weight control and intensive diabetes management. The program includes adjustments to diabetes medications to enhance weight reduction and improve glycemia, dietary modification, and activity instructions.
45755207|NCT03860558|Other|No Intervention|Participants will not undergo an intervention.
45600612|NCT03135509|Drug|CC-220|CC-220 gelatin capsules
45600613|NCT05461118|Procedure|Experimental:Treatment group|Osteotomy surgical planning to be done using intraoperative mixed reality augmentation of a commercially available navigation platform.
45600614|NCT02265107|Other|exercise training|The program of exercise training (ET) was employed for 6 consecutive months with 3 sessions per week. The training of physical activity consisted of a combination of aerobic and resistance exercises for upper and lower limbs. Each session included: (1) 5-minute warm-up, (2) 30 minutes of aerobic exercise (performed in treadmills and stationary bikes); (3) 20 minutes of resistance exercises with dumbbells for upper limbs and ankle support for lower limbs (exercises preformed in diagonals) that consisted of 6 sets of 10 resistance exercises repeated for upper limbs, and the same number of sets for lower limbs; and (4) 5-minute cool-down, totaling ninety minutes of session per day (90min/day) and, two hundred and seventy minutes per week (270min/week).
45600615|NCT05434910|Other|Changes in mean arterial pressure|MAP set at 65 mmHg for 25 min by infusion of noradrenaline. MAP set at 80 mmHg for 25 min by infusion of noradrenaline. MAP set at 95 mmHg for 25 min by infusion of noradrenaline.
45600616|NCT02265419|Device|Extracorporeal treatment with the Cytosorb adsorber|The extracorporeal treatment with the Cytosorb-Adsorber will be started 6 hours after heart surgery operation, the extracorporeal treatment duration will be 24 hours and the observation time 90 days.
45600617|NCT01494233|Drug|250 mg LX1033 tablets|250 mg LX1033 tablets administered orally
45600618|NCT01494233|Drug|Placebo tablet|Matching placebo tablet administered orally
45600619|NCT05379296|Behavioral|Diabetes Prevention Program Plus (DPP+)|The DPP+ includes the CDC-approved DPP lifestyle program expanded to include a CDC-approved module on hypertension prevention and treatment
45600620|NCT05379296|Behavioral|Diabetes Prevention Program (DPP)|CDC-approved DPP lifestyle program
45600621|NCT05378828|Device|Using anti-collision Sensors on electric wheelchairs|use of anti-collision sensors on the electric wheelchair during 3 weeks
45600622|NCT05378828|Other|Use of an electric wheelchair without sensors|Use of an electric wheelchair without sensors for 3 weeks before using anti-collision sensors then during 3 weeks after using the anti-collision sensors.
45600623|NCT01418261|Device|Renal denervation (Symplicity Catheter System)|
45600624|NCT01418261|Diagnostic Test|Renal angiogram|
45600625|NCT01417091|Drug|BPS804|
45600626|NCT01412177|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
45755208|NCT00656305|Device|ExAblate MRfFUS|MR guided focused ultrasound.
45755209|NCT00656305|Device|Sham|sham comparator
45600627|NCT01412177|Drug|Placebo|Single intratympanic injection of placebo
45600628|NCT01411163|Drug|Creatine monohydrate|Up to 30 grams daily creatine monohydrate
45600629|NCT00156533|Drug|Zolpidem|10 mg of Zolpidem
45755210|NCT03856814|Device|ELVeS® Radial® 2ring slim fiber used for EndoVenous Laser Ablation|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
45600630|NCT00156533|Drug|Sugar Pill|
45600631|NCT01410695|Drug|masitinib 3 mg|
45600632|NCT01410695|Drug|masitinib 6.0 mg|
45600633|NCT01410695|Drug|methotrexate|
45600634|NCT01410695|Drug|Placebo (methotrexate)|
45600635|NCT01410695|Drug|Placebo (masitinib)|
45600636|NCT01660022|Drug|100mg OZ439 single oral dose|100mg OZ439 oral suspension single dose
45600637|NCT01660022|Drug|Placebo|Placebo
45600638|NCT01660022|Drug|300 mg OZ439 single oral dose|300mg OZ439 oral suspension single dose
45600639|NCT01660022|Drug|160mg Piperaquine single oral dose|160 mg Piperaquine tablet
45600640|NCT01660022|Drug|480mg Piperaquine single oral dose|480 mg Piperaquine tablet
45600641|NCT01660022|Drug|1440mg Piperaquine single oral dose|1440 mg Piperaquine tablet
45600642|NCT01660022|Drug|800 mg OZ439 single oral dose|800mg OZ439 oral suspension single dose
45600643|NCT01406561|Drug|OMS103HP-S|Proprietary concentration and formulation of OMS103HP in solution (OMS103HP-S) for injection into each 3 liter vehicle irrigation solution bag for use during meniscectomy surgery
45600644|NCT01406561|Drug|Vehicle|3 Liter bags of vehicle irrigation solution for use during meniscectomy surgery
45600645|NCT02265575|Drug|Hyaluronic Acid|rehydration using hyaluronidase-assisted subcutaneous infusion
45600646|NCT02265653|Drug|BIIL 284 BS tablet C|
45600647|NCT02265653|Drug|BIIL 284 BS tablet D|
45600648|NCT02265653|Drug|BIIL 284 BS WIF tablet|
45600649|NCT01396811|Drug|33525|Daily for 14 days
45600650|NCT01396811|Drug|Placebo|Daily for 14 days
45755211|NCT03868423|Drug|Brigatinib|90 mg orally QD for 7 days followed by 180 mg orally QD continuously thereafter. One cycle of therapy will consist of 28 days of treatment.
45755212|NCT03868423|Other|Laboratory Biomarker Analysis|Correlative studies
45755213|NCT03868423|Other|Quality-of-Life Assessment|Ancillary studies
45600651|NCT03135353|Device|3D saline infusion sonohysterography|instillation of saline in the uterine cavity using pediatric foley's catheter, then performing 3D ultrasound scan of the uterus and adenexae
45600652|NCT03135353|Device|Office Hysteroscopy|an outpatient procedure done to assess the uterine cavity using the office hysteroscopy
45600653|NCT02265731|Drug|azacitadine|75 mg/m2 by IV infusion or subcutaneous dosing
45600654|NCT02265731|Drug|venetoclax|Step-up doses of venetoclax to the designated cohort dose
45600655|NCT02265731|Drug|rituximab / IDEC-C2B8|375 mg/m2 on Week 6
45452124|NCT02268682|Other|Educator-Guided|The Transplant Educator supports the Explore Transplant at Home materials by facilitating a conversation about the content of the materials. The role of the Educator is filled by an experienced dialysis healthcare provider who can support a patient as they learn about their treatment options. The program is split into a series of four modules and the Educator conversations are guided by a Transplant Educator Guide and Patient Tracking Tool. This tool is intended to provide direct talking points for the Educator and is also a place where the patients' responses, questions, or concerns can be documented.
45600656|NCT02265731|Drug|rituximab / IDEC-C2B8|500 mg/m2 Week 10 Day 1 and thereafter
45600657|NCT02265809|Drug|Aldesleukin|
45600658|NCT02265887|Other|standard of care|No intervention, this a patient registry and is purely an observational study
45600659|NCT01388933|Drug|TU-100|15g daily, orally as 5g three times daily for 8 consecutive weeks
45600660|NCT01388933|Drug|Matching Placebo|15g as 5g three times daily, orally for 8 consecutive weeks
45600661|NCT01372475|Device|Hymovis Intra-articular Injection|Hymovis Intra-articular injection
45600662|NCT01372475|Procedure|Phosphate Buffered Saline Injection|Placebo Intra-articular injection
45600663|NCT02266043|Device|Pre-epiglottic baton plate (PEBP)|"modified acrylic palatal plate in which a velar extension resembling a spur or baton shifts the base of the tongue forward.~This treatment is the standard care for infants with Pierre-Robin-Like Phenotype in the participating study centers and not assigned by protocol."
45600664|NCT04453631|Device|active tDCS|26 transcranial direct current stimulation sessions, each lasting 20 minutes, with a current intensity of 2 mA, the cathode placed over the right dorsolateral prefrontal cortex and the anode placed over the left deltoid muscle.
45600665|NCT04453631|Device|sham tDCS|tDCS is controlled in this intervention: sham mode.
45600666|NCT04453631|Behavioral|CBT-UP|15 psychotherapy sessions (1/week) following the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders developed by Barlow et al. 2018.
45600667|NCT04453631|Behavioral|Psychoeducation|To control for the cognitive-behavioral intervention we will use psychoeducation materials.
45600668|NCT01369589|Drug|P-552|P-552 will be administered as 10 mL mouth rinse to be swished in the mouth fro 30 seconds and then completely expectorated.
45600669|NCT01369589|Drug|Placebo|Placebo will be administered as 10 mL mouth rinse to be swished in the mouth for 30 seconds and then completely expectorated.
45600670|NCT00156065|Drug|Haloperidol|2-8 mg BID
45600671|NCT00156065|Drug|Asenapine|5 or 10 mg BID
45600672|NCT00156065|Drug|Asenapine|5 or 10 mg BID
45600673|NCT05591573|Dietary Supplement|Low glycemic index drink|Fruit flavoured drink with low glycemic index sugar (300 ml)
45600674|NCT05591573|Dietary Supplement|High glycemic index drink|Fruit flavoured drink with high glycemic index sugar (300 ml)
45600675|NCT04476173|Drug|Methoxyflurane - Penthrox|ACS patients who received inhaled methoxyflurane as analgesic treatment
45600676|NCT04476173|Drug|Morphine|ACS patients who received intravenous morphine as analgesic treatment
45600677|NCT05570981|Diagnostic Test|Laryngeal sensitivity testing|Direct stimulation of the laryngeal adductor reflex, measurement of laryngeal EMG and our capability to assess functional laryngeal response to an inhalational challenge with laryngoscopic techniques.
45600678|NCT01361555|Drug|Placebo matching with BMS-820836|Tablet, Oral, 0.0 mg, Once daily, 54 weeks
45600679|NCT01361555|Drug|BMS-820836|Tablet, Oral, 0.5 mg, Once daily, 54 weeks
45600680|NCT01361555|Drug|BMS-820836|Tablet, Oral, 1.0 mg, Once daily, 54 weeks
45600681|NCT01361555|Drug|BMS-820836|Tablet, Oral, 2.0 mg, Once daily, 54 weeks
45755214|NCT03868423|Other|Questionnaire Administration|Ancillary studies
45755215|NCT01670240|Drug|Adalimumab|
45452125|NCT01229644|Drug|Crenolanib (CP-868,596)|Highly potent inhibitor of both PDGFR receptors alpha and beta
45600682|NCT01554956|Biological|Human Plasminogen|Eye Drops
45600683|NCT01360853|Drug|ON 01910.Na|ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
45755216|NCT01670240|Drug|Placebo|
45755217|NCT04404686|Drug|Indomethacin|Per vagina administration of 100 mg followed by a second 100 mg dosage the following day
45452126|NCT02267902|Drug|DA-1229|
45600684|NCT01360853|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
45600685|NCT01360853|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
45755218|NCT04404686|Drug|Nifedipine|Per os administration according to current protocol of 20mg each 20 minutes for 1 hour followed by 20 mg q8 for 48 hours.
45755219|NCT00675415|Diagnostic Test|Capnography|Capnography: Passive measurement of carbon dioxide via a special bite block which allows graphic assessment of the subject's respiratory activity
45600686|NCT05377970|Other|Thinkific Prehabilitation Exercise Program|Prehabilitation exercise program through the Thinkific platform
45600687|NCT05377580|Drug|Placebo|Participants will receive placebo IV or SC
45600688|NCT05377580|Drug|IBI112|Participants will receive IBI112 IV or SC
45600689|NCT05377580|Drug|IBI112|Participants will receive IBI112 IV or SC
45600690|NCT01355393|Biological|HER-2/neu peptide vaccine|Given ID
45600691|NCT01355393|Biological|sargramostim|Given ID
45600692|NCT01355393|Drug|rintatolimod|Given ID
45600693|NCT05425472|Drug|HR070803|HR070803
45755220|NCT01674374|Other|placebo|Given PO
45755221|NCT01674374|Procedure|quality-of-life assessment|Ancillary studies
45600694|NCT02266355|Drug|Omalizumab|Omalizumab 300 mg SQ every 2 weeks
45600695|NCT05542901|Diagnostic Test|Joint Position Sense Analysis|The Xsens DOT Motion Capture System will be used to analyze joint position sense.
45600696|NCT02266511|Drug|Flomax®, Norman II facility|
45600697|NCT02266511|Drug|Flomax®, Nishine facility|
45600698|NCT02266589|Drug|Hydrocortisone|Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
45600699|NCT02266667|Device|2 NEMOST rods : bilateral vertebral-pelvic implantation|Implantation of two NEMOST rods (bilateral vertebral-pelvic implantation)
45600700|NCT02266667|Device|1 NEMOST rod :unilateral vertebral-pelvic implantation|Implantation of one NEMOST rod (unilateral vertebral-pelvic implantation)
45755222|NCT01674374|Other|questionnaire administration|Ancillary studies
45755223|NCT01674374|Drug|Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules|Given PO
45755224|NCT01674452|Behavioral|home-based group (HBG)|Participants in the home-based group (HBG) were advised to exercise, a minimum of 4 times per week, but they were encouraged to exercise a total of 5-7 days per week. After individual assessment, a group of home-exercise selected of the manual was explained and performed one by one. The home-exercises were re-executed at each fortnightly visit, when necessary corrections were made and the next step stipulated by manual was taken, according to the patient's progress.
45755225|NCT01674452|Behavioral|supervised exercise group (SEG)|Patients in the supervised exercise training group (SEG) participated in supervised individual exercise sessions 2 times per week. A physical therapist supervised these sessions. Exercise sessions included: 30 minutes of global exercises that involved stretching, range of motion, muscle strengthen and another 30 minutes of functional training (gait, balance and use of the arm in daily activities).
45755226|NCT00676585|Drug|Normal Saline|Normal Saline
45600701|NCT01330979|Drug|AR-12286 0.5% Ophthalmic Solution|Ophthalmic Solution
45600702|NCT02266823|Behavioral|Social Cognitive Theory|The intervention, which combines behavioral counseling with mobile self-monitoring, will be based on SCT which focuses on the role played by self-referent thought in the maintenance of behavior change. Within SCT, behavior change and maintenance are influenced strongly by the individual's perceived self-efficacy.
45600703|NCT01321463|Drug|PH-797804|6 mg oral tablet once daily for 12 weeks
45600704|NCT01321463|Drug|Placebo|Placebo oral tablet once daily for 12 weeks
45600705|NCT01311713|Drug|CEP-9722|CEP-9722 is administered daily or twice-daily for six 28-day cycles. Dose escalation will proceed until the MTD is identified.
45600706|NCT01311713|Drug|CEP-9722|CEP-9722 is administered daily or twice-daily for six 28-day cycles. Patients will be administered CEP-9722 at the MTD identified in Part 1.
45600707|NCT02266901|Procedure|endoscopic drainage|Endoscopic percutaneous access was obtained through surgical drains or after ultrasound-guided percutaneous drainage with a thin scope , and transluminal procedures with large scopes through the leak hole. All the procedures were performed under general anesthesia and carbon dioxide insufflation. Debridement was done by pus aspiration and irrigation.
45600708|NCT01300013|Drug|Placebo|48-hour infusion of placebo
45600709|NCT01300013|Drug|Omecamtiv mecarbil|48-hour infusion of omecamtiv mecarbil; dose strength will depend on cohort assignment.
45755227|NCT00676585|Drug|Hydrocortisone|Hydrocortisone 100mg
45755228|NCT03856580|Behavioral|Alternative long-acting PrEP injection strategies|"Participants in the two intervention groups will complete injection procedures (e.g., self-injection, injection by healthcare providers at drop-in clinics) to determine if this could facilitate improved adherence to an inert version of long-acting cabotegravir injections"
45755229|NCT03856580|Behavioral|mHealth adherence app|"Participants in the two experimental arms will be given a smartphone application, designed to facilitate adherence (this app will be developed during earlier phases of the study using in-depth interviews and design session groups)"
45755230|NCT00658411|Drug|deferoxamine|Given intravenously or subcutaneously over 8-12 hours daily for at least three weeks prior to transplantation date and continue until the day before the participant receives their donor's stem cells.
45755231|NCT01674530|Drug|Lubiprostone|24 mcg Capsules to be given in the experimental arm with Placebo Of AMITIZA
45755232|NCT01674530|Drug|Lubiprostone|24 mcg Capsules with placebo of Lubiprostone ( Manufactured by Dr Reddy's Laboratories Ltd)
45755233|NCT01674530|Drug|Placebo|24 mcg capsules of both experimental Lubiprostone and AMITIZA
45934892|NCT00210418|Behavioral|Education and communication to improve feeding practices|The education and communication to improve infant and young child feeding was an integral part of the intervention. In the preventive arm, this intervention was targeted to pregnant and lactating mothers and mothers of children 0-24 months of age. The education was done using mother's groups In the recuperative arm, the BCC intervention was only targeted to pregnant and lactating women and mothers of malnourished children under the age of five.
45600710|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.00013%|Cumulative daily dose is below the travoprost ophthalmic solution, 0.004% once daily dose
45600711|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.00033%|Cumulative daily dose equals the travoprost ophthalmic solution, 0.004% once daily dose
45600712|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.001%|Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
45600713|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.00267%|Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
45600714|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.004%|
45600715|NCT01298687|Drug|Travoprost Vehicle|Inactive ingredients used as an active comparator
45600716|NCT02267057|Drug|Paracetamol|Paracetamol granulate supplied by Weifa (Paracet) and 1 g paracetamol tablets produced by Kragerø tablettproduksjon for blinding purposes.
45600717|NCT02267057|Drug|Buprenorphine|Buprenorphine 5 micrograms/hour and 10 micrograms/hour transdermal system produced by Mundipharma, identical to placebo transdermal system.
45600718|NCT02267057|Drug|Paracetamol placebo|Paracetamol placebo tablets produced by Kragerø tablettproduksjon.
45600719|NCT02267057|Drug|Buprenorphine placebo|Buprenorphine transdermal system placebo produced by Mundipharma.
45600720|NCT04476095|Device|Active PBMT|Active PBMT will be applied using a device with 152 emitters (wavelength - 808 nm; dose - 3000 J; treatment time - 600 s), in the low back region.
45600721|NCT04476095|Device|Placebo PBMT|The placebo PBMT will be applied using the same device as that of active PBMT but without any emission of therapeutic dose. Moreover, the irradiated site and the irradiation time were the same as that of active PBMT. Patients received a total dose of 0 J in the placebo mode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
45444458|NCT04274283|Other|Matched Tumour and Blood Sample - Research Pathway|"For patient's undergoing surgery fresh tissue will be collected from the initial surgery and frozen until shipment to the Oxford BRAIN MATRIX Lab. Matched blood sample for germline DNA will be taken post-Platform Study entry. For patients with progression with available tumour samples from previous tumour surgery, blood will be collected and sent to Oxford along with their tumour samples.~Samples will be shipped together to Oxford for molecular analysis (Whole Genome Sequencing (WGS) and EPIC array). The BRAIN MATRIX neuropathology and genomics team will produce an integrated report (histology, WGS, Heidelberg Classifier) for each case in consultation with the local neuropathology team. Once data is available, a virtual MDT with the BRAIN MATRIX neuropathology, genomics team and local site will be held to ensure all relevant information is incorporated in the final BRAIN MATRIX diagnostic report. The resulting integrated histological-molecular report will be available to local sites"
45444459|NCT04274283|Other|Matched Tumour and Blood Sample - NHS GMS pathway|Tessa Jowell BRAIN MATRIX centres in England can submit matched tissue and blood samples for Whole Genome Sequencing through the standard of care NHS Genomic Medicine Service pathway via their Genomic Laboratory Hub. For those from Devolved Nations, samples must go to the Oxford BRAIN MATRIX Laboratory who can facilitate the processing of samples through an alternative NHS GMS GLH or via the research pathway.
45600722|NCT04475861|Dietary Supplement|L-arginine supplements and nutritional supports|The enrolled subjects will then be randomized into two groups. The subjects will receive either L-arginine (the study group) or another amino acid supplement (the control group), with 60 patients in each group. All the food intake of the subjects during the 4 weeks of the study will be recorded and supervised by responsible dietitians.
45600723|NCT05328557|Drug|CUG252|CUG252 will be administered by subcutaneous (SC) injection
45600724|NCT05328557|Drug|Placebo|Placebo will be administered by subcutaneous (SC) injection
45600725|NCT02267213|Drug|Lipotecan|Administer 40mg Lipotecan at D1, D8, D15 of each cycle.
45600726|NCT05309135|Drug|HCEC-1|HCEC-1 = human cultured corneal endothelial cells and Rho kinase Y-27632 inhibitor
45600727|NCT05307809|Other|Blood sample collection|Blood sample collection
45600728|NCT05307809|Other|Skin sample collection|Skin sample collection
45600729|NCT02267291|Other|Non-invasive positive pressure ventilation|Ventilatory support to alter intrathoracic pressure
45600730|NCT02267369|Behavioral|Media-assisted fitness program|Participants can register workshops online, track program participation, and receive promotional health messages online.
45600731|NCT02267369|Behavioral|Social network-assisted fitness program|Participants can register workshops online and track program participation. Participants are put into anonymous online social networks and receive real-time activity updates from 4-6 peers.
45600732|NCT02267369|Behavioral|Basic fitness program|Participants can register workshops online and track program participation.
45755234|NCT01799551|Behavioral|Ca CBT|Clients in intervention group will receive a CBT intervention using a manual. Intervention was developed for use in primary and secondary care using a series of qualitative studies (Naeem et al a, 2010, Naeem et al c, 2009, Naeem et al, 2009, Naeem et al, in press) during the last 5 years in Pakistan and has proven to be effective in a pilot study (Naeem et al, 2011). Intervention will consist of 6 sessions and will focus on psycho-education, symptoms management, changing negative thinking, problem solving, improving relationships and communication skills. One person from the family will be involved as a facilitator.
45911009|NCT02002247|Drug|Placebo|All patients will receive an IV bolus of normal saline (equals to 40ml prepared solution) within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of normal saline accordingly. Then on every further morning during ICU-stay, patients will receive an IV bolus of normal saline via central or peripheral venous access until death, discharge from ICU to the ward (treatment may continue in a step down or intermediate care unit), or for a maximum of 10 days.
45911010|NCT02002260|Device|Levonorgestrel intrauterine system|
45911011|NCT02002260|Drug|Combined oral contraceptives|
45911012|NCT02002273|Procedure|Switching level of suction|
45934893|NCT00069069|Drug|Intransal instillation of E-selectin|Intranasal recombinant human E-selectin
45600733|NCT01293461|Drug|CBX129801|Subcutaneous injection
45600734|NCT01293461|Drug|Placebo|Subcutaneous injection
45600735|NCT05260541|Drug|60 mg PRAX-114 or 40 mg PRAX-114|Once daily oral treatment for 4 weeks
45600736|NCT05260541|Drug|Placebo|Once daily oral treatment for 4 weeks
45600737|NCT05260541|Drug|40 mg PRAX-114|Once daily oral treatment for 8 weeks
45600738|NCT05255237|Drug|Jaktinib|75mg BID
45600739|NCT01291901|Biological|NP2|NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin. The drug will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
45600740|NCT01291901|Biological|Placebo|The placebo (vehicle) will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
45600741|NCT04475627|Diagnostic Test|Cardiovascular Magnetic Resonance (CMR) imaging at 1.5T|Long and short axis bSSFP cines images, long and short axis tagging images and aortic cine images will be obtained. Participants will be randomised to either have cine or tagging images obtained first.
45600742|NCT04475627|Diagnostic Test|Cardiovascular Magnetic Resonance (CMR) imaging at 3T|Long and short axis bSSFP cines images, long and short axis tagging images and aortic cine images will be obtained. Participants will be randomised to either have cine or tagging images obtained first.
45600743|NCT05252663|Procedure|Quake device training|In Quake breathing, patients were advised to take a deep breath and hold it for 3-5 seconds. The patient had the mouthpiece firmly sealed to the lips and were asked to inhale and exhale completely
45934894|NCT00041327|Biological|filgrastim|5 ug/kg/d
45600744|NCT05252663|Procedure|Traditional chest physiotherapy|postural drainage - percussion
45600745|NCT01262261|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
45600746|NCT05231525|Device|WiTOF|Data collection on the WiTOF monitor
45755235|NCT00676897|Drug|Simvastatin|Simvastatin 40mg PO or NGT
45600747|NCT05231525|Device|TOFscan|Data collection on the TOFscan monitor
45600748|NCT02267681|Drug|Fentanyl|Intravenous fentanyl for sedation/analgesia
45600749|NCT02267681|Drug|Alfentanil|Intravenous alfentanyl for sedation/analgesia
45600750|NCT02267681|Drug|Propofol|Intravenous propofol for sedation
45600751|NCT02267759|Device|McGrath videolaryngoscopy|After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, McGrath videolaryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
45600752|NCT02267759|Device|Macintosh laryngoscopy|After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, Macintosh laryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
45600753|NCT02138786|Drug|selinexor|"60 mg dose twice weekly, on Days 1 and 3 of weeks 1-4 of each 4-week cycle; dose may be increased to 80 mg after Cycle 1 unless clinically contraindicated (Protocol V.5.0).~60 mg dose twice weekly on Days 1 and 3 of weeks 1-3 of each 4-week cycle; dose may be increased to 80 mg at Cycle 3 Day 1 unless clinically contraindicated (Protocol V.4.0).~60 mg/m² dose, based on BSA, twice weekly, on Days 1 and 3 of weeks 1-3 of each 4-week cycle (Protocol V. 3.0).~60 mg/m² dose, based on BSA, twice weekly, on Days 1 and 3 of weeks 1-4 of each 4-week cycle (Protocol V. < 3.0)."
45600754|NCT05177939|Drug|NPB-01|NPB-01 will be administered for the treatment of autoimmune encephalitis
45600755|NCT05177939|Drug|NPB-01-ME|NPB-01-ME will be administered for the treatment of autoimmune encephalitis
45600756|NCT05174507|Drug|empagliflozin|Empagliflozin (Jardiance®; Boehringer Ingelheim (Schweiz) GmbH) is a highly selective, reversible inhibitor of the sodium glucose co-transporter 2 (SGLT2). Treatment consists of a single oral tablet of 25 mg of empagliflozin (Jardiance®) two hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
45600757|NCT05174507|Drug|anakinra|Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra) in a 100 mg/0.67ml solution for SC injection. Treatment consists of a single subcutaneous injection of 100 mg Anakinra (Kineret®) three hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
45600758|NCT05174507|Other|saline subcutaneous (s.c.) (placebo)|Placebo for anakinra is 0.67 ml of sterile 0.9 % saline solution s. c. Treatment consists of a single subcutaneous injection of matched placebo (0.67 ml of 0.9 % saline) three hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
45600759|NCT05174507|Other|tablet per oral (p.o.) (placebo)|Placebo for empagliflozin is Winthrop P® (Zentiva, Frankfurt/Main) lactose tablet. Treatment consists of a single oral tablet of matched placebo two hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
45600760|NCT01480154|Drug|Akt Inhibitor MK2206|Given PO
45600761|NCT01480154|Drug|Hydroxychloroquine|Given PO
45755236|NCT00676897|Drug|Placebo|Corn Starch
45755237|NCT03852758|Behavioral|Outdoor Exercise|2 outdoor exercise sessions per week
45755238|NCT03852758|Behavioral|Indoor Exercise|2 indoor exercise sessions per week
45755239|NCT02115074|Drug|Fluvastatine|"Escalation dose : Level 1: 2mg/kg/day. Level 2: 4mg/kg/day. Level 3: 6mg/kg/day. Level 4: 8mg/kg/day.~Per os from D1 to D14 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
45600762|NCT05172869|Procedure|Suprainguinal Performed FICB|Linear ultrasound probe places above inguinal ligament sagittally, close to the femoral crease and superior-lateral to the femoral artery. It is aimed to spreading local anesthetics under the fascia iliaca medial-laterally
45600763|NCT05172869|Procedure|Infrainguinal Performed FICB|Linear ultrasound probe places below inguinal ligament transversally, close to the femoral crease and lateral to the femoral artery. It is aimed to spreading local anesthetics under the fascia iliaca medial-laterally
45755240|NCT02115074|Drug|Celebrex|"Dose levels : 100 mg twice a day (< 20 kg), 200 mg twice a day (20-50 kg), 400 mg twice a day (> 50 kg)~Per os from D1 to D28 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
45755241|NCT03850730|Drug|Pazopanib|Active pharmaceutical ingredient plus excipients filled into a capsule for the lower dosing necessary in this study
45755242|NCT01674686|Drug|Sarpogrelate|Sarpogrelate 100mg twice a day
45755243|NCT01674686|Drug|Atorvastatin|Atorvastatin 80mg daily
45755244|NCT02082392|Drug|Escitalopram|
45755245|NCT02082392|Drug|Placebo|A substance or treatment of no intended therapeutic value in a pill form.
45755246|NCT02100800|Other|MR and CT measurements of emphysema quantification|
45755247|NCT01674764|Procedure|Early surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
45755248|NCT01674764|Procedure|Late surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
45755249|NCT03849794|Other|Experimental Group|"Chiropractic Care A chiropractor will see participants in the experimental group about 3 times per week using a pragmatic approach for 4 weeks, and each session will be approximately 15-20 minutes in duration. The spinal adjustments performed in this study will be high-velocity, low-amplitude thrusts to the spine, pelvic joints, extremities or instrument-assisted adjustments~Physiotherapy:~Physiotherapists will see participants in each group 3 times per week for four weeks. Each session will be approximately 40 minutes in duration. Physiotherapy interventions are likely to include stretches and exercises, massage and mobilization as required."
45755250|NCT03849794|Other|Control group|The control group will receive the same physiotherapy intervention as the experimental group at the same frequency of care. The control group will also attend three passive movement sessions with the chiropractor each week, primarily to minimise the psychological effect of the interaction with the chiropractor, but also to act as a physiological control. These passive movement sessions will be 15 minutes in duration.
45600764|NCT05595278|Diagnostic Test|(CBC) ,(NT-proBNP) ,(cTnT)|complete blood count (CBC) including RDW with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT) in a cohort of acute myocardial infarction (AMI) patients.
45600765|NCT02267915|Drug|subcutaneous Rituximab|MabThera 1400 mg solution for subcutaneous injection
45755251|NCT03355976|Drug|Nivolumab|240mg flat dose every 2 weeks
45755252|NCT03355976|Drug|Ipilimumab|Ipilimumab 1mg/kg every 6 weeks
45755253|NCT03293030|Drug|Dupilumab|Dupilumab treatment
45600766|NCT05408468|Behavioral|FAMCOPE-ICU|(1) FAMCOPE-ICU is a digital eHealth emotion regulation and coping intervention. FAMCOPE-ICU contains three digital modules representing the three interventional doses. Corresponding with Gross's Extended Process Model of Emotion Regulation, the three respective doses entail assessments, adaptive feedback, and interactive activities pertaining to understanding their affective experiences, learning strategies to regulate emotions and stress, and practicing these skills in a virtual decision-making task. Each dose of the intervention is expected to last 10-15 minutes
45600767|NCT04456478|Procedure|pH at 7.38 ± 0.02|In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.38 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
45600768|NCT04456478|Procedure|pH at 7.22 ± 0.02|In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.22 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
45600769|NCT02233595|Radiation|Chemoradiation|
45600770|NCT02267993|Drug|recombinant human thrombopoietin|Patients received subcutaneous injection of recombinant human thrombopoietin at a dose of 300 U/kg body weight once daily at a platelet count of < 50×109/L, and recombinant human thrombopoietin treatment ceased at a platelet count of ≥20×109/L if platelet is not transfused.
45600771|NCT04258592|Drug|(18F)MFBG|One intravenous injection of 4 MBq/kg (adults) One intravenous injection of 2 MBq/kg (minor participants)
45600772|NCT04258592|Device|PET/CT|Adult patients will undergo a dynamic PET scan for the first 30 minutes, followed by 3 static whole-body PET/CTs at 60 ± 10 min, 120 ± 30 min and 180 ± 30 min post injection. Pediatric patients will undergo, depending on what is feasible for the child, at least 1 and up to 2 static whole-body PET/CTs. In patients 12 years or older, also a dynamic PET scan can be performed.
45600773|NCT04258592|Other|Venous blood samples|Blood samples will be obtained for laboratory safety evaluation for initial screening and safety evaluation after injection. Furthermore, in patients undergoing a dynamic PET scan venous blood samples will be obtained for metabolite analysis and activity measurements at various time points post injection (5 ± 2 min, 10 ± 5 min, 20 ± 10 min, 40 ± 20 min, 60 ± 30 min and 120 ± 60 min in adult participants; 5 ± 2 min, 10 ± 5 min, 30 ± 15 min, 50 ± 25 min, 90 ± 30 min in minor participants).
45600774|NCT02268071|Drug|Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence|For patients with average of HBPM values <135/85mmHg at baseline, the antihypertensive treatment will be stopped for 1 year (half dose for 3 days then interruption)
45600775|NCT02233673|Behavioral|Financial incentives|Participants receive a behavioral intervention and financial incentives for meeting gestational weight gain goals.
45652934|NCT05056103|Device|TrachFlush|The attending nurses activate the TrachFlush when there are secretions present in the larger airways that need to be removed. If this results into a push of airway secretions past and above the cuff of the endotracheal tube, no further action is needed. If unsuccessful, the nurse will perform a standard tracheal suctioning procedure to remove the secretions. In a subset of patients with an endotracheal tube that allows subglottal suctioning, the exact amount of airway secretions present above the cuff will be measured each time the TrachFlush is used.
45652935|NCT04336163|Device|Optical Coherence Tomography|Skin imaging to determine vascular characteristics such as plexus depth, vessel diameter, and vessel density.
45652936|NCT05139381|Drug|Mepolizumab|Treatment with Mepoluzimab
45652937|NCT05614505|Dietary Supplement|Ready to use therapeutic foods|locally produced therapeutic foods
45652938|NCT05093673|Device|Cathodal Cerebellar tDCS|2 mA of cathodal tDCS is induced between two 5cm X 5cm saline soaked sponges where the cathode sponge is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. The stimulation will be delivered at an intensity of 2 mA for a maximum of 25 minutes.
45755254|NCT01674842|Radiation|Radiation Therapy|Once daily, Monday - Friday for six weeks
45755255|NCT01674842|Drug|Cisplatin|Intravenously, once weekly for six weeks
45755256|NCT03845894|Drug|Liposomal bupivacaine|Interscalene brachial plexus blockade using liposomal bupivacaine (expanded with plain bupivacaine)
45755257|NCT03845894|Drug|Bupivacaine with adjuvants|Interscalene brachial plexus blockade using plain bupivacaine with adjuvants: clonidine, epinephrine, buprenorphine, dexamethasone.
45755258|NCT04404764|Drug|Nusinersen Injectable Product|The patient´s treatment is provided by SUS. The following dosage scheme of nurinersen is the one approved by ANVISA (Brazilian National Health Surveillance Agency): Nusinersen, 12 mg (5 mL) on days 0 (zero), 14 and 28. A fourth dose will be on day 63 with a maintenance dose once every 4 (four) months. The study will NOT have direct influence on the care received by patients. Data on adherence, interventions, hospitalizations, mechanical ventilation, procedures and adverse events will be obtained from the patients´ medical records.
45755259|NCT03161132|Drug|Olaparib|Combination of continous olaparib 300mg for oral administration plus Pegylated Liposomal Doxorubicin (PLD), followed by maintenance treatment further described.
45934895|NCT00041327|Biological|recombinant interferon alfa|9 mU subcutaneously per day for one year
45934896|NCT00041327|Drug|Etoposide|50 mg/m2/day continuous 96 hr infusion, days 1-4
45600776|NCT01261403|Biological|PDA001|Dose escalation study: Subjects will be assigned to 1 of 2 treatment groups (1 unit or 4 units vs. vehicle control) based on the order in which they enroll in the study. Intravenous infusion will be administered on days 0 and 7. Nonresponders will be unblinded after 12 weeks of study. Non- responders on vehicle control will be re-dosed with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart). Nonresponders taking active PDA001 will enter the safety follow-up portion of the study. Responders at 12 weeks will continue in the safety and efficacy follow-up portion of the study until 12 months of study. Responders will be treated for RA flare between 3-9 months of study with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart).
45600777|NCT01261403|Drug|Vehicle Controlled Placebo|"Cohort Dose Level 1: 4 units vehicle controlled placebp infused on Day 0 and Day 7~Cohort Dose Level 2: 4 units vehicle controlled placebo infused on Day 0 and Day 7"
45600778|NCT02268149|Drug|BIIL 284 BS|
45600779|NCT02268149|Drug|Prednisone|
45600780|NCT02268149|Drug|Placebo|
45600781|NCT01258907|Drug|MLDL1278A|Single intravenous dose
45600782|NCT01258907|Drug|MLDL1278A|Repeating intravenous dose
45755260|NCT03161132|Drug|Pegylated Liposomal Doxorubicin|PLD 40mg/m2 every 28 days intravenous
45600783|NCT01258907|Drug|placebo|Repeating intravenous dose
45600784|NCT01258907|Drug|statin, stable dose|Repeating oral dose
45600785|NCT01255709|Drug|Arm T1: Primatene Mist HFA|epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
45600786|NCT01255709|Drug|Arm T2: Primatene Mist HFA|epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
45600787|NCT01255709|Drug|Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)|epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
45600788|NCT02529488|Device|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL|Multifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
45600789|NCT02233907|Drug|Ventilat® - metered dose inhaler|
45600790|NCT05407454|Other|Questionnaire|The original form of the Diabetes Quality of Life-Brief Clinical Inventory was first developed in 1999 to establish a valid and reliable form of diabetes-specific quality of life. Inventory items were developed to address the issues that have the greatest impact on assessing patient self-care behaviors and satisfaction with diabetes care. Items are ranked on a 5-point Likert scale and are in two general formats. One format includes satisfaction with treatment and quality of life and is scored from 1 (very satisfied) to 5 (not very satisfied). The second format includes the frequency of adverse effects of diabetes itself or diabetes treatment and offers response options from 1 (never) to 5 (always). Therefore, higher scores on the DQL-BCI items and subscales include negative values indicating problem frequency or dissatisfaction. In order to use the DQL scale more efficiently in clinics, Burroughs et al. organized the 15-item DQL-BCI in 2004.
45600791|NCT01254773|Drug|Experimental Bapineuzumab|Bapineuzumab 2 mg, Bapineuzumab 7 mg, Bapineuzumab 20 mg, Placebo
45600792|NCT05424224|Device|MagVita|rTMS system
45600793|NCT01253603|Drug|QAW039 capsules once daily for 28 days|
45755261|NCT01674920|Behavioral|Choices|The 12-week intervention included 1.5 hour classes each week. Topics included nutrition, physical activity, and psychosocial skills based in Resiliency.
45600794|NCT01253603|Drug|Placebo to QAW039 capsules once daily for 28 days|
45600795|NCT01253603|Drug|Fluticasone propionate inhaler twice daily for 28 days|
45600796|NCT02268305|Drug|MSM 1000mg twice a day (6000 mgs)|MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.
45600797|NCT02268305|Other|Placebo capsules twice a day|Placebo is a capsule filled with rice flour.
45600798|NCT02268383|Drug|ACE-536|ACE-536 1.0 mg/kg once every 3 weeks by subcutaneous injection
45600799|NCT01329419|Drug|adefovir dipivoxil|Basically there is no treatment allocation. Subjects who would be administered of adefovir at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
45600800|NCT01235585|Drug|Placebo|Oral doses, once a day for 52 weeks
45600801|NCT01235585|Drug|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
45600802|NCT01235585|Drug|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
45600803|NCT01329341|Other|Service Dogs|Service dogs will be trained to help Veterans with PTSD
45600804|NCT01235039|Drug|VIAject®25|Two vial presentation for reconstitution and single dose of 12 IU subcutaneous injection and 25 IU/mL
45600805|NCT01235039|Drug|VIAject®7|One vial presentation and single dose of 12 U for subcutaneous injection and 100 IU/mL
45755262|NCT03844256|Combination Product|nivolumab 480mg|Immuno-chemoradiotherapy
45755263|NCT03844256|Combination Product|nivolumab 3mg/kg, ipilimumab 1mg/kg|Immuno-chemoradiotherapy
45911013|NCT02002286|Drug|Tripterygium Wilfordii Hook F extract (TwHF extract)|The extract Tripterygium wilfordii Hook F (TwHF), a traditional Chinese medication, has been used as anti-inflammatory therapy to treat autoimmune diseases including rheumatoid arthritis and Crohn's disease.
45600806|NCT01235039|Drug|Insulin Lispro|One vial presentation and single dose of 12 IU for subcutaneous injection and 100 IU/mL
45600807|NCT02268539|Procedure|ablation|Ablation ranging from 20-25 watts / 30-45 seconds
45600808|NCT02268617|Other|Treadmill Walking|Following instructions and familiarization with the treadmill, participants will walk on the treadmill for 20 minutes total with rest periods as needed. Treadmill speed will be set at each participant's overground comfortable walking speed for the first 5 minutes, provided that they can walk safely. If necessary the speed will be lowered until a safe gait is achieved. After 5 minutes the speed will be incrementally increased by10% each 5 minutes (3 times) as long as a safe gait (i.e., no abnormal vital signs, excessive effort, or loss of balance occurrences) can be maintained. If the gait pattern becomes unsafe or more abnormal the speed will revert to the previous safe speed and be maintained at this level until the end of training session.
45755264|NCT03844256|Combination Product|nivolumab 1mg/kg, ipilimumab 3mg/kg|Immuno-chemoradiotherapy
45755265|NCT01675076|Drug|Dabigatran|NOAC
45755266|NCT01675076|Drug|Rivaroxaban|NOAC
45755267|NCT01675076|Drug|Apixaban|NOAC
45755268|NCT03018080|Drug|Pembrolizumab|IV (in the vein) on day 1 of a 21 day cycle
45600809|NCT05129501|Behavioral|Experimental|The Tiwahe Wicagwicayapi seven-session program is for children ages 10 to 14 who are Native American and/or living in poverty and their caregivers. The program begins with a traditional Lakota meal followed by family time and break-out time for caregivers only and children only. The program includes skill-building activities as well as the integration of Lakota language, history, and culture. The program is facilitated by diverse individuals, predominantly Native Americans in Rapid City and surrounding tribal communities.
45600810|NCT01234025|Drug|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
45600811|NCT01234025|Drug|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
45600812|NCT01234025|Drug|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
45600813|NCT01234025|Drug|Prednisone|5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle
45600814|NCT01234025|Drug|Docetaxel|75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle
45600815|NCT01232543|Drug|Product 0405|Product 0405 will be administered topically, twice daily for 28 days.
45600816|NCT05103839|Behavioral|Gentle Yoga|Yoga classes are twice a week for up to 10 weeks with a trained yoga instructor at a location in the community. Classes will last up to 75 minutes.
45600817|NCT01221077|Drug|OSI-906|As of 01 March 2013, OSI-906 is no longer being administered
45600818|NCT01221077|Drug|Erlotinib|Erlotinib administered orally
45600819|NCT01221077|Drug|Placebo|As of 01 March 2013, the matching placebo is no longer being administered
45600820|NCT02234297|Drug|BLZ-100|
45600821|NCT04475159|Procedure|Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)|Pressurized Intraperitoneal Aerosol Chemotherapy will be delivered to the abdominal cavity by means of laparoscopy.
45600822|NCT04475003|Other|Teaching|Teaching session about anaphylaxis
45600823|NCT01208129|Drug|NAB001|nail lacquer, once daily, 52 weeks
45600824|NCT01208129|Drug|Placebo control|nail lacquer, once daily, 52 weeks
45600825|NCT01207115|Drug|ABT-652|ABT-652 capsules - twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm
45600826|NCT01207115|Drug|Placebo|Placebo capsules - twice daily for 8 weeks
45600827|NCT01207115|Drug|Naproxen|Naproxen capsules - twice daily for 8 weeks
45600828|NCT01186991|Drug|Onartuzumab|Onartuzumab will be administered as intravenous (IV) infusion at a dose of 10 milligrams per kilogram (mg/kg) on Day 1 and Day 15 of each 28-day cycle. The dose of onartuzumab will be based on the participant's weight at screening and will remain the same throughout the study.
45600829|NCT01186991|Drug|Bevacizumab|Bevacizumab will be administered as IV infusion at a dose of 10 mg/kg on Day 1 and Day 15 of each 28-day cycle. The dose of bevacizumab will be based on the participant's weight at screening and will remain the same throughout the study.
45600830|NCT01186991|Drug|Paclitaxel|Paclitaxel will be administered as IV infusion at a dose of 90 milligrams per meter-squared (mg/m^2) on Day 1, Day 8, and Day 15 of each 28-day cycle.
45600831|NCT01186991|Drug|Bevacizumab Placebo|Placebo matching to bevacizumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
45755269|NCT03018080|Drug|Paclitaxel|IV (in the vein) on days 1 and 8 of a 21 day cycle
45600832|NCT01186991|Drug|Onartuzumab Placebo|Placebo matching to onartuzumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
45755270|NCT02029430|Drug|aldoxorubicin|
45755271|NCT01675232|Other|Soak and smear|Corticosteroid ointment applied to wet skin once a day and dry skin once a day.
45755272|NCT01675232|Other|Dry Smear|Corticosteroid ointment applied to dry skin twice a day.
45755273|NCT01675388|Other|Hypothermia|Hypothermia to 33.5 deg C
45755274|NCT01673438|Drug|aldoxorubicin|
45911014|NCT02002286|Drug|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
45444460|NCT03804177|Procedure|immediate implant placement with melatonin hyaluronic acid vit C|immediate implant placement with melatonin and hyaluronic acid and systemic administration vitamin C
45444461|NCT03804177|Procedure|immediate implant placement without melatonin hyaluronic acid vit C|immediate implant placement without melatonin and hyaluronic acid and systemic administration vitamin C
45600833|NCT02268773|Drug|Asasantin®|
45600834|NCT02268773|Drug|Acetylsalicylic acid low dose|
45600835|NCT02268773|Drug|Acetylsalicylic acid high dose|
45600836|NCT01183949|Drug|AT7519M|"Part A: Nine patients will receive AT7519M as an intravenous infusion on days 1, 4, 8 and 11 of a three week cycle. The starting dose of AT7519M will be 21mg/m^2/dose and will be increased to 27mg/m^2/dose during subsequent cycles in the absence of AT7519M-related toxicities.~Part B: Amendment clarified there will be no further exploration of AT7519M as a monotherapy.~Part C: Amendment modified dose escalation to a conventional 3 + 3 design with a maximum total of 14 patients will be treated at the maximum tolerated dose."
45600837|NCT01183949|Drug|Bortezomib|Part C will treat between 3-26 patients with a combination of bortezomib and AT7519M in a dose escalation design. The starting doses for the dose escalation are bortezomib 1 mg/m2 and AT7519M 14 mg/m2.
45755275|NCT03720782|Device|LEGION Porous HA Tibial Baseplate and/or the LEGION Porous HA CR Femoral Component|LEGION Porous HA Tibial Baseplate (with and without holes) and/or the LEGION Porous HA CR Femoral Component
45755276|NCT03839342|Drug|Binimetinib|MEK inhibitor, 45mg oral tablet
45755277|NCT03839342|Drug|Encorafenib|BRAF inhibitor, 450mg oral capsule
45755278|NCT03838796|Drug|lenvatinib|for patients <60kg, lenvatinib 8mg bid po for patients >60kg, lenvatinib 12mg bid po
45755279|NCT03838796|Procedure|TACE|The patient underwent transfemoral hepatic artery angiography one month after surgery to observe whether there was tumor staining in the liver. If there was suspicious tumor staining, micro-catheter was superselected to the tumor blood vessel, the embolization agents and chemotherapy drugs were injected. If there was no tumor staining, a small amount of embolization agents were slowly injected into the artery.
45755280|NCT03719690|Drug|Tipifarnib|Tablet for oral administration
45755281|NCT03719690|Device|HRAS Detection Assay|In Vitro Assay to detect HRAS mutations
45934897|NCT00041327|Drug|cyclophosphamide|750 mg/m2 IV on day 5
45600838|NCT01183637|Device|Kensey Nash Corp. Cartilage Repair Device|To perform the Cartilage Repair Device implantation procedure, the surgeon first removes the damaged cartilage. Then, the surgeon creates a cylindrical hole in the bone below the area of damaged cartilage. The Cartilage Repair Device is then implanted into the hole so that the surface is level with the surrounding native cartilage. The Cartilage Repair Device will then absorb blood and bone marrow from the bone to begin the healing process.
45600839|NCT01183637|Procedure|Microfracture|To perform the microfracture technique, the surgeon will first remove the damaged cartilage. Then, the surgeon will make a number of small fractures in the bone below the area of damaged cartilage. The fractures cause the bone to bleed and a clot to form over the exposed bone. Over time, the clot forms a layer of fibrocartilage over the bone.
45600840|NCT02268929|Device|Accu-Chek Smart Pix Software|Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
45755282|NCT01675466|Procedure|early laparoscopy|Laparoscopy under performed by the surgeon on duty or his/her deputy. The aim is to achieve this within 12 hours of randomisation. This will be performed under general anaesthetic and involve the necessary drugs. The procedure will require laparoscopy instruments. There will be a umbilical port which will be 10mm in size and one 5mm port below this. If pathology is found, a further port will be needed to perform treatment.
45600841|NCT02268929|Device|Accu-Chek Smart Pix readout Device|Smartpix device for data upload out from blood glucose meter devices
45600842|NCT01096979|Drug|LIPO-102|subcutaneous injection
45600843|NCT01096979|Drug|Placebo|Placebo
45600844|NCT02269007|Biological|inactivated quadrivalent influenza vaccine (split virion)|0.5ml inactivated quadrivalent influenza vaccine (split virion) for each subject, one dose
45600845|NCT02269085|Drug|Ibrutinib|"Phase I Starting Dose: 420 mg by mouth daily on Days 1 - 28 of a 28-day cycle.~Phase II Starting Dose: MTD from Phase I."
45600846|NCT02269085|Drug|Carfilzomib|"Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8 ,9, 15 and 16 in Cycles 1 - 12, and Days 1,2 and 15,16 of Cycle 13 and beyond.~Phase II Starting Dose: MTD from Phase I."
45755283|NCT01675466|Procedure|General anaesthesia|
45755284|NCT01675466|Device|Laparoscopic instruments|
45755285|NCT04747106|Biological|plasma exchange|when ADP inhibition >30%, plasma exchange, once or twice a week, 1000-1500ml plasma was exchanged for each time
45755286|NCT01675700|Drug|Nitroglycerin patch|Nitroglycerin 0.1 mg/hr patch
45600847|NCT02269085|Behavioral|Phone Calls|Study staff calls participant after end-of-dosing visit every 6 months for 5 years. These calls should take about 2-3 minutes.
45600848|NCT02532764|Drug|QR-010|Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton
45755287|NCT01676558|Drug|131I-rituximab|
45600849|NCT02532764|Drug|Placebo|Normal Saline
45755288|NCT01675856|Other|Urgent endoscopy|Defined by oesophagogastroduodenoscopy within 6 hours of first presentation of Prince of Wales Hospital
45755289|NCT01675856|Other|Early endoscopy|Defined by oesophagogastroduodenoscopy within 24 hours of first presentation of Prince of Wales Hospital
45755290|NCT02510300|Drug|Sofosbuvir (SOF)|Exposure of interest for participants who received a SOF-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
45755291|NCT02510300|Drug|Ledipasvir/Sofosbuvir (LDV/SOF)|Exposure of interest for participants who received a LDV/SOF-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
45755292|NCT02510300|Drug|Sofosbuvir/Velpatasvir (SOF/VEL)|Exposure of interest for participants who received a SOF/VEL-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
45755293|NCT02510300|Drug|Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)|Exposure of interest for participants who received a SOF/VEL/VOX-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
45755294|NCT00678535|Drug|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m^2) will be administered intravenously over 120 minutes followed by weekly intravenous infusion of cetuximab 250 mg/m^2 over 60 minutes in each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
45755295|NCT00678535|Drug|Capecitabine|Capecitabine 1000 mg/m^2 will be administered orally twice daily from evening of Day 1 to morning of Day 15 for every 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
45755296|NCT00678535|Drug|Cisplatin|Cisplatin 80 mg/m^2 will be administered intravenously with infusion over 1 to 4 hours on Day 1 of each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
45755297|NCT04404374|Procedure|A-PRF/EMD|Comparing healing effect of an autologous and a xenogenic product
45755298|NCT03834116|Device|Inspiratory muscle training|A pressure threshold device will be used to deliver IMT, which is commercially available by Phillips Respironics.
45755299|NCT01675934|Procedure|Retroflexion with the adult colonoscope.|
45755300|NCT01675934|Procedure|Retroflexion with the pediatric colonoscope.|
45755301|NCT03832790|Other|observation|observation
45755302|NCT00659737|Drug|Aprepitant|40mg tablet
45600850|NCT01173731|Drug|AFQ056|
45600851|NCT01092065|Drug|AFQ056 with L-dopa|hard gelatin capsule to be taken bid for six weeks
45600852|NCT01092065|Drug|Placebo|hard gelatin capsule to be taken bid for six weeks
45600853|NCT05626829|Drug|Tranilast|Tranilast capsules 100mg 3 times per day when reradiation
45600854|NCT01173497|Drug|INIPARIB + irinotecan|21 day cycle
45600855|NCT02528942|Radiation|Radiation therapy|Radiation therapy will be given to study patients.
45600856|NCT01171313|Drug|XP21279 and carbidopa (experimental)|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed XP21279 and Carbidopa
45600857|NCT01171313|Drug|Sinemet (comparator)|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed Sinemet.
45600858|NCT01171313|Drug|Placebo for XP21279 and carbidopa|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for XP21279 and carbidopa
45600859|NCT01171313|Drug|Placebo for Sinemet|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for Sinemet
45755303|NCT00659737|Drug|Scopolamine|1.5 mg patch delivering transdermally in vivo approx. 1.0mg over 3 days
45755304|NCT03832634|Diagnostic Test|Fetal Genome Profiling.|Once pregnancy is achieved, patients will undergo non-invasive collection of trophoblast cells (trophoblast retrieval and isolation from the cervix, TRIC) at an early gestational age, approximately 5-6 weeks. The patient will also be screened with blood work for carrier status for genetic conditions.
45600860|NCT05373992|Behavioral|Screen Time Restriction (ST-Restricted)|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) for the first 72-hours following the initial clinic visit. Following the first 72-hours of restricted screen-time, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
45600861|NCT05373992|Behavioral|Aerobic Exercise (AE)|Engage in 30-minutes of aerobic exercise daily for the first 72-hours following the initial clinic visit in the form of a stationary exercise bike, treadmill, or outdoors. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate (HR). Following the first 72-hours of prescribed AE, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
45600862|NCT05373992|Behavioral|Screen-time restricted plus aerobic exercise (STR+AE)|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) while concurrently engaging in daily aerobic exercise in the form of a stationary exercise bike, treadmill, or outdoors, for the first 72-hours following the initial clinic visit. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate (HR). Following the first 72-hours of prescribed STR+AE, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
45600863|NCT05373992|Behavioral|Stretching Only|Participants will be instructed to follow a prescribed stretching program for the first 72-hours following the initial clinic visit. Following the first 72-hours of prescribed stretching, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
45600864|NCT02269319|Drug|MRX-I|Oral MRX-I 800mg given twice a day for 10 days
45600865|NCT02269319|Drug|Linezolid|Oral linezolid 600mg given twice a day for 10 days
45600866|NCT01071239|Device|CliniMACs device|Donor Peripheral blood progenitor cells will use CD34+ selection with the use of the CliniMACs device
45600867|NCT01071239|Drug|Busulfan|Chemotherapy administered as a part of the HSCT conditioning regimen.
45600868|NCT01071239|Drug|Fludarabine|Chemotherapy administered as a part of the HSCT conditioning regimen.
45600869|NCT01071239|Drug|Cyclophosphamide|Chemotherapy administered as a part of the HSCT conditioning regimen.
45600870|NCT01071239|Drug|ATG|Chemotherapy administered as a part of the HSCT conditioning regimen.
45600871|NCT02269553|Device|TMJ(TM) NextGeneration|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts.
45600872|NCT02269553|Device|Standard Hard TMJD Splint|The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch.
45600873|NCT05624489|Behavioral|Engagement Strategies|The study's mobile app (Oralytics) will be used to deliver engagement prompts. The prompts contain messages that leverage three engagement strategies: reciprocity, reciprocity by proxy, and curiosity.
45600874|NCT01156415|Drug|AGO178|
45600875|NCT01156415|Drug|AGO178|
45600876|NCT01057667|Drug|RO5024048|1000mg bid po, 24 weeks
45600877|NCT01057667|Drug|Ribavirin [Copegus]|1000mg or 1200mg po daily
45600878|NCT01057667|Drug|peginterferon alfa-2a [Pegasys]|180mcg sc weekly
45755305|NCT00660049|Device|SNaP Advanced Wound Care System|Application of negative pressure device daily per instructions
45755306|NCT00660049|Other|SNaP|Daily use
45755307|NCT00660049|Other|SNaP|Daily application per protocol
45755308|NCT04763876|Drug|Ketorolac Injection 15 mg|A single dose of 15 mg ketorolac administered intramuscularly.
45755309|NCT04763876|Drug|Ketorolac Injection 60 mg|A single dose of 60 mg ketorolac administered intramuscularly.
45600879|NCT01039805|Drug|GSK962040 (50 mg)|Cohort 1 = 50 mg
45600880|NCT01039805|Drug|Placebo|matching placebo
45600881|NCT01039805|Drug|GSK962040 (75 mg)|Cohort 2 = 75 mg
45600882|NCT02527148|Device|OtisMed® ShapeMatch® Technology|The appropriate Stryker ShapeMatch® Cutting Guides will be used to guide the surgeons bone resections. The surgeon will implant the knee prostheses following the surgical protocol for Triathlon® Knee System with OtisMed® ShapeMatch® Technology
45755310|NCT00680797|Drug|Testosterone|Testosterone gel
45755311|NCT00680797|Drug|Estrogen|Estrogen patch
45755312|NCT02081456|Other|Soft Tissue Mobilization|Patients in the STM group received treatment in supine, with their head resting on one pillow and the involved UE positioned in abduction and external rotation to preload the neural structures of the upper limb. Manual pressure was applied to the soft tissues of the upper quadrant in a deep, stroking manner with the intention to improve the mobility of the soft tissues surrounding the pathway of the neural structures of the upper limb as well as any tender or tight tissues. The therapist spent approximately 7 minutes on the neck and scapular region, 4 minutes on the upper arm, and 4 minutes on the forearm and hand. The therapist was allowed to vary the time spent on each region according to his/her assessment of the patient's condition. The procedure lasted a total of 15 minutes.
45755313|NCT02081456|Device|Therapeutic Ultrasound|Patients received therapeutic US applied for a period of 5 minutes to the most painful region of the neck, then a second 5-minute dose at the most painful region of the upper extremity. The US dose was 0.5 w/cm2, with sonation time 50% and frequency 1 MHz.40,52 The patient lay supine with the hand of the involved upper extremity placed on the abdomen and the elbow supported on a pillow. The two US doses and interaction time with the patient lasted a total of 15 minutes in an attempt to have equal patient/therapist contact between the two groups.
45755314|NCT02984852|Drug|Darunavir (DRV)|Darunavir 800 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/TAF(10mg).
45755315|NCT02984852|Drug|Cobicistat (COBI)|Cobicistat 150 milligram (mg) will be taken orally in FDC together with DRV(800mg)/FTC(200mg)/TAF(10mg).
45600883|NCT02527148|Device|Stryker Precision Knee Navigation|Stryker PrecisioN Knee (4.0) Navigation System, comprising of computer hardware and software and associated instrumentation, will be used for intra-operative alignment and orientation of implant. Navigation trackers will be secured to the femur and tibia and registration of the limb will be undertaken according to the PrecisioN Knee System surgical technique.Femoral and tibial resections, followed by device implantation, will be performed according to the Triathlon Knee System Surgical Protocol.
45600884|NCT02527148|Procedure|Total Knee Replacement|
45755316|NCT02984852|Drug|Emtricitabine (FTC)|Emtricitabine 200 milligram (mg) will be taken orally in FDC together with COBI(150mg)/DRV(800mg)/TAF(10mg).
45755317|NCT02984852|Drug|Tenofovir Alafenamide (TAF)|Tenofovir Alafenamide 10 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/DRV(800mg).
45600885|NCT02527148|Device|Stryker Triathlon® Total Knee System|"Prosthetic components to be implanted including~Triathlon® Cruciate Retaining (CR) Total Knee System (cemented), including Femoral Component and Primary Tibial Baseplate;~Triathlon® Cruciate Substituting (CS) X3® polyethylene insert;~Triathlon® X3 Patella (asymmetric) - treated selectively by surgeon."
45600886|NCT01037231|Biological|Oxalobacter formigenes|NLT (not less than) 10^7 CFU oxalobacter formigenes twice daily for 24 weeks
45755318|NCT00557193|Drug|Asparaginase|Given IV, IM, or PO
45600887|NCT01037231|Drug|Placebo|placebo
45600888|NCT05624255|Other|Ophthalmologic consultation|Complete ophthalmologic examination including angio-OCT
45600889|NCT02291614|Drug|AMG 211|continuous intravenous infusion (cIV) infusion in cycles from 7 to 28 days
45600890|NCT02270177|Other|Telemedicine, videoconsultation|We are investigating the use of videoconsultations (through telemedicine technology) in patients with primary headaches.
45600891|NCT05372900|Other|Test Product|Whey Protein Isolate with Mulberry leaf extract
45600892|NCT05372900|Other|Control Product|Wheat Protein Hydrolysate
45600893|NCT01027013|Drug|rebamipide 2% ophthalmic suspension|Instill one drop in each eye four times daily for 12 weeks.
45600894|NCT01027013|Drug|placebo eye drops|Instill one drop in each eye four times daily for 12 weeks.
45600895|NCT05570630|Behavioral|VAX-MOM COVID-19 Intervention|The multi-component VAX-MOM COVID-19 intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
45600896|NCT05570630|Other|Standard of Care|Standard vaccine education and processes provided to patients by obstetric practices.
45600897|NCT01024907|Radiation|proton beam radiation therapy|Undergo radiation
45600898|NCT01024907|Procedure|quality-of-life assessment|Ancillary study
45600899|NCT01024907|Other|questionnaire administration|Ancillary study
45600900|NCT02270333|Device|Inspiratory muscle training|"Treatment group received inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).~The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.~The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
45600901|NCT02270333|Device|Sham inspiratory muscle training|"Control group received sham inspiratory muscle training (IMT) at fixed workload, 5% of MIP using threshold loading device (POWERbreathe Classic device IMT Technologies Ltd. Birmingham, England).~The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
45755319|NCT00557193|Drug|Cyclophosphamide|Given IV
45755320|NCT00557193|Drug|Cytarabine|Given IV or IT
45755321|NCT00557193|Drug|Daunorubicin Hydrochloride|Given IV
45755322|NCT00557193|Drug|Dexamethasone|Given IV or PO
45755323|NCT00557193|Drug|Etoposide|Given IV
45755324|NCT00557193|Biological|Filgrastim|Given IV or SC
45600902|NCT04197076|Drug|anti-PD-1 or anti-PD-L1|immunotherapy anti-PD-1 or anti-PD-L1
45600903|NCT04197076|Drug|EGFR-TKI, ALK inhibitor, ROS1 inhibitor|targeted therapy EGFR-TKI, ALK inhibitor, ROS1 inhibitor
45600904|NCT04197076|Drug|investigator decided|chemotherapy
45600905|NCT02270489|Biological|AFFITOPE® PD01A + Adjuvant|s.c. injection
45600906|NCT02270489|Biological|AFFITOPE® PD03A + Adjuvant|s.c. injection
45600907|NCT02270489|Biological|Adjuvant without active component|s.c. injection
45600908|NCT04887454|Behavioral|Once-Weekly HIIT|Participants in this group will receive a 16-week intervention of HIIT once weekly supervised by certified athletic coaches. Participants will perform four 4-minute intervals at 85%-95% peak heart rate with a 3-minute active recovery between each 4-minute interval. Participants will repeat the 25-minute HIIT bout three times with 30-60 minutes break in between each 25-minute HIIT bout. Health information provided to the usual care control group will be made available to the participants in the HIIT groups.
45600909|NCT04887454|Behavioral|Thrice-Weekly HIIT|Participants in this group will receive a 16-week intervention of HIIT thrice weekly supervised by certified athletic coaches. Participants will perform four 4-minute intervals at 85%-95% peak heart rate with a 3-minute active recovery between each 4-minute interval. Health information provided to the usual care control group will be made available to the participants in the HIIT groups.
45755325|NCT00557193|Other|Laboratory Biomarker Analysis|Correlative studies
45755326|NCT00557193|Drug|Lestaurtinib|Given PO
45755327|NCT00557193|Drug|Leucovorin Calcium|Given IV
45755328|NCT00557193|Drug|Mercaptopurine|Given PO
45755329|NCT00557193|Drug|Methotrexate|Given IV, IT, or PO
45755330|NCT00557193|Drug|Methylprednisolone|Given IV
45755331|NCT00557193|Drug|Pegaspargase|Given IM
45755332|NCT00557193|Other|Pharmacological Study|Correlative studies
45755333|NCT00557193|Drug|Prednisone|Given PO
45755334|NCT00557193|Drug|Therapeutic Hydrocortisone|Given IT
45755335|NCT00557193|Drug|Vincristine Sulfate|Given IV
45804190|NCT05662202|Combination Product|Vehicle and red light LED lamp|"Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (Vehicle-PDT):~Topical application of up to 3 tubes vehicle on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing.~PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit."
45600910|NCT04887454|Other|Usual Care|Participants in the usual care control group will receive health education delivered by research personnel. This program will consist of eight two-hour bi-weekly sessions covering major health issues relating to obesity including causes, prevalence, epidemiology, associated diseases, healthy diet, caloric restriction advice, physical activity, stress management, adequate sleep, as well as lifestyle counseling/consultation and goal-setting/record-keeping strategies for behavioral changes.
46066515|NCT00832026|Device|Trans Nasal Insufflation (TNI) [nasal canula]|"Trans Nasal Insufflation, or TNI, uses air at flow rates delivered through a small nasal canula to reduce the severity and frequency of sleep apnea events.~By using TNI we hope to increase the amount of air that the patient can breathe during periods of obstructive sleep disordered breathing."
45600911|NCT02270723|Drug|"5% Human Albumin  Behring"|Intravenous infusion of 5% Human Albumin during major surgery
45600912|NCT02270723|Drug|Lactated Ringer|Intravenous infusion of Lactated Ringer during major surgery
45600913|NCT04475237|Other|CT-scan evaluation and segmentation|CT-scans will be evaluated (to see if they are included in the research group) and segmented if they are accepted.
45600914|NCT01138163|Drug|Docetaxel plus bavituximab or placebo|Patients will be randomized to receive docetaxel plus placebo, docetaxel plus 1 mg/kg bavituximab, or docetaxel plus 3 mg/kg bavituximab in the Combination Therapy Period. The Combination Treatment Period for each patient will begin on Study Day 1. Docetaxel, 75 mg/m2, will be given on Day 1 of each 21 day cycle for up to 6 cycles, and placebo or the assigned dose of bavituximab will be given weekly. Docetaxel administration will occur every 21 days. All patients who complete the Combination Therapy Period (or discontinue for any reason other than disease progression or toxicity) will be eligible to enter the Monotherapy Period. Patients will continue to receive assigned blinded treatment (placebo or 1 or 3 mg/kg bavituximab) weekly until progression or toxicity.
45600915|NCT02526524|Drug|Met DR|metformin delayed-release tablets
45600916|NCT02526524|Drug|Met IR|metformin immediate-release tablets
45600917|NCT02526524|Drug|Placebo|
45600918|NCT01022801|Drug|Entecavir|Capsule, P.O., 0.01, 0.1 or 0.5 mg, once daily for 24 weeks
45600919|NCT05628467|Drug|Antidepressive Agents|Compare the signal obtained from the pharmacovigilance database study between adults over 65 who fall on antidepressants versus those who fall on other drugs
45600920|NCT05628389|Behavioral|Educational materials|Patient educational materials to address insufficient knowledge about harms of tobacco use and cessation.
45600921|NCT05628389|Behavioral|Phone counseling|Cessation counseling to address insufficient patient self-efficacy and motivation.
45600922|NCT05628389|Drug|Nicotine Replacement Therapy|Nicotine patches to address nicotine withdrawal symptoms in patients.
45600923|NCT05628389|Behavioral|Provider training|Provider training to address insufficient knowledge and self-efficacy to deliver AAA/AAC to patients.
45600924|NCT05628389|Behavioral|Electronic reminders|Electronic reminders to address the lack of integration of AAA/AAC into practice.
45600925|NCT05628311|Other|placebo|placebo administered subcutaneously (SC) once a week.
45600926|NCT05628311|Drug|IBI362|IBI362 administered subcutaneously (SC) once a week.
45600927|NCT05422274|Device|Transcranial Pulse Stimulation|A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on improving inattention and hyperactivity .
45600928|NCT05598515|Behavioral|Time-Restricted Feeding|Participants will be asked to eat for only 8 hours out of 24 hours in a day.
45600929|NCT05422118|Diagnostic Test|ascitic fluid calprotectin|ascitic fluid calprotectin
45600930|NCT01128335|Drug|MMF(1000mg bid) + tacrolimus + standard of care medications|MMF(1000mg bid) + tacrolimus + standard of care medications
45600931|NCT01128335|Drug|sotrastaurin (200mg bid) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
45600932|NCT01128335|Drug|sotrastaurin (200mg bid) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
45600933|NCT01128335|Drug|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
45600934|NCT04422938|Other|Manuel chest compressions handled by clinicians|Compressions will be handled by human efforts
45600935|NCT04422938|Device|LUCAS™ 2 Chest Compression System|LUCAS-2 model piston-based mechanical chest compression device was used for mechanical chest compressions
45600936|NCT01012895|Drug|BMS-790052|Tablets, Oral, 60 mg, once daily, 24 weeks
45600937|NCT01012895|Drug|BMS-650032|Tablets, Oral, 600 mg, twice daily, 24 weeks
45600938|NCT01012895|Drug|BMS-650032|Tablets, Oral, 200mg, twice daily, 24 weeks
45600939|NCT01012895|Drug|BMS-650032|Tablets, Oral, 200 mg, once daily, 24 weeks
45600940|NCT01012895|Drug|Pegylated-interferon alfa-2a|Syringe, Subcutaneous Injection, 180 µg, once weekly
45600941|NCT01012895|Drug|Ribavirin|"Tablets, Oral~For subjects weighing < 75 kg: 1000 mg; For subjects weighing ≥ 75 kg: 1200 mg~Twice daily (< 75 kg: 400 mg in ante meridian (AM) and 600 mg in post meridian (PM); ≥ 75 kg: 600 mg in AM and PM), 24 weeks"
45600942|NCT05405582|Combination Product|Community-based differentiated HIV prevention incl.PrEP with SRH|Community-based model of care, that consists of social mobilisation by area-based peer-navigator into decentralised sexual reproductive health (SRH) and HIV care (incl. PrEP).
45600943|NCT05405582|Other|Primary Health Clinic based HIV prevention and care|Primary Health Clinic (PHC) based initiation and follow-up with HIV testing and standard HIV prevention and treatment package. Family planning support and syndromic management for STIs as per South African National Department of Health Guideline.
45600944|NCT02526290|Device|Intranasal Lacrimal Neurostimulator (Oculeve)|Neurostimulation device
46066516|NCT00680901|Drug|Lapatinib|5 pills at 250mg each once daily
46066517|NCT00680901|Drug|Placebo|5 pills once daily
46066518|NCT00680901|Drug|Capecitabine|1700mg/m2/day in two daily doses
46066519|NCT00680901|Drug|Oxaliplatin|130mg/m2 on day 1
46066520|NCT00678821|Other|Aerobic exercise|Supervised aerobic exercise and educational lectures for 10 weeks
45600945|NCT01009775|Drug|YM155|intravenous infusion
45600946|NCT01009775|Drug|Docetaxel|intravenous infusion
45600947|NCT02319148|Drug|itraconazole|itraconazole dosed at 200 mg
45600948|NCT02319148|Drug|diltiazem|diltiazem dosed at 240 mg
45600949|NCT02319148|Drug|SR verapamil|SR verapamil dosed at 240 mg
45804191|NCT02029443|Drug|Acalabrutinib|Participants will receive acalabrutinib as stated in the arms' description.
45804192|NCT05659238|Behavioral|the effect on language development & attention|Tv & other electronic devices effects onn children's language development & attention
45600950|NCT02319148|Drug|PF-00489791|PF-00489791 20 mg single dose administration
45600951|NCT02526212|Behavioral|G-BMT|The G-BMT intervention will include weekly group visits (for 8 weeks) where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. Group visits will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
45600952|NCT02526212|Behavioral|Treatment as usual|Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
45600953|NCT02526212|Drug|Buprenorphine|All participants will continue to receive maintenance treatment with buprenorphine-naloxone
45600954|NCT05627921|Device|Extracorporeal Shock Wave Therapy|Spastic muscles will be determined by examination. Botulinum toxin-A will be injected into the spastic muscles with Stumplex. 1 week after the injection, patients will receive 3 sessions of radial ESWT treatment, 1 session/week. rESWT application will be applied with the 'MODUS ESWT' device and a 35 mm radial soft applicator will be used. rESWT will be applied with a soft applicator. The soft applicator is designed for application to sensitive and painful areas and applications will be painless.Shock waves will be applied at 1500/beat, 8 Hz, 0.030 Mj/mm2, 2 bar per muscle.
45600955|NCT05627921|Drug|Botilinum Toxin injection|Spastic muscles will be determined by examination. Botulinum toxin-A will be injected into the spastic muscles with Stumplex.
45600956|NCT04423172|Device|the new tissue containment system|Using the new tissue containment system during Laparoscopic hysterectomy. The divice is a soft specimen bag in which the uterus tissue is sealed and quickly morcellation and removed through vagina. The divice is named the new tissue containment system.
45600957|NCT05573165|Other|3 hours of preoperative fasting for breast milk|3 hours of preoperative fasting for breast milk
45600958|NCT05573165|Other|4 hours of preoperative fasting for breast milk|4 hours of preoperative fasting for breast milk
45600959|NCT04880044|Diagnostic Test|EsoCheck/EsoGuard (EC/EG)|EC is a swallowed capsule on a tethered catheter that obtains a touch sample of the distal esophagus. The obtained sample is placed in a buffer and sent to a diagnostics lab for testing of methylated markers from extracted DNA. EG is a methylated DNA test . A positive EG is associated with Barrett's esophagus at all its stages.
45600960|NCT04880044|Diagnostic Test|Esophago-gastro-duodenoscopy (EGD)|SOC diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum. Tissue samples collected.
45600961|NCT03873545|Procedure|Cryopreserved Osteochondral Allograft|This tissue is a laser-etched, cryopreserved fresh osteochondral allograft that was developed as a single-stage alternative for articular cartilage restoration.
45600962|NCT05371106|Other|exposure to mycotoxins|self-report eating questionnaire
45600963|NCT05572697|Behavioral|Digital Cognitive-behavioral therapy for insomnia (dCBT-I)|6 week sleep intervention delivered via a smartphone app while taking part in inpatient multimodal rehabilitation for chronic pain lasting 2+2 weeks.
45600964|NCT05572697|Behavioral|Usual care|Inpatient multimodal rehabilitation for chronic pain lasting 2+2 weeks.
45600965|NCT05627843|Dietary Supplement|Curcumin capsules 1 gm|Dietary supplement
45600966|NCT05627843|Dietary Supplement|Placebo capsule|placebo corn starch
45600967|NCT05564117|Drug|Semaglutide|Semaglutide tablets orally once daily for 64 weeks.
45600968|NCT05564117|Drug|Placebo semaglutide|Semaglutide placebo-matching tablets orally once daily for 64 weeks.
45600969|NCT05403242|Drug|RC48-ADC|2.0 mg/kg, IV, d1, every 2 weeks; or 2.5 mg/kg, IV, d1, every 2 weeks
45600970|NCT05403242|Drug|S-1|40-60 mg, bid po, d1-10, every 2 weeks
45804193|NCT03226223|Drug|Intranasal Methamphetamine|Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)
46066521|NCT00572169|Drug|Velcade|Will be given in central venous catheter
45600971|NCT05368532|Other|Temperature|The temperature will be reduced for approximately one hour.
45600972|NCT05627765|Behavioral|Standard treatment (ST) arm|Participants will receive a brief smoking cessation intervention based on the asking about tobacco use, Advising smokers to quit, Assessing their willingness to quit,Assisting in quitting, and Arranging for follow-up and relevance, risks, rewards, roadblocks and repetition models at baseline. Booster interventions will be provided to ST arm at 1-week, 1-month, 3-month, and 6-month follow-up.
45600973|NCT05627765|Other|Integrated Intervention (II) arm|Participants will receive brief advice on alcohol use based on the FRAMES model, which is a well-established and effective brief intervention for drinking.
45600974|NCT01004081|Drug|BIIB021|BID orally for 28 days
45600975|NCT01004081|Drug|BIIB021|TIW orally for 28 days
45600976|NCT01004081|Drug|exemestane (Aromasin)|Daily in tablet form for 28 days
45600977|NCT05402150|Behavioral|Behavioral Activation|"instruction to create a list of individual positive activities.~instruction to include daily positive activities and fill out a mood protocol, which covers the time period shortly before, during and after the activity."
45600978|NCT05402150|Behavioral|Mindulness and Gratitude|"instruction to fill out a mindfulness diary: reflection of daily pleasant situation, instructing the participants to revisit the impressions of their 5 senses during this situation, in addition they should specify how long they have actually dealt with these pleasant impressions of the situation they reflected upon~instruction to do a gratitude exercise and name one or more things they are generally grateful for each day."
45600979|NCT05402150|Behavioral|Combination of Behavioral Activation and Mindfulness and Gratitude|This group will do a combination of the two intervention types.
45600980|NCT01003379|Drug|TC-5619|TC-5619-238 will be provided as hard gelatin capsules in strengths of 1mg, 5mg, and 25mg.
45600981|NCT01003379|Drug|Placebo|Placebo will be provided with exactly the same shape, size and appearance.
45600982|NCT05401916|Drug|Tramadol|Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
45600983|NCT05401916|Drug|Paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
45600984|NCT05401916|Drug|Ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
45600985|NCT01119833|Drug|GMI-1070|Intravenous GMI-1070 given twice a day during hospital stay for sickle cell pain crisis
45600986|NCT01119833|Drug|Placebo|Intravenous Placebo given twice a day during hospital stay for sickle cell pain crisis
45600987|NCT01113593|Drug|Formoterol Fumarate|Inhalation solution
45600988|NCT01113593|Drug|Formoterol Fumarate|Inhalation solution
45600989|NCT01113593|Drug|Formoterol Fumarate|Inhalation solution
45600990|NCT01113593|Drug|Foradil Aerolizer|Dry powder inhaler
45600991|NCT01113593|Drug|Foradil Aerolizer|Dry powder inhaler
45600992|NCT01001351|Drug|PRT-201|Applied topically during surgery.
45600993|NCT01001351|Drug|Placebo|Applied topically during surgery
45755336|NCT04764500|Other|examination of stool sample|Each participant provides stool samples before and after travelling, after 2, 4, 6, 8, 10, 12, 16, 20 and 52 weeks. Stool samples will be used for isolating both a) ESBL E. coli strains and b) pan-sensitive E. coli strains. Part of the stool sample is stored for isolation of further E. coli clones and microbiota analysis of the isolation of other microbiota strains. All found Enterobacteriaceae will be screened for additional resistance such as Carbapenem and Colistin. In case of a specific resistance, this will be confirmed with additional phenotypic and genotypic tests such as ROSCO disk and polymerase chain reaction (PCR) based panel and whole genome sequencing in order to detect specific resistance mechanisms and genes. Bacteria will be sequenced using Illumina and Nanopore based sequencing. Bioinformatic analysis will allow to determine the whole bacterial genome with containing resistance genes and also describe the microbiota diversity over time in single individuals.
45755337|NCT04764500|Other|patient questionnaire|Each participant will have to provide a questionnaire before and after travelling, as well after 2, 4, 6, 8, 10, 12, 16, 20 and 52 weeks.
45600994|NCT04137224|Biological|IgPro20|Human normal immunoglobulin for subcutaneous administration
45600995|NCT04137224|Biological|IgPro10|Human normal immunoglobulin for intravenous administration
45600996|NCT04137068|Behavioral|Reduced Activity|Participants reduce their activity level to <5,000 steps/day and <50 % of baseline steps.
45600997|NCT05401760|Procedure|Group A :combined phacoaspiration and angle surgery|"Partial thickness scleral flap to access the canal of schlemm.~2 side ports will be fashioned.~Trypan blue will be injected to aid visualization of the anterior capsule & continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~The nucleus and cortex will be aspirated.~Posterior capsulrehxis and limited anterior vitrectomy will be done.~Corneal incisions will be sutured with 10-0 Nylon suture.~Using metal trabeculotomes to open thetrabecular meshwork after accessing the canal of schlemm.~Suturing of scleral flap with 10-0 Nylon suture."
45755338|NCT04764500|Other|examination of blood sample|Each participant will have to provide a blood sample before and after travelling and after 6, 12 and 20 weeks. A serum sample (5mL) for antibody measurement and a 50 ml blood sample for recovery of peripheral blood mononuclear cells (PBMCs in 6 CPTs) for cell mediated immunity will be collected. Serum and PBMCs will allow the analysis of anti-E. coli humoral and cellular responses in order to characterize the individual immune response to specific bacteria over time. Single nucleotide polymorphisms associated with humoral and cellular immune responses will be characterized and linked to immunological and clinical phenotypes and endpoints of the study.
45755339|NCT00660517|Drug|MP29-02|azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray one spray per nostril twice a day
45755340|NCT00660517|Drug|azelastine Hcl|azelastine Hcl nasal spray one spray per nostril two times a day
45755341|NCT00660517|Drug|fluticasone propionate|fluticasone propionate 200 mcg nasal spray one spray per nostril two times a day
45444462|NCT03815877|Dietary Supplement|Nescafe Gold ® coffee|"Nescafe Gold ® coffee (5gm per 100cc water containing 170 mg of caffeine) will be used for all the women in the intervention group.~- patients will drink 100cc coffee with 1 tea spoon added sugar at 3, 6 and 9 hours after the surgery."
45444463|NCT03815877|Dietary Supplement|Nescafe Gold DECAF® coffee|"Nescafe Gold DECAF coffee (5 gm per 100cc water containing 5-10 mg of caffeine) will be used for all the women in the control group.~the control group will drink 100cc decaffeinated coffee with 1 tea spoon added sugar at 3, 6 and 9 hours after the surgery."
45600998|NCT05401760|Procedure|Group B : phacoaspiration only|"2 side ports will be fashioned.~Trypan blue will be injected to aid visualization of the anterior capsule & continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~The nucleus and cortex will be aspirated.~Posterior capsulrehxis and limited anterior vitrectomy will be done.~Corneal incisions will be sutured with 10-0 Nylon suture."
45600999|NCT05401682|Other|Cox chiropractic care|Manual distraction of spine in a prone position using specially assisted table
45601000|NCT05367752|Other|Myofascial release with TENS conductive glove|"Before each MR session, light massage and stretching was applied for five minutes as preparation for the manipulations. The massage included the effleurage technique followed by petrissage and kneading on the cervical and thoracic areas (on the upper three parts of the trapezius muscle, in the suboccipital area, and on the paraspinal cervical muscles). Stretching was applied to the following muscles: upper part of the trapezius, levator scapulae, and the sternocleidomastoid muscle.~Upper trapezius myofascial release, unilateral gross stretch, vertical gross stretch, focused stretch, cranial base myofascial release, gross release of the sternocleidomastoid muscle, and release of the suprahyoid and infrahyoid muscles."
45755342|NCT00660517|Drug|placebo|placebo nasal spray one spray per nostril two times a day
45755343|NCT04764032|Diagnostic Test|Echocardiography|Echocardiography will be undertaken by a range of appropriately competent practitioners including; intensive care clinicians, cardiologists and specialist echocardiographers. Imaging obtained will be in keeping with the protocol required for a Focused Intensive Care Echo (FICE) scan and should include ECG monitoring at all times. A focused dataset will be used to answer the primary outcome. If available and the echocardiographers competency and experience permit, further measures of RV function will be obtained at this time.
45755344|NCT02141581|Biological|Fluzone® (IM)|This vaccine is given intramuscularly (IM)
45755345|NCT02141581|Biological|Fluzone® Intradermal (ID)|This vaccine is given intradermally (ID)
45755346|NCT02141581|Biological|2011-2012 FluMist®|This vaccine is given intranasally
45755347|NCT03828344|Biological|hUC-MSC suspension|Patients will be treated at dose of 0.75×10^6 cells/kg of body weight (Cohort 1) or 1.5×10^6 cells/kg of body weight (Cohort 2) via a single IV infusion using a blood transfusion kit.
45755348|NCT03828344|Biological|Placebo|Placebo contains the same cell suspension as BX-U001 but without cells.
45755349|NCT04594226|Procedure|EA combined with medication|"Primary acupoints include Ashi points, Jiaji acupoints and Xi-cleft points. Jiaji points on the ipsilateral side will be selected according to the corresponding ganglia involved by HZ. Xi-cleft points will be selected based on the distribution regions of PHN. For pain sites that mainly distributed in the gallbladder meridian, GB36 will be selected. For pain sites that mainly distributed in the stomach meridian, ST34 will be selected. For pain sites that mainly distributed in the gallbladder meridian, BL63 will be selected. For pain sites that mainly distributed in the large intestine meridian, LI7 will be selected. Supplementary acupoints will be chosen based on TCM syndrome differentiation.~Operation: Two paired of acupoints are connected to the EA apparatus. EA parameter is selected as 2/100Hz wave. EA intensity is selected according to the patients' endurance. Needles will be retained and EA will last for 30 mins for each session."
45444464|NCT03277352|Drug|INCAGN01876|In Phase 1 subjects will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose and schedule according to cohort and treatment group enrollment. In Phase 2, subjects will be administered IV study drug at the recommended dose from Phase 1.
45444465|NCT03277352|Drug|Epacadostat|Epacadostat will be self-administered orally at the protocol-defined dose.
45755350|NCT04594226|Drug|Medication|The dosage of gabapentin starts from 100mg Tid. 100mg-300mg can be increased every 3-7 days and taken in three doses, but the total amount is not more than 1800mg/day. The dosage of gabapentin will be adjusted according to the patient's condition until his pain is effectively controlled. After maintaining the medication for two weeks, the dosage can be gradually reduced and 100mg can be reduced every 3-7 days.
45444466|NCT03277352|Drug|Pembrolizumab|Pembrolizumab will be administered IV at the protocol-defined dose.
45755351|NCT01568060|Other|Infanrix-IPV data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
45755352|NCT04747262|Behavioral|SPACE|SPACE program, an evidence-based protocol that has been proven to be efficent in childhood anxiety disorders and OCD (Lebowitz, 2013; Lebowitz, Omer, Hermes & Scahill, 2014)
45755353|NCT03826628|Drug|rapamycin|Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks
45755354|NCT03826628|Drug|placebo|Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks
45755355|NCT04747028|Diagnostic Test|Dmf score|A chart to calculate the caries index
45755356|NCT04090983|Behavioral|Cognitive-behavioral therapy (Hesslinger protocol)|Cognitive-behavioral therapy in a group format focusing on improving symptoms of ADHD, specifically by using skills in counteracting hyperactivity and impulsiveness, and promoting mindful awareness.
45755357|NCT04090983|Behavioral|Cognitive-behavioral therapy (CADDI protocol)|Cognitive-behavioral therapy in a group format focusing on improving inattentive symptoms of ADHD, specifically by using skills in organizing, executing, and completing activity, and promoting mindful awareness.
45755358|NCT03755570|Diagnostic Test|Repeatable Assessment of Neuropsychological Status|Cognitive Function Test (Questionnaire-based)
45755359|NCT03755570|Diagnostic Test|Hospital Anxiety and Depression Scale|Cognitive Function Test (Questionnaire-based)
45755360|NCT03755570|Diagnostic Test|Frontal Assessment Battery|Cognitive Function Test (Questionnaire-based)
45755361|NCT03755570|Diagnostic Test|Trail Making Test Part A and B|Cognitive Function Test (Questionnaire-based)
45755362|NCT03755570|Diagnostic Test|Test of Premorbid Functioning|Cognitive Function Test (Questionnaire-based)
45755363|NCT03029949|Behavioral|ACT with VR|6 weekly 120-minute group sessions of acceptance and commitment therapy with vestibular rehabilitation, and brief (approximately 15 minute) individual follow-up sessions at 1 and 3 months after the group treatment
45755364|NCT03029949|Behavioral|self-treatment VR|booklet written on vestibular rehabilitation for self-treatment
45755365|NCT03029949|Other|clinical management|clinical management and pharmacotherapy as usual for chronic dizziness
45755366|NCT03885518|Other|Playground Stencils|The stencils (hopscotch, agility trail, foursquare, bullseye, etc.) will be painted on the playgrounds at each childcare center. A toolkit and training video will be distributed to staff at each center to aid in instructing the children on how to perform the tasks.
45755367|NCT04055961|Device|Atrial Fibrillation Ablation|A procedure used to treat an irregular heart rhythm (arrhythmia)
45755368|NCT03991299|Drug|Botox 200 UNT Injection|Botox will be injected into duodenums of subjects by endoscopy.
45444467|NCT01302093|Drug|Racecadotril Film-Coated Tablet (FCT)|A single 100 mg dose of an experimental Racecadotril FCT administered orally with 240 ml of water, with a 7- day washout between visits
45444468|NCT01302093|Drug|Racecadotril Capsule|A single 100 mg dose of a marketed Racecadotril capsule administered orally with 240 ml of water, with a 7-day washout between visits
45444469|NCT03803865|Behavioral|Mindfulness Training|Guided mindfulness meditation and stress management training
45444470|NCT03803865|Behavioral|Reflection and Problem Solving|Guided reflection,problem solving,and analytical thinking training
45444471|NCT03803709|Dietary Supplement|inulin|inulin given at different dosis from day 3 to day 20
45755369|NCT03885362|Device|Dexcom G6 and Abbott Freestyle Libre|Dexcom G6 - continuous glucose monitoring device - blinded. CE mark 2018 Abbott Freestyle Libre - flash glucose monitoring device. CE mark 2014
45601001|NCT05367752|Other|Myofascial release without TENS conductive glove|"Before each MR session, light massage and stretching was applied for five minutes as preparation for the manipulations. The massage included the effleurage technique followed by petrissage and kneading on the cervical and thoracic areas (on the upper three parts of the trapezius muscle, in the suboccipital area, and on the paraspinal cervical muscles). Stretching was applied to the following muscles: upper part of the trapezius, levator scapulae, and the sternocleidomastoid muscle.~Upper trapezius myofascial release, unilateral gross stretch, vertical gross stretch, focused stretch, cranial base myofascial release, gross release of the sternocleidomastoid muscle, and release of the suprahyoid and infrahyoid muscles."
45755370|NCT03751436|Drug|Enzalutamide|Given PO
45755371|NCT03751436|Drug|Venetoclax|Given PO
45601002|NCT05367752|Other|Conventional TENS|Two 40*50mm silicone electrodes were placed with the negative electrode on the trigger point of the trapezius muscle and the positive one on the acromion. The current frequency was 120Hz and pulse duration 80ms for 30 minutes. This protocol has been proposed by Ebadi et al. (2021)
45601003|NCT05367752|Other|Sham TENS|Two 40*50mm silicone electrodes were placed with the negative electrode on the trigger point of the trapezius muscle and the positive one on the acromion. The current frequency was 120Hz and pulse duration 80ms for 30 minutes. This protocol has been proposed by Ebadi et al. (2021)
45755372|NCT03819530|Dietary Supplement|Vitamin and Mineral Powder|Vitamin and mineral nutritional supplement. Each packet is 1g of powder, to be taken with food.
45601004|NCT05401214|Drug|Niraparib plus Abiraterone Acetate (Nira/AA) combination|Nira 100 milligrams (mg)/AA 500 mg combination will be administered orally as immediate-release film coated tablets.
45601005|NCT05401214|Drug|Prednisone/Prednisolone|Prednisone/Prednisolone 10 mg will be administered orally.
45601006|NCT02532374|Other|Nicorette® inhalator|Subjects will inhale the Nicorette® inhalator (15 mg) at the rate of one deep inhalation every 15 seconds on average, over approximately 20 minutes (80 inhalations in total).
45601007|NCT02532374|Other|P3L|Subjects will inhale P3L (50 µg/puff, 80 µg/puff and 150 µg/puff) at the rate of one inhalation every 30 seconds on average, over approximately 6 minutes (i.e., 12 inhalations in total).
45601008|NCT05399186|Other|Early preoperative assessment and optimization|The interventional group received early preoperative assessment and optimization (6-12 months) prior to total joint arthroplastic surgery in cooperation between hospital and primary care
45601009|NCT05418296|Device|A novel digital health device|A videogame-generated virtual world designed for the AD/ADRD care dyad.
45601010|NCT01745588|Drug|Pomalidomide|
45601011|NCT01745588|Procedure|stem cell|
45601012|NCT01745588|Drug|Dexamethasone|
45755373|NCT02279667|Drug|BIA 2-093|oral suspension 50 mg/mL
45755374|NCT02279667|Drug|BIA 2-093|200 mg tablet
45755375|NCT02279667|Drug|BIA 2-093|800 mg tablet
45755376|NCT03750968|Drug|Carotenoid Group|Softgel active ingredients: Lutein 10 mg and Zeaxanthin 2 mg in safflower oil
45755377|NCT03750968|Dietary Supplement|Control Group|Placebo ingredients: Safflower oil
45755378|NCT03833271|Biological|Influenza vaccine, Immune function|Comparing immune function and seroconversion after immunizing healthy children and juvenile idiopathic arthritis (JIA) children treated with different type of medication with influenza vaccine.
45755379|NCT03818672|Drug|Rifaximin|Rifaximin 550 MG BID
45755380|NCT03749564|Behavioral|SMT|"The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort."
45755381|NCT03749564|Behavioral|Activation Exercises|Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
45755382|NCT03749564|Behavioral|Mobilizing Exercises|Mobilizing exercises include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
45755383|NCT03749564|Behavioral|Extended SMT|Additional 6 SMT sessions provided
45444472|NCT03803709|Dietary Supplement|placebo|maltodextrine given at different dosis from day 3 to day 20
45601013|NCT01745588|Drug|Clarithromycin|
45601014|NCT05367128|Other|Dual task training|All participants will receive cognitive dual task training for 30 min/session, 2-3 sessions/week for 4-6 weeks (a total of 12 sessions). The cognitive dual task training includes 15 min of cognitive task combining with standing task and 15 min of cognitive task combining with walking task. The differences among group are the instructions of task prioritization given by the therapist
45601015|NCT05366738|Drug|Vonoprazan|Orally via tablet
45601016|NCT05366738|Drug|Vonoprazan|Orally via sprinkle pellets
45601017|NCT05399108|Procedure|Ultrasound Guided Lateral Approach Catheterization of Jugular Internal Vein|The jugular internal vein is displayed on its short axis. On the image are displayed the trapezius muscle and layers of skin. Just above the trapezius muscle using the in-plane technique is done puncture of the vein. By Seldinger's technique, catheterization is done. The whole procedure is done according to the newest international recommendations for central vein catheterization.
45755384|NCT03155373|Diagnostic Test|Cardiac catheterisation|Pre-operative left heart catheterisation +/- right heart catheterisation
45755385|NCT03155373|Diagnostic Test|Cardiopulmonary exercise testing|Pre and post-operative cardiopulmonary exercise testing
45755386|NCT03155373|Diagnostic Test|Pulmonary function tests|Pre and post-operative pulmonary function tests
45601018|NCT05399108|Procedure|Ultrasound Guided Conventional Approach Catheterization of Jugular Internal Vein|The jugular internal vein is displayed on its short axis. The cannulation is done by the conventional approach (middle approach - the most frequently used).
45601019|NCT05364788|Other|Retrospective tissue sample analysis|Acquisition of archival Formalin Fixed Paraffin Embedded (FFPE) human tissue from appendix cancer primary tumour and peritoneal metastases, which are stored in NHS pathology - taken from standard care biopsies.
45601020|NCT05399030|Drug|ICP-332|ICP-332 will be administered as tablet
45601021|NCT05399030|Other|Placebo|Matching placebo will be administered as tablet
45601022|NCT05417828|Device|Emulation of Active Daily Living tasks with a robotic device (SPINDLE)|SPINDLE will provide an assistive and resistive force to aid in rehabilitating the subject's upper limb
45755387|NCT03155373|Diagnostic Test|Cardiac MRI|Pre and post-operative cardiac MRI
45755388|NCT03155373|Other|Quality of life survey|Pre and post-operative quality of life survey (SF36)
45755389|NCT03155373|Procedure|Mitral valve operation|Clinically indicated mitral valve repair/replacement +/- coronary artery surgery +/- tricuspid valve surgery +/- atrial fibrillation surgery
45601023|NCT05398874|Combination Product|Ginkgo biloba extract + standard treatment( paracetamol+Diclofenac100mg SR)|120 mg leaf extract , twice daily in addition to Diclofenac 100 mg Once daily + paracetamol 1g Twice daily
45755390|NCT03155373|Procedure|Myocardial biopsies|Right and left epicardial ventricular biopsies taken at time of clinically indicated surgery
45755391|NCT03878342|Radiation|Radiotherapy|two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines
45601024|NCT05398874|Combination Product|placebo in addition to the standard treatment|placebo in addition to the standard treatment
45601025|NCT01281176|Drug|Carboplatin|Given IV
45601026|NCT01281176|Other|Laboratory Biomarker Analysis|Correlative studies
45601027|NCT01281176|Drug|Paclitaxel|Given IV
45601028|NCT01281176|Other|Pharmacological Study|Correlative studies
45601029|NCT01281176|Drug|Vorinostat|Given PO
45601030|NCT05417516|Radiation|Whole Breast Irradiation (WBI)|The dose fractionation and prescription is 26Gy in 5 fractions to the PTV once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
45601031|NCT05417516|Radiation|Partial Breast Irradiation (PBI)|The dose fractionation and prescription is 26Gy in 5 fractions to the PTV prescribed at the isocentre of the treatment fields treated once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
45755392|NCT03878342|Other|No Radiotherapy|No Irradiation- Active surveillance
45755393|NCT03985449|Other|Uterine Fibroid Option Grid encounter patient decision aid (text only)|The uterine fibroid Option Grid patient decision aid facilitates choice awareness and deliberation about treatment options when clinicians and patients discuss the management of uterine fibroids. The content is organized in a tabular format and is based on patients' frequently asked questions.
45601032|NCT02525744|Drug|LY900014|Administered SC
45601033|NCT02525744|Drug|Insulin Lispro (Humalog)|Administered SC
45755394|NCT03985449|Other|Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures)|The Picture Option Grid uses the same evidence as the text version while integrating images and simpler text, thus utilizing pictorial superiority to help patients better understand and remember information more easily compared to just using words.
45755395|NCT03985449|Other|Uterine Fibroid Option Grid encounter patient decision aid (online)|Clinicians can click a link in the electronic health record that will lead them to the EBSCO Health website where they can click the treatment options relevant to the patient and generate a decision aid.
45755396|NCT03984903|Other|Multimedia Learning of Exercises|Patients learn exercise from multimedia content.
45755397|NCT03984903|Other|Face-to-face Learning of Exercises|Physiotherapist teach exercises to patients
45601034|NCT05417360|Dietary Supplement|Akkermansia muciniphila|"During the weight management period (weeks 8 to 32), the pasteurized A. muciniphila product will be orally consumed in water at least 15 min before breakfast for a period of 6 months (24 weeks) capsules. It appears as a white homogenous powder.~."
45601035|NCT05417360|Dietary Supplement|Placebo|During the weight management period (weeks 8 to 32), the placebo product will be orally consumed in water at least 15 min before breakfast for a period of 6 months (24 weeks). It appears as a white homogenous powder.
45601036|NCT05417204|Behavioral|Abdominothoracic biofeedback|A standard biofeedback technique (3 sessions over a 4-week period) directed at controlling the muscular activity (postural tone) of the abdominal walls, will serve as active intervention in the experimental group, and as a sham intervention in the active comparator group.
45755398|NCT03984903|Other|Manual Therapy|Myofascial Release Techniques and Joint Mobilizations to the Lumbal Area
45755399|NCT03984903|Other|Home Exercise Program|Patients do at least 20 minutes motor control exercise in a day at home.
45755400|NCT03749018|Drug|Cyclophosphamide|Given IV
45755401|NCT03749018|Drug|Doxorubicin Hydrochloride|Given IV
45755402|NCT03749018|Drug|Etoposide|Given IV
45755403|NCT03749018|Biological|Nivolumab|Given IV
45755404|NCT03749018|Drug|Prednisone|Given PO
45755405|NCT03749018|Biological|Rituximab|Given IV
45755406|NCT03749018|Drug|Vincristine Sulfate|Give IV
45755407|NCT03111147|Device|0 degrees humeral component version|RTSA with humeral component positioned in 0 degrees of version
45601037|NCT05361902|Radiation|Adaptive radiotherapy according to UPRATE protocol|According to previously reported STAMPEDE trial (Parker et al.), patients will be treated with 6 weekly fractions of 6 Gy. According to local protocol the target will consist of prostate and entire seminal vesicles. Additional CT-scans will be made prior to and directly following each fraction. For more details, see study description
45934898|NCT00041327|Drug|doxorubicin hydrochloride|10 mg/m2/day as a continuous 96-hour infusion days 1-4
45601038|NCT05396066|Diagnostic Test|Muscle evaluation|Repeated maximal voluntary contraction
45601039|NCT05361746|Device|Scotchbond Universal Plus Adhesive|Eligible teeth with Class-V NCCLs randomized to the SBU+ treatment group will undergo restoration(s) using Scotchbond Universal Plus (SBU+) Adhesive using total-etch mode and Filtek Universal Restorative material.
45601040|NCT05361746|Device|Scotchbond Universal Adhesive|Eligible teeth with Class-V NCCLs randomized to the SBU Control group will undergo restoration(s) using Scotchbond Universal Plus (SBU) Adhesive using total-etch mode and Filtek Universal Restorative material.
45601041|NCT05360810|Device|Wei Nasal Jet Tube|"comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures~airway devices which can use for gastrointestinal procedures"
45601042|NCT05360810|Device|Gastro Laryngeal Tube|comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures
45601043|NCT05360732|Drug|FOLFIRINOX|Alternating FOLFOX and FOLFIRI administered via intravenous infusion. FOLFOX: Oxaliplatin 85 mg/m2 on Day 1; Leucovorin 400 mg/m2 on day 1; 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours. FOLFIRI: Irinotecan 180 mg/m2 on day 1, leucovorin 400 mg/m2, 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours
45601044|NCT00152477|Drug|Carboplatin|"10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle.~Each cycle to be repeated every three weeks for a maximum of six cycles."
45601045|NCT00152477|Drug|Paclitaxel|6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.
45601046|NCT00152477|Drug|CDP791 10mg/kg|CDP791 20mg/mL vial CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
45601047|NCT00152477|Drug|CDP791 20mg/kg|CDP791 20mg/kg CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
45601048|NCT01112423|Drug|BMS-823778|Capsules, Oral, 2 mg, once daily, 28 days
45601049|NCT01112423|Drug|BMS-823778|Capsules, Oral, 10 mg, once daily, 28 days
45601050|NCT01112423|Drug|BMS-823778|Capsules, Oral, 20 mg, once daily, 28 days
45601051|NCT01112423|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
45601052|NCT05558891|Behavioral|THRIVE|Toward Hope, Recovery, Interpersonal Relationships, Values and Engagement (THRIVE), is a brief, suicide-specific, narrative, recovery-focused, 60 minute intervention. THRIVE includes three components: 1) Sharing the suicide narrative; 2) Completing the Lifeline and Meaning Reconstruction; 3) Completing the Meaningful Living Plan (MLP).
45755408|NCT03111147|Device|30 degrees humeral component retroversion|RTSA with humeral component positioned in 30 degrees of retroversion
45601053|NCT05558891|Behavioral|Usual Care|Care as Usual in this Crisis Stabilization Unit includes medication management, medication management, safety planning Intervention, group psychoeducation, discharge planning, and community linkages
45601054|NCT01111955|Drug|BMS-823778|Capsules, Oral, 2 mg, once daily, 28 days
45601055|NCT01111955|Drug|BMS-823778|Capsules, Oral, 10 mg, once daily, 28 days
45601056|NCT01111955|Drug|BMS-823778|Capsules, Oral, 20 mg, once daily, 28 days
45601057|NCT01111955|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
45601058|NCT01111955|Drug|Metformin|Capsules, Oral, ≥ 1500 mg, once daily, 28 days
45601059|NCT02525588|Device|Triathlon CS fixed bearing total knee prosthesis|The patient will receive either the N2Vac polyethylene inlay or the X3 polyethylene inlay for their CS total knee.
45601060|NCT01106807|Drug|Epiduo vehicle gel|500 microliters of Epiduo vehicle gel on one half-face twice daily for six weeks
45601061|NCT01106807|Drug|CD07223|500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks
45601062|NCT01106807|Drug|CD07223|500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks
45601063|NCT01106807|Drug|Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel|500 microliters Epiduo Gel on one of the half-face for the morning dose
45601064|NCT04256174|Drug|AK120 or placebo- Part 1- Cohort 1|Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects
45601065|NCT04256174|Drug|AK120 or placebo- Part 1- Cohort 2|Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects
45601066|NCT04256174|Drug|AK120 or placebo- Part 1- Cohort 3|Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects
45601067|NCT04256174|Drug|AK120 or placebo- Part 1- Cohort 4|Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects
45601068|NCT04256174|Drug|AK120 or placebo- Part 1- Cohort 5|Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects
45601069|NCT04256174|Drug|AK120 or placebo- Part 2- Cohort 1|Multiple low doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
45601070|NCT04256174|Drug|AK120 or placebo- Part 2- Cohort 2|Multiple medium doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
45601071|NCT04256174|Drug|AK120 or placebo- Part 2- Cohort 3|Multiple high doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
45755409|NCT03952065|Drug|PD1/PDL1 inhibitor|Infusion of PD1/PDL1 inhibitor through peripheral vein or neck artery.
45755410|NCT03815396|Drug|INBRX-101/rhAAT-Fc|INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein (rhAAT-Fc).
45755411|NCT01931163|Drug|Everolimus|
45755412|NCT04763642|Procedure|pancreaticoduodenectomy|Robotic Whipple operation Open Whipple operation Laparoscopic Whipple operation
45755413|NCT04763486|Drug|Cefazolin (Cefamezin)|Cefamezin 2 gr within 6 hour of delivery
45601072|NCT04256174|Drug|AK120 or placebo- Part 2- Cohort 4|Multiple high doses of AK120 or placebo are administered subcutaneously as a bi-weekly dose for a total of three doses to subjects with moderate-to-severe atopic dermatitis.
45601073|NCT05533229|Drug|Fentanyl|The trial aims to study the quality of anesthesia and analgesia provided by fentanyl and bupivacaine versus morphine and bupivacaine
45601074|NCT05533229|Drug|Morphine|The trial aims to study the quality of anesthesia and analgesia provided by fentanyl and bupivacaine versus morphine and bupivacaine
45601075|NCT00153179|Drug|acipimox|subjects will receive acipimox 250 mg orally every 6 hours (or matching placebo) for 7 days, including a dose at 6am on the morning of the study testing visit
45601076|NCT00153179|Drug|placebo|matching placebo
45601077|NCT05358158|Procedure|Intraoperative air leak test|A standard 28 Fr chest drain is inserted through the anterior port hole with all port holes closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
45601078|NCT05358158|Procedure|Intraoperative chest drain removal|Chest drain is removed intraoperatively.
45601079|NCT05358158|Procedure|Standard chest drain placement|Chest drain is left in pleura.
45601080|NCT05627531|Behavioral|Narrative Medicine|Intervention group completes pre- and post-intervention measures, composition book and guided reading, discussion, and writing with narrative medicine coordinator.
45601081|NCT05357144|Behavioral|Loyalty card program at drug shops & supply of HIVST and SRH products|"Consenting drug shops will receive:~training on Malkia Klabu implementation;~HIVST training (same as comparison drug shops);~procedures for referring to youth-friendly HIV/SRH services;~a monthly supply of HIVST reserved for free distribution to AGYW, with free price stickers and pre-packaged with referral information; and~reimbursement for SRH products given to AGYW (e.g., birth control pills)."
45601082|NCT05357144|Behavioral|Comparison drug shops|Consenting drug shops in the comparison arm catchment areas will have access to the Maisha Meds inventory management application system for offline digital recording of HIVST, HIVST kits earmarked for free to AGYW, guidance on HIV care referral plan to facilitate linkage to nearby health facilities for AGYW. These control drug shops will not participate in Malkia Klabu (Queen Club) program implementation.
45601083|NCT05532839|Other|High intensity interval training|The therapy lasted 6 weeks, and HIIT comprised of two 12-24 × 30 second high-intensity runs separated by thirty seconds of relaxation.
45601084|NCT05532839|Other|Moderate intensity continuous training|The MICT ran continuously for 24-48 minutes. From the day of the six weeks intervention strategies, the mentioned assays were conducted: Yo-Yo Intermittent Recovery Test level 1, repeated sprint ability , sprint test, alter of way test which is t drill, and physical activity enjoyment scale and shuttle run. Through these trainings, individuals in both groups must follow the old their balanced meal.
45601085|NCT02531594|Behavioral|SBIRT|"The Social Worker will provide caregivers with the brief (10-15 minute) Advise, Assess, Assist intervention based on the Clinical Practice Guidelines, and tailored on levels of motivation to quit and tobacco dependence. Patients in this group will receive Nicotine Replacement Therapy vouchers, immediate connection to cessation resources, and intervention materials."
45601086|NCT02531594|Behavioral|HHC|"The Social Worker will provide caregivers with the brief (10-15 minute) Lets Go! 5-2-1-0 intervention which is a child obesity prevention program. Patients in this group will receive motivational interviewing in regards to helping children and families eat healthy and be active. This group will receive water bottle vouchers, immediate connection to 5-2-1-0 resources, and intervention materials."
45755414|NCT02988063|Drug|Polidocanol Endovenous Microfoam (PEM)|Polidocanol endovenous microfoam (PEM) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee. PEM improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
45601087|NCT02743949|Drug|Vonoprazan|Vonoprazan over-encapsulated capsules
45601088|NCT02743949|Drug|Esomeprazole|Esomeprazole over-encapsulated tablets
45601089|NCT02743949|Drug|Esomeprazole Placebo|Esomeprazole placebo-matching capsules
45601090|NCT05627297|Other|CEUS and CEMRI|contrast-enhanced ultrasound and contrast-enhanced MRI examination
45601091|NCT05627141|Other|Photobiomodulation; Cryotherapy, Massage|"Photobiomodulation: the 20 participants will receive active photobiomodulation or sham immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session. Cryotherapy combined with compression: the 20 participants will receive effective cryotherapy (10-12°C for 20 min) combined with high compression, or sham (25°C for 20 min) combined with light compression, on the lower limbs, immediately after the protocol. induction of muscle damage and fatigue. Effective cryotherapy or sham will be applied in a randomized and crossover manner, with an interval of 15 days between each evaluation session.~Massage: the 20 participants will receive the effective massage or sham immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session."
45601092|NCT02531438|Drug|Omadacycline|Injection for IV; Oral tablets
45601093|NCT02531438|Drug|Moxifloxacin|IV solution; Oral tablets
45601094|NCT02289898|Drug|Demcizumab|administered intravenously
45804194|NCT05620771|Drug|Atezolizumab and Bevacizumab|Patients will receive atezolizumab + Bevacizumab for 21 days after standard of care therapy is complete.
45934899|NCT00041327|Drug|lamivudine|150 mg bid
45444473|NCT01303575|Behavioral|HIV, STI and Pregnancy Prevention Curriculum|"A complete internet-based, It's Your Game...Keep It Real Intervention Program"
45601095|NCT02289898|Drug|Abraxane®|administered intravenously
45601096|NCT02289898|Drug|gemcitabine|administered intravenously
45601097|NCT02289898|Drug|Placebo|
45601098|NCT01660412|Drug|Standard of Care First|For the second injection, and randomly after that, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to ~7.40.
45804195|NCT05620771|Drug|Y90 + TKI|Patients will receive TKI for 21 days after standard of care therapy is complete.
45804196|NCT05716880|Drug|Ketosteril|Daily dose = 1 tabl / 5 kg of ideal body weight
45934900|NCT00041327|Drug|prednisone|60 mg/m2 given orally days 1-5
46066522|NCT00572169|Drug|Thalidomide|Capsule taken by mouth
45755415|NCT03746600|Behavioral|Project TRAC: Tracking and Reducing Alcohol Consumption|The TRAC intervention for people living with HIV/AIDS focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. It requires eight 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the eight sessions of intervention content, participants will complete smart phone-based self-monitoring of medication adherence and alcohol consumption, which will be discussed during intervention sessions.
45601099|NCT01660412|Drug|ph Altered first|For the first injection, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to ~7.40. For the second injection, the standard of care will be given, and randomly after that either standard of care, or pH altered will be given.
45601100|NCT04255628|Diagnostic Test|FDG PET|Cancer patients who scheduled whole body FDG-PET image scan for clinically indicated.
45601101|NCT01659554|Drug|Cisplatin|Cisplatin (75 mg/m2) prepared in 2L normal saline.
45601102|NCT01659554|Drug|Doxorubicin|Doxorubicin (25 mg flat dose) prepared in 500 ml dialysis fluid (glucose or icodextrin-based).
45601103|NCT05355350|Drug|Piperacillin / Tazobactam Injection|4.5 grams QID
45601104|NCT05355350|Drug|Meropenem|1 gram TID
45601105|NCT05415020|Behavioral|Lifestyle Behavior Protocol|Virtual training on building a skillset to improve lifestyle behavior that reduces migraine attacks
45601106|NCT05415020|Behavioral|Sham Behavior Protocol|Virtual training on the disease of migraine and how migraine can progress to chronic migraine.
45601107|NCT05355116|Device|Physiolab S1|A cryocompression device capable of circulating ice-water through a cuff at 6-12℃ with either a static pressure of 25mmHg or dynamic pressure of 25-50 mmHg or 25-75mmHg. The lowest temperature setting, and highest pressure setting will be used for this study.
45601108|NCT05355116|Device|Breg Vpulse|A cryocompression device capable of circulating ice-water through a cuff at no lower than 5.5℃ with a dynamic peak pressure of 50 mmHg. The temperature of the ice-water, and the applied pressure, is not modifiable by the user.
45444474|NCT01303575|Behavioral|Control Curricula|A computer-based, science education program that does not contain elements of sexual health education
45444475|NCT04975737|Biological|GamTBvac|The subunit recombinant tuberculosis vaccine GamTBvac (lyophilisate for preparation of solution for subcutaneous administration, 5.35 mg / dose)
45601109|NCT05355116|Device|Aircast Cryo/Cuff|A cryocompression device capable of circulating ice-water through a cuff at an undefined, non-modifiable temperature with a static pressure that is also undefined and non-modifiable. The device will be applied as per the manufacturer's instructions, which will represent its maximum capability.
45601110|NCT05355116|Device|GameReady|A cryocompression device capable of circulating ice-water through a cuff at 1-12℃ with a dynamic pressure of 5-15 mmHg, 5-50 mmHg, or 5-75 mmHg. The lowest temperature setting, and highest pressure setting will be used for this study.
45444476|NCT04975737|Biological|Placebo|Placebo for subcutaneous administration
45601111|NCT05355116|Device|Physiolab Gel Therapy Wrap|A cryocompression cuff that applies an undefined, non-modifiable temperature with a static pressure that is also undefined and non-modifiable. The device will be applied as per the manufacturer's instructions, which will represent its maximum capability.
45601112|NCT04255082|Other|assess the impact of mindfulness-based interventions on inpatients' and outpatients' stress, patient-provider communication, and other measures of SDM at MDMC.|"Effectiveness of the mindfulness-based intervention which will be assessed by:~Baseline and post-intervention perception of stress and anxiety Impact of stress on communication Emotional/Brain state Level of SDM during a pivotal visit with provider e.g. treatment planning visit (for outpatients only) The Emotional Distress-Anxiety (PROMIS, 2016), Communication Short Form (Cella, PROMIS, 2013), Emotional/Brain State Question (Mellin, 2017) and The Shared Decision Making dyadic OPTION scale (Melbourne, 2016) will be used to evaluate these outcomes.~Feasibility of such a study in the patient population and setting. This will be measured by the barriers encountered and the ability to successfully carry out the study."
45601113|NCT01054196|Drug|lenalidomide|daily dose dependent on dose-escalation schedule
45601114|NCT01054196|Drug|melphalan|100 mg/m2 given Days -2 and -1
45601115|NCT01659320|Drug|Minocycline|Minocycline 100 mg twice daily for 8 weeks
45755416|NCT03815006|Device|Free Style Libre 2|FreeStyle Libre 2 (FSL2) is a novel glucose monitoring device (Flash glucose monitoring) in the form of a disc worn on the arm for 14 days and a hand-held reader which is designed to largely replace the recommended 4-10 painful finger-stick blood glucose tests required each day for the self-management of type 1 diabetes (T1D).
45755417|NCT03877406|Drug|Empagliflozin 10 MG|addition of empagliflozin 10 MG
45444477|NCT01303653|Procedure|endoscopic closure of gastrointestinal fistulas and perforations|novel endoscopic tissue closure devices will be used for endoscopic closure of gastrointestinal fistulas or perforations
45444478|NCT03812913|Behavioral|psychological evaluation|"Neuropsychological and experimental tasks will assess cognitive and socio-cognitive functions.~Questionnaires will assess psychoaffective aspects (depression, anxiety, self-esteem), and social and behavioral functioning."
45444479|NCT03815955|Behavioral|Non-Sedentary Behaviour Modelling|Consistent with social learning theory, the primary care provider and the DIGMA support team will model, demonstrate, and verbalize aspects of increased confidence to perform the 1-hour appointment in a standing position and offer a variety of strategies to cope and overcome any feelings of discomfort. Emphasis will be placed on the strategies the primary care team uses to break sitting with standing and light, incidental movements. It will be anticipated that the participant will observe cues and relevant information specific to their behaviour change and engage in minimal sedentary behaviour.
45444480|NCT01301703|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)|a single 0.5-mL intramuscular injection into the deltoid muscle of the upper arm
45444481|NCT02814838|Drug|Ladarixin|Ladarixin oral capsule
45444482|NCT02814838|Drug|Placebo|Placebo oral capsule
45444483|NCT03803007|Drug|Intravenous ACT017 1000 mg|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
45444484|NCT03803007|Other|Intravenous Placebo|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
45444485|NCT03812757|Diagnostic Test|Supraclavicular fossa US scanning|As previously stated.
45444486|NCT03802149|Drug|Ulipristal Acetate|90mg Ulipristal Acetate 18-24-hours prior to dilation and evacuation
45601116|NCT05414084|Dietary Supplement|Oral (poly)phenol challenge test (OPCT)|Nutritional challenge with standardized (poly)phenol-rich tablets
45755418|NCT03877406|Drug|Hypoglycemics Oral|dose escalation of hypoglycemics oral
45601117|NCT05392712|Device|Magnetometer|inspection equipment for magnetocardiography
45444487|NCT02036632|Device|Eye Patching|
45601118|NCT05413148|Biological|Subtenon injection of Wharton jelly derived mesenchymal stem cells|Single subtenon's injection for single eye
45601119|NCT05413148|Biological|Subtenon injection of Wharton jelly derived mesenchymal stem cell exosomes|Single subtenon's injection for single eye
45601120|NCT05413148|Other|Placebo|Single Subtenon injection of saline for a single eye
45601121|NCT05412992|Drug|DMTS Patch|DMTS applied before surgery and worn for 96 hours
45601122|NCT05412992|Drug|Placebo Patch|Matching patches that have no active drug applied before surgery and worn for 96 hours
45601123|NCT05392322|Other|Self-help skills|Self-help skills were given to down's syndrome children 3 times per week upto 15 minutes.
45601124|NCT05392322|Device|Virtual video reality gaming|Virtual video reality gaming was given to children with down's Syndrome 3 time per week upto 15 minutes.
45755419|NCT03746054|Combination Product|Optimal medical treatment|Life style modifications, Monitoring of the risk factors and Optimal medical treatment Lipid-lowering treatment, anti-platelet treatment and ACEi or AT2 antagonists treatment for a total duration of 24 months
45755420|NCT03746054|Combination Product|usual clinical practice|usual clinical practice in each center
45601125|NCT00821132|Other|Genetic study of ALS families|Collection and analysis of genetic material, medical and family histories from families with ALS
45601126|NCT01660334|Drug|Voriconazole|"Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
45601127|NCT05352932|Diagnostic Test|pancreatic duct biopsy|"Enrolled patients will undergo a baseline assessment, including CP history, clinical symptoms, imaging tests, laboratory tests, etc.~Then, according to the clinical standard of diagnosis and treatment of chronic pancreatitis, ERCP (with or without Extracorporeal Shock Wave Lithotripsy (ESWL) / endoscopic lithotripsy) will be performed for patients with calculi; pancreatic stent or nasopancreatic stent will be placed for patients with pancreatic duct stenosis. During ERCP, the patient's pancreatic tissue will be biopsied and sent for pathological examination."
45601128|NCT05006378|Dietary Supplement|Chamomile Tea|Chamomile tea bags consumed by subjects as described in study arms section.
45601129|NCT05006378|Dietary Supplement|Chamomile Extract Capsule|"Chamomile extract capsules consumed by subjects as described in Experimental: Chamomile Extract Capsule study arms section."
45601130|NCT05006378|Dietary Supplement|Placebo Capsule|"Placebo capsules consumed by subjects as described in Placebo Comparator study arms section."
45601131|NCT04973072|Behavioral|One large reward treatment|Participants will be awarded S$300 for reaching the PBF goal at the end of 12 weeks.
45755421|NCT03874754|Other|Tailored Technology-Enhance Home-based exercise program (iHBE)|The tailored technology enhanced home-based exercise (iHBE) program is a 12-week program with 1 assessment home visit session, 5 home visits and 7 phone follow ups during exercise. The technologies, a wearable device, and a smartphone application, will be used as a tool to monitor physical performance (heart rate [HR], step count), provide immediate feedback, send daily reminding message through Mobile Ecological Momentary Assessment (mEMA). The coded raw data without personal identification information from the wearable device will be sent to the servers where the investigators can store it in the database alongside the mEMA data and create custom reports showing Heart Rate (HR) 30 minute before each Ecological Momentary Assessment (EMA) survey, showing HR and previous self-report responses before/ after each automatically triggered EMA.
45755422|NCT03025269|Drug|Ocrelizumab|This is not a drug intervention study, we are doing an observational study with those who have been prescribed Ocrelizumab by their neurologists during clinical routine appointments
45755423|NCT03029871|Biological|Ad5-yCD/mutTKSR39rep-ADP Adenovirus|oncolytic adenovirus
45755424|NCT03744026|Device|SonoCloud-9|Escalating numbers of ultrasound beams at constant acoustic pressure
45755425|NCT03744026|Drug|Carboplatin|Dose of carboplatin infusion is AUC4-6
45755426|NCT03872258|Behavioral|Control|Counseling on physical activity
45755427|NCT03872258|Behavioral|Intervention group|Program of combined exercise and a Smartband for 6 months.
45755428|NCT03806114|Procedure|Posterior Approach Precautions|These patients will be advised not to bend their leg or trunk more than 90 degrees, avoid crossing the leg or crossing midline, and rotating the leg inwards. Patients will also be instructed to put a pillow in between their legs while sleeping for 6 weeks and to avoid bathing for 6 weeks.
45755429|NCT03806114|Procedure|Anterior Approach Precautions|These patients will be advised to avoid extending the leg back, rotating the leg outwards, and lifting their bottom when lying down after their surgery for 6 weeks.
45804197|NCT05716880|Other|Medium Protein Diet (MPD)|MPD: daily protein intake of 0.8-1.0 g/kg of ideal body weight + up to 5 g based on daily proteinuria
45934901|NCT00041327|Drug|vincristine sulfate|0.4 mg/m2/day as a 96-hour continuous infusion days 1-4
45934902|NCT00041327|Drug|zidovudine|300 mg bid
45444488|NCT03815565|Procedure|continuous femoral block|infusion of anesthetic by PCA pump
45444489|NCT02047552|Drug|Iron sucrose|Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT < 25%, (2) Serum iron concentration < 150 ug/mL, and (3) Serum ferritin concentration < 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.
45444490|NCT02047552|Drug|Oxandrolone|10 mg PO Q12 hours for seven days
45444491|NCT02047552|Drug|IV iron placebo|100 mL normal saline
45601132|NCT04973072|Behavioral|Small wins treatment|The cash rewards that participants will receive are capped by $300 and depend on which IGs they achieve and whether they maintain their progress at the end of the 12 weeks. Specifically, given the PBF goal, the Loss Target (LT) is the difference between the initial PBF measured at the first visit and the PBF goal, i.e., LT = initial PBF - PBF goal. Then, the IG1 is to achieve 25% of the LT, the IG2 is to achieve 50% of the LT, and the IG3 is to achieve 75% of the LT. Participants will earn $75 credits to their accounts on the programme website for reaching each intermediate goal. Also, when they miss IG1 and/or IG3, they can earn the previous missing $75 credits if they reach the IG2 and the LT. At the end of the 12 weeks, they will lose some or all the credits that they have accumulated if they fail to maintain the progress, and they will only receive the corresponding amount in cash
45601133|NCT01660256|Drug|OPC-12759|Instillation, 4 times/day for 4 weeks
45601134|NCT01660256|Drug|Placebo|
45601135|NCT02034123|Drug|GSK2879552|Subjects will receive GSK2879552orally with approximately 200 milliliter (mL) of water.
45601136|NCT05392088|Other|DATA EXTRACTION|"For all patients enrolled Data Mart COVID-19 developed within Generator Real World will be used to automatically extract both structured and unstructured data from hospital databases of patients infected from SARS-CoV-2.The specific data that which will be exploited are:~Demographics data;~Patient comorbidities, vital signs and symptoms at the time of admission;~Laboratory analysis;~In-hospital complications (e.g.: need for non-invasive or invasive ventilation, access to intensive care unit, length of hospitalization, use of glucocorticoids or antibiotics, death);~Blood gas exchange information;~Radiological reports;~Medications at the time of admission, during hospitalization and at the time of discharge;~Vaccination status."
45601137|NCT05392088|Other|FOLLOW-UP|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 12 months from hospital discharge, during which the incidence of MACE, dysrhythmias, inflammatory heart disease and/or thrombotic disorders (both as incidence of the composite and as incidence of each individual components) in the past months will be investigated.
45444492|NCT02047552|Drug|Oxandrolone placebo|similar color and size sugar pill
45444493|NCT01303731|Drug|Bupivacaine and Fentanyl|Spinal anesthesia with Marcaine Spinal 0.5% Heavy 7.5 mg (1.5 ml) diluted in 0.75ml of patient's CSF (0.25 ml)with addition of Fentanyl 12.5 mcg (total 2.5 ml)
45601138|NCT05076825|Other|Neurodynamic Sliding|Participants supine with their cervical and thoracic spine supported in a forward flexed position. Simultaneous hip and knee flexion will be alternated dynamically with simultaneous hip and knee extension. The therapist will change the arrangement of movement depending on the tissue resistance level.
45601139|NCT05076825|Other|Static Stretching|Participent lying supine, the therapist will passively position the subject into the straight leg raise position without discomfort or pain to the point where resistance to movement will be first felt.
45601140|NCT04968938|Drug|3,4-methylenedioxymethamphetamine|Behavioral: Therapy
45601141|NCT05412758|Dietary Supplement|Oral Stimulant Drink|For the AROMA 1 study patients will be requested to consume a nutrient drink (approximately 200 ml) that includes natural ingredients found within a typical human diet. Following consumption of the drink, serial breath tests will be performed to determine varying levels of VOC production in breath
45601142|NCT03144141|Other|Electrical recording of uterine activity by EHG either directly at the emergency or at the hospitalization|Electrical recording of uterine activity by EHG either directly at the emergency or at the hospitalization
45601143|NCT02330367|Drug|AC0010|"Phase 1: AC0010 will be administered in escalating dosages in a period of 28-day cycles.~Phase 2: AC0010 will be administered twice-daily at RP2D."
45755430|NCT03806114|Procedure|No Precautions|For the non-precautions group, there will be no mention of precautions by any providers before, during, and after surgery. No equipment will be given, but a list of self-care equipment will be available for 'comfort' purposes. Patients will be instructed to avoid bathing for 4 weeks. All groups will have instructions to use a walking aid and a toilet seat if needed, to weight-bear as tolerated, and to avoid driving for 3 weeks.
45755431|NCT03741842|Behavioral|COMBO-KEY|The intervention will last for eight weeks with four home visits and five phone coaching sessions. It will also consist of a 4-item resource package for stroke survivors (including a stroke self-management and self-discovery workbook, a health and life planning toolkit, and videos on sharing of experience by survivors who managed their post-stroke challenges successfully, and a stroke self-management quick reference guide). A telephone hotline for survivors and caregivers to seek information and support related to stroke self-management will also be established. A programme protocol will be developed to ensure the consistent delivery of the programme.
45934903|NCT00210457|Drug|Lanreotide (Autogel formulation)|
45934904|NCT00210496|Drug|topiramate; almotriptan malate|
45934905|NCT00210535|Drug|Topiramate; Placebo|
45934906|NCT00210574|Drug|topiramate|
45934907|NCT00210613|Drug|Dapoxetine|
45444494|NCT01303731|Drug|Bupivacaine|Spinal anesthesia with Marcaine Spinal 0.5% Heavy 12.5 mg (2.5 ml)
45444495|NCT03815487|Device|Medtronic MiniMed 670G Insulin Pump in Auto Mode|This kind of intervention will be part of the intensified insulin therapy for type 1 diabetic patients. The system will help to keep blood glucose in a defined range by automatic assisted adaption of insulin dosing.the HCL provides a lot more automatic functions to keep glucose in target compared to SAP.
45444496|NCT03815487|Device|Medtronic MiniMed 670G Insulin Pump without Auto Mode|Sensor augmented pump therapy means the addition of alerts according to high or low glucose values as well as trend arrows showing actual glucose trends to pump therapy. There is no automatic adaption of insulin dosing. The patients must respond manually after alarm or according to the trend arrows.
45452127|NCT01226290|Device|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy.
45452128|NCT02267980|Drug|Sevoflurane|Inhalation anesthetic agent
45452129|NCT02267980|Drug|Ketamine|Intravenous anesthetic agent
45452130|NCT02267980|Drug|Saline|Isotonic solution for placebo group
45452131|NCT01225666|Drug|MOD-4023|liquid solution for subcutaneous injection - 30% of the cumulative weekly dose achieved with daily rhGH, Once weekly
45452132|NCT01225666|Drug|MOD-4023|liquid solution for subcutaneous injection - 45% of the cumulative weekly dose achieved with daily rhGH, Once weekly
45452133|NCT01225666|Drug|MOD-4023|liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, Once weekly
45601144|NCT05352464|Other|cervical traction with EMG biofeedback|"Continuous traction for 15-20 minutes in sitting position on average at an angle of 15-25 degrees of cervical flexion or in the most pain-free position.~Ask the patient to assume sitting position on a comfortable chair. Place surface electrodes of EMG biofeedback at the level of C5-6 Para spinal muscles to pick up the activity of the muscles and convert it to vis-ual and auditory impulses produced from the device. Tell the patient to try to relax the tension of the neck muscles as much as he can by lowering the visual and auditory impulses from the device"
45601145|NCT05352464|Other|cervical traction and conventional physical therapy|Continuous traction for 15-20 minutes in sitting position on average at an angle of 15-25 degrees of cervical flexion or in the most pain-free position
45601146|NCT02318602|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
45601147|NCT05352152|Diagnostic Test|Next generation sequence|Next generation sequence will be used to detect the pathogens in ascites.
45601148|NCT05077215|Drug|EG-007|A Repurposed Drug
45601149|NCT05077215|Drug|Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection|Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.
45601150|NCT05077215|Drug|Lenvatinib Capsules|Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, and talc.
45601151|NCT02330679|Drug|Desvenlafaxine|The intervention will consist of a 2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine (a SNRI medication)
45601152|NCT02330679|Drug|Placebo|
45601153|NCT05559008|Drug|Azacitidine Injection|Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes
45601154|NCT05559008|Drug|Dasatinib|Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes
45601155|NCT05559008|Drug|Linperlisib|Azacitidine Injection，SC and Linperlisib PO will be administered in T2 subtypes
45601156|NCT05559008|Drug|Tucidinostat|Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
45601157|NCT05559008|Drug|SHR2554|Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
45601158|NCT05559008|Drug|Camrelizumab|Camrelizumab and Apatinib will be administered in T3.2 subtypes
45755432|NCT03803150|Procedure|PRA approach|A preauricular incision will be made that extends downwards in a curvilinear fashion in the cervicomastoid skin crease, though any variation in this incision will suffice. The great auricular nerve will be preserved and the flap raised in the subdermal fat plane, superficial to the superficial musculoaponeurotic layer to allow access to the masseter adjacent to the anteroinferior edge of the parotid gland, just below the parotid duct. Branches of the facial nerve will be readily identified and avoided with or without loupe magnification, on the surface of the masseter muscle.
45601159|NCT05559008|Drug|Apatinib|Camrelizumab and Apatinib will be administered in T3.2 subtypes
45601160|NCT05076669|Other|stoma follow-up|delivery and enhanced follow-up by the FSK HHN provided, in particular, by stomal therapy nurse consultants and patient-relation experts during in-person or remote appointments in addition to the routine care delivered and prescribed by the sites
45601161|NCT05076669|Other|standard of care|routine management of stoma
45755433|NCT03803150|Procedure|RT approach|The incision for the retromandibular approach begins 5mm below ear lobe and continues 3 to 3.5cm inferiorly. Initial incision begins through skin and subcutaneous tissues,platysma muscle ,(SMAS), parotid capsule Dissection is continued until the only tissue remaining on the posterior border of the mandible will be the periosteum of pterygomassetric sling,then the fracture site will exposed and reduced.
45601162|NCT05389904|Other|Arm 1: Routine care|Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, will receive standard of care.
45601163|NCT05389904|Other|Arm 2: Preemptive C. difficile infection prevention bundle|Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, will receive a preemptive prevention bundle for C. difficile. The prevention bundle will include enhanced room cleaning, C. difficile precautions (staff entering room must wear gown and gloves and wash hands with soap and water upon exiting the room), pharmacist review and optimization of antibiotics and antacids, and consideration of vancomycin prophylaxis.
45601164|NCT02318368|Drug|Ficlatuzumab|
45601165|NCT02318368|Drug|Erlotinib|
45601166|NCT02318368|Drug|placebo|
45601167|NCT05351840|Drug|LivaloV|Treatment A, Tablet, Oral, QD for 7 Days
45601168|NCT05351840|Drug|A|Treatment B, Tablet, Oral, QD for 10 Days
45601169|NCT05351840|Drug|LivaloVA|Treatment C, Tablet, Oral, QD for 7 Days
45601170|NCT05076201|Behavioral|Patients with completed rehab|The main objective is to measure the level of cocaine craving, 6 months after the end of their detoxification treatment (outpatient or full hospitalization), in patients with a diagnosis of moderate to severe dependence (DSM 5) to cocaine and co-addiction, or not, to alcohol and / or psychostimulants. To evaluate cocaïne craving,the questionnaire CCQ-Brief will be used.
45601171|NCT05557526|Other|Expectation optimization|A short (2-5 min) verbal intervention will be createad individually based on the expectation of the patient towards the procedure.
45601172|NCT05063175|Other|Conventional Physical Therapy Protocol|The conventional physical therapy protocol was prescribed to correct the kyphotic posture of the dorsal spine, and improve postural balance stability during standing and walking. The conventional therapeutic protocol for every child was three sessions per week for 12 successive weeks. Every treatment session was applied for two hours with a few minutes rest in between them.
45601173|NCT05063175|Other|TheraTog orthotic undergarment with its strapping system|TheraTog orthotic undergarment with its strapping system was conducted for 8 hours daily for 12 successive weeks. It is made to be fitted directly on the skin as undergarments.
45601174|NCT05350826|Other|Ambulatory medical assistance|Ambulatory medical assistance is a patient-empowerment program and consists to programmed phone calls (bi-monthly for the first 6 months then monthly for the following 6 months) delivered by an oncology nurse, in link with the hematologist.
45601175|NCT05075733|Other|Survey|Survey was sent to all the Americas Hepato-Pancreato-Biliary Association's members
45601176|NCT05053425|Drug|Venetoclax|given po.
45755434|NCT03872024|Device|For the first 60 patients: 3 XXL probe prototypes of the FibroScan 630 Research Model|"After the patient informed consent form signature and during the patient pre-operative routine hospitalization, the following examinations will be done:~An ultrasound examination~One examination with the FibroScan® 430 mini fitted with the XL+ probe (commercial reference)~Three examinations with the FibroScan® 630 Expert - Research model fitted with the 3 XXL probe prototypes."
45755435|NCT03872024|Device|From patient 61 to patient 120: 1 XXL probe prototype of the FibroScan 630 Research Model|"After the patient informed consent form signature and during the patient pre-operative routine hospitalization, the following examinations will be done:~An ultrasound examination~One examination with the FibroScan® 430 mini fitted with the XL+ probe (commercial reference)~One examination with the FibroScan® 630 Expert - Research model fitted with 1 adjusted XXL+ probe prototype (H+F prototype probe)."
45755436|NCT03870854|Procedure|PEFA VT ablation technique|Catheter ablation guided by PEFA technique
45601177|NCT05053425|Drug|Azacitidine|given sc.
45601178|NCT05053425|Drug|Cladribine|given ivgtt.
45601179|NCT05053425|Drug|Cytarabine|given sc or ivgtt.
45601180|NCT05053425|Drug|Idarubicin|given ivgtt.
45601181|NCT02318134|Procedure|Fecal Microbiota Transplantation|FMT via a nasoduodenal tube with fresh bacteria from healthy donor
45601182|NCT02318134|Drug|normal saline|Normal saline via a nasoduodenal tube.
45601183|NCT05541380|Other|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
45601184|NCT03142503|Dietary Supplement|Diet + supplementation|Supplementation of 1g of fish oil, 3 time a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.
45601185|NCT03142503|Dietary Supplement|Diet + placebo|Supplementation of 1g of soybean oil, 3 times a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.
45601186|NCT03142503|Dietary Supplement|Placebo|Supplementation of 1g soybean oil, 3 times a day.
45601187|NCT05350436|Behavioral|Balance Conditions|"Balance Conditions: (~ 5 minutes in total)~Balance Condition 1 (Feet 20cm apart)~Balance Condition 2 (Feet together)~Balance Condition 3 (Tandem stance)~Initial measurements of balance conditions serve two purposes: it generates a postural control baseline for us without the attribution of singing conditions, furthermore it allows us to separately measure long-term singing experience's effect on postural control, by assessing tasks differing in difficulty level. Balance conditions will be randomised to prevent a learning effect."
45755437|NCT03869996|Procedure|fast track care protocol|fast track care consists in educational preoperative preparation for patients, particular strategies for controlling pain and bleeding and intensive early rehabilitation protocol.
45601188|NCT05350436|Behavioral|Singing|"Singing Conditions: (~ 15 minutes)~Warmup - including jaw and breathing exercises~Singing Condition 1 (Spoken Happy Birthday - Traditional Tempo)~Singing Condition 2 (Sung Happy Birthday - Traditional Tempo~Singing Condition 3 (Spoken Happy Birthday - Fast Tempo)~Singing Condition 4 (Sung Happy Birthday - Fast Tempo)~Singing Condition 5 (Spoken Happy Birthday - Slow Tempo)~Singing Condition 6 (Sung Happy Birthday - Slow Tempo)~Link to singing instructional video:~https://www.dropbox.com/s/tro58i6vx6i6w3a/Singing%20Balance%20Exercise%20Video.mp4?dl=0~Time stamps for the video:~Warmup (including jaw exercises and breathing exercises) - beginning at 2:55 until 6:06~Happy Birthday protocol - beginning at 15:26 until 20:21"
45601189|NCT03142269|Procedure|360°anterior capsule polishing|360°anterior capsule polishing was performed with double-ended capsule polisher
45601190|NCT02317510|Procedure|combined anesthesia|Combined Spinal Epidural Anesthesia for laparoscopic cholecystectomy
45601191|NCT02317510|Procedure|general anesthesia|General anesthesia for laparoscopic cholecystectomy
45601192|NCT05350124|Drug|Ascorbic acid|vitamin C (200 mg) capsule
45601193|NCT05350124|Drug|Tocopherol|vitamin E (400 IU) capsule
45601194|NCT05350124|Drug|Placebo capsule|Placebo one pill only
45601195|NCT05350124|Drug|Placebo capsule|Placebo two pills only
45755438|NCT03869996|Procedure|standard care protocol|standard care protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol.
45755439|NCT03869450|Device|Restylane Volyme|Hyaluronic based filler
45755440|NCT03869450|Device|Restylane Defyne|Hyaluronic based filler
45755441|NCT03869450|Device|Restylane Lyft Lidocaine|Hyaluronic based filler
45601196|NCT02329899|Other|Second step of investigations|"Second step according to results of the first step:~exploration of coagulation factors;~factor XIII and fibrinolysis investigations;~investigation of platelet function;~investigation of thrombocytopenia."
45601197|NCT05389826|Device|mHealth App|We will compare the degree of improvement in phosphate control with respect to baseline values and report any adverse event. Nephrologist will use a web management system to provide results of phosphorus levels and medical recommendations to the patient, mediated by a cloud IT environment. In addition, patients will receive alerts, suggestions, and general information. They will also be able to communicate with nephrologists and interact with their corresponding group of fellow patients.
45601198|NCT02329977|Other|standard barium meal examination|All eligible patients received standard barium meal examination, MRCP and enhanced abdominal CT.
45601199|NCT05389436|Procedure|Ambulatory care|The surgery is performed in ambulatory setting
45601200|NCT05389436|Procedure|Inpatient care|The surgery is performed during inpatient care
45601201|NCT02317432|Behavioral|Comparison of a combined CBT + exercise intervention and enhanced usual care|
45755442|NCT03868514|Device|TiLOOP® Bra Pocket|Primary or secondary breast reconstruction following mastectomy with titanised polypropylene mesh TiLOOP® Bra Pocket
45934908|NCT00210691|Drug|Risperidone|
45601202|NCT05075655|Device|Endobronchial ultrasound guided miniforceps biopsy and transbronchial needle aspiration|"Mediastinal node is sampled using three path of classic ultrasound guided transbronchial needle aspiration (EBUS-TBNA).~A reduce size forceps is then inserted inside the mediastinal node via the duc EBUS-TBNA made and biopsies (EBUS-MFB) are made using real time ultrasound guidance."
45601203|NCT03143673|Device|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement Surgery.
45601204|NCT05018871|Biological|autologous adipose derived mesenchymal stem cells|cultured autologous adult adipose derived mesenchymal stem cells
45601205|NCT05388578|Device|Blood pressure monitor|Participants will receive the Withings BPM connect monitor and do weekly self-measurements of blood pressure.
45601206|NCT05388578|Device|Weighting scale|Participants will receive the Withings Body scale and do weekly self-measurements of their body weight and BMI.
45601207|NCT05388578|Device|Activity tracker|Participants will receive the Withings Move to automatically keep track of their number of steps and activity type.
45601208|NCT05388578|Device|ECG device|Participants will receive the Withings Move ECG to make daily measurements of heart rhythm, an algorithm will detect abnormalities in heart rhythm such as atrial fibrillation.
45601209|NCT05018793|Biological|autologous adipose derived mesenchymal stem cells|cultured autologous adult adipose derived mesenchymal stem cells
45601210|NCT05344586|Other|Hamstring stretching program with neural load|Participants will perform a hamstring stretch with neural load on their dominant leg. They will stretch five days a week, carrying out two repetitions of one minute each, taking a thirty second break in between. The stretch will be performed in a standing position with their dominant leg on a surface at a mid-thigh height approximately, where their knee is not fully stretched and remains unlocked and their back is in a neutral position. Participants will be encouraged to keep a maximum stretching sensation without feeling any pain. To perform the stretch, different tension parameters will be added in the following order (the next parameter shall not be introduced until the previous one has been exhausted): ankle dorsiflexion, cervical and craniocervical flexion, and hip flexion.
45601211|NCT05344586|Other|Hamstring stretching program without neural load|Participants will perform a hamstring stretch without neural load on their dominant leg. They will stretch five days a week, carrying out two repetitions of one minute each, taking a thirty second break in between. The stretch will be performed in a standing position with their dominant leg on a surface at a mid-thigh height approximately, where their knee is not fully stretched and remains unlocked and their back is in a neutral position. Participants will be encouraged to keep a maximum stretching sensation without feeling any pain. To perform the stretch, tension will be added by flexing their hip, keeping their ankle relaxed and their spine neutral.
45601212|NCT03143907|Behavioral|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, and in the pilot study conducted at the Early Psychosis Program at London Health Sciences Centre in London, Ontario. Its youth-focus and emphasis on building social and emotional competencies through mindfulness make it a promising intervention for youth recovering from their first episode of psychosis.
45601213|NCT05348174|Behavioral|Virtual Reality Assisted Guided Imagery (VRAGI)|The visual landscape consists of a computer-generated immersive virtual world with nature-based imagery (i.e., trees, birds, mountains, water) and accompanying soundscapes with guided imagery.
45601214|NCT03143751|Drug|NaCl20% (Continuous hyperosmolar therapy)|"Early intravenous administration (<24 hours after traumatic brain injury) of NaCl20% for a minimal duration of 48 hours (continued for as long as is necessary to prevent intracranial hypertension)~1-hour bolus (15 g if Na+ < 145 mmol/L; 7.5 g if 145 < Na+ < 150 mmol/L; or no bolus) followed by 1 g/hour as long as Na+< 150 mmol/L, reduced to 0.5 g/L if 150 < Na+ < 155 mmol/L, Discontinuation when 155 mmol/L<Na+"
45601215|NCT03662607|Behavioral|Virtual reality experience|"Baseline wellness self-assessment administered (reporting on absence or presence and degree of severity of headache, nausea, dizziness, fatigue and vision abnormalities)~Seated comfortably and free of direct obstruction~Shown individual components of the VR system (View-Master with smartphone; headphones); given instructions; encouraged to ask questions.~Begin the VR experience. Study personnel stay in the room & provide guidance and answer questions regarding the technology~When VR experience concluded, wellness self-assessment will be administered again."
45601216|NCT02330133|Behavioral|Women's Reproductive Health|Targeted text and video information on website for women aged 25-55 to avoid unplanned pregnancy and sexually transmitted infections
45601217|NCT02330133|Behavioral|Online sexual health content|Online general text-based information about reproductive health issues and strategies for preventing sexually transmitted infections
45601218|NCT04925427|Behavioral|Case Management and Peer Recovery|A blend between a Critical Time Intervention (CTI) case management model and a peer recovery coaching approach. CORI will employ peer-based case management/recovery coaching and other transitional services (e.g., peer navigation) to provide support and service linkages to medication-assisted treatment (MAT) and harm reduction interventions to reduce subsequent opioid use and related harms.
45601219|NCT04925427|Behavioral|Naloxone-Only|Participants will be trained on naloxone administration, and upon re-entry, they will be given a naloxone kit and information on local resources for harm reduction, SUD treatment, and additional supportive services.
45601220|NCT03143517|Diagnostic Test|Stool collection|Stool sample collected by a subject who have been diagnosed with IBD, IBS or other GI disorder. The stool sample is tested in a laboratory where fecal calprotectin levels are quantified.
45601221|NCT02329821|Other|hartmann solution|hartmann solution infusion in patients for hepatic resection
45601222|NCT03143439|Behavioral|Fathers Advancing Communities Together (FACT) program|The FACT program offers fathers and their families responsible parenting, healthy relationship, and economic stability services and activities.
45755443|NCT04403906|Diagnostic Test|PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test)|The PCL COV05 - COVID 19 Ag Rapid FIA test has FSC and CE approvals for the qualitative detection of SARS-CoV-2 Antigens from human oropharyngeal swabs and deep sputum samples. The manufacturer is PCL Corporation Ltd 17F, 128 B-dong, Courthouse-ro, Songpa-gu, Seoul, South Korea.
45755444|NCT01212926|Device|Echographic analysis of myocardial deformation in 2D strain|
45755445|NCT03800108|Procedure|Personalized DBS adjustments|Individualized stimulation adjustments based on pre- and post- DBS implantation MRIs
45755446|NCT03799874|Drug|Inhaled Carbon Monoxide at 200 ppm|Inhaled Carbon Monoxide at 200 ppm for 90 minutes daily for 3 days.
45601223|NCT00494234|Drug|KU-0059436 (AZD2281) (PARP inhibitor)|oral
45601224|NCT00494234|Drug|KU-0059436 (AZD2281) (PARP inhibitor)|
45601225|NCT02329665|Device|NeedleWays™ System|A total of 50 consecutive subjects scheduled for clinically indicated CT guided needle intervention procedure will be invited to enroll in the study.
45601226|NCT04861623|Other|Orange juice|Orange juice will be purchased commercially.
45601227|NCT04861623|Other|Placebo juice (Fanta)|Fanta will be purchased commercially.
45601228|NCT02329509|Procedure|two stage palate surgical repair|two stage palate surgical repair with a hard palate closure at 3 to 4 years old
45755447|NCT03799874|Other|Inhaled Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
45755448|NCT04747184|Other|DNA extraction and 16S rRNA sequencing|DNA extraction using QIAamp® DNA mini kit (QIAGEN) was done under aseptic techniques in the sterile room for all samples according to the manufacturer instructions. The DNA extracts for the 54 samples collected (27 from asthmatic patients and 27 from healthy subjects) were stored at -80° C in a sterile Eppendorf tubes until they were sent to the Molecular Research (MR DNA) Lab (Molecular Research LP, Shallowater, TX, USA) for sequencing.
45755449|NCT03795506|Device|Nocturnal Temperature controlled Laminar Airflow (TLA) Treatment|12 weeks of overnight treatment with active TLA device
45755450|NCT03795506|Device|Placebo TLA Device|12 weeks of overnight use of placebo TLA device
45755451|NCT03795038|Device|Lipoprotein Apheresis MONET and DALI|Three apheresis treatments assigned to one type of apheresis system of MONETand DALI
45755452|NCT03795038|Device|Lipoprotein Apheresis DIAMED and DALI|Three apheresis treatments assigned to one type of apheresis system of DIAMOND and DALI
45755453|NCT03794882|Combination Product|Quadratus Lumborum Block|30 mL of .25% bupivacaine with 2.5mcg/mL epinephrine will be injected on both sides of the mid-abdomen posterior to the mid-axillary line.
45755454|NCT03794882|Procedure|Standard Medical Management|Standard medical management typically includes perioperative multimodal analgesia utilizing acetaminophen, opioids, non-steroidal anti-inflammatory drugs, and dexamethasone
45444497|NCT03815799|Procedure|Bilateral Erector Spinae Block|A linear ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. 40 ml bupivacaine/lidocaine mixture will be injected into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS).
45601229|NCT02329509|Procedure|One stage Palate Surgical repair|One stage palate repair at the age of 9 to 24 months old
45755455|NCT03736928|Biological|AbobotulinumtoxinA dose level 1 or 2|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
45755456|NCT03736928|Other|placebo|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
45452134|NCT01225666|Drug|MOD-4023|liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, every-other week (50% of the two-weekly cumulative dose)
45601230|NCT05556746|Drug|Bedaquiline|Daily therapy for 8 weeks
45601231|NCT05556746|Drug|Clofazimine|Daily therapy for 8 weeks
45601232|NCT05556746|Drug|Pyrazinamide|Daily therapy for 8 weeks
45601233|NCT05556746|Drug|Delamanid|Daily therapy for 8 weeks
45601234|NCT05556746|Drug|Rifampin|Daily therapy for 26 weeks
45601235|NCT05556746|Drug|Isoniazid|Daily therapy for 26 weeks
45601236|NCT05556746|Drug|Ethambutol|Daily therapy for 8 weeks
45601237|NCT05556746|Drug|Pyrazinamide|Daily therapy for 8 weeks
45601238|NCT05346770|Behavioral|Behavioral Intervention|A behavioral intervention could include changing the time of day a drug is taken.
45601239|NCT05346770|Diagnostic Test|Diagnostic Test|A patient may receive a pharmacogenomic test via cheek swab to find PGx results. This is a benign intervention with little to no risk to the patient.
45601240|NCT05346770|Other|Data Analysis|Medication safety reviews, and retrospective or prospective data analysis may occur as a result of participation in a case study.
45601241|NCT04815993|Drug|SYN-020 delayed release capsule|SYN-020, is an opaque, white, size 3 HPMC capsule for oral administration containing enteric-coated, delayed-release pellets.
45601242|NCT05554406|Drug|Azacitidine|Given SC or IV
45601243|NCT05554406|Procedure|Biospecimen Collection|Undergo collection of blood
45601244|NCT05554406|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
45601245|NCT05554406|Drug|Cytarabine|Given IV
45601246|NCT05554406|Drug|Daunorubicin Hydrochloride|Given IV
45601247|NCT05554406|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
45601248|NCT05554406|Drug|Venetoclax|Given PO
45601249|NCT04834869|Biological|BNT162b2|Receiving either the first dose only or both doses of BNT162b2 vaccine (Pfizer-BioNTech COVID-19 Vaccine)
45601250|NCT04834869|Biological|mRNA-1273|Receiving either the first dose only or both doses of mRNA-1273 vaccine (Moderna COVID-19 Vaccine)
45601251|NCT04834869|Biological|AZD1222|Receiving either the first dose only or both doses of AZD1222 vaccine (AstraZeneca-Oxford University COVID-19 Vaccine)
45755457|NCT03736928|Biological|AbobotulinumtoxinA dose 3|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
45755458|NCT03736928|Biological|AbobotulinumtoxinA dose 4|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
45755459|NCT01101464|Drug|Asenapine 3x5mg followed by 1x15mg|Three 5 mg sublingual tablets (15 mg) given twice daily for 2 days followed by one 15 mg sublingual tablet given twice daily for 1.5 days
45755460|NCT01101464|Drug|Asenapine 1x15mg followed by 3x5mg|One 15 mg sublingual tablet given twice daily for 2 days followed by three 5 mg sublingual tablets (15 mg) given twice daily for 1.5 days.
45755461|NCT03736538|Drug|Nitrous Oxide|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
45755462|NCT03736538|Drug|Placebo gas|Placebo gas given at 50% nitrogen [inert]/50% oxygen.
45755463|NCT01676948|Drug|ACZ885|
45755464|NCT01676948|Drug|Canakinumab|
45934909|NCT02966613|Device|GMK Medacta Total Knee arthroplasty|Total Knee arthroplasty
45934910|NCT00210730|Drug|epoetin alfa|
45934911|NCT00397124|Device|PET/CT imaging|
45601252|NCT04834869|Biological|CoronaVac|Receiving either the first dose only or both doses of CoronaVac (Sinovac COVID-19 Vaccine)
45601253|NCT04834869|Biological|Sinopharm|Receiving either the first dose only or both doses of Sinopharm Vero Cell COVID-19 Vaccine
45601254|NCT04834869|Biological|Gam-COVID-Vac|Receiving either the first dose only or both doses of Gam-COVID-Vac (Sputnik V)
45601255|NCT04834869|Biological|JNJ-78436735|Receiving JNJ-78436735 (Janssen COVID-19 Vaccine)
45601256|NCT04834869|Biological|CVnCoV|Receiving either the first dose only or both doses of CVnCoV (CureVac COVID-19 vaccine)
45601257|NCT04834869|Biological|NVX-CoV2373|Receiving either the first dose only or both doses of NVX-CoV2373 (Novavax COVID-19 vaccine)
45601258|NCT04834869|Biological|BBV152|Receiving either the first dose only or both doses of BBV152 (Covaxin COVID-19 vaccine)
45601259|NCT05341544|Device|Parasym device|The study will utilize the Parasym device (Parasym Health, London, United Kingdom) paired with compatible electrodes to administer the transcutaneous LLTS.
45601260|NCT05341544|Device|Sham device|Sham device
45601261|NCT04803591|Drug|Tranexamic Acid|Tranexamic Acid will be administered as an injectable solution (500mg/5ml or 1000mg/10ml).
45601262|NCT05341232|Behavioral|Lego Robot Programming Active Challenges|Participants will adapt their own Lego robot programs to achieve specific task goals.
45601263|NCT05341232|Behavioral|Lego Robot Programming Procedural Methods|Participating will undergo Lego robot programming training that engages them to follow fixed programming coding steps.
45601264|NCT05341232|Behavioral|Board Games|Participants will play board games with each other.
45601265|NCT04555863|Device|haMSter smartphone app|the app tracks patient reported outcomes
45601266|NCT04750785|Other|No Intervention|Administered as specified in the treatment arm.
45601267|NCT05536856|Drug|a new effervescent mixture 5-florouracil formula|30 patients will apply a new effervescent mixture 5-florouracil formula prepared at faculty of pharmacy (Girls) - Al-Azhar university
45601268|NCT05536856|Drug|5-Fluorouracil plain powder|30 patients will apply the 5-florouracil plain powder on the selected patch followed by 3 milliliters of water till complete dissolution of the powder
45601269|NCT04251806|Diagnostic Test|neonatal polysomnography|This procedure will allow the detection of sleep-disordered breathing in the neonatal period.
45601270|NCT04251806|Diagnostic Test|2-year Bayley Exam|This procedure will evaluate neurodevelopmental outcomes.
45601271|NCT04251806|Diagnostic Test|2-year polysomnography|This procedure will allow the detection of sleep-disordered breathing at 2 years of age.
45601272|NCT04468893|Behavioral|Online Intervention Mental Health COVID-19|The Online Intervention Mental Health COVID-19 aims to provide to the target population a self-applied intervention based primarily on Positive Psychology, aimed at the recognition and development of strengths and virtues from the well-being approach. In addition, it is supported by elements of Cognitive Behavioral Therapy such as the components of emotion and the Antecedent-Response-Consequence (ARC) model of emotions. Elements of Behavioral Activation Therapy are also included, such as the importance of physical exercise and the relationship between physical anxiety and its effects on anxiety and depression. The intervention is made up of 15 modules that are adapted to the symptoms that the population may suffer from the global contingency caused by the COVID-19 pandemic. In addition to the Positive Psychology modules, a module with psychoeducation on grief and loss was added.
45601273|NCT04735263|Drug|Atorvastatin 80mg|Patient will be receiving 80mg of Atorvastatin, if they are able to tolerate it from the start to the end of the study.
45601274|NCT00493298|Drug|Tysabri|According to the local prescribing information
45601275|NCT02329119|Other|electrophysiological recordings|
45755465|NCT01676948|Drug|Canakinumab|"Patients rolling over into this study from CACZ885G2301E1 (Cohort 1) will continue on their established canakinumab dose of either 4 mg/kg SC given every 4 weeks or 2mg/kg SC given every 4 weeks, until eligible for dose reduction.~Canakinumab-naïve patients"
45755466|NCT01676948|Drug|Canakinumab|Patients rolling over into this study from CACZ885G2301E1(Cohort 2) will receive a standard canakinumab dose of 4mg/kg SC given every 4 weeks, until eligible for dose reduction
45911015|NCT02002312|Drug|Lu-177-DOTA-girentuximab|"Drug: In-111-DOTA-girentuximab At day 1, every patient received girentuximab at a dose of 10 mg coupled to DOTA and labeled with 5 mCi of In-111.~Drug: Lu-177-DOTA-girentuximab At day 8-10, every patient receives girentuximab at a dose of 10 mg coupled to DOTA and labeled with 65 mCi/m2 of Lu-177. If eligible, patients are retreated at a dose 75% of the previous dose, for a total of not more than three treatments."
45601276|NCT02329041|Device|McGrath Series 5|one kind of videolaryngoscopes, which are widely used in airway management.
45601277|NCT02329041|Device|Airtraq|another kind of videolaryngoscopes, which are also widely used in airway management.
45601278|NCT04343469|Procedure|Bariatric Surgery (RYGB or LSG)|Morbidly obese subjects will receive either RYGB or LSG, and the effect of bariatric surgery-induced weight loss on brain inflammation will be assessed
45934912|NCT04722328|Diagnostic Test|CSF metagenomic next generation sequencing (mNGS)|TestCSF routine, biochemical, smear staining (Gram staining, acid fast staining, ink staining), culture and mNGS。
45601279|NCT02329353|Drug|Lactobacillus brevis CD2 Lozenges|Each lozenge contains not less than 1 billion Colony forming unit of Lactobacillus brevis CD2
45601280|NCT03143205|Behavioral|AWARENESS for Sexual Minorities|9 session, individually delivered, cognitive behavioral intervention focused on modifying sexual minority stress responses to reduce the impact of sexual minority stress experiences.
45601281|NCT03143205|Behavioral|Writing tasks|Writing sessions to explore daily activities.
45601282|NCT04244955|Other|Semi-directive interviews|The interviews, carried out by the child psychiatrist, will be semi-directive and short (15 to 30 minutes) one-on-one with the child or adolescent so that the presence of the parents does not influence the responses. The CPTS-RI index, which has 20 questions, will be filled, as well as other questions to understand what is problematic for the child.
45601283|NCT02329197|Drug|Human Chorionic Gonadotropin (HCG)|intrauterine injection of HCG prior to embryo transfer in an IVF cycle
45652939|NCT05093673|Behavioral|Semantic Feature Analysis (SFA)|Semantic Feature Analysis (SFA) is a treatment technique designed to improve lexical retrieval by increasing the level of activation within a semantic network. The treatment will proceed according to a series of steps including naming aloud the target picture, generating semantic features, naming aloud the target picture again, and generating a sentence using the target word.
45601284|NCT03142347|Procedure|Remote endarterectomy|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of xenopericardium. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
45601285|NCT03142347|Procedure|Remote endarterectomy + DCB balloon|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of xenopericardium. And balloon angioplasty of superficial femoral artery with DCB balloon is perform. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
45601286|NCT04662723|Drug|Corticosteroid|To reduce the progression of renal damage in IgAN Patients
45601287|NCT04662723|Drug|Renin-angiotensin sytem blockers|To reduce the progression of renal damage in IgAN Patients
45601288|NCT04662723|Drug|Sodium-glucose cotransporter 2 inhibitor|To reduce the progression of renal damage in IgAN Patients
45601289|NCT00326690|Device|Blue Egg Device|
45601290|NCT04642911|Other|Long term follow up|Undergo long term follow up, including copy number measurement safety evaluations diseases specific product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study
45601291|NCT05307926|Drug|PD-1 inhibitors|For patients with PVTT, they received adjuvant therapy of PD1 (200mg intravenously every 3 weeks for a total of 18cycles) plus Lenvatinib (8mg orally once a day for 1 year) 2-4 weeks after surgery; for patients with other high-risk factors for recurrence, they PD-1(200mg intravenously every 3 weeks for a total of 9cycles) monotherapy 2-4 weeks after surgery.
45601292|NCT05307926|Procedure|TACE|Patients with high-risk factors for recurrence received 1 TACE about a month after surgery.
45601293|NCT04634643|Other|Usual diet and physical activity|Patients will be followed up to assess the effect of the usual diet and physical activity on development of NAFLD
45755467|NCT04403672|Device|performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection|"IEDCR uses many different kits for COVID-19 detection. These kits include, (1) A*Star Fortitute Kit 2 for COVID-19 detection (Singapure), (2) Sansure Biotec Limited (China), (3) ModularDx Kit (TIB Molecular Biology, Germany, and (4) DaAn Kit (China). Among these 2 kits, A*Star Fortitude Kit 2 has been known as the best kit in IEDCR depending on its performance because it rarely generates false positive or false negative results.~A*Star Fortitude Kit 2 is used for confirmation of any discordant results for other kits in IEDCR. That is, IEDCR uses A*Star Fortitude Kit for COVID detection as the Gold Standard. In our case, this is the main reason for the selection of this kit in order to compare the performances of RealDetect™ COVID-19 RT-PCR kit."
45601294|NCT02329275|Procedure|Testicular biopsy|
45601295|NCT04026945|Drug|Lidocaine|Sustained-release lidocaine injection
45601296|NCT03895047|Other|tomographic EEG Neurofeedback Training|EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex, the insula and the anterior cingulate cortex and deliver feedback for the patient
45601297|NCT02328729|Procedure|mandibular block with Epinephrine|Delivery of mandibular block anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
45601298|NCT02328729|Procedure|C-CLAD-IL with Epinephrine|Delivery of C-CLAD-ILanesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
45601299|NCT02328729|Procedure|Infiltration with Epinephrine|Delivery of infiltration anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
45601300|NCT02328729|Procedure|Mandibular block without Epinephrine|Delivery of mandibular block anesthesia for dental treatment with Mepivacaine 3% without Epineprine
45601301|NCT02328729|Procedure|C-CLAD-IL without Epinephrine|Delivery of C-CLAD-ILanesthesia for dental treatment with Mepivacaine 3% without Epineprine
45601302|NCT02328729|Procedure|nfiltration without Epinephrine|Delivery of infiltration anesthesia for dental treatment with Mepivacaine 3% without Epineprine
45755468|NCT03786224|Behavioral|Contingency Management|Six months of cannabis abstinence will be incentivized using a standard contingency management approach involving an escalating schedule of payment for abstinence and attendance.
45755469|NCT03785834|Procedure|Punch Biopsy|The patient will undergo two 6 mm punch biopsies into the affected extremity at the most proximal portion of the redness.
45755470|NCT01676792|Drug|SR-T100 gel with 2.3% of SM in Solanum undatum plant extract|Self administered topical SR-T100 gel on lesion(s) including its peripheral normal skin approximately 1cm around the lesion with the amount of 0.02 g/cm squared with occlusive dressing once daily. Patients who is unable to tolerate with occlusive dressing is instructed 3 times daily in the morning, afternoon & before bed time. Medication should be reapply after bathing or cleaning.
45601303|NCT04608513|Drug|ACT-1014-6470|Soft capsules for oral administration
45755471|NCT03728036|Behavioral|conventional rehabilitation|The investigated cohort will be exposed to 'standard care' including conventional rehabilitation therapy.
45755472|NCT03655262|Behavioral|Unconscious Neuro-reinforcement|Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete x day(s) of neuro-reinforcement.
45601304|NCT04608513|Drug|Placebo|Soft capsules for oral administration
45601305|NCT04608357|Diagnostic Test|Needle Core Biopsies|Not an interventional study
45755473|NCT03725930|Drug|Clonidine|clonidine intranasal premedication in preschool infants
45755474|NCT03725930|Other|Placebo|Placebo intranasal premedication
45934913|NCT00210769|Drug|paliperidone ER Oros|
45934914|NCT00069186|Drug|Creatine Monohydrate|
45601306|NCT04577313|Behavioral|Behavioral Self-Regulation Adherence Counseling|Telephone-delivered counseling to focus on cognitive-behavioral skills to improve HIV treatment adherence.
45601307|NCT02328963|Drug|Everolimus|"Everolimus : 0.75 bid, targeted to 3-8 ng/ml~Cyclosporin A :~CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.~Corticosteroids :~Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study~Basiliximab :Day 0: 20 mg ; Day 4: 20 mg"
45601308|NCT02328963|Drug|mycophenolic acid|"Mycophenolic acid :~1080 mg bid for one month, then 720 mg bid~Cyclosporin A :~CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.~Corticosteroids :~Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study~Basiliximab :Day 0: 20 mg ; Day 4: 20 mg"
45601309|NCT03520647|Drug|Cyclophosphamide|This research protocol is therefore designed to evaluate the safety and effectiveness of using an unmanipulated G-CSF mobilized peripheral stem cell allograft from a haploidentical donor and post-transplant cyclophosphamide for patients with SAA, or SAA evolving to MDS, or PNH that has proven to be refractory to conventional immunosuppressive therapy (IST) in patients who lack an HLA-matched donor (sibling/ or matched unrelated donor.
45601310|NCT03520647|Other|Peripheral Blood Stem Cells|This research protocol is therefore designed to evaluate the safety and effectiveness of using an unmanipulated G-CSF mobilized peripheral stem cell allograft from a haploidentical donor and post-transplant cyclophosphamide for patients with SAA, or SAA evolving to MDS, or PNH that has proven to be refractory to conventional immunosuppressive therapy (IST) in patients who lack an HLA-matched donor (sibling/ or matched unrelated donor.
45601311|NCT04536207|Other|Cryotherapy (apparatus)|Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy is also used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancer and to treat abnormal skin cells by dermatologists
45601312|NCT03353259|Combination Product|Tranexamic acid and Tocilizumab|The first intervention is Tranexamic acid, The second intervention is Tocilizumab
45601313|NCT04527627|Behavioral|Nursing Empowerment Intervention|"Nursing empowerment intervention The intervention will be carried out during the ICU discharge planning. A Patient Information Guide for Intensive Care Unit patients will be developed.~The guide will be based on the findings obtained in a previous qualitative study and on previous studies on patient empowerment and education. Its structure will take into account the dimensions of empowerment: bio-physiological, functional, social, experience, ethics and the financial aspect. The guide will be reviewed by experts in the development of information guides for patients and family members and will be evaluated by the participating ICUs before use.~EG patients will receive the intervention verbally and in booklet format from the study nurses at each ICU."
45601314|NCT04477239|Behavioral|Gluten (behaviour)|Gluten is a protein normally present in the daily diet of healthy volunteers not suffering from gluten related disorders, in far greater quantities (10-20 g/day) than those used in this study (10 mg-1 g/day).
45601315|NCT04477239|Behavioral|Placebo (behaviour)|Placebo is composed of pregelatinized maize starch Ph.Eur. 97.5%; magnesium stearate Ph.Eur. 1.5%; micronized silica Ph.Eur. 0.5%; Micronized talc Ph.Eur. 0.5% (NOT containing preservatives, colorings, or gluten).
45601316|NCT04513743|Diagnostic Test|24/7 EEG™ SubQ|24/7 EEG™ SubQ device will be worn by each subject for 365 nights
45601317|NCT04248218|Behavioral|Active Rehabilitation Group/Case|If the patient is in the active rehabilitation group, the patient will receive instructions based on the latest CDC concussion management guidelines that specify a symptom-limited progressive return to full activities. This group will be instructed to take at least 10,000 steps a day for five days on their pedometers. In addition, they will also watch a two-minute video by the PI and research team reinforcing the active rehabilitation instructions.
45601318|NCT02289820|Biological|MEDI7510|RSV sF antigen plus adjuvant
45601319|NCT02289820|Biological|IIV|Marketed Inactivated Influenza Vaccine
45601320|NCT04437537|Device|PHOENIX Wound Matrix|PHOENIX Wound Matrix will be applied to each subject's DFU following debridement.
45601321|NCT04247594|Drug|Voxelotor|synthetic small molecule supplied as 500 mg tablets
45755475|NCT03781388|Drug|Bupivacaine|Determination of the dose will rely on the outcomes of the preceding 7 patients receiving the same dose, as the number of previous patients to consider is a function of the target dose. Among all patients who received a certain dose, a proportion of successful outcomes will be determined (P(d)); if P(d) <0.90, and at least one of the previous 7 patients who received the same dose had an unsatisfactory outcome, the next patient will receive a pre-determined increment of 0.75 mg of bupivacaine. Alternatively, if P(d) 0.90 and the previous 7 patients who received the same dose had successful outcomes, the next patient will receive a pre-determined decrement of 0.75mg of bupivacaine. Otherwise, the dose will remain the same.
45755476|NCT03652220|Behavioral|Meditation Based Lifestyle Modification|8 weekly modules, each 3.5 hours of Life ethics, Yoga exercises and Mantra Meditation
45755477|NCT03652220|Other|Minimal treatment|Drug continuation under medical supervision
45755478|NCT03652220|Other|Multimodal specific treatment:|Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR
45934915|NCT00210808|Drug|topiramate|
45444498|NCT03815799|Other|Control|Standard perioperative and postoperative analgesia protocol will be given consisting of paracetamol 1 gr IV and tenoxicam 20 mg IV initiated after induction of anesthesia. At the end of the operation patients will receive meperidine 0.5 mg/kg IV before extubation. Postoperative pain levels will be determined by Numeric Rating Scale (NRS) system, 20 minutes intervals in the first hour and at 2th, 6th, 12th and 24 th hour. For the first hour in the postoperative care unit, tramadol 50 mg IV will be given for rescue analgesia with minimum 20 minutes between doses, in patients showing a NRS ≥ 4. Paracetamol 1 g / 12 hour will be given during ward follow-up. In the ward in patients showing a NRS ≥ 4 tramadol 50 mg IV will be given for analgesia.
45444499|NCT03815422|Procedure|Regional anesthesia|Short lasting sciatic nerve block and long lasting plantar block with distal deep peroneal block
45444500|NCT03276728|Drug|AMG 986 IV|AMG 986 solution for infusion
45755479|NCT03780062|Biological|S100B protein dosing|Patients under antiplatelet therapy and who have a minor traumatic brain injury will have a blood samples with protein S100B dosage on arrival to the emergency room and after they will have a brain scanner between 4 and 8 hours after the trauma to analyse the negative predictive value with a treshold of 0.105 μg/L
45755480|NCT03779204|Behavioral|Mentorship|The mentors will be encouraged to incorporate the key relationship-based components of natural mentors (e.g., a 'coach' or 'cheerleader' role) to assist with mainstream integration. The mentors will have more flexibility than a typical formal mentorship program in the types of activities they pursue with their mentees. They will not be mandated to attend shelter-based social events, but rather engage in activities that direct their mentees away from the shelter system (and their old identities as homeless youth) and toward the mainstream (e.g., meeting for coffee at a local university campus). All of the mentors will meet monthly with their mentees for two years. In addition, the mentor will be encouraged to touch base with their mentee via phone or text message every week. If a mentor is unable to continue their role and there are at least six months left in the study, the study participant will be matched with a new mentor.
45601322|NCT04425915|Biological|Convalescent Plasma|Dose-250 ml Frequency - 2 doses on consecutive days Duration -Start by day 3 of symptom onset (of severe COVID-19 as in inclusion criteria) in eligible patients
45755481|NCT03779204|Behavioral|Rent Subsidies|Participants will receive rent subsidies ($500 for those living in Toronto, $400 for those living in Hamilton or St. Catherine's due to differences in cost of living) for 24 months.
45755482|NCT03779048|Behavioral|Behavioral Treatment|Behavioral treatment (BT) for weight loss includes diet and physical activity recommendations and behavior therapy strategies. All participants will complete an initial 4-week BT run-in, delivered in individual, 20-30 minute weekly sessions. After the end of the run-in, participants will be offered an additional 24 weeks of 20-30 minute individual BT sessions, occurring weekly for the first 12 weeks and every other week for the last 12 weeks (total of 18 visits).
45755483|NCT03779048|Drug|Placebo|The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
45601323|NCT04425915|Other|Standard of Care|The Ministry of Health and Family Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity which may be periodically updated. For the management of ARDS or sepsis the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented. (Ref: Guidelines on Clinical Management of COVID-19. MoHFW, GoI.2020.)
45601324|NCT04350723|Procedure|Awake Proning|The duration of proning will be a total of 8-10 hours with 1-2 hours break in supine position.
45755484|NCT03779048|Drug|Phentermine 15 MG|The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
45601325|NCT05307536|Combination Product|Autologous BMMNCs transplantation and educational intervention|"Biological/ Vaccine: Autologous bone marrow-derived mononuclear cell infusion (BM-MNCs) will be administrated at baseline, and the second infusion will be performed six months after the first administration. For each transplantation, the bone marrow will be harvested through an anterior iliac crest puncture under general anesthesia in the operating theatre. The volume collected depends on the patient's body weight based on our experience from a previous study as follows: 8 ml/kg for patients under 10 kg; [80 ml + (body weight in kg - 10) x 7 ml] for patients above 10 kg but no more than 250 ml in total.~Educational intervention: 6 months based on the Early Start Denver Model"
45601326|NCT05307536|Combination Product|Educational intervention|Educational intervention: 6 months based on the Early Start Denver Model
45601327|NCT02289742|Device|Nelfilcon A multifocal contact lenses|
45601328|NCT02289742|Device|Nelfilcon A toric contact lenses|
45601329|NCT02289742|Device|Nelfilcon A sphere contact lenses|
45601330|NCT02328651|Drug|Ribavirin plus Xiao'er jiebiao oral liquid|"For mild (Phase I) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, ivgg, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.~For moderate (Phase II) patients:~recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2~5ml/kg,iv, Bid~tid）"
45755485|NCT03724136|Procedure|Intravenous Bone Marrow Stem Cell (BMSC) Fraction|14 cc of BMSC fraction separated from bone marrow aspirate and filtered with 150 micron filter and administered intravenously.
45755486|NCT03724136|Procedure|Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction|Approximately 1 cc of BMSC fraction separated from bone marrow aspirate and administered to the nasal mucosa topically.
45755487|NCT03724136|Procedure|Near Infrared Light|Near Infrared Light will be administered using an FDA cleared medical device on the preoperative day and the first postoperative day as tolerated to the general area of the frontal bone.
45755488|NCT03778580|Dietary Supplement|Pyridoxamine Dihydrochloride|pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid
45755489|NCT03778580|Drug|placebo|placebo
45755490|NCT03722342|Drug|TTAC-0001 and pembrolizumab combination|"Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)~Treatment groups: 3 dose levels~Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~Cycle: 3 weeks (21 days per cycle)"
45755491|NCT03722108|Combination Product|Regorafenib and Irinotecan|Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) combined with regorafenib (160 mg daily on D2-8 and D16-22 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
45755492|NCT03722108|Drug|Irinotecan|Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
45755493|NCT03776552|Other|Rapid weight loss (RWL) program|16-week rapid weight loss (RWL) program (8-week low energy diet (LED) followed by 8-week gradual increased energy intake) and a subsequent 36-week weight-maintenance follow-up
45755494|NCT03776552|Other|Gradual weight loss (GWL) program|16-week gradual weight loss (GWL) program (moderate calorie restriction) and a subsequent 36-week weight-maintenance follow-up
45601331|NCT02328651|Drug|Ribavirin|"For mild (PhaseI) patients : recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip.~For moderate (PhaseII) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2~5ml/kg, iv, Bid~tid）"
45601332|NCT05306522|Other|Spinal stabilization exercise|The effects of telerehabilitation based spinal stabilization exercise in chronic stroke patients will be investigated.
45601333|NCT03111693|Other|Unenhanced Coro-CT|All unenhanced coroCT examinations are performed on the same 64-Row CT scanner (discovery CT 750 HD scanner, GE Helthcare), using prospective ECG-triggerring.
45601334|NCT03111459|Device|Medtronic Valiant Thoracoabdominal Stent Graft System|The Medtronic Valiant Thoracoabdominal Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components The system is comprised of two investigational devices that include the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.
45755495|NCT03775070|Drug|Simvastatin|"Starting dosage: in adult, the dose of simvastatin is 10 mg once daily. In children, the dose is 0.25mg/Kg/day (maximum dose: 10 mg/d).~Target dosage: in adult, the dose of simvastatin is 20 mg once daily. In children, the dose is 0.5mg/Kg/day (maximum dose: 20 mg/d).~The basic anti-congestive medication will be kept as the same.~The dosage may be titrated to a lesser dose by investigators according to the patient's condition."
45601335|NCT02289352|Drug|Brimonidine|
45601336|NCT02289352|Drug|placebo|
45601337|NCT05509712|Behavioral|Focus Groups to Refine MobileMen App Content|Participants are shown a clickable wireframe of the proposed new app features, including competition, animated badges, leaderboard, and incentives. Focus group members discuss perceptions, ease of use, and interest in the app design/features and identified additional or unnecessary features for adopting and maintaining physical activity (PA).
45601338|NCT05509712|Behavioral|Beta testing of MobileMen App Prototype|Project staff present the clickable wireframe prototype and have men navigate and test features using a structured script. Staff track participant responses in notes, as well as through both recording via a side profile and the device screen. At the conclusion of the session, participants complete surveys measuring satisfaction, helpfulness, and usability.
45601339|NCT02039973|Behavioral|Task-sharing approach to group therapy|"Participants will also identify, select and clarify common concerns/problems; provide orientation to steps in problem-solving; break down identified problems into manageable pieces; choose pieces of problem to address in facilitated discussion of problem solving for implementing solutions; support the sharing of feedback of strategies used in problem-solving and maintaining pleasurable activities.~Additionally, the intervention to aim to effect behavior by: explaining the links between problems, negative thoughts, choices made on a day-to-day basis, behaviors, and mood (symptoms of depression); facilitate sharing of practical skills to tackle problems, to change mood-related thoughts, choices and/or behaviors; offer and provide feedback on homework assignments to encourage practice of skills; and help participants attribute reported improvements to the use of new skills during feedback sessions."
45601340|NCT02039973|Behavioral|Enhanced standard of care|
45601341|NCT03143361|Procedure|Aortic valve replacement|All surgical procedures used for both traditional and mini-invasive aortic valve replacement, as well as transcatheter valve implantation.
45601342|NCT05338034|Drug|HPG1860|The dosage form for clinical research is a dry-filled capsule for oral administration manufactured as strengths of 3 mg, 5 mg, and 8 mg.
45601343|NCT05338034|Drug|Placebo|Capsule
45601344|NCT02315560|Device|TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS|electrical stimulation of the nerves in the foot on the incidence of nocturnal enuresis (bedwetting) in children
45601345|NCT02328417|Other|Consecutive radical cystectomies|Pre-, intra- and post-operative clinical measures during radical cystectomy clinical process
45601346|NCT05337566|Drug|Azithromycin Pill + Cefuroxime|Azithromycin 500 mg (2 tablets) per orally in the evening before the operation and single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
45601347|NCT05337566|Drug|Placebo + Cefuroxime|Placebo (2 tablets) per orally in the evening before the operation and single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
45601348|NCT02328495|Drug|Misoprostol|"Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
45755496|NCT03774758|Diagnostic Test|Guardant Health ct-DNA LUNAR assay|Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.
45755497|NCT03645824|Drug|Pacritinib|Patients receive up to 4 cycles of pacritinib before allo-SCT
45755498|NCT02083406|Drug|800mg OZ439 prototype formulation 1|
45755499|NCT02083406|Drug|800mg OZ439 prototype formulation 2|
45755500|NCT02083406|Drug|800mg OZ439 prototype formulation 3|
45755501|NCT02083406|Drug|960mg PQP|
45934916|NCT00210847|Drug|tramadol, acetaminophen|
45934917|NCT00210886|Drug|levofloxacin|
45601349|NCT02328495|Other|Bladder Filling|"Patients in bladder filling group will be instructed to drink one liter of water and to avoid urination during the one and half hour period before office hysteroscopy procedure..A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used."
45444501|NCT03276728|Drug|AMG 986 PO|AMG 986 tablets for oral (PO) administration
45601350|NCT02522624|Behavioral|Decision Aid (DA)|Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of health insurance plans in addition to usual care.
45601351|NCT04886986|Drug|225Ac-J591|30 - 40 KBq/kg (dose-escalation) every 8 weeks, for up to 2 cycles. Administered together with 177Lu-PSMA-I&T. Intravenous administration.
45601352|NCT04886986|Drug|177Lu-PSMA-I&T|6.8 GBq (fixed dose) every 8 weeks, for up to 2 cycles. Administered together with 225Ac-J591. Intravenous administration.
45601353|NCT04886986|Drug|68Ga-PSMA-11|[185 ±74 MBq or 5 ±2 mCi] intravenous during screening, 12 weeks, 24 weeks. Imaging agent for PSMA PET/CT.
45601354|NCT03077841|Other|Laboratory Biomarker Analysis|Correlative studies
45601355|NCT03077841|Radiation|Partial Breast Irradiation|Undergo hypofractionated partial breast irradiation
45601356|NCT03077841|Other|Questionnaire Administration|Ancillary studies
45601357|NCT02287402|Drug|AO-128|AO-128 tablet
45601358|NCT05335616|Other|Guideline|Hypothetical guideline regarding the indications and treatment steps involved in dental restoration repair.
45601359|NCT05335616|Other|Treatment fee item|Arrangement of a hypothetical treatment fee item which can be charged in addition to the actual repair restoration.
45601360|NCT02993601|Device|Heartfelt-1|The patients will stand in front of the Heartfelt-1 in order for images to be captured and the volume of their lower legs measured.
45601361|NCT02993601|Device|Weighing scales|The patient will be asked to stand on standard medical weighing scales, to measure their weight.
45601362|NCT02993601|Other|Medical grading of oedema|A member of the research team will assess the severity of the peripheral oedema on a scale of 1-5.
45601363|NCT02993601|Other|Baseline assessements|At the point study participants are recruited, their age, sex, diagnosis, aetiology of heart failure, LVEF (Left ventricular ejection fraction), medical and device therapy, time since diagnosis, BNP (B-type Natriuretic Peptide), CRP (C-Reactive Protein), renal function (EGFR), Haemoglobin, albumin and urinalysis will be assessed unless recent (less that 6 months old) results are available. The number of Heart failure hospital admissions in the last 2 years, LACE score, co-morbidities will also be noted.
45755502|NCT03718832|Other|Fresh Food Farmacy|Patients are prescribed fresh food by a dietician, fill the prescription each week at the FFF clinic, receive training on how to use the food, and training in diabetes self management.
45601364|NCT02993601|Device|Water displacement method|This will involve filling a gauge with lukewarm water (27-35oC +-2oC) up to the appropriate level. The appropriate level is determined by the water stabilising after some has flown out of the gauge into the waste bucket. Once the water level is stable the patient, who is sitting on a chair will be gently plunging the foot (naked) in the gauge until their foot is flat on the bottom on the gauge. The water flowing out of the gauge into the measuring bucket will be collected until the flow of water stops. Four small marks with non-toxic /non-permanent pen will be made on the lower leg of the patient to indicate where the water level was at. The water which has been collected in the measuring bucket will be weighted with precision scales to determine the volume of water displaced by the insertion of the foot. The patient's foot will then be dried.
45601365|NCT02993601|Device|Callipers measurements|This will involve making 4 marks on one of the foot/lower leg (small cross) using non-toxic / non- permanent pen. The measurement will consist of making 6 measurements between those marks using callipers, and reporting the distance on a calibrated tape.
45601366|NCT02993601|Device|Measuring tape|The measurements taken using a medical tape measure will involve the circumference of the ankle to be measured as well as the circumference at the level of the arch of the foot. The medical tape used will be a CE marked disposable medical measuring tape to minimise the risk of infection. The measurements will be done on both feet.
45601367|NCT02913495|Drug|Vaginal Progesterone|
45601368|NCT02913495|Drug|Intramuscular Progesterone (17 alpha hydroxprogesterone caproate)|
45444502|NCT03276728|Drug|Placebo PO|Matching placebo tablets for oral administration
45601369|NCT05335226|Procedure|Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation|Patients will receive umbilical cord blood allogeneic stem cell transplantation at the same day as the haploidentical stem cell transplantation. (HLA 6-10/10, TNC≥1-3×10-7/Kg)
45601370|NCT05335226|Procedure|haploidentical hematopoietic stem cell transplantation|Receive haploidentical hematopoietic stem cell transplantation (HLA 6-10/10)
45601371|NCT02314780|Drug|Heme arginate 3mg/kg|
45601372|NCT02314780|Drug|Heme arginate 1mg/kg|
45601373|NCT02314780|Drug|Placebo|
45601374|NCT02288182|Device|Straumann VivOss|Patients will receive Straumann VivOss for sinus augmentation.
45601375|NCT02288182|Device|Geistlich Bio-Oss|Patients will receive Geistlich Bio-Oss for sinus augmentation.
45601376|NCT03143049|Drug|PCD|"For PCD, patients will be treated as follows: PO pomalidomide 4mg from D1-21, PO cyclophosphamide 400mg on D1, 8 and 15, and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
45755503|NCT03773666|Drug|Durvalumab|Durvalumab is a monoclonal antibody (an antibody is a protein produced by the body's immune system) that works by blocking the Programmed Cell Death Ligand 1 (PD-L1), a protein on cancer cells that stops the body's immune system from killing cancer cells.
45755504|NCT03773666|Drug|Oleclumab|Oleclumab is a monoclonal antibody that works by reducing the amount of adenosine, a small molecule called a metabolite that binds to adenosine receptors on immune cells to regulate the immune system and suppress the immune response. Reducing the amount of immunosuppressive adenosine can increase the body's immune response to kill cancer cells.
45934918|NCT00210925|Drug|topiramate|
45601377|NCT03143049|Drug|PD|"For PD, Patients will be treated as follows: PO pomalidomide 4mg from D1-21 and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
45601378|NCT03110835|Radiation|Radioiodine|Administration of radioiodine
45601379|NCT05304104|Behavioral|Cognitive Behavioral Therapy (CBT)|The treatment has three stages. Stage 1 consists of presentation of the CBT model; introduction and discussion of the structure, goals, interventions, and expected outcome of treatment; education regarding binge eating and dieting; and the introduction of self-monitoring techniques for identifying problematic eating practices and triggers. Stage 2 consists of maintaining the normalized eating and self-monitoring procedures but becomes increasingly cognitively oriented. Stage 3 focuses on practicing skills, consolidation of progress and relapse prevention. Treatment will adhere to a manual developed by Dr. Masheb (PI), adapted for Veterans, and written at a seventh-grade reading level.
45601380|NCT02286466|Behavioral|Health Education Program|Participants in the control group will receive a health education program using a tablet computer identical to the intervention group. The content of this program is adapted from a health education intervention used as the control condition for a cognitive behavioral stress and affect management intervention in a NIH-funded randomized controlled trial of a quality of life intervention for patients with advanced prostate cancer (R21CA102761, PI: Penedo). The program consists of the same number of sessions as the intervention group and includes general information about health and well-being. Specifically, control participants will learn information about topics such as healthy eating, exercise, memory and cognition, and side effects in the context of a cancer diagnosis and treatment.
45601381|NCT02286466|Behavioral|CBT Mobile Application|The CBT intervention is brief, consisting of 6 modules lasting approximately 30 minutes each. Sessions focus on skills for relaxation, coping with cancer-related worries, as well as activity planning and pacing. Prior to starting the program, a trained research assistant will meet with participants in a private office setting to orient them to the software and instruct them on the use of the mobile tablet device. Once patients are comfortable with the functions and features of the mobile app, they will be encouraged to self-administer the intervention on their study-issued tablet at home and during their regularly scheduled oncology visits, for example while receiving chemotherapy infusion or waiting for a doctor's appointment or tests.
45601382|NCT03111069|Procedure|Abdominal Surgery|"Resectable Intra-Abdominal/Pelvic Tumors Group: Participants receive peritonectomy, omentectomy, cytoreduction, (complete surgical tumor resection, no gross residual disease).~Unresectable Intra-Abdominal/Pelvic Tumors Group: Participants receive debulking surgery (90% resection) , with no more than 5mm thick residual implants, totaling no more than 2.5cm2 of residual tumor."
45601383|NCT03111069|Drug|Doxorubicin|"Dose Escalation: Heated Doxorubicin delivered by Hyperthermic Intraperitoneal Chemotherapy (HIPEC). After abdominal surgery two large bore catheters are placed in the peritoneal cavity through the incision. Starting dose of Doxorubicin is 15 mg/L of HIPEC perfusate.~Dose Expansion Starting Dose: MTD from Dose Escalation."
45601384|NCT03111069|Radiation|Intra-Operative Radiation|Standard dose brachytherapy delivered to the residual pelvic tumor sites.
45601385|NCT03110757|Biological|GLA-AF|Previously referred to as Gluco-pyranosylphospho-lipid A aqueous formulation (GLA-AF). It is a toll-like receptor-4 agonist
45601386|NCT03110757|Biological|Hepatitis B Virus Vaccine (Recombinant)|A non-infectious subunit viral vaccine derived from hepatitis B surface antigen (HBsAg) produced in yeast cells.
45601387|NCT03110757|Biological|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel
45601388|NCT02313766|Other|PPV : positive pressure ventilation|Inspiratory pressure support ventilation (12 cmH2O) without PEEP
45601389|NCT02313766|Other|PEEP : PPV + PEEP|Inspiratory pressure support ventilation (12 cmH2O) with PEEP (6 cmH2O)
45601390|NCT05303870|Other|Improving access to psychological therapies (IAPT)|"IAPT services provide evidence-based treatments for people with depression and anxiety disorders, and comorbid long-term physical health conditions or medically unexplained symptoms. IAPT services are characterised by three key principles:~Evidence-Based psychological therapies at the appropriate dose: NICE recommended therapies matched to the mental health problem, at the intensity and duration designed to optimise outcomes.~Appropriately trained and supervised workforce.~Routine outcome monitoring."
45601391|NCT03110991|Behavioral|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)
45601392|NCT03110991|Behavioral|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)
45601393|NCT05303792|Drug|Cyclophosphamide|Given IV
45601394|NCT05303792|Drug|Vincristine|Given IV
45601395|NCT05303792|Drug|Dexamethasone|Given IV or PO
45601396|NCT05303792|Biological|Inotuzumab Ozogamicin|Given IV
45601397|NCT05303792|Drug|Methotrexate|Given IV or PO
45601398|NCT05303792|Drug|Cytarabine|Given IV
45601399|NCT05303792|Drug|Methylprednisolone|Given IV
45601400|NCT05303792|Biological|Rituximab|Given IV
45601401|NCT05303792|Drug|Prednisone|Given PO
45601402|NCT05303792|Drug|Mercaptopurine|Given PO
45444503|NCT03276728|Drug|Placebo IV|Matching placebo solution for infusion
45601403|NCT05303792|Drug|Doxorubicin|Given IV
45601404|NCT03110913|Other|dietary intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from lentils and 3 levels from lentils with rice.
45601405|NCT05610566|Device|the HighLife Trans-Septal Transcatheter Mitral Valve Replacement System|The HighLife TMVR system is composed of a Transcatheter Mitral Valve (TMV), a subannular implant (SAI), and their delivery systems and accessories. The TMV is a 28mm mitral bioprosthesis made of a self-expanding Nitinol frame covered with polyester graft and supporting bovine pericardium leaflets. The bioprosthesis is used in conjunction with the Sub-Annular Implant (SAI), comprising a ring (made of polycarbonate urethane (PCU), nitinol, gold markers and polyester (Dacron) to be placed around the mitral valve apparatus to stabilize the position of the mitral valve implant.
45444504|NCT01301859|Behavioral|TIP|Treatment visits as usual with MD
45601406|NCT05080569|Drug|Progesterone Vaginal Product|3dd200mg
45601407|NCT05080569|Drug|Placebo|3dd1 vaginal capsule
45755505|NCT03770858|Drug|Crisaborole|Subject to apply topical crisaborole twice daily to the affected atopic dermatitis areas
45444505|NCT02260024|Other|High fat, high caloric meal|
45601408|NCT05383508|Other|CA35|Nicotine concentration: 3.5 % e-liquid flavor: Tobacco
45601409|NCT05383508|Other|CM35|Nicotine concentration: 3.5 % e-liquid flavor: Menthol
45601410|NCT05383508|Other|Cig|Subjects' preferred brand of commercially available, regular or mentholated cigarettes
45601411|NCT03145467|Drug|Paracetamol|1000 mg of paracetamol (Parol Tablet - Atabay İlaç Fabrikası A.Ş.) Oral (PO) was given 100 patients
45601412|NCT03145467|Drug|Zolmitriptan|Zolmitirptan 2,5 mg (Zomig Tablet - Astra Zeneca) oral (PO) was given 100 patients
45601413|NCT05302856|Diagnostic Test|Blood test (CMV IGG, Anti sperm antibody, Testosterone levels)|Peripheric blood extraction
45601414|NCT02030925|Drug|IW-3718|
45601415|NCT02030925|Drug|Matching Placebo|
45601416|NCT05080413|Device|Laser shoes|Path Finder® is a device that is fixed to the noses of the patient's shoes using a rubber strap, and laser-marks the place to be stepped on the ground of the opposite foot when walking. It is installed on both feet to relieve the symptoms of freezing of gait.
45601417|NCT05080413|Device|Metronome|The metronome, which makes a sound with a constant beat, is known to have an effect on the symptoms of Freezing of Gait in Parkinson's disease patients. At a rate of 80 beats per minute, the volume of sound that the patient can fully recognize is set to resolve the freezing of gait using the metronome sound.
45601418|NCT05506826|Other|fine motor activities|patient will perform fine motor exercises like therapy ball exercises, therapy putty exercises, table top exercises, moving beans, stacking pennies and rubber band resistances exercises etc. for 30 minutes along with conventional therapy
45601419|NCT05506826|Other|conventional therapy and mirror therapy|Patients in this group will receive conventional therapy for four weeks sixty minutes per day, five days per week. In addition, receive thirty minutes of mirror therapy, which included periodic wrist flexion-extension, flexion and extension exercises of fingers on non paralyzed limb
45755506|NCT03770858|Device|Scratch sensor|advanced, flexible and wearable skin sensor
45755507|NCT03770468|Procedure|Blood drawl|
45444506|NCT02260024|Drug|Pramipexole IR tablets|
45444507|NCT02260024|Drug|Pramipexole SR C|
45601420|NCT04039893|Diagnostic Test|Systematic axillary ultrasound imaging|Before surgery, all patients will be explored with a pre-defined systematic and reproducible axillary ultrasound imaging workflow intending to establish the number of neoplastic lymph nodes.
45601421|NCT04039893|Diagnostic Test|Sentinel node|Sentinel nodes will be identified with a radioisotope tracer and blue dye or fluorescein.
45601422|NCT04039893|Procedure|Excision of suspicious lymph nodes|Nodes suspected to be infiltrated both by physical exploration and/or ultrasound will be excised and evaluated separately.
45601423|NCT04039893|Procedure|Two steps axillary node clearance|Axillary node clearance will be performed in two steps comprising inferior and superior clearance. The second intercostobrachial nerve will be considered the limit defining the border between superior and inferior axilla.
45601424|NCT05301764|Combination Product|LVGN6051 and Anlotinib|"LVGN6051: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits. Anlotinib: Rout of administration is oral. The initial dose of anlotinib was 12 mg for subjects with body surface area ≥ 1.5m2 and 10 mg for subjects with body surface area < 1.5m2. If the subjects in the combined treatment group were not tolerated, the dose of anlotinib was reduced to 10 mg for subjects with body surface area ≥ 1.5m2 and 8 mg for subjects with body surface area < 1.5m2.~One cycle is 3 weeks, including oral for 2 weeks and withdrawal for 1 week."
45601425|NCT03143283|Behavioral|Safety Study Lethal Means Counseling|Clinicians provide applicable families with locking devices and handouts on safe storage of firearms and medications.
45601426|NCT05332574|Biological|GB263T|Participants will receive IV infusions of GB263T at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive GB263T at predefined dose levels and frequency, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days.
45601427|NCT02328183|Drug|Polymyxin B|administrate drug by 0.75-1.25 mg/kg/dose intravenously q 12 hrs both saline and dextrose solution can be dissolved duration 7-14 days
45444508|NCT02260024|Drug|Pramipexole SR C2|
45444509|NCT02260024|Drug|Pramipexole SR C2A|
45444510|NCT02260024|Drug|Pramipexole SR C2B|
45444511|NCT05169489|Biological|bbT369|bbT369 is a genetically modified autologous T cell immunotherapy product consisting of T cells that are transduced with a single lentiviral vector (LVV) to express anti-CD79a and anti-CD20 chimeric antigen receptors (CARs) and transfected with an mRNA encoding the CBLB-targeting megaTAL enzyme to edit the CBLB gene, suspended in a cryopreservative solution.
45444512|NCT03800667|Drug|Ascorbic Acid 1000 MG|1000 mg ascorbic acid (Vitamin C) for 1 month post-op after an elective gynecological surgery.
45601428|NCT05610488|Drug|FARICIMAB 6 Mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [VABYSMO]|Intravitreal injection of faricimab 6 mg at baseline (week 0), at week 4, 8, 12 (=4x loading) and each of the following treat and extend visits
45601429|NCT01646398|Biological|13-valent pneumococcal conjugate vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
45601430|NCT01646398|Biological|23-valent pneumococcal polysaccharide vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
45755508|NCT04762784|Drug|Tocilizumab|Tocilizumab treatment: Tocilizumab infusion 8mg/Kg，Once per month for 3 months.
45755509|NCT04762784|Drug|Glucocorticoids|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 15mg per day in 3 months.
45755510|NCT00003644|Drug|carboplatin|
45755511|NCT00003644|Drug|paclitaxel|
45755512|NCT03641378|Other|Palliative Care Intervention|team of clinicians that specialize in the lessening (palliation) of many distressing symptoms
45755513|NCT03641378|Other|Standard Transplant Care|Standard care per hospital guidelines
45755514|NCT02142049|Drug|Ibrutinib|Ibrutinib
45934919|NCT00211003|Drug|doripenem|
45601431|NCT05080101|Other|Conventional Therapy Program|Patients in control group (n=14) will receive 40-mins conventional physiotherapy session for 3-days per week, over 6 weeks. Conventional physiotherapy will consist of stretching and strengthening exercises, postural alignment exercises, as well as electrotherapy such as transcutaneous electric magnetic stimulation (TENS) which will be applied to lumbar region with a frequency of 100 Hz, 50-100 μsec current duration for 20 minutes, hotpack which will be applied to lumbar region for 20 mins, and ultrasound application which will be applied to the lumbar region with a Chattanooga Intelect Mobile device at a frequency of 1 MHz, at a dose of 1.5 W/cm2, for 6 minutes using a 10 cm2 head.
45601432|NCT05080101|Other|Basic Body Awareness Therapy Group Program|Patients in study group (n=14) will receive Basic Body Awareness Therapy (BBAT) 3 days in a week, over 6 weeks in addition to conventional physiotherapy. BBAT will consist of flexibility exercises and various cognitive exercises in supine, position, sitting position and standing position. These exercises will be consist of exercises such as body scanning, breathing, sound resonance.
45601433|NCT05527886|Other|AAROM|AAROM with knee to wall exercise, 3x30 reps
45601434|NCT05527886|Other|Slow Load|Single leg heel raise, 3x10 reps
45601435|NCT05527886|Other|Plyometric|Double leg 5 inch wall hops, 3x10 sec
45601436|NCT02328261|Drug|Icotinib|Icotinib (125 mg tablet) is orally administered three times daily until disease progression or unaccepted toxicity.
45601437|NCT05527652|Device|Self-Supporting Nasopharyngeal Airway (ssNPA)|The ssNPA device is made of a single piece of flexible, medical-grade silicone. It is inserted through one nostril and extends to the anatomic position bypassing the upper airway obstruction above the epiglottis.
45601438|NCT02328339|Other|Tea|Black tea infusion equivalent to approximately 530 mg total polyphenols expressed as gallic acid equivalents
45601439|NCT02328339|Other|Placebo|Placebo matched to tea with respect to taste and appearance
45601440|NCT05301452|Radiation|Intravascular Irradiation of Blood (ILIB)|The laser treatment will be performed by a speech therapist and will have the following parameters: wavelength of 808 nm. It will be done twice a week for 8 weeks, in 20-minute sessions.
45601441|NCT05301452|Radiation|Placebo Intravascular Irradiation of Blood (ILIB)|The photobiomodulation procedure will be simulated, but with the laser turned off. It will be done twice a week for 8 weeks, in 20-minute sessions.
45601442|NCT05301452|Procedure|Orofacial Myofunctional Therapy|"Myofunctional therapy will be performed by a speech therapist specialized in the area. It will consist of 1 weekly session, where the functions of breathing, chewing and swallowing will be evaluated and addressed.~The following exercises will be indicated: nasal hygiene, inflated cheeks with the tip of the tongue on the palate, lingual sweep, tongue thrust against the palate, tongue touch on the last molars, chewing of soft solids and bolus assembly (20 minute therapy session)."
45601443|NCT03141723|Other|KMC & WHO protocol (0-1 hour)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
45601444|NCT03141723|Other|KMC, WHO protocol & bag (0-1 hour)|In addition infants will be placed in a plastic bag (clear polyethylene nonmedical low-cost [3 cents per bag] linear low-density bag measuring 10 × 8 × 24 in. and 1.2 mil thick) that will cover the infant's torso and lower extremities.
45601445|NCT03141723|Other|KMC & WHO protocol (1-24 hours)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive
45601446|NCT03141723|Other|KMC, WHO protocol & bag (1-24 hours)|In addition infants will be placed in a plastic bag (clear polyethylene nonmedical low-cost [3 cents per bag]
45601447|NCT05301374|Behavioral|Watching Cartoon|Children in the cartoon group before the procedure, they chose one of the cartoons predetermined by the researchers. The children in the cartoon group started watching a cartoon of their choice 2 minutes before the procedure and they kept watching until the procedure was ended.
45601448|NCT05079867|Device|Cochlear implantation|Electrode surgically implanted in patient's cochlea to improve hearing
45755515|NCT02142049|Drug|DA-EPOCH-R|Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
45755516|NCT02142049|Drug|Lenalidomide|Lenalidomide
45601449|NCT05382104|Drug|Maribavir|Maribavir 400 mg tablet single oral dose under three different food conditions depending upon the treatment sequence allocation on Day 1 of each treatment period
45601450|NCT03892239|Behavioral|RunIn3 Prevention Program|"The intervention will be delivered online. Every two weeks we will send a link to participants that will direct them to an online questionnaire. The online questionnaire will collect information on complaints and symptoms related to running, and the volume, intensity and frequency of running practice within the 2-week period. If the participant reports any symptom and if she/he accepts a suggestion regarding running training, an algorithm embedded in the online system will automatically suggest a training volume for the next two weeks based on the distance and/or duration reported by the participant.~Through a website we will make available informative texts, videos and infographics in order to increase the participant's knowledge regarding topics such as: musculoskeletal symptoms; foot strike patterns; training workload; running shoes; warming-up/cooling-down, stretching; and concomitant strength training."
45601451|NCT03892239|Behavioral|Feedback Based Surveillance|The intervention will be delivered online. Every two weeks we will send a link to participants that will direct them to an online questionnaire. The online questionnaire will collect information on complaints and symptoms related to running, and the volume, intensity and frequency of running practice within the 2-week period. If the participant reports any symptom and if she/he accepts a suggestion regarding running training, an algorithm embedded in the online system will automatically suggest a training volume for the next two weeks based on the distance and/or duration reported by the participant.
45444513|NCT02037178|Other|First ultrasound reading|First ultrasound reading of the sub-renal abdominal aorta by a general practitioner.
45755517|NCT03640286|Device|VeSTAL|The aim of this study is to evaluate the efficacy of non-invasive electrical vestibular nerve stimulation in combination with a lifestyle modification program, as a method of reducing excess body weight and body fat, as compared to a sham device in combination with the same lifestyle modification program.
45755518|NCT03717194|Drug|Ertugliflozin|Ertugliflozin as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
45755519|NCT03717194|Drug|Placebo|Placebo as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
46066523|NCT00572169|Drug|Dexamethasone|A pill taken by mouth
45601452|NCT04246814|Device|LG1|Application of LASER AsGa 904nm 10 J/cm².
45601453|NCT04246814|Device|LG2|Application of LASER AsGa 904nm 8 J/cm².
45601454|NCT04246814|Device|LG3|Application of LASER AsGa 904nm 4 J/cm².
45601455|NCT04246814|Device|CC|Application of placebo LASER.
45601456|NCT04246814|Procedure|Dressing|Application of Helianthus annuus oil dressing.
45601457|NCT03141879|Other|HUR equipment resistance training intervention|Resistance training intervention
45601458|NCT05079711|Device|SavvyCheck Vaginal Yeast Test (rapid, point-of-care diagnostic test)|The SavvyCheck Vaginal Yeast Test is a lateral flow immunochromatographic qualitative test for detection of Candida antigen in vaginal secretions, sampled by a swab as an aid for identification of vulvovaginal candidiasis (VVC), as a primary cause of vaginal yeast infections. The SavvyCheck Vaginal Yeast Test is designed for use by women experiencing vaginal symptoms, including: increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination. The SavvyCheck Vaginal Yeast Test is indicated for OTC use.
45601459|NCT01646320|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
45601460|NCT01646320|Drug|Placebo matching with Dapagliflozin|Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
45601461|NCT01646320|Drug|Saxagliptin|Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
45601462|NCT01646320|Drug|Metformin immediate release (IR)|Tablets, Oral, ≥ 1500 mg, Twice daily, Up to 52 weeks
45601463|NCT05331950|Other|Office Workers|Office Workers which will be observed/exposed with different task and different factors
45601464|NCT05079555|Device|Robotic rehab|Patients using the robotic platform SWalker
45601465|NCT03141645|Other|Fluid loading|Patients in the preoperative intravenous fluid loading group (group F) will receive ringer lactate solution 10ml/kg in 15 minutes before starting operation.
45601466|NCT03141645|Drug|Ondansetron|Patients in the ondansetron group (group O) will receive an 8 mg of intravenous ondansetron in 15 minutes before finishing operation
45601467|NCT05610410|Other|Laser speckle contrast analysis|Peripheral endothelial function assessment using Laser speckle contrast analysis and Peripheral reactive hyperemia assessment using EndoPAT
45601468|NCT05330546|Procedure|Densah burs|using Densah burs to prepare implant osteotomy
45601469|NCT05330546|Procedure|Ridge expansion screws|using Ridge expansion screws to prepare implant osteotomy
45601470|NCT05330234|Device|OnTrack Tools|"The intervention is the OnTrack Tools system consisting of a graphical user interface (GUI) used to manage patients who are users of the OnTrack rehabilitation system. Participants will be asked to complete clinical and non-clinical tasks in simulation using OnTrack Tools. The themes for the scenarios of use presented in each of the three phases are summarised below:~Phase 1 - Account creation, system onboarding and general system navigation. Phase 2 - Individual patient management. Phase 3 - Content and data management."
45601471|NCT05300204|Other|Self-help strategies for depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding self-help strategies for depression."
45601472|NCT05300204|Other|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding general information about depression"
45601473|NCT05299502|Behavioral|Nutritional Intervention|4 individual 1-hour in person (or virtual, according to potential public health restrictions and patients' preference) motivational interviews (12, 18, 24 and 30 weeks) with a registered dietitian will be conducted to elaborate S.M.A.R.T. (Specific,Measurable, Attainable, Relevant, Timely) goals regarding diet, based on the 2019 Canada's Food Guide. Between those individual follow-ups, 4 phone calls with the registered dietitian will be provided (15, 21, 27, 33 weeks). Throughout the study, 10 informative nutritional video clips will also be provided. Participants receiving the intervention will have access to an online Facebook private community to discuss and share experiences, thus maintaining motivation and providing social support.
45755520|NCT03716180|Drug|Paclitaxel|"Paclitaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug"
45601474|NCT05381090|Diagnostic Test|Venous blood collection|Participants will undergo venous blood collection following an overnight fast and 5, 60 and 180 minutes following food intake.
45601475|NCT05610332|Drug|Camrelizumab|Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.
45601476|NCT05610332|Drug|Albumin Taxol|Albumin paclitaxel was administered intravenously (without pretreatment) for 30 min on the first day of each cycle
45601477|NCT05610332|Drug|FLOT scheme|"Docetaxel 50mg/m2, ivgtt, d1; Oxaliplatin 85 mg/m2, ivgtt, d1; Calcium folinate 200mg/m2, ivgtt, d1; 5-fluorouracil 2600mg/m2, 24h civ, d1,~4 cycles before and after operation, q2w"
45601478|NCT05298410|Other|Limitless|Participants will be instructed to take Limitless for 30 days.
45601479|NCT05329142|Diagnostic Test|Surplus sample toxicology analysis|Anonymised surplus blood sample will be analysed for drugs and their metabolites by way of Mass Spectrometry and LGC Group, Cambridge.
45601480|NCT02524730|Device|Primary total knee replacement (Scorpio NRG CR Total Knee System)|Scorpio NRG CR Total Knee System
45601481|NCT05297786|Drug|Lanadelumab Injection [Takhzyro]|Lanadelumab 300 mg subcutaneous injection
45601482|NCT05297786|Drug|Placebo|Placebo injection
45601483|NCT05609396|Behavioral|Behaviorally enhanced reminder letter|Behavioral interventions to increase FIT-based colorectal cancer screening uptake
45755521|NCT03716180|Drug|Trastuzumab|Trastuzumab works by targeting the HER2/neu receptor on cancer cells
45755522|NCT03716180|Drug|Pertuzumab|Pertuzumab is a monoclonal antibody which targets the surface of the cells human epidermal growth factor receptor 2 protein (HER2) on the cancer cell, interfering with HER2 causing cancer cell death
46066524|NCT00572169|Drug|Adriamycin|Given into the vein (IV) by a continuous infusion through a central catheter
45601484|NCT05297630|Other|Evaluation of the evolution of biological markers from the biobank.|The evolution of sST2, copeptin, chromogranin, NGAL, suPAR and cystatin will be evaluated between Day 0 and Month 1
45601485|NCT05327426|Biological|Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT)|Sanofi's licensed IPOL trivalent inactivated polio vaccine (NDC 49281-860-78) delivered at the dose-sparing fractional volume of 1/5 the full dose (0.1mL) admixed with 0.47µg of recombinant double mutant [LT(R192G/L211A)] Enterotoxigenic Escherichia coli heat labile toxin (dmLT) adjuvant.
45601486|NCT05327426|Biological|Intradermal fractional dose inactivated polio vaccine (fIPV)|Sanofi's licensed IPOL trivalent inactivated polio vaccine (NDC 49281-860-78) delivered at the dose-sparing fractional volume of 1/5 the full dose (0.1mL).
45601487|NCT05327426|Biological|Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain|Monovalent oral polio vaccine (OPV) challenge administered as a test of mucosal immunity.
45601488|NCT05327270|Drug|Nivolumab|Given by IT
45601489|NCT05526092|Other|Dietary intervention|Changes in metabolism, microbiota, vitality and comprehensive health after 6 week consumption of oat / rice.
45601490|NCT05297396|Other|Slow Tapering of Chronic Opioid Therapy|Clinically prescribed daily opioids reduced by no more than 10 morphine milligram equivalent per day (MMED) each month for 12 months
45601491|NCT05297240|Drug|Belantamab mafodotin|At least one dose of belantamab mafodotin as part of the compassionate use or the expanded access program in Spain between November 2019 and June 2021.
45601492|NCT05505266|Other|observational|observational
45601493|NCT05598398|Device|V.A.C.Ulta™ Negative Pressure Wound Therapy System|"The V.A.C.Ulta™ Negative Pressure Wound Therapy System is a 510(k) - cleared, Class II device (K100657) with the following indication for use: the V.A.C.Ulta™ Negative Pressure Wound Therapy System is an integrated wound management system that provides Negative Pressure Wound Therapy with an instillation option."
45601494|NCT05598398|Other|Standard of Care (Wet-to-dry dressings)|Wet-to-dry dressings
45601495|NCT05503472|Other|observational|observational
45601496|NCT05296382|Drug|Tebipenem tablet form|Tebipenem tablets will be administered intact or crushed
45601497|NCT05296382|Other|Tube feeds|Tebipenem tablets will be administered with or without tube feeds
45601498|NCT05525780|Drug|GB-5001|Depending on the cohort, volume will be varied to administer.
45755523|NCT03715244|Procedure|Spinal anesthesia with short-acting local anesthetics|Spinal anesthesia in patients with duration of surgery < 90 minutes
45755524|NCT03715244|Procedure|General anesthesia (current standard)|General anesthesia in patients with duration of surgery < 90 minutes
45755525|NCT03634982|Drug|RMC-4630|RMC-4630 for oral administration
45755526|NCT03714620|Drug|Ketamine|Ketamine 0.15 mg/kg vs. 0.3 mg/kg IVPB over 15 minutes
45755527|NCT03634436|Drug|SHR-1209|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
45755528|NCT03634436|Drug|Placebo|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
45601499|NCT05525780|Drug|Placebo|A matched volume of placebo product will be administered to each subject in each cohort.
45755529|NCT03709784|Other|Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care|This is an observational study of adult patients with SMA to examine the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) for up to 30 months.
45755530|NCT03631628|Device|Transcutaneous electrical nerve stimulation (TENS)|TENS will be delivered to the median and radial nerves at the wrist regions. The stimulation frequency will be 100Hz and with an intensity just below the motor threshold.
45755531|NCT03631628|Behavioral|Mirror Therapy (MT)|"A customised angle-adjustable frame with a mirror board will be used. All subjects are instructed to perform~Wrist flexion and extension exercise~Forearm pronation and supination exercise~Gripping exercises~Fingers opposition exercises bilaterally during the 30 minutes period."
45755532|NCT03631628|Behavioral|sham-Mirror Therapy (sham-MT)|"A customised angle-adjustable frame with a mirror board will be used while the reflecting surface of the mirror was covered with paper. All subjects are instructed to perform~Wrist flexion and extension exercise~Forearm pronation and supination exercise~Gripping exercises~Fingers opposition exercises bilaterally during the 30 minutes period."
45601500|NCT05525780|Drug|Oral cohort|Single dose of Aricept tablet
45601501|NCT05269082|Other|No intervention|This is a non-interventional study.
45601502|NCT05324696|Device|autoinflation device|The authors developed a new standardized, inexpensive and simple device, based on Moniri. The Device is formed by a T tube with a unidirectional valve. A mask with the capacity of covering the child's mouth and nose, providing hermetic seal, and a balloon are connected to 2 ends of the T tube. Blowing the balloon trough the mask, with different types of maneuvers, will force the opening of the Eustachian tube and subsequent reabsorption of the middle ear effusion.
45755533|NCT03631628|Behavioral|Conventional Rehabilitation Program|All subjects attended 1 hour multi-disciplinary conventional rehabilitation program offered by the Rehabilitation Clinic of The Hong Kong Polytechnic University. The conventional rehabilitation program involves the training of upper and lower limbs in order to improve the muscle strength, balance and functional mobility.
45755534|NCT03631550|Device|Relivion active|1 hour self-administered occipital and supraorbital transcutaneous nerve stimulation
45601503|NCT05497856|Other|Integrated neuromuscular inhibition technique|Ischemic compression will be applied for 90 seconds followed by the SCS technique with a reduction in pain of at least 70%. it will be held for 20-30 sec followed by the Muscle energy technique in which the isometric contraction will be held for 7-10 sec and then the stretch will be held for 30 sec. This will be repeated 5 times per session with a 30-second rest interval in between each repetition Session will be held 3 times per week for 2 consecutive weeks
45601504|NCT05497856|Other|Myofascial Release|Deep sustained pressure on the trigger points will be applied with thumb in 5-7/10 pain tolerance and maintained for 60 seconds and then will be released in a vertical direction followed by stretch of the rhomboid muscle held for 30 sec. This Sustained manual pressure will be applied for 3 times each followed by a stretch per session with a 30 sec rest interval in between .Session will be held 3 times per week for 2 consecutive weeks.
45601505|NCT01658150|Drug|isradipine|Isradipine is a medication that acts by blocking a specific type of receptor in the brain called a calcium channel
45601506|NCT02285998|Biological|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine
45601507|NCT02285998|Biological|Inactivated Influenza Vaccine|Intramuscular injection of vaccine
45601508|NCT05295524|Other|Kaftrio utilization in real life|daily utilization of PHEAL-CR-K application at home and VOC (volatile organic compound) measure of exhaled air for a group of the patients
45601509|NCT05295368|Other|Multicomponent intervention|Intervention includes four components 1) training nurses as health coaches for motivational conversation and CKD specific lifestyle counseling on diet and exercise, using hybrid follow-up approach of in-person, telephone, and secure video sessions; 2)Training physicians in algorithm-based standardized management of CKD and hybrid care delivery;3) subsidy on sodium-glucose transport protein-2 inhibitors (SGLT-2i) for CKD; and 4) regular CKD case review meetings.
45601510|NCT05294510|Other|STAR Sick Child Job Aid|The STAR Sick Child Job Aid is a modified ICCM protocol that includes the addition of a point-of-care C-reactive protein (CRP) test to inform antibiotic treatment decisions for children presenting with febrile acute respiratory illness who do not have any danger signs. If CRP ≥ 40 mg/L, the village health worker (VHW) will dispense amoxicillin per local guidelines. If CRP < 40 mg/L, the VHW will advise symptomatic care alone including acetaminophen for fever and additional fluids to maintain hydration.
45601511|NCT05323916|Behavioral|"Neuroproprioceptive facilitation, inhibition"|"Participants will undergo a standard comprehensive intensive rehabilitation program three hours a day for three weeks and moreover one hour a day of neuroproprioceptive facilitation, inhibition physical therapy."
45601512|NCT05323916|Behavioral|Technology based physical therapy|Participants will undergo a standard comprehensive intensive rehabilitation program three hours a day for three weeks and moreover one hour a day of technology based physical therapy.
45601513|NCT05323916|Behavioral|Effectively managed rehabilitation implementing the recommendations of the World Health Organization|Participants will undergo a four hour a day for three weeks of effectively managed comprehensive intensive rehabilitation implementing the recommendations of the World Health Organization.
45755535|NCT03631550|Device|Relivion Sham|1 hour self-administered Sham occipital and supraorbital transcutaneous nerve stimulation
45755536|NCT03629912|Behavioral|Socially-Based Exercise Intervention for Older Adults|A socially-based app that incorporates exercise and/or health education into a format familiar and engaging to older adults, designed to improve adherence to health-promoting behaviors
45755537|NCT03629288|Other|Lactose tab|Tablet containing lactose Procedure: Periodontal treatment Scaling and root planning
45601514|NCT05323916|Behavioral|Standard care|Participants will undergo standardly provided care including face to face physiotherapy (bed mobility, transfers, gait, therapeutic exercises, positioning, education).
45601515|NCT01658072|Procedure|Peri-Articular Injection|Use of a different analgesic protocol, based on a peri-articular injection
45601516|NCT01658072|Procedure|Epidural Patient Controlled Analgesia (Epidural PCA)|Epidural analgesia pathway.
45601517|NCT05293184|Other|Observational study only|
45601518|NCT05293106|Biological|Platelet Transfusion|All platelet transfusions will be given as 10mL/kg as is considered standard of care.
45601519|NCT05322668|Device|Prototypes (812A-v1), (812C-v1), (812D-v1) and (812F-v1)|"All the subjects will receive all the treatment in the same order.~On each hand 2 devices will be attributed as follow:~Prototypes (812A-v1) will be applied on an area of the back of the patient's right hand, on healthy skin~Prototypes (812C-v1) will be applied on an area of the back of the patient's right hand, on healthy skin~Prototypes (812D-v1) will be applied on an area of the back of the patient's left hand, on healthy skin~Prototypes (812F-v1) will be applied on an area of the back of the patient's left hand, on healthy skin"
45601520|NCT02285920|Drug|Spironolactone|The trial will be conducted in 2 phases - a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.
45755538|NCT03629288|Drug|Azithromycin|Tablet containing 500mg Azithromicyn. Procedure: Periodontal treatment Scaling and root planning
45755539|NCT01676870|Behavioral|1x4 aerobic interval training|"endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 5min cool-down."
45755540|NCT01676870|Behavioral|4x4 aerobic interval training|"endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 3 min active pause between each interval, 5min cool-down."
45755541|NCT01676870|Behavioral|traditional moderate training|moderate intensity treadmill training (50-70% of HRmax) for a minimum of 30min, 5 times a week for 16 weeks (2 supervised sessions and 3 or more home).
45601521|NCT05292872|Drug|Obeticholic Acid 5 MG|once daily, oral administration
45601522|NCT05292872|Drug|Obeticholic Acid 10 MG|once daily, oral administration
45755542|NCT04763096|Drug|Advagraf|"Researchers must check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5~10ng/ml of study treatment. Duration of treatment The investigational product will be administered for 24 weeks. (The lowest blood levels shall be adjusted at the discretion of the researchers, taking a blood sample is carried out in the morning before administrated of Investigational Product)~Tacrolimus blood level is 3-10 ng/ml for 6 months prior to screening and during the maintenance therapy.~( ① -1day to enrollment : swich to the day before ADVAGRAF®, ② 0day to enrollment : the day swich to ADVAGRAF® )~Duration of treatment the investigational product will be administered for 24 weeks."
45755543|NCT05347472|Other|Smartphone application|the smartphone application intervention will consist daily physical therapy exercises program. The application will include all the videos about the exercises and all information about the repetition, frequency, intensity, and position.
45755544|NCT05347472|Other|Sham Smartphone application|ham application that includes information and general advice about UI only
45601523|NCT05292872|Drug|Standard of Care: UDCA|No study medication is provided by the sponsor or by the investigators. The decision to initiate, continue or discontinue UDCA, or to modify UDCA dosing, is entirely at the discretion of the treating physician as per their standard of care and is in no way influenced by the sponsor or participating institutions. UDCA utilization is recorded and included in the study record.
45755545|NCT04762940|Device|Robotic|"The Amadeo® Manual Robotic System (Tyromotion GmbH, Graz, Austria) is designed for rehabilitative treatment of the hand and fingers providing robot-assisted exercise for the finger flexors and extensors. This system has a controlled position, active, active-assisted and passive exercise mode, it also allows isometric exercises with visual feedback provided during computerized games that emphasize flexion and extension.~Robotic treatment will be conducted three times a week with 24 sessions (a month and a half of treatment) with assisted therapy: It allows to carry out the movement by force of the fingers themselves, compensating the range of movement that the user does not perform; and interactive therapy: it allows to carry out active finger movement oriented to tasks or games. These can be configured to adapt them as much as possible to the capabilities of the user."
45755546|NCT04762940|Device|Vibration|Vibration duration of approximately 20 minutes with a high vibration frequency will be conducted prior to robotic treatment. The intensity and timing of this treatment has been based on previous protocols, as previously justified in this project. Vibration therapy, with proprioceptive stimuli through sensors placed on the distal phalanges of the fingers, modulation from lower to higher frequency being possible (high frequency vibration of 300 Hz).
45755547|NCT03627728|Drug|Regorafenib|regorafenib/placebo
45601524|NCT04422548|Procedure|AI-assisted Colonoscopy|This is a multi-center prospective randomized controlled study comparing real-time AI-assisted colonoscopy versus standard colonoscopy in a real-life setting.
45601525|NCT04422548|Procedure|Standard Colonoscopy|Standard Colonoscopy
45601526|NCT05322044|Behavioral|Financial incentives|Financial incentives dependent upon adherence will be given to participants alongside additional EMD associated app features for 12-weeks.
45601527|NCT05321888|Other|Mechanical Ventilation|Standard Protocol
45601528|NCT05321888|Other|Mechanical Ventilation with Postural drainage|This Group will be treated by postural drainage and mechanical ventilation for two consecutive days
45601529|NCT02035137|Radiation|131I-MIBG|
45601530|NCT02035137|Drug|Vincristine|
45601531|NCT02035137|Drug|Irinotecan|
45601532|NCT02035137|Drug|Vorinostat|
45601533|NCT05321810|Drug|Apixaban|This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.
45601534|NCT05321810|Drug|Warfarin|This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.
45601535|NCT03142737|Other|Red kidney bean intake|Each participant will consume 1/2 cup of cooked red kidney bean
45601536|NCT03142737|Other|Eggs intake|Each participant will consume 2 cooked large eggs.
45601537|NCT03142737|Other|Peanut butter intake|Each participant will consume 2 tablespoons of peanut butter.
45601538|NCT03142737|Other|Ground beef intake|Each participant will consume 2 ounces of 90% lean ground beef.
45601539|NCT03142737|Other|Intact beef intake|Each participant will consume 2 ounces of intact beef.
45601540|NCT05321498|Drug|XPro1595|XPro1595 will be delivered by subcutaneous injection once a week.
45601541|NCT05321498|Drug|Placebo|Placebo will be delivered by subcutaneous injection once a week
45601542|NCT03141801|Device|DELFI PTS Personalized Tourniquet System for Blood Flow Restriction Training|cuff is inflated to 80% of an individuals limb occlusion pressure
45601543|NCT03141801|Other|Eccentric Exercise with BLAST Leg Press System|4 sets of 10 repetitions of an eccentric leg press exercise performed at 70% of the 1 repetition maximum
45601544|NCT03141801|Other|Concentric Exercise with BLAST Leg Press System|4 sets of 10 repetitions of an concentric leg press exercise performed at 70% of the 1 repetition maximum
45755548|NCT03627728|Other|placebo|regorafenib/placebo
45755549|NCT03704792|Device|FibroScan 530 Compact|The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
45755550|NCT03623984|Drug|Gallium Dotatate|Radioguided Surgery for Pancreatic- Neuroendocrine Cancers
45755551|NCT03554720|Device|ATTUNE PS Knee|The ATTUNE PS Knee is the standard implants.
45755552|NCT03554720|Device|ATTUNE S+ PS Knee|The ATTUNE S+ PS Knee is the enhanced fixation.
45755553|NCT04403594|Other|dry needling|dry needling followed by functional electrical stimulation and treadmill training
46066525|NCT00572169|Drug|Cisplatin|Given into the vein (IV) by a continuous infusion through a central catheter
45452135|NCT01225276|Drug|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam . The maintenance doses to be infused 7 times will be 2.0 g/kg every 21 (+/-4) days.
45452136|NCT01225276|Drug|Placebo|Loading dose at baseline (Week 0) in Placebo arm will be corresponding volume of an authorised 0.9% saline solution . The maintenance doses of the 0.9% saline solution to be infused 7 times will be given every 21 (+/-4) days.
45452137|NCT01225276|Drug|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 1.0 g/kg every 21 (+/-4) days.
45452138|NCT01225276|Drug|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 0.4 g/kg every 21 (+/-4) days.
45452139|NCT02268136|Drug|BIII 890 CL|
45452140|NCT02268136|Drug|Placebo|
45452141|NCT01224262|Biological|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)|A single vaccination of Fluzone alone
45452142|NCT01224262|Biological|LIQ001 (0.45mg)|A single vaccination of 0.45 mg LIQ001
45452143|NCT01224262|Biological|LIQ001 (1.8mg)|A single vaccination of 1.8 mg LIQ001
45452144|NCT04475458|Procedure|Ultrasound-guided dorsal penile nerve block|This block is performed by the anesthesiologist, after sedation. With an in-plane approach, the tissues around the dorsal penis nerves are visualized. The needle has to pass through Buck's fascia and there the local anesthetic is released.
45452145|NCT01222702|Drug|Cadazolid|Cadazolid, provided as powder (250 mg, 500 mg or 1000 mg) to be reconstituted as a suspension prior to oral administration
45452146|NCT01222702|Drug|Vancomycin|Vancomycin, provided as capsules (125 mg) for oral administration
45452147|NCT01222702|Drug|Placebo-matching cadazolid|Placebo of cadazolid powder for oral suspension
45601545|NCT05292248|Behavioral|Confidently Navigating Financial Decisions and Enhancing Financial Wellbeing in Dementia Caregiving|Multicomponent psychoeducational intervention focused on financial wellbeing
45601546|NCT05291624|Diagnostic Test|AAGL Endometriosis Classification score - ULTRASOUND|At baseline, ultrasonographic evaluation of patients by following AAGL Endometriosis Classification
45601547|NCT05291624|Diagnostic Test|AAGL Endometriosis Classification score - SURGERY|Within 1 month from enrollment, surgical evaluation of patients by following AAGL Endometriosis Classification
45601548|NCT05264870|Drug|Norepinephrine|treatment of postspinal hypotension
45601549|NCT05264870|Drug|Norepinephrine|treatment of postspinal hypotension
45601550|NCT02327871|Device|Esophageal cooling device (and usual standard procedure)|Standard treatments for resuscitation after CA will follow local, national, and international guidelines. Core temperature is measured using urinary Foley catheters and/or arterial temperature monitoring if available. During TH, sedation and analgesia is performed in routine. Neuromuscular blockade is induced to favor cooling and prevent shivering if necessary. Circulatory function is monitored by arterial catheter if necessary and blood pressure is maintained as usually. Hypotension is treated with dobutamine catecholamines titrated according cardiac output monitored using echocardiogram, or PiCCO® systems. Fluid management is left at the discretion of the attending physician. Prognostication after CA uses serial clinical examinations, biomarkers, transcranial Doppler, Electro-Encephalo-Gram, cerebral CT-scan or MRI, and/or Somato-Sensory-Evoked-Potential.
45601551|NCT02327559|Behavioral|Mind in Labor (MIL): Working with Pain in Childbirth|The Mind in Labor (MIL) mindfulness intervention for pregnant women and their partners integrates mindfulness strategies for coping with labor pain and fear and formal mindfulness meditation with traditional childbirth education. The MIL intervention is held over 3 consecutive weekend days (Friday - Sunday) for a total of 16 hours of mindfulness skills training for childbirth preparation and labor pain management. Mindfulness strategies for coping with labor-related pain and fear are taught in an interactive, experiential format, with periods of didactic instruction.
45755554|NCT00680953|Drug|Denosumab|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
45755555|NCT00680953|Drug|Placebo|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
45601552|NCT02327559|Behavioral|Treatment as usual (TAU)|"The treatment as usual TAU active comparison condition includes participation in a standard care childbirth education course, chosen by participants in the TAU arm from a pre-approved list of hospital- and community-based childbirth education courses comparable in length and quality to MIL, but without any mindfulness meditation, mindful movement/yoga, or other core mind/body component (e.g., hypnosis)."
45601553|NCT05264714|Drug|Rimegepant|150 mg oral disintegrating tablet every other day for one week
45601554|NCT04249232|Drug|Abaloparatide 80 micrograms per Pen dose|prefilled injector pen to deliver 80 micrograms daily subcutaneously
45601555|NCT04249232|Drug|Placebo prefilled injector pen|prefilled injector pen to deliver inactive solution daily subcutaneously
45652940|NCT05093673|Device|Sham|2 mA of cathodal tDCS is induced between two 5cm X 5cm saline soaked sponges where the cathode sponge is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
45652941|NCT04790591|Procedure|Same-day surgery|To be allowed same-day discharge certain postoperative criteria have to be met. These are categorized into four dimensions - vital parameters, urinary function, bleeding, and mobilization.
45755556|NCT00680953|Drug|Alendronate sodium hydrate|Oral tablet once a week for 24 months
45755557|NCT03154801|Other|Paramedical care|Paramedical early detection of sexual dysfunction and sexual health counseling
45755558|NCT00681031|Biological|ZOSTAVAX®|One dose (0.65 mL) contains: Varicella-zoster virus, Oka/Merck strain, (live attenuated) not less than 19400 PFU
45755559|NCT03803696|Behavioral|Enhanced Standard Care|"Baseline data collection, registration and randomization~Inform primary transplant clinician of sexual dysfunction causing distress~Receive American Cancer Society sexual educational material"
45755560|NCT03803696|Behavioral|Multimodal Intervention to Address Sexual Dysfunction|"Baseline data collection, registration and randomization~- 3 Monthly visits with trained study nurse practitioners~Referral to specialist if~Psychological etiology~Sexual Trauma~Relationship Discord~Concern for Malignancy or anatomic scarring requiring surgery"
45755561|NCT00660985|Drug|Adapalene|Gel, 0.3%, 2g, once daily for 30 days
45755562|NCT00660985|Drug|Adapalene|Gel, 0.1%, 2g, once daily for 30 days
45755563|NCT03551522|Drug|Seladelpar|10 mg, 20 mg, or 50 mg
45444514|NCT02037178|Other|Second ultrasound interpretation|The untrasound images recorded by general practitioners will be interpreted a second time by an expert in vascular medecine, and evaluated for their image quality.
45755564|NCT03551522|Drug|Placebos|Matching placebo Capsule
45755565|NCT03704714|Drug|Cyclophosphamide|Given IV
45755566|NCT03704714|Drug|Doxorubicin Hydrochloride|Given IV
45755567|NCT03704714|Biological|Nivolumab|Given IV
45755568|NCT03704714|Drug|Prednisone|Given PO
45755569|NCT03704714|Other|Quality-of-Life Assessment|Ancillary studies
45755570|NCT03704714|Biological|Rituximab|Given IV
45755571|NCT03704714|Drug|Vincristine Sulfate|Given IV
45755572|NCT02984774|Procedure|Cystectomy|Segment of cystic wall from the patients for planned cystectomy was taken after operation and was preserved at -80º Celsius for further analysis
45755573|NCT02984774|Procedure|Endometrial sampling|Endometrial sampling was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
45755574|NCT02984774|Procedure|Peripheric blood sampling|4 cc peripheric venous blood was sampled into the EDTA(Ethylenediaminetetraacetic acid)-containing tubes during catheterization for anesthesia was preserved at 4º Celsius for further analysis
45755575|NCT02984774|Procedure|Ovarian tissue sampling|2cm linear tissue sample from ovarian cortex was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
45601556|NCT05079087|Procedure|Pericapsular nerve group blockade|The PENG-block will be administered under ultrasound (US) guidance with a low frequency curvilinear probe. The probe will be placed parallel to the inguinal crease at the level of the anterior superior iliac spine. Scanning will be done with gradual caudal movement of the probe. After the anterior inferior iliac spine (AIIS) is visible, the probe will be turned slightly medial until the hyperechoic continuous shadow of the superior pubic ramus is visible. The Psoas muscle with its prominent tendon will be identified just above the pubic ramus. The target is the plane between the 2 structures. While aligning the pubic ramus in the center of the image and targeting the pubic ramus just medial to the AIIS, a 22 Go 10 cm needle will be introduced and 20 ml of anesthetic solution administered.
45601557|NCT05079087|Drug|Midazolam Ketamine arm|Patients in the second group will undergo sedation and analgesic treatment with Ketamine and Midazolam titrated to the best Verbal Rating Score without respiratory and cardiovascular depressant effect.
45601558|NCT03144999|Biological|AAVCAGsCD59|AAVCAGsCD59 is administered as a single intravitreal injection in an office setting
45601559|NCT05263622|Other|Split-mouth administration for group B|"Plaque disclosing agent application and instructions to patients for a correct oral hygiene;~Airflow deplaquing with EMS handpiece (quadrants Q1 and Q3) and with Mectron handpiece (quadrants Q2 and Q4)~Calculus removal with EMS ultrasound handpiece (Q1 and Q3) and with Mectron handpiece (Q2 and Q4)"
45601560|NCT05263622|Other|Split-mouth administration for group A|"Plaque disclosing agent application and instructions to patients for a correct oral hygiene;~Airflow deplaquing with EMS handpiece (quadrants Q2 and Q4) and with Mectron handpiece (quadrants Q1 and Q3)~Calculus removal with EMS ultrasound handpiece (Q2 and Q4) and with Mectron handpiece (Q1 and Q3)"
45601561|NCT02327949|Device|W-Shaped Angular Plate|Treatment of posterior wall fracture of the acetabulum with a W-Shaped Angular Plate
45601562|NCT02327949|Device|Reconstruction Plate|Treatment of posterior wall fracture of the acetabulum with a Reconstruction Plate
45601563|NCT03145233|Other|Isometric exercise programme|Exercise programme where the muscle length and joint angle do not change due to the limb being held in a static position
45601564|NCT03145233|Other|Isotonic exercise programme|Exercise programme where both the muscle length and joint angle do change, consisting of concentric muscle actions (where the muscle shortens) and eccentric muscle actions (where the muscle lengthens)
45601565|NCT05262842|Drug|JS001+IMP4297|"Phase I: Dose Escalation The primary endpoints are the safety and tolerability of the combination, including the incidence and nature of DLTs and the determination of the MTD and RP2D. A 3 + 3 dose-escalation (60mg,80mg,100mg)design will be used. Patient in each dose level will be treated with toripalimab 240mg in combination with senaparib.~Phase Ib: Dose Expansion This part will commence after the RP2D is determined and will further evaluate the safety and anti-tumor activity of toripalimab and senaparib in patients with specific types of advanced solid tumors. Patients will be enrolled concurrently into 5 exploratory cohorts with approximately 20 patients each cohort."
45601566|NCT02522780|Drug|Mesalamine|Pharmaceutical form: Granules in sachet; Route of administration: Oral use
45601567|NCT02522780|Drug|Placebo|Pharmaceutical form: Granules in sachet; Route of administration: Oral use
45601568|NCT03618225|Drug|Oral Duloxetine 60mg|duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
45601569|NCT03618225|Drug|placebo pill|placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
45601570|NCT05319860|Drug|Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV)|Standard of care for CINV includes anti-nausea medication as needed after chemotherapy regimen given for up to 12 weeks.
45755576|NCT02336360|Drug|Flortaucipir F18|No flortaucipir administered in this study. Subjects received flortaucipir in an Avid-sponsored study.
45755577|NCT00661141|Drug|Antizol|
45755578|NCT00661141|Drug|Placebo|
45755579|NCT00661141|Other|Ethanol|oral dose of ethanol (0.5 g/kg)
45601571|NCT05319860|Drug|Aromatherapy Care|An aromatherapy inhaler provided for use as needed after chemotherapy regimen given for up to 12 weeks. One normal inhale is equal to one dose of aromatherapy. Participants can use the aromatherapy as often as needed.
45601572|NCT03566199|Drug|Panobinostat Nanoparticle Formulation MTX110|Given IT
45601573|NCT03566199|Drug|Convection-Enhanced Delivery (CED)|Undergo CED
45601574|NCT05290688|Genetic|50 ml blodd sampling|50 ml blood sampling for genetic analysis (expression profiles of microRNAs)
45601575|NCT03561831|Drug|Propofol|propofol based anesthesia
45601576|NCT03561831|Drug|Sevoflurane|sevoflurane based anesthesia
45652942|NCT02633527|Drug|Placebo|Placebo was administered once daily
45652943|NCT02633527|Drug|100mg SPN-812|100mg SPN-812 was administered once daily and compared to placebo
45652944|NCT02633527|Drug|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
45652945|NCT02633527|Drug|300mg SPN-812|300mg SPN-812 was administered once daily and compared to placebo
45652946|NCT02633527|Drug|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
45755580|NCT03616730|Diagnostic Test|NICOM (non-invasive cardiac output monitor)|Transthoracic bio-reactance, or the non-invasive cardiac output measurement [NICOMTM, Cheetah Medical Inc., Portland, OR] system, is a new technique that is able to measure multiple hemodynamic parameters with four transdermal electrodes placed on the patients' thorax. It is based on frequency- and phase-modulation of the voltage signal measured in response to an applied transthoracic current. It has shown acceptable accuracy, precision and responsiveness for cardiac output monitoring in patients experiencing a wide-range of hemodynamic situations and is a FDA-approved device.
45755581|NCT03702764|Diagnostic Test|CCTA|128-multislice CT coronary angiography and complex atherosclerotic plaque analysis, with the use of CT imaging post-processing techniques.
45755582|NCT03616574|Drug|CA102N|CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim).
45755583|NCT03616574|Drug|LONSURF|LONSURF is a cytotoxic combination treatment of 2 new drugs: trifluridine, a thymidine-based nucleoside analog, and tipiracil, an inhibitor of thymidine phosphorylase.
45444515|NCT01302171|Drug|granulocyte colony stimulating factor (GCSF)|10mcg/kg per day 5 days
45444516|NCT01302171|Procedure|bone marrow mononuclear cells|intra coronary injection of stem cells or placebo
45601577|NCT03145155|Behavioral|Integrating services for noncommunicable diseases in continuum of care for mothers and children|The intervention package will comprise of two components, (1) utilization of CoC card and (2) health education on CoC in maternal, newborn and child health (MNCH), NCD and nutrition. The CoC card will be distributed to mothers by midwives at the time of receiving ANC. The CoC card includes CoC services from first antenatal care(ANC) to last postnatal care(PNC) including four ANC, skilled birth attendance (SBA) and four PNC and essential services. Pregnant women will get stickers if they receive above services. Health education will be given by Public Health Supervisors 2 at the health facilities. Health education will be given three times during pregnancy and one time during postpartum period with pamphlets and posters.
45601578|NCT03145155|Behavioral|Ordinary health education for pregnant women|The ordinary health education intervention will cover schedule for ANC, delivery and PNC; danger signs; birth preparedness and nutrition. Health education will be given three times during pregnancy and one time during postpartum period with pamphlets and posters.
45601579|NCT05289830|Drug|Escitalopram|Participants will receive Escitalopram 2 weeks: 10 mg/day (1 capsule) 8 weeks: 20 mg/day (2 capsules) 2 weeks: 10 mg/day (1 capsule)
45755584|NCT00681265|Drug|glycerin|Eye drop with active agent glycerin 1%, new topical ophthalmic formulation with polylysine-graft-polyethylene glycol as an excipient, single instillation.
45755585|NCT00681265|Drug|polyethylene glycol 400/propylene glycol|Eye drop with the active agents polyethylene glycol 400 0.4% /propylene glycol 0.3%, topical ophthalmic formulation, single instillation
45755586|NCT03548324|Device|HHHFNC|Application to HHHFNC to treat respiratory distress syndrome in preterm infants previously demonstrated to be stable on a non-invasive respiratory support (HHHFNC or NCPAP).
45755587|NCT03548324|Device|NCPAP|Application to NCPAP to treat respiratory distress syndrome in preterm infants previously demonstrated to be stable on a non-invasive respiratory support (HHHFNC or NCPAP).
45601580|NCT05289830|Other|Placebo|Participants will receive placebo supplements 2 weeks: 1 capsule 8 weeks: 2 capsules 2 weeks: 1 capsule
45601581|NCT05262296|Procedure|Laparoscopic Surgeon|Laparoscopic Arm This cohort of participants will have their procedure completed by a human surgeon.
45601582|NCT05262296|Procedure|Robotic Arm|This cohort of participants will have their procedure completed by the Versius Surgical Robotic System.
45601583|NCT05230485|Other|CPAP level|The level of continuous distending pressure (or positive end-expiratory pressure) chosen on CPAP
45601584|NCT03142971|Procedure|focused shock wave therapy|
45601585|NCT03142971|Procedure|ultrasound therapy|
45601586|NCT05261984|Procedure|Resistance exercise|Weighted knee extensions in four sets targeting 8-12 repetitions to failure.
45601587|NCT05261984|Dietary Supplement|Oral protein supplementation|24 grams of hydrolyzed whey protein.
45755588|NCT01677104|Drug|GLP-1|GLP-1 and its analogues will be compared with placebo with and without prior DPP-IV inhibition
45911016|NCT02002325|Drug|Tissue-type plasminogen activator (alteplase)|Intravenous tissue-type plasminogen activator (alteplase) 0.6mg/kg body-weight up to a maximum of 60 mg, 10% as bolus, 90% over 1 hour as infusion (plus other standard treatment if needed)
45755589|NCT01677104|Drug|Placebo|
45755590|NCT00661453|Drug|Valproic Acid and Levocarnitine|Drug: Valproic Acid and Levocarnitine; syrup; dosage is by weight
45755591|NCT03547622|Drug|MAT taper with galantamine|Following taper from MAT (methadone or buprenorphine) participants will be given galantamine daily with access to a CBT4CBT computer program
45755592|NCT03547622|Drug|MAT taper with placebo|Following taper from MAT (methadone or buprenorphine) participants will be given placebo daily with access to a CBT4CBT computer program
45911017|NCT02002325|Other|Standard care|Standard treatment for acute stroke without intravenous alteplase.
45911018|NCT02002364|Procedure|tracheal intubation|
46066526|NCT00572169|Drug|Cyclophosphamide|Given into the vein (IV) by a continuous infusion through a central catheter
45444517|NCT03275246|Device|X-PSI Knee System|Patients are operated with X-PSI Knee System guides
45601588|NCT05261750|Biological|Auto-Dendritic Adjuvant Therapy|Treatment with standard medical therapy (radiotherapy or chemoradiation) and auto-dendritic adjuvant therapy via intramuscular 3 times injection every 1 week.
45601589|NCT05261750|Biological|Allo-Dendritic-Secretome Adjuvant Therapy|Treatment with standard medical therapy (radiotherapy or chemoradiation) and allo-dendritic-secretome adjuvant therapy 2 cc 1 times injection, and then followed by auto-dendritic therapy via intramuscular 3 times injection every 1 week.
45601590|NCT05078385|Drug|AGLE-102|In this protocol, 2nd degree burn wounds will receive direct application of EVs derived from bone marrow MSCs. We have observed success with this type of approach in the past using bone marrow stem cells including MSCs. We have evidence that EVs derived from MSCs are responsible for many of the healing effects produced by MSCs and may be a safer, more reliable alternative to allogeneic cell therapy. This protocol is designed to develop a safe and ideal method of administering bone marrow cell Extracellular Vesicles to wounds.
45601591|NCT05260658|Drug|CFTX-1554|CFTX-1554 is a new chemical entity that binds to the angiotensin II type 2 receptor (AT2R).
45601592|NCT05260658|Drug|Placebo|CFTX-1554 matching placebo
45601593|NCT05327192|Other|No intervention, only sampling|No intervention
45601594|NCT03144843|Drug|Apatinib|Apatinib 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
45601595|NCT03144843|Drug|Placebos|Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
45601596|NCT05078307|Procedure|OHR VS OHV|"Control group : use of the OHR system to perform an Operative Hysteroscopy by Resection of the fibroid.~Experimental group : use of the OHV system to perform an Operative Hysteroscopy by Vaporization of the fibroid."
45755593|NCT00681889|Drug|Ranibizumab|10 Patients will receive treatment (Ranibizumab)
45911019|NCT02002377|Drug|Aflibercept|Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks
45911020|NCT02002390|Drug|Fingolimod|A sphingosine-1-phosphate receptor regulator
46066527|NCT00572169|Drug|Etoposide|Given into the vein (IV) by a continuous infusion through a central catheter
45601597|NCT05288348|Drug|Sufentanil 30 MCG Sublingual Tablet|30 microgram sublingual tablet administered using sublingual applicator
45601598|NCT05288348|Drug|standard care pain treatment|standard care pain treatment given in Emergency Department
45601599|NCT03111615|Drug|Aromatase Inhibitors|"Aromatase Inhibitor to start immediately after diagnosis of a Luminal Invasive Breast Carcinoma Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement.~Venlafaxin 75 mg is to be administrated cases indicated"
45755594|NCT03697538|Procedure|Nerve Block for pain control post-revision total knee arthroplasty|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
45755595|NCT03610490|Biological|Autologous Tumor Infiltrating Lymphocytes MDA-TIL|Given IV
45755596|NCT03610490|Drug|Cyclophosphamide|Given IV
45755597|NCT03610490|Drug|Fludarabine|Given IV
45755598|NCT03610490|Biological|Interleukin-2|Given IV
45755599|NCT03610490|Other|Quality-of-Life Assessment|Ancillary studies
45755600|NCT02869945|Genetic|Identification of COMT HH, COMT HL or COMT LL genes|COMT HH, COMT HL or COMT LL genes identification
45755601|NCT02869945|Other|Brain MRI with resting state scan|MRI scan with resting state study to be performed to assess the compensation mechanisms at the networks level.
45755602|NCT02869945|Other|Brain MPET|Monophotonic emission tomography with I-123-Ioflupane to assess the level of dopaminergic denervation.
45755603|NCT03610022|Drug|Treatment with vismodegib|Vismodegib 150 mg capsules is administered daily with or without food until disease progression or unacceptable toxicity. Patients are followed in the dermatologic unit of Bordeaux University Hospital (Saint André Hospital) every month. At each consultation, clinical and biological datas, and two blood samples are collected just before taking the drug. One sample is for vismodegib quantification (pharmacokinetic protocol), and the other for the determination of alpha-1 glycoprotein acid level
45601600|NCT05259800|Other|Peppermint oil vapors|Subjects will be exposed to vapor of peppermint oil
45601601|NCT05259800|Other|Mineral Oil|Subjects will be exposed to vapor of placebo (mineral oil)
45601602|NCT05078151|Diagnostic Test|Whole-Body Diffusion Weighted MRI|MRI at baseline, after four and eight weeks of treatment and at disease progression or treatment discontinuation.
45601603|NCT05257382|Procedure|ENB followed by trans-bronchial biopsy and trans-bronchial cryobiopsy|After having performed the ENB procedure to reach the identified lung lesion, biopsies will be performed (six forceps trans-bronchial biopsies and one trans-bronchial lung cryobiopsy)
45601604|NCT05287490|Device|FormaV and VTone|Eligible subjects will receive 3 treatments(every 2 weeks) with the FormaV and VTone Applicators according to the study protocol.
45755604|NCT00682357|Drug|Methylprednisolone and Lidocaine|Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg
45755605|NCT00682357|Drug|Methylprednisolone and Lidocaine|Methylprednisolone 16 mg intra-articular and lidocaine 20 mg
45911021|NCT02002403|Drug|Danazol|
45911022|NCT02002429|Procedure|Intra-articular injection|Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
45444518|NCT02047630|Drug|Generic latanoprost|
45601605|NCT03111303|Device|mechanical ventilation|Connection to mechanical ventilator
45601606|NCT05287334|Device|Electrical impedance tomography measurement|During standard blood donation, donors' chest bioimpedance will be measured using electrical impedance tomography.
45601607|NCT05318534|Drug|GL-0719|Administration route: intravenous infusion
45601608|NCT05318534|Drug|Placebo|Administration route: intravenous infusion
45601609|NCT03199755|Drug|ACT|Current approved drug for treating malaria
45601610|NCT03199755|Drug|DLA1|Experimental drug treatment, single dose.
45601611|NCT03199755|Drug|DLA2|Experimental drug treatment, doubled the dose of DLA1.
45601612|NCT05318066|Drug|Ringer Lactate and Norepinephrine infusion|"Arm Fluids (FL)- 500 mL of ringer lactate over 10 minute prior to the administration of procedural medications.~Arm Vasopressor (VP)- Patients in this group would receive norepinephrine infusion at a dose of 0.08 μg/kg/min over 10 minutes prior and 5 minutes after tracheal intubation."
45652947|NCT04093739|Device|G7 Freedom Constrained Liners|Patients that have been implanted with the G7 Freedom Constrained Liners to repair hip malfunction and/or disease.
45755606|NCT00682357|Drug|Placebo and Lidocaine|Placebo and lidocaine 20 mg
45755607|NCT03609944|Procedure|ERCP with miES|Endoscopic retrograde cholangiopancreatography with minor papilla endoscopic sphincterotomy
45755608|NCT03609944|Procedure|EUS|Endoscopic ultrasound
45755609|NCT00662155|Drug|Zolpidem|sedative-hypnotic
45755610|NCT00662155|Drug|Placebos|Placebo
45755611|NCT03546608|Drug|Tepotinib|Participants will receive a single oral dose of tepotinib in Part 1.
45755612|NCT03543098|Procedure|Early Surgery|Subjects will undergo surgery within 6 weeks after injury.
45755613|NCT03543098|Procedure|Delayed Surgery|Subjects will undergo surgery 12 to 16 weeks after injury.
45755614|NCT03543098|Procedure|Early Rehab|Subjects will undergo rehabilitation that will include unrestricted range of motion exercises and use of a weightbearing as tolerated gait starting after the first post-operative visit with the surgeon.
45755615|NCT03543098|Procedure|Delayed Rehab|Subjects will undergo rehabilitation that will include use of a knee brace locked in extension, no range of motion exercises and use of non-weightbearing gait for the first 4 weeks after surgery.
45911023|NCT02002429|Procedure|Medial branch block|Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
45911024|NCT02002429|Procedure|Saline injection|Injection into the affected facet joint(s) with 0.5 ml of normal saline. All subjects in the group will receive radiofrequency denervation.
45755616|NCT00684541|Behavioral|Interpretation Modification Program|"The IMP protocol includes twelve 30-min sessions delivered over a 6-week period. Each session will comprise 220 trials. In each trial, participants will first see either a non-threat or a threat (e.g. graceful or clumsy) word on the computer screen. They will then see an ambiguous sentence (e.g. You dance at the party) and will be asked to indicate if the word and sentence were related by pressing a corresponding key. Participants will receive positive feedback (i.e., You are correct!) when they endorse a non-threat interpretation or reject a threat interpretation of an ambiguous sentence. Participants will receive negative feedback (i.e., You are incorrect.) when they endorse a threat interpretation or reject a non-threat interpretation of an ambiguous sentence."
45755617|NCT00684541|Behavioral|Interpretation Control Condition|Participants assigned to the PC completed an identical procedure to the IMP procedure except that feedback about participants' performance was not contingent on the type of interpretation (i.e., non-threat or threat) endorsed. Thus, participants in the PC received positive feedback 50% of the time when viewing a threat interpretation and 50% of the time when viewing a non-threat interpretation.
45755618|NCT05347394|Drug|VX-708|Solution or suspension for oral administration.
45601613|NCT05317910|Other|MUSIC CARE|"Relaxation-type receptive musical intervention technique. The standardized 20-minute musical sequence is broken down into several phases that gradually lead the patient to relaxation using the new U-Mount technique [1, 2] (Figure 1). The effect works by reducing the musical rhythm, orchestral formation, frequencies and volume (the U descending phase). After a maximum relaxation phase (lower part of the U), a re-activating phase (ascending branch of the U) is followed."
45755619|NCT05347394|Drug|Placebo|Placebo matched to VX-708 for oral administration.
45755620|NCT00662545|Drug|Entecavir with continued standard of care antiretroviral therapy|1 mg by mouth daily
45601614|NCT05317754|Behavioral|Mindful breathing|"Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~There is no limit to the number of times informal practice can be performed during the day.~Use of a diary is necessary to record the time and duration of all formal and informal practices.~The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
45601615|NCT05317754|Behavioral|Prostrations, according to Tibetan Buddhist tradition|"Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~There is no limit to the number of times informal practice can be performed during the day.~Use of a diary is necessary to record the time and duration of all formal and informal practices.~The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
45755621|NCT00662545|Drug|continued standard of care with tenofovir in addition to emtricitabine or lamivudine|continued standard of care with tenofovir in addition to emtricitabine or lamivudine
45755622|NCT03696446|Behavioral|Virtual Cardiac Rehabilitation Program|This group will receive their Rehab program primarily online through a secure web-based platform with a trained facilitator.
45755623|NCT03696446|Behavioral|Case Managed Home Program|This group will receive their Rehab program over the phone with a trained facilitator
45755624|NCT03693716|Procedure|Dynamic Anterior Stabilization|All-arthroscopic trans subscapular Long Head of the Biceps tenodesis in the anterior-inferior glenoid with all-suture anchors
45755625|NCT03539198|Radiation|Proton Stereotactic Body Radiation Therapy (SBRT) (5 fractions; 3500-4500 cGy)|Patients will be receiving proton SBRT
45755626|NCT03539198|Radiation|Proton Stereotactic Body Radiation Therapy (SBRT) (3-5 fractions; various dose and fractionation regimens depending on treatment site).|Patients will receive proton SBRT.
45755627|NCT03539198|Drug|Nivolumab 3 mg/kg IV q2 weeks|Patients will receive Nivolumab x2 cycles before SBRT q2 weeks, and continued q2 weeks after SBRT until progression or at the discretion of the treating physician.
45755628|NCT03539198|Radiation|Proton or Photon SBRT (3-5 fractions; various dose and fractionation regimens depending on treatment site).|Patients with further oligoprogression (5 or fewer sites) will be eligible to receive additional SBRT to all sites of oligoprogression.
45755629|NCT00663169|Biological|canakinumab|10 mg/kg intravenous infusion 250 mL over 2 hours.
45755630|NCT00663169|Drug|dexamethasone|12 mg intravenous infusion 50 mL over 30 minutes.
45755631|NCT00663169|Other|placebo matching canakinumab|5% glucose in water intravenous infusion.
45755632|NCT00663169|Other|placebo matching dexamethasone|Placebo intravenous infusion.
45755633|NCT04762004|Behavioral|Maternal speech|In both intervention conditions, speaking and singing, the mothers were asked not to touch the baby but to pay close attention to his/her reactions and to modulate the voice accordingly. A nurse was present during all procedures.
45934920|NCT00211042|Other|No intervention|This is an observational study. No medication will be given to the participants. Participants will receive standard-of-care treatment from their individual physicians.
45444519|NCT02047630|Drug|Brand-name latanoprost|
45444520|NCT03815331|Drug|Xiaflex®|medication indicated for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Xiaflex belongs to a family of enzymes called collagenases. Collagenases are proteinases that hydrolyze collagen in its native triple helical conformation under physiological conditions, resulting in lysis of collagen deposits. The signs and symptoms of Peyronie's disease are caused by a collagen plaque. Injection of XIAFLEX into a Peyronie's plaque, which is comprised mostly of collagen, may result in enzymatic disruption of the plaque. Following this disruption of the plaque, penile curvature deformity and patient bother caused by Peyronie's disease are reduced
45444521|NCT03815331|Drug|Aveed|Aveed® is an FDA-approved medication for treatment of hypogonadism (low testosterone). It is not approved for the treatment of Peyronie's Disease. Aveed® 750 mg/3mL injection will be placed intramuscularly at the beginning of study, at four weeks, at 10 weeks thereafter.
45601616|NCT05317754|Behavioral|The Koan Mu, according to Zen Buddhist tradition|"Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~There is no limit to the number of times informal practice can be performed during the day.~Use of a diary is necessary to record the time and duration of all formal and informal practices.~The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
45601617|NCT05317754|Behavioral|The mirror exercise, according to Toltec tradition|"Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~There is no limit to the number of times informal practice can be performed during the day.~Use of a diary is necessary to record the time and duration of all formal and informal practices.~The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
45601618|NCT05387109|Drug|penpulimab combined with anlotinib|penpulimab: fixed dose of 200 mg, administered on the first day of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14, orally once a day, about half an hour before breakfast (the daily dose should be as much as possible), taken with warm water, and repeated every 3 weeks
45601619|NCT04422704|Behavioral|Technology-based-Intervention|"The intervention is intended to address the concerns and needs that emerge from the participants' interviews. The intervention is based on the principles of the process of adaptation to retirement defined by Atchley and the Prochaska and Diclemente Model on the phases of preparation for retirement. The material to be used will be based on existing resources for retired people, awareness through multimedia material and knowledge of possible contributions of different technological devices to the retirement process.~The sessions consisted of showing different exercises and devices to perform physical activities, cognitive training, relaxation activities, counselling about healthy eating and leisure-time activities."
45601620|NCT02327793|Drug|Nitroglycerin|
45601621|NCT02327793|Drug|Labetalol|
45601622|NCT05081661|Other|Motor Imagery Program|The intervention group of the study will undergo standard postoperative physical therapy treatment at their therapist. Beginning on the third day after surgery, the participant will begin an motor imagery program to be performed three times a week for four weeks. A session lasts between fifteen and twenty minutes. It begins with a body awareness phase followed by a series of three to five one-minute exercises to be repeated three times, with a one-minute break between each exercise. The program is performed independently at home using a standardized audio tape.
45755634|NCT04762004|Behavioral|Maternal singing|In both intervention conditions, speaking and singing, the mothers were asked not to touch the baby but to pay close attention to his/her reactions and to modulate the voice accordingly. A nurse was present during all procedures.
45755635|NCT04762004|Behavioral|Standard care|the newborn was placed by the nurse in the incubator in the standard care conditions recommended for painful procedures (supine position, wrapped and contained by the nest).
45755636|NCT00663403|Drug|Daptomycin|Daptomcyin 8 mg/kg infused intravenously every 48 hours
45755637|NCT00004418|Drug|glyceryl trierucate/glyceryl trioleate|Administration of glyceryl trierucate/glyceryl trioleate
45755638|NCT00663793|Drug|Acyline|300 mcg/kg
45755639|NCT00663793|Drug|Testosterone|"24 hours after acyline administration on Day 2 immediate release Testosterone (T) 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
45755640|NCT00663793|Drug|Finasteride|1 mg PO once daily [day -2 to day 12) 14 days total
45755641|NCT03690986|Biological|VX15/2503|Given IV
45755642|NCT03690986|Biological|Ipilimumab|Given IV
45755643|NCT03690986|Biological|Nivolumab|Given IV
45755644|NCT03606746|Biological|MDR-103|MDR-103 Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
45755645|NCT00667381|Device|Real-time Ultrasound Guidance (Site-Rite 5 or 6 machine)|Real-time ultrasound guidance will be used to aid in femoral artery cannulation. This will occur with a 7 MHz ultrasound probe covered with a sterile cover.
45934921|NCT00211120|Drug|Epoetin Alfa|
45934922|NCT00211159|Drug|EPAX 1050TG|
45934923|NCT00211198|Drug|ONTAK (denileukin difitox, DAB389IL-2)|
46066528|NCT00505063|Biological|Immunization Schedule patients <7 years.|"Time 0 months: Prevnar 13 #1, Hib #1~Time 1 months: Pediarix #1~Time 2 months: Prevnar 13 #2, Hib #2~Time 3-4 months: Pediarix #2~Time 4-6 months: Draw post vaccine titers~Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations."
45444522|NCT04305470|Drug|Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)|One time oral dose on day of surgery (20 mg/kg bodyweight)
45444523|NCT02036788|Other|Occlusion test|Occlusion test to assess the correct positioning of esophageal balloon catheter when the patient is breathing spontaneously.
45452148|NCT01222702|Drug|Placebo-matching vancomycin|Placebo of vancomycin capsules
45452149|NCT01204762|Drug|pegIFN|Syringe, Subcutaneous, 180 μg, Once Weekly, 48 weeks
45452150|NCT01204762|Drug|pegIFNα-2a|Syringe, Subcutaneous 180 μg, Once Weekly, 48 Weeks
45452151|NCT01204762|Drug|PegIFN lambda|Syringe, Subcutaneous, 180 µg, Once weekly, 48 weeks
45452152|NCT01204762|Drug|Entecavir|Tablet, Oral, 0.5 mg, Once daily, 12 weeks initial monotherapy followed by 48 weeks of combination therapy with PegIFN lambda
45601623|NCT05081661|Other|Placebo program|"The control group of the study will undergo standard postoperative physiotherapy treatment at their therapist. On the third day after surgery, the participant will begin a relaxation program inspired by the mindfulness tool called Bodyscan that acts as a placebo mental imagery program. Nevertheless, the program created for this technique does not follow the Bodyscan guidelines (Jon Kabat-Zinn, 2005), as we do not want there to be any effects in favor of improved body perception on the participants, which could bring an additional biai to the study. For the sake of understanding, we have used the term body visualization in the various documents distributed to the participants. The program is to be performed three times a week for four weeks. A session lasts between ten and fifteen minutes. The program is performed independently at home using a standardized audio tape."
45601624|NCT02327715|Drug|Emtricitabine|emtricitabine were given to each patients from week 28 pregnancy to 24 weeks after delivery
45601625|NCT05255588|Device|EarlyTect® CRC test|A highly accurate and sensitive real time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE/qMSP) for measuring SDC2 methylation in stool DNA to detect CRC.
45601626|NCT02966379|Device|cochlear implantation|"Surgery is standardized in order to have the same procedure for all patients and to preserve a maximum of residual hearing:~Corticosteroïds (1mg/kg solumedrol) at anesthetic induction ,~mastoidectomy + posterieur tympanostomy ,~insertion through round window,~stop at the first resistance point"
45755646|NCT03605654|Biological|MDR-102|Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
45755647|NCT03605654|Drug|Immunosuppressive Agents|Standard Anti-Rejection Medications that would be given to kidney transplant recipients who are outside the study
46066529|NCT00505063|Biological|Immunization Schedule patients > or = to 7 years and <11 years of age|"Time 0 months: Hib #1, Prevnar 13 #1, Hepatitis B #1~Time 1 month: Td#1, IPV #1(inactivated polio virus vaccine), Hepatitis B #2~Time 2-3 months: Prevnar 13 #2, Hib #2~Time 3-6 months: Td #2, Draw post vaccine titers Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations."
45601627|NCT05314946|Procedure|No feeding tube placed|The experimental arm will forego placement of a feeding tube.
45601628|NCT05314946|Procedure|Placement of a percutaneous feeding tube|The standard arm will have a feeding tube placed (G-tube or GJ-tube by IR; or surgically placed J-tube)
45601629|NCT02957799|Behavioral|Accountable Condition|Mothers will receive home visits by government-funded CHW who will be trained under Philani as well as receive ongoing monitoring and supervision. CHW will monitor mother's health and linkage to care; CHW will refer all mothers to local clinics for HIV, blood sugar, and pregnancy testing. CHW will also have a mobile phone to record information at each visit. CHW will log their home visits each day, rate the content and skills addressed on the mobile phone, weigh children, and report outcome achievements (e.g., receiving the child grant, immunizations, breastfeeding, and retention/ adherence to HIV care). The CHW in this arm will receive data-informed supervision. CHW will be monitored weekly with review of contact logs, recorded outcomes, and random site visits by supervising in-service training on a monthly basis. The Accountable Condition will last for two years (until the child is 24 months old).
45601630|NCT02957799|Behavioral|Control Condition|Mothers will receive home visits by government-funded CHW who will be trained under Philani as well as receive supervision and monitoring consistent with local government practices. CHW will monitor mother's health and linkage to care. CHW will refer all mothers to local clinics for HIV, blood sugar, and pregnancy testing. The Control Condition will last for two years (until the child is 24 months old).
45601631|NCT02951013|Other|restrictive transfusion|Transfusion will start when the hemoglobin concentration falls below 6.0 g/dL
45601632|NCT02951013|Other|liberal transfusion|
45601633|NCT05285150|Other|Survey|It´s a survey
45601634|NCT03141489|Dietary Supplement|Tubefeeding|NICE guidelines regarding refeeding syndrome, based on a very cautious refeeding regime reaching estimated calorie and protein needs within 7 days, compared to a protocol at Diakonhjemmet Hospital using a higher starting rate, reaching estimated needs within 3 days.
45601635|NCT04243226|Device|telehealth-based aerobic walking exercise|The aim of this study is to develop exercise prescription of TBI patients and then to evaluate the effectiveness of programmed aerobic exercise to improve psysical-psycho-social health such as cognitive status, 6 minutes walk test, depression relief, motivation, symptom, resilience and quality of life.
45601636|NCT05081505|Behavioral|Structural exercise course|12-week structured exercise class, team competition, social support, and incentive strategy
45601637|NCT05081505|Behavioral|Autonomous group class|12-week autonomous group class, team competition, social support, and incentive strategy
45755648|NCT02336438|Dietary Supplement|glucomannan|Glucomannan is a natural, odorless soluble fiber that is found in the konjac plant. It will be given during the Intervention Phase in conjunction with the MMTT and then for 5 days at home with meals.
45755649|NCT00667615|Drug|rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim|Patients will be treated with 6 cycles of rituximab, cyclophosphamide, etoposide, prednisone and vorinostat every 4 weeks. Quality of life determinations will be obtained at the beginning of each cycle of chemotherapy and at each visit during the first year of followup.
45755650|NCT03537482|Drug|APG-2575|APG-2575 will be administered as an oral tablet
45755651|NCT00667693|Device|Macintosh laryngoscope|Intubation with Macintosh laryngoscope
45755652|NCT00667693|Device|Pentax AWS|Intubation with Pentax AWS
45755653|NCT03604640|Other|Physical Training|Physical exercise program and health education
45755654|NCT03687008|Behavioral|Cognitive Computer Based Intervention|25 sessions [each 30-45 minutes, 5 days a week / for 5 weeks], supervised by trained coaches
45755655|NCT00667849|Device|Exogen 4000+|Low-intensity pulsed ultrasound (LIPUS)
45755656|NCT00667849|Device|Sham|sham device identical to active device with the exception of administration of ultrasound
45755657|NCT03532958|Drug|BNZ-1|PEGylated peptide inhibitor of IL-2, IL-9, and IL-15
45755658|NCT03532958|Drug|Normal saline|Dose volume consistent with weight-based dosing of BNZ-1
45755659|NCT02998489|Other|Fast milk advancement|30-40 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
45601638|NCT05283122|Procedure|Mostafa Maged Technique|pfannestiel incision . dissection of the bladder downwards , and Ligation of the uterine arteries on both sides then , we turn over the upper part of the lower uterine segment onto the lower part of the lower uterine segment from the inside of uterine cavity .We do this turnover (flipping ) by our hands and holding the imaginary line by two Allis forceps and by making three knots by three needles in the lower edge of the uterine incision and we enter the needles of simultaneously into the lower segment through the uterine cavity , at the same level of , the inside wall of lower uterine segment to drag the upper (half) part of the lower uterine segment on the lower part of lower uterine segment ( sandwich - like ) Third , we stitch the both sides of the flipped lower uterine segment , then we do plication of the anterior lower uterine segments to strengthen the wall of the flipped lower uterine segment and place a drain in the doglus pouch
45601639|NCT05080803|Drug|intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone|intravitreal administration
45601640|NCT02285062|Drug|lenalidomide|
45601641|NCT02285062|Drug|Placebo|
45601642|NCT02285062|Drug|Rituximab|
45601643|NCT02285062|Drug|Cyclophosphamide|
45601644|NCT02285062|Drug|Doxorubicin|
45601645|NCT02285062|Drug|prednisone|
45601646|NCT02285062|Drug|vincristine|
45601647|NCT02431767|Biological|PENNVAX®-GP HIV-1 DNA vaccine|Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
45601648|NCT02431767|Biological|Interleukin-12 (IL-12) DNA adjuvant|Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
45601649|NCT02431767|Biological|Placebo|Sterile Water for Injection, USP. Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
45601650|NCT04422782|Other|For each routine sample, an additional tube will be collected to measure the osmotic pressure in the blood and urine|Interventional research protocol involving the human person category 2 at risk and minimal constraints
45601651|NCT05082363|Combination Product|C4d evaluation in lupus nephritis in serum and renal tissue|C4d plasma levels were analyzed by a unique assay specifically detecting C4d arising from complement activation and C4 plasma levels were quantified with competitive ELISA. SLE patients in activitity with and without lupus nephritis In patient with lupus nephritis we will evaluate the C4d after developing remission in the form of reduction of proteinurea less than .5g/g measured as PCR as complete response and less than50% reduction in proteinurea in partial response according to KIDGO guide line Percutaneous renal biopsies were performed in SLE and non-SLE patients under ultrasonographic guidance. 10% formalin-fixed tissue was embedded in paraffin. Four μm-thick sections were stained with hematoxylin and eosin (H&E), periodic acid-Schiff (PAS), periodic acid methenamine silver (PAM), masson-trichrome and polyclonal rabbit anti-human C4d antibody, Renal biopsy specimens of SLE patients were assessed using the most recent modification of the World Health Organization (WHO)
45601652|NCT05512598|Drug|HB0034|HB0034, a single dose
45601653|NCT04422860|Drug|Gum Arabic varnish|Powdered exudate from various Acacia species, especially A. senegal (Leguminosae).
45601654|NCT04422860|Drug|Proflourid Varnish,VOCO|5% NaF varnish
45601655|NCT04422860|Drug|MI Varnish,GC Japan Inc.|CPP-ACP with fluoride based varnish
45601656|NCT03141333|Behavioral|Teleintervention|Participants of this group will have access to the following sections in the web plate-form: information, forum, chat and live online consultation. The teleintervention consists of having access to the forum, chat and live online consultation sections of the web plate-form.
45601657|NCT05314010|Drug|MIL62|"Phase 1b:participants will receive IV MIL62 500 mg or 1000 mg on Day 1 and Day 15.~Phase 3:Participants will receive IV MIL62 on Day 1, Day 15 and Day 183 of the RCP at the dose confirmed in the phase Ib. The participants who enter the OLP will receive IV MIL62 on Day 1 and matching placebo on Day 15, followed by a single IV dose of MIL62 every 6 months until maximum of 6 months after the last participant enters the OLP."
45601658|NCT05314010|Other|Placebo|Phase 3:Participants will receive IV placebo matched to MIL62 on Day 1, Day 15 and Day 183 of the RCP. The participants who enter the OLP will receive IV MIL62 on both Day 1 and Day 15, followed by a single IV dose of MIL62 every 6 months until maximum of 6 months after the last participant enters the OLP.
45601659|NCT02327637|Behavioral|Moderate Activity|Ambulation 150 feet, two times per day
45601660|NCT05230563|Device|Ti-LUNG|"Participating clinicians will perform two image interpretations on all cases. One period the clinicians only will perform lung nodule detection on chest CT images, and the other period will perform lung nodule detection on chest CT images with the aid of Taihao lung CT decision support system. In each interpretation, all lung nodule is marked by each radiologist. This test collects chest computerized tomography cases for computer analysis, and evaluates whether the TaiHao lung CT decision support system helps doctors make more accurate diagnoses."
46066530|NCT00505063|Biological|Immunization Schedule patients > or = to 11 years of age|"Time 0 month: Hib#1, Prevnar 13#1, Hepatitis B #1~Time 1 month: Tdap(BOOSTRIX), Hepatitis B #2~Time 2-3 months: Hib #2, Prevnar 13#2, Menactra~Time 3-6 months: IPV, Draw post vaccine titers~Time 6-12 months: Gardasil (dose #2 given 2 months after first dose, and dose #3 given 6 months after first dose)"
45601661|NCT05313620|Drug|Tofacitinib|Tofacitinib 5 MG/day per clinical practice
45601662|NCT05313620|Drug|Infliximab Adalimumab y Golimumab|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice or or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice.
45601663|NCT05063019|Diagnostic Test|MRI|Magnetic resonance imaging and enterography before surgery
46066531|NCT00001360|Drug|0-15 Water|
46066532|NCT00631280|Behavioral|Choice|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a decision aid. Parent treatment preferences will be elicited and parents will receive coaching in deliberation about striking a balance between benefit and tolerable side effects. Parent will then choose the week that was best for their child and plan their next steps. Parents will also receive a consultation report that contains a physician dosage recommendation.
45755660|NCT02998489|Other|Traditional milk advancement|20 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
45755661|NCT02827513|Drug|CTN SR1|
45755662|NCT02827513|Drug|CTN XR1|
45755663|NCT02827513|Drug|CTN XR2|
45601664|NCT04243148|Combination Product|Home exercise program for 12 months.|Physical exercise at home: At the beginning of the study, group sessions will be conducted with 5 patients of 1-hour duration, where they will be taught the individualized program according to their physical condition and they will be given the necessary material (pedaling, dumbbells and elastic bands) and paper support on the program, also using the Vivifrail method through infographics. The group session will be repeated every 3 months to check the compliance of the program by reviewing daily activity, evaluate possible problems and review the exercises. The program will consist of aerobic and anaerobic exercise by pedaling (cardiovascular resistance) and resistance exercises with dumbbells and elastic bands (muscular strength), flexibility training by stretching, and coordination and balance exercises. Patients will perform 3 sessions per week of 20-30 min. increasing progressively according to tolerance up to 45-60 min. each.
45601665|NCT04243148|Combination Product|Multispecies probiotic: Vivomixx®|"Multispecies probiotic: Vivomixx® is a probiotic mixture of 8 bacterial strains:~Streptococcus thermophilus DSM 24731® / NCIMB 30438, Bifidobacterium breve DSM 24732® / NCIMB 30441, Bifidobacterium longum DSM 24736® / NCIMB 30435*, Bifidobacterium infantis DSM 24737® / NCIMB 30436*, Lactobacillus acidophilus DSM 24735® / NCIMB 30442, Lactobacillus plantarum DSM 24730® / NCIMB 30437, Lactobacillus paracasei DSM 24733® / NCIMB 30439, Lactobacillus delbrueckii subsp. bulgaricus DSM 24734® / NCIMB 30440**~* Re-classified as B. lactis ** Re-classified as L. helveticus The active agent will be supplied as an envelope of 4.4 g with a dose of 450x109 million live bacteria per envelope with maltose and silicon dioxide as excipients, administered 2 times/day throughout the study."
45601666|NCT04243148|Combination Product|Branched-chain amino acids (BCAA)|Branched-chain amino acids (BCAA): In addition to the exercise program and the probiotic, patients in the intervention group will receive BCAA supplements (powder in 8:1:1 ratio in favor of L-leucine) 10 g 30-60 min. before the exercise session throughout the study, in order to enhance the effect of exercise on muscle mass and improve cognitive function. We have chosen this dose based on the literature data and the satisfactory results obtained with this dose in our previous study. BCAA supplements will be supplied by the Pharmacy Service of our center.
45601667|NCT04243148|Combination Product|No specific intervention.|Follow up as a clinical practice
45601668|NCT04571697|Drug|Methotrexate|No intervention or treatment will be administered as part of this study. Data of participants with first claim for a methotrexate in the patient's history are included.
45601669|NCT04571697|Drug|Anti-TNF|No intervention or treatment will be administered as part of this study. Data of participants with first claim for an anti-TNF in the patient's history are included. Anti-TNF includes infliximab, golimumab, etanercept, certolizumab, and adalimumab.
45601670|NCT05482334|Drug|Sargramostim for Injection|Recombinant human GM-CSF
45755664|NCT02827513|Drug|CTN XR3|
45755665|NCT03683810|Dietary Supplement|Lactoferrin|Lactoferrin in tablets 4g/daily
45601671|NCT05482334|Drug|Saline Placebo|Bacteriostatic Saline
45601672|NCT05082129|Device|TransiCap|The TransiCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan.
45755666|NCT03683810|Drug|Recombinant human erythropoietin|Recombinant human erythropoietin (rHuEPO, epoetin alfa)
45755667|NCT01824745|Other|educational intervention|Receive the SCP-BCS template booklet
45601673|NCT05253794|Drug|Colchicine 0.6 mg|oral tablet daily for 6 months
45601674|NCT05253794|Drug|Placebo|oral tablet daily for 6 months
45601675|NCT05081973|Other|A model for predicting extubation success based on extubation readiness estimator and lung ultrasonography score|"Parameters to be recorded before and after extubation to create a new dual extubation model from all babies who met the extubation criteria included in the study:~Lung ultrasound score: Lung ultrasound will be performed prior to the extubation and after the extubation. Lung aeration will be scored based on three chest areas for each side (upper anterior, lower anterior and lateral) and a score of 0 to 3 points will be given for each area (Total score ranges from 0 to 18 points).~Probability of Successful Extubation: It will be calculated by extubation readiness estimator provided by the website named http://extubation.net/.~This parameter will be calculated only 1 hour prior to the scheduled extubation time."
45755668|NCT01824745|Other|counseling intervention|Receive counseling sessions with a patient navigator
45755669|NCT01824745|Procedure|standard follow-up care|Receive standard follow-up care
45755670|NCT01824745|Procedure|quality-of-life assessment|Ancillary studies
46066533|NCT00631280|Behavioral|Recommendation|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a consultation report that also contains a physician dosage recommendation.
45755671|NCT01824745|Other|questionnaire administration|Ancillary studies
45755672|NCT03530852|Device|Relizorb|Tube feeds run across device to digest fats.
45755673|NCT01587235|Drug|Ezetimibe/simvastatin|Algorithm based treatment using 10/10mg, 10/20mg and 10/40mg ezetimibe/simvastatin combination tablets orally once daily.
45755674|NCT01587235|Drug|Other Statin|Participants are prescribed a statin (any other than Vytorin) as per routine standard of care
45755675|NCT03532880|Drug|Olaparib Pill 50 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
45755676|NCT03532880|Drug|Olaparib Pill 100 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
45934924|NCT00211276|Drug|ONTAK (denileukin diftitox)|
45601676|NCT03140943|Drug|Carfilzomib, Thalidomide and Dexamethasone|"Carfilzomib will be given on days 1,2,8,9,15,16 in a 4-week (28 day) cycle during induction cycles 1-12, followed by days 1,2,15,16 in a 4-week cycle during maintenance cycles 13-18 (section 4.0) Dexamethasone, 40mg po will be given on days 1,8,15, 22 in a 4-week cycle during induction cycles 1-12, followed by days 1,15, in a 4-week cycle during maintenance cycles 13-18.~Thalidomide, 100mg po will be given daily during induction cycles 1-12 only."
45601677|NCT05312138|Device|Repetitive Transcranial Magnetic Stimulation|The treatment will be internally cooled 70 mm double coil and 110 mm round coil, accompanied by a physiotherapist and neurologist. The coil will be placed on the precentral gyrus. Practices will be held, with each session lasting 20 minutes. Cortical excitability will be provided by high frequency (HF) stimulation (5-Hz).
45601678|NCT05312138|Device|Transcutaneous Posterior Tibial Nerve Stimulation|The treatment parameters will be applied with a pulse current time of 200 μsec, a fixed frequency of 10 Hz, a treatment time of 20 minutes, and a current intensity that the patient can tolerate, which will not cause flexion in the big toe or fan movement in the other fingers. Self-adhesive surface electrodes will be used for stimulation. During the treatment, the patient will lie on his back. The negative electrode will be placed 2 cm posterior to the medial malleolus and the positive electrode will be placed 10 cm proximal.
45601679|NCT04257279|Procedure|ExcelsiusGPS™|The ExcelsiusGPS™ is a Robotic Positioning System that includes a computer controlled robotic arm, hardware, and software that enables real time surgical navigation and robotic guidance using radiological patient images (pre-operative CT, intra-operative CT and fluoroscopy), using a dynamic reference base and positioning camera.
45601680|NCT04128423|Biological|AMV564|AMV564 will be administered daily
45755677|NCT03532880|Drug|Olaparib Pill 150 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
45755678|NCT03532880|Drug|Olaparib Pill 200 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
45755679|NCT03532880|Drug|Olaparib Pill 250 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
45601681|NCT05282966|Diagnostic Test|QSant-TM Urine Test|QSant™ is a needle free urine test collected in-home or in-clinic to aid in the evaluation and management of kidney transplant recipients' allograft status. QSant evaluates 6 kidney-specific biomarkers.
45601682|NCT03137745|Other|thromboelastography|thromboelastography was done pre HIPEC ,post HIPEC and first and second postoperative days
45755680|NCT03532880|Drug|Olaparib Pill 300 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
45601683|NCT05281016|Behavioral|Usual Care|"Participants will be offered standard care which consists of the following:~Clinic consultation with physician and dietician,~pamphlets on weight management principles."
45755681|NCT03532880|Radiation|Radiotherapy|The total prescribed dose will be 30 Gy in ten daily fractions of 3 Gy each delivered during business days over 2 calendar weeks.
45755682|NCT03530306|Device|PS1-PS4|Participants in this arm shall be given PS1 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
45755683|NCT03530306|Device|PS6-PS10|Participants in this arm shall be given PS6 during the first half of treatment and PS10 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
45755684|NCT03530306|Device|PS7-PS4|Participants in this arm shall be given PS7 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
45755685|NCT03530306|Device|PS9-PS6|Participants in this arm shall be given PS9 during the first half of treatment and PS6 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
45755686|NCT01796509|Other|Medical, psychological, social|After having given his consent, the patient filled auto questionnaire, and then randomized either in follow up arm (i.e. intervention group) or in no follow up arm (i.e. control group). In the follow up arm, medical, psychological and social consultation will be planned within the first seven days after inclusion, and then 3, 6, 12 months. During medical consultation a general examination will be performed, muscle strength, cognitive function, functional disabilities will be assessed with help of MRC, MMS. During psychological consultation, anxiety and depression will be assessed with the help of HAD, IES. The psychologist will also have a free interview. During social consultation personal and professional reinsertion will be assessed.
45755687|NCT03601442|Biological|CTL019|CTL019
45755688|NCT02998099|Drug|Rivipansel|A single dose of IV rivipansel over 20 minutes.
45444524|NCT02036788|Other|Thoraco-abdominal compressions|Thoraco-abdominal compressions to assess the correct positioning of esophageal balloon catheter when the patient is sedated and paralyzed.
45755689|NCT00705133|Drug|Treprostinil|For both SQ and IV routes, treprostinil will be started in the hospital at 1ng/kg/min and titrated up by 1ng/kg/min every 1-3 days as tolerated
45601684|NCT05281016|Behavioral|Online community LITE programme|"Participants will be invited to participate in the online community LITE programme. Participants will also receive basic sports equipment for the online programme.~The online community LITE programme will consist of 2 sessions a week for 4-5 months. Each session is 1 hour long. The programme will deliver 3 domains: physical activity, nutrition and behaviour. It consists of relatively unstructured sessions comprising of cooking and nutrition classes, games and sports and peer support."
45601685|NCT02035917|Device|Locking plate|
45601686|NCT02035917|Device|Non-Locking plate|
45601687|NCT05253716|Other|ONS|Immunonutritional supplement
45601688|NCT02038257|Procedure|MKTP (melanocyte keratinocyte transplant procedure)|Each subject will have the melanocyte keratinocyte transplant procedure on 4 distinct areas using the two different techniques being studied (carbon dioxide laser and dermabrasion) and the two different dressings being studied (vaseline impregnated gauze and collagen dressing).
45601689|NCT02038257|Device|Collagen Dressing|Each subject will have MKTP on 4 distinct areas. Two of these areas will be dressed with a collagen dressing.
45601690|NCT02038257|Device|Vaseline Impregnated Gauze|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be dressed with vaseline impregnated gauze.
45601691|NCT02038257|Device|Carbon Dioxide Laser|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using a carbon dioxide laser.
45601692|NCT02038257|Device|Dermabrasion|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using dermabrasion.
45911025|NCT02002442|Other|Mouthwash|An investigator will give the patient the assigned mouthwash based on the randomized group allocation. 30ml of the mouthwash will be given to the subject in a sterilized calibrated tube. The subject will be asked to rinse for 60 seconds. Then, the patient will spit the mouthwash.
45601693|NCT05311436|Behavioral|Experimental - Intensive nutrition counselling for pregnant, adolescent and under2 children|"Pregnant women: Intensive dietary counseling using diet chart for locally available food, and to attend antenatal care services from local ANC providers, daily Iron, folic acid, and calcium supplementation~Adolescent girls: Behavioral: Group sessions in the nutrition centers with the adolescent girls will be conducted twice monthly for six months. Iron and folic acid (200 mg ferrous fumarate and 200 μg folic acid); once weekly for 3 months; zinc 10 mg daily for 1 month~Children <2 years: Behavioral counseling sessions through monthly home visits on Infant and Young Child feeding, Growth monitoring and promotion, and water sanitation and hygiene, and food safety,~Severely stunted children: 1 egg supplementation for 3 months and 1 sachet of multiple micronutrient powder (1 RDA of vitamin A and C, iron-folic acid, and zinc) daily for 6 months."
45601694|NCT05210205|Dietary Supplement|EAA|EAA-enhanced protein snack bars
45601695|NCT05210205|Dietary Supplement|Energy Dense|Energy dense snack bars (same calories in a smaller volume of food)
45601696|NCT05210205|Dietary Supplement|Control|Low energy dense snack bars (same calories in a greater volume of food)
45601697|NCT05253404|Device|Ambu® AuraOnce™ Disposable Laryngeal Mask|Switching endotracheal tube to laryngeal mask at sevoflurane 2.63-2.97%, Removing endotracheal tube when spontaneously generating tidal volume of >4ml/kg, EtCO2<45mmHg, Train of four ratio >70-90%.
45755690|NCT02998255|Drug|Single dose of 2L PEG|Patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. Patients began to drink 2 L of PEG 4-6 hours before colonoscopy at a rate of 250 mL every 15 minutes.
45755691|NCT02998255|Drug|Split dose of 4L PEG|All patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. the participants began to drink the first 2 L of PEG at 7:00-9:00 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
45755692|NCT00652717|Drug|Ezetimibe|Ezetimibe 10 mg daily for 42 days.
45755693|NCT00652717|Drug|simvastatin|simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
45911026|NCT02002455|Device|PET/CT, PET/MRI, mpMRI|FACBC dose 370 megabecquerel (MBq)
45911027|NCT02002468|Other|Test result sent by letter|
45911028|NCT02002468|Other|Test result conveyed by general practitioners|
45444525|NCT01560039|Device|TMS|Transcranial magentic stimulation of the motor cortex. Device Details : Model is Magstim TMS Rapid. Manufacturer : MAGSTIM CO LTD. Spring Gardens, Whitland, Carmarthenshire, Wales, U.K., SA34 0HR
45601698|NCT05204355|Diagnostic Test|MRI|Patients will be imaged using MRI
45601699|NCT05204355|Drug|Hyperpolarized Xe129|Hyperpolarized Xe129 will be used to image the lungs of a subset of participants.
45601700|NCT05204355|Diagnostic Test|HRCT|High Resolution Computer Tomography
45601701|NCT05310890|Behavioral|Tai chi training|Tai chi, also called tai chi chuan, is an ancient Chinese form of exercise originally created as a fighting art. It is a kind of gentle physical exercise and stretching, which involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
45601702|NCT05310890|Behavioral|Group activity|A organizer will lead the subjects to participate in group activities once a quarter. In group activities, there will be popular science lectures and interactive games.
45601703|NCT05199753|Drug|LM-108|Administered intravenously
45911029|NCT02002481|Other|transport|The manikin will be resuscitated during a transport in a vessel by a professional team (emergency physician / paramedic).
45911030|NCT02002585|Procedure|Renal denervation|Catheter based renal sympathetic denervation is a endovascular method used for the treatment of resistent hypertension.
45911031|NCT02002598|Drug|Bendamustine|"Bendamustine will be administered IV on days 1 and 2 with dose escalation up to 90 mg/m2 of each 28-day cycle.~Dose escalation is as follows:~-1 | 60 mg/m2~| 70 mg/m2~| 70 mg/m2~| 90 mg/m2~| 90mg/m2~| 90 mg/m2"
45911032|NCT02002598|Drug|Carfilzomib|"Carfilzomib will be administered IV on Days 1, 2, 8, 9, 15, and 16 every 28 days.~Dose Escalation is as follows:~-1 | 27 mg/m2~| 27 mg/m2~| 36 mg/m2~| 36 mg/m2~| 45 mg/m2~| 56 mg/m2"
45911033|NCT02002598|Drug|Dexamethasone|Dexamethasone will be administered PO or IV, 20 mg, on 1, 2, 8, 9, 15, 16 and 22, 23 of each 28-day cycle.
45911034|NCT02002611|Drug|Lobeglitazone|
45755694|NCT04387591|Procedure|Fu's subcutaneous needling(FSN)|In this study, the doctor will use a disposable Fu's subcutaneous needling(FSN) to penetrate the subject's skin of the middle of medial epicondyle and radial styloid process. Then the doctor will push forward the needle parallel to the skin surface (maintaining in the subcutaneous layer), towards the subject's medial epicondyle. The docotr will sway the needle 50 times in 30 seconds. After swaying the needle, the doctor will instruct the subject to do elbow flextion for 10 seconds resisting the doctor's opposite force, then the subject take a rest for 10 seconds. The above actions(elbow flexion and rest) are 3 repetitions. Then the subject do palmar flexion in the position of elbow flexion for 10 seconds resisting the doctor's opposite force, and take a rest for 10 seconds. These actions are also 3 repetitions. After the above reperfusion approach of muscles, the doctor will take out the needle to finish the treatment.
45755695|NCT04387591|Procedure|Transcutaneous Electric Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENSor TNS) is the use of electric current produced bya device to stimulate the nerves for therapeuticpurposes. TENS, by definition, covers the completerange of transcutaneously applied currents usedfor nerve excitation although the term is often usedwith a more restrictive intent, namely to describe thekind of pulses produced by portable stimulators usedto treat pain. The unit is usually connected to theskin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width,frequency and intensity. Generally TENS is applied athigh frequency (>50 Hz) with an intensity below motorcontraction (sensory intensity) or low frequency (<10Hz) with an intensity that produces motor contraction
45601704|NCT05199753|Drug|An Anti-PD-1 Antibody|Administered intravenously
45601705|NCT05253092|Other|Virtual mindfulness meditation|Subjects will participate in 30 minutes of a virtual mindfulness meditation session, totaling eight sessions.
45601706|NCT01352741|Drug|Tapentadol Prolonged Release|100 - 500 mg per day orally twice daily for a maximum of 12 weeks
45601707|NCT01352741|Drug|Tapentadol Prolonged Release with Pregabalin|Tapentadol Prolonged Release 100 - 300 mg per day with Pregabalin 150 - 300 mg per day orally twice daily for a maximum of 12 weeks
45601708|NCT01352741|Drug|Tapentadol Prolonged Release open label maintenance|100 - 400 mg per day Tapentadol Prolonged Release orally administered twice daily
45601709|NCT03111225|Diagnostic Test|massage|a 15 minutes thoracic massage will be added to the regular physical therapy treatment
45601710|NCT05279768|Biological|UC-MSCs|Treatment with tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (growth medium) for 30 days.
45601711|NCT05279768|Biological|Secretomes|Treatment with tablet (placebo) once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.
45601712|NCT05279768|Biological|UC-MSCs and Secretomes|Treatment with tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.
45755696|NCT00553891|Drug|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months.
45755697|NCT00553891|Drug|placebo nasal spray|One spray in each nostril once daily for 3 months.
45755698|NCT03599492|Diagnostic Test|SMART Pill Pre-TIPS|Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
45911035|NCT02002611|Drug|Warfarin|
45911036|NCT02002624|Device|PSI|
45911037|NCT02002624|Device|Conventional instrumentation|
45601713|NCT05279768|Biological|Control|Treatment with Metformin once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (growth medium) for 30 days.
45601714|NCT05176431|Device|ESWT (wave type: focused)|Extracorporeal Shock Wave Therapy, device: Electronica, Pagani, Italy
45601715|NCT05176431|Device|ESWT (wave type: radial)|Extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
45601716|NCT05176431|Device|ESWT (wave type: sham)|Extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
45601717|NCT04422392|Drug|Carboplatin|(IV, Q3W)
45601718|NCT04422392|Drug|Pemetrexed or Nab-paclitaxel|Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel (Squamous NSCLC) (IV, Q3W)
45601719|NCT04422392|Drug|PD-1 antibody|(IV, Q3W)
45601720|NCT04458987|Behavioral|Expert patient in addictology|"EP's Intervention, with patients hospitalized for addiction withdrawal. These are weekly individual interviews, in room, proposed by the EPs to inpatients.~The content of the intervention will be defined trough the results of step one of the study."
45601721|NCT04399863|Behavioral|ETOILE therapeutic education|ETOILE is a patient education program, in accordance with French recommendations, which offers to patients and caregivers the opportunity to follow a customized educational training on their disease. Better quality of life and enhanced autonomy are the aim of this program.
45911038|NCT02002637|Device|Latella Knee Implant System|
45911039|NCT02002663|Drug|ropivacaine 0.2%|PCA morphine 0.5 mg/ml bolus 1 mg LO 5 min max 20 mg in 4 hs
45911040|NCT02002663|Drug|Methylprednisolone 1mg/kg|
45911041|NCT02002663|Drug|saline 0.9%|
45911042|NCT02002715|Drug|Inhaled budesonide|inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
45911043|NCT02002741|Drug|Paracetamol|Ibuprofen 3 doses administered q24h + Paracetamol 12 doses administered q 6h
45601722|NCT05310266|Procedure|Transversus abdominis plane block|The investigators performed transversus abdominis plane block to that patient group for postoperative analgesia
45601723|NCT05310266|Procedure|Quadratus Lumborum Block|The investigators performed quadratus lumborum block to that patient group for postoperative analgesia
45601724|NCT03973593|Behavioral|Enhancing contraceptive counseling on method continuation and switching|Health care workers and Community Health Volunteers will be trained on a contraceptive counseling package that enhances information on method continuation and switching. This will be done in the ten intervention facilities prior to enrollment of clients into the cohort study.
45601725|NCT05310032|Drug|HSG4112|Once-daily oral adminstration
45601726|NCT05310032|Drug|Placebo|Once-daily oral adminstration
45601727|NCT05251532|Other|Kinesio Taping|In addition to Kinesio Tex tape distortion taping, conventional rehabilitation is applied.
45601728|NCT05251532|Other|Conventional Rehabilitation|Conventional rehabilitation practices are carried out
45601729|NCT05627063|Drug|ABSK121-NX|In the escalation part, patients will receive a single dose of oral ABSK121-NX on Day -7 followed by a 7-day washout (Day -7 dosing day as 1st day of wash out) as a run-in period to access the safety and PK of ABSK121-NX. Then, patients will continuously receive ABSK121-NX once daily (QD) starting at C1D1 and continuing in subsequent cycles (28-day cycles). The starting dose is 3mg QD. In the expansion part, patients will each receive oral ABSK121-NX at the RDE in repeated 28-day cycles.
45601730|NCT03863067|Procedure|Epiduroscopy|Using epiduroscopy to treat the ligamentum flavum hypertrophy with Resaflex ,an instrument with Quantum Molecular Resonance for tissue coablation.
45601731|NCT00911963|Drug|VCH-222 or matching placebo|capsule, oral, 4 doses once daily or twice daily, 3 days
45601732|NCT00911963|Drug|VCH-222 or matching placebo|capsule, oral, 400 mg twice daily or 750 mg twice daily, 12 weeks
45601733|NCT00911963|Biological|peginterferon alfa-2a|subcutaneous injection, 180 μg, once weekly, 48 weeks
45601734|NCT00911963|Drug|ribavirin|tablet, oral, 1000-1200 mg daily based on body weight, 48 weeks
45601735|NCT03139461|Other|PT-REFER Capacity-building Toolkit|"Written guidelines for building partnerships with physical therapists. Information includes information on who to contact, how to contact them, and how to present information about the program (e.g., evidence base, program structure)~Support from Change Agent~Technical Assistance Calls"
45601736|NCT03139539|Device|Ioban|
46066534|NCT02585206|Behavioral|Personalization|"Phase I Factor~Personalized text messages using the participant's username and gender (Check out the EX Community for tips/support from other men who have quit. They've been there and can help you do this, QuitForever!). Both data points will be pulled from BecomeAnEX registration data."
45755699|NCT03599492|Diagnostic Test|SMART Pill Post TIPS|Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
45911044|NCT02002741|Drug|Placebo|Ibuprofen 3 doses administered q24h + Placebo : 12 doses administered q 6h
45601737|NCT00991757|Drug|carisbamate|Open-Label Extension: 400 mg/day (up to a maximum of 1200mg/day) given in 2 equally divided doses for up to 1 year (or until carisbamate is available by prescription or the sponsor terminates the study).
46066535|NCT02585206|Behavioral|Integration|"Phase I Factor~Interactive messages to facilitate engagement via text with the 6 interactive intervention components of the BecomeAnEX web intervention:~Set your quit date Cigarette tracker Beat your smoking triggers Build your support system Choose a quit smoking aid Community~Integration will allow interaction with the web-based program via text message; for example, when a user sets a quit date via the website, it will trigger text messages tailored to the quit date; likewise, if a user sets a quit date via the text system, it will be populated in the website and drive the user experience online."
45601738|NCT04257201|Other|Yellow Oyster -- 84 g|Participants will consume the standardized test day salad plus 84 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
45601739|NCT04257201|Other|Yellow Oyster -- 168 g|Participants will consume the standardized test day salad plus 168 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
45601740|NCT04257201|Other|White button -- 84 g|Participants will consume the standardized test day salad plus 84 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
45601741|NCT04257201|Other|White button -- 168 g|Participants will consume the standardized test day salad plus 168 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
45601742|NCT04257201|Other|Control|Participants will consume the standardized test day salad only
45601743|NCT01657292|Drug|Oleogel-S10 ointment|Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing
45601744|NCT01657292|Device|Octenilin® wound gel|Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing
45755700|NCT03682094|Drug|VSL#3|Probiotics are dietary supplements composed of live microorganisms that are normally found within the human microbiome. Probiotics, specifically Lactobacilli and Streptococcus salivarius, have been shown to alter oral microbial composition and to inhibit oral pathogens that contribute to dental caries and periodontal disease. The probiotic chosen for this study is VSL#3, a blend of 8 strains of bacteria, including Lactobacillus and Streptococcus salivarius. VSL#3 has been well tolerated, with minimal adverse effects. VLS#3 was chosen as the treatment substance for this project due to its successful use in trials examining an array of outcomes and its combination of several strains of bacteria.
45911045|NCT02002754|Drug|Bambuterol Hydrochloride tablets|Bambuterol Hydrochloride tablets(10mg) 3 tablets qd for three days(swallowed by warm water at 0.5-1h after each meal)
45911046|NCT02002780|Behavioral|Day Camp|"The intervention will be delivered using a day camp structure, on a weekend or during school break in July 2011. Separate interventions will be offered for boys and girls. Each intervention will include two full days (0900 to 1600) of group activities lead by the researchers. Details of the camp activities will be developed by the researchers, based on the types of psychosocial stress identified during the screening phase of the project."
46066536|NCT02585206|Behavioral|Dynamic Tailoring|Individually tailored message to remind/reinforce users about BecomeAnEX information/tools they have already used, or to prompt users to take actions they have not yet taken.
46066537|NCT02585206|Behavioral|Message Intensity|"Phase I Factor~Varying levels of text message intensity over a 12-week period."
46066538|NCT02585206|Behavioral|Optimal-Adherence Text|Optimal-adherence text message intervention developed in Phase I
45444526|NCT01560039|Other|Neurofeedback|EEG neurofeedback based on the primary motor cortex
45601745|NCT04326491|Diagnostic Test|Breath Biopsy|Analysis of breath samples to identify volatile molecules specific to HCC
45601746|NCT04167033|Drug|Hormone replacement therapy:effect on ventricular repolarization|Hormone replacement therapy and QTc measurement
45601747|NCT04167033|Diagnostic Test|ECG|QTc measurement
45601748|NCT00907907|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil Tablet 500 mg
45601749|NCT00907907|Drug|CellCept® Tablets|CellCept® Tablets, 500 mg
45601750|NCT03140553|Drug|TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)|TCH (docetaxel/carboplatin/trastuzumab) versus EC followed by TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer
45601751|NCT05279456|Biological|Advax-CpG55.2 adjuvanted recombinant spike protein|recombinant SARS-CoV-2 spike protein formulated with Advax-CpG55.2 adjuvant
45601752|NCT05278988|Drug|PRS Regimen V|PRS Regimen V(bedaquiline, delamanid, clofazimine, pyrazinamide)
45601753|NCT05278988|Drug|MDR-TB Treatment Regimen(WHO)|Treatment according to WHO MDR-TB treatment guidelines (2019)
45755701|NCT00684775|Combination Product|Work Plus Naltrexone Contingency|"Vivitrol, an extended-release depot formulation of naltrexone, was used. Participants were offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) were randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the Work Plus Naltrexone Contingency condition earned access to working and earning salary by taking depot naltrexone injections once per month."
45444527|NCT01560039|Other|Sham neurofeedback|Sham EEG neurofeedback
45601754|NCT00905567|Drug|Topiramate 2 x 25 mg tablet|
45601755|NCT00905567|Drug|Topamax® Tablet 2 x 25 mg|
46066539|NCT04266626|Other|kinesiotaping therapy|Kinesiotaping is a new therapeutic technique that gives support to the lip and tongue base muscles without restricting range of motion or blood flow.
46066540|NCT04266626|Other|oral motor manipulation therapy|Manipulation therapy include tapping and massage of oral motor muscles including orbicularis oris and base of tongue.
45601756|NCT03137901|Device|Capstesia|Picture of the arterial waveform taken with a smartphone
45601757|NCT05277896|Drug|Ketamine|Intravenous ketamine as the sedative for induction of anesthesia during emergency tracheal intubation
45601758|NCT05277896|Drug|Etomidate|Intravenous etomidate as the sedative for induction of anesthesia during emergency tracheal intubation
45601759|NCT02282020|Drug|OLAPARIB|300 mg olaparib tablets taken orally twice daily. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria.
45601760|NCT02282020|Drug|Single agent chemotherapy|Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
45601761|NCT03847701|Other|Balanced diet high in Slowly Digestible Starch|The carbohydrates present in high Slowly Digestible Starch diet were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during three months.
45911047|NCT02002793|Other|Early stage abdominal drainage|Ultrasound/CT/GUS guided abdominocentesis and drainage with single-chamber deep venous catheters shoule be implemented and the catheter should be removed when abdominal drainage flow≤100ml in two successive days;
45444528|NCT02047708|Drug|Zibotentan|Selective endothelin-A antagonist
45601762|NCT03847701|Other|Balanced diet low in Slowly Digestible Starch|The carbohydrates present in low-Slowly Digestible Starch diet were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during three months.
45601763|NCT05249972|Drug|AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)|Topical cutaneous spray
45601764|NCT05249972|Drug|Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)|Topical foam
45601765|NCT05249972|Other|Placebo|Placebo cutaneous spray
45601766|NCT00904943|Drug|Topiramate Capsules, 25 mg|2 x 25 mg Capsules
45601767|NCT00904943|Drug|Topamax® Capsules, 25 mg|2 x 25 mg Capsules
45601768|NCT03137979|Biological|GMSCs and collagen scaffolds|Patients in this group were given GMSCs and collagen scaffolds.
45601769|NCT03137979|Biological|Collagen scaffolds|Patients in this group were given collagen scaffolds.
45601770|NCT03137979|Procedure|Open flap debridement|The patients in this group will only receive the treatment of open flap debridement.
45601771|NCT05277740|Device|Eye-tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
45601772|NCT03137589|Other|Telemedical support|Participating sites will be advised by telemedicine support.
45601773|NCT00902291|Biological|AGS-1C4D4|IV infusion
45601774|NCT00902291|Biological|Gemcitabine|IV infusion
46066541|NCT02585128|Other|Delirium assessment|During the first post-procedural five days all patients will be evaluated on a daily basis for delirium occurrence by the CAM (Confusion Assessment Method) or CAM - ICU (Confusion Assessment Method - Intensive Care Unit)
45444529|NCT03799809|Drug|Intrabronchial Voriconazole instillation|Efficacy of intrabronchial voriconazole instillation for inoperable pulmonary aspergilloma
45601775|NCT05276726|Drug|JAB 21822|Administered orally
45601776|NCT03137667|Other|School-located Influenza Vaccination|Children in the intervention arm are enrolled in schools in Monroe County, New York that are offering school-located influenza vaccination clinics during school hours
45601777|NCT05218460|Device|MRI examination|All subjects (healthy and pathological subjects) will have an MRI examination with a component of the MRI system under development.
45601778|NCT05152251|Other|Evaluation|Individuals' activity participation levels and the restrictive or supportive factors affecting their participation levels and their effects on quality of life will be evaluated.
45601779|NCT05378009|Behavioral|relaxation and physical activity|This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose), Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time), physical activity ( five session per the week conducted on treadmill, 30 minutes in the first treatment month and 40 minutes in the second treatment month)
45601780|NCT05378009|Behavioral|relaxation|This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose) and Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time)
45601781|NCT05217680|Biological|Bevacizumab|Administration of monthly intravitreal bevacizumab (4-12 injections)
45601782|NCT05217680|Biological|Lucentis®|Administration of monthly intravitreal ranibizumab (4-12 injections)
45601783|NCT03637023|Behavioral|Virtual Reality|Virtual Reality Based Rehabilitation including static balance, dynamic balance and walking
45601784|NCT03637023|Behavioral|Exercise Therapy|The conventional physical Therapy program includes parameters for improving strength, flexibility, transfers, posture, balance and coordination, and sensory stimulation. These activities consist of various types of exercises that focus on lower extremity movements.
45755702|NCT03681860|Biological|ChAdOx185A|ChAdOx1 85A is an adenoviral vaccine based on a vector that is a chimpanzee adenovirus isolate Y25 expressing the M.tb antigen 85A. Adenoviruses are attractive candidates for use as viral vectors and have been used as vaccine vectors for a number of conditions; however, the use has been limited by the high level of anti-vector immunity present in humans in whom adenovirus is a ubiquitous infection. This has led to the consideration of simian adenoviruses, which are not known to cause pathology or illness in humans and to which the prevalence of anti-vector antibodies is low. The ChAdOx1 vector has been developed by the University of Oxford and been used with different inserts for vaccination, for example the vaccine ChAdOx1 NP+M1 has demonstrated an excellent safety profile in the Influenza trial FLU004. A BCG - ChAdOx1 85A - MVA85A prime boost regime is more protective than BCG alone in mice.
45601785|NCT05197673|Behavioral|Theory of planned behaviours (TPB) based intervention|Intervention group will receive TPB-based education program to improve workers' attitude toward SARS-CoV-2 and raise their intention to vaccination and virus testing. The intervention will be implemented at the baseline with measurements repeated at the 3rd month, 6th month and 9th month. The standardized mode of intervention includes face-to-face/online seminar (depends on the COVID-19 situation), message via mobile phone, promotion pamphlet, etc.
45601786|NCT05275790|Device|Vestal device|Battery powered non-invasive neurostimulation device
45601787|NCT05275790|Behavioral|Lifestyle intervention|All subjects will be prescribed a diet plan and instructed to follow it for the duration of the 12-week study. The diet plan will be designed by the P.I. who is a qualified, obesity management coach.
45601788|NCT02281552|Drug|Tofacitinib|tofacitinib modified release 11 mg tablet administered once time a day for 12 weeks
45601789|NCT02281552|Drug|Tofacitinib|tofacitinib immediate release 5 mg tablet administered twice a day for 12 weeks
45601790|NCT03832647|Combination Product|Epiduo|100 per arm Adapalene/ Benzoyl Peroxide
45755703|NCT03681860|Biological|MVA85A|Modified vaccinia virus Ankara (MVA) is a highly-attenuated strain of vaccinia virus which cannot replicate in human cells. It is known to be highly immunogenic in UK adults but has been less immunogenic in African children and infants. It is suitable for use as a viral vector in a prime-boost regime in new vaccine development. It has an excellent safety record as it was administered intradermally to approximately 120,000 people during the smallpox eradication campaign, and has since been used in numerous clinical trials of candidate vaccines against viral, mycobacterial and protozoal infections.
45755704|NCT03681860|Biological|BCG|BCG is the only vaccine currently approved for use against Tuberculosis.
45755705|NCT00685477|Drug|Experimental Sequence ABC|Drug will be given over 15 minutes, followed by infusion over 30 minutes, followed by infusion over 60 minutes
45755706|NCT00685477|Drug|Experimental Sequence ACB|Drug infused over 15 minutes, followed by infusion over 60 minutes, followed by infusion over 30 minutes
45755707|NCT00685477|Drug|Experimental Sequence BAC|Drug will be given over 30 min infusion, followed by 15 minute infusion, followed by 60 minute infusion
46066542|NCT02585128|Other|MMSE (Mini Mental State Examination)|
45601791|NCT03832647|Drug|Salicylic Acid|Salicylic Acid
45601792|NCT03832647|Other|Hydréane légère|moisturizer
45601793|NCT00901979|Drug|LCQ908A|
45601794|NCT00901979|Drug|LCQ908A|
45601795|NCT00901979|Drug|LCQ908A|
45601796|NCT00901979|Drug|LCQ908A|
45601797|NCT00901979|Drug|LCQ908A|
45601798|NCT00901979|Drug|Placebo|
45601799|NCT00901979|Drug|Sitagliptin|
45601800|NCT00901979|Drug|metformin|
45601801|NCT05249582|Other|Virtual Reality|Virtual reality wireless headset
45601802|NCT05249582|Other|Television Condition|Individuals will mimic hand movements of a pre-recorded video of an individual playing the virtual reality climbing game
45601803|NCT03806361|Procedure|Fat grafts supplemented with ADRC|Isolation of ADRC from fat aspirates and its use for supplementation of fat grafts.
45601804|NCT03806361|Procedure|Structural fat grafting|Fat grafts without supplementation of ADRC
45601805|NCT03778671|Drug|Levobupivacaine|Patients will receive Levobupivacaine 5%
45601806|NCT03778671|Drug|Dexmedetomidine Injection [Precedex]|Patients will receive Levobupivacaine 5% + 1 µg/kg dexmedetomedine
45601807|NCT03778671|Drug|fentanyl|Patients will receive Levobupivacaine 5% + 1 µg/kg fentanyl
45601808|NCT00978497|Drug|placebo|oral BID
45601809|NCT00978497|Drug|ANA598|oral 200mg BID
45601810|NCT00978497|Drug|ANA598|oral 400mg BID
45601811|NCT00978497|Drug|Peginterferon|180 μg dose via subcutaneous injection weekly
45601812|NCT00978497|Drug|Ribavirin|oral 1000 mg/day for patients who weighed < 75 kg and 1200 mg/day for patients who weighed ≥ 75 kg
45601813|NCT05478434|Device|Cortico-cortical stimulation plus robot-assisted therapy|15 sessions of cortico-cortical stimulation between the PPC and the M1 of the lesioned hemisphere and robot-assisted therapy. Paired-pulse stimulation (PAS) technique, with 5ms inter-stimulus time between the two areas (PPC to M1), will be done through two high-power Magstim 200 machines (Magstim® Rapid²). To stimulate the M1 area, the coil will be placed tangentially to the scalp at a 45° angle to the midline, to stimulate the PPC area the center of the coil will be positioned over P4 (10-20 EEG system) tangentially to the skull with the handle pointing downward and slightly medial (10°). Robot-assisted therapy will be performed with an Armeo® Power II (Hocoma), an integrative system composed by a robotic exoskeleton device connected to a laptop for the audio-visual biofeedback for the upper limb therapy.
45755708|NCT00685477|Drug|Experimental Sequence BCA|Drug will be given over 30 min infusion, followed by 60 minute infusion, followed by 15 minute infusion
45755709|NCT00685477|Drug|Experimental Sequence CAB|Drug will be given over 60 min infusion, followed by 15 minute infusion, followed by 30 minute infusion
45755710|NCT00685477|Drug|Experimental Sequence CBA|Drug will be given over 60 min infusion, followed by 30 minute infusion, followed by 15 minute infusion
46066543|NCT02585128|Other|Barthel index|
45601814|NCT05478434|Device|Sham cortico-cortical stimulation plus robot-assisted therapy|15 sessions of sham cortico-cortical stimulation between the PPC and the M1 of the lesioned hemisphere and robot-assisted therapy. Sham paired-pulse stimulation (PAS) will be done through two high-power Magstim 200 machines (Magstim® Rapid²). To simulate the real stimulation, the coils will placed in the same sites with different inclination respect to the scalp (90°). Robot-assisted therapy will be performed with an Armeo® Power II (Hocoma), an integrative system composed by a robotic exoskeleton device connected to a laptop for the audio-visual biofeedback for the upper limb therapy.
45601815|NCT03692715|Drug|Ciprofloxacin|Oral or intravenous ciprofloxacin prior to shockwave lithotripsy.
45601816|NCT03692715|Drug|Placebo|identical oral placebo if oral cipro was used, or intravenous saline alone in a blinded fashion if IV cipro was used prior to shockwave lithotripsy.
45601817|NCT05216120|Drug|Pemigatinib 4.5 MG|"Pemigatinib 4.5 mg tablets taken 3 times per day [daily dose of 13.5 mg (3 tablets)] for 14 consecutive days followed by 7 days off medication in 21-day cycles~Doses will be self-administered at home. Participants will be instructed to take study medication at the same time each day, with or without food."
45601818|NCT00973817|Biological|ELAD plus standard of care treatment|Use of ELAD plus standard of care
45601819|NCT00973817|Other|Standard of care|Standard of care in the treatment of AOCH will be administered
45601820|NCT03558789|Biological|bovine lactoferrin|mouthwash
45601821|NCT05215496|Diagnostic Test|[18F]fluoro-PEG-folate PET/CT scan|A dynamic FR-targeted PET scan, a low-dose CT scan without contrast agents, and a static FR-targeted PET scan will be obtained
45601822|NCT05161091|Device|Topical application of Orosol®|Orosol® is a 20 ml aluminum bottle equipped with a spray without propellant gas for local application. Simply shake the bottle gently, apply the product to the injured surface by pressing your finger on the spray to deliver the product (4 to 5 times so as to form a thin film on the surface of the mouth) . It is recommended to use Orosol® every 2 hours at the start of treatment and then 3 to 4 times a day. The maximum duration of treatment will be 28 days. Eating or drinking should be avoided for the first 15 to 30 minutes after applying the product.
45601823|NCT05161091|Device|Topical application of Placebo comparator|Placebo comparator is a 20 ml aluminum bottle equipped with a spray without propellant gas for local application. Simply shake the bottle gently, apply the product to the injured surface by pressing your finger on the spray to deliver the product (4 to 5 times so as to form a thin film on the surface of the mouth) . It is recommended to use Placebo comparator every 2 hours at the start of treatment and then 3 to 4 times a day. The maximum duration of treatment will be 28 days. Eating or drinking should be avoided for the first 15 to 30 minutes after applying the product.
45601824|NCT05248958|Other|Turkish Validity and Reliability of The CRAVE Scale|The aim of this study is to adapt the Cravings for Rest and Volitional Energy Expenditure (CRAVE) scale to Turkish society and to make its validity and reliability in Turkish.
45601825|NCT00890591|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary|olmesartan medoxomil tablets,or olmesartan medoxomil/hydrochlorothiazide tablets, if necessary + amlodipine tablets, if necessary. All interventions are once-daily for 4 to 9 weeks
45755711|NCT03594890|Biological|OVX836 (Intramuscular)|2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
45755712|NCT03594890|Biological|Placebo (Intramuscular)|2 consecutive administrations of placebo at Day 1 and Day 29.
45755713|NCT03594890|Biological|OVX836 (Intranasal)|2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
45755714|NCT03594890|Biological|Placebo (Intranasal)|2 consecutive administrations of placebo at Day 1 and Day 29.
45601826|NCT05248334|Drug|Ranibizumab Injection|"The Ranibizumab group was treated with one intravitreal injection of 0.5 mg/0.05 ml ranibizumab (Lucentis, Basel, Novartis) at baseline. While additional panretinal photocoagulation was performed if there was sufficient space and view to fill in the previously untreated areas, if needed. Repeated injections will be given after 4 weeks when the clearing of VH was incomplete (for a maximum of two injections).~If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed."
45601827|NCT05248334|Procedure|PPV|Vitrectomy to remove vitreous hemorrhage and take additional panretinal photocoagulation. If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/tractive retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed.
45601828|NCT05214560|Device|Spinal needle|Insertion of a spinal needle to perform the neuraxial procedure.
45601829|NCT03140787|Drug|Nasal Spray of Lidocaine HCL|This spray consists of lidocaine hydrochloride-epinephrine hydrochloride
45601830|NCT03140787|Drug|Infiltration injection of Lidocaine HCL|This is the ordinary method of establishing anesthesia for patients undergoing dental treatment for caries.
45601831|NCT00889967|Drug|Ciprofloxacin for Inhalation|100 mg once daily by inhalation for 28 days
45601832|NCT00889967|Drug|Ciprofloxacin for Inhalation|150 mg once daily by inhalation for 28 days
45601833|NCT00889967|Drug|Placebo|Placebo once daily by inhalation for 28 days
45601834|NCT05214404|Other|Patients diagnosed with ulcerative colitis|Patients with ulcerative colitis diagnosed by endoscopy and histopathology
45601835|NCT03317223|Drug|CJ-12420/Clarithromycin/Amoxicillin|CJ-12420 or Lansoprazole +Clarithromycin/Amoxicillin will be administrated twice a day, for 7 days
45601836|NCT00889889|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
45601837|NCT00889889|Biological|Placebo|Placebo
45601838|NCT02284906|Drug|Pioglitazone|Pioglitazone tablets
45601839|NCT02284906|Drug|Placebo|Pioglitazone placebo-matching tablets
45601840|NCT05273138|Other|Blood sampling and skin biopsy|Blood sampling and skin biopsy
45755715|NCT02997943|Behavioral|Step 1 Treatment: APP|Participants will receive a smartphone app to track weight, dietary intake and physical activity, and a technology core consisting of web-based weekly lessons, wireless scale, and activity tracker. Participants will use their own smartphone to receive the study smartphone application.
45755716|NCT02997943|Behavioral|Step 1 Treatment: APP + Coaching|Participants will receive a smartphone app to track weight, dietary intake and physical activity; a technology core consisting of web-based weekly lessons, wireless scale, and activity tracker; 12 weekly telephone coaching sessions. Participants will use their own smartphone to receive the study smartphone application.
45601841|NCT02566863|Drug|Dexmedetomidine|1 mcg/kg over 10 minutes, followed by a maintenance infusion titrated to achieve desired clinical effect - Richmond Agitation Scale between 0 and (-) 3. Holter ECG recording before start of infusion and during infusion for 25 minutes.
45601842|NCT05137847|Drug|Remitoro|Intravenous infusion.
45601843|NCT02434263|Device|Hydra TAVI|Percutaneous Replacement of the Diseased Aortic Valve
45601844|NCT04127318|Behavioral|Pedaling Group|Participants will pedal at low-moderate intensity using a stationary pedal ergometer concurrent to their immunotherapy infusion (30 minutes).
45601845|NCT02398617|Other|Decision Making Intervention|At their regularly scheduled admission follow-up visit with seven days of discharge, participants will be asked to bring their medical decision maker and participate in a semi-structured supplemental palliative care/education session facilitated by a heart failure nurse practitioner trained in palliative care discussions. Domains included in the intervention will include disease literacy and understanding, goals of care, legal issues for patients with terminal illness, symptom management, health-related quality of life, caregiver burden, patient autonomy, healthcare utilization, and establishment of end-of-life plans.
45601846|NCT00968825|Drug|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel) Dose D applied topically at Baseline (Day 0) to the lateral canthal lines
45601847|NCT00968825|Drug|Placebo|Placebo (Dose E) applied topically at Baseline (Day 0) to the lateral canthal lines
45601848|NCT00967811|Drug|Formulation E1 of L-PPDS|Control of IOP compared to baseline for Formulation E1 of the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
45601849|NCT00967811|Drug|Formulation E2 of L-PPDS|Control of IOP compared to baseline for Formulation E2 of experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
45601850|NCT05214014|Biological|Autologous Regulatory Т-cells|Autologous Regulatory Т-cells obtained from CD4+CD25+ cells isolated from PBMC and cultured with the cocktail of cytokines and antibodies to induce proliferation of Tregs
45601851|NCT05214014|Other|Standard treatment according to the clinical protocols|Standard treatment of Systemic Sclerosis according to the clinical protocols
45601852|NCT05074563|Other|REsOluTioN (Resilience Enhancement Online Training for Nurses)|The online REsOluTioN training involves virtual or face-to-face mentorship sessions and facilitated online interactive group sessions on four topics (Building hardiness and maintaining a positive outlook, Intellectual flexibility and Emotional Intelligence; Achieving life balance and enabling spirituality and Reflective and critical thinking). The training will be of four-week duration. Over the four-week period, the training will comprise 4x120 minute facilitated online group sessions; 4x30 minute independent learning activities; and eight 3:1 online mentoring sessions delivered between 30 and 60 minutes at flexible timings.
45601853|NCT05074563|Other|Control|Nurses randomised to the control group will only be invited to take part in the pre- and post- intervention surveys, but will not use the online training. However, after completing the survey, nurses will be given the opportunity to complete the pre-work and access the facilitated sessions of the training so that they can receive their CPD certificate.
45601854|NCT05271344|Dietary Supplement|Nutritional Products|Omega 3 : 1 softgel, 3 x/d Probiotics : 1 caps / d Prebiotics : 1 measuring spoon of powder to be diluted in water, 1x/d Vitamin D : 1 tablet, 2x/d
45601855|NCT04474457|Drug|Favipiravir|"Turkish patient cohort diagnosed with COVID-19 and previously initiated treatment with Favipiravir."
45601856|NCT02879305|Drug|Daprodustat|Daprodustat dose is based on prior ESA dose, the dose is adjusted thereafter in order to achieve the target range.
45601857|NCT02879305|Drug|rhEPO|The initial ESA dose is based on converting the prior ESA dose to the nearest available study rhEPO dose and is administered IV. The dose is adjusted thereafter in order to achieve the target range.
45601858|NCT02879305|Drug|Placebo|Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
45601859|NCT02879305|Drug|Iron therapy|Participants will receive supplemental iron therapy if ferritin is <=100 ng/mL or TSAT is <=20%. The investigator will choose the route of administration and dose of iron.
45601860|NCT05084469|Procedure|PET-MRI in pain-free remission period|Patients will performed PET-MRI scans. A first 30 minutes acquisition will be performed at time=60min after injection. A second 75 minutes acquisition will be performed at time=150min. Each scans will contain functional dynamic [18F]F13640 PET acquisition, anatomical and functional MRI images acquisition and pain evaluation using a score visual analogic scale.
45601861|NCT05247398|Other|Dynamic Stability Exercise Program|The thumb CMC DS intervention involves four 60-minute occupational therapy visits as well as a daily home program across a 8-week period. Clinic visits focus primarily on home program coaching, and progression of the exercise regimen. Home programs involve daily exercises which follow the intensity and duration recommended for older adults.
45601862|NCT00884507|Drug|Placebo|po daily for 24 weeks
45601863|NCT00884507|Drug|RO5313534|1mg po daily for 24 weeks
45601864|NCT00884507|Drug|RO5313534|5mg po daily for 24 weeks
45601865|NCT00884507|Drug|RO5313534|15mg po daily for 24 weeks
45601866|NCT03139383|Other|dextrose solution|The patients received 5%D/N/2 during surgery
45601867|NCT03139383|Other|saline solution|The patients received NSS during surgery
45601868|NCT05270408|Device|Active Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 1mA to the scalp.
45601869|NCT05270408|Device|Active Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 2mA to the scalp.
45601870|NCT05270408|Device|Sham Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver no current to the scalp.
45601871|NCT02281318|Biological|Mepolizumab|Humanised Immunoglobulin G (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with sterile water for injection, just prior to use
45601872|NCT02281318|Drug|Placebo|Sterile 0.9% sodium chloride solution
45601873|NCT02281318|Drug|SOC|Standard of Care (SOC) will differ by participants, however it will include high dose ICS with at least one other controller, e.g. LABA, with or without maintenance OCS
46066544|NCT02585128|Other|HADS (Hospital Anxiety and Depression Scale)|
46066545|NCT02585128|Other|MNA-SF (Mini Nutritional Assessment - Short Form)|
46066546|NCT02585128|Device|NIRS (Near-Infrared Spectroscopy)|Regional cerebral oxygen saturation monitoring during TAVI procedure
45601874|NCT00880217|Drug|Atomoxetine 80 mg/d|40-mg capsule for 3 days, followed by 80-mg capsule once daily for 39 days
45601875|NCT00880217|Drug|Placebo|Placebo capsule once daily for 42 days
45601876|NCT00880217|Drug|OROS methylphenidate HCl 54 mg/d|36-mg capsule for 3 days, followed by 54-mg capsule once daily for 39 days
45601877|NCT00880217|Drug|JNJ-31001074 3 mg/d|3-mg capsule once daily for 42 days
45601878|NCT00880217|Drug|JNJ-31001074 1 mg/d|1-mg capsule once daily for 42 days
45601879|NCT00880217|Drug|JNJ-31001074 10 mg/d|10-mg capsule once daily for 42 days
45601880|NCT05213390|Other|Dora|DORA uses a variety of AI technologies to deliver the patient follow-up call, including: speech transcription, natural language understanding, a machine-learning conversation model to enable contextual conversations, and speech generation. Together, these technologies cover the input, processing and analysis, and output needed to maintain a natural conversation. DORA is configured to deliver calls through a telephone connection as a real-time, stand-alone system: the operator inputs individual patient details to initiate the call and completes a summary in the electronic health record (EHR) afterwards.
45601881|NCT03139617|Procedure|Fascia Iliaca Compartment Block (FICB)|"The FICB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block. Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel. Lignocaine 2% for local anaesthetic infiltration at punctured site.A blunted needle (Plexufix® 24G x 2, B Braun Melsungen AG 34209 Germany).A line was drawn from pubic tubercle to anterior superior iliac spine, the punctured point is 2-3cm distal to the point where medial 2/3rd and lateral 1/3rd of the line meet. Loss of resistance 2 times indicated the punctured of fascia lata and iliaca.A total volume of Ropivacaine 0.375% per body weight was given with repeated aspiration."
45601882|NCT03139617|Procedure|3 in 1 femoral block (FNB)|"The FNB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block.Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel.Lignocaine 2% for local anaesthetic infiltration at punctured site.An insulated stimulating needle (Stimuplex® D Plus 22g x 2, B Braun Melsungen AG 34209 Melsungen Germany). Ultrasound was used to locate the femoral vessel and nerve and by using 'in plane' technique, the skin was punctured with the insulated needle and advance in transverse plane at around 30 angle to the skin. Local anaesthetic solution as per ideal body weight given after negative aspiration of blood ."
45601883|NCT01657760|Drug|citalopram|citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.
45601884|NCT00966953|Drug|Fluoride|Brush twice daily
45601885|NCT00966953|Drug|Triclosan/Fluoride toothpaste|Brush twice daily
45601886|NCT00966953|Drug|Fluoride|Brush twice daily
45601887|NCT00966953|Drug|Fluoride|Brush twice daily
45601888|NCT00966953|Other|antibacterial plant extract|Brush twice daily
45601889|NCT03137511|Other|Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist|Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist
45601890|NCT05247320|Drug|Sotalol Injection|Standard of care IV sotalol infusion for atrial arrhythmias
45601891|NCT00876863|Drug|CERE-110: Adeno-Associated Virus injection Surgery|Injecting CERE-110 2.0 X 10^11 vg into brain during surgical procedure.
45601892|NCT00876863|Procedure|Placebo Surgery|Placebo Surgery
45601893|NCT05084079|Drug|CSII with formula-based initial insulin regimen|Initial total daily insulin dose(TDD) for CSII was calculated with a formula :（estimate TDD-1(eTDD-1) = 0.35× body weight (kg) + 2.05× FPG (mmol/L) + 4.24×triglyceride(mmol/L) + 0.55× waist circumference (cm) - 49.1）, 42% of which was assigned as total basal dose and 58% as total premeal dose, with the pre-meal doses divided into 30:35:35 for breakfast, lunch and dinner.
45601894|NCT05084079|Drug|CSII with weight-based initial insulin regimen|TDD for CSII was started with 0.5 IU/kg, 50% of which was assigned as total basal dose and 50% as total premeal dose, and the total pre-meal dose was divided equally before each meal.
45601895|NCT02280304|Behavioral|Inner Resources for Veterans (IRV)|Mindfulness and breath-focused mantra therapy which uses techniques that encourage present moment attention for the purpose of improving self-monitoring and self-regulation
45601896|NCT02280304|Behavioral|Essential Skills therapy|This active comparator is adapted from a therapy utilized at multiple VAs as a psychoeducational AND symptom management treatment for PTSD. In it, participants learn about mTBI and PTSD symptoms and coping information for PTSD.
45755717|NCT02997943|Behavioral|Step 2 Treatment Strategy: Modest Step-up|In addition to first line treatment, participants identified as non-responders will be provided an additional mHealth intervention component (push notifications) for the remaining 12 weeks.
46066547|NCT02585128|Other|CIRS (Cumulative Illness Rating Scale)|
46066548|NCT04266782|Other|Exercise program followed by long walk in group|The subjects will be included in a training exercise program for three months followed by a long-walk in group
45444530|NCT02036866|Other|Transcutaneous Electrical Nerve Stimulation|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 8 hours per day for 1 week.
45601897|NCT03137277|Procedure|screening colonoscopy|"Introduction and forwarding of the device up to caecum/terminal ileum. Then withdrawal and inspection of colonic wall. Biopsies and polypectomies if necessary. overall and diagnostic (only withdrawal) times being recorded separately.~Polyps are documented with regards to location (caecum, ascending, transverse and descending colon, sigmoid and rectum), size (open forceps or snare for comparison) and morphology using the Paris classification (polypoid pedunculated or sessile, non-polypoid slightly elevated/flat/depressed, ulcerous) Polyps were then resected using biopsy forceps or cold snare (for polyps < 5 mm), or conventional polypectomy according to local standards."
46066549|NCT04266782|Other|Exercise program followed by long walk in group (controls)|The controls matched for age will perform the same exercise program and long walk as the PD subjects
46066550|NCT00941720|Drug|busulfan|IV busulfan 0.8 mg/kg every 6 hours x 16 doses
45601898|NCT00963053|Drug|VA111913 TS and placebo|VA111913 TS twice daily for a maximum of 6 days during one menstrual cycle followed by placebo twice daily for up to a maximum of 6 days during a second menstrual cycle in a cross over design
45601899|NCT05246852|Behavioral|healthy lifestyle education|A total of 6 sessions on physical activity, nutrition, substance abuse, sexual life, check-up, accidents and injuries will be organized for the adolescents in the intervention group. The sessions will be organized every other week. Each session will be conducted in three stages. First Stage: The researcher will provide training on the subject of the session for nearly 15 minutes. Second Stage: The researcher will show animation film (nearly 3 to 5 minutes) developed by him/her related to the session. Third Stage: Groups of six will be created for the Philips 66 technique application and a spokesman will be chosen. Each group will have an online meeting and discuss the session subject in six minutes under the administration of the researcher. The spokesman of each group will present the discussion outcome in the big group meeting at the end of the discussion. The researcher will summarize the subject after the presentation of each spokesman and terminate the session.
45601900|NCT04240808|Biological|UCD19 CAR T Cells|Lymphodepleting chemotherapy followed by infusion of UCD19 CAR T Cells (Lentiviral Vector [LV] Transduced Autologous Peripheral Blood Lymphocytes)
45601901|NCT05084001|Drug|silver diamine fluoride|topical application of the agent on tooth surface
45601902|NCT05084001|Drug|sodium fluoride varnish|topical application of the agent on tooth surface
45601903|NCT05084001|Other|tonic water|topical application of tonic water on tooth surface
45601904|NCT00961805|Behavioral|Dance|Belly dance classes twice a week for 16 weeks. Each class had a maximum of eight students. The classes were administered by a physiotherapist with eight years of experience in belly dance. Classes began with a warm-up exercise, followed by the predetermined movements for the day, choreography and a cool-down exercise. The participants received a compact disc with music and an exercise book with the history and movements proposed for the program. Beginning in the fourth week, a set sequence of movements in the form of choreography was established for memorization and training at home.
45601905|NCT00961805|Other|Control Group|The control group did not receive any intervention. They attended all assessments and remained on the waiting lis (after the end of the study was offered to this group the same treatment in the intervention group).
45601906|NCT05245916|Drug|IBI397|IBI397 single-agent dose escalation： Subjects will receive IBI397 until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
45601907|NCT05245916|Drug|IBI397+Sintilimab|IBI397 in combination with sintilimab： Subjects will receive IBI397 combination therapy with sintilimab until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
45601908|NCT05245916|Drug|IBI397+Rituximab|IBI397 in combination with rituximab： Subjects will receive IBI397 combination therapy with rituximab until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
45755718|NCT02997943|Behavioral|Step 2 Treatment Strategy: Vigorous Step-up|In addition to the first line treatment, participants identified as non-responders will be provided an additional mHealth intervention component (push notifications) plus a traditional weight loss intervention component (coaching, meal replacements).
45601909|NCT03137199|Biological|hMSCs|intravenous infusion of bone marrow-derived allogeneic stem cells
45755719|NCT03593408|Drug|Dexmedetomidine|Administered for sedation management per hospital protocol
45601910|NCT04878484|Biological|TCRT-ESO-A2|TCRT-ESO-A2 is an autologous cell therapy comprised of a subject's T cells stimulated ex vivo and transduced with a lentiviral vector encoding an affinity enhanced TCR targeting tumor-associated antigen NY-ESO-1.
45755720|NCT03593408|Drug|Fentanyl|Administered for sedation management per hospital protocol
45601911|NCT00875459|Drug|VIAject™|Subcutaneous injection 25 IU/mL
45601912|NCT05244746|Procedure|rectus sheath block|blocking the nerve underneath the rectus muscle by bupivicaine
45601913|NCT03837353|Drug|DKN-01|DKN-01 is a large molecular weight protein that will be given as a flat dose on a Days 1 and 15 of a 21-day cycle in Dose-Escalation Cohort 1A and Dose-Expansion Cohort 1B. DKN-01 will be given on Days 1 and 15 on a 28-day cycle in Dose-Escalation Cohort 2A and Dose-Expansion Cohort 2B. The dose of DKN-01 will be administered as an intravenous (IV) infusion over 60 (±) 15 minutes.
45755721|NCT03593408|Drug|Midazolam|Administered for sedation management per hospital protocol
45755722|NCT03593408|Drug|Morphine|Administered for sedation management per hospital protocol
45755723|NCT00686257|Device|Total face mask (interface for NPPV)|NPPV is applied by this mask, as long as NPPV is received.
45755724|NCT00686257|Device|Comfort full or RT040 oronasal mask (interface for NPPV)|NPPV is applied by one of these masks (Comfort full or RT040 masks used at Rhode Island Hospital and Tufts Medical Center respectively), as long as NPPV is received.
45755725|NCT04403360|Procedure|ESPB|Ultrasound guided performance of ESPB at T12 level after the induction of anesthesia but before the start of the surgery
45755726|NCT04403360|Procedure|Local infiltration by the surgeon|Local infiltration of anesthetics at surgical site after skin incision
45755727|NCT00395473|Drug|MK0653, ezetimibe / Duration of Treatment: 6 Weeks|
45755728|NCT00393211|Drug|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
45755729|NCT00393211|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
45755730|NCT03676556|Drug|Lidocaine|Two sterile gauzes will be dampen with the content of the syringe (20ml lidocaine 0.5%) and apply on the wound. After 7-15minutes of waiting to the effect, the wound treatment will start.
45755731|NCT03676556|Drug|Saline Solution|Two sterile gauzes will be dampen with the content of the syringe (20ml saline serum) and apply on the wound. After 7-15minutes of waiting to the effect, the wound treatment will start.
45755732|NCT03521804|Device|SoundBite™ Crossing System Active Wire 14|Successful crossing of the CTO into the true arterial lumen distal to the occlusion, following use of the SoundBite™ Crossing Wire during the procedure and using antegrade only approach. An antegrade only approach may involve Antegrade Dissection Re-Entry (ADR) with or without the use of specialized devices (i.e. Stingray). The absence of successful retrograde crossing of a collateral will still be considered an antegrade only approach.
45755733|NCT00686803|Drug|PL3994|Study drug
45601914|NCT03837353|Drug|Docetaxel|Docetaxel will be administered as an IV infusion over approximately 60 (±15) minutes on day 1 of a 21-day cycle in Cohorts 1A and 1B. In Cohort 1A, docetaxel must be dosed at 75 mg/m2 on cycle 1 day 1. Docetaxel can be dosed at 75 mg/m2 or 60 mg/m2 in subsequent cycles depending on clinical discretion and dose modification guidelines. Regardless of dose, docetaxel must be dosed in 21-day cycles. In Cohort 1B, cycle 1 day 1 dosing of docetaxel will either be 75 mg/m2 or 60 mg/m2 depending on clinical discretion.
45601915|NCT03140709|Drug|Oxytocin|"Induction-Vaginal Delivery: Begin at 1mU/min IV infusion and increase by 2mU/30min q30min to a max of 30mU/min. Postpartum infusion adjusted to 2U/hr.~Cesarian Delivery: 1U bolus via IV at delivery, followed by 7.5U/hr up to 30U/hour max depending on uterine tone. Postpartum infusion adjusted to 2U/hr"
45601916|NCT05168150|Behavioral|Experimental: Experimental Group - Intelligent Continuous Expertise Monitoring System group|During each of the practice task they will receive real-time auditory feedback instructed by the intelligent system. After each attempt, a student takes a 5-minute break. They will be shown the errors they made during the task regarding five performance metrics. After seeing each error, they will be shown video demonstration to learn how to expertly perform at each performance metrics. On their 6th attempt they will perform on the realistic scenario without any feedback given.
45601917|NCT05168150|Behavioral|Experimental Group In-person expert-mediated instruction group|During each of the practice task, students will receive verbal feedback from the expert instructor present in the room. After each task, experts will summarize their performance and outline the errors the student made. Based on the student's performance, expert will demonstrate how to expertly perform the task in the simulation, and how to improve their performance in the next attempt. Students will perform the 6th attempt on the realistic scenario without any instruction given.
45601918|NCT05083767|Other|Experimental|The study protocol of WBV includes twelve weeks of whole-body vibration training provided to the Type 2 diabetic patients. It was recommended to all participants that they follow their regular diet and medication during the training. Two sets of six 1-minute vibration squats were designed with 20 seconds of rest, 3 times weekly for a duration 12 weeks (total workout time 36 minutes a week), using a vertical vibration machine. The six static positions consisted of (a) a deep squat position (knee angle 900) (b) an elevated squat position (knee angle 1250) (c) an elevated squat position (with elevated heels) (d) a slight knee flexion1 (hand straps with shoulder bending) (e) a slight knee flexion (hand straps with shoulder abduction) and (f) a slight knee flexion 3 (hand straps with elbow flexion). The training load steadily increased from the initial vibration of 30 Hz and the platform amplitude was raised from 2 mm at week 1 to 40 Hz and from 4 mm at week 5 to the completion of training.
45601919|NCT05083767|Other|Control|The control group was advised to their normal physical activity level, diet, and medication.
45755734|NCT00686803|Drug|Placebo|Placebo
45444531|NCT02036866|Other|Physical Therapy Exercises|Patients will be given detailed verbal and hands-on instruction in a home exercise program. This program will consist of 6 exercises modeled from established protocols focuses on improving lower extremity strength. Patients will be instructed to do the exercises daily and to progress the exercises over the week for a maximum of 30 repetitions per day for 1 week.
45601920|NCT05166590|Behavioral|Sleep Restriction|Sleep Deprivation
45601921|NCT02283658|Drug|Everolimus|Given PO
45601922|NCT02283658|Other|Laboratory Biomarker Analysis|Correlative studies
45601923|NCT02283658|Drug|Letrozole|Given PO
45601924|NCT00872885|Drug|GRT6005|liquid formulation, 200 to 600 µg, single dose, one day
45601925|NCT00872885|Drug|Morphine|60 mg
45601926|NCT00872885|Drug|Placebo|single dosage
45601927|NCT05088213|Procedure|suction mini percutaneous nephrolithotomy|18Fr suction sheath (Weili, China) was inserted, and 12Fr mini-nephroscope was used, kidney stones was fragmented by pneumatic lithotriptor (LithoClast Master, Switzerland) or Ho:YAG laser（0.8-1.0W*20-30Hz）, and stone fragments was sucked out with the suction sheath.
45444532|NCT02036866|Other|No Intervention|Patients will be instructed to maintain their usual activity level.
45601928|NCT05088213|Procedure|standard percutaneous nephrolithotomy|24-30Fr sheath was inserted, and 20Fr nephroscope (Richard Wolf, Germany) was used, kidney stones was disintegrated and sucked out by ultrasonic-lithotripter (LithoClast Master, EMS, Switzerland or ShockPluse-SE, Olympus).
45601929|NCT00871481|Biological|ipilimumab|Given IV
45601930|NCT00871481|Drug|cyclophosphamide|Given IV
45444533|NCT03812523|Drug|Duloxetine 60 mg qd|60 mg tablet Taken by mouth, Once Daily for 180 Days
45444534|NCT03812523|Drug|Lorcaserin|10 mg tablet Taken by mouth Twice Daily for 180 Days
45601931|NCT00871481|Procedure|biopsy|Optional correlative studies
45601932|NCT00871481|Biological|aldesleukin|Given SC
45601933|NCT00871481|Other|immunohistochemistry staining method|Correlative studies
45444535|NCT05697406|Drug|Hyperpolarized 13C-Pyruvate|Imaging tumors pre and post administration of hyperpolarized 13-C pyruvate injection.
45601934|NCT00871481|Genetic|polymerase chain reaction|Correlative studies
45601935|NCT00871481|Other|immunoenzyme technique|Correlative studies
45601936|NCT00871481|Biological|therapeutic cytotoxic T lymphocytes|Given IV
45755735|NCT03519230|Drug|Pamiparib capsule|60 mg twice daily (BID), orally (per os-PO)
45755736|NCT03519230|Drug|Placebo capsule|60mg BID, PO
45755737|NCT02144233|Procedure|Occlusal adjustment|"The first step consists of the elimination of premature tooth contacts during retruded jaw closure.~The second step included reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance)"
45444536|NCT03799575|Behavioral|Transmission Electron Microscopy analysis|Morphology of two vitreal side of Internal Limiting Membrane in contact
45755738|NCT02144233|Procedure|Placebo occlusal adjustment|Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
45444537|NCT04216251|Drug|AMR101|AMR101-oral predetermined protocol dosage, daily for a minimum of 8 weeks and maximum of 12 weeks
45444538|NCT03562312|Other|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
45601937|NCT05166122|Diagnostic Test|Artificial Intelligence|Introduction of digitized system with an AI tool to detect and intrepret the severity of diabetic retinopathy and presence of diabetic macular edema in screening for diabetes patients
45601938|NCT05088135|Device|Bilateral Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM.|It will be divided three groups as bilateral Auricular Vagus Nerve Stimulation (VSS). Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM. Auricular Vagus Nerve Stimulation will be performed for 20 minutes with a frequency of 10 Hz and a pulse width of 300 µs.
45601939|NCT05088135|Device|Unilateral-Right Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM.|It will be divided three groups as unilateral-right Auricular Vagus Nerve Stimulation (VSS). Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM. Auricular Vagus Nerve Stimulation will be performed for 20 minutes with a frequency of 10 Hz and a pulse width of 300 µs.
45601940|NCT05088135|Device|Unilateral-Left Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM.|It will be divided three groups as unilateral-left Auricular Vagus Nerve Stimulation (VSS). Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM. Auricular Vagus Nerve Stimulation will be performed for 20 minutes with a frequency of 10 Hz and a pulse width of 300 µs.
45755739|NCT03592472|Drug|Pazopanib|All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.
45755740|NCT03592472|Drug|Abexinostat|The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
45755741|NCT03592472|Other|Placebo|The starting dose and schedule of abexinostat matching placebo will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of placebo should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
45444539|NCT03562312|Other|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
45755742|NCT00269191|Drug|MK0663, etoricoxib / Duration of Treatment 12 Weeks|
45755743|NCT00269191|Drug|Placebo or Ibuprofen / Duration of Treatment 12 Weeks|
45755744|NCT02997631|Device|MEDi Robot|Distraction therapy using an interactive humanoid robot
45755745|NCT00690235|Drug|Pramlintide|180mg subcutaneous injections, twice daily
45755746|NCT00690235|Drug|Placebo|180mg subcutaneous injections, twice daily
45755747|NCT04387279|Other|Interview|Surveys on medical use patterns and patient's perceptions about COVID-19
45755748|NCT00092833|Drug|Comparator: ezetimibe|Ezetimibe (MK0653) 10 mg once daily for 3 years.
45601941|NCT05456165|Drug|GRT-C901|An individualized neoantigen cancer vaccine using an adenovirus vector administered via intramuscular (IM) injections at Visit 1 and boost at Visit 6.
45755749|NCT01799083|Drug|Decitabine|A continuous 5-day lower-dose decitabine transfusion will be performed for patients during each treatment cycle, and autologous cytokine-induced killer cells may be transfused or chemotherapy may be also added.
45755750|NCT01799083|Biological|cytokine-induced killer cell|Autologous cytokine-induced killer cells may be used for patients before and after decitabine treatment.
45444540|NCT05503251|Other|Best Practice|Receive usual care
45755751|NCT01795573|Biological|Cultured Treg cells|Co-culturing of recipient dendritic cells and donor Treg. Treg administration will occur 2 days before the allogeneic stem cell transplant (i.e. day -2 with reference of day 0 as stem cell infusion date).
45755752|NCT01799161|Biological|gp96-Ig Vaccine|
45444541|NCT05503251|Behavioral|Neuropsychological Assessment|Undergo neuropsychological evaluation
45601942|NCT05456165|Drug|GRT-R902|An individualized neoantigen cancer vaccine using a self-amplifying mRNA (samRNA) vector administered via IM injection at Visits 2, 4, 9, and 12.
45755753|NCT01799161|Drug|Theophylline|300 mg capsule daily of Theophylline during 1st course, then adjusted dose
45755754|NCT01799161|Other|Oxygen|24-hr oxygen delivered via nasal cannula or oxygen mask during 1st course, then adjusted dose.
46066551|NCT00941720|Drug|cyclophosphamide|IV cyclophosphamide 60 mg/kg over 4 hours x 2 days
46066552|NCT00941720|Procedure|autologous hematopoietic stem cell transplantation|infusion of autologous hematopoietic stem cells of at least 2.0 x 106 CD34+ cells/kg on day 0
45444542|NCT05503251|Other|Quality-of-Life Assessment|Ancillary studies
45601943|NCT05456165|Drug|Atezolizumab|Dose of 1680 mg administered once every 4 weeks (Q4W) via intravenous (IV) infusion at Visits 1-13.
45601944|NCT05456165|Drug|Ipilimumab|Dose of 30 mg administered via subcutaneous (SC) injection only with the first dose of GRT-C901 at Visit 1 and GRTR902 at Visit 2.
45755755|NCT01799161|Procedure|Immunologic Evaluation|Frequency of IFN-y,CD8 cells in response to vaccine in available tumor samples Blood draw to assess immunological response [frequency of CD4+, FoxP3 (Treg), et al] in treated patients.
45755756|NCT02997397|Procedure|tourniquet(+)|A novel atraumatic tourniquet technique, applied via placing a vascular clamp widely on both the infundibulopelvic ligament and uterine arteries.
46066553|NCT02583568|Drug|Bevacizumab-800CW|three days prior to surgery bevacizumab-800CW will be administered
45444543|NCT05503251|Other|Questionnaire Administration|Ancillary studies
45444544|NCT03799029|Other|Cognitive training|Participants will train at home during 25 sessions (about 45 minutes each) over a maximum of 5 weeks. Investigators will verify compliance via Internet and call participants and their legal guardians once a week. A reward system will be established with participants. Five sessions of metacognition (1 hour each) are added.
45601945|NCT05456165|Drug|Adjuvant chemotherapy|Administered according to standard of care.
45755757|NCT02997397|Procedure|tourniquet(-)|
45755758|NCT02997007|Device|active tDCS|Participants will receive active tDCS over the angular gyrus on five consecutive days
45755759|NCT02997007|Device|sham tDCS|Participants will receive sham tDCS over the angular gyrus on five consecutive days
45601946|NCT05083689|Drug|Injections of 1.25 mg of intravitreal bevacizumab with Timolol and Dorzolamide|31 cases in intervention group receive injections of 1.25 mg of intravitreal bevacizumab monthly for 3 months (months 0, 1 and 2) with topical drops of Timolol twice a day and Dorzolamide twice a day
45601947|NCT05083689|Drug|Injections of 1.25 mg of intravitreal bevacizumab with artificial tears|31 cases in control group receive intravitreal injection of 1.25 mg bevacizumab monthly for 3 months (months 0, 1 and 2) plus artificial tears (twice a day as a placebo)
45601948|NCT00871325|Drug|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
45601949|NCT00871325|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
45601950|NCT00871325|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
45601951|NCT05243264|Behavioral|Empower@Home|The intervention is a 10-week course of internet-based cognitive behavioral therapy. During the active intervention phase, participants will receive a weekly check-in call to see how they are doing. The weekly check-in call is intended to be brief and last no more than 10 minutes on average.
46066554|NCT02583802|Drug|Ear pills|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.
46066555|NCT02583802|Drug|Shengmai capsule|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks.
45444545|NCT02047864|Dietary Supplement|Creatine monohydrate|
45601952|NCT03492307|Other|Weight-Based Flow for High Flow Nasal Cannula (HFNC) (2L/kg/minute)|A weight-based flow for HFNC.
45601953|NCT03492307|Other|Standard Flow for HFNC (Maximum 8L/minute)|Maximum flow of 8L/minute.
45601954|NCT05165966|Biological|High-dosage of COVID-19 vaccine (Vero cell), Inactivated|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
45601955|NCT05165966|Biological|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
45601956|NCT00870155|Drug|dirucotide|500mg, intravenous, every 6mos until regulatory approval, denial or sponsor termination
45601957|NCT03122691|Drug|cannabis|Cannabis will be self-administered by study participants
45601958|NCT03497221|Behavioral|Education intervention|The same description of arm Education intervention.
45601959|NCT03497221|Behavioral|Visual identity campaign|The same description of arm Visual identity campaign.
45601960|NCT05165732|Biological|Experimental vaccine 1|Inactivated COVID-19 vaccine manufactured by Sinovac Life Sciences Co., Ltd.600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
45601961|NCT05165732|Biological|Experimental vaccine 2|Inactivated COVID-19 vaccine manufactured by Beijing Institute of Biological Products Co.,Ltd.4ug inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
45601962|NCT05165732|Biological|Experimental vaccine 3|Inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd.200WU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
45601963|NCT04474769|Other|Educational intervention for preceptors|
45601964|NCT04477083|Drug|inhalable hydroxychloroquine (HCQ)|inhalable hydroxychloroquine (HCQ) plus supportive and symptomatic treatment
45601965|NCT04477083|Drug|supportive and symptomatic treatment|supportive and symptomatic treatment
45601966|NCT04674397|Radiation|Radioisotope GFR test|
45601967|NCT04422158|Dietary Supplement|Nuun electrolyte tablet|Each table contains 2 grams of carbohydrate and a combination of electrolytes. calcium (13mg, 1%DV), sodium (300mg, 13%DV), potassium (150mg, 3%DV), magnesium (25mg, 6%DV), and chloride (40mg, 2%DV).
45601968|NCT04422158|Other|water|water
45601969|NCT02279524|Drug|Aramchol|"Subjects will be administered Aramchol as follows:~One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.~One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.~Two tablet of Aramchol matching placebo. The tablets should be taken orally in the morning within 30 min after breakfast with a glass of water (250 ml).~Subjects are allowed to omit study drugs up to 3 consecutive days during the study."
45601970|NCT03140319|Biological|Fibroblast|Transplantation of 20 million cell by three injection
45601971|NCT03140319|Biological|Placebo|Injection of Placebo
45755760|NCT00006110|Biological|trastuzumab|infusion 4 mg/kg load week 1; 2 mg/kg weekly thereafter for 12 weeks
45755761|NCT00006110|Drug|cyclophosphamide|600 mg/m2, intravenous infusion every 3 weeks for four cycles
45755762|NCT00006110|Drug|doxorubicin hydrochloride|60 mg/m2 intravenously, 5-10 minutes, every 3 weeks, up to 12 weeks
45755763|NCT00006110|Drug|paclitaxel|90 mg/m2 weekly, intravenously 1 hour after herceptin, given weekly up to 12 weeks or 175 mg/m2, intravenously every 3 weeks, up to 12 weeks (only if not receiving Herceptin®)
45755764|NCT00006110|Procedure|conventional surgery|Surgical excision will take place 12-13 weeks for the neo-adjuvant herceptin setting and 12-13 weeks in the non-herceptin setting. Surgery will take place prior to chemotherapy in the adjuvant herceptin setting
45755765|NCT00691327|Device|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
45755766|NCT04403438|Other|ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.|ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.
45755767|NCT02997241|Biological|OncoCare|Personalized monitoring
45755768|NCT02997241|Drug|chemotherapy for colorectal carcinoma|chemotherapy for colorectal carcinoma
45601972|NCT03489655|Behavioral|Maintenance Phase Intervention|The CHW will utilize motivational interviewing techniques over phone calls to reinforce all asthma education provided in the AI phase, including asthma basics, triggers and reduction strategies, purpose of medications, and steps for proper medication use. The CHW will identify barriers the participant is facing in management of their asthma and set goals to overcome them. The CHW will encourage regular visits with the Primary Care Physician and assist with referrals for other medical and social services, as needed. CHWs will check-in with participants via phone, monthly for the first 6 months and bi-monthly in the remaining 6 months Participants will receive bi-monthly data collection follow-up phone calls by a Research Assistant.
45601973|NCT04474067|Other|No intervention|This is an observational study, with no intervention.
45601974|NCT05478122|Device|Trachospray for awake videolaryngoscopy|Subjects will be asked to inhale 4 ml lidocaine 4% via the Trachospray device
45601975|NCT04568395|Other|TCIG|Use a TCIG
45601976|NCT04568395|Other|ECIG|Use an ECIG
45755769|NCT03591770|Biological|SHINGRIX|"SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized gE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
45755770|NCT04403750|Procedure|Combined laser-surgical technology of RRD treatment|"Nd-YAG laser excision of the vitreoretinal traction zone~Pneumatic retinopexy (10% C3F8)~barrier laser photocoagulation around retinal break after retinal attachment (2-3 days after pneumatic retinopexy)"
45755771|NCT00692185|Drug|Olanzapine|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of olanzapine once each evening for 8 weeks.
45601977|NCT04568395|Other|sham control|Use a sham control (empty ECIG)
45601978|NCT00861809|Drug|GSK962040 25 mg|25 mg
45601979|NCT00861809|Drug|Placebo|placebo comparator
45601980|NCT00861809|Drug|GSK962040 50 mg|50 mg
45755772|NCT00692185|Drug|Placebo|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of placebo once each evening for 8 weeks.
45601981|NCT00861809|Drug|GSK962040 1250 mg|125 mg
45911048|NCT02002793|Other|Late stage abdominal drainage|Despite that it matches one of the cirteria as the study group:1．Intravesical pressure≥20cmH2O or 2．CT scan:acute peripancreatic liquid collection, the patients continue acquire prearranged integrative treatment and will not accept early stage abdominal drainage until any of the followings emerge:1.Intra-abdominal apartment syndrome; 2. Pancreatic pseudocyst;3. Pancreatic or peripancreatic necrosis;
45911049|NCT02002806|Other|Alcohol Injection|Celiac plexus neurolysis by alcohol injection
45601984|NCT03138759|Drug|Pexidartinib|Orally, on Day 2
45601985|NCT03138759|Drug|Probenecid|Orally, on Day 2
45601986|NCT03079921|Drug|Phentolamine|Physiologic receptor blockade (α1-receptor).
45601987|NCT03079921|Drug|Propranolol|Physiologic receptor blockade (β2-receptor).
45601988|NCT03079921|Drug|Placebo|100mL bag of Normal Saline Solution (NSS).
45601989|NCT04473989|Drug|recombinant teriparatide for injection|weekly subcutaneous administration of 40 ug
45601990|NCT04473989|Drug|Placebo|weekly subcutaneous administration of 40 ug
45601991|NCT05209490|Procedure|Femoral nerve blockade under ultrasound control with a peripheral nerve stimulator|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated.If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic femoral nerve block is performed."
45755773|NCT04348526|Procedure|Corticision|Surgical intervention is going to be used in the interdental areas between the lower anterior teeth to accelerate tooth movement. Three incisions are going to be made
45755774|NCT04348526|Procedure|Traditional orthodontic treatment|No surgical intervention will be used, just normal orthodontic sequence of procedures.
45755775|NCT04270279|Drug|Xueshuanxinmaining tablet|A kind of Chinese patent medicine
45755776|NCT04270279|Drug|Xueshuanxinmaining placebo|The simulant of Xueshuanxinmaining tablet
45755777|NCT04270279|Drug|Nitroglycerin tablets|Be used when angina attack
45911050|NCT02002806|Other|Placebo Injection|
45911051|NCT02002845|Device|robotic surgery using the da Vinci Surgical System|
45911052|NCT02002858|Drug|Nicotine Patch|
45601992|NCT05209490|Procedure|femoral nerve blockade under ultrasound control without a peripheral nerve stimulator|"Under ultrasound visualization guidance, the needle owas positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
45911053|NCT02002858|Behavioral|Depression and Anxiety Smoking Cessation Treatment|Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
45911054|NCT02002858|Behavioral|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
46066556|NCT02852564|Drug|Ethacrynic Acid|One oral dose at 50 mg prior to bladder tumor removal surgery
46066557|NCT04481230|Drug|99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg|1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg (D0)
45601993|NCT05083455|Drug|Rivaroxaban|Any rivaroxaban dispensing claim is used as the exposure group
45601994|NCT05083455|Drug|Enoxaparin|Any enoxaparin dispensing claim is used as the reference group
45601995|NCT04414423|Procedure|bone marrow concentrate alveolar cleft grafting|patients will undergo surgery to repair alveolar cleft with autogenous bone graft combined with bone marrow concentrate
45601996|NCT04414423|Procedure|Autogenous alveolar grafting|patients will undergo surgery to repair alveolar cleft with autogenous bone graft
45755778|NCT03590288|Procedure|Transjugular intrahepatic portosystemic shunt|"Covered stents will be used, that will be dilated to 8 or 10 mm according to the hemodynamic response. The aim will be to reduce the portacaval pressure gradient (PPG) below to 25-75% of baseline. Not paralleled TIPS or over-dilatation are allowed.~Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of big portosystemic collaterals feeding the varices.~After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted.~Measurement of portacaval pressure gradient will be done immediate after TIPS, then repeated 1-3 days and at 1 month after the procedure.~A TIPS revision will be performed once shunt dysfunction is suspected."
45755779|NCT03515096|Drug|Eltrombopag|Eltrombopag 50 mg; po; from day 1 to platelet is completely effective recovered after HSCT.
45755780|NCT03515096|Drug|rhTPO|rhTPO 15000 u; subcutaneously injection; from day 1 to platelet is completely effective recovered after HSCT.
45755781|NCT00692341|Drug|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
45755782|NCT00692341|Drug|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
45755783|NCT00692341|Drug|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
45755784|NCT03674840|Procedure|angle kappa based SBL-3 implantation|SBL-3 implantation based on kappa angle guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
45755785|NCT03674840|Procedure|0 to 180 degree SBL-3 implantation|SBL-3 implantation in the direction of 0 to 180 degree guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
45755786|NCT03514394|Behavioral|Usual Care|The clinic's usual care includes counseling, substance use disorder treatment, peer support services, and some elements of traditional BA (not the modified BA).
45755787|NCT03514394|Behavioral|Modified Behavioral Activation (Task Sharing)|This intervention will include all core elements of Behavioral Activation (BA), which is a behavioral intervention that identifies work, social, health, or family activities that patients have stopped engaging in because of their mood. The intervention will also include a Task Sharing modification, which will allow clinicians and care managers to more efficiently share the tasks involved in BA.
45755788|NCT00589849|Procedure|T-wave Alternans|T-wave alternans is an electrocardiographic finding that is defined as the beat-to beat fluctuation in the amplitude or shape of T wave
45755789|NCT00525629|Dietary Supplement|Walnuts|48 Grams of Walnuts Daily
45755790|NCT00525629|Dietary Supplement|Control|Control Diet with No Walnuts
45755791|NCT03511976|Behavioral|Tier 1 Classroom Management|The primary teacher for each participating student will receive consultation related to implementing Tier I management strategies at a classroom level for all students including the target child (see Appendix C). Consultation will be provided by trained study personnel and the strategies will be implemented by the general education teacher (i.e., the end user of the intervention)
45755792|NCT03511976|Behavioral|Daily Report Card (DRC)|Students in the RTI DRC condition will receive Tier II strategies, namely an individualized DRC. Behavioral consultants will meet with teachers to identify appropriate behavioral targets and establish a DRC according to established protocol (see our website for an example http://ccf.fiu.edu/for-families/resources-for-parents/printable- information/). Consultants will also meet with parents to develop a plan for reinforcing the DRC at home using a hierarchical menu of rewards/privileges that will be provided contingent on meeting daily goals.
45755793|NCT03511976|Behavioral|Enhanced DRC (DRC-E)|"In this condition, students who did not show sufficient response to the Phase 1 DRC will receive additional and more intensive Tier II supports.~Following student assignment to RTI-E, the teacher will have meet with one of the consultants to complete a functional behavior analysis (FBA) to identify remaining target behaviors and ascertain their function. The consultant and teacher will then use the completed FBA to develop a treatment plan for an enhanced DRC (DRC-E).~Tier II enhancements will be chosen to directly map on to the functions of the target behaviors as outlined in the FBA."
45755794|NCT03511976|Drug|Stimulant|Students will receive either a long-acting methylphenidate preparation or a long-acting mixed amphetamine salts preparation based on parent consultation with the study physician. The prescribed medication will be taken daily.
45755795|NCT00692419|Behavioral|Symptom management nurse intervention|A symptom management nurse will facilitate the management of pain, sexual dysfunction and depression in patients enrolled in one arm of the study
45755796|NCT00692419|Behavioral|Feedback intervention|Pain, sexual dysfunction and depression will be assessed monthly and feedback will be given to renal providers on the presence and severity of these symptoms. Treatment will be left at the discretion of the renal provider
45755797|NCT04763018|Device|iTEAR100|Neurostimulation external nasal nerve to stimulate tear production
46066558|NCT04481230|Drug|99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg|1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg (D0)
45601997|NCT00861185|Drug|senicapoc|Loading Dose: 80 mg twice daily x 3 days Maintenance Dose: 40 mg daily for remainder of the treatment period (total 4 weeks)
45601998|NCT00861185|Drug|Placebo|Placebo looks identical to active study medication and will be dosed according to the same dosing regimen
45601999|NCT05163080|Biological|SurVaxM|Consists of a synthetic peptide conjugate that stimulates immune responses capable of killing cancer cells that express the survivin molecule. Multiple copies of the multiplied peptide (SVN53-67/M57) are conjugated to Keyhole Limpet Hemocyanin (KLH) yielding a molecule designated as SVN53-67/M57-KLH. The SVN53-67/M57-KLH conjugate (SurVaxM)produces immune responses in mice and humans that are cross-reactive to the wild-type survivin molecule expressed by tumor cells. The survivin peptide in SurVaxM is a defined antigenic peptide comprised of 15 amino acids that encompass multiple epitopes capable of binding human MHC Class I and murine H2-Kb molecules. SurVaxM also contains a core antigenic epitope that has been modified by substitution of methionine for cysteine at amino acid position 57 (i.e., M57).
45444546|NCT03798873|Device|FeelWell™ Compression garment|"Registered FDA class I device:~The FeelWell™ Compression garment is a custom-made orthopedic abdominal binder with full or half-body support. The garments are made of 70% polyamide and 30% elastane and OEKO-TEX certified confirming human-ecological safety of textiles. The company uses a wrap knitting to ensure an optimal compression and durability. The garment has two 360 degrees whalebones in the front and two in the back to provide support for the posture, reinforcing compression on the abdomen and lower-back."
45602000|NCT04477005|Device|ERCP and insertion ofBio-degradable bile duct stent|ERCP is an accepted mode of treatment and patients rarely need surgery for bile leaks and bile duct stents. Endoscopic management involves sphincterotomy (cutting open the Sphincter of Oddi) and insertion of a plastic or metal stent. Instead of placing a plastic stent bio-degradable stent will be placed. They will be followed up on Day 1, 7,30, 60,90 and 180 days. they will have abdominal x-ray on day 90 and day180.
45602001|NCT04473911|Drug|FLUDARABINE|predetermined dose, intravenously, a predetermined times per cycle Given in both pre stem cell and post stem cell cycles
45602002|NCT04473911|Drug|CYCLOPHOSPHAMIDE|◦Cyclophosphamide predetermined dose, predetermined number of times in Given in pre-stem cell Regimen #1 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
45602003|NCT04473911|Radiation|TBI|Total body irradiation (TBI) once per cycle.
45602004|NCT04473911|Drug|Melphalan|Melphalan, infusion, determined dosage, once per cycle
45602005|NCT04473911|Drug|Sirolimus|Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral: Please note that doses of sirolimus can be adjusted at the treating physician's discretion given the multiple drugs and other situations which affect its metabolism
45602006|NCT04473911|Drug|Mycophenolate mofetil|◦Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle
45602007|NCT04473911|Drug|RGI-2001|IV, predetermined dose, weekly to 6 total doses
45602008|NCT04473911|Drug|CYCLOPHOSPHAMIDE|◦Given in Post Stem Cell cycle of Regimen #1 and #2 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
45602009|NCT02322073|Procedure|Laparoscopic surgery|Roux-en-Y gastric bypass or other benign laparoscopic surgery
45602010|NCT03138915|Procedure|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.
45602011|NCT03138915|Procedure|CTA|Radiomic features were extracted from CTA images.
45602012|NCT05162222|Drug|Danicamtiv|Specified dose on specified days
45755798|NCT05559827|Drug|Isatuximab|Isatuximab treatment at a dose of 10 mg/kg by intravenous route. The first injection of isatuximab will be performed at randomization (month 6 +/- 2 days). A second injection may be performed at day 15 if the reticulocytes <10 G / L, and a third at day 29 if reticulocytes <10 G / L. Patients will be assessed on day 1, day 15, day 29, day 45, 2 months, 3 months, 6 months and 9 months after randomization.
46066559|NCT04481230|Drug|99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg|1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg (D0)
46066560|NCT04476238|Dietary Supplement|Inosine|2 grams of inosine dissolved in 250 ml water taken by mouth
46066561|NCT04476238|Other|Placebo|250 ml water taken by mouth
45444547|NCT03798873|Behavioral|Increase Mobility|Subjects will work with exercise physiologist and physical therapist to increase mobility, strength and activity
45602013|NCT05162222|Drug|Itraconazole|Specified dose on specified days
45602014|NCT05162222|Drug|Diltiazem|Specified dose on specified days
45602015|NCT02283268|Biological|Recombinant von Willebrand Factor (rVWF)|rVWF will be administered by intravenous bolus infusion. Participants planned for major surgery will undergo a baseline pharmacokinetic assessment prior to surgery. The peri- and postoperative substitution regimen will be individualized according to the PK results, intensity and duration of the hemostatic challenge, and the institution´s standard of care.
45602016|NCT05241158|Behavioral|Counselling with visual aid|patients were counselled about the procedure, complications and the post-procedure recovery phase and shown a 5 minutes animated video of the gastroscopy or colonoscopy procedure
45602017|NCT05241158|Behavioral|Counselling|Patients counselled about the procedure, complications and the post-procedure recovery phase
45602018|NCT05088057|Drug|Camrelizumab|200mg on Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles (Q3W), intravenous (IV) infusion.
45602019|NCT05088057|Drug|Doxorubicin|60mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.
45755799|NCT02122445|Device|Cramer Sports Motion Tape|lower body exercises with and without Cramer Sports Motion tape applied to the hip
45444548|NCT02047942|Behavioral|Center-based cardiac rehabilitation|
45444549|NCT02047942|Behavioral|Home-based training with telemonitoring guidance|
45444550|NCT03812445|Dietary Supplement|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus,Bifidobacterium lactobacillus,Lactobacillus paracasei,Lactobacillus rhamnosus and Lactobacillus fermentium with does of 8*10^9 Colony-Forming Units(CFU) *2/d for 3 months.
45444551|NCT02049970|Drug|dexmedetomidine|1 ml 100 mcg dexmedetomidine+ 15 ml 0.25 % bupivacaine are applied around brachial plexus
45444552|NCT02049970|Drug|bupivacaine|30 ml 0.25 % bupivacaine is applied around brachial plexus
45602020|NCT05088057|Drug|Cyclophosphamide|600 mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.
45602021|NCT05088057|Drug|Docetaxel|75mg/m² on Day 1 of Cycles 1-4 (Q3W) or Cycles 5-8 (Q3W) of the neoadjuvant phase of the study, IV infusion;
45602022|NCT03132025|Drug|"Apatinib and Capecitabine"|"Combine Apatinib and Capecitabine to Maintain Treating Metastatic Colorectal Cancer"
45602023|NCT03132025|Drug|"Capecitabine"|"Single Drug Capecitabine to Maintain Treating Metastatic Colorectal Cancer"
45602024|NCT00857285|Drug|olmesartan medoxomil|olmesartan medoxomil oral tablets, once daily for up to 12 weeks
45602025|NCT00857285|Drug|losartan potassium|losartan oral tablets, once daily for up to 12 weeks
45602026|NCT05238896|Drug|Baricitinib Oral Tablet [Olumiant]|Baricitinib 4 mg/d oral route for 42 days
45755800|NCT00694603|Drug|Cetuximab|Given intravenously once per week.
45602027|NCT05238896|Drug|Placebo|Placebo, 4 mg/d, oral route for 7 days, then Baricitinib 4 mg/d oral route for 5 weeks
45602028|NCT05087901|Diagnostic Test|Multifocal electroretinogram|A device that records electric potentials generated by the retinal photoreceptors and neural elements in a multifocal fashion
45602029|NCT04461457|Combination Product|211-astatine MX35 F(ab')2|Alpha emitting radionuclide 211At conjugated to monoclonal antibody MX35 F(ab')2. Targeting the sodium phosphate transporter (NaPi2b).
45602030|NCT04473833|Procedure|Serial Transvaginal Ultrasonography|Participants will undergo transvaginal ultrasonography (TVS) to detect ovarian cancer as part of the Kentucky Ovarian Cancer Screening Program. Those with normal findings will repeat the TVS in one year. Those with abnormal results will repeat the screening in 4-6 weeks.
45602031|NCT05087511|Other|motor and sensory development assessment|Peabody Motor Development Scale 2 was used to evaluate motor development and Dunn's Sensory Profile was used to evaluate sensory processing.
45602032|NCT05161598|Drug|Teclistamab|Teclistamab will be administered subcutaneously (SC).
45602033|NCT02322307|Other|HealthPROMISE users|"Patients using HealthPROMISE will be asked to use the application once every two weeks at a minimum to provide updates on health information. Providers can use the data entered by patients in real time. Patients will get alerts requesting them to contact their providers if their quality of life scores fall below a certain threshold or their symptoms scores are worrisome. Both patients and physicians are also sent regular notifications with data about their own health or health of their patient panel respectively. Both patients and providers are encouraged to use existing communication tools (phone, office visits, personal health records) since direct patient-physician messaging is not provided in the HealthPROMISE platform. Reminders through app, email and SMS will be used to facilitate patient engagement.~Physicians will also be encouraged to check the physician panel to see how patients are doing through weekly updates and monthly quality improvement meetings."
45602034|NCT02322307|Other|Control Group|In order to eliminate a placebo effect, patients in both groups will get an app customized for IBD. Physician and rest of care team will not be blinded since they will use HealthPROMISE dashboard to get alerts and notifications.
45602035|NCT00855179|Drug|Red vine leaf extract (AS 195)|Antistax film-coated tablet 360 mg
45755801|NCT05559281|Other|Botulinum|injection of Botulinum Toxin injection in lip muscles following cleft lip repair surgically.
45755802|NCT05559281|Procedure|Fisher technique|The cleft lip will be treated surgically using the Fisher technique only.
45755803|NCT03509792|Behavioral|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
45755804|NCT03509792|Behavioral|Attention placebo|Smartphone activity for same amount of time.
45755805|NCT05559203|Behavioral|danceSing Care|The programme was a digital movement and music programme with resources from danceSing Care (https://dancesingcare.uk/) and consisted of three movement sessions and one music session each week, the recommended dose agreed between danceSing Care and the Advisory group, each lasting about 20 minutes. Also, the danceSing care resources were designed to suit older adults with physical and cognitive impairments (residents with mobility aids and/or dementia). Movement sessions included chair and standing fitness, which started with a warm-up and finished with stretching exercises. Sessions were managed and supervised by care home activity coordinators.
45755806|NCT03582722|Drug|Orlistat|Participants will be instructed to take one 60mg capsule of orlistat with each meal containing fat, up to three capsules daily, for six months. A multivitamin will be provided to be taken once daily, at bedtime.
45755807|NCT03582722|Drug|Placebo capsule|Participants will be instructed to take one placebo capsule to match 60mg of orlistat with each meal containing fat, up to three capsules daily, for six months. A multivitamin will be provided to be taken once daily, at bedtime.
45755808|NCT05621369|Behavioral|Participant self-assessment surveys|At enrollment, participants are asked to complete a baseline health history, family history, and a participant-reported symptom inventory.
45602036|NCT00855179|Drug|Placebo|Placebo tablets identical to those containing Anstistax 360 mg
45602037|NCT05206604|Drug|PF-07295324|Ointment
45602038|NCT05206604|Drug|PF-07259955|Cream
45602039|NCT02278354|Drug|Flortaucipir F18|IV injection, 370 megabecquerel (MBq) (10 mCi)
45755809|NCT05621369|Behavioral|Psoriasis Draw|Participants are asked to draw the location and size of psoriasis they currently experience. Participants are provided a body template onto which they can draw on their screen. Investigators estimate the percentage of body area affected.
45755810|NCT05621369|Behavioral|Psoriasis Area Photo|Participants are asked to take a picture of a representative psoriasis plaque and indicate the location of the plaque. They are asked to take a picture of the same area over time. The investigators are developing computer vision algorithms to assess the plaque.
45755811|NCT05621369|Behavioral|Finger and Toe Photos|Participants are asked to take pictures of the back of each hand and the top of each foot. These photos can be used to assess finger and toe swelling as well as psoriatic nail involvement. The investigators are developing computer vision algorithms to assess psoriatic nail involvement and digit swelling.
45444553|NCT02048020|Drug|paclitaxel|Given IV
45602040|NCT02278354|Procedure|Brain PET scan|positron emission tomography (PET) scan of the brain 75-105 minutes post injection
45602041|NCT03137043|Other|Questionnaire|Subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Asthma Control Test, Morisky-Green Questionnaire and St George's Respiratory Questionnaire.
45602042|NCT03137043|Other|Software of Big Data|Software of big data is a powerful data treatment algorithm works closely with Spanish Data Protection Agency as an example on how to reuse clinical information without conflicting with necessary data privacy. The system will process a vast amount of information (big data), so that the impact of random errors will be minimized.
45602043|NCT04461379|Biological|BCG vaccine|A single dose BCG vaccine intradermally (deltoid region of the right arm) 0.1 ml, equivalent to 0.075 mg of attenuated Mycobacterium bovis . (Tokio 172 strain)
45602044|NCT04461379|Other|Placebo|A single dose intradermally ((deltoid region of the right arm) 0.1 ml of NaCl 0.9% solution
45444554|NCT02048020|Drug|carboplatin|Given IV
45444555|NCT02048020|Radiation|intensity-modulated radiation therapy|Undergo IMRT
45444556|NCT02048020|Procedure|quality-of-life assessment|Ancillary studies
45755812|NCT05621369|Behavioral|Digital Jar Open|Participants are asked to internally and externally rotate the phone as it rests on a flat surface. Participants perform each direction (internal and external) and each arm (left and right) in turn. Gyroscope sensors measure the degree of rotation.
45602045|NCT00854945|Drug|ON 01910.Na|1800 mg/day as a 24-hour continuous intravenous infusion administered three times a week every 2 weeks
45602046|NCT05238350|Procedure|Acupressure|Acupressure was performed two days a week for four weeks with a total of eight sessions on the ST34, ST35, ST36, SP9, SP10, GB34 acupuncture points following an acupressure practice guide prepared by the researcher.
45602047|NCT04461145|Behavioral|command|The participant was asked to walk along the walkway while backward counting numbers with increment of seven starting from a randomly given number.
45602048|NCT05650138|Other|Jacobson's progressive muscular relaxation technique|subjects will receive Jacobsons muscle relaxation technique. Patients will be demonstrated with the technique to contract and relax various groups of muscles, to coordinate contractions and relaxations with deep breaths and to perform the entire procedure with eyes closed in supine lying down position. Every subject will perform this supervised relaxation for 6 repetitions during a single session on once a day basis for four weeks.
45602049|NCT05650138|Other|30 min walk|30 minutes walk twice a week for 4 weeks
45755813|NCT05621369|Behavioral|30 Second Walk|Participants are asked to walk in a straight line for 30 seconds. Gait is measured by gyroscope and accelerometer sensors. The investigators examine step-dependent and sequence-dependent features from these sensors. The investigators apply feature selection and classifier algorithms to analyze these data.
45602050|NCT05205746|Biological|Recombinant NDV Vectored Vaccine for SARS-CoV-2|Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
45602051|NCT05205746|Biological|Placebo|Physiological saline solution of Sodium Chloride at 0.9% After mask opening ChAdOx-1-S[recombinant]) Intramuscular
45602052|NCT05083221|Behavioral|Hear-Talk-Activity audiological program|The participants were randomly assigned to either the experimental group or the waiting-list control group, using a computer-generated list of random numbers.
45602053|NCT00852839|Drug|Placebo|Placebo to match oromucosal formulation of 552-02
45602054|NCT00852839|Drug|552-02|The oromucosal formulation of 552-02 contains 552-02 (25 μg/mL), surfactant, flavoring agents, a humectant, and preservatives.
45602055|NCT01517659|Device|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
45602056|NCT04876612|Procedure|Transforaminal epidural steroid injection (TFESI)|Well trained pain physician performs all the fluoroscopy-guided transforaminal epidural steroid injection (TFESI), who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For TFESI, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under fluoroscopy guidance at the patient's symptom complaining level. After confirming with a contrast medium, 3 ml of 0.1875% ropivacaine and 5 mg of dexamethasone are administered.
45602057|NCT05087433|Other|Progressive Relaxation Exercises|The trainer performed the PRE exercise online with the nurses. The video recording of the progressive relaxation exercises was shared with the nurses participating in the study on WhatsApp groups. Nurses were asked to perform the PRE application in accordance with the commands in the video recordings. In addition, a guide in which the steps of applying progressive relaxation exercises for each muscle group were written was given to the nurses. It was stated that they should do the application regularly for 25-30 minutes in the morning every day at home for a month. The PRE application was reminded daily from the WhatsApp group for the nurses to apply regularly to the sessions and not to disrupt the sessions. Nurses shared the messages stating that they were doing the PRE application on a daily basis for four weeks on WhatsApp groups.
45755814|NCT05621369|Other|Psorcast mobile application|Participants complete all described behavioral interventions via a dedicated iPhone app, Psorcast.
45755815|NCT00590161|Drug|pentoxifylline (PTX)|400 mg PO tid
45444557|NCT02824029|Drug|Ibrutinib|Given PO
45444558|NCT02824029|Other|Laboratory Biomarker Analysis|Correlative studies
45602058|NCT00955799|Drug|Neramexane mesylate|Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day
45602059|NCT00955799|Drug|Placebo|Double-blind treatment period of 29 weeks placebo
45602060|NCT04876534|Drug|Tocilizumab 20 Mg/mL Intravenous Solution|Intravenous administration
45602061|NCT04876534|Drug|MethylPREDNISolone Injectable Solution|Intravenous administration
45602062|NCT03492073|Behavioral|Emotional Supportive Mindfulness-based Program|Mindfulness training
45602063|NCT03492073|Behavioral|Emotional Supportive Program|Narrative-orientated therapy.
45755816|NCT00590161|Drug|placebo|placebo tid
45444559|NCT02824029|Other|Pharmacological Study|Correlative studies
45444560|NCT03562390|Drug|Irinotecan|The patients will receive treatment using intravenous irinotecan hydrochloride until the patient develops disease progression or fulfills a withdrawal criterion.
45444561|NCT01302405|Drug|PRI-724|Dose escalation
45444562|NCT05690932|Drug|PBI-200 Tablet|Single dose of PBI-200 tablet
45755817|NCT03672110|Drug|Advagraf|intervention: different advagraf dosing in the study compared to the control arm, see above
45755818|NCT03581942|Drug|Ibrutinib|(MTD) Dose Escalation level 2: Ibrutinib 840 mg daily
45755819|NCT03581942|Drug|Copanlisib|(MTD) Copanlisib 60 mg weekly (3w on/1w off)
45911055|NCT02002897|Device|Fractional carbon dioxide laser|Fractional carbon dioxide laser (10,600 nm), a session once per month, total of 3 sessions with full clinical evaluation and investigations before and one month after the last session of treatment.
45911056|NCT02002897|Device|Ultraviolet A1 phototherapy (UVA1)|localized UVA1 phototherapy (340-400 nm), low dose irradiation, at a rate of 3 sessions per week , total of 24 sessions with full clinical evaluation and investigations before and after treatment and clinical follow up one month after treatment.
45444563|NCT05690932|Drug|PBI-200 Capsule|Single dose of PBI-200 capsule
45444564|NCT05690932|Drug|PBI-200 Suspension|Single dose of PBI-200 suspension
45444565|NCT03798249|Other|Gluten|Tereos
45444566|NCT03798249|Other|Placebo|Nestlé Health Science
45602064|NCT05087043|Device|Oral motor stimulation (OMS) and The supplemental nursing system (SNS)|OMS and an SNS were applied to preterm infants in the experimental group. Oral stimulation intervention provides assisted movement to activate muscle contraction and provides movement against resistance to build strength. The cheeks (internal and external), lips, gums, tongue, and palate were stimulated by finger-stroking following the protocol. OMS consisted of intra (oral region) and peri-oral stimulation (around the oral region). The OMS was administered three times a day by a nurse, from the day of initiation of oral feeding to the day of independent oral feeding 15 minutes before the feeding schedule. A bottle/container was filled with breast milk before the process and given to the baby via SNS while the baby was holding the mother's breast. The SNS consists of a syringe/container and a feeding catheter. One end of the feeding probe is inside the syringe/container, while the other end of it is fixed to the mother's nipple using plaster.
45602065|NCT05082753|Drug|Ivermectin tablets (3 mg Ivermectin)|Two Ivermectin tablets were administered orally.
45755820|NCT04825067|Device|Respiratory Sensor measurements|The participant will receive 2 Respiratory Sensors and 1 gateway with wireless compatibility and a welcome packet with instructions for use, a reminder description of the study purpose and procedures, and research staff contact information. Research staff will contact participants to ensure appropriate setup of the Respiratory Sensor and training on proper use. Research staff will ask the subject to place the Respiratory Sensor on the top left-side of the chest. The Respiratory Sensor continuously collects and monitors respiratory data. The participant will be instructed to change each Respiratory Sensor after 24-48 hours. Subjects will be asked to charge each Respiratory Sensor once it is removed. Subjects will exit the study upon completion of the 90-day follow-up.
45755821|NCT00590395|Drug|18FDG (an FDA-approved radiopharmaceutical)|Route: Intravenous, Dosage: 5-10mCi, frequency: Single Administration
45755822|NCT00006170|Drug|Bupropion|smoking cessation medication aid
45755823|NCT00006170|Drug|Placebo|A matched placebo pill
45755824|NCT00006170|Behavioral|weight concerns intervention|cognitive behavioral treatment to address weight concners
45755825|NCT00006170|Behavioral|smoking cessation intervention|Cognitive behavioral intervention for smoking cessation
45755826|NCT02996539|Other|Clinical examination and laboratory measurements|Subjects were interviewed by a physician regarding their medical history, history of hypoglycemic attacks, smoking status, and alcohol consumption. Concentrations of blood urea nitrogen (BUN) and serum creatinine (SCr) were analyzed by the urease-ultraviolet rate method and picric acid method, respectively. Serum uric acid was determined using the enzymatic colorimetric method. Serum hemoglobin A1c (HbA1c) was measured by liquid enzymatic assay. Urine albumin and urine creatinine were found through immune turbidimetric analysis and the enzymatic method, respectively.
45602066|NCT05082753|Drug|Stromectol ® tablets|Two Ivermectin tablets were administered orally.
45602067|NCT02443831|Procedure|Leukapheresis|Patients will undergo an unstimulated leukapheresis to isolate the required immune cells to produce the CD19/22 CAR T-cells
45602068|NCT02443831|Drug|Lymphodepletion with fludarabine|Patients will receive lymphodepleting chemotherapy with iv fludarabine 30 mg/m2 on days -7 to -3 prior to CD19/22CAR T-cell infusion.
45755827|NCT02123849|Drug|Aspirin|Given PO
45755828|NCT02123849|Other|Laboratory Biomarker Analysis|Correlative studies
45755829|NCT02123849|Other|Placebo|Given PO
45755830|NCT01798303|Drug|LY2940094|Administered orally
45755831|NCT01798303|Drug|Placebo|Administered orally
45755832|NCT05347160|Procedure|Biodentine|using of biodentine , calcium hydroxide and platelet rich fibrin as pulpotomy agents
45755833|NCT03505112|Other|Goal-directed therapy|"The patients in GDT group will receive intravenous crystalloid fluid or vasopressor or inotropic agent according to the goal-directed therapy protocol utilizing FloTrac / EV1000 clinical platform (Edwards Lifesciences, Irvine, CA, USA).~After induction of anesthesia, the baseline stroke volume index (SVI) is measured and then 200-250 ml of crystalloid is administered over 5-10 minutes. If SVI increase by ≥10%, 200-250 ml of crystalloid is given repeatedly until the increase in SVI <10%. If SVI does not increase by ≥10% and there is no decrease in mean arterial pressure (MAP), revaluate SVI every 10 minutes. Despite an increase in SVI of <10% after fluid challenge, if a decrease in MAP is accompanied by cardiac index (CI) ≤ 2.5 L/min/m2, dobutamine is administered by continuous infusion. If there is a decrease in MAP but no decrease in CI, start low dose norepinephrine continuous infusion."
45755834|NCT05558969|Drug|pregnant women taking magnesium|The patient group who received magnesium as a 4-6 g loading and 2-3 g/h maintenance dose to prevent convulsions in preeclampsia. Pregnant will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
45755835|NCT05558969|Drug|Placebo|Pregnant women who do not receive magnesium therapy and who will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
45755836|NCT00590707|Device|Deeper sedation|The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 0.
46066562|NCT05593042|Biological|CoronaVac®|The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in pre-load syringes (0.5 mL) with 600 SU/0.5mL of inactivated SARS-CoV-2.
45602069|NCT02443831|Drug|Lymphodepletion with cyclophosphamide|Patients will receive lymphodepleting chemotherapy with iv cyclophosphamide 0.5 g/m2 on days -4 to -2 prior to CD19/22CAR T-cell infusion.
45602070|NCT02443831|Biological|CD19/22 CAR T-cells|A single dose of 1 x 10^6/kg CD19/22CAR transduced T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
45602071|NCT00851045|Drug|Irinotecan|Solution, IV, 180 mg/m2, Q14 days, Until PD
45602072|NCT00851045|Drug|5-Fluorouracil (bolus)|Solution, IV, 400 mg/m2, Q14 days, Until PD
45602073|NCT00851045|Drug|5-Fluorouracil (infusional)|Solution, IV, 2400 mg/m2, Q14 days, Until PD
45602074|NCT00851045|Drug|Leucovorin calcium|Solution, IV, 400 mg/m2, Q14 days, Until PD
45602075|NCT00851045|Drug|CT-322|Solution, IV, 2 mg/kg, Q7 days, Until PD
45602076|NCT00851045|Drug|Bevacizumab|Solutions, IV, 5 mg/kg, Q14 days, Until PD
45602077|NCT00851045|Drug|Bevacizumab Placebo (saline solution)|Solution, IV, 0 mg/kg, On day 8 of a 2-week cycle, Until PD
45602078|NCT05086887|Diagnostic Test|Malaria diagnostic tests (RDT and PCR) and serology for malaria and other parasitic diseases|All individuals are tested. Individuals with demonstrated parasitic disease are referred to the Infectious diseases or Pediatric clinic for evaluation and treatment.
45602079|NCT04876378|Procedure|Magnetic Resonance Imaging|Undergo MRI
45602080|NCT04876378|Other|Questionnaire Administration|Complete questionnaires
45602081|NCT00850577|Drug|Paclitaxel|Solution, IV, 200 mg/m2, Q21days, 6 cycles
45602082|NCT00850577|Drug|Carboplatin|Solution, IV, AUC=6, Q21days, 6 cycles
45602083|NCT00850577|Drug|CT-322|Solution, IV, 2 mg/kg, Q7days, Until PD
45602084|NCT00850577|Drug|Bevacizumab|Solution, IV, 15 mg/kg, Q21days, Until PD
45602085|NCT00850577|Drug|Bevacizumab placebo (ie saline solution)|Solution, IV, 0 mg/kg, On days 8 and 15 of a 3-weekly cycle, Until PD
45602086|NCT04919733|Device|Fluoroscopy reduction|To decrease, using 3-D mapping systems, the amount of fluoroscopy needed to implant a CIED
45602087|NCT04876222|Procedure|Acute CAG|The patient is triaged directly to the catheterization laboratory for acute evaluation including ECHO, acute CAG and PCI if indicated according to guidelines.
45602088|NCT05086653|Procedure|Surgery|Sutured by Prolene 3-0 with two layers of pledge
45602089|NCT01657370|Drug|MK-1602|"Three administrations of the same dose of MK-1602 on separate days. All 3 doses are either 1, 10, 25, 50 or 100 mg of MK-1602. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration."
45602090|NCT01657370|Drug|Placebo|"Three administrations of placebo for MK-1602 on separate days. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration."
45602091|NCT01657370|Drug|Rescue medication|"If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs]), anti-emetics, triptans, opiates or other medication not explicitly excluded."
45602092|NCT00838981|Drug|Modafinil|Modafinil is started at 200mg on the first day of week 1 (treatment phase) and increased to 400mg by the end of that week. Subjects will continue to receive 400mg/day for the remainder of the study.
45602093|NCT00838981|Drug|Sugar Pill|placebo, sugar pill will mirror active drug
45602094|NCT00838981|Behavioral|Contingency Management|Subjects in the CM conditions will earn vouchers for providing cocaine-free urine specimens. Subjects will be informed of the urine test results when available and, for subjects in the CM condition, receive a voucher at that time if the sample is negative. Subjects in the CM condition earn a minimum of $3 for each urine sample they submit that is negative for cocaine. Voucher amounts will escalate by $1 per consecutive clean urine sample submitted up to a maximum of $15 per clean sample.
45602095|NCT00838981|Drug|Methadone|Subjects will be started on 30 mg of methadone and the dose will be increased as tolerated to reach 60 mg at the end of the first 1-2 weeks of the induction phase. Methadone dosing will bestabilized. During methadone maintenance (weeks 1-11 of treatment phase), subjects continue to receive their maintenance doses of methadone plus modafinil or placebo.
45602096|NCT00838981|Behavioral|cognitive behavioral treatment|All subjects will receive a manual-guided CBT treatment over the course of their 16-week participation. This manual-guided therapy promotes abstinence through a functional analysis of high-risk situations and coping skills training.
45602097|NCT00838981|Behavioral|Voucher Control|Subjects in the Yoked-Control condition (YC) will be paired with a CM subject. Subjects in the YC condition will be informed that they will receive vouchers according to an unpredictable schedule, and that they cannot control when they will receive these vouchers or how much they will be worth.
45602098|NCT05082675|Procedure|HLA Matched allogeneic transplant|
45602099|NCT00849797|Drug|Oxcarbazepine|600 mg Tablet
45602100|NCT00849797|Drug|Trileptal®|600 mg Tablet
45602101|NCT05082441|Drug|Liposomal bupivacaine|Exparel mixed with bupivacaine to be infiltrated in the subcutaneous region of the wound instead of plain bupivacaine
45602102|NCT05082441|Drug|Bupivacaine Hydrochloride|plain bupivacaine subcutaneous injection as standard of care control
45602103|NCT00950885|Biological|Low Dose Melatonin|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
45602104|NCT00950885|Biological|Placebo|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
45602105|NCT00950885|Biological|High Dose Melatonin|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
45602106|NCT05159414|Device|Pulse Electrical Stimulation|Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
45602107|NCT00849485|Drug|Levetiracetam|750 mg Tablet
45602108|NCT00849485|Drug|Keppra®|750 mg Tablet
45602109|NCT05237258|Behavioral|Specialty Palliative Care|Participants assigned to specialty palliative care will be cared for by both oncology and palliative care clinicians during their hospital stays for AML.
45602110|NCT05237258|Behavioral|Primary Palliative Care|Participants assigned primary palliative care will be cared for by oncology clinicians who have been trained in palliative care during the hospital stays for AML.
45602111|NCT03140397|Dietary Supplement|Placebo|
45602112|NCT03140397|Dietary Supplement|6-prenylnaringenin|
45602113|NCT03140397|Dietary Supplement|8-prenylnaringenin|
45602114|NCT05235854|Drug|Injection of corticosteroids (Diprostène®)|Diprostène® will be injected into the knee. This is a 1 ml syringe of Betamethasone 2 mg, suspension for injection in pre-filled syringe.
45755837|NCT00590707|Device|Moderate sedation|The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 4-5.
45444567|NCT02048098|Drug|Vaginal misoprostol|400 µg vaginal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg vaginal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
45602115|NCT05074251|Diagnostic Test|HIV self test|For women allocated to the intervention arm, the participant will be given HIV self testing and counseling on their use & importance of partner testing, to take home to their partner(s).
45602116|NCT05074251|Behavioral|Counseling and referral for partner testing|Counseling and refer participant's partner for facility based HIV testing
45602117|NCT05086445|Drug|LY3502970|Administered orally
45602118|NCT05086445|Drug|Placebo|Administered orally
45602119|NCT05158478|Diagnostic Test|blood glucose measurement, blood glucose monitor for personal use|measurement of the blood glucose concentration using the blood glucose monitor for personal use (TJ100)
45602120|NCT05158478|Diagnostic Test|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device (YSI 2300 Stat Plus)
45602121|NCT05086185|Diagnostic Test|Kalemic Response to Orange Juice|100% pulp-free orange juice
45602122|NCT05086185|Dietary Supplement|Kalemic Response to Orange Juice with Fiber|100% pulp-free orange juice with psyllium-based fiber added
45602123|NCT05047445|Biological|COVIDITY (SCOV1 and SCOV2) administered via needle-free intradermal injection|Two 0.2 mg doses of the plasmid DNA vaccine SCOV1 (administered on Day 1 and Day 29), followed by two 0.2 mg doses of the plasmid DNA vaccine SCOV2 (not before Days 113 and 141 [doses 4 weeks apart]).
45602124|NCT05047445|Biological|COVIDITY (SCOV1 and SCOV2) administered via needle-free intramuscular injection|Two 1.0 mg doses of the plasmid DNA vaccine SCOV1 (administered on Day 1 and Day 29), followed by two 1.0 mg doses of the plasmid DNA vaccine SCOV2 (not before Days 113 and 141 [doses 4 weeks apart]).
45602125|NCT05047445|Biological|COVIDITY (SCOV2 only) administered via needle-free intradermal injection to vaccine naive and/or previously vaccinated participants|Two 0.8 mg doses of the plasmid DNA vaccine SCOV2 administered on Day 1 and Day 29
45602126|NCT05047445|Biological|COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to vaccine naive and/or previously vaccinated participants|Two 4.0 mg doses of the plasmid DNA vaccine SCOV2 administered on Day 1 and Day 29
45602127|NCT05047445|Biological|COVIDITY (SCOV2 only) administered via needle-free intradermal injection to previously infected participants|A single 0.8 mg dose of the plasmid DNA vaccine SCOV2 administered on Day 1
45602128|NCT05047445|Biological|COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to previously infected participants|A single 4.0 mg dose of the plasmid DNA vaccine SCOV2 administered on Day 1
45602129|NCT05203484|Device|Multielecotrde Mapping|Multielectrode Mapping with Pentaray/Octaray
45602130|NCT05203484|Device|Point-by-point mapping|Point-by-point mapping with QDot
45602131|NCT04854291|Other|Administration of donor FMT|Intracaecal infusion of FMT
45602132|NCT04854291|Other|Administration of placebo|Intracaecal infusion of carrier solution
45602133|NCT00841529|Device|Medtronic LAA Occlusion Device|Placement of the occlusion band on the LAA
45602134|NCT04851405|Behavioral|Otago Exercise Programme+ (OEP+)|"Physiotherapists (PTs) will receive OEP and BAP training. They will provide at home visits and follow-up phone calls to the older adult participants (5 at home visits and 3 phone calls).~Older adults will have access to the OEP app."
45602135|NCT04851405|Behavioral|Otago Exercise Programme (OEP)|PTs will receive OEP training. They will provide at home visits and follow-up phone calls to the older adult participants (5 at home visits and 3 follow-up phone calls).
45602136|NCT05235542|Drug|AK104|IV infusion,Specified dose on specified days
45602137|NCT05235542|Drug|AK117|IV infusion,Specified dose on specified days
45602138|NCT05235542|Drug|Capecitabine tablets|Oral,Specified dose on specified days
45602139|NCT05235542|Drug|Oxaliplatin|IV infusion,Specified dose on specified days
45602140|NCT05235542|Drug|Cisplatin|IV infusion,Specified dose on specified days
45602141|NCT05235542|Drug|Paclitaxel|IV infusion,Specified dose on specified days
45602142|NCT05235542|Drug|Irinotecan|IV infusion,Specified dose on specified days
45602143|NCT05235542|Drug|Docetaxel|IV infusion,Specified dose on specified days
45602144|NCT05235542|Drug|5-FU|IV infusion,Specified dose on specified days
45602145|NCT00840281|Drug|Cefzil® 500 mg tablets|1 x 500 mg, single-dose fasting
45602146|NCT00840281|Drug|Cefprozil 500 mg Tablets|1 x 500 mg, single-dose fasting
45755838|NCT03504800|Device|Optical Coherence Tomography|This device will be used to tightly classify corneal irregularities and determine eligibility of candidates from Group A into Groups B & C.
45602147|NCT05086029|Diagnostic Test|Superb Microvascular Imaging|Superb microvascular imaging (SMI) is a new ultrasound technology that can diferen-tiate blood flow signals from artifacts by using a new algorithm.
45602148|NCT03134807|Other|Observation prospective|No intervention
45602149|NCT05073705|Behavioral|Self-management intervention|Intervention condition. The intervention to be tested will emerge from Aim 2 -- a self-management intervention for ALHIV to facilitate their transition to adult HIV care
45602150|NCT05202938|Diagnostic Test|ultrasound cardiography|Ultrasound to check heart functions and systolic ejection fraction.
45602151|NCT05202938|Diagnostic Test|FDG PET scan|FDG venous injection and positron emission tomography scan.
45755839|NCT05557019|Device|Booster Balloon Catheter|The Booster balloon therapy (i.e. partial occlusion of the CS lumen with a subsequent backward pressure elevation without obstructing the CS blood flow) will start immediately after a successful PCI of the culprit coronary lesion in the LAD, with TIMI-II flow restoration. The Booster balloon therapy will then be continued for up to 90 min, but not less than 60 min.
45755840|NCT05549141|Other|treadmill gait training with gait facilitators|6 sessions of 30 minutes each of treadmill gait training with functional electrical stimulation as a gait facilitator
45602152|NCT05202938|Diagnostic Test|Palmitate PET scan|C11-Palmitate venous injection and positron emission tomography scan.
45602153|NCT05202938|Diagnostic Test|Acetate PET scan|C11-Acetate venous injection and positron emission tomography scan.
45602154|NCT05202938|Diagnostic Test|Blood sampling|Collecting 20ml of venous blood.
45602155|NCT00840203|Drug|Rowasa® 4 gm/60 mL Rectal Enema|1 x 4 gm/60 mL, single-dose
45602156|NCT00840203|Drug|Mesalamine 4 gm/60 mL Rectal Enema|1 x 4 gm/60 mL, single-dose
45444568|NCT02048098|Drug|Buccal misoprostol|400 µg buccal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg buccal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
45602157|NCT05071755|Procedure|Gastrectomy|Radical Total Gastrectomy, Radical Partial gastrectomy (Proximal / Subtotal)
45602158|NCT05155982|Biological|COVAC-1|Intramuscular vaccine against SARS-CoV-2
45602159|NCT05155982|Biological|Saline Placebo|Intramuscular injection of saline placebo
45602160|NCT04820283|Behavioral|Care manager intervention (nurse)|In this intervention, a primary care nurse provides the participant with self-management support to manage stress-related problems. The participant meets with the nurse face-to-face for typically 2 to 6 sessions.
45602161|NCT04820283|Behavioral|CBT|In this intervention, the participant receives therapist supported self-help CBT. The participant randomized to this arm can choose to receive the treatment via an online treatment platform or via bibliotherapy, i.e., a self-help book.The treatment is comprised of 12 modules or chapters, which entail information about stress management techniques including behavioral activation and exposure. The participant that chooses online CBT is guided by a therapist who provides feedback on homework assignments through written asynchronous text messages; the patient who chooses bibliotherapy is guided by a therapist in typically 2 to 5 face-to-face sessions at a primary care clinic.
45602162|NCT00838799|Drug|RGH-896|45 mg TID, capsules, 14 weeks.
45602163|NCT00838799|Drug|RGH-896|30 mg TID, capsules, 14 weeks.
45602164|NCT00838799|Drug|RGH-896|15 mg TID, capsules, 14 weeks.
45602165|NCT00838799|Drug|pregabalin|100 mg, TID, capsules, 14 weeks.
45602166|NCT00838799|Drug|placebo|TID, capsules, 14 weeks.
45602167|NCT05234216|Other|Informed consent|the investigator will verify the inclusion criteria, the patient's understanding of the protocol and will obtain oral informed consent
45602168|NCT05234216|Procedure|Surgery|The patient will undergo surgery in accordance with standard care
45602169|NCT05234216|Behavioral|Comfort scale|The patient will be evaluated, in the post-operative care unit, with a comfort scale
45602170|NCT05234216|Behavioral|Pain|The patient will be evaluated, in the post-operative care unit, with a pain scale
45755841|NCT05549141|Other|treadmill gait training not-associated with gait facilitators|6 sessions of 30 minutes each of treadmill gait training
45755842|NCT00671528|Drug|Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)|Betamethasone diproprionate 0.05%, clotrimazole 1%, and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area 2 times a day (BID), morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
45602171|NCT05234216|Other|Questionnaires|Evaluation of the Experience of Local/General Anesthesia
45602172|NCT05025735|Drug|Dapagliflozin 10Mg Tab|"Hyperglycemia is an expected effect of PI3K inhibitors given the pivotal role of PI3K in mediating the response to insulin in multiple tissues. Blocking insulin signaling by p110α inhibitors leads to glycogen breakdown in the liver along with decreased glucose uptake in peripheral tissues. The resulting hyperglycemia causes a compensatory response of increase insulin secretion by the pancreas.~If concurrent treatment with dapagliflozin can abrogate the alpelisib induced hyperglycemia and subsequent rebound hyperinsulinemia it may significantly improve the therapeutic efficacy of alpelisib."
45602173|NCT05085639|Biological|GLS-5130|GLS-5310 DNA plasmid vaccine
45602174|NCT05085639|Biological|Placebo|Placebo
45602175|NCT04230590|Other|Observational|"Participants will not receive any study intervention.~During the 24-week study period, participants will complete five assessment visits and passive digital data from participant's smartphone and study-provided wrist wearable device will be collected."
45755843|NCT00671528|Drug|Cream (betamethasone diproprionate and gentamicin)|Betamethasone diproprionate 0.05% and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
45444569|NCT01302561|Dietary Supplement|Sucrose|5 g of sucrose twice daily for 24 weeks
45602176|NCT00836069|Drug|No drug name provided by Sponsor; drug referenced as PD 0332334|Experimental study drug for generalized anxiety disorder, oral tablet, at a total daily dose of 450mg or 600mg, twice daily for 8 weeks and then 2 weeks of dose tapering.
45602177|NCT00836069|Drug|Paroxetine|FDA Approved medication for generalized anxiety disorder, oral tablet, at 20mg, once daily for 8 weeks and then 2 weeks of dose tapering.
45602178|NCT00836069|Drug|Placebo|inactive substance, oral tablet, once per day, for 10 weeks.
45602179|NCT05023395|Drug|MEE-HU Medicus|This investigational medicinal product (MEE-HU Medicus) is a patented mixture of amino acids and pentose sugar. The mixture according to the invention in particular is suitable as medicine for resistance-breaking of antibiotic resistances of pathogens, in particular for resistance-breaking of multiple antibiotic resistances, a method for decreasing bacterial resistance to antibiotics.
45602180|NCT05023395|Other|Placebo|Placebo
45755844|NCT00671528|Drug|Cream (betamethasone diproprionate)|Betamethasone diproprionate 0.05% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
45602181|NCT05155670|Device|WRL HX MCP|WRL HX MCP is a non CE marked class IIa medical device designed for clinical application in hand rehabilitation; it consists in a cable-driven robotic MCP orthosis providing flexion-extension of the metacarpo-phalangeal joint. WRL HX MCP features and a series-elastic actuators (SEA) architecture for compliant actuation of MCP flexion-extension and a self-aligning mechanism to absorb human/robot joint axes misplacement. Exoskeleton module is mounted on a dorsal hand support and connected to its electronic box through wires.
45602182|NCT03134729|Drug|Ropivacaine for Serratus Plane Block (SPB)|Serratus Plane Block (SPB) injection of low concentration Ropivacaine (30 ml, 0.3%), in the plane between the External Intercostal Muscle and the Serratus Anterior Muscle.
45602183|NCT03134651|Device|Monitoring brain function|
45602184|NCT03134651|Drug|propofol|
45602185|NCT05202860|Biological|HPV Vaccine|(Gardasil 9 human papilloma vaccine)
45602186|NCT05202860|Biological|PLACEBO vaccine|Isotonic saltwater sham vaccine
45602187|NCT05020847|Dietary Supplement|Standard F75|F-75 contains 75 kcal and 0.9 g protein per 100 ml
45602188|NCT05020847|Dietary Supplement|Alternative F75 with CMV|Alternative F75 With CMV contains cereal flour, oil, sugar, powdered milk with complex mineral-vitamin (CMV)
45602189|NCT05020847|Dietary Supplement|Alternative F75 without CMV|Alternative F75 without CMV contains cereal flour, oil, sugar, powdered milk without complex mineral vitamin (CMV).
45602190|NCT05202782|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given IV
45602191|NCT05202782|Other|Quality-of-Life Assessment|Ancillary studies
45602192|NCT05202782|Other|Questionnaire Administration|Ancillary studies
45602193|NCT05202782|Drug|Zanubrutinib|Given PO
45602194|NCT05430659|Other|observational study|Retrospective observational study
45602195|NCT05202080|Other|Opioid Counseling and Pain Coping Skills Video|The intervention will be in the form of a video of a PowerPoint presentation with instructions and exercises designed to coach patients about catastrophizing, coping skills, mindfulness and behavioral modification techniques, in addition to providing education regarding postoperative analgesia and opioid use.
45602196|NCT00935987|Drug|CYT387|"For the Part 1 dose-escalation portion of the study, patients will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 100 mg/day. CYT387 will be orally self-administered as a single daily dose beginning on Day 1 of the study, and thereafter at approximately the same time each day of the 28-day cycle. It is recommended that all doses be preceded by a 2-hour fast from food and beverages, and be followed by a 1-hour post-dose fast from food and beverages.~Twenty additional patients will be assigned to a 150 mg BID (twice daily) dosing schedule. CYT387 will be orally self-administered twice-daily with doses approximately 10-12 hours apart beginning on Day 1 of the study, and thereafter at approximately the same times each day of the 28-day cycle.~For the Part 2 dose confirmation portion of the study, patients will be assigned to either 150 mg or 300 mg QD (once daily) dose groups."
45602197|NCT05155124|Drug|Cetuximab + trifluridin tipiracil|Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks; trifluridin tipiracil will be administered in a dose de-escalation design: dose level 1: 35 mg/m2 twice daily on days 1-5 once every 2 weeks; Or dose level 0: 30 mg/m2, twice daily, Days 1-5, once every 2 weeks;
45602198|NCT04473677|Diagnostic Test|The new qFIT and colonoscopy with pathological examination|Detect hemoglobin in stool by the new qFIT before colonoscopy, detect colon lesion using colonoscopy and pathological examination.
45602199|NCT05232578|Radiation|Early salvage radiotherapy (eSRT)|"eSRT administered immediately after the confirmation of the biochemical relapse (PSA ≈ 0.2ng/ml).~66-70Gy will be delivered to the bed of prostate. Radiotherapy will be optionally accompanied by androgen deprivation therapy."
45755845|NCT05347706|Dietary Supplement|formula|Enteral feeding is started with in the first 24 hours of life. Human milk is encouraged, and preterm formula is fed when human milk is not available due to mother's or family's condition. Patients with feeding intolerance are temporarily fed with AAF or EHF instead of human milk or preterm formula. Once the patients with feeding intolerance show clinical improvement, AAF or EHF feeding is discontinued, and the previous feeding, either human milk or preterm formula is resumed
45602200|NCT05232578|Radiation|Delayed Salvage radiotherapy (dSRT)|"dSRT administered if PSA levels increase to ≥ 0.4 ng/ml.~66-70Gy will be delivered to the bed of prostate. Radiotherapy will be optionally accompanied by androgen deprivation therapy."
45602201|NCT04438343|Other|Impairment-specific and augmented intervention|Balance and lower extremities strength training
45755846|NCT01798121|Biological|To compare new PPD to reference standard material|Aplisol@ will be compared to reference standard material
45755847|NCT01798121|Biological|Reference standard|Response of reference standard material compared to Aplisol@.
45755848|NCT00590863|Drug|SSRI + placebo|Participants will take escitalopram (10 - 20 mg/day)+ placebo (1 to 3 pills per day). Medications taken orally. Participants will take escitalopram plus placebo for up to 28 weeks. Dosages were adjusted as need at each clinic visit.
45602202|NCT04438343|Other|Conventional physical therapy|Trunk and upper extremity training
45602203|NCT05200832|Other|Online questionnaire|Participants will be asked to complete an online questionnaire about their health and quality of life since the start of the pandemic.
45602204|NCT05200832|Other|Semi-structured interview|20 participants (10 from each group) will be randomly selected to participate in a semi-structured interview focusing on their perception of their health and quality of life since the start of the pandemic.
45602205|NCT00927641|Drug|Ketoprofen Patch|Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days
45602206|NCT00927641|Other|Placebo Patch|Two placebo patches placed on target ankle once daily for 14 days
45602207|NCT05200364|Drug|STRO-002|intravenous antibody drug conjugate
45602208|NCT05200364|Drug|Bevacizumab|anti-VEGF agent
45444570|NCT01302561|Dietary Supplement|Galactooligosaccharide|2.5 g galactooligosaccharide plus 2.5 g sucrose twice daily for 24 weeks
45602209|NCT05200208|Dietary Supplement|Citicoline supplement|Participants with AD will receive dietary citicoline supplements in addition to the standard of care donepezil. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A & B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months.
45602210|NCT05200208|Other|Placebo|Participants with AD will receive a placebo supplement in addition to the standard of care donepezil. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A & B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months.
45755849|NCT00590863|Drug|Escitalopram + Bupropion SR|Participant will take Burpopion SR (150 to 450 mg/day) + Escitalopram (10 to 20 mg/day) for up to 28 weeks. Medications taken orally. Bupropion SR was blinded, and escitalopram was given open label. Dosages were adjusted as need at each clinic visit.
45602211|NCT00835991|Drug|Glyburide/Metformin 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fed
45602212|NCT00835991|Drug|Glucovance® 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fed
45602213|NCT05200052|Drug|Colchicine 0.5 mg Oral Tablet|Colchicine loading dose 1 mg and maintenance dose 0.5 mg for 6 months in addition to standard anti ischemic treatment.
45602214|NCT05399693|Procedure|platelet transfusion|platelet transfusion realised for Hematopoietic stem cells graft or for acute leukemia
45602215|NCT05152862|Procedure|Laser|Retinal laser photocoagulation
45602216|NCT05152862|Procedure|Anti VEGF|Anti-VEGF intravitreous injection
45602217|NCT05230082|Other|Acupuncture|Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
45602218|NCT04986293|Device|CPAP|Different settings of CPAP and BiPAP will be tested using a home mechanical ventilator
45602219|NCT00925535|Drug|Lersivirine|1000 mg once daily for 10 days
45602220|NCT00925535|Drug|Rifabutin|300 mg once daily for 10 days
45602221|NCT00925535|Drug|Lersivirine|1000 mg once daily for 10 days
45602222|NCT00925535|Drug|Rifabutin|300 mg once daily for 10 days
45602223|NCT05148494|Drug|Fleet Enema|standard pre-op application, see arm description
45602224|NCT05148494|Drug|Pico-Salax|standard pre-op application, see arm description
45602225|NCT04964609|Device|EmbracePlus|"A device intended for use by researchers and healthcare professionals for continuous collection of physiological parameters in home and healthcare settings.~Parallel blood gas analysis to determine oxyhemoglobin saturation (SaO2) using an ABL-90 multi-wavelength oximeter."
45602226|NCT02276872|Drug|oral treprostinil|
45602227|NCT05147480|Other|internet-based mother-baby yoga|Mother-baby yoga group classes given by physiotherapists via Zoom Video Communications
45602228|NCT05146388|Other|EHR-Based Approach|The intervention will be built directly into the EHR. E-prescriptions will be generated with pharmacy instructions for all prescription medications. The intervention will impart: 1) inclusion with e-Rx request for pharmacy to keep metric-only (mL-only) dosing on Rx label and 2) inclusion of guidance on the e-Rx requesting that the pharmacy give an optimal tool based on an algorithm. Algorithm for dosing tool recommendation: 1) for a prescribed dose of <= 1mL, optimal tool is 1 mL syringe, 2) for >1 mL to 5 mL, use a 5 mL syringe, 3) for >5mL to 10mL, use 10 mL syringe.
45602229|NCT00835367|Drug|Amlodipine-benazepril 10 mg-20 mg capsules|1 x 10-20 mg
45602230|NCT00835367|Drug|Lotrel® 10 mg-20 mg capsule|1 x 10-20 mg
45602231|NCT04236518|Behavioral|Diets with either predominantly animal protein sources.|20 men or postmenopausal women will follow for 4 weeks a controlled diet with a protein fraction constituted mainly from animal sources. At the end of the intervention period, a post-prandial exploration will be conducted with the administration of a high-fat, high-sugar meal and subsequent blood and urine sampling.
45602232|NCT04236518|Behavioral|Diets with predominantly plant protein sources|20 men or postmenopausal women will follow for 4 weeks a controlled diet with a protein fraction constituted mainly from vegetal sources. At the end of the intervention period, a post-prandial exploration will be conducted with the administration of a high-fat, high-sugar meal and subsequent blood and urine sampling.
45602233|NCT04236440|Drug|BAY2586116 (A1)|160 μg BAY2586116 (nasal spray administration)
45602234|NCT04236440|Drug|Placebo (A2)|Placebo matching BAY2586116 (nasal spray administration)
45602235|NCT04236440|Drug|BAY2586116 (B1)|160 μg BAY2586116 (nasal drops)
45602236|NCT04236440|Drug|BAY2586116 (B2)|80 μg BAY2586116 (nasal spray)
45602237|NCT04236440|Drug|BAY2586116 (B3)|160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril)
45602238|NCT04236440|Drug|BAY2586116 (C)|160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril). It is the same procedure as described under part B3.
45602239|NCT00924989|Drug|OSI-906|Administered orally
45602240|NCT00924989|Other|Placebo|Matching placebo administered orally
45602241|NCT04235738|Other|Observational|"ER2 is a simple and standardized clinical tool. The results of the questionnaires performed in ER2 study will be used. The assessment component of ER2 consists of 6 very simple closed-ended format questions (i.e., yes versus no) which are: Age category (≥ 85), male, polypharmacy (≥ 5 different medications per day), use of formal (health care or social professional) and/or informal (family and/or friend) home support, use of a walking aid regardless of its type, and temporal disorientation (inability to give the current month and/or year). A score of five points is assigned to the items use of walking aid and temporal disorientation, whereas, for the other items, the assigned score is one point. The weighting of points for ER2 items is based on the results of our previous studies. Scores range from 0 (lowest risk) to 14 (highest risk). ER2 scores stratify the risk for short-term ED adverse events into three levels: low, moderate and high."
45602242|NCT02276560|Drug|Neoadjuvant Cisplatin, nab-paclitaxel|Cisplatin (75mg/m2) D1, nab-paclitaxel 125 mg/m2) D1, 8, 15; repeat each 28 D cycle x 2 then surgery
45755850|NCT00590863|Drug|Venlafaxine XR + Mirtazapine|Participants will take Venlafaxine XR (75 to 225 mg/day) + Mirtazapine (15 to 45 mg/day) for up to 28 weeks. Medications taken orally. Venlafaxine XR was blinded, and mirtazapine was given open label. Dosages were adjusted as need at each clinic visit.
45755851|NCT05347628|Drug|PLB1004|PLB1004 is a capsule in the form of 10mg and 40mg.
45755852|NCT04799171|Other|Isometric Contraction Exercise - Young Adults (Age group 18-39)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
45602243|NCT02276560|Drug|Adjuvant Cisplatin,nab-paclitaxel|Cisplatin 75mg/m2 D1,nab-paclitaxel 125mg/m2 D1, 8, 15, repeat each 28D cycle x 2
45755853|NCT04799171|Other|Isometric Contraction Exercise - Middle Age Adults (Age group 40-59)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
45755854|NCT04799171|Other|Isometric Contraction Exercise - Old Adults (Age group >60)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
45755855|NCT03501992|Behavioral|Current care|The current care arm consists of the contemporary efforts now in practice to support provider recommendation including a shared, standard immunization schedule, a shared rooming process, a shared well child visit schedule, a shared electronic prompt at point-of-care of vaccines due.
45602244|NCT02276560|Drug|Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine|Cisplatin 75mg/m2 D1 + pemetrexed 500mg/m2 D1 or Gemcitabine 1000 mg/m2 D1, 8 (if SqCC) repeat each 21 D Cycle x 4
45602245|NCT05199896|Behavioral|Behavioral protocol|A touch sensitive computer screen either displaying a downscaled (45cm long) image of the rod (for the sighted), or supporting a same sized wooden rod (for the blind), will be placed on the table in front of the participant to record their localization performance. They will be instructed to use their left index fingertip to indicate on the image of the screen (for sighted) or on the wooden rod (for the blind) the position where they have felt the touch provided to the 90 cm long they held in their right dominant hand. Participants will wear a headset playing white noise to prevent any auditory localization cues when the long rod will be touched. The rod will be touched by a computer controlled solenoid. Thus, participants will respond with a hand gesture on the image or rod and will be asked to validate the position by pressing a foot-pedal with their left foot.
45602246|NCT05199896|Device|EEG protocol|"The EEG protocol will be similar as the behavioral one described above, with the distinction of taking place in two separate sessions: one where the rod are touched, and one where their hand is touched. The participant will hold a rod in each hand and he will have to indicate on which rod he felt the touch.~Additionally electrophysiological responses will be continuously recorded using a 65 channel ActiCap system (Brain Products)."
45602247|NCT05199896|Device|fMRI protocol|"The same behavioral task and procedures of the behavioral protocol described above will be applied, adapted to take into account the constraints posed by the magnetic environment of the MR scanner. The participant will be placed on the scanner bed and provided with earphones that will both protect against the noise of the machine (80dB) and ensure a continuous communication with the participant.~During the fMRI sessions, the participant will solve the same rod localization behavioral task while we will record brain activations by measuring the brain oxygen level dependent signal via Echo Planar Imaging sequences. We will use an MRI compatible tactile stimulator to touch the hand-held rod and participants location judgement will be recorded by using an MRI-compatible tablet, positioned on their abdomen, where the participant will have to indicate the judged position."
45602248|NCT05198414|Other|Focus group|Qualitative research methodology with healthcare workers
45602249|NCT04954859|Drug|GSK3228836|No study drug will be administered in this study. Eligible participants who received prior treatment with GSK3228836 in the parent studies will be included.
45602250|NCT05197946|Diagnostic Test|MRI|Research unsedated MRI scans (outside of usual care) will be performed using a 3T Philips scanner at the F.M. Kirby Research Center. An MRI scanning protocol will be at the F.M. Kirby Research Center; the protocol will not last more than 1.5 hours. Acquisitions will include a triplanar survey, functional and anatomical multi-slice imaging of the brain as well as MRI of selected spinal levels. Protocols will be used that do not involve use of contrast agents and limit power/tissue absorption as well as otherwise remain within FDA and Kirby Center safety regulations. When possible, MRI will be performed within 3 months of initial survey/interview administration. If MRI is scheduled >3 months after initial survey/interview administration, a brief survey will be re-administered to screen for changes in pain/clinical status.
45602251|NCT02276482|Drug|Tedizolid Phophate|Tedizolid Phophate 200 mg, IV and/or oral for 6 days
45602252|NCT02276482|Drug|Antibiotic comparator|Antibiotic comparator drug, IV and/or orally for 10 days. Antibiotic comparator included the following: Vancomycin, Linezolid, Clindamycin, Flucloxacillin, Cefazolin, Cephalexin.
45602253|NCT02276482|Drug|Aztreonam|In countries and/or sites where aztreonam is available, adjunctive aztreonam (IV) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with gram-negative aerobic pathogens.
45602254|NCT02276482|Drug|Metronidazole|Metronidazole (IV or oral) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with anaerobic pathogens.
45602255|NCT05197166|Other|Acute Clinical Settings|Acute clinical settings, like hospitals, where students are exposed to normal daily shift activities, involving prolonged walking and standing positions.
45602256|NCT05649670|Other|Mobile Stroke Unit deployment|Deployment of an MSU + conventional ambulance, allowing prehospital CT-scan imaging with intracranial CT angiography. This will allow prehospital intravenous thrombolysis and optimal triage (i.e. accurate identification of patients with large vessel occlusion, who are eligible for mechanical thrombectomy).
45602257|NCT00924833|Drug|placebo|placebo tablet BID
45602258|NCT00924833|Drug|Carvedilol|Carvedilol 25 mg tablets. One tablet twice daily.
45602259|NCT00924833|Drug|Nebivolol|nebivolol 5 mg tablets. One nebivolol tablet daily. One placebo tablet daily.
45755856|NCT03501992|Behavioral|Reminder-recall|The communication will use expectant (announcement-style or presumptive) language noting the child's HPV vaccination status and stating that the child's provider strongly recommends the child receive the HPV vaccination now. The communication will also describe availability of topical anesthetics (less pain), indicate the availability and convenience of nurse visits for HPV vaccination (less fuss), and describe the immunological and logistical benefits of early vaccination (right now).
45755857|NCT03501992|Behavioral|Audit-and-feedback|The intervention includes two components. The first is a missed opportunities audit-and-feedback. The second is a provision of a strong recommendation provider-toolkit, along with a broad education of the practice staff-nurses, medical secretaries, receptionists, and clinical assistants-regarding the nature of the intervention, its goals, and its likely impact on the practice. The broad education will be conducted through supervisory communications only to practice staff in practices allocated to the intervention at the beginning of the step.
45755858|NCT03501992|Behavioral|Combined reminder-recall and audit-and-feedback|The combination reminder-and-audit arm consists of a simultaneous application of the intervention tested in the reminder-recall arm and the intervention tested in the audit-and-feedback arm.
45755859|NCT04815005|Other|Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.|Differences in diagnosis, genotype, lipid profile treatment allocation among HoFH patients worldwide.
45755860|NCT00591019|Drug|Modafinil|200 mg/day, morning dose
45755861|NCT00591019|Other|Placebo|Sugar pill once per day in the morning.
45602260|NCT05229770|Dietary Supplement|Fruit smoothie|Participants randomised to the intervention arm will receive a 250 ml fruit smoothie as diet supplement for 20 weeks in addition to the regular OAT clinic follow-up. The fruit smoothies will be marketed products including combinations of the following fruits: apple, pineapple, mango, bananas, orange, blueberries, passion fruit, coconut, lime, and blackcurrant. The participants will receive a mixture of different smoothie types with the option of removing alternatives based on preferences. Fruit smoothie products will come in plastic bottles and will be delivered directly to the participants on a weekly basis. Each participant will receive a total of seven smoothie bottles per week with an oral agreement with each participant to consume one of these per day. Delivery of fruit smoothie will generally be given in parallel with delivery of OAT medication.
45602261|NCT05228756|Other|Accelerometer|Participants will complete 16 exercise sessions at home wearing an accelerometer
45602262|NCT00922571|Procedure|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
45602263|NCT00922571|Device|FS Laser System|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
45602264|NCT05142254|Drug|Tadalafil|2.5-5 mg/day
45602265|NCT05142254|Drug|Hydroxyurea|20 mg/kg/day
45602266|NCT05142254|Drug|Placebo|identical placebo to tadalafil created by Bond Biochemical, who is manufacturing the tadalafil as well.
45602267|NCT00835211|Drug|Desmopressin Acetate 0.2 mg Tablets|4 x 0.2 mg, single-dose fasting
45602268|NCT00835211|Drug|DDAVP® 0.2 mg Tablets|4 x 0.2 mg, single-dose fasting
45602269|NCT05227820|Drug|NE3107|Participants will take 20mg twice daily (BID) approximately 12 hours apart. The dose will be stable the duration of the study intervention (3 months)
45755862|NCT02128919|Device|tDCS|Transcranial Direct Current Stimulation
45755863|NCT02996695|Drug|Artesunate|Artesunate is a succinic ester of artemether.
45755864|NCT02996695|Drug|Chloroquine|4-aminoquinolone, antimalarial agent for oral administration
45755865|NCT02996695|Biological|PfSPZ (NF54) Challenge|Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
45755866|NCT02996695|Other|Placebo|Placebo
45755867|NCT00359138|Drug|desloratadine|5 mg tablet once daily
45755868|NCT00359138|Drug|levocetirizine|5 mg capsule once daily
45755869|NCT00359138|Drug|Desloratadine placebo tablet|once daily
45755870|NCT00359138|Drug|Levocetirizine placebo capsule|once daily
45755871|NCT00003404|Radiation|Adjuvant Radiotherapy|Adjuvant radiation therapy
45602270|NCT00834977|Drug|Amlodipine-benazepril 10 mg-20 mg capsules|1 x 10-20 mg
45602271|NCT00834977|Drug|Lotrel® 10 mg-20 mg capsule|1 x 10-20 mg
45602272|NCT05304377|Drug|ELVN-001|orally once daily
45602273|NCT05227664|Drug|AK117|AK117 at a dose of 45mg/kg via intravenous (IV) infusion on Days 1,8 ,15 and 22of each 28-day cycle until disease progression or unacceptable toxicity
45602274|NCT05227664|Drug|AK112|AK112 at a dose of 20mg/kg via intravenous (IV) infusion on Days 1and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
45755872|NCT00697801|Drug|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
45755873|NCT00697801|Drug|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
45755874|NCT00697801|Drug|Placebo|Placebo delivered by nebulization twice daily for 6 weeks
46066563|NCT05593042|Biological|Omicron Vaccine|"An experimental intervention consisting of a booster dose of an inactivated Omicron variant vaccine.~The active ingredient is the SARS-CoV-2 virus (Omicron variant) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, packed in a pre-load syringe, and contains one dose (0.5mL) of 1200 SU of inactivated SARS-CoV-2 Omicron variant."
45602275|NCT05227664|Drug|Nab paclitaxel|Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
45602276|NCT05227664|Drug|paclitaxel|Paclitaxel at a starting dose of 90 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
45755875|NCT03670316|Drug|Algorithm Treatment|Varenicline was selected as the first line of treatment for patients willing to take a medication twice per day and wanting cessation. Following varenicline, bupropion and then NRT are subsequent options. In terms of preference for NRT, nicotine patches would be the first option followed by lozenge, gum, inhaler, and nasal spray. The order of NRT within the algorithm is based upon patient familiarity and number of clinical trials supporting their use. Combination NRT (e.g., patch and lozenge) or adding NRT to varenicline or bupropion is offered to participants who have made an unsuccessful quit attempt with these medications in the past. If none of these medications are appropriate, then the participant is offered counseling only.
45755876|NCT03670316|Other|Quitline only|eTAU participants will complete the same algorithm questions but will not have this information sent to their provider, although their provider may elect to prescribe medication as part of standard of care. Participants will be referred to a quitline for behavioral support services for cessation.
45755877|NCT05503979|Drug|Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]|1 tab every 24 hrs for 12 weeks
45755878|NCT02996461|Biological|VRC-ZKADNA090-00-VP|VRC-ZKADNA090-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
45755879|NCT04703621|Drug|Daratumumab Injection|subcutaneious daratumumab administration
45755880|NCT03669302|Other|Robotic gait training|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a pulse train at 30 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
45602277|NCT05226650|Other|Regular meal pattern|6 meals every day
45602278|NCT05226650|Other|Irregular meal pattern|It consists of consuming a different number of meals every day (between 3 and 9).
45602279|NCT05304143|Other|Virtual Immersive Reality Glasses|"The day of the examination, the patient will go to the MRI room and he will be fitted with virtual reality glasses compatible with the MRI equipment. The patient will visualize relaxing contents in open spaces with music and verbal instructions during all the procedure. The contents will be previously validated by the clinical psychologist of the center with experience in this regard.~During the test, the patient's heart rate will be monitored."
45602280|NCT05304143|Other|Conventional nurse support|Patients will be treated using the usual support technique to reduce anxiety in the Diagnostic Imaging service
45602281|NCT05226494|Drug|fb-PMT|Daily dosing based on patient weight
45602282|NCT05291819|Other|Imaging informed treat-to-target|"A treat-to-target treatment strategy incorporating information from ultrasound assessment of joints, tendons and entheses (at every visit), and magnetic resonance imaging (MRI) of spine and sacroiliac (SI)-joints at baseline and 1 year, in addition to clinical information~Specifically, this means that these additional measures will be added to conventional treat to target:~If evidence of enthesitis (power Doppler>0 in enthesis) or axial inflammation (SPARCC score ≥ 2* in SI-joint or SPARCC score ≥ 5 in presence of clinical symptoms of axial disease) on imaging the patient will progress directly to biological disease modifying antirheumatic drug in the treatment algorithm~If evidence of ongoing inflammation (power Doppler>0) on ultrasound assessment of joints, tendons or enthesis, the patient will be classified as not having reached their treatment target"
45602283|NCT05291819|Other|Conventional treat-to-target|Patients are treated according to an algorithm based on current European recommendations. The conventional treatment target, applicable to both arms and the target in the conventional arm, is all of: Disease Activity index in PSoriatic Arthritis (DAPSA) remission (≤4), Enthesitis ≤1, Psoriasis Body Surface Area ≤3%
45602284|NCT05472662|Drug|Placebo 152a|Placebo pMDI formulated with the 152a propellant
45602285|NCT05472662|Drug|Placebo 134a|Placebo pMDI formulated with the 134a propellant
45602286|NCT05226338|Drug|D-0502|Formulation 1 Formulation 2 Formulation 3
45602287|NCT00834743|Drug|Glucophage® XR 750 mg Tablets|1 x 750 mg, single-dose fasting
45602288|NCT00834743|Drug|Metformin ER 750 mg Tablets|1 x 750 mg, single-dose fasting
45602289|NCT04896502|Behavioral|Standard of Care Education|Education regarding recognition and removal of in-home asthma triggers
45602290|NCT04896502|Other|Interactive Video (IAV) Telemedicine|Interactive video assessment of asthma triggers in the home.
45602291|NCT00834587|Drug|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose non-fasting
45602292|NCT00834587|Drug|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose non-fasting
45755881|NCT03669302|Device|Robotic gait training and low-frequency transspinal stimulation|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a single pulse at 0.3 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
45755882|NCT03669302|Device|Robotic gait training and high-frequency transspinal stimulation|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a pulse train at 30 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
45755883|NCT02996383|Device|Internal fixation|Internal fixation of the fracture with a Targon FN implant (BBraun Ltd, Germany)
45755884|NCT02996383|Device|Cemented Hemiarthroplasty|Replacement of the femoral head with a cemented hemiarthroplasty
45755885|NCT04541225|Drug|NUV-422|NUV-422 is an investigational drug for oral dosing.
45755886|NCT02996227|Procedure|TAP block|Transversus Abdominis Plane (TAP) blocks will be performed preoperatively. An in-plane ultrasound will be used in TAP block procedure.
45755887|NCT02996227|Procedure|Epidural analgesia|Epidural catheters will be inserted preoperatively.
45755888|NCT02996227|Drug|EXPAREL|Once the target area is positioned, plain bupivacaine 0.25%, 20ml will be given to open the space and then single dose (10ml) of liposomal bupivacaine (Exparel) mixed with saline (10 ml) will be injected in each side. Total dose of Exparel will be 20 mL.
45755889|NCT02996227|Drug|Bupivacaine|Once an epidural catheter is successfully positioned, an infusion will be initiated intraoperatively. Bupivacaine standard solution without additives will be prepared for each patient in epidural group.
45755890|NCT03497936|Behavioral|Women's Stories|Women's Stories is a brief, HPV vaccination promotion intervention. It presents vaccine information and videos of HPV vaccine decision making. It also includes follow up vaccine reminder text messages.
45755891|NCT05455541|Diagnostic Test|AI augmented POCUS examination|Internists will perform POCUS studies as they consider appropriate for patient management. Interpretation of the POCUS exams will be aided by machine learning based analysis of the videos.
45602293|NCT04228094|Other|TDApp1: an eHealth intervention|TDApp1 is a tool that uses GRADE heuristics to formulate participatory, individualized and automated therapeutic recommendations for patients with Attention Deficit Hyperactivity Disorder
45602294|NCT05649592|Diagnostic Test|Magnetic Resonance Hydrolipid Separation Imaging|"MRHS was used to measure different muscle percent fat of core muscles. MRHS, also called Dixon imaging, mainly used the different resonant frequency between the hydrogen nuclei in water and in fat to perform the data acquisition at different echo times (TE). The Dixon sequence basically acquires two images, one image with water and fat signals in-phase and the other with water and fat signals out-of-phase: the sum and subtraction of the two images allow the production of a water-only image and a fat-only image. Scanning equipment: 3.0T superconducting Siemens Skyra Scanner.~Scanning parameters: TR5.36ms, TE1.24ms, Flip Angle 9°, number of layers was 44-60, thickness of layer was 5.0 mm, layer interval 1.0mm, FOV50cm×50cm, the scanning time was 12s×5."
45602295|NCT05226260|Behavioral|Default Duration order Panel|The SSTI order panel will present itself when a provider types in either a drug name or diagnosis (cellulitis, impetigo, etc). Clinicians in control clinics will have access to a basic order panel which will include diagnosis and corresponding antibiotic of choice. Clinicians in intervention clinics will have access to order panels with the following additional components: prepopulated order duration fields that default to the recommended treatment duration.
45602296|NCT04875754|Genetic|ICM-203|Intra-articular injection
45602297|NCT04875754|Drug|Placebo (saline solution)|Intra-articular injection
45602298|NCT00918983|Drug|NX-1207|Single intraprostatic injection of 2.5 mg NX-1207
45602299|NCT00918983|Drug|Placebo|Single intraprostatic injection of placebo
45602300|NCT05649514|Procedure|Polysomnography|Polysomnography will be performed for 24 hours at inclusion and 24 months
45755892|NCT00698035|Drug|Testosterone Cream|1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
45755893|NCT00698035|Drug|Estring|2mg ring inserted vaginally once every 12 weeks
45755894|NCT04762394|Behavioral|The Child Behavior Checklist (CBCL),|It consists of 113 items; the parents complete it to detect emotional and behavioural problems in children and adolescents aged 6 to 18 years. It is scored on a three-point Likert scale (0=absent, 1= occurs sometimes, 2=occurs often). The time duration for item responses is the past six months.
45602301|NCT05649514|Behavioral|Neuropsychological assessment|A full neuropsychological assessment will be performed at inclusion, 12 and 24 months
45602302|NCT05649514|Behavioral|Questionnaires on sleep and behavioural problems|Questionnaires on sleep and behavioural problems
45602303|NCT05649514|Procedure|Actimetrics|Measurement of actimetrics for 14 days at inclusion and at 24 months
45602304|NCT05649514|Other|Biomarker assay|Determination of the biomarkers Aβ42, Aβ40, Tau and P-Tau in blood and in the cerebrospinal fluid
45602305|NCT00834431|Drug|Famciclovir 500 mg Tablets|1 x 500 mg, single-dose fasting
45755895|NCT05439161|Device|surgery|2 types of filtering glaucoma surgeries (classic trabeculectomy as gold standard, and newer XEN glaucoma microstent) are compared against each other in a prospective multicentric randomized study
45755896|NCT05595629|Behavioral|App-based remote blood pressure monitoring|Fully synched bluetooth-enabled remote blood pressure monitoring using a smartphone application. The digital health company, Twistle, has modified an existing postpartum hypertension pathway in their app according to our hospital's management algorithm.
45755897|NCT05595629|Behavioral|text-message based remote blood pressure monitoring|Participants will receive automatic blood pressure cuffs and instructions as to how to upload their measurements to the Electronic Medical Record.
45755898|NCT03496844|Diagnostic Test|F-18 fluciclovine-PET/CT scan|PET/CT imaging with F-18 fluciclovine
45755899|NCT01793311|Other|decaffeinated coffee|contains caffeine 0.5-2 mg
45755900|NCT01793311|Other|regular dose coffee|contains 91.8 mg of caffeine
45602306|NCT00834431|Drug|Famvir® 500 mg Tablets|1 x 500 mg, single-dose fasting
45602307|NCT05138900|Radiation|SBRT|SBRT for central non small cell lung cancer
45602308|NCT00917111|Drug|Nasal CO2|Four times a day for 14 days
45602309|NCT00917111|Drug|Inactive Placebo Gas|Placebo
45755901|NCT01793311|Other|high dose coffee|contains 144 mg of caffeine
45755902|NCT05572463|Combination Product|Sintilimab + IBI110|IBI110 infusion in combination with Sintilimab (IBI308) infusion will be given on a Q3W schedule
45755903|NCT02995993|Drug|Moss-aGal (recombinant human alpha-galactosidase A produced in moss)|Single i.v. Infusion of 0.2 mg/kg moss-aGal over 60 minutes
45755904|NCT02996071|Procedure|laparoscopic sleeve gastrectomy|a sleeve gastrectomy operation that is performed laparoscopically.
45755905|NCT02339389|Other|Labor analgesia|Measuring maternal ventilation after placement of epidural analgesia compared to baseline
45755906|NCT02129075|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC or ID
45755907|NCT02129075|Drug|Poly ICLC|Given SC
45755908|NCT02129075|Biological|Recombinant Flt3 Ligand|Given SC
45755909|NCT03662204|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
45755910|NCT02775903|Drug|Azacitidine|Administered by subcutaneous injection on Days 1 to 7 of each 4-week treatment cycle.
45755911|NCT02775903|Biological|Durvalumab|Administered by intravenous infusion on Day 1 of every 4-week treatment cycle.
45755912|NCT04444973|Procedure|Balloon pulmonary angioplasty|Balloon dilatation of sub segmental pulmonary artery web disease
45755913|NCT01679912|Other|phone to the call center|recommendations to phone to the call center for all the patients who have an acute attack
45755914|NCT01782443|Drug|Ziv-aflibercept|
45602310|NCT04875767|Device|HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)|General surgical and anaesthetic risks apply to the subjects included in the trial. Microfracture and BMA are surgical techniques currently being used and are approved for use in Canada. The HA-scaffold that will be used in this trial (Hyalofast®, Anika Therapeutics Inc.) has European CE Mark for use in all joints. We will obtain a Health Canada approval to use the Hyalofast® product in the hip for this trial.
45602311|NCT05191940|Radiation|Particle-therapy using protons or carbon ions|According to the radiation plan (between 25 and a maximum of 40 Gy). Planning Target Volume 1 : 25 Gy (Relative Biological Effectiveness) in 5 fractions of 5 Gy (Relative Biological Effectiveness) Planning Target Volume 2 : A simultaneous integrated boost (SIB) will be delivered to the Planning Target Volume 2: 40 Gy (Relative Biological Effectiveness) in 5 fractions of 8 Gy (Relative Biological Effectiveness).
45602312|NCT05191940|Diagnostic Test|Blood sampling|Evaluation before treatment-start, after treatment and follow-up period.
45602313|NCT05191940|Diagnostic Test|Magnetic resonance imaging|For treatment planning as well as for follow-up radiological tumor assessment.
45602314|NCT05191940|Diagnostic Test|Computertomography|For treatment planning as well as for follow-up radiological tumor assessment.
45602315|NCT05191940|Diagnostic Test|18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)|For treatment planning as well as for follow-up radiological tumor assessment.
45602316|NCT05653115|Procedure|Bariatric surgery|Bariatric surgery
45602317|NCT00834275|Drug|Cefadroxil 500 mg Capsules|1 x 500 mg
45602318|NCT00834275|Drug|DURICEF® capsules 500 mg|1 x 500 mg
45602319|NCT05191472|Biological|Pembrolizumab|Given IV
45602320|NCT00834197|Drug|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose non-fasting
45602321|NCT00834197|Drug|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose non-fasting
45602322|NCT05190692|Device|Use simulators in Obstetrics vaginal examination|"Two simulators will be used in the study:~(1st ) : PROMPT Flex Birthing Simulator Advanced - Light (PRODUCT NO. 80106).UK, 2020 .~2nd): PROMPT Flex Cervical Dilatation & Effacement Module -Light (PRODUCT NO. 80102),Uk,2020.~Both will be used to perform obstetric vaginal examination before examination of patients"
45602323|NCT05224310|Procedure|PECS block, SAP block|performing either PECS block or SAP block
45755915|NCT03573752|Other|outpatient management for promontofixation by laparoscopy|postoperative H8 exit after laparoscopic promontofixation
45602324|NCT00833495|Drug|Prednisolone Acetate 0.12% (Pred Mild®)|Indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary.
45452153|NCT04475068|Procedure|Lateral Position (left and right lateral decubitus)|Prior to initiating the protocol, patients will be sedated deeply with sedatives and opioids and paralyzed. Patients will be evaluated in 5 positions sequentially: 1) Supine 2) Left lateral 3) Supine 4) Right lateral 5) Supine. The side with the least ventilation evaluated by EIT will define which side will start the sequence. Each step will last 30 minutes. Aeration measured by Electric Impedance Tomography (EIT) and lung ultrasound, distribution of the lung ventilation and perfusion measured by EIT, ventilator and hemodynamic parameters, esophageal pressure, and blood gas analysis will be recorded at the end of each step. Continuous monitoring of blood pressure, heart rate and saturation of arterial blood (SpO2) will be carried out during all steps of the protocol to assess the tolerance to the procedure.
45602325|NCT00833495|Drug|FOV1101-00|This investigational drug is a low dose cyclosporine (also known as cyclosporine A; CsA) formulation for topical ocular administration. FOV1101-00 is presented as a solution for topical ophthalmic administration in two strengths, concentration 1 or concentration 2 w/v cyclosporine in citrate buffered aqueous vehicle. Application is intended as four times per day.
45602326|NCT00833495|Drug|Prednisolone Acetate 1% (Pred Forte®)|PRED FORTE® is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary. Care should be taken not to discontinue therapy prematurely.
45602327|NCT00833495|Drug|Placebo|The vehicle is an eye drop that contains only the inactive ingredients of FOV1101-00.
45602328|NCT05223998|Procedure|Full-thickness skin microcolumns implantation|Surgical harvest and implantation of FTSM on an open wound requiring coverage.
45755916|NCT03573752|Other|questionnaire|Each patient will complete a questionnaire on the experience of management, both in terms of pain management, anxiety and overall satisfaction.
45755917|NCT04392791|Other|balneotherapy|Balneotherapy, a medical remedy, with medically and legally recognized mineral waters for therapeutic and rehabilitation purposes
45755918|NCT01679990|Biological|PLX-PAD Low dose|
45602329|NCT00830219|Drug|Ropinirole HCl 0.25 mg Tablets|1 x 0.25 mg, single dose fed
45755919|NCT01679990|Biological|PLX-PAD high doses|
45755920|NCT01679990|Biological|Double Placebo|
45755921|NCT01679990|Biological|high dose +Placebo|
45602330|NCT00830219|Drug|Requip® 0.25 mg Tablets|1 x 0.25 mg, single dose fed
45755922|NCT05461703|Behavioral|Planet Nutrition Program|It is a 6-month school-based obesity prevention program that includes: nutrition education sessions, physical activity and family participation.
45755923|NCT00700063|Drug|PEP005 Topical Gel|0.005%, two days treatment
45755924|NCT00700063|Drug|PEP005 Topical Gel|0.01%, two days treatment
45755925|NCT00700063|Drug|PEP005 Topical Gel|0.015%, two days treatment
45755926|NCT00700063|Drug|Vehicle gel|two days treatment
45755927|NCT00700063|Drug|PEP005 Topical Gel|0.005%, three days treatment
45755928|NCT00700063|Drug|PEP005 Topical Gel|0.01%, three days treatment
45755929|NCT00700063|Drug|PEP005 Topical Gel|0.015%, three days treatment
45755930|NCT00700063|Drug|Vehicle gel|three days treatment
45755931|NCT03568682|Behavioral|Nutritional counseling + urban gardening|Peer nutritional counseling and urban gardens
45755932|NCT05400005|Other|Dietary protein|"Intervention of the study include consuming a higher protein diet. Depending on the group allocation, this is done by asking the subjects to follow My Healthy Plate diet and consumption of 20g of protein isolates (casein or soy)."
45602331|NCT05223062|Other|Disease activity in psoriatic arthritis (DAPSA)|DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level. The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (< 4) and low disease activity (< 14).
45602332|NCT05223062|Other|Compliance-Questionnaire-Rheumatology (CQR)|"The CQR is a self-administered questionnaire that was developed with the aim of correctly identifying patients that were classified as low adherers (taking <80% of their medication correctly). The four point Likert answering scale ranges from; Definitely don't agree (scored 1) to Definitely agree (scored 4) with lower scores indicating lower levels of adherence. Total score is between 0 and 100."
45602333|NCT05223062|Other|The Brief Illness Perception Questionnaire (BIPQ)|The Brief Illness Perception Questionnaire (BIPQ) is a questionnaire that assesses a number of beliefs about illness which are thought to be related to coping and help-seeking behavior. Each item is scored between 0 and 10. Maximum total score is 80. Higher scores represents that the patient has a concerned perception of illness.
45602334|NCT05223062|Other|The Beliefs About Medicines Questionnaire (BMQ)|The Beliefs About Medicines Questionnaire (BMQ) is a tool for evaluating people's beliefs about medicines. The BMQ comprises two sections: the BMQ-Specific which assesses representations of medication prescribed for personal use and the BMQ-General which assesses beliefs about medicines in general. It has a total of 18 questions scored with a 5-point Likert scale. Higher scores represent more powerful beliefs.
45602335|NCT05223062|Other|Hospital Anxiety and Depression Scale (HADS)|Hospital Anxiety and Depression Scale (HADS) determines the levels of anxiety and depression that a person is experiencing. The HADS is a fourteen item scale that generates: Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
45602336|NCT05223062|Other|The Psoriatic Arthritis Quality of Life (PsAQoL)|The Psoriatic Arthritis Quality of Life (PsAQoL) measure is a disease specific patient-reported outcome measure which measures the effect that psoriatic arthritis has on a patient's quality of life. It is a self-administered, 20-item questionnaire that takes about three minutes to complete. The answers are restricted to true or false.A high score on the PsAQoL indicates a lower quality of life. Total score is between 0 and 20.
45602337|NCT05135468|Drug|CU-40102 Spray|topical application, 1~4 sprays each time, once daily
45602338|NCT05221970|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
45602339|NCT05221970|Behavioral|Positive Psychology - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
45602340|NCT05221970|Behavioral|Autogenic Training - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
45602341|NCT05191004|Drug|NUV-422|NUV-422 is an investigational drug for oral dosing.
45602342|NCT05191004|Drug|Fulvestrant|Fulvestrant
45602343|NCT02274766|Drug|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 13 weeks.
45602344|NCT02274766|Other|Placebo|Oral capsules to be administered once nightly at bedtime, for 13 weeks.
45602345|NCT05134922|Drug|Gedatolisib|Gedatolisib is a potent, reversible dual inhibitor that selectively targets phosphoinositide 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in biochemical and cellular assays.
45602346|NCT04757363|Drug|regorafenib|regorafenib (80 mg on days 1-21 of the 28-day cycle)
45602347|NCT04757363|Drug|nivolumab|nivolumab (240 mg on days 1 and 15 of the 28-day cycle).
45602348|NCT04757363|Drug|FOLFOX chemotherapy with oxaliplatin|FOLFOX chemotherapy with oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV), 5-FU (400 mg/m2 IV bolus), and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h).
45602349|NCT00829673|Drug|Dexmethylphenidate Hydrochloride|10 mg Tablet
45602350|NCT00829673|Drug|Dexmethylphenidate Hydrochloride|10 mg Tablet
45602351|NCT05221658|Drug|HLX07+HLX10+ Cisplatin+5-FU|HLX07 1000mg + HLX10 200mg + Cisplatin 50 mg/m2 + 5-FU 2400mg/m2
45602352|NCT05221658|Drug|HLX07|HLX07 1000mg iv Q2w
45602353|NCT03134495|Other|all children with at least one prescription of PPI|all children with at least one prescription of PPI
45602354|NCT03134495|Other|all children with no prescription of PPI|all children with no prescription of PPI
45602355|NCT04875676|Biological|VXA-G1.1-NN|Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with double-stranded RNA Adjuvant
45602356|NCT05133596|Other|Clinical examination|The investigator will conduct a clinical examination to rule out other causes of olfactory impairment independent of COVID-19. The investigator will also collect the following information: socio-demographic data (age, sex, blood type, weight, height, etc.), history of olfaction disorder symptoms, past or current treatments received and tobacco/alcohol consumption.
45602357|NCT05133596|Other|Blood collection|12ml-blood sample
45602358|NCT05133596|Other|Olfactory evoked potentials|Olfactory evoked potentials will be recorded during olfactory tests.
45602359|NCT05133596|Other|Brushing of olfactory slits|collection of olfactory slits cells.
45602360|NCT05133596|Other|Neurological examination and neuropsychological assessment|"MOCA, BREF~CVLT~WAIS IV, MEM III~Right-side and left-side empan, Trail Making Test A and B (TMT), verbal fluency tests, PASAT, Attention Assessment Test~Benton's Line Judgement, VOSP~Assessment of psychological status, fatigue and screening for psychiatric comorbidities: depression & anxiety scales (HAD scale, mADRS depression scale, STAI anxiety scale), Fatigue Severity Scale."
45602361|NCT05133596|Other|Nasal endoscopy|Nasal endoscopy
45602362|NCT05133596|Other|Assessment of olfactory and taste functions|"scales: VAS and TSS~Sniffin Stick test"
45755933|NCT03904173|Diagnostic Test|Multi-parameter tests|Prosigna Breast Cancer Prognostic Gene Signature Assay (PAM50) risk of recurrence (ROR) analysis CE marked assay termed Prosigna™ using digital bar code technology (NanoString Technologies Inc.).
45755934|NCT03568292|Other|Best Practice|Receive standard of care
45755935|NCT03568292|Other|Laboratory Biomarker Analysis|Correlative studies
45602363|NCT05375591|Other|Non-Interventional Study|First nodule detection CT scans as per eligibility criteria will be used as input into in-house software to extract multiple radiomic features and used to develop a machine learning based classifier to differentiate nodule aetiology. Scans will also be used as input in to a deep learning/convolutional neural network models to perform automated imaging classification.
45602364|NCT05189366|Behavioral|Sophrology|"Sophrology is a relaxation method that's sometimes referred to as hypnosis, psychotherapy, or a complementary therapy.~Sophrology uses techniques such as: hypnosis, visualization, meditation, mindfulness, breathing exercises, gentle movements, body awareness...~Sophrology techniques may be useful during medical procedures that cause stress and discomfort.~Sophrology techniques may be useful during medical procedures that cause stress and discomfort.~Patients will receive 6 sessions of sophrology"
45602365|NCT05189366|Behavioral|Speech therapy|Speech therapy is a treatment that can help improve communication skills. patients will benefit from two speech therapy sessions per week for 6 months, lasting from 30 minutes to 1 hour depending on the patient's general condition.
45602366|NCT05189288|Drug|D418 Tab.|1T
45602367|NCT05189288|Drug|CKD-388 Tab.|1T
45602368|NCT05220254|Behavioral|MindCotine's VR app|The MindCotine program would be a 6-week intervention to help users utilize mindfulness based skills, and involves virtual exposure therapy.
45602369|NCT05188196|Procedure|alveolar ridge preservation|Alveolar ridge preservation and augmentation commonly are performed immediately after tooth extraction to preserve or increase ridge volume within or beyond the skeletal envelope that exists at the time of extraction.
45602370|NCT05132114|Diagnostic Test|Lugol's iodine test|Intraoperative application of Lugol's iodine (i.e. staining of the cervix with Lugol's iodine solution)
45755936|NCT03568292|Device|Oculus Rift Headset|Subject wears headset for virtual reality intervention during bone marrow biopsy or lumbar puncture procedure
45755937|NCT03568292|Other|Questionnaire Administration|Ancillary studies
45444571|NCT01303809|Other|Enhanced Recovery After Surgey for Sleeve Gastrectomy|"Intraoperative:~Pre-op carbohydrate loading~No pre-op GIK while NBM~Pre-medication~Dexamethasone 4mg as antiemetic, IV Paracetamol (first dose) Parecoxib 40mg~Ondansetron regularly for first 48 hours and Cyclizine, Droperidol or Scopaderm as rescue antiemetics~Fluid restriction~Standardised method of anaesthesia~Give 40ml 0.5% bupivacaine with adrenaline administered prior to placement of laparoscopic port sites~10ml 0.75% ropivacaine diluted to 50ml with 0.9% normal saline solution administered to surgical site prior to procedure~Postoperative:~Rescue PCA for up to 12 hours. Oxynorm 5mg for rescue pain. Oxycontin 20mg bd/prn postoperatively~Maintenance IV fluids (60ml/hr plasmalyte to be stopped 0800 day 1 post op). Clear oral fluids 2 hours post op. Bariatric free oral fluids morning of day 1~Post operative oxygenation~Incentive spirometry~Drains (e.g. IDC) removed in recovery~Full mobilisation 4-8 hours post op)~Early Follow up"
45444572|NCT03666442|Drug|XELOX|Xelox chemotherapy,that oxaliplatin 130mg/m2 d1,capecitabine 1000mg/m2 twice daily d1-14,every 3 weeks
45444573|NCT05081271|Biological|Homologous booster|Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa
45444574|NCT05081271|Biological|Heterologous booster|Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa
45444575|NCT02050126|Device|Lumenis UltraPulse Encore.|Treatment using Lumenis UltraPulse Encore.
45602371|NCT05219474|Diagnostic Test|Cochlear implant Computer Model Implementation|"The computer model will use standard Cochlear Implant settings to evaluate psychophysical and speech understanding abilities and sound quality with standard CI settings and then use these measures to build subject-specific models and determine experimental active electrode conditions to be tested: model-optimized, and two best-electrodes settings (2 types); 3) evaluate speech understanding and sound quality measures after using experimental settings regularly for 1.5 months; and 4) compare performance across experimental and clinical conditions.~The analysis will include four levels of repeated measures with active CI electrode conditions. These levels include the clinical baseline condition (all available electrodes active) and three experimental conditions (model-optimized, best-electrodes, and restricted best-electrodes)."
45602372|NCT05131100|Drug|Somavert|As provided in real world practice
45602373|NCT05187104|Biological|Cultured retinal stem and progenitor cells|Cultured retinal stem and progenitor cells injected subretinally
45602374|NCT05187104|Other|Standard treatment according to the clinical protocols|Standard treatment of age-related macular degeneration according to the clinical protocols
45602375|NCT02370238|Drug|paclitaxel|paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15)
45602376|NCT02370238|Drug|Reparixin|reparixin oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
45755938|NCT04343495|Device|Wearable Ultra Violet (UV) and blue-light sensors|Non-blinded
45755939|NCT01933425|Drug|rocuronium|
45755940|NCT01933425|Drug|sugammadex|
45755941|NCT01933425|Drug|placebo|
45452154|NCT02235922|Other|Dual task training|The dual task training consisted of individuals subjected to a multicomponent exercise program associated to cognitive tasks.
45452155|NCT02235922|Other|Conventional training|The conventional training consisted of individuals subjected to a multicomponent exercise program.
45452156|NCT02236078|Drug|High dose isoniazid|See arm description
45452157|NCT01198834|Drug|MRX-7EAT|Application of up to two patches at the discretion of the investigator for up to 7 days.
45452158|NCT01198834|Drug|Placebo|Application of up to two patches at the discretion of the investigator for up to 7 days.
45452159|NCT01198834|Drug|Lidocaine|Application of up to two patches at the discretion of the investigator for up to 7 days.
45755942|NCT04239599|Radiation|Hypofractionated IMRT Radiation treatment|
45755943|NCT00594061|Device|Iowa/Nucleus 10/10 mm and Freedom Cochlear Implantation|Participants will receive one standard Nucleus Freedom electrode array and an Iowa/Nucleus 10/10 mm electrode array on the contralateral side.
45602377|NCT02370238|Drug|placebo|placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
45602378|NCT05186012|Drug|APG-1252|APG-1252 administered via intravenous infusion for 30 minutes weekly (Day 1, 8, 15, 22).Every 28 days as a cycle.
45602379|NCT05186012|Drug|Chidamide|Chidamide 30mg orally BIW. Every 28 days as a cycle.
45602380|NCT05130164|Radiation|CBCT|Cone beam computed tomographic images selected for age estimation
45602381|NCT05129696|Behavioral|Treatment (T)|Children area offered to participate in bimonthly group sessions. Each session will have materials and activities appropriate for children spanning a 6-month range (6-12 m, 12-18 m, 12-24 m, 24-30 m) and can accommodate a maximum of 10 children per age group. If more households are interested than can be accommodated by the program, interested families will be randomly selected for participation. A total of 40 children per site will be able to participate in the ECD activities at any one time. With bi-monthly meetings, each child will be exposed to 12 sessions for each age group, and is eligible to transition to the next.
45602382|NCT05129696|Behavioral|Treatment + (T+)|Caregivers/children participating to the group ECD sessions will be invited to play within a play space equipped with books, and homemade/purchased age-appropriate toys. This will be phased in after 6 months of implementation.
45602383|NCT05129384|Dietary Supplement|B. infantis EVC001 or Lactose Placebo|Infant probiotic
45602384|NCT05109104|Drug|CAP UnScented|Sunscreen lip balm.
45602385|NCT05109104|Drug|CAP Herbal Mint Flavour|Sunscreen lip balm.
45602386|NCT05109104|Drug|CAP Mountain Berry Flavour|Sunscreen lip balm.
45602387|NCT05109104|Drug|SPF Standard Sunscreen|SPF Standard (7 percent [%] Padimate-O and 3% Oxybenzone)
45602388|NCT05108870|Drug|HB-201|A anti-cancer vaccine that treats HPV-related cancers.
45602389|NCT05108870|Drug|HB-202|A anti-cancer vaccine that treats HPV-related cancers.
45602390|NCT05108870|Drug|Carboplatin|Chemotherapy drug.
45755944|NCT05327543|Behavioral|Iyengar Yoga|Iyengar Yoga focuses on the correct alignment of the body while practicing the physical exercises of yoga. Props are used to support the body in finding the right alignment. Relaxation is also part of this intervention. Participiants receive 1x90 min guided yoga class per week for 8 weeks and are encouraged to continue their practice at home daily for at least 30 minutes.
45602391|NCT05108870|Drug|Paclitaxel|Chemotherapy drug.
45602392|NCT05108870|Procedure|Transoral Robotic Surgery|Transoral robotic surgery is a procedure to remove mouth and throat cancers in which a surgeon uses a sophisticated, computer-enhanced system to guide the surgical tools.
45755945|NCT05327543|Behavioral|Meditative Yoga|Meditative Yoga in the context of this study means practicing the physical exercises of yoga as well as meditation. Additionally, each week one of the yamas/niyamas, which are ethical principles to live by in the Yoga philosophy, will be presented at the beginning of each class and will form the theme of the class. Participants receive 1x90 min guided yoga class per week for 8 weeks and are encouraged to continue their practice at home daily for at least 30 minutes.
45755946|NCT02996149|Procedure|Endoscopic lung volume reduction coil treatment|
45755947|NCT03565172|Diagnostic Test|isokinetic dynamometer with ultrasound|children are lying prone on a isokinetic dynamometer with ultrasound which stretches spastic and paretic plantarflexors muscles very slowly until maximal torque tolerated. The parameters can be measured.
45602393|NCT05108636|Other|Therapeutic Touch|Therapeutic touch; It is a low-cost, non-contra-indications, easy-to-apply and non-invasive form of complementary therapy that can be applied anywhere and at any time (Vanaki et al., 2016). Therapeutic touch was developed by Krieger in 1975 as a nursing intervention to help and even heal the patient by balancing the patient's energy field (Marta et al., 2010). The basic assumption of therapeutic touch is that people have energy fields and these energy fields interact with the environment (Hanley, 2008). Therapeutic touch aims to harmonize, renew and heal the flow of the human energy field by removing the blockages of a person's biofield (Mueller et al., 2019). Unlike other touch-based methods such as massage therapy, therapeutic touch does not require the practitioner to physically touch the patient. Instead, the practitioner uses their hands to focus their energy and intent to help the recipient (Hanley, 2008).
45602394|NCT05108636|Other|Music Rest|The use of music in the treatment of diseases has been seen in many civilizations since ancient times. In ancient Greek and Roman communities, individuals resorted to music to get rid of their humanitarian problems, while in Ancient Egypt, music was used to give strength to patients during birth (Kor & Adar, 2016). In today's studies, it has been determined that music positively affects the physiological parameters, nutrition, hospital stay and sleep of the patients (O'Toole et al., 2017; Van Der Heijden et al., 2016). It is important that the sound level is within the appropriate limits while listening to music to the patients. The American Academy of Pediatrics recommends a sound level between 45dB- a maximum of 65dB (ACOG - AAP, 2012). The World Health Organization recommends a sound level of 35 dB during the day and 30 dB at night (Berglund et al., 2000).
45602395|NCT05128604|Device|Gastroenterostomy|Endoscopic ultrasound guided gastroenterostomy
45602396|NCT04421612|Behavioral|Co-mestring (co-coping)|8 modules with the aim to reduce stress, increase coping of social isolation and coping with the consequences of reduced positive experiences
45602397|NCT02370160|Biological|DT2219ARL|DT2219ARL at assigned dose IV on day 1, 3, 5, 8 and day 15, 17, 19, and 22. Up to 2 additional courses of DT2219ARL may be given until disease progression and/or unacceptable toxicity.
45755948|NCT03565172|Other|Visual Analog Scale (VAS)|the discomfort level will be measured by Visual Analog Scale (VAS) completed by children. 0 = no discomfort and 10 = maximum discomfort
45452160|NCT01198834|Drug|Etodolac|Application of up to two patches at the discretion of the investigator for up to 7 days.
45452161|NCT01193140|Drug|veliparib|Dose orally twice daily for 7 days, consecutively, every cycle
45452162|NCT01193140|Drug|Temozolomide|Dose orally once daily for 5 days, consecutively, every cycle
45452163|NCT04474522|Genetic|Non-invasive Preimplantation genetic testing for aneuploidy status|In the intervention group, comprehensive chromosome screening using NGS will be performed according to the recommendations of the company in all SCM samples. Sequence of replacement shall be altered by the NiPGT result after morpholgy.
45452164|NCT04474756|Device|custom-made adjustable mandibular advancement device|a custom-made mandibular repositioning device (MRD), available under medical prescription for the treatment of adult obstructive sleep apnea (OSA) and snoring. It maintains the mandible in an advanced position along the occlusal plane. This ensures patient comfort and treatment efficacy.
45602398|NCT05126342|Drug|Niraparib|Niraparib starting dose of study treatment will be based upon the patient's baseline body weight and baseline platelet count. Patients with a baseline body weight ≥77 kg and baseline platelet count ≥150 x 10^9/L may start with niraparib 300 mg (3 x 100 mg capsules) daily unless the dose has not already been reduced to 200 mg in a prior treatment line. Patients with a baseline body weight <77 kg or a baseline platelet count <150 x 10^9/L will be administered niraparib 200 mg (2 x 100 mg capsules) daily.
45602399|NCT05126342|Drug|Dostarlimab|Dostarlimab (TSR-042) is administered 500 mg iv Q3W for the first 12 weeks. For the remainder of the study dostarlimab (TSR-042) is administered 1000 mg iv Q6W.
45602400|NCT05126108|Procedure|Thyroid and parathyroid surgery|Thyroid and parathyroid surgery
45602401|NCT05126108|Other|Recurrent nerves monitoring|Recurrent nerves monitoring
45602402|NCT05183516|Biological|tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|Tdap is a combination vaccine that protects against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).
45602403|NCT02273908|Other|No intervention|The study is observational
45602404|NCT05102708|Other|Prognostic factors of severe COVID-19|prognostic factors: patients´ epidemiological characteristics (such as age, sex), comorbidities, length of hospitalization, critical care admission, treatments received, laboratory results, vital signs.
45602405|NCT05473910|Drug|SOC + TSC-100|HA-1 positive
45602406|NCT05473910|Drug|SOC + TSC-101|HA-2 positive or HA-1 negative
45755949|NCT03565172|Diagnostic Test|Stretching|the ankle of children will be mobilized for 5 minutes (first two weeks) to 10 minutes (last two weeks).
45602407|NCT05473910|Other|Control|SOC alone
45602408|NCT05180708|Drug|QTORIN 3.9% rapamycin anhydrous gel|QTORIN 3.9% rapamycin anhydrous gel
45755950|NCT01795417|Device|RF XP200|Four weekly non-invasive periorbital wrinkles treatment with RF XP200 device
45602409|NCT05180708|Drug|Vehicle|Matching vehicle (QTORIN anyhydrous gel)
45602410|NCT02273752|Drug|Everolimus|Given PO
45602411|NCT05180630|Device|Audeo P90 hearing aid with custom earmolds using dynamic venting|Audeo P90 hearing aids coupled to custom earmolds that use dynamic venting.
45602412|NCT05180630|Device|Audeo P90 hearing aid with Open domes|Audeo P90 hearing aid coupled with non-custom, manufacturer open domes
45602413|NCT05180630|Device|Audeo P90 hearing aid with Vented domes|Audeo P90 hearing aid coupled with non-custom, manufacturer vented domes
45602414|NCT05180084|Behavioral|Cognitive behavior therapy|Internet-based CBT intervention based on CBT theory, self-determination theory and self-compassion therapy for low self-esteem among young adults.
45602415|NCT05179538|Behavioral|Cued picture-naming therapy|The proposed study will administer Cued Picture-Naming Treatment (CPNT) four days per week for four weeks (i.e. 16 sessions). During therapy, participants will attempt to name eight consecutive presentations of the same black and white picture, for each of the 20 pictures, with cueing from the administrator. Trials will include (1) independent naming, (2) orthographic cueing (i.e. the written word beneath the picture.), (3) repeating, (4) naming after a short delay (i.e. approximately three seconds), (5)semantic cueing (i.e. three cues providing semantic information about the target will be spoken to the participant by the clinician), (6) phonological cueing (i.e. the first sound and letter will be spoken by the clinician), (7) repeating, and (8) naming after a short delay. The administrator will provide the correct response for each incorrect participant response and will ask the participant to repeat it.
45602416|NCT02273596|Drug|ALXN1840|Individualized oral doses of ALXN1840.
45602417|NCT05124236|Radiation|preoperative radiosurgery|single fraction radiosurgery
45602418|NCT05124236|Radiation|postoperative hypofractionated stereotactic radiotherapy|5 fraction stereotactic radiotherapy /fractionated radiosurgery
45602419|NCT01656200|Biological|Live attenuated Japanese encephalitis vaccine SA14-14-2|Live attenuated Japanese encephalitis vaccine SA14-14-2
45755951|NCT01795417|Device|XP200 RF device|4 RF treatments of periorbital region on one side of the face
45755952|NCT05322317|Other|ADVANCE-PC training via ECHO|To assess the feasibility of using a technology-based platform to deliver the ADVANCE-PC program to multiple primary care clinics. This model will be based on the ECHO program, a tele-mentoring program which uses communications technology to provide facilitated education, case review, and peer-to-peer problem solving remotely. Our working hypothesis is that the use of ECHO will be efficient (allowing several clinicians and teams to be supported simultaneously while creating a community of practice), feasible (that clinicians will enroll and share experiences via mentoring, guidance, feedback, and didactic education), and have the potential to impact patients as clinicians perceptions shift to favor ACP, their skills increase, and they are able to integrate ACP for patients with dementia into their clinic.
45755953|NCT02723019|Behavioral|Volunteer Peer Mentor+Behavioral Health Nurse|Intervention group participants receive intervention services from a Volunteer Peer Mentor and a Behavioral Health Nurse
45755954|NCT03487016|Drug|Gemcitabine|Arm A
45755955|NCT03487016|Drug|Nab-paclitaxel|Arm A
45755956|NCT03487016|Drug|5-FU|Arm B Arm C
45755957|NCT03487016|Drug|Irinotecan Liposomal Injection|Arm B Arm C
45755958|NCT03487016|Drug|Oxaliplatin|Arm C
45755959|NCT02622295|Behavioral|Single-session electrically induced exercise|A single session of electrically induced exercise to the quadriceps and hamstring muscle groups of people with paralysis.
45755960|NCT02622295|Behavioral|Electrically-induced exercise training|Multiple sessions of electrically induced exercise to the quadriceps and hamstring muscle groups for up to 3 years in people with paralysis.
45755961|NCT01677806|Procedure|Percutaneous vertebroplasty|Percutaneous vertebroplasty Placement of PMMA into vertebral compression fracture
45755962|NCT01677806|Other|Conservative therapy|Conservative therapy mainly consists of optimal pain medication. Pain management is titrated according to patients' needs, including analgesia, bed rest, and physical support (bracing).
45755963|NCT02335671|Procedure|Intra-operative Magnetic Resonance Imaging (MRI)|
45602420|NCT05102552|Drug|SPN-817, Treatment B|SPN-817 Treatment B, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
45602421|NCT05102552|Drug|SPN-817, Treatment C|SPN-817 Treatment C, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
45602422|NCT05102552|Drug|BIS-001, Treatment A|BIS-001 is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
45602423|NCT05101616|Drug|camrelizumab+chemotherapy|camrelizumab 200mg，ivdrip，q3w； albumin nanoparticle of paclitaxel 260 mg/m2、 ivdrip，d1，q3w； oxaliplatine 85mg/m2、ivdrip，d1，q3w； S-1 40 mg/m2，po, bid，d1~d14，q3w. 3 cycles.
45602424|NCT05101616|Drug|Chemotherapy|albumin nanoparticle of paclitaxel 260 mg/m2、 ivdrip，d1，q3w； oxaliplatine 85mg/m2、ivdrip，d1，q3w； S-1 40 mg/m2，po, bid，d1~d14，q3w. 3 cycles.
45602425|NCT05096390|Drug|Axitinib Oral Tablet [Inlyta]|Axitinib 5 up to 10mg twice a day
45602426|NCT05096390|Drug|Pembrolizumab Injection [Keytruda]|Pembrolizumab intravenously over 30 min minutes at 200 mg every 3 weeks
45602427|NCT02369848|Device|Shockwave Lithoplasty System|
45602428|NCT05649202|Other|Xpert® HCV Viral test|an additional sample of 5 ml of blood will be taken for real-time HCV PCR by Xpert®, in addition to the blood samples taken as part of routine care.
45602429|NCT05649202|Other|FibroScan® test|A non invasive test made on a small area of skin coated with a gel
45602430|NCT05118074|Diagnostic Test|Creatinine, eGFR|Compare diagnostic tests to reference methods
45602431|NCT05116982|Dietary Supplement|ORGONO Living Silica Acacia Gum-MMST Powder|Participants will consume one capsule per day and one bottle per day. Capsule composition: Acacia Gum 336.1 mg/capsule; Monomethylsilanetriol 34.9 mg/capsule; Hydroxypropyl methylcellulose 95 mg/capsule. Bottle composition: water 100 ml. Silicon content per dose: 10.4 mg.
45602432|NCT05116982|Dietary Supplement|ORGONO Living Silica Malto-OSA Powder|Participants will consume one capsule per day and one bottle per day. Capsule composition: Maltodextrin 311.4 mg/capsule; Silicic acid 35.6 mg/capsule; Hydroxypropyl methylcellulose 95 mg/capsule. Bottle composition: water 100 ml. Silicon content per dose: 10.4 mg.
45755964|NCT02335671|Other|Mass Spectrometer Analysis of Tissue Sample|Analysis of Tissue Sample
45755965|NCT04148807|Behavioral|Progressive Walking with Gait Retraining|A progressive walking program with gait retraining will be performed on a treadmill at self-selected comfortable walking speed wearing an inertial measurement unit (IMU) on the medial aspect of the distal tibia. The (vertical) peak positive acceleration (PPA) of the tibia is a measure of tibial shock. Subjects will be provided real-time audio feedback to reduce PPA by 20% of their average peak PPA. During retraining sessions, a faded feedback approach will be used. Feedback will be provided continuously during the first four sessions and will be faded over the last 4 sessions. Walking time will increase over the 8 sessions.
45755966|NCT04148807|Behavioral|Progressive Walking Program|A progressive walking program will also be performed on a treadmill where subjects will walk at a self-selected comfortable speed with the same walking times per session as the retraining group without any feedback or retraining cues.
45755967|NCT05346926|Device|3D-printed cast|The 3D-printed casts are produced using 3D print technology based on software by Belgian software company: The patient's forearm is scanned with a tablet (duration: approx. 5 min), whereupon the cast is printed overnight according to the scan (duration: approx. 4h) and adjusted to the patient during the next appointment.
45755968|NCT05346926|Device|Conventional cast|A conventional plaster cast is applied for treatment of the distal radius fracture.
45755969|NCT01936389|Drug|AR-12286|
45755970|NCT05292209|Drug|Riluzole 50 MG|Riluzole 50mg tablets
45602433|NCT05116982|Dietary Supplement|ORGONO Living Silica Collagen Booster|Participants will consume one capsule per day and one bottle per day. Capsule composition: Hydroxypropyl methylcellulose 320 mg/capsule. Bottle composition: water 99.9646 g/100 ml; Silicic acid 23.65 mg/100 ml; Monomethylsilanetriol 11.75 mg/100 ml. Silicon content per dose: 10.4 mg.
45602434|NCT05116982|Dietary Supplement|Placebo|Participants will consume one capsule per day and one bottle per day. Capsule composition: Hydroxypropyl methylcellulose 320 mg/capsule. Bottle composition: water 100 ml.
45602435|NCT02368210|Drug|122-0551 Foam|Topical Foam
45602436|NCT02368210|Drug|Vehicle Foam|Topical Foam
45602437|NCT05114018|Dietary Supplement|Pasteurized A. muciniphila|Daily oral dose
45602438|NCT05114018|Dietary Supplement|placebo|Placebo = identical to verum regarding the form, size, taste, color and intake
45755971|NCT03023319|Drug|Bosutinib|100mg daily for 4 cycles (21 days per cycle)
45755972|NCT03023319|Drug|Pemetrexed|500 mg/m2 every 21 days for 4 cycles
45755973|NCT01679522|Procedure|single-port laparoscopic surgical staging|single-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
45755974|NCT01679522|Procedure|Four-port laparoscopic surgical staging|Four-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
45755975|NCT02980653|Drug|Megestrol acetate (MA) 400 mg/day|Megestrol acetate (MA) will be given on 400 mg/day as eligible patient begin CCRT. Total treatment period is for a maximum of 12 weeks calculated from the date of first dose.
45755976|NCT03560648|Device|High definition surface electromyography combined with accelerometer|HD-sEMG and accelerometer data will be collected by Mobita 32® (TMSi) device.
45602439|NCT05178524|Drug|BIFICO|Live combined Bifidobacterium, Lactobacillus and Enterococcus Capsules
45602440|NCT05177978|Dietary Supplement|Phosphatidylserine|Phosphatidylserine containing supplement (2 x chewable gummies/day; Total daily dose of 100 mg elemental phosphatidylserine)
45602441|NCT05177978|Dietary Supplement|Placebo|Placebo comparator (2 x chewable gummies/day, matched to shape and color without active ingredient)
45755977|NCT05265065|Biological|Tozinameran - Standard Dose|"Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 30 µg in 0.3 ml. Liquid for injection. Single dose."
45602442|NCT02273050|Drug|Saxagliptin 5 mg|Tablet, Oral, 5 mg, Once daily in the morning
45602443|NCT02273050|Drug|Placebo 5 mg for Saxagliptin|Tablet, Oral, 5 mg, Once daily in the morning
45602444|NCT02273050|Drug|Placebo 500 mg for metformin (with titration)|Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
45602445|NCT02273050|Drug|Metformin 500 mg with titration|Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
45755978|NCT05265065|Biological|Tozinameran - Fractional Dose|"Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 15 µg in 0.15 ml. Liquid for injection. Single dose."
45602446|NCT05175248|Behavioral|Plant-based Intervention Group|Participants in the intervention group will be instructed in ways to adopt a plant-based diet, use appropriate methods of food preparation, and make meals enjoyable and appetizing. The plant-based diet primarily emphasizes whole grains, vegetables, beans and legumes, and fruits. Animal products and added oils will be proscribed and the use of ultra-processed foods, sugar, and sugar-sweetened beverages will be discouraged. Fat intake will be limited to 20-30 g/day.
45602447|NCT05173922|Behavioral|Safety in Dementia|Safety in Dementia is an online tool that, in a stepwise fashion, guides a caregiver individual through decisions related to firearm access for a person with dementia. It includes information and a comparison of the options and their risks and benefits. It guides the caregiver through clarification of personal feelings and values and identifying their decision/plan. The control group will view national Institute on Aging Home Safety Checklist.
45755979|NCT03559634|Diagnostic Test|Intervention Group|The electronic application will collect screening health information and contraceptive preferences about the participant. Then, using branch logic, decide which contraceptive options the participant would qualify for based on health history answers. Contraceptive choices being offered include the contraceptive implant, injection, pill, patch, or ring. They will then be able to watch videos about methods they are eligible for. The participant can then decide if they would like to start a medication they qualify for in the ED.
45602448|NCT02272816|Drug|Carboplatin AUC-10|Carboplatin AUC-10 according to the Calvert formula [10 x (glomerular filtration rate (ml/min) + 25)]mg given in 5% glucose over 1 hour every 21 days for 3 or 4 cycles.
45755980|NCT03559634|Other|Control Group|The electronic application will collect screening health information and contraceptive preferences about the participant. Then, using branch logic, decide which contraceptive options the participant would qualify for based on health history answers. This includes the contraceptive implant, injection, pill, patch, or ring. They will then be able to watch videos about methods they are eligible for. Participants will then be given follow up information on outpatient locations where they can receive these contraceptive methods.
45755981|NCT01936467|Device|Standard technique EUS-FNA|Standard suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with use of 10cc suction syringe.
45755982|NCT01936467|Device|Capillary suction technique for EUS FNA|Capillary suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously
45755983|NCT02995759|Other|Seizure Action Plan|The action plan will be electronically formatted in the EMR. After electronic creation, the primary neurologist and patient/caregiver will create a patient-specific plan.
45755984|NCT01677338|Drug|13C-uracil|PO, the Semi-solid Test Meal containing 100 mg of 13C-uracil . Perform the Breath Test.
45755985|NCT01677338|Drug|99mTc sulfur colloid|PO, the Solid Test Meal containing 500 uCi 99mTc sulfur colloid. Perform the Scintigraphy.
45755986|NCT02995447|Other|differences between surface and intracerebral EEG|No intervention is performed. Im- and explantation of intracerebral electrodes is performed for clinical and not for study purposes. The only difference between study and non-study patients is that the surface as well as the intracerebral EEG is recorded and stored in the former, while it is discarded in the latter.
45755987|NCT03557216|Diagnostic Test|Colonoscopy|Anal introduction of a long, flexible, tubular instrument about 1/2-inch in diameter that transmits an image of the lining of the colon so the doctor can examine it for any abnormalities
45755988|NCT03557216|Diagnostic Test|Fecal immunochemical and occult blood test|A test for fecal occult blood looks for blood in your feces. It can be a sign of a problem in the digestive system, such as a polyp or cancer in the colon.
45602449|NCT05173610|Radiation|Radiation: Stereotactic body radiotherapy (SBRT)|"Patients will be treated with stereotactic body radiotherapy (SBRT) for oligometastasis from hepatocellular carcinoma.~Target delineation The GTV is set using diagnostic CT, MRI, PET-CT, etc. CTV is delineated including the microscopic range in GTV and internal margin using 4D-CT. The PTV is expanded by considering the uncertainty of the daily patient posture setting and placement.~Radiotherapy All patients are treated using 3D-CRT, IMRT, or VMAT. Total dose and fractionations will be determined depending on the location and character of the metastasized tumor. Detailed radiation prescriptions is summarized in the following paragraph.~i. Liver: 48-60 Gy in 4 fractions ii. Lung: 45-60 Gy in 3-4 fractions iii. Brain: 27-30 Gy in 3-5 fractions iv. bone: 24-40 Gy in 3-5 fractions v. adrenal gland: 30-60 Gy in 3-8 fractions vi. other organ: depending on the clinicians' decision"
45755989|NCT03557216|Diagnostic Test|Fecal calprotectin test|Calprotectin is a protein released by neutrophils. When there is inflammation in the colon, neutrophils move to the area and release calprotectin, resulting in an increased level in the stool. This test measures the level of calprotectin in stool as a way to detect inflammation and lesions in the colon.
45755990|NCT03088280|Drug|Thymoglobulin|reduced dose (3mg/Kg)
45755991|NCT03087968|Drug|GS-4997|Experimental drug
45755992|NCT03087968|Drug|Prednisolone|Control drug that is also administered with the Experimental drug, GS-4997. This drug is used in both arms.
45755993|NCT03087968|Device|HepQuant SHUNT Test|"The HepQuant SHUNT Liver Diagnostic Kit is intended for use in the quantitative detection of 13C-cholate and d4-cholate in blood serum, collected after the intravenous administration of 13C-cholate and the oral ingestion of d4-cholate. The device is indicated to assess the severity of liver disease.~For use by health care professionals. Administer the test under a physician's supervision. The HepQuant Analytical Testing Laboratory must analyze the serum samples."
45755994|NCT03087968|Drug|Placebo|Placebo
45602450|NCT05113238|Procedure|Assisted gamete activation|compare two different assisted gamete activation protocols to improve ICSI outcome
45602451|NCT04869436|Drug|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Dupilumab will be administered subcutaneously for 6 months (1 initial 600mg dose + 5 300mg doses every 4 weeks)
45602452|NCT05094284|Device|BioFreedom Ultra|this is a registry only
45602453|NCT04421846|Other|Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)|Collection of biological samples and clinical/paraclinical data
45602454|NCT02271880|Other|Medication as usual|Physicians will prescribe medication as usual to the adolescent.
45602455|NCT02271880|Other|STAR|Adolescents and their parents will receive 6 sessions of psychosocial treatment to improve adolescents' motivation to use medication and to develop parent/teen contracting with the goal of setting medication adherence goals.
45755995|NCT05241743|Other|radiological examination, pain, nomophobia, phone addiction|120 patients who applied to the clinic with the complaint of neck pain and were diagnosed with cervical hypolordosis by radiological examination will be included in the study. After giving the necessary verbal and written information about the study, a link will be sent to the phones of the patients whose informed consent was obtained. Patients will access evaluation questions and survey questions via this link. Personal information with the Sociodemographic Data Form prepared by us; pain severity by Visual Analogue Scale (VAS); phone addiction level with the Smartphone Addiction Questionnaire (Young Population); nomophobia levels will be evaluated with the Nomophobia Scale.
45602456|NCT05171894|Drug|Hemopfin+PDF|All qualified subjects randomized to treatment will receive green light therapy with 5 mg/kg Hemoporfin. Subjects in both treatment groups will enroll into three LED light doses sequentially, beginning with the lowest fluence. All subjects in the control group will receive vehicle PDT for the first treatment followed by active drug, Hemoporfin, during the second and third cycles of treatment.
45602457|NCT05171894|Drug|Vehicle+PDF|All qualified subjects randomized to treatment will receive green light therapy with Vehicle (Saline). Subjects in both treatment groups will enroll into three LED light doses sequentially, beginning with the lowest fluence. All subjects in the control group will receive vehicle PDT for the first treatment followed by active drug, Hemoporfin, during the second and third cycles of treatment.
45602458|NCT05170256|Drug|Trastuzumab|Addition of trastuzumab to standard treatment (fluoropyrimidine/platinum doublet with pembrolizumab)
45602459|NCT05386979|Procedure|Opioid free anesthesia technology|We have adopted a variety of methods to replace the use of opioids in the process of balanced anesthesia.
45755996|NCT03845049|Other|Inclusion examinations|Pregnancy test, Visual acuity, ocular pressure, color retinophotography, OCT-SD (the Heidelberg SDOCT Spectralis, or the Cirrus HD-OCT, model 5000, Zeiss), OCT-angiography and fluorescein angiography and wide-field angiogram
45755997|NCT03845049|Drug|Aflibercept Injection [Eylea]|Intravitreal injection of aflibercept at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
45602460|NCT05111600|Drug|Transplantation|Implantation of autologous cultured grafts containing genetically modified stem cells for restoration of functional skin on pre-selected areas
45602461|NCT02367352|Drug|Alisertib|Alisertib tablets
45755998|NCT03845049|Drug|SHAM injection|Intravitreal injection of SHAM at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
45755999|NCT03845049|Other|Examinations during study (every month)|visual acuity, ocular pressure, OCT-SD, OCT-angiography and ocular fundus and a pregnancy test at M6
45756000|NCT05252819|Diagnostic Test|Magnetic Resonance Imaging and an optional blood test|One whole-Body MRI that takes approximately 35minutes One blood test, which it is an optional component at this stage
45756001|NCT00594997|Behavioral|Education|Students receive an educational intervention delivered by a member of our staff in conjunction with the teacher as well as a health education entertainer
45602462|NCT02367352|Drug|Paclitaxel|Paclitaxel intravenous solution
45602463|NCT05091476|Device|OPTiC System|OPTiC System procedure
45602464|NCT05468216|Other|MovIn-Lessons group|The MovIn-Lessons intervention will consist of infusing PA in math, English and natural sciences lessons in primary education. The movement will be integrated in the learning activities for at least 20 minutes per session, at different physical intensities.
45602465|NCT02365636|Drug|TV-45070|TV-45070 is an ointment applied topically twice daily to area of pain.
45602466|NCT02365636|Drug|Placebo|The matching placebo ointment contained only the excipients of the active treatment; also applied topically twice daily to area of pain.
45602467|NCT05168774|Drug|Elamipretide|Elamipretide is a tetra peptide with limited blood brain barrier penetration being developed for use in a variety of mitochondrial disorders, including FRDA, mitochondrial myopathy and Barth Syndrome.
45602468|NCT01655498|Device|vaginal bowel control system (LivSure)|
45602469|NCT04998266|Other|Performing following WHO (World Health Organization)|The CLA group will perform exercises following WHO (World Health Organization) prescription
45602470|NCT04998266|Other|Performing on their needs|The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
45602471|NCT04875520|Other|Screening testing strategy|The intervention we are evaluating is the use of weekly screening testing among students and staff.
45602472|NCT04875520|Other|No screening testing strategy|a group of schools will not receive screening testing.
45602473|NCT04998188|Procedure|Collagen|Patients will be treated with a single injection of collagen (2 ml) in the knee joint affected by osteoarthritis
45602474|NCT04998188|Procedure|Placebo (saline solution)|Patients will be treated with a single injections of saline solution (2 ml) in the knee joint affected by osteoarthritis
45602475|NCT04997642|Behavioral|neuropsychiatric and cognitive testing questionnaires|"Demographic data such as race, sex, age Family History Risk Factor Questionnaire Hoehn and Yahr Stage UPDRS Parkinson's symptom checklist Medication list Neuropsychological Test Battery Behavioral Exams~Geriatric Depression Scale Quality of Life Questionnaire~PDQ-39, SF-12"
45756002|NCT00594997|Behavioral|Control (pre and post surveys)|Students fill out a pre and post survey and then receive the same intervention given to the controls.
45756003|NCT03790839|Drug|Sitagliptin|Sitagliptin (Januvia® 100 mg tablets for oral administration)
45756004|NCT03790839|Drug|Dorzagliatin|Glucokinase activator currently under development
45602476|NCT04997486|Behavioral|Time restricted eating|Participants will be asked consume all meals/snacks during a ~9-h daily eating period (~15-h fasting).
45602477|NCT02270944|Biological|GBS Vaccine|Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
45602478|NCT02270944|Biological|GBS Vaccine|Lyophilized formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
45602479|NCT05051774|Behavioral|1. Education|Three monthly face-to-face group education with 8 to10 participants using a validated educational booklet will be provided by the researcher at the study hospital.
45756005|NCT05230589|Drug|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
45444576|NCT02050204|Behavioral|Intervention|The intervention was a 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors (Kossek et al., in press). The change process was an integration of two previously evaluated interventions (Hammer et al., 2011; Kelly et al., 2011). A facilitator led 8 hrs of participatory sessions to transition employees from a time-based to a results-based work culture. Supervisors participated in all change activities plus 4hrs of training in supportive supervision. Training in family supportive supervision was implemented with behavioral computer-based training (cTRAIN, NWeta, Lake Oswego, OR) followed by 2 rounds of goal-setting and behavioral self-monitoring using an iPod Touch (Habitrack, OHSU, Portland, OR).
45602480|NCT05051774|Behavioral|2. Exercise|"The exercise intervention comprised of two elements as follows:~Three monthly hospital-based supervised group exercise consists of 8 to 10 participants. First two sessions: warm-up exercise-5 minutes, brisk walking-20 minutes at low intensity with music, and cool-down exercise-5 minutes. Third session: brisk walking for 30 minutes at moderate intensity with music.~Twelve-weeks home-based exercise: The participants will be asked to continue the exercise performed in the previous week at the hospital with music at least five times per week."
45602481|NCT05051774|Behavioral|3. Telephone follow-up|A 20-minutes telephone follow-up at weeks 3, 7, and 11 for strengthening the volition of the participant to perform the exercise and follow the healthy diet at home.
45602482|NCT05648734|Drug|Corticosteroids alone|(≥ 20 mg prednisolone or its equivalent for ≥ 10 days after hospital discharge)
45602483|NCT05648734|Drug|Corticosteroids + Colchicine|(≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Colchicine (1 mg/day for ≥ 10 days)
45602484|NCT05648734|Drug|Corticosteroids + Pirfenidone|(≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Pirfenidone (267 mg TID for ≥ 14 days)
45602485|NCT05648734|Drug|Corticosteroids + Colchicine + Pirfenidone for ≥ 14 days|(≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Colchicine (1 mg/day for ≥ 10 days) + Pirfenidone (267 mg TID for ≥ 14 days)
45602486|NCT05085704|Device|Magnetic resonance imaging|Medical imaging technique used in radiology to form pictures of the anatomy.
45602487|NCT05051462|Behavioral|Family / systemic constellation therapy|Family / systemic constellation therapy is a short-term group counseling intervention aiming to help clients better understand and resolve their conflicts within their personal systems, which in turn might lead to a decrease in psychopathological or functional somatic symptoms. The personal system addressed is most often the family but other inter- or intrapersonal systems (e.g., ego parts, victim-perpetrator dyads) can also be the target of the intervention.
45602488|NCT02365558|Drug|Evacetrapib|Administered orally
45602489|NCT02365558|Drug|Omeprazole|Administered orally
45444577|NCT03812211|Dietary Supplement|Active Supplement|Examine the effects of a multi-faceted supplement comprised of vitamins, minerals and naturally occurring and plant extracts approved for consumption of in overweight/obese men and women
45602490|NCT05085548|Drug|ProAgio Dose Levels (DL) 1,2,3|ProAgio is administered to study participants by intravenous injections once every 14 days.
45602491|NCT05085548|Drug|ProAgio Dose Levels (DL) 4,5,6|ProAgio is administered to study participants by intravenous injections once every 7 days.
45602492|NCT05085548|Drug|ProAgio Dose Levels 4a,5a,6a|ProAgio is administered to study participants by intravenous injections once every 7 days with a drug holiday after every 5 administrations.
45602493|NCT02365480|Drug|Berberine Chloride|Given PO
45602494|NCT02365480|Other|Laboratory Biomarker Analysis|Correlative studies
45602495|NCT02365480|Other|Placebo Administration|Given PO
45756006|NCT03088046|Drug|Micronized Progesterone|"Anovulatory women with Polycystic ovary syndrome and clinical hyperandrogenism attended in our Hospital will participate in the study. A patient information sheet will be provided and written consent will be obtained. Patients who give written consent will participate in the trial. All patient information will be confidential and only be available to researches involved in the study.~Blood samples will be collected at baseline (Sample #1) and between the 3rd and the 5th day of withdrawal after 7 days of 100mg vaginal MP every 12 hours of administration(Sample#2)."
45602496|NCT05051072|Procedure|"Assessment of the trigeminal nerve by diffusion tensor MRI and in resting state in the context of essential neuralgia"|"Assessment of the trigeminal nerve by diffusion tensor MRI and in resting state in the context of essential neuralgia"
45756007|NCT05221619|Drug|Nipocalimab|Depending on the dose received at their last administration in the MOM-M281-006 (NCT04119050) study, participants will continue to receive either nipocalimab dose-1 every 2 weeks (Q2W) or nipocalimab dose-2 every 4 weeks (Q4W) by intravenous (IV) infusion.
45756008|NCT03088124|Drug|Apalutamide|Patients will take orally everyday 240 mg of Apalutamide.
45756009|NCT00700375|Drug|Sodium bicarbonate|8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
45756010|NCT00700375|Drug|Sodium Chloride|8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
45756011|NCT01677884|Drug|Bevacizumab|Every 3 weeks : 7.5 mg/kg intra arterial in 2 hours at D1
45756012|NCT01677884|Drug|Capecitabine|Every 3 weeks: 2000 mg/m²/d in 2 times/d from D1 to D4
45602497|NCT05050526|Behavioral|Real-time videoconference-based Exercise program|12-week exercise program consisting of two weekly 45 minute group-based sessions, remotely supervised by a professional via real-time videoconference. Each session will consist of a warm-up (5-10 min), general strengthening (30 min) and cool-down (5-10 min). Warm-up will include general joint mobility and exercises focused on increasing heart rate. General strengthening will include 4 series of 6 exercises (2 for lower limb, 2 for upper limb and 2 for the trunk) performed with minimal equipment, combining body-weight and elastic-band exercises. Three difficulty levels will be set for each of the exercises, and progression will be made at weeks 5 and 9. Participants will be asked to work in a given rate of perceived exertion (between 3 and 5 in Borg's CR10 scale) and not to reach failure in any of the exercises. Cool-down will include stretching and breathing/relaxing exercises.
45602498|NCT05648656|Drug|TXA Nebulization|Nebulization with TXA 500mg/ 5mL 8 hourly for 2 days plus standard care of therapy
45602499|NCT05648656|Other|0.9% NS Nebulization|Nebulization with 0.9% normal saline (NS) 5mL 8 hourly for 2 days plus standard care of therapy
45602500|NCT05050214|Drug|Obinutuzumab|Each patient will be treated for 1 month and received a total of 3 doses. The first dose of Obinutuzumab (1000 mg) will be split in two separate infusions; on the first day each patient will receive 100 mg and the next day 900 mg of Obinutuzumab. Obinutuzumab (1000 mg) will be also administered at two and four weeks after the first infusion. Obinutuzumab will be administered after standard premedication.
45602501|NCT02270242|Drug|Aspirin|
45602502|NCT02270242|Drug|Placebo|
45602503|NCT02270242|Drug|ticagrelor|
45602504|NCT05049746|Other|Discussion|Participate in discussion
45602505|NCT05049746|Other|Interview|Participate in interview
45602506|NCT05049746|Other|Questionnaire Administration|Complete questionnaire
45602507|NCT04875364|Drug|Eszopiclone|2mg of Eszopiclone just before going to sleep.
45602508|NCT04875364|Other|Supplemental Oxygen|Constant oxygen flow at 4 Liters per minutes for the duration of time in bed via nasal cannula.
45602509|NCT04875364|Device|Continuous Positive Airway Pressure (CPAP)|A standard CPAP device will be provided using the settings as prescribed by the treating physician.
45602510|NCT04875286|Other|Electronic Health Record Review|Medical records reviewed
45602511|NCT04875286|Other|Questionnaire Administration|Complete questionnaires
45602512|NCT05082584|Drug|Vadadustat|Vadadustat tablet orally once a day for 52 weeks
45602513|NCT04869124|Drug|Dapagliflozin|Dapagliflozin propanediol (FORXIGA) tablet: 10 mg once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.
45602514|NCT04869124|Drug|Placebo|Placebo tablet, matching Dapagliflozin, once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.
45602515|NCT04421066|Procedure|Gingival and bone sample collection|Gingival and bone samples will be collected from the sites affected by peri-implantitis during their surgical treatment of peri-implantitis or histological and epigenetic analysis.
45444578|NCT03812211|Dietary Supplement|Placebo supplement|Examine the effects of a placebo supplement in overweight/obese men and women, compare to the active supplement
45602516|NCT04421066|Procedure|Healthy individuals|Gingival and bone samples will be collected from the extraction sites for histological and epigenetic analysis.
45602517|NCT02364388|Device|Imagio IUS|Imagio diagnostic gray-scale ultrasound
45602518|NCT02364388|Device|Imagio OA/US|Diagnostic opto-acoustic +gray-scale ultrasound
45602519|NCT04995224|Other|Assessment of Psychophysiological factors|Investigating the presence of psychophysiological factors (depression, anxiety, catastrophizing) by questionnaires.
45602520|NCT04995224|Biological|Assessment of Biological factors|Investigating autonomic nervous function using heart rate recording, colon biopsy samples, microbiota, and blood cytokines levels. (Colon biopsy samples are obtained when colonoscopy is performed for clinical reasons. Blood samples and stool samples will be taken when participants come to the hospital for colonoscopy)
45602521|NCT04995224|Genetic|Assessment of Genetics|Genetic data investigated by another cohort study (IBD BioResource study) will be utilized in the analysis of this study.
45602522|NCT04995224|Behavioral|Assessment of Quality of Life|Investigating QOL by questionnaires.
45602523|NCT04995224|Biological|Assessment of Biological factors|Investigating colon biopsy samples (Colon biopsy samples are obtained when colonoscopy is performed for clinical reasons).
45602524|NCT05648578|Other|Reiki attempt|Four reiki sessions were applied twice a week, on the same days of the week, lasting 25-35 minutes each.
45602525|NCT05648266|Drug|Continous SAPB (Ropivacain)|postoperative SAPB and pain catheter with continous administered (5ml/h Ropivacain 0,2%) for 48h
45602526|NCT05648266|Other|institutional standard of care pain medication protocol|institutional standard of care pain medication protocol
45602527|NCT05082038|Device|Mandibular partial rehabilitation with IF Tapared implants|2 IF Tapared Implants (Group IF) on one side of the mandible
45602528|NCT05082038|Device|Mandibular partial rehabilitation with CF Tapared implants|2 CF Tapared Implants (Group CF) on the other side of the mandible
45602529|NCT02363686|Procedure|FEES|A thin, flexible endoscope designed for assessment of laryngeal structures is passed through the nose to the oropharynx, visualizing the laryngeal structures, and the base of tongue and the pharynx. If needed 4% topical lidocaine and/or oxymetazoline (Afrin) will be administered. Swallowing will then be evaluated directly with six food boluses of 5 ml each. All patients will be allowed to swallow spontaneously without a verbal command to swallow. Video of the examinations will be recorded and presence of dysphagia will be designated independently by 3 different observers (one pulmonary physician and two speech language pathologists (SLPs)). This procedure will take 5-10 minutes. The camera will then be removed.
45756013|NCT01677884|Drug|Irinotecan|Every 3 weeks: 200mg/m² in 30mn IV at D1 (if oxaliplatin in first line) or oxaliplatin 130mg/m² in 2h IV at D1 (if irinotecan in first line)
45756014|NCT02124083|Drug|Vorinostat|Histone deactylase inhibitor
45756015|NCT02405078|Drug|Chemotherapy|Given standard salvage chemotherapy
45756016|NCT02405078|Procedure|Computed Tomography|Undergo FDG-PET/CT scan
45756017|NCT02405078|Drug|Fludeoxyglucose F-18|Undergo FDG-PET/CT scan
45756018|NCT02405078|Procedure|Positron Emission Tomography|Undergo FDG-PET/CT scan
45756019|NCT00701389|Drug|telcagepant potassium|Single oral dose of 2 x 300 mg capsules.
45756020|NCT00701389|Drug|sumatriptan|single oral dose of 100 mg sumatriptan
45602530|NCT02363686|Procedure|BSE|Following the FEES, a speech language pathologist (SLP) will perform a noninvasive bedside swallow evaluation (BSE). The SLP will be blinded to the results of the FEES, and the name of the SLP performing the BSE will not be recorded. No other identifying information will be collected regarding the SLP performing the test.
45602531|NCT05079776|Other|Physical length measurement|Physical length will be measured and images will be collected for AI to estimate the length
45602532|NCT02268916|Behavioral|Counseling|OT led counseling
45602533|NCT02268916|Behavioral|Usual education|At the end of the study, will receive OT-led counseling
45602534|NCT05047094|Device|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
45602535|NCT05047094|Drug|Pembrolizumab|200 mg administered as an intravenous infusion over 30 minutes every 3 weeks
45602536|NCT04993352|Drug|recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection|0.05mL (12.5mg/0.5mL/vial) HLX-04-O solution at a 4-week interval for intravitreal injection
45602537|NCT04992026|Procedure|robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection|Robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection will be performed.
45602538|NCT04992026|Drug|1.Abiraterone Acetate Tablets|1000mg(4 tablets, 250mg per tablet) daily for 6 cycles
45602539|NCT04992026|Drug|Prednisone Acetate Tablets|5 mg oral low dose prednisone taken along with Abiraterone Acetate Tablets
45911057|NCT02002923|Procedure|Pulmonary vein isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
45911058|NCT02002923|Drug|Botulinum Toxin|Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
45602540|NCT04992026|Drug|Luteinizing Hormone-Releasing Hormone Analog|Hypodermic injection of Luteinizing Hormone-Releasing Hormone Analog every 4 weeks including goserelin, leuprolide, triptorelin ect.
45602541|NCT05077826|Device|North Coast Medical Activadose II|tES device model Activadose II (North Coast Medical, Morgan Hill, CA, USA) programed to deliver tES.
45756021|NCT00701389|Drug|sumatriptan placebo|single oral dose
45602542|NCT04991402|Device|Dolutegravir-based antiretroviral therapy|"This study focuses on the impact of Dolutegravir (DTG)-based antiretroviral therapy (ART) on metabolic health of women and children in pregnancy, delivery and beyond. In order to understand the potential adverse effects of DTG, pregnant women living with HIV- both those initialing DTG-based ART in pregnancy as well as those who were established on DTG-based ART prior to pregnancy, will be less than or equal to 14 weeks' gestation at enrollment to allow for detection of metabolic abnormalities as they begin to develop during the course of pregnancy.~This is considered standard of care."
45756022|NCT00701389|Drug|telcagepant potassium placebo|single oral dose of 2 MK-0974 placebo capsules
45444579|NCT02050282|Other|Supplementary NT-proBNP measurement|In patients randomized to the strategy with supplementary measurement of NT-proBNP, a blood sample will be drawn from the peripheral venous catheter that is routinely inserted and analyzed immediately using a COBAS H232 and Roche Diagnostics NT-proBNP assay.
45602543|NCT04420832|Procedure|Surgical treatment|Se above
45911059|NCT02002949|Procedure|Short daily hemodialysis|5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center
45602544|NCT04420832|Other|Non-surgical treatment|See above
45444580|NCT03811977|Dietary Supplement|Lutein syrup|12- week dietary supplementation with lutein syrup (20 mg lutein/day)
45444581|NCT03811977|Dietary Supplement|Placebo syrup|12- week dietary supplementation with placebo syrup (0 mg lutein/day)
45444582|NCT02050360|Drug|Sildenafil 40 mg|
45602545|NCT02518490|Device|Sapphire Lens|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
45602546|NCT02518490|Device|enfilcon A|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
45602547|NCT04989998|Device|Hip7 Software on Kick/ CORI platforms|Total hip arthroplasty surgery using Hip7 software on Kick or CORI platforms using R3 Polarstem implants.
45602548|NCT04989998|Device|Conventional surgical procedures|THA surgery using standard, manual instrumentation and digital templating techniques using R3 polarstem implants.
45602549|NCT05046938|Behavioral|Motivational İnterviewing|Students with food addiction will be provided with motivational interviews about food addiction in 5 sessions, each of which varies between 6-8 groups.
45756023|NCT03979235|Diagnostic Test|Motor function assessment|perform motor function assessment by using scales, sEMG, and inertia sensors
45602550|NCT05077436|Drug|Vamifeport Formulation 1|Vamifeport Formulation 1 is available as 60 mg oral capsules
45602551|NCT05077436|Drug|Vamifeport Formulation 2|Vamifeport Formulation 2 is available as 60 mg oral capsules
45602552|NCT05042102|Combination Product|Donepezil + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
45756024|NCT01796587|Device|LoFric Origo|
45756025|NCT02336594|Drug|RDEA3170 10 mg|
45756026|NCT02336594|Drug|RDEA3170 2.5 mg|
45756027|NCT03964181|Other|Change in school start times|Elementary start times changed from 9:00 a.m. to 8:00 a.m.; middle school start times changed from 8:00 a.m. to 8:50 a.m.; high school start times changed from 7:10 a.m. to 8:20 a.m.
45602553|NCT05042102|Combination Product|Donepezil + Placebo CRT|Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
45602554|NCT05042102|Combination Product|Placebo medication + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
45602555|NCT05042102|Combination Product|Placebo medication + Placebo CRT|Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
45602556|NCT05076890|Dietary Supplement|15 mg/g Full Spectrum Hemp Extract|HPMC capsules containing full spectrum standardized hemp extract in liquid form.
45602557|NCT05076890|Dietary Supplement|50 mg/g Full Spectrum Hemp Extract|HPMC capsules containing full spectrum standardized hemp extract in liquid form.
45602558|NCT05076266|Other|Questionnaire|Complete the survey questions
45602559|NCT05041010|Drug|Neu2000KWL group|1st infusion of 750mg in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 ± 1 hours, twice a day.
45602560|NCT05041010|Drug|Placebo group|1st infusion of the same volume of saline in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 ± 1 hours, twice a day
45602561|NCT04210076|Behavioral|MBAT-T|The MBAT-Team program builds on the basic 4-week, 8-hour MBAT-Soldier program. In addition to the basic program, MBAT-Team includes exercises promoting the cultivation of attention and emotion regulation in the service of effective team interactions (e.g., mindful communication and listening; monitoring and attention to the activities and emotional states of others, and additional practices to promote collective mindfulness).
45602562|NCT04210076|Behavioral|MBAT-I|The MBAT-Individual program is based on the basic 4-week, 8-hour MBAT-Soldier curriculum.
45602563|NCT05075798|Other|No intervention,|pure observational study
45602564|NCT05074940|Drug|Amivantamab|Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).
45602565|NCT04986566|Other|Best Practice|Use standard reporting procedures
45602566|NCT04986566|Behavioral|Health Education|Use Aetonixx app
45602567|NCT04986566|Other|Medical Device Usage and Evaluation|Wear Vivofit 4
45602568|NCT04986566|Other|Quality-of-Life Assessment|Complete questionnaires
45602569|NCT05038982|Drug|Abrocitinib|During the study period, subjects will take one Abrocitinib 200 mg tablet once daily orally. Subjects will be directed to take doses of Abrocitinib at approximately the same time of day.
45602570|NCT05074472|Drug|ZB131|ZB131 will be administered once weekly by intravenous infusion with the weight at baseline used for mg/kg dose calculations.
45444583|NCT02050360|Drug|Sildenafil 80 mg|
45444584|NCT02050360|Drug|Placebo|
45602571|NCT05074238|Other|Zinc containing suncreen|"The study participant will be randomized via a randomization tool within the REDCap database as to which half of the wound (A or B) the patient will be asked to apply zinc containing sunscreen for the duration of the study."
45602572|NCT05036798|Drug|Tislelizumab|"Chemotherapy regimen:~Gemcitabine 1g/m2 Oxaliplatin 100mg/m, D1, q3W2 Tislelizumab 200mg D1 Q3w Lenvatinib 4mg Po QD"
45602573|NCT04984850|Other|Oral chemotherapy information and support|Multimodal intervention : (1) handouts and videos presenting information and supportive resources for common oral chemotherapy related issues, (2) phone call(s) from a nurse in oncology, and (3) e-reminders to take medication. The intervention will be available to experimental group participants on mobile platform.
45602574|NCT05073224|Diagnostic Test|Active Straight Leg Raise Test|The ASLR test is a well-established clinical test that assesses stability of the lumbar spine/pelvis, posterior pelvic pain severity, and ability to activate the abdominal muscles. It is performed in supine. Participants are instructed to raise one leg, with the knee straight, to a heel height of 20 cm. The leg is held at the top for 5 seconds, then slowly lowered to the ground. The participant is asked to report perceived difficulty to raise the leg on a 0 to 5 scale (0=not at all difficult; 5=unable to lift leg) and pain on a 0 to 10 scale (0=no pain; 10=worst possible pain). If difficulty or pain are rated at a 1 or higher, the test is repeated with the researcher providing external compression of the pelvis. If perceived difficulty or reported pain are lower with compression, the test is considered positive for lumbopelvic instability. The test is then repeated on the opposite limb.
45602575|NCT05073224|Other|Active Straight Leg Raise Fatigue Task|The protocol is similar to the ASLR test, except that the participant is instructed to maintain the elevated leg off the ground for as long as possible. A biofeedback air cuff will be placed under the participant's lumbopelvic region to assess movement of the spine/pelvis. The cuff will be inflated to 40 mm Hg, and the participant instructed to keep the needle as close to 40 mm Hg as possible throughout the test; no information will be provided on how to affect cuff pressure, but visual feedback of cuff pressure will be provided throughout the task. Ratings of perceived exertion (RPE) and pain will be obtained from participants every 30-60 seconds. Task failure will be defined as a heel height ≤10 cm or a change in cuff pressure ≥20 mm Hg. Both limbs will be tested, but in different sessions. The order of limb testing (dominant vs non-dominant) will be randomized and counter-balanced. Limb dominance will be self-reported.
45756028|NCT01799317|Drug|Vitamin D2|These patients will receive standard of care vitamin D 1,25 therapy with intervention of vitamin D2
45756029|NCT03925025|Drug|Magnesium Sulfate|Treatment in addition to standard therapy
45756030|NCT03925025|Drug|Nimodipine|Treatment in addition to standard therapy
45444585|NCT02940860|Drug|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes."
45444586|NCT02940860|Drug|Iron sucrose|Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial. Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended.
45602576|NCT05073224|Other|Lower Extremity Strength Testing|"A straight leg raise maximal voluntary contraction (MVC) of each lower extremity an MVC of the hip extensors of the grounded limb will be performed in supine before and within 2 minutes of completing the ASLR fatigue task. The straight leg raise MVC will be performed with a custom-made load cell instrumented strength testing device, which consists of a rigid platform on which the participant will lie. At the foot of the device is a tower that houses 2 load cells connected to a lightly padded push plate.~The hip extension MVC will be performed on a force plate. Before the ASLR fatigue task, a minimum of 3 MVC trials will be performed for each muscle group, with a minimum of 1 minute rest between trials; the highest peak force will be considered the MVC. Only 1 MVC trial per muscle group will be performed following the ASLR Fatigue Task."
45602577|NCT05073224|Diagnostic Test|Ultrasound imaging of abdominal wall|Real time ultrasound will be used to assess inter-recti distance above and below the umbilicus. Participants will be assessed with B Mode images in supine at rest, in supine while lifting their head, and in supine while performing a straight leg raise. The Principle Investigator has training and experience in musculoskeletal ultrasound.
45602578|NCT04983914|Device|Transcorneal Electrostimulation via OkuStim System|Transcorneal electrostimulation, usually applied once per week for 30 min (home-use).
45756031|NCT01677962|Biological|Poly-ICLC|
45756032|NCT01677962|Biological|dendritic cell|
45602579|NCT04983602|Other|Comprehensive Geriatric Assessment arm|The intervention will involve a comprehensive geriatric assessment which will be provided by a geriatric doctor, physiotherapist, occupational therapist, social worker, pharmacist and specialist nurse.,
45602580|NCT04983602|Other|EDPLUS|EDPLUS involves a 6 week physiotherapy led community based intervention involving 3 home visits and weekly telephone support.
45602581|NCT05036252|Diagnostic Test|Cardiopulmonary Exercise Test|All enrolled participants will undergo a cardiopulmonary exercise test (CPET). The CPET will be conducted using an electronic motorized treadmill with 12-lead ECG monitoring performed by ACSM-certified exercise physiologists.
45602582|NCT05036252|Diagnostic Test|Echocardiogram|Resting assessment of LVEF and GLS will be evaluated through Conventional 2D and Doppler echocardiograms will be performed per protocol using a commercially available ultrasound scanner, according to the American Society of Echocardiography (ASE) recommendations for a comprehensive examination.
45602583|NCT05036252|Diagnostic Test|Echocardiography|As soon as possible following completion of the CPET, subjects will be placed in the supine position and 2D echocardiographic images will be obtained in the apical 4-/ 3-/2-chamber views.
45602584|NCT05034770|Other|major ozone autohemotherapy|This treatment is based on treating 100 ml of the pa- tient's blood with 100 ml of O3 followed by reinfusion in the donor, in a fast procedure. Each patient received 10 sessions of autohemotherapy with O3 twice a week.
45756033|NCT05161247|Other|Zona pellucida sperm selection|Sperm selection for ICSI based on the spermatozoa ability to adhere to immobilized zona pellucida proteins.
45756034|NCT05161247|Other|Conventional sperm selection|Sperm selection for ICSI based on the sperm morphology.
45756035|NCT05161247|Other|Intracytoplasmic Sperm Injection (ICSI)|Normal ICSI procedure.
45911060|NCT02002949|Procedure|Conventional hemodialysis|3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
45911061|NCT02002962|Procedure|radiofrequency ablation|
45911062|NCT02002962|Drug|Botulinum Toxin Type A injection|
45911063|NCT02002988|Procedure|endomyocardial BT injection|
45911064|NCT02003001|Drug|Botulinum Toxin|
45602585|NCT05071898|Drug|Semaglutide Pen Injector [Ozempic]|Participants will receive subcutaneously injected semaglutide (0.25 mg/wk) for 4 weeks followed by semaglutide (0.5 mg/wk) for an additional two weeks.
45602586|NCT05034458|Dietary Supplement|Crohn's disease exclusion diet|Patients will receive, in addition to their normal treatment, polymeric formula + diet
45756036|NCT00595153|Drug|Pulmicort|inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
45602587|NCT01364870|Device|Placebo TENS|"Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide treatment at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working."
45756037|NCT03419468|Other|Self Geriatric Assessment Measure (SGAM)|Self Geriatric Assessment Measure
45756038|NCT05151965|Procedure|Bankart Repair and Remplissage|"Arthroscopic Bankart repair with a minimum of 3 anchors~1 or 2 anchor Remplissage subsequently performed with percutaneous anchor insertion in the base of the Hill-Sachs defect, and sutures passed in a horizontal mattress configuration 1 cm apart, tied in the subacromial space."
45756039|NCT05151965|Procedure|Latarjet Coracoid Transfer|Coracoid transfer performed via deltopectoral approach with horizontal subscapularis split. Graft placed in the conventional orientation, secured with 2 screws, ensuring the graft is not lateral to the glenoid rim.
45911065|NCT02003027|Drug|BT injection|
45911066|NCT02003040|Device|Mespere Venus 1000 CVP System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject. A CVP measurement is recorded at time of patient's hospital admission and discharge. CVP readings will remain concealed from the treating team.
45911067|NCT02003066|Procedure|Standard fluid therapy|In Standard fluid therapy group, the administration of fluid will be guided to maintain mean blood pressure more than 65 mmHg, urine output more than 0.5 ml/kg/hr, and central venous pressure less than 14 mmHg.
45911068|NCT02003066|Procedure|Conservative fluid therapy|In Goal directed fluid therapy group, the administration of fluid will be guided by stroke volume variation. The anesthesiologist will infuse volulyte (Fresenius Kabi, Bad Homburg, Germany) 200 ml if stroke volume variation is over 12%. If cardiac index is below 2.5 l/min/m2 and stroke volume variation is below 12%, start dobutamine.
45911069|NCT02003079|Behavioral|Cystic Fibrosis Questionnaire (Revised) for Teens/Adults|
45911070|NCT02003092|Drug|RX-5902|escalating doses (mg)
45602588|NCT01364870|Device|Active TENS|High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
45602589|NCT04209218|Drug|Dexamethasone|Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.
45602590|NCT04209218|Other|Targeted blood pressure management|Blood pressure is maintained within ±10% from baseline.
45602591|NCT04209218|Drug|Placebo|Placebo (2 ml normal saline) is administered before anesthesia induction.
45602592|NCT04209218|Other|Routine blood presure management|Blood pressure is maintained according to routine practice.
45602593|NCT04209062|Device|Medical device validation|The medical devices will both record electrical signals for comparison
45602594|NCT02268526|Biological|CSJ148|CSJ148 IV q 4weeks
45602595|NCT02268526|Drug|Placebo|Placebo IV q 4weeks
45602596|NCT04981262|Dietary Supplement|Stimulance|Intervention with Prebiotic supplement
45602597|NCT04981184|Device|Gait and balance measurement|Virtual gait training procedures are included. Balance training procedures with Biodex Balance system are included too.
45602598|NCT05033366|Diagnostic Test|Proov Test|Rapid response urine PdG and LH test strips, Proov
45602599|NCT05033132|Drug|Balstilimab|Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody
45602600|NCT05033132|Drug|Balstilimab + Zalifrelimab|An anti-PD-1 monoclonal antibody in combination with a cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody
45602601|NCT05031338|Device|Carpal Tunnel Release|Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the SX-One MicroKnife with ultrasound guidance.
45602602|NCT05031338|Procedure|Carpal Tunnel Release|Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the traditional mini-open technique without ultrasound guidance.
45602603|NCT05070026|Other|uni-portal VATS group|patients received pulmonary lobectomy under general anesthesia by using uni-portal VATS method
45602604|NCT05070026|Other|three port VATS group|patients received pulmonary lobectomy under under general anesthesia by using three port VATS method
45602605|NCT04980326|Behavioral|Doing What Matters (DWM)|The original DWM program consists of a self-help guide called 'Doing What Matters in Times of Stress', that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. In this study, DWM will be delivered as an online intervention. The DWM intervention, i.e. both the audio recordings and the self-help guide, will be adapted for use on a smartphone or other device with internet access during Phase 1 of RESPOND. The format of DWM is innovative in that it seeks to ensure that key intervention components are delivered as intended through the use of pre-recorded audio, without the burden of extensive training and supervision. In the online application tool a new module is released every week so participants will be asked to go through the entire DWM intervention within 5 weeks with weekly guidance from a helper.
45756040|NCT02995291|Drug|OraVerse|1.7ml OraVerse (0.4 mg phentolamine mesylate) will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). Oraverse will be injected at the same site Bupivacaine was injected.
45602606|NCT04980326|Behavioral|Problem Management Plus (PM+)|PM+ is a new, brief, psychological intervention program based on cognitive behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support. Across the five 90-minute sessions participants may talk to trained non-professional. PM+ has four core features, and it is brief. In this study, the delivery mode of the PM+ intervention will be flexible, with remote delivery in phases of the pandemic when physical distancing rules apply. This is a future-oriented attempt towards a more holistic mental health care system that can flexibly switch between modes of delivery (e.g. remotely (e.g. Zoom) or face-to), depending on the needs and the specific containment measures that apply, and the specific preferences and needs of the participant.
45602607|NCT04980326|Behavioral|Psychological First Aid (PFA)|PFA is a brief intervention consisting of providing basic information for peer support in times of emotional distress
45602608|NCT04979702|Behavioral|Active Control|Participants will complete a 3-month exercise and physical activity intervention supported by online recourses
45602609|NCT04979702|Behavioral|mHealth technology assisted exercise counselling|Participants will complete a 3-month exercise and physical activity intervention supported by online recourses, exercise counselling sessions and mHealth technology
45602610|NCT05068466|Drug|INCB054707|Administered Orally
45756041|NCT02995291|Drug|Saline Water (Control)|1.7ml saline water will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). The water will be injected at the same site Bupivacaine was injected.
45911071|NCT02001818|Drug|Nilotinib, Pegylated interferon alpha-2b, Imatinib|All patients joining the study will receive treatment with oral nilotinib at 300mg twice daily. This will be given as monotherapy for 3 months initially, prior to commencement of combination therapy with Pegylated interferon alpha-2b added to nilotinib. Patients intolerant of nilotinib will have the option of switching to imatinib.
45911072|NCT02003118|Drug|AKR 202|
45911073|NCT02003118|Drug|Placebo|
45602611|NCT05068466|Drug|Placebo|Administered Orally
45602612|NCT04218968|Drug|Carvedilol|Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and carvedilol titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the adrenergic blocker carvedilol, resulting in a decreased clinical phenoconversion rate to parkinsonism.
45602613|NCT04218032|Device|sphygmomanometer, SpyghmoCor, CNAP500|blood pressure is measured with developed new non-invasive technology, oscillometry from the fingertip, and compared to non-invasive standard blood pressure measurement using a standard sphygmomanometer/SpyghmoCor device/CNAP500 device.
45911074|NCT02003131|Biological|Trophic factors from umbilical cord mesenchymal stem cells|
45602614|NCT05067764|Procedure|Aponeurectomy with grafting|"The lipofilling is performed, once the incisions are closed and is performed with the Puregraft® system.~The fat graft is taken from the posterior, medial and anterior sides of the arm, by skin puncture. Approximately 10 cc are harvested, allowing a reinjection of about 2 cc per digital radius treated. After conditioning, the fat graft is redistributed to the curettage areas through the skin incisions."
45756042|NCT03418844|Other|Self-questionnaires of living conditions and quality of life|Patients will complete self-questionnaires of living conditions and quality of life (MFI-20, FACT-G/FACT-O, FACT/COG-NTX, FACT-Cog, HADS, Insomnia Severity Index , International Physical Activity Questionnaire)
45756043|NCT03418844|Diagnostic Test|Cardiac, pulmonary, auditory and biological assessment|"Patients will perform :~Cardiac assesments (ECG, Carotid and humeral Doppler ultrasound, Trans-thoracic echocardiography 2D and 3D)~Pulmonary and auditory assesment ( Respiratory Functional Exploration, Tonal audiogram)~Blood tests"
45756044|NCT02408432|Other|Laboratory Biomarker Analysis|Correlative studies
45756045|NCT02408432|Other|Standard of Care|Undergo mesenchymal stem cell infusion
45756046|NCT02408432|Drug|Mesenchymal Stem Cell Transplantation|Undergo mesenchymal stem cell infusion
45911075|NCT02003157|Procedure|hypnosis during embryo transfer or usual transfer procedure|
45911076|NCT02003235|Device|Daily watching videos using Reviview™, a dichoptic video display device, for 60 min|
45444587|NCT04142541|Device|Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System)|The Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection is indicated for improving the carotid luminal diameter in patients with clinically significant carotid artery stenosis and for the simultaneous capture and removal of embolic material during angioplasty and stenting.
45756047|NCT01798043|Other|Cardiac MRI with pacemaker stimulation|Patient is undergoing a Cardiac MRI at enrollment and 12 months later
45756048|NCT01798043|Other|Cardiac MRI with and without pacemaker stimulation|Patient is undergoing a Cardiac MRI at enrollment and 12 months later
45756049|NCT03087734|Device|Implantation of new model of bar with oblique stabilizers|Implantation of new model of bar with oblique stabilizers
45756050|NCT03087734|Device|Implantation of regular bar with perpendicular stabilizers|Implantation of regular bar with perpendicular stabilizers
45756051|NCT03900767|Other|Electronic Health Record intervention|AAC
45756052|NCT03900767|Behavioral|Smoking Cessation Intervention|Receive standard Utah Quitline treatment
45756053|NCT03900767|Behavioral|Telephone-Based Intervention|Receive text messages
45444588|NCT02037646|Other|Qualitative fecal immunochemical test|This test measures the amount of blood within the submitted stool specimen
45756054|NCT03900767|Behavioral|Telephone-Based Intervention|Receive phone calls
45756055|NCT04403048|Procedure|Provisional DCB approach PCI procedure|Intervention is explained in detail in group description
45756056|NCT04403048|Procedure|Standard provisional approach PCI procedure|Intervention is explained in detail in group description
45756057|NCT00595231|Drug|SYN111|500 mg for 1 week followed by 1000 mg for 7 weeks
45756058|NCT00595231|Drug|Placebo|0 mg tablets
45756059|NCT02400554|Behavioral|Yappalli|"Month 1-3: Up to 8 group sessions on Choctaw history, traditions, cultural systems, & women's roles. Up to 3 individual Motivational Interviewing (MI) sessions to identify community leadership & personal change goals on the main outcome.~Month 2: Overnight Culture Camp to strengthen group cohesion & synthesize goals.~Month 3: Walk for a week on the Choctaw Trail of Tears, upon completion make a commitment to conduct a community-wide event based on personal & leadership goals & experience on the Trail.~Months 3-12: Up to 6 group meetings to plan community leadership events related to ATOD & obesity prevention. Includes: digital storytelling training to create a story related to ATOD & obesity prevention & an individual MI booster session to revise their personal & community leadership goals.~Month 12: Share digital stories & community event experiences & undergo a ceremony to transition to health leaders within their communities."
45756060|NCT02995603|Device|Nano-X patient rotation|Patients are required to completed validated questionnaires to quantify their experience of horizontal rotation.
45756061|NCT03736733|Other|physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
45756062|NCT03736733|Other|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
45756063|NCT02995057|Device|Gold- or silver-coated, or uncoated nickel microneedles|The stratum corneum of the participants will be breached with the gold- and silver-coated, or uncoated nickel microneedles.
45804198|NCT04735991|Behavioral|Kapok Initiative|"The detailed process is:~After randomization, the Kapok assistant will contact the patient's family~The family of the patient joins the Kapok Initiative. They will participate in a 60-minute training program for 27 days, which is taught online by experts; The contents of the lectures are as follows: 1) Doctors are also mortal; 2) New medicines and new therapies; 3) Alternative therapies; 4) Don't panic during the operation; 5) Pain relief; 6) Side effects of treatment; 8) About the truth; 9) New topics; 10) Anti-cancer cost-effectiveness; 11) Medical insurance; 12) Commercial medical insurance; 13) Exercise and rehabilitation; 14) Nutrition and Foods to increase leukocytes level; 15) Long-term persistence; 16) Acceptance Change; 17) Two new roles; 18) Future expectation."
45911077|NCT02003248|Device|transcranial magnetic resonance guided focused ultrasound pallidotomy|Focused ultrasound is an attractive method for non-invasive thermal ablation of soft tissue, including functional brain targets. Treatment begins by acquiring a series of MR images of the target organ. The physician then identifies a target volume in the MR images, and delineates the treatment contours on the images. Therapy planning software calculates the parameters required to effectively treat the defined target volume. During the treatment, an ultrasound transducer generates a point of focused ultrasound energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, enabling neurophysiological assessment in the low range, and thermal coagulation at higher ranges. MR images acquired during sonication provide a quantitative, real-time temperature map of the target area to confirm the location of the sonication and the size of the affected region.
45602615|NCT05067764|Procedure|Aponeurectomy alone|The patient is installed in dorsal decubitus position and the arm to be treated is anesthetized by axillary block. The procedure is performed in the operating room, respecting all the rules of asepsis and safety in force. A tourniquet is placed on the arm to be treated and inflated to 250mmHg. Broken incisions are then made opposite the cords to be excised, which are located by palpation. Once the noble elements have been identified, the excision of the cords and fibrous nodules can be done as completely as possible. Sometimes an arthrolysis procedure is necessary in order to restore extension to a joint that has been fixed in a flexion position for several years. Skin closure is most often possible by direct suture or by means of local fatty skin flaps. In some cases, the surgeon may use total skin grafts, or directed healing in certain areas where direct skin suture is not possible.
45602616|NCT04978142|Device|transcranial Direct Current Stimulation (tDCS)|Non-invasive neuromodulation employing a direct current, applied using a DC STIMULATOR PLUS manufactured by NeuroConn Technology by NeuroCare. This is a micro-processor-controlled constant current source. It meets the highest safety standards thanks to (hardware- and software-based) multistage monitoring of the current path. By continuously monitoring electrode impedance it can detect insufficient contact with the skin and automatically terminate stimulation. This is a reliable method of avoiding any injury to the patient.
45602617|NCT05066750|Behavioral|Mindful breathing|Participants watch a 10 minute mindful breathing video
45602618|NCT05066750|Behavioral|Control video|Participants watch a 10 minute control video
45602619|NCT04977362|Other|Enhanced Recovery After Surgery|Enhanced recovery after surgery is a multimodal, transdisciplinary care approach for patients undergoing surgical procedures. It is implemented in various surgical specialties, among others in cardiac surgery. The care approach aims at promotion of recovery of the patients throughout their perioperative process, reduction of complications, and early return to normal activities.
45602620|NCT04977362|Other|Treatment as Usual|treatment as usual according to standard care in heart valve surgery
45602621|NCT05028374|Drug|"A single booster dose of the Moderna mRNA COVID-19 vaccine"|All participants will receive a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly. This is an open label, non-randomized trial.
45602622|NCT02268214|Drug|Dapagliflozin|Tablets
45602623|NCT02268214|Drug|Placebo for dapagliflozin|Tablets
45602624|NCT02521376|Drug|Entospletinib|Entospletinib 100 mg tablet administered orally
45602625|NCT05064722|Device|Self Forming Magnets (SFM)|To create the duodenal-ileal diversion, the duodenal magnet will be placed transorally in the proximal duodenum and the distal magnet will be placed in the ileum. Magnets are coupled and a compression induced anastomosis is created.
45602626|NCT04421300|Behavioral|smile exercise|"Launch the smile face recognition APP on smart phone, after user guidance and pretest, a smile exercise will display on the phone, while facing the front camera on the phone, participant will do an exercise emphasizing facial movements, as exaggerated as possible. The exercise last for 8 weeks and 4 times a day"
45602627|NCT04421300|Drug|0.1% sodium hyaluronate eye drop|0.1% sodium hyaluronate, 4 times a day, the time is in the morning, lunchtime, afternoon and evening. the interval between two training time is 2 hours, 1 hour before and after can be added or subtracted by users, 8 weeks.
45444589|NCT02037646|Other|Quantitative fecal immunochemical test|This test detects presence or absence of blood within a submitted stool specimen.
45602628|NCT05026736|Other|Quality-of-Life Assessment|Ancillary studies
45602629|NCT05026736|Biological|Sintilimab|Given IV
45756064|NCT05102279|Dietary Supplement|Giving subjects different phosphorus diets at different stages of the trial|Ordinary phosphorus diet: Phosphorus content 1500mg High phosphorus diet: Phosphorus content 2500mg (inorganic phosphorus is added to the ordinary phosphorus diet) Low phosphorus diet: Phosphorus content 500mg (Protein content is achieved through chicken albumen and addition of low-phosphorus whey protein powder) The ratio of plant protein and animal protein is the same as the other two diets. In addition, calcium-magnesium tablets and potassium chloride salt are added to achieve the same calcium, magnesium and potassium content as the other two diets.) There are 2 recipes for each diet. Ensure that the energy, protein, fat, carbohydrate, calcium, magnesium, sodium, potassium, oxalic acid content, vegetable protein and animal protein ratio are basically the same: Energy: 2100kcal (30kcal/kg, standard body weight 70kg) Protein: 110g Fat: 55-60g Carbohydrate: 300g Calcium: 600-700mg Magnesium: 350-400mg Sodium: 4600mg Potassium: 2500mg
45756065|NCT02474173|Other|Laboratory Biomarker Analysis|Correlative studies
45756066|NCT02474173|Drug|Onalespib|Given IV
45602630|NCT04868812|Device|SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy|SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy; MonaLisa Touch CO2 fractionated laser
45602631|NCT02268058|Drug|Acetaminophen|routine administration of medication for a 72 hour period
45602632|NCT02268058|Drug|Ibuprofen|routine administration of medication for a 72 hour period
45756067|NCT02474173|Drug|Paclitaxel|Given IV
45756068|NCT02474173|Other|Pharmacological Study|Correlative studies
45756069|NCT03482102|Drug|Tremelimumab|Tremelimumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
45756070|NCT03482102|Drug|Durvalumab|Durvalumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
45756071|NCT03482102|Radiation|Radiation|Radiation therapy is used to shrink cancer cells.
45756072|NCT02995135|Drug|BAY987517|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code: Z43-094)"
45756073|NCT02995135|Drug|SFP Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
45756074|NCT03481010|Procedure|PAO with hip arthroscopy|Participants who are randomized to the Scope-PAO group will receive central compartment hip arthroscopy in addition to the PAO.
45756075|NCT03481010|Procedure|PAO without hip arthroscopy|"Participants who are randomized to the PAO-only group will receive a Bernese Periacetabular Osteotomy (PAO) for treatment of hip dysplasia."
45756076|NCT01798199|Other|The training by Verve System|
45756077|NCT02402270|Drug|NuLYTELY® (PEG 3350)|
45756078|NCT02402270|Drug|ECP-019|
45756079|NCT02402270|Drug|MoviPrep® (PEG 3350)|
45444590|NCT02037646|Procedure|Colonoscopy|Patients with positive tests will be subjected to colonoscopy to determine presence or absence of advanced colorectal neoplasms.
45602633|NCT05025878|Dietary Supplement|[U-13C]Glucose|Patients are intravenously infused with 28g of [U-13C]glucose over a 5 hour period. Briefly, [U-13C]glucose will be provided by intravenous line containing 8g of [U-13C]glucose in 60 mL over 10 min. After 10 minutes, 4g of [U-13C]glucose will be administered over an hour. This process will continue until the patient's ascites is drained, or after 5 hours. We will monitor blood glucose levels during infusions using a continuous glucose monitor.
45756080|NCT03502967|Drug|Hyperpolarized [1-13C] Pyruvate|Bolus injection of study drug
45602634|NCT02267824|Device|Extraoral OrthoPulse® PBM|Patients carry out daily extraoral OrthoPulse® PBM treatments at home.
45602635|NCT02267824|Other|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office.
45602636|NCT05025722|Other|Non Interventional|This is an observational study.
45602637|NCT05648188|Biological|Sample|Sample of whole blood and tissue for ex vivo expression of A2R, CD39, CD73 and P2RX7
45602638|NCT04974164|Biological|Inactivated COVID-19 Vaccine|Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen
45602639|NCT05062460|Other|1 hour Blood glucose monitoring|Consented patients who are diagnosed with gestational diabetes will be randomized to 1-hour postprandial blood glucose monitoring.
45602640|NCT05062460|Other|2 hour blood glucose monitoring|Consented patients who are diagnosed with gestational diabetes will be randomized to 2 hour post prandial blood glucose monitoring
45602641|NCT04972760|Drug|Baricitinib|Baricitinib, 4 mg/d, oral route for 24 weeks
45602642|NCT04972760|Drug|Placebo|Placebo, 4 mg/d, oral route for 24 weeks
45602643|NCT04971902|Other|Pharmacogenetic Test|Cheek swab sample with PGx results lab analysis
45602644|NCT05023772|Procedure|Stereotactic Laser Ablation|MR Guided laser ablation therapy
45602645|NCT05023772|Radiation|Stereotactic Radiosurgery|Precise delivery of radiation to spinal tumor
45602646|NCT05023772|Diagnostic Test|MRI guided laser ablation|Surgery will take place in intraoperative suite to include operating room and MRI scanner
45602647|NCT05062382|Behavioral|Complementary feeding intervention|"The study promoted eggs.~GAIN provided training to egg farmers to increase their egg production and marketing, helped increase mother's access to eggs by making them more available in local kiosks and getting retailers to display promotional messages around eggs, conducted sensitization workshops with retailers to increase egg purchases, and employed a demand creation campaign."
45602648|NCT05061758|Drug|LY3056480|LY3056480 is an inhibitor of gamma-secretase
45602649|NCT02267746|Drug|Tazarotene (Fabior™)|
45602650|NCT02267746|Drug|Tazarotene (Actavis)|
45602651|NCT02267746|Drug|Vehicle foam|
45602652|NCT05021822|Procedure|Erector spinae plane block|Bilateral erector spinae plane block will be performed preoperatively under ultrasound guidance using 15 ml bupivacaine on each side
45602653|NCT05021666|Drug|Placebo|matching placebo
45602654|NCT05021666|Drug|PB 718|dose in the next group will be determined following a review of data from the previous group
45602655|NCT04971824|Procedure|Physiotherapeutic intervention|The physiotherapy consists in performing visceral manipulation of the pelvic and abdomen organs as well as doing special exercises (volunteers get a handout with instructions on how to exercise). The exercises include ones from the Mojzis´s method, Dynamic neuromuscular stabilisation, yoga or other therapeutic methods used by physiotherapists.
45602656|NCT02362360|Device|Coloplast Test Product|A new 2-piece ostomy appliance developed by Coloplast A/S
45602657|NCT02362360|Device|Comparator (Hollister)|Comparator is a Hollister FlexWear baseplate (ileostomy) or a Hollister SoftFlex baseplate (colostomy) both used with a Hollister open bag.
45756081|NCT03502967|Drug|Hyperpolarized [2-13C] Pyruvate|Bolus injection of study drug
45444591|NCT02037646|Other|Cost analysis|Data on direct and indirect costs to patient and institution will be collected at each patient visit related to screening.
45602658|NCT04970108|Drug|Egito|EGITO Egito coated tablet. EMPAGLIFLOZIN PLACEBO Empagliflozin placebo coated tablet. TELMISARTAN PLACEBO Telmisartan coated tablet.
45602659|NCT04970108|Drug|Empagliflozin + telmisartan|Drug: EMPAGLIFLOZIN Empagliflozin 25 mg coated tablet. Drug: TELMISARTAN Telmisartan 40/80 mg coated tablet. EGITO PLACEBO Egito placebo coated tablet.
45602660|NCT02362282|Behavioral|Gait training|Treatment will include coordination exercises and over ground gait training for impaired muscle groups and related gait deficits. The therapy will be provided by a clinical physical therapist specializing in rehabilitation for stroke patients, according to established, conventional guidelines. The protocol was used in the investigators' prior studies, and is designed to restore voluntary control of ankle dorsiflexion during swing phase; hip flexion during swing phase, knee flexion at toe-off, knee flexion during swing phase; knee extension before heel strike; knee control during stance phase; pelvic control during stance phase; and whole body balance control during weight shifting. Newly-learned coordinated movements will be integrated into practice of coordinated gait components. Cognitive rehabilitation will begin with the least difficult aspects of attention control, and progress to the more difficult. Home practice and generalization exercises will be assigned.
45602661|NCT02362282|Behavioral|cognitive training|Cognitive training is designed to enhance attention, intention, executive function, decision making and reaction time. Commercially available computer software will be used, as well as custom cognitive training.
45756082|NCT00701935|Drug|placebo|subcutaneous injection, twice a day
45602662|NCT02362282|Behavioral|Arm training|Treatment will include coordination exercises for reaching and grasping. Activities will include movement of shoulder, elbow, wrist and fingers.
45602663|NCT04969952|Other|For interventional module|Using vedio to assist physicians introducing advance care planning to cancer patients
45602664|NCT05061290|Other|Control Porridge|Maize porridge containing 54Fe as iron sulfate
45602665|NCT05061290|Other|Reference Porridge A|Maize porridge counting 58Fe as iron sulfate with ascorbic acid
45602666|NCT05061290|Other|Test Porridge B|Maize porridge containing 57Fe and fortified with Moringa leaf powder as iron source
45602667|NCT05061290|Other|Test Porridge C|Maize porridge containing 57Fe and fortified with Boabab fruit powder as iron source
45756083|NCT00701935|Drug|exenatide|subcutaneous injection, twice a day, 10mcg
46066564|NCT05593042|Biological|Trivalent Vaccine|"An experimental intervention consisting of a booster dose of an inactivated trivalent (CZ02 strain, ancestral, Delta, and Omicron variants) variant vaccine.~The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral, Delta, and Omicron variants) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in a pre-load syringe containing one dose (0.5mL) (1200 SU of inactivated SARS-CoV-2 WT, 1200 SU of inactivated SARS-CoV-2 Delta variant, and 1200 SU of inactivated SARS-CoV-2 Omicron variant)."
45602668|NCT05061290|Other|Test Porridge D|Maize porridge containing 54Fe and fortified with Moringa leaf and Baobab fruit powder as iron source
45602669|NCT02361580|Other|Diary|Subject keeps diary of recovery
45602670|NCT04421534|Drug|Lactoferrin|adding lactoferrin to standard of care treatment regimens
45602671|NCT05059028|Other|Oxytocin massage AND music therapy|"Oxytocin massage: It is a massage that will accelerate the work of the parasympathetic nerves in order to transmit the oxytocin production stimulus to the posterior lobe of the brain. Massage the scapula from the cervical 7th to the 5th-6th spine, spinal (vertebral), 1-2 cm around the spine, both thumbs up and then 2-3 times down, in a small circular clockwise, downward and upward movements. It is a form of massage by pressing hard.~Music intervention: In order to decide on the type of music to be played to the mothers during breastfeeding, three samples (Pentatonic, Büzürk makam and classical music) selected by the researcher will be asked to the postpartum mother, and the music preferred by the mothers will be determined. It will be ensured that mothers listen to the music determined 5 minutes before the breastfeeding session for 7 days and continue breastfeeding while the same music is playing."
45602672|NCT05058638|Drug|Aquamin|Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
45602673|NCT05017064|Device|Cryotherapy group|The use of intraoral ice pack during root canal treatment
45602674|NCT05017064|Other|Control group|No cryotherapy will be used
45602675|NCT02520284|Biological|Andecaliximab|Andecaliximab 150 mg administered via SC injection
45602676|NCT02520284|Biological|Placebo|Placebo matched to andecaliximab administered via SC injection
46066565|NCT02583412|Biological|Bexsero®|Multicomponent meningococcal B vaccine
45602677|NCT05057234|Diagnostic Test|FoundationOne liquid CDx|FoundationOne liquid CDx testing
45602678|NCT05057234|Behavioral|Quality of life questionnaires|Quality of life questionnaire - EQ5D
45602679|NCT04205552|Drug|Nivolumab 10 MG/ML Intravenous Solution|Neoadjuvant 2 cycles, every two weeks (q2w) Nivolumab 240 mg i.v. over 30 min
45602680|NCT04205552|Drug|Relatlimab 10 MG/ML Intravenous Solution|Neoadjuvant 2 cycles, every two weeks (q2w) Relatlimab 80 mg i.v. over 30 min
45602681|NCT02517866|Drug|Azilsartan Medoxomil|Azilsartan medoxomil tablets
45602682|NCT04966520|Other|Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS)|"Accelerated iTBS will be used to stimulate the regions of interest of mPFC and L-DLPFC nodes in cancer survivors or patients.~Accelerated iTBS will be administered in a single half-day period to allow for a 50minutes interval between any two treatments to minimize interference effects between treatments. Thus, there will be ~10 minute sessions of stimulation x 2 applications per node x 2 nodes (L-DLPFC, mPFC) = 40 total minutes of daily stimulation - each session delivers 1800 pulses in a 5 Hz triplet burst frequency, 2 second trains with intertrain interval of 8 seconds; triplets occur with 50 Hz frequency, as per standard iTBS protocols for depression treatment. The treatment will be offered for five consecutive days."
45602683|NCT04965740|Drug|Cannabis|Recreational Cannabis
45602684|NCT04964726|Behavioral|Real-time fMRI dyadic neurofeedback|Participants will attempt to regulate their partner's brain activation in a specified brain region via real-time fMRI neurofeedback.
45602685|NCT05054738|Behavioral|Combined Recovery Program|A six-session treatment group designed to explore goals, values, and personal strengths about making a change for overall quality of life, health and well-being combined with skill building designed for helping to live a more stable life in their own home that will include money management for financial success and home maintenance.
45602686|NCT05054738|Behavioral|Stable & Able (S&A)|A 90-day Home Telehealth program designed to help maintain skills to stay sober.
45602687|NCT04215848|Drug|Budesonide/Formoterol Fumarate 160 MCG-4.5 MCG Inhalation Powder|After the patients who have all criteria, they will be randomized to take Budesonide/formoterol (160/4.5 μg/d) as need when they have symptoms.
45602688|NCT04215848|Drug|Budesonide 200Mcg Inhalation Powder|After the patients who have all criteria, they will be randomized to take Budesonide (200 μg) twice daily
45602689|NCT04215146|Drug|Paclitaxel|Paclitaxel 80 mg/m^2 1-hour IV infusion on days 1, 8, and 15 of a 28-day cycle.
45602690|NCT04215146|Biological|Pelareorep|Pelareorep 4.5 x 10^10 TCID50 1-hour IV infusion days 1, 2, 8, 9, and 15, 16 of a 28-day cycle.
45602691|NCT04215146|Drug|Avelumab|Avelumab 10 mg/kg (not more than 800 mg) 1-hour IV infusion days 3 and 17 of a 28-day cycle.
45602692|NCT04949750|Other|Paper - based cognitive training|Cognitive training
45602693|NCT04214678|Procedure|Underwater clip closure|Closure of post-resection defect with endoscopic clips by underwater technique
45602694|NCT04214678|Procedure|Conventional clip closure|Closure of post-resection defect with endoscopic clip by conventional technique
45602695|NCT05010200|Biological|PGV-001|personalized genomic peptide vaccine
45602696|NCT05010200|Biological|Poly-ICLC|immune modulator
45444592|NCT02037646|Other|Anxiety scores|Hospital Anxiety and Depression Scale (HADS) questionnaire
45444593|NCT02037646|Other|Patient satisfaction scores|A 5-point patient satisfaction score will be documented at each patient visit related to screening.
45602697|NCT05010200|Biological|CDX-301|soluble recombinant human protein to work on stem cell
45602698|NCT04949360|Behavioral|Online Cognitive-Behavioral Therapy for Insomnia and complementary therapies|The CBTi-O and CBTi-O+ interventions are based on real life user experience. The users will have access to different versions of the platform. The intervention will last eitght weeks.
45804199|NCT05419297|Drug|Buprenorphine Buccal Film [Belbuca]|buprenorphine buccal film is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
45804200|NCT05419297|Other|Urine Drug Screening|Urine drug screening to include controlled prescription medication as well as illicit substances to monitor compliance
45602699|NCT04949360|Behavioral|Regular Cognitive Behavioural Therapy for Insomnia|This is the gold standard behavioral treatment for insomnia and will be performed by independent board-certified sleep psychologists. The treatments will last eight weeks and the appointments will be made by video-calls.
45602700|NCT04949360|Behavioral|Sleep hygiene - minimal intervention|It is composed by educational material about normal sleep pattern and sleep hygiene. It will be delivered by regular mail and email.
45602701|NCT02515994|Device|senofilcon C|Investigational contact lens
46066566|NCT02583412|Biological|Havrix®|Hepatitis A vaccine
45602702|NCT02515994|Device|comfilcon A|Marketed Monthly Replacement Lens (Control)
45602703|NCT04947800|Device|Pulmonary rehabilitation program + EA Lung Mu-Shu+ St36|Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lung Mu-Shu points and St36 points
45602704|NCT04947800|Device|Pulmonary rehabilitation program + Lv7/Gb26|Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lv7/Gb26 points
45602705|NCT04959266|Drug|Adavosertib|Patients will receive a single dose of Adavosertib orally in arm A, B, and C.
45602706|NCT04959266|Drug|Itraconazole|Patients will receive Itraconazole orally once daily for 7 days in arm A.
45602707|NCT04959266|Drug|Rifampicin|Patients will receive Rifampicin orally once daily for 13 days in arm B.
45602708|NCT04959266|Drug|Omeprazole|Patients will receive Omeprazole orally once daily for 5 days in arm C.
45602709|NCT04957862|Procedure|Robotic Assisted Evacuation|On the day of surgery, the patient is placed in the prone position. After the Mayfield skull clamp is positioned to reduce interference, the videometric tracker of robot will automatically scan the preliminary markers to complete patient-to-image registration. Following the registration, the robotic arm will move on command according to the planned puncture trajectory and stop at a defined distance to the marked target point. The entry point is marked on the scalp along the puncture trajectory, then a scalp incision and burr-hole drilling will be performed. After penetrating the dura with unipolar electrocautery, a drainage tube will be gently inserted to the defined depth under the indication of the disinfected robotic arm. The liquefied hematoma will be withdrawn slowly by a 10 mL syringe.
45602710|NCT04957628|Behavioral|Harmful alcohol use treatment|Patients identified through routine hospital screening as having a potentially harmful alcohol use (AUDIT-C 4-6 points (men) / 3-5 points (women) will receive information about the possible harmful effects of their drinking and will be advised to reduce their consumption. Patients identified with more excessive drinking patterns (AUDIT-C > 6 (men) / > 5 (women) will be assessed with blood sample analysis of relevant alcohol biomarkers, psychological assessments for alcohol addiction and withdrawal symptoms, and if necessary referral to alcohol addiction treatment. Patients with severe withdrawal symptoms will be put in CIWA-Ar observation.
45602711|NCT04957628|Behavioral|Non-prescribed psychoactive medicinal use treatment|Patients with prescription on psychoactive medicinal drugs are pharmacologically assessed using serum sample analysis. Patients identified with discrepancy in prescribed doses and serum concentrations will have doses adjusted, or be referred to addiction treatment. Patients identified with psychoactive medicinal drugs other than those prescribed will be advised to quit those medications, or be referred to addiction treatment.
45602712|NCT04956458|Procedure|Lumbar motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
46066567|NCT05509816|Drug|Midazolam|Administered orally.
45602713|NCT04956458|Procedure|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
45602714|NCT05009030|Drug|COVID-19 vaccine|Lung cancer patients will receive an anti-COVID19 vaccine approved by the European Medicines Agency according to the guidelines approved by the regulatory authorities
45602715|NCT05008484|Device|NMES|Subjects will undergo 4.5 months of open kinematic chain resistance training followed by 4.5 months of closed kinematic chain using simple rowing approach
45602716|NCT05008484|Drug|Vitamin D|2000IU oral vitamin D supplementation daily for 9 months
45602717|NCT05008484|Procedure|Passive movement|Subjects will perform simple passive movement exercise for their legs while sitting in their wheelchairs at their home. The frequency of the training will be twice weekly. .
45602718|NCT04212416|Drug|Leflunomide|Given PO
45602719|NCT05007314|Behavioral|Biocriminological Evidence|Participants in each of the two main groups see a case with and a case without a neurobiological explanation for criminal offending.
45602720|NCT04947722|Behavioral|PREVENT Program|A standardized PREVENT educational program will be offered to each intervention LTC home and health-care staff. The curricula includes video modules with fracture-prevention care recommendations and an orientation to the Fracture Prevention Toolkit. Using the Fracture Risk Scale (i.e., a clinical decision support tool embedded in the RAI-MDS 2.0), the LTC team will identify residents at high-risk for fracture and will implement the fracture prevention recommendations into care plans on an individual resident basis.
45602721|NCT04947254|Drug|Abiraterone Acetate|Given PO
45602722|NCT04947254|Drug|Antiandrogen Therapy|Given ADT
45602723|NCT04947254|Drug|Apalutamide|Given PO
45602724|NCT04947254|Procedure|Biopsy|Undergo biopsy
45602725|NCT04947254|Drug|Niraparib|Given PO
45602726|NCT04947254|Drug|Prednisone|Given PO
45602727|NCT04947254|Radiation|Radiation Therapy|Undergo radiation therapy
45602728|NCT05005910|Drug|Vonoprazan|Vonoprazan 20 mg oral every 12 hours (total 72 hours)
45602729|NCT05005910|Drug|PPIs IV infusion|Pantoprazole 80 mg IV loading then 8 mg/hr
45804201|NCT05419297|Device|actigraph|Subjects will wear this device to monitor sleep and activity
46066568|NCT05509816|Drug|Imlunestrant|Administered orally.
46066569|NCT02584972|Other|no intervention required|no intervention required
46066570|NCT04078750|Behavioral|Tailored medication adherence plan|Comparison of mean daily medication adherence between intervention and control groups over 3 months, as measured by MEMS caps.
46066571|NCT02581852|Other|Cross sectional assessment|Assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning
45602730|NCT04954664|Biological|Allograft particles hydrated with rhPDGF|Allograft particles should be hydrated with GEM21S for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
45602731|NCT04954664|Biological|Allograft particles hydrated in a conventional way with saline.|Allograft particles should be hydrated with saline for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane
45602732|NCT04946864|Drug|APG-2575|APG2575 monotherapy
45602733|NCT04946864|Drug|Palbociclib|combination APG2575+pablociclib
45602734|NCT04945148|Drug|Metformin|Metformin 2000 to 3000mg/day daily will be started by 6 weeks after histological diagnosis and 7 days before the start of RT-TMZ and will continue until progression.
45602735|NCT04945148|Radiation|Radiation IMRT|2 Gy x 5 days for 6 weeks to be started 7 days after first administration of Metformin and by 7 weeks after histological diagnosis
45602736|NCT04945148|Drug|Temozolomide|75 mg/m² daily from first to last day of radiation (IMRT) and then 150 to 200 mg/m² x 5 days every 28 days cycle for 12 cycles
45602737|NCT02516306|Drug|EV06 Ophthalmic Solution|
45602738|NCT02516306|Drug|Placebo Ophthalmic Solution|
45602739|NCT02516228|Device|GTEN 100|"Stimulation will be focused on the seizure generating cortex. All patients enrolled in the study will have a pre-treatment baseline evaluation period. During this time, the patient (and/or family) will maintain the seizure diary that simply tracks the number of seizure the patient experiences each day.~During this baseline period, two two-hour EEG recordings (to be completed on 2 separate days) will be acquired. This baseline EEG data will be used to establish baseline inter-ictal spike rate as well as classification of the inter-ictal spikes used to localize seizure onset zone. Using the localization information, patients will be treated with the device for five concurrent days."
45602740|NCT04953806|Behavioral|Step-CBT|Participants will complete Step-CBT, an integrative 12-week physical activity and cognitive behavioral therapy (CBT) intervention, delivered by a licensed clinical psychologist. Sessions will take place once per week for 60 minutes using VA Video Connect. Each session will include core components 1) Reviewing physical activity goals, prescribing new step count goal, and problem-solving barriers and 2) The weekly CBT intervention module.
45602741|NCT04420910|Other|Non-Motor Symptoms|NMSs of the participants were evaluated using the Non-Motor Symptoms Scale (NMSS). The scale consists of 30 yes-no questions and is administered face to face with the therapist.
45602742|NCT04420910|Other|Balance|To measure balance, the Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) was used. The participants were asked to position themselves in a comfortable position on the platform, and their foot position coordinates were recorded. The participants focused on a characteristic dot on the monitor screen. Their task was to balance the body in such a way that the dot was in the center of a circle displayed on the monitor at the point of intersection of the coordinate axes. The test consisted of three 20 s trials, each separated by 10 s breaks. Measurements were conducted while their eyes were open and close, and the results were analyzed by calculating the average value of the measurements.
45756084|NCT03087188|Other|Utilization of inhalator|"After written consent patients will be asked whether they know how to use the inhalator and for how long therapy has been already conducted. Patients using the inhalator correctly have completed the study at this point. If patients have demonstrated incorrect use of the inhalator, a film sequence with instructions will be shown via a tablet. The learning success will be assessed subsequently. When patients show correct application, they will be asked to come back for a follow-up visit within 2 to 8 weeks, otherwise they will be retrained by study staff. At the follow-up visit another demonstration evaluation will be performed.~While demonstrating patients will use the inhalator without any drug that could have any medicinal effect on them."
45602743|NCT04420910|Other|Lower Limb Strength|A Biodex® System 4 Dynamometer device was used to evaluate muscle strength. The participants' dominant extremity was determined by asking them the foot with which they most often hit the ball.The dynamometer arm of the device was placed at the lateral condyle level of the knee, and the belt at the distal end of the dynamometer was attached to the lower leg on the malleolus. Knee flexion and extension movements were evaluated in sitting position between 90ᵒ flexion and 0ᵒ extension angles. The individual was asked to perform it with the maximum strength, while the therapist motivated the individual with verbal stimulation.
45756085|NCT03432143|Other|Community Reviewers|Intervention manuscripts will be reviewed by both a trained community member and scientific reviewers. Community reviewers will follow each journal's instructions regarding electronic access to manuscripts, use of drop-down menus and free-text boxes to address specific aspects of the review, and completion within the time frame specified by the journal.The journal editorial team will use all reviews to make decisions about acceptance, revision, or rejection of manuscripts.
45756086|NCT03087266|Procedure|FM-SRP|Non surgical periodontal treatment performed in all dentition within 1-2 appointments in a 24 hour time frame.
45756087|NCT03087266|Procedure|Q-SRP|Non surgical periodontal treatment performed in 4 sessions comprising of a quadrant (1/4) of the dentition each. Performed in 3 weeks time frame.
45756088|NCT02995213|Behavioral|Accelerometer based feedback about paretic arm use|
45756089|NCT02984696|Drug|1 mg of transdermal estradiol daily and 10mg of oral MPA|
45756090|NCT03277313|Biological|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
45756091|NCT03277313|Biological|GAMMAGARD LIQUID|GAMMAGARD LIQUID IGI (Human), 10% Solution
45756092|NCT00596167|Drug|Intravenous antibiotics|Each subject will receive a single dose of 15 mg/kg vancomycin; 2 mg/kg gentamicin and 250 mg levofloxacin administered intravenously over a one-hour infusion period through the venous limb of their HD access (or tunneled catheter) via an IV pump.
45756093|NCT03087032|Drug|Liraglutide|Patients will receive adding Liraglutide to prandial insulin Lispro. The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week. The dose was maintained until study completion. Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
45756094|NCT03087032|Drug|insulin glargine|Individuals randomized to adding insulin Glargine to prandial insulin Lispro will be instructed on a titration schedule, adjusted every 3 days. Patients subcutaneously self-injected once-daily at approximately the same time each day.
46066572|NCT02583334|Device|Verum acupuncture (30# acupuncture needle)|Acupuncture will be applied by inserting acupuncture needle into acupoints (LI4, LI11, LR3, ST36, SP6, GB34)
45602744|NCT04420910|Other|Functional mobility|The Timed Up and Go test (TUG) was used in the evaluation of functional mobility. . For this test, participants were seated on a standard armless chair and a cone was placed 3 meters away from the chair. Participants were instructed to stand up and (1) walk towards the cone, (2) turn around the cone, (3) walk back to the chair, and (4) sit back on the chair. It was stated that patients should walk without running but as fast as possible. Dual task performance was performed by adding cognitive and motor tasks into the TUG.
45602745|NCT05003570|Drug|Remifentanil|Dosage forms and strengths: 3 mL Vial/1 mg lyophilized powder. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
45756095|NCT04974125|Procedure|Drain|A 10 mm suction drain is placed through a trocar in the right hypochondrium (liver).
45756096|NCT04974125|Procedure|Manual exsufflation|Exsufflation through the trocar opening.
45602746|NCT05003570|Drug|Fentanyl|Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
45602747|NCT05002478|Other|Prone positioning|Turn patient in prone position after surfactant administration.
45602748|NCT04944680|Behavioral|Transcranial Direct Current Stimulation therapy|Transcranial Direct Current Stimulation with two saline-soaked electrodes (5cm x 7cm) is applied by our occupational therapist. The anode is placed on the ipsilesional primary motor cortex (C3/C4). The cathode is placed on the contralesional shoulder. The current is 1.5 milliampere and lasts 20 minutes.
45602749|NCT04944680|Behavioral|Motor imagery therapy|Stroke patients are asked to watch a video about the upper extremity movement. The video lasts 20 minutes. The contents are as follows: the patients are asked to relax the muscles for the first 2 minutes; the action refers to shoulder flexion and extension, elbow flexion and extension, forearm pronation and supination, wrist flexion and extension, finger flexion and extension, and corresponding daily functional activities for 16min; the patients are asked to relax their mind and body for the last 2 minutes.
45602750|NCT04944680|Behavioral|Transcranial Direct Current Stimulation and motor imagery therapy|The treatment parameters are the same as the above. It should be emphasized that the participants sit and perform the motor imagery task while receiving Transcranial Direct Current Stimulation.
45602751|NCT05001698|Biological|Anifrolumab|intravenous infusion (IV)
45602752|NCT04421144|Procedure|orthognathic surgery|patients with maxillofacial disharmony will undergo orthognathic surgery using CAD/CAM Cutting Guides and Customized Titanium Plates.
45602753|NCT04944134|Biological|COVID-19 Vaccination|Receipt of full COVID-19 vaccination
45756097|NCT02994745|Drug|Fimasartan, Atorvastatin|
45756098|NCT03480074|Procedure|Staple Ligation|Using a stapler that staples the DVC and then cuts it.
45756099|NCT03480074|Procedure|Selective Suture Ligation|Suture the DVC, suspend it to the pubic bone, and then cut.
45756100|NCT03480074|Procedure|Single Suture Ligation|Cut the DVC, then pinpoint a specific blood vessel needed to sew/suture.
45756101|NCT01678118|Behavioral|Patient Navigator|The pt navigator will phone (email, text, or other preferred method of contact) pts prior to the date of previously set individual goals (e.g. going to an appt, getting their cessation medications filled, etc) as a reminder & to discuss barriers such as finances, transportation or ambivalent motivation. In this manner, pts receive navigation services tailored to their individual needs & barriers. Once pts are connected with a cessation service (defined as either using cessation medication or at least 1 contact with a Quitline or community-based cessation counselor)or provider-prescribed cessation medication usage, continues the navigation intervention will be considered complete. W/I the 3 month engagement period, pts will receive up to 6 contacts from the Pt Navigator following referral from primary care provider. Consistent with recommended pt navigation practice, the navigator will provide feedback to primary care provider regarding cessation services that the pts are receiving.
45756102|NCT00703261|Drug|atorvastatin|Participants will be asked to self-administer one atorvastatin 10 mg or 80 mg tablet at approximately the same time each day.
45756103|NCT00703261|Drug|placebo|Participants will be asked to self-administer one tablet of placebo to atorvastatin 10 mg or 80 mg at approximately the same time each day.
45756104|NCT02982785|Behavioral|Standard post-operative rehabilitation|
45756105|NCT03225677|Procedure|blood draw and muscle biopsy|One venous catheter will be used for bolus injection of multiple labeled AA at the beginning .The second venous catheter will inserted in the other arm for 5 ml of arterialized venous blood draw.Following the infusions, a single muscle biopsy will be performed from the vastus lateralis of the thigh using the Bergstromm needle.
45756106|NCT02339545|Device|Coronary Orbital Atherectomy plus Stenting|
45756107|NCT04912115|Drug|Ketamine|Ketamine is an FDA-approved N-methyl-D-aspartate (NMDA) receptor-modulating drug pharmacologically classified as an NMDA receptor antagonist (also noted to be a weak opioid receptor agonist).
45756108|NCT04912115|Drug|Midazolam|Midazolam is a benzodiazepine used for anesthesia, procedural sedation, trouble sleeping, and severe agitation.
45602754|NCT02514824|Drug|MLN0128|Investigational mTOR kinase inhibitor
45602755|NCT05000996|Procedure|Bariatric Surgery|Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG)
45602756|NCT04999592|Drug|Standard of care without prophylaxis|Administer antibiotics in response to infection
45602757|NCT04999592|Drug|Antibiotic prophylaxis|Ceftriaxone 2 gm IV q12h for 3 days
45602758|NCT04999358|Behavioral|Protein education|The protein education session is pre-recorded and will describe in lay terms: the health issues associated with low protein intake, the amount of protein to eat in a day, and provide useful information to increase protein intake. This information will focus on the quality and amount of protein eaten, primarily using a whole-food approach. For example, the education sessions will give ideas for everyday foods that can be added to regular meals, favouring plant proteins, fish, lean meat, poultry, low fat dairy and eggs. The education session has been provided in conjunction with an NHS dietitian.
45756109|NCT03452774|Other|Clinical Trial Matching|Using a proprietary application programming interface (API) linked to existing electronic health records (EHR) platforms, individual clinical data is extracted, analyzed and matched to a parametric database of existing institutional and non-institutional CT. Machine learning algorithms allow for dynamic matching based on CT allocation and availability for optimized matching.
45756110|NCT04346147|Drug|Imatinib tablets|Imatinib 400 mg QD oral
45756111|NCT04346147|Drug|Baricitinib Oral Tablet|Baricitinib 4 mg QD oral
45804202|NCT05419297|Behavioral|PROMIS 29|questionnaire will be administered once a week via e-dairy to monitor mood and sleep
45756112|NCT04346147|Other|Supportive tratment|Any therapeutic intervention aimed at the control of clinical deterioration is contemplated without initiating or having previously initiated any drug with potential beneficial effect previously described in vitro or in pre-clinical / clinical models against SARS-CoV-2 prior to patient recruitment.
45602759|NCT04999358|Behavioral|Standard education|Dietary advice provided as part of standard cardiac rehabilitation will be pre-recorded and provided to the control group. This education session will be in addition to usual care.
45602760|NCT02514746|Biological|Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine|0.5 mL subcutaneous injection
45756113|NCT00703729|Device|Cold Compression (CC)|The device is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The device will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
45756114|NCT00703729|Other|Ice Wrap (IW)|The ice bag is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The ice bag is placed on the shoulder and the elastic wrap is used to hold the bag in place. The ice will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
45756115|NCT03478358|Drug|177Lu-DOTA-EB-TATE 1|The patients were intravenously injected with single dose 0.37GBq-0.74GBq (10-30 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
45756116|NCT03478358|Drug|177Lu-DOTA-TATE|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
45602761|NCT02483078|Drug|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
45602762|NCT02483078|Drug|Placebo|
45756117|NCT03478358|Drug|177Lu-DOTA-EB-TATE 2|The patients were intravenously injected with single dose 1.85GBq (50 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
45756118|NCT03478358|Drug|177Lu-DOTA-EB-TATE 3|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
45756119|NCT03478358|Drug|3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine)|The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and amino acids (lysine and arginine).
45756120|NCT03478358|Drug|3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)|The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine).
45756121|NCT04200833|Drug|Golimumab|subcutaneous injection
45602763|NCT02483078|Drug|Optimized Background Regimen|Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.
45602764|NCT02452190|Drug|Reslizumab|Reslizumab will be administered subcutaneously in a dose of 110 mg every 4 weeks.
45602765|NCT02452190|Drug|Placebo|Matching Placebo
45756122|NCT04193579|Behavioral|Language Treatment|Recording of a mother's voice reading a children's storybook.
45756123|NCT04193579|Behavioral|Control Treatment|Standard of Care
45756124|NCT01678352|Biological|Tumor Lysate Vaccine|Cohort 1 Cohort 2 Cohort 3
45756125|NCT01678352|Drug|Imiquimod|Cohort 1 Cohort 2 Cohort 3
45756126|NCT02994667|Device|Permanent Pacemaker Placement|
45756127|NCT04185701|Other|SiVIEW software|Eye examination by a technician with the SiVIEW software
45756128|NCT04185701|Other|Expert|Eye examination by an expert including optimal correction in distance and near vision
45756129|NCT01678430|Drug|Ofatumumab|
45756130|NCT01678430|Drug|Chlorambucil|
45756131|NCT01678430|Drug|Bendamustine|
45756132|NCT04149743|Diagnostic Test|Standard of Care with Hemotag|Comparison of outcomes
45756133|NCT02853149|Behavioral|Spinal Cord Injury (SCI)|"The SCI Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program."
45804203|NCT05419297|Other|sit to stand test|Subjects will complete this daily with specific instructions through the e-diary
45804204|NCT05419297|Other|numerical rating scale pain score|subjects will be asked a pain score in the morning, prior to, and after sit-to-stand testing, and at night
45602766|NCT02514122|Drug|Ketamine|Patients will receive a subcutaneous injection of ketamine (at a dose of 1mg/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
45602767|NCT02514122|Drug|Saline|Patients will receive a subcutaneous injection of saline (at a dose of 0.02cc/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
45602768|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 0.1 mg/kg - 10 mg/kg, Every 2 weeks, 3 years depending on response
45602769|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
45602770|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
45602771|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
45602772|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
45602773|NCT04017871|Other|MRI|MRI at baseline and J90
45602774|NCT04017871|Other|Electro-Encephalography-High Density (children with unilateral PC only)|Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90
45602775|NCT04017871|Other|3D and EMG analysis|3D and EMG analysis at baseline and J90
45602776|NCT04017871|Other|care and classic activities|physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.
45756134|NCT02853149|Behavioral|Caregiver Intervention(CCC)|"The Caregiver Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program."
45756135|NCT02853149|Behavioral|Caregiver Control (CC)|The Caregiver Control group will also discuss ways in which health and fitness can be improved through exercise and nutrition and will also be offered a fully paid membership to the an exercise fitness center to encourage them to exercise and consume a healthy diet. Unlike the Caregiver Intervention group(CCC) the lifestyle recommendations will be provided by internet authorities such as Web Medical(WebMD), the US Department of Agriculture, and the US Department of Human Health Services, which are dependable websites that promote healthy ways of living.
45602777|NCT04017871|Device|Accelerometers|During 5 days a sensor at each wrist to quantify their movement.
45602778|NCT02322463|Drug|Arab children|Treatment with Oxycodone
45602779|NCT03964207|Drug|Tiotropium Respimat® (T1)|inhalation solution
45602780|NCT03964207|Drug|Tiotropium Handihaler® (T2)|Inhalation Powder
45602781|NCT03491995|Drug|Quadruple therapy|Moxifloxacin, omeprazole sodium bicarbonate, nitazoxanide, doxycyclin
45756136|NCT01678664|Drug|Everolimus|10 mg per day of everolimus during 24 months or until progression disease
45756137|NCT01678664|Device|embolization|2 sessions embolization with spheric particles
45756138|NCT01678664|Drug|Doxorubicin|2 sessions chemoembolization with 10 mg of lipiodol with 100 mg of doxorubicine
45602782|NCT03491995|Drug|Classic treatment|Omeprazole, amoxycillin, clarithromycin
45602783|NCT02322541|Other|Garlic Intervention|Participants will consume an Allium-free controlled diet for 3 days. On the 4th day, they will consume a test meal containing garlic followed by blood and urine collections for 10 hours. On the 5th day, participants will have a fasting blood and urine collection.
45756139|NCT04084301|Procedure|High CPB flow|Target CPB flow 2.9 L/min/m2 throughout the CPB period
45602784|NCT04462003|Drug|Apixaban|10 mg/12 h for 1 week followed by 5 mg/12 h
45756140|NCT00597493|Drug|Sorafenib and Temozolomide|Temozolomide (50 mg per meter-squared of body surface area)every day by mouth in combination with sorafenib. Sorafenib will be taken by mouth twice every day. The dose of sorafenib will be 400 mg (2 x 200mg tablets).
45756141|NCT03087422|Behavioral|Text message intervention|The intervention consists in sending text messages with orientation that helps in homecare, specifically attempting to minimize chemotherapy side effects.
45756142|NCT02708147|Other|Physiotheraphy + Conventional treatment|The experimental group will receive 5 physiotherapy sessions at home or in a physical therapy office. The respiratory techniques follow a flowchart which begins with saline instillation into the nose and nasopharyngeal cleaning techniques. Then to clear the lung slow inspiratory and slow and forced expiratory techniques will be used. The application of vibration is also included on the flowchart. During the sessions, educational information will also be provided.
45756143|NCT02708147|Other|Conventional treatment|Medication and observation by a physician/paediatrician. Only evaluations will be made at baseline and on the 3th, 5th and 21st days and an interview 30 days after.
45602785|NCT04462003|Drug|Enoxaparin|1mg/Kg/sc/12h
45756144|NCT03086954|Biological|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
45756145|NCT02999893|Drug|APR-246|APR-246 (also known as PRIMA-1MET), a first-in-class agent targeting mutant p53 resulting in re-expression of wild-type p53 activity.
45756146|NCT03086720|Procedure|Sodium hypochlorite|Application of 10% sodium hypochlorite (60 seconds) after the etching procedure and before the adhesive system.
45756147|NCT03086720|Procedure|Water|Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
45602786|NCT04460989|Procedure|arthroplasty|total knee replacement
45756148|NCT04044443|Device|IMPEDE or IMPEDE-FX|Peripheral vascular embolization
45756149|NCT03086798|Procedure|Magill forceps|Magill forceps techniques to facilitate nasotracheal tube advancement into trachea
45756150|NCT03086798|Procedure|cuff inflation|cuff inflation techniques to facilitate nasotracheal tube advancement into trachea
45756151|NCT03990779|Diagnostic Test|Echocardiography|Echocardiographic examination before and after cardiopulmonary bypass
45756152|NCT03450668|Device|mOm incubator|24 hour usage of test incubator
45756153|NCT03450668|Device|standard incubator|standard incubator
45602787|NCT03489265|Drug|Eluxadoline 100 mg|100 mg capsule-shaped tablet by mouth taken twice per day
45602788|NCT03489265|Other|Placebo|Matching capsule-shaped placebo tablets taken by mouth twice per day
45602789|NCT03497065|Procedure|non-surgical periodontal treatment|scaling, root planing, polishing, and oral hygiene education was performed
45602790|NCT03344341|Drug|Dapagliflozin|Starting dose of dapagliflozin is 5 mg once daily, taken orally in the morning, before or after breakfast. From the third week,the dose can be increased to 10 mg once daily, and last to the end of the study.
45602791|NCT03344341|Drug|Acarbose|Acarbose was started from 50 mg once a day at dinner during the first week and titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.
45602792|NCT03260881|Drug|Liraglutide Pen Injector [Victoza]|Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
45602793|NCT03260881|Drug|matching liraglutide-placebo pre-filled pens|Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
45756154|NCT03963167|Drug|BDP/FF/G fixed combination|Fixed combination of Inhaled Corticosteroid (ICS) / Long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) that contains Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (G).
45756155|NCT03086252|Procedure|Red Blood Cell Transfusions (RBCT)|Undergo patient-driven RBCT
45756156|NCT03963089|Procedure|Tidal volume_6mL/kg|Set tidal volume to 6mL/kg for 1 minute
45756157|NCT03963089|Procedure|Tidal volume_10mL/kg|Set tidal volume to 10mL/kg for 1 minute
45602794|NCT03238495|Drug|Taxotere, Carboplatin, Herceptin + Pertuzumab|TCH+P chemotherapy every 3 weeks for 6 cycles: Taxotere 75mg/m2, Carboplatin AUC 6, Herceptin 6mg/kg (first cycle loading dose of 8mg/kg), Pertuzumab 420mg (first cycle loading does of 840mg)
45602795|NCT03238495|Drug|Metformin|TCH+P chemotherapy every 3 weeks for 6 cycles. Metformin 850 mg daily during the first cycle, then 850 mg twice daily for the remaining 5 cycles.
45602796|NCT02536339|Drug|Pertuzumab|Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
45602797|NCT02536339|Drug|Trastuzumab|Participants will receive trastuzumab at a dose of 6 milligrams per kilogram (mg/kg) of body weight once weekly via IV infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
45602798|NCT01869361|Drug|Indomethacin|Study drug
45602799|NCT01869361|Drug|Placebo|Control drug
45602800|NCT02322619|Drug|Moxifloxacin Tablets 400 mg|Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
45602801|NCT01578967|Drug|Brentuximab vedotin|IV, 1.8mg/kg, every 3 weeks for 6 cycles.
45602802|NCT01578967|Drug|ABVD|"Doxorubicin - 25mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.~Bleomycin - 10u/m2 IV, Day 1 and 15, every 28 days, 2-6 cycles Vinblastine - 6mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.~Dacarbazine - 375mg/m2 IV over 30 minutes, Day 1 and 15, every 28 days, 2-6 cycles."
45444594|NCT03799965|Other|ERAS (Enhanced Recovery After Surgery ) are evaluated|In this arm ERAS( Enhanced Recovery After Surgery) protocol will be inserted.The findings regarding the patients under ERAS protocol are evaluated based on evidence.
45756158|NCT03963089|Procedure|Tidal volume_14mL/kg|Set tidal volume to 10mL/kg for 1 minute
45756159|NCT03963089|Procedure|Fluid loading|Administer 10mL/kg of crystalloid for 5 minutes
45756160|NCT04402112|Drug|Pitavastatin|1mg, 2mg, or 4mg, Once a day, at least 8 weeks
45756161|NCT00597727|Drug|Peanut SLIT|Liquid peanut protein drops diluted in glycerin which are dosed under the tongue.
45756162|NCT00597727|Drug|Placebo SLIT|Liquid glycerin without peanut which are dosed under the tongue.
45756163|NCT03952403|Drug|HLX10, an engineered anti-PD-1 antibody|HLX10 will be administered as IV infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until loss of clinical benefit or up to 2 year.
45756164|NCT03952403|Drug|HLX04, a bevacizumab biosimilar|HLX04 will be administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
45756165|NCT03952403|Drug|Carboplatin|Carboplatin will be administered at area under the concentration-time curve (AUC) 5 on Day 1 of each 21-day cycle for 4 cycles, or until loss of clinical benefit whichever occurs first.
45756166|NCT03952403|Drug|Pemetrexed|Pemetrexed will be administered as IV infusion at a dose of 500 milligrams per square meter (mg/m2) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
45756167|NCT01678742|Dietary Supplement|High-protein diet|"The high-protein diet is made up of 50% carbohydrate, 40% of protein and 10% of fat, providing 480 kcal.~A protein part of the high-protein diet is mostly composed of a grilled Jeju red horsehead fish, a special product of Jeju island in Korea."
45756168|NCT01678742|Dietary Supplement|Standard diet|The standard diet is made up of 60% carbohydrate, 20% of protein and 20% of fat, providing 480 kcal.
45756169|NCT03474770|Drug|BIS-001ER|BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
45756170|NCT03952169|Dietary Supplement|Lactobacillus paracasei dietary supplement|a commercial probiotic dietary supplement
45756171|NCT03952169|Other|Placebo controls|placebo with a similar appearance to probiotics supplement
45756172|NCT04270201|Other|Saliva collection|Saliva collection
45756173|NCT02998645|Drug|eltrombopag|Film-coated tablets (12.5 mg, 25 mg, 50 mg and 75 mg) administered orally, once daily. Dosing is done according to age and ethnicity (East Asian)
45804205|NCT05419297|Behavioral|patient global impression of function|subjects will be asked three questions once a day to assess their personal impression of functional status
45602803|NCT01186003|Drug|Detemir|Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
45602804|NCT03496909|Behavioral|Standard OT|12 weekly sessions of occupational therapy tailored to patients with RFS secondary to breast cancer treatment. Sessions can include manual therapy, education, and active and passive range-of-motion, etc.
45804206|NCT05419297|Behavioral|PROMIS - sleep|Subjects will answer 5 questions about sleep every morning via e-diary
45602805|NCT03496909|Behavioral|PhysioTouch|12 weekly sessions of occupational therapy tailored to patients with RFS secondary to breast cancer treatment. Sessions can include use of the PhysioTouch electronic massager in lieu of manual therapy, education, and active and passive range-of-motion, etc.
45756174|NCT02998645|Drug|Cyclosporine|"Supplied in oral soft gel capsules or oral solution and dosage is based on body weight and administered every 12 hours. Dosing is titrated individually according to therapeutic trough level for 6 months. After 6 months (for responders), tapering of cyclosporine must be done as follows:~6-9 months: at the 6 months visit, the dose must be reduced by 25% for 3 months~9-12 months: at the 9 months visit, the dose must be further reduced by 25% for another 3 months~12-24 months: maintain dose"
45602806|NCT02322697|Drug|Intravenous administration of L-carnitine|Chronic intravenous administration of L-carnitine (1000mg on each dialysis session) for 1 year in hemodialysis patients
45602807|NCT05149963|Other|Cognitive Behavioural Therapy (CBT) for Chronic Loneliness|Participants will receive an average of 12 50-minute sessions of Cognitive Behavioural Therapy (CBT) aiming to reduce their feelings of loneliness
45602808|NCT03488875|Behavioral|mMBRT|Madison Mindfulness-Based Resilience Training (mMBRT) is an 8-week mindfulness-based intervention developed specifically for police officers, which is similar to and inspired by a program developed by researchers at Pacific (OR) University (Christopher, Goerling et al., 2016). mMBRT includes 8 weekly 2-hour classes involving guided meditation practice, gentle movement, and group-based discussion (the 7th class is a longer, 4-hour class). The total class time is about 18 hours over 8 weeks, and participants are asked to engage in home practice for up to 30 minutes/day, 6 days/week throughout the intervention.
45602809|NCT03485989|Other|Hazelnuts|Dry roasted, individually packaged hazelnuts provided from the Hazelnuts Marketing Board of Oregon
45602810|NCT03485833|Diagnostic Test|EEO and EIO test|velocity time integral of the aorta measured by transesophageal echocardiography after end-expiratory and end-inspiratory occlusion test
45602811|NCT03488797|Behavioral|Supervised web- and home-based exercise intervention|"The intervention group gets access to a training platform. Every week, 3 training videos of 20 minutes each will be released on that platform with the aim to perform those during the ongoing week.~Each exercise session is arranged in a video session with child friendly instructions and executions for the different exercises. The videos serve as a virtual training partner and exercise will be performed simultaneously while watching the video~The overall training volume is 72 session calculated from 3 sessions per week over a duration of 24 weeks (6 month)"
45602812|NCT02322853|Drug|Tamoxifen|hormonotherapy
45602813|NCT02322853|Drug|Ralimetinib (LY2228820 dimesylate)|
45602814|NCT03488719|Drug|Metoprolol Succinate 25 MG|Metoprolol 25mg
45602815|NCT03488719|Drug|Metoprolol Succinate 50 MG|Metoprolol 50mg
45602816|NCT03488719|Drug|Metoprolol Succinate 100 MG|Metoprolol 100mg
45756175|NCT03450122|Biological|Aldesleukin|Given SC
45756176|NCT03450122|Biological|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
45756177|NCT03450122|Drug|Cyclophosphamide|Given IV
45756178|NCT03450122|Biological|Dendritic Cell-targeting Lentiviral Vector ID-LV305|Given ID
45756179|NCT03949907|Other|Nutritional counseling alone|"Nutritional counseling consists of a personalized dietary prescription (including sample meal plans and recipe suggestions) tailored on personal eating patterns and food preferences, in order to achieve estimated protein-calorie requirements and to take into account chewing and swallowing abilities. Regular consultation by a registered dietitian will be also provided every 10 days by means of face-to-face interviews (at scheduled follow-up visits - chemotherapy cycle) and telephone interviews (planned between chemotherapy cycles and as required by the patient). In the presence of significant reduction of normal food intake, the use of oral nutritional supplements will be also considered.~In the presence of body weight loss >10% of the weight recorded at enrollment, patients allocated to this group group will be censored and treated according to current supportive care guidelines, including home parenteral nutrition."
45756180|NCT03949907|Other|Early supplemental parenteral nutrition plus nutritional counseling|"Patients will receive nutritional counseling in combination with systematic early supplemental home parenteral nutrition since diagnosis.~Supplemental home parenteral nutrition will be prescribed, provided daily and adjusted throughout the study (approximately every 10 days, until the end of the scheduled first-line chemotherapy) according to estimated protein-calorie oral intakes, in order to satisfy estimated requirements. Home parenteral nutrition will be infused mainly during night hours, using multi-chamber bags containing olive oil-based lipid emulsions, when not contraindicated."
45756181|NCT00707863|Drug|Escitalopram|10 mg of Escitalopram by mouth once a day for 8 weeks
45602817|NCT02743871|Biological|PF-06817024|Subjects will be given one dose of PF-06817024 intravenously
45602818|NCT02743871|Other|Placebo for PF-06817024|Subjects will be given one dose of placebo for PF-06817024 intravenously
45602819|NCT02743871|Biological|PF-06817024|Subjects will be given one dose of PF-06817024 subcutaneously
45602820|NCT02743871|Other|Placebo for PF-06817024|Subjects will be given one dose of placebo for PF-06817024 subcutaneously
45602821|NCT02743871|Biological|PF-06817024|Subjects will be given two doses of PF-06817024 intravenously
45602822|NCT02743871|Other|Placebo for PF-06817024|Subjects will be given two doses of PF-06817024 intravenously
45602823|NCT02743871|Biological|PF-06817024|Subjects will be given 2 doses intravenously
45602824|NCT02743871|Other|Placebo for PF-06817024|Subjects will be given 2 doses intravenously
45602825|NCT02743871|Biological|PF-06817024|Subjects will be given doses of PF-06817024 intravenously
45602826|NCT02743871|Other|Placebo for PF-06817024|Subjects will be given doses of Placebo intravenously
45602827|NCT02447653|Device|G7 HA Acetabular Component|G7 HA Acetabular Component
45602828|NCT02447653|Device|G7 PPS Acetabular Component|G7 PPS Acetabular Component
45602829|NCT05150665|Procedure|En-masse retraction|"Power chain and Crimpable hook for En-Masse Retraction Retraction will start on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 200 g per side) extending between the crimpable hooks and the miniscrew"
45602830|NCT05150665|Procedure|Two step Retraction|"Retraction of canine started on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 150 g per side)followed by anterior teeth retraction on 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 160 g per side) extending between the crimpable hooks and the mini-screw."
45602831|NCT03496831|Drug|Biologic Agents|
45756182|NCT00565643|Device|modified sodium hyaluronic acid and carboxymethylcellulose|Adhesion barrier applied at the time of initial cesarean delivery
45602832|NCT03488485|Drug|Direct Acting Antivirals|DAAs given in patients with viremic chronic hepatitis C
45756183|NCT00565643|Device|Placebo|Routine abdominal closure without placement of adhesion barrier
45756184|NCT00708019|Behavioral|PRO-SELF PLUS Pain Management Program|The psychoeducational intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve cancer pain management. Patients in both groups will be seen in their homes over the course of 10 weeks with phone calls conducted in between the home visits. Patients in the HIGH-DOSE group will receive 6 visits and 10 phone calls [total time 12.3 hours]. Patients in the LOW-DOSE group will receive 4 visits and 6 phone calls [8.0 hours]. Follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. Both quantitative and qualitative analyses will be conducted to evaluate patient outcomes.
45602833|NCT00821249|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
45756185|NCT05246501|Other|Simulation|A case scenario with a diagnosis of dementia was used in the study. The scenario consisted of preliminary preparation, implementation and evaluation parts. Psychiatric nursing laboratory practice was applied to the students in the scenario study group. An elderly female standard patient who was diagnosed with dementia took part in the scenario. During this simulation, students were expected to perform mental state examination of the patient, use therapeutic communication techniques and ensure environmental safety.
45756186|NCT05246501|Other|No simulation|The students in the control group did not receive simulation training.
45756187|NCT04386733|Other|no intervention, it was an observational study which looked at the reasons for surgical cancellations|the investigators observed how many patients had their surgeries cancelled and analysed the reasons of these cancellations
45756188|NCT05246423|Diagnostic Test|Observation group|Patients with paroxysmal atrial fibrillation undergo cardiopulmonary exercise testing, echocardiography, 24-hour ambulatory electrocardiographic monitoring and plasma biomarkers' measurement
45756189|NCT02321527|Drug|Perflutren Protein-Type A Microspheres Injectable Suspension|Participants receive a subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension (OPTISON™) before breast ultrasound.
45756190|NCT02321527|Device|Contrast-Enhanced Ultrasound (CEUS)|Ultrasound images of breast and videos of tumor and lymph nodes in underarm area taken after Perflutren Protein-Type A Microspheres Injectable Suspension injection.
45756191|NCT02321527|Procedure|Biopsy + Radioactive Seed Placement|Biopsy of sentinel lymph node that was identified in ultrasound performed, and a titanium clip marker inserted into the node. After biopsy, a radioactive seed may be inserted into the node to allow surgeon to find and remove it during surgery.
45756192|NCT02321527|Behavioral|Phone Call|Participant called by phone 30 days after seed is removed to check for any side effects. This phone call should take about 10 minutes.
45756193|NCT03889535|Device|Resin strip crowns|"Technique:~I.Select shade of resin-based composite II.Rubber dam isolation III.Select primary incisor celluloid crown form with mesiodistal width similar to the tooth to be restored and trim the selected crown form to fit.~IV.Remove decay with slow speed round bur. Perform pulp therapy, if indicated. V.Reduce incisal edge by 1.5 mm VI.Reduce interproximal surfaces by 0.5 to 1.0 mm with feather edge at gingival margin. The interproximal walls should be approximately parallel.~VII.Reduce buccal surface by 1.0 mm and lingual surface by 0.5 mm with feather edge at gingival margins.~VIII. Round line angles IX.Etch for 15 to 20 seconds, rinse and air dry X. Apply bond and polymerise XI. Fill crown form to 2/3 full with composite resin and seat onto the tooth. Remove excess material with hand instrument. Polymerise.~XII. Remove celluloid crown form with scaler XIII. Finish and polish"
45756194|NCT03889535|Device|Zirconia crowns|I.Choose appropriately sized crown based on tooth's dimension; evaluate occlusion. II.Rubber dam isolation. III.Remove decay, perform pulp therapy if indicated. IV.Prep mesial half of incisal edge to complete thickness of 001 donut bur. V.Prep and blend distal half of incisal edge to create uniform incisal reduction. VI. Create chamfer margin at gum line at least half the thickness of bur tip. VII. Taper incisal half lingually to create a thin incisal edge. VIII. Remove cingulum and 0.75-1.25mm of lingual enamel; blend together forming smooth, slightly concave surface extending to tissue. IX. Thin incisal half. X.With 004 flame bur, remove chamfer margin at tissue level. Keep bur parallel to long axis of tooth. Remove chamfer in incremental steps, XI. Extend tip of bur full 2mm subgingivally. While hugging bur axially along root surface, make 3 circumferential passes. XII.Clean tooth and control bleeding. XIII.Cement crown with pure glass ionomer cement
45756195|NCT01798511|Procedure|Nasogastric Tube Feeding|A nasogastric tube will be placed into the stomach of patients.
45756196|NCT01798511|Other|Conventional Nutritonal Management|Patients who are to have CNM will be on nil-by-mouth regimen until they either develop signs of severe AP (in which case nasojejunal tube feeding will be introduced) or the signs of AP mitigate (in which case clear liquids (as tolerated) followed by oral food (as tolerated) will be introduced)
45756197|NCT02998411|Other|Titration|
45804207|NCT05716802|Behavioral|dance/movement therapy|dance/movement therapy plus treat as usual
45602834|NCT00821249|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care; Part 3: standard of care.
45602835|NCT00821249|Drug|Dexamethasone, steroid; oral|Part 3: standard of care.
45602836|NCT03496753|Device|Led Therapy|The following will be the phototherapeutic parameters: total spot area: 1.44 cm²; continuous emission mode; output power: 10 mW; infrared wavelength (880 to 904 nm); fluence: 4 J/cm²; and application time: 10 minutes/session. Sessions will be held three times a week on alternating days for six consecutive weeks, totaling 18 sessions.
45602837|NCT00825539|Drug|AQW051|
45602838|NCT00825539|Drug|Placebo|
45602839|NCT03485599|Diagnostic Test|ELIZA , Westron blot|Blood sample will be taken then rapid test by ELIZA will be done if positive then confirmatory test by Westron blot will be done
45602840|NCT03752723|Drug|GX-I7|i.m.
45602841|NCT03752723|Drug|Pembrolizumab|i.v.
45602842|NCT03752723|Drug|cyclophosphamide|i.v.
45602843|NCT02322931|Procedure|Intra-operative C-arm CT imaging|"Two intra-operative C-arm 3D reconstruction scans with the Ziehm Vision FD Vario 3D immediately after treatment implantation, once with the TRUS probe inserted and once with the TRUS probe removed. This involves approximately 10 fluoroscopy snapshots of the prostate.~Two TRUS Sagittal B-mode sweeps and two TRUS axial B-mode sweeps, once mid-way, i.e. after implanting a sub-set of the seeds, and once at the end of the implantation procedure.~One Cine loop C-arm scan in the sagittal plane while retracting the probe.~One 3D C-arm scan immediately after the treatment, with the TRUS probe removed and the patient in the supine position (i.e. legs down)."
45602844|NCT04472585|Drug|Ivermectin Injectable Solution|Subcutaneous Ivermectin 200ug/kg body weight 48 hourly
45602845|NCT04472585|Other|Injectable Placebo|0.9% normal saline
45602846|NCT04472585|Drug|Zinc|Zinc Sulphate 20mg 3 times a day
45602847|NCT04472585|Drug|Placebo empty capsule|Placebo empty capsule
45756198|NCT01798277|Procedure|Catheter Ablation|Catheter ablation of ventricular tachycardia will employ three-dimensional mapping Fast Anatomical Mapping or CARTOSOUND technology (Biosense Webster Inc.), and the Thermocool Navistar catheter (Biosense Webster Inc.).
45756199|NCT01798277|Drug|Medical therapy (sotalol or amiodarone)|Patients will be tiered to one of two possible antiarrhythmic drugs (sotalol or amiodarone).
45756200|NCT04344847|Procedure|Laparoscopic sleeve gastrectomy|Excision of Gastric GIST along fundus or body of stomach in the same specimen of LSG with safety margin 1-2cm
45756201|NCT00598507|Drug|ZK-EPO|Participants were treated with 16 mg/m^2 of ZK-EPO (EpothiloneZK) (Sagopilone) administered as a single 3 hour intravenous infusion every 21 days. Prior to each treatment, participants were premedicated with either granisetron or ondansetron and additional anti-emetics if needed. Chemotherapy was continued until disease progression, withdrawal of consent, or for unacceptable treatment-associated toxicity.
45756202|NCT00566579|Procedure|Cryotherapy|Double freezing technique
45756203|NCT00566813|Drug|Islet Cell Transplant|1-3 allogeneic islet transplants; two doses of basiliximab 20 mg iv.; sirolimus po trough levels 10-15 ng/ml X 3 months, then 7-10 ng/ml; tacrolimus po trough levels 3-6 ng/ml
45756204|NCT00566813|Drug|Islet Cell Transplant plus|1-3 allogeneic Islets of Langerhans transplantations; two doses of basiliximab 20 mg iv.; sirolimus po daily to maintatin serum levels 12-15 ng/mL for 3 months, and 7-10 ng/mL thereafter; tacrolimus po twice daily to maintain serum levels 3-6 ng/mL; etanercept 50 mg IV before islet transplant, 25 mg subcutaneously post-transplant days 3, 7, 10; exenatide subcutaneously 5 mcg pre-transplant and twice daily for I week, then increased to 10-mcg twice daily for 6 months after the last islet transplant.
45602848|NCT04472585|Drug|Oral Ivermectin|0.2mg/kg/day
45756205|NCT00088166|Drug|hCRF|hCRF ; open-label dexamethasone that the patient is currently taking
45911078|NCT02003261|Behavioral|Unified Protocol with Treatment As Usual|"Unified Protocol(UP) is a transdiagnostic cognitive-behavioral therapy for depressive and anxiety disorders, which is developed by Dr. Barlow and his colleagues at Boston university.~UP is weekly, face to face, individual psychotherapy consisting of 9 to 20 sessions. Average session number is 16 sessions. Contents of the treatment includes motivational enhancement, psychoeducation of treatment rationale and emotion, emotion awareness training, cognitive reappraisal, avoidance and emotion driven behaviors, interoceptive exposure and emotion exposure."
45602849|NCT03496519|Drug|Dose Escalation of Durvalumab and Trabectedin|"There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be an increase in Trabectedin for each cohort, given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.~Cohort -1: Durvalumab 1125mg with Trabectedin 0.5mg/m2~Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2~Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2~Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2~Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2"
45602850|NCT03496519|Drug|Dose Expansion of Durvalumab and Trabectedin|There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be a fixed dosage of Trabectedin for each cohort, whatever was determined to be the safest dose during the Dose Escalation Phase, and it will be given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.
45756206|NCT00088166|Drug|placebo hCRF|placebo hCRF 2mg/day and open-label dexamethasone that they are taking
45756207|NCT00566969|Drug|sugar pill|Subjects randomized to placebo, carvedilol 25mg or 50mg
45756208|NCT00566969|Drug|Carvedilol 25 mg|subjects randomized to placebo, carvedilol 25mg or 50mg
45756209|NCT00566969|Drug|Carvedilol 50 mg|subjects randomized to placebo, carvedilol 25mg or 50mg
45756210|NCT03086564|Biological|ADCC & TACE|Experimental groups will be given TACE as well as Activated-Dendritic Cells(1-2*10^8,intravenous drip),simultaneously.Cyclophosphamide(250mg/cm2,intravenous drip) will be used two days before TACE performed.
45756211|NCT03086564|Procedure|TACE|TACE solely in the first day of a clinical course.
45911079|NCT02003261|Other|Treatment As Usual|Most of the TAU will be drug therapy or nonsystematic supportive psychotherapy.
46066573|NCT02583334|Device|Sham acupuncture|Streitberger device will be applied by onto acupoints (LI4, LI11, LR3, ST36, SP6, GB34). The device will not really insert the blunt needle into skin but let the participants feel like real acupuncture (Lancet 1998; 352: 364-365.).
45756212|NCT05363423|Procedure|Draf III procedure with lateral pedicled nasoseptal flaps applied|"The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre. Type 1 flaps consisted of mucosa over the lateral nasal wall, and type 2 flaps consisted of the aforementioned mucosa and corresponding septal mucosa. After Draf III procedure, type 1 flaps were used to cover the bare bone of the ipsilateral frontal process and part of the ipsilateral anterior frontal table, which also constituted the bare bone area of the Draf II procedure. Type 2 flaps were used to cover for the bare bone of the ipsilateral frontal process and bilateral anterior or posterior frontal table."
45756213|NCT05363423|Procedure|Draf III procedure without any flap applied|"The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre."
45602851|NCT03485521|Procedure|The tracheobronchial aspiration|"Reading of the procedures of the tracheobronchial aspiration (legislative framework, rules of hygiene, procedures, undesirable effects) The Practical Group participates in a practical work lasting two hours and the Stimulation Group is in simulation with a procedural practice of tracheobronchial suction as part of a simulation sequence. This group benefits from the methodology of the simulation with a part of briefing, a part simulated session and to finish the debriefing.~The experiment finished with a real activity on patients with tracheotomy with in this environment the reproduction of the procedure"
45602852|NCT03726905|Other|respiratory muscles training|4 weeks respiratory muscles training aimed on respiratory muscles endurance and lengthening expiration time
45602853|NCT03726905|Other|sham respiratory muscles training|4 weeks sham respiratory muscles training with the help of breathing simulators, with a breathing resistance level set at 0
45602854|NCT03726905|Other|aerobic training|12 weeks treadmill walking
45602855|NCT03485443|Drug|%0.9 NaCl 10ml/kg|Fluid administration
45602856|NCT03485443|Drug|%0.9 NaCl 20ml/kg|Fluid administration
45602857|NCT00814073|Drug|Masitinib|Masitinib 6 mg/kg/day
45602858|NCT00814073|Drug|Placebo|Matching placebo
45602859|NCT00814073|Other|Best Supportive Care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglicate, antidepressants, leukotriene antagonists, interferon-alpha, 2-CdA, and corticosteroids.
45756214|NCT00598663|Device|insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System)|6 months of pump plus continuous glucose sensing in conjunction to SMBG
45602860|NCT02442115|Other|Treatment of Functional Constipation by|The NASPGHAN protocol is used by pediatric gastroenterologist to treat functional constipation. Status is monitored at 4 visits and adjustments to treatment are made based on clinical standards and judgment.
45756215|NCT00598663|Device|insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)|insulin pump with smbg to be worn for 6 months. 15 days in each 6 week period blinded continuous glucose sensing will be conducted.
45602861|NCT05150353|Procedure|MRI|Wrist MRI
45602862|NCT00813605|Other|FOLFIRI|"Day 1 of each Cycle~Combination Therapy of:~irinotecan 180 mg/m2 90-minute infusion leucovorin 400 mg/m2 2 hour infusion 5-FU 400 mg/m2 IV bolus 5-FU 2,400 mg/m2 46-48 hour infusion"
45602863|NCT00813605|Biological|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that selectively binds to Death Receptor-5 (DR-5)
45602864|NCT00813605|Other|Placebo|Inactive dummy agent (to maintain blind)
45756216|NCT04350489|Other|Non-surgical periodontal treatment|Conventional non-surgical periodontal treatment were performed
45602865|NCT00813605|Biological|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1
45602866|NCT05134285|Other|blood pressure,BMI, blood sample|Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.
45602867|NCT00724841|Drug|Obatoclax Mesylate|Obatoclax Mesylate (GMX1777) at various doses in combination with temozolomide
45602868|NCT00724841|Drug|Temozolomide|
45602869|NCT00811889|Other|Placebo|Placebo
45602870|NCT00811889|Drug|Bardoxolone Methyl (RTA 402)|Oral, Once Daily
45602871|NCT03488329|Dietary Supplement|Individual nutritional therapy|"Guidance from a clinical dietician.~Individual nutrition plan~A package containing foods and drinks, which will cover their nutritional needs the first day after discharge.~A goodiebag containing samples on protein-rich milk-based drinks.~Telephone follow-up after 4 and 30 days and the possibility to call the dietician in case of questions about nutrition."
45602872|NCT00811499|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
45602873|NCT00811499|Drug|Placebo; oral|matching placebo
45602874|NCT00811499|Drug|Placebo; oral|multiple dose, single schedule
45602875|NCT03496441|Other|Fecal sample collection for analysis|Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs); Iron and heme measurements in the samples.
45602876|NCT03675815|Drug|Darunavir (DRV) 800 milligram (MG) Oral Tablet|800 milligrams (mg) orally once daily for 96 weeks
45602877|NCT03675815|Drug|Ritonavir 100 MG Oral Tablet|100 mg orally once daily for 96 weeks
45602878|NCT03675815|Drug|N(t)RTIs|Choice of N(t)RTIs determined by clinician guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection
45602879|NCT03675815|Drug|Dolutegravir 50 MG Oral Tablet|50 mg orally once daily for 96 weeks
45602880|NCT03675815|Drug|TDF 300 MG Oral Tablet|300 mg orally once daily for 96 weeks
45602881|NCT03675815|Drug|3TC 300 MG Oral Tablet|300 mg orally once daily for 96 weeks. Choice of 3TC or FTC will be determined by clinician
45602882|NCT03675815|Drug|FTC 200 MG Oral Cap|200 mg orally once daily for 96 weeks. Choice of emtricitabine or lamivudine will be determined by clinician
45602883|NCT05091697|Behavioral|Multicomponent treatment VIRTUAL FIBROWALK + TAU|To assess the effectiveness and cost-utility of the virtual multicomponent program (Fibrowalk)
45756217|NCT02987673|Procedure|MGB/OAGB|
45756218|NCT02987673|Procedure|LSG|
45756219|NCT03731819|Diagnostic Test|Abbreviated PB MRI|Abbreviated PB MRI which targets table time of 10 minutes. For MRI acquisition, standard dose of commercially available MR contrast agent (Gadovist, Bayer, Germany) is used on weight-based dosing (0.1mmol/kg).
45756220|NCT00704353|Drug|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.
45756221|NCT00704353|Drug|Standard Medical Care (SMC)|Per product label
45602884|NCT05068219|Procedure|Usual physical therapy|"Standard rehabilitation for diaphragmatic paresis~EFA (Expiratory Flow Acceleration) at the upper thoracic level.~PEP (Positive Expiratory Pressure).~Expectoration if necessary (coughing up and spitting out)"
45602885|NCT05068219|Procedure|Contract-Relax technique|"The diaphragmatic CR is done in a semi-sitting position.~The CR is composed of 4 steps :~First maximum inspiration expiration with position of the hands of the physiotherapist on the last ribs and without resistance (Goal: taking rhythm).~Second maximum inspiration expiration : Free inspiration, expiration with pressure on the last ribs to bring the diaphragm into internal stroke.~Maximum inspiration against resistance, then maximum expiration with increased pressure.~Maximum inspiration with dynamic release of resistance (Goal: hyperextension of the diaphragm) followed by maximum expiration with resistance to allow an increase in expiratory flow."
45756222|NCT05246033|Drug|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
45756223|NCT05246033|Drug|Placebo for TransCon CNP|Weekly subcutaneously injection of placebo.
45602886|NCT03560609|Device|Ophthalmodynamometer|The ODM (Baillart ophthlmodynamometer) is a disc attached to a piston that induces a controlled force on a fixed area. The device will be used to apply a pressure within the range of 10 mmHg - 50 mmHg 4 times to each eye. Each increase of pressure will last approximately 30 seconds. The device is FDA approved and will be used as routinely used in clinical practice
45602887|NCT03560609|Device|Goldmann applanation tonometer|The Goldmann applanation tonometer (Haag-Streit, Basel, Switzerland) measures the IOP after the eye is numbed with a drop of anesthetic (proparacaine), which is approved by the FDA. Proparacaine is part of routine patient care using a tonometer regardless of participation in this study. The instrument's tip lightly touches the surface of the cornea and the IOP is measured. The device is FDA approved is routinely used in clinical practice.
45602888|NCT03560609|Device|Pentacam|This device maps the cornea and provides pachymetry, topography and corneal aberration maps. The device is FDA approved and routinely used in clinical practice.
45602889|NCT03560609|Device|ORA|ORA is an air puff tonometer that applies controlled force to flattens the cornea and provides the corneal hysteresis and corneal resistance factor. The device is FDA approved and routinely used in clinical practice.
45602890|NCT03560609|Device|Optical Coherence Tomography (OCT)|OCT is a non-contact,real-time, high resolution, and reproducible imaging modality that provides in-vivo optical cross-sectional scanning of the retina, the ONH and of the anterior segment structures including the cornea. Clinical staff will perform subject testing, not research coordinators. Information about these non-FDA approved OCTs and the multi-modal adaptive optics system can be found in appendices A, B, C, and D. With all devices, the participant sits in a slit lamp like frame. A low power laser light is projected toward the back of their eyes while the subject fixates on a target. None of the systems produce harmful radioactive radiation.
45602891|NCT04896619|Other|Kori tofu bread|34.5 grams of Kori-tofu, mixed in 3 slices of wheat bread.
45602892|NCT04896619|Other|Whey protein bread|Matched whey protein, soy oil and maltodextrin/cellulose, mixed in 3 slices of wheat bread
45602893|NCT03131791|Device|Shock Wave|42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.
45602894|NCT03131791|Drug|Botulinum toxin A|42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.
45602895|NCT03131947|Other|HIV positive patients|As above
45602896|NCT03471065|Device|SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV|Patients will be implanted with the SAPIEN 3 Ultra THV (20, 23 and 26 mm) or SAPIEN 3 THV (29 mm) using the SAPIEN 3 Ultra Delivery System.
45602897|NCT05057221|Drug|Uproleselan|Uproleselan should be administered intravenously (IV) into a peripheral line, a central catheter, or a peripherally inserted central line catheter (PICC). Infusion should take place at a steady rate over a period of 20 minutes ±2 minutes using a syringe pump or IV pump.
45756224|NCT00598819|Device|CDI 1000 COM|CDI 1000 COM sensors were attached to subject's forehead for a 12 hour period.
45756225|NCT00087698|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 4 cycles
45756226|NCT00087698|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 4 cycles
45756227|NCT03755739|Drug|Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy|vein, artery, or intra-tumor infusion of checkpoint inhibitor (CPI) such as Pembrolizumab and/or Ipilimumab, plus chemotherapy to destroy cancer cells and release tumor antigen for improving CPI therapeutic efficacy.
45756228|NCT05363033|Device|sarcopenia nursing guidance mobile application was developed|The application enhanced participants' sarcopenia-related knowledge and awareness regarding self-care
45756229|NCT05245721|Drug|Nalbuphine|Caudal nalbuphine injection in pediatrics undergoing infra-umbilical surgeries
45756230|NCT05245721|Drug|Bupivacain|Caudal bupivacaine in pediatrics undergoing infra-umbilical surgeries
45756231|NCT04402892|Other|35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients )|Patients hospitalized for CoV-2-SARS will be sampled at inclusion (Day 0), at day 21, at 3 months and at 6 months .
45756232|NCT04402892|Other|35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)|Patients who have recovered from CoV-2-SARS will be sampled at inclusion (Day 0), at 3 months and at 6 months .
45756233|NCT03472586|Biological|Ipilimumab|Given IV
45756234|NCT03472586|Biological|Nivolumab|Given IV
45756235|NCT03472586|Drug|Embolization Therapy|Undergo immunoembolization
45756236|NCT02987985|Drug|Acetaminophen, gabapentin|acetaminophen 15 mg/kg, gabapentin 10 mg/kg
45756237|NCT02987985|Drug|Acetaminophen|acetaminophen 15 mg/kg
45602898|NCT00805805|Drug|Tetrathiomolybdate|120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime, for one week to test gastric tolerance. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. Serum ceruloplasmin levels measured weekly will be used as a surrogate measure of copper status, with a target of 10-15 mg/dl (normal 20-40). When target Cp levels are reached, usually in 4-8 weeks, a maintenance dose of usually 40-80 mg of TM/day, divided half with a major meal, and half away from food at bedtime will be established (vary from 10 mg to 120 mg/day).
45602899|NCT00805805|Other|Placebo|Arm 2 will basically mirror Arm 1 with the patients receiving 120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime the first week. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. With the dosage being reduced at about the same frequency as the patients receiving TM
45602900|NCT03488173|Drug|Lansoprazole capsules|"Test 1: 30 healthy volunteers will be included and randomized into 3 groups (10 for each). During the study session, subjects will receive a single dose of Lansoprazole capsules 30 mg in sequence of T-R-R in group A; R-T-R in group B; and R-R-T in group C.~Test 2: 12 healthy volunteers will be recruited and randomized to 2 groups (6 for each). Subjects in group A will receive a single dose of experimental drug in sequence of fast-fed condition; while in group B, subjects will receive the same dose and drug but in fed-fast order."
45602901|NCT03466541|Behavioral|Riskbruk|The Riskbruk model incorporates alcohol screening through a widely employed alcohol screening questionnaire, the Alcohol Use Disorders Identification Test (AUDIT) and a standard alcohol biomarker, carbohydrate-deficient transferring in serum (CDT), with brief consultations using the motivational interviewing (MI) technique. MI is a collaborative conversation style used to increase awareness and reflection around one's own drinking habits, as well as strengthening the person's motivation for a lifestyle change. The conversation style includes expressing empathy through reflective listening, communicating respect and acceptance of the participants and their feelings, and open up for self-reflection and exploration around the drinking behaviour.
45602902|NCT03466541|Behavioral|Balance|Balance is a new Norwegian eHealth programme, and incorporates two approaches to behaviour modification interventions: a brief interventions and an intensive self-help programme. The intervention is based on cognitive-behavioural and self-help principles, and is given to the participants through multiple interactive sessions.
45602903|NCT03488095|Behavioral|BCI for SLT and BQ Use in Adolescents: A CRT|BCI for SLT and BQ Use in Adolescents: A CRT is aimed towards changing Adolescenst behaviors regarding their SLT and BQ use to as to reduce Oral cancer Burden within population because of this.
45756238|NCT02987985|Drug|Ketamine , Lidocaine , Dexmedetomidine|Ketamine 0.5 mg/kg, Lidocaine 1 mg/kg, Dexmedetomidine 0.3 mcg/kg
45602904|NCT03420521|Drug|Nivolumab|240mg IV over 60 minutes Q2W
45602905|NCT03420521|Drug|Ipilimumab|1mg/kg IV over 30 minutes Q6W
45602906|NCT02323009|Device|Esophageal Balloon|Esophageal balloon was used to measure esophageal pressure (Paux) which was used as an estimate of pleural pressure. Transpulmonary pressure (Ptp) was calculated as the difference between airway pressure (Pao) and Paux. Applied PEEP was then adjusted to overcome negative Ptp which we maintained between 0 to 10 cm H20. All measurements were made at end-expiration.
45602907|NCT02323009|Other|Cstat|PEEP was adjusted to achieve the best CStat in this group of patients
45756239|NCT02987985|Drug|Fentanyl, Dexmedetomidine|Fentanyl 0.5 mcg/kg, Dexmedetomidine 0.3 mcg/kg
45756240|NCT02987985|Drug|Dexamethasone , Ondansetron|Dexamethasone 150 mcg/kg, Ondansetron 50 mg/kg
45602908|NCT03488017|Device|Ocular Coil|Non-invasive ocular device
45602909|NCT04750759|Drug|Niclosamide + Camostat|Niclosamide will be applied in combination with camostat.
45602910|NCT04750759|Other|Placebo|Placebo to interventional drug
45602911|NCT03382925|Procedure|cervical interlaminar with lidocaine|Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.
45602912|NCT03382925|Procedure|cervical interlaminar with normal saline|Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline
45756241|NCT02987985|Drug|Sevoflurane|Sevoflurane (dose titrated to effect)
45602913|NCT03382925|Drug|Lidocaine|2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.
45602914|NCT03382925|Drug|Triamcinolone Acetonide|2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.
45602915|NCT03382925|Drug|Normal saline|2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.
45602916|NCT03496363|Diagnostic Test|TSH , T4|Thyroid stimulating hormone
45602917|NCT03485131|Device|Transcranial direct-current stimulation (tDCS)|Stimulation sessions will be conducted twice a day on 5 consecutive weekdays. The twice daily sessions will be separated by at least 3 hours (one in the morning and the other one in the PM). The duration of treatment will be 4 weeks
45602918|NCT03485131|Device|Placebo|Placebo/sham stimulation: After 40 seconds of real stimulation of 2 mAmp to simulate the tDCS induced skin sensation, only a small current pulse is delivered every 550 msec (110 mAmp over 15 msec) through the remainder of the 20-minute period
45756242|NCT02987985|Drug|Sevoflurane, Fentanyl|Sevoflurane (dose titrated to effect), Fentanyl as needed (dose at anesthesiologist's discretion)
45756243|NCT05245487|Diagnostic Test|DNA repair gene mutation analysis|Prospective monitoring of patients with next-generation sequencing for blood mutations
45756244|NCT03739749|Procedure|Arthroscopic superior capsular reconstruction|The superior capsule of patients with irreparable rotator cuff tears will be reconstructed using an autograft or an allograft
45756245|NCT03626129|Procedure|Oximetry guided deflation|"At the cath.lab. (Step 1) a hemostasis test is performed: oxymetry device on the thumb, compress a.ulnaris, evaluate if curve on device (=Patent hemostasis). If patent no further action. If not patent, air is deflated until a.radialis is patent (curve on device and no bleeding). If bleeding occurs before patency then re-inflate 1-2 ml. air until hemostasis (=no patent hemostasis). In patients with Patent hemostasis no action is taken in sixty minutes whereafter the TR-band is fully deflated (Step 2), and if bleeding then air is re-inflated until hemostasis and step 2 is repeated every 20 minutes until the TR-band is fully deflated with hemostasis. If no patent hemostasis at cath.lab. a hemostasis test is performed after 20 min. If patent hemostasis is achieved no action is taken in sixy minutes (as above). If still not patent then further action as in group A."
45756246|NCT03715959|Procedure|Aspiration of Breast|Undergo NAF
45756247|NCT03715959|Procedure|Biospecimen Collection|Undergo NAF
45602919|NCT03487939|Drug|FOLFOXIRI|IRINOTECAN 150 mg/m^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
45756248|NCT00708721|Drug|Clofarabine|Clofarabine is a rationally designed, second generation purine nucleoside analogue. Clofarabine was designed as a hybrid molecule to overcome the limitations and incorporate the best qualities of both fludarabine (F-ara-A) and cladribine (2-CdA, CdA) both of which are currently approved by various regulatory authorities for treatment of hematologic malignancies.
45756249|NCT00087152|Drug|Capecitabine|1,000 mg/m^2 by mouth twice daily Days 1-14 of each 21 day cycle
45756250|NCT00087152|Drug|Imatinib mesylate|400 mg by mouth daily
45756251|NCT05362799|Drug|Letrozol (Femara, Novartis)|Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days.
45756252|NCT05362799|Drug|Letrozol (Femara, Novartis) combined with Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt)|Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
45756253|NCT05362799|Drug|highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland)|Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry.
45756254|NCT05362799|Drug|highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) combined with metformin|Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
45602920|NCT00796523|Behavioral|Happiest Baby videotape|a videotape demonstrating the Happiest Baby on the Block technique for calming crying infants
45602921|NCT00796523|Behavioral|control videotape|a videotape with general newborn care instructions
45602922|NCT03496129|Behavioral|Personalized feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
45602923|NCT03496129|Behavioral|Personalized feedback and text messages|"Experimental: Personalized feedback and text messages~Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions."
45602924|NCT03496129|Behavioral|Information Only|"Active Comparator: Information Only~Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message."
45602925|NCT05210543|Other|not applicable, observational study|Patients do not receive intervention; observational study
45756255|NCT01940523|Drug|Topical Tranexamic Acid|3 vials of tranexamic acid (1g tranexamic acid in 10cc each) must be mixed in the operating room by the team at the start of surgery with 45cc of saline solution (for a total of 3g tranexamic acid in 75mL solution). This solution will be applied to the open joint surfaces with two 60mL syringes (one with 60mL and one with 15m). The solution will be left in contact with the tissues for five minutes. The surgeon will suction away excess solution. The site may be irrigated before or after the tranexamic acid bath as long as the solution is in contact for at least five full minutes. After that, the tourniquet will be released and the rest of the surgery will proceed according to the standard of care.
45756256|NCT01940523|Drug|Intravenous Tranexamic Acid|1 vial (1g of IV tranexamic acid in 10mL solution) will be administered prior to inflation of the tourniquet. A second 1g dose of IV tranexamic acid will be given during initiation of the closure after the tourniquet is deflated and during closure.
45756257|NCT04403282|Drug|Eflornithine Topical|Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
45756258|NCT04403282|Drug|Placebo Eflornithine Topical|Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
45756259|NCT02994199|Other|Active video gaming|Participants will engage in active video game play using two off-the-shelf (OTS) and two adapted controllers using the Wii gaming console. Controllers are: OTS balance board, OTS gaming mat, Adapted balance board, Adapted gaming mat.
45804208|NCT05716802|Behavioral|treatment as usual|The patients received regular daily antipsychotic medication and supportive psychotherapy once a week. They also participated in daily activities from Monday to Friday for at least two hours each day, including indoor activities (watching TV, playing games, playing poker) and outside activities (walking and doing radio gymnastics).
45804209|NCT03226457|Drug|Empagliflozin 25mg|Empagliflozin (SGLT2 inhibitor) 25 mg once daily for 6 weeks
45444595|NCT03799965|Other|ERAS are not evaluated|In this arm ERAS( Enhanced Recovery After Surgery) protocol will not be inserted.The findings regarding the patients under ERAS protocol are evaluated based on evidence.
45444596|NCT02048254|Radiation|brachytherapy|
45444597|NCT02048254|Radiation|IMRT|
45602926|NCT03487861|Diagnostic Test|observational(urinary biomarker for kidney allograft fibrosis)|After an informed consent is obtained, urine specimens will be collected prospectively before kidney transplantation (if available) and 3rd and 7th day, 1st, 3rd, and 6th month post-transplant. About 35~50ml of urine sample is collected from each patient. For each urine specimen, 0.5 ml of a protease inhibitor mixture (5mM 4-(2-animoethyl) benzensulfonyl fluoride hydrolchloride, 2 μM Leupeptin-hemisulfate, and 3.3 mM Sodium azide) is added. To remove urinary sediments including whole cells, large membrane particles, and other debris, urine specimens are centrifuged at a rate of 4000 rpm for 15 minutes at 4 ℃. An aliquot of supernatant is stored at -80 ℃ until use. Urinary biomarkers including transglutaminase 2 are quantified using ELISA or CBA. In addition, urinary exosomes are isolated and analyzed. When a for-cause biopsy is done for some patients, the correlation between biomarkers and pathologic diagnosis will be assessed.
45602927|NCT00796289|Drug|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'high target' study dose, which is estimated to be 800 picograms/ml
45602928|NCT00796289|Drug|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day(every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'medium target' study dose, which is estimated to be 400-600 picograms/ml
45602929|NCT00796289|Drug|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'low target' study dose, which is estimated to be 200 picograms/ml
45602930|NCT00796289|Drug|clomiphene citrate|Oral, 50 mg daily for 5 days
45602931|NCT00796289|Drug|placebo clomiphene citrate|oral, taken for 5 days
45602932|NCT00796289|Drug|placebo GnRH patch|Placebo transdermal patch with a high target delivery of placebo(every 90 minutes). New patch to be applied every 12 hours.
45602933|NCT04460443|Drug|sofosbuvir|Sofosbuvir once daily
45602934|NCT04460443|Drug|Sofosbuvir ledipsavir|Sofosbuvir ledipsavir once daily
45602935|NCT04460443|Drug|Daclatasvir|Daklatasuvir tablets
45602936|NCT04460287|Dietary Supplement|DHA Wet Mixing method|Children will drink milk contain 100 mg DHA wet mixing daily for 30 days
45602937|NCT04460287|Dietary Supplement|DHA Dry Blending Method|Children will drink milk contain 100 mg DHA dry blending daily for 30 days
45602938|NCT04460287|Dietary Supplement|Fish Oil|Children will have this intervention every day for 30 days
45602939|NCT00711035|Biological|Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection|"Follow-up Assessments: The timing of follow-up visits is based on the date of CTL infusion. If a patient has multiple CTL doses the schedule resets again at the beginning so follow up relates to the last CTL dose.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
45602940|NCT04460521|Drug|N-Acetyl cysteine|In addition to splinting, both groups will receive an oral tablet to take daily for 8 weeks. Participants assigned to the experimental group will receive oral NAC (500 mg PO daily for eight weeks; based on recommended daily dose for use as an antioxidant and dosing in previous human clinical trials and animal studies), and those assigned to the control group will be given a similar looking placebo with identical instructions. Tablets will be provided in a blister pack to assist with compliance.
45602941|NCT04460521|Device|Wrist Splint|Participants in both arms will be given a standard prescription for a prefabricated night splint which keeps the wrist in a neutral position and instructed on proper use and the importance of consistent use. To limit splint variability, we will ensure that splint prescriptions are written such that a MedSpec Wrist Lacer II splint is obtained from the patient's pharmacy. This is the most commonly available brand locally and meets the criteria for wrist, metacarpophalangeal, and interphalangeal joint positioning. They will be advised to wear the splint consistently during sleeping hours on their affected wrist for eight weeks, as is the standard of practice.
45602942|NCT00710567|Device|DuraHeart Left Ventricular Assist System (LVAS)|The DuraHeart LVAS is implanted in using open heart surgery
45602943|NCT02323087|Device|FLEXICULT™ SSI-Urinary Kit|Urine culture and sensitivity testing will be performed on the intervention group by means of a POCT, the FLEXICULT™ SSI-Urinary Kit. The kit is designed as an ordinary Petri dish but with higher sides. The Petri dish is divided into 6 compartments: 1 large one for quantitative analysis and 5 smaller ones for susceptibility testing (Fig. 1). The agar in each of the smaller compartments contains 1 of 5 antimicrobials: trimethoprim, sulfamethoxazole, ampicillin, nitrofurantoin and mecillinam. The agar plate is flooded with the urine specimen for a couple of seconds and then incubated at 35°C over night. The following day the plate is read. When reading the compartment for quantitative analysis the lower limit is:103 colony-forming units (cfu) per milliliter.
45602944|NCT02323087|Device|ID FlexicultTM|Point of care culture will be performed using ID FlexicultTM,which is a chromogenic agar plate for identification and quantitation of urinary tract pathogens. The agar plate is for cultivation of urine, which makes it possible to identify the bacteria and quantitate the amount of bacteria. Based on bacterial colony color and size can be determined which bacteria are involved. For example, an E. coli bacteria will grow with big red colonies, and Enterobacter sp. will grow with large dark blue / purple colonies. The sample is seeded with a 10 uL inoculation needle, the lid is applied and the agar plate incubated with the lid down at 35 0C overnight. The plate is read the next day
45602945|NCT00698789|Drug|INCB019602|5 mg of INCB019602 in AM with placebo administration in PM
45602946|NCT00698789|Drug|INCB019602|20 mg in AM with placebo administration in PM
45602947|NCT00698789|Drug|INCB019602|5 mg in PM with placebo administration in AM
45602948|NCT00698789|Drug|INCB019602|20 mg in PM with placebo administration in AM
45756260|NCT03577379|Other|Whole Blood Fibrin Clot|For all patients assigned to the treatment group, 35mL of whole blood will be obtained during surgery by an anesthesiologist. 5 mL of the blood will be sent for pre-clot formation cell count evaluation for platelets, red blood cells and white blood cells. The remaining 30mL will be placed into a sterile container with a sintered glass cylinder supported by the lid for fibrin clot formation. The clot formation cups will be placed on a rotator at room temperature for 10 minutes at 125rpm. The fibrin clot will be removed and 5mL of the post-clot serum sent for post-clot formation cell count evaluation for platelets, red blood cells, and white blood cells.
45602949|NCT00698789|Drug|INCB019602|7.5 mg in PM QoD with placebo administration in AM as well as PM on non-active dose days
45602950|NCT00698789|Drug|Placebo|Placebo administration in AM or PM depending on treatment arm dosing regimen.
45602951|NCT00698789|Drug|Metformin|Stable dose metformin monotherapy
45602952|NCT03484975|Device|Observation group|Collect coronary images with a hybrid IVUS OCT system.
45602953|NCT03367169|Procedure|minimally invasive method|type of surgical technique
45602954|NCT03367169|Procedure|open reduction method|type of surgical technique
45602955|NCT03484897|Other|P927 - LICHTENA DermAD CREMA CORPO|The study cream was applied once a day (at the morning or at the evening), preferentially always at the same hour, with a mild massage, for an uninterrupted period of 1 month
45602956|NCT00790127|Drug|HQK-1001|HQK-1001 capsules (10, 20, 30 or 40 mg) administered once a day, orally, for 56 days
45602957|NCT00790127|Drug|Placebo|Matching placebo capsules administered once a day, orally, for 56 days
45602958|NCT03484741|Biological|MSC and PRP|MSC are collected from autologous bone marrow mononuclear cells (BMNC) and allogeneic umbilical cord tissue (UC-MSC) under sterile conditions and combined with activated platelet-rich plasma (PRP) to treat this disease.
45602959|NCT03360929|Drug|AZD3759|Strength: 50mg/tablet, 100mg/tablet Dosage and administration: Twice daily administration under fasting state.
45602960|NCT03487783|Drug|Aripiprazole Oral Solution|Aripiprazole 2-20 mg/day (2-20 mL/day)
45602961|NCT03487783|Drug|Placebo Oral Solution|Placebo 2-20 mg/day (2-20 mL/day)
45602962|NCT03335033|Combination Product|Contrast-enhanced ultrasound|Subjects will receive a low mechanical index (0.17-0.20) imaging during ultrasound contrast agent intravenous infusion. Real-time cine-loop including longitudinal and transverse images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the carotid artery will be acquired and digitally stored for offline analysis. Also use of a 3D ultrasound transducer to evaluate the feasibility of using US images with contrast to assess the residual diameter of the diseased vessel. Specifically, two 3D acquisitions of each lesion would be obtained after contrast has been injected.
45602963|NCT03335033|Device|Shear Wave Elastography|Shear wave elastography will be performed with the General Electric Logiq E9 scanner acquiring images of each plaque in the longitudinal and transverse imaging planes. In each plane 10 measurements will be made and the in-phase/quadrature (IQ) data will be saved for further analysis. The plaque area in the imaging plane will be user-defined to extract the wave velocity values for a ROI analysis.
45602964|NCT03335033|Device|Ultrasound Examination|A standard carotid US examination using Duplex imaging will performed using a linear array transducer to obtain longitudinal and transverse images. All ultrasound measurements will be made by a trained registered vascular technologist. Severity of stenosis of the plaque will be measured based on established protocol and guidelines.
45602965|NCT03495739|Drug|RDG-17012 Capsule|Dabigatran Etexilate tosylate 150mg
45602966|NCT03495739|Drug|Dabigatran Etexilate Mesylate 150 MG Oral Capsule|Dabigatran Etexilate mesylate 150mg
45602967|NCT03298061|Drug|Mepolizumab|Mepolizumab will be available as lyophilized powder for injection to be reconstituted with sterile water for injection, prior to use. Subjects will be dosed with mepolizumab at a dose of 300 mg which will be administered as three separate 100 mg SC injections every 4 weeks. The injections will be administered into any of the upper arm, thigh or anterior abdominal wall.
45602968|NCT03298061|Drug|Prednisolone|Subjects who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included.
45602969|NCT04188769|Device|constant deep pressure applied by an air splint|inflation of the Johnstone air splint gives a constant local deep pression on the hemiplegic arm
45756261|NCT02994433|Drug|Nitrous Oxide|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
45756262|NCT02994433|Drug|Placebo gas|Placebo gas given at 50% nitrogen [inert]/50% oxygen.
45602970|NCT04188769|Device|intermittent deep pressure applied by an air splint|continuous inflation and deflation of the Johnstone air splint gives an intermittent local deep pression on the hemiplegic arm
45602971|NCT04188769|Device|uninflated air splint|no deep pressure applied by the air splint
45602972|NCT04188769|Other|contralateral movement|non-hemiplegic arm is flexed and extended 5 times, with a weight of 5kg in the hand, in order to trigger hypertonia in the hemiplegic arm
45602973|NCT04166539|Behavioral|Questionnaires|You will be asked to complete a questionnaire about your family history of neurological diseases and current and past physical thinking activities.
45602974|NCT04166539|Behavioral|Interviews|Behavioral and Memory interviews will take place with the patient.
45602975|NCT04166539|Other|Blood draw|Have a sample of blood drawn (4.2-5 tablespoons) for clinical and research tests.
45602976|NCT04166539|Radiation|Magnetic Resonance Imaging|Each MR examination takes about 45 minutes and does not require the use of needles, medication or contrast enhancement. You will lie on your back and enter the MR scanner for the study, during which time you will hear knocking noises. People with pacemakers, aneurysm clips, cochlear implants, or metal/foreign objects in their eyes are not permitted to undergo MR studies. We will review your implants and determine your eligibility.
45756263|NCT02994433|Device|MRI|MRIs done on all participants, this is a tool we are using to measure outcomes. No treatment is from an MRI.
45756264|NCT01679288|Device|Ultrasound (Trademark:VScan; Manufacturer:General Electrics)|Standardized measurements were made and aorta was tried to be visualized in its entirety, and a minimum of three hard copy images were obtained: upper transverse subxiphoid section, lower transverse section for distal view of aorta, and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm).
45756265|NCT04388189|Drug|Duloxetine|FDA approved antidepressant
45602977|NCT04166539|Diagnostic Test|Echocardiogram|Each echocardiogram takes about 30 minutes. This test uses sound waves to look at your heart. The person doing the test will press on your chest with a machine to obtain the pictures. The pressure may be uncomfortable. The echocardiogram will involve an image enhancement agent infusion to obtain better images.
45602978|NCT00686933|Drug|ABT-089|Subjects will take up to 80 mg daily for 24 months
45602979|NCT04071613|Drug|Tenecteplase|Route: IV bolus injection Frequency: once only, within 4.5 hours of stroke onset
45602980|NCT04071613|Drug|Intravenous tissue plasminogen activator (tPA)|Route: Intravenous (IV) infusion (10% as bolus and the remainder over 60 minutes) Frequency: once only, within 4.5 hours of stroke onset
45444598|NCT01303887|Drug|Rituximab|Rituximab 375mg/m2 IV day 1,repeated every 21 days for 8 cycles. All patients who have achieved a CR or PR to induction therapy will receive rituximab maintenance (375mg/m2 every 2 months for 2 years).
45602981|NCT04063969|Other|Assessment of radiation safety climate|"The rating tool contains 28 statements which cover 5 dimensions (Leadership, communication, commitment, resources, risk awareness) of the radiation safety climate. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement. A composite radiation safety climate score is calculated by adding ratings on all items.~Minimum scale score 28 - Maximum scale score 140"
45602982|NCT04063969|Other|Assessment of radiation safety behavior|The rating tool contains 2 statements which cover 2 dimensions of the radiation safety behavior. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement. A composite radiation safety behavior score is calculated by adding ratings on both items Minimum scale score 2 - Maximum scale score 10
45602983|NCT04063969|Other|Assessment of radiation safety knowledge and motivation|"The rating tool contains 2 statements which cover the radiation safety knowledge and behavior. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement.~Minimum item score 1 - maximum item score 5"
45602984|NCT04063969|Other|Data collection|Collection of patient-related data points Demographic information: ASA-classification, BMI Procedure related information: Procedural time, approach, contrast usage case difficulty Radiation safety parameters: Air Kerma, DAP, fluoroscopy time
45602985|NCT00683423|Drug|BMS-741672|Tablets, Oral, 100 mg, once daily, 3 weeks
45911080|NCT02003274|Other|Clamp-Mixed Meal|"Standard clinical parameters will be assessed in all patients.~Metabolic tests:~A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out in type 1 diabetic patients to assess insulin sensitivity, as previously described (1).~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump~This test will determine the time courses of:~1. plasma glucose, 2. 13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
45756266|NCT04388189|Drug|Bupropion|FDA approved antidepressant
45756267|NCT02994277|Device|1° Phase: UVa algorithm 2° Phase: ITBA/UNLP algorithm|The UVa algorithm is an already established mathematical model that can be programmed in DiAs software to manage glycaemia in T1DM through a subcutaneous insulin pump and a continous glucose monitoring. This algorthm works on a meal announcement basis and will be tested during the first phase of the trial. The ITBA/UNLP algorithm is a new development with safety mechanisms improved and without need of meal anouncement. This algorithm will be tested during the second phase of the trial.
45756268|NCT05362643|Other|Acupuncture|Manual acupuncture on acupoint Tai Xi(KI3), bilateral;Sanyinjiao (SP6), bilateral; Zusanli (ST36), bilateral; Shenmen (HT7) unilateral, in the arm without arteriovenous fistula;Guan Yuan (CV4), unilateral, attempt to achieve De qi sensation. After generating needling sensation, needles were manipulated for one minute, every ten minutes during needle retention (20 minutes), using Sterilized stainless steel needle (0,25x25mm; Tewa, asia-med GmbH).
45756269|NCT05362643|Other|Sham Acupuncture|Manual acupuncture performed as superficial needling (5mm depth) on non-acupuncture points without an attempt to achieve De qi sensation and without stimulation, lasting 20 minutes, using Sterilized stainless steel needle (0,25x25mm; Tewa, asia-med GmbH).
45756270|NCT00599053|Drug|Azithromycin|10 mg/kg IV per dose given for 10 days
45756271|NCT05223023|Other|questionnaire|"All of the therapists who works in the pediatric rehabilitation area were assessed with the scale of 50 questions named Opinions of Physiotherapists Working in the Area of Pediatric Rehabilitation on Treatment Types, Efficiency and Training"
45756272|NCT05362565|Biological|Salivary Sampling|"The DNA study will be carried out from saliva sample~1 saliva sample per patient will be performed at the inclusion visit"
45756273|NCT02999971|Other|circuit class therapy in water|The circuit, the main part of the session, include a series of 10 different workstations, arranged to progress in complexity, in order to work several segments of the body, oriented towards a functional recovery objective. These stations will be made up of task-specific activities for gait, balance and dexterity. Time in each workstation will be 5 minutes divided as follows: 4 minutes work period and 1 minute rest period, of these, last 30 seconds will be change period for crossing from one workstation to the next. After 50 minutes, each patient will have covered the 10 workstations, thus working in all of the objectives pursued in the realization on this CCT: gait, balance and dexterity.
45444599|NCT01303887|Drug|Cyclophosphamide|Cyclophosphamide 250mg/m2 PO day 1-3, repeated every 21 days for 4 (R-FC) or 8 cycles (R-CVP)
45444600|NCT01303887|Drug|Vincristine|Vincristine 1.4mg/m2 IV day 1,repeated every 21 days for 8 cycles.
45804210|NCT03226457|Drug|Placebo oral capsule|Capsules containing microcrystalline cellulose Ph Eur over encapsulated in a hard gelatine capsule shell to match the active comparator once daily for 6 weeks
45444601|NCT01303887|Drug|Prednisolone|Prednisolone 40mg/m2 PO day 1-5, repeated every 21 days for 8 cycles.
45444602|NCT01303887|Drug|Fludarabine|Fludarabine 40mg/m2 PO day 1-3,repeated every 21 days for 4 cycles
45602986|NCT00683423|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 3 weeks treatment period, 2 weeks washout, and 2 weeks follow-up
45602987|NCT03484663|Device|central venous catheter (small catheter drainage)|Insertion central venous catheter ( small catheter drainage ) after uniport vats to decrease hospital stay and to easy drainage after procedure
45602988|NCT00680069|Biological|Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005|Inactivated monovalent subvirion influenza A/H5N1/Indonesia/05/05 (clade 2) vaccine administered via intramuscular injection. Low Dose Group will receive 15 mcg intramuscularly (IM), High Dose Group will receive 90 mcg IM. Subjects who received previous clade 1 vaccine will receive 1 dose, clade 1 vaccine-naive subjects will receive 2 doses 28 days apart.
45602989|NCT05149807|Drug|SHR-1701 injection|SHR-1701 injection Tegafur Gimeracil Oteracil Potassium Oxaliplatin
45602990|NCT05149807|Drug|Placebo|Placebo Tegafur Gimeracil Oteracil Potassium Oxaliplatin
45602991|NCT00679991|Drug|PRT-201|Applied topically to AVF during surgery
45602992|NCT00679991|Drug|PRT-201|Dose escalation study. Drug/placebo administered at the time of fistula creation
45602993|NCT04459897|Other|Evaluation of epithelioid and gigantocellular granulomas within the hepatic parenchyma by histopathology approach.|: Retrospective histopathology review done by an expert of histopathology analysis (DAPI cell labeling). Analysis of the percentage of epithelioid cells and the percentage of gigantocellular granulomas in hepatic parenchyma of patient diagnosed for Hepatitis Granulomatous
45602994|NCT00678119|Biological|AGS-003|Dendritic cell Immunotherapeutic
45602995|NCT00678119|Drug|Sunitinib|An approved drug for the treatment of RCC
45602996|NCT03484585|Drug|Rogaratinib (BAY1163877)|Single dose, intake orally, 200 mg
45602997|NCT03487393|Device|magnetic facial nerve stimulation|Magnetic stimulation of facial nerve.
45602998|NCT02812667|Drug|Nivolumab + Plinabulin|
45602999|NCT03495583|Other|Early introduction|Consumption of 2g/week of cow's milk, hen's egg, wheat, peanut, sesame and fish protein from 3 months of age (alongside breastfeeding)
45804211|NCT03226457|Drug|Frusemide|Renal Physiology Test (RPT) days will be performed at week 1 and week 6 on each arm of this crossover trial. On these RPT days participants will undergo oral water loading (15mls/kg) and frequent urination at 30 minute intervals to gain a steady state diuresis. At a set time point, an intravenous bolus of furosemide at a dose of half the participant's usual loop diuretic dose will be administered.
45444603|NCT02048410|Dietary Supplement|Lactobacillus paracasei B21060|combination of probiotic (Lactobacillus paracasei B21060) and prebiotics (arabinogalactans, xyloooligosaccarides) and amine (L-glutamine)
45444604|NCT02048410|Other|low satured diet|
45603000|NCT02799095|Drug|ALKS 4230|Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period
45603001|NCT02799095|Drug|ALKS 4230 + pembrolizumab|IV infusion of ALKS 4230 over 30 minutes given daily for 5 consecutive days followed by an off-treatment period; pembrolizumab administered IV once with ALKS 4230 on the first day of each cycle
45603002|NCT02011321|Drug|clevidipine|clevidipine infusion x4 hours
45603003|NCT03487315|Diagnostic Test|immunoblot|immunoblot
45603004|NCT03965377|Behavioral|Home Safety Hero Computer Game|Home Safety Hero computer game presents players with virtual rooms in a home where vilians have planted safety risks. It involves the player taking the role of a body guard for a child. It has three phases: 1. Identifying risks in a set of rooms (e.g., burn, falling, suffocation, poisoning); 2. Identifying risks and then selecting a resolution to reduce the risk or eliminate it entirely; and 3. Identifying risk when faced with distractions typical to home environments (e.g., phone ringing, fire engine siren sounds, a moving child).
45603005|NCT01352585|Drug|Anagrelide hydrochloride|0.5 mg hard capsules, dosing decisions will be made by the treating physician
45603006|NCT03878407|Other|Monitoring of ARCH variants|Blood samples will be tested for mutations, before patients are given Standard of Care chemotherapy/radiation or after given Standard of Care chemotherapy/radiation. Another testing is done after 3 months and after 1 year if positive for ARCH.
45603007|NCT03484507|Drug|Chlorhexidine|1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
45603008|NCT03484507|Drug|Povidone-Iodine|1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
45603009|NCT03484507|Drug|Prednisolone Sodium Phosphate|1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
45444605|NCT02050438|Procedure|Total Knee Arthroplasty|
45444606|NCT02050516|Other|micro-well group culture dish|an embryo culture dish containing nine micro-wells in the middle.
45444607|NCT02050594|Drug|Ipilimumab|
45603010|NCT03484507|Drug|Hydroxypropyl Methylcellulose|1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
45603011|NCT03484507|Drug|Prednisolone Sodium Phosphate|1 drop 4 times daily for weeks 6-9, then 2 times daily for weeks 10-11
45603012|NCT03484507|Drug|Hydroxypropyl Methylcellulose|1 drop 4 times daily for weeks 4-5
45603013|NCT02773355|Drug|liraglutide 3.0 mg|Patients will be treated with commercially available Saxenda® prescribed according to routine clinical practice at the discretion of the treating physician.
45603014|NCT03484351|Other|Fall Monty Activity Programme (FallMAP)|The programme delivered during this feasibility study will consist of a total of 12 multifactorial falls prevention group exercise sessions of 90-100 minutes in duration, followed by a 20-30 minute social activity. The sessions will be offered over a period of 8 weeks. Each session will comprise (a mix of) seven program components of the intervention: 1) falls prevention education, 2) FaME group-based exercises for strength and dynamic balance, 3) (Preparing for) home exercises, 4) Interactive, virtual reality gamefied exercises, 5) Getting on and off the floor / floorwork / safe landing & falls technique activities, 6) Home falls hazard evaluation and 7) A social activity after the exercise session.
45603015|NCT04582487|Other|bone marrow and/or peripheral blood samples withdrawal|bone marrow and/or peripheral blood samples evaluation
45444608|NCT02994758|Other|Personalised treatment|Treatment based on NGS or DSRT
45444609|NCT04096443|Biological|Fecal microbial transplant (FMT)|Oral fecal microbial transplant capsules
45444610|NCT05076747|Behavioral|Cardiovascular training|8 weeks of cardiovascular training
45603016|NCT03495349|Other|safety and effectiveness of the usual treatments of diabetic foot infections|clinical and biological follow-up necessary to assess the safety and effectiveness of the medical treatments, MOS-SF survey (36-Item Short Form Survey) to study the quality of life.
45603017|NCT02744183|Behavioral|Exercise|Moderate intensity exercise
45603018|NCT02744183|Behavioral|Breakfast|Breakfast consumption
45603019|NCT02744183|Behavioral|Maintain habitual habits|Normal physical activity and dietary behaviors maintained
45603020|NCT03484195|Drug|FOLFOXIRI|Irinotecan 150 mg/m^2 IV over 1h, day 1 + Oxaliplatin 85 mg/m^2 IV over 2h, day 1 + L-Leucovorin 200 mg/m^2 IV over 2h, day 1 + 5-Fluorouracil 2800 mg/m^2 IV 48h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months)
45603021|NCT02713607|Drug|Doxycycline|Given doxycycline to acne subjects
45603022|NCT04526821|Drug|Bovine Lactoferrin|Bovine Lactoferrin 600mg daily for 12 weeks (3 chewable tablets of 100mg , twice a day), for 12 weeks plus personal portection provided from the hospital.
45603023|NCT04526821|Dietary Supplement|Maltodextrin|Maltodextrin 600mg daily for 12 weeks (3 chewable tablets of 100mg, twice a day), for 12 weeks plus personal portection provided from the hospital.
45603024|NCT02690441|Behavioral|Cognitive Behavioural Therapy|Cognitive behavioural therapy conducted individually. 10 weekly sessions, first session lasts 90 minutes, the remaining sessions last 45 minutes.
45603025|NCT02690441|Behavioral|Physical Exercise|Manualised exercise. 15 weekly sessions with instructor, and two weekly unsupervised sessions performed individually.
45603026|NCT02690441|Behavioral|Placebo control|One follow-up telephone call à 15 minutes each week for 15 weeks. Aims to control for therapist contact in physical exercise condition and total duration of treatment.
45603027|NCT03487237|Biological|Ddimer testing|Included patients will undergo a formal work up for pulmonary embolism: Ddimer testing, followed if positive by a computed tomography pulmonary angiogram or V/Q scan.
45603028|NCT02323243|Device|"Allium  Bulbar Urethral Stent  (BUS) system"|
45603029|NCT03487159|Device|MRE (Magnetic Resonance Elastography)|The device is using to evaluate liver fibrosis stage
45603030|NCT02681549|Drug|Pembrolizumab plus Bevacizumab|Pembrolizumab will be administered on day 1 of every cycle until disease progression or withdrawal from study. Bevacizumab will be administered in addition to pembrolizumab on day 1 of cycles 1, 2, 3, and 4 (or alternative cycles if bevacizumab is held during these cycles). Three weeks constitutes one cycle.
45603031|NCT02323399|Drug|Phenylephrine|one of six initial treatments Phenylephrine Hydrochloride Injection (PHI) will be initially administered to approximately 50 subjects as an intravenous bolus (IV-B) at Low (1 μg/kg), Med (3 μg/kg), or High (5 μg/kg) level; PHI will be initially administered to approximately 50 subjects as a continuous intravenous infusion (IV-I) at Low (0.25 μg/kg/min), Med (0.75 μg/kg/min), or High (1.25 μg/kg/min) level]; each initial treatment group will have two PK sampling schedules.
45603032|NCT03642769|Other|Fluid administration|Fluid administration of bolus and maintenance fluids
45756274|NCT02999971|Other|circuit class therapy on land|The circuit, the main part of the session, include a series of 10 different workstations, arranged to progress in complexity, in order to work several segments of the body, oriented towards a functional recovery objective. These stations will be made up of task-specific activities for gait, balance and dexterity. Time in each workstation will be 5 minutes divided as follows: 4 minutes work period and 1 minute rest period, of these, last 30 seconds will be change period for crossing from one workstation to the next. After 50 minutes, each patient will have covered the 10 workstations, thus working in all of the objectives pursued in the realization on this CCT: gait, balance and dexterity.
45756275|NCT01941927|Drug|Trametinib (GSK1120212)|Trametinib is a highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity.
45804212|NCT04344626|Device|Intra-operative brain tonometry|Once the brain is exposed during surgery, a sterilized digital tonometer will be used to obtain brain tissue stiffness measurements at various locations of the cortex established based on results of pre-operative work-up. Precise stereotactic coordinates for each measurement will be recorded in a neuronavigation software to facilitate comparisons with results of other tests.
45804213|NCT05610787|Device|EXCOR Active Driving System for Pediatric VAD|The EXCOR Active Driving System - will be used with the EXCOR Pediatric VAD.
45804214|NCT04344548|Biological|Allogeneic NK transfer|Three doses of allogeneic NK cell transfer
45444611|NCT05076747|Behavioral|Standard Therapy|8 weeks of Standard Therapy
45603033|NCT03504553|Other|Noise reduction|All activity will cease when the patient enters the operating room and nonessential personnel will be removed. Ambient lighting will be reduced and communication devices muted.
45603034|NCT02589197|Device|Group 1 (Medial-Pivot)|EVOLUTION® Total Knee Arthroplasty Medial Pivot system with CS inserts
45603035|NCT02589197|Device|Group 2 (Posterior-Stabilized)|Zimmer® NexGen® Total Knee Arthroplasty system with PS inserts
45603036|NCT03483805|Dietary Supplement|Protalsafe|mix of prebiotic, probiotic and plant extract in powder form, to be diluted in water
45603037|NCT03483805|Dietary Supplement|Placebo|maize maltodextrin in powder form, to be diluted in water
45603038|NCT04472741|Device|difference between colonoscopes|patients have been randomly assigned for colonoscopy with FUSE or HD SFV endoscopes with or without Endocuff
45603039|NCT03438877|Procedure|Intensive dosage of PD|Within the first month since PD initiates, PD prescription will be adjusted to achieve the minimum target of 3.5. It's anticipated to prescribe the dosage with automatic PD (APD) or manual PD as 24-36L/day of dialysate, 1.5-2L/exchange, and 16 cycles. Anyway, it depends on the characteristics of the patients, including residual renal function, peritoneal memberane properties. The Kt/V goal will be compromised by clinical assessment for the patient, which means PD will not induce additional treatment, such as fluid infusion.
45444612|NCT03309020|Procedure|Cataract surgery|Cataract surgery and aqueous humor sampling.
45444613|NCT02806960|Drug|Nasal Glucagon|Administered intranasally.
45444614|NCT03718143|Drug|Combination AZD1775 with AraC|AZD1775 days 1-5 & 8-12 AraC days 1-5 & 8-12
45444615|NCT03718143|Drug|AZD1775 only|AZD1775 days 1-5 & 8-12
45444616|NCT02955134|Drug|Talcid®|Talcid® is allowed to be taken when patients feel stomach pain, acid reflux or heartburn. Continuous taking time should not exceed one week.
45603040|NCT03438877|Procedure|Regular dosage of PD|Within the first month since PD initiates, PD prescription will be adjusted to achieve the minimum target of 2.1. It's anticipated to prescribe the dosage with automatic PD (APD) or manual PD as 9-12L/day of dialysate, 1.5-2L/exchange, and 6 cycles. Anyway, it depends on the characteristics of the patients, including residual renal function, peritoneal memberane properties. The Kt/V goal will be compromised by clinical assessment for the patient, which means PD will not induce additional treatment, such as fluid infusion.
45756276|NCT01941927|Drug|GSK2141795|GSK 2141795 is an ATP competitive subnanomolar pan-AKT inhibitor. In order to measure the true potency of GSK 2141795, potency (Ki*) values were determined in a filter binding assay using lower enzyme concentrations (0.1, 0.7, and 0.2 nM for human AKT1, AKT2, and AKT3, respectively). Using a sandwich ELISA, GSK 2141795 inhibited phosphorylation of GSK-3β in BT474 and LNCaP cell lines with EC50 values of 143 and 34 nM, respectively. Since phosphorylation of GSK-3β can be modulated by other enzymes (PKA, PKC, and RSK),cellular activity of GSK 2141795 was evaluated using a phospho-PRAS40 ELISA. GSK 2141795 inhibited the phosphorylation of PRAS40 with EC50 values of 39 and 55 nM for BT474 and LNCaP cells, respectively.
45756277|NCT05220917|Drug|SGLT2 inhibitor|Any SGLT2i dispensing claim
45444617|NCT02955134|Drug|Chinese medicine prescription|"The Chinese medicine application prescription is composed of pinellia 9g, radix scutellariae 10g, rhizoma coptidis 8g, rhizoma zingiberis 10g, radix curcumae 10g, rhizoma atractylodis 10g, roasted bighead atractylodes rhizome 10g, radix astragali 15g, spreading hedyotis herb 20g, scutellariae barbatae 20g, salvia miltiorrhiza bge 10g, the stem of noble dendrobium 10g, radix pseudostellariae 10g, fructus aurantii immaturus 10g, cortex magnoliae officinalis 10g, rhizoma curcumae 10g, ginger 3g, jujube 6g.~Patients take 200ml each time, twice a day. Treatment duration are 24 weeks."
45603041|NCT02323477|Biological|stem cell transplantation|Human allogeneic umbilical cord MSC or autologous BM-MNC transplantation
45603042|NCT04472819|Drug|SHR2285 tablet|single dose or multi-dose
45603043|NCT04472819|Drug|Placebo|single dose or multi-dose
45603044|NCT03294187|Device|Wrist-worn wearables|See arm/group description.
45603045|NCT00675623|Drug|Dimebon|Dimebon, 5 mg orally three times daily for six months
45603046|NCT00675623|Drug|Dimebon|Dimebon 20 mg orally three times daily for six months
45603047|NCT00675623|Drug|Placebo|Placebo three times daily for six months
45603048|NCT04473521|Device|Investigational denture adhesive cream|The denture adhesive application will be controlled by weight (1.00g +/-0.05g) applied to the maxillary denture only.
45603049|NCT04473521|Device|Super Poligrip Free|The denture adhesive application will be controlled by weight (1.00g +/- 0.05g) applied to the maxillary denture only.
45756278|NCT05220917|Drug|DPP-4 inhibitor|Any DPP-4 inhibitor claim
45444618|NCT02955134|Drug|Placebo|The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 24 weeks.
46066574|NCT04080310|Drug|Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin|"This study is a multicenter, randomized, open-label, parallel, phase IV trial. The study is planned to include 272 patients with clinical ASCVD requiring optimal statin therapy.~After enrollment, subjects are randomized into two groups in a 1:1 manner. patients in combination therapy group(rosuvastation 10mg and ezetimibe 10mg daily) will be provided a fixed-dose single pill comibation and patients in the intensive statin group will receive rosuvastatin 20mg daily."
45603050|NCT04473287|Other|reflexology practice|Reflexology is a reliable and holistic complementary and alternative treatment method that means that the body's specific glands, organs and regions are stimulated by applying a special pressure with the fingers on the hands, feet and ears. When the literature is analyzed, it has been determined that reflexology is applied effectively before, during and after surgery, including different surgical procedures, and it is emphasized that one of the most important areas is patients who underwent Coronary Artery Bypass Graft (CABG) surgery. In this study, it is thought that reflexology application to patients undergoing CABG surgery on nursing care will contribute to the nursing literature by examining the effect of reflexology on pain, anxiety, fatigue, sleep and physiological parameters.
45603051|NCT01352507|Drug|Tadalafil|Administered Orally
45603052|NCT01352507|Drug|Sildenafil|Administered Orally
45603053|NCT04497779|Procedure|Biospecimen Collection|Undergo collection of blood and/or nasopharyngeal swabs
45603054|NCT04497779|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
45603055|NCT04497779|Other|Electronic Health Record Review|Donors and recipients have their medical records reviewed.
45603056|NCT04497779|Other|Questionnaire Administration|Ancillary studies
45603057|NCT00672191|Biological|AGS-004|HIV-1 Immune Therapy
45756279|NCT05220917|Drug|GLP-1RA|Any SGLT2i dispensing claim
45756280|NCT05220917|Drug|2nd generation SU|Any 2nd generation SU claim
45756281|NCT01942707|Procedure|abdominoplasty with Scarpa's Fascia|During surgical detachment of the abdominal flap the Scarpa´s fascia is preserved.
45603058|NCT02361346|Drug|MT-3724 Phase 1|Intravenous dosing Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.
45603059|NCT02361346|Drug|MT-3724 Phase 2|Intravenous dosing on Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 1 hour on each dosing day over 21 day cycle up to 6 cycles and then can be continued for 6 additional cycles.
45603060|NCT04460963|Other|Adrenomedullin|Adrenomedullin sample evaluation
45603061|NCT00873275|Biological|bevacizumab|5mg/kg IV day 1 and 15 of each 28 day course of treatment
45603062|NCT00873275|Drug|FOLFOX regimen|Leucovorin, 5-FU and Oxaliplatin
45603063|NCT00873275|Drug|fluorouracil|400 mg/m2 IV bolus immediately following leucovorin on days 1 and 15 of a 28 day course of treatment. Then 2.4 gm/m2 IV continuous infusion over 46 hours immediately following bolus dose on days 1 and 2 and 15 and 16 of a 28 day course of treatment
45603064|NCT00873275|Drug|leucovorin calcium|400 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
45603065|NCT00873275|Drug|oxaliplatin|85 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
45603066|NCT00873275|Drug|ursodiol|Dose escalation in cohorts (3 patients/cohort) from an initial dose of 125 mg PO BID through 625 mgs PO BID beginning on Day -6 from infusion of bevacizumab and FOLFOX continuing for the duration of the treatment.
45603067|NCT00873275|Genetic|RNA analysis|Analysis on discard tissues
45603068|NCT00873275|Genetic|gene expression analysis|Determined in normal and malignant tissues in patients who undergo surgical resection after treatment on this trial
45603069|NCT00873275|Genetic|polymerase chain reaction|Analysis on discard tissues
45603070|NCT00873275|Genetic|western blotting|Determined on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment
45756282|NCT01942707|Procedure|Abdominoplasty without Scarpa´s Facia|During surgical detachment of the abdominal flap the Scarpa´s fascia is removed.
45603071|NCT00873275|Other|immunohistochemistry staining method|Performed on tumor blocks from the primary and the metastases from the patients on study
45603072|NCT00873275|Other|laboratory biomarker analysis|Performed on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment
45603073|NCT00873275|Other|pharmacological study|Day 0, day 7 before treatment, 1/2 hour after the start of treatment, 1, 2, 3, 4, and 8 hours after the start of treatment.
45603074|NCT00873275|Procedure|positron emission tomography (PET)|Patients will undergo PET scan imaging as part of their original staging or at baseline. If the PET scan was more than 2 weeks prior to Day 0 from study treatment, there will be a PET scan at Day 0. In any case there will be a PET scan when the patient completes treatment.
45603075|NCT04403243|Drug|Colchicine|0.5mg twice a day per os during the first three days and then 0.5mg daily per os if weight < 86 kg or 0.5mg twice a day per os if weight > 85kg for seven days.
45603076|NCT04403243|Drug|Ruxolitinib 5 MG|Ruxolitinib - 5mg twice a day per os for ten days
45603077|NCT04403243|Drug|Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]|Secukinumab - 300mg subcutaneously singly
45603078|NCT04403243|Other|standard therapy|standard therapy for COVID 19
45603079|NCT00779519|Drug|TTP435|
45603080|NCT00779519|Drug|Placebo|
45603081|NCT05648032|Combination Product|lyophilized platelet (30ng) and triamcinolone acetonide 10mg|Ultrasound-guided injection of lyophilized platelet (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide into the hypoechoic area of common extensor tendon (in lateral epicondylopathy) or around calcific spots (in supraspinatus calcific tendinitis)
45603082|NCT05648032|Other|lyophilized platelet (30ng)|Ultrasound-guided injection of PLT (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL normal saline into the hypoechoic area of common extensor tendon (in lateral epicondylopathy) or around calcific spots (in supraspinatus calcific tendinitis)
45603083|NCT05648032|Drug|triamcinolone acetonide 10mg|Ultrasound-guided injection of 1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide into the hypoechoic area of common extensor tendon (in lateral epicondylopathy) or around calcific spots (in supraspinatus calcific tendinitis)
45603084|NCT02272361|Other|laparoscopic sacrocolpopexy|
45603085|NCT02272361|Other|vaginal mesh surgery|
45603086|NCT00774761|Drug|fluticasone propionate/formoterol fumarate|inhalation suspension
45603087|NCT00774761|Drug|fluticasone propionate|inhalation suspension
45603088|NCT00774761|Drug|formoterol fumarate|inhalation solution
45603089|NCT02267278|Drug|Ruxolitinib|Ruxolitinib taken by mouth 2 times each day in a 28-day cycle. Patients receive Ruxolitinib alone for first 3 months, and then Pracinostat added. Starting dose of Ruxolitinib based on patients' platelet count. Dose of Ruxolitinib may be increased or decreased at discretion of treating physician prior to initiation of Pracinostat.
45756283|NCT00086996|Drug|fluorouracil|Before surgery: 180 mg/m2/day by 24-hour infusion days 8 through 43. After surgery:180 mg/m2/day by 24-hour infusion days 1 through 36.
45756284|NCT00086996|Drug|oxaliplatin|Before surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29. After surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29.
45756285|NCT00086996|Procedure|conventional surgery|The surgical technique will depend upon the location and extent of tumor and individual surgeon preference.
45756286|NCT00086996|Radiation|radiation therapy|Starting Day 8, patients will be treated 5 days/week at 180 centigray (cGy)/day times 25 fractions to a total dose of 4,500 cGy.
45756287|NCT05362253|Procedure|Micro-Conjunctival Autograft Combined with Amniotic Membrane Transplantation|"Disinfection, anaesthesia and excision of recurrent pterygium are the same as conventional autologous conjunctival transplantation.~The biological freeze-dried amniotic membrane (Jiangxi Ruiji Biological engineering technology Co., Ltd., Nanchang, China), equivalent in size to the exposed scleral surface, was flat mounted on the exposed scleral area , and the amniotic membrane was fixed on the superficial sclera with 10-0 suture.~After amniotic membrane graft was fixed, 2% lidocaine was applied to the superior temporal conjunctiva.~Take the conjunctival epithelial graft with the length equivalent to the neck of recurrent pterygium and the width of 1.5mm ~ 2.0mm, and translate it on amniotic membrane surface near corneal limbus. The conjunctival flap was secured with 10-0 suture.~Last, tobramycin and dexamethasone eye ointment was applied and bandaged with dressing."
46066575|NCT02584894|Device|rTMS 1Hz|trauma exposure + repeated transcranial magnetic stimulation at 1Hz
45603090|NCT02267278|Drug|Pracinostat|Starting dose of Pracinostat 60 mg by mouth 1 time each day for 3 alternating days every 3 weeks starting on Day 1 of Cycle 4.
45603091|NCT02267278|Behavioral|Questionnaire|Questionnaire regarding quality of life completed at baseline, within 3 days before Day 1 of Cycles 1 - 6, and then every 3 cycles after that.
45603092|NCT04383509|Behavioral|Cognitive Control Training|Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
45804215|NCT03226691|Drug|Plerixafor|Single-dose subcutaneous administration of plerixafor (Mozobil®) at 240 μg/kg
46066576|NCT02584894|Device|rTMS 10Hz|trauma exposure + repeated transcranial magnetic stimulation at 10Hz
46066577|NCT02584894|Behavioral|psychoneurological assessment|psychoneurological assessment
46066578|NCT02584894|Device|conductivity meter|electrodermal conductance measure
45603093|NCT04383509|Behavioral|Active Control|Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
45603094|NCT00772343|Biological|0.9% Normal Saline|0.5 mL, intramuscular on Days 0, 7, and 28
45603095|NCT00772343|Biological|Clostridium difficile toxoid vaccine|0.5 mL, intramuscular on Days 0, 7, and 28
45603096|NCT00772343|Biological|Clostridium difficile toxoid vaccine with adjuvant|0.5 mL, intramuscular on Days 0, 7, and 28
45603097|NCT00772343|Biological|Clostridium difficile toxoid vaccine|0.5 mL, intramuscular on Days 0, 7, and 28
45603098|NCT05647954|Drug|HX008 + TACE|HX008 Subjects receive HX008 200 mg intravenous (IV) ,day1,every 3 weeks (Q3W) Procedure: TACE cisplatin 75 mg/sqm, day1, every 6 weeks; fotemustine 100 mg/sqm, day2, every 6 weeks; lipiodol is usually 5-10 ml (According to the location and number of lesions).
45603099|NCT05647954|Drug|Temozolomide + TACE|"Temozolomide Subjects receive Temozolomide 200 mg/sqm intravenous (IV),day1-5, every 3 weeks (Q3W)~Procedure: TACE :~cisplatin 75 mg/sqm, day1, every 6 weeks; fotemustine 100 mg/sqm, day2, every 6 weeks; lipiodol is usually 5-10 ml (According to the location and number of lesions)."
45603100|NCT05647954|Drug|Pembrolizumab|Subjects receive Pembrolizumab 2 mg/kg intravenous (IV),day1, every 3 weeks (Q3W)
45603101|NCT04874116|Behavioral|Office Guidelines Applied to Practice (Office-GAP) + Mobile text messaging|Office-GAP incorporates shared decision-making and a decision/support checklist to be completed during office visits, to foster patients' investment in their own care. Way to Health is a cell phone messaging service that informs and encourages patients to adhere to goals and improve communication.
45603102|NCT04874116|Behavioral|Mobile text messaging|Way to Health is a cell phone messaging service that informs and encourages patients to adhere to goals and improve communication.
45603103|NCT00770081|Drug|vildagliptin|50mg qd
45603104|NCT00770081|Drug|sitagliptin|25mg qd
45603105|NCT02360098|Other|Emergence from Anesthesia|There are no study related interventions in this study and perioperative care of these patients will be as per our standard practice The only study related protocol would be collecting the data on the emergence from anesthesia. The data will be collected from the time of turning off the anesthetic agents till the discharge from recovery room. Data collected include, vital signs, Glasgow coma scale( GCS), and Riker agitation- sedation score.. The patients will be assessed every 5 minutes for the first 30 minutes and every 10 minutes for the next 60 minutes.
45603106|NCT02273297|Other|Maternal factors|
45603107|NCT02273609|Drug|Vitamin K antagonists (acenocoumarol or warfarin)|"INR values of patients treated with acenocoumarol or warfarin in the last 12 months will be recorded according to clinical practice of each center.~No specific recommendation about treatment will be provided by sponsor."
45444619|NCT02955134|Drug|Compound Azimtamide Entieric-coated Tablets|Compound Azimtamide Entieric-coated Tablets are qualified by China Food and Drug Administration. These tablets are allowed to be taken when patients feel fullness, belching or anorexia. Continuous taking time should not exceed one week.
45444620|NCT02048488|Drug|TSR-011|Number of cycles until progression or unacceptable toxicity develops.
45756288|NCT05362253|Procedure|Conventional Autologous Conjunctival Transplantation|"Routine disinfection and anaesthesia.~To bluntly separate and excise pterygium.~Remove pterygium tissue on the corneal surface with a round blade.~Place a cotton ball slightly infiltrated with diluent Bleomycin A5 Hydrochloride for Injection on the exposed sclera for 1 minute and flushed away later.~After anesthesia, take the superior temporal conjunctival epithelium equal to the size of the exposed scleral and translate it to the exposed scleral surface (the limbus side of the graft corresponds to the limbus of the graft bed), and fixed with 10-0 suture.~The free conjunctival margin of the conjunctival flap sampling area was sutured intermittently with 10-0 suture.~Apply tobramycin dexamethasone eye ointment and wrap the eyes with dressing after operation."
45911081|NCT02003274|Other|IVGTT-Mixed Meal Arm|"Standard clinical parameters will be assessed in all subjects.~Metabolic tests:~A. IVGTT. A frequently sampled intravenous glucose tolerance test (IVGTT) in healthy controls will be carried out in study 1 and study 3 to assess insulin sensitivity.~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter.~This test will determine the time courses of:~1. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
45444621|NCT03799887|Behavioral|0% unweighed BWSTT|"30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 0% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions)."
45444622|NCT03799887|Behavioral|10% unweighed BWSTT|"30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 10% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions)."
45603108|NCT02273843|Drug|High-dose vitamin D 3|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU
45603109|NCT02273843|Drug|Conventional-Dose Vitamin D 3|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU
45603110|NCT02273921|Other|EEG recording|EEG is recorded once for each participant
45603111|NCT00666497|Drug|Azacitidine|75 mg/m2/day for 5 days, subcutaneous (SC) injection, Days 1 - 5 of every 28-day cycle
45603112|NCT00666497|Drug|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 12 doses, 28-day cycle
45603113|NCT00666497|Drug|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 10 doses, 28-day cycle
45603114|NCT02274077|Drug|EXPAREL|
45603115|NCT02274077|Drug|Normal Saline|
45603116|NCT00765323|Drug|Octreotide Implant|84 mg octreotide subcutaneous implant for 6 months
45603117|NCT00765323|Drug|Sandostatin LAR Depot|Injections of Sandostatin LAR (dose range ~10-40 mg every 28 days)
45444623|NCT03799887|Behavioral|20% unweighed BWSTT|"30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 20% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions)."
45756289|NCT03453203|Other|Osteopathic Manipulative Treatment Using Counterstrain|Described in arm/group descriptions
45603118|NCT02274701|Other|Holistic Needs Assessment|An assessment completed by the patient in cancer care. It is recommended that this assessment is completed at key points in the care pathway, such as at diagnosis, post treatment and beginning of end of life care. The aim of this assessment is to allow the patient to discuss their most important needs as identified by them. The clinician will take any appropriate action. This may range from listening to the patient to referring to another member of the multi-disciplinary team.
45603119|NCT02275637|Device|implantable cardioverter defibrillator|
45603120|NCT04346459|Procedure|"Tracheal intubation through Fastrach - Group A"|"Insertion of the intubating laryngeal mask Fastrach and blind tracheal intubation through the device"
45603121|NCT04346459|Procedure|"Tracheal intubation through I-gel - Group B"|"Insertion of the supraglottic airway device i-gel and tracheal intubation through the device guided by a fiberoptic bronchoscope"
45603122|NCT04346459|Procedure|"Tracheal intubation through Protector - Group C"|"Insertion of the laryngeal mask Protector and tracheal intubation through the device guided by a fiberoptic bronchoscope"
45603123|NCT00760955|Drug|TAK-583|TAK-583 5 mg, tablets, orally, once daily for up to 6 months.
45603124|NCT00760955|Drug|TAK-583|TAK-583 50 mg, tablets, orally, once daily for up to 6 months.
45911082|NCT02003287|Other|VFSS|Videofluoroscopic Swallow Study
45444624|NCT01304043|Drug|chemotherapies protocols|Cisplatine 20 mg/m² IV Etoposide 100 mg/m² IV Bléomycine 30 mg IV
45603125|NCT00760955|Drug|TAK-583|TAK-583 100 mg, tablets, orally, once daily for up to 6 months.
45444625|NCT03562234|Diagnostic Test|MR|Liver fat (measured as a percentage - hepatic fat fraction) will be measured by Magnetic Resonance imaging
45603126|NCT00760955|Drug|Placebo|TAK-583 placebo-matching tablets, orally, once daily for up to 6 months.
45603127|NCT02276495|Other|ACB Control - 20 ml saline injection for ACB|Adductor Canal Block Control (20 ml saline injection)
45603128|NCT02276495|Drug|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block|Adductor Canal Block Study (20 ml 0.5% Ropivacaine)
45603129|NCT02276495|Drug|Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline|"100 mLs of a solution containing:~Ropivacaine 2 mg/mL (49.25 mL) + Epinephrine 1 mg/mL (0.5 mL) + Ketorolac 30mg/mL (1mL) + Clonidine 100 mcg/mL (0.8 mL) + 0.9% Normal saline (48.45 mL)"
45603130|NCT02276729|Other|Mirror Box Therapy|Mirror box therapy (MBT) is a relatively new therapeutic intervention that is gaining recognition within OT for the potential it offers in rehabilitation of upper limb function in stroke patients. It is postulated that mirror visual feedback can stimulate neural recovery in the brain using mirrored movements of the non-affected upper limb. It is thought that visual feedback helps recruit dormant motor pathways that replace the damaged pathways and encourage the return of movement to improve upper limb function.
45603131|NCT02277587|Drug|Plenadren|Oral Tablets: 20-25-30 mg
45603132|NCT02277587|Drug|Conventional glucocorticoid therapy|Oral Tablets: 20-25-30- 37.5 mg
45444626|NCT03562234|Diagnostic Test|LiMAx|Liver function will be measured using the relatively new CE licenced non-invasive LiMAx (Liver Maximum Capacity) test device, manufactured by Humedics GmbH
45603133|NCT02277899|Other|Communication regarding overweight status|Pediatrician-patient/parent communication regarding child's high weight status
45603134|NCT02277899|Other|Risk-factor assessment and counseling|Counseling regarding cardiovascular risk factor assessments/results.
45603135|NCT02277899|Other|Lifestyle behavior assessment and counseling|Counseling regarding diet and lifestyle changes to improve weight status.
45911083|NCT02003287|Other|FEES|Fiberoptic Endoscopic Swallow Study
45911084|NCT02003313|Biological|Group T|0.5ml, Intramuscular
45603136|NCT02277899|Other|Interval follow-up to readdress weight|Interval follow-up to readdress weight, prior to the next well-child visit one year later. Follow-up could include ongoing care through nutrition and/or an intensive weight-management program.
45603137|NCT02277899|Other|Patient-centered communication|Patient-centered communication will be scored as the ratio of patient to doctor-centered communication regarding weight topics. Means will be calculated for total and weight-communication-specific pediatrician, child, and parent-talk time, and patient, doctor, and the ratio of patient/doctor-centered communication scores. For the primary hypothesis, biomedical information-giving (for example, risk-factor communication) will be treated as patient-centered because the principal investigator's focus groups suggest that parents want this information, and prior research suggests that including biomedical-information giving improves the correlation of Roter's patient-centeredness measure with patient health status and satisfaction scores.
45756290|NCT01943565|Drug|Hydromorphone 25mcg|Intrathecal Hydromorphone 25mcg
45756291|NCT01943565|Drug|Hydromorphone 50mcg|Intrathecal Hydromorphone 50mcg
45756292|NCT01943565|Drug|Hydromorphone 100mcg|Intrathecal Hydromorphone 100mcg
45756293|NCT01943565|Drug|spinal anesthesia|bupivacaine 0.75% 1.6 mL (12mg)
45756294|NCT05362175|Device|Obstetric ultrasound|ultrasound measurement of the cross sectional area of umbilical cord within 1 cm from the cord insertion in to fetal abdomen and the standard Hadlock's formula
45756295|NCT03316859|Drug|Naloxegol 25 MG|Naloxegol 25 mg administered 1 hour pre-operatively
45911085|NCT02003313|Biological|Group C|0.5ml, Intramuscular
45911086|NCT02003326|Other|Inflammatory markers|
45911087|NCT02003339|Other|Additional RMIs|
45756296|NCT03316859|Other|Placebo pill|Placebo pill administered 1 hour pre-operatively
45911088|NCT02003378|Device|Pacemaker sensor set to MV|Pacemaker sensor set to minute ventilation
45911089|NCT02003378|Device|Pacemaker sensor set to XL|Pacemaker sensor set to accelerometer
46066579|NCT02584894|Device|electrocardiogram|heart rate measure
45603138|NCT04320407|Device|Osia 2 System|The external Sound Processor, Osia 2 Active Osseointegrated Implant System for Bone Conduction, captures and digitizes the sound which is transferred to the internal implant where it is converted to an electrical signal.
45603139|NCT00758303|Drug|Low Dose TRIA-662|One Capsule 3 times a day
45603140|NCT00758303|Drug|High Dose TRIA-662|3 Capsules 3 times daily
45756297|NCT04401878|Drug|Sphenopalatine Ganglion Block using 2% lidocaine|Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril. The patients are then examined by TCD.
45756298|NCT01880073|Device|FemVue device|The device will be used in conjunction with what is now considered the standard of care to determine if it's as effective.
45603141|NCT00758303|Drug|Placebo for TRIA-662|Matching Placebo for TRIA-662 taken 3 times a day
45603142|NCT00664625|Drug|BMS-791325|Capsules, Oral, Once Daily, Single Dose
45603143|NCT00664625|Drug|Placebo|Capsules, Oral, Once Daily, Single Dose
45603144|NCT00663767|Drug|Placebo; oral|dose 1, dose 2
45603145|NCT00663767|Drug|Placebo; oral|dose 1
45603146|NCT00663767|Drug|ARRY-371797, p38 inhibitor; oral|dose 1: multiple dose levels
45603147|NCT00663767|Drug|ARRY-371797, p38 inhibitor; oral|dose 1: multiple dose levels; dose 2
45756299|NCT05216159|Behavioral|HAPA behavioural counselling + weekly HAPA worksheets|Behavioural counselling grounded in the Health Action Process Approach (HAPA; ie., action planning and coping planning) paired with weekly HAPA based worksheets delivered through a mobile application, SEMA3, to reduce consecutive workplace sedentary behaviour.
45756300|NCT04270058|Drug|inotersen|TEGSEDI injection, for subcutaneous use
45756301|NCT01679366|Drug|Placebo|1 tablet 2 times daily
45756302|NCT01679366|Drug|Probiotics|1 tablet twice daily
45756303|NCT05362019|Drug|Compound Norethisterone Enanthate Injection|Combined injectable contraceptive use
45756304|NCT05362019|Other|One-to-one Service|"A mobile phone based service system will be used to pushing contraceptive knowledges, reminding injection, providing consultation on adverse reactions and ect."
45756305|NCT05362019|Other|Family Planning Service|routine family planning service and contraceptive service.
46066580|NCT00933686|Drug|Saizen®|Saizen® (Somatropin) 0.006 milligram per kilogram (mg/kg) will be administered subcutaneously daily for 12 months. Dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 1, 3, 7 and 9.
45603148|NCT00663767|Drug|Celecoxib, COX-2 inhibitor; oral|dose 1
45603149|NCT00663767|Drug|Placebo; oral|dose 2
45603150|NCT00663767|Drug|ARRY-371797, p38 inhibitor; oral|dose 2
45603151|NCT00662597|Drug|ASA404|
45603152|NCT00662597|Drug|Placebo|
45603153|NCT00662597|Drug|carboplatin|
45603154|NCT00662597|Drug|Paclitaxel|
45603155|NCT02266888|Biological|Rituximab (Rituxan®)|2 Doses: 375 mg/m^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/-2 days).
45603156|NCT02266888|Biological|Placebo|Placebo for Rituximab (Rituxan®). 2 Doses: 375 mg/m^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/-2 days).
45603157|NCT00660959|Drug|lixivaptan|oral capsule
45603158|NCT00660959|Drug|placebo|oral capsule
45603159|NCT01641952|Drug|Rituximab|Rituximab at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
45603160|NCT00757757|Drug|MCS110|Anti-M-CSF antibody
45603161|NCT00660881|Biological|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only PBS as a vehicle/buffer for the infusion procedure.
45603162|NCT02278835|Other|breathing exercises|3 sets of 10 repetitions of deep breathing exercises
45603163|NCT02278835|Device|incentive spirometry|3 sets of 10 repetitions of deep breathing exercises with incentive spirometry
45603164|NCT02278835|Device|Intermittent positive pressure breathing|20 minutes breathing with intermittent positive pressure
45603165|NCT02278835|Device|Continuous positive airway pressure|20 minutes breathing with continuous positive airway pressure
45603166|NCT02359552|Drug|Rasagiline|
45603167|NCT02359552|Drug|Placebo|
45603168|NCT02279537|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
45603169|NCT02279693|Other|CBCT|10 participants will receive a cone beam computed tomography (CBCT) repositioning
45603170|NCT02279693|Other|fiducial marker (kV imaging)|10 participants will receive a kV imaging of fiducial marker repositioning.
45756306|NCT03654105|Drug|Cytisine|"Cytisine administration will be randomized 1:1 in standard (40 days)and prolonged treatment (84 days).~Subjects will be educated on how to take the product and informed about possible adverse effects."
45756307|NCT03654105|Drug|Acetylsalicylic acid|The treatment will consist of Acetylsalicylic acid at 100mg once a day
45756308|NCT03654105|Other|Diet Modification and Physical Activity Increase|"It will be proposed:~an optimal diet with the aim of favoring control of weight, abdominal fat and adequate nutritional status without increasing the levels of IGF-I and inflammatory factors or glycemic peaks, with periodic verification of the results~a regular and sustainable physical activity program with periodic verification of the results."
45756309|NCT03654105|Diagnostic Test|early lung cancer detection|standard treatment for early lung cancer detection with ultra low dose CT
45756310|NCT03654105|Diagnostic Test|spirometry with CO test|spirometry with CO test
45756311|NCT03654105|Other|anthropometic data collection|anthropometic data collection
45756312|NCT03654105|Other|blood test|blood test to assess the metabolic and inflammatory profile
45756313|NCT05361863|Device|Orthodontic brackets|Interventions involving orthodontic brackets of different slot sizes
45756314|NCT05361707|Drug|Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension|Once Daily
45756315|NCT04388111|Drug|Morphine|10mg of Morphine delivered Intraosseously
45756316|NCT01880697|Biological|TIVc|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, cell-based)
45603171|NCT02279693|Radiation|IGRT Associated With IMRT|
45603172|NCT05647720|Procedure|Distalization combined with upper third molars extraction|After surgical extraction of unerupted upper third molars, the maxillary first molars were distalized using a labial bow with two soldered crimpable hooks distal to the upper lateral incisors. The labial bow fitted in the flying tube of the upper first molar bands. It was anchored bilaterally to the infra-zygomatic mini-implant by closed coil spring that applied a force of 300gm on each side
45603173|NCT05647720|Procedure|Distalization without upper third molars extraction|The maxillary first molars were distalized , without extracting upper third molars, using a labial bow with two soldered crimpable hooks distal to the upper lateral incisors. The labial bow fitted in the flying tube of the upper first molar bands. It was anchored bilaterally to the infra-zygomatic mini-implant by closed coil spring that applied a force of 300gm on each side
45603174|NCT02280005|Device|WAK Treatment|Hemodialysis with WAK device.
45603175|NCT04249115|Device|Nano-Pulse Stimulation (NPS)|Electrical pulses (nanosecond duration) applied directly to target SK lesions using sterile single-patient use treatment tips with microneedles.
45603176|NCT02280083|Drug|Botulinum Toxin Type A for Injection|"HengLi002(Botulinum Toxin Type A for Injection,also known as HengLi®)"
45603177|NCT02280083|Drug|placebo|placebo
45603178|NCT00752297|Drug|Preservative-free Saline|Subjects will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
45756317|NCT03309137|Device|Chlorhexidine flush|"For patients randomized to the CHG-LockTM device, attach a attach a BD Posiflush ™ 0.9% Sodium Chloride (Na Cl) 10ml syringe and a CHG-Lock™ device for each IV line that is to be locked. Follow hospital approved protocol for flush, volumes and hand hygiene.~After a Catheter has been locked, before re-accessing the catheter for further sampling or infusions, all fluid should be aspirated from the catheter to clear the device of CHG, Heparin and the like. This should also confirm patency of the device.~Discard the syringe and device in biohazard waste.~Blue Cap the IV as per routine practice."
45603179|NCT00752297|Drug|Mentor Purified Toxin|All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of PurTox. Subjects will have many Treatment Visits throughout the course of the three-year study.
45603180|NCT04472273|Procedure|high-flow nasal cannula / classic nasal cannula|The oxygen given with nasal cannula cannot be humidified, causing drying in mucous membranes at high flow rates of more than 4L/min and problems in patient compliance.This situation prevents us to increase the oxygen FiO2 rate applied to the patient above 40%.According to the nasal cannula high-flow nasal cannula where heated and humidified oxygen can be delivered, oxygen therapy can be applied at a flow rate of 25L/min.It provides high flows easily, prevents the airway epithelium from drying out and improves mucus cleansing, causing a decrease in anatomical dead space.It provides discharge of expired air in the upper airways.It increases alveolar ventilation.It offers a stream adjusted to all children.Flow and titration can be adjusted according to the child's weight and effect.
45603181|NCT00656357|Drug|SYN117 Placebo|Placebo
45603182|NCT00656357|Drug|SYN117 80 mg|SYN117 80 mg
45603183|NCT00656357|Drug|SYN117 160 mg|SYN117 160 mg
45603184|NCT00656357|Drug|Cocaine 10mg|IV Cocaine 10mg
45603185|NCT00656357|Drug|Cocaine 20mg|IV Cocaine 20mg
45603186|NCT00656357|Drug|Cocaine 40mg|IV Cocaine 40mg
45603187|NCT00656357|Drug|Saline|IV Cocaine Placebo
45603188|NCT02280395|Drug|RUT058-60|Prior to closure of the abdomen at the end of the surgical repair, each subject will undergo lavage with approximately 900 mL of RUT058-60 administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
45603189|NCT02280395|Drug|Sterile saline for irrigation|Prior to closure of the abdomen, each subject will undergo lavage with approximately 900 mL of sterile saline administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
45603190|NCT00747929|Drug|S-2367 Placebo|four placebo tablets (total dose = 0 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for a total of 54 weeks,
45756318|NCT05361629|Procedure|Intralesional steroid administration|Treatment by administering steroids into the lesion
45756319|NCT05361629|Procedure|Intraoperative cavity steroid administration|Treatment by administering steroids into the surgical cavity
45756320|NCT03197675|Other|Acupuncture|Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture and 8 treatments of auricular acupuncture). Relative pain levels will be measured via the NRS by a member of the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
45911090|NCT02003456|Drug|Cardiac PET scan w/18F-Fluorodeoxyglucose and rubidium-82|Study subjects will undergo a Cardiac PET scan that will take approximately 20 minutes to complete. In addition to standard clinical rubidium-82/18F-fluorodeoxyglucose (FDG) PET imaging, during a separate imaging session, participants will be infused with a second dose of the radio-tracer rubidium-82 during FDG imaging scan that will take an additional 10 to 15 minutes to complete.
45603191|NCT00747929|Drug|S-2367 800 mg|two 400 mg S-2367 tablets (total dose = 800 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for a total of 54 weeks
45603192|NCT00747929|Drug|S-2367 1600 mg|four 400 mg S-2367 tablets (total dose = 1600 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for total of 54 weeks,
45603193|NCT00747929|Other|Reduced Calorie Diet|A diet with restricted calorie content
45603194|NCT00744731|Drug|placebo|placebo for 1 week
45603195|NCT00744731|Drug|carisbamate|400 mg/day to 1,200 mg per day
45603196|NCT02280629|Drug|LT-02|LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily
45603197|NCT02280629|Drug|Placebo|LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily
45603198|NCT02280629|Drug|Mesalamine|LT-02 PLACEBO twice daily AND mesalamine 500mg three-times daily
45603199|NCT03134573|Drug|Interferon beta-1b (Betaferon, BAY86-5046)|Solution for injection
45756321|NCT01881087|Drug|Hyperbaric Levobupivacaine 0.75%|Each 4 ml of the administred solution contains: Chlorhydrate Levogyre Bupivacaine 30 mg, Glucose 290.8 mg and water for injection c.s.
45603200|NCT03134573|Device|Betaconnect auto-injector|Auto-injector for application of Betaferon solution which automatically covers injection related data
45603201|NCT03134573|Device|myBETAapp|Medical device which can be connected with Betaconnect auto-injector and displays injection related data to patients and offers tracking of patient reported data at the wellness- tracker
45756322|NCT05352893|Drug|Imsidolimab high dose|intravenous
45756323|NCT05352893|Drug|Imsidolimab low dose|intravenous
45603202|NCT00743795|Drug|placebo|oral BID
45603203|NCT00743795|Drug|GS-9190|40 mg oral BID
45603204|NCT00743795|Drug|Peginterferon Alfa 2a|All subjects received a fixed dose of 180 μg PEG via subcutaneous injection on a weekly basis.
45603205|NCT00743795|Drug|Ribavirin|Ribavirin supplied as 200 mg Copegus® tablets (1000 mg for subjects weighing < 75 kg and 1200 mg for subjects weighing ≥ 75 kg) were given in a divided daily dose.
45603206|NCT04232033|Other|Fibroblast growth factor 21 infusion|Infusion of Fibroblast growth factor 21
45603207|NCT04232033|Other|Placebo infusion (saline)|Infusion of Saline
45603208|NCT03134417|Dietary Supplement|Vitamin D and magnesium|Daily vitamin D and magnesium supplements are given to participants daily for 12 weeks.
45756324|NCT05352893|Other|Placebo|intravenous
45603209|NCT03134417|Dietary Supplement|Vitamin D|Daily vitamin D supplements are given to participants daily for 12 weeks.
45603210|NCT03134417|Dietary Supplement|Placebo|Daily placebo are given to participants daily for 12 weeks.
45603211|NCT03135041|Dietary Supplement|Fiber-containing dietary supplement|Effects of fiber-containing dietary supplement on weight loss during energy restriction
45603212|NCT03135041|Dietary Supplement|Placebo|Effects of placebo supplement on weight loss during energy restriction
45603213|NCT03134261|Diagnostic Test|WB-MRI|scanning methods
45603214|NCT03134261|Diagnostic Test|SPECT-CT|scanning methods
45603215|NCT03134261|Diagnostic Test|Cholin-PET-CT|scanning methods
45603216|NCT03134261|Diagnostic Test|PSMA-PET-CT|
45756325|NCT01944423|Drug|d-cycloserine|d-cycloserine is a medication thought to be associated with fear extinction.
45756326|NCT01944423|Drug|Pill Placebo|
45756327|NCT01944423|Drug|Nicotine replacement therapy|All participants will receive Nicoderm CQ®, 24-hour transdermal nicotine patches and will be educated about the use of the patch at the session immediately prior to quit date. They will be instructed to apply one patch daily, beginning on quit date (week 5). Participants will use the 3-step tapering Nicoderm process (21-mg, 14-mg, and 7-mg). This regimen has been used in previous trials with a similar formulation of the patch (Fiore, 2000). A meta-analysis found no differences in outcome between 16- or 24-hour patches (Fiore et al., 1994). Participants who continue to smoke or lapse after quit day will not be instructed to discontinue the patch until their smoking level reaches 4 cigarettes/day for 4 days. Smokers who lapse during treatment will be encouraged to set a new quit date and continue their cessation attempt.
45804216|NCT03721029|Device|Intraoperative nerve monitoring,|Intraoperative nerve monitoring, via electromyography, enables real-time identification of the location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function.
45804217|NCT03721029|Procedure|standard of care robotic-assisted radical prostatectomy|With out the usage of intraoperative nerve monitoring
45804218|NCT00003159|Drug|carboplatin|
45603217|NCT00649025|Drug|FlutiForm 250/10|SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
45603218|NCT00649025|Drug|SKP-Fluticasone|SKP Fluticasone 250 ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
45603219|NCT00649025|Drug|Flovent Fluticasone HFA|Flovent 250 ug HFA is a pMDI that delivers after priming 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
45603220|NCT02743793|Procedure|Blood Draw|
45603221|NCT04219163|Biological|CLL-1.CAR T cells|"Dose escalation study with 3 dose levels:~DL1: 1x10^7 cells/m2, DL2: 3x10^7 cells/m2, DL3: 1x10^8 cells/m2~If excessive dose limiting toxicity attributed to the product occurs at dose level one, we will request permission from FDA to treat at dose level -1: 5×10^6 cells/m2"
45603222|NCT00647231|Drug|HKT-500 Topical Patch|Treatment with Ketoprofen Topical Patch
45603223|NCT00647231|Other|Placebo Patch|Treatment with placebo patch
45603224|NCT00739739|Drug|PD 0299685 at 15mg BID|5 mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study
45603225|NCT00739739|Drug|PD 0299685 at 30mg BID|10mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study. Initial 2 week titration period at 15mg BID.
45603226|NCT00739739|Drug|placebo for PD 0299685|Capsules identical in appearance to PD 0299685, 3 to be taken in the morning and at bedtime for the duration of the study
45603227|NCT00640523|Drug|forodesine HCl|2 x 100mg capsules daily
45603228|NCT00739349|Drug|NOVA22007 ''Cyclosporine''|Cyclosporine 0.05% Ophthalmic Cationic Emulsions
45804219|NCT00003159|Drug|cisplatin|
45603229|NCT00739349|Drug|NOVA22007 ''Cyclosporine''|Cyclosporine 0.1% Ophthalmic Cationic Emulsions
45603230|NCT00739349|Drug|vehicle/placebo|vehicle/placebo
45603231|NCT00627419|Drug|IPI-504|Dose as a 30 to 60 minute IV infusion as part of a 21-day treatment cycle until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for patient withdrawal. IPI-504 will be administered twice weekly on Study Days 1, 4, 8, and 11 of each 21-day cycle.
45603232|NCT00152009|Drug|SPD503 (Guanfacine hydrochloride) (2 mg)|
45603233|NCT00152009|Drug|SPD503 (3 mg)|
45603234|NCT00152009|Drug|SPD503 (4 mg)|
45603235|NCT00152009|Drug|Placebo|
45804220|NCT00003159|Drug|docetaxel|
45804221|NCT00003159|Drug|gemcitabine hydrochloride|
45603236|NCT04182035|Other|patient-tailored therapy|The subjects in the PTT group will receive the individual tailored treatment program combining best evidence active and passive treatment strategies (manual therapy, individual exercises) in combination with education tailored to the individual situation of the patient and selected home exercises. 9 individual therapy sessions will be performed, in combination with 9 additional home exercise sessions.. NRS and NDI-scores will be monitored before every treatment. The therapist will register when the cut-off score of 30% NDI reduction is present in order to determine the evolution in pain/disability reduction. The importance of self-efficacy will be emphasized and tailored home-exercises will be monitored and adjusted every week.
45603237|NCT04182035|Other|Non-patient tailored therapy: generalized exercise program|The NPTT will receive an individual (hands-off) treatment, which includes an active neck exercise program, non-tailored education and non-tailored home exercises, according to a previously published program with good results.53 The sessions will be performed once a week under supervision (9 therapy sessions, standard exercise program) and once a week by the patient at home (9 home exercise sessions, standard exercise program).
45804222|NCT00003159|Drug|ifosfamide|
45603238|NCT04182035|Other|Education|Education considering neck pain information
45603239|NCT02280707|Other|Grab a Cup, Fill it Up|The intervention involved installing promotional posters encouraging students to drink water as well as cup dispensers stocked with disposable 5 ounce cups near water fountains in school lunchrooms.
45603240|NCT04473131|Other|No intervention|Only blood samples will be taken from participants for this study
45603241|NCT02280785|Drug|Brentuximab vedotin|Brentuximab vedotin must not be administered as an IV push or bolus. It must be administered in 100ml-250ml of 0.9% saline by intravenous infusion over 30 minutes once every 3 weeks.
45603242|NCT04158635|Drug|Bosentan|Given PO
45603243|NCT04158635|Drug|Gemcitabine|Given IV
45603244|NCT04158635|Drug|Nab-paclitaxel|Given IV
45603245|NCT04158635|Other|Quality-of-Life Assessment|Ancillary studies
45603246|NCT04158635|Other|Questionnaire Administration|Ancillary studies
45603247|NCT02280941|Other|single photon emission computed tomography|Single photon emission computed tomography (SPECT) imaging will be done.
45603248|NCT04314089|Drug|GT103|intravenously (dose depending)
45603249|NCT04096937|Other|Focus groups|Focus groups will be conducted with adult stakeholders and with youth in Appalachia. Feedback from the focus groups will guide cultural tailoring of the Journey of Hope in Appalachia intervention for use in a later phase.
45603250|NCT04473209|Procedure|non-surgical periodontal therapy|supra and subgingival debridement
45603251|NCT02281019|Procedure|ERCP (Endoscopic Retrograde Cholangiopancreatography)|ERCP procedure will be performed to visualize bile ducts.
45603252|NCT02281019|Device|SpyGlass DVS and SpyGlass Digital Simple (DS)|Cholangioscopy using SpyGlass™ DVS or SpyGlass DS will be performed post ERCP for direct viewing of the bile ducts. What is seen during the procedure will determine a course of treatment. Among the options are biopsies taken, stones treated/removed, or a stent placed
45603253|NCT02281253|Dietary Supplement|dietary fibre plus L-carnitine bread|"The enriched bread consisted of a mix of wheat flour, vegetable flour, rye flour, wheat gluten, soy protein, soluble and insoluble dietary fibre, inulin, guar gum, L-carnitine salt, diacetyl tartaric, enzymes, ascorbic acid, water and yeast.~Patients were recommended to consume the bread twice per day with main meals."
45603254|NCT02281253|Dietary Supplement|Placebo bread|The placebo group received commercially available bread with a similar macronutrient composition and energy intake to that consumed by the enriched bread group but without L-carnitine and dietary fibre. Patients were recommended to consume the bread twice per day with main meals.
45603255|NCT00734435|Drug|zonisamide SR plus olanzapine|zonisamide SR 90 mg given twice daily and olanzapine 10 mg to 20 mg daily for 10 weeks (maintenance period)
45603256|NCT00734435|Drug|Placebo plus olanzapine|Placebo given twice daily and olanzapine 10-20 mg for 10 weeks (maintenance period)
45603257|NCT04040231|Biological|Galinpepimut-S|Galinpepimut-S will be administered alone on weeks 0 and 2. Participants will receive the galinpepimut-S vaccine and nivolumab over 16 weeks in the initial treatment phase.
45804223|NCT00003159|Drug|mitomycin C|
45804224|NCT00003159|Drug|paclitaxel|
45911091|NCT02003469|Device|Ambulatory Blood Pressure Monitoring|All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
45444627|NCT02048566|Device|ImaCor PM|The ImaCor ClariTEE (hTEE) device is a transesophageal echocardiography system. It produces a single-plane two-dimensional image. The ImaCor probe is a 5.5 mm detachable probe; it can remain in situ for up to 72h and allows for reassessment of the patient's hemodynamic progress and the effect of selected interventions at any time. The probe is connected to a dedicated echocardiographic system which allows the for the recording of digital loops and performance of basic two-dimensional measurements. ImaCorPM subjects will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, at the time of occurrence of defined new organ system deterioration and/or at least every 4 hours during the first 72h after study inclusion or until one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
45603258|NCT04040231|Drug|Nivolumab|Participants will receive nivolumab and the galinpepimut-S vaccine over 16 weeks in the initial treatment phase.
45603259|NCT04040231|Biological|Sargramostim|All participants will receive Sargramostim (GM-CSF) 70 mcg injected subcutaneously on days 0 and -2 of each cycle
45603260|NCT02281331|Dietary Supplement|Supplement|supplement/placebo plus exercise training
45603261|NCT00624845|Drug|OMS103HP|Maximum 6 bags of OMS103HP irrigation solution
45603262|NCT00624845|Drug|Vehicle|Maximum of 6 bags of vehicle irrigation solution
45603263|NCT00728351|Drug|vildagliptin + metformin|
45603264|NCT00728351|Drug|metformin|1000 bid metformin
45911092|NCT02003482|Radiation|Postop IMRT for head/neck cancer|Patients will be enrolled in study through the duration of their radiation therapy, approximately 6-8 weeks. After which time no further evaluations will be made.
45804225|NCT00003159|Drug|vinblastine sulfate|
45804226|NCT00003159|Drug|vinorelbine tartrate|
45804227|NCT00003159|Procedure|conventional surgery|
45804228|NCT00003159|Procedure|neoadjuvant therapy|
45603265|NCT00622193|Drug|anamorelin HCl|50 mg tablet
45756328|NCT01944423|Behavioral|Panic and Smoking Reduction Treatment|PSRT incorporates elements of standard smoking cessation treatment (i.e., counseling plus NRT) with procedures for reducing panic and enhancing tolerance to withdrawal sensations. Written therapist and patient manuals will be used and followed at all times to ensure standardized delivery of the treatment. Interventions that uniquely focus on addressing panic, fears and intolerance of anxiety, bodily-related sensations, and affect-relevant withdrawal symptoms include: (1) interoceptive exposure; (2) corrective information about anxiety and cognitive interventions designed to teach patients alternatives to catastrophic misinterpretations of the sensations and their feared consequences; and (3) situational exposure.
45603266|NCT00622193|Drug|anamorelin HCl|100 mg tablet
45756329|NCT03112499|Procedure|PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using either balloon (20 atm) or Amplatz serial dilators a 30F access channel is created. Lithotripsy is performed using ultrasound lithotripter and stone fragments are removed by grasping forceps. At the end of the operation a 18F Council type catheter is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Council and JJ catheter are removed,in the absence of complications, the second and tenth postoperative day, respectively.
45603267|NCT00622193|Drug|placebo|placebo tablet
45603268|NCT00616811|Drug|vildagliptin|
45603269|NCT00616811|Drug|Sitagliptin|
45603270|NCT02265952|Drug|REGN1500 250 mg SC/15 mg/kg IV/450 mg SC|Participants received single dose of REGN1500 subcutaneous (SC) injection of 250 milligrams (mg) at Week 0 (Day 1), followed by single dose of REGN1500 intravenous (IV) injection of 15 milligrams per kilogram (mg/kg) at Week 2 (Day 15) and then followed by 4 doses of REGN1500 SC injection of 450 mg once weekly starting from Week 12 (Day 85). Only the first 2 enrolled participants received 4 weekly REGN1500 450 mg SC doses at weeks 12, 13, 14, and 15 per the protocol. This dose regimen was removed under protocol amendment 4. Participants were followed for a period of 24 weeks (through Week 26 [Day 183]) after the last dose of study drug in the main study period.
45756330|NCT03112499|Procedure|mini-PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using Amplatz serial dilators a 16F access channel is created. Lithotripsy is performed using using 270mm Ho: YAG laser fiber and stone fragments are removed by grasping forceps. At the end of the operation a 10F nephrostomy tube is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Nephrostomy tube and JJ catheter are removed, in the absence of complications, the second and tenth postoperative day, respectively.
45756331|NCT03112499|Procedure|RIRS|Under general anesthesia and patient in lithotomy position, a 0.035 hydrophilic safety wire is inserted in the ureter under fluoroscopic guidance. Subsequently 8-10 F dilators are used for dilation of the ureter.Insertion of a second working wire follows above which a 14F ureteral sheath is placed. Lithotripsy with a flexible ureteroscope using 270mm Ho: YAG laser fiber follows.Remaining stone fragments are removed by a 2,2F nitinol basket. At the end of the operation a JJ indwelling ureteral catheter is placed over the safety wire. Discharge is performed in the absence of complications, the first postoperative day while JJ catheter is removed on the 10th postoperative day.
45603271|NCT00615251|Drug|DR-2011|Progesterone vaginal ring for approximately 10 weeks
45603272|NCT00615251|Drug|Crinone 8%|progesterone vaginal gel for approximately 10 weeks
45756332|NCT05305313|Drug|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
45603273|NCT03946397|Other|Mulstisensory massage|7 minutes of hand massage followed by multisensory immersion (lights and music) for 23 minutes
45603274|NCT00614705|Drug|PH-797804|6 mg dose in oral capsule form, once daily for 28 days
45603275|NCT00614705|Drug|Placebo|oral capsule form, once daily for 28 days
45603276|NCT02265796|Drug|Ranolazine|"Ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
45603277|NCT02265796|Drug|Sugar pill|"500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
45603278|NCT05647642|Drug|Precedex and dormicum|Premedication
45603279|NCT04873726|Device|Magnetic Tape® aplication|Magnetic tape® is applied without creating any tension on the lumbar paravertebral skin to assess changes in pupil size
45603280|NCT04873726|Device|Kinesiology Tape|Kinesiology tape is applied without creating any tension on the lumbar paravertebral skin to assess changes in pupil size
45603281|NCT02357368|Drug|Depot medroxyprogesterone acetate (DMPA)|DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15.
45603282|NCT02357368|Device|Etonogestrel implant (Eng-Implant)|A standard nexplanon rod implant will be placed at study week 3 by a trained clinician.
45603283|NCT02357368|Device|Levonorgestrel intrauterine device (Lng-IUD)|A standard Mirena IUD will be placed at study week 3 by a trained clinician.
45603284|NCT02357368|Device|ParaGard® T 380A Intrauterine Copper Contraceptive|A standard ParaGuard IUD will be placed at study week 3 by a trained clinician.
45603285|NCT05647486|Other|30-day postoperative outcome|The 30-day postoperative outcome after elective EVAR and the role of possible predictors among patients' baseline characteristics were assessed
45603286|NCT04873570|Drug|Moxifloxacin 400mg|Moxifloxacin 400mg IR tablet
45603287|NCT05647408|Drug|Dexamethasone|The nominal doses were similar, volunteers were randomly assigned to receive a single dose of DXM by IV bolus of 1.5 mL (equivalent to 6 mg of dexamethasone) or the same dose intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
45756333|NCT05305313|Drug|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
45603288|NCT03287245|Drug|Idasanutlin|All participants will receive 150 milligrams (mg) idasanutlin orally, once daily for 5 days, every 28 days, until treatment discontinuation or end of study (up to 2 years). Intra-participant dose-escalation to 200 mg daily for 5 days may be permitted after Cycle 3 for those who demonstrate no hematocrit (Hct) control and/or for those with inadequately controlled leukocytosis and/or thrombocytosis in which the investigator judges that better control is important.
45603289|NCT02323555|Other|Paramedic telephone consultation|
45603290|NCT03487081|Behavioral|Social regulation|Participants will be instructed to help another person think about their negative events differently using an emotion regulation strategy called reappraisal.
45756334|NCT05270603|Other|ICARUS intraoperative adverse events calculator|"The ICARUS calculator is a web-based tool that uses answers to Boolean, yes/no questions to determine the iAE grade (appendix I). The calculator providers iAE grade outputs for the 5 iAE classification systems.~https://garnmile.com/iaecalc/~Development of the ICARUS calculator was performed as follows: Referencing the 5 classification systems, we first assembled a list of Boolean questions based on the iAE grade descriptions. This list was distilled to the minimum number of questions necessary to represent all descriptions in the combined list of iAE grades. Next, these questions were used to independently establish the conditional logic required to determine iAE grade for each classification system. The questions and logic were translated into Hypertext Preprocessor (PHP), a server-side programming language, and JavaScript, a client-side scripting language."
45603291|NCT03487081|Behavioral|Self regulation|Participants will be instructed to think about their negative events by reframing the meaning of the event. This is a typical strategy in emotion regulation research known as reappraisal.
45603292|NCT03483727|Device|SIMMAXMARCHERYAN|Digital cognitive aid during the management of simulated combat wounded.
45603293|NCT02323633|Device|Braingear Brainbuds Pulsed Current stimulation device|Transcranial Pulsed Current stimulation (tPCS) at random noise oscillating frequencies for a duration of 20 minutues
45603294|NCT02323633|Device|Sham|No transcranial Pulsed Current Stimulation (tPCS)
45603295|NCT03483493|Behavioral|Exposure Response Prevention for tics|The intervention consists of evidence-based interventions adapted from previously published treatment manuals on Exposure and Response Prevention (ERP) and established behavioural intervention for tics protocols. Each of the 10 modules includes age-appropriate texts, animations and exercises. Prticipants are instructed to practice suppressing their tics, this is known as 'response prevention'. Then, with the help of their parent/carer, the participant is instructed to provoke premonitory urges (the urge to tic often felt before the tic is expressed) and try to supress the need to express/demonstrate the tic, this known as 'exposure'.
45603296|NCT03483493|Other|Psychoeducation for tics|The comparator intervention reviews the definition of tics, natural history, common presentations, prevalence, aetiology, risks and protective factors and strategies for describing tics to other people etc. Problem-solving and development of expertise in tic disorders is emphasised. The intervention includes strategies for promoting positive behaviours which will be rewarded by a parent as a parallel element to the tic control practice in the behavioural therapy arm. There is no information on tic control within the management package.
45603297|NCT03483415|Drug|Morphine Sulfate|Intravenous morphine infusion with PCA: Solution was concentration of 0.5 mg/mL. Loading dose of 1 mg, 0.5 mg of bolus dose and 20 min of locking time.
45603298|NCT03483415|Drug|Bupivacaine|Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine
45603299|NCT03487003|Drug|rocuronium|After standard anesthetic monitoring (non-invasive blood pressure monitor, pulse oximetry, 3-lead echocardiography), patients are inhaled with sevoflurane. When the patients asleep, 0.3 mg/kg rocuronium is administered. After 2 min, flexible laryngeal mask airway (fLMA) is inserted using standard method. The fLMA is inflated with air to 40 cmH2O using manometry. The oropharyngeal leak pressure (OLP) was determined by the method described by Lopez-Gil and colleagues.
45756335|NCT01798667|Drug|DA-8031|
45756336|NCT01798667|Drug|Placebo|Placebo of DA-8031, undistinguishable
45756337|NCT01749137|Drug|RM-493|
45756338|NCT01749137|Drug|Placebo|
45756339|NCT04388657|Diagnostic Test|Echo-Doppler|Utrasound Doppler of the lower limbs
45603300|NCT03487003|Drug|saline|After standard anesthetic monitoring (non-invasive blood pressure monitor, pulse oximetry, 3-lead echocardiography), patients are inhaled with sevoflurane. When the patients asleep, 0.3 mg/kg saline is administered. After 2 min, flexible laryngeal mask airway (fLMA) is inserted using standard method. The fLMA is inflated with air to 40 cmH2O using manometry. The oropharyngeal leak pressure (OLP) was determined by the method described by Lopez-Gil and colleagues
45603301|NCT03486925|Drug|oxytocin treatment|intranasal administration of oxytocin (24IU)
45603302|NCT03486925|Drug|placebo treatment|intranasal administration of placebo
45603303|NCT03486847|Procedure|Repetitive recruitment with PEEP|Apply sustained airway pressure of 30-40 cmH2O for 10-20 seconds before suegery and once an hour during surgery. PEEP is set to 7 cmH2O.
45756340|NCT00600925|Drug|gentamicin-collagen sponge dipped in saline|2 gentamicin-collagen sponges inserted before closure of the laparotomy
45756341|NCT02673203|Device|Continuous Glucose Monitoring System (CGMS)|The CGMS consists of 3 parts: sensor, transmitter and monitor. The small sensor measures the glucose levels from the interstitial tissue. The transmitter is attached on top of the sensor and connects wirelessly to the monitor. The sensor is sterile and comes in an unopened package. It has a plastic wire-like tip that is placed under the skin and continuously measures the glucose levels. One of the study physicians will insert the CGMS wire-like tip under the volunteer's skin with the use of the DEXCOM sensor insertion kit. The transmitter is snapped to the sensor pod and the sensor/transmitter unit will be attached to the skin with an adhesive patch. The monitor is the size of a small hand-held device with a digital screen that displays a graph showing the glucose levels from the previous 4-24 hours.
45756342|NCT02673203|Behavioral|Food log|The Food Record will ask about amount and type of food consumed throughout the day. The participants will also register how hungry they are before the meal and how full they feel after they ate, and type and duration of physical activity
45603304|NCT03486847|Procedure|One recruitment with PEEP|Apply sustained airway pressure of 30-40 cmH2O for 10-20 seconds before surgery. PEEP is set to 7 cmH2O.
45756343|NCT02653001|Other|Stool sample collection|Collection of complete stool sample
45603305|NCT03483259|Drug|Sulfatinib T capsule|Sulfatinib T capsules were produced by Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd. production.
45603306|NCT03483259|Drug|Sulfatinib R capsule|Sulfatinib R capsules were produced by Beijing Yiling Bioengineering Technology Co., Ltd.
45756344|NCT02560181|Radiation|HDR brachytherapy|Whole gland salvage
45603307|NCT02262754|Drug|PF-06372865|Dose level 1 daily dosing BID for 1 week followed by dose level 2 daily BID for 3 weeks
45603308|NCT02262754|Drug|Placebo|Placebo for PF-06372865 and placebo for naproxen daily
45603309|NCT02262754|Drug|Naproxen|500 mg BID for 4 weeks
45603310|NCT03483181|Drug|Xarelto (rivaroxaban)|An oral anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received rivaroxaban during one day prior to or two days after orthopedic surgery during the hospitalization.
45603311|NCT03483181|Drug|Lovenox (enoxaparin)|An injectable anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received enoxaparin during one day prior to or two days after orthopedic surgeries during the hospitalization.
45603312|NCT02323711|Device|2-octyl cyanoacrylate|If the subject is allocated to the experimental group, they would receive 2-octyl cyanoacrylate in place of a primary dressing consisting of their non-adherent composite dressing (Tefla) and a secondary dressing of Army Battle Dressing (ABD).
45603313|NCT03486769|Device|M1 stimulation|stimulating primary motor cortex with anodal transcranial direct current stimulation
45603314|NCT03486769|Device|PMC stimulation|stimulating premotor cortex with anodal transcranial direct current stimulation
45603315|NCT03486769|Device|aIPS stimulation|stimulating anterior intraparietal sulcus with anodal transcranial direct current stimulation
45756345|NCT01881867|Biological|Glycosylated Recombinant Human Interleukin-7|Given SC
45756346|NCT01881867|Other|Laboratory Biomarker Analysis|Correlative studies
45756347|NCT01882413|Other|No intervention|No intervention
45603316|NCT03486769|Behavioral|hand motor task|hand motor task for 30 minutes during transcranial direct current stimulation
45603317|NCT03069937|Drug|Docetaxel|The docetaxel dose is a 75mg/m2 intravenous (given through the vein) injection.
45603318|NCT03069937|Drug|Degarelix|Degarelix will be given as a subcutaneous (given under the skin) injection in the abdomen. The first dose will be a 240mg dose; all other doses will be 80 mg.
45603319|NCT03486691|Other|Routine measurement of left lobe|Routine preoperative measurement of left lobe
45603320|NCT03486691|Other|control group|no routine preoperative measurement of left lobe
45756348|NCT02338973|Drug|Interferon gamma-1b|
45756349|NCT03458403|Procedure|Motions during gastroscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for. The endoscope is removed halfway up the esophagus and inserted into the pylorus to the descending duodenum. The gesture is repeated three times.
45756350|NCT00601627|Biological|panitumumab|
45756351|NCT00601627|Drug|capecitabine|
45756352|NCT00601627|Drug|fluorouracil|
45756353|NCT00601627|Drug|gemcitabine hydrochloride|
45756354|NCT00601627|Radiation|radiation therapy|
45756355|NCT01882725|Device|Erchonia HP Scanner (HPS)|The Erchonia HP Scanner (HPS) Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
45603321|NCT03486613|Other|PROM registration via the DANBIO App on a smartphone|PROM data is reported through the DANBIO smartphone app
45756356|NCT01883427|Drug|Placebo|placebo containing saline+glucose
45756357|NCT01883427|Drug|Glucose oxidase|a hydrogen peroxide producing enzyme that creates an acidous environment to which rhinoviruses are sensitive.
45756358|NCT02527187|Biological|10 HEP/mL Betula verrucosa allergen extract|The investigational product contained 10 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
45756359|NCT02527187|Biological|25 HEP/mL Betula verrucosa allergen extract|The investigational product contained 25 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
45756360|NCT02527187|Biological|50 HEP/mL Betula verrucosa allergen extract|The investigational product contained 50 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
45756361|NCT02527187|Biological|100 HEP/mL Betula verrucosa allergen extract|The investigational product contained 100 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
45756362|NCT01947153|Drug|Metformin|Free combination
45756363|NCT01947153|Drug|Linagliptin|Fixed dose combination
45603322|NCT03486613|Other|PROM registration via the touch screen solution|PROM data is reported through the touch screen solution
45603323|NCT03483025|Other|Skin Testing of Hair cleansing products|6 different commercially available shampoos
45603324|NCT02262364|Biological|APS|See above
45603325|NCT00309985|Drug|androgen-deprivation therapy|LHRH analogs are administered with a variety of techniques such as subcutaneously, intramuscularly, or insertion, while antiandrogens (flutamide and bicalutamide) were given orally.
45603326|NCT00309985|Drug|docetaxel|Given IV
45603327|NCT02261974|Device|Active Treatment Viveve|Subject will receive 90 Joules/cm2 radiofrequency energy to the vaginal introitus
45756364|NCT01947153|Drug|Metformin|Combination
45756365|NCT01947153|Drug|Linagliptin|Free combination
45804229|NCT03228017|Drug|Aspirin and/or Atorvastatin|This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.
45804230|NCT02978300|Device|NIV/HFNC|Pressure support level to achieve an expired tidal volume between 6 and 8 ml/kg of predicted body weight Positive end expiratory pressure from 5 to 10 cm H2O, aiming a PEEP level ≥ 8 cm H2O FiO2 set to achieve SpO2 ≥ 92%
45804231|NCT02978300|Device|HFNC|Gas flow of 60 l/min and FiO2 set to achieve SpO2 ≥ 92%
45804232|NCT03706833|Device|Edwards PASCAL System|Transcatheter mitral valve repair with the Edwards PASCAL System
45603328|NCT02261974|Device|Sham Treatment Viveve|Subject will receive ≤ one (1) Joule of radiofrequency energy to the vaginal introitus
45603329|NCT02356588|Drug|Sufentanil Tablet 30 mcg|
45603330|NCT02356588|Drug|Placebo Tablet|
45603331|NCT04445389|Drug|GX-19|DNA vaccine expressing SARS-CoV-2 S-protein antigen
45603332|NCT04445389|Drug|Saline|Saline
45603333|NCT03482947|Drug|ultrasonography-guided TAP block|(1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine).
45603334|NCT03482947|Drug|Caudal epidural block|(1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine)
45603335|NCT02323789|Drug|Mesenchymal stromal cells|TC-MSC: a cell product containing mesenchymal stromal cells. Mesenchymal stromal cells are adherent non-haematopoietic multipotent cells that are expanded from bone marrow from healthy donors, using platelet lysate as source of growth factor.
45603336|NCT03482869|Diagnostic Test|walking ability|Included patients will perform a 6 min walk test
45603337|NCT03486535|Drug|Infraclavicular Brachial Plexus Blocks|All patients will receive Infraclavicular Brachial Plexus Blocks with the mixture of lidocaine and bupivacaine. This is an observational study, because all patients will receive the same blocks with the same doses of the local anesthetics. The only difference between groups is including patients with or without Diabetes Mellitus diagnosis. The intervention is the same and these patients cannot be randomized. The aim is investigating the effect of this local anesthetic mixture in Diabetic patients.
45603338|NCT03486535|Drug|Infraclavicular Brachial Plexus Blocks|All patients will receive Infraclavicular Brachial Plexus Blocks with the mixture of lidocaine and bupivacaine. This is an observational study, because all patients will receive the same blocks with the same doses of the local anesthetics. The only difference between groups is including patients with or without Diabetes Mellitus diagnosis. The intervention is the same and these patients cannot be randomized. The aim is investigating the effect of this local anesthetic mixture in Nondiabetic patients.
45603339|NCT02324023|Device|Endoscopic ultrasound|All patients will be evaluated by EUS and CE-EUS, using radial EUS instruments. The EUS scope will be inserted under direct vision, passed by the tumour and examination should begin during withdrawal at 7.5 MHz. The tumour will be characterized describing its echogenicity, echo structure, size, extent into the bowel wall and surrounding structures, and it will be staged using the modification of the TNM classification, based on a five-layer intestinal wall model. The presence/absence of power Doppler signals will be noted. For CE-EUS parameters for objective measurement of tumour perfusion will include maximum intensity of enhancement, mean transit time, time to peak (wash-in time), wash-in slope, area under the curve, representing indirectly blood flow or blood volume in CRC patients.
45603340|NCT02355028|Drug|LHA510 ophthalmic suspension|
45603341|NCT02355028|Drug|LHA510 vehicle|Inactive ingredients used as a placebo comparator
45603342|NCT02355028|Drug|Ranibizumab ophthalmic solution|For intravitreal (IVT) injection
45603343|NCT01595503|Procedure|rTMS with fMRI-based targeting|Inhibitory (low frequency) 1-Hz rTMS will be applied to the secondary auditory cortex during 10 daily 20-minute treatment sessions. An fMRI scan combined with a language task will be used to localize the secondary auditory cortex, followed by neuronavigation to identify the scalp location overlying the targeted cortex.
45756366|NCT05094557|Behavioral|Experimental Group 1: Body swapping VR intervention + psychoeducational video + Treatment As usual|The patient will be embodied in his/her own avatar and will maintain a conversation with a counsellor's avatar of his/her choice. Once the experiment starts, the patient, embodied in his/her own body, will start describing his/her problem in terms of subjective experiences of being obese in daily life. Then, he/she will be body swapped to the counsellor's body and try to respond to the problem just manifested by the patient. The crucial aspect here is that the patient, from the counsellor's viewpoint, will see a representation of his/her real body when looking at the patient's avatar speaking and moving. Therefore, the patient will have the opportunity to see himself/herself in first person (1PP) and second person (2PP) perspectives.
45603344|NCT01595503|Procedure|rTMS with landmark-based targeting|Inhibitory (low frequency) 1-Hz rTMS will be applied over the left temporoparietal cortex (TPC) during 10 daily 20-minute treatment sessions, with the stimulating coil located midway between the left temporal (T3) and parietal (P3) scalp landmarks, using the International 10-20 system for EEG.
45603345|NCT05647330|Drug|Hydroxychloroquine Combined With Gemcitabine|Hydroxychloroquine combined with chemotherapy
45603346|NCT01138189|Procedure|Wavefront-guided LASIK|Wavefront-guided LASIK in one eye using the Allegretto excimer laser
45603347|NCT01138189|Procedure|Wavefront-optimized LASIK|Wavefront-optimized LASIK in one eye using the Allegretto excimer laser
45603348|NCT04460755|Other|Control group|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
45603349|NCT04460755|Other|Whitening toothpaste 1|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
45804233|NCT03706833|Device|Abbott Mitraclip System|Transcatheter mitral valve repair with the Abbott Mitraclip System
45804234|NCT00355927|Procedure|Sedation with IV propofol|Propofol(50 microgram/kg/min.), I.V. for 5-10 minutes, Until a level of light sedation is achieved
45804235|NCT00357422|Procedure|Operation|No drug needed
45911093|NCT02003482|Device|CT for Radiation Treatment Planning|Treatment planning CT scans will be required to define tumor, clinical, and planning target volumes. This study requires CT scans prior to initiation of treatment then again on the third and sixth week of radiation treatment
45911094|NCT02003495|Biological|MCV-ACYW135 Vaccine Group|0.5ml, intramuscular
45603350|NCT04460755|Other|Whitening toothpaste 2|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
45603351|NCT04460755|Other|Whitening toothpaste 3|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
45603352|NCT04460755|Other|Whitening toothpaste 4|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
45603353|NCT04460755|Other|Whitening toothpaste 5|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
45603354|NCT02524093|Behavioral|Positive Mental Training|Positive Mental Training consists of twelve eighteen minute audio tracks. Each is listened to in turn every day, once a day for a week (or at least 5 days in a week). This means that to use the treatment properly you need to spend 18 minutes a day for 12 weeks listening to it. Each track guides the listener through different instructions which aim to build skills and bring about positive change. The programme begins with simple relaxation, going on to support the creation of pictures in your head of safe places and a more positive future.
45911095|NCT02003495|Biological|MPV-ACYW135 Vaccine Group|0.5ml, intramuscular
45603355|NCT02524093|Other|treatment as usual|
45603356|NCT01643668|Drug|Busulfan|Busulfan as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
45603357|NCT01643668|Drug|Clofarabine|Clofarabine as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
45603358|NCT01643668|Procedure|Allogeneic Stem Cell Infusion|Allogeneic stem cell transplantation after reduced intensity conditioning with busulfan / clofarabine chemotherapy
45603359|NCT03131323|Procedure|• Flexible fiberopticnasopharyngoscope|".~II- Equipments:~Flexible fiberopticnasopharyngoscope, 2.7 mm in diameter and fiberoptic light cable.~The camera: fitted with Three-CCD (Charged Couple Device) sensors.~A high resolution monitor.~A recording unit. III- Positioning:Infants and small children have to be held by a parent or an adult. Older children and adolescents usually tolerate office flexible nasopharyngoscopy once the procedure is explained. If office flexible nasopharyngoscopy failed because the child is not cooperative or if there is excessive secretions, general anesthesia may be required [8].~IV- Technique: Lubricant gel will be applied to the tip of the endoscope which will be now will be passed along the floor of the nose, between the inferior turbinate and the nasal septum, till it reaches the nasopharynx. Now the entire nose and the nasopharynx could be thoroughly examined and any abnormal findings could be detected and documented."
45603360|NCT05388331|Other|No intervention|No intervention
45603361|NCT03495193|Other|Exercise training|Exercise training will be performed 3x/week. After 2 sessions, training volume and intensity will progress over the first 4 sessions ramping up the number of sets to increase the volume. The full volume prescription will consist of: 1) 5 movements to improve strength and muscle mass (leg press, knee extension, chest press, overhead press, pull down), 3 sets each of 8-12 repetitions (~30 total repetitions); 2) trunk exercises to improve postural stability (trunk extension and flexion); 3) 3-4 bodyweight exercises (selected from a menu) to improve power and balance (e.g. step up, squat, jump squat, lunge, side lunge, push-up, assisted pull-up, assisted dip). Bodyweight movements will be modified as necessary to match abilities.
45804236|NCT00357422|Procedure|Percutaneous ethanol injection therapy|99% ethanol, 2-4cc per one session, two to three sessions per single procedure for one week
45444628|NCT02048566|Device|ImaCor SM|The ImaCor ClariTEE (hTEE) device is a transesophageal echocardiography system. It produces a single-plane two-dimensional image. The ImaCor probe is a 5.5 mm detachable probe; it can remain in situ for up to 72h and allows for reassessment of the patient's hemodynamic progress and the effect of selected interventions at any time. The probe is connected to a dedicated echocardiographic system which allows the for the recording of digital loops and performance of basic two-dimensional measurements. ImaCorSM subjects will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, follow-up assessment intervals are at the discretion of the treating physician for the first 72h after study inclusion. hTEE monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
45911096|NCT02003495|Biological|MPV-A Vaccine Group|0.5ml, intramuscular
45911097|NCT02003495|Biological|MCV-AC Vaccine Group|0.5ml, intramuscular
45911098|NCT02003495|Biological|Hib Vaccine Group|0.5ml, intramuscular
45603362|NCT03495193|Behavioral|Sleep hygiene|Subjects randomized to the no-exercise group will receive a handout with tips for improving sleep. Additionally, study staff will provide the title page for a book on sleep relaxation techniques that is recommended for persons with sleeping difficulty. Dr. Amara will review the sleep tips with the subjects and make recommendations for improving current sleep habits. Subjects will be contacted by telephone every 4 weeks during the 16-week intervention period.
45603363|NCT02260882|Biological|PNEUMOVAX™ 23|PNEUMOVAX™ 23 (23-Valent Pneumococcal Polysaccharide Vaccination, V110, PPV23)
45603364|NCT00112411|Drug|Bronchodilator|
45603365|NCT00035503|Drug|etiprednol dicloacetate|
45603366|NCT03482401|Dietary Supplement|Polyphenol|Patients consume 3 capsules/day (474 mg phenolics/day) from the biopsy-confirmed breast cancer diagnosis to the surgery
45603367|NCT04312789|Drug|Avatrombopag|Given PO
45756367|NCT05094557|Behavioral|Experimental Group 2: VR intervention without body swapping + psychoeducational video + Treatment As usual|"Participants from the Experimental Group 2 will be embodied in their own body and will participate in pre-established discourse provided by the chosen counsellor, who will ask about the perceived barriers for engagement with a healthier lifestyle and will give practical recommendations about how to achieve a healthier and happier life, in terms of healthy eating and physical activity. No body swapping will take place for this group. Participants will also continue receiving Treatment As usual plus a Psychoeducational video with useful information about how to engage with a healthier lifestyle."
45756368|NCT05094557|Behavioral|Control Group: Psychoeducational video + Treatment As usual|Participants from the Control Group will receive their Treatment As Usual plus a Psychoeducational video. Treatment as usual will consist of regular medical, nutritional and/or psychiatric follow-ups with the obesity specialists of the Vall d´ Hebron University Hospital and standard routine tests. These visits aim to provide practical recommendations about how to achieve a gradual weight loss and engage more with physical exercise.
45603368|NCT05152225|Diagnostic Test|Brain MRI|Brain MRI performed routinely in patients with EI
45603369|NCT05152225|Diagnostic Test|digital subtraction angiography (DSA)|Digital Subtraction Angiography (DSA) performed routinely in patients with EI
45603370|NCT02260804|Biological|CT-P10|375mg/m2, IV on day1 of 4 cycles in induction period, and 12 cycles in maintenance period.
45603371|NCT02260804|Biological|Rituxan|375mg/m2, IV on day1 of 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
45603372|NCT02324101|Device|Hsp90|Detect plasma Hsp90α concentration
45603373|NCT03482323|Behavioral|Exercise|Our exercise class intervention is based on current best evidence and will be tailored for each participant's ability for exercise. The exercise classes is also designed to fit into the guidelines for exercise in adults aged 18 years and above with a long term health condition. During the 12 weeks in the training, exercises will be varied (mixing up time spent on bikes and walking) along with the intensities of exercise varied to keep the classes more engaging for participants and maintaining compliance to the programme.
45603374|NCT03482323|Behavioral|Tai-Chi|Our tai-chi classes will be based on a 24-form Yang style of tai-chi exercise set.
45603375|NCT03495037|Behavioral|Real World Strategy Training|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
45603376|NCT03495037|Behavioral|Psychosocial Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.
45603377|NCT03486457|Drug|Tofacitinib|tablets, 5 mg BID x 6 months
45603378|NCT03486457|Other|Placebo|tablets, to match tofacitinib 5 mg BID x 3 months
45603379|NCT03486457|Drug|Tofacitinib|tablets, 5 mg BID x 3 months
45603380|NCT04460599|Other|Observation|Observation of recorded neurological signs
45603381|NCT04460365|Dietary Supplement|10 mg Lutein, 2 mg zeaxanthin, 10 mg meso-zeaxanthin|"This is a lutein (10mg), zeaxanthin (2mg) and meso-zeaxanthin (10mg) one-a-day food supplement which combines all three macular carotenoids.~These three nutrients are found at the back of the eye, at the macula, where they form the macular pigment (yellow colour). Meso-zeaxanthin is particularly concentrated at the centre of this pigment.~Lutein and zeaxanthin can be found in fruits and dark green leafy vegetables and meso-zeaxanthin is present in some species of fish and seafood."
45603382|NCT04460365|Other|Placebo|Softgel capsule containing sunflower oil (no active ingredients)
45603383|NCT02260648|Drug|Evacetrapib|Administered orally
45603384|NCT02260648|Drug|Ezetimibe|Administered orally
45603385|NCT02260648|Drug|Atorvastatin|Administered orally
45603386|NCT02260648|Drug|Placebo|Administered orally
45603387|NCT05151913|Other|Exploratory|Fecal microbiome
45603388|NCT04179019|Drug|Amlodipine|Amlodipine (10mg daily, as tolerated by blood pressure parameters) for 2 weeks
45603389|NCT04157101|Behavioral|Health Coaching|The 12-session remote health coaching intervention assists Veterans in developing and maintaining health behaviors that meet their life goals. Veterans begin by discussing their symptoms, the impact of their symptoms, and their beliefs about Pain-CMI. Next, the Veteran identifies discrepancies between where they are and where they want to be for 5 lifestyle factors. The first half of treatment focuses on providing education about the 5 lifestyle factors. Veterans are introduced to behavior change/health coaching principles. The major focus is on behavior change and development of long-term healthy habits. During the last session, Veterans develop a long-term plan to maintain behavioral changes after the 12-week program and identify the skills that they can utilize moving forward.
45756369|NCT02987595|Other|Whole-grain rye, high lignan|Intervention week 1-8: 50 g rolled rye + 50 g puffs + 4 pieces of crisp bread + 70 g pasta. Additionally for intervention week 4-8: 4 lignan capsules per day
45756370|NCT02987595|Other|Whole-grain wheat, low lignan|Intervention week 1-8: 100 g puffs + 4 pieces of crisp bread + 70 g pasta.
45756371|NCT02993965|Other|Vaccine Reminder/Recall|The investigators will be sending recall notices via phone call or postcard to 11-17 year olds or 11-14 year olds who are eligible but lacking HPV vaccine doses recorded in the Colorado Immunization Information System (CIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention) for bringing children 11-17 years old up to date on HPV vaccination. They will also be testing the effectiveness and cost effectiveness of using mail vs. phone call reminder notices (as compared to no intervention) for bringing 11-14 year olds up to date on HPV vaccination.
45756372|NCT02476409|Drug|tolvaptan|Study will test the addition of tolvaptan to augmentation of loop diuretic as standard of care for outpatients presenting with worsening heart failure.
45756373|NCT02476409|Other|Placebo|Placebo for tolvaptan
45603390|NCT04157101|Behavioral|Supportive Psychotherapy|"Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was . ) in order to help identify experiences for discussion in session. The control consists of 12 weekly sessions delivered via telephone or video and will be delivered by bachelor's, or master's level providers."
45911099|NCT02003521|Device|Lung Flute|A low frequency wave is generated at the mouth by exhaling through a mouthpiece over a laminar surface (Reed) inside the Lung Flute®. The resulting low frequency acoustic wave that is produced travels retrograde into the lower airways and lung parenchyma and increases mucociliary clearance. Patients expel air with the force required to blow out a single candle. Patients concentrate on producing a low tone through the device while breathing in a proscribed pattern. Twenty repetitions of a single two-breath pattern are performed with the device to complete a diagnostic session.
45603391|NCT02260492|Drug|OT329 (combination of fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Solis dry powder inhaler
45756374|NCT02993887|Behavioral|Resourcefulness Training|This intervention will include a one time face to face instruction on Resourcefulness Training that entails 8 self-help and help-seeking skills plus viewing short video vignettes of caregivers describing application of the resourcefulness skills. In addition, participants will use daily journaling to describe application of the resourcefulness skills in their daily caregiving with their technology-dependent child.
45603392|NCT02260492|Drug|Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Diskus dry powder inhaler
45603393|NCT02260492|Drug|Placebo|Placebo (lactose) administered via the Solis dry powder inhaler
45603394|NCT04135417|Biological|HAV|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
45603395|NCT03966625|Diagnostic Test|tissue transglutaminase autoantibodies|celiac disease-specific autoantibodies
45444629|NCT02048566|Other|Control PM|Group Control protocolized monitoring (ControlPM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, at the time of occurrence of defined new organ system deterioration or at least every 4 hours for the first 72h after study inclusion. Protocolized monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
45444630|NCT02048566|Other|Control SM|Group Control standard monitoring (ControlSM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, follow-up measurement intervals are at the discretion of the treating physician for the first 72h. Data collection from standard monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
45444631|NCT01304121|Device|Bioactive glass (SP53P4)|Commercial resorbable bone graft substitute (Vioxid Ltd)
45603396|NCT05151757|Other|A standard image training set|The standard image training set will consist of about 50 normal optic nerve images of people without glaucoma and about 50 images of people with glaucoma. Training is done in 3 modules.
45603397|NCT02260258|Drug|Rocuronium|Neuromuscular Blockade
45603398|NCT02260258|Drug|Normal Saline|Normal Saline
45756375|NCT02993887|Behavioral|Mindfulness|The mindfulness intervention will include the use of an app daily via Stop, Think, Breathe.
45911100|NCT02003547|Drug|AMA0076|
45911101|NCT02003547|Drug|Placebo|
45911102|NCT02003560|Radiation|accelerated partial breast irradiation|9 x 4.1 Gy accelerated partial breast irradiation delivered by 3D-CRT or IMRT over 5 consecutive days, using twice-a-day fractionation.
45911103|NCT02003586|Dietary Supplement|plant-based ingredient|
45911104|NCT02003586|Dietary Supplement|No plant-based ingredient|
45444632|NCT02050672|Dietary Supplement|Myo-inositol|
45444633|NCT02050672|Other|untreated|
45444634|NCT01302639|Dietary Supplement|Comparison of different combinations of polyphenols with respect to effects on fat oxidation|EGCG, resveratol and genistein
45444635|NCT03811366|Drug|Meticorten|All patients were treated with 3-day methylprednisolone pulse therapy followed by 1mg/day oral prednisone with slow tapper over a median 13 months
45444636|NCT03561922|Device|RETINA IMPLANT Alpha AMS|Implantation of the subretinal RETINA IMPLANT Alpha AMS
45444637|NCT03274466|Device|Closed Incision Negative Pressure Therapy (ciNPT)|Closed Incision Negative Pressure Therapy applied through a foam bolster with a wicking interface fabric that includes 0.019% ionic silver at 125 mmHg of negative pressure for 5-7 days.
45444638|NCT03274466|Device|Standard of Care Dressing|A standard silver-impregnated dressing applied to a closed surgical incision for 5-7 days post-operatively.
45444639|NCT03811431|Procedure|Contrast enhanced ultrasound guided liver biopsy|Conventional liver biopsy
45603399|NCT05151679|Drug|Chelated Iron|"Treatment will be started 24rh after initial visit women will be randomized used random sequence computer generated list in such a way that every patient had equal chance to be among any of the two groups either to group 1 , where they will receive I.V ferrous sucrose in the E.U in Women's Health Hospital Assuit University as an i.v infusion in 250 ml 0.9% sodium chloride slowly over 30 minutes.~The total required dose of iron will be divided into three doses, which will be given every 3 days, and the maximum daily dose is 200mg ( 2 ampoules )."
45603400|NCT05151679|Drug|Iron sucrose|to group 2 where they will receive chelated oral iron, they will be given iron chelated amino acid containing 15 mg of elemental iron once daily for 6 weeks. the women will be advised to take 1 tab of iron chelated amino acid containing 15mg of elemental iron once daily with meals for 6 weeks from the day of recruitment.
45603401|NCT02324257|Drug|RO6958688|RO6958688 is given as an intravenous (IV) infusion as a single administration in Part I, and QW, Q3W, or as a combined QW/Q3W step up dosing regimen (cycle = 7 days in the QW regimen and cycle = 21 days in the Q3W regimen) in Part II of the study.
45603402|NCT02324257|Drug|Obinutuzumab|Obinutuzumab is given as an IV infusion at a dose level of 2000 mg on Day -13 or 1000 mg on Days -13 and -12 prior to the treatment start with RO6958688 on Cycle 1 Day 1.
45603403|NCT02324257|Drug|Tocilizumab|Tocilizumab will be administered as an IV infusion as necessary to treat adverse events.
45603404|NCT05151289|Biological|Blood test at time of inclusion for sFlt-1/PlGF ratio|As part of the research, a blood sample is taken to measure the sFLT-1 and PlGF ratio at the inclusion visit.
45603405|NCT05151289|Biological|Follow-up blood test 2 to 4 weeks after inclusion|As part of the research, a blood sample is taken to measure the sFLT-1 and PlGF ratio at the follow-up visit (about 2-4 weeks after inclusion). This second sample is not mandatory for the evaluation of the study's main endpoint.
45756376|NCT02999737|Biological|Platelet Rich Plasma for 4 sessions|Injection of autologous platelet rich plasma into areas of alopecia on the scalp every month x 3 sessions then every 3 months x 1 session (total 4 sessions)
45603406|NCT05151289|Diagnostic Test|Placenta analysis for all included patients, even in case of normal birthweight|"After delivery, the placenta of each included patient is sent to anatomo-pathology (even in case of normal weight of the baby at birth). An anatomopathologist referent, designated for the study in each center, performs an analysis (aware of the clinic but not of the sFLT-1/PlGF ratio results), according to the benchmark criteria grid. Local analysis will classify the placenta as vascular IUGR or nonvascular IUGR."
45603407|NCT03486145|Dietary Supplement|fruit and vegetable juice supplement|"FVS was provided by Isagenix International LLC in identically sealed bottles labeled labeled B. Subjects were not told which supplement they received. Each bottle contained one serving (two ounces) of the supplement."
45603408|NCT03486145|Dietary Supplement|Placebo|"PRU was provided by Isagenix International LLC in identically sealed bottles labeled labeled A. Subjects were not told which supplement they received. Each bottle contained one serving (two ounces) of the supplement."
45603409|NCT05151055|Dietary Supplement|Lactezin|100 mg lactoferrin, 11 IU vitamin E (as alpha tocopherol), and 5 mg zinc (as zinc gluconate)
45603410|NCT05151055|Dietary Supplement|Placebo|starch
45603411|NCT03911089|Other|UCD Anamix Infant|UCD Anamix infant with DHA and ARA is an amino acid based infant medical food containing only the essential amino acids, carbohydrate, fat, vitamins, minerals and trace elements.
45603412|NCT02260180|Drug|A-101|Topical Solution
45756377|NCT02999737|Biological|Platelet rich plasma for 2 sessions|Injection of autologous platelet rich plasma into areas of alopecia on the scalp every 3 months x 2 sessions (total 2 sessions)
45756378|NCT01884519|Biological|Fluarix/Influsplit SSW® (2013-2014 season)|1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
45756379|NCT02468687|Drug|N-methyl-pyrrolidone|NMP will be taken each morning as a single daily dose of oral suspension at a concentration of 50mg/ml on an empty stomach at least 30 minutes prior to food.
45756380|NCT02993653|Radiation|High-dose Intensity-modulated radiotherapy|Pelvic High-dose Intensity-modulated radiotherapy with stereotactic radiotherapy or intracavitary radiotherapy
45756381|NCT05022485|Device|ZNN Bactiguard tibia|Tibia fracture fixation
45756382|NCT01808937|Other|Morphea|
45444640|NCT02806726|Device|iDesign 1.3-PRESBY treatment|Software used to calculate the LASIK treatment profile including a presbyopic correction component for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
45756383|NCT01269853|Drug|Bevacizumab|"Experimental portion of this proposal:~This trial will have two experimental arms that will be open labeled and non-randomized.~ARM 1 (If the patient has multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until progression on MRI scan.~Repeat Cycle"
45756384|NCT01269853|Drug|Bevacizumab|"ARM 2 (If the patient has no multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: No biweekly IV Bevacizumab treatment~If MRI shows progression then repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression Repeat Cycle"
45804237|NCT05647538|Procedure|Bilateral uterine artery ligation|Bilateral UAL was done 2 cm under the Kerr incision (lower segment transverse). A 2-Vicryl absorbable suture (Ethicon, Neuilly-surSeine, France) was introduced from the anterior to posterior views of the myometrium 2-3 cm medial to the descending part of the uterine vessels within an avascular area in the broad ligament and tied. Following the surgery, the uterine tone and hemorrhage were managed.
45444641|NCT02806726|Device|iDesign 1.3 treatment|Software used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
45444642|NCT02037802|Device|B-Braun, Perifix® ONE Paed, Germany|caudal epidural catheterization bupivacaine fentanyl
45444643|NCT02037802|Drug|Pethidine|pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
45444644|NCT02037802|Drug|Propofol|fentanyl propofol atracurium besylate
45444645|NCT02037802|Drug|Bupivacaine|
45444646|NCT02037802|Drug|Fentanyl|
45756385|NCT02429063|Other|Bright White Light|The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The BWL Litebook® looks identical to the DRL and utilizes 24 white light-emitting diode (LED) lights and does not emit ultraviolet light.
45756386|NCT02429063|Other|Dim Red Light|The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The DRL Litebook looks identical to the BWL box and contains red lights rather than white LED lights.
45756387|NCT02993809|Biological|BM-ECs and PRPE|
45756388|NCT02993809|Biological|BM-ECs|
45603413|NCT03799393|Behavioral|CIAS (Computer Intervention Authoring Software)|This is a digital application that allows families to interact with a tablet computer to receive educational information customized to the patient's age and size. allows authors to develop screening, assessment, and intervention tools for patients without requiring new programming. The CIAS intervention is programmed using tailored branching logic to allow a custom path through the intervention based on the respondent's answers. Delivery of the intervention uses a two-dimensional avatar narrator character that mimics the conversational structure of person-delivered brief interventions.
45603414|NCT03799393|Behavioral|Standard Printed Discharge Instructions|Patients/families will receive standard, printed discharge instructions. This is a 5 page general document from our Injury Prevention Center that describes appropriate car restraint safety for all age groups, not specific to the child enrolled.
45603415|NCT03796819|Procedure|lymphadenectomy|Patients would undergo routine hepatoduodenal lymphadenectomy at the time of ICC resection
45603416|NCT02353468|Drug|Bortezomib|Given IV
45603417|NCT02353468|Drug|Lenalidomide|Given PO
45603418|NCT02353468|Drug|Dexamethasone|Given PO or IV
45603419|NCT02523859|Drug|Propofol|Hypnotic drug used for anesthesia
45603420|NCT02523859|Drug|Remimazolam|Benzodiazepine being developed for sedation and anesthesia.
45603421|NCT04865146|Device|TRIGEN™ INTERTAN™|Femoral fracture treated with INTERTAN 10S Nail
45603422|NCT04459741|Dietary Supplement|Dietary salt (Sodium chloride)|Dietary salt used was sodium chloride tablets (from the research consolidated midland corporation division, New York, USA) which participants crashed and put in their food and/or ingested. Each tablet weighed one (1) gram and contained 394 mg of sodium and 606 mg of chloride.
45603423|NCT04459663|Drug|Toripalimab injection combine with Axitinib|The patients in the group will be infused intravenously with fixed dose of 240mg JS001 on the first day of each cycle. Oral Axitinib 5mg bid (recommended interval of about 12 hours) was given daily from the second day of the initial cycle
45603424|NCT02349412|Other|Early palliative care|
45603425|NCT04459975|Other|Non interventional study|"Comorbidities, creatinine levels, urinary analysis, hemodynamic, respiratory status, co-medication will be collected from medical files for each patient.~Specific datas from patients with AKI will be collected from medical files For severe acute patients, serum and urinary analysis will performed to identify the underlying cause of kidney injury For severe AKI patients who will die, post-mortem renal biopsy will be performed, for histopathological analysis"
45603426|NCT04460053|Procedure|Neurofilament light protein measurement in Isolated limb perfused patients|A prospective feasibility trial measuring neurofilament light protein in peripheral blood as a biomarker for neurotoxicity after isolated limb perfusion.
45603427|NCT02259400|Device|NSIPPV|In N-SIPPV, the physician will set : an initial PEEP of 4-6 cmH20; a peak inspiratory pressure (PIP) of 15-20 cmH2O ; an inspiratory time (IT) of 0.3-0.4 seconds; a flow rate of 6-10 L/min and a respiratory rate (RR) of 40 bpm with the lowest FiO2 to maintain a oxygen saturation (SpO2) of 88-93%. Weaning from N-SIPPV will be performed with a reduction of the RR to 15 bpm with a PIP of 10-15 cmH2O and PEEP of 4 cmH2O and will be stopped when the baby will not show signs of RDS and with a fraction of inspired oxygen (FiO2)< 0.3.
45603428|NCT02259400|Device|BiPAP|In BiPAP, the physician will set : an initial low CPAP-level of 4-6 cmH20 and high CPAP-level of 8-9 cmH20; a time high of 1 second and a pressure exchange rate of 20 bpm, with the lowest FiO2 to maintain a SpO2 of 88-93%. Weaning will start with a progressive reduction of the set pressure exchange rate ( minimum 15 pressures exchange/min), followed by the reduction of the higher level-CPAP down to 6 cmH20 and lower level-CPAP down to 4 cmH20. BiPAP will be stopped when the baby will not show signs of RDS and with a FiO2 < 0.3.
45756389|NCT01886235|Procedure|Diagnostic Microscopy|Undergo intravital microscopy
45756390|NCT01886235|Drug|Fluorescein Sodium Injection|Given IV
45756391|NCT01886235|Other|Laboratory Biomarker Analysis|Correlative studies
45756392|NCT01886235|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45756393|NCT02206841|Procedure|Liver biopsy|Percutaneously liver biopsy will be performed for evaluate steatosis and fibrosis.
45756394|NCT02206841|Device|ARFI|Acoustic radiation force impulse (ARFI) imaging will be performed for evaluate fibrosis of liver.
45756395|NCT02206841|Device|SWE|Supersonic shear wave elastography (SWE) will be performed for evaluate fibrosis of liver.
45756396|NCT02206841|Device|Transient elastography|Transient elastography will be performed for evaluate fibrosis of liver.
45444647|NCT01302717|Device|LV pacing|The left ventricular lead are positioned preferentially at the posterolateral or lateral venous branches of the coronary sinus.
45444648|NCT01302717|Device|RV pacing|The right ventricular lead are positioned at the right ventricular apex.
45756397|NCT02993575|Drug|Flucloxacillin|Dose according to summary of product characteristics (SPC) or local protocols: intermittent and continuous infusion
45756398|NCT02999581|Dietary Supplement|C4 Extreme, C4 Extreme (without Advantra Z)|
45756399|NCT02993497|Device|Infrared camera|In patients undergoing spinal anesthesia, the respiratory parameters are measured using an Infrared camera.
45756400|NCT02993497|Device|RVM(Respiratory Volume Monitor)|In patients undergoing spinal anesthesia, the respiratory parameters are measured using an RVM(Respiratory Volume Monitor).
45756401|NCT05010941|Device|Hypotension Prediction Index|Hypotension Prediction Index monitored via radial arterial line
45444649|NCT02051530|Dietary Supplement|tryptophan depletion|tryptophan depletion involves the ingestion of an amino acid mixture that is devoid of tryptophan. on the other day participants receive placebo, being the same mixture but including tryptophan
45603429|NCT03481855|Device|Lower-body-low-pressure chamber|The lower-body-low-pressure chamber administers a negative pressure to the lower part of the body (below the waist) to induce a central hypovolaemia by pooling of blood in the legs according to Tymko, M. FACETS, Bd. 1, Nr. 1, S. 225-244, März 2017 and Esch, B.T.A. et al. AJP Adv. Physiol. Educ., Bd. 31, Nr. 1, S. 76-81, März 2007.
45911105|NCT02003599|Device|Laser therapy|The low level laser therapy used in this trial will be Photon Lase III (DMC, approved by ANVISA for medicinal purposes). This InGaAIP laser emits a pulsed 660 nanometer beam with an average output of 80 milliwatts and the average energy density delivered to the breast will be 3 J/cm2.
45603430|NCT03481699|Behavioral|Incremental theory of personality|"The experimental intervention (originally developed by David S. Yeager and colleagues) teaches that individuals have the potential to change. It has three main parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled by thoughts and feelings in brains, and that pathways in the brain have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by upperclassmen to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative. This self-persuasive writing exercise has been shown to facilitate the internalization of the intervention message, building on a long line of research on cognitive dissonance."
45756402|NCT02993419|Drug|Bacillus licheniformis Intervention|On the basis of the use of antibiotics in children with symptomatic treatment, the addition of experimental drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
45756403|NCT02993419|Other|placebo Intervention|On the basis of the use of antibiotics in children with symptomatic treatment, the addition of placebo drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
45756404|NCT01798433|Device|One stent technique alone|One stent technique alone with drug-eluting stent
45756405|NCT01798433|Device|One stent technique + Elective FKB|One stent technique + Elective FKB with drug-eluting stents + balloon
45756406|NCT01798433|Procedure|Provisional approach|Provisional approach with drung-eluting stents
45444650|NCT03797703|Drug|Lidocaine Hydrochloride 2% gel enema|Insertion of Lidocaine Hydrochloride 2% gel enema rectally immediately following the procedure.
45444651|NCT02048644|Drug|fostair|beclometasone dipropionate 200mcg and formoterol 12 mcg delivered by inhaler, twice a day for 28 days
45444652|NCT02048644|Drug|placebo|placebo matched inhaler 2puffs to be taken twice a day for 28 days
45756407|NCT01798433|Device|Elective 2-stent|Elective 2-stent with drug-eluting stents
45756408|NCT00602953|Other|No intervention planned.|This is a cross-sectional observational study, no intervention is planned.
45756409|NCT01998191|Other|Explicit case note review checklist (nurse)|"A checklist to be used to screen notes for features of avoidable death used by nurses.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
45756410|NCT01998191|Other|Explicit case note review checklist (physician)|"A checklist to be used to screen notes for features of avoidable death, used by a nurse.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
45444653|NCT03797781|Other|Lower limb immobilisation (leg brace) with varying levels of protein intake|Single leg immobilisation via leg brace and crutches, the groups have different amounts of protein intake
45444654|NCT03562078|Behavioral|Tai Chi Quan|the first section of Yang style 108 form, including 10-minute warm-up, 40-minute training, and 10-minute cool-down exercise, twice a week
45444655|NCT01302795|Drug|Canakinumab|Monoclonal antibody inhibiting interleukin 1 beta
45444656|NCT02048800|Drug|Treosulfan|Treosulfan will be administered over 3 days prior to HSCT at the following dose: 10 g/m2 (children aged < 3months) or 12 g/m2 (children aged 3/12 months) or 14 g/m2 (children aged > 12 months)
45756411|NCT01998191|Other|Explicit case note review checklist (MDT)|"A checklist to be used to screen notes for features of avoidable death used by a nurse and an expert physician.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
45804238|NCT03358355|Drug|unacelyated ghrelin|We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.
45444657|NCT03811353|Diagnostic Test|T-MOE|Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale.
45444658|NCT02048956|Other|Hydrotherapy intervention|Participants randomized to the exercise programme received a training in a swimming pool focused on dance therapy.
45911106|NCT02003599|Device|Placebo|In the control group, 26 patients will be submitted to a laser, but the laser will be disabled without affecting its apparent function , five days a week before radiotherapy .
45911107|NCT02003651|Dietary Supplement|Quick Defense|Echinacea product from Gaia Herbs.
45603431|NCT03481699|Other|Educational Intervention|The educational intervention involved scientific information about the human brain. It was designed to be parallel to the experimental intervention and, hence, it has also three main parts. First, participants are asked to read scientific information about the different areas of the brain and their specialties. Second, participants read several testimonials written by upperclassmen about their transition to high school and how their brains help them to adapt to the new space and all the physical differences of the building and the classes. Finally, participants are asked to write a letter to another student explaining the main things he or she has learned about the brain and thinks are important for adapting to the new physical environment in high school.
45756412|NCT02329587|Other|ERP plus tDCS|Participants in the ERP plus tDCS arm will receive an 11-session program, including 10 sessions which include both tDCS and ERP. During these sessions, 20 minutes of anodal tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
45603432|NCT05150899|Drug|Tamsulosin Hcl 0.4Mg Cap|alpha blocker
45756413|NCT02329587|Other|ERP plus sham tDCS|Participants in the ERP plus sham tDCS arm will receive an 11-session program, including 10 sessions which include both sham tDCS and ERP. During these sessions, 20 minutes of sham tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
45756414|NCT02999503|Behavioral|Nutritional education|Nutritional education trough a personal online nutritional consultant
45603433|NCT05150899|Drug|fexofenadine 180 mg Oral tablet|antihistaminic
45603434|NCT01530997|Radiation|Intensity Modulated Radiotherapy (IMRT)|All patients will receive IMRT. Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day, respectively. The PTV-HR will include the gross tumor and the PTV-SR will include the lymph nodes at risk for harboring micro-metastatic disease (i.e. subclinical disease).
45603435|NCT01530997|Drug|Cisplatin|Cisplatin, 30mg/m2, will be given intravenously over 60 minutes weekly during IMRT; 6 total doses for a total of 180 mg/m2. It is preferred that the doses be administered on days 1, 8, 15, 22, and 29, and 36 of IMRT; however, this is not mandatory.
45603436|NCT01530997|Procedure|Limited surgical evaluation|4 to 14 weeks after completion of CRT, patients will have at least a biopsy of the primary tumor and limited neck surgery to remove those lymph nodes that were involved with cancer prior to CRT.
45603437|NCT00593905|Drug|Sitaxsentan|Sitaxsentan sodium 100 mg tablet every morning
45603438|NCT00593905|Drug|Bosentan, Ambrisentan|Bosentan 125 mg tablet twice daily Ambrisentan 5-10 mg tablet once daily
45603439|NCT03477253|Procedure|Laparoscopic cholecystectomy|The use of laparoscopic cholecystectomy in management of acute calculous cholecysitits
45603440|NCT03481621|Device|Acupuncture|Needle size: #32(0.22 mm), 1-1.5 inch(30-40 mm long); Acupuncture time and frequency: 45 min per session, once or twice per week, for 6-12 sessions total (in 6 weeks).
45603441|NCT03481621|Other|Standard care|PT, pain medications, nerve block, etc
45603442|NCT02948647|Other|Standard of care plus sugar-reduction education|This is a 12-week intervention where subjects will be educated on how to monitor their added sugar consumption. They will be asked to eliminate consumption of sweetened beverages for the 12-week period and will be receiving a weekly delivery of water bottles to their homes to displace the sweetened beverages in their home environment.
45756415|NCT00603187|Drug|Acyline|20 mg GIPET enhanced oral dose, daily for 7-days
45603443|NCT03477097|Other|Nutrition, exercise and social network intervention|
45756416|NCT01944761|Behavioral|Exercise Program|"Designed to improve cardio-respiratory fitness, the exercise program will be conducted for 12 weeks at a frequency of 3-4 sessions per week. Each exercise session will be conducted after school for a total duration of 90 minutes (group sessions) or 30 minutes (home-based sessions). Group session activities will include i) warm-up (i.e. walk/jog, games) [10 mins], ii) aerobic training/fitness games [30 mins], iii) organized sports [30 mins], iv) cool down (i.e. stretching, low intensity games) [10 mins] and v) snack and reward (15 mins).~Participants in the Group setting had three 90-minute group sessions per week. Participants in the Combined setting had two 90-minute group sessions and two 30-minute individual home-based sessions per week."
45756417|NCT00603889|Biological|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
45756418|NCT04766879|Device|Transfluthrin|Passive emanator with formulated transfluthrin
45756419|NCT04766879|Device|Placebo|Passive emanator with formulated inert ingredients
45756420|NCT01886937|Drug|Phentermine|After 7 days of phentermine 37.5 mg administration, food intake should be less than after 14 days of placebo.
45756421|NCT01886937|Drug|placebo|Food intake as measured by a laboratory study should be greater after 7 days of placebo administration compared to seven days of phentermine administration.
45756422|NCT00708877|Procedure|Liver Transplantation|Transplantation will initially be performed with deceased donor livers using the technique of caval-sparing hepatectomy unless suspected caudate involvement or caudate atrophy is a concern regarding the resection margin. Patients will be assigned a provisional Model for End-Stage Liver Disease (MELD) score by the United Network for Organ Sharing (UNOS) Regional Review Board that will make a recipient eligible for transplantation within three months at the time of listing (typically 20-24). A segment of donor iliac artery will be used as an interposition graft to the recipient infrarenal aorta. The hilus will be avoided during dissection and the bile duct, hepatic artery, and portal vein will be divided as low as possible. A frozen section of the bile duct margin will be performed and patient will undergo pancreaticoduodenectomy if positive.
45756423|NCT01447667|Procedure|Magnetic resonance elastography|Magnetic resonance elastography before RFA and Liver biopsy of 2 HCC tissue and 2 non tumor liver parenchyma tissue
45756424|NCT02993341|Drug|Tranexamic Acid|
45756425|NCT02993341|Other|Saline Wash|
45756426|NCT01948947|Device|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
45911108|NCT02003651|Dietary Supplement|Placebo|Placebo
45444659|NCT02048956|Other|Control group|Standard exercises of hydrotherapy
45444660|NCT03797625|Drug|Irinotecan|60mg/m2，D1，8
45444661|NCT03797625|Drug|DDP|60mg/m2，D1
45444662|NCT03797625|Drug|Endostar|15mg/d，d1-d7 civ
45444663|NCT02051842|Drug|Metadoxine|
45756427|NCT01948947|Device|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
45603444|NCT02259088|Drug|Ranibizumab (RFB002)|Ranibizumab 0.5 mg/0.05 mL for intravitreal injection
45603445|NCT02259088|Procedure|Laser|Laser photocoagulation according to Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines
45603446|NCT02259088|Drug|Sham injection|Imitation of an intravitreal injection consisting of an empty vial and an injection syringe without a needle
45603447|NCT02259088|Procedure|Sham laser|Imitation of an active laser
45603448|NCT02880241|Drug|MMV390048|Tablets of 20mg each
45603449|NCT02830477|Biological|Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973|unmodified, full length recombinant FVIII
45603450|NCT02259010|Drug|Alisertib|Alisertib tablets
45603451|NCT02259010|Drug|Itraconazole|Itraconazole oral solution
45603452|NCT02329951|Procedure|Facet intervention|Diagnostic block of the nerves innervation the lumbar facet joint. If this block is positive (greater or equal to 50% relief), the participant will proceed to radiofrequency nerve ablation when the pain returns
45603453|NCT02329951|Procedure|Sacroiliac joint injection|Injection of steroid and local anesthetic into SI joint
45603454|NCT02329951|Procedure|Epidural steroid injection|Transforaminal or interlaminar injection of steroid epidurally
45603455|NCT03481387|Device|prosthetic aortic valve (PERCEVAL S valve)|The PERCEVAL S heart valve (PERCEVAL S valve) is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The PERCEVAL S valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.
45756428|NCT01334801|Procedure|Blood Draw|"Two tubes of blood (about five tablespoons) will be drawn for research purposes, and these will be analyzed for the following tests:~BNP (Brain Natriuretic Peptide)~(PFA) Platelet Function Analyzer 100~von Willebrand Factor (vWF) antigen~(vWF) multimers~(vWF) *activity by latex aggregation~Plasma stored for development of new testing approaches"
45756429|NCT04270903|Device|EPR measurement|Subject put in a magnet, magnetic field sweeping around 40 mTesla. Irradiation with a wave with a frequency of 1.1 GHz. A resonator (surface coil) is put at the surface of the skin (arm). The EPR signal is recorded.
45756430|NCT04387799|Diagnostic Test|Serology for Covid-19|Antibody tests designed to provide results to individuals or healthcare providers can show whether someone was previously infected with SARS-CoV-2 being the RT-PCR negative for the population of patients
45756431|NCT01219075|Dietary Supplement|soy isoflavones|Given orally
45756432|NCT01219075|Other|placebo|Given orally
45756433|NCT01219075|Other|questionnaire administration|Ancillary studies
45756434|NCT01219075|Procedure|magnetic resonance imaging|Correlative studies
45444664|NCT02806414|Drug|Ivermectin|
45603456|NCT05647018|Procedure|Primary Percutaneous coronary angiography|Percutaneous coronary intervention (PCI) refers to a family of minimally invasive procedures used to open clogged coronary arteries in patients presenting with myocardial infarction, through which installment of stents or intracoronary injection of drugs can take place.
45603457|NCT05154019|Behavioral|Managing Minds at Work Online Training|"The intervention will be an online, interactive training course which will include evidence-based material, guidance, and practical exercises. The training will cover the following topics, presented as a series of independent, stand-alone modules:~Module one: Looking after your own mental health Module two: Designing and managing work to promote mental well-being Module three: Management Competencies that Prevent Work-related Stress Module four: Developing a Psychologically Safe Workplace Module five: Having conversations about mental health at work Each module will be designed to take between 20 and 30 minutes to complete. Participants will be permitted by their employer to complete the training within their work time. The training is self-led, so each participant can progress through each module at their own pace and at a time that suits them."
45603458|NCT02021773|Drug|LBR-101 High Dose|Subcutaneously Administered LBR-101 Monthly x 3
45603459|NCT02021773|Drug|LBR-101 Low Dose|Subcutaneously Administered LBR-101 Monthly x 3
45603460|NCT02021773|Drug|Placebo|Subcutaneously Administered Placebo (Vehicle) Monthly x 3
45603461|NCT05153785|Drug|Lidocaine|Intravenous perioperative Lidocain for pain Control and improvement of postoperative recovery
45603462|NCT05153785|Drug|Normal saline|Placebo
45603463|NCT00151775|Drug|olmesartan medoxomil|"Cohorts A and B: 2.5mg to 40mg olmesartan, as a suspension (depending on weight), once daily. Tablets were used to prepare a suspension.~Cohort C: 0.3mg/kg olmesartan ,as a suspension, once daily"
45603464|NCT00151775|Drug|placebo|Cohorts A, B, C: placebo, once daily
45756435|NCT01219075|Procedure|biopsy|Correlative studies
45756436|NCT01219075|Other|immunohistochemistry staining method|Correlative studies
45756437|NCT01219075|Other|laboratory biomarker analysis|Correlative studies
45444665|NCT04964115|Other|Cohort study|This cohort study does not involve an intervention
45603465|NCT00151775|Drug|olmesartan medoxomil|"Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg. Tablets were used to prepare the suspension or were given directly.~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg"
45603466|NCT02258464|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update)
45603467|NCT02258464|Drug|Placebo (saline)|Up to 6 cycles of saline injection
45603468|NCT02258464|Other|Background hormonal therapy|Prescribed by PI and was provided as long as patient can tolerate treatment. It must be prescribed as per local label in country participating.
45756438|NCT01219075|Procedure|mammography|Correlative studies
45756439|NCT03393975|Biological|BAX930|Participants in prophylaxis cohort will receive IV infusions of 40 IU/kg BAX 930 ORT during Period 1 and Period 2 and switch to BAX 930 SIN during Period 3 for six months once in a week or twice in a week. In On-demand cohort participants will receive daily IV dose of BAX-930.
45756440|NCT03393975|Biological|Standard of care|Participants will receive Investigator-recommended Standard of care (SoC).
45756441|NCT04693637|Biological|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion
45603469|NCT03476941|Drug|Gentamicin Sulfate Inj 20mg/2ml vial for injection|Irrigate surgical drain with total amount of 5 mg in 10 ml volume twice/day for 7 days or until drain removal if less than 7 days of therapy.
45603470|NCT03476941|Drug|Clindamycin phosphate 6 mg/1ml for injection|Irrigate surgical drain with total amount of 12 mg in 10 ml volume once daily for 7 days or until drain removal if less than 7 days of therapy.
45603471|NCT03476941|Other|Placebo|The placebo group will receive drain irrigation twice/day
45603472|NCT03481153|Device|Transcranial direct current stimulation (tDCS)|tDCS is a safe, non-invasive neurostimulation technique that can modulate neural excitability in the brain to positively impact cognition, behaviour and mood, particularly when combined with a behavioural intervention
45603473|NCT03476863|Procedure|Alveolar Recruitment Maneuver|Patients in the Experimental Group will be submitted to ARM, immediately after abdominal desinflation of the pneumoperitoneum (PNP). The ARM will be performed with PEEP of 15 cmH2O for thirty seconds, 20 cmH2O for thirty seconds, 25 cmH2O for thirty seconds, 30 cmH2O for one minute and a inspiratory plateau pressure of 15 cmH2O above PEEP, totaling two minutes and thirty seconds.The data of the TIE will be continuously recorded and the hemodynamic and respiratory function variables such as heart rate (HR), respiratory rate (RF), mean arterial pressure (MAP), peripheral oxygen saturation (SpO2) and final gas expiratory pressure carbon dioxide (PETCO2) will be recorded in several moments: immediately after the monitoring, and the patient is still on spontaneous ventilation, 5min after orotracheal intubation, after the installation of the pneumoperitoneum, before and after the execution of the MRA and in the Post-OP, in the first 24h, along with new lung function tests.
45603474|NCT03476863|Procedure|Conventional mechanical ventilation|Immediately after intubation, patients will undergo mechanical ventilation with the ventilator (Dixtal DX 5020) in volume controlled mode with an ideal tidal volume of 7 ml / kg body weight, a set frequency to maintain a carbon dioxide of 35-42 mmHg, and an inspiratory / expiratory ratio of 1: 2. The inspiratory oxygen fraction (FIO2) will be 0.5.
45603475|NCT00609323|Drug|lidocaine and tetracaine cream 7%/7%|One treatment of up to 400 cm2 Cream applied for 60 minutes.
45603476|NCT00609323|Drug|Placebo|One treatment of up to 400 cm2 Cream applied for 60 minutes.
45603477|NCT05139277|Diagnostic Test|CONVIVO system|Approximately 2-5 minutes following administration of FNa in situ imaging will be performed by the participating surgeon ensuring proper technique. Prior to entering the surgical field, the probe will be covered in a disposable sterile sheath that is manufactured with quality assurance for this purpose. The probe will gently be held against the tissue interface while imaging occurs. Again this will only be in regions that would normally be resected or sampled in routine clinical care. Following image acquisition, a neuropathologist present in the operating room, will review and capture each image.
45756442|NCT00086684|Drug|Pentosan polysulfate sodium 100 mg|One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning, afternoon, and evening) for 24 weeks
45756443|NCT00086684|Drug|Placebo|One placebo capsule 3 times a day (morning, afternoon and evening) for 24 weeks
45756444|NCT00086684|Drug|Pentosan polysulfate sodium 100 mg|One 100 mg pentosan polysulfate sodium capsule in the morning, and 1 matching placebo capsule in the afternoon and evening for 24 weeks
45756445|NCT02999425|Other|Education|Educational intervention
45756446|NCT02992873|Device|Layperson allocated to start CPR and fetch nearest AED|Dispatching laypersons to fetch an AED and start CPR in out-of-hospital cardiac arrest
45756447|NCT02992873|Device|Layperson allocated to start CPR|Dispatching laypersons to start CPR out-of-hospital cardiac arrest
45756448|NCT02987907|Drug|Dexamethasone|use dexamethasone 10mg (2ml) I.A. during TACE
45756449|NCT02987907|Drug|Normal Saline|use normal saline 2ml I.A. during TACE
45756450|NCT02992795|Device|BrainPulse|JanMedical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to tge brain motion using an array of sensors placed on the head.
45756451|NCT04402814|Diagnostic Test|Clungene rapid test cassette|Blood will be tested for the presence of IgG and IgM antibodies using the Clungene rapid test cassette.
45756452|NCT01887171|Drug|Tacrolimus|1000 ml of HTK solution (Custodiol, Dr. Franz Köhler Chemie GmBH) cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
45756453|NCT01679444|Procedure|Magnetic Resonance Spectroscopy|
45756454|NCT00713479|Drug|Varenicline, then placebo|Subjects receive MA infusions on certain days first under varenicline (10 days) then under placebo (8 days) after a 14-24 day washout in order to determine study medication safety and tolerability
45756455|NCT00713479|Drug|Placebo, then varenicline|Subjects receive MA infusions on certain days first under placebo (10 days) then under varenicline(8 days) after a 14-28 day washout in order to determine study medication safety and tolerability
45756456|NCT01679678|Device|PolyHeal 2|PolyHeal is a sterile medical device
45756457|NCT01679678|Device|Polyheal|PolyHeal is a sterile medical device that is comprised of negatively charged 5-micron polystyrene microspheres suspended in
45756458|NCT01679756|Procedure|Laparoscopic right hemicolectomy for cancer|After induction of anesthesia, a foley catheter and an NG tube will be inserted. All patients will have their NG tubes removed after the procedure. During the procedure patients will be placed in Trendelenburg position with 15 degrees of tilt and with a right side up (tilt to the left of 25 degrees). A Veres needle will be inserted and pneumoperitoneum induced and maintained at 12 mmHg for the entire duration of the procedure. Under direct vision, three 10-12mm trocars will be inserted in the left abdominal wall. The ileocolic vessels, the right colic vessels (when present), the right branch of the middle colic vessels and the right gastroepiploic vessels will be ligated intracorporeally at their origin using clips. Anastomosis are described in each arm description.
45911109|NCT02003664|Drug|Baclofen ER|Comparison of Baclofen ER to placebo using a 2 to 1 chance of receiving Baclofen ER, the medication
45911110|NCT02003664|Drug|Placebo|Comparison of placebo to Baclofen ER using a 1 in 3 chance of receiving placebo
45911111|NCT02003677|Drug|Faster-acting insulin aspart|Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
45603478|NCT05139277|Other|Conventional histologic evaluation|Following image acquisition, the tissue region imaged with the CONVIVO system will then be biopsied using biopsy forceps. This will be passed immediately off the surgical field as a research specimen and provided to a member of the research team to be prepared for conventional histologic evaluation. The specimen will be labeled with the deidentified subject and sample number. This sequence will then be repeated for each successive sample.
45603479|NCT00605735|Drug|BMS-582949|Tablets, Oral, 300 mg, once daily, 12 weeks
45603480|NCT00605735|Drug|Placebo|Tablets, Oral, placebo, once daily, 12 weeks
45756459|NCT03470558|Other|Dietary habits|Sleeve gastrectomy patients will be asked to monitor dietary habits before surgery and at 2, 6, and 12 months after surgery.
45756460|NCT02990689|Device|Trifocal Intraocular Lens|bifocal intraocular lens (IOL)
45756461|NCT02990689|Device|Bifocal Intraocular Lens|trifocal intraocular lens (IOL)
45756462|NCT02990689|Device|Low Addition Bifocal Intraocular Lens|low near addition intraocular lens (IOL)
45756463|NCT03467750|Drug|Ketorolac|Patients in this group will receive 0.5mg/kg of ketorolac, administered intravenously.
45756464|NCT03467750|Drug|Standard of Care|"All patients will undergo inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl will be administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen will be administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron will be given.~A rescue dose of 0.5-1mcg/kg of IV Fentanyl will be available for use at the end of the procedure. The decision to administer will be left to the discretion of the attending anesthesiologist. The choice to give this will be made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure.~The PACU nurses, who will be blinded to ketorolac administration, will evaluate the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg will be administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg will be administered."
45756465|NCT02998957|Device|AcuTENS|Stimulation of acupuncture point Dingchuan using transcutaneous electrical nerve stimulation (TENS) instead of needles
45756466|NCT02998957|Device|Sham AcuTENS|Portable TENS electrostimulation device with no electrical output
45756467|NCT03414086|Other|Healthy Control|Ten healthy adult patients evaluating serum, PBMC's, and RNA.
45756468|NCT03414086|Other|Myositis in Remission|Ten patients (four who have polymyositis, six dermatomyositis) from our database who are followed in the Myositis Center. We will collect serum, PBMC's, and RNA samples will be obtained at baseline and at six months. Remission is defined as a global myositis disease activity score less than or equal to 1 on the MDAAT assessments with no new immunosuppressive drug or glucocorticoid use and no increase in dose of either in the preceding year.
45756469|NCT02992483|Drug|MIK665|MIK665
45756470|NCT02992639|Behavioral|Control group|The participants who included in control group did not receive any treatment.
45756471|NCT02992639|Behavioral|Weight loss group|The participants who included in weight loss group followed a 12-week weight loss program consisting of a 300 kcal/day reduction of thier usual caloric intakes
45756472|NCT03085706|Biological|PBMC autotransplantation|Fourteen amyotrophic lateral sclerosis (ALS) patients are received peripheral blood mononuclear cell (PBMC) autotransplantation.
45756473|NCT03085550|Procedure|Fat grafting|Single treatment fat grafting infiltrated into diabetic ulcer wound
45756474|NCT03085550|Procedure|Fat grafting + platelet rich plasma|Single treatment fat grafting mixed with autologous platelet rich plasma infiltrated into diabetic ulcer wound. Autologous PRP is obtained using the ANGEL(TM) Concentrated Platelet Rich Plasma (cPRP) Separation Device which is FDA-regulated and CE certified
45756475|NCT02998801|Other|IPAD|Patients undergoing surgery will watch the video using an PAD
45756476|NCT02998801|Other|VR Goggles|Patients undergoing surgery will watch the video using goggles
45756477|NCT02992405|Behavioral|FOCUS Resilience Enhancement Program|Each couple or family will have 10 weekly 75 minute sessions comprising the treatment protocol.Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the 10-week treatment is completed (T2).
45804239|NCT05414383|Device|CADx|A novel CADx system for real-time histopathological prediction of colorectal neoplasia, by using non-magnified conventional white-light and image enhanced endoscopy.
45911112|NCT02003677|Drug|insulin aspart|Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
45911113|NCT02003703|Biological|Recombinant Hepatitis B Virus Vaccine|
45911114|NCT02003729|Device|Portable Sleep Monitor|ApneaDx™ is a new PM that uses a microphone to record breath sounds and an acoustical analysis algorithm of breath sounds to determine the AHI.
45603481|NCT02682901|Drug|Cycloset|Cycloset 1.6 -3.2 mg/day
45603482|NCT02682901|Drug|Placebo|Non-active placebo for cycloset
45603483|NCT00603863|Biological|IMMU-107 (hPAM4)|90Y-hPAM4 once weekly for 3 weeks gemcitabine once weekly for 4 weeks
45603484|NCT04472039|Device|optical coherence tomography (OCT)|OCT visualizes the retinal layers by backreflection of light
45603485|NCT04459195|Behavioral|2 Minute Static Stretching|Stretching applications will be applied to the first group for 2 minutes. Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 30 seconds of rest and and the individuals will be asked to participate in the exercise actively.
45603486|NCT04459195|Behavioral|5 Minute Static Stretching|Stretching applications will be applied to the first group for 5 minutes. Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 30 seconds of rest and and the individuals will be asked to participate in the exercise actively.
45603487|NCT04471961|Genetic|Exome sequencing in pediatrics cancers|This pediatric oncology study proposing a global approach integrating trio-based whole exome sequencing, somatic DNA and RNA analysis will improve the recognition of genetic predisposition and the characterization of target therapies in children with cancer.
45603488|NCT02258074|Drug|Nicotinamide|
45603489|NCT02258074|Drug|Lanthanum Carbonate|
45603490|NCT02258074|Drug|Placebo (for Nicotinamide)|Sugar pill manufactured to mimic Nicotinamide 750 mg capsule
45603491|NCT02258074|Drug|Placebo (for lanthanum carbonate)|Sugar pill manufactured to mimic Lanthanum Carbonate 500 mg capsule
45603492|NCT03476785|Behavioral|High intensity exercise|Subjects will perform high intensity aerobic exercise in addition to moderate intensity sessions 4-5 times per week.
45603493|NCT03476785|Behavioral|Yoga|Subjects will perform strength and flexibility exercises.
45603494|NCT04471571|Other|Resin infiltration and microabrasion for MIH-affected incisors|MIH-affected incisors will be treated with microabrasion followed by resin infiltration as a combined treatment
45756478|NCT02992405|Behavioral|Waitlist (No Study Treatment)|Participants assigned to the Waitlist (No Treatment) group will receive the study intervention only after the 10 weeks of the immediate treatment phase has been completed. Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the immediate treatment phase is completed (T2).
45603495|NCT04471571|Other|Resin infiltration for MIH-affected incisors|MIH-affected incisors will be treated with resin infiltration alone
45603496|NCT03476707|Other|Anemia|Hematocrit less than 0.39
45603497|NCT04472975|Drug|Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS|Individuals with MS exposed to one or more DMDs (beta-interferon, glatiramer acetate, natalizumab, fingolimod, dimethyl fumarate, teriflunomide, alemtuzumab, daclizumab or ocrelizumab; regardless of dose, frequency or duration of treatment) between 1st January 1996 and 31st March 2018 in five Canadian provinces.
45603498|NCT02281487|Procedure|Hysterectomy plus Tubectomy|hysterectomy with tubectomy
45756479|NCT02998723|Other|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
45756480|NCT02998723|Other|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
45603499|NCT02281487|Procedure|Hysterectomy|standard hysterectomy
45603500|NCT02281487|Device|light microscopy|analysis of the incidence of dysplastic lesions (defined as: nuclear atypia, pilling of epithelial cells, multiple mitosis), if any, in the removed Fallopian tubes by light microscopy (Leica DM4000)
45603501|NCT04473053|Drug|Nafamostat Mesilate|Nafamostat has been shown to have potential antiviral effects against MERS CoV and is thought to possibly inhibit SARS CoV2 infection via inhibition of viral entry due to inhibition of TMPRSS2. In addition, nafamostat has potent anticoagulant properties which may provide benefit in patients with DIC, a common finding in serious cases of COVID-19. Nafamostat has been broadly well tolerated in clinical trials in patients with DIC and acute pancreatitis.
45756481|NCT04402580|Drug|Rituximab Biosimilar|for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
45603502|NCT04473053|Drug|TD139|TD139 is a specific inhibitor of galectin-3 which has been investigated in healthy volunteers and patients with IPF. No serious drug related serious adverse events have been reported to date. TD139 had no impact on cardiac, haematological or biochemical measures of safety during trials in humans to date. Beneficial effects on biomarker measures of lung inflammation were observed in patients with IPF. It is the purpose of this investigation to examine the potential for delivery of this inhibitor in pre-ventilator patients hospitalised with COVID-19 to examine whether this may lead to detectable changes in blood biomarkers, reduce viral load and also reduce disease severity such as time to ventilation.
45603503|NCT04473053|Other|Standard care|Patients will receive standard care.
45756482|NCT04402580|Drug|Mycophenolate Mofetil|1,200 mg/1,73 sqm orally divided in 2 daily doses
45911115|NCT02003755|Procedure|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
45603504|NCT05646784|Drug|Cerebiome|Evaluate the effect of oral intake of a probiotic agent, on clinical and plasma inflammatory markers, in a subgroup of target patients versus a subgroup treated with placebo, in combination with conventional treatment, during the patient's stay in the hospital, and after his discharge, for a total duration of 12 weeks
45603505|NCT05646784|Drug|Placebo|Placebo effect: Evaluate the effect of oral intake of a placebo, on clinical and plasma inflammatory markers, in a subgroup treated with placebo, in combination with conventional treatment, during the patient's stay in the hospital, and after his discharge, for a total duration of 12 weeks
45603506|NCT02281565|Behavioral|survey|Survey about Knowledge, Attitude and Practice About Blood Donation
45603507|NCT01643044|Behavioral|Nutrition time control/placebo intervention|This time-control intervention, designed in part to help promote research assistant blinding as to participant condition, focused on proper infant nutrition using a computer-delivered, interactive format and videos.
45603508|NCT01643044|Behavioral|Computer-delivered, brief intervention on alcohol use|A single 20-minute interactive computer-delivered intervention designed to promote motivation to change prenatal alcohol use, without presuming the participant to be currently using alcohol while pregnant.
45756483|NCT01275781|Drug|[14C]-AZD9742|1000 mg intravenous over 2 hours
45756484|NCT04402736|Behavioral|The modified Barthel Index-based rehabilitation nursing program|The intervention with the program based on the MBI classified function of patients into five levels, with every 20 points as a level, Each level corresponds to different training items. Training items included self-care training and training in transfer activities, sitting balance, walking, and sit-to-stand, etc. Each training session lasting at least 30 minutes, two sessions per day, for seven continuous days. During the intervention, the rehabilitation therapist's conventional treatment is not interfered.
45756485|NCT04402736|Behavioral|Usual care|Patients in the control group received clinical usual care including the activities of daily living assessment, early mobilization guide and health education. During the intervention, the rehabilitation therapist's conventional treatment is not interfered.
45756486|NCT00709891|Device|cobas® 4800 HPV Test|
45756487|NCT03085160|Behavioral|Learning to Breathe|Six-session group program that involves meditation and interactive activities to learn mindfulness skills for coping with stress
45756488|NCT03085160|Behavioral|Health Education|Six-session group program that covers topics important for healthy living such as avoiding drug use, conflict resolution, bullying, sun safety and others
45603509|NCT02281643|Drug|Doxycycline|200mg oral doxycycline will be administered immediately (early) in the experimental arm or delayed in the comparator arm
45603510|NCT02281721|Device|Surpass Flow Diverter(s)|Endovascular placement of a Surpass Flow Diverter(s) for the treatment of an intracranial aneurysm(s)
45603511|NCT01642732|Other|Everolimus, lupron, bicalutamide, and radiation|"Everolimus - there are five dose levels (2.5mg. every 48 hrs.,2.5mg./day, 5mg./day, 7.5mg./day, and 10mg./day) based on the initial expectations of toxicity and the incidence of toxicity of subjects already treated. Subjects will be on one dose level throughout the study. Subjects will receive everolimus starting on study day 1.~Radiation therapy will start on day 60-70 (44 treatments, at 5 treatments a week for a little longer than 8 weeks).~Bicalutamide (50 mg. tablets daily) will begin on study day 10-14, approximately 2 months prior to Radiation Therapy.~Lupron injections will begin on study day 15 to 25, approximately 2 months prior to Radiation Therapy. The typical dose schedule is either one injection (22.5 mg. dose)every 3 months for a total of 8 injections or one injection (30 mg. dose) every 4 months for a total of 6 injections.~Radiation, bicalutamide, and everolimus will end between study day 120-130. Lupron will end at 24 months on study."
45603512|NCT02283437|Behavioral|Problem-solving Based Bibliotherapy Program|The PSBPF will complete the bibliotherapy (self-help) and problem-solving manual developed by the research team for caregivers of people with schizophrenia spectrum disorders.
45603513|NCT02283437|Behavioral|Behavioral Management and Education Program|Two trained advanced practice psychiatric nurses who are experienced in psychiatric rehabilitation and group programs will lead the behavioral management and education group, which is guided by a validated treatment protocol based on the research team's (Chien and Wong, 2007) and McFarlane et al.'s (2001) family management programs for schizophrenia.
45603514|NCT04872712|Procedure|Press needles|Manual acupuncture using press needles
45603515|NCT04872712|Procedure|Filiform Needles|Manual acupuncture using filiform needles
45603516|NCT04892524|Other|Virtual multidisciplinary review|The virtual multidisciplinary review involves participants being reviewed by a multi-disciplinary team of specialist doctors, nurses and radiologists in a virtual environment. The team will analyse radiologic scans and make a recommendations for any follow-up scans, procedures or appointments that may be required
45603517|NCT02281799|Drug|Azathioprine|"Patients will be commenced on an alternative thiopurine to that used initially, according to the standard dosing schedule used by their IBD clinician.~For example, if the initial thiopurine-related pancreatitis occurred while taking Azathioprine, the patient will be restarted on 6-MP, and vice versa."
45603518|NCT02281877|Procedure|Neuromuscular electrical stimulation (NMES)|5x/week, 2x/day, for 45 minutes/session
45603519|NCT02281877|Behavioral|Standard Rehabilitation Protocol|Standard physical therapy after TKA
45603520|NCT02283515|Drug|Rosuvastatin|Rosuvastatin (RSV) is one of new synthetic, second-generation, sulfur-containing, hydrophilic statin, a highly efficient competitive inhibitors of HMG CoA Reductase having important role in reducing serum cholesterol concentrations and lowers the risk of cardiovascular disease.
45603521|NCT00600275|Drug|BGT226|
45603522|NCT00589823|Drug|Fentanyl citrate|nasal spray, 100, 200, 400 or 800 mcg dosage according to need, to treat up to four episodes of BTCP per day
45603523|NCT00589823|Drug|Immediate release morphine sulphate|drug dose as required by patient taken to treat up to four epsiodes of BTCP per day
45603524|NCT02283593|Behavioral|eChange.se|7 modules: 1. Making a decisional balance 2. Setting a goal for alcohol consumption 3. Learning self control skills 4. Identifying risk situations 5. Dealing with urges 6. Dealing with emotions and with social pressure 7. Developing a crisis plan
45603525|NCT02282033|Device|The Moderato System|The BackBeat Moderato System incorporates traditional pacing modes and algorithms to provide pacing support to patients with all conditions currently indicated for dual chamber pacing. In addition, a special pacing algorithm was developed to reduce blood pressure.
45603526|NCT02257684|Drug|pegcrisantaspase|
45603527|NCT02283671|Biological|Tolerogenic Dendritic cells loaded with myelin peptides|Somatic-cell therapy medicines application
45603528|NCT04441697|Diagnostic Test|Multiple sleep latency tests|The investigators measure the objective sleepiness by recording the electro-encephalogramm during four experimental diurnal naps. They also perform a nocturnal polysomnography prior to the tests for a better interpretation.
45603529|NCT02282189|Device|Oscillating Positive Expiratory Pressure (Aerobika ®)|The oPEP system combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.
45603530|NCT02190721|Drug|tbo-filgrastim|5 μg/kg
45603531|NCT00581477|Drug|Droxidopa Oral Product|Droxidopa administered in increasing dosages up to 300 mg
45603532|NCT03134339|Drug|Nicotine saline 0.00mcg/kg/s|saline 0.00mcg/kg/s
45603533|NCT03134339|Drug|Nicotine 0.24 mcg/kg/s|nicotine 0.24 mcg/kg/s
45603534|NCT03134339|Drug|Nicotine 0.048 mcg/kg/s|nicotine 0.048 mcg/kg/s
45603535|NCT03134339|Drug|Nicotine 0.024 mcg/kg/s|nicotine 0.024 mcg/kg/s
45603536|NCT02282267|Drug|Gefitinib|Iressa 250mg oral daily
45603537|NCT03473041|Procedure|Hybrid sling|sling formed of surgeon tailored autologous rectus sheath and polypropylene arms
45603538|NCT03473041|Procedure|TVT-O|midurethral transobturator vaginal tape
45603539|NCT02283905|Drug|amphotericin-B|continuously infused
45603540|NCT02283905|Drug|voriconazole|intravenously or orally administered
45603541|NCT05152771|Other|KETOGENIC DIET|"This will be a prospective cohort study. All families with children who have been newly diagnosed with confirmed SSPE (based on Dyken's Criteria) will be approached to start the low glycemic index diet (liberalized kind of KD). A thorough dietary history will be taken from the parents/caregivers, and they will be counseled by a trained dietitian on the diet, all pros and cons, and the format. After the verbal agreement, formal consent will be taken from the parent/ caregiver for initiation of the diet.~These patients are usually already admitted in the hospital for initial diagnosis and management. Therefore the initiation of the diet will be in the hospital during their admission if the parents/ caregivers agrees. A minimum of 2-3 days would be required to train the parents/caregivers."
45603542|NCT04771975|Behavioral|Exercise Counselling|See previous description for MatchQEP (Intervention) group.
45756489|NCT00710203|Device|Pulsed dye laser|One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
45756490|NCT00710203|Procedure|Curettage|A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.
45756491|NCT00710203|Procedure|Electrodesiccation|A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
45756492|NCT00710203|Other|No treatment|A fourth lesion will not be treated and will serve as a control.
45911116|NCT02003768|Drug|Propofol|80 patients are randomly allocated into two groups: In TIVA group, propofol based total intravenous anesthesia is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
45444666|NCT02049034|Other|Lixisenatide|"Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.~Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days."
45444667|NCT02049034|Other|Placebo|Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.
45911117|NCT02003768|Drug|Desflurane|80 patients are randomly allocated into two groups : In Des group, inhalation anesthesia using desflurane is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
45444668|NCT04929015|Procedure|Biospecimen Collection - blood and tissue sample collection|The original tissue sample from each patient will be obtained at time of surgery or prior to surgery. Plasma for ctDNA will be obtained at baseline, pre-surgery, post-surgery and every 3 months up 2 years
45444669|NCT04929015|Other|Electronic Health Record Review|Medical record reviewed
45444670|NCT03561844|Other|aromatherapy|Each of participants in the aromatherapy (inhalation) group will receive inhalation aromatherapy and those in the aromatherapy (massage) group will receive aromatherapeutic massage. As to the waiting control group, participants will be given either one of these two interventions after the implementation phase is completed.
45444671|NCT02049112|Device|Salivary equivalent|14-day treatment with salivary equivalent sticks
45444672|NCT02049112|Device|Aequasyal|14-day treatment with Aequasyal oral spray
45603543|NCT04771975|Behavioral|Partner Matching|"All participants will be matched with another participant (fellow BCS) and will facilitate / support exercise with their partner for the duration of the study.~Participants will be matched based on personal and cancer-related characteristics."
45603544|NCT04471025|Procedure|USG guided infraclavicular block|USG guided infraclavicular block was applied to patients either by conventional two-person technique or by one person Jedi technique according to the allocated group. On Group I single operator controlled the probe with one hand while controlling the needle and the syringe on the other hand with the Jedi technique. The needle was held between the index finger and the middle phalanx of the middle finger, and the syringe was held with fingers 4 and 5, with the plunger part to the thumb in the palm. On Group II, operator used the probe and needle with different hands while an assistant controlling the syringe to aspirate or inject local anesthetic.
45603545|NCT04471181|Device|Endovascular repair of ruptured abdominal aortic aneurysm (EVAR) with Medtronic Endurant|Endovascular repair (EVAR) of ruptured abdominal aortic aneurysms with Medtronic Endurant II, and IIs device
45603546|NCT00497159|Other|Placebo|Placebo TID x 90 days
45603547|NCT00497159|Drug|Dimebon|Dimebon 20 mg TID x 90 days
45603548|NCT02523937|Other|Soluble Fibrin|Evaluating the diagnostic performances of the assay in terms of sensitivity, specificity, negative and positive predictive values; from calculation of the area under the curve in comparison with the D-dimers.
45603549|NCT04470947|Diagnostic Test|Next generation functional drug screening|High-throughput image based in-vitro drug screening on primary patient tumor cells
45603550|NCT04470947|Diagnostic Test|Comprehensive genomic profiling|Comprehensive targeted profiling of genetic aberrations on primary patient tumor material
45603551|NCT03480997|Combination Product|Albuterol Sulfate and Ipratropium Bromide|
45603552|NCT03480997|Combination Product|Albuterol Sulfate|
45603553|NCT00572585|Drug|AEB071|
45603554|NCT00572585|Drug|Placebo|
45603555|NCT04660747|Drug|Oral anticoagulant|Direct oral anticoagulants or vitamin K antagonists
45603556|NCT03131401|Diagnostic Test|Diagnosis of lymphatic filariasis|Field validation of the diagnostic performance of diagnostic tests for infection with W. bancrofti.
45603557|NCT03131401|Diagnostic Test|Diagnosis of lymphatic Filariasis and onchocerciasis|Field validation of the diagnostic performance of diagnostic tests for infection with both W. bancrofti and O. volvulus.
45756493|NCT02990923|Device|High-Flow Needleless Valve|
45756494|NCT02990923|Device|DualCap Disinfection Devices|
45756495|NCT04386109|Other|No intervention - exposure is to COVID-19|No intervention - exposure is to COVID-19
45756496|NCT00710905|Device|AcrySof ReSTOR Aspheric IOL models SN6AD1 and SN6AD3|Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, AcrySof ReSTOR +4 IOL in the other eye following cataract removal.
45756497|NCT04386421|Other|Video on oral hygeine instructions|A 3 minute video will be shown providing information regarding the care of the dentition during Fixed appliance treatment along with the importance of patient compliance and cooperation. The video will also be showing the consequences of poorly followed instructions such as gingivitis and white spot lesions.
45756498|NCT04386421|Drug|Plaque disclosing tablets|"Plaque disclosing tablets:~Product: 2-Tone Disclosing Tablets Young Dental Manufacturing 13705 Shoreline Court East Earth City, MO 63045 Composition: Flavor, SD Tutti Fruiti 1 %, D and C Red 1 % and FD and C Blue 1 %"
45756499|NCT01887327|Procedure|Phototherapy|Phototherapy starts within 30 minutes before or after injection
45603558|NCT03131401|Diagnostic Test|DEC Patch|Field validation of the diagnostic performance of diagnostic tests for infection with O. volvulus.
45603559|NCT04471259|Other|Classification statistics|We classified patients by gender, age, recovery time,etc
45603560|NCT05154877|Device|OMNI PET/CT Scan|The subject will undergo two PET/CT scans, one on the standard of care scanner and one on the OMNI scanner.
45603561|NCT00570635|Drug|XL820|XL820 capsules administered orally as a single agent at a dose of 800 mg daily
45603562|NCT00570635|Drug|XL820|XL820 capsules administered orally as a single agent at a dose of 300 mg twice daily
45444673|NCT02049112|Device|Biotene|14-day treatment with Biotene oral spray
45603563|NCT02348008|Drug|MK-3475|Arm A: Phase 1b Cohort 1: 200mg IV; Arm A: Phase 1b Cohort 2: 200mg IV
45603564|NCT02348008|Drug|Bevacizumab|Arm A: Phase 1b Cohort 1: 10mg IV; Arm A: Phase 1b Cohort 2: 15mg IV
45603565|NCT02348008|Drug|MK-3475|Arm B: Phase II Treatment: 200mg IV
45603566|NCT02348008|Drug|Bevacizumab|Arm B: Phase II Treatment: administered at the maximum safe dose of 10mg or 15mg as established in the Phase 1b dose escalation cohort study.
45444674|NCT01302873|Drug|BGG492A|
45444675|NCT01302873|Drug|BGG492A|
45603567|NCT00569387|Biological|HyperAcute(R)-Pancreatic Cancer Vaccine|100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
45603568|NCT04468087|Drug|Atazanavir|600 mg (2 capsules) twice daily on the first day and 300 mg (1 capsule) twice daily for the subsequent 9 days.
45603569|NCT04468087|Drug|Daclatasvir 60 mg|initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once daily for 9 days.
45603570|NCT04468087|Drug|Sofusbuvir + Daclastavir 60 mg|400 mg twice daily (2 capsules) on the first day and 400 mg (1 capsules) once daily for the subsequent 9 days (sofusbuvir) + initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once a day for 9 days (daclastavir)
45603571|NCT04468087|Drug|Placebo Atazanavir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
45603572|NCT04468087|Drug|Placebo Daclatasvir 60 mg|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
45603573|NCT04468087|Drug|Placebo Sofusbuvir + Daclatasvir 60 mg|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
45444676|NCT02049190|Drug|onapristone|
45603574|NCT05152693|Other|Low variety|Meal components are mixed together on the plate
45444677|NCT02049190|Drug|abiraterone|
45444678|NCT03811509|Drug|bisphosphonate|antiresorptives
45444679|NCT02037412|Drug|Ticagrelor|Ticagrelor - 180 mg loading and 90 mg bid maintenance for 3 months
45444680|NCT02037412|Drug|Clopidogrel|Clopidogrel - 600 mg loading and 75 mg qd maintenance for 3 months
45444681|NCT03811119|Device|MANTA vascular closure device|Collagen based vascular closure device
45444682|NCT03811119|Device|Suture based vascular closure device|Suture based vascular closure device (ProGlide)
45444683|NCT03810885|Other|Bread with reduced salt content|Bread with gradually lowered salt content
45444684|NCT03810885|Behavioral|Dietary advice|Participants will receive information on how to lower salt and increase potassium intake
45444685|NCT03810885|Other|Bread with standard salt content|Bread with normal salt content
45444686|NCT03932019|Drug|Jitongning tablet(High-dose )|Jitongning tablet,3tablets,bid,treat 12 weeks
45603575|NCT05152693|Other|High Variety|Meal components are served separately on the plate
45603576|NCT05152693|Other|Small Portion Size|Small meal portion size
45603577|NCT05152693|Other|Large Portion Size|Large meal portion size
45603578|NCT05152693|Other|With Beverage|Meal served with water
45603579|NCT05152693|Other|Without Beverage|Meal served without water
45603580|NCT00569153|Drug|TAK-700|"Phase 1 portion of study:~TAK-700 dose escalation. Tablets administered orally, twice daily until disease progression or occurrence of an unacceptable adverse event.~Phase 2 portion of study:~Patients will receive one of 4 treatments:~TAK-700 at 300 mg twice/day~TAK-700 at 400 mg and 5 mg prednisone twice/day~TAK-700 at 600 mg and 5 mg prednisone twice/day~TAK-700 at 600 mg once/day in the morning"
45603581|NCT05153005|Other|examination methods|Some advanced methods: mannose protein (Mp1p), (1,3)- β- D-glucan (G antigen) and Cryptococcus capsular antigen (CrAg) serological detection, qPCR, dd- PCR and mass spectrometry identification, QFC.
45603582|NCT05137951|Device|Rebee sensor|Rebee is a wearable motion sensor package of sensor with its own mobile application, which measures range of joint movement in different planes easily which the patient able to wear the sensor and move easily to measure ROM and record the measurement at the application software Digital goniometer Goniometry has been described as a tool to measure angle. It gives the physician a useful method to diagnose musculoskeletal function in terms of ROM, monitor the progress of an intervention, record the data for future follow-up, and meet statutory and legal requirements for impairment rating and disability determinations where applicable
45603583|NCT00495131|Drug|Pegylated interferon alfa-2a plus ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 24 weeks
45756500|NCT01887327|Drug|Stannsoporfin|Stannsoporfin (3.0 or 4.5 mg/kg) administered by intramuscular (IM) injection (a shot in the muscle)
45603584|NCT00495131|Drug|Pegylated interferon alfa-2a plus ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 48 weeks
45756501|NCT01887327|Drug|Placebo|Matching placebo administered by IM injection
45756502|NCT04386889|Other|Vasculitis In SLE|20 SLE female Egyptian patients, among them we are going to study the vasculitic pattern incidence.
45603585|NCT05137327|Behavioral|Classroom Behavior Support (CBS) Condition|An individualized teacher consultation program that includes observation and performance feedback and techniques borrowed from Motivational Interviewing and Cognitive Behavioral Therapy (CBS). It is designed to address barriers to implementation and improve teacher practices and student outcomes.
45756503|NCT04386031|Diagnostic Test|Throat culture for fungal pathogens|Throat culture for fungal pathogens will be taken before surgery, at post-operative day (POD) 3 and 2 weeks after the operation
45603586|NCT05137327|Behavioral|Standard Problem Solving Consultation|A standard problem solving approach to teacher consultation that includes observation and brief performance feedback. It represents current best practice in teacher consultation.
45603587|NCT05103241|Drug|[14C] GP681|40 mg suspension containing 100μCi of [14C]GP681
45603588|NCT02257372|Drug|UMEC DPI|The UMEC DPI will contain one blister strip which will have 30 blisters of UMEC as dry powder blended with lactose and magnesium stearate, with no companion strip. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously.
45603589|NCT02257372|Drug|Placebo DPI|The matching placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
45603590|NCT02257372|Drug|ICS/LABA medication|Participants will use ICS/LABA combinations that are approved for the treatment of COPD at approved doses and frequency including SERETIDE 500/50mcg twice daily, FSC 500/50 mcg twice daily generic products such as AIRFLUSAL FORSPIRO inhaler 500/50mcg twice daily or ROLENIUM ELPENHALER inhaler 500/50mcg twice daily and SYMBICORT TURBUHALER inhaler at doses of 200/6mcg twice daily and 400/12mcg twice daily. The ICS/LABA will be sourced from local commercial stock while on the study
45756504|NCT02987751|Drug|Glargine + Glulisine|Glargine should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit and Glulisine should be taken 20 minutes before breakfast/dinner, the dose is adjusted as per postprandial blood glucose during each visit
45756505|NCT02987751|Drug|Premixed analogue insulin (70/30)|Premixed analogue insulin should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit.
45756506|NCT04387123|Procedure|Vaginoscopy|Vaginoscopic examination and possible operative endoscopic management
45756507|NCT01889355|Device|AgaMatrix Blood Glucose Monitor|
45756508|NCT04385719|Drug|Remdesivir|Remdesivir (GS-5734) is a nucleoside analogue with in vitro activity against filoviruses EBOV, SUDV, BDBV and MARV, in addition to arenaviruses and coronaviruses
45756509|NCT00082628|Drug|Placebo|Placebo matched to serostim® as subcutaneous injection.
45756510|NCT00082628|Drug|Serostim® 4 mg|Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.
45756511|NCT00082628|Drug|Serostim® 2 mg|Serostim® 2 mg as subcutaneous injection on alternate days.
45756512|NCT01275859|Drug|Letrozole, Lapatinib|Letrozole 2.5mg po qd+ Lapatinib 1500mg po qd for 18-21 wks
45756513|NCT01950039|Drug|Betaine|Betaine or placebo administered orally in divided doses over 12 weeks
45756514|NCT01950039|Drug|Placebo|Placebo administered orally in divided doses over 3 months
45756515|NCT03409016|Other|Blood Testing|Patients will undergo therapy per standard protocol. There are no study-related medications or interventions beyond blood testing.
45444687|NCT03932019|Drug|Jitongning tablet(Low-dose )|Jitongning tablet,2tablets,bid,treat 12 weeks Jitongning tablet placebo,1tablet,bid,treat 12 weeks
45444688|NCT03932019|Drug|Placebo|Jitongning tablet placebo,3tablets,bid,treat 12 weeks
45756516|NCT01275937|Drug|Esomeprazole|Esomeprazole 40 mg IV daily is given for three days. Thereafter, the patients receive 40 mg Esomeprazole orally daily for two months.
45756517|NCT01275937|Drug|esomeprazole|esomeprazole 160 mg/day continuous infusion is given for three days. Thereafter, the patients receive 40 mg nexium orally daily for two months.
45756518|NCT03029793|Other|Biomarkers Testing|CRT resistance biomarkers will be detected before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
45756519|NCT03029793|Other|Functional Imaging analysis|The SUV value and texture parameters of 18F-FDG PET-CT as well as ADC values DWI-MRI will be measures before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
45756520|NCT04761926|Device|Audiometry|"Audiometry: Thresholds from the audiogram obtained when Ponto 4 were fitted. Pure tone air conduction (AC) and bone conduction (BC) audiometry conducted at the visit.~Speech recognition in quiet: Speech intelligibility is measured in a soundproof room using the Matrix sentences presented from a loudspeaker. The Matrix test includes five-word sentences with a fixed syntactical structure and limited contextual cues. A list of 20 sentences is compiled from these words, ensuring that no sentence is repeated twice. This test will be obtained both unaided and aided (with and without the Ponto 4(s)).~Sound field Audiometry: Detection of sound field thresholds presented from a loudspeaker. Thresholds will be obtained both unaided and aided and the test order will be balanced between subjects. During these measurements, the Ponto 4 will be programmed in omni-directional mode, with noise reduction and feedback management system turned off."
45756521|NCT02990455|Drug|Reduced nicotine cigarettes|Participants will be assigned to undergo two experimental conditions (i.e., exclusive smoking of RNC Low or Moderate in their home environment for 7 days) in a double-blind, randomized, crossover design. The two experimental conditions will be separated by a 7-day period of return to smoking of participants' own brand of cigarette.
45756522|NCT01889667|Drug|ORMD-0801 Dose # 1|Oral Insulin Formulation
45756523|NCT01889667|Drug|ORMD-0801 Dose # 2|Oral Insulin Formulation
45756524|NCT01889667|Drug|Placebo|Oil Capsules
45756525|NCT00711997|Biological|DTA-H19|Cohort #1: 4 mg DTA-H19 intratumorally 2 times per week for 2 weeks Cohort #2: 8 mg DTA-H19 intratumorally 2 times per week for 2 weeks
45603591|NCT02257372|Drug|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules will be issued throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline.
45603592|NCT00566657|Biological|riferminogene pecaplasmid|"Formulation: 5 ml glass vials containing 2,5 ml riferminogene pecaplasmid~Route: intramuscular (IM) injection of 2.5 mL in the ischemic leg to be treated"
45603593|NCT00566657|Biological|Placebo (for riferminogene pecaplasmid)|"Formulation: 5 ml glass vials containing 2,5 ml placebo~Route: IM injection of 2.5 mL in the ischemic leg to be treated"
45603594|NCT05059015|Diagnostic Test|CERVICAL HPV|A screening test with an HPV test is performed by a health professional plus cytology taking, if it reports positive, colposcopy and biopsy are taken, those with a CIN2 + report are directed to receive treatment.
45603595|NCT05059015|Diagnostic Test|SELF SAMPLING HPV|A screening test is performed with an HPV test by self-testing, if it reports positive, women will receive ablative treatment according to eligibility criteria. If they do not meet the criteria for ablation, they will be referred for excisional treatment.
45756526|NCT00712075|Behavioral|CBSST+PDA|PDA-Assisted Cognitive Behavioral Social Skills Training (CBSST+PDA) includes weekly group therapy sessions, each 90 minutes in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis. Participants utilized PDAs to assist with homework completion and compliance.
45756527|NCT00712075|Behavioral|Cognitive Behavioral Social Skills Training|Cognitive Behavioral Social Skills Training includes weekly group therapy sessions, each 2.5 hours (30 min lunch break) in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis.
45756528|NCT00712075|Behavioral|PDA-only|To control for the effects of having a PDA, a third group was provided PDAs for the same duration as the other two groups. Participants had access to the same basic functions (calendar, contact list, etc.) as the CBSST+PDA group, but did not have any homework or weekly group meetings.
45756529|NCT01891305|Drug|VT-1161|
45756530|NCT01891305|Drug|placebo|
45756531|NCT01276015|Drug|Botulinum Toxin Type A|BoNT-A (Dysport, Ipsen) ,into the medial gastrocnemius (MG) and LG muscles unilaterally on the affected spastic hemiplegic side; dose mean± SE, 283.3± 24.7 U.. The mean dose/kg injected was 14.4± 0.8, range from 8.5 to 20 U/kg, diluted in 2.5 ml saline. frequency: once.
45756532|NCT03830593|Procedure|Laparoscopic Adrenalectomy|minimally invasive lateral transperitoneal adrenalectomy
45756533|NCT01950663|Device|RETeval|RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy by measuring the response of the retina to a flash of light.
45603596|NCT05050747|Drug|hCG|endometrial injury by pipelle on day 8-9 of the same cycle of ovulation induction
45603597|NCT00566345|Biological|Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)|Trivalent, non-adjuvanted vaccine; dose: 0.5 ml
45603598|NCT00566345|Biological|Phosphate buffered saline|Packaged in syringes identical to those used for the investigational vaccine; dose: 0.5 ml
45603599|NCT02256982|Drug|Gemcitabine|
45603600|NCT02256982|Drug|Cisplatin|
45603601|NCT02256982|Procedure|Surgery|Surgical Resection and Lymphadenectomy
45603602|NCT02256982|Radiation|Radiation|Radiation Therapy
45603603|NCT05014867|Procedure|Embryo transfer method|"Sequential embryo transfer on day 3 and day 5 in a frozen cycle~Sequential embryo transfer on day 3 and day 5 in a fresh cycle~Sequential embryo transfer on day 3 and day 5 after performing PGS~Conventional Day 5 frozen embryo transfer"
45603604|NCT03476629|Other|Physical activity|Effects of different physical activity programs
45756534|NCT02130635|Drug|GSK2269557 100 MCG|100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
45756535|NCT02130635|Drug|GSK2269557 500 MCG|500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
45756536|NCT02130635|Drug|PLACEBO|Lactose administered using a matching dry powder inhaler device
45756537|NCT01276093|Procedure|PVI ablation|Pulmonary Vein Ablation using RF.
45756538|NCT01276093|Drug|Amiodarone|Amiodarone tablets
45756539|NCT03370185|Drug|Duvelisib|Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles
45444689|NCT02052076|Behavioral|Meal pattern|
45603605|NCT00492869|Drug|AEB071|
45756540|NCT01892007|Behavioral|Cogmed RM - Online adaptive working memory training|
45756541|NCT01892007|Behavioral|Cogmed RM - Online non-adaptive (placebo) working memory training|
45756542|NCT00725959|Behavioral|Online social networking HIV prevention|messages about HIV posted in online social networking sites
45756543|NCT02990143|Procedure|Ologen|Ologen® CM,a biodegradable scaffold matrix, induces a regenerative non-scarring wound healing process without using anti-fibrotic agents.
45756544|NCT00557973|Drug|XP19986 SR1, 10 mg BID|XP19986 Sustained Release (SR) 10 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
45756545|NCT00557973|Drug|XP19986 SR1, 20 mg BID|XP19986 Sustained Release (SR) 20 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
45603606|NCT04860154|Drug|Hematoporphyrin|Patients with negative skin test of hematoporphyrin Injection (3.0-5.0mg/Kg plus saline 250 mL intravenous drip, the drip was completed within 1 hour) and keep patients away from the light. The first PDT therapy was performed 24 hours after infusion of hematoporphyrin injection by ERCP. The biliary tumor necrosis was observed and the biliary tract was cleaned up 24 hours later and then PDT therapy showed again if necessary. Multiple plastic stents or bald metal stents will be placed. Follow up regularly after the procedure, PDT therapy would be given again in 3 months.
45603607|NCT03480607|Drug|Dexmedetomidine group|0.75 ml of 0.5% Bupivacaine in conjunction with 0.5 mcg/kg dexmedetomidine
45603608|NCT03480607|Drug|Dexamethasone group|0.75 ml of 0.5% Bupivacaine in conjunction with 0.1 mcg/kg dexamethasone
45603609|NCT00492323|Drug|placebo|twice daily for 4 weeks
45603610|NCT00492323|Drug|carisbamate|200 mg tablet twice daily for 4 weeks
45756546|NCT00557973|Drug|XP19986 SR1, 30 mg BID|XP19986 Sustained Release (SR) 30 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
45603611|NCT05646472|Diagnostic Test|Frailty multidimensional assessment|"Each Centre will administer SUNFRAIL frailty assessment tool to the enrolled older adults and, according to the specific alerts triggered by the answers provided, older adults will be subjected (at the same time or subsequently) to one or more validated in-depth tests (already included in the SUNFRAIL+ platform) in order to perform further diagnostic or dimensional evaluations.~During the observation phase, subjects will be given different health promotion activities, depending on the assessment.~During the follow-up phase, 6 months after enrolment, SUNFRAIL tool and in-depth tests will be administered again. In addition, during the follow up, the extent to which exposure to interventions has influenced the quality of life of older adults will be measured and the number of users enrolled by territorial services, based on user care needs. In addition, the level of satisfaction and usability of the SUNFRAIL+ solution by health and social care professionals will be measured."
45603612|NCT04954261|Diagnostic Test|CAPD|CAPD evaluation every day per 12hours during their stay in PICU
45756547|NCT00557973|Drug|Placebo|Placebo tablets to match active intervention, taken twice a day (BID) for approximately 26 days with titration and taper periods. Also taken during placebo washout periods.
45603613|NCT00489203|Drug|beclomethasone dipropionate|Given orally
45603614|NCT00489203|Drug|placebo|Given orally
45603615|NCT00489203|Drug|tacrolimus|Given after transplant
45911118|NCT02003794|Drug|0.9% NaCl solution|0.9% NaCl solution intravenous infusion: 100 ml/hr for three days.
45911119|NCT02003820|Behavioral|video modeled social story|Patient will watch a Youtube compatible video of a child in the same age range as the study participants demonstrating proper brushing technique. The video will be paired with written subtitles created using the Social Story format. The subtitles will be read to the participant as the video plays. The patient will watch the video immediately before each brushing session morning and night for the three week intervention. After the intervention period the video will be made available on Youtube.com for the participants to use as they wish.
45911120|NCT02003833|Device|Poly-L-lactic acid|Sculptra injections
45911121|NCT02003833|Device|Placebo comparator|saline injections
45911122|NCT02003872|Device|Spatz 3 intragastric balloon|Intra gastric balloon implanted using gastroscopy
45911123|NCT02003885|Drug|increment of desflurane|"After achieving stable hemodynamics and BIS 40-60 with desflurnae 0.5 MAC and remifentanil 0.7-1.0 mcg/kg/min (T1), data including S', E', A', EF, E, A and BIS are determined.~After 10 min exposure to the increased desflurane dosage 1.0 MAC (T2), data are determiend. After 10 min exposure to the increased desflurane dosage 1.5 MAC (T3), data are determined.~Reduction of BP is managed by the increment of phenylephrine infusion"
45911124|NCT02003937|Behavioral|Aerobic conditioning|Subjects performed 12 weeks of aerobic training on a stationary cycle ergometer. Subjects compleeted a total of 42 training sessions of 30min. exercise at an individually adjusted moderate workload.
46066581|NCT00933686|Drug|Placebo and Saizen®|Placebo matched to Saizen® will be administered for the first 6 months followed by treatment with Saizen® (Somatropin) 0.006 mg/kg subcutaneously daily for next 6 months. Saizen® dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 7 and 9.
45603616|NCT00489203|Drug|methotrexate|Given after transplant
45804010|NCT02360371|Drug|Within-subject test of blinded study medication|Within-subject double-blind, randomized, placebo-controlled, residential human abuse potential study. All participants received 4mg oral hydromorphone on study day 2 and a subset continued into the randomized portion for study days 3-5 wherein they received placebo, 2mg hydromorphone, and 8mg hydromorphone in randomized order. Only one dose was administered per day and following randomized all participants received each dose in random order. Outcomes were collected during 8-hour residential-based sessions and included metrics of FDA human abuse potential testing as well as secondary outcomes of laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition. Participants were genotyped for rs-1799971 status and results were analyzed as between-group comparisons based upon genotype.
45603617|NCT00489203|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo stem cell transplant
45603618|NCT03480529|Drug|drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom|Drugs susceptible to induce arthritis, lupus, hepatitis, or capillary leak syndrom
45603619|NCT05646394|Drug|Dual antiplatelet therapy|Aspirin plus any of clopidogrel, ticagrelor or prasugrel
45603620|NCT05646394|Drug|Combined antithrombotic therapy|Combination of a vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with low-dose aspirin.
45603621|NCT05646394|Drug|Vitamin K antagonist standard intensity|vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 2.0-3.0
45603622|NCT05646394|Drug|Vitamin K antagonist high intensity|vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 3.0-4.0
45603623|NCT00563459|Drug|carisbamate|400-1200 mg/day for 12 months
45603624|NCT00563459|Drug|topiramate|200-400mg/day for 12 months
45603625|NCT00563459|Drug|levetiracetam|1000-3000mg/day for 12 months
45603626|NCT04947631|Drug|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg once daily for 48 weeks
45603627|NCT04947631|Drug|Dutasteride|Dutasteride 0.5 mg once daily for 48 weeks
45603628|NCT04947631|Drug|Tadalafil|Tadalafil 5 mg once daily for 48 weeks
45603629|NCT04947631|Drug|DKF-313 placebo|Once daily for 48 weeks
45603630|NCT04947631|Drug|Dutasteride placebo|Once daily for 48 weeks
45603631|NCT04947631|Drug|Tadalafil placebo|Once daily for 48 weeks
45603632|NCT00561743|Drug|Bortezomib + pegylated liposomal doxorubicin HCl + dexamethasone|
45603633|NCT05068921|Drug|TQB2858 injection|TQB2858 is an anti-programmed death ligand 1（PD-L1）/transforming growth factor-β （TGF-β） bi-functional fusion protein.
45603634|NCT00488267|Drug|ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Transdermal patch applied to the knee for 12 hours daily.
45603635|NCT00488267|Drug|Placebo Matrix/CHADD Patch|Transdermal patch applied to the knee for 12 hours daily.
45603636|NCT00488267|Drug|Ketoprofen matrix/placebo CHADD Patch|Transdermal knee applied to the knee for 12 hours daily.
45603637|NCT00560183|Drug|Q8003 (morphine sulfate and oxycodone hydrochloride)|Capsules, four different mg dosage strengths
45603638|NCT00560183|Drug|Placebo|Capsules
45603639|NCT02736721|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a in doses between 90 and 450 mcg will be administered subcutaneously once weekly until medically indicated as judged by the treating investigator.
45603640|NCT00542633|Drug|VIAject™|Dosage as individually required
45603641|NCT00542633|Drug|Regular Human Insulin|Dosage as individually required
45603642|NCT02283983|Other|mittens and booties|
45603643|NCT02283983|Other|cooling helmet|
45603644|NCT00485225|Drug|EN3270|Transdermal Therapeutic System
45603645|NCT02523547|Drug|Cavir|0.5mg/day
45804011|NCT02362321|Drug|Dexamethasone|Patients received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
45804012|NCT02362321|Other|Placebo|Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
45804240|NCT05716568|Other|Contrast dose reduction, CT-angiography|Contrast dose reduction for CT-angiography in pre-operative aorta
45603646|NCT02523547|Drug|Baraclude|0.5mg/day
45603647|NCT00483977|Drug|Oxycodone|Oxycodone: oral controlled release, 20 mg, twice a day for 2 weeks
45603648|NCT00483977|Drug|Placebo|Placebo: oral for 2 weeks.
45603649|NCT00483977|Drug|PF-000592379|PF-00592379: oral, 30 mg, once a day for 2 weeks
45603650|NCT04891549|Procedure|Tension band fixation|Fracture fixation of the patella fracture with tension band.
45603651|NCT04891549|Procedure|Plate fixation|Fracture fixation of the patella fracture with a plate.
45603652|NCT00481325|Drug|pexacerfont|Tablets & Capsules, Oral, 300mg loading dose then 100 mg, once daily, 1 week loading dose then 8 weeks
45603653|NCT00481325|Drug|escitalopram|Tablets & Capsules, Oral, 10-20mg, once daily, 1 week loading dose then 8 weeks
45603654|NCT00481325|Drug|placebo|Tablets & Capsules, Oral, 0 mg, once daily, 1 week loading dose then 8 weeks
45603655|NCT04838431|Other|Blood sample and ultrasound at first trimester|The blood sample and the ultrasound are part of the routine care for the aneuploidy screening at first trimester. We deepened the biochemicals and biophysical markers for predicting the risk for large for gestational age infants
45603656|NCT04809025|Device|endoscopy|gastroscope
45603657|NCT04809025|Procedure|Surgery|radical gastrectomy
45603658|NCT00480701|Drug|[123I]-IBVM|Subjects will be asked to undergo an injection of 123-I IBVM followed by up to three approximately thirty minute SPECT scans during the next 24 hours.
45603659|NCT04803409|Device|Splenic Ultrasound|Splenic Ultrasound: Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care
45603660|NCT02523703|Biological|glutamate and aspartate|
45603661|NCT00542009|Drug|CE-326,597 100 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
45603662|NCT00542009|Drug|CE-326,597 50 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
45603663|NCT00542009|Drug|CE-326,597 25 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
45603664|NCT00542009|Drug|Placebo|Placebo to match CE-326,597 tablets to be administered orally, once daily with morning meal for duration of trial (84 days).
45603665|NCT00542009|Drug|CE-326,597 5mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
45603666|NCT03480451|Other|Multi-Disciplinary Patient Centered Rehab and Education|"This project is being withdrawn. No revisions to Intervention is available.~Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being"
45603667|NCT00539201|Drug|GSK706769|
45603668|NCT03480295|Device|Hyaluronic acid 0.4% and Taurine 0.5%|4 drops /day in addition to the ongoing glaucoma treatment
45603669|NCT03480295|Device|Hyaluronic acid 0.2%|4 drops /day in addition to the ongoing glaucoma treatment
45603670|NCT02282423|Behavioral|Pre-study dietary and exercise instruction.|All subjects will be instructed to continue their normal diet during the three days prior to study, to not consume alcohol the day before study, and to not engage in exercise for 48 hours before all studies.
45603671|NCT02282423|Procedure|Screening examination and oral glucose tolerance test|All subjects will have screening exam and OGTT at the Clinical Studies Infusion Unit at Mayo Clinic in Arizona at 7-8 am after having eaten nothing after 10 PM the night before, and have a screening examination and 75 g OGTT, as described
45603672|NCT02282423|Procedure|Euglycemic clamp|On a separate day, subjects will have a two-hour euglycemic clamp ((80 mU insulin/(m2.min)) at the Clinical Studies Unit at Mayo Clinic Arizona at 7-8 am after an overnight fast. A muscle biopsy will be taken before the insulin infusion, to serve as the resting biopsy (3). Biopsy specimens (150-300 mg) will be frozen immediately in liquid nitrogen and stored in liquid nitrogen until they are processed
45603673|NCT02282423|Procedure|VO2max.|VO2max.
45603674|NCT02282423|Behavioral|Acute exercise bout|The single acute exercise bout will be performed as described (3). It consists of 4 sets of 12 min each (8 min @ 70% VO2max, 2 min @ 90%, 2 min rest, repeat X 4). Biopsies are taken 30 min and 24 hr after end of exercise. Resting biopsies are taken on the glucose clamp day
45603675|NCT02282423|Procedure|Percutaneous needle muscle biopsies|Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing. We routinely obtain 150-300 mg muscle (wet weight), which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein, as described (2, 3, 12).
45603676|NCT02284061|Other|physical activities adapted to children|
45603677|NCT04379791|Other|Data collection from routine medical records|Data collection from routine medical records for criteria for fracture related infections (FRI) and for wound complications. Data collection from routine medical records for risk factors.
45603678|NCT00538343|Drug|berubicin hydrochloride (RTA 744)|
45603679|NCT04458025|Other|Standard rehabilitation program|Standard rehabilitation will start 4 weeks after surgery according to the standard of cre
45603680|NCT04458025|Other|Early rehabilitation program|Early rehabilitation program will start 2 weeks
45603681|NCT02282501|Other|enteral feeding by nasogastric tube.|method of administration enteral feeding by nasogastric tube.
45603682|NCT03476395|Other|shoulder range of motion in IR/ER, strength of the IR/ER muscles and Scapular Dyskinesis Test. Core endurance test.|Passive shoulder range of motion using a digital application Clinometer. Isometric strength of the shoulder IR/ER using a HHD measured. Scapular Dyskinesis Test uses a visual scoring system. Core Endurance is teste by measuring the time (s).
45603683|NCT00473525|Drug|Placebo|Placebo QD
45603684|NCT00473525|Drug|PF-00734200 10 mg QD|10 mg QD
45603685|NCT00473525|Drug|PF-00734200 20 mg QD|20 mg QD
45603686|NCT00473525|Drug|PF-00734200 5 mg QD|5 mg QD
45603687|NCT00473525|Drug|PF-00734200 2 mg QD|2 mg QD
45603688|NCT03472963|Drug|Single dose of Genvoya® and a single 800 mg dose of Darunavir®|Men will be instructed to take Single dose of Genvoya® and a single 800 mg dose of Darunavir® per oral
45603689|NCT02523079|Behavioral|Cognitive Behavioral Group Therapy for Insomnia|
45603690|NCT02523079|Behavioral|Cognitive Behavioral Self-help Therapy for Insomnia|
45603691|NCT02523079|Behavioral|Sleep Hygiene Guidance|
45603692|NCT02282579|Drug|Pazopanib|Non interventional study
45603693|NCT02282657|Device|ECCO2R will be initiated during the 2-hour run-in time|"A single (15.5 to 19 Fr) veno-venous ECCO2R catheter will be inserted percutaneously (jugular vein strongly suggested).~Catheters should be rinsed with heparinized saline solution before insertion Once the catheter has been inserted each line will be filled with an heparinized saline solution before its connection to the extracorporeal circuit The ECCO2R circuit will be connected to the catheter and blood flow set, depending on the device, up to 1000 mL/min.~Initially, sweep gas flow through the ECCO2R device will be set at zero (0 LPM) such as to not initiate CO2 removal through the device.~Anticoagulation will be maintained with unfractionated heparin to a target aPTT of 1.5 - 2.0X baseline. A bolus of heparin is suggested at the time of cannulation."
45804013|NCT05719376|Drug|Monofer (experimental)|Monofer 200mg : OP-28day, OP-21day, OP-7day, OP day, POD #7 IV injection, Mircera 120mcg SQ : OP-7 day~OP-1day
45756548|NCT04507685|Other|Lifestyle (Diet and Exercise)|"The LG diet will comprise 20% carbohydrate, 30% protein, and 50% fat (<10% saturated fat). It will have a low glycaemic load; include plant and animal protein; non-starchy vegetables and salad greens; and some low-sugar fruit. Participants will be encouraged to incorporate a variety of foods rich in monounsaturated and polyunsaturated fats in their diet.~The control diet will comprise 50% carbohydrate, 20% protein and 30% total fat (<10% saturated fat). It will reflect the Health Promotion Board's (HPB) recommendations to reduce dietary fat, emphasize wholegrains and include a variety of fruits and vegetables. In contrast to the LG diet, the control diet will have a higher glycaemic load with a greater proportion of energy derived from unrefined carbohydrate foods.~Concurrent to the dietary intervention and consistent with physical activity guidelines, all participants will undertake a 60-min structured exercise program incorporating aerobic/ resistance exercises 3-4 days/week."
45756549|NCT00790049|Drug|ARRY-371797, p38 inhibitor; oral|single dose and multiple dose, escalating
45603694|NCT02282657|Other|Neuromuscular blocking agents (NMBA)|Patients will receive NMBA starting in the run-in period and continued for the first 24 hours and thereafter will be directed by the attending physician
45603695|NCT02282657|Device|Ventilation|Following the 2-hour run-in time, VT will be reduced gradually to 5 mL/kg. Sweep gas initiated then VT decreased to 4.5 then 4 mL/kg and PEEP adjusted to reach 23 ≤ Pplat ≤ 25 cm H2O.
45603696|NCT02282657|Other|Level of carbon dioxide released at the end of expiration|EtCO2 will be monitored for safety purposes. Blood gases will be analyzed 20-30 minutes after each VT reduction
45603697|NCT02282657|Other|Respiratory Rate|RR will be kept what it was at baseline
45603698|NCT02282657|Other|Sweep gas flow|Sweep gas flow will be adapted to maintain the same EtCO2
45603699|NCT02282657|Other|Ventilation will be adapted|If PaCO2> 75 mmHg and/or pH < 7.2, despite respiratory rate of 35/min and optimized ECCO2R, VT will be increased to the last previously tolerated VT.
45603700|NCT02282657|Other|Respiratory rate will be adapted|If PaCO2 remains within the target range, respiratory rate will be progressively decreased to a minimum of 15/ min and facilitated by increases in sweep flow.
45603701|NCT04216381|Diagnostic Test|Trauma Specific Frailty Index Questionnaire|questionnaire to assess patient's pre-injury health condition
45603702|NCT00465959|Drug|trospium chloride inhalation powder (TrIP)|
45603703|NCT00465959|Drug|Placebo|
45603704|NCT00465803|Drug|Travoprost 0.004%/timolol 0.5% ophthalmic solution|One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months using the Dosing Aid
45603705|NCT00465803|Drug|Travoprost ophthalmic solution, 0.004%|One drop in the study eye(s) once daily at 8 PM for twelve months using the Dosing Aid
45603706|NCT00465803|Drug|Timolol maleate ophthalmic solution, 0.5%|One drop in the study eye(s) once daily at 8 AM or twelve months using the Dosing Aid
45603707|NCT04176445|Device|Orthostatic board posture|Patients will be verticalized at at 45º, 60º and 80º using an orthostatic board. The total posture protocol will last 30 minutes
45603708|NCT04176445|Other|Bedside sitting posture|Patients will be placed at the bedside, with support for the back and upper limbs. They will be kept at 90º of hip and knee flexion and feet supported. The total posture protocol will last 30 minutes.
45603709|NCT02282891|Drug|Propofol|Induction of general anesthesia using propofol 2mg/kg
45603710|NCT02282891|Drug|Propofol-Ketamine|Induction of general anesthesia using a mixture of 1.5 mg/kg:0.75 mg/kg propofol/ketamine
45756550|NCT00790049|Drug|Placebo; oral|matching placebo
45756551|NCT01892865|Other|Scheduling using historical means|Scheduling will be performed taking into account historical means only for anesthetic, operative, and turn around time
45756552|NCT01892865|Other|Scheduling using regression modeling system|A regression model that uses predictor of operative length will be used to predict operative, anesthetic, and turn around time length
45756553|NCT01668563|Procedure|surgical management|Surgical clipping will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these non-ISAT aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
45603711|NCT00464633|Drug|alvocidib|"1st dose: 30 mg/m2 as a 30-minute intravenous (IV) infusion followed by 30 mg/m2 as a 4-hour continuous infusion~Then, every treatment week, depending upon the patient's objective response to initial therapy:~30 mg/m2 over 30 minutes followed by 50 mg/m2 over 4 hours or~30 mg/m2 over 30 minutes followed by 30 mg/m2 over 4 hours."
45603712|NCT03479983|Dietary Supplement|AMX160|500 mg Phyllanthus emblica L. fresh fruit extract capsules
45603713|NCT03479983|Dietary Supplement|Placebo|500 mg roasted rice powder in visually identical capsules
45603714|NCT00464555|Procedure|Islet transplant|Transplantation of pancreatic islet cells
45603715|NCT00464555|Drug|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
45603716|NCT00464555|Drug|Basiliximab|Will replace antithymocyte globulin in all islet transplantations after the first one
45603717|NCT00464555|Drug|Lisofylline|An anti-inflammatory that may reduce the rate at which islet cells die.
45603718|NCT00464555|Drug|Sirolimus|Maintenance immunosuppressive therapy
45603719|NCT00464555|Drug|Tacrolimus|Maintenance immunosuppressive therapy
45603720|NCT03476161|Device|3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive. 4069-6103 / 4069-6114 / 4069-6203 / 4069-6214|One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
45603721|NCT03476161|Device|3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive. 3069-6103 / 3069-6114 / 3069-6203 / 3069-6214|One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
45603722|NCT03479749|Device|RegenoGel-OSP, RegenoGel|RegenoGel-OSP (A) and RegenoGel (B) are visco-supplements intended for the intra-articular treatment of OA.
45603723|NCT00464243|Drug|volinanserin|oral administration
46066582|NCT04078048|Dietary Supplement|Antioxidants (Vitamin C, E )|For eight weeks, Vitamin C group was intervened with tablet vitamin c 500 mg once a day ,vitamin E group was intervened with Tablet vitamin E 600 I U twice a day.
46066583|NCT04079998|Device|Procellera®|Application of Procellera® dressing.
45603724|NCT00464243|Drug|placebo|oral administration
45603725|NCT02283047|Behavioral|DIET|Lifestyle intervention through hypocaloric diet
45603726|NCT02283047|Behavioral|DIET & MODERATE CONTINUOUS TRAINING|Lifestyle intervention through hypocaloric diet and exercise at moderate intensity (60-80%peakHR) continuous mode, and high volume (45 min).
45603727|NCT02283047|Behavioral|DIET & HIGH VOLUME HIIT|Lifestyle intervention through hypocaloric diet and exercise at high intensity (80-95%peakHR) interval mode, and high volume (45 min).
45603728|NCT02283047|Behavioral|DIET & LOW VOLUME HIIT|Lifestyle intervention through diet and exercise at high intensity (80-95%peakHR) interval mode, and low volume (20 min).
45603729|NCT03336541|Drug|Ketamine|Ketamine (0.5 mg/kg in 100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.
45603730|NCT03336541|Drug|Placebo|Placebo (100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.
45603731|NCT03472729|Other|AGE-ON Workshop|Series of workshops to reduce social isolation through technology use.
45603732|NCT00525941|Drug|NBI-34060|10 mg capsules; dosed as needed for falling back asleep after a bothersome awakening provided there are at least 4 hours remaining in bed; no more than one dose per night.
45603733|NCT03476083|Drug|Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.|All mothers will receive TDF therapy. However, group A will initiate TDF at the gestational week of 14-16, while group B will initiate TDF at the gestational week of 28. All infants will receive a series of three hepatitis B vaccines (at birth, age of weeks 4 and 24). In addition, the infants in the group B will receive HBIg injection at birth.
45603734|NCT02284139|Drug|Arm EGF ointment 1ppm|EGF Ointment 1ppm evenly apply to skin lesion every 12 hr/ day
45603735|NCT02284139|Drug|Arm EGF ointment 20 ppm|EGF Ointment 20 evenly apply to skin lesion every 12 hr/ day
45603736|NCT02284139|Drug|Arm Placebos|EGF Ointment 0ppm evenly apply to skin lesion every 12 hr/ day
45603737|NCT02738203|Drug|Vaginal 2% Lidocaine|Patient-administered vaginal Lidocaine jelly verse surgical lubricant jelly
45603738|NCT02738203|Drug|Surgical Lubricant Jelly|Patient-administered vaginal surgical lubricant jelly verse Lidocaine jelly
45603739|NCT02284217|Device|EVD|ICP monitoring will be done in parallel for both HS-1000 and ICP monitoring via an EVD device (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals will last from 30 minutes to 6 hours, continuously depending on the patient's clinical condition. Each such interval may occur three times a day or more depending on the clinical condition of the patient.
45603740|NCT03479359|Behavioral|Routine review of DRE results by attending doctors|Let the internship regularly compare DRE result and the pathology outcome of prostate biopsy of each patient.
45603741|NCT00519389|Biological|H5N1 VLP Vaccine|Two doses - Day 0 & Day 28
45603742|NCT00519389|Biological|Placebo|Two doses - Day 0 & Day 28
45603743|NCT04459429|Device|Change of cannula size|During nasal High Flow Therapy with fixed flow of 8 l/min, the cannula size will be changed from smaller-to-larger or larger-to-smaller
45603744|NCT00458861|Biological|BG9924|Subcutaneous administration of BG9924 given every other week for 12 weeks
45603745|NCT00458861|Other|Placebo Comparator|Subcutaneous administration of placebo given every other week for 12 weeks
45804014|NCT05719376|Drug|control group|Ferritin<100, TSAT<20 : Monofer 200mg IV, twice/ Ferritin 100~200, TSAT<20 : Monofer 200mg IV, once / Ferritin 201~500, TSAT<20 : Monofer 100mg IV, once / Not administer in any other case
46066584|NCT04079998|Other|Standard of Care|Application of standard of care dressings as prescribed.
45603746|NCT00457457|Drug|Tamsulosin|Tamsulosin hydrochloride capsules, 0.4 mg. Tamsulosin hydrochloride is an antagonist of alpha1A adrenoceptors in the prostate
45603747|NCT00457457|Drug|UK-369,003|UK 369,003 is a highly selective and potent inhibitor of PDE5. It has increased selectivity for PDE5 over PDE6 (>80 fold) compared to sildenafil (~10 fold). Two recently completed trials have shown efficacy for UK-369,003 in treating subjects with ED
45603748|NCT04459039|Drug|1000 mL 0.9% sterile saline|Within 12 h of surgery, the experimental group received 1000 mL 0.9% sterile saline intravenously.
45603749|NCT04459039|Drug|250 mL 0.9% sterile saline|Within 12 h of surgery, the control group received 250 mL 0.9% sterile saline intravenously.
46066585|NCT05379140|Behavioral|Three Weekly Therapeutic Chinese Massage Sessions|Participants in the therapeutic Chinese massage group received three weekly 25-minute therapeutic Chinese massage sessions. The intervention included acupressure to points along the distal lower extremity acupuncture points of the Gall Bladder Channel (GB 40 and then 34). Further Chinese Massage incorporates kneading, rolling, movement of the ankle, rotating, pulling, and scrubbing to the lower extremity.
46066586|NCT05379140|Behavioral|Three Weekly Placebo Massage Sessions|The placebo massage group received three weekly 25-minute placebo massage that included gentle rubbing to the foot and toes without point stimulation or other techniques of Chinese Massage. The control group had the opportunity to receive the treatment after the study was completed.
45603750|NCT02958007|Behavioral|Peer Education on Exercise for Recovery|A 24-week group-based peer coaching intervention delivered by a VA Peer Specialist, to promote participation in a supervised fitness training program and general physical activity
45756554|NCT01668563|Procedure|Endovascular management|Endovascular treatment will also be performed as soon as possible following randomization,according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents or flow-diverters, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
45756555|NCT03309033|Procedure|Biospecimen Collection|Undergo collection of blood samples
45756556|NCT03309033|Other|Questionnaire Administration|Complete questionnaire
45756557|NCT00726739|Biological|aldesleukin|IL-2 Alone - administer 10 x 10^6 International Units subcutaneously (SQ) will be given on day 1 and day 2 every 4 weeks until disease progression or for a maximum of 12 treatment cycles.
45756558|NCT00726739|Biological|allogeneic large multivalent immunogen vaccine|Allogeneic tumor cell membrane-coated large multivalent immunogen (LMI [1 x 10^7, 5-μm silica spheres]) will be given as an intradermal injection every 4 weeks for up to 12 injections. Each vaccine dose will be 0.2 ml.
45603751|NCT02958007|Behavioral|Enhanced supervised fitness training|A 24-week intervention to promote participation in a supervised fitness training program and general physical activity, which includes individual support from non-peer staff
45603752|NCT03476005|Behavioral|proficiency based progression training|proficiency based progression training supported by technology enhanced learning
45603753|NCT00517439|Drug|Copegus|1000/1200mg po daily for 24 weeks
45603754|NCT00517439|Drug|Pegasys|180 micrograms sc weekly for 24 weeks
45603755|NCT00517439|Drug|Pegasys|90 micrograms sc weekly for 24 weeks
45603756|NCT00517439|Drug|RO4588161|1000mg po bid for 24 weeks
45603757|NCT00517439|Drug|RO4588161|500mg po bid for 24 weeks
45756559|NCT00569309|Biological|Streptococcus pneumoniae|Patients will receive 0.5 mL Prevnar in the deltoid muscle during weeks 9, 17, and 25 after autologous hematopoietic stem cell transplantation (HSCT)
46066587|NCT05408962|Other|Blood and urine collection, anthropometric analysis and answering to questionnaires|During the visit to the recruitment center, participants will sign an informed consent. They will have to be in fasting condition for blood and urine collection. In addition they will answer the lifestyle questionnaire and the Food Frequency Questionnaire and will be submitted to an anthropometric analysis and evaluation of blood preassure and heart rate.
45444690|NCT03810963|Combination Product|HIIT-FES Cycling combined with Nutritional Counseling|High intensity interval training functional electrical stimulation cycling for 30 minutes, three days per week for eight weeks, Nutritional counseling over the telephone for 30 minutes once per week for eight weeks.
45603758|NCT00517439|Drug|RO4588161|1500mg po bid for 24 weeks
45603759|NCT02724085|Drug|TP-271|TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
45603760|NCT03472651|Drug|test treatment: flupentixol/melitracen|0.5 mg flupentixol and 10 mg melitracen, film-coated tablet, single dose
45756560|NCT00569309|Other|laboratory correlative studies|Approximately 30-mL of blood will be collected and sent to the appropriate research lab(s) for processing.
45756561|NCT00569309|Other|quality-of-life assessment|Responses to Hospital Anxiety and Depression Scale, 9-item brief fatigue inventory 57, brief pain inventory, and the FACT-G. This should take each patient approximately 10-15 minutes to fill out all these surveys per instance.
45756562|NCT01952301|Device|Xenogeneic Collagen Matrix|A type I and III porcine collagen matrix, as cleared by FDA (K012423)
45756563|NCT01952301|Device|Free Gingival Graft|Autogenous, full-thickness soft tissue graft harvested from patient's palate.
45603761|NCT03472651|Drug|reference treatment: flupentixol/melitracen|0.5 mg flupentixol and 10 mg melitracen, coated tablet, single dose
45603762|NCT05204849|Device|IRRAflow|Ventriculostomy using IRRAflow with active irrigation and aspiration
45603763|NCT05204849|Procedure|Standard ventriculostomy|Standard passive external ventricular drainage
45603764|NCT03131557|Device|Line extension of the Phonak Audéo B product family|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
45756564|NCT04470089|Drug|Myramistin|Oromucosal application
45756565|NCT00714571|Behavioral|Mnemonic strategy training (MST)|
45756566|NCT00714571|Behavioral|Repeated exposure (XP)|
45756567|NCT00714571|Behavioral|Subtracting Cues training|
45756568|NCT00569855|Drug|Phenoxybenzamine|0.125 to 1 mg/kg given i.v. over 15 to 45 minutes in preparation for cardiopulmonary bypass; may be continued at 0.125 mg/kg/day in ICU
45804015|NCT02413879|Device|CleanCision|Wound protection during colorectal surgery.
45444691|NCT03810963|Other|Nutritional Counseling Only|Nutritional counseling over the telephone for 30 minutes once per week for eight weeks.
45444692|NCT02052154|Biological|Prime-boost pneumococcal immunization|2 months between the 2 vaccines
45603765|NCT03131557|Device|Phonak Audéo B|Phonak Audéo B will be fitted to the participants individual hearing loss.
45603766|NCT03475927|Other|Concerning and knowledge about radiation hazard questionnaire|Concerning and knowledge about radiation hazard questionnaire to determine the concerning and knowledge of radiation hazard among surgeon and anesthesiologist
45603767|NCT00517049|Drug|PRO95780|Intravenous repeating dose
45603768|NCT00517049|Drug|rituximab|Intravenous repeating dose
45603769|NCT03479125|Diagnostic Test|Ultrasound|Subjects will be observed to estimate the adjusted event rate for hepatocellular carcinoma with or without cirrhosis previously treated with emricasan or placebo.
45603770|NCT00514865|Drug|ONO-2333Ms|5-10 mg QD for 8 weeks
45603771|NCT00514865|Drug|ONO-2333Ms|0 mg QD for 8 weeks
45603772|NCT00514865|Drug|ONO-2333Ms|1-2 mg QD for 8 weeks
45804016|NCT05718908|Dietary Supplement|Food supplement|FibrofixPlus® is an authorized food supplement.
45804241|NCT02959268|Device|Al-Sense|Liner for diagnosis of amniotic fluid leakage verified by standard clinical diagnostic tests
45804242|NCT00356005|Drug|azithromycin plus artesunate|
45804243|NCT00356005|Drug|Artesunate|
45603773|NCT02283203|Drug|APOTEL max|The study drug is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein.
45603774|NCT02283203|Drug|Placebo|Placebo is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein. Placebo contains water for injection and inactive vehicles.
45603775|NCT02536183|Device|Magnetic resonance high intensity focused ultrasound|Magnetic resonance (MR)-high intensity focused ultrasound (HIFU) provides precise controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator that is completely non-invasive and non-ionizing.
45603776|NCT02536183|Drug|Lyso-thermosensitive liposomal doxorubicin|A heat-activated formulation of liposomal doxorubicin with unique property of heat-activated release of doxorubicin, an active agent in most pediatric solid tumors.
45603777|NCT00448721|Drug|Perifosine|Perifosine will be administered orally at 100mg PO daily with food.
45756569|NCT02991781|Other|Biofeedback and Neurofeedback Training|The protocol will consist of 5 sessions of skin temperature biofeedback and 20 sessions of a neurofeedback training protocol that will consist of Alpha-Theta ratio up-training. The aim of the training is to reach a crossover state, were initially Alpha activity will increase and then in a deeper state, the Theta activity will take over. This state is associated with a reverie and disidentification with problems, stress or traumatic experiences. Therefore, the subjects will learn how to increase their Theta/Alpha ratio.
45603778|NCT02523313|Drug|Nivolumab + Placebo|Nivolumab will be applied at a dose of 3 mg/kg given as IV infusion every 2 weeks for up to 1 year after initial dosing or until PD + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10.
45603779|NCT02523313|Drug|Nivolumab + Ipilimumab|Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) will be applied as IV infusion every 3 weeks for 4 doses. Both study drugs are to be administered on the same day over the first 12 weeks + Nivolumab-Placebo on weeks 3, 5, 9 and 11. After week 12 Nivolumab is given as maintenance and will be applied at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
45756570|NCT02991781|Drug|Varenicline use for smoking cessation|The protocol will consist 1 mg varenicline use twice daily following a 1-week titration for 3 months.
45756571|NCT02991781|Other|Sham Neurofeedback|Subjects will receive equal sessions of sham neurofeedback, and thus serve as a control group for the analysis and design of the study.
45756572|NCT02991781|Other|Passive Control|Subjects will not receive any intervention, but they will be measured via a clinical and psychometric evaluation with a time-difference of 3 months. This is equal to the intervention time. Hence, the subjects in this intervention type will serve as a control group for the analysis and design of the study.
45911125|NCT02003950|Other|Snack Condition Specification|Individuals recieve a different snack for every week of the study. This is viewed as 4 phases. Phase 1 measures of habitual chocolate candy consumption (1 week), Phase 2 assesses participants' chocolate consumption while anticipating an oncoming chocolate candy restriction (1 week), Phase 3 is the total chocolate candy restriction period, but participants will be given 3 non-chocolate-candy snack substitutes in a random order (1 week per snack type, 3 weeks total), and Phase 4 examines participants' chocolate candy consumption when the 3-week restriction is lifted (1 week).
46066588|NCT04445896|Other|Qualitative Interview|Qualitative Interview to explore thoughts and feelings related to previous discussions around care at end of life
45603780|NCT02523313|Drug|Double Placebo Control|Placebo instead of Nivolumab and Placebo instead of Ipilimumab will be applied as IV infusion every 3 weeks for 4 doses. Both placebos are to be administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab is given as maintenance and will be applied intravenously every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
45603781|NCT02452034|Drug|Posaconazole IV solution|Posaconazole by IV solution twice on Day 1, then once daily on Days 2-10.
45603782|NCT02452034|Drug|Posaconazole powder for oral suspension|Posaconazole once daily by PFS for a minimum of 10 days
45603783|NCT04471103|Other|Participation in a Delphi survey|Participants will be asked to participate in an online Delphi survey (using one of two randomly allocated methods) to rate the importance of outcomes that should be measured to determine the effect of treatment for neonatal encephalopathy. Outcomes will be prioritised on their importance in a consensus-driven manner.
45603784|NCT02283359|Drug|Selinexor|Selinexor is a potent slowly reversible covalent Selective Inhibitor of Nuclear Export (SINE) that specifically blocks the karyopherin protein Exportin 1 or XPO1.
45603785|NCT02283359|Drug|Irinotecan|Irinotecan is a topoisomerase inhibitor and is approved by FDA to treat colorectal cancer. It is administered intravenously.
45756573|NCT01893801|Drug|nab-paclitaxel|25 mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
45756574|NCT01893801|Drug|Cisplatin|25mg/m2 (or 50mg/m2) given intravenously (IV) on days 1 and 8 of a 21 day cycle
45911126|NCT02003989|Other|ophthalmologic examination and MRI|thorough investigation of patients, not included in usual care.
46066589|NCT02729974|Procedure|ROTEM|rapid testing of blood clot formation
45603786|NCT02284295|Other|exposure to respirable silica dust|History of exposure to respirable silica dust due to job
45603787|NCT02284295|Other|exposure to aromatic hydrocarbons|history of exposure to aromatic hydrocarbons due to job
45603788|NCT02284451|Other|Video or Pictorial Brochure|Participants will receive HIV/AIDS and HIV testing information by video or by pictorial brochure according to patient health literacy level (lower or higher) and language (English or Spanish).
45756575|NCT01893801|Drug|gemcitabine|1000mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
45756576|NCT00570089|Drug|Ranolazine|500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
45804244|NCT00376337|Drug|Micafungin|IV
45804245|NCT00376337|Drug|Systemic antifungal therapy|IV
46066590|NCT02729974|Procedure|standard treatment|visual assessment of blood loss and clotting function every 30 minutes, combined with standard laboratory testing when indicated
46066591|NCT00937040|Drug|OROS MPH|Optimal Patient Dose (18 mg-72 mg) once daily for 6 weeks
45911127|NCT02004002|Behavioral|Weight maintenance with normal protein intake|Control group will consume 1.4 g/kg/d of protein; consistent with the average protein intake in the US population.
45911128|NCT02004002|Behavioral|Weight maintenance with protein restriction|Protein restriction group will receive the Institute of Medicine RDA of 0.8 g protein/kg body wt/d.
45603789|NCT00513617|Drug|Arginine|Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
45603790|NCT00513617|Drug|Placebo|Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
45603791|NCT00511043|Drug|PTK787|PTK787 - 1250mg p.o. daily. Initial dose of 750mg p.o daily starting on day 1 and increased weekly to an intermediate dose of 1000 mg and then a target dose of 1250mg unless a grade ≥ 2 toxicity. Patients who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or patient non-compliance with the protocol requirement.
45911129|NCT02004015|Drug|injection of placebo|0.5 mg/kg milligram(s)/kilogram
45911130|NCT02004015|Drug|injection of NMBA|
45603792|NCT00508625|Drug|AMG 951 (rhApo2L/TRAIL)|AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5).
45911131|NCT02004028|Drug|VS-6063|
45603793|NCT00508625|Drug|Bevacizumab|Bevacizumab is a recombinant humanized version of a murine antibody to vascular endothelial growth factor (VEGF).
45603794|NCT00508625|Drug|Carboplatin|Standard platinum based chemotherapy
45911132|NCT02004041|Drug|VLY-686|capsules containing 50 mg VLY-686
45603795|NCT00508625|Drug|Paclitaxel|Standard taxane chemotherapy
45603796|NCT02284529|Drug|Orectalip|Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1
45603797|NCT02482298|Drug|Ticagrelor|Two arms: 1) 10 mg ticagrelor + 45 mg ticagrelor placebo or 2) 45 mg ticagrelor + 10 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening, at least 12 hours apart) from randomization until the end of treatment.
45603798|NCT02482298|Drug|Placebo|10 mg ticagrelor placebo + 45 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening at least 12 hours apart) from randomization until the end of treatment
45603799|NCT02284607|Drug|MHAA4549A|MHAA4549A single, intravenous dose administration, lower dose level
45603800|NCT02284607|Drug|MHAA4549A|MHAA4549A single, intravenous dose administration, higher dose level
45603801|NCT02284607|Drug|Placebo|Matching placebo to MHAA4549A administration
45603802|NCT02286479|Procedure|Incision and Drainage|In the incision and drainage group, the abscesses are incised, irrigated by sterile solutions and drained conventionally.
45911133|NCT02004041|Drug|Placebo|Sugar capsule to mimic VLY-686 50 mg capsule
45603803|NCT02286479|Procedure|Loop drainage|In the loop drainage group, two small incision are made on each side of abscess. The pus are drained and septations are seperated by a forceps. Abscess cavitary irrigated by sterile solution. Sterile, non-powder, non-latex surgical gloves cuff is inserted in one incision and taken out from the other insicion. Then two tips of cuff are tied loosely.
46066592|NCT00937040|Drug|Placebo|Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily for 6 weeks
45603804|NCT04470479|Drug|Pilocarpine Hydrochloride|Oral pilocarpine hydrochloride 5mg tablets were administered four times a day for 10 weeks to half the group of selected patients. The other half ingested placebo in the same way. At the end of this period and after two weeks of washing out the medications, the patients had to invert the treatments.
45603805|NCT04470479|Drug|Placebo|Placebo
45603806|NCT02286557|Drug|Methelphenidate|All participants will undergo 4 weeks of treatment with Methelphenidate and 4 weeks of placebo
45603807|NCT02286557|Drug|Placebo|
45603808|NCT00385697|Drug|Teplizumab|IV dosing daily for 14 days times 2 courses
45603809|NCT00385697|Other|Placebo|IV dosing daily for 14 days times 2 courses
45603810|NCT00383513|Biological|Epratuzumab|360 mg/m^2 four consecutive 12-week maintenance cycles beginning with 2 consecutive weekly administrations each lasting ≤ 1 hour
45603811|NCT00382811|Drug|phenoxodiol|400mg phenoxodiol three times daily in 28 day cycles.
45603812|NCT00382811|Drug|carboplatin|AUC=2 weekly in 28 day cycles
45603813|NCT00382811|Drug|placebo|every 8 hours daily in 28 day cycles
45603814|NCT02286635|Drug|Deflazacort and rifampin|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21-desacetyldeflazacort (21 desacetyl-DFZ). The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone. Rifampin is a potent inducer of drug metabolism by inducing a variety of hepatic and intestinal CYP enzymes, especially CYP3A4. Rifampin is a semi-synthetic antibiotic.
45804246|NCT05716490|Device|Incisional negative pressure wound therapy|Application of negative pressure wound therapy for prophylaxis of surgical site occurrences
45804247|NCT05716490|Other|Control group - standard wound dressing|Covering of surgical wound with standard wound dressing
45911134|NCT02004054|Other|measure of pupil diameter|The measure will use infra-red cameras
45911135|NCT02004067|Drug|Restasis|Restasis is an ophthalmic emulsion containing cyclosporine 0.5 mg/mL, produced by Allergan Inc.
45911136|NCT02004067|Drug|Refresh Endura|Refresh Endura is a topical lubricant produced by Allergan, Inc.
45911137|NCT02004106|Drug|RO6895882|Participants will receive RO6895882 at different dose levels and schedules defined in respective arms as IV infusion.
45911138|NCT02004119|Drug|KHK4577|
45911139|NCT02004119|Drug|Placebo|
46066593|NCT00937040|Drug|OROS MPH Tablets|Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
45603815|NCT02286635|Drug|Deflazacort and Clarithromycin|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects. It is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone. Clarithromycin is a semi-synthetic macrolide antibiotic. Clarithromycin is active in vitro against a variety of aerobic and anaerobic gram-positive and gram-negative bacteria as well as most mycobacterium avium complex (MAC) bacteria. Additionally, the 14-OH clarithromycin metabolite also has clinically significant antimicrobial activity. Clarithromycin is indicated for the treatment of mild to moderate infections such as pharyngitis/tonsillitis.
45603816|NCT00440531|Biological|Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB™ (currently licensed product) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
45603817|NCT00440531|Biological|Comparator: Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
45603818|NCT00440531|Biological|Comparator: ENGERIX-B™ (currently licensed product)|ENGERIX-B™ given IM (Intramuscular) in 3 doses of 20 mcg (micrograms)/1.0 mL each over 6 months.
45603819|NCT02286791|Behavioral|Mindful Awareness Program|For Mindful Awareness Program, 40-minutes weekly sessions for 12 weeks, followed by 40-minutes monthly for 6 months. The mindful awareness practice techniques to be taught to the elderly include: (1) mindfulness of the senses practice; (2) the body scan practice; (3) walking meditation practice; (4) 'movement nature meant' practice; and (5) visuo-motor limb tasks
45603820|NCT02286791|Behavioral|Health Education Program|"For the Health Education Program, weekly sessions of 40 minutes for 12 weeks, followed by monthly sessions of 40 minutes for 6 months.~Week 1: Diabetes Mellitus Week 2: Hypertension Week 3: Home Safety Week 4: Medications Week 5: Diet Week 6: Depression Week 7: Dementia Week 8: Anxiety Week 9: Sleep Week 10: Exercise Week 11: Coping with bereavement Week 12: Social support"
45603821|NCT00380159|Drug|elvucitabine|elvucitabine 10 mg in combination with background ART
45603822|NCT00380159|Drug|Lamivudine|
45603823|NCT00380159|Drug|Emtricitabine|
45603824|NCT00437021|Drug|Placebo (subcutaneous)|0.9 percent (weight/volume) sodium chloride injection, United States Pharmacopeia [Sterile Saline Placebo (SSP)].
45603825|NCT00437021|Drug|Placebo (scarification)|Physiologic normal saline for injection.
45603826|NCT00437021|Biological|Dryvax®|Dryvax® Vaccinia Vaccine (~10^5 [plaque forming units (pfu)/dose] given via scarification, titer 10^8 pfu per mL after reconstitution).
45603827|NCT00437021|Biological|IMVAMUNE®|IMVAMUNE® Vaccinia Vaccine delivered by subcutaneous (SC) route at titer 1X10^8 Tissue Culture Infections Dose50 per 0.5 mL dose.
45603828|NCT00375791|Drug|perifosine|100 - 150 mg daily
45603829|NCT00375791|Drug|dexamethasone|20 mg twice weekly
45603830|NCT00375401|Drug|CP-945,598 Treatment A|Arm includes CP-945,598 Treatment A plus Dietary, Physical Activity, and Weight Loss Counseling
45603831|NCT00375401|Drug|CP-945,598 Treatment B|Arm includes CP-945,598 Treatment B plus Dietary, Physical Activity, and Weight Loss Counseling
45603832|NCT00375401|Drug|Placebo|Arm includes Placebo plus Dietary, Physical Activity, and Weight Loss Counseling
45603833|NCT02286869|Procedure|Three different mechanical ventilation modes|patients are randomly assigned to every arm. Baseline is the period immediatly before the study phase. The study phase is the sequence of three consecutive trials of different modes of mechanical ventilation. Every trial lasts 30 min plus 10 min of acclimation.
45603834|NCT02513732|Device|XIENCE Xpedition 2.25 mm stent|Patients receiving XIENCE Xpedition 2.25 mm stent
45603835|NCT00432185|Drug|PEP005|0.25% PEP005 Gel
45603836|NCT02287103|Other|Skipping Breakfast|NoB: The patients will omit the breakfast, will continue the overnight fast until lunch, then will eat only lunch and dinner.
45603837|NCT02287103|Other|Eating Breakfast|YesB: will eat all three meals
45603838|NCT00431873|Drug|MGCD0103|MGCD0103 Administered orally three times per week.
45603839|NCT00431015|Drug|IPI-504|IV Hsp90 inhibitor
45603840|NCT02287181|Drug|Remifentanil|short acting opiate
45603841|NCT02287181|Drug|Propofol|hypnotic drug
45603842|NCT02287181|Other|Bispectral index|electroencephalograph
45603843|NCT02287259|Drug|olanzapine|
45603844|NCT02287259|Drug|lithium|
45603845|NCT00429923|Drug|Difluprednate|
45603846|NCT00429923|Drug|Difluprednate|
45603847|NCT00429923|Drug|Placebo|
45756577|NCT00570089|Drug|Placebo|Placebo, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
46066594|NCT00937040|Drug|Placebo Tablets|Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks
46066595|NCT02583178|Device|Aegis Sierra Ligation System|The SLS is a series of devices designed for epicardial ligation of the left atrial appendage through a minimally invasive transcatheter approach.
46066596|NCT00673387|Drug|pramlintide acetate|subcutaneous injection, twice a day
46066597|NCT00673387|Drug|metreleptin|subcutaneous injection, twice a day
46066598|NCT00673387|Drug|placebo-P|subcutaneous injection, twice a day
45603848|NCT02284685|Behavioral|Promoting Eating Disorder Treatment among College Students|Online intervention designed to identify and increase help-seeking among undergraduates with previously undiagnosed/untreated eating disorders
45603849|NCT04470557|Diagnostic Test|D-dimer,CBC.ESR,CRP,|Complete blood count (for patients and control subjects): was done on CELL-DYN 3700 (Abbott-Germany) and blood film was stained by leishman staining, the morphology of red blood cells. CRP titre estimation by latix method .ESR erythrocyte sedimentation rate estimation (1:5) by Westerngreen tube method.
45603850|NCT04470557|Diagnostic Test|Liver function tests ,serum ferritin and PCR for COVID-19 .|"Serum ferritin was performed for all subjects on Modular P auto analyzer (Roche Diagnostics, Mannheim, Germany),~• Liver function tests ( aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase) and kidney funcrion were performed for all subjects on Modular P auto analyzer (Roche Diagnostics, Mannheim, G ermany),"
45603851|NCT00372437|Drug|MGCD0103|MGCD0103 as an oral dose three times per week.
45603852|NCT00372437|Drug|Gemcitabine|Gemcitabine 1000mg/m<2> intravenously days 1, 8, 15 of a 28 day cycle.
45603853|NCT00369473|Drug|AMG 108|125 mg via SC (subcutaneous) injection every 4 weeks
45603854|NCT00369473|Drug|AMG 108|250 mg via SC (subcutaneous) injection every 4 weeks
45603855|NCT04470791|Biological|F(ab)2 antivenom therapy (antivipmyn®).|Antivipmyn is an equine origin antivenom produced by Institute Bioclon in Mexico (Silanes Laboratories, México). The snake venoms used to create the F(ab')2 fragments are from Crotalus durissus and Bothrops asper. The number of doses of each patient depended on the classification and evolution, as indicated by the manufacturer for grade II envenoming: from 6 to 10 bottles of F(ab)2 antivenom therapy, intravenously, as an initial dose. One dose (bottle) consisted of 10 mL of polyvalent concentrated and modified horse antibodies treated by enzymatic digestion to neutralize the Bothrops asper venom to not less than 780 lethal dose 50 (LD50), and the Crotalus basiliscus venom to not less than 790 LD50.
45603856|NCT04470791|Procedure|Local cryotherapy.|Interval cryotherapy consisted of applying a plastic bag (the size of the bag depending on the size of the lesion, approximately 28 x 46 cm) two-thirds filled with crushed ice (frapped) wrapped in a towel applied for 20 minutes every 4 hours at the site of the snakebite throughout the hospital stay. New ice bags were used after 4 hours.
45603857|NCT00425321|Drug|RWJ-445380 100 mg|RWJ-445380 100 mg once daily for up to 12 weeks
45603858|NCT00425321|Drug|RWJ-445380 200 mg|RWJ-445380 200 mg once daily for up to 12 weeks
45603859|NCT00425321|Drug|RWJ-445380 300 mg|RWJ-445380 300 mg once daily for up to 12 weeks
45603860|NCT00425321|Drug|Placebo|Placebo once daily for up to 12 weeks
45603861|NCT00425165|Drug|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution one time during the study.
45603862|NCT00364247|Drug|CG5503 IR;tapentadol|
45603863|NCT00424697|Drug|placebo|
45603864|NCT00424697|Drug|lorazepam|
45603865|NCT00424697|Drug|GW876008|
45603866|NCT00422981|Drug|AL-108|5 mg QD
45603867|NCT00422981|Drug|AL-108|15 mg BID
45603868|NCT00422981|Drug|Placebo|Placebo
45603869|NCT00419081|Drug|Forodesine Hydrochloride Sterile Solution, 5 mg/mL|
45603870|NCT00419081|Drug|Forodesine Hydrochloride Capsules (100 mg)|
45603871|NCT00360035|Drug|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
45603872|NCT02287337|Procedure|Manipulation|High velocity low amplitude thrust joint manipulation to cervical spine facet joints
45911140|NCT02004145|Behavioral|Positive Psychology|The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
45603873|NCT02287337|Procedure|Exercise|Therapeutic exercises to the cervical, thoracic and scapular musculature
45603874|NCT00417287|Drug|PX-12|3 hour intravenous infusion as a dose of either 54 mg/m2 or 128 mg/m2 daily for 5 days every three weeks.
45603875|NCT00356681|Drug|AMG 706 placebo|Blinded placebo
45603876|NCT00356681|Drug|Bevacizumab|Bevacizumab is a recombinant, humanized anti-VEGF monoclonal antibody.
45603877|NCT00356681|Drug|AMG 706|AMG 706 is a small organic molecule that has been shown in preclinical pharmacology and PK studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively targeting all known VEGF, PDGF and Kit receptors.
45804017|NCT00354991|Drug|losartan potassium (+) hydrochlorothiazide|Patients took losartan 50 mg /HCTZ 12.5 mg orally once daily for 13 weeks. At Weeks 0, 4 and 8 if the blood pressure goal was not reached then the losartan/HCTZ combination will be titrated upwards according to the following scheme: losartan 50/HCTZ 12.5 to losartan 100/HCTZ 12.5 to losartan 100/HCTZ 25.
45603878|NCT00356681|Drug|Paclitaxel|Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.
45603879|NCT02284763|Other|EtCO2|Initial data collection during BCP was performed following three conditions were satisfied: after start of surgery; at least 15 min after BCP (for stabilization of MAP); after ventilation frequency was adjusted to produce EtCO2 of 27-29 mmHg with tidal volume of 8 ml/kg. Data was collected every 3 min after decreasing ventilation frequency by 1-2 breaths/min to increase EtCO2 until 42-45 mmHg. Once the value of EtCO2 42-45 mmHg was reached, ventilator frequency was increased in the same way to decrease EtCO2 until 27-29 mmHg. Fraction of inspired oxygen of 50% was maintained and end-tidal desflurane concentration was adjusted to achieve bispectral index values of 40-55 during data collection.
45603880|NCT00417209|Drug|Larotaxel (XRP9881)|administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
45603881|NCT00417209|Drug|5-Fluorouracil|administered as IV infusion from Day 1 to Day 4
45911141|NCT02004145|Behavioral|Control Condition|The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
45911142|NCT02004171|Other|electronic cigarette|V2 Cigs with 24 mg nicotine cartridges
45603882|NCT00417209|Drug|Capecitabine|administered orally from Day 1 to Day 14 q3w
45603883|NCT02284841|Device|Hilotherm cooling face mask|Hilotherapy - use of an external cooling device; a facial mask through which water circulates at a controlled temperature, allowing continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
45911143|NCT02004171|Drug|nicotine inhaler|nicotine inhaler with 10 mg nicotine cartridges
45603884|NCT03789773|Device|Millimeter-Wave Holographic Imaging|Undergo mm-wave holographic imaging
46066599|NCT00673387|Drug|placebo-M|subcutaneous injection, twice a day
45603885|NCT04470635|Diagnostic Test|ELISA|Saliva sample collection
45603886|NCT04470401|Drug|AbobotulinumtoxinA|application of 1cc of placebo (saline) or 1cc of abobotulinumtoxinA in both subscapularis and pectoral major muscles
45603887|NCT04470401|Drug|Saline|application of 1cc of placebo (saline) or 1cc of abobotulinumtoxinA in both subscapularis and pectoral major muscles
46066600|NCT00607490|Behavioral|Cognitive-Behavioral Therapy|Behavioral, cognitive, sex therapy and relaxation interventions administered to teach self-management skills for pain control.
45603888|NCT00355355|Drug|Talaporfin sodium|LS11 (Talaporfin Sodium) slowly administered (3-5 min.) in a free flowing intravenous drip at a dose of 1 mg/kg.
45603889|NCT00355355|Device|Interstitial Light Emitting Diodes|200 J/cm per Light Source at 20 mW/cm light energy
45444693|NCT03797079|Procedure|ESP block|A high-frequency linear ultrasound probe will be placed superficial to erector spinae muscle (ESM) in a parasagittal plane 3 cm lateral to the midline at the level of fifth thoracic vertebra. Three muscles will be identified superficial to the hyperechoic transverse process shadow: trapezius (uppermost), rhomboids major (middle), and ESM (lowermost). After local infiltration of skin and using in-plane approach, an 18 G Tuohy needle will be inserted, until the tip lay between the rhomboid major muscle and ESM.
45444694|NCT03797079|Procedure|TEA|Skin will be locally infiltrated at the site of needle insertion, and 18 G Tuohy needle will be introduced until its tip lay in the epidural space of the T5-T6 thoracic intervertebral space.
45603890|NCT00355355|Procedure|Percutaneous placement of device in the liver|Litx™ treatment group undergo CT or Ultrasound guided percutaneous placement of a single, two, three, or four Light Sources depending on their tumor characteristics. No more than 4 Light Sources will be used at a single treatment. The Light Source(s) may be used in a single lesion or in multiple lesions.
45603891|NCT00355355|Procedure|Standard Care|The standard of care could include any one of the following treatment options: Percutaneous Ethanol Injection (PEI), Transcatheter Arterial Chemoembolization (TACE), Radio Frequency Ablation (RFA), Cryotherapy, Systemic Chemotherapy, or other modalities that may be used at a particular institution.
45603892|NCT00407303|Drug|Obatoclax mesylate|30 mg, 45 mg
45603893|NCT00407303|Drug|Bortezomib|1.0mg/m2, 1.3 mg/m2
45603894|NCT00351767|Drug|placebo|Topically applied
45444695|NCT03797079|Device|Catheter insertion|After obtaining loss of resistance, 20 G epidural catheter will be threaded for 5 cm and then fixed on the skin.
45603895|NCT00351767|Drug|telbermin|Topically applied
45603896|NCT02287571|Device|Derotation splint|This group is the actual intervention group.
45603897|NCT02287571|Device|elastic bandage|This group is the routine treatment (control) valid in the clinical practice.
45603898|NCT03134105|Other|Monthly Feedback on activity and patient-reported angina|Providers will receive monthly updates on step count and patient reported angina for each of their patients, with data derived from a wearable fitness tracker and every other week emailed surveys
45603899|NCT03134105|Other|End-of-Study Feedback|Providers will receive an end-of-study update on step count and patient reported angina for each of their patients, with data derived from a wearable fitness tracker and every other week emailed surveys
45603900|NCT02287649|Other|blood sample|
45603901|NCT00344045|Drug|Paracetamol|IV Solution, Intravenous, 100 mL (10 mg/mL), 4 times at 6-hour intervals, 24 hours
45804018|NCT05718752|Diagnostic Test|Maximal incremental exercise test|Gas exchange are measured during all the test on ergocycle until oxygen consumption reach its maximum value
45804019|NCT05718752|Diagnostic Test|30-min submaximal exercise test|A 30-min submaximal test on ergocycle. Gas exchange are measured during all the test. Blood samples are collected before, at the end of exercise and after 3 hours of recovery
45804020|NCT00355069|Behavioral|electronic (computer based) provider feedback tool|All sites received a Basic Pediatric Chronic Care Model; 2x2 factorial design allocated the additional Medication Assessment Prompt and family education across the four sites as well.
45804021|NCT02986399|Other|Fast track patient pathway|Admittance: Ambulance - Radiology - Orthopaedic ward. Focus on preoperative information, stress reduction, pain relief, early mobilization and nutritional status.
45911144|NCT02004184|Drug|maintenance pemetrexed|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
45603902|NCT00344045|Drug|Placebo|IV Solution, Intravenous, 100 mL (0 mg/mL), 4 times at 6-hour intervals, 24 hours
45603903|NCT02256436|Biological|pembrolizumab|IV infusion
45603904|NCT02256436|Drug|paclitaxel|IV infusion
45603905|NCT02256436|Drug|vinflunine|IV infusion
45603906|NCT02256436|Drug|docetaxel|IV infusion
45603907|NCT00343109|Biological|HER-2/neu intracellular domain protein|Given ID
45603908|NCT00343109|Procedure|leukapheresis|Optional correlative studies
45603909|NCT00343109|Other|laboratory biomarker analysis|Correlative studies
45603910|NCT00343109|Biological|sargramostim|Given ID
45603911|NCT00343109|Other|immunologic technique|Correlative studies
45603912|NCT00343109|Biological|synthetic tumor-associated peptide vaccine therapy|Given ID
45603913|NCT02287727|Other|Laboratory Biomarker Analysis|Correlative studies
45603914|NCT02287727|Drug|Regorafenib|Given PO
45603915|NCT02481830|Drug|Nivolumab|
45603916|NCT02481830|Drug|Topotecan|
45603917|NCT02481830|Drug|Amrubicin|
45804022|NCT00357890|Device|Insulin pump therapy|CSII initiated within 1 month of diagnosis
45804023|NCT00357890|Drug|Multiple daily injections using insulin glargine + rapid acting analog|MDI as control
45804024|NCT02959424|Other|Spanish Northwestern Esophageal Quality of Life questionnaire|
45603918|NCT00405743|Drug|CP-4055|CP-4055 Continuous IV infusion
45603919|NCT00405743|Drug|CP-4055|CP4055 2 and 4 hour IV infusion
45603920|NCT00336713|Drug|Saredutant (SR48968C)|oral administration (capsules)
45603921|NCT00336713|Drug|Placebo|oral administration (capsules)
45603922|NCT00403169|Drug|lenalidomide|drug
45603923|NCT00332657|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|One 0.5 mL injection into the PJD at 6-month intervals for 42 months
45603924|NCT00332657|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL injection into the PJD at 6-month intervals for 42 months
45603925|NCT00332657|Other|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.
45603926|NCT03133949|Other|Establish the clinical, biological and radiological characteristics of patients|Establish the clinical, biological and radiological characteristics of patients
45911145|NCT02004184|Drug|pemetrexed at progression|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
45911146|NCT02004197|Drug|Quadruple Allopathic therapy|
45911147|NCT02004197|Drug|Pylorex plus|
45911148|NCT02004210|Procedure|transarterial radioembolization (TARE)|transarterial radioembolization
45603927|NCT00330473|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 9 months ( if patient chooses Human Insulin Inhalation Powder option)
45603928|NCT00330473|Drug|Insulin|patient specific dose, oral or injectable, before meals and/or as needed, 9 months. ( patients and investigator determine standard option therapy)
45603929|NCT00327743|Drug|larotaxel|IV infusion on Day 1 of a 21-day cycle
45603930|NCT00327743|Drug|capecitabine|oral, twice daily, Day 1-Day 14 of a 21-day cycle
45603931|NCT02284997|Device|MGDRx® EyeBag|Class 1 Medical Device, registered with the Medicines and Healthcare products Regulatory Agency. UK Patent: GB2421687B. The EyeBag is made of silk and 100% brushed black cotton and filled with flax / linseed. When heated, this device is intended to warm the eyelids. This melts the meibum and clears the meibum obstruction of the MGs.
45603932|NCT00326183|Biological|VAQTA®|0.5 ml injection VAQTA®; 2nd 0.5 ml injection VAQTA® 24 week period of treatment.
45603933|NCT00326183|Biological|ProQuad|0.5 ml injection ProQuad; 2nd 0.5 ml injection ProQuad®. 24 week period of treatment.
45603934|NCT02285075|Drug|temocillin PK/PD in haemodialysis|Pharmacokinetic study measuring total and free temocillin concentrations just before, and at 0.5, 3, 6, 12, 20 (before dialysis) and 24 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 1-day interval; just before and at 0.5, 3, 6, 12, 24, 36, 44 (before dialysis) and 48 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 2-day interval, and just before and at 0.5, 3, 6, 12, 24, 36, 48, 68 (before dialysis) and 72 (at the end of dialysis) hours after start of the infusion if patients were dialysed with a 3-day interval in order to determine basic PK and PD parameters in patients treated with intermittent haemodialysis and temocillin (Vd, T1/2, protein binding, clearance, reduction rate and T > MIC of 8 and 16 mg/L).
45603935|NCT00322517|Drug|SU014813|100 mg capsule/day for 6 cycle of 21 days
45603936|NCT02285231|Dietary Supplement|Arginyl-fructose|
45603937|NCT02285231|Dietary Supplement|Placebo|
45603938|NCT00321815|Drug|PF-3512676 + Erlotinib|"PF-3512676 0.2 mg/kg subcutaneously on days 1, 8 and 15 of each 21 day cycle until disease progression or unacceptable toxicity.~Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity"
45603939|NCT00321815|Drug|Erlotinib|Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
45603940|NCT02287805|Other|qualitative survey|
45911149|NCT02004210|Procedure|transarterial chemoembolization (TACE)|transarterial chemoembolization
45603941|NCT02287805|Other|quantitative survey|
45804025|NCT02118818|Genetic|Next generation sequencing|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD.
45911150|NCT02004223|Radiation|Dose escalation using stereotactic boost|"This is a dose escalation study. Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level.~The first dose level will be 20Gy in 2 fractions to PTV and 25Gy to Gross Target Volume (GTV) if identified. The second dose level will be 22Gy in 2 fractions to PTV and 27.5Gy to GTV if identified. The dose level will be 24 Gy in 2 fractions to PTV and 30Gy to GTV if identified.~Following stereotactic boost, all participants will receive 46Gy in 23 fractions radiotherapy to the prostate / seminal vesicles +/- lymph nodes."
45911151|NCT02004301|Drug|Radiolabelled T4 Tablet|
45911152|NCT02004301|Drug|Radiolabelled T6 Tablet|
45911153|NCT02004314|Drug|Chloroquine|
45911154|NCT02004327|Drug|DW1029M300mg|DW1029M300mg PO Once
45911155|NCT02004327|Drug|DW1029M600mg|DW1029M300mg 2 tablets Once
45603942|NCT00398879|Drug|Perifosine|Perifosine 50 mg/d qd
45603943|NCT00398879|Drug|Capecitabine|Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks
45603944|NCT00398879|Other|Perifosine Placebo|Placebo to Perifosine 50 mg/d qd
45603945|NCT00309179|Drug|E7820 plus cetuximab|Escalating doses from 40 mg/m^2 irinotecan plus E7820 in combination with cetuximab.
45603946|NCT02481050|Drug|Eribulin Mesylate|Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes biweekly on Day 1 and Day 15 of each 28-day cycle.
45804026|NCT05676554|Other|An Enhanced Psychological Mindset Session for Adolescents|"It is a ten-minute psychoeducation video (animation) delivered on the internet, followed by five minutes of stories from fictional students about how they used the concepts. Participants then complete three multiple choice questions aimed to assess their understanding and ability to apply concepts from the video, followed by 'letter of advice' task where participants have to give advice to a fictional younger student based on the information presented in the animation and videos.~The intervention itself was developed by Perkins et al (2021) based on promoting a growth mindset. It was deemed to be a feasible and acceptable tool to promote mental health (Perkins et al., 2021) in their feasibility trial."
45603947|NCT00394199|Drug|Fluticasone propionate/Formoterol Fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
45603948|NCT00394199|Drug|Fluticasone propionate 100|Fluticasone 100 is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
45603949|NCT00394199|Drug|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
45603950|NCT02287961|Procedure|Standard proctologic examination|(with digital rectal examination and 2 anal swabs) at initial inclusion visit, M12 and M24 follow-up visits and if applicable M6 and M18 control visits
45603951|NCT02287961|Procedure|High resolution anoscopy|at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits
45603952|NCT02287961|Procedure|Biopsy(ies) during High Resolution Anoscopy|only if lesion suggestive of AIN detected during High Resolution Anoscopy
45603953|NCT02287961|Procedure|High Resolution Anoscopy biannually|Only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
45603954|NCT02511782|Device|D-SQUAME Skin Sampling Discs|A D-SQUAME Skin Sampling Disc is a noninvasive patch that collects skin cell samples when affixed to the superficial stratum corneum (top layer of skin). The patch is applied with gentle pressure to the desired quadrant of the forearm and removed 2 minutes after application.
45603955|NCT00394121|Drug|Fluticasone propionate/formoterol fumarate|
45603956|NCT02480114|Other|Educational Intervention|Undergo oral care and pain management education session
45603957|NCT02480114|Drug|Gabapentin|Given PO
45603958|NCT02480114|Other|Pain Therapy|Receive usual oral health care
45603959|NCT02480114|Other|Quality-of-Life Assessment|Ancillary studies
45603960|NCT02480114|Other|Questionnaire Administration|Ancillary studies
45603961|NCT02480114|Drug|Oxycodone/Acetaminophen|Analgesia
45603962|NCT02480114|Drug|Hydrocodone/Acetaminophen|Analgesia
45603963|NCT02480114|Drug|Fentanyl|Transdermal Analgesia
45603964|NCT02480114|Drug|Ibuprofen|NSAID Analgesia
45603965|NCT02480114|Drug|Magic Mouthwash|Oral Solution to treat mucositis
45603966|NCT00309023|Drug|BMS-663513|mg/kg, intravenous (IV), 0.3, 1, 3, 6, 10 or 15 mg/kg, once every 3 weeks (q 3 wks), 12 weeks depending on response
45603967|NCT05202041|Other|AccuFFRangio-guided strategy|In this study, the AccuFFRangio-guided strategy will be applied to in the AccuFFRangio group in which calculation of the AccuFFRangio values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to PCI revascularization will be carried out. If AccuFFRangio ≤ 0.80, then simultaneous PCI revascularization of target blood vessels will be carried out. If AccuFFRangio > 0.80, then no PCI revascularization of target blood vessels will be carried out.
45603968|NCT05202041|Other|Angiography-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 70% (visual estimation) and suited for PCI revascularization will undergo PCI revascularization.
45603969|NCT00303251|Drug|TKI258|
45603970|NCT00299507|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals
45603971|NCT00299507|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL posterior juxtascleral depot injection at 6 month intervals
45603972|NCT00299507|Other|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6 month intervals
45603973|NCT02285309|Procedure|Cardiac Surgery and enoximone|Does diastolic function change with cardiac surgery +/- enoximone
45603974|NCT02479880|Drug|Tenofovir DF|300 mg tablet administered orally once daily for up to 96 weeks
45603975|NCT02479880|Radiation|DEXA Scan|Dual energy x-ray absorptiometry (DEXA) scans administered at protocol-specified time points
45603976|NCT00297401|Drug|ruboxistaurin|32 mg, QD, PO, up to 8 weeks
45603977|NCT00297401|Drug|placebo|QD, PO, up to 8 weeks
45603978|NCT02285387|Procedure|Rhythm control|"Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation~Cardioversion after 1 month~Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)~If AF recur, RFCA"
45603979|NCT02285387|Procedure|Rate control|"No AAD, just anticoagulation~HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin)~Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study."
45603980|NCT00297089|Drug|ABT-751|200 mg ABT-751 daily for 14 days every 21 days
45603981|NCT00297089|Drug|pemetrexed|Standard pemetrexed every 21 days
45603982|NCT00297089|Drug|placebo|Placebo daily for 14 days every 21 days
45911156|NCT02004327|Drug|DW1029M1200mg|DW1029M300mg 4 tablets PO Once
45911157|NCT02004340|Device|ear vagus nerve stimulator|
45603983|NCT02479802|Biological|Albumin|"27 plasma exchange procedures using Albumin 5% (estimated 3000 mL per plasma exchange) as replacement solution:~three weeks of intensive treatment with two plasma exchanges per week~twenty-one weeks of maintenance treatment with one weekly plasma exchange"
45603984|NCT00390845|Drug|SB681323|15 milligrams (mg)/day
45603985|NCT00390845|Drug|Placebo|
45603986|NCT00286793|Drug|AT-101|Oral
45603987|NCT02285465|Drug|ASP3700|Oral
45603988|NCT02285465|Drug|Placebo|Oral
45603989|NCT02288039|Other|Social Identity goal-based Intervention|Phase 1: collaborative group discussion in order to establish what group members want to achieve by the end of their 8-week pulmonary rehabilitation programme. Phase 2: further collaborative group discussion with the emphasis on evaluating, monitoring, and providing feedback on goal attainment. Phase 3: focus group interviews with an emphasis on reviewing the goal setting process that patients have engaged with.
45603990|NCT02285699|Drug|SSRIs|12-weeks of standard SSRi treatment for those interested in Phase II of the study.
45603991|NCT02288351|Other|Mix Nutrient Meal|Before Surgery: Subjects will have a visit where they will have a mixed nutrient stimulation test. They will be asked to fast for 12 hours prior to this visit (except water). During the visit they will drink an 8 ounce mixed nutrient liquid meal in 5 minute intervals over 20 minutes. During this visit a catheter will be placed in a vein in their arm for blood sample collections. A total of 50 ml of blood will be collected, (10 ml before drinking the mixed nutrient drink, at 30 minutes, at 60 minutes, at 90 minutes and 120 minutes after the mixed nutrient drink).
45603992|NCT02288351|Other|labs|Fasting Plasma Glucose (FPG) and insulin will be added to the standard pre-operative labs.
45603993|NCT02288351|Other|Biopsy|Intra-operatively: Subjects will undergo a standard laparoscopic Roux-en-Y Gastric Bypass (RYGB). During the surgery a 2cm tissue sample of the Roux limb will be taken by the doctor and frozen.
45603994|NCT02288351|Other|Second Mix Nutrient Meal|2 months post-operatively a second mixed nutrient stimulation test will be performed following the same process used pre-operatively.
45603995|NCT02288351|Other|Second biopsy|. Patients will also be scheduled to undergo a second upper endoscopy and a 2cm biopsy of the Roux limb will be taken by the doctor and frozen in liquid nitrogen.
45603996|NCT02288351|Device|PET/CT|Lastly, subjects will have a positron emission tomography/computed tomography (PET/CT) scan with Fluorodeoxyglucose (FDG) to evaluate the glucose in the Roux limb after surgery.
45603997|NCT02288429|Drug|colistimethate sodium|
45603998|NCT03133637|Drug|ceftriaxone|Eligible infants will receive ceftriaxone as standard of care for sepsis
45603999|NCT00267371|Device|PFO Closure with Premere investigational device.|PFO Closure with Premere investigational device.
45604000|NCT00267371|Drug|Medical management/current medications per standard of care by personal physician.|Medical management with current medications per standard of care by personal physician.
45604001|NCT00265655|Drug|Satraplatin|Patients will receive 80mg/m2 Satraplatin on Days 1-5 of Cycles 1 and 2. A cycle consists of 21 days.
45604002|NCT00254891|Drug|PF-3512676 + Paclitaxel + Carboplatin|"PF-3512676: 0.2 mg/kg subcutaneously Days 8 and 15 of each 21 day cycle x 6 cycles then weekly as maintenance until disease progression or unacceptable toxicity.~Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.~Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles."
45604003|NCT00254891|Drug|Paclitaxel + Carboplatin|"Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.~Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles."
45604004|NCT02479412|Drug|800 μg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
45604005|NCT02479412|Drug|250 µg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
45604006|NCT02479412|Drug|58 µg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
45604007|NCT02479412|Drug|Placebo once daily|Once daily dosing of Placebo to AZD7594 for 14 days; each dose of Placebo inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
45604008|NCT02479412|Drug|Salbutamol|Inhalation as needed
45604009|NCT02285933|Other|virtual reality training|Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Exercises challenge sitting balance control, reaching and shifting the base of support; for example, controlling a ball as it rolls down a maze or reaching to put dishes away in a virtual kitchen. The difficulty of the games is monitored to maintain a challenge to sitting balance. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre of pressure to ensure that the participant is adequately challenged during the VRT.
45604010|NCT02285933|Other|control|Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Control group exercises require limited hand and arm movements; for example, using an arm to move a fish along a simple pathway or using the arms to pop balloons without reaching. Control group participants are strapped into their chair to minimize trunk movement. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre during the VRT.
45911158|NCT02004392|Drug|EVP-6124|
45911159|NCT02004405|Other|strengthening exercise|"The experimental group (STRE) will receive strengthening training in Station for lifting weight exercises (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks."
45604011|NCT02286011|Biological|MNC (Mononuclear cells)|"The cells are infused into the TA muscle of the lower limb randomized as Group A (experimental) intramuscularly. The infusion is made with a needle, 26 gauge, at 4 points of the TA muscle a specific depth given by the neurophysiological study. The total volume infused will be 2 ml, 0.5 ml at each point.~For infusion is as painless as possible for the patient to comply exactly with stereotactic indications of neurophysiology, the infusion was made at a uniform controlled rate and for this, the syringe is placed on a Yesargil arm, equipped with a microinjector and controlled infusion device."
45911160|NCT02004405|Other|flexibility exercise|The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
45604012|NCT02286011|Other|Saline|The placebo, 2ml of saline, will be infused like in the experimental arm.
45604013|NCT00254579|Drug|CP-675,206|15 mg/kg Q12W dosing regimen
45604014|NCT00252005|Drug|Apixaban|
45604015|NCT02288507|Drug|Sorafenib|Sorafenib 400mg PO BID for Cohort 1, if 2 or more patients with dose-limiting toxicity toxicity (DLT), Chort -1 is sorafenib 200mg PO BID, if 2 or more patients with DLT, sorafenib 200mg PO daily
45604016|NCT02288507|Radiation|yttrium-90 radioembolization|Yttrium-90 SIR-Spheres microspheres are instilled through a catheter into a branch of the hepatic artery
45911161|NCT02004418|Radiation|11C-Choline|
45911162|NCT02004457|Behavioral|ABBT|
45911163|NCT02004457|Other|TAU|
45911164|NCT02004470|Procedure|Active lavage and suction|Active lavage and suction of the right upper quadrant will be performed as the laparoscopic procedure is about to be terminated.
45604017|NCT02288585|Dietary Supplement|Plant sterols|Plant sterols
45604018|NCT02288585|Dietary Supplement|Placebo product|Placebo product
45604019|NCT02286167|Other|Diet modification|All patients will be participate in the intermittent, modified Atkins diet
45604020|NCT00231257|Device|Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent|Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent
45604021|NCT00231257|Procedure|Brachytherapy|Brachytherapy
45604022|NCT02286245|Other|focused Telephonic Medical Advice|The physician will implement a protocol of care to each patient call for an isolated fever and/or symptoms of gastroenteritis: medical advice, drug prescription by phone and supervisory board
45604023|NCT02286245|Other|Usual practice|The physician will decide for the same disease (isolated fever and/or symptoms of gastroenteritis) the need of telephone advice with or without drug prescription, home visit by a doctor, emergency department services with or without EMS system.
45604024|NCT00224003|Drug|Sodium Ferric Gluconate Complex in Sucrose.|
45604025|NCT00390533|Drug|Saredutant|oral administration (capsules)
45604026|NCT00390533|Drug|Placebo|oral administration (capsules)
45604027|NCT00216593|Drug|galantamine hydrobromide|
45604028|NCT00390143|Biological|Meningococcal vaccine 134612|One intramuscular dose during the primary study
45604029|NCT00390143|Biological|Mencevax™ ACWY|One subcutaneous dose during the primary study
45604030|NCT00206687|Biological|Spheramine (BAY86-5280)|Bilateral implantation of Spheramine into the postcommissural putamen, each side at a dose of 325,000 cells
45911165|NCT02004483|Procedure|Percutaneous Coronary Intervention|Percutaneous coronary intervention is performed according to standard practice. Direct stenting is required for the procedure as it is done in most coronary interventions today. After insertion of the non-inflated stent into the coronary lesion there should still be flow to the distal vessel. The stent should be implanted at high-pressure with balloon inflation lasting for 60 seconds to allow adequate expansion of the stent. Post-dilatation should be performed if required. However, this should be done more than 5 minutes after stent implantation.
45911166|NCT02004496|Device|Consilium|Patients use a mobile application to track their subjective well-being and adverse events (AE) while ambulant chemotherapy. The mobile app supports the patients in the structured and standardized entry of their data and is developed specifically for this study.
45604031|NCT00206687|Procedure|Placebo|Sham surgery procedure without penetration of the dura mater. Nothing wil be implanted into the brain.
45604032|NCT00389675|Drug|Darusentan|Darusentan capsules at a dose of 50, 100, or 300 mg administered orally once daily
45604033|NCT00389675|Drug|Guanfacine|Guanfacine 1 mg capsules administered orally once daily
45604034|NCT02288663|Other|measurement of morphological parameters|measurement of morphological parameters : thigh perimeter, leg perimeter, arm perimeter.
45604035|NCT02288663|Biological|a blood sample|One single blood sample to assay SCr (enzymatic), BUN (blood urea nitrogen), cystatin C, CRP, Na, K, Cl, albuminemia.
45604036|NCT02288663|Biological|albumin or blood in urine|dipstick analysis for albumin or blood in urine
45604037|NCT02288663|Device|Dual X-ray absorptiometry (DXA)|measurement of lean body mass by whole-body DXA
45604038|NCT02288663|Device|Bioelectric Impedance Spectroscopy (BIS)|measurement of lean body mass by BIS
45604039|NCT02288663|Biological|51Cr-EDTA plasma clearance|measurement of 51Cr-EDTA plasma clearance to determine GFR
45604040|NCT02286323|Device|Bonfils|Bonfils Intubation Fiberoscope
45604041|NCT02286323|Device|Macintosh|Direct laryngoscopy using Macintosh Laryngoscope
45604042|NCT02288741|Drug|Anthracycline/dexamethasone-based induction chemotherapy|4 cycles of anthracycline/dexamethasone-based chemotherapy
45604043|NCT02288741|Drug|Dexamethasone for control of symptoms|2 x 4 days of dexamethasone (day 1-4 and day 8-11: 40mg)
45604044|NCT02288741|Drug|Tumor-reduction chemotherapy and stem cell mobilization|Ifosfamide (day 1-3: 1.900mg/m² iv), epirubicin (day 1: 75 mg/m² iv), etoposide (day 1-3: 120 mg/m² iv) and G-CSF (day 5 until end of apheresis: 5µg/kg sc)
45604045|NCT02288741|Procedure|Stem cell apheresis|stem cell apheresis in peripheral blood, sought amount of CD34-cells: 6 * 10E6/kg
45604046|NCT02288741|Drug|Tandem high-dose chemotherapy (melphalan)|Two cycles of high-dose melphalan (day -3 and day -2: 70mg/m²)
45911167|NCT02004509|Drug|Anticoagulant|Anticoagulant treatment will be started in case of subclinical atrial fibrillation (>5,5 hours per day) be diagnosed by cardiac implantable electronic device at intervention group, or clinical atrial fibrillation in both groups.
45911168|NCT02004535|Procedure|Cochlear Implantation|The standard surgical procedure for a cochlear implant will be used. The asymmetric participant will receive the cochlear implant in the deaf ear.
45604047|NCT02288741|Procedure|Autologous peripheral blood stem cell transplantation|Two infusions of collected stem cells (day 0: 2*10E6 CD34-cell/kg per transplantation)
45604048|NCT04470323|Diagnostic Test|Flow cytometry|Lymphocyte subsets in peripheral blood were assessed by staining 50 µl of blood sample with 5 µl of Fluoroisothiocyanate (FITC)-conjugated- PD-1, phycoerythrin (PE)-conjugated-CD8, peridinium-chlorophyll-protein (Per-CP)-conjugated-CD4, Peridinium-chlorophyll-protein (Per-CP)-conjugated anti-CD3 and allophycocyanin (APC) conjugated anti-CD28.
45604049|NCT04470245|Diagnostic Test|magnetic resonance imaging (MRI)|Our study will include healthy volunteers (to refine the scanning sequence) and patients undergoing surgery for CTS. Patients will be scanned before and after their operation using cutting-edge diffusion MRI techniques.
45911169|NCT02004548|Drug|Metatinib Tromethamine|
45604050|NCT05726045|Behavioral|Standard smoking cessation program (SCP)|Each subject will receive a standard SCP as group treatment once a week (1h) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra & Buchkremer, 2004), and will be carried out by a qualified therapist.
45604051|NCT05726045|Behavioral|Cognitive remediation treatment (CRT)|The cognitive remediation treatment (CRT) employs a chess-based battery of tasks (delivered through an app-based online tool), two times per week over six weeks (60min duration per session).
45604052|NCT05726045|Behavioral|High-intensity interval training (HIIT evening)|"The high-intensity interval training will be delivered through an app environment with several choices of exercise, two times per week over six weeks.~The training will include a 5-minutes warm-up and cool down phase. In between, participants will perform four 4-minutes blocks of exercise at high intensity, interspersed with three 3-minute blocks of low intensity (total of 35 minutes exercise)."
45604053|NCT02450552|Drug|Ezogabine|Potiga is FDA-approved for adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments.
45604054|NCT02450552|Drug|Placebo|Matched placebo
45604055|NCT02508428|Device|Hip Replacement with crosslinked Marathon polyethylene|Comparison of Marathon and Enduron polyethylene
45604056|NCT02508428|Device|Hip Replacement with noncrosslinked Enduron polyethylene|
45604057|NCT02448680|Biological|Coagulation FVIIa (Recombinant)|A cross over design to assess the efficacy of 2 separate dose regimens (75 µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX
45604058|NCT02448446|Drug|ranibizumab 0.3mg|intravitreally administered
45604059|NCT02447744|Behavioral|Mindfulness based intervention|The intervention is an 8-week structured mindfulness based behavioral intervention program that teaches mindfulness meditation, mindful yoga and psychological knowledge about stress.
45604060|NCT04923386|Other|None (not interventional)|This is not an intervention
45604061|NCT04200560|Other|Rhythmic Handgrip Exercise|60 minute rhythmic handgrip exercise
45604062|NCT04200560|Other|Chronic Exercise Training|Handgrip exercise training consisting of three 60-minute training sessions per week for eight weeks.
45604063|NCT02478632|Drug|Subjects do not receive study medication in this study 202094|Participants do not receive study medication in this study 202094.
45604064|NCT02478398|Biological|Short ragweed pollen allergen extract|One sublingual tablet containing 12 units of Amb a 1-U, once daily (QD) for up to 35 weeks.
45604065|NCT02478398|Biological|Placebo|One placebo sublingual tablet, QD for up to 35 weeks.
45604066|NCT02478398|Drug|Self-injectable epinephrine|Intramuscular (IM) injection with suggested doses of 0.15 mg for participants weighing 15-30 kg (33-66 pounds) or 0.3 mg for participants weighing ≥30 kg (≥66 pounds), as needed for severe allergic reactions. Epinephrine was only provided in countries/study sites where it was a regulatory requirement.
45604067|NCT02478398|Drug|Albuterol/Salbutamol|Inhalation of albuterol 90 mcg/puff or salbutamol 100 mcg/puff metered dose inhaler (MDI), as needed as asthma rescue medication for those participants with asthma
45911170|NCT02004574|Drug|Calcipotriol/betamethasone dipropionate gel|"All enrolled subjects will receive Xamiol® gel once daily for 8 weeks during the induction period and then will be assessed according to IGA at the end of 8-week induction period. Those subjects determined to be Responder by IGA will be randomized to one of the following three treatment groups and they will continue their therapy with randomized maintenance regimens for the duration of additional 8 weeks."
45911171|NCT02004587|Drug|Gemigliptin|Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.
45911172|NCT02004600|Procedure|Photodynamic therapy (PDT)|1 session of Photodynamic therapy (PDT) on epidermis dysplasia
45911173|NCT02004626|Drug|Collagenase|"Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records."
46066601|NCT00607490|Behavioral|Supportive Psychotherapy|Patient-centered talk therapy to assist participants in expressing their thoughts and feelings.
45604068|NCT02478398|Drug|Loratadine|5 mg (1 mg/mL syrup or 5 mg tablet) for participants 5 years old or 10 mg (1 mg/mL syrup or 10 mg tablet) for participants 6 to 17 years old, as needed for rhinoconjunctivitis symptoms
45604069|NCT02478398|Drug|Olopatadine|Opthalmic solution, 1 drop (0.1%) per affected eye twice daily (BID), as needed for rhinoconjunctivitis symptoms
45604070|NCT02478398|Drug|Mometasone furoate monohydrate|Intranasal spray, at doses of 1 spray (50 mcg/ spray) per nostril for participants 5 to 11 years old or 2 sprays (50 mcg/spray) per nostril for participants 12 to 17 years old, as needed for rhinoconjunctivitis symptoms
45604071|NCT02478164|Drug|Ponatinib|
45604072|NCT02476994|Drug|Clinolipid|
45604073|NCT02476994|Drug|Intralipid|Standard-of-Care Soybean Oil-Based Lipid Emulsion
45604074|NCT02508194|Biological|MEDI7510|RSV soluble fusion protein (sF) antigen plus glucopyranosyl lipid A in stable emulsion (GLA-SE) adjuvant
45604075|NCT02508194|Biological|IIV|Marketed Inactivated Influenza Vaccine
45604076|NCT02508194|Other|Placebo|Sterile Saline
45604077|NCT02508116|Genetic|CYP2C19 genotyping|The study utilizes a genotyping device, SpartanRx™ (Spartan Bioscience, Ottawa, Canada) that provides identification of a patient's CYP2C19 *2, *3, and *17 genotypes determined from genomic DNA from a buccal swab sample with 1 hour turnaround time
45604078|NCT01653782|Behavioral|Kundalini yoga|Guided training twice a week for six weeks. Self instructing cd for home practice
45604079|NCT01653782|Behavioral|Self care advice|"Evidence based advice from caregiver about keeping active, exercise and a written self care pamphlet The Back book"
45604080|NCT01653782|Behavioral|Exercise|"Strength training at a gym supervised by a physical therapist twice a week during 6 weeks. Self training instruction was provided. A written self care pamphlet The Back book"
45604081|NCT02318329|Drug|FPA144|FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.
45604082|NCT02022631|Other|Alternative summary of findings table format|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
45604083|NCT02022631|Other|Current summary of findings table format|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
45604084|NCT01962337|Drug|FPA008|Infusion
45604085|NCT01962337|Drug|Placebo|Infusion
45604086|NCT00687505|Drug|FP-1039|Intravenous weekly administration
45604087|NCT03472417|Device|Active partial rebreathing device|
45604088|NCT03472417|Device|Dummy partial rebreathing device|
45604089|NCT05259319|Drug|Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ]|Treatment given every 21 days during 24 months or until progression
45604090|NCT05259319|Drug|Tiragolumab|Treatment given every 21 days during 24 months or until progression
45604091|NCT05259319|Radiation|Stereotactic body radiation therapy (SBRT)|Radiothérapy is delivered as a hypofractionated schedule of 3 doses of 8Gy (idealy on Monday, Wednesday and Friday, or 3 sessions over a week, respecting at least 24 hours between each fraction)
45604092|NCT05259007|Dietary Supplement|propolis solved in lactic acid solvent|propolis given as a dietary supplement which was solved in a lactic acid solvent.
45604093|NCT05259007|Drug|Amoxicillin-Clarithromycin-Lansoprazole|H pylori eradication treatment
45604094|NCT05259007|Other|IV saline 0.9%|Physiological serum solution is given as a placebo
45604095|NCT05259007|Other|Lactic acid|given to determine if the improvement of the symptoms are due to propolis or the solvent
45604096|NCT02255656|Drug|alemtuzumab GZ402673|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
45604097|NCT00380653|Drug|sapacitabine|
45604098|NCT04099537|Behavioral|Computerized cognitive training|Participants are trained to approach or avoid stimuli of skin using a joystick. Participants are to pull or push the joystick toward or away when skin stimuli are present. Thus, behaviorally, there may be an increase, decrease, or no change in approach tendencies towards skin.
45604099|NCT03472339|Drug|Diclofenac Sodium|Group A-Intramuscular diclofenac sodium+oral placebo Group B-Oral diclofenac sodium+ intramuscular placebo
45604100|NCT03472261|Drug|Botulinum toxin type A|Dysport
45604101|NCT03472261|Other|Upper extremity orthoses|Twister
45604102|NCT03472261|Other|Home exercise program|Specific exercises for pronation deformity
45604103|NCT03479047|Diagnostic Test|assess diaphragmatic displacement (DD) using ultrasonography|During a spontaneous breathing trial (SBT) we will simultaneously, for all included patient, assess diaphragmatic displacement (DD) using ultrasonography, respiratory rate (RR) and tidal volume (VT) on ventilator screen.
45604104|NCT03478813|Behavioral|Voiding school|Children are educated on the kidneys, bladder and bowel function, the importance of regular voiding and drinking habits, and avoidance of constipation. Balloons, books, videos, animations, the pictures of a satisfied and irritated bladder and a poo-cars formula track are used to exemplify the function of urinary and defecation systems. During toilet visits children are given advise about an adequate and relaxed toilet posture with the help of little bench under the feet if needed. Each child also make their own timetable for peeing, pooing, and water drinking times, which they then should learn to follow in day-care, pre-school and at home. At the end of each session child, parent and public health nurse/urotherapist discuss any individual advice and the homework for the next time.
45604105|NCT05369728|Other|Coronary CT in 1st line compared to the strategy with functional test in 1st line in patient at Intermediate Risk of Developing Stable Coronary Disease:|Coronary CT in 1st line compared to the strategy with functional test in 1st line in Patients at Intermediate Risk of Developing Stable Coronary Disease:
45604106|NCT03478735|Procedure|Ultrasound Guided Greater Occipital Nerve Block at C2|Ultrasound guided injection
45756578|NCT00727597|Drug|Efavirenz 600mg|"QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~To resolve a Grade 3 or 4 Adverse Event~The subject experienced a virologic failure (as defined in section 3.6.2)~The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)"
45756579|NCT00727597|Drug|Boosted Lexiva|"Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~To resolve a Grade 3 or 4 Adverse Event~The subject experienced a virologic failure (as defined in section 3.6.2)~The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)"
45604107|NCT03478735|Procedure|Landmark-Based Greater Occipital Nerve Block|Traditional landmark-guided technique at the superior nuchal line. This approach relies solely on superficial bone-based anatomic landmarks to infiltrate local anesthetic and corticosteroid around the nerve at the level of the superior nuchal line.
45604108|NCT03951025|Dietary Supplement|Melatonin oral administration|One tablet with1 mg of melatonin and 82 mg of excipients
45604109|NCT03951025|Dietary Supplement|Melatonin sublingual administration|One tablet with 1 mg of melatonin and 82 mg of excipients
45604110|NCT02255500|Drug|Bupivacaine FNB|A single administration of bupivacaine HCl 0.5% with epinephrine 1:200,000 in 20 mL volume will be administered within 2 hours prior to the surgical procedure as an ultrasound-guided FNB.
45756580|NCT04748913|Device|Radiographic examination|Standardized bitewing radiographs will be performed by the principal investigator
45756581|NCT04748913|Device|Scanning with DIAGNOcam|The surface of the selected teeth will be examined under near infrared light using the DIAGNOcam device
45604111|NCT02255500|Drug|EXPAREL Infiltration|A single dose of EXPAREL 266 mg expanded to 60 mL with preservative-free sterile normal saline will be infiltrated into the surgical site just prior to wound closure.
45756582|NCT04748913|Device|Scan with DIAGNOcam and Indocyanine|One the dye has been applied, a new series of images will be taken with Diagnocam
45756583|NCT04748913|Diagnostic Test|Visual-tactile exploration with separation|The point of contact will be open in the corresponding proximal area of the lesion using an elastic orthodontic separator
45604112|NCT03475693|Drug|Magnesium Oxide|400 mg Magnesium oxide tablet given once in the ED, and prescribed to take BID for 5 days total after discharge
45604113|NCT03475693|Drug|Acetaminophen|500 mg tablets given once in the ED, and prescribed to take BID for 5 days total after discharge.
45604114|NCT03475693|Drug|Zofran ODT 4 MG Disintegrating Oral Tablet|Given once in the Emergency department
45604115|NCT05258461|Other|use of a smartphone app for adverse event management|At their enrollment, patients will receive detailed introduction and adequate assistance on the use of the smartphone app. The smartphone app will offer proper advice for adverse event management based on calculated results by artificial intelligence on the innovative app, which was developed by YL et al. It was specifically intended for risk prediction, early prevention, as well as management of symptoms and concerns during adjuvant chemotherapy in the treatment of breast cancer. The app consisted of 4 modules: (1) Module 1: clinical data collection. (2) Module 2: risk evaluation for 12 common adverse events during breast cancer chemotherapy. (3) Module 3: personalized prophylaxis based on predicted risks of adverse events. (4) Module 4: Q&A platform.
45604116|NCT05258461|Other|conventional adverse event management|Chemotherapy-related adverse events in the control group will be managed with symptomatic treatment, dietary and lifestyle prescription according to the doctors' clinical experience. For example, colony-stimulating factors and antibiotics may be used for febrile neutropenia, loperamide (or diphenoxylate plus atropine) as prophylaxis for diarrhea, together with eating low-lactose and low-fat frequent small meals. 5-hydroxytryptamine 3 receptor antagonist, neurokinin 1 receptor antagonist, and/or dexamethasone would be prescribed for patients at high risks of vomiting.
45604117|NCT05156749|Device|short-arm fiberglass cast|fracture stabilization of salter harris I/II fractures with a fiberglass short-arm cast
45604118|NCT05156749|Device|long-arm fiberglass cast|fracture stabilization of salter harris I/II fractures with a fiberglass long-arm cast
45756584|NCT04386473|Device|pacemaker|electrode is implanted in left bundle branch in LBBP; electrode is implanted in right ventricular outflow tract septal in RVOP
45756585|NCT04387045|Behavioral|Guilty feelings|Participants write for 20 minutes about situations that have caused them feelings of guilt throughout their lives.
45756586|NCT00571259|Drug|Heparin 1000U/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
45756587|NCT00571259|Drug|4% Sodium Citrate with Gentamicin 320 mcg/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
45756588|NCT01893879|Drug|placebo for study drug|Given PO
45756589|NCT01893879|Drug|(RS)2-(3-benzoylphenyl)-propionic acid|Given PO
45756590|NCT01893879|Other|laboratory biomarker analysis|Correlative studies
45604119|NCT03475615|Drug|Oxaliplatin|130mg/m2, d1, q3w
45604120|NCT03475615|Drug|Paclitaxel|40mg/m2 ip，d1、8 ,q3w
45604121|NCT03475615|Drug|S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules)|40mg/m2 Bid po，d1-14,q3w
45604122|NCT03478501|Behavioral|Decision Aid|This intervention is a tablet based Lethal Means Decision Aid with proposed use to augment lethal means counseling in emergency departments for patients at risk of suicide.
45604123|NCT03478423|Drug|Codeine|30mg tablets. Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
45604124|NCT03478423|Drug|Oxycodone|5mg tablets. Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
45604125|NCT03478423|Drug|Hydromorphone|1mg tablets.Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
45756591|NCT01894503|Drug|S8 Sinus Implant (mometasone furoate, 1350 mcg)|Bioabsorbable sinus implant with 1350 mcg of mometasone furoate released over 90 days
45756592|NCT02991547|Other|Observational|
45756593|NCT00571493|Drug|Bortezomib|Patients will receive bortezomib in four dose cohorts ( .8. 1.0, 1.3, 1.5 mg/m²). Patients will receive bortezomib on days -11, -8, -5, and -2 before infusion of autologous stem cells.
45756594|NCT00571493|Drug|BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)|"All study patients will receive BEAM per the standard institution protocol:~BCNU (carmustine): 300 mg/m²on day -5 etoposide 100 mg/m² twice daily on days -5, -4, -3, and -2 cytarabine 100 mg/m² twice daily on days -5, -4, -3, -2 melphalan: 140 mg/m² on day -1 before infusion of autologous stem cells."
45604126|NCT03478345|Behavioral|endocrine disruptor chemical reduction intervention|Participants will take part in a 4-week intervention consisting of a modified (shortened) version of the Diabetes Prevention Program diet and physical activity group education program, with instructions to reduce endocrine disruptor chemical exposure through changes in food handling and personal care products.
45604127|NCT03475537|Device|transcranial direct current stimulation|the treatment of transcranial direct current stimulation
45604128|NCT03131011|Other|UV fluorescent ink|"The use of UV tattoo ink results in a tattoo that is visible only under an ultraviolet light. Conventional black tattoo ink is replaced with UV ink for the application of radiotherapy dot tattoos. Handheld UV flashlights are used to make the tattoos visible for use during radiotherapy treatment set-up."
45604129|NCT03130933|Procedure|Lower third molar surgery|"All surgical procedures were performed under local anaesthesia (alveolar nerve block) with 2% lidocaine chloride. The full-thickness mucoperiosteal flap was raised using buccal approach, adequate osteotomy was done using micromotor handpiece and bur, and third molar removal was finished using elevating instruments in the appropriate direction. Removal of bone dust, granulation tissue and broken tooth fragments were done in order to wound toileting. Gentle, sterile saline irrigation was done on the end.~Primary closure of the surgical area was done using 3-0 silk sutures."
45604130|NCT03130933|Drug|Amoxicillin 500 Mg|The tested subgroups received a prophylactic single dose of 4 x 500 Mg Amoxicillin one hour prior the lower third molar surgery.
45604131|NCT03130933|Other|Placebo|The control subgroups received a prophylactic single dose of placebo one hour prior the lower third molar surgery.
45604132|NCT05155969|Drug|Esketamine|esketamine (0.3 mg/kg in 100 ml normal saline) is intravenously infused 40 minutes before anesthesia induction
45604133|NCT05155969|Drug|Normal saline|Normal saline will be administrated intravenously at the dural opening, with a total dose of 0.5 ml/kg and continual infusion for 40 minutes.
45756595|NCT02991391|Other|None, use of a questionnaire|Telephone health survey using 2015 Behavioral Risk Factor Surveillance Survey in Texas, Florida, South Carolina, and Kentucky that includes questions regarding tobacco exposure and respiratory symptoms
45756596|NCT02990065|Dietary Supplement|PROTEIN SUPPLEMENTATION|
45756597|NCT00571961|Drug|Kaletra (lopinavir/ritonavir)|4 tablets, once a day (800 mg/dose) on Days 2 through 14 of this study
45756598|NCT00571961|Drug|buprenorphine|Buprenorphine will be obtained through prescription at the subject's drug treatment program.
45756599|NCT00571961|Other|Clinical evaluations/Blood draws|Physical examinations, vital sign measurements, 12-lead electrocardiogram (ECG), clinical laboratory evaluations (blood chemistry and blood counts), PK blood draws.
45756600|NCT02990377|Behavioral|RL-supported IVR intervention|Participants in the intervention group receive interactive voice response calls where they are asked to report information about their health and medications using their touch-tone phone. Based on their responses, participants may receive brief or extended motivational messages during the call, or they may be assigned to receive a 20 minute motivational enhancement session with a study therapist over the phone.
45756601|NCT04386655|Behavioral|Brain Injur Coping Skills - Telemedicine|"BICS sessions (both in-person and telemedicine) will occur once a week for 12 weeks. Each session will last two hours.~Modules of BICS include: Introduction to Brain Injury, Expectations for Recovery, Tips on Managing Challenging Problems, Learning about Depression after the Brain Injury, The 4 R's of Stress Management, Communicating Effectively with Professionals"
46066602|NCT03927430|Procedure|pars plana vitrectomy with membrane peeling|23-gauge pars plana vitrectomy with peeling of the epiretinal and internal limiting membrane as well as air- or gastamponade
45604134|NCT03784417|Device|EUS-guided laser ablation|EUS-guided LA will be performed with an endoscopic ultrasound guided approach using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge flexible needle that is inserted in the working channel of the echoendoscope.
45604135|NCT03472183|Other|biopsies of colon|Removal of additional biopsies of colon during the course of a colonoscopy planned for usual medical follow-up of patient
45756602|NCT00572117|Drug|Topiramate|Medication will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
45604136|NCT03472105|Dietary Supplement|New Nordic Renal Diet|One week ingesting a phosphorus reduced diet containing a total of 850 mg of phosphorus/day compared to one week of a habitual diet
45604137|NCT02523157|Other|Wellbeing Plan|The Wellbeing Plan is a short self-help leaflet designed to improve emotional wellbeing of women during and after pregnancy by providing information, raising awareness, helping a woman identify her own symptoms, provide coping strategies, and identify key people who can support the woman during this time.
45604138|NCT02523157|Other|Control task|Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
45604139|NCT05112913|Biological|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
45604140|NCT05112913|Biological|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
45604141|NCT05112913|Biological|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
45604142|NCT05112913|Biological|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 3|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
45604143|NCT05112913|Biological|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 3|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
45604144|NCT05112913|Biological|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 3|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
45604145|NCT05112913|Biological|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 1|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
45604146|NCT02523781|Other|information pamphlet|The intervention group receives the information pamphlet
45604147|NCT04458961|Procedure|One-stage|A one-stage revision operation involves one operation to remove the joint, thoroughly cleaning the infected area and then implanting a new joint immediately.
45604148|NCT04458961|Procedure|Two-stage|A two-stage revision operation involves two operations: the joint is removed in one operation, a temporary spacer device is inserted, then the infection is treated with antibiotics, and then a new joint is implanted in a second operation.
45604149|NCT03478189|Procedure|use of O-arm surgical imaging|during acetabular fracture surgery , use of O-arm surgical imaging with
45604150|NCT03475459|Drug|NPC-15 and/or Placebo|The dosage and regimen of the study drug in each period is the following. Period I : NPC-15 placebo granules 8 g Period II : NPC-15 placebo granules 4 g + NPC-15 granules 0.2% 4 g (melatonin 8 mg) Period III : NPC-15 granules 0.2% 8 g (melatonin 16 mg)
45604151|NCT03478111|Drug|CMAB008|the study drug
45604152|NCT03478111|Drug|MTX|basic therapy drug
45604153|NCT03478111|Drug|Remicade|active comparator
45604154|NCT03478033|Drug|Rifampicin|Rifampicin capsules, 150mg
45604155|NCT03478033|Drug|Rifabutin|Rifabutin capsules, 150mg
45604156|NCT03477955|Procedure|PEEK interspinous spacer|To study the Adjacent Segment Degeneration incidence in the supradjacent segment following short lumbar fusion between PEEK and Silicon Interspinous spacers.
45604157|NCT03477877|Behavioral|Indashyikirwa Couples Training|A training curriculum for heterosexual couples in Rwanda comprising 20 3-hour modules (60 hours total) delivered to groups of 15 couples (30 people). Each module facilitated by male and 1 female facilitator. Curriculum topics include: types and uses of personal and interpersonal power (power within, power over, power with, power to), gender, gender based violence, triggers for intimate partner violence, conflict management, economic development, sexuality, alcohol, social norms and community change. Delivered by RWAMREC.
45604158|NCT03477877|Behavioral|Indashyikirwa Activist Training|This training is offered to a subset of individuals who complete the couples curriculum (randomly selected from among those who are are willing and eligible). These individuals are trained to serve as community activists, teach peers about the types of power (power within, power over, power with, power to), and advocate for community change to prevent intimate partner violence. Delivered by RWAMREC.
45756603|NCT01895127|Drug|Eculizumab|
45756604|NCT01895127|Biological|Immunoglobulin|
46066603|NCT02583100|Behavioral|Intensive Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial, (2) receive an analysis of their video-recorded operative technique by surgeon peers, (3) directly observe a peer surgeon with lower fistula rate, and (4) develop a personalized action plan with a target for improvement.
45756605|NCT01895127|Procedure|Plasmapheresis|
45756606|NCT02991235|Dietary Supplement|PRJ212|6 capsules of study product will be taken daily and orally.
45756607|NCT02991235|Dietary Supplement|Placebo|6 capsules of study product will be taken daily and orally.
45756608|NCT04362059|Device|COVSurf Drug Delivery System|Device introduces surfactant to the patients lungs
45756609|NCT04362059|Other|Standard of Care|Standard of care treatment for respiratory illness
45804027|NCT05675696|Other|Esophageal Catheter|Newly designed external monitor that will capture esophageal pressure from a proprietary nasogastric tube combined with simultaneous pressure, flow, and volume measurements from the ventilator tubing.
46066604|NCT02583100|Behavioral|Routine Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial
45604159|NCT03477877|Behavioral|Indashyikirwa Opinion Leader Training|"Training delivered to opinion leaders (political office holders, religious leaders, service providers), in intervention communities. Training comprised 8 x 3 hour sessions (24 hours) delivered for groups of up to 40 participants. Introduces Opinion Leaders to the concepts of power (power within, power over, power with, power to) and to essential concepts around women's legal rights. Delivered by Rwanda Women's Network."
45604160|NCT03477877|Other|Indashyikirwa Women's Spaces|"Establishment of 1 Women's Space per intervention sector -- a physical space with trained facilitators on duty from which support and referrals for women experiencing IPV could be offered and ad hoc programming responsive to community needs and interest can be run. Typical activities include once-off open trainings for community members on the concepts of power (power within, power over, power with, power to), essential concepts around women's legal rights, conflict management in families, etc. Delivered by Rwanda Women's Network."
45604161|NCT03477877|Behavioral|Village Savings and Loan Association (VSLA)|A standard Village Savings and Loan Association program as run nationwide by CARE Rwanda.
45604162|NCT03477799|Device|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a safe method for non-invasively modulating cortical excitability through the use of weak electrical currents (usually of 1-2 mA) circulating between two scalp electrodes (i.e., an anode and a cathode) placed over the target cortical regions. The effects of tDCS on brain activity are polarity-dependent, such that anodal stimulation generally enhances cortical excitability by depolarizing cell membranes and increasing neuronal firing rates, while cathodal stimulation generally results in the opposite effect. Because of its neural effects, tDCS has been increasingly used to gauge the functional relationship between cognitive/behavioural dimensions and putatively relevant neurocircuitry
45604163|NCT05231551|Procedure|Placental tissues|Placental tissues are collected after aspiration of abortion products. They are treated immediately in order to isolate placental stem cells. Organoid culture is established and the obtained embryoids are cultured in monophasic or biphasic oxygen conditions. Extra organoids are cryopreserved in liquid nitrogen
45604164|NCT03477565|Device|Kinesio tape lymphatic drainage technique application|Kinesio Tex Tape strips are applied following Dr.Kase draining techinique. The choice of tape's length and strips' number is based on the area of breast edema and/or presence of seroma, which must be completely covered. The patch is cut into fan strips. The major base is positioned near the functioning lymph node stations closest to the edema and/or seroma area. The bases and the tails of the fan must be applied with zero tension, while for the central part is reached 15-25% of tension. The first application takes place on the 1st post-operative day, while the second is performed on the 7th post-operative day. In case the tape is detached from one application to another, it is necessary that the patient resume in the clinic for a new application to ensure continuity of the therapeutic effect; otherwise the patient is eliminated from the study. The experimental group also receives the expected standard treatment, consisting in physiotherapeutic evaluation and counselin.
45604165|NCT03477487|Biological|XT-150|Human IL-10 variant transgene in a plasmid DNA vector
45756610|NCT02992171|Behavioral|care management by oncology nurses|The intervention employs a care management approach to facilitate provision of primary palliative care within existing oncology clinic structures. The intervention is deployed through a series of nurse-led encounters occurring before or after regularly-scheduled oncology clinic visits.
45756611|NCT01276561|Procedure|Single Incision Splenectomy|Patients will undergo laparoscopic splenectomy through a single incision
45756612|NCT01276561|Procedure|Laparoscopic Splenectomy|Patients will undergo laparoscopic splenectomy with 4 ports, placement is surgeon dependent
45756613|NCT01953081|Drug|TD-8954|
45756614|NCT01953081|Drug|Metoclopramide|
45756615|NCT02991313|Device|Endocardial Ablation Procedure|
45756616|NCT00572897|Drug|Fludarabine, Melphalan +/- ATG|"Conditioning regimen for Allogenic Stem Cell Transplant:~Related Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily)~Unrelated Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily) ATG (Thymoglobulin®) days -3 to -1 (0.5 mg/kg IV on day -3 [given over 6 hours], and 2 mg/kg on days -2 and -1 [given over 4 hours])"
45756617|NCT01276717|Drug|Drug: Carfilzomib|Carfilzomib 30 minutes infusion daily for days 1, 2, 8, 9, 15, 16, Every 28 days. A maximum of 13 cycles will be administered.
45756618|NCT01276717|Drug|Vorinostat|Vorinostat by mouth twice daily on days 1, 2, 3, 8, 9, 10, 15, 16 and 17. Maximum 13 cycles.
45756619|NCT02991157|Drug|Nimodipine|
45756620|NCT01953237|Behavioral|MedActive|Participants randomized to the MedActive condition will complete a 1-hour training session on MedActive, which will include ascertaining their antipsychotic administration schedule that will be pre-programmed into the application along with other personalized features. Each participate will be asked to use the medActive application over the following three months. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period.
45756621|NCT01953237|Device|Smartphone|
45756622|NCT04386499|Dietary Supplement|Resveratrol|mixture of trans-resveratrol 150 mg (REVIFAST), folic acid 400 mcg, vitamin D, vitamin B12 and vitamin B6
45756623|NCT04386499|Dietary Supplement|Folic acid|400 mcg of folic acid
45756624|NCT01276795|Dietary Supplement|Oral Nutrition Support|The patients will sip the oral nutrition support (in the form of a drink) over the course of 4 hours within each 6 hour study. Each patient will be studied once before surgery and once after surgery.
45756625|NCT01896687|Device|Scrambler|Electrotherapy
45756626|NCT00573287|Drug|clozapine|clozapine--tabs, 450mg. max, daily, 24 weeks
46066605|NCT00933608|Drug|memantine|participants will be asked to take memantine (20mg/day) for 16 weeks
45756627|NCT00573287|Drug|risperidone|risperidone--tabs, 6mg max, daily, 24 weeks
45756628|NCT04385797|Other|Telephone interview|Sociodemographic data. Clinical data. PMCI/MD quality of life, cognition, depression, technophilia and perceived stress and caregiver quality of life and burden assessments.
45756629|NCT05735925|Diagnostic Test|Skin Swab & Skin Biopsies & Blood Sample|These intervention will be necessary to phenotype the immune cells that are present in the skin and blood of HS patients
45804028|NCT02112578|Drug|Meclizine|25 mg, 3 times per day up to 30 days
45804029|NCT02112578|Drug|Dimenhydrinate|50 mg, 3 times per day up to 30 days
45804030|NCT01958762|Other|Invitation for oral cavity cancer screening|
45604166|NCT03477409|Other|plasticizers|The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites
45604167|NCT05189197|Drug|Zanubrutinib + R-CHOP|"Zanubrutinib 160 mg BID administered by oral every day of each 21-day cycle. Rituximab 375 mg/m2, Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 (maximum total 2 mg) administered by IV infusion on Day 1 of each 21-day cycle.~Prednisone 100 mg administered by oral on Day 1-5 of each 21-day cycle. After 6 cycles of zanubrutinib and R-CHOP combination therapy, patients achieved CR will continue to receive zanubrutinib 160mg BID for 1 year."
45604168|NCT05084599|Drug|Metaraminol 2.7μg/kg/min|After spinal anesthesia, the patient was placed in a supine position until the fetus was delivered, and metaraminol was given at an initial rate of 2.7μg/kg/min throughout the process.
45604169|NCT05084599|Drug|Metaraminol 2μg/kg/min|After spinal anesthesia, the patient was placed in left-tilt position until the fetus was delivered, and metaraminol was given at an initial rate of 2μg/kg/min throughout the process.
45604170|NCT03472027|Biological|BCD-145|Anti-CTLA-4 monoclonal antibody, IV infusion
45604171|NCT02505542|Biological|Certolizumab Pegol|"Active substance: Certolizumab Pegol~Pharmaceutical form: Prefilled syringe~Concentration: 200 mg / ml~Route of Administration: Subcutaneous injection"
45604172|NCT02505542|Other|Placebo|"Active substance: Placebo~Pharmaceutical form: Prefilled syringe~Concentration: 0.9 % Saline~Route of Administration: Subcutaneous injection"
45604173|NCT00701623|Drug|heparin|patients will receive the application of one of two types of heparin directly on the injured area
45756630|NCT04385641|Other|Cell infusion for Dose-finding (Group A)|Group A：HLA-I and HLA-II molecular typing were performed at the serological and molecular levels, and the HLA-I and HLA-II molecular antigens of donor and subjects match on 3, 4, 5 or 6 / 6. After the successful matching, the non myeloablative immunosuppressive pretreatment with cyclophosphamide (900 mg / m＾2 / day) and fludarabine (30 mg / m＾2 / day) will be performed 6, 5, 4 and 3 days before the infusion of UCB-NK cells. After the pretreatment, the cell infusion was started on day 0, and the cell infusion could be divided into 50% and 50% for two consecutive days or every other day. To ensure clinical safety, if treatment-related adverse events reach DLT after the first infusion, the cell infusion will stop.
45604174|NCT00701623|Drug|heparin|patients will receive the application of one of two types of heparin directly on the injured area
45604175|NCT00701623|Drug|folder water|patients will receive the application of folder water directly on the injured area
45604176|NCT03109483|Other|Geriatric Activation Program Pellenberg|intensive multicomponent physical therapy week program
45604177|NCT03471949|Other|CGM in a population with normal OGTT|The population with normal OGTT will use CGM and document their values as well as be documenting a capillary blood glucose value
45604178|NCT04589221|Behavioral|Ad libitum energy intake|Investigate ad libitum energy intake according to degree of food processing and eating behaviour
45756631|NCT04385641|Other|Cell infusion for Extended research (Group B)|Group B：Non myeloablative immunosuppressive pretreatment and cell transfusion were the same as group A.
46066606|NCT00933608|Drug|Placebo|participants will be asked to take 2 tablets per day to match active drug
45604179|NCT04456153|Drug|Experimental Group|Continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days
45604180|NCT04456153|Drug|Placebo Group|Continued standard of care therapy together with matching placebo
45604181|NCT02475980|Behavioral|Comprehensive contraception counseling|The study intervention will consist of comprehensive contraceptive counseling through a standardized bundle of services, including a 10-minute educational DVD, handouts on contraceptive methods, and one-on-one contraceptive counseling by the PED physician.
45604182|NCT04403971|Drug|0.12% Chlorhexidine Oral Liquid Product|The intervention group 1 received 10ml 0.12% chlorhexidine solution for oral rinse twice a day.
45604183|NCT04403971|Drug|Listerine Oral Liquid Product|The intervention group 2 received 10ml Listerine solution for oral rinse twice a day.
45604184|NCT04403971|Other|Normal Saline Product|The control group received 10ml normal saline for oral rinse twice a day.
45604185|NCT02447432|Biological|Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation)|4 doses by intramuscular injection in the right left anterolateral thigh
45604186|NCT02447432|Biological|Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation)|4 doses by intramuscular injection in the right anterolateral thigh
45604187|NCT02447432|Biological|DTPw-HBV/Hib|3 doses by intramuscular injection in the left anterolateral thigh
45653311|NCT03067207|Behavioral|MARS-A|The intervention will consist of the 8-week mindfulness meditation program designed for adolescents with chronic health conditions.MARS-A is based on two established mindfulness-based interventions for adults: MBSR and MBCT. The content of the program will be the same for in-person and e-health groups: all participants will receive eight 90-minute weekly evening sessions led by two trained and experienced mindfulness providers. Sessions will include short meditation practices, breathing exercises, guided discussion, mindful movements and inquiry, adapted to the context of chronic illness. Every session will start with a brief review of home practice and will close with a discussion of the home practice for the following week.
45653312|NCT04994301|Diagnostic Test|Lung T1 MRI|Evaluation of lung T1 MRI to Assess Lung Disease
45756632|NCT01896921|Drug|Switch to Maraviroc + Raltegravir or Dolutegravir|Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks
46066607|NCT02582944|Device|Olympus BF-180 bronchoscope (standard adult)|-Standard of care
46066608|NCT02582944|Device|Veran Spinview Thoracic Navigation System|-Electromagnetic navigation
45604188|NCT04923230|Behavioral|Cannabis Actions and Practices Resource for Parents|The Cannabis Actions and Practices (CAP) resource is a parent-focused approach to help MM parents address marijuana use and attitudes by their adolescents. CAP includes information about the effects of marijuana on adolescent behavioral health, brain development, and social functioning. CAP also integrates motivational strategies to foster The CAP intervention focuses on building parenting skills and teaching strategies to: (1) limit adolescent exposure to cannabis products and parent cannabis use at home, (2) improve parent communication about their MM use, expectations about youth marijuana use, and attitudes about the potential harms of adolescent cannabis use, (3) improve monitoring, and (4) increase positive reinforcement for youth abstinence. Parents meet with an interventionist for two individual 75-minute sessions involving presentations, discussions, and behavioral rehearsal of key parenting skills.
45756633|NCT01276873|Device|Tracheal aspiration close system|use of closed system in comparision to open system to tracheal aspiration of nweborns, analyzing pain and climical variations associated.
45756634|NCT05735847|Procedure|Total Knee Arthroplasty (TKA)|The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with TKA involves the replacement of both the medial and lateral compartments of the knee.
45756635|NCT05735847|Procedure|Unicompartmental Knee Arthroplasty (UKA)|The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with UKA involves the replacement of one compartment.
45604189|NCT02446886|Drug|Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)|"Adrenocorticotropic hormone (ACTH) gel, a long-acting formulation of the full sequence ACTH that includes other pro-opiomelanocortin (POMC) peptides, is considered an alternative to corticosteroids in the treatment of relapses (currently FDA approved for this indication).~ACTH (H.P. Acthar®) gel exerts direct anti-inflammatory and immune-modulating effects within the CNS, specifically on infiltrating macrophages and resident microglia as well as protecting mature oligodendrocytes from inflammation-related damage and excitotoxicity. These effects are mediated not only via induction of endogenous corticosteroid production but also via effects on melanocortin receptors."
45604190|NCT04351243|Drug|Gimsilumab|Gimsilumab is a fully human monoclonal antibody (mAb).
45604191|NCT04351243|Drug|Placebo|Normal saline
45756636|NCT01897077|Drug|Peanut Dissolving Film|
45604192|NCT04164121|Drug|Phenlarmide Tablets|Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.
45604193|NCT04164121|Drug|Placebos|Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.
45756637|NCT00749749|Drug|Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)|The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride
45756638|NCT00749749|Drug|ON-Q PainBuster Post-op Pain relief System|5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])
45756639|NCT02993263|Device|VectraplexECG System with CEB®|The device will be used after noncardiac surgery
45756640|NCT01898013|Drug|Pregnenolone|
45756641|NCT01898013|Drug|Placebo|
45756642|NCT02991937|Drug|Piperacillin/Tazobactam|24 hours of IV antibiotic administration
45756643|NCT02991937|Procedure|Surgical Treatment|Appendectomy
45756644|NCT02999269|Device|MECTA Spectrum 5000Q Amplitude|Current
45756645|NCT00420667|Drug|Enoxaparin|
45756646|NCT02328807|Procedure|Radio-Frequency Ablation (RFA)|RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
45756647|NCT01277107|Drug|Zaleplon AP formulation|Gastric retentive dual release Zaleplon
45756648|NCT01277107|Drug|Placebo capsule|Identical placebo capsule
45756649|NCT04768959|Behavioral|FelizMente|The intervention aims to improve well-being, without denying the existence of symptoms or problems, focusing on generating positive emotions and actions congruent with the person's values through 11 weekly 90-minute group sessions. The multi-component intervention manual was composed of evidence-based exercises of Positive Psychoterapy Interventions, Acceptance and Commitment Therapy and Mindfulness and was theory driven according the broaden-and-build-theory (Fredrickson, 2001) and the self-serving model of paranoia (Murphy et al., 2018). It was also informed by previous pilot studies carried out on people with paranoid tendencies (see Valiente et al., 2020) and with Severe Psyquiatric Condition samples.
45604194|NCT04132141|Other|Virtual Reality Headset with curated content|clinicians will wear VR immersive headset for up to 15 minutes during their break
45756650|NCT05735691|Procedure|High-Intensity Treadmill Training|Participants will walk on a treadmill at a speed that produces 70-80% of age-adjusted heart rate reserve or a rating of perceived exertion of 17/20. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts, with 2-3 minutes rest between bouts.
45756651|NCT05735691|Procedure|Treadmill Training with Perturbations|Participants will walk on a treadmill and a perturbation of the treadmill will be produced every 20s. Perturbations will randomly occur in the forward, backward, right or left directions, with a perturbation size set to 80% of stability threshold. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts with 2-3 minutes rest between bouts.
46066609|NCT02582944|Device|Olympus UM-S20-17S|-Endobronchial ultrasound mini-probe
45604195|NCT03475303|Behavioral|early hospital discharge|early hospital discharge at 8-12 hours for women undergone elective cesarean section
45604196|NCT05008003|Drug|Standard of care|Standard of care treatment as per the hospital guidelines
45604197|NCT05008003|Dietary Supplement|Vitamin D3|A daily dose of 5000 IU vitamin D3 for 7 days.
45911174|NCT02004626|Drug|Kollagenase|"Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records."
45604198|NCT03475225|Drug|Cholecalciferol|Cholecalciferol delivery
45604199|NCT03475225|Drug|Placebo Oral|manufactured to mimic Cholecalciferol
45604200|NCT03448939|Drug|S5G4T-1|Once a day topical cream
45604201|NCT03448939|Drug|S5G4T-2|Once a day topical cream
45604202|NCT03433261|Dietary Supplement|Ketogenic Diet|Eat a ketogenic diet (low carbohydrate, high fat diet) for 72 hrs prior to the experiment and consume a dietary ketone supplement 60 minutes before the experiment.
45604203|NCT03851107|Behavioral|Engagement in 6-week community-based activity program|Participants engage in a 6-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 6 weeks - the actual intervention phase.
45604204|NCT03691207|Drug|AL101|"AL101 is a small-molecule that inhibits gamma secretase, an enzyme which plays a key role in the activation of the Notch signaling pathway by releasing the Notch intracellular domain (NICD) of all four Notch receptors from the membrane.~In patients with aberrant Notch signaling, AL101 may inhibit Notch signaling and potentially impede tumor growth.The drug is administered intravenously"
45604205|NCT02504294|Biological|Epoetin Hospira Arm|Epoetin Hospira Arm: Epoetin Hospira will be administered intravenously (IV) per the analogous version of the Fresenius Medical Care North America (FMCNA) cMAB 1 (inclusive of version 1.0, 1.1,...)erythropoietin stimulating agents (ESA) dosing algorithm for Epoetin Hospira for 24 weeks. Subjects will have Epoetin Hospira initiated using the same ESA dose level and frequency of administration for Epogen prior to randomization into the trial. Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
45604206|NCT02504294|Other|Standard of Care Arm|Standard of care arm: No interventions will be performed in this arm for the clinical study; and subjects will receive ongoing standard of care, which includes Epogen administered IV per the FMCNA cMAB 5 (inclusive of versions 5.0, 5.1,....) ESA dosing algorithm and IV iron per the FMCNA protocol that is standard of care, at FMCNA clinics during the contemporaneous 24 week period.
45604207|NCT02504294|Drug|IV Iron|Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
45604208|NCT02446418|Drug|Fluticasone Furoate|FF 92 mcg or 184 mcg blended with lactose administered once daily via ELLIPTA DPI
45604209|NCT02446418|Drug|Vilanterol|Vilanterol 22 mcg blended with lactose and magnesium stearate administered once daily via ELLIPTA DPI
45604210|NCT02446418|Drug|Fluticasone propionate|FP 250 mcg or 500 mcg blended with lactose administered twice daily via DISKUS DPI
45604211|NCT02446418|Drug|Salmeterol|Salmeterol 50 mcg blended with lactose administered twice daily via DISKUS DPI
45604212|NCT02446418|Drug|Budesonide|Budesonide 200 mcg or 400 mcg blended with lactose administered twice daily via TURBUHALER DPI
45604213|NCT02446418|Drug|Formoterol Fumarate|Formoterol Furoate 6 mcg or 12 mcg blended with lactose administered twice daily via TURBUHALER DPI
45604214|NCT02255422|Drug|Omaveloxolone capsules, 2.5 mg|
45756652|NCT05735691|Procedure|Standard Treadmill Training|Participants will walk on a treadmill at a speed that produces 30-40% of age-adjusted heart rate reserve. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts, with 2-3 minutes rest between bouts.
45604215|NCT02255422|Drug|omaveloxolone capsules, 5 mg|
45604216|NCT02255422|Drug|omaveloxolone capsules, 10 mg|
45604217|NCT02255422|Drug|Placebo capsules|
45604218|NCT02255422|Drug|omaveloxolone capsules, 20 mg|
45604219|NCT02255422|Drug|omaveloxolone capsules, 40 mg|
45756653|NCT01277185|Dietary Supplement|Low Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a lower (600-1200 mg/d)level of calcium in the first camp followed by the opposite (higher calcium diet)regime in the second camp.
45911175|NCT02004639|Radiation|Masticators sparing techniques|
45604220|NCT02255422|Drug|omaveloxolone capsules, 80 mg|
45604221|NCT02255422|Drug|omaveloxolone capsules, 160 mg|
45604222|NCT02445794|Drug|Low dose cohort|RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.
45604223|NCT02445794|Drug|High dose cohort|RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.
45604224|NCT02475278|Biological|NoV GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide for IM injection
45604225|NCT02254486|Drug|NER1006|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
45604226|NCT02254486|Drug|Trisulfate solution|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
46066610|NCT02582944|Procedure|Biopsy|
45756654|NCT01277185|Dietary Supplement|High Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a higher (1100-2300mg/d)level of calcium in the first camp followed by the opposite (lower calcium diet)regime in the second camp.
45604227|NCT05556538|Procedure|Transforaminal Epidural Steroid Injection|Patients are placed in the prone position, with a pillow under their abdomen (to reduce lumbar lordosis) and taken to the operating table. The procedure area is cleaned 3 times with povidone-iodine antiseptic and covered with a sterile cover. In order to view the foramen to be processed, the fluoroscopy arm is evaluated at AP-oblique / cranial or caudal angles to obtain an optimal image. Local anesthetic (3 cc 2% prilocaine) is injected into the skin and subcutaneous tissue. The spinal Quincke 21-gauge 90 mm needle is advanced by targeting the relevant foramen under the guidance of fluoroscopy image. Needle position is confirmed by taking a lateral view. Needle aspiration is checked for blood. 1-2 ml of contrast material is injected to confirm that there is no vascular distribution and that it is in the epidural space. When distribution without vascular invasion is observed, an injection of a mixture of 10 mg dexamethasone, 1 cc saline and 1 cc (0.5%) bupivacaine is performed.
45756655|NCT01277263|Device|Diffuse Optical Spectroscopy Imaging|Monitoring Breast Cancer during chemo therapy
45756656|NCT05735613|Procedure|osteotome crestal sinus lifting|Full thickness flap elevated to expose the crest of alveolar ridge. Pilot drill used to start the osteotomy preparation, which should be ended 1mm short of sinus floor. The drills can be sequentially used to widen the osteotomy site to the same level (1 mm short of the sinus floor), an osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level, the osteotome will be tapped gently to fracture up the sinus floor.Clinical check for membrane still intact, blocking the patient's nostrils and asking the patient to blow through his or her nose. Xenograft will be added as the grafting material and pushed to the sinus through the osteotomy site until the desired height of sinus elevation will be gained, the implant fixture will be inserted. Smart peg will be placed on implant and Ostell will be used to record ISQ.
45756657|NCT05735613|Procedure|osseodensification crestal sinus lifting|Full thickness flap elevated to expose the crest of alveolar ridge. Pilot drill used to start the osteotomy preparation, which should be ended 1mm short of sinus floor. Change the drill motor to reverse-densifying Mode (counterclockwise drill speed 800-1500 rpm with copious irrigation), Begin with the densah bur (2.5mm) until 1 mm short of the sinus floor, use the next wider Densah Bur (3.0mm) in the same mode and advance it into the previously created osteotomy with modulating pressure and a pumping motion. When feeling the haptic feedback of the drill reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments, the next wider densah drills advance in the osteotomy.Clinical check for membrane still intact. Xenograft added and pushed to the sinus through the osteotomy site then the implant fixture will be inserted.
45756658|NCT05735613|Procedure|piezoelectric crestal sinus lifting|initial osteotomy will be performed with a 2-mm twist drill to remove the cortical bone, then the intralift tips (Intralift; TKW1, TKW2, TKW3,TKW4, TKW5; Satelec). TKW1 to TKW4 tips have diameters of 1.35 mm, 2.1 mm, 2.35 mm, and 2.8 mm and will be used to gradually widen the access canal to the Schneider membrane, gentle pressure will be applied on the tips to deepen the pathway, and a sterile spray (80 mL/min) cooling the tips to avoid heat injury. The TKW5 tip will be then inserted into the access canal, and the ultrasonic activation for 5 seconds with internal irrigation of 40 mL/min and repeated at 50 mL/min and then 60 mL/min. The sinus membrane will be pushed upward by the hydraulic pressure, the floating of the sinus membrane will be evaluated, and then the TKW4 (Ø 2.8 mm) will be used again to widen the access canal to the sinus membrane before plugging the bone graft.xenograft added. Implant fixture inserted and flap statured
45756659|NCT02987361|Device|DC-STIMULATOR PLUS|2mA for 20minutes a day, 5 days per weeks, totally 2 weeks
45756660|NCT01274533|Drug|Lenalidomide|25mg or 10mg (based on creatinine clearance) once daily for days 1-21 of a 28 day cycle
45756661|NCT01277497|Drug|Sevelamer carbonate|Sevelamer carbonate 1,600 mg three times daily with meals
45756662|NCT01277497|Drug|Calcium acetate|Calcium acetate 1,334 mg three times daily with meals for 12 weeks
45604228|NCT04859062|Drug|lidocaine gel 2%|assessing its efficacy in decreasing muscle traction pain,In the operation room, we started inhalational induction of anesthesia with sevoflurane till the patient is deeply anesthetized. In the experimental group, we applied lidocaine gel 2% abundantly below both eyelids of the surgical eye for at least 3 minutes before the surgical incision, while nothing was applied to patients in the control group.
45604229|NCT04859062|Other|control group|In the operation room, we started inhalational induction of anesthesia with sevoflurane till the patient is deeply anesthetized. In control group, we didn't apply lidocaine gel 2% to the operative eye .
45604230|NCT05645926|Procedure|Percutaneous coronary intervention (PCI)|Patients who underwent percutaneous coronary intervention (PCI), including percutaneous transluminal coronary angioplasty (PTCA), and coronary stent insertion
45604231|NCT05645926|Procedure|Coronary artery bypass grafting (CABG)|Patients who underwent coronary artery bypass grafting (CABG)
45604232|NCT05538598|Procedure|Intramuscular Dry Needling|The insertion of thin monofilament needles (without injectate) into a tight band of muscle. The needles will be inserted into the muscle for ~10 seconds.
45604233|NCT04872166|Drug|BTX-A51|One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of 5 days on/2 days off.
45756663|NCT05735535|Drug|Antiviral Agents|two-drug one-pill once day
45911176|NCT02004639|Other|electro-acupunture treatment|electro-acupunture treatment and sham-EA
45911177|NCT02004652|Drug|Prucalopride|Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
45604234|NCT04864210|Drug|Liposomal bupivacaine|Surgeons will perform an intercostal nerve block in the operating room under thoracoscopic guidance while the patient is asleep under anesthesia. This intervention (block) is one of the standards of care but the medication (liposomal bupivacaine) currently is not FDA approved for this type of block.
45756664|NCT01956279|Drug|Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x 28 days
45604235|NCT04864210|Drug|Bupivacaine|An anesthesiologist trained in regional anesthesia will perform a paravertebral block in the hospital's pain service unit. This intervention is standard of care and will use plain bupivacaine with epinephrine as the medication
45604236|NCT05645848|Device|Ultrasonography|Abdominal ultrasound in pregnant women with placenta previa
45604237|NCT05519878|Other|Best Practice|Undergo routine treatment and usual follow up care
45604238|NCT05519878|Device|Bright White Light Therapy|Undergo bright white therapy
45604239|NCT05519878|Behavioral|Occupational Therapy|Undergo occupational therapy
45604240|NCT05519878|Other|Questionnaire Administration|Complete questionnaires
45604241|NCT05645770|Combination Product|ECG, computerized task|ECG for cardiac waves computerized task for prospective memory
45604242|NCT05650918|Biological|MesoPher|autologous monocyte-derived dendritic cells loaded with PheraLys (tumor cell lysate)
45604243|NCT05650918|Biological|Mitazalimab|agonistic human monoclonal (IgG1) antibody targeting CD40
45756665|NCT01956279|Drug|Placebo|Placebo 50mg BID x 14 days, followed by Placebo 150 x 14 days, followed by Placebo 250 mg BID x 28 days
45604244|NCT01641640|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
45604245|NCT01641640|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
45604246|NCT01641640|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
45604247|NCT05644678|Device|Fixed appliances|Metal brackets with a straight-wire prescription will be used. Patients will be treated conventionally.
45604248|NCT05644678|Procedure|Corticotomy|Patients will be treated in conjunction with a surgical intervention using metal brackets with a straight-wire prescription. Corticotomy (alveolar perforation and piezocision) will induce acceleration in canine traction movement during the orthodontic treatment in only one group.
45604249|NCT05650762|Device|Cinesteam|Cinnamon-based Secondary dressing
45604250|NCT04419922|Behavioral|Smartphone Contingency Management Intervention|Participants will provide baseline data on their recent substance use and smoking habits/severity. Participants will 1) download the DynamiCare Rewards app, and 2) receive a Carbon Monoxide breath testing device (iCO™ Smokerlyzer®) and reloadable debit card for receiving financial incentives. Participants will follow instructions on the app to take breath tests and receive incentives if the carbon monoxide breath result is less than 6 ppm (Cessation mode) or lower than 3 of the last 4 tests (Shaping mode). The app will use GPS to track if patients have attended their scheduled BrightView appointments (GPS is not used at any other time) and reward them for all kept appointments. The participant will also be able to view Cognitive Behavioral Therapy (CBT) modules on the app and receive incentives upon completing each module. At all times, the participant retains the right to choose whether to use and when to use the app, device, and funds for a total period of 4 months.
45604251|NCT05650450|Device|DES+DCB|Hybrid approach is defined as overlapping or slightly (2-3 mm) superimposing a new generation DES for a de novo long (>38 mm) lesion (located in the larger, more proximal part of the vessel -reference vessel diameter -RVD >2.75 mm-) and DCB inflation for a concomitant and contiguous de novo small vessel disease (distally located with RVD ≤2.75 mm ≥ 2.0 mm)
45604252|NCT05650216|Drug|Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)|"Neoadjuvant treatment period:~Radiotherapy: Primary lesions and adjacent lymph nodes: The mode of involved field irradiation (IFI) is adopted, no preventive radiation is given. The total dose is 41.4Gy, 1.8Gy/23f. Distal lymph nodes ≥ 5cm away from the primary lesion: low-dose radiotherapy with a total dose of 4Gy, 0.5Gy/8f, Day1 to Day4, Day22 to Day25.~Chemotherapy: Carboplatin(AUC=2), Nab-paclitaxel(80mg/m2), Day1/8/15/22/29. Immunotherapy: Camrelizumab(200mg, Day5, Day26).~Perioperative period:~Undergo surgery within 4-6 weeks after neoadjuvant therapy~Adjuvant treatment period:~Camrelizumab: (200mg, Q3W)，continued for up to 1 years，until PD or intolerable toxicity."
45604253|NCT05092672|Behavioral|Exercise|Participants will engage in moderate-intensity (40-59% HRR) exercise for 30 min
45604254|NCT04419610|Biological|TRV027|peptide for infusion
45604255|NCT04419610|Other|sodium chloride 0.9%|placebo comparator for infusion
45604256|NCT04848688|Drug|Moxidectin 2 mg|Monotherapy, oral administration, single-dose, fixed-dose, 4 tablets a 2 mg to yield an 8 mg final dose.
45604257|NCT04848688|Drug|Ivermectin 3 mg|Monotherapy, oral administration, single-dose, weight dependent, The number of tablets will be adjusted according to the patients' weight to yield 200 ug/kg final dose.
45604258|NCT04848688|Drug|Placebo|Monotherapy, oral administration, single dose, matching number of tablets to either moxidectin or ivermectin
45604259|NCT05079568|Device|Oculus Go VR headset|Virtual reality programs consisting of interactive games, meditation and deep breathing exercises, and passive virtual reality experiences designed to facilitate relaxation.
45604260|NCT05079568|Device|Sham Oculus Go VR headset|Virtual reality program with two-dimensional nature video
45604261|NCT05471908|Behavioral|As-needed follow up|At hospital discharge, participant receives a recommendation for PRN follow-up. Recommendation informs participant that scheduling a follow-up visit is not needed at discharge and suggests that participant follow symptoms after discharge to decide if a visit is ultimately needed or not.
45756666|NCT00351793|Device|Knee Implant|Total knee replacement with Genesis II posterior stabilized knee
45756667|NCT01272817|Procedure|Nonmyeloablative Allogeneic Transplant|Cladribine 0.14 mg/kg/day for five days, melphalan 100 mg/m2 on one day
45756668|NCT01272817|Procedure|Nonmyeloablative Allogeneic Transplant|Total lymphoid irradiation 100cGy/day times 10 days (Monday through Friday)
45756669|NCT01956435|Device|Excimer Light Treatment|Excimer light treatment will be performed on one leg of every subject as the intervention while the subjects other leg will serve as a control
45804031|NCT05717270|Procedure|Two-layered suture repair|The ruptured Achilles tendon will be sutured in two-layer.
45911178|NCT02004652|Drug|Placebo|Vitamin, 50mg, tablet.
45911179|NCT02004678|Drug|DS-1150b|
45604262|NCT05471908|Behavioral|Automatic follow-up|At hospital discharge, participant receives a recommendation for automatic follow-up. Recommendation instructs participant to schedule a follow-up visit and attend the visit even if symptoms get better.
45604263|NCT05466526|Procedure|High frequency deep sclerotomy (HFDS)|The surgery was performed using the abee® glaucoma tip of Oertli phacoemulsiﬁcation machine (Cata-rhex3, Switzerland) and goniolens. During the procedures, nasal six pockets penetrating 1mm deep from the trabecular meshwork to Schlemm's canal will be formed to promote the aqueous humor outflow.
45604264|NCT05369650|Drug|Lidocaine Hydrochloride, Injectable|The lidocaine group 1, 1.5 and 2 groups were injected with 1% lidocaine 1.5mg/kg (ideal body weight, 10min infusion) after anesthesia induction, respectively, and then continued to infuse 1% lidocaine. 1mg/kg.h, 1.5mg/kg.h, 2mg/kg.h (ideal body weight) until the end of the operation, and a patient-controlled intravenous analgesia (PCIA) pump containing lidocaine (PCIA) 0.3-1.5mg/kg after surgery. h to 72h after surgery.
45604265|NCT05071612|Drug|AD109|Oral administration at bedtime
45604266|NCT05071612|Drug|AD504|Oral administration at bedtime
45604267|NCT05071612|Drug|Atomoxetine Hydrochloride|Oral administration at bedtime
45604268|NCT05071612|Drug|Placebo|Oral administration at bedtime
45604269|NCT05069740|Drug|Salsalate Pill|Salsalate acts as an NFkB inhibitor to reduce systemic inflammation
45604270|NCT05069740|Drug|Placebo|Placebo for the salsalate intervention
45604271|NCT01639144|Biological|PRP and PPP|Autogenous PRP and PPP
45604272|NCT01601626|Drug|Standard-dose Lopinavir/Ritonavir|Two LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry to Week 72.
45604273|NCT01601626|Drug|Double-dose Lopinavir/Ritonavir|Four LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry through Week 72.
45604274|NCT01601626|Drug|Raltegravir|One 400 mg tablet orally twice daily from entry to Week 72.
45604275|NCT01601626|Drug|Isoniazid|300 mg orally once daily from entry through Week 24.
45604276|NCT01601626|Drug|Pyridoxine|25 mg orally once daily from entry to Week 24.
45604277|NCT01601626|Drug|Pyrazinamide|20 to 30 mg/kg orally once daily (not to exceed 2 g per day) from entry through Week 8 study visit (or until completion of intensive TB treatment as determined after dose adjustment in accrual period 1 participants).
45604278|NCT01601626|Drug|Ethambutol|15 to 20 mg/kg orally once daily from entry through Week 8 study visit (or until completion of intensive TB treatment as determined after dose adjustment in accrual period 1 participants).
45604279|NCT01601626|Drug|Rifabutin|300 mg of rifabutin orally once until LPV/RTV is started; then the dose will be reduced to 150 mg daily from the start of LPV/RTV through Week 24.
45604280|NCT01601626|Drug|Rifampin|Weight-based dose; for weight < 45 kg: 450 mg orally once daily; for weight > 45 kg: 600 mg orally once daily, from entry to week 24.
45604281|NCT05428150|Drug|Esbriet 267 MG Oral Capsule|Reference Formulation
45604282|NCT05428150|Drug|EXCL-100, 600 MG Oral Tablet|Test Formulation
45604283|NCT05643508|Drug|(D) DWC202206|Drug of DWC202206 A mg
45604284|NCT05643508|Drug|(D) DWC202207|Drug of DWC202207 B/C mg
45604285|NCT05643508|Drug|(P) DWC202206|Placebo of DWC202206 A mg
45604286|NCT05643508|Drug|(P) DWC202207|Placebo of DWC202207 B/C mg
45604287|NCT05642728|Other|Case management follow-up program|The case manager will monitor asthma control (asthma control test, ACT) and adherence to treatment with questionnaires (inhaler adherence test, TAI) and electronic prescription withdrawal (e-prescription). The case manager will make decisions based on these results and according to pre-designed medical instructions. In addition, the patient will be able to contact the case manager for advice during periods of worsening symptoms. The patient will contact the case manager via a mobile app with messaging and video call option, as well as a contact phone number and email for consultations.
45604288|NCT02737501|Drug|Brigatinib|Brigatinib tablets
45604289|NCT02737501|Drug|Crizotinib|Crizotinib tablets
45604290|NCT04848220|Drug|Temanogrel|Participants will receive a single intravenous dose of temanogrel on Day 1 (Day 1 of PCI procedure)
45604291|NCT04848220|Drug|Placebo|Participants will receive a single intravenous dose of temanogrel matching placebo on Day 1
45604292|NCT01640314|Biological|Cell derived subunit trivalent nonadjuvanted vaccine|A single 0.5 mL dose of the cell derived subunit trivalent nonadjuvated influenza vaccine (TIVc) supplied in prefilled syringes and administered intramuscularly in the deltoid muscle (preferably) of the non dominant arm.
45604293|NCT05642182|Drug|Drug (SFA002) Vitamin D, Magnesium|Capsules
45604294|NCT05642182|Drug|Drug (SFA002) Vitamin D, Magnesium and Propionate|Capsules
45604295|NCT03471637|Other|Compassion-Focused Therapy|"Compassion-Focused Therapy 11 weeks of Compassion-Focused Therapy [based on Compassion-Focused Therapy for Dummies (Welford, 2016)]"
45604296|NCT03471559|Drug|Cannabidiol|single or multiple dosing
45604297|NCT03475069|Other|Custom Designed Exercises|
45604298|NCT03475069|Other|Plates Exercises|
45604299|NCT03475069|Other|Calisthenics Exercises|
45756670|NCT01277575|Device|rtACS stimulation (Verum condition)|Repetitive, transorbital alternating current stimulation (rtACS) is applied with multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 microA. Current intensity is individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation
45604300|NCT05641870|Procedure|Sample collection|Tumor samples will be collected as standard diagnostic procedure at diagnosis. Plasma samples from whole blood extractions will also be collected at diagnosis, after chemoradiotherapy, and every 3 months from there until completing one year of follow-up.
45604301|NCT05641870|Diagnostic Test|Characterization of the tumoral tissue genomic alterations|Genomic alterations of tumor tissue samples will be analyzed locally by next-generation sequencing when material is adequate, as standard diagnostic procedure.
45604302|NCT05641870|Drug|Chemoradiation treatment regimen and maintenance (if amenable)|Patients will be treated with standard chemotherapy (following the clinical practice at each institution). Radiotherapy will be delivered concurrently when feasible with a total dose of 60-66 Gy. In selected cases, due to frailty of the patient or impaired pulmonary function, radiotherapy will be delivered sequentially. In tumors with positive PD-L1 expression, a year of durvalumab 10 mg/m2 every 2 weeks will be administered if there are no contraindications.
45604303|NCT05641870|Diagnostic Test|Genomic and methylation analysis in liquid biopsy|"Blood samples for ctDNA genomic and methylation analysis (4 mL of plasma for each sample) will be sent to the Guardant Health Laboratories in the US and analyzed after Contractual Agreement signature, using the Guardant Reveal test.~This liquid biopsy test uses ctDNA to detect presence of MRD and monitor for recurrence after definitive surgical/systemic therapy for patients with cancer. It has been validated in early-stage colorectal cancer and integrates assessment of somatic alterations with an epigenomic cancer signature to identify the presence of methylation signatures associated with cancer versus normal DNA."
45604304|NCT03471481|Other|No Intervention. Study is Cross Sectional in nature|No Intervention. Study is cross sectional in nature
45604305|NCT03526549|Biological|EN3835|Collagenase Clostridium Histolyticum (CCH)
45604306|NCT05052034|Other|Music|Through headphones, the patients would listen to different types of music during the intervention.
45604307|NCT05641480|Device|Transcutaneous electrical acupoint stimulation&Music therapy|"Procedure: electro-acupuncture;Points: Shenting（DU24）, Benshen（BG13）, Tou Wei （ST8）.The specially-made pad is stick on pierced acupoints, until local sour and heavy feeling coming. The electric stimulator is applied to bilateral BG13 and ST8, with dilatational wave,10/50 Hz and electric current 1-5mA(milliampere).Every session lasts for 30 min per day. The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each participants in all.~Selecting the participants' music of memory and music of favourite(Music is purchased and downloaded from music stores), forming a personalized music playlist, and the decibel level is suitable for participants.~The treatment is designed based on recent literature research in 10 years, former result and expert consensus.~Other Names:~JS-502-A Intelligent and portable electroacupuncture~apparatus(Han's low frequency neuromodulator, made in China)"
45756671|NCT01277575|Device|placebo condition|A clicking sound is presented and the same electrode montage set-up is used during rtASC- and Placebo-stimulation, except that placebo patients received no current (stimulator turned off).
45756672|NCT01270087|Drug|Adalimumab|40 mg IV every 14 days
45756673|NCT01277653|Device|tumor maker interval shortly|tumor maker interval every 3 month
45604308|NCT05641480|Drug|Donepezil hydrochloride tablets or carpalatine bitartrate tablets|"① Donepezil hydrochloride tablets 5 mg, once a day, one tablet each time, before going to bed. The treatment period is 6 months.~② Carpalatine heavy tartrate tablets 1.5mg, 1 tablet/time 2 weeks before treatment, twice a day, breakfast and dinner with food, swallow. If there is no obvious adverse reaction after 2 weeks, the dosage can be increased to 2 tablets/time, twice a day. The treatment period is 6 months."
45756674|NCT01958073|Drug|Conjugated Estrogen Vaginal Cream|
45756675|NCT01958073|Drug|Estradiol Ring|
45604309|NCT05047198|Procedure|Control - Catheter Ablation for VT|"Currently standard of care involves surgical resection of myocardial scarring in structural heart disease. Imaging is performed to identify culprit areas for ablation, pre procedural imaging involves echocardiography, CT scanning and PET imaging to assess cardiac function, ischemia, inflammation and scarring. Radiofrequency energy is delivered via catheter to the targets and is performed under sedation or anesthesia using multiple catheters placed in the heart while the patient is anticoagulated. A conventional approach will be used advancing multiple catheters via femoral veins and/or arteries under a combination of fluoroscopic, ultrasound and electroanatomic guidance. Ablation targets include an arrhythmogenic focus or the critical isthmus of the VT circuit and/ or substrate identified on preprocedural imaging or low voltage areas, scar, identified during endocardial mapping. CA procedures for VT are often long, averaging approximately 5 hours ."
45756676|NCT01958073|Drug|Placebo|
45756677|NCT01270165|Drug|telbivudine|600mg, oral daily over 12 months
45756678|NCT05740215|Drug|F520|F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)
45756679|NCT05740215|Drug|Lenvatinib|Lenvatinib capsules
45756680|NCT01272661|Behavioral|Enhanced Curriculum|Brief health literacy focused modules on breastfeeding delivered in the home by Community Health Workers
45756681|NCT01272661|Behavioral|Enhanced Curriculum+Breastfeeding Doula|In the Doula Program, the Community Health Worker and mother will identify a support person (e.g. grandma, father, friend) who commits to learning about breastfeeding with the mother at home visits, and then helps her with breastfeeding postpartum.
45756682|NCT01272661|Behavioral|Enhanced Curriculum +Father Support|In the Father Support Program, mothers will give their partners father-friendly breastfeeding information and an invitation to a 3-week breastfeeding education group for fathers that includes a resource specialist or resource information for child support, re-entry and job services.
45756683|NCT05740137|Device|AI-assisted colonoscopy|The patients in the intervention group will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
45756684|NCT01277731|Drug|Methylprednisolone|Run-in period: dexamethasone 10-20mg q day iv during chemotherapy Treatment period: methylprednisolone 60-125mg iv during chemotherapy
45756685|NCT02283333|Behavioral|BATE-G|Behavioral Activation and Therapeutic Exposure - Grief therapy is delivered in 7 weekly sessions to the participant.
45756686|NCT02283333|Behavioral|Standard Treatment|Cognitive Restructuring and Supportive Grief Counseling is delivered in 7 weekly sessions to the participant.
45756687|NCT00728923|Drug|NPL-2003|Minocycline (NPL-2003) daily for 12 weeks
45756688|NCT01277809|Behavioral|Interpersonal Interaction|Participants will receive stationary 1:1 interaction time with the same research personnel who conduct the third group walking session at each individual care facility in order to control for the interpersonal interaction likely to be involved in the walking program (Interpersonal Interaction Group; IIG). This group will receive the equivalent interpersonal interaction time with research personnel as those participating in the WPG group. This interaction time will occur with the participant stationary, rather than walking with the researcher.
45756689|NCT01277809|Behavioral|Walking Program|Participants will walk five times per week, supervised by a licensed physiotherapist. Subjects will in general gradually increase their daily supervised walking time as tolerated to a maximum of 30 minutes once per day. The distance and number of minutes walked each time will be recorded. Interpersonal interaction will occur during the walking sessions, and will be similar in quality and quantity to that during the Interpersonal Interaction Group.
45911180|NCT02004678|Other|Placebo|
45911181|NCT02004717|Drug|DS-8895a|
45756690|NCT01277965|Other|50%VO2maxTBR50|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 50%
45756691|NCT01277965|Other|50%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 80%
45756692|NCT01277965|Other|75%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (75% VO2max),a temporary basal rate will be reduced by 80%
45756693|NCT01277965|Other|75%VO2max TBR100|Turning off the pump (75%VO2max TBR100).However, in order to maintain the study blindfold, the pump will be switched off but not removed
45444696|NCT03797079|Drug|Bupivacaine|After the negative aspiration for blood, a bolus dose of 15 ml 0.125% plain bupivacaine will be injected in the catheter, followed by a continuous infusion of 0.25% plain bupivacaine at the rate of 0.1 ml/kg/h for 48 hours
45604310|NCT05047198|Procedure|Treatment - Non-Invasive Radio Ablation for VT|Patients undergoing a non-invasive RA procedure for VT similarly require medical stabilization and multimodal imaging prior to treatment. A non-invasive electrophysiology study is performed under light sedation using ECGi mapping. This procedure requires only the placement of an IV cannula for light sedation, uses the ICD to stimulate VT which is mapped in real time using the ECGi mapping system. The multimodal imaging data is digitally fused and combined with the ECGi data to identify the VT circuit(s) and to attain the targets for radio-ablation. This analogue process is performed off-line by a physician team. The treatment plan is sent for alignment on a 4D planning CT performed with breath holding in the radiotherapy suite. Final treatment targets are reviewed by the local treating team and discussed with our collaborators remotely. Thereafter the patient is booked for a 15 minute out-patient radiotherapy treatment performed on a standard linear accelerator.
45604311|NCT03474991|Drug|Celestamine®|Children in KIDS-STEP will be receiving either oral betamethasone (Celestamine®) or oral placebo dosed once daily for two consecutive days. Celestamine® N 0.5 liquidum is a betamethasone solution and will be used in the active comparator arm. Study medication will be administered orally once a day on two consecutive days. A standard dose of 0.1-0.2 mg/kg will be used. All doses used in KIDS-STEP fall into the range of recommended doses according to the Summary of Medical Product Characteristics.
45604312|NCT05640934|Drug|Melatonin|The patients will be given 5 mg melatonin the night before surgery, 12 hours before the scheduled time of surgery, followed by another 5 mg melatonin two hours before surgery.
45604313|NCT05640934|Drug|Placebo|The patients will be premedicated with placebo tablets, which will be administered at the same times as the melatonin group.
45604314|NCT05037370|Device|Wave-Front Optimized (WFO) ablation vs Topography-guided (TG) ablation|Patient will undergo PRK or LASIK using WFO ablation in one eye and TG ablation on contralateral eye
45604315|NCT05634304|Behavioral|A mobile app self-management (mSM) program|The mSM program is developed on Bundura's self-efficacy theory, which provides four sources of information for SM. The strategies of the mSM consist of mobile app to management program including peer support, appraisal, goal setting and self-monitoring of exercise for OA and symptom management.
45604316|NCT03377803|Combination Product|VP-102 - Cantharidin, Topical Film Forming Solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
45604317|NCT03377803|Combination Product|Placebo -Topical Film Forming Solution without VP-102|Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
45604318|NCT03474835|Diagnostic Test|ISCHEMIC HEART DISEASE diagnostic|ISCHEMIC HEART DISEASE diagnostic
45604319|NCT05013580|Procedure|Guided bone regeneration (GBR)|Bone grafts will be placed in the patient's jawbone, along with a membrane to cover the bone grafts. A horizontal incision over the edentulous ridge crest will be made along with vertical incisions if indicated. Buccal and lingual full thickness mucoperiosteal flaps will be reflected to expose the alveolar bone. Intra-marrow penetration (decortication of the alveolar bone to increase vascular supply to the bone grafts) at the surgical site alveolar bone will be made with a high-speed hand piece and diamond bur. Bone allograft material will be placed to fill the alveolar bone defect. The bone graft will then be covered with a membrane and secured with sutures.
45604320|NCT03471325|Procedure|Plaque disclosed with air flow|air polishing with prior plaque disclosing
45604321|NCT03471325|Procedure|Plaque disclosed with rubber cup|rubber cup polishing with prior plaque disclosing
45604322|NCT03471325|Procedure|Non plaque disclosed air flow|air polishing with no prior plaque disclosing
45604323|NCT03471325|Procedure|Non plaque disclosed rubber cup|rubber cup polishing with no prior plaque disclosing
45604324|NCT04844164|Drug|Cholecalciferol 15000 UNT/ML Oral Solution|A single dose (150,000 IU) of cholecalciferol aqueous solution per os
45604325|NCT03469921|Drug|administered therapeutic regimens|administered therapeutic regimens
45756694|NCT01277965|Other|Rest|Patient will be in rest, basal insulin flow rate will not be change
45756695|NCT01898403|Drug|Indocyanine green solution|Administered peri-tumoral and intradermally
45756696|NCT01898403|Drug|Isosulfan blue (ISB)|Administered peri-tumoral and intradermally
45756697|NCT01898403|Diagnostic Test|Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC)|
45756698|NCT01901211|Other|Exergaming Intervention|The exergaming system will be installed into the participants' homes. Players will pedal the exergame bike in order to move their game avatar. Headsets allow players to communicate with each other in real-time. Participants will play the games 3 to 5 times per week, during scheduled game times. Players will wear a heart rate (HR) monitor and will achieve game benefits for reaching their target HR. They will be asked to exercise in a target HR zone of 40-65%HR reserve. Each week, participants will receive a call from a research assistant (RA), who will provide feedback on their exercise progress and a HR goal for each week. The RA will also record physical and social activities engaged in and any difficulties like leg pain or technical issues.
45756699|NCT00715741|Other|FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3 -5 cm water|FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3-5 cm water
45756700|NCT00715741|Other|FiO2 0.3 without PEEP|FiO2 0.3 without PEEP
45604326|NCT05392972|Behavioral|Assessment of stress, resilience and associated factors in anesthesia professionals|Assessment of stress, resilience and associated factors in anesthesia professionals
45604327|NCT03474757|Other|Data Collection|Data will be extracted from July 2009 to the last available database extraction
45604328|NCT03110809|Dietary Supplement|Capsinoid|Capsinoids are nunpungent analogs of capsaicin that activate BAT by stimulating sensory neurons in the gastrointestinal tract. Chronic ingestion of capsinoids may stimulate the development or recruitment of new BAT from precursor stem cells within white adipose tissue depots.
45604329|NCT03110809|Dietary Supplement|Placebo|Placebo for capsinoid. Capsule contains no active ingredients.
45604330|NCT05372770|Device|Flourish Vaginal Care system|Flourish includes Restore® vaginal moisturizing gel, a Class II medical device cleared by the FDA, in addition to two other kit components
45604331|NCT02523625|Device|Ultrasound of temporal and axillary arteries|Each patient will have a clinical assessment and ultrasound examination of both temporal and axillary arteries
45604332|NCT05368714|Behavioral|Economic Empowerment (EE)|EE will be provided via a child development account (CDA). CDAs provide children with basic financial education, introduce them to formal financial institutions, and incentivize them to save by matching their deposits. Any of the child's family members, relatives, or friends will be allowed and encouraged to contribute towards the CDA. The account will be matched with money from the program. The maximum family contribution to be matched by the program will be an equivalent of US $10 per month per family or US $120 for the 12-month intervention period.
45604333|NCT05368714|Behavioral|Multiple Family Group based Family Strengthening (MFG-based FS)|MFG-based FS approach is a family-centered, group delivered, evidence-informed, strength-based intervention designed for children and adolescents whose families struggle with poverty and associated stressors. MFG is based on building support for parents and families by providing opportunities for parents and children to communicate in a safe setting with other families who have shared experiences. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support. Participants in this study arm will receive 16 session of MFG-based FS sessions, delivered by delivered by trained Community Health Workers and Parent Peers.
45604334|NCT05368714|Behavioral|EE plus MFG-based FS|EE plus MFG-based FS directly addresses both the economic needs and mental health functioning. It will consists of an EE intervention that comprises a family monetary savings program using CDAs, and a family-based dialogue and training via MFG focused on strengthening family relationships and mental health challenges.
45604335|NCT03000829|Other|Tele-intensivist consultation|Standardized consultation to on-site cardiac arrest team by off-site intensivist via two-way audiovisual link using a mobile telemedicine cart
45604336|NCT03000829|Other|"Simulated observation by ICU physician"|Display of silent, pre-recorded, non-interactive videotape of an ICU physician. The on-site cardiac arrest team will be told that an intensive care physician is observing the mock code.
45604337|NCT03469765|Other|does not apply|biological sample taking: urine, blood
45604338|NCT04419844|Procedure|Tar with Botox|Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect with Botox injection .
45604339|NCT03469687|Device|Symax uncemented hip stem|
45604340|NCT05361538|Device|True circular microwave needle|Use true circular microwave needle for thermal ablation
45604341|NCT03474601|Other|Dynamic hormone study and Magnetic resonance imaging|"Medical history~Imaging examination including brain magnetic resonance imaging~Blood (Basal hormone study and follow-up study) and pituitary tumor tissue"
45604342|NCT05623072|Device|Active tDCS|20 min, 2 milliampere (mA), Anodal tDCS in vmPFC
45604343|NCT05623072|Device|Sham tDCS|20 min, vmPFC Sham tDCS
45604344|NCT04854772|Behavioral|Mind Body Syndrome Therapy for Long Covid|The intervention consists of a mind-body based intervention for the COVID long haul syndrome. The components of the intervention include knowledge therapy, desensitization, emotional expression, and stress reduction techniques.
45604345|NCT05357248|Device|BT-NCBT-00X|the intervention group will consist of 20 patients to receive the BT-NCBT-00X treatment for 90 days. They will receive a baseline MRI-PDFF, Fibroscan and have the tests repeated at 90 days.
45604346|NCT05420194|Other|Postural stability measurement|Postural stability of the participants will be evaluated with the NeuroCom Balance Master Static Posturography device. Evaluations will be carried out in the presence of two physiotherapists to prevent the patient from falling. Posturography devices allow us to quantitatively evaluate posture and balance and obtain objective results by measuring postural sway.
45604347|NCT05420194|Other|Timed Up and Go test|During the Timed Up and Go test, which is applied to evaluate dynamic balance and performance, the participant is asked to get up from the chair, walk 3 meters and sit back on the chair. The participant's time to complete the test is recorded. Completion of the test for more than 10 seconds indicates an increased risk of falling
45604348|NCT05008432|Diagnostic Test|Home sleep apnea testing|Participants will be monitored with a WatchPAT device for home based diagnosis of OSA (for patients hospitalized with HFpEF, the sleep test may be performed in the hospital or at home).
45604349|NCT05352880|Diagnostic Test|serum magnesium level, FEMg|"Blood (serum) for: Magnesium (Mg).Urea, creatinine. Calcium (ca), phosphorus (ph).Sodium (Na), potassium (k), chloride (CL).Fasting blood glucose, cholesterol, triglycerides. Intact PTH, 25OH vitamin D.uric acid, albumin. CBC.~Trough level of cyclosporine or tacrolimus. ii. Urine for:24 hour urinary: Mg, Ca, Ph, Cl and protein. Spot urine sample to calculate fractional excretion of Mg (FEmg)~. Detailed history taking, Thorough Systemic physical examination."
45604350|NCT05348512|Other|spectral imaging|non-contact, non-invasive hyperspectral and multispectral imaging without a diagnostic test
45604351|NCT05348512|Other|photoplethysmography|non-invasive pulse oximetry without a diagnostic test
45604352|NCT04999462|Other|Full-fat fermented dairy|Subjects assigned to the full-fat fermented dairy condition will consume 1 serving/d each of full-fat yogurt (plain or reduced sugar varieties) and full-fat fermented cheese.
45604353|NCT04999462|Other|Low-fat fermented dairy|Subjects assigned to the low-fat fermented dairy condition will consume 1 serving/d each of low-fat yogurt (plain or reduced sugar varieties) and lower-fat fermented cheese (e.g., reduced-fat or low-fat fermented cheese).
45756701|NCT00715741|Other|FiO2 >0.9 with 3-5 cm water PEEP|FiO2 >0.9 with 3-5 cm water PEEP
45756702|NCT00715741|Other|FiO2 >0.9 without PEEP|FiO2 >0.9 without PEEP
45604354|NCT04999462|Other|Non-dairy, non-fermented foods|Subjects assigned to the control condition will consume 2 servings/d of nondairy, nonfermented foods with a macronutrient composition that is similar to that of the low-fat fermented dairy condition.
45604355|NCT05344066|Other|Best NHS Care|Personalised advice and support from a diabetes dietician to follow NICE healthy eating diet and physical activity recommendations for GDM.
45604356|NCT05344066|Other|Intermittent Low Energy Diet|Two non-consecutive days of a food based 1000 kcal diet and five days of the NICE healthy eating diet and physical activity recommendations for the best NHS care group.
45604357|NCT04853992|Drug|LEO 152020|LEO 152020 is a small drug molecule which can bind to the histamine 4 receptor (H4R). LEO 152020 is a tablet for oral administration.
45604358|NCT04853992|Drug|LEO 152020 placebo|LEO 152020 placebo is a tablet for oral administration. LEO 152020 placebo contains the same excipients in the same concentration as the LEO 152020 tablet, except the medical ingredient, LEO 152020.
45604359|NCT05608954|Other|Bobath Concept|Handling of the Bobath Concept
45604360|NCT05608954|Other|Pediasuit|Pediasuit
45604361|NCT05608954|Other|Locomotor training|Locomotor training
45604362|NCT05608954|Other|Stretching|Active, passive, active-assisted stretching
45756703|NCT05735379|Drug|Deprescribing anticholinergic and sedative mediications|Deprescribing plan targeting a reduction in Drug Burden Index score of ≥ 0.5
45756704|NCT00750373|Procedure|Valve surgery with removal of vegetations|Early valve repair or replacement with removal of vegetations within 48 hours of randomization
45604363|NCT05608954|Other|Psychomotricity|Psychomotor skills
45604364|NCT05608954|Other|Virtual reality|Virtual reality
45604365|NCT05603338|Procedure|LSG with omental band|LSG with omental band
45756705|NCT05739903|Drug|DA-1229_01 5/1000mg (Before)|single dose administration (one tablet once a day)
45756706|NCT05739903|Drug|DA-1229_01 5/1000mg (After)|single dose administration (one tablet once a day)
45756707|NCT02987517|Other|Increased running cadence gait retraining|Runners use an increased cadence, or step rate, 7.5% greater than baseline preferred cadence
45756708|NCT02987517|Other|Forefoot Strike gait retraining|Runners use a forefoot strike running gait instead of a rear foot strike running gait.
45911182|NCT02004730|Device|ABSORB implantation|ABSORB implantation for long (> 24mm) single vessel disease
45604366|NCT05603338|Procedure|LSG|just to do sleeve gastrectomy
45604367|NCT04988308|Drug|Bermekimab|Bermekimab will be administered subcutaneously.
45604368|NCT04988308|Drug|Adalimumab|Adalimumab will be administered subcutaneously.
45604369|NCT04988308|Drug|Placebo|Placebo will be administered subcutaneously.
45604370|NCT04984798|Drug|Vitamin E|Twice daily oral supplementation with Vitamin E for 6-9 weeks.
45604371|NCT04974658|Procedure|Inter-semispinal plane block|Ultrasound Inter-semispinal plane block in block group
45604372|NCT04843228|Behavioral|Cognitive Bias Modification|There will be four sessions of CBM. Each session will consist of two different part. The first part of the intervention will be the training based on the ambiguous scenario paradigm for perfectionism developed by Dodd (2019). Participants will need to complete word fragments in the last part of the scenario to resolve the ambiguity of the scenario. Then, a comprehension question will be presented to them to underscore the interpretation condition. Feedback will be given after each question. For the second part of the intervention aimed to intervene intolerance to uncertainty, word sentence association paradigm for intolerance to uncertainty developed by Oglesby (2017) will be used. In this intervention, participants will be asked to judge the relatedness of words and sentences which will be presented to them. Feedback will be given after each word-sentence.
45604373|NCT04843228|Behavioral|Cognitive Bias Modification for Control Group|For the first part of the intervention, the control group will be presented with the same procedures as the active group; however, feedbacks will be given to resolve the scenarios in a neutral way. When it comes to the second part of the intervention, different word-sentence pairings will be presented to the control group.
45756709|NCT02987517|Other|Strengthening exercises|foot and ankle strengthening exercises performed by all subjects to prepare musculoskeletal tissues for requirements of new running gait.
45756710|NCT00751777|Biological|heat-labile enterotoxin of E. coli (LT)|Travelers' Diarrhea Vaccine System
45756711|NCT00751777|Biological|Placebo|Travelers' Diarrhea Vaccine System
45756712|NCT01902459|Biological|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
45756713|NCT01902459|Other|Standard of Care|Standard of Care will be manual compression (MC) with or without a topical absorbable hemostat (TAH) or any other adjunctive hemostasis technique that is deemed by the surgeon to be his/her standard of care.
45756714|NCT01274611|Drug|Botulinum Toxin Type A|Botox will be injected into the underarm, targeting the sweat glands, to stop underarm sweating.
45756715|NCT01274611|Device|Suction-Curettage|The doctor will insert a suction tool into two small incisions in order to suction out the sweat-producing glands. It is similar to liposuction, but instead of suctioning out fat, the doctor suctions out the layer of the deep skin where the sweat glands are located to decrease underarm sweating.
45756716|NCT05735145|Drug|paclitaxel combined with platinum|Adjuvant chemotherapy with paclitaxel combined with platinum
45756717|NCT00729781|Device|Polyester Implants|Three polyester (PET) implants will be implanted in each side of the nose affected by external NVC. See the detailed description for information about the implant procedure.
45756718|NCT01903005|Drug|Higher bioavailability BNX sublingual tablets|Once daily, open-label treatment with higher bioavailability BNX sublingual tablets for 24 weeks
45604374|NCT04843072|Device|Evolut R/PRO bioprosthesis|To compare Evolut R/PRO versus Sapien S3/Ultra in failing surgical bioprostheses
45604375|NCT04843072|Device|Edwards Sapien S3/Ultra bioprosthesis|Edwards Sapien S3/Ultra bioprosthesis
45604376|NCT03751007|Biological|AG019 - Low Dose|Solid, orally administered capsule - 2 capsules per day for 1 day (single dose) or 8 weeks (repeat dose)
45604377|NCT03751007|Drug|Teplizumab|Daily IV infusions of Teplizumab during the first 12 days of AG019 treatment. Total cumulative dose is approximately 17mg (dose calculation based on body surface area).
45604378|NCT03751007|Drug|Placebo-AG019|Formulated identically to AG019 with the active ingredient removed.
45604379|NCT03751007|Drug|Placebo-Teplizumab|Formulated identically to teplizumab with the active ingredient removed.
45604380|NCT03751007|Biological|AG019 - High Dose|Solid, orally administered capsule - 6 capsules per day for 1 day (single dose) or 8 weeks
45604381|NCT03751007|Biological|AG019 - High Dose|Solid, orally administered capsule - 6 capsules per day for 8 weeks.
45604382|NCT05725967|Procedure|Primary Obesity Endoscopic Procedures|Any primary endoscopic procedure for treatment of obesity including endoscopic sleeve gastroplasty (ESG), intragastric balloons (IGB), Aspiration therapy, pylorus sparing antral myotomy (PSAM), primary obesity surgery endoluminal (POSE), gastroplasty with endoscopic myotomy (GEM).
45604383|NCT05725967|Procedure|Endoscopic Revision of Bariatric Surgical Procedures|Any endoscopic revision procedure in a post-bariatric surgical patient, including transoral outlet reduction (TORe), restorative obesity surgery endoluminal (ROSE), argon plasma coagulation of the outlet (APC), endoscopic suturing.
45604384|NCT05725967|Procedure|Bariatric Surgery Procedures|Any bariatric surgical procedure including Roux-en-Y gastric bypass (RYGB), laparoscopic sleeve gastroplasty (LSG), laparoscopic adjustable gastric banding (LAGB)
45604385|NCT05725967|Device|Endoscopic Sleeve Gastroplasty, Trans-oral Outlet Reduction|Any endoscopic procedure using an endoscopic suturing device for primary obesity treatment or revision of post bariatric complications.
45604386|NCT05725967|Device|Intragastric Balloon|An endoscopic bariatric procedure involving the placement of an intragastric balloon.
45604387|NCT05725967|Device|Primary obesity surgery endoluminal, Restorative obesity surgery endoluminal|Any endoscopic procedure using an endoscopic plicating device for primary obesity treatment or revision of post bariatric complications.
45604388|NCT05725967|Device|Argon Plasma Coagulation, Gastroplasty with Endoscopic Myotomy, Bariatric Endoscopic Antral Myotomy, Pylorus Sparing Antral Myotomy|Electrosurgical interventions for obesity. Use of electrosurgical devices, such as electrocautery for the primary treatment of obesity or obesity related complications.
45604389|NCT05725967|Device|Aspiration Therapy|Placement of an aspiration therapy device for the treatment of obesity.
45604390|NCT02230007|Drug|MEOPA|3 sessions of reeducation using MEOPA
45604391|NCT02230163|Biological|anti-CHIKV hyperimmune immunoglobulins|Anti-CHIKV immunoglobulins (CHIKVIg) were purified after the Tégéline manufacturing process from a pool of 583 plasma samples from donors in the convalescent phase of CHIKV infections. Anti-CHIKV hyper immune intravenous immunoglobulin (50 mg/ml) is prepared as a powder to be reconstituted. The therapeutic regimen will consist of 2 doses of 0.5 g/kg 12 hours apart.
45756719|NCT01278121|Dietary Supplement|Diet A|3 days, 6 meals a day
45756720|NCT01278121|Dietary Supplement|Diet B|10 days, 6 meals a day
45604392|NCT02230319|Other|Cryotherapy|
45604393|NCT02230319|Drug|Paclitaxel|
45604394|NCT04580537|Drug|Enstilar|Daily application on affected fingers (nail plates, nail folds, and surrounding skin)
45756721|NCT00614029|Device|Sumatriptan (via Intraject System)|0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt
45756722|NCT01905423|Drug|Albendazole (annual)|Albendazole 400 mg pnce annually
45604395|NCT04580537|Device|Ablative fractional laser|Pre-treatment of affected fingers (nail plates, nail folds)
45604396|NCT04546841|Biological|multipeptide cocktail|"Three groups of participant will be administered the multipeptide cocktail~Part I: Age 18-55 at the time of screening~Part II: Age 56-74 years at the time of screening~Part III: Age ≥ 75 years at the time of screening"
45604397|NCT00112073|Drug|bapineuzumab|IV, Q13w
45604398|NCT00112073|Other|placebo|IV Q13w
45604399|NCT00141323|Drug|lasofoxifene|0.5 mg once per day, orally
45604400|NCT00141323|Other|placebo|placebo
45604401|NCT00141323|Drug|lasofoxifene|0.25 mg once per day, orally
45604402|NCT00135395|Drug|Atazanavir+ritonavir|Capsules, Oral, 300mg/100mg, once daily, 24 weeks.
45604403|NCT00135395|Drug|Lopinavir+ritonavir|Capsules, Oral, 800mg/200mg, twice daily, 24 weeks.
45604404|NCT05725889|Device|recation time test|visual-finger tapping and auditory reaction time tests
45604405|NCT02230397|Other|plantaricin a (active product)|Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
45604406|NCT02230397|Other|placebo product|Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
45604407|NCT02230553|Drug|Lapatinib|
45604408|NCT02230553|Drug|trametinib|
45604409|NCT02259023|Other|Liquid: Sugar sweetened beverage consumption|Sugar sweetened beverage consumption
45756723|NCT01905423|Drug|Diethylcarbamazine (annual)|Diethylcarbamazine 6 mg/kg once annually
45756724|NCT01905423|Drug|Albendazole (semiannual)|Albendazole 400 mg twice annually
45756725|NCT01905423|Drug|Diethylcarbamazine (semiannual)|Diethylcarbamazine 6 mg/kg twice annually
45756726|NCT04345549|Other|Individualised Ayurveda|Saline warm water gargle, Steam, Paracetamol for body temperature and plenty fluid and rest, Food and herbs recommendation as per individual Ayurveda constitution, Using Ginger/ lemon/ turmeric/ honey recommended as per individual, Yoga breathing
45756727|NCT05734911|Drug|Niraparib|We did not set a fixed starting dose and strict medication standard,compared with a randomized controlled trial.In our study,enrolled patients received different oral doses of niraparib until disease progression, severe toxicity occurred, or death in reality. We were interested in the dose adjustment and duration of niraparib in real world.
45756728|NCT01278355|Device|Ear acupuncture|Ear acupuncture
45604410|NCT02259023|Other|Solid: Grain based desserts and candy consumption|Grain based desserts and candy consumption
45604411|NCT05726201|Diagnostic Test|ultrasound|Point-Of-Care Ultrasound (POCUS) As an Early Screening Tool for Diagnosing Skull Fractures In Children With Mild Closed Head Injuries
45604412|NCT02230631|Other|No treatment given|Two different questionnaires will be applied to patients during a regular clinical visit.
45604413|NCT02230709|Other|Dry Needling|Needling with acupuncture needle in a myofascial trigger point.
45604414|NCT02230709|Other|"TENS and dry needling"|Application of TENS current after dry needling technique
45604415|NCT02230787|Device|Recession coverage without Emdogain|In the control group subjects the recession coverage surgery will be performed without Emdogain.
45604416|NCT02230787|Device|Recession coverage with Emdogain|In the test group subjects the recession coverage surgery will be performed with Emdogain.
45604417|NCT03530735|Other|Finger-prick Autologous Blood (FAB)|"Patients will be instructed to use FAB therapy by:~Hand hygiene with soap and water. Dry, then wipe their fingertip with an alcohol street before leaving to air dry.~Use a diabetic lancet to prick their cleaned fingertip.~Squeeze 5 drops of blood form their finger into 10ml of saline.~Gargle the blood-saline mixture for 5 minutes.~Swallow the blood-saline mixture.~Repeat this 4 times per day."
45604418|NCT05723549|Drug|HCP1803-3|Take it once per period
45604419|NCT05723549|Drug|RLD2002|Take it once per period
45604420|NCT05723549|Drug|HCP1904-1|Take it once per period
45604421|NCT03530579|Behavioral|Educational group trainings|"Participants will receive 6 two and a half hour educational group training's over the course of 6 months. These sessions will be led by a trained CHW in your language and will be held on a monthly basis in a community based location.~Session 1: What is Diabetes~Why is Prevention Important~Session 2: Nutrition Session 3: Physical Activity Session 4: Cardiovascular Disease & Diabetes Complication Session 5: Stress Management Session 6: Access to Service"
45604422|NCT03530579|Behavioral|Community Health Care Worker|A community health care worker answer your questions about diabetes and refer participant to a physician. Survey will be completed at the start of the study and during the 3rd, 6th and 12th months
45604423|NCT03530501|Other|Diet|Very low calorie ketogenic diet followed by low calorie diet
45604424|NCT03530501|Dietary Supplement|Synbiotic1|B. lactis, Lactobacillus rhamnosus, B. longum ES1 and prebiotics fiber
45604425|NCT03530501|Dietary Supplement|Synbiotic2|B. animalis subsp. lactis and prebiotics fiber
45604426|NCT04261049|Drug|Triamcinolone Acetonide Extended-Release Injectable Suspension|A single ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) intra-articular knee injection.
45604427|NCT05715359|Procedure|Reconstruction|Standardized template for reconstruction of continious defects of the jaws.
45604428|NCT00094991|Drug|Muraglitazar|
45604429|NCT03133715|Procedure|laparoscopic repair|surgical repair of ventral hernia using laparoscopic repair
45604430|NCT03133715|Procedure|robot-assisted repair|surgical repair of ventral hernia using robot-assisted repair
45604431|NCT00057473|Drug|carboplatin + irinotecan|Solution, IV, Carbopaltin AUC 4 mg/ml.min every 21 days; irinotecan 12 mg/m2/day x 10 days , Minimum of two cycles of chemotherapy projected to be up to 6.
45604432|NCT00057473|Drug|irinotecan|Solution, IV, irinotecan 12 mg/m2/day x 10 days, minimum of two cycles of chemotherapy projected to be up to 6.
45604433|NCT00050687|Drug|Gallium maltolate|
45604434|NCT00035789|Drug|Entecavir|
45756729|NCT05739825|Other|FMT from healthy donors|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through FMT
45756730|NCT01270477|Other|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment for 2,5 hours at maximum 14 meters (standard table in Norway).
45604435|NCT00035633|Drug|Entecavir|
45604436|NCT00028301|Drug|Atazanavir|
45604437|NCT00028301|Drug|Lopinavir/Ritonavir|
45604438|NCT00028067|Drug|Atazanavir|
45604439|NCT00028067|Drug|Nelfinavir mesylate|
45604440|NCT00005795|Drug|arsenic trioxide|
45604441|NCT00004907|Drug|busulfan|
45604442|NCT00004907|Drug|cyclophosphamide|
45604443|NCT00004907|Drug|etoposide|
45604444|NCT00004907|Procedure|allogeneic bone marrow transplantation|
45604445|NCT00004907|Procedure|bone marrow ablation with stem cell support|
45604446|NCT00004907|Procedure|peripheral blood stem cell transplantation|
45604447|NCT00004907|Radiation|radiation therapy|
45756731|NCT01278433|Biological|IMOVAX Polio™: Inactivated Poliomyelitis Vaccine|0.5 mL, Intramuscular
45604448|NCT05726123|Device|The Exopulse Mollii Suit on a Fibromyalgia patient|The present study consists of a comparative, randomized, controlled and clinical trial conducted to explore and compare the acute and chronic effects a treatment session with the Exopulse Mollii Suit, a treatment session with the Exopulse Mollii Suit combined with VR and a training session have on a Fibromyalgia patient.
45604449|NCT04469777|Drug|erythropoietin|Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
45604450|NCT00004895|Drug|octreotide acetate|
45604451|NCT05372783|Drug|STI-9199|STI-9199 is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
45604452|NCT05372783|Drug|Placebo|Diluent solution
45604453|NCT03527849|Behavioral|Mindfulness-Based Stress Reduction|The intervention will be an MBSR course.
45604454|NCT03527849|Behavioral|Health Enhancement Program|Propose to use an active control training, the Health Enhancement Program (HEP), an intervention designed to isolate mindfulness as a testable active ingredient. HEP and MBSR are structurally equivalent in that they share the same amount of in- and out-of class work time. The content of the HEP intervention meet the following criteria: (1) class activities match MBSR activities as closely as possible, (2) activities represent valid, active, therapeutic ingredients in their own right, and (3) these ingredients do not include mindfulness.
45604455|NCT00004181|Drug|busulfan|
45604456|NCT00004181|Drug|cyclophosphamide|
45604457|NCT00004181|Procedure|allogeneic bone marrow transplantation|
45604458|NCT00004181|Radiation|radiation therapy|
45604459|NCT00004175|Drug|cyclophosphamide|
45604460|NCT00004175|Drug|docetaxel|
45604461|NCT00004175|Drug|doxorubicin hydrochloride|
45604462|NCT00004175|Procedure|conventional surgery|
45604463|NCT05708573|Drug|Rosuvastatin|In Treatment Period 1, participants will receive a single oral tablet of rosuvastatin in the morning of Day 1. In treatment period 2, on the morning of Day 4, participants will receive a single 20 mg dose of rosuvastatin (co-administered with the morning dose of ALXN2040).
45604464|NCT05708573|Drug|ALXN2040|In Treatment Period 2, participants will receive oral tablets of ALXN2040 three times daily on Days 1 through 7.
45604465|NCT00004169|Drug|carboplatin|
45604466|NCT00004169|Drug|cyclophosphamide|
45604467|NCT00004169|Drug|etoposide|
45604468|NCT00004169|Procedure|peripheral blood stem cell transplantation|
45604469|NCT00004169|Radiation|radiation therapy|
45756732|NCT05739747|Other|Questionnaire|"All patients should complete the following questionnaires:~On the day of surgery:~Patient registration.~Complete medical history.~Gendolcat scale (including the Spanish version of the SF-12 scale).~Spanish version of the catastrophizing scale."
45604470|NCT04468295|Procedure|Bonding|Bonding of upper and lower arches including 2nd maxillary molars with bracket prescription Roth 0.018 inch
45604471|NCT04468295|Procedure|Leveling and alignment|Leveling and alignment till 0.016 x0.022 Ni Ti
45604472|NCT04468295|Procedure|Extraction|Extraction of maxillary 1st premolars
45604473|NCT04468295|Procedure|Retraction|En-masse retraction using 0.017x0.025 TMA T loop
45604474|NCT04468295|Procedure|Digital models|impression taking and digital scanning
45604475|NCT04468295|Procedure|measurement|Assessment the rate of retraction for 6 months
45604476|NCT00002429|Drug|Lamivudine/Zidovudine|
45604477|NCT00002429|Drug|Nelfinavir mesylate|
45604478|NCT00002429|Drug|Stavudine|
45604479|NCT00002429|Drug|Didanosine|
45604480|NCT00002411|Drug|Nelfinavir mesylate|
45604481|NCT00002411|Drug|Lamivudine|
45604482|NCT00002411|Drug|Stavudine|
45604483|NCT00002411|Drug|Zidovudine|
45604484|NCT00002411|Drug|Didanosine|
45604485|NCT03530033|Drug|Lidocaine|Local injection of lidocaine reduces muscle tremor
45756733|NCT05739747|Other|Questionnaire|The investigators should complete a questionnaire during the surgical procedure specifying the anesthetic technique used, drugs and doses used and record any incident during the surgical procedure
45756734|NCT05739747|Other|Questionnaire|The investigators should complete a questionnaire 24 hours after surgery to assess the possible presence of postoperative pain as well as the intensity and need for rescue analgesia.
45756735|NCT05739747|Other|Questionnaire via telephone call|At 3 months, patients will be called and a structured questionnaire will be completed to assess the presence of chronic postoperative pain.
45756736|NCT05739747|Other|Physical examination|Those women who, after the telephone call, are considered to have chronic post-surgical pain will undergo a physical examination to confirm it. The type of pain and its intensity will also be evaluated. The impact on their daily physical activity and quality of life will be evaluated by means of a questionnaire.
45756737|NCT01906515|Device|Continuous non-invasive hemoglobin monitoring|Anesthesiologist is provided with real-time continuous non-invasive hemoglobin monitoring to influence care provided to patient
45756738|NCT00730483|Drug|PVA microporous hydrospheres/doxorubicin hydrochloride|
45604486|NCT03527771|Device|Video-assisted CPR|Emergency call using a Software capable of video Transmission for Video assistance in CPR
45604487|NCT03527771|Drug|telephone-assisted CPR|Emergency call with telephone assistance in CPR
45604488|NCT03529721|Other|zumba dance fitness|females in this group will be instructed to engage into12 classes of 60-minute Zumba® fitness over an 8-week period of continuous dance movements to Latin music with varying intensity level throughout the sessions. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced.
45604489|NCT03529721|Other|non zumba dance|participants in this group will be doing their normal daily activities throughout the 8-week period.
45604490|NCT03529643|Drug|Dexmedetomidine|Anesthesia with sevoflurane-remifentanil-dexmedetomidine
45604491|NCT03529643|Other|Without dexmedetomidine|Anesthesia with sevoflurane-remifentanil
45604492|NCT03529331|Drug|Morphine Sulfate Immediate Release|15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days
45604493|NCT03529331|Drug|Oxycodone/Acetaminophen|5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days
45604494|NCT03529331|Drug|Hydrocodone/Acetaminophen|5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days
45604495|NCT04441541|Other|Treadmill with auditory feedback|Participants will receive training 3 times per week for 4 weeks (12 sessions).
45604496|NCT04441541|Other|Treadmill with visual feedback|Participants will receive training 3 times per week for 4 weeks (12 sessions).
45604497|NCT04441541|Other|Treadmill with auditory and visual feedback|Participants will receive training 3 times per week for 4 weeks (12 sessions).
45604498|NCT04441541|Other|Treadmill training|Participants will receive training 3 times per week for 4 weeks (12 sessions).
45604499|NCT03529253|Drug|Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily|Alirocumab group receive Alirocumab75mg/2week subcutaneous injection plus Rosuvastatin10mg/daily by oral for 9 months.
45604500|NCT03529253|Drug|Rosuvastatin calcium10mg|Rosuvastatin10mg/daily by oral for 9 months.
45604501|NCT03532607|Other|Music|Patients will listen to soothing music for 30 minutes before their standard of care botox injection
45604502|NCT03532529|Other|not applicable, it is an observational study|not applicable, it is an observational study
45604503|NCT05725343|Drug|Canakinumab|Canakinumabwill be administered up to three years, or until lung cancer diagnosis, unacceptable toxicity or physician/subject's decision to withdraw, whichever comes first.
45604504|NCT05725343|Drug|Placebo|placebo will be administered up to three years, or until lung cancer diagnosis, unacceptable toxicity or physician/subject's decision to withdraw, whichever comes first.
45604505|NCT04469309|Other|Group I Brandt-Daroff Exercises|"In group I Brandoff Exercises will be performed using standard method, in which the patient is in the sitting position on examination table, the patient moves into the lying position on the affected side on the shoulder, with the head angled upward with about 45. The patient stays in this for 30 s and then goes back to the sitting position, looks forward and remains in this position for 30 s as well. The patient repeats the same procedure for the other side, too.~The patient performs this maneuver 2 times, twice a day. For total 9 days for 3 weeks. Pre, mid and post assessment."
45604506|NCT04469309|Other|Group II Half-Somersault Maneuver|In group II Half-Somersault Maneuver will be done, the patient performs this maneuver 2 times, twice a day. For total 9 days for 3 weeks.
45604507|NCT03529175|Drug|Abraxane (nab-paclitaxel)|
45604508|NCT03529175|Drug|Gemcitabine|
45604509|NCT05330351|Diagnostic Test|Gastric Ultrasound|The investigators will compare gastric fluid volume as determined by ultrasound pre-induction vs. gastric volume aspirated via an orogastric tube post-intubation. The results will be stratified into low risk, moderate risk and high risk for aspiration based on ultrasound exam by an investigator off-line.
45604510|NCT04469387|Procedure|Limited decompressions at adjacent segment with asymptomatic pre-existing spinal canal stenosis|In terms of limited decompression at the adjacent segment, partial laminotomy, flavectomy, and bilateral medial facetectomies up to the pedicle will be performed. Complete laminectomy and destroy of posterior ligament complex will be avoided.
45604511|NCT04469387|Procedure|Responsible segments fused|In terms of responsible segments fused, L4-5 and L5-S1 were fused using posterior lumbar interbody fusion (PLIF).
45604512|NCT05725265|Device|Large-area low-level laser therapy(Venusure)|The wavelength was 980±15nm, average dose was 10-40nm/cm2 and maximal output was 1000mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions
45604513|NCT05725265|Device|Conventional low-level laser therapy|The wavelength was 808 nm and maximal output was 60 mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions.
45604514|NCT04468373|Device|WA-NG (NG-IMT) Telescope Prothesis|The WA-NG telescope prosthesis is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
45604515|NCT05725187|Device|MobiCare|It is a 9.2g wearable electrocardiogram device, mobiCARE, in the form of a patch, and the model name is MC200M.
45604516|NCT05725109|Other|Hepatitis C Treatment Alerts in CHORUS™|Clinical Health Outcomes Reporting & Utilization Service (CHORUS™) is a web-based healthcare analytics and reporting solution that transforms electronic health record data into meaningful information for healthcare providers. CHORUS™ generates a weekly email report that alerts clinics to patients with certain conditions who have a scheduled appointment in the coming week and may require close attention. CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. In the after period of this study, the alert will identify patients with active hepatitis C infection.
45604517|NCT05725109|Other|Standard of Care|CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. NO alerts identifying patients with active hepatitis C infection will be disseminated.
45604518|NCT03527693|Device|Lipogems injection|Micro-fragmented adipose tissue (10 cc) was injected intra-articular after the arthroscopic procedure (shaving or shaving + meniscectomy).
45604519|NCT03527615|Other|Clinical Pharmacist Medication Review|Programmatic review of physician orders for direct anticoagulants by clinical pharmacists.
45604520|NCT03532061|Behavioral|FamCare Program|6 in-person sessions of biweekly home care problem-solving skills training (FamCare) delivered by a health educator.
45604521|NCT03532061|Other|Caregiver Support Group|6 in-person caregiver support group sessions held biweekly and moderated by a health educator.
45604522|NCT00002207|Drug|Stavudine|
45604523|NCT00002207|Drug|Didanosine|
45604524|NCT03529097|Drug|0.9% Sodium-chloride|2 liters of 0.9% NaCl IV fluids
45604525|NCT03529097|Drug|Placebos|2 liters of 0.9% NaCl bag covered with black bag so the participant could not tell the fluids are not dripping to his vain
45604526|NCT03529097|Drug|Optalgin, Voltaren, Morphine|Oral and IV Optalgin, Voltaren IM (intramuscular), Morphine IV. All according to the pain intensity and with concordance to the physician.
45604527|NCT05614349|Drug|Paxlovid|This adaptive platform trial will assess therapeutics for SARS-CoV-2 in out-patient settings. The first intervention arm is Paxlovid.
45604528|NCT05614349|Drug|Other|As this trial progresses, therapeutics for SARS-CoV-2 in out-patient settings to be evaluated will be determined by the Canadian COVID-19 Out-Patient Therapeutics Committee, which will evaluate the latest evidence on new therapeutics and makes recommendations to the Steering Committee.
45604529|NCT05614349|Other|Other|As this trial progresses, therapeutics for SARS-CoV-2 in out-patient settings to be evaluated will be determined by the Canadian COVID-19 Out-Patient Therapeutics Committee, which will evaluate the latest evidence on new therapeutics and makes recommendations to the Steering Committee.
45604530|NCT03531983|Procedure|fixation of tochentric fractures by gamma nail|• Thirty patients with recent traumatic extracapsular proximal femoral fractures were treated using a short gamma nail of third-generation assembly
46066611|NCT05380544|Device|Extracorporeal Shockwave Therapy|ESWT will be given at 0.1mJ/mm2, 5 pulses/second and penetration of 5mm. Each intervention will be delivered in 3x30minute sessions over 7 days.
45911183|NCT02004743|Behavioral|Intervention|"Psychological guidelines and PET~Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD."
45911184|NCT02004743|Other|Treatment as usual|"Participants will experience treatment as usual.~Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD"
46066612|NCT04264520|Behavioral|PTSD Psychoeducation + Skills Intervention|A brief computer-assisted intervention (psychoeducation + skills) for pregnant women with elevated PTSD symptoms.
45604531|NCT03531749|Dietary Supplement|HIV+ MRPJ|supplemented with (1g/d) MRPJ
45756739|NCT01907607|Drug|PD 0332991|"PD-0332991 was administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.~PD-0332991 was dosed on a flat scale of 125 mg (1 capsule x 100 mg/day, 1 capsule x25 mg/day) will be administrated orally o.d on a 21 days on / 7 days off dosing schedule. One cycle is considered to consist of 4 weeks of PD-0332991 administration.~Patients should be instructed to administrate PD-0332991 with a sufficient amount of water at least 1 hour prior to a meal or at least 2 hours following a meal and to swallow the required number of capsules at approximately the same time on each day."
45444697|NCT02049268|Drug|Nicotine + Alcohol|14 mg nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach blood alcohol level (BAL) = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
45604532|NCT03531749|Dietary Supplement|HIV+ ascorbic acid|Supplemented with (1g/d) AA
45604533|NCT03531671|Device|Binocular-OCT|Binocular Optical Coherence Tomographer used to assess both eyes in the same session without the need for a trained assistant.
45604534|NCT05265689|Behavioral|Bike Club|"Administration of a bicycle safety education program to children ages 9-12 based on Let's Go NC!. Let's Go NC! includes observational skill checklists for instructors to track participant progress throughout the program, on-bicycle skills practice, hazard anticipation and avoidance, and traffic law importance and consequences. Additionally, participants will go on a capstone ride to practice their skills across varying transportation and recreation infrastructure and settings. The program will be administered at various sites across Iowa City."
45604535|NCT05265689|Behavioral|Bike Club Plus|Same as Bike Club, with the addition of a parent training component. Parents from these dyads will receive a training session on bicycling safety best practices, tips for practicing with their children at home, and feedback on how their child performed in the program (including areas in need of improvement).
45604536|NCT03531593|Diagnostic Test|Ultrasound Elastography|Ultrasound elastography is a new, noninvasive technique that can assess the stiffness of the liver by the evaluation of how sound waves propagate through the liver parenchyma.
45604537|NCT05583305|Diagnostic Test|Imaging assessment|Investigators shall perform cranial MRI examinations. The scanning protocol will employ an MRI scan protocol with T1-weighted, T2-weighted, FLAIR, susceptibility weighted imaging, diffusion weighted imaging, and time-of-flight magnetic resonance angiography (MRA) sequences. In addition, high-resolution magnetic resonance vessel wall imaging (HRMRI) allows assessment of the vessel wall using specific the SPACE sequence and the MATCH sequence. Assessors of the HRMRI images shall be blinded to the group allocation and clinical information.
45604538|NCT05583305|Diagnostic Test|Neurosonology assessment|Investigators shall perform carotid duplex ultrasonography (CD) assessment, focusing on the peak systolic (PSV) and end diastolic velocity (EDV) of bilateral extracranial internal carotid arteries (ICA) Brightness mode imaging shall gauge the intimal thickness and plaque characteristics (if any) of bilateral ICAs.
45604539|NCT05583305|Diagnostic Test|Blood Test|Nine milliliters of EDTA blood will be drawn during the research clinic visit for evaluation of the degree of neurovascular inflammation. Serum plasminogen activator inhibitor-1 (PAI-1) and high-sensitive C-reactive protein (hsCRP) are markers of vascular inflammation, atherosclerosis, and thrombotic risk. Serum neurofilament light chain (NfL) is a biomarker for neuroaxonal injury that correlates with small vessel disease.
45604540|NCT03527459|Behavioral|SPARC B|SPARC B includes all aspects of the SPARC A clinical program, as well as targeting negative cognitions of perceived burdensomeness.
45604541|NCT03527459|Behavioral|SPARC A|SPARC A is an existing clinical program with a general focus on negative cognitions.
45604542|NCT03528863|Behavioral|Online Mindfulness Meditation|Receive web-based mindfulness meditation
45604543|NCT03528863|Other|Questionnaire Administration|Ancillary studies
45604544|NCT03528785|Drug|Irinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic Acid|"Oxaliplatin 60 mg/m2 IV in 120 minutes) on Days 1 and 15 of each cycle~Irinotecan Liposomal Injection [Onivyde] (60 mg/m2 IV over 90 minutes) on Days 1 and 15 of each cycle~Levofolinic acid (200 mg/m2 IV over 30 minutes) on Days 1 and 15 of each cycle~5FU (2.400 mg/m2 IV over 46 hours) on Days 1 and 15 of each cycle"
45604545|NCT03531437|Drug|1.5 mg estradiol and 2.5 mg nomegestrol acetate|
45604546|NCT03531437|Drug|15 µg ethinylestradiol and 60 µg gestodene|
45604547|NCT03527381|Drug|Nitric Oxide|40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.
45604548|NCT03527381|Other|Standard CPB|Standard CPB protocol of delivery of air gas mixture to the cardiopulmonary bypass circuit during cardiac surgery.
45604549|NCT03527303|Behavioral|Meditation|10 minute per day, 8 week digital meditation
45604550|NCT03528707|Dietary Supplement|Symbiter-Omega|"Symbiter Omega which contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×101"
45604551|NCT03528707|Dietary Supplement|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
45756740|NCT01270633|Device|PriMatrix|Following sharp debridement, application of PriMatrix dermal repair scaffold in conjunction with moist wound therapy
45756741|NCT01270633|Other|Standard of Care|Following sharp debridement, moist wound therapy
45756742|NCT01278511|Other|Canadian C-Spine rule|Emergency medicine undergraduates will accompany prehospital emergency crews and apply the Canadian C-Spine rule, though cervical collar will be applicated per current protocol.
45911185|NCT02004756|Other|Exercise Program|The Fontan cohort will subsequently complete a 12-week moderate intensity exercise intervention whereby individualized activity-based home interventions will be prescribed (i.e., sample activities: walking, jogging, swimming, cycling, soccer). More specifically, individualized weekly exercise programs for participants will be provided incorporating two specific exercise components.
45444698|NCT02049268|Drug|Placebo Nicotine + Alcohol|Placebo nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach BAL = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
45444699|NCT02049268|Drug|Nicotine + Placebo Alcohol|14 mg nicotine patch applied in combination with 400 mL orange juice beverage with a trace of alcohol to create placebo alcohol mixture.
45756743|NCT05734833|Dietary Supplement|Culturelle Probiotic + Fiber|The experimental group will receive the study product which is Culturelle Probiotic + Fiber
45604552|NCT05246189|Other|Telephone Call|"Eligible subjects will be pre-selected by the study investigators on the basis of the medical file. A letter of information about the study will be sent to all the pre-selected eligible patients, with the exception of patients who have expressed an objection to the processing of their data for research purposes during their treatment.~The investigators will contact eligible patients by telephone approximately 2 weeks after the mailing of the information letter. During this telephone call, the investigator will answer any questions the patient may have about the study and will collect the patient's non-objection to participate in the study and their responses to the questionnaire."
45604553|NCT04441151|Behavioral|Pulmonary rehabilitation therapy|Comprehensive interventions based on comprehensive evaluation and customization of patients, including, but not limited to, exercise training, education and behavioral changes, aimed at improving the physiological and psychological status of patients with chronic respiratory diseases, and urge patients to adhere to health promotion activities for a long time.
45604554|NCT05239793|Other|NJOY e-cigarette|NJOY e-cigarette with Virginia Tobacco flavored 5% nicotine pods
45604555|NCT05223179|Biological|CODA-VAX H1N1|Intramuscular Live Attenuated Influenza H1N1 Vaccine
45604556|NCT05223179|Biological|Flucelvax Quad|Licensed Seasonal Injectable Influenza Vaccine
45604557|NCT05223179|Other|Saline|Saline
45604558|NCT05543447|Device|Flow Diverter Treatment with DERIVO 2 Heal Embolisation Device|Flow diversion therapy fpr intracranial aneurysm treatment.
45604559|NCT05724485|Drug|Branched-chain Amino Acid|12.45 grams of BCAA orally per day before bedtime
45604560|NCT05724485|Drug|Placebo|12.45 grams of Maltodextrin orally per day before bedtime
45604561|NCT05724407|Other|Diagnostic assistance tool|"Diagnostic assistance tool for analysis of 5 prognostic and predictive markers of breast cancer (HER2, Ki67 Index, Mitoses, Estrogen Hormone Receptor, Hormone Progesteron receptors hormone of Progesteronereceptor).~Each anatomo-histopathological slide will be re-read 3 times:~Reading 1: first reading by a pathologist in the care setting~Reading via the standard care procedure (microscope and physical slides)~Reading 2: Second reading by another pathologist from the same center, as part of the research.~Reading via the standard procedure of care (microscope and physical slides)~Reading 3: Third reading by the initial physician, with the algorithmic tool MoSi4BCa after digitization of the slides by a laboratory technician and after a wash-out period of 2 months."
45604562|NCT03527225|Other|Music|The patient's preferred music will be played during the first radiotherapy treatment session from speakers located inside the treatment room. The duration of the music will be 10 to 20 minutes. The music will be turned off at the patient's request if it bothers them. Length of music playing and if the patient requested that it be turned off, will be recorded.
45604563|NCT04468997|Drug|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.375mg), Vitreous injection, injection once;
45604564|NCT04468997|Drug|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.75mg), Vitreous injection, injection once;
45911186|NCT02004769|Drug|Trastuzumab|Trastuzumab (Herceptin) will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks (q3w), until disease progress or intolerable toxicity.
45604565|NCT04468997|Drug|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once;
45604566|NCT04468997|Drug|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once;
45604567|NCT04468997|Drug|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once every 4 weeks, three times continuously, then injection as needed within 9 months.
45604568|NCT04468997|Drug|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once every 4 weeks, three times continuously, then injection as needed within 9 months.
45604569|NCT04469153|Other|No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests|No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests
45604570|NCT04468217|Diagnostic Test|Obtainment of nasopharyngeal, oropharyngeal, buccal, nasal and saliva samples|Each patient will undergo a sample collection where two nasopharyngeal samples will be obtained, one of them with lysis buffer as the transport medium and the other with the AAA-Safe solution as the transport medium. Oropharyngeal, buccal, nasal, and salivary samples will also be obtained using AAA-Safe as the transport medium
45604571|NCT04441385|Drug|Maraviroc 300 mg|Patients will receive maraviroc 300 mg twice daily for 14 days
45604572|NCT04441385|Other|Standard care therapy|Subjects randomized to control group will be on standard care treatment according to the Ministry of Health and Local Guidelines and Protocols.
45756744|NCT05734833|Other|Placebo|The Placebo comparator arm will receive placebo sachets
45756745|NCT01909011|Device|Active CES|The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.
45756746|NCT01909011|Device|Sham CES|The CES sham group will receive sham CES (device off) for 20 minutes 5 times per week for two weeks.
45756747|NCT00753337|Device|Assurant® Cobalt Iliac Stent System|Iliac Stenting
45911187|NCT02004769|Drug|Docetaxel|Docetaxel 60mg/m2 (on day 1) every 3 weeks for 6 cycles.
45756748|NCT03029637|Device|RBBs with no or minimal preparation of their abutment teeth|Placement of resin bonded bridges on teeth with no or minimal cutting of their supporting teeth
45756749|NCT03029637|Device|RBBs with routine tooth preparation of their abutment teeth|Placement of resin bonded bridges on teeth after routine cutting of their supporting teeth
45911188|NCT02004769|Drug|Capecitabine|Capecitabine (Xeloda) 2000mg/m2d, d1-14, every 3 weeks until disease progress or intolerable toxicity.
45911189|NCT02004782|Drug|Prednisolone|Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
46066613|NCT05380310|Device|"Active SMART ANGEL solution"|Nurse intervention according to the alert level + traditional monitoring
45911190|NCT02004782|Drug|Placebo Oral Tablet|Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE
45604573|NCT03531359|Device|TIBD|Table-based Interactive Distraction using video-games will be used to prove efficacy in preventing preoperative anxiety.
45604574|NCT03531359|Drug|Midazolam|Administration of midazolam oral or rectal 30 minutes to one hour prior to transfer to the theater.
45604575|NCT03531281|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo-HCT
45604576|NCT03531281|Drug|Cyclophosphamide|Given IV
45604577|NCT03531281|Drug|Etoposide|Given IV
45604578|NCT03531281|Drug|Goat Milk|Given human lysozyme goat milk PO
45604579|NCT03531281|Other|Laboratory Biomarker Analysis|Correlative studies
45604580|NCT03531281|Biological|Palifermin|Given IV
45604581|NCT03531281|Drug|Sirolimus|Given PO
45604582|NCT03531281|Drug|Tacrolimus|Given IV and PO
45604583|NCT03531281|Radiation|Total-Body Irradiation|Undergo FTBI
45604584|NCT03528629|Drug|Zolbetuximab|Zolbetuximab will be administered as a 2-hour intravenous infusion.
45604585|NCT03528473|Other|Exercise|"The exercise intervention consists of 60 minutes sessions, divided into 40 minutes of aerobic exercise and 20 minutes of circuit training for muscular strength and flexibility exercises.~Aerobic exercise is performed using treadmill, exercise bikes, syncro and arm-ergometers, gradually increasing the exercise intensity, after a 10 minutes period of warming-up, to 60-80 % of Maximum Heart Rate.~Resistance training consists of resistance exercises for large muscle groups, performed with body weight-exercises and isotonic machines."
45604586|NCT05724251|Other|healthy|no intervention
45604587|NCT05724251|Other|periodontitis|no intervention
45604588|NCT05724095|Other|high frequency acupoint stimulation|electrodes are attached to area of acupoints and electrical stimulation at 10/50 Hz is given
45604589|NCT05724095|Other|low frequency acupoint stimulation|electrodes are attached to area of acupoints and electrical stimulation at 2/10 Hz is given
45604590|NCT05724095|Other|electrodes attached|electrodes are attached to area of acupoints
45756750|NCT03029481|Drug|Ganitumab|The patient will receive ganitumab, 18 mg/kg/dose intravenously every 2 weeks until clinical progression or decision to move to an alternate therapy.
45756751|NCT00731341|Procedure|Cryoablation for the treatment of uterine fibroids|Needle will be inserted into the fibroid via the cervix through a hysteroscope channel. Gas is circulated through the sealed needle to form an iceball at the tip. After insertion, the needle will be cooled to a temperature of below -100°C to freeze the tissue of the fibroid.
45756752|NCT05739669|Device|EEG recording with the comparator device Micromed Brain Quick|Each patient will undergo a visit in a clinic, during which a 15 minutes long EEG trace with a CE-certified wet electrode EEG Device (Micromed Brain Quick) will be recorded by specialized staff.
45756753|NCT05739669|Device|"EEG recording with the investigational device Atlas with dry electrodes clinic/specialized staff"|"During the same visit when the wet electrode EEG is recorded, the patient will be subjected to a second 15 minutes long EEG recording with the investigational device Atlas with dry electrodes, which will be conducted by specialized staff"
45911191|NCT02004795|Radiation|BNCT + IG-IMRT|Single faction of BNCT (20 Gy) plus IG-IMRT (40 Gy/20 fractions)
45604591|NCT05724017|Behavioral|Street Games Intervention|The children to be included in the study will be grouped in groups of 10 according to their age groups. Groups of 10 people consist of six sessions in total, two days a week for three weeks. Applications will be made in the school garden. In the meetings, games that attract the attention of children will be discussed, suitable games will be played, origami, painting and story sharing will be made. In the study, the independent variable street games intervention will be applied.
45604592|NCT05508191|Device|Fractional CO₂ Laser|Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. Half of the face will be irradiated with AMIⓇ fractional CO₂ laser according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.5 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.
45604593|NCT05508191|Device|Microneedle|Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. The other half of the face will be treated with DrPenⓇ dermapen according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.5 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.
45604594|NCT04468685|Drug|Ondansetron|Interperitoneal administration in the gall bladder bed
45604595|NCT04468685|Drug|Normal saline|Interperitoneal administration in the gall bladder bed
45604596|NCT05099861|Other|No intervention|this is an observational study
45604597|NCT03528395|Other|Semi-immersive virtual reality|Each participant will receive 24 additional sessions of semiinmersive virtual Reality therapy sessions on Monday, Wednesday and Friday, after realizing the conventional therapy sessions. The duration of each VR session will be gradually increased in time-intensity (5 minutes during the first week to 20 minutes during the last week) and motor requirements.
45604598|NCT03528395|Other|Conventional Rehabilitation|Conventional rehabilitation consisting of five weekly sessions of Physical therapy and Occupational Therapy, based on a task-oriented approach, lasting 45 minutes each.
45604599|NCT03528317|Other|Alternate day fasting|Alternate day fasting with a high protein diet
45604600|NCT03531203|Dietary Supplement|Soursop supplementation|The soursop supplementation was given to treatment group (with soursop group) 2 times a day for 100 g each for 3 months period.
45604601|NCT03531203|Other|Placebo|Control group (without soursop group) was left without treatment during study period
45604602|NCT05070299|Behavioral|Psychosexual Educational Partner Program (PEPP)|A communication and intimacy promotion kit consisting of three modules devoted to information sharing, partner communication and activities for building intimacy.
45604603|NCT03531125|Procedure|Endoscopic Ultrasound|Endoscopic ultrasound for tumour biopsy collection
45604604|NCT03531125|Procedure|Pancreaticoduodenectomy|Surgery to remove pancreatic tumour
45604605|NCT03531047|Procedure|Customised CXL|As for standard CXL, following mechanical removal of the corneal surface layer (epithelium), 0.1% riboflavin drops will be applied every 2 minutes for 10 minutes prior to ultraviolet A (UVA) irradiation - UVA power, distribution and timing as determined by analysis of Pentacam tomography scans. A bandage contact lens will be applied to encourage regrowth of the corneal surface and reduce post-operative pain.
45604606|NCT03109925|Device|DC Lumi Bead, BTG|Embolic agent which is radio-opaque
45604607|NCT04440917|Drug|Camrelizumab|200mg, iv, on day 1, 15, 29, 43
45604608|NCT04440917|Drug|Apatinib Mesylate|250 mg po, qd, 28 days as a cycle, 2 cycles in total
45604609|NCT04192019|Drug|Micro-glucagon|Administration of 80 µg (micro-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
45604610|NCT04192019|Drug|Mini-glucagon|Administration of 150 µg (mini-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
45604611|NCT03526913|Procedure|PRP|PRP: autologous platelet-rich plasma
45604612|NCT03526913|Procedure|STSG|skin graft: Split Thickness Skin Grafting (STSG)
45604613|NCT05469815|Behavioral|Lost Children Society Game|36 online therapeutic role-playing sessions spread over 36 weeks, one session per week
45604614|NCT05464823|Other|Molecular Functional Portrait|Participants will be asked to allow previously-collected tumor tissue to be used for the MF Portrait test
45604615|NCT03526757|Other|Standing Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of Pilates exercises focusing on orthostatic position, for twelve weeks. The following equipment will be used: The Cadillac, Reformer and Chair, emphasizing balance training in the orthostatic position.
45604616|NCT03526757|Other|Standard Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of the standard sequence of Pilates exercises (traditional sequence of the contemporary / classical method) for twelve weeks. The exercises will be performed using the same equipment used in the intervention group, but following the dorsal decubitus, sedestation and orthostasis, in a time-balanced distribution in each session.
45604617|NCT05455931|Drug|Poteligeo|Poteligeo treatment will be used as prescribed by the Investigator in accordance with the terms of the reimbursed indication within the relevant country. The assignment of the patient to a particular therapeutic strategy falls within current practice and the prescription of Poteligeo is clearly separated from the decision to include the patient in the study.
45604618|NCT05062031|Device|Defocus Incorporated Multiple Segments® (DIMS®) lenses|Daily wear for 24 months. Lenses have a central monofocal optical zone correcting spherical or spherocylindrical ametropia, surrounded by a ring made up of 300 defocusing pellets. This lens geometry reduces the phenomenon of blurred image projected in the retinal periphery, encountered when myopic eyes are corrected with monofocal lenses.
45604619|NCT05062031|Drug|Atropine 0.05% eyedrops|One drop each evening in both eyes for 24 months.
45604620|NCT05062031|Device|Monofocal lenses|Daily wear for 24 months
45604621|NCT02740049|Drug|VR588|Evaluation of the efficacy of a novel JAK/STAT inhibitor, VR588, in isolated epithelial cells from asthma patients
45604622|NCT05017415|Device|uroflow measurement|Non-invasive urodynamic measurement wireless uroflowmeter UROCAP™ IV, Goby System Laborie
45604623|NCT05017415|Device|Bladder ultrasound|Ultrasound of post void residual urine bladderscan CUBEscan BioCon 700
45604624|NCT05446571|Drug|Letermovir|Maternal daily administration of 240 milligrams of letermovir (1x240 mg-tablets) up-until delivery or TOP Placebo of Valaciclovir ; daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP
45604625|NCT05446571|Drug|Valacyclovir|Maternal daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP Placebo of letermovir : (1x240 mg-tablets) up-until delivery or TOP
45604626|NCT05439005|Drug|Dexmedetomidine|Dexmedetomidine+Lidocaine
45604627|NCT03528239|Other|Refugee patients|To investigate characteristics of outpatient visits of refugee patients
45604628|NCT03528161|Other|Measurement of hypersensitive troponin|"Telephone follow-up at one month, 3 months and 6 months by a clinical research technician. Collection of serious adverse events, reports of hospitalization.~The hypersensitive troponin assay will be recently proposed in a short-term risk stratification score after syncope (30 days), the canadian syncope risk score. If hypersensitive troponin benefits from interesting performances it needs to be evaluated prospectively, as measured only in 47.9% of syncope in this study. Hypersensitive troponin could be a prognostic marker of early serious adverse cardiovascular events in syncope."
45756754|NCT05739669|Device|"EEG recording with the investigational device Atlas with dry electrodes home/lay people"|"The patients will record their own EEGs at home daily for 14 days, using the investigational device Atlas with dry electrodes"
45756755|NCT04279171|Diagnostic Test|Greyson NDE scale|Questionnaire to detect occurence of NDE. A NDE is identified if score > or = 7/32
45604629|NCT05434481|Other|Mitochondrial dynamic analysis in the aorta samples and metabolomic profiling in the aortic diseases|"For each patient: a segment of aorta will be sampled and cutted into 4 parts~1 fragment placed in a Falcon tube containing DMEM (Dulbecco's Modified Eagle Medium, Thermo Fisher®), temporarily stored at + 4°C, for primary culture of smooth muscle cells will allow analysis of the mitochondrial network.~1 fragment placed in a Falcon tube containing Allprotect Tissue Reagent (QIAGEN®), stored at -80°C for gene (RT-PCR) and protein (Western Blot) analysis.~2 fragments each placed in dry cryotube stored at - 80°C will be used for metabolomic analysis.~For each patient, 2 arterial blood samples will be collected before general anaesthesia~One tube of whole blood stored at -80°C for metabolomic analysis.~One tube of blood stored at -80°C for plasma cytokines"
45604630|NCT03528083|Other|Bronchiolitis quality improvement|Patients in the intervention group will undergo a quality improvement process to improve care quality for bronchiolitis at our hospital.
45604631|NCT03528005|Behavioral|Multi-domain intervention|60 minutes cognitive training, 45 minutes physical exercise, 15 diet nutrition and intermittent disease management consultation
45604632|NCT03526601|Diagnostic Test|NT-proBNP, echocardiography|screening
45604633|NCT05387837|Drug|D-4517.2|D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)
45604634|NCT03526523|Behavioral|Mindfulness-based stress reduction|8 weekly 2.5-hour group sessions of mindfulness based stress reduction, led by a certified MBSR instructor
45604635|NCT05258747|Drug|Olaparib tablets, 150 mg|Olaparib tablets, 150 mg of Lek Pharmaceuticals d.d., Slovenia
45604636|NCT05258747|Drug|Lynparza® (olaparib) tablets 150 mg|Lynparza® (olaparib) tablets 150 mg Manufactured for: AstraZeneca Pharmaceuticals LP, Wilmington, DE
45604637|NCT05724641|Diagnostic Test|MRI perfusion imaging using ASL's non-invasive technique|Patients will undergo through an MRI-scan using the ASL MRI sequence, as described per protocol.
45604638|NCT04468139|Drug|Quercetin|Dietary Supplement: Quercetin Treatment a daily dose of quercetin (500 mg) will be taken orally by proven COVID-19 cases intervention
45604639|NCT04468139|Dietary Supplement|bromelain|Dietary Supplement:Bromealin Treatment a daily dose of bromelain(500 mg) will be taken orally by proven COVID-19 cases intervention
45604640|NCT04468139|Drug|Zinc|zinc 50 mg orally daily dose will be taken orally by proven COVID-19 cases intervention
45604641|NCT04468139|Drug|Vitamin C|vitamin c 1000 mg orally daily by proven COVID-19 cases intervention
45756756|NCT04279171|Diagnostic Test|DES dissociation scale|Screening for dissociative symptoms
45756757|NCT04279171|Diagnostic Test|WHOQOL-SRPB|WHOQOL-SRPB is an instrument developed to evaluate how spirituality, religiosity and personal beliefs (SRPB) are related to quality of life in health and health care.
45756758|NCT04279171|Diagnostic Test|cerebral magnetic resonance imaging|Types of images to be acquired: T1, T2, Diffusion Weighted Imaging-DWI, Fluid Attenuated Inversion Recovery and spectroscopy
45756759|NCT01911351|Drug|Nitrous Oxide|Patients randomized to the intervention arm will receive nitrous oxide plus standard management for their minor procedure.
45444700|NCT02049346|Drug|Epoetin alpha or beta (Epoetin group)|"Erythropoetin doses in that were adjusted according to the approved prescribing information, without additional restrictions.~Doses of erythropoetin were decreased by 25% for Hb values >12 and ≤13 g/dL and increased by 25% for Hb <11 and ≥10 g/dL. erythropoetin doses were increased by 50% for Hb <10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses for all patients were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study."
45756760|NCT04276051|Device|Cryoablation of the Vagus Nerve|The Visual ICE Cryoablation System is a mobile console system intended for cryoablative tissue destruction using a minimally invasive procedure. The Visual-ICE System uses high-pressure argon gas that circulates through closed-tip cryoablation needles to induce tissue freezing. Active tissue thawing is achieved by circulating helium gas through the needles or, alternatively, by the use of Galil Medical i-Thaw technology. The procedure will be done under CT guidance and involves a 4-5 mm scalpel incision followed by percutaneous probe placement about the posterior gastroesophageal junction (the location of the posterior vagal trunk). The probe will create a zone of decreased temperature (-20 to -40 degrees Celsius) involving the posterior vagal nerve fibers/plexus. The cryoablation process will include a 3-minute freeze, followed by a 1-minute thaw, and a second 3-minute freeze and 1 minute thaw.
45911192|NCT02004821|Dietary Supplement|Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat). One bottle per day during 14 days.|
45911193|NCT02004860|Drug|Protopic (R)|Protopic® 0.1% ointment - 2 applications per week for 6 months
45911194|NCT02004860|Drug|Mycoster (R)|Mycoster 1% - 2 applications per week for 6 months
46066614|NCT05380310|Device|"Inactive SMART ANGEL solution"|No alert + traditional monitoring + alert in case of imminent life threat
45604642|NCT03526445|Drug|Glucagon|Glucagon (4 ng/kg/min)
45604643|NCT03526445|Drug|Saline|Placebo
45604644|NCT04939649|Drug|Ketamine|A sub-anaesthetic dose of ketamine will be administered for up to a four-week course of twice-weekly infusions.
45604645|NCT04939649|Drug|Midazolam|A sub-anaesthetic dose of midazolam will be administered for up to a four-week course of twice-weekly infusions.
45604646|NCT04927949|Drug|cangrelor perfusion during PCI|Cangrelor perfusion (started before PCI) with intravenous bolus of 30 microgram/kg, followed by a perfusion of 4 microgram/kg/min during 2 hours or until the end of the PCI if longer
45604647|NCT04927949|Procedure|standard PCI|primary PCI without cangrelor
45604648|NCT04589819|Drug|Teriparatide|Teriparatide, an injectable synthetic parathyroid hormone, will be tested to evaluate its efficacy for decreasing the convalescence after a diaphyseal tibial stress fracture, a specific bone stress injury.
45604649|NCT04589819|Drug|Placebos|Placebo will be a sugar solution of the manufacturer's design.
45604650|NCT03525587|Other|"Use of MAGHD App/MAGHD Framework"|Patients daily related outcomes will be recorded thanks to the development, implementation and validation of a Smartphone app (MAGHD App) integrated with a software framework able to merge patient's daily activities data on well-being status, QoL, physical activities and sexual function with clinical data collected in their record chart (extrapolated from already available Institutional Databases).
45604651|NCT03526367|Drug|hydration plus rosuvastatin therapy|In experimental group,a loading dose of rosuvastatin 20mg then 10 mg daily followed for at least 7 days and hydration（3ml/kg/h）last 12 hours after randomized
45604652|NCT03526367|Drug|Standard therapy|Prohibition of use any statins from randomized to 12 hours after procedure; The hydration or not is determined by physicians but 1 ml/kg/h at most.
45604653|NCT04467983|Drug|Denosumab Injection|Denosumab alone: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.
45604654|NCT04467983|Drug|Abaloparatide|Combination therapy: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.
45604655|NCT04839731|Drug|Combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream|Apply twice per day for allotted time
45604656|NCT04839731|Drug|Nourivan Base Cream|Apply twice per day for allotted time
45604657|NCT03525509|Drug|Methadone hydrochloride|Epidural bolus of 4mg of preservative free methadone hydrochloride (4mL of 1mg/mL solution)
45604658|NCT03525509|Drug|Morphine Sulfate|Epidural bolus of 4mg of preservative free morphine sulfate (4mL of 1mg/mL solution)
45604659|NCT04528355|Drug|data collection|Study subjects will receive alemtuzumab, melphalan, thiotepa, fludarabine and hydroxyurea-based, reduced-intensity conditioning regimen in accordance with clinical practice at UPMC Children's Hospital of Pittsburgh at the discretion of the treating physician. Medical data will be abstracted from subject's medical charts once the patient signs the informed consent.
45604660|NCT04836923|Behavioral|"LIver FrailTy intervention (LIFT)"|Novel physical therapy intervention to decrease frailty in pre-transplant patients
45604661|NCT04836923|Behavioral|"Realistic Effort Action Planning intervention (REAP)"|This intervention is an interactive behavioral interviewing process to engage patients in their care
45604662|NCT04826627|Other|glycemia|capillary glycemia
45604663|NCT04808453|Drug|CPI-300|CPI-300 will be administered via intravenous infusion on Day 1 of a 14-Day cycle
45911195|NCT02004899|Drug|Fentanyl|After obtaining informed consent, patients are randomized into one of two treatment groups or a control group by a computer generated random number table. After confirmation of epidural placement following test dose administration, a loading dose of 10 ml 0.08% Bupivacaine containing 20 mcg Fentanyl is administered after adding 1.6 ml 0.9% NaCl (Sodium Chloride) in the control group (F20).
45604667|NCT04758611|Device|eShunt™ Implant|The eShunt™ Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system as a minimally invasive treatment for communicating hydrocephalus.
45604668|NCT03525353|Other|Endoscopic retrograde cholangiopancreatography - No Intervention have been used other than standard of care|No intervention has been used and this is an observational study
45604669|NCT04702451|Procedure|Dispersion ablation + PVI|Ablation of spatio-temporal dispersion electrograms in combination with pulmonary vein antrum isolation
45604670|NCT04702451|Device|VX1|VX1-based dispersion mapping
45604671|NCT04702451|Procedure|PVI|Pulmonary vein antrum isolation
45604672|NCT03525275|Device|Battlefield Acupuncture|Battlefield Acupuncture uses ASP semi-permanent needles inserted into their ears for pain attenuation in 5 known points. Both groups receive their respective post-surgical rehabilitation protocols
45604673|NCT03525275|Procedure|Post-surgical shoulder protocol|Surgery specific post-surgical physical therapy protocol
45756761|NCT04276051|Behavioral|Lifestyle Intervention|The lifestyle intervention structure will include three face-to-face counseling sessions at baseline, 3 and 6 months. Dietary counseling to follow a low carbohydrate diet will be provided by a registered dietitian. Focus will be on increasing fruits and vegetables and decreasing refined sugars and processed foods. It will also include motivational interviewing, goal setting and nutrition education. In addition, subjects will be encouraged by exercise physiologist to slowly increase physical activity to at least 150 minutes weekly. There will be weekly phone calls or texts (participants' choice) providing a total of 26 points of contact recommended by the United States Preventive Services Task Force.
45756762|NCT01278589|Dietary Supplement|Plantago asiatica L. extract 5g|Liquid (80g) containing Plantago asiatica L. extract 5g
45604674|NCT04699721|Drug|nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5|3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day)
45756763|NCT01278589|Dietary Supplement|Plantago asiatica L. extract 10g|Liquid (80g) containing Plantago asiatica L. extract 10g
45756764|NCT01278589|Dietary Supplement|Plantago asiatica L. extract 20g|Liquid (80g) containing Plantago asiatica L. extract 20g
45756765|NCT01278589|Dietary Supplement|Placebo|Liquid (80g) without Plantago asiatica L. extract
45756766|NCT05734677|Behavioral|Emotion regulation group|90 minute sessions once a week for 8 weeks, in groups of eight participants. DBT, MBT and MBI inspired, psychoeducative intervention.
45604675|NCT04398407|Behavioral|Coaching and Advancement for Peer Providers (CAPP)|The CAPP intervention will combine executive coaching approaches and techniques with the specific needs and environmental demands of individuals working as PSS. A person who has been a PSS and trainer of PSS nationally has developed the CAPP intervention using the expertise of Center staff, the Harvard Institute of Coaching (IOC) and our Peer Advisory Group. Individuals randomized to the experimental condition will receive 16 individual coaching sessions tailored to the specific job stressors they are experiencing. CAPP is designed to address the following issues: role confusion, lack of clarity about job tasks, conflict with other providers, burnout, lack of organizational commitment and job satisfaction.
45756767|NCT05734599|Device|NMR-based metabolic profiling|Clinical parameters and VCTE results of each patient will be collected. Patients will be grouped into two groups according to VCTE, FIB-4 and NFS, and undergo NMR-based metabolic profiling
45604676|NCT03526289|Biological|GIP1-42 infusion|5-hour GIP1-42 infusion (time point 0-300 minutes)
45604677|NCT03526289|Other|Saline|5-hour infusion of saline (placebo) (time point 0-300 minutes)
45604678|NCT03525197|Dietary Supplement|Whey protein-based supplement|High quality protein supplement to be consumed twice daily
45604679|NCT03525197|Dietary Supplement|Collagen protein-based supplement|Lower quality protein supplement to be consumed daily
45604680|NCT03526211|Device|FES cycling|On the patient, three pairs of electrodes will be applied on tibial hamstring, quadriceps and gluteal muscles of each lower limb. Cycloergometer will be installed in passive mode. Then, optimal stimulation intensity for each muscle will be defined. During twenty minutes, neuromuscular electrical stimulation will generate a passive pedaling on cycloergometer.
45604681|NCT04284293|Biological|CNS10-NPC implantation|All patients will receive a single, unilateral, subretinal injection of CNS10-NPC
45604682|NCT04257383|Other|Sugira Muryango|"Strong Families, Thriving Children Sugira Muryango is a home-visiting intervention that empowers low-income families enrolled in Rwanda's social protection system to support early childhood development and healthy family functioning."
45604683|NCT03526133|Diagnostic Test|Polysomnography (PSG) and wireless sensor Oxistar|Monitoring the apnea-hypopnea index (AHI) derived from PSG and the oxygen desaturation index (ODI) obtained by the Oxistar.
45756768|NCT04385407|Drug|Sofosbuvir + Simeprevir + Ribavirin|
45756769|NCT00731653|Drug|Combination Product: BCI-024 + BCI-049|BCI-024 and BCI-049 once a day at bedtime for 6 weeks
45756770|NCT00573989|Drug|erlotinib hydrochloride|
45756771|NCT00573989|Drug|pemetrexed disodium|
45756772|NCT00573989|Procedure|quality-of-life assessment|
45756773|NCT00573989|Radiation|intensity-modulated radiation therapy|
45756774|NCT02286921|Drug|Testosterone cypionate|Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
45756775|NCT02286921|Drug|Enzalutamide|Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
45756776|NCT02286921|Drug|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
45756777|NCT02987439|Other|Pulmonary rehabilitation|The intervention is pulmonary rehabilitation
45756778|NCT05734521|Biological|avalglucosidase alfa-NGPT (GZ402666) IV|intravenous infusion
45756779|NCT05734521|Biological|avalglucosidase alfa-NGPT (GZ402666)|exposed via pregnancy and lactation
45911196|NCT02004912|Other|Mentoring intervention|The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
45604684|NCT05179499|Drug|Norepinephrine|Norepinepherine should be prepared and delivered at a concentration of 16 micrograms/ml
45604685|NCT05179499|Other|Balanced Crystalloid|IV fluids administered as per standard care
45604686|NCT03525977|Procedure|Fascia iliaca block arm|The fascia iliaca block will be performed by the anesthesiologist on call
45604687|NCT03525899|Procedure|Pars plana vitrectomy|Pars plana vitrectomy combined with Internal limiting membrane peeling, inverted internal limiting membrane flap insertion into the macular hole, or lens anterior or posterior capsular flap insertion into the macular hole
45604688|NCT03525821|Drug|Ketamine Hydrochloride|intranasal use of ketamine 1mg/kg with nitrous oxide
45604689|NCT04643015|Diagnostic Test|MRI|"Briefly, new MRI sequences will be used on a patient who is undergoing a scheduled, clinically necessary MRI exam. Any new research sequence will be scanned in addition to the clinically required sequences and will not interfere with the clinical scan other than requiring five to ten minutes of additional table time. There will be no invasive measures under this protocol."
45604690|NCT04623671|Biological|CAP-1002|100-mL (total volume) infusion of 150M CDCs in 5% Human Serum Albumin (HSA)
45604691|NCT04623671|Biological|Placebo|Matching placebo solution
45756780|NCT05739357|Device|NIRS, EEG|During the carotic clamp, if cerebral oxygenation decreased for more than 12 % on the operating side from the baseline value, simple interventions as, increasing arterial blood pressure, increasing arterial carbon dioxide tension or increasing oxygen inspiration concentration will be performed.
45756781|NCT00574067|Drug|Buprenorphine +OTP|Buprenorphine thrice weekly and counseling for four months while in pre-release prison, with referral for continued treatment at an opioid agonist treatment (OTP) program upon release. Such treatment lasts for 1 year in the community. Buprenorphine dosage, following an induction period,is 32 mg Mondays and Wednesdays and 48 mg Fridays
45911197|NCT02004938|Device|Sonosite Titan Ultrasound Machine|
45604692|NCT04467047|Biological|Mesenchymal Stromal Cells infusion|Intravenous 1*10E6 MSCs/kg body weight Mesenchymal Stromal Cells infusion
45604693|NCT04467203|Drug|Fadanafil|"Seven subjects in group A will receive treatment in the following order:~At Day 1, a single dose of Fadanafil 100mg will be administered orally after overnight fasting->~At Day 8, a single dose of Fadanafil 100mg will be administered orally with high fat meal;Seven subjects in group B will receive treatment in the following order:~At Day1, a single dose of Fadanafil 100mg will be administered orally with high fat meal-> At Day 8, a single dose of Fadanafil 100mg will be administered orally after overnight fasting"
45604694|NCT03525665|Other|Metabolic activity measured by FDG-PET|To evaluate whether metabolic activity measured by FDG-PET (SUV max) at time of relapse is predictive of patient's outcome.
45604695|NCT04227821|Other|Vasopressor and/inotrope therapy|In pediatric patients admitted to the pediatric intensive care, with the persistent hemodynamic instability after fluid resuscitation, the vasopressor and/or inotrope therapy will be initiated
45604696|NCT04221035|Drug|Vincristine|1.5 mg/m^2 (max dose 2 mg)
45604697|NCT04221035|Drug|Carboplatin|750 mg/m^2
45604698|NCT04221035|Drug|Etoposide|175 mg/m^2
45604699|NCT04221035|Drug|Cyclophosphamide|1050 mg/m^2
45604700|NCT04221035|Drug|Vindesine|3 mg/m^2/day (max dose 6 mg)
45604701|NCT04221035|Drug|Dacarbazine|200 mg/m^2/day
45604702|NCT04221035|Drug|Ifosfamide|1500 mg/m^2/day
45604703|NCT04221035|Drug|Doxorubicin|30 mg/m^2/dose
45604704|NCT04221035|Drug|Busulfan|< 9kg: 1.0 mg/kg/dose 9 kg to < 16 kg : 1.2 mg/kg/dose 16 kg to 23 kg : 1.1 mg/kg/dose >23 kg to 34 kg: 0.95 mg/kg/dose >34 kg: 0.8 mg/kg/dose Infusion IV over 2 hours Administration every 6 hours for a total of 16 doses
45604705|NCT04221035|Drug|Melphalan|140 mg/m^2/dose IV short infusion (15'), at least 24 h after the last busulfan dose
45604706|NCT04221035|Drug|Thiotepa|300 mg/m^2/day over 2 hours
45604707|NCT04221035|Radiation|Radiotherapy|21.6 Gy 21.6 Gy + boost de 14.4 Gy
45604708|NCT04221035|Drug|Dinutuximab Beta|Patients >12 kg are dosed based on the BSA: 10 mg/m^2/day Patients ≤ 12 kg are dosed according to their body weight: 0.33 mg/kg/day
45604709|NCT04221035|Drug|Cisplatin|80 mg/m^2/24h
45604710|NCT04221035|Drug|Temozolomide 100 MG|100 mg/m²/Day from D0-D4
45604711|NCT04221035|Drug|Irinotecan|50 mg/m²/jour de J0 à J4
45756782|NCT00574067|Drug|Buprenorphine +CHC|Buprenorphine thrice weekly and counseling provided in pre-release prison for 4 months, with referral for continued treatment for 1 year in the community at a community health center (CHC). Following an induction period, buprenorphine dosing will be 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
45756783|NCT00574067|Drug|Counseling +OTP|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at an opioid agonist treatment program to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
45756784|NCT00574067|Drug|Counseling +CHC|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at a community health center to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
45756785|NCT05734443|Behavioral|non-treadmill trip training|Participants practice volitional and reactive stepping responses that mimic those needed when recovering balance after tripping.
45756786|NCT05734443|Behavioral|treadmill trip training|Sudden treadmill changes in speed (from standing) induce trip-like losses of balance, after which participants take steps to recover balance and establish a stable gait pattern. This is repeated over a range of speeds to both provide training variability and to individualize training to each participant's capability.
45604712|NCT01601704|Drug|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.
45604713|NCT01601704|Drug|PBO|Placebo. Administered in addition to the weight management program.
45604714|NCT01601704|Behavioral|Weight Management Program|A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.
45604715|NCT04842682|Biological|Solo 0.3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
45911198|NCT02004951|Device|Misago RX|
45911199|NCT02004951|Device|Zilver PTX|
45911200|NCT02005003|Behavioral|Inhibitory task|Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
45911201|NCT02005003|Procedure|Blood samples|Hormone levels will be analyzed from blood samples obtained before and after a caloric preload given at each visit
45911202|NCT02005003|Biological|Feces collection|Feces samples will be collected on the morning of each visit, before and after each 2-week intervention period, as well as after each 2-week washout period following each intervention period.
45604716|NCT04842682|Biological|Solo 1 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 1.0 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
45604717|NCT04842682|Biological|Solo 3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
45911203|NCT02005003|Procedure|Caloric preload|A caloric preload will be given to participants, following which blood will be taken at 65 minutes later (specified in Blood sampling) following the ingestion of the caloric preload.
45604718|NCT04842682|Biological|Combi 0.3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid; and combined with DNA-HIV-PT123 HIV-1 at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
45604719|NCT04842682|Biological|Combi 1 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 1.0 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
45604720|NCT04842682|Biological|Combi 3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
45604721|NCT04842214|Behavioral|Oncological Rehabilitation|Multidimensional rehabilitation
45604722|NCT04969276|Biological|Quadrivalent Inactivated Influenza High Dose|Sterile suspension for injection in a pre-filled syringe Intramuscular injection
45911204|NCT02005003|Behavioral|Food selection task|Participants are given the opportunity to write and use a computer program to specify amount and type of food would ideally like to consume
45604723|NCT04969276|Biological|COVID-19 mRNA Vaccine (nucleoside modified)|Sterile suspension (white to off-white) in multidose vial Intramuscular injection
45604724|NCT04969198|Drug|Combination nicotine replacement therapy (Nicotine patch + nicotine mini-lozenge)|Nicotine patch and mini-lozenge dosing will be based off the 2008 Public Health Services (PHS) Clinical Practice Guideline and package insert with adjustments to account for the delayed start 1-week post-TQD. All participants will receive 2mg mini-lozenge due to the superior palatability of the 2mg lozenges. Participants are encouraged to use at least 5 mini-lozenges per day for the full 8 weeks. Participants who report any smoking or nicotine use (e.g., even a cigarette puff, e-cigarette use) in the 3 days before C-NRT distribution will receive 4 weeks of 14mg and 4 weeks of 7mg nicotine patches. Participants who report complete abstinence from smoking and nicotine in the 3 days before C-NRT distribution will receive 8 weeks of 7mg nicotine patches.
45604725|NCT05304676|Other|Experimental: KTT group|This group will receive neurodevelopmental treatment along with kinesotape and neuromuscular electrical stimulation
45604726|NCT05304676|Other|Active Comparator: conventional treatment|Group B will receive neurodevelopment treatment along with neuromuscular electrical stimulation.
45604727|NCT04666636|Drug|Placebo|Participants will take one pill (placebo) daily for the first week and two pills daily for the remaining 15 weeks.
45604728|NCT04666636|Drug|Mirabegron|Participants will take one pill (50mg Mirabegron) daily for the first week. For week two, participants will take two pills (50mg and 25mg Mirabegron). Unless there are side effects, for the remaining 14 weeks participants will take two pills (50mg each) daily.
45604729|NCT05298748|Other|Womb sound recordings|"Womb sounds will be chosen from commercially available (Amazon) womb recordings using a recording that most closely resembles the womb including maternal heart rate, fetal heartbeat, respiratory sounds, bowel popping sounds and frequency spectra as described by Parga, Daland 2018 et al."
45604730|NCT05288920|Procedure|Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection|Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection
45756787|NCT01913535|Drug|CERC-501|"Low dose of CERC-501 will be 10 mg/day during the first phase (3 days) and during the second phase (3 days).~High Dose of CERC-501 will be 20 mg/day during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days."
45911205|NCT02005003|Behavioral|Memory task|Participants perform short memory tasks on each visit
45604731|NCT05288920|Drug|Transforaminal injection of Steroids alone|Transforaminal injection of Steroids alone
45911206|NCT02005003|Behavioral|Food consumption task|Participants are given a selection of food items to consume on each visit
45604732|NCT05265520|Procedure|His-CRT implantation|The pathophysiological process is utilized in His-Bundle corrective pacing, resulting in a faster and more homogeneous activation of the heart pacing directly via the intrinsic conduction system of the heart accompanied by a right atrial endocardial lead and a right ventricular endocardial lead.
45604733|NCT05265520|Procedure|BIV-CRT implantation|Biventricular cardiac resynchronization therapy has been shown to improve outcomes by delivering synchronized electrical stimuli to the right and left ventricles utilizing an an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.
45604734|NCT04943380|Diagnostic Test|Cxbladder|The Cxbladder Detect test, developed by Pacific Edge Ltd (O'Sullivan 2012; Holyoake 2008; National Health Committee 2015b) is a molecular diagnostic test, which consists of five mRNA transcripts measured in a small volume of urine.
45911207|NCT02005042|Behavioral|Feedback on smartphone|Receive personalized feedback (EMI) on smartphone regarding physical activity
45911208|NCT02005055|Procedure|Surgical excision with adjuvant high-dose-rate brachytherapy|The keloid was excised extralesionally and subsequently a metal tipped Varisource catheter was positioned between the dermal edges of the wound, 5 mm below the surface of the skin and extending out of the skin beyond the wound. Primary wound closure was performed and patients were transferred to the radiation department, where the catheter was connected to the Iridium-192 remote control afterloader. The planning target volume was defined as a cylinder along the axis of the scar, with a central diameter of 5mm. Patients received 2 fractions of HighDoseRate brachytherapy. Within 4 hours after the resection, the first brachytherapy fraction of 6 Gy at 5mm of the source axis was given. Within 24 hours after the first fraction a second fraction of 6Gy was administered to a total dose of 12Gy in 2 days. After the second fraction the catheter was gently removed.
45911209|NCT02005068|Drug|Ceftaroline|The duration of treatment will vary based on type of infection (acute osteomyelitis or joint infection) and if MRSA positive or negative.
45911210|NCT02005081|Device|Actifuse SHAPE|Actifuse Synthetic Bone Graft substitutes mixed with bone marrow aspirate in cervical spine fusion. Actifuse is a synthetic, porous, silicate-substituted hydroxyapatite and has shown that this maximizes a favorable bony response.
45911211|NCT02005081|Device|Autograft with Demineralized Bone Matrix|autograft mixed with demineralized bone matrix in cervical spine fusion.
45911212|NCT02005107|Drug|Venlafaxine IR and Venlafaxine XR|
45911213|NCT02005120|Drug|Bevacizumab|Intrapleural administration of bevacizumab
45911214|NCT02005120|Drug|recombinant human endostatin|Intrapleural administration of recombinant human endostatin
45911215|NCT02005159|Other|Microbiological studies|
45911216|NCT02005198|Other|No treatment given|Subject will only fill out a questionnaire when entering the non-interventional study
45911217|NCT02005224|Other|LCHF diet and a bout of exercise|Low-carbohydrate/high-fat diet; effect on insulin sensitivity, lipid profile, weight and body composition. Participants ingested LCHF diet for three weeks before undergoing an oral glucose tolerance test. The same afternoon the participated in an one hour indoor bicycle training at 75% at HFpeak. The following morning they underwent a new oral glucose tolerance test. Body composition and weight were measured before and after the intervention. Oral glucose tolerance test was also performed before the intervention for baseline. Blood samples were collected before and after the intervention for lipid profile analyses.
45911218|NCT02005237|Behavioral|Aerobic Exercise|3-months exercise program tailored to the individual level of aerobic fitness. Patients will exercise on a bicycle ergometer (2-3 session per week) according to a predefined training plan with increasing duration and intensity
45911219|NCT02005263|Procedure|Salpingography|Infusion of typically 1-2 mL of air bubbles in to the uterine cavity to assess whether they disappear through the ostia in to the Fallopian tubes.
45911220|NCT02005302|Drug|1,25(OH)2 Vitamin D3|Oral 1,25(OH)2 Vitamin D3 by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
45604749|NCT05373940|Device|ICD implantation|"This group will undergo an ICD implantation (type and manufacturer at the discretion of the local investigator) in addition to heart failure medical therapy optimization.~Patients of the HFOT+ICD group will be scheduled for ICD implantation."
45604750|NCT05373940|Device|No ICD implantation|"Patients of the HFOT alone group will not undergo ICD implantation (except if they develop sustained ventricular arrhythmias and fulfil for secondary prevention ICD implantation), and continue with medical therapy optimization only."
45604751|NCT04909138|Device|DRG stimulation 20 Hz 30/90|Stimulation delivered at 20 Hz and 30 seconds ON, 90 seconds OFF
45604752|NCT04909138|Device|DRG stimulation 5 Hz 30/90|Stimulation delivered at 5 Hz and 30 seconds ON, 90 seconds OFF
45604753|NCT04419142|Procedure|Total infrapatellar fat pad excision|Exposure for total knee arthroplasty (TKA) commonly includes total excision of the infrapatellar fat pad (IPFP). The rationale behind this is to obtain improved access to the lateral tibial plateau allowing a more accurate bone cut, baseplate placement and easier management of soft tissue interposition in the bone and cement interface. However, there is growing concern that as the IPFP is a highly vascularized and innervated fibrous adipose tissue filling the anterior compartment of the knee, its complete excision may have a detrimental effect on knee biomechanics and ultimately, TKA outcome. The reason for this effect has been suggested to be patellar tendon (PT) scarring and shortening via ischemic contracture following impaired vascularization, maintenance and biological repair of the tendon.
45756788|NCT01913535|Drug|Placebo|"For patients randomly assigned to the placebo/ placebo sequence, study medication will be placebo during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days."
45756789|NCT01914159|Drug|Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)|Monthly intravitreal injections
45756790|NCT05739279|Diagnostic Test|STAR-Sonographic Thigh Adjustment Ratio|With ultrasonography, anterior thigh muscle thickness on the dominant extremity side will be measured at a 50% level between the anterior superior iliac spine and the upper pole of the patella in the supine position. The STAR-sonographic thigh adjustment ratio will be calculated by dividing the anterior thigh muscle thickness (mm) by the body mass index.
45911221|NCT02005302|Drug|Vitamin D2|Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
45911222|NCT02005302|Dietary Supplement|low protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of 0.6g-0.8g/kg/d.
45911223|NCT02005302|Dietary Supplement|normal protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of more than 0.8g/kg/d.
45911224|NCT02005315|Drug|Vantictumab|Administered intravenous (IV) infusion.
45604754|NCT04419142|Procedure|Partial infrapatellar fat pad excision|It has been suggested in the literature that partial infrapatellar fat pad excision instead of total excision would diminish the potential negative effect on patellar tendon and knee biomechanics. However, there is only limited data in the literature and choice of total/partial infrapatellar fat pad excision in TKA remains debatable.
45604755|NCT04908046|Drug|HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .|"Patient starts the initial dose treatment with 5mg QD of HMPL-295S1, during dose escalation, single-dose PK evaluation will be carried out firstly in each dose group.~At the first therapeutic dose level, the single-dose treatment period is 5 days; from the 2nd dose level, the sponsor can determine the adjustment of single-dose treatment period to 3-5 days based on the available PK profile.~Subsequently, the patients will receive oral HMPL-295S1 QD continuously in a therapeutic cycle of 28 days (Day 1 - 28 of each cycle), until reaching the criteria on the end of treatment. The patients in RP2D extended cohort will enter the consecutive treatment period directly."
45604756|NCT05256940|Behavioral|Motivational Interviewing to Address Suicidal Ideation- Revised (MI-SI-R)|Motivational Interviewing to Address Suicidal Ideation (MI-SI-R) was developed to help Veterans resolve ambivalence about living by increasing the motivation to live, that is delivered in three sessions in person, virtually, or by telephone.
45604757|NCT05256940|Other|Enhanced usual care (EUC)|Enhanced usual care (EUC) includes safety plans administered or reviewed by research therapists, care coordination, and access to a 24-hour crisis hotline.
45604758|NCT04899544|Behavioral|Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C)|Pivotal Response Treatment in autism center.
45604759|NCT04899544|Behavioral|Home-Based Pivotal Response Treatment (PRT Intervention (PRT-H)|Pivotal Response Treatment in home environment.
45604760|NCT05371444|Behavioral|Training with restriction of the DoF|The intervention is based in the training of a single DoF of the upper extremity with restriction of the rest DoF of the arm and trunk that aren't being trained being restrained by an exoskeleton
45604761|NCT05371444|Behavioral|Training without restriction of the DoF|The intrevention is based in the training of the upper extremity movements without the restriction of DoF
45604762|NCT05370976|Drug|Cytotect®CP|"Cytotect®CP in two phases:~Induction phase: 1 ml/kg/week for 4 weeks Maintenance phase: 1 ml/kg/2 weeks for 12 weeks or corticosteroid dose < 0.5 mg/kg, according to which condition occurs first.~Patients developing CMV infection under Cytotect®CP must be given standard anti-CMV treatment (Gancyclovir or Foscarnet) according to their center procedure. Cytotect®CP will be maintained"
45604763|NCT04890106|Drug|Test - Bimatoprost 0.01% Ophthalmic Solution|Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 2 hours for 42 days.
45604764|NCT04890106|Drug|Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)|Subjects in the second arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm ± 2 hours for 42 days.
45604765|NCT04645732|Behavioral|Personalized exercise therapy and self-management support program|See description under Arms
45604766|NCT04645732|Other|Usual care|See description under Arms
45604767|NCT04840654|Procedure|Caudal Block|"A caudal block is a procedure that will help lessen a child's pain after an operation.~100 subjects will be randomized to this block procedure."
45604768|NCT04840654|Procedure|Pudendal Block|"form of local anesthesia commonly used in the practice of obstetrics to relieve pain during the delivery of baby by forceps.~100 Subjects will be randomized to this block procedure."
45604769|NCT04840498|Behavioral|Autism Research|Measuring aspects such as self esteem, social skills, and social anxieties.
45604770|NCT05247190|Behavioral|Treating self-criticism|A psychological treatment given i a group format targeting self-criticism. The treatment is based on treatment principles from Cognitive behavior therapy, Self-compassion, Acceptance and Commitment Therapy and also contains psychoeducation. The group treatment consists of 8 sessions delivered once a week for 2 hrs during 8 weeks in a child- and adolescent psychiatric outpatient setting.
45604771|NCT04640194|Drug|Alteplase|Alteplase
45604772|NCT04640194|Procedure|Standard of care|Standard of Care (SOC) includes any supportive measures applied in hospital, specifically on an intensive care unit (ICU), such as for example the use of non-invasive or invasive ventilation, oxygen masks, haemodynamic support, if needed, sedation, as well as medical therapies commonly used in patients suffering from acute respiratory distress syndrome (ARDS) or its complications. SOC should include best possible treatment regimen established locally and should be in line with current guidelines for ARDS treatment.
45756791|NCT05739279|Diagnostic Test|Hand Grip Strength|Hand grip strength will be measured with a Jamar dynamometer used in the second grip position, in a sitting position with shoulders adducted and neutrally rotated, elbows flexed to 90°, and forearms/wrists in the neutral position. Three repetitive measurements will be made from the dominant side and the maximum value obtained for analysis will be taken.
45756792|NCT05739279|Diagnostic Test|Chair Stand Test|For the 5-repeat stand-up test, patients will be asked to get up from a chair without an armrest and sit (at the start) five times as fast as possible with their arms crossed over their chest.
45756793|NCT05739279|Diagnostic Test|6 Meter Gait Speed|For walking speed measurements, patients will be asked to stand with both feet touching the starting line and walk at their normal speed on a 6-meter track after the command. The time between the start and end will be measured with a stopwatch and converted to meters/second. Three consecutive measurements will be made for both and average values will be taken for the analyses.
45756794|NCT00575159|Drug|GSK189075|investigational drug
45604773|NCT05228158|Drug|Tazemetostat|Tazemetostat oral tablets.
45756795|NCT00575159|Drug|placebo|placebo comparator
45756796|NCT01915173|Drug|Supplement|Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C
45756797|NCT01915173|Drug|Placebo|Lactose tablets
45756798|NCT01915173|Behavioral|Expanded Interview|
45756799|NCT01915173|Behavioral|Standard Interview|
45756800|NCT01915563|Procedure|REST|After a SBT patients will be extubated as usual or reconnected to mechanical ventilation for 60 min before extubation.
45756801|NCT00576251|Drug|Tobramycin 0.3%/Dexamethasone 0.05%|Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days
45604774|NCT05214664|Procedure|Anesthesia|"Once the anesthesia is performed by the Anesthesia practitioner either with the EZ-Block® device or by the conventional freehand technique, the surgical procedure will be performed in the same way in both arms, and for each tooth, by the Surgery practitioner:~The Surgery practitioner takes charge of the patient after a post-anesthesia time of 10 minutes and performs a new antisepsis then completes the anesthesia by anesthetizing the buccal and lingual nerve with a carpule of 1.8ml of articaine + adrenaline at 1/200000.~The Surgery practitioner starts the surgical procedure.~In the absence of pain, the practitioner Surgery carries out the surgical act in its totality (situation of success for the principal criterion of the study) then records the EVA at the end of the intervention."
45604775|NCT05206084|Device|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS)|Subjects in this arm will be treated with IBS
45604776|NCT05206084|Device|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System|Subjects in this arm will be treated with XIENCE
45604777|NCT04833166|Device|CMAC D-blade videolaryngoscope with full or partial glottic view|Deliberate achieving full or partial glottic view on C MAC D-blade video laryngoscope and comparing time and ease of intubation with both arms
45604778|NCT05356390|Other|Stabilization exercises|"Stabilization training is an active form of physical therapy designed to strengthen muscles to support the spine and help prevent lower back pain.~Group A performed stabilization exercises for 4 weeks. In stabilization exercises, floor bridging, heel prop and alternate arm and leg exercises were administered in iliopsoas, gluteal and hamstring groups.~On eligible participants baseline assessment was done,3 sessions were given 3days per week, post intervention assessment was taken at 4th week."
45604779|NCT05356390|Other|Muscle energy techniques|"Muscle Energy Technique (MET) is a is a form of manual therapy, widely used in Osteopathy, that uses a muscle's own energy in the form of gentle isometric contractions to relax the muscles via autogenic or reciprocal inhibition and lengthen the muscle.~Muscle energy techniques were given to group B. These techniques are active form of manual therapy in which patient uses its own energy on request to aid in treatment.~On eligible participants baseline assessment was done,3 sessions were given 3days per week, post intervention assessment was taken at 4th week."
45604780|NCT04852042|Behavioral|mHealth|Participants will receive 2-3 text messages daily. The messages will include information to promote healthy eating and physical activity.
45604781|NCT04852042|Behavioral|CHW support|The CHW will provide behavioral counseling to participants guided by a study website related to their healthy eating and physical activity goals.
45604782|NCT05199298|Other|"Mandala Activity-Based Breastfeeding Program"|Training modules for breastfeeding and Maternal -infant attachment will be implemented with pregnant women in the study group at 32-36 weeks of gestation. The training will be explained by the researchers by shooting a video. In addition, for each week, mandala drawings will be videotaped by the researcher who received mindfulness-based art therapy training and will be sent to the Whatsapp accounts of the pregnant women. t 36 weeks of gestation, the Prenatal Attachment Scale and Spielberger State Anxiety Inventories will be sent to mothers as Google forms. The mother will be called 24 hours after the birth and the situation of having a problem with breastfeeding will be determined. In the first week, in the first and second months after the birth, questionnaire forms and online questionnaires will be applied to the mothers, apart from the follow-up and counseling in the postpartum 2nd month, the posttests of the scales
45604783|NCT05198362|Other|Placebo|Inactive comparator
45604784|NCT05198362|Drug|Tesomet|Fixed-dose combination
45604785|NCT05196100|Device|Amparo confidence socket|Confidence socket involves thermoplastic material being moulded onto the patient's residual limb and a socket is produced in a single session. The socket can be remoulded to adjust to changes in residual limb volume.
45604786|NCT05355220|Device|Silver Spike Point Therapy (SSPT)|Silver Spike Point Therapy (SSPT) means passing an electric current through the skin surface with the triangle spike silver coated metal electrode. SSPT was reported by Hyoto and Kitade in Edinburg, Scotland. 3rd World Congress on Pain in 1981; It has a number of advantages over traditional narcotic medication in pelvic girdle pain management. It does not depress the cardiovascular, respiratory, or the metabolic systems and has no apparent effect on the sensorium
45604787|NCT05355220|Other|Conservative Managment|2 sets of 10 repetitions Bridging, Cat & cow exercises, Back press exercises, stretching of hip external rotators and extensors 20 sec / stretch
45604788|NCT05188222|Drug|Maltodextrin solution|The oral preparation of 50 grams of Maltodextrin solution mixed in 400 mL of water
45604789|NCT05188222|Drug|Placebo solution|Specifically formulated placebo to provide a similar taste and texture to Maltodextrin, without the same carbohydrate characteristics
45604790|NCT05354206|Other|Electrophysiology assessment - corticospinal tract|Kinematics and cortical spinal motor excitability
45604791|NCT05354206|Other|Electrophysiology assessment - reticulospinal tract|Kinematics and reticular spinal motor excitability
45604792|NCT05354206|Other|Training with some stimulation|Motor task combined with real or sham stimulation
45604793|NCT04839484|Device|Study Product|up to 2cc per injection of filler placed into nasolabial fold.
45604794|NCT04839484|Device|Active Control|up to 2cc per injection of filler placed into nasolabial fold.
45604795|NCT04411264|Device|virtual reality|Use of a virtual reality headset while caring for chronic wound dressings
45756802|NCT00576251|Drug|TOBRADEX|TOBRADEX 1 drop in both eyes 4 times daily for at least 3 days
45756803|NCT05739201|Procedure|interscalene nerve block|Patients will receive interscalene nerve block, in which the patient will be in supine position with the head turned to the contralateral side using an ultrasound scan to identify the C5 and C6 nerve roots between the scalene muscles.15 ml of 0.25% Bupivacaine will be deposited between the C5 and C6 nerve roots, within the interscalene groove using a 22 gauge-regional block needle.
45756804|NCT05739201|Procedure|anterior suprascapular nerve block|Patients will receive anterior suprascapular nerve block, in which the patient will be in supine position with the head turned to the contralateral side, using an ultrasound the nerve will be traced as it diverges from the brachial plexus to lie under the omohyoid muscle in the supraclavicular fossa. 15 ml of 0.25% Bupivacaine will be deposited lateral to the suprascapular nerve, underneath the omohyoid muscle using a 22 gauge-regional block needle.
45911225|NCT02005315|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered by intravenous (IV) infusion.
45911226|NCT02005315|Drug|Gemcitabine|Gemcitabine will be administered by intravenous (IV) infusion.
45604796|NCT04818112|Behavioral|ATVV|A 15-minute behavioral intervention that mothers administer once daily to their infant for 3 months providing Auditory, Tactile, Visual, and Vestibular (ATVV) stimulation. Multisensory stimuli are presented in gradual progression. Mother-infant engagement is attempted throughout ATVV so that mothers learn to identify, interpret and adapt to their infants cues. ATVV can be given without eye to eye gaze making it appropriate for newborns. ATVV is offered contingent on infant cues to promote self-regulation and withdrawn if any persistent disengagement cues. Mothers are taught how to adapt ATVV as their infant grows. Fidelity to the intervention is checked with weekly phone calls and monthly study visits. Mothers also receive a daily text from REDCap to document an intervention frequency log.
45604797|NCT04818112|Behavioral|Attention control|Mothers in the Attention Control group receive a similar amount of daily texts, weekly phone call and in-person study visit attention as mothers in the ATVV group, but with distinctly different content. Over the first 3 postnatal months, mothers learn safe infant-care that includes content on diapers, infant clothing, blankets, infant care including bathing, sleep positions, sleep habits, holding the baby, safety of infant equipment, breastfeeding, formula, and age appropriate toys.
45604798|NCT04810156|Drug|Mycophenolate Mofetil|Day 1: MMF 500 mg twice a day Day 2: MMF 1000 mg twice a day
45604799|NCT04810156|Drug|Solu-Medrol|2 mg/kg/day
45604800|NCT04810156|Drug|Ursodeoxycholic acid|Patients with mixed or cholestatic liver injury pattern will also be administrated peroral UDCA according to weight
45604801|NCT04810156|Drug|Prednisone tablet|Shift from solu-medrol IV to peroral prednisolon. A tapering plan will be performed.
45604802|NCT04805554|Other|Joint Insights decision aid|The Joint Insights decision aid was developed by Dell Medical School faculty in collaboration with OM1, a health outcomes and predictive analytics company. This decision aid uses patient-report outcome measures (PROMs) - specifically, the PROMIS Global and the KOOS JR - along with patient clinical and demographic information (age, sex, race, ethnicity, chronic narcotic use, body mass index), in machine-learning-based predictive analytic models to provide personalized estimates of likely benefit or harm from total knee replacement surgery. The tool is designed to collect PROMs or pull in PROMs collected through other systems (e.g., an EHR or a third-party PROM platform). It also provides condition-specific education to patients with knee OA and allows a patient to reflect on and document their preferences and goals. The personalized risk/benefit report generated by the decision aid is meant to be discussed with the patient's provider to enhance shared decision making.
45604803|NCT04851028|Behavioral|Music Therapy|Music therapy is a non-pharmacological intervention, in which music and its elements are used professionally as an intervention in medical, educational, and everyday environments with individuals, groups, families, or communities who seek to optimize their quality of life and improve their physical, social, communicative, emotional, intellectual, and spiritual health and wellbeing. This therapy has shown to provide significant benefits for individuals with cognitive decline living in care homes, enhancing social-cognitive functions and reducing behavioural symptoms (Brotons & Koger, 2000; Hsu et al., 2015; Zhang et al., 2017).
45604804|NCT05183230|Behavioral|WellPATH-PREVENT|WellPATH-PREVENT is a novel personalized, easy to use, mainly stand-alone mobile intervention which focuses on the exclusive use of the WellPATH tablet app and includes training meetings during hospitalization, and virtual post-discharge coaching meetings. The meetings aim to: a) identify stressors and triggers of negative emotions associated with increased suicidal ideation or with suicidal behavior; b) develop techniques (text or video) to increase cognitive reappraisal ability; c) incorporate the techniques into the WellPATH app and promote the use of WellPATH during stressful incidents, triggers of negative emotions, or scheduled brief training sessions; and d) remotely update the triggers, negative emotions, and techniques in the app.
45604805|NCT05183230|Behavioral|Optimized WellPATH-PREVENT|The Optimized WellPATH-PREVENT intervention will be as described above, but based on the results of the Proof-of-Concept (R61) Phase, an expert committee will help select the duration (6 or 12 weeks) that shows greater improvement in cognitive reappraisal.
45604806|NCT04850092|Other|Positional change from supine to prone|Patient is turned from supine to prone position for spine surgery
45604807|NCT04849156|Other|Sperm selection by thermotaxis|Selection of healthy sperm by thermotaxis procedure
45604808|NCT05176054|Other|Health service program|The program will be implemented into the experimental group, the program has been designed as a three-stage model including hospital management, transition care, and post-acute stage care.
45604809|NCT05175664|Other|Long-term study|No intervention. Investigations: cognitive tests, blood samples, pupillometry, actigraphy, and FDG-PET/MR brain scan.
45604810|NCT05175664|Other|Short-term study|No intervention. Investigations: blood samples and pupillometry.
45604811|NCT05175664|Other|Cross-sectional study|No intervention. Investigations: cognitive tests, pupillometry and actigraphy.
45604812|NCT04411342|Diagnostic Test|Albumin creatinine ratio|normal range of albumin in urine in patients with type 2 diabetes
45604813|NCT04837924|Procedure|fascia iliaca compartment block, (FICB) (levobupivacaine hydrochloride 0,25% 40 ml)|Land mark technique will be used to perform FICB on the side of the hip fracture. The injection site is one centimetre caudal from the junction between medial 2/3 and lateral 1/3 in the imaginary line between anterior superior iliac spine and ipsilateral pubic tubercle. The goal is to administer local anesthetic in the fascia iliaca compartment.
45604814|NCT04837924|Drug|paracetamol 1 gram IV|paracetamol 1 gram IV every six hours, 4 times in 24 hours
45604815|NCT04837924|Drug|Rescue analgesic tramadol 100 mg IV if needed|Rescue analgesic, if needed, tramadol 100 mg in 100 ml saline (0,9% Sodium chloride) IV, up to 4 times in 24 hours
45604816|NCT04837924|Procedure|Sham injection|Sting with blunt needle, (without piercing the skin), same site as fascia iliaca compartment block
45756805|NCT05739201|Procedure|Peri-capsular nerve group block|Patients will receive PENG block, in which the patient will be in supine position and the patient's arm will be placed in external rotation and abducted at 45 degrees, using an ultrasound the humeral head, the tendon of the subscapularis muscle and the deltoid muscle over it will be defined, 15 ml of 0.25% Bupivacaine will be placed between the deltoid muscle and subscapularis tendon using a 22 gauge-regional block needle.
45911227|NCT02005328|Device|Tested product : DC161-DP0291|Application of product in the mouth twice daily
45911228|NCT02005328|Device|Tested product : DC161-DP0292|Application of product in the mouth twice daily
45756806|NCT00578279|Drug|dehydrated alcohol|subject randomized to 10ml or 20ml of dehydrated alcohol one time during the EUS-CPN procedure
45604817|NCT05406544|Other|FD qualitative study on quality of life|Patients will be contacted and focus groups will be organized with 6 to 8 patients presenting different types of FD: monostotic, polyostotic, with or without craniofacial damage. Several focus-groups will be conducted with men only or women only. Patients will be led in a semi-directive manner by a moderator who will use an interview grid listing all the topics to be addressed: symptoms, self-image, psychological and emotional well-being, difficulties in daily life and adaptative strategies. The discussions will be recorded and transcribed verbatim. Data will be analyzed manually by 2 investigators and with the help of a semantic analysis software. The objective is to bring out common notions about the quality of life of patients, their psychological and emotional well-being, their difficulties in daily life and their coping strategies according to their condition. Differences or similarities between men and women will be investigated.
45604818|NCT05406544|Other|FD quantitative sudy on quality of life and olfaction.|Participants will receive 3 questionnaires to complete: the SF36 questionnaire (quality of life), the SELF-MOQ questionnaire (olfaction evaluation) and a demographic questionnaire. Other data required for the study will be extracted from the medical record: age, weight, height, affected bone sites, Radiological/ biological activity data, sensorial deficit, medication. For each questionnaire, scores will be calculated and compared between the different FD patient populations according to sex, age and type of FD.
45604819|NCT04831996|Drug|parsaclisib|parsaclisib will be administered orally after 8 hours of fasting.
45604820|NCT04796272|Other|Adapted and individualized physical training program|Physical training program adapted and individualized according to each patient in this group
45604821|NCT04796272|Other|traditional training program|Same training program for all patients in this group
45604822|NCT05406466|Drug|Tislelizumab|a PD-1 immune check inhibitor
45604823|NCT05406466|Drug|Lenvatinib|multitargeted receptor tyrosine kinase inhibitor
45604824|NCT05406466|Drug|Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
45604825|NCT05152420|Drug|VMX-C001|VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
45604826|NCT05152420|Drug|Placebo|VMX-C001 matched placebo
45604827|NCT05152420|Drug|Apixaban|FXa Inhibitor
45604828|NCT05152420|Drug|Rivaroxaban|FXa Inhibitor
45604829|NCT05152420|Drug|Edoxaban|FXa Inhibitor
45756807|NCT01916655|Behavioral|Self-Management Care|Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy
45756808|NCT01916655|Behavioral|Self-Management Mobile Care|Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy via mobile phone
45452165|NCT03951064|Device|Esophageal balloon|All patients in both groups will have an esophageal balloon catheter inserted by a research investigator. The catheter will be inserted into their nare while upright (head of bed >30 degrees) to a depth slightly more than the estimated distance from the lower sternum to the back of the ear (typically around 60 cm). Gastric positioning will be confirmed with abdominal compression testing and the catheter then retracted 10 - 20cm into the lower esophagus. Placement will be confirmed with the presence of cardiac oscillations on the esophageal probe. The probe will then be secured to the patient's nasal opening using tape.
45604830|NCT05142202|Radiation|Breast Irradiation after Breast-Conserving Surgery|All recruited participants will be treated with adjuvant to breast-conserving surgery accelerated partial breast irradiation with multicatheter interstitial brachytherapy technique and prescribed five times 5,4 Gy delivered in 3 consecutive days (6 hours minimum gap between the fractions). Treatment starts not later than 12 weeks after surgery (optimally 4-8 weeks), after wound healing, and obtaining the final pathological report with full immunohistochemistry and proper risk group assignment.
45604831|NCT01601470|Drug|LCZ696|LCZ696 400mg QD was administered alone for 4 days and in combination with sildenafil for 1 day
45756809|NCT01916655|Behavioral|Usual Care|standard and typical CPAP educational and support protocol; is the base level education and support that is provided in the other two interventions in this study.
45756810|NCT00578669|Drug|Fluoxetine|20mg once daily for 16 weeks
45756811|NCT00578669|Drug|Dextrose|Once daily for 16 weeks
45604832|NCT01601470|Drug|Sildenafil|Sildenafil 50 mg single dose was administered alone for 1 days and in combination with LCZ696 400mg QD for 1 day
45604833|NCT04556656|Drug|Pridopidine|Pridopidine hard gelatin capsule
45604834|NCT04556656|Drug|Placebo|Pridopidine-matching placebo hard gelatin capsule
45604835|NCT05403346|Device|CoviDx™ Covid-19 Antigen Self-Test|All patients will self-collect a mid-turbinate nasal swab for CoviDx™ Covid-19 Antigen self-testing
45604836|NCT05400616|Procedure|Microbiome Transplant|A raw microbiome, is collected from a donor without any sinonasal health problems, as a nasal lavage.
45756812|NCT05733585|Device|Purabond|hemostatic efficacy of PuraBond
45756813|NCT01917513|Device|G-EYE™ colonoscopy|G-EYE™ colonoscopy
45756814|NCT01917513|Device|Standard Colonoscopy|Standard Colonoscopy
45756815|NCT00578903|Drug|Cytoxan|Cytoxan will be given at 50 mg/kg per dose for 4 successive days.
45756816|NCT00578903|Drug|Campath|Campath will be given at a dose of 3 mg for patients whose weight is between 5 and 15 kg; at a dose of 5 mg for patients whose weight is between 16 and 30 kg; and at a dose of 10 mg for patients whose weight is greater than 30 kg. The last dose of Campath should be 24 hours or more before stem cell infusion.
45756817|NCT00578903|Radiation|Total Body Irradiation (TBI)|TBI will be given at a dose of 200 cGy for 6/6 HLA match and at a dose of 400 cGy in two fractions of 200 cGy each for 5/6 HLA matched donor.
45911229|NCT02005328|Device|Tested product : DC161-DP0293|Application of product in the mouth twice daily
45911230|NCT02005328|Device|Reference product: solution for oromucosal sprays|Application of product in the mouth twice daily
45911231|NCT02005341|Device|nanOSS|
45911232|NCT02005341|Device|Autograft|
46066615|NCT00764569|Device|Fluorescence/Elastic Scattering Spectroscopy|Fluorescence/Elastic Scattering Spectroscopy Oral tissue measurement
45756818|NCT00578903|Drug|FK-506|FK-506 will be given at a dose of 0.03 mg/kg/day via continuous infusion over 24 hours from 4pm on day -2 until engraftment or when patient is able to take by mouth (PO), then 0.03 mg/kg PO every 12 hours.
46066616|NCT04253054|Other|Cardiovascular risk factors|Different level of cardiovascular risk factors, such as aging, hypertension, diabetes, dyslipidemia, smoke, alcohol drink, obesity and et al, associated with genetics, environments and lifestyles
45604837|NCT05400616|Procedure|Placebo|Normal saline.
45604838|NCT05108506|Behavioral|No Strict need to void following surgery|Certain patient will be randomized without a strict need to void prior to discharge following surgery.
45604839|NCT05108506|Behavioral|Strict need to void following surgery|Certain patient will be randomized with a strict need to void prior to discharge following surgery.
45604840|NCT04418986|Procedure|opposite clear corneal incisions (OCCI)|"Coaxial small incision cataract surgery was performed for all cases using a 2.8 mm keratome placed at steep meridian and 1-mm paracentesis was made 90 degrees apart with a 20-gauge microvitrectomy blade. Surgery was performed with a 30-degree, 0.9-caliper phacoemulsification tip (microtip) with a divide and conquer technique.~In the OCCI group, a single penetrating incision was created with 2.8 mm keratome in the clear cornea, 1.5 mm anterior to limbal blood vessels, centered over the steep meridian and opposite the phacoemulsification incision."
45604841|NCT04418908|Drug|Cetrorelix acetate, 0.25 mg/day|All participants self-administered GnRHant daily between the baseline and follow-up visits (cetrorelix acetate, 0.25 mg/day).
45604842|NCT04418908|Drug|Estradiol Patch, 0.025 Mg/24 Hours Weekly Transdermal Film, Extended Release|Active estradiol transdermal patch.
45604843|NCT04418908|Drug|Placebo patch|Placebo patch designed to match active Climara patches.
45604844|NCT04546126|Drug|Dexamethasone (Group 2)|Participants will take 1 mg dexamethasone 2x a day for 3 days to suppress cortisol production.
45604845|NCT04546126|Drug|Cosyntropin (Group 3)|Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
45604846|NCT04546126|Combination Product|PET/CT Scan with FNP-59|FNP-59, a radiotracer, is administered for PET/CT scans.
45604847|NCT04762498|Biological|Pegloticase and Methotrexate (MTX)|16 mg IV dose of pegloticase q4 weeks co-administered with 15 mg oral dose methotrexate weekly
45604848|NCT04762498|Biological|Pegloticase and Methotrexate (MTX)|Potential higher IV dose of pegloticase (between 24-32 mg) q4 weeks co-administered with 15 mg oral dose methotrexate weekly and/or potential reduction of infusion duration
45604849|NCT04527328|Device|AKST1210|AKST1210
45604850|NCT04527328|Other|Sham Control (No Intervention)|A covered surrogate object of similar size and shape as the investigational device
45604851|NCT04527328|Procedure|Hemodialysis|Hemodialysis
45604852|NCT05397808|Other|Pilates Training|The group that received pilates training.
45604853|NCT05397808|Other|breathing and relaxation exercises|The group who received breathing and relaxation exercises with a home program.
45604854|NCT04747288|Diagnostic Test|Traditional Chinese Medicine pattern|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) and non AIDDES Healthy Controls subjects will take the Traditional Chinese Medicine pattern diagnosis.
45604855|NCT04747288|Diagnostic Test|Traditional Chinese Medicine tongue diagnosis|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) and non AIDDES Healthy Controls subjects will take the Traditional Chinese Medicine tongue diagnosis.
45604856|NCT04747288|Diagnostic Test|Heart rate variability|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Heart rate variability.
45604857|NCT04747288|Diagnostic Test|Schirmer's test|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Schirmer's test.
45604858|NCT04747288|Diagnostic Test|Ocular Surface Diseast Index (OSDI)|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Ocular Surface Diseast Index (OSDI).
45604859|NCT04747288|Diagnostic Test|EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI)|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI).
45604860|NCT04747288|Diagnostic Test|36-Item Short Form Survey (SF-36)|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the 36-Item Short Form Survey (SF-36).
45604861|NCT05304910|Drug|Lu AG09222|Lu AG09222 will be administered per schedule specified in the arm description.
45604862|NCT05304910|Drug|Placebo|Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
45604863|NCT04821934|Other|TR|"TR is a specific remote tele rehabilitation program on exercise activity managed by the physiotherapist (PT) at home, this is the experimental group. PT will explain the rehabilitation program at hospital discharge by the use of a brochure and videos. TR will include an early exercise re-conditioning program [aerobic exercise at the free body (with or without tools), cyclette and walking with a pedometer] comprising 20 sessions of 60 minutes/day, 6 out of 7 days to be performed at home, for one month after discharge. The sessions will be self-managed by the patients 4 times a week and an expert PT will remotely supervise 2 times a week through a dedicated platform. The program will be progressively incremental and divided into 4 different levels of intensity (0- 3).~In addition to this specific rehabilitation program, the patients will be followed by a nurse tutor once a day for two weeks and once a week for a further two weeks in a program of Telesurveillance."
45604864|NCT04821934|Other|TSu|"The patients of this group will perform a usual Telesurveillance and will be considered as control group.~All patients, at discharge from the hospital, will be provided with a finger pulse oximeter and a dedicated application (app) on their personal smartphone and will be advised on free physical activity to be performed at home. The nurse will check through scheduled calls (once a day for two weeks and once a week for a further two weeks) the patient's health condition, vital parameters and drugs administration. Patients will be able to contact the nurse at each time, in case of specific need, out of the scheduled call, 7/7 days.~A follow up by phone will be planned by nurse tutor at 2 months from the end of the study."
45604865|NCT04466501|Device|ACR LAB|"The ACR | LAB is a prescription-only, nurse- or clinician-conducted in vitro diagnostic (IVD) device. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm."
45604866|NCT03525041|Procedure|CABG|CABG will be performed using standard surgical techniques. All procedures will be performed with cardiopulmonary bypass(CPB). Saphenous vein(SV)will be used as conduit but harvesting methods will not be prescribed, and utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, judging by the surgical investigator.
45756819|NCT00578903|Drug|Methotrexate|Methotrexate will be administered on day +1, day +3, day +6 and day +11 at a dose of 5 mg/m2. The day +11 dose may be omitted at the discretion of the bone marrow transplant (BMT) in-patient attending physician.
45756820|NCT00578903|Procedure|Stem cell infusion|Where possible patients will receive bone marrow. Marrow will be collected as per National Marrow Donor Program (NMDP) guidelines to provide a volume of 15-20 ml/kg of marrow and/or 2-4 X 10^8 nucleated cells/kg. In case marrow cannot be collected, peripheral blood stem cell (PBSC) will be substituted. A minimum of 5-6 X 10^6 CD 34+ cells/kg should be collected, with a target of 10 X 10^6/kg.
45604867|NCT03525041|Procedure|mitral valve annuloplasty|Surgical techniques for mitral valve annuloplasty may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation.
45756821|NCT01918761|Drug|Dacomitinib, Pemetrexed|Pemetrexed 500mg/m2 i.v (q21d) Dacomitinib 45mg orally (continuous)
45604868|NCT04831450|Drug|Cemiplimab-Rwlc|350 mg Cemiplimab administered via intravenous infusion over 30 minutes on Day 1 of a 21-day cycle.
45604869|NCT03248375|Radiation|Radiation Segmentectomy|The administration of radioactivity in a branch of an artery of the liver
45604870|NCT04830982|Drug|IV Diazoxide|500 micromoles added to one liter of cardioplegia
45604871|NCT04830982|Other|Placebo|Placebo added to one liter of cardioplegia
45604872|NCT04821544|Behavioral|Mindfulness-based intervention (with a focus on self-compassion; MBSC)|8-week MBSC intervention with a focus on increasing self-compassion
45604873|NCT03524963|Drug|Cilostan CR Tab.|Cilostan CR Tab. 200mg once a day for 5 days
45604874|NCT03524963|Drug|Pletaal SR Cap.|Pletaal SR Cap. 200mg once a day for 5 days
45604875|NCT04821466|Device|Virtual Reality Headset to provide a Virtual Reality Experience|Participants will utilise a Virtual Reality experience for distraction therapy via a Virtual reality headset. Participants will wear the Virtual reality headset to be immersed in a multimedia experience.
45604876|NCT03524885|Procedure|Short implant placement|"Ten patients will be randomly selected for the short implants option, 2 or 3 implant 4-5 mm length and 4 mm diameter (Syra Short, Sweden & Martina, Padua, Italy) will be positioned. The healing cap will be immediately connected and a vycril suture will be done after soft tissue reflection.~After three months an acrylic screw-retained bridge will be delivered. After further three months, a definitive restauration with a metal ceramic bridge will be seated."
45604877|NCT03524885|Procedure|Bone regeneration with longer implants|"Ten patients will be randomly assigned to the regenerative group, 2 or 3 implant from 10 to 13 mm length intentionally exposed putting the implant platform 2 or 3 mm apical to CEJ of the adjacent tooth will be inserted.~A horizontal and vertical regeneration following GBR technique will be performed using not-resorbable PTFE titanium reinforced membrane (Cytoplast Osteogenics, US) fixed by titanium pins or miniscrews to ensure the perfect stability (Pro-fix, Cytoplast Osteogenics, US)."
45604878|NCT04466423|Behavioral|Small group meetings (COMPASS: COlleagues Meeting to Promote And Sustain Satisfaction)|The first 15 minutes of each session will be semi-structured discussion involving i) check in and ii) dialogue about the assigned question. Group leaders will be provided 3-4 discussion questions for each session. The group (or the leader) can choose the one they are most interested in and will then spend 10-15 minutes discussing the question together. Questions will touch on key themes for discussion (see the attached topics list) and are derived from our previous intervention studies. The remainder of the time can be used for socializing and building relationships with colleagues.
45604879|NCT04150822|Other|Registry and Saliva sample|Non-interventional registry with saliva sample collected for DNA analysis
45604880|NCT04466033|Device|Magneto Microcatheter|All patients will be treated with Magneto Microcatheter
45604881|NCT05302804|Other|Hot environment|38°C, 60% relative humidity
45604882|NCT05302804|Biological|Menthol Gel|application of 5% menthol gel from shoulder to wrist and mid thigh to ankle
45604883|NCT05302804|Biological|Control Gel|application of hypoallergenic gel from shoulder to wrist and mid thigh to ankle
45604884|NCT05302804|Other|Exercise|treadmill walking 3.5 mph at 5% grade
45604885|NCT04062305|Behavioral|Hand Function Test|Complete tasks that test grip strength, pinch strength, and ability to use and feel with hands
45604886|NCT04062305|Procedure|Navigated Transcranial Magnetic Stimulation|Undergo nTMS
45604887|NCT04062305|Other|Quality-of-Life Assessment|Ancillary studies
45604888|NCT04062305|Other|Questionnaire Administration|Ancillary studies
45756822|NCT00579137|Biological|Campath -1H|"Given intravenous on Days -8,-7, and -6~Campath dose is weight based: for patients less than 15 kg the dose is 3 mg; for patients >15 kg to 30 kg the dose 5 mg; for patients > 30 kg the dose is 10 mg"
45756823|NCT00579137|Drug|Fludarabine|"Given intravenous on Days -8,-7,-6,-5, and -4~Dose is 30 mg/m2"
45756824|NCT00579137|Biological|Anti-CD45|"Given intravenous over 6 hours on Days -5,-4,-3, and -2~Dose is 400 microgram/kg"
45756825|NCT00579137|Procedure|Stem cell infusion|stem cells are infused on day 0
45756826|NCT04290377|Device|BMI-assisted motor imagery OT|As the goal of the intervention is to promote finger extension in participants who are unable to extend his/her finger due to stroke, the pneumatic glove provides extension assist when appropriate brain activity is present. The brain activity is obtained by Functional Near-Infrared Spectroscopy (fNIRS). Hypothetically, this will repeatedly induce brain activation that is related to finger extension.
45756827|NCT04290377|Other|Motor imagery OT|In Motor imagery OT, Subjects try to extend their fingers (imagine) without BMI assistance. All other setting is equal to BMI-assisted motor imagery OT.
45756828|NCT00580073|Drug|FOLFOX4|oxaliplatin (85mg/m2 on days 1 and 15 of each cycle)+ 5FU Bolus (400mg/m2 on days 1, 2, 15, and 16 of each cycle) + 5FU CI (600mg/m2 on days 1, 2, 15, and 16 of each cycle) + Leucovorin (200mg/m2 on days 1, 2, 15, and 16 of each cycle)
45756829|NCT00580073|Drug|Cetuximab|Cetuximab 400mg/m2 on day 1 only, 250mg/mr on days 8, 15, and 22 of each cycle.
45604889|NCT04722250|Device|Medtronic Evolut PRO, Evolut PRO+ or Evolut FX (where commercially available) TAV Systems|TAVR treatment with Medtronic Evolut PRO, PRO+ System or Evolut FX System (where commercially available)
45604890|NCT04722250|Device|Edwards SAPIEN 3 or SAPIEN 3 Ultra THV Systems|TAVR treatment with Edwards SAPIEN 3 or SAPIEN 3 Ultra System
45604891|NCT04514848|Device|INSTI Multiplex HIV-1/2 Syphilis AB test|For the detection of antibodies to syphilis and HIV
45604892|NCT04514848|Device|Multiplo Rapid TP/HIV test|For the detection of antibodies to syphilis and HIV
45604893|NCT04508764|Other|Families Accelerating Cascade Testing Toolkit|-Online family history assessment, video of Siteman Cancer Center genetic counselors, physicians and patients highlighting the importance of cascade genetic testing, reviewing and receiving a family letter and gene information sheet, reviewing websites/online resources, and offering a family visit with a genetic counselor
45604894|NCT04508140|Procedure|Hepatic Biopsy|In this trial a biopsy from the hepatic lesion to be injected will be mandatory on C1D1 and C2D1, prior to the BO-112 administration. On the same timepoints, a biopsy from a non-hepatic, non-injected lesion will be optional.
45604895|NCT04508140|Drug|BO-112 with Pembrolizumab|. The study treatment consists of the combination of BO-112 given intratumorally inside the liver metastasis at the dose of 1gm in 1.2 mL in combination with intravenous pembrolizumab given at the fixed dose of 200 mg. This treatment will be given every 3 weeks, with a maximum duration of 35 cycles (2 years). Of note, during the first cycle, BO-112 will be administered on D1 and D8.
45604896|NCT04829188|Behavioral|Structured Telephone Support (STS)|Structured telephone support (STS) consists of post-discharge assessment, education, and medication reconciliation delivered telephonically by a health plan case manager, home care as needed, and follow-up with the primary care within seven days post-discharge.
45604897|NCT04829188|Behavioral|Low-intensity Remote Patient Monitoring (RPM-Low)|Questions are pushed to members multiple times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team.
45604898|NCT04829188|Behavioral|High-intensity Remote Patient Monitoring (RPM-High)|Questions are pushed to members multiple times per week for up to 90 days post-discharge. Questions include monitoring vital signs for worsening infection but also ask about factors that would indicate worsening of underlying heart or lung conditions, such as weight gain or shortness of breath. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team.
45604899|NCT04829188|Behavioral|Standard Response Team|RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, nurses contact the patient and/or the patients' PCP or specialist to coordinate care and ensure timely follow-up.
45604900|NCT04829188|Behavioral|Enhanced Response Team|RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans. In addition to reacting to RPM triggers, team members (e.g., CRNP, social workers, nurses) meet with the patient in-person or virtually in the week after discharge and at least twice more in the next 90 days, conduct assessments and a pharmacy review, develop care plans, and discuss advance directives.
45604901|NCT03323944|Biological|huCART-meso cells|Intravenous administration or local delivery of lentiviral transduced huCART-meso cells.
45604902|NCT04820452|Biological|Low dose IBI302|Low dose IBI302 intravitreal injection given as every other month after three loading monthly injection
45604903|NCT04820452|Biological|High dose IBI302|High dose IBI302 intravitreal injection given as every other month after three loading monthly injection
45604904|NCT04820452|Drug|Aflibercept|Intraocular injection
45604905|NCT05298202|Biological|Capsaicin|application of capsaicin gel from shoulder to wrist and mid thigh to ankle
45604906|NCT05298202|Biological|Control Gel|application of hypoallergenic gel from shoulder to wrist and mid thigh to ankle
45604907|NCT05298202|Other|Exercise|treadmill walking 3.5 mph at 5% grade
45604908|NCT05298202|Other|Hot environment|38°C, 60% relative humidity
45756830|NCT00580151|Drug|clonidine|3-5 microgram per kilogram every 6 hours for 10 days
45756831|NCT00580151|Drug|placebo|1 dose every 6 hours
45756832|NCT01919697|Drug|Plecanatide|
45756833|NCT00580229|Drug|prednisone|prednisone 40mg by mouth 30-60 minutes prior to rituximab
45756834|NCT00580853|Drug|varenicline|2mg/day, with 1-week lead-in medication period The starting dose is 0.5 mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5 and then 1mg twice daily for days 4-7. 1mg administered during laboratory session (day 8).
45756835|NCT00580853|Drug|bupropion|300mg/day, with 1-week lead-in medication period The starting dose is 150mg/day for days 1-3, 300mg/day for days 4-7. 300mg administered during laboratory session (day 8).
45756836|NCT00580853|Drug|Placebo|Placebo
45756837|NCT05739045|Drug|nivolumab combined with SOX|nivolumab + SOX (3 cycles) before surgery → radical surgery (D2) → nivolumab + SOX (3 cycles) after surgery → nivolumab monotherapy maintenance (11 cycles);
45756838|NCT00604019|Drug|Dopamine|Dopamine 5-20 mcg/kg/min to pre-determined max of 20
45756839|NCT00604019|Drug|Norepinephrine|Norepinephrine 5-20 mcg/min, to a pre-determined max of 20
45604909|NCT01637272|Drug|SOM230|Pasireotide (SOM230) sc injection was provided as solution for injection in individual 1-point-cut 1 mL ampule, containing nominally 200 μg of pasireotide (as free base). Doses: 50, 100, 150 and 200 μg. Pasireotide im LAR depot injection was provided as micro particles powder in vials containing nominally 10, 20, 40 & 60 mg of pasireotide (as free base) & solvent for suspension for injection in ampules for the reconstitution of the LAR micro particles. Doses: 10, 20, 30, 40 or 60 mg
45604910|NCT05224726|Other|Platelet Rich Plasma|Applying 5cc of PRP preparation on uterine incision after it has been sutured.
45604911|NCT04458922|Drug|Atezolizumab|Given IV
45604912|NCT04458922|Procedure|Biopsy|Correlative studies
45604913|NCT04458922|Procedure|Biospecimen Collection|Correlative studies
45604914|NCT04458922|Procedure|Computed Tomography|Undergo CT scan
45604915|NCT04809064|Procedure|Arthroscopic Bankart repair procedure|Bankart repair with remplissage consists of arthroscopic anterior inferior capsulolabral repair with arthroscopic infraspinatus tenodesis to the posterior humeral head.
45604916|NCT04809064|Procedure|Open Bankart|Open Bankart repair consists of anterior capsulorrhaphy with labral repair.
45604917|NCT04809064|Procedure|Latarjet|Latarjet consists of open transfer of the coracoid to the anterior glenoid bone deficiency.
45604918|NCT04809064|Other|Post-Operative Rehabilitation|Post-operative rehabilitation will be conducted following surgical procedure-specific rehabilitation guidelines and will be progressed based on individual needs.
45604919|NCT03262558|Other|No intervention|Patients will undergo standard clinical routine practice in this indication
45604920|NCT05327452|Behavioral|Supervised Home-Based Exercise|Online supervised aerobic and resistance exercise
45604921|NCT05327452|Behavioral|Unsupervised Home-Based Exercise|Unsupervised aerobic and resistance exercise (UNSUP)
45604922|NCT05327452|Behavioral|Attention Control|Stretching Program
45604923|NCT03178864|Drug|Rivaroxaban|Rivaroxaban 20 mg daily (15 mg daily in participants with a CrCl 30-49 mL/min as per the Cockroft-Gault equation)
45604924|NCT03178864|Drug|Standard of care|Accepted standard of care as per American Heart Association/American Stroke Association Guidelines (initial use of unfractionated heparin or low-molecular weight heparin with transition to an oral vitamin K antagonist or continuation with low-molecular weight heparin) with choice of agent at the treating physician's discretion.
45604925|NCT01636960|Biological|PegIFN alfa-2b|
45604926|NCT04827238|Diagnostic Test|Standardized Invasive Hemodynamics|The SIH technique is a standardized, reproducible and efficient way of obtaining hemodynamic measurements.
45756840|NCT05732571|Other|Breathing techniques over 12 sessions / 6 weeks inc yoga|as above
45756841|NCT00581399|Device|NO-NUMO™ High Vacuum Body Cavity Drainage System|(1) disposable NO-NUMO™ body cavity drainage tubes, (2) disposable Vario™ fluid management canisters and (3) Vario™ portable vacuum pump
45756842|NCT00581399|Device|PVC Chest Tube|Standard PVC Chest Tube Sizes 14-36 French
45756843|NCT01922115|Drug|Trospium Chloride|Subject will be administered either placebo or 60 mg dosage of Sanctura XR for treatment of overactive bladder. Subject will take Sanctura XR once every morning. Blood will be drawn for plasma extraction at each visit.
45604927|NCT05323552|Procedure|Laparoscopic TEP hernia repair without curare and without orotracheal intubation.|"All the techniques and protocols used for this monocentric study are standardized:~The anesthesia is general, the anesthetic products administered are identical,~ventilation is ensured by the use of a laryngeal mask airway, without curare administered~the surgery is an extraperitoneal laparoscopy with an optical trocar under the umbilical and two operators with the placement of a preformed type 3G polypropylene prosthesis~the analgesic protocol is free of opioids (Opioid Free Anesthesia - OFA)"
45604928|NCT04036708|Behavioral|Wetting method (WTM)|The wetting method is an evidence-based, simple process to remove cyanogens from cassava flour. It involves teaching women to add water to cassava flour and allow it to stand for 2 h in the sun or 5 h in the shade for the hydrogen cyanide gas to escape. Colorfully illustrated and durable laminated posters depicting the WTM will be distributed to participating households. Women will receive this training bi-weekly for 12 months
45756844|NCT01922115|Drug|Placebo|
45604929|NCT04036708|Behavioral|Mediational Intervention for Sensitizing Caregivers (MISC)|The study team will use MISC to train DRC mothers in practical day-to-day activities with their children to enhance 5 key mediational processes: 1) focusing (getting the child's attention and engaging directing them to learning experiences); 2) exciting (communicating excitement, appreciation, and affection with the learning experience); 3) expanding (making the child aware of how the learning experience transcends the present situation and can include past and future issues beyond the immediate need of the moment); 4) encouraging (emotional support to foster the child's sense of security and competence); and 5) regulating (helping to direct the child's behavior in constructive ways with a goal towards self-regulation).
45604930|NCT04194970|Device|With WBM smart insole system to monitor compliance of specified weight bearing limits data in live feedback on and off situations|"Weight Bearing Protocol (Duration: Post-Op. 6 week)~Post-op 3 week non-weight bearing (%0 body weight of patient)~Post- op 3 week touch down weight bearing (%10-%20 body weight of patient) Group I - monitoring with device while the live feedback mechanism turned on Group II- monitoring with device while the live feedback mechanism turned off"
45756845|NCT00081770|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|1.5 ug/kg/week subcutaneously (SC) for 48 weeks
45756846|NCT00081770|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|1.0 ug/kg/week SC for 48 weeks
45756847|NCT00081770|Drug|REBETOL (ribavirin; SCH 18908)|weight based dose 800-1400 mg/day orally (PO) for 48 weeks
45756848|NCT00081770|Biological|PEGASYS (peginterferon alfa-2a)|180 ug/week SC administered for 48 weeks
45756849|NCT00081770|Drug|COPEGUS (ribavirin)|1000-1200 mg/day PO for 48 weeks
45756850|NCT05731323|Drug|D-cycloserine|Daily oral D-cycloserine dosed 25mg/17.5kg body weight during TMS treatment days (20 days).
45756851|NCT05731323|Device|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
45756852|NCT00605423|Drug|Fluocinolone Acetonide/Medidur|0.2 ug/day implant
45756853|NCT00605423|Drug|Fluocinolone Acetonide/Medidur|0.5 ug/day implant
45604931|NCT04808362|Biological|OMO-103|OMO-103 will be administered intravenously as 30 min infusion once weekly
45604932|NCT04193176|Drug|Gefapixant|Administered twice daily as an oral tablet of 45 mg
45604933|NCT04193176|Drug|Placebo|Administered twice daily as a placebo oral tablet matching gefapixant
45604934|NCT03054142|Other|no intervention|
45604935|NCT04020484|Behavioral|Making Mindfulness Matter© (M3)|Making Mindfulness Matter© (M3) is an interactive online parent and child program that incorporates mindful awareness, social-emotional learning skills, neuroscience, and positive psychology. This program was modelled after the school-based MindUP™ program for use in the community and augmented to integrate a parent component. M3E is a facilitator-led program that integrates attitudes, skills, and behaviours related to mindfulness and social-emotional learning (SEL). During the 8-week concurrent parent and child manualized program, parents learn the same core principles as children: how our brains work, stress and the brain, mindful breathing, mindful sensing, mindful movement, perspective taking, optimism, and gratitude/acts of kindness.
45604936|NCT01636258|Behavioral|Stress Management|Every other week
45604937|NCT01636258|Behavioral|Diet|Every other week
45604938|NCT01636258|Behavioral|Exercise|Every week
45604939|NCT01636258|Behavioral|Culinary education|Every other week
45604940|NCT04381624|Other|Exercise program|exercise program in 12 sessions, of approximately one hour, distributed in 3 sessions per week during a month
45604941|NCT04009876|Drug|nal-IRI|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
45604942|NCT04009876|Procedure|Surgical resection|Surgical resection of the tumour
45604943|NCT04009876|Other|Watch-and-wait|No surgery approach
45604944|NCT04009876|Drug|5-FU/LV|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
45604945|NCT04009876|Drug|Oxaliplatin|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
45604946|NCT05287516|Other|Breakfast meal|A meal consisting of breakfast biscuits and water.
45604947|NCT04826302|Other|Myofascial treatment|"40 minutes of myofascial intervention: 10 min in each of the following regions with the patient face up:~Thoracolumbar fascia and abdomen~C7-T4 and sternum~Suboccipital area~Temporary area"
45604948|NCT04826302|Other|Sham myofascial treatment|"40 minutes of sham myofascial intervention: 10 min in each of the following regions with the patient face up and with the contact of the physiotherapist through a towel and without any intention:~Thoracolumbar fascia and abdomen~C7-T4 and sternum~Suboccipital area~Temporary area"
45604949|NCT05309902|Drug|Soticlestat|Soticlestat tablet.
45756854|NCT05730699|Biological|divozilimab|anti-CD20 monoclonal antibody
45604950|NCT05309902|Drug|Placebo|Soticlestat placebo-matching tablet.
45604951|NCT05309902|Drug|Moxifloxacin|Moxifloxacin over-encapsulated tablet.
45604952|NCT05309902|Drug|Placebo|Moxifloxacin placebo-matching capsule.
45604953|NCT05281744|Behavioral|Dementia Care Consultation program|The Dementia Care Consultation program uses a telephone-based intervention to provide an in-depth, personalized service for individuals living with ADRD and their care partners. It consists of comprehensive needs assessments, creation and implementation of personalized care plans, monitoring and revising care plans, disease education and support coaching, referrals to community-based organizations for service and support, and access to assistance.
45604954|NCT02993068|Other|Educational Intervention|Watch genetic testing online educational video
45604955|NCT02993068|Other|Genetic Counseling|Receive post-telephone genetic counseling
45604956|NCT02993068|Other|Genetic Counseling|Receive pre-telephone genetic counseling
45604957|NCT02993068|Other|Laboratory Biomarker Analysis|Correlative studies
45604958|NCT02993068|Other|Questionnaire Administration|Ancillary studies
45604959|NCT02987686|Drug|Topical Infliximab|Aside from the standard treatment, patients will receive topical infliximab ( 10mg/ml) four (4) time per day for four (4) weeks.
45604960|NCT05369026|Other|Single leg immobilization|2 weeks of single-leg immobilization
45604961|NCT02983240|Device|Electrical Uterine Pacemaker|The catheter is placed under ultrasound guidance into the posterior vaginal fornix next to the external cervical os. The electrode connectors are attached to the EI device. Activating the EI device involves: 1) turning the current pulse duration rotary dial clockwise to the desired setting; this is an important setting and should be set at 20ms; 2) turning the current frequency rotary dial clockwise to the desired setting; 3) turn on the EI device on with the on/off toggle switch; 4) SLOWLY turning the current strength rotary dial clockwise to the desired setting, at this time the red light should be flashing. Usually 5-10mA of current is sufficient, but 20 mA is a maximum. Based on the tocometer recordings the least amount of EI current is given to inhibit the uterine contractions.
45604962|NCT02504216|Drug|Rivaroxaban (Xarelto, BAY59-7939)|2.5 mg, twice daily, orally, tablet
45604963|NCT02504216|Drug|Rivaroxaban-Placebo|matching placebo, twice daily, orally, tablet
45604964|NCT04817176|Behavioral|Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program|Experimental Arm: The program is a 6-week group, telehealth intervention for older adults with possible MCI. The intervention uses Motivational interviewing and cognitive behavioral therapy strategies to enhance motivation and help participants overcome personal obstacles to following health-behavior recommendations. Specifically, the program examines the use of a Mediterranean ketogenic type of nutrition to target mild cognitive impairment. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
45604965|NCT04817176|Other|Ketogenic Nutrition Program|Active Comparator Arm: 6-week group, telehealth intervention for older adults. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
45756855|NCT05730699|Drug|Placebo|Placebo
45756856|NCT00606047|Radiation|Magnetic resonance imaging (MRI)|Participation in this study will involve patients coming to the hospital after regular work hours for an MRI of the hip joints.
45756857|NCT01923129|Drug|Prazosin given 6 hours prior to catheter removal in the 24 hour group|Prazosin given orally (1 mg) 6 hours prior to catheter removal (hour 18 postoperatively)
45756858|NCT00581867|Drug|Insulin Aspart|40IU insulin aspart applied intranasally
45756859|NCT00581867|Drug|Placebo|Placebo
45756860|NCT01925469|Drug|Benzocaine|
45604966|NCT04355650|Other|Clinical decision support tool|Adults (aged 18-64 years) who meet DSM-5 diagnostic criteria for non-psychotic unipolar major depressive disorder (MDD) and meet study eligibility criteria will receive 8 weeks of open-label treatment with an SSRI or SNRI antidepressant. Depressive symptoms will be assessed using the subject- and clinician-rated versions of the 16-items QIDS scale (QIDS-SR and QIDS-CR) and the 17-item HAMD at baseline, week 2 (via telephone), week 4, and week 8; with an additional phone contact at week 24. The QIDS scale scores at 2- and 4-weeks will be entered into the AHI-based clinical decision support tool, and the outcome predicted by the tool (e.g., the predicted eventual treatment outcome at 8 weeks) will be recorded. Clinicians and patients will be blinded to the clinical decision support tool prediction of outcome provided at the 2- and 4 weeks.
45604967|NCT05277922|Drug|C21|C21 in ascending doses of 15, 50, 150, 500 and 1000 µg
45604968|NCT05277922|Drug|Sodium Nitroprusside|Ascending doses of 4, 8 and 16 µg
45604969|NCT04354870|Drug|Hydroxychloroquine (HCQ)|Loading dose: 600 mg, oral, 1 day Maintenance dose: 200 mg, oral, daily, for 90 days
45604970|NCT02917096|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
45604971|NCT02917096|Drug|Fludarabine|Given IV
45604972|NCT02917096|Drug|Fludarabine Phosphate|Given IV
45604973|NCT02917096|Other|Laboratory Biomarker Analysis|Correlative studies
45604974|NCT02917096|Drug|Melphalan|Given IV
45604975|NCT02917096|Other|Pharmacological Study|Correlative studies
45604976|NCT02917096|Drug|Ruxolitinib|Given PO
45604977|NCT02917096|Drug|Ruxolitinib Phosphate|Given PO
45604978|NCT02917096|Drug|Sirolimus|Given PO
45604979|NCT02917096|Drug|Tacrolimus|Given IV and PO
45604980|NCT04816552|Behavioral|CHoBI7 mHealth program Arm|We will start delivery of this intervention with a pictorial module delivered in the home during two 30 minute visits on cholera transmission and prevention after enrollment. Households will be provided a handwashing station, a covered water vessel, and chlorine tablets. Households will then receive the CHoBI7 WASH mHealth program voice and text messages on handwashing with soap and water treatment bi-weekly.
45604981|NCT04816552|Behavioral|general message on oral rehydration solution (ORS)|general message on oral rehydration solution (ORS)
45604982|NCT04419298|Diagnostic Test|Cardiac MRI|"Cardiac MRI be taken to acute CO poisoned patients with elevated TnI [during acute (within 7 days after CO exposure) and chronic phase (at 4-5 months after CO exposure)]~TTE be taken to acute CO poisoned patients with elevated TnI [At the ED and during admission (within 7 days after CO exposure)]"
45604983|NCT05276050|Device|active F8-coil delivered rTMS|Multiple trains of rTMS in a day, for multiple days.
45604984|NCT05276050|Device|active H-coil delivered rTMS|Multiple trains of rTMS in a day, for multiple days.
45756861|NCT01925469|Drug|Saline spray|A saline spray will be used in the placebo group
45756862|NCT02139137|Other|Computerized Cognitive Training - active|Cognitive training using working memory span task
45756863|NCT02139137|Other|Computerized cognitive training - sham|Sham training condition
46066617|NCT04253054|Other|Aging related health problems|Aging related health problems
45604985|NCT02473952|Drug|IGIV-C|IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified
45604986|NCT02473952|Drug|Placebo|
45756864|NCT05729061|Device|Assist-Knee|Investigational prosthetic knee-ankle device
45756865|NCT05729061|Device|Prosthetic Knee|Commercially available prosthetic knee devices
45604987|NCT04194424|Other|Multidisciplinary weight loss program|Diet and behavioral therapy,and supervised exercise sessions
45604988|NCT04194424|Other|Standard Care|General lifestyle tips
45604989|NCT04194424|Drug|Metformin Hcl 850Mg Tab|1 tablet, twice daily
45604990|NCT02863978|Other|Multimodal signal acquisitions|"Cardiac and respiratory signals are collected from the clinical monitoring routinely gathered in hospital neonatal units.~Movement quantification and baby's sounds are extracted thanks to a dedicated system which will collect images and sound with microphones and cameras."
45604991|NCT02473640|Drug|SYN-004|
45604992|NCT02473640|Drug|Esomeprazole|
45604993|NCT02473640|Drug|Ceftriaxone|
45604994|NCT03895996|Drug|AVT001|autologous dendritic cell therapy
45604995|NCT03895996|Other|Placebo|matched placebo
45604996|NCT01637584|Drug|Prazosin|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
45604997|NCT01637584|Drug|Placebo|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
45604998|NCT03883906|Biological|Viral Specific T-cells (VSTs)|VSTs will be infused into stem cell transplant recipients
45604999|NCT03875092|Biological|Pembrolizumab|IV infusion
45605000|NCT03875092|Drug|Paclitaxel|IV infusion
45605001|NCT03875092|Drug|Nab-paclitaxel|IV infusion
45605002|NCT03875092|Drug|Carboplatin|IV infusion Carboplatin dose should not exceed 900 mg.
45756866|NCT05729061|Device|Prosthetic Ankle|Commercially available prosthetic ankle devices
45756867|NCT05729061|Device|Prosthetic Foot|Commercially available prosthetic foot devices
45756868|NCT05729061|Device|Ankle-Foot Orthosis|Commercially available ankle-foot orthosis devices
45756869|NCT00583661|Device|EXCOR Pediatric|Extracorporeal Ventricular Assist Device
45756870|NCT01925781|Drug|Nicotine polacrilex|2 mg and 4 mg gum will be used according to the FDA approved product labelling
45756871|NCT01925781|Other|STAM 1100mAh CE4 eGo Clearomizer|
45756872|NCT01927575|Device|Standard X-Ray + CT|Standard of Care X-Ray Imaging + CT
45756873|NCT01927575|Device|Standard X-Ray + MRI|Standard of Care X-Ray Imaging + MRI
45605003|NCT03875092|Drug|Saline placebo for pembrolizumab|IV infusion
45605004|NCT03860584|Dietary Supplement|MFGM-enriched full-fat dairy milk|MetS adults with metabolic endotoxemia will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial to test the independent benefits of MFGM. For each 2-wk arm, they will receive MFGM-enriched full-fat dairy milk (3 servings/d) or a matched dairy milk that instead contains soy phospholipid/lecithin (control). Milks have been formulated with soy lecithin or MFGM at 10% phospholipid (relative to total lipid content). This delivers MFGM at ~10-times that in full-fat dairy milk, which reflects that consumers obtain MFGM from dairy foods other than whole milk.
45605005|NCT03860584|Dietary Supplement|Soy phospholipid/lecithin milk|MetS adults with metabolic endotoxemia will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial to test the independent benefits of MFGM. For each 2-wk arm, they will receive MFGM-enriched full-fat dairy milk (3 servings/d) or a matched dairy milk that instead contains soy phospholipid/lecithin (control). Milks have been formulated with soy lecithin or MFGM at 10% phospholipid (relative to total lipid content).
45605006|NCT05274958|Behavioral|Patient-rated outcome measures and educational videos|PROMs are scales that are validated in behavioral health for tracking symptoms of depression, anxiety, and other conditions. They can be self-administered or given by a clinician. Mytonomy videos are short, educational videos about the patient's primary condition. All patients receive PROMs on entering our clinic. The difference in this intervention is those randomized to the active treatment will receive monthly PROMs and mytonomy video(s) until their appointment with the clinician. Usual care patients will only have PROMs at the intake and then at the appointment with their assigned clinician.
45605007|NCT04816396|Behavioral|reminiscence Therapy|Application Stages of Reminiscence Therapy Based on Roy Adaptation Model Week 1 (Session 1):Introduction-Meeting-Infancyand Family Life Week 2 (Session 2):Childhood and School Years Week 3 (Session 3):Unforgettable Historical Periods,Old movies, Old Songs Week 4 (Session 4):Loved, meals,Desserts and Recipes,Nutrition Style Week 5 (Session 5):Work and Marriage Week 6 (Session 6):Home and Garden Works,Animals, Plants Week 7 (Session 7): Travels, Vacation Memories Week 8 (Session 8): Celebration Memories, Evaluation Posttest Closing.
45605008|NCT05207488|Dietary Supplement|Fructooligosaccharides (FOS)|FOS (NUTRAFLORA® P-95, Ingredion) supplements (10g/day) will be consumed daily mixed with water.
45605009|NCT05207488|Behavioral|Exercise|During the intervention period, all participants will perform 6 weeks of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk.).
45756874|NCT01927575|Device|TOMO|Fujifilm Digital Radiographic AcSelerate CsI System with Tomosynthesis
45605010|NCT05207488|Dietary Supplement|Placebo|Maltodextrin (Globe 18DE Maltodextrin, Ingredion) supplements (10g/day) will be consumed daily mixed with water.
45605011|NCT04806958|Other|PulsePoint notification|"The PulsePoint interface software monitors each 9-1-1 call on dispatch computers and is automatically triggered by particular conditions including call type (e.g. suspected cardiac arrest) and location type (public location). When triggered, the system pushes location data to all PulsePoint mobile application users within 400 meters of the emergency location.~When a mobile device running the PulsePoint Respond application receives the alert data from the PulsePoint system, the device alarms with auditory, tactile (vibration) and visual stimuli. The application presents a map showing the exact location of the suspected cardiac arrest and the closest public access defibrillator."
45605012|NCT04806646|Drug|Sonidegib|TS1: assumption 14 days on and 14 days off. TS2: assumption 7 days on and 21 days off.
45756875|NCT01927887|Drug|Ferumoxytol|Ferumoxytol will be administered as an undiluted intravenous injection dose of 6 mg/kg body weight, up to a maximum dose of 510 mg, delivered at a rate of up to 1ml/sec. Each ml of the supplied agent contains 30 mg of elemental iron and the dose will be titrated based on patients body weight in kilograms; for example at a dose of 6 mg/kg, the dose for a 50 kg person will be 50 x 6 = 300 mg. As the vial contains 30 mg/ml, 10 cc of the dose will correspond to the required 300 mg dose.
45756876|NCT01927887|Device|Nanoparticle MRI|Each subject will have one MRI scan. At the initial pre-scan visit, the subject will receive the ferumoxytol infusion. Within 48-72 hours after ferumoxytol infusion, a scan will be performed. Subjects will be imaged at Massachusetts General Hospital using commercial 3.0T imaging systems using dedicated neck coil and approved imaging protocols. The MR imaging will include conventional T1 and T2 weighted spin echo and 3 D gradient echo sequences.
45756877|NCT01929057|Procedure|Skin biopsy|4-millimeter punch biopsies will be performed on all subjects (acne patients and healthy controls)
45756878|NCT01929057|Procedure|Blood draw|Approximately half a tube of blood will be drawn from all participants in the study
45756879|NCT00081458|Drug|Placebo|placebo injectable subcutaneously daily into thigh or abdomen
45756880|NCT00081458|Drug|Teduglutide 0.05 mg/kg/d|Teduglutide 0.05 mg/kg/d daily injectable subcutaneously into the thigh or abdomen
45756881|NCT00081458|Drug|Teduglutide 0.1 mg/kg/d|Teduglutide 0.1 /g/kg/d daily injection subcutaneously into thigh or abdomen
45756882|NCT00610727|Drug|Prochlorperazine 0.5 mg IV over 5 sec|IV Prochlorperazine for bioavailability
45756883|NCT00610727|Drug|Inhaled prochlorperazine 0.625 mg|Inhaled Staccato Prochlorperazine 0.625 mg
45756884|NCT00610727|Drug|Inhaled prochlorperazine 1.25 mg|Inhaled Staccato Prochlorperazine 1.25 mg
45911233|NCT02005367|Behavioral|Natural Recovery-Horticulture|"Participants in Natural Recovery-Horticulture received a one-hour small group therapy session during the week using Horticulture modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time.~Natural Recovery participants also pursued four hours of gardening on each weekend day while DAP-CP attended large-group lectures."
45756885|NCT00610727|Drug|Inhaled prochlorperazine 2.5 mg|Inhaled Staccato Prochlorperazine 2.5 mg
45756886|NCT00610727|Drug|Inhaled prochlorperazine 5 mg|InhaledStaccato Prochlorperazine 5 mg
45911234|NCT02005367|Behavioral|Natural Recovery-Art/Music|Participants in Natural Recovery-Art/Music received a one-hour small group therapy session during the week using Art/Music modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time. Natural Recovery participants also pursued four hours of art or music on each weekend day while DAP-CP attended large-group lectures.
45911235|NCT02005380|Other|Text-based task|Participants are required to take text-based exercise.
45911236|NCT02005380|Other|Graphic-based Task|Participants are required to take the graphic-based exercise.
45605013|NCT02503202|Biological|V920 Consistency Lot A|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot A, live, attenuated, sterile solution for intramuscular injection
45605014|NCT02503202|Biological|V920 Consistency Lot B|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot B, live, attenuated, sterile solution for intramuscular injection
45605015|NCT02503202|Biological|V920 Consistency Lot C|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot C, live, attenuated, sterile solution for intramuscular injection
45605016|NCT02503202|Biological|V920 High-dose Lot|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine high-dose lot, live, attenuated, sterile solution for intramuscular injection
45605017|NCT02503202|Biological|Placebo to V920|Sodium chloride 0.9%, sterile solution for intramuscular injection
45605018|NCT02728102|Procedure|Tumor Cell Collection|Patients will undergo aspiration of 30 mL of bone marrow from which myeloma cell preparations will be generated. Myeloma cells will be isolated and frozen for subsequent vaccine generation for patients randomized to the vaccine arm (randomization occurs after transplant and recovery).
45605019|NCT02728102|Procedure|Autologous Stem Cell Transplant|Patients will receive an autologous graft with a minimum cell dose of 2.0 x 10^6 CD34+ cells/kg patient actual body weight per autologous transplantation.
45605020|NCT02728102|Drug|Melphalan|Autologous hematopoietic cell transplant will be done with high-dose melphalan of 200mg/m^2 at the schedule and timing according to institutional practices.
45605021|NCT02728102|Procedure|Leukapheresis|Blood samples will be collected through a catheter in the neck or chest and leukapheresis will be performed using standard clinical procedures.
45605022|NCT02728102|Biological|Myeloma vaccine|The target dose is 3 x 10^6 fusion cells per vaccine. A minimum of 3 x 10^6 total fusion cells will be required to proceed with vaccine administration. Patients who have <3 x 10^6 total fusion cells will not proceed with vaccination. Patients will receive the DC/MM fusion vaccine on day 1 of cycles 2, 3, and 4 of lenalidomide maintenance. Vaccine will be administered by subcutaneous injection in the upper thigh.
45605023|NCT02728102|Drug|GM-CSF|100 ug GM-CSF will be given subcutaneously in the upper thigh and daily for a total of 4 days of each cycle.
45605024|NCT02728102|Drug|Lenalidomide|Maintenance therapy with lenalidomide will begin between 90 and 100 days after stem cell infusion. Lenalidomide will be administered initially at a dose of 10 mg per day continuously. Cycle duration during maintenance therapy is 28 days. Patients will continue lenalidomide for two years from initiation of therapy.
45605025|NCT02502734|Drug|Fluticasone furoate|FF will be provided as a dry powder inhaler containing 50 μg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
45605026|NCT02502734|Drug|Placebo|Placebo will be provided as dry powder inhaler containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
45605027|NCT02502734|Drug|Salbutamol|Salbutamol will be provided as a inhaler.
45605028|NCT04193878|Drug|Inhaled budesonide and formoterol|aerosolized doses of budesonide (1.0 mg/2 ml) and formoterol (20 mg/2 ml) twice daily for up to 5 days
45605029|NCT04193878|Drug|Inhaled placebo|aerosolized saline (4 ml of 0.9% saline) twice daily for up to 5 days
45605030|NCT02473250|Drug|Fluoxetine|Bipolar depressed patients will be treated with fluoxetine in combination with a mood stabilizer (valproate).
45605031|NCT02473250|Drug|Citalopram|Bipolar depressed patients will be treated with citalopram in combination with a mood stabilizer (valproate) if fluoxetine is not clinically warranted.
45605032|NCT04253626|Drug|Ferumoxytol Injection [Feraheme]|510mg intravenous ferumoxytol
45605033|NCT04253626|Drug|Ferrous Sulfate|325mg oral ferrous sulfate
45911237|NCT02005406|Device|Experimental group and control groupl|JET
45605034|NCT02501642|Behavioral|Concussion Coach|smart phone app with educational material on postconcussion symptoms and behavioral self-monitoring/strategies
45605035|NCT02501642|Other|Treatment as usual|Treatment as usual
45605036|NCT03840148|Drug|Cefepime/VNRX-5133 (taniborbactam)|Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period for 7 days (up to 14 days for patients with bacteremia). Patients will also receive meropenem placebo administered via IV over 30 minutes.
45605037|NCT03840148|Drug|Meropenem|Meropenem will be administered q8h IV over 30 minutes for 7 days (up to 14 days for patients with bacteremia). Patients will also receive cefepime/VNRX-5133 placebo administered via IV over a 2-hour period.
45605038|NCT04253548|Behavioral|iPeer2Peer Support Mentorship Program|iPeer2Peer is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
45605039|NCT04821778|Radiation|Radiotherapy|50-66Gy/1.8-2.2Gy/25-30f
45756887|NCT00610727|Drug|Inhaled prochlorperazine 10 mg|InhaledStaccato Prochlorperazine 10 mg
45756888|NCT00610727|Drug|Inhaled placebo|Inhaled Staccato Placebo (0 mg)
45756889|NCT00610727|Drug|Prochlorperazine 10 mg IV over 5 sec|Prochlorperazine 10 mg IV over 5 sec for patient qualification
45756890|NCT05738655|Dietary Supplement|Pumpkin seed extract (Low dose)|Pumpkin seed extract standardized with specific peptides (300 mg/day)
45605040|NCT04821778|Drug|Platinum based chemotherapy|q1-3W according to physician's preference
45605041|NCT04821778|Drug|Paclitaxel based chemotherapy|q1-3W according to physician's preference
45605042|NCT04821778|Drug|Immunotherapy|Anti-PD-1/PD-L1 Antibody
45605043|NCT04821778|Drug|5-FU Analog based chemotherapy|W1-5 qW or d1-14, q3W according to physician's preference
45605044|NCT04821778|Drug|Nimotuzumab|200-400mg, d1,qW
45605045|NCT04251130|Drug|2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine|A small molecule aimed for binding and PET-imaging of aggregated tau protein in the human brain.
45605046|NCT03825952|Device|MERM - medication event reminder monitor|The MERM will help measure adherence to ART in routine clinical care.
45605047|NCT02706730|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
45605048|NCT04419220|Other|Doppler Ultrasound|Flow measurements using Doppler ultrasound
45756891|NCT05738655|Dietary Supplement|Pumpkin seed extract (High dose)|Pumpkin seed extract standardized with specific peptides (600 mg/day)
45756892|NCT05738655|Dietary Supplement|Placebo|Placeo (300 mg/day)
45605049|NCT04806334|Diagnostic Test|MRI imaging of the pelvis/bladder|The pelvic MRI will be multiparametric (mp)-4D MRI incorporating high resolution diffusion weighted imaging (HR-DWI).
45605050|NCT04806334|Diagnostic Test|genomic analysis of tumor|Single cell RNA sequencing of transurethral resection of bladder tumor (TURBT)
45605051|NCT02706262|Other|Metabolically abnormal obese - Mediterranean diet|The effect of consuming a Mediterranean diet will be examined over 3 different phases: (i) weight maintenance for 4 to 8 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a Mediterranean diet but will prepare all their food at home. No food will be provided during this portion of the study.
45605052|NCT02706262|Other|Metabolically abnormal obese - Low carbohydrate ketogenic diet|The effect of consuming a low-carbohydrate, ketogenic diet will be examined over 3 different phases: (i) weight maintenance for 4 to 8 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a low carbohydrate ketogenic diet but will prepare all their food at home. No food will be provided during this portion of the study.
45605053|NCT02706262|Other|Metabolically abnormal obese - Plant-based, very-low-fat diet|The effect of consuming a plant-based, very-low-fat diet will be examined over 3 different phases: (i) weight maintenance for 4 to 8 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a plant-based, very-low-fat diet but will prepare all their food at home. No food will be provided during this portion of the study.
45605054|NCT04825210|Behavioral|Integrated Behavioral Health - Prevention|IBH-P consists of 15-30 minute visits with mothers as part of the 1, 2, 4, and 6 month well-child visits. The intervention is delivered by doctoral level pediatric psychologists that are an integrated member of the primary care team.
45605055|NCT04825210|Behavioral|Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 4th Edition|Bright Futures curriculum will be delivered by the pediatrician as part of the 1, 2, 4 and 6 month well-child visits.
45605056|NCT02622100|Device|Bioresorbable Vascular Scaffold|
45605057|NCT02611024|Drug|Lurbinectedin|lurbinectedin (PM01183) 4 mg vials
45605058|NCT02611024|Drug|Irinotecan|irinotecan 40 mg, 100 mg or 300 mg vials
45605059|NCT02443688|Drug|CTX-4430|
45605060|NCT02443688|Drug|Placebo|
45605061|NCT03812614|Behavioral|FAM ACT|Patient and Support Person (dyad) will receive a Diabetes Complications Risk Assessment profile and introduction session, Support Person-focused information/skills training through 4-6 extended DSME sessions, case management contacts with CHW throughout the duration of the 6-month intervention, and guidance on how to prepare for and participate in healthcare appointments.
45605062|NCT03812614|Behavioral|I-DSMES|Patient only will receive a Diabetes Complications Risk Assessment profile and introduction session, 4-6 group DSME sessions, case management contacts with CHW throughout the duration of the 6-month intervention, and guidance on how to prepare for and participate in healthcare appointments.
45605063|NCT04814992|Behavioral|Computer-Assisted Preoperative CBT Intervention (PAINTrainer)|Subjects will be asked to complete eight (8) 30- to 45-minute educational sessions during the 4 weeks prior to your surgery. In addition to the computer based training sessions, there is a motivational interviewing component that requires subjects to meet with a member of the study team weekly for a total of four (4) 30- to 45-minute meetings to help manage opioid medication use. It is expected that subject participation in this arm of the study will be a total of 12 hours over the course of the entire study.
45605064|NCT04419376|Device|driving pressure|Mechanically ventilated patients (via ETT or trachestomy) were recorded for patients whose ventilation duration lasted at least 24 hours.We divided the patients into two groups by calculating the oxygenation index (OI): [mean airway pressure(MAP) × fraction of inspired oxygen (FiO2) ]/ partial pressure of oxygen in arterial blood (PaO2) × 100) used in the classification of PALICC, including pARDS and non-pARDS.
45605065|NCT02602756|Radiation|Protontherapy|Proton-therapy consists in four consecutive sessions. The experimental arm consists in eight sessions. Irradiation is administered over two weeks, delivering a total dose of 60 Cobalt Gris Equivalent (CGE is the physical Gray dose multiplied by a biological factor of relative efficiency of 1.1 for protons compared to photons).
45605066|NCT04222504|Behavioral|Provision of sexual health preventative services in the salon setting|"Participants at intervention salons will be offered a choice of receiving daily PrEP and/or contraceptives (oral and injectables). Participants that elect to receive at least PrEP or contraceptives will also be offered STI testing.~Follow-up visits will be planned for 3, 6, 9, and 12-months. Attendance at follow-up visits for monitoring and medication refill will be encouraged using text message reminders, WhatsApp support groups, and lottery-based incentives for free salon services."
45605067|NCT02443298|Drug|placebo|Matching placebo for risankizumab
45605068|NCT02443298|Drug|risankizumab|Monoclonal IgG antibody
45605069|NCT02500706|Drug|Faster-acting insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal. Postmeal dosing is defined as injecting 20 minutes after the start of the meal.
45605070|NCT02500706|Drug|insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal.
45605071|NCT02500706|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted
45605072|NCT02442830|Device|Early Video Capsule Endoscopy|"The intervention is the use of video capsule endoscopy as the first test in a patient presenting to the ED with active bleeding. The capsule allows for visualization of the entire GI tract.~Once a capsule has been given to a study patient, a staff member will use the capsule's real-time viewer to see if there is any active bleeding in the stomach. If bleeding is seen the investigators will pursue an upper endoscopy. If no bleeding is seen a staff member will review the entire findings of the capsule and make a decision regarding which therapeutic measure to pursue."
45605073|NCT04922762|Behavioral|Moderate Intensity, Normal Volume Exercise Training|"Week 1 3 days/week for 20 minutes/day Performed at 70% of heart rate maximum~Week 2 3 days/week for 30 minutes/day Performed at 70% of heart rate maximum~Weeks 3-10 3 days/week for 45 minutes/day Performed at 70% of heart rate maximum"
45605074|NCT04922762|Behavioral|High Intensity, Normal Volume Exercise Training|"Week 1 3 days/week for 31 minutes/day 10 minute warm up at 50% of heart rate maximum 2 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 7 minute cool down at 50% of heart rate maximum~Week 2 3 days/week for 38 minutes/day 10 minute warm up at 50% of heart rate maximum 3 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 2 TIMES 7minute cool down at 50% of heart rate maximum~Weeks 3-10 3 days/week for 45 minutes/day 10 minute warm up at 50% of heart rate maximum 4 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 3 TIMES 7 minute cool down at 50% of heart rate maximum"
45605075|NCT04922762|Behavioral|Moderate Intensity, High Volume Exercise Training|"Week 1 5 days/week for 20 minutes/day Performed at 70% of heart rate maximum~Week 2 5 days/week for 30 minutes/day Performed at 70% of heart rate maximum~Weeks 3-10 5 days/week for 45 minutes/day Performed at 70% of heart rate maximum"
45605076|NCT04201496|Combination Product|Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Participants with be provided with Empagliflozin to take daily for approximately 10 weeks. Along with the study medication, participants will initially use the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks.
45605077|NCT04201496|Combination Product|Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks|Participants with be provided with Empagliflozin to take daily for approximately 10 weeks. Along with the study medication, participants will initially use the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks.
45605078|NCT04201496|Device|No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Participants will initially use the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Empaglizflozin will not be provided to this group.
45605079|NCT04201496|Device|No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks|Participants will initially use the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Empaglizflozin will not be provided to this group.
45605080|NCT02500550|Biological|ATIR101|T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).
45605081|NCT02500550|Procedure|Haploidentical hematopoietic stem cell transplantation (HSCT)|"CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:~Total Body Irradiation (TBI) regime~Non-TBI regime~(See below for details)"
45605082|NCT02500550|Procedure|TBI regime|"Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)~Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3~Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7~Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV."
45605083|NCT02500550|Procedure|Non-TBI regime|"Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4~Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7~Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1~ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV."
45605084|NCT02517034|Other|Comprehensive Geriatric Assessment|Follow geriatric assessment-driven treatment plan
45605085|NCT02517034|Other|Quality-of-Life Assessment|Ancillary studies
45605086|NCT02517034|Other|Questionnaire Administration|Ancillary studies
45605087|NCT02517034|Other|Survey Administration|Ancillary studies
45605088|NCT02456974|Procedure|blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care|
45756893|NCT03081104|Device|hystroscopy|The uterine cavity will be distended with saline or glycine, depending on the polarity of the resection system.with a maximum irrigation pressure of 110mmHg. The retained products will be resected from top to bottom with surgical resector without electric power. The use of forceps or curettes to facilitate the removal of material is permitted. If active bleeding occurs , elective coagulation by hystroscope is done to stop intrauterine bleeding. The deficit of distending media should be calculated at the end of procedure.
45911238|NCT02005419|Drug|Gemcitabine|Patients receive gemcitabine 1000 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment, and also receive placebo (Arm I)/ metformin (Arm II) on days 1-28. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
45444701|NCT02049346|Drug|Darbepoetin alfa|"Subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol. Doses of Darbepoetin alfa were decreased by 25% for Hb values >12 and ≤13 g/dL and increased by 25% for Hb <11 and ≥10 g/dL. Darbepoetin alfa doses and increased by 50% for Hb <10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses were adjusted so that haemoglobin concentrations were remain within a target range of 11-12 g/dL during the study.~If a dose of Epoetin alpha/ beta does not equate exactly to a unit dose of Darbepoetin alfa at switching, then the nearest available unit dose of Darbepoetin alfa was used."
45452166|NCT03951064|Procedure|Intervention Spontaneous Breathing Trial (SBT) and Extubation|Patients in the Intervention group will undergo an SBT regardless of their PEEP level. The PEEP that generates a Ptp of 0 will be considered their optimal PEEP, and this will not be lowered for the SBT. The Intervention Group SBT will consist of a trial of a pressure support of 5 cm H2O and Optimal PEEP.
45452167|NCT03951064|Procedure|Control Spontaneous Breathing Trial and Extubation|Patients in the Control group will undergo an SBT when they reach a PEEP ≤8 cm H2O. This is the current standard of care based on the SBT protocol at UNC Hospitals. SBT and extubation prior to meeting these criteria will be based on primary medical team's discretion and will be recorded for analysis and safety tracking.
45756894|NCT03081104|Device|ultrasound|The transducer was held on the abdomen to obtain a longitudinal image of the uterus and cervix and provide the surgeon with a visual reference of the gestational sac, cervical canal and any instruments passed into the uterus.The progress of the operation was continuously monitored as the uterine contents were evacuated under visual control.
45756895|NCT03081104|Procedure|Aspiration|The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used.
45605089|NCT02456974|Procedure|blood sampling in patients receiving piperacilline-tazobactam as part of routine clinical care.|
45605090|NCT02456974|Procedure|blood sampling in patients receiving vancomycin as part of routine clinical care.|
45605091|NCT02456974|Procedure|blood sampling in patients receiving teicoplanin as part of routine clinical care.|
45605092|NCT02456974|Procedure|blood sampling in patients receiving meropenem as part of routine clinical care.|
45605093|NCT02456974|Procedure|blood sampling and urine smapling in patients receiving ciprofloxacin as part of routine clinical care.|
45605094|NCT02456974|Procedure|blood sampling in patients receiving amikacin as part of routine clinical care.|
45605095|NCT02446366|Other|Laboratory Biomarker Analysis|Correlative studies
45756896|NCT00584831|Device|senofilcon A|toric contact lens
45605096|NCT02446366|Other|Quality-of-Life Assessment|Ancillary studies
45605097|NCT02446366|Radiation|Stereotactic Body Radiation Therapy|Undergo hypofractionated SBRT
45605098|NCT04814446|Biological|Vaccination|Intramuscular injections of 0,5 ml will be administered at M0, M2 and M6
45605099|NCT04797286|Drug|Sildenafil|Sildenafil 20 mg three times a day. This is the approved dose for the treatment of pulmonary arterial hypertension. It is being studied in this trial with a population who has mildly elevated pulmonary pressures.
45605100|NCT04797286|Other|Placebo|Oral pill placebo.
45605101|NCT03696628|Other|Electrocardiogram|heart testing
45605102|NCT03696628|Other|physical examination|done by the investigator
45605103|NCT03696628|Other|echocardiography|heart testing
45605104|NCT03696628|Biological|blood test|A sample of blood will be taken to each patient or healthy children in order to generate hiPSC-cardiomyocytes
45605105|NCT03682276|Biological|Ipilimumab|Ipilimumab is a monoclonal antibody given as an immunotherapy
45605106|NCT03682276|Biological|Nivolumab|Nivolumab is a monoclonal antibody given as an immunotherapy
45605107|NCT04797130|Device|Hospital Fit 2.0|HF consists of a smartphone app combined to an accelerometer. HF provides patients and physiotherapists direct feedback on patients' physical activity behavior.. Individual goals regarding the number of minutes per day spent walking can be set by the therapist. HF also shows patients insight into their own recovery progress. During every treatment, the physiotherapist will evaluate the extent of functional recovery. In addition, Hospital Fit will give physiotherapists the option of creating a patient-specific exercise program supported by videos. During every treatment session, the patient and physiotherapist will evaluate (and if necessary adapt) the amount of activity performed since the previous treatment, the extent of functional recovery and the exercise program.
45605108|NCT05653024|Drug|Salbutamol|8 puffs of 100 mcg inhaled salbutamol administered with spacer
45605109|NCT05653024|Drug|Placebo|8 puffs of placebo inhaler administered with spacer
45605110|NCT04814134|Device|CPNS Therapy|Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
45605111|NCT04814134|Other|Standard of care|Available standard treatment
45605112|NCT04796974|Device|Cention|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Basic Filling Material). Procedures will be done using local anesthesia. The cavity is excavated and filled according to the guidelines for ordinary restorative techniques
45605113|NCT04813276|Behavioral|Strong Together serious game|The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants receive weekly notifications for 12 weeks alerting them that a new serious game session is available and encourage them to complete one session per week.
45605114|NCT04813276|Behavioral|Enhanced Care as Usual|A self-advocacy patient brochure published by the National Coalition for Cancer Survivorship. This guide is not a part of usual care, but is freely available on the Internet.
45605115|NCT02167906|Other|arterial stiffness measurement|
45605116|NCT04813198|Behavioral|TIPSTART|TIPSTART is a multimodal, cognitive behavior-based therapy integrating peer-sharing, technology, aerobic and resistance training.
45605117|NCT05652946|Device|Tyromotion, Fourier Intelligence, Thera-Trainer, EKSO Bionics|Participants to receive at least 5 sessions with advanced rehabilitation technology including at least one, or multiple, of the following devices: Amadeo, Diego, Myro, Arm Motus EMU, Pelma Motus, Tigo, Balo, EKSO NR. Sessions are 45 (+/- 5) minutes
45605118|NCT05652946|Other|Standard inpatient rehabilitation therapy|Standard inpatient rehabilitation therapy without advanced rehabilitation technology
45605119|NCT04418752|Other|Psychological therapy|"The National Institute for Health and Care Excellence (2018) specifies NET as a psychological intervention for the treatment of PTSD or prominent symptoms of PTSD in adults. NET is a short-term treatment which incorporates elements of CBT exposure therapy and testimonial therapy. In exposure therapy, clients are encouraged to repeatedly discuss traumatic experiences in detail, including emotions and sensory experiences (Schauer, Elbert, & Neuner, 2011).Testimonial therapy involves the construction of a detailed and coherent report of the survivor's biography including an explicit description of the traumatic events (Neuner, Schauer, Roth & Elbert, 2002, pp.5-6). Therefore, NET aims to embed the traumatic experience within the context of the person's life and the mechanisms of change are theorised to be exposure and habituation to the traumatic experience and the reconstruction of autobiographical memory."
45756897|NCT00584831|Device|balafilcon A|toric contact lens
45911239|NCT02005419|Drug|Metformin|Metformin will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
45756898|NCT00584831|Device|omafilcon A|toric contact lens
45756899|NCT00584831|Device|lotrafilcon B|toric contact lens
45452168|NCT03951064|Procedure|Intervention Weaning after Tracheostomy|Based on the use of optimal PEEP in this group, and the experience in the previous study protocol, the investigators will place patients in the Intervention group on Tracheostomy Collar Trial ONLY with a speaking valve. This simulates the normal process of utilizing the upper airway to maintain lung inflation that is performed automatically when a patient does not have an artificial airway.
45605120|NCT04813042|Behavioral|Working Out Dads|"The WOD is a manualised group intervention underpinned by solution-focused therapy and social cognitive theories. Psychoeducation about the transition to fatherhood and its potential impacts on wellbeing and family relationships is provided. Fathers are encouraged to share practical ideas for managing stress, revisit previous strategies, validate what they are doing well, and explore solutions.~The group discussion is followed by a structured group fitness session provided by a personal trainer. This session focuses on body weight exercises, cardio-based activities, stretching, mobility and incidental activity.~Fathers in the WOD study arm receive 10 weeks of encouraging text messages - one each week during the intervention, and four in the weeks after. These will be sent via the WhatsApp group created for each WOD group. These text messages and the WhatsApp group are designed to facilitate fathers' active engagement with the intervention, and to maintain contact with each other."
45605121|NCT04813042|Behavioral|Usual care|The Usual Care arm, also known as 'Talking about being dad' comprises a telephone consultation with a qualified mental health professional. Topics including in this consultation include: (a) discuss family and fathering; (b) health and wellbeing; (c) mental health symptoms and conduct a risk assessment for suicidal ideation; (d) current supports and support needs; (e) provide referral options to telephone support services (PANDA; MensLine); and (f) encourage a general practitioner visit to discuss a mental health care plan.
45605122|NCT02499770|Drug|Carboplatin|
45605123|NCT02499770|Drug|Placebo|
45605124|NCT02499770|Drug|Trilaciclib|
45605125|NCT02499770|Drug|Etoposide|
45605126|NCT05652712|Drug|Toripalimab|"Toripalimab injection, recommended dose is 3 mg/kg, intravenous infusion every 2 weeks or 240 mg fixed dose, intravenous infusion every 3 weeks.~Other treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients."
45605127|NCT04418674|Drug|Ketamine|in this group, patient will receive ketamine at 0.3mg/kg intravenously.
45605128|NCT04418674|Drug|Fentanyl|In this group, the patients will receive fentanyl at 1.5mcg/kg intavenously.
45605129|NCT04418596|Radiation|bi-planer radiography (EOS), Conventional rediography (Hip+pelvis)|low dose radiation medical imaging to visualise the hip joint and lumbo-pelvic complex specifically.
45605130|NCT02442284|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
45605131|NCT02442284|Drug|Ribavirin|Tablet
45605132|NCT03781960|Drug|Abemaciclib|Abemaciclib will be given at a dose of 150mg by mouth twice daily continuously for the duration of trial therapy.
45452169|NCT03951064|Procedure|Control Weaning after Tracheostomy|The control group will be placed on Tracheostomy Collar Trial with no requirement for speaking valve. They may utilize a speaking valve if tolerated and desired, but there is no requirement as there is in the Intervention group.
45605133|NCT03781960|Drug|Nivolumab|Nivolumab will be administered at a dose of 480mg IV every 28 days. Treatment with nivolumab will begin after an initial 7-day treatment period with abemaciclib monotherapy.
45605134|NCT04795882|Biological|BCMA CAR T cells|Infusion with ATIMP: BCMA CAR T-cells
45605135|NCT04795882|Biological|BCMA/CD19 CAR T cells|Infusion with ATIMP: BCMA/CD19 CAR T-cells
45605136|NCT02442206|Drug|QVA149|QVA149 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
45605137|NCT02442206|Drug|Placebo|Placebo to QVA140 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
45756900|NCT03081260|Other|Patellar resurfacing|The resurfacing of the patella is generally done at the end of the surgery, after having ejected the patella. A frontal bone cut is made using a dedicated ancillary to remove the entire cartilage. Orifices are then made in the patella so that the polyethylene implant can be accommodated with studs which will be cemented on the joint face of the ball joint.
45756901|NCT03081260|Other|Patellar non-resurfacing|Non-resurfacing of the patella does not involve any additional surgical action
45756902|NCT01929291|Biological|Boostrix|Single intramuscular injection
45756903|NCT01929291|Other|Safety data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form
45756904|NCT03084848|Other|Training|25 training sessions of 15 minutes per day, 5 days a week for a month of crystallised intelligence
45911240|NCT02005419|Drug|placebo|Placebo will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
45911241|NCT02005432|Drug|Intravitreal Ranibizumabe|Intravitreal injection 0,05ml Ranibizumabe
45605138|NCT05182450|Other|Mango leaf extract capsule|Single dose
45605139|NCT05182450|Other|Placebo capsule|Single dose
45756905|NCT03084848|Other|Training|25 training sessions of 15 minutes per day, 5 days a week for a month of inhibitory control
45756906|NCT01929759|Drug|Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)|Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks
45756907|NCT03085082|Diagnostic Test|blood type test|a blood sample will be withdrawn from the subjects tested by anti A anti B and anti D antigens to detect the individuals blood group and RH. then statistical analysis to detect presence of a relationship between skeletal types of malocclusion and ABO blood groups
45605140|NCT04794868|Diagnostic Test|CCTA-derived high risk plaque characteristics|Presence of CCTA-derived high risk plaque characteristics
45605141|NCT04794868|Diagnostic Test|CFD-derived hemodynamic parameters|CFD-derived hemodynamic parameters
45605142|NCT05652244|Device|Mini-implants|En masse retraction of upper anterior teeth will be applied where mini-implants will be used as an anchor unit. Anterior teeth retraction will be initiated after completion of the leveling and alignment phase via closed nickel-titanium coil springs applying 150 g of force per side.
45605143|NCT05652244|Device|Transpalatal arche (TPA)|Two-step retraction of upper anterior teeth will be applied where transpalatal arches (TPAs) will be used as an anchor unit. Teeth retraction will be initiated after completion of the leveling and alignment phase via closed nickel-titanium coil springs applying 150 g of force per side.
45605144|NCT02499146|Drug|Palbociclib|125 mg orally once daily with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle
45605145|NCT02499146|Drug|Letrozole|2.5 mg , orally once daily (continuously)
45605146|NCT05652166|Other|telephone interview|telephone call to parents to know the information given following the ingestion of foreign body by their child
45605147|NCT03544138|Device|Hummingbird Tympanostomy Tube System (H-TTS)|The H-TTS is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure.
45605148|NCT03542344|Drug|BI 1015550|Single rising oral dose
45605149|NCT03542344|Drug|Placebo|Single rising oral dose
45605150|NCT01634854|Drug|Vaginal Misoprostol|Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
45605151|NCT01634854|Drug|Intravenous Oxytocin|"Dosage: 2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.~Route of administration: intravenous"
45605152|NCT05173792|Drug|AK119|Subjects will receive AK119 intravenously.
45605153|NCT03542188|Behavioral|Primary Stroke Center (PSC)|Transport to a primary stroke center for early IV-thrombolysis followed by a secondary transport to a comprehensive stroke center for EVT if needed.
45605154|NCT03542188|Behavioral|Comprehensive Stroke Center (CSC)|Direct transport to a comprehensive stroke center for IV-thrombolysis and early EVT.
45605155|NCT05651776|Other|Physical Therapy, Exercise|Outpatient physical therapy intervention incorporating golf related assessment of skills and prescribed exercises including postural, balance, and club swing
45605156|NCT03541408|Other|Control|Standard Of Care without Preventative Delirium Protocol
45605157|NCT03541408|Other|Preventative Delirium Protocol|Preventative Delirium Protocol
45605158|NCT04811794|Other|Physical examination, diagnostic tests, laboratory tests|Physical examination, diagnostic tests (e.g. lung function test, echocardiography, audiometry), and laboratory tests (e.g. kidney parameter, hormonal levels) depend on examined organ system.
45605159|NCT04811794|Other|Personal history|Personal history on diagnosis, treatment, and socioeconomic factors
45605160|NCT02469896|Drug|Tocilizumab|IV Infusion
45605161|NCT02469896|Other|Placebo|IV Infusion
45605162|NCT05651698|Device|HeartMan Intervention group|The system uses wrist-band sensors to monitor patients' physical activity and physiological parameters. These data are connected to a decision support system, providing medical advice to patients concerning physical exercise, nutrition, medication intake, clinical measurements, environment management, and mental support. The decision support system is based on predictive models, clinical care guidelines and expert knowledge. The advice will be personalized according to each individual patient's medical and psychological profile, and will be presented to the patient through the user interface of a mobile application on a smartphone.
45605163|NCT05651464|Drug|Vancomycine|Application of 15-20 mg per kgKG Vancomycine I.V. prior to ECMO liberation
45605164|NCT01897480|Biological|LY2875358|Administered IV
45605165|NCT01897480|Drug|Erlotinib|Administered Orally
45756908|NCT03084692|Behavioral|Therapeutic Yoga and Resistance Exercise|Combined Program of Yoga and Resistance Exercise
45911242|NCT02005432|Drug|panfotocoagulation (PASCAL)|
45605166|NCT02441114|Drug|HCP0910 and HGP1011|Inhalation of HCP0910 (Seretide 250 diskus (Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 72.5 mcg)) and HGP1011 (Spiriva capsule for inhalation (Micronized Tiotropium Bromide Monohydrate 22.5 mcg))
45605167|NCT03461848|Other|CYPHP Evelina London Model of care|Universal services offer, Paediatric hotlines, Education and training for health professionals, Online decision support tools and guidelines, Young people-friendly access to primary care, and Resilience training in schools, Targeted services offered dependent on need. Children with any of the tracer conditions will be offered pathway based care including early intervention for physical and related mental health needs, paediatric nursing support, care plans shared with schools, medication reviews, and peer-led parenting support. Self-management support, social support signposting, and safety-netting are offered to all.
45605168|NCT03461848|Other|Enhanced Usual Care|Universal services offer, Paediatric hotlines, Education and training for health professionals, Online decision support tools and guidelines, Young people-friendly access to primary care, and Resilience training in schools, Self-management support, social support signposting, and safety-netting are offered to all.
45605169|NCT02498678|Procedure|Tetanus|tetanic electric stimulation
45605170|NCT04793698|Other|Compassion meditation|10 week meditation course taught in 90-minute groups
45605171|NCT04793698|Behavioral|Applied relaxation|10 week applied relaxation course taught in 90-minute groups
45756909|NCT03437330|Drug|Empagliflozin (Jardiance®)|Empagliflozin Dose/frequency: 10 mg once daily for 12 weeks Route of administration: oral Reference group: Insulin glargine (Lantus®) Dose/frequency: see below FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia < 3.9 mmol/L occurs) FBG 7-8 mmol/L: +4 IU (stop when FBG is reduced by 1.0 mmol/L or documented hypoglycemia < 3.9 mmol/L occurs) FBG > 8 mmol/L: +6 IU (stop when FBG is reduced by 1.5 mmol/L or documented hypoglycemia < 3.9 mmol/L occurs)
45911243|NCT02005432|Drug|panfotocoagulation (PRP) single shoot (ETDRS)|
45911244|NCT02005458|Drug|YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
45911245|NCT02005458|Drug|YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
45911246|NCT02005458|Drug|YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
45605172|NCT03427996|Procedure|Rotational atherectomy|Percutaneous coronary intervention with rotational atherectomy
45605173|NCT02441036|Device|Ultherapy Treatment|Focused ultrasound energy delivered below the surface of the skin.
45605174|NCT02498444|Drug|Treprostinil|Administration of drug (treprostinil) vs placebo (saline) in the post-operative period
45605175|NCT04792372|Procedure|Initial periodontal treatment|Conventional periodontal treatment (scaling and root debridement) will be conducted
45444702|NCT02049346|Drug|Methoxy polyethylene glycol-epoetin beta|"Patients in that arm received Intravenous MIRCERA monthly. The initial dose was 120 mcg, 200 mcg or 360 mcg, for patients had previously received a weekly dose of Epoetin alpha/ beta of less than 8000 IU, between 8000 to16 000 IU or more than16000IU respectively. MIRCERA doses were adjusted according to the approved prescribing information, without additional restrictions.~Doses of MIRCERA were decreased by 25% for Hb values >12 and ≤13 g/dL and increased by 25% for Hb <11 and ≥10 g/dL. MIRCERA doses were increased by 50% for Hb <10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses of MIRCERA were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study."
45605176|NCT05235256|Procedure|bilateral sphenopalatine ganglion block|peripheral n block
45605177|NCT05235256|Procedure|bilateral greater occipital nerve block|bilateral greater occipital nerve block
45605178|NCT05235256|Drug|lidocaine plus dexamethasone|lidocaine plus dexamethasone
45605179|NCT04792216|Other|Wild Salmon|Wild salmon fillets
45605180|NCT04792216|Other|Farmed Salmon|Farm salmon fillets
45605181|NCT02497976|Biological|Certolizumab pegol|400 mg
45605182|NCT02497976|Drug|Placebo|Normal saline
45605183|NCT05651386|Other|Diet|No blinded, no controlled intervention.
45605184|NCT05651308|Behavioral|Care coordination delivered based on perceived need|If proxies for patients in intervention group report on the survey that they experience difficulty coordinating care among the patients' providers, the patient will be selected for care management services. Those services will attempt to address the problems with care coordination that the proxy reported.
45605185|NCT05651308|Behavioral|Care coordination delivered based on usual care (e.g. discharge from hospital)|If a patient is discharged from a hospital, the patient will be selected for care management services.
45605186|NCT03347188|Drug|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
45605187|NCT03347188|Drug|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
45605188|NCT03347032|Procedure|Remote ischemic preconditioning|Serial inflations and deflations as detailed in the arm/group descriptions
45605189|NCT03347032|Procedure|Control|Serial inflations and deflations as detailed in the arm/group descriptions
45605190|NCT04791514|Drug|Treprostinil Palmitil|Administered by oral inhalation using a Plastiape capsule-based Dry Powder Inhaler
45605191|NCT04810546|Dietary Supplement|Jarrow Formulas Oral Bovine Lactoferrin Supplement|Lactoferrin (Apolactoferrin) 250mg contains ~17.6 mg/100g of iron
45605192|NCT04596826|Drug|Dronabinol 5 MG|oral administration
45444703|NCT03561532|Other|Fecal microbiota transplantation (FMT)|FMT administered into the cecum of the patient in colonoscopy.
45605193|NCT04596826|Drug|Dronabinol 10 MG|oral administration
45605194|NCT04596826|Drug|Placebo|oral administration
45605195|NCT02440568|Drug|Cytarabine|Cytarabine (100mg/m^2/day) in 1000ml NS as a continuous IV infusion over 24 hours x 7 days.
45605196|NCT02440568|Drug|Idarubicin|Idarubicin (12 mg/m^2/day) IVPB in 100 mL NS over 15 minutes daily from Days 1 to 3.
45605197|NCT02440568|Drug|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 0.625mg/m^2
45605198|NCT02440568|Drug|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 1.25mg/m^2
45605199|NCT02440568|Drug|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 2.0mg/m^2
45605200|NCT02440568|Drug|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 3.0mg/m^2
45444704|NCT03561532|Other|Placebo|Autologous FMT (fecal suspension made of patients own feces) administered into the cecum of the patient in colonoscopy.
45605201|NCT04921436|Procedure|cardiac surgery|prophylactic use of antibiotic-inhibitors
45605202|NCT00931606|Biological|Biological: ACE-011|up to 4 subcutaneous doses of ACE-011 given once every 28 days
45605203|NCT00931606|Drug|Placebo|up to 4 subcutaneous doses of placebo given once every 28 days
45605204|NCT05643664|Procedure|prosthetics of the abdominal aorta|aneurysmectomy is performed with prosthetics of the abdominal aorta using the standard technology.
45605205|NCT05643664|Procedure|prosthetics of the abdominal aorta after determining the safe zones of clamping|aneurysmectomy is performed with prosthetics of the abdominal aorta using the standard technology. Before surgery, multispiral computed tomography data is evaluated using artificial intelligence and safe zones of aortic and arterial clampings are determined. Intraoperatively, clamping is performed in the settlement zones.
45605206|NCT04783090|Drug|MT1013|bispecific peptide as a CaSR agonist and a functional OGP analogue
45605207|NCT04790734|Drug|Sedation drugs|Different sedation drugs
45911247|NCT02005458|Drug|PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
45605208|NCT04566562|Diagnostic Test|Brain Imaging|Magnetic Resonance Imaging (MRI) using diffusion weighted pseudo-continuous arterial spin labeling (DW-pCASL) .
45605209|NCT04566562|Diagnostic Test|Cognitive Testing|Wide Range Assessment of Memory and Learning (WRAML 2) and Montreal Cognitive Assessment (MoCA)
45605210|NCT04566562|Diagnostic Test|Blood Biomarkers|Inflammatory Markers
45605211|NCT00679120|Device|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
45605212|NCT00679120|Device|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
45605213|NCT00679120|Device|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery (porous coated and HA coated)
45605214|NCT04789954|Biological|Eptacog alfa, activated|A dose sequence for each injection will be randomly selected from the following doses: 10 μg/kg, 30 μg/kg, 90 μg/kg, or 270 μg/kg, separated by a wash-out period of 3 days.
45605215|NCT04420624|Drug|Colchicine|1 mg (or 0.5mg) tablet of colchicine taken once a day for 1 month
45605216|NCT04341064|Behavioral|SHINE Intervention|[see arm/group descriptions]
45605217|NCT05168332|Behavioral|EMG-BF guided patellar taping|EMG-BF guided patellar taping Maximum voluntary isometric contraction exercise at 60, and 90 degrees angle.
45605218|NCT05168332|Behavioral|sham patellar taping without EMG-BF guided stimulation; maximum voluntary isometric contraction exercise|sham patellar taping without EMG-BF guided stimulation; maximum voluntary isometric contraction exercise
45605219|NCT03090191|Biological|Clostridium difficile vaccine|Toxoid-based Clostridium difficile vaccine
45605220|NCT03090191|Biological|Placebo|Normal saline solution (0.9% sodium chloride)
45605221|NCT04782778|Drug|Bupivacaine 0.25% Injectable Solution|1 mg/kg Bupivacaine (0.25%)
45605222|NCT04782544|Other|Buttermilk Powder|Treatment with 5.0 g of buttermilk powder daily for 10 weeks.
45605223|NCT04782544|Other|Anhydrous Milk Fat|Treatment with 5.0 g of milk powder (90% anhydrous milk fat, 10% buttermilk powder) daily for 10 weeks.
45605224|NCT00543712|Drug|PRO95780|Intravenous repeating dose
45605225|NCT00474604|Procedure|diffusion-weighted magnetic resonance imaging|A scan will be performed.
45605226|NCT00474604|Procedure|dynamic contrast-enhanced magnetic resonance imaging|A scan will be performed.
45605227|NCT00474604|Procedure|magnetic resonance spectroscopic imaging|A scan will be performed.
45605228|NCT00434434|Drug|omalizumab|Aged Liquid; subcutaneous repeating dose
45605229|NCT00434434|Drug|omalizumab|Lyophilized; subcutaneous repeating dose
45605230|NCT00434434|Drug|placebo|Subcutaneous repeating dose
45605231|NCT04047797|Drug|Ixazomib|Given by mouth
45605232|NCT04047797|Drug|Ixazomib Citrate|Given by mouth
45605233|NCT04047797|Biological|Rituximab|Given Intravenous
45605234|NCT03524807|Device|Electrophysiologic therapy|Pelvic floor electrophysiological therapy is used after common gynecologic surgery to record anal exhaust time and micturition time after surgery and endometrium recovery of intrauterine adhesions.For intrauterine adhesions patients, Drug: Aspirin(low dose of Aspirin after operation)Device: intrauterine balloon (insert intrauterine balloon after operation)
45605235|NCT04020107|Other|Compressive garment and Somatosensori Remediation|Each patient will benefit successively: from a classic care, over a period of 2 to 4 months, then will be treated with compressive or low compressive garments associated with specific proprioceptive physiotherapy program during the next 4 months. Finally, the 4 last months, patient will made adapted physical activity with both dance sessions strengthening the body diagram and stretching sessions
45605236|NCT04002401|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
45605237|NCT04002401|Drug|Rituximab|Administered intravenously
45756910|NCT03437330|Drug|Insulin Glargine (Lantus®)|"insulin glargine shall be titrated according to the following scheme: If FBG 6-7 mmol/L: reduce fasting glucose by 0.5 mmol/L If FBG 7-8 mmol/L: reduce fasting glucose by 0.75 mmol/L~If FBG 8-9 mmol/L: reduce fasting glucose by 1.0 mmol/L Thus, insulin glargine doses should be adapted as follows:~FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia < 3.9 mmol/L occurs) FBG 7-8 mmol/L: +3IU (stop when FBG is reduced by 0.75 mmol/L or documented hypoglycemia < 3.9 mmol/L occurs) FBG > 8 mmol/L: +5 IU (stop when FBG is reduced by 1.0mmol/L or documented hypoglycemia < 3.9 mmol/L occurs)"
45756911|NCT05738499|Other|Character strengths-based structured treatment and education programme (CSSTEP)|This CSSTEP intervention included both psychological and educational contents, and the intervention type was psycho-educational intervention. The implementation process lasted for three weeks. CSSTEP mainly includes two main components. The first part is character strengths-based intervention. The second part is educational intervention, which is structured treatment and education programme for stroke patients. The two components were combined and optimized on the basis of theoritical and empirical evidences, and then this kind of complex intervention suitable for Chinese clinical stroke patients was obtained.
45452170|NCT01192906|Drug|Placebo|Oral doses, once a day for 52 weeks
45452171|NCT01192906|Drug|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
45452172|NCT01192906|Drug|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
45605238|NCT04002401|Drug|Fludarabine|Administered according to package insert
45605239|NCT04002401|Drug|Cyclophosphamide|Administered according to package insert
45911248|NCT02005497|Other|HealthLinks|
45911249|NCT02005523|Drug|RNS60|
45911250|NCT02005523|Drug|Saline|
45452173|NCT01189396|Drug|A006|Albuterol DPI with 180 mcg Albuterol/inhalation
45452174|NCT01189396|Drug|Placebo DPI|Placebo DPI with 0 mcg Albuterol/inhalation
45452175|NCT01189396|Drug|Proventil-HFA|Albuterol MDI with 90 mcg Albuterol/inhalation
45452176|NCT05626972|Drug|Tenecteplase|Patients will be randomized 1:1 to standard dose tPA (0.9 mg/kg) or TNK (0.25mg/kg) before endovascular therapy (EVT)
45452177|NCT01187836|Drug|TRV120027|Dose range (starting at 0.1 mcg/kg/min) of TRV120027 administered for 14 hours.
45452178|NCT01187836|Drug|Placebo|Placebo administered for 14 hours.
45452179|NCT02268760|Drug|BILN 2061 ZW single rising doses|
45452180|NCT02268760|Drug|Placebo|
45452181|NCT02268760|Drug|BILN 2061 ZW fixed dose|
45452182|NCT02268760|Other|Standardized breakfast|
45605240|NCT03995225|Behavioral|Smartband automatic smoking detection and brief mindfulness interventions|Smartband/smartphone based automatic smoking monitoring, notification and real-time brief mindfulness interventions
45605241|NCT03046511|Drug|Cefazolin|A post- procedure administration of Cefazolin will be compared with a pre-operative intravenous dose
45605242|NCT03956537|Device|NEO Pedicle Screw System™|The NEO Pedicle Screw System™ is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion.
45605243|NCT03956537|Device|Neo Cage System™|Neo Cage System™ is intended to be used with bone graft material to facilitate interbody fusion and to be used with the NEO Pedicle Screw System™
45911251|NCT02005575|Drug|Bupivacaine and Dexamethasone|The standard of care is to use a regional block solution containing both decadron and bupivicaine.
45605244|NCT03522779|Dietary Supplement|Tart cherry Juice|Tart cherry juice will be used to compare antioxidant and oxidative stress levels in human plasma following a high fat meal.
45605245|NCT03522779|Other|High-fat meal|A high fat meal will be given to elicit postprandial oxidative stress.
45605246|NCT03522779|Other|Exercise|The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve.
45605247|NCT03522623|Other|Non-interventional study|Non-interventional study
45605248|NCT02439320|Drug|Lasmiditan 100 mg|
45605249|NCT02439320|Drug|Lasmiditan 200 mg|
45605250|NCT02439320|Drug|Placebo (matches lasmiditan doses)|
45605251|NCT04936256|Device|Clareon|Clareon monofocal intraocular lens (IOL)
45605252|NCT02469038|Device|AccuCath catheter|Ultrasound-guided insertion of an AccuCath catheter during a standard of care procedure.
45605253|NCT02469038|Device|Control|Ultrasound-guided insertion of a conventional IV catheter during a standard of care procedure.
45605254|NCT02468648|Drug|Sofosbuvir|An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection
45605255|NCT02468648|Drug|GS-5816|An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.
45605256|NCT02468414|Biological|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
45911252|NCT02005575|Drug|Placebo|
45605257|NCT02468414|Biological|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
45605258|NCT02466386|Drug|SPD489|Participants will receive 5 mg of SPD489 capsule orally once daily in the morning and titrated in a step-wise fashion up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached.
45605259|NCT04936100|Device|"Assessment of distance and near visual acuity using Vision Screening module of Easy Vision application"|"The presenting visual acuity will be assessed using the Vision Screening module of the Easy Vision application."
45605260|NCT04936100|Device|"Assessment of distance and near visual acuity using Test Yourself module of Easy Vision application"|"The presenting visual acuity will be assessed using the Test Yourself module of the Easy Vision application."
45605261|NCT04936100|Device|"Assessment of distance and near visual acuity using Peek Acuity application"|"The presenting visual acuity will be assessed using the Peek Acuity application."
45605262|NCT04936100|Other|Assessment of distance and near visual acuity using the conventional methods|"The presenting visual acuity will be assessed using the conventional methods [Chart: Tumbling E optotype for assessing distance visual acuity and Handheld chart: Tumbling E Near Point Vision Chart for assessing near visual acuity]"
45605263|NCT04936022|Other|Isometric Exercise|Prescribed 6 months of isometric exercise training (three sessions per week, comprised of 4 x 2-minute bouts with 2-minute recovery periods in-between).
45605264|NCT04936022|Behavioral|Standard care lifestyle advice|Healthy lifestyle advice for hypertension, given by a healthcare professional.
45605265|NCT04935866|Other|Near-infrared spectroscopy (NIRS)|Non invasive brain oxygenation monitoring with Near-Infrared Spectroscopy (NIRS) technology. Patients enrolled in the NeurO2 study will have bilateral NIRS sensors applied to the forehead according to manufacturer recommendations. Data will be monitored continuously throughout the study intervention in the parent trials (HEMOTION and SAHaRA trials) in the neurocritical care unit. Data will be extracted from the device at the end of the study period.
45605266|NCT01633060|Drug|Fulvestrant|Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
45605267|NCT01633060|Drug|BKM120|BKM120 100 mg once daily
45605268|NCT01633060|Drug|BKM120 matching placebo|BKM120 matching placebo, once daily
45605269|NCT03522467|Drug|MRCP001|MRCP001 is a formulated whole-plant cannabis oil extract, that may help manage poorly controlled chronic pain.
45605270|NCT03914495|Dietary Supplement|Inulin|Powdered inulin will be provided in pre-weighed portions for consumption in a 1 week titration to reduce GI side effects with a 21 day intervention at full dose.
45605271|NCT03914495|Dietary Supplement|Placebo|Powdered maltodextrin will be provided in pre-weighed portions for consumption in a 1 week titration with a 21 day intervention at full dose.
45605272|NCT03906695|Drug|ASTX727|oral decitabine 5mg + cedazuridine
45756912|NCT05738499|Other|Structured treatment and education programme (STEP)|The STEP programme is aimed at the treatment needs of stroke patients, considering the education level and cultural background of patients, screening important health education content, and planning and grading of patients' education. The intervention consisted of three educational sessions, focusing on patients' daily life, post-stroke rehabilitation and secondary prevention.
45756913|NCT01271803|Drug|Cobimetinib|Participants will receive cobimetinib 60 to 100 mg at any of the 3 dosing schedules with or without vemurafenib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
45756914|NCT01271803|Drug|vemurafenib|Participants will receive vemurafenib 720 or 960 mg along with cobimetinib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
45605273|NCT03906695|Drug|ASTX727|oral decitabine 5mg + cedazuridine
45605274|NCT03906695|Drug|ASTX727|oral decitabine 10mg + cedazuridine
45605275|NCT03906695|Drug|ASTX727|oral decitabine 20mg + cedazuridine
45605276|NCT03906695|Drug|ASTX727|oral decitabine 10mg + cedazuridine
45605277|NCT04938596|Combination Product|Respiratory bundle|"Provision of N95 masks and strong recommendation of use to all household contacts and the index case when sharing a room together, for 2 weeks~Recommendation to index case to sleep in a room alone, with the door closed and avoid sharing room with others during 2 weeks~Promotion of strategies to improve house ventilation during 2 weeks~Provision of a TB leaflet and nurse education about TB transmission."
45605278|NCT03524651|Drug|Ferrous Sulfate|Blisters of 10 capsules containing 150 mg of ferrous sulfate.
45605279|NCT03524651|Drug|Fe-ASP|Boxes of 10 vials of 15 ml containing 800 mg of Iron protein acetyl aspartate.
45605280|NCT03524651|Drug|Ferrous Sulfate|Boxes of 10 vials of 15 ml containing inactive ingredients of Omalin.
45605281|NCT03524651|Drug|Fe-ASP|Blisters of 10 capsules containing inactive ingredients of Microfer.
45605282|NCT03878459|Drug|Pioglitazone 45 mg|patients will be started on 15 mg and the dose escalated to the maximal tolerated dose
45605283|NCT03878459|Drug|Placebo|PATIENTS WILL RECEIVE PLACEBO
45605284|NCT02819141|Drug|Dexmedetomidine|Patient will receive a maintenance intravenous infusion of medication (Dexmedetomidine) and have access to self-controlled sedation medication (Dexmedetomidine) for anxiety.
45605285|NCT03524573|Procedure|Appendectomy|Appendectomy is the surgical removal of the appendix.
45605286|NCT03852329|Device|Lateral skull base navigation|"Patient preparation: The participant is prepared for the surgery according to clinical standards.~System setup: The hardware components of the investigational device are set up~Tripod fixation: The tripod with integrated registration fiducials is fixed on the participant's skull.~CBCT imaging: A CBCT image of the participant is acquired~Image processing: The CBCT data is loaded on the navigation platform. The registration fiducials are automatically detected in the image data and relevant anatomy is segmented using an otologic planning software.~Measurements: The navigation software is started, and the fiducial positions and segmentations loaded. The measurements are conducted.~Treatment: The surgery is conducted by the surgeon according to clinical standards"
45605287|NCT01632904|Drug|Ruxolitinib|Ruxolitinib will be orally self-administered at a starting dose of 10 mg (two 5 mg tablets) twice a day. Dose increases of 5 mg (1 tablet) in twice-daily increments are permitted after 4 weeks and again after 8 weeks of therapy for subjects who meet prespecified criteria for inadequate efficacy.
45605288|NCT01632904|Drug|Hydroxyurea (HU)|Hydroxyurea (500 mg capsules) will be orally self-administered at the dose that the subject was receiving previously. The dose may be increased after 4 weeks and again after 8 weeks of therapy to optimize efficacy for subjects meeting prespecified criteria.
45605289|NCT01632904|Drug|HU-placebo|"All placebo will be self-administered, and dosing will be the same as with the blinded dose.~When adjustments are made to the ruxolitinib dose, the dose of HU-placebo will be adjusted concurrently."
46066618|NCT02558023|Drug|Urapidil|"Urapidil (Eupressyl*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.~The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.~Maximum dose of 30 mg.h-1."
45605290|NCT01632904|Drug|Ruxolitinib-placebo|"All placebo will be self-administered, and dosing will be the same as with the blinded dose.~When adjustments are made to the HU dose, the dose of ruxolitinib-placebo will be adjusted concurrently."
45605291|NCT05473000|Behavioral|Exercise|Submaximal and maximal exercise
45605292|NCT05473000|Other|Ozone|Delivery of ozone air pollution at 170ppb
45605293|NCT05473000|Other|Room air|Delivery of room air
45605294|NCT04240756|Behavioral|Behavioral Parent Training|Parents will receive 10 sessions of behavioral parent training with components specifically targeted toward parents with ADHD. Treatment will be delivered via telehealth.
45605295|NCT04240756|Drug|Extended release mixed amphetamine salts (MAS)|The MAS protocol will include a 2-4 -week open-label titration beginning at 20 mg and dose level will be increased weekly at telehealth visits with the psychopharmacologist until an optimal response or maximum dose of 60 mg.
45756915|NCT05722587|Other|Pain science education|High school students receiving a day of pain science education in multiple formats, lectures, experiential, completing a task which consolidates the information.
45756916|NCT00585377|Drug|Bevacizumab and Erlotinib|Erlotinib 150 mg/day orally plus bevacizumab 15 mg/kg intravenously every 21 days
46066619|NCT02558023|Drug|Nicardipine|"Nicardipine : IV~1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.~Maximum dose of 6 mg.h-1"
45605296|NCT03834779|Behavioral|DOORS-CHW Intervention|"The behavioral intervention has been developed for a collaborative CHW and re-entry program intervention that targets HIV outcomes, substance use and recidivism in HIV+ jail releasees.~Participants will be randomized to the DOORS+CHW intervention versus TAU and all participants will undergo study follow-up visits at 3, 6 and 12 months. In other words, participants randomized to the intervention arm will meet with the CHW and a staff member from DOORS. One of the primary study aims is a randomized controlled trial of an intervention which has a reasonable probability of improving the health and well-being of the subject by improving linkage to social services and the HIV clinic. The control arm will receive standard of care (referrals to case management)."
45756917|NCT00080288|Drug|Armodafinil 150 mg/day|Armodafinil 150 mg taken 30 minutes to 1 hour before the start of the night shift, but no later than 2300, only on nights worked.
45756918|NCT00080288|Drug|Placebo|Matching placebo tablets once daily
45756919|NCT05722119|Diagnostic Test|FilmArray GI|Rapid multiplex Polymerase Chain Reaction (PCR) assay for digestive infectious agents in stool sample in the baseline diagnostic tests panel
45756920|NCT05499507|Behavioral|COH|Incorporates two, evidence-based individual-level interventions (home blood pressure telemonitoring coupled with the interactive obesity treatment approach, that includes nutrition and physical activity text messages with tailored feedback) and an institutional-level intervention (anti-racism training of providers and staff along with patient feedback to inform respectful care).
45605297|NCT03522389|Procedure|AOT with gait training|"AOT with gait training composes of program of watching video in different views of normal walk for 5 min.~After that, participants will receive gait training program. The program consists of warm-up, gait training, cool-down, and stretching. Gait training is classified into the different levels of difficulty in each week. The 1st week will be walking over the markers followed by 100 steps/min of metronome. The second week will be walking over the markers followed by 120 step/min of metronome. The 3rd week will be walking followed by 120 step/min of metronome but not has the markers. The 4th week will imagine and imitate the walking in the 2nd week but not has the markers and metronome."
45605298|NCT03522389|Procedure|Gait training|"To control a total time of training, the gait training group will watch video of Vincent van Gogh's painting for 5 min. After that, participants will training the gait as protocol of experimental group.~The program consists of warm-up, gait training, cool-down, and stretching. Gait training is classified into the different levels of difficulty in each week. The 1st week will be walking over the markers followed by 100 steps/min of metronome. The second week will be walking over the markers followed by 120 step/min of metronome. The 3rd week will be walking followed by 120 step/min of metronome but not has the markers. The 4th week will imagine and imitate the walking in the 2nd week but not has the markers and metronome."
45605299|NCT03522389|Other|Education|There will be no intervention exercise program provide for the control group. They will receive education about dementia such as definition, etiology, sign and symptom, and caring.
45605300|NCT04467125|Drug|Eutectic Lidocaine Prilocaine|Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed.
45605301|NCT04467125|Drug|Subcutaneous Lidocaine|Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected by the provider at the removal site in an amount decided on by the provider.
45605302|NCT03522311|Procedure|Vitrectomy|
45605303|NCT02692313|Drug|Epinephrine|Dose response of epinephrine infusion
45605304|NCT02692313|Other|Saline infusion|Placebo
45605305|NCT03726437|Behavioral|RealConsent|"This 3-hour web-based program consists of four 45-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama (Squad), which allow for the modeling of positive behaviors and illustrate both positive and negative outcome expectations. Behaviors modeled include drinking safely (e.g., eating before drinking, pacing, and drinking water), having a game plan before going out, communicating with male sex partners, engaging in protective dating behaviors, use of resistance strategies, self-defense strategies and bystander intervention with the goal of reducing risk of being sexually assaulted."
45605306|NCT03726437|Behavioral|Stress and Mood Management|"This 3-hour general health promotion web-based program consists of four 45-minute modules (Stress Management, Managing Depression, Managing Anxiety, and Treatments that work) that provide a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise."
45605307|NCT02465528|Drug|Ceritinib (LDK378)|Ceritinib was to be administered orally once daily at a dose of 750 mg (5 capsules of 150 mg) on a continuous dosing schedule. A complete treatment cycle was defined as 28 days of once daily continuous treatment with ceritinib.
45756921|NCT05499507|Behavioral|COH+|Includes all components of COH plus interpersonal support for Black women by Black women (community doula care, mental health services, and lactation support).
45756922|NCT02984618|Procedure|Sphenopalatine ganglion block|Cotton- tipped applicators inserted up through the nose followed by infusion of ligdocaine through the applicators.
45756923|NCT02984618|Procedure|Epidural blood patch|Autologous sterile blood (20ml) will be infused in the lombar epidural space.
45756924|NCT00610883|Drug|LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU|LSA4 intervention includes three phases: induction, consolidation and maintenance
45911253|NCT02005588|Drug|amino acid chelated iron|the drug will be given to pregnant women 14-18 weeks' gestation who prove to have iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily. for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
45605308|NCT02438384|Behavioral|Video|This is a 10 minute interactive video which provided information to the viewer regarding the safe and effective use of analgesics for acute musculoskeletal pain at home. The focus is on acetaminophen, NSAIDs, and opioids.
45605309|NCT02438384|Behavioral|Phone follow-up|The call will be made by the study coordinator, who is a medical student. Any patients reporting a pain score in the past 24 hours of 4 or more will be re-contacted by an emergency physician with special training in geriatric pain management. This individual will provide recommendations to the patient regarding treatment options.
45756925|NCT03084458|Behavioral|Fitbit|The Fitbit device will allow experimental group participant access to their daily step count.
45756926|NCT05721183|Behavioral|NOST|"The intervention is to implement NOST, which includes:~observation and recording of compliance with hand hygiene recommendations identification of areas for improvement training or other actions taken to improve IPC in general or compliance with hand hygiene.~Thus, the intervention includes both observation of compliance and any additional improvement measures initiated as a result of the introduced NOST.~When the intervention group has implemented and followed NOST for a year, the investigators will measure compliance with hand hygiene recommendations and reported HAIs, in wards that have had NOST and in wards that have not introduced NOST.~The intervention arm will be followed over time with repeated measurements of both compliance with hand hygiene and other outcome measures, to see if the effect increases in line with implemented observations and quality improvement measures, or if the effect decreases during the study period."
45756927|NCT01798745|Drug|JNJ-54452840|Once daily intravenous injection(s) (medication is injected into a vein) at doses ranging from 20 mg to 240 mg, given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
45911254|NCT02005588|Drug|iron salt (ferrous fumarate)|this drug will be given to pregnant women 14-18 weeks' gestation with iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily, and for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
45605310|NCT02463032|Drug|GTx-024|To determine whether either or both doses result in an acceptable clinical benefit rate.
45605311|NCT04943354|Behavioral|Taking a person's venous blood|Collection of 5 ml of the patient's venous blood, carried out according to standard rules.
45605312|NCT02545205|Device|Hybrid Assistive Limb (HAL)|Intensive gait training with Hybrid Assistive Limb (HAL) is performed, 1 session/day, 4 days/week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective walking time with HAL).
45605313|NCT02545205|Other|Conventional gait training|The conventional gait training is performed according to current best evidence based practice and may include over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support and training of gait function in activities of daily living.
45605314|NCT02532257|Drug|Ibrutinib|Given PO
45605315|NCT02532257|Other|Laboratory Biomarker Analysis|Correlative studies
45605316|NCT02532257|Drug|Lenalidomide|Given PO
45605317|NCT02532257|Biological|Rituximab|Given IV
45605318|NCT03524261|Biological|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Breast Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
45605319|NCT03524261|Procedure|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
45605320|NCT02496884|Drug|DS-5565|DS-5565 7.5 mg tablet for oral use
45605321|NCT02496884|Drug|Placebo|Placebo tablet for oral use to match DS-5565 7.5 mg tablet
45605322|NCT02215187|Behavioral|Problem-Solving Training (PST)|Training in problem-solving skills to be applied to military caregiver problems.
45605323|NCT02215187|Behavioral|Attention Control|Social contact control (health education/no skill training)
45605324|NCT03133091|Drug|PIEB: Patient Intermittent Epidural Boluses|Each patient were randomized to PIEB (7 ml bolus every 30 minutes, with extra boluses (PCEA) of 6 ml every 20 minutes) or PCEA (5 ml in continuous perfussion + PCEA of 5 ml every 15 minutes).
45605325|NCT03133091|Drug|PCEA: Patient Controlled Epidural Analgesia|Each patient were randomized to PIEB (7 ml bolus every 30 minutes, with extra boluses (PCEA) of 6 ml every 20 minutes) or PCEA (5 ml in continuous perfussion + PCEA of 5 ml every 15 minutes).
45605326|NCT02462876|Device|GORE® VIABAHN® Endoprosthesis|Treatment of Popliteal Artery Aneurysm with the GORE® VIABAHN® Endoprosthesis.
45605327|NCT04466813|Device|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle.~1 session in upper trapezius muscle moving the needle up and down ten times."
45605328|NCT04466813|Device|Control-Dry Needling|Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles
45605329|NCT03501095|Diagnostic Test|Vocal analysis and Laryngostroboscopy|"Vocal analysis study the acoustic emission of the pneumo-phono-articulatory system, i.e. the vocal signal. Currently, digital technology instruments enable the processing and analysis of the verbal signal quickly and reliably, also offering graphical products and numerical data. Among the various existing software products for the study of the vocal signal, PRAAT is available. In practice, the vocal parameters are acquired in a non-invasive way with a microphone.~Laryngostroboscopy is one of the most widely used techniques for laryngeal clinical evaluation. This is a non-invasive endoscopic practice performed by means of a flexible fibroscope, which, through a pulsed light source, allows visualization of the chordal movement."
45756928|NCT01798745|Other|Placebo|Once daily matching intravenous injection(s) (medication is injected into a vein) given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
45756929|NCT05496777|Procedure|Home-based prehabilitation program|The home-based prehabilitation program will consist of a four-week program, where patients are expected to perform a high-intensity interval training on a home-trainer combined with functional mobility training three times a week. The program is partly supervised by a trained physiotherapist.
45756930|NCT00088010|Drug|Arzoxifene|20mg, oral, tablet, once a day for 36 months
45911255|NCT02005614|Procedure|Gamma Knife Radiosurgery|"Treatment will be administered on an outpatient basis. No other treatment, investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's brain metastases.~Gamma knife radiosurgery is a one day out-patient procedure. Time from initiation of treatment (premedication and placement of a stereotactic frame) until end of treatment (completion of radiation delivery and removal of stereotactic frame) ranges from 3 to 16 hours."
45605330|NCT03386721|Drug|simlukafusp alfa|simlukafusp alfa will be administered as per the dosage regimen mentioned in arm descriptions.
45605331|NCT03386721|Drug|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab will be administered as per the dosage regimen mentioned in arm descriptions.
45605332|NCT03386721|Drug|Gemcitabine|Single-agent treatment administered as per approved protocol.
45605333|NCT03386721|Drug|Vinorelbine|Single-agent treatment administered as per approved protocol.
45605334|NCT02462720|Drug|Varithena®|Varithena® treatment in accordance with full prescribing information and instructions for use
45756931|NCT00088010|Drug|Placebo|oral, tablet, once a day for 36 months
45756932|NCT03084380|Biological|Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs|transcatheter arterial chemoembolization + CAR-T infusion
45756933|NCT03084380|Drug|Fludarabine|Fludarabine will be administered at dose of 25mg/m2/d
45911256|NCT02005653|Drug|Diethylcarbamazine|Diethylcarbamazine 300 mg tablet as single dose per day for 12 days
45911257|NCT02005653|Drug|Albendazole|Experimental
45911258|NCT02005653|Drug|Doxycycline|Experimental
45911259|NCT02005679|Behavioral|application of the mini-mental state test|
45452183|NCT01095562|Drug|ABT-126|ABT-126 Dose 1, ABT-126 Dose 2
45452184|NCT01095562|Drug|Placebo|Placebo
45452185|NCT01174732|Drug|albuterol inhalation powder|A006 albuterol inhalation powder, 120 mcg/inhalation, one inhalation
45452186|NCT01174732|Drug|albuterol inhalation powder|A006 albuterol inhalation powder, 180 mcg/inhalation, 1 inhalation
45452187|NCT01174732|Drug|albuterol inhalation powder|A006 albuterol inhalation powder, 120 mcg/inhalation, 2 inhalations
45452188|NCT01174732|Drug|albuterol inhalation powder|A006 albuterol inhalation powder, 180 mcg/inhalation, 2 inhalations
45452189|NCT01174732|Drug|Placebo|placebo, lactose inhalation carrier
45605335|NCT02462720|Device|Radiofrequency ablation|Radiofrequency ablation conducted per physicians' standard of care.
45605336|NCT03524105|Behavioral|Program for Parents (Parenting Program)|Program for Parents (Parenting Program) is implemented by a mental health professional and offered to groups of ~15 parents during the school day and during after school hours. The Program for Parents includes 2-hour sessions provided weekly over a 4-month period. The Program for Students (Friends School Social Emotional Learning Program) is implemented by classroom teachers in the classroom with 90 minute lessons and activities once a week for 14 weeks
46066620|NCT00607568|Drug|Atomoxetine|"atomoxetine 40mg per day or placebo~For Phase I, subjects will be assigned to atomoxetine or placebo for 4 days. Subjects will then have a 4-15 day washout period and will be crossed over to the alternative treatment for Phase II."
46066621|NCT00606164|Drug|Bryostatin for Injection|A single one-hour intravenous infusion of 10 or 15 ug/m2 Bryostatin for Injection on Day 1
45605337|NCT03524105|Behavioral|Thrive Professional Learning|Professional Learning is delivered to teachers in groups of 20-40 4 times a year over a two-year period. Professional Learning is delivered to leaders in groups of 20 - 40 three times a year over the same two-year period.
45605338|NCT03524027|Procedure|Posterior Vertebral Column Resection (PVCR)|Posterior Vertebral Column Resection (PVCR) Surgical Technique for Correction of Adolescent Thoracolumbar Congenital Kyphoscoliosis (CKS) Spinal Deformity
45605339|NCT02246218|Drug|RAVICTI|
45605340|NCT05393661|Other|inpatient physical therapy poststroke|routine care
45605341|NCT03523949|Behavioral|PNE|The PNE will be delivered by a physiotherapist in a single, group-based session.
45605342|NCT05085093|Biological|HPV vaccine|Patients choose to be vaccinated or not to be vaccinated with HPV vaccine according to their own wishes
45444705|NCT03796845|Other|No limited movement after surgery|Participants should move their arms from the first postoperative day, with unrestricted movement, with an amplitude above 90º for flexion and abduction of shoulder.
45605343|NCT03522155|Behavioral|Patient-centered communication of life expectancy|The intervention arm will test if patient-specific LE estimates via a targeted, patient-centered communication approach paired with LE-specific conjoint analysis data improves decisional conflict, quality of LE discussion, and reduces rates of overtreatment of Genitourinary malignancies.
45605344|NCT05084781|Procedure|Coblation Debridement (FLOW90)|bipolar radiofrequency energy
45605345|NCT03521921|Device|Mitraclip|Edge-to edge mitral valve repair
45605346|NCT05084703|Other|Functional tests|"Symmetry indices between the two limbs obtained thanks to the scores of the functional tests : Y balance test~Muscle endurance index obtained from functional test scores : Closed Kinetic Chain Upper Extremitie Stability test"
45605347|NCT05081739|Diagnostic Test|Prospera Transplant Assessment|"Prospera™ detects allograft rejection noninvasively and with high accuracy by measuring the fraction of dd-cfDNA in the patient's blood, without the need for prior donor or recipient genotyping.~Prospera is a commercially available LDT developed by Natera, Inc. Natera is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA)."
45605348|NCT03523637|Behavioral|Interoceptive Exposure|The intervention Interoceptive Exposure (IE) is an exposure to bodily sensations used in treatment of variety of problems where body sensations are experienced as threatening. This psychological technique is about focusing attention on pain, 'staying with the pain' without trying to escape it.
45605349|NCT05074017|Device|3 nasopharyngeal swab|3 nasopharyngeal swabs to conduct 2 rapid antigen tests for SARS-CoV-2 and a RT-PCR
45605350|NCT02244580|Device|MammaTyper™|MammaTyper™ kit is a molecular in vitro diagnostic test for the quantitative detection of the ribonuclease acid (RNA) expression status of the genes for estrogen receptor (ESR1), progesterone receptor (PGR), human epidermal growth factor receptor 2 (HER2) and proliferation antigen KI 67.
45605351|NCT05073939|Drug|Oral Oxytocin|Administration of oxytocin (24 international units) orally
45605352|NCT05073939|Drug|Oral Placebo|Administration of placebo orally
45605353|NCT04789018|Other|Educational Intervention|Attend virtual genetics board
45605354|NCT04789018|Other|Survey Administration|Complete survey
45605355|NCT04789018|Other|Interview|Complete interview
45756934|NCT03084380|Drug|Cyclophosphamide|Cyclophosphamide will be administered at dose of 40mg/kg for 1 day and then fludarabine will be given for the next 5 days and then the T cells will be administered
45756935|NCT00586001|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Cognitive-behavioral treatment in development for emotional disorders
46066622|NCT00606164|Drug|Placebo|A single one-hour intravenous infusion of placebo on Day 1
45452190|NCT01174732|Drug|albuterol inhalation aerosol|albuterol inhalation aerosol, 90 mcg/inhalation, 2 inhalations
45452191|NCT01174732|Drug|albuterol inhalation aerosol|albuterol inhalation aerosol, 90 mcg/inhalation, 4 inhalations
45452192|NCT01077700|Drug|ABT-288 Low Dose|
45452193|NCT01077700|Drug|Placebo|inactive substance
45452194|NCT01077700|Drug|ABT-288 High Dose|
45452195|NCT03903172|Device|Abdominal binder|Abdominal binder
45452196|NCT02236234|Biological|HPV vaccine|HPV vaccine
45452197|NCT02268838|Drug|E6007|
45452198|NCT02268838|Drug|E6007 matching placebo|
45452199|NCT03876808|Device|Bair Hugger™ Temperature Management Unit Model 750|Forced-air temperature management unit used for preoperative and intraoperative participant warming
45452200|NCT03876808|Device|3M™ Bair Paws™ Flex Gown|Bair Paws™ patient warming gown used for preoperative and intraoperative participant warming
45452201|NCT01076764|Drug|Otamixaban|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
45452202|NCT01076764|Drug|Placebo (for Otamixaban)|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
45452203|NCT01076764|Drug|UFH|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
45452204|NCT01076764|Drug|Placebo (for UFH)|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
45605356|NCT05065125|Device|digital single-operator cholangioscopy|"Duodenoscope passes through esophagus and stomach to the papilla of Vater~SpyScope DS Catheter passes through the duodenoscope and into common bile duct~After direct visualization of anastomosis site stricture, guidewire is passed through SpyScope DS Catheter above the stricture site."
45605357|NCT03521843|Device|balloon dilation only|The balloon dilation only will be used to treat the femoropopliteal in-stent restenosis.
45605358|NCT03521843|Device|balloon dilation+local drug delivery|The balloon dilation and local drug delivery will be used to treat the femoropopliteal in-stent restenosis.
46066623|NCT04266548|Procedure|Superselective Intra-arterial Hepatic Injection of Indocyanine Green (ICG) for Fluorescence Image-guided Segmental Positive Staining|The patients with single HCC which is planned to received laparoscopic hepatectomy were involved. Procedures were performed in conventional angiography room. The celiac trunk was catheterized and a microcatheter was advanced into segmental hepatic artery branches which supplied the HCC. The 5cc 0.125 mg/cc ICG was injected from super-selective hepatic artery in operative room. A Near-Infrared laparoscope was used to detect the fluorescent signal to assess the correspondence between arterial-based fluorescence demarcation and ultrasound-based surgical demarcation.
46066624|NCT00604916|Other|standardized oral care protocol - electronic toothbrush|a standardized 20-minute oral care protocol using an electronic toothbrush to clean and moisturize oral cavity twice daily.
45605359|NCT02244424|Behavioral|Tools for Teen Moms|"The Tools for Teen Moms intervention is a novel social media intervention platform designed by the investigators which includes cell phone text message reminders, and infant feeding website, and Facebook to increase infant-centered feeding through daily behavioral challenge activities (challenges) for this population. The intervention consists of 6 weeks of daily challenges and will be delivered within the infant's first 6 months of life."
45605360|NCT04206982|Procedure|Destruction of Marshall bundles|Destruction of Marshall bundles by ethanol 96% infusion (2 separate injections of 5ml on 1 minute each) followed by ablation of the distal coronary sinus bundles, the ridge and the saddle.
45605361|NCT04206982|Procedure|Pulmonary veins isolation|Achievement of a wide disconnection of the right and left pulmonary veins.
46066625|NCT00604916|Other|mimic protocol|a mimic 20-minute protocol involving moisturizing and attention control was performed for the same intervals.
46066626|NCT04610710|Procedure|Operation|Operation for deep infiltrating endometriosis
45605362|NCT04206982|Procedure|Linear ablation in the left and right atria|Ablation of the mitral, the roof, and the cavo-tricuspid isthmus.
45605363|NCT03521765|Other|Cancer education|Those participants in the OT intervention group were given a consultation based on a CRC education handbook by an occupational therapist for discharge preparation (about 30 minutes) and after each follow-up visit to the clinic (about 15-20 minutes); the non-intervention group participants were given a CRC education handbook (the same handbook) only for discharge preparation. For the first OT consultation, in the first 15 minutes, the occupational therapist educated the participants based on the CRC education handbook chapter by chapter. The next 15 minutes, the occupational therapist interacted with the participants and provided them customized lifestyle suggestions. For the each following (second and third) consultations, occupational therapists interacted with the participants and provided customized suggestions based on the participants' lifestyle at home.
45605364|NCT05254301|Other|Intervention group|This personalised multimodal treatment considers evidence- and practice-based elements (e.g., self-management, individual guidance & follow-up, low-threshold activities, homebased functional training & better follow-up guidance afterwards).
45605365|NCT05433610|Device|Non-invasive Ventilation|Exercise capacity testing using the device
45605366|NCT04192630|Device|CVisc50 OVD|Bausch + Lomb CVisc50 Cohesive OVD
45605367|NCT04192630|Device|ProVisc OVD|ProVisc OVD
45605368|NCT04192630|Procedure|Cataract Surgery|Cataract Surgery
45605369|NCT00159783|Drug|asenapine|Asenapine, 40 weeks
45605370|NCT00159783|Drug|Olanzapine|Olanzapine, 40 weeks
45605371|NCT04158154|Other|Evidence-based fixed-dose combination protocol based treatment|The intervention has been adapted based on a local needs' assessment including exploration of health care workers and patient's knowledge, attitudes, and behaviors related to HTN, causes, consequences, and treatment. Implementation pathways have been developed with particular attention to overcoming modifiable barriers to HTN treatment and control across capability, intentional, and system domains using CFIR. Sites will randomly be assigned to receive either: Step 1 amlodipine 5mg; Step 2 amlodipine 5 mg + losartan 50 mg (as 2 separate pills); Step 3 amlodipine 10 mg + losartan 100 mg (as 4 separate pills); Step 4 amlodipine 10/losartan 100/HCTZ 25 (as 2 single pill combo) or Step 1 amlodipine 5mg; Step 2 amlodipine 5 mg + losartan 50 mg (as 1 single pill combo); Step 3 amlodipine 10 mg + losartan 100 mg (as 2 single pill combo); Step 4 amlodipine 10/losartan 100/HCTZ 25 (as 2 single pill combo).
45605372|NCT01089101|Procedure|Biospecimen Collection|Undergo blood sample collection
45605373|NCT01089101|Drug|Selumetinib|Given PO
45605374|NCT04682067|Behavioral|Contingency Management|Escalating financial incentives contingent upon biochemical evidence of abstinence
45605375|NCT04682067|Behavioral|Usual Care smoking cessation|Usual care smoking cessation support
45605376|NCT01023737|Drug|Hydroxychloroquine|The HCQ study dose levels are defined as 400mg/day, 600mg/day, 800mg/day and 1000mg/day (oral dosing)during the phase I MTD determination. HCQ will be administered starting on Day 2 of Cycle 1 and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
45756936|NCT02986737|Device|ACURATE neo™ and ACURATE TA™ LP|ACURATE neo™ Aortic Bioprosthesis and ACURATE TA™ LP Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
45756937|NCT03080792|Behavioral|Experimental: moderate to high-intensity exercise|2x per week endurance exercise (continuous moderate and high intensity intervall training on a cycle ergometer) and progressive resistance training (machine based hypertrophy training)
46066627|NCT04610710|Procedure|Fertility treatment|In vitro fertilisation (IVF) and IVF-intracytoplasmic injection (ICSI)
45605377|NCT01023737|Drug|Vorinostat|Oral administration of Vorinostat will be begin on Cycle 1 Day 1 at 300mg and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
45605378|NCT03523403|Other|Apples|3 whole Ontario-grown Gala apples
45756938|NCT05738421|Diagnostic Test|fiberoptic endoscopic evaluation of swallowing|Questionnaire, FEES, OPES
45605379|NCT04136314|Behavioral|Decision-Framed Survey|Survey will ask all subjects for will be asked to indicate basic demographic information, such as age, sex, race, and education level. Also, subjects will indicate whether they have been diagnosed with psoriatic arthritis. Importantly, patients will complete the survey questions anonymously, and no direct patient identifiers or HIPPA-protected information will be collected. Subjects will then be asked to indicate their preference for a hypothetical injectable medication after exposure to [A] a gain-framed message or [B] a loss-framed message.
45605380|NCT03138837|Diagnostic Test|Magnetic resonance imaging|Diffusion Weighted Magnetic resonance imaging
45605381|NCT00646204|Drug|Memantine|10 mg bid
45605382|NCT00646204|Drug|placebo|2 tabs bid
45605383|NCT03140007|Device|single operator cholangioscopy|If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
45605384|NCT03140007|Device|ERCP guided brushing and biopsy|• If patients are randomized to the Control arm, then they will undergo an ERCP. ERCP-based impression of malignancy (yes/no/indeterminate) will be recorded. ERCP-guided brushing and ERCP-guided biopsy will be performed.
45605385|NCT04128904|Procedure|IVF|"Fertilisation with standard in vitro fertilisation (IVF). For details please see Project Description."
45605386|NCT04128904|Procedure|ICSI|"Fertilisation with intracytoplasmic sperm injection (ICSI). For details please see Project Description."
45605387|NCT02936323|Drug|PEN-221|PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose of 1 mg with each subsequent cohort increased starting dose level until MTD is reached.
45605388|NCT02936323|Drug|PEN-221|PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose at recommended Phase 2a dose established in Phase 1.
45605389|NCT04625751|Other|CO2-enriched air|To assess cardiovascular reactivity
45605390|NCT04625751|Other|Meal response test|Meal response test to assess changes in splanchnic blood flow.
45605391|NCT04105270|Drug|Oral Restorative Microbiota Therapy (RMT) Capsules|Patients with PD-L1 TC expression will receive sixteen doses of oral RMT capsules weekly
45605392|NCT04105270|Drug|Durvalumab 1500 mg IV|Patients with PD-L1 TC expression receive durvalumab 1500 mg IV every 4 weeks (Q4W) until disease progression or for a maximum of two years from the 1st dose of durvalumab
45605393|NCT04105270|Drug|Cisplatin/pemetrexed or Carboplatin/pemetrexed|Patients with PD-L1 TC receive cisplatin/pemetrexed or carboplatin/pemetrexed given every 3 weeks (Q3W) for 4 cycles followed by pemetrexed maintenance given Q3W
45605394|NCT04105270|Other|Placebo|Sixteen doses of oral placebo capsules given weekly
45605395|NCT03523247|Behavioral|whole food, plant based diet|whole food, plant based diet featuring vegetables, fruits, legumes, whole grains, seeds, and nuts
45605396|NCT04596891|Behavioral|Psychotherapy|Eight sessions of exposure therapy combined with mindfulness delivered via videoconferencing platform.
45605397|NCT04067596|Procedure|epiphysiodesis|"The procedure consists of sterilizing the growth cartilage of the various localizations (distal femur and proximal tibia).~Under general anesthesia under scopic control, the growth cartilage will be approached from both sides in order to curse the growth zone.~This procedure is monitored throughout the procedure with iterative X-rays, to ensure complete curettage of the growth cartilage. The average duration of the intervention is 1 hour and a half.~At the end of the procedure, there will be on each limb, 2 operative scars on each side of the knee, 8 scars in all.~Closing will be done with resorbable stitches A simple dressing will be applied to each scar and a Zimmer splint in extension will be installed postoperatively to limit the painful mobilizations in acute phase."
45605398|NCT04590573|Behavioral|Cognitive behavioural couple therapy (CBCT), Emotion focused couple therapy (EFCT), Wait-list control (Control)|5 sessions in CBCT, EFCT and Control (3 hours per session), 6-8 pairs of couples per group and around 7 groups will be held.
45605399|NCT05044221|Other|Former ICU patient and caregiver workshops|In depth interviews and workshops will be conducted with individuals enrolled in the study.
45605400|NCT05044221|Other|Health care professional workshops|In depth interviews and workshops will be conducted with individuals enrolled in the study.
45605401|NCT02701543|Device|Ranger Drug Eluting Balloon|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
45605402|NCT02701543|Device|In Pact Drug Eluting Balloon|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
45605403|NCT04770064|Drug|High-dose/short-duration Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. It has senolytic properties that may provide therapeutic benefit for those with knee osteoarthritis. Participants will be asked to take approximately 20 mg/kg of body mass for 2 consecutive days, followed by a 28-day washout period, and then another 2-day administration.
45605404|NCT04770064|Drug|Low-dose/sustained-duration Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. It has senolytic properties that may provide therapeutic benefit for those with knee osteoarthritis. Participants will be asked to take one, 100 mg capsule of fisetin daily for 90 days.
45605405|NCT04770064|Other|Oral placebo capsule|Participants will be asked to take one, 100 mg oral placebo capsule (corn starch) daily for 90 days.
45756939|NCT00084344|Drug|4-hydroxytamoxifen|
45756940|NCT00084344|Procedure|breast imaging study|
45756941|NCT00084344|Procedure|radiomammography|
45452205|NCT01076764|Drug|Eptifibatide|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
45452206|NCT01076764|Drug|Placebo (for Eptifibatide)|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
45452207|NCT02269072|Drug|Testosterone|Testosterone cream applied daily for two weeks
45452208|NCT02269072|Drug|Nesiritide|Administered IV once during the study
45452209|NCT02269072|Drug|Leuprolide|Administered twice during the study by injection
45452210|NCT02269072|Drug|Anastrozole|Daily pill for 8 weeks
45444706|NCT03811210|Behavioral|portion size|"Smaller than normal portion size - the intervention is the main meal component size perceived as 'smaller than normal' that participants are provided with during lunch and dinner in the laboratory.~Small-normal portion size - the intervention is the main meal component size perceived as 'small-normal' that participants are provided with during lunch and dinner in the laboratory.~Large-normal portion size - the intervention is the main meal component size perceived as 'large-normal' that participants are provided with during lunch and dinner in the laboratory."
45605406|NCT05393349|Behavioral|Empowering the patient and caregiver for early and safe discharge of patients with geriatric hip fractures|Orthopaedic surgeon, geriatrician, physiotherapists, occupational therapists, and nurses will make videos (each 3-5 minutes long) which are available to the patients and caregivers during both the hospitalization period and after discharge. They will complement the therapists' training sessions and allow revision of the contents by the patients and caregivers anytime. The patients and caregivers will be asked to complete an assessment after they view the videos to reinforce the knowledge they learn in the videos. Caregivers can be patient's relatives, friends or domestic helper who can commit to visiting the patient at least two days per week during the early discharge period.
45605407|NCT03474523|Other|Experimental group|"Cavitation: 70% intensity, 30 minutes apply plane electrode and 10 minutes focal electrode.~Presotherapy: 30 minutes application of 35% intensity, compression 35seg, pause 15seg, speed 9"
45605408|NCT03474523|Other|Control group|"Diathermy-Radiofrecuency: 30 minutes at 70% intensity (40-43ºC) in manual resistive modality and 10 minutes in automatic capacitive modality.~Presotherapy: 30 minutes application of 35% intensity, compression 35seg, pause 15seg, speed 9"
45605409|NCT03584477|Device|Robot InMotion 2.0|Repetitive work of large numbers of targeted alternative movements with or without assistance. The passage between with and without assistance taking place according to the evolution of performance judged by the investigator therapist. Note that the duration of the training using the assisted mode should be at least 3 weeks, i.e. half of the total duration of treatment.
45605410|NCT03584477|Other|Conventional rehabilitation|Conventional rehabilitation implemented by an occupational therapist, involving stretching movements in submaximal passive amplitude, inhibition postures (Bobath), active efforts assisted of varied difficulty, exercises of direction of the arm towards a target with or without elbow support and grasping tasks, adapted to the capacities of the paretic upper limb.
45605411|NCT05393115|Other|Square wave breathing|difference in time to failure from the two breathing modes
45605412|NCT02243176|Drug|Saxagliptin|The dose of saxaglitpin will be 5mg oral qd.
45605413|NCT02243176|Drug|Acarbose|Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose.
45605414|NCT03432715|Behavioral|Student Wellness Champions|"Student Wellness Champions participate in a training to, develop a rapport, and build trust with the wellness specialist. SWCs will meet once/week during lunch. The SWC's will receive a health education/ health literacy curriculum in order to be well-versed on the importance of being active and eating healthy foods and how to communicate health information to key stakeholders to enact policy change and to fellow students to enact behavior change. These students will work with the Wellness Specialist and Wellness Champion to implement wellness policies and practices.~Target policies/practices will be presented as a menu of options. The mechanisms used to enact change are based in the tenets of health literacy anchored in nutrition and PA promotion. Components of the curriculum include raising awareness of school system's local wellness policies and improving student skills surrounding the five standards of health literacy, using examples/activities linked to the local wellness policy."
45605415|NCT03432715|Behavioral|Teacher Wellness Champions|"Schools will be asked to identify a Wellness Champion (WC), someone at the school who is passionate about creating a healthy school environment. All WC's will be asked to attend a Wellness Champions for Change (WCC) training, led by a Wellness Specialist (health educator part of our study team). The WC's will learn about the skills necessary to make health promoting changes to the School Environment.~Following the WCC training, the Wellness Champion will receive technical assistance from the Wellness Specialist. The Wellness Specialist will work with the Wellness Champion and the school's Wellness Team to conduct a needs assessment, and develop and implement a school action plan. The Wellness Specialist will provide support and resources to the Wellness Champion and the school to help them work towards their goals. All Wellness Champions in a given school system will meet monthly, as a group, with their Wellness Specialist to discuss progress, pitfalls, and successes."
45605416|NCT00692939|Biological|autologous CD34-selected peripheral blood stem cells transplant|high-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
45605417|NCT00692939|Drug|Alemtuzumab|Transplant conditioning
45605418|NCT00692939|Drug|ATG|Transplant conditioning
45605419|NCT00692939|Drug|Melphalan|Transplant conditioning
45756942|NCT02986815|Other|[11C]Acetate Brain Imaging|Patients will be imaged on a Siemens Biograph 64 slice PET CT scanner. After placing the patient on the scanner and securing the head in a head restraint, a low dose CT of the brain will be acquired. Images with 3 mm slice thickness and spaced at 1.5 mm intervals will be reconstructed in a 300 mm field of view. The purpose of the CT is for image localization and attenuation correction and it is not considered to be a diagnostic quality CT. Following the completion of the CT, the [11C]Acetate will be administered. A dynamic PET image will be acquired in 3D list mode for a total of 30 minutes.
45756943|NCT03084068|Other|Human dehydrated umbilical cord allograft|human dehydrated umbilical cord allograft
45452211|NCT02269072|Drug|Placebo|Inert cream otherwise identical to testosterone cream applied daily for two weeks
45452212|NCT01071850|Drug|ipragliflozin|oral tablet
45452213|NCT01071850|Drug|Metformin|oral tablet
45452214|NCT01071850|Drug|Placebo|oral tablet
45452215|NCT01071226|Device|CliniMACS (CD+3, CD+19 depletion)|Patient's in Stratum 1 will receive grafts that have undergone CD3+, CD19+ depletion
45452216|NCT01071226|Device|CliniMACS (CD 34+ positive selection)|Patient's in Stratum 2 will receive peripheral blood progenitor cells that have undergone CD34+ selection
45452217|NCT01071226|Other|HSCT|Peripheral Blood Stem Cell Transplant
45452218|NCT03758404|Biological|adeno-associated virus vector AAV- CNGA3|Adeno-associated virus (AAV) gene therapy for defects in CNGA3 gene
45605420|NCT00692939|Drug|Thiotepa|Transplant conditioning
45756944|NCT03084068|Other|Placebo|Open rotator cuff surgery with standard suture repair
45605421|NCT00692939|Drug|Rituximab|Transplant conditioning
45605422|NCT00692939|Drug|Cyclophosphamide|Mobilization
45605423|NCT00692939|Drug|G-CSF|Mobilization
45605424|NCT00692939|Drug|Mesna|Mobilization
45605425|NCT04551261|Drug|GLS4|It is a new dihydropyrimidine antiviral drug that interferes the assembly of HBV core granule.
45605426|NCT04551261|Drug|RTV|"It is HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection;~It is a CYP3A inhibitor combined with other drug to increase the exposure in human."
45605427|NCT04551261|Drug|TAF|It is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.
45605428|NCT04690387|Biological|AV-COVID-19|Autologous dendritic cells previously incubated with SARS-CoV-2 spike protein
45605429|NCT04690387|Other|GM-CSF|GM-CSF as an adjuvant
45605430|NCT03534401|Behavioral|ARCHES Kenya|ARCHES: Contraceptive counselors in intervention clinics will receiving training to ) provide counseling and education regarding risk of partner detection of contraceptive methods, and women's and girls' strategies to use contraceptive methods to minimize partner detection risk integrated into standard contraceptive counseling, b) make brief inquiries to allow clients the opportunity to disclose experiences of RC and IPV (i.e., screening), c) provide method-specific counseling based on this information and the method chosen by the client, d) provide supported linkage of IPV survivors to local IPV support services (i.e. warm referral), and e) offer palm-sized educational materials on RC and IPV, as well as IPV services to all clients.
45605431|NCT04769830|Other|Bowel sound|The characteristic data of bowel sounds, such as 24-hour average intestinal rate, duration of gastrointestinal sounds, amplitude, maximum frequency and average frequency, were collected to observe the differences of intestinal sounds among different AGI grades.
45605432|NCT04534257|Device|SELUTION Sirolimus DCB|Suitable lesions will be treated with SELUTION Sirolimus DCB
45605433|NCT04528953|Behavioral|Interval walking and Qigong exercise|"Interval walking: The subjects will be asked to complete daily 30 minutes of walking in two 15-minute bouts with the rest interval for at least 0.5 an hour and not more than 2 hours between each bout.~Qigong exercise: mind-body exercise using the six healing sound Qigong exercise will be used because it is easy to learn, requires minimal physical capability, and can be performed even in a sitting body position."
45605434|NCT04946955|Other|Application and website with or without promotion|Development of an application and a website to de-stigmatise mental health and support the user in seeking help
45605435|NCT05392647|Drug|Hetrombopag|All eligible patients were given hetrombopag orally at an initial dose of 5 mg once daily after overnight fasting (>8 hours of fasting) and at least 2 hours before a meal . The dose of hetrombopag could be modified on the basis of the platelet count of patients after 2 weeks of administration.
45605436|NCT04064723|Device|Randomization between prosthetic components|Patients are randomized between two types of stem components and two types of cup components in total hip arthroplasty. Thus randomized between 4 different groups.
45605437|NCT04922619|Device|tonotopy based fitting then default fitting|Cochlear implant with default fitting then tonotopy based fitting
45605438|NCT04922619|Device|default fitting then tonotopy based fitting|Cochlear implant with tonotopy based fitting then default fitting
45605439|NCT03523013|Device|CPAP|CPAP treatment with different pressure for OSA patients
45605440|NCT04476927|Device|DiaNose|"DiaNose system is an electronic nose device that can smell diseases in the exhaled breath of patients in real time. The recognition of Volatile Organic Compounds (VOCs) in breath samples approach is non-invasive and for safe diagnosis of diseases.~The DiaNose prototype system consists the following elements:~A Soft Tube connected to a Sensors Chamber - The soft tube is made of medical grade silicon. The subject blows air into the tube for a few seconds and the exhaled air is directed through the sensors chamber. This unit is for single use.~Sensors Reading Unit- a multi used unit for sensors signals measurement. The Sensor Reading Unit is connected to a Laptop either via a Data Acquisition Instrument - Commercial unit for resistance measurements (https://www.tek.com/keithley-switching-and-data-acquisition-systems/keithley-daq6510) (option A ) or directly by a USB cable (option B).~Laptop - Laptop is used to activate and save the test measurements."
45605441|NCT04444323|Other|3D Telemedicine|The intervention is a consultation conducted using a 3D form of telemedicine
45605442|NCT03522935|Drug|Elafin|Elafin subcutaneous.
45605443|NCT03522935|Drug|Placebo|Placebo subcutaneous.
45605444|NCT03110445|Biological|rVV-740CTA|non replicating recombinant vaccinia virus expressing 7 Cancer Testis Antigen (CTA) epitopes together with CD80 and CD154(40L)
45605445|NCT03382457|Device|Transcatheter Tricuspid Valve Reconstruction|Reconstruction of the tricuspid valve through a transcatheter approach
45605446|NCT03138681|Drug|Placebo|placebo is given intravenously twice a day for 14 days
45605447|NCT03138681|Drug|ATP|ATP (100mg) is given intravenously twice a day for 14 days
45756945|NCT00611351|Biological|anti-thymocyte globulin|
45911260|NCT02005705|Other|Outpatient Management of Low-risk Patients|"Labs will be obtained within 2-3 days of discharge from ED~Clinic visit will be scheduled within 3 days of discharge from ED~EGD will be scheduled within 7 days of discharge from ED~Phone follow-up at day 7 and 30"
45605448|NCT03138681|Drug|Phosphocreatine|Phosphocreatine (1g) is given intravenously twice a day for 14 days
45756946|NCT00611351|Drug|busulfan|
45756947|NCT00611351|Drug|cyclophosphamide|
45756948|NCT00611351|Drug|mycophenolate mofetil|
45911261|NCT02005705|Other|Inpatient Management of Low-risk Patients|"Labs will be obtained on day of discharge or day 2-3~EGD will be performed in the hospital~Phone follow-up at day 7 and 30"
45756949|NCT00611351|Drug|tacrolimus|
45756950|NCT00611351|Genetic|polymerase chain reaction|
45756951|NCT00611351|Genetic|polymorphism analysis|
45756952|NCT00611351|Other|flow cytometry|
45756953|NCT00611351|Other|laboratory biomarker analysis|
45756954|NCT00611351|Other|pharmacogenomic studies|
45911262|NCT02005718|Drug|Cholecalciferol|
45911263|NCT02005731|Device|Low intensity linear focused shockwave device ('Renova')|
45911264|NCT02005744|Drug|CKD-501|CKD-501 0.5mg, PO(per oral), once
45605449|NCT04839861|Behavioral|Mightier Family Games|Mightier Family Games includes five offline card games that can be played by two or more people. During card game play, one player wears the Mightier heart rate monitor, and can see a representation of their heart rate on a separate screen within the Mightier app. Each game includes elements that are tied to heart rate.
45605450|NCT04839861|Behavioral|Mightier online gameplay|"Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own."
45605451|NCT05392569|Other|Deep Brain Stimulation|"In addition to standard micro electrode recordings, we propose to measure:~surface potentials at the scalp (EEG) evoked by stimulation at the DBS electrode site~micro electrode potentials at the DBS electrode site evoked by stimulation at the median and tibial nerves~local field potentials at the DBS electrode site evoked by stimulation at the median and tibial nerves~surface EMG in the first dorsal interosseus and gastrocnemius muscles during stimulation at the DBS electrode site."
45605452|NCT04796103|Procedure|Dextrose Prolotherapy|In the patients in the prolotherapy injection group, at the 1st, 4th and 7th weeks, the insertion points of the ligaments and tendons that are sensitive with pressure around the knee (medial collateral ligament (2), lateral collateral ligament (2), quadriceps tendon (1) and patellar tendon (1)) A total of 6 ml of 5% dextrose, 1 ml each, will be applied periarticularly. In addition, home exercise program will be given to this group.
45605453|NCT04796103|Procedure|Serum Physiological Group (placebo control group)|In the patients in serum physiological injection group, at the 1st, 4th and 7th weeks, the insertion points of the ligaments and tendons that are sensitive with pressure around the knee (medial collateral ligament (2), lateral collateral ligament (2), quadriceps tendon (1) and patellar tendon (1)) A total of 6 ml of saline will be applied periarticularly. In addition, home exercise program will be given to this group.
45605454|NCT04376853|Device|Apple Watch Series 5|Digital monitoring via Apple Watch
45605455|NCT05392491|Other|No intervention|No intervention. It is an observational study
45605456|NCT05392257|Drug|Rituximab + zanubrutinib + lenalidomide|Rituximab at 375mg / m2, Day 0; Zanubrutinib 160mg bid continuously oral; Lenalidomide 25mg qd oral on days 1-21; 28 days as a course of treatment
45605457|NCT00002663|Biological|Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)|EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
45605458|NCT02240680|Drug|placebo|placebo matching linagliptin 5 mg
45605459|NCT02240680|Drug|linagliptin|5 mg once a day
45605460|NCT05391867|Drug|Lenvatinib|Tyrosine kinase inhibitor
45605461|NCT04247217|Radiation|HDR salvage brachytherapy|In patients receiving HDR salvage brachytherapy for locally relapsed prostate cancer serial biopsies will be performed at 4 different time points.
45605462|NCT02288975|Device|CytoSorb 300ml device (3804606CE01)|
45605463|NCT03110679|Biological|injection of autologous bone marrow concentrate|
45605464|NCT03110679|Biological|injection of hyaluronic acid.|
45756955|NCT00611351|Other|pharmacological study|
45756956|NCT00611351|Procedure|allogeneic bone marrow transplantation|
45605465|NCT02290067|Device|Blood glucose monitoring system (Omnitest 3)|
45605466|NCT02290067|Device|Blood glucose monitoring system (Omnitest 5)|
45605467|NCT02290067|Device|Blood glucose monitoring system (Omnitest 5D)|
45605468|NCT02289131|Procedure|Tooth Brushing Protocol|A 2-minute tooth brushing protocol, followed by a mouthwash rinse and application of moisturizer for a total of approximately 15 minutes.
45605469|NCT05391789|Drug|Ulinastatin|Patients would be given 400000 or 800000units of ulinastatin (specification: 100000 units / vial) dissolved in 50 ml of 0.9% normal saline intravenously for at least 1 hour, once every 8 hours. It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), halve the dose and continue to use it for 2 days, with a total course of treatment of at least 3 days
45605470|NCT05391789|Drug|Placebo|Patients would be given 50 ml of 0.9% normal saline intravenously for at least 1 hour once every 8 hours.It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), continue to use it for 2 days, with a total course of treatment of at least 3 days.
45605471|NCT02290301|Drug|gemigliptin|
45756957|NCT00611351|Procedure|allogeneic hematopoietic stem cell transplantation|
45756958|NCT00611351|Procedure|peripheral blood stem cell transplantation|
45756959|NCT05738343|Other|dieta mediterranea|nutritional education or Mediterranean food scheme
45756960|NCT00611897|Drug|N-acetylcysteine and ketamine|Active drug (N-acetylcysteine)
45756961|NCT00611897|Drug|placebo and ketamine|placebo N-acetylcysteine
45756962|NCT04401644|Diagnostic Test|Novel laser inferometry test for CORONA virus|detection of virus particles by light absorbtion patterns.
45756963|NCT05711823|Drug|Aprepitant in combination with granisetron and dexamethasone|Patients with unresectable hepatocellular carcinoma will receive aprepitant in combination with granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.
45756964|NCT05711823|Drug|Granisetron and dexamethasone|Patients with unresectable hepatocellular carcinoma will receive granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.
45756965|NCT03080714|Device|Topcon DRI OCT Triton (plus)|The Topcon DRI OCT Triton (plus) is an OCT machine used for diagnostic purposes
45756966|NCT03080714|Device|3D OCT-1 Maestro|The 3D OCT-1 Maestro is an OCT machine used for diagnostic purposes
45756967|NCT03080324|Drug|Fentanyl sublingual|Fentanyl sublingual
45756968|NCT03080324|Drug|Fentanyl ev|Fentanyl ev
45756969|NCT03080324|Drug|Placebo sublingual|Placebo sublingual
45756970|NCT03080324|Drug|Placebo ev|Saline
45605472|NCT04699071|Drug|pembrolizumab and lenvatinib|"All patients will receive oral lenvatinib daily plus intravenous pembrolizumab 3-weekly.~A cycle is 21 days. Allowances will be made for stepwise dose reductions of lenvatinib due to treatment-related toxicities.~Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, (CTCAE) Version 5.0.~Patients are planned to continue therapy until disease progression, intolerable toxicity, or withdrawal of patient consent."
45605473|NCT02289287|Behavioral|Self-Management group-intervention|At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). The group-intervention (SM program) will begin after enrollment of at least 4 participants to the intervention group, and within no longer than 5 weeks since enrollment. The intervention will include 12 weekly sessions, each session 2.5 hour long, and will be based on well-known SM interventions that were found effective for stroke patients in the U.S. Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
45605474|NCT02289287|Behavioral|Standard Care|At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). Standard care will include 'one-on-one' sessions in each paramedical discipline as given regularly in this setting (average of 15-20 sessions per patient). Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
45605475|NCT02239978|Behavioral|Postural perturbation|Participants will undergo between 50 and 100 postural perturbations (quick movements of the support surface) in multiple directions. These perturbations will be between 9 and 24cm, and between 18 and 56 cm/s depending on participant tolerance.
45605476|NCT02290379|Drug|TNX-201 35 mg|Drug: TNX-201 35 mg
45605477|NCT02290379|Drug|TNX-201 70 mg|Drug: TNX-201 70 mg
45605478|NCT02290379|Drug|TNX-201 140 mg|Drug: TNX-201 140 mg
45605479|NCT02290379|Drug|Racemic isometheptene 70 mg|Active Comparator: Racemic isometheptene 70 mg
45756971|NCT03080558|Drug|Indocyanine green|Use of Indocyanine Green during Rectal shaving by laparoscopy.
45756972|NCT03083834|Diagnostic Test|Cosyntropin stimulation test|At 0800h to 0900h, a 25 mm plastic intravenous line will be inserted in an antecubital vein. Then, 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). Serum cortisol and salivary free cortisol will measured just before ACTH administration and 30 minutes later.
45756973|NCT03404180|Procedure|Peripheral nerve block|All enrollees will have ultrasound-guided femoral and sciatic nerve blocks placed per current practice at research site. Single-injection obturator and lateral femoral cutaneous nerve blocks will also be performed.
45756974|NCT03404180|Drug|Intravenous Sedatives|Intravenous sedation using propofol or dexmedetomidine will be administered.
45605480|NCT02290379|Drug|Placebo|Drug: Placebo
45605481|NCT04688307|Behavioral|Motivational interviewing|Motivational interviewing for smoking reduction and adherence to diet and physical activity for obtaining ideal body weight
45605482|NCT02290457|Behavioral|core strength training|"Both training programs will last 6 weeks and comprise 2 training sessions per week with a total of 12 training sessions for each intervention group. Each training session will last 30 min, starting with a brief warm-up program mainly consisting of core strength exercises at moderate intensities and ending with a cool-down program (i.e., dynamic stretching). During the main part of training, both groups mainly conduct the big 3 exercises as described by McGill. These will include the curl-up, side bridge, and quadruped position. In other words, every single training session will consist of frontal, dorsal, and lateral core exercises. The only difference between the 2 intervention groups is that the CSTU protocol comprise core exercises that will be conducted on unstable elements (e.g., TOGU© DYNAIR PRO, THERA-BAND© STABILITY TRAINER), whereas the CSTS program will contain the same exercises on stable surface only."
45605483|NCT03139851|Drug|Cyclophosphamide 50mg|One tablet per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
45605484|NCT03139851|Drug|Pembrolizumab 100 MG in 4 ML Injection|IV infusion every 3 weeks. Pembrolizumab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
45605485|NCT02289365|Drug|2000 mg of JBM-TC4 per day|2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
45756975|NCT03404180|Procedure|Lateral femoral cutaneous nerve blocks|After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
45756976|NCT03404180|Procedure|Obturator nerve blocks|After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
45756977|NCT04761380|Diagnostic Test|balloon-based tongue pressure measurement device|The probe was inflated at a baseline pressure of 19.6 kilopascal (kPa). To measure MTP, the balloon was positioned on the anterior palate with the lips closed. Subjects raised their tongue and compressed the balloon onto the palate with maximal voluntary muscular effort for approximately 7s. The measurement was taken three times with a 1-min interval. The maximum value was recorded as the MTP.
45756978|NCT03402230|Drug|Broccoli Sprout/Broccoli Seed Extract Supplement|Given PO
45756979|NCT03402230|Other|Laboratory Biomarker Analysis|Correlative studies
45756980|NCT03402230|Other|Questionnaire Administration|Ancillary studies
46066628|NCT04323670|Device|"Selectra 3D guiding catheter"|His lead measurements
45756981|NCT02780609|Drug|Selinexor|Selinexor will be given orally 2 to 3 hours prior to high dose-melphalan IV infusion. Phase I: Dose escalation beginning with 40 mg to determine the recommended Phase II dose (RPh2D). Phase II: Treatment at RPh2D.
46066629|NCT00574951|Drug|motesanib diphosphate|
45605486|NCT02289365|Drug|3000 mg of JBM-TC4 per day|3 capsules of 500 mg JBM-TC4, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
45756982|NCT02780609|Drug|Melphalan|Melphalan 100 mg/m^2 IV over 30-45 minutes.
45756983|NCT02780609|Drug|Dexamethasone|Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1).
45605487|NCT02289365|Drug|3000 mg of PEG-400 per day|3 capsules of 500 mg polyethylene glycol 400 (PEG-400), oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
45605488|NCT03967288|Drug|Chloroprocaine Injection [Clorotekal]|1% chloroprocaine Hydrochloride Injection (50 mg/5 mL) for intrathecal use
45605489|NCT03967288|Drug|Bupivacaine Hydrochloride 0.75% Injection Solution|0.75% bupivacaine Hydrochloride injection in 8.25% dextrose for intrathecal use
45605490|NCT04636281|Other|Active and passive static stretching exercises|Different group of muscles will be stretched one by one, tricep brachii, bicep brachii, wrist exentsor etc
45605491|NCT03521609|Behavioral|Emotional intelligence intervention|Brief group intervention based on emotional intelligence
45605492|NCT02289443|Other|complete denture|Comparison of different procedures
45605493|NCT02289521|Device|Transcranial Direct Current Stimulation|"We will use a non-invasive, reversible transcranial direct current stimulation (tDCS) using a low-intensity electrical current. We will use Anodal and Sham tDCS.~Anodal: Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20min. To decrease current-induced injuries, at the beginning, the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out).~Sham: The parameters mimics the A-tDCS (i.e. electrode placement, fade-in and current intensity), except the duration of stimulation: the current will reach to 1.5mA in 30 seconds (fade-in) and lasts only for 30 seconds (to give the initial sensation of stimulation)."
45605494|NCT04167111|Dietary Supplement|Cholecalciferol|Vitamin D
45605495|NCT02290535|Procedure|patients|The 16-electrode belt will be applied to patient's chest. Following vital signs will be recorded: respiratory rate at rest breathing, heart rate, transcutaneous oxygen saturation. Then impulse oscillometry (IOS) will be performed in a sitting position. After that, subjects with cooperation willingness will get a body plethysmography. A spirometry / forced breathing maneuvers will be performed. All patients will receive 2 strokes salbutamol inhaler for bronchospasmolysis. Please note that inhalation of salbutamol is not study related. It is used in the clinical routine to examine the reversibility of the bronchial obstruction in patients with obstructive lung disease in course of the lung function test. Ten minutes later measurements described above will be repeated.
45605496|NCT02290535|Procedure|probands|Probands will receive the same treatment as patients, but without bronchospasmolysis.
45605497|NCT03962062|Drug|Moxidectin|2 mg tablets
45605498|NCT02289599|Drug|E2307|
45605499|NCT02289599|Drug|E2307 Matching Placebo|
45605500|NCT03140085|Biological|PYO Phage|Intravescial instillation
45605501|NCT03140085|Drug|Antibiotics|Oral application
45605502|NCT03140085|Other|Sterile bacteriology media|Sterile bacteriology media, with identical color as bacteriophage preparation
45605503|NCT02289677|Device|ATMOS Scope|Video-laryngoscopy 1
45605504|NCT02289677|Device|COOPDECH|Video-laryngoscopy-1
45605505|NCT02289677|Device|AirTraq|Optical-laryngoscopy
45605506|NCT03873844|Behavioral|Speed of Processing Training|"Speed of Processing Training (SOPT). Speed of processing training involves trainer-guided practice of computer-based video games. The games require the player to identify targets that are presented very briefly. SOPT has the primary aim of improving the fluid ability of mental processing speed such that trainees can process increasingly more information and increasingly more complex information over briefer periods of time. The training primarily involves practice with feedback. Trainers also offer suggestions, encouragement, and personalized modifications of difficulty for the trainee according to a specified protocol. At a display speed and task difficulty level tailored to their ability, trainees practice blocks of 16 trials. Trainees receive immediate feedback after each trial and see their total correct trials at the end of each block of trials. Trainers tell the trainees that their goal is to achieve performance of 10 to 12 correct trials for each training block."
45756984|NCT02780609|Procedure|Autologous Hematopoietic Cell Transplantation (HCT)|Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy.
45756985|NCT02780609|Drug|Fosaprepitant|Fosaprepitant at 150 mg IV on days -3 and -2.
45756986|NCT05345912|Drug|CG-745 IV Solution|CG-745 IV: Supplied as 125 mg/vial Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion
45756987|NCT05345912|Drug|CG-750 125mg capsule|CG-750 capsule: Supplied as 125 mg/capsule Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3
45756988|NCT05345912|Other|PO Placebo|PO Placebo: Supplied as placebo capsule (same appearance as in CG-750 Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3
45756989|NCT05345912|Other|IV Placebo: 0.9 % normal saline|IV Placebo: 0.9 % normal saline Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion
45756990|NCT03089918|Drug|11C-JNJ-63779586|Participants will receive IV injection with 11C-JNJ-63779586 in Part A and Part B.
45756991|NCT03080090|Behavioral|Aerobic exercise|Individuals will work with a YMCA personal trainer to engage in aerobic exercise 3 times a week (25 mins each) for 15 weeks.
45756992|NCT03080090|Behavioral|Smoking Cessation Intervention|Individuals will work with a national quitline to help them with their smoking cessation goals and make a quit attempt at week 5 of the program.
45452219|NCT02269228|Drug|Asasantin ER|
45452220|NCT02269228|Drug|Placebo|
45452221|NCT03722212|Diagnostic Test|METAglut1|A blood draw is performed on each patient for the METAglut1 test, and sent to Laboratoire CERBA, Saint-Ouen l'Aumône, France, for sample analysis.
45452222|NCT05626660|Other|Coronary angiography and percutaneous coronary intervention|Coronary angiography and percutaneous coronary intervention via radial approach
45452223|NCT01167244|Drug|BMS-690514|Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
45452224|NCT05624320|Drug|AGN-190584|miotic for treatment of presbyopia
45605507|NCT03873844|Behavioral|Transfer Package from CI Therapy|Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
45605508|NCT05391399|Device|Interlocking detachable coils system|Mainly used to block or slow blood flow in the peripheral vascular system during embolization procedures.
45605509|NCT05391399|Device|Interlock Fibered IDC Occlusion System|Mainly used to block or slow blood flow in the peripheral vascular system during embolization procedures.
45605510|NCT02239510|Drug|Senna|1 capsule (50 mg) Senna daily for 12 weeks
45605511|NCT02239510|Drug|Linzess|1 capsule (145 mcg) of Linzess once daily for 12 weeks
45605512|NCT04507581|Other|electrical impedance tomography during anaesthesia|Before induction of the anaesthesia, before the radiological procedure when the induction is terminated, after the termination of the radiological procedure, before transport to the Post anaesthesia Care Unite (PACU), and before the discharge from the PACU after 2 hours of monitoring ventilation distribution changes by thoracic electrical impedance tomography are measured (each measurement will last 1 min). For this, resulting potential differences are measured, and impedance distribution sampled at 30 Hz will be calculated by an automated linearized Newton-Raphson reconstruction algorithm (9). Relative change in poorly ventilated lung regions (silent spaces) and end-expiratory lung impedance (EELI) and measures of ventilation inhomogeneity such as the global inhomogeneity index will be calculated as described previously, using customised software (Matlab R2013a, The MathWorks, Nattick, Massachusetts, USA)(10-12).
45605513|NCT02290847|Behavioral|Cognitive Processing Therapy (cognitive only version; CPT-C)|CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions (Resick, Monson, & Chard, 2008; Resick & Schnicke, 1993). CPT is delivered in three phases: education, processing, and challenging. The manualized treatment focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
45605514|NCT03139929|Diagnostic Test|MSFP|MSFPhold and MSFParm
45605515|NCT04788004|Other|Online survey|There are no interventions planned for this study. This is an observational study only.
45605516|NCT04426929|Other|Conventional exercise therapy|Coldpack, TENS, Ultrasound agents and conventional exercise therapy (codman, wand, isometric exercise) will be applied.
45605517|NCT04426929|Other|Closed Chain Exercise Group|An exercise program consisting of 3 phases that runs from simple to difficult and includes closed kinetic chain exercises and proprioceptive exercises will be implemented in this group.
45605518|NCT04426929|Other|Video Based Exercise Group|Closed chain exercises based on video games will be applied. These exercises also include proprioceptive exercises.
45605519|NCT03521453|Other|PEPPER robot|Presence of a Robot (PEPPER Robot), designed and programmed to give informations, using a screen and vocal. All the patients in the second period will have access to,the robot, while waiting for the visit.
45605520|NCT02291081|Other|Comprehensive non invasive cardiovascular examination|"Comprehensive non invasive cardiovascular examination~Anamnesis with the participants~File recherche,Physical examination~Documentation of the cardiovascular and antiretroviral medical therapy~Electrocardiogram~Transthoracic echocardiography~Exercise electrocardiogram~Exercise Montreal Cognitive Assessment test~Exercise the Grooved Pegboard test~Blood collection~Questionnaire to quality of life and health economics"
45605521|NCT04057677|Behavioral|Bed Rest Intervention|The participant will remain in bed rest for 10 days at the clinical research unit at TRI, AdventHealth, Orlando.
45605522|NCT04057677|Behavioral|Exercise Program|During the first 4 weeks following bed rest, participants will perform a combination of aerobic and resistance exercise training with a certified exercise physiologist 3 days per week at the TRI exercise training facility.
45605523|NCT05384925|Other|comparison|abdominal surgery as a risk factor for diverticulosis
45605524|NCT03521297|Drug|Probiotic|UDCA combined probiotic
45605525|NCT03521297|Dietary Supplement|Placebo|UDCA combined placebo
45605526|NCT04393701|Procedure|Additional blood sampling|Additional blood sampling on blotting paper will be done in neonates in Normandy, France, compared to National neonatal screening program
45605527|NCT03521375|Procedure|Open Surgery|Conventional open surgery is undertaken through a single incision +/- rib resection and with rib spreading. The operation is performed under direct vision with isolation of the hilar structures (vein, artery and bronchus) which are dissected, ligated and divided in sequence and the lobe of lung resected. The procedures may be undertaken using ligatures, over sewing or with staplers. Lymph node management is undertaken in accordance with the International Association of the Study of Lung Cancer (IASLC) recommendations where a minimal of 6 nodes / stations are removed, of which 3 are from the mediastinum that includes the subcarinal station. The thoracotomy is closed in layers starting from pericostal sutures over the ribs, muscle, fat and skin layers.
45756993|NCT03086096|Device|LifePearl Microspheres loaded with Irinotecan|LifePearl Microspheres are embolisation microspheres for transcatheter chemoembolisation (TACE), that can be loaded with chemotherapeutic agents. In this registry, LifePearl Microspheres will be loaded with Irinotecan.
45756994|NCT03083600|Dietary Supplement|Plant-based Protein Hydrolysate 1|Plant-based Protein Hydrolysate 2 for 12-weeks
45756995|NCT03083600|Dietary Supplement|Plant-based Protein Hydrolysate 2|Plant-based Protein Hydrolysate 2 for 12-weeks
45756996|NCT03083600|Dietary Supplement|Placebo|Cellulose Placebo for 12-weeks
45756997|NCT03402152|Drug|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
45756998|NCT03402152|Drug|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
45756999|NCT03402152|Drug|Placebo|Placebo oral capsule
45757000|NCT05346146|Drug|Sintilimab; Gemcitabine; Albumin-paclitaxel|Sintilimab: 200mg IV Q3W D1; Gemcitabine: 1000mg/m2 IV Q3W D1,8; Albumin-paclitaxel：125mg/m2,IV,D1,D8,Q3W
45605528|NCT03521375|Procedure|Video Assisted Thoracoscopic Surgery (VATS)|VATS lobectomy is undertaken through one to four keyhole incisions without rib spreading. The use of 'rib spreading' is prohibited as this is the key intra-operative manoeuvre which disrupts tissues and causes pain (and is used in open surgery). The procedure is performed with videoscopic visualisation without direct vision. The hilar structures are dissected, stapled and divided. Endoscopic ligation of pulmonary arterial branches may be performed. The fissure is completed and the lobe of lung resected. Lymph node management is the same as described for open surgery. The incisions are closed in layers and may involve muscle, fat and skin layers. This definition of VATS lobectomy is a modification of CALGB 39802.
45605529|NCT03140163|Radiation|ULD-CT|Siemens Healthcare SOMATOM FORCE Ultra Low Dose chest CT
45605530|NCT03140163|Radiation|CXR|Conventional chest radiograph
45605531|NCT02289911|Other|Didactic training in the FAST|Participants in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
45605532|NCT04381299|Other|autologous platelet rich plasma|The cortex of selected ovary will be injected with 1 mL of autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
45605533|NCT04381299|Other|saline solution|The cortex of contralateral ovary will be injected with 1 mL of saline solution (SS). Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
45605534|NCT02291159|Device|DNHS ® (Dry Needling for Hypertonia and Spasticity)|Dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
45605535|NCT02291159|Device|Sham Dry Needling|Sham dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
45605536|NCT02294123|Other|3 tortillas and white bread|Type crossover clinical trial in adults 20-69 years. Three groups of participants were included for each category (n = 27 in each group): 1) adults with diabetes, b) adults with overweight c) clinically healthy adults. The glycemic and insulinemic index was measured for each group of participants given in random order the 3 types of Tortilla and white bread
45605537|NCT03139695|Diagnostic Test|Ultrasound|High resolution Ultrasound of the Diaphragm and Intercostal muscles
45757001|NCT03083522|Drug|Ojeok-San|Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
45757002|NCT03083522|Drug|Placebo|Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
45605538|NCT03984539|Behavioral|Cognitive Behavioural Therapy-Enhanced|CBT-E is a 20-session transdiagnostic eating disorders treatment based on the principles of cognitive behavioural therapy which has been developed over the past 40 years. The treatment focusses on tracking and modifying eating behaviours, providing psychoeducation, addressing overvaluation of weight and shape, body image, food restriction and restraint, emotion regulation, and relapse prevention.
45605539|NCT03984539|Behavioral|Cognitive Behavioural Therapy-Ten|CBT-T is a 10-session treatment based on cognitive behavioural therapy. It was developed based on clinical experience as well as core components of evidence-based versions of CBT for eating disorders, including CBT-E. The aim of the intervention is to provide only the hypothesized critical elements of CBT for eating disorders so that the interventions can be provided quicker.
45757003|NCT05346380|Device|Olympus VE2 NIR Imaging System|A prospective, (NSR), single-center feasibility study of the Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm.
45757004|NCT05346380|Drug|Indocyanine green|intravenous delivery of low-dose 0.15 mg/kg of ICG combined with Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm
45757005|NCT03084926|Drug|MP0274|Intravenous infusion of MP0274 as single agent at four planned dose levels, every three weeks until progressive disease, unacceptable toxicity or patient withdrawal for other reasons
45757006|NCT03083444|Diagnostic Test|Ultrasound|Measurement of thickness of radial artery wall thickness by ultrasound
45757007|NCT03087110|Biological|Matched sibling donor cord blood cell infusion|Single dose intravenous infusion of 12/12 HLA matched sibling donor cord blood cells (>1x10^7 cells/kg)
45757008|NCT03080246|Behavioral|Strength Training Exercise|
45757009|NCT00613379|Drug|PRO 140|10 mg/kg PRO 140, one IV dose (N=10)
45757010|NCT00613379|Drug|PRO 140|5 mg/kg PRO 140, one IV dose (N=10)
45757011|NCT00613379|Drug|Placebo|PBO, one IV dose (N=10)
45757012|NCT03088592|Device|Deep Brain Stimulation|Subjects will have awake or asleep DBS surgery with STN or GPi placement. Microelectrode recordings will define the electrophysiological target prior to lead implantation. Cortical recordings will be done using µECoG grids (2.0 x 0.8 cm) placed over the cortex through the same burr hole used for lead implantation. Neural recordings will be made continuously throughout the procedure: before, during, and after DBS, and at all levels of anesthesia. A pulse generator will be connected and implanted either during the operation or within 7-10 days post-operatively. Subjects will be admitted overnight for observation with anticipated discharge the next morning. The researchers will also be collecting other routine data points (length of surgery, stereotactic accuracy, length of hospital stay, and post-operative complications).
45757013|NCT03080168|Device|Actigraph|This is NOT an intervention but a monitoring device. All participants will wear an Actigraph for the duration of their inpatient stay, as well as complete paper and computer assessments.
45757014|NCT01271725|Drug|Vinorelbine 25 mg/m2 weekly|Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy
45757015|NCT01271725|Drug|Afatinib 40mg once daily (OD)|Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
45757016|NCT01271725|Drug|Paclitaxel 80 mg/m2 weekly|Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
45757017|NCT00587483|Drug|Lidocaine|Lidocaine is a class I (sodium channel block) antiarrhythmic drug
45757018|NCT00587483|Drug|Amiodarone|300 mg
45757019|NCT00587483|Drug|Placebo|Saline
45605540|NCT03140241|Procedure|PDR measurement|"PDR measurement at two standardized times perioperatively:~: anesthetized subject by propofol sedation until sedation depth monitor NeuroSense® (NeuroWave Systems Inc, Cleveland, OH) between 40-50~: administration of remifentanil via effect site target concentration (Minto-model) at 5 ng/ml, in the absence of adjustments in sedation depth"
45605541|NCT02291393|Device|80 lead ECG|
45605542|NCT03139773|Dietary Supplement|Control Breakfast Beverage|Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
45605543|NCT03139773|Dietary Supplement|Omega-3 Breakfast Beverage|Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
45605544|NCT02291471|Drug|T0001，10mg|
45605545|NCT02291471|Drug|T0001，20mg|
45605546|NCT02291471|Drug|T0001，35mg|
45757020|NCT04279886|Other|Three-dimensional scans|All included healthy volunteers received 6 three-dimensional scans, utilizing 3 different scanning systems (2 scans per system)
45757021|NCT03401060|Drug|Denosumab|Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
45605547|NCT02291471|Drug|T0001，50mg|
45605548|NCT02291471|Drug|T0001，65mg|
45605549|NCT02291471|Drug|T0001，75mg|
45757022|NCT03401060|Drug|Placebo|Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
45757023|NCT05247437|Behavioral|Digital Intensive Lifestyle Intervention|The FitD consists of 8 digital lessons on how to improve dietary and exercise habits using self-monitoring, goal-setting, cognitive restructuring, and other behavioral and cognitive strategies. The FitD app offers a virtual coach that guides the participant to complete the treatment.
45757024|NCT05247437|Behavioral|Digital Self-Help Control Condition|The digital self-help control condition consists of educational materials related to diet and exercise. The materials are open for access all at once. There is no guidance by a virtual coach or digital lessons.
45757025|NCT01270321|Drug|Everolimus|Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)
45444707|NCT04898283|Biological|10,000 MG01 +10,000 T521|Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupressaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
45444708|NCT04898283|Biological|30,000 MG01 +10,000 T521|Purified allergen extract polymerized with glutaraldehyde, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupressaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections.
45605550|NCT03899961|Drug|Oxytocin|Oxytocin 2.5 U i.v.
45605551|NCT03899961|Drug|Carbetocin|Carbetocin 100 µg i.v.
45605552|NCT02294201|Device|Spatial Repellent product with active ingredient|Spatial Repellent product
45605553|NCT02294201|Device|Active ingredient|Transfluthrin (Active ingredient)
45605554|NCT02294201|Device|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
45605555|NCT04079673|Procedure|Patient controlled epidural analgesia|Patient controlled epidural analgesia with marcaine 0.66mg/ml +fentanyl 1.75mcg/ml for postoperative pain control
45757026|NCT01270321|Drug|Pasireotide|Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
45757027|NCT01270321|Drug|Everolimus and Pasireotide|Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
45452225|NCT01037062|Drug|Entecavir|Tablet, P.O. 0.5, 1 mg, once daily
45605556|NCT04079673|Drug|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia with morphine 1mg/ml for postoperative pain control
45605557|NCT02291627|Device|MAC|direct laryngoscopy
45452226|NCT03687502|Drug|Sulfur hexafluoride lipid-type A microspheres|Contrast Enhanced Ultrasound of the appendix
45452227|NCT03655678|Biological|CTX001|Administered by IV infusion following myeloablative conditioning with busulfan
45452228|NCT03654976|Biological|HDM SLIT-tablet|Sublingual allergy immunotherapy tablet, for daily administration (1 tablet per day)
45452229|NCT03654976|Other|Placebo|Placebo sublingual tablet, for daily administration (1 tablet per day)
45605558|NCT02291627|Device|Coopdech|Video laryngoscopy
45605559|NCT02291627|Device|AirTraq|optical laryngoscopy
45605560|NCT02462486|Drug|Abicipar Pegol|Abicipar pegol intravitreal injection.
45605561|NCT02462486|Drug|Ranibizumab|Ranibizumab intravitreal injection.
45605562|NCT02462486|Other|Sham Procedure|Sham injection.
45605563|NCT05370963|Drug|Hylase versus dexmedtemodine|fluroscopic guided lumber epidural injection
45757028|NCT03400826|Drug|Simvastatin 40mg|The Treatment Group subjects will orally intake encapsulated Simvastatin 40 mg tablets daily for the 12 weeks duration with water in the evening.
45757029|NCT03400826|Drug|Placebo 40 mg|The Placebo group will orally intake encapsulated Starch 1500, 40 mg Placebo for 12 weeks duration with water in the evening.
45757030|NCT01271023|Device|Control-to-Range Automated Insulin Management System|The devices that will be used in the Closed-Loop Control System are standardized across all study sites and include the DexCom Seven Plus Continuous Glucose Monitor (CGM), the OmniPod insulin pump, and the FreeStyle blood glucose meter. The Closed-Loop Control System will be used during all 3 admission visits.
45757031|NCT03086486|Drug|Pretomanid|200mg tablets
45757032|NCT03086486|Drug|Linezolid|Scored 600mg tablets
45605564|NCT03521219|Drug|Apatinib|Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
45757033|NCT03086486|Drug|Bedaquiline|100mg tablets
45757034|NCT03086486|Drug|Placebo Linezolid|Scored 600 mg tablets
45605565|NCT05318157|Drug|AIT drops|Once a day
45757035|NCT00614315|Device|FLAIR™ Endovascular Stent Graft|The FLAIR™ Endovascular Stent Graft is designed to treat venous anastomotic stenoses of AV access grafts, providing both structural support of the site following angioplasty (stent), and a barrier to locally recurrent flow-limiting neointimal tissue growth (covering/graft).
45605566|NCT05318157|Drug|Clarityne, Rhinocort and Emedastine Difumarate Eye Drops|The following drugs were permitted as allergy symptoms-relieving medications according to the actual needs in groups: Clarityne, Rhinocort and Emedastine Difumarate Eye Drops, Once a day
45605567|NCT02294279|Drug|Qvar (100 mcg)|2 puffs twice daily; 400 mcg daily over 4 weeks treatment period
45605568|NCT03136653|Biological|MP0250 plus BOR+DEX|"6 mg/kg or 8 mg/kg or 12 mg/kg of MP0250, IV (in the vein,) on day 1 of each 21 day cycle. Bortezomib and Dexamethasone according to label.~Number of Cycles: until progression or unacceptable toxicity develops."
45605569|NCT03110237|Other|Control Balance Training (BT) class|Circuit training class with 11 stations, including: step-ups, ball kicking, balance beam, sit to stand, walk and carry, tandem walking, walking over a mat, walking up a ramp, walking at different speeds, speed walk, dual task walking.
45605570|NCT03110237|Other|Fallproof Balance Training (BT) class|There are four categories of exercises in this approach including: center of gravity control training (e.g. multi-directional weight shifts in standing, standing with altered base of support), multisensory training (e.g. standing on compliant surfaces, eyes open/closed), postural strategy training (e.g. resisted perturbation to facilitate ankle, hip or step strategy), and gait pattern variation training (e.g. walking with altered base of support , walking over and around obstacles). Each training category will be allocated 5 minutes with two exercises in each category. An additional 5 minutes will be allotted for games to challenge balance (balloon volleyball, pass the potato, circle soccer).There will be opportunity for group discussion and observational learning.
45605571|NCT03110289|Other|superdonor FMT|"Fecal microbiota transplantation (FMT) is the transfer of feces from a healthy superdonor to the patient."
45605572|NCT03110289|Other|autologous FMT|Fecal microbiota transplantation (FMT) with feces from the patient him/herself
45605573|NCT02294357|Drug|Carfilzomib|
45757036|NCT02287779|Drug|SHP626|
45757037|NCT02287779|Drug|Placebo|
45757038|NCT00732901|Drug|Escitalopram|Escitalopram: once daily 10 mg on days 1-3, 20 mg on days 4-24 and 10 mg on days 25-28
45757039|NCT00732901|Drug|Placebo|Once daily days 1-28
45757040|NCT03083210|Drug|Lanreotide|Lanreotide, at a dose of 120mg subcutaneous injection every 28 days.
45757041|NCT05689034|Drug|Azvudine|Azvudine po. 5mg daily for 7 days
45757042|NCT05689034|Drug|Placebo|Placebo po. 5 tablets daily for 7 days
45757043|NCT00616109|Drug|sunitinib|Sunitinib will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2-week rest period to form a complete cycle of 6 weeks.
45757044|NCT02330523|Device|allograft + x-link collagen membrane|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Allograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. X-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
45911265|NCT02005757|Drug|Bredinin tablet 150mg|Bredinin 150mg qd vs Bredinin 50mg tid
45911266|NCT02005757|Drug|Bredinin tablet 50mg|Bredinin 150mg qd vs Bredinin 50mg tid
45911267|NCT02005770|Drug|Sevoflurane|
45911268|NCT02005770|Drug|Propofol|
45757045|NCT02330523|Device|xenograft + non-x-link collagen|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Xenograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. Non-x-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
45757046|NCT05688878|Device|Threshold electrical stimulation|Threshold stimulation (EDS) is based on low-intensity (<100 Hz) and long-duration current and is applied with superficial electrodes. Threshold stimulation provides a natural proprioception by depolarizing the sensory and motor nerves without causing any muscle contraction.This treatment will be applied for 4 weeks, 3 days a week, for 1 hour.
45757047|NCT03390764|Procedure|4:1 closure group|In this arm the incisions are closed by the 4:1-technique
45757048|NCT03390764|Procedure|RTL plus 4:1 closure group|In this arm the incisions are closed by a reinforced tension-line suture in addition to the 4:1-technique
45757049|NCT04401488|Biological|Prevenar 7 and Prevenar 13|pneumococcal conjugate vaccines
45911269|NCT02005783|Drug|DBD|DBD:one dose of medicine twice per day, orally
45911270|NCT02005783|Drug|Epirubicin|Epirubicin:90mg/m2, d1, q3w*4
45605574|NCT02294357|Drug|Dexamethasone|If the patient was receiving steroids at the equivalent of > 8 mg of dexamethasone weekly either intravenously (IV) or Per Orem (PO) in combination with carfilzomib, the same drug(s), dose(s) and schedule(s) of steroids will be continued. If the patient was not receiving steroids or was receiving less than the equivalent of 8 mg of dexamethasone weekly, then he/she will be given 8 mg of dexamethasone (IV or PO) prior to each carfilzomib administration.
45605575|NCT02294357|Drug|Prednisone|f the patient was receiving prednisone, at the equivalent of > 8 mg of dexamethasone weekly PO in combination with carfilzomib, he/she will continue to receive prednisone at the same dose and schedule.
45605576|NCT02294357|Drug|Methylprednisolone|If the patient was receiving methylprednisolone at the equivalent of > 8 mg of dexamethasone weekly either IV or PO in combination with carfilzomib, he/she will continue to receive methylprednisolone at the same dose and schedule.
45605577|NCT02294357|Drug|Lenalidomide|given at same dose and schedule as patient was receiving while being treated with twice weekly carfilzomib at 27 mg/m2
45605578|NCT02294357|Drug|Pomalidomide|administered PO at 4mg daily on days 1-21 of a 28 day cycle
45605579|NCT03880539|Drug|bezlotoxumab|Adding BEZLO to SOC oral VAN pulse/taper
45605580|NCT03880539|Drug|Vancomycin Oral|SOC vancomycin pulse/taper
45605581|NCT03843021|Other|VAD Infection Prevention Survey|Healthcare providers caring for VAD Therapy recipients will answer questions regarding processes of care at their institutions.
45605582|NCT03518021|Drug|Naloxone, intranasal|"Active compound naloxone 14 mg/ml, (±10%). Nasal spray will be administered with one puff (100 microL ±10%) in one nostril (1.4 mg dose) using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued."
45605583|NCT03518021|Drug|placebo, intranasal|"Same spray but without naloxone. Nasal spray will be administered with one puff (100 microL +/- 10%) in one nostril using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued."
45605584|NCT03518021|Drug|Naloxone, intramuscular|Intramuscular comparator Naloxone Hydrochloride 0.4 mg/ml will be administered as a 2 ml intramuscular (IM) injection in the deltoid muscle, total dose of 0,8 mg naloxone IM
45605585|NCT03518021|Drug|placebo, intramuscular|Intramuscular Sodium Chloride Injection 9mg/ml, will be administered as a 2 ml intramuscular injection in the deltoid muscle
45605586|NCT02495948|Device|Lotrafilcon B contact lenses|
45605587|NCT02495948|Device|Samfilcon A contact lenses|
45605588|NCT02495948|Device|Hydrogen peroxide solution|Used as a cleaning, disinfection, and storage solution for silicone hydrogel and soft contact lenses
45605589|NCT02495948|Device|Saline solution|Used for rinsing contact lenses, as needed
45605590|NCT03132857|Other|Assess the state of knowledge of the subjects falling or at risk, their risk of recurrence or first episode, compared to medical knowledge.|Assess the state of knowledge of the subjects falling or at risk, their risk of recurrence or first episode, compared to medical knowledge.
45605591|NCT03734289|Behavioral|Caregiver Coaching|Online coaching sessions will occur weekly for 6 weeks. Web-based courses containing instructional materials that deal with preventing and reducing care resistant behavior (CRB) within intimate care (dressing, bathing, toileting) and treatment regimens (medication, therapeutic activities) after the initial study visit. The NeuroNS-Care intervention is an innovative distance-learning , internet based, family caregiver coaching program; one for the caregivers of persons with dementia and one for the caregivers of persons recovering from TBI. It will be delivered using Instructure's Canvas™ web-based platform.
45605592|NCT03132935|Procedure|Telemedical support|Telemedical support by a physician in a telemedicine centre
45605593|NCT02461628|Behavioral|Malaria RDT & conditional voucher for ACT from retail sector|Trained community health volunteers will offer eligible household members free malaria rapid diagnostic tests and a voucher allowing the purchase of a qualified ACT at a reduced fixed price in the retail sector conditional on a positive test
45605594|NCT03110211|Procedure|Physical Therapist Evaluation|Participants assigned to this group will receive an initial evaluation and treatment recommendations by a physical therapist.
45605595|NCT03110211|Procedure|Primary Care Physician|Participants assigned to this group will receive an initial evaluation and treatment recommendations by a primary care physician.
45605596|NCT02294513|Device|Standard audiologic rehabilitation (incl. HI)|The intervention consists of standard audiologic rehabilitation in which participants are fit with at least one hearing instrument (HI).
45605597|NCT02294591|Drug|N-acetylcysteine|Add-on treatment of NAC
45605598|NCT02294591|Drug|Placebo|Add-on treatment of placebo
45605599|NCT03110367|Behavioral|Pain Reframing Intervention|Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways (e.g., using more open-ended questions, to follow in on children's answers by providing new details about the event, to talk more about emotions, and to praise children's answers).
45757050|NCT04761536|Other|Rectal cancer case centralization|In November 2016, the decision to centralize rectal cancer patients to only one surgical unit was taken, with only two surgeons performing the procedures. Furthermore, a close collaboration with local Gastroenterology Units and General Practiotioners was started in order to increase colorectal cancer case referral to our unit. At the same time, we decided to promote the use of laparoscopy and to implement ERAS protocol in our colorectal surgery practice.
45911271|NCT02005783|Drug|Cyclophosphamide|Cyclophosphamide:600mg/m2, d1, q3w*4
45911272|NCT02005783|Drug|Docetaxel|Docetaxel:75mg/m2, d1, q3w*4
45605600|NCT03110367|Behavioral|Attention Control Group|Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience.
45911273|NCT02005796|Other|Dietary intervention|
46066630|NCT02584816|Biological|BRV-PV Lot A + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
45605601|NCT03521063|Drug|Budesonide|Drug: Budesonide inhalation suspension
45605602|NCT03521063|Drug|Poractant Alfa|Drug: Poractant alfa intratracheal suspension
45605603|NCT03521063|Drug|Saline|Sodium chloride injection 0.9%
45605604|NCT02294669|Device|Turris Facet Fuser|Study participants will have a Turris Facet Fuser inserted into the contralateral facet joint, instead of a state of the art contralateral pedicle screw system.
45605605|NCT04056273|Other|Guide sheath group|After the lesion was found by rEBUS, insert the rEBUS into a guide sheath and re-locate the lesion. Fix the guide sheath at that position and perform transbronchial biopsy and brushing through the guide sheath.
45605606|NCT04056273|Other|Conventional group|After the lesion was found by rEBUS, mark the location and depth. Insert the biopsy forceps and cytology brush to the marked depth of that bronchiole to perform biopsy and brushing.
45605607|NCT03520985|Drug|Pomalidomide|"Pomalidomide (4 mg p.o.) will be administered on every other day of each 28-day treatment cycle.~Treatment duration:~Treatment cycles are repeated until confirmed disease progression."
45605608|NCT03520985|Drug|Dexamethasone|"For patients ≤ 75 years of age:~Low-Dose Dexamethasone (40 mg p.o.) will be administered once per day on days 1, 7, 15, and 21 of a 28-day cycle.~For patients > 75 years of age:~Low-Dose Dexamethasone (20 mg p.o.) will be administered once per day on days 1, 7, 15, and 21 of a 28-day cycle.~Treatment duration:~Treatment cycles are repeated until confirmed disease progression."
45605609|NCT04010721|Device|Experiment 1|Stimulation of one electrode at a time
45605610|NCT04010721|Device|Experiment 2:|Stimulation in groups of 4, 8 and 12 electrodes
45605611|NCT04010721|Device|Experiment 3|Stimulation total duration from 10 to 600 ms
45605612|NCT03517943|Drug|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
45605613|NCT03517943|Drug|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
45605614|NCT04005495|Behavioral|Teaching kitchen program|The teaching kitchen program will include five 4-hour Saturday classes every other weekend over the course of 10 weeks (5 sessions totaling 20 hours of instruction). It will be taught by subject matter experts from the Emory University faculty and staff as well as potentially from the community. The classes will include the scientific rationale, practical applications, and recommendations for implementing self-care components into participants' daily lives. Experiential learning will include hands-on cooking demonstrations, mindfulness-based lunches, a yoga session, and a group exercise session. Rather than being prescriptive, the lectures and demonstrations are geared to inspire self-designed and personalized alterations in dietary patterns and behaviors that will match participants' culture, preferences, and health conditions. Biometrics and survey instruments will be assessed at 4 times: at baseline, after the 10-week program, and at 6 and 12 months after the program.
45605615|NCT02294747|Device|Sliding Hip Screw with Trochanteric Stabilization Plate|
45605616|NCT02294747|Device|Sliding Hip Screw without Trochanteric Stabilization Plate|
45605617|NCT03541005|Dietary Supplement|Obex|After concluded the six months of treatment, patients will be follow-up during six months without consumption of Obex
45605618|NCT03541005|Dietary Supplement|Placebo|After concluded the six months of treatment, patients will be follow-up during six months without consumption of the placebo.
45605619|NCT02291783|Drug|HTL0009936|Single dose
45605620|NCT02291783|Drug|HTL0009936 placebo|Placebo single dose
46066631|NCT02584816|Biological|BRV-PV Lot B + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
45444709|NCT04898283|Other|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients
45444710|NCT03561688|Device|Foot orthotics|Insoles for shoes
45605621|NCT03445923|Other|Time lapse monitoring (KID Score)|The unique information that is obtainable from taking Pictures each 10 minutes throughout the development of the embryos will be used in the form of a special score (KID score). The score is comprised out of several key developmental parameters.
45605622|NCT02291939|Procedure|Parotidectomy|Surgical Intervention with the FMwand Surgical System
45605623|NCT03138993|Behavioral|Patient decision aid|Web-based patient decision aid plus a paper workbook.
45605624|NCT03138993|Behavioral|General sleep education|Web-based information about sleep plus a paper workbook
45605625|NCT02294825|Procedure|various surgical procedures in endometriosis|Shaving, disc excision and colorectal resection; ureterolysis or ureter resection; bladder resection; ablation of endometriomas using plasma energy; excision and ablation of deep and superficial lesions
45605626|NCT03138525|Other|Blood sampling (MS)|Blood samples will be collected before initiation of Ocrelizumab treatment and after 6 and 12 months of treatment.
45605627|NCT03138525|Other|Blood sampling (controls)|Blood samples will be collected once at enrollment.
45605628|NCT02294903|Procedure|Coiled Bipolar Radiofrequency Ablation|Radiofrequency ablation by use of bipolar electrodes
45605629|NCT03383211|Other|RNAseq|Transcriptome profiling of peripheral blood using RNA sequencing technology
45605630|NCT03517787|Other|FES+TE|Group receive FES+therapeutic exercise during 6 weeks (twice a week). Altogether 8 exercises are conducted, each done 3 sets and 12 repetitions during first three weeks and 4 sets during last three weeks of intervention).
45605631|NCT03517787|Other|TE|Group perform only therapeutic exercise. Exercises are the same between all 4 groups.
45605632|NCT03517787|Other|REF-FES+TE|Group perform FES+TE, but only participate in 1 session to collect reference data.
45605633|NCT03517787|Other|REF-TE|Group perform only therapeutic exercise, but only participate in 1 session to collect reference data.
45605634|NCT03823521|Drug|Cardioplegia Solution|Cardioplexol™ will be adminstered in cardiac surgery as cardioplegic solution
45605635|NCT03520907|Drug|Transversalis Fascia Plane Block|block will be performed under real-time ultrasound guidance
45605636|NCT03520907|Drug|Ilioinguinal/iliohypogastric Nerve Block|block will be performed under real-time ultrasound guidance
45444711|NCT03561688|Device|Standard insole|Sham foot orthotic
45444712|NCT01304433|Drug|Venofundin 6% / Tetraspan 6%|Venofundin 6% / Tetraspan 6%
45605637|NCT03136341|Drug|Abobotulinum toxin A|Dosing will be determined at each study visit based upon muscles involved
45605638|NCT03136341|Other|Placebo|Dosing will be determined at each study visit based upon muscles involved
45605639|NCT04465175|Drug|Magnesium Sulfate|Second dose magnesium sulphate infusion over one hour
45605640|NCT04465175|Drug|Placebo|Normal saline (2.5 ml/kg) infusion over one hour
45605641|NCT03158883|Drug|Avelumab|Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 [±2] days).
45605642|NCT03158883|Radiation|Stereotactic ablative radiotherapy (SAR)|SAR: the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated.
45605643|NCT02292017|Device|Embolization of intracranial aneurysm|Cerebral angiogram will be performed, target aneurysm measurements are performed including dome height, width, and depth as well as the neck length. Aneurysm volume will be calculated. During the embolization, framing, filling, and finishing should be done with Target Coils. In the event of aneurysms with a wide neck a Neuroform Stent may be used to ensure the best clinical and angiographic outcome. Immediate post procedure angiography is performed using the same pre-treatment views to assess results and complications.
45605644|NCT03041649|Other|GT button change - Mic-Key|After 2 months with each button, parents will be asked which button they prefer at the 4-month post-operational follow-up visit.
45605645|NCT03041649|Other|GT button change - Mini One|After 2 months with each button, parents will be asked which button they prefer at the 4-month post-operational follow-up visit.
45605646|NCT03520829|Device|Intuitive Plan|dosimetric planning software
45605647|NCT03138291|Device|Somnodent|Each pregnant women will be treat with a Somnodent
45757051|NCT00249769|Biological|Live Japanese encephalitis vaccine SA 14-14-2 (LJEV)|Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) is lyophilized powder that looks like a milky-white crisp cake. After reconstitution, it turns into a transparent orange red liquid. Its container is a vial. It is stored and transported between 2°C to 8°C and protected from light. Each single human dose is 0.5 ml containing not less than 5.4 log particle flux unit (PFU) of live Japanese Encephalitis (JE) virus. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 200411129-3 manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China.
45757052|NCT00249769|Biological|Measles Vaccine (MV)|"The Serum Institute of India (SII) measles vaccine provided routinely in the Expanded Program on Immunization (EPI) of the Philippines was the measles vaccine provided to the study participants. The vaccine met the requirements of the World Health Organization (WHO).~SII measles vaccine contained live attenuated (freeze-dried) Edmonston-Zagreb strain measles virus propagated on human diploid cells (HDC). Each single human dose when reconstituted in a volume of 0.5 ml contains no less than 1000 Cell culture infectious dose 50% (CCID50) of live virus particles. SII measles vaccine is presented as a yellowish-white dry cake. The vaccine should be reconstituted with the diluent supplied (sterile water for injection). A sterile disposable syringe and needle are supplied separately. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 2979."
45605648|NCT02292095|Procedure|TAPB group|transverse abdominis plane block will be conducted by ultrasound and a single-injection of 20ml 0.75% ropivacaine will be conducted for nerve block at the end of surgery.After surgery,participants in this group will also receive patient controlled intravenous analgesia.
45911274|NCT02005809|Procedure|second look endoscopy|Second look endoscopy includes observation or prophylactic bleeding control of ESD site.
45911275|NCT02005822|Drug|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
45605649|NCT02292095|Procedure|PCIA group|The formula of patient controlled intravenous analgesia included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total, they received a loading dose of 2 ml followed by an infusion rate of 1 ml/h with bolus of 2 ml, the lock time was set at 15 min
45605650|NCT03138447|Device|Basal Insulin Titration Application|"Healthcare Providers (HCP) and the principal investigator (PI) will use an HCP portal to initiate a basal insulin titration algorithm. HCPs can customize the titration algorithm for every participant. Once a participant is prescribed an algorithm, they can download a mobile app on their phone with their HCPs corresponding titration plan. The app will prompt participants to enter their fasting glucose daily. Based on their fasting glucose and their HCPs titration plan, the application will display the participants daily basal insulin dose."
45605651|NCT03517709|Other|Primary Care Physician Management of blood pressure|"You will receive a 30-minute education session about your blood pressure medications and the need to take them every day.~Your primary care physician will make recommendations on your optimal target blood pressure range and medication recommendations. ."
45605652|NCT03517709|Device|Withings Smart Blood Pressure Monitor|We will use the Withings Smart Blood Pressure Monitor for daily blood pressure measurements.
45605653|NCT03136575|Behavioral|Qigong|a 30 minutes exercise program, 3 times a week and lasts for 6 weeks during radiotherapy course
45605654|NCT03136575|Behavioral|Wait-list control|patients enrolled in this group are informed orally to have exercise only and are arranged in a waiting list
45605655|NCT02429791|Drug|DTG 50 mg|Participants will take one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet will contain 52.62 mg dolutegravir sodium salt, which is equivalent to 50 mg dolutegravir free acid.
46066632|NCT02584816|Biological|BRV-PV Lot C + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
45605656|NCT02429791|Drug|RPV 25 mg|Participants will take one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet will contain 27.5 mg of rilpivirine hydrochloride, which is equivalent to 25 mg of RPV.
45605657|NCT02429791|Drug|CAR|CAR will include following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI
45605658|NCT03109899|Behavioral|Sex Pro mobile Application|Mobile mHealth app that provides HIV risk assessment, home HIV/STI testing options, and PrEP uptake support for young Black MSM.
45605659|NCT03109977|Drug|Zr-DFO-pertuzumab PET/CT|Zr-DFO-pertuzumab studies will be performed as hybrid PET/CT examinations with known HER2-positive malignancy
45605660|NCT03520673|Diagnostic Test|Urodynamics|All the men in the study will receive the urodynamics procedure as a reference test.
45605661|NCT03022539|Radiation|Repeat CT scan|
45605662|NCT03520595|Drug|Arnica 200 drug 3 pills,3 times daily for 3 days|CLP with ostectomy done in patients whose biologic width and crown height is insufficient
45605663|NCT03520595|Drug|Diclofenac Sodium 50mg twice daily|CLP with ostectomy done in patients whose biologic width and crown height is insufficient
45605664|NCT03520595|Drug|Placebo pills and distilled water 3 pills,3 times daily|CLP with ostectomy done in patients whose biologic width and crown height is insufficient
45605665|NCT03517553|Device|EMS users in ESRD|use of passive electrical muscle stimulation on quadriceps muscle 3 times a week for patients in dialysis
45605666|NCT02295137|Procedure|Using pre-procedural CTA to guide advanced EVAR procedure|
45605667|NCT02295215|Other|Exercise|Exercise Training for 4 months
45605668|NCT03520439|Drug|Mifepristone|Oral mifepristone 10mg (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
45605669|NCT03520439|Drug|Placebo|Oral Placebo Oral Tablet 1# (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
45605670|NCT04543227|Behavioral|Opioid Use 90-Days Post Treatment|Survey conducted 90-days post treatment to determine use of opioid medications in relation to burn or knee arthroscopy pain
45605671|NCT04542993|Dietary Supplement|Zinc Picolinate|Zinc Picolinate (50 mg PO TID x 5 days)
45605672|NCT04542993|Dietary Supplement|Resveratrol|Resveratrol 2 grams po BID x 5 days
45605673|NCT04542993|Dietary Supplement|Zinc Picolinate Placebo|Zinc Picolinate Matched Placebo PO TID x 5 days
45605674|NCT04542993|Dietary Supplement|Resveratrol Placebo|Resveratrol Matched Placebo PO BID x 5 days
45605675|NCT03520361|Drug|Oral sulfate solution (OSS)|Compositions/177ml : Sodium sulfate 17.5g, Potassium sulfate 3.13g, Magnesium sulfate 1.6g
45605676|NCT03520361|Drug|2L PEG/Asc|Compositions/1L : Sodium chloride 2.89g, Potassium chloride 1.015g, Anhydrous sodium sulfate 7.5g, Polyethylene glycol 3350 100g, Ascorbic acid 4.7g, Sodium ascorbate 5.9g
45605677|NCT03517397|Behavioral|Mobile Contingency Management|Participants will be offered 6 counseling sessions, nicotine replacement therapy, and a smartphone app that remotely verifies participant identity and smoking abstinence and automatically credits a gift card account for evidence of smoking abstinence.
45605678|NCT03002415|Other|Guided water intake|"Verbal and written guidelines will be given for the patient to ingest the daily volume of water calculated by the weight (30 ml / kg / day) for 14 days. Patients will receive an acrylic glass with a mark in 200 ml and will be instructed to take the number of glasses a day corresponding to the calculated volume (30 ml / kg). Patients will also receive a leaflet indicating how many glasses of water they will need to take. They will also be instructed to mark with an X the number of glasses of water that they actually drank daily during the fourteen days of intervention."
45605679|NCT03002415|Other|Placebo - free demand water intake|Patients are instructed to drink water and other liquids on demand. Patients are asked to note on a food record food and liquids and quantities consumed throughout the day. Patients are advised to make a four-day food diary out of the 14 days.
45605680|NCT02132611|Device|Diamondback 360® Coronary OAS Micro Crown|The Diamondback 360® Coronary OAS Micro Crown consists of a diamond-coated crown mounted to a shaft. The OAD ablates occlusive material in order to facilitate stent delivery. During orbit, forces press the crown against the coronary plaque, reducing calcified plaque on the vessel wall.
45911276|NCT02005835|Other|Community based peer support|"Community-based Support from Peer Mothers (Expert mothers):~Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support in community prior to each visit Monthly support groups in community Home visits for each missed appointment"
45911277|NCT02005835|Other|Facility-based Peer Support|"Facility-based Peer Support to provide the following at the clinic~Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support at facility Weekly support groups provided in clinic Phone call, SMS, or home visit for each missed appointment"
45605681|NCT02292173|Drug|Trametinib|"Dose Escalation:~Level 1: 1 mg daily. Level 2: 1.5 mg daily. Level 3: 1.5 mg daily. Level 4: 2 mg daily.~Dose Expansion:~Maximum Tolerated Dose (MTD)"
45911278|NCT02005848|Biological|Alpha-1 Antitrypsin|
45911279|NCT02005848|Other|Placebo|Placebo
45605682|NCT02292173|Drug|Sorafenib|"Dose Escalation:~Level 1: 200 mg twice daily. Level 2: 200 mg twice daily. Level 3: 400 mg twice daily. Level 4: 400 mg twice daily.~Dose Expansion:~Maximum Tolerated Dose (MTD)"
45605683|NCT02295293|Drug|Rhus Coriaria L. (Rhus)|500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks
45605684|NCT02295293|Drug|Placebo|Placebo capsule: 1 capsule twice daily for 6 weeks
45605685|NCT03520205|Procedure|Quadratus Lumborum Block|Bilateral block using ultrasound will be performed before surgery and after surgery on patient using Stimuplex 100mm needle with Bupivacaine 0.25% 0.4 mL/kg, maximum dose 25 mL each side under general anaesthesia
45605686|NCT03520205|Procedure|Continuous Epidural|Patient will be given 6 mL/hour of Bupivacaine 0.25% for intraoperative analgesia and continued epidural 6 mL/hour Bupivacaine 0,125% as postoperative analgesia in 24 hours.
45605687|NCT03517319|Drug|Normal Saline 0.9% 1.2 ml|
45605688|NCT03517319|Drug|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U|
45605689|NCT03517319|Drug|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U|
45605690|NCT03517319|Drug|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U|
45605691|NCT03517319|Drug|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U|
45605692|NCT03133169|Diagnostic Test|blood sample|blood sample for measuring liver and kidney function, CBC, ferritin level and erythrocyte glutamine level
45605693|NCT03133169|Diagnostic Test|Tricuspid regurge velocity|Tricuspid regurge velocity will be measured by doppler echocardiography denoting the pulmonary hypertension risk in children
45605694|NCT03517241|Diagnostic Test|functional magnetic resonance imaging (fMRI)|Retinotopic mapping using functional magnetic resonance imaging (fMRI) is based on MR images acquired with blood-oxygenation-level-dependent (BOLD) contrast to reveal areas of neuronal activity in the visual cortex
45605695|NCT03517241|Diagnostic Test|Microperimetry (MP)|MP allows localized testing of retinal sensitivity of foveal, parafoveal and even more peripheral macular regions
46066633|NCT02584816|Biological|ROTARIX + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week (Third dose-Placebo)
45757053|NCT05688800|Device|conventional therapy|Participants in control group will receive conventional physical therapy treatment including Conventional TENS high frequency (90-130hz) low intensity according to the patient sensation for 30-45 min(Gozani, 2019) , continuous ultrasound with frequency 1 MHz and intensity 0.8 W/cm 2 will be applied by slow circular perpendicular movements with slightly deep pressure. Application time was 5 minutes at each side of the level of C7_T4 along the medial borders of the scapulae width, infra-red radiation will be four 15 minutes and directed perpendicular to the inter-scapular area, centered at the level of C7_T4 long and between the 2 medial borders of the scapulae width . Also combined stretching and strengthening exercise will be added due to its greater pain-relieving effect
45757054|NCT05688800|Other|Experimental group 1 : pressure release technique|Participants who are assigned to this group will receive conventionalphysical therapy treatment in addition to pressure release technique. the participant will be positioned either sitting or prone position according to his preferred position, the researcher will apply the pressure release procedure by a pressure below the PPT dependent onsoft tissue release. When the researcher detected a reduction in soft tissue resistance, the amount of compression will be increased. The pressure should -33- be nonpainful, applied at slow rate, and will maintained until release of tissue barrier. Further pressure was increased to reach a new barrier. The pressure will last 60 seconds. With the thumb or the second and third fingers, the non-painful manual therapy approach was applied to the active MTrPs of therhomboid muscle
45605696|NCT03517241|Diagnostic Test|Optical coherence tomography (OCT)|Optical Coherence Tomography (OCT) is a non-invasive diagnostic technique that renders an in vivo cross sectional view of the retina.
45911280|NCT02005900|Drug|Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART|Multicenter, prospective, double-blind, randomized study of 48 weeks duration, in which the effect of 4 g daily of DHA vs 4 g daily of placebo (oleic acid) are studied on modulation of the Triglycerides and other lipids in patients with HIV infection under HAART treatment.
45911281|NCT02005926|Procedure|Wire-localized abnormal node|Before the sentinel lymph node biopsy (SLNB) operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance to localize the abnormal node. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
45605697|NCT03517241|Diagnostic Test|Blue light fundus autofluorescence imaging (FAF)|Fundus autofluorescence imaging (FAF), is a non-invasive diagnostic technique focusing on the fluorescent properties of pigments in the retina to generate images.
45605698|NCT03517241|Diagnostic Test|Visual testing|Best-corrected visual acuity will be measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. Reading acuity and reading speed will be examined using Radner Reading Charts. Reading acuity is measured in logRAD unit (= reading equivalent of logMAR) and in critical font size (critical reading size), reading speed is measured in words per minute (wpm). Contrast sensitivity will be determined using Pelli-Robson contrast sensitivity charts.
45605699|NCT03520127|Device|Intact Breast Lesion Excision System (BLES)|Intact BLES is an automated, percutaneous biopsy device capable of delivering a surgical quality specimen for histological review of breast abnormalities. It is uniquely suited to maintain lesion architecture within the biopsy sample, providing an opportunity for pathological assessment and the potential avoidance of an open surgical procedure.
45605700|NCT02292251|Behavioral|Device-assisted therapy|
45605701|NCT02292251|Behavioral|Therapy-based occupational therapy|
45605702|NCT02295449|Device|biopsy sample performed after the SonoVue® injection|
45605703|NCT03517007|Other|Opt-Out Protocol|Should an eligible patient pass the safety screen and be randomized to the intervention arm of the trial, the designated pharmacist will approach the patient's primary provider in charge of antibiotic decision-making The pharmacist will inform the provider the patient's antibiotics can be de-escalated unless the provider opts out.
45605704|NCT03516929|Diagnostic Test|carotid duplex, both LL arterial duplex|assessment of carotid stenosis and lower limb peripheral ischemia.
45605705|NCT03516851|Procedure|Precision bypass group|With the brain cortex exposed after craniotomy, an initial ICG fluorescence angiography will be performed. ICG fluorescence angiography using Flow800 software to determine blood flow velocity and cortical perfusion in different candidate receptors. And electromagnetic neuronavigation system is used to evaluate the cerebral flow under different candidate recipient vessels. The treatment planning station will be situated based on the multimodal neuronavigation data. The vessel was chose as the receptor with lower flow velocity and lower cerebral perfusion area to perform anastomosis. Then a direct bypass surgery will be performed just like in the empirical direct bypass surgery group.
45605706|NCT02295527|Other|Home-based physical exercise intervention|Progressive strengthening of muscle groups ankle dorsi flexors, knee extensors and hip abductors and progressive balance training according to individual capacity:weight-bearing, limits of stability, change of position/direction, maintenance of static and dynamic stability, anticipatory adjustments using different bases of support and different sensory conditions. Dynamic exercises involving spin on its own axis, sitting and standing, up and down stairs, functional reach, steps in different directions and walk training. In the first session the physiotherapist will choose two exercises that best address the participant function goals and will add more exercises each week according to the level of participants' ability and motivation. Participants will receive a detailed booklet, containing photos and instructions of the12 exercises.Visits to follow up exercises will be conducted by the physiotherapists to progress the exercises.
45605707|NCT02295527|Other|Control Group Usual Care|This group will receive usual care and will not have any disadvantage in participating in the study. We understand that usual care is what participant receives based on the network of health care in which he/she is inserted. The participants will receive at baseline assessment a diary falls logbook and a guidance booklet containing information about prevention of falls, fractures and bone health that will be explained at the moment.
45605708|NCT03520049|Drug|Oseltamivir|
46066634|NCT02584738|Drug|Nebulized Magnesium Sulfate|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4 (150 mg) per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours."
45605709|NCT03520049|Drug|Placebo|
45605710|NCT02292329|Dietary Supplement|Acai puree, frozen blended it with banana|150g of acai fruit, frozen blended it with banana.
45757055|NCT05688800|Other|Experimental group 2: thoracic spine manipulation|Thoracic spine manipulation will be performed as screw thrust manipulation technique; the vertebral transverse processes will beforced from posterior to anterior direction. The direction of the manipulation should be identified by applying springing test to the adjacent spinous process to determine the painful and stiff segment. Patient will be prone and researcher hand placement will be positioned as the following one pisiform on the right facet of the above, and the other pisiform on the left facet of the below vertebrae.A slack will be taken up. The thrust applied directly toward the patient once
45605711|NCT02292329|Dietary Supplement|Control Macronutrient matched|Macronutrient matched control in water and also prepared with banana.
45605712|NCT03517631|Biological|shRNA-modified CD34+ cells|Infusion of CD34+ cells transduced with shRNAs.
45605713|NCT03517631|Drug|Low dose busulfan preconditioning|A single dose of 1 mg/kg busulfan administered every 6 hours for 4 times as preconditioning for transplantation.
45605714|NCT03517631|Drug|Busulfan preconditioning|A single dose of 1 mg/kg busulfan administered every 6 hours for 8 times as preconditioning for transplantation.
45605715|NCT02295605|Other|water-based exercises|water-based exercise strengthening protocol for lower limb muscles
45605716|NCT02295605|Other|land-based exercises|land-based exercise strengthening protocol for lower limb muscles
45605717|NCT02295683|Device|Renal Denervation|
45605718|NCT02292407|Device|LigaSure Precise instrument|LigaSure Precise instrument is used during Axillary Lymph Node Dissection Technique: Dead space closure Technique: Omission of postoperative drain
45605719|NCT02292485|Behavioral|Survey|Physicians complete survey to better understand their readiness to implement lung cancer screening programs in their practice settings. Surveys administered to physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.
45605720|NCT03516773|Drug|EB612 (EBP05)|Entera Bio's proprietary drug for the administration of PTH(1-34) orally
45605721|NCT03516773|Drug|NATPARA/NATPAR|A PTH replacement (PTH [1-84]; NATPARA (Shire-NPS Pharmaceuticals, Inc., Lexington, Massachusetts) was approved by the United States (US) Food and Drug Administration (FDA) in April 2015 / NATPAR (Shire Pharmaceuticals Ltd., Dublin, Ireland) was approved by the European Medicines Agency in April 2017 for use as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Like many other hormonally active peptides, PTH (1 84); NATPARA is parenterally administered. In this protocol when a specific formulation is referenced (e.g. NATPARA) it may be read interchanged with the alternate formulation (e.g. NATPAR).
45605722|NCT03516695|Device|TheraSphere®|Intra-arterial Yttrium-90 glass microspheres
45605723|NCT05187455|Drug|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg at reappearance of the second twitch of the train-of-four (TOF).
45757056|NCT03083054|Biological|Autologous dendritic cells electroporated with WT1 mRNA|Production and application of autologous dendritic cells vaccines, 4 doses, biweekly
45757057|NCT00249613|Behavioral|Women-Only|Gender-responsive treatment for women only
45911282|NCT02005939|Dietary Supplement|Pomegranate extract|All randomised participants to the intervention arm receive one pomegranate capsule daily for 4 weeks
45444713|NCT03564873|Drug|Omacetaxine|Phase I is a dose escalation phase. Patients will be enrolled into one of three cohorts to receive omacetaxine subcutaneously (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
45605724|NCT02295761|Behavioral|Lifestyle counseling (Fb)|Facebook-delivered lifestyle counseling
45605725|NCT02295761|Behavioral|Lifestyle counseling + activity monitor (Fb+Act)|Facebook-delivered lifestyle counseling and self-monitoring physical activity using Polar activity monitor
45605726|NCT03519815|Device|Ectoin® Eye Spray - Colloidal|eye spray to be applied to the closed eye lid
45605727|NCT03519815|Device|Liposomal eye spray Tears Again®|eye spray to be applied to the closed eye lid
45605728|NCT03133013|Device|SLEEPSCOPE|Brainwave measurement device which is connected to the participant by an electrode attached to the forehead and another electrode behind one ear
45605729|NCT02461160|Drug|TAK-915 suspension|TAK-915 oral suspension
45605730|NCT02461160|Drug|Midazolam|Midazolam oral solution
45605731|NCT02461160|Drug|Placebo|Placebo-matching TAK-915 suspension
45605732|NCT02461160|Drug|TAK-915 tablet|TAK-915 tablet
45605733|NCT02295839|Behavioral|Sleep Hygiene and Relaxation Education|Intervention group participants receive a nurse-led, one-hour 1:1 educational session including education about sleep in children and a description of what is known about sleep and fatigue issues in children with cancer. The session also includes strategies to improve sleep hygiene in children. Information about relaxation to promote sleep is outlined and two children's books designed to promote relaxation using the principles of deep breathing are given to the parent(s). A handout containing all the information covered is given to the parent(s).
45605734|NCT02292563|Procedure|Colonoscopist only|Only Colonosopist Observe during Colonoscopy (single observer)
45605735|NCT02292563|Procedure|Experienced Endoscopy Nurse Participation|Experienced Endoscopy Nurse Participation Observation during Colonoscopy (Both endoscopist and endoscopic nurse observe)
45605736|NCT02295917|Device|Transvaginal sonography|Transvaginal sonography
45605737|NCT03516539|Device|Group ML|Mcgrath videolaryngoscope
45605738|NCT03516539|Device|Group DL|Macintosh laryngoscope
45757058|NCT03434678|Drug|Propofol+ Rocuronium+ Fentanyl 2 mcg/kg+ Inhalational Agent, Bupivacaine 0.125% + Fentanyl 5 mcg/ml|Patient will have their epidural started at the beginning of the surgery and receive fewer opioid drugs. The epidural is continued into the recovery room.
45757059|NCT03434678|Drug|Propofol+ Rocuronium+ Fentanyl + Inhalational|Patient will have the standard intraoperative management during surgery and have the epidural started just before being taken to the recovery room.
45757060|NCT03434678|Procedure|Open Pancreaticoduodenectomy|Whipple' Procedure
45757061|NCT03082820|Diagnostic Test|Pain-related evoked potentials (PREP)|PREP were performed bilaterally with a concentric surface electrode at twice the individual pain threshold.
45757062|NCT03082820|Diagnostic Test|Quantitative Sensory Testing (QST)|QST was performed bilaterally following the protocol of the German Network on Neuropathic Pain.
45911283|NCT02005991|Drug|PF-05212377|Single, oral dose administration of 70 mg PF-0521377 using a capsule formulation.
45605739|NCT02292641|Procedure|New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery|Currently there are no validated criteria or guidelines for judging whether advanced primary or recurrent colorectal cancer can be successfully removed and for selecting which patients should undergo this form of more radical surgery as is exenterative surgery. We are proposing that by validating the detailed evaluation of imaging of the tumour distribution within the pelvis using a new radiological staging classification, this will enable clear selection criteria to be established and will improve surgical planning.
45605740|NCT01653704|Behavioral|observational role|observational role in crisis scenario
45757063|NCT03082820|Diagnostic Test|Nerve conduction studies (NCS)|NCS were performed with patients only.
45757064|NCT00733135|Device|SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device|Catheter-based excision of moderate to severely calcified plaque located in the SFA and/or popliteal artery.
45605741|NCT01653704|Behavioral|active role|active role in managing crisis scenario
45605742|NCT03519737|Device|tPA in combination with the Sonolysis Headframe (TUS)|tPA: 60 minutes per approved labeling TUS insonation via the Sonolysis Headframe: minimum 90 minutes - maximum 120 minutes
45605743|NCT03519737|Device|tPA in combination with the Sonolysis Headframe (Sham TUS)|tPA per approved labeling Sham (inactive) TUS insonation via the Sonolysis Headframe: minimum 90 minutes - maximum 120 minutes
45605744|NCT03516461|Procedure|Selective Microbiota Transplantation (SMT)|Selective microbiota transplantation for patients via nasointestinal tube (once per day for 3 days)
45605745|NCT03516461|Procedure|Fecal Microbiota Transplantation (FMT)|Fecal microbiota transplantation for patients via nasointestinal tube or gastroscopy (once per day and no more than 3 times)
45605746|NCT02292797|Other|Prevalence assessment|Assessment of the prevalence of rosacea in the general population per country using subject questionnaire and dermatologist diagnosis
45605747|NCT03516383|Device|PWVi|
45605748|NCT02292953|Other|Serum Prolactin levels|blood samples will be drawn from patients undergoing ICSI to analyse serum prolactin levels
45605749|NCT02293031|Device|"Gene-activated matrix Nucleostim"|"Gene-activated matrix Nucleostim is bone graft substitute consisting of collagen-hydroxyapatite composite scaffold and DNA plasmids with gene encoding vascular endothelial grothw factor (VEGF-A165) in concentration 100-120 ng/mg which is an active substance of gene-therapeutic drug Neovasculgen®."
45605750|NCT02296073|Drug|Midazolam|midazolam 3～5μg/kg•min for maintenance of sedation.
45605751|NCT02296073|Drug|Dexmedetomidine|Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
45605752|NCT02296073|Drug|Dexmedetomidine|Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
45757065|NCT05688722|Procedure|Supine position|Patients preoxygenated in supine position before endotracheal intubation
45757066|NCT05688722|Procedure|20 degree head elevation position|Patients preoxygenated in 20 degree head elevation position before endotracheal intubation
45757067|NCT05688722|Procedure|30 degree head elevation position|Patients preoxygenated in 30 degree head elevation position before endotracheal intubation
45605753|NCT02296073|Drug|Dexmedetomidine|Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
45605754|NCT02296073|Drug|Fentanyl|Fentanyl 0.5～4 μg/(kg.h) for maintenance of analgesia
45605755|NCT02296073|Other|assessment|Ramsay score for sedation assessment, Facial expression, leg movement, activity, cry, and consolability score (FLACC) for analgesia assessment.
45757068|NCT05688722|Procedure|45 degree head elevation position|Patients preoxygenated in 45 degree head elevation position before endotracheal intubation
45757069|NCT05445921|Drug|Stellate Ganglion Block|The stellate ganglion will be identified using ultrasound guidance, and after a test does of 1% lidocaine, 1% mepivacaine will be injected near the stellate ganglion.
45605756|NCT02296151|Other|Gluteus medius strengthening|Hip abductor, gluteus medius strengthening
45605757|NCT02296151|Other|iliotibial band stretches|Iliotibial band stretches
45605758|NCT03516149|Other|Foam Rolling Exercise|Foam rolling exercise will be performed actively. Participants will use a foam roller for exercise. They will position the foam roller on the chair. Afterwards, they will use their body weights to rub the elbow area (biceps brachii muscle) with this foam. There will be 2 sets and each set will be 1 minute. Single set contains 10 repetitions in 1 minute with 30 seconds resting period between sets
45605759|NCT03519425|Other|Optimised HIV screening and linkage to care|As described in group descriptions
45605760|NCT03519425|Other|Optimised tuberculosis screening and linkage to care|As described in group descriptions
45605761|NCT03132779|Drug|Intralipid|Adose of intralipid given and rechecking NKcells activity
45605762|NCT02293187|Dietary Supplement|vitamin D3|Dose for intervention arm is 800 IU/day for first 4 months. At 4 months, if vitamin D level <70 nmol/L, a second 800 IU capsule will be added to regimen (total of 1600 IU/d) for remainder of study.
45605763|NCT02293187|Other|Placebo|Those in the placebo group will receive 1 capsule for first 4 months. At 4 month visit, one capsule will be added to regimen to be taken throughout the remainder of the study.
45605764|NCT03519191|Behavioral|Healthy Relationships Education (HRE)|Healthy Relationships and Economic Pathways involves formal classes in Healthy Relationship Education (HRE), comprehensive case management, and support services and referrals to services.
45757070|NCT05688644|Device|InterStim II|Sacral neuromodulation
45757071|NCT05736627|Other|Online|Online research course delivered live digitally at a distance.
45757072|NCT00617981|Drug|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
45757073|NCT00617981|Drug|5% Dextrose Solution|Single 30 minute intravenous infusion
45757074|NCT03433742|Other|Blood levels drawn|The patients will have their bloods drawn at the Hospital for Special Surgery during their regular, standard of care visit. The laboratory at the Hospital for Special Surgery will then test their bloods to determine the metal ion levels.
45757075|NCT03389750|Drug|Intravenous Challege Drug|Intravenous administration of opioid drugs (oxycodone, oxymorphone, morphine, hydromorphone), for the purpose of comparison of their abuse potential among each other, and in comparison to placebo (saline).
45757076|NCT05694507|Other|Mental Well-being Chatbot|The chatbot contents are developed by Clinical psychologists and well-being promotion officers. Content includes relationships, stress, value, emotion, and positive psychology.
45757077|NCT05688566|Device|pinnacle trainer|The pinnacle trainer (S776MA, SportsArt, Taiwan) was used in this study.
45757078|NCT03837873|Drug|Rituximab|rituximab 750mg/m2 i.v. on day 0
45757079|NCT03837873|Drug|Etoposide|50mg/m2, continuous i.v. on day 1-4
45757080|NCT03837873|Drug|Vincristine|0.4mg/m2, continuous i.v. on day 1-4
45605765|NCT03519191|Behavioral|HRE+Technology Bootcamp|HRE + Technology Bootcamp involves formal classes in Healthy Relationships Education (HRE), comprehensive case management, support services and referral to services, 6-week intensive website and professional development training, and paid work experience developing a website for a local small business and mentorship.
45605766|NCT02296385|Dietary Supplement|Triple Strength Fish Oil|Triple Strength Fish Oil
45605767|NCT03519113|Biological|GC1102 80,000 IU|recombinant human hepatitis B immunoglobulin
45605768|NCT03519113|Biological|GC1102 100,000 IU|recombinant human hepatitis B immunoglobulin
45757081|NCT03837873|Drug|Doxorubicin|10mg/m2, continuous i.v. on day 1-4
45757082|NCT03837873|Drug|Dexamethasone|30mg/day, i.v. on day 1-5 for R-DA-EDOCH regimen; 40mg/day, i.v. on day 1-4 for R(2)-DHAP regimen
45757083|NCT03837873|Drug|Cyclophosphamide|750mg/m2, i.v. on day5
45757084|NCT03837873|Drug|Lenalidomide|25mg/day, p.o. on day 0-9
45757085|NCT03837873|Drug|Cisplatin|100mg/m2 continuous i.v. on day 1
45757086|NCT03837873|Drug|Cytarabine|2g/m2 q12h, i.v. on day 2
45757087|NCT03082742|Drug|Hydrochlorothiazide|
45757088|NCT03082742|Drug|Furosemide|
45605769|NCT03519113|Biological|I.V HBIG|human anti-hepatitis B Immunoglobulin
45605770|NCT03519035|Other|To pass different questionnaires|Patients will have to pass different questionnaires (DIB-R, DES II, THQ, PCL-S, PSAS, qualitative questionnaire) in order to compare the characteristics between BDL patients with and without hallucinations.
45605771|NCT03518957|Behavioral|Exercise|"Week 1: Patients will undergo an introductory session where the occupational therapist will assess the general condition and physical fitness of the subjects.~Week 1 to Week 12: Group exercise sessions supervised by a physiotherapist, twice per week, each session lasting 1 hour, with no more than 8 participants in each group exercise session. The exercise regimen for each session will be personally tailored for the subjects, and will include stretching, cardiovascular and strength training, and cooling down exercises.~Week 12 onwards: Patients will receive phone calls- monthly for the first 6 months and then 3 monthly up to the 2-year mark, to encourage them to continue with their exercise regimen at home."
45605772|NCT03516071|Drug|Brivanib 800 mg, QD|Brivanib Alaninate 800 mg QD, PO
45605773|NCT03516071|Drug|Brivanib 400 mg, BID|Brivanib Alaninate 400 mg BID, PO
45757089|NCT05434533|Drug|Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)|IV 1gm
45757090|NCT03432650|Drug|Bupivacaine + dexamethasone|Anesthetic that will help treat pain and sensation after hip arthroscopy
45757091|NCT03432650|Device|Ultrasound|Ultrasound will help guide the anesthesiologist in performing the nerve block
45757092|NCT00248833|Biological|25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine|The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 25µg with and without adjuvant were administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.
45757093|NCT00248833|Biological|50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine|The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 50µg without adjuvant was administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.
45757094|NCT00668525|Drug|Escitalopram|Escitalopram low dose, oral administration, once daily dosing for 8 weeks.
45757095|NCT00668525|Drug|Placebo|Placebo, oral administration, once daily dosing for 8 weeks
45757096|NCT00668525|Drug|Escitalopram|Escitalopram high dose, oral administration, once daily dosing for 8 weeks
45757097|NCT05736549|Drug|Bupivacaine-Liposomal Bupivacaine|A medication mixture of 40 ml (20 ml LB and 20 ml 0.25% plain bupivacaine) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
45605774|NCT02296463|Biological|RSV F Vaccine with adjuvant (0.5mL injection)|
45605775|NCT02296463|Biological|RSV F Vaccine (0.5mL injection)|
45605776|NCT02296463|Biological|Hepatitis A Vaccine (0.5mL injection)|
45605777|NCT02296463|Biological|Placebo (0.5mL injection)|
45605778|NCT02293265|Drug|Short Acting Beta Agonist (SABA)|Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments
45605779|NCT02293343|Other|blood profile|
45757098|NCT05736549|Drug|Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate|A medication mixture of 40 ml (40 ml 0.25% plain bupivacaine, 10 mg DEX and 80 mg MPA) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
45757099|NCT03082508|Device|Algisyl|Algisyl device (implants) administered during a surgical procedure
45757100|NCT03082508|Drug|Standard Medical Therapy|as per protocol
45757101|NCT05688488|Drug|Curcumin|Curcumin was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
45757102|NCT05688488|Drug|Mitomycin-C|Mitomycin-C was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
45757103|NCT05423457|Behavioral|Vegan diet|The participants were advised to eat foods in their original type.
45757104|NCT00669383|Drug|betamethasone|12 mg IM q 24 hours x 2 doses
45757105|NCT00669383|Drug|placebo|Placebo IM q 24 hours x 2 doses
45757106|NCT00733993|Drug|Caffeine 150 MG|Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
45605780|NCT02296541|Biological|DNA Nat-B env|4 mg to be administered as 1 mL intramuscularly (IM) by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
45605781|NCT02296541|Biological|DNA CON-S env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
45605782|NCT02296541|Biological|DNA Mosaic env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
45605783|NCT02296541|Biological|MVA-CMDR|1×10^8 plaque forming units (pfu) to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
45605784|NCT02296541|Biological|Placebo for DNA Nat-B env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
45605785|NCT02296541|Biological|Placebo for DNA CON-S env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
45605786|NCT02296541|Biological|Placebo for DNA Mosaic env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
45605787|NCT02296541|Biological|Placebo for MVA-CMDR|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
45605788|NCT03518879|Other|ASTHMA-Educator mobile application|The on-site delivered ASTHMA-Educator mobile application.
45605789|NCT02495168|Drug|Generic Budesonide/Formoterol Fumarate Dihydrate|Oral inhalation, generic formulation of the brand-name product.
45605790|NCT02495168|Drug|Symbicort® (Budesonide/Formoterol Fumarate Dihydrate)|Oral inhalation, brand-name product.
45605791|NCT02495168|Drug|Placebo|Oral inhalation, no active ingredient.
45605792|NCT03518645|Device|OPN strategy|Predilatation with OPN balloon will be performed as a lesion preparation for BVS Absorb implantation.
45605793|NCT03518645|Device|standard strategy|Predilatation with standard balloon will be performed as a lesion preparation for BVS Absorb implantation.
45605794|NCT02293421|Other|Obstructive sleep apnea|
45605795|NCT02293577|Device|continuous glucose monitor|In this study all subjects will wear a continuous glucose monitor for 5 days.
45605796|NCT04934072|Drug|FKS518|Participants will receive FKS518 via subcutaneous injection, every 26 weeks.
45605797|NCT04934072|Drug|US-licensed Prolia|Participants will receive US-licensed Prolia via subcutaneous injection, every 26 weeks.
45605798|NCT03518567|Drug|Smoked marijuana cigarettes: High THC dose (6% THC)|Smoked marijuana cigarettes (High THC dose [6% THC])
45605799|NCT03518489|Drug|Lappaconitine Adhesive Patch|to evaluate the efficacy of lappaconitine adhesive patch in alleviation radiation induced mucositis pain
45605800|NCT03518489|Drug|standard care|Standard care will include mouth wash with antibiotics.
45605801|NCT02296619|Procedure|TAP block|Using real time ultrasound imaging, bilateral, 20 ml 0,25% bupivacaine inject into the area between the internal oblique and transverse abdominis muscle
45605802|NCT02296619|Procedure|Control|A sham band-aid will be applied to the abdomen of subjects
45605803|NCT02296697|Device|Low-level laser therapy AlGaInP|Pressure ulcers will be treated with AlGaInP 660 nm laser, wich will be used once a day, five days per week, dosed with 6 J/cm2. Laser therapy is applied punctually in each 1cm2 of the ulcer.
45605804|NCT02296697|Device|High-frequency therapy with O3 formation|High-frequency laser therapy will be applied with spherical electrode, wich contains neon gas inside, from a short distance from the pressure ulcer. The application will last 15 minutes, with increasing intensity from 80 to 100% for ozone formation, once a day, five days per week.
45605805|NCT02296697|Other|Wound dressing with saline solution|Wound dressing will be done daily on patients from the three groups during the study period. On patients who will receive laser therapy and high frequency, the pressure ulcer will be sanitized with worm saline solution in order to clean the wound. This cleaning will be done before and after the interventions.
45605806|NCT02494778|Drug|Pridopidine|45 mg BID
45605807|NCT04465019|Device|Exoskeleton Rehabilitation|The EKSO GT® was operated by a Licensed Physical Therapist who was certified to control the device. We followed a strictly established protocol for operating the device during the rehabilitation process as established by the company.
45605808|NCT04464941|Behavioral|a composite intervention with both group and individual components for oral health promotion program|"The group intervention consisted of:~1. Group oral health education 2. Display of Bass tooth-brushing methods 3. Broadcasting of songs as tooth-brushing reminders; The individual interventions included:~1. Instruction in the Bass tooth-brushing method, 2. Individual behavioral modification method"
45605809|NCT04933838|Device|atelocollagen|"This collagen-contained product is used to supplement tendon, ligament, muscle, and (biological) membrane that is missing or damaged during internal/surgical treatment and surgery.~Patients with chronic low back pain are randomized after obtaining informed consent for the study.~Participants are divided into group A (atelocollagen) and group B (control). A physical examination for lumbar pain was performed and evaluated trigger points in multifidus, erector spinae, and quadratus lumborum muscles.~After physical exam, cross sectional area of each muscle is measured by ultrasound in both gorup.~Group A will receive atelocollagen mixture (atelocollagen 3 mL + 1% lidocaine 3 mL) and group B will receive local anesthetics only (Normal saline 3 mL + 1% lidocaine 3 mL).~Each participants will be injected 1 mL of injectate into each muscle on both sides (total 6 mL)."
45605810|NCT03518411|Other|Cognitive Behavioral Therapy|One-Session Unified Protocol
45605811|NCT04933526|Drug|Flumatinib|Flumatinib 600mg QD orally form 1 to 12 months
45605812|NCT04933526|Drug|Dasatinib|Dasatinib 100mg QD orally form 1 to 12 months
45757107|NCT00733993|Drug|Placebo|Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
45757108|NCT00733993|Drug|Amphetamine|Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
45605813|NCT04933448|Other|Ketogenic Diet|The ketogenic diet (KD) is an alternative feeding regimen that has been in use since 1921. It is a high-fat, low carbohydrate, and moderate protein diet. There are various forms of the KD. The classic KD consists of long-chain triglycerides with a fat-to-combined-protein-and-carbohydrate ratio that can vary. At the investigating institution, it is standard of care to initiate a ketogenic diet at a ratio of 2:1, and to increase the ratio to 3:1 or 4:1 as needed to achieve ketosis.
45605814|NCT02293811|Other|Analysis|"An additional blood sample (10ml) will be taken on the day of hospitalization to achieve the genomic studies in search of mutations in constitutional DNA of circulating lymphocytes and acquired mutations of DNA circulating.~We will use the technique of tissue-microarray to analyze the expression level of P2RX7 both in epithelial cells than in stromal cells inflammatory.~Genotyping will be conducted partly on colonic biopsies and also on blood samples (to demonstrate the feasibility of this technique much less debilitating)."
45605815|NCT03518333|Device|Injection of adipose derived cells into penis|Injection of Icellator-derived cells
45605816|NCT03518255|Other|Nature video|After signing the Informed Consent Form, the participants will respond to a demographic questionnaire to characterize the sample and then they will watch nature videos. After that, will be applied a scale questionnaire about the physical and psychological symptoms of chemotherapy in the positive and negative mood of that patient.
45605817|NCT02293889|Dietary Supplement|Vitamin D3 2000IU/daily 3 months|Vitamin D will be provided in the form of a daily capsule over 3 months containing 2000IU of Vitamin D3 suspended in oil (manufactured and provided by DSM) with the aim of raising 25OHD levels to sufficiency (>50nmol/L) by 3 months.
45605818|NCT02293889|Behavioral|PA intervention People with Osteoarthritis Walking Programme|The PA intervention will aim to increase levels of PA safely in our defined population. Participant are given a pedometer at the start of the intervention and encouraged to record their daily step counts and set step goals using the online system provided (POW: People with osteoarthritis walking programme).
45605819|NCT02293889|Other|Placebo capsule (Vitamin D): edible oil|Placebo capsules will be administered over 3 months, as daily capsules (identical to Vitamin D capsules) containing edible oil (manufactured and provided by DSM)
45605820|NCT02293967|Drug|MT-1303|
45605821|NCT03518177|Other|Hospital-based pulmonary rehabilitation|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program including breathing exercises, treadmill walking, cycle ergometer, arm ergometer training and strengthening trainning with free weights at hospital.
45605822|NCT03518177|Other|Home-based pulmonary rehabilitation|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program including breathing exercises, free-walking, and strengthening training with free weights at home
45757109|NCT00733993|Drug|Caffeine 300 MG|Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
45605823|NCT02297009|Procedure|Buccal swab|Buccal swabs will be taken from the volunteers
45605824|NCT03518099|Biological|blood sampling|Two tubes of 5ml of blood will be collected for Serum collection, 3 tubes of 5 ml of blood taken for plasma collection and 2 tubes of 7 ml of blood taken for DNA collection
45605825|NCT02297087|Genetic|Standard of care based on target(s) identified via GWS.|
45605826|NCT02297165|Behavioral|olfactory stimulation program|"8 individual sessions of olfactory stimulation at the rate of 2 sessions per week. 3 semi-directed interviews will be help (one at the beginning of the trial, the second 5 weeks later and the third at 6 month).~For each session, patients have to smell two different odors (previously selected from a panel presented to the patient during first visits) and then they are invited to evoke memories and feelings related to each odor."
45605827|NCT03514745|Device|GlideScope|Endobronchial intubation is performed using the GlideScope.
45605828|NCT03514745|Device|Lighted stylet|Endobronchial intubation is performed using a lighted stylet.
45605829|NCT02298335|Drug|prednisone|Full-dose induction period: Prednisone 1mg/kg.day, maximum 60mg/day, orally, divided into 3 times; Protracted tapering period: orally, no ask for fract. dos.
45605830|NCT03514667|Dietary Supplement|nanomicielle curcumin|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicielle curcumin or placebo. nanomicielle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
45605831|NCT03514667|Dietary Supplement|placebo|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicielle curcumin or placebo. nanomicielle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
45757110|NCT03089762|Biological|Intra-articular injection of SVF plus PRP|administering SVF and PRP intra-articularly into patients with osteoarthritis grade 1 and 2
45757111|NCT03029559|Other|Intermittent Hypoxia|"A single session of IH will last for 45 minutes and will consist of alternating phases of hypoxia(FiO2 :9%-11%) and hyperoxia (FiO2 :22%-38%).~Each hypoxic interval will last for 2 minutes whereas the hyperoxic interval lasts for 1 minute each (15, two-minute episodes of hypoxia and 15, one-minute episodes of hyperoxia)."
45757112|NCT03029559|Other|Inspiratory Threshold Loading|Subjects will undergo inspiratory threshold loading using a commercially available Threshold IMT device (Power breathe®). ITL will be administered at an intensity of 80% of the individual's maximal inspiratory pressure (MIP). The subjects will be instructed to take 10 deep, forceful breaths through the threshold device followed by at least 2 minutes of rest. The process will be repeated 4 more times for a total of 5 sets of 10 breaths each.
45911284|NCT02005991|Drug|PF-05212377|Single, oral dose administration of 20 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arm 1.
45444714|NCT03564873|Drug|Azacitidine|Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
45605832|NCT04465097|Drug|Tucidinostat|Tucidinostat: 30 mg BIW (Monday and Thursday) from week 3 to week 26
45605833|NCT04465097|Drug|Exemestane|Exemestane: 25 mg QD from week 1 to week 26.
45605834|NCT04465097|Drug|Ovarian function suppression|If the patient is premenopausal, leuprorelin 3.75mg or goserelin 3.6 mg will be injected every 28 days.
45605835|NCT02298413|Device|PCI with Absorb scaffold|Implantation of biovascular scaffold during PCI
45605836|NCT03515525|Diagnostic Test|Closed-suction drain fluid volume|To evaluate the clinical value of postoperative drain fluid volume for detection of hematoma, an intra-individual comparison of drain secretion volumes between sides affected by hematoma and the uneventful contralateral breasts was performed.
45605837|NCT02297243|Device|Sinopsys Lacrimal Stent|The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
45605838|NCT02298569|Behavioral|multi-pronged program to improve early postpartum discharge|"Better team integration and changes to promote interprofessional collaboration and communication between healthcare providers involved in pre- and post-natal care in a perinatal network.~Transition optimization: all involved healthcare professionals will complete a specific form during pregnancy and hospitalization to coordinate support safe process, and to improve quality transitions to outpatient midwives and pediatrician. A check-list will be completed by the mother to assess whether she agrees to early discharge and that she is aware of its conditions Implementation of best practices about early discharge after delivery to improve safety of early discharge particularly for neonates at risk (jaundice and dehydration)."
45605839|NCT02297321|Device|Describe patch|Application of Describe patch over tattoo for approximately 5 minutes during Q-switched laser treatment
45605840|NCT02297399|Drug|PEG-ascorbate 2L|"Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.~Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 2 sachets (labelled A and B) of the investigational product and take their contents diluted in 1 liter of water. Two other sachets, also labelled A and B, will be taken diluted in 1 liter of water 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken."
45605841|NCT02297399|Drug|PEG 4L|"Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.~Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken."
45605842|NCT02493764|Drug|Imipenem|Imipenem 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
45605843|NCT02493764|Drug|Relebactam|Relebactam 250 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
45605844|NCT02493764|Drug|Cilastatin|Cilastatin 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
45605845|NCT02493764|Drug|Piperacillin|Piperacillin 4000 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
45605846|NCT02493764|Drug|Tazobactam|Tazobactam 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
45605847|NCT02493764|Drug|Linezolid|Linezolid 600 mg administered open-label by IV every 12 hours for up to 14 days
45605848|NCT02297477|Drug|atovaquone-proguanil|A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg respectively)
45605849|NCT02297477|Drug|artesunate-atovaquone-proguanil|A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg daily respectively) in addition to 4 tablets containing 50mg artesunate (200mg daily)
45605850|NCT02298725|Other|DGA Diet Plan|A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with food group recommendations set in the 2010 Dietary Guidelines for Americans.
45605851|NCT02298725|Other|NHANES Diet Plan|"A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with the NHANES What we eat in America report."
45605852|NCT03515447|Other|Non interventional study|
45605853|NCT02460380|Drug|Vitamin D3|Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
45605854|NCT02460380|Other|Placebo|Women in the placebo arm received once capsule of placebo once weekly for eight weeks
45605855|NCT02297555|Device|ENDOBARRIER®|This medical device consists of a tube (impermeable fluoropolymer) inserted endoscopically and secured by hooks in the wall of the duodenal bulb. From the anchor site, this duodeno-jejunal sheath covers 60 cm in the small intestine. It thus limits the contact of nutrients with digestive juices (bile and pancreatic juice) and initial absorption, at least in part mimicking duodenal exclusion of the gastric bypass, one of the techniques of bariatric surgery.
45605856|NCT03514511|Drug|LEO 138559|LEO 138559 is a compound in development at LEO Pharma A/S
45605857|NCT03514511|Drug|LEO 138559 placebo|LEO 138559 placebo
45605858|NCT02493062|Device|Sonohysterogram|The sonohysterogram can measure the size and depth of the uterine scar allowing better predictive values for future pregnancies.
45605859|NCT02299115|Drug|Prednisolone|Corticosteroid
45605860|NCT02299115|Drug|Vigabatrin|Antiepileptic
45757113|NCT03029559|Other|Sham Intermittent Hypoxia|Subjects will be exposed to a session of sham Intermittent hypoxia.This will consist of breathing room air for 45 minutes through a hypoxicator.
45605861|NCT04932356|Other|Therapeutic education by phone|The patients who participate in the intervention group, after their face-to-face visit, will undergo a fortnightly reinforcement by telephone of diabetes education (review of diet, physical exercise, doubts about insulin or oral medication and the registry of blood glucose controls). In addition, emotional support will be provided to the patient, along with a semester calendar with scheduled calls to carry out the intervention, at a specific time.
45605862|NCT04932356|Other|Therapeutical education traditional|The patients participating in the study will be visited in person every six months where the control group will follow the usual protocol of the health center in the face-to-face visits, with their respective analyzes and pertinent tests, together with health education and adherence to pharmacological treatment.
45605863|NCT02297711|Procedure|Total ExtraPeritoneal|This is a keyhole operation which will use one small incision at the 'belly button' followed by two small incisions of approximately 5mm in diameter below the 'belly button' . A lightweight mesh is then placed over the inguinal ligament to reinforce the weakness. This approach is keyhole in nature with visualisation of the inguinal canal from behind - posteriorly.
45605864|NCT02297711|Procedure|Open minimal suture repair|This is best described as open minimal repair and involves a small incision into the groin of the affected side. Once the inguinal canal is exposed the back wall is repaired using a simple suture to reinforce the weakness. This approach is open surgery in nature with visualisation of the inguinal canal from in front - anteriorly.
45605865|NCT02297789|Device|Investigative Full Face Mask with Headgear|
45605866|NCT02297867|Drug|ADSCs|autologous ADSCs
45605867|NCT03515291|Biological|iMP cells|Immunomodulatory progenitor cells
45605868|NCT03515291|Other|Control injection|Cell suspension solution
45605869|NCT03515213|Drug|Fenofibrate|145mg of fenofibrate
46066635|NCT02584738|Drug|Nebulized isotonic saline|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic saline per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours."
46066636|NCT02584738|Drug|Nebulized Salbutamol|Nebulized salbutamol 2.5mg (2-5 years) or 5 mg (≥6 years)
45605870|NCT03515213|Drug|Placebo|Placebo
45605871|NCT02297945|Drug|metyrapone|Single arm study
45757114|NCT04279808|Procedure|dilator depth|For soft tissue dilation just after guidewire insertion in central venous catheterization through the right internal jugular vein, investigators will measure the distance between the skin puncture site and outside of anterior wall of the vein with real-time ultrasonography in the measured depth group. Next, practitioner will insert the dilator by the measured length and continue to insert the central venous catheter. For the conventional group as a control group, practitioner will perform the central venous catheterization with a manner used routinely by the practitioner.
45757115|NCT01271257|Drug|Misoprostol|20 microgram PO per hour for 8 doses or 80 microgram PO per 4 hours for 2 doses
45757116|NCT03089294|Device|Aries ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites)
45757117|NCT04385329|Other|Shock wave therapy on plantar fascia extended to the gastrocnemius-soleus trigger points|Enrolled subjects were treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician with more than five years of expertise, using a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf®). At each treatment session, with the patients lying in prone decubitus position, the enthesis of the plantar fascia and the gastrocnemius-soleus trigger points were clinically targeted and treated with a perpendicular technique.
45757118|NCT04385329|Other|Shock wave therapy on plantar fascia only|Enrolled subjects were treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician with more than five years of expertise, using a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf®). At each treatment session, with the patients lying in prone decubitus position, the enthesis of the plantar fascia was clinically targeted and treated with a perpendicular technique.
45757119|NCT03082430|Biological|autologous PRP.|one autologous PRP patient in this study and monitor and follow the evolution of pain and the knee function
46066637|NCT02584738|Drug|Ipratropium bromide|Nebulized ipratropium bromide 250 mcg
45605872|NCT02492984|Drug|Intravenous infusions of Xyntha|Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
45605873|NCT03515135|Behavioral|Metacognitive Executive Function Training|Training the executive funtions of preshcool ADHD children through tasks and games repeatly but with fun. Giving the parents strategies to help the prechool ADHD childred coping the symptoms and develop EF in the reallife.
45605874|NCT03514355|Behavioral|Mindfulness-Based Stress Reduction|8 weekly 2.5 h sessions plus one day of practice
45605875|NCT03132623|Drug|andrographolide sulfonate|Xiyanping injection 10-20ml/d, With 0.9% Sodium Chloride Injection 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
45605876|NCT03132623|Drug|andrographolide sulfonate simulation|Xiyanping injection simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.
45757120|NCT03082352|Drug|BF-Metoprolol Tablet 100mg|BF-Metoprolol Tablet 100mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
45757121|NCT03082352|Drug|Betaloc Tablet 100mg|Betaloc Tablet 100mg will be used as a comparator drug for the BE study
46066638|NCT02584738|Drug|Methylprednisolone or Prednisolone|Begin with intravenous methylprednisolone or oral prednisolone 2 mg/kg/day for each treatment
46066639|NCT02559349|Other|Stool Collection|
46066640|NCT00764647|Behavioral|Education program for family caregivers of frail elders|Family caregiver participants in the educational program will receive an educational course presented by the investigator that focuses on the care of the frail elder and themselves. The course will involve four to five consecutive weekly sessions, each 2 1/2 to 3 hours long. The educational program will be offered biannually, spring and fall seasons.
46066641|NCT04421950|Dietary Supplement|Wild blueberry containing foods|Foods that contain wild blueberry supplement to deliver up to 30 grams of blueberry powder
46066642|NCT04421950|Dietary Supplement|Placebo containing foods|Foods that do not contain the blueberry powder but a placebo
45605877|NCT03514199|Other|Mediterranean-type diet|"Recommendations: ingest whole grains; three or more servings/day (various fresh fruits/vegetables); three or more servings/week of fish or seafood; white meat to red and processed meat (red meat to one serving or less/day); oilseed mix - 30g/day (nuts: 15g/day, almonds: 7.5g/day, hazelnuts: 7.5g/day); extra virgin olive oil (30ml/day: 2 soup spoons/day) as the main source of fat in the salads; two or more servings per week of sofrito; two servings/day of low-fat dairy products; limit to one serving/week the intake of fatty and cured cheeses; recommendation of 7 glasses per week of red wine (recommendation for habitual drinkers): 1 cup/day of 100ml for women and 1-2 cups/day of 150ml for men; limit to one serving/week the intake of chocolate with more than 50% cocoa."
45605878|NCT03514199|Other|Low fat diet|Recommendations: choose grilled, cooked, baked or soaked preparations; avoid frying (sweet or salty); avoid excess fat in the preparations and season the foods with herbs at will (marjoram, basil, oregano, onion, green seasoning, sweet pepper, sage, etc.); avoid frequent ingestion of sausages such as ham, turkey breast, among others; avoid eating fatty meats and strip the skin of poultry before preparation; avoid eating sweets and fatty foods; avoid ingesting bakery products, such as leafy, tart, savory pasta.
45605879|NCT03515057|Diagnostic Test|Single lead handheld electrocardiogram|Screening for atrial fibrillation during outpatient primary care office visits among patients 65 years and older
45605880|NCT03514979|Biological|Pneumococcal Polysaccharide Conjugate vaccination and Pneumococcal Polysaccharide Vaccination|Pneumococcal vaccines
45605881|NCT03513965|Behavioral|Symptoms as Positive Signals Mindset|In this intervention, both arms receive the same strategies for managing symptoms and receive the same level of support regarding symptoms. However, Symptoms as Positive Signals Mindset families are additionally encouraged to think of symptoms as a positive signal that their immune system is becoming increasingly desensitized to their allergen. For each arm, four families (six to seven patients per group) meet monthly for eight months in the clinic with at least two members of the patient support team. These visits are an opportunity for families to harness peer support and ask questions, and include a variety of activities that depict symptoms in different ways.
45605882|NCT03513965|Behavioral|Symptoms as Side Effects Mindset|In this intervention, both arms receive the same strategies for managing symptoms and receive the same level of support regarding symptoms. For each arm, four families (six to seven patients per group) meet monthly for eight months in the clinic with at least two members of the patient support team. These visits are an opportunity for families to harness peer support and ask questions, and include a variety of activities that depict symptoms in different ways.
45605883|NCT02298101|Drug|Technetium-99m - Diethylenetriaminepentaacetic acid|Solution placed on the nebulizer reservoir
45605884|NCT02298101|Device|Aeroneb Solo Adapter|Nebulizer
45605885|NCT02298101|Device|Opti-Mist Plus Nebulizer|Standard jet nebulizer
45605886|NCT02298101|Other|Planar scintigraphy|Imaging technique to investigate whole lung deposition
45605887|NCT02298101|Other|Single photon emission computed tomography|Imaging technique to investigate regional pulmonary deposition
45605888|NCT02298101|Other|Spirometry|FEV1, FVC assessment
45757122|NCT03431168|Drug|Azithromycin/TMPS|2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
45757123|NCT03431168|Drug|Placebo/TMPS|2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
45605889|NCT01680159|Drug|TA-650|
45757124|NCT02290509|Biological|Flublok Quadrivalent|Intramuscular injection of study vaccine
45757125|NCT02290509|Biological|Inactivated Influenza Vaccine (IIV4)|Intramuscular injection of study vaccine
45605890|NCT02299193|Behavioral|Cognitive Behavioral Therapy|6 weekly, 20 minute online sessions about how thoughts and behaviors can affect sleep
45605891|NCT02299193|Behavioral|Healthy Sleep Habits|6 weekly, 20 minute online sessions about healthy sleep practices
45605892|NCT02491892|Drug|Pertuzumab|Participants will receive one of two IV treatment regimens with pertuzumab: either 420 mg every 3 weeks, with an initial 840-mg loading dose, or 1050 mg every 3 weeks with no loading dose administered.
45605893|NCT03476811|Drug|0.25% Marcaine at 2ml/hr and pain medications|Subcutaneous pain control with OnQ Subcutaneous Drug pump
45605894|NCT03476811|Device|Placement of OnQ Drug pump|Subcutaneous placement of OnQ drug pump with normal saline infusion
45757126|NCT03089450|Device|CGBio stent|Percutaneous Coronary Intervention
45757127|NCT03089450|Device|Biomatrix flex|Percutaneous Coronary Intervention
45757128|NCT03082274|Diagnostic Test|ConfirmMDx|ConfirmMDx is a molecular diagnostic assay which utilizes DNA isolated from biopsy tissues to determine if aberrant DNA methylation is occurring in three genes: GSTP1, RASSF1 and APC. ConfirmMDx is currently available to clinicians for use in cancer-negative extended-core biopsies to determine if occult cancer is present in the prostate.
45757129|NCT03082274|Diagnostic Test|SelectMDx|SelectMDx for Prostate Cancer is a reverse-transcription PCR (RT-PCR) assay performed on post-DRE, first-void urine specimens from patients with clinical risk factors for prostate cancer, who are being considered for biopsy. The test measures the mRNA levels of the DLX1 and HOXC6 biomarkers, using KLK3 as internal reference gene, to aid in patient selection for prostate biopsy.
45757130|NCT05736393|Device|Back Exosuit|The device is worn like a backpack. It weighs 6 pounds. Participants will be able to perform movements naturally in the device. A ribbon serves as an external muscle to reduce the load and effort during lifting. As participants bend forward, the device assists the participant by supporting some of their body weight by gently pulling back. As participants stand up, the device assists them by gently pulling their trunk upright. Participants will feel the level of assistance change slightly as they move faster or slower. Participants will use this device during 20-40 minutes of physical therapy exercises during 12 visits over 4-6 weeks. Once it is fit and adjusted to each participant's comfort, the physical therapist will control the level of assistance the device provides similarly to how they would adapt any given exercise. Participants may start with more assistance and wean down over the course of the study.
45757131|NCT04402034|Behavioral|Application of tele-rehabilitation|Individuals that will perform the virtual reality intervention.
45757132|NCT03089528|Device|Videolaryngoscopy|the trachea will be intubated with a videolaryngoscope
45757133|NCT03089528|Device|laringoscope|the trachea will be intubated with a laringoscope
45605895|NCT03514823|Other|Inspiratory Muscle Training (IMT)|Inspiratory muscle training (IMT) are breathing exercises used to increase strength and endurance of the respiratory muscles.
45605896|NCT03514823|Other|No Inspiratory Muscle Training (IMT)|No inspiratory muscle training.
45605897|NCT02972853|Behavioral|Mindfulness Training for Primary Care (MTPC)|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home - A Pilot Study"
45605898|NCT03513809|Device|Thoracic electrical impedance tomography|Non invasive, radiation-free, bedside monitoring tool for distribution of pulmonary ventilation.
45605899|NCT04931888|Behavioral|EMPOWER|EMPOWER is an adapted social emotional learning (SEL) and wellness education initiative delivered to a community of refugee families that was developed through a pre-pilot in the New Haven Afghan refugee community in 2020. Unlike traditional school-based SEL curricula, EMPOWER partners with community organizations to provide translated and trauma-informed wellness education to family units. The program combines in-person (socially distant) and remote delivery of culturally-informed physical, emotional, and medical wellness tools adapted from evidenced-based behavioral medicine, refugee trauma and recovery, and community health research.
45605900|NCT04931810|Behavioral|All Nations Breath of Life|Same.
45605901|NCT02834403|Drug|L-NMMA|Nitric oxide synthase inhibitor
45605902|NCT02834403|Drug|Docetaxel|Mitotic inhibitor, cytotoxic
45605903|NCT02834403|Drug|Amlodipine|Long-acting calcium channel blocker
45605904|NCT02834403|Drug|Pegfilgrastim|Colony-stimulating factor
45605905|NCT02834403|Drug|Enteric-coated aspirin|non-steroidal anti-inflammatory drug
45605906|NCT02302313|Device|CO2 laser and ANI monitor|Painful skin stimuli of variable intensity will be delivered by a CO2 laser used at the power of 0.3 W for each stimulation (6/phases) and this for each of the 3 phases (critical consciousness or hypnosis). During each stimulation, ANI values will be identified by the Physiodoloris ® monitor, through 3 standard ECG electrodes placed on the thorax of the subject.
45605907|NCT03435315|Other|Treadmill Exercise- behavioral approach|12-session, 6-week treadmill exercise program utilizing behavioral techniques while walking
45605908|NCT03435315|Other|Treadmill Exercise- traditional approach|12-session, 6-week traditional treadmill exercise program
45605909|NCT02299271|Drug|Ropivacaine|0.375% ropivacaine as a one-time, 60 milliliter injection
45605910|NCT02299271|Drug|Saline|Saline as a one-time, 60 milliliter injection.
45605911|NCT02302391|Other|PK analysis|Quantification of Serum Levels and subsequent pharmacokinetic (PK) modelling.
45605912|NCT03405753|Dietary Supplement|Aronia, washout and then placebo|Three tablets three times à day for three months then washout for three months, then three placebo tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
45605913|NCT03405753|Dietary Supplement|Placebo, washout and then aronia|Three tablets three times à day for three months, then washout for three months, then three aronia tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
45605914|NCT02302469|Drug|Revlimid|Three cohorts of subjects will be successively exposed to escalating doses of Lenalidomide (15, 20 and 25mg once daily on days 1-21 of a 28 day cycle).
45605915|NCT02664597|Procedure|ADNEXMR Scoring System|Patients will undergo a pelvic MR imaging (1.5T or 3T) as routinely performed, including morphological sequences (T2, T1 with and without fat suppression and T1 after dynamic gadolinium injection) and functional sequences (perfusion and diffusion-weighted sequences). Prospectively, a senior radiologist analyzes the different MR criteria to characterize adnexal masses. The reader will classify the mass using ADNEXMR SCORING system and the patient will be managed according to the score
45605916|NCT02664597|Other|Standard strategy|In control group, the complex adnexal mass will be managed according to the standard strategy and treatment plan routinely used by the multidisciplinary team.
45605917|NCT02302547|Drug|triple therapy|Dosage treatment and usual prescription
45605918|NCT02302547|Drug|dual therapy|1 tablet (200mg/245mg) daily for 48 weeks
45605919|NCT01190787|Drug|velcade subcutaneous melphalan prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
45605920|NCT01190787|Drug|velcade cyclophosphamide prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
45605921|NCT01190787|Drug|velcade prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
45605922|NCT02662881|Device|PerFuse Percutaneous Decompression System|Core decompression with PerFuse
45757134|NCT00618839|Biological|StrataGraft Skin Tissue|StrataGraft™ skin tissue is provided as a suturable circular patch of stratified epithelial tissue composed of a living dermal matrix (containing dermal fibroblasts) overlaid with human epidermal cells (NIKS™ cells).
45605923|NCT02662881|Device|BioCUE Platelet Concentration System|PRP injection through the PerFuse cannula into core decompression site
45605924|NCT03515369|Drug|Babaodan oral capsule|On the basis of conventional liver protecting treatment, take Babaodan oral capsule within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
45757135|NCT00618839|Procedure|Cadaver allograft|The standard of care for temporary coverage of full thickness skin defects is coverage with cadaver allograft until the wound can be autografted.
45757136|NCT03089372|Device|ARIES-ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
45605925|NCT03515369|Drug|Placebo oral capsule|On the basis of conventional liver protecting treatment, take Placebo oral capsule began within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
45605926|NCT02634411|Drug|8 days of effective antibiotic treatment|"Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).~Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 8 days."
45605927|NCT02634411|Drug|15 days of effective antibiotic treatment|"Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).~Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 15 days."
45605928|NCT03513575|Other|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test flavored milk drink without any intervention.
45605929|NCT03513575|Other|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
45605930|NCT03513575|Other|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
45605931|NCT03513575|Other|Group 4: Fluoridated tooth paste|The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention.
45605932|NCT03513575|Other|Group 5: Polyol containing gum|The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention.
45605933|NCT03513575|Other|Group 6: 1% sodium bicarbonate solution|The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
45757137|NCT03082040|Behavioral|home-based breathing training|The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks. Participants in the control condition will participate the same breathing training after a four-week waiting list period.
45605934|NCT02302625|Behavioral|Cognitive behavior therapy|Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
45605935|NCT03334461|Combination Product|Exposure to oral antiseptics or enamel remineralisation agent|
45605936|NCT02302703|Other|low FODMAP diet vs Gluten free diet|
45605937|NCT03513419|Behavioral|The AMOR Method|The parent resilience training involves a series of eight weekly 90-minute group sessions with up to 8 parents of young children with ASD (4- 10:11 years old) per group, as well as three individual sessions.
45605938|NCT04542525|Device|ACRYSOF IQ PanOptix Toric Trifocal IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism
45605939|NCT04542525|Procedure|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use
45605940|NCT03513341|Other|No intervention|No intervention is given to the participants. This is an observational study exploring the students' levels of physical activity and sedentary behaviour in their natural setting.
45605941|NCT02582619|Other|Focus groups, semistructured interviews and Delphi rounds|
45605942|NCT02302781|Other|Questionnaires|Several validated questionnaires, depending on moment in fertility work up or treatment.
45605943|NCT02302937|Procedure|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm )|laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
45605944|NCT02302937|Procedure|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port LESS (12 to 15 mm transumbilical).
45757138|NCT03089138|Drug|Regan Tangjiang|The treatment duration is 3 consecutive days.
45757139|NCT05737563|Drug|PD-1 Inhibitors|Teripulimab 240mg, injection or Carrelizumab 200mg, injection, every 3 weeks.
45757140|NCT05737563|Drug|Irinotecan|Irinotecan: 200mg/m2, injection (For patients who are confirmed to be homozygous for UGT1A1*6 or UGT1A1*28 or UGT1A1*6 and UGT1A1*28 at the same time, the starting dose of CPT-11 is 150 mg/m2).
45757141|NCT05737563|Drug|Capecitabine tablets|Capecitabine: 1600 mg/m2/d, oral, 2 weeks on and 1 week off.
45757142|NCT05385783|Drug|CYB003|CYB003 is a synthetic psilocybin analog.
45757143|NCT05385783|Behavioral|Psychotherapy|Manualized psychotherapy (called EMBARK) performed by facilitators
45911285|NCT02005991|Drug|PF-05212377|Single, oral dose administration of 10 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arms 1 and 2.
45757144|NCT05385783|Drug|Placebo|Placebo
45911286|NCT02006017|Other|Evidence summary alone plus a recommendation|
45605945|NCT04464551|Drug|[14C]D-0316 suspension|Before administration, the drug preparation was placed at room temperature, and 40ml drinking water was added into each bottle to prepare suspension for the subjects to take. 40ml pure water was injected again. After washing the container, the subjects took orally. Repeat the previous step, and then used 160ml purified water. After the administration container was moistened for several times, the subjects took all the moistening lotion. Pay attention not to splash the liquid during mixing outside the bottle
45605946|NCT02299583|Other|Preventive intervention trauma-informed early intervention|Every department appoints 2-4 health care professionals as child welfare officers (CWOs) who will be responsible for carrying out the intervention at the department. Whenever a child or adolescent is present in the department a CWO will be send for. The intervention consists of four distinct elements: 1) A standardized plan of action for the appointed health care CWOs on how to conduct trauma-informed health care for children and their families shortly after exposure to a PTE, 2) a training program for CWOs on trauma-informed support and communication with children and their families, 3) a supervision program for the CWOs, and 4) three psychoeducational booklets for young children, older children, and parents. The booklets will be given to the families by the CWOs.
45605947|NCT03252093|Drug|Angiotensin-(1-7)|Subcutaneous injection of 200 mcg/kg/day
45605948|NCT03252093|Drug|Placebo for Angiotensin-(1-7)|Subcutaneous injection of Placebo
45605949|NCT04931498|Other|Questionnaire|Medical history, demographics and lifestyle factors will be assessed by the participant.
45757145|NCT05385783|Behavioral|Psychological Support|Manualized psychological support performed by facilitators
45605950|NCT04931498|Other|Anthropometric measurements: height, weight, and body fat|Height measured by stadiometer. Weight and body fat measured by Tanita scale bioelectrical impedance analysis.
45605951|NCT04931498|Other|Blood pressure and heart rate|Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.
45605952|NCT04931498|Procedure|Venepuncture (GMPR)|"A blood sample of approximately 50 ml of venous blood will be taken. From the obtained blood sample, measurements will include a full blood count and the following phenotyping tests:~Flow cytometry to quantify cell surface expression of key erythroid markers~Proteomic analysis of isolated erythrocytes using mass spectrometry"
45757146|NCT03082118|Device|Vesair Bladder Control System|Intravesical balloon
45605953|NCT04931498|Procedure|Venepuncture (SWAP70)|"A blood sample of approximately 50 ml of venous blood will be taken. From the obtained blood sample, measurements will include a full blood count and the following phenotyping tests:~Flow cytometry to quantify cell surface expression of key markers~Fluorescence-Activated Cell Sorting (FACS) to assess B-cell receptor signalling and to isolate cell type-specific RNA for transcriptome analysis~Immunoglobulin isotype titre analysis in plasma~Isolation of monocytes for subsequent use in phagocytosis assays"
45605954|NCT02299661|Drug|DS-1093a|DS-1093a, single oral doses up to 50 mg
45605955|NCT03510767|Drug|TQ-B3525|TQ-B3525 p.o. qd
45605956|NCT02436356|Device|Osteoprobe-Reference Point Indentation (RPI)|Diagnostic tool used for bone indentation to measure the ability of the tissue to resist microindentation (bone mineral strength).
45605957|NCT02436356|Radiation|Dual-energy X-ray absorptiometry (DXA) Scans|Assessment of Fracture Risk
45605958|NCT02436356|Radiation|MRI|Determines bound water and pore water of bone.
45605959|NCT03510611|Drug|Ensartinib with fed or fasting|The two groups of subjects were given an equal dose of Ensartinib capsules (225 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of Ensartinib.
45605960|NCT02299739|Drug|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
45605961|NCT02299739|Procedure|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
45605962|NCT02299739|Procedure|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
45605963|NCT02299739|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
45605964|NCT02299739|Procedure|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
45605965|NCT02436200|Device|Neuromuscular Electrical Stimulation|Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol.
45757147|NCT03081962|Drug|Bundle|Combination of antibiotic intraperitoneal irrigation with gentamicin and clindamycin solution, use of Triclosan-impregnated sutures and mupirocin application over the skin staples.
45757148|NCT03081962|Procedure|Standard care|Standard care measures include decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care protocol, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
45757149|NCT05345756|Device|Intraoral protraction device|Use of modified lingual arch with indirect anchorage from screws between lower lateral incisor and lower canine to protract maxilla after ALT-RAMEC protocol
45757150|NCT05345756|Device|Extraoral protraction device|Facemask which is an extraoral appliance used for maxillary protraction
45911287|NCT02006017|Other|Evidence summary alone|
45605966|NCT02299817|Drug|Denosumab|"Prolia is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones). In women who have been through the menopause Prolia reduces the risk of fractures in the spine and elsewhere in the body, including in the hip.~Prolia is also used to treat bone loss in men receiving treatment for prostate cancer that increases their risk of fracture. Prolia reduces the risk of fractures in the spine.~Recently denosumab was found to be effective in preventing osteoporosis related fractures in post-menopausal women by blocking RANKL and thereby inhibiting the development and activity of osteoclast."
45605967|NCT02299817|Drug|Placebo|Placebo
45605968|NCT01679613|Drug|Nintedanib|low or medium dose depending on pilot part
45605969|NCT01679613|Drug|Nintedanib|low dose oral administration
45605970|NCT01679613|Drug|Ketoconazole|oral administration
45605971|NCT01679613|Drug|Nintedanib|low dose oral administration
45757151|NCT05736315|Other|Placebo dairy beverage|Placebo dairy beverage (placebo) is a sweetened dairy beverage.
45757152|NCT03088982|Other|Questionnaire|"FPs who had agreed to participate worked according to the following plan: first, the multimorbid patient was asked to give his/her consent to participate in the study once the terms had been explained to him/her. After that, FPs completed a questionnaire about their patient.~The purpose of this questionnaire was to explore potential decompensation risk factors within the themes and subthemes of multimorbidity."
45911288|NCT02006043|Drug|Erlotinib 150mg|
45605972|NCT01679613|Drug|Nintedanib|low or medium dose depending on pilot part
45605973|NCT01679613|Drug|Ketoconazole|oral administration
45605974|NCT02489630|Drug|Ketamine|0.1mg/kg ketamine IV
45605975|NCT02489630|Drug|Normal Saline|1ml/kg normal saline placebo
45605976|NCT02489630|Drug|opiate analgesic|0.1mg/kg dose of morphine (or morphine equivalent) at 30 min time intervals based on patient pain score or more frequently upon request
45605977|NCT03513263|Procedure|Scaling and polishing|An electronic scaler will be used to clean the gums
45605978|NCT03513263|Other|oral hygiene instructions|It will include 15-minute oral session with visual and verbal information on how to use a toothbrush, dental floss, and mouthwash correctly; how to clean bridges and dentures; and how and why to use a plaque disclosing test to perform tooth cleaning
45605979|NCT03138213|Procedure|Total laparoscopic pancreaticoduodenectomy|Total laparoscopic pancreaticoduodenectomy
45605980|NCT03138213|Procedure|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy
45605981|NCT04918082|Other|Quality of life questionnaires|Patients' quality of life will be assessed with self-reported items through both the EORTC-QLQ-C30 and EORTC-QLQ-BR23 modules.
45605982|NCT02739347|Device|Active Trans-cranial direct-current stimulation|Active stimulation group will receive 20 min of 2 mA direct current stimulation.
45911289|NCT02006082|Device|Telemedicine video-consultation (TVC)|All patients enrolled in the study, were previously monitored by TVC, and the number and length of hospital stays within 6 and 12 months following TVC were compared to similar numbers before TVC in comparable time periods. Thus, TVC is actually not to be considered as an intervention.
46066643|NCT00765271|Drug|Abacavir|"Group 1 will be instructed to take • Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study~Group 2 will be instructed to take~• Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study"
46066644|NCT00765271|Drug|Darunavir/ritonavir|"Group 1 will be instructed to take~• Three 300mg Darunavir tablets and one 100mg ritonavir tablet once a day for 14 days (on days 2 - 15)"
45605983|NCT02739347|Device|Sham Trans-cranial direct current stimulation|This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.
45605984|NCT05089773|Procedure|The arterial switch operation|"The ASO is a procedure that emerged as an anatomically as well as physiologically appropriate solution to the transposition of the great arteries. The aorta and pulmonary artery are detached from their native roots and reattached to the opposite root; thus, the pulmonary root becomes the neo-aorta, and the aortic root becomes the neo-pulmonary artery.~The coronary arteries are transplanted from the aorta/neo-pulmonary artery to the pulmonary artery/neo-aorta."
45605985|NCT02435966|Device|Dry needling|Dry needling of the most active trigger point either in the upper trapezius or the levator scapulae with 40mm x 0,32mm ener-qi guided needles (EQ1132)
45605986|NCT02435966|Device|Sham Dry needling|Sham Dry needling with a retractile needle (Park Sham Placebo Acupuncture Device) of the most active trigger point either in the upper trapezius or the levator scapulae
45605987|NCT02435966|Other|Manual therapy|Standard manual therapy in the upper trapezius or the levator scapulae
45605988|NCT00590265|Device|Northern Light Technology (SADelite lamp) bright light-therapy|10 000 lux for 30 minutes
45605989|NCT00590265|Device|Northern Light Technology (SADelite lamp) Dim light-therapy|<100 lux for 30 minutes
45605990|NCT05089539|Drug|Angiotensin Receptor-Neprilysin Inhibition|Sacubitril/valsartan [100 mg] bid). Continuous treatment was maintained for at least three months.
45605991|NCT05089539|Drug|Placebo|Placebo [100 mg] bid). Continuous treatment was maintained for at least three months.
45757153|NCT05736237|Genetic|Whole exome sequencing|With Next Generation Sequenzing
45757154|NCT03088904|Biological|FluMist® Quadrivalent|LAIV4 vaccine dosage is 0.2 mL. Vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
45757155|NCT03088904|Biological|Fluzone® Quadrivalent vaccine|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
45757156|NCT04768491|Drug|Dacomitinib|effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.
45911290|NCT02006173|Drug|Lidocaine|Xylocaine is a 2 % lidocaine hydrochloride contained liquid anesthesia
45911291|NCT02006173|Drug|Normal Saline|
45605992|NCT02299973|Procedure|FMT with donor stool|fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from a healthy pool of donors and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the treatment group
45605993|NCT02299973|Procedure|FMT with own stool|fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from the patients and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the control group
45605994|NCT05089383|Drug|Utrogestan|PROSPECTIVE STUDY
45757157|NCT05374863|Device|Neuromuscular electrical stimulation (NMES) - Active|The NMES will be held for 20 minutes. Biceps musculature and bilateral wrist and finger flexors stimulated. For patients undergoing hemodialysis for fistula in the upper limb, NMES will be performed only in the limb without a fistula. points of points 4 electrodes in each, being 2 points of longitudinal position in the muscular belly of the biceps, and other 2 in the ventral region of the forearm. the parameters: frequency of 80 Hz, pulse frequency of 350 ms, time of 5 seconds and 10 seconds. The possibility will be greater for each patient who will have the contraction. Patients will be instructed to perform an isometric contraction of wrist and finger flexors during electrical stimulation.
45605995|NCT02300051|Behavioral|STPGP and RPGT|
45605996|NCT02300051|Drug|TAU|
45605997|NCT02303249|Other|Review of discharges and cross-sectoral video conferencing immediately after discharge|The intervention is video conference which is randomized and is an intervention that is assigned by the investigator.
45757158|NCT05374863|Device|Neuromuscular Electrical Stimulation (NMES) - Sham|It will be performed in the same way as in the experimental group, however, the intensity of the actuality will only reach the sensitive threshold.
45605998|NCT05088993|Other|Antigravity treadmill training|This group received antigravity treadmill training 100% weight bearing
45605999|NCT05088993|Other|Conventional exercise program|This group received the conventional exercise program only.
45606000|NCT03510533|Other|Evaluation of the rates of the autoantibodies directed against the neuropeptides (ghrelin and alpha-MSH) controlling involved in food intake regulation|blood samples (12ml) and stool samples (30g) collections
45606001|NCT03301935|Procedure|Electrophysiology testing and exercise stress testing|Each patient will perform an exercise stress test on bicycle before an invasive electrophysiological test. Both examinations will be performed according to current Clinical practice.
45606002|NCT03513185|Drug|Deanxit, SSRI or SRNI|After recruiting participants and collecting the baseline data, the SSS-CN, PHQ-15, PHQ-9 and GAD-7 questionnaires will be carried out. An independent diagnosis will be made by primary care physician using the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criterion standard. Deanxit, selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI) will be selectively prescribed according to the severity category assessed by physician. Two, 6,10 weeks after patients with correspondent medications, a face-to-face interview, telephone interview or mobile-apps survey will be underwent to follow-up using the SSS-CN, PHQ-15, PHQ-9 and GAD-7 checklists.
45606003|NCT04464395|Drug|CPI-006|Participants will receive a single dose of CPI-006 at one of four dose levels (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 5.0 mg/kg) along with standard of care.
45606004|NCT04464395|Other|Standard of Care|Participants will receive standard of care treatment only.
45606005|NCT01679301|Device|Pulse Dose (Sleep Mode)|SimplyGo Portable Oxygen Concentrator has two different modes of use 'Sleep Mode', or pulsed oxygen and continuous dose.
45606006|NCT01679301|Device|Continuous Dose|SimplyGo Portable Oxygen Concentrator has two different modes of use 'Sleep Mode', or pulsed oxygen and continuous dose.
45606007|NCT03513107|Other|ospeoporosis score|"Scores will be calculated as indicated in their respective studies after collecting the data pertaining to them (Crandall, 2015); (Cass & Shepherd, 2013); (Reginster, et al., 2004); (Adler, et al., 2003); (Cadarette, et al., 2000); (Weinstein & Ulery, 2000); (Black, et al., 1998); (Lydick, et al., 1998).~Data will be treated as dichotomous for both DXA T-scores and screening scores (i.e. Osteoporosis (Yes or NO) versus positive/negative score)."
45606008|NCT03513029|Device|VytronUS Ablation System|Catheter Ablation for Paroxysmal Atrial Fibrillation
45606009|NCT05088837|Other|muscle energy technique|MET was performed in the form of post-isometric relaxation technique for iliopsoas, hamstrings, and erector spinae and quadratus lumborum muscles. the limb was taken very slightly beyond the restriction barrier and was held there for 10-30 seconds, it was done 3 times per session for 12 sessions.
45606010|NCT05088837|Other|ice and heat packs|Applying 20 minutes: 10 minutes hot,10 minutes cold on sacroiliac area, 3 times per week for 12 sessions
45606011|NCT03512951|Other|Digital signal processing algorithms|The intervention consists in applying five processing on some recorded speech signals. In particular, the processing performed by one specific algorithm is compared against the four other. The applied processing is supposed to restore sound externalization (expected audio-visual fusion).
45911292|NCT02006186|Behavioral|Bicycle Train|The Bicycle Train intervention consists of research staff members who bike to and from school with enrolled participants
45911293|NCT02006199|Behavioral|mindfulness meditation|8 weeks of mindfulness meditation specified for OCD patient
45911294|NCT02006212|Procedure|If any intraoperative EEG abnormality and/or asymmetry is detected a cerebral CT scan will be performed in the immediate postoperative period|
45911295|NCT02006225|Drug|Plerixafor|
45606012|NCT02951559|Device|Nasal Brushing|"Nasal brushing will be performed in non-sedated patients as follows. After administration of a local vasoconstrictor (1% epinephrine) with the use of a nasal tampon, inserted into the nasal cavity of the patient to locate the olfactory mucosa lining the nasal vault. A sterile, disposable brush (Copanflock, Copan, Brescia, Italy) will be inserted gently rolled on the mucosal surface, withdrawn,and immersed in 0.9% saline solution, UTM (Universal Transporter Medium) or 4% formaldehyde. Two swabs will be collected for each nostril."
45606013|NCT04464239|Drug|TS-142|TS-142 tablets
45606014|NCT04464239|Drug|TS-142 Placebo|TS-142 matching placebo tablets
45606015|NCT02300207|Device|electronic acupuncture treatment instrument|Electroacupuncture was performed using small-sized (1.5 cm) cutaneous electrode pads placed bilaterally at the PC-6 points of the forearms (Supplementary Figure 1). The intensity of the electrical stimulation was adjusted to produce the most intense tolerable electrical sensation without muscle contractions or uncomfortable feelings at a frequency of 50 Hz using the Hwato electronic acupuncture treatment instrument (Model No. SDZ-II; Suzhou Medical Appliances Co, Ltd, Suzhou, China).
45606016|NCT03512873|Drug|Tranilast|Subjects will be treated with tranilast
45606017|NCT01678911|Drug|Gralise|"Subjects will start at 600mg and titrate up by 600mg a week for two weeks (to 1800mg), then remain on 1800mg steady state dose of medication (or placebo pills) for 2 weeks. If intolerable side effects occur, the dose may be reduced to last tolerable dose at the discretion of the PI. A 2-week down-titration will be used. Subjects will have 1 week of wash-out before repeating the above procedure for the other arm of the study (placebo or medication)."
45606018|NCT03510377|Other|Aquatic physical intervention|For structured aquatic physical intervention group, the Ai-Chi method was selected. Ai-Chi is a simple aquatic exercise and relaxation method that uses a combination of deep breathing and slow movements of the arms, legs and torso in continual flowing patterns. The Ai-Chi intervention will occur in an hydrotherapy pool (34C).
45606019|NCT03510377|Other|On-land physical intervention|For controlled comparison of the structured physical intervention group the Tai-Chi method was selected (the same movements as the Ai-Chi). The Tai-Chi intervention will occur in a room.
45606020|NCT03510377|Other|Non physical intervention|The people who will be part of the non physical intervention will practice guided imagery of the Ai-Chi method. The guided imagery intervention will occur in a room.
45606021|NCT03132701|Drug|Magnesium|Mg is administered during anesthesia until 5 minutes before surgery ends
45606022|NCT03132701|Drug|Saline|Same volume of saline is infused until 5 minutes before surgery ends
45606023|NCT02322099|Drug|Alendronate|alendronate 70 mg tablets to be administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART initiation
45606024|NCT02322099|Drug|Placebo|Sugar pill manufactured to mimic alendronate 70 mg tablet administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART
45606025|NCT02322099|Dietary Supplement|calcium carbonate and colecalciferol|Calcium carbonate 1250 mg (equivalent to 500 mg of elemental calcium) and colecalciferol 400 iu (equivalent to 10 micrograms of vitamin D3) tablets administered twice daily for a total of 14 weeks, commencing 2 weeks prior to ART initiation
45606026|NCT02322099|Drug|Tenofovir disoproxil|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing for 48 weeks
45606027|NCT02487446|Drug|QVA149|QVA149 capsules for inhalation, delivered via QVA149 single dose dry powder inhaler (SDDPI)
45606028|NCT02487446|Drug|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
45606029|NCT02487446|Drug|Placebo (umeclidinium/vilanterol)|Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
45606030|NCT02487446|Drug|Placebo (QVA149)|Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
45606031|NCT03512795|Biological|Blood samples|An additional blood tube will be taken during the patient's follow-up blood collection.
45606032|NCT05081349|Drug|Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine|Combination therapy
45606033|NCT05081349|Drug|Hydroxycarbamide 500 Mg Oral Capsule|Single agent
45606034|NCT05081349|Drug|L-Carnitine, 250 Mg Oral Capsule|single agent
45606035|NCT03512717|Device|Potenfill|Maximum: 22ml
45606036|NCT03512717|Device|Powerfill|Maximum: 22ml
45606037|NCT03132545|Diagnostic Test|SenseWear Armband (SWA) monitoring|Participants wore the SWA on their right arm
45911296|NCT02006238|Device|Farabloc|The participants will be randomly received Farabloc (experimental) for one week, followed by a 7 day washout and then crossed over to received the Nylon fabric (placebo) for one week.
45911297|NCT02006238|Device|Nylon Fabric|The participants will be randomly received Nylon fabric (placebo) for one week, followed by a 7 day washout and then crossed over to receive Farabloc (experimental) for one week.
45606038|NCT03132545|Diagnostic Test|total body dual-energy X-ray absorptiometry|DEXA was used to estimate abdominal visceral adipose tissue and subcutaneous adipose tissue
45606039|NCT05071599|Device|Twin Arch Brackets|Twin Arch Brackets characterized by double horizontal slots which make it capable to accept two arch wire at the same time which in turn can achieve a better control over orthodontic tooth movement
45606040|NCT04464005|Drug|Magnesium sulfate 33% solution|Topical pads with cold magnesium sulfate 33% solution will be given 5 times/day for 15 minutes
45606041|NCT04464005|Other|Cold water|Topical pads with cold water will be given 5 times/day for 15 minutes
45606042|NCT02303327|Radiation|EBRT + HDR brachytherapy boost|Standard radiotherapy (EBRT, 23 fractions) with the addition of High Dose-Rate (HDR) brachytherapy boost within 3 weeks of beginning or finishing the EBRT.
45606043|NCT02303327|Radiation|Hypofractionated Dose Escalation Radiotherapy|Radiation therapy (higher radiation dose per treatment) will be given once a day, five days a week, over approximately 5 weeks.
45606044|NCT02303327|Drug|Androgen deprivation therapy|28 months of androgen deprivation therapy (injections every 4 months for a total of 28 months)
45606045|NCT05377593|Device|eminoplasty with patient specific Zirconium dioxide onlay implant|Eminoplasties will be done for patient with chronic condylar dislocation using patient specific zirconium dioxide implants
45606046|NCT03510299|Device|Mcgrath|McGrath assisted insertion of LMA flexible
45606047|NCT03510299|Device|Control|Digital manipulation technique of LMA flexible insertion
45606048|NCT03136419|Dietary Supplement|Lactobacillus casei DG|Lactobacillus casei DG probiotic supplementation for 8 weeks
46066645|NCT00765271|Drug|Raltegravir|"Group 1 will be instructed to take • Two 200mg Raltegravir tablets twice daily for 14 days (on 16 - 29)~Group 2 will be instructed to take~• Two 200mg Raltegravir tablets twice daily for 14 days (on days 2-15)"
45606049|NCT03136419|Dietary Supplement|Placebo|Placebo supplementation for 8 weeks
45606050|NCT03510221|Dietary Supplement|Antioxidants capsules|1 capsule of cranberry, 1 capsule of blueberry, and 1 capsule of pomegranate extracts were offered during 4 weeks
45606051|NCT05068089|Procedure|Nissen fundoplication|Nissen fundoplication, numbers, reasons and length of hospitalizations, gastrointestinal symptoms and survival
45606052|NCT05068089|Biological|Enteral nutrition|Type and switch of enteral nutrition formula (tube, PEG, PEJ)
45606053|NCT03510143|Device|Neoveil (Polyglycolic Acid Mesh)|Apply the Neoveil (Polyglycolic Acid Mesh) in the neck node dissection area in thyroid cancer surgery.
45606054|NCT03510065|Device|Prevision®|One time Evaluation with documentation of one follow-up visit
45606055|NCT04541511|Diagnostic Test|6-minutes walking test on a corridor|6-minutes walking test on a corridor : patient will be asked to achieve the longest possible distance without running. He/she will be allowed to take breaks if he/she feels the need to do so.
45606056|NCT04541511|Diagnostic Test|6-minutes walking test on a treadmill|6-minutes walking test on a treadmill : patient will be asked to achieve the longest possible distance without running on the treadmill. He/she will be allowed to take breaks if he/she feels the need to do so.
45606057|NCT03509987|Device|HemaCue|comparing hemoglobin (Hb) levels determined by point of care testing HemaCue and arterial blood gas analyzer with an automated hematology analyzer in critically ill geriatric patients.
45606058|NCT03509831|Drug|INT-2150|"Period: INT-2150~Period: Irsogladine maleate 2 mg+Nizatidine 150 mg"
45606059|NCT03509831|Drug|Irsogladine maleate 2 mg+Nizatidine 150 mg|"Period: Irsogladine maleate 2 mg+Nizatidine 150 mg~Period: INT-2150"
45606060|NCT02303483|Dietary Supplement|Nicotinamide riboside (NIAGEN TM, ChromaDex, CA, USA )|
45606061|NCT02303483|Dietary Supplement|Placebo|
45606062|NCT05046327|Drug|Avatrombopag 20 mg Oral Tablet|Avatrombopag administered at a frequency to maintain a target platelet count between ≥50 and ≤150×10⁹/L
45606063|NCT03509753|Dietary Supplement|High Fiber|See intervention description.
45606064|NCT03509753|Dietary Supplement|Low Fiber|See intervention description.
45606065|NCT05378061|Drug|Pituitary adenylate cyclase activating polypeptide-38|Study participants will be allocated to receive continuous intravenous infusion of 10 pmol/kg/min PACAP-38.
45606066|NCT05378061|Drug|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
45606067|NCT02303561|Behavioral|CHAMP|Families assigned to this arm will receive tailored asthma education and behavioral skills focused on improving asthma and weight management.
45606068|NCT02303561|Behavioral|Health education|Families assigned to this arm will receive tailored asthma education and general health education on a variety of topics.
45606069|NCT02303639|Procedure|Radiofrequency catheter ablation|Catheter ablation with an open-irrigated tip ablation catheter and 3D electroanatomical mapping
45606070|NCT02303639|Drug|Antiarrhythmic drug therapy|Amiodarone (or sotalol) for prevention of VT/VF relapses
45606071|NCT02303717|Device|Percutaneous coronary intervention|Percutaneous coronary stent implantation
45606072|NCT02303717|Drug|Dual antiplatelet therapy|Dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel or ticagrelor will be recommended for 12 months duration in the Xience stent arm but only 4 months duration in the Synergy stent arm.
45606073|NCT04487847|Diagnostic Test|18F-PSMA-1007 PET/CT|18F-PSMA-1007 PET/CT
45606074|NCT03509597|Behavioral|Aerobic Exercise|Physical exercise training consisting of aerobic exercise and strength/resistance training.
45606075|NCT03509597|Behavioral|Cognitive Training|Cognitive remediation program using REHACOP rehabilitation program.
45606076|NCT03509597|Behavioral|Treatment as usual|Standard care for schizophrenia + Leisure and free time activities.
45606077|NCT03509597|Behavioral|Occupational Activities|Engagement in activities aimed to keep patients actively involved in demanding tasks.
45606078|NCT04820127|Behavioral|personalized care preceded by a standardized assessment|"personalized intervention plan (PIP) proposed to the patient/caregiver dyad to correct potentially reversible causes of psycho-behavioral symptoms. This PIP will be re-evaluated and adapted at each visit by the nurse in close collaboration with the GP;~PIP implementation will be based on a close follow-up during the 18 months follow-up coordinated by the nurse (3 memory consultation visits, 3 home visits (with the GP) and 6 phone calls). This follow up will be enhanced with the use of a web platform (allowing teleconsultation, tele-expertise and telemonitoring);~specific training on psycho-behavioral symptoms for caregivers at baseline and during follow-up will be performed. On line training on psycho-behavioral symptoms management for GP will be available;"
45606079|NCT03509519|Other|NMES-Millicurrent|Stimulating electrodes will be applied to the quadriceps muscle of each leg 3 times a week for 4 weeks (12 sessions) for 40min per leg.
45606080|NCT02303873|Drug|Alendronate|Alendronate was administrated as 70 mg/week orally (Fosamax, Merck Sharp & Dohme．LTD.).
45606081|NCT03138135|Behavioral|HOME Study intervention|Access to home HIV test kits, home STI self-collection kits, the HOME Study website, and the SexPro HIV risk assessment tool.
45606082|NCT03138135|Behavioral|Control|Counseling about the importance of quarterly HIV/STI testing and a PrEP information pamphlet.
45757159|NCT05374863|Device|Aerobic exercise with cycle ergometer|The exercise will be performed from the adaptation and positioning of a cycle ergometer (Mini Bike E5 Acte Sports®) in front of the hemodialysis chair. Each session will consist of three phases: duration (5 minutes), conditioning (20 minutes) and cool-down (5 minutes). During the development and cool-down phases, patients will be instructed to maintain a lower exercise intensity, with a level between 1 and 3 on the modified BORG scale. In the conditioning phase, patients will be instructed to slightly increase the intensity of the exercise, levels between 4 and 7 on the modified BORG scale. During exercise, patients will be asked every 5 minutes about the level of effort, and the load on the cycle ergometer will be possible to reach an intensity between 4 and 7 on the modified Borg Scale.
45606083|NCT04506099|Device|TINS Active protocol|Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect, verified with contraction of the rectus abdominis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
45606084|NCT04506099|Device|Sham protocol|Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible until contraction is seen in the rectus abdominis. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect. The intensity level will be set to 1mA . If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable.
45757160|NCT03081572|Diagnostic Test|Platelet aggregation|Platelet aggregation
45757161|NCT03398252|Drug|Doxazosin XL|Participants will be randomized to receive increasing doses of doxazosin XL (0, 4, and 8 mg).
45606085|NCT02739269|Other|Serum AMH measurement|Serum AMH is measured one month before the IVF treatment
45606086|NCT02739269|Other|AFC measurement|Early follicular phase AFC is measured one month before the IVF treatment
45606087|NCT04757493|Drug|Prucalopride 2mg|Both prucalopride 2mg and placebo will be administered for 6 weeks. Primary outcome will measure at 2nd and 6th week of treatment.
45757162|NCT03398252|Drug|Placebo|Participants will be randomized to receive a placebo for doxazosin XL.
45757163|NCT04402268|Device|Cardioverter-defibrillator|We analyzed how many HCM patients reached an end-point of sudden cardiac death defined as adequate intervention of cardioverter-defibrillator or sudden cardiac arrest.
45757164|NCT02285283|Drug|Itraconazole|
45757165|NCT02285283|Drug|Placebo|
45757166|NCT05688098|Drug|Irbesartan/Amlodipine High FDC|Irbesartan/Amlodipine High FDC
45606088|NCT03509363|Behavioral|Stroke physiotherapy home exercise video|a set of exercise video with QR code provided in home exercise pamphlets
45757167|NCT05688098|Drug|Irbesartan|Co-administration of Irbesartan and Amlodipine High
45606089|NCT02303951|Drug|Vemurafenib|Run-In: Day 1-21 960 mg bid orally, Day 22-28 720 mg bid orally Triple-Treatment (week 5 ongoing): 720 mg bid orally
45606090|NCT02303951|Drug|Cobimetinib|Run-In: Day 1-21 60 mg od orally Triple-Treatment (week 5 ongoing): 60 mg od 21/7 orally (3 weeks on drug, 1 week off)
45757168|NCT05688098|Drug|Amlodipine High|Co-administration of Irbesartan and Amlodipine High
45757169|NCT02285907|Other|Macronutrient and Fiber Matched BEEF|The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
45444715|NCT03564873|Drug|Omacetaxine|Phase II is a maximum tolerated dose phase. Phase I will determine the maximum tolerated dose (highest amount that can be safely administered). Patients will receive omacetaxine subcutaneously at the maximum tolerated dose (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
45606091|NCT02303951|Drug|Atezolizumab|Triple-Treatment (week 5 ongoing): 840 mg Q2W i.v
45757170|NCT02285907|Other|Macronutrient and Fiber Matched SOY|The participants will consume the macronutrient and fiber matched SOY lunch on a single testing day. SOY contained 33% protein, 43% CHO, and 24% fat; the SOY meal contained 24 g of textured soy protein concentrate (Boca Foods, WI).
45757171|NCT02285907|Other|Serving Size Matched BEEF|The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
45757172|NCT02285907|Other|Serving Size Matched SOY|The participants will consume the serving size matched SOY lunch on a single testing day. SOY contained 24% protein, 49% CHO, and 24% fat; the SOY meal contained 14 g of textured soy protein concentrate (Boca Foods, WI).
45757173|NCT04402424|Diagnostic Test|Faecal Immunochemical Testing|Stool samples for both point of care and laboratory based faecal immunochemical testing via device specific sampling sticks
45606092|NCT04406415|Drug|Nafamostat Mesilate|Oral nafamostat, 10, 50, 100, or 200 mg administered three times daily for up to 5 days
45606093|NCT04406415|Drug|Placebo|Oral placebo administered three times daily for up to 5 days
45606094|NCT02304029|Device|MRI|
45757174|NCT03429140|Drug|Gel-One|an injection of Gel-One® (hyaluronan, 3 mL) 1-2 weeks after ACL surgery
45757175|NCT03429140|Other|Saline Placebo|a placebo injection (saline, 3 mL) 1-2 weeks after ACL surgery
45757176|NCT04768179|Drug|3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)|Low dose aspirin for 14 days plus ivermectin at 200 mcg/kg/day or 600 mcg/kg/day for 3 days
45757177|NCT03081494|Drug|spartalizumab (PDR001)|100 mg lyophilisate in vial received 400 mg every 4 weeks
45757178|NCT03081494|Drug|regorafenib|120 mg once daily first 21 days of each 28-day cycle (=4 weeks)
45757179|NCT05658471|Other|Standardized Research E-Cigarette (SREC)|Standardized Research E-Cigarette (SREC) will be obtained through NJOY, LLC and provided at the hospital stay.
45757180|NCT05658471|Other|Over the Counter E-Cigarette (EC)|Usual brand e-cigarettes will be provided at the hospital stay.
45757181|NCT05658471|Behavioral|Biological Samples|Blood, urine, and expired carbon dioxide will be obtained during the course of the study.
45757182|NCT05658471|Other|Smoking-related Questionnaires|Nicotine and Smoking behavior and dependence questionnaires will be administered at screening, before and during hospital stays.
45757183|NCT03081728|Device|Interscalene Block with Ropivacaine Hcl 0.2% Inj Vil 10Ml|bolus 10ml of 0.5% ropivacaine followed by infusion @ 2ml/hr of 0.2% ropivacaine
45606095|NCT05738187|Procedure|local cryotherapy treatment|cryotherapy
45606096|NCT02304107|Drug|FSH|75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days
45606097|NCT02304107|Drug|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.
45606098|NCT03137823|Diagnostic Test|throat culture|throat culture - from the tonsills and from the bucal surface
45606099|NCT02304185|Biological|gp140, 50 mcg|Glycoprotein 140 (gp140) vaccine containing 50 microgram (mcg) total protein will be administered intramuscularly on Day 1 and Day 29.
45606100|NCT02304185|Biological|gp140, 50 mcg + Adjuvant|The gp140 vaccine containing 50 mcg total protein mixed with 0.425 milligram (mg) aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
45606101|NCT02304185|Biological|gp140, 250 mcg|The gp140 vaccine containing 250 mcg total protein will be administered intramuscularly on Day 1 and Day 29.
45606102|NCT02304185|Biological|gp140, 250 mcg + Adjuvant|The gp140 vaccine containing 250 mcg total protein mixed with 0.425 mg aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
45606103|NCT02304185|Drug|Placebo|Placebo matched to gp 140 vaccine drug product will be administered intramuscularly on Day 1 and Day 29.
45606104|NCT03195855|Other|Manual therapy / joint mobilisations|Manual therapy is a common form of treatment employed usually by physiotherapists, in order to help increase range of motion of a specific joint region by restoring the arthrokinematic accessory gliding and rolling movement that is associated with normal joint movement. The hypothesised mechanism of action for this is that improvements of gliding and rolling will normalise osteokinematic rotation and consequently enable the normalisation of active movements. Another possible mechanism of action of mobilisations includes increasing the extensibility of the noncontractile capsular and ligamentous tissues. The effectiveness of passive accessory gliding techniques to increase joint ROM has been widely explored in the literature; with some studies revealing an increase in ankle dorsiflexion and others no change in ankle dorsiflexion. However, the subjects taking part in these studies were people without diabetes and mostly people with ankle sprains or ankle instability.
45606105|NCT02304263|Drug|iohexol|5mL bolus of 300 mg/ml iohexol (Omnipaque) over 2 minutes
45606106|NCT04376619|Other|remote ischemic preconditioning|inflation and deflation of cuff 5min each cycle repeated 3 times
45606107|NCT04376619|Other|KDIGO guidelines|KDIGO stands for Kidney disease Improving global outcomes guidelines, and have guidelines for prevention and treatment of AKI which is considered standard of care.
45606108|NCT03509285|Drug|Alprazolam Placebo|100 mg lactose tablets
45606109|NCT03509285|Drug|Cenobamate placebo|Sugar pill manufactured to mimic cenobamate 100 mg tablet
45606110|NCT03509285|Drug|Alprazolam|0.5 mg and 1.0 mg alprazolam tablets
45606111|NCT03509285|Drug|Cenobamate|100 mg tablet
45606112|NCT05738109|Other|Self-Talk Journals|Participants randomized to the intervention group will receive a physical copy of the 91-day self-talk journal during the baseline meeting. Participants will also be introduced the purpose of the journal and its intended usage (i.e., daily journaling). Intervention participants will not be offered guidance or feedback on the journal after these initial instructions, in order to emulate an ad libitum usage. Control group participants will not receive any contact with the researchers outside of the planned questionnaires and to receive their journal at the three-month timepoint.
45606113|NCT03509129|Behavioral|TECH (Technology)|"Participants will receive a theory-based physical activity program. They will enroll in the study as part of a self-selected group of 3-8 individuals. They will be provided with a personal step goal and Fitbit Alta HR for self-monitoring physical activity. They will also have access to a study website that will be accessible across conventional and mobile platforms. They will be asked to visit the website each week to receive behavior change information and guidance.~Device: Fitbit Alta HR"
45606114|NCT03509129|Behavioral|TECH+COMP (Technology + Competition)|"Participants will receive the same intervention components as the TECH group, as well as a team competition. The competition will be based on the following two aspects: total daily steps accumulated relative to group size and total number of points retained for achieving weekly physical activity challenges.~Device: Fitbit Alta HR"
45606115|NCT04384029|Other|Covid-19 + patients|all the patients hospitalized in Geneva and SARS-Cov2 positive
45606116|NCT02300363|Drug|Treatment A (rosuvastatin)|10 mg rosuvastatin administered on Day 1 and Day 13
45606117|NCT02300363|Drug|Treatment B (LX4211)|400 mg LX4211 administered on Day 7 through Day 13
45606118|NCT02300363|Drug|Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)|10 mg rosuvastatin + 400 mg LX4211 administered concomitantly on Day 13
45606119|NCT04370613|Behavioral|Prospective Imagery visualization task|Participant visualizes brief mental imagery of prospective situations of different valence (neutral, positive, negative).
45606120|NCT03318523|Drug|Placebo|Administered as specified in the treatment arm
45606121|NCT03318523|Drug|BIIB054|Administered as specified in the treatment arm.
45757184|NCT03081728|Drug|IV diclofenac and IV paracetamol|iv diclofenac 75 mg TDS iv paracetamol 1gm TDS
45911298|NCT02006277|Drug|Crizotinib prototype microsphere 0.529 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
45606122|NCT03135951|Drug|SPI-2012|Supplied in prefilled, single-use syringes for subcutaneous injection and administered on Day 2 of each cycle.
45606123|NCT02300441|Other|ECG, blood pressure and oximetry|
45606124|NCT03509051|Biological|B vaccination|One intramuscular injection of Bexsero (multicomponent B vaccine) from 6 months after transplant. A second similar dose will be given 2 months later.
45606125|NCT04185285|Device|Percutaneous coronary intervention, stents|
45606126|NCT02300519|Other|blood sampling|Samplings will be taken on 4 citrated S-monovette tubes, 3 citrated tubes and 1 EDTA tube, namely 36.5 ml for each volunteer
45606127|NCT03508973|Other|Sculpta|
45606128|NCT03512639|Drug|Homeopathic Medication|Homeopathic medication (Arnica montana and the Bellis perennis) were given to women in the study group following mastectomy and reconstruction to reduce post operative seroma
45606129|NCT03512639|Drug|Placebo|placebo was given to women in the control group following mastectomy and reconstruction to reduce post operative seroma
45606130|NCT04120701|Drug|mFOLFOX6|Patients receive adjuvant chemotherapy every 2 weeks during 6 months: FOLFOX6m (5-FU, leucovorin and oxaliplatin).
45606131|NCT02304419|Drug|Galunisertib|Administered orally.
45606132|NCT02304497|Other|Platelet Rich Fibrin|Procedure: Platelet Rich Fibrin obtained
45606133|NCT03135795|Drug|Sufentanil|Patients received intravenous sufentanil 0.5μg/kg for induction,and received PCA after surgery with sufentanil 1ug/ml using a controlled infusion pump, which was programmed to use a loading dose of 2ml, background infusion at 2m/h, PCA dose of 1ml, lockout time of 10min, and maximal dose of 12ml within 1 hour period.
45606134|NCT03135795|Drug|dexmedetomidine|Patients received intravenous dexmedetomidine 1μg/Kg for induction.
45606135|NCT03135795|Drug|propofol|Patients received intravenous propofol 2mg/Kg for induction, and received intavenous pump of propofol (0.3-0.6mg/kg/h) for maintenance.
45606136|NCT03135795|Drug|Rocuronium|Patients received intravenous rocuronium 0.6mg/Kg for induction.
45606137|NCT03135795|Drug|sevoflurane|Patients received inhalation of sevoflurane (1-2%) for maintenance.
45606138|NCT03135795|Drug|remifentanil|Patients received intavenous pump of remifentanil (0.1-0.2ug/kg/min) for maintenance.
45606139|NCT03135795|Drug|Parecoxib|Parecoxib 40mg was given single intravenously before incision.
45606140|NCT03471169|Drug|Desirable TEG|"Change the type and dose of antithrombotic therapy and obtain desirable TEG results.~Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol."
45606141|NCT03471169|Drug|Undesirable TEG|Don't change the type and dose of antithrombotic therapy and obtain undesirable TEG results. Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.
45606142|NCT02300597|Other|Internet based support and coaching|Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
45606143|NCT03474289|Drug|SHR-1316|Monotherapy
45606144|NCT04958967|Drug|Furmonertinib 240mg|treated subjects will receive Furmonertinib 240mg/day
45606145|NCT04958967|Drug|Furmonertinib 160mg|treated subjects will receive Furmonertinib 160mg/day
45606146|NCT02304575|Other|Questionnaires|"Questionnaires:~For examinee: European Organization for Research and Treatment of Cancer quality of life questionnaire of 30 items and testicular cancer module of 26 items (EORTC QLQ-30 + QLQ-TC-26), Multidimensional Coping Inventory, The Meaning Test for cognitive function, cognitive orientation questionnaires.~For partner: Multidimensional Inventory of quality of life (QoL) for Adults, Multidimensional Coping Inventory."
45606147|NCT02304575|Other|Hormonal Function measurement|Plasma levels of: follicular stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), prolactin, free androgen index.
45606148|NCT03469531|Drug|Nimotuzumab|Patients receive nimotuzumab IV over 90 minutes on days 1, 8, 15, 22, 29, 36,43.
45606149|NCT03469531|Drug|Cisplatin|Patients undergo cisplatin, 25-40 mg/m2 a week for 4 or 5weeks
45606150|NCT03469531|Radiation|external-beam radiation|Patients undergo pelvic EBRT once daily, 5 days a week, for 5 weeks for a total of 45-50.4Gy
45606151|NCT03469531|Radiation|brachytherapy|high-dose rate brachytherapy,6Gy once weekly,for a total of 24-30Gy
45757185|NCT05651217|Device|disposable urinary catheter|The trial group was intervened with disposable sterile urinary catheter. The model of the trial group includes two chamber type (Fr8, Fr10, Fr12, Fr14, Fr16, Fr18, Fr20, Fr22, Fr24) and three chamber type (Fr16, Fr18, Fr20, Fr22, Fr24).
45757186|NCT05651217|Device|super smooth antibacterial urinary catheter|the control group was intervened with ultra smooth antibacterial catheter. The control group models include single chamber (6Fr, 8Fr, 10Fr, 12Fr, 14Fr, 16Fr, 18Fr, 20Fr, 22Fr, 24Fr), double chamber (6Fr, 8Fr, 10Fr, 12Fr, 14Fr, 16Fr, 18Fr, 20Fr, 22Fr, 24Fr, 26Fr, 28Fr, 30Fr), and three chamber (16Fr, 18Fr, 20Fr, 22Fr, 24Fr, 26Fr)
45606152|NCT05737953|Diagnostic Test|cfDNA methylation sequencing and proteome analysis|Sequencing of cfDNA methylation and proteomic analysis of two sets of capsular fluid samples
45606153|NCT05737719|Behavioral|Rehabilitation before knee surgery (prehab)|Physiotherapy strategies for preparing the patient awaiting the surgical procedure
45606154|NCT05737719|Behavioral|Post-surgery rehabilitation|Physiotherapy strategies to manage post-surgery recovery
45606155|NCT03512483|Behavioral|Virtual Atrial Fibrillation Clinic|Participants in the intervention group will receive usual GP care plus the vAFC which consists of telehealth appointments with Nurse Practitioner/Cardiologist and access to an AF specific educational website. It is anticipated the vAFC, as with the onsite clinic, will include a maximum of four scheduled telehealth appointments: an initial appointment following randomization, at 4-6 weeks, 3 months, and 6 months.
45606156|NCT02304653|Other|Clinical descision making|Chage in diagnosis before and after the presentation of the reults of CRP and Leucocytes
45606157|NCT05737641|Other|water ingestion|ingestion of water after an 8h-fasting period
45606158|NCT05737641|Dietary Supplement|jelly ingestion|ingestion of jelly after an 8h-fasting period
45606159|NCT05159011|Behavioral|AGILITY (Access to Genetic Information Leveraging Innovative TechnologY)|information about genetic testing through technology
45606160|NCT02300675|Behavioral|therapeutic education program|
45606161|NCT03309007|Drug|Metformin|Total daily dose titrated up to 1500 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
45606162|NCT03309007|Drug|Placebo Oral Tablet|Total daily dose titrated up to 1944 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
45757187|NCT05688020|Drug|Tranexamic acid|Tranexamic acid will be injected as part of the injectate during endoscopic resection.
45606163|NCT03133143|Behavioral|Cognifit|CogniFit is an Internet browser-based digital brain training program, to improve cognitive abilities based on a personalised brain training regimen. Participants are instructed to play all games assigned by cognifit from three categories (memory, spatial perception, and mental planning) during each training session. After playing the games in these three categories, they are free to choose which exercises they wish to play.
45606164|NCT03133143|Behavioral|SIMS 4 (Maxis, Inc)|The Sims 4 is a life simulation PC game. It is purely an entertainment game without known cognitive or health-related outcomes. Does not iclude high-intensity action and competition. This specific game and non-competitive games like it in general do not improve attention, working memory, or other cognitive abilities despite being engaging and fun.
45606165|NCT03508817|Drug|Atropine Sulfate 0.01% Eye Drops|atropine eye drop in study eye once nightly for two years.
45606166|NCT02961517|Other|Questionnaire|Anonymous questionnaire collecting basic sociodemographic data about the participant and information regarding their preferences for the method of delivery format of patient education information
45606167|NCT02300753|Drug|EPI-743|EPI-743 is a quinone oxidation product of alpha-tocotrienol
45606168|NCT05158777|Biological|Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.|live varicella-zoster virus in 0.5 mL of sucrose, sodium chloride, potassium chloride, sodium glutamate, phosphate and injection water per injection
45606169|NCT05158777|Biological|Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd|live varicella-zoster virus in 0.5 mL of mannitol, dextrose tincture, sucrose, trehalose, human serum albumin and injection water per injection
45757188|NCT05688020|Drug|Epinephrine injection|Epinephrine will be injected as part of the standard injectate used during endoscopic resection.
45757189|NCT02986971|Device|New IMD|The contraceptive implants of the subjects in this arm are removed by the new IMD.
45606170|NCT03508583|Other|Participation|"The mpoc 56 and mpoc 20 will be field-tested with a sample of 300 parents of children with disabilities residing in the Turkey.~Professionals working with children with disabilities will be assessed with MPOC SP questionnaires"
45606171|NCT03469453|Behavioral|Internet-Delivered Cognitive Behavioral Therapy|Therapist-supported CBT delivered online.
45606172|NCT02300831|Other|Data Collection|Non interventional prospective data collection
45606173|NCT01678209|Other|fMRI scans|2 fMRI scans 6-8 weeks apart
45606174|NCT01678209|Drug|Atomoxetine arm|Flexible dose titration with atomoxetine prescribed at weekly visits for 6-8 weeks
45606175|NCT01678209|Drug|Methylphenidate arm|Flexible dose titration with methylphenidate for 6-8 weeks, with optional post study stabilization visits.
45606176|NCT02239120|Drug|optional ASA as comedication|optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
45606177|NCT02239120|Drug|placebo to ASA|placebo to comparator drug
45606178|NCT02239120|Drug|placebo to optional ASA as comedication|optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
45606179|NCT02239120|Drug|placebo to dabigatran etexilate|placebo
45606180|NCT02239120|Drug|ASA 100 mg|active comparator drug
45606181|NCT02239120|Drug|dabigatran etexilate|active drug
45606182|NCT04091893|Behavioral|Usual care/wait list|Individuals in this group can continue with their usual care (but receive no museum-based intervention)
45606183|NCT04091893|Behavioral|Art Rx|Individuals in this group participate in a specialized tour of an art museum
45606184|NCT04091893|Behavioral|Artful Meditation|Individuals in this group participate in a meditation and art appreciation program at an art museum
45606185|NCT02304731|Other|Physical Exercise|Incremental running
45606186|NCT04013269|Device|CytoSorb-Therapy|Additional use of Cytosorb-Adsorber in patients with septic shock and need for continuous renal replacement therapy
45606187|NCT04464863|Other|Kinematic metrics|kinematic metrics recorded with Kinect (register brand) and extracted with Akira (register brand)
45606188|NCT05158699|Drug|Bromfenac|Bromfenac topical eye drops (Yellox)
45606189|NCT05158699|Drug|Dexamethasone|Dexamethasone topical eye drops
45606190|NCT05158699|Drug|Triamcinolone Acetonide|0.25ml of 40mg/ml (10mg) triamcinolone acetonide (Triesence/Vistrec) will be injected subconjunctivally
45606191|NCT05158699|Drug|Ketorolac-Phenylephrine Ophthalmic 0.3%-1% Intraocular Solution|Omidria is added to the irrigation fluid used during cataract surgery. At the end of surgery, the anterior chamber will be filled with the ketorolac solution.
45606192|NCT03508505|Device|Venoarterial extracorporeal oxygenation|Veno-arterial extracorporeal oxygenation (VA-ECMO) is inserted in the acute setting in case of cardiac low output after adult cardiac surgery in order to provide cardiopulmonary support to recovery or as bridge to transplantation.
45757190|NCT05687864|Diagnostic Test|Polysaccharide superparamagnetic ferric oxide injection|The polysaccharide superparamagnetic ferric oxide injection is a clinical diagnostic reagent
45757191|NCT00618917|Genetic|Manganese Superoxide Dismutase Plasmid Liposome|15 ml of liquid that contains either 0.3 mg, 3.0 mg or 30.0 mg (depending on which cohort is open when the subject is entered) of MnSOD PL This will be given on Day 1 and 3 of each week of the experimental treatment for a total of 14 doses.
45757192|NCT00618917|Drug|carboplatin|Chemotherapy to stop the growth of tumor cells.
45911299|NCT02006277|Drug|crizotinib prototype microsphere 0.470 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
45911300|NCT02006277|Drug|crizotinib prototype microsphere 0.420 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
45606193|NCT05158465|Behavioral|Motivational Interviewing|Intervention will include 3 one-on-one motivational interviewing sessions and 3 follow-up calls with a trained MI health educator. These sessions aim to promote better oral hygiene and oral health.
45606194|NCT04464629|Drug|Dextenza|Intracanalicular sustained release dexamethasone insert 0.4 mg
45606195|NCT04464629|Drug|Prednisolone Acetate|Topical Prednisolone acetate 1% ophthalmic suspension
45606196|NCT02304887|Drug|Bis, SERM Teriparatide, Denosumab|Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.
45606197|NCT03474133|Drug|Brentuximab Vedotin|brentuximab vedotin 1,8 mg/kg, intravenous infusion every 21 days, up to 16 infusions per patient during study period
45606198|NCT02300909|Procedure|Lumbar Decompression Surgery|Lumbar Decompression Surgery
45606199|NCT02300909|Procedure|Microdiscectomy Surgery|Microdiscectomy Surgery
45606200|NCT02300909|Other|Dehydrated Human Amnion/Chorion Membrane (dHACM)|Application of Dehydrated Human Amnion/Chorion Membrane (dHACM)
45606201|NCT03474055|Biological|Liquid Rotavirus Vaccine|Liquid Rotavirus Vaccine and Lyophilized Rotavirus Vaccine
45606202|NCT03512171|Drug|Dextroamphetamine|One oral dose of dextroamphetamine (0.43mg/kg). The amphetamine is given in order to induce the release of their own dopamine for study with positron emission tomography (PET).
45606203|NCT03512171|Drug|Placebo|One oral dose of placebo to estimate D2 receptor levels at baseline with PET imaging (necessary to calculate dopamine release in the amphetamine condition).
45606204|NCT03512171|Diagnostic Test|[18F]Fallypride|Radioligand for measuring dopamine D2 receptors with positron emission tomography (PET)
45606205|NCT03512171|Diagnostic Test|[18F]-FE-PE2I|Radioligand for measuring dopamine transporters with positron emission tomography (PET)
45606206|NCT05158075|Behavioral|Approach-Avoidance Bias Modification|In this task participants must zoom in or zoom out a food image according to its format (vertical or horizontal) using their smartphone device. 90% of healthy food images will appear in the format to be approached (for example, vertical), while only 10% of unhealthy images will appear in that format (to ensure concentration on the task). The format to be approached will be counterbalanced. Participants will practice the task at home at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
45606207|NCT05158075|Behavioral|Inhibition Training|In this App participants are instructed to touch green circle items as quickly as possible, but to withhold their response and not to press on the red circle items, using their smartphone device. Some images are food, some non-foods. Participants can choose which food categories they would like to train to resist. The food-specific inhibition training condition included pictures of high-calorie foods always paired with the no-go signal. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
45606208|NCT05158075|Behavioral|Implementation of Intentions|"Participants establish one intention related to food and one related to exercise, and write when, where and how they will implement each one, possible inconveniences to do it, and how they will overcome them. Furthermore, motivational cues (why I eat) will be considered (negative emotions -I'm bored; social motives -eat a piece of cake you are offered in a party; politeness/conformity with others' expectations; pleasure). The implementation of intentions related to food will be written in format: if… then…. This format allows for the consideration of the health goals and medium and long-term objectives for each of the participants. The intention related to food will focus on unhealthy snacking habits whenever possible. Participants will read and visualized their implementation of intentions at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones."
45606209|NCT05158075|Behavioral|Episodic Future Thinking|Participants will decide health-related goals and anticipate positive future personal events at various time points (next month, 2-3 months and 4-6 months), from which contextual, temporal and emotional cues should be obtained. Goals and future events will be matched to generate episodic future thinking cues that include the necessary keys to facilitate their effectiveness. Participants will read and visualized their three cues at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
45606210|NCT05158075|Behavioral|Sham Approach-Avoidance Bias Modification|Participants must zoom in or zoom out a food image according to the format (vertical or horizontal) using their smartphone device. 50% of healthy food images and 50% of unhealthy food images will appear in the format to be approached (for example, vertical). The format to be approached will be counterbalanced. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
45606211|NCT05158075|Behavioral|Sham Inhibition Treatment|In this App participants are instructed to touch green circle items as quickly as possible, but to withhold their response and not to press on the red circle items, using their smartphone devices. Some images are food, some non-foods. Participants can choose which food categories they would like to resist. High-calorie and low-calorie foods will be paired with the go signal on 50% of trials and with the no-go signal on 50% of trials. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
45606212|NCT05158075|Behavioral|Setting Intentions|Participants will choose 10 items of healthy foods to eat whenever they want to eat unhealthy food. They will also order a list of physical activities that they could do to lose weight. Participants will read their lists (food and exercise) at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
45757193|NCT00618917|Drug|paclitaxel|Chemotherapy to stop the growth of tumor cells. This drug kills tumor cells by inducing multipolar divisions. Cells entering mitosis in the presence of concentrations of paclitaxel equivalent to those in human breast tumors form abnormal spindles that contain additional spindle poles.
45757194|NCT00618917|Radiation|Radiation Therapy|1.9-2.1 Gy daily 5 times per week (4-6 hr after the first MnSOD PL dose). The total dose planned at 77.0 Gy with a range of 69-84Gy in 34-38 fractions over 7-8 weeks.
45757195|NCT05736081|Procedure|Intravitreal dexamethasone implant|Intravitreal implant of dexamethasone 0.7 mg with previous topic anesthesia and iodine drops
45757196|NCT00619073|Drug|clopidogrel + aspirin|Clopidogrel 75mg plus aspirin 81mg, tablet by mouth daily for 14 days.
45757197|NCT00619073|Drug|placebo|Placebo plus aspirin 81 mg, tablet by mouth daily for 14 days.
45606213|NCT05158075|Behavioral|Recent Episodic Thinking|Participants will match habits and positive recent past events (1 day ago, 2 days ago, 1 week ago), both unrelated to food or physical activity, to establish their cues. Participants will read and visualized their three cues at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
45606214|NCT05158075|Behavioral|Motivational Interviewing|Participants will assist a 90-minute group Motivational Interviewing session to maximize motivation and adherence to the program. The session will be guided through open questions and empathic reflections and affirmations to promote change talk. Participants will share their personal aims to reduce weight, improve their diet and increase their level of physical activity. Further, participants will talk about obstacles they have had on previous occasions, their expectations, and their motivations in regards to weight loss. When needed, information will be provided with the elicit-provide-elicit format. Sessions will end with an individual empathic summary for each participant's interventions.
45606215|NCT05158075|Behavioral|Nutritional intervention|Participants will maintain a 60-minute group session with a nutritionist and will watch a 20-minute video to match and complete relevant information on nutrition. The nutritionist will design a 6-week individualized diet that participants will receive after the initial assessment. When the 6-week diet ends, participants will assist another 60-minute group session with the nutritionist and will watch another video intended to teach them how to design their own healthy diet and maintain long-term healthy eating habits.
45606216|NCT05158075|Behavioral|Physical exercise intervention|Participants will maintain a 60-minute group session with a physical exercise professional and will watch a 20-minute video to match and complete relevant information on exercise. The physical exercise professional will design a 6-week physical exercise planning that participants will receive after the initial assessment. After those 6-weeks, participants will assist another 60-minute group session with the physical exercise professional and will watch another video intended to teach them how to design their own physical activity planning and maintain long-term healthy exercise habits.
45606217|NCT03512327|Other|Autoimmune protocol (AIP) diet|Autoimmune protocol diet, designed as a 6 week step wise elimination phase followed by 5 week maintenance phase.
45606218|NCT02757235|Procedure|Irrigation fluid of body temperature|Irrigation fluid of body temperature will be used during burr hole evacuation of chronic subdural hematoma
45444716|NCT03564873|Drug|Azacitidine|Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
45606219|NCT02757235|Procedure|Irrigation fluid of room temperature|Irrigation fluid of room temperature will be used during burr hole evacuation of chronic subdural hematoma.
45606220|NCT02304965|Behavioral|Daily physical activity|A combination of walking (> 10.000 steps per day) and cycling on a stationary bicycle at home at an individual intensity. For the activity walking patients need to walk at a certain speed (e.g. 3 km/h) in order to be in the range of pulsatility as obtained from their pre-training treadmill test. For cycling a defined power in watt and duration will be given to each patient as defined from the pre-training cycling test.
45606221|NCT05157763|Drug|EscharEx 5% (EX-02 formulation)|EX-02 5% will be topically applied in a thick layer of 2-3 mm on the lesion surface for 8-12 hours including 5-10 mm margins and covered with an occlusive dressing. A new vial should be used for each application. Each patient will be treated with 7 applications.
45606222|NCT02305043|Other|non-interventional|non-interventional
45606223|NCT04457869|Drug|F520|3mg/kg every 3 weeks
45606224|NCT02305121|Device|TFNA|All investigated procedures are part of the standard of care treatment. Only the parker mobility score is study-specific. All patients included are followed up from the time point of enrollment until three months after surgery
45606225|NCT03739099|Device|Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions|Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data
45606226|NCT03512093|Other|Retrospective chart review|A retrospective chart review of preterm neonates born in one of the birthing SMRU unit between January 2008 and December 2017 and for whom a medical chart is available. In addition we propose to analyze the growth trajectory, the prevalence of anemia (Hct < 33%) and the level of neurodevelopment achieved in the first year of life reported in the clinical charts of preterm neonates born < 34+0 weeks of gestation.
45606227|NCT03512093|Other|Focus Group Discussion (FGD) of the medical staff|Focus Group Discussion (FGD) of the medical staff working in the SCBU firstly on the benefits and difficulties in using existing guidelines for preterm care and secondly on the feasibility and acceptability of changes in the guidelines 3-6 months after their implementation.
45757198|NCT00619073|Drug|Aspirin|Aspirin 81mg tablet by mouth continued daily alone for 43 days after day 14.
45757199|NCT05687630|Other|elastic band resisted exercise|muscle strengthening exercise, 10-15 times of each set, for 3 sets
45444717|NCT02806024|Drug|Tranexamic Acid|
45757200|NCT00620711|Device|Olympic Cool Cap|Olympic Cool Cap will be applied to infants 32-35 weeks gestation who meet criteria for HIE.
45757201|NCT05687552|Device|pet -ct|assessment of added value of pet -ct in patients with gastric cancer and how patient get benefit from this finding
45757202|NCT05341869|Procedure|Para-cervical block|Block of inferior hypogastric plexus with local anesthetic
46066646|NCT04416568|Drug|Nivolumab|"Combination Therapy: Nivolumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles.~Monotherapy: Starting with cycle 5 nivolumab at predetermined dosage on day 1 and day 15 of a 28-day cycle"
46066647|NCT04416568|Drug|Ipilimumab|Combination Therapy: Ipilimumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles
46066648|NCT05269381|Drug|Cyclophosphamide|Given IV
46066649|NCT05269381|Biological|Neoantigen Peptide Vaccine|Receive personalized neoantigen vaccine SC
46066650|NCT05269381|Biological|Pembrolizumab|Given IV
46066651|NCT05269381|Biological|Sargramostim|Given SC
46066652|NCT04411186|Procedure|Standard Enhanced Recovery After Surgery (ERAS) Protocol|Subjects receive standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations.
45606228|NCT03512093|Other|Interviews of mothers|Interviews of mothers who delivered preterm neonates (< 37+0 weeks of gestation) to understand the challenges they faced while caring for their child.
45606229|NCT03690427|Other|Traditional hookah smoking|Charcoal-heated hookah smoking
45606230|NCT03690427|Other|Electronic hookah inhalation|Electronic hookah bowl
45606231|NCT02305199|Drug|Hartmann's solution|Hartmann's solution containing 200 mg/L of calcium chloride, 300 mg/L of potassium chloride, 6 g/L of Sodium chloride, 3.1 g/L of Sodium lactate.
45606232|NCT02305199|Drug|Normal saline|Fluid containing Sodium chloride 9 g/L
45606233|NCT03469375|Drug|modified-FOLFIRINOX|LAPC patients with mFOLFIRINOX-based neoadjuvant therapy or not was set as the main intervention
45606234|NCT03512015|Other|The Lung Cancer App - LuCApp|The Intervention Arm receiving LuCApp (The Lung Cancer App) in addition to standard care
45757203|NCT04401722|Procedure|PANCREATICODUDENECTOMY|dissection and removal of periampulary tumour with 3 reconstruction PJ, HJ, and GJ
45606235|NCT03512015|Other|Standard care|The Standard-of-Care patients receiving following the same schedule identified for LuCApp patients with paper questionnaires during clinic visits, or at home (having received paper questionnaires during the previous visit) or via telephonic interviews with the research team.
45606236|NCT03548779|Behavioral|Pre-visit prep|Patient and provider surveys will be used to measure the impact of pre-visit preparation on the primary outcomes of engagement of participants in the clinical interaction and their view of the interaction as patient-centered, in addition to secondary outcomes that may be affected by this intervention (described above). The study investigators will test the hypothesis that patients will benefit from pre-visit preparation by: (1) rating their clinical encounters as more patient-centered and (2) asking more questions during their clinical encounters.
45606237|NCT03548779|Diagnostic Test|usual care + exome seq|Provider surveys will be used to assess impact of exome sequencing on diagnostic thinking and management planning. Health utilization and condition-specific general clinical outcomes will be assessed from health records data.
45606238|NCT01603407|Drug|Prednisone|daily prednisone (0.75 mg/kg/day) tablets for 36-60 months
45606239|NCT01603407|Drug|Prednisone|intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off) tablets for 36 to 60 months
45606240|NCT01603407|Drug|Deflazacort|daily deflazacort (0.9 mg/kg/day) tablets for 36-60 months
45606241|NCT05302570|Radiation|Hypofractionated Proton Beam Therapy|5 fractions of 5 Gy of PBT to clinical tumor volume +/- an additional simultaneous 1 Gy per fraction to any pre-determined at-risk margin (for a total of 6 Gy per fraction x 5 fractions for at-risk margins as a simultaneous integrated boost (SIB)).
45606242|NCT02305355|Drug|Omega-3-acids ethylesters 90 4g|
45606243|NCT02305355|Drug|Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin|
45606244|NCT02305511|Device|Peripheral venous catheterization|Cannulation using standard method
45606245|NCT02305511|Device|Jamshidi|intraosseous access using the Jamshidi device
45606246|NCT02305511|Device|BIG|intraosseous access using the BIG device
45606247|NCT02305511|Device|Cook|intraosseous access using the Cook device
45757204|NCT00670241|Drug|calcipotriol and betamethasone (LEO 80185 gel)|Once daily application
45606248|NCT02305511|Device|EZIO|intraosseous access using the EZIO device
45606249|NCT03511703|Drug|Apatinib|Apatinib, a small molecule anti-angiogenic targeted drug that has been demonstrated to be safe and effective after failure of standard chemotherapy for advanced gastric cancer, has been initially successful in phase II clinical trials for the treatment of unresectable advanced HCC patients. The efficacy of ralfiny in the treatment of Oriental population (ORIENTAL study) is better. The randomized, doubleblind, multi-center phase III clinical study of apatinib second-line treatment of advanced hepatocellular carcinoma showed a good efficacy and safety. Currently, Phase III clinical studies of apatinib in HCC patients undergoing systemic chemotherapy or sorafenib treatment have progressed. Initial results lso showed good efficacy and safety.
45606250|NCT03511703|Drug|Chemotherapy drugs+Iodized oil|Intra-arterial infusion chemotherapy for tumors, commonly used chemotherapy drugs include anthracyclines, platinum, etc.; chemotherapeutic drugs and embolic agents are mixed together and injected through the blood supply artery of the tumor. The most commonly used embolic agent for TACE treatment is a lipiodol emulsion. First infusion of some chemotherapy drugs, the general infusion time should not be <20 min. Then another part of the chemotherapeutic drugs and lipiodol were mixed into emulsions for embolization. The amount of lipiodol is generally 5-20 ml, not more than 30 ml.
45606251|NCT03495661|Procedure|Decompression|Central decompression of the stenotic segment(s) with undercutting of the lateral recesses.
45606252|NCT02305589|Drug|Sugammadex|Muscle relax reversing agent
45606253|NCT05157373|Diagnostic Test|Endometrial sampling and Peripheral blood collection|The endometrial biopsy will be performed with a pipette. The pipelle will be inserted gently through the cervix and into the uterus. The pipelle procedure takes approximately one minute and involves gently moving the pipelle back and forth to obtain a sample. Then 10cc of peripheral blood will be collected.
45606254|NCT05157373|Behavioral|FSFI Scale|"The participants will fill up the Female Sexual Function Index (FSFI) questionnaire.~The FSFI is a 19-item self-report questionnaire designed to measure sexual functioning in women. It assesses six domains of sexual function: sexual desire, sexual arousal, lubrication, orgasm, satisfaction, and pain (i.e., pain associated with vaginal penetration)."
45606255|NCT02305667|Device|Macintosh|double lumen tube intubation using the Macintosh laryngoscope
45606256|NCT02305667|Device|Glidescope®|double lumen tube intubation using the Glidescope® videolaryngoscope. The distal portion of a left-sided DLT will be angulated to the right concealing the distal orifice of the tracheal lumen. The DLT will be advanced directly through the vocal cords after initial 90° clockwise rotation, the stylet will be removed, and then the DLT will be advanced gently while rotating in a 180° couterclockwise direction
45606257|NCT02305667|Device|Airtraq®|double lumen tube intubation using the Airtraq® videolaryngoscope.
45757205|NCT00670241|Drug|LEO 80185 vehicle|Once daily application
45757206|NCT00670241|Drug|Tacalcitol ointment|Once daily application
45757207|NCT03088670|Drug|Gosogliptin|20 mg per day, dose titration to 30 mg per day at Week 4 as required Administration: orally
45757208|NCT03088670|Drug|Vildagliptin|50 mg per day, dose titration to 100 mg per day at Week 4 as required (50 mg twice a day) Administration: orally
45606258|NCT02305667|Device|King Vision™|double lumen tube intubation using the King Vision™ videolaryngoscope. the distal 21 cm of the left-sided DLT will be bended to replicate the curve of the non-channeled blade and the proximal curve of the DLT remains directed to the right side. Then, after initial 90° clockwise rotation, the bronchial cuff passes through the vocal cords, the stylet of the DLT will be withdrawn and the DLT will be rotated 180°counterclockwise while advancing the DLT to the desired depth.
45606259|NCT05157295|Drug|OnabotulinumtoxinA|100 U of Onabotulinumtoxin A diluted in 10 mL of saline injected into the wall of the detrusor muscle at various sites
45606260|NCT03771898|Drug|SHP611|Participants will receive 150 mg of SHP611 IT via IDDD or LP once weekly for 106 weeks.
45606261|NCT02301221|Procedure|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
45757209|NCT03088670|Drug|Metformin|"1000 mg per day starting Week 12 (500 mg twice a day), dose titration to 2000 mg per day at Week 16 as required (1000 mg twice a day).~Administration: orally"
46066653|NCT04411186|Procedure|ERAS and 5 Lung Protective Interventions|"Subjects will receive the standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations. The subject will also receive the following lung protective interventions:~Pressure control ventilation-volume guaranteed (PCV-VG) ventilation at approximately 7cc/kg of predicted body weight (derived from combination of sex and height) Positive end-expiratory pressure (PEEP) 7cm H2O5 Immediately post intubation recruitment breath (30cm water for 30 seconds) Every 1 hour recruitment breath (30cm water for 30 seconds) 40% FIO2 initially - titrate up as necessary to maintain SPO2 >94%"
45606262|NCT02301221|Drug|Vancomycin and bowel lavage|An initial vancomycin regimen (500 mg orally two times per day for 3 days), followed by bowel lavage before the infusion of a solution of donor fecal microbiota.
45606263|NCT03339141|Procedure|Intubation position|The investigators assess two different patient's intubation position : supine position and 25° head-up position looking at the intubation score (POGO score).
45606264|NCT02305745|Other|Observational|
45606265|NCT03288363|Device|tDCS|20 sessions of tDCS stimulation on dorsolateral prefrontal cortex with the apparatus DC-Stimulator Plus (Neuroconn)
45606266|NCT03511547|Device|Pitch Patch|The patients will be operated by shoulder arthroscopy according to the internationally standardized procedure. Patients allocated this group will receive a synthetic (Pitch-Patch™ [PP]) augmentation.
45606267|NCT03511547|Device|ArthroFlex|The patients will be operated by shoulder arthroscopy according to the internationally standardized procedure. Patients allocated this group will receive a biologic patch (ArthroFlex® [AF]) augmentation.
45606268|NCT03122431|Drug|Thalidomide|Thalidomide 100 mg/day
45606269|NCT03122431|Drug|Hydroxychloroquine reduced|Hydroxychloroquine 2.5 mg/kg/day
45606270|NCT03122431|Drug|standard dose of HCQ|Hydroxychloroquine 5.0 mg/kg/day
45606271|NCT03263637|Drug|AZD4573|AZD4573 will be administered as a intravenous (IV) infusion.
45606272|NCT03736018|Diagnostic Test|CTCA|Computed Tomography Cardiac angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
45606273|NCT03511469|Other|Control Group|Control Group: Standart rehabilitation
45606274|NCT03511469|Other|Isokinetic Group|Concentric group: Standart rehabilitation + isokinetic training
45606275|NCT05297656|Other|Instrument Assisted Soft Tissue Mobilization|Instrument Assisted Soft Tissue Mobilization with graston tecnique and Home exercises programe
45606276|NCT05297656|Other|Sham Instrument Assisted Soft Tissue Mobilization|Instrument Assisted Soft Tissue Mobilization to be applied superficially so it is not like a real graston tecnique and Home exercises programe
45606277|NCT05297656|Other|Home exercises programe|Only Home exercises programe
45606278|NCT02990481|Biological|TRK-950|Intravenously over 60 minutes, on day 1, 8 and 15 of each cycle
45606279|NCT02990481|Biological|TRK-950|"Low dose: intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle~High dose: intravenously over 60 minutes, on day 1 and 15 of each cycle"
45606280|NCT02990481|Biological|TRK-950|Low dose: Intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle
45606281|NCT03508427|Other|Daily self-monitoring|Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.
45606282|NCT05248360|Device|Hydrogen-oxygen mixed gas(H2-O2) inhalation|H2-O2 inhalation, 900ml/min, 2h/d * 4 weeks (≥5 days/week)
45606283|NCT05248360|Device|Air inhalation|Air inhalation, 900ml/min, 2h/d * 4 weeks (≥5 days/week)
45606284|NCT03511313|Device|Renal denervation|After a renal angiography according to standard procedures, subjects are treated with renal denervation (with sterile irrigated deflectable ablation catheter in renal artery), if without renal anatomic abnormality not detected by Renal CT/CTA.
45606285|NCT03511313|Diagnostic Test|Renal angiography|A renal angiography according to standard procedure.
45606286|NCT05092503|Drug|JINZHEN Granules for Oral Solution|JINZHEN granules will be dissolved in drinking water and administered orally.
45606287|NCT05092503|Drug|Placebo|Placebo granules will be dissolved in drinking water and administered orally.
45606288|NCT02506465|Device|iTIND|Temporary Implantable Nitinol Device (iTIND)
45606289|NCT02506465|Procedure|Sham Arm|Foley catheter will be placed and immediately removed.
45606290|NCT05092425|Other|no intervention|no intervention
45606291|NCT02235454|Device|SDOCT-GMPE software|Noninvasive imaging of the optic nerve in patients with existing glaucoma
45606292|NCT02305823|Drug|Aripiprazole|
45606293|NCT02305823|Drug|Quetiapine|
45757210|NCT03088358|Drug|TeaRx|
45757211|NCT03088358|Drug|Enoxaparin|
45757212|NCT03081026|Diagnostic Test|Bilateral hip to ankle x-ray, exam and strength testing.|Only an X-Ray is performed and reviewed to identify any growth disturbances.
45444718|NCT02806024|Drug|Placebo Drug|50 cc Normal Saline IV
45606294|NCT02305823|Drug|Ziprasidone|
45757213|NCT00671177|Procedure|water immersion colonoscopy|instillation of 300cc of water in the rectum
45757214|NCT00671177|Procedure|standard air colonoscopy|air instillation in colon for visualization
45757215|NCT03396068|Drug|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
45757216|NCT03396068|Drug|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
45757217|NCT03383978|Biological|NK-92/5.28.z|Intracranial application of NK-92/5.28.z, 1x10E7-1x10E8
45606295|NCT03471091|Device|NIV with the integrated tele-monitoring management program|Noninvasive positive pressure ventilation with the integrated tele-monitoring management will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly.
45606296|NCT05376189|Dietary Supplement|400 IU|An Oral Vitamin D3 400 IU will be given once daily for a total of 8 weeks
45606297|NCT05376189|Dietary Supplement|5000 IU|An Oral Vitamin D3 5000 IU will be given once daily for a total of 8 weeks
45606298|NCT05376189|Dietary Supplement|10000 IU|An Oral Vitamin D3 10000 IU will be given once daily for a total of 8 weeks
45606299|NCT05376189|Drug|Fixed Drug Combination|Standard Tuberculosis Regimen in a form of Fixed Drug Combination (FDC) given for Spondylitis Tuberculosis.
45606300|NCT02235298|Drug|Dapagliflozin|5 mg taken orally once daily. After 2 weeks, if there are no safety issues as per treating physician discretion, the dose can be titrated up to 10 mg orally taken once daily.
45606301|NCT02235298|Drug|Metformin|500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL
45606302|NCT02235298|Drug|Placebo|Placebo pill taken once daily to mimic Dapagliflozin
45606303|NCT02305901|Drug|repaglinide|single dose on day 1 of visits 2 and 3
45606304|NCT02305901|Drug|BI 187004 tablet|multiple doses on days 8-13 of visit 2 and days 1-7 of visit 3
45606305|NCT02305901|Drug|bupropion extended release tablet|single dose on day 3 of visits 2 and 3
45606306|NCT03473899|Device|rESWT|"rESWT will be performed as follows:~Nine rESWT sessions~Three sessions per week~rESWT device: Swiss DolorClast (Electro Medical Systems, Nyon Switzerland), EvoBlue handpiece, 15 mm applicator~2500 rESWs per session, with energy density between 0.12 and 0.16 mJ/mm^2, depending on what the patient tolerates~rESWs applied at 15 Hz~Application of rESWs in prone position, with the patient lying on an examination table~Exact location of the application of rESWs determined by clinical and ultrasonographic examinations~Treatment of both the side of injury and the entire affected muscle (from distal to proximal in order to relax the affected muscle)~No use of local anesthesia.~In addition, patients will receive a specific rehabilitation program."
45606307|NCT03473899|Device|Sham-rESWT|"Sham-rESWT will be performed as rESWT described in Arm rESWT + RP, but with a specially designed placebo EvoBlue handpiece that looks and sounds like the EvoBlue handpiece of the Swiss DolorClast, but does not generate radial shock waves. This is achieved by blocking the projectile shortly before it strikes the metal applicator. The placebo EvoBlue handpiece will not emit any radial shock wave energy.~In addition, patients will receive a specific rehabilitation program."
45606308|NCT04657263|Other|Vaccine coverage assessment|Vaccine coverage assessment
45606309|NCT03942887|Drug|Rituximab|Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg. At any time during the study, a rituximab biosimilar is allowed as a substitute for the bio-originator rituximab.
45606310|NCT03942887|Drug|endoxan|Patients will be intravenously treated with a total of 6 infusions of cyclophosphamide 500mg every 2 weeks. Before every infusion of cyclophosphamide patients will receive intravenous granisetron to prevent nausea.
45606311|NCT03942887|Drug|Methylprednisolone|Patients are given 1-3 pulses of 500mg methylprednisolone i.v. up to a maximum cumulative dose of 3000mg, taking into account any doses of intravenous methylprednisolone administered within 12 weeks prior to screening.
45606312|NCT03942887|Drug|Prednisolone|after intravenous pulse methylprednisolone, oral prednisolone will be given at a dose of 1mg/kg daily and tapered according to the recommendations
45606313|NCT05136391|Drug|XTR003|Single dose of 8.0-10 mCi of XTR003 will be injected on the first day of the study (Day 1). Serial whole-body PET imaging will be acquired after dose injection.
45606314|NCT04619199|Diagnostic Test|Blood sample|Blood sample performed at the inclusion and during the follow-up.
45606315|NCT02234596|Drug|Nintedanib|Nintedanib 200mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days continuously, unless interrupted for intolerable toxicity.
45606316|NCT02305979|Drug|Loratadine|
45606317|NCT04499937|Behavioral|Streak incentive|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will start with a $0 balance and will earn a fixed amount for each response.
45606318|NCT04499937|Behavioral|Loss-based incentive|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will start with the maximum balance and will lose a fixed amount for each response they do not complete.
45606319|NCT04499937|Behavioral|Flat-fee control status quo condition|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will receive the maximum compensation at the end of the study.
45606320|NCT04499937|Behavioral|Flat-Fitbit control status quo condition|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will keep the Fitbit at the end of the study.
45606321|NCT02306057|Procedure|Pre BCPC|Routine catheterization before surgical procedure Bidirectional CavoPulmonary Connection
45606322|NCT02306057|Procedure|Pre TCPC|Routine catheterization before surgical procedure Total CavoPulmonary Connection
45606323|NCT02306057|Procedure|BCPC surgery|Surgical procedure Bidirectional CavoPulmonary Connection
45757218|NCT03383978|Drug|Ezabenlimab|Intravenous infusion of Ezabenlimab 240mg q 3 weeks
46066654|NCT05402332|Drug|AVTX-801|D-Galactose medical grade supplement
46066655|NCT02583022|Drug|PAC-14028 cream 1.0%|Topical application
45757219|NCT00620945|Drug|Phenoxybenzamine|"Use of Phenoxybenzamine:~Loading dose given at the time of going on CPB:~For patients with obstructing lesions on systemic side:~0.25 mg/kg dose in the bypass circuit~None intravenous~For patients without obstructing left sided lesions:~0.5 mg/kg in the bypass circuit~0.5 mg/kg I.V. at cannulation~Maintenance dose given in the post-operative period:~0.3 mg/kg I.V. every 8 hours till oral intake is started or for first 48 hours~0.3 mg/kg P.O. every 8 hours for next 24 hours~0.15 mg/kg P.O. every 8 hours for next 24 hours and then stop~Hold PBZ if the patient is on norepinephrine infusion or the mean arterial pressure is lower than that allowed for the age group"
45606324|NCT02306057|Procedure|TCPC|Surgical procedure Total CavoPulmonary Connection
45606325|NCT03704350|Dietary Supplement|controlled diet|Participants will consume a diet that is controlled in its daily contents of oxalate, calcium, vitamin C and sodium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements (vitamins, calcium or other minerals, herbal supplements, nutritional aids), to exercise strenuously, or to consume food or drink that is not provided to them as part of the controlled diet.
45606326|NCT05737407|Other|LUS-guided choice of Peep|Choice of Peep guided by lung ultrasound to avoid atelectasis
45606327|NCT05737407|Other|Standard choice of Peep|Choice of Peep according to standard practice
46066656|NCT02583022|Drug|PAC-14028 cream vehicle|Topical application
45606328|NCT05219812|Drug|BAY2395840|Tablet, intake orally.
45606329|NCT05219812|Drug|Placebo for BAY2395840|Tablet, intake orally.
45606330|NCT02306135|Other|n/a- this is an observational study|
45606331|NCT04539951|Drug|Sertraline 200 milligram(mg)|All included participants will receive sertraline, initially at 50mg/d, with a weekly 50mg/d further increase, to the maximum recommended dosage (200mg/d) or to the maximum tolerated dosage (less than 200mg/d). Patients will be on their maximum dose by week 4, so allowing an assessment of response at 12 weeks
45606332|NCT04539951|Drug|Sertraline 300 milligram(mg)|In experimental phase II, the patients in this group will remain on sertraline (higher dosage): where sertraline 200mg has been tolerated, dosage will be increased by 50mg fortnightly to a maximal dose of 300mg/d or to the maximum tolerable dose (less than 300mg/d).
45606333|NCT04539951|Drug|Fluvoxamine|Fluvoxamine will be initiated at a dose of 50mg/d, increasing quickly to a maximal dose of 300mg/d or the maximum tolerated dose by week 4.
45606334|NCT04539951|Drug|Venlafaxine|venlafaxine will be initiated at 75mg/d, increasingly weekly by 75mg/day, to a maximal dose of 300 mg/d or the maximum tolerated dose.
45606335|NCT04539951|Drug|Augment with Memantine|Sertraline will be augmented with memantine initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d (10mg twice daily) or the maximum tolerated dose
45606336|NCT04539951|Drug|Augment with Aripiprazole|Sertraline will be augmented with aripiprazole, initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d or the maximum tolerated dose
45606337|NCT02306213|Drug|Hydroxyethylstarch 6% 130/0.4|Use of Hydroxyethylstarch intraoperatively, for cardiopulmonary bypass use and postoperatively in the intensive care unit
45606338|NCT02306213|Other|standard volume therapy|
45444719|NCT04843371|Diagnostic Test|Photoplethysmography|Photoplethysmography (PPG) is a non-invasive technique that can detect volumetric changes in the peripheral blood. It only requires skin contact and relies on light absorption. PPG is a good indicator of the cardiovascular dynamics in the human body. PPG has been incorporated into various new smartphones and wearable devices such as, smartwatches and fitness wristbands making it readily available to all consumers. This sensor can record biometrics such as, heart rate, blood pressure, oxygen saturation, etc.
45606339|NCT04539327|Drug|Rucaparib|Participating local sites (GEICO-associated hospitals with expertise in gynecological cancer management) will enter clinical data of those patients who have previously participated in the rucaparib access program (RAP) in Spain and have given their consent.
45606340|NCT03508349|Diagnostic Test|IST|Women in the control group will receive routine care, which does not include testing for malaria with a rapid diagnostic test unless symptomatic for malaria. Women in the intervention group will receive this additional testing for malaria at each antenatal care, regardless of whether she is symptomatic for malaria.
45606341|NCT02234362|Drug|vortioxetine|Eligible subjects will initiate the treatment with 5 mg/day for two days and then 10 mg/day starting on Day 3. The dosage may be increased from 10 mg/day to 15 mg/day at Visit 2 or Visit 3. At Visit 4, the dosage may again be increased from 10 to 15 mg/day or from 15 to 20 mg/day, based on patient response and tolerability.
45606342|NCT04434807|Procedure|Minimally invasive hematoma evacuation|Neurosurgery performed via burr hole or minicraniotomy and using the Aurora surgiscope and evacuator (Integra Lifesciences)
45757220|NCT03088436|Device|preoperative prone MRI and supine second-look ultrasound data|Patients were examined using a standard clinical MRI protocol in the prone position with both arms placed above the head. Second-look ultrasonographies were performed. Patients were instructed to lie supine, with their hands behind their heads.
46066657|NCT02583022|Drug|Elidel cream 1%|Topical application
46066658|NCT00764725|Drug|conventional DMARD combination|MTX+SSZ+Plaquenil; can be changed to MTX+cyclosporin within protocol
46066659|NCT00764725|Biological|MTX plus anti-TNF|MTX + infliximab; can be changed to MTX + etanercept within protocol
45606343|NCT02301455|Behavioral|Text messaging|persistently hypertensive participants will be randomized to receive these tailored, motivational text messages
45606344|NCT02301533|Behavioral|Shikamana Intervention|See arm description
45606345|NCT02301533|Behavioral|Standard Care|See arm description
45606346|NCT04415541|Behavioral|Psychodynamic Psychotherapy|Intensive psychotherapy that is psychodynamically oriented.
45606347|NCT04415541|Behavioral|Usual Care|Conventional treatment offered in the community.
45757221|NCT05687318|Device|DeFrame|DeFrame can analyze colonoscopy medical images generated by electronic digestive endoscopy equipment to automatically identify, label and screen capture polyps in the colon.
45606348|NCT03508271|Other|Non-Interventional|Non-Interventional
45606349|NCT05092113|Drug|a compound glutamine capsule/a compound glutamine capsule simulated placebo|A compound glutamine capsule/a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
45606350|NCT02234284|Behavioral|Health Coaching|Patient COPD education; Correct use of inhalers and nebulizers; Red flags and when to seek medical care; Dyspnea management; Patient decision making and action plans around, exercise, smoking cessation; nutrition, exacerbations; Ensuring appropriate preventive services (pneumovax, flu); Depression screening; Reinforcing clinician education and use of treatment guidelines by primary care providers; Identifying gaps in care, areas where care not in line with care plan; Facilitating communication between patients, pulmonary specialists and primary care providers; Connecting with community resources; Access to psychosocial services; Working with pulmonary specialist to provide recommended exercise program; Working with patient family members and caregivers.
45606351|NCT05737251|Behavioral|PoET|PoET consists of two online-sessions, each 3.5 hours within groups of 30 people. The following lessons regarding positive psychology constructs were conducted (including short information on each construct and specific exercises): happiness, hope, humour, optimism, gratitude, self-efficacy, flow, meaningfulness, forgiveness, spirituality and resilience.
45606352|NCT02306369|Behavioral|Internetdelivered exposure-based CBT|The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, and adapted for adolescents and their parents. The feasibility of the treatment were tested in a pilot study during 2012. Components in the treatment are exposure for symptoms and parent training. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
45606353|NCT05091489|Other|Qualitative assessment about PrEP acceptability|Qualitative research among key-populations, community and healthcare workers, and decision and policy makers, including focus group and semi-directive interviews
45606354|NCT02301845|Drug|Diatoms Shells|Instillation of suspended diatom shells - 10 mg q12h
45606355|NCT05091411|Biological|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
45606356|NCT03508037|Other|Neuromodulation electroencephalographic signals and functional electrical stimulation based|First, the subject performs twenty reaching movements without assistance with the damaged arm resting on a robot (ArmeoSpring), with the aim of finding the Contingent Negative Variation (CNV). Then, he or she executes five courses of twenty movements receiving functional electrical stimulation (FES), either at the moment in which he or she wishes to move (experimental group), or half a second before or after (control group).
45606357|NCT04309305|Device|EksoGT™, Ekso Bionics, Berkley, CA, USA|The Robotic Exoskeleton is a device that will be strapped to the chest and legs and worn over the shoulders like a backpack that will assist in walking.
45606358|NCT04309305|Other|Standard of Care|Standard gait therapy provided by licensed physical therapists post stroke.
45606359|NCT04309305|Other|No Intervention|Testing Only
45606360|NCT02306447|Device|rPMS and rTMS|"rPMS Stimulation of the neck muscles in five medial-lateral movements starting from the neck: left and right trapezius and deltoid muscle, trapezius and lattissimus dorsi muslce, and over the backbone. 20 stimuli per movement with 2s inter-train interval; four repetitions for each of the five movements; the first 20 trains with a frequency of 5Hz, the second 20 trains at 20Hz; stimulation at individual comfortable level (20-30% stimulator output); round coil.~rTMS 20Hz stimulation with 2000 stimuli over the left dorso-lateral prefrontal cortex at 110% motor threshold; followed by 1Hz stimulation with 2000 stimuli over the left temporo-parietal cortex; stimulation intensity 110% motor threshold; butterfly coil.~For stimulation we use MagPro X100 (Medtronic, Denmark)."
45757222|NCT00621179|Drug|Leuprolide acetate in depot suspension|Leuprolide acetate in depot suspension 3.75 mg intramuscularly every 28 days x 3
45757223|NCT00621179|Other|No intervention|
45757224|NCT00247273|Drug|risedronate|tablet, 5 mg risedronate, once a day for 2 years
45606361|NCT05737173|Drug|Leukocyte-rich platelet-rich plasma|Intra-articular knee injection
45606362|NCT05737173|Drug|Leukocyte-poor platelet-rich plasma|Intra-articular knee injection
45606363|NCT05737173|Drug|Corticosteroid|Intra-articular knee injection
45757225|NCT00247273|Drug|risedronate|oral, 150 mg risedronate, once a month for 2 years
45757226|NCT05685524|Diagnostic Test|DNA methylation test|Cell-free DNA were extracted from plasma collected from individuals of cancer and non-cancerous disease groups, then the DNA was bisulfite converted and tested by DNA methylation assay based on real-time PCR platform.
45757227|NCT05480462|Biological|Clodivac|A dose of 0.5 ml should be administered intramuscularly into deltoid muscle.
45757228|NCT05480462|Biological|Td-Impfstoff Merieux|One dose (0.5 ml) intramuscular, preferably in the deltoid muscle of the upper arm.
45757229|NCT05056233|Other|Systane Hydration lubricant eye drops|Sterile solution indicated for the temporary relief of burning and irritation due to dryness of the eye
45757230|NCT00671723|Drug|Normal saline:|Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
45757231|NCT00671723|Drug|Hypertonic Saline|Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
45757232|NCT00671723|Drug|Dornase alpha|2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
45757233|NCT05685446|Other|Ice water|Ingestion of 175 ml iced tap water 15 minutes prior to elective gastroscopy
45757234|NCT01799681|Behavioral|an 8-week blended indoor-outdoor exercise program|stretching, strength and functional training, Balance Dance, Modified Wing Chun, Square stepping exercise, and fall-prone activities practice
45606364|NCT03510923|Other|Inspection and palpation of the appendix|The removed appendix will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen. The appendix will not be opened. The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination. Subsequently, all specimens will be sent for histopathological examination. Histopathological examination will be conducted according to the local protocol. In case of a neoplasm of the appendix, the treatment strategy is discussed and decided by the local multidisciplinary team. If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
45606365|NCT03510923|Other|Inspection and palpation of the gallbladder|The removed gallbladder will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen. The gallbladder is opened in its length, without cutting the cystic duct, and is inspected and palpated. The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination. Subsequently, all specimens will be sent for histopathological examination. Histopathological examination will be conducted according to the local protocol. In case of a neoplasm of the gallbladder, the treatment strategy is discussed and decided by the local multidisciplinary team. If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
45757235|NCT01799681|Behavioral|an 8-week upper limb and hand exercise program|upper limb stretching and strengthening, hand agility exercises, knot tying and Chinese calligraphy
45606366|NCT05091177|Diagnostic Test|Serum acetylcholine receptor antibody, erythrocyte deposition rate, hypersensitive C protein, neostigmine test,thymus CT, low frequency repeated nerve stimulation|Use relevant instruments for inspection
45606367|NCT02302001|Device|Silicone Implant|
45606368|NCT05737095|Procedure|Pulmonary ultrasound|Within 6 hours of admission to Neonatal Pediatrics and Intensive Care
45606369|NCT03507959|Other|OLP scientifically-objective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a scientifically-objective manner.
45606370|NCT03507959|Other|OLP personally-affective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a personally-affective manner.
45606371|NCT03507959|Other|DP scientifically-objective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a scientifically-objective manner.
45606372|NCT03507959|Other|DP personally-affective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a personally-affective manner.
45606373|NCT02469285|Dietary Supplement|Modified pork|Pork with modified fatty acid composition
45606374|NCT02469285|Dietary Supplement|Pork|Pork with normal fat composition
45606375|NCT02469285|Dietary Supplement|Pork and berries|Pork with normal fat composition and Finnish berries
45757236|NCT02289105|Behavioral|Mandatory active choice|the mandatory active choice group, will be presented two forms at the same time. The first form will be a legally valid AD. The second form will be a declination form. Participants in the intervention arm will be required to complete, and submit either of the two forms the task.
45757237|NCT01799759|Behavioral|Online intervention|Child online intervention is 8 modules based on the Health Promotion/Transtheoretical Model Parent online intervention is 6 modules based on enhancing authoritative parenting,support and role models for improved nutrition, physical activity and health child body mass percentile
45757238|NCT01799759|Other|Completion of instruments only|Parent and child subejects in the waiting list control only complete surveys, body composition and fitness tests
45757239|NCT05687240|Behavioral|Qigong/Tai Chi|Participants will engage in 8 weeks of gentle movement/mindfulness videos provided in a daily text prompt, asking that this be practices most days of the week. A choice of practice video links will be provided, ranging from 10-30 minutes in length, and later confirmation texts will be employed to document if practiced, and what length was chosen.
45757240|NCT05687240|Behavioral|Heart rate variability biofeedback|"Randomized participants will be coached to practice a breathing technique that focuses attention on the sensations in the heart area, slowing and deepening the breath, and activating through memory or imagery a positive emotion. This practice is used along with a feedback device that provides information on achievement of the heart rate variability target, coherence that represents a neurocardiac state associated with vagal tone, or balance."
45757241|NCT03382106|Drug|Sildenafil 20 MG|Sildenafil, 20mg three times daily for 3 month period.
45757242|NCT03382106|Drug|Placebo Oral Tablet|Placebo manufactured to look like Sildenafil 20 MG
45757243|NCT03382106|Diagnostic Test|Pulse wave velocity|Vascular pulse measurement at the radial, brachial, femoral, and carotid arteries are taken using a tonometer probe.
45757244|NCT03382106|Diagnostic Test|Carotid artery compliance and stiffness|An echocardiogram is done by using a probe placed on the skin.
45757245|NCT03382106|Diagnostic Test|Pressure wave reflection|Carotid pulse measurement taken using a tonometer probe
45757246|NCT00622427|Drug|Ramelteon|8 mg tablets every night for 2 weeks
45606376|NCT02233738|Behavioral|Group Motivational Interviewing (GMI)|Participants randomized to Group Motivational Interviewing (GMI) will receive four structured, back-to-back, 90-minute sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
45606377|NCT02233738|Behavioral|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to GMI (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
45606378|NCT03507881|Device|fusion|Internal fixation
45606379|NCT04217577|Dietary Supplement|Dried plums|10-16 dried plums/day, approximately 100-120 g/day
45606380|NCT03135717|Dietary Supplement|Nutritional care|"Diagnosis of protein energy wasting : anthropometry, calculation of the nutrient intakes, evaluation of appetite, evaluation of gastrointestinal syndromes, hand grip test and bioimpedancemetry~Treatment of protein energy wasting : estimation of nutritional requirements, prescription of oral nutritional supplement or artificial nutrition, physical rehabilitation~Multidisciplinary approach (nephrologists, dieticians, physiotherapists, nurses)~Evaluation of the nutritional treatment (plasma albumin and prealbumin, weight evolution, muscle strength and body composition)"
45606381|NCT02306525|Procedure|Arthroscopic surgery of the hip joint|Arthroscopic treatment of Femoroacetabular Impingement
45606382|NCT03507803|Other|Gait Biofeedback|Feedback will appear on screen in front of participants during walking. If their foot is too inverted (determined by researcher) the object on the screen will turn red and an audio tone will be heard. If the participant corrects the foot position, the object will turn green and the audio tone will not be heard.
45606383|NCT04122261|Device|the MicroHand S endoscopic instrument control system|Using the MicroHand S endoscopic instrument control system to treat gallstone or cholecystitis in minimal invasive surgery.
45606384|NCT04122261|Device|the da Vinci endoscopic instrument control system|Using the da Vinci endoscopic instrument control system to treat gallstone or cholecystitis in minimal invasive surgery.
45606385|NCT05158439|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
45606386|NCT05091099|Drug|Alendronate|On time Zoledronate: Zoledronate would be given (one dose for one year) after the completiong of denosumab on time Alendronate and Zoledronate: Alendronate would be given one month before the the completiong of denosumab and the following 3 months (Total four months). After the completion of Alendronate, Zoledronate would be given (one dose).
46066660|NCT05297266|Device|IscAlert|Insertion of a CO2- and temperature sensor in the distal part of the replanted extremity
45606388|NCT05197426|Drug|Oral Azacitidine|Specified dose on specified days
45757247|NCT00622427|Drug|Placebo|placebo tablets for every night for 2 weeks
45444720|NCT02037490|Behavioral|Grow2Gether|"Participants in this intervention will:~Participate in Facebook group of 6-12 peers for about 8 months, led by a professional group mentor.~Complete an intervention video activity approximately weekly:~View educational videos addressing topics related to healthy infant growth~Create photos/videos modeling healthy behaviors and post them to the group~Provide and receive feedback on posts~Be encouraged to share information with key caregivers of their child~Attend group party soon after enrollment, to meet peers and group leader in person."
45606389|NCT05197426|Other|Placebo|Specified dose of specified days
45606390|NCT03505151|Drug|BI 409306 (C-13/N-15)|i.v solution
45606391|NCT03505151|Drug|BI 409306|Film-coated tablet
45606392|NCT02306681|Other|No treatment given|This study comprises of a two-part SAQ (Self-Assessment Questionnaire). Paired responses to SAQ1 and SAQ2 will be used to estimate the differences in the frequency of hypoglycaemic episodes between the retrospective and prospective periods.
45444721|NCT04815291|Device|Receives SCOUT at biopsy|SCOUT Reflector
45606393|NCT02232880|Drug|Abatacept|All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
45606394|NCT02232880|Drug|Placebo|All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
45757248|NCT05469854|Drug|Linaprazan glurate|Oral tablet containing 25mg linaprazan glurate, an inhibitor of gastric H+, K+-ATPase by K+-competitive binding.
45606395|NCT02896855|Drug|Docetaxel|Docetaxel (75-mg/m^2) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
45606396|NCT02896855|Drug|Pertuzumab|Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
45606397|NCT02896855|Drug|Placebo|Placebo matched to pertuzumab was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
45757249|NCT00622895|Drug|fludarabine phosphate|Given IV
45757250|NCT00622895|Drug|Mycophenolic Acid|Given PO
45757251|NCT00622895|Drug|tacrolimus|Given PO
45757252|NCT00622895|Radiation|total-body irradiation|Undergo TBI
45757253|NCT00622895|Procedure|bone marrow transplantation|Undergo transplantation
45444722|NCT02052232|Other|Experimental protein powder sachet|mixed with 8 oz. water
45444723|NCT02052232|Other|Control protein powder sachet|mixed with 8 oz. water
45606398|NCT02896855|Drug|Trastuzumab|Trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
45606399|NCT05090943|Other|QOL to be completed by the participant|The scales (PUTS, OCI, TS-QOL, ASRS, GAD-7, PHQ9, TAPS) to be completed by the participant
45606400|NCT03504995|Device|Focal irreversible electroporation of the prostate cancer|Irreversible electroporation is a non-thermal tissue ablation technique in which short duration electrical fields are used to permanently permeabilize the cell membrane.
45606401|NCT02311439|Drug|FOLFIRINOX + CRT|"Induction 4 times chemotherapy, FOLFIRINOX regimen, consisted of Oxaliplatin at a dose of 85 mg/m2 D1, 2-hour I.V + Irinotecan 180 mg/m2 D1 90-minute I.V. + Leucovorin 200 mg/m2 2- hour I.V, D1,2 + (5-FU) dosed at 400 mg/m2, administered as an intravenous bolus on day 1 and day 2, followed by a continuous intravenous infusion of 600 /m2 over a 20- hours period on day 1 and day 2. Treatment will be administered every 2 weeks. G-CSF will be administrated according to the need.~In non-progressed cases, will be followed by consolidation concurrent radiotherapy with capecitabine 625 mg/m2 BID.~Radiotherapy :~A fractionated dose of 50.4Gy /28 fractions/15 MeV photon energy generated by Dual-energetic Linear Accelerator."
45606402|NCT02311517|Drug|Ropivacaine|90 patients are randomly allocated into two groups: ropivacaine group (n=45), saline group (n=40). In the ropivacaine group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg of 0.375% ropivacaine after induction of anesthesia. In the saline group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg saline after induction of anesthesia.
45606403|NCT02311517|Drug|Normal Saline|
45757254|NCT00622895|Procedure|reduced intensity allogeneic hematopoietic stem cell transplantation|Undergo transplantation
45757255|NCT00622895|Procedure|quality-of-life assessment|Ancillary studies
45606404|NCT05377437|Other|Natural Language Processing|Natural Language Processing: classification and regression tasks.
45606405|NCT02232802|Drug|Enoxaparin Sodium|comparison of bioavailability of generic Enoxaparin Sodium and Clexane
45606406|NCT02232802|Drug|Enoxaparin Sodium|comparison of bioavailability of generic Enoxaparin Sodium and Clexane
45606407|NCT04463459|Drug|Vitamin C, Vitamin E|Vitamin C (500mg) twice daily and Vitamin E (400mg) once daily
45606408|NCT04018677|Device|TOGETHER|TOGETHER is a mobile application software by Medable Inc.
45606409|NCT04463381|Procedure|choledochotomy techniques during LCBDE|
45606410|NCT05736783|Other|plyometric exercises|"st week Wall touches 3x30 s Split squat jumps 2x40 Lateral cone jumps 2x30 Cone hops with 180 turn 4conesx10~nd week Wall touches 4x30 s Split squat jumps 2x40 Lateral cone jumps 2x30 Cone hops with 180 turn 4 cones x 30~rd week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30~th week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30 Drop jump 45.72 cm 45.72 cm (20)~th week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30 Drop jump 45.72 cm 45.72 cm (30)~th week Wall touches 6x30 s Split squat jumps 2x70 Lateral cone jumps 2x60 Cone hops with 180 turn 4 cones x 40 Drop jump 45.72 cm (40)"
45606411|NCT05736783|Other|strenghtening of quadriceps and hamstring|1st to 3rd week l 4th to 6th week Squat 2x12 3x8 l 3x10 4x6 Knee extension 3x12 3x8 l 2x10 2x6 Nordic hamstring 3x3 3x3 l 3x4 3x4
45606412|NCT02762773|Procedure|non-dissection of inferior rectus sheath|Non-dissection of inferior rectus sheath
45606413|NCT02762773|Procedure|control|Dissection of inferior and superior aspect of the rectus sheath
45606414|NCT03534375|Other|The study is an observational cross sectional study|An intervention will not be performed
45606415|NCT03507335|Device|chest strap and PPG-device for monitoring the rhythm|chest strap and PPG-device for monitoring the rhythm during 24 hours for both groups (atrial fibrillation and sinus)
45757256|NCT00622895|Other|laboratory biomarker analysis|Correlative studies
45757257|NCT00622895|Other|flow cytometry|Correlative studies
45757258|NCT00622895|Procedure|biopsy|Punch biopsy of skin involved with scleroderma
45911301|NCT02006277|Drug|crizotinib oral solution|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
45606416|NCT02289313|Behavioral|Healthy Youth Living Program|Physical activity and healthy eating program at the Alternative Learning Center co-developed by students, school staff and academic partners.
45606417|NCT03419195|Other|Cardiovascular exercise training|Following the completion of baseline testing, both subject groups will undergo supervised cardiovascular exercise training 3 times per week for 3 months (plus a 3 week ramp-up). Exercise training will take place on a treadmill, stationary bicycle, elliptical, rowing machine, or combination of machines. Each session will last 1 hour, which includes a 5 minute warm-up, 50 minutes of exercise, and a 5 minute cool down.
45757259|NCT00734305|Drug|MM-121|Dose escalation Frequency - once weekly
45757260|NCT05304195|Diagnostic Test|Glucocerebrosidase|Blood sample (10ml) for GCase activity
45757261|NCT05304195|Genetic|GBA gene|Blood sample (10ml) for variants or mutations of the GBA gene
45757262|NCT01278823|Procedure|laparoscopic roux en y gastric bypass operation|roux en y gastric bypass operation
45757263|NCT01278823|Other|medical management|latest type 2 diabetes medications, lifestyle/behavior modification and dietary regimen
45757264|NCT01799291|Behavioral|Decision Making Tutorial|"A web-based presentation focused on key cognitive de-biasing strategies, including helping clinician participants: consider alternative diagnoses (e.g., symptom checklists); decrease reliance on memory (e.g., mnemonics); and incorporate Bayesian reasoning (e.g., actuarial approaches)."
45757265|NCT05023005|Other|Strain-Counterstrain treatment of piriformis muscle|Participant will lay prone on table with affected leg close to edge of table. Piriformis muscle tender point is identified and palpated. Then patient leg is passively moved off table and passive hip flexion, abduction, and possible internal/external rotation is added to reduce tender point by 70% or more. This is done passively. This position is held for 90 seconds and then participant is passively returned back to neutral prone position with leg on table. Tender point is palpated again to reassess for change in pain (using subjective visual analog scale). An algometer is also used pre and post to assess objective change in pressure pain threshold.
45757266|NCT00623441|Device|Endeavor Zotarolimus Eluting Coronary Stent|Drug eluting stent
45757267|NCT05625867|Other|Psychological and quality of life questionnaires|At 4/5 months and at 9 months
45606418|NCT05090709|Other|Spinal Mobilisation Intervention|30 minutes spinal mobilisations, rate = 0.37Hz, 22 beats per minute, force = less than grade 1, threshold of 80N, location = L1-L5.
45757268|NCT05625867|Other|Interdisciplinary consultation at 4/5 months|About ten days after the questionnaires were administered
45606419|NCT05090709|Other|General Massage|30 minutes manual touch with no specifications or recordings on rate, pressure or location of touch.
45606420|NCT04457011|Drug|High dose Susu Xiao'er Zhike Granules 1 bag|High dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 20.25g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
45606421|NCT04457011|Drug|Middle dose Susu Xiao'er Zhike Granules 1 bag|Middle dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 10.13g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
45606422|NCT04457011|Drug|Extremely-low dose Susu Xiao'er Zhike Granules 1 bag|Extremely-low dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 0.51g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
45606423|NCT02311595|Procedure|reduced port laparoscopic distal gastrectomy|
45606424|NCT03586102|Dietary Supplement|High protein supplementation|To increase protein content of human milk, a fixed amount of commercially available hydrolyzed bovine protein will be added to fortified human milk. With this pragmatic approach, preterm infants assigned to the high protein supplementation group will receive > 4.5 g/kg/day of enteral protein after establishment of full enteral feeding.
45606425|NCT03586102|Dietary Supplement|Standard protein supplementation|Infants assigned to the standard protein supplementation group will receive fortified human milk (< 4.5 g/kg/day of enteral protein)
45606426|NCT05735223|Procedure|Maximal urethral length preservation technique of robot assisted radical prostatectomy (RALP).|Stretched flaccid penile length (SFPL) was measured by a single male assessor at preoperative visit, and at the time of catheter removal (10 days post-surgery). The subjects were blinded to the measurements to prevent bias. Multiparametric MRI (MP-MRI) of the prostate were reviewed when available for surgical planning. All subjects underwent RALP with MULP using the technique previously published by Hamada et al. Continence defined as requiring no pads was assessed at 3 and 6 months postoperatively.
45606427|NCT04456855|Procedure|Locoregional surgery|Patients had pathologically confirmed operable stage IV breast infiltrating carcinoma at initial presentation, and had locoregional surgery for the breast cancer.
45606428|NCT02306837|Drug|Bu-CY-E|mini Bu-Cy-E as consolidation chemotherapy after autologous HSCT
45606429|NCT04778644|Drug|CBD|Oral gel capsule CBD
45606430|NCT04778644|Drug|Placebo|Oral gel capsule placebo
45606431|NCT02434328|Drug|Brolucizumab ophthalmic solution|Ophthalmic solution for IVT injection administered as a 6 mg/50 µL dose
45606432|NCT02434328|Drug|Aflibercept ophthalmic solution|Ophthalmic solution for IVT injection administered as a 2 mg/50 µL dose
45606433|NCT02307071|Device|Cefaly Kit Arnold|Occipital neurostimulation can have a therapeutic effect in chronic migraine treatment, thus representing a possible therapeutic option in patients that do not respond to any medication.
45606434|NCT04785274|Device|non-invasive hemoglobin (SpHb)|hemoglobin measuring device
45606435|NCT04457791|Behavioral|Personalized dietary advice|Via an self-developed website and algorithm, participants will receive digital personalized dietary advice to increase dietary fiber intake, aiming to reduce constipation complaints. The advice is personalized on phenotype (habitual diet, gender)
45606436|NCT04539093|Other|Exposure of interest - Use of left ventricular assist device (LVAD)|Mechanical circulatory support devices such as left ventricular assist device is used as a treatment option for patients with end-stage heart failure.
45606437|NCT02311751|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
45606438|NCT04778176|Combination Product|continuous oral delivery of levodopa/carbidopa|The system consists of a reusable custom dental retainer, its case, and a pre-filled, single-use container which continuously releases levodopa/carbidopa into the back of the mouth.
45757269|NCT00672737|Drug|Remifentanil|Remifentanil was administered as a computer-controlled infusion, targeting two different effect site concentrations, 1 and 2 mcg/mL, in randomized order.
45606439|NCT04457635|Behavioral|Psychotherapy|
45606440|NCT03507179|Other|3d printed denture|construction of a 3d printed denture through a recent method instead of conventional processing
45606441|NCT03507179|Other|conventional dentures|conventional dentures
45606442|NCT04785196|Drug|APG-115|Dose escalation of APG-115 in combination with label dose of toripalimab, four dose levels of APG-115 will be tested: 50, 100, 150, and 200mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as 3 weeks a cycle.
45606443|NCT04785196|Drug|Toripalimab|Toripalimab is administrated following CDE approved label dose, i.e.: 240 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.
45606444|NCT05733819|Device|Subject-specific optimized RAS|Walking with metronome-based RAS cueing
45606445|NCT05733819|Behavioral|Active Walking|Walking without RAS cueing
45606446|NCT05110027|Drug|Enpatoran|Participants will receive single oral dose of enpatoran tablet on Day 1
45606447|NCT05110027|Drug|[14C]enpatoran microtracer|Participants will receive single oral dose of non-labeled enpatoran solution spiked with microtracer of [14C]enpatoran on Day 1 of Period 1.
45757270|NCT00672737|Procedure|Cold pain threshold and tolerance|Ice water was used to assess cold-related pain threshold and tolerance, defined as the time that the volunteers could keep their hands in the water before they started feeling pain or this feeling becomes unbearable, for threshold and tolerance, respectively.
45757271|NCT00672737|Device|Heat pain threshold and tolerance|TSAII Neuroanalyzer (Medoc Advanced Medical Systems, Durham, NC), was used to assess the heat-related pain and tolerance of the volunteers defined as the respective temperatures where they started feeling as painful or unbearable.
45757272|NCT00672737|Procedure|Polysomnography|All volunteers underwent a polysomnography study at home or at Stanford Sleep Center, approximately one week before their experimental pain assessment in the laboratory
45911302|NCT02006277|Drug|crizotinib prototype microsphere 0.529 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
45606448|NCT05110027|Drug|[14C]enpatoran microdose|Participants will receive intravenous [14C]enpatoran microdose administered at 1.5 hours after the oral dose of enpatoran on Day 1 of Period 2.
45606449|NCT02311829|Other|Telephone follow-up device|For patients in the DST group only: Phone calls by clinical psychologist at J 15 at 2, then every 2 months until M12.
45606450|NCT05174026|Other|Fludeoxyglucose F-18|Given IV
45606451|NCT05174026|Procedure|Magnetic Resonance Imaging|Undergo 18F-FDG PET-MRI
45606452|NCT05174026|Procedure|Positron Emission Tomography|Undergo 18F-FDG PET-MRI
45757273|NCT03380078|Behavioral|Teams Leadership Institute (TLI)|TLI is training for leaders in how to improve implementation of evidence-based interventions in community settings. TLI includes 5 key components : 1. Assessment: The Implementation Leadership Scale (ILS) and Implementation Climate Scale (ICS) will be completed by first-level leaders participating in the intervention, his/her subordinates (i.e. providers) and executive leaders. 2. Initial Training: a 3-hour didactic and interactive session that includes training in implementation leadership Leaders will develop a plan for using specific implementation support strategies. 3. Coaching: Weekly, brief (15-30 min) coaching calls keep leaders on track with goals and plans. Coaching includes review of progress toward goals, updating plan based on emergent issues, and problem solving. 4. Follow up : At month 4, leaders attend a 2-hour booster session . 5. Graduation: TLI programs will have a group-based graduation for the leaders and provider trainees at EBI training completion.
45444724|NCT03811197|Behavioral|Dietary counseling via face to face meeting|All subjects received individual MNT and individual dietary recommendations based on DASH (Dietary Approaches to Stop Hypertension) diet plan for 6 months (Part A). Dietary counseling is provided by a trained dietitian. Months 9 and 12 - follow up (Part B).
45606453|NCT05089513|Procedure|Robotic surgery|Robotoc surgery (Da Vinci) in both donor and recipient
45606454|NCT05376813|Procedure|CT-Scan and MRI|CT-Scan and MRI examination for shoulder will be performed on healthy volunteers.
45606455|NCT05076253|Drug|Ivermectin|Ivermectin plus standard care
45606456|NCT05076253|Drug|Placebo|Standard care
45606457|NCT04776928|Behavioral|Push reports|"Surgeons in the experimental arm will receive provider-level push report notifications through an email displaying their personal prescribing performance compared to Michigan Opioid Prescribing Engagement Network (OPEN) prescribing guidelines and their de-identified peers.~The push report will also include a link to the secure MSQC data platform that displays more information about the case so the surgeon can further investigate prescribing information. The email will also contain contact information for the study team so as to help any surgeons troubleshoot, learn more, request to stop receiving reports, etc."
45444725|NCT03811197|Behavioral|Telemedicine|All subjects received an additional dietary counseling for 6 months (via internet, messenger or telephone) two weeks after each standard visit will be added to the counseling (Part A). Standard and additional dietary counseling (T) are provided by a trained dietitian. Months 9 and 12 - follow up (Part B).
45606458|NCT02311985|Other|Coagulogram-based protocol|The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on international normalised ratio (INR), partial thromboplastin time (PTT), platelet count and/or fibrinogen. If INR >1.5 or PTT >50 sec., fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets <50,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or fibrinogen <150 mg/dL, cryoprecipitate is administered (dose: 01 unit/Kg).
45606459|NCT02311985|Other|Thromboelastometry-based protocol|The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on rotational thromboelastometry (ROTEM(R)). If CTex <80 sec. and A10ex >40 mm, then no blood transfusion is performed; when CTex >80s, then fresh frozen plasma is administered (dose: 10 mL/Kg); and/or A10ex <40 mm or A10fib >10 mm, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or A10ex <40 mm or A10fib <10 mm, cryoprecipitate is administered (dose: 01 unit/Kg).
45911303|NCT02006277|Drug|crizotinib prototype microsphere 0.470 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
45911304|NCT02006277|Drug|crizotinib prototype microsphere 0.420 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
45444726|NCT03811197|Behavioral|Hypnotic Suggestions|"All subjects received individual hypnotic suggestion (HS) for 6 months as a supplementary method for dietary counseling. HS will be adapted to the small steps method used in the management of obesity. During the visit, HS will be recorded and the individual will listen to it every day (Part A). HS will be provided by a physician, qualified in the field of hypnotherapy. Months 9 and 12 - follow up (Part B)."
45911305|NCT02006277|Drug|crizotinib capsule|Subjects will receive a single 250-mg oral dose of crizotinib.
45444727|NCT02049580|Drug|Thiotepa|Thiotepa (10 mg/kg /day) will be administered every 12 h, at day -6
45444728|NCT02049580|Drug|Fludarabine|"Fludarabine (30mg/m2/day x 4 days) will be dosed according to renal function. For decreased creatinine clearance (CCr) (≤ 61 mL/min) Fludarabine dosage should be reduced as follows:~CCr 46-60 mL/min, fludarabine = 24 mg/ m2/day"
45606460|NCT02311985|Other|Restrictive strategy|The interventions for this protocol include transfusion of fresh frozen plasma and/or platelets (random or aphaeresis), based on INR and platelet count. If INR >5, fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets <25,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis).
45606461|NCT03473587|Behavioral|Motivational interview|A lay health advisor will engage the subject in a motivational interview to promote the importance of colorectal cancer screening
45606462|NCT03473587|Behavioral|Standard of care|A lay health advisor will provide the subject with a brochure promoting the importance of colorectal cancer screening
45606463|NCT03504761|Device|ClariCore Optical Biopsy System|Demonstrate the efficacy and safety of the ClariCore System in obtaining prostate biopsies utilizing real-time tissue classification.
45606464|NCT05077839|Drug|Trifluridine/Tipiracil|Trifluridine/tipiracil was approved in the third-line treatment of advanced colorectal cancer. Its efficacy in the first-line treatment was unknown.
45606465|NCT04782973|Other|AMAZE (TM) Disease Management Platform|Providing patients with smartphone app that will integrate with provider facing dashboard within electronic medical record.
45606466|NCT05077683|Drug|Rivaroxaban 2.5 MG [Xarelto]|Experimental group: usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) + rivaroxaban 2.5mg twice daily.
45606467|NCT05077683|Drug|DAPT strategy|usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) +
45606468|NCT03132233|Dietary Supplement|Beta-hydroxybutyrate calcium and magnesium salt|Exogenous ketone body in mineral salt form.
45606469|NCT03132233|Other|placebo powder|matched placebo powder to the IMP.
45606470|NCT04565977|Other|Observational|Retrospective chart review
45606471|NCT02678715|Device|Solubrux®|prefabricated device adaptable by temperature
45606472|NCT02678715|Device|Customized Appliance|customized device fabricated in the dental laboratory
45606473|NCT02678715|Device|Somatics®|standard device
45606474|NCT02307227|Drug|Trastuzumab|
45606475|NCT02307227|Drug|Paclitaxel|
45606476|NCT02307227|Drug|Epirubicin|
45606477|NCT02307227|Drug|Docetaxel|
45606478|NCT03473509|Other|CKD Registry|Health Service intervention
45606479|NCT02307305|Drug|Duloxetine|"Phase I (preemptive): 2 hour before surgery (30mg for 1 day)~Phase II (titration): POD#1~6 (30mg for another 6 days)~Phase III (maintenance): POD#7~13(60mg for 7 days)~Phase IV (tapering-1): POD#14~20 (30mg for 7 days)~Phase V (tapering-2): POD#21~27 (30mg another every day for 7 days)"
45606480|NCT02307305|Drug|celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone|Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)
45606481|NCT05118451|Procedure|3 d visualization technology|3D visualization technology refers to the conversion of 2d imaging data such as CT and MR into 3D stereoscopic images through computer calculation, analysis and reconstruction, visually separating the shapes and spatial distribution features of targets such as liver, blood vessels and tumors directly, accurately and quickly to present three-dimensional views. Combined with transparency, rotation, scaling and measurement techniques, real-time and interactive 3D dynamic analysis of 3d visual model is carried out. In addition, the computer was used to simulate the operation, and the feasible surgical plan was discussed. The best surgical plan was selected based on the patient's individual data.
45606482|NCT02660229|Drug|Oxycodone Hydrochloride|Oxycodone injection
45606483|NCT02660229|Drug|Morphine Sulphate|Morphine sulphate injection
45606484|NCT02307383|Drug|Lactitol|
45606485|NCT02307383|Drug|Lactobacillus|
45606486|NCT04719247|Procedure|Pulpotomy|Irreversibly damaged dental pulp is partially removed and a dressing either Turmeric or Thymus Vulgaris or Nigella Sativa or Aloe Vera is placed. Clinical and Radiographic signs and symptoms are assessed and compared with Formocresol.
45606487|NCT02232178|Drug|2 100mg Xaracoll implants|
45606488|NCT02232178|Drug|3 100mg Xaracoll implants|
45911306|NCT02006277|Drug|crizotinib oral solution|Subjects will receive a single 250-mg oral dose of crizotinib.
45911307|NCT02006290|Drug|PF-06412562|single oral split dose 30+20 mg QD
45444729|NCT02049580|Drug|Cyclophosphamide|"Pre-transplantation Cyclophosphamide(Cy) 30 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -5.~Cy will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the Adjusted IBW (AIBW)~Cyclophosphamide [50 mg/kg/day IBW] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
45606489|NCT02232178|Drug|150mg Bupivacaine HCl injection|
45606490|NCT05094921|Other|Aquatic Halliwick method|The Halliwick Concept is a detailed swimming programme based on the scientific principles of body mechanics and the properties of water intended to educate individuals with special needs to be water safe and to move independently in the water as much as possible (Lambeck & Stanat 2001a).The programme consists of 10 specific progressive stages that are achieved without the use of floatation devices (Lambeck & Stanat 2001b).
45606491|NCT05094921|Procedure|Conventional physical therapy|Conventional selected exercise program for 60 minutes ,3 session per week for 3 successive months aiming to improve the motor functions of the children in form of: (1) Neuro-developmental technique, (2) Back and abdominal exercises to improve postural control and correct spinal deformities (3) improving postural responses, (4) Flexibility exercises of the soft tissue (5) Strengthening exercise (particularly knee extensors, hip abductors and the ankle dorsi-flexors muscles and (6) Improving standing, weight transfer and shift and finally facilitation of normal walking pattern .
45606492|NCT02307461|Drug|IPI-145 (duvelisib)|High single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) high single oral dose
45606493|NCT02307461|Drug|IPI-145|Low single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) low single oral dose
45606494|NCT02307461|Drug|IPI-145|High single oral dose IPI-145 test formulation (capsule) with a high-fat meal and without food
45606495|NCT04457323|Drug|Metoprolol|S-Metoprolol XR 25 mg and 50 mg Film Coated Tablets
45606496|NCT04457323|Drug|Metoprolol|Beloc® (Metoprolol) Zok 50 mg and 100 mg Controlled Release Film Tablets
45606497|NCT04768036|Other|IMPROVE DD VTE Tool|"Universal SMART on FHIR platform-based EHR-embedded IMPROVE VTE CPR with electronic order entry incorporated into required admission and discharge EHR workflow."
45606498|NCT04448431|Drug|Vortioxetine|10 or 20 mg/day, capsules, orally
45606499|NCT04448431|Drug|Desvenlafaxine|50 mg/day capsules, orally
45606500|NCT02307539|Procedure|Psychosocial Assessment and Care|Undergo PCPI
45606501|NCT02307539|Other|Palliative Therapy|Undergo PCPI
45606502|NCT02307539|Other|Quality-of-Life Assessment|Undergo QOL assessment
45911308|NCT02006290|Drug|Placebo|tablet, matching placebo, QD
46066661|NCT01557751|Genetic|Whole blood for genotyping|This study requires genotyping by extracting DNA from blood sample. A blood sample will be drawn once during visit 2 (day of surgery) or any other time prior to that after the signing of informed consent. Four vacutainers of which hold 8.5 mL will be drawn during this time totaling approximately 34 mL of blood which completes the genomic sampling portion of the study.
45757274|NCT03380078|Behavioral|Motivational Enhancement (TIPS for Training)|The TIPS module applies MI principles and strategies to address attitudinal barriers and improve engagement in training. I AIM HI and CPRT trainers (in the TIPS Conditions ) will incorporate MI during training and ongoing consultation/coaching with providers to increase provider engagement and problem solving throughout training: 1. Providers will receive a call designed to provide information about training and the intervention. 2. During the workshop, trainers will assess concerns about participating and will use reflective problem solving to address barriers . Trainers will work with the provider to develop a plan through the use of Planning Worksheets . 3. During each consultation , planning worksheets will be updated collaboratively with the provider. 4. Providers will receive a weekly motivational text to encourage on-going participation.
45606503|NCT02307539|Other|Questionnaire Administration|Undergo questionnaire administration
45606504|NCT04784962|Device|Revitive Medic Neuromuscular Stimulation Device|Usage of the Revitive NMES device - 1-6 sessions daily (30 minutes per session).
45757275|NCT03380078|Behavioral|Classroom Pivotal Response Teaching (CPRT)|CPRT is a naturalistic behavioral intervention adapted from pivotal response training (PRT) for use during classroom activities to target social, communication, behavior, and learning skills. CPRT is a manualized program with user-friendly materials for training, intervention planning and fidelity monitoring provided in printed and web-based formats. CPRT has an established training plan and the training curriculum that follows the manual. Training and coaching including standard EBI training is conducted by MA or postdoctoral level researchers with extensive training and experience with CPRT.
45606505|NCT04784962|Device|Revitive Medic Neuromuscular Stimulation Device (Sham)|Usage of the Sham Revitive NMES device - 1-6 sessions daily (30 minutes per session)
45606506|NCT05094765|Biological|FMT|Fecal Microbiota Transplantation
45606507|NCT03507023|Dietary Supplement|Metabolaid®|500 mg per day, in fasting conditions.
45606508|NCT03507023|Dietary Supplement|Placebo|500 mg per day, in fasting conditions.
45606509|NCT05713149|Other|Surgical flap and anti-bacterial agents|Surgical flap and anti-bacterial agents
45606510|NCT02307695|Drug|Saxagliptin|saxagliptin 5 mg p.o. qd, 24 week
45606511|NCT02307695|Drug|Insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
45606512|NCT05161975|Dietary Supplement|Vitamin K2|Volunteers will be randomly assigned to vitamin K2 or placebo group and consume one tablet of the food supplement per day.
45606513|NCT05712291|Procedure|Total knee arthroplasty using the active robotic surgical system|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
45606514|NCT05712291|Device|TSolution One TCAT, and system for planning TPlan|the active robotic surgical system TSolution One TCAT, and system for planning TPlan
45606515|NCT05712291|Procedure|total knee arthroplasty using the standard manual technic|total knee arthroplasty using the standard manual technic
45606516|NCT03504605|Other|Online self-compassion intervention|Parents are asked to write in an online text box about a parenting event in which they felt shame. They are then given a validated set of instructions asking them to reflect on the event and write self-compassionate responses.
45606517|NCT02523391|Drug|TA-8995|Capsule
45606518|NCT02523391|Drug|TA-8995|Tablet
45606519|NCT03135639|Other|NeuroConn Plus Stimulator tACS|Transcranial alternating current stimulation (tACS) is a novel, noninvasive brain stimulation approach in which weak electric currents are applied to the scalp. The electric currents that are applied to the scalp are in a sine-wave pattern.
45606520|NCT03135639|Other|NeuroConn Plus Stimulator Sham|For sham stimulation, the participant receives up to 1 minute of tACS stimulation until the stimulation fades. This mimics the same skin sensations that a participant would experience during a tACS session.
45606521|NCT03469141|Device|Pressure Relief Monitoring System|Biofeedback provided to the intervention group via the smartphone app will include: Visual (e.g., phone notification bar) and auditory reminders if PR (pressure relief) is not performed as scheduled, Real-time feedback during performance of PR maneuvers to ensure adequate PR (e.g., the app will indicate if the duration of PR is sufficient), and Aggregate counts of daily PR activity.
45606522|NCT03504527|Drug|triple combinations|inhaled budesonide(160ug,bid),formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
45606523|NCT03504527|Drug|double combinations|inhaled formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
45606524|NCT02307773|Drug|Case Group|Consecutively, all the participants were assigned to case group with additional 2 puffs of the 10% lidocaine spray on the tip of endoscope, same medication which was used for prior pharyngeal anesthesia, or to control group with conventional pharyngeal anesthesia without further treatment. Then we compared the primary outcome measures, such as, frequency of belching and retching of two groups.
45606525|NCT03504449|Other|neoadjuvant chemoradiotherapy|
45606526|NCT01678131|Drug|Vaniprevir 600 mg|Vaniprevir capsules, were administered orally, twice per day (BID) to achieve a final daily dose of 600 mg on Days 1 through 6; and a single dose of 600 mg, orally, on Day 7.
45757276|NCT03380078|Behavioral|An Individualized Mental Health Intervention for ASD (AIM HI)|A package of well-established, evidence-based behavioral strategies designed to reduce challenging behaviors in children served in MH service settings. AIM HI is a manualized program with user-friendly materials for training, intervention planning and fidelity monitoring provided in printed and web-based formats. AIM HI is a package of evidence-based parent-mediated and child focused strategies, designed to reduce behavior problems in children with ASD ages 5 to 13 served in MH programs. AIM HI has an established training plan and the training curriculum follows the manual. Training and coaching is conducted by MA or postdoctoral level researchers with extensive training and experience with AIM HI.
45757277|NCT05296395|Other|Lactobacillus Plantarum 299v in fermented oat drink|The intervention is a probiotic lactobacillus that is contained in food products in the US
45606527|NCT01678131|Biological|Peg-IFN alfa-2b|Peg-IFN alfa-2b was administered at 1.5 µg/kg per week by subcutaneous injections on Days 1, 8, 15 and 21
45606528|NCT01678131|Biological|Ribavirin|Ribavirin capsules were administered on Days 1-21, orally, twice daily for a total daily dose of 600 - 1400 mg, depending on the participant's weight
45606529|NCT01678131|Procedure|Liver samples from FNA|Liver samples were collected from Day 7 up to Day 10 by FNA at 3 of 5 specified postdose timepoints.
45606530|NCT01678131|Drug|Vaniprevir 300 mg|Vaniprevir capsules were administered orally, twice per day to achieve a final daily dose of 300 mg on Days 1 through 6; and a single dose of 300 mg, orally, on Day 7.
45606531|NCT01678131|Procedure|Liver samples from CNB|Liver samples were collected from Day 8 up to Day 10 by CNB at 1 of 3 specified postdose timepoints.
45606532|NCT04579783|Drug|Triamcinolone Acetonide|Group A: 40mg triamcinolone acetonide (1mL) + 4mL normal saline
45606533|NCT04579783|Drug|Dextrose 5% in water|Group B: 5mL 5% dextrose
45606534|NCT03504371|Device|bilateral erector spinae block|The patient placed in a lateral position and transducer placed in a longitudinal orientation 3 cm lateral to the T7 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. An 8-cm 22-gauge block needle will be inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between rhomboid major and erector spinae muscles, as evidenced by visualization of local anesthetic spreading in a linear pattern between erector spinae and the bony acoustic shadows of the transverse processes. 20 mL of 0.25% bupivacaine will be injected then it will be repeated on the other side and preformed in the same way to achieve sensory block T5-T10 .
45606535|NCT03504371|Device|Thoracic epidural anesthesia|patients will receive TEA where an epidural catheter will be placed at the T7-8 interspace after proper sterilization and positioning of the patient in the sitting position then standard technique of application will be applied, then a test dose consists of 3 ml of 1.5% preservative free lidocaine with 1:200,000 epinephrine will be injected followed by 5-6 ml of bupivacaine 0.25%.
45606536|NCT02231164|Drug|docetaxel|intravenous chemotherapy drug
45606537|NCT02231164|Drug|docetaxel|intravenous chemotherapy drug
45606538|NCT02231164|Drug|placebo|oral placebo
45606539|NCT02231164|Drug|nintedanib|oral experimental therapy
45606540|NCT02457182|Other|Mindfulness-based Stress Reduction (MBSR)|
45606541|NCT02457182|Other|Usual medical therapy|
45444730|NCT03537729|Behavioral|Salient Cues|Salient cues are those that capture the individual's attention. Information that is complex, novel, and difficult to identify takes more processing resources than those that are simple and familiar. Cues such as pictures and wall hangings, along with bright and meaningful signs, will be placed at key decision points within the senior communities.
45606542|NCT03506789|Drug|Dexamethasone|Dexamethasone 24 mg
45606543|NCT03506789|Drug|Placebos|Isotonic saline
45606544|NCT04776694|Drug|Dupilumab|
45606545|NCT02312297|Drug|Minocycline hydrochloride|extended release tablets 135 mg
45606546|NCT05108974|Drug|Choline Bitartrate|Powdered drink mix for daily consumption
45606547|NCT03504293|Procedure|Combinatory EUS and ERCP|EUS performed as a supplementary procedure in addition to ERCP
45606548|NCT03473431|Drug|Ketamine|single infusion of 0.5 mg / kg ketamine
45606549|NCT03473431|Other|control|physiological solution at 0.9 % with the same physical characteristics of ketamine solution,
45606550|NCT03681704|Drug|HuangQi Decoction|HuangQi Decoction 150ml twice a day for 24 weeks
45606551|NCT03681704|Drug|HuangQi Decoction placebo|traditional Chinese medicine placebo mimic HuangQi Decoction 150ml twice a day for 24 weeks
45606552|NCT03377452|Behavioral|Behavioral Education Intervention I|Manual-based education program focusing on sleep and sleep apnea provided in individual sessions.
45606553|NCT03377452|Behavioral|Behavioral Education Intervention II|Manual-based education program focusing on sleep and sleep apnea provided in individual sessions.
45606554|NCT05161585|Diagnostic Test|ctDNA dynamic monitoring|ctDNA is detected before operation, before chemotherapy, and then every three months for 2 years, 10 times in total.
45606555|NCT04930250|Other|Beverage powder with 12% oat bran processed with method A|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
45606556|NCT04930250|Other|Beverage powder with 12% oat bran processed with method B|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
45606557|NCT04930250|Other|Beverage powder with 12% oat bran processed with method C|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
45444731|NCT03537729|Behavioral|Spaced Retrieval Education|Spaced Retrieval (SR) is an evidence-based memory strategy that is used to teach individuals with memory loss new or previously known information. In this study, participants in Arm 3 will receive twelve 30-minute educational sessions to help them use the salient cues to find their way.
45444732|NCT03797235|Procedure|Dominant Arm|The volume of local anesthetic used for the block of the ulnar and median nerve will be 5 times the estimated 95% effective dose (ED 95 ) of LA needed to block the nerve relative to the nerve cross-sectional area. The ED 95 for the ulnar nerve has been elucidated to be 0,11ml/mm2. The same ED 95 will be used for the median nerve.
45606558|NCT04930250|Other|Placebo Comparator: Minimally-processed oat bran (Positive Control)|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
45606559|NCT04930250|Other|Placebo Comparator: Readily-digestible carbohydrate (negative control)|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
45606560|NCT02378805|Drug|ACE-inhibitor|observational study!
45606561|NCT02378805|Drug|AT1-inhibitor|observational study!
45606562|NCT02378805|Drug|HMG-Coenzyme inhibitor (statin)|observational study!
45606563|NCT02378805|Drug|Spironolactone|observational study!
45606564|NCT02378805|Drug|Paricalcitol|observational study!
45757278|NCT05296395|Other|Heat-Killed Placebo control fermented drink|The intervention is the GoodBelly StraightShort that has been treated to heat kill all Lp299v
45606565|NCT02378805|Drug|SGLT2 inhibitor|observational study!
45606566|NCT04532437|Other|artificial intelligence-based skin aging simulation|Photographs of the volunteers' facial skin will be taken in the Department of Dermatology at baseline using a modern skin analysis photo system (VISIA®, Canfield Scientific, Parsippany, NJ, USA) and afterwards a simulation of the participants' facial skin aging will be performed with the VISIA® photo analysis System.
45606567|NCT04532437|Other|electronic questionnaire 1|Electronic questionnaire about current sun-related knowledge and protective behaviours via link with smartphone before and after the skin aging simulation.
45606568|NCT04532437|Other|electronic questionnaire 2|Participants report their perception of the interventions and their motivation for improved sun protection by completing an electronic questionnaire after the skin aging simulation.
45606569|NCT02230384|Drug|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week
45606570|NCT02230384|Drug|Placebo Pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week
45606571|NCT04286113|Behavioral|control group|will receive standard medical care where research assistant will give pamphlets, with one size fits all recommendations for diet/nutrition, physical activity and sleep, to 10 subjects with comorbid HTN and T2D.
45606572|NCT04286113|Behavioral|Lifestyle management|Will use passive ubiquitous sensing through FitBit to 1)learn behavioral profiles of subjects who have pre-HTN/HTN and/or pre-diabetes /Diabetes 2) provide personalized recommendations through mobile based messaging app that will increase the likelihood of engaging in health diet/nutrition, physical activity and sleep practices
45606573|NCT05094375|Drug|Vaginal Misoprostol 600 mcg|"All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 600 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 600 mcg each (3 tablets of 200 mcg per dose).~Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.~A specimen bottle to collect the POC if passed out.~Two pairs of disposable gloves.~Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
45606574|NCT05094375|Drug|Vaginal Misoprostol 800 mcg|"All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.~A specimen bottle to collect the POC if passed out.~Two pairs of disposable gloves.~Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
45757279|NCT05687006|Procedure|Colour Doppler Ultrasound|The main perforators were examined using a LOGIQ S8/V1 CDU device (GE Healthcare, Chalfont St Giles, Great Britain) with a linear transducer of frequency 4-11 MHz. Measured parameters were: 1) calibre of artery and vein; 2) Peak systolic velocity (PSV) of blood in the artery [cm/s]; 3) blood velocity in the perforator vein [cm/s]; 2) the thickness of the subcutaneous tissue of the lower abdomen measured 4 cm caudal and lateral to the umbilicus. Any additional perforators were marked nor have CTA deducted XY coordinates of marked perforators changed based on the CDU examination. The same sonography surgeon performed all CDU examinations. The time duration of the CDU examination was measured.
45757280|NCT04400708|Procedure|adductor canal block|After the end of the surgery, at the arrival of PACU, the patient's leg is prepared and draped in a sterile manner. Assisted by the high-frequency linear ultrasound transducer, we target the mid-thigh level and the 22-gauge/8cm needle is introduced in plain through the sartorius muscle. the correct position for the tip of the needle in the adductor canal is checked and a bolus injection of 0.5% ropivacaine 15ml is given.
45444733|NCT03797235|Procedure|Non-dominant arm|The volume of local anesthetic used for the block of the ulnar and median nerve will be 5 times the estimated 95% effective dose (ED 95 ) of LA needed to block the nerve relative to the nerve cross-sectional area. The ED 95 for the ulnar nerve has been elucidated to be 0,11ml/mm2. The same ED 95 will be used for the median nerve.
45606575|NCT04458181|Behavioral|Positive Peer Journaling (PPJ)|"PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve subjective wellbeing in recovery and reduce relapse. PPJ uses journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing good and bad things that happened and things for which one is grateful. Good wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as recovery, work/school, spirituality, home and household, and health."
45606576|NCT02738801|Drug|GLPG1690 600 mg QD|GLPG1690 capsules, administered at a dose of 600 mg, orally QD
45606577|NCT02738801|Drug|Placebo QD|Matching placebo capsules, administered orally QD
45444734|NCT03796923|Other|Early follow-up visit after discharge|Early follow-up visit and different degrees of specialized care after discharge
45444735|NCT03796923|Other|Comprehensive geriatric assessment (CGA)|Comprehensive geriatric assessment (CGA) during admission
45444736|NCT03796923|Other|Continued geriatric care|Continued specialized geriatric care after discharge
45606578|NCT04345861|Drug|Hydroxychloroquine + placebo|hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11)
45606579|NCT04345861|Drug|hydroxychloroquine + azithromycin|Combination hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11) Azithromycin 500mg (day 1) then 250 mg (Day 2 to Day 5)
45606580|NCT02067819|Device|Active Oral Orthotic Treatment|Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
45606581|NCT02067819|Device|Placebo Oral Orthotic Treatment|After two weeks, this treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
45606582|NCT04305067|Other|Exercise|Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be asked to complete one home-based aerobic exercise sessions each week. At baseline, 16 weeks and 3 month followup patients will complete a physical fitness assessment (30 second sit to stand and six minute walking tests) and a range of quality of life questionnaires. Upon completion of the 16 week exercise intervention, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.
45606583|NCT03506711|Diagnostic Test|Isometric Handgrip Exercise during magnetic resonance imaging|Coronary endothelial function are assessed by MRI with imaging studies done at baseline (at rest) and during IHE (under stress). Maximum grip strength is determined using an MRI-compatible dynamometer (Grip Force Fiber Optic Response Pad, Current Designs Inc., Philadelphia, USA) prior to baseline imaging.
45606584|NCT03504059|Behavioral|Long-term educational program|Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
45606585|NCT03504059|Behavioral|Short-term educational program|Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
45606586|NCT04438473|Dietary Supplement|pectin-supplemented enteral nutrition feeding|sequential supplementation with combination of 90ml pectin and 500ml enteral nutrition formula for 7 days
45606587|NCT04438473|Other|enteral nutrition feeding|standard formula enteral nutrition feeding without pectin for 7 days
45606588|NCT02230306|Drug|Cobimetinib|60mg once a day; will be taken on days 1-21 of each 28 day treatment cycle; will be taken in combination with Vemurafenib;
45606589|NCT02230306|Drug|Vemurafenib|960mg twice a day; 28 day treatment cycle; will be taken in combination with Cobimetinib;
45606590|NCT04266379|Device|Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions|Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data
45606591|NCT04266379|Device|Continuous Subcutaneous Insulin Infusion and Continuous Glucose Monitoring|Insulin delivered subcutaneously by a pump and manage by the patient with the help of a CGM sensor
45606592|NCT02308319|Drug|Tenofovir disoproxil fumarate|300mg q.d. per oral
45606593|NCT05095545|Drug|AV5080|Hard gelatin capsules with a white body
45606594|NCT05095545|Other|Placebo|Hard gelatin capsules with a white body
45606595|NCT02312375|Drug|Fimasartan|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
45606596|NCT02312375|Drug|Amlodipine|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
45606597|NCT04216225|Other|pre-hospital tourniquet placement|patients with extremity injuries presenting with or without pre-hospital tourniquet placement.
45606598|NCT05062174|Drug|Mifepristone 200 MG|Orally, one time dosage of 200 mg
45606599|NCT05062174|Procedure|Prophylactic mastectomy|Planned prophylactic mastectomy (having one or both breasts removed).
45606600|NCT05095467|Procedure|HIPEC|The abdominal cavity will be filled with paclitaxel 120mg/m2 heated at 43℃ for 1 hour with a hyperthermic circulation machine.
45606601|NCT05095467|Drug|Paclitaxel-albumin|albumin paclitaxel D1, D8; S-1: D1-D14
45606602|NCT05095467|Drug|Tegafur-gimeracil-oteracil potassium|40mg bid(BSA<1.5 m2) ，60mg bid(BSA>=1.5 m2); D1-D14, po, bid.
45606603|NCT05095467|Procedure|Surgery+HIPEC|gastrectomy with D2 lymphadenectomy+HIPEC procedure
45606604|NCT02312453|Procedure|Posterior approach|We adopted the technique as described by Hebbard et al.
46066662|NCT00775099|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 mg/min).
45444737|NCT03796923|Other|Possible follow-up visit from GP|Usual care: follow up visit from GP within one week after discharge
45444738|NCT02805790|Drug|Elamipretide|4 weeks of treatment with 40 mg elamipretide administered once daily subcutaneously
45444739|NCT02805790|Drug|Placebo|4 weeks of treatment with placebo administered once daily subcutaneously
45606605|NCT03270982|Device|Comprehensive SRS Replacement|This system consist of a proximal humeral replacement, distal humeral replacement, or total humeral replacement.
45606606|NCT02312531|Drug|Hepatitis B immunoglobulin|Hepatitis B immunoglobulin 200 IU injection at gestational week 20, 24, 28, 32, 34, 36, 38, 39, and 40 in HBIG group mothers.
45606607|NCT04234477|Drug|Beta-blocker strategy|Clinicians within the intervention groups will be free to use whatever dosing amount and frequency of their assigned medication class that they deem as medically appropriate, including the decision to use intermittent IV boluses versus continuous infusions.
45606608|NCT04234477|Drug|Calcium channel blocker strategy|Clinicians within the intervention groups will be free to use whatever dosing amount and frequency of their assigned medication class that they deem as medically appropriate, including the decision to use intermittent IV boluses versus continuous infusions.
45444740|NCT01302951|Drug|Moxifloxacin 400 mg|The patients receive MXF 400 mg as one hour intravenous infusion at randomized timed intervals prior to liver resection.
45606609|NCT04234477|Drug|Physician preference strategy|"This strategy allows for usual care, with providers selecting their preferred rate-control agent. IV beta-blockers available through the inpatient pharmacy include metoprolol or esmolol, and IV calcium channel blockers include diltiazem and verapamil."
45606610|NCT05056168|Other|Dermatology-Specific Treatment Satisfaction Instrument|Study subjects will also be administered a dermatology-specific treatment satisfaction questionnaire, as well as other questionnaires including the generic validated Treatment Satisfaction Questionnaire for Medication (TSQM-9) and the validated Dermatology Life Quality Index (DLQI). Study participants will also self-report their disease severity using PGA. Depending on patients' preferred method of interacting with the study team, the investigators will collect their responses to these questionnaires either in-person, over the phone, or electronically via secure research platforms.
45606611|NCT04533711|Behavioral|OA-PCP Intervention|The OA-PCP intervention includes brief physical activity (PA) counseling delivered via phone by a PA Coach trained in relevant aspects of PA and motivational interviewing. During the initial call, the PA Coach will ask participants about their current physical activity level and work with them to set physical activity goals. Then, after the first call, participants in this group will receive a call about two weeks later, then at about 3 months, 6 months, 9 months and 12 months later. During these calls, the PA coach will ask participants' about their progress toward PA goals and work with them to address any barriers or challenges. The coach will also help participants to identify any programs or resources that may help them to achieve their PA goals. Participants in this group will be asked to wear a wrist-worn monitor to help them track their PA during the intervention period. Also, if participants approve, the coach will use an online program to view their PA data.
45606612|NCT04533711|Behavioral|Attention Control|"This group will receive an intervention in the same dose (e.g., number and duration of phone calls and emails) as the OA-PCP group, but the content will not be PA-specific. During the first call, the Coach will discuss 2 topics, for which the amount of content parallels call #1 for the OA-PCP: What is OA? OA Diagnosis and OA Risk Factors. During the second call, the Coach will discuss the topic of Health Care Providers and Overview of OA Treatment Guidelines. Call topics for 3, 6, 9 and 12- month follow-up calls will be: Pain Medications, Mechanical Treatments (e.g., knee braces, footwear, joint protection), Complimentary and Alternative Therapies and discussion of OA and Mental Health, Sleep and Fatigue."
45606613|NCT02449031|Drug|TOBI® PODHALER®|
45606614|NCT02449031|Drug|TOBI®|tobramycin inhalation solution, USP
45606615|NCT02449031|Drug|Bethkis®|tobramycin inhalation solution
45606616|NCT02449031|Drug|Cayston®|aztreonam for inhalation solution
45606617|NCT04232449|Drug|PREDNISON Galepharm Tabl. 20 mg|5 daily- doses of 40 mg (2 tablets of 20 mg) of prednisone
45606618|NCT04232449|Drug|placebo tablets|5 daily- doses of placebo (2 tablets)
45606619|NCT03469063|Dietary Supplement|AferBio|Patients will use the product (AferBio/Placebo) once a day for seven days, and then twice a day, continuously (for a total of three months of use).
45606620|NCT01680861|Drug|Tacrolimus|Tacrolimus dosing (rTd) is planned, 0.1 mg/kg PO BID - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.
45606621|NCT01680861|Drug|Everolimus|Everolimus initiated at 0.75 PO BID and will be adjusted in order to achieve target everolimus trough levels of 3-8 ng/ml.
45606622|NCT01680861|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|EC-MPS 720 mg PO BID - beginning on 1st postoperative day.
45606623|NCT01680861|Drug|Corticosteroids|Corticosteroids will be given as per our center protocol, i.e., a bolus of 500 mg of Methylprednisolone intravenously at surgery and daily x2, followed by 1.0 mg/kg, then 0.5 mg/kg orally until weaned off completely by 7-10 days postoperatively - the plan is for corticosteroids to be discontinued by 7-10 days postoperatively in both groups.
45606624|NCT04182607|Procedure|kidney transplant|Clinical data will be collected from electronic medical records (EMRs) on donors and recipients who underwent a minimally invasive kidney transplantation procedure
45606625|NCT02308397|Other|Normal gluten containing bread|Group 1 will begin with Normal gluten containing bread(A) and then move to bread B,C and D
45606626|NCT02308397|Other|Bread with reduced gliadins content|Group 2 will begin with Bread with reduced gliadins content (B) and then move to bread A, C and D
45606627|NCT02308397|Other|Bread with reduced ATIs content|Group 3 will begin with Bread with reduced ATIs content (C) and then move to bread A, B and D
45606628|NCT02308397|Other|Bread with reduced overall protein content|Group 4 will begin with Bread with reduced overall protein content (D) d then move to bread A, B and C
45606629|NCT02229214|Drug|Qsymia|
45606630|NCT02229214|Drug|Placebo|
45606631|NCT03470779|Other|Physiotherapy|Treatment group participants will participate in weekly group physiotherapy and psychotherapy sessions as part of the standard program procedure.
45606632|NCT03470779|Other|Psychotherapy|Treatment group participants will participate in weekly group physiotherapy and psychotherapy sessions as part of the standard program procedure.
45606633|NCT02308553|Drug|Nintedanib|Nintedanib (150 mg or 200 mg BID)
45606634|NCT02308553|Drug|Nintedanib-Placebo|Placebo (150 mg or 200 mg BID)
45606635|NCT02308553|Drug|Paclitaxel|Paclitaxel as 90mg/mw infusion day 1, 8, 15 q28 (6 cycles)
45606636|NCT04458415|Other|Traxi Panniculus Retractor (TPR)|Surgeon uses the Traxi Panniculus Retractor (TPR) surgical retraction device to retract the panniculus during C-Section.
45606637|NCT04458415|Other|Silk Tape|Surgeon uses silk tape to retract the panniculus during C-Section.
45606638|NCT05094063|Other|patient education by mobile application|Training will be given to the patients in the experimental group.
45606639|NCT03503981|Other|Psychotherapy|There are different psychotherapy models offered across the units. All patients receive individual treatment and group therapy or psychoeducative groups.
45606640|NCT04458493|Behavioral|satiety|satiety ratings, appetite and desire to eat (10-point visual analogue scale) will be measured at 30, 60 and 120 minutes after each meal replacement drink
45606641|NCT04458493|Dietary Supplement|Dietary Supplement: Generation UCAN supplementation|meal replacement, Generation UCAN supplement, 400ml, 20% solution
46066663|NCT00775099|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using Badimon Chamber
46066664|NCT02582710|Dietary Supplement|VASCAZEN|6 weeks treatment with an optimized formulation of omega 3 before the carotid endarterectomy
45757281|NCT04400708|Procedure|control group|After the end of the surgery, at the arrival of PACU, the patient's leg is prepared and draped in a sterile manner. Assisted by the high-frequency linear ultrasound transducer, we target the mid-thigh level and the 22-gauge/8cm needle is introduced in plain through the sartorius muscle. the correct position for the tip of the needle in the adductor canal is checked and a bolus injection of normal saline15ml is given.
45757282|NCT03367442|Other|no intervention|no intervention
45606642|NCT05094999|Device|Proprioceptive stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
45606643|NCT05094999|Device|Sham stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
45606644|NCT03503903|Procedure|Wet Cupping|CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46), which are the recommended sites for headache (12). The cupping technique procedure was conducted in five phases:Primary suction,Area disinfection,Scarification,Secondary suction and bloodletting,Removing and dressing.
45606645|NCT05093985|Other|Neuromuscular electrical stimulation with blood flow restriction|Neuromuscular electrical stimulation with blood flow restriction
45606646|NCT03523663|Other|no intervention. measure eye movement data|
45606647|NCT03503825|Drug|[Tc-99m]-RPI-T-087 Injection|A single intravenous injection of [Tc-99m]-RPI-T-087 followed by SPECT/CT imaging of the knee (all subjects) and whole body planar imaging (Healthy volunteers only)
45606648|NCT05374785|Drug|CPL409116|CPL409116 contained in the tablet called PG242 (60 mg)
45606649|NCT05374785|Other|Placebo|Tablets without CPL409116 as an active substance
45606650|NCT03470701|Other|Mailed Urinalysis Smartphone Kit|Patients who fail to complete albuminuria screening after the initial reminder to do so, will be contacted by phone and offered a mailed smartphone urinalysis kit. Agreeable patients will then receive the mailed kit and instructions to use their smartphone camera to analyze a urine dipstick.
45606651|NCT02308631|Procedure|ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY|The endoscope was manipulated until the light approached the pre-set for the use of transillumination site and puncture with the Loop Fixture II gastropexy kit
45606652|NCT05093907|Drug|BEY1107|Administer once daily, PO, 3-week continuous dose.
45606653|NCT05093907|Combination Product|Capecitabine|Administer twice daily, PO, 2-week continuous dose, followed by 1-week rest period.
45606654|NCT03793543|Drug|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
45606655|NCT02228980|Biological|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.25 mL Intramuscular (2 doses given 28 days apart)
45606656|NCT02228980|Biological|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
45757283|NCT05001945|Drug|MLS-101 (Part I)|MLS-101 tablet(s) by mouth once or twice daily.
45606657|NCT02228980|Biological|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
45606658|NCT02228980|Biological|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
45606659|NCT03506555|Procedure|Laparoscopic peritoneal entry technique: Veress needle versus Hasson|According to randomization, the closed (Veress needle) or the open (Hasson) laparoscopic entry technique was utilized for general surgical operations
45606660|NCT05093751|Other|Observation|This study does not involve any intervention to subjects.
45606661|NCT03783091|Drug|Hydroxocobalamin|Single IV administration of Vitamin B12
45606662|NCT03783091|Drug|Placebo|Single IV administration of saline
45757284|NCT05001945|Other|Placebo (Part I)|Placebo tablet(s) by mouth once or twice daily.
45757285|NCT05001945|Other|Placebo (Part II)|Placebo tablet(s) by mouth once daily.
45444741|NCT03796533|Drug|Posaconazole|"PCZ will be used as recommended in tablet formulation at an initial dosage of 300 mg twice a day on the first day and then once a day at a dose of 300 mg the following days.~PCZ prophylaxis will be started on the same day as the start of chemotherapy and will be continued until the end of aplasia.~The dosage of the PCZ can be adjusted according to the results of the PCZ assay. It may be interrupted if the transaminase level is greater than 3 times higher than normal (3N) or on medical decision."
45606663|NCT05057481|Drug|Mycophenolate Mofetil 500mg|MMF 2gram/day orally for 12 weeks
45606664|NCT05057481|Drug|Rituximab|375 mg/m2 of rituximab given intravenously weekly for 4 weeks.
45606665|NCT02312609|Drug|Minocycline hydrochloride|extended release tablets 135 mg
45606666|NCT03470623|Device|bioabsorbable screws|Hallux valgus are treated with a distal chevron osteotomy of first metatarsal and fixed using the bioabsorbable screw
45606667|NCT03470623|Device|steel screws|Hallux valgus are treated with a distal chevron osteotomy of first metatarsal and fixed using the steel screw
45606668|NCT05374707|Behavioral|MOTIVATIONAL INTERVIEWING|Motivational interviewing is a form of interview conducted with a patient-centered approach in order to enable people to discover and solve the obstacles to behavior change.
45606669|NCT03506399|Drug|Lanabecestat|Administered orally
45606670|NCT03506399|Drug|Oral Contraceptive|Administered orally
45757286|NCT05001945|Drug|MLS-101 (Part II)|MLS-101 tablet(s) by mouth once daily.
45757287|NCT00673127|Drug|Ketoconazole, Hydrocortisone and Dutasteride|"Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Pills should be taken with food or milk.~Dutasteride: 0.5mg orally once a day on an empty stomach or after eating a meal"
45757288|NCT04998123|Device|SeizureStop Device|Intersectional Short Pulse (ISP) Stimulation will be performed using SeizureStop Device. The ISP stimulation method proposed in this study is to increase the intensity of stimulation delivered to targeted brain regions, while minimizing the peripheral effects of stimulation. For sham stimulation, no settings will be modified.
45757289|NCT05684666|Other|Slow Breathing Exercise (SBE)|"Slow Breathing Exercise (SBE) delivered in a relaxed supine posture on a couch with keeping the feel flat and knee flexed to 90 degree.~Participants were instructed to make six breaths per minute for 30 minutes per session, twice a week for 4 weeks."
46066665|NCT02582710|Dietary Supplement|PLACEBO|6 weeks treatment with a placebo before the carotid endarterectomy
45606671|NCT04616365|Procedure|Semi-Elective Lung Transplantation|When suitable donor lungs become available for a consented recipient, the transplant procedure (anesthesia starting time) will be allowed to begin earliest at 6am with the lungs being preserved at 10°C cold static preservation upon organ arrival to our hospital using a specific incubator, regardless of when donor cross clamp occurs. The maximum time allowed between donor cross clamp and recipient anesthesia initiation will be 12h.
45606672|NCT04993911|Other|Experimental Group|"Assessment will be performed pre and post of intervention. Intervention will be given 3 days a week for 8 weeks. Each session will include a 5-min warm-up on a fitness bike or treadmill before commencement of the program and a 5-min cool period. Participants of this group will receive balance training with conventional treatment. Participants will perform between 2 sets of 5 and 7 repetitions of each exercise.~Single leg balance~Walking forward~Walking backward~Side stepping~Walk heel to toe~Static exercises with eyes close or open~CONVENTIONAL EXERCISE PROGRAM :~TENS for 15 minutes~Hot pack for 15 minutes~Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~Quadriceps/hamstring isometric exercises.~ROM and active stretching of the hamstring and quadriceps muscle.~Active ankle pump.~Squats,step-up, sit to stand, calf raises~Straigh leg raising exercise in crook lying position"
45606673|NCT04993911|Other|Control Group|"Participants of this group will receive only conventional therapy which will include; before beginning the program, each session will feature a 5-minute warm-up on a fitness bike or treadmill, followed by a 5-minute cool-down. Participants of this group will receive only conventional therapy which will include.~CONVENTIONAL EXERCISE PROGRAM :~TENS for 15 minutes~Hot pack for 15 minutes~Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~Quadriceps/hamstring isometric exercises.~ROM and active stretching of the hamstring and quadriceps muscle.~Active ankle pump.~Squats,step-up, sit to stand, calf raises~Straigh leg raising exercise in crook lying position"
46066666|NCT00936884|Drug|Methylnaltrexone|"Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; 0.4 mL (8 mg) every other day if weight between 38 and < 62 kg; or 0.0075 mL/kg (0.15 mg/kg) every other day if weight between 27 and <38 kg.~Study duration: 2 weeks double-blind period (MNTX treatments) followed by 12 weeks open-label extension period (MNTX treatments)."
45606674|NCT02228590|Drug|APL-130277|Apomorphine Hydrochloride, Sublingual Thin Film
45606675|NCT03503279|Device|McGrath MAC® Video Laryngoscope|McGrath MAC® Video Laryngoscope have been developed to secure the airway and improve the management of difficult intubation. McGrath MAC® is a self-contained VL with a single-use blade; its structure is similar to the ML, but without the channel that guides the tube and a mounted LCD screen on the handle that is connected to a miniature camera with a light source at the tip of the blade, allowing the clinicians to directly observe surrounding anatomical airway structures during a tracheal intubation
45606676|NCT04489537|Biological|MarzAA|A cross over design to assess the efficacy of a dosing regimen of 60 µg/kg of MarzAA compared with standard of care for the treatment of bleeding episodes.
45606677|NCT05374629|Behavioral|Use different methods of teaching|Both groups will receive a smoking cessation education guideline and post-test three months after the intervention.
45757290|NCT05684666|Other|Progressive Muscle Relaxation (PMR) Technique|"Progressive Muscle Relaxation (PMR) Technique delivered in a relaxed supine posture on a couch with keeping the feel flat and knee flexed to 90 degree.~Participants were instructed to complete all sixteen steps of PMR technique for 30 minutes per session, twice a week for 4 weeks."
45757291|NCT01799837|Drug|[C-11]MENET|PET imaging involves injecting small amounts of a radioactive material into the blood stream. The radioactive material is attached to a drug called MENET that will give information about how the brain interacts with a protein called norepinephrine (NE).
45757292|NCT00246259|Drug|Risperidone long-acting injection (LAI)|Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion.
45757293|NCT00246259|Drug|Oral Antipsychotic|Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg.
45757294|NCT05281263|Biological|CPI-RSV-F Vaccine (BLB-201)|see arm/group description
45444742|NCT03796377|Drug|St Johns Wort Extract|20 mg rivaroxaban after supplementation with St. John's wort extract (Jarsin®) twice daily 450 mg po for 2 weeks.
45444743|NCT03796377|Drug|Rivaroxaban|20 mg rivaroxaban.
45757295|NCT04400786|Procedure|intermittent treatment|According to the feeling of pain, the on-demand treatment group is prescribed with or without Imrecoxib (100mg/tablet, 100mg.prn.po), but the maximal dose does not exceed 100 mg per time, twice (morning and evening) per day. The duration lasted for 24 weeks.
45757296|NCT04400786|Procedure|continuous treatment|The continuous treatment group is prescribed Imrecoxib (100mg.bid.po) regardless of the pain in the treatment course for 24 weeks.
45757297|NCT00624221|Procedure|Descemet's stripping endothelial keratoplasty|Small incision corneal transplant procedure to treat dysfunctional endothelium.
45757298|NCT03317834|Device|Navio ™ Robotic-assisted Surgical System|Total Knee Replacement
45757299|NCT05686928|Drug|Cetaphil Healing Ointment|Topical ointment application twice daily
45757300|NCT00673439|Drug|fondaparinux|Dosage form: subcutaneous injection; dosage: 7.5 to 10.0 mg; frequency and duration: daily until blood test results rule out confirmed HIT - for patients with confirmed HIT, continue daily until INR (blood clotting) measurement rises to at least 2
45757301|NCT00673439|Drug|warfarin|Dosage form: oral; dosage: 2.5 to 5.0 mg; frequency and duration: (for confirmed HIT only) once daily, to begin when blood platelet count reaches at least 100,000, and continue for approximately 4 weeks
45757302|NCT03316118|Drug|bupivacaine|Group 1 will receive genicular nerve block using bupivacaine
45757303|NCT03316118|Drug|saline|Group 2 will receive genicular nerve block using normal saline
46066667|NCT00936884|Drug|Placebo|"Subjects received matching placebo injections.~Study duration: 2 weeks double-blind period (placebo treatments) followed by 12 weeks open-label extension period (MNTX treatments)."
46066668|NCT04048135|Drug|BIO89-100|Subcutaneous injection
46066669|NCT04048135|Other|Placebo|Subcutaneous injection
46066670|NCT04077892|Drug|budesonide|SAR patients received treatment of a combination of budesonide and montelukast tablet or only intranasal budesonide randomly for 14 days
46066671|NCT02582788|Other|Bathing Additive|
45757304|NCT03029013|Drug|Apatinib|Apatinib， 250 mg qd，po，after 7 days , paclitaxel (135-175 mg/m2) and platinum two drug standard chemotherapy, 21 days as a treatment cycle，during the chemotherapy of 7-21 days continue to offer the Apatinib. without disease progress, after 4 chemotherapy cycles, patients continue to accept the Apatinib maintenance treatment.
45757305|NCT00674219|Drug|Memantine|Namenda 10mg BID for 12 weeks
46066672|NCT00606242|Drug|Fluticasone|Inhaled Fluticasone, either 100 or 1000 mcg per day
45606679|NCT04932057|Other|Action observation Training|Action observation training is a relatively new rehabilitation approach in which the subject is asked to carefully observe the actions presented through a video clip or performed by an operator.
45606680|NCT04932057|Other|Action Practice|Participants perform an upper extremity functionality test a couple of times.
45606681|NCT04932057|Other|Observation|Participants will watch a slide show of landscape
45606682|NCT04784182|Dietary Supplement|probiotic plus prebiotic supplement|Daily consumption of probiotic containing at least 5 billion CFU per day total bacteria including Lactobacillus helveticus and Bifidobacterium longum and prebiotic containing 4 grams of fructooligosaccharides (FOS)
45757306|NCT03378908|Behavioral|Intervention Treatment|Both groups (conventional and treatment) will have the same nutritional composition, with 40% carbohydrates, 20% protein and 40% total fat (preferently monounsaturated fatty acids).
45606683|NCT04784182|Dietary Supplement|placebo|Daily consumption of visually similar placebo pills
45606684|NCT02308865|Other|multi disciplinary palliative care monthly consultations|multi disciplinary palliative care consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a worship person.The primary consultation within 3 weeks inclusion and then every month at the same time that consultations onco-respiratory
45606685|NCT03374371|Diagnostic Test|high-throughput sequencing|technique of high-throughput sequencing of the markers present in the genome of the S. epidermidis strains responsible for infection in order to help to discriminate the true infections of the contaminations
45606686|NCT04912479|Device|connected watch|connected watch that provide to patients with information on their sleep quality and their performed activities
45606687|NCT05030038|Biological|Fecal swab collection|Participants will collect fecal sample at home and either mail in the sample, or drop it off at the lab
45606688|NCT05030038|Biological|Blood samples|Participants will have approximately 1 teaspoon of blood withdrawn from a vein, for research, on 2 different occasions. The total amount of blood withdrawn during the study will be approximately 2 teaspoons.
45606689|NCT02309021|Other|Sport|
45606690|NCT02309021|Other|Non-sport activities|
45444744|NCT03796299|Diagnostic Test|Assessment of expression of MCM5 in the urine (ADX Bladder)|Each participant will be asked to urinate in a plastic container. Urine will be centrifuged afterwards, then the expression of MCM5 protein will be examined in cells from urine sediment. For this purpose, it is planned to use the Arquer Diagnostics ADXBLADDER test. It is an enzyme linked immunosorbent assay (ELISA) using two monoclonal antibodies directed against two different epitopes. Both antibodies have high affinity and specificity for the MCM5 antigen.
45444745|NCT03796143|Behavioral|The Mindfulness and Acceptance Workbook for Depression|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
45757307|NCT00674297|Drug|Fluvastatin|Fluvastatin 40 mg daily for 3 months
45757308|NCT05608317|Device|ALLEVYN Non-Adhesive|"ALLEVYN Non-Adhesive combines patient comfort with the tri-layer fluid management system that enables moist wound healing. It utilizes a unique triple action technology that manages fluid to maintain optimal moist wound healing conditions. It is ideal for fragile and sensitive skin due to its non-adherent wound contact layer and soft and conformable construction.~ALLEVYN Non-Adhesive consists of the following layers:~Breathable top film~Highly absorbent foam core~Non-adhesive wound contact layer"
45606691|NCT05163379|Other|MOBILIZATION|EARLY MOBILIZATION OF INTUBE PATIENTS AND ITS EFFECTS OF MOBILIZATION
45606692|NCT04831827|Other|IVR Reminder|Participants will receive an interactive voice reminder (IVR) to complete mt-sDNA screening at day 7 and 21.
45606693|NCT04831827|Other|Phone call from research team|Patients will receive a scripted phone call from the research team to remind them to complete the mt-sDNA screening at day 7 and 21.
45606694|NCT04831827|Other|EHR Portal message|Patients will receive an EHR patient portal message with a scripted message to remind them to complete the mt-sDNA screening at day 7 and 21.
45606695|NCT03503201|Dietary Supplement|Chromium|chromium supplementation as capsules of 200 micrograms of chromium picolinte (Arab company for pharmaceuticals and medicinal plants) daily for 2 months before ICSI cycle
45606696|NCT03631225|Diagnostic Test|Vectra|Each arm will have the Vectra test however, scores will not be provided for the Usual Care Arm until end of study (12 month time point)
45606697|NCT05093283|Device|Virtual Reality Glasses|Virtual Reality Glasses
45606698|NCT02312843|Behavioral|Exercise/Aerobic|
45606699|NCT02312843|Behavioral|Exercise/Stretching|
45606700|NCT05095077|Drug|Tadalafil 40 MG|Single dose on study day 1/2
45606701|NCT05095077|Drug|Placebo|Identical to active IMP
45606702|NCT05376033|Other|root canal filling with Ceraseal sealer|root canal filling with Ceraseal sealer
45757309|NCT00246025|Drug|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, once a day, oral administration
45757310|NCT00246025|Drug|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, once a day, oral administration
46066673|NCT04048369|Diagnostic Test|Rapid diagnosis of influenza in the emergency medical service|Comparison at the University Hospital of Clermont-Ferrand of a test performed in the Adult Emergencies Department by the nursing staff (point-of-care testing) to a test carried out in the core laboratory (classical testing).
45606703|NCT02312921|Other|PREDICT|Allied dental personnel provide screening and preventive services in community settings and case managers serve as patient navigators to arrange referrals of children who need dentist services. The intervention is paired with a compensation system for high performance (pay-for-performance) with efficient performance monitoring. PREDICT focuses on: 1) identifying eligible children and gaining caregiver consent for services in community settings (e.g., schools); 2) providing risk-based preventive and caries stabilization services efficiently at these settings; 3) providing curative care in dental clinics; and 4) incentivizing local delivery teams to meet performance benchmarks.
45606704|NCT03602833|Drug|Compound 451238|Each patient will receive compound 451238 until disease progression unacceptable toxicities.
45606705|NCT05087355|Diagnostic Test|PCR or antigen test for Covid 19 or Inluenza|PCR or antigen test for Covid 19 or Inluenza
45606706|NCT02309177|Drug|nab-Paclitaxel|
45606707|NCT02309177|Drug|Nivolumab|
45606708|NCT02309177|Drug|Gemcitabine|
45606709|NCT02309177|Drug|Carboplatin|
45444746|NCT03796143|Behavioral|The Cognitive Behavioral Workbook for Depression|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
45444747|NCT02049736|Drug|Telbivudine|
45444748|NCT01303029|Drug|Gemcitabine+erlotinib|Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
45606710|NCT05060835|Other|Virtual assistants offering medical recommendations to health care profesionals|the project will interconnect, following a federated approach, large, distributed cancer imaging repositories, currently used for AI tools training and validation, with patient registries and EHRs of cancer-related data and supports exploitation of relevant unstructured data through novel Natural Language Processing (NLP) tools
45606711|NCT02227108|Drug|Moxetumomab Pasudotox|Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
45606712|NCT03564145|Drug|S5G4T-1|Once a day topical cream
45606713|NCT02309255|Other|no intervention|
45606714|NCT05388253|Behavioral|Static Stretching|Using Static Stretching exercises
45606715|NCT05388253|Behavioral|Deep Kneading Massage|Using Deep Kneading Massage technique
45606716|NCT04964895|Other|Questionnaires|"Patients will fill in multiple questionnaires for this study :~EORTC quality of life questionnaire (QLQ) QLQ-C30, EORTC Shq22, Male Sexual Health Questionnaire (MSHQ) only for Men, FSFI (only for women)"
45606717|NCT02312999|Drug|Plasmalyte|
45606718|NCT02312999|Drug|Volulyte|
45606719|NCT05163067|Behavioral|Combined aerobic exercise and cognitive training program|Participants will take part in a combined aerobic exercise and cognitive training program. The program will include moderate cycling exercise and cognitive game resolving at the same time. The tasks will be instructed and supervised by a fitness expert and a trained clinical neuropsychologist.
45444749|NCT01303029|Drug|Gemcitabine+erlotinib+capecitabine|Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Capecitabine will be administered orally 1.660 mg/m2 day from day 1 to day 21. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
45444750|NCT02052388|Drug|Daptomycin|Active Comparator
45444751|NCT02052388|Drug|Brilacidin|Experimental Drug
45444752|NCT03795987|Device|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
45444753|NCT02051140|Dietary Supplement|Freeze-dried Strawberry|12g freeze-dried strawberry (powder), twice daily with water, for 90 days
45606720|NCT04863261|Other|Cabenuva Scheduling Alerts in the Retention & Huddle modules of the CHORUS App|The CHORUS App has been developed as a tool for clinicians to easily visualize important patient information from their smart phones. Relevant information is electronically distributed and placed within the corresponding module in the CHORUS HCP mobile app for iOS and Android.
45606721|NCT02313077|Biological|MVA-BN-filo|One 0.5 mL intramuscular (IM) injection of 1E8 (50%Tissue Culture Infectious Dose [TCID50]) on Day 1 (Groups 1 and 2), or on Day 29 (Group 3), or on Day 57 (Group 4), or on Day 15 (Group 5).
45606722|NCT02313077|Biological|Ad26. ZEBOV|One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1 (Groups 3, 4 and 5), or on Day 29 (Group 1), or on Day 57 (Group 2).
45606723|NCT02313077|Other|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 (Groups 1 and 3), or on Day 1 and 57 (Groups 2 and 4).
45606724|NCT03423355|Drug|Dapagliflozin (Forxiga®)|10mg p.o. daily
45606725|NCT03423355|Drug|Hydrochlorothiazide 25 mg|25mg p.o. daily
45606726|NCT03423355|Drug|Placebo matching Dapagliflozin|Placebo matching Dapagliflozin p.o. daily
45606727|NCT04481997|Other|Exposure to Anti-thrombotic treatment agents and glucose lowering therapy|Exposure to Anti-thrombotic treatment agents and glucose lowering therapy
45606728|NCT02226562|Drug|Potassium nitrate and sodium fluoride|3.0% w/w potassium nitrate mouthwash with 0.02% sodium fluoride
45606729|NCT02226562|Drug|Standard fluoride dentifrice|Standard fluoride dentifrice containing 1000 ppm fluoride as SMFP
45606730|NCT04430985|Drug|Oxaliplatin|Day 1 in cycle 1-4: 100 mg/m2 intrahepatic administration Day 1 in cycle 5-8: oxaliplatin 85 mg/m2 i.v.
45606731|NCT04430985|Drug|5-Fluorouracil|Day 1 each cycle: 400 mg/m2 i.v. bolus, 2400 mg/m2 i.v.over 46 hrs
45606732|NCT04430985|Drug|Leucovorin|Day 1 each cycle: 400 mg/m2 i.v.
45606733|NCT04430985|Drug|Nivolumab|Day 3 in cycle 3 to 8: 3 mg/kg i.v.
45606734|NCT04430985|Device|Ipilimumab|Day 3 in cycle 3 and 6: 1 mg/kg i.v.
45606735|NCT03506243|Biological|Follitrope PFS|Follitrope PFS
45606736|NCT03506243|Biological|Gonal-f pen|Gonal-f pen
45606737|NCT03365635|Drug|Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]|Same as described in arm description
45606738|NCT04774497|Other|Oxygen inhalation treatment group|Oxygen inhalation group: oxygen inhalation was started on the first day of chemotherapy, and the oxygen inhalation volume was 2 L / min, 8 hours / day for 3 consecutive days.
45606739|NCT04774497|Other|Control group|The control group was not given oxygen inhalation.
45606740|NCT04413357|Other|Balanced Nutritional Drink|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as Supplemental Nutrition.
45606741|NCT04413357|Other|Diabetes Specific, Balanced Nutritional Drink (DMA)|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat, designed for people living with diabetes and intended for use as Supplemental Nutrition available in retail setting.
45606742|NCT04413357|Other|Diabetes Specific, Balanced Nutritional Drink DMB|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat, designed for people living with diabetes and intended for use as Supplemental Nutrition.
45606743|NCT04030585|Device|Robot|Patients with upper limb amputation using myoelectric prosthesis will done robot-assisted exercise program
45606744|NCT04030585|Other|Home exercise|Patients with upper limb amputation using myoelectric prosthesis will done home exercise program
45606745|NCT04410549|Diagnostic Test|Optical Coherence Tomography (OCT)|To perform OCT in pulmonary artery of patient with COVID-19
45606746|NCT04456231|Drug|Plenvu|Patients will receive Plenvu for preparation of endoscopy
45444754|NCT02051140|Dietary Supplement|Strawberry Placebo|12g blue, strawberry-flavored powder, twice daily with water, for 90 days
45444755|NCT01303107|Drug|Bupivacaine|single dose of 15 mg by a slow injection rate of 1 mL/s
45606747|NCT02313311|Other|time-lapse imaging|Embryos are observed using time-lapse imaging (Primo Vision®). It is an incubator with a compact, sealed, and digitally inverted camera unit which can automatically acquire images.The system can record the actual developmental stage of the embryos, all the recorded images can be saved to be analyzed later using a special software program.
45606748|NCT04658277|Drug|Clarithromycin|Patients in the intervention arm will take Clarithromycin 250mg daily.
45606749|NCT04658277|Other|Usual care|Patients will receive usual medical care
45606750|NCT03506165|Combination Product|Periodontal treatment|oral hygiene instructions, periodontal debridement and removal of other etiologic factors
45606751|NCT04456777|Drug|Vortioxetine|vortioxetine will be administreted for 3 months
45606752|NCT02874430|Drug|Metformin Hydrochloride|Given orally
45606753|NCT02874430|Drug|Doxycycline|Given orally
45606754|NCT04336371|Diagnostic Test|Self-administered questionnaires|Self-administered questionnaires by the patient will be given during visits in the following order:the self-administered questionnaires concerning the announcement consultation will be completed by the patient after consultation waiting room; self-questionnaires will be given in just before the operation waiting room (D0) just before the suture removal points (J10) and just before the follow-up visit (M3).
45444756|NCT03562000|Device|Cough Assistance and Systematic Non-Invasive Ventilation|"A standardised bundle of intervention will be tested using the combination of two medical devices previously used in daily clinical practice but without guideline and objective selection criteria, namely:~A mechanical cough assistance technic using the Cough Assist device (Model E70® by Philips Respironics, Carlsbad, CA, USA) before extubation then after extubation then 3 times a day (with possible additional treatment on demand) during 7 days maximum (with a possible cessation if the patient has strictly no bronchial overload during three consecutive physiotherapy sessions)~A systematic Non-Invasive ventilation during 24h minimum to indirectly improve the clearance of bronchial overload and to reduce the overall risk of re-intubation related a relative hypoventilation associated to the weak cough."
45606755|NCT05390983|Procedure|Carotid endarterectomy with stent removal|Standard carotid endarterectomy will be extended with the stent removal
45606756|NCT03506087|Behavioral|Advance care planning coaching session.|A 60-minute in-person coaching session. The advance care planning coach, trained in motivational interviewing, will use a flexible script and checklist to assess the participant's readiness to engage in advance care planning and guide the participant forward in the process, proceeding at the participant's pace. Some participants may complete advance directives while others will not get that far. Some participants may receive a follow-up session 2-4 weeks later. Typically this 20 to 30-minute conversation will be by phone, but it may be conducted at the clinic as indicated for the participant.
45606757|NCT03506087|Behavioral|Printed advance care planning materials|Participants are provided with a folder containing an advance care planning guide developed by the Coalition for the Supportive Care of Kidney Patients for persons with Chronic Kidney Disease. The patient folder also contains the advance directive form used by the clinic that is appropriate to the state.
45606758|NCT04650633|Drug|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
45606759|NCT04456621|Radiation|PBT|Proton beam radiotherapy 70 gray relative biological equivalent (GyRBE)/10 fractions (Fx) or 60 GyRBE/5 Fx
45606760|NCT04055103|Other|Monthly feedback, education and linking hospitals|- Give monthly feedback from LROI-data (revision rate & patient reported outcome measures) as well as other outcomes from the participating hospital (length-of-stay, readmission and complications), combined with education on how to use this information for improvement. This will be send monthly by email to the intervention group. Further, hospitals with worse performance for a certain outcome will be linked to hospitals with good performance for this outcome.
45606761|NCT05162989|Device|iCare HOME2 vs iCare IC200|Measurement of IOP with iCare HOME2 compared with iCare IC200.
45606762|NCT02444039|Device|SL-D301|Slit Lamp
45606763|NCT02444039|Device|DC-4|Digital Camera Attachment
45606764|NCT02444039|Device|SL-3G|Slit Lamp
45606765|NCT03470467|Other|No intervention|No intervention planed
45606766|NCT04621071|Dietary Supplement|Probiotics (2 strains 10x10^9 UFC)|Probiotic vs Placebo (1:1)
45606767|NCT04621071|Dietary Supplement|Placebo (potato starch and magnesium stearate)|Probiotic vs Placebo (1:1)
45606768|NCT02309567|Other|Blood Collection|
45606769|NCT05160727|Drug|Tislelizumab|200mg ivgtt d1 q3w
45606770|NCT05160727|Drug|Irinotecan|"Concurrent Chemoradiotherapy:~Irinotecan: 80mg/m2/w (UGT1A1*28 and *6: 6/6+GG) or 65mg/m2/w (UGT1A1*28 and *6: 6/7+GG or 6/6+GA) or 50mg/m2/w (UGT1A1*28 and *6: 7/7+GG or 6/6+AA or 6/7+GA) Consolidation therapy: 2 weeks after the completion of chemoradiotherapy. Irinotecan: 200mg/m2 ivgtt d1 q3w."
45606771|NCT05160727|Radiation|radiotherapy|radiotherapy
45757311|NCT00246025|Drug|Dabigatran Etexilate|Dabigatran etexilate 220 mg capsule, once a day, oral administration
45757312|NCT00246025|Drug|placebo|matching placebo capsule, once a day, oral administration
45606772|NCT03506009|Drug|Argatroban combined with rt-PA|Argatroban as a 100-ug/kg bolus over 3 to 5 minutes was administered intravenously within 1 hour of the tPA bolus followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%).
45606773|NCT03506009|Drug|rt-PA|Intravenous throbolysis with 0.9mg/kg rtPA.
45606774|NCT04538157|Other|Comprehensive Geriatric Assessment|A CGA is a diagnostic and therapeutic intervention which initially identifies an older person's medical, functional, psychosocial problems and then tailors coordinated management plans to address them.
45606775|NCT03130855|Drug|inferior alveolar nerve block with 4% articaine|an anesthetic technique using 4% articaine anesthetic solution
45606776|NCT03130855|Drug|buccal infiltration with 4% articaine|anesthetic technique using 4% articaine anesthetic solution
45606777|NCT04463927|Other|non-nutritive sucking|intervention group received a sterile gloved finger during the examination for retinopathy of prematurity
45606778|NCT04456543|Procedure|pressure monitoring|garment pressures were monitored using the portable pressure measuring device and the compression garment was adjusted so that the pressure was maintained at the therapeutic range of 15 - 25 mmHg.
45606779|NCT05374551|Other|Transcranial magnetic stimulation|Transcranial magnetic stimulation will be used to stimulate brain activity in a brain region of experimental interest (lateral parietal cortex) and in a control brain region (vertex). All participants will experience both forms of stimulation, in separate sessions. Stimulation will be applied as a probe to understand the basic phenomenon of how brain processes support episodic memory.
45606780|NCT02309801|Dietary Supplement|Daidzin|Super-Absorbable Soy Isoflavones, LifeExtension, USA. Single oral dose of 4 capsules (containing 80 mg of daidzin-daidzein).
45606781|NCT02309801|Dietary Supplement|Alcohol|Alcohol single oral dose
45606782|NCT04860349|Other|High Intensity Interval Training|4-weeks of high intensity interval training, 3 sessions/week on alternate days. each session for 20 minutes, excluding the warm-up and cool-down.
45606783|NCT03505931|Device|Implantation of Eluvia stent|Implantation of Eluvia stent
45606784|NCT04456387|Drug|Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection|Participants received on-demand treatment, doses range from 30 IU/kg to 50 IU/kg, or doses divided on the discretion of the Investigator.
45606785|NCT04456387|Drug|Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection|Participants received prophylaxis treatment at 50 IU/kg every three days.
45757313|NCT03311594|Drug|Low Alcohol|Low Alcohol Consumption
45757314|NCT03311594|Drug|Moderate Alcohol|Moderate Alcohol Consumption
45444757|NCT03562000|Procedure|control group using the current gold standard of care after extubation, namely the manual drainage by a physiotherapist and the consensual use of Non-invasive ventilation|"After extubation, the physiotherapy will be managed according to standard care and cough assistance will be only manual. The use of a dedicated cough assistance device will be allowed if the bronchial overload clearance is repeatedly insufficient according to the physiotherapist in charge.~Non-invasive ventilation will not be systematic and only used in case of pre-defined condition, such as: age > 65 years-old, BMI > 30, Chronic cardiac failure, COPD, hypercapnia at the end of the weaning trial, post-operative admissions after abdominal and thoracic surgery."
45444758|NCT03795909|Drug|Ruxolitinib|Ruxolitinib （2.5 mg twice daily for patients if the age<14 years and the weight <25kg，5 mg twice daily for patients if the age<14 years and the weight≥25kg, 10mg twice daily for patients if the age ≥14 years and<18 years）
45444759|NCT03795909|Drug|Dexamethasone|Dexamethasone (10mg/m2.d) delayes for the first 2 weeks（form week 1 to 2),(5mg/m2.d) from week 3 to 4，(2.5mg/m2.d) from week 5 to 6），1.25mg/m2.d for week 7，and dropped off on week 8.
45606786|NCT02456636|Behavioral|Fee-for-Service Model (FFS, In clinic individual visits)|To be performed by participant's doctor or other healthcare professional in their doctor's office.
45606787|NCT02456636|Behavioral|Patient Centered Medical Home (PCMH, In clinic group visits)|To be performed by a registered dietitian, a nurse or other healthcare professional in their local setting.
45606788|NCT02456636|Behavioral|Disease Management (DM, Phone group visits)|To be performed by obesity treatment specialists with relevant graduate training and experience with weight loss counseling via telephone.
45606789|NCT02226172|Drug|Glasdegib (PF-04449913)|Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.
45606790|NCT02226172|Drug|Placebo|Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
45606791|NCT03505853|Drug|Givosiran|single dose of givosiran by subcutaneous (sc) injection
45606792|NCT03505853|Drug|5-probe cocktail|includes midazolam, caffeine, losartan, omeprazole, and dextromethorphan
45606793|NCT05388019|Other|Multidisciplinary team clinic and assessments (Cardiopulmonary exercise test, six-minute-walk-test, MoCA, Quality of Life questionnaires)|Subject will receive care from a multidisciplinary team (physical therapy, occupational therapy, palliative care, social work) in addition to their standard of care VAD clinic visits. Subject will also perform a CPET, six-minute-walk-test, MoCA, and be administered quality of life questionnaires.
45606794|NCT05388019|Behavioral|Caregiver Self-Assessment|Primary caregivers of both interventional VAD patient cohorts will be administered a Caregiver Self-Assessment to assess burnout.
45606795|NCT02309879|Drug|Remifentanil infusion|Patients in Remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
45606796|NCT02309879|Drug|Lidocaine infusion|Patients in Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
45757315|NCT03311594|Drug|Placebo Alcohol|Placebo Alcohol Consumption
45757316|NCT03311594|Other|Pain Induction|10% capsaicin solution placed on forearm and heat induction
45757317|NCT03311594|Other|No Pain Induction|Water placed on forearm
45757318|NCT05069051|Drug|Belimumab 200 MG/ML [Benlysta]|Patients obtain belimumab treatment in combination with rituximab and venetoclax
45757319|NCT05069051|Drug|standard of care|Patients obtain the standard of care: combination rituximab and venetoclax
45606797|NCT02309879|Drug|Magnesium sulphate infusion|Patients in Magnesium group received an intravenous bolus injection of 50 mg/kg magnesium sulphate plus an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
45606798|NCT02309879|Drug|Magnesium sulphate and Lidocaine infusion|Patients in Magnesium and Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
45757320|NCT05019053|Behavioral|Coping Crew|Coping Crew consists of five 60-minute virtual intervention sessions coinciding with five weeks of EMI. Participants will receive psychoeducation, challenge cognitive biases or mythbust, and participate in behavioral exposure and behavioral experiments. An EMI component of this treatment will be included for the purpose of treatment monitoring and homework tracking. Participation in this EMI component involves the daily report of levels of anxiety, depression, stress, and loneliness. When participants endorse elevated levels on any of these constructs, they will receive a targeted message reminding them of the topics covered in COPING CREW. One month after the intervention session, COPING CREW participants will complete follow-up questionnaires and interview. Participants will also participate in a feedback session 3 months after the intervention.
45606799|NCT01676961|Biological|romiplostim|Given SC
45606800|NCT03874351|Device|non-invasive transcranial direct current stimulation (tDCS)|"Active tDCS: transcranial direct current stimulation at intensity 1.5mA for 20 minutes per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right.~Sham tDCS: transcranial direct current stimulation at intensity 1.5mA for 30seconds followed by 0 mA current for remaining time of the 20-minute intervention per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right."
45606801|NCT05015998|Other|Non-interventional|Epidemiology of anemia associated with chronic kidney disease, rather than to evaluate specific drugs
45606802|NCT02309957|Device|BioMatrix CRD|
45444760|NCT02049892|Other|Metal Ion Levels|
45444761|NCT03795597|Drug|Carfilzomib|Carfilzomib is an anti-cancer drug acting as a selective proteasome inhibitor that is used to treat Multiple Myeloma.
45444762|NCT03795597|Drug|Busulfan IV|Busulfan is an anti-cancer drug acting as a bifunctional alkylating agent that is used to treat Multiple Myeloma.
45606803|NCT05081115|Diagnostic Test|ABCDE-Stress Echo|Each laboratory will adopt the preferred Echo stress among physical pharmacologic or pacing stress according to guidelines recommendations. Pharmacologic testing will be with dobutamine or vasodilators (dipyridamole, adenosine or regadenoson) according to physician preferences, patients' contraindications, local availability and cost. Pacing stress can be performed with transesophageal or with external permanent pacemaker. A standardized format with the ABCDE protocol will be followedl. Step D is easy with vasodilator, less easy with dobutamine, not easy and less feasible - impossible with (peak or post) treadmill exercise. Our recommendation is to use semi-supine exercise, capturing coronary flow signal in early or intermediate stages when most flow increases and feasibility is still high. When treadmill is used, step D is skipped; if information is deemed important, a vasodilator test can be performed at 30' after the end of exercise focused on CFVR and heart rate response.
45606804|NCT05081115|Diagnostic Test|SE diastolic assessment|The diastolic assessment should be included into all exercise SE tests by measuring standard Doppler-derived mitral inflow velocity, pulsed Tissue Doppler of mitral annulus, and retrograde tricuspid gradient of tricuspid regurgitation, at intermediate load of exercise and/or 1- 2 min after the end of the exercise. We will also assess, at baseline, intermediate load (50 watts) and peak-post stress: end-diastolic left ventricular volume index; end-systolic left ventricular volume index; ejection fraction and both stroke volume and cardiac output (to assess conventional contractile reserve); mitral regurgitation and left ventricular outflow tract obstruction; pulmonary artery systolic pressure; B-lines; right ventricular free wall strain to assess the presence of right ventricular dysfunction; left atrial volume index; peak atrial longitudinal strain; and mitral inflow E velocity and mitral annulus e' tissue Doppler velocity; global longitudinal strain (GLS).
45757321|NCT03376880|Other|1 year follow-up testing|The approach of the study is not in studying the effectiveness of the intervention stimulus, the dose response of diet and exercise, or the rate of weight loss but only the response to 1) weight loss and regular exercise or 2) continued weight gain.
45757322|NCT01271335|Biological|collagenase|Lyophilized powder / sterile dosage form for single local intravascular administration via the occluded coronary.
45757323|NCT05596929|Diagnostic Test|Artificial intelligence|After the patients under triage classification to which randomly allocates in two groups. The group with AI intervention and the other without AI intervention.
45757324|NCT00624923|Drug|Salsalate|Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months
45444763|NCT03795597|Drug|Melphalan IV|Melphalan is an anti-cancer drug acting as alkylating agent that is used to treat Multiple Myeloma.
45757325|NCT00624923|Drug|Placebo|Placebo matched to Salsalate, seven tablets daily by mouth, divided into two doses, for 30 months
45444764|NCT02802592|Drug|Epogen|1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
45757326|NCT03310892|Behavioral|Generic message|Generic message
45757327|NCT03310892|Behavioral|Tailored message|Tailored message
45444765|NCT02802592|Drug|Normal Saline|1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
45444766|NCT03637972|Other|Ventilated cigarettes only|Participants given vouchers that are exchanged for ventilated cigarettes study cigarettes.
45444767|NCT03637972|Other|Unventilated cigarettes only|Participants given vouchers that are exchanged for unventilated cigarettes study cigarettes.
45606805|NCT05081115|Diagnostic Test|SE Right ventricular function assessment|Right ventricular function will be assessed at baseline and peak stress with variations of tricuspid annular plane systolic excursion, an index of right ventricular longitudinal function, and right ventricular fractional area change (a load-dependent index of right ventricular inlet function). To distinguish between genuine right ventricular dysfunction and/or pathological increases in pulmonary vascular load, we will combine systolic pulmonary artery pressure and right ventricular end-systolic area to calculate right ventricular end-systolic pressure-area relation. Peak systolic tricuspid annulus velocity and conventional indices of left ventricular systolic and diastolic function will also be measured at baseline and peak stress according to the standard ABCDE-FGLPR protocol. Right ventricular free wall strain combined with interventricular septum strain will be assessed. Left ventricular function, wall motion score index and E/e' at baseline and peak stress.
45606806|NCT05081115|Diagnostic Test|SE in heart donors|The examination of the heart starts with a resting transthoracic echocardiography. Exclusion criteria are: resting wall motion score index>1.0; ejection fraction <45%; diastolic dysfunction of grade 2 or more; hemodynamically significant (moderate or higher) valve regurgitation or stenosis; severe left ventricular hypertrophy (left ventricular mass index >175 g/m2). A pharmacological SE with dipyridamole (0.84 mg/kg over 6 minutes) is recommended. The diagnostic end-points are stress-induced RWMA and abnormalities in global LVCR. All images will be analyzed as per guidelines similarly to the other projects, with emphasis on wall motion score index and LVCR based on ejection fraction and force. The hearts excluded from donation for RWMA or abnormal LVCR could however be collected for heart valve preparation and evaluated by coronary angiography and by pathological examination according to local facilities.
45606807|NCT03505775|Diagnostic Test|23Na magnetic resonance imaging|Imaging/diagnostic: Evaluation of the muscular and cutaneous sodium storage by 23Na magnetic resonance imaging. 23Na magnetic resonance imaging: 23NA-MRI protocol on a 3T scanner (Magnetom PRISMA, Siemens, Erlangen) implementing a 3D sequence.
45606808|NCT03505697|Other|inspiratory muscle training|Inspiratory Muscle Training was performed with an exercise tool (Powerbreath®) with a resistance range of 0-90. The training intensity was started with 30% of the Maximum Inspiratory Pressure (MIP) value obtained as a result of the mouth pressure measurement16, training was progressively increased from 30% to 60% considering that they were terminal-stage pulmonary disease patients. Patients were asked to perform IMT for 15 minutes, twice a day, 7 days a week, for 3 months.
45606809|NCT03505697|Other|Pulmonary rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band"
45606810|NCT04954690|Behavioral|Structured Program of exercise for Recipients of Kidney Transplantation (WC)|Structured Program of exercise for Recipients of Kidney Transplantation (weekly coaching)
45606811|NCT04954690|Behavioral|Structured Program of exercise for Recipients of Kidney Transplantation (WC + CG)|Structured Program of exercise for Recipients of Kidney Transplantation (weekly coaching + caregiver participation)
45606812|NCT04954690|Behavioral|Usual Care|Usual Care
45606813|NCT03942627|Behavioral|Mindfulness Program|The intervention consists of two brief videos (one introducing the NICU portion of the program and one introducing the portion of the program addressing the transition home), as well as a series of mindfulness practices delivered via audio recordings to assist mothers in managing stress during the NICU stay and another series for the transition home.
45606814|NCT03942627|Behavioral|Infant Health Education Program|The active control condition consists of two brief videos (one introducing the NICU portion of the program and one introducing the portion of the program addressing the transition home), as well as a series of audio recordings providing information on infant health and development for mothers to use during the NICU stay and another series for the transition home.
45606815|NCT02987023|Procedure|uterus transplantation|Uterus transplantation from live donor
45606816|NCT03505619|Behavioral|ASSIST 1.0|10 weeks intervention applying a person-centred approach by using goal setting and smart products.
45606817|NCT03876483|Behavioral|Virtual peer support group|Intervention package will consist of a WhatsApp group setup and organized by the study. Participants will be divided into 1-3 WhatsApp groups, each with 10-55 youth. Each group will be facilitated by a study staff member trained as a counselor. The facilitator will send weekly messages to the group. Messages from the facilitator will not contain overtly HIV-related language. These messages are intended to spark unstructured discussion among study participants, or with the facilitator, at any time through the WhatsApp group or individually. Subsequent messages from the study will answer participant questions or correct misinformation. Standard operating procedures (SOPs) will be developed for standardizing responses to the questions received so that study staff follow national guidelines and local practice standards to respond.
45606818|NCT02476786|Behavioral|FACT-B|The FACT-B (Version 4) is a 37-item measure that contains the four general subscales along with the Breast Cancer-Specific subscale that assesses symptoms/concerns of particular relevance to breast cancer (e.g., body image, arm swelling and tenderness).
45606819|NCT02476786|Drug|Goserelin|
45606820|NCT02476786|Drug|Anastrozole|
45606821|NCT02476786|Drug|Exemestane|
45606822|NCT02476786|Drug|Fulvestrant|
45606823|NCT02476786|Drug|Tamoxifen|
45444768|NCT03637972|Other|Access to Experimental Marketplace: Ventilated cigarettes + alternative nicotine delivery systems|Participants given vouchers that are exchanged for ventilated cigarettes + alternative nicotine delivery systems cigarettes.
45444769|NCT03637972|Other|Access to Experimental Marketplace: Unventilated cigarettes + ANDS|Participants given vouchers that are exchanged for unventilated cigarettes + ANDS.
45444770|NCT03406611|Drug|Pegtibatinase|Pegtibatinase sterile solution for subcutaneous injection
45444771|NCT03406611|Drug|Placebo|Normal saline for subcutaneous injection
45444772|NCT02053324|Combination Product|AvidinOX/ST2210|One intralesion injection of AvidinOX followed by an intravenous infusion of ST2210
45444773|NCT03383679|Drug|Darolutamide|treatment with darolutamide
45444774|NCT03383679|Drug|Capecitabine|treatment with capecitabine
45606824|NCT02476786|Other|Archived tissue collection|
45606825|NCT02820961|Drug|entinostat|An orally available histone deacetylases inhibitor (HDAC)
45606826|NCT02820961|Drug|exemestane|Aromatase inhibitor
45606827|NCT04430673|Other|Home-School based VR system trial|Commercially available VR games operated Raspberry pi micro computer and Oculus Quest VR headsets provided for 2 weeks at dose and intensity selected by participants.
45606828|NCT04658173|Drug|remimazolam-alfentanil combination|Group remimazolam-alfentanil combination received 10 µg/kg alfentanil and 0.3mg/kg remimazolam over 30 seconds, followed by an infusion of remimazolam at 0.2 to 1 mg/kg/hr and alfentanil at 0 to 1ug/kg/min. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, remimazolam 0.1mg/kg was used in the form of bolus, as rescue drugs, and alfentanil 5ug/kg when additional analgesia is needed
45606829|NCT04658173|Drug|propofol-alfentanil combination|Group propofol-alfentanil combination received 10 µg/kg alfentanil and 1 mg/kg propofol over 30 seconds followed by an infusion of propofol at 2 to 6 mg/kg/hr. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, propofol 0.5 mg/kg was used in the form of bolus, as rescue drugs，and alfentanil 5ug/kg when additional analgesia is needed
45606830|NCT03505541|Biological|Adiponectin and TNFa|Adiponectin and TNFa are adipokines. Will be added to the myometrial biopsies to investigate their effect on the force of contractility
45606831|NCT02399410|Drug|perioperative chemotherapy plus bevacizumab|preoperative and postoperative combination chemotherapy with bevacizumab
45606832|NCT02399410|Procedure|cytoreductive surgery|complete or nearly complete removal of synchronous or metachronous peritoneal carcinomatosis from CRC.
45606833|NCT02399410|Drug|Intraperitoneal Oxaliplatin|Pump-driven intraperitoneal administration of oxaliplatin
45606834|NCT03636165|Drug|Methylprednisolone|The local infiltration solution containing 1.25mg Methylprednisolone per milliliter.
45606835|NCT03636165|Drug|Ropivacaine|The local infiltration solution containing 2mg Ropivacaine per milliliter.
45606836|NCT02310113|Other|NIRS|Measurment of skeletal muscle oxygenation by near-infrared spectroscopy
45606837|NCT03635151|Behavioral|Telephone Assessment and Skill-Building Kit (TASK III) Group|The TASK III group will receive a TASK III Resource Guide that we developed and 8 weekly calls from a nurse. The nurse will call again a month later. The TASK III nurse will help you assess your needs and concerns, build your skills as a caregiver, and refer you to community resources.
45606838|NCT03635151|Behavioral|Information Support and Referral (ISR) Group|The ISR group will receive an American Heart Association brochure and 8 weekly calls from a nurse. The nurse will call again a month later. The ISR nurse will provide information, support, and referral to community resources.
45606839|NCT04766632|Device|Brain PET-CT of 18F-DOPA|PET-CT is a nuclear medicine exam with radiopharmaceutical injection of 18F-DOPA for the patient
45606840|NCT02310191|Procedure|Carotid stenting|Procedures will be carried out via the femoral approach following a Seldinger technique. All patients will be on long-term aspirin (100 mg/day) and a 525-mg loading dose of clopidogrel. A dose of 10 000 units unfractionated heparin will be administered at the beginning of the intervention. A cerebral protection device (FilterWire EZ™; Boston Scientific, Natick, Massachusetts, USA) will be use in all patients if possible. The type of covered stent and other specific intervention strategies will be left to the discretion of the interventional radiologists. After predilatation of the stenosis (if needed), an appropriate stent for each stenosis will be implanted and then dilated using a balloon catheter.
45606841|NCT03769519|Behavioral|ARICA|Personalized ARICA (AdheRence to Inhaled Corticosteroids in Asthma) intervention package.
45606842|NCT02310347|Drug|dronabinol|
45606843|NCT02310347|Drug|Placebo|
45606844|NCT02310425|Drug|S. boulardii|50 mg/kg twice daily
45606845|NCT02310425|Drug|Placebo|he control group (group C) did not receive S. boulardii (nor other probiotics)
45606846|NCT03124875|Device|LimFlow Stent Graft System|Creation of an AV fistula in below-the-knee vasculature for the treatment of critical limb ischemia.
45606847|NCT02310503|Procedure|Mohs surgery|A surgical technique used primarily in the treatment of skin neoplasms, especially basal cell or squamous cell carcinoma of the skin. This procedure is a microscopically controlled excision of cutaneous tumors either after fixation in vivo or after freezing the tissue. Serial examinations of fresh tissue specimens are most frequently done.
45606848|NCT05096247|Device|TempSure|This device is an RF device.
45606849|NCT05096247|Device|Icon|This device works with IPL (Intense Pulsed Light) handpieces.
45606850|NCT02310659|Other|No intervention|No intervention
45606851|NCT05374161|Behavioral|Acceptance and Commitment Therapy|The ACT-based intervention will be delivered in a group format. Due to the COVID-19 pandemic and given that breast cancer patients are considered a vulnerable population, the intervention will be administered online through a GDPR compliant platform. The six, weekly, 90-minute treatment sessions (total of 9 hours) will be conducted in groups of approximately 8-10 participants and one therapist.
45606852|NCT05374161|Other|Waitlist Control Group|Participants randomized to the WL condition will be asked to continue receiving the services they receive from anti-cancer associations (receiving care from nurses, or/and support from social workers, or/and physiotherapy or/and individual psychological support from licensed psychologists just like the women in the experimental condition).
45606853|NCT02310737|Procedure|sharp incision|The fascia will be opened with a sharp scissors in cesarean section
45606854|NCT02310737|Procedure|blunt incision|Fascia distracted from the muscle tissue with a blunt maneuver in cesarean section
45606855|NCT02310815|Device|ReSure Sealant|
45606856|NCT02310893|Behavioral|Combined Contingency Management and Peer Navigation|
45606857|NCT02310893|Behavioral|Contingency Management|
45606858|NCT02310893|Behavioral|Peer Navigation|
45606859|NCT01391949|Behavioral|Detailed feedback|Once a week subjects will receive feedback about the total time spent cycling and walking in the previous week. Subjects in this intervention group will also receive feedback about average cycling speed, distance pedaled, average walking speed, and distance walked in the previous week.
45606860|NCT01391949|Behavioral|Basic feedback|Once a week subjects will receive feedback about total time spent cycling and walking in the previous week.
45757328|NCT05593653|Drug|Suvorexant|20mg taken at bedtime for 4 weeks
45757329|NCT05593653|Drug|Placebo|placebo taken at bedtime for 4 weeks
45606861|NCT03505463|Other|Blood samples|"Three blood samples will be collected from the injured participants. The assessment points are <72 hours, 7 days and 365 days post-injury.~One blood sample will be collected from the healthy participants. The collection will be performed as part of clinical diagnostic at the Department of Neurology at Aarhus University Hospital.~Laboratory analysis of the collected samples comprise Flow Cytometry and assay techniques."
45606862|NCT03505463|Other|Cerebrospinal fluid sample|"Three cerebrospinal fluid samples will be collected from the injured participants. The assessment points are <72 hours, 7 days and 365 days post-injury.~The collected samples will be analysed by Flow Cytometry and assay techniques. One cerebrospinal fluid sample will be collected from the healthy participants. The collection will be performed as part of clinical diagnostic at the Department of Neurology at Aarhus University Hospital.~Laboratory analysis of the collected samples comprise Flow Cytometry and assay techniques."
45606863|NCT03505463|Other|Clinical examination|Clinical examinations will be performed at <72 hours, 7 days and 365 days post-injury.
45606864|NCT04429425|Procedure|epidural anesthesia|epidural anesthesia through epidural injection of a local anaesthetic combined with an opioid
45606865|NCT03502889|Procedure|SPANK Block (Sensory Posterior Articular Nerves of the Knee)|Injection of local anesthetic into the tissues on the posterior aspect of the knee to provide sensory blockade of the articular nerves of the knee.
45606866|NCT03502889|Procedure|Adductor Canal Block|Injection of local anesthetic into the inner thigh under ultrasound guidance to provide sensory blockade to the anterior aspect of the knee
45606867|NCT03502889|Drug|Ropivacaine Hcl 0.5% Inj Vil 30Ml|Amide local anesthetic, this concentration is commonly used to achieve surgical level anesthesia. The drug itself is not being studied and the same concentration will be used in all participants.
45606868|NCT03502889|Device|Pajunk sonoplex stim needle|Echogenic needle used for ultrasound guided nerve blockade.
45606869|NCT04533477|Procedure|Reconstructing forked corpus spongiosum (FCS)|During the routine standardized surgery, the FCS should be cut off along both sides of the middle urethral plate before dissecting the glans wings and then dissected along the penile tunica albuginea closely from the near to the far side of the penis until the top of the penis head was reached. The corpus spongiosum on both sides will be reserved for the two wings of the glans. The two wings of the glans should be carefully expanded to at least the 3 o'clock and 9 o'clock positions of the penis. Some cases of small glans should be dissected to the 2 o'clock and 10 o'clock positions to close the two wings of the glans with no tension when performing glansplasty. Additionally, the original FCS on both sides should be combined at the coronal sulcus, thereby covering the surface of the new urethra.
45606870|NCT04533477|Procedure|Routine standardized surgery|When the urethral plate can be preserved after degloving, the investigators chose the surgical method according to the width of the urethral plate. If the width of the urethral plate is ≥6 mm, tubularized incised plate (TIP) urethroplasty will be performed, whereas if the width of the urethral plate is <6 mm, the onlay island flap (ONLAY) technique will be performed. When the urethral plate can not be preserved after degloving, transverse preputial island flap urethroplasty (Duckett) will be performed.
45606871|NCT02310971|Biological|CVac|Cvac will be administered via intradermal injection, every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses for a total of 6
45606872|NCT04463537|Procedure|Body Temperature Measurements|"measurements were carried out on the patients in the study firstly by not changing the position of the auricle. The duration was measured by stop watch and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale.~The measurement was then repeated after a minute, this time by changing the position of the auricle. The duration was measured for this position and the results were recorded in the data form."
45606873|NCT01676727|Device|CoreValve aortic valve|Implantation of CoreValve aortic valve via direct aortic approach
45606874|NCT05375487|Other|Carbonated Natural Mineral Water|750 mL/day of carbonated natural mineral water, with high content of bicarbonate, calcium, and magnesium, in three portions of 250 mL (one portion 30 minutes prior to lunch, one during the afternoon and the last portion minutes before dinner), during 4 weeks.
45606875|NCT05375487|Other|Low Mineral Water|750 mL/day of low mineral water (one third prior to lunch, one third during the afternoon and the last third 30 minutes before dinner), during 4 weeks.
45606876|NCT03745651|Drug|Ruxolitinib cream|Ruxolitinib 0.75% or 1.5% cream.
45606877|NCT03745651|Drug|Vehicle cream|Ruxolitinib matching vehicle cream.
45606878|NCT05098353|Drug|Quetiapine|25-75 mg per day for 6 weeks
45606879|NCT05098119|Drug|Sintilimab, Nab-paclitaxel, Carboplatin|Neoadjuvant Therapy
45606880|NCT05098119|Procedure|Surgical resection|Standard of care
45606881|NCT05098119|Drug|Sintilimab|Adjuvant Therapy
45911309|NCT02006303|Procedure|Green light PVP|The green light laser has a wavelength of 532 nm which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. The procedure uses the technology of high-powered laser light combined with fiber optics to vaporize the overgrowth of prostate cells quickly and accurately. As the surgeon directs the laser at the prostate, the intense pulses of light emitted from the fiber are absorbed by the blood. Within moments, the temperature of the blood becomes so great it causes the nearby cells to vaporize. Once the procedure is completed, patients have immediate post-operative symptom relief and dramatic improvements in symptoms, urinary flow rates, and bladder emptying.
46066674|NCT04078438|Device|neurofeedback augmentation|"Neurofeedback training was performed using a Neurocybernetics EEG Biofeedback system (Neurocybernetics Inc., Encino, CA, USA). The neurofeedback protocol was determined by the neurofeedback team, which included 3 psychiatrists, in consideration of the patient's main symptoms.~The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. Patients in the neurofeedback augmentation group received sensorimotor rhythm (SMR) beta or beta training for 30 minutes, and then alpha/theta (A/T) training for 30 minutes in each session.~To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions. The medication-only (treatment as usual, TAU) group maintained the same medication use as that before the study."
46066675|NCT04078438|Drug|treatment as usual|The neurofeedback augmentation group and the medication-only group maintained the same medication use as that before the study.
45444775|NCT02037880|Procedure|Lumbar puncture|
45606882|NCT04437849|Device|Home Telemonitoring System|Home Telemonitoring System (HTS) The HTS consists of an App that daily collects measurements of weight, blood pressure, heart rate and symptoms (checklist of symptoms questions). The HTS processes the data and generates and sends an alert to the physicians if a risk situation occurs (measurements are outside of normal ranges). The App has also an educational functionality that allows learning about lifestyle, self-care and healthy habits for HF patients. For this purpose, the application: a) has a section that answers frequent questions, b) has a question and answer game about HF, and c) sends educational messages to the patients every day.
45606883|NCT02738879|Drug|Sitagliptin|Sitagliptin 100 mg, oral, once daily for 30 weeks
45606884|NCT02738879|Drug|Placebo to sitagliptin|Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks
45606885|NCT02738879|Drug|Metformin|At least 1500 mg/day, oral, twice daily for participants entering the study on immediate-release metformin + sitagliptin or a fixed dose combination (FDC).
45606886|NCT02738879|Drug|Metformin XR|At least 1500 mg/day, oral, once daily for participants entering the study on extended-release metformin + sitagliptin or a FDC.
45606887|NCT02738879|Drug|Insulin glargine|Insulin glargine (LANTUS®) initiated at 10 units and titrated based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L); administered once daily subcutaneously.
45606888|NCT04880109|Drug|APX-115|Oral administration of APX-115 100 mg capsule once daily for 14 days
45606889|NCT04880109|Drug|Placebo|Oral administration of placebo capsule once daily for 14 days
45606890|NCT04830501|Drug|TT-00434|Once daily [QD], 28 days/cycle.
45606891|NCT03587493|Other|BLOOD SAMPLE ANALYSIS|Peripheral venous blood sampling just before lung transplantation, at day 15 and at post-transplantation M1 for lymphocyte phenotyping by cytometry
45606892|NCT04815681|Behavioral|Common Elements Toolbox|COMET is an online unguided self-help intervention that lasts approximately 40-50 minutes.
45606893|NCT04815681|Behavioral|Active Control|The active control condition includes an online self-awareness program that lasts approximately 40-50 minutes. Participants in the control condition will receive access to the intervention after data collection for the study has been completed.
45606894|NCT03502811|Device|MitraClip NTR/XTR System|Percutaneous mitral valve repair using the MitraClip NTR/XTR system.
45606895|NCT05097573|Device|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, stretch marks, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 4 treatments approximately 4 weeks apart.
45606896|NCT04456309|Other|No intervention,|pure observational study
45606897|NCT03502655|Other|Experimental: Intervention message (first phase)|Effect of positive communication on pain during intravenous cannulation in an emergency department delivered by a recorded message
45606898|NCT03502655|Other|Placebo Comparator: Control message (first phase)|Effect of usual communication on pain during intravenous cannulation in an emergency department delivered by a recorded message
45606899|NCT03502655|Other|Experimental: Intervention message (second phase)|Effect of positive communication on pain during intravenous cannulation in an emergency department delivered by a care provider
46066676|NCT04078438|Other|psychotherapy placebo sessions|To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions instead of neurofeedback training sessions. These sessions included psychological assessment and supportive psychotherapy.
45606900|NCT03502655|Other|Placebo Comparator: Control message (second phase)|Effect of usual communication on pain during intravenous cannulation in an emergency department delivered by a care provider
45606901|NCT03470389|Procedure|HVPG measurement|Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.
45606902|NCT05097417|Combination Product|traditional Chinese medicine and ablation in the primary tumor sites|Patients will be treated with traditional Chinese medicine and ablation in the primary tumor sites
45606903|NCT05097417|Procedure|ablation|Patients will be treated with ablation in the primary tumor sites
45606904|NCT04289311|Behavioral|Voice Crisis Alert V2|An mHealth intervention (app) with multiple components for self-management behavior development. Components include: electronic educational information, symptom monitoring and tracking, communication with a provider, health history entry and storage (including medication adherence).
45606905|NCT03253913|Drug|Sirolimus|Patients will have been on a stable dose of sirolimus prior to enrolling and will continue that throughout the study.
45606906|NCT03253913|Drug|Resveratrol|Escalating doses of resveratrol will be given throughout the study. Patients will start at 250mg daily for 8 weeks, followed by 500mg daily for 8 weeks, and 500mg BID for the last 8 weeks.
45606907|NCT03397719|Behavioral|Treatment Condition|This group will receive three hours of parent coaching per week, one hour per week will involve feedback on parent usage of coached strategies based on parent recorded interactions with their children.
46066677|NCT00607646|Drug|Dehydroepiandrosterone|Placebo tablets or tablets containing DHEA will be given orally before each hyperinsulinemic clamps on day 1 (x 2). Placebo tablets or tablets containing DHEA will be given orally before Day 2 hyperinsulinemic hypoglycemic clamp x 1.
46066678|NCT00607646|Drug|Placebo|Placebo oral administration prior to each clamp period x2 on day 1. Hyperinsulinemic hypoglycemia on day 2.
45606908|NCT03397719|Behavioral|Control Group|This group will receive in-vivo parent coaching three hours per week.
45606909|NCT04455919|Other|Wait-list group|The wait-list group benefit from a 8-week yoga program after the interventional group
45606910|NCT04455919|Other|Yoga group|During 8 weeks, the intervention group attended weekly yoga sessions and had to practice poses at home
45606911|NCT03237819|Drug|Sulfate, Magnesium|"Magnesium sulphate will be administered at a dose of 6g over 20 min intravenously followed by a continuous infusion of 6g / 24h for 3 days.~For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of 1,5g of magnesium sulfate)"
45606912|NCT03237819|Drug|Placebo - Concentrate|For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of glucose 5% as placebo)
45606913|NCT03468907|Drug|Telbivudine 600mg|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg daily between gestational weeks 24 and 28.
45606914|NCT03468907|Drug|Tenofovir disoproxil fumarate 300mg|Pregnant mothers who opted for antiviral therapy would start on oral TDF 300 mg daily between gestational weeks 24 and 28.
45606915|NCT03505385|Behavioral|Co-created intervention - Get Ready (GR)|"The Get Ready (GR) intervention was delivered one-to-one with the care home resident and a relevant family member during a 12-week period:~The familiarisation stage aimed to build a rapport with two long-term achievement goals to sit less and move more with the resident and the family member and consisted of two sessions, one in week 1 (50-60minutes) and the other in week 3 (30-40 minutes).~The ramping up stage aimed to review the rapport and reach an achievable consensus with the resident and the family member. It consisted of two sessions, one in week 5 and the other in week 7 (20-30 minutes each).~The maintenance stage aimed at integrating behaviours and included two sessions, one in week 9 and the other at week 12 (20-30 minutes each). Sessions 5 and 6 were used to understand how the resident was getting on with their short-term GR goals, facilitating some problem-solving discussions."
45606916|NCT05356221|Device|Ponto Sound processor|Bone Anchored Hearing solution fitted to compensate for the subjects hearing loss
45606917|NCT02313467|Drug|Topical application of 1.5% Butenyl ALA|
45606918|NCT02313467|Drug|Topical application of sham control|
45606919|NCT05089851|Procedure|Onabotulinumtoxin A|Subjects will receive 20 - 24 units to the crows feet (10 - 12 units per side)
45606920|NCT05089851|Combination Product|Facial Cleanser|Facial Cleanser to be used by participants twice daily
45606921|NCT05089851|Combination Product|Facial Moisturizer|Bland moisturizer to be used by study participants after serum twice daily.
45606922|NCT05089851|Combination Product|Sunscreen|Bland Sunscreen to be used by study participants after serum and moisturizer in the morning. Sunscreen to be reapplied if continuous sun exposure occurs.
45606923|NCT00515671|Behavioral|Illness Management and Recovery|a structured curriculum to help mental health consumers manage their illnesses and pursue goals related to recovery from mental illness
45606924|NCT00515671|Behavioral|Problem Solving|Weekly problem-solving support group
45606925|NCT02311127|Device|SecurAcath|Devices secures PICC subcutaneously and remains in place during the complete dwell time of the PICC
45606926|NCT02311127|Device|StatLock|Device secures PICC however, device has to be changed weekly
45606927|NCT04657809|Combination Product|Insulin film|Insulin suspension vials
45606928|NCT04657809|Device|Fast dissolving film|Fast dissolving film
45606929|NCT02313545|Drug|IZN-6NVS Cream|"IZN-6NVS, a hydrocream containing three herbal extracts, is a polymolecular agent derived from botanical sources. It is composed of a blend of three herbal extracts, Centella asiatica, Echinacea purpurea, and Sambucus nigra.~Cream concentration: 5%"
45606930|NCT04457167|Device|Robot-assisted|robot-assisted surgery
45606931|NCT04457167|Procedure|Not robot-assisted surgery|Not robot-assisted surgery
45606932|NCT05350917|Drug|Tislelizumab|"Tislelizumab: 200 mg, d1, intravenous infusion (ivgtt) administration, 21 days as a cycle.~DisitamabVedotin : 2mg/kg, d1, intravenous drip (ivgtt) administration, 21 days as a cycle.~Pyrotinib maleate tablets: 320 mg each time, Qd, orally administered within 30 minutes after breakfast, 21 days as a cycle.~Continuous administration until disease progression, death, toxicity intolerance, withdrawal of informed consent, or other reasons specified in the protocol; for patients who still benefit after comprehensive evaluation after initial disease progression, the investigator may decide whether to continue the treatment with the experimental drug ."
45606933|NCT02313701|Other|Standardized visual presentation|Visual presentations will address what type of procedure they will undergo, the risks and benefits of the procedure (i.e. injury to nearby organs, risks of infection and bleeding, risk of re-operation), alternative treatments to the procedure, what to expect during the pre-operative period, and what to expect in the post-operative period (i.e. urinary catheter, constipation, pain management, hospital stay).
46066679|NCT03875599|Other|Pulmonary Rehabilitation|Respiratory Physiotherapy, Exercise Therapy, Patient Education
45606934|NCT03019497|Behavioral|Specific Modules|Educational session about a specific related problem
45606935|NCT03019497|Behavioral|Cognitive behavioral therapy|PTSD of participants in both conditions will be addressed with cognitive-behavioral intervention strategies. These strategies are: (a) psychoeducation on PTSD, (b) anxiety management training, (c) restructuring irrational thoughts, (d) imaginative and / or in vivo exposure to memories and situations avoided, and (e) strategies for the prevention of relapse.
45606936|NCT02311205|Procedure|Conventional Transarterial Chemoembolization (TACE)|On demand conventional TACE will be performed in all the patients after enrollment and can be continued until intrahepatic CR, TACE failure or consent withdrawal. Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
45606937|NCT02311205|Drug|sorafenib|Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
46066680|NCT00606398|Procedure|surgical resection for patients with both intra- and extra-hepatic metastases|Simultaneous resection with R0 intent of intra-abdominal metastases from CRC. For patients with extra-abdominal disease, sequential resection will be permitted
45606938|NCT05064657|Procedure|Bubble blowing method|"The investigators were used Bubble blowing method and ball squeezing method.~To child were used a ball squeezing method during the blood collection process."
45606939|NCT02313779|Behavioral|Lovingkindness Meditation (LKM)|Compassionate behavior training (REVISE)
45606940|NCT02313779|Behavioral|Mindfulness Meditation|
45606941|NCT05390749|Drug|Orelabrutinib|Orelabrutinib will be given as 150mg orally d1-d21 for 6 cycles,every 21 days for 1 cycle.
45606942|NCT05390749|Drug|Pomalidomide|Pomalidomide will be given as 4mg d1-d14 for 4 cycles,every 21 days for 1 cycle.
45606943|NCT05390749|Drug|Rituximab|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
45606944|NCT05390749|Drug|Methotrexate|methotrexate 3.5g/m2 civ d1/cycle5-6
46066681|NCT00770263|Drug|Erlotinib|
46066682|NCT00770263|Drug|Temsirolimus|
46066683|NCT02691026|Drug|Pembrolizumab|
45606945|NCT02813655|Drug|Tetracosactide (Synacthène®)|"Tetracosactide, manufactured by Sigma-Tau® laboratories and marketed under the name of Synacthène®.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 1 mg of Synacthène® intravenously during 20 minutes. Four vials of 1 ml of Synacthène® will be added to a bag of 100 ml of physiological saline. The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
45606946|NCT02813655|Drug|placebo saline (0.9% NaCl)|"placebo saline manufactured by the laboratory Aguettant: 10ml vial, 4 mL will be collected and added to a bag of 100 ml of saline.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 4 ml of placebo saline added to a bag of 100 ml of physiological saline ( 104 ml of physiological saline). The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
45606947|NCT02313857|Biological|Viralym-C|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-C infusion. If a patient has multiple Viralym-C infusions the schedule resets again at the beginning so follow up relates to the last Viralym-C infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 35 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
45606948|NCT04936113|Biological|FB-401|Topical
45606949|NCT03468829|Biological|ALX-0171 Dose 1|Oral inhalation of ALX-0171 Dose 1 once daily for a maximum of 14 days
45606950|NCT03468829|Biological|ALX-0171 Dose 2|Oral inhalation of ALX-0171 Dose 2 once daily for a maximum of 14 days
45606951|NCT03468829|Biological|Placebo|Oral inhalation of Placebo once daily for a maximum of 14 days
45606952|NCT02313935|Other|LLM|LLM training Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
45606953|NCT02313935|Other|FFA|PTC training Participants use the FitForAll exergaming computer platform as the physical training component (PTC)
45606954|NCT02313935|Other|Brain Fitness|CTC training Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
45606955|NCT02313935|Other|VideoGrade|Active cognitive training by use of the VideoGrade software by AUTH.
45606956|NCT04912791|Procedure|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
45606957|NCT05334927|Behavioral|Medicine Overuse Headache/New Daily Persistent Headache|At the end of the 24th month visit, the patient is free to choose whether to conduct a face-to-face visit once a year until death.
45606958|NCT05334927|Behavioral|Chronic Migraine|long-term follow-up
45606959|NCT05334927|Behavioral|Patients with other types of primary headache|No collection Brain imaging、Cognitive function test、Biological sample
45606960|NCT02316197|Drug|MSC2490484A (M3814)|Participants received MSC2490484A capsules at escalated dose from 100 mg to 400 mg orally from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
45606961|NCT04010851|Behavioral|Peer co-led educational group|The intervention is delivered in a group format, which takes the form of a full day's training, focusing on ADHD diagnosis, its treatment, how to cope with the challenges related to living with ADHD, as well as coping with challenges of parenting a child with chronic health conditions. After this one day-intervention, the participants can continue in self-help groups, which meet once a week for a 2-hour evening session. User representatives lead these weekly self-help groups, which do not require user-fees and aim to offer practical tools, support and information to increase the parent's skills, knowledge and confidence. Participants are encouraged to adopt an active role in order to achieve a positive parent/provider partnership.
45606962|NCT04010851|Behavioral|Comparator treatment as usual|Control group will receive treatment as usual, including different treatment options that can help alleviate the symptoms of ADHD and arm families with the tools needed to better handle problem behaviors when they arise. These interventions include: medication, psychotherapy, or a combination of these two approaches.
45606963|NCT02314013|Drug|Cephalosporin + Metronidazole|intravenous antibiotics injection (3rd generation cephalosporin + metronidazole)and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
45757330|NCT05680688|Other|Manual Therapy|"Postero-anterior mobilizations: the physiotherapist will place his thumbs on the posterior surface of the spinous process of the vertebra previously assessed as the most painful to mobilise. The oscillations will be performed at the frequency of 1 oscillation per second and will be performed 3 series of 3 minutes, with a 1 minute rest interval.~Pressure: The point of greatest pain shall be treated by maintained pressure in each of the following areas: right upper trapezius, left upper trapezius, right paravertebral musculature and left paravertebral musculature. Pressure shall be applied to each of the points for 1 minute.~Massage: Pressure is applied to the muscles by sliding along the muscle belly. This will be done slowly to control the pain that is being provoked. 3 minutes will be carried out on each upper trapezius, sliding from the acromion to the occipital and another 3 minutes on the paravertebral musculature on each side, sliding from T1 to the occipital."
45757331|NCT00625391|Drug|Placebo|500 mg medicinal starch pills daily
45757332|NCT00625391|Drug|Green Tea Polyphenols (GTP)|500 mg green tea polyphenols daily
45757333|NCT00625391|Drug|Placebo+Tai Chi (TC)|500 mg medicinal starch daily and Tai Chi (3x/week) for 24 weeks
45757334|NCT00625391|Drug|GTP+TC|500 mg GTP daily plus TC exercise (3x/week) for 24 weeks
45757335|NCT04954287|Biological|CVXGA1 low dose|see arm/group description
45757336|NCT04954287|Biological|CVXGA1 high dose|see arm/group description
45757337|NCT03375866|Other|Pretzels|Subjects consume 240 kcal of pretzels daily for 16 weeks.
45757338|NCT03375866|Other|Mixed nuts|Subjects consume 240 kcal of mixed nuts daily for 16 weeks.
46066684|NCT05400148|Drug|Bupivacaine Hydrochloride|Patients who were administered an analgesic PENG block with a dose of 2.5mg/kg with either lov (<20ml) or high volume (>20ml)
46066685|NCT00770419|Other|medical chart review|
45757339|NCT00735787|Biological|Placebo|Loading dose of 2 placebo subcutaneous (SC) injections (0.8 ml) at Week 0 followed by 1 injection SC eow from Week 1 to Week 15.In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27.
45757340|NCT00735787|Biological|Adalimumab|Loading dose of 80 mg adalimumab SC (two 40 mg injections) followed by 40 mg adalimumab SC eow.
46066686|NCT00770419|Other|questionnaire administration|
45606964|NCT01677195|Drug|ACCS100|ACCS100 is not absorbed. The dose is estimated based on the volume of the gastrointestinal tract. We estimate that the average human intestinal tract has a volume of approximately 4 liters. In the high dose group, the effective concentration in the gut is 0.75 milligrams per milliliter. In the low dose, the effective concentration in the gut is 0.375 milligrams per milliliter. The test article is made by filling gelatin capsules with 500 milligrams of ACCS100. There are no excipients used in the manufacturing process of the test article.
45606965|NCT01677195|Drug|Placebo|Placebo is calcium carbonate, USP. This calcium mineral does not absorb mycotoxins, specifically aflatoxin and fumonisin. This mineral has approximately the same physical appearance as active test article.
45606966|NCT03468751|Drug|HLX10|recombinant humanized anti-PD-1 monoclonal antibody against solid cancers
46066687|NCT00770419|Procedure|psychosocial assessment and care|
45606967|NCT02314091|Procedure|onlay mesh hernioplasty|
45606968|NCT02316275|Other|No post-operative activity restrictions|Patients are to resume regular activity immediately after mid-urethral sling surgery. The investigators will determine the impact of unrestricted post-operative activity on continence outcomes of mid-urethral sling surgery in women with stress urinary incontinence (SUI). Investigators will measure the effect of unrestricted post-operative activity on early health-related quality of life (HRQOL). A Productivity Loss form for cost-effective analysis will be asked of the patient.
45606969|NCT02316275|Other|Standard post-operative activity restriction|
45606970|NCT04470063|Drug|DDO-3055 tablets|Multi-dose for DDO-3055 tablets
45606971|NCT04470063|Drug|Placebo|Multi-dose for Placebo
45606972|NCT05331807|Dietary Supplement|Omega-3 FA|Two capsules of 1000mg fish oil daily (Each soft gel capsule contains 180mg EPA and 120 mg DHA)
45606973|NCT05331807|Dietary Supplement|Vitamin D|one capsule of vitamin D3 weekly (one D3 capsule contains 50,000 IU)
45606974|NCT05331807|Combination Product|Combined Omega-3 and Vitamin D Supplementation|Two capsules of 1000mg fish oil daily (Each soft gel capsule contains 180mg EPA and 120 mg DHA) and one capsule of vitamin D3 weekly (one D3 capsule contains 50,000 IU)
45606975|NCT05390593|Device|iTBS-1800|Participants in the 1800-pulse intermittent TBS (iTBS-1800) active stimulation group will receive three-pulse 50-Hz pulses for 2 weeks at an intensity of 80% active motor threshold (MT) to Left DLPFC, twice a day. Stimulation will use a MAG & More stimulator.
45606976|NCT05390593|Device|iTBS-1200|Participants in the 1200-pulse intermittent TBS (iTBS-1200) active stimulation group will receive three-pulse 50-Hz pulses for 2 weeks at an intensity of 80% active motor threshold (MT) to Left DLPFC, twice a day. Stimulation will use a MAG & More stimulator.
45606977|NCT02316509|Drug|GDC-0927|GDC-0927 will be administered as per schedule specified in the respective arm.
45757341|NCT02986893|Behavioral|Dietary Intervention|Participants will be assigned to follow a specific diet for 6 months. This will involve meetings with the study nutritionist at least monthly as well as regular assessments related to adherence and effects.
45606978|NCT02898181|Device|Tragus stimulation|Active LLTS will be performed by use of a transcutaneous electrical nerve stimulation (TENS) device with electrodes attached to the tragus of the ear.TENS will be applied continuously for 8 hours daily (4 hours twice daily)
45606979|NCT02314325|Drug|ADVATE [Antihemophilic Factor (Recombinant)]|In Arm 1 prior patients will be dosed as per body weight 20-40 IU/kg 5-7 infusions per fortnight
45606980|NCT02314325|Drug|ADVATE [Antihemophilic Factor (Recombinant)]|In Arm 2 patients who have completed arm 1 will cross over onto an individualised PK tailored alternate day dosing regimen
45606981|NCT02680171|Behavioral|Prism Goggles|Patients in the experimental condition will wear prism goggles while completing a computerized aiming task. This prisms will shift the patients' vision 10 degrees rightward, causing a recalibration of visuo-motor information. Prism adaptation will be carried out over several days.
45757342|NCT02986893|Behavioral|Non-dietary Intervention Arm|Participants will be requested to follow their usual diet and attend monthly meetings at the MS center to discuss various topics with a focus on wellness in MS for 6 months.
45444776|NCT02037880|Device|Magnetic Resonance Imaging (MRI) of the brain|
45606982|NCT02680171|Other|Non-Shifting Goggles|Non-shifting goggles are worn instead of prism goggles, while completing the same computerized aiming task as those assigned to the prism adaptation.
45757343|NCT04349943|Other|nutrition therapy|With enteral nutrition as the preferred solution, the gradual transition from slow to fast, from lean to dense, from essential to whole protein type is conducted.
45757344|NCT05418062|Behavioral|Acceptance and commitment therapy (ACT)|8 weekly 2 hour sessions of ACT group for CD patients with chronic pain. Manual available on request
46066688|NCT04267484|Device|GPS and travel diary|WP1: GPS tracker for 2 weeks and a daily diary about activity (travel diary).
46066689|NCT04267484|Other|e-decision support platform|WP2 and WP3: An e-decision support platform that will foster shared decision making about options to stay safe at home for the older adult.
45606983|NCT03502499|Drug|Half-normal saline|Use of half-normal saline as an irrigant for open-irrigated ablation catheters
45606984|NCT03502499|Drug|Normal saline|Use of normal saline as an irrigant for open-irrigated ablation catheters
45757345|NCT00628589|Drug|Inhaled loxapine 5 mg|Inhaled loxapine 5 mg
45757346|NCT00628589|Drug|Inhaled loxapine 10 mg|Inhaled loxapine 10 mg
45757347|NCT00628589|Drug|Inhaled placebo|Inhaled placebo
45606985|NCT04402827|Diagnostic Test|Susceptibility to infection|"ACE2 and CD26 receptor study: After genomic DNA extraction and quantification using a NanoDrop-1000, 14 ACE2 SNPs (rs1978124, rs2048683, rs2074192, rs2106809, rs2285666, rs233575, rs4240157, rs4646142, rs4646155, rs4646156, rs4646188, rs4830542, rs6632677, and rs879922) will be studied. In addition, one CD26 (DPP4) SNP (rs7608798) will be analysed (qualitative measure).~SARS-CoV-2 CD4/CD8 T cell response: SARS-CoV-2 peptides (Prot-S, Pros-N and Port-M) will be used to activate CD4 and CD8 T cells. Cytokines released, such as IFNg, TNFa, IL4, IL17A, and IL2, from each cell subset will be measured by flow cytometry (quantitative measure).~KIR characterization: Characterization of the presence of 14 genes plus 2 pseudogenes of KIR gene family (qualitative genotyping) by PCR, mRNA expression profiling (quantitative measures) by RT-PCR, and phenotyping of human NK cells analyzing different KIR receptors (quantitative measure) by flow cytometry, will be analyzed."
45606986|NCT04707261|Drug|Dapagliflozin|Participants will receive dapagliflozin 10 mg once daily
45606987|NCT04707261|Drug|Placebo|Participants will receive placebo once daily
45606988|NCT02316665|Device|continuous positive airway pressure|continuous positive airway pressure treatment during three months with adherence recording
45757348|NCT04953897|Drug|ASTX727|Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
45606989|NCT02316665|Device|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
45606990|NCT04671381|Behavioral|Hearing Evaluation|Behavioral thresholds for pure tones will be conducted along with speech perception measures.
45606991|NCT04671381|Device|Personal Sound Amplification Product (PSAP) Fitting and Orientation|Study participants will be fitted with binaural PSAPs in addition to receiving information on how to use and care for their devices.
45606992|NCT04671381|Behavioral|Four Weeks of Aural Rehabilitation|Participants will receive four weeks of information sessions to help them adjust to their over-the-counter hearing aid and their hearing loss.
45606993|NCT04671381|Device|Provision of Personal Sound Amplification Products (PSAPs)|Study participants will receive binaural PSAPs. Participants will fit their PSAPs based on manufacturer guidelines without the help of an audiologist.
45606994|NCT03501641|Other|image-based virtual reality learning|The participants will use a whole-view, 360 degree image-based virtual reality to learn a competence of history taking and physical examination for otolaryngology and they can see the response of the staffs and standard patients (including image, voice, face expression, movement, ... etc).
45606995|NCT03501641|Other|video-based learning|voice of the staffs and standard patients.
45606996|NCT05101941|Procedure|Immediate dental implants|Implants will be immediately placed in sockets associated with chronic periapical granuloma Extraction of non-restorable Teeth with periapical granuloma and socket debridement will be done then implants will be placed
45757349|NCT03375242|Drug|crizotinib|"XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
46066690|NCT04078360|Behavioral|AMBIT (Alcohol use disorders- mobile based Brief Intervention treatment) intervention|"The intervention will consist of participants receiving messages and/IVR calls not more than twice or thrice a week on their mobile phone for a duration of 8 weeks. Messages/IVR calls will be sent through VIAMO's technology platform. Each week messages will be focussed on specific content areas derived from the formative research of the study. Some of the components of the intervention include:~Self awareness messages~Self reflection messages~Motivational messages~Messages on safe drinking, alcohol reduction, drinking management, risk management, craving management and drinking alternatives.~Health education messages~Personalized feedback and information~Help-seeking resources~Goal setting messages"
45606997|NCT02314481|Drug|MPDL3280A|Intravenous (IV) infusion, as monotherapy of in combination with chemotherapy
45606998|NCT02314481|Drug|Vemurafenib|Film coated tablet
45606999|NCT02314481|Drug|Alectinib|capsule
45607000|NCT02314481|Drug|Trastuzumab emtansine|Powder for concentrate for solution for infusion
45757350|NCT04813445|Drug|Xingnaojing injection|Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
45757351|NCT01271569|Drug|Fospropofol disodium|Fospropofol disodium： 0.5g
45757352|NCT05589597|Drug|EO4010|Sequential assignment
45607001|NCT05160337|Diagnostic Test|Biomarker based IVD tests|Biomarker based IVD tests
45607002|NCT04437771|Other|Safety and efficacy assessments|Long term disease and gene therapy specific safety evaluations and efficacy assessments
45607003|NCT04437459|Other|High-fat shake|Participant consumes a high-fat test shake. Blood is drawn before and 4 hours after this shake to measure triglycerides.
45607004|NCT04437459|Other|Pure glucose solution|Participant consumes 75 grams of pure glucose. Blood is drawn before and 2 hours after this drink to measure glucose.
45607005|NCT02316743|Drug|Levothyroxine supplementation|T4 supplementation for heart failure patients with subclinical hypothyroidism.
45607006|NCT05160259|Radiation|Radial visualization of the foramen arcuale atlantis|In patients with diagnosed Kimmerle's anomaly, using transcranial Doppler sonography to determine the degree of changes in blood flow in the vertebral arteries
45607007|NCT04428567|Behavioral|Dual-Task Treadmill exercise + Cognitive Training|The dual-task regimen will include treadmill exercise of 5-10 min warm-up and cool-down, 30 minutes of running towards target heart rate, combined with respond demands with the addition of cognitive tasks. The level of duration and intensity of treadmill exercise will progressively increase over the duration of 6 weeks.
45607008|NCT03502421|Drug|Ketamine|Low dose continuous infusion of ketamine 0.3 to 0.5 mg/kg per hour
45607009|NCT05160103|Other|Cosmetic Formulations|Topical emulsions containing anti-aging ingredients
45757353|NCT05686772|Drug|Dopamine partial agonists|Use of antipsychotics (i.e., dopamine partial agonists vs dopamine antagonists)
45757354|NCT05686772|Other|Psychiatric comorbidities|Mainly substance use disorders and personality disorders
45757355|NCT05686772|Other|Sex|Biological sex at birth
45757356|NCT05686772|Other|Gender|Current gender identity
45607010|NCT04371861|Device|Peripheral Artery Treatment|Peripheral lesions may be treated by any standard of care methods of treatment.
45607011|NCT03502343|Drug|Modified Gemcitabine plus nab-Paclitaxel Combination Chemotherapy|"All patients will receive slow (over 30-40 minutes) intravenous administration of nab-paclitaxel (125 mg/m2) on days 1 and 15, and gemcitabine (1000 mg/m2) on days 1, 8, and 15 of a 28- day cycle (every 4 weeks). Treatment will discontinue if disease progression or intolerable toxicity is observed, if the patient withdraws from the study, or at the physician's discretion.~Dose reduction of the chemotherapeutic agent and/or delay of administration is allowed if serious treatment-related AEs occur, according to specified guideline in study protocol (Level 1: 100% -> 80%; Level 2: 80% -> 60%). If dose reduction is needed more than Level 2, the patient will be dropped from the trial."
45757357|NCT05686772|Other|Socioeconomic status|Including main source of income, employment status, homelessness
45757358|NCT05686772|Other|Gambling history|History of gambling (i.e., recreational or problematic) prior to admission in the clinics
45444777|NCT04743219|Procedure|Selective removal to soft dentin, Biodentine|"Carious tissue removed until its complete elimination from the lateral walls of the cavity using a round tungsten carbide bur at low speed until consistency of hard dentin around perimeter. With a manual excavator, the central cariogenic biomass will be removed, specifically the superficial part of the necrotic and demineralized caries dentin.~In the Biodentine group, Biodentine (Septodont) will be placed on the base of the cavity with a thickness of 2 mm.~The last step will be to perform a definitive direct resin restoration according to clinical indication."
45607012|NCT05390515|Drug|Tildrakizumab Prefilled Syringe|IL-23 inhibitor
45607013|NCT04345887|Drug|Spironolactone 100mg|2x100 mg spironolactone for 5 consecutive days
45607014|NCT04345887|Drug|Placebo oral tablet|2 x1 placebo tablet
45607015|NCT03818971|Other|electroretinogram (flash, pattern and multifocal)|we measured the waves a, b, oscillatory potentials, back ground noise and i for the flash ERG, the waves P50 and N95 for the pattern ERG and the P1, N1 and N2 for the multifocal ERG
45607016|NCT03132311|Biological|Yellow Fever vaccination (17 DD Biomanguinhos)|One intramuscular injection
45607017|NCT04339023|Drug|Open-Label Placebo|in addition to Treatment as usual, patients receive placebos without concealment (open-label placebo, OLP)
45757359|NCT04771871|Drug|Epirubicin|Epirubicin is an antitumor antibiotics with good activity on breast cancer. It has less cardiotoxic effect than doxorubicin
45607018|NCT04339023|Other|treatment as usual|usual medication intake following minimally invasive TLIF. TAU consists of 3 gram Paracetamol per os a day, a patient-controlled morphine pump (Maximum of 2 milligram (mg) every 12 minutes) and rescue medication (1000 mg of Metamizol, maximum every 6 hours)
45757360|NCT04771871|Drug|Cyclophosphamide|Cyclophosphamide is a cytoxic drug indicated for the treatment of many malignancies including breast cancer
45757361|NCT04771871|Drug|Paclitaxel|Paclitaxel is a taxane chemotherapy agent indicated for the treatment of many cancers including breast cancer. It can be used alone or in combination with other drugs
45757362|NCT04771871|Drug|Carboplatin|Carboplatin is a platinum compound indicated for the treatment of many types of malignancies including breast cancer
45757363|NCT05589207|Diagnostic Test|Vascular wall invaded|Inferior vena cava vascular wall is invaded according to pathologic examination on the postoperative tumor thrombus/ vascular wall specimen.
45452230|NCT02269306|Drug|clomiphen citrate|The study was carried out on 150 patients with PCOS. Initial clomiphen citrate (CC) doses were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, doses were increased to 100 and 150 mg daily in subsequent cycles. First ovulation with CC was used as the end point.
45607019|NCT05374083|Procedure|Alveolar ridge preservation using autogenous demineralized dentin block graft|Atraumatic extraction of non restorable tooth, then the extracted tooth will be prepared and demineralized by hydrochloric acid (HCL) acid and inserted as demineralized dentin block graft in the socket
45607020|NCT05374083|Procedure|Alveolar ridge preservation using particulate deproteinized bovine bone graft|Atraumatic extraction of non restorable tooth, then the socket will be packed by particulate deproteinized bovine bone
45607021|NCT01989949|Drug|TP-434 (Eravacycline) reconstituted and administered via an IV infusion|
45607022|NCT05390437|Dietary Supplement|Nutritional intervention with Ready to use theraputic food (RUTF) and prebiotic GOS (galacto oligosaccharides) in combination|4gm of prebiotic GOS ( Galactooligosaccharides) and Ready to use theraputic food (RUTF) as per WHO standard on daily basis for 60 Days
45607023|NCT05390437|Dietary Supplement|Ready to use theraputic food (RUTF) and Starch (placebo)|Ready to use therapeutic food (RUTF) as per WHO standard and (Starch Placebo) soluble in water and mix in food on daily basis for 60 Days
45607024|NCT02316821|Drug|RTA 402|
45607025|NCT02316821|Drug|Placebo|
45607026|NCT02316899|Drug|linaclotide|Oral administration once daily
45607027|NCT02316899|Drug|Placebo|Oral administration once daily
45607028|NCT01727011|Radiation|IPAS|
45607029|NCT02314793|Drug|ASP2205|oral
45607030|NCT02314793|Drug|Placebo|oral
45607031|NCT00928447|Drug|rHuPH20|0.25 milliliter (mL) Intradermal (ID) syringe push bolus injection of rHuPH20
45607032|NCT00928447|Drug|Placebo|0.25 mL ID syringe push bolus injection of placebo control
45607033|NCT02314871|Other|Epidural analgesia|see Arm/group description
45607034|NCT02314871|Drug|Piritramide|see Arm/group description
45607035|NCT02314871|Drug|Morphine|see Arm/group description
45607036|NCT05159635|Device|Active Living programme and wearable technical aids|attend 6 weeks active living programme and apply wearable technical aids for 8 weeks.
45607037|NCT05159635|Device|Wearable technical aids|apply wearable technical aids for 8 weeks.
45607038|NCT02317055|Other|imaging|
45607039|NCT02224846|Drug|Tadalafil|Administered orally
45607040|NCT03569761|Behavioral|Colorectal Cancer Screening Decision Aid|Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments.
45607041|NCT03569761|Behavioral|Control Group|Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments. Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments.
45607042|NCT02317133|Biological|Blood samples|Compared to routine practice, 3 additional tubes of blood will be drawn for the observational needs of this study.
45607043|NCT02317133|Biological|Stool samples|Stool samples will be collected for the observational needs of this study (and are not part of routine practice).
45607044|NCT02522923|Other|Physical Therapist|The participant will receive an evaluation and intervention from a physical therapist. The patient will be referred onward to other providers as needed.
45607045|NCT02522923|Other|Primary Care Provider|The participant will receive an evaluation and intervention from a primary care provider. The patient will be referred onward to other providers as needed.
45607046|NCT02314949|Procedure|intestinal transplantation|
45607047|NCT04925128|Other|treadmill|Data collection procedure will be comprised of total 6 weeks, 5 days of session per week. Initially taken baseline values will be taken after every two weeks i.e 2nd , 4th and 6th.
45607048|NCT04463303|Other|lung ultrasound|patient with or without weaning induced pulmonary adema
45607049|NCT03470077|Drug|IV nalbuphine 0.1 mg/kg with induction of anesthesia.|"Group A: 40 patients will receive IV nalbuphine 0.1 mg/kg with induction of anesthesia.~."
45607050|NCT03470077|Drug|IV nalbuphine 0.1 mg/kg at the end of surgery.|Group B: 40 patients will receive IV nalbuphine 0.1 mg/kg at the end of surgery just before discontinuation of anesthesia.
45607051|NCT04463147|Device|Needle-pilotTM device|The main objective aims to compare the procedure time between conventional real time ultrasound guidance and guidance with Needle-pilotTM device.
45607052|NCT01632280|Device|Transcranial Direct Current Stimulation (tDCS)|"tDCS is a well-established, safe and noninvasive neuromodulation technique that is based on the application of a weak direct current to the scalp that flows between two electrodes-anode and cathode. Although there is substantial shunting of current in the scalp, sufficient current penetrates the brain to modify the transmembrane neuronal potential, and thus influence the level of excitability and modulate the firing rate of individual neurons.~In this study, participants will receive 10 daily sessions of tDCS (sham/real) over a period of two weeks."
45607053|NCT02315105|Procedure|Laparoscopic Greater Curvature Plication|LGCP is a procedure in which the stomach is folded inwards to that its capacity to hold amount of food is decreased dramatically. This is done under general anesthesia. The operation takes about 1 hour and is done laparoscopically. The attachments of the stomach to the spleen are feed up and the outside is folded inside and stitched up to keep it from folding in. To ensure that the surgeon has not obstructed the passage in or out of the stomach, a tube ( Bougie) is placed in the stomach at the time of the creation of the fold and checked again at the end of the procedure with a camera in the stomach which is placed through the mouth (EGD- upper endoscopy) to ensure the desired outcome is achieved.
45607054|NCT04455763|Procedure|SVF|Adipose-derived stromal vascular fraction
45607055|NCT04455763|Other|Splint|Thumb brace (Actimove® Rhizo Forte)
45607056|NCT03502109|Other|Medication review with follow-up|Medication review with follow-up: trained pharmacists will conduct consecutive medication reviews by detecting and resolving drug related problems, educational interventions and applying pharmacotherapy changes made in collaboration with physicians.
45607057|NCT05159323|Diagnostic Test|Diffusion Spectrum Imaging|A novel diffusion-based magnetic resonance imaging method
45607058|NCT05237999|Behavioral|KopOpOuders-PTSD|See arm description
45607059|NCT03519295|Drug|MPDL3280A|MPDL3280A (atezolizumab) will be administered every 2 weeks at 800 mg for 12 months.
45607060|NCT03519295|Drug|mDCF|Patients will receive 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5FU at 1200 mg/m2/day for 2 days) every 2 weeks
45607061|NCT02317211|Dietary Supplement|Anthocyanin|Extract of blueberry and huckleberry （MEDOX，http://www.medox.no/english）
45607062|NCT02317211|Dietary Supplement|placebo|starch
45607063|NCT05159167|Other|Baduanjin, a type of Qigong|Baduanjin is very popular in China. There is increasing evidence to support its positive effects on health outcomes in various groups of people with physical and mental disorders.
45607064|NCT02224690|Drug|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
45607065|NCT02224690|Drug|Placebo|Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
45607066|NCT03501407|Diagnostic Test|Blood samples|1 or 2 blood samples will be collected from the patient.
45607067|NCT03501407|Diagnostic Test|skin biopsy|A skin biopsy will be performed on the periphery of the erythema migrans
45607068|NCT05390281|Diagnostic Test|increase in serum creatinine|any of the following: increase in serum creatinine by ≥ 0.3 mg/dl within 48 h of surgery or increase in serum creatinin
45607069|NCT03501329|Combination Product|Biological,Psychological and Social support|
45607070|NCT05150431|Drug|Parecoxib|Parecoxib 40mg will be administered to the experimental group if the patient has no contraindication.
45607071|NCT05150431|Drug|Placebo|This is normal saline 2ml, which is equal to the volume of parecoxib solution. Placebo will be injected to placebo group 15 minutes before the end of the surgery.
45607072|NCT03501251|Drug|Moxidectin 8mg|Participants will receive the tablet with clean water and a package of biscuits.
45607073|NCT03501251|Drug|Moxidectin 8 mg + albendazole 400 mg|Participants will receive the tablets with clean water and a package of biscuits.
45607074|NCT03501251|Drug|Moxidectin 16 mg|Participants will receive the tablets with clean water and a package of biscuits.
45607075|NCT03501251|Drug|Moxidectin 16 mg + albendazole 400 mg|Participants will receive the tablets with clean water and a package of biscuits.
45607076|NCT03501251|Drug|Moxidectin 24 mg|Participants will receive the tablets with clean water and a package of biscuits.
45607077|NCT03501251|Drug|Moxidectin 24 mg + albendazole 400 mg|Participants will receive the tablets with clean water and a package of biscuits.
45607078|NCT03501251|Other|Placebo|Participants will receive the tablet with clean water and a package of biscuits.
45607079|NCT05163691|Drug|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
45607080|NCT05163691|Drug|Placebo|GH001 Placebo administered via inhalation
45757364|NCT01278979|Device|"Objective measurements of perineal tears with Peri-Rule"|"Four measurements will be used in this study.~Depth of tear, from the fourchette into the greatest depth of the perineal body.~Length of tear, from the fourchette to the apex of the vaginal tear.~Length of tear, from the fourchette along perineal skin towards the anus.~Length of the perineal body, from the fourchette to outer margin of anus."
45607081|NCT03501017|Other|physical activity program|"The 12-week physical activity program was implemented under the guidance of nurse, in outdoors with the group, 5 days a week with warm up and cooling down for 10 minutes and normal walking tempo at a moderate pace for 30-45 minutes (3-6 km/hour).~Application of WHO Smoking Cessation Algorithm: After fagerström test was applied, the modified smoking cessation algorithm of WHO was applied to the individuals and those who decided to quit smoking were referred to smoking cessation outpatient clinics."
45607082|NCT03501017|Other|Routine Practice|As routine practice, a brochure provided from the Public Health Directorate on protection from CVD was delivered to the individuals in the control group.
45607083|NCT05390203|Diagnostic Test|Penile duplex study, Hormonal Assay (Total Testosterone, Prolactin and E2)|we will do penile duplex and hormonal profile preoperatively and 6 months postoperatively.
45607084|NCT02315183|Other|This is an observational Study|THis study has no intervention
45607085|NCT01634152|Drug|Placebo|2 actuations once daily in the evening
45607086|NCT01634152|Drug|Tiotropium low dose mcg|2 actuations once daily in the evening
45607087|NCT01634152|Drug|Tiotropium high dose|2 actuations once daily in the evening
45607088|NCT05391217|Other|Remote assessment of patient reported outcomes and daily activity|Electronic patient-reported outcomes (NIH PROMIS) will be collected and combined with remotely monitored physical activity, heart rate, and sleep, as measured with a Fitbit (Sense).
45607089|NCT02315417|Drug|gevokizumab|
45607090|NCT02315417|Drug|Placebo|
45607091|NCT02315417|Drug|gevokizumab open-label|
45607092|NCT05120323|Behavioral|vDOT Intervention Group|The vDOT intervention group will submit video clips of doses of inhaled controller asthma medication via the Emocha® smartphone application with each prescribed dose of inhaled controller medication. Each video will include a date and time stamp of the medication dose. Participant videos will be evaluated by trained personnel using an inhaler technique checklist to score each dose and create a report detailing the steps that were taken to complete the medication dose.
45607093|NCT05063227|Diagnostic Test|Observational: analgesia monitoring indices and changes in heart rate|After the end of surgery (defined as the time of skin closure or wound dressing), but before awakening (BIS will still be < 60), SPI, PPI and NOL are recorded in a quiet setting without any other stimulation. Within the five minutes data acquisition period nociception indices are recorded every minute (T0, T1, T2, T3, T4, T5). The highest SPI, PPI and NOL are used for further analysis.
45607094|NCT03501953|Behavioral|Physical Activity|Six weeks of instructor-led physical activity sessions.
45607095|NCT05390125|Other|A team, proficiency based progression, simulation training programme|The training programme will consist of two components (i) a short online training course including video examples of high performing teams and also poor practice (ii) a ward-based team huddle simulation training and assessment programme. The design and shape of the training and assessment will be based on the development of robust metrics. The design of the metrics and programme will centre around use in the acute hospital setting but will be readily adaptable to the obstetric, paediatric setting. The process of validating the metrics and building the online and simulation course involves the review of videotapes of safety huddle performance.
45607096|NCT02317523|Behavioral|Behavioral Activation|Six face-to-face sessions (60 minutes each) of Behavioral Activation (BA) therapy
45607097|NCT02317523|Behavioral|Information and Support|Six face-to-face sessions (60 minutes each) of Supportive Therapy
45757365|NCT01278979|Other|Visual and digital assessment|Midwifes assessing perineal tears as standard procedure with visual and digital examination of the perineal tear.
45757366|NCT03374930|Procedure|Multiple rapid swallows test|Multiple rapid swallows test consists in giving to patient 4 to 6 sips of 2 mL of water, with an interval less than 4 seconds between the different sips.
45607098|NCT04338555|Procedure|Transcutaneous electrical acupoint stimulation|TEAS group will receive electrical stimulation of acupoints at Neiguan and Shenmen points for 30 min every hour during the surgery.
45607099|NCT02315495|Drug|Saxagliptin|
45607100|NCT02315495|Drug|Acarbose|
45607101|NCT04286139|Behavioral|SHAPE|The SHAPE intervention provides information for carers, and maintains the dignity and autonomy of the person with dementia, supporting them in planning for the future with their family. The person with dementia attends an online 10 week facilitator lead group based course. It is designed to develop self-management skills in areas including decision-making, symptom management and social interaction. It also provides information on the disease process and the development of healthy behaviors in a supportive learning environment to prevent problems that are common in the later stages of the disease. The adjunctive e-learning platform for carers provides the same information that the person with dementia receives plus additional material and signposting to support them in their role. This will empower the whole family to support and enable more effective self-management by the person with dementia, and enhance their ability to plan ahead together and make key decisions jointly.
45607102|NCT02317601|Drug|methylprednisolone sodium succinate|Single dose Intravenous
45607103|NCT02317601|Drug|placebo saline|
45607104|NCT03862807|Drug|Patisiran|Patisiran was administered via IV infusion.
45607105|NCT04274751|Device|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation
45757367|NCT04386577|Dietary Supplement|Vitamin D3 (cholecalciferol)|Eligible participants were assigned by chance to one of four groups: (1) daily vitamin D3 and omega-3; (2) daily vitamin D3 and omega-3 placebo; (3) daily vitamin D placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. At baseline, year 2 and year 4 of the trial, a subcohort of 1,054 VITAL participants living within driving distance of Boston, Massachusetts received detailed in-clinic health assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. During CTSC visits, participants have a clinical exam, including measurement of height, weight, other anthropometrics, blood pressure, and physical performance. They also provide fasting blood and urine samples, and undergo 2-hour oral glucose tolerance testing, lung function testing (spirometry), electrocardiograms, bone mineral density testing, 2D-echocardiography, and assessments of thinking and mood.
45444778|NCT04743219|Procedure|Selective removal to soft dentin, No Base|"Carious tissue removed until its complete elimination from the lateral walls of the cavity using a round tungsten carbide bur at low speed until consistency of hard dentin around perimeter. With a manual excavator, the central cariogenic biomass will be removed, specifically the superficial part of the necrotic and demineralized caries dentin.~In the No base group, no bioactive material will be placed as a liner, the 3M Scothcbonf Universal Plus adhesive will be placed directly over the remaining dentin surface.~The last step will be to perform a definitive direct resin restoration according to clinical indication."
45607106|NCT03501875|Radiation|CAC Score|Computed tomography angiography (CTA) with an injection of iodine-rich contrast material
45607107|NCT03500861|Other|Dry Needling|"The trigger point DN procedure was performed by a certified physiotherapist. While the patient was sitting, the therapist firstly cleaned the area with alcohol. Then, DN was applied into the active TrPs on the basis of the technique described by Hong (19). The needle remained in the trigger points for 20 minutes. Upon removal of the needle, the area was compressed firmly with a cotton swab for 60 secs. The DN procedure used sterile stainless-steel acupuncture needles of 0.25x40 mm and 0.25x 25 mm dimensions (Hua Long ®). DN was applied three times a week for 2 weeks, in previously diagnosed active trigger points located in the musculature of the head and the neck.~the Sham Dry Needling procedure was applied into the adipose tissue located at any area where an active TrPs was absent."
45607108|NCT04262895|Drug|TTI-0102|TTI-0102 is a cysteamine precursor.
45444779|NCT04722315|Dietary Supplement|Modified Atkins diet|12 weeks of modified Atkins diet
45607109|NCT04262895|Drug|Placebo|Placebo
45607110|NCT02522455|Other|Flow-cycle ventilation|Pressure support level set as per previous pressure requirements to deliver a tidal volume of 5ml/kg (the same pressure amount used as the peak inspiratory pressure in the time-cycled mode)
45607111|NCT02522455|Other|Time-cycle ventilation mode|Peak inspiratory pressure set to deliver 5ml/kg tidal volume, Rate set as per previous requirements
45607112|NCT05101785|Drug|Lidocain hydrochloride 2 % with epinephrine|Local anesthesia infilteration in children
45607113|NCT05101785|Drug|Articaine chloride 4% with epinephrine|Articaine chloride 4% with epinephrine
45607114|NCT02315573|Procedure|Wrist block anesthesia|The carpal tunnel release surgery will be performed under wrist block anesthesia. Group 1 will have the wrist block performed with Lidocaine and epinephrine, while Group 2 with Bupivacaine and epinephrine.
45444780|NCT03561610|Dietary Supplement|sip feed|normal oral Nutrition + sip feed (Fresubin2.0®; covers individual energy and nutrient demands; high in protein)
45444781|NCT03561610|Dietary Supplement|gumdrops|normal oral Nutrition + gumdrops (Nutrimed®; covers individual energy and nutrient demands; high in protein)
45607115|NCT02724241|Other|one time exposure to e-cig with nicotine|one time exposure to e-cigarette vapor with nicotine
45607116|NCT02724241|Other|One time exposure to e-cigarette without nicotine|One time exposure to e-cig without nicotine
45444782|NCT03795519|Drug|[14C]-olinciguat|oral capsule
45444783|NCT02037958|Device|Laryngeal Mask Airway-Supreme|Patients who receive the LMA-S
45444784|NCT02037958|Device|Endotracheal Tube|Patients who receive endotracheal intubation
45607117|NCT02724241|Other|one time exposure to empty e-cigarette|one time exposure to empty e-cigarette (sham control)
45607118|NCT04228731|Procedure|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total knee arthroplasty
45607119|NCT04228731|Procedure|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total knee arthroplasty
45444785|NCT02053402|Drug|Vitamin D|Vitamin D daily for six months
45444786|NCT04650945|Other|isCGM group|As previously described
45607120|NCT02315651|Dietary Supplement|Coenzyme Q10|A snack containing 60 mg of Coenzyme Q10. The snack contains also dried fruits and nuts, and their content are identical to this of placebo.
45607121|NCT02315651|Dietary Supplement|Placebo|A snack identical to the trial snack, but without Coenzyme Q10. The snack contains also dried fruits and nuts.
45607122|NCT05366725|Drug|Avelumab|As provided in real world practice
45607123|NCT04437693|Drug|Hydroxychloroquine|The treatment group that will receive Hydroxychloroquine (HCQ) 400mg twice a day on day 1 followed by 400 mg weekly for 7 weeks
45607124|NCT02317679|Drug|Bosentan|Patients with PWS resistant to PDL treatment will be included. The treatment by Bosentan (twice daily :2 mg/kg and maximum 62,5 mg) will be given 1 day before the PDL irradiation (maximum area treated 100 cm2) and continued for 14 days. The clinical improvement of the lesions will be evaluated by comparing standardized pictures, 14 days after the end of the treatment by Bosentan which corresponds to 1 month after the laser PDL irradiation. The evaluation will be realized by 2 independent physicians blinded to the area treated or not. Hemoglobin and SGOT/SGPT will be controlled before and after the treatment by Bosentan.
45607125|NCT02317679|Device|Pulsed dye laser (PDL)|A test area of the PWS will be treated by pulsed dye laser (PDL) (λ= 595 nm, 7 mm spot diameter, τp= 1.5 ms, same energy density used at the last session for each subject).
45607126|NCT05389969|Other|digital arch scanning|"Scanning of the maxillary and mandibular dental arch will be performed for the same group of patients twice. The first time is before bracket positioning using two different scanners and the three different techniques. The second time is after brackets positioning using the same two different scanners and the same three different scanning techniques.~Then these scans will be compared to by superimposition techniques and linear measurement techniques."
45444787|NCT04639011|Drug|Duloxetine|Three doses of 60 mg of oral duloxetine will be given to participants (right before operation, postop day 1, postop day 2)
45444788|NCT04639011|Other|Placebo|Three doses of placebo will be given to participants (right before operation, postop day 1, postop day 2).
45444789|NCT04639011|Other|Standard of care (SOC) for tibial plateau surgery|Postoperative IV administration of opioids via a patient controlled analgesia (PCA) system which utilizes a hydromorphone pump.
45444790|NCT02053558|Drug|Systemic lidocaine|Systemic lidocaine group will receive a lidocaine 1.5 mg/kg bolus after induction of anesthesia followed by a 2mg/kg/hr infusion and sham bilateral TAP blocks with normal saline 15mL on each side.
45607127|NCT05009667|Device|Angiography-derived Index of Microcirculatory Resistance|"caIMR will be measured by pressure sensors which are produced by Suzhou Rainmed Medical Technology Co., Ltd.~caIMR is calculated based on angiography images and Hyperemic Pa estimated from resting Pa according to prespecified equation."
45607128|NCT05009667|Device|Pressure wire-based Index of Microcirculatory Resistance|"IMR will be measured by thermodilution method with pressure wire and arterial physiological detector which are produced by St. Jude Medical.~IMR = Pd ∙Tmn"
45607129|NCT02315807|Device|transcranial direct current stimulation|
45607130|NCT03475381|Drug|Ivacaftor+lumacaftor|1 year follow-up after initiation of ivacaftor+lumacaftor
45607131|NCT04531995|Device|CANKADO PRO-React Onco|CANKADO PRO-React Onco is approved as class I medical device within the European Union (registration number DE /CA59 /371/2020-R/Hd) and is compliant with the FDA classification for Mobile Medical Devices (2015) Appendix B. The purpose of CANKADO PRO-React Onco is to be an automated digital support for patients to help them decide how urgent it is to contact the attending physician based on the symptoms they independently record in the system. It supports patients with cancer under systemic, anti-tumor or anti-hormonal therapy in adjuvant, neoadjuvant, post-neoadjuvant or palliative situations. It is unsuitable for patients undergoing radiotherapy, cell and gene therapy, surgical procedures or alternative healing methods.
45607132|NCT02315963|Other|Performance Feedback|Performance Feedback regarding the patients efforts and accomplishments during the patients stay in the rehabilitation clinic, an expected average of 6 weeks. The data available about the patients progress will be analysed and processed to create a visual illustration shown to the patient on a daily bases.
45607133|NCT05389891|Other|Hemoglobinopathy Nursing Program|"Hemoglobinopathy Nursing Program is more informative for Groupe 1 than Group 2"
45607134|NCT03855111|Other|Standard Acupuncture / Moxibustion|Standard (Fixed) Active Acupuncture / Moxibustion protocol aimed at reducing lower limb neuropathic pain/discomfort.
45607135|NCT03855111|Other|Individualized (Tailored) Active Acupuncture / Moxibustion|Individualized (tailored) protocol Acu/Moxa - Active. Acu/Moxa prescription based on TCM assessment. Protocol aimed at reducing lower limb neuropathic pain/discomfort.
46066691|NCT04078360|Behavioral|Face to face Brief Intervention|The intervention will consist of the participants receiving the BI based on the WHO Mental Health Gap Action Programme (mhGAP) intervention from a trained researcher. The BI will be conducted over a single session (5-10 mins).
46066692|NCT04078360|Behavioral|BI leaflet intervention|The intervention will consist of an educational BI leaflet consisting of health information on alcohol consumption, and tips to manage and reduce drinking.
46066693|NCT00765427|Drug|QLT091001|7-day repeated dose
46066694|NCT00605228|Drug|MOVIPREP|2L Drug
46066695|NCT00605228|Drug|COLOPEG|4L Drug
46066696|NCT00765505|Behavioral|Exercise Group|Sixteen week intervention where subjects will be progressed to four days per week for 45 minutes per session, 180 minutes minimum per week, of moderate intensity supervised exercise.
45607136|NCT02316041|Procedure|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
45607137|NCT02316041|Device|ReLEx® (SMILE)|
45607138|NCT03419221|Procedure|PET/CT Positron emission tomography (PET) using small radiotracers, a special camera and a computer to evaluate organ and tissue functions|"Open-label randomized controlled superiority trial in patients with SAB without infective endocarditis at the time of inclusion comparing whole-body PET/CT in arm A and routine care with performance of imaging studies according to anamnesis and clinical symptoms in arm B. To demonstrate that PET/CT is associated with a 20% higher frequency of detection of DFI during SAB, the inclusion of 145 patients in each arm is required.~Randomization will be stratified on centre and SAB setting of acquisition (healthcare vs community)."
45607139|NCT03419221|Other|Patients' routine care with performance of explorations based on anamnesis and clinical symptoms|Patients' routine care with performance of explorations based on anamnesis and clinical symptoms
45757368|NCT04386577|Drug|fish oil|Eligible participants were assigned by chance to one of four groups: (1) daily vitamin D3 and omega-3; (2) daily vitamin D3 and omega-3 placebo; (3) daily vitamin D placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. At baseline, year 2 and year 4 of the trial, a subcohort of 1,054 VITAL participants living within driving distance of Boston, Massachusetts received detailed in-clinic health assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. During CTSC visits, participants have a clinical exam, including measurement of height, weight, other anthropometrics, blood pressure, and physical performance. They also provide fasting blood and urine samples, and undergo 2-hour oral glucose tolerance testing, lung function testing (spirometry), electrocardiograms, bone mineral density testing, 2D-echocardiography, and assessments of thinking and mood.
45757369|NCT04766411|Other|Unresisted sprint training|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
45757370|NCT04766411|Other|Resisted sprint training with load equal to 10% of body weight|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
45757371|NCT04766411|Other|Resisted sprint training with load equal to 20% of body weight|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
45757372|NCT04766411|Other|Control trial|Participants will not perform any sprint training protocol
45757373|NCT05686694|Other|Video Education|"Sharing of Planned Education Videos on Instagram In this research, the platform where planned video education will be shared was determined as Instagram, which is the most used social media platform by pregnant women. In the Instagram user name @ogttegitim account, 6 education videos that will be created and shared."
45757374|NCT04270669|Biological|intravitreal injection of RC28-E 0.5mg|The patient received one treatment of RC28-E 0.5mg in the test group
45757375|NCT04270669|Biological|intravitreal injection of RC28-E 1.0mg|The patient received one treatment of RC28-E 1.0mg in the test group
45757376|NCT04270669|Biological|intravitreal injection of RC28-E2.0mg|The patient received one treatment of RC28-E 2.0mg in the test group
46066697|NCT00765505|Behavioral|Health Education Group|Sixteen week intervention. This group will not receive specific exercise education or prescription but will be asked to participate in biweekly health education sessions
46066698|NCT02584582|Drug|Liraglutide|
46066699|NCT02584582|Drug|Exenatide|
45607140|NCT04454983|Device|Lipiflow Thermal Pulsation System|The LipiFlow Console provides the user interface and control elements of the system, including all software, algorithms and control elements. The Activator, a single-use sterile device, delivers automated therapeutic energies to each meibomian gland. Its contoured design vaults the cornea and protects the eye allowing a maximum therapeutic temperature of 43 degrees Celsius to reach glands from the inner eyelid. Insulation protects the cornea from exceeding a safe 39.5 degrees Celsius, while a pressure feedback loop sends pulsed sequences to expel blockages. Force equalization protects the globe from pressure transmission by focusing energy only on the eyelid. Delivered through the LipiFlow Activator, Vectored Thermal Pulse™ technology applies a combination of heat and pressure to the inner eyelid to safely remove gland obstructions and stagnant gland content. Therapeutic motion provides proximal-to-distal peristalsis to clear gland contents.
45607141|NCT04454983|Device|iLux System|The iLux™ System is used to apply localized heat and pressure to a patient's eyelids. The system consists of a handheld instrument coupled to a single-use, sterile disposable component that is positioned to bridge the eyelid. The iLux device allows view of the eyelid through a magnifier, then warms the eyelid to 40 to 42˚C, then force-limited compression is applied manually to express the melted meibum from obstructed glands. Warming is accomplished using light energy emitted from LEDs in the Instrument. The LEDs are located behind a clear window on the open end of the Shroud. Two wavelengths of light are used: lime-green (568 nm) and near-infrared (850 nm). A mechanism in the Instrument allows the operator to apply pressure to the eyelid by controlling the movement of the Outer Pad using finger pressure applied to the Compression Control button. The force applied to the Compression Control is measured by a sensor in this mechanism.
45607142|NCT04462757|Drug|Anakinra 100Mg/0.67Ml Inj Syringe|100 mg interleukin-1 receptor antagonist (r-meth-Hu-IL-1Ra), anakinra; marketed as Kineret® in 0.67 mL prefilled syringe for single use
45607143|NCT04535505|Diagnostic Test|Detection pathogenic pertussis by cross primer constant temperature amplification (CPA) and drug resistant genes of erythromycin by CRISPR technology|This is an observational study and there are no interventions. The purpose of the study is to compare the accuracy （including sensitivity and specificity）of the new CPA platform based on CRISPR technology detection method and the gold standard in detecting pertussis patients.
45607144|NCT04462679|Other|COMMIT mHealth application|We will develop Community-based mHealth Motivational Interviewing Tool (COMMIT) using iterative design and testing with frequent, structured input from the key stakeholders: community health workers (CHWs), their supervisors and youth living with HIV (YLWH).The tool will be used by community CHWs in Achham, Nepal to: 1) obtain decision-support to deliver motivational interviewing (MI) for patients in their communities, and 2) capture consented audio recordings of client interactions for review and feedback by their supervisors, allowing CHWs to maintain MI skills beyond the initial training period.
45607145|NCT02522689|Procedure|Endoscopic kidney stone surgery|Ultra-mini PCNL will be performed.
45607146|NCT02522689|Procedure|Endoscopic kidney stone surgery|Micro PCNL will be performed.
45607147|NCT04534101|Behavioral|Virtual Reality Mindfulness|This study is designed to test the feasibility, acceptability and effectiveness of VR mindfulness in patients as they undergo various medical therapies to treat their acute or chronic conditions.
45607148|NCT02320799|Behavioral|interpersonal psychotherapy|Interpersonal psychotherapy is an evidence based, structured, brief psychotherapy which improves relationships in order to improve mood and reduce anxiety
45607149|NCT02320799|Behavioral|treatment as usual|Clinic psychosocial treatment as usual
45607150|NCT04934943|Diagnostic Test|mini_FC|100 ml of Crystalloids infused over 1 minute - data recording and new baseline - FC 4 ml/kg in 10 minutes - data recording
45607151|NCT05037409|Drug|PF-06823859|low dose or high dose intravenous infusion
45607152|NCT05037409|Drug|Placebo|Intravenous infusion
45607153|NCT03498599|Behavioral|Novelty facilitated extinction|In the novelty-facilitated extinction design, the aversive outcome (i.e., mild unpleasant electrical pulse) is omitted and replaced by a low volume auditory tone.
45607154|NCT03498599|Behavioral|Standard Extinction|During standard fear extinction the expected aversive outcome is omitted.
45757377|NCT05233293|Procedure|Spyglass + RFA|SpyGlass direct Vision guided RFA
45757378|NCT05233293|Procedure|Cytobrush + RFA|After Cytobrush ,taking RFA through ERCP
45757379|NCT03373604|Drug|18F-MK-6240|18F-MK-6240 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
45757380|NCT03373604|Procedure|Lumbar Puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
45757381|NCT00755131|Other|Exercise-based Cardiac Rehabilitation program|Trained patients attend the exercise training protocol for 6 months on hospital ambulatory-based regimen 3 times/week. Training sessions are supervised under continuous electrocardiography monitoring by a cardiologist, a physiotherapist and a graduate nurse. Each session is preceded by a 5-min warming-up and followed by a 5-min cooling-down. Exercise is performed for 30 min on a bicycle ergometer with the target of 60-70% of the peak oxygen consumption achieved at the initial symptom-limited cardiopulmonary exercise test. Exercise protocol is performed with a gradual increase in exercise workload until the achievement of the predefined target.
45757382|NCT05680454|Biological|Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)|For Low-dosage group, a 3-dose regimen administered at months 0, 2 and 6. For Mid-dosage group, a 3-dose regimen administered at months 0, 2 and 6. For High-dosage group, a 3-dose regimen administered at months 0, 2 and 6.
45757383|NCT05680454|Biological|Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine|A 3-dose regimen administered at months 0, 2 and 6.
45757384|NCT04944927|Other|Recording of clinical parameters and electrocardiogram parameters|Retrospective recording of demographic information (age, sex, age at diagnosis), genetic information, cardiological information, pharmacological treatments, electrocardiogram data. All above data will be deidentified.
46066700|NCT02584582|Procedure|Liquid meal test|
46066701|NCT02584582|Other|No drug (Baseline day)|
45444791|NCT02053558|Drug|TAP BLOCK with ropivacaine|TAP block group will receive bilateral TAP blocks using ultrasound guidance with 0.5% ropivacaine 15mL on each side and a bolus and infusion of normal saline after induction of anesthesia.
45607155|NCT03130543|Dietary Supplement|Rice cereal|Standard formula thickened with rice cereal
45607156|NCT03130543|Dietary Supplement|Enfamil AR|Enfamil AR formula
45607157|NCT03500783|Drug|Nitric Oxide|40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during coronary artery bypass grafting.
45607158|NCT03500783|Other|Standard CPB|Standard protocol of delivery of air gas mixture to the cardiopulmonary bypass circuit
45607159|NCT03353233|Drug|Ropivacaine|Local anesthetic (numbing drug)
45607160|NCT03353233|Procedure|Interspace Between the Popliteal Artery and Capsule of the Knee (iPACK) Block|An ultrasound guided nerve block using a numbing medication called ropivacaine that numbs the nerves to the back of the knee.
45607161|NCT03353233|Drug|Saline|An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
45607162|NCT02320877|Device|Mandibular Advancement Device (Somnomed Flex)|The SomnoDent Flex™ MAS is a custom-made, titratable MAS that is validated in randomized controlled trials described in literature
45607163|NCT03323281|Other|Neuropsychological assessments|Maintenance of approximately 1h30 with a neuropsychologist or a physician trained in neuropsychological assessments in Diabetic Type 1 or Type 2 with foot wound hospitalization and Diabetic Type 1 or Type 2 without a foot wound or antecedent Of foot wound (podological risk grade 0 to 2, including foot of Charcot)
45607164|NCT03500705|Device|Mirror Therapy|Mirror Therapy involved the patient sitting on a chair at a table with a standard mirror placed on the table in the mid-sagittal plane between both arms, with the reflective side of the mirror facing the non-affected arm. The patient is instructed to observe the reflection of the non-affected arm during the sessions. The patient was not given any instruction on the use of the affected arm.
45607165|NCT03500705|Other|Cross-Education of Strengthening.|Cross-education of strengthening involves training one side of the body with the intention of producing strengthening gains on both sides of the body. In this case the strengthening was done on the non-affected arm of each stroke patient.
45607166|NCT04455607|Behavioral|perturbation training|A Randomized control trial we will compare two perturbation motor learning paradigms with different challenge level of the practice condition (i.e. blocked practice vs random practice). According to motor learning theory we hypothesize that a) healthy older adults will benefit more from random practice. The purpose of this stage is to investigate the effects of task practice order (random vs blocked) on motor learning (i.e. responding to perturbations during walking) in older adults. According to motor learning theory we hypothesize that a) healthy older adults will benefit more from the random motor learning approach as compared to using blocked practice.
45607167|NCT03052855|Other|Magnetic Resonance Imaging (MRI) and biological samples|Participants will have to do a MRI and biological samples.
45444792|NCT03809949|Drug|Fentanyl Opioid anesthesia|To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
45607168|NCT02317835|Device|DFUPS|The DFUPS device is a two-camera instrument for capturing images of feet
45607169|NCT03498365|Behavioral|MCDA|Experimental decision support
45607170|NCT03498365|Behavioral|Delphi|Standard support
45607171|NCT05234593|Dietary Supplement|EmpowerPlus Lightning Sticks|multinutrient supplement containing vitamins, minerals, amino acids and antioxidants taken one Stick daily by dissolving the powder on or under the tongue
45607172|NCT02318069|Biological|FSME-immune|0.5 ml im as scheduled in the 5 arms
45607173|NCT05167903|Other|Normal Diet|All praticipants in ND will perform supervised and monitored RT three time per week for the 10 weeks of intervention. The ND group will consume all meals between 6 am - 10 pm (16 h eating window with 8 h of fasting, ad-libitum).
45607174|NCT05167903|Behavioral|Time-restricted eating|All participants in TRE will perform supervised and monitored RT three time per week for the 10 weeks of intervention. Participants in the TRE group will be instructed to consume all meals between 12pm to 8pm, and to avoid consumption of food or caloric drinks during the fasting period (8 h eating window with 16 h of fasting).
45607175|NCT02321033|Dietary Supplement|soft drinks|soft drinks with palatinose and maltodextrin
45607176|NCT01322971|Drug|Metronidazole|Metronidazole 500mg orally twice daily for seven days
45607177|NCT01322971|Drug|Placebo|Placebo will be administered orally twice daily for seven days
45607178|NCT02318147|Procedure|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor
45607179|NCT02318147|Drug|The traditional treatment|the traditional treatments according to associated guidelines
45757385|NCT04928703|Drug|Ketamine|Ketamine IV administration
45444793|NCT03809949|Drug|Saline Nonopioid anesthesia|To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
45444794|NCT03561454|Device|IORT|Intra-Operative Radiation Therapy
45607180|NCT04454281|Drug|Naloxone Hydrochloride 0.4 MG/ML|Drug will be topically applied to the corneal surface then study evaluations will ensue.
45607181|NCT03498053|Behavioral|Marlboro|Participants smoke Marlboro during the first experimental day, ad libitum.
45607182|NCT03498053|Behavioral|Marlboro Prime|Participants smoke Marlboro Prime during the second experimental day, ad libitum.
45607183|NCT03498053|Behavioral|Marlboro Prime (ventilation holes taped)|Participants smoke Marlboro Prime (filter ventilation holes taped) during the third experimental day, ad libitum.
45757386|NCT04278950|Drug|Povidone-Iodine|For the PVP-I group, the final concentration of available iodine in the solution will be 0.01%, (from diluting 10% PVP-I solution), as previously demonstrated to be below ciliotoxic levels of 1.25% and greater than 0.01% which is the lower limit of active potency.
45757387|NCT04278950|Drug|Placebos|The placebo will be 2.5mL of saline with brown food coloring.
45757388|NCT00755755|Drug|PGL4001 (ulipristal) and iron|tablets
45757389|NCT00755755|Drug|PGL4001 matching placebo and iron|tablets
45757390|NCT00755755|Drug|PGL4001 (ulipristal) and iron|Tablets
45444795|NCT03807622|Device|EV1000NI Clinical Platform: Noninvasive Hemodynamic Monitoring utilizing ClearSight System|EV1000NI Clinical Platform: Noninvasive Hemodynamic Monitoring utilizing ClearSight System
45444796|NCT03810027|Diagnostic Test|Bladder diary|3-day bladder diary
45444797|NCT02053636|Drug|lucitanib|
45607184|NCT05389579|Device|electric blanket|"After the patients were taken to their own beds after surgery, the researcher covered them with a wool blanket from the top of clavicle to the bottom of their feet, put the sphygmomanometer on the arm without an IV line, positioned the sphygmomanometer so that the instrument panel was on the blanket and measured the patients' blood pressure. Then, the electric blanket was operated at the warm level for the experimental group, and it was turned off and unplugged when their body temperature reached 36.0 °C."
45607185|NCT02318225|Drug|Misoprostol|"Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
45607186|NCT02318225|Drug|Placebo|"Placebo will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
45444798|NCT04577079|Device|Evaluation of the need of emergency medical services|The main aim of this study is to validate the use of IPFM in a hospital setting by evaluating the association of IPFM output with 1) clinical urgency and severity of the conditions (using Emergency Severity Index [ESI], an international triaging protocol for emergency units, and an assessment by triage nurse); and 2) actual diagnoses made by the hospital doctors. The objective is also to assess the correlation of IPFM output with redirection or referral to various specialties
45607187|NCT03500627|Drug|OP-101|Intravenous Injection of OP-101 in healthy volunteers.
45757391|NCT05410808|Other|Questionnaires and physical examination|Patients will be examined and demographic data, disease characteristics will be recorded. Health Survey Questionnaire Short Form 36 , coronavirus disease 2019 anxiety scale ,Obsession with coronavirus disease 2019 scale, and Resilience scale for adults will be answered
45607188|NCT05095597|Procedure|Injection of hUC-PRP by hysteroscopy|PRP previously frozen at -80ºC (6±2 mL) will be defrozen after checking donor-receptor compatibility and viral safety study. PRP (4±2 mL) will be activated with 5% CaCl2 and immediately injected (4±2 mL) in the sub-endometrial wall via hysteroscopy.
45607189|NCT05095597|Drug|Oestraclin|Patients will receive estrogenic therapy, based on estradiol, for 10±2 days (oestraclin, topical cream, 5µg daily for 10±2 days).
45607190|NCT05095597|Procedure|Umbilical cord blood collection|The SCU will be collected using a blood collection bag containing anticoagulant. This step will be performed by the medical and nursing staff of the obstetrics service of the HUP La Fe. The blood collection bags will be the following, or similar: Cord Blood Collection Bags from MACOPHARMA; CPD Umbilical Cord Bag from GRIFOLS.
45607191|NCT05095597|Procedure|Endometrial biopsy|Biopsies will be taken by specialized medical personnel by aspiration with an intrauterine cannula (pipelle or cornier). Samples will be collected in 15 mL tubes (or in a larger capacity container if needed) containing PBS or RNA later until frozen at -80ºC, at the IVI Foundation facilities. Prior to freezing (in a 1.8-2 mL cryotube) the PBS will be removed and the sample cleaned in a Petri dish if needed.
45757392|NCT05410808|Other|Questionnaire|Demographic data will be recorded. Health Survey Questionnaire Short Form 36 , coronavirus disease 2019 anxiety scale ,Obsession with coronavirus disease 2019 scale, and Resilience scale for adults will be answered
45757393|NCT05676398|Diagnostic Test|Ambulatory rhythm recording|Ambulatory rhythm recording by use of a wearable patch-type device.
45757394|NCT05410574|Behavioral|Family-based Behavioral Weight Loss Treatment|The treatment includes: 1) the Traffic Light Eating Plan; 2) the Traffic Light Activity Program, 3) a variety of behavioral change strategies e.g., stimulus control, self-monitoring, planning, goal setting and 4) facilitation of support in the family and peer environments to optimize the durability and generalizability of health habits across multiple social and environmental contexts
45757395|NCT05672888|Drug|Jaktinib|100mg of Jaktinib (given as two 50mg tablets) administered orally Twice daily(BID) with best available treatment.
45607192|NCT03497819|Biological|CARTmeso CART19|Autologous chimeric antigen receptor T cells with murine scFv, 41BB co-stimulatory domain and CD3ζ signaling domain targeting mesothelin or CD19
45757396|NCT05672888|Drug|Placebo|Placebo (given as two placebo tablets) administered orally BID with best available treatment.
45757397|NCT03308474|Other|Routine care as per site standard.|Physician's choice according to patient's needs.
45757398|NCT05686616|Drug|Dapagliflozin Propanediol Hydrate 12.3 mg|Forxiga 10mg will be added on the conventional treatment for SGL2 inhibitor group.
45757399|NCT02292537|Drug|Nusinersen|Administered by intrathecal (IT) lumbar puncture (LP) injection
45757400|NCT02292537|Procedure|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
45757401|NCT05686538|Other|iDLI|TCRab/CD19 depleted DLI 14 days after allogeneic stem cell transplantation. Targeted cell doses: >10e7 NK cells/kg and >10e6 TCRgd cells/kg
45757402|NCT00674765|Drug|Seroquel|400 mg/day
45757403|NCT00674765|Drug|Placebo|400 mg/day
45757404|NCT04761068|Device|VEST|Venous External Support for vein grafts in CABG
45757405|NCT05394896|Device|ACUMEN (Edwards Lifesciences, Irvine, USA)|ACUMEN sensor generates HPI index which should predict hypotension. Based on HPI index, Eadyn and dP/dTmax values anaesthesia should somministrate liquid or drugs to prevent hypotension.
45757406|NCT05394896|Device|Invasive Blood Pressure|Invasive Blood Pressure permits continue monitoring of blood pressure (routine standard for kidney transplant surgery)
45757407|NCT00676013|Procedure|Integra|Grafting using the Commercial product Integra as a skin substitute over full thickness burn following excision.
45757408|NCT00676013|Procedure|AlloDerm|Grafting using the commercial product AlloDerm as a skin substitute
45757409|NCT00676013|Procedure|Homograft|Grafting using homograft as a skin substitute
45607193|NCT02318381|Procedure|Dissection of the superior transverse scapular ligament|After treatment of the rotator cuff tear, the arthroscopic procedure will also proceed with the dissection of the superior transverse scapular ligament, in order to release pressure from the suprascapular nerve.
45607194|NCT03497741|Diagnostic Test|procalcitonin measurement|For each patient were blood cultures were taken, a procalcitonin level was determined
45607195|NCT01378429|Drug|ciclesonide nasal aerosol|ciclesonide nasal aerosol (74 mcg)
45607196|NCT01378429|Drug|Placebo|Placebo
45607197|NCT03500393|Behavioral|Remotely Supervised Exercise (REM)|REM is designed to follow in the tradition of stepped care behavioral interventions. As such, participants who are successfully engaging in the prescribed exercise are provided minimal and automated encouragement and praise. Participants who demonstrate less adherence are given interventions that are tailored in content and intensity, depending on the level of success and the nature of the barriers to success
45607198|NCT03500393|Behavioral|Unsupervised Exercise (UNSUP)|The control condition represents a minimalist intervention that could occur in any setting: (1) enthusiastic provision on an exercise prescription and (2) provision of a fitness device (i.e., the Garmin VivioActive) that can help participants track their exercise engagement. Participants are instructed in how to use the device to track their adherence to the exercise prescription.
45911310|NCT02006303|Procedure|Prostatic artery embolization|Prostatic artery embolization consists of gaining access into the patients arterial system via a common femoral artery puncture using a small needle and sheath. Once the access is established, a micro-catheter is navigated through the arterial system using X-ray guidance into the arteries feeding the prostate. There, small polyvynil alcohol plastic beads are injected to block the blood flow to the prostate. By doing so, the prostate undergoes an ischemic injury and there is reduction in gland size and relief of obstructive symtpoms.
45607199|NCT01599754|Drug|Axitinib|Axitinib 5 mg twice daily
45607200|NCT01599754|Drug|Placebo|Placebo twice daily
45607201|NCT05400343|Procedure|Standard care (control group)|"Following 24 hours from admission to the ICU, the standard care will be continued according to conventional ICU protocols~The mean fluid intake will range from (2-3L per day) targeting zero or slightly negative balance (up to - 300ml). Various parameters will be used to attain this goal based on case-by-case clinical judgment."
45607202|NCT05400343|Procedure|US-guided ﬂuid management (active group)|Within 24 hours from admission to the ICU, IVC and lung sonography will be performed every other day and according to their measurements, the volume of fluid therapy will be adjusted.
45607203|NCT05400343|Other|Standard ICU Care|All patients will receive the usual care for 24 hours according to ICU policies. The main target is to maintain an adequate intravascular volume and good urine output. The mean fluid intake will range from (2-3L per day) targeting zero or slightly negative balance (up to - 300ml). Various parameters will be used to attain this goal based on case-by-case clinical judgment. Lung sounds, heart rate, blood pressure, temperature, urine output, Lactate, haemoglobin, haematocrit, serum urea, creatinine, sodium, potassium, chloride, and bicarbonate values
45607204|NCT02321189|Drug|LONGEVINEX|let everyone of the participants oral 1 capsule containing 100 mg LONGEVINEX
45607205|NCT02321189|Drug|placebo|let everyone of the participants oral 1 capsule containing 100 mg placebo
45607206|NCT05400187|Behavioral|Body composition assessment and smart-phone based counselling|"As for the body composition assessment, body fat and muscle thickness, body fat percentage and distribution will be measured and a brief face-to-face counseling soon after the measurement will be implemented to the participants. Body assessment were measured by the InBody 270 (Biospace, Seoul, Korea) device, which provides a convenient way of accurate body fat measurement comparable with those obtained using air displacement plethysmography (ADP) (about 90% precision).~As for the Whatsapp-based counselling and communication session, qualitative dietary counselling will be offered every two weeks through the Whatsapp. One session contains 15 minutes, including the topics like making a balanced diet (55 % glucose, 30 % lipids and 15 % proteins), diversifying food intake, dietary advices and recommendations in healthy eating behaviors (e.g., eat slowly, eat at a regular time, avoid to skip a meal, drink at least 1.5 L of water each day)."
45607207|NCT02321267|Drug|ranibizumab, aflibercept, pegaptanib, verteporphin|ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
45607208|NCT05389501|Behavioral|Social policy intervention to support women of reproductive years|"The project team will attempt to address this challenge by delivering the following interventions through social workers in underdeveloped primary healthcare settings to promote maternal and child health:~Developing a database on a digital app of participants in the study and use the data for development of an Index for Maternal Health and Wellbeing~Conducting a Community Assessment Needs~Conduct a psychosocial needs assessment~Develop interprofessional health workforce collaboration~Measure basic clinical health indicators~Provide health awareness and literacy training to participants"
45607209|NCT02321345|Other|Palliative Care Support|Palliative care meetings Quality of Life Assessments
45607210|NCT05165953|Other|no intervention|there was no intervention in the study
45607211|NCT02318459|Other|high intensity interval training-HIIT|HIIT 4 times a week, 30 minutes duration
45607212|NCT02318459|Other|Traditionnal group rehabilitation|Traditionnal group rehabilitation, 3 times a week, 1 hour duration
45607213|NCT05399797|Other|Educational training|Pharmacists in the intervention group will given detailed online educational training on how to recognize and manage acute uncomplicated urinary tract infections in adults.
45757410|NCT00676013|Procedure|Autograft|grafting using patients own skin from a separate donor site
45911311|NCT02006316|Procedure|Microsurgical subinguinal varicocelectomy|
45911312|NCT02006329|Device|acupuncture|
45911313|NCT02006355|Drug|Ropivacaine|
46066702|NCT05380232|Behavioral|Leisure-time physical activity|Self-reported leisure-time physical activity, categorized as; zero (reference), >0-7.49 MET-hrs/week, 7.5-14.9 MET-hrs/week, or ≥15 MET-hrs/week.
45444799|NCT04574895|Other|Hematology Review|VTE study team will review VTE risk percentages provided via automated report daily on weekdays and approach the primary team directly if the patient is appropriate for clinical antithrombotic interventions.
45444800|NCT02053714|Behavioral|Diabetes self-management and education|
45607214|NCT04462445|Drug|Pazopanib|
45607215|NCT04764370|Device|WeFlow-Ach Moduler Embedded Branch Stent Graft System|The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.
45607216|NCT05389267|Drug|Kinezodianone R hydrochloride|Eyedrops
45607217|NCT05389267|Drug|Placebo|Placebo
45607218|NCT02318537|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
45607219|NCT02318537|Drug|Placebo Solution|A matching oral solution containing no cannabidiol.
45607220|NCT05399719|Other||no intervention
45607221|NCT05165797|Biological|platelet activation factors|platelet activation factors of subject blood
45607222|NCT02318615|Procedure|Immediate Axillary Plasty|Immediate Axillary Plasty would be performed to reduce the formation of scar in the axilla.
45607223|NCT04462211|Procedure|Implementation of management pharmacological protocol of constipation|"first 48 hours:~polyethylene glycol 3350 (about 17 grams) 1 every 8 hours enterally.~Patients who have vomiting and / or gastric residue greater than 500 mL (in a timely measurement every 6 hours) will also be given domperidone 10 mg every 8 hours intravenously.~Patients who have excessive abdominal distension will be administered in addition, levosulpiride 25 mg every 8 hours intravenously.~48 hour evaluation:~Patients who do not have bowel movements will be administered lactulose or sodium phosphate enema.~For patients who do not have a bowel movement, administration of neostigmine intravenously or of naloxone enterally will be evaluated.~Every patient who uses one or more prokinetics will have an electrocardiogram.~Any patient who has bowel movements during management, doses of polyethylene glycol 3350 will be adjusted according to the daily goal of bowel movements, the days of treatment of the prokinetics will be adjusted, for a maximum of 5 consecutive days."
45607224|NCT04462211|Procedure|Implementation of bundle of prevention and non-pharmacological management|"Bundle of prevention:~Start early enteral nutrition.~Optimize and / or decrease opioid doses.~Start early mobilization.~Non-pharmacological management bundle~Select laxative and/or prokinetic/s to manage constipation.~Optimize and / or decrease doses of opioids and sedatives.~Start early mobilization.~Pharmacological reconciliation."
45607225|NCT04642261|Drug|Empagliflozin 10 MG|Empagliflozin 10mg daily
45607226|NCT04642261|Drug|Placebo pills|Identical in appearance to empagliflozin 10mg daily
45607227|NCT05399407|Other|Health e-coaching|Management of overweight / obesity
45607228|NCT02318771|Radiation|Radiation Therapy (RT)|Undergo RT
45607229|NCT02318771|Drug|MK-3475|Given IV
45607230|NCT03149081|Drug|Boswellia|Boswellia is an extract from frankincense
45607231|NCT03500003|Other|Acute milk intake|Food matrix: milk
45607232|NCT03500003|Other|Acute Yogurt intake|Food matrix: yogurt
45607233|NCT04454749|Diagnostic Test|Blood test|Mesurement of E2, P4, LH, FSH hormones
45607234|NCT04454749|Diagnostic Test|Ultrasound|Follicular measurement and endometrium measurement
45607235|NCT02318849|Behavioral|Web intervention|interactive website using social media and gamification
45607236|NCT02318927|Device|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement. Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant. Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab. Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
45607237|NCT04955197|Diagnostic Test|exfoliated cytology|Micronuclei (MN) are small chromatin bodies in the cytoplasm formed by chromosome fragments or whole chromosomes that fail to be included in the nuclei during cell division. They are considered as a sensitive indicators of genetic damage. They are usually found in the basal cells of epidermis and are shed as exfoliated cells on maturation. Hence micronuclei assay can be used as monitoring of genetic damage, as it is increased in oral neoplastic conditions. Consequently, detection of micronuclei in exfoliated cells indicates an increased risk for cancer
45607238|NCT04462913|Other|no intervention|This is an observation study, with no intervention
45757411|NCT05567601|Drug|DOXIL/CAELYX|40 mg/m2 as a 90-minute IV infusion via a central venous catheter or peripheral vein
45607239|NCT04936399|Biological|Nivolumab|Participants will receive Nivolumab after prior chemotherapy as part of an early access to medicines scheme (EAMS) program in the United Kingdom (UK)
45607240|NCT02319083|Procedure|Coronary artery bypass surgery|Patients will undergo coronary artery bypass grafting
45607241|NCT02319161|Drug|Calcium channel blocker and beta blocker|The patients in which systolic blood pressure increased to 150 mmHg and above following tourniquet inflation and in which a bolus dose of calcium channel blocker 10 mg (Diltizem, Mustafa Nevzat İlaç Sanayi Aş) (Group I) or beta blocker 0.5mg/kg (Brevibloc, Eczacıbaşı İlaç Sanayi Aş) (Group II) were administered intravenously constituted the study groups.
45607242|NCT02138110|Device|Neuro-Spinal Scaffold|Implantation of a Neuro-Spinal Scaffold into the epicenter of the post-irrigation contusion cavity during open spine surgery
45607243|NCT02319239|Radiation|Fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
45607244|NCT02319239|Radiation|hypofractionated|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months
45607245|NCT02319239|Radiation|stereotactic fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months
45607246|NCT02321579|Dietary Supplement|vitamin B-6|50 mg/d
45607247|NCT02321579|Dietary Supplement|Glutathione|500 mg/d
45757412|NCT00755911|Biological|Tissue Repair Cells (TRC)|30-50 ml of bone marrow is aspirated from subject and processed into TRC autologous bone marrow tissue graft. 10ml of TRC will be absorbed onto gelfoam carrier and placed in extraction socket.
46066703|NCT00765583|Drug|Restylane|Treatment of the nasolabial folds with Restylane at Day 0/Baseline, Month 4.5, Month 9 and Month 18.
45757413|NCT00755911|Device|Control|Control subjects only receive standard gelfoam carrier. It promotes healing after tooth extraction
45607248|NCT02321579|Dietary Supplement|Dextrins|50 mg/d
45607249|NCT04852120|Other|No intervention|Compound Sodium Picosulfate Granules administered by the patient prior to X-ray examination, endoscopy or surgery when judged clinically necessary in accordance to usual practice consistent with the local prescribing information.
45607250|NCT03499925|Behavioral|cognitive behaviors|Telephone consultation effectiveness and cognitive behaviors
45607251|NCT03499925|Behavioral|Telephone consultation|Telephone consultation effectiveness and cognitive behaviors
45607252|NCT02321657|Other|iPad app containing art, music and games|An iPad app that takes demographic information on a child and suggests suitable art, music and games for use by the anaesthetist and nurse to distract them during anaesthetics
45607253|NCT02321657|Other|Toys, books and games|Games, books and toys used to distract
45607254|NCT01584934|Drug|Sodium oxybate|Treatment is started and continued for 6 weeks at patient's home. Patients receive 3g/night during the first week, and 4,5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4,5 g/night for 1 week, followed by 3g/night for 1 week. The next 2 weeks, patients are not treated.
45607255|NCT01584934|Drug|Placebo|Placebo treatment is started and continued for 6 weeks at patient's home. Patients receive 3 g/night during the first week and 4.5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4.5 g/night for 1 week, followed by 3 g/night for 1 week. The next 2 weeks, patients are not treated.
45607256|NCT03109691|Drug|bupivacaine|group 1
45607257|NCT03109691|Drug|Dexamethasone|group 2
45607258|NCT03109691|Device|ultrasound|in all groups
45607259|NCT03499847|Behavioral|standardised face-to-face counselling session|the healthcare provider will conduct a standardised face-to-face counselling session guided with subjects guided by a check-list of topics to cover regarding the Advanced Medical Directive.
45607260|NCT03499847|Behavioral|advanced medical directive pamphlet|A standardised pamphlet containing information about the Advanced Medical Directive produced by the Ministry of Health, Singapore.
45607261|NCT01575730|Procedure|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 460 mg/m², duration: 30 minutes, temperature 37°C
45757414|NCT05664932|Biological|Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001|Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
45757415|NCT05664932|Biological|ZF2001|Intramuscular injection of ZF2001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
45757416|NCT05565339|Device|PMEIs|To evaluate audiological outcomes three months (± four weeks) post-operatively, the air-bone gap (ABG) will be assessed. The primary objective is to achieve an ABG ≤ 20 dB by more than 50 % of patients after PMEI implantation. To evaluate safety of the devices adverse events will be collected in the time period beginning with implantation until three months (± four weeks) after the implantation. To assess whether implantation of PMEI affects residual hearing pre- and post-operative bone conduction thresholds will be evaluated.
45757417|NCT00676793|Drug|Polyphenon E|Four 200mg capsules daily taken with a meal, for the duration of the study.
45444801|NCT01560273|Device|Aspen Spinous Process Fixation Device|The Aspen device will be placed as posterior fixation to Posterolateral Fusion (PLF)
45757418|NCT04279262|Other|attendance by community first responders for medical emergencies|The investigators will purposively sample patients, relatives, and ambulance staff identified from records of patients who have been attended by a CFR in a rural location in the previous six months. Where possible the investigators will interview patients, relatives, CFRs and ambulance staff attending the same event. GPs will be purposively sampled from rural areas of the ambulance services involved. Investigators will recruit a maximum variation sample of patients (according to age, sex, condition, and ethnicity), ambulance staff (sex, experience, ethnicity and role), CFR (sex, ethnicity, length of experience, skill level) and CFR scheme leads (independent charity and ambulance trust overseen schemes).
45757419|NCT00737737|Drug|MS Contin|
45757420|NCT00737737|Drug|Placebo|
45452231|NCT01167166|Drug|rigosertib|The dose of rigosertib will be 2400 mg/24h as an intravenous continuous infusion over 72 or 120 hours every 2 weeks for 2 cycles then as oral capsules administered at a dose of 560 mg twice daily on a continuous basis.
45607262|NCT01575730|Procedure|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 460 mg/m², duration: 30 minutes, temperature 41°C
45607263|NCT01575730|Drug|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 200 mg/m², duration: 90 minutes, temperature 37°C
45607264|NCT03499769|Procedure|natural orifice|laparoscopic total colon surgery and patients who are removed from the natural orifice and conventional will gather
45607265|NCT03497351|Drug|Nicardipine|The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Nicardipine was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.
45757421|NCT04279418|Dietary Supplement|Mixed functional foods supplementation|In this project, taking the method of random, double blindness and control, participants in the mixed functional foods group will take functional foods with main compositions of ginsenoside, green tea polyphenols and marine collagen peptide for three months. After that, neuropsychological tests and neuroimaging biomarkers will be compared between functional food group and placebo group.
45607266|NCT03497351|Drug|Urapidil|The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Urapidil was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.
45607267|NCT02223754|Device|lotrafilcon B|Soft contact lens to be worn as daily wear, monthly replacement modality.
45757422|NCT04279418|Dietary Supplement|Placebo|In this project, taking the method of random, double blindness and control, participants in the placebo group will take placebo for three months. After that, cognitive changes and neuroimaging biomarkers will be compared between functional food group and placebo group.
46066704|NCT04299958|Other|Patient diary|In the first visit they will be examined by a neurologist with experience in headache disorders and NH diagnosis will be reviewed. Patients will be invited to participate into the study and they will provide and sign informed consent form. They will be instructed and trained to complete the prospective headache diary during 14 days. A follow up visit will be done within 15 to 30 days to review the data and analyze possible sources of bias.
45444802|NCT02052934|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5 cohorts receive 3 doses ranging from 1 mcg to 50 mcg.
45444803|NCT02052934|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5b cohort receive 3 doses of 25 mcg.
45607268|NCT02223754|Device|etafilcon A|Soft contact lens to be worn as daily wear, daily disposable modality.
45607269|NCT02321735|Behavioral|Quality of life questionaire|Patients will participate in a QOL questionaire followed by a phone interview
45607270|NCT03132389|Other|No intervention|All patients included in the study will be offered the same examination and treatment procedure as the patients who are not included. Identical procedures and examinations will be performed in participants and non-participants.
45607271|NCT02319395|Genetic|Blood Sampling and DNA collection|"One blood sampling during the study. A small number (1 to 5) of markers type tag SNPs or coding SNP  (single nucleotide polymorphism, SNP) will be selected for each of the selected genes, for a total of 50 markers (representing 20 to 25 genes). Non-silent coding SNP, that may have a functional effect, will be included as a priority. Genotyping is carried out by the method of genotyping VeraCode Goldengate."
45607272|NCT02321813|Behavioral|quality of life pathway|Quality of life measurement, diagnosis and tailored therapy (pain therapy, psychotherapy, social support, nutrition, stoma care, physiotherapy, fitness)
45607273|NCT02321813|Other|placebo control|Quality of life measurement
45607274|NCT02223364|Drug|Peripheral nerve blocks with Bupivacaine|Subjects received Bupivacaine 0.5% preoperatively, then Bupivacaine 0.2% upon post anesthesia care unit (PACU) arrival via femoral nerve block, then Bupivacaine 0.25% via single-injection sciatic nerve.
45607275|NCT02223364|Drug|Intra articular injection with Ropivacaine|Subjects received an intra articular injection with Ropivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Ropivacaine dose depended upon body weight: 50-74.9 kg: 200 mg, 75-99.9 kg: 300 mg, 100-125 kg: 400 mg.
45607276|NCT02223364|Drug|Intra articular injection with liposomal bupivacaine|Subjects received an intra articular injection with liposomal bupivacaine, a total volume of 120 mL injected in the periarticular structures by the surgeon. Patients weighing 50-125 kg received 266mg of Liposomal Bupivacaine.
45607277|NCT02319473|Other|JAC Registry|patients who received acute reperfusion therapy
45607278|NCT03497273|Drug|Itacitinib|Itacitinib administered orally once daily at the protocol-defined dose.
45607279|NCT03497273|Drug|Corticosteroid|Either oral prednisolone or intravenous methylprednisolone at the investigator's discretion.
45607280|NCT01378975|Drug|Vemurafenib|960 mg oral doses twice daily until disease progression, unacceptable toxicity or consent withdrawal.
45607281|NCT03499535|Behavioral|Radon & Smoking Synergistic|Participants viewed health information detailing the risks of developing lung cancer from exposure to radon gas, smoking, and their synergistic effects. This intervention represents the type of information most commonly presented in radon risk communications.
45757423|NCT05199051|Combination Product|Gemtuzumab ozogamicine - Cytarabine - Gilteritinib|See Arms description paragraph
45757424|NCT04400552|Dietary Supplement|ONS Pre-op + ONS Post-op|Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively and post-operatively up to participants being discharged from the hospital.
45757425|NCT04400552|Dietary Supplement|ONS Pre-op + ONS Post-op + ONS Post-op 3 months|Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively, post-operatively up to participants being discharged from the hospital and an extended oral nutrition supplementation post-operatively up to 3 months.
45607282|NCT03499535|Behavioral|Radon Only|Participants viewed health information detailing the risks of developing lung cancer from radon exposure. No information about the risks for developing lung cancer associated with smoking or its synergistic effect with radon exposure are included.
45607283|NCT03499535|Behavioral|Radon and Smoking Isolated|Participants viewed health information detailing the risks of developing lung cancer from radon exposure and smoking. No information describing the synergistic effects of smoking and radon exposure on lung cancer risk are included.
45607284|NCT03499535|Behavioral|EPA|Health information modeled after the Environmental Protection Agency's (EPA) pamphlet on radon risk.
45607285|NCT03499535|Behavioral|Idaho|Health information modeled after the Idaho Department of Health and Human Welfare's pamphlet on radon risk.
45607286|NCT02321891|Device|NeuroConn DC Stimulator Plus, tDCS|transcranial electrical stimulation intervention with two experimental protocols
45607287|NCT04803604|Behavioral|CASCADE (CAre Supporters Coached to be Adept DEcision partners)|CASCADE (CAre Supporters Coached to be Adept DEcision partners) is a multicomponent, lay coach-led supportive care intervention designed to increase family caregivers' skills in providing decision support to individuals with advanced cancer. In a series of weekly, one-on-one, 15-20 minute, in-person or telephone sessions, family caregivers receive psychoeducation on principles of providing effective social support and decision partnering, decision support communication, and Ottawa Decision Guide training as well as monthly follow-up.
45607288|NCT05165719|Diagnostic Test|Corona-T-test|Corona-T-test - a single-color enzymatic ELISpot kit for the detection of interferon-gamma (IFNɣ), produced by the National Research Center for Hematology aiming detection of SARS-CoV-2-specific T cells
45607289|NCT02321969|Dietary Supplement|GTE (green tea extract)|6 GTE tablets per day. Daily dose is equivalent of 9 cup-of-green tea per day (0.9 g/day GTE, 0.6 g/day epigallocatechin gallate [EGCG]).
45607290|NCT05376709|Dietary Supplement|Short-Term Calorie Reduction|Align with the R-CHOP regimen, patients in the experimental group will first perform water fast 24 hours before (day 0) and during the first day of R-CHOP (day 1) when they receive Rituximab, Vincristine, Doxorubicin, cyclophosphamide, and prednisolone. On day 2, they will resume normal calorie intake until the day before the next cycle of chemotherapy. While each cycle of R-CHOP takes 21 days, most patients will receive a total of 6-8 cycles over four to six months.
45607291|NCT03497195|Diagnostic Test|Screening at community level|comparison of chest x-ray and Xpert Ultra versus CRP and Xpert Ultra for active community based screening
45607292|NCT02222896|Drug|Chlorhexidine Gluconate|2% CHG solution on cloth
45607293|NCT02222896|Other|Vehicle|Excipients of CHG product only
45607294|NCT02222896|Drug|DynaHex-2|2% CHG solution
45607295|NCT05165563|Procedure|Treatment of implant single crown|Digital or Conventional Workflows for treatment of implant single crown and materials used.
45607296|NCT03499457|Drug|Amoxicillin|chalange test of 50 mg, and after an hour 500 mg
45607297|NCT04680403|Other|Exercise|supervised exercise paired with coaching on behavior change techniques over 12 weeks (3 weekly sessions) and will have monthly phone follow-ups and clinic follow-ups after 3 and 6 months.
45607298|NCT03499379|Device|Mirena|A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.
45607299|NCT03499379|Device|Paraguard|A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
45607300|NCT05165407|Drug|Sintilimab|Sintilimab 200mg will be intravenously administered on Day 1 of each cycle
45607301|NCT05165407|Drug|IBI310|IBI310 1mg/kg be intravenously administered on Day 1 of every 2 cycle
45607302|NCT05165407|Drug|Surufatinib|Surufatinib 250mg will be taken orally once daily continuously
45607303|NCT02322203|Dietary Supplement|Niacin Extended Release|Subjects will receive a 2 week supply of the dietary supplement Rugby Extended Release Niacin (250 mg/tablet) Niacin and will be instructed to take 2 tablets per day (500 mg/day) for the first seven days and then increase to 4 tablets per day (1000 mg/day) during the following 7 days. Subjects will then be escalated to 2000 mg/day for 14 weeks.
45607304|NCT02222818|Device|Conducted AF Response (CAFR)|The CAFR algorithm is currently available in the Medtronic market-released devices and intended to promote delivery of CRT pacing during conducted AT/AF episodes.
45607305|NCT02222818|Device|Conducted AF Response Plus (CAFRPlus)|The CAFRPlus algorithm is part of the CRTee feature set. This feature set has a diagnostic element that tracks the loss of effective CRT pacing that is occurring over time, both during normal sinus rhythm (NSR) and during AF. It also has an interventional element (i.e. CAFRPlus) that uses this evaluation of effective CRT pacing to adjust the pacing rate during AF to decrease loss of effective CRT pacing.
45607306|NCT04638751|Drug|Immunotherapy|Checkpoint inhibitor
45607307|NCT04638751|Drug|Chemotherapy|Any form of chemotherapy
45607308|NCT04638751|Procedure|CRC surgical resection|Surgical resection to remove colorectal cancer
45607309|NCT04638751|Procedure|Colonoscopy|Standard-of-care colonoscopy for CRC screening
45757426|NCT04400552|Dietary Supplement|Usual intake Pre-op + ONS Post-op|Participants will follow a meal plan of 2000 kcal / day using conventional foods for 14 days pre-operatively and consume oral nutrition supplementation (ONS) in addition to normal diet post-operatively up to participants being discharged from the hospital
45444804|NCT03810261|Dietary Supplement|Oil-based vitamin D|Participants will receive oil-based VALENS vitamin D, 1000 IU/day for 8 weeks.
45757427|NCT00245011|Biological|filgrastim|Filgrastim will be administered post post chemotherapy until target WBC (white blood cell) count is achieved.
45607310|NCT02319629|Drug|URSODIOL|preventive treatment with Ursolit to reduce the incidence of gallstones formation after bariatric surgery
46066705|NCT04266002|Other|Validation of Charter score for the CNS diffusion of antiretroviral drugs|IHFB001 (Neuroplustrois) is a pilot study, phase IV, open-label, multicenter in Ile-de-France region, trying to demonstrate the improvement of cognitive change after treatment characterized by its better diffusion in the central nervous system. The characteristics of the change in treatment are (Cn - Ci) ≥ 3 and Cn ≥ 9, where Cn is the Charter score of the new treatment and Ci the Charter score of the initial treatment.
46066706|NCT00765739|Other|Neuromuscular electrical stimulation|neuromuscular electrical stimulation that produce 40% of the maximum voluntary contraction
45607311|NCT02319629|Drug|Placebo|
45607312|NCT04455373|Procedure|pediatric vascular bypass grafting|pediatric vascular bypass grafting
45607313|NCT02322437|Other|Home treatment|Patients are treated at home whenever possible and appropriate
45607314|NCT02322437|Other|Treatment As Usual|Patients are treated at a mental hospital
45607315|NCT04691362|Drug|Tranexamic Acid Oral Product|Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration
45607316|NCT04691362|Drug|Tranexamic acid injection|Intravenous administration of 1 gramme tranexamic acid 30 minutes before skin incision and 1 gramme intravenous tranexamic acid 4 hours after first administration
45607317|NCT03499223|Drug|Ranibizumab 0.5mg|3 intravitreal injections of ranibizumab 0.5mg, approximately 1 month apart
45607318|NCT03499223|Drug|THR-317 8mg|3 intravitreal injections of THR-317 8mg, approximately 1 month apart
45607319|NCT03499223|Drug|Sham injection|3 sham injections, approximately 1 month apart. No actual injections. No medication is used.
45607320|NCT01421290|Procedure|Surgery|Knee surgery
45607321|NCT01421290|Other|Conservative comparator|Kinesitherapy, intra-articular injection, wearing a brace, thermotherapy, intake of supplements.
45607322|NCT04561453|Diagnostic Test|Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring|All patients in the study will have organoid creation and organoid drug sensitivity screening attempted on their fresh tumor tissue from surgical resection. All patients will also have blood taken pre-operatively and at multiple post-operative time points to monitor circulating tumor DNA.
45607323|NCT04559893|Behavioral|Collaborative Care|Collaborative care consists of a team of providers that includes a care coordinator, a primary care provider (PCP) and a behavioral health consultant (BHC), who provide evidence- and measurement-based care to a panel of patients using a clinical registry. In our model, the CC team also includes a behavioral health psychotherapist (BHP) who consults on a regular basis but does not deliver direct care.
45607324|NCT01416688|Procedure|assessment of therapy complications|Will be given by questionnaire
45607325|NCT01416688|Procedure|psychosocial assessment and care|Will be given by questionnaire
45607326|NCT01416688|Procedure|quality-of-life assessment|Will be given by questionnaire
45607327|NCT03497117|Device|Lung Clearance Index|To assess the efficiency of ventilation distribution and gas mixing by measuring the rate of clearance of an inert gas (nitrogen) from the lungs.
45607328|NCT03497117|Drug|MRI with PFP|"Description: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)~Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
45607329|NCT04454593|Other|no intervention|This is an observation study,with no intervention
45607330|NCT02319707|Drug|Oxytocin|"The study group: divided into two groups:~• Intramuscular treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.~• Combined treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor."
45607331|NCT02319707|Drug|Oxytocin in 100 ml NaCl 0.9%|"The control group:~pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department)."
45607332|NCT05165017|Biological|AlloRx Stem Cells®|Umbilical cord-derived allogeneic mesenchymal stem cells
45607333|NCT05165017|Other|Placebo control|Placebo infusion without mesenchymal stem cells
45607334|NCT02319785|Behavioral|RAT-NMES|This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive neuromuscular electrical stimulation (NMES) concurrently with RAT.
45607335|NCT02319785|Behavioral|RAT-MT|This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive mirror therapy instead of functional activities training after RAT.
45607336|NCT02319785|Behavioral|Mirror therapy|This protocol includes mirror therapy and functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
45607337|NCT02319785|Behavioral|Unilateral RAT|"This protocol includes warm-up, unilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.~The unilateral RAT session uses the robot-assisted arm trainer, InMotion Isokinetic Testing and Evaluation System."
45757428|NCT00245011|Drug|ifosfamide|Ifosfamide administered IV.
45757429|NCT00245011|Procedure|peripheral blood stem cell transplantation|Peripheral blood stem cell transplantation is done 14 days after 2nd dose of Samarium is delivered
45757430|NCT00245011|Radiation|Sm-EDTMP (low dose)|Sm-EDTMP (low dose) administered after autologous stem cell collection
45607338|NCT02319785|Behavioral|Bilateral RAT|"This protocol includes warm-up, bilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.~The unilateral RAT session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany)."
45757431|NCT00245011|Radiation|sm-EDTMP (higher dose)|Upon blood cell count recovery from Sm-EDTMP (low dose), Sm-EDTMP (higher dose) is administered followed in 14 days by peripheral blood stem cell transplantation.
45757432|NCT05191641|Other|Individualized nursing care|Individualized nursing care based on the Professional Values Model for parents of pediatric oncology patients
45757433|NCT00628901|Procedure|Uterine Fibroid Embolization (UFE)|Uterine Fibroid Embolization is used in treating Uterine Fibroids. The procedure involves injecting embolization particles into the fibroid via the uterine artery which causes the fibroid to shrink or subside. Patients are usually released from the hospital the day after the procedure.
45757434|NCT00628901|Device|Contour SE™ Microspheres|Polyvinyl alcohol Microsphere embolization devices intended to provide targeted vascular occlusion or reduction of blood flow upon selective placement and are currently marketed for use in hypervascular tumors, including leiomyoma uteri and arteriovenous malformations
45757435|NCT00628901|Device|Embosphere® Microspheres|Biocompatible, hydrophilic, nonresorbable, microspheres used in the embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.
46066707|NCT00765739|Other|voluntary strengthening exercise|contracting the quadriceps muscle voluntarily to produce 40% of maximum voluntary contraction
46066708|NCT00765973|Drug|Topotecan Liposomes Injection (TLI)|TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
46066709|NCT00765973|Drug|Topotecan Liposomes Injection (TLI)|TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
46066710|NCT05378516|Other|no intervention|no intervention
45607339|NCT02319785|Behavioral|Conventional rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RAT and MT groups.
45607340|NCT01368718|Procedure|Active CPAP is compared with sham CPAP as a control intervention.|Patients are randomized into active or control arm. After the first treatment, a washout period is installed,after which therapy is switched according to the cross-over protocol. A CPAP device consists of a unit that generates airflow, which is directed to the airway via a mask. With active CPAP, the generated airflow creates a positive pressure and prevents upper airway collapse. With sham CPAP, the generated airflow creates a very low pressure.
45607341|NCT02322515|Other|Intervention taping|A rigid patellar taping will be used for the correction in lateralization of the patella and more stabilization of the knee.
45444805|NCT03810261|Dietary Supplement|Water-based vitamin D|Participants will receive water-based VALENS vitamin D, 1000 IU/day for 8 weeks.
45607342|NCT02322515|Other|Placebo Taping|A rigid patellar taping will be used in the vertical position and without no correction in lateralization of the patella and/or stabilization of the knee.
45607343|NCT01368250|Procedure|Transcatheter Aortic Valve Implantation|Minimal Invasive Implantation of a biological prosthesis in Aortic Position
45607344|NCT02319863|Procedure|hepatectomy (conventional method)|A Simple Technique of Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy
45607345|NCT02319863|Procedure|hepatectomy (rapid ligating)|
45607346|NCT04506385|Dietary Supplement|probiotics|In the first phase: 10 subjects have added in the diet a daily dose of 1 billion of freeze-dried LDD01 probiotics (A arm), 12 individuals are supplemented with a daily dose of 1 billion of the DLBL mix (B arm). In the second phase: 10 individuals are supplemented with a daily low dose of probiotics blend (C arm) and 10 individuals are supplemented with a daily high dose of probiotics blend (D arm).
45607347|NCT05398861|Drug|Utidelone Combined with Bevacizumab|Utidelone： 30 mg/m2/day, IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle Bevacizumab：10mg/kg (IV), on day 1 of each 21 days.
45607348|NCT03499145|Device|Ophthalmology diagnostic system.|An artificial intelligence to make comprehensive evaluation and treatment decision of ocular diseases.
45607349|NCT04586101|Device|Trainings application|Participants have to train with the developed trainings application over six weeks. For this, individual training plans are implemented in the application based on orthopedic joint status and training recommendations of a sports scientist.
45607350|NCT05398549|Other|Conventional Physical therapy|Subjects in group A was treated with conventional physical therapy i.e. grade 1 and 2 mobilization and stretching exercise
45607351|NCT05398549|Other|Virtual reality group|group B was treated with virtual reality stimulation given for 30 minutes per session through kinetic Xbox with sensory accelerator model no.1414. Two traditional training activities was used to improve shoulder Range of motion i.e. badminton and American baseball activity 12 times of the training.
45607352|NCT02448329|Drug|AZD1775|AZD1775 225 mg BID q 12 hours (x5 doses, 2.5 days) administered days 1~3
45607353|NCT02448329|Drug|paclitaxel|paclitaxel 80 mg/m2 given days 1, 8 and 15 of a 28 day cycle
45607354|NCT03498989|Other|preterm formula milk|"A. complete blood picture~B. C-reactive protein~C. Serum electrolytes~D. Plain x-ray and abdominal ultrasound."
45607355|NCT03498989|Other|exclusive breast milk|exclusive breast milk
45607356|NCT03498833|Other|Test-retest reliability testing|Set of patient reported outcome measures
45607357|NCT05398393|Drug|oral Tenofovir Amibufenamide 25mg each day|patients in three groups respectively take one tablet of Tenofovir Amibufenamide(25mg) every day
45607358|NCT05398393|Drug|lipid lowering drugs (e.g. Atorvastatin and amlodipine.)|lipid lowering drugs, , patients in group B1 continue take lipid lowering drugs
45607359|NCT03498755|Behavioral|Mobile phone audio messaging|"Audio messages will be pushed to participants' mobile phones twice weekly on a set schedule in discrete modules that include basic information related to each of the four behavioral domains followed by an integration of the information across behaviors through relatable, character-driven narratives that enable message recipients to engage with the content through a real-world context."
45607360|NCT03498755|Behavioral|Peer-to-peer learning|Women participants in each community will meet twice monthly for peer-to-peer learning sessions to reinforce the content of audio messages. These sessions will further use women's empowerment approaches including critical examination of gender dynamics, and discussions of solutions for equitable decision-making and control of resources within households. These discussions will be facilitated with male household members and grandmothers in separate learning sessions that will be held three times throughout the intervention period.
45607361|NCT03498755|Behavioral|Conditional cash transfer|Participants will receive a conditional cash transfer to support their fish smoking business. The payment will be conditional on their participation in entrepreneurship trainings and the use of the investment into their fish smoking business.
45607362|NCT03498755|Behavioral|Entrepreneurship training|Entrepreneurship training will focus on commonly lacking business knowledge, with an emphasis on establishing fundamental entrepreneurial skills (i.e., customer care, accounting), sound business management and decision-making, building strong and sustainable business relationships, and encouraging the use of loans for their intended purposes. This training will be introduced during the credit and savings group (CSG) meetings that will occur twice per month.
45607363|NCT03498755|Behavioral|Market price information|Average market prices for fresh and processed fish at community, district, and regional markets will be disseminated via audio message calls (using Viamo's Infoline platform) to the mobile phones of women with the price information in their preferred language. These market prices will be collected twice weekly by Viamo field enumerators and sent to regional coordinators for validation. A second, independent validation will be carried out to ensure that there are no discrepancies.
45607364|NCT03498755|Behavioral|Improved smoke ovens|Local private sector artisans will construct and serve as suppliers of the new ovens. The promotion, uptake and impact of these improved Ahotor ovens will be tested among study participants. Awareness-raising workshops held in each community will promote the Ahotor in concert with a public retrofitting of a Chorkor stove. Immediately following this event, one month later, and three months later, study participants will receive additional one-on-one counseling to provide further support on the proper use of the smoke oven, as well as on optimal handling and smoking practices to enhance product quality.
45607365|NCT01356628|Drug|PD-0332991|PD-0332991, 125mg, 3 cycles
45607366|NCT01339078|Procedure|Plastic stenting|The patients receive plastic stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 3 months, for a total duration of 1 year.
45607367|NCT01339078|Procedure|Kaffes stenting|The patients receive Kaffes stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 6 months, for a total duration of 1 year.
45607368|NCT03498677|Behavioral|presentation order|section presentation one
45607369|NCT03498677|Behavioral|alternative presentation order|section presentation two
45607370|NCT04190134|Behavioral|Socially Assistive Robot for Low Vision Rehabilitation|A socially assistive robot will be customized to engage in dialog and conversations to motivate and encourage optimal use of new magnification devices for reading at home by individuals with vision loss.
45607371|NCT02319941|Drug|ticagrelor|
45607372|NCT02319941|Drug|clopidogrel|
45607373|NCT02320019|Drug|Placebo|Placebo matching YH14618
45607374|NCT02320019|Drug|YH14618|
45607375|NCT02320097|Other|Foot pressure measurement|"Description of the foot pressure measurement:~The subject stands on the platform, with the heels and buttocks touching a vertical plane and the head held freely. The subject then moves his/her head backwards so that it touches the vertical plane. Next, he/she turns the head to the right and then towards the left. Each of these positions is maintained for 2 minutes.~The platform's sensors measure the anteroposterior foot pressure distribution during the various acquisitions."
45607376|NCT02320331|Behavioral|PILI Lifestyle Program|A 12-week Individual-focused Behavioral Weight Loss Intervention. Our 12-week intervention is modeled after the Diabetes Prevention Program's (DPP) Lifestyle Intervention. Each of the 8 lessons of this 12-week intervention will be done in a group classroom setting via trained community peer educators for a total of 8 group meetings as outlined above. Lesson 1 through 4 will be done every week, once a week, for 4 weeks followed by every other week for the remaining 4 lessons (lessons 5 through 8). Each group meeting will have between 12 to 15 people and take 1 to 1 ½ hours to complete. After completing the 12-week behavioral weight loss intervention, participants will participate in an additional 6 lessons. A lesson will be done once-a-month. These 6 lessons will teach participants how to involve their family and friends in their healthy lifestyle changes.
45607377|NCT02320409|Drug|Sulfatinib|250mg Sulfatinib ,single dose,oral
45607378|NCT05164861|Dietary Supplement|"kombucha-based beverage Black currant with juniper"|"kombucha-based beverage: drinking water, black tea, kombucha, black currant berries, juniper berries, inulin, vitamins (B1, B2, B6, niacin, folic acid). Nutritional value in 100 ml: carbohydrates - 2.57 g (including sucrose - 0.22 g, glucose - 1.32 g, fructose - 1.03 g), inulin - 1.15 g (46%*), vitamin B1 - 0.4 mg (29%*), B2 - 0.21 mg (13%*), B6 - 0.48 mg (24%*), niacin - 2.74 mg (15%*), folic acid - 24.0 mcg (12%*). Energy value/Caloric content - 54 kilojoules/13 kcal (* - % of the recommended daily allowance, according to the Technical regulations of the Customs Union #022/2011).~Portion's volume - 220 ml. Daily intake: 1 portion"
45607379|NCT05164861|Dietary Supplement|"kombucha-based beverage Strawberries with lime"|"Ingredients: drinking water, black tea, kombucha, strawberries, lime leaves, inulin, vitamins (B1, B2, B6, niacin, folic acid).~Nutritional facts per 100 ml: carbohydrates - 3.1 g (including sucrose - 0.18 g, glucose - 1.45 g, fructose - 1.47 g), inulin - 1.15 g (46%*), vitamin B1 - 0.27 mg (19%*), B2 - 0.25 mg (16%*), B6 - 0.54 mg (27%*), niacin - 3.42 mg (19%*), folic acid - 37.0 mcg (19%*). Energy value/Caloric content - 53 kilojoules / 15 kcal~* - % of the recommended level of daily consumption (according to the Technical regulations of the Customs Union #022/2011) Portion's volume - 220 ml. Daily intake: 1 portion"
45607380|NCT04462133|Diagnostic Test|Dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR)|Empirical H. pylori eradication treatment versus tailored therapy based on DPO-PCR results
45607381|NCT05164627|Drug|Dexmedetomidine|patients will receive Dexmedetomidine infusion (0.2 mcg/kg/hr) from the start of the surgery till the end of it.
45444806|NCT03810261|Dietary Supplement|Vitamin D capsules|Participants will receive vitamin D capsules with starch-adsorbed vitamin D (powder), 1000 IU/day for 8 weeks.
45607382|NCT05164627|Drug|Magnesium Sulphate|patients will receive Magnesium infusion (10 mg/kg/hr) from the start of the surgery till the end of it.
45607383|NCT05164627|Drug|Normal saline|After patient arrival at the PACU, Paediatric Anaesthesia Emergence Delirium (PAED) scale ,Ramsay sedation scores (RSS), emergence agitation, HR, and mean arterial blood pressure (MAP) were recorded every 5 min during the first 30 min, then every 10 min for the remaining 30 min of the recovery room stay. Patients were then transferred to the ward. All postoperative observations and scores were performed by the same anesthesiologist who was blinded to the group assignment
45607384|NCT04461977|Other|True acupuncture|"The selection of acupuncture points is based on Traditional Chinese Medicine (Wen, 2011) and on previous studies (Jeong,2018; Bao,2018), selected as main points: bilateral baxie, SJ5, bafeng, KID3 and ST36. Modifications or additional secondary points may be indicated according to clinical judgment throughout treatment. The needles will be inserted at a depth of 10 - 15 mm, being gently manipulated to obtain de qi sensation. The needles will be left for 20 - 25 minutes. There will be once a week acupuncture treatment, for 8 consecutive weeks. The acupuncture needles will be sterile, disposable stainless steel needles size 0.20 x 30 mm, of Korean brand Dong Bang, Chungcheongnam-do."
45607385|NCT04461977|Other|Sham acupuncture|"Patients will receive needling at non-acupuncture points with superficial needling without manipulation to obtain de qi, located near the real points in the hands and feet. The needles will also be left for 20 - 25 minutes. There will be once a week acupuncture treatment, for 8 consecutive weeks. There will be once a week acupuncture treatment, for 8 consecutive weeks. The acupuncture needles will be sterile, disposable stainless steel needles size 0.20 x 30 mm, of Korean brand Dong Bang, Chungcheongnam-do."
45444807|NCT05659342|Other|ELDOA Technique|"the patients treated with ELDOA technique, followed for 3 alternative days for 4 weeks.~the ELDOA techniques for level L4/L5 and L5/S1 were applied. the ELDOA positions hold for one minute, 3 alternative days for 4 weeks under supervision.~Hot pack (10-15 minutes) McKenzie Extension Exercises"
45607386|NCT04454359|Dietary Supplement|Multi-nutrient supplement|
45607387|NCT04454359|Dietary Supplement|Placebo|
45607388|NCT02320565|Procedure|3D Laparoscopy|3D Laparoscopy approach
45607389|NCT02320565|Procedure|Standard Laparoscopy|Standard laparoscopy approach
45607390|NCT02320643|Device|Seratom® PA mesh|Partially absorbable mesh
45757436|NCT03307070|Behavioral|Cognitive Behavioral Therapy for individuals with TBI|Cognitive Behavioral Therapy for depression that has been adapted for a population who has experienced a moderate to severe Traumatic Brain Injury. This is a 12 week long treatment for depression with weekly visits that challenges negative thoughts and behaviors. This version has been specifically developed for the study to account for specific cognitive needs of individuals who have experienced a moderate to severe TBI.
46066711|NCT04077814|Device|Foot Drop Stimulatio - Neuro Orthosis|Walkaide is the Foot drop stimulator (FDS) on the peroneal nerve provides active dorsiflexion of muscle during the swing phase of gait.
46066712|NCT04077814|Device|Transcranial direct brain stimulation|Transcranial direct brain stimulation on motor cortex
45452232|NCT02269384|Procedure|Experimental Noxious Stimulus|Localized manual pressure will be placed up predetermined points on the lower extremity until maximum pain tolerance levels are reached.
45757437|NCT03307070|Other|Waitlist Control|Participants will be randomized to a waitlist. They will attend biweekly study sessions for 12 weeks to track progress, but will receive their treatment as usual.
45607391|NCT03496961|Behavioral|Yan Nian Jiu Zhuan Fa|Yan Nian Jiu Zhuan Fa are the kneading methods while cognitive behavior education is the psychological education
45607392|NCT05111743|Drug|Brolucizumab|Participants received brolucizumab injection during the index period
45607393|NCT03494543|Procedure|Endoscopic Papillectomy|Endoscopic resection of ampullary of Vater neoplasms
45607394|NCT02322671|Drug|Reference Montelukast|It is available as pink, round, bi-convex-shaped chewable tablet of reference 5 mg montelukast sodium (innovator product). that has to be placed on the tongue and chewed immediately.
46066713|NCT00775177|Drug|Doxycycline monohydrate 100mg tablets|Bioequivalence Doxycycline monohydrate 100mg tablets fasting condition
45607395|NCT02322671|Drug|Test 1 Montelukast|It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
45607396|NCT02322671|Drug|Test 2 Montelukast|It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 2: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
45607397|NCT05096143|Drug|Sacubitril/valsartan|Participants who were prescribed with Sacubitril/valsartan
45607398|NCT05096143|Drug|ACEi/ARB|Participants who were prescribed with Angiotensin-converting enzyme inhibitors/Angiotensin II receptor antagonists (ACEi/ARB)
45607399|NCT04248517|Other|mHealth Intervention|Participants will download the app onto their smartphone and complete ecological momentary assessements
45607400|NCT02322905|Behavioral|Emotion Regulation Therapy|8 sessions of ERT
45607401|NCT05697289|Other|satisfaction survey|Non-comparative longitudinal observational study over 12 months conducted during usual follow-up of patients living with HIV-1 and having changed treatment for an injectable dual therapy with prolonged release cabotegravir-rilpivirine. Decision to change treatment and follow-up of patients are part of routine care. Study is proposed after the doctor has taken the decision to modify treatment, the patient has accepted and injectable dual therapy is prescribed. It is based on self-questionnaires to collect patient perceptions (Patient-Reported Outcomes) and clinical and biological data collected routinely at inclusion and during follow-up visits.
45607402|NCT03494465|Procedure|PHACOEMULSIFICATION|"Standard phacoemulsification with intraocular lens implant will be perform within 60 days after allocation. If IOP target is not achieve, patients will be treated as in medical treatment group"
45607403|NCT03494465|Drug|MEDICAL GLAUCOMA TREATMENT|The escalation of topical hypotensive medications will be carried out with the following sequence: 1. single topical medication; 2. double topical therapy; 3. triple topical therapy. Beginning, with the exception of individual contraindications, with prostaglandin analogs, followed by topical beta-blockers, carbonic anhydrase inhibitors and finally alpha-agonists.Target IOP will be used in both groups to inform the need of escalation of therapy; in patients with ocular hypertension the target IOP will be 21 mmHg. In patients with mild glaucoma target IOP will be 18 mmHg, and in patients with moderate glaucoma the target IOP will be 15 mmHg.
45607404|NCT04191031|Device|ioveraº|Cryoneurolysis
45444808|NCT05659342|Other|Mechanical Lumbar Traction|"Mechanical Traction Technique: traction unit, 50% of body weight was applied with the patients lying in supine position, with the hip and knee at 90 degree flexion, and legs were supported. Traction were applied for 3 alternative days for 4 weeks.~Hot pack (10-15 minutes) McKenzie Extension Exercises"
45607405|NCT04191031|Device|ioveraº sham|ioveraº sham
45607406|NCT03496727|Procedure|Serratus anterior plane block|Serratus anterior plane block+patient controlled analgesia
45607407|NCT03496727|Procedure|Patient controlled analgesia|Patient-controlled analgesia
45607408|NCT03494387|Drug|Oxygen|80% versus 30% inspiratory oxygen concentration
45757438|NCT02980419|Behavioral|presentation of visual and vestibular stimuli|In each participant the investigators will assess verticality perception in whole-body upright position by use of the SVV, the SPV and the SHV after static roll-tilt at ±90deg over 5min. Measurements will be obtained on a motor-driven turntable and two different roll-tilt positions will be applied (±90°). A visual line (SVV), a rod (SHV) or the turntable itself will be adjusted to indicate perceived direction of vertical. A total of three measuring sessions, each lasting about 60 minutes are scheduled.
45757439|NCT05686460|Behavioral|ice massage|"After the students who met the sample selection criteria applied Student Information Form. On the first day of the participating students' menstruation, prior to the application (when the pain started), the Visual Analogue Scale (VAS), General Comfort Questionnaire (GCQ) and Dysmenorrhea Follow-up Form were filled in at the pre-test. The Hegu point of the participating students was detected with the acupuncture point finder. Ice cubes whose dimensions were 2x2x2 cm were wrapped with gauze and placed in a plastic bag. Vaseline® jelly was spread on the application area. The application applied 2 minutes of ice massage 7 times at 15-second intervals. The participants' pain levels were assessed three times, as soon as the application was over, 30 and 60 minutes after the application (Post-test).~On the second day of menstruation, the participants were asked to fill in the VAS, GCQ, and Effects of Dysmenorrhea Scale (EDS)."
46066714|NCT05378360|Biological|DWP708|Placebo Comparator: Placebo of DWP708 / BID / up to 28 days Experimental: DWP708 10 ug/g / BID / up to 28 days Experimental: DWP708 20 ug/g / BID / up to 28 days Experimental: DWP708 40 ug/g / BID / up to 28 days
45607409|NCT03494387|Drug|Antioxidants|Antioxidants versus placebo
46066715|NCT00766129|Device|Taxus stent implantation|Patients will be treated with implantation of Taxus stent
45607410|NCT03723265|Device|Cardiac Resynchronization Therapy|
45607411|NCT02322983|Behavioral|Control of Stress|To control stress were measured (at different times: T1, T2, T3 and T4) Venham's Score, Heart Rate, Respiratory Rate, and the titration of gases.
45607412|NCT03496649|Drug|Dysport 500 Unit Powder for Injection|Dysport administered by intramuscular injection
45607413|NCT03496493|Device|All patients|Peripheral arterial oxygen saturation recording with both study devices
45607414|NCT03494309|Procedure|Open Reduction & Internal Fixation|Patients underwent surgery and the fractures were reduced under direct vision followed by internal fixation with titanium plates and screws
45444809|NCT01614483|Other|Yellow cassava|Daily provision of 375 g boiled yellow cassava for 18 weeks, 6 days/week Daily provision of placebo capsule for 18 weeks, 6 days/week
46066716|NCT00766129|Device|Luc-Chopin stent|Patients will be treated will implantation of Luc-Chopin stent
45607415|NCT03494309|Procedure|Closed Reduction & External Fixation|Patients underwent closed reduction of the fracture and external fixation by arch bars & guided elastics
45607416|NCT02324621|Drug|Oral ONC201|Given PO
45607417|NCT02324621|Other|pharmacological study|Correlative studies
45607418|NCT02324621|Other|laboratory biomarker analysis|Correlative studies
45607419|NCT04487431|Drug|BAY1817080|Oral single dose
45607420|NCT04487431|Drug|[14C]BAY1817080|Oral single dose
45607421|NCT02324777|Drug|Cannabis|Cannabis sativa L. subsp. indica, variety indica blends of flowering heads that have been air-dried, milled, destemmed and fine ground, stored in glass vials with aluminum caps in 100 mg dose size.
45607422|NCT02324777|Device|Volcano® Medic Vapourizer|"Volcano® Medic vapourizer is licensed for medical administration of cannabis in Canada March 2010 (Licence No. 82405).~The contents of a vial of drug product formulation will be transferred to the Volcano® Medic's filling chamber (sample-holder) equipped top and bottom with fine wire mesh to retain the finely ground material. The filling chamber will be placed atop the main body of the unit and then have a, 12.5 L, heat-resistant Medic Valve balloon affixed. Active components are vapourized at 190 °C. The ensuing vapour is captured in the balloon and inhaled by the study subject using a standardized inhalation technique."
45607423|NCT05681845|Drug|NNC0365-3769 (Mim8)|Participants will receive a single dose of Mim8 subcutaneously in the abdomen.
45607424|NCT03496415|Device|remote ischemic conditioning|Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)
45607425|NCT03496415|Device|sham remote ischemic conditioning|sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg
45607426|NCT05397925|Behavioral|ADSProgram - Self management for substance dependence program|GENERAL STRUCTURE OF THE MODEL - 8 sessions: One initial - assessment; 1 to 6 Intermediates - empowerment (Flexible number of intermediate sessions according to the person's need and accessibility, interlude 1 week minimum, up to a maximum of 3 weeks); 1 Final - autonomy; Duration of sessions: 20-60 min; Context: Outpatient specialized addictions unit. Private room needed; Preferred approach: Individual, face-to-face or virtual consultation. Complementary approach: In groups of up to 4 people, when peer support or sharing feelings are needed: Clinical focus 1 - Concerning the problematic use of substances, 2 - Related to health knowledge in general, 3 - Related to health-seeking behavior and adherence, 4 - Related to self-knowledge and well-being, 5 - Related to social role and personal dignity, 6 - Related to the family process.
45607427|NCT05397925|Behavioral|Treatment as usual - Regular nursing consultation on a medication-based program|Regular individual assessment on: substance used (kind of substance, consumption way, frequency), way of living, social relationship, health status nursing diagnoses. To support on this, therapeutic interventions, medication delivery and management support.
45607428|NCT03496337|Other|Assessment of motor and process skills test|At baseline and follow-up (after 8-10 weeks) all patients are assessed with AMPS in addition to the standard test of Canadian Occupational Performance Measure (COPM) hand grip strength and joint range of motion.
45607429|NCT02324855|Other|Chest physiotherapy plus usual care|Subjects will perform daily chest physiotherapy during at least 30 minutes. Patients will perform a slow expiratory airway clearance technique combined with positive expiratory pressure device (Acapella device, Murray et al.) Each patient will receive 12 supervised professional sessions (once a month).
45607430|NCT03821545|Other|Lidocaine|Lidocaine will be administered at a dose of 1.5 mg/kg prior to surgical incision followed by an infusion at a rate of 1.5-2 mg/kg/hr until the end of surgery.
45607431|NCT03821545|Other|Ketamine|Ketamine will be administered at a dose of 0.5 mg/kg in a bolus prior to surgical incision followed by an infusion at a rate of 0.1-0.2 mg/kg/hr until the end of surgery.
45607432|NCT03821545|Other|Lidocaine and Ketamine|Lidocaine will be administered at a dose of 1.5 mg/kg prior to surgical incision followed by an infusion at a rate of 1.5-2 mg/kg/hr until the end of surgery. Ketamine will be administered at a dose of 0.5 mg/kg in a bolus prior to surgical incision followed by an infusion at a rate of 0.1-0.2 mg/kg/hr until the end of surgery.
45607433|NCT03821545|Other|Placebo (0.9% NaCl)|Bolus and continuous placebo infusion (0.9% NaCl) will be equally administered at the same dose as the aforementioned anesthetics until the end of the surgery.
45607434|NCT02324933|Drug|Fentanyl|Fentanyl Patient Controlled Analgesia for post-operative pain management
45607435|NCT01378195|Behavioral|CBT-based program for dementia caregivers|Participants will receive a CBT-based program [Cognitive Behavioral Therapy], containing videos, workbook, and website.
45607436|NCT01378195|Behavioral|Educational/Resources program|Participants will receive a traditional educational/resources program, containing videos, workbook, and website.
45444810|NCT01614483|Other|White cassava|Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/ week Daily provision of placebo capsule for 18 weeks, 6 days/ week
45607437|NCT02323061|Procedure|BCI using EEG signals|A robot hand will be used and controlled by the system in real time based on EEG pattern for identification of motion intention for hand movements in the cortex.
45607438|NCT03739723|Other|Resource allocation to improve surgical learning environments|If a hospital/program is assigned to the intervention arm, they will receive numerous resources including a program-specific learning environment and resident well-being report, a Wellness Toolkit, coaching webinars, and in-person/virtual conferences to help improve their surgery learning environment and residents' well-being.
46066717|NCT00607802|Biological|leukocyte therapy|
46066718|NCT00607802|Genetic|polymerase chain reaction|
45444811|NCT01614483|Other|White cassava|Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/week Daily provision of B-carotene capsule (1400 µg B-carotene)
45444812|NCT02037724|Dietary Supplement|supplement containing 60 mg iron sulfate|control agent
45444813|NCT02037724|Dietary Supplement|iron rich food supplement (60 mg iron)|contains 60 mg of iron
46066719|NCT00766207|Other|Clinical decision support|multi-faceted decision support
46066720|NCT00766207|Other|stream-lined clinical alert|electronic notification that a medication is potentially teratogenic
46066721|NCT04299022|Other|Vivigen Cellular Bone Matrix|Allograft bone matrix
45607439|NCT02325089|Device|Mandibular advancement device|Use of a mandibular advancement device every night during one year. Device will be titrated to reduce or - if possible - eliminate snoring and sleep apnea.
45607440|NCT02325089|Device|Placebo|Placebo oral appliance will be identical to the mandibular advancement device without, however, the attachemnt to allow mandibular advancement. It will be used every night during one year.
45607441|NCT03735589|Biological|Alpha-type-1 Polarized Dendritic Cells|Given ID
45607442|NCT03735589|Biological|Autologous Natural Killer Cell-like CTLs|Given IP
45607443|NCT03496103|Biological|ragweed pollen|three hours ragweed pollen in a allergen exposure chamber
45607444|NCT03496025|Device|Electrical muscle stimulation|The intervention consists of activating paralyzed facial muscles with electrical stimulation.
45607445|NCT03495947|Behavioral|high flow nasal cannula|24 hours of continuous use in the immediate post-extubation period.
45607446|NCT01378117|Drug|Sitagliptin|Sitagliptin 50-100mg po once daily
45757440|NCT05686460|Behavioral|music medicine|After the students who met the sample selection criteria applied Student Information Form. On the first day of the participating students' menstruation, prior to the application (when the pain started), the Visual Analogue Scale (VAS), General Comfort Questionnaire (GCQ) and Dysmenorrhea Follow-up Form were filled in at the pre-test. Depending on their preference, each participant wearing personalized headphones was played instrumental music in the pre-menstruation period for 30 minutes. The volume of the music was adjusted based on the verbal feedback or facial expressions of the students. The participants' pain levels were assessed three times, as soon as the application was over, 30 and 60 minutes after the application (Post-test). On the second day of menstruation, the participants were asked to fill in the VAS, GCQ, and Effects of Dysmenorrhea Scale (EDS).
46066722|NCT00770497|Drug|Pioglitazone|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for up to 10 weeks."
46066723|NCT00770497|Drug|Pioglitazone and ramipril|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
45607447|NCT01378117|Drug|glargine|glargine once daily
45607448|NCT01378117|Drug|lispro|lispro before meals
45607449|NCT02325167|Behavioral|EBT|participants assigned to the intervention arm will receive 2 manualised therapy sessions with focus on mindfulness and activating resources delivered by trained therapists at the Clinic of Palliative Care
45607450|NCT02325167|Behavioral|treatment-as-usual|participants assigned to the treatment-as-usual arm will receive 2 supportive sessions delivered by trained therapists at the Clinic of Palliative Care
45607451|NCT02323139|Drug|Azacitidine and LDE255|Azacitidine at maximum tolerated dose. LDE255 at dose escalation (200, 400 or 800 mg)
46066724|NCT00770497|Drug|Ramipril|"Pioglitazone placebo-matching tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
46066725|NCT00606710|Device|Cognis 100-D, Teligen DR, VR 100 HE|ICD or CRT - Therapy
45444814|NCT02037724|Dietary Supplement|iron rich food supplement (10 mg iron)|contains 10 mg iron
45607452|NCT04444609|Other|Blood tests sputum, nasal lavage and brushing|Venesection, sputum nasal lavage and brushing if appropriate
45607453|NCT02325245|Drug|Metformin|Metformin tablet 500 mg three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, metformin will continue until 24 weeks.
45607454|NCT02325245|Drug|Placebo|Placebo three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, placebo will continue until 24 weeks.
46066726|NCT05285852|Other|Dry Needling|Dry needling technique is maneuvered by different skilled health practitioners aiming to reduce central sensitization, i.e., the hypersensitivity to pain of the central nervous system. It is also apprehended to reduce the local and referred pain, and improve the muscle activation patterns leading to improved range of motion.
46066727|NCT05285852|Other|Placebo Dry Needling|Placebo Dry Needling only causes a pricking sensation
45444815|NCT02037724|Dietary Supplement|supplement containing 10 mg iron sulfate|control agent
45607455|NCT05618899|Other|HIGH INTENSITY INTERVAL TRAINING|Training should be done on treadmill for 25-30 minutes.. Training proceed for 1 month once a day
45607456|NCT05618899|Other|MODERATE INTENSITY EXERCISE|moderate intensity exercises consist of generally 30-60 minutes of aerobic exercises at 64-76% of peak heart rate. Training should be done on treadmill for 30-60 minutes. Training proceed for 1 month once a day
45607457|NCT03819361|Diagnostic Test|pulse-oximetry|Patients with suspected OSA will be monitored with 14 nights of pulse-oximetry prior to the already planned in-hospital single-night sleep study at the University Hospital Zurich
45607458|NCT03494231|Drug|HLX06|recombinant fully human anti-VEGFR2 monoclonal antibody against cancers
45607459|NCT05616091|Device|painful stimulation by using a laser device (DEKA Stimul 1340, Calenzano, Italy)|In each of the two sessions, 80 experimental painful stimuli of different intensities (2.5 J, 3 J, 3.5 J, 4 J) will be applied using the laser device listed above.
45607460|NCT05397613|Behavioral|STAIR|Clinician led session that hones in on a particular deficit within these skills, including identifying and labeling emotions, managing emotions, tolerating distress, accepting feelings and increasing positive emotions, identifying trauma-based interpersonal schemas, identifying conflict between trauma-related feelings and goals, role plays surrounding issues of power and control, and role-plays related to developing flexibility in interpersonal situations involving power differentials. STAIR is a cognitive-behavioral treatment that addresses emotion regulation and interpersonal difficulties and their impact on daily living.
46066728|NCT04048291|Behavioral|Brisk walking and balance training|6 months of combined brisk walking and balance training
46066729|NCT04048291|Behavioral|Upper limb exercise|6 month of hand dexterity training
46066730|NCT02581696|Drug|Lafutidine|Lafutidine 10mg, 1 tablet, bid
46066731|NCT02581696|Drug|Irsogladine maleate|Irsogladine maleate 2mg, 2 tablet, qd
46066732|NCT04265924|Other|fraction of inspired oxygen (FIO2)|The fraction of inspired oxygen (FIO2) is given accordingly (>0.85 for the >0.85 group, and <0.7 for the <0.7 group) to the patients during the surgery.
45607461|NCT02323373|Drug|Tranexamic Acid - topical|Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this study arm, the drug is administered topically on the wound.
45607462|NCT02323373|Drug|Placebo|100 ml of saline solution administered with anesthesia during 10 minutes
45607463|NCT02323373|Drug|Tranexamic Acid - intravenous|Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this arm, the drug is administered intravenously.
45607464|NCT03328663|Other|CARE|Promote effective coping and reduce caregiving burden.
45607465|NCT03328663|Other|Standard Transplant Care|Standard cared administered by the hospital.
45607466|NCT03495635|Behavioral|Big Brothers Big Sisters Community-Based Mentoring Program|One-to-one mentoring provided by an adult volunteer with training and ongoing monitoring and support from program staff.
45607467|NCT02325479|Drug|Enaoxaprin sodium|intrauterine administration after oocyte pickup as the main experimental intervention
45607468|NCT02325479|Drug|tissue culture media|intrauterine administration after oocyte pickup as placebo
45607469|NCT04455529|Other|ESUS|Embolic stroke of undetermined source (ESUS) designates patients with nonlacunar cryptogenic ischemic strokes in whom embolism is the likely stroke mechanism.
45607470|NCT03495401|Dietary Supplement|fortified synbiotic milk|100 ml fortified (7,47 mg ferrous sulphate and 4,33 mg zinc acetate) synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
45607471|NCT03495401|Dietary Supplement|non-fortified synbiotic milk|100 ml non-fortified synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
45607472|NCT05236231|Drug|Macitentan 10 mg|Macitentan 10mg tablet will be administered orally as per assigned treatment sequence.
45607473|NCT05236231|Drug|Tadalafil 20 mg|Tadalafil 20mg tablet will be administered orally as per assigned treatment sequence.
45607474|NCT05236231|Drug|Macitentan 10 mg/Tadalafil 20mg FDC|FDC of Macitentan 10 mg/Tadalafil 20 mg will be administered orally as single dose tablets.
45607475|NCT02325557|Drug|ADXS31-142|starting at 1x10^9 cfu IV
45607476|NCT02325557|Drug|ADXS31-142 + Pembrolizumab (MK-3475)|starting at dose from Part A + 200mg of Pembrolizumab
45607477|NCT03495323|Drug|LY3300054|LY3300054 is a monoclonal antibody that targets programmed cell death ligand 1 (
45607478|NCT03495323|Drug|Prexasertib|Prexasertib work by preventing the cancer cells from being able to repair damaged DNA (one of the building blocks of a cell) which then leads to cell death
45607479|NCT03130387|Device|Office Hysteroscope|Diagnosis of C.S niche in patients wit AUB by office hysteroscope
45607480|NCT02323451|Device|Medical Chitosan|intra-articular injection
45607481|NCT02323451|Drug|Sodium Hyaluronate Injection|intra-articular injection
45607482|NCT02323529|Drug|Nitisinone|All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks. The dose of nitisinone in the study will be the same as the one prescribed at completed screening visit. Dose will be 1-2 mg/kg body weight.
45607483|NCT02325635|Other|Educational Training|Intervention/Training offered to endoscopists only.
45607484|NCT02975869|Other|Standard Leukemia Care|
45607485|NCT02975869|Other|Palliative Care|
45607486|NCT03493997|Combination Product|Radiotherapy+IAluril®+Ialuril Soft Gels®|Radiotherapy+IAluril®+Ialuril Soft Gels®
45607487|NCT03493997|Radiation|Radiotherapy only|Radiotherapy only
45607488|NCT05397301|Procedure|Controlled sedoanalgesia|Controlled sedoanalgesia was applied with Bispectral index and dexmedetomidine
45607489|NCT02323607|Drug|Pacritinib|Given PO
45607490|NCT02323607|Drug|Cytarabine|Given IV
45607491|NCT02323607|Drug|Daunorubicin Hydrochloride|Given IV
45607492|NCT02323607|Drug|Decitabine|Given IV
45607493|NCT02323607|Other|Laboratory Biomarker Analysis|Correlative studies
45607494|NCT02323607|Other|Pharmacological Study|Correlative studies
45607495|NCT02323685|Biological|SANGUINATE™|Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
45607496|NCT02325869|Device|Bell Balloon Catheter|An angioplasty procedure to open the blockage in blood vessels will be performed. Standard angioplasty procedure includes local analgesia of the groin area and a small cut through which the procedure will be performed. An introducer sheath (thin tube) will be inserted. The Bell Balloon dilatation will then be inserted. The Bell Balloon works in fashion similar to standard balloon with the same physical and behavioral characteristics. Upon deflation, debris from the blockage is withdrawn into the cavity formed between the deflated balloon and its outer capsule. Then balloon is retracted and retrieved through the guiding catheter, together with the captured debris and trap it between the outer surface of the balloon and the inner surface of the membrane.
45607497|NCT02323763|Other|fMRI Scanning|Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes. fMRI will be used to determine brain activation and differences in intertemporal discounting.
45607498|NCT02323841|Procedure|conservative treatment|we performed pelvic lymphadenectomy before neoadjuvant chemotherapy and conization as conservative treatments
45607499|NCT02325947|Device|hand exoskeleton, brain-computer interface (BCI),|Hand exoskeleton, brain-computer interface (BCI) 10 sessions of 45-minutes
45607500|NCT02325947|Device|hand exoskeleton, sham BCI|Hand exoskeleton, sham BCI 10 sessions of 45-minutes (BCI imitation)
45607501|NCT02323919|Behavioral|SystemCHANGE|consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.
45757441|NCT05186181|Behavioral|In situ fenestration|Interventional therapy of aortic dissection. In situ needle fenestration of left subclavian artery.
45607502|NCT02323919|Behavioral|CHANGE+|consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.
45607503|NCT02323919|Behavioral|Usual Care|Participants will receive only the routine care provided to CRP patients. This care consists of assessment of exercise capacity, graduated exercise training (consisting of exercising three times a week at the cardiac rehabilitation center on treadmill or cycle, counseling about safe exercise {warm-up procedures, pulse taking, attending to body cues for exertion levels} and advisement to exercise on days between CRP sessions). At the end of the CRP, individuals are given an exercise prescription that includes their target heart rate and they are counseled to exercise at least 5 times a week for 30 minutes. This information is provided by the CRP personnel, usually in the form of individual informal conversations during exercise at the CRP.
45607504|NCT03493841|Drug|Alpha Lipoic Acid|Lipoic acid is an over the counter supplement. Two different forms, R and racemic are available. R-lipoic acid is the naturally occurring form. Racemic lipoic acid is the most commonly available supplement.
45607505|NCT03493763|Diagnostic Test|5hmC profile in plasma cell-free DNA after liver resection|Peripheral blood is drawn every 3 months after liver resection for 5hmC test (Time frame: 2 years or until tumor recurrence).
45607506|NCT03495089|Diagnostic Test|dermal electrochemical conductance (DEC)|The patient will undergo DEC quantification using the Sudoscan® device.(Sudoscan®, Impeto Medical, France)
45607507|NCT03495089|Diagnostic Test|Monofilament testing|Monofilament testing by Semmes-Weinstein 5:07 MFT (10 g),
45607508|NCT03493373|Other|Exercise|The exercise program will consist of: 1) warm up - consisting of stretches of large muscle groups of the upper limbs, lower limbs and trunk and by general mobility exercises; 2) strength training of moderate intensity; 3) balance training; 4) Cooling - will consist of performing overall stretching combined with deep breathing.
45607509|NCT03493373|Other|Neural mobilization|Neural gliding mobilization will target mainly the lower limb nerves and will be performed in series of 10 repetitions with 1 minute interval between series.
45607510|NCT02324231|Other|39.0°C temperature limit defining fever|Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
45607511|NCT02324231|Other|38.5°C temperature limit defining fever|Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
45607512|NCT03494855|Device|SyMRI Software|The MDME sequence aims to provide whole absolute quantification of T1, T2, PD and B1 inhomogeneity in 5 minutes at typical clinical resolution (0.8 x 0.8 x 5mm). SyMRI software then allows a user to synthesize any almost image contrast (T1, T2, PD, FLAIR, IR, DIR, etc) by adjusting imaging parameters after the fact.
45607513|NCT03494699|Behavioral|Multidisciplinary prevention|group cognitive training (every month) App-based Cognitive Training at Home (using smartphone application) physical activity/body weight/smoking & alcohol cessation monitoring and feedback
45607514|NCT02445443|Device|LEGION Hinge Knee System|All enrolled/treated subjects will receive the LEGION Hinge Knee System.
45607515|NCT05118737|Drug|Colchicine|colchicine to be used among COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab
45452233|NCT02269384|Behavioral|Memory of Experimental Noxious Stimulus|Subjects will be asked to visualize previously experience experimental noxious stimulus
45607516|NCT03491813|Device|oscillometric device|"The blood pressure will be measured by the Automatic blood pressure monitor(Oscillometric) named the OMRON M2 basic® device was provided by Omron Healthcare company.~This monitor uses inflation by Fuzzy-Logic controlled by electric pump and an automatic rapid pressure release valve for the deflation , its cuff allows BP measurements in arm circumference of 22-42 cm. The device measure BP and pulse rate with a pressure range of 0-299 mmHg and pulse rate range of 40-180 beats/min."
45607517|NCT05107973|Other|Baduajin|The intervention will consist in a 1 hour supervised Baduajin sessions conducted once a week a certified instructor with more than 10 years of experience. Each session will start with 5 min of warm up, 50 minutes of Baduajin and 5 min of cool down. In the main part the participants exercise the wholes set of Baduajin that consist of eigth forms.
45607518|NCT05129111|Device|PHYSICAL VIBRATION OF THE PAROTID GLANDS|The system will be placed bilaterally in the parotid glands and assessed the efficacy of the salivary secretion by sialometry before and after the stimulation
45607519|NCT03493139|Behavioral|Physical Activity Across the Curriculum|Activity breaks will be designed for delivery in the classroom without reconfiguration of the classroom space. Activities will emphasize whole body movements, using large muscle groups. Each break includes multiple activities. Each activity lasts about 2 minutes. There will be a total of about 20 minutes of physical activity done each school day.
45607520|NCT04987931|Drug|Talazoparib|This retrospective chart review study focuses on patients with HER2- ABC with gBRCA1/2m initiating talazoparib on or after October 16, 2018 and ≥18 years of age at initiation of talazoparib.
45607521|NCT04734275|Drug|AZD5718|Subjects will receive single doses of AZD5718 on 3 occasions, separated by at least 7 days washout, under fasted and fed conditions.
45607522|NCT04714151|Drug|K-877 ER 0.2 mg/day (once daily)|K-877 ER 0.2 mg tablet
45607523|NCT04714151|Drug|K-877 ER 0.4 mg/day (once daily)|K-877 ER 0.4 mg tablet
45607524|NCT04714151|Drug|K-877 IR 0.2 mg/day (twice daily)|K-877 IR 0.1 mg tablet
45607525|NCT04702217|Other|Training program|A 16-week training program consisting of 2-3 visits per week, and 60 minutes per visit. The program will be done as group exercise under supervision from physiotherapists with special interest in POTS.
45607526|NCT04894019|Device|Continuous invasive blood pressure monitoring|Continuous invasive blood pressure monitoring using an arterial catheter
45757442|NCT05539053|Drug|N Acetylcysteine A|paclitaxel + N-Acetylcysteine orally short course
46066733|NCT00607958|Drug|tipranavir/ritonavir (dose reduction)|tipranavir/ritonavir 500/100 BID
45607527|NCT04894019|Device|Intermittent non-invasive blood pressure monitoring|Intermittent non-invasive blood pressure monitoring using upper-arm cuff oscillometry
45607528|NCT04831307|Other|[68Ga]Ga-HTK03149 PET/CT|200 MBq/m2 of body surface area, with a 200 MBq minimum adult administered activity will be injected intravenously prior to perform the PET/CT
45757443|NCT05539053|Drug|N Acetylcysteine B|paclitaxel +N Acetylcysteine orally long course
45607529|NCT04441931|Drug|LY3832479|Administered IV.
45607530|NCT04441931|Drug|Placebo|Administered IV.
45607531|NCT03492983|Dietary Supplement|Intervention group|10 g/day of high cocoa content chocolate for six months.
46066734|NCT02582554|Behavioral|NutriSTEP|Provision of nutrition risk screening with NutriSTEP (a nutrition risk screening questionnaire for preschoolers) and nutrition education with NutriSTEP related materials
45607532|NCT03491735|Other|collection of data from patient files|recording of patient data and its input into an excel sheet from which statistics will be derived
45607533|NCT03492905|Behavioral|Internet-based Cognitive Behaviour Therapy (iCBT)|Guided self-help for 7 weeks. Contact with therapist 2 times per week.
45607534|NCT03492827|Drug|chlorhexidine acetate gargle|observe whether it can achieve the effect of preventing postoperative infection
45607535|NCT04381247|Diagnostic Test|Molecular diagnostics in HAP and VAP|Airway samples will be analyzed both by standard and molecular based microbiological analysis.
45607536|NCT04461197|Device|customised foot orthoses|The foot orthoses for group A were custom made using phenolic foam molds of the feet. Separated molds were made of both feet for all the participants. . The insole was made based on a positive mold of plaster with 45 Shore cork materials with horizontal thrusts just proximal to the metatarsal heads, with the intention of correcting the pathological subtalar pronation, with a 3mm bilateral raising of the heel and a bilateral latex metatarsal bar.
45607537|NCT04461197|Device|orthotic insole|For group B, a flat insole of polyester resin was made, fitting it to the foot's size.
45444816|NCT02053870|Other|Physiotherapy+conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks. Additionally, they will be involved in 9 sessions (3 times a week during 2 weeks) of respiratory physiotherapy including breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.
45607538|NCT04254809|Behavioral|Re-Evaluating Suicidal Thoughts|Re-Evaluating Suicidal Thoughts (REST) is a is a computerized intervention designed to mitigate the experiential avoidance of suicidal thoughts. Over the course of approximately 30 minutes, individuals are provided with psychoeducation regarding the incidence rate, origin, conceptualization, and misconceptions of suicidal thoughts. Empirical evidence is presented to provide a scientific understanding of suicidal thoughts, and is aided through the use of metaphors to make concepts more accessible to viewers. REST draws from therapeutic strategies rooted in cognitive behavioral therapy (CBT) and Acceptance and Commitment Therapy (ACT) to further suggest tips for accepting (cp. approving of) the occurrence of suicidal thoughts, and introduces mindfulness and acceptance strategies for coping with them.
45607539|NCT04254809|Behavioral|Healthy Social Living|To control for potential effects of time and presentation of educational material on study outcome variables, participants randomized to the control intervention will complete a computerized psychoeducation program regarding the benefits of social support networks. Across approximately 20 minutes of audiovisual slides, participants are informed of the ways in which social connections buffer against loneliness and facilitate social learning, provided tips for expanding and maintaining their social network, and administered a brief quiz to assess for comprehension.
45607540|NCT04620005|Other|Observational|Survey
45607541|NCT03491657|Behavioral|virtual reality distraction (Yes VR)|
45607542|NCT03491657|Behavioral|music distraction (No VR)|
45607543|NCT03492749|Diagnostic Test|Saliva monitoring|The first objective of this project is to verify the feasibility of using the analysis of salivary concentration of BU during individual adjustments of this drug in the period that precedes HSCT
45607544|NCT03491579|Drug|Epacadostat|Epacadostat orally two times daily (BID) for two cycles (28 days each) in combination with standard induction chemotherapy (Cladribine and Cytarabine)
45607545|NCT03491579|Drug|Cladribine|Standard chemotherapy
45607546|NCT03491579|Drug|Cytarabine|Standard chemotherapy
45607547|NCT03901391|Diagnostic Test|Whole Exome Sequencing|Whole Exome Sequencing
45607548|NCT04600895|Drug|Favipiravir|Favipiravir
45607549|NCT04600895|Drug|Placebo|Placebo
45607550|NCT03492593|Other|lycopene|A tomato oleoresin containing lycopene
45607551|NCT03492593|Other|beta-carotene|13C beta-carotene
45757444|NCT05663294|Radiation|external beams radiotherapy|"External beam radiation therapy uses high doses of radiation to destroy cancer cells and shrink tumors. A large machine aims radiation at the cancer. The allowed schedules for external beams radiotherapy are:~40 Gy in 15 fractions;~30 Gy in 5 fractions;~40 Gy or 38.5 in 10 twice-daily fractions (each daily dose must be separated by at least 6 hours)."
45757445|NCT05663294|Radiation|brachytherapy|"Brachytherapy is a form of radiation therapy where a sealed radiation source is placed inside or next to the area requiring treatment.~The schedule for brachytherapy are:~32 Gy in 8 twice-daily fractions for HDR;~30.3 Gy in 7 twice-daily fractions for HDR;~50Gy 0.60-0.80 Gy/hour (1 pulse/hour, 24 hours/day) for PDR."
45757446|NCT00629525|Drug|RAD001|RAD001 at a dose of 10 mg PO daily
45757447|NCT00244855|Other|pharmacological study|Correlative studies
45757448|NCT00244855|Biological|rituximab|Given IV
45757449|NCT00244855|Drug|dexamethasone|Given IV
46066735|NCT00770575|Drug|Pioglitazone and atorvastatin|"Pioglitazone 30 mg, capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increase to:~Pioglitazone 45 mg, capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks."
46066736|NCT00770575|Drug|Atorvastatin|"Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increased to~Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks."
45607552|NCT03492593|Other|control|emulsified liquid meal alone
45757450|NCT00244855|Other|laboratory biomarker analysis|Correlative studies
45757451|NCT05182203|Drug|biologic/targeted therapy|TNF inhibitors or the JAK inhibitors
45607553|NCT03492515|Drug|recombinant human thrombopoietin|If platelet count <30×10^9/L and with haemorrhage or risk of bleeding,the patients began to receive subcutaneous injection of TPO with the dose of 300 Unit/kg qd,duration ≤14 days;If platelet count is between 30×10^9/L and 50×10^9/L, the dose will be 300 Unit/kg qod;If platlet count ≥100×109/L, stop this treatment;After delivery, if platelet count <30×10^9/L and with haemorrhage or risk of bleeding,subcutaneous injection of TPO with the dose of 300 Unit/kg qd or qod will be given at a duration ≤14 days;If platelet count is between 30×10^9/L and 50×10^9/L, the dose will be 300 Unit/kg qw;If platlet count ≥100×109/L, stop the treatment.
45607554|NCT03492515|Drug|Platelet Concentrate|according to the their conditions, use if necessary
45607555|NCT03491501|Other|Ergonomic evaluation using questionnaires|Employees will be provided with questionnaires such as the 'Rapid Entire Body Assessment' and NIOSH to obtain information regarding ergonomic working situations
45607556|NCT04499729|Device|IntelliCare|IntelliCare provides self management and collects symptom self-report data. Symptom severity scores are displayed to the care manager, allowing them to manage the patient's care. The app also provides a secure messaging service for communication between the care manager and the patient.
45607557|NCT04499729|Behavioral|Treatment as Usual (TAU)|Treatment as usual in the Rush Collaborative Care service
45444817|NCT02053870|Drug|Conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
45607558|NCT03491423|Other|Short and fast step test without measurement of pulmonary gas exchange|For one minute, the patient should climb up and down a 17.5 cm high step as quickly as possible while holding onto a bar in front of the step.
45607559|NCT03491423|Biological|glucose meter|glucose meter to measure lactatemia
45607560|NCT03491423|Other|ECG / heart rate|ECG and heart rate (HR) collection by telemetry
45607561|NCT03491423|Other|questionnaires|VAS pain assessment and evaluation of effort perception according to Borg's scale
45607562|NCT03491423|Other|Short and fast step test with measurement of pulmonary gas exchange|For one minute, the patient should climb up and down a 17.5 cm high step as quickly as possible while holding onto a bar in front of the step.
45607563|NCT03492359|Device|Thora-3Di|Device that uses a grid of structured light to measure chest and abdominal wall movement
45607564|NCT03492359|Device|Body Plethysmography|A pulmonary function test (PFT) for measuring total lung volume.
45607565|NCT03492359|Device|Spirometry|A pulmonary function tests (PFT) for measuring maximal forced expiratory flow and volume.
45607566|NCT03130621|Diagnostic Test|Gene detection|Next-generation sequencing
46066737|NCT00606788|Device|SmartCare/PS (Automated Weaning)|Patients received computer-driven protocolized weaning
45607567|NCT03132077|Procedure|total knee arthroplasty|surgical intervention for end stage of knee osteoarthritis
45607568|NCT04384055|Diagnostic Test|Lung Ultrasound|Lung ultrasound will be performed on patients undergoing investigation for covid-19 based on a nasopharyngeal PCR.
45607569|NCT05396989|Other|No intervention|No intervention
45607570|NCT04461353|Drug|Aerolized Hydroxychloroquine Sulfate|sterile AHCQ 100 mg/mL for inhalation, is a clear solution packaged in clear glass vials and stored at room temperature.
46066738|NCT00606788|Procedure|Conventional weaning|Patients received physician-directed non-protocolized weaning
45607571|NCT04461353|Other|Placebo|The placebo product and diluent solution is sodium chloride inhalation solution, United States Pharmacopeia (USP) 0.9%.
45607572|NCT05191615|Behavioral|Job crafting training|"Consists of two main parts. In the first part, both managers and employees will be trained in the principles of SDT and JD-R. For managers, particular attention will be paid to the provision of need support and work values. For employees, particular attention will be paid to employees' opportunities for job crafting and promoting their basic psychological need satisfaction at work.~In the second part of the intervention, participants will have the opportunity to discuss their current health status and receive preventive health recommendations from a preventive care specialist."
45607573|NCT04034459|Drug|Bevacizumab|Bevacizumab 5 mg/kg BW iv over 30 to 90* min day 1
45607574|NCT04034459|Drug|Irinotecan|Irinotecan 150 mg/m² iv, 30 - 90 min. day 1
45607575|NCT04034459|Drug|Folinic acid|Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1
45607576|NCT04034459|Drug|Oxaliplatin|Oxaliplatin 85mg/m² day 1
45607577|NCT04034459|Drug|5-FU|5-FU 3000 mg/m² iv over 48 h days 1-2
45607578|NCT04034459|Drug|Cetuximab|Cetuximab initially 400 mg/m² with infusion rate of ≤5 mg/min., subsequently 250 mg/m² iv with infusion rate of ≤10 mg/min. days 1+8
45607579|NCT03284021|Device|Fractional erbium-glass 1550 nm laser|The fractional erbium-glass 1550 nm laser will be applied to the previously 100 cm2 determined area of the scalp with the following parameters: 5-10 mm tip, 5-10 mJ, pulse energy 500-1500 MTZ/cm2 density, one to twopasses, static mode.
45607580|NCT03491189|Device|Lag screw fixation|surgical fixation
45607581|NCT03491189|Device|Helical blade fixation|surgical fixation
46066739|NCT04108078|Behavioral|Health Policy Plus (HP+)|HP+ is a stigma-reduction intervention that is designed to reduce stigmatizing attitudes and beliefs among all workers (clinical and non- clinical) in a healthcare facility.
46066740|NCT04108078|Behavioral|Many Men Many Voices (3MV)|3MV is a group-level HIV prevention intervention designed specifically for use with Black men who have sex with men (MSM). It is a 7- session intervention that is facilitated by trained peers. The intervention has previously been adapted and used with MSM in Ghana.
46066741|NCT04108078|Behavioral|HIV Education, Empathy and Empowerment (HIVE3)|The HIVE3 is a telephone-based peer support intervention. It utilizes trained peers, who are also MSM, to provide emotional, informational and affirming support via text message or phone. The intervention was developed specifically for use with MSM in Ghana and demonstrated acceptability and feasibility in a preliminary study in Ghana.
46066742|NCT00770731|Drug|Torisel (Temsirolimus)|Starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle
45444818|NCT03327675|Other|68Ga-PSMA (HBED-CC) PET|68Ga-PSMA PET/MR
45444819|NCT02053012|Device|PVT-192|PVT-192 Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurement.
45444820|NCT03795441|Biological|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection on Day 1.
45444821|NCT02053948|Procedure|Pursestring Wound Closure|
45607582|NCT03491111|Other|Respiratory muscle training for EMT+IMT|2 times per day and 5 day per week, 6 weeks, training with breathing trainer.
45607583|NCT03491111|Other|Regular Rehabilitation|Regular Rehabilitation: 2-3 times a week, 6 weeks.
45607584|NCT03491111|Other|Respiratory muscle training for EMT|5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
45607585|NCT03914885|Genetic|ATLCAR.CD30|Administered at a dose of 2 x 10^8 cells/m2
45607586|NCT03914885|Drug|Bendamustine|Administered as a dose of 70mg/m2/day over 3 consecutive days; maybe dose reduced per treating physician discretion based on prior toxicities and the patient's clinical status
45607587|NCT03914885|Drug|Fludarabine|Administered at a dose of 30mg/m2/day over 3 consecutive days; given concomitantly with bendamustine
45607588|NCT03491033|Drug|chemotherapy|All of the patients in this study underwent NAC regimens consisting of taxane and platinum combination chemotherapy. After NAC, all of the patients underwent interval debulking surgery. Subsequently, additional cycles of chemotherapy were administered after IDS to complete a total of 6 cycles at the discretion of the treating physician.
45607589|NCT03490955|Other|salad dressing (canola oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (canola oil) one time in the morning
45607590|NCT03490955|Other|salad dressing (canola oil)|Subjects will consume a vegetable salad with dressing (canola oil) one time in the morning
45757452|NCT05179785|Device|Continuous Theta Burst Stimulation (cTBS)|cTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely that can decrease the excitability of cortical neurons. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions
45757453|NCT05179785|Device|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely to increase the excitability of cortical neurons. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions.
45607591|NCT03490955|Other|black pepper|Subjects will consume a vegetable salad without dressing (canola oil) but with black pepper one time in the morning
45607592|NCT03490955|Other|salad|Subjects will consume a vegetable salad without dressing (canola oil) and without black pepper one time in the morning
45607593|NCT03490955|Other|Salad dressing (olive oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (olive oil) one time in the morning
45607594|NCT03490955|Other|Salad dressing (corn oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (corn oil) one time in the morning
45757454|NCT03359408|Behavioral|Dementia Care Management (DCM)|"A specialised discharge management, based on Dementia Care Management (DCM; Thyrian et al. 2017, Eichler, Thyrian, Fredrich et al. 2014, Eichler, Thyrian, Dreier et al. 2014, Dreier et al. 2016, ) will be applied to subjects with cognitive impairment. Specifically qualified will conduct comprehensive data assessments during the hospital stay, assess recommendations at discharge and assess unmet needs at home. Supported by a a computerized Intervention Management (IMS) and in close cooperation with the discharging hospital, treating physicians and other care providers, they will develop, implement and monitor a treatment and care plan. Interventional home visits will take place at the participants homes."
46066743|NCT00770731|Drug|Hycamtin (Topotecan)|Starting Dose 0.8 mg/m^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle
46066744|NCT00770731|Drug|Velcade (Bortezomib)|Starting Dose 0.3 mg/m^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle
45607595|NCT03490955|Other|Salad dressing (sunflower oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (sunflower oil) one time in the morning
45607596|NCT03490955|Other|Salad dressing (flaxseed oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (flaxseed oil) one time in the morning
45607597|NCT03779243|Dietary Supplement|Melatonin 5mg and Sleep Education|Melatonin 5mg daily and sleep education for 6 weeks following injury or surgery.
45607598|NCT03779243|Other|Placebo|Daily placebo pills for 6 weeks following injury or surgery.
45607599|NCT03274271|Behavioral|Action planning|Action planning is the behaviour change technique used to make users specify their goal (what they are going to do, when, where, ...).
45607600|NCT03274271|Behavioral|Coping planning|Coping planning is the behaviour change technique used to make users think about possible hindrances and according solutions when trying to reach their goal.
45607601|NCT03274271|Behavioral|Self-monitoring|Self-monitoring is the behaviour change technique used to make users keep track of their goal.
45607602|NCT03274271|Behavioral|Feedback and tips|In this intervention, users receive tailored feedback on their current health behaviour and tips and tricks to reach their goals. This tips and tricks include the behaviour change technique 'eliciting social support'.
45607603|NCT03757013|Drug|Apremilast|Apremilast
45607604|NCT03669497|Radiation|Hypo fractionated whole breast radiotherapy|Hypo fractionated radiotherapy to the whole breast and SCF to a dose of 26 GY in 5 fractions with simultaneous integrated boost in advanced incurable breast cancer
45607605|NCT02736409|Drug|Oral Budesonide Suspension (OBS)|OBS 2mg twice daily
45607606|NCT02736409|Drug|Placebo|Matching Placebo dose
45607607|NCT02444117|Other|functional rehabilitation of social communication|
45607608|NCT03490721|Other|Clustering care|During 20 minutes, preterm infants will receive a cluster care with 2 minutes of hand containment.
45607609|NCT03503357|Other|IFT Testing1|Command List A
45607610|NCT03503357|Other|IFT Testing 2|Command List B
45607611|NCT03503357|Other|IFT Testing 3|Command List C
45607612|NCT03503357|Other|IFT Testing 4|Command List D
45607613|NCT03099707|Behavioral|Treatment Ambassador|"This multi-component intervention, titled the Treatment Ambassador Program, will target people living with HIV who have not initiated ART within 3 months of testing positive. Our intervention will last for 8 sessions over 8-14 weeks, and will aim to address the three steams of influences on decision-making through a system of patient navigation and support with an assigned partner living with HIV who is trained in motivational interviewing. It will be aimed at addressing barriers to ART initiation identified through our prior qualitative research, as framed through the Theory of Triadic Influence, by addressing the three streams of influences on decision-making through a system of patient navigation and support."
45607614|NCT05396911|Behavioral|Youth Brief Tobacco Intervention|The universal prevention program was designed as a group intervention to include components of effective tobacco control programs for youth and young adults. The intervention lasts approximately 45 minutes and is delivered in a classroom setting, utilizing a Socratic teaching style and evoking participation using the principles of motivational interviewing. The Y-BTI targets all tobacco products with the goals to enhance motivation for youth to quit tobacco or remain tobacco-free, reduce intentions to use tobacco, promote peer discussions around the impact of using tobacco, and correct cognitive misperceptions around tobacco use.
45607615|NCT05396911|Behavioral|Automated Text Messaging|The ATM intervention is automated because all messages are pre-written, and their timing is pre-planned. Therefore, all students will receive the same content at the same time. The ATM intervention will last four weeks, with three - five messages sent per week. The automated program will include a mix of static and responsive messages. Specifically, some messages will be designed to maintain or enhance knowledge about tobacco use by providing facts to the student, for example, listing the negative health effects of tobacco use. Other messages will promote engagement and reflection from the student. To promote refection, some messages will request a response, but in a way that maintains confidentiality. To ensure confidential information is not sent to the text messaging program, messages that need a response will include the appropriate replies, while reflection questions will be left open-ended.
45607616|NCT03414515|Device|Endovascular intervention|Endovascular treatment with stent or balloon according to current practice
45607617|NCT05396677|Drug|Acetaminophen|2 x 500 mg acetaminophen (one time)
45607618|NCT05396677|Other|Placebo|2 x 500 mg microcrystalline cellulose (one time)
45607619|NCT03490643|Other|Postural Analysis|posture and plantar pressure analysis
45607620|NCT03490643|Other|plantar pressure analysis|posture and plantar pressure analysis
45607621|NCT04461743|Other|No intervention|No intervention, regular therapy
45607622|NCT02906033|Other|New perioperative practice model|The one and same anesthesia nurse takes care of the patient during the entire perioperative process and even pays the patient a visit to the ward the day after surgery.
45607623|NCT05396521|Other|Blood Flow Restriction|Group 2 (experimental) will receive standard of care physical therapy to be done with blood flow restriction therapy (BFR). This method includes standard of care physical therapy while occluding blood flow.
45757455|NCT00737893|Drug|Placebo|Saline injection (solution prepared by research pharmacy) subcutaneously given the day before surgery, day of surgery, and the day after surgery.
45757456|NCT00737893|Drug|Erythropoietin (EPO)|Erythropoietin (EPO)-induced Protein 29, Human; 20,000 units subcutaneously given the day before surgery, day of surgery, and the day after surgery.
45757457|NCT03357926|Diagnostic Test|24 hour Holter ECG Monitoring|24 hour Holter ECG Monitoring
45757458|NCT00631319|Drug|OROS hydromorphone|hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
45757459|NCT00631319|Drug|Placebo|Placebo
45444822|NCT02053948|Procedure|Gunsight Skin Incision and Closure Technique|
45607624|NCT05396521|Other|Standard of Care Physical Therapy|Group 1 (Control) will receive standard of care physical therapy.
45607625|NCT05131867|Drug|nimodipine|(60 mg/4 hours) orally or via nasogastric tube
45607626|NCT05131867|Drug|Oral Nimodipine and milrinone|Oral Nimodipine then after the diagnosis of vasospasm is confirmed, start milrinone bolus
45607627|NCT02221882|Drug|LY3164530|Administered IV.
45757460|NCT05686382|Procedure|Continuous Wound Infusion|continuous local anesthetic infiltration of the wound
45757461|NCT05686382|Procedure|TAP block|ultrasound guided injection of local anesthetic in the fascial plane between the internal oblique and transversus abdominis muscles
45757462|NCT00244621|Drug|candesartan cilexetil (Atacand)|0.05 mg/kg once daily oral liquid dose
45757463|NCT00244621|Drug|candesartan cilexetil (Atacand)|0.20 mg/kg once daily oral liquid dose
45757464|NCT00244621|Drug|candesartan cilexetil (Atacand)|0.40 mg/kg once daily oral liquid dose
45757465|NCT05686304|Behavioral|Internet-based self-help money management program|The online money management program course will consist of 4 weekly modules, incorporating the key components of money management and the Model of Human Occupation (MOHO), including the concept of money management, money management skill, and risk of financial exploitation.
46066745|NCT05379764|Other|Embodiment|Embodiment of a real human in a virtual human (avatar) means that the real human feels incarnated in the avatar. This happens when the real human sees the VRscenario from first person perspective, that the real human can make the avatar move (=agency over the avatar), multi-sensorial integration (=there is a link between the brain of the real human and the avatar. Example, when the avatar sits on a chair, the real human will too and he feels that he is sitting on a chair. Or when the avatar is moving the real human is doing the same movement (and of course the brain of the real human is aware of this movement)) and co-location (= avatar and real human have the sane posture).
46066746|NCT05379764|Other|Observation|The person is looking at the VR scenario as if s/he was looking at a TV
45607628|NCT05213689|Behavioral|Educational comic book|An educational comic book was developed with qualitative data collected from an earlier study phase involving focus groups with youth from Bidi Bidi. The comic book is focused on HIV testing information and decision making as it follows the story of youth in Bidi Bidi who are seeking out HIV testing. Each youth in the appropriate arm with receive a copy of the comic book and together with 5-10 other youth will meet with a PN to read through and discuss the comic book. The comic will also include blank pages so that the youth can participate in the dialogue of the comic book. The comic will be available in English, Bari and Juba Arabic.
46066747|NCT04287478|Biological|Bacteriophage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
46066748|NCT04264598|Biological|sIPV|The Medium dosage sIPV was developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the medium dosage sIPV were 15 DU, 45 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.
46066749|NCT04264598|Biological|Commercialized sIPV|The commercialized sIPV was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.The antigen contents of type I, type II and type III polioviruses in the commercialized sIPV were 30 DU, 32 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.
45444823|NCT01569633|Drug|Metclopramide|Dose of metoclopramide is 0.1miligram per kilogram every eight hours for 7-14 days.
45607629|NCT05213689|Diagnostic Test|HIV Self-testing|Participants will receive HIVST kits so that they can perform their HIV testing.
45607630|NCT02837783|Drug|Linaclotide|Oral, once daily
45607631|NCT02837783|Drug|Placebo|Oral, one daily
45607632|NCT05396365|Diagnostic Test|Dynamometry|Hand grip dynamometer measure of strength and anthropometric measurements
45607633|NCT00280189|Procedure|Radiofrequency ablation of pulmonary malignancies|Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
45607634|NCT00280189|Behavioral|Quality of life assessment|Quality of life assessment is administered prior to the Radiofrequency ablation procedure and every 3 months for 1 year following the procedure.
45607635|NCT00280189|Behavioral|Assessment of pain|Pain scores are obtained prior to the procedure, daily X 7 starting on the day of surgery, and then every 3 months for 1 year.
45607636|NCT02221648|Drug|Placebo|Subjects will be randomization to receive either the study drug or the placebo group.
45607637|NCT02221648|Drug|AbobotulinumtoxinA Treatment|Subjects receive intervention injections with the study drug arbobotulinumtoxinA.
45607638|NCT05007145|Drug|PD-1 inhibitor|PD-1 Inhibitor 200mg D1 Q3W
45607639|NCT05007145|Drug|Albumin-Bound Paclitaxel|125 mg/m^2 D1/D8 Q3W
45607640|NCT05007145|Drug|Cisplatin|75 mg/m^2 D1 Q3W
45607641|NCT05007145|Radiation|Radiation|40Gy/2.0Gy
45607642|NCT04661878|Behavioral|Social Support|The app will provide opportunities for participants to interact with each other as well as trained peer mentors to receive and provide social support.
45607643|NCT04661878|Behavioral|Informational Resources|The app will provide opportunities for participants to review HIV-related health information in engaging formats (e.g., activities, multi-media resources, and answer to users' health questions)
45607644|NCT04661878|Behavioral|Self-Monitoring and habit formation|The app will provide opportunities for participants to track their treatment adherence and schedule tailored reminders.
45607645|NCT04661878|Behavioral|Goal setting and action planning|The app will provide opportunities for participants to identify goals, select action items, and receive tailored feedback on the action plan.
45607646|NCT04952857|Drug|cholecalciferol 6 lakh IU|vitamin D levels and serum calcium will be assessed at day 3,7, 14.
45607647|NCT05440279|Device|digital patient support|"Intervention takes place through a regular electronic therapy support in addition to standard care that is defined as follows:~Emails to patients with personalized, automated feedback on their therapy (derived from device data received via modem or data entered by the patient via electronic questionnaire),~electronic questionnaires (web-based) on possible problems during therapy and subjective therapy success,~possibility to set personal adherence goals every week,~links to explanations and videos on therapy and the handling of therapy equipment and accessories,~provision of data for the trial center in the event of contact by the patient, as well as for routine therapy monitoring."
45757466|NCT00680225|Drug|Ranibizumab injection and TTT - ICG based|Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
46066750|NCT04264598|Biological|Commercialized IPV|The commercialized Salk IPV was manufactured by Sanofi Pasteur S.A.The antigen contents of type I, type II and type III polioviruses in the commercialized IPV were 40 DU, 8 DU and 32 DU. The vaccine was in liquid form, 0.5 ml per dose.
46066751|NCT00770887|Procedure|Self administration|Subjects will self administer injections of 104 mg of the subcutaneous formulation of depot medroxyprogesterone acetate (depo-subQ provera 104).
45607648|NCT02220712|Drug|OPC-14597 IMD|Administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals
45607649|NCT04923295|Drug|Dapagliflozin 10Mg Tab|Effect of Dapagliflozin on ultrafiltration and PET results among peritoneal dialysis patients
45607650|NCT04908163|Behavioral|Mediterranean diet-based nutritional education intervention|The patients in the nutritional intervention group will receive dietary advice on how to follow a Mediterranean diet. The dietary recommendations will be given at the beginning of the study by nutritionists using comprehensive written material.
45757467|NCT04603391|Drug|di-Methylphenidate plus Cannabidiol|Subjects will be administered one (1) 10 mg tablet of dl-methylphenidate (Ritalin®) plus CBD 750 mg (administered as 7.5 ml of Epidiolex® solution [100 mg/ml] of CBD)
45607651|NCT04908163|Behavioral|Mediterranean diet-based culinary intervention|The culinary intervention will be developed integrating eight culinary and nutritional workshops that will be given every week, twice per week, during one-month intervention. The duration of each culinary and nutritional workshop will be 1 hour, thus, the program will provide a total of hours of nutritional education and a total of 8 hours of nutritional and cooking training. The courses will take place in a well-equipped kitchen from the Basque Culinary Center and participants will be connected online in order to be able to cook and practice at the same time. All cooking classes will begin with a theoretical introductory part that aim to explain the main take-home messages from the workshop. Subsequently, every class will be characterized by a hands-on part that will include the demonstration and practical preparation of different elaborations based on the use specific cooking techniques and healthy ingredients.
45607652|NCT05396209|Procedure|Hydrated Amniotic Membrane Plug|Using Hydrated Amniotic Membrane plug with vitrectomy to try to close refractory macular hole
45607653|NCT05396209|Procedure|ILM filling|The ILM filling technique - Rossi et al show that ILM filling technique was more efficacious in closing full-thickness macular holes larger than 630μm, in which the free ILM after peeling is plug into the area of the macular hole
45607654|NCT05396209|Procedure|Conventional ILM peeling|Peeling with complete removal of the internal limiting membrane within the vascular arch
45607655|NCT05396131|Device|Lung Sealant|The Aeriseal System uses a polymer foam to block or seal fissures, peripheral airways, alveoli, and collateral channels to achieve lung volume reduction.
45607656|NCT05396131|Device|Endobronchial Valve (EBV)|The Zephyr EBV System are one way valves inserted into the airways to reduce lung hyperinflation.
45607657|NCT02219932|Drug|fampridine|
45607658|NCT02219932|Drug|Placebo|Matched placebo
45607659|NCT04453813|Drug|Toripalimab plus concurrent chemo-radiotherapy|"Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of toripalimab are concurrently used during radiotherapy and other 9 cycles of toripalimab are used after the end of radiotherapy. (A total of 11 cycles).~Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy"
45607660|NCT04453813|Drug|Concurrent chemo-radiotherapy|"Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy"
45607661|NCT05393557|Other|Upfront preparation of microcirculation to minimize risks of no-reflow and reperfusion injury|Tirofiban (intra-coronary bolus of 25µg/Kg) + Nitroglycerin (intracoronary 100-200 µg) + Verapamil (intracoronary 100-200 µg, yet excluding patients with 2nd or 3rd degree AV block, HR < 60, or SBP <100 mmHg) + 2 cycles of intermittent balloon inflation
45607662|NCT01138696|Other|Questionnaires|KOOS, IKDC, SF-36, Lysholm, Tegner, VAS),
45607663|NCT01138696|Other|RX|X-rays and clinical investigation of the knee 20 years after surgery
45607664|NCT00959140|Device|CD3+ T cell depletion|"The peripheral blood stem cell product is engineered to deliver a dose of 15 to 20 x10^7 CD3+ cells/kg recipient body weight. Other components of the graft will not be manipulated and the recipient will receive the total number of cells collected with the exception of minimal losses that occur during the process of CD3+ T cell isolation. Following collection, CD3+ T cells will be enumerated and a portion of the product containing 15 to 20 x10^7 CD 3+ cells/kg will be set aside. The remainder of the product will be depleted of CD3+ T cells.~Following CD3+ T cell depletion, the CD3+ T cell depleted product will then be combined with the unmanipulated product to provide the specified levels of CD3+ T cells/kg recipient body-weight. The graft is infused into the patient on the same day as selected and within 24 hours of donor aphaeresis."
45757468|NCT04603391|Drug|di-Methylphenidate plus Cannabidiol Placebo solution|Subjects will be administered one (1) 10 mg tablet of dl-methylphenidate (Ritalin®) 7.5 ml of Epidiolex® placebo solution containing no CBD.
45757469|NCT05686148|Other|Vibration|The device used for vibration application is produced to control pain and direct attention by providing 6000/min vibration. According to Melzack and Wall's Gate Control Theory, the application of local vibration reduces perceived pain by stimulating nerve fibers. Therefore, it should be ensured that the device is in full contact with the skin. The device can be used again by wiping with 70% alcohol. The device is placed 3 cm above the area to be injected. Vibration is applied to the area for 5 minutes before the procedure.
45757470|NCT01271647|Drug|Yin and Yang tonic granules|Yin and Yang tonic granules,18g per time,two times per day,six months
45757471|NCT01271647|Drug|placebo|granules,18g per time,two times per day,six months
45757472|NCT03368456|Behavioral|S4E|S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV/STI testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol & drug use, HIV & STIs and a forthcoming module on tobacco prevention and cessation.
45757473|NCT03368456|Behavioral|Usual Care|Participants in Usual Care (i.e., Control Condition) will not receive the S4E intervention from the study staff. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources, and reproductive and healthcare services.
45607665|NCT04631965|Behavioral|Transition support service|The hospital-wide transition support service provides systematic care coordination for young patients prior to the transfer of care
45607666|NCT00846430|Drug|Peg-Interferon alpha-2b|age and weight dependant
45607667|NCT00846430|Drug|Celecoxib (Celebrex)|age and weight dependant
45607668|NCT00846430|Drug|Temozolomide (temodar)|age and weight dependant
45607669|NCT00846430|Drug|Vincristine Sulfate (Oncovin)|age and weight dependant
45607670|NCT04454125|Behavioral|AQI intervention|The intervention arm will receive AQI education, an asthma action plan containing AQI information and recommendations, and will be required to demonstrate ability to check AQI (either via airnow.gov website or downloaded AirNow smartphone app).
45607671|NCT04454125|Other|Routine care|The routine care arm will be provided with general AQI education and an asthma action plan not containing AQI information.
45607672|NCT02219464|Device|Nasopharyngeal catheter|
45607673|NCT02219464|Device|Nasal Cannula|
45607674|NCT02219464|Procedure|Oxygen Supplementation|Initially set at 3 liters/minute
45607675|NCT02219464|Procedure|Sedation|Midazolam 2mg IV, Fentanyl 100mcg IV, Propofol 100 mcg/kg/min. Additional doses of propofol at the discretion of the attending anesthesiologist.
45607676|NCT04454047|Procedure|Extracapsular arthroscopy|Extracapsular arthroscopy method was used to treat refractory tennis elbow
45757474|NCT03356990|Dietary Supplement|Resistant Starch|"Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose (one bag) of Hi-Maze 260 or High RS Gummy Chews in the morning and the other half dose (one bag) in the evening."
45444824|NCT01569633|Drug|Erythromycin|Dose of erythromycin is 1 miligram per kilogram every eight hours
45444825|NCT01569633|Drug|placebo|The dose of sugar water is 1 ml per 8 hours.
45607677|NCT04418284|Other|survey|online survey
45607678|NCT04592575|Other|Vestibular Evaluation|Each patient will have a full vestibular evaluation by a physical therapist
45607679|NCT02219308|Procedure|Paracervical Block (PCB)|"Drug: 1% Lidocaine Hydrochloride~Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix and 18 mL 1% buffered lidocaine solution evenly distributed between 4 o'clock and 8 o'clock positions of cervix with standard 22 gauge spinal needle.~IUD placement then proceeds"
45607680|NCT02219308|Procedure|No Paracervical Block (Sham PCB)|"Drug: 1% Lidocaine Hydrochloride~Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix with standard 22 gauge spinal needle. Capped spinal needle is then held against the cervix at 4 o'clock and 8 o'clock positions of cervix, lightly so as not to cause blanching, indentation, or pain.~IUD placement then proceeds"
45607681|NCT05439577|Drug|Mucopolysaccharide Polysulfate Cream|Patients using Hirudoid® alone
46066752|NCT04076722|Behavioral|Stress reactivity stimuli|An evaluated speech task delivered to participants after baseline testing.
45607682|NCT05439577|Drug|Mucopolysaccharide Polysulfate Cream and glucocorticoids|Patients using Hirudoid® and glucocorticoids (Combination therapy, but not always)
45607683|NCT05387005|Diagnostic Test|UBT|H. pylori diagnostic test: C13 urea breath test
45607684|NCT05387005|Diagnostic Test|HPSA|H. pylori diagnostic test: H. pylori stool antigen test
45607685|NCT05387005|Diagnostic Test|UBT and HPSA|H. pylori diagnostic tests: H. pylori serology test, C13 urea breath test
45607686|NCT05387005|Diagnostic Test|Serology (two stage)|H. pylori diagnostic test: H. pylori serology test
46066753|NCT04265690|Behavioral|Cooking classes|Participants will receive 2 cooking classes (each 1-hour long) during their Centering group-care visit at the BMC teaching kitchen, taught by a Registered Dietitian. The recipes taught during the cooking classes will follow the Special Supplemental Nutrition Program for Women, Infants, and Children, the 2015-2020 Dietary Guidelines for Americans, and recommendations from The American College of Obstetricians and Gynecologists.
46066754|NCT04265690|Behavioral|Text messages|Participants will receive text messages, through a password secured phone, based on their content and frequency preferences.
46066755|NCT00775255|Drug|clarithromycin 250 mg/5 mL powder for oral suspension|
45757475|NCT00738049|Drug|darusentan 100 mg|All subjects will receive oral darusentan 100 mg for a total of 2 weeks and placebo for 2 weeks.
45757476|NCT04536935|Behavioral|Mobile Mental Health App - 1|Free mobile mental health application that focuses on meditation
45757477|NCT04536935|Behavioral|Mobile Mental Health App - 2|Free mobile mental health application that assists with coping with COVID-19
45757478|NCT04536935|Behavioral|Mobile Mental Health App - 3|Free mobile mental health application that focuses on positive psychology.
45757479|NCT04536935|Behavioral|Mobile Mental Health App - 4|Free mobile application that addresses mental health issues through mood tracking
46066756|NCT02582398|Other|Light Therapy|One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.
46066757|NCT02582398|Other|Placebo Light|The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (<400nm or >500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.
46066758|NCT00606866|Drug|placebo|Placebo for four weeks
46066759|NCT00606866|Drug|Sorafenib|Sorafenib 200 mg twice daily
45444826|NCT02053090|Behavioral|Group Education and Stretching|
45607687|NCT03087175|Device|MGuard stent|MGuard micronet mesh-covered stent in treatment of STE and NSTE-ACS
45607688|NCT03087175|Device|Drug eluting stent and bare metal stent|Drug eluting stent and bare metal stent in treatment of STE and NSTE-ACS For example, Resolute Onyx
45607689|NCT05385523|Procedure|Rhomboid Intercostal and Sub-Serratus block technique (RISS)|The patient will be placed in lateral position. A linear ultrasound transducer of frequency 6-12 MHz will be placed medial to the lower border of the scapula in a sagittal plane. A 38-mm 22-gauge will be inserted under real-time in-plane from craniocaudal between the rhomboid major and intercostal muscles. After negative aspiration, single injection of 10 ml of the local anesthetic mixture will be administered at the T6 7 level. The spread of local anesthetic solution under the rhomboid muscle will be visualized by ultrasonography. Then the ultrasound probe will be moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscle for the sub-serratus block at T 8-9 level. The needle will be advanced from its previous position and a further of 10 ml of the local anesthetic mixture will be injected.
45757480|NCT05645276|Drug|AK129 IV infusion|AK129 is administered intravenously according to the frequency and dosage of administration at different stages.
46066760|NCT00606866|Drug|Sorafenib|Sorafenib, 400 mg twice daily
45444827|NCT02053090|Procedure|Group Acupuncture|
46066761|NCT00766285|Biological|Trivalent inactivated influenza vaccine|Standard trivalent influenza vaccine consisting of 15 mcg per antigen (45 mcg total) by intramuscular deltoid injection.
45607690|NCT05385523|Procedure|General Anaesthesia|"Fentanyl (1 μg/kg), propofol (2-3mg/kg) and atracurium (0.3-0.5 mg/kg) will be injected intravenously 3-5 minutes after oxygenation. A single-lumen endotracheal tube will be used to complete ventilation. The ventilator ventilation mode is volume control mode, and the patient's end-expiratory carbon dioxide level is maintained at 35-40 mmHg throughout the anesthesia process. During the anesthesia maintenance phase, 2% sevoflurane mixed with 60% oxygen.~After general anaesthesia induction, all patients will receive RISS block with different local anesthetic drug mixture according to randomization."
45607691|NCT05385523|Drug|dexamedatomidine|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 1 Mcg/kg dexamedatomidine in 2 mL.
45607692|NCT05385523|Drug|dexamethasone|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 8mg dexamethasone in 2 mL.
45607693|NCT05385523|Drug|saline|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine+ 2 mL normal saline.
45607694|NCT04481347|Device|Sleep EEG recording using a DREEM® headband|Sleep EEG recording using a Dreem® headband (Rythm, Paris, France), an EEG recording device adapted to sleep conditions and completely non-invasive
45607695|NCT04481347|Other|Montreal Cognitive Assessment (MoCA)|Neuropsychological assessment using the The Montreal Cognitive Assessment (MoCA) questionnaire to detect postoperative cognitive dysfunction
45607696|NCT04481347|Device|Intraoperative EEG recording using a Sedline® monitoring|Intraoperative brain function monitoring using a Sedline® module (Masimo corporation) to evaluate the state of the brain under anesthesia
45444828|NCT03795051|Device|Navigated Transcranial Magnetic Stimulation|This study is a feasibility trial. Each participant will receive 30sessions of 10 Hz or 20 Hz rTMS over the left DLPFC. The rTMS interventions will be guided by a neuronavigation system (StimGuide TMS Navigation System, Magstim, Ltd. Carmarthenshire, UK) for navigation to the treatment location and to ensure consistent placement and orientation of the coil during and between each session. For the purpose of this protocol, these sessions are referred to as nTMS.
45444829|NCT02054026|Behavioral|Reducing the Risk|
45607697|NCT04318561|Diagnostic Test|Gallium-68 NODAGA-LM3 PET/CT|Twenty patients will take this intervention. They will be further divided into two sub-groups with the same interventional radiopharmaceutical (Gallium-68 NODAGA-LM3) but different scanning protocols (Protocol A and Protocol B). The first enrolled 8 patients will go with Protocol A, who will undergo serial whole-body PET/CT scans at multiple time points (5m, 10m, 20m, 40m, 1h, 2h) after administering 40ug/150-200MBq Gallium-68 NODAGA-LM3. Baseline safety assessment will be conducted right before the study. The following 12 patients will go with Protocol B, who will undergo a whole-body PET/CT scan at 1 hour after administering 40ug/150-200MBq Gallium-68 NODAGA-LM3.
45607698|NCT04318561|Diagnostic Test|Gallium-68 DOTA-LM3 PET/CT|Twenty patients will take this intervention. They will be further divided into two sub-groups with the same intervention radiopharmaceutical (Gallium-68 DOTA-LM3) but different scanning protocols (Protocol C and Protocol D). The first enrolled 8 patients will go with Protocol C, who will undergo serial whole-body PET/CT scans at multiple time points (5m, 10m, 20m, 40m, 1h, 2h) after administering 40ug/150-200MBq Gallium-68 DOTA-LM3. Baseline safety assessment will be conducted right before the study. The following 12 patients will go with Protocol D, who will undergo a whole-body PET/CT scan at 1 hour after administering 40ug/150-200MBq Gallium-68 DOTA-LM3.
45607699|NCT04318561|Diagnostic Test|Gallium-68 DOTATATE PET/CT|All patients have to do a Gallium-68 DOTATATE PET/CT scan (40ug/150-200MBq, 1h post-injection) for comparison on the next day of LM3 scan. Safety assessment and tolerability of the previous LM3 study will be conducted right before the study.
45607700|NCT05439265|Other|Electronic medical record order panel and resident involvement|Prior to 2014, there was no formal process for evaluation of patients with HIT. In November of 2014, an EMR tool was created in an effort to improve heparin allergy documentation and HIT management. This EMR tool prompts the medical team to perform the 4T score, displays the appropriate HIT labs, alternative anticoagulation strategies, instructs the nurse to apply an allergy bracelet, and notifies the pharmacy resident through the order verification queue. The pharmacy resident then performs an independent 4T score, discontinues all heparin products, documents the heparin allergy in the medical record, and assesses the need for alternative anticoagulation.
45607701|NCT04655053|Behavioral|Goal intention|Researcher instructs participants to adopt and learn the goal intention requesting them to write it three times and verbally repeat once.
45607702|NCT04655053|Behavioral|Implementation intention to initiate the behavior|Researcher instructs participants to adopt and learn the goal intention and the plan requesting them to write it three times and verbally repeat once.
45607703|NCT04655053|Behavioral|Implementation intention to manage the goal preference (avoiding behavior or not)|Researcher instructs participants to adopt and learn the goal intention and the plan requesting them to write it three times and verbally repeat once.
45607704|NCT03910621|Drug|Miglustat|capsule, oral use
45607705|NCT03950401|Procedure|Monocryl|subcuticular Monocryl wound closure
45607706|NCT03950401|Procedure|Nylon|wound closure using nylon suture on the skin
45757481|NCT04416633|Drug|Durvalumab|500-mg/120-mg IV
46066762|NCT00766285|Biological|Trivalent Baculovirus-expressed Influenza HA vaccine|Influenza virus hemagglutinin proteins expressed in insect (SF+) cells under serum free conditions by recombinant baculovirus.
46066763|NCT05367700|Drug|HS-10382(Part 1: Dose escalation)|Single or multiple dose(s) of HS-10382 once daily.
46066764|NCT05367700|Drug|HS-10382(Part 2: Dose expansion)|HS-10382 is administered orally once daily.
46066765|NCT00775333|Procedure|Outcome after carpal tunnel release|Follow the outcome after standard carpal tunnel release in diabetic and non-diabetic patients
46066766|NCT02581774|Other|normal delivery tracking|normal delivery tracking
45444830|NCT03795285|Diagnostic Test|Expression of neutrophil CD64|Expression of neutrophil CD64 will be measured by Flow cytometry. In addition, sTREM-1 will be measured in the serum by ELISA
45444831|NCT02054182|Drug|Vitamin D|Vitamin D 2 500 IU daily from enrolment (within 24 hours of hospitalization) until discharge from hospital
45452234|NCT02269384|Behavioral|Memory of Prior Significant Injury|Subjects will visual prior significant injury or a predetermined lower extremity region in control subjects.
46066767|NCT04265456|Drug|Pregabalin 100mg|Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
45607707|NCT02218372|Drug|Fidaxomicin oral suspension|Participants from birth to < 6 years of age received weight based doses of fidaxomicin oral suspension (32 mg/kg/day with a maximum dose of 400 mg/day divided in 2 doses) 2 times daily for 10 days.
45607708|NCT02218372|Drug|Fidaxomicin tablets|Participants aged ≥ 6 years to < 18 years of age received a 200 mg fidaxomicin tablet 2 times daily for 10 days.
45607709|NCT02218372|Drug|Vancomycin oral liquid|Participants from birth to < 6 years of age received weight based doses of vancomycin oral liquid (40 mg/kg/day with a maximum dose of 500 mg/day divided in 4 doses) 4 times daily for 10 days.
45607710|NCT02218372|Drug|Vancomycin capsules|Participants aged ≥ 6 years to < 18 years of age received a 125 mg vancomycin capsule 4 times daily for 10 days.
45607711|NCT03762655|Device|Neuro-Spinal Scaffold|"The investigational product (Neuro-Spinal ScaffoldTM or Scaffold) is a porous bioresorbable polymer scaffold comprised of a synthetic biomaterial, poly(lactic-co-glycolic acid)-b-poly(L-lysine) (PLGA-PLL). The Scaffold is cylindrical in shape (3 mm diameter) and is available is three lengths (6 mm, 8 mm, 10 mm) for optimal fit in the intraspinal lesion cavity.~Based upon pre-clinical testing, the Scaffold is expected to be resorbed from the site of implant within 4 to 8 weeks."
45607712|NCT05439187|Procedure|hernia repair|Open or laparoscopic hernia repair with mesh placement.
45607713|NCT05439109|Device|Topographical landmark technique of endotracheal tube placement|An endotracheal tube will be placed inside the trachea after measuring the individual's estimated tracheal dimensions.
45607714|NCT05439109|Device|Intubation guide mark technique of endotracheal tube placement|An endotracheal tube will be placed in this group by using the intubation guide mark.
45607715|NCT02218216|Device|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
45607716|NCT02217982|Drug|Simethicone|
45607717|NCT02217982|Drug|Loperamide|
45607718|NCT02217982|Other|Peanut Butter|
45607719|NCT00587314|Other|Biopsy|Biopsies for research purposes will be obtained when returning for clinically indicated surveillance of Barrett's Esophagus
46066768|NCT04265456|Drug|Acetaminophen 1300mg|Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
45607720|NCT02254408|Drug|Presatovir|Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
45607721|NCT02254408|Drug|Placebo|Tablets administered orally or via nasogastric tube
45607722|NCT02207608|Drug|Hyaluronic Acid|Add hyaluronic acid to BCG Treatment
45607723|NCT02207608|Drug|BCG (Immucist®)|Usual BCG treatment
45607724|NCT03530995|Drug|Belumosudil|Development candidate
45607725|NCT03530995|Drug|Itraconazole|Perpetrator drug
45607726|NCT03530995|Drug|Rabeprazole|Perpetrator drug
45607727|NCT03530995|Drug|Rifampicin|Perpetrator drug
45607728|NCT03530995|Drug|Omeprazole|Perpetrator drug
45607729|NCT02217436|Device|iPad|iPad with age-appropriate applications, videos, and music
45607730|NCT02217436|Other|Standard Care|All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
45607731|NCT03467503|Dietary Supplement|Blueberry + soluble fiber|Dietary frozen blueberries and soluble fiber for 20 weeks
45607732|NCT05438875|Drug|all-trans retinoic acid|ATRA 10 mg, 2 times a day, orally.The treatment course is 12 weeks.
46066769|NCT04379518|Other|Best Practice|Receive standard of care
45607733|NCT05438875|Drug|Eltrombopag|The initial dose of eltrombopag is 50 mg/time, once a day, and the dose is increased when the platelet count is lower than 5×109/L, the maximum is 75 mg/d, and the dose is higher than 200×109/L. When the drug is temporarily discontinued, the drug is re-administered according to the platelet count.The treatment course is 12 weeks.
45607734|NCT05371483|Diagnostic Test|24-hour Ambulatory Blood Pressure Monitoring|Arm blood pressure cuff that will automatically inflate every 15-30 minutes to check blood pressure while awake and asleep over 24 hours. Patient will also complete a sleep diary and wear an actigraphy watch during this test.
45607735|NCT05371483|Diagnostic Test|Oculo-Cognitive Addition Test (OCAT)|Tracks users' eye movements as they complete a simple mental addition test.
45607736|NCT04740307|Biological|Pembrolizumab/Quavonlimab|Pembrolizumab/Quavonlimab (400 mg/25 mg) administered via IV infusion Q6W.
45607737|NCT04740307|Drug|Lenvatinib|Lenvatinib 12 mg (body weight [BW] ≥60 kg) or 8 mg (BW <60 kg) administered orally every day (QD).
45607738|NCT04740307|Biological|Pembrolizumab|Pembrolizumab (400 mg) administered via IV infusion Q6W, in the event of intolerable toxicity to pembrolizumab/quavonlimab.
45607739|NCT02207530|Drug|MEDI4736|MEDI4736 monotherapy
45607740|NCT05438797|Drug|Adoptive TIL-TCM transfer therapy|Abraxane:100-200 mg/m2，QD×1D;Cyclophosphamide:15-35 mg/kg/d，QD×2D. Biological: Adoptive TIL-TCM transfer therapy
45607741|NCT03467347|Drug|VR: 200 mg DPV + 320 mg LNG|One silicone elastomer vaginal ring (VR) containing the active ingredients dapivirine (DPV) and levonorgestrel (LNG), formulated as IPM VR: 200 mg DPV + 320 mg LNG (Ring-102)
46066770|NCT04379518|Biological|Recombinant Interferon Alfa-2b|Given IV
46066771|NCT04379518|Drug|Rintatolimod|Given IV
46066772|NCT04264364|Procedure|Laparoscopic sleeve gastrectomy|Bariatric surgical intervention
46066773|NCT04264364|Procedure|Endoscopic sleeve gastroplasty|Endoscopic bariatric procedure
45452235|NCT02269384|Procedure|Mental Challenge Test|Subjects will count backwards from 100 by specified amounts as rapidly as possible
45607742|NCT05438641|Drug|BZDP-Sparing Protocol|BZDP-Sparing group includes subjects primarily treated with a non-BZDP agent (e.g., Alpha-2 agonists and/or anticonvulsants). Rescue with BZDP-based treatment allowed if there is symptomatic breakthrough- as measured by CIWA > 15.
45607743|NCT05438641|Drug|BZDP-Based Protocol|Patients in this arm will received active treatment based on conventional BZDP-based protocol; additional BZDP are permitted for patients who are still symptomatic, based on CIWA-Protocol.
45607744|NCT03467269|Diagnostic Test|Brush sign|presence of a brush sign in MRI image in acute cerebral ischaemia
45607745|NCT05359315|Drug|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10*7 Units per mg of protein
45607746|NCT02616055|Drug|tesevatinib|
45607747|NCT05331391|Behavioral|Brief mobile SMART Exercise Support Program|Patients will receive 1) a brief SMART Exercise individual face-to-face session; 2) a theory-based instant messaging (WhatsApp/WeChat) and telephone-delivered health coaching on a 2-stage tapering schedule. Stage 1 (week 1 to 6): daily messages and two biweekly phone calls for exercise habit formation. Stage 2 (week 7 to 12): messages twice a week and monthly phone calls for exercise habit maintenance.
45607748|NCT05326711|Behavioral|Telerehabilitation-based motor imagery training|"Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies."
45607749|NCT05307289|Other|Biposy|Biopsy at inclusion visit and at disease progression if applicable
45607750|NCT04697173|Other|Single consent|A single consent form for possible procedures the child may undergo while in the PICU
45607751|NCT03467035|Other|Inflammasone|Serum level of cytokine and RT-PCR for PBMC
45607752|NCT02207374|Drug|semaglutide|Subject will receive either a dose of 0.5 or 1.0 mg of semaglutide once weekly (subcutaneous (s.c.) injection).Treatment duration 56 weeks.
45607753|NCT02207374|Drug|DPP-4 inhibitor|Subjects will receive one DPP-4 inhibitor in addition to pre-trial OAD monotherapy, if any, for 56 weeks.
45607754|NCT03466957|Other|3D printed applicator|add-on cap for oblique needles, 3D printed Vienna-like applicator, individual vaginal cylinder for intracavitary/interstitial application
45607755|NCT03466879|Device|SYNUS Pain Relief device|SYNUS Pain Relief is a handheld micro-current TENS device used for the temporary relief of sinus pain.
45607756|NCT02217280|Drug|Injection with Gadolinium|Gadavist (gadobutrol) injection is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system
45607757|NCT02786537|Drug|SOF/LDV (sofosbuvir/ledipasvir)|Sofosbuvir/Ledipasvir (400/90 mg) for approximately 12 to 24 weeks (treatment duration and use of ribavirin is per discretion of HCV provider)
45757482|NCT05640752|Diagnostic Test|2019 ESC guideline-determined diagnostic strategy|ESC-PTP is calculated using age, sex and type of chest pain according to 2019 ESC guideline for the diagnosis and management of CCS and RF-CL is calculated using age, sex, type of chest pain, hypertension, dyslipidemia, diabetes, smoking and family history of CAD based on the publication of Winther et al., respectively. According to ESC strategy, subjects with ESC-PTP ≤5% are classified into low risk group and ones with ESC-PTP ≥15% are classified into high risk group. For subjects with ESC-PTP of 5%-15%, ones with RF-CL ≥15% are classified into high risk group and ones with RF-CL <15% are classified into low risk group. CCTA should be referred for a subject in high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
45757483|NCT05640752|Diagnostic Test|2016 NICE guideline-determined diagnostic strategy|For subjects assigned to NICE strategy, ones with nonanginal chest pain and normal ECG were classified into low risk group and ones with typical and atypical angina or nonanginal chest pain with abnormal ECG were classified into high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
45607758|NCT02786537|Drug|PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)|Ombitasvir/paritaprevir/ritonavir (12.5/75/50mg) (2 tablets taken orally) and Dasabuvir (250 mg tablet) (1 tablet twice daily) with food for 12 to 24 weeks (treatment duration as per HCV provider)
45607759|NCT02786537|Drug|EBR/GZR (elbasvir/grazoprevir)|Elbasvir/grazoprevir (50/100mg) tablet once daily with or without food with or without RBV for 12 to 16 weeks
45607760|NCT02786537|Drug|Ribavirin|200 mg pills (1-3 pills, 1-2 times per day)
45607761|NCT03307759|Drug|Pembrolizumab|Pembrolizumab
45757484|NCT02291133|Procedure|Electrochemotherapy|Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation
45607762|NCT03307759|Radiation|Radiotherapy (SABR)|Radiotherapy
45607763|NCT02216812|Drug|500 mg vitamin c, 1 pill per day for 6 weeks|
45607764|NCT02216812|Drug|1 placebo pill for 6 weeks|
45607765|NCT05433727|Diagnostic Test|videodermoscopy, lesional capillaroscopy|videodermoscopy and lesional capillaroscopy will be performed under different magnification levels to the skin lesions and data will be recorded.
45607766|NCT05433259|Device|Overnight orthokeratology|Subjects require to wear the lenses every night, with a recommended time of 6-8 hours.
45607767|NCT04762186|Drug|human SARS-CoV 2 specific T lymphocytes|"In dose level one, SARS-CoV-2 infected patients will receive 1,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In dose level two SARS-CoV-2 infected patients will receive 5,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In parallel, all patients will receive the current SoC treatment for COVID-19."
45607768|NCT03466645|Drug|Vancomycin|The 1st group receives vancomycin an hour before craniotomy
45607769|NCT03466645|Drug|Cefazolin|The 2nd group receives cefazolin an hour before craniotomy
45607770|NCT05432557|Procedure|external oblique intercostal plain block (EOIP)|A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation at the sixth intercostal space in the anterior midaxillary line. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the external oblique muscle. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected.
45607771|NCT05432557|Procedure|subcostal transversus abdominis plane block (SCTAP)|The US probe will be placed immediately below the costal margin on oblique plane toward the lateral close to midline to identify the rectus abdominis muscle. The transversus abdominis muscle will be identified lying posterior to the rectus muscle. An 8cm 22-gauge block needle will be inserted using an in- plane approach. transversus abdominis plane will be accessed by placing the needle adjacent to costal margin but medial to linea semilunaris. The needle will be advanced slowly in-plane to promote hydrodissection along the oblique subcostal line. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected.
45607772|NCT05432557|Other|control group|No LA injection
45607773|NCT05432479|Dietary Supplement|Probiotic|Single strain probiotic in a form of a sachets with a daily dose of 1.0E+9 Colony Forming Unit (CFU) per day for 4 weeks
45607774|NCT05432479|Dietary Supplement|Placebo|Placebo
45607775|NCT02695277|Device|AtriCure Bipolar System|
45607776|NCT02695277|Device|Standard Endocardial Ablation with Catheter|
45607777|NCT02695277|Device|AtriClip® PRO LAA Exclusion System|
45607778|NCT02695277|Device|Endocardial Ablation with Catheter|
45607779|NCT02695277|Device|Repeated Endocardial ablation(s)|
45607780|NCT05430451|Behavioral|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
45607781|NCT05430451|Behavioral|Referral card|The content consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information, and strong supporting messages or slogans.
45607782|NCT05430451|Behavioral|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
45607783|NCT05430451|Behavioral|Simple physical exercise training|The simple exercises consist of a) Zero-time exercises (ZTEx), b) handgrip exercises, and c) resistance exercises. Participants will receive handgrips and elastic bands, and trained smoking cessation ambassadors will demonstrate and encourage the use of handgrip and elastic bands onsite with an instruction leaflet.
45607784|NCT05430451|Behavioral|Simple physical exercises with instant messaging support|During the 3-month instant messaging support, smoking cessation counselors will deliver regular messages to encourage the practices of simple physical exercise, provide strategies for managing craving and withdrawal symptoms, and provide information on smoking-related knowledge and available smoking cessation services. Our trained smoking cessation counselors will also provide real-time support upon participants' inquiries.
45607785|NCT05430451|Behavioral|SMS|SMS on follow-up survey reminders
45607786|NCT04461665|Other|vitamin D|vitamin D supplement 10 μg daily for 2 months
45607787|NCT02252536|Drug|gabapentin enacarbil|Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day
45607788|NCT02252536|Drug|Placebo|Placebo tablet, white to off-white, oval shaped tablets, taken 2 times per day
45607789|NCT02725619|Behavioral|CBT|
45607790|NCT02725619|Behavioral|PST|
45607791|NCT05277259|Device|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
45607792|NCT05277259|Other|Kinesiotaping|Elastic band to be used to stretch the upper trapezius muscle in the desired direction.
45607793|NCT05277259|Other|Conventional Physical Therapy|Conventional physical therapy will be consisted of hotpack, therapeutic ultrasound and tens applications.
45607794|NCT03490487|Drug|conventional antiepileptic drugs|will receive conventional antiepileptic drugs only. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
45607795|NCT03490487|Drug|oral steroid|will receive oral steroid for 3 months beside conventional antiepileptic drugs. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
45757485|NCT02291133|Device|Cliniporator Vitae®|"Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.~The maximum duration of procedure is 90 minutes, after liver mobilization."
45757486|NCT02291133|Drug|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2)
45607796|NCT05277103|Behavioral|Exploring predictors of response to a peer-mediated communication intervention for minimally verbal preschoolers with ASD|The intervention, Stay-Play-Talk with iPad, incorporates SGD instruction and peer training, both demonstrated to be effective in increasing communication and social interactions of preschool-age children with ASD. Children with ASD will be provided with an iPad with Touch Chat voice output app (the SGD) to use throughout the project. Two peers are recruited for each child with ASD. Research staff will implement peer training for three 30-min sessions, with peers taught to: STAY - sit close; PLAY- share and take turns; and TALK with iPad - look and listen/push and talk. After peers are trained, they will take turns engaging in common preschool games and preferred play activities with one assigned child with ASD (1 child:1 peer). Treatment will be provided for 15-20 min, twice per week for 8 weeks in the classroom.
45607797|NCT03492203|Behavioral|Active Cognitive Remediation|Cognitive remediation engages participants in computerized exercises meant to improve cognitive functions and provides therapist feedback for how these improvements manifest in everyday life. The novel components of CR in this study will be the delivery of treatment remotely.
45607798|NCT03492203|Behavioral|Cognitive Remediation Control|The investigators have developed a 'comparison' cognitive remediation treatment in collaboration with the same company that produced the cognitive exercises. These procedures include the same stimuli but are adjusted without increasing cognitive load.
45607799|NCT03492203|Behavioral|Online computer exercises|There are 30 unique cognitive exercises in the program (sbtpro.com). The investigators will prescribe 24 exercises in the domains most commonly impaired in MDD: six targeting executive functions, ten targeting memory, and eight targeting attention and working memory. The specific activities are prescribed in a fixed, systematic order, such that the participants have a schedule of exercises that address several different cognitive domains each week and return to exercises in subsequent weeks. Parameters are automatically adjusted based on participant performance across 30 difficulty levels. Participants are prescribed two 20-minute sessions per day, five days per week, for the duration of the study.
45607800|NCT03492203|Behavioral|Strategy monitoring|Therapists communicate with participants in asynchronous private and group forums, where specific responses to questions prime flexible strategy formation, monitoring of strategies, and bridging to real world functioning. Participants use logs to track their own strategies and upload this information to the forum for therapist feedback. The purpose of the therapist responses is to reinforce the development of multiple strategies and help supplement or reshape those that are concrete, based on a predetermined list of strategies developed for each of the computer exercises.
45607801|NCT03492203|Behavioral|Bridging strategies|The online forum will have illustrations for bridging cognitive abilities and problem solving strategies related to each game to experiences in the real world. An at home workbook will also be used to facilitate active application of skills in various domains (e.g., work, socialization, recreation, household maintenance).
45607802|NCT05271331|Drug|ESP block with saline|Bilateral ultrasound guided injection of saline in the erector spinae plane (below erector spinae plane muscle group and above the transverse process of the vertebra)
45607803|NCT05271331|Drug|Wound infiltration with saline|Blinded injection of saline in the skin, subcutaneous tissue and muscles at the site of surgical incision
45607804|NCT05271331|Drug|ESP block with local anesthetic|Bilateral ultrasound guided injection of local anesthetic (ropivacaine 0.35%, 40ml) in the erector spinae plane (below erector spinae plane muscle group and above the tranverse process of the vertebra)
45607805|NCT05271331|Drug|Wound infiltration with local anesthetic|Blinded injection of local anestetic (ropivacaine 0.35%, 40ml) in the skin, subcutaneous tissue and muscles at the site of surgical incision.
45607806|NCT03490409|Device|Thigh compression stocking|Thigh compression stocking
45607807|NCT05267197|Other|3D Telemedicine|3D Telemedicine system
45607808|NCT05267197|Other|2D Telemedicine|2D Telemedicine system
45607809|NCT03466567|Drug|Semaglutide|A single dose of 3 mg semaglutide tablet alone will be administered orally. Trial product administration will take place in the morning after overnight fasting for at least 6 hours.
45607810|NCT03466567|Drug|Probenecid|A dose of 500 mg probenecid (2 tablets of 250 mg) will be administered orally twice daily for 3½ days (7 trial product administrations in total). On the 4th day, the last probenecid administration will take place 2 hours prior to administration of a single dose of 3 mg oral semaglutide tablet. The last trial product administrations will take place in the morning after overnight fasting for at least 6 hours.
45607811|NCT03466567|Drug|Ciclosporin|A single dose of 600 mg ciclosporin (6 capsules of 100 mg) will be administered orally 1 hour prior to administration of a single dose of 3 mg oral semaglutide tablet. Trial product administration will take place in the morning after overnight fasting for at least 6 hours.
46066774|NCT05379608|Procedure|Intermittent hypoxic-hyperoxic training|"IHHT will be carried out using the ReOxy normobaric hypoxic therapy apparatus (Bitmos GmbH, Germany, 26790/10221, 04/10/2019).~Each patient will undergo a hypoxic test to assess the individual response to hypoxia. The minimum safe SpO2 value is 82%, and the maximum allowable heart rate increase during exercise is + 50% of the starting value. When these parameters are reached, an automatic switch to the supply of a hyperoxic gas mixture (35-40% oxygen) occurs till the SpO2 level is 100%. During each training session a hypoxic gas mixture is supplied to the patient in an intermittent mode, alternating with the supply of a hyperoxic gas mixture. On average, each workout includes 6 of the above cycles. The total time of inhalation of a hypoxic gas mixture during one procedure is 20-30 minutes."
46066775|NCT05379608|Procedure|Intermittent hypoxic-hyperoxic training/control|"IHHT will be carried out using the ReOxy normobaric hypoxic therapy apparatus (Bitmos GmbH, Germany, 26790/10221, 04/10/2019).~A control group of 30 patients will undergo a simulated IHHT course (with the same exposure time and number of sessions as intervention group - 15 sessions, 40-minutes long each, 5 workouts per week for 3 weeks). Patients of this group will breathe normoxic gas mixture (ordinary humidified air is supplied through the mask) during the entire session."
46066776|NCT04378426|Drug|Nitrous Oxide|PTSD participants in this arm will receive and admixture of up to 50% nitrous oxide and 50% oxygen plus intravenous saline
46066777|NCT04378426|Drug|Midazolam|PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
45607812|NCT01209767|Device|cryolipolysis|During cryolipolysis, the system drew fat tissue into an applicator then exposed the extracted fat tissue to cold temperatures. The cold exposure caused fat cells to die, with the goal to decrease the raised areas of cellulite
45607813|NCT01209767|Procedure|Subcision|Subcision was performed by inserting a specially designed needle under the skin after local numbing medication is injected. The needle is moved in a repetitive motion parallel to the skin to separate the surface tissue from the deeper scar tissue with the goal to improve the dimpling caused by these tissues sticking together.
45607814|NCT01209767|Other|Control|
45607815|NCT03466489|Device|Floraseal|FloraSeal is a cyanoacrylate-based sealant used in the prevention of surgical site infections.
46066778|NCT04378426|Drug|Nitrogen|PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
45607816|NCT02252146|Drug|IMO-8400|MO-8400 given subcutaneously twice weekly
45607817|NCT03130153|Drug|Aspirin Powder|Aspirin powder to be dissolved in water and to be used as mouthwash twice daily for 7 days after tooth extraction.
45607818|NCT03130153|Drug|Normal saline|Normal saline to be used as mouthwash twice daily for 7 days after tooth extraction among non-hypertensive subjects.
45607819|NCT05391373|Behavioral|Laughter therapy|Each session started with a 10-minute breathing exercise accompanied by relaxing music, followed by 20-minute laughing exercises. Afterwards, the session was ended with a 10-minute meditation accompanied by relaxing music.
45607820|NCT02500589|Behavioral|Behavioral mood management|The mood-management sessions are informed by CBT and emphasize psycho-educational and skills-based approaches to CBT. CBT has been used extensively to address mood management. Specifically, SMK-MM enhancement includes behavioral activation, cognitive restructuring (working with automatic thoughts, problem solving, and behavioral skills (i.e., activity scheduling, relaxation training/controlled breathing). The SMK-MM-enhanced participant manual will also include additional worksheets developed for the investigator's pilot based on Lewinsohn's self-help guide to controlling depression. The main objective of the worksheets will be to provide Veterans with an opportunity to gain mastery over selected behavioral and cognitive skills thought to facilitate mood management. As is customary in CBT, homework based on the worksheets will be discussed during counseling calls.
45607821|NCT02500589|Other|Health education|"In the contact-equivalent health education condition, participants will receive parallel smoking cessation content on the same schedule as in the MM-enhanced arm; however, health education content will supplant the MM content. The educational content will be based on the VA National Center on Health Promotion and Disease Prevention's Health Living Messages on such topics as being safe, eating wisely, getting recommended immunization and screening tests, and being involved with the participant's health care. Participants also will receive chronic-disease-specific self-management information."
45607822|NCT03466333|Drug|Enalapril Maleate|Enalapril maleate will be encapsulated; participants will take the drug once a day for 6 months following delivery.
45757487|NCT00680459|Drug|70% ethanol|70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
45757488|NCT00680459|Drug|heparin flush solution|heparin flush (10 units/ml) lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. Heparin lock solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
45757489|NCT04760366|Other|fascial- muscular lengthening therapy|"Patients in this group will receive interventional therapy~To perform this technique:~Have the patient in side lying position~Hip is maximally flexed to shorten the iliopsoas muscle.~Therapist fingers should be on to the targeted area.~Apply gentle pressure in upward direction.~While maintain the pressure, stretch the muscle by moving the hip in extension through full ROM.~Therapist will maintain the pressure in opposing direction. This is considered as one pass. This technique is performed bilaterally. Patients in this group will also receive the conventional therapy which will include:~Hot pack for 15 minutes.~Myofascial release of iliopsoas.~TENS for 15 minutes."
45757490|NCT04760366|Other|Stretching's of iliopsoas muscle|"Patients in this group will receive the interventional therapy which will include:~Stretching's of iliopsoas muscle which can be done in two positions:~modified lunge position.~The prone stretch.~Patients in this group will also receive the conventional therapy which will include:~Hot pack for 15 minutes.~Myofascial release of iliopsoas~TENS for 15 minutes."
45757491|NCT04760366|Other|the conventional therapy|the conventional therapy
45757492|NCT04400864|Other|Dietary intervention|dietary counseling based on the principals pf the dietary intervention group.
46066779|NCT04378426|Drug|Oxygen|inhaled gas
46066780|NCT04378426|Drug|Saline|Placebo infusion
46066781|NCT05281172|Behavioral|Guided Self-Change therapy (GSC)|The GSC program follows a motivational cognitive-behavioral approach designed to minimize resistance in drug behavior changes, prevent relapse risk, and increase motivation to quit. The GSC consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.
45607823|NCT03466333|Drug|Placebo oral capsule|The placebo will be encapsulated; participants will take the drug once a day for 6 months following delivery. It will be identical in appearance to the IMP.
45607824|NCT05382715|Drug|Ozanimod|Specified Dose on Specified Days
45607825|NCT03492047|Dietary Supplement|low dose N-acetylcysteine|N-acetylcysteine 600mg twice daily
45607826|NCT03492047|Dietary Supplement|high dose N-acetylcysteine|N-acetylcysteine 1200mg twice daily
45607827|NCT03492047|Drug|Paclitaxel|Paclitaxel 80mg /m2 IV
45607828|NCT05380687|Diagnostic Test|Inspiratory hold|A short period (< 30 seconds) during which both inspiratory and expiratory valves of the ventilator circuit are closed at the end of inspiration. It is used to asses expiratory force generation (maximal expiratory pressure, MEP) and frequently used in clinical practice.
45607829|NCT05380687|Diagnostic Test|Expiratory hold|A short period (< 30 seconds) during which both inspiratory and expiratory valves of the ventilator circuit are closed at the end of expiration. It is used to asses static PEEP and inspiratory force generation (maximal inspiratory pressure, MIP & occlusion pressure, ∆Pocc) and is frequently used in clinical practice.
45607830|NCT05380687|Diagnostic Test|Ultrasound of respiratory muscles|Ultrasound of the diaphragm, parasternal intercostal muscle and internal oblique muscle will be performed during each block. Thickening fractions, calculated as thickness at end-inspiration minus thickness at end-expiration divided by thickness at end-expiration, are used to assess the contribution of the muscle to the tidal volume. A median over 5 breaths will be calculated.
45607831|NCT05380687|Other|PEEP 10|Positive End-Expiratory Pressure of 10cmH2O for 30 minutes
45607832|NCT05380687|Other|PEEP 5|Positive End-Expiratory Pressure of 5cmH2O for 30 minutes
45607833|NCT05380687|Other|PEEP 0|Positive End-Expiratory Pressure of 0cmH2O for 30 minutes
45607834|NCT05138393|Other|Active self-corrective exercises|Scoliosis specific exercises with an Active self-corrective approach. Non-specific physical activity 60 minutes per day.
45607835|NCT05138393|Other|Observation|Non-specific physical activity 60 minutes per day.
45607836|NCT02251990|Drug|Grazoprevir/Elbasvir|FDC tablet containing 100 mg of grazoprevir and 50 mg of elbasvir taken q.d. by mouth for 12 weeks.
45607837|NCT02251990|Drug|Placebo|Placebo tablet matching grazoprevir/elbasvir FDC tablet taken q.d. by mouth for 12 weeks.
45607838|NCT02508571|Other|Direct swallowing training (DST)|The DST consists of placing a bolus of 0.05-0.2 mL of formula milk (if the parents refuse, distilled water) via a 1-mL syringe directly on the medial-posterior part of the tongue approximately at the level of the hard and soft palate junction. The volume is started with 0.05 mL, and increased in increments of 0.05 mL to a maximum of 0.2 mL until the swallowing reflex is observed. Once the minimal volume necessary to initiate the swallow reflex is identified, it is used for the duration of the training. The bolus is provided every 30 sec over the 15-minute program or as tolerated. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
45607839|NCT02508571|Other|Oral sensorimotor stimulation (OSMS)|The OSMS consists of a 15-minute stimulation program, whereby the first 12 minutes involve stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consist of sucking on a pacifier. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
45607840|NCT02508571|Other|Sham intervention|The sham intervention consisted of the therapists placing his/her hands into the incubator or bassinet for 15 minutes without touching the infants. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
45607841|NCT03490097|Drug|Simvastatin 10mg|tablets
45607842|NCT03490097|Drug|sofosbuvir plus daclatasvir|sofosbuvir 400mg daclatasvir 60 mg daily for 12 weeks.
45607843|NCT04453735|Drug|Atorvastatin mylan 40 Mg Oral Tablet|Oral tablet on regular prescription
45607844|NCT03490019|Drug|Metformin|500, 850 or 1000 mg depending on body weight once daily for 24 weeks
45757493|NCT00632411|Drug|Nicotine Patch|"Participants who smoke more than 20 cigarettes per day will use a 21-mg patch for 4 weeks, a 14-mg patch for the next 2 weeks, a 7-mg patch for the next 2 weeks, and then no patch.~Participants who smoke between 10 to 19 cigarettes per day will use a 14-mg patch for 4 weeks, a 7-mg patch for the next 4 weeks, and then no patch.~Participants who smoke between 5 to 9 cigarettes per day will use a 7-mg patch for 8 weeks and then no patch.~The proactive group will be given 8 weeks of patch treatment and the reactive group will be given 2 weeks of patch treatment."
45757494|NCT00632411|Behavioral|Tobacco Quit Line Program|"Phone session 1 will focus on smoking reduction.~Phone session 2 will focus on preparing to quit and surviving the first days as a non-smoker. A quit date will be set in 7 to 10 days. Nicotine patches will be sent to participant with detailed instructions for patch use.~Phone session 3 will focus on the first days after the quit date.~Phone session 4 will focus on a review of progress and challenges of quitting. Plans to manage high-risk situations will be discussed.~Phone session 5 will focus on short-term relapse prevention.~Phone session 6 will focus on long-term relapse prevention."
45757495|NCT03356366|Other|MRI 3T|Magnetic Resonance Imaging 3 Tesla
46066782|NCT05281172|Behavioral|Psychoeducation program about healthy habits|The psychoeducational program will include talks about healthy habits such as physical activity, relaxation, and sleep hygiene. This intervention consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.
46066783|NCT04094506|Drug|ASP1948|Intravenous
45607845|NCT03491969|Drug|Alpha-Lipoic Acid(α-LA)|200 mg, po, tid
45607846|NCT03491969|Drug|Placebos|200 mg, po, tid
45607847|NCT05349409|Drug|SHR-A1811|SHR-A1811 for Injection: Given IV.
45607848|NCT05349409|Drug|Fluzoparib Capsule|Fluzoparib Capsule: Given PO.
45607849|NCT02251912|Drug|Intranasal Oxytocin|10 insufflations (40IU of oxytocin total) given 3 initially then 2 times daily for 12 weeks
45607850|NCT02251912|Drug|Placebo|10 insufflations (same solution as active treatment minus oxytocin) given 3 initially and then 2 times daily for 12 weeks
45607851|NCT04453579|Behavioral|Telephonic interview during the Italian lockdown.|The interview was composed of socio-demographic items lockdown, and dichotomous questions about physical and mental health in relation to the COVID-19 emergency
45607852|NCT01976273|Device|1064nm Q-switch Laser|
45607853|NCT01976273|Other|Glycolic Acid Peels|
45607854|NCT02206048|Drug|Proflavine|0.01% proflavine solution topically applied to cervix before high-resolution microendoscopy (HRME) imaging.
45607855|NCT02206048|Procedure|High-Resolution Microendoscopy (HRME) Imaging|in-vivo high-resolution microendoscopy (HRME) images of cervical adenocarcinoma in situ (AIS) performed immediately prior to conization.
45607856|NCT03466177|Diagnostic Test|Non-invasive, multimodal retinal imaging|Ocular exam including the application of different non-invasive ocular imaging techniques
45607857|NCT03466177|Diagnostic Test|Cerebral imaging|amyloid-PET and MRI
45607858|NCT03466177|Diagnostic Test|Neuropsychiatric testing|neuropsychiatric test battery
45607859|NCT03466177|Diagnostic Test|Venous blood sampling|fasting laboratory tests and apoE genotyping
45607860|NCT01704209|Drug|Fibroblast Treatment|
45607861|NCT01704209|Procedure|Vehicle|
45607862|NCT03466021|Drug|Liraglutide|Initially 0.6 mg daily, increasing weekly with 0.6 mg, until 3.0 mg is reached.
45607863|NCT03466021|Drug|Placebo|Matching injection
45757496|NCT03356366|Other|MRI 1,5T|Magnetic Resonance Imaging 1,5 Tesla
45757497|NCT03356366|Other|MRI 7T|Magnetic Resonance Imaging 7 Tesla
45607864|NCT03489083|Other|Strength training|Strength training was performed three times per week for twelve weeks. Supervised (by qualified sport and exercise scientists) exercise was performed in a gym on three non-consecutive days of the week. Each session lasted ~60 min and consisted of a warm up, the resistance exercise training and a cool down. The training programme consisted of a combination of upper and lower body exercises using gym equipments, free weights and body weight as the primary resistance. The twelve weeks of strength training were divided into three mesocycles of four weeks each. The resistance training was performed using two to three sets per exercise at intensities between 12-15 repetition maximum-RM.
45607865|NCT03489083|Other|No Training|"Control group performed a placebo stretching/relaxing session once a week (for adherence purposes) for twelve weeks. To avoid any significant adaptation, all stretching exercises (for large muscle groups only) were performed at very low intensity without any significant discomfort."
45607866|NCT03465943|Drug|Ringer|1L of Ringer's solution as a preload in one group.
45607867|NCT03465943|Drug|Voluven|500 ml of voluven will be given in combination with 500 ml Ringer's solution as a preload in the other group.
45757498|NCT05106465|Device|Konectom platform|Administered as specified in the treatment arm.
45757499|NCT04840329|Behavioral|Education|One-time educational session about menstrual health and endometriosis
45757500|NCT05685836|Drug|Bevacizumab Zirconium Zr-89|See Arm description.
45757501|NCT05685758|Other|FTP-based therapeutic mobile-app|Participants are expected to play games within the mobile app and complete the available daily levels of 4 out of 5 games on at least 4 days per week for 8 weeks.
45757502|NCT00632489|Drug|LBH589|LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.
45757503|NCT00632489|Drug|Capecitabine|Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
45757504|NCT00632489|Drug|Lapatinib|Lapatinib, 1000 mg PO daily will be added to this combination.
45757505|NCT04349709|Behavioral|Brief school-based DBT-A|The intervention is inspired to Dialectical Behavior Therapy for Adolescents (DBT-A) (Rathus & Miller, 2015, Mazza et al, 2016; Cappelluccio, 2019). It consists in four monthly 2-hour sessions (for a total of 8 hours) scheduled during school-time. All the sessions are conducted by two psychotherapists trained about DBT. During the sessions, the model of emotions is described through a role-play between conductors. Subsequently, teens are trained about main emotional regulation skills. Moreover, basic elements of distress tolerance, mindfulness and interpersonal efficacy are introduced too.
45757506|NCT05096481|Biological|PEP-CMV|The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.
45757507|NCT05096481|Drug|Temozolomide|Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1
45607868|NCT00793169|Procedure|Blood Draw|Serum levels were measured
45757508|NCT05096481|Biological|Tetanus Diphtheria Vaccine|Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.
45757509|NCT04387721|Other|Kind of trifocal IOL|Patients will be divided between groups based on pre-surgery corneal astigmatism. Group FineVision is made up of patients with corneal astigmatism less than 1 D. Groups FineVision Toric is made up pf patients with corneal astigmatism more than 1.25 D
46066784|NCT00605618|Drug|BMS-777607|Suspension/Tablet, Oral, Dose escalation to an MTD from a starting dose of 10 mg, once daily, until disease progression/subject discontinuation
45607869|NCT05335447|Drug|GLPG3667 capsule|On Day 1, participants will receive a single oral dose of GLPG3667
45607870|NCT05335447|Drug|[14C]-GLPG3667 solution for infusion|On Day 1, participants will receive a single microtracer microdose of [14C]-GLPG3667 as an intravenous infusion
45607871|NCT05335447|Drug|[14C]-GLPG3667 capsule|On Day 1, participants will receive a single oral dose of [14C]-GLPG3667
45607872|NCT03465865|Device|optical coherence tomography|optical coherence tomography enables diagosis of macular structures and therefore provides information on macular hole closure.
45607873|NCT04112407|Device|Blue Light Phototherapy|Phototherapy in the blue light spectrum
45607874|NCT04112407|Drug|Benzyl Peroxide|Benzyl peroxide wash to be used preoperatively during showering to the operative shoulder site.
45607875|NCT04112407|Other|Control|Standard surgical site preparation with no P. acnes pretreatment
45607876|NCT02205814|Drug|Fasitibant- low dose|Single intra-articular injection of low dose of fasitibant
45607877|NCT02205814|Drug|Fasitibant- intermediate dose|Single intra-articular injection of intermediate dose of fasitibant
45607878|NCT02205814|Drug|Fasitibant- high dose|Single intra-articular injection of high dose of fasitibant
45607879|NCT02205814|Drug|Placebo comparator|Single intra-articular injection of placebo
45607880|NCT02662985|Drug|AIN457 (secukinumab)|"Is a recombinant monoclonal antibody which neutralizes the activity of IL-17A, and has been shown to be effective in treating patients with moderate-to-severe plaque psoriasis.~Secukinumab 150 mg provided in 1 mL pre filled syringes (PFS) for s.c. injection. The 300 mg dose was administered as 2 × PFS injections."
45757510|NCT03355274|Diagnostic Test|Transcutaneous Oximetry|"The examination of transcutaneous Oximetry dynamic measurement with palmar face of both forearms during two consecutive maneuvers known as the candlestick (hands up)."
45757511|NCT03355274|Diagnostic Test|Photopletysmography|Maneuvers are repeted with the photoplestysmography sensors and in front of a Kinect camera.
45757512|NCT03355274|Other|Questionnaires of Quality of Life (QoL)|Each subject complete 2 QoL questionnaires : Sf-12 (Short Form 12) and DASH (Disabilities of the Arm, Shoulder and Hand).
45757513|NCT00243841|Radiation|Stereotactic Body Radiation|Arm A: Childs A - receive 3 fractions. Arm B: Childs B - receive 5 fractions.
45757514|NCT05093439|Diagnostic Test|Heart Rate Variability|Heart rate variability wil be calculated from patients' 10 sec ECG with a dedicated software (Kubios).
45607881|NCT02662985|Drug|Placebo|Secukinumab placebo was provided in a 1 mL PFS for s.c. injection.
45607882|NCT03462199|Dietary Supplement|Actazin (green kiwi powder) High Dose|Participants will consume 4 capsules (600 mg green kiwi powder) daily for 28-days
46066785|NCT00608192|Behavioral|Testing, Education, & Counseling (TEC)|Trained research staff will provide a two-session HIV/hepatitis education class. Participants will also be offered serological testing for hepatitis A, B and C, and HIV (optional), and off-site referrals for vaccination and hepatitis care. The content of the TEC intervention is evidence based. The TEC condition is comparable to screening and education methods commonly used in many drug treatment settings. Those in the TEC intervention group who do not adhere to needed off site vaccinations will be offered on site vaccination 30 days after vaccination referral.
45607883|NCT03462199|Dietary Supplement|Actazin (green kiwi powder) Low Dose|Participants will consume 4 capsules (150 mg green kiwi powder) daily for 28-days
45607884|NCT03462199|Dietary Supplement|Control Formula (Actazin green kiwi powder + PreticX prebiotic)|Participants will consume 4 capsules (150 mg green kiwi powder + 250 mg PreticX prebiotic) daily for 28-days
46066786|NCT00608192|Behavioral|Hepatitis Care Coordination (HCC)|HCC Participants will be offered serological testing and counseling for hepatitis A, B and C, and HIV (optional). HCC participants will be offered on-site hepatitis A and B combination vaccination at the methadone clinic. They will also receive a two-session HIV/hepatitis education class with Motivational Interviewing. In addition, participants will receive 6 months of weekly case management to facilitate entry into hepatitis care.
46066787|NCT02581462|Drug|FLOT alone|"Pre-operative therapy:~Docetaxel 50 mg/m², d1, d15, d29, d43~Oxaliplatin 85 mg/m², d1, d15, d29, d43~Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~Docetaxel 50 mg/m², d1, d15, d29, d43~Oxaliplatin 85 mg/m², d1, d15, d29, d43~Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~5-FU 2600 mg/m², d1, d15, d29, d43"
46066788|NCT02581462|Biological|FLOT + Herceptin/Pertuzumab|"Pre-operative therapy:~Herceptin 8/6 mg/kg, d1, d22, d43~Pertuzumab 840 mg, d1, d22, d43~Docetaxel 50 mg/m², d1, d15, d29, d43~Oxaliplatin 85 mg/m², d1, d15, d29, d43~Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~Herceptin 8/6 mg/kg, d1, d22, d43~Pertuzumab 840 mg, d1, d22, d43~Docetaxel 50 mg/m², d1, d15, d29, d43~Oxaliplatin 85 mg/m², d1, d15, d29, d43~Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~5-FU 2600 mg/m², d1, d15, d29, d43."
46066789|NCT00668863|Drug|FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)|FOLFIRI treatment with Sunitinib on Day, Irinotecan 180M/M IV , l-Leucovorin 200M/M, 5FU 400M/M bolus and 2400M/M in 46-hour continuous infusion on Day1 each 42 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
46066790|NCT00668863|Drug|Sunitinib|37.5mg daily P.O., 4 weeks On 2weeks Off each 42 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
46066791|NCT04077736|Drug|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 million IU five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82). Then all patients were followed up for 3 months
46066792|NCT04085614|Device|PCI with Dynamic Coronary Roadmap|Standard of care PCI with Dynamic Coronary Roadmap
46066793|NCT04085614|Device|PCI without Dynamic Coronary Roadmap|Standard of care PCI without Dynamic Coronary Roadmap
46066794|NCT00608348|Procedure|Hyperinsulinemic glucose clamp procedures|2 hours of either euglycemic or hypoglycemic glucose clamping
46066795|NCT00608348|Procedure|moderate exercise|90 minutes of moderate exercise with either hyperinsulinemia or euinsulinemia
46066796|NCT00766441|Drug|Sitagliptin|tablet, 100mg, once daily, 4 weeks
46066797|NCT00766441|Drug|sulphonylurea|sulphonylurea, variable, od or bd, during ramadan
46066798|NCT00766519|Other|volume optimization|"Fluid management:~basal fluid administration = 5 ml/kg/h lactated Ringer's solution~+ systematic minimization of the arterial pulse pressure variation (PPV) to 10% or less by volume loading (6% hydroxyethyl starch) throughout surgery~hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) only if PPV is > 10%"
46066799|NCT00766519|Other|standard volume administration|"Fluid management:~basal fluid administration = 5 ml/kg/h lactated Ringer's solution~hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) according to predetermined algorithm primarily based on mean arterial pressure, heart rate, and urine output, and secondary on PPV"
46066800|NCT00771043|Drug|TYSABRI and AVONEX|TYSABRI and AVONEX treatment per package insert.
46066801|NCT00771121|Drug|urea/lactic acid|new emulsion type
46066802|NCT00771121|Drug|Placebo|only emulsion base
46066803|NCT04267250|Drug|PF-06700841|60 mg by mouth (PO) once daily (QD).
45757515|NCT03832400|Biological|MET-2|MET-2 is a defined consortium of human commensal bacteria derived from a healthy donor, which has the full metabolic functional capacity of fecal microbiota.
45757516|NCT03832400|Drug|Placebo oral capsule|Placebo oral capsule which is identical to the MET-2 capsules.
45607885|NCT03462199|Dietary Supplement|Livaux (gold kiwi powder) High Dose|Participants will consume 4 capsules (600 mg gold kiwi powder) daily for 28-days
45607886|NCT03462199|Dietary Supplement|Livaux (gold kiwi powder) Low Dose|Participants will consume 4 capsules (150 mg gold kiwi powder) daily for 28-days
45757517|NCT00681083|Device|Heated breathing tube (CPAP with ThermoSmart)|CPAP with ThermoSmart - heated passover humidifier, with heated breathing tube
45757518|NCT00681083|Device|Non heated breathing tube (CPAP with conventional humidification)|CPAP with conventional humidification - heated passover humidifier, no heated breathing tube
46066804|NCT04267250|Drug|Ethinyl estradiol (EE) and levonorgestrel (LN)|Oral tablet containing 30 mcg EE and 150 mcg LN.
46066805|NCT00775489|Drug|Nasal steroid Beclomethasone|Beclomethasone nasal steroids to be given to a very well controlled glaucoma patients to find if this normal dose will lead to increase in intraocular pressure up to 20% where the study will be stopped at this point.
46066806|NCT00775489|Drug|Saline|control group will receive normal saline inhaler
46066807|NCT00771199|Drug|Transdermal Therapeutic System (TTS)-Fentanyl|Participants will receive 1 transdermal patch of TTS-fentanyl containing 12 micrograms per hour (mcg/h) for 28 days. Dose can be increased or decreased as per Investigator's discretion up to 100 mcg/h.
46066808|NCT04264130|Drug|Artesunate-Pyronaridine|Subjects received artesunate-pyronaridine according to their body weight once per day for three days.
46066809|NCT04264130|Drug|Artemether-Lumefantrine|subjects received artemether-lumefantrine according to their body weight twice per day for three days.
46066810|NCT04264130|Drug|Artefenomel-Ferroquine|Subject received a single dose of artefenomel-ferroquine according to their body weight
46066811|NCT00775567|Dietary Supplement|Fructose powder|30g in 250ml water twice a day
46066812|NCT04267016|Diagnostic Test|TruGraf Testing - Peripheral blood gene expression profiling|5 mL collection PAXgene blood sample
45757519|NCT05074875|Other|Questionnaires and Patient Reported Outcomes (PROs)|"EuroQol 5 Dimensional Quality of Life Questionnaire (EQ-5D).~St. George's Respiratory Questionnaire (SGRQ)~Impact of Events Scale Revised (IES-R)~Generalized Anxiety Disorder 7-Item (GAD-7)~Patient Health Questionnaire (PHQ-9)"
45757520|NCT05074875|Diagnostic Test|Nasal Swab COVID-19 reverse transcription polymerase chain reaction test (RT-PCR)|If required by the local site's COVID-19 guidelines, subjects should have the COVID-19 RT-PCR Nasal Swab collected at the beginning of the visit or within 5 days prior to the scheduled visit.
45757521|NCT05074875|Genetic|Blood Samples for Biomarkers|Venous blood will be collected using pre-labeled tubes.
45757522|NCT05074875|Diagnostic Test|High Resolution Computed Tomography|Subjects will have HRCTs at Visits 1, 2, 3, and 4. Inpatient HRCT scans will be collected during the baseline visit (V0 or V1)
45757523|NCT05074875|Diagnostic Test|Physical Exam and Vital Signs|"A complete physical exam, including height, weight, general appearance, neck, lungs, cardiovascular system, abdomen, extremities, and skin will be performed at Visit 1.A brief physical exam will be completed at subsequent visits, including weight, general appearance, lungs, cardiovascular symptoms, extremities, and other body systems pertinent to the participants health status, at the discretion of the investigator.~Blood pressure, heart rate, and oxygen saturation will be collected at all visits, prior to blood draws and after subjects have rested."
46066813|NCT02557867|Drug|Dexmedetomidine|Dexmedetomidine 0.5 μg/kg over 10 minutes and then, 0.5 mcg/kg/h throughout surgery.
46066814|NCT00605774|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infused over two hours during experimental period on Day 2
46066815|NCT00605774|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infusion during hyperinsulinemic euglycemic clamp on day 2
46066816|NCT04264286|Drug|Prophylactic esmolol|Patients will receive prophylactic esmolol after the end of the surgery
46066817|NCT04264286|Drug|Placebo|Patients will prophylactic placebo after the end of the surgery
46066818|NCT04356976|Device|Ventralex|Repair of hernia using Ventralex patch in sublay position
46066819|NCT04356976|Other|Stratafix|Repair of hernia without mesh. Defect closed with Stratafix suture.
46066820|NCT04077502|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation
46066821|NCT02582476|Drug|Bumetanide|Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
46066822|NCT02582476|Drug|Placebo|Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
46066823|NCT02582320|Drug|Ibrutinib|A longitudinal survey will be carried out by collecting data of patients who received at least 1 dose of Ibrutinib. All patients will be observed for at least 12 months from the treatment start.
46066824|NCT02582086|Other|BOR15001L7|Active cream with 5% 15019L0
46066825|NCT02582086|Other|Placebo|Placebo Cream with 0% 15019L0
46066826|NCT04078204|Drug|Butylphthalide Soft Capsules|The experimental group will receive the Butylphthalide Soft Capsules during the 24-month intervention period. After the 24-month intervention,The experimental group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
46066827|NCT04078204|Drug|placebo Soft Capsules|The placebo group will receive the Placebo Soft Capsules during the 24-month intervention period. After the 24-month intervention,The placebo group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
46066828|NCT04249414|Device|PulmoVista 500|"Monitoring of Ventilation and Perfusion with the PulmoVista 500 during clinical routine.~No medical interventions required"
46066829|NCT04076488|Other|Dividat Fit|tablet based, remote assisted home-training
46066830|NCT05325658|Other|FEES, treatment with modified diet, electrical swallowing muscle stimulation.|Endoscopic swallowing assessment (FEES) consists of three parts:1) assessment of mouth, throat anatomy and more; 2) the patient is given to swallow a certain amount and consistency of liquids and solid food. 3) evaluated: preparation of the bolus for swallowing, aspiration. An 8-point Penetration-Aspiration scale is described.Swallowing exercises. Swallowing exercises are also used in practice, which can help coordinate the swallowing muscles or stimulate the nerves involved in the swallowing reflex.Transcutaneous electrical stimulation is a method of treating dysphagia in which weak electrical impulses stimulate the muscles in the neck area associated with swallowing. In patients with oropharyngeal dysphagia, patients have great difficulty swallowing water of normal consistency or other non-thick liquids, so they should be thickened with special thickeners to such an extent that the patient does not experience discomfort and be able to swallow.
46066831|NCT00935012|Drug|tafamidis|Once daily 20 mg oral tafamidis (soft gelatin capsule)
46066832|NCT05373914|Drug|Cudetaxestat (BLD-0409)|Cudetaxestat - 250mg tablets (orally)
46066833|NCT05373914|Drug|Control: Matching Placebo|Placebo - 250mg tablets (orally)
46066834|NCT00932360|Device|TENS|Active TENS, Placebo TENS and No Treatment TENS
46066835|NCT00668707|Dietary Supplement|melatonin|20 mgs ingested nightly
46066836|NCT00668707|Dietary Supplement|placebo|similar to experimental in all ways except for lack of active ingredient
46066837|NCT05064514|Device|Transcatheter Tricuspid Valved Stent Graft|All participants meeting the inclusion and none of the exclusion criteria will be enrolled. A custom-made Transcatheter Tricuspid Valved Stent Graft based on CT to define anatomic dimensions will be made. The system consists of a custom-made valved stent graft delivery system, a custom-made valved stent graft bioprosthesis and a loading system. The bioprosthesis is self-expanding and consists of a stent graft spanning from the inferior vena cava to the superior vena cava and a lateral bicuspid valve element made of thin porcine pericardial leaflets requiring a low closing pressure, and Nitinol support structures. The participants will undergo a minimally invasive, catheter-based procedure to implant the bioprosthesis which is delivered through a 24 French delivery system via transfemoral access. The device can be repositioned and is retrievable.
46066838|NCT00766909|Drug|cyclosporine|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.155 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 4 mg/kg 2 times daily for 8-11 days."
46066839|NCT00766909|Drug|tacrolimus|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.0012 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 0.1 mg/kg 2 times daily for 8-11 days."
46066840|NCT00766909|Other|Capsules and isotonic saline|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.06 ml/kg isotonic saline over a maximum duration of 5 hours.~For Dialysis patients (study 2): Placebo capsules 2 times daily for 8-11 days."
46066841|NCT02581228|Device|ML-PrediCare|
46066842|NCT04059952|Procedure|Electroconvulsive Therapy|Electrical currents are passed through the brain to intentionally trigger a controlled seizure in order to produce a therapeutic change in neuro-chemistry and circuitry.
46066843|NCT00775801|Device|FLD|Artificial lumbar disc
46066844|NCT00775801|Device|Control|Artificial lumbar disc
46066845|NCT00767065|Radiation|Cardiac Computed Tomography|Patients randomised to the CCT arm will undergo 128-channel cardiac computed tomography with delayed acquisition. Patients will receive beta-blockade if necessary prior to the scan to achieve a heart rate of less than 70/min. An unenhanced scan will be performed in all patients to assess coronary artery calcium score. Patients will then undergo contrast enhanced CCT. After a bolus tracking acquisition, injection of 120mls iodinated contrast at 5ml/s will be followed by 40ml normal saline/contrast (in 50:50 proportion), also at 5ml/s. Imaging will be performed with a gated cardiac CT protocol. Where possible (stable rhythm and heart rate <70bpm) a low dose technique will be utilised. When not possible a retrospective gating method will be employed. In the latter case the ECG will be used to assign the images to their respective phases of the cardiac cycle. 10 minutes after contrast injection, a second prospectively gated scan will be acquired to assess myocardial enhancement patterns.
46066846|NCT00767065|Other|Standard care|Further investigations as decided by the patient's clinical team, according to best normal practice. These may include some or all of: further blood tests, exercise stress testing and myocardial perfusion scintigraphy. These may be conducted either during the initial hospital admission, or subsequently as an outpatient.
46066847|NCT04229836|Drug|Tildrakizumab 100 mg Solution for Injection|Participants will be treated with tildrakizumab 100 mg.
46066848|NCT00771433|Biological|filgrastim|Given subcutaneously
46066849|NCT04053790|Drug|lactobacillus LB|administration of different doses of Lactobacillus LB according to the treatment groups described previously
46066850|NCT04053790|Other|placebo|a tablet of placebo every 12 hours given by mouth
46066851|NCT00668395|Drug|Efavirenz|The metabolism and pharmacokinetics of efavirenz were assessed at a single 600 mg oral dose of efavirenz and after subjects took multiple doses of efavirenz (600 mg/day orally for 17 days).
46066852|NCT05674396|Radiation|Stereotactic body radiotherapy|Participants will receive radiation as per the schedule discussed with the study doctor.
46066853|NCT05674396|Radiation|Traditional Palliation|Participants will receive radiation as per the schedule discussed with the study doctor.
46066854|NCT00668317|Drug|Omeprazole|20 mg BD tablet 8 weeks duration
46066855|NCT00668317|Drug|Ranitidine|300 mg od nocte tablet 8weeks duration
46066856|NCT00775879|Drug|Induction with Sevoflurane|
46066857|NCT00767221|Drug|Budesonide|8 mg PL-56 once daily for six months
46066858|NCT04024072|Drug|Brinzolamide 1% ophthalmic suspension|Test product
46066859|NCT04024072|Drug|Azopt 1% Ophthalmic Suspension|Reference product
46066860|NCT00771511|Drug|capsaicin|capsaicin cream 0.1% 10 ml applied to cervix
46066861|NCT00771511|Drug|Placebo|Only lidocaine gel will be appled to the cervix
46066862|NCT04021576|Other|preventative training program|complementary training of leg-, hip- and core-strength/stability
46066863|NCT00775957|Procedure|FLT-PET scan|imaging scan
46066864|NCT00775957|Procedure|FDG-PET scan|imaging scan
46066865|NCT03828214|Device|Robotic exoskeleton for walking assist|Participants will have two testing sessions in this within-subject design experiment. The conditions under which walking will be evaluated are control (normal) walking, walking with the exoskeleton assistance and walking immediately following exoskeleton walking. The conditions under which stair walking (ascending and descending) will be evaluated include control (normal) stairs and exoskeleton assisted stairs. Assistance is provided by The Honda Walking Assist (HWA) System is a robotic device developed by Honda R&D Corporation ®, Japan. The devices computer-activated motors use hip angle information to guide assistance delivered through the thigh straps to the legs in time with the walking cycle. The maximum torque delivered is 4 Newton-meters.
46066866|NCT00776113|Drug|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol fasting
46066867|NCT04076332|Other|Decision aid|Decision aid is a tool that helps patients become involved in decision making on choosing treatment plans. Decision aid provides information about the options and outcomes, and by clarifying personal values.
46066868|NCT04075786|Other|Survey|Each participant will be shown 40 (forty) 3D ultrasound images of uterus of normal women without infertility and 40 (forty) infertile women with uterus with narrowing in the middle third diagnosed by hysteroscopy + 3D ultrasound and associated infertility (T, Y or I shaped).
46066869|NCT00670111|Device|Insignia Plus / Ultra (Guidant/Boston Scientific)|Cardiac pacing using any Guidant/Boston Scientific Implantable Pacemaker System with rate-modulation and any compatible intracardiac lead system.
46066870|NCT04077658|Behavioral|HeartMath|HeartMath is a program where individuals learn heart rate variability biofeedback. Essentially, they learn breathing exercises that reduce their heart rate. The HeartMath program will be administered via an application on the smartphone and ear monitor.
46066871|NCT04077658|Behavioral|Waitlist Control|Standard of Care Migraine Treatment
46066872|NCT00771589|Device|Active Knee Prosthesis|Motorized External Knee Prosthesis for above knee amputees.
46066873|NCT05244148|Device|IP1 - Stérimar BLOCKED NOSE Baby nasal spray|1 to 2 sprays per nostril at least 2 twice a day and, as needed, up to a maximum of 6 times a day.
46066874|NCT05244148|Device|IP2 - Stérimar Stop & Protect Cold Baby + standard of care|1 to 2 sprays per nostril at least 2 twice a day and, as needed, up to a maximum of 6 times a day.
46066875|NCT05244148|Behavioral|Standard of Care|hydration + rest at home + if needed paracetamol
46066876|NCT00767377|Drug|EOF5|epirubicin 50 mg/m2 day 1, oxaliplatin 130 mg/m2 day 1, and 5-FU 375-425 mg/m2/d day 1 through 5 continuous infusion, repeated every 3 weeks
46066877|NCT02580448|Drug|Seviteronel|Seviteronel given daily with evening meal in 28 day cycles
46066878|NCT00776191|Drug|Physioneal 35|Physioneal 35® for eight weeks, followed by Physioneal 40® for eight weeks
46066879|NCT00776191|Drug|Physioneal 40|Physioneal 40® for eight weeks followed by Physioneal 35® for eight weeks
46066880|NCT04008238|Drug|Trabectedin|- Trabectedin will be prescribed as per market authorization and will be administered by intraveinous infusion (1,5 mg/m²) every 3 weeks. A treatment cycle is defined as a 3-weeks period
46066881|NCT04077034|Dietary Supplement|Probiotic Formula Bacillus subtilis DE111®|Probiotic Formula Bacillus subtilis DE111®, 1 billion colony forming units (CFU) per day for 8 weeks
46066882|NCT04077034|Dietary Supplement|Placebo comparator|Placebo comparator, once a day for 8 weeks
46066883|NCT03789760|Drug|SaiLuoTong capsule|500 subjects are randomly divided into two groups by 3:1. 375 subjects in the active group take two pills(120mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
46066884|NCT03789760|Drug|placebo|500 subjects are randomly divided into two groups by 3:1. 125 subjects in the control group take two pills(120mg) of placebo each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
46066885|NCT04223674|Diagnostic Test|Serological screen and treat|Multi-antigen sero-diagnostic test for measurement of P. vivax antibodies in plasma from finger stick as a means to detect hypnozoite carriers for treatment
46066886|NCT02580682|Drug|Sanfu herbal patch|The formula of the patch consists of Huang Qi (Astagalus Membranaceus), Fu Zi (Aconiti Lateralis Radix Praeparata), Yan Hu Suo (Rhizoma Corydalis), Xi Xin (Herba As5ari), Bai Jie Zi (Semen Sinapis Albae) and Rou Gui(Cortex Cinnamomi), in a proportion of 2:2:1:1:2:1.
46066887|NCT02580682|Drug|Sanfu moxibustion|Moxibustion is a kind of thermal therapy without any feeling of pain or swell.Moxibustion exerts its therapeutic effect by thermal power and the application of moxa.
46066888|NCT02580682|Drug|Sanfu herbal patch and moxibustion|use Sanfu moxibustion followed by Sanfu herbal patch
46066889|NCT03776890|Behavioral|DeStress for Health Program|The program will consist of 4 in person sessions that are based on empirically supported Positive Psychosocial Well-Being PPWB components including Optimism, Mindfulness, Positive Reprisal as well as Strengths-based Cognitive Behavioral Therapy (SBCBT) to improve behavioral self-regulation towards health-related goals. Research staff will conduct face-to-face surveys with participants at baseline and at end of program. Finally, we will conduct a phone-based survey 30 days after program completion to assess sustainability of intervention effects.
46066890|NCT00672139|Drug|Methylnaltrexone bromide|
46066891|NCT00776269|Procedure|argon laser and radiofrequency|
46066892|NCT02557789|Drug|Lefamulin|Lefamulin administered iv or orally in the fasted state and orally in the fed state
46066893|NCT00771823|Drug|Maraviroc|Maraviroc 300 mg twice daily for the first 14 days of the study. Placebo twice daily for the last 14 days of the study
46066894|NCT00771823|Drug|Maraviroc|"Placebo twice daily for the first 14 days of the study.~Maraviroc 300 mg twice daily for the last 14 days of the study."
46066895|NCT05224648|Device|TOF scan train of four ratio monitoring|Device : TOF Scan For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
46066896|NCT05224648|Device|ITF device tetanus stimulation monitoring|Device ITF For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
45607887|NCT03462199|Dietary Supplement|Placebo (microcrystalline cellulose)|Participants will consume 4 capsules containing no active ingredients daily for 28-days
46066897|NCT04219540|Drug|XR-B (SUBLOCADETM)|XR-B (SUBLOCADETM) contains buprenorphine, a partial opioid agonist, and is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days. Following induction and dose adjustment with sublingual buprenorphine, the recommended starting dose is 300 mg monthly for the first two months followed by a maintenance dose of 100 mg monthly thereafter. XR-B is administered monthly only by subcutaneous injection in the abdominal region. Study clinical staff will have flexibility to continue the 300mg dose for greater than 2 months, or use the 100mg dose for initial induction, if the participant's opioid use history or clinical status at the time of dosing support these decisions.
46066898|NCT04219540|Drug|XR-NTX|XR-NTX (Vivitrol®) produces a 30-day mu opioid receptor antagonist blockade Induction procedures require detoxification off opioids (5-7 days since last opioid use), a negative opioid urine toxicology, negative self-report of any recent opioid use, and a naloxone challenge. The naloxone challenge consists of 0.4-0.8mg of IV/SC/IM naloxone followed by the observation of no opioid withdrawal symptoms, or the use of oral naltrexone (12.5-25mg) followed by 1-2 hours of observation. XR-NTX is then delivered as a 380mg (4cc) intramuscular injection to the upper outer gluteus (buttock). Study interventions are FDA-approved, used in accordance with FDA-labeling and will be administered by a study clinician
45757524|NCT05074875|Diagnostic Test|Medical Research Council Sum Score|The Medical Research Council Sum Score (MRC-SS) is used globally to detect peripheral muscle strength and to help diagnose ICU-acquired muscle weakness. The MRC-SS ranging from 0 (complete paralysis) to 60 (normal).
45757525|NCT05074875|Diagnostic Test|Hand Grip Strength|Each subject will have hand grip strength measured at each visit. This is being done in order to assess the maximum isometric strength of hand and forearm muscles.
46066899|NCT05674084|Diagnostic Test|Capillary refill time|CRT will be measured by applying firm pressure to the ventral surface of the index finger distal phalanx with a glass microscope slide. The pressure will be increased until the skin is blank and then maintained for 10 seconds. The time for return of the normal skin color will be registered with a chronometer, and > 3 seconds is defined as abnormal. Light and ambient temperature will be the same for all individuals.
45757526|NCT05074875|Diagnostic Test|Spirometry|Spirometry will be assessed at Visits 1, 2, 3 and 4. Each site will use its own spirometry machine. Each subject should use the same machine at each visit and conduct measurements at approximately the same time. Before any testing, the maneuver should be demonstrated to the subject. The spirometry should be reviewed by the investigator.
45757527|NCT05074875|Diagnostic Test|Diffusing Capacity of Carbon Monoxide|The site will use its own DLCO equipment for measurements at Visits, 1, 2, 3, and 4. The Single-breath DLCO maneuver will be carried out in accordance with the 2017 American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines. Subjects should use the same device at approximately that same time at each visit. The maneuver should be demonstrated to the subject prior to the test.
45757528|NCT05074875|Diagnostic Test|6 Minute Walk Test|"The 6 Minute Walk Test (6MWT) will assess exercise capacity and tolerance. 6MWTs will be conducted at Visits 1, 2, 3, and 4.~The procedure of the 6MWT should be explained and demonstrated to the subject prior to the start of the test."
45757529|NCT05074875|Diagnostic Test|Sit to Stand (STS) Measurement|The STS will be conducted at Visits 1, 2, 3, and 4 to assess the physical functioning of the adult participants.
45757530|NCT01798979|Drug|GLPG0634|Each subject will receive multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.
45757531|NCT01798979|Drug|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8)
45757532|NCT00738361|Drug|nab-paclitaxel|150 mg/m2 weekly for 3 of 4 weeks every 28 days.
45757533|NCT02337062|Drug|APD421|
45757534|NCT02337062|Drug|Placebo|
45757535|NCT01279213|Drug|paliperidone clozapine|dose 3 to 12 mg paliperidone ER daily during 12 weeks
45757536|NCT00681473|Radiation|Proton Radiation Therapy|Once daily, Monday through Friday, for 6 weeks.
45757537|NCT03301922|Behavioral|Metacognitive therapy and work-focused interventions|Metacognitive therapy and work-focused interventions, up to maximum 12 sessions, with weekly session of 45-60 minute duration. The metacognitive treatment program is based on Wells' manual. The work-focused intervention is based on Lagerveld and Blonk. The interventions are run in parallel.
45757538|NCT03301922|Other|Waiting list|Waiting list
45757539|NCT00634283|Drug|venlafaxine|venlafaxine IR 150mg
45607888|NCT05304247|Other|questionnaire and clinical examination|Prevalence and Risk Factors of Black Tooth Stains and Their Relation With Caries Experience in Primary Teeth of A Group of Preschool Children
45607889|NCT02545673|Behavioral|Enhanced linkage to care|
45607890|NCT02545673|Behavioral|Standard-of-care plus|
45607891|NCT04080271|Device|18F-FDG PET/CT|18F-fludeoxyglucose positron emission tomography/computed tomography
45607892|NCT03489005|Drug|BIA 5-1058|"Subjects will receive BIA 5-1058 tablets (containing 100 mg) as single, oral doses 30 minutes after the start of a moderate mealas follows:~400 mg BIA 5 1058, as 4 × 100 mg tablets and 8 placebo tablets~1200 mg BIA 5 1058, as 12 × 100 mg tablets"
45757540|NCT01279291|Biological|KHK2866|Potentially therapeutic monoclonal antibody for the treatment of advanced cancer and ovarian cancer.
45757541|NCT01279291|Drug|Gemcitabine and Carboplatin|Combination chemotherapy with KHK2866 to treat advanced platinum-sensitive ovarian cancer. Gemcitabine dose 1000 mg/m2, Carboplatin dose AUC=4
46066900|NCT04212442|Behavioral|Independent Living Program for Affordable Housing.|"Two-month program intended to increase physical activity and function, including the following 4 steps:~Environmental and Policy Assessments: Nurse facilitator works with the affordable housing staff to identify and recommend feasible interventions to alter the environment, policy, and procedures to optimize resident function and physical activity.~Education: Nurse educates residents and study partners in the principles of the Independent Living Program, using established materials and adult learning techniques.~Establishing Resident Goals: The nurse completes Capability Assessment Forms and helps resident set goals to increase function and physical activity.~The nurse helps to motivate and mentor residents and study partners to achieve and maintain their goals, using evidence-based approaches."
46066901|NCT04077112|Behavioral|Parent Child Interaction Therapy|Behavioral parent training program targeting parent-child relationship
46066902|NCT02581150|Procedure|Treatment of Occlusive Arterial Disease|Regarding the intervention, the technique used during the diagnostic and/or therapeutic procedure shall be left to the operator's discretion, except the use of an arterial closure device (ACD). In the ambulatory hospitalisation arm, the ACD use will be mandatory. In the conventional hospitalisation arm, ACD will be used at the discretion of the interventionalist.
46066903|NCT03960580|Drug|OPN-375|OPN-375, BID
45607893|NCT03489005|Drug|Placebo Oral Tablet|"Matching placebo tablets administered as follows:~- placebo, as 12 × 0-mg tablets"
46066904|NCT02581072|Drug|SB204 4%|Applied topically once
46066905|NCT02581072|Drug|SB204 8% or 12%|Applied once topically
46066906|NCT02581072|Drug|Vehicle|Applied topically once
46066907|NCT03955900|Other|No intervention|Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
46066908|NCT03955042|Drug|Pemetrexed|Pemetrexed 900 mg/m^2 on Day 1 of each 21-day cycle. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
46066909|NCT02580526|Procedure|V-E mask ventilation for one minute|"V-E approach maintains mouth open, creates larger oral cavity and allow positive pressure generated during inspiration to push forwards submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
46066910|NCT02580526|Procedure|C-E mask ventilation for one minute|"Using C-E technique, the operator's fingers pressure mouth closed and push posteriorily the soft tissue of submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique . Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
46066911|NCT03744676|Biological|lisocabtagene maraleucel|lisocabtagene maraleucel will be administered as single dose intravenous (IV) injection
46066912|NCT03717922|Device|Low Intensity Focused Ultrasound Pulsation|BOLD fMRI will be collected during two conditions (given that the timecourse of LIFUP related changes is unknown, sham will always precede the LIFUP condition). LIFUP (previously used in primary sensory cortices will be administered in 75 sonifications at 210 KHz frequency with pulse repetition frequency of 500Hz, 35mW/cm2, sonification duration 0.5s with 7s inter-stimulation intervals. Sham LIFUP will involve the same procedures (e.g. participant provided the same instructions) except the sonification will not occur.
46066913|NCT03717922|Device|SHAM Ultrasound|BOLD fMRI will be collected while the ultrasound trandsducer is not turned on. Participants are unable to tell whether the transducer is on or off.
46066914|NCT00570739|Drug|Metformin HCl and Colesevelam Placebo|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg placebo tablets once daily for 16 weeks
46066915|NCT00570739|Drug|Metformin HCl tablets and Colesevelam tablets|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg tablets once daily for 16 weeks
46066916|NCT00570739|Drug|Colesevelam placebo|Six colesevelam 625 mg placebo tablets will be given once a day for 16 weeks
46066917|NCT00570739|Drug|Colesevelam|Six colesevelam 625 mg tablets will be given once a day for 16 weeks.
46066918|NCT03689530|Behavioral|Peer Support|"Participants will be paired with a peer supporter. They will meet in person one time and then be in contact by phone or texting on a weekly basis for the first 6 months of a year.~During the final six months of the year, the peer supporter and participant will be in touch at least monthly. The peer supporter will help link participants to existing health system and community diabetes prevention programs, support their engagement in formal programs, maintain achieved gains, and support participants to initiate and sustain healthy behaviors to prevent diabetes.~The 95 peer supporters who consented to participate in the study are included in this arm, along with the participants who were randomized to this arm, in the participant flow. The peer supporters were not randomized to the arm; rather, they consented to deliver the intervention. Although 95 consented, only 68 met with at least one peer, the first step in intervention delivery."
46066919|NCT03689530|Behavioral|Enhanced Usual Care|Participants will receive brief education and folder of information and resources.
46066920|NCT02580214|Dietary Supplement|Impact|600 ml of Impact, Nestle for 5 days prior to surgery
46066921|NCT03649204|Behavioral|HY-PAD|Hybrid intervention that includes supervised on-site and home-based components in people with PAD
45607894|NCT03489005|Drug|Moxifloxacin 400 mg|"Administered as follows:~- 400 mg moxifloxacin, as 1 × 400-mg tablet"
45607895|NCT03462121|Drug|RPh201|RPh201 is a well-defined extract from a botanical source
46066922|NCT04076098|Drug|Minocycline Hydrochloride|Administration of Periocline gel into the periodontal pockets will be carried out until it overflows the pockets
46066923|NCT04076254|Drug|Albumins|albumin 5%
46066924|NCT04076254|Drug|Fluid|Ringer Lactate
46066925|NCT03943030|Other|Pulmonary rehabilitation|The PR program will consist of supervised physical exercise sessions, which will be held 3 times a week for 8 weeks, and weekly educational sessions. Exercise sessions include aerobic exercise (30 min to 45 min) and lower limb and upper limb strength training, as well as warm-up and muscle stretching exercises after exercise. The exercise load will be individualized and determined from the patients' baseline tests, being increased progressively throughout the sessions. A baseline evaluation will be performed, which will be repeated after 9 weeks, including: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes usually used in the assistance to evaluate PR will also be measured.
46066926|NCT03938116|Other|Healing Hearts Together|Participants in the HHT group will be assembled in groups and attend 8 weekly 2-hr sessions at UOHI led by 2 facilitators with psychology training. Sessions: 1) focus on understanding love, attachment, and their relationship to heart health; 2) provide an opportunity to share experiences related to cardiovascular disease with partners and peers; and 3) assist in identifying and improving communication patterns that may inhibit positive interactions and healthy behaviours. Participants are introduced to concepts through didactic presentations, videos, group and couple discussion and homework exercises. Participants will receive a folder containing copies of in-session and take-home exercises as well as the Hold Me Tight book to review between sessions.
45757542|NCT01279291|Drug|paclitaxel|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. Paclitaxel will be administered weekly at a dose of 80 mg/m2.
46066927|NCT00771979|Drug|AZD0530|of both the Phase II and Phase III AZD0530 125mg tablet variants (A and B) in a random order.
46066928|NCT00771979|Drug|AZD0530|Part II: Single doses of AZD0530 125mg oral solution and 2 out of 4 125mg tablet variants (C, D, E and F) in a random order.
46066929|NCT05674240|Device|Intrathecal Targeted Drug Delivery|Intrathecal drug delivery systems (IDDs) deliver small doses of analgesics directly to the spinal cord.
46066930|NCT05674240|Combination Product|Conservative medical management|Including physical therapy, oral or transdermal medications and injections
46066931|NCT05094934|Drug|NNC0385-0434 A 100 mg|All participants will receive the same dose (100 mg) of the study medicine NNC0385-0434, which will be given for 10 days in a row. Participants will get the study medicine in a tablet taken orally once-daily. The study medicine needs to be taken in the morning after overnight fasting and 30 minutes before the first meal of the day.
46066932|NCT00767689|Drug|Vitamin B 6|vitamin b6 100 mg po daily
46066933|NCT00767689|Drug|placebo|placebo is given in the placebo arm
46066934|NCT04076956|Device|Anterior Cruciate Ligament Reconstruction|Reconstruction of the Anterior Cruciate Ligament using an interference screw
46066935|NCT00772057|Drug|Propranolol|Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure <90 mm Hg or pulse rate <55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
46066936|NCT00772057|Drug|Placebo|Placebo tablets given two times daily.
46066937|NCT04193956|Other|Standard-of-care procedures|Patients receive standard of care anti-PD-1 treatment as monotherapy or in combination with other checkpoint inhibitors. Related assessments, as laboratory assessments, CT-thorax-abdomen and FDG-PET will be performed according to clinical routine procedures.
46066938|NCT04193956|Other|Study procedures|Patients will undergo tumor biopsies, venous blood sampling and feces sampling in combination with a food questionnaire before, during and at the end of standard of care anti-PD-1 treatment.
46066939|NCT00776347|Drug|Donepezil|Dosage: 3mg PO/day for the first 2 weeks and 5mg PO/day for the next 14 weeks Duration: 16 weeks
46066940|NCT00776347|Drug|Donepezil|
45757543|NCT01279291|Drug|pegylated liposomal doxorubicin|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. PLD will be administered weekly at a dose of 40 mg/m2.
45757544|NCT05628818|Device|Transcranial Direct Current Stimulation (tDCS)|Real anodal tDCS over the left dorsolateral prefrontal cortex in acute stroke patients to improve dysexecutive syndrome. Intensity: 2 mA. Stimulation period: 20 minutes.
45757545|NCT05628818|Device|Sham Transcranial Direct current Stimulation|Sham anodal tDCS over the left dorsolateral prefrontal cortex: anodal tDCS. Intensity: 2 mA. Stimulation period: 1 minute. Afterwards, the device will automatically shut down but the sham stimulation period will last a total of 20 minutes.
46066941|NCT00776425|Drug|Epoetin beta|Epoetin beta subcutaneously or intravenously at a dose of 150 IU per kg of body weight thrice weekly or 30000 IU once weekly.
46066942|NCT03913702|Drug|Ketorolac Tromethamine|2ml of injectable Ketorolac (30mg/ml) will be mixed with 8ml of lidocaine HCL (1% without epinephrine) and delivered into the subacromial joint (total of 60mg of active substance in 10ml).
46066943|NCT03913702|Drug|Methylprednisolone Acetate|1ml of injectable Methylprednisolone (80mg/ml) will be mixed with 9ml of lidocaine HCL (1% without epinephrine) and delivered into the subacromial joint (total of 80mg of active substance in 10ml)
46066944|NCT03909412|Drug|Carfilzomib|Carfilzomib will be administered over 10 minutes for the 20 mg/m2 and 27 mg/m2 dose and over 30 minutes for all higher doses.
46066945|NCT03909412|Drug|Cyclophosphamide|Cyclophosphamide dosed at 2gm/m2 administered over 1 hour.
46066946|NCT03909412|Drug|Dexamethasone|Dexamethasone 40mg IV/PO to be administered as a premedication.
46066947|NCT03909412|Drug|Granulocyte Colony-Stimulating Factor|On day 7 subjects will initiate high dose G-CSF injections at 14mcg/kg daily (with a cap of 1440mcg daily).
46066948|NCT00772135|Drug|sildenafil citrate|capsule of 50 mg , 90 minutes before exercise study
46066949|NCT00776503|Drug|VORINOSTAT|vorinostat; 400mg once daily; increasing duration (7-10-14 days)
45757546|NCT02986425|Other|STRIP intervention|"The STRIP intervention consists of 9 steps:~structured history taking of medication~recording medication and diagnoses in STRIPA~structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria~communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation~shared decision-making with the patient with possible adaptation of the recommendation~optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions)~generation of general practioner (GP) report~delivery of the report to the patient and to the GP (optional additional direct communication)~follow-up"
46066950|NCT04075006|Drug|Ketamine|standard of care plus Ketamine infusion at a fixed rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
45757547|NCT02986425|Other|Control|Standard care in the department where the trial is conducted. To keep the patients and the blinded team members blinded one questionnaire will be conducted by the intervention team in both arms. This is considered a SHAM intervention.
45757548|NCT04400942|Diagnostic Test|Transvaginal ultrasound|Transvaginal ultrasonographic scan aims to evaluate number, size (diameter and volume), location and appearance of submucous uterine myomas, concomitant presence of adenomyosis
45757549|NCT04400942|Behavioral|Anamnesis|Anamnesis aims to collect data about age, BMI, previous hormonal therapies (such as ulipristal acetate or gonadotropin-releasing hormone agonists) with submucous uterine myomas
46066951|NCT00772213|Procedure|MIGTS treatment|treatment of multiple trauma patients in the MIGTS
46066952|NCT04188106|Drug|Varenicline Pill|FDA approved starter kit of varenicline (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7) followed by FDA-approved dose of varenicline (1 mg twice daily) for the remaining 11 weeks
46066953|NCT04188106|Drug|Hydroxyzine Pill|For the first week, participants will receive 50 mg nightly for the first 3 days, then twice daily, 25 mg in the morning and 50 mg at night for the remaining 12 weeks.
46066954|NCT00669955|Drug|Omeprazole, amoxicillin, clarithromycin|Triple therapy given for 7 days at a dose of omeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID
46066955|NCT00669955|Drug|Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole|Pylera is a three in one capsule containing bismuth subcitrate potassium 120 mg, metronidazole 125 mg and tetracycline 125 mg given as 3 capsules QID, with omeprazole 20 mg BID.
46066956|NCT04176874|Procedure|Robotic-assisted diastasis of the rectus abdominis muscles repair|Diastasis of the rectus abdominis muscles repair using the Intuitiv SI robot
46066957|NCT00772291|Drug|pregabalin|pregabalin 150-600mg/day during 8 weeks
46066958|NCT00772291|Drug|placebo|placebo drug during 8 weeks
46066959|NCT00767845|Other|questionnaire/survey administration|
46066960|NCT04048525|Procedure|CVVHD|CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
46066961|NCT04048525|Procedure|CVVH|CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter infusion to maintain a theoretical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
46066962|NCT03595150|Drug|Diclofenac|Diclofenac rectally given before the ERCP to prevent pancreatitis
46066963|NCT00776581|Procedure|CSEA with PCA|Records regarding combined spinal-epidural analgesia with patient-controlled pump
46066964|NCT00776581|Procedure|CSEA with IBI|Records regarding combined spinal-epidural analgesia with intermittent bolus injection
46066965|NCT00776581|Procedure|EA with PCA|Records regarding epidural analgesia with patient-controlled pump
45444832|NCT01239693|Dietary Supplement|IFA|Women during pregnancy: 1 tablet of iron+ folate daily until delivery (60 mg iron + 400 ug folic acid) Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of calcium (200 mg), akin to placebo Children from 6 to 18 months of age: None
45607896|NCT03462121|Other|Placebo|Inactive placebo consisting of the therapeutic vehicle
45607897|NCT03462043|Combination Product|ND0612|s.c. infused
45607898|NCT03462043|Combination Product|CLES|Carbidopa-Levodopa Enteral Suspension.
46066966|NCT00776581|Procedure|EA with IBI|Records regarding epidural analgesia with intermittent bolus injection
45607899|NCT01631812|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
45607900|NCT02323295|Radiation|Radiation (Surgical Arm)|For surgical candidates, the standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease)
45607901|NCT02323295|Radiation|Radiation (Non-surgical Arm)|Non-surgical candidates receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma)
45607902|NCT02323295|Procedure|Malignant Tumor Surgery|Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor
46066967|NCT03565744|Behavioral|B'N Fit POWER|Participants will undergo a medical assessment and using an Electronic Medical Record (EMR) template, providers will screen for a healthy weight and the 7 target behaviors. Participants will set goals with the provider to attain one of the target behaviors and will receive an EMR-generated treatment plan summarizing healthy weight and target behavior goals. At 20-minute follow-up visits during the school day, the provider will review weight and target behavior attainment and monitor co-morbidities and barriers to participation. Group 1 participants will also have access to daily MMCC afterschool programming from 3-6pm from September through May each year with tailored programming including weekly core nutrition, behavior, and cooking classes and at least five hours of physical activity.
46066968|NCT04047667|Procedure|cone beam CT guided transbronchial cryobiopsy|CBCT images are acquried and reviewed in axial, coronal and sagittal planes to most accurately assess the cryoprobe position within the lung parenchyma and relative to other thoracic structures. The minimum probe-to-pleura distance will be measured. If the position of cryoprobe is proper, TBCB will be perfomed.
46066969|NCT03922828|Diagnostic Test|CT scans|CT surveillance, Lung biopsy, Lung resection
46066970|NCT02580916|Other|SCQOLIT questionnaire|"Participants will be invited to complete the SCQOLIT and EQ-5D (used for comparison purposes, given its widespread use in other healthcare contexts in the UK) questionnaires [Appendices C & D) at:~baseline (after histological diagnosis of a NMSC is confirmed - both Groups)~3 months - either by postal (Group 1) or face-to-face (Group 2) dependent on whether the patient is returning to the Dermatology clinic for routine follow-up~at 6-9 months in the dermatology clinic if the patient is deemed high risk (squamous cell carcinoma with high risk clinicopathological features as listed by the National British Association Dermatologists Multiprofessional Guidelines for management of SCC) (Group 2 only)"
46066971|NCT00768157|Drug|antiviral treatment (lamivudine or entecavir)|antiviral treatment (lamivudine 100mg per day or entecavir 0.5mg per day)
46066972|NCT00768157|Procedure|radical resection of HBV-related HCC|Procedure/Surgery - radical resection of HBV-related HCC
45911314|NCT02006368|Other|Blood Collection and autologous re-infusion|"Subjects will donate one unit of whole blood. This unit will be stored at 4°C for a predefined storage period. A variety of in vitro metabolic and functional platelet assays will be performed on the stored unit.~After the storage period, an aliquot from the whole blood unit will be processed to obtain platelets. The subject will return and donate a fresh sample of whole blood (43 mls) from which a fresh aliquot of platelets will be obtained. The stored and fresh platelets will each be labeled with a different radioisotope (either Chromium-51 or Indium-111) and reinfused into the subject. Using two different radioisotopes enables separate tracking of both the stored and fresh platelets. Follow-up blood samples will be drawn at 2 hours and on days 1, 2, 3, 5, 7±1 and 10±2. Stored and Fresh platelet recoveries and survivals will be calculated."
45911315|NCT02006394|Dietary Supplement|Fish Oil|fish oil capsules
46066973|NCT04076878|Device|Mollii|The Mollii method is provided in a tight fitting, whole body suit with multiple electrodes that can be set individually. The Mollii method uses low frequencies and low intensities that evokes sensory input but does not directly elicit muscle contractions. The theoretical background of this treatment method primarily refers to the concept of reciprocal inhibition, i.e. that sensory input from a muscle may inhibit the activation of an antagonistic muscle through the activation of the disynaptic reciprocal Ia inhibitory pathway.
46066974|NCT00671749|Drug|adapalene gel, 0.3%|Applied once daily at bedtime
46066975|NCT00671749|Drug|clindamycin/benzoyl peroxide gel|Applied once daily in the morning
46066976|NCT04149106|Drug|Sulfadoxine pyrimethamine + Amodiaquin|Monthly dose of SPAQ over three days for SMC
46066977|NCT04149106|Drug|Dihydroartemisinin piperaquin|Monthly dose of DHAPQ for SMC
46066978|NCT03889600|Other|REDD-CAT|After obtaining informed consent from a participant and gathering baseline data, the study RA will send a flag in the EMR to notify the nurse care manager that a patient has enrolled in the REDD-CAT pilot. The nurse care manager will then incorporate the administration of the REDD-CAT to the patient as part of standard care discharge planning. He or she will utilize the REDD-CAT results report as a guideline for generating appropriate referrals to address unmet social needs identified.
46066979|NCT00768235|Other|yoga practice|The yoga program comprised 70 min sessions, 3 times/week during 12 weeks
45911316|NCT02006394|Dietary Supplement|Polyphenol Capsules|delphinidin polyphenol capsules
46066980|NCT02580604|Drug|Calcium Chloride/Calcium Gluconate|Calcium (as either calcium chloride or calcium gluconate in half normal saline) will be delivered via IV during exercise to keep serum ionized calcium levels above baseline. The clamp is modeled after the hyperglycemic glucose clamp.
46066981|NCT02580604|Drug|Placebo|Saline Infusion
46066982|NCT00768313|Device|titanium rod|comparison of rods of varying yield strengths and their ability to hold correction of scoliosis.
46066983|NCT00768313|Device|ultra strength stainless steel rod|interventions involving rods of various strength to treat scoliosis
46066984|NCT00768391|Biological|IMC-3G3|Intravenously, once every week for Cohorts 1 through 3 and once every other week for Cohorts 4 and 5. Starting dose will be 4mg/kg in Cohort 1, with dose doubling between cohorts. Dose escalation of 100% (2 x previous dose) Dose escalation increment reduced to 33% (1.33 x previous dose). Cohorts 4 and 5 will receive 15mg/kg and 20mg/kg, intravenously, once every other week.
46066985|NCT00669877|Drug|Rituximab|375 mg/m2 IV days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses.
45444833|NCT01239693|Dietary Supplement|MMN|Women during pregnancy: 1 tablet of multiple micronutrients daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of multiple micronutrients Children from 6 to 18 months of age: None
45444834|NCT01239693|Dietary Supplement|LNS|Women during pregnancy: 1 sachet of LNS-P&L (20 g of LNS) daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily sachet of LNS-P&L (20 g of LNS) Children from 6 to 18 months of age: 2 daily sachet of LNS-20gM (20 g of LNS)
45911317|NCT02006394|Dietary Supplement|Corn Oil Capsules|Corn Oil Capsules
45911318|NCT02006394|Dietary Supplement|Corn starch capsules|Maltodextrin capsules
45911319|NCT02006394|Other|Reduced glycemic index bread products|Made by Zone Labs
45911320|NCT02006394|Other|Market variety bread products|placebo bread products
45911321|NCT02006433|Device|Deep Brain Stimulation|Local anesthesis, MRI and CT scan of the brain followed by implantation of the stimulation device
46066986|NCT00669877|Drug|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) starting after rituximab completed (odd courses).
46066987|NCT00669877|Drug|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
46066988|NCT00669877|Drug|Vincristine|2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses)
46066989|NCT00669877|Drug|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses)
46066990|NCT00669877|Drug|G-CSF|10 mcg/kg
46066991|NCT00669877|Drug|Cytarabine|100 mg intrathecal day 7 +/- 2 days (odd courses); 3 gm/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
46066992|NCT00669877|Drug|Methotrexate|200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 after the completion of Rituximab.
46066993|NCT04047901|Other|exercise training|Patients undergo 16 weeks of physical training
46066994|NCT00922051|Device|Transcutaneous electrical nerve stimulation (TENS)|
46066995|NCT00922051|Device|Transcutaneous electrical nerve stimulation (TENS)|Placebo
46066996|NCT00772681|Drug|docetaxel and cisplatin|3 cycles of docetaxel 75mg/m2 and 100mg/m2 cisplatin combination every 3 weeks
46066997|NCT02557633|Biological|Grass MATA MPL 10200|
46066998|NCT02557633|Biological|Grass MATA MPL 18200|
46066999|NCT02557633|Biological|Placebo|
46067000|NCT04143646|Behavioral|Web-based prevention program|"Telemetric control of risk factors, e-learning, contacts by e-mails/apps. If no response telephone calls.~In a substudy evaluation of disclosure of genetic risk."
46067001|NCT02557711|Device|ultrasound elastography, acoustic radiation force impulse|Two physiatrists will perform ultrasound elastography and ARFI for intra-rater and inter-rater reliability evaluation.
46067002|NCT05325424|Procedure|Laparoscopic splenectomy|The laparoscopic splenectomy was performed by the same surgical team.
46067003|NCT00772759|Drug|AZD3199 Turbuhaler®|240, 720 and 2160 μ g, single and multiple (o.d. for 12 days)
46067004|NCT00772759|Drug|Placebo Turbuhaler®|single and multiple (o.d. for 12 days)
45444835|NCT03323151|Drug|Ixazomib|Ixazomib 3 mg by mouth on days 1, 8 and 15 by mouth days 1-28 of a 28 day cycle. Dose may be de-escalated (Ixazomib 3 mg) or escalated (Ixazomib 4 mg) dependent on dose-limiting toxicities.
45607903|NCT03461809|Other|Ocular acupuncture|Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
46067005|NCT03866668|Drug|Esomeprazole|Esomeprazole Dosage (Weight Less Than 20 kg) -- 10 mg QD for 8 weeks Esomeprazole Dosage (Weight 20 kg or Greater) -- 10 mg QD for 4 weeks followed by 20 mg QD for 4 weeks
46067006|NCT00772837|Drug|Omeprazole + Clarithromycin + Amoxycillin|Omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BD and Amoxycillin 1g BD for 1 week
46067007|NCT00772837|Drug|Omeprazole + placebo antibiotics|omeprazole 20 mg bid for 1 week along with placebo antibiotics for 1 week
46067008|NCT03863704|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|To apply transcutaneous electrical stimulation using a TENS unit to the ear or the leg.
46067009|NCT00776971|Other|Sugar-sweetened soft drink|500mL as a preload drink
46067010|NCT00776971|Other|Aspartame-sweetened soft drink|500mL as a preload drink
45757550|NCT04400942|Procedure|Operative hysteroscopy|Operative hysteroscopy allows a direct evaluation of number, size (diameter and volume), location and appearance of submucous uterine myomas. This exam allows the resection of the myomas.
45757551|NCT00682565|Drug|CK-1827452 24mg and 6 mg iv infusion|I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr
46067011|NCT00776971|Other|Semi-skimmed milk|500mL as a preload drink
46067012|NCT00776971|Other|Water|500mL as a preload drink
46067013|NCT03850288|Other|Neuropsychological assessment : Stroop task|"Stroop task is an interference task assessing cognitive inhibitory control. This paper-and-pencil task aims to evaluate the inhibition of an automated process such as reading by asking participants to name the color of color names written in a different color ink.~This test is non-invasive."
46067014|NCT03850288|Other|Neuropsychological assessment : Go No Go task|"Go No Go task assessing motor inhibitory control. This computer-based task is designed to evaluate motor inhibition by asking participants to respond to a stimulus as quickly as possible by inhibiting another distractor stimulus.~This test is non-invasive."
46067015|NCT00773071|Device|SPECT/CT guided LM/SL|Pre-operatively, SLNs will be detected by low-dose SPECT/CT (99mTc-cystein rhenium colloids, 1cc/1mCi). Intra-operatively, a blue-dye (Patent Blue, 2cc) and a gamma-probe guidance will be used to detect the SLN nodes. All blue-stained and/or hot lymph nodes with a radioactivity greater than 10% of the hottest node will be considered as SLNs. Serial sections of SLNs will be analyzed by H-E staining. In cases of negative H-E, the SLNs will be further analyzed by immunochemistry (CKAE1/CKAE3, and high molecular weight Cytokeratin 34BE12). Non-SLNs will be analyzed as usual in routine by H-E.
45444836|NCT03323151|Drug|Ixazomib|Ixazomib 4 mg by mouth on days 1, 8 and 15 of a 28 day cycle until progression or unacceptable toxicity.
45444837|NCT03323151|Drug|Ibrutinib|Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle. Dose may be de-escalated (Ibrutinib 420 mg) or escalated (Ibrutinib 560 mg) dependent on dose-limiting toxicities.
45444838|NCT03323151|Drug|Ibrutinib|Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle until progression or unacceptable toxicity.
45444839|NCT03795129|Behavioral|SleepLife Application w/FitBit|"Subjects receive a FitBit. Subjects receive access to the SleepLife Application. Subjects receive training and assistance setting up use and access to the SleepLife Application.~Subjects' physicians will receive subject sleep data. Subjects and physicians have the option of messaging each other through the SleepLife application."
46067016|NCT03492424|Device|cryotherapy|Subjects will receive focal cryotherapy for treatment of prostate cancer
46067017|NCT00773149|Drug|Alemtuzumab (CAMPATH 1H) associated to G-CSF|"All patients receive Alemtuzumab in 3 successive phases:~Phase A: Test week: 3mg, then 10mg, then 30mg every other day for one week to test for tolerance.~Phase B: 30mg 3 times a week for 12 to 18 administrations until response or progression/failure has been documented.~Phase C: in patients in CR, maintenance with Alemtuzumab: 3 injections one week every 2 months."
46067018|NCT04994938|Other|Diet Intervention|Participants will engage in discussions about healthy eating one time per week led by a trained peer leader for 12-weeks.
46067019|NCT04994938|Other|Exercise Intervention|Participants will participate in a group exercise session led by a trained peer leader 2-times per week for 12-weeks.
46067020|NCT00768703|Device|Percutaneous endoscopic fetal tracheal occlusion/unocclusion|Between 26-28 wks' gestation, percutaneous endoscopic placement of the tracheal balloon. Between 32-34 wks' gestation, percutaneous endoscopic removal of the balloon.
46067021|NCT00768781|Behavioral|Mindfulness-Based Stress Reduction|The rationale for treatment is that MBSR targets arousal, which is a prominent perpetuating factor of insomnia. Each session meets weekly for 120 minutes and consists of a therapist-led mindfulness meditation, followed by a discussion of the meditation and its application into the participant's everyday life. For homework, each participant is required to practice formal meditation at least 45 minutes a day, 6 days per week. Participants will be provided a tape, an mp3 file, or CD to aid in the participant's personal practice at home. Formal meditations that will be led and discussed include eating meditation, body scan, sitting meditation, Hatha Yoga, and walking meditation. In addition, informal mindfulness practices will be discussed.
46067022|NCT00768781|Behavioral|Mindfulness-Based Therapy for Insomnia|MBTI treatment includes the hypothesized active elements of both mindfulness meditation and behavior therapy for insomnia. The intervention includes 8 weekly sessions. Each session meets weekly for approximately 120 minutes. The general format of each session includes formal mindfulness meditation (quiet and movement meditations) and instructions for the behavioral intervention, with a focus on integrating the principles of mindfulness with these instructions. Each participant is required to practice formal meditation for at least 45 minutes a day, 6 days per week as homework. Participants are provided a tape, mp3 file, or CD to aid in the participant's personal practice at home.
46067023|NCT00768781|Behavioral|Wait-List + Behavioral Therapy for Insomnia|This delayed treatment condition consists of an 8-week monitoring period (sleep diaries, PSAS) and then BT. The BT treatment consists of 8 sessions of behavioral interventions for insomnia, with instructions targeting the nighttime symptoms of insomnia. The primary components of this treatment package are stimulus control, sleep restriction, and sleep hygiene education. In the BT condition, each weekly session lasts 120 minutes and consists of formal instructions for the behavioral interventions along with a time for discussion of the application of these instructions into each participant's unique circumstances.
46067024|NCT00777361|Drug|AZD3480|Iv single dose, 4-hour infusion of 25 mg
46067025|NCT00777361|Drug|AZD3480|Oral solution single dose of 50 mg
46067026|NCT02556853|Device|Determination of tube position by ultrasound.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by ultrasound (Sonoscape S6®). The ultrasound probe will be placed between the 2nd and 3rd intercostal space at the level of the midclavicular line parallel to the line. The probe will be slightly moved or tilted until the pleural line is identified. If lung sliding is identified then the ventilation of the lung will be considered adequate. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
46067027|NCT02556853|Other|Determination of tube position by auscultation.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by auscultation of the upper lung fields. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
46067028|NCT00768859|Drug|paclitaxel, trastuzumab and carboplatin|paclitaxel; 70 mg/m2 trastuzumab; 2 mg/kg (loading dose 4 mg/kg) carboplatin; AUC = 3
46067029|NCT00768937|Drug|Sorafenib|All patients will receive Sorafenib (800 mg/day) p.o. beginning two weeks before the first TACE and every day thereafter until patient death or premature withdrawal from study.
46067030|NCT00768937|Procedure|Transarterial chemoembolisation (TACE)|TACE will be carried out with doxorubicin (75 - 50 - 25 mg/m2, depending on serum bilirubin levels ≤ 1.5, 1.5 - 3, 3 - 5 mg/dL) : lipiodol (1:1) in a total volume of 20 mL; after administration of doxorubicin:lipiodol, additional embolisation will be carried out with bead block-endospheres. TACE will be repeated every 4 weeks for 3 cycles; additional cycles will be offered if clinically indicated (but no PEI or RF-ablation should be carried out after inclusion into the study)
46067031|NCT04047745|Drug|Liposomal bupivacaine|interscalene nerve block administered before surgery using 133 mg liposomal bupivacaine with 10mL 0.5% ropivacaine
46067032|NCT04047745|Drug|Ropivacaine injection|interscale nerve block administered before surgery using 30mL 0.5% ropivacaine
46067033|NCT00773227|Procedure|Autologous myoblasts transplantation and myotomy|Graft of autologous cell muscles (myoblasts) isolated from unaffected limb muscles into the pharyngeal muscles of patients diagnosed as suffering from OPMD and surgical procedure (myotomy)
46067034|NCT00777439|Drug|Domperidone|10 mg of oral domperidone will be administered 4 times daily. This dose may be increased to 20 mg 4 times daily or 30 mg 4 times daily, depending on how the subject responds to the drug.
46067035|NCT00882999|Drug|LY2127399|Administered via Injection
46067036|NCT00882999|Drug|Placebo|Administered via Injection
46067037|NCT00769093|Drug|Ferumoxytol|2 mg/kg
46067038|NCT00671437|Procedure|FDG-PET/CT|
46067039|NCT00671437|Drug|Cetuximab|
46067040|NCT02556697|Device|Bronchoscopy with in vivo confocal endomicroscopy|A bronchoscopy with in vivo confocal endomicroscopy is done for patients with a suspicion of emphysema or for patients with a suspicion of scleroderma
46067041|NCT04162353|Biological|BCMA-CD19 cCAR T cells|BCMA-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
45757552|NCT00682565|Drug|CK-1827452 12.5mg capsule|12.5mg oral immediate release capsule
46067042|NCT00777517|Drug|Lipitor|A single dose of 10 mg Lipitor tablet
46067043|NCT00777517|Drug|Atorvastatin pediatric formulation|A single dose of 10 mg atorvastatin pediatric formulation
45757553|NCT00682565|Drug|CK-1827452 48 mg and 11 mg iv infusion|I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr
45757554|NCT00682565|Drug|CK-1827452 25mg capsule|25mg oral immediate release capsule
46067044|NCT00769171|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg every 24 h
45757555|NCT00682565|Drug|Placebo iv infusion|Matching placebo iv infusion
45757556|NCT00682565|Drug|Placebo capsule|Matching placebo oral immediate release capsule
45757557|NCT04788537|Behavioral|Training to Understand and Navigate Emotions and Interactions (TUNE In)|A three-part cognitive behavioral treatment strategy to improve social functioning in adults with autism spectrum disorder. TUNE In includes components to address the many behavioral domains involved in social functioning, including social motivation, social anxiety, social cognition, social skills, and generalization of the skills to community settings.
45757558|NCT05685680|Procedure|total mesorectal excision in rectal carcinoma|total mesorectal excision laparoscopic versus open technique in management of rectal carcinoma
46067045|NCT00769171|Drug|Ceftriaxone + Metronidazole|Ceftriaxone 2 g every 24 h and Metronidazole 500 mg every 12 h
46067046|NCT02579980|Procedure|DCE and DWI MRI|Dynamic Contrast Enhanced MRI (DCE-MRI) and Diffusion Weighted MRI (DW-MRI): DW-MRI is a technique for quantifying the increase in water diffusion caused by cellular necrosis or apoptosis in tumors within days of therapy. DCE-MRI is frequently used in preclinical and early clinical trial assessment of anti-angiogenic and vascular disrupting compounds, also within hours of therapeutic intervention.
45757559|NCT04367883|Drug|Antihistamine|No intervention is performed. We propose an observational study.
45757560|NCT04367883|Drug|Amantadine|No intervention is performed. We propose an observational study
45757561|NCT04367883|Drug|ACEI|No intervention is performed. We propose an observational study.
46067047|NCT02579980|Procedure|Surgery|Standard of care procedure for sarcoma patients
46067048|NCT00769249|Other|questionnaire administration|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
45757562|NCT04367883|Drug|ARB|No intervention is performed. We propose an observational study.
45757563|NCT04367883|Other|Influenza vaccine and COVID|No intervention is performed. We propose an observational study.
46067049|NCT00769249|Other|study of socioeconomic and demographic variables|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
45757564|NCT00635453|Behavioral|Dietary Advice|The content of the dietary intervention follows the recommendations of the guidelines of the Brazilian Ministry of Health for healthy feeding of children younger then two years.
45757565|NCT03148743|Biological|Fecal microbiota|fecal microbiota transplantation
45757566|NCT04329039|Drug|Somatostatin analog|Somatostatin analog plus perioperative antibiotics Placebo plus perioperative antibiotics
45757567|NCT02135861|Procedure|DCE-MRI scans|Subjects will be placed supine in the scanner and will be prepared for intravenous contrast agent administration. The contrast agent is administered using a power injector before imaging.
45757568|NCT02135861|Other|Gadobutrol|Gadobutrol at a dose less than or equal to 0.1 millimoles per kilogram (mmol/kg) will be given intravenously as a bolus using a power injector.
45757569|NCT05627024|Drug|30% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 30%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Manual lung recruitment maneuvers will be performed after tracheal intubation and before tracheal extubation, however when intraoperative oxygen saturation is less than 92% the manual lung recruitment maneuver will be done too. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
46067050|NCT00769249|Procedure|psychosocial assessment and care|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
46067051|NCT00777595|Drug|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
46067052|NCT00777595|Drug|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
45911322|NCT02006485|Drug|Ublituximab + TGR-1202|Ublituximab IV infusion TGR-1202 oral daily dose
46067053|NCT00777595|Drug|Placebo|Inhaled solution, single dose of placebo
46067054|NCT00777595|Drug|Moxifloxacin|Tablet, oral, 400mg, single dose
45911323|NCT02006485|Drug|Ublituximab + TGR-1202 + ibrutinib|Ublituximab IV infusion TGR-1202 oral daily dose Ibrutinib oral daily dose
45757570|NCT05627024|Drug|60% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 60%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
45757571|NCT00635609|Drug|Doxycycline hyclate (Doryx)|150mg/day, oral, delayed release tablets
45757572|NCT00635609|Drug|Doxycycline hyclate|100 mg/day, oral, tablets, immediate release
45911324|NCT02006485|Drug|Ublituximab + TGR-1202 + bendamustine|Ublituximab IV infusion TGR-1202 oral daily dose Bendamustine IV infusion
46067055|NCT02579746|Behavioral|DASHNa-CC|The 8-week DASHNa-CC intervention incorporated Dietary Approach to Stop Hypertension (DASH) diet, sodium reduction with the food therapy of Traditional Chinese Medicine, and included an intervention manual, two sessions of classroom instruction delivered in Mandarin, and a 20-minute telephone follow-up.
46067056|NCT02579746|Behavioral|usual care|education booklet, encouragement of physician visit, use of public health resources if needed
45757573|NCT04347902|Drug|Intravenous Lipid Emulsion|Various types of intravenous lipids
46067057|NCT02581618|Other|remote ischemic preconditioning|Blood pressure cuff inflation up to 200mmHg in the non-dominant arm before guiding catheter engagement
46067058|NCT00769405|Drug|fluorouracil|Given IV
46067059|NCT00769405|Drug|leucovorin calcium|Given IV
46067060|NCT00769405|Drug|oxaliplatin|Given during surgery
46067061|NCT00769405|Procedure|hyperthermia treatment|Given intraperitoneally during surgery
46067062|NCT00882921|Biological|Idursulfase|Patients received idursulfase as prescribed by their physician following locally approved prescribing information. Patients will not be provided idursulfase by Shire Human Genetic Therapies, Inc. or the HOS.
46067063|NCT02829502|Drug|Byetta|Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
46067064|NCT02829502|Drug|Normosaline|Single dose of subcutaneous injection of 20 μL normosaline (placebo).
46067065|NCT02635191|Drug|Tailored Group|All the patients who enrolled in this arm will be received endoscopy followed by biopsy for antimicrobial susceptibility testing and cytochrome P450 isoenzyme 2C19 genotype. 10 days tailored therapy will be given including one Proton Pump Inhibitor ( Rabeprazole0.4-0.5mg/kg.d,bid. or Esomeprazole0.8-1.0mg/kg.d,bid) and two antibiotics (Amoxicillin30-50mg/kg.d bid, Clarithromycin15-20mg/kg.d bid, Metronidazole15-20mg/kg.d bid ) based on the cytochrome P450 isoenzyme 2C19 genotype and the antimicrobial susceptibility.
46067066|NCT02635191|Drug|Standard group|All the patients who enrolled in this arm will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) .
46067067|NCT00773539|Procedure|PVI using an open irrigated tip catheter|transseptal PVI using thermocooled ablation catheter (Biosense) with confirmation of conduction block
46067068|NCT00773539|Procedure|PVI using a closed irrigated tip catheter|transseptal PVI using the CHILLI II catheter from BOSTON with confirmation of conduction block
46067069|NCT00773539|Procedure|PVI using a cryoballoon|transseptal PVI using the cryoballoon from CRYOCATH
46067070|NCT00773617|Behavioral|ICAT|ICAT is a new manual-based psychotherapy treatment for bulimia nervosa (BN) that focuses on emotions and bulimic behavior.
46067071|NCT00773617|Behavioral|CBT|CBT is a highly structured, manual-based psychotherapy that has been shown to be effective in the treatment of BN. CBT focuses on cognitions and bulimic behavior.
46067072|NCT02579824|Drug|DS-3032b|Escalation DS-3032b starting dose level 90 mg/day administered once daily by mouth on Days 1 - 21 of a 28 day cycle. For Dose Expansion maximum tolerated dose from Dose Escalation Phase.
46067073|NCT02635113|Device|Gait Synchronized Vibration System|A wearable vibratory shoe that delivers stimulus to the soles that is synchronized with step resulting in improved gait.The shoe consists of two externally mounted vibration units (tactors). The vibration units allow for variation of both frequency and amplitude of stimulation independently. Using the pressure sensors and timing data, gait velocity, cadence, swing time, stance phase and double support time will be analyzed to assess features of their gait performance during the Dynamic Gait Index with and without vibratory stimuli.
45757574|NCT03298802|Drug|Hydrochlorothiazide 50mg Tablet|Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.
45757575|NCT03298802|Drug|Placebo Tablet|Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum
45757576|NCT02137499|Device|geko device|Small transcutaneous electrical stimulator. Manufactured in UK by Firstkind UK Ltd, and licensed for use in humans
45757577|NCT01799369|Behavioral|Surgical Apgar Score|Post-operative care influenced by Surgical Apgar Score
45757578|NCT05618756|Dietary Supplement|Acute oral CBD supplementation|1 ml hemp oil containing 300 mg CBD, within gelatin capsules, ingested orally.
45911325|NCT02006498|Drug|Sillymarin|Sillymarin is derived from the milk thistle plant, Silybum marianum, a herbal remedy that has been used for centuries for diseases of the liver. It is a complex mixture of 6 major flavonolignans (silybins A and B, isosilybins A and B, silychristin, and silydianin), as well as other minor polyphenolic compounds.
46067074|NCT02557165|Procedure|Muscle biopsies|Muscle biopsies will allow acces to samples for observational studies. Vastus latetalis: needle biopsy (Bergstrom technique). Diaphragm: open biopsy performed by thoracic surgeon during lung surgery.
46067075|NCT05673850|Drug|NET or NCT|In this study, we included 518 ER-positive BC patients who received either neoadjuvant endo-crine therapy (NET) or neoadjuvant chemotherapy (NCT).
45757579|NCT05618756|Dietary Supplement|Acute oral placebo supplementation|1 ml hemp oil containing no CBD, within gelatin capsules, ingested orally.
45757580|NCT03294668|Behavioral|KONTAKT Australia|KONTAKT is a manualized Social skills group training program designed for children and adolescents on the Autism Spectrum aimed at improving communication, social interaction skills, the severity of ASD symptoms, and the ability to empathise and adapt in a group setting. The KONTAKT participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
45757581|NCT03294668|Other|Super Chef|The Super Chef is a cooking group designed for this study for adolescents on the Autism Spectrum, aimed at teaching basic cooking skills in a social environment. The Super Chef participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
45757582|NCT05339984|Procedure|Partial hepatectomy (open approach)|preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
46067076|NCT00777673|Drug|Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim|"Eligible patients will receive:~nab-paclitaxel IV on days 1, 8, and 15. Treatment will be repeated every 28 days 28 days for 4 courses.~Carboplatin IV on day 1. Treatment will be repeated every 28 days for 4 courses.~Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 4 courses.~After completion of the above regimen, patients will receive:~Doxorubicin IV on day 1. Treatment will be repeated every 14 days for 4 courses.~Cyclophosphamide IV on day 1. Treatment will be repeated every 14 days for 4 courses.~Bevacizumab IV on day 1. Treatment will be repeated every 14 days for 2 courses.~Patients will then proceed with:~- Surgery including axillary staging~A minimum of 4 weeks post operatively, patient will receive:~- Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 8 courses."
45757583|NCT05339984|Procedure|liver transplantation|preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
45607904|NCT02215954|Drug|FE 999169|FE 999169 is a white crystalline powder for oral solution. Each sachet (16.1 g) contains sodium picosulfate hydrate 10 mg, magnesium oxide 3.5 g and anhydrous citric acid 12 g as well as orange flavour, potassium bicarbonate and sodium saccharin as excipients. FE 999916 is dissolved by mixing the contents of the sachet with approximately 150mL of cold water in a cup before administration.
45607905|NCT02215954|Drug|Niflec|Niflec is a white-yellowish powder for oral solution. Each plastic sachet (137.155 g) contains sodium chloride 2.93 g, potassium chloride 1.485 g, sodium bicarbonate 3.37 g and sodium sulfate anhydrous 11.37 g, as well as macrogol 4000, saccharin sodium hydrate, flavour as excipients. Niflec is dissolved in water to make approximately 2 L of solution before administration.
45607906|NCT04645927|Dietary Supplement|flaxseed beverage|"Pizzey Ingredients Inc. introduced a flax beverage product that is a plant-based beverage product that is designed as an alternative to non-diary milks (almond milk & soy milk). Each 330 ml serving of flax beverage contains 15 g flaxseed, which amounts to 3.75 gm of omega-3 fatty acid. Preventing MCI or even AD may be within reach, if appropriate measures are taken early enough using strategies such as dietary supplementation."
45607907|NCT04645927|Dietary Supplement|control beverage|Oat fibre control. For 180 days (6 months) participants will consume 2 servings of 330 ml of placebo beverage (i.e. normal fiber beverage; control) per day.
45607908|NCT04641949|Procedure|Lower body negative pressure (LBNP)|LBNP is a model of experimental hypovolemia, whereby the lower body is exposed to negative pressure leading to sequestering of blood in the lower body and central hypovolemia. LBNP will be induced stepwise with increments of 10 mmHg, each level lasting 1 min. LBNP will be terminated at symptoms or signs of impending hemodynamic collapse.
46067077|NCT00656721|Device|Flutter Valve|"Flutter Valve (Scandipharm, Birmingham, AL) is shaped like a pipe with a hardened plastic mouthpiece at one end, a plastic protective, perforated cover at the other end, and a high-density stainless steel ball resting in a plastic circular cone on the inside. When the patient expires, a vibratory effect is transmitted to airways by the steel ball oscillation in order to facilitate mucociliary clearance.~In our study, the use of the equipment was guided by a registered physical therapist, but the position (angle) was determined by the patient, according to his/her adaptation and perception of effectiveness of sputum clearance. The patients remained comfortably seated, breathing through the device for 15 minutes, starting from the total pulmonary capacity, and being free to cough. Thereafter, a 5-minute session of cough was done."
45757584|NCT05339984|Procedure|Portal vein embolization|preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
45757585|NCT05606978|Behavioral|FASTb|FAST blended
45757586|NCT05606978|Behavioral|FASTr|FAST regular
45757587|NCT03066843|Drug|ALA (5-aminolevulinic acid)|ALA (5-aminolevulinic acid) will be applied to subjects' skin for either zero time incubation or one hour incubation
45757588|NCT03066843|Device|Blue light therapy|Subjects will be exposed to blue light
45757589|NCT03291392|Genetic|Gene expression or biomarkers exploration|
45757590|NCT00684047|Biological|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Preliminary Part (I)
45444840|NCT03795129|Behavioral|FitBit w/Minimal to No SleepLife App.|"Subjects will receive a FitBit. Subjects will be told about the SleepLife Application (but not be shown how to access it).~Subjects will receive no training with regard to how to access SleepLife Application.~Subjects' physicians will receive no subject sleep data."
45911326|NCT02006498|Drug|Placebo|Placebo capsule with same appearances as study drug
45911327|NCT02006524|Device|'MyDiagnostick|
45444841|NCT02803138|Drug|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
45444842|NCT02803138|Drug|Dasabuvir|Tablet
45444843|NCT02803138|Drug|Ribavirin|Tablet
45444844|NCT02803138|Behavioral|Patient support program|Supportive services provided to participants included reminder calls, emails, text messages, a Care Coach, and educational/informational materials.
45757591|NCT00684047|Biological|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Primary Part (II)
45757592|NCT00684047|Procedure|Manual Compression|Manual Compression. Primary Part (II)
45757593|NCT05062928|Other|Virtual coach|This group will be trained and assessed by the virtual coach.
45444845|NCT01305525|Device|St. Jude Medical Spinal Cord Stimulation Systems|Spinal cord stimulation
45757594|NCT04301505|Other|Intervention 1|Checklist will be delivered at the beginning of the study. The educational intervention program will consist of a checklist that provides family physicians with COPD management for the elderly.
45757595|NCT04301505|Other|Intervention 2|The same checklist will be delivered at the beginning of the study and repeated after 6 months.
45757596|NCT00636077|Device|Polyflux HD-C4 Big|Three consecutive treatments with the HD-C4 Big. During the third treatment, dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
45911328|NCT02006537|Drug|GSK2256294|GSK2256294 is a 5 mg capsule administered orally as a 10 mg dose in the fasted or fed state
45911329|NCT02006589|Drug|Candesartan cilexetil (GW615775, Test formulation)|Test formulation candesartan cilexetil 8 mg will be supplied as round, biconvex pink tablets with PX 8 embossed in one face.
45757597|NCT00636077|Device|HD-C4 Small|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
45607909|NCT01941719|Behavioral|Enhanced foot care education|In addition to the standard foot care education, personalized, computer-animated plantar pressure maps in both barefoot and in-shoe conditions were demonstrated once at baseline visit. The demonstration includes diabetic foot education on the topic of diabetic neuropathy and how barefoot walking can lead to skin breakdown and ulcer formation, which can lead to infection and eventual amputation. The education also highlights the high plantar pressures experienced by individuals while barefoot versus in-shoe and how proper footwear is necessary in conjunction with other standard self-foot care measures to prevent injury and complications.
45607910|NCT01941719|Behavioral|Standard Foot Care Education|"At baseline, a trained staff individually reviewed and dispensed the following brochures: Prevent diabetes problems: Keep your diabetes under control (NIH Publication No. 07-4349) and Prevent diabetes problems: Keep your feet and skin healthy (NIH Publication No. 07-4282) along with a 1-page summary of each brochure. Also, a 1-page supplementary diabetic shoe wear educational material was reviewed and dispensed. Keep your diabetes under control stresses sugar, blood pressure, and medication control, and nutrition and physical activity, and checking feet daily for cuts, blisters, sores, swelling, redness, or sore toenails. Keep your skin and feet healthy emphasizes the importance of checking feet daily, highlighting diabetic foot complications that can arise from neuropathy, poor circulation and dry skin, and the importance of supportive, protective, and accommodative shoewear and annual foot exams."
46067078|NCT02556619|Behavioral|Early Palliative Care/Symptom Control|"Establish palliative care goals~Determination of Medical Power of Attorney~Discuss/plan code status/advance directives~Document palliative care goals~Symptom Assessment and Control~Pain-treatment with opioid and non-opioid medications~Itching-H2 blockers, steroids~Nutrition-appetite stimulated with Megace, review low sodium diet~Ascites/edema- optimize ascites management with Lasix or Aldactone. In refractory cases intermittent paracentesis can be performed~Nausea- treated with anti-emetics~Jaundice and Body Image- counselling regarding symptoms~End-of-Life Care~Discuss religious preferences~Assess for distress- ensure interaction with Cancer Resource Center~Hospice- charity Hospice options for select patients."
46067079|NCT04162119|Biological|BCMA-PD1-CART Cell|This study was a single-center, open-label, single-arm, non-randomized clinical trial, which was divided into 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patient in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, we select the safest dose and recruit more patients for CART test to explore its effectiveness.
46067080|NCT02579902|Dietary Supplement|Vitamin D3 (Cholecalciferol)|50000 IU Vitamin D3 (Cholecalciferol) will be given as one gelcaps every 2 weeks for a period of 6 months.
46067081|NCT02579902|Dietary Supplement|placebo|placebo will be given in identical gelcaps once every 2 weeks for a period of 6 months.
46067082|NCT02557087|Drug|Hyoscine|
45757598|NCT00636077|Device|Optiflux 160NR|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
46067083|NCT02557087|Drug|Pethidine|
45757599|NCT00636077|Device|Optiflux 200NR|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
45757600|NCT05315336|Drug|L-DEP and PD-1 antibody|Doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14; PD-1 antibody injection 200mg day 5; L-asparaginases 6000iu/m2 day2, day4. This regimen was repeated after 2 weeks.
45757601|NCT00636389|Device|Polyflux 210H dialyzer|Three consecutive treatments with the Polyflux 210H dialyzer. All study treatments will be performed in the standard hemodialysis mode.
45757602|NCT00636389|Device|Polyflux HD-C4|Three consecutive treatments with the Polyflux HD-C4 dialyzer. All study treatments will be performed in the standard hemodialysis mode.
46067084|NCT02634879|Behavioral|Incentive Change|
45757603|NCT04747977|Drug|OTX-DED|0.2mg dexamethasone ophthalmic insert
46067085|NCT02579590|Drug|Depot Medroxyprogesterone Acetate 150 mg|"the DMPA user where they are using Depot Medroxyprogesterone Acetate 150 mg (DMPA; Phrmcia) injection every 3 month"
46067086|NCT02579590|Drug|Implanon( 68 mg etonogestrel implant)|where they are using etonogestrel 68 mg implant (Implanon; Organon)
46067087|NCT02579590|Drug|Cerazette pills (75 micrograms desogestrel)|where they are using desogestrel 75 micrograms (Cerazette; Organon), one pill every day for 28 days without pill-free interval.
45757604|NCT04747977|Drug|OTX-DED|0.3mg dexamethasone ophthalmic insert
45757605|NCT04747977|Drug|OTX-DED|Hydrogel vehicle ophthalmic insert
45757606|NCT04746716|Other|Phone call|Phone call to the patient to complete quality of life scales
46067088|NCT00773851|Procedure|mesh fixation by transfacial sutures|mesh fixation by transfacial sutures
46067089|NCT00773851|Procedure|mesh fixation by staples|mesh fixation by staples
45607911|NCT02215252|Drug|PF-05089771 150 mg|PF-05089771 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
45607912|NCT02215252|Drug|Matched placebo for PF-05089771 150 mg and pregabalin 300 mg|Matched placebo for PF-05089771 150 mg twice daily and pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
45757607|NCT04387409|Biological|VPM1002|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
45757608|NCT04387409|Biological|Placebo|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
45757609|NCT04746495|Drug|Placebo|Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period and will take a placebo once a day for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will begin the Eplerenone treatment for another 4 weeks.
45757610|NCT04746495|Drug|Eplerenone 50mg|Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period of Eplerenone for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will then begin the Placebo treatment for another 4 weeks.
45757611|NCT04387487|Behavioral|Multimedia video information|"During pre anesthesia visit after regular pre anesthesia check up patient will be asked to fill the Hamilton scoring questionnaire about anxiety.~After this a multimedia video information about spinal anesthesia of around 6 minutes will be shown to the intervention group during pre anesthesia visit. This video will contain explanation about how spinal anesthesia procedure is conducted. Patient will be allowed to ask questions.~On the day of surgery in the pre surgical area again Hamilton scoring questionnaire will be asked with the patients to check the level of anxiety."
46067090|NCT02634957|Behavioral|absolute voice rest|absolute voice rest is the complete elimination of any vocalization (no sounds, speaking or whispering)
45607913|NCT02215252|Drug|Pregabalin 300 mg|Pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
45607914|NCT02215252|Drug|PF-05089771 150 mg + Pregabalin 300 mg|PF-05089771 150 mg twice daily oral capsules with pregabalin 150 mg twice daily oral capsules. Treatment period = 4 weeks.
46067091|NCT03846544|Drug|CFA-double pick up|In the study group, 225 IU of rFSH will continue after the first oocyte retrieval (OR). Antagonist administration will be initiated when at least one follicle measuring ≥14 mm will be present in the ultrasound. If one or more follicles ≥17 mm are observed, patients will undergo a second triggering with hCG 5000 IU and a second OR will be performed. In case of patients with no follicular development following 10 additional days of rFSH post-OR
46067092|NCT02634723|Biological|Octocog alfa (recombinant human coagulation factor VIII)|
46067093|NCT00769717|Behavioral|Wellness-Centered (HUGS)|A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
45607915|NCT04630093|Diagnostic Test|Panel-based pharmacogenetic genotyping|A DNA sample by saliva (via mouthwash swish and expectorate collection) or buccal cell (via buccal brush) will be obtained for pharmacogenetic testing and questionnaires will be administered at baseline and then again at 3 months and 6 months after receiving PGx results.
45607916|NCT03461731|Device|Control|laser beam only
46073598|NCT04241172|Device|Experimental: Immersive Virtual Reality (HIVR)|"the HIVR exercises will be performed using Nirvana system, a medical device based on virtual reality specifically designed to support motor rehabilitation, by projecting aquatic scenarios on the floor that simulates the movement and the noise of the water due to the motor exercise execution by the patient. In particular, the following virtual reality scenarios will be used:~Swimming pool: the environment represents a swimming pool (water and edge). The patient must perform exercises by moving the lower limbs while sitting on a chair. The virtual environment gives the sensation of having the lower limbs immersed in water above the knees;~Water metal: the environment gives the feeling of being immersed in water up to the waist. The subject interacts with the virtual water performing walking exercises and receiving a visual and auditory biofeedback."
45757612|NCT04257071|Behavioral|Usual Care|The usual care for MS involves standard patient neurology visits and encounters with pharmacists, financial counselors and social workers if patients need any financial assistance with medication or other expenses.
45444846|NCT02054260|Drug|Surgicel|
45757613|NCT04257071|Behavioral|OOP Cost Communication and Optimization|OOP Cost Communication and Optimization includes personalized discussion of OOP cost estimates for treatment plan obtained through an online price transparency tool, personalized analysis of patients' expenses by financial counselor, and patient enrollment in any cost optimization opportunities for which patient is eligible using a comprehensive financial navigation program.
45757614|NCT03347786|Drug|Verapamil|Intra-arterial delivery of verapamil following mechanical thrombectomy procedure
45757615|NCT00636701|Device|Repetitive Transcranial Magnetic Stimulation|We will position a coil over the motor cortex of the head and give a series of stimulations (called magnetic pulses).
45757616|NCT03288974|Drug|POMALYST® (Pomalidomide)|The recommended starting dose of POMALYST is 4 mg once daily taken orally on Days 1 to 21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on Days 1, 8, 15 and 22 of each 28-day treatment cycle
45757617|NCT03286634|Drug|Daunorubicin|Given IV
45444847|NCT03795207|Combination Product|SBRT + Durvalumab|"Durvalumab, MEDI4736, is a immunotherapy,~SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy"
45607917|NCT03461731|Device|800 nm laser|800 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
45607918|NCT03461731|Device|combination laser|800 nm and 905 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
45607919|NCT03461731|Device|905 nm laser|905 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
45607920|NCT04894721|Drug|Ivermectin|0,6mg/kg of weight orally on days 1 and 7
45607921|NCT04894721|Other|Placebo|A substance with similar physical characteristics as ivermectin, without the active drug ingredient
45607922|NCT05258539|Other|Questionnaire|"Telephone calls at 2, 3 and 5 years with :~Lifestyle follow-up questionnaire.~Satisfaction questionnaire."
46067094|NCT00769717|Behavioral|Weight-Centered (LEARN)|The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
46067095|NCT04075942|Procedure|Atrophic Anterior Maxillary Ridges|Use of modified cortical shell technique grafted with customized Xenograft bone shell
46067096|NCT02634567|Behavioral|Cogmed Working Memory Training (CWMT)|The CWMT (Cogmed) method consists of 25 training sessions done online. Each participant assigned to the training group will complete eight exercises for five weeks with five sessions every week. Each session consists of a selection of various tasks that target the different aspects of attention/working memory. Participants will engage in weekly discussions over the phone for about 1 hour with an assigned Cogmed coach who will provide support and encouragement over the 5 weeks.
45607923|NCT02204410|Dietary Supplement|Omega-3 Fatty Acid|
45607924|NCT02204410|Drug|ADHD Medication|
45607925|NCT05149079|Dietary Supplement|Cod protein hydrolysate|Rest raw materials (RRM) from cod (Fjordlaks AS, Norway) are used for the hydrolysis production (Food Grade). Freshly minced RRM is treated wth enzymes optimized to generate bioactive hydrolysates using facilities and techniques approved for human consumption.
45607926|NCT05149079|Dietary Supplement|Placebo|Whey protein powder, commercially available
45607927|NCT02522143|Behavioral|Informational sessions describing BPD characteristics|Control intervention consists of informational sessions describing BPD characteristics/ treatment and time- / stress-management skills
45757618|NCT03286634|Drug|Prednisolone|Given PO or IV
45444848|NCT03795207|Radiation|SBRT|SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy
45444849|NCT02056210|Drug|Mozobil|Subcutaneous injection of 0.24 mg/kg Mozobil once at 8:30am
45444850|NCT03794973|Biological|TOL-3021|TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.
45444851|NCT03794973|Other|TOL-3021 Placebo|TOL-3021 Placebo
45444852|NCT02038114|Behavioral|Instructed to read patient education pamphlets|The intervention in this study is the administration of patient education pamphlets and instructions to read them. Half of all patients who participate in this study will be required to read pamphlets on symptoms that are relevant to them (i.e. symptoms that they are experiencing). Subsequent to reading pamphlets, patients will complete study questionnaires to assess their impact.
45607928|NCT02522143|Behavioral|Condensed-DBT treatment intervention|The Intervention consists of an 8-week manual based psychoeducational group utilizing modified condensed-DBT Treatment manual previously used in a treatment study (Moen et al, 2012).
45607929|NCT04043377|Drug|injection of 68Ga-DOTATATE|PET after injection of 68Ga-DOTATATE 2 MBq/kg (Max. 200 MBq); intra-venous; single injection, at M0 followed by a coronary CTA to localize the signal in coronary arteries Consultation and low-dose cardiac CT for coronary calcium scoring performed at M12 and M24 after inclusion.
45607930|NCT03488537|Device|AeonoseTM|Breath test
45607931|NCT03488459|Behavioral|Routine preoperative information from a nurse|Routine preoperative information from a nurse.
45607932|NCT03488459|Behavioral|Additional information support from a psychologist|Routine preoperative information from a nurse + additional information support from a psychologist.
45607933|NCT02250274|Biological|LAIV|Licensed and approved Live Attenuated Influenza Vaccination (LAIV) will be preferentially given to all children aged 5-8 years old as recommended by Advisory Committee on Immunization Practices. A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given LAIV will be used. The rest of the children aged 9-17 years old will receive IIV.
45607934|NCT02250274|Biological|IIV|"A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given IIV will be used. The rest of the children 9-17 years old will receive LAIV.~[Note: Although we do not anticipate exhausting the supply of LAIV, should this occur, children aged 5-8 will be offered IIV as it is also approved in this age group and should be used if LAIV is unavailable.]"
45607935|NCT03129997|Dietary Supplement|Gluten test food|Dietary supplement: corn muffins with 7.5g of gluten/muffin Two muffin were blindly administered for 21 days
45607936|NCT03465631|Device|SMART Glove system with tDCS|combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke.
45757619|NCT03286634|Drug|Vincristine|Given IV
45757620|NCT03286634|Drug|Epirubicin|Given IV
45757621|NCT03286634|Drug|E-coli L-asparaginase|Given IM or IV
45607937|NCT03465631|Device|SMART Glove system with sham-tDCS|combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke.
45757622|NCT03286634|Drug|6-Mercaptopurine|Given PO
45607938|NCT04772092|Biological|Blood samples|"during the routine blood test, collection of additional blood samples:~1 x 5 mL heparinized tube for plasma collection and storage~1 heparinized 5 mL tube for immunophenotyping~4 x 10 mL EDTA tubes for white blood cell (WBC) collection and cryopreservation"
45607939|NCT04772092|Other|Data collection|"clinical examination data~test results to measure the degree of geriatric fatigability~Frailty screening questionnaire for neoplasia patients (G8 score)"
45607940|NCT04588051|Drug|Cabozantinib|60mg daily
45757623|NCT03286634|Drug|Methotrexate|Given IV, PO or IT
45757624|NCT03286634|Drug|Hydrocortisone|Given IT
45757625|NCT03286634|Drug|Cytarabine|Given IV, IT or SC
45757626|NCT03286634|Drug|Cyclophosphamide|Given IV
45757627|NCT03345290|Device|PET with a cerebral step|Positron Emission Tomography with a cerebral step before to carry out the standard Position Emission Tomography
45757628|NCT03345290|Device|Central blood pressure measurement|Central blood pressure measurement
45757629|NCT03345290|Other|Neurocognitive tests|Mini Mental State Examination, MMSE, Mini International Neuropsychiatric Interview MINI and Frontal Assessment Batery FAB
45757630|NCT05011682|Behavioral|Regular diet|participant's usual diet during 2 weeks
45757631|NCT05011682|Behavioral|10-point nutrition plan|controlled portions of low glycemic index carbohydrates, avoidance of rapidly absorbed carbohydrates, adjustment of timing of meals and snacks, and attention to personal and cultural barriers to implementation
45757632|NCT03286556|Drug|Autoantibody Reductive Therapy|TPE x 9, rituximab x 2, IVIG x 4. See arm/group descriptions for additional details.
45757633|NCT03286556|Drug|Treatment as Usual (TAU)|Antibiotics and steroids
45757634|NCT03285152|Other|Ketogenic Diet (KD)|specially-formulated very low carbohydrate meals (KD)
45757635|NCT03285152|Other|Standard Diet (SD)|counseling on maintaining adequate nutritional intake from a normal diet (SD)
45757636|NCT04400630|Other|Physical exercise|The experimental group will receive supervised physical exercise treatment by high-intensity interval training (HIT), alternating high and moderate intensities (20 min). The participants will exercise two non-consecutive days per week for 16 weeks under supervision by exercise specialists.
45757637|NCT05000294|Drug|Atezolizumab|Subjects on both the phase Ib and phase II portions of this study will receive 1680 mg intravenously of atezolizumab on Day 1 of each 28 day cycle.
45607941|NCT04255511|Device|Twin Block|Functional appliance
45607942|NCT04255511|Device|Fixed orthodontic appliance|Braces
45757638|NCT05000294|Drug|Tivozanib|Subjects in both the phase Ib and phase II portions of the study will take tivozanib orally once daily on Days 1-21 of each 28 day cycle. Subjects on the phase Ib will be assigned to receive either 1.34 mg/day (Dose level 0) or 0.89 mg/day (Dose level -1). Subjects in the phase II portion of the study will receive 0.89 mg/day.
45757639|NCT00637247|Drug|imexon in combination with gemcitabine|875 mg/m^2 imexon IV + 1000 mg/m^2 gemcitabine IV
45757640|NCT00637247|Drug|imexon placebo + gemcitabine|imexon placebo IV + 1000 mg/m^2 gemcitabine IV
45757641|NCT04998032|Biological|supaglutide injection+metformin|supaglutide subcutaneous injection under RP3D dose combined with metformin treatment
45757642|NCT04998032|Other|placebo+metformin|placebo subcutaneous injection combined with metformin treatment
45757643|NCT04995692|Behavioral|Telehealth Education for Asthma Connecting Hospital and Home|TEACHH aims to provide educational support to families managing childhood asthma throughout the transition from hospital to home, and includes several core components: 1) Health literacy-informed inpatient teaching for child and caregiver including pictorial materials, hands-on demonstration, and use of teach-back/show-back techniques; 2) Facilitated identification of rescue and controller medications using color- and shape-coded medication labels and a pictorial asthma action plan; and 3) A pair of virtual follow-up visits after discharge to reinforce inpatient teaching and support families during the shift from acute exacerbation to preventive care management. Virtual visits will be completed using the Zoom platform on smartphones or other compatible devices, 2-4 days after discharge (first visit) and 3 weeks after discharge (second visit). All intervention activities will be completed within 1 month of discharge.
45757644|NCT04995692|Behavioral|Standard Care (SC) Comparison Group|Patients in the SC group will receive standard impatient management, including pre-recorded asthma education videos shown prior to discharge and the hospital action plan. PCP follow-up with be scheduled within a week of discharge. All SC measures will also be provided to subjects randomized to TEACHH.
45607943|NCT05154370|Drug|Intravenous steroid|This study does not limit treatment methods. Patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. Immunomodulatory therapies are necessary for the remission stage. All drugs are used in accordance with relevant guidelines.
45607944|NCT03465553|Radiation|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with advanced thoracic cancer
45757645|NCT04388033|Biological|Dendritic Cell/Tumor Fusion Vaccine|Vaccine is derived from the participants dendritic cells and tumor cells.
45757646|NCT04388033|Drug|Interleukin-12|Given subcutaneously at dose of 6ug twice for interval of one hour.
45757647|NCT04388033|Drug|Temozolomide|Following concomitant radiation (2 Gy/day x 30 days) and TMZ-chemotherapy (75 mg/m2/ day x 42 days) , maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle.
45757648|NCT03267680|Drug|Cyclophosphamide|Given IV
45757649|NCT03267680|Drug|Indomethacin|Given PO
45757650|NCT03267680|Biological|IRX-2|Given via submucosal injection or SC
46067097|NCT03843424|Behavioral|eSOC program|American Medical Association (AMA) recommended staged approach to childhood obesity screening and counseling
45757651|NCT03267680|Other|Laboratory Biomarker Analysis|Correlative studies
45607945|NCT03488381|Device|Soccer Heading|"Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer headings, separated by one minute intervals.~Soccer Kicking: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer kicks, separated by one minute intervals."
45607946|NCT05230849|Device|dry needling|is a physiotherapy treatment for neurological patients and studies the efficacy of dry needling by studying several pre-treatment and post-treatment variables after the experimental treatment.
45757652|NCT03267680|Dietary Supplement|Multivitamin|Given zinc-containing multivitamin PO
45607947|NCT05230849|Other|convencional treatment|is a physiotherapy treatment for neurological patients
45607948|NCT04461431|Procedure|Arthroscopic anatomical reconstruction of the posterolateral structure of the knee|Arthroscopic anatomical reconstruction of the posterolateral structure of the knee for patients with injury of the posterolateral structure of the knee
45607949|NCT04461119|Drug|Evenamide|oral capsules for 4 weeks of treatment
45757653|NCT03267680|Drug|Omeprazole|Given PO
45757654|NCT03267680|Other|Placebo|Given via submucosal injections or SC
45757655|NCT03267680|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
45757656|NCT04179929|Drug|Pediatric-type of chemotherapy|Pediatric type chemotherapy (induction, early and delayed consolidation, reinduction, maintenance). Induction (VCR,PDN,PegASP,DNR). Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP). Reinduction (VCR, PDN, PegASP, DNR). Maintenance (Methotrexate, Mercaptopurine)
46067098|NCT03843424|Behavioral|FBT program|An intensive,comprehensive, behavioral intervention aligned with the US Preventive Services Task Force recommendations for childhood obesity screening and counseling.
46067099|NCT02634489|Drug|Tamsulosin HCl|Oral
46067100|NCT02634489|Drug|Solifenacin Succinate|Oral
45757657|NCT04179929|Procedure|allogeneic HSCT|allogeneic HSCT
45757658|NCT04760756|Other|Fragility Fracture Integrated Rehabilitation Management|"At least 2 hours of rehabilitation management per day~Including occupational therapy (training to improve daily life performance)~Inpatient (the first 2 weeks): daily management (body control ability, mobility ability, hygiene management, etc.)~Outpatient (2-6 weeks): management once a week~The management period is for 2 weeks (1 week after surgery)"
45757659|NCT02980731|Drug|Venetoclax|Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.
45757660|NCT04994288|Biological|Supaglutide injection|Supaglutide 1mg/0.5ml , 2mg/0.5ml ,3mg /0.5ml
45607950|NCT04461119|Drug|Placebo|oral capsules for 4 weeks of treatment
45607951|NCT02213458|Behavioral|Navigated Care|"Navigated Care emphasizes continuous and personalized care and is based on 3 modules: the Caregiver Module that includes educational interventions and connects families with community resources, the Decision-Making Module that facilitates proactive medical, financial, and safety decisions, and the Medication Module that identifies inappropriate medication usage via pharmacist review. Innovative technology in the form of a dashboard functions as a patient care management system used by Care Team Navigators (CTNs)."
45757661|NCT04994288|Other|placebo injection|placebo injection 0.5ml
46067101|NCT02634489|Drug|EC905|Oral
46067102|NCT02579512|Other|Extra-corporeal ECG signal analysis|The NIA algorithm is similar to the traditional 12-lead ECG equipment. By analyzing patient data, NIA algorithm provides more detailed results compared to traditional 12-lead ECG. Patients with suspected coronary artery disease are conventionally diagnosed and treated by cardiac catheterization. However, cardiac catheterization is invasive procedure. Unless clinical diagnosis is evident before cardiac catheterization, a treadmill exercise test, a nuclear medicine myocardial perfusion test, or a multi-direction coronary CT angiogram is usually performed to increase the accuracy of diagnosis. But these examinations are not accessible to all patients, and are time-consuming and costly.
45757662|NCT04345835|Procedure|Percutanous nephrolithotomy (PCNL)|different procedure positioning
45757663|NCT04400396|Dietary Supplement|standard HM fortification|Based on the assumed energy and macronutrient composition of HM, the commercial multi-component HM fortifier was added, in order to compensate identified nutritional deficits.
45757664|NCT04400396|Dietary Supplement|target HM fortification|Based on the measured energy and macronutrient composition of HM, modular protein and fat supplements are added, in addition to the commercial multi-component HM fortifier, in order to correct identified specific nutritional deficits. For this purpose, an Excel program to calculate modular protein and fat supplements to be added to fortified HM was developed and registered (Nona R, Cardoso M, Portuguese Directorate of Intellectual Property Services, IGAC-DSPI, nº 480/2020, 26 February 2020)
46067103|NCT05674162|Behavioral|Unobserved|Participants walk a distance of 40 meters wearing the XSens sensors, unobserved by the researcher.
45757665|NCT04164173|Device|EzPAP|Patient will receive 10 min EzPAP 4 times daily
46067104|NCT05674162|Behavioral|Observed|Participants walk a distance of 40 meters wearing the XSens sensors, observed by the researcher.
46067105|NCT05674162|Radiation|Unobserved & Measured|Participants walk a distance of 40 meters wearing the XSens sensors, unobserved by the researcher and aware of the gait measurement by the sensors.
45607952|NCT03465397|Diagnostic Test|biomarkers driven immunosuppressive therapy|the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk
45607953|NCT03461575|Drug|HU007|cyclosporine 0.02%, trehalose 3%
45607954|NCT03461575|Drug|Restasis|cyclosporine 0.05%
45607955|NCT03461575|Drug|Moisview|trehalose 3%
45607956|NCT03131843|Drug|Alcohol|Alcohol cleansing swab/wipe
45607957|NCT03131843|Drug|No alcohol|No alcohol will be used; alcohol cleansing swab/wipe will be used at a different injection site
45607958|NCT03461341|Other|High intensity postoperative oncologic surveillance|High intensity surveillance protocol using routine cross-sectional imaging (computed tomography or positron emission tomography with computed tomography).
46067106|NCT00582712|Drug|Lithium carbonate|Lithium 300mg by mouth, three times daily, escalating to a lithium level of 0.8-1.2; Continue until progressive disease/unacceptable toxicity; Evaluate every 4 weeks.
46067107|NCT04161963|Device|SD-OCT|Optical Coherence Tomography of the maculy with Heidelberg Spectralis SD-OCT
45607959|NCT04125173|Other|Pneumoperitoneum pressure = 15mmHg|Randomized pneumoperitoneum 1
45607960|NCT04125173|Other|Pneumoperitoneum pressure = 12mm Hg|Randomized pneumoperitoneum 2
45607961|NCT04125173|Other|Pneumoperitoneum pressure = 10mmHg|Randomized pneumoperitoneum 3
46067108|NCT04161963|Device|OCT-A|swept source Optical Coherence Tomography Angiography with Zeiss Plex Elite 9000 of the macula
45607962|NCT05072561|Diagnostic Test|Sentinel lymph node scintigraphy|"During the surgery, right after the identification of the primary, 18-37 MBq of 99mTc-Nanocolloids in two ml will be injected at four peritumoral locations. After a brief waiting time (5-10'), the thoracic surgeon will perform the clinical intervention, including the lobectomy (the injection sites will be resected alongside the tumour) and lymphadenectomy, according to the best clinical practice. All the excised lymph nodes will be ex vivo counted using a gamma probe: those with a detectable activity (at least 10% of the hottest lymph node) will be considered as SLN. Thereafter, the mediastinum will be scanned using the gamma probe and a handheld gamma-camera (the latter will not be employed in case of robotic-assisted surgery); any further source of radioactivity will be investigated and, should further lymph nodes be identified, these will be also resected and classified in SLN or non-SLN, based on ex vivo activity."
45607963|NCT03489473|Diagnostic Test|18F-FES PET CT scan|PET CT scan with estrogen tracer
45757666|NCT04164173|Device|Metaneb|Patient will receive 10 min Metaneb 4 times daily
45757667|NCT04164173|Device|Intermittent Positive Pressure Breathing (IPPB)|Patient will receive 10 min IPPB 4 times daily
45607964|NCT02213380|Procedure|method of anesthesia|"General anesthesia and regional anesthesia.~General anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) will be used in group GA.~Regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) will be used in group RA"
45607965|NCT03488147|Drug|Esomeprazole|20 mg esomeprazole tablet
45607966|NCT03488147|Drug|Placebo Oral Tablet|resembling esomeprazole tablet
45607967|NCT03488069|Other|Survey|Submission of survey answers
45757668|NCT04400162|Behavioral|Usability of the CCT|Evaluation of the usability of the provided training.
45757669|NCT04400162|Behavioral|Changes in regards to the depressive disorder|Evaluation of depressive symptoms and whether they change in regards to the provided training.
45757670|NCT03281096|Drug|Berberine hydrochloride|patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 3 years.
45607968|NCT05234801|Device|DARCO™ Headed Cannulated Screw|The DARCO™ Headed Cannulated Screw is a multi-size screw system designed to be used over a guide pin or wire with instrumentation to provide interfragmentary compression and stability for bone fracture/fragment fixation.
45607969|NCT05234801|Device|ORTHOLOC™ 3Di Recon-Midfoot/Flatfoot System|A multi-indication foot reconstruction solution providing indication specific implants and instruments designed to address the unique demands of the forefoot and midfoot.
45607970|NCT05234801|Device|ORTHOLOCTM 3Di 2 Foot Reconstruction System: CROSSCHECK™ Module|A comprehensive fixation system consisting of a wide variety of plate options, created with the purpose of stabilization and fixation of fractures, revision procedures, joint fusion and reconstruction of small bones of the feet.
45607971|NCT03797261|Drug|Venetoclax|tablet, oral
45607972|NCT03797261|Drug|AMG 176|solution, intravenous
45757671|NCT03281096|Drug|Placebo|pill manufactured to mmic Berberine hydrochloride 100mg tablet
45757672|NCT04731987|Behavioral|Beverage consumption|"Volunteers will consume, in random order, daily 330 ml of 1 experimental beverage per period (Orange Juice, Control Beverage, Control Beverage supplemented with hesperidin) for 6 weeks in each period.~At the beginning and the end of each period, exploration will be conducted at fasted state and at post-prandial state after the administration of a high-fat high-sugar meal."
45757673|NCT03280394|Diagnostic Test|Liquid Biopsy|Assessing whether plasma cell free DNA improves the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that, at disease presentation, refine the diagnostic workup in mature B-cell tumor patients and, upon treatment, early identify the emergence of resistance mutations.
45757674|NCT05564390|Drug|Azacitidine|Given IV or SC
45757675|NCT05564390|Procedure|Biospecimen Collection|Undergo collection of blood samples
45757676|NCT05564390|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
45757677|NCT05564390|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
45757678|NCT05564390|Drug|Cytarabine|Given
45757679|NCT05564390|Drug|Daunorubicin Hydrochloride|Given IV
45757680|NCT05564390|Procedure|Echocardiography|Undergo ECHO
45757681|NCT05564390|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
46067109|NCT02754778|Behavioral|conditional workout|6 month of regular conditional workout 1-3 times a weak
46067110|NCT02579668|Other|Language Therapy|
46067111|NCT03920566|Other|Anti-Xa level|Anti-Xa level taken before commencing enzalutamide and repeated after 4 weeks of treatment
46067112|NCT02578498|Dietary Supplement|High carbohydrate intake|Carbohydrate intake < 50 gram
46067113|NCT02578498|Dietary Supplement|Low carbohydrate intake|Carbohydrate intake > 250 gram
45607973|NCT03487991|Behavioral|Personalized sleep intervention|Personalized feedback and recommendations based on study observations of sleep behavior and how participants cope with potentially sleep disruptive cognitions on their frequency and impact and on sleep efficiency. A written report is provided to participants and their initial modifications are monitored.
45757682|NCT05564390|Procedure|Multigated Acquisition Scan|Undergo MUGA
45757683|NCT05564390|Procedure|Mutation Carrier Screening|Undergo rapid genetic testing
46067114|NCT02742454|Procedure|Standard 30-60 Seconds Cord Clamping|The infant will be stimulated to breathe after birth. If the infant is not breathing well, the cord will be clamped at 30 seconds. If the baby is breathing well, the cord will be clamped at 60 seconds. Ventilatory assistance will be given after cord clamping.
46067115|NCT02742454|Procedure|VentFirst 120 Seconds Cord Clamping|The infant will be stimulated to breathe after birth. If the infant is not breathing well, Positive Pressure Ventilation by face mask will be given starting at 30 seconds. If the baby is breathing well, Continuous Positive Airway Pressure (CPAP by face mask) will be given starting at 30 seconds. The cord will be clamped at 120 seconds.
45757684|NCT05564390|Drug|Venetoclax|Given PO
45444853|NCT03792789|Device|mCIMT with real rTMS|"Modified constraint induced movement therapy will be provided to all children according to predefined protocol.~rTMS will be provided using figure of eight shaped coil and TMS stimulator ((Magventure Denmark, X100 with mapoption) over contra-lesional primary motor cortex over 10 sessions of 20 minutes each spread over 4 weeks. Each session will comprise priming ( 10 minutes of 6Hz rTMS at 90% of resting motor threshold, delivered in two trains per minute with 5 seconds per train and 25-seconds intervals between trains (a total of 600 priming pulses)). Priming will be followed immediately by additional 10 minutes of 1Hz rTMS at 90% of resting motor threshold without interruption (a total of 600 low-frequency pulses)."
46067116|NCT00582790|Drug|IL2|Interleukin-2 will be given at a starting dose of 7 MU/m2/day by subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles.
46067117|NCT00582790|Drug|Zoledronic acid|Zoledronic acid will be given on day 1 intravenously over 15 or 30 minutes starting at 400mcg. If no significant increase in gamma delta-T cell augmentation is seen, the dose of zoledronic acid will be increased in the subsequent cycle up to a maximum dose of 3mg.
45607974|NCT03487835|Other|Kinesiotape|
45607975|NCT03487835|Other|No application|This group have no application during study time
45607976|NCT03413735|Other|Green Tea Extract|Confections containing green tea extract that will be ingested daily for 4 weeks
45757685|NCT04261257|Other|Cardiac scanner|"As part of the usual care of patients hospitalized for stroke, the following examinations are carried out: a trans-thoracic cardiac ultrasound, a transesophageal cardiac ultrasound according to the needs of patient's care, an echo-doppler of the supraaortic trunks, a CT angiography of the supraaortic trunks, a transcranial doppler, a biological assessment, a 24-hour holter or long-term holter.~The additional examination, specific to the research, corresponds to a cardiac scanner, which does not require the additional injection of contrast medium, carried out during the cerebral artery scanner within 36 hours of discovering the stroke. Within 3 days after inclusion, a trans-thoracic cardiac ultrasound, and a transesophageal cardiac ultrasound according to the needs of patient's care are carried out."
45757686|NCT05563844|Drug|PM 8.4 mg/m2|1 case, Take the medicine once on D1,D 1-21.
45757687|NCT05563844|Drug|PM 11.2 mg/m2|1 case, Take the medicine once on D1,D 1-21.
45444854|NCT03792789|Device|mCIMT with sham rTMS|"Modified constraint induced movement therapy will be provided to all children according to predefined protocol.~Sham rTMS will be given using a sham coil."
45452236|NCT02236468|Other|Enhanced-Homestead Food Production Program (old)|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010
45757688|NCT05327816|Biological|RSV preF-based Vaccine|RSV preF-based vaccine will be administered as intramuscular injection.
45757689|NCT05327816|Drug|Placebo|Placebo will be administered as intramuscular injection.
45757690|NCT04725591|Device|Dexcom G6 Continuous Glucose Monitoring|Collection of glucose data
45607977|NCT03413735|Other|Placebo|Confections containing no green tea extract that will be ingested daily for 4 weeks
45607978|NCT02202850|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
45607979|NCT02202850|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
45607980|NCT03489395|Drug|Edoxaban|Edoxaban 60 mg once a day for 4 weeks. Edoxaban 30 mg/day in patients with body weight ≤60 kg, or with concomitant therapy with verapamil/quinidine/dronedarone.
45607981|NCT03489317|Drug|Metformin|Participants with high glucose levels will usually be prescribed Metformin 250 mg three times daily. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
45607982|NCT03489317|Behavioral|lifestyle modification|Participants with metabolic syndrome will be offered advice on modifying their diets and exercise regimes. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
45607983|NCT03489317|Drug|Simvastatin 10mg|Participants with elevated lipid levels will usually be prescribed simvastatin 10 mg at night. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
45607984|NCT03489317|Drug|Amlodipine 5mg|Participants with high blood pressure could be prescribed antihypertensive medicine such as Amlodipine. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
45607985|NCT02212678|Drug|N-acetylcysteine capsule|N-acetylcysteine capsule
45607986|NCT03489239|Drug|Tenofovir Alafenamide|subjects switching from Entecavir to single arm TAF 25mg
45757691|NCT04725591|Device|MEDISAFE WITH External Insulin Pump|Insulin delivery
45757692|NCT04725591|Device|Diabeloop Software (Model predictive control)|Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
45757693|NCT04725591|Other|Declaration of meals|Patient inputs related to meals
45757694|NCT04725591|Other|No declaration of meals|No patient inputs related to meals
45607987|NCT04870775|Behavioral|Mindfulness Training Program|Mindfulness training program to reduce psychotropathological symptoms in hospital workers
45607988|NCT04761250|Dietary Supplement|Lifestyle|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
45607989|NCT03489161|Drug|Buprenorphine|buprenorphine/naloxone 4mg/1 mg for Clinical Opioid Withdrawal Scale (COWS) scores between 8 and 12, or 8mg/2mg S/L ≥ 12 by the sublingual route
45444855|NCT00131235|Drug|Sulfadoxine-pyrimethamine treatment twice during pregnancy|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.~2 placebo tablets for azithromycin taken at the same time points."
45607990|NCT04804709|Drug|Panobinostat 15 MG|After each instance of opening the BBB using specific parameters of focused ultrasound in the specific number of tumor sites (one, two, or three), the subjects will receive oral Panobinostat (15 mg/m^2).
45607991|NCT04804709|Device|Focused Ultrasound with neuro-navigator-controlled sonication|"The purpose of this study is to evaluate the feasibility of opening the BBB safely using specific parameters of focused ultrasound in progressive/recurrent diffuse midline gliomas in one, two, or three tumor sites. The trial will follow a 3+3 Number of Tumor Sites (NOTS) escalation scheme. The number of tumor sites in reference to here is the number of openings in the blood-brain barrier using Focused Ultrasound (FUS). Subjects will start the first cycle of the treatment arm with 1 tumor site and move on to incrementing NOTS levels if no dose-limiting toxicities (DLTs) are observed."
45607992|NCT04690673|Drug|Paracetamol|1 g oral paractamol
45607993|NCT04690673|Diagnostic Test|Paracetamol concentration measurements and lipidomic assessment|Paracetamol concentration is measured from saline-, urine-, venous blood- and fingerprick- samples at timely intervals. Also serum lipidomic assessment is performed from venous blood samples.
45607994|NCT03104075|Biological|Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein|One to two years after receiving the randomly-assigned vaccination, participants may opt to receive administration of a second pneumococcal vaccine with Pneumovax 23
45607995|NCT03104075|Biological|Pneumococcal Vaccine Polyvalent|One to two years after receiving the randomly-assigned vaccination, participants may opt to receive administration of a second pneumococcal vaccine with Prevnar-13
45607996|NCT03038087|Device|SENSE Device|"The SENSE device transmits a low power tailored electro-magnetic pulse across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of two parts:~A molded plastic headpiece containing the antenna array, and~A processing control unit.~The SENSE device will be placed on the subject within 15 minutes of a baseline head CT, or as soon as practicable. The SENSE device will be set to scan every 10 minutes until the device is removed after completion of the SENSE measurement corresponding to the 72 hour CT scan. The investigator will be blinded to the data collected from the SENSE device."
45607997|NCT02907983|Drug|Stellate Ganglion Block Injection with Bupivicaine|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
45607998|NCT02907983|Drug|Saline injection|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
46067118|NCT00773929|Drug|TAK-593|"Tablets of TAK-593 investigational drug for oral administration, tablets in 2 strengths: 1 mg and 4 mg tablets.~Administration will initially be 4 mg, once a day and transition to 2 mg BID schedule dependant on safety"
46067119|NCT00777907|Device|Pipeline Embolization Device (PED)|1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach.
46067120|NCT00777907|Device|Coil embolization|Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed.
46067121|NCT00774007|Drug|mesalazine|
45757695|NCT04725591|Other|Remote monitoring (Telemedicine)|Remote follow up by care health providers team
45757696|NCT03343574|Other|Abdominal Strengthening Exercise|Abdominal strengthening exercises involve the muscles of the abdomen. These exercises are to be done in different positions like lying down (recumbent) position, sitting and standing positions. The person performing the exercise contracts the abdominal muscles for a predetermined number of times (up to 10 times), holds the contracted position for up to 10 seconds and then releases the contraction to relax and return to the original state. These exercises are done for three times everyday.
46067122|NCT00774007|Drug|placebo|
46067123|NCT00774085|Other|No intervention was given|Participants included patients treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
46067124|NCT00769873|Drug|Enoxaparin|Lovenox 40mg SC daily (30mg SC daily if creatinine clearance < 30) for 21 days
46067125|NCT00777985|Drug|bosentan|62.5 mg b.i.d for 4 weeks
46067126|NCT00777985|Device|nasal continuous positive airway pressure (CPAP)|Daily application throughout sleep for 4 weeks
46067127|NCT00769951|Other|medical chart review|Data will be obtained from patients medical records at baseline, 6 months, 1 year, and 3 years.
46073599|NCT04241172|Procedure|Traditional Hydrotherapy (TH)|"The TH group exercises will be performed in a swimming pool suitable for hydrotherapy treatments. In particular, patients will perform:~exercises with a patients sitting on the swimming pool edge with lower limb immersed in the water;~flexion-extension of the knee;~leg and hip circling;~flexion-extension of the ankle;~triple flexion;~water walking exercises."
45757697|NCT02890095|Procedure|Breast cancer surgery|"First, 2 specific adipose tissue samples will be performed during the surgery :~1 sample near the tumor, to measure the contaminants (dioxins, PCBs, organochlorine pesticides, polybrominated compounds)~1 remote sample of the tumor bed, superficial, at least 5 cm from the tumor, to be used to determine the level of expression of hormone receptors and to establish the expression profiles, after cutting and inclusion in paraffin blocks for marking IHC.~These withdrawals are made during surgery, during surgery, as part of the intervention and the remodeling of the mammary gland (standard care for patients). This is unused balance for diagnostic.~Before anaesthesia : specific blood samples (for the determination of circulating pollutants and for the analysis of gene polymorphism)"
45757698|NCT02890095|Procedure|plastic surgery|"The excision piece will follow the classical pathological circuit.~A specific charge of subcutaneous adipose tissue will be performed as part of research on the surgical specimen. This sample will be used:~measuring contaminants (dioxins, PCBs, organochlorine pesticides, polybrominated compounds)~to determine the level of expression of hormone receptors and to establish the expression profiles, after cutting and inclusion in paraffin blocks for marking IHC. These samples are all made during surgery, for usual care surgery these patients.~Before anaesthesia : specific blood samples (for the determination of circulating pollutants and for the analysis of gene polymorphism)"
45444856|NCT00131235|Drug|Sulfadoxine-pyrimethamine at 4-week intervals|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 placebo tablets for azithromycin taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
46067128|NCT00769951|Other|questionnaire administration|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care. The assessments include the Lawton's nine-item Instrumental Activities of Daily Living (IADL); the Katz's Activity of Daily Living (ADL); the Timed Up and Go Test; the Karnofsky Physician-Rated Performance Rating Scale (KPS); the number of falls in the past 6 months; the Mini Nutritional Assessment (MNA); the Body Mass Index; the percent of unintentional weight loss in the past 6 months; the Medical Outcomes Study (MOS) Social Support Subscale (emotional/information and tangible subscales); the MOS Social Activity Limitations Measures; the Charlson Comorbidity Index; the Cumulative Index Rating Scale Geriatrics (CIRS-G); the ACE-27; the Folstein's Mini-Mental State Examination (MMSE); the Geriatric Depression Scale (GDS); the Functional Pain Scale; and a list of medications.
46067129|NCT00769951|Procedure|cognitive assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
45607999|NCT03487679|Other|Fasting|Participants will undergo one day of habitual eating followed by 36 hours of water-only fasting and final day of habitual eating consuming the exact same diet consumed on the first eating day. Blood draws will be performed on Day 1 in a 10-12 hr fasted state and 2 hour postprandial state and again on Day 3 in a 36hr fasted state and a 2 hour post prandial state. Microbiome samples and blood glucose data will be collected throughout the course of the study.
45444857|NCT00131235|Drug|Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 azithromycin tablets (each 500 mg) taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
45608000|NCT02841215|Drug|Ivermectin 200 µg/kg|Oral ivermectin 200 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other) daily on skin (D0 to D28)
45757699|NCT02980497|Other|Listerine Zero Mouthwash (without alcohol)|20 ml of rinse for 30 seconds, twice a day
46067130|NCT00769951|Procedure|psychosocial assessment and care|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
45608001|NCT02841215|Drug|Ivermectin 400 µg/kg|Oral ivermectin 400 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other)daily on skin (D0 to D28)
45608002|NCT02799641|Drug|Diazepam|5 mg Diazepam
46067131|NCT00769951|Procedure|quality-of-life assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
45608003|NCT02799641|Drug|Lidocaine|2 ml of 2% lidocaine
45608004|NCT02799641|Other|Placebo pill|Placebo pill
46067132|NCT00770107|Drug|Thiamine|Supplementation of thiamine (vitamin b1) 300 mg per day, once daily, for a duration of 4 weeks
46067133|NCT00770107|Drug|Placebo|Placebo, once daily, for a duration of 4 weeks
45757700|NCT02980497|Other|Listerine Antiseptic Mouthwash (with alcohol)|20 ml of rinse for 30 seconds, twice a day
45757701|NCT05325086|Other|Adapted information arm|A adapted booklet will be delivered to patients at the start of the stay. This booklet contains adapted information about the pulmonary rehabilitation targetting the characteristics of the openness to experiences personality traits
45444858|NCT03795831|Device|ClearSight feasibility testing|A cuff is placed on a finger of the patient. The ClearSight system uses a volume clamp technology allowing measuring of continuous blood pressure waveform. Note: There will only be observational recordings, no interventions
46067134|NCT00770185|Drug|ridaforolimus|oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)
45444859|NCT03793023|Drug|Teneligliptin 20mg|
45608005|NCT02799641|Other|Placebo injection|Placebo injection
45608006|NCT03487601|Other|transcranial direct current stimulation|Active treatment will consist of a mild electrical current (2mA) administered via saline-soaked sponge electrodes placed along the intact scalp for 30 minutes a day for five days.
45608007|NCT03487601|Other|sham transcranial direct current stimulation|Sham stimulation will involve brief delivery of current in a manner that does not result in changes in neuronal firing patterns, but that is perceived as active treatment by participants.
45608008|NCT03487523|Behavioral|Text Message|As already stated
45444860|NCT02801578|Drug|Ibrutinib|Cycle 1 daily dose of ibrutinib is 420 mg (3 capsules), in the second cycle 280 mg (2 capsules), and in the third cycle 140 mg (1 capsule).
45608009|NCT03486041|Behavioral|Comprehensive Behavior Modification|Behavior therapy approach to BFRBs involving targeted intervention tactics chosen in accordance with the modality of functioning (ex: Sensory, Cognitive.....) seeming to cause the most frequent and problematic urges to engage in the BFRB. Therapist and client work together, using careful assessments including detailed self-monitoring, to determine what behavioral methods will suffice for lasting change.
45608010|NCT03486041|Behavioral|Attention|Weekly brief calls from therapist to check on safety and clinical status. No focus on TTM.
46067135|NCT00770185|Genetic|gene expression analysis|
46067136|NCT00770185|Other|immunohistochemistry staining method|
45608011|NCT03485963|Biological|HST-NEETs|The primary objective of this study is to evaluate the safety and tolerability of expanded HIV-specific T cell therapy (HST-NEETs) in HIV-infected individuals suppressed on cART. Patients with a partial response or stable disease 8 weeks after T-cell infusion were eligible to receive additional T-cells, consisting of the same number of cells as their second injection.
45608012|NCT03485885|Dietary Supplement|Standardized maqui berry extract enriched in anthocyanins|Single oral intake of 1000mg standardized maqui berry extract (in 4 capsules - 250mg each) with 200ml still water
45608013|NCT04388501|Drug|Milvexian|Participants will receive milvexian capsules orally qd for 5 days as per the assigned treatment sequence.
45608014|NCT04388501|Drug|Atorvastatin|Participants will receive atorvastatin tablets orally qd for 5 days as per the assigned treatment sequence.
46067137|NCT00770185|Other|laboratory biomarker analysis|
46067138|NCT00774241|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
45608015|NCT03485807|Behavioral|Mindfulness Training (MT)|2 week SmartPhone-based mindfulness training
45608016|NCT03485807|Behavioral|Active Coping Training (CT)|2 week SmartPhone-based structurally equivalent coping training
45757702|NCT05325086|Other|Neutral information arm|A neutral booklet will be delivered to patients at the start of the stay. This booklet contains neutral information about the pulmonary rehabilitation
45757703|NCT05320250|Other|Single saliva collection|1 ml of saliva will be collected with Salivette swabs.
45757704|NCT05320250|Other|Saliva collection, longitudinal|1 ml of saliva will be collected with Salivette swabs. Subjects diagnosed with PD will undergo assessments and saliva sampling before starting rehabilitation treatment (T0), at the end of treatment (T1) and 3 months after the end of treatment (T2).
45757705|NCT04260867|Other|Essential Oil|Those randomized to the treatment group will have containers filled with the essential oil of their choice.
46067139|NCT00774241|Drug|docetaxel|75mg/m2 every 3 weeks for 18 weeks
46067140|NCT00774319|Radiation|conventional radiotherapy with 'high' dose cisplatin|"radiotherapy: 5 fractions/week, total treatment time 7 weeks. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions.~100 mg/m2 cisplatin iv on day 1, 22 and 43"
46067141|NCT00774319|Radiation|accelerated radiotherapy with 'low' dose cisplatin|Accelerated radiotherapy 6 fractions/week, total treatment time 6 weeks. During one of the weekdays two fractions will be delivered with an interval of at least 6h. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions cisplatin 40 mg/m2 iv on day 1,8,18,22,29,35
46067142|NCT00881751|Biological|bevacizumab|Given IV
46067143|NCT00881751|Drug|erlotinib hydrochloride|Given orally
46067144|NCT00881751|Drug|sorafenib tosylate|Given orally
46067145|NCT02634255|Drug|Rocuronium elective surgery|Rocuronium onset time in patients undergoing inguinal herniorrhaphy
46067146|NCT02634255|Drug|Rocuronium emergency surgery|Rocuronium onset time in patients undergoing appendectomy
46067147|NCT02634255|Drug|Propofol|
46067148|NCT02634255|Drug|Fentanyl|
46067149|NCT02634255|Other|Ringer Lactate|
46067150|NCT02634255|Device|Acceleromyography device|
46067151|NCT04161651|Device|eversense|eversense CGM
46067152|NCT02634021|Drug|dexmedetomidine group|intravenous loading of dexmedetomidine for 1 mcg/kg
46067153|NCT02634021|Drug|midazolam group|intravenous loading of midazolam for 0.1 mg/kg
46067154|NCT02634099|Device|blood measurement|Hemoglobin measurement
46067155|NCT02634099|Device|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
46067156|NCT02634099|Device|hemoCue|non invasive method of hemoglobin measurement
46067157|NCT04161729|Drug|Magnesium Sulfate|Intravenous magnesium sulfate 20 mg/kg in 100ml isotonic saline 0.9% over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.
46067158|NCT04161729|Drug|Isotonic saline 0.9%|Isotonic saline 0.9% 100ml over a 15-min period before induction of anesthesia and thereafter continuous i.v. infusion until surgery completion in dosage identical to magnesium sulfate group.
46067159|NCT04161573|Behavioral|Watching ironic stories|All the participants would be asked to watch a series of self-made stories which are figurative or literal. They have to figure out what is the real meaning of the character's statement. The whole procedure will be done with a computer.
46067160|NCT04161339|Drug|Hydroxychloroquine|400mg/daily of hydroxychloroquine for 8 weeks
46067161|NCT04161339|Drug|Placebo oral tablet|Amido pills/daily for 8 weeks
46067162|NCT00934856|Drug|Docetaxel|Docetaxel will be administered on Day 1 of each 3-week cycle at a dose specified in the respective arms (as per summary of product characteristics [SmPC]).
46067163|NCT00934856|Drug|Pertuzumab|Pertuzumab at a loading dose of 840 mg IV infusion on Day 1 of Cycle 1 followed by maintenance dose of 420 mg IV infusion on Day 1 of each 3-week cycle.
46067164|NCT00934856|Drug|Trastuzumab emtansine|T-DM1 will be administered on Day 1 or Day 2 of each 3-week cycle at a dose specified in the respective arms.
46067165|NCT04265612|Procedure|"Pico® negative pressure dressing"|"Pico® negative pressure dressing that will be placed in the operating room in both sternal wound and saphenectomy.The dressing will remain on for 7 days without waking up, unless it is saturated, in which case only the dressing will be changed"
46067166|NCT04265612|Procedure|"Aquacel Surgical® hydrogel dressing"|"Aquacel Surgical® hydrogel dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed."
46067167|NCT00934700|Other|Xenon gas|30% Xenon gas inhaled for 24 hours
46067168|NCT05369624|Other|Pulmonary rehabilitation home-based program intervention group (PRHP)(IG)|"The strength training program included upper and lower limb exercises, initially with no weights but progressively adding weights once a week depending on symptoms, in 2 sets with 6-8 repetitions, for at least 5 days a week. The exercises recommended were the 'hanger' (which exercises the latissimus dorsi muscle), 'butterfly' (pectoralis major muscle), 'neck press' (triceps brachii and deltoids), leg flexion (biceps femoris and gastrocnemius) and leg extension (quadriceps femoris).~As resistance training, patients could choose between walking or cycling 3 to 5 days per week, for at least 20 minutes, increasing the duration of the exercise weekly, depending on their symptoms"
45608017|NCT04339595|Biological|Tildrakizumab|Participants who have participated and completed the long-term extension phase of the reSURFACE 2 study (NCT01729754) and 12 weeks after the last Tildrakizumab dose will be included in the present study. Participants will not receive any study medication during the present study. Participants will remain in the study for 96 weeks or until they initiate any systemic therapy for psoriasis (including phototherapy), whichever occurs first.
46067169|NCT00930176|Biological|Human Coagulation FACTOR X|Standard dose 25IU/kg to be administered at the Baseline Visit (1st PK assessment) and at the repeat PK assessment. Also administered to treat a bleed or to prevent a bleed.
46067170|NCT04263116|Procedure|Balloon Assisted Maturation|Angioplasty was performed under direct vision with or without the use of a guidewire using a 1 mm larger balloon than the size of the vein. BAM is performed over the whole length of the vein sparing the spatulated end of the vein
46067171|NCT05171270|Other|Questionnaire|PsAID questionnaire
46067172|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 10 mcg/kg IV
46067173|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 100 mcg/kg IV
46067174|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 200 mcg/kg IV
46067175|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 25 mcg/kg IV
46067176|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 50 mcg/kg IV
46067177|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of Placebo IV
46067178|NCT00778141|Drug|metformin HC1 750 mg extended-release tablets|
46067179|NCT00778219|Device|devices for tracheal intubation|tracheal intubation by laryngoscope or lightwand
46067180|NCT00774475|Drug|comparison of different dosage of clopidogrel|clopidogrel 75 mg/day versus clopidogrel 150 mg/day
46067181|NCT00774475|Drug|doubled therapy|clopidogrel 150 mg/day
46067182|NCT00669331|Drug|Inhaled mannitol|400mg dose of Mannitol BD (twice a day) for 52 weeks
46067183|NCT00669331|Drug|Matched control|50mg dose of Mannitol BD (twice a day) for 52 weeks
45608018|NCT03487289|Procedure|natural orifice|laparoscopic right colon surgery and patients who are removed from the natural orifice and conventional will gather
45608019|NCT01823237|Device|Transcranial Magnetic Stimulation|
45608020|NCT02249182|Drug|LDV/SOF|LDV/SOF FDC administered orally once daily
45757706|NCT04260867|Other|No Essential Oil|Those randomized to the control group will then be given empty single-use handheld aromatherapy containers containing no essential oil.
46067184|NCT00932126|Drug|PF-03758309|Oral PF-03758309 will be administered in capsules (once or twice daily) until toxicity, progressive disease, or patient refusal to continue on therapy. The starting dose is 1 mg once daily.
46067185|NCT00778297|Biological|Vaccination with FluvalAB FL-K-004 trivalent flu vaccine|Treatment: 6 μg HA/strain/dos of FluvalAB FL-K-004 trivalent influenza vaccine will be administered once (at Day 0).
45444861|NCT03794895|Device|Doppler|Doing doppler for women having IUCD associated menorrhagia
45444862|NCT03794505|Drug|Methylprednisolone Acetate|depo-medrol 40 mg
45608021|NCT02249182|Drug|RBV|Ribavirin (RBV) oral solution or capsules will be administered orally in a divided daily dose based on weight
45608022|NCT01428635|Drug|Eltrombopag Olamine|Given PO
45608023|NCT04006769|Drug|Entacapone|Entacapone tablet
45608024|NCT04006769|Drug|Imatinib Mesylate|Imatinib Mesylate tablet
45444863|NCT03794505|Drug|Lidocaine 2% Injectable Solution|2ml of 2% lidocaine
45608025|NCT03487211|Drug|Duloxetine|Duloxetine 30mg PO once daily for 1 week followed by an increase to 60mg PO once daily
45608026|NCT03487211|Drug|Escitalopram|Escitalopram 10mg PO once daily for 1 week followed by an increase to 20mg PO once daily
45608027|NCT03485339|Diagnostic Test|genome testing|blood sampling via venipuncture
45608028|NCT05150405|Drug|QLF31907|In this study, seven dose groups were proposed. The frequency of administration was once every two weeks, and four weeks was one therapeutic cycle. The subjects will receive the six cycle of QLF31907 treatment at most.
45608029|NCT03487133|Drug|bortezomib/dexamethasone|"Induction therapy ->1cycle=28 days 1,2,3week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 4week : none maintenance therapy ->1cycle=28 days~1week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 2,3,4week : none"
45608030|NCT03641339|Other|One vector feeding|Participants will undergo one feeding by one of three colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies)
45608031|NCT03641339|Other|Four vector feeding|Participants will undergo four feedings by one of three colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies), each about 2 weeks apart, with the same vector type.
45608032|NCT02248480|Drug|Duloxetine|Administered orally
45608033|NCT02248480|Drug|Placebo|Administered orally
45444864|NCT03794505|Drug|Ropivacaine HCl Inj 7.5 MG/ML|25 mg
45452237|NCT02236468|Behavioral|WASH/malaria behavior change|WASH/malaria behavior change communication
45452238|NCT02236468|Dietary Supplement|LNS distribution|Distribution of Nutributter (Fanga Degue) for children
45608034|NCT03564587|Behavioral|AWAKE|Behavioral intervention called Achieving Wellness After Kancer in Early Life (AWAKE) is focused on increasing hope in order to improve quality of life and health-promoting behaviors in survivors of young adult cancer. The AWAKE mobile app contains eight modules for participants to complete over 8 weeks with the ability to review prior modules. Participants receive a prompt on their mobile device weekly to complete each module and/or they will receive a text reminder. The app includes health education messaging, weekly homework assignments, the ability to track progress towards goals with self-monitoring and graphical depictions of progress, videos of inspirational materials, and a portal for interacting with their coach.
45608035|NCT01653158|Drug|CP-751,871|"CP-751,871 was given intravenously [IV] every 3 weeks in escalating doses ranging from 0.1 mg/kg up to 20 mg/kg.~Standard doses of Docetaxel were given every 3 weeks with CP-751,871. Study therapy was continued until disease progression, lack of tolerability for up to 17 cycles (approximately 1 year)."
45608036|NCT01653158|Drug|Docetaxel|Docetaxel up to 75 mg/m^2 was administered intravenously [IV] on Day 1 of each 3-week dosing cycle.
45608037|NCT00701207|Drug|nicotine patch|daily transdermal patch 7 mg, 14mg, 21 mg. 3 months
46067186|NCT00778297|Biological|Vaccination with FluvalAB trivalent influenza vaccine|Treatment: 15 μg HA/strain/dos of FluvalAB trivalent influenza vaccine will be administered once (at Day 0).
46067187|NCT05156216|Other|Patient education|Knowledge and beliefs about the condition and its management influences patient behavioural intentions, including treatment choices. Thus, patient education may play an important role in facilitating desirable behaviours with the aim of education being to develop accurate beliefs about treatment options and empower people to choose wisely for their current needs and circumstances.
45608038|NCT02247466|Drug|Rocuronium and Sugammadex|
46067188|NCT00779233|Drug|Zidovudine tablets 300 mg|
45608039|NCT03417479|Other|Gabapentin|
45608040|NCT03317795|Drug|Levonorgestrel IUS|LNG-IUS was FDA-approved for the treatment of heavy menstrual bleeding in 2009 and previously for contraception in 2000. The LNG-IUS is a T-shaped device with a polyethylene body containing a hormone reservoir, holding a total of 52 mg of levonorgestrel. LNG-IUS initially releases 20 micrograms of the progestin per day, which decreases to less than half that amount after 5 years of use. The levonorgestrel causes stromal pseudodecidualization, decreases endometrial thickness, and lowers uterine vascular density.
46067189|NCT04265300|Dietary Supplement|Creative Roots|The Creative Roots beverage is a coconut water-based drink with three flavors Mixed Berry, Watermelon Lemonade, and Peach Mango. The ingredients are as follows and are the same for all three flavors: water, coconut water concentrate, citric acid, stevia leaf extract, natural flavor, rosemary extract (to preserve flavor). Contains: coconut
46067190|NCT00607178|Biological|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
46067191|NCT00607178|Biological|placebo for influenza vaccine|Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
46067192|NCT00778453|Other|Hospital-based mCIT|restraint of the unaffected arm and practice of the affected arm
46067193|NCT00778453|Other|Hospital-based BIT|bilateral symmetric, repetitive arm training
45452239|NCT02236468|Other|Enhanced-Homestead Food Production Program (new)|Participation in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014
45757707|NCT04245501|Other|Cognitive Bias Modification for Interpretations (CBM-I)|Computerized intervention in which youth see word-sentence pairs personalized to their anxiety symptoms, and indicate whether these are related. Youth receive feedback aimed to reduce interpretation bias.
45757708|NCT04245501|Other|Interpretation Control Condition (ICC)|"Computerized control condition in which youth see word-sentence pairs personalized to their anxiety symptoms. Youth indicate whether these are related, but are not provided with feedback that aims to train a reduction in interpretation bias."
45757709|NCT05301686|Procedure|Patients with Cyclop lesion|Arthroscopy with resection of Cyclop formation
45757710|NCT02652429|Drug|Inhaled Nitric Oxide|
45757711|NCT04952480|Radiation|Dose-escalated adaptive radiotherapy|Adaptive planning of Radiation Therapy with two re-plans of the treatment field through course of therapy with the shrinking treatment fields according to tumor response to escalate dose, as allowed by dose to organs-at-risk.
46067194|NCT00778453|Other|Hospital-based TR|hospital-based traditional rehabilitation : OT or PT or therapist-based training
46067195|NCT00778453|Other|Home-based mCIT|restraint of the unaffected arm and practices of the affected arm
46067196|NCT00778453|Other|Home-based BAT|bilateral symmetric, repetitive arm training
46067197|NCT00778453|Other|Home-based TR|home-based traditional rehabilitation:OT or PT or therapist-based training
46067198|NCT02556463|Drug|MEDI9197|Subjects will receive MEDI9197 (every 4 weeks) as monotherapy (or MEDI9197 every 8 weeks + durvalumab every 4 weeks)(PA6)
46067199|NCT02556463|Biological|durvalumab|Subjects will receive durvalumab every 4 weeks
46067200|NCT00779389|Drug|Erlotinib|Erlotinib 150mg will be taken once a day for 14-21days.
46067201|NCT00779389|Drug|Dasatinib + Placebo|Dasatinib (100 mg) once a day for 14-21 days.
46067202|NCT00779389|Drug|Erlotinib plus Dasatinib|Erlotinib (150 mg PO qD) plus Dasatinib (100 mg PO qD) 14-21 days
46067203|NCT00779389|Drug|Placebo|Placebo for 14-21 days.
46067204|NCT00779389|Drug|Erlotinib|Erlotinib 150 mg for 14-21 days.
46067205|NCT00778609|Drug|EV/DNG (Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one capsule SH T00658ID for 28 days per cycle for 6 treatment cycles no pill-free interval
46067206|NCT00778609|Drug|Encapsulated Microgynon + Placebo|Day 1 to 21; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Day 22 to 28 placebo
46067207|NCT05357534|Other|Physical activity|Physical activity: 10 km run on a treadmill
46067208|NCT04265144|Biological|Blood samples|62 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
46067209|NCT04265144|Other|Biopsy|Skin biopsies
46067210|NCT04265144|Other|Bronchoalveolar samples|50 ml of bronchoalveolar samples if pulmonary flare requires this type of exploration
45608041|NCT03317795|Drug|Tranexamic Acid|Tranexamic Acid was FDA-approved for the treatment of heavy menstrual bleeding in 2009. Tranexamic Acid is a plasminogen-activator inhibitor that blocks fibrinolysis and reduces plasmin activity. A special formulation was designed for the treatment of heavy menstrual bleeding that reduces gastrointestinal side effects, brand name Lysteda which will be prescribed as 1300 mg to be taken three times per day for up to 5 days of the menstrual period.
45608042|NCT02202616|Drug|Glycopyrronium /Indacaterol maleate|Glycopyrronium 50mcg/Indacaterol maleate 110mcg once daily by a breezhaler device
45608043|NCT04863677|Behavioral|High Intensity Interval Training(HIIT）|Last 12 weeks (3 sessions per week)
45608044|NCT04863677|Behavioral|Moderate Intensity Continuous Training(MICT）|Moderate Intensity Continuous Training(MICT）
45608045|NCT03315221|Other|Test product|HMF with added lipids - Intervention group
45608046|NCT03315221|Other|Control product|Commercially available HMF (without lipids) - control group
45608047|NCT02455388|Dietary Supplement|High added sugar diet|Controlled feeding study. Participants will be provided with daily coolers containing foods with high (25%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
45757712|NCT04952480|Drug|Chemotherapy|Concurrent standard of care platinum doublet based therapy
46067211|NCT00774553|Drug|AZD1656|Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
46067212|NCT00774553|Drug|Placebo|Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
46067213|NCT00774631|Procedure|Mild induced hypothermia (32-34°C)|"Mild Induced hypothermia:~Investigators are advised to use the cooling techniques as used in patients with cardiac arrest. Thus, the choice of cooling method will be left to investigators. Hypothermia will be induced by cold saline infusion as described in appendix 5 [6, 48]. Core temperature will be monitored by oesophageal probe and maintained between 32°C and 34°C during 48 hours and followed by strictly passive rewarming. During this phase of treatment, patients will receive deep sedation associated with neuromuscular blockers. Centers participating to the trial will have expertise in cooling methods."
46067214|NCT00774631|Procedure|local recommendations and guidelines|"Investigational procedure:~This study evaluates the impact of mild induced hypothermia (32-34°C) during 48 hours followed by passive rewarming according to recommendations described in appendix. All treatment will be according to local recommendations and guidelines of medical societies and literature. Physicians are advised to use these recommendations; however, the best treatment option for the individual patient should be used.~Controls will receive standard care and will be also be deeply sedated for 48 hours."
46067215|NCT05153174|Drug|Sulforaphane|This is an over-the counter nutritional supplement. Participants will be given the extra strength tablets.
46067216|NCT00778765|Drug|400 mg Gabapentin Capsules|
46067217|NCT00774865|Procedure|MIBI and CTA|Rest and Stress MIBI and CT Angiography
46067218|NCT00774943|Drug|AMG 557|A total of 4 cohorts will be administered multiple doses of drug or placebo subcutaneously. Dose escalation will take place by cohort.
46067219|NCT02556151|Procedure|Repetitive lumbosacral magnetic stimulation (rTLSMS)|Patients randomized to Six sessions of weekly therapy with either 1 HZ or 5 Hz or 15 Hz magnetic stimulations of the lumbar and sacral regions.
46067220|NCT00779935|Biological|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
46067221|NCT03873181|Device|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in laparoscopic abdominal, gynecological, or urological surgeries.
46067222|NCT00780013|Drug|metformin hydrochloride liquid 500 mg per 5 mL|
46067223|NCT00778843|Dietary Supplement|Viusid|Viusid, three oral sachets daily during 24 weeks
46067224|NCT00778843|Other|Placebo|Placebo three oral sachets daily during 24 weeks
46067225|NCT00780091|Other|classical monitoring strategy|intensive on-site monitoring, consistently with the pharmaceutical industry practices
46067226|NCT00780091|Other|optimized monitoring strategy|optimized on-site monitoring, depending on patient's risk
46067227|NCT00667225|Drug|cantharidin's vehicle|Cantharidin's vehicle is composed of: Hydroxypropylcellulose, Acetone, and Collodion Flexible. The vehicle will be topically applied to molluscum lesions at each visit. Only two lesions will be treated at the first visit, and up to 20 lesions can be treated at subsequent visits.
46067228|NCT00667225|Drug|Cantharidin 0.7%|Subjects in this arm will receive cantharidin at all visits. At the first visit, up to 2 lesions can have application with cantharidin. All other visits will have up to 20 lesions with application of the cantharidin. During every visit, lesions will be counted and subjects will be assessed for any adverse events.
46067229|NCT00784381|Device|computer-assisted counselling about target drugs|implementation in experimental units of a software coupled to electronic prescribing system . This software is operating in patients with creatinine clearance below 60 ml/mn. When a target drug is prescribed to such a patient, the software checks if the drug is contraindicated due to impaired renal function, and if not checks if the dose is appropriate relatively to creatinine clearance value
46067230|NCT02556541|Procedure|IV puncture guided by ultrasound|
46067231|NCT00784537|Drug|ABVD|"ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm A (Observation)"
46067232|NCT00784537|Drug|ABVD and Radiotherapy|"ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm B, Radiotherapy, in patients in CR, on the area of initial bulky disease (see above for the definition of nodal and/or mediastinal bulk)."
46067233|NCT00780169|Drug|sorafenib + FOLFIRI|"escalating doses of sorafenib and irinotecan~sorafenib starting dose 400 mg/day~irinotecan starting dose 80 mg/m2 on day 1"
45608048|NCT02455388|Dietary Supplement|Low added sugar diet|Controlled feeding study. Participants will be provided with daily coolers containing foods with low (5%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
46067234|NCT00789841|Device|Magnetic Tracking System (MTS) and radio-opaque markers|MTS: A small magnetic pill (6x15mm) is swallowed by the patient and the movement of this pill is registered by a sensor (coordinates x,y,z angles θ, φ) and depicted af graphs on a computer screen. For determination of GITT a capsule containing 10 radio-opaque markers is ingested every day for six days, on day seven an abdominal x-ray is performed.
46067235|NCT00780325|Drug|CG100649 (2 mg)|CG100649 capsules: 2 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
46067236|NCT00780325|Drug|Celecoxib|Celecoxib (Celebrex®) capsules: 200 mg; single oral administration (Part 1 and 3)
46067237|NCT00780325|Drug|Placebo capsules|Placebo capsules: 198 mg silicified microcrystalline cellulose + 2 mg talc, multiple oral administrations (Part 1 and 3)
45608049|NCT03245411|Behavioral|Intervention|All participants in this group will receive the standard of care intervention provided by the RN. This includes:Education in the clinic setting,Printed information about the chemotherapy drug and chemotherapy side effects. The RN will be blinded to the arm of study to which each patient is allocated.
45608050|NCT03876119|Drug|Intraarterial alteplase|See arm/group descriptions.
45608051|NCT03876119|Drug|Placebo|See arm/group descriptions.
45608052|NCT03487055|Biological|TK006|Subcutaneous injection in the upper arm
45608053|NCT04774913|Procedure|Chronic total occlusion(CTO) percutaneous coronary intervention (PCI)|CTO PCI completed as a two step procedure with an initial planned CTO modification and a completion procedure after 8-12 weeks
45608054|NCT04751045|Procedure|EUS liver biopsy|Endoscopic ultrasound guided liver biopsy
45757713|NCT04711005|Drug|(2R,6R)-Hydroxynorketamine hydrochloride|(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine. (2R,6R)-Hydroxynorketamine hydrochloride will be administered intravenously over a 40-minute period as a solution in a 25 mM sodium phosphate 0.9% w/v saline solution. The investigational drug product will be diluted into a 53 mL total volume of formulant.
45757714|NCT04711005|Drug|Placebo|Placebo will be made up of a 0.9% w/v saline solution (53 mL total volume) administered via slow IV infusion over a 40-minute period.
45608055|NCT03486977|Procedure|Evaluation of disease and follow-up|Correspondence medical consultation with specific device
45757715|NCT02294253|Drug|Buprenorphine/naloxone|30 day oral Buprenorphine/naloxone
45757716|NCT04926818|Drug|Fingolimod|Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).
46067238|NCT00780325|Drug|Naproxen|Naproxen (Naprosyn®) tablets: 500 mg, single oral administration (Part 3)
46067239|NCT00780325|Drug|Acetazolamide|Acetazolamide (generic, immediate release) tablets: 250 mg, single oral administration (Part 3)
46067240|NCT00780325|Drug|CG100649 (8 mg)|CG100649 capsules: 8 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
46067241|NCT02556229|Drug|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) with reinjection every 4 weeks only in case of CNV activity (PRN regimen) until 52 weeks.Therefore, each patient receives between 1 and 13 injections in the whole study.
46067242|NCT00929864|Drug|Abatacept|Syringes, Subcutaneous, 125 mg/syringe for Subcutaneous, Weekly Subcutaneous injections, 24 months (729 days)
46067243|NCT00929864|Drug|Adalimumab|Syringes, Subcutaneous, 40 mg, Biweekly Subcutaneous injections, 24 months (729 days)
46067244|NCT05022667|Device|PTeye|The surgeon will first take 5 baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent) using the disposable sterile fiber probe that is connected to the PTeye console, as per device functionality requirements.
46067245|NCT00597753|Drug|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
46067246|NCT00597753|Drug|Epoetin Alfa|Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
46067247|NCT04262804|Drug|Margetuximab|Margetuximab IV
46067248|NCT04262804|Drug|Trastuzumab|Trastuzumab IV
45608056|NCT02455076|Drug|Exenatide|Exenatide is dispensed via a 1.2 mL prefilled pen with 250 mcg/mL solution for subcutaneous (s.c.) injection and will be administered twice daily starting at 5 mcg per dose, either in the abdomen, thigh or upper arm. Exenatide injections will be given within 60 minutes prior to morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart between doses). The exenatide dose will be increased to 10 mcg twice daily after 1 month based on clinical response.
45608057|NCT02455076|Drug|Glargine|"Glargine will be given once daily, at the same time of day. If the BG is between 140-200 mg/dL, the dose will be 0.2 units/kg/day; for BG levels 201-400 mg/dL, the dose will be 0.25 units/kg/day. The patients will be discharged on glargine once daily at 50% of the hospital dose.The total daily dose (TDD) of glargine is based on the patient's fasting BG levels for the last 2 days.~FBG >180 mg/dL, no hypoglycemia; glargine increased by 4 IU.~FBG >140 mg/dL, no hypoglycemia; glargine increased by 2 IU.~FBG 100-140 mg/dL, no hypoglycemia; no change in dosage.~FBG 70 - 99 mg/dl, decrease glargine by 4 IU or 10% of TDD.~FBG or RBG < 70 mg/dl, decrease glargine by 8 IU or 20% of TDD.~FBG or RBG < 40 mg/dl, decrease dose of glargine by 30%."
46067249|NCT04262804|Drug|Chosen Chemotherapy (Capecitabine)|Capecitabine tablet
46067250|NCT04262804|Drug|Chosen Chemotherapy (Vinorelbine )|Vinorelbine IV
45608058|NCT02455076|Drug|Rapid-acting insulin analogs|"If the BG levels are >140 mg/dL, rapid acting insulin analogs will be administered following the supplemental/sliding scale protocol. If a patient is able and expected to eat all or most of his/her meals, supplemental insulin will be administered before each meal and at bedtime following the usual dose of the sliding scale protocol. If a patient is not able to eat, supplemental insulin will be administered every 6 hours following the sensitive dose of the sliding scale. If the BG is 141-180 mg/dL, then 2,3 or 4 units of insulin will be given; for BG 181 - 220 mg/dL; the units of insulin will be 3, 4 or 6; for BG 221 - 260 mg/dL, the units of insulin will be 4,5 or 8; for BG 261 - 300 mg/dL, the units of insulin will be 5, 6 or 10; for BG 301 - 350, the insulin will be 6, 8 or 12 units; for BG 351 - 400 mg/dL, the units of insulin will be 7,10 or 14; for BG> 400 mg/dL, the insulin will be 8,12 or 16 units."
45608059|NCT03485183|Device|White/Pink Noise|White and/or pink noise will be played from 2200 to 0700 using the PicTek® white noise machine.
45608060|NCT03485183|Other|Control Group|Standard of care including lights on during the day and off at night, getting the patient out of bed for meals, presence of a large wall clock in the room, updating the whiteboard with current day, consistent reorientation of patient, geriatrician consults as needed, and pain management.
46067251|NCT04262804|Drug|Chosen Chemotherapy (Gemcitabine )|Gemcitabine IV
45757717|NCT04926818|Drug|Ofatumumab|Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).
45608061|NCT04929236|Drug|Panzyga|Intravenous immunoglobulin formulation
45608062|NCT02433080|Behavioral|Shape-Up following cancer treatment|"The programme is based on Social Cognitive Theory and Control Theory. The focus of the programme lies on self-control, self-efficacy, and relapse prevention."
45757718|NCT04926818|Drug|Siponimod|Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).
46067252|NCT00665431|Drug|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
45757719|NCT04926818|Other|Fingolimod placebo|Fingolimod matching placebo capsule
46067253|NCT00665431|Drug|celebrex|200 mg celecoxib qd
46067254|NCT00665431|Other|Placebo|sugar pill bid
45757720|NCT04926818|Other|Siponimod placebo|Siponimod matching placebo tablet
45757721|NCT04926818|Other|Ofatumumab placebo|Ofatumumab matching placebo autoinjector
45757722|NCT02295735|Device|Mepilex® Border Sacrum and Mepilex® Border Heel|
45757723|NCT00684983|Drug|Capecitabine|Given PO
45757724|NCT00684983|Biological|Cixutumumab|Given IV
45757725|NCT00684983|Drug|Lapatinib Ditosylate|Given PO
45757726|NCT00684983|Other|Quality-of-Life Assessment|Ancillary studies
46067255|NCT00665431|Drug|Rescue Antacid|Antacid Tablets
46067256|NCT02633709|Drug|Itraconazole|Itraconazole will be administered as an oral 200 mg dose twice daily from Day 1 to Day 8 in Part 3.
46067257|NCT02633709|Other|Placebo|In Part 1 of the study matching oral placebo will be administered once on Day 1.
46067258|NCT02633709|Drug|Risdiplam|Single ascending oral doses of Risdiplam will be administered on Day 1 of Part 1. In Part 2 a single dose of Risdiplam will be once administered under fasted and once under fed conditions. In Part 3 a single dose of Risdiplam will be once administered alone (Period 1) and once concomitantly to itraconazole (Period 2).
46067259|NCT04265066|Diagnostic Test|microcirculation|measurement of microcirculation
46067260|NCT04264988|Procedure|Stopping of pelvic bleeding via several surgical methods|Those surgical methods were pelvic packing, electrocautery, energy devices, suturing, fastener, muscle welding, procoagulant chemicals, and combination of those
46067261|NCT00657033|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (Vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
46067262|NCT00657033|Drug|Placebo|Identical placebo tablets will be matched for each vardenafil dosage and will be indistinguishable from active treatment
46067263|NCT05146310|Device|I.SPACE®|"I.SPACE® is a viscoelastic sodium hyaluronate gel use as a surgical aid in ophthalmic anterior segment surgery by maintaining the intraocular space and protecting the corneal endothelium.~The baseline injection is performed at V1. The volume of product to use will be at the Investigator discretion, and will be completely removed after surgery."
46067264|NCT00784615|Procedure|Blood samples, transvaginal ultrasound|Total testosterone, bioavailable testosterone, Free androgen index, Total cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, insulinemia, OGTT, HOMA index, Adiponectin, C Reactive Protein
46067265|NCT02633553|Radiation|adjuvant radiotherapy|50Gy/25Fx
45608063|NCT03092219|Device|TEOSYAL RHA Redensity|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
45608064|NCT04634123|Other|Pulpotomy therapy by White Portland Cement|Carious asymptomatic primary anterior teeth will be removed of dental caries likely to produce vital pulp exposure . The access will be refined using a sterile no. 4 or 6 round bur in a slow-speed handpiece . The remaining pulp will be treated using pulpotomy therapy by White Portland Cement
45608065|NCT04634123|Other|Pulpotomy therapy by White MTA|Carious asymptomatic primary anterior teeth will be removed of dental caries likely to produce vital pulp exposure . The access will be refined usinga sterile no. 4 or 6 round bur in a slow-speed handpiece . The remaining pulp will be treated using pulpotomy therapy by White MTA
45608066|NCT04460261|Other|Functional Inspiratory Muscle Training|Both groups were trained 3 days a week under the supervision of a physiotherapist and other days of the week without a supervisor. The treatment program consisted of 4 weeks of foundation IMT followed by 4 weeks of functional IMT. Foundation IMT was applied during the first 4 weeks of training. The participants were asked to sit in a comfortable upright position. Following the foundation IMT, all participants underwent four weeks of functional IMT. Initially, all participants were taught diaphragmatic breathing and activating abdominal wall musculature. Each training session started with warm-up exercises and ended with cool-down exercises. During the loading phase, core stability, dynamic trunk activation and postural control exercises were applied together with IMT.
45608067|NCT04460105|Drug|Lanadelumab|Participants will receive 300 mg of lanadelumab IV infusion on Day 1 and Day 4.
46067266|NCT04263740|Procedure|Kinesio Taping|Taping for 3 days every week and two sessions of PT twice a week. The PI also instructed the patient to inform him if the tape gets off or become loose. KT was removed after 72 hours, and then reapplied after a few days rest to allow the skin to recover and to avoid skin irritation. The patient was instructed to refrain from getting the tape wet for 30 to 45 minutes after application to allow for better adherence. Patients were also instructed to be careful during dressing and undressing so the tape does not get caught with their clothes if the edges of the tape get slightly loose. No physical therapy treatment or taping was provided during the rest period except for the prescribed home exercise program. Patients in both groups received the same traditional physical therapy treatment two times a week.
46067267|NCT04263740|Procedure|Traditional Physical therapy|Traditional physical therapy was in the form of patient education, manual therapy and therapeutic exercises. Patient education focused on the natural history of the condition and its favorable prognosis, positive thinking, and encouragement of activity participation. Patient education was delivered through one-on-one discussion by the principal investigator.
45911330|NCT02006589|Drug|Candesartan cilexetil (Reference treatment)|Reference treatment of candesartan cilexetil 8 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (008 embossment in the plain face and A CG in the scored face).
45911331|NCT02006602|Drug|Candesartan cilexetil (GW615775, Test formulation)|Test formulation candesartan cilexetil 16 mg will be supplied as round, biconvex white tablets with PX 16 embossed in one face and scored in the other face.
45608068|NCT04460105|Other|Placebo|Participants will receive placebo matching IV infusion on Day 1 and Day 4.
45608069|NCT03486743|Behavioral|Educational video on LARC|Participants will watch a short educational video on long acting reversible contraceptive or LARC
45608070|NCT03485027|Drug|XELOX regimen|reintroduction of the XELOX regimen in the third or later line treatment after the same chemotherapy to which tumor has already proved to be resistant
45608071|NCT03485027|Drug|FOLFOX regimen|reintroduction of the FOLFOX regimen in the third or later line treatment after the same chemotherapy to which tumor has already proved to be resistant
45608072|NCT03485027|Drug|FOLFIRI regimen|reintroduction of the FOLFIRI regimen in the third or later line treatment after the same chemotherapy to which tumor has already proved to be resistant
45608073|NCT03485027|Drug|IRI regimen|reintroduction of the irinotecan single agent in the third or later line treatment after the same chemotherapy to which tumor has already proved to be resistant
45608074|NCT03486665|Other|Blood Sampling|Blood samples will be taken from all patients and healthy volunteers.
45608075|NCT03486665|Other|CSF Sampling|CSF sample will be taken from hospitalized newly diagnosed patients only.
45608076|NCT02887859|Biological|Human Acellular Vessel (HAV)|Patients will be implanted with a Human Acellular Vessel (HAV) as a femoro-popliteal bypass conduit using standard vascular surgical techniques
45608077|NCT03486587|Drug|Bacillus Cereus tablets|Bacillus Cereus tablets was taken two tablets three times a day.
45608078|NCT03484949|Diagnostic Test|pre-endoscopic screening risk assessment|pre-endoscopic screening risk assessment
45608079|NCT02432846|Biological|Intuvax (INN: ilixadencel)|Therapeutic dose (10 million cells/dose): allogeneic, pro-inflammatory dendritic cells.
45757727|NCT04189341|Drug|Erector spinae plane block (Group E)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
45608080|NCT02432846|Drug|Sunitinib|Cytostatic/cytotoxic drug: protein kinase inhibitor .
45608081|NCT03484793|Other|AESOP service system|Investigators develop an electronic reminder in CPOE system which notifies physicians when there appears to be an inappropriate prescription. At the time, a physician saves a typed prescription, our system analyzes the patient's medications, diseases and uses the knowledge base to determine whether a medication is uncommonly prescribed to all diseases in a given prescription. If the system detects the common associations of medications and diseases in a given prescription, it considers an appropriate prescription, and, if not, an actionable reminder is shown onscreen. To the right of each suggested uncommon medication is a reason why the reminder is appearing. Physicians can accept the reminder or ignore the reminder.
45608082|NCT03486509|Drug|Afatinib|afatinb 40mg po bid
45911332|NCT02006602|Drug|Candesartan cilexetil (Reference treatment)|Reference treatment of candesartan cilexetil 16 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (016 embossment in the plain face and A CH in the scored face).
45608083|NCT03484715|Behavioral|Physical Activity Intervention|A physical activity programme will be developed by the researcher for each participant. Integral to each physical activity programme will be a walking component (i.e. structured and gradual increases in daily walking time) and sit-to-stand exercises (i.e. a specified number of repeated rises from a chair). The rest of the physical activity programme will be tailored around each participant's specific functional goal and will be based on repeating particular functional activities. This programme will take place on 3 days per week in month 1, 4 days per week in month 2 and 3, and 5 days a week in month 4.
45608084|NCT01546571|Biological|POL-103A|POL-103A is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
45608085|NCT01546571|Biological|POL-103A without API|Placebo is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
45608086|NCT04460807|Drug|Exemestane|Exemestane in addition to standard therapy, in Experimental arm.
45608087|NCT04460807|Other|Placebo oral tablet|Placebo in addition to standard therapy, in Control arm.
45608088|NCT03484637|Other|Lifestyle-medicine intervention|
46067268|NCT02633319|Behavioral|Skilful Parenting|Skilful Parenting is a 2-week group-based parenting intervention delivered by Investing in Children and Our Societies to caregivers who are members of farmer groups in participating villages. It reinforces positive parenting practices, empowering parents to address the challenges that they face in bringing up their children. The intervention helps create parent peer groups to share ideas, support, information, and resources in the community. The intervention involves weekly sessions with farmer groups, awareness raising amongst local authorities and communities, and the establishment of parent peer groups. Topics consist of the following issues related to parenting: roles and responsibilities; family relations; communication; values; positive discipline; child protection; and family budgeting.
46067269|NCT02633319|Other|Agrics|Agrics provides smallholder farmers, organized in farmer groups, with access to farm inputs on a credit basis, and agricultural extension and advisory services to improve farming techniques and improve market connections. These services include an intensive intervention during planting season and then ongoing support after the initial 3-month intervention.
46067270|NCT04262570|Device|Multispectral Optoacoustic Tomography (MSOT) and Magnetic Resonance Imaging (MRI)|Non-invasive transcutaneous imaging of molecular muscle components
46067271|NCT00784771|Behavioral|Hypnotherapeutic Olfactory Conditioning (HOC)|
46067272|NCT04161261|Procedure|Electrical Stimulation|To measure the facial nerve stimulation threshold for one mid-array and one apical electrode of the implant using the pulse-train stimuli
46067273|NCT00607334|Behavioral|Word-learning|Exposure to five nonwords for three sessions of controlled interaction with the experimenter
46067274|NCT00607334|Behavioral|Word-learning|Exposure to five nonwords for three sessions of controlled interaction with the experimenter
45608089|NCT02432144|Drug|UX003|solution for intravenous (IV) infusion
45608090|NCT05388461|Other|electroconvulsive therapy|electroconvulsive therapy
46067275|NCT00789919|Procedure|Delivery of infant|Vaginal delivery or cesarean section, whichever is indicated
45608091|NCT05388383|Device|Ti-robot|Tianji ROBOT--Orthopedic surgery robot led by Beijing Jishuitan Hospital
45608092|NCT02246998|Drug|STB|150/150/200/300 mg fixed dose combination (FDC) tablet administered orally once daily with food
45608093|NCT02246998|Drug|TVD|200/300 mg FDC tablet administered orally once daily with food
45608094|NCT02246998|Drug|ATR|600/200/300 mg FDC tablet administered orally once daily on an empty stomach at bedtime
45608095|NCT02246998|Drug|RTV|100 mg tablet administered orally once daily with food
45608096|NCT02246998|Drug|ATV|300 mg capsule administered orally once daily with food
45608097|NCT02246998|Drug|ABC/3TC|600/300 mg FDC tablet administered orally once daily with food
45608098|NCT02246998|Drug|Iohexol|1500 mg solution administered intravenously at baseline, and at Weeks 4, 8, 16, and 24
45608099|NCT04928222|Combination Product|Doxorubicin-containing MNA|A 15 x 15 millimeter array containing 400 dissolvable microneedles delivering active agent
45757728|NCT04189341|Drug|Modified-thoracolumbar interfascial plane block|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
45757729|NCT03339596|Drug|Erythropoietin|40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 4 times as intravenous infusions over 15 minutes.
45757730|NCT03339596|Drug|Saline|1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
45911333|NCT02006615|Device|Functional near infrared spectroscopy|Using high-sensitivity infrared to detect the active brain areas
45608100|NCT04928222|Drug|Placebo-containing MNA|A 15 15 x 15 millimeter array containing 400 dissolvable microneedles containing placebo
45608101|NCT02486588|Other|Messaging|See detailed study description for overview of the different messaging interventions in this study
45608102|NCT02486588|Other|Financial incentives|See detailed study description for overview of the different financial incentive-based interventions in this study
45608103|NCT00805961|Radiation|Radiation therapy|Radiation therapy, 2.0 Gy daily, 5 days per week by single daily dose, to a total of 60 Gy over 6 weeks
45608104|NCT00805961|Drug|Temozolomide|Temozolomide 75mg/m2 by mouth daily, beginning day 1 of radiation therapy and continuing through the last day of radiation therapy
45608105|NCT00805961|Drug|Bevacizumab|Bevacizumab 10mg/kg IV, every 2 weeks, beginning day 1 of radiation therapy
45608106|NCT00805961|Drug|Bevacizumab|Bevacizumab 10mg/kg IV, every 2 weeks, beginning Week 11
45608107|NCT00805961|Drug|Everolimus|Everolimus 10mg by mouth daily, beginning Week 11
45608108|NCT02202538|Device|Indego|Indego
45911334|NCT02006615|Device|rTMS|To modulate brain cortex
45911335|NCT02006745|Drug|Ribavirin|24 weeks in those achieving RVR (undetectable HCV RNA at 4 weeks) or 48 weeks in those not achieving RVR
46067276|NCT04161105|Procedure|Dry needling|Dry needling is an invasive procedure involving inserting acupuncture needles directly into trigger points within muscles. The needle is partially withdrawn and re-inserted repeatedly to maximally stimulate the muscle and it's fibers.
46067277|NCT00934622|Device|AcrySof® ReSTOR® Aspheric IOL|AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL) implanted into the study eye following the cataract extraction surgery
45608109|NCT03484481|Dietary Supplement|Oral Nutritional Support; Nutrena|Patients in group 1 and 3 take ONS 200 ml/day twice a day at home. Patients in group 2 and 3 received IDPN administrations. ]. Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.
46067278|NCT00657111|Drug|CS-8958 formulated as dry powder|CS-8958, formulated as a dry-powder and will be administered from capsules containing 5 mg CS-8958 and lactose to 25 mg (placebo) inserted into a FlowCaps inhaler device.
45608110|NCT03484481|Dietary Supplement|Intradialytic Parenteral Nutrition; Kabiven central|Patients in group 2 and 3 received IDPN administrations Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.
45608111|NCT03484403|Other|Lumbar back brace|A brace that supports the lumbar region of the spine.
45608112|NCT03484403|Behavioral|Back school|Back school consists of patient education physical therapy exercise instruction.
45608113|NCT02454608|Drug|Verapamil HCl|Verapamil represents a calcium channel blocker which binds to the alpha subunit of L-type voltage dependent calcium (Cav1) channels thereby blocking the influx of calcium ions into the host cell. While Verapamil is classically used to promote the relaxation of cardiac and smooth muscle cells, recent evidence has suggested that it may also function as an immunomodulator in astrocytes, hepatocytes, and T-cells. Further research has demonstrated that Verapamil is capable of specifically reducing Th2 associated inflammation in asthma. These findings raise the provocative question as to whether Verapamil could also be effective in reducing inflammation in chronic rhinosinusitis with nasal polyps.
45757731|NCT05534438|Radiation|Stereotactic body radiotherapy|SBRT will be initiated as soon as possible, at not beyond 8 weeks of baseline measurements. Recommended dosing is per department standards for oligometastatic disease (ie, 10 Gy x 3 or 7-8 Gy x 5 fractions daily, excluding weekends and departmental holidays)
46067279|NCT00657111|Other|Placebo|placebo capsules containing 25 mg lactose
46067280|NCT04160871|Behavioral|Family Connections|Intervention includes 12 sessions that follow a group format of 2 hours with a weekly frequency. FC program (Hoffman and Fruzzetti, 2005) is divided into six modules: 1: Updated information and research on BPD; 2: Psychoeducation on the development of BPD, available treatments and comorbidity; 3: Individual skills: self-control of emotions, mindfulness, reality acceptance skills, validation skills, etc. and skills of relationship to promote emotional well-being problem management (family skills); 4: Family skills to improve the quality of relationships in family interactions; 5: Communication skills and effective self-expression; and 6: Problem management. All modules include Practice exercises and homework. In addition, throughout the program, in order to increase social support, the FC program provides a forum where participants can stay in touch, share common problems and solutions.
46067281|NCT04160871|Behavioral|Treatment As Usual|"The intervention lasts for 3 months and includes 12 sessions that follow a group format of 2 hours and with a weekly frequency. It includes the following components: Psychoeducation about personality disorders and, specifically, BPD and how these disorders evolve. Problems associated with BPD (eg, alcohol and / or drug use, eating disorders, etc.). The importance of modeling in family members: change of attitude towards difficult situations to reduce the escalation of tension and re-establish a healthy relationship between the patient and family. The handling of problems. Crisis management: Development of safe plans for when the patient is in emotional escalation."
46067282|NCT02633475|Genetic|IL-10 polymorphism|The IL-10 genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
46067283|NCT04032405|Procedure|CAF+CTG+i-prf|combined connective tissue graft (CTG) and injectable platelet rich fibrin (i-prf) with coronally advanced flap (CAF)
46067284|NCT04160637|Diagnostic Test|Immediate postoperative PTH serum sampling and cut-off value identification|The patients will undergo immediate post-thyroidectomy PTH sampling in order to establish a cut-off value for identifying patients at risk for postoperative hypocalcemia within the first 5 postoperative days.
46067285|NCT04160949|Other|No Intervention|There is no intervention for this study.
45608114|NCT02454608|Other|Placebo|Capsule with the same characteristics (size, color, smell) as Verapamil HCl.
45608115|NCT05152433|Device|E-BRAiN therapy|The therapy system E-BRAiN is a purpose-built therapy system using a socially interactive humanoid robot and provides individualised therapy for arm rehabilitation based on the evidence-based therapies arm basis training, arm ability training, or mirror therapy for arm rehabilitation (paresis) or neurovisual training (neglect).
45608116|NCT05152433|Behavioral|Conventional therapy|Conventional therapy specifies the neurorehabilitation therapy as applied as regular treatment.
45608117|NCT05152355|Drug|Budesonide 200 microgram/Puff, HFA MDI|Participants will inhaled 2 puffs of budesonide 200 mcg HFA MDI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.
45757732|NCT02337218|Device|SENSUS Pain Management System|An electrical stimulation device worn on a band around the leg. This device was determined to be non-significant risk by the FDA.
45757733|NCT05533502|Dietary Supplement|Combined Plant-Based Protein and Marine-Based Multi-Mineral Supplement|Ingestion of the Test Product at 07.00am - Fava-bean protein concentrate dosed at 0.33 g/kg body mass and Aquamin F dosed at 800mg in 500 ml water volume. Supplied by Marigot Limited, Strand Farm Currabinny, Co. Cork, Ireland
45608118|NCT05152355|Drug|Budesonide 100 microgram/Actuation Powder for Inhalation|Participants will inhaled 4 puffs of budesonide 100 mcg DPI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.
46067286|NCT04160403|Other|physical therapy intervention|NDT bases on neuroplasticity by which the brain change and reorganize itself and its processes according to practice and experience by a) facilitation of normal postural alignment and movement patterns; b) inhibition of the involvement during developmental and functional activities; and c) using sensory feedback (manual contact, visual integration, somatosensory reinforcement) for recovering function
45757734|NCT05533502|Dietary Supplement|Placebo Control|Ingestion of the Control Product at 07.00am - 500ml water volume.
46067287|NCT02633007|Drug|CVT-301 (levodopa inhalation powder)|Capsules containing l-dopa, designed to deliver ldopa to the lung using the CVT-301 inhaler. CVT-301 will be administered 3 times, 4 hours apart, and 1 hour following the administration of carbidopa.
46067288|NCT02633007|Drug|Carbidopa|Administered orally according to the carbidopa dosing schedule.
46067289|NCT02633007|Other|Placebo|Placebo of CVT-301 is administered in the same way as the investigational product, except that it does not contain l-dopa.
45608119|NCT03484247|Other|Infraclavicular brachial plexus block|Infraclavicular block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration, via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)
46067290|NCT04160793|Device|Genital Nerve Stimulation|Implantation the vaginal way a stimulation's electrode to the dorsal nerve of the clintoris in local anesthesia
45608120|NCT03484247|Other|axillary brachial plexus block|Axillary nerve block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)
45608121|NCT02246764|Drug|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
45608122|NCT02246764|Drug|AR-13324 Ophthalmic Solution 0.02% BID|1 drop BID, AM/PM, OU
46067291|NCT00881361|Drug|systemic chemotherapy|
45608123|NCT02246764|Drug|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
45608124|NCT02246764|Other|Placebo|1 drop QD, AM, OU
45608125|NCT03486431|Radiation|Stereotactic Ablative Radiotherapy (SABR)|A minimum of thirty patients will be included for each dose level. An interval of at least 24 weeks from the first patient treatment to the next patient treatment at each dose level will be respected. In the meantime, more patients will be included in the previous dose level, in an effort to establish the secondary endpoints. In case 1-5 patients present with dose-limiting toxicity (DLT) at 6 months after SABR, thirty additional patients will be included at the same dose level. The maximal tolerated dose will be defined as the dose level below which at least 10 patients present with a dose-limiting toxicity at 6 months after SABR.
45608126|NCT04188574|Drug|BB2603-1|Treatment with topical spray twice-daily (BID) BB2603-1: 0.01% terbinafine
45608127|NCT04188574|Drug|BB2603-3|Treatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine
45911336|NCT02006745|Drug|Telaprevir|12 weeks in those achieving RVR, 24 weeks in those not achieving RVR (HCV RNA >25 but <1000 iU/mL at week 4) or 48 weeks in those not achieving RVR (HCV RNA >1000 iU/mL at week 4).
45608128|NCT04188574|Drug|BB2603-10|Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine
45608129|NCT04188574|Other|Vehicle|Treatment with topical spray twice-daily (BID): 0.3% polyhexanide/ 20% ethanol/ water formulation.
45608130|NCT03484169|Other|intervention group|"The training of PNF pelvic patterns for motor learning in GI will be performed twice a week by a trained and experienced researcher for six weeks (CHRISTIANSEN et al., 2017). At each training session, there will be three repeated movements in each pelvic pattern:~Combination of isotonic (concentric, stabilizing and eccentric) of the anterior elevation pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the previous depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior elevation pattern;"
45608131|NCT04508153|Device|Leva Pelvic Digital Health System|Pelvic floor muscle training using the pelvic digital health system to treat pelvic floor disorders, specifically stress urinary incontinence.
45608132|NCT04508153|Other|Kegel exercises|"Pelvic floor muscle training (PFMT), commonly referred to as Kegel exercises, is a first line conservative treatment for pelvic floor disorders, specifically stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (SMUI)."
45608133|NCT03487757|Other|Core Stabilization Exercises|Jeffrey's core stabilization exercise training protocol will be performed to the training group. This protocol includes exercises progressing gradually from level 1 to level 3. Level 1; static contraction training on a stable surface, level 2; dynamic training on a stable surface, level 3; dynamic and resistant training on an unstable surface.
45608134|NCT03487757|Other|No Intervention|Since no training is given to the control group during the study period, it is ethically necessary to give the same training to the control group if the benefit is achieved when the study is completed.
45608135|NCT03484091|Drug|Hyruan-One|single dose intra-articular injection
45608136|NCT03484091|Drug|Hylan G-F 20|single dose intra-articular injection
45608137|NCT03484091|Drug|Normal saline|single dose intra-articular injection
45608138|NCT03486353|Drug|FF-10501-01|FF-10501-01 round film-coated tablets are immediate release and come in 3 dosage strengths: 50 mg (tan), 100 mg tablets (red) and 200 mg (yellow). Each tablet contains the active ingredient (FF-10501-01 white crystalline powder) and other excipients. All dosage strengths are packaged 32 tablets to a bottle. FF-10501-01 should be stored at room temperature (20 - 25 °C).
45608139|NCT03486353|Drug|Azacitidine|azacitidine at a dose of 75 mg/m2 either subcutaneously (SC) or intravenously (IV) x 7 days every 28 days
45911337|NCT02006771|Other|Southern Chinese meal|White rice (1 bowl), stir fried choi sum (0.5 bowl) and stir fried lean pork (0.5 bowl) cooked with maize oil
46067292|NCT00881361|Procedure|axillary lymph node dissection|
46067293|NCT00881361|Procedure|neoadjuvant therapy|
46067294|NCT00881361|Procedure|sentinel lymph node biopsy|
46067295|NCT00881361|Procedure|therapeutic conventional surgery|
46067296|NCT00881361|Procedure|ultrasound imaging|
46067297|NCT01000727|Drug|Darapladib 160 mg|Lp-PLA2 inhibitor
45608140|NCT02454530|Biological|Nivestim®|
45608141|NCT04460651|Drug|Icosapent ethyl (IPE)|"Participants in this arm will receive study medication IPE with the following dosage schedule:~8 g of IPE (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of IPE (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)"
45608142|NCT04460651|Drug|Placebo|Participants in this arm will receive placebo with the following dosage schedule: 8 g of placebo (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of placebo (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)
45608143|NCT03483857|Behavioral|Peer Navigation|Utilizing Peer Navigators for HIV-Positive MSM for increase in uptake along the continuum.
45608144|NCT04460729|Drug|Capmatinib|400 mg administered orally twice daily
45608145|NCT04927832|Other|SUDOSCAN and EMG (electromyogram)|The participants are evaluated clinically by a neurologist with evaluation by DN4 questionnaire, treatments and comorbidities (alcohol consumption, diabetes, etc.). They undergo from exploration by SUDOSCAN according to the already established methodology and an EMG
45608146|NCT03483779|Drug|Ginkgo biloba pills|Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
45608147|NCT03483779|Drug|placebo pills|Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
45608148|NCT04492241|Drug|Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution|TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Study Arm Component: Ginkgo Leaf Extract and Armillariella Mellea Powder, konjac (sweetener), purified water.
45608149|NCT04492241|Drug|Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution|TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Placebo Arm Component: Caramel color (food color), konjac (sweetener), sucrose octaacetate (food additive), sodium benzoate (food additive), purified water.
46067298|NCT01000727|Drug|Placebo|Placebo administered
45608150|NCT04927286|Behavioral|Learning to Breathe|Learning to Breathe is an evidence-based mindfulness curriculum for adolescents
45608151|NCT04927286|Behavioral|Campus Connections|Campus Connections is a mentoring program for at-risk adolescents
46067299|NCT01000727|Other|Standard Therapy|Guideline mandated therapy for individual's condition
46067300|NCT04160247|Procedure|Immediate implant placement|Implants are placed in fresh socket
46067301|NCT04160247|Procedure|Angulated screw-retained crowns placement|To insert the restorations by angulated screw systems
46067302|NCT04160247|Procedure|Cemented crowns placement|To cement the restorations onto the implant abutment
45608152|NCT05151575|Behavioral|supervised group-based walking and non-supervised individual-based walking interventions|Group exercise interventions tended to be systematic and supervised by professionals. The current intervention is proposing to conduct a randomized control trial that is not only examining the nature of walking on older adults' well-being but also involving the elements of group-based and professional supervision intervention, aiming at comparing with the individual-based intervention without professional supervision. Qualified professional fitness trainers (1 male and 1 female separately for male and female groups, respectively) will be involved in the group-based intervention programs in order to provide appropriate guidance and supervision to the participants. Whereas, the non-supervised individual-based intervention will be conducted by a research assistant (males and females) to ensure the attendance and general safety, but without providing professional advice or supervision.
46067303|NCT04160559|Other|green tea|The investigators require patients to regularly drink green tea during the trial period.
46067304|NCT04160481|Dietary Supplement|FruitFlow|300mg tomato extract
46067305|NCT04160481|Dietary Supplement|Placebo|Maltodextrin
46067306|NCT00881205|Drug|Rivastigmine transdermal patch|Transdermalapplication of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. All patches are round, beige in color.
46067307|NCT00881205|Drug|Placebo|Transdermal application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. Matching the size, shape and color of rivastigmine patches.
45608153|NCT03483701|Behavioral|Cognitive Remediation Therapy|The intervention of interest for participants in the experimental group is the addition of up to 5 hours per week of computerized cognitive exercises. Cognitive training can be done at home on a computer. For participants without access to a computer, a laptop/tablet computer with the necessary software will be provided for the duration of training. Participants will be able to complete the cognitive exercises on their own schedule, with participation verified by the software. Participants will also receive 1 hour/week of individual coaching to discuss cognitive remediation progress, e.g. to learn about different cognitive domains and develop ways to generalize their cognitive remediation gains.
45911338|NCT02006771|Other|Northern Chinese meal|Noodles (1 bowl) and shredded pork with sweet bean sauce (0.5 bowl) cooked with blend oil
46067308|NCT00879879|Drug|losartan|50 mg losartan taken daily by mouth in capsule form for 1 year
46067309|NCT04157283|Diagnostic Test|MRI brain, visual evoked potential, Cerebrospinal Fluid, Sexual dysfunction measure, Depressive symptoms assessment and Multiple Sclerosis Quality of Life-54(MSQOL-54)|"Neurophysiological Evaluation:~Visual Evoked Potential (VEP).~Imaging Evaluation:~Conventional MRI.~Cerebrospinal Fluid (CSF):~Sexual dysfunction measure: through the international index of erectile function (IIEF), female sexual function questionnaire (SFQ) and the sexual Quality of life male and female version (SQoL) (American Psychiatric Association, 1994).~Depressive symptoms assessment through The BDI (The Beck Depression Inventory) which is the most common instrument measuring the severity of depression.~Fatigue symptoms were evaluated through fatigue subscale of Multiple Sclerosis Quality of Life-54(MSQOL-54)."
46067310|NCT00661999|Biological|darbepoetin alfa|Given by injection
46067311|NCT00661999|Dietary Supplement|ferrous sulfate|Given by mouth
46067312|NCT00661999|Drug|sodium ferric gluconate complex in sucrose|Given by IV
46067313|NCT00661999|Other|placebo|Given by mouth
46067314|NCT00661167|Drug|ABI-007|ABI-007 260 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
46067315|NCT04156737|Device|TECNIS Symfony plus IOL Model ZHR00V|IOL replaces the natural lens removed during cataract surgery
45608154|NCT02431676|Drug|Metformin|Participants will receive metformin, an oral medication for type 2 diabetes.Participants randomized to the metformin intervention will receive metformin up to 2,000 mg per day.Dosing can be flexible, two or three times per day with meals as tolerated for 12 months.
45608155|NCT02431676|Behavioral|Coach Directed Behavioral Weight Loss|Behavioral-based telephonic coaching with web-based support to promote healthy lifestyle and weight loss in overweight and obese adults.The goal of this intervention is to achieve at least 5% weight loss in the first six months of the intervention and maintain these improvements through month twelve by meeting dietary and exercise goals
46067316|NCT04156737|Device|Trifocal Intraocular lens|IOL replaces the natural lens removed during cataract surgery
46067317|NCT00661245|Device|TOGA|Transoral Gastroplasty (TOGA®) System for gastric stapling.
46067318|NCT00661245|Device|Control|The control device (bougie dilator) is a FDA-cleared (Class II) device.
45608156|NCT02431676|Behavioral|Self-control weight loss|
45608157|NCT04460417|Behavioral|Enhanced Care|The session began with the therapist reviewing the participants' personal feedback sheet within the context of clear messaging that there is no safe level of smoking and of how smoking affects the participant individually and the Black community collectively. The participant was encouraged to quit smoking, else to reduce smoking if abstinence was not desired, and to use NRT within the next week to help foster behavior change and alleviate withdrawal symptoms. This portion of the counseling was presented within a culturally-targeted framework such that myths regarding NRT common among persons with low health literacy were discussed and debunked and historical mistrust of the medical community and concerns about exploitation were also addressed. Each participant in EC was offered a starter kit of NRT with a one week supply of patches or lozenges.
45608158|NCT04460417|Behavioral|TAU|"Participants met with a research assistant for 3-5 minutes and received the National Cancer Institute (NCI) pamphlet Clearing the Air and access to related online resources, which includes brief advice to quit smoking and medication information. They did not receive counseling or specialized care and were advised to refer to the resources should they be interested in quitting smoking."
46067319|NCT04156815|Radiation|1,565nm NAFL|1,565nm M22-ResurFx NAFL can deliver additional benefits to existing acne scar and skin texture. Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas.
46067320|NCT04156815|Drug|Oral isotretinoin|Oral isotretinoin has remained the most effective medication for moderate-to-severe AV.Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.
46067321|NCT04156815|Other|Pricking blood therapy|Pricking blood therapy (PBT) is a modified acupuncture strategy that is adapted to treat inflammatory related diseases. It has been shown to be effective in treatment of many chronic and acute inflammatory conditions including vasomotor rhinitis, acute herpes zoster and acute gouty arthritis,suggesting a potential efficacy for AV as well. At the end point of each session of laser treatment, an acupuncture practitioner performed a PBT in the areas within 1.5 cm radius of the five facial acupoints (Yintang, Zhukong, Sun, Yingxiang, Cuanzhu) (Figure 1). These areas usually appeared intensive erythema. A facial sheet mask was used to clean the face after PBT, and the face was cooled by air cooler for 10 minutes.
46067322|NCT04156425|Drug|Escitalopram+golimumab|Escitalopram will be administered at 10-20 mg/d during the acute phase. Golimumab will be administered at the dose of 50mg every month during the acute phase.
46067323|NCT04156425|Dietary Supplement|Escitalopram+Calcium Tablet|Escitalopram will be administered at 10-20 mg/d during the acute phase. Calcium tablet will be administered at 2000mg/d during the acute phase.
46067324|NCT04156425|Drug|Escitalopram|Escitalopram will be administered at 10-20 mg/d during the acute phase.
46067325|NCT02555059|Drug|Cipro (Ciprofloxacin, BAYQ3939)|Treatment parameters following the physician's decision based on the summary of product characteristics.
45608159|NCT05151419|Procedure|bronchoscpe|bronchoscopic biopsy from lung mass using cryobiopsy and forceps
45608160|NCT03483545|Combination Product|Follitropin delta and HP-hMG|Follitropin delta dose will be determined by AMG and weight in Kg. Highly purified human menopausal gonadotrophin will be determined by follitropin delta dose and body weight in Kg
46067326|NCT00790075|Drug|risperidone|liquid risperidone was administered on a mg/kg basis to a child needing seclusion. 0.015mg/kg was the start dose. Dose was increased to 0.02mg/kg if duration of episode was >30 minutes.
45911339|NCT02006771|Other|American meal|Hamburger with cheese (1 piece), French fries (117 g) cooked with canola blend oil and Coca-cola classic (21 fluid ounces)
46067327|NCT04156503|Other|Palm olein vs Lard|A 5-hour postprandial feeding intervention with 2-weeks washout in between. Blood samples will be collected at hour 0 (baseline) before test meal, and hour 3, 4 and 5 after consumption of test meal.
45911340|NCT02006771|Other|South Indian meal|Basmati rice (1 bowl), chicken curry dish (0.5 bowl), dry vegetable dish (i.e. green beans mixed with herbs) (0.5 bowl), yogurt made with milk powder mainly (0.5 bowl), pickle made with lemon, salt, chilli powder, Asafoetida and vegetable based oil (1 tablespoon)
45911341|NCT02006797|Other|reconciliation|medication reconciliation at discharge and communication of this intervention to patient's community pharmacist
46067328|NCT00785083|Drug|FTY720|
45608161|NCT03483467|Other|Omnigen|For those randomised onto the investigational arm, a dual layer of the Omnigen product will be applied at baseline and at every fortnightly trial visit until healing or the end of the 12 week period whichever occurs first, according to the standard study procedure.
45911342|NCT02006810|Behavioral|Induction of endothelial function variations|
46067329|NCT00785083|Drug|Placebo|
46067330|NCT02631681|Behavioral|Group based exercise|Supervised group based combined aerobic and resistance training for 12 weeks as part of our normal clinical practice.
46067331|NCT00780637|Drug|Bradykinin|Patients receive 0, 10, 20, and 40 ng/100cc forearm volume/min of bradykinin intrabrachial.
46067332|NCT00785161|Device|Penumbra System|Mechanical Thrombectomy in acute stroke
45608162|NCT03483467|Other|Dummy Packaging|For those randomised into the control arm, dummy packaging will be opened at the time of application of standard of care, to ensure the same experience is received to those on the experiential arm.
45608163|NCT05151341|Diagnostic Test|Urine collection (150ml)|Urine collection will be tacken at inclusion. The sample will be thereafter separate into three to realise different analyzes (standard cytology, Visiocyt test, FGFR3 analysis)
45608164|NCT05151341|Other|Blood sample (20 ml)|"Blood sample will be tacken at inclusion, ONLY for case patients that agreed upon this. This sample will be addition to the collection for further research."
45608165|NCT05151107|Diagnostic Test|"The radiographic images were collected through a software called PACS which combined with a viewer for image processing, that allows the calculation of the residual stomach area (RSA)."|Upper gastrointestinal radiographie
45608166|NCT03483389|Drug|Alcohol, Ethyl|Randomized within-subjects design
45608167|NCT03483389|Other|Alcohol, Ethyl - placebo|Randomized within-subjects design
45608168|NCT03486275|Device|Hygie|Prototype video game called Hygie, accessible on the Internet, on the 5 most common reasons of consultation in general practice using 9 articles from independent journals based on evidence (reviews by Prescrire and Minerva).
45608169|NCT03486275|Device|Source articles|9 articles from independent journals based on evidence (reviews by Prescrire and Minerva), about the 5 most common reasons of consultation in general practice, accessible on the Internet.
45608170|NCT03483311|Other|skin biopsy before and after NB-UVB phototherapy|skin biopsy before and after NB-UVB phototherapy to measure tissue resolvin D1
46067333|NCT00661401|Biological|gammaglobulin|They were administered a polyvalent, pasteurized liquid immune globulin subcutaneously (human 16% Beriglobin ®, Germany) with doses ranging from 57 to 132 mg/kg/week in order to maintain the same dosage they received by intravenous route monthly previous to this protocol. After a wash-out period (15 weeks) of the subcutaneous immunoglobulin administration, blood was collected every 4 weeks immediately before infusions. The infusions were administered using battery-powered ambulatory syringe drivers together with 10 or 20 ml syringe and infusions sets according to a pre-defined protocol (Gardulf et al, 2006).
46067334|NCT00790153|Drug|Insulin|Insulin infusion given during 3 hours at one occasion.
46067335|NCT00790153|Drug|AZD1656|Single dose oral suspension given at one occasion.
46067336|NCT00911391|Device|Oesophageal Doppler|Non-invasive measurement of doppler-derived cardiovascular variables (CO, aortic flow rate). Used safely over 800, 000 times
46067337|NCT00911391|Procedure|Intraoperative fluid restriction|Current best practice of avoiding fluid overload by intraoperative fluid restriction
46067338|NCT00785317|Drug|Angemin vs Activelle|1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP or 1 mg of oral E2 in continuous combination with 0.5 mg of NETA during six months.
46067339|NCT05017831|Behavioral|Family Based Treatment|Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.
46067340|NCT05017831|Behavioral|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is an adjunctive treatment focused on increasing set-shifting ability and developing meta-cognition. CRT is a behavioral treatment that presents tasks to participants in a standardized order within each session. Each task has a number of levels. Participants stay at the same task-based level until mastered. They then move up a level on that task. participants can be at different levels on different tasks within each session. After completion of tasks, participants are asked to reflect on their thought processes in solving the tasks. Standard prompts are used to guide the discussion.
45608171|NCT03486119|Other|nivolumab|Subjects will be treated with 3mg/kg in nivolumab IV every 2 weeks for a maximum of 12 months.
46067341|NCT00661791|Behavioral|Massage therapy without exercise|Infants will receive massage twice a day; 15 minutes each.
45757735|NCT05298722|Diagnostic Test|Imaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires.|"The images of CT-scans and MRI with DWI shall be processed with specific software to define the direction of diffusion tensors and indicate the direction (red, green, blue coloring for x,y,z, components of the vector) and intensity (anisotropy, brightness of voxels). Further analysis will be performed by fiber tracking which gives a clear indication of functional connectivity of adjacent tissues.~Genetic profilling of liquid biopsies: evolution of the number CTCs in blood samples of patients and subsequent phenotyping of the cells; longitudinal analysis of driver mutations and epigenetic changes in cfDNA; genotyping of germline variations~Questionnaires for patient reported outcomes and health economic analysis~EQ-5D-5L~PAN 26~HADS"
45757736|NCT02641587|Other|CHTP 1.2|Ad libitum use of the CHTP 1.2 for 5 days in confinement followed by 85 days in an ambulatory setting.
46067342|NCT00661791|Behavioral|Massage therapy with exercise|Infants will receive massage with exercise twice a day; 15 minutes each.
46067343|NCT04156269|Biological|BCMA-CS1 cCAR T cells|BCMA-CS1 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
46067344|NCT00790231|Device|urodynamic procedure|introduction of the urodynamic catheter into the bladder and assessment of the bladder function
46067345|NCT00661869|Other|Wellness Program|36 weeks of educational and supportive interventions
46067346|NCT05001217|Drug|Conventional medication|Levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.
46067347|NCT05001217|Drug|Chinese herbal medicine treatment|"Huanglian Wendan Decoction~Jin Gui Shen Qi Pill~Liu Wei Di Huang Pill plus Tian Ma Gou Teng Decoction~Bu Yang Huan Wu Decoction"
46067348|NCT02631603|Drug|Placebo|Administer Placebo as anti-inflammatory
46067349|NCT02631603|Drug|Prednisolone|Administer Prednisolone as anti-inflammatory
46067350|NCT00790309|Procedure|Weight loss surgery|Weight loss surgery
46067351|NCT00790309|Procedure|Laparoscopic abdominal surgeries|laparoscopic abdominal surgeries
46067352|NCT04156113|Other|Yo-Yo intermittent recovery test (level 1)|The Yo-Yo intermittent recovery test (level 1) will be administered once.
46067353|NCT00790387|Drug|Enoxaparin|Enoxaparin was administered at the commencement of PCI at a dose of 0.75 mg/kg
46067354|NCT00790387|Drug|Tirofiban|
46067355|NCT00790387|Drug|unfractionated heparin|
45608172|NCT05151029|Device|Elastography|new dignostic tool
46067356|NCT00661947|Other|Dr Pepper sweetened with sucrose or high fructose corn syrup|Comparison of different formulations of fructose.
46067357|NCT00662103|Behavioral|exercise intervention|"Arm I (progressive, aerobic exercise program): Patients undergo aerobic exercise training over approximately 45 minutes (not including warm-up or cool-down exercises) 3 days a week for 18 months.~Arm II (progressive, resistance exercise program): Patients undergo resistance exercise training 3 days a week for 18 months."
46067358|NCT00662103|Other|laboratory biomarker analysis|All biomarkers will be measured from urine, blood and plasma obtained from participants by the Oregon Health & Science University (OHSU) General Clinical Research Center (GCRC). Upon exit from the study we will confirm the presence/absence of metastatic disease, via verbal verification by the subject, in order to ensure that biomarkers were primarily reflective of bone turnover changes and not to metastases.
45911343|NCT02006849|Drug|Acthar|FDA approved drug being used in this study for sub-nephrotic proteinuria. Given Investigational New Drug (IND) exemption by FDA.
46067359|NCT00662103|Other|questionnaire administration|Patients complete questionnaires at baseline and periodically during the study to assess demographic (i.e., age, income) and disease-specific (i.e., stage, treatment) variables, self-report mental and physical function, presence of chronic medical conditions, symptoms, fatigue, exercise outside the study exercise intervention, dietary intake, and psychosocial function.
46067360|NCT00662103|Other|survey administration|Administered at measured at baseline, 3, 6, 12, and 18 months
46067361|NCT00662103|Procedure|assessment of therapy complications|Follow-up every 6 months (measured at baseline, 3, 6, 12, and 18 months )
45444865|NCT05625243|Other|Bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) with Precontoured circumferential matrix system (Palodent 360, Dentsply Caulk, Millford DE, USA)|A suitable size precontoured circumferential matrix band (Palodent 360, Dentsply Caulk, Millford DE, USA) will be selected and placed. Teeth separation will be acquired with a suitable size wedge (Palodent V3, Dentsply Caulk, Millford DE, USA) and a separation ring (Palodent V3 universal ring, Dentsply Caulk, Millford DE, USA). Then the bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) will be applied and light cured according to the manufacturer instructions.
45608173|NCT03482999|Device|TissuGlu Surgical Adhesive|
45608174|NCT05154149|Other|Neck Disability Pain Index|Single time collection of the data
46067362|NCT00662103|Procedure|fatigue assessment and management|The Schwartz Cancer Fatigue (SCF) scale, a 6-item scale that specifically assesses the level of subjective fatigue that the participant is currently experiencing. The SCF has been used to measure fatigue in previous exercise studies. The Piper Fatigue Scale (PFS) consists of 22 items and four subscales: behavioral/severity, affective meaning, sensory and cognitive/mood. The scale has been shown to detect reductions in fatigue in cancer patients undergoing behavioral interventions to reduce fatigue, including exercise. Responses are averaged for subscale and total scores with higher scores indicating more fatigue. The PFS has been used to measure fatigue in previous studies of illness and/or medical treatments. 15 minute survey
45911344|NCT02006875|Device|rTMS|Interventions started on the next weekday after pretest and were performed once a day for 15 consecutive weekdays. Participants in the E and C groups received rTMS (either real or sham, 1 Hz, 15 minutes), followed by a session of physical therapy for 45 minutes.
46067363|NCT00662103|Procedure|management of therapy complications|An interim safety/efficacy review will occur after the first half of enrolled participants completes their 3 month testing appointment (or after 3 months of exercise). The interim safety review will be overseen by OHSU NCI-designated Cancer Institute, while the efficacy review will be conducted by an independent monitor, Dr. George Knafl, a biostatistician in the OHSU School of Nursing, who is not a member of the study personnel.
46067364|NCT00662103|Procedure|psychosocial assessment and care|We will include a 6-item measure of self-efficacy for exercise that has been validated in adults (Nigg, 2002) and has been used by Dr. Bennett (Co-I) in current work in cancer survivors. 5 min. survey
46067365|NCT04156035|Drug|Lamotrigine|Orally; 300 mg
46067366|NCT04156035|Drug|Ketamine|Intravenously; 0.12 mg/kg during the first minute followed by a continuous infusion of approximately 0.31 mg/kg/h over approx. 40 min
46067367|NCT04156035|Drug|Placebo Pretreatment|Lamotrigine Placebo
46067368|NCT04156035|Drug|Placebo Infusion|Ketamine Placebo
45608175|NCT03482765|Dietary Supplement|Probiotic 1|The product under investigation is a unique probiotic.
45608176|NCT03482765|Dietary Supplement|Probiotic 2|The product under investigation is a unique probiotic.
45608177|NCT03482765|Other|Placebo|Microcrystalline Cellulose
45608178|NCT03482687|Behavioral|Me & You: Building Healthy Relationships|Me & You: Building Healthy Relationships is a classroom- and computer-based healthy relationships curriculum for middle school students. It consists of thirteen 25-minute lessons: 5 classroom, 5 computer-only, and 3 classroom-computer hybrid. The curriculum integrates group-based classroom activities (e.g., role-plays, group discussion, and other skill-building activities) and computer-based activities, some of which are individually tailored. The curriculum was adapted from an existing effective sex education and relationship curriculum, It's Your Game…Keep it Real (IYG), which was enhanced to more explicitly address teen dating violence (TDV).
45911345|NCT02006901|Procedure|microdecompression|a minimal invasive surgical technique
45608179|NCT03131609|Other|Container|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
45608180|NCT03131609|Other|Silver Impregnated Wipe|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
45911346|NCT02006901|Procedure|laminectomy|The traditional open surgical technique: decompression with removal of the spinous process, lamina and often the medial facets
45911347|NCT02006914|Dietary Supplement|Chromium Picolinate|Subjects will be asked to take chromium picolinate; 2 tablets per day, 1000 mcg or a placebo for a total of 8 weeks.
45911348|NCT02006940|Device|miniprobe Alveoflex|Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
45911349|NCT02006953|Procedure|Bolus feeding schedule following gastrostomy tube placement|
46067369|NCT00662337|Drug|Diphenhydramine hydrochloride|After a ten-hour fast and a one-hour fluid restriction prior to each dosing period, subjects received supervised dosing of their first 25 mg treatment with approximately eight ounces of water. Following a seven-day washout, the comparison treatment was administered according to thye same procedure.
46067370|NCT00662415|Device|mirror-box treatment|15 minutes daily for 4 weeks
46067371|NCT00662415|Behavioral|observation|observation
46067372|NCT00665353|Drug|pioglitazone|Traditionally used in the treatment of type 2 diabetes to increase insulin sensitivity. Participants will take 30 mg daily in tablet form.
46067373|NCT00665353|Drug|peginterferon|Used in the treatment of HCV. Participants will receive 180 mcg subcutaneously once a week.
46067374|NCT00665353|Drug|ribavirin|Used in the treatment of HCV. Participants will receive 1000 to 1200 mg orally per day depending on weight.
46067375|NCT00597207|Device|AutoPulse|Mechanical device that provides chest compression
46067376|NCT00597207|Other|Manual|Manual chest compression
46067377|NCT00662493|Behavioral|Motor control retraining program|Specific retraining of VMO activation in a low-load situation,and progressed to integrate more functional positions. Use of dual channel biofeedback was incorporated
45911350|NCT02006953|Procedure|Continuous chimney feeds following gastrostomy tube placement|
46067378|NCT00662493|Behavioral|Quadriceps strengthening program|4 exercises focused on quadriceps strengthening commencing at a resistance of 60% 1 repetition maximum. Each exercise was performed for 3 sets of 10 repetitions
46067379|NCT00785395|Drug|Oxytocin infusion|Up-down dosing determination
46067380|NCT00662571|Drug|acamprosate|acamprosate 333mg tabs, 2tabs 3times per day = 1998mg/day
45608181|NCT03131609|Other|Funnel|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
45608182|NCT03131609|Other|Castile-soap wipe|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
46067381|NCT00780793|Drug|progressive spacing of TNF-blocker injections|"Experimental arm~Progressive spacing of TNF-blocker injections according to the following algorithm :~if DAS28 ≤ 2.6 at trimestrial assessment: go for step N+1~if DAS28 > 2.6 and DAS28 change ≤ 0.6: continue at step N~if DAS28 > 2.6 and DAS28 change > 0.6 : return to step N-1 (relapse as defined by the European expert consensus).~Step 0 (inclusion) :~Adalimumab 40 mg / 14 days~Etanercept 50 mg / 7 days~Step 1 :~Adalimumab 40 mg / 21 days~Etanercept 50 mg / 10 days~Step 2 :~Adalimumab 40 mg / 28 days~Etanercept 50 mg / 14 days~Step 3 :~Adalimumab 40 mg / 42 days~Etanercept 50 mg / 21 days~Step 4 :~TNF-blocker stop"
46067382|NCT00780793|Drug|DMARD maintenance|DMARD maintenance
46067383|NCT00662727|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
46067384|NCT00662727|Device|Placebo|Placebo
46067385|NCT00661635|Drug|placebo|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, placebo twice daily (BID) on Days 2 to 5
45608183|NCT01654250|Drug|NWP09|Methylphenidate, variable dose, daily dosing, 1 week duration
45608184|NCT01654250|Drug|Placebo|Placebo
45608185|NCT02523833|Drug|Salbutamol|Salbutamol after spirometry, plethysmography and forced oscillation technique.
45608186|NCT03482531|Other|mathematical model|mathematical model: regression equation that calculates the mean time from insert placement to delivery for each patient, based on every patient's characteristics (parity, BMI, cervical dilation and state of membranes)
45608187|NCT04349579|Drug|Rifamycine|Local anesthesia was obtained using 2 ml articaine hydrochloride 40 mg/ml with epinephrine 0.01 mg/ml . The horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under sterile saline irrigation. Following the extraction, granulation tissues were removed, and bleeding was controlled. Finally, extraction socket was irrigated with the solution which contains 250 mg rifamycine and the mucoperiosteal flap was repositioned by 3.0 silk sutures.
45911351|NCT02006966|Drug|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
46067386|NCT00661635|Drug|valdecoxib|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg once daily (QD)on Days 2 to 5.
45608188|NCT04349579|Drug|Saline Solution|Local anesthesia was obtained using 2 ml articaine hydrochloride 40 mg/ml with epinephrine 0.01 mg/ml . The horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under sterile saline irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures.
45608189|NCT04234529|Dietary Supplement|AMATEA™|"AMATEA™ is a patented dietary supplement consisting of a unique blend of caffeine and polyphenol antioxidants; standardized at 20% caffeine, 30% chlorogenic acids (similar to green coffee).~Total of 1.35g of AMATEA containing 270mg of caffeine."
45608190|NCT04234529|Dietary Supplement|Caffeine|1.08g of microcellulose and 270mg of caffeine.
45608191|NCT04234529|Other|Placebo|1.35g of microcellulose
45608192|NCT01652690|Biological|Denosumab|This is an non-interventional study, therefore denosumab is administered as part of routine care and not for purposes of the study.
45911352|NCT02006966|Drug|Normal saline infusion|In group C, the patients receive same volume of normal saline
45911353|NCT02006992|Other|RTF Infant Formula|a RTF extensively hydrolyzed infant formula
45911354|NCT02006992|Other|Powder Infant Formula|a powdered extensively hydrolyzed infant formula.
46067387|NCT00661635|Drug|valdecoxib|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg twice daily (BID) on Days 2 to 5.
46067388|NCT00790465|Dietary Supplement|dark chocolate|21 g/d of dark chocolate for 2 weeks (7 g. before each meal). 7 grams of dark chocolate at day 1 during manometry.
46067389|NCT00790465|Dietary Supplement|placebo chocolate with crossover to dark chocolate|Placebo at day 1 during manometry, and than crossover to dark chocolate for 2 weeks treatment.
45608193|NCT05154071|Other|Collection of medical data|Collection of adverse events, of mortality, length of hospitalization
45608194|NCT03482219|Other|Occupational therapy|The Occupational therapy intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education. The home app intervention involves one session of education with the occupational therapist.
46067390|NCT04155957|Other|Rapid Recovery Rehabilitation Programme|"Usual intervention at Hospital Clínic de Barcelona for post-operative rehabilitation of TKA patients. Participants, already at home after hospital discharge, must perform 5 different exercises 4 times a day (twice in the morning, twice in the afternoon).~Participants are also encouraged to walk and stretch their legs. Domiciliary visits by a physiotherapist start at approximately 2 weeks after the surgery to help participants do the exercises."
46067391|NCT04155957|Device|ReHub|"Participants use a telerehabilitation platform, ReHub, as a guide to perform the TKA rehabilitation exercises of the Rapid Recovery Rehabilitation Programme intervention.~The exercise plan in ReHub is carried out by a site physiotherapist on the first day after discharge by using ReHub to acquire the participant's movement pattern with a wearable inertial sensor that transmits data to the platform.~The wearable inertial sensor participants must wear tracks movement while they do the TKA rehabilitation exercises. Movement is analysed and feedback is given in real time. At the end of each exercise, participants can select if they have felt pain in a scale from 1 to 10. A physiotherapist monitors the participants' progress remotely."
46067392|NCT02555761|Drug|Alcaftadine Ophthalmic Solution 0.25%|Alcaftadine Ophthalmic Solution 0.25% (Lastacaft®) as prescribed as standard of care in clinical practice.
46067393|NCT04155879|Drug|Colchicine Tablets|Administration of Colchicine at a dose of 0.5mg 2x a day for six months.
46067394|NCT04155879|Procedure|Cardioversion|Electrical or pharmacologic restoration of sinus rhythm
46067395|NCT00662805|Drug|Salmeterol/Fluticasone propionate|Open label, of Salmeterol/Fluticasone propionate (50/500 μg) twice daily via dry powder inhaler (DPI)
46067396|NCT02555137|Other|'prediction score' and 'rule-out criteria'|The combination of the 'prediction score' and the 'rule-out criteria' constitutes an accurate follow-up after PE aimed at diagnosing CTEPH in early stages.
45608195|NCT03482219|Other|Home app intervention|The app consists of videos depicting each exercise and ability to track adherence to exercises.
45608196|NCT04914026|Other|Biomarker analysis|Blood collection. Blood samples will be collected at diagnosis, during surveillance, during treatment and every 3-6 months
46067397|NCT00662883|Drug|PMI-150 (intranasal ketamine HCl); mometasone furoate|"1 dose PMI-150 (intranasal ketamine HCl); day 1~mometasone furoate, daily; days 2-15~1 dose PMI-150 (intranasal ketamine HCl); day 15"
46067398|NCT00662961|Procedure|Periosteum|Periosteum fixation
46067399|NCT00662961|Procedure|Bone|Bone tunnel fixation
45757737|NCT02641587|Other|CC|Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement followed by 85 days in an ambulatory setting.
45757738|NCT00638651|Device|1064 nm Nd:YAG laser|The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy
45608197|NCT03481517|Drug|Bupivacaine|Bupivacaine 5 mL subcutaneous injection to surgical wound during operation.
46067400|NCT00785473|Dietary Supplement|cholecalciferol|cholecalciferol capsules, 20,000 IU weekly for 2 years and calcium carbonate 500 mg daily
46067401|NCT00785473|Dietary Supplement|calcium carbonate|calcium carbonate 500 mg daily for 2 years
46073600|NCT04241172|Procedure|Traditional Rehabilitation (TR)|"The TR group exercises will be performed in the gym with a physiotherapist. In particular, patients will perform:~exercises with a patient sitting on a chair (3 minutes per exercise):~flexion-extension of the knee;~leg and hip circling;~flexion-extension of the ankle;~triple flexion;~walking (with and without aids)."
45757739|NCT00638651|Drug|Imiquimod, 5% cream|2 weeks after the laser procedure the imiquimod will be applied 3 times a week for one month
45757740|NCT02584647|Drug|PLX3397|PLX3397 is a small molecule that potently and selectively inhibits macrophage colony-stimulating factor receptor (FMS), Kit, and FMS-like tyrosine kinase 3 (Flt3)-internal tandem duplication (ITD) kinases, which regulate key components of the tumor microenvironment and oncogenic variants of these kinases that drive certain tumors.
45757741|NCT02584647|Drug|Sirolimus|"Sirolimus is a macrocyclic lactone that binds to tacrolimus (FK506) binding protein 12 and inhibits mammalian target of rapamycin (mTOR) resulting in cell-cycle arrest and apoptosis.~Sirolimus is currently approved as an immunosuppressive agent for organ transplantation and more recently, as a component of cardiac arterial stents because of its potent antiproliferative effects on fibroblasts responsible for restenosis after such a procedure (26) Sirolimus is commonly administered orally on a daily basis, in doses ranging from 2 to 40 mg/day."
45757742|NCT00685139|Drug|Zonisamide 100 mg Capsule|100 mg capsule administered after an overnight fast.
45757743|NCT00685139|Drug|Zonisamide (Zonegran®) 100 mg Capsule|100 mg capsule administered after an overnight fast.
45608198|NCT03482063|Dietary Supplement|Swisse Ultiboost Memory + Focus|"B vitamins help energy release, help with metabolism of food into energy, assist energy production and vitality.~Vitamin B5 helps support normal mental performance. Brahmi, Ginkgo, Vitamin B12 and B3 help support brain function. Ginkgo helps maintain healthy circulation and delivery of oxygenated blood to the brain.~Brahmi supports memory function and recall. Vitamin B5, B6 are important for adrenal function, assist adrenal glands during stress periods.~Vitamin B2, B3, B5, B6, B12 help relieve tiredness and fatigue."
45608199|NCT03482063|Other|Placebo|riboflavin (2.2mg)
45608200|NCT03481439|Other|Collection of a Pharmaceutical intervention|collection of pharmaceutical interventions carried out by the pharmaceutical team in the care uni in Primary and secondary cohort
45608201|NCT02429258|Drug|Farxiga|Farxiga 10mg/day
45911355|NCT02007005|Drug|abnobaVISCUM Fraxini|intravesical instillation 6 times, once weekly, in increasing dosages until dose-limiting-toxicity occurs
45608202|NCT02429258|Drug|Placebo|Placebo
45608203|NCT02429258|Drug|Metformin|Metformin background therapy >/= 1500mg/day
45608204|NCT02429258|Drug|Insulin|Insulin >/= 30 units
45608205|NCT05153993|Other|Fascia stretch|"Stretch of the fascia plantaris during 3x30, 5x/week, 6 weeks"
46067402|NCT02631291|Behavioral|Behavioral self-monitoring|Behavioral self-monitoring will teach older adults to pay attention to their daily lifestyle practices and the conditions in which they occur. Behavioral self-monitoring is crucial for detecting change early, thereby preventing complications (mental illness symptom burden) that are associated with disruptions in healthy lifestyle practices. The steps of behavioral self-monitoring include: (1) selecting a goal, (2) paying attention to some aspect of behavior, and (3) recording some details of that behavior in a diary.
45608206|NCT03481127|Behavioral|Integrated psychological care|Additional possible strategies used may include supportive or validating interventions, increasing/introducing/reinforcing coping strategies, psychoeducation; distress tolerance skills; brief cognitive behavioral therapy; cognitive restructuring; activity scheduling; acceptance; and relaxation/mindfulness.
45608207|NCT03481127|Other|Surveys|"NCCN Distress Thermometer~PROMIS Depression & Anxiety~Quality of Life (SF-12)~Brief COPE~Patient awareness and satisfaction survey"
45608208|NCT03481127|Procedure|Blood draw|"For patients with ovarian, fallopian tube, or primary peritoneal cysts~Optional~Enrollment, 3 months after enrollment, and 6 months after enrollment"
45608209|NCT03481127|Procedure|Fresh tissue from ovary|"For patients with ovarian, fallopian tube, or primary peritoneal cysts~Optional~At time of standard of care surgery"
45608210|NCT02201524|Drug|PF-04965842|Subjects will receive 200 mg PF 04965842 twice daily for 4 weeks
45608211|NCT02201524|Drug|PF-04965842|Subjects will receive 400 mg PF 04965842 daily for 4 weeks
46067403|NCT02631291|Behavioral|Behavioral self-monitoring + Motivational interviewing|Participants will receive the same Behavioral self-monitoring intervention; participants in this condition will interact with a 'lifestyle coach' about their recorded behaviors, weekly. The lifestyle coach will use motivational interviewing to enhance older adults' confidence and intrinsic motivation to engage in healthy lifestyle practices.
46067404|NCT00785551|Drug|quinine sulfate|2 x 324mg given in one dose to healthy subjects
45608212|NCT02201524|Drug|PF-04965842|Subjects will receive 200 mg PF 04965842 daily for 4 weeks
45608213|NCT02201524|Other|Placebo|Subjects will receive placebo for 4 weeks
45608214|NCT03982901|Diagnostic Test|Mental Stress Test|In this study, we compare MSIMI prevalence in the two groups (chest pain group and no chest pain group). Each subject in both groups receive the same mental stress test process, and the mental stress test process have 3 consecutive stress tests, which including: Stroop Color-Word test; Public speaking with anger recall test and Mental arithmetic test.
45608215|NCT03937583|Drug|Fludeoxyglucose 18F|"The performance of the 18 FDG PET-CT will require fasting of at least 6 hours, and the glycemia will have to be lower than 126 mg / dL before the injection of 3-5 MBq / kg of 18FDG. Intravenous injection will follow a period of approximately 60 minutes in a quiet room.~Computed tomography (CT) will be performed from the middle of the forehead to the feet with normal and shallow breathing using a low dose adjustment Iodinated contrast will not be administered intravenously."
45608216|NCT02453048|Biological|BPZE1|Intranasal live, attenuated vaccine
45608217|NCT02453048|Other|Placebo|Diluent
46067405|NCT00785551|Drug|quinine sulfate|2 x 324mg given as one dose to subjects with mild renal impairment
45608218|NCT05153681|Other|Peloid Therapy|Peloid therapy; A total of 10 sessions were applied for 30 minutes by heating the proximal part of the sole of the foot, including the heel part, at a temperature of 45 degrees. Kinesioband application: One strip is prepared as a rake with a length of about 25 cm, and the other strip is prepared as an I tape with a length of about 20 cm. The ankle is in a neutral position of 90 degrees. Lymphatic and mechanical correction technique is applied. Afterwards, the band is activated.
46067406|NCT00785551|Drug|quinine sulfate|2 x 324mg given as one dose to subjects with moderate renal impairment
46067407|NCT04031937|Other|Psychomotor assessment|the intervention include a depression scale, an anxiety scale, a sensory profile scale, a body image questionnaire, a self-esteem questionnaire, a psychomotor retardation scale and a standardized assessment of : muscle tone (dangling and extensibility); gross motor skills (walks, jump, static balance, dynamic balance); manual performance; manual praxis; adaptation of rhythm; manual gnosis; executive function
46067408|NCT00780949|Other|intestinal biopsies|intestinal biopsies during routine endoscopy
45911356|NCT02007018|Device|Negative Pressure Wound Therapy|Prevena™ Incision Management System (PIMS) (Kinetic Concepts Inc. (KCI), San Antonio, TX) is an incisional vacuum assisted closure (PIMS) device intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudates via the application of negative pressure wound therapy The PIMS applies continuous pressure to the closed surgical site at 125 mm Hg and is attached to a 45 mL canister for collection of exudate.
46067409|NCT02631369|Device|Heidelberg Spectralis OCT device|
46067410|NCT00790777|Drug|Paliperidone ER|
46067411|NCT00663195|Drug|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks
46067412|NCT00791011|Drug|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).
46067413|NCT00791011|Other|Vorinostat|Vorinostat, a second generation polarplanar compound, binds to the catalytic domain of the histone deacetylases (HDAC).
45608219|NCT02523989|Other|study group|Explore the relationship of heavy metals and health related quality of life, including the relationship between the developmental delays and polymorphism of arsenic methylation enzymes, arsenic methylation capability and blood metals. Identify the interaction of children function, health condition, and quality of life and arsenic methylation and blood metals in children with developmental delays.
45608220|NCT04926896|Procedure|Traditional iliac crest bone harvesting surgery|The experimental group and the control group do not have special requirements; perform the surgery according to the normal operation methods of different sites.
45608221|NCT04926896|Procedure|Minimally invasive bone harvesting surgery|Minimally invasive bone harvesting surgery
45608222|NCT03798041|Behavioral|Debridement Within 24 Hours After Surgery|Debrided within 24 hours after surgery
45608223|NCT05153603|Drug|Olaparib mono-maintenance therapy|Olaparib mono-maintenance therapy in patients with newly diagnosed, histologically confirmed, advanced (FIGO stage III-IV) ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer is defined as drug exposure. At least one dose of olaparib tablets monotherapy as maintenance therapy will be required.
45608224|NCT04459325|Biological|Tigerase® and best available care|Nebulised dornase alfa [2.5 mg BID] for 7 days
46067414|NCT00791011|Other|Bortezomib|A dipeptide boronic acid analogue with antineoplastic activity.
46067415|NCT00663273|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
46067416|NCT00663429|Drug|Atiprimod|Oral, 14 days on / 14 days off; 30mg capsules
46067417|NCT00781027|Procedure|Phacoemulsification|Comparison of longitudinal phacoemulsification and torsional phacoemulsification
45608225|NCT04459325|Other|Best available care|Patients will receive the usual care in accordance with good practice.
45608226|NCT03697421|Other|Relationship Education|"We will provide the following 4 activities: 1) marriage and relationship education [using a modified version of the empirically supported Loving Couples, Loving Children (LCLC); 2) pre-marital education and marriage skills; 3) marriage enhancement and marriage skills for married couples; and 4) divorce reduction and relationship skills.~All couples will be expected to participate in 24 hours of core relationship education workshops (including parenting education). Since parental financial support represents a core element of family stability, relationship education workshops will address motivation for providing financial support through employment for all couples (employed and unemployed) as well as how to manage conflicts over money. All couples will be invited to supplemental workshops (with couples from other cohorts) on topics of specialized interest, including employment services and financial literacy (i.e. budgeting, debt, etc.)."
45608227|NCT03697421|Other|Employment Services|For couples in need of job search, job retention, and career advancement services, we will provide employment services.
46067418|NCT02555917|Procedure|anterior cruciate ligament reconstruction|Twenty patients planed to undergo anterior cruciate ligament reconstruction by preserving remnant and other twenty patients undergo anterior cruciate ligament reconstruction by preserving remnant.
45608228|NCT04459949|Device|Sharkskin|Use of Sharkskin ILM forceps
45608229|NCT04459949|Device|Grieshaber|Use of Grieshaber ILM forceps
45608230|NCT05153213|Procedure|Finger lengths|Vernier caliper was used to measure finger length
45608231|NCT05153213|Procedure|Conventional method|Gillis gauge was used to measure occlusal vertical dimension
45608232|NCT05152901|Drug|EpiPen ®.|A single dose of 0.3 mg epinephrine via intramuscular injection into the anterolateral aspect of the thigh on Day 1 Visit 2.
45608233|NCT05152901|Drug|Epinephrine (0.3mg) inhaled|Participants will be administered 0.3mg of first inhaled dose of epinephrine once daily on day 2 of Visit 2
46067419|NCT00781105|Drug|Telbivudine|600 mg/day, oral tablets, once daily, 52 weeks
46067420|NCT00785863|Other|Placebo|Placebo IV before placebo infusion
46067421|NCT00785863|Drug|Remifentanil|placebo IV and remifentanil infusion
46067422|NCT00785863|Drug|Ketorolac and remifentanil|Ketorolac IV and remifentanil infusion
46067423|NCT00785863|Drug|Parecoxib and remifentanil|Parecoxib IV and remifentanil infusion
46067424|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide administered intravenously at 1.5 mg/kg/hr for 3 hours
46067425|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
46067426|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
46067427|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours
46067428|NCT00664105|Drug|Carboplatin|"Carboplatin will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.~Carboplatin will be given once every three weeks as a 30-minute intravenous infusion immediately following the infusion of docetaxel. Patients will receive two cycles of consolidation treatment."
45608234|NCT05152901|Drug|Epinephrine (1.3mg)|A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 1.3 mg epinephrine.
45608235|NCT05152901|Drug|Epinephrine (4mg)|A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 4 mg epinephrine
46067429|NCT00664105|Drug|Docetaxel|"Docetaxel will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.~Docetaxel will be given once every three weeks administered as a one-hour IV infusion. Patients will receive two cycles of consolidation treatment (1 cycle = 3 weeks)."
46067430|NCT00664105|Radiation|radiation therapy|Radiotherapy will be administered daily X 5 day/week for 34 days beginning on Day 1 of the study. Radiotherapy will follow immediately after the infusions of docetaxel and carboplatin.
46067431|NCT04155645|Drug|AZD8233 subcutaneous injection|Randomized subjects will receive SC dose of AZD8233 (dose 1, dose 2, and dose 3) injection.
45608236|NCT02137252|Drug|Naltrexone|
45608237|NCT02137252|Drug|Sugar Pill|
45608238|NCT03481049|Behavioral|Usual CM|Behavioral reinforcement for alcohol abstinence
45608239|NCT03481049|Behavioral|High-Magnitude CM|Behavioral reinforcement for alcohol abstinence
46067432|NCT04155645|Drug|Placebo|Randomized subjects will receive SC dose of placebo injection.
46067433|NCT04155801|Dietary Supplement|Salix Probiotic Blend|Oral capsule. The probiotic strains comprise the Salix Probiotic Blend include 3 strains of Bifidobacterium lactis (Bl-04®, Bi-07®, HN019) and 2 strains of lactobacillus (Lactobacillus acidophilus [NCFM]® and Lactobacillus paracasei [Lpc-37]®).
46067434|NCT00785941|Biological|IMC-A12|"Cohort 1~6 mg/kg I.V., once every other week for 4 weeks"
46067435|NCT00785941|Biological|IMC-A12|"Cohort 2~10 mg/kg I.V., once every other week for 4 weeks"
45608240|NCT03481049|Behavioral|Shaping CM|Behavioral reinforcement for alcohol abstinence
45608241|NCT02201290|Drug|Eltrombopag Tablets|Eltrombopag tablets will be white, round film coated tablets containing eltrombopag olamine equivalent to 12.5 mg, 25 mg, 50 mg and 75 mg of eltrombopag. The 12.5 mg tablet will be smaller than the 25 mg, 50 mg and 75 mg tablets. Subjects will receive maximum dose of 75 mg once daily (QD).
45608242|NCT02201290|Drug|Eltrombopag PfOS|Eltrombopag PfOS is a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet will contain eltrombopag olamine equivalent to 20 mg of eltrombopag per gram of powder. Subjects will receive maximum dose of 75 mg once daily (QD)
46067436|NCT00785941|Biological|IMC-A12|"Cohort 3~15 mg/kg I.V., once every other week for 4 weeks"
46067437|NCT00785941|Biological|IMC-A12|"Cohort 4~21 mg/kg I.V., once every other week for 4 weeks"
46067438|NCT00785941|Biological|IMC-A12|"Cohort 5~27 mg/kg I.V., once every other week for 4 weeks"
46067439|NCT00663585|Behavioral|Vipassana Meditation|12 day retreat where participants learn to meditate
45608243|NCT03481673|Behavioral|COPE for Asthma|The intervention will consist of 7 weekly sessions (30 minutes each). COPE for Asthma is a manualized, cognitive behavior skills-building intervention to improve the physical and mental health outcomes of children with asthma and elevated symptoms of anxiety or depression.
46067440|NCT02555605|Drug|Dexmedetomidine|Children up to the age of 16 years requiring MRI under deep sedation with at least 3 characteristics of respiratory morbidities were identified as having increased risk for adverse respiratory events. Dexmedetomidine was administered as a first bolus of 1 mcg•kg-1 over 10 min, followed by a continuous infusion at 1.0 mcg•kg-1•h-1. Sedation level was assessed by Ramsay Sedation Scale and it was initially recorded at 1-min interval. If the child failed to achieve a minimum RSS of 5, this bolus was repeated once again and the continuous infusion was subsequently increased to 2 mcg•kg-1•h-1. In addition, propofol 0.5 mg.kg-1 iv. was allowed to be administered, in patients still exhibiting movement that could interfere with image acquisition.
46067441|NCT00663663|Behavioral|Telephone-Delivered Intervention 1|Intervention 1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Intervention 1 will include: (1) education about the role of cognitions (particularly catastrophizing) and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Each intervention 1 session will include a brief relaxation exercise practiced over the phone.
46067442|NCT00663663|Behavioral|Telephone-Delivered Intervention 2|Intervention 2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain.
46067443|NCT00791167|Drug|Paliperidone ER|
46067444|NCT04155255|Other|MyBFF@school|
46067445|NCT00781183|Other|pulmonary rehabilitation|6-weeks of in-patient pulmonary rehabilitation or 12-weeks of out-patient pulmonary rehabilitation
46067446|NCT00663741|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 2 weeks off) + CDDP (60 mg/m2 on Day 8) / 35 days / cycle
46067447|NCT00663741|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (25 mg/m2 bid, 3weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days / cycle
46067448|NCT00663741|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days cycle
46067449|NCT00661687|Device|Currently Marketed PureVision Contact Lens.|Contact lens for continuous wear
46067450|NCT00661687|Device|Alternate Design of the PureVision Contact Lens.|Contact lens for continuous wear
46067451|NCT04155177|Procedure|training for french ambulatory caesarean section|"The participant will be first invited to consult a theoretical support and a video treating on FAUCS.~After that, he will be asked to be the first assistant, in a FAUCS procedure with one of the two senior surgeons assigned for the study.~In a second step, the trainee will have to perform all the steps of the FAUCS, assisted by one of the two senior surgeons . During each surgery, Operative time will be measured, while an evaluation on four stages according to the Zwisch model of supervision will performed by the senior surgeons .~Once, the two seniors agree on the highest level assessment for the resident, he will be allowed to operate alone FAUCS procedures and will be evaluated by the measurement of operating times, the neonatal outcomes and the occurrence or not of complications.~finally, total number of FAUCS procedures required for each resident in order to master the technique will be determined."
46067452|NCT00791245|Biological|Particulated Juvenile Cartilage Allograft|Particulated Juvenile Cartilage Allograft
46067453|NCT00663897|Drug|lansoprazole|lansoprazole, 30 mg, once daily for 14 days
46067454|NCT00663897|Drug|mosapride|mosapride, 5 mg, thrice daily for 14 days
46067455|NCT00663975|Drug|DCI 1020|capsules (4,000 units of lipase) will be administered with meals and snacks
46067456|NCT00664053|Dietary Supplement|DHEA|50mg daily for 6 months
46067457|NCT00664053|Behavioral|Yoga|2 sessions per week for 6 months
46067458|NCT00664053|Dietary Supplement|Placebo|Placebo supplement every day for 6 months
46067459|NCT00664053|Behavioral|Aerobics|Walking/chair aerobics program 2 sessions per week for 6 months
46067460|NCT00664131|Other|Neurological Examination/Questionnaires|See Detailed Description section for description of treatment plan.
46067461|NCT04031859|Drug|acetylsalicylic acid|It's a VTE risk stratification tool or procedure that will be used after total knee replacement (TKR) to help surgeons in choosing the tailored VTE prophylaxis according to patients' specific VTE risk, this tool will stratify the TKR-patient in one of three risk-groups: Low high risk who will be prescribed Aspirin upon hospital discharge as extended VTE prophylaxis post TKR surgery, or moderate high risk group who will be prescribed oral anti coagulant (like rivaroxaban) as extended prophylaxis, and the last group is very high risk group who will be prescribed parenteral anticoagulant ( like Enoxaparin) plus compression devices.
46067462|NCT00664287|Drug|niacin (+) laropiprant|Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.
46067463|NCT00664287|Drug|placebo (unspecified)|Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
46073601|NCT00620113|Drug|Odanacatib|Odanacatib tablets 10 mg, 25 mg, or 50 mg (depending upon randomization), taken orally once weekly for 52 weeks.
45444866|NCT05625243|Other|Bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) with Precontoured sectional matrix systym (Saddle matrix, TORVM, Moscow, Russia)|A suitable size precontoured sectional matrix band (Saddle matrix, TORVM, Moscow, Russia) will be selected and placed. Teeth separation will be acquired with a suitable size wedge (fixing wooden wedges, TORVM, Moscow, Russia) and a separation ring (Delta ring, TORVM, Moscow, Russia). Then the bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) will be applied and light cured according to the manufacturer instructions.
45608244|NCT02200510|Behavioral|Self-management intervention for Adolescents with SCD|Chronic Disease Self-Management Program
45608245|NCT02200510|Behavioral|Patient Portal Intervention for Adolescents with SCD|MyChart for SCD intervention
45608246|NCT05152745|Other|Placebo OGGT|"After overnight fasting, blood glucose level was assessed through a capillary drop blood The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups.~Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis."
45608247|NCT05152745|Other|Ginger aqueous extract|"After overnight fasting, blood glucose level was assessed through a capillary drop blood The intervention group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water, followed by 100mL of ginger extract (0.2g). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups.~Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis."
45608248|NCT05152667|Device|levonorgestrel-releasing intrauterine device (LNG-IUS)|Intervention is administered proceeding the ICSI
46067464|NCT00664365|Drug|GSK958108|GSK958108 oral tablets will be available with dosing strengths of 1 milligram, 5 milligrams, 25 milligrams and 50 milligrams. It will be a brownish-yellow film coated round shape tablet. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
46067465|NCT00664365|Drug|Placebo|Placebo tablets will be brownish-yellow film coated round shape tablets, administered orally. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
46067466|NCT00664443|Behavioral|Dispatch-assisted CPR Instructions|Pre and post assessment of bystander CPR frequency and impact on victim survival related to Dispatch-assisted CPR Instructions given since 2004
46067467|NCT00664599|Drug|Rituximab|Infusion of Rituximab, 1500 mg, two times with 15 days interval. Patients receive also Methotrexate (15 mg weekly) and Prednisolone (0.5 mg/daily).
46067468|NCT00664599|Drug|Cytotoxic Combination|Pulse cyclophosphamide 1000 mg in perfusion, once monthly monthly. Azathioprine 3 mg/kg/body weight daily + prednisolone 0.5 mg/kg/daily.
46067469|NCT02631135|Drug|Remifentanil|In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
46067470|NCT02631135|Drug|Propofol|BIS values were arranged 40-60 until the end of operation
46067471|NCT02631135|Drug|Dexmedetomidine|0.5 microgram/kg infusion, no changes
46067472|NCT02631135|Drug|Rocuronium|0.5 mg/kg iv for intubation, no change
46067473|NCT00664677|Drug|Terameprocol (EM-1421)|Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off.
46067474|NCT00596817|Drug|Placebo|capsules, daily, orally
46067475|NCT00596817|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
46067476|NCT01000649|Drug|FE 202158 1.25|FE 202158 at dose 1.25 ng/kg/min infused.
45444867|NCT05625243|Other|Bulk-fill resin composite (X-tra fill, Voco, Cuxhaven, Germany) with Precontoured circumferential matrix system (Palodent 360, Dentsply Caulk, Millford DE, USA)|A suitable size precontoured circumferential matrix band (Palodent 360, Dentsply Caulk, Millford DE, USA) will be selected and placed. Teeth separation will be acquired with a suitable size wedge (Palodent V3, Dentsply Caulk, Millford DE, USA) and a separation ring (Palodent V3 universal ring, Dentsply Caulk, Millford DE, USA). Then the bulk fill resin composite (X-tra fill, Voco, Cuxhaven, Germany) will be applied and light cured according to the manufacturer instructions.
45608249|NCT02452892|Device|LFMS|Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.
45608250|NCT03185663|Other|traction-stuck|continuous pulling method: tensile force is exerted directly on the skin by means of adhesive strips, connected to weight
46067477|NCT01000649|Drug|FE 202158 2.5|FE 202158 at dose 2.5 ng/kg/min infused.
46067478|NCT01000649|Drug|FE 202158 3.75|FE 202158 at dose 3.75 ng/kg/min infused.
46067479|NCT01000649|Other|Placebo|Isotonic saline infused.
46067480|NCT00664833|Behavioral|Levitra (Vardenafil, BAY38-9456)|The Primary Care Physician (PCP) received the educational intervention
46067481|NCT00664833|Behavioral|Levitra (Vardenafil, BAY38-9456)|The Subject received the educational intervention
46067482|NCT00664833|Behavioral|Levitra (Vardenafil, BAY38-9456)|Both the Primary Care Physician (PCP) and the subject received the educational intervention
46067483|NCT00664833|Other|No Education|No education provided to either the Primary Care Physician (PCP) or the subject.
46067484|NCT00664911|Other|chemotherapy|
46067485|NCT02870699|Device|Evonail|film-forming solution containing water Evaux naturally rich in lithium, strontium and manganese with UV filter
46067486|NCT02870699|Device|Placebo excipient|film forming excipient solution
46067487|NCT00666835|Drug|HX575 epoetin alfa Hexal AG|HX575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin
46067488|NCT00666835|Drug|ERYPO®, Janssen-Cilag|Solution for i.v. injection
46067489|NCT02870777|Combination Product|MRD-directed therapy|The purpose of this study is to establish risk stratification based on cytogenetics at diagnosis and MRD analysis after induction chemotherapy and before consolidation chemotherapy to determine whether a MRD directed therapy for low and intermediate AML patients has positive results in terms of overall survival.
46067490|NCT04352231|Dietary Supplement|High Fiber Diet Intervention|Plant-based diet with a targeted quantity of 35 g of dietary fiber per day, from a variety of fiber types. Each meal will be balanced to provide all essential nutrients and portions will be of adequate size to ensure participants are satiated. Participants on both diet interventions will be given multivitamin supplements in order to ensure they are receiving essential vitamins and minerals.
46067491|NCT04352231|Dietary Supplement|Low Fiber Diet Intervention|Animal based diet (meat, dairy) with a targeted quantity of 10 g of dietary fiber per day. Each meal will be balanced to provide all essential nutrients and portions will be of adequate size to ensure participants are satiated. Participants on both diet interventions will be given multivitamin supplements in order to ensure they are receiving essential vitamins and minerals.
46067492|NCT00911469|Drug|AS902330|3, 10, 30, 100 or 300 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30, 100, 300 µg or highest tolerated dose intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
46067493|NCT00911469|Drug|Placebo|Placebo or, 3, 10, 30, 100 or 300 µg intra-articular injection per subject in SAD cohorts and placebo or, 10, 30, 100, 300 µg or highest tolerated dose of AS902330 intra-articular injection per week for three weeks per subject in MAD cohorts.
46067494|NCT00665379|Other|Regular Compression therapy (Trico bandages)|Application of marketed Trico compression bandages used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. The bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
45608251|NCT03185663|Other|a pillow between the legs|setting up a pillow between the legs before the care
46067495|NCT00665379|Other|New Compression therapy (C2L bandages)|Application of marketed compression bandages C2L used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. he bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
46067496|NCT00879411|Drug|Micardis|
46067497|NCT00665535|Procedure|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3, or 4 hours
46067498|NCT00665535|Procedure|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3 or 4 hours
46067499|NCT01000493|Drug|orvepitant|Neurokinin-1 (NK-1) antagonist
45608252|NCT03048227|Device|Continuous Glucose Measurement (CGM)|Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).
46067500|NCT01000493|Other|Placebo|Inactive placebo to match orvepitant 60 mg dosage form
46067501|NCT00671151|Drug|Theophylline|Theophylline 100 mg bid for 3 months
46067502|NCT04153461|Procedure|MINI-PERCUTANEOUS NEPHROLITHOTOMY|MINIPERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 15 FR, LASER DUSTING OF THE STONE, NEPHROSTOMY TUBE 12 FIXATION
46067503|NCT04153461|Procedure|STANDARD PERCUTANEOUS NEPHROLITHOTOMY|PERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 24 FR, ULTRASOUND OR LITHOCLAST DISINTEGRATION OF THE STONE AND FORCEPS EXTRACTION OF THE FRAGMENTS, NEPHROSTOMY TUBE 22 FIXATION
46067504|NCT00671307|Drug|rhu-pGelsolin|IV formulation of recombinant plasma gelsolin formulated as 10 mg/ml given as a single IV infusion over 1 hour
46067505|NCT00671307|Drug|Placebo|Vehicle control given as IV infusion over 1 hour
46067506|NCT00666757|Drug|duloxetine|30-120 milligrams (mgs) orally daily for 12 weeks
46067507|NCT00666757|Drug|fluoxetine|20-80 mgs orally daily for 12 weeks
45608253|NCT05152589|Diagnostic Test|hearing test|Auditory Brainstem Response (ABR) Test
45911357|NCT02007018|Other|Usual Care of Surgical Wound|Patients will receive pre-operative antibiotics consisting of 1g cefazolin (or in the case of an allergy, an alternative e.g. ciprofloxacin/vancomycin) and 500 mg metronidazole given intravenously within the 30 minute prior to beginning the operative procedure. In cases extending > 4 hours, a second dose of each of the antibiotics will be administered. Hair at the operative site will be removed, if required, immediately prior to the skin incision using electric clippers. The abdomen will be prepped using 2% Chlorhexidiene solution (or 10% povidone if allergic). After closure of the skin, the surgical wound will be covered with a sterile adhesive dressing (Tegaderm), which will remain in place until the morning of post-operative day (POD)#2, unless saturated, in which case it is standard practice to change the dressing if the physician is in agreement. On POD#2, the surgical team will remove the initial dressing and daily dressing changes with standard gauze will be initiated.
45911358|NCT02007057|Procedure|Suprascapular nerve block|
46067508|NCT00666757|Drug|citalopram|20-40 mgs orally daily for 12 weeks
46067509|NCT00666757|Drug|paroxetine|20-50 mgs orally daily for 12 weeks
46067510|NCT00666757|Drug|sertraline|50-200 mgs orally daily for 12 weeks
46067511|NCT01000337|Drug|Sevoflurane|Sevoflurane concentration for induction of anesthesia 7-8%, for maintenance of anesthesia 2%.
46067512|NCT01000337|Drug|Propofol|Propofol to induce anesthesia 2.5 mg/kg, for maintenance of anesthesia 6 mg/kg/h
46067513|NCT02869763|Dietary Supplement|10 g ethanol|"31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
46067514|NCT02869763|Dietary Supplement|20 g ethanol|"63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
46067515|NCT02869763|Dietary Supplement|Water|400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.
46067516|NCT00671463|Procedure|Pancreatic duct stenting|In the treatment arm, patients will have a pancreatic duct stent placed prior to having their distal pancreatectomy.
46067517|NCT04153383|Drug|Milrinone Injection|giving IV milrinone: 50 mcg/kg loading dose by IV push over 10 minutes, then 0.375-0.75 mcg/kg/min IV
45444868|NCT03023007|Procedure|Loco-regional anaesthesia|Loco-regional anaesthesia
45911359|NCT02007057|Procedure|Interscalene nerve block|
45911360|NCT02007083|Procedure|Bilateral laminotomy (BL)|
45911361|NCT02007083|Procedure|Unilateral laminotomy with crossover (UL)|
46067518|NCT00671619|Drug|ESBA105|eye drops
46067519|NCT04153227|Diagnostic Test|Bone mineral density (BMD)|Bone mineral density (BMD) measured by Dual-energy X-ray absorptiometry (DXA).
46067520|NCT02629653|Device|endovascular cooling (Zoll system)|The Zoll IVTM is an endovascular cooling system that consists of a control module (either CoolGard 3000 or Thermogard XP), a CoolGard start-up kit, and an ICY catheter (either IC-3585 AE or IC-3585).
46067521|NCT00671697|Drug|Arsenic Trioxide|
45608254|NCT05152511|Combination Product|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy is a specially designed cabinet for infants and neonates with a barometric pressure equal to 760 mmHg for 20 minutes daily, then gradually increase up to one hour daily for 5 days per week (fig. 1). The chamber was kept warm. The babies were fed before entering the chamber and if signs of hunger appear during therapy. The baby was continuously monitored with pulse oximeter. Older children are managed in the conventional Hyperbaric oxygen chamber with the same regimen.
45757744|NCT03338036|Device|Heart Rate Variability Biofeedback|HRV biofeedback constitutes initial training with the android device and application, and HRV training performed at home. This training will occur twice daily, and each session will take five minutes.
45608255|NCT04459481|Device|bending angle|patients in 70-degree bending angle group are intubated with video stylet at 70-degree bending angle patients in 90-degree bending angle group are intubated with video stylet at 90-degree bending angle
45608256|NCT02135848|Drug|GSK1278863|GSK1278863
46067522|NCT00671697|Drug|Decitabine|
45608257|NCT02135848|Drug|Placebo|Placebo
45608258|NCT02568449|Drug|Nintedanib|Given PO
46067523|NCT00666679|Drug|Comparator: mometasone|mometasone (inhalation powder, 220 mcg once-daily, for approximately 6 weeks)
46067524|NCT00666679|Drug|Comparator: montelukast|montelukast (inhalation powder, 1 mg once-daily, for approximately 2 weeks)
46067525|NCT00666679|Drug|Comparator: placebo (unspecified)|Placebo (Placebo once-daily, for approximately 2 weeks)
46067526|NCT04031781|Device|repetitive transcranial magnetic stimulation (rTMS) 100% motor threshold|Each rTMS session consisted of a single train of 900 total pulses over 3 minutes duration.
46067527|NCT04031781|Device|repetitive transcranial magnetic stimulation (rTMS) 50% motor threshold|Each rTMS session consisted of a single train of 900 total pulses over 3 minutes duration.
46067528|NCT00786097|Drug|Dermacyd PH_DETINLYN (Lactic Acid)|
45757745|NCT03338036|Device|Neurofeedback|LORETA Z-Score neurofeedback training will occur three times per week with a trained study investigator.
45757746|NCT00685295|Drug|Fentanyl|Fentanyl rapid dissolving tablet 100mcg
45757747|NCT00685295|Drug|Lansoprazole|lansoprazole 15mg rapidly dissolving tablet
45757748|NCT00685295|Drug|Oxycodone|Oxycodone 5/325 mg tablet
45757749|NCT02319291|Device|P.F.C. Sigma PS150 RP Total Knee System|Total Knee Arthroplasty - surgical procedure to replace knee with metal implant
45757750|NCT00686231|Drug|Nitroglycerin 15mg|15mg Nitroglycerin applied topically to one wrist
45757751|NCT00686231|Drug|Nitroglycerin 30mg|30mg Nitroglycerin applied topically to one wrist
45757752|NCT00686231|Drug|Lidocaine 20mg|20mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo
45757753|NCT00686231|Drug|Lidocaine 40mg|40mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo
45757754|NCT00686231|Drug|Placebo|Topical skin moisturizing cream with same appearance as active agent
45757755|NCT04122053|Behavioral|Intervention group with genotype information|Results of genotyping will be translated into personalised dietary recommendations. Subjects will be informed about their genotypes from the beginning of the study. The importance of personalised recommendations will be explained.
45757756|NCT04122053|Behavioral|Control group without genotype information|Subjects will receive personalised dietary recommendations, but at the beginning they will not be informed about their genotypes and the meaning of personalisation. Information about their genotype will be given to the participants at the and of study.
45757757|NCT04278716|Other|Safe return to play checklist|this objective checklist will be utilized by the physical therapy staff and surgeon to determine whether an athlete is safe to return to their sport
45757758|NCT05278208|Drug|LUTATHERA® (Lutetium Lu 177 dotatate)|Lutathera: IV administration maximum dose of 200 mCi once every 8 weeks (one cycle) for total of 4 cycles (8 months)
45757759|NCT03335774|Drug|Hydrocortisone Acetate Suppository, 25 mg (Nivagen)|One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
46067529|NCT00791401|Drug|ER OROS Paliperidone|
46067530|NCT00786253|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg on demand use
46067531|NCT00786253|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil daily dosing 10 mg
45608259|NCT03477227|Device|Short stocking|Patients in the experimental group will be asked to wear new type of compression stockings for four weeks post-operatively
45608260|NCT03477227|Device|Usual stocking|Patients in the control group will be asked to wear usual type of compression 2 class stockings for four weeks post-operatively
45608261|NCT03480815|Device|Nocturnal Temperature Controlled Laminar Flow Device|Record of the time to first asthma exacerbation, lung function and exhaled NO level
45608262|NCT03480815|Other|None Device|Record of the time to first asthma exacerbation, lung function and exhaled NO level
45608263|NCT03477149|Device|Easyx|Embolization will be done with Easyx liquid agent.
45608264|NCT03480737|Device|Magstim Super Rapid2 stimulator, 10 Hz condition|10 Hz (2,000 pulses) at left DLPFC
45608265|NCT03480737|Device|Magstim Super Rapid2 stimulator, Sham condition|sham
45608266|NCT03480737|Device|Magstim Super Rapid2 stimulator, iTBS condition|50 Hz, iTBS (600 pulses) at left DLPFC
45757760|NCT03335774|Drug|Placebo (Vehicle) Suppository (Nivagen)|One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
45757761|NCT05520320|Device|Hypothermic oxygenated machine perfusion (any device)|After static cold storage, all grafts included in this study are subjected to >1 hour of hypothermic oxygenated machine perfusion at 4-12°C with an acellular perfusion solution.
46067532|NCT02556073|Other|Smartphone action|Smartphone applications (Apps) can provides a platform not only to share health information at the point-of-living, including health assessments, personalized health plans, but also to remind the patients' medication adherence regularly. With the application of modern smartphone-based asthma self management deserves further investigation to improve asthma control.
46067533|NCT02556073|Drug|usual care|fluticasone/salmeterol 125/25 ug/puff, 2 puff bid plus salmeterol as-needed
46067534|NCT00595413|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
45757762|NCT03335540|Biological|Nivolumab|Specified dose on specified day
46067535|NCT00595413|Drug|Atacicept: with loading dose|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
45608267|NCT03477071|Procedure|Angioplasty for Transplant Renal Artery Stenosis (TRAS)|The angioplasty is an endovascular treatment for artery stenosis, which could be associated with stenting or not.
45608268|NCT03476993|Biological|BCD-085|All patients will receive BCD-085 (subcutaneous injections) once a week during the period of induction of remission, then once every 2 weeks during the period of remission maintenance and then once every 4 weeks during the period of accumulation of treatment effect. All patients will receive ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day.
45608269|NCT03476915|Other|ultrasound examination of the hip joint|US examination by US machine , Midray model DP-2200 made in China , with a high frequency (5-10 MHZ) linear transducer using the previously described Graf method for assessment of both hip joints.
45608270|NCT02738333|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
45608271|NCT02738333|Drug|SOF|400 mg tablet administered orally once daily
45608272|NCT02738333|Drug|RBV|Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, > 60 kg to ≤ 80 kg = 800 mg, and > 80 kg = 1000 mg)
45608273|NCT04900103|Other|ITV-Pal|Use of new technologies for volunteering
46067536|NCT00595413|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg once a week for 25 weeks.
45608274|NCT04884893|Drug|Nitrous Oxide|50% nitrous oxide
45608275|NCT02135692|Biological|Mepolizumab|Mepolizumab is a fully humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be supplied as a lyophilised cake in sterile vials for individual use.
45608276|NCT02135692|Drug|SOC|Standard of Care (SOC) will differ by participant, however it will generally include oral corticosteroids and an inhaled controller medicine (an inhaled corticosteroid plus a long acting beta agonist) and/or short acting beta agonists
45608277|NCT04839809|Drug|CC-92480|Oral
46067537|NCT00595413|Biological|Adalimumab|Adalimumab (Humira®) will be administered subcutaneously at a dose of 40 mg every other week for 25 weeks.
46067538|NCT00781261|Drug|Zoledronic Acid|Subjects in the intervention group B will be given 5mg Zoledronic acid as a single injection.
46067539|NCT00781261|Drug|Placebo|Subjects in the control group will receive a placebo drug for a similar period
46067540|NCT02629497|Dietary Supplement|Primrose oil|T2DM patients and matched controls subjects will be given Primrose oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
45608278|NCT04839809|Other|Placebo|Oral
45608279|NCT04830839|Behavioral|Recovery after Stress Toolkit (ReSeT)|ReSeT involves online modules with parallel videoconferencing sessions. ReSeT integrates two evidence-based treatment methods: cognitive behavioral therapy coping skills (coping CBT) and direct exposure to trauma reminders through a trauma narrative.
45608280|NCT04664309|Other|No intervention|No intervention
45608281|NCT02429414|Device|Non-Video Double Lumen Tube (DLT)|Participant receives non-video double lumen tube (DLT) placement before surgery.
45608282|NCT02429414|Procedure|Fiberoptic Bronchoscopy (FOB)|Fiberoptic bronchoscopy (FOB) performed to check placement of non-video DLT.
45608283|NCT02429414|Device|Video Double Lumen Tube (VDLT)|Participant receives video double lumen tube (VDLT) placement before surgery.
45608284|NCT02135614|Drug|Presatovir|Presatovir 200 mg (4 x 50 mg tablets) administered orally
45608285|NCT02135614|Drug|Presatovir placebo|Presatovir placebo tablets administered orally
45608286|NCT04331483|Other|Physical activity program|"Supervised sessions of at least 15 minutes 4 times a Week combined with unsupervised sessions.~The supervised activities include moderate-intensity aerobic activities (exercise bike), muscle strengthening (dumbbells, elastic bands, medicine balls) and playful situations (ball games, cooperative games, body expression games).~Each patient can also do unsupervised sessions, autonomously, on the bike thanks to a smartphone application developed by the Kiplin company, with challenges to be carried out by teams of 2 to 5 people (team including several patients, possibility to include relatives) over periods of 1 to 3 weeks per challenge."
45608287|NCT03480113|Behavioral|Mindfulness-based Intervention|mindful breath, body scan, sitting meditation and walking meditation and so on.
45608288|NCT03480113|Behavioral|Physical fitness intervention|giving the lessons of stretch exercise, aerobics to strength muscle and lung fuctions.
46067541|NCT02629497|Dietary Supplement|Fish Oil|T2DM patients and matched controls subjects will be given Fish oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
46067542|NCT02554825|Behavioral|Healthy Futures|Healthy Futures is an age-appropriate program that targets change at different social ecological levels-individual, interpersonal, and organizational. The main component is a classroom-based relationship education curriculum, Nu-CULTURE, offered in 6th, 7th, and 8th grade for eight 50-minute sessions each year. A number of supplemental efforts aim to enhance the Nu-CULTURE program and create social supports: 1) virtual classrooms where participating youth are encouraged to visit age-appropriate youth websites; 2) daily interactive parental connection forms linked with Nu-CULTURE, a parent website, and workshops (True Connections); 3) a 10-week after-school program, Rhymin' it Write, encourages youth leadership; 4) a 6-week summer program, Code A, engages youth during out-of-school time after 8th grade.
46067543|NCT02554825|Behavioral|Control|The Control Curriculum offers students in the control group two 50-minute classes each year on general health education topics. Students in the 6th grade receive a class on puberty/reproduction and a class on bullying prevention; students in the 7th grade receive two classes on dating-violence prevention; and students in the 8th grade receive two classes on mental health promotion.
46067544|NCT00786331|Drug|Pemetrexed|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 of a 21 days cycle
46067545|NCT00786331|Drug|Pemetrexed plus carboplatin|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 and Carboplatin AUC 5 i.v. over approximately 30 minutes on day 1 (beginning approximately 30 minutes after the end of the pemetrexed infusion) of a 21 days cycle
46067546|NCT01000025|Drug|PF-00299804|PF-804 45 mg PO, daily
46067547|NCT01000025|Drug|Placebo|Placebo 45 mg PO, daily
46067548|NCT00791713|Drug|Paliperidone ER|
45608289|NCT03480035|Procedure|lightwand intubation|intubation using lightwand
45608290|NCT03479879|Drug|Estradiol|Estradiol
45608291|NCT03479879|Drug|Placebo Oral Tablet|Placebo
45608292|NCT03479879|Drug|Misoprostol|Misoprostol
45608293|NCT03476447|Other|B. infantis EVC001|A once-daily oral feeding of B. infantis EVC001 will be mixed with breast milk and provided to infants for 28 consecutive days.
45608294|NCT03476447|Other|Lactose|A once-daily oral feeding of a lactose placebo will be mixed with breast milk and provided to infants for 28 consecutive days.
45608295|NCT03479801|Procedure|Thyroid Surgical Methods|Different methods of thyroid surgery, including conventional open thyroidectomy, transoral endoscopic thyroidectomy via vestibular approach, and endoscopic thyroidectomy via breast approach.
45608296|NCT03479645|Behavioral|Serial text messages and mailed FIT kit|"Pre-alert SMS offering Opt-out of mailed FIT kit~Mailed home FIT kit~SMS A - Reciprocity message~SMS B - Offer for second FIT kit if lost/did not receive~Plus SMS A + C if second mailed FIT is requested.~SMS C - Salience message"
45608297|NCT03479567|Other|Gait accelerometry|accelerometric assessment of gait (Dynaport Hybrid): 7m walk in 3 conditions (normal pace, fast, double task)
46067549|NCT00595335|Drug|Rituximab|Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
46067550|NCT00595335|Drug|Saline|Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
46067551|NCT00595335|Drug|Methylprednisolone|Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
46067552|NCT00781417|Dietary Supplement|Vitamin D|50,000 IU once a week for 12 weeks then every other week for 40 weeks
46067553|NCT00781417|Other|Placebo|Matching Placebo
46067554|NCT00781495|Device|Sensewear Bodymedia armband|To assess physical activity levels patients will wear Sensewear bodymedia armband
46067555|NCT00672087|Genetic|Genomic and proteomic biomarker discovery|Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods
45608298|NCT03479567|Other|balance accelerometry|accelerometric assessment of balance (Dynaport Hybrid) during 10 seconds trial in 3 conditions (side-by-side, semitandem, tandem)
45608299|NCT03479567|Other|Fine motor skill test|assessment of fine motor skills with Purdue Pegboard, with dominant hand, non-dominant hand and bimanual
46067556|NCT00672165|Biological|ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195|A single infusion of 225Ac-HuM195 will be administered at a starting dose of 0.5 μCi/kg. Additionally, 100 mCi of 213Bi-HuM195 have been administered with full dose cytarabine (200 mg/m2 daily for 5 days) without dose-limiting toxicity.Serial sampling of blood, urine, and bone marrow will be performed following treatment to determine the toxicity, pharmacokinetics, immunogenicity, and antileukemic effects. Three to six patients will be treated at each dose level. Dose escalation will proceed if less than 33% of patients in a cohort experience dose-limiting toxicity.Patients will be followed until completion of therapy as outlined in the study, loss to follow-up, death, or until the day the patient is removed from the study.
46067557|NCT00661609|Drug|AZD4877|Intravenous (IV)25mg/weekly
46067558|NCT04293809|Drug|Exparel Injectable Product|bupivacaine liposome injectable suspension
46067559|NCT04293809|Drug|Bupivacaine Hydrochloride|1.3%, 13.3 mg/mL
45757763|NCT03335540|Biological|Relatlimab|Specified dose on specified day
46067560|NCT00672321|Genetic|gene expression analysis|
46067561|NCT00672321|Genetic|mutation analysis|
45444869|NCT01304745|Behavioral|Physical training in group|Physical training in group, 6-9 participants, two times av week (1.5 hours) over a period of 16 weeks, focusing on strength and endurance training including body awareness and relaxation.
46067562|NCT00672321|Genetic|polymorphism analysis|
45608300|NCT03479567|Diagnostic Test|Paratonia Assessment Instrument (PAI)|diagnosis of paratonia based on passive movement of the four limbs
46067563|NCT00672321|Other|laboratory biomarker analysis|
46067564|NCT00672321|Other|questionnaire administration|
46067565|NCT04153071|Device|OPUS system|Each subject will have a single cutaneous treatment of their lower abdomen, with variable treatment parameters. Punch biopsies will be obtained from each treatment section, for in-vivo histological evaluations.
45608301|NCT03479567|Other|myotonometric measurement of muscle tone|MyotonPRO measurement of muscle tone
45608302|NCT03479489|Other|Human dehydrated amnion chorion allograft|Closed hemorrhoidectomy patched with dehydrated human amnion chorion allograft
45757764|NCT03335540|Biological|Cabiralizumab|Specified dose on specified day
45757765|NCT03335540|Biological|Ipilimumab|Specified dose on specified day
45757766|NCT03335540|Drug|IDO1 Inhibitor|Specified dose on specified day
45757767|NCT03335540|Radiation|Radiation Therapy|Specified dose on specified day
45911362|NCT02007083|Procedure|Spinous Process Osteotomy (SPO)|
45911363|NCT02007148|Drug|capecitabine|twice a day
45608303|NCT03479411|Drug|Itraconazole Powder|Itraconazole administered as a dry powder for inhalation (PUR1900)
45608304|NCT03479411|Drug|Itraconazole 200 mg|Sporanox® Oral Solution
45911364|NCT02007148|Drug|Docetaxel|cycles repeated every 3 weeks
45911365|NCT02007161|Drug|Diclofenac potassium 50 mg|Diclofenac potassium 50 mg
46067566|NCT00672399|Drug|exenatide|Subcutaneously injected, 10 mcg, single doses
46067567|NCT00672399|Drug|Moxifloxacin|oral, 400 mg tablet, single doses
46067568|NCT00672399|Drug|Placebo|Subcutaneously injucted in an amount equivalent to exenatide; or orally as a tablet identical in appearance to Moxifloxacin. Both are single doses
46067569|NCT00661531|Drug|Estrace|Estrace 10 mg three times daily will be administered for 3 months.
46067570|NCT00661531|Drug|Anastrozole|After 3 months of estrace, patients who do not have evidence of disease progression will then be switched to received Anastrozole 1 mg daily as long as their disease benefits from this treatment
46067571|NCT00998309|Drug|Azithromycin SR|Zithromax SR 2g, taking once for treatment.
46067572|NCT02629575|Device|stenting with the Coroflex ISAR sirolimus-eluting stent|coronary stenting
46067573|NCT00791791|Procedure|standardized pain stimulus|a tetanic stimulus (30s, 50 Hz, 60mA) applied as standardized pain stimulus
46067574|NCT00781573|Drug|Clopidogrel|Clopidogrel, 75 mg QD, for one year
46067575|NCT04293965|Drug|Single ascending dose of X842|A total of 7 dose groups will be set for the ascending dose: 5.6 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 225 mg. In the 5.6 mg dose group, 4 subjects will receive X842; in the 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 225 mg dose groups, 8 subjects in each group will receive X842. Each subject can only receive a certain dose level and cannot enter in multiple dose groups repeatedly.
46067576|NCT04293965|Drug|Multiple ascending dose of X842|Two dose groups will be set, including the groups receiving the recommended phase II dose and a higher dose; Eight subjects will be enrolled in each group, with half male and half female, who will receive X842 once daily for 5 consecutive days. Each subject can only receive a certain dose level and cannot enter in multiple dose groups repeatedly.
46067577|NCT04293965|Other|Food Effect|Twelve subjects (appropriate ratio of male to female) screened for eligibility will be randomized into Group A and B. The 6 subjects in Group A will take the study drug (X842) in fasted condition and subject in Group B will take the study drug in fed condition in the 1st cycle. In the 2nd Cycle, subjects in Group A will take the study drug in fed condition, and subjects in Group B will take the study drug in fasted condition. The interval between the two cycles is at least 7 days.
45608305|NCT03476057|Diagnostic Test|Device： NGS sequencing cfDNA|NGS sequencing cfDNA and Tumor Burden
45608306|NCT03131297|Procedure|treatment by radiofrequency|Radiofrequency might destroy fistula tract without lesion of anal sphincter.
45608307|NCT04134455|Procedure|Mesh reinforcement|Once the surgery is over. The closure is made with the 4: 1 rule, then an onlay mesh is placed that exceeds 3 cm on each side the wound is fixed with suture.
45608308|NCT04134455|Procedure|RTL reinforcement|Once the surgery is finished, the ared is reinforced by placing a longitudinal suture parallel to the edge of the wound 0.5 cm, then the wound is closed with a 4: 1 rule but the suture enters lateral to the reinforcement suture
46067578|NCT00672789|Behavioral|Blood smear education|education at baseline and three month follow-up
46067579|NCT00672789|Other|standard education|standard education
46067580|NCT00791947|Drug|CHOEP + G-CSF followed by BEAM|"CHOEP:~Cyclophosphamide: 750 mg/m2 i.v. day1 Hydroxydaunorubicin: 50 mg/m2 i.v. day1 Vincristine: 1.4 mg/m2 (max 2 mg) i.v. day 1 Etoposide: 100 mg/m2 i.v. day 1-3 Prednisone: 100 mg daily p.o. day 1-5~BEAM:~Carmustine: 300 mg/m2 i.v. day 1 Etoposide: 100 mg/m2 i.v. x2 daily day 2-5 Cytosine arabinoside: 200 mg/m2 i.v. x2 daily or 400 mg/m2 as continuous 24 hrs i.v. infusion, day 2-5 Melphalan: 140 mg/m2 i.v. day 6"
46067581|NCT02629263|Dietary Supplement|Viscous Fiber|Meta- analysis of Randomized Controlled Trials
45608309|NCT03131375|Drug|Dexmedetomidine|Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group A receives a 50 ml NS infusion containing 1 mcg kg-1 Dexmedetomidine drug Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B, and 0.16 mg kg-1 in Group A. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index , Train of four ratio.
45608310|NCT03131375|Drug|Normal saline|Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group B receives a volume matched Normal saline infusion. Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index, Train of four ratio.
46067582|NCT00671541|Drug|Merogel Nasal Stent and Nasopore Stent|Merogel Nasal Stent and Nasopore Stent
46067583|NCT00671541|Drug|Nasopore Stent and either Gentamycin or Bacitracin|Nasopore Stent with Bacitracin (100,000 units in 10cc(NSS)or Gentamycin(80mg in 10cc NSS)
45608311|NCT03131375|Device|Bispectral index|Group A and B: Monitoring depth of anesthesia by BIS device and adjusting propofol infusion according to measurements, aiming to BIS values: 40-60
45608312|NCT03131375|Device|Train of four ratio|Group A and B: Monitoring recovery of neuromuscular function with TOF-Watch device, to ensure TOFR equals or greater than 90% at the end of the procedure
45608313|NCT03475901|Other|Virtual Reality App|Virtual reality app produced by KindVR played via a stereoscopic head mounted display (Samsung GearVR) and headphones that the patient will wear over their eyes and ears.
45608314|NCT03479333|Device|Short implant|Short implant will be placed depending on the previous randomization. For that, a surgical access will be done, and the implant will be placed, cover screw will be installed and the access closed. The patient will receive the definitive crown after five months after the short implant installation.
45608315|NCT03479333|Device|Standard implant with sinus lift|First, a surgical access will be performed, followed by sinus lift procedure. Next, a standard implant will be placed, cover screw will be installed and the access closed. The patient will receive the definitive crown after five months after the short implant installation.
45608316|NCT03475823|Dietary Supplement|Sideritis Scardica|Sideritis Scardica is a popular, naturally un-caffeinated Eastern European tea extract derived from the ironwort plant
45608317|NCT03475823|Dietary Supplement|Ginkgo biloba|Ginkgo biloba is an extract from the ginkgo tree comprising ginkgolides and bilobalide. In this trial Ginkgo acted as an active control.
45608318|NCT03475823|Dietary Supplement|Placebo control|An inert encapsulated powder provided by Finzelberg.
45608319|NCT03479177|Behavioral|High Intensity Interval Training|The exercise sessions will be based on exercises the participant can confidentially engage in (regular push-ups vs. knee push-ups vs. wall push-ups). The goal will be to engage in three exercise sessions per week. The participants will receive weekly telephone calls during the first month and bi-weekly calls during months 2 and 3. The exercise counselor will also engage in dialogue that will motivate the participant to exercise.
46067584|NCT00781729|Behavioral|Yoga, one hour class, 3 times per week, for 24 weeks|Yoga, one hour class, 3 times per week, for 24 weeks
46067585|NCT00781729|Behavioral|Luncheon Seminar Series, once per month, for 24 weeks|Luncheon Seminar Series, once per month, for 24 weeks
46067586|NCT04152681|Drug|Apatinib|Apatinib with a dosage of 250mg once daily for 4 weeks, in the absence of unacceptable toxicity or severe deterioration.
46067587|NCT00999713|Drug|Calfactant|Endotracheal calfactant, up to 3 doses if subject qualifies
45608320|NCT03946553|Other||No intervention
45608321|NCT05259293|Other|No intervention - retrospective study|This is a retrospective study. No intervention.
45608322|NCT05259215|Other|physiotherapy|Standard usual care physiotherapy after stroke
45444870|NCT01304745|Behavioral|Educational and counseling in group|Educational and counseling groups with 6-9 participants, with seven group meetings 2.5 hours over a period of seven weeks. Each session starts with a (20 minutes) lecture were one out of seven different topics are presented (Fatigue, sexuality, coping and coping strategies, etc).
45444871|NCT03792945|Drug|local injection|In addition to the local injection, carpal tunnel brace will be given.
45608323|NCT03479021|Diagnostic Test|Welch-Allyn Spot Vision Screener|photograph of the eye
45608324|NCT03475589|Drug|apatinib|Patients with advanced (stage IV) gastric cancer, non-small-cell lung cancer (NSCLC), breast cancer or ovarian cancer will be included in this study to receive apatinib treaetment starting from 250 mg Qd and closely monitored for ADRs during apatinib treatment, with dosage adjustment performed as needed to make the treatment tolerable to the patients.
45608325|NCT03929471|Other|Target weight correction protocol|The intervention group will undergo target weight correction process based on time averaged fluid overload measurement (by bio-impedance).
45608326|NCT03478709|Other|volume expansion|Volume expansion when the patient has a dependent preload evaluated by a positive leg lever test (variation of more than 10% of the VES). It corresponds to the intravenous administration of 500 ml of Ringer lactate over 10 min.
45608327|NCT03478709|Other|norepinephrine|Vasopressor agent when the patient has persistent arterial hypotension related to postoperative vasoplegia syndrome. Norepinephrine is administered during persistent hypotension (MAP <60mmHg) despite volume expansion. It corresponds to continuous intravenous norepinephrine administration to obtain a MAP of more than 70 mmHg
45608328|NCT03478631|Other|High-nitrate dehydrated vegetable powder|A mixed combination of vegetable powders that are naturally high in nitrate content, such as beet, spinach, and kale
45608329|NCT03478631|Other|Low-nitrate dehydrated vegetable powder|A mixed combination of vegetable powders that are naturally low in nitrate content, such as peas, tomato, broccoli, carrots, and brussel sprouts
45608330|NCT03478475|Dietary Supplement|cholecalciferol (Euro-Pharm International, Canada)|
45757768|NCT05265494|Device|Non invasive neuromodulation NESA (XSIGNAL device)|"The study volunteers are treated with the NXSIGNAL® device in sessions of 60 minutes, twice a week and for 5 weeks (10 sessions).~• The skin must be clean, free of creams and grease, lectrodes are connected to the control console and the targeting electrode located in over the intervertebral area between C7 and T1 (cervical area) and will follow the central treatment pattern with the following combination:~2 sessions: Program 1 (30 min), Program 7 (15min) and Program 8 (15min).~4 sessions: Program 2 (15min), Program 7 (30 min) and Program 8 (15min)~4 sessions: Program 7 (60min)"
45757769|NCT04278638|Radiation|IORT|IORT in surgery of laryngocarcinoma
45608331|NCT03478475|Other|Placebo|Placebo pill (microcrystalline cellulose 66.3%, starch 33.2%, magnesium stearate 0.5%)
45608332|NCT03475433|Device|Actigraphy device|Both groups will receive an actigraphy device that will passively measure their movement data.
45608333|NCT03475355|Behavioral|Live movement observation (Upper Limbs)|"All participants will be subjected to two 15-minute sessions per day of the Live movement observation of the upper limbs. The activities of the upper limbs will be based on some relevant activities of daily life such as drinking from a glass, combing, opening a box or eating an apple. The tasks will be both unimanual and bimanual.~Every day, before starting the physical training, the patient will be asked to look carefully at the therapist who shows 20 different daily routine activities (actions) performed with the upper limb."
45608334|NCT03475355|Behavioral|Video Observation (Upper Limbs)|"All participants will be subjected to two 15-minute sessions per day of the video observation of upper limbs movements. The activities of the upper limbs will be based on some relevant activities of daily life such as drinking from a glass, combing, opening a box or eating an apple. The tasks will be both unimanual and bimanual.~Every day, before starting the physical training, the patient will be asked to carefully watch a video showing 20 different daily routine activities (actions) performed with the upper limb."
45757770|NCT04278638|Procedure|surgery|total laryngectomy or hemilaryngectomy
45757771|NCT04278638|Radiation|External radiotherapy|External radiotherapy
45757772|NCT05255822|Drug|INNA-051|Liquid for intra-nasal administration
45757773|NCT05255822|Other|Placebo|Liquid for intra-nasal administration
45757774|NCT05514470|Other|Skin biopsy|"A skin biopsy performed on the forearm or thigh depending on the patient's age and wishes, with a biopsy punch with a diameter of 3 to 4 mm depending on the child's age (3 for children under 3 years, 4 beyond).~Culture of fibroblasts and immortalization."
45757775|NCT00643097|Biological|PEP-3 vaccine|Given intradermally
45757776|NCT00643097|Biological|sargramostim|Given intradermally
46067588|NCT00999713|Other|Air placebo|Endotracheal air administration
45444872|NCT03792945|Device|extracorporeal shock wave therapy|In addition to all ESWT participants, carpal tunnel brace will be given.
45444873|NCT05579925|Biological|CM310|CM310 600 mg + 300 mg, subcutaneous injection
45444874|NCT01304823|Dietary Supplement|lactisole|flavoring agent/sweet taste antagonist
45444875|NCT01304823|Other|mixed liquid meal|Ensure Plus
45757777|NCT00643097|Drug|Temozolomide|Standard of care chemotherapy
45757778|NCT03333668|Drug|Lisdexamfetamine dimesylate|Lisdexamfetamine dimesylate (30mg for smaller, 50mg for larger boys) tablet
45757779|NCT03333668|Drug|Guanfacine Extended Release Oral Tablet|Guanfacine Extended Release (0.05mg/kg) tablet
45757780|NCT03333668|Drug|Placebo|Vitamin C (10mg) tablet
45911366|NCT02007174|Drug|Bevacizumab|
46067589|NCT00781807|Other|multi-module rehabilitation program|"The multi-module rehabilitation program includes:~Nutrition management~Home-based ergometer training program~Psychosocial support"
46067590|NCT00672867|Drug|Clevudine|30mg
45608335|NCT03475355|Behavioral|Live Movement Observation (Lowe Limbs)|"All participants will be subjected to two 15-minute sessions per day of the Live movement observation of the lower limbs. Tasks to avoid freezing will be based on strategies such as touching the thigh, taking side or back steps, counting out loud while walking.~Every day, before starting the physical training, the patient will be asked to carefully watch the therapist who will show 20 different movement strategies to avoid episodes of freezing the pace (FOG)."
45608336|NCT03475355|Behavioral|Video Observation (Lower Limbs)|All participants will be subjected to two 15-minute sessions per day of the video observation of lower limbs movements. Tasks to avoid freezing will be based on strategies such as touching the thigh, taking side or back steps, counting out loud while walking. Every day, before starting the physical training, the patient will be asked to carefully watch a video that will show 20 different movement strategies to avoid episodes of freezing the pace (FOG).
46067591|NCT00672867|Drug|Adefovir dipivoxil|10mg
45608337|NCT03475355|Behavioral|Static Picture Observation and Upper Limbs Exercise|"Participants will watch for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. The patient will be presented a sequence of images for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, they will be displayed together with an intrusive image (intruder) that the patient you will be asked to identify so that your attention span can be controlled in real time. Participants will then be invited to perform limb movements as far as possible for 2 minutes according to a standard sequence involving joint mobilisations of upper limbs, and simulating that performed by the experimental groups."
45608338|NCT03475355|Behavioral|Static Picture Observation and Lower Limbs Exercise|"Participants will watch for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. The patient will be presented a sequence of images for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, they will be displayed together with an intrusive image (intruder) that the patient you will be asked to identify so that your attention span can be controlled in real time. Participants will then be invited to perform limb movements as far as possible for 2 minutes according to a standard sequence involving joint mobilisations of lower limbs, and simulating that performed by the experimental groups."
46067592|NCT00786721|Device|Diffuse Optical Spectroscopy|muscle properties scanning
46067593|NCT00997373|Drug|Letrozole|2.5 mg daily from the day of enrollment to the day before surgery, generally about 3 weeks
46067594|NCT04152759|Drug|Drug: BAT2506 injection Other Names: Simponi(EU-licensed)|"Drug: BAT2506 injection Each subject will receive single subcutaneous injection of 50 mg BAT2506 Injection or Simponi(EU-licensed).~Other Names:~Simponi(EU-licensed)"
45911367|NCT02007174|Drug|Medical Treatment|Care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
46067595|NCT04047043|Diagnostic Test|serum taurine|blood sample for serum taurine level
46067596|NCT00672945|Drug|PRX-03140|
46067597|NCT00672945|Drug|Placebo|
46067598|NCT02869607|Other|Data collection|
46067599|NCT00792025|Drug|sunitinib malate|
46067600|NCT00786877|Other|Improved biomass cookstove with exterior ventilation|Improved cookstove design installed in house that is higher efficiency and is vented to the exterior.
46067601|NCT00786877|Other|Phase 2 intervention arm (LPG stove)|LPG two burner stove with a 12 month supply of LP gas.
46067602|NCT04293731|Dietary Supplement|Symbiter-Smectite|Symbiter-Smectite contains biomass of alive probiotic microorganism symbiosis, colony forming units - CFU/g: Lactobacillus - 1.0х109, Bifidobacterium - 1.0х109, Lactococcus - 1.0х108, Propionibacterium - 1.0х108 and Acetobacter - 1.0х105; and smectite gel (250 mg)
46067603|NCT04293731|Dietary Supplement|Placebo|Placebo
46067604|NCT00673023|Other|Dietary experiments|Dietary Supplement: high PUFA diet followed by high SFA diet
46067605|NCT02870231|Drug|NNC9204-0530|Once-daily subcutaneous (s.c., under the skin) administration.
46067606|NCT02870231|Drug|liraglutide|Once-daily subcutaneous (s.c., under the skin) administration.
46067607|NCT02870231|Drug|placebo|Once-daily subcutaneous (s.c., under the skin) administration
46067608|NCT02554747|Device|Navigated laser|Aflibercept, Navilas®
46067609|NCT02554747|Device|Conventional laser|Aflibercept, Pascal
46067610|NCT00911781|Other|No intervention|We are only asking for photographs from parents.
46067611|NCT02869685|Radiation|radiotherapy|
46067612|NCT00663871|Dietary Supplement|Fish Oil|Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.
46067613|NCT00663871|Dietary Supplement|Soybean Oil (Placebo)|Participants will take 2 grams of soybean oil supplements on a daily basis.
46067614|NCT02869919|Other|AKI|Vitamin D levels
46067615|NCT04152447|Device|VR device|Patients use a VR device
46067616|NCT00628979|Behavioral|CBT|cognitive- behavioral treatment for panic disorder.
46067617|NCT02629029|Procedure|Pre-op CTA with IV contrast|Preoperative mapping of perforators by computed tomography angiography (CTA) could prove valuable in head and neck free flap transfer and shorten the operation time significantly. This modality could provide useful information for H&N cancer reconstruction in difficult cases, especially in patients with large or through-and-through defects that might need multiple perforators in flap design. In addition, near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) angiography can provide robust, intraoperative, objective data to optimize the free flap skin paddle design while potentially minimizing patient morbidity.
46067618|NCT02629029|Device|Computed tomography angiography (CTA)|
46067619|NCT02870075|Behavioral|Fed exercise|Participants consumed a meal (Fed) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
46067620|NCT02870075|Behavioral|Fasted exercise|Participants remained fasting (Fasted) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
46073602|NCT00620113|Dietary Supplement|Vitamin D3|Two Vitamin D3 tablets (5600 IU total) taken orally once weekly for 52 weeks.
46067621|NCT02629341|Dietary Supplement|Functional yogurt powder|"Once daily during 24 weeks, 150g of yogurt powder enriched with:~Calcium (mg) 501 D3 Vitamin (Colecalciferol) (μg(UI)) 6(240) K Vitamin (μg) 80 C Vitamin (mg) 100 Zinc (mg) 10,39 Magnesium (mg) 250,5 L-Leucin (g) 1 Lactobacillus plantarum 3547 (ufc) 1x10e10"
45608339|NCT03475199|Device|FabLife|"A personnalized dietary program depending on the patient's phenotype and genotype~The daily intake of a dietary supplement, developped in the context of male infertility."
46067622|NCT02629341|Dietary Supplement|Control yogurt powder|Once daily during 24 weeks, 150g of yogurt powder not enriched, isocaloric and with an equal macronutrient composition than the functional yogurt
46067623|NCT02869997|Device|Aspect BIS XP (A-2000) Bispectral Index Patient Monitor|
46067624|NCT00782041|Drug|Oxaliplatin|85 mg/m²
46067625|NCT00782041|Drug|5-FluoroUracil|2,000 mg/m²
45608340|NCT03645707|Behavioral|CAR Training and Psychoeducational Sessions|"Participation in the CAR Training Program, a 1-day training program developed by the J&J Human Performance Institute (HPI). The CAR Training Program uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.~Participants will attend eight weekly follow-up psychoeducational group sessions facilitated by a licensed mental health counselor that will meet for 90 minutes. The themes of these sessions will be RISE - Resilience, Insight, Self-Compassion, and Empowerment. Due to limited time and flexibility in sessions, participants will practice skills through optional homework activities to facilitate learning between sessions."
45608341|NCT03475121|Combination Product|Combination Chemotherapy plus Intrathecal Topotecan|Adjuvant chemotherapy with a reduced dose (compared to GALOP I protocol) of carboplatin
46067626|NCT00782041|Drug|Folinic acid|20 mg/m²
46067627|NCT00673491|Other|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period. Defining characteristics of clinical pathways includes: an explicit statement of the goals and key elements of care based on evidence, best practice, and patient expectations; the facilitation of the communication, coordination of roles, and sequencing the activities of the multidisciplinary care team, patients and their relatives; the documentation, monitoring, and evaluation of variances and outcomes; and the identification of the appropriate resources.
46067628|NCT00673569|Drug|erlotinib hydrochloride|
45608342|NCT03475121|Combination Product|Higher Dose Combination Chemotherapy plus Intrathecal Topotecan|GALOP I-based systemic adjuvant therapy plus intrathecal topotecan
45608343|NCT03475121|Combination Product|Higher Dose Combination Chemotherapy plus Intrathecal Topotecan and Orbital Radiotherapy|GALOP I-based systemic adjuvant therapy plus intrathecal topotecan and orbital radiotherapy (45 Gy) up to chiasm
46067629|NCT00673569|Genetic|gene expression analysis|
45608344|NCT03475121|Other|No Adjuvant Therapy|Patients will not receive any adjuvant therapy after enucleation of the affected eye.
45608345|NCT03478319|Drug|ACE-2494 or placebo|Recombination fusion protein
45608346|NCT03131063|Other|Antibiotic plasma dosage|Measurement of the concentration of antibiotics administered as part of the routine care of intensive care patients
45608347|NCT03474809|Device|Blood sampling|Daily blood samples which will be taken for the PSP measurement using the AbioScope as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein [CRP] and Procalcitonin [PCT]).
45608348|NCT03478241|Device|Group 1: single file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using OneShape Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
45608349|NCT03478241|Device|Group 2: multiple file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using Revo S Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
45608350|NCT03478241|Device|Group 3: single file reciprocal motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using WaveOne Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
46067630|NCT00673569|Genetic|protein expression analysis|
46067631|NCT00673569|Other|immunoenzyme technique|
45444876|NCT05571579|Biological|blood and/or csf collection|"blood and/or collection~Only once :~1 tube of blood of 4 mL on dry tube with or without gel,~2 tubes of blood of 4 mL on EDTA tube, If CSF collected for diagnosis is available, it can be sent for storage in the collection."
45608351|NCT02523755|Drug|Epidural analgesia Ropivacaine|Measurement of regional distribution as assessed by EIT before and after injection of local anesthetics
45608352|NCT02523755|Drug|Absence of epidural analgesia|Measurement of regional distribution as assessed by EIT before and after delivery
46067632|NCT00673569|Other|immunologic technique|
46067633|NCT00673569|Other|laboratory biomarker analysis|
46067634|NCT00673569|Procedure|needle biopsy|
46067635|NCT00787033|Drug|PF-04554878|Oral pills at increasing dose twice daily, 21 day cycle, continuous treatment schedule until progression of disease, unacceptable toxicity, or patient request. Some patients will undergo serial biopsy and/or FDG-PET imaging
46067636|NCT00792181|Drug|Midazolam|Midazolam 1 mg: 70 years or more and less than 70 kg Midazolam 2 mg: under 70 years and 70 kg or more
46073603|NCT00620113|Dietary Supplement|Calcium carbonate|Calcium carbonate 500 mg tablet taken orally every day for 52 weeks.
45444877|NCT01304901|Drug|montelukast 4 mg granule|Children had received single dose of 4 mg oral montelukast after first dose of nebulized salbutamol and systemic glucocorticoids.
45444878|NCT01304901|Drug|Montelukast placebo granüle|Children had received single dose of oral placebo montelukast granule after first dose of nebulized salbutamol and systemic glucocorticoids.
45444879|NCT02953899|Behavioral|Contingency Management|In addition to Cognitive Behavioural Therapy, this intervention uses small incentives to reinforce study attendance and gambling abstinence.
45444880|NCT02953899|Behavioral|Cognitive Behavioural Therapy|This intervention uses psychoeducation, behavioural strategies, and cognitive restructuring to assist the participant in their efforts to become abstinent from gambling.
46067637|NCT00792181|Other|Course intervention - a professional development course for caregivers.|The nursing intervention involves a professional development course for caregivers. The course is expected to deepen the caregivers' knowledge about the encounter with patients as well as cardiovascular treatment.
45608353|NCT05258123|Drug|Ginkgo Biloba Extract|Ginkgo biloba extract with 360mg was administered
45608354|NCT05258123|Drug|Placebo oral tablet|Placebo with nine tables was administered
45608355|NCT03478085|Other|Oxygen guided exercise therapy|Subjects exercise to a certain intensity based on 15% muscle oxygen desaturation.
45608356|NCT02168842|Drug|Isradipine|Oral capsules Isradipine IR, up to 10 mg, taken twice daily
45608357|NCT02168842|Drug|Placebo (for Isradipine)|Sugar Pill manufactured to look like Isradipine but has no active ingredients
45608358|NCT02200042|Radiation|Image Guided Radiation Therapy|Patients undergo 15 fractions of image-guided radiation therapy delivered over 19-26 or 27-34 days.
45608359|NCT02199028|Drug|Hyaluronidase|150 units/ml - subjects injected 1 milliliter (ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.
46067638|NCT00673647|Behavioral|Cognitive-behavioral treatment|10 sessions of individual psychotherapy including cognitive-behavioral treatment, motivational enhancement and a psychosocial problem training.
46067639|NCT00792337|Drug|simvastatin|10 mg per oral once daily for 8 weeks
46067640|NCT00792337|Drug|B1-6-12|1 table per day for 8 weeks
45757781|NCT03280160|Drug|Ibrutinib 140 MG Oral Capsule [Imbruvica]|"Ibrutinib will be administered orally 420 mg (3 x 140 mg capsules) once daily on a continuous schedule on an outpatient basis until disease progression or unacceptable toxicity.~After 12 cycles of ibrutinib, patients that do not achieve a complete response (CR) will be treated with the combination of ibrutinib and ofatumumab. Patients in CR after 12 cycles of ibrutinib will continue with ibrutinib alone.~Ofatumumab will be administered by IV infusion, 300mg on Day 1 and 1,000 mg on Day 8 of cycle 13, followed by 5 monthly infusions of 1,000 mg (Day 1 of subsequent 28-day cycles for cycles C14, C15, C16, C17, and C18).~A treatment cycle will be defined as lasting 28 days"
45757782|NCT04683315|Drug|mFOLFIRINOX Treatment Regimen|This therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).
45757783|NCT04683315|Drug|Gemcitabine/Nab-paclitaxel Treatment Regimen|This regimen will be nab-paclitaxel and gemcitabine.
46067641|NCT00673725|Drug|Locobase® REPAIR|emollient
46067642|NCT00787111|Drug|Fluoxetine (prozac)|Formulation: ODT
46067643|NCT00673803|Procedure|cataract surgery|cataract surgery with implantation of an IOL
46067644|NCT04152525|Other|Psychoeducation|The mindfulness-based education programme that was conducted by the researcher and aimed at increasing self-efficacy in substance addicts was conducted within eight sessions, 2 days a week for 4 weeks.
46067645|NCT00782197|Device|PRGF Intraarticular injection|Three consecutive PRGF injections each one week apart.
45444881|NCT01304979|Procedure|Acupuncture therapies|Acupuncture therapies combined in treatment: application of ear seeds; acupuncture; and acupuncture with gua sha treatment designed to relieve pain and facilitate recovery.
45757784|NCT04683315|Radiation|Chemoradiation|50.4 Gy in 28 fractions.
45757785|NCT05502146|Drug|Noradrenaline Bitartrate|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
46067646|NCT00782197|Device|Hyaluronic Acid Intraarticular injection|Three consecutive Hyaluronic acid (EUFLEXXA) injections, each one week apart.
45444882|NCT01304979|Procedure|Control|Indirect therapies that mimic direct therapy intervention
45757786|NCT05502146|Drug|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.5 mL)
46067647|NCT04152291|Dietary Supplement|Ethyl-Eicosapentaenoic Acid (E-EPA)|3,9 grams of EPA is added to participants' normal diet.
46067648|NCT00782353|Drug|ANA598 200 mg bid or placebo|ANA598 200 mg bid or placebo
46067649|NCT00782353|Drug|ANA598 400 mg bid or placebo|ANA598 400 mg bid or placebo
46067650|NCT00782353|Drug|ANA598 800 mg bid or placebo|ANA598 800 mg bid or placebo
46073604|NCT00620113|Drug|Placebo|Dose-matched placebo tablets to odanacatib, taken orally once weekly for 52 weeks.
46073605|NCT00830115|Drug|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
46073606|NCT02824302|Other|Survey|Patients coming for induction of labor will be handed a survey regarding their expectation of their coming labor pain. And then will be followed up after 24 hours of their delivery.
46073607|NCT02824068|Drug|glucosidase alfa|Long-term use in an observational study of licenced drug
46073608|NCT00633672|Drug|Esomeprazole|20mg Oral tablet once daily
46073609|NCT00633672|Drug|Ranitidine|150mg oral twice daily
46073610|NCT00633672|Drug|Esomeprazole|40mg oral tablet once daily
45608360|NCT02199028|Other|Control|No hyaluronidase administered into insulin infusion set.
45608361|NCT03347123|Drug|Epacadostat|Phase 1: Epacadostat at the protocol-defined dose twice daily. Phase 2: Epacadostat at the recommended dose from Phase 1.
45608362|NCT03347123|Drug|Nivolumab|Nivolumab at the protocol-specified dose and schedule.
45608363|NCT03347123|Drug|Ipilimumab|Ipilimumab at the protocol-specified dose and schedule.
45608364|NCT03347123|Drug|Lirilumab|Lirilumab at the protocol-specified dose and schedule.
45608365|NCT03474419|Procedure|laser surgery|laser surgery
45608366|NCT03131141|Drug|BC-3781|Lefamulin (BC-3781) is a potent, semi-synthetic antibacterial belonging to a novel class for systemic human use known as the pleuromutilins
45608367|NCT05258045|Radiation|F18 FDG|Radioactive material
45608368|NCT03477929|Drug|Ganirelix Acetate|multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
45608369|NCT03477929|Drug|Cetrorelix Acetate|multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
45608370|NCT03474341|Diagnostic Test|MRI|"Anatomical (T2W) and functional MRI (DWI and DCE) at a 1.5T Siemens or Philips scanner~DWI series: sagittal (sIVIM) and high-resolution transversal (HR tDWI)~DCE serie: dynamic20~In total, three MRI scan series (before, during, after nCRT)~Measurements: i.a. change in apparent diffusion coefficient (ADC) or area-under-the-gadolinium-concentration time curve (AUC) within tumor delineation over time, radiological (qualitative) assessment of residual disease"
46067651|NCT00996593|Biological|Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)|Patients will receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of Anti-B1 Antibody (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of 35 mg Anti-B1 Antibody containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,001-149,999 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
46067652|NCT00570661|Drug|ITF2357|ITF2357 orally administered at the cumulative daily dose of 1.5 mg/kg, achieved by administration of different dose strengths identifiable by different colours.
45608371|NCT03474341|Diagnostic Test|PET-CT|"According to European Association of Nuclear Medicine (EANM) Research Ltd guidelines (EARL)~In total one additional PET-CT (during nCRT) for study purposes. A PET-CT scan at diagnosis and after nCRT are included in the standard diagnostic work-up for esophageal cancer.~Measurements: i.a. change in TLG (Total Lesion Glycolysis), SUVmax (Standardized Uptake Value) or Ktrans within tumor delineation over time"
46067653|NCT00787345|Other|simulation based training|simulation based training in aseptic techniques that included specified AT categories
46067654|NCT02870153|Drug|SOX|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days
45444883|NCT05624853|Drug|pregabalin sustained release tablet|pregabalin sustained release tablet 150mg qd for 8weeks
45444884|NCT05624853|Drug|pregabalin immediate release capsule|pregabalin immediate release capsule 75mg bid for 8weeks
46067655|NCT02870153|Drug|XELOX|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
46067656|NCT00934544|Drug|Ruxolitinib|5 mg tablets packaged as 60-count in high-density polyethylene bottles
46067657|NCT00934544|Drug|Best Available Therapy (BAT)|Prescribing and usage per respective package inserts
46067658|NCT02554669|Behavioral|postprandial and postabsorptive physical activity on treadmill|
46067659|NCT00787501|Drug|SSRI|SSRI: 25 patients will receive 14 weeks of an FDA approved selective serotonin reuptake inhibitor (SSRI), administered under the supervision of a staff psychiatrist. After an initial 30-45 minute session patients will be seen for 15-30 minute sessions for 16-20 sessions over 14 weeks. Medication will begin with 10mg escitalopram daily (or its equivalent), increased to 30 mg/day (or its equivalent) by week 6 if pt has not achieved a minimum level of response (i.e., CGI < 2) and tolerability is adequate. Nonresponse at week 10 (CGI < 2) will be cause for medication switch or augmentation.
46067660|NCT00787501|Behavioral|CBT|Cognitive Behavior Therapy: 40 patients will receive 16- 20 60 minute sessions of procedurally determined Cognitive Therapy (Beck, 1979) over 14 weeks. Patients will begin with 2 sessions per week which may be reduced to once per week in the latter part of the study period if the patient is responding to the therapy. Cognitive Therapy is designed to teach skills that help to reduce depressive severity. Each session will be videotaped and will include homework to be completed and brought to the following session.
46067661|NCT00792493|Drug|ORM-12741|Alternating panel multiple dose escalation
45608372|NCT03474341|Diagnostic Test|Endoscopy|Additional endoscopy and/or endoscopic ultrasonography (EUS) with biopsies of the primary tumor site and other suspected lesions in the esophagus after completion of nCRT and prior to surgery
45608373|NCT03474341|Diagnostic Test|Blood samples|"Blood samples at three different time points (before, during and after nCRT) will be collected~Blood will be collected in cell-free DNA collection tubes~Purpose: isolation of ctDNA and subsequent mutation analysis by means of Next Generation Sequencing~Measurements: the presence of, and changes in, ctDNA during nCRT"
45608374|NCT03477773|Other|High-intensity exergaming|Perform high-intensity exercise whilst playing a developed exergame. A full warm-up performed prior to the session was performed (~70% HRmax). Periods of exercise were performed at an intensity >85% HRmax for periods of 10, 20 and 30s, interspersed with periods of rest, for a total of 2-3 minutes per session. Heart rate was monitored throughout the intervention.
46067662|NCT05325320|Behavioral|SMI/SIA Stigma Reduction Intervention|Online course designed to reduce stigma behaviors towards serious mental illness and suicide ideation and attempt among medical students. It aims to improve medical students' healthcare delivery skills.
46067663|NCT05325320|Other|Disaster Preparedness Course|Online course designed to improve professionals' skills and competencies for engaging in disaster preparedness.
46067664|NCT00787579|Device|Bifocal spectacles|+1.50D bifocal spectacles
46067665|NCT00787579|Device|Prismatic bifocal spectacles|+1.50D bifocal spectacles combined with 3Δ base-in prisms
46067666|NCT04264832|Other|Clinical data collection|"Basic characteristics: Participants were carefully characterized with regard to a general health history, a medical history, clinical, demographic and anthropomorphic measurements, skin problems (hirsutism is modified by Ferriman-Gallwey (mF-G) score , global acne score and premature alopecia).~A transvaginal ultrasound scan was performed on every participant during a clinical examination to determine the number of follicles and ovarian volume.~Metabolic and other assessments: General gynecological examination, prolactin, thyroid, androgen, LH, FSH, DA, 5-HT, metabonomics, glucose, insulin, triglyceride (TG), LDL and HDL were determined, OGTT was performed.~Questionnaires: The perceived stress scale(Chinese 14-item PSS), self-rating anxiety scale (SAS）, self-rating depressive scale(SDS) were used to assess the participants' mental health status. The MOS item short from health survey (SF-36) was used to assess the quality of life ."
46067667|NCT00787657|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients after first clinical events suggestive of MS (according to SMPC) and patients with RRMS within the first two years of diagnosis
46073611|NCT00848653|Device|CRT device|market approved CRT device
46073612|NCT02547103|Other|Chlorhexidine gluconate-soaked cloths|
45444885|NCT02799472|Drug|GSK3196165|GSK3196165 is supplied as liquid and will be administered as SC injection.
45444886|NCT02799472|Drug|Placebo|0.9% weight by volume (w/v) sodium chloride solution administered as SC injection.
46067668|NCT04263662|Other|Analgesia-Sedation algorithm|The analgesia-sedation algorithm is a suggested protocol for approach to providing analgesia and sedation to patients admitted to the pediatric ICU who are newly intubated. The approach focuses on using dexmedetomidine as the primary sedative, non-opioids as the primary analgesia, then stepwise approach to adding in adjunctives (e.g. opioids, non-benzodiazepines) with the intention of minimizing benzodiazepine exposure and utilizing minimal-dose effective analgesia/sedative dosing.
46067669|NCT00999167|Drug|HPN-100|Part B: 6 mL BID for 16 weeks.
45608375|NCT03477695|Device|ambulatory use of the Upright device|Patients will wear the UpRight for a period of two month
45608376|NCT03474263|Biological|Biologic: IC14 (monoclonal antibody against human CD14)|IC14 intravenous infusion daily for four days on two successive weeks then MR-PET Scan evaluation for impact on glial activation.
45608377|NCT05221853|Diagnostic Test|cardiovascular magnetic resonance|CMR scan at 3 Tesla
45608378|NCT02817815|Device|Electrocardiogram (ECG)|
45608379|NCT02817815|Biological|Blood sampling from the cephalic vein|
46067670|NCT00999167|Drug|Placebo|Part B: same as experimental arm
46067671|NCT00787735|Behavioral|Counseling compliance|Rates of attendance to call counseling session over specific time points
45608380|NCT02817815|Biological|Blood sampling from the femoral vein|Blood sampling will be done during radiofrequency ablation of AF procedure, after the introduction of catheter
45608381|NCT02817815|Biological|First blood sampling from left atrium|Blood sampling will be done during radiofrequency ablation of AF procedure, after transeptal punction
45608382|NCT02817815|Procedure|Atrial stimulation|Patients will receive atrial stimulation with the catheter positioned in the coronary sinus to induce AF
46067672|NCT04264754|Procedure|Blood collection|Peripheral blood will be collected via routine venipuncture procedure
45608383|NCT02817815|Biological|Second blood sampling from left atrium|After 20min of continuous AF, a blood sampling from left atrium will be done
45608384|NCT03477617|Other|Intraoperative Hemodynamic Algorithm|Anesthesiologists are instructed to use the study's algorithm to manage intraoperative hypotension in response to the cardiac output monitor values.
45608385|NCT03477617|Combination Product|Usual hemodynamic management|Anesthesiologists are instructed to manage intraoperative hypotension based on their usual clinical care, without information from cardiac output monitor
45608386|NCT03473951|Diagnostic Test|Hyperuricemia|Hyperuricemia vs. normouricemia
45608387|NCT03477461|Drug|terlipressin|a continuous infusion of terlipressin (0.4 mg/kg/h) was initiated
45608388|NCT05084729|Device|Imagio OA/US|Imagio optoacoustic
45608389|NCT02553161|Drug|Escitalopram|Youth in the MED condition will be given the USFDA approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks. Titration will be no faster than 5mg/week. This titration guideline was drawn from the escitalopram package insert for pediatric dosing, which states that target doses may be achieved by 4 weeks.
45608390|NCT02553161|Behavioral|Cognitive behavioral Psychotherapy|All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
45608391|NCT03473717|Device|classic method|"Put the Pozzi forceps to draw the uterus by the cervix to horizontalize it and align uterine cavity in the direct axis of cervix.~Insert the hysterometer to measure the uterus depth.~Locate the uterine depth on the inserter tube."
45608392|NCT03473717|Device|direct method|"Place the ring on the inserter tube 3 to 4 cm from the end as a marker.~Insert the tube into the cervix until you feel the passage of the internal orifice of the cervix or until the ring is in contact with the external orifice of the cervix, the tube does not enter the uterine cavity"
45608393|NCT04987697|Behavioral|counseling|nine 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor (LMHC).
46067673|NCT00782587|Drug|Chemophase|40 mg mitomycin with 800,000 U rHuPH20 total volume of 40 mL instilled
46067674|NCT04293497|Diagnostic Test|Cytology staining|"Two staining will be performed in cytology specimens obtained from same patient. The cytology specimen will be obtained using endoscopic ultrasound-guided fine needle aspiration. Three types of slides (direct smear, thinprep, surepath) are prepared for staining.~conventional cytology staining method~new cytology staining method using antibody of methionyl-tRNA synthetase 1"
46067675|NCT04264676|Drug|Metronidazole Oral Tablet|Supplement of metronidazole 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.
45757787|NCT05502146|Drug|Noradrenaline Bitartrate|An intravenous bolus of norepinephrine 8 mcg will be administered for management of maternal hypotension.
46067676|NCT04264676|Drug|Placebo oral tablet|Supplement of placebo oral tablet 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.
46067677|NCT02869373|Behavioral|spinal stabilizaton exercise|In Exercise group, spinal stabilization exercise program was carried out 3 days a week for 8 weeks.
46067678|NCT00608660|Other|acupuncture|staging acupuncture
46067679|NCT00608660|Other|acupuncture and moxibustion|staging acupuncture and moxibustion
46067680|NCT00608660|Other|electroacupuncture|staging electroacupuncture
46067681|NCT00608660|Other|acupuncture along yangming tendons|staging acupuncture along Yangming musculature
46067682|NCT00608660|Other|acupuncture|non-staging acupuncture
46067683|NCT02869841|Drug|Levobupivacaine continuous infusion|Levobupivacaine continuous infusion to rectus sheath catheters
46067684|NCT02869841|Drug|levobupivacaine bolus dosing|Levobupivacaine bolus dosing to rectus sheath catheters
46067685|NCT02869841|Drug|single bolus of levobupivacaine|Levobupivacaine single dose to rectus sheath catheters
46067686|NCT02869841|Other|Placebo|No rectus sheath analgesia
46067687|NCT00782665|Procedure|Biopsy|1 centimeter x 1/2 centimeter piece cut from uterus
46067688|NCT00607412|Behavioral|Integrated psychotherapy for PTSD and substance use|integrated, present focused psychotherapy for PTSD and substance use disorders tailored to women who have experienced intimate partner violence
46073613|NCT02547103|Other|Normal saline|
45608394|NCT04961723|Diagnostic Test|(OraQuick® HCV Self-Test|The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.
46067689|NCT00607412|Behavioral|12-step based supportive therapy|supportive psychotherapy based on 12-step model
45608395|NCT04459169|Procedure|diagnostic algorithm|Cardiac amyloidosis diagnosed according to Gillmore's algorithm
45608396|NCT02523521|Behavioral|Physical activity program|physical activity program for a bronchopulmonary dysplasia children.
45608397|NCT04458779|Device|CPAP|CPAP will be given after obstructive sleep apnea being diagnosed in the acute stage of stroke.
46067690|NCT00609440|Other|physiotherapeutic treatment|At first, the patient was submitted to a conventional physiotherapeutic treatment and respiratory exercises; then, we gave emphasis to the motor development marks and to the march training; eventually, the kid was conducted to hydrotherapy.
46067691|NCT00637637|Drug|indinavir sulfate|
45444887|NCT02799472|Drug|MTX|Capsule, tablet or liquid administered orally or as SC injection.
45911368|NCT02007174|Drug|Medical Treatment|Care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
45444888|NCT02799472|Drug|Folic (or folinic) acid|Capsule, tablet or liquid and will be administered orally.
45608398|NCT01296581|Drug|X-82|Dose escalation starting at 20 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
45757788|NCT05502146|Drug|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.5 mL)
45757789|NCT02302365|Device|Spectra Optia® Apheresis System|White Blood Cell Depletion
46067692|NCT00637637|Drug|ritonavir|
46067693|NCT00637637|Radiation|radiation therapy|
46067694|NCT00570505|Device|LAP-BAND System|Reduction of food intake due to creation of smaller stomach pouch
46067695|NCT05136482|Device|Cryocompression|A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will exert a constant pressure of 25 mmHg throughout each test session. The device will pump temperature-controlled cold water through the cuff in order to reduce the skin temperature around the knee (and intra-articular temperature). Depending on the condition, the temperature of the water being pumped through the device will be either 6, 8, 10, or 12℃. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature >15℃.
46067696|NCT02869529|Other|Data collection|
46067697|NCT02555995|Device|OCT scan (as yet unnamed)|OCT scan (as yet unnamed) of the eye with investigational device; newly developed sparse OCT retina scanner by Artorg Center Bern and Berner Fachhochschule Biel
46067698|NCT00931892|Dietary Supplement|Gluten|3g
46067699|NCT00931892|Dietary Supplement|Gluten|10g
45757790|NCT03333590|Biological|rAAVrh74.MCK.GALGT2|Adeno-associated virus serotype rh74 carrying the GALGT2 gene under the control of a MCK promoter (rAAVrh74.MCK.GALGT2) will be delivered one time to each of the lower limbs through the femoral artery using an intravascular limb infusion technique (ILI)
45911369|NCT02007174|Procedure|Argon laser treatment|
45911370|NCT02007187|Drug|Danhong injection|A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
45452240|NCT01035502|Drug|Elacytarabine plus idarubicin|"Elacytarabine 1000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.~Idarubicin will be administered IV at a fixed dose of 12 mg/ m2/d IV on d 1-3 q3w.~It is intended that patients receive remission-induction treatment either as two combination courses, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d or one combination course, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d followed by one course elacytarabine 2000 mg/m2/d single therapy."
45452241|NCT01030432|Drug|BMS-650032|Tablets, Oral, 200 mg, Twice Daily, 48 weeks
45911371|NCT02007187|Other|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) (2007) issued by Chinese Society of Cardiology of Chinese Medical Association
45911372|NCT02007187|Drug|Placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
46067700|NCT00666211|Other|educational intervention|Participants will be educated on pain management.
46067701|NCT00666211|Other|Titrated pain management|Pain will be Monitored and Medication Titrated
46067702|NCT00666211|Other|questionnaire administration|Participants will be given questionnaires to complete.
46067703|NCT05331326|Drug|RC48-ADC|RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
46067704|NCT00878709|Drug|neratinib|
46067705|NCT00878709|Other|placebo|
46067706|NCT00927758|Drug|fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg|fluticasone propionate/salmeterol diskus
46067707|NCT00782977|Other|Nasal oxygen therapy|Arm 1: Nasal cannulae with no oxygen flow. Arm 2: Nasal cannulae with oxygen flow at 5 L/min Arm 3: Nasal cannulae with oxygen flow at 10 L/min
46067708|NCT00783055|Other|Individually tailored programmes|Individualised intervention programmes based on individual wishes for daily activities
46067709|NCT00608738|Other|informational intervention|
46067710|NCT00608738|Other|medical chart review|
46067711|NCT00608738|Other|questionnaire administration|
46067712|NCT00608738|Procedure|assessment of therapy complications|
46067713|NCT00608738|Procedure|management of therapy complications|
45608399|NCT03223805|Other|Respiratory Distress Symptom Intervention|"The RDSI comprises of four components~Controlled breathing techniques - consists of diaphragmatic breathing exercises and calming techniques practised twice a day and used as needed for episodes of intense breathlessness and/or anxiety~Cough suppression techniques - includes education (capacity for voluntary cough easing, identifying warning signs for cough and replace with modified swallow technique or relaxed throat breath~Acupressure: a small number of acupressure points are taught: L7, L9, LI4 (located on the hand and wrist areas), CV21 and 22 (sternum), and ST36 (knee). Patients can select any of these points in any combination to apply pressure for one-minute at least twice a day for symptom relief~Exercise: Individually-tailored exercise plan, for example, walking incrementally increasing distances in their local environment, incorporating breathing techniques as required"
46067714|NCT00783445|Behavioral|Community-Based Exercise Program (C-FIT)|Participants will do 1 hour of exercise two to three times each week in a community setting for 1 year, while being supervised by a personal coach.
45608400|NCT03067961|Other|Salmonella Typhi (S. Typhi)|Investigating the role of typhoid toxin in the pathogenesis of enteric fever
45608401|NCT02962817|Other|Educational intervention|
45608402|NCT02962817|Other|Video explaining the clinical practice guidelines on low back pain|
45757791|NCT04027361|Drug|Amphetamine Extended Release (ER) Tablet 20 mg|A single 20 mg dose of amphetamine ER Tablet, orally administered
45608403|NCT03473093|Drug|Pregabalin 150mg|One group will receive oral pregabalin with morphine infusion
45608404|NCT03473093|Drug|Morphine|One group will receive morphine infusion 20 microgram/kg/h
45608405|NCT02898623|Other|No intervention|Evaluation of performance of immunoassays based on the detection of antibodies directed against Mycobacterium tuberculosis antigen
45608406|NCT02523131|Device|FlorenceM|"The automated closed loop system (FlorenceM) will consist of:~Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature.~An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device."
45608407|NCT02523131|Device|Medtronic insulin pump 640G|Next generation sensor-augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM. Glucose suspend features will be turned off.
45608408|NCT04339049|Drug|lidocaine spray|four puffs (10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
45608409|NCT04339049|Drug|vaginal misoprostol|vaginal misoprostol 200 mcg given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
45608410|NCT04339049|Drug|placebo|vaginal placebo given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
46067715|NCT00783445|Behavioral|Self-Help Exercise Program (HOME)|After a fitness evaluation, participants will be given an exercise prescription and recommendations for home-based, self-mediated progressive exercise. Participants will be expected to do 1 hour of exercise two to three times each week for 1 year.
46067716|NCT00783523|Drug|Doxycycline or Placebo|Randomized to Doxycycline 100mg 2x/day or Placebo 2x/day for 1 or2-weeks pre-operatively.
45608411|NCT04331249|Procedure|surgery or catheter based cardiac procedure (catheter ablation)|patients with implanted CIED (pacemaker, ICD or CRT) that undergo any surgery or any catheter based cardiac procedure (e.g. radiofrequency ablation)
45608412|NCT02198794|Drug|SD-809|SD-809 will be administered per dose and schedule specified in the arm.
45608413|NCT02198794|Drug|Placebo|Placebo matching to SD-809 will be administered per schedule specified in the arm.
45608414|NCT02133664|Drug|lipoic acid and omega-3 fatty acids|alpha lipoic acid as racemic form at 1,200 mg per day omega-3 fatty acids as fish oil concentrate containing a daily dose of 1.35 grams docosahexanoic acid and 1.95 grams of eicosapentaenoic acid
46067717|NCT00927368|Procedure|ultrasound guidance alone|The Tuohy needle was inserted in out-plane approach. Needle placement was considered adequate when the tip was visualized beneath the fascia iliaca; the catheter was then introduced 5 cm beyond the needle tip. Electrical stimulation was not used.
46067718|NCT00927368|Procedure|ultrasound guidance and needle stimulation|For the ultrasound guidance and needle stimulation group, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA (2 Hz, pulse width 0.1 msec). Subsequently, the catheter was threaded 5 cm beyond the needle tip without additional electrical stimulation.
46067719|NCT00927368|Procedure|ultrasound guidance and catheter stimulation|The Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA. At that point, the peripheral nerve stimulator was then disconnected from the stimulating needle and connected to the proximal end of the catheter. The catheter was then advanced 5 cm past the needle tip. If the motor response disappeared during catheter advancement, the catheter was withdrawn slightly until the response returned. Needle orientation and catheter advancement were adjusted as necessary to elicit quadriceps contractions via the catheter with a stimulating current ≤0.5 mA.
45608415|NCT02133664|Drug|Placebo|placebo lipoic acid and placebo oil
45911373|NCT02007304|Behavioral|Eccentric exercise training|12 weeks of lower leg eccentric training
46067720|NCT00783601|Drug|Comparator: MK0524 + placebo|Two 150 mg MK0524 tablets + one placebo tablet in the matching image of montelukast 10 mg once daily for 3 weeks
46067721|NCT00783601|Drug|Comparator: MK0524 + montelukast|Two 150 mg MK0524 tablets and one 10 mg montelukast tablet once daily for 2 weeks
45911374|NCT02007317|Drug|Oshadi D & Oshadi R|Anti tumor agents
46067722|NCT00783601|Drug|Comparator: placebo + montelukast|Two placebo tablets in the matching image of MK0524 150 mg and one 10 mg tablet montelukast once daily for 2 weeks
46073614|NCT02547103|Other|mupirocin ointment|
46067723|NCT00783601|Drug|Comparator: Placebo|During the double-blind treatment periods, patients receive either two placebo tablets in the matching image of MK0524 150 mg or one placebo tablet in the matching image of montelukast 10 mg in a crossover manner. During the washout period before the crossover to the opposite treatment sequence, patients receive two placebo tablets in the matching image of MK0524 150 mg and one placebo tablet in the matching image of montelukast 10 mg once daily for two weeks.
46067724|NCT00783679|Device|NICO device|"Measurement of cardiac output and simultaneous blood sampling.~The subjects' cardiac output will be measured by NICO device and also by thermodilution method. Simultaneously blood samples will be drawn from the pulmonary artery catheter and arterial line. The calculated and measured cardiac output values will be compared for accuracy."
45608416|NCT02133352|Drug|Ranolazine|Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated
46067725|NCT04259840|Other|Observation|Soft tissue implant measurements
46067726|NCT00783757|Device|Optical Imaging|TOBI scan performed before the participant starts cancer treatment and at the start of each treatment cycle
46067727|NCT05331092|Other|Cryotherapy|20 minutes of cryotherapy on the dominant ankle with ice bags
46067728|NCT00783913|Other|Visumotor Upper Extremity Training|Control
46067729|NCT00783913|Other|Anodal/Sham tDCS|Condition
45608417|NCT04750252|Biological|StroMel|Autologous MSC
45608418|NCT02167594|Drug|Flortaucipir F18|IV injection, 370 megabecquerel (MBq) (10 mCi)
45608419|NCT02167594|Procedure|Brain PET scan|positron emission tomography (PET) scan of the brain 75-105 minutes post-injection
45608420|NCT04418128|Drug|Nafamostat Mesylate|The Nafamostat mesilate group received continuous intravenous infusion of 0.1-0.2 mg/kg/h of nafamostat mesilate mixed with 5% DW.
45608421|NCT02555657|Biological|pembrolizumab|
45608422|NCT02555657|Drug|capecitabine|
45608423|NCT02555657|Drug|eribulin|
45608424|NCT02555657|Drug|gemcitabine|
45608425|NCT02555657|Drug|vinorelbine|
45608426|NCT01998815|Procedure|Laparoscopic Roux-en-Y gastric bypass surgery|
45608427|NCT01897571|Drug|Tazemetostat|
46067730|NCT04261868|Device|Virtual Reality|New treatment for amblyopia therapy using playing games
46067731|NCT04261868|Other|Patching|Patching
46067732|NCT00787813|Drug|N-Acetyl Cysteine|oral daily dose of 0.6 g of N-acetyl cysteine in effervescent form
46067733|NCT00787813|Drug|Placebo|
46067734|NCT04261634|Procedure|Concentrated Growth Factor Membrane|Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
46067735|NCT04261634|Procedure|Platelet Rich Fibrin|Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
46067736|NCT00787969|Biological|rituximab|Give IV
45608428|NCT00908687|Biological|A/H5N1|A/H5N1 Low Dose
45608429|NCT00908687|Biological|A/H5N1|A/H5N1 High Dose
45608430|NCT00908687|Biological|LT Adjuvant Patch|LT Adjuvant Patch Low Dose
45608431|NCT00908687|Biological|LT Adjuvant Patch|LT Adjuvant Patch High Dose
45608432|NCT05155475|Procedure|Ultrasound endoscopy|After identification of the lesion, the common bile duct will be identified and followed by the point of dilation due to the compression of the known lesion up to the hilum of the liver
45608433|NCT04216433|Procedure|endovascular surgery|"an innovative, less invasive procedure used to treat problems affecting the blood vessels, such as an aneurysm, which is a swelling or ballooning of the blood vessel. The surgery involves making a small incision near each hip to access the blood vessels."
45608434|NCT02523365|Procedure|interventional therapy|cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
45608435|NCT03473405|Device|Air Barrier System|The Air Barrier System is a device that uses localized clean air flow to shield a surgery site from ambient airborne microorganisms that are shed into the air from people present in the operating room.
45608436|NCT03473405|Other|Control|The Air Barrier System will be deployed onto the surgical field, but the airflow will not be activated, so this is a sham control comparator.
45608437|NCT02195518|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate tablets supplied will be white, almond-shaped, film-coated tablets containing 300 mg of TDF. Each tablet contains the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, pregelatinised starch, croscarmellose sodium, and magnesium stearate.
45608438|NCT05154617|Diagnostic Test|Standard surgical monitoring, along with the Flo Trac® system monitoring.|Under standard thoracic anesthesia protocol, extra monitoring will be done by FloTrac® System using a minimally invasive sensor in combination with an advanced monitoring device to derive cardiac output (CO) and cardiac index (CI) parameters through arterial pulse pressure waveform analysis. Intraoperative blood gases collection will be at different intraoperative times. From this data, calculations will be performed to obtain DO2, DO2i, O2ER, and O2ERi.
46067737|NCT00787969|Drug|cladribine|Give IV
46067738|NCT00787969|Drug|temsirolimus|Give IV
46067739|NCT00787969|Biological|Filgrastim|Give SC
46067740|NCT00787969|Biological|Pegfilgrastim|
46067741|NCT00609596|Drug|GI198745|
45608439|NCT03990077|Drug|HL-085|HL-085 ( Capsule) is one MEK inhibitor.
45608440|NCT03990077|Drug|Docetaxel|Docetaxel is an antineoplastic drug by inhibiting microtubule depolymerization, and attenuating of the effects of bcl-2 and bcl-xL gene expression.
45608441|NCT03914261|Drug|Risankizumab|Tablet
45608442|NCT03896789|Other|PEGASUS Program for Care|This is in essence a checklist of pediatric guidelines to follow for participants who meet inclusion criteria. Site staff will receive training in how to implement this pathway into their usual care.
45608443|NCT03626285|Procedure|Bone Marrow Transplantation|Undergo BMT
45608444|NCT03626285|Device|CliniMACS CD34 Reagent System|CD34 selection ex vivo
45608445|NCT03626285|Procedure|Peripheral Blood Stem Cell Transplantation|Receive CD34-selected peripheral blood stem cells from related or unrelated donors
45608446|NCT05134415|Other|RELX ENDS Tobacco Flavor 1|2-week ad libitum use of the RELX ENDS tobacco flavor 1
45608447|NCT05134415|Other|RELX ENDS Tobacco Flavor 2|2-week ad libitum use of the RELX ENDS tobacco flavor 2
46067742|NCT05007470|Drug|VSL #3 112.5 Capsule|VSL#3 is a commercial probiotic mixture consisting of eight bacterial strains: Four strains of Lactobacillus (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus delbrueckii subspecies bulgaricus), three strains of Bifidobacterium (Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), and one strain of Streptococcus (Streptococcus salivarius subspecies thermophilus).
46067743|NCT05007470|Other|Placebo|100 mg sugar
46067744|NCT00608816|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infusion during a two hour experimental period on Day 2
46067745|NCT00608816|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infusion during two hour experimental period on Day 2
46067746|NCT02535273|Drug|Dexmedetomidine|load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.
46067747|NCT02535273|Drug|Lidocaine|local anesthesia：0.67% lidocaine local anesthesia layer by layer to the periosteum at the puncture site，Establish puncture channel, injection 5ml 0.67% lidocaine into the vertebral body through the catheter, and observe 5-10min before operation
45608448|NCT05134415|Other|RELX ENDS Menthol Flavor 1|2-week ad libitum use of the RELX ENDS menthol flavor 1
45608449|NCT05134415|Other|RELX ENDS Menthol Flavor 2|2-week ad libitum use of the RELX ENDS menthol flavor 2
45608450|NCT03461861|Drug|AGB101 220 mg|AGB101 oral dose of 220 mg/day capsule, given as once-daily dosing.
46067748|NCT02535273|Drug|Low-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery
46067749|NCT02535273|Drug|Moderate-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery
46067750|NCT02535273|Drug|High-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery
46067751|NCT02535273|Drug|normal saline|Intravenous injection normal saline equal quantity，completed within 10 minutes. Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
45608451|NCT03461861|Other|Placebo|Placebo, oral capsule given once-daily.
45608452|NCT04458389|Drug|TY101|"Dose escalation: TY101 0.3mg/kg or 1mg/kg or 3mg/kg or 10mg/kg 200mg Intravenous Q3W, 2 years depending on response.~Dose expansion: Subjects received TY101 injection for a maximum of 2 years until progressive disease, intolerant toxicity, death, or withdrawal from the study occurred."
45608453|NCT03380507|Drug|Triple therapy group|Refer to arms description
45608454|NCT03390335|Other|Pressure|Subjects undergo altitude exposure, diving exposure, and return to altitude. Altitudes: 8,000, 10,000, 12,000, or 15,000 feet Dives: 60 or 100 feet of sea water
45608455|NCT03390335|Other|Breathing Gas|Subjects will breathe air, 35% Oxygen, Balance Nitrogen, or 100% Oxygen during the diving exposure
45608456|NCT05050721|Other|CT imaging|clinical, radiological and biochemical parameters associated with disease progression
45608457|NCT03471533|Dietary Supplement|nutraceutical: experimental product|84 days of consumption
45608458|NCT03471533|Dietary Supplement|placebo|84 days of consumption
46067752|NCT05006066|Other|Temporal Summation|4 type of stimulations applied on the right arm
46067753|NCT00788047|Drug|Dextromethorphan|Dextromethorphan HCl 30 syrup single dose
46067754|NCT00788047|Drug|Dimebon + Dextromethorphan|Dimebon 20 mg tablets given three times daily for 14 days plus Dextromethorphan HCl 30 syrup single dose administered on Day 12
46067755|NCT04152369|Procedure|Anti-microbial prophylaxis for an endourological procedure or ESWL|anti-microbial prophylaxis according to urine culture results
46067756|NCT00674037|Other|monetary incentive|75 euros for each patient included
46067757|NCT05331014|Drug|LivaloVA|For 8 weeks(PO, QD)
45608459|NCT03471455|Drug|Isotretinoin|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
45608460|NCT03471455|Drug|Terbinafine|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
45608461|NCT03471455|Drug|Itraconazole 200 mg|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
45608462|NCT04902677|Other|Cross-sectional|No intervention
45608463|NCT04749173|Drug|DWRX2003, 96mg|Drug: Placebo Intramuscularly injection at predefined injection sites
45608464|NCT04749173|Drug|DWRX2003, 432mg|Drug: Placebo Intramuscularly injection at predefined injection sites
45608465|NCT04749173|Drug|DWRX2003, 144mg|Drug: Placebo Intramuscularly injection at predefined injection sites
45608466|NCT04749173|Drug|DWRX2003, 144mg|Drug: Placebo Intramuscularly injection at predefined injection sites
45608467|NCT03258905|Behavioral|Grounding enhanced app|A mobile app that uses the Seeking Safety grounding chapter content, enhanced with features designed to create strong engagement and interactivity
45608468|NCT03258905|Behavioral|Grounding text-only app|A mobile app that uses the Seeking Safety grounding chapter content in text format only
45608469|NCT04745897|Other|eTB Catalogue of Recommendations (eTB)|eTB Catalogue of Recommendations (eTB)
45608470|NCT04745897|Other|World Health Organization Tuberculosis Website (WHO TB)|World Health Organization Tuberculosis Website (WHO TB)
45608471|NCT04670159|Behavioral|Online Education|Online ergonomics, exercise and physical activity training will be provided 3 times a week for 6 weeks. The trainings it is planned to be made with a video-based online platform called Edpuzzle. With the online classroom created, the student education will be provided. A total of 18 training videos will be prepared, each video is 6-10 minutes. After the training there will be an individual motivational interview with the students in the this group with the zoom application. With motivational interview solutions by revealing the willingness, obstacles and indecision of the student to transfer the learned information to his daily life will be recommended.
46067758|NCT05331014|Drug|LivaloV|For 8 weeks(PO, QD)
46067759|NCT05331014|Drug|VA|For 8 weeks(PO, QD)
46067760|NCT00788281|Procedure|laparoscopic surgery|surgery would be performed by laparoscope
46067761|NCT00788281|Procedure|open surgery|surgery would be performed by traditional surgery.
45757792|NCT04682847|Drug|Ferumoxytol injection|This is a prospective observation study of 1.5T MR-Linac-SPION imaging with Ferumoxytol for radiotherapy planning in patients with pre-existing liver condition in order to increase safety of liver SBRT with assessment of tumor and hepatic parenchyma response.
45608472|NCT04670159|Behavioral|Information With Brochure|An e-brochure will be prepared for students in this group to provide information on ergonomics, physical activity and exercise. and the e-brochure will be sent to the students via e-mail after the initial evaluation.
45608473|NCT04461821|Diagnostic Test|Real-time SESI-MS breath analysis|Participants will be asked to refrain from eating, drinking, chewing gum use or brushing their teeth at least 1 hour before the measurements will be performed. Room temperature and lighting will be set at the same level for all measurements. Participants will exhale through a disposable mouthpiece into a commercially available SESI source (FIT S.L., Spain). While performing full exhalations, the subjects will keep the pressure through the sampling line at a fixed value monitored by a digital manometer. Breath prints will be collected in real-time recording multiple replicates (typically six in positive and negative ion mode). The whole procedure is absolutely non-invasive and is usually accomplished without any effort in around 15 min per subject.
45608474|NCT04461821|Diagnostic Test|Off-line breath analysis|In young children below the age of 4 not capable of completing the on-line exhalation maneuvers, or in cases when the patient needs cannot approach the mass spectrometer, the sample will be collected off-line. They will be asked to exhale into a bag that will be transported to the lab and deflated into the mass spectrometer for analysis. Exhaled breath of patients under anesthesia will also collected using available ventilation system in the operation theatre.
45757793|NCT04024085|Other|completion of the test created Time to be Ready to Void|completion of the test created (Time to be Ready to Void) The participants have to stand up from a chair with armrests, walk 6 meters to the toilet, open the door and turn on the light, close the door, undress and position themselves to urinate
46067762|NCT04259684|Drug|gases Nitric Oxide (gNO)|Participants in the intervention group will receive gNO blended into the fresh gas flow of the cardiopulmonary bypass (CPB) oxygenator and maintained at 20 ppm via an Ikaria INO Max DSIR (Mallinckrodt Pharmaceuticals, St. Louis, Missouri, USA), with continuous sampling of NO and NO2 concentration from a port adjacent to the oxygenator. The gNO delivery will be initiated when the patient is on CPB and stopped once the patient comes off CPB.
46067763|NCT05232266|Drug|Caralluma Fimbriata|Caralluma fimbriata in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
46067764|NCT05232266|Drug|Placebo comparator - Microcrystalline cellulose|Placebo comparator in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
46067765|NCT00788515|Drug|Volinanserin (M100907)|2 mg tablets QD
46067766|NCT00788515|Drug|Lormetazepam|1 mg tablets (overencapsulated) QD
46067767|NCT04259606|Dietary Supplement|Cassia Cinnamon|Reddish - brown to light brown, typical sweet and aromatic free flowing powder.
45757794|NCT04011839|Drug|Levobupivacaïne|Use of Levobupivacaïne instead ropivacaïne
46067768|NCT04259606|Other|Calcined magnesia|White, odor, color and flavorless thin powder.
46067769|NCT00788749|Drug|Prednisolone|tablets 25 mg/day
46067770|NCT00788749|Drug|Placebo|tablets once daily
45757795|NCT05208710|Biological|Vaccination with PANHPVAX 10µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 10µg antigen
45757796|NCT05208710|Biological|Vaccination with PANHPVAX 40µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 40µg antigen
46067771|NCT00788749|Other|fluticasone nasal drops|fluticasone nasal drops 800mcg/d
46067772|NCT00788749|Other|fluticasone nasal spray|fluticasone nasal spray 400 mcg/d
46067773|NCT00609752|Drug|prednisolone|Standard treatment regimens based on body weight will be used (approximately 2 mg per kg), with a stepwise dose reduction over a 10-14 week period.
46067774|NCT00609752|Dietary Supplement|Alicalm (polymeric liquid formula)|"Subjects will receive all of their nutritional requirements in the form of a nutritionally balanced polymeric feed, volume based on EAR for age. Duration of 5 to 8 weeks with subjects returning to a normal unrestricted diet by 10 weeks."
46067775|NCT00662857|Drug|Technosphere® Insulin Inhalation Powder|TI Inhalation Powder, two 15 U cartridges
45444889|NCT03794271|Procedure|Pupilometer guided anesthesia|"At least 10 min after anesthesia induction by target-controlled infusion of propofol and remifentanil, baseline values for pupillary diameter is recorded before any surgical procedure.~During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60. Remifentanil Ce is adapted every 5 min based on the changes of pupillary diameter. If the pupillary diameter is increased by more than 30% compared to baseline value, remifentanil concentration is increased by 0.5 ng/ml. If the pupillary diameter is maintained between 5 and 30 % change compared with baseline, remifentanil is not modified. In a case of pupillary diameter is decreased less than 5 % change of baseline, remifentanil concentration is decreased by 0.5 ng/ml."
45444890|NCT03794271|Procedure|SPI guided anesthesia|During the operation, SPI value should be maintained between 20 and 50 by changing the infusion rate of remifentanil. Even if the SPI is maintained within the target range, the remifentanil infusion rate is increased by 0.5 ng/ml in a case of the SPI value suddenly arises by more than 10.
45444891|NCT03792321|Drug|Testosterone Undecanoate|1000 mg i.m. every 10 weeks
45444892|NCT03792321|Drug|Placebo|
46067776|NCT00662857|Drug|Technosphere Insulin® Inhalation Powder|TI Inhalation Powder, one 30 U cartridge
46067777|NCT00662857|Drug|RAA Population|RAA Population: All subjects received a single 10 IU sc injection of insulin lispro.
46067778|NCT04261400|Behavioral|MAMAACT|Improved communication regarding warning signs of pregnancy complications
46067779|NCT00788905|Device|Allient System|The Allient System uses a different type of blood pump and a lower volume of dialysate.
45444893|NCT01305057|Other|Pyridoxine tri-isopalmitate|2% dosage, oil-in-water emulsion, twice a day, 28 days
45444894|NCT03792243|Procedure|Complication|Readmission, reoperation
45452242|NCT01030432|Drug|BMS-650032|Tablets, Oral, 200 mg, Twice Daily, 12 or 24 weeks, depending on response
45452243|NCT01030432|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, 48 weeks
45757797|NCT05208710|Biological|Vaccination with PANHPVAX 100µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 100µg antigen
45757798|NCT03983291|Behavioral|FaReWell Depression|Facial massage and force exercise
45757799|NCT04878380|Device|Fitbit|A consumer sleep tracker will be used to monitor sleep patterns throughout the study
45757800|NCT04878380|Behavioral|Sleep education tips|Sleep tips will be provided before the intervention phase
45608475|NCT04461821|Diagnostic Test|Blood analysis|Blood analysis done in patients who undergo regular blood sampling needed for clinical routine laboratory controls. This includes i) children and adolescents receiving medications which require TDM ii) patients with acute diseases such as TD1 and pneumonia and iii) patients with chronic diseases such as asthma bronchiale. For those patients where a blood sample is drawn during the clinical routine, an additional blood sample consisting of only several blood drops will be collected using the same blood sampling line. No additional venous puncture for research purpose will be done.
45608476|NCT04461821|Diagnostic Test|Saliva analysis|During the diagnostic and therapeutic work-up of T1D patients, saliva samples are collected during the clinical routine. For those patients, additional samples will be obtained by clinically trained investigators.
45608477|NCT04461821|Diagnostic Test|Urine analysis|During the diagnostic and therapeutic work-up of T1D patients, urine samples are collected during the clinical routine. For those patients, additional samples will be obtained by clinically trained investigators.
45608478|NCT02952365|Drug|Tissue sealant|Application of tissue sealant on eyes undergoing LASIK enhancement
46067780|NCT04992728|Other|Restricted Spectrum Magnetic Resonance Imagining|Restriction Spectrum Magnetic Resonance Imaging (RS-MRI), which uses magnetism instead of x-rays to build up a picture of the inside of the body. The scan is completely painless but can be rather noisy and requires the patient to lie very still inside the center of a large, doughnut-shaped magnet for approximately 30-60 minutes complete the imaging.
46067781|NCT00878553|Drug|placebo|tablet at bedtime
45608479|NCT02824679|Drug|hyoscine butylbromide|20 - 40 mg of hyoscine butylbromide is given intravenously during the first stage of labor
45608480|NCT02824679|Drug|saline|0.9%normal saline
46067782|NCT00878553|Drug|SKP-1041 (experimental formulation of zaleplon)|tablet at bedtime
46067783|NCT05220020|Procedure|TACE(Transcatheter arterial chemoembolization)|Hepatic arterial chemoembolization treatment
45608481|NCT03473015|Device|PICSO|The PICSO Impulse catheter is a 8F double lumen catheter with a 15.5x20mm long balloon at the distal end. The balloon inflates and deflates cyclically once deployed in the coronary sinus, leading to intermitted coronary sinus pressure increase. The catheter is connected to the console through two pneumatic tubes in which helium is shuttled to and from the balloon. In addition, the coronary sinus pressure is monitored through the center lumen of the catheter.
46067784|NCT05220020|Drug|Lenvatinib|Experimental group(Synchronous treatment group): the first course of TACE treatment was started after 2-3 weeks Lenvatinib treatment.Control group:(Sequential treatment group)patients with uncontrolled TACE progression after TACE treatment were sequentially treated with Lenvatinib.
45608482|NCT03472937|Procedure|Transcervical Foley catheter placement for cervical ripening|Subjects will be randomized have cervical ripening with a transcervical Foley catheter in either the inpatient or outpatient setting.
45757801|NCT04878380|Behavioral|Goal-setting|During the intervention phase, the Goal-Setting group will be additionally rewarded for achieving sleep goals, i.e. 30 mins longer than their habitual sleep duration and sleeping before midnight.
45757802|NCT03793439|Drug|Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial|Tofacitinib 5mg oral table twice daily for 16 weeks
45757803|NCT03793439|Diagnostic Test|Spirometry|Spirometry testing at baseline, week 4, week 8, week 12, and week 16
45757804|NCT03793439|Genetic|RNA Sequencing|RNA sequencing test at baseline and week 16
45757805|NCT03793439|Diagnostic Test|Laboratory testing|Laboratory testing at baseline and weeks 2, 4, 8, 12 and 16
45757806|NCT03793439|Drug|Corticosteroid|Taper corticosteroids starting at week 4
45757807|NCT03793439|Drug|Tofacitinib 5mg [Xeljanz] 1 year open-label extension|After 16 weeks, subjects who meet the primary end-point will be permitted an optional one year open-label extension.
45757808|NCT04672083|Drug|CPT31|CPT31 (cholesterol-PIE12-2-trimer) is a novel D-peptide HIV entry inhibitor that binds with high affinity to a conserved hydrophobic pocket within the gp41 trimer
45757809|NCT04672083|Drug|Placebo|matching placebo
45444895|NCT03792399|Behavioral|feedback counseling|Professoinal CGM in combination with diet and exercise record is used as teaching material to help patient realize their blood glucose pattern and to modify their behavior after counseling feedback.
45444896|NCT03794115|Procedure|Treatment for ovarian cancer|The treatment for ovarian cancer includes the debulking surgery and platinum-based chemotherapy.
45757810|NCT00687167|Drug|Zonisamide 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
45757811|NCT00687167|Drug|Zonisamide (Zonegran®) 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
46067785|NCT00789061|Drug|Proton pump inhibitor|One dosage/day/year
45444897|NCT05624697|Procedure|sticky bone housed in PEEK Shell|Patient specific Sticky Bone/Implant housing PEEK shell in Anterior Atrophic Maxilla
45452244|NCT01030432|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, 0 or 12 weeks (depending on response) beginning at Week 12
46067786|NCT00996437|Drug|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline, 4 and 8 weeks
46067787|NCT00996437|Drug|Saline|Saline injection of 0.5mg at baseline, 4 and 8 weeks
46067788|NCT00789139|Device|ICM Implantation|Sub cutaneous implantation of the ICM
46067789|NCT04985396|Drug|Platelet Rich Plasma (PRP) group|Platelet Rich Plasma (PRP) group will be intervened with PRP injection. The collection of 30 ml blood of patients into acid citrate dextrose tube under aseptic condition will be done and subjected for centrifugation at 2000 rpm (soft spin) through digital centrifuge machine speed control (REMI, R-8C PLUS). There will be three layers of blood, among them the supernatant layer and buff coat of plasma will be again subjected to centrifuge at 3000 rpm (hard spin). The upper two thirds of the tube containing platelet poor plasma will be discarded and finally, the lower one third concentrated platelet plasma superficial buffy coat will be injected into medial calcaneal tuberosity at the most tender point.
46067790|NCT00789217|Procedure|Immediate skin test|Intradermal test with immediate reading
46067791|NCT04248842|Device|Continuous monitoring system|Patients recruited will be continuously monitored with Isansys Lifetouch patch, Isansys wireless blood pressure monitor (Meditech Blue BP-05), Nonin WristOx 3150 as well as departments standard monitors
45608483|NCT02287493|Other|Pharmacokinetic Analysis|
45608484|NCT03665363|Other|SCOPE|SCOPE is a internet-delivered, coach-guided, psychoeducational intervention, intended to serve as a first-line intervention for intellectually able adolescents and young adults with ASD. The SCOPE program is based on information comprising neuropsychology, pedagogy, and also interdisciplinary clinical experience regarding ASD. The content is aimed at providing information about typical and specific impairments of ASD, as well as the associated strengths.
45608485|NCT03665363|Other|Self-study|Active control consisting of directed self-studies on internet.
46067792|NCT00609830|Behavioral|Tailored Materials|Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participants' stage of change with respect to each behavior.
45757812|NCT04277780|Device|Continuous Glucose Monitoring Sensor|Placement of continuous glucose monitor sensor for 14 days. Instructions on how to peel off the sensor and mail it back to the clinician.
45757813|NCT04277780|Other|Diabetes Management Instructions|Instructions on checking fingerstick blood glucose and information on the required equipment including glucose test strips, lancets, and glucometer. Instructions on how to log blood glucose values onto the blood glucose log sheet for 14 days, and how to mail it back to the clinician.
45757814|NCT05208554|Behavioral|Integrated health counseling and step prescription|8 weekly dyad-based sessions with a health counselor to train couples in the use of communal coping strategies to support one another in achieving physical activity goals plus individualized step prescription based on remotely-monitored Fitbit-derived step counts the week prior
45757815|NCT00687713|Drug|Bupropion|150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper.
45757816|NCT00687713|Other|Placebo|Placebo
45757817|NCT02304159|Drug|daclatasvir|
45757818|NCT02304159|Drug|Sofosbuvir, Sovaldi|
45757819|NCT02304159|Drug|Ribavirin|
46067793|NCT00609830|Behavioral|Tailored Materials Plus Physician Feedback|Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participant's stage of change with respect to each behavior. In additon, the participant's physician received information concerning the participant's status on each behavior targeted.
45608486|NCT05159141|Behavioral|Behavioral sleep intervention|The intervention consists of an infant behavioral sleep protocol. In the tailored intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings.
46067794|NCT00609830|Behavioral|Generic Materials|Participants received generic written educational materials about osteoporosis prevention.
46067795|NCT00609830|Behavioral|No Information|Participants received no informational materials.
46067796|NCT00674193|Other|pharmacological study|Correlative studies
45757820|NCT02143973|Drug|nalbuphine HCl ER|nalbuphine HCl ER
45757821|NCT04400240|Behavioral|CALLS|The CALLS program will consist of 12 weeks of service delivery that will include one standard educational session by telephone or in-person meeting every week. The weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving. Weekly content will be adapted from the twelve modules of the Peer Approaches to Lupus Self-management (PALS) study, and further tailored according to prominent barriers to care in the scientific literature. Content will include: 1) Medication adherence; 2) Communication with provider; 3) Patient engagement; 4) Recognizing and treating depression; 5) Overcoming socioeconomic barriers; 6) Social Support network; 7) Appointment/ Lab adherence; and 8) Transportation.
45757822|NCT03028701|Drug|Formoterol/Budesonide 12/400 mcg Discair|Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®
45757823|NCT03686696|Drug|Beta blocker|Patients randomized to beta-blockade will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
45757824|NCT03686696|Drug|ACEI|Patients randomized to ACE inhibitor will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
46067797|NCT00674193|Other|laboratory biomarker analysis|Correlative studies
46067798|NCT04968379|Drug|Ferric carboxymaltose|Intravenous
46067799|NCT04263506|Other|Vignette with emphasis on supervisor's opinion|A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without the description of supervisor's advice that does not oppose to detrimental research practice (i.e. the supervisor is fine with whatever the PhD student decides in the dilemma).
45444898|NCT03792009|Device|Paracervical block|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
45444899|NCT03792009|Drug|5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
45444900|NCT03792009|Drug|Normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
46067800|NCT00784069|Drug|Lactic Acid|Lactic Acid (Dermacyd Breeze)
45452245|NCT01030432|Drug|Placebo|Tablets, Oral, 0 mg, twice daily 24 weeks
45608487|NCT05158985|Other|phonophoresis|treatment
45608488|NCT05158985|Other|exercises|treatment
45608489|NCT03602495|Drug|Donafenib|Donafenib 0.3g Bid orally, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
45608490|NCT03602495|Drug|Placebo|Matching placebo Bid orally, continuously.
45757825|NCT03686696|Drug|ARB|Patients randomized to Angiotensin receptor blockers will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications
45757826|NCT02267655|Drug|inhaled Nitric Oxide - 30 mcg/kg IBW/hr|inhaled Nitric Oxide in 30 mcg/kg IBW/hr doses Part 1
45757827|NCT02267655|Drug|inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr|inhaled inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr dose titration
45757828|NCT02267655|Drug|inhaled nitric oxide 75 mcg/kg IBW/hr|inhaled nitric oxide 75 mcg/kg IBW/hr -Part 2b
45757829|NCT00689819|Behavioral|Exercise|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
45911375|NCT02007330|Drug|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion (0.1mg/kg) for 1minutes after induction of anesthesia. After 1 minutes, lidocaine infusion continued at rate of 1.5mg/kg/hr during operation, and discontinued before move the patients to PACU.
46067801|NCT02628951|Drug|Ramucirumab|Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
45608491|NCT03259373|Behavioral|Early Patient-Level and Provider-Level Educational Intervention|"Letters to patients that (1) explain to the patient that he or she appears to have AF, characterize the risk of stroke, and emphasize that although there may be a medical reason, the patient does not seem to be on an anticoagulant and (2) encourage the patient to discuss this with his or her provider to ask if he or she might benefit from OAC therapy to prevent stroke.~Early intervention letters to providers explain this project, the nature of the problem, and identify a list of the provider's patients who have been contacted, as the provider and patient letters will be sent at approximately the same time; describe evidence and guidelines regarding oral anticoagulation."
46067802|NCT02628951|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
45608492|NCT03259373|Behavioral|Delayed Provider-Level Educational Intervention|Delayed intervention letters to patients' providers, where they may be identified, that explain this project, the nature of the problem, and identify a list of their patients who are flagged as at risk for stroke and have not been treated with an oral anticoagulant; describe evidence and guidelines regarding oral anticoagulation.
45444901|NCT01305135|Drug|azacitidine and idarubicin|azacitidine:100mg, 75mg/m²/d, during 7days every 28 days (D1-D7). Idarubicin: 5mg/ml, 5mg/m²/d (palier1) or 10mg/m²/d (palier2), D8
45444902|NCT03793959|Dietary Supplement|Synbiotic Supplement|
45911376|NCT02007330|Drug|Normal saline infusion|In group C, the patients receive same volume of normal saline
45911377|NCT02007408|Drug|Paracervical block|
45911378|NCT02007408|Drug|Lidocaine spray|
45911379|NCT02007408|Drug|Paracervical block + lidocaine spray|
46067803|NCT00662311|Drug|vorinostat|Given PO
46067804|NCT00662311|Drug|paclitaxel|Given IV
45444903|NCT03793959|Dietary Supplement|Placebo|
45444904|NCT03793647|Device|Electrical muscle devise|evaluate two types of EMS stimulation of legs
45444905|NCT03792087|Drug|SmofKabiven Peripheral|Total Parenteral Nutrition
45444906|NCT03792087|Drug|Hospital compounded emulsion|Total Parenteral Nutrition
45444907|NCT01305603|Drug|Bupivacaine|On both sides of the abdomen 30 ml of bupivacaine 2.5 mg/ml will be injected. This is a total of 60 ml of bupivacaine 2.5 mg/ml.
45444908|NCT01305603|Procedure|Injection|Injection under ultrasound-guidance
45444909|NCT01305291|Other|placebo|
45444910|NCT01305291|Dietary Supplement|digestion-resistant maltodextrin|
45444911|NCT03791931|Diagnostic Test|oxidative stress measurement|oxidative stress measurement
45444912|NCT02058784|Drug|pracinostat|
46067805|NCT00662311|Radiation|radiation therapy|Undergo radiation therapy
46067806|NCT00674349|Procedure|surgery|staging surgery
45444913|NCT03793725|Drug|SHR1210|Anti-PD-1 Antibody
45444914|NCT03793725|Drug|Apatinib|Anti-angiogenic drugs
45444915|NCT02054416|Device|ArtAssist© Device|The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.
45444916|NCT01305369|Drug|Prasugrel|"Patients will be blindly and randomly allocated to treatment A (prasugrel 10 mg daily) or B (placebo) for 15 days. After a 15-day wash-out period, patients who had initially been allocated to treatment A will be allocated to treatment B, and vice versa."
45444917|NCT02056366|Drug|α-lipoic acid|α-lipoic acid 600mg PO medication,Per day, For 6weeks α-lipoic acid 1200mg PO medication,Per day, For 6weeks
45452246|NCT01030432|Drug|Peginterferon Alfa-2a|Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 48 weeks
46067807|NCT00929708|Drug|AZD3199|Dry powder for inhalation, o.d., 4 weeks
46067808|NCT00929708|Drug|formoterol|Dry powder for inhalation, b.i.d., 4 weeks
46067809|NCT00929708|Drug|Placebo|Dry powder for inhalation, b.i.d., 4 weeks
46067810|NCT00674427|Biological|CD3/CD28 Activated T cells|Subjects who are not in CR will receive one infusion of high dose aDLI
46067811|NCT00674427|Biological|CD3/CD28 Activated T cells|Subjects in CR 6-12 weeks after the first dose of Activated Donor Lymphocyte Infusion (aDLI) will continue to receive aDLI every 3 months for up to a year.
46067812|NCT00789295|Other|Mediterranean diet and Low-Carbohydrates diet|The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%) versus Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)for 4 weeks
46067813|NCT00674505|Device|Lumen Biomedical FiberNet Embolic Protection System|to demonstrate the safety and filter efficiency of the Lumen Biomedical FiberNet Embolic Protection System during the performance of primary renal stenting in the treatment of pts with a high grade ostial atherosclerotic renal lesion(s).
45608493|NCT03226847|Procedure|Pulmonary Vein Isolation|Standard antral pulmonary vein isolation using radiofrequency ablation catheters
45608494|NCT05158673|Dietary Supplement|Placebo of Cocoa flavonoids|Dietary supplement: The administration of two capsules of 500 mg orally of placebo (excipient q.s. starch capsule) 1 every 12 hours, for 12 weeks
45608495|NCT05158673|Dietary Supplement|Cocoa flavonoids|Dietary supplement: Two 500 mg capsules of the flavonoid supplement (whose total flavonoid content is 15 mg/capsule) orally every 12 hours (one in the morning and one at night) for 12 weeks
45608496|NCT03202667|Drug|Empagliflozin 25mg|Treatment with empagliflozin 25mg once daily for 28 days
45608497|NCT03202667|Drug|Placebo|Treatment with Placebo oral tablet once daily for 28 days
45608498|NCT02133742|Drug|Axitinib|Axitinib at starting dose of 5 mg and 3 mg BID.
45608499|NCT02133742|Drug|MK-3475|MK-3475 with two dose levels: 2 mg/kg every three weeks to find the maximum tolerated dose and continue treatment in a dose expansion phase.
45608500|NCT03472859|Device|PHOTOLASE|This is the investigational yellow laser (PHOTOLASE)
45608501|NCT03472859|Device|KTP|This is the traditional green laser (KTP)
45608502|NCT03472781|Other|No intervention. A retrospective case review|No intervention. A retrospective case review on demographics, etiology, clinical features, diagnosis, secondary complications, treatment and outcomes of intraocular inflammation in children aged 16 years and below that presented to uveitis clinic in Singapore National Eye Centre from January 1989 to January 2017.
45608503|NCT03472703|Other|Break-Lunch time|The time for the break and lunch will be contrary, depending on their visit/session
45608504|NCT05157893|Device|Virtual reality based analgesic therapy|The intervention is a single 15 min VR therapy. The VR therapy is consisted of VR device and software. The model of VR device used is Pico Neo 3 Pro. The software run on the VR device delivers two types of contents: 1) A 7min of computer-generated 360 video of underwater scene with therapeutic music to distract patients' attention on pain and make patients passively relax. 2) An 8min guided relaxation in which patients are transported to seaside with narrative to achieve image and breathing relaxation.
45608505|NCT03032705|Device|SonicFill™ 2|The intervention in arm 1 is SonicFill™ 2, a sonic-activated, bulk fill dental composite system for posterior restorations that requires no additional capping layer.
45934925|NCT02966574|Device|whole body MRI|The examination will be conducted in the pretreatment assessment of breast cancers with a high metastasis risk and in the monitoring of metastatic breast cancers. The examination is performed without intravenous injection of contrast medium, from the top of the skull to mid-thigh using diffusion weighted sequences in the axial plane, T1-weighted sequences in the coronal plane, STIR T2 weighted sequences in the coronal plane and T1-weighted sequences in the sagittal plane on the spine. Total examination duration is one hour. The interpretation of the results is made by two independent reporters with a complementary expertise, according to a systematic lecture grid.
45608506|NCT03032705|Device|Filtek™ Supreme|The intervention in arm 2 is Filtek™ Supreme Ultra, a Universal Nanocomposite dental restorative material that is visible-light activated and designed for use in anterior and posterior restorations of any class.
45608507|NCT05157815|Dietary Supplement|Soluble Fibre|10g soluble corn fibre to be consumed twice per day
45608508|NCT05157815|Dietary Supplement|Calorie Matched Control|2g maltodextrin consumed twice per day
45608509|NCT02523053|Procedure|Hepatectomy|Surgical removal of all lesions
45608510|NCT02523053|Drug|5-Fluorouracil|Surgical removal of all lesions and intraoperative controlled release 5-Fluorouracil therapy
45608511|NCT02605733|Device|EEG|amplitude integrated electroencephalography
45608512|NCT02605733|Device|NIRS|regional tissue oximetry
46067814|NCT04965025|Procedure|Multi-stage urethroplasty with graft inlay in first stage|Herein, the graft will be used in the first stage and the second stage will solely consist of retubularizing the urethra.
45934926|NCT00211315|Drug|anecortave acetate|
45608513|NCT05157737|Other|Electrophysiological detection of KCNQ2 mutation|Electrophysiological detection of KCNQ2 mutation performed using patch clamp technique in an in vitro cell model. Analyze the association between phenotype and genotype.
45608514|NCT05157737|Other|Multi-modal brain image and EEG|Multi-modal brain image include brain magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT). The electroencephalogram (EEG) incuding video electroencephalogram (VEEG) and sleep electroencephalogram (SEEG).
45608515|NCT05157737|Other|Omics testing|Omics testing include proteomics, metabolomics, transcriptomics.
45608516|NCT04457921|Other|deep tissue massage|Experimental group received deep tissue massage twice at 11st and 23rd hours after cesarean section.
45608517|NCT02180243|Behavioral|Yoga/Acupuncture|Individuals randomized to this group will participate in iRest Yoga Nidra and auricular acupuncture.
45608518|NCT02180243|Other|Gulf War Health Education|Participants randomized to this group will take part in a health education group.
46067815|NCT04965025|Procedure|Multi-stage urethroplasty with graft inlay in second stage|Herein, the graft will be used in the second stage and the first stage will solely consist of opening the urethra longitudinally.
45608519|NCT05157347|Other|Robot-assisted Training|The gait training in this study uses an exoskeletal wearable robot (Product name: ANGEL LEGS M20, Angel robotics, Co., Ltd.) consisting of a wearable part, a hip or knee joint gear providing the auxiliary force, and a controller backpack. This product is a powered orthopedic device for gait rehabilitation and treatment such as the lower limb muscle reconstruction and joint motion recovery in patients or handicapped individuals. The product consists of a power part, a controller part and a gear part, while the device is powered by an electric motor and the device motion induces the gait posture to support the lower limbs and allow the gait training to be performed.
46067816|NCT02628795|Behavioral|PRT + FM|Supervised progressive resistance training + functional mobility training (PRT+FM) 3 days per week for 16 weeks post-surgery.
46067817|NCT02628795|Other|Usual Care|Post-surgical usual care activities including any prescribed physical therapy
45608520|NCT05157347|Other|Conventional Therapy|The conventional gait rehabilitation has been performed as a 1:1 training session between the therapist and a stroke patient.
45608521|NCT03472625|Diagnostic Test|Screening and diagnosis of aphasia, dysarthria, dysphagia|"Screening (day 2 +/- 1; day 7 +/-1): NIHSS (National Health Institute Scale) 9 and 10 scores, dysphagia screening (nurse), speech-, and language screening (speech therapist)~Diagnostic assessment (day 2 +/-1-):~Dysphagia: MASA (Mann Assessment of Swallowing Abilities), FOIS (Functional Oral Intake Scale) Dysarthria: perceptual assessment, NSVO-Z (Nederlands spraakverstaanbaarheidsonderzoek - zinnen) Aphasia: ScreeLing, BNT (Boston Naming Test)"
45608522|NCT05138315|Device|Metamorphopsia quantification|Alleye App and M.chart examinations will be performed pre- and postsurgically.
45608523|NCT03472391|Behavioral|Physical Therapy|A 4-week (2 exercise session af week, of 40 minutes )tailored physiotherapeutic exercise program. The sessions are individually and supervised by physical therapist and tailored to patients with severe anorexia nervosa. The exercise program mainly consist of strength training exercises without any equipment other than a floor mat.
45608524|NCT05115071|Behavioral|Childbirth preparation education|"Purpose: The aim of the birth preparation education is to eliminate the fears and concerns of pregnant women about birth and to prepare them for birth during the Covid-19 Pandemic process.~Education hours: The education will be completed in total two weeks and eight hours, consisting of two days and four hours each week.~Method: The education will be given online through the Microsoft Teams application. Each training day will consist of two lessons. Each lesson will last 45 minutes. There will be a 15-minute break between the two lessons. The first lesson will be conducted in the form of a question and answer session with a power-point presentation.In the second lesson, relaxation exercises will be applicated and evaluations will be taken at the end of the lesson.~The group that will receive the education: Healthy pregnant women between 24-34 weeks of gestation will be included in the training. Trainings will continue with closed groups."
45608525|NCT04457609|Drug|Oseltamivir|Current standardized treatment for Covid-19
45444918|NCT03793569|Behavioral|Peer discussion group|Subjects in the intervention group will be asked to attend one peer group between four and eight weeks postpartum. Peer groups will be expected to last approximately one hour. Each peer group will include 5-10 new mothers. A facilitator will be present for these groups, but the hope is to have mothers discuss with each other their postpartum experience and activities of their newborn at home.
46067818|NCT04261322|Radiation|x ray exposure|exposure of whole body to x ray
46067819|NCT00674895|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
46067820|NCT00609908|Procedure|Split skin graft|After wound bed preparation the skin defect is covered with a skin transplant (split skin graft)
45608526|NCT04457609|Drug|Azithromycin|Current standardized treatment for Covid-19
45608527|NCT04457609|Biological|Umbilical Cord Mesenchymal Stem Cells|Adjuvant therapy on top of current standardized treatment (Oseltamivir + Azithromycin)
45608528|NCT05157269|Drug|Nitazoxanide|Two NTZ 300 mg extended release tablets administered orally with food twice daily for 5 days
45934927|NCT00211354|Drug|Anecortave Acetate|ancortave acetate 15 mg. juxtascleral injection every 6 months for 24 months.
46067821|NCT00609908|Procedure|skin stretching device|after woundbed preparation the wound is primarily closed by aid of the skin stretching device
46067822|NCT00609908|Procedure|serial excision|as much scar as possible is excised, whereafter the wound is closed
46067823|NCT00609908|Procedure|skin stretching device|after the scar is excised, the wound is primarily closed by aid of the skin stretching device
45444919|NCT03793491|Other|TCI scale|TCI scale : Evaluation of the patient's personality with the TCI before that the treatment by continuous infusion started.
46067824|NCT00789451|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
46067825|NCT00996281|Drug|Azilsartan medoxomil and chlorthalidone|Combination tablet.
45608529|NCT05157269|Drug|Placebo|Two matching placebo tablets administered orally twice daily for 5 days
45934928|NCT00211393|Drug|ketoconazole|600mg. /day for 6 weeks
45934929|NCT00211432|Drug|Anecortave Acetate Sterile Suspension (15 mg)|
45608530|NCT05157269|Dietary Supplement|Vitamin Super-B Complex|Vitamin Super-B Complex administered orally with food twice daily for 5 days to maintain the blind
45934930|NCT00211471|Drug|anecortave acetate|
45934931|NCT00211549|Drug|IDEA-033|
45934932|NCT00211588|Drug|galantamine|
45934933|NCT00211627|Device|KEEPASLEEP enhanced breathing device|
45934934|NCT00211666|Behavioral|Nurse management, home blood pressure monitors, and a chronic disease self management course.|
45934935|NCT00211705|Behavioral|Diet|
45934936|NCT00211705|Drug|Diet+pravastatin|
45934937|NCT00211744|Drug|topiramate|
45934938|NCT00211783|Procedure|fMRI|there is no intervention
46067826|NCT00996281|Drug|Olmesartan medoxomil and hydrochlorothiazide|Combination tablet.
46067827|NCT04259528|Device|Pediatric endoscopic ultrasound|endoscopic ultrasound at the esophageal stricture site to assess echo texture and esophageal layers
46067828|NCT04046653|Dietary Supplement|Allin|Dietary supplement
46067829|NCT04046653|Dietary Supplement|Sulforaphane|Dietary supplement
46067830|NCT04046653|Dietary Supplement|Placebo|Dietary supplement
45608531|NCT04457765|Drug|Povidone-Iodine (PVP-I)|1.25% Povidone-Iodine (PVP-I) (also known as betadine) to be used pre-procedure in the operating room via irrigation into the nasal cavity to act as viricidal preparation for the procedure. 240mL of 1.25% PVP-I will be distributed evenly among the right and left nasal cavities using a a 70mL syringe.
46067831|NCT00675129|Behavioral|Dialectical behavioral therapy for adolescents (DBT-A)|"Patients randomised to DBT-A will receive 16 weeks treatment, with one weekly session (60 minutes)of individual therapy, one weekly session of multifamily skills training (120 minutes), and telephone coaching outside therapy sessions.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus & Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
46067832|NCT00675129|Behavioral|Treatment as usual|Patients randomised to EUC will received standard care (16 weeks) at five participating child and adolescent outpatient clinics from therapists not trained in or practising DBT. According to pilot study data EUC will most likely consist of psychodynamic therapy, various forms of family therapy and supportive therapy.
45608532|NCT04457375|Diagnostic Test|TDC|measurements
45608533|NCT03472313|Drug|[18F]MNI-958|Healthy Volunteers recruited for the study will undergo a single [18F]MNI-958 injection and PET scan.
45608534|NCT03130907|Device|Placement of ureteral stent|will randomize groups to either receive a postoperative ureteral stent or not.
45608535|NCT03130751|Behavioral|Pocket Coach for AYA with Cancer|The Pocket Coach for AYA with Cancer is a psychosocial intervention to be delivered through a mobile platform. Intervention content is based on Mindfulness Based Stress Reduction (MBSR) and the Resilience in Illness Model [Dr. Joan E. Haase et al] and includes modules on relaxation, mindfulness, cognitions, and self-compassion.
45608536|NCT05156801|Device|ArchSinus stent|Post FESS unilateral placement of the ArchSinus stent into the randomized ethmoid sinus cavity.
45608537|NCT04865393|Drug|SPR206|SPR206 100 mg single-dose IV infused over 1 hour
45608538|NCT04805879|Biological|FMT oral Capsules|Each dose of FMT capsules consists of 20 capsules. The 20 over encapsulated capsules are derived from 100 grams of stool donated by a healthy indvidual that was screened to have no mental health issues or chronic or contagious doseases. Each capsule will contain 0.67 ml of pelleted intestinal microbes. Therefore it is considered that the 20 capsules are equivalent to 100 grams of stool
46067833|NCT04259294|Behavioral|Caspar Telerehabilitation|"The experimental group will receive home-based treatment program through mobile apps while control group will receive through a written home program sheets. The training contents will be equivalent, including trunk and lower limb strengthening and stretching, coordination, balance, and functional exercises that will be related to patients' daily living activities in their home.~The frequency and duration of the home program will be compromised by both the therapist and the patient. The videos of the home program will be sent to patients' app in smartphone by the therapist in the experimental group. Patients will perform the exercises while watching the videos in the app. After each exercise will be done, patient's performance feedback will be captured by the smartphone and will be sent back to the case therapist each time through the app while those in the control group will record their performance in a log sheet given by the therapists."
46067834|NCT04293887|Drug|Recombinant human interferon α1β|Saline needle 2ml + recombinant human interferon α1β10ug bid nebulization inhalation
45608539|NCT04805879|Biological|Placebo Capsules|Placebo Capsules that will look and weigh the same as the FMT oral capsules.
45608540|NCT04457999|Device|Lipiflow Thermal pulsation|Single vectored thermal pulsation treatment for dry eye
45608541|NCT03472235|Device|Microneedle|"TCA peeling session: Facial skin will be cleansed with tap water and degreased by rubbing with an alcohol sponge .~Then TCA 25% will be applied to the whole face by cotton tipped applicator or gauze pad. The entire face will be treated until complete frosting occur.~The patients will be instructed to wash their faces to decrease the burning sensation.~Combined session: starts with microneedle using microneedle device (Derma pen) The skin of each patient is cleaned with anti septic solution and anesthetic cream may be applied to lessen discomfort.~(Dermapen) will be applied on the lesional skin in four direction, vertical, horizontal and in the two diagonal until pin point bleeding occur which will be gently massaged .~After 10 minutes TCA peeling will be applied TCA peeling will be done for 8 session with 2 weeks interval between each session.~Microneedle will be done for 4session with 4 weeks interval between each session."
45608542|NCT05156489|Device|Fractionated Laser (Pixel CO2-Alma)|The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28±4) and at visit 4 (day 56±4) into vestibule, following the IFU of the device.
45608543|NCT05156021|Drug|anti-VEGF|To compare different injection times of anti-VEGF agents in PDR patients with NVG who underwent PPV combined with PRP and pressure-reducing valve implantation
46067835|NCT04259216|Behavioral|IMPACT Intervention|Brief remote session + tailored, daily 8-week mobile application facilitated messaging secondary prevention intervention.
45608544|NCT04637243|Other|Treatment of Benign or Malignant Liver and Bile Duct Diseases|Available treatment of Benign or Malignant Liver and Bile Duct Diseases
45608545|NCT03470987|Procedure|Phase I Periodontal therapy|Oral hygiene instuction, scaling and root planning
45608546|NCT03470987|Dietary Supplement|Metabolic control|Calorie restricted diet
45934939|NCT00211822|Procedure|fMRI|fMRI
45934940|NCT00211900|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine|single IM dose totalling 200 mcg of conjugate
45934941|NCT00211939|Drug|calcium acetate|667 mg gelcap, 2-4 t.i.d titrated to serum phosphorus level
45934942|NCT00211939|Drug|sevelamer|1-3 tablets t.i.d, titrated to serum phosphorus level
45934943|NCT00211939|Drug|atorvastatin|20 mg PO qD (in PhosLo group), or held until D60 (sevelamer group); titrate by LDL levels and liver function tests
45934944|NCT00211978|Drug|calcium acetate|667 mg gelcaps, 1-3 t.i.d. (titrated to serum phosphorus level)
45934945|NCT00211978|Drug|placebo|gelcap, 1-3 t.i.d. (titrated to serum phosphorus level)
45934946|NCT00212017|Drug|voglibose|
45934947|NCT00212017|Behavioral|diet and exercise therapy|
45934948|NCT00212056|Drug|ANP(hANP)|0∙025 μg/kg per min for 3 days(intravenous)
46067836|NCT04259216|Other|Control: Enhanced Online Resources (EOR)|EOR group participants will receive standardized information on cyberbullying.
46067837|NCT00675207|Drug|Brimonidine purite 0.15%|A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.
46067838|NCT00675207|Drug|Dorzolamide 2%|A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.
46067839|NCT00675207|Drug|Brinzolamide 1%|A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.
46067840|NCT00795223|Drug|morphine and bupivacaine|0.3 mg morphine for spinal together with 0.5% bupivacaine for femoral nerve block
45608547|NCT03470909|Procedure|Skin-Sparing Mastectomy (SSM)|"For patients undergoing SSM, 10 points of interest in radial localization have been selected for investigation of the presence of residual breast tissue.~The points are located under the remaining skin envelope and will be investigated by performing small biopsies with a cervical biopsy forceps.~Additionally, the distance between the surface of the specimen and the glandular tissue will be explored at five points at the base of the removed breast.~These histological sections will be radially oriented."
46067841|NCT00795223|Drug|spinal morphine and marcaine|0.3 mg spinal morphine together with 0.25% bupivacaine for femoral nerve block
46067842|NCT00795223|Drug|morphine and bupivacaine|0.2 mg morphine for spinal 0.5% bupivacaine for femoral nerve block
46067843|NCT00795223|Drug|morphine and bupivacaine|0.2 mg morphine for spinal together with 0.25% bupivacaine for femoral nerve block
46067844|NCT00795301|Drug|Capecitabine, Cetuximab, Oxaliplatin|
46067845|NCT00675285|Drug|montelukast sodium|one tablet 5 mg once/day for 4 weeks
46067846|NCT00675285|Drug|placebo|one tablet 5 mg once/day for 4 weeks
46067847|NCT04258982|Other|no intervention|no intervention
46067848|NCT00792961|Device|Endomicroscopy|Rigid drop-in endomicroscope imaging probe
46067849|NCT00675363|Procedure|Protocolized Sedation|Nurse-directed protocol for administering sedation and/or analgesia.
46067850|NCT00675363|Procedure|Protocolized sedation, with daily interruption|Nurse-directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
46067851|NCT05211908|Procedure|Composite resin restoration with Self Etch adhesive protocol and absence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the D-SE group, the universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
46067852|NCT05211908|Procedure|Composite resin restoration with Seletive enamel etch adhesive protocol and absence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the D-SELETIVE group a 37% phosphoric acid will be applied only at the enamel margin for 15s, then rinsed with water for 20s, and slightly dry. The universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
46067853|NCT05211908|Procedure|Composite resin restoration with Self Etch adhesive protocol and presence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the SD-SE group, the universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
46067854|NCT05211908|Procedure|Composite resin restoration with Seletive enamel etch adhesive protocol and presence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the SD-SELETIVE group a 37% phosphoric acid will be applied only at the enamel margin for 15s, then rinsed with water for 20s, and slightly dry. The universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
46067855|NCT00795379|Behavioral|Interoceptive Exposure|Exposure to internal stimuli.
45444920|NCT03793491|Other|PDQ-39 scale|PDQ-39 scale: Comparison of life quality before and after the starting of he treatment by continuous infusion.
45444921|NCT02056444|Drug|Tranexamic Acid|
45757830|NCT00689819|Behavioral|Exercise|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
45757831|NCT00689819|Behavioral|Weight Loss|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
45757832|NCT00689819|Behavioral|Low Sodium Diet|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
45911380|NCT02007421|Procedure|Participants asked questions about recent experiences of anal intercourse in the last six months.|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
45911381|NCT02007421|Procedure|High Resolution Anoscopy|The HRA is performed on HIV positive and HIV negative participants by study doctor after an examination of the perianal region and perineum. The plastic anoscope is inserted into the anal canal and visualised under high resolution magnification. Biopsy samples will be taken by the clinician for histological assessment if there are any detected abnormalities.
45934949|NCT00212056|Drug|Control|placebo
46067856|NCT00996203|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks for 24 weeks
45608548|NCT03470909|Procedure|Nipple-Sparing Mastectomy (NSM)|"For patients undergoing NSM, 14 points of interest in radial localization have been selected for investigation of the presence of residual breast tissue, i.e. comparing to SSM, 4 additional biopsies will be taken behind the peripheral part of the areola.~The points are located under the remaining skin envelope and will be investigated by performing small biopsies with a cervical biopsy forceps.~Additionally, the distance between the surface of the specimen and the glandular tissue will be explored at five points at the base of the removed breast.~These histological sections will be radially oriented."
45608549|NCT05151497|Other|Experimental group:Halliwick + Método Watsu|Carrying out the Ten Points Program through the Halliwick Concept, together with the Watsu Method through a series of relaxation maneuvers and mobilization of the body in float, and an immersion time of 15 minutes without doing physical activity in a pool at a temperature of 30ºC , to decrease spasticity of various muscles.
45608550|NCT05151497|Other|Control group:Halliwick|Exclusive use of treatment through the Halliwick Concept Ten Point Program, along with immersion in hot water to reduce spasticity in various muscles.
45608551|NCT04476251|Biological|E7 T-Cell Receptor (TCR)|Patients will receive up to 3x10^10 E7 T-Cell Receptor (TCR) T cells (i.e. TCR+ cells).
45653313|NCT03065881|Device|RETeval|The RETeval device measures the retina's electrical response to light, called an electroretinogram (ERG). The standards body ISCEV [1] recommends collecting normative data for ERGs to provide waveforms and statistically relevant measurements representing the range of ERGs from people with normal vision. LKC Technologies provides this information with their UTAS product line and wishes to collect such a database for the newest device: the RETeval device. As the RETeval device uses a different electrode to measure the ERG, the normal data for the UTAS product line is not transferable to the RETeval device. Ophthalmic practitioners would also like ERG examples of specific retinal disorders to help diagnose patients with abnormal ERGs. The RETeval device is FDA cleared (K142567),
46067857|NCT00996203|Drug|DMARDs (disease-modifying antirheumatic drugs)|stable doses at investigator's prescription
46067858|NCT04258748|Behavioral|Motivational Interviewing (MI)|In each of the four MI counseling sessions that were delivered, the researcher approached mothers in small groups of 5 via three phases, in 15-30 minutes, to establish rapport/ alliance in the first phase, to identify health needs in the second phase and finally to reinforce dental needs in the third phase.
45444922|NCT01305447|Behavioral|Exercise Behaviour Maintenance|Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to remind the participants of the self-regulatory skills they learned during group discussion.
45757833|NCT00689819|Behavioral|Smoking Cessation|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
45911382|NCT02007447|Drug|OCYTOCINA - SPRAY NASAL|The initial sample is divided into two groups (A and B): group A receive oxytocin intranasal for 8 weeks 24UI twice a day (3 applications per nostril 4UI 12/12 hours); group B will receive placebo for 8 weeks
46067859|NCT04258748|Behavioral|Gaming and MI|In each of the four MI counseling sessions, the researcher approached mothers via three phases, in 15-30 minutes, to establish rapport/ alliance, to identify and finally reinforce dental needs in the same pattern as MI group. In addition, the children were engaged in 'Happy Teeth, Healthy Kids' which is an android tablet game that was included in the MI session scheduled for the mothers. Children were told to follow correct steps of brushing in order to obtain happy bright teeth. This helped the children realize that brushing teeth will give them a bright smile.
46067860|NCT04258748|Behavioral|Conventional dental health education|It was delivered through a 15-minutes oral health session given to mothers of preschoolers. Mothers were given brief information about causes of dental caries and role of plaque, toothbrush size, diet / frequency of sweet snacks, brushing technique, toothpaste and fluoride use as well as regular dental visits. Participants were then shown a short educational video about prevention of dental caries among children coupled with oral hygiene instructions. At the end of the session, participants were given a leaflet reinforcing the information to take home.
46067861|NCT00675519|Behavioral|Motivational enhancement therapy|Motivational enhancement therapy begins with the assumption that the responsibility and capacity for change lie within the client. The therapist begins by providing individualized feedback about the effects of the patient's drinking. Working closely together, therapist and patient explore the benefits of abstinence, review treatment options, and design a plan to implement treatment goals.
46067862|NCT00789763|Drug|Gemcitabine|300 mg/m2/one per week, i.v., during 5 weeks.
46067863|NCT00789763|Radiation|Radiotherapy|1.8 Gy/day 5 days per week during 5 weeks (total dose 45Gy)
45608552|NCT05075681|Drug|Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide|"Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide.~Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI (only for Haploidentical and unrelated donor), Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;"
45608553|NCT03472001|Other|Reflection and feedback|2-hour training involving 10 written clinical cases to encourage students to practice thinking like a dermatologist in their clinical reasoning, and to help students build adequate illness scripts of skin diseases
45608554|NCT03472001|Other|Lecture|Traditional didactic lecture which uses the same clinical cases
45608555|NCT03470753|Other|Number of Exercises|Subjects will receive either 2 or 4 exercises to evaluate the short-term recall and performance.
45444923|NCT01305447|Behavioral|Smoking Relapse prevention booklets|Participants will be given Brandon et al. (2000, 2004) smoking relapse prevention booklets following exercise program.
45444924|NCT01305447|Behavioral|Contact control|No treatment, but equal contact time as the other intervention arms. Topics of women's health, unrelated to exercise will be discussed in group-mediated sessions(control).
45911383|NCT02007460|Behavioral|Exercise|multidirectional unilateral hopping exercise
45911384|NCT02007486|Other|Cardiopulmonary Exercise Testing|Symptom-limited incremental exercise testing (10 watts/min) on an electronically braked cycle ergometer
46067864|NCT00789763|Drug|Sorafenib|200-800 mg/day p.o. during 5 weeks
45444925|NCT02665234|Drug|1% Tavilermide Ophthalmic Solution|1% Tavilermide BID Dosing
45608556|NCT03470753|Other|Type of Instruction|The type of instruction in phase 1 will be compared: Instruction by providing a handout only vs being instructed by a provider and practiced by the patient with provider feedback.
45444926|NCT02665234|Drug|Placebo Ophthalmic Solution|Vehicle Ophthalmic Solution
45444927|NCT05624229|Drug|Proton Pump Inhibitors|PPI infusion stopped in standard group after endoscopy while continue to use for 5 days in experimental group
45444928|NCT02038192|Behavioral|Living with Hope Program|"The Living with Hope Program is based on the research team's grounded theory study Hope and Connection. The film  Connecting with Hope reflects the findings of the grounded theory study. Stories of the Present has been utilized in the team's previous research with family caregivers of persons with advanced cancer."
45444929|NCT02038192|Behavioral|Stories of the Present|Stories of the Present is a directed journaling activity in which participants write in a journal at the end of the day their challenges, hope and hope for tomorrow
45444930|NCT03793413|Procedure|Lingual frenotomy|A lingual frenotomy will be performed using a CO2 laser - using the NFANT bottle feeding system, the intervention arm will be compared against the observation arm to determine if there are changes in lingual mobility parameters during bottle feeding.
45444931|NCT03793101|Procedure|BiMICS|Biaxial microincision cataract surgery implies performing of 2 corneal incisions under 1.8mm, removal of the crystalline lens with the use of ultrasounds and implantation of the artificial intraocular lens.
46067865|NCT05211752|Other|eVOG (Mobile VideoOculoGraphy)|"Eyes movements assessed with e-VOG (mobile application, that uses the face detection features of the front camera to detect and record eye movements).~Study duration is about 20 minutes, the day the subject performs his standard video-oculography examination in routine care (using Eye-Tracker®T2)"
46067866|NCT00675675|Behavioral|Comprehensive Behavioral Intervention for Tics (CBIT)|Habit Reversal Training plus functional assessment/intervention designed to identify and ameliorate tic triggers (antecedents) and maintaining consequences.
46067867|NCT00675675|Behavioral|Minimal Contact Waitlist|Bimonthly phone check-in to assess clinical status and enhance subject retention
46067868|NCT00793117|Procedure|packing|packing in middle meatus for duration of 5 day
46067869|NCT00609050|Behavioral|Self-Regulated Exercise with Telephone Reinforcement|The self-regulated exercise with telephone reinforcement group will engage in a three-times-a-week (or more) at home exercise regimen for 6 months during which they may choose the mode of exercise. They will receive weekly telephone calls about exercise and airway clearance. After 6 months, they will be instructed to maintain their self-regulated exercise activity for the remaining 6 months of the study, but they will not receive telephone calls
45452247|NCT01030432|Drug|Peginterferon Alfa-2a|Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 24 or 48 weeks, depending on response
45608557|NCT03470753|Other|Delivery Type|In phase 2 subjects will be provided 4 exercises using only a handout vs delivered to them electronically with the addition of a video.
45608558|NCT03470753|Other|Mobile Reminder|A text-message based mobile reminder tool will be utilized to engage with subjects via texting on a daily basis to provide reminders and encouragement to perform their home exercises.
45608559|NCT04939181|Device|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents:~pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA."
45608560|NCT04939181|Device|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
45608561|NCT03902093|Diagnostic Test|Morphology changes with extended wear hearing aid|Possible changes in morphology due to wearing an extended wear hearing aid device will be assessed with imaging
45608562|NCT03855449|Behavioral|Task Analysis Intervention Group|Will conduct 9 week in-person group sessions of the DECIDE curriculum with recruited volunteers. This is part 1 or phase I of the eventual pilot clinical trial. Participants will attend weekly group sessions to learn problem-solving skills and management of their diabetes.
45608563|NCT03795233|Biological|Fecal microbiota transplant G3 capsules|After standard of care therapy with oral vancomycin, frozen oral FMT capsules will be provided in a formulation designed to deliver the product to the large intestine. 30 FMT capsules will be administered over a 2 hour period under direct observation
45608564|NCT03795233|Other|Oral Vancomycin alone|Standard of care will be provided with oral vancomycin therapy.
45608565|NCT03645863|Drug|MT-6548|Oral tablet
45608566|NCT03645863|Drug|Iron supplement A|Oral tablet
45608567|NCT03645863|Drug|Iron supplement B|Oral tablet
45608568|NCT03645863|Drug|Iron supplement C|Oral tablet
45757834|NCT00689819|Drug|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
45911385|NCT02007525|Behavioral|Yoga intervention|Participants will attend one weekly 60 minute hatha yoga class taught by a certified yoga instructor for 6 weeks. Each participant is to practice yoga at home 3-5 days per week. Paper logs will be provided to record date, time and duration of yoga practice each week.
45608569|NCT03645863|Drug|Iron supplement D|Oral tablet
45911386|NCT02007551|Behavioral|Mealtime Intervention|The mealtime intervention constitutes once a week visits from a trained volunteer for 8 weeks, each visit lasting 90 minutes and comprising of preparing and sharing a meal together with the participant.
45911387|NCT02007564|Behavioral|LIFE Intervention|RSVs received intensive training in the manualized intervention, including practice opportunities. The manual and accompanying workbook consist of instructions about using the steps of problem solving to decide on a period of life and creative activity project; constructing a project; evaluation of the activity; and additional questions. With the help of the RSV, dyads narrow the focus to one time period in the patients' life that could be adequately represented in one tangible project (scrapbook, audiotapes). The RSV and dyad brainstormed ways to portray the life story and then narrowed the focus to one meaningful project. The dyad gathered all necessary materials (such as pictures) and actively worked on completing a portion of the project between sessions.
45911388|NCT02007590|Device|Aerosure 25 Hz|Active Aerosure device
45911389|NCT02007590|Device|Aerosure Sham|Device designed to appear identical to active device but with HFAO mechanism disabled
45608570|NCT03564119|Drug|S5G4T-1|Once a day topical cream
45608571|NCT03564119|Drug|S5G4T-2|Once a day topical cream
45608572|NCT04457063|Procedure|PKP|"The horizontal axis was marked with a pointed marker at the slit lamp immediately before surgery.~TICL loading into the STAAR injector cartridge~Temporal clear corneal 3 mm incision & 2-side ports then viscoelastic injection into the AC~Implantation of the TICL using the injector, then rotation according to the implantation diagram guided with Mendez protractor, and lastly placement of the haptics under the iris.~Pupil constriction with A.Ch.~Washing the viscoelastic &Wound hydration.~Topical antibiotic steroids (Vigamox and Tobradex) 4 times /day for 3weeks"
46067870|NCT00609050|Behavioral|Standard Treatment|The attention control group will receive standard recommendations for exercise activity, during the first 6 months, as is common in our clinic. Also during the first 6 months, they will receive weekly telephone calls about airway clearance. For the final 6 months of the study, the attention control group will cross over to self-regulated exercise without telephone reinforcement.
46067871|NCT00609050|Behavioral|Qualitative Approach|A qualitative naturalistic approach is nested within the primary experimental framework to explore the experiences of the children and parents, in both groups, with the exercise regimen.
46067872|NCT02873741|Procedure|Perianal and Digital Anorectal Exam|The physician will inspect the outside of the anus and use a gloved finger to feel the anus for any masses.
46067873|NCT02873741|Procedure|Cervical Swabs|A speculum will be inserted into the vagina to visualize the cervix. The sample for research tests will be collected with one ThinPrep cytobroom inserted into the cervix. Collection will be same for the sample to be paced in the RNA storage solution for future biomarker studies.
46067874|NCT02873741|Procedure|Anal Swabs|The anal cytology specimen will be collected by inserting a saline moistened cotton-tipped swab into the anus, rotating it clock-wise for 20 seconds, and placed in SurePath. The first twenty participants will have anal cells collected in two different ways for validation/optimization: 1) saline moistened Dacron swab placed directly in ThinPrep medium and 2) Medscand Cytobrush Plus, a special brush, placed directly into ThinPrep medium. After validation/optimization is complete for up to 20 participants, the best collection method will be selected and will be used for all future enrolled participants.
45608573|NCT04531241|Device|ACUVUE® OASYS 1-DAY|senofilcon A contact lenses made with a novel manufacturing technology
45608574|NCT04531241|Device|ACUVUE® OASYS 1-DAY|senofilcon A contact lenses made with the current manufacturing technology
46067875|NCT02873741|Procedure|High Resolution Anoscopy (HRA)|High Resolution Anoscopy is a procedure that allows for examination and evaluation of the anal canal. Using a small thin round tube called an anoscope, the anal canal is examined with a high resolution magnifying instrument called a colposcope. Application of a mild acidic liquid (acetic acid or diluted vinegar) or a brown iodine-based solution (Lugol's) onto the anal canal facilitates evaluation of abnormal tissue such as anal dysplasia. If abnormal staining is seen using acetic acid (dense white lesion) or Lugol's solution (bright yellow lesion) a biopsy of that area will be obtained.
46067876|NCT04258670|Other|No intervention|Patients in these cohorts will not be given anti-filariasis therapies because these drugs are not approved for use in patients with high worm burdens (>20,000 Mf/mL)
46067877|NCT02554357|Drug|Exparel block in arthroscopic shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
45608575|NCT04503707|Drug|Follitropin Delta|The Intervention (solution for injection) is delivered with a pre-filled injection pen. The REKOVELLE dose will be based on a recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the ELECSYS AMH Plus Immunoassay.
46067878|NCT02554357|Drug|Bupivacaine block in shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
46067879|NCT00877929|Drug|Telmisartan 80|Telmisartan 80 mg
46067880|NCT00877929|Drug|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
46067881|NCT00877929|Drug|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
46067882|NCT04258514|Procedure|Virtual Reality during vasectomy|Virtual Reality
46067883|NCT04258514|Procedure|Standard Vasectomy|No Virtual Reality
45608576|NCT03471923|Diagnostic Test|Neurological Examination|The family members and healthy volunteers will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of cervical dystonia and other sensory abnormalities. If the subject is found to have cervical dystonia or any other sensory abnormalities, the subject will be excluded from the study.
46067884|NCT00795457|Biological|GAA/TT-peptide vaccine and poly-ICLC|Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
46067885|NCT00795457|Biological|GAA/TT-peptide vaccine and poly-ICLC|Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
46067886|NCT00931268|Device|Macrolane VRF 30|One administration
45444932|NCT05622370|Drug|Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB)|"Brivaracetam tablets (trade name: Briviact) Specification: 50mg/ piece Batch number: 34244 Content: 100.0% Date of purchase: September 2022~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach.~Expiry date: April 2025 Storage conditions: sealed, stored at 20-25℃, allowing short-term temperature deviation of 15-30℃ Manufacturer: Union Chimique Belge Pharm, UCB Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd."
45452248|NCT01030432|Drug|Ribavirin|Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 48 weeks
45452249|NCT01030432|Drug|Ribavirin|Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 24 or 48 weeks depending on response
45452250|NCT02269462|Drug|Efavirenz|600 mg once daily in combination with other drugs (e.g. tenofovir and emtricitabine)
45452251|NCT02269462|Drug|Nevirapine|200 mg twice daily in combination with other drugs (e.g. tenofovir and emtricitabine)
45444933|NCT05622370|Drug|Brivaracetam sustained-release tablets 100mg|"Brivaracetam sustained-release tablets Specification: 100mg/ tablet Batch number: 22081201 Content: 102.5% Date of production: August 12, 2022 Expiry date: August 11th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach."
46067887|NCT00793195|Drug|Intralipid 20%|Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
45608577|NCT03471923|Diagnostic Test|Assessment of Non-Motor Features|All subjects will be assessed for four non-motor symptoms, including (1) spatial discrimination threshold, (2) temporal discrimination threshold, (3) vibration-induced illusion of movement, and (4) kinesthesia.
45608578|NCT03470597|Other|dietary iodine restriction on subjects with iodine overload|In this case registry study (observational study),all intervention will be performed not for research purposes, but only part of routine treatment, which will be recorded in database of the registry study.
45608579|NCT02522897|Drug|Ranibizumab|
45608580|NCT02522897|Device|Laser|
45608581|NCT04406987|Procedure|decompression|surgical technique for neural decompression varied based on surgeon's preference, but always with preservation for spinous processes. Either open with or without microscope or using tubular retractors.
45608582|NCT04406987|Procedure|fusion|fusion techniques consisted besides decompression of additional implantation of pedicle screws with rods, with or without intervertebral fusion and cage(s). Non-instrumented technique with allograft bone. Fusion technique on surgeon's discretion.
45608583|NCT04351061|Drug|Acetazolamide|Acetazolamide 500 mg by mouth twice per day for 7 consecutive days.
45608584|NCT03130829|Dietary Supplement|Oligo Fucoidan|Oral, twice daily
45608585|NCT03130829|Dietary Supplement|Placebo|Oral, twice daily
45608586|NCT04318145|Drug|PL-3994 Aqueous Intravenous Solution Dose Ascention|Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion
45608587|NCT04318145|Drug|PL-3994 Aqueous Intravenous Solution Single Dose|Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion
45608588|NCT04206761|Drug|QVM149|QVM149 is an investigational drug consisting of 150μg indacaterol acetate, 50μg glycopyrronium bromide and 160μg mometasone furoate. The drug is delivered as powder in hard capsules via Breezhaler, a breath-activated device which will deliver a specific dose of medication
45608589|NCT04206761|Drug|High Dose Dual Therapy (ICS/LABA)|High dose inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) in any approved drug formulation and delivery device.
45608590|NCT03931187|Behavioral|Cognitive progressive muscular relaxation therapy|This therapy combines cognitive psychotherapy and progressive muscular relaxation, intervened 6 times with 1-1.5 hour each time. The whole therapy will last round 28-30 days during IVF-ET.
45608591|NCT03181529|Drug|Psilocybin|Participants will receive a moderately high psilocybin dose in the first session and will receive either a moderately high or high psilocybin dose in the second session.
45608592|NCT02726009|Drug|Degarelix|
45608593|NCT03914105|Procedure|Without music|"The starting condition will be without music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be no music for the duration."
45608594|NCT03914105|Procedure|With music|"The starting condition will be with music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be music for the duration."
45608595|NCT02259725|Drug|regorafenib|Given PO
45608596|NCT02259725|Other|laboratory biomarker analysis|Correlative studies
45608597|NCT03668639|Drug|Akynzeo|Weekly administration of akynzeo for five weeks.
45608598|NCT03668639|Drug|Dexamethasone|Weekly administration of dexamethasone 12 mg Day 1, 8 mg Day 2-3, and 4 mg Day 4 for five weeks.
45608599|NCT03556319|Dietary Supplement|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
45608600|NCT03556319|Dietary Supplement|Placebo|Placebo Comparator
45608601|NCT03470441|Drug|FDY-5301|FDY-5301 will be administered once, intravenously, by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
45608602|NCT03470441|Other|Placebo|Placebo will be administered intravenously by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
45608603|NCT03470363|Drug|Sevoflurane Volatile Liquid|
45608604|NCT03470363|Drug|Bupivacaine / SUFentanil|
45608605|NCT03471689|Behavioral|Mindfulness meditation|Participants will be trained to use mindfulness meditation to reduce pain perception.
45608606|NCT03471689|Behavioral|Positive reappraisal|Participants will be trained to use positive reappraisal to reduce pain perception.
45608607|NCT03469895|Drug|ibrutinib ou idelalisib|treatment by ibrutinib or idelalisib for autoimmune cytopenia
45608608|NCT05160857|Drug|Herombopag Olamine|The initial dose of hetropapa is recommended to be 7.5mg, once a day, oral on an empty stomach, and can only be eaten after oral administration for 2 hours, so as to avoid taking it with meals.
46067888|NCT00793195|Drug|SMOFlipid 20%|Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
45608609|NCT03469817|Diagnostic Test|MRI|"Patients who are part of Arm 2 will undergo an MRI at their 1 year post-operative visit."
46067889|NCT00996125|Biological|CervarixTM|Subjects will receive three doses of the Cervarix vaccine intramuscularly according to a 0, 1, 6-month schedule.
46067890|NCT00996125|Other|Control|Subjects will receive three doses of control intramuscularly according to a 0, 1, 6-month schedule.
46067891|NCT00793273|Drug|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug Levemir® in daily clinical practice
46067892|NCT04301141|Other|Virtual Reality Assisted Cognitive Behavioural Therapy|The intervention will be delivered in NHS services and will involve using VR to assist the delivery of conventional CBT for the treatment of social anxiety in autistic adolescents. Social situations that are commonly anxiety-evoking for this patient group will be simulated in VR and used for exposure (a typical component of CBT for social anxiety). Therapists will use a modular approach involving optional modules such as psychoeducation on anxiety in the context of ASD, managing expectations of outcome and emotional literacy training. Essential modules include rapport building, introducing the use and purpose of VR, and exposure (incorporating VR). Because CBT is delivered in routine clinical practice, the VR exposure sessions will be the main subject of interest.
46067893|NCT04979780|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using US Optum De-Identified EHR data.
46067894|NCT04979780|Drug|Low molecular weight heparin (LMWH)|Retrospective cohort analysis using US Optum De-Identified EHR data. LMWH (dalteparin, enoxaparin, tinzaparin)
46067895|NCT04979780|Drug|Direct Oral Anticoagulants (DOAC)|Retrospective cohort analysis using US Optum De-Identified EHR data. DOAC (apixaban, dabigatran, edoxaban, rivaroxaban).
46067896|NCT04045951|Other|Myopia prediction algorithm|Candidate predictors included age at examination, SER, and annual progression rate. Using these predictors, the algorithm will be used to predict SER at 3 years.
46067897|NCT04598009|Drug|Binimetinib|Taken orally (PO) twice a day (BID)
46067898|NCT04598009|Drug|Imatinib|Taken orally (PO) once a day (QD)
46067899|NCT05330624|Biological|plague vaccine(F1+rV)|plague vaccine(F1+rV) (Lanzhou Institute of Biological Products Co.,Ltd) of 1.0ml, three doses
46067900|NCT00793351|Procedure|Reduced-intensity allogeneic hematopoietic stem cell transplantation|"Treatment Scheme~Enrollment - Pre-RIST treatment - RIST~4 cycles of conventional chemotherapy will be given prior to RIST.~Surgery will be done whenever possible prior to RIST.~Local radiotherapy will be applied whenever possible prior to RIST.~topotecan + cyclophosphamide) regimen will be used for pre-RIST conventional chemotherapy.~Cyclophosphamide/Fludarabine (CyFlu) regimen will be used as conditioning regimen for matched related or unrelated SCT. CyFlu-ATG regimen will be used as conditioning regimen for mismatched related SCT."
45608610|NCT05160779|Other|Analysis of genetic polymorphisms of vasoactive peptides in COVID-19|Evaluate the frequency of the insertion/deletion (I/D) polymorphism in the ACE gene; to assess the frequency of polymorphism in the bradykinin B2 receptor gene; to assess the frequency of the polymorphism in the CK-M gene and compare the frequencies of these polymorphisms between patients with severe and mild conditions.
45608611|NCT05160623|Drug|Povidone-Iodine 1 % Topical Solution|Povidone-Iodine 1 % topical solution on a makeup remover pad, used to clean the lids and lashes once daily
46067901|NCT02628639|Device|high-density electroencephalography|
45608612|NCT05160623|Drug|Eyelid cleansing wipes|EYECARE FORTE eyelid wipes (Dr. Fischer, Israel), used to clean the lids and lashes once daily
45608613|NCT04713137|Dietary Supplement|Erythritol|50g erythritol dissolved in 300mL tap water.
45608614|NCT04713137|Dietary Supplement|Sucrose|33.5g sucrose dissolved in 300mL tap water.
45608615|NCT04713137|Dietary Supplement|Sucralose|0.0558g sucralose dissolved in 300mL tap water.
45608616|NCT04713137|Dietary Supplement|Water|300mL tap water.
45608617|NCT03470207|Procedure|Post-pulmonary embolism follow up protocol|Structured post-pulmonary embolism follow up protocol (outlined in Aim 1)
46067902|NCT00610064|Radiation|Baseline neuroimaging|Baseline neuroimaging using PET and MRI of the brain in patients before sacral neuromodulation
46067903|NCT00610064|Radiation|Neuroimaging during sacral neuromodulation|Neuroimaging during sacral neuromodulation using PET
45608618|NCT05159921|Other|Access to an automated conversational agent (SurgInfoBot)|See above under arm/group descriptions.
45608619|NCT04676009|Other|Exercise arm :|"Patients will receive physical activity recommendations at inclusion.~At each treatment cure, patients will receive pre-exercise nutritional recommendations and an acute physical exercise prior to immunotherapy and chemotherapy. The acute physical exercise will last 35 minutes and will be intermittent and individualized based on the results obtained by the patient during an endurance test on a ergocyle performed prior to treatment.~3 blood sampling times (2 EDTAsx10 mL) will be specially added to the study and will take place before exercise (1), after exercise (2) and 12 hours after the start of treatment (3).~A nutritional assessment will be carried out during the first and last treatment cure.~They will also benefit a home walking program. These patients will have to wear an activity tracker tracker during all intervention (3 months).~They will have a phone follow-up every 10 days (± 3 days) after each treatment cure for the study duration."
45911390|NCT02007603|Drug|Administration of Amoxicillin / clavulanic acid|Patients receive amoxicillin / clavulanic acid due to clinical necessity
45911391|NCT02007603|Drug|Ampicillin / sulbactam|Patients receive ampicillin / sulbactam due to clinical necessity
45608620|NCT05159843|Behavioral|Therapeutic education|"Participants randomized to this arm receive therapeutic education during four sessions of four consecutive days. An advanced practice nurse who specializes in diabetes will teach these sessions. The sessions will have small groups of five patients and it will last of one hour each day. The outline of the session is as follow (Figure 1):~First session: Insulin administration and blood glucose self-analysis Second session: Management of hypoglycemia and hyperglycemia Third session: Healthy diet adapted to the diabetic patient Four session: Physical exercise"
45608621|NCT04456985|Dietary Supplement|Folic acid and vitamin B12|Take folic acid and VitB12 for 3 consecutive days before surgery
46067904|NCT04292951|Procedure|Fluid and inotropic/vasoactive management protocol|GDT protocol: keep SVV 10-13% and give fluid when SVV > 13%, give inotropic to maintain CI 2.5-4 L/min/m2, give vasoactive drugs to maintain SVRI 1,900-2,400 dynes-sec/cm-5/m2 Control protocol: keep CVP 8-12 mmHG and give fluid when CVP < 8 mmHg, give inotropic/vasoactive to maintain normal blood pressure and heart rate
46067905|NCT00795613|Drug|ESCALATED BEACOPP|Esc.BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 200 mg/m2/ev/die1°- 3° Doxorubicine35 mg/m2/ev/die 1° Cyclophosphamide1250 mg/m2/ev/die 1° Vincristine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/b.m./die 1°- 7° Prednison40 mg/m2/b.m./die 1°-14° G-CSF300mcg/die s/c from day 8 until PMN>1000/ul Recycle every 21 days Esc.R-BEACOPP as above plus Rituximab 375 mg/m2/ev/ die 1° Recycle every 21 days Baseline BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 100 mg/m2/ev/die 1°-3° Doxorubicine25 mg/m2/ev/die 1° Cyclophosphamide650 mg/m2/ev/die 1° Vincrinstine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/os/die 1°-7° Prednison40 mg/m2/os/die 1°-14° Recycle every 21 days Baseline R-BEACOPP as above plus Rituximab375 mg/m2/ev/ die 1° Recycle every 21 days
46067906|NCT00795613|Drug|CONVENTIONAL ABVD|ABVD(cycle repeats every 28 days) Doxorubicine25 mg/m2 iv days 1,15 Bleomicine10,000 units/m2 iv days 1,15 Vinblastine6 mg/m2 iv days 1,15 Dacarbazine375mg/m2 iv days 1,15 This will be given at full dose and on schedule,regardless of blood count.
46067907|NCT00675753|Genetic|Blood spot specimens will be drawn|Blood spot specimens will be drawn from mother-baby dyads in the control and experimental groups and sent for genotyping
45608622|NCT04456985|Dietary Supplement|brown sugar aqueous|take 20 ml of brown sugar aqueous solution with the same concentration as the intervention group 3 days before the operation
46067908|NCT04293263|Combination Product|2gether app used by trained personal|"each of the elderly in the study group will listen to personalized music twice a week for an hour each time together with a musical partner. Joint listening is performed with 2 pairs of headphones that connect via a splitter to the partner's cell phone. A listening session will take place in a period of 30 minutes and not more than 60 minutes.~Musical partner - A person trained in the program's work plan, which includes contact with empathic listening and the use of a dedicated application developed for it. A musical partner will meet with the same elderly person throughout the study period.~Empathetic listening - a situation in which a person listens to music with another person, while the music enables contact and deepening the connection between people."
46067909|NCT00675831|Device|CliniMACS CD25 Reagent Device|Used to engineer CD25+ depleted donor lymphocytes which will be infused intravenously over 5-10 minutes
46067910|NCT04263428|Behavioral|Irregular sleep|Experimental-induced sleep variability
45608623|NCT05159609|Device|Closed loop auditory stimulus|50ms of low volume pink noise delivered during slow wave sleep
45608624|NCT04456907|Other|platelet rich plasma|Autologous platelet-rich plasma (PRP) was prepared using the RegenKit THT system (RegenLab SA, Le Mont-sur-Lausanne, Switzerland) following the manufacturer's instructions. Medical technicians, who had been well-trained by the manufacturer, were responsible for the process of PRP preparation. For each patient, 8-10 mL of venous blood was drawn and collected to the commercial RegnLab THT tube, which contained 1 mL sodium citrate. After single centrifugation at 3400 revolutions per minute (rpm) for 8 minutes, 4-5 mL of PRP was yielded with leukocytes maintained at physiological levels and red blood cells depleted. Then, the blood components were separated, with the platelet pellet resting on the separating gel. PRP for later application was obtained by re-suspending the platelet pellet in the plasma supernatant by gently inverting the unopened RegenKit THT tube 5 to 10 times.
45608625|NCT04456907|Other|saline injection|saline injection
45608626|NCT03470129|Device|fissure sealing|sealing of occlusal fissures with either the conventional sealant, Helioseal F, or the new sealant, Helioseal F Plus, which provides an additional feature and an improved formulation
45608627|NCT04456751|Other|Redo op|Patients with a redo operation
45608628|NCT03469583|Drug|EYP001|EYP001 self administered capsules, morning, with non carbonated water
45608629|NCT03469583|Drug|Entecavir 1 MG|Entecavir self administered tablets, morning, with non carbonated water
45757835|NCT00689819|Behavioral|Weight Loss|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
45608630|NCT04442477|Dietary Supplement|Enriched Protein Fractions|Enriched protein fractions
45608631|NCT04442477|Dietary Supplement|Protein Fraction|Protein fractions
45608632|NCT03470051|Diagnostic Test|QT Ultrasound|All subjects will be asked to agree to an ultrasound-guided breast needle biopsy by a qualified radiologist experienced in this procedure if not already completed prior to study entry.
45608633|NCT03469973|Procedure|Partial adenoidectomy|"The procedure will be completely visualized with a 45 degrees, 4- mm nasal endoscope; the upper part of the adenoid will be removed using the microdebrider, while the lower part will be preserves to maintain the velopharyngeal competence.~• Adenoid enlargement causing Obstructive Sleep-Disordered Breathing (OSDB) with velopharyngeal insufficiency (proved or suspected)."
45608634|NCT04096313|Diagnostic Test|HbA1c, Lipids, UACR|compare diagnostic tests to reference methods
45911392|NCT02007603|Procedure|Blooddraws for pharmacokinetic profiling|Blood will be sampled at multiple timepoints during multiple hemodialysis sessions
45911393|NCT02007616|Other|Non-action video game training|Based on cognitive training Lumosity
45608635|NCT05096039|Drug|Sacubitril/valsartan|Beneficiaries with one or more prescription claim with an NDC for sacubitril/valsartan (from the PDE file) during the 90-day episode window. Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
45608636|NCT05096039|Drug|ACEI or ARB and no sacubitril/valsartan|Beneficiaries with one or more prescription claim with an NDC for any ACEI/ARB and no prescription claims for sacubitril/valsartan during the 90-day episode window. Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
46067911|NCT00800761|Drug|Deferoxamine and Deferiprone|comparison of two arms: the first one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die plus deferiprone tablets 75 mg/kg three times/die versus the second one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die
46067912|NCT00800761|Drug|Deferoxamine|deferoxamine vials,40 mg/kg,12 hours/die
45608637|NCT05604131|Drug|Deferiprone Tablets|Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.
45608638|NCT05604131|Drug|Placebo|Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.
45608639|NCT03469271|Drug|1,25 (OH)2 D3|0.25 micrograms, taken daily for eight weeks, orally
45608640|NCT03469271|Other|Inspiratory isometric resistance training|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.Participants in the active groups will breathe against a resistance set to generate 30% of maximal inspiratory pressure (PImax).
45608641|NCT03469271|Drug|Oral Placebo|Placebo will be created to mimic the appearance of the study drug
46067913|NCT04220645|Other|Opportunstic treatment|opportunistically treating HCV infection immediately when hep C patients are hospitalized for acute care in psychiatric, addiction treatment or somatic wards
46067914|NCT04220645|Other|Standard of care|Referral at discharge
46067915|NCT00676221|Drug|Myfortic|"Mycophenolate Mofetil (Cellcept) discontinued at Baseline visit. Mycophenolate Sodium(Myfortic)commenced the following day at equimolar doses orally BID.~Cellcept 1000mg bid = Myfortic 720mg bid"
45608642|NCT03469271|Other|Sham Inspiratory Isometric Resistance Training|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles. Participants in the sham group will train daily against a resistance set to only 15% PImax.
45608643|NCT03469271|Device|Threshold Inspiratory Muscle Trainer (IMT)|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.
45608644|NCT05163197|Procedure|Transperineal Laser Ablation of Prostate Cancer|Minimal invasive transperineal laser ablation treatment for prostate cancer
45608645|NCT05162963|Other|fixed implant denture|Patients will receive four or six dental implants, four in the mandible or six in the maxilla, depending on the arch to be treated. After an osseointegration phase of 4 to 6 months, two implant prostheses will be made for each patient, one removable, the other fixed. According to the randomization, during an initial period of 6 months, half of the patients will be using the removable prosthesis, the other half the fixed prosthesis. A 15-day washout will be performed. Then, during a second period of 6 months, the patients will be using the second prosthesis.
45608646|NCT05162963|Other|removable implant denture|removable implant denture
45608647|NCT03500237|Behavioral|Team-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. In addition to the online program, a guide from the Online Therapy Unit team will respond within one business day of the client's email. The team of guides consist of registered social workers, psychologists or supervised graduate students, with experience delivering ICBT. Amount of contact will be personalized to participants' needs.
45608648|NCT03500237|Behavioral|Self-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no psychoeducational support will be provided. A team member from the Unit will contact the participant only if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms).
45653314|NCT05047575|Other|REASSURE|REASSURE utilizes remote patient-reported outcomes assessments to comprehensively assess symptoms, promotes practice change by providing feedback reports to oncologists and engaging primary care providers (PCPs) in survivorship care, and reduces the burden of follow-up by substituting an oncology visit for thriving survivors with reassurance messaging and encouragement to pursue preventive care.
45653315|NCT03065959|Drug|reldesemtiv|oral
45911394|NCT02007629|Drug|Riociguat (Adempas, BAY63-2521)|Riociguat / BAY63-2521 film-coated tablets will be used in this study at a dosage of either 0.5, 1.0, 1.5, 2.0, and 2.5 mg. 3 times daily
45911395|NCT02007642|Procedure|Blood sampling / Body fluid sampling|"During the hospitalization of the patient, when a sampling is done for classic follow-up and diagnosis, additionnal blood sampling will be done, for the PATHOQUEST method.~Other body fluids might be taken (if the sampling is done for the classic follow-up), such as cerebrospinal fluid, ascite..."
46067916|NCT05206136|Device|Ultrasonography|Neck and Low back muscles will be evaluated by ultrasound.
46067917|NCT00800917|Drug|Temsirolimus|25 mg weekly IV
46067918|NCT00800917|Drug|Bevacizumab|10 mg/kg every 2 weeks
46067919|NCT04276337|Diagnostic Test|LiquidSCAN(Trade Mark) / CancerSCAN(Trade Mark)|LiquidSCAN : detection of circulating DNA CancerSCAN : detection of somatic mutation using tumor tissue
46067920|NCT00676299|Drug|JNJ-26483327|
46067921|NCT05003102|Drug|Dexmedetomidine Hydrochloride - Cycling|Dexmedetomidine Hydrochloride infusion at 0.5 mcg/kg titrated to 0.3 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr.
46067922|NCT05003102|Drug|Fentanyl - PICU Standard|fentanyl infusion at 1 mcg/kg/hr up to a max drip rate of 5 mcg/kg/hr
46067923|NCT05003102|Drug|Dexmedetomidine Hydrochloride - PICU Standard|Dexmedetomidine Hydrochloride infusion at 0.3 mcg/kg titrated to 0.5 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr
45608649|NCT05142059|Diagnostic Test|Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with Charcot-Marie-Tooth disease type 1A|The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter. A final analysis will be carried out at 1 year from the first according to the same methods as the initial assessment.
45757836|NCT00689819|Behavioral|Low Sodium Diet|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
45757837|NCT00689819|Behavioral|Smoking Cessation|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
45608650|NCT03361865|Drug|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
45608651|NCT03361865|Drug|Epacadostat|Epacadostat administered orally twice daily.
46067924|NCT00676377|Drug|Neostigmine|2.5 mg of neostigmine intravenously in 250 ml normal saline over a period of thirty minutes ,Half Life 3 Hours
46067925|NCT00676377|Drug|Saline|Saline Placebo
45608652|NCT03361865|Drug|Placebo|Matching placebo administered orally twice daily.
45608653|NCT05053763|Drug|Remimazolam|The study was carried out using a biased coin design up-and-down sequential method, where the dose of remimazolam administered to each patient depended on the response of the previous one with success/failure duodenoscopy insertion during ERCP are required for reliable estimates. The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size). Duodenoscopy insertion was conducted when MOAA/S≤1.The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement). if a patient had a failure duodenoscopy insertion, the dose of remimazolam was increased by 0.025mg/kg in the next subject. If a patient had a successful duodenoscopy insertion the next subject was randomised to receive either a lower dose (with a decrement of 0.025mg/kg), with a probability of b = 0.11, or the same dose, with a probability of 1-b = 0.89.
45608654|NCT02982083|Drug|Raloxifene hydrochloride|20 patients consume raloxifene hydrochloride oral tablet daily for one year.
45608655|NCT02982083|Drug|Placebo Oral Tablet|20 patients consume placebo oral tablets daily for one year.
46067926|NCT00795691|Behavioral|low-carbohydrate diet|ketogenic low-carbohydrate diet in patients with type 2 diabetes
46067927|NCT00795691|Behavioral|low-fat diet|low-fat diet in patients with type 2 diabetes
46067928|NCT00676533|Drug|Cipro XR (Ciprofloxacin, BAYQ3939)|3 tablets of Cipro XR 500 mg and were instructed to take 1 tablet per day for 3 days.
46067929|NCT04261244|Radiation|preoperative radiotherapy|preoperative radiotherapy instead of postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
46067930|NCT04261244|Radiation|postoperative radiotherapy|postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
45608656|NCT04996901|Other|no intervention|no intervention
45608657|NCT02421341|Drug|Fentanyl|During study visits 2 and 3 you will receive an intrathecal (fluid filled space surrounding the spinal cord) injection of either fentanyl or placebo (saline). Fentanyl is an opiate (narcotic) drug and a common medication, however the way fentanyl is being used in this study is considered investigational.
46067931|NCT04211363|Drug|Roflumilast 0.3% cream|Roflumilast 0.3% cream for topical application.
46067932|NCT04211363|Drug|Vehicle Cream|Vehicle cream for topical application.
45911396|NCT02007668|Other|Kinesio Taping|Kinesio taping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the lumbar spine.
45911397|NCT02007681|Behavioral|Reduction of sedentary time by breaking it with low intensity physical activity|One 5-10 minute break per hour during the work day using a software that alert the participant, and perform 6000 steps above the baseline number of steps/day (previously evaluated), by adopting several domain specific strategies, during 7 days.
46067933|NCT04052295|Procedure|surgical diaphragmatic plication|The plication was done by the same surgeon either via a 7-8 cm long lateral thoracotomy and entrance to the pleural cavity through the eighth intercostals space on the affected side or using VATS (video-assisted thoracoscopic surgery) procedure. It was performed under single lumen intubation general anaesthesia. The diaphragm with the abdominal content was pushed caudally till the normal position of the copula achieved. At this position a fold of about 5 cm is made using traction forceps of the reluctant diaphragm. Polypropylene sutures (zero or 1) were used to perform the plication of the diaphragm. in making a fold on itself. The plication was performed using interrupted polypropylene U-stitches; usually, it started from posterior part to the anterior part of the diaphragm. We merged every two rows with continuous polypropylene sutures. The diaphragm became tough and firm and returned to its normal position. An intercostal tube was inserted, and the thoracotomy was closed in layers.
46067934|NCT00676767|Dietary Supplement|Resistant Starch Type 4|
46067935|NCT00676767|Dietary Supplement|Dextrose|
46067936|NCT00676767|Dietary Supplement|Puffed wheat|
46067937|NCT04263272|Other|Upper Body Circuit Training Program|16 week seated upper body exercise for persons with Spinal Cord Injuries. Participants will attend 2-3 exercise sessions a week, sessions have a mix of SCI community members and inpatients.
46067938|NCT00676845|Drug|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
45608658|NCT02421341|Procedure|Catheters|A catheter (small plastic tube placed in a blood vessel) will be placed in an artery in your arm and a second catheter will be placed in a vein in your leg. Local anesthetic will be used to minimize discomfort. These catheters will allow us to measure blood pressure, leg blood flow and draw blood.
45757838|NCT00689819|Drug|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
45757839|NCT02209545|Drug|Misoprostol|25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
45608659|NCT02421341|Other|Exercise|You will be asked to exercise, ride a stationary bike, at maximal exertion.
45608660|NCT02421341|Radiation|DEXA|During study visit one you will have a DEXA scan. This procedure requires you to lie on a table while a small x-ray tube passes under your body.
45608661|NCT02421341|Other|Pulmonary Function Tests|During study visit one you will be asked to perform 5 different breathing tests to help us better understand your lung function.
45608662|NCT02421341|Other|Blood Draw|You will have approximately 350 mls (1.25 cups) of blood drawn during the duration of this study.
45608663|NCT02421341|Other|Chemosensitivity Test|Using a bag you breath in and out your own air.
45608664|NCT02421341|Drug|Placebo|
45608665|NCT02149121|Biological|CT-P10|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
46067939|NCT00676845|Drug|placebo|dosage form: tablet; frequency: daily; duration: 3 weeks
46067940|NCT00676845|Drug|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
46067941|NCT00676845|Drug|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
45608666|NCT02149121|Drug|Rituxan|US-licensed reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
45608667|NCT02149121|Drug|MabThera|EU-approved reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
46067942|NCT04946708|Other|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions. All participants (and immediate caregiver if necessary) will receive training in: 1) basic device management (join a zoom meeting, watch a YouTube video), 2) use of the portable spirometer and its associated app, 3) use of finger pulse oximeter and 4) recording of the values in a dairy.
46067943|NCT04152057|Drug|Pyrotinib Maleate Tablets|400mg/d,po qd,q3w, 4 cycles
46067944|NCT04152057|Drug|Albumin Paclitaxel|125mg/m2,ivggt,d1,q3w,4 cycles.
46067945|NCT04152057|Drug|Trastuzumab|The first week load dose 4mg / kg, followed by 2mg / kg per week, d1,ivggt,q3w,4 cycles.
46067946|NCT00610142|Drug|pimecrolimus 1% cream|twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
46067947|NCT00610142|Drug|hydrocortison 1% cream|twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
46067948|NCT04151823|Drug|Vitamin D3|2 ml per day SMART D3 MATRIX Smartfarma S.r.l. Via San Vittore 40 - 20123 MILAN: 2 mL of product will give 1600 UI/die of VIT D3.
46067949|NCT04151823|Drug|Immunofos|Postbiotics will be given at the dose of 80 mg/day. immunofos from Lactobacillus paracasei CNCM I-5220).
46067950|NCT04151823|Other|Promotion of physical activity|Promotion of physical activity will be encouraged at t0, t1, t2
45757840|NCT02209545|Drug|Placebo|25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
45608668|NCT01353521|Procedure|Contrast-enhanced ultrasound|A contrast-enhanced ultrasound utilizes intravenous gas-filled microbubbles to enhance visualization in real time.
45608669|NCT04456283|Behavioral|Survival|5 year survival after Chemoradiation theraphy for Rectal Cancer
45608670|NCT05162885|Procedure|Socket Preservation technique|Implant placement after Socket preservation Technique with sodium alderonate versus sticky bone in salama&salama Class 3 labial wall defect
46067951|NCT04151823|Other|Healthy food habits promotion|Promotion of healthy food habits will be encouraged at t0, t1, t2
45757841|NCT04858958|Drug|Furmonertinib 160mg|randomized to 160mg QD
45757842|NCT04858958|Drug|Furmonertinib 240mg|randomized to 240mg QD
45757843|NCT04102293|Procedure|NSK Endo motor Endomate|Rotary instrumenation used in pulp therapy
45757844|NCT04102293|Procedure|manual K-files|manual instrumentation used in pulp therapy
45757845|NCT00690833|Drug|topical desonide hydrogel 0.05%|apply the smallest amount of study medication possible that is just sufficient to cover all lesions of the standard cortisone-type medication twice daily (morning and evening) for up to 4 weeks to all of their AD lesions
46067952|NCT00995345|Drug|KRP-104|Tablet
45608671|NCT05390957|Behavioral|Acceptance Based Behavioural Therapy - Revised|The study intervention is a revised, updated version of a previously studied eight-module (8-week) online, acceptance-based behavioural therapy (ABBT) for chronic pain that was tailored specifically to a military, RCMP, and veteran population. The online treatment material is administered via the WebCAPSI Therapy program.
45608672|NCT05162417|Other|Methylene Blue|1mg/ml of Methylene as a solution will be used two times, first immediately after scaling and root planning, second after two weeks of the first treatment.
45608673|NCT05162417|Other|Toluidine Blue O|1mg/ml of Toluidine blue o as a solution will be used two times, first immediately after scaling and root planning, second after two weeks of the first treatment.
45653316|NCT03065959|Drug|Placebo|oral
45653317|NCT05463939|Drug|Teclistamab|Teclistamab will be administered subcutaneously (SC).
46067953|NCT00995345|Drug|Placebo|Tablet
46067954|NCT05199038|Drug|Octreotide|Octreotide infusion for 2 days in patients with bleeding esophageal varices.
46067955|NCT04262960|Device|Device: active CPAP|auto-PAP with pressure between 4 and 20 cm H2O will be administered to randomized patients
46067956|NCT04262960|Device|Device: sham-CPAP|The sham-CPAP will be fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al, with pressure that no greater than 1cm H2O.
46067957|NCT00660907|Drug|dapagliflozin|Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks
46067958|NCT00660907|Drug|glipizide|Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks
45608674|NCT04165343|Radiation|Positron Emission Tomography (PET) on EXPLORER|"Positron Emission Tomography (PET): Your blood sugar level will be checked by a finger stick before the PET scan. A small amount of radioactive tracer (approximately 0.5 teaspoons) will be injected into a vein in your arm before the imaging test. You will be asked to lay on your back on the EXPLORER scanner platform with both of your arms over the head during the duration of the test. A small amount of blood (1 tablespoon) will be collected after the test. This test will last for up to one (1) hour. This is a research test. Although the results may be available it cannot be used for clinical care. If any incidental findings are noted, it will be reported to you."
45608675|NCT04165343|Diagnostic Test|Magnetic Resonance Imaging|MRI will be performed that can measure both the liver stiffness or fibrosis by a method called MR elastography (MRE) and the amount of fat deposited in the liver by MR proton density fat fraction (MR-PDFF). You will be asked to lay on your back on the scanner platform with both of your arms over the head during the duration of the test. MRE and MRI-PDFF are Food and Drugs Administration (FDA) approved tests and the results will be available to you. This test will last up to one (1) hour.
45608676|NCT04165343|Diagnostic Test|Echocardiogram and Electrocardiogram|You will have baseline echocardiogram images and electrocardiogram (ECG) taken and will be asked to walk on a treadmill, which will increase in elevation and speed every 3 minutes until you can go no longer. This usually takes 9 to 12 minutes. Immediately after exercise, echocardiogram images and ECG will be taken again. The total time you will be in the stress lab including prep time and recovery is about 60 minutes. Wear comfortable or exercise clothing and walking/running shoes. You will be asked to not eat or drink (except for water) for 4 hours prior to the time of your test. Please drink water the day of the test so you are not dehydrated. This is an FDA approved test and the results will be available to you.
45608677|NCT04165343|Diagnostic Test|Blood test|We will order laboratory blood tests as part of this research study and up to 3 tablespoons of blood will be collected for routine clinical and other laboratory tests relevant to the study. If you are able to become pregnant, you will have a urine pregnancy test before you begin the study.
45608678|NCT04101617|Behavioral|Oral Health education including printed educational material|Printed and online educational materials were developed and provided to pediatricians so they can share relevant information about caries control to parents of toddlers. A previous interview was performed to pediatricians as focus groups to know how they are doing their evaluations and what do they take into account during the children visits in order to identify where to focus for the training what it is necessary to change. After that pediatricians were trained to give oral health recommendations. So, to the intervention group, the pediatricians will give these recommendations to the parents and also they will give them a printed educational material previously developed for the project.
45608679|NCT03966989|Behavioral|Performance Feedback|Performance feedback offline that benchmarks providers' own performance to that of their peers
45757846|NCT02110641|Behavioral|Weight Loss Counseling|The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.
46067959|NCT00660907|Drug|metformin hydrochloride|Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks
46067960|NCT04992572|Drug|Propofol Injection|25mg Propofol administered by injection
46067961|NCT04992572|Drug|Lidocaine Hydrochloride, Injectable|Licocaine administered locally via injection.
45757847|NCT03686306|Drug|Sildenafil|"Sildenafil citrate 140 mg/day (single morning oral dose of 140 mg) for a total duration of 24 weeks. + advice to walk for a total duration of 6 months.~Treatment will be proposed in addition to optimal treatment (Antiplatelet + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
46067962|NCT05083052|Other|Propolis 15%|oothpaste formulation with 15% propolis.
46067963|NCT05083052|Other|Propolis 10%|Toothpaste formulation with 10% propolis.
46067964|NCT05083052|Other|Placebo|Formulation of toothpaste without active ingredient.
45911398|NCT02007694|Behavioral|Virtual Reality Exposure Therapy (VRET)|Graded exposure to feared specific stimulus by computer-generated 3D virtual environments.
46067965|NCT04031703|Drug|Paclitaxel|Paclitaxel chemotherapy (injection)
46067966|NCT04031703|Drug|Carboplatin|Carboplatin chemotherapy (injection)
46067967|NCT04031703|Drug|Epirubicin|Epirubicin chemotherapy (injection)
46067968|NCT04031703|Drug|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
46067969|NCT04031703|Drug|5-fluorouracil|5-fluorouracil chemotherapy (injection)
46067970|NCT04031703|Drug|Docetaxel|Docetaxel chemotherapy (injection)
46067971|NCT05081258|Procedure|passive Alveolar Molding|A passive palate plate (passive Alveolar Molding) will be inserted within the first week after birth. The pAM appliance will be modified on regular appointments and remain until surgical lip closure (6-7 months of life). After surgical lip closure, infants will receive a nostril retainer and the treatment with the pAM appliance will continue until palate closure (10-12 months of life).
46067972|NCT05081258|Procedure|Nasoalveolar Molding|A passive palate plate will be inserted within the first week after birth. A nasal stent will be added to the palate plate after one week (NAM appliance). The NAM appliance will be modified on regular appointments and remain until surgical lip closure (6-7 months of life). After surgical lip closure, infants will receive a nostril retainer and will be treated with a passive palate plate without nasal stent until palate closure (10-12 months of life).
46067973|NCT00795847|Drug|Preminent (losartan/hydrochlorothiazide combination drug)|Preminent 1T qd (Arm 1) or losartan 100 mg (Arm 2) was given for 3 months.
45608680|NCT05162339|Other|No intervention was made|No intervention was made
45608681|NCT05162183|Drug|Glimepiride|Glimepiride dispensing claim is used as the reference group.
45757848|NCT03686306|Drug|Placebo|"Placebo (single morning oral dose) + advice to walk for a total duration of 24 weeks.~Treatment will be proposed in addition to optimal treatment (Antiplatelet + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
46067974|NCT00877773|Drug|Temsirolimus|25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
46067975|NCT00610220|Device|Fiberglass short arm cast|Cast will be applied for a 4-week period
46067976|NCT00610220|Device|Prefabricated wrist splint|Splint will be applied for a 4-week period
46067977|NCT00659815|Device|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.|Daily care for contact lenses.
45608682|NCT05162183|Drug|Liraglutide|Liraglutide dispensing claim is used as the exposure group.
45608683|NCT05390489|Drug|Cascara pulp arabica gayo coffee cream|extract of cascara pulp arabica gayo coffee
45608684|NCT03770741|Other|Modify cardio-respiratory support to avoid cerebral hypoxia|modification of cardio-respiratory support based on an evidence-based treatment guideline
45608685|NCT03770741|Other|Treatment as usual|Monitoring and treatment according to local guidelines and practice
45608686|NCT03469115|Diagnostic Test|Serum blood|Serum blood test for laboratory analysis to determine level of alpha defensin
45608687|NCT03755687|Other|Art Therapy Intervention|Standardized mixed media art directives.
45608688|NCT05161559|Procedure|Etching with phosphoric acid gel (3M ESPE, St. Paul, MN, USA)|Etching enamel surface using phosphoric acid gel (3M ESPE, St. Paul, MN, USA)
45608689|NCT05161559|Procedure|Self-etch adhesive (Kuraray, Tokyo, Japan)|No Etching enamel surface using phosphoric acid (self-etch technique) (Kuraray, Tokyo, Japan)
45608690|NCT05161559|Procedure|Chemical bond adhesive (GC, Corporation, Tokyo, Japan)|Chemical bond with hydroxyapatite crystals of Enamel (GC, Corporation, Tokyo, Japan)
45608691|NCT03736655|Device|Interposition supraciliary implant|Surgical placement of an interposition supraciliary implant in the supraciliary space
45608692|NCT05161403|Drug|Hyaluronic acid|"Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~use of this natural substance is a simple and cost-effective technique and is easily tolerated by children."
45608693|NCT05161403|Dietary Supplement|honey|"Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~Use of this natural substance is a simple and cost-effective technique and is easily tolerated by children."
45608694|NCT05077397|Device|StO2|InSpectra Tissue Spectrometer Model 1615 probe (Hutchinson Technology Inc. Hutchinson, MN, USA) probes will be placed on the skin area corresponding to the patients' liver lodge prior to induction of anesthesia. In addition, the probes of both devices will be placed in the renal site on the same side. Basal values will be measured with both devices and StO2 values in the devices will be recorded every 15 minutes. Probes will not be removed during surgery and for 24 hours postoperatively.
45608695|NCT05077397|Device|O3|O3TM Regional Oximeter System (O3 System, Masimo Corporation, Irvine, CA) probes will be placed on the skin area corresponding to the patients' liver lodge prior to induction of anesthesia. In addition, the probes of both devices will be placed in the renal site on the same side. Basal values will be measured with both devices will be recorded every 15 minutes. Probes will not be removed during surgery and for 24 hours postoperatively.
45757849|NCT04349553|Biological|ZH9PA and ZH9|150mL vaccine for oral administration
45757850|NCT04349553|Biological|Placebo|150mL vaccine for oral administration
45608696|NCT02523209|Device|HR-pQCT|HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at the tibia and the radius levels in humans.
45608697|NCT02523209|Device|DEXA|The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA (Dual Energy X-ray Absorptiometry) device that allows short duration measurements ( <15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
45608698|NCT03561701|Drug|Oteseconazole (VT-1161)|Oteseconazole (VT-1161) 150mg capsule
45608699|NCT03561701|Drug|Placebo|matching placebo capsule
45757851|NCT04349553|Biological|ZH9PA|150mL vaccine for oral administration
46067978|NCT00659815|Device|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.|Daily care for contact lenses
46067979|NCT00994643|Biological|Rituximab|Given IV
46067980|NCT00994643|Biological|Interleukin-2|Given SC
46067981|NCT00912171|Drug|budesonide (Aircort 50 nasal spray)|50 mcg per nostril once daily for cycles of 21 days with a break of 7 days for 6 months
46067982|NCT00912171|Drug|montelukast (Singulair)|Daily administration in 4 mg chewable tablet for children younger than 6 years or in 5 mg tablet for children 6 years and older
46067983|NCT00800995|Dietary Supplement|SOD|
46067984|NCT00800995|Dietary Supplement|Sham|
46067985|NCT04293575|Device|MitraClip|transcatheter MitraClip device (Abbott Vascular, Santa Clara, California)
46067986|NCT00677391|Drug|Sibutramine|Capsules, Wk 0: 10mg, once daily; Wks 4-24: 10mg or 15mg, once daily, dosage escalation based upon investigator's assessment.
46067987|NCT00677391|Drug|Placebo|Capsules, once daily
46067988|NCT00629057|Biological|MVA-BN-PRO|1x10e8 TCID50 q 4 wks x 6
46067989|NCT00629057|Biological|MVA-BN-PRO|2 x 10e8 TCID50 q 4 wks x 6
45653318|NCT04993365|Biological|Experimental Group|The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
45911399|NCT02007707|Behavioral|Tobacco LHW|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
45608700|NCT04455893|Other|Stratified Transplant Survival|The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs. Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ. excellent transplant survival = [number of patients surviving after transplant with excellent organ]/[number of patients for whom excellent organ was accepted for transplant] marginal transplant survival = [number of patients surviving after transplant with marginal organ]/[number of patients for whom marginal organ was accepted for transplant]
46067990|NCT00629057|Biological|MVA-BN-PRO|4 x 10e8 TCID50 q 4 wks x 6
46067991|NCT00660829|Drug|Placebo|Placebo
46067992|NCT00660829|Drug|0.15% Azelastine Hydrochloride|0.15% Azelastine Hydrochloride 822 mcg
45444934|NCT05622370|Drug|Brivaracetam sustained-release tablets 50mg|"Brivaracetam sustained-release tablets Specification: 50mg/ piece Batch number: 22082501 Content: 100.0% Date of production: September 02, 2022 Expiry date: August 24th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach."
46067993|NCT00677469|Drug|Cholestyramine|2 grams BID
46067994|NCT00677469|Drug|Cholestyramine|1 gram BID
45757852|NCT04831190|Behavioral|Tailored Exercise Intervention|The exercise program to be implemented for neuro-oncology patients will combine aerobic, resistance, balance, and flexibility exercises delivered in one-to-one setting (i.e., personal training) twice per week, for 12 weeks. Based on needs and preferences, participants will have the option to join a circuit-type group class once per week in place of one of their personal training sessions. During COVID-19, all sessions will be delivered remotely. If facilities are open and deemed safe for cancer patients, participants will have the option to attend an in-person session, integrated in the community. Whether delivered in-class or remotely, the intervention will follow exercise progression principles (i.e., frequency, intensity, time, type, overload, and progression) over the 12-weeks, with tailoring of any exercise to meet individual participant needs, with aims of promoting wellness and physical function. The exercise intervention is based on the Alberta Cancer Exercise (ACE) program.
45757853|NCT04078269|Biological|Dendritic cell immunotherapy|Intravenous infusions of MIDRIXNEO-LUNG DCs every 2 weeks, using an intra-patient dose escalation scheme progressing along the following range: 10 x10E6 DCs (minimal dose), 20 x 10E6 DCs, 40 x 10E6 DCs, 80 x 10E6 DCs, 100 x 10E6 DCs (maximal dose), until exhaustion of the batch or occurrence of grade ≥3 toxicity event
45757854|NCT04078269|Biological|Antigen-specific DTH|Intradermal injection of 1 x 10E6 MIDRIXNEO-LUNG DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of induction of antigen-specific immune responses as part of in vivo immunomonitoring (delayed-type hypersensitivity cutaneous reaction as test read-out)
45757855|NCT04078269|Biological|Control DTH|Intradermal injection of 1 x 10E6 MIDRIX-CTRL DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of background (i.e. non-antigen-specific) reactivity (delayed-type hypersensitivity cutaneous reaction as test read-out)
45757856|NCT00644657|Drug|Clopidogrel|All subjects will receive a 300 mg loading dose
45608701|NCT03426605|Drug|Open Label LAM-003|LAM-003
45608702|NCT03401099|Procedure|Radiofrequency ablation of CTI|Delivery of radiofrequency energy to the cavotricuspid isthmus (region of right atrial tissue between the tricuspid annulus and the inferior vena cava) until bidirectional block is achieved
45608703|NCT03401099|Procedure|Cryoballoon PVI|Cryoballoon application to the pulmonary veins aiming for Pulmonary Vein Isolation
45608704|NCT04923269|Drug|LY3532226|Administered SC.
45608705|NCT04923269|Drug|Placebo|Administered SC.
45757857|NCT05154890|Drug|Pegtarviliase|Administered IV
45608706|NCT03205553|Procedure|SoC Staged Silo Closure|Serial reductions will be performed with silastic silo placement for staged reduction using umbilical tape ties. The silo is assessed daily on morning rounds by the surgical team. Once the abdominal contents are at the level of the fascia, the abdomen is closed in the operating room. The average day to closure historically from CHND data is 5 days.
45757858|NCT05154890|Drug|Pegtarviliase|Administered SC
46067995|NCT00677469|Drug|Placebo powder|1 gram BID
46067996|NCT00629135|Drug|Moxifloxacin/Metronidazole or Piperacillin/Tazobactam|Antibiotic therapy for patients with intra-abdominal abscesses; Intervention consists of antibiotic treatment of the patients with intraabdominal abscess with either the combination of Moxifloxacin and Metronidazole or Piperacillin/Tazobactam.1. Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily. 2. Piperacillin / Tazobactam 4,5 g administered intravenously three times daily.
46067997|NCT00795925|Drug|propiverine hydrochloride|"coated tablets containing 5 mg~consecutive dose escalation of 5 mg, 10 mg or 15 mg propiverine b.i.d."
45653319|NCT04993365|Biological|Control Group|The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
45653320|NCT03067363|Drug|MOR107|MOR107 solution for injection
46067998|NCT04293419|Drug|Durvalumab (MEDI4736)|6 cycles of mFOLFOX6 (oxaliplatin, leucovorin and fluorouracil) followed by long course chemoradiotherapy (50.4 Gy together with capecitabine) followed by surgery. Patients will receive durvalumab 1500 mg every 4 weeks during induction chemotherapy, chemoradiotherapy and waiting period until surgery.
46067999|NCT00801073|Procedure|Human Amniotic Membrane Transplantation|Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
46068000|NCT02873663|Procedure|Plasma and head hair collection|Plasma and head hair collection
46068001|NCT00793429|Drug|Prucalopride|
46068002|NCT00793429|Other|Placebo|
46068003|NCT00801151|Drug|Zolinza (vorinostat), vinorelbine|"Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.~Barring dose limiting toxicities the dose of vorinostat will escalate in several steps (300 mg po qd 7/21 days, 300 mg po qd 21/21 days, 400 mg po qd 7/21 days, 400 mg po qd 21/21 days).~Patients may receive a maximum of 6 cycles of study medication."
46068004|NCT00796081|Drug|ER OROS paliperidone, paliperidone ER|
46068005|NCT00793507|Other|Oral Health Care Early Intervention Project|The intervention group will receive routine preventive dental care, 2 to 4 times per year depending on risk of caries. The intervention group will also receive pre-scheduling, reminders, and care coordination by the dental hygienist. The control group will receive usual care, but will not receive pre-scheduling, reminders, or care coordination by the dental hygienist. In order to determine the incidence of early childhood caries at study enrollment, both intervention and control groups will receive a standardized oral examination with an assessment of caries presence and extent on the day of enrollment, at 12 months and at 24 months after enrollment. Both children in the control group and intervention group will be referred to a dentist if found to need restorative care.
46068006|NCT00877383|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
46068007|NCT00877383|Drug|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together with the manufacturer's proprietary inhalation device (HandiHaler®).
45608707|NCT03205553|Drug|Peritoneal Dialysis Solution/Dextrose 1.5%|Serial reductions will be performed with silastic silo placement for staged reduction with adjuvant direct peritoneal resuscitation (DPR). A JP drain will be securely placed through the top of the silo beneath the fascia at the base of the small bowel mesentery for instillation of dialysate fluid and aspiration of peritoneal fluid. The sterile syringe will then be connected to the JP drain. The dialysate fluid administered via JP drain as a bolus infusion every 6 hours until the abdominal wall is closed (generally 3-5 days), but not to exceed 7 days maximum. Fluid will be warmed at bedside using dry heat not to exceed 37°C/98°F. The initial bolus infusion will be 10 mL/kg of dialysate. If tolerated, each subsequent infusion will be increased by 10 mL/kg up to a goal infusion of 40 mL/kg (to a maximum volume of 100 mL) as tolerated. Dialysate will dwell for 1 hour after instillation of fluid. Any excess fluid will then be removed via JP drain.
46068008|NCT00877383|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
45608708|NCT03166085|Drug|PU-H71|PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle
45608709|NCT03166085|Drug|Nab-paclitaxel|nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1
46068009|NCT00796159|Drug|Olmesartan medoxomil|olmesartan medoxomil 20 mg and HCTZ 12.5 mg
46068010|NCT00993473|Drug|Insulin glargine (HOE901)|"100 U/mL commercial solution for injection available as both disposable pen devices Solostar® each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve the following glycemic targets without hypoglycemia:~Fasting blood glucose (BG) between 90 and 145 mg/dL (5.0 to 8.0 mmol/L), inclusive,~Bedtime BG between 120 and 180 mg/dL (6.7 to10.0 mmol/L), inclusive,~Nocturnal BG between 80 and 162 mg/dL (4.4 to 9.0 mmol/L), inclusive; and~HbA1c <7.5%."
46068011|NCT00993473|Drug|Neutral Protamine Hagedorn (NPH) insulin|"NPH insulin 100 U/mL commercial (Huminsulin Basal) solution for injection available as both disposable pen devices (Huminsulin Basal Pen) each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve glycemic targets as described above for insulin glargine"
46068012|NCT00993473|Drug|Insulin lispro|Insulin lispro used as the principal bolus insulin; regular human insulin permitted. Administration: multiple injection before meals and/or at bedtime at the discretion of the Investigator.
46068013|NCT00660595|Drug|Quetiapine|Oral administration
46068014|NCT00660595|Drug|Risperidone|Oral administration
46068015|NCT00929240|Drug|bevacizumab [Avastin]|15 mg/kg iv on day 1 of each 3 week cycle (maintenance phase)
45757859|NCT00645047|Behavioral|Telemedicine CBT|Use of Videoconfrence Technology To Provide Cognitive Therapy
45757860|NCT00645047|Behavioral|In-Person CBT|In-Person Provision Of Cognitive Therapy
45608710|NCT05390255|Drug|Mometasone furoate nasal spray hormone|This group of patients received mometasone furoate nasal spray hormone treatment throughout the study.
45608711|NCT05390255|Drug|Mometasone furoate nasal spray hormone + oral hormone|The patients in this group were given oral hormone therapy for 14 days in the first month and the fourth month under the background of mometasone furoate nasal spray hormone treatment throughout the course.
45608712|NCT05390255|Drug|Mometasone furoate nasal spray hormone + omalizumab|The patients in this group were injected with omalizumab once a month under the background of mometasone furoate nasal spray hormone treatment, for a total of 6 times.
45608713|NCT04456829|Dietary Supplement|Resveratrol drink|Subjects will consume a bottle of resveratrol drink for two months.
45757861|NCT04613024|Drug|Topamax|Experiment randomized group will be prescribed Topamax before and after surgery with follow up at regular interval
45608714|NCT04456829|Dietary Supplement|Placebo drink|Subjects will consume a bottle of placebo drink for two months.
45608715|NCT05390177|Behavioral|Video type|One of two videos presenting health research findings (each 2.5 minutes in length) will be shown to a participant.
45608716|NCT02810171|Behavioral|Cognitive Behavioral Therapy|A therapy which teaches patients coping skills to manage anxiety and gradually yet repeatedly exposes patients to anxiety-provoking thoughts and situations until the anxiety habituates/diminishes.
45608717|NCT02810171|Behavioral|Relaxation Therapy|An active control therapy with minimal effects on anxiety symptoms. If randomized to this therapy, participants will have the option to cross-over to CBT once the relaxation therapy arms has been completed.
45608718|NCT04802681|Device|FFR-measurement with different pressure guidewires|Measuring FFR with different pressure guidewires
45608719|NCT01865617|Biological|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes|Given IV
45757862|NCT04613024|Drug|Gabapentin|Control group will be prescribed gabapentin after surgery with follow up at regular interval
45757863|NCT04819334|Other|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
45608720|NCT03469037|Device|Optiflow with an inspired fraction of oxygen of 100%|Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 100%
45608721|NCT03469037|Device|Optiflow with an inspired fraction of oxygen of 21%|Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 21%
46068016|NCT00929240|Drug|capecitabine [Xeloda]|1000 mg/m2 po bid on days 1-14 of each 3 week cycle (maintenance phase)
46068017|NCT00796237|Device|Whole body vibration therapy|In their regular physiotherapy sessions, the subjects in the experimental group will receive WBV (20-240Hz, 10-minute sessions, 1 session per day, 5 sessions per week). The vibration loading will be carried out using the Fit-Vibe System (Germany), which is a vibration platform that is capable of generating vertical vibration.
46068018|NCT00796237|Other|standing on the vibration platform but no vibration will be applied|The subjects in this group will perform the same exercises on the vibration platform as in the experimental group for the same duration, but no vibration will be given.
46068019|NCT04292249|Other|Blood sampling|Analysis will be performed using commercially available analyses (suPARnostic® kit (validated to measure suPAR concentrations between 0.6 and 22 ng/mL) (ViroGates)). HsCRP will be measured by high sensitivity CRP assays (Tina-quant hs-CRP latex assay (validated to measure CRP concentrations between 0.3 - 20 mg/L) (Roche/Hitachi)). In patients with CRP>20 mg/L a regular CRP-measurement will be performed.
46068020|NCT00801307|Device|spirometer|According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.
45608722|NCT02492867|Radiation|Response-driven Adaptive Radiation Therapy|
45608723|NCT02492867|Drug|Carboplatin|AUC 2 concurrent with RT; AUC 6 during consolidation. Given IV
45608724|NCT02492867|Drug|Paclitaxel|40 mg/m^2 IV concurrent with RT; 200 mg/m^2 during consolidation. Given IV
45608725|NCT02492867|Device|FDG-PET|
46068021|NCT02869139|Other|Mentholated lip moisturizer and ice popsicle|Mentholated package of measures
46068022|NCT02869139|Other|Non-mentholated lip moisturizer and ice popsicle|Non-mentholated package of measures
46068023|NCT00677703|Other|Daily Text Messages|"Text message reminders to take oral contraception daily:~Each text message will be a short educational message listing the benefits of contraceptive use and providing instructions for avoiding common medication errors."
46068024|NCT00793663|Drug|Xenon|Inhalational gas; maximum dose allowed: 70 % Xenon; the duration of the treatment will be defined through anesthesia-time.
46068025|NCT00793663|Drug|Sevoflurane|Inhalation gas; age adapted MAC-values; the duration of the treatment will be defined through anesthesia-time
46068026|NCT00793663|Drug|Dexamethasone|Intravenous use, 4 mg, single shot
46068027|NCT00793663|Drug|NaCl|Intravenous use; single shot
46068028|NCT00793663|Drug|Ondansetron|Intravenous use; 4 mg; single shot
45608726|NCT02492867|Device|V/Q SPECT|
45608727|NCT02492867|Drug|Durvalumab|10 mg/kg during consolidation. Given IV
46068029|NCT00793663|Drug|NaCl|Intravenous use; single shot
46068030|NCT00610298|Device|whole body vibration using a Galileo vibrating platform|whole body vibration at 20 hertz for 3 minutes 3 to 5 days per week for up to 12 weeks
46068031|NCT02628561|Device|Transcranial direct current stimulation|
46068032|NCT02628561|Behavioral|Constraint-Induced Movement Therapy|
45452252|NCT02261506|Other|7 days of adequate antibiotic treatment durations|We will not be randomizing patients to any specific antibiotic regimen. Patients will be randomized to fixed durations of adequate treatment: 7 versus 14 days. The selection of antibiotic(s) will be at the discretion of the treating team, although the research team will check to ensure that the selected antibiotics have an 'adequate' spectrum of coverage for the bacterial pathogen(s) isolated in the blood culture.
45608728|NCT02458313|Drug|DMXB-A|150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.
45608729|NCT02458313|Other|Placebo|Placebo capsules b.i.d. for 12 weeks
46068033|NCT04258202|Other|Alveolar recruitment maneuver|The two methods for performing an alveolar recruitment maneuver. Alveolar recruitment maneuvers consisted of a stepwise increase in tidal volume to a plateau pressure of 30 cm H2O versus a stepwise increase in PEEP H2O to a plateau pressure of 30 cm H2O.
45608730|NCT05200195|Procedure|Liver transplantation|Deceased or living donor liver transplantation for the cure of hepatocellular cancer on cirrhosis
45608731|NCT02522221|Drug|Warfarin|Warfarin is an oral vitamin K antagonist anticoagulant.
45608732|NCT02522221|Drug|tecarfarin|Tecarfarin is an oral vitamin K antagonist anticoagulant
45608733|NCT05389943|Drug|Oral administration of vitamin D3|the effect of oral supplement in postmenopausal women.
45608734|NCT05389943|Drug|Vitamin D3 50000 UNT Oral Capsule|In postmenopausal women with BMD less than 32 ng/ml
45608735|NCT05389943|Dietary Supplement|milk, Dietary and life style modifications.|Postmenopausal women with BMD greater than 32 ng/ml
45608736|NCT04575961|Drug|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles
45608737|NCT04542109|Behavioral|READyR A|Two active sessions to conduct an individually-tailored dementia-related needs assessment, incorporating the participant's care values and objective data from remote in-home monitoring.
45608738|NCT04542109|Behavioral|READyR B|Active comparator. Two sessions to deliver general information about dementia-related care needs.
45608739|NCT03461263|Other|phonophoresis treatment using pumpkin seeds oil|phonophoresis treatment using pumpkin seeds oil
45608740|NCT02522975|Drug|EPIAO®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
45608741|NCT02522975|Drug|EPREX®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic /anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
45608742|NCT04508803|Drug|HX008，Niraparib|Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.
45608743|NCT04508803|Drug|HX008，Niraparib|Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.
45608744|NCT04508803|Drug|HX008，Niraparib，Trastuzumab|Subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day;Trastuzumab 8mg/kg in the first cycle and 6mg/kg after the first cycle intravenously once every 3 weeks; Every 3 weeks is a cycle.
45608745|NCT04508803|Drug|HX008，Niraparib，Pyrrolitinib|"HER-2 negative subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Neirapali orally per day. Every 3 weeks is a cycle.~Her-2 positive subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day; Pyrrolitinib is taken orally at 400mg per day; Every 3 weeks is a cycle."
45608746|NCT04453501|Drug|favorable outcome|Whether patient under such regimen had a favorable outcome (no transfer in intensive care unit or death)
46068034|NCT04151745|Procedure|external pacemaker switched off|When a hemodynamically stable state is achieved, the external pacemaker will be switched off for 30 minutes. Hemodynamic parameters will be acquired directly prior to switching off, 15 respectively 30 minutes after switching off, and 15 minutes after switching back on. To gain insight in the natural course of stunning, this routine will be repeated the next morning.
46068035|NCT02553811|Diagnostic Test|accuracy diagnostic|effectiveness of the ultrasonography and electromiography for best performance and diagnostic accuracy in carpal tunnel syndrome
46068036|NCT04932980|Drug|Aflibercept|administration of anti-VEGF Aflibercept (Eylea)
45608747|NCT04106063|Other|KID SSQ12 questionnaire|During a face to face interview (maximum 15 minutes), the child will complete a short questionnaire (KID SSQ12 questionnaire) to assess his auditory difficulties
45608748|NCT04492033|Drug|CTX-009 (ABL001)|CTX-009 (ABL001) will be administered biweekly.
45608749|NCT04492033|Drug|Paclitaxel|Paclitaxel will be administered weekly.
45608750|NCT04492033|Drug|Irinotecan|Irinotecan will be administered biweekly.
45608751|NCT04458233|Procedure|long axis FNA method|"). A long-axis view (i.e., a longitudinal image of the needle) is obtained by placing the US probe in a parallel position relative to the course of the needle. Short-axis and long-axis views can be used for both US assistance and guidance of FNA procedure. Correspondingly, approaching the nodule with the needle from the lateral or frontal aspect results in either a long axis or short axis view of the needle on the US screen"
45608752|NCT03461185|Drug|EGFR-TK Inhibitor|EGFR-TKIs include but are not limited erlotinib, gefitinib
45608753|NCT03461185|Drug|Anti-Angiogenic Drugs|Anti-Angiogenic Drugs contain endostatin, apatinib and anlotinib
46068037|NCT04932980|Drug|Brolucizumab|administration of anti-VEGF Brolucizumab (Beovu)
46068038|NCT04932980|Procedure|early treat and extend (T&E)|extension of treatment intervals (T&E) from the beginning of treatment
46068039|NCT02554045|Drug|Tadalafil|Patients will take tadalafil 2.5 mg tablet every morning for 8 weeks and then withdraw tadalafil for 8 weeks
46068040|NCT02554045|Drug|Placebo|Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
45608754|NCT04453423|Drug|Anlotinib + Pemetrexed+Carboplatin|"Anlotinib: 12mg, QD, PO, d1-14, 21 days per cycle~Carboplatin: AUC 5 on day 1 of 21 days per cycle~Pemetrexed: 500mg/m2 iv on day 1 of 21 days per cycle"
45608755|NCT04453423|Drug|Pemetrexed|500mg/m2 iv on day 1 of 21 days per cycle(maintenance phase)
46068041|NCT05330390|Drug|Levetiracetam|Epilepsy, treatment with levetiracetam
46068042|NCT00677859|Biological|MultiStem®|Patients will receive a single IV infusion of MultiStem® 2 days after HSCT.
46068043|NCT00677859|Biological|MultiStem®|Patients will receive either 3 weekly IV infusions or 5 weekly infusions of MultiStem®
46068044|NCT00993317|Drug|Placebo of CDP870|Given every 2 weeks until Week22 (SC)
45608756|NCT04453423|Drug|Anlotinib + Pemetrexed|"Anlotinib:12mg, QD, PO, d1-14, 21 days per cycle(maintenance phase)~Pemetrexed:500mg/m2 iv on day 1 of 21 days per cycle(maintenance phase)"
45608757|NCT04453423|Drug|Anlotinib|12mg, QD, PO, d1-14, 21 days per cycle(maintenance phase)
45608758|NCT04453189|Drug|JNJ-64417184|Participants will receive single dose of JNJ-64417184 in fed condition on Day 1 in assigned treatment sequence.
45608759|NCT04453189|Drug|Lansoprazole|Participants will receive lansoprazole once daily in fasted condition on Day 1 to 4 under fasted condition and 2 hours before single dose of JNJ-64417184 in fed condition on Day 5 in assigned treatment sequence.
46068045|NCT00993317|Drug|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week 22(SC)
46068046|NCT00993317|Drug|Methotrexate|"Received treatment with Methotrexate(MTX)for at least 24 weeks prior to the Baseline Visit.~The dose and route of administration of MTX had to have been stable for at least 8 weeks prior to the Baseline Visit. The minimum stable dose of MTX allowed is 10mg weekly."
45608760|NCT04453189|Drug|Famotidine|Participant will receive famotidine in fasted condition on Day 1 in assigned treatment sequence.
45653321|NCT03067363|Drug|Placebo|Solution for injection manufactured to match MOR107 solution for injection
45653322|NCT03067363|Other|Low sodium diet|Diet designed to restrict sodium intake to 40 mmol/day
46068047|NCT00801385|Drug|erlotinib hydrochloride|
46068048|NCT00801385|Drug|sorafenib tosylate|
46068049|NCT00801385|Genetic|DNA analysis|
46068050|NCT00801385|Genetic|mutation analysis|
46068051|NCT00801385|Genetic|polymerase chain reaction|
46068052|NCT00801385|Genetic|protein analysis|
46068053|NCT00801385|Genetic|protein expression analysis|
46068054|NCT00801385|Other|immunohistochemistry staining method|
46068055|NCT00801385|Other|laboratory biomarker analysis|
45608761|NCT05158855|Dietary Supplement|Bacillus subtilis spore extract|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronavirus. This product could have a vaccine like activity within the intestinal environment.
46068056|NCT04258124|Other|Control motor intervention|The intervention through motor control will consist in the application of the protocol described by Hidalgo-Peréz et al. The objective of the application of the technique is to produce an increase in the strength of the deep cervical musculature. The exercises will be performed with the subject in different positions: supine, quadrupedic and standing position. The physiotherapist will be placed in standing position in front of the subject. The intervention will be carried out in 3 sessions with 3 exercises of 15 repetitions, and with breaks of 40 seconds between each series and exercise.
45608762|NCT03465241|Diagnostic Test|the ctDNA dynamic monitoring|To detect ctDNA in patients using the second generation of high-throughput gene sequencing (NGS)
45608763|NCT05103085|Diagnostic Test|Rapid diagnostic orientation test (TROD) for Hepatitis C|Inclusion of patients during the consultation with the gastroenterologist, before hospitalization in the digestive endoscopy department. Each consenting patient benefits from a HCV screening using TROD on the day of their hospitalization in the department.
45608764|NCT03461107|Other|No intervention|
45608765|NCT02521987|Procedure|8mm port|Participate in this arm will have their procedure performed with an 8mm laparoscopic port.
46068057|NCT02628483|Dietary Supplement|Fish Oil|1000mg fish oil per capsule (325mg EPA + 225mg DHA)
46068058|NCT02628483|Dietary Supplement|Fish Oil|1000mg fish oil per capsule (300mg EPA + 200mg DHA)
45608766|NCT02521987|Procedure|12mm port|Participate in this arm will have their procedure performed with a 12mm laparoscopic port.
45608767|NCT03465163|Device|Deep Brain Stimulation|The device is called the Medtronic Activa PC+S system. Two devices will be implanted per participant. The electrodes will be surgically implanted bilaterally into the hippocampus and anterior nucleus of the thalamus.
45608768|NCT03465085|Drug|Unfractionated heparin|Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
45608769|NCT03465085|Drug|Streptokinase|Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
45608770|NCT03465007|Drug|Hydrocortisone|we will give IV Hydrocortisone 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD treatments.
46068059|NCT04045873|Device|extracorporeal membrane oxygenation|The VA-ECMO procedure will be performed by femoral artery access, and the IABP will then be implanted in the contralateral femoral artery.
45608771|NCT03465007|Drug|Normal saline|we will give IV normal saline 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD
45608772|NCT05066113|Device|Radiofrequency-Based treatment|"RF-based treatments use electrothermolysis to deliver heat energy to targeted structures in the skin, such as hair follicles or glands by the use of insulated needles. The investigators will use radio frequency based treatment on a pre-selected skin area (about 3cm x 3cm or 1 ¼ x 1 ¼ inches in size) on either your left or right underarm that is eligible for assessment, study treatment, and biopsy.~Participants will receive clinical assessments, photography, questionnaires, up to 3 treatments of RF-based selective electrothermolysis to pre-selected areas of the axillary skin, up to 2 4-mm skin biopsies for up to 5 study visits."
46068060|NCT05330156|Procedure|Transurethral resection of the prostate|- After an initial cysto-urethroscopy assessment done, Transurethral resection of the prostate is performed using the bipolar system with normal saline irrigation, under spinal or general anesthesia.
45608773|NCT03464929|Device|Airtraq indirect laryngoscopy|Attempt to intubation using the Airtraq device
45608774|NCT03464929|Device|King Vision indirect laryngoscopy|Attempt to intubation using the King Vision device
45608775|NCT03461029|Device|BIS monitor|The investigators placed on the forehead of all patients the sensor BIS quatroTM, that connects with the monitor, and they registered sedation and recorded the values obtained.
46068061|NCT05330156|Procedure|transurethral enucleation of prostate|After an initial cysto-urethroscopy assessment done, transurethral enucleation of prostate is performed using the bipolar system with normal saline irrigation, under spinal or general anesthesia.
46068062|NCT00677001|Drug|R306465|
45452253|NCT02261506|Other|14 days of adequate antibiotic treatment durations|
46068063|NCT02628249|Dietary Supplement|Base protein|0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
46068064|NCT02628249|Dietary Supplement|Sufficient protein|1.75 g/kg/d protein provided as crystalline amino acid modeled after egg protein.
46068065|NCT02628249|Dietary Supplement|Branched chain amino acids|Branched chain amino acids modeled after egg protein.
45452254|NCT02269540|Drug|Sertraline|selective serotonin reuptake inhibitor
45452255|NCT02269540|Drug|Citalopram|selective serotonin reuptake inhibitor
45653323|NCT04993131|Procedure|Liver transplant|Liver transplant.
45452256|NCT02269540|Drug|N-acetylcysteine (NAC)|natural health product
45444935|NCT04895787|Behavioral|Gait + aerobic exercise|Following skill-based gait training, the participants in the AEX group will engage in 20 minutes of moderate to high intensity aerobic exercise on a recumbent bicycle. The participants will first perform a brief warm-up, followed by 20 minutes of moderate to high intensity aerobic exercise pedaling at 60-80 rpm with a target heart rate range between 60-70% of heart rate reserve (HRR). Given the potential of having autonomic dysfunction in this population, it has been suggested that a RPE scale between 14-17 is appropriate.
45608776|NCT03460951|Diagnostic Test|cervical MRI|Cervical MRI will be performed in all of the patients and controls on a 3.0-T scanner (Discovery MR750, General Electric (GE) Medical Systems, Milwaukee, WI, USA)
45608777|NCT04414345|Drug|CNM-Au8|"Drug: CNM-Au8~Administration: Oral~Dosage: 30 mg or 60 mg daily"
45608778|NCT04414345|Drug|Matching Placebo|"Drug: Matching Placebo~Administration: Oral~Dosage: 2 bottles daily"
46068066|NCT02628249|Dietary Supplement|Essential amino acids|Essential amino acids modeled after egg protein.
45608779|NCT05030155|Drug|Mepolizumab|300 mg/month subcutaneous
45608780|NCT05030155|Drug|cyclophosphamide/azathioprine|Patients with FFS≥1 will receive cyclophosphamide then azathioprine
45608781|NCT05030155|Drug|Placebo|Patients with FFS=0 will receive placebo
45608782|NCT03460873|Procedure|holmium laser enucleation of the prostate|undergo holmium laser enucleation of the prostate
45608783|NCT05014321|Device|EC16 medical device (CE marked)|Application on brown spots located on the face (1 treatment during the study).
45608784|NCT05014321|Device|device prototype (810A-v1)|Application on brown spots located on the face (4 treatments during the study).
45608785|NCT05014321|Device|device prototype (810B-v1)|Application on brown spots located on the face (4 treatments during the study).
45608786|NCT05014321|Device|device prototype (810C-v1)|Application on brown spots located on the face (4 treatments during the study).
45608787|NCT04965337|Drug|ASC42|ASC42 tablet administered orally
46068067|NCT02628249|Dietary Supplement|Non essential amino acids|Non essential amino acids modeled after egg protein.
45608788|NCT04965337|Drug|Placebo|Matching placebo administered orally
45608789|NCT03460795|Biological|MSC and Tregs|conventional plus MSC and Tregs or placebo treatment
46068068|NCT01030133|Device|Operator Role Real TMS|"In two of the four visits, the participant will be assigned to the operator condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice."
46068069|NCT01030133|Device|Receiver Role Real TMS|"In two of the four visits, the participant will be assigned to the receiver condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The receiver's performance on the task will be unrelated to his/her stimulus painfulness. Each participant will play each role twice."
46068070|NCT01030133|Device|Operator Role Sham TMS|"In two of the four visits, the participant will be assigned to the operator condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice."
46068071|NCT01030133|Device|Receiver Role Sham TMS|"In two of the four visits, the participant will be assigned to the receiver condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The receiver's performance on the task will be unrelated to his/her stimulus painfulness. Each participant will play each role twice."
46068072|NCT01030133|Device|All Participants Operator Role|All participants in Operator Role (Receiving real or sham TMS)
46068073|NCT00677937|Behavioral|Modified DESMOND education and ongoing support|6 hours of education with 1 month of inclusion, 3 years of ongoing support including annual refresher sessions
46068074|NCT04291781|Biological|RC18 160mg|subcutaneous injection RC18 160mg on the upper arm, abdomen, or upper thigh outside;
46068075|NCT04291781|Biological|RC18 240mg|subcutaneous injection RC18 240mg on the upper arm, abdomen, or upper thigh outside;
46068076|NCT04291781|Biological|placebo|subcutaneous injection placebo on the upper arm, abdomen, or upper thigh outside;
46068077|NCT04257968|Diagnostic Test|Ultrasonography|carotid ultrasonography (IMT and elastography)
46068078|NCT04257968|Diagnostic Test|MRI|MRI of carotid artery and brain
45608790|NCT04452799|Drug|Hesperidin and Diosmin mixture|Interventional Clinical Trial
45608791|NCT04453111|Biological|Placenta-derived MMSCs|Cryopreserved placenta-derived multipotent mesenchymal stem / stromal cells
45608792|NCT04453111|Biological|Bone marrow-derived MMSCs|Cryopreserved bone marrow-derived multipotent mesenchymal stem / stromal cells
45608793|NCT04453111|Drug|Hyalgan 20 mg in 2 ML Prefilled Syringe|Hyaluronic Acid 20 mg
45608794|NCT03464851|Diagnostic Test|Carotid Stenotic Scan (CSS)|"Placement of the CSS instrument on the carotid arteries to measure degree of stenosis~of the carotid artery. The CSS scan takes about 1-2 minutes to gather data for real-time analysis by the processor on the device cart."
45608795|NCT03460717|Other|Peripheral Nerve Field Stimulation by Thermal Micro-Cautery|The most painful points over the knee received an intense heat by a metal rod for 0.5 seconds.
45608796|NCT03460639|Radiation|Active laser|Three points on the masseter muscle (upper, middle and lower portions) and one point on the anterior temporal on each side of the face will be irradiated with a wavelength of 780 nm, radiant exposure of 134 J/cm2, power of 50 mW and irradiance of 1.675 W/cm2 for 80 seconds per point, resulting in an energy of 4 J per point and total energy of 32 J per volunteer.20,21 Point application will be performed with a conventional tip in contact with the skin (beam spot: 0.04 cm2).
45608797|NCT03460639|Radiation|Sham laser|The same procedures will be performed in the sham group, but the device will be switched off and a recording of the emission sounds will be used to give the volunteer the auditory sensation of laser therapy.
45608798|NCT03460639|Diagnostic Test|Control group|In this group, we will only induce fatigue.
45757864|NCT00645827|Other|IICE Dosing|Subcutaneous insulin was dosed according to an equation (too long for publication here) which gives the patient's 24 hour SC insulin requirement. If patient was eating, 65% of equation result was given as insulin glargine SC qHS and 35% of equation result was divided evenly between three qAC doses of insulin aspart. If patient was not eating, 100% of ISC was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + [3 x scheduled aspart dose]). For BG < 70 mg/dL, ½ ampule D50W IV x1 was given.
45757865|NCT00645827|Other|Healthcare Provider dosing|Twenty-four hour subcutaneous insulin dosing requirement was determined according to the judgment of the patient's healthcare provider. If patient was eating, insulin glargine SC qHS and three qAC doses of insulin aspart was given according to the judgment of the patients's healthcare provider. If patient was not eating, 100% of insulin was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + [3 x scheduled aspart dose]). For BG < 70 mg/dL, ½ ampule D50W IV x1 was given.
46068079|NCT04257968|Diagnostic Test|Neuro Psychological Assessment Battery|Hopkins Verbal Learning Test Digit Span WAIS-IV Stroop Color Word test Trail Making Test Brixton Spatial Anticipation Test Fluency letter (B-D-H) Fluency animal naming Symbol Digit Substitution WAIS-IV
46068080|NCT04257968|Diagnostic Test|Questionaires|Cognitive Failures, Depression, Anxiety, Fatigue, Speech handicap, fear for recurrence, Quality of Life.
45608799|NCT03464773|Other|PIUO Pathway|See arm descriptions
45608800|NCT03468595|Device|ultrasonic (Piezon Master 700) performed with Listerine|
45608801|NCT03468595|Device|ultrasonic (Piezon Master 700) performed with CHX|
45757866|NCT04816604|Drug|GB002 (seralutinib)|Capsule containing GB002 (seralutinib)
45757867|NCT04816604|Device|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 (seralutinib) delivery
45757868|NCT01799447|Behavioral|Early intervention|Interventions by health visitors with 18 months training in the Marte Meo method in order to promote relations between parents and infants.
45757869|NCT04746482|Procedure|single visit root canal retreatment|cases that were subject to root canal retreatment performed in single visit
45757870|NCT04399850|Other|Hypnosis group|Patients who receive hypnosis
45757871|NCT01933815|Drug|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
45444936|NCT04895787|Behavioral|Gait + resistance exercises|Following skill-based gait training, the participants in the REX group will engage in resistance training, which will target major muscle groups important for daily activities. The resistance training will be provided with free weights or therabands at an intensity of 8-12 repetition maximum (RM). Each muscle group should be trained with 8-12 repetitions ranging from 1 to 3 sets with resting intervals provided between each set. The target RPE scale will be set between 14-17, and the training load will be progressively increased as the participants improved.
45444937|NCT04895787|Behavioral|Gait + conventional physical therapy|Following skill-based gait training, the participants in the CPT group will receive conventional physical therapy, which may include stretching exercise, balance training, or practice over-ground walking based on the participant's need.
45444938|NCT04895787|Behavioral|Gait + rest|Following skill-based gait training, the participants will sit and rest on a chair.
45452257|NCT02269540|Drug|Existing depression medication treatment|Continuation of depression medication treatment already taken prior to study enrollment except for drugs with affinity for MAO-A or potentially influencing MAO-A levels, including phenelzine, tranylcypromine, moclobemide, cytomel and lithium
45608802|NCT03468595|Device|ultrasonic (Piezon Master 700) performed with serum|
45608803|NCT03464695|Device|O2matic|Continous measurement of SpO2 during an admission with COPD, and closed-loop control of oxygen-delivery to maintain SpO2 within a target interval.
45608804|NCT03468517|Other|Bathe method:|BATHE technique, on the other hand, is one of the short therapeutic consultation techniques that strengthen the doctor-patient relationship. BATHE stands for the initials of the questions that include the titles for Background, Affect, Trouble, Handling and Empathy. It allows evaluating the physiological stress of the patients quickly. BATHE method necessitates an empathetic expression that includes the view of the patient in addition to asking the key questions by the doctor doing the interview
45608805|NCT04453345|Drug|thalidomide + prednisone + methotrexate|thalidomide 50-100mg daily at bedtime + prednisone 0.5mg/kg qod to 1mg/kg qd + methotrexate 10mg/m2 per week. 4 months one cycle, up to 3 cycles. After get partial remission, thalidomide maintenance will continue up to 2 years.
45757872|NCT01933815|Drug|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
45757873|NCT03239210|Drug|Ondansetron|5-HT3 (serotonin receptor type 3) antagonist commonly used to treat nausea and vomiting
45757874|NCT03239210|Drug|Placebo|placebo equivalent
45757875|NCT02144519|Behavioral|Healthy Eating and Physical Activity|Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
45757876|NCT04606316|Drug|Nivolumab-Placebo|Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
45757877|NCT04606316|Drug|Nivolumab|Given as intravenous (IV) infusion into a vein.
45444939|NCT03791775|Drug|Polidocanol foam (Atossisclerol® 3%)|The procedure will be performed in the Sims position or lithotomy position. A modified Blonde-Blanchard technique will be adopted, with the tangential injection of polidocanol foam into the submucosa of the apex of each hemorrhoidal pile, without exceeding three piles, and using a self-lighting open-ended anoscope and a 20-G needle in order to reduce bleeding
45608806|NCT02322593|Drug|TAS-118 plus Oxaliplatin|
45608807|NCT02322593|Drug|S-1 plus Cisplatin|
45444940|NCT01730937|Drug|sorafenib tosylate|Given PO
46068081|NCT00877071|Drug|LC Bead loaded with doxorubicin|LC Bead is a new product specifically designed for TACE. LC Bead microspheres will be loaded with between 50-100mg of doxorubicin for each of several TACE procedures. The bead will utilize embolic induced ischemia as well as local chemotherapy in an effort to downstage unresectable HCC to liver transplantation
46068082|NCT04292795|Device|Therapeutic Ultrasound|The Intervention will be provided according to the set protocols used in previous literature.
46068083|NCT04292795|Device|Short wave diathermy|The Intervention will be provided according to the set protocols used in previous literature.
46068084|NCT00678093|Other|Application of the SNAG technique|SNAG is a painless and gentle manual technique, mimicking a slide with concurrent active movement, performed in the lumbar spine (in this study) by an experienced manual therapist-physiotherapist.
46068085|NCT02868905|Procedure|Blood sample|
46068086|NCT02628171|Other|Base Diet|Participants will receive a controlled diet with 0 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
46068087|NCT02628171|Other|Base Diet with Cashew Nuts|Participants will receive a controlled diet with 42 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
46068088|NCT00610376|Behavioral|Preschool handwashing intervention program|This preschool-based intervention program used a multi-pronged approach that included elements aimed at preschool staff, children, and school nurses, as well as hygienic changes to the classroom environment.
46068089|NCT00610376|Behavioral|Home component intervention|The home component was intended to reinforce handwashing practices through education in the home. It consisted of a video, a magnet, and a card.
46068090|NCT02868827|Drug|Cholecalciferol|400000 international Units of cholecalciferol will be dissolved in 45 ml of fresh milk (Nestle) and it will be given to interventional group patients through enteral route within 24 hours of ICU admission as a single dose.
46068091|NCT02868827|Other|Milk (Nestle)|45 ml of Nestle milk will given to patients assigned as placebo
45608808|NCT03464539|Dietary Supplement|PG low molecular weight chitosan|The product 1000 mg of Polyglucosamine was administered three times per day before and in between main meals
45608809|NCT01633541|Drug|AT-101|Patients will receive AT-101 40 mg orally two times a day.
45608810|NCT01633541|Drug|Docetaxel|Docetaxel (Taxotere) 75 mg/m2
46068092|NCT02869061|Procedure|Liposuction|
46068093|NCT02869061|Procedure|Transurethral bladder neck resection.|
46068094|NCT02869061|Biological|ADRC|Injection of ADRC suspension will be performed endoscopically into the bladder neck close to the site of resection.
46068095|NCT02869061|Other|ADRC isolation|ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in up to 9.5 ml of normal saline.
46068096|NCT04151589|Behavioral|ANGEL Intervention Package and Toolbox|The interventional measures include emergency work flow management app on smartphone, specialized training, assessment of quality improvement outcomes and feedback on a regular basis, patient-centred management frame based lean six-sigma, and other specialised approach.
46068097|NCT02867657|Behavioral|Mindfulness|Five days MBSR curriculum with meditation and yoga
46068098|NCT02627859|Device|Durolane SJ|1ml single intra-articular injection in ankle
45608811|NCT01633541|Drug|Cisplatin|Cisplatin 100 mg/m2
45608812|NCT01633541|Drug|Carboplatin|Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg
45608813|NCT03460561|Procedure|Thoracic epidural block (TEA)|Under complete aseptic precautions and before induction of GA, thoracic epidural catheter was inserted using a 17 gauge, Tuohy epidural needle by a midline approach. T9-T10 interspace was chosen for the injection after skin infiltration by 5 mL of lidocaine 1%. The epidural space was identified by the loss of resistance technique then the catheter was introduced 2 cm into the epidural space, and epidural test dose of 3 mL of lidocaine 2% with 1:200,000 adrenaline was injected to exclude vascular or subarachnoid position.
45608814|NCT03460561|Procedure|Rectus sheath block (RSB)|"Under aseptic technique, the rectus muscle was imaged with the ultrasound probe, A broadband (5-12 MHz) linear array probe of Sonosite ™ 3000 ultrasound (FUJIFILM, Sonosite EDGE II -UAS) in a transverse orientation at or immediately above the level of the umbilicus, with an imaging depth of 4-6 cm.~Inserting the needle: An 18G Tuohy needle was introduced few millimeters from the probe using an in plane technique in an angle of 45 degrees to the skin. (posterior rectus sheath and fascia transversalis). Under direct vision, the needle tip was advanced to the desired position where 20 mL of (levo-bupivacaine 0.25% Fentanyl 30 μg) were injected causing hydro dissection of the rectus muscle away from the posterior rectus sheath. The technique is repeated on the opposite side."
45608815|NCT04456595|Biological|Adsorbed COVID-19 (inactivated) Vaccine|Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
45608816|NCT04456595|Biological|Placebo|Placebo of Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
45608817|NCT04934371|Device|Transcranial Direct Current Stimulation (tDCS)|TDCS is a procedure that sends weak electrical currents between points on the scalp. Some of this current flows through the brain, and may induce temporary changes in brain activity lasting 30-60 minutes beyond the time of stimulation. TDCS is believed to be very low risk. TDCS has been applied in more than 4900 studies and hundreds of people to treat various neurological and psychiatric conditions, including depression, epilepsy, chronic pain and Parkinson's. In this study we will use tDCS to suppress symptom of tinnitus and hyperacusis.
46068099|NCT02867579|Behavioral|"evaluation of the child quality attachment (Strange situation)"|
46068100|NCT02868593|Other|Pharyngeal swab|
45608818|NCT04934371|Device|Sham TDCS|Sham control will be administered to the same area as active TDCS
45608819|NCT05389475|Procedure|anoplasty in treatment of post hemorroidectomy anal stenosis|Diamond flap versus V-Y flap
45608820|NCT03460405|Biological|Vi-DT Vaccine|1 dose of Vi-DT Vaccine
45608821|NCT03460405|Biological|Vi Polysaccharide Vaccine|1 dose of Vi Polysaccharide Vaccine
45608822|NCT03460405|Biological|IPV Vaccine|1 dose of IPV Vaccine
45608823|NCT05166005|Drug|vitamin D|Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week or low dose vitamin D (2,000 IU daily).
46068101|NCT00678405|Behavioral|Breathlessness Intervention Service|Breathlessness Intervention Service (BIS) consists of a clinical specialist physiotherapist & palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease (cancer & non-cancer) using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social & physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); & pharmacological review. Thus BIS seeks to enhance the self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs & allied health professionals (with medical consent).
46068102|NCT00678405|Behavioral|Best supportive care (Standard Care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory, cardiology, neurology or oncology) which may include specialist nurse input, and primary care services.
46068103|NCT00987389|Procedure|Plasma Exchange|Plasma exchange is a procedure whereby blood is taken from the body and separated by a machine into blood cells and plasma, which is the liquid part of blood. The plasma is discarded and the blood cells are returned to the body with a plasma substitute.
46068104|NCT00987389|Other|No Plasma Exchange|No plasma exchange.
45608824|NCT05389397|Behavioral|Outreach|Mailed letter, secure message or telephone outreach will be used depending on arm enrolled
45608825|NCT03464305|Drug|acetylsalicylic acid|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
45608826|NCT03464305|Drug|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
45608827|NCT02522741|Behavioral|Parenting STAIR|Parenting-STAIR is an adaptation of a 16 session study therapy entitled Skills Training in Affective and Interpersonal Regulation/Modified Prolonged Exposure (STAIR/MPE). It generally is comprised of approximately 23 sessions and includes seven didactic interaction parenting sessions. There are threskill building in areas such as e modules within Parenting STAIR: 1) Module 1 focuses on skill building (awareness of emotional states, management of negative feelings, regulation of emotional intensity, etc.); 2) Module 2 involves the processing of memories of trauma and creating a coherent and meaningful life narrative; 3) Module 3 includes both the mother and child, and focuses on increasing maternal attunement and improving parenting skills.
45608828|NCT05383781|Other|Hip and Knee focused exercises|Exercises which improves muscle strength, ROM
46068105|NCT00987389|Drug|Glucocorticoids [Standard Dose]|During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a standard regimen.
46068106|NCT00987389|Drug|Glucocorticoids [Reduced Dose]|During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a reduced regimen.
46068107|NCT00929162|Drug|ZD4054 Zibotentan|10 mg oral tablets once daily
46068108|NCT00929162|Drug|Paclitaxel|175mg/m2 IV on day 1 every 3 weeks
46068109|NCT00929162|Drug|Carboplatin|Carboplatin AUC of 5.0 IV on day 1 every 3 weeks
45608829|NCT05383781|Other|Short foot exercise|The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.
45608830|NCT05381441|Behavioral|Safety Action Feedback and Engagement (SAFE) Loop|Nursing units randomized to the intervention arm will undergo the SAFE Loop intervention, which involves five Key Attributes: (1) obtaining input from nurses on which problems to address; (2) focusing on selected high-priority events, (3) prompting nurses to report the high-priority events for a designated period and write more informative reports; (4) following standardized investigative procedures to integrate information from sources internal and external to CSMC, and (5) providing feedback to nurses about safety problems and mitigation plans. During all phases, the SAFE Loop Team collaborates with frontline nurses and Unit Managers.
45608831|NCT03464227|Drug|UCB0107|"Pharmaceutical form: solution for infusion~Route of administration: intravenous use"
45608832|NCT03464227|Other|Placebo|"Pharmaceutical form: intravenous infusion~Route of administration: intravenous use"
45608833|NCT05388071|Other|Usage of telemedicine and tele-consultation for treatment|Telemedicine will be used to treat patients at an ambulance station. The medical interventions will be performed by a TeleSAN after delegation through a tele-EMS-physician if possible.
45608834|NCT04877743|Other|None (Observational study)|The main data sources for the study will be participants and their medical records. Vaccination details will be verified by a vaccination card, batch/lot number, and/or using a regional vaccination register. Participants will report all study outcomes using the study app, web portal, or call centre. Participants can also select a proxy to communicate on their behalf: a caregiver, family member, or other trusted individual. Participants will be asked for an emergency contact in case of death or incapacity.
46068110|NCT00929162|Drug|Placebo|matching placebo for ZD4054 10 mg
46068111|NCT02627625|Drug|Tiotropium|4 inhalations
46068112|NCT00678483|Drug|rimonabant (SR141716)|once daily
46068113|NCT00610454|Drug|Levetiracetam|
46068114|NCT04292015|Diagnostic Test|Optos ultra-widefield retinal imaging (Optos California)|retinal imaging device
46068115|NCT04151355|Drug|Atorvastatin 20mg|atorvastatin (20 mg once daily)
46068116|NCT05068700|Device|Integrated Pulmonary Index|Medtronic Capnostream 35p monitoring parameter
46068117|NCT05068700|Device|Standard capnography monitoring|Medtronic Capnostream 35p monitoring parameter
45444941|NCT01730937|Radiation|stereotactic body radiation therapy|Undergo SBRT
45452258|NCT02261584|Device|Microwave Thermal Coagulation|Microwave thermal coagulation of splenic parenchyma.
45608835|NCT03464149|Diagnostic Test|One armed study, blood from each patient is analysed by four assays ( two 3rd generation and two 2nd generation assays)|Intact PTH Assay (Siemens Healthcare Diagnostics Inc); LIAISON 1-84 PTH Assay (Diasorin); PTH (1-84), biointact (Roche Diagnostics); PTH, intact (Roche Diagnostics)
45608836|NCT03936413|Device|Bay Labs EchoGPS Echcoardiogram|An echocardiogram will be performed in this arm using the Bay Labs EchoGPS. The Bay Labs EchoGPS system is an ultrasound system which uses the techniques of computer vision to analyze echocardiography images in real time. It then provides feedback to the user to optimize the images, and once they meet a specific level of quality it automatically records the images.
45608837|NCT03936413|Device|Native Terason Echocardiogram|An echocardiogram will be performed in this arm using a native Terason echocardiography system. This system will not have any artificial intelligence assistance in image optimization or selection.
46068118|NCT04291625|Procedure|Levator muscle resection|"Surgery was performed under general anaesthesia. Two milliliters of 2% lidocaine with 1:100 000 epinephrine is injected subcutaneously. After the upper eyelid incision at the desired crease line, the orbital septum was opened and the preaponeurotic fat was identified and dissected off the levator aponeurosis. The aponeurosis was disinserted from the tarsus, and the complex of levator aponeurosis and Muller muscle was dissected free from the conjunctiva. The desired eyelid height was determined from the proposed formula.~Satisfactory Intraoperative lagophthalmos was defined as a difference of less than 1 mm between recommended by the formula and actual intraoperative lagophthalmos.~After permanent fixation, a caliper was used for precise measurement of lagophthalmos in a supine position. Additional sutures were placed on the medial and lateral sides for satisfactory eyelid contour. The redundant levator complex was excised. Eyelid crease was made by placing three interrupted sutures"
45608838|NCT03464071|Device|Hyperinflation with mechanical ventilator|increase in initial positive inspiratory pressure until reaching a peak pressure of 40 cmH2O and PEEP equal to 7 cmH2O
45608839|NCT03464071|Device|Manual hyperinflation|the manual resuscitation bag will be connected to the oxygen system at five liters per minute. The participant will be disconnected from the ventilator and then initiate a slow inspiration with inspiratory pause followed by abrupt expiration, totaling twelve (12) cycles / minute.
46068119|NCT00678717|Procedure|Autonomic Evaluation|Orthostatic vital signs will be determined by measuring heart rate (HR) and brachial blood pressure (BP) during a tilt table test. The degree of vagal mediated sinus arrhythmia will be assessed during controlled breathing (5 seconds inhalation and 5 seconds exhalation during 90 seconds), and the sinus arrhythmia parameters will be calculated as the difference and ratio of the longest to the shortest RR interval. The sympathetic response during breath hold will be measured. Responses of BP, HR, MSNA will be acquired during Valsalva maneuver. The valsalva ratio of heart rate will be calculated from the maximum of heart rate during or shortly after straining and the minimal depressed heart rate in the overshoot phase IV. Blood pressure and MSNA increase during isometric handgrip maintained at 30% of maximal voluntary contraction for five minutes will be determined. The blood pressure and MSNA response will be measured during cold pressor test with the hand in ice water for 1 minute.
46068120|NCT00609284|Drug|cetuximab|D-7, D1, D8, D15, D22, D29, D43, D50
46068121|NCT00609284|Drug|Carboplatin, 5FU concomitant|Carboplatin 70mg/m²/D ; 5FU 600 mg/m²/D, D1-4, D22-25, D43-46
46068122|NCT00609284|Radiation|Radiotherapy|70 Gy in 7 weeks
45608840|NCT05165615|Device|Insulin Pump t:slim X2 with Control-IQ technology|Usage of Insulin pump t:slim X2 with Control-IQ technology in previous users of AndroidAPS
45608841|NCT03463837|Other|Treatment with JUUL 5%, Virginia Tobacco|JUUL 5%, ENDS for 5-days in confinement
45608842|NCT03463837|Other|Treatment with JUUL 5%, Cool Mint, ENDS|JUUL 5%, ENDS for 5-days in confinement
45608843|NCT03463837|Other|Treatment with JUUL 5%, Mango, ENDS|JUUL 5%, ENDS for 5-days in confinement
45608844|NCT03463837|Other|JUUL 5%, Creme Bruele, ENDS|JUUL 5%, ENDS for 5-days in confinement
45608845|NCT03463837|Other|Combustible cigarette|Exclusive use of combustible cigarette for 5 days in confinement.
45608846|NCT03463837|Other|Smoking Cessation|No smoking for 5-days in confinement.
45608847|NCT03460249|Other|BP measurement|the BP will be measured in the chair position followed by the table position and also in the reverse sequence
45608848|NCT03788213|Radiation|3 week RT|40 Gy in 15 fractions over 3 weeks to the whole breast or chest wall. Patients undergoing breast conservation therapy will receive additional boost radiotherapy to the tumor bed. The supraclavicular fossa will be treated in patient with node positive disease or those receiving neoadjuvant chemotherapy. IMC and Axillary radiotherapy will be given as per the institutional policy. Boost Dose schedule for BCS patients will be 8 Gy delivered in 15 fractions simultaneously with tangential EBRT. In institutions planning for sequential boost, a dose of 12 Gy in 4 fractions will be delivered after whole breast EBRT.
45608849|NCT03788213|Radiation|1 week RT|26 Gy in 5 fractions over 1 week to the whole breast or chest wall. Treatment volumes will be same as the control arm. Additional boost will be delivered to patients who have undergone breast conservation. Boost Dose schedule for BCS patients will be 6 Gy delivered in 5 fractions simultaneously with tangential EBRT. In institutions planning for sequential boost, a dose of 12 Gy in 4 fractions will be delivered after whole breast EBRT.
45608850|NCT04455737|Other|injection of indigo carmine|Ex vivo intra-arterial injection of 20 ml indigo carmine solution (10mL, 0.4% indigo carmine with 10mL, 0.9% saline solution) in the transanal total mesorectal excision specimen via the inferior mesenteric artery.
45757878|NCT04606316|Drug|Ipilimumab-Placebo|Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
45757879|NCT04606316|Drug|Ipilimumab|Given as intravenous (IV) infusion into a vein.
45452259|NCT02261584|Device|Partial Splenic Embolization|Femoral artery approach will be used for splenic artery catheterization with the tip of the catheter always well advanced selectively into the splenic artery. Embolizing agent will be injected in small increments. Arteriography in between divided doses will be done to document the extent of devascularization.
46068123|NCT04291937|Drug|Lurbinectedin|Powder for concentrate for solution for infusion in 4 mg vials
46068124|NCT00678873|Procedure|Single Incision Laparoscopic Cholecystectomy|A single trans-umbilical incision laparoscopic cholecystectomy will be performed by standard fashion and under general anesthesia.
45757880|NCT04606316|Procedure|Surgery|Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.
46068125|NCT04257890|Behavioral|Cognitive behavioral therapy|The CBT focuses on cognitive restructuring to reduce the specific key maladaptive beliefs on Internet gaming suggested by King's model, and develop useful coping skills (self-regulation/control, emotion regulation, problem-solving coping) that are adapted from previous CBT for adolescent IGD. In addition, it provides training on relapse-prevention and maintenance techniques.
46068126|NCT04257890|Other|Education material about IGD|Printed education material introducing IGD will be distributed.
45757881|NCT03480971|Drug|Tempol|Investigational product is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) oral solution. Tempol solution is an orange-colored, aqueous solution containing 7% Tempol along with xanthan gum, xylitol, aspartame, acesulfame potassium, sodium saccharin, alcohol, peppermint and wintergreen oils.
45757882|NCT03480971|Drug|Placebo Solution|The placebo contains the same excipients as the active product plus FD&C Yellow #6 for color matching.
46068127|NCT04257890|Other|Education material about CBT|Printed education material introducing CBT will be distributed.
46068128|NCT04151511|Procedure|Continuous Erector Spinae Plane Block|"Continuous Thoracic Epidural Thoracic Epidural Analgesia~Continuous Erector Spinae Plane Block"
45608851|NCT04870801|Drug|Respirogen Micro-Oxygen|Enteral (rectal) delivery of Respirogen Micro-Oxygen
45757883|NCT05148806|Diagnostic Test|self-administered lateral flow assays|The lateral flow device to be used is the Fortress COVID-19 Total Antibody Device for the detection of IgM and IgG SARS-CoV-2 against the spike protein. The device has been evaluated for use in detecting anti-S in transplant patients and found to have a sensitivity of 92% and specificity of 95%.
46068129|NCT00992459|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (~17.4mL) delivers equivalent amount of PBA in 40 tablets of NaPBA.
45608852|NCT03468959|Behavioral|Maternal Supplemental PUFA Intake|Maternal Supplemental PUFA Intake included sources from the questionnaires and plasma
45608853|NCT03468439|Other|Femoral nerve block with phenol|
46068130|NCT00992459|Drug|Buphenyl (NaPBA)|Buphenyl (NaPBA) will be the comparator drug to HPN-100 in this study.
46068131|NCT00930722|Drug|quinapril|per label as non interventional study
46068132|NCT00679107|Device|Use of OP-1 Putty in Uninstrumented posterolateral fusion|Use of OP-1 Putty in Uninstrumented posterolateral fusion
46068133|NCT00679185|Behavioral|expressive writing|four non-emotional writing assignments
45608854|NCT05165303|Drug|lidocaine with propofol|different concentrations of lidocaine added to propofol varying from
45608855|NCT03129919|Device|Carriere SLX® (Passive self-ligating braces)|Changes in the inclination of the incisors, expansion of the arches at the end of the alignment and leveling phase of the orthodontic treatment
45608856|NCT03129919|Device|Empower® (Interactive self-ligating braces)|Changes in the inclination of the incisors, expansion of the arches at the end of the alignment and leveling phase of the orthodontic treatment
45608857|NCT03129841|Behavioral|Early dinner+Diet|Subjects are asked to eat dinner meals between 7:00- 7:30 PM in the ED group, while they are on a multidisciplinary weight loss plan for 12 weeks.
45608858|NCT03129841|Behavioral|Late dinner+Diet|Subjects are asked to eat their dinner meal between 10:30-11:00PM, while they are on a multidisciplinary weight loss plan for 12 weeks.
45757884|NCT04614129|Diagnostic Test|Low Dose CT|All participants will have a low dose chest CT either within one year of enrollment or after enrollment
46068134|NCT04990622|Dietary Supplement|Flavonoid-rich diet|Inclusion of foods rich in flavonoids.
45608859|NCT05165147|Other|no intervention|no intervention
45608860|NCT03468361|Other|Natural Product Petroselinum crispum (Parsley)|Parsley herb, in fresh form will be obtained from the local market available. The herb will be properly washed with distilled water and dried properly for 10 to 15 days under shade in the lab. Soft gelatin capsules will be filled with parsley powder (dried herb) in amount normally recommended in daily routine (1g) will be administered to patients once daily.
45608861|NCT03468361|Other|Placebo|Soft gelatin capsules will be filled with 1 gram of lactose (inert pharmaceutical ingredient) and will be administered to patients once daily.
46068135|NCT00912249|Behavioral|Horticulture Therapy|We will design courses of Horticultural therapy to provide to the Patients in Day Care Unit
46068136|NCT00610610|Drug|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in the following manner: week 1: 12.5 mg per day, week 2: 25 mg per day, week 3: 37.5 mg per day, wk 4: 50 mg per day and week 5: 62.5 mg per day.
46068137|NCT00610610|Drug|Placebo|Same shape Placebo
46068138|NCT00912327|Biological|Imprime PGG|Imprime PGG, 4 mg/kg, i.v. over 2 hr, weekly in 6 week cycles and Cetuximab, initial dose will be 400 mg/m2 via i.v., and subsequent doses will be 250 mg/m2 via i.v., weekly in 6 week cycles
46068139|NCT04257812|Drug|Ceftolozane/tazobactam|"The dose will be 1g ceftolozane + 0,5 g tazobactam every 8 hours or 2 g ceftolozane + 1 g tazobactam, it´s recommended to use this last dose regimen in patients with pneumonia or septic shock of any focus.~The patients will be followed as it´s done habitually. There will be done infection focus cultures and others according to usual clinical practice. It´ll be determined the clinical response and mortality in the days 14 and 30 after the beginning of the medicine, respectively.~The Ceftolozane-Tazobactam levels determination will always be made in state of equilibrium (after the third dose). Four samples will be collected:~Just before the antibiotic infusion.~One hour after the antibiotic infusion.~Three hours after the antibiotic infusion.~Six hours after the antibiotic infusion."
45608862|NCT03511781|Radiation|Hypofractionated Radiotherapy|Palliative Hypofractionated radiotherapy 35 GY in 10 fractions over 2 weeks in advanced incurable Breast Cancer
45608863|NCT03468283|Other|mobile application for diabetes|Intervention was mobile application and individualized regular message feedback sent by healthcare professionals.
45608864|NCT05165069|Drug|Mecobalamin 5 MG Disintegrating Oral Tablet|Mecobalamin 0.5mg / time, 3 times / day,was taken continuously for 6 months
45608865|NCT05165069|Drug|placebo|placebo 0.5mg / time, 3 times / day,was taken continuously for 6 months
45608866|NCT03376763|Drug|Abilify maintena|Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)
46068140|NCT00992225|Drug|LY573636-sodium|Dose is adjusted to target a specific maximum concentration (Cmax) based on patient laboratory parameters, administered intravenously every 28 days until disease progression or other criteria for patient discontinuation are met
46068141|NCT02627703|Other|Oncotype DX|The Oncotype DX® assay is a multi-gene reverse-transcriptase-polymerase-chain-reaction (RT-PCR) test that analyzes the expression of 21 genes, and quantifies the 10 year distant breast cancer recurrence risk in patients with stage I and II, lymph node negative, estrogen receptor positive disease who plan to be treated with tamoxifen for 5 years.
46068142|NCT04257734|Other|observation|different serum antibodies status
46068143|NCT02868749|Device|Hyaluronic Acid filler|Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in one side of the abdomen or one breast, 3 weeks to 4 months before the surgery.
46068144|NCT02868749|Device|Hyaluronic Acid filler|Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in other side of the abdomen or other breast, 5 to 9 days before the surgery.
46068145|NCT00659581|Drug|Telmisartan|Oral administration
46068146|NCT02627547|Behavioral|Normal training|5-10 hours of endurance training each week
45608867|NCT03463681|Drug|Cabometyx|cabozantinib 60 mg orally once daily
45608868|NCT03459703|Behavioral|Early Time-Restricted Feeding|Eat all meals between 7 am - 3 pm for an average of ≥6 days per week.
46068147|NCT02627547|Behavioral|De-training|No training
46068148|NCT00679497|Biological|MVA-B|"Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~-~ 1 x 10e8 pfu/ml~3 immunisations at week 0, 4 and 16"
45444942|NCT03791697|Other|Telehealth 2 week postoperative visit|"The patient randomized into the telephone follow up group, will be contacted, at the pre-scheduled date and time, by the urogynecology clinic nurse. The nurse will utilize a scripted series of postoperative questions, which are consistent with questions asked during our standard postoperative clinic visits.~Vital signs and physical examination will be deferred for the patients in the telephone follow up group.~Any patient responses that are not consistent with a usual postoperative course will be escalated to an in person visit. However, these patients will remain in the group, to which they were originally randomized, for research analysis purposes. (Intent to treat)"
45608869|NCT03459703|Behavioral|Control Schedule|Eat all meals over a 12-hour or longer period for an average of ≥6 days per week.
45608870|NCT03459703|Behavioral|Structured Weight Loss Program|A structured weight loss program with physical activity recommendations and dietary counseling.
45608871|NCT03468881|Other|Communication Skills Training Package (KEW)|A training package (called KEW: Know, Encourage and Warm-up) for therapeutic radiographers to manage emotional talk with breast cancer patients in treatment.
45608872|NCT03459547|Device|dental implant|Local anesthesia, flap preparation, dental implant insertion, flap suture, healing abutment insertion. Peri-implant soft tissue samples taken prior to implant placement and 24 hours after.
45608873|NCT03468803|Diagnostic Test|Beta D Glucan test|Measurement of BDG before, during and after surgery
45608874|NCT05164913|Other|Achenbach Child Behavior Checklist （CBCL）scale|Use the Achenbach Child Behavior Checklist （CBCL）scale to assess children's behavior
45608875|NCT03459313|Other|Active group|For this study, the Frisk.Friidrott (Healthy.Athletics/Track&Field) website has been developed. The purpose of the website is to provide an easy-to-use tool that can assist coaches and parents involved in youth athletics with information how to structure training and recovery planning, provide guidance on possible injuries, and provide other information on health for youth athletes.
45608876|NCT03468725|Drug|XPF-008|Capsule filled with XEN1101
45608877|NCT03468725|Drug|Microcrystalline Cellulose|Placebo capsule
45608878|NCT03459235|Other|quality of life|Assessment of the impact of digestive sequelae (LARS score) and genitourinary sequelae (score IPSS, USP, FSFI et IIEF) in Patients With Rectal Cancer using validated questionnaires on quality of life (EORTC QLQ-C30 et QLQ-CR 29).
45608879|NCT05164679|Behavioral|multimodal training (MMT)|Supervised multimodal exercise training (MMT) performed 1-2 hours weekly for 19 weeks
45608880|NCT03459157|Drug|HIV prevention package including PrEP|All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (TDF 300 mg + FTC 200 mg), daily or on-demand, according the participant's choice, immunisation against hepatitis B, individualised peer-led support (for adherence and prevention), group discussions, condoms, and lubricants.
45608881|NCT03468127|Other|Soy foods|Isolated soy protein, soy protein, soybean products, soy milk
45608882|NCT05153135|Drug|Ribociclib|Participants who initiated CDK4/6i therapy
45608883|NCT05153135|Drug|Palbociclib|Participants who initiated CDK4/6i therapy
45608884|NCT05153135|Drug|Abemaciclib|Participants who initiated CDK4/6i therapy
45608885|NCT02950415|Behavioral|virtual|Parent is present via an internet pad (iPad)
45608886|NCT02950415|Behavioral|coaching|Parent learns what to say verbally to soothe child
45608887|NCT02950415|Behavioral|physical|Parent is present in the operating room
45608888|NCT02950415|Behavioral|no coaching|Parent does not learn what to say verbally to soothe child
45608889|NCT05091749|Biological|blood samples|troponin measurement
46068149|NCT00679497|Biological|Placebo|-3 immunisations at week 0, 4 and 16
46068150|NCT00796393|Dietary Supplement|Lactobacillus helveticus R0052, Bifidobacterium bifidum R0071, Bifidobacterium infantis R0033|1 pill per day for 12 weeks
46068151|NCT00796393|Dietary Supplement|Starch of potato|1 pill per day for 12 weeks
46068152|NCT00793741|Drug|somatostatin|Somatostatin may be used to suppress endogenous insulin secretion
46068153|NCT00796471|Drug|Paliperidone ER|
46068154|NCT00991289|Drug|Nitazoxanide (NTZ)|500 mg twice daily, taken orally with food
46068155|NCT00991289|Drug|Pegylated interferon alfa-2a (PEG)|180 micrograms via subcutaneous injection once weekly
46068156|NCT00991289|Drug|Ribavirin (RBV)|Weight-based dosing; 1,000 mg daily, taken orally, for people weighing less than 75 kg or 1,200 mg for people weighing at least 75 kg.
46068157|NCT00801463|Drug|tripterygium wilfordii (TW)|Pre 30mg/d +TW 120 mg/d, po for 12 weeks
45608890|NCT03463447|Device|Electronic Dynamometer|Mensuration of the handgrip strength of each volunteer using an electronic dynamometer.
46068158|NCT04150809|Other|No intervention|There is no intervention for this study
46068159|NCT04046029|Drug|Bivalirudin|Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
46068160|NCT04046029|Drug|Heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
46068161|NCT00679653|Drug|sibutramine|8-wks, sibutramine, 10 mg, capsules, once daily
46068162|NCT00679653|Drug|sibutramine|8-wks, sibutramine, 15 mg, capsules, once daily
45444943|NCT03789123|Drug|Estradiol valerate/dienogest|The effects of drugs given for endometrioma and contraception will be observed on ovarian reserve, endometrioma size and pain score.
45444944|NCT05471817|Drug|Elinzanetant (BAY3427080)|Capsule, oral, single dose
46068163|NCT00679653|Drug|verapamil/trandolapril|2 wk Run-in phase, antihypertensive therapy only
46068164|NCT00679653|Drug|metoprolol/HCT|2 wk Run-in phase, antihypertensive therapy only
46068165|NCT00679653|Drug|felodipine/ramipril|2 wk Run-in phase, antihypertensive therapy only
46068166|NCT02868983|Other|Integration|"The intervention consists of training for practice leaders, BHCs, PCPs, and office staff, a Protocolized Redesign Process support for practice redesign, and a toolkit of suggested tactics for implementing Tasks A through D:~A. Identification B. Assessment C. Treatment D. Surveillance"
46068167|NCT00793897|Drug|BMS-754807|Tablets, Oral, escalating doses starting at 10 mg, continuous or intermittent, until disease progression, unacceptable toxicity or at the subject's request
45757885|NCT04399616|Other|Risk Map|The tool we test in this project (the visual hazard map) aims to enable the practitioner to quickly identify critical areas for systematically implementing relevant safe practices (appropriate for each situation).
45757886|NCT00646763|Drug|G-CSF, GM-CSF administered at extremities|Injection site Extremities: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a twice daily schedule of G-CSF/GM-CSF until stem cell collection is complete.
46068168|NCT00793897|Drug|Paclitaxel|Vials, IV, 200 mg/m2, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
45608891|NCT03463447|Device|Hydraulic dynamometer|Mensuration of the handgrip strength of each volunteer using a hydraulic dynamometer.
45608892|NCT02616185|Biological|PF-06755992|PF-06755992 will be administered on Day 1 of Cycles 1 and 2.
45608893|NCT02616185|Biological|PF-06755990|PF-06755990 will be administered using a device on Day 29, 57 and 85 of each cycle.
45608894|NCT02616185|Device|TDS-IM Electroporation Device|TDS-IM electroporation device and associated supplies will be used for PF-06755990 administration
45757887|NCT00646763|Drug|G-CSF and GMCSF administered at abdomen|Injection site Abdomen: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a BID schedule of G-CSF/GM-CSF until stem cell collection is complete.
45757888|NCT03237572|Drug|Pembrolizumab|Pembrolizumab (200 mg)
45757889|NCT03237572|Device|High-intensity focused ultrasound (HIFU)|Ablation will target 50% of the tumor, up to 3 cubic centimeters
46068169|NCT00793897|Drug|Carboplatin|Vials, IV, 6 mg/mL.min, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
46068170|NCT00679887|Procedure|ischemic compression|Active Comparator, ischemic compression, 3 times a week,5 weeks
45444945|NCT05471817|Drug|Dabigatran etexilate|Capsule, oral, single dose
45444946|NCT03788889|Drug|Ketamine|Ketamine infusion
45444947|NCT03788889|Drug|Phenobarbital|Phenobarbital intravenous injection
45444948|NCT03788889|Drug|Lorazepam|Standard of Care
45444949|NCT03788889|Drug|Placebo A|Placebo injection
45608895|NCT02616185|Biological|Tremelimumab|PF-06753388 will be administered every 28 days.
45757890|NCT02986347|Procedure|Intravenous regional anesthesia (Bier)|Intravenous regional anesthesia (Bier Technique)
45757891|NCT02986347|Procedure|Local anesthesia with adrenaline|local anesthesia with adrenaline without limber garroting (Lalonde Technique)
46068171|NCT00793975|Biological|IMC-1121B|"Cohort 1~2 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
46068172|NCT00793975|Biological|1121B|"Cohort 2~4 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
46068173|NCT00793975|Biological|1121B|"Cohort 3~6 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
46068174|NCT00793975|Biological|1121B|"Cohort 4~8 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
45444950|NCT03788889|Drug|Placebo B|Placebo infusion
45444951|NCT01306227|Drug|L-Thyroxine|Treatment with L-Thyroxine:7,5 µg/kg/day. Oral treatment (one drop =5µg) in the morning, once a day.
45452260|NCT05621122|Other|This is an observational study|This is an observational study. The control group (omnivours) will be compared with all otgher groups
45608896|NCT02616185|Biological|PF-06801591|PF-06801591 will be administered every 28 days.
45608897|NCT02616185|Biological|PF-06753512|Combination of adenovirus (AdC68) + plasmid DNA (pDNA) + tremelimumab
45608898|NCT03463369|Biological|JNJ-64300535|Participants will receive JNJ-64300535 vaccine by electroporation-mediated IM injection on Day 1, Week 4, and Week 12.
46068175|NCT00793975|Biological|1121B|"Cohort 5~10 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
46068176|NCT00793975|Biological|1121B|"Cohort 6~13 mg/kg once a week for 4 weeks, followed by a 2-week observation period."
45608899|NCT03463369|Biological|Placebo|Participants will receive 1 mL (0.9 percent [%] sodium chloride [NaCl]) of placebo solution matching to JNJ-64300535 electroporation-mediated IM injection on Day 1, Week 4, and Week 12.
45608900|NCT03463369|Drug|Nucleos(t)ide Analogs (NA)|Participants will receive NA as a standard of care treatment.
45608901|NCT05697419|Behavioral|deep breathing, muscle relaxation, and mindfulness|5-10-minute group sessions will be administered to DPT students teaching them the NIH recommended strategies of deep breathing, muscle relaxation or mindfulness.
46068177|NCT00793975|Biological|1121B|"Cohort 7~16 mg/kg once a week for 4 weeks, followed by a 2-week observation period."
46068178|NCT00679965|Drug|AN2690, 2.5%|Once daily application for 90 days and 3 x weekly for 90 days
46068179|NCT00679965|Drug|AN2690, 5%|Once daily application for 90 days and 3 x weekly for 90 days
46068180|NCT00679965|Drug|AN2690, 7.5%|Once daily application for 90 days and 3 x weekly for 90 days
46068181|NCT00679965|Drug|AN2690 Solution Vehicle|Once daily application for 90 days and 3x weekly for 90 days
46068182|NCT00930644|Drug|teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 24 months
46068183|NCT05251051|Behavioral|pediatric physical therapy|Pediatric physical therapists will provide weekly home therapy using standard of care/best evidence procedures
46068184|NCT05251051|Other|Care Coordination|A navigator will be assigned who will assist families in obtaining Early Intervention services and other therapy services if needed
46068185|NCT02627469|Behavioral|Extended professional oral hygiene care|Weekly professional oral hygiene performed by dental hygienists
46068186|NCT02627469|Device|Electric toothbrush (Oral-B Professional Care 7000)|Weekly professional oral hygiene performed by dental hygienists
46068187|NCT02627469|Device|1100 ppm sodium fluoride dentifrice (Zendium Classic)|Weekly professional oral hygiene performed by dental hygienists
46068188|NCT00796783|Drug|Cushing's syndrome confirmation|
46068189|NCT00680277|Dietary Supplement|spirulina ß-carotene|an acute dose of spirulina up to 5 g
46068190|NCT00680277|Dietary Supplement|spirulina ß-carotene|vitamin A value of spirulina ß-carotene
46068191|NCT00794053|Procedure|detecting lymph node metastasis by staining|this started by collar incision, development of sub-platysmal skin flaps and separation of strap muscles in the midline. This was followed by exposure of the thyroid gland; identification of the thyroid tumour; injection of the dye into the tumour; waiting for the dye to reach the lymph nodes; identifying the stained node; labeling it as the sentinel node (SLN); performing total thyroidectomy and bilateral central neck dissection.
46068192|NCT00680355|Dietary Supplement|golden rice|An acute dose of cooked golden rice containing ~ 1 mg of ß-carotene
45444952|NCT01306227|Drug|water|Oral treatment with water. Equal number of drop of water as compared with the treatment arm (according to the body weight of the newborn) in the morning, once a day.
45608902|NCT03468049|Biological|Topical App. of Allium Cepa Extract|Topical Application of Allium Cepa Extract (oil)
45608903|NCT03468049|Biological|Phonophoresis of Allium Cepa Extract|Phonophoresis of Allium Cepa Extract (oil)
45608904|NCT03468049|Biological|Raw Mashed Allium Cepa Application|Raw Allium Cepa (onion bulb) Mashed
45608905|NCT03468049|Other|Standard Physiotherapy Group (SPG)|This will consist of Massage and therapeutic exercise for the management of shoulder pain post stroke
45608906|NCT05697341|Procedure|Ultra-Mini-PCNL|treatment to extract or disintegrate renal stones
45608907|NCT05697341|Procedure|Stented SWL|treatment to disintegrate renal stones in the presence of a JJ
46068193|NCT00680355|Dietary Supplement|corn oil 0g|0 g of corn oil in the golden rice meal
46068194|NCT00680355|Dietary Supplement|corn oil 10g|10g corn oil in the golden rice meal
46068195|NCT00680355|Dietary Supplement|coren oil 5 g|golden rice meal with 5 g corn oil
46068196|NCT00801697|Biological|DNA Vaccine|4 mg VRC-HIVDNA044-00-VP administered as 1 mL
46068197|NCT00801697|Biological|DNA Vaccine placebo|1 mL VRC-PBSPLA043-00-VP
46068198|NCT00801697|Biological|rAd35|VRC-HIVADV027-00-VP 1 x 10^10 PU administered as 1 mL
46068199|NCT00801697|Biological|rAd35 placebo|1 mL VRC-PBSPLA043-00-0VP
46068200|NCT00801697|Biological|rAd5|4 mg VRC-HIVADV038-00-VP administered as 1 mL
46068201|NCT00801697|Biological|rAd5 placebo|1 mL VRC-DILUENT013-DIL-VP
46068202|NCT02626299|Drug|Docosahexaenoic acid - 800mg/day|All participants will take 1000 mg/DHA per day (1 capsule will be labeled with 200 mg; 2 capsules will be masked with 400 mg each)
46068203|NCT02626299|Drug|Docosahexaenoic acid - 200mg/day|The control group will receive 1-capsule containing 200 mg DHA/d.
46068204|NCT02626299|Other|Placebo|Participants will receive 2 capsules (masked) containing half soybean oil and half corn oil equaling 800 mg.The soybean and corn oil combination does not contain DHA.
46068205|NCT00794131|Biological|GL-ONC1|a genetically-engineered vaccinia virus (encoding Renilla luciferase-Aequorea green fluorescent protein fusion, β-galactosidase, and β-glucuronidase )
46073615|NCT05659524|Other|Nasal saline irrigation|"The following nasal care recommendations have been approved by the study protocol committee for patients randomized to the treatment arm with saline irrigations:~Postoperative days 1 through 3: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily.~Postoperative day 3 to week 12: patients will begin twice daily sinus irrigation rinse (e.g., NeilMed Sinus Rinse). They will perform 240 mL sinus rinses BID. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative."
46073616|NCT02822664|Behavioral|Pedophiles patients|cerebral MRI and/or cerebral PET imaging
46073617|NCT02822664|Behavioral|Healthy subjects|cerebral MRI and/or cerebral PET imaging
46073618|NCT02822664|Device|PET/MRI|
46073619|NCT00841165|Device|Continuous Positive Airway Pressure|Full face CPAP at 5cm H2O and 100% oxygen
46073620|NCT00841165|Device|Non-rebreather oxygen mask|Oxygen administered through a non-rebreather mask
46073621|NCT02823756|Procedure|Physical Therapy|Exercise, education, spinal manipulation
46073622|NCT00841243|Dietary Supplement|Nutrison (Nutricia)|During 48 weeks of treatment, the patient will receive at T=0, 2, 4, 8, 12, 18, 24, 36, 48 weeks dietary advise combined with daily nutritional support in the form of a nutritional supplement drink at bedtime.
45911400|NCT02007707|Behavioral|Healthy Eating|Eating Healthy and Physically Active for You and Your Family - This is a attention-control comparison group using a family-based psycho-education intervention delivered through lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about healthy eating and physical activity through 2 small-group education sessions and 2 individual phone calls over a 2-month period. Participants will receive writing information about smoking cessation resources.
45911401|NCT02007746|Other|Liver transient elastography (Fibroscan)|Fibroscan will be performed as a measure of liver stiffness. The study will be obtained free of charge in this study.
46068206|NCT00684489|Drug|clinical hypertension specialist-no specific med. Any anti-hypertension meds.|assignment to a clinical hypertension specialist. Drugs used were hypertension medications were: chlorothiazide, hydrochlorothiazide, polythiazide indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, ditiazem, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, clonidine, clonidine patch, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
46068207|NCT00684489|Drug|renin guided therapeutics-no specific med. Any anti-hypertensive med.|renin guided therapeutics-chlorothiazide, chlorthalidone, hydrochlorothiazide, polythiazide, indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol, pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, chlonidine, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
46068208|NCT00684801|Other|questionnaire administration|Patients complete questionnaires.
46068209|NCT00684801|Procedure|quality-of-life assessment|Patients undergo quality-of-life assessments.
45608908|NCT04857307|Drug|Alprazolam|"Pharmaceutical form: Inhalation powder.~Study participants will receive Staccato alprazolam at prespecified time-points."
45608909|NCT03467893|Drug|Antacids|number aof antacids treatment after PPI stop
45608910|NCT03463291|Device|MRI|"T1 weighted image.~Fast spin-echoT2 weighted image.~Short inversion recovery (STIR).~T1-fat suppressed images.~Diffusion weighted sequences with different b values 0-1000 s/mm2 with qualitative assessments by the different b values as well as quantitative assessment by measurement of the ADC values."
46068210|NCT00990821|Drug|90 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered intravenous (IV) over 15 minutes
45608911|NCT03463213|Behavioral|SHE Tribe|Social network-based peer-facilitated intervention to promote adoption of health behavior
45911402|NCT02007746|Other|Ferriscan|Ferriscan will be done to assess the quantity of liver iron in iron overloaded subjects.
45911403|NCT02007746|Procedure|Liver biopsy in iron overloaded subjects.|Liver biopsy will be done and the results will be compared to Fibroscan results.
45608912|NCT01328431|Other|Brief Intervention with NRT Initiation|Brief Negotiated Interview is a manual-guided therapy designed for the ED setting. The purpose is to assist subjects to change some aspect of their smoking and to decide to start nicotine replacement therapy while in the ED. It combines techniques from motivational interviewing and stages of change. a 6-week supply of nicotine replacement therapy is given in the form of patches and gum and subjects are encouraged to use both concurrently. Patches come in 21 mg, 14 mg, and 7 mg doses and the dosage is determined based on how many cigarettes per day a subject is smoking. All subjects receive 400 pieces of 2 mg nicotine gum. All subjects complete a referral form for the state's Smokers' Quitline which is then faxed directly to the Quitline's vendor.
45608913|NCT03457363|Device|DTM will be add above NC|After oxygenation by classical nasal cannula, the DTM will be place above NC
45444953|NCT01305681|Device|LoFric® catheters during clean intermittent catheterization|LoFric® catheters during clean intermittent catheterization
45444954|NCT03788733|Drug|Melatonin 3 mg|1 time a day for 8 weeks
45444955|NCT03788733|Drug|Placebo Oral|1 time a day for 8 weeks
45608914|NCT03456115|Device|Mechanical nasal dilator|Participants will be asked to trial 5 different mechanical nasal dilators. 4 of which are commercially available and one of which is the investigational device being studied for feasibility. The 4 commercially available nasal dilators include Breathe Right, Max Air, Sleep Right, Nozovent. The fifth device is the study team's investigational device dubbed the Schnozzle.
45608915|NCT03456037|Other|hepatitis viruses|There are 5 main hepatitis viruses, referred to as types A, B, C, D and E. These 5 types are of greatest concern because of the burden of illness and death they cause and the potential for outbreaks and epidemic spread. In particular, types B and C lead to chronic disease in hundreds of millions of people and, together, are the most common cause of liver cirrhosis and cancer.The aim is to investigate incidence of HBsAg, anti-HCV in serum samples and evaluation of biomarkers taken from patients who were followed the intensive care unit of Sakarya University Training and Research Hospital.
45608916|NCT05170711|Procedure|hypotensive anesthesia|hypotensive anesthesia
45608917|NCT05170711|Procedure|normotensive anesthesia|normotensive anesthesia group
45608918|NCT03454945|Drug|Vibramycin|Antibiotic
45608919|NCT03454945|Device|Phototherapy|UVA+Psoralen
45608920|NCT03467737|Other|Normal sorghum porridge, algal starch|Normal sorghum porridge with 13C-labeled algal starch was fed, breath tested, as the first arm of an alpha-amylase sufficiency assessment in healthy and moderately malnourished children.
45653324|NCT05428813|Behavioral|art therapy techniques|Art therapy is a method that allows individuals to increase their self-awareness and realize their emotions better through artistic techniques.
45911404|NCT02007759|Device|VitalStim|This group will receive active VitalStim treatment.
45911405|NCT02007759|Device|Sham VitalStim|This group will receive a sham VitalStim intervention.
45911406|NCT02007772|Device|nHF|nasal high-flow is used over a period of 6 weeks (outpatient)
45911407|NCT02007772|Device|BiPAP|BiPAP is used over a period of 6 weeks (outpatient)
46068211|NCT00990821|Drug|100 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
46068212|NCT00990821|Drug|100 MK-0517 (PS80) + 2 mg midazolam|MK-0517 (Non-PS80 formulation), 1 mg/mL, administered IV over 15 minutes. Midazolam is co-administered as a single oral 2-mg dose of midazolam with MK-0517.
45608921|NCT03467737|Other|Normal sorghum porridge, algal dextrins|Normal sorghum porridge with 13C-labeled starch limit dextrins was fed, breath tested, as the second arm of an alpha-amylase sufficiency assessment in healthy and moderately malnourished children.
45608922|NCT03467737|Other|Normal sorghum porridge, labeled flour|Normal sorghum porridge with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
45608923|NCT03467737|Other|Modified sorghum porridge, labeled flour|Modified sorghum porridge with shear stirring to reduce viscosity with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
46068213|NCT00990821|Drug|115 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
46068214|NCT00990821|Drug|150 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
46068215|NCT00990821|Drug|40 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
45757892|NCT00649961|Drug|Melatonin injection|"A single intravenous infusion of melatonin will be given to each infant over 6 hours so that successive groups will receive increasing doses until the correct dose for age is found.~Based on the pharmacokinetics and clearance of melatonin in adults an approximate dose has been calculated. The starting dose of melatonin will be 0.1 microgram/kg/hr to be given over 6 hours intravenously. The range of expected dose is 0.1-0.5 microgram/kg/hr."
46068216|NCT00990821|Drug|100 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
46068217|NCT00990821|Drug|150 mg MK-0517 (Non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
46068218|NCT00990821|Drug|Placebo|Placebo matching MK-0517
46068219|NCT00990821|Drug|40 mg Aprepitant|Aprepitant, oral, tablet, single dose
46068220|NCT00990821|Drug|125 mg Aprepitant|Aprepitant oral tablet, single dose
45608924|NCT03467737|Other|Thinned sorghum porridge, labeled flour|Thinned sorghum porridge treated with an alpha-amylase liquifying enzyme with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
45608925|NCT03467737|Other|Modified sorghum porridge, octanoic acid|Modified sorghum porridge with shear stirring to reduce viscosity with addition of 13C-labeled octanoic acid was fed, breath tested, for gastric emptying assessment in healthy and moderately malnourished children.
45608926|NCT03454087|Other|Enteral Dextrose Infusion|A standard solution of 50% Dextrose (0.85 kcal/mL) will be infused via enteral route at a rate of 10 mL per hour for a duration of 24 hours.
45608927|NCT03454087|Other|Free Water Infusion|An infusion of free water will be initiated via enteral route at a rate of 10 mL per hour for a duration of 24 hours.
45608928|NCT03454009|Behavioral|Multimodal hygiene intervention|hygiene supplies including hand sanitizer, hand sanitizer surface disinfectant wipes and tissues, along with the following educational materials: a 2-minute electronic educational video; weekly 30-second electronic videos; and an educational flyer.
45608929|NCT01857115|Drug|Carfilzomib|
45608930|NCT01857115|Drug|Cyclophosphamide|
45757893|NCT05137028|Other|Otago Exercise|"Otago exercise protocol~Strengthening exercise:~Resistance exercise for knee flexors, knee extensors, hip abductor, ankle dorsiflexors, ankle planterflexors~Balance exercise:~knee bending, backward walking, walking and turning around, sideway walking, tendem stance, tendem walking, one leg stand, heel walking, toe walking, heel to toe walking, sit to stand, stair walking"
45757894|NCT03235232|Drug|BREMEN eye drops|1 drop in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
45757895|NCT03235232|Drug|Combigan®|1 drop of Combigan® in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
45757896|NCT03344471|Other|Passation of questionnaires|Specific questionnaires (Perinatal PTSD Questionnaire evaluating the Post-Traumatic Stress Disorder) and (NEO-FFI evaluating personality)
45757897|NCT01781637|Drug|Omalizumab|subcutaneous injection
45757898|NCT01781637|Drug|placebo|subcutaneous injection
45757899|NCT04783142|Other|High-fiber, low-protein diet|Diet will consist of at least 15g fiber above baseline and less than 10% of calories from protein.
45757900|NCT04783142|Other|Low-fiber, high-protein diet|Diet will consist of less than 15g fiber and greater than 18% of calories from protein
46068221|NCT00990821|Drug|2 mg Midazolam|Midazolam oral tablet, single dose
46068222|NCT00801853|Drug|Aerovant|Aerovant 1mg bid (dry powder)
46068223|NCT00801853|Drug|Aerovant|Aerovant 3mg bid (dry powder)
46068224|NCT00801853|Drug|Aerovant|Aerovant 10mg bid (dry powder)
46068225|NCT00801853|Other|placebo|placebo control (dry powder)
46068226|NCT00990665|Device|CRT-D and LV lead (Quartet™ lead and Promote Q® device system)|Promote Q CRT-D and Quartet LV lead
46068227|NCT00658567|Drug|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, for six weeks
46068228|NCT00658567|Drug|Pimavanserin tartrate (ACP-103)|20 mg, tablet, once daily by mouth, for six weeks
46068229|NCT00658567|Drug|Pimavanserin tartrate (ACP-103)|Placebo, tablet, once daily by mouth, for six weeks
46068230|NCT00875433|Drug|BIBW 2992|patients to receive continuous oral daily dosing of BIBW 2992
46068231|NCT04292093|Behavioral|Home rehabilitation training|The rehabilitation training will be provided via Lumosity platform. Participants will be asked to play computer video-games aimed at strengthening specific sub-functions pertaining to the macro area of executive functions for 30 minutes a day, 5 days a week, for a total of 8 weeks. Specifically, 20 games out of a total of 64 available games provided by the platform have been selected. The selected games are aimed at training 4 cognitive skills: memory, attention, cognitive flexibility and problem solving. In particular, 5 different games were chosen for each cognitive ability.
46073623|NCT02822586|Radiation|TSEB Therapy|TSEB is a type of radiation treatment in which the skin over the whole body is treated with electron radiation beams. All participants will receive the same standard TSEB dose and treatment schedule. During TSEB, patients are treated in a standing position on a rotating platform.
46068232|NCT04292093|Behavioral|Home control activity|The control group will watch a series of animated / TV shows suitable for the sample age, again for 30 minutes a day, 5 days a week, for 8 weeks. The videos will be provided by the experimenter and participants will watch them on their personal computer. At the end of each videos, participants will answer a series of multiple-choice questions aimed at evaluating the attention deployed to the content of the videos.
46068233|NCT04291235|Procedure|Airway Management Pathway|Patients in this group will receive several components that comprise airway management pathway: (1) daily spontaneous breathing trials (SBTs); (2) prompt extubation following successful extubation readiness criteria; (3) high-flow nasal oxygen for at least 24 hours following extubation.
46068234|NCT04291235|Procedure|Usual Care|Patients in this group will be treated according to usual care, which may include extubation or tracheostomy timed according to treating physicians' discretion.
46068235|NCT00684957|Drug|Recombinant Human Growth Hormone|300 mcg sc qd (which may be increased to 400 mcg sc qd after 4 weeks)
46068236|NCT00684957|Drug|Recombinant human IGF-1|30 µg/kg for first 4 weeks (may be increased thereafter based on IGF-1 levels)
46068237|NCT02868515|Other|Hot cereal contain 3 g dietary fiber|Intervention involves consumption of a hot cereal over 14 day period
46068238|NCT04898491|Other|Pain assessment using a behavioral scale|"The pain of the subjects will be evaluated by two independent observers and with a blind result between them, coinciding with the application of two painful procedures used in routine practice: suction of tracheal secretions and the pressure in the nail bed by means of a pressure algometer. In addition, a painless procedure will also be performed to establish an element of control with the procedures painful. This will consist of the application of gentle friction with a cloth gauze, on a part of healthy skin tissue of the patient. The measurement will be performed twice for each patient and procedure depending on the level of sedation, so that the first measurement will be performed with a deeper sedation level and the second with a change in sedation level to moderate-mild.~In turn, the pain assessment will be carried out in three moments: first or baseline measurement, during the application of the painless and 15 minutes after finishing the procedures."
46068239|NCT00685191|Drug|Salvage antiretroviral therapy including raltegravir|Initiation of raltegravir-including salvage antiretroviral therapy
46068240|NCT02626143|Other|Investigational nutrient-rich whey protein formula|
46068241|NCT02626143|Other|Cow's milk based formula|
45608931|NCT01857115|Drug|Dexamethasone|
45608932|NCT03467659|Other|Cracked whole wheat porridge|Large particle whole wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
45608933|NCT03467659|Other|Semolina wheat porridge|Large particle refined wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
45608934|NCT03467659|Other|Whole wheat flour porridge|Small particle whole wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
45608935|NCT03467659|Other|Refined wheat flour porridge|Small particle refined wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
45608936|NCT03467659|Other|Refined wheat flour porridge,fine bran|Small particle refined wheat porridge with small particle bran was tested for gastric emptying rate, glycemic response and appetitive response.
45608937|NCT03467659|Other|Refined wheat flour porridge,coarse bran|Small particle refined wheat porridge with large particle bran was tested for gastric emptying rate, glycemic response and appetitive response.
45608938|NCT04754893|Device|Healthdot application|Healthdot device is applied on subject's chest after surgery
45608939|NCT03462901|Procedure|Percutaneous intramedullary fixation of displaced midshaft clavicular fractures .|A group of 15 patients admitted to Assiut university with midshaft clavicular fractures treated by operative fixation of the fracture by single elastic rod through medial approach under image intensifier
45608940|NCT03462823|Device|Osteoconductive scaffold-hamstring tendon composite repair|The device under study is a composite bone substitute composed of a natural mineral matrix of bovine origin, reinforced with biodegradable synthetic polymers and natural collagen derivatives of bovine origin (smartbone, IBI S.A., Switzerland).
45608941|NCT03462823|Device|Hamstring tendon-only repair|ACL-reconstruction using hamstring autograft with hybrid fixation in accordance with in-house standard of care.
45608942|NCT03453541|Drug|Ketorolac Tromethamine|Ketorolac Tromethamine 0.5 mg/kg IV up to a maximum dose of 30mg, in the form of Ketorolac Tromethamine solution for IV/IM use 30mg/ml single dose vial at the completion of the tonsillectomy in the operating room.
45757901|NCT03330665|Behavioral|Meditation|Meditate 3 times a week using headspace app
45608943|NCT03453541|Drug|0.9% Normal Saline|0.9 % Normal saline 1ml/60kg up to a maximum dose of 1ml IV bolus (an equivalent volume as per kg Ketorolac Trimethamine dose) at the completion of the tonsillectomy in the operating room.
45608944|NCT03453463|Other|exercise|3x week predominately resistance exercise for 18 months
45608945|NCT05072041|Device|Nexsphere™|Nexsphere™ is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.
45757902|NCT04349397|Behavioral|Medication Tracking Form|Parents will complete medication tracking form for 5 days after child's surgery. They will track medications administered, pain scores, nausea and vomiting
45757903|NCT04350099|Other|quetionnary|Participants will complete self-questionnaires at different times during the epidemic
45757904|NCT00652145|Drug|mesalamine|Increase dose by 2.4gm per day over baseline dose
45757905|NCT01618851|Radiation|Radiotherapy with IMRT and CyberKnife Boost|"Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the PTV and critical normal structures. The homogeneous CT model shall be used.~The prescribed PTV dose of 19.5 Gy shall be given in 3 fractions using the CyberKnife. At least three fiducials should be identified for each treatment. If fewer than three fiducials can be tracked, then additional fiducials will be placed, and the patient replanned. Fiducial locations in the images will be extracted and compared to the fiducial locations in the CT scans to estimate target movements.~For IMRT, Daily doses of 180 cGy are to be delivered to the PTV 5 days a week to a total dose of 4500 cGy in 25 fractions."
46068242|NCT00685269|Drug|Eszopiclone|Eszopiclone 3 mg QD
46068243|NCT00685269|Drug|Placebo|Placebo tablet
46068244|NCT00794209|Drug|i.v fentanyl, AeroLEF|"i.v fentanyl~5 mL of AeroLEF in Opti-Mist 750E continuous flow nebulizers (Maersk Medical Inc., (USA), McAllen, Texas)~5 mL, of AeroLEF in Misty-Neb continuous flow nebulizers (Allegiance Healthcare Corp., McGaw Park, Illinois)~5 mL of AeroLEF in PARI LC-Plus continuous flow nebulizers (PARI Respiratory Equipment Inc., London, Ontario)~3 mL, of AeroLEF in AeroEclipse breath-actuated nebulizers (Trudell Medical International, London, Ontario) - reference device."
46068245|NCT00985985|Drug|Nicotine|2 mg or 4 mg nicotine lozenge
46068246|NCT00985985|Drug|Placebo|placebo lozenge
46068247|NCT00685347|Drug|Levalbuterol HFA MDI|"levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~Arm #A~Xopenex HFA MDI"
46068248|NCT00685347|Drug|Racemic Albuterol|"racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~Arm #B~Proventil HFA MDI"
46068249|NCT00796939|Device|Green light mask|Participants will receive approximately 10,000 lux from green light-emitting diodes.
45608946|NCT03462667|Behavioral|Stoma Boot Camp|Educational session designed to prepare people for living life with a stoma.
45608947|NCT03462667|Other|Standard of Care|Patients receive normal pre-surgery standard of care.
45608948|NCT03462589|Drug|SY-008|The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
45608949|NCT04944277|Other|ThoughtFullChat Application|A subscription-based mobile platform that empowers users to proactively engage with their mental health via self-serve tools and 1-on-1 daily bite-sized coaching with certified mental health professionals.
45608950|NCT00893789|Drug|Armodafinil|Armodafinil 50 mg/day
45608951|NCT00893789|Drug|Armodafinil|Armodafinil 150 mg/day
46068250|NCT00796939|Device|Red Light Mask|Participants will receive approximately 0.5 lux from white light-emitting diodes covered by a red gel.
46068251|NCT00685425|Drug|Levalbuterol HFA MDI|"levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~Arm #A~Xopenex HFA MDI"
46068252|NCT00685425|Drug|Racemic Albuterol|"racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~Arm #B~Proventil HFA MDI"
46068253|NCT04290455|Device|Microblepharoexfoliative procedure with BlephEx™|The device will be used to clean both upper and lower eyelid in the office visit.
46068254|NCT04290455|Procedure|Eyelid cleansing with eyelid wipes (Optase)|Eyelid cleansing will be done with eyelid wipes (Optase) by one clinician
46068255|NCT04290455|Procedure|Daily eyelid cleansing with eyelid wipes (Optase)|Patients in both arms will be instructed to do self-eyelid cleansing with eyelid wipes (Optase) daily at home for 21 days
46068256|NCT00794287|Other|Taking blood samples|No intervention is done. Only blood samples are taken.
46068257|NCT00685503|Drug|Ranibizumab|
46068258|NCT00802009|Drug|Dexamethasone|Dexamethasone 8 milligrams (liquid) will be added to standard anesthetic solution administered during routine brachial plexus nerve blockade.
46068259|NCT00802009|Drug|Mepivicaine|Standard anesthetic solution administered during routine brachial plexus nerve blockade.
46068260|NCT02868437|Device|intrauterine self-cross-linked hyaluronic acid gel|intrauterine self-cross-linked hyaluronic acid gel will apply after curettage for retained product after second trimester abortion
46068261|NCT00685581|Dietary Supplement|Ruminant trans fatty acid enriched diet - lowest ratio|the lowest R-TFA/SFA ratio obtained from dairy cows in Winter period
46068262|NCT00685581|Dietary Supplement|Ruminant trans fatty acid enriched diet - medium ratio|the medium R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 4.1% flax seed
46068263|NCT00685581|Dietary Supplement|Ruminant trans fatty acid enriched diet - highest ratio|the highest R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 9% flax seed
46068264|NCT00802087|Drug|hydrocodone|Extended Release tablet
46068265|NCT00802087|Drug|hydrocodone & acetaminophen combination|Immediate Release tablet, hydrocodone and acetaminophen combination product
46068266|NCT04291157|Other|CVD risk estimation incorporating the PRS and guideline based preventive interventions.|Total CVD risk estimation using SCORE plus PRS and European Society of Cardiology (ESC) CVD prevention guideline based interventions.
46068267|NCT04291157|Other|Standard GP care|Usual GP care (opportunistic CVD prevention)
46068268|NCT04139811|Other|Pars Plana Vitrectomy|vitrectomy with and without ILM peeling
45608952|NCT00893789|Drug|Armodafinil|Armodafinil 250 mg/day
45608953|NCT00893789|Other|Placebo|Placebo
45608954|NCT04864483|Other|Meal timing in relation to time of starting the fast|as described
45608955|NCT03449329|Procedure|SIP|The intervention group will receive a SIP block
45608956|NCT03451357|Diagnostic Test|Dependence degree already certificated by Dependence Law.|The European Council defines dependence as the state in which people, due to causes linked to the lack or loss of physical, psychological, or intellectual autonomy, are in need of assistance and/or significant help to carry out common activities of daily life. In primary care, the nurses in charge are trained of data collection. This situation needs of formal care provided by health or/and social workers, private or public.
45608957|NCT04858867|Radiation|rhTSH-stimulated I-124 dosimetry|"Preparation:~Low iodine diet 7 days prior to I-124 ingestion until 24 hours post-ingestion~Thyrogen injections 24 and 48h prior to I-124 ingestion~Procedures following Jentzen et al:~Ingestion of capsule with 37±10% MBq I-124~I-124 PET/CT at 24 and 96h post-ingestion~Blood draws at 2, 24 and 96h post-ingestion~Whole body counting at 2, 24 and 96h post-ingestion"
45608958|NCT04858867|Radiation|Intra-therapeutic I-131 dosimetry|"Procedures following EANM guidelines:~I-131 SPECT/CT at 2, 6, 24, 96 and 144h post-ingestion~Blood draws at 2, 6, 24, 96 and 144h post-ingestion~Whole body counting at 2, 6, 24, 96 and 144h post-ingestion"
45757906|NCT03233126|Drug|KRN23|Subjects will receive subcutaneous injections of KRN23 every 2 weeks from Week 0 through Week 86
45757907|NCT03241589|Other|Direct to patient facing mobile apps introduction|VA employees and Veterans begin use of OCC's direct to patient facing mobile app.
45757908|NCT03231722|Drug|Panitumumab|6 mg/kg iv over 60 minutes, day 1
46068269|NCT00923936|Drug|Liposomal Doxorubicin|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m^2 and bevacizumab every 3 weeks for six cycles.
45757909|NCT03231722|Drug|Irinotecan|150 mg/sqm iv over 60 minutes day 1
45757910|NCT03231722|Drug|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
45757911|NCT03231722|Drug|l-leucovorin|200 mg/sqm iv over 2 hours
45757912|NCT03231722|Drug|5-fluorouracil|400 mg/sqm iv bolus, day 1 followed by 2400 mg/sqm 48 h-continuous infusion, starting on day 1;
45757913|NCT02298933|Drug|Eculizumab|300 mg single-use vials
45757914|NCT03163199|Device|Translesional Hemodynamic Measurement|Measurement of hemodynamics using the NAVVUS catheter during endovascular therapy
45757915|NCT04349085|Device|Effective PBMT/sMF|A cluster with 20 diodes, manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used: 4 diodes of 905 nm (1.25 average power, 50 W of peak power for each diode), 8 diodes of 850 nm (40 mW of average power for each diode) and 4 diodes of 633 nm (25 mW average power for each diode). Effective PBMT/sMF will be applied in direct contact with the skin and light pressure in: 4 sites in the knee extensor/hip flexor muscles, 3 sites in the knee flexor/hip extensor muscles and 1 site in the plantar flexor muscles. The effective PBMT/sMF will be applied to both lower limbs. The dose used for applications will be approximately 270 J for knee extensors/hip flexors, 180 J for knee flexors/hip extensors, and 60 J for plantar flexors.
45757916|NCT04349085|Device|Placebo PBMT/sMF|A cluster manufactured by Multi Radiance Medical® (Solon, OH, USA) with 20 diodes will be used: Placebo PBMT/sMF will be applied in direct contact with the skin and light pressure in: 4 sites in the knee extensor/hip flexor muscles, 3 sites in the knee flexor/hip extensor muscles and 1 site in the plantar flexor muscles. The placebo PBMT/sMF will be applied to both lower limbs. The dose used for applications will be approximately 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
45757917|NCT04597112|Other|Myofascial Release Technique|Myofascial release focuses on reducing pain by easing the tension and tightness in the trigger points. Therapist will gently massage the myofascia and feel for stiff or tightened areas. Normal myofascia should feel pliable and elastic. The therapist will begin massaging and stretching the areas that feel rigid with light manual pressure. The therapist then aids the tissue and supportive sheath in releasing pressure and tightness. The process is repeated multiple times on the same trigger point and on other trigger points until the therapist feels the tension is fully released.
45757918|NCT04597112|Other|Exercise|"Exercise is recommended by physical therapists for most cervical radiculopathy patients.~In this study, a customized exercise program will be applied for patients with cervical radiculopathy."
45757919|NCT04746326|Procedure|Failure conservative treatment|Surgery was performed in patients who failed conservative treatment.
45757920|NCT04746326|Procedure|Surgery|Surgery was performed in patients who had generalized peritonitis and perforation.
46068270|NCT00923936|Drug|Bevacizumab|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m^2 and bevacizumab every 3 weeks for six cycles. Maintenance phase dose: IV bevacizumab every 3 weeks for 11 cycles.
46068271|NCT04121351|Other|Singing participation|Participants will follow a 15 minute protocol consisting of the components of a Singing for Lung Health class, and a short period walking on a treadmill.
46068272|NCT00797017|Drug|fentanyl|Infection, starting with 12mcg/h (flexible dose)
46068273|NCT00797017|Drug|fentanyl|(CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
46068274|NCT00797017|Drug|fentanyl|Bone Fracture, starting with 12mcg/h (flexible dose)
46068275|NCT00797017|Drug|fentanyl|(FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
46068276|NCT00797017|Drug|fentanyl|Other Deformity, starting with 12mcg/h (flexible dose)
46068277|NCT00797017|Drug|fentanyl|(LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
45757921|NCT04746326|Other|Conservative treatment|Conservative treatment was performed in patients who had no generalized peritonitis and perforation.
45757922|NCT02959775|Biological|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
45757923|NCT02959775|Biological|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
45757924|NCT04399304|Procedure|simultaneous bilateral high tibial osteotomy|One-stage simultaneous bilateral high tibial osteotomy
45757925|NCT04399304|Procedure|Staged bilateral high tibial osteotomy|Two-stage bilateral high tibial osteotomy
45757926|NCT04761848|Drug|Cilostazol 50 MG|Cilostazol 50 MG tablet twice daily
45757927|NCT04761848|Drug|Placebo|Placebo tablet twice daily
45757928|NCT01459497|Radiation|Radiation Therapy|Image-Guided Radiation Therapy (IGRT)60 Gy in 15 fractions in 3 weeks
45757929|NCT01459497|Radiation|Conventional radiation|Conventional radiation 60-66 Gy in 30-33 fractions in 6-7 weeks
45757930|NCT03277196|Drug|Ivacaftor|Ivacaftor will be administered every 12 hours (q12h) from Day 1 through the morning dose of the Week 96 Visit.
45757931|NCT04278248|Biological|23-Valent Pneumococcal Polysaccharide Vaccine|1 dose according to age of subjects. Single intramuscular dose contains 0.5ml 23-Valent Pneumococcal Polysaccharide Vaccine.
46068278|NCT00797017|Drug|fentanyl|Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
46068279|NCT02626221|Other|Non Interventional Study|Non Interventional Study
46068280|NCT02868359|Other|No Intervention|The study is observational.
46068281|NCT05330000|Drug|4 mg/kg Voriconazole|Low dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 4 mg / kg for 80 min.
46068282|NCT05330000|Drug|6 mg/kg Voriconazole|High dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 6 mg / kg for 120 min.
45608959|NCT03451201|Behavioral|High Intensity Interval Training|High Intensity Interval Exercise Training in cycle ergometer, exercising at 80% of maximal capacity during one minute alternated with exercise at 50% of maximal capacity during 4 minutes intervals, for a total of 30 minutes. Three times a week for 8 weeks
45757932|NCT02334267|Device|Group 1: GranuFlo|Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using NaturaLyte, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
45757933|NCT02334267|Device|Group 2: NaturaLyte|Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using GranuFlo, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
45608960|NCT03451201|Behavioral|Moderate Continuous Exercise Training|Moderate Continuous Exercise Training 3 times a week for 8 weeks at 50% of maximal capacity
46068283|NCT00794443|Drug|YM529 / ONO-5920|Oral
46068284|NCT04139889|Diagnostic Test|Confocal Laser Endomicroscopy|"Confocal laser microendoscopy (CLE) as a new non-invasive imaging technique can be used for optical biopsy, which can perform real-time microscopic information of tissue in vivo at cellular level with resolutions up to 1μm and magnifications up to 1000 times. CLE is now being increasingly used with very promising results in gastroenterology, especially in the diagnostic investigation of Barret's esophagus, stomach cancer, colorectal cancer and various lesions of the biliary tract. With an intravenous injection of fluorescein, probe-based CLE (pCLE: GastroFlex probe with the Cellvizio laser system, Mauna Technologies, Paris, France) allows us to view the interstitial spaces, cells, and small capillaries in a window of 240 μm and to a depth of 60 μm."
46068285|NCT00924950|Drug|Taclonex Ointment and Hydrogel Patch|Each patient will have bilateral symmetrical psoriatic plaques. One plaque will be treated with Taclonex Ointment daily along with Hydrogel Patch daily. All treatment will be for 4 weeks.
46068286|NCT00924950|Drug|Taclonex Ointment|Taclonex ointment daily for one psoriatic plaque.
46068287|NCT00685737|Drug|1-MNA|Capsule
45608961|NCT03451201|Other|Non-exercise|Conventional care for sedentary Type 1 Diabetes Controls. No intervention.
45608962|NCT05697263|Other|Periodization of training|Participants in the three arms will exercise the same dose and number of sessions distributed in three different ways.
46068288|NCT00685737|Drug|Placebo|Capsule
45608963|NCT03449251|Drug|Apelin|Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.
45757934|NCT04056962|Drug|Tacrolimus ointment|topical application of tacrolimus for treatment of superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
45757935|NCT00693485|Drug|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
45608964|NCT03449251|Drug|Relaxin|Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.
45757936|NCT00693485|Drug|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
45757937|NCT00693485|Drug|Sham (no implant)|Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
45608965|NCT03449251|Drug|Normal saline|Vehicle
45757938|NCT03942081|Device|Ulcer Measurement Software|Photos being taken of foot ulcers. Software estimation of foot ulcer being compared to actual measured size.
46068289|NCT04291547|Device|BALM|An online Behavioural Activation programme for young people with mild to moderate low mood/depression. The programme comprises 10 treatment sessions lasting 30 to 45 minutes
46068290|NCT00797251|Procedure|Anatomical right posterior sectionectomy of the liver by IOUS-guided finger compression.|The technique consists in IOUS-guided finger compression of the right posterior portal pedicle at the level closest to the tumor but oncologically suitable. This method allows us to anatomically mark the area of resection with nor hilar plate nor IOUS-guided puncture of vessels, which are up to date the only two techniques available to perform anatomical right posterior sectionectomy - namely the removal of segment 6 and 7.
46068291|NCT02868203|Device|OCT|OCT after stent implantation
45757939|NCT00693719|Drug|Etoposide|50 mg PO x14 days followed by 2 weeks off, 28 day/Cycle
46068292|NCT02868203|Device|eLuting stent|
45757940|NCT00693719|Drug|Irinotecan hydrochloride|Irinotecan 100 mg/m2 IV days 1 and 15, 28 day/Cycle
45757941|NCT00653861|Device|JUVÉDERM™ Injectable Gel with Lidocaine|Single treatment, volume determined by investigator
45757942|NCT00653861|Device|JUVÉDERM™ Injectable Gel|Single treatment, volume determined by investigator
45757943|NCT00654329|Drug|Saline|Normal saline, given intranasally
45757944|NCT00654329|Drug|Fentanyl|Fentanyl, nasal transmucosal, 2 micrograms/kilogram
45757945|NCT00654329|Drug|Dexmedetomidine|Dexmedetomidine, transmucosal, 1 microgram/kilogram
45757946|NCT00654329|Drug|Dexmedetomidine|Dexmedetomidine, 2 microgram/kilogram, transmucosal route
45608966|NCT03449251|Diagnostic Test|Verapamil|NO independent challenge agent
45608967|NCT03449251|Diagnostic Test|LN Monomethyl arginine|Basal NO synthase inhibitor
45608968|NCT05696483|Drug|OLX-07010 Active|25 and 75 mg capsules
45608969|NCT05696483|Drug|OLX-07010 Placebo|25 and 75 mg capsules
45608970|NCT03450811|Procedure|Inguinal hernia repair|Lichtenstein procedure or laparoscopic method (Total extraperitoneal) inguinal hernia repair
45608971|NCT05695859|Drug|99mTc-DARPinG3 SPECT/CT|One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection
45608972|NCT02522819|Device|CPAP|Use of CPAP over 5 nights for the treatment of obstructive sleep apnea in the acute phase of stroke.
45608973|NCT03450655|Other|10-week aerobic exercise program|An aerobic exercise program consisting of 45-60 minute sessions 3 times a week for 10 weeks.
45757947|NCT00695435|Drug|TOBRADEX Ophthalmic Suspension|TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline
46068293|NCT00685815|Drug|Ferric Carboxymaltose (FCM)|500mg FCM in 250cc NS IV over one hour, once on Day 3, once on Day 4
46068294|NCT00685815|Drug|Placebo|250cc NS IV over one hour, once on Day 3, once on Day 4
46068295|NCT00802165|Device|Electroacupuncture|Group is given a total of four electroacupuncture treatments to evaluate it's anesthetic effectiveness
46068296|NCT00802165|Device|Sham electroacupuncture|Sham electroacupuncture treatment gives comparison to the experimental group
45757948|NCT00695435|Drug|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline
45757949|NCT00695435|Drug|TOBREX Ophthalmic Solution|TOBREX Ophthalmic Solution 1 drop each eye at baseline
46068297|NCT04881188|Diagnostic Test|Survey|Patients with chronic low back pain in in-patient multimodal pain therapy. Three survey times, questionnaires
45608974|NCT05164601|Diagnostic Test|Echocardiography test|Contrast echocardiography and coronary angiography
45608975|NCT05322499|Drug|Camrelizumab|200mg/dose intravenous infusion, D1, once every 3 weeks (q3w);
45608976|NCT05322499|Drug|Irinotecan|100-125mg/m2，d1，d8；q21d
46068298|NCT02553889|Drug|ISIS 416858|subcutaneous injection
46068299|NCT02553889|Drug|Placebo|subcutaneous injection
45608977|NCT05322499|Drug|Paclitaxel|135-175mg/m2，d1，Q3W
45757950|NCT00654953|Drug|sertraline|Sertraline hydrochloride (200 mg/day) will be administered once daily. While subjects are at RCA-NLR they initially receive 50 mg/day of sertraline. This dose is gradually increased over a 3-week period until subjects receive 200 mg. When subjects are transferred to the outpatient program, they will be administered capsules once weekly, with take-home doses given in blister packs to take once a day for the rest of the week.
45757951|NCT00654953|Drug|Placebo|Placebo (cellulose or lactose) administered twice per day for 12 weeks.
45757952|NCT00654953|Drug|gabapentin|Gabapentin (Neurontin; Parke-Davis; 1200 mg/day) will be administered twice daily. Initially, patients will receive 200 mg twice daily on days 1-5, 400 mg twice daily on days 6-10, then 600 mg twice daily on days 11 on. Subjects are then maintained on this dose for the duration of the trial, unless side-effects are too severe, in which case the dose of gabapentin is decreased to no less 800 mg/day. If symptoms persist, subjects' participation would then be terminated.
45757953|NCT01790165|Drug|TDT067 and Lamisil|Topical administration of TDT067 and single oral administration of 250 mg Lamisil tablet
46068300|NCT00685893|Behavioral|Education|We include information about end-of-life decision-making, communication skills, pain and symptom management, and withdrawal of life support. The primary methods of delivery will be a grand rounds lecture by one of the physician investigators and the viewing of an educational video for nurses and respiratory therapists. The content of the educational components will be structured to cover four topics: the principles of decision-making about end-of-life care in the ICU; communication with patients, families and the ICU team; pain and symptom management; and, the principles and practice of withdrawal of life support.
46068301|NCT00685893|Behavioral|Local Champions|We identify physicians, nurses and other clinicians from each hospital to serve as the local champions. The role of the local champions is to help implement the intervention and be a role model for end-of-life care in the ICU. Local champions participate in interactive education and training sessions with the investigators and the other local champions from their institution to discuss barriers to good end-of-life care at their location and to strategize about how to overcome those barriers.
46068302|NCT00685893|Behavioral|Institution Feedback|We provide feedback to the institution from the hospital specific family satisfaction data we collect. All feedback is presented as aggregated data for the institution without any personal identifiers.
46068303|NCT00685893|Behavioral|Academic Detailing|Study staff meet with ICU directors with 4 goals. The first goal is to familiarize the director with the educational content of the intervention. Secondly, the results of the family satisfaction data collected are shared without identifying information. The aggregated results of the other participating hospitals are disclosed, also without identifiers. Third, we elicit and discuss the institution-specific barriers to providing high quality end-of-life care in the ICU. Lastly, we hope that by educating the directors we can engage these clinical leaders to serve as role models in their institutions.
45608978|NCT05322499|Drug|Paclitaxel-albumin|100-135mg/m2, d1、d8，Q3W
45608979|NCT05322499|Drug|Docetaxel|60-75mg/m2，d1，Q3W
45608980|NCT05322499|Drug|Anlotinib|12mg，qd，d1-d14，q3w
45608981|NCT05164523|Diagnostic Test|24-hour rhythm Holter|Before starting their newly prescribed medication, the investigators will apply 24-hour rhythm Holter and repeat it at the end of the trial.
45608982|NCT05164523|Diagnostic Test|36 item Short Form Survey (SF-36)|Before starting their newly prescribed medication, the investigators will apply SF-36 survey and repeat it at the end of the trial.
45608983|NCT05661617|Diagnostic Test|Nine Hole Peg Test, Purdue Pegboard Test, Box and Block Test|"Research participants were tested in one meeting after giving informed consent, answering a few short questions regarding health status and filling out a short questionnaire using the Czech extended version of the manual for the Nine Hole Peg Test, Purdue Pegboard Test and Box and Block Test, and always according to a predetermined order. Intentionally, all research participants from experimental group with a dominant right upper limb will be tested as if they were left-handed, and vice versa.~All research participants from normative study were tested normally according to the Czech extended manuals for those tests."
45608984|NCT03449173|Drug|Sunitinib|small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor
45608985|NCT03823001|Diagnostic Test|virtual biopsy (VB) monitoring protocol|"PSA bi-annually or more often according to the discretion of the urologist.~Annual DRE.~Visit with the urologist bi-annually.~Multi-parametric MRI (mpMRI) every year for 3 years.~Transrectal ultrasound (TRUS) biopsy at the end of the 3rd year."
45608986|NCT04760041|Drug|Midazolam nebulized|midazolam nebulized
45757954|NCT02299089|Drug|octreotide FluidCrystal® injection depot|
46068304|NCT00685893|Behavioral|Institutional Forms|We have developed a set of orders that encompass the various aspects of withdrawing life support from patients. Individual department directors at each hospital will decide if they want to implement a similar order form at their institution and whether they want to modify the form to fit their specific institutional needs. In addition to the order forms, we encourage hospitals to develop a family pamphlets and resources that can be given to families to provide education about the intensive care unit experience.
45608987|NCT04760041|Drug|Midazolam oral solution|midazolam given oral
46068305|NCT04880174|Diagnostic Test|serological testing|Antibody testing for Sars-COV-2 antibodies in blood.
46068306|NCT04256564|Procedure|Central venous catheterization|A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance
46068307|NCT02626065|Biological|blood sampling|Blood samples (44mL) will be taken before starting treatment with Nivolumab and at week 2, week 12, week 54 or at relapse (before week 54)
46068308|NCT02626065|Drug|Nivolumab|injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.
46068309|NCT00794755|Dietary Supplement|Vitamin K1 (Phytonadione)|Vitamin K1 tablets (100 micrograms per tablet) will be taken by patients randomized to the Vitamin K arm. Dosage is two tablets per day (200 micrograms per day) to be taken with warfarin for the 6 month study period.
46068310|NCT00794755|Dietary Supplement|Placebo|Lactose-based placebo tablets (identical in appearance to the Vitamin K1 tablets) will be taken by patients randomized to the placebo arm. Dosage is two tablets per day to be taken with warfarin for the 6 month study period.
46073624|NCT02822586|Drug|Brentuximab vedotin|An antibody-drug conjugate (ADC) that targets CD30. A standard dose of brentuximab vedotin will be administered to all patients by intravenous infusion 3 weeks prior to initiation of TSEB and then every 3 weeks for 3 cycles.
46073625|NCT04239768|Device|MonoDermà HA gel combined to a low level laser|"Two intradermal injections of the filler were performed during the basal and after 1 month, on the middle and inferior third of the face (1ml for each face side) using a needle (30G).~Immediately after both injection procedures, LLLT session were performed on the same face area for a total of 8 minutes, using three different wavelengths (450 nm, 650 nm and 1064 nm) simultaneously."
45608988|NCT05164445|Diagnostic Test|Transbronchial forceps biopsy|All patients with peripheral lung lesion suspected of lung cancer detected on the chest computed tomography (CT) and mini probe endobronchial ultrasound (RP-EBUS) scans were enrolled. Transbronchial forceps biopsy (TBFB) was performed for all these patients.
45608989|NCT05164445|Diagnostic Test|Transbronchial forceps biopsy+Transbronchial cryobiopsy|All patients with peripheral lung lesion suspected of lung cancer detected on the chest computed tomography (CT) and RP-EBUS scans were enrolled. TBFB was performed for all these patients. In addition, all of these patients, with no contraindications, underwent transbronchial cryobiopsy (TBCB)
45608990|NCT03449017|Behavioral|E-cig use|Self-administration of e-cig (10 puffs in 5 minutes) prior to lab task, self-administration of e-cig (10 puffs in 5 minutes) prior to ad lib alcohol, and ad lib e-cig use throughout ad lib alcohol paradigm.
45608991|NCT05391347|Other|Orange oil aromatherapy|5 minutes before the invasive procedure, 3 ml of orange oil were dripping onto the sponge, and the patient was told to breathe slowly at a distance of 3 cm and to smell during the process.
45608992|NCT05322421|Other|Topical Olive Oil|Olive oil will be placed in 200 ml opaque glass containers. For each application, a new stick with a sponge will be submerged into one of the agents to absorb then coat the tongue, buccal mucosa, lips, and hard palate. Patients will be instructed to refrain form eating for 1 hour after the application
45608993|NCT05322421|Other|Sodium bicarbonate 5% solution|Sodium bicarbonate 5% solution will be placed in 200 ml opaque glass containers. For each application, a new stick with a sponge will be submerged into one of the agents to absorb then coat the tongue, buccal mucosa, lips, and hard palate. Patients will be instructed to refrain form eating for 1 hour after the application
45653325|NCT05046561|Drug|STRI Formula|STRI Formula is a combination of food based substances (botanicals, vitamins, minerals, and protein) with multiple, distinct, synergistic, direct and indirect antiviral effects against SARS-CoV-2
45757955|NCT01129791|Behavioral|Raw Milk|Organic whole raw cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. for 8 days. After a 1-week wash-out period, pasteurized cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
45757956|NCT01129791|Behavioral|Pasteurized Milk|Organic whole pasteurized cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
45757957|NCT01129791|Behavioral|Non-dairy milk|Unflavored soy milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or pasteurized cow's milk were consumed in the same fashion for another 8 days each.
45444956|NCT03791385|Behavioral|Picture Exchange Communication System (PECS)|A communication system frequently used with non-verbal children with autism spectrum disorders (ASD) that uses a series of pictures that describe how a certain activity is done, in our case showing a structured method and technique for teeth brushing.
45653326|NCT05046561|Drug|Placebo|Placebo oral capsule
45653327|NCT05419219|Device|the multi-domain Tai Chi Digital therapy Software Application|regular Tai Chi exercise, 40 Hz gamma sound stimulation and 18 BPM breath control exercise
45757958|NCT00655811|Drug|Capsaicin|Topical application, 0.1%, Capzasin HP; Chattem Inc., Chattanooga, TN, U.S.A
45757959|NCT00655811|Drug|Placebo moisturizing cream|Placebo moisturizing cream with no active ingredient (Cetaphil; Galderma Laboratories LP, Fort Worth, TX, U.S.A.)
45653328|NCT05728333|Drug|Tirofiban|Intravenous tirofiban before endovascular thrombectomy.
45608994|NCT05163977|Procedure|Blumgart Anastomosis|The anti-mesenteric border of the jejunal loop proximal to the hepatico-jejunostomy is brought against the pancreatic stump. With the pancreatic stump retracted by the stay sutures, the transected end of pancreatic duct is first identified and secured by means of a blunt tipped probe. Each trans-pancreatic, suture was performed using a single Polydioxanone (PDS) 3 -0 blunt needle. We usually take 4 sutures, 2 on each side of the duct. The process is repeated in the same manner with the remaining sutures which are tightened at the end to approximate the jejunum loop to the stump. A small stab incision is then made at the anti-mesenteric border of the jejunum and a duct to mucosa anastomosis is constructed using an interrupted 5-0 Prolene. The process is completed by placing each of the retained needles through the seromuscular layer of the anterior jejunal wall and each knot is tied over the jejunal wall which is then warped over the cut end of the stump
46068311|NCT04164641|Device|Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic|Physical therapy evaluation (range of motion, strength, mobility, scale). Noraxon based gait assessment on treadmill while barefoot and with instrumented inner soles. Over ground walking assessment (with wireless instrumented inner soles, observational gait analysis while climbing stairs, ramps, curbs). Noraxon gait assessment and walking on treadmill will be video recorded for assessment. Standard measure of functionality and 6 minute walk test will be conducted. Patient will be fitted with corrective orthotics, based on usual care. Physical therapy re-evaluation. Noraxon based gait assessment and foot assessment (any areas of irritation, callus formation, swelling, ulcer formation, and gait mobility irregularities will be monitored and reassessed) throughout the study.
46068312|NCT00685971|Dietary Supplement|5000 IU of cholecalciferol|5 drops taken once daily for 12 weeks
45608995|NCT05163977|Procedure|Cattell Warren Anastomosis|It is a two layer, interrupted, end to side pancreatico-jejunostomy. First an interrupted sutures between the posterior capsule and the seromuscular layer of the jejunum was constructed using PDS 3-0 , then a duct to mucosa interrupted sutures were taken using PDS 5-0 and finally interrupted sutures between the anterior capsule and the jejunum . The main difference here is that the sutures are taken in a conventional way which is tangential to the pancreatic capsule and parenchyma
45608996|NCT04754035|Drug|Venetoclax|venetoclax 20 mg, 50 mg, 100 mg
45444957|NCT05403801|Behavioral|STAMP+CBT application|Use the STAMP+CBT mobile app for 4 weeks (intervention period, 4 weeks for content introduction, extended 2 weeks for review of content if patient's request this
45444958|NCT03791541|Behavioral|Pharmacist services|Additional pharmacist/pharmacy student follow-ups, counseling, and other services
45444959|NCT03791463|Drug|salvianolic acid A|Following an overnight fast of at least 10 hours, a single dose of 90 mg salvianolic acid A will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
45444960|NCT01306383|Other|SODIS Bottle|SODIS Bottles used by SODIS group to treat their drinking water
45444961|NCT04753515|Drug|dexmedetomidine combined with midazolam and remifentanil.|Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.5 mcg/kg dexmedetomidine over 5 min via separate syringe pumps.
45444962|NCT04753515|Drug|propofol combined with midazolam and remifentanil.|Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.33 mg/kg propoful over 5 min via separate syringe pumps.
45444963|NCT05358327|Device|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
45444964|NCT01306461|Drug|Timolol and Tafluprost|"Preservative-free Timolol eye drops administered twice daily concomitantly with preservative-free Tafluprost eye drops administered once daily~Treatment period 6 months"
45608997|NCT04754035|Drug|Imbruvica Oral Product|Imbruvica 140 mg
45608998|NCT04452643|Biological|BACMUNE (MV130)|BACMUNE (MV130) is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10^9 bacteria / mL)
45608999|NCT04452643|Other|Placebo|Placebo is a solution on sodium chloride at 0.9%
45609000|NCT04455659|Device|Trans-cutaneous Electrical Nerve Stimulation|TENS that was applied once daily, three times per week for 8 weeks. Each treatment session was conducted for 20 minutes, two electrodes were positioned over the perineal area between anus and scrotum on the Centrum tendineum, while the other two electrodes were applied under the buttocks medially at the level of the ischial spines (medial to the ischial spines bilaterally) with the patient in comfortable supine hook-lying position with abducted hips. to prevent burn beneath the electrodes, the surface area of the electrode should be equal to or greater than 4 cm2 to minimize the heat production. In addition, to decrease the current density between electrodes, the inter-electrode distance was less than the cross sectional area of the electrode
45609001|NCT04455659|Procedure|Conventional physical therapy exercise|physical therapy program for 30 minutes, and 3 times per week for 8 weeks in the form of strengthening exercise, clam - shell exercise, and stretching exercise focusing on obturator internus muscle, range of motion exercise for the hip and pelvis musculature for 30 minute three times a week for consecutive 8 weeks , each type of exercise was performed for a duration of 6 seconds and repeated 10 times
45609002|NCT05322265|Procedure|laparoscopic surgery for renal and adrenal diseases|type of treatment for patients underwent to laparoscopic surgery for renal and adrenal diseases with intraoperative complications
46068313|NCT00685971|Dietary Supplement|placebo|5 drops once daily for 12 weeks
46068314|NCT00802243|Drug|leflunomide|
46068315|NCT00988637|Drug|Vectical™ Ointment weekdays and Clobex® Spray weekends regimen|Vectical™ Ointment 3 µg/g, topical, apply twice daily on weekdays (Mon-Fri) and Clobex® Spray 0.05% twice daily on weekends (Sat-Sun) for 28 days
46068316|NCT00988637|Drug|Clobex® Spray morning and Vectical™ Ointment evening regimen|Clobex® Spray 0.05%, topical, apply once each morning and Vectical™ Ointment 3 µg/g, topical, apply once each evening for 28 days
46068317|NCT00802321|Drug|Dutasteride|Subjects will receive a single dose of 2, 3 or 4 mg of dutasteride based on random assignment.
46073626|NCT02822274|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-70_R84-064)
45609003|NCT04455581|Drug|SHR-1209|SHR-1209 administered by subcutaneous injection Atorvastatin or Rosuvastatin combined with Ezetimibe oral
45609004|NCT02164864|Drug|Dabigatran Etexilate 110mg|Active treatment
45444965|NCT01306461|Drug|Fixed Dose Combination of tafluprost and timolol|"Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops administered once daily.~For masking purposes also: vehicle for timolol administered twice daily~Treatment period 6 months"
45444966|NCT01306539|Procedure|Stimulation of the subthalamic nucleus|Stimulation is delivered to the subthalamic nucleus at experimentally prescribed settings.
45444967|NCT03791307|Other|Traditional Pilates group|The participants will perform only exercises based on the traditional Pilates method, 2 times a week, for 50 minutes, for 16 weeks.
45609005|NCT02164864|Drug|Warfarin 3mg|Active comparator
45609006|NCT02164864|Drug|Aspirin|Active comparator
45609007|NCT02164864|Drug|Dabigatran Etexilate 150mg|Active treatment
45609008|NCT02164864|Drug|Clopidogrel or Ticagrelor|Active comparator
45609009|NCT02164864|Drug|Clopidogrel or Ticagrelor|Active comparator
45609010|NCT02164864|Drug|Warfarin 5mg|Active comparator
45609011|NCT02164864|Drug|Clopidogrel or Ticagrelor|Active comparator
45609012|NCT02164864|Drug|Warfarin 1mg|Active comparator
45609013|NCT05163743|Dietary Supplement|Low Calorie Ketogenic Diet|The very low-carbohydrate diet will be hypo caloric and aim to provide less than 50 g of carbohydrates per day. the participants will be counseled to choose vegetarian and healthy sources of fat and protein and to avoid trans fat. Then, gradual reintroduction of carbohydrates will take place following the second vaccine dose.
45609014|NCT05322109|Diagnostic Test|CMR|Clinically indicated cardiac magnetic resonance tomography executed according to international guideline recommendations.
46073627|NCT00841399|Biological|E75 + GM-CSF vaccine|Dose escalation scheme involving three patients each receiving injection of 100, 500, or 1,000 mcg E75 + GM-CSF monthly for 6 months. HLA-A2 and HLA-A3 status determined. HLA-A2+ and HLA-A3+ patients receive the vaccine; HLA-A2- and HLA-A3- enrolled to the control arm.
45609015|NCT05579249|Drug|Semaglutide|Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks.
45609016|NCT05579249|Drug|Orlistat|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os [by mouth] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
45609017|NCT05579249|Drug|Phentermine/Topiramate|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os [by mouth] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
45609018|NCT05579249|Drug|Naltrexone/Bupropion|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os [by mouth] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
45609019|NCT05579249|Drug|Liraglutide|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os [by mouth] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
45609020|NCT03129685|Procedure|HALED|This is attained via a laparotomy involves isolation of the arterial blood supply of the tumor-containing liver lobe (the ipsilateral hepatic artery as well as the extrahepatic arterial collaterals) while preserving the feeding veins.
45609021|NCT05549609|Biological|XSTEM-VLU|XSTEM-VLU is an allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cell (MSC) product for the treatment of venous leg ulcers.
45609022|NCT05549609|Other|Vehicle|CryoStor CS10 cryomedium
45609023|NCT02419807|Drug|Indocyanine Green Solution|Given subdermally
45609024|NCT02419807|Radiation|Technetium Tc-99m Sulfur Colloid|Given via injection
45609025|NCT02419807|Procedure|Lymphoscintigraphy|This is a method used to check the lymph system for disease. A radioactive substance that flows through the lymph ducts and can be taken up by lymph nodes is injected into the body. A scanner or probe is used to follow the movement of this substance on a computer screen. Lymphoscintigraphy is used to find the sentinel lymph node (the first node to receive lymph from a tumor), which may be removed and checked for tumor cells. Lymphoscintigraphy is also used to diagnose certain diseases or conditions, such as lymphoma or lymphedema.
45609026|NCT02419807|Procedure|Axillary Lymph Node Biopsy|Undergo biopsy
45609027|NCT05163587|Combination Product|low GI composite flour|low GI composite flour orally in chapati form (3times/day)
45609028|NCT05163509|Combination Product|Unity-based MR-Linac guided Radiotherapy|The radiotherapy was delivered using the Unity-based MR-Linac treatment machine.
45609029|NCT02194387|Dietary Supplement|Dietary Intervention|Record dietary intake 4-7 days per week
45609030|NCT02194387|Dietary Supplement|Dietary Intervention|Record dietary intake 1 day per week
45609031|NCT02194387|Other|Internet-Based Intervention|Receive email coaching
45609032|NCT02194387|Other|Internet-Based Intervention|Participate in social networking
45609033|NCT02194387|Other|Laboratory Biomarker Analysis|Correlative studies
45609034|NCT02194387|Other|Questionnaire Administration|Ancillary studies
46073628|NCT02822118|Drug|Chang'an I Recipe|Patients in this group were administered the Chang'an I Recipe, 150ml/bag, 3 times/day for 8 weeks.
45609035|NCT02194387|Behavioral|Telephone-Based Intervention|Receive telephone coaching
45609036|NCT02194387|Behavioral|Telephone-Based Intervention|Receive text messages
45609037|NCT05386589|Drug|Molnupiravir|Four 200 mg capsules administered orally as a single dose
45609038|NCT01998529|Drug|Cisplatin|Starting dose of hyperthermic cisplatin 120 mg/m2. Perfusion continued for 60 minutes after adding the cisplatin at a target temperature of 41 C (+0.5 C).
45609039|NCT01998529|Drug|Amifostine|Amifostine administered intravenously over 15 minutes beginning 30 minutes (+ 15 minutes) after the cisplatin perfusion.
45653329|NCT05728333|Drug|Alteplase|Intravenous alteplase before endovascular thrombectomy.
45609040|NCT02522663|Other|24/7-telephone support|ICU nurses answer the calls from treated AVR patients during the first month after discharge, and use an evidence-based information manual to answer questions from the patients.
45609041|NCT03448861|Device|Polso Wearebale watch|The objective of the Polso™ feasibility study is to demonstrate the suitability of Polso™ as a data acquisition and processing platform by comparison with the conventional British version of EWS (UK-NEWS) on aggregate and on each individual parameter score. Although in a full NEWS system, the frequency of testing is determined by the score itself, this aspect will not be evaluated, in the event that a divergence of scores would complicate clinical evaluation and correspondence of readings. In addition, good clinical practice calls for patient care to be fully motivated by the NEWS currently in use, as opposed to the experimental Polso™. Therefore, this compromise will be made, which will still permits system evaluation.
45609042|NCT04455191|Procedure|Thawing Embryos in Advance|Thaw Embryos one day in Advance
45609043|NCT04455191|Procedure|Thawing Embryos on the Day of Transfer|Thaw Embryos on the morning of transfer day.
46068318|NCT00686283|Behavioral|PEP intervention|This study will explore the feasibility of adherence to a personalized exercise prescription (PEP) in adolescents with type 1 or type 2 diabetes. The PEP intervention consists of a 2-hour group education session and a 16-week personalized exercise plan implemented in the home or community setting with the use of parental support and care ambassadors. Care ambassadors will maintain consistency of interactions with specific families for the duration of the PEP intervention. This consistency will aid in establishing rapport with the adolescents and parents to answer any questions and provide guidance for adhering to the PEP plan. The PEP intervention will be mutually planned with each teen and parent based upon the assessment of the teen's personal and cultural choices, including family and community resources. Exercise frequency, duration, and intensity for the teen with diabetes will be documented with a MTI ActiGraph accelerometer (Fort Walton Beach, FL).
46068319|NCT00802399|Procedure|Partial Lacrimal Punctual Occlusion|Cauterization of the edge of all lacrimal punctum was carried out in all patients
46068320|NCT00686361|Drug|Choline supplementation|Chart data, height, weight, pulmonary function, dietary intake and a venous blood and urine sample will be collected at enrollment then every 3 months for 9 months. Choline supplementation will be from enrollment for 6 months, with follow up at 3 months post supplementation. To avoid additional hospital visits and blood draws, and to co-ordinate with pulmonary function, hematology, clinical chemistry tests as part of clinical care, each subject will be seen at routine scheduled clinic appointments, which are every 3 months.
46068321|NCT04162925|Behavioral|Cancer screening education for breast, colon and oral cancers|Bedside education one-on-one by showing screening video and handouts at the end of educational session for breast, colon and oral cancer. Patient who are agreeable to oral cancer screen during hospitalization perform oral cancer screening
46073629|NCT02822118|Drug|Placebo|Patients in this group were administered the placebo, 150ml/bag, times/day for 8 weeks.
46073630|NCT00848809|Procedure|Blood sample|9 blood samples will be sent to the laboratory for the subjects in the SLED cohort
46073631|NCT00848809|Procedure|Blood sample|10 blood samples will be collected and sent to the laboratory for the subjects in the intermittent hemodialysis cohort.
46073632|NCT04240938|Procedure|Dacryocystorhinostomy|Anastomosis between lacrimal sac and nasal cavity
45609044|NCT04707937|Other|Online education|Access to online modules about brachytherapy education in addition to receiving regular standard of care education
45609045|NCT04707937|Other|Regular standard of care education|Access only to regular standard of care education
45609046|NCT04455971|Behavioral|Orgasmic Meditation|Orgasmic Meditation (OM) is a form of meditation that increases bodily awareness during structured, partnered female genital stimulation over a 15-minute period.
45609047|NCT04688749|Diagnostic Test|Electrical Impedence Spectroscopy DermaSense|Two sets of measurements will be performed to each subject, either at a nevus in contrast with a nearby clear patch of skin. The duration of each measurement will last for approximately 1.5 minutes and the excel file will be directly available to researcher, allowing him/her for data storage and data visualization.
45609048|NCT05321797|Other|Aerobic Training|This group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 12-week period
46073633|NCT00848887|Biological|Adjuvanted and un-adjuvanted influenza vaccines|16 different formulations of trivalent influenza vaccine and 1 marketed influenza vaccine comparator.
45609049|NCT05321797|Other|Conventional Physiotherapy|This group will be administered with Conventional Physiotherapy that includes 5 minutes of stretching exercises for quadriceps, hamstrings and gastrocnemius, 5 minutes of trunk control training, 5 minutes walking in the hall with and without the therapist assistance, walker or crutches, and finally 5 minutes of breathing exercises for Relaxation
45609050|NCT02521909|Device|ProMark (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
45609051|NCT02521909|Device|Root ZX II (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
45757960|NCT03931551|Drug|Olaparib [Lynparza®] plus Trastuzumab [Herceptin®]|Participants will receive olaparib (300 mg tablets, orally twice daily during 21-day cycles) in combination with herceptin (intravenous dose of 4 mg/kg body weight with subsequent weekly doses of 2 mg/kg or subcutaneous dose of 600 mg every 3 weeks) until progression or unacceptable toxicity.
45609052|NCT02521909|Device|NRG Rider (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
45609053|NCT04455113|Diagnostic Test|Phosphorus level|infusion
45609054|NCT03448705|Biological|4Fluart ID suspension for injection study drug 1 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)|Route of administration: intradermal, Dosage: 1 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.
45609055|NCT03448705|Biological|4Fluart ID suspension for injection study drug 2 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)|Route of administration: intradermal, Dosage: 2 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.
45609056|NCT03448705|Biological|3Fluart suspension for injection, influenza vaccine (whole virion, inactivated, adjuvanted)|Route of administration: intramuscular, Dosage: 6 μg HA/strain / 0.5 ml, Package: 0.5 ml in one ampoule from which a total of 0.5 ml is equal to a single dose, Dosage regimen: 1 x 0.5 ml, Treatment duration: single dose.
45609057|NCT03857867|Device|Tactile Stimulation Glove|A glove device produces non-painful sensory (tactile) vibratory stimulation to the fingertips of Parkinson's patients.
46068322|NCT00802477|Procedure|Application of autologous blood products.|Autologous blood products (platelet rich and platelet poor plasma) produced by the PlasmaxTM Plus Plasma Concentration System will be applied to the surgical site.
45911408|NCT02007785|Behavioral|CO-OP treatment protocol|Participants with Parkinson's disease will be participating in up to 12 one-on-one treatment sessions with 2 sessions per week, for up to 6 weeks. Each session will last 45-60 minutes. During these treatment sessions, each participant will be taught a problem-solving strategy that teaches individuals to monitor and adjust their own actions. Participants will be guided by the principal investigator to select 5 individual treatment goals to work on during treatment. Sessions will continue until all 5 treatment goals have been met or until 12 sessions have been completed, whichever occurs earlier. Initially, each participant's respective primary caregiver will be required to attend treatment sessions, so that the caregiver may be familiar with the treatment strategy in order to coach the participant with Parkinson's disease when you he or she uses the strategy at home.
45911409|NCT02007798|Drug|dexmedetomidine|2 ml of dexmedetomidine at a concentration of 100 ug/ml is diluted by 98 ml normal saline to a concentration of 2 ug/ml. The required amount of experimental drugs is confirmed according to the weight and grouping, and diluted using normal saline to 20 ml.
45911410|NCT02007798|Drug|normal saline|100 ml per bag
46068323|NCT00802477|Procedure|Standard Modified Radical Mastectomy|Mastectomy per standard procedure without the application of autologous blood products.
46068324|NCT00686439|Drug|adalimumab|subcutaneous injection 40mg on alternate weeks
45609058|NCT04637425|Drug|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
45609059|NCT04637425|Drug|Placebo|Matched tablets without any active substance.
45757961|NCT02011685|Behavioral|Home BP Telemonitoring (HBPTM)|Participants will take home BP readings 3 days per week (morning and evening), one week out of every month for 12 months. BP readings will be transmitted wirelessly to a secure server. Patients' physicians will receive home BP reports via secure email before every scheduled appointment for the duration of the study to facilitate necessary treatment intensification and medication adjustments.
46068325|NCT00686439|Drug|adalimumab|subcutaneous injection 40mg every other week
46068326|NCT04161755|Drug|Atezolizumab|Atezolizumab will be administered 6 weeks post-tumor resection (+/- 2 weeks)
46068327|NCT04161755|Biological|RO7198457|RO7198457 will be administered 9 weeks post-tumor resection (+/- 2 weeks)
46068328|NCT04161755|Drug|mFOLFIRINOX|mFOLFIRINOX regimen will be administered 21 weeks post-tumor resection (+/- 2 weeks)
45757962|NCT02011685|Behavioral|Nurse Case Management (NCM)|Participants will complete 20 counseling phone calls with a nurse case manager (NCM) during the 12-month intervention: weekly calls for Months 1-2; biweekly calls for Months 3-4; and monthly calls for Months 5-12. The NCMs will provide self-management education, medication and appointment reminders, and will facilitate patient-provider communication. They will counsel patients on specific self-management behaviors using problem solving and motivational interviewing techniques. Target behaviors will include dietary changes, physical activity, weight loss, medication adherence, and smoking cessation. NCMs will also review patients' clinical information and provide feedback about abnormal lab results, and will communicate with the patient's physician as needed (e.g., regarding barriers).
45757963|NCT00974415|Procedure|CO2|CO2 treatment delivered to randomized flank at each study visit
45757964|NCT00974415|Procedure|Sham|Sham treatment to other flank at each study visit
46068329|NCT00797329|Other|chart review|"cholesterol~cognitive profiles~violent behavior"
46068330|NCT04031235|Behavioral|Sleep Baby, Safe and Snug|Specially designed children's book, 14 pages, rhyming, illustrated in color, written at a Kindergarten reading level. Each page spread highlights AAP-recommended safe sleep practices. AAP safe sleep recommendations listed on the back cover.
46068331|NCT04031235|Behavioral|Read Baby, Every Day|Specially designed children's book, 14 pages, rhyming, illustrated in color, written at a Kindergarten reading level. Each page spread highlights AAP-recommendations regarding the importance of reading and talking to infants. Recommendations and benefits of reading with infants are listed on the back cover as well.
46068332|NCT00797407|Dietary Supplement|Creatine|Creatine 5 gm orally twice a day for 5 days, followed by 5 gm once a day
45609060|NCT05128331|Dietary Supplement|spermidineLife|dietary supplement that is made of natural wheat germ extract with high spermidine content
45609061|NCT05128331|Dietary Supplement|Placebo|dietary supplement that is made of cellulose.
45609062|NCT03448549|Drug|Oxaliplatin|adjuvant chemotherapy
45609063|NCT03448549|Drug|Tegafur，gimeracil and oteracil potassium|adjuvant chemotherapy
45609064|NCT03448549|Drug|Xeloda|adjuvant chemotherapy
45609065|NCT03679091|Drug|low-dose ticagrelor|low-dose ticagrelor (60.0 mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of clopidogrel (75mg once daily).
45609066|NCT03679091|Drug|Clopidogrel|clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of low-dose ticagrelor (60.0 mg once daily).
45609067|NCT04627831|Drug|CE-Iohexol|Captisol-Enabled™ Iohexol as needed for the diagnostic procedure. Volume will be determined according to medical need.
46068333|NCT02625987|Procedure|Continuous intradermic stitch|Appendectomy wound closure with an intradermic Polyglactina 910 stitch
45609068|NCT04627831|Drug|Iohexol|Iohexol as needed for the diagnostic procedure. Volume will be determined according to medical need.
45609069|NCT01628926|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
45609070|NCT01628926|Drug|Ropinirole|Ropinirole oral administration TID up to 15.0 mg/day
45609071|NCT01628926|Drug|Placebo|SPM962-placebo patch and Ropinirole-placebo tab
46068334|NCT02625987|Procedure|Separated stitches|Appendectomy wound closure with a separated stitches.
46068335|NCT00797485|Biological|bevacizumab|Given IV
45609072|NCT05321641|Behavioral|Mobile phone message reminders.|Utilising mobile messaging service to send reminders to people with epilepsy to take antiseizure medications and sending reminders to primary health facilities to restock anti-seizure medications.
45757965|NCT00696293|Drug|Duloxetine|Duloxetine up to 120 mg/day + Clinical Management
45757966|NCT00696449|Drug|Adapalene|All Subjects will treat the face once daily in the evening.
45757967|NCT00696449|Behavioral|frequent visits|This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.
45757968|NCT00696449|Behavioral|electronic reminder|This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.
46068336|NCT00797485|Drug|capecitabine|Given orally
46068337|NCT00797485|Drug|fluorouracil|Given IV
46068338|NCT00797485|Drug|irinotecan hydrochloride|Given IV
46068339|NCT00797485|Drug|leucovorin calcium|Given IV
46068340|NCT00686673|Behavioral|Providing tailored message on disclosing terminal illness|an experimental intervention group that receives a decision aid consisting of targeted educational video and manual providing a protocol for disclosing terminal illness and aimed at improving communication between patients and their family
46068341|NCT00686673|Behavioral|Providing non-tailored message on pain control|an attention control group that receives non-tailored video and manual on pain control
46068342|NCT00686751|Drug|paricalcitol|Dosage Form: Intravenous administration. Dosage: 0.01 micrograms/kilogram of body weight. Frequency: 2 HD treatments of each study week (depending on phase of study). Duration: 4 weeks.
46068343|NCT00686985|Drug|Carboplatin, docetaxel|Carboplatin AUC 5, Docetaxel 75 mg/m2, q 3 weeks, 4-6 cycles, 12-18 weeks
46068344|NCT00923702|Biological|Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)|The participants received either one, two or three doses of the avaccine. Each injection contains 20 microgram type 6, 40 microgram type 11, 40 microgram type 16, and 20 microgram type 18.
46068345|NCT00687063|Drug|insulin detemir|Start dose and frequency of insulin detemir is to be decided by physician. The choice of patient is also at the discretion of Physician
46068346|NCT00802555|Drug|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity, or other discontinuation criterion is met
46068347|NCT00687141|Drug|AZD0328|Oral solution administered orally once per day on day 1, and then day 3 through to day 14. Specific dose depends on dose panel.
46068348|NCT00687141|Drug|Placebo|Administered orally as a solution once per day on day 1, and then day 3 through to day 14.
46068349|NCT00687375|Procedure|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using Transabdominal preperitoneal (TAPP) Approach
46068350|NCT00687375|Procedure|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using totally extra peritoneal (TEP) Approach
46068351|NCT05192083|Behavioral|Self-management and Support|A smartphone-based self-management support programme includes a 30-min face-to-face or online session at baseline, 3 phone calls and 2-month mobile messages
46068352|NCT02866955|Drug|Estramustine|140mg/4 caps/day
45609073|NCT05313659|Drug|Ketamine Hydrochloride|intramuscular ketamine hydrochloride at dose of 0.7 mg/kg at the time of turning the inhalational agent off
45609074|NCT05321563|Behavioral|iDECIDE (Drug Education Curriculum: Intervention, Diversion, and Empowerment)|iDECIDE is a 4 session curriculum that addresses topics such as the neurobiology of substance use, adolescent brain development, industry tactics, motivations for using substances, risk and protective factors, triggers, healthy alternatives, core values, and long-term goal setting. These topics are taught via facilitated discussions, videos, worksheets, and handouts. Facilitators are selected by schools and community agencies to receive free trainings conducted by the iDECIDE team, which includes personnel from the Massachusetts Department of Public Health, Massachusetts General Hospital (MGH) Center for Addiction Medicine, and the Institute for Health and Recovery.
45609075|NCT03129373|Device|Cryogenic treatment of warts|Treatment of common and plantar wart by cryotherapy treatment.
46068353|NCT02866955|Drug|Tamoxifen|20mg/day
46068354|NCT00794911|Behavioral|Quality of Life Therapy|8 weekly individual counseling sessions
46068355|NCT00794911|Behavioral|Supportive Therapy|8 weekly individual counseling sessions
46068356|NCT02625753|Drug|Codeine|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
46068357|NCT02625753|Drug|paracetamol|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
45757969|NCT00696449|Behavioral|Parent reminder|In this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.
46068358|NCT02625753|Drug|placebo|Patients submmitted to photorefractive keratectomy received placebo, in the form of a pill of similar appearance to the comparator, every 6h for 72h after the
46068359|NCT04907006|Drug|SY-004 capsule|After fasting for 10 hours, subjects in group 1 took one SY-004 (80mg) orally on an empty stomach on the day of administration with 240ml warm water; Subjects in group 2 began to eat high-fat breakfast 30 minutes before administration , and took one SY-004 capsule（80mg） orally with 240ml warm water. The subjects in both groups were fasted within 4 hours after taking the medicine, and drinking water was forbidden within 1 hour before and after taking SY-004.
46068360|NCT02625675|Other|Ultrasound scan|
46068361|NCT04257422|Other|Intentional Rounding|"A new method of nursing care named Intentional Rounding. The intentional roundings are planned rounds, conducted at regular intervals by nursing staff to anticipate care, comfort, hospitality and psychological needs of hospitalized users."
46068362|NCT04139421|Behavioral|Shinrin-Yoku|Shinrin-Yoku is a traditional Japanese practice of getting in touch with nature through walking in the forest in a relaxed way using all five senses.
46068363|NCT04257656|Drug|Remdesivir|RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
46068364|NCT04257656|Drug|Remdesivir placebo|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
46068365|NCT04139031|Device|Ultrasonographic measurement of corrected flow time in carotid artery|Corrected carotid artery flow time is measured using 6-13 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed while the Doppler beams were adjusted to ensure < 60° of angle for the best signal. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).
46068366|NCT05329844|Drug|Vildagliptin 50 MG|50 mg Vildagliptin as single-dose per study period
46068367|NCT00687999|Drug|pegylated interferon alpha and ribavirin|standard pegylated interferon alpha and ribavirin
46068368|NCT00688077|Drug|Calcitonin|Calcitonin 200 IU/ml, single subcutaneous injection, experimental group
46068369|NCT00688077|Drug|Placebo|NaCl 0,9 % 1ml, single subcutaneous injection, placebo group
46068370|NCT00688233|Device|Seifi's Functional|Patient with Class II Division 1 and Deepbite malocclusion will wear the Seifi's Functional to get the benefit of skeletal and dentoalveolar correction.
46068371|NCT00923156|Drug|aliskiren|Aliskiren 150 mg once daily up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site
45609076|NCT04800133|Biological|Tozinameran|mRNA vaccine developed by BioNTech against COVID-19
45757970|NCT00696449|Behavioral|Standard of care|"This group is considered to be the standard of care arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits."
45609077|NCT04800133|Biological|CoronaVac|Inactivated virus vaccine developed by SinoVac against COVID-19, intramuscular
45757971|NCT03916263|Drug|Metformin|Traditional care including diet, exercise and metformin
45757972|NCT03916263|Other|One-On-One Dietary Instruction|Participant receives one-on-one dietary counseling from study personnel
45757973|NCT03916263|Other|Video Dietary Instruction|Participant receives video dietary instruction
45757974|NCT00696761|Drug|Alfuzosin|10mg, once daily, 12months
45757975|NCT00696761|Drug|Alfuzosin|10mg, once daily, 12months
45757976|NCT00696761|Drug|Alfuzosin|10mg, once daily, 12months
45757977|NCT00696761|Drug|Alfuzosin|10mg, once daily, 12months
45757978|NCT00656201|Drug|Crinone 8% Vaginal Gel|Crinone 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) once a day beginning the second day following oocyte retrieval (Study Group A) continuing until the pregnancy test is negative or until the 10th week of pregnancy.
45757979|NCT00656201|Drug|Intramuscular Progesterone|Progesterone-50 mg intramuscularly once a day beginning the day after oocyte retrieval continuing until the pregnancy test is negative or if positive, switching to Crinone 8% intravaginal gel until the 10th week of pregnancy.
46068372|NCT00923156|Drug|ramipril|2.5 mg , 5.0 mg or 10 mg once daily
46068373|NCT00923156|Drug|Placebo to aliskiren|matching placebo to aliskiren in double blind phase
46068374|NCT00923156|Drug|Placebo to ramipril|Matching placebo to ramipril capsule in double blind phase
45609078|NCT04800133|Biological|CoronaVac, intradermal|Inactivated virus vaccine developed by SinoVac against COVID-19, intradermal
45609079|NCT05322187|Drug|PD-1 inhibitor|Sequential PD-1/PD-L1 Inhibitor and LENvatinib treatment after chemotherapy resistance
45609080|NCT03129295|Drug|MPC-SHRC|Oral tablet four times a day for 3 days
45609081|NCT03129295|Drug|Placebo Oral Tablet|Oral tablet four times a day for 3 days
45609082|NCT01628848|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
45609083|NCT01628848|Drug|Placebo|Placebo transdermal patch
45609084|NCT04396717|Biological|Pritumumab|Pritumumab IgG1 human monoclonal antibody
45609085|NCT03448315|Device|tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions)
45609086|NCT03448237|Other|Speech Therapy|Speech therapy adapted to the child, at least 25 sessions over 9 months.
45653330|NCT04447651|Other|Recommendation for treatment with immunotherapy|Patients with a SF3B1, U2AF1 or SRSF2 mutation will be reviewed by the molecular tumor board and treatment recommendations will be given to the patient's treating oncologist.
45653331|NCT05370703|Behavioral|My A:care|Mobile application with Motivational messages
45653332|NCT05370703|Behavioral|Smart Coach|Mobile application with Motivational messages
46068375|NCT00688311|Dietary Supplement|Synbiotic 2000|A preparation consisting of 4 species of probiotic bacteria (10^10 each) combined with 4 types of dietary fiber (2.5g each).
46068376|NCT00688311|Dietary Supplement|Placebo|Placebo
46068377|NCT00688389|Other|case/control|case: infected dengue fever people control:healthy people
46068378|NCT04257266|Device|Ice Pack Cooling|5 ice packs (Cryo cooling pack or commercial ice pack) will be placed on the subject for 30 mins after exercise-induced hyperthermia
46068379|NCT02625831|Other|Biological analysis|"Biological analysis :~ficolin-3~anti-ficolin 3 antibodies~anti-C1q antibodies"
45757980|NCT00759291|Drug|acipimox|250 mg tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
46068380|NCT04256954|Behavioral|Peer navigation intervention|A peer navigator will assist those assigned to the intervention group access community mental health, medical care and substance use services. Peer navigators will help create linkages to services
45757981|NCT00759291|Drug|Placebo|1 tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
46068381|NCT04203602|Procedure|telepresence discharge|Patients will be seen during ward rounds by the multidisciplinary team physically present, but with the surgeon remotely present via a telepresence robot.
46068382|NCT04203602|Other|Conventional discharge|Patients will be seen during ward rounds by the whole multidisciplinary team physically present, including the surgeon.
46068383|NCT00688779|Drug|AZD8848|Concentrate for nasal spray,solution 60 mg/g
46068384|NCT00688779|Drug|Placebo|
46068385|NCT04203992|Behavioral|Videogame|"True Champion is an educational, values-based game that aims to empower young athletes to make informed decisions to avoid doping.~Participants engaging in the videogame sessions will encounter a series of thought-provoking situations and knowledge tests. Players will help their assigned character navigate through these curriculum-rich scenarios in order to reach their performance goals in a healthy and ethical way."
46068386|NCT04203992|Behavioral|Control|Participants will be given an anti-doping booklet prepared by UNESCO. This booklet is considered standard educational material, i.e. what might be presented to young athletes as part of their regular sports curriculum.
45609087|NCT03448237|Other|Proprioceptive treatment|"Proprioceptive treatment adapted to the child.~This treatment aims to stabilize a central reference instability revealed to Maddox Postural by the use of neurosensory decoys::~Proprioceptive stimulation of oculomotor muscles (active prisms).~Oral somatosensory stimulation (ALPH).~Proprioceptive antigravity stimulation (proprioceptive sole).~Proprioceptive reprogramming exercise.~Following the teaching of the University Diploma: Perception-Action, Learning Disorders (University of Bourgogne, France)"
45609088|NCT02164318|Other|Handgrip training|
46068387|NCT00688857|Drug|Diazoxide choline|Diazoxide choline controlled-release coated tablets versus Diazoxide choline controlled-release uncoated tablets administered orally once daily
46068388|NCT00688857|Drug|Diazoxide choline|Diazoxide choline controlled-release uncoated tablets versus Diazoxide choline controlled-release coated tablets administered orally once daily
46068389|NCT00689013|Other|Personalized letter|On Day 1 of the 2nd month, a personalized letter (addressing specific patient) was mailed to current pharmacy patients with indications for the Zostavax vaccine. Current patients were defined as those receiving at least one prescription medication from the pharmacy within 6 months. The personalized letter provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
46068390|NCT00689013|Other|Flyer advertisement|Beginning on Day 1 of the 2nd month, flyer advertisements were distributed with all pharmacy sales. Flyer advertisements provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
45757982|NCT00657605|Drug|Recombinant methionyl human leptin|Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
45757983|NCT00756405|Behavioral|Antioxidant diet|Participants were asked to increase antioxidant-rich food intake to approximately double their daily habitual intake and take a placebo pill.
45757984|NCT00756405|Dietary Supplement|Antioxidant supplement|Participants were asked to consume their usual diet and take a supplement containing carotenoids, mixed tocopherols, vitamin C and selenium, designed to approximately double their daily habitual intake.
46068391|NCT00689013|Other|Newspaper press release|During the first week of the 2nd month, local newspapers published press releases. The press release provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
46068392|NCT04203758|Other|Cereal products based on rye|Participants will receive a fixed amount of rye based cereals products, corresponding to approx 650 kcal/day.
46068393|NCT04203758|Other|Cereal products based on wheat|Participants will receive a fixed amount of wheat based cereals products, corresponding to approx 650 kcal/day.
46068394|NCT04256798|Drug|Chlorhexidine mouthwash|0.2% Chlorhexidine digluconate
46068395|NCT04256798|Drug|Oxygen|Oxygen 80-100%
46068396|NCT04256798|Drug|Oxygen|Oxygen 21-30 %
46068397|NCT00687843|Drug|Tegafur-gimeracil-oteracil potassium (TS-1)|80 mg/m2, PO from day 1 to day 28 of each 42 day cycle. Number of Cycles: 8
46068398|NCT00687843|Drug|Krestin (PSK)|3 g, PO from day 1 to day 336
45609089|NCT02164318|Drug|Nitroglycerin ointment|
45609090|NCT03436199|Drug|ADS-5102, 137 mg|Oral capsules
45609091|NCT03436199|Drug|ADS-5102, 274 mg|Oral capsules
45609092|NCT03436199|Other|Placebo|Oral capsules
45609093|NCT02131636|Drug|AGN-199201|AGN-199201 applied to the face once daily for 29 days.
45757985|NCT00756405|Dietary Supplement|Placebo|Participants were asked to consume their usual diet and take a placebo pill.
46068399|NCT04139187|Other|Combined training with power and strength exercises|"The training will be compose by power and strength exercises and divided in two days. One day with the exercises: vertical jumps, box jumps, sit-ups, back-extension and guided squat. The second with half squat jumps, high straight jumps, bounding jumps, drop jumps and sprint. Both days will be started with warm up on treadmill running lasting 5 minutes at 6.5-7.5 km/h.~The training protocol includes 20 sessions with 2 sessions per week during 10 weeks (2 weeks to adaptation and others 8 to training with progression of load after 4 weeks)."
45609094|NCT02131636|Drug|Vehicle to AGN-199201|Vehicle to AGN-199201 applied to the face once daily for 29 days.
45609095|NCT02131324|Drug|DFD06 Cream|
46068400|NCT00689169|Drug|ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)|Zevalin 0.4 mCi/kg: D-14 BCNU 300 mg/m² : D-6 Etoposide 100 mg/m²/12h : D-6 D-5 D-4 D-3 Aracytine 200 mg/m²/12h : D-6 D-5 D-4 D-3 Melphalan 140 mg/m²: D-2
46068401|NCT00689169|Procedure|ASCT|ASCT : D0
46068402|NCT00689169|Drug|Rituximab|Rituximab 250 mg/m² :D-21 D-14
46068403|NCT00610844|Procedure|pulmonary radiofrequency ablation|CT-guided pulmonary radiofrequency ablation
46068404|NCT00610922|Dietary Supplement|Docosahexaenoic acid (DHA)|DHA 20 mg per day through 12 months of life
46068405|NCT04203914|Drug|Empagliflozin Tablets|Add-on 25mg once daily
46068406|NCT04260620|Device|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
45609096|NCT02131324|Drug|Clobetasol Propionate Cream 0.05%|
45609097|NCT02734693|Drug|dasotraline 4mg|dasotraline 4mg/day
46068407|NCT00874731|Drug|Ridaforolimus 100 mg|Part 1: A single oral dose of 100 mg ridaforolimus (10 x 10 mg tablets) was given on Day 2.
45757986|NCT00697541|Drug|0.18% COL-118 facial gel (1.8 mg brimonidine)|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
45757987|NCT00697541|Drug|0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically.
45757988|NCT00697541|Drug|Advanced Eye Relief|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
46068408|NCT00874731|Drug|Ridaforolimus 40 mg|Part 2 (optional): Ridaforolimus 40 mg (4 x 10 mg tablets) was received on a regimen of daily oral doses for 5 consecutive days followed by 2 days off-drug.
46068409|NCT00874731|Drug|Placebo|Part 1: A single oral dose of placebo (10 x placebo tablets) was given on Day 1.
46068410|NCT02625519|Drug|Urinary follicle-stimulating hormone|Ovarian stimulation with highly purified urinary follicle-stimulating hormone
46068411|NCT02625519|Drug|Recombinant follicle-stimulating hormone|Controled ovarian stimulation with recombinant follicle-stimulating hormone
46068412|NCT00912483|Biological|heparin sodium - Blausiegel|Heparin sodium - 5.000UI/0.25mL, twice a day for 7 days and 2 hours before the surgery
46068413|NCT00912483|Biological|Heparin sodium - APP|Heparin sodium - 5.000USP/mL, twice a day for 7 days and 2 hours before the surgery
46068414|NCT00689247|Drug|AZD1305|oral solution, single dose
46068415|NCT00689247|Drug|AZD1305|iv infusion, single dose
46068416|NCT00689403|Drug|AZD1305|Extended release capsules, oral single doses
46068417|NCT00689403|Drug|AZD1305|Extended release capsules, oral single doses
46068418|NCT00924638|Device|Reveal® XT Insertable Cardiac Monitor|The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.
46068419|NCT04257032|Drug|Rosuvastatin|Tablet
46068420|NCT04257032|Drug|Rosuvastatin + BI 1323495|Tablets
46068421|NCT04257032|Drug|Dabigatran etexilate|Capsule
46068422|NCT04257032|Drug|Dabigatran etexilate + BI 1323495|Capsule and tablets
46068423|NCT04256720|Behavioral|No intervention|No intervention - questionnaire study
46068424|NCT00874497|Drug|tetomilast|Oral tetomilast 25 mg once daily for 2 weeks followed by 50 mg once daily for 2 years.
46068425|NCT00874497|Drug|placebo|Placebo for 104 weeks (2 years)
46068426|NCT00924560|Drug|91-day Levonorgestrel Oral Contraceptive|"Levonorgestrel/ethinyl estradiol 0.15/0.03 mg and ethinyl estradiol 0.01 mg tablet.~Take 1 tablet daily"
46068427|NCT00924560|Drug|28-day Levonorgestrel Oral Contraceptive|Levonorgestrel/ethinyl estradiol 0.10/0.02 mg tablet and placebo. Take 1 tablet daily
46068428|NCT00689559|Drug|AZD3480|AZD3480 capsules qd, oral, 22 days
45609098|NCT02734693|Other|Placebo|placebo/day
45609099|NCT04455269|Device|AIRFLOW® with PLUS® powder and PIEZON® scaler|Air-polishing will be use as main instrument for biofilm and stains removal, followed by ultrasonic scaling
45609100|NCT04455269|Device|PIEZON® scaler and rubber cup with abrasive paste|Application of ultrasonic scaler on the entire dentition, followed by residual biofilm and stains removal and polishing
45609101|NCT04749394|Drug|Camrelizumab, PD-1 monoclonal antibody|Camrelizumab 200mg IV, Q3W, until clinical progression/deterioration or confirmed radiological progression, or up to 1 year.
45609102|NCT04749394|Drug|Apatinib, VEGFR2 antibody|Apatinib 250mg PO, QD, until clinical progression/deterioration or confirmed radiological progression, or up to 1 year.
45609103|NCT02193880|Device|Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.|Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
45609104|NCT05400707|Diagnostic Test|Assessment of vital signs|heart rate, blood pressure, body temperature, respiration rate, peripheral capillary haemoglobin oxygen saturation)
45609105|NCT05400707|Diagnostic Test|Assessment of impaired mobility on presentation (IMOP)|Assessment of IMOP: defined as being unable to stand unaided or walk without help
45609106|NCT05400707|Diagnostic Test|Assessment of level of consciousness by AVPUC scale|Assessment of level of consciousness by AVPUC scale (alert, new confusion, verbal, pain, unresponsive, new confusion)
45609107|NCT05400707|Diagnostic Test|Assessment of symptoms patients presenting when admitted to ED|Questionnaire with a predefined list of 37 symptoms
45609108|NCT05400707|Diagnostic Test|Assessment of current living situation in patients of 65 years and older|Questionnaire to assess living situation (living at home independently, living at home with help by family members or professional services, and living in a retirement or nursing home)
45757989|NCT00697541|Drug|COL-118 facial gel vehicle|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
45609109|NCT05400707|Diagnostic Test|Assessment of elder abuse (EA)|The ED Senior AID tool is a questionnaire with 15 questions to identify elder abuse
46068429|NCT00689559|Drug|Placebo|Placebo qd, 12 days
45609110|NCT05400707|Diagnostic Test|Assessment of caregiver burden:|"The caregiver will be asked 4 questions about caregiver burden: do you feel emotionally burdened by caring for your relative?, is caring for your relative a physical strain for you?, has the care of the relative negatively affected the relationship with someone close (family, care recipient)?, is caring for your relative a financial burden for you?."
45609111|NCT05069675|Procedure|vitrectomy|vitrectomy with gas tamponade
45757990|NCT04514913|Radiation|Multidetector Computed Tomography (MDCT) Scan|This is a low-dose CT scan of the chest using no contract material.
45757991|NCT04514913|Procedure|Virtual Navigation Bronchoscopy (VNB)|This is a procedure where a camera will be inserted into the lung in order to guide sample collection of bronchoalveolar lavages, bronchail brushes and endobronchial biopsies.
46068430|NCT00689559|Drug|Aripiprazole|single dose on day 5
46068431|NCT00689637|Drug|AZD3480|AZD3480 capsules qd, 12 days
46068432|NCT00689637|Drug|Placebo|Placebo capsules qd, 12 days
46068433|NCT00689637|Drug|Warfarin|Warfarin: single dose on day 6
46068434|NCT00689715|Procedure|Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection|A curvilinear-array echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration, ethanol lavage and paclitaxel injection. The maximum possible volume of cyst fluid was aspirated, and the needle tip was carefully maintained inside the cyst to avoid parenchymal injury. Ethanol was injected into the collapsed cyst until the original shape was restored, and a lavage was then performed for 3-5 minutes. Pure ethanol (99%) was used for all patients except the first 2 in whom 88% ethanol was used. After reaspiration of the injected ethanol, the cyst cavity was injected with a solution containing 3 mg/mL paclitaxel and the needle then carefully retracted. The high viscosity of paclitaxel necessitated dilution in 0.9% normal saline for administration via a 22G needle. The volume of the paclitaxel solution administered was the same as the volume of the cyst fluid aspirated.
46068435|NCT00689949|Dietary Supplement|folic acid|0.4 mg of folic acid per day
46068436|NCT04256642|Procedure|Erector Spinae Plane Block|A nerve block that injects local anesthetic in the Erector Spinae Plane
46068437|NCT04256642|Drug|Intrathecal morphine|Intrathecal morphine at the time of spinal anesthesia
46068438|NCT00611000|Dietary Supplement|folic acid|
46068439|NCT00611000|Genetic|DNA methylation analysis|
46068440|NCT00611000|Genetic|gene expression analysis|
46068441|NCT00611000|Genetic|microarray analysis|
46068442|NCT00611000|Genetic|polymorphism analysis|
46068443|NCT00611000|Other|laboratory biomarker analysis|
46068444|NCT04031157|Device|Predictix Antidepressant|Predictix Antidepressant guided treatment
45609112|NCT05321485|Other|MedicijnWijs|"The mobile phone app MedicijnWijs will guide the participants with their azathioprine therapy during 6 weeks. Information about azathioprine is given as well as general information about IBD, specified to disease modality (Crohn's Disease and Ulcerative Colitis). Contact details of the patient's pharmacy are listed, questions about the patient's symptoms are asked, and push notifications are added to remind the patients to take their medication.~At the beginning of the 6-weeks guidance, two validated questionnaires that are translated and validated in Dutch will have to be filled in: the MARS-5 and the IBD-KID2. After 6 weeks, the participants have to fill out the same questionnaires again to assess potential changes in the scores compared to baseline. Also, a number of questions will be asked to assess the ease of use of MedicijnWijs."
45609113|NCT05159219|Drug|Colchicine Pill|Anti-inflammatory
45609114|NCT05159219|Other|Placebo|Inert ingredients
45609115|NCT03590899|Device|Optical coherence tomography angiography (Zeiss Cirrus HD OCT 5000 AngioPlex)|Non-invasive, non-contact optical coherence tomography angiography scans of the retina are done per built-in device protocol using the Zeiss Cirrus HD OCT 5000 AngioPlex machine.
45609116|NCT04453943|Device|Exoskeleton Walking - with or without FES|The study involves validation of computer algorithms to estimate and control walking movements. The Rifton E-Pacer motorized walker, arm crutches, parallel bars, or a conventional walker may be used in order to assist donning and doffing of the exoskeleton system, standing, and walking for all subjects, at any time during experimentation. Walking movements will be elicited by the hybrid walking platform that combines a powered exoskeleton and an FES system. The powered exoskeleton can provide joint actuation at the hip and knee joints of a participant. The FES system can stimulate the quadriceps, hamstrings muscle, glutes, and ankle muscles.
45609117|NCT04453943|Device|Exoskeleton Sitting to Standing - with or without FES|The study involves validation of computer algorithms to estimate and control sitting/standing movements. The Rifton E-Pacer motorized walker, arm crutches, parallel bars, or a conventional walker may be used in order to assist donning and doffing of the exoskeleton system, standing, and walking for all subjects, at any time during experimentation. Sitting/Standing movements will be elicited by the hybrid walking platform that combines a powered exoskeleton and an FES system. The powered exoskeleton can provide joint actuation at the hip and knee joints of a participant. The FES system can stimulate the quadriceps, hamstrings muscle, glutes, and ankle muscles.
45757992|NCT00697697|Drug|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
45609118|NCT05321329|Drug|Capecitabine|Capecitabine is a deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.Capecitabine is a Nucleoside Metabolic Inhibitor. The mechanism of action of capecitabine is as a Nucleic Acid Synthesis Inhibitor.
45609119|NCT02521831|Drug|Spinal Anesthesia (bupivacaine)|Bupivacaine is an amide-type, long-acting local anesthetic. Brand names include Exparel, Marcaine, and Sensorcaine.
45609120|NCT02521831|Drug|General Anesthesia (isoflurane)|Isoflurane is a fluorinated ether with general anesthetic and muscle relaxant effects. Brand names include Forane and Terrell.
45609121|NCT03448003|Other|Cancer Prevention|Attend IO prevention program
45609122|NCT03448003|Other|Questionnaire Administration|Ancillary studies
45609123|NCT01425541|Drug|estrace|0.5-1 mg once a day PO for 7 days
46068445|NCT04260386|Other|Non-Interventional|"During the cardiac arrest scenario, the delegates observing will be asked to refer to the maternal cardiac arrest proforma and record those details of events that they are able to see/hear from the video link. In addition, the proforma will be provided to the team taking part in the simulation. One or more team members would routinely be given the role of 'scribe', recording events as they occur. The proforma is accompanied by explanatory notes on how to use it.~Delegates (observers plus scribes) will then be asked to complete a questionnaire, seeking their opinions on the usefulness of the proforma. Questionnaires will be linked to the written consent forms by a participant ID number."
45609124|NCT01425541|Drug|Progesterone|20 mg/ml, 25-100 mg, Three times a day at 0700, 1500, and 2300 hr for 7 days
46068446|NCT00690027|Procedure|Emergency portacaval shunt|
46068447|NCT00690027|Procedure|Emergency and long-term endoscopic sclerotherapy|
45757993|NCT00697697|Drug|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
46068448|NCT00690105|Drug|tacrolimus 0.1%|ointment
46068449|NCT00690105|Drug|fluticasone 0.005 %|ointment
46068450|NCT00923078|Behavioral|Auditory Cognitive Training|The program entails six computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and adapt in difficulty to individual performance, giving constant feedback about progress. Each of the six exercises focuses on a distinct process: (1) auditory processing speed, (2) discriminating sounds, (3) sound precision, (4) sound sequencing, (5) working memory, and (6) narrative memory. Training was administered in a supervised clinical laboratory setting at a frequency of five 60-minute sessions per week over 4 weeks.
45609125|NCT04455035|Other|Comparator: Retrospective Group(Control)|The control group for this study will be obtained from a retrospective chart review of electronic health records of patients with incomplete cleft lip who underwent surgery without any presurgical interventions.
45609126|NCT04455035|Device|Prospective Group|"The study population for the prospective aspect will include recruited newborns with untreated unilateral incomplete cleft lip.~DynaCleft® + Nasal Elevator therapy will be discussed with parent(s) as a presurgical orthopedic option while awaiting primary cleft lip surgical repair that typically occurs between the ages of 3 to 6 months.Study duration will be up to three months of presurgical intervention.Photographs are to be taken at initial visit prior to presurgical intervention and later at completion of the DynaCleft® therapy immediately prior to lip surgery. Angles to be pictured are to include the standard anterior-posterior, profile, and worms-eye view.~Linear measurements will be obtained with a ruler and registered in millimeters. A goniometer will be used to measure angles."
45757994|NCT03889275|Biological|MEDI5395|Participants will receive multiple dose levels of MEDI5395 over several days as stated in arm description.
45757995|NCT03889275|Biological|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
45757996|NCT04349163|Other|Questionnaire|CD-RISC 25 questionnaire
45609127|NCT03129763|Behavioral|60mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 60mmHg.
45609128|NCT03129763|Behavioral|70mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 70mmHg.
45609129|NCT03129763|Behavioral|80mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 80mmHg.
45757997|NCT00657917|Drug|Paromomycin +Gentamicin topical cream|WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy.
45757998|NCT01959945|Biological|Flublok® Quadrivalent Influenza Virus Vaccine|Intramuscular (Relevant year formulation)
45757999|NCT01959945|Biological|Fluarix Quadrivalent® Influenza Virus Vaccine|Intramuscular (Relevant year formulation)
45758000|NCT00700661|Drug|montelukast|One montelukast 4-mg chewable tablet (CT) administered once daily at bedtime. Duration of Treatment: 48 Weeks
45758001|NCT00700661|Drug|placebo (unspecified)|Matching-image Montelukast placebo. Duration of Treatment: 48 Weeks
45444968|NCT03791307|Other|Modified Pilates group|The participants will perform exercises based on the Pilates method alternated with active rest periods on treadmill ergometer, 2 times a week, for 50 minutes, for 16 weeks.
45911411|NCT02007811|Biological|allogeneic donor derived B-lymphocytes|CD3+-depleted, CD19+-enriched, cryopreserved (single administration after day 120 following allogeneic stem cell transplantation, donor-identical) in 4 groups with escalating doses
45911412|NCT02007824|Device|ULSD-12D|wound cleansing and debridement using ULSD-12D
45911413|NCT02007824|Device|SONOCA-180|wound cleansing and debridement using SONOCA-180
45758002|NCT03856749|Other|Remote wheelchair skills training|"Prior to the first training session, the trainer will be provided with the results from the assessment immediately preceding training to provide him/her time to individualize the training session. Trainer will provide self-study materials (the Caregiver Handbook and caregiver-training video-recording) and an explanation on how these materials should be used.~The wheelchair user and caregiver will be trained together on wheelchair skills, using the principles of the Wheelchair Skills Training Program, as outlined in the Wheelchair Skills Program Manual using remote technology. Each training session will be with a trainer-to-dyad ratio of 1:1 1 dyad = 1 manual wheelchair user + his/her caregiver. Training will continue until the goals have been met and retained (for at least one subsequent session), using up to 4 training sessions that will each last up to 60 minutes at intervals a minimum of 3 days."
45609130|NCT03129763|Behavioral|90mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 90mmHg.
45609131|NCT03129763|Behavioral|100mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 100mmHg.
46068451|NCT00923078|Behavioral|Visual Cognitive Training|The program entails five computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and, following our laboratory procedures, calibration testing is repeated every 5th session. Exercises adapt in difficulty to individual performance, giving constant feedback about progress. Each of the five exercises focuses on a distinct process: (1) visual precision, (2) visual processing speed, (3) divided attention, (4) visual working memory, and (5) useful field of view. Training was administered in a supervised clinical laboratory setting at a frequency of five 40-minute sessions per week over 4 weeks.
45609132|NCT03447925|Drug|Medicinal Plant|Medicinal Plant Extract with vaseline cream
45609133|NCT03447925|Drug|Salicylate|Salicylate 10% with vaseline cream
45609134|NCT03447925|Drug|Vaseline|Vaseline cream
45609135|NCT05399225|Diagnostic Test|Platelets to lymphocytes ratio and procalcitonin|Platelets to lymphocytes ratio and procalcitonin in sepsis
45609136|NCT03447847|Other|Water|1 liter of water in meals; 1 liter out of meals
46068452|NCT04139265|Diagnostic Test|biologic analysis (ferritinemia, transferrin saturation coefficient)|Each patient will follow a blood test in order to compare between ferritinemia and transferrin saturation coefficient in iron deficiency diagnosis
46068453|NCT00694317|Drug|Zaleplon|Short term treatment of insomnia
46068454|NCT04260152|Device|Geistlich Fibro-Gide|Surgical recession root coverage with coronally advanced flap in combination with Geistlich Fibro-Gide
46068455|NCT04260152|Procedure|Connective Tissue Graft (CTG|Surgical recession root coverage with coronally advanced flap in combination with CTG
45609137|NCT04928183|Other|Carbon monoxide rebreathe|Carbon monoxide exposure to increase blood (Carboxyhemoglobin) COHb safely to ~10%
45609138|NCT04928183|Drug|Sodium Nitroprusside|Bolus Sodium Nitroprusside (SNP) injection for endothelium-independent vasodilation measure
45609139|NCT04928183|Drug|Phenylephrine Hydrochloride|Bolus Phenylephrine injection for observe α1-mediated vasoconstriction during mild exercise
45609140|NCT05399147|Other|fiberoptic intubation classic technique|classic fiberoptic intubation
45609141|NCT05399147|Other|fiberoptic intubation tube 1st technique|tube 1st technique
45609142|NCT05320861|Drug|[14C]SJP-0008|Single oral dose of [14C]SJP-0008
45609143|NCT04622189|Device|Action observation training|"Integration of four main tools:~PATIENT INTERFACE, which has been implemented to present stimuli with a user friendly interface, with personalized menu and with the possibility to manage the training program; user personal page containing user information and history of activities with daily performance are stored too.~MOCAP during action imitation will be recorded using MindMotion infrared camera to capture the trunk movement while an electromagnetic system (Trackstar from NDI) will be used to record fingers fine movements.~EEG data will be collected during video observation using an Enobio wireless system integrated with the platform."
45758003|NCT00658385|Genetic|GCSF, Central venous line placement, Stem cell Collection (leukapheresis)|"Daily injections under the skin of a GCSF. This is done for 5 to 6 days. On days 1, 3,5, and if need on day 6. To collect stem cells, we need good access to this blood. If the patient has good veins, we do this by placing an IV on each one of their arms. The peripheral blood stem cell collection is usually an outpatient procedure and takes about 3 to 4 hours. You will have blood work and a physical exam on days one, three, and five while you are getting GCSF.~These will be done again 24 hours after your stem cells are collected."
45758004|NCT00652847|Drug|ezetimibe|ezetimibe 10 mg/day for a six week course of treatment.
45758005|NCT00652847|Drug|statins|patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase
45758006|NCT00652301|Drug|ezetimibe|ezetimibe 10 mg tablet. Duration of Treatment 31 Weeks.
45609144|NCT04311073|Drug|Tranexamic Acid|IV Tranexamic acid in 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.
46068456|NCT04136613|Device|Copper Intra uterine contarceptive device ( Cu-T 380A)|Insertion of the Cu-T 380A during cesarean delivery immediately after placental removal.
46068457|NCT00978731|Drug|Dasatinib|"Tablets, Oral, The dosing ranges from 50mg to a total of 240mg daily with the following 3 schedules:~5 days on, 2 days off~6 days on, 1 day off~Continuous daily dosing~Once Daily (QD) or Twice Daily (BID) dosing, Subjects will be treated until progression of disease despite escalation/reductions of dose to the level deemed safe by available data, until intolerable/unacceptable toxicity or until subject withdrawal from the study or discontinuation of the study"
46068458|NCT04136535|Drug|Pemetrexed|Pemetrexed，500mg/m²，ivgtt ，d1，q3w
46068459|NCT04136535|Drug|Carboplatin|Carboplatin，AUC 5.0，ivgtt，d1，q3w，
46068460|NCT04136535|Drug|Anlotinib|Anlotinib ，12 mg，po，qd，d1-14，q3w；
46068461|NCT00694629|Drug|rifampin|tablet, 10 mg/kg, daily, 8 weeks
46068462|NCT00694629|Drug|rifapentine|tablet, 10 mg/kg, daily, 8 weeks
46068463|NCT00694629|Drug|rifapentine|tablet, 15 mg/kg, daily, 8 weeks
45609145|NCT04311073|Drug|Placebos|IV normal saline 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.
45758007|NCT00652301|Drug|Comparator: Placebo (unspecified)|matching placebo tablet. Duration of Treatment 31 Weeks.
45758008|NCT00652301|Drug|simvastatin|simvastatin 20 mg tablet. Duration of Treatment 31 Weeks.
45758009|NCT01961271|Drug|Buprenorphine transdermal patch|Please see Arm Description.
45758010|NCT01963143|Biological|Gammaplex (5%)|
46068464|NCT00694629|Drug|rifapentine|20 mg/kg, daily, 8 weeks
46068465|NCT02868125|Radiation|X ray radiography|All studied patients will undergo an x-ray radiography of the operated hip. This protocol is a part of the investigators' common practice policy regardless of the study.
46068466|NCT00912639|Drug|Paclitaxel loaded Polymeric micelle|Genexol-PM at a dose of 300mg/m2 was diluted in 500 ml of 5% dextrose solution or normal saline and infused i.v. for 3 h on day 1.Treatment was repeated every 3 weeks until either disease progression or intolerance. A minimum of 6 cycles was recommended.
46068467|NCT02866409|Procedure|scalp block|"In this group following nerves were blocked-~Supra-orbital nerve~Supra-trochlear nerve~Zygomatico-temporal nerve~Auriculo-temporal nerve~Posterior auricular branches of the greater auricular Nerve~The greater, lesser, and third occipital nerves"
46068468|NCT02866409|Procedure|infiltration|The incision site was infiltrated with drug. {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}.
46068469|NCT02866409|Drug|Dexmedetomidine|Dexmedetomidine was administered as a dose of 1 µg/kg in 20 ml 0.25% bupivacaine for scalp block or infiltration.
46068470|NCT02866409|Drug|Bupivacaine|20 ml of Bupivacaine 0.25% was administered to the patients either in the form of scalp block or infiltration
46068471|NCT04136925|Other|questionnaire|questionnaire before and after race
46068472|NCT02867969|Other|Motor training|The motor training will comprise of demanding coordinative exercises based on commercially available developed by Microsoft Game Console (XBOX Kinect™) exergames that specifically target ataxia dysfunctions.
46068473|NCT00694785|Drug|ARC1779|"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.7 mg/kg given over the remaining 72 hours at a rate of 0.0004 mg/kg/min.~Group NT3"
45444969|NCT01306695|Behavioral|New York University Caregiver Intervention (NYUCI)|"The NYU Caregiver Intervention (NYUCI) has substantial evidence of efficacy. This intervention is unique in its emphasis on family support and in providing ongoing availability of the counselor. While the NYUCI is being implemented in several communities, its effectiveness in the Hispanic community of Northern Manhattan has not been tested. The first component of the intervention consists of two individual and four family counseling sessions that include relatives suggested by the caregiver. The second component of the intervention is participation in a support group to provide the caregiver with continuous emotional support and education. The third component of the treatment is ad hoc counseling the continuous availability of counselors to caregivers and families to help them deal with crises and with the changing nature and severity of their relatives' symptoms over the course of the disease."
46068474|NCT00694785|Drug|ARC1779|"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.3 mg/kg given over the next 72 hours.~Group T3"
46068475|NCT00694785|Drug|ARC1779|"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.8 mg/kg given over the remaining 72 hours at a rate of 0.0009 mg/kg/min.~Group NT6"
46068476|NCT00694785|Drug|ARC1779|"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.0 mg/kg given over the remaining 72 hours.~Group T6"
45444970|NCT01306695|Other|Community Health Worker (CHW) Case Management|The CHW intervention will consist of 2 visits in month 1, followed by monthly visits until month 6. The main role of the CHW will be to provide access to existing education and referral resources about dementia and caregiving. The CHW will carry a blackberry or iPhone type device with real time access to email, text, the internet, and telephone. Thus, the CHW will be able to provide participants with real time information from pertinent websites such as CUMC, Alianza, and the NY chapter of the Alzheimer's Association. CHW will also provide participants with their phone number and email address for ad-hoc contacts.
45444971|NCT01305837|Drug|methylprednisolone|500 mg of methylprednisolone taken in 3 days every month
45444972|NCT03790995|Procedure|Robot assisted laparoscopic prostatectomy|
45609146|NCT05398991|Device|the Coronary Covered Stents System manufactured by Shanghai MicroPort Medical (Group) Co., Ltd.|the Coronary Covered Stents System contains a covered stent and a delivery system
45609147|NCT05320783|Other|music|Classical music pre-selected was started to the patients with individual comfortable volume.
45609148|NCT05320783|Other|control|music player was not started.
45609149|NCT04453865|Behavioral|Project EMPOWER|Project EMPOWER is a web-based, self-administered SSI for parents that takes about 30 minutes to complete
45609150|NCT04453865|Other|Online Resources and Referrals|Information sheet containing materials about the nature of child anxiety and a list of national resources related anxiety treatment.
45758011|NCT01963143|Biological|Gammaplex 10|
45758012|NCT03822351|Drug|Durvalumab + Oleclumab|Durvalumab + Oleclumab
45758013|NCT03822351|Drug|Durvalumab|Durvalumab
45758014|NCT03822351|Drug|Durvalumab + Monalizumab|Durvalumab + Monalizumab
45758015|NCT04486599|Device|Electromagnetic Navigation|The echo-guided sclerotherapy procedure, assisted by electromagnetic navigation, will be carried out in a clean room during the day hospitalisation and followed by a control Echo-Doppler carried out 2 hours after the procedure.
45758016|NCT01963845|Drug|Sitagliptin|
45758017|NCT01963845|Drug|Placebo|
45758018|NCT02332863|Device|Back-loaded Needle (Device)|"Fiducial marker placement via a traditional 22G back-loaded needle will be performed with multiple endpoints recorded:~total length of procedure~how many markers are successfully deployed~technical success~Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation."
45758019|NCT02332863|Device|Preloaded Needle (Device)|"Fiducial marker placement via a novel 22G preloaded needle will be performed with multiple endpoints recorded:~total length of procedure~how many markers are successfully deployed~technical success~Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation."
46068477|NCT05834010|Biological|Fecal Microbiome Transplant|Fecal matter from healthy age/sex matched established and screened donors, recruited from the Danish Blood-donor system
46068478|NCT05833997|Procedure|Monopolar Transurethral resection of bladder tumor|"Patients randomized to Monopolar TURBT will be operated using a 26F continuous-flow resectoscope sheaths and a single-pole working element to exclusive use of the resection. The power will be set to cut in 80w and 60w. The technique that will be performed will be the classic endoscopic resection from the top of the tumor until reaching the base, taking a sample from the base of the lesion (muscle layer). Fragments will be removed through an Ellik evacuator, and the solution used will be 3% glycine. After the procedure, the patient will will be catheterized with a silicon catheter number 22F with three ways and continuous irrigation.~After 30-60 days of the first procedure, all patients diagnosed with a lamina propria invasion in the uro-pathology analysis (T1) will be submitted to a new monopolar TURBT."
45444973|NCT01306773|Drug|H1N1 convalescent plasma and oseltamivir|Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma containing >= 1:160 of neutralizing antibody to Pandemic influenza A H1N1
45758020|NCT01963923|Behavioral|Pulmonary Rehabilitation Program|The pulmonary rehabilitation program includes an endurance training with a cycloergometer, a strength training with elastic bands and two dairy sessions of incentive spirometry with a volume-oriented device.
45758021|NCT01965561|Device|CRoC|Use of Combat Ready Clamp (CRoC)
45758022|NCT01965561|Device|AAJT|Use of Abdominal Aortic and Junctional Tourniquet (AAJT)
45758023|NCT01965561|Device|JETT|Use of Junctional Emergency Treatment Tool (JETT)
45758024|NCT01965561|Device|SJT|Use of SAM Junctional Tourniquet (SJT)
45758025|NCT02984462|Procedure|percutaneous Akin osteotomy|The act to AKIN is osteotomy in percutaneous; This technique can be performed with or without fixation, and both methods make reference in the literature. With fixation method to get rid of the risk of loss of the surgical reduction of the misalignment, but requires an additional surgical procedure marked by the implementation of a percutaneous cannulated screw on part of the osteotomy. Without fixing method allows to get rid of this gesture, and risk a possible annoys by osteo-synthesis material. Surgical dressings of surgery of hallux valgus allow to keep the reduction for 15 days. Both techniques give excellent results and are performed in our service of routinely.
45758026|NCT03207854|Procedure|Biospecimen Collection|Undergo collection of peripheral blood, bone marrow, and tissue
45758027|NCT03207854|Other|Laboratory Biomarker Analysis|Correlative studies
45758028|NCT03207854|Other|Questionnaire Administration|Ancillary studies
45758029|NCT00658619|Drug|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
45758030|NCT00658619|Drug|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
45444974|NCT01306773|Drug|Oral Oseltamivir alone|Oral Oseltamivir 75mg bid during ICU hospitalization
45444975|NCT05557305|Device|Videogame therapy|There will be 5 video game-type applications for virtual therapy, each with a specific therapeutic objective, which will be administered by trained personnel, depending on the characteristics of each patient.
45444976|NCT05557305|Other|Conventional therapy|Occupational therapy with different play materials
45444977|NCT03788499|Other|Massage of Maxillofacial and Oral Cavity|Massage of Maxillofacial and Oral Cavity is performed five times a day, each part lasts 1-2 minutes, repeating 3 cycles. The maxillofacial and oral massage last from the first day of radiotherapy to three months after last radiotherapy.
45444978|NCT03790761|Behavioral|PREP 8.0 Curriculum|The PREP 8.0 curriculum is an experiential curriculum designed to be implemented in a workshop or educational setting. Using techniques of cognitive-behavioral marital therapy and communication-oriented marital enhancement, PREP aims to help couples achieve high levels of relationship functioning and prevent marital problems. The PREP approach is based on research in the field of relational and marital health and success conducted at the University of Denver.
45444979|NCT03788265|Device|Lipogems|harvest and inject micro-fragment adipose tissue
45444980|NCT03788031|Other|Acuity training|The intervention will be a vision therapy. On each trial, a properly oriented stimulus will be presented randomly at one of the four locations on a flat monitor screen. The visual task is to identify the location of the stimulus.
45609151|NCT03447691|Drug|Des (volatile anesthetic-desflurane)|Inducing unconciouness with 1.5 to 2 mg/kg of propofol, Intubation is performed 3 minutes after administration of remifentanil 1-2 mcg / kg and rocuronium 0.6 mg / kg. Desflurane concentration is maintained 3-7% (0.7-1.1 MAC) and remifentanil continuous infusion (0.02-0.2 mcg / kg / min).
45609152|NCT03447691|Drug|TIVA (Total intravenous anesthesia with propofol and remifentanil)|TIVA group is administered with intravenous anesthetic using commercial target controlled infusion (TCI) pump. Anesthesia is induced and maintained with 2-6 mcg / ml propofol and 2-6 ng / ml remifentanil, which are converted to the effect site concentration. After administrating rocuronium 0.6mg/kg, intubation is performed.
45758031|NCT00658619|Other|Sham (no implant)|Sham in one or both eyes on Day 1 and Month 6.
45758032|NCT01966419|Drug|ornithine phenylacetate|Ornithine phenylacetate for continuous IV infusion at dose levels predicated on level of hepatic decompensation
45758033|NCT01966419|Drug|placebo intravenous infusion|Placebo for continuous IV infusion that is visually identical to the experimental product
45911414|NCT02007837|Drug|Combined aspirin and multinutrient supplement|Single capsule with 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12 mixed.
45911415|NCT02007837|Other|Daily text reminder text messages|
46068479|NCT05833997|Procedure|Holmium Laser resection of bladder tumor (HoLEBT)|"It will be used a 24-26F continuous-flow resectoscope sheath with a specific working element to use with a 600µm fiber to Laser Holmium.~Patients will be operated with the Megapulse 70w (Richard Wolf) and laser will be set to deliver the energy of 0,5J and 30-40Hz frequency, 15-20W of final energy. The solution used will be 0,9% saline solution. The resection will start from the base of the lesion, reaching the muscle layer to obtain a sample and resection of the whole tumor, without fragmentation. After this, the morcellation will be performed in the apex of tumor sparing the base with a long nephroscope, and the patient will will be catheterized with a silicon catheter number 22F with three ways and continuous irrigation. The morcellated product will be sent to the pathology lab for detailed analysis."
46068480|NCT05833984|Drug|IMM01|IMM01 (1.0, 1.5, 2.0 mg/kg) QW IV in the dose escalation part. IMM01 (dose determined in the dose escalation part) QW IV in the dose expansion part.
45758034|NCT01966809|Drug|Photofrin photodynamic therapy.|"The subjects will receive a dose of 2.5 mg/kg of Photofrin intravenously 24 hours before planned surgical resection. Tumor resection will be carried out in the standard fashion in order to achieve the maximum tumor resection compatible with preservation of neurological function. After resection, Intralipid will be infused into the craniotomy and kept for approximately 45 min, while PDT will be performed. The illumination time will be calculated from the power density (mW) emitted by the laser and the radius (r) of the cavity to deliver a total light dose of 240 J/cm2 at a using the following formula:~Treatment Time (sec) = Light dose (J/cm2) x Cavity surface (cm2) x 1000 Power density (mW) Cavity Surface (cm2) = 4 x 3.14 x r2 The optical fiber will be placed in the center of the surgical cavity and photoillumination will commence. After PDT, the Intralipid solution will be removed and the wound will be closed. The subject will be sent to the intensive care area for recovery."
46068481|NCT05833984|Drug|Tislelizumab|Tislelizumab 200mg Q3W IV
45609153|NCT03524209|Device|Percutaneous instrumentation of the thoracolumbar spine|The spine is stabilized cranially and caudally of the level of spondylodiscitis. The percutaneous instrumentation consists of a rod and pedicle screw construct. The vertebrae are instrumented through minimal skin incisions using a fluoroscopic guidance or a spinal navigation system based on 3D imaging.
45609154|NCT03524209|Other|Brace|Brace treatment is associated in patients presenting back pain and a risk for vertebral body collapse due to infection with subsequent kyphotic deformity of the thoracolumbar spine
46068482|NCT05833971|Drug|cadonilimab+chemotherapy|cadonilimab plus cisplatin and Nab-PTX, Q3W
46068483|NCT05833932|Drug|Suhexiang Pill|Suhexiang Pill is an approved traditional Chinese patent medicine.
46068484|NCT05833919|Drug|Eribulin Mesylate|"The dose of Eribulin as the ready to use solution is 1.23 mg/m2 which should be administered intravenously over 2 to 5 minutes on Days 1 and 8 of every 21-day cycle. The amount of Eribulin required (calculated above) will be withdrawn from the appropriate number of vials into a syringe. This may be injected directly as an IV bolus over 2-5 minutes or diluted in up to 100 ml 0.9% sodium chloride (NaCl) for IV infusion over 2-5 minutes.~The dose of Eribulin may be reduced or discontinued during any cycle in accordance with the toxicity modifications described in this chapter. Toxicities will be managed by treatment interruption and dose reduction. Once the dose has been reduced, it cannot be increased at a later date"
46068485|NCT05833919|Drug|Capecitabine|Capecitabine use in breast cancer is registered as monotherapy in advanced breast cancer after failure of a taxane- and anthracycline-containing chemotherapy or for patients for whom an anthracycline is contraindicated. Capecitabine is available in tablets of 150 and 500 mg. The recommended dose as a single agent is 1,250 mg/m2 b.i.d. (twice daily) for 14 days repeated on day 22. The tablets should be swallowed with water within 30 minutes after a meal. Caution is recommended in patients with ischemic heart disease or coronary artery disease and/or in therapy with sorivudine and analogs, coumarins, and phenytoin.
46068486|NCT05833893|Drug|XPO1 inhibitor|COPL + XPO1 inhibitor (Selinexor, 60 mg, po., d1,8,15)
46068487|NCT05833867|Drug|Sacituzumab govitecan|8 mg/kg Sacituzumab Govitecan is to be administered intravenously in 21-day cycles on Day 1 and Day 8; the next cycle should start a minimum of 14 days after the Day 8 dose (i.e., the Day 8 infusion will be counted as the first day of that 14-day period).
45609155|NCT05398835|Behavioral|Online interventions promoting HIV self-testing|1) viewing an online video promoting HIVST, 2) visiting the project webpage containing demonstration video of how to use HIVST kits, information about local HIV epidemic and benefits of HIV testing and HIVST, and a discussion forum containing positive feedback of HIVST users, and 3) having access to a chargeable HIVST services implemented by the CBO
46068488|NCT05833867|Radiation|Adaptive Radiotherapy|Concurrently, participants will receive an individualized tailored plan for radiation therapy.
45609156|NCT04601909|Drug|FX-322|active comparator
45609157|NCT04601909|Other|placebo|placebo
45609158|NCT04923659|Drug|Carbamazepine|600 mg reconstituted as one table. Administered once
46068489|NCT05833854|Other|Virtual reality glasses group|It is suggested that the use of virtual reality glasses during the injection will positively affect the pain and fear levels in children who received penicillin injection in the pediatric emergency department where the study was conducted.
45609159|NCT04923659|Drug|Lorazepam|2.5 mg mg reconstituted as one table. Administered once
45609160|NCT04923659|Drug|Dextromethorphan|150 mgmg reconstituted as one table. Administered once
45609161|NCT04923659|Drug|Nimodipine|30 mg reconstituted as one table. Administered once
45444981|NCT03788031|Other|Occlusion therapy|Participants will be required to patch the good eye for 20 days, 1 hour per day.
45609162|NCT04923659|Drug|Placebo|Administered once
45609163|NCT05398679|Drug|Cefaclor|cefaclor intravenous 2 gr/day
45609164|NCT05398679|Drug|Ciprofloxacin Tablets|500-750 mg/12 hrs (maximum 3g x day)
45609165|NCT05398679|Drug|Ciprofloxacin Injection|1200 mg/day maximum dose IV
46068490|NCT05833854|Other|Manual pressure group|In the pediatric emergency department where the study was conducted, pressure will be applied to the area to be injected for 10 seconds before the injection procedure in children who received penicillin injection. Pressing with the thumb of the hand, which will be passive in the pressing application, will be understood by the whitening of the nail, and thus pressure will be applied to the skin. It is suggested that it can positively affect pain and fear levels.
46068491|NCT05833841|Diagnostic Test|Surface Electromyography and Video fluoroscopy|Surface EMG of three muscle groups (masseter, submental, and infrahyoid) and video fluoroscopy with Omnipaque
46068492|NCT05833828|Procedure|on-pump surgery|"the surgery will be performed on-pump"
46068493|NCT05833828|Procedure|off-pump surgery|"the surgery will be performed off-pump"
46068494|NCT05833815|Drug|Everolimus 10 mg|Oral Everolimus 10 mg daily in addition to standard of care i.e. GemOx or CapOx
46068495|NCT05833815|Drug|Standard of care|GemOx or CapOx
46068496|NCT05833802|Other|virtual anti-cancer drug|the virtual anti-cancer drug was formulation generated by computer modeling and artificial intelligence technology
46068497|NCT05833789|Device|Magnetic Flexible Endoscope (MFE)|After colonoscopy has been completed with the legacy colonoscope, the MFE will be introduced into the colon and traverse from the rectum to the cecum.
46068498|NCT05833763|Drug|Glofitamab|Glofitamab is provided as liquid concentrate for IV infusion. Each vial contains 10mg of glofitamab.
46068499|NCT05833763|Drug|Pirtobrutinib|Pirtobrutinib is supplied as immediate release film-coated tablets containing 50 mg, or 100 mg of active compound. Tablets are supplied in labelled, HDPE bottles and sealed with child-resistant closures.
46068500|NCT05833763|Drug|Obinutuzumab|Obinutuzumab is provided as a single dose 1000 mg liquid concentrate for infusion containing of 25 mg/mL obinutuzumab.
46068501|NCT05833763|Drug|Tocilizumab|Tocilizumab is provided as a liquid concentrate for IV infusion. Each vial contains 200mg/10mL concentrate solution
46068502|NCT05833750|Other|Reflexology|In the intervention group, reflexology was applied to the feet twice a week for 8 weeks.
45758035|NCT03744429|Other|Mediterranean Diet|Participants will be provided with meals that follow a Mediterranean meal plan.
46068503|NCT05833737|Drug|Belantamab mafodotin|Injection for refractory/relapsed multiple myeloma
46068504|NCT05833724|Drug|Chidamide|Subjects will receive a single dose of 30 mg chidamide. Twice a week.
45758036|NCT01967121|Device|Compex unit's Active Recovery® program|Compex unit's Active Recovery® program will be performed for 15 minutes once per day.
46068505|NCT05833711|Drug|Froniglutide|SC Weekly Injection
46068506|NCT05833711|Drug|Placebo|SC Weekly Injection
45609166|NCT05398679|Drug|Clindamycin Oral Capsule|600 mg/8 hours (maximum 1.800 mg x day)
45609167|NCT05398679|Drug|Clindamycin Injection|600 mg/8 hours (maximum 1.800 mg x day) IV
45609168|NCT05398679|Drug|Dicloxacillin Oral Capsule|1g/8 hours (maximum 4 gr day)
45609169|NCT05398679|Drug|Dicloxacillin|1g/8 hours (maximum 4 g x day) IV
45609170|NCT05398679|Drug|Fusidic Acid Only Product in Oral Dose Form|0,750g/12 hours (maximum 1,5 g x day)
45609171|NCT05398679|Drug|Fusidic Acid Only Product in Parenteral Dose Form|0,75 g/12 hours (maximum 1,5 g x day)
45609172|NCT05398679|Drug|Levofloxacin Oral Tablet|0.5g/12-24hours (maximum 1 g x day)
45609173|NCT05398679|Drug|Levofloxacin Injection|0.5g/12-24hours (maximum 1 g x day)
45758037|NCT01967121|Other|Ice application|Participants will apply ice on their hamstring for 15 minutes three times per day until muscle soreness is no longer present
45758038|NCT04575584|Drug|Molnupiravir|Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
45758039|NCT04575584|Drug|Placebo|Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
45758040|NCT04277702|Drug|Montelukast 10mg|Oral administration of 10mg of montelukast daily for 12 months
45758041|NCT04277702|Procedure|Endovascular treatment|Percutaneous transluminal angioplasty combined with bare-metal stenting of lower limbs arteries
45758042|NCT04277702|Drug|Standard anti-platelet treatment|Standard antithrombotic treatment for patients undergoing endovascular procedures
46068507|NCT05833698|Diagnostic Test|Elevation of NLR|Blood test
46068508|NCT05833685|Other|no intervention|no intervention
46068509|NCT05833672|Drug|Terelizumab|q3w Terelizumab 200mg on day 1 of each cycle
46068510|NCT05833672|Drug|CapeOx|Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
46068511|NCT05833659|Procedure|The breast reconstruction method after single-port insufflation endoscopic nipple-sparing mastectomy|Group A:The prepectoral breast reconstruction. Group B:The subpectoral breast reconstruction
45609174|NCT05398679|Drug|Linezolid Oral Tablet|0,6 g/12 hours (maximum 1200 mg x day)
45609175|NCT05398679|Drug|Linezolid Injectable Product|0,6 g/12 hours (maximum 1200 mg x day)
45609176|NCT05398679|Drug|Moxifloxacin tablet|0,4 g/day (maximum 400 mg x day)
45609177|NCT05398679|Drug|Moxifloxacin Injectable Product|0,4 g/day (maximum 400 mg x day)
45609178|NCT05398679|Drug|Rifampicin Only Product in Oral Dose Form|0,3-0,5 g/12 hours (maximum 1200 mg x day)
45609179|NCT05398679|Drug|Rifampicin Only Product in Parenteral Dose Form|0,3-0,6 g/12 hours (maximum 1200 mg x day)
45609180|NCT05398679|Drug|Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]|sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)
45609181|NCT05398679|Drug|Sulfamethoxazole / Trimethoprim Injectable Product|sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)
45609182|NCT05398679|Drug|Tedizolid Oral Tablet|200 mg tedizolid (maximum x day)
45609183|NCT05398679|Drug|Tedizolid Injection|200 mg (maximum x day)
45609184|NCT05398679|Drug|Amoxicillin Capsules|1 gr/6 hours (4 g x day)
45609185|NCT05398679|Drug|Amoxicillin|1 gr/6 hours (4 g x day) Intravenous
45609186|NCT05398679|Drug|Cefaclor Capsules|2 gr/day
45609187|NCT04817501|Other|Taking 5 ml of venous blood at different time intervals|
45609188|NCT04817501|Other|Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any|
45758043|NCT03999788|Procedure|lumbar puncture and blood withdrawal|lumbar puncture performed to detect OCB for diagnostic purposes and blood withdrawal for SNP screening
45444982|NCT03790605|Drug|1 % curcumin chip|CURCUMIN CHIP: 4x5x0.5mm chip of 1% curcumin in biodegradable hydroxy propyl methyl cellulose vehicle
45609189|NCT04634279|Behavioral|Collaborative care Plus|Collaborative care consists of a team of providers that includes a care coordinator, a primary care provider (PCP) and a behavioral health consultant (BHC), who provide evidence- and measurement-based care to a panel of patients using a clinical registry. In this model, the CC team also includes a behavioral health psychotherapist (BHP) who consults on a regular basis but does not deliver direct care. In the Collaborative Care Plus condition, the care coordinator involves family in care, teaches family about naloxone use, and provides Caring Contacts, a suicide prevention method, to patients.
45609190|NCT04617353|Procedure|NO-based treatment of sterno-mediastinitis|"Preparation of a postoperative wound in case of infectious complications. A mandatory sampling material for culture and antibiotic sensitivity is collected before and after the air plasma flow treatment.~Direct effect of the air-plasma flow on the entire wound surface in sterilization mode with an exposure of 2-3 minutes for each surgical wound, until the level of bacterial contamination decreases to 10-5 and below.~The technique of using air-plasma flow when closing a wound after preventing infectious complications in it.~In the postoperative period, daily air-plasma flow treatment in sterilization mode along the suture line for 3 minutes. Penetrating drainage NO supply in the biological stimulation mode daily for 10 days, with an exposure of 1-2 minutes up to 10 days, with a volume of up to 2 liters per minute.~Collecting wound culture from the drainage containers on 1-3-7-12 days to detect pathogens and the bacterial number."
45609191|NCT04617353|Procedure|Treatment of sterno-mediastinitis|patients who were treated for sterno-mediastinitis according to clinical guidelines, the main method of which is a permanent irrigation and aspiration flow drainage method, as well as a Vacuum Assisted Closure (VAC) system of dressings for vacuum drainage
45911416|NCT02007850|Drug|ropivacaine|Patients receive 15 ml of 0.25% ropivacaine pre-operatively through femoral block catheter, followed by 0.2% ropivacaine continuous mode or patient controlled mode for 2 days after surgery
46068512|NCT05833646|Device|Group 1|In each group, patients will be applied both standard subcutaneous heparin injection and with ShotBlocker.
46068513|NCT05833646|Device|Group 2|In each group, patients will be applied both standard subcutaneous heparin injection and with virtual reality glasses.
46068514|NCT05833646|Device|Group 3|In each group, patients will be applied both standard subcutaneous heparin injection and with cold application.
46068515|NCT05833594|Dietary Supplement|Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs|The Experimental group received a combination of omega-3 fatty acids, and glutamine, whereas the control group received standard formula.
46068516|NCT05833581|Other|New York Heart Association Classification Guide|The New York Heart Association Classification Guide is a questionnaire that assists in guiding the provider in selection of the patient's class
46068517|NCT05833568|Device|Active Transcranial alternative current stimulation|"GTEN 200 (Magstim-EGI, OREGON, USA). The current will be administered via an amplifier connected to an EEG system of 128-Channel Geodesic Sensor Net (Magstim-EGI, Oregon, USA) with sponge-based electrode nets.~tACS stimulation will be applied for 20 minutes for 5 consecutive days via a bilateral electrode montage of 5 electrodes per hemisphere over parieto-occipital cortical sites. Specific stimulation electrodes for both conditions will be: [right hemisphere: E83, E90, E96, E84, E91] and for the [left hemisphere: E58, E65, E70, E66, E59]. The intensity of the applied alternative current (AC) will be a maximum of 1 mA peak-to-peak. The stimulation frequency will be adjusted to 10 Hz (median value of the alpha frequency band) for the tACS condition."
46068518|NCT05833568|Device|SHAM Transcranial alternative current stimulation|"GTEN 200 (Magstim-EGI, OREGON, USA). The current will be administered via an amplifier connected to an EEG system of 128-Channel Geodesic Sensor Net (Magstim-EGI, Oregon, USA) with sponge-based electrode nets.~SHAM stimulation will be applied for a 2-minute ramp-up, then the current will stop for 20 minutes, followed by a 2-minute ramp-down. This will be applied for 5 consecutive days via a bilateral electrode montage of 5 electrodes per hemisphere over parieto-occipital cortical sites. Specific stimulation electrodes for both conditions will be: [right hemisphere: E83, E90, E96, E84, E91] and for the [left hemisphere: E58, E65, E70, E66, E59]. The intensity of the applied alternative current (AC) will be a maximum of 1 mA peak-to-peak. The stimulation frequency will be adjusted to 10 Hz (median value of the alpha frequency band) for the ramp-up and down in the SHAM conditions."
46068519|NCT05833555|Behavioral|MH task-sharing training|Providers will be trained to screen for MH, provide education, refer, and coordinate to range of social services. MH training typically consists of education and resources, such as one-time workshops and toolkits, provided with limited technical assistance.
46068520|NCT05833555|Behavioral|Supervision|Additionally, Community Health Workers (CHWs) will receive bi-weekly group supervision for the first 6-months, and monthly supervision for the remaining year on Zoom from a supervisor at Center for Innovation in Mental Health.
46068521|NCT05833555|Behavioral|Learning Collaborative|A learning collaborative with multidisciplinary teams from various healthcare organizations will support continuous quality improvement and develop develop structured approach to improve provision of care.
46068522|NCT05833555|Other|Technology Intervention|To be determined by community crowdsourcing after the first phase of implementation of the multisector collaborative care for MH task-sharing.
46068523|NCT05833542|Behavioral|Health education materials|Participants will receive informational material (designed to be self-guided), including a video and an information sheet about current HIV treatment options (i.e., long-acting injectable and daily oral antiretroviral therapy). These materials will provide a comparison of the risks and benefits of long-acting injectable and oral regimens, set expectations about clinic visits, present information about side effects, and provide additional resources for patients to assist them in preparing to discuss HIV treatment and support options with their medical case manager and clinical provider. Participants receiving this intervention will be offered/pointed to these materials by a medical case manager or patient navigator and will be encouraged to review the materials on their own, but may also go over the materials with staff during a medical case management visit.
45444983|NCT03790605|Other|Placebo chip|PLACEBO CHIP: 4x5x0.5mm chip (identical to test chip except for the active therapeutic ingredient) in biodegradable hydroxy propyl methyl cellulose vehicle
45444984|NCT03790605|Procedure|Scaling and root planing|Routine full mouth scaling and root planing within 48 hours will be performed at baseline prior to local placement of the chips
46068524|NCT05833542|Behavioral|Patient-provider decision tool|Participants will receive a shared patient-provider assessment and decision-making tool, utilizing techniques from Motivational Interviewing and based on the Ottawa Patient Decision Aid framework, for weighing each patient's treatment options and their fit to patient interests, needs, assets, and constraints. The tool will facilitate and record patient-provider agreement on an antiretroviral treatment and support-services plan, to be integrated into the broader existing medical case management care plan signed by both patient and provider. The tool will be administered during a medical case management visit and completed by the participant and a patient navigator or medical case manager.
46068525|NCT05833516|Diagnostic Test|Cardiac Catheterization|The primary operators will wear real time radiation dose monitoring at the left eye, right eye, thorax and abdomen level. At the end of each cardiac catheterization procedure the cumulative radiation dose (measured in µSv) data at each level will be collected. Difference in the cumulative radiation dose exposure between both the study groups (HARRA vs left arm drag over) will be analyzed.
46068526|NCT05833503|Behavioral|Integrative Couple Treatment for Addiction (ICT-A)|Couple-based intervention called Integrative Couple Treatment for Addiction (ICT-A).
45609192|NCT04867421|Other|No intervention|No intervention
45444985|NCT03788109|Procedure|device: combined solid state HRiM|The HRiM catheter (Medical Measurement Systems, Enschede, The Netherlands) incorporating 36 pressure sensors, spaced at 2 cm in the stomach and esophagus and at 1 cm in the LES and upper esophageal sphincter (UES), and 16 impedance channels throughout the esophagus, will be placed transnasally, after topical anesthesia. Manometry will be used to record pressures in the stomach, the esophagus, the LES and the UES. In this way, it is possible to detect and characterize TLESRs, and to measure GA. The impedance channels will be used to measure bolus movement, and thus to detect and characterize gastro-esophageal reflux.
45444986|NCT03787953|Drug|Anti-PD-1/PD-L1 antibodies|The study is a real-world study. According to the actual medical history of patients, the usage of anti-PD-1/PD-L1 antibodies was collected.
45444987|NCT05590689|Drug|Gliolan|A repetitive dose of Gliolan will be administrated in combination with radiotherapy (radiodynamic therapy)
45609193|NCT05398055|Drug|Azithromycin + Doxycycline|azithromycin 500 mg orally every 24 hours for three dose plus doxycycline 100 mg orally every 12 hours for 7 days
45609194|NCT05398055|Drug|Placebo + Doxycycline|doxycycline 100 mg orally every 12 hours for 7 days plus placebo 1 capsule every 24 hours, 3 doses
45609195|NCT05397977|Device|mechanical traction group|"In the mechanical traction group, 26 people with cervicogenic headache will be traction with the Chattanooga Tru Trac traction device, 6 days a week for 2 weeks.~Persons to be mechanically traction will be placed on their backs on the treatment bed with their necks on the neck collar of the device. After the patients are fixed to the head, the pulling force of the device will start with 10% of the patient's body weight, the device will be set as 60 seconds of pulling force and 20 seconds of relaxation. In subsequent sessions, the pulling force will be gradually adjusted based on the patient's previous traction therapy, tolerance, and symptom response. Each session will take 15 minutes.~Participants will be given 20 minutes of TENS, 20 minutes of hotpack and 4 minutes of ultrasound, and the exercise will be given as a home program."
46068527|NCT05833503|Behavioral|Treatment individual as usually offered|Individual-based treatment as usually offer by the specialized centres in addiction.
46068528|NCT05833477|Drug|Recombinant human erythropoietin|Recombinant human erythropoietin treatment three times per week for three weeks
46068529|NCT05833451|Other|Reiki|Reiki, one of integrative practices, is an energy therapy involving the use of energy that flows naturally from the hands of the practitioner to strengthen the body's ability to heal itself in order to increase well-being. Reiki improves well-being in many areas, ensures that blood and lymph circulation is maintained properly, regulates blood pressure and pulse rate by stimulating the autonomic nervous system, increases comfort, reduces depression and anxiety levels. In this way, Reiki facilitates physical and mental relaxation and promotes health
46068530|NCT05833425|Device|Respiratory Pressure Meter (MicroRPM)|Peripheral muscle strength, respiratory muscle strength and postural controls of all adolescents will be evaluated. The values of the scoliotic and healthy groups will be compared.
46068531|NCT05833399|Drug|Quetiapine, olanzapine, mirtazapine, carbamazepine, sertraline, amitriptyline, chlorpromazine and risperidone|Medications are prescribed orally for outpatient or inpatient treatment of addicted patients.
46068532|NCT05833373|Device|Vagal stimulation with the device tVNS from tVNS Technologies GmbH|The tVNS device is used to stimulate the Ramus auricularis of the Nervus vagus with a dedicated ear electrode for at least one hour per day on a daily basis. Stimulation frequency is 20Hz, pulsewidth is 200µs and amplitude is determined individually.
45609196|NCT05397977|Other|manuel traction group|"Manual traction, one of Cyriax's neck mobilization techniques, will be applied to the MTG. Vertebrobasilar artery test will be applied to the patients before starting the treatment, and manual traction will be applied to the patients in case the vertebrobasilar artery test is negative. Manual traction technique will be applied to the cervical region for 15 minutes. While applying manual traction, the patient will be placed on his back with his head hanging off the bed. Grasp the occiput with one hand and under the chin with the other. Manual traction will be applied by keeping the neck neutral and the occiput slightly extended. After applying traction for a few seconds, it will be slowly released and returned to the starting position, and the application will be made for 15 minutes.~20 minutes of TENS, 20 minutes of hotpack and 4 minutes of ultrasound will be applied to the participants, and the exercise will be given as a home program."
45609197|NCT04818281|Biological|SARS-CoV-2 VLP Vaccine|VLP adjuvanted vaccine
45609198|NCT04818281|Biological|Placebo|0.9% NaCl
46068533|NCT05833373|Device|Sham stimulation with the device tVNS from tVNS Technologies GmbH|The tVNS device is used to stimulate the Ramus auricularis of the Nervus vagus with a dedicated ear electrode for at least one hour per day on a daily basis. In this case to perform a sham stimulation a non conducting ear electrode is used. The device is set to the same settings with a frequency of 20Hz, a pulsewidth of 200µs and an amplitude that is determined individually.
46068534|NCT05833295|Procedure|Downhill walking|Change in the H/M ratio after a downhill walk.
46068535|NCT05833295|Procedure|Walking on flat ground|Change in the H/M ratio after a Walking on flat ground
45609199|NCT04519541|Device|Non-Invasive Thermal Ablation of the Medial Branch Nerves using the Neurolyser XR|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
45609200|NCT04365101|Biological|CYNK-001|CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
45609201|NCT05397665|Drug|AT-007|AT-007, aldose reductase inhibitor
46068536|NCT05833269|Behavioral|Mindfulness and Compassion based Intercare program for parental burnout reduction (IBAP-BP)|The interventions is an adaptation of an 8-week program called Mindfulness and Compassion based Intercare program designed to reduce burnout. The adaptation includes a parental burnout risk and resource balance framework, focusing on factors such as parental perfectionism, low emotional intelligence, lack of parenting practices, excess parental responsibilities, lack of co-parental support, and lack of social support. The program consists of 8 modules with practical and theoretical activities and daily tasks that require 10-30 minutes. The modules cover topics such as mindfulness, coping with stress, empathy, and self-care. Formal meditation practices include body exploration, sitting, movement, walking, eating, acceptance, compassion, and gratitude. The program also includes descriptions and motivation for practices related to identifying values that promote parenting, time management, attentive parenting techniques, and emotional management.
46068537|NCT05833269|Behavioral|Educational material|On a weekly basis, participants will receive reminder emails highlighting specific risk factors associated with parental burnout. These risk factors include parental perfectionism, low emotional intelligence, lack of parenting practices, excessive responsibilities, and lack of support. Each week, the reminder email will cover a different topic, providing participants with relevant information.
46068538|NCT05833269|Behavioral|Reminder by email|Every week, participants will receive two reminder emails: one with a list of activities to complete during the week and another containing information about parental burnout. This approach aims to support participants in staying engaged with the program.
46068539|NCT05833269|Behavioral|Whatsapp support group|The participants will have the option to join a WhatsApp group with 25 other members from the specific group to receive daily greetings, group support, and have general doubts resolved.
46068540|NCT05833269|Behavioral|Journaling|As part of the mindfulness intervention, participants are required to write in a journal every day with the purpose of cultivating awareness of bodily sensations, emotions, thoughts, and impulses. Each week, the journaling topic focuses on a different area, including pleasant experiences, unpleasant experiences, needs and resources, communication difficulties, and sharing resources. In contrast, the control group's journaling activity involves free writing about everyday issues, thoughts, and ideas.
46068541|NCT05833269|Behavioral|Guided relaxation excercise|Participants receive a 10 and 20-minute relaxation exercise guide called the Jacobson Progressive Relaxation, which they are expected to practice daily.
46068542|NCT05833204|Procedure|Laparoscopic colporrhaphy with 0-caliber barbed absorbable suture|After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber barbed absorbable suture (V-Loc ™, Covidien, Medtronic)
45444988|NCT05590689|Radiation|Radiodynamic therapy|Radiotherapy will be performed in combination with Gliolan administration
45444989|NCT01306851|Drug|Fibrin glue|In the intervention group, 5 or 10 ml of fibrin glue are applied in the anastomotic line.
45444990|NCT03790449|Behavioral|PreLiFe-programme|The intervention group will receive a mobile preconception lifestyle programme (the PreLiFe-programme) in addition to standard care for 12 months or until an ongoing pregnancy is confirmed by ultrasound. The PreLiFe-programme includes a mobile application (PreLiFe-app) with the same treatment information as the attention control group in combination with a lifestyle programme. This new lifestyle programme includes tailored advice and skills training on diet and physical activity and mindfulness exercises. Additionally couples will be offered interaction with a health care provider through text messages and telephone interaction following the concept of blended care.
45444991|NCT03790449|Behavioral|Attention Control Programme|The standard care serving as control for this intervention is fertility treatment i.e. IVF with or without ICSI according to local protocols for infertility patients. This implies no guidance on lifestyle. However, to have attention control the control group will receive an attention control programme. The attention control programme includes a mobile application (app) with treatment information including medication instructions, reminders of injection of human Chorionic Gonadotropin (hCG) and time of fertility treatment appointments for 12 months or until an ongoing pregnancy is confirmed by ultrasound.
45609202|NCT05397665|Drug|Placebo|Liquid oral suspension
45609203|NCT05397509|Other|Olive leaf tea|250 mL of Olive leaf tea and a high-glycemic breakfast
45609204|NCT05397509|Other|Placebo tea|250 mL of placebo tea and a high-glycemic breakfast
45609205|NCT01378325|Drug|Phenylephrine|Prophylactic variable rate of phenylephrine infusion started at 0.75 µg/kg/min vs saline
45609206|NCT01378325|Drug|saline|Prophylactic variable rate of saline infusion where we adjusted the pump at a starting rate of 0.75 µg/kg/min, equivalent to 0.0075 mL/kg/min of saline
45609207|NCT05397275|Other|progressive muscle relaxation+breathe exercises|progressive muscle relaxation+breathe exercises
45609208|NCT05397275|Other|breathe exercises|breathe exercises
45609209|NCT04070105|Device|Compliant Adaptive Energy Storage and Return Foot|The primary concept of the CAESAR foot is to switch from a walking foot to a running foot with the push of a button
45609210|NCT04070105|Device|Conventional Prosthetic Foot|This is a commercial prosthetic foot that has been prescribed to the individual
45609211|NCT04070105|Device|Commercial High Activity Foot|This is a commercially available prosthetic foot designed for high-activity individuals
45609212|NCT04298177|Device|Atrial fibrillation ablation using the QDOT® catheter|Atrial fibrillation ablation will be performed using the QDOT® catheter. The ablation mode will be selected according to the MDCT-derived LAWT information.
45609213|NCT04298177|Procedure|Standard atrial fibrillation ablation|Atrial fibrillation ablation will be performed using the SmartTouch® catheter. The ablation parameters will be adjusted according to the settings previously described in the CLOSE study.
45609214|NCT04288193|Drug|Recommendation to Deprescribe|Recommendation to Deprescribe
45609215|NCT03967379|Behavioral|Mobile App + enhanced standard care|An intervention to help address sexual dysfunction among HCT survivors
45609216|NCT03967379|Other|Enhanced Standard Care|Standard of care administered by the institution
45609217|NCT03855995|Procedure|Whole blood sample|Whole blood samples will be collected from all enrolled children hospitalised and suspected of having an AESI or meningitis.
45609218|NCT05396651|Other|low fodmap diet|elimination of high fodmap diet - High FODMAP diet: ice cream, soft cheese , yoghurt, cabbage , cauliflower, green bean, garlic, okra, onions, snow peas, broccoli, avocado , apple, mango , dates, watermelon, legumes , pulses, wheat , pasta , artificial sweeteners
45609219|NCT05396651|Other|NICE guidelines for IBS|"follow NICE guidelines for IBS :have regular meals and take time to eat. avoid missing meals or leaving long gaps between eating. drink at least 8 cups of fluid per day, especially water or other non-caffeinated drinks, for example herbal teas.~restrict tea and coffee to 3 cups per day. reduce intake of alcohol and fizzy drinks."
45609220|NCT05396573|Biological|RQ3013|A single dose of 30 μg/0.15 mL, a single dose of 60 μg/0.3 mL
45609221|NCT05396573|Biological|Comirnaty|A single dose of 30 μg/0.3 mL
45609222|NCT03854903|Drug|Palbociclib|Palbociclib is taken orally.
45609223|NCT03854903|Drug|Bosutinib|Bosutinib is taken orally.
45609224|NCT03854903|Drug|Fulvestrant|Fulvestrant is given as an intramuscular injection.
46068543|NCT05833204|Procedure|Laparoscopic colporrhaphy with standard 0-caliber absorbable suture|After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber absorbable suture made of a coated braided thread (Vicryl; Ethicon Inc, Sommerville, NJ)
46068544|NCT05833165|Behavioral|Feasibility of a supportive approach|Evaluating reasons for patients to use the approach
46068545|NCT05833152|Procedure|total knee arthroplasty|To observe the postoperative functional outcome of patients with knee extension lag at different angles
46068546|NCT05833087|Behavioral|Schema therapy|30 sessions of schema therapy. The therapy was developed by Jeffrey Young and others and encompasses elements from cognitive behavioral, psychodynamic, and gestalt therapies, as well as attachment theory.
46068547|NCT05833087|Behavioral|Other psychotherapy|In this arm, psychotherapy can be psychodynamic, cognitive behavioral, interpersonal or other evidence-based psychotherapies, aimed at changing cognitions, behavior, improve social relations and uncover unconstructive psychological patterns.
45609225|NCT03812471|Device|3D volume acquisitions|2 abdominal volumes 2 thigh volumes 2 head volumes
45609226|NCT03812471|Device|2D standard measurements and 3D volumes acquisitions|"1 abdomen circumference measurement~1 femur length measurement~1 head circumference measurement~1 bi-parietal diameter measurement~1 abdominal volume~1 thigh volume~1 head volume"
46068548|NCT05833087|Other|Standard care package content|"The patient is offered prescription and monitoring of psychopharmacological treatment of up to 5 hours by a psychiatrist, when appropriate.~Additionally, patients have up to 3 hours of preparatory and diagnostic sessions and up to 4 hours of meetings with the participation of next-of-kin and/or collaboration partners in other public instances."
46068549|NCT05833009|Device|Acupuncture|All the groups receive respective treatment 3 times a week for the first eight weeks, twice a week for another 8 weeks, and once a week for the last 4 weeks.
46068550|NCT05832996|Drug|Refresh Plus Preservative-free Lubricant Eye Drops|Refresh Plus Preservative-free Lubricant Eye Drops at 4 degree Celsius
45609227|NCT01093573|Drug|midostaurin|Given orally
46068551|NCT05832983|Behavioral|Guided Meditation|In private exam room, the study registered nurse (RN) will read a prepared two minute guided meditation to patient.
46068552|NCT05832983|Other|Aromatherapy|In private exam room, study RN will first affix an Elequil Aromatab to patient's clothing on either their upper arm or chest (whichever the patient prefers and/or as clothing allows).
46068553|NCT04274699|Diagnostic Test|Hemosonics Quantra coagulation monitor|There is no categorisation or allocation of any subject to any intervention vs non-intervention group. Blood sampling and the addition of a Quantra coagulation test is the only 'intervention', and the sampling protocol is identical for all subjects. Post-testing treatment of all subjects is as per established routine and Quantra results will not be used by clinical team.
46068554|NCT05832970|Other|Brief skin cooling|Brief skin cooling will be applied to the hand using the cold-bath immersion
45609228|NCT01093573|Drug|azacitidine|Given IV
45609229|NCT01093573|Other|bone marrow aspiration|Correlative study: Pretreatment bone marrow aspirates or blood [(3 ml in EDTA tube (purple top)] will be analyzed according to local institution guidelines to determine whether blasts contain wild type Flt3, ITD, or Flt 3 mutations.
45609230|NCT01093573|Other|mutation analysis|Correlative study
45609231|NCT01093573|Other|Pharmacokinetic study|Correlative study: Concentrations of unchanged midostaurin and its major metabolites, CGP52421 and CGP62221 in plasma samples will be determined using a validated liquid chromatography / mass spectrometry method.
45609232|NCT03484039|Behavioral|Medication Adherence|Some subjects will be enrolled in a medication adherence course.
45609233|NCT03484039|Behavioral|Seizure Documentation|Some subjects will be enrolled in a seizure documentation course.
45609234|NCT03484039|Behavioral|Memory Improvement|Some subjects will be enrolled in a memory improvement course.
45609235|NCT03484039|Behavioral|Stress Management|Some subjects will be enrolled in a stress management course.
45609236|NCT05396339|Drug|IAE0972|IAE0972 is an investigational product
45609237|NCT03367741|Drug|Cabozantinib S-malate|Given PO
46068555|NCT05832905|Behavioral|Mobile and Wearable-assisted Case Management|The MCM group received case management and Mobile-and wearable recording. The actual intervention for Panic disorder, including pharmacotherapy or psychological treatment is the same as in MCM and TAU group
46068556|NCT05832879|Behavioral|OUD Telehealth Platform|The platform is intended to encourage engagement in treatment with medications for opioid use disorder (MOUD) through a chat dialogue with users
45609238|NCT03367741|Biological|Nivolumab|Given IV
45609239|NCT05396261|Device|Film forming silicone gel (7-0940)|Anecdotal evidence suggests that genital conditions in women associated with vaginal atrophy improve with the use of film-forming silicone dressings.
45609240|NCT03402503|Drug|Montelukast buccal film|Film with active investigational product (montelukast) inserted and applied on inner cheek
45609241|NCT03402503|Other|Placebo buccal film|Film with placebo (no active drug) inserted and applied on inner cheek
45653333|NCT05350345|Other|Root-cause analysis|The first part of this study involves a report with a root-cause analysis done by the students. The second part is a gamification in which they have to evaluate each other and give feedback.
45609242|NCT03447613|Procedure|surgery|All participants were scheduled to have elective total hip or knee replacement surgery, ureteroscopic lithotripsy and transurethral resection of the prostate under spinal anesthesia at the Shanghai 10th People's Hospital. After 5 years, the investigaors will follow up the participants including cognitive functions, PET-CT, thickness of Retinal Nerve Fiber Layer.
45609243|NCT03447535|Other|Semi-directive interview (Kiddy Sads)|semi-directive interview (Kiddy Sads) conducted as part of the care
46068557|NCT05832853|Behavioral|Wu Qin Xi exercise|The training schedule for Wu Qin Xi consisted of two phases: the first phase lasted for eight weeks, while the second phase lasted for 16 weeks. In the first phase, Wu Qin Xi group was given twice repetitions of the intervention. The second phase consisted of three repetitions of the Wu Qin Xi group. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
45609244|NCT03447535|Other|SDQ questionnaires (strenghs and difficulties questionnaire)|SDQ questionnaires (strenghs and difficulties questionnaire) conducted as part of the care
45609245|NCT04454177|Device|HUAWEI watch|HUAWEI Watch will be assigned to patients within 24 hours before TAVR. HUAWEI Watch GT series can continuously monitor and record multiple biometric parameters heart rate, step counts, sleep cycles and can detect and record the pulse oxygen saturation, as well as analyze QRS complexes and P waves after triggering.
45609246|NCT05174845|Drug|1L PEG + ASCORBIC ACID|"2-Day Split-Dosing: The patient has taken the product in the evening before the scheduled colonoscopy and mandatory additional clear fluid. The patient has taken the second dose with mandatory additional clear fluids on the morning of the colonoscopy.~Same Day: The patient has taken the first dose of the product on the day of the colonoscopy and take mandatory additional clear fluid. After a 1-2 hour break, the patient has taken a second dose plus additional clear mandatory fluid."
45653334|NCT01364727|Drug|Amrubicin|35 mg/m2; IV on days 1-3 each 3 week cycle
45653335|NCT02633215|Device|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
46068558|NCT05832853|Behavioral|Wu Qin Xi, resistance training and endurance training|During the first 8 weeks, the training consists of learning and consolidating the movements of the Wu Qin Xi. In the second 16 weeks, participants perform a full set of movement exercises. Each resistance training session contained two lower-body exercises (seated calf raises and hip abduction) and three upper-body exercises (lateral pull downs, biceps curls, and triceps push downs) and two sets for each exercise. Endurance training is performed by continuous walking on an undisturbed indoor track for 15 min. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
46068559|NCT05832853|Behavioral|Resistance training and endurance training|Each resistance training session contained two lower-body exercises (seated calf raises and hip abduction) and three upper-body exercises (lateral pull downs, biceps curls, and triceps push downs) and three sets for each exercise. Endurance training is performed by continuous walking on an undisturbed indoor track for 30 min. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
46068560|NCT05832827|Drug|MK-3475|Pembrolizumab will be administered at a dose of 200 mg by intravenous infusion every 21 days (3 weeks) for up to 35 cycles.
46068561|NCT05832827|Drug|Lenvatinib|Lenvatinib will be administered at a dose of 8 mg orally QD every 21 days (3 weeks) for up to 4 cycles in the induction phase, followed by 20 mg QD for up to 31 cycles in the maintenance phase. Then, further maintenance therapy with lenvatinib will be allowed until progression or unacceptable adverse events.
46068562|NCT05832827|Drug|Carboplatin|Carboplatin will be administered at a dose of AUC 5 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.
46068563|NCT05832827|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m^2 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.
46068564|NCT05832801|Other|( low FODMAP diet )|A low FODMAP diet is a group of fermentable, short-chained carbohydrates: Fermentable Oligo-, Di- Monosaccharides, and Polyoles (FODMAP).
46068565|NCT05832801|Other|(Pilates exercises)|Pilates exercises will be in the form of Swan, One leg up-down, Leg circles, Single leg stretch, Saw, Side kicks, The hundred,. Pelvic lift on the ball, Sit-ups with the ball, Stretching on the ball. exercise Dose will be First month (1st-8th session) 1 set of 8 repetitions Second month (8th-16th session) 2 sets of 10 repetitions
46068566|NCT05832775|Biological|MRx0029|Megasphaera massiliensis MRx0029 (Treatment A) and Placebo
46068567|NCT05832775|Biological|MRx0005|Parabacteroides distasonis MRx0005 (Treatment B) and Placebo
46068568|NCT05832762|Procedure|Endovascular treatment (EVT) + Best medical treatment (BMT)|Endovascular treatment (EVT) in the experimental arm can be performed with any recanalization strategy based on the operator's choice, and anatomical and radiological situation: MT using aspiration or stent retriever, with or without stenting (CE-labelled) or angioplasty. In case of acute stenting, the use of antiplatelet drugs will be based on the operator's preference, anatomical situation, and risk of hemorrhage.
46068569|NCT05832762|Procedure|Best medical treatment (BMT)|Administration of drugs is at the treating physician's discretion (for example, intravenous fibrinolysis, anticoagulants, or antiplatelet agents) according to the local standards of care, but not intra-arterial therapies.
46068570|NCT05832749|Device|Ophtesis Bio 3% ophthalmic viscosurgical device|Intraocular surgery of the anterior segment, including cataract extraction and intraocular lens (IOL) implantation. The viscoelastic properties of OphtesisBio 3.0% allow lubrication, support and protection of ocular tissues during ophthalmic surgery. Maintains the depth of the anterior chamber during surgery, allows for efficient manipulation with reduced trauma to the corneal endothelium and other surrounding tissues.
46068571|NCT05832749|Device|Healon Endocoat 3% ophthalmic viscosurgical device|"Healon@ EndoCoat OVD is an ophthalmic viscoelastic containing 3% sodium hyaluronate indicated for use as a surgical aid in patients undergoing ophthalmic anterior segment procedures including:~Cataract surgery with an intraocular lens~Cataract surgery without an intraocular lens~Secondary intraocular lens implantation~Healon@ EndoCoat maintains a deep chamber during anterior segment surgery, aids in tissue manipulation during surgery, enhances visualization during the surgical procedure and protects the corneal endothelium and other ocular tissue. The viscoelasticity of the solution maintains the normal position of the vitreous face and prevents formation of a flat chamber during surgery. It may also be used to coat intraocular lenses and insertion instruments prior to intraocular lens implantation."
46068572|NCT05832736|Procedure|Robotic hemi-prostatectomy with urethral preservation|Robotic hemi-prostatectomy with urethral preservation
46068573|NCT05832723|Device|650 nm low-level red-light|Typically, children who uses the 650 nm low-level red-light will be recruited into this study. The use of any other myopia intervention is not restricted except for low concentrations of atropine. Because atropine will cause pupils dilated, the amount of light entering the eye can not be controlled, and red-light is a laser, to be safe, we need to take certain consideration of the amount of light-entering. Participants receive the 650 nm low-level red-light intervention not because they are enrolled in a study, they would receive the intervention in the same manner and intensity if they were not enrolled in the study.
46068574|NCT05832697|Drug|Ursodeoxycholic Acid 250 Mg Oral Tablet|Administration of Ursodeoxycholic Acid 250 Mg Oral Tablet or Ursodeoxycholic Acid 100 Mg Oral Tablet
46068575|NCT05832684|Drug|ZVS101e|ZVS101e contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human wild type CYP4V2 gene.
46068576|NCT05832671|Procedure|Erector Spinae muscle block|In the ESB group, the patient will be placed in the lateral position. The site of surgery is upward. After skin preparation using 10% povidone-iodine, a high-frequency linear ultrasound transducer will be placed over the ipsilateral site of surgery 1-2 cm lateral to the spine at the T10 level, counting upward from the sacrum. After identifying the erector spinae muscles and transverse process, a needle will be inserted with an in-plane technique in the craniocaudal direction
46068577|NCT05832671|Procedure|caudal block|In the CB group, patients will be placed in a lateral position. An ultrasound transducer is first placed transversely at the midline to obtain a transverse view of the 2 cornua, the sacrococcygeal ligament, sacral bone, and sacral hiatus. At this position, the ultrasound transducer will be twisted to 90° to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and will be subsequently placed between the 2 cornua and on visualization of the frog sign (the 2 sacral cornua identified as 2 hyperechoic reverse U-shaped structure) the needle will be inserted into the sacral canal under direct real-time longitudinal visualization. After negative aspiration for blood or cerebrospinal fluid, bupivacaine (0.25%) 2.5 mg/kg will be injected over a one minute period while observing an ultrasound longitudinal image.
46068578|NCT05832645|Other|Meditation with guided tea consumption|Mindful consumption of tea along with an approximately 10-min guide
46068579|NCT05832645|Other|Breathing meditation|10-min breathing meditation
46068580|NCT05832632|Behavioral|Headspace Basics Program|30-day smartphone-based mindfulness intervention consisting of 10 minutes per day. The program consist of generic mindfulness techniques such as breath awareness, body scans, mindful noting of thoughts and emotions.
46068581|NCT05832632|Behavioral|Headspace Breathing Exercises|30-day smartphone-based breathing exercises. Each exercise consists of box breathing for 1 minute and participants are instructed to complete 10 sessions corresponding to 10 minutes per day.
45934950|NCT00212095|Drug|docetaxel and ketoconazole|"Docetaxel will be obtained locally from the manufacturer. Storage conditions for unopened vials, reconstitution, and storage conditions for the reconstituted solution will follow the manufacturer's recommendations. Docetaxel solutions should be prepared and stored in glass, polypropylene or polyolefin containers. Non-PVC containing and polyethylene-lined administration sets should be used.~Ketoconazole is available commercially in 200 mg tablet. Ketoconazole is to be administered at a dose of 200mg BID orally for six doses, starting two days before docetaxel administration. The fifth dose should be administered on the day of and before administering docetaxel, while the sixth dose should be administered in the evening of the day of docetaxel administration."
46068582|NCT05832632|Behavioral|Headspace Stress Program|20-day smartphone-based mindfulness intervention consisting of 15 minutes per day. The Stress program content is based on well-established concepts and practices within stress management, and mindfulness, and is targeted to people with elevated stress.
46068583|NCT05832632|Behavioral|Active Control (Audiobook)|30-day smartphone-based Audiobook book consisting of 10 minutes per day.
46068584|NCT05832619|Drug|SSRI|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
46068585|NCT05832619|Device|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
46068586|NCT05832619|Device|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20*1.5mm or φ0.20*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
46068587|NCT05832606|Other|Food box containing 30 different plants|Food boxes during first 12 weeks of therapy. Clinical follow-up until end of immunotherapy.
45609247|NCT04157855|Procedure|Abdominal Plane Block(s) with depot Steroids|APB Steroids treatment: under real time ultrasound guidance, a 100 mm needle is introduced into the specified plane (subcostal TAP for upper abdomen pain, posterior TAP for lower abdomen pain or TQL for flank and lower abdominal pain). Normal saline (10 ml) is used to open the fascial plane (saline hydrodissection). Then 40 mg of depomedrone diluted in 10 ml of 0.25% levo-bupivacaine is injected into the plane. . A total of 80 mg of depomedrone (steroid) will be used.
45609248|NCT05320315|Device|Foto Ultra ISDIN® Solar Allergy Fusion Fluid|The tested MD is a very high protection sunscreen
46068588|NCT05832593|Other|Immunohistochemistry|Immunohistochemical expression of ERCC1
46068589|NCT05832580|Drug|Etidronate|Etidronate in capsules of 200 mg or 400 mg.
46068590|NCT05832580|Drug|Placebo|Placebo in similar capsules
46068591|NCT05832567|Device|Active rTMS|Subjects will undergo repetitive transcranial magnetic stimulation, each session lasting 20 minutes.
45609249|NCT04155203|Drug|Mupirocin Calcium|mupirocin cream
45609250|NCT04155203|Drug|Mupirocin Calcium|Reference mupirocin cream
45609251|NCT04155203|Drug|Vehicle|vehicle control cream
45609252|NCT05320081|Biological|CD30 CAR-T|"Subjects need to complete a series of checks before reinfusion of CD30 CAR-T cells as baseline information for subjects after non-myeloablative pretreatment. The subject was reinfused with CD30 CAR-T cells (10±3)×10^6/kg on the 0th day of the first dosing cycle (the investigator decided the specific reinfusion dose based on the subject's own/disease conditions and preparation conditions in vitro ), concurrent oxygen inhalation and monitoring (ECG, blood pressure and blood oxygen monitoring). The reinfusion was completed in about 30 minutes, and the tube was flushed with saline.~Note: CAR-T cell infusion and reinfusion dose are based on the subject's condition."
45609253|NCT05320081|Drug|Camrelizumab|Received Camrelizumab treatment on the 15th day after CAR-T cell reinfusion, and then received Camrelizumab treatment every 2 weeks.
45609254|NCT04238143|Procedure|Tissue Stromal Vascular Fraction (tSVF) Arm 1|Harvesting subcutaneous tSVF with sterile, disposable microcannula system
45609255|NCT04238143|Biological|PRP Concentrate Arm 1|Preparation of PRP Concentrate via sterile Terumo-Harvest System
45609256|NCT04238143|Procedure|Tissue Stromal Vascular Fraction (tSVF) Arm 2|Harvesting subcutaneous tSVF with sterile, disposable microcannula system
45609257|NCT04238143|Biological|PRP Concentrate Arm 2|Preparation of PRP Concentrate via sterile Terumo-Harvest System
45609258|NCT04238143|Procedure|Cellular Stromal Vascular Fraction (cSVF) Arm 2|Isolation-Concentration of cSVF via sterile enzymatic digestion (Liberase TM, Sterile Roche)
45758044|NCT03999788|Procedure|Intermittent theta burst stimulation (iTBS) therapeutic protocol for spasticity|iTBS will be delivered over the scalp site corresponding to the leg area of primary motor cortex contralateral to the affected limb. The active motor threshold (AMT) will be defined as the minimum stimulation intensity required to evoke a liminal motor potential from the Soleus muscle during voluntary contraction. The stimulation intensity will be about 80% of AMT. The iTBS stimulation protocol consists of 10 bursts, each burst composed of three stimuli at 50 Hz, repeated at a theta frequency of 5 Hz every 10 s for a total of 600 stimuli (200 s). If no MEP will be detectable from the contralateral leg, the site of stimulation will be determined as symmetrical to the motor hot spot. If no MEP will be detectable even from the contralateral leg the coil will be held tangentially to the scalp with its centre placed 1 cm ahead and 1 cm lateral from CZ (10-20 EEG system). In these cases, stimulation intensity will be set to 50% of the maximum stimulator output.
45758045|NCT03258632|Behavioral|Drinking Options - Motivate, Shared Decisions, Telemonitor (DO-MoST)|Patients will attend one 50-minute individual session with a Decision Coach (a trained clinical provider, e.g., MSW). Patients in DO-MoST will also attend 6 biweekly 15-minute telephone sessions from the same Decision Coach.
45758046|NCT03257150|Procedure|Irreversible Electroporation|Irreversible electroporation (IRE) is a process that uses the NanoKnife system to sent electrical currents to a cancer tumor which will disrupt the tumor cell and therefore causing the cell to die. Eligible patients will undergo in situ IRE performed via laparotomy surgery.
45758047|NCT03257150|Device|NanoKnife System|A system consisting of electrode probes connected to a machine. The probes will be surgically placed around the tumor.
46068592|NCT05832567|Device|Sham rTMS|Subjects will undergo sham repetitive transcranial magnetic stimulation, each session lasting 20 minutes.
45934951|NCT00212173|Drug|Sibutramine|
45934952|NCT00212173|Dietary Supplement|Slim Fast|
45934953|NCT00212212|Dietary Supplement|selenium|200 µg selenium as selenate
45934954|NCT00212212|Dietary Supplement|selenium|400 µg selenium as selenate
45934955|NCT00212212|Dietary Supplement|selenium|200 µg selenium as selenomethionine
45609259|NCT04238143|Procedure|Cellular Stromal Vascular Fraction (cSVF) Arm 3|Isolation-Concentration of cSVF via sterile enzymatic digestion (Liberase TM, Sterile Roche)
45609260|NCT04238143|Drug|Sterile Normal Saline (IV Solution)|Suspension of cSVF in 500 cc Sterile Normal Saline (IV Solution)
45609261|NCT03447457|Device|High-flow oxygen|HFNC is continuously applied via large-bore nasal prongs with a gas flow rate of 50 L/min and a FiO2 adjusted to maintain a pulse oxymetry at least 92%
45609262|NCT03447457|Device|Standard oxygen|nasal cannula, face mask or non-rebreathing reservoir mask
45609263|NCT05392439|Device|taVNS|transcutaneous auricular vagal nerve stimulation
45609264|NCT05392439|Device|sham-taVNS|transcutaneous stimulation at the elbow area
45609265|NCT04073615|Drug|Rivoceranib|Film-coated tablets
45609266|NCT04073615|Drug|Trifluridine/Tipiracil|Film-coated tablets
45609267|NCT03129529|Device|Focused shock wave|The outcome evaluation include ankle range of motion (ROM), modified Ashworth scale (MAS),modified Tardieu scale (MTS), baropodometric measurement, and gait speed.
45609268|NCT03129529|Device|Radial shock wave|The outcome evaluation include ankle range of motion (ROM), modified Ashworth scale (MAS),modified Tardieu scale (MTS), baropodometric measurement, and gait speed.
45609269|NCT04060199|Drug|Viltolarsen|IV infusion
45609270|NCT04060199|Drug|Placebo|IV infusion
45609271|NCT03447301|Dietary Supplement|Extra virgin olive oil (30mL daily)|Intervention arm will take 30 mL of Extra virgin olive oil daily.
46068593|NCT05832567|Dietary Supplement|Open Placebo|The open placebo will consist of an inactive substance pill commonly used in clinical trials and given to the subject in a regular pill dispenser.
45609272|NCT05387447|Behavioral|Conversational Voice Assistant-Enhanced|Interactive routine is based on tailoring to the participants type of pain and personality.
45609273|NCT05387447|Behavioral|Conversational Voice Assistant-Standard|Interactive routine is a basic interaction with the voice assistant.
45609274|NCT05320003|Diagnostic Test|Inky foot analysis|Inky foot analysis to confirm the diagnosis of pes planus
45609275|NCT05320003|Diagnostic Test|Evaluation of plantar pressure with pedobarography|Evaluation of plantar pressure distribution by pedobarography in individuals with pes planus
46068594|NCT05832554|Device|nasal airway|nasopharyngeal airway
46068595|NCT05832554|Device|oral airway|oropharyngeal airway
46068596|NCT05832528|Other|Low-FODMAP diet|6-week Low-FODMAP diet in patients with functional dyspepsia
46068597|NCT05832515|Drug|Fludarabine Phosphate for Injection|Intravenous injection of fludarabine phosphate at a dose of 30 mg/m2 from day -5 to day -2 of immunoablative conditioning regimen.
45609276|NCT05320003|Diagnostic Test|Balance assessment with computerized posturography|Evaluation of fall risk with computerized posturography
45758048|NCT03256994|Device|Yttrium-90 loaded SIR-Spheres microspheres|Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
45758049|NCT03256994|Behavioral|QLQ-C30 with HCC module|In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT-FR will incorporate a quality-of-life questionnaire. CIRT-FR will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient
45444992|NCT03790527|Procedure|CBM training|participants will be random-assigned into one of training groups. Participants in the modification group will receive modified training of 400 trials for six sessions during six days, the same as the sham group.The difference between these two groups is the proportion of push/pull trials. The sequence of the interventions will be counterbalanced across participants, and the callback will be conduct after one week.
45609277|NCT05303311|Drug|Bupivacaine Hydrochloride|intrathecal injection of bupivacaine alone
45609278|NCT05303311|Drug|Pethidine plus Dexamethasone|Intrathecal injection of pethidine plus dexamethasone
45609279|NCT03304249|Behavioral|iAmHealthy Healthy Lifestyles Program|iAmHealthy is behavioral intervention focused on nutrition, behavior and physical activity that engages parents and children in treatment using mobile health (mHealth) technology. Meetings are approximately one hour. Participants will log in for 8 weekly group sessions, followed by 6 monthly sessions.
45609280|NCT03304249|Other|Newsletter|Weight loss materials delivered via a newsletter. Each newsletter will cover nutritional, exercise, and behavioral suggestions to improve the child's health. The newsletter will be sent in the mail once a month for 8 months.
45609281|NCT03447145|Drug|TQ-B3203|dose escalation, 2/4/6/10/14/18mg/m2
45609282|NCT03127579|Behavioral|Longer meal duration|Participants have 50% more time to eat than usual
45609283|NCT03447067|Procedure|computer guided surgical|has three cutting guided plane for identify the position of place of the third molar, it have beveled cut for stability after remove the teeth and placing the bony window
45609284|NCT03447067|Procedure|Conventional surgery|Low speed motor with surgiacl round burs and surgical fissure for removal a covering bone with decapitation and guttering formation
45609285|NCT03447067|Device|CBCT|For measuring the bone removeal
45609286|NCT03447067|Device|CBCT|for identifed the nerve
45609287|NCT03057613|Drug|Pembrolizumab|200mg every 3 weeks for 16 weeks given by IV infusion
45609288|NCT03057613|Radiation|IMRT 60-66Gy|60-66Gy for 6 weeks
45609289|NCT03446911|Radiation|SABR|Prior to surgery (lobectomy), patients receive stereotactic ablative radiotherapy.
45609290|NCT03446911|Combination Product|SABR + pembrolizumab|Prior to surgery (lobectomy), patients receive stereotactic ablative radiotherapy + 2 rounds of pembrolizumab
45609291|NCT02974621|Biological|Bevacizumab|Given IV
45609292|NCT02974621|Drug|Cediranib|Given PO
45609293|NCT02974621|Drug|Cediranib Maleate|Given PO
45609294|NCT02974621|Drug|Olaparib|Given PO
45609295|NCT02974309|Behavioral|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer
45609296|NCT02974309|Behavioral|Routine|All youth in this condition are asked to follow the routines set by their clinical care team.
45609297|NCT03446833|Device|The LFP Beta aDBS System|The LFP Beta aDBS System is intended for use in patients receiving DBS for Parkinson's Disease where LFPs may be recorded and analyzed.
45609298|NCT03446755|Device|intra uterine Cook balloon|Insertion of a hearth shaped intrauterine balloon immediately after hysteroscopic adhesiolysis and left in place for 7 days under antibiotic prophylaxis.
45609299|NCT02733367|Drug|Infacort®|Infacort® is a dry granule formulation of hydrocortisone stored in capsules available in different strengths (0.5, 1.0, 2.0 and 5.0 mg).
45609300|NCT03446677|Other|Postural Stability Testing|Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks. Data of center of pressure, antero-posterior sways and medial-lateral sways were collected in each of the conditions. Each task took 30 seconds to be performed. The first 4 tasks were performed with the mat on the hard surface of the floor. These 4 tasks are as follows: standing with eyes open, standing with eyes closed, standing with eyes open looking and actively moving head upward and downward, and standing with eyes closed and the head actively moving upward and downward. The subjects were asked to perform four more tasks while standing on a thick piece of balance foam that was placed on top of the MatScan®. The remaining 4 tasks are as follows: standing with eyes open, standing with eyes closed, standing with eyes open looking and actively moving the head upward and downward, and standing with eyes closed with head actively moving upward and downward.
45609301|NCT03446599|Drug|Hydroxocobalamin|One intravenous dose of 5mg hydroxocobalamin, which is the current FDA-approved adult dose for carbon monoxide poisoning, reconstituted in 200ml normal saline will be administered over 10-15minutes at the time of initiation of cardiopulmonary bypass.
45934956|NCT00212212|Dietary Supplement|placebo|placebo tablet
45609302|NCT03446599|Drug|Methylene Blue|One intravenous dose of methylene blue 2mg/kg, which has been the accepted dose for vasoplegia, diluted in 200ml normal saline will be administered over 10-15minutes at the time of initiation of cardiopulmonary bypass.
45609303|NCT03446599|Drug|Normal saline|200ml normal saline will be administered intravenously over 10-15minutes at the time of initiation of cardiopulmonary bypass.
45609304|NCT05230225|Behavioral|Physician Notification Letter|Receiving the electronic Physician Notification Letter to highlight echocardiography results that are consistent with or may be consistent with severe AS and to be reminded of ACC/AHA Clinical Practice Guideline recommendations regarding the management of severe AS.
45609305|NCT02856451|Biological|Nivolumab|Specified dose on specified days
45609306|NCT03979183|Behavioral|Lumbopelvic, stretching, aerobic and relaxation exercises|Intervention program will comprises brisk walks and small choreographies, global and analytical stretching exercises, as well as lumbopelvic stabilization exercises (with intensity and volume progression)
45609307|NCT03684655|Drug|[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)|[18F]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
45609308|NCT05164783|Combination Product|Sanacoach Parkinson (SCP)|A web-based monitoring tool for patients with PD, using questionnaires. It includes nine parts: 1) A 89-question, quarterly questionnaire about PD-symptoms. 2) Questionnaire responses are converted to scores on 16 PD-related domains. Both the current score and the score's change compared to the previous questionnaire are visible. 3) An interim evaluation is sent after 6 weeks with questions on any domains where a patient indicated problems. 4) A medication monitor can be initialized by the treating physician to evaluate the effect of a therapeutic change. 5) A consultation preparation module allows patients to indicate which topics they want to discuss during an outpatient visit. 6) Patients can ask for 'calling advise' if they are unsure whether to contact their physician. 7) Patients and healthcare providers can send each other text messages. 8) Interactive learning modules about PD. 9) Annual evaluation regarding patient satisfaction, self-management and healthcare consumption.
45609309|NCT05136859|Procedure|preserve|preserve the perivascular fat of the target cephalic vein
46068598|NCT05832502|Drug|GBS6|The investigational products are GBS6 and placebo (saline control). The GBS6 dose will be GBS6 20mcg without AlPO4 (equivalent to 240 mcg/mL) 0.5mL dose or 20 mcg CPS/serotype).
46068599|NCT05832489|Drug|Placebo|"Patients will have 2 imaging sessions (MRI and EEG) after either:~methylphenidate immediate release 25 mg~placebo~in a cross-over design. The two imaging sessions will be separated by 1 to 7 weeks."
46068600|NCT05832489|Drug|Methylphenidate immediate release 25mg|"Patients will have 2 imaging sessions (MRI and EEG) after either:~methylphenidate immediate release 25 mg~placebo~in a cross-over design. The two imaging sessions will be separated by 1 to 7 weeks."
46068601|NCT05832476|Other|No intervention|No intervention
45444993|NCT03790527|Procedure|Sham training|participants will be random-assigned into one of training groups. Participants in the modification group will receive modified training of 400 trials for six sessions during six days, the same as the sham group.The difference between these two groups is the proportion of push/pull trials. The sequence of the interventions will be counterbalanced across participants, and the callback will be conduct after one week.
45444994|NCT05544123|Other|pathological stage|breast cancer molecular subtyping and pathological TNM stage
45653336|NCT04990869|Dietary Supplement|Nicotinamide Riboside|The patients will receive 1 g of Nicotinamide Riboside or placebo orally every morning and evening for 6 weeks.
45653337|NCT04990869|Dietary Supplement|Placebo|Placebo
45934957|NCT00212251|Behavioral|moderate exercise and healthy, low-fat diet|
45934958|NCT00212290|Drug|pioglitazone|
45934959|NCT00212290|Drug|nateglinide|
45934960|NCT00212290|Drug|placebo|
45934961|NCT00212329|Procedure|T Cell Proliferation and Autoreactivity Assays|
45934962|NCT00212329|Procedure|Cellular Immunoblot Assays|
45934963|NCT00212329|Procedure|Tetramer Studies|
45934964|NCT00212329|Procedure|Cytokine ELISPOT|
45934965|NCT00069381|Behavioral|Psychotherapy treatment|
45934966|NCT00212368|Drug|Zinc acetate|
45934967|NCT00212407|Biological|Umbilical Cord Blood Transplantation|
45444995|NCT03790215|Drug|Dydrogesterone|The investigators give participants oral dydrogesterone(as described in arm description).After 3 cycles of treatment, the investigators evaluate the treatment effects.
45934968|NCT00411580|Biological|CAD106|
45934969|NCT00411580|Drug|Placebo|
45934970|NCT00411658|Device|Investigational Device|
45934971|NCT00411658|Device|Experimental|
45934972|NCT00411658|Other|Cryopreserved|
45934973|NCT00073203|Drug|R228060|
45934974|NCT00073203|Drug|Placebo and Paroxetine|
45934975|NCT00411697|Biological|Engerix™-B Kinder|Intramuscular injection, 1 dose
45934976|NCT00411736|Drug|Study medication, azithromycin or placebo|Granulate for syrup in the group under 8 years, 40 mg/ml. Dose: 5 mg/kg/day in one daily dose.
45609310|NCT03916783|Behavioral|Combination intervention|"The FDA will be a matched savings account held in the child's name with the parent or caregiver as the co-signer, in a financial institution registered by the Central Bank (Bank of Uganda). The account opened will be matched with money from the program up to a match cap of 72,000 Uganda shillings (an equivalent of $20) a month per family for the 9-month intervention period.~The FDAs will be complemented with four sessions of Financial Literacy and Management (FL&M) and two sessions of cancer education conducted over a 4-week period. The two cancer-specific education sessions will use UCI materials to address: 1) definitions of cancer, potential causes, signs and symptoms, and importance of cancer testing; 2) debunking cultural explanations for the causes of cancer and misconceptions (beliefs, values, norms and prevailing attitudes)regarding cancer that largely impede service use."
45609311|NCT03129451|Diagnostic Test|Microbiome specimens in stool|Analyzing Microbiome specimens in stool
45609312|NCT03446443|Drug|Honghe Fujie lotion|Before application，wash the vaginal area with water and dry it. Take10ml Hong He Fujie into dilution bottles，added to 100ml with warm boiled water, using diluted lotion for the rinse of vulva and vagina, twice daily for 7days.
45609313|NCT03446443|Drug|Metronidazole Suppositories|Before bedtime，wash the vaginal area and put 0.5g Metronidazole Suppositories into posterior vaginal fornix，once daily for 7days.
45609314|NCT03446365|Behavioral|ASMAS|A high school peer led group intervention for middles school students targeting asthma education and asthma management practices.
45609315|NCT03446365|Behavioral|Asthma education plus child health|Health educator led intervention focused on asthma education and other child health topics.
45609316|NCT03443557|Other|oral nutrition supplement|receiving prescription of oral nutrition supplement during hospitalization
45609317|NCT03443479|Device|Non-Invasive Ventilation|Treatment with Non-Invasive Ventilation by BiPAP. Different BiPAP models are in use. Ventilation parameters set at the discretion of the treating physician.
45609318|NCT03443479|Device|High-Flow Nasal Cannula|Treatment with a High-Flow Nasal Cannula. The Optiflow device by Fisher&Paykel used in all cases. Flow and fraction of inspired oxygen (FiO2) parameters at the discretion of the treating physician.
45609319|NCT03443401|Procedure|Standard physical therapy care|standard plan of care delivered to patient with chronic low back within scope of licensure
45609320|NCT04452487|Behavioral|decisions of limitations and stop processing|Compliance of the modalities of decisions of limitations and stop processing
45609321|NCT03446209|Drug|Tocilizumab Infusion RoAcemtra (EU)|Experimental arm's patients will obtain TCZ intravenously once every 4 weeks for 28 weeks
45609322|NCT03446209|Drug|0.9% physiological saline|"Experimental arm's patients will obtain saline intravenously once every 4 weeks for 16 weeks. If necessary, patients will get rescue medication after week 16 to week 28."
45609323|NCT03688555|Drug|ACT-774312|ACT-774312 will be available as hard gelatin capsules containing 200 mg of ACT-774312
45609324|NCT03688555|Drug|Placebo|Matching placebo hard gelatin capsules
45758050|NCT03225794|Diagnostic Test|Simian foamy virus Infection|Plasma samples are tested for the presence of antibodies directed against foamy viruses by western blotting (WB). The BHK-21 cell line infected with a chimpanzee foamy virus is used as a source of viral antigen. Samples are considered to be positive if there is net reactivity against the GAG doublet (70 to 74 kD). High molecular weight DNA will be extracted, from either buffy coats, cell cultures, or both, for molecular biology studies. The presence and quality of the DNA will be verified by amplification of a fragment of the beta-globin gene. Two regions of foamy virus genomic DNA will be amplified by nested PCR, using generic amplimers, giving rise to fragments of the integrase gene (425 bp) and LTR (109 bp).
45934977|NCT00411736|Drug|Azithromycin or placebo tablets|Tablets of 250 mg, azithromycin or placebo. Dosage: 1 tablet every other day for participants with a weight less than 40 kg´s. 1 tablet every day for participants weighing 40 kg´s or more.
45444996|NCT01307085|Procedure|remote ischemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
45609325|NCT05102071|Drug|empagliflozin|empagliflozin
45609326|NCT05102071|Drug|metformin|metformin
45609327|NCT05102071|Drug|sulfonylurea|sulfonylurea
45609328|NCT00260585|Procedure|Survey of client health, personal habits, family history|A questionnaire is administered at the time of consent.
45609329|NCT00260585|Procedure|Blood specimen for non-DNA and DNA parts|Blood specimen is collected prior to surgery or at the time of scheduled routine surgical procedure(s), and at the time of routine follow-up visits
45609330|NCT00260585|Procedure|Biopsy of esophageal/stomach tissue, lymph nodes, tumor|Tissue from the biopsies is collected intraoperatively.
45609331|NCT00260585|Procedure|Biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushing from routine clinical surveillance endoscopies|Tissue from the biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushings are collected intraoperatively.
45609332|NCT03443869|Drug|Letermovir|LET 480mg (or 240 mg when administered concomitantly with cyclosporin A) once daily for 28 weeks
45609333|NCT03443869|Drug|Valganciclovir|900 mg VGCV tablet orally, once daily for 28 weeks
45609334|NCT03443869|Drug|Acyclovir (ACV)|400 mg over-encapsulated ACV tablet orally, every 12 hours for 28 weeks
45609335|NCT03443869|Drug|Placebo to ACV|Over-encapsulated placebo tablet orally, every 12 hours for 28 weeks
45609336|NCT03443869|Drug|Placebo to LET|Placebo to LET tablet orally, once daily for 28 weeks
45934978|NCT00411814|Drug|GSK679586|Active Drug
45934979|NCT00411814|Drug|Placebo|Saline
45444997|NCT05694975|Drug|Vitamin C|The total dosage of vitamin C for the treatment group is 24 g per day.
45444998|NCT05694975|Drug|Placebo|The total dosage of placebo(5% glucose) for the control group is 24 g per day.
45609337|NCT03443869|Drug|Placebo to VGCV|Placebo to VGCV tablet orally, once daily for 28 weeks
45609338|NCT05383937|Other|Speech Therapy INTENS-DYS|During the six research month, children included in the intensive arm will benefit of two daily hours speech therapy during two weeks. Those one will be carried out between the second and the fourth month.
45609339|NCT03892265|Other|Observational Study|No intervention is included in this observational study.
45609340|NCT04454099|Diagnostic Test|4 kind of FOBT and colonoscopy with pathological examination|Detect Hb in stool by 4 kind of FOBT and detect colon lesion using colonoscopy and pathological examination.
45609341|NCT05345405|Behavioral|Dyadic CARE|Dyadic CARE involves two telehealth sessions with a clinician, the survivor, and a supporter of the survivor's choice. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
45609342|NCT05345405|Behavioral|Supporter-Only CARE|Supporter-only CARE involves two telehealth sessions with a clinician and a supporter of the survivor's choice, without the survivor present. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
45609343|NCT05342441|Procedure|QT graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the quadriceps tendon without bone block.~The QT graft is harvested through a 4-5 cm incision at the upper pole of the patella. A graft sized 10-12 mm in with and app. 6 mm in depth is harvested from the middle part of the tendon.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The ST/Gr graft is fixed proximally with the RIGIDFIX® Curve Cross Pin System (DePuy Synthes) and distally with a Milagro skrew (DePuy Synthes) or similar."
45609344|NCT05342441|Procedure|ST/Gr graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the semitendinosus and gracilis muscles.~The ST/Gr graft is harvested through a 4-5 cm incision at the pes anserinus. Both the semitendinosus and the gracilis tendon is identified and harvested. The tendons are prepared and folded to a four-stranded graft with a total diameter of 7-10 mm.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The ST/Gr graft is fixed proximally with the RIGIDFIX® Curve Cross Pin System (DePuy Synthes) and distally with a Milagro skrew (DePuy Synthes) or similar."
45609345|NCT05342441|Procedure|BPTB graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the patella tendon with bone block (bone-patellar-tendon-bone).~The BPTB graft is harvested through two 4-5 cm incisions, one on the tibial tuberosity and one on the patella. The middle 10 mm of the patella tendon plus 20-30 mm bone plugs at each end from corresponding tibia and patella is harvested.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus. The BPTB graft is fixed both proximally and distally with a Milagro skrew (DePuy Synthes) or similar."
45609346|NCT05341661|Device|Butterfly Prostatic Retraction Device|Implantation of the Butterfly device
45609347|NCT03349723|Drug|BI 1265162|Single rising dose groups
45758051|NCT04276766|Other|Crossover intervention|"Drink consumption was followed by regular BP measurements and collection of saliva samples every 30 minutes for four hours. Microcirculatory measurements were then repeated and saliva and urine samples were collected again.~After the last measurement subjects were provided with a standardized meal with a very low nitrate intake to eat within 30minutes. Participant then left the research centre and they were asked to collect a saliva sample after two hours from the completion of the meal. This was immediately followed a dose of labelled nitrate (4mg in 100ml of distilled water) to drink within one minute. Subjects were then asked to collect six additional saliva samples until the next morning (four before going to bed and two in the morning), accompanied by measurements of resting BP.~Cross-over assessments were then repeated in the same order at Visit 3, followed a wash-out period of at least one week before entering the second arm of the study."
45609348|NCT03349723|Drug|Placebo|Single rising dose groups
45609349|NCT03130361|Device|Non-Invasive Ventilation|
45758052|NCT04276844|Diagnostic Test|Ultrasonography using the two-dimensional (2D) mode|Diaphragmatic amplitude assessed by ultrasonography during quiet breathing and after sniff test, before the surgery and at day 7 post-surgery in all patients.
45444999|NCT01305915|Behavioral|Getting Back on Track|The intervention, entitled Getting Back on Track, is two hours in duration and delivered by a multidisciplinary team representing nursing, radiation therapy, social work, rehabilitation services, and nutrition from the Breast Cancer Clinic at Princess Margaret Hospital. Relying on the content of the Getting Back on Track booklet, clinical experience and the principles of adult education, this team developed scripts for each component of the class.
45445000|NCT03787875|Procedure|periodontal treatment|In the study group, periodontal scaling and root planning treatment of the 4 quadrants was performed for two consecutive weeks without the use of antiseptics or antibiotics, and the patients were instructed in oral hygiene, including both brushing techniques and proximal hygiene.
45445001|NCT03790371|Drug|Misoprostol|vaginal misoprostol prior IUD insertion
45445002|NCT03790371|Drug|Placebos|vaginal placebo tablet prior IUD insertion
45445003|NCT03787563|Drug|Herbal Tea|All participants will be given the intervention in an infusion tea bag. Participant will be instructed to take one tea bag three times a day at before breakfast, lunch and dinner meals. At the time of randomization both active and placebo infusion bag will be provided.There will be one day of washout period after 2 days on treatment.
45445004|NCT03787563|Drug|Placebo Tea|Similar looking inert placebo tea.
45445005|NCT01307475|Other|PTSD Checklist-Specific|Completed by patients before clinical examination; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
45445006|NCT01307475|Other|Modified Flanagan Quality of Life Scale|Completed by patients before clinical examination; it is a 16-item survey designed for use in persons with chronic illness.
45609350|NCT05332769|Genetic|FLIM parameters|Cumulus samples (CCs) will be collected following the protocol on the day of oocyte pick up (OPU). CCs are frozen by the cryo-tech method, then stored in liquid nitrogen at -196oC. Information of CC samples and processed date/time is recorded. After all, samples are collected, they will be transferred to The Needleman Lab, Northwest Lab Building 359,52 Oxford Street Cambridge MA 02138 to measure mitochondria metabolism using FLIM.
45609351|NCT03445975|Procedure|3-in-1 perineal care washcloths|The 3-in-1 washcloth was used for daily routine perineal skin hygiene and after each diaper/underpad change. This procedure was intended for cleansing, moisturizing, and application of a barrier protection (dimeticone 3%). 3-in1 washcloths pH range is 3.5 to 5.0.
45609352|NCT05327933|Procedure|Surgery plus endovascular MMA embolization|A micro catheter is inserted transfemorally into the branches of the middle meningeal artery (MMA) in a minimally invasive manner and the periphery is occluded using polyvinyl alcohol (PVA) particles to prevent future bleeding. If the desired catheter position cannot be achieved due to the anatomical conditions, a more proximal closure of the MMA using Onyx® or micro-electric coils is performed. Embolization of the MMA by PVA particles with sizes between 40-300 µm is preferred over embolization by coils and Onyx®, since the capillary network of the dura is entirely blocked when using particles. In order to identify the vessels to be closed, a digital subtraction angiography (DSA) is performed.
45609353|NCT05327933|Procedure|Surgery alone|Evacuation of cSDH
45609354|NCT04452409|Device|low level laser|The laser therapy device (660 nm) consisted of abdominal straps containing 4 LED clusters, having 72 LEDs each, applied in the study group paticipants around the patients abdomen and waist after cleaning the target area and wearing safety goggles20, for 30 min., 2 times per week over 12 weeks
45609355|NCT04452409|Other|Mediterranean diet|recommend healthy diet component evaluated periodically by 24 hour recall
45609356|NCT03130517|Drug|intravenous immunoglobulin|giving intravenous immunoglobulin to neonates included in inclusion criteria in a dose of 0.5-1 gm
45609357|NCT03445897|Drug|miltefosine plus intralesional pentamidine|miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
45609358|NCT03445819|Procedure|Group A: Surgical Treatment|Open reduction and internal fixation (ORIF) of the patellar fracture will be performed using screws, wires, pins, or plate fixation at the discretion of the treating surgeon
45609359|NCT03445819|Other|Group B: Conservative Treatment|Patients randomized to non-operative treatment will receive identical treatment to the operative group, minus the surgery.
45609360|NCT04548791|Biological|Coagulation Factor VIIa variant|Single intravenous dose and ascending doses of subcutaneous injection of MarzAA, followed by a fixed dose of MarzAA for the treatment of bleeding episodes
45609361|NCT04967053|Procedure|sleeve gastrectomy|Laparoscopic sleeve gastrectomy gives long-standing improvement or resolution of obesity-related conditions and also survival benefit. It is highly cost-effective. Surgical procedures for the treatment of obesity.
45609362|NCT04950439|Other|Collect blood sample|A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.
45609363|NCT05306951|Diagnostic Test|Computed tomography|Head computed tomography
45445007|NCT01307475|Other|Center for Epidemiologic Studies Depression Scale|Completed by patients before clinical examination; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
45445008|NCT01307475|Other|Functional Enquiry Form|Completed by patients before clinical examination; it is a checklist of medical problems.
45445009|NCT01307475|Other|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
45445010|NCT01307475|Other|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination, minus breasts, genitalia or rectum.
45445011|NCT01307475|Other|PTSD, Depression, and FSS-Focused Examination|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of symptoms, signs, and perceptions that may be related to FSS, PTSS, or depressive problems.
45445012|NCT01307475|Other|Freeman-Sheldon Specific Quality of Life Survey|Completed after data analysis from the existing surveys and clinical examination, it will be a specific quality of life survey developed and tested during the study; it will take into consideration individual's total health outcome.
45609364|NCT04938115|Biological|CD7 CART|Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
45609365|NCT03237611|Drug|Aprepitant 125 mg|Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
45758053|NCT04276844|Diagnostic Test|Respiratory Functional Explorations|Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV) and total lung capacity (TLC) measured at day 7
45758054|NCT03950570|Drug|Abraxane|"The doses of ORIN1001 in both dose escalation and dose expansion will be 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600mg, 800 mg, 1,000 mg, 1,200 mg Weekly paclitaxel will be 80 mg/m2 given intravenously for the dose escalation and dose expansion phases.~cohorts as follows: 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, 1,000 mg, 1,300 mg and 1,500 mg administered for 21 days (one cycle)."
45609366|NCT03237611|Drug|Fosaprepitant 115 MG|Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
45609367|NCT03237611|Drug|Dexamethasone|Dexamethasone will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 20mg on day 1 of chemotherapy
45609368|NCT03237611|Drug|Ondansetron 16 MG|Ondansetron will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 16mg on day 1 of chemotherapy
45758055|NCT04498910|Drug|LY3451838|Administered IV
45758056|NCT04498910|Drug|Placebo|Administered IV
45934980|NCT00212485|Procedure|Power Doppler Sonography|Power Doppler with gray-scale sonography is used to detect and quantify alterations in vascularity inside knee, elbow and ankle joints.
45609369|NCT03208387|Diagnostic Test|Diffusion tensor imaging (DTI)|DTI quantifies the degree to which water diffuses in different directions through a given brain region. The use of DTI as an in vivo index of the integrity of white matter has been applied to many disease states using several proprietary and open-source software programs (e.g. FSL 5.0). DTI tractography, employed via toolboxes such as Probtrackx within the FSL 5.0, allows the identification of white matter tracts connecting cortical and subcortical regions of interest. Furthermore, structural connectivity as measured with DTI does not duplicate functional connectivity as measure with rs-fcMRI, but rather provides complimentary perspectives.
45609370|NCT03208387|Diagnostic Test|Resting state functional connectivity MRI (rs-fcMRI)|rs-fcMRI is a relatively new neuroimaging technique that has been applied to studying multiple clinical populations including ADHD, schizophrenia, major depressive disorder, and other neurological disorders. The approach exploits measurement of changes in brain blood oxygenation (BOLD) as is employed in task based functional MRI (measuring changes in focal cortical vascular oxygenation when engaged in a defined task, e.g. motor movement). Neuroimaging data will be collected as soon as possible (can be the same day), for up to 6 weeks.
45609371|NCT03208387|Behavioral|Wechsler Intelligence Scale for Children - 5th edition (WISC-V)|Will gather IQ data and is the gold standard for IQ assessment for those between the ages of 6:0 and 16:11 years.
45609372|NCT03208387|Behavioral|California Verbal Learning Test (CVLT-C)|Validated measure of verbal learning and memory for those between the ages of 5:0 and 16:11.
45609373|NCT03208387|Behavioral|Beery Test of Visual Motor Integration 6th edition|Measure designed to assess visual-motor functioning of subjects between the ages of 2-99 years old by copying designs using paper and pencil.
45609374|NCT03208387|Behavioral|Grooved Pegboard|This is a standard assessment of fine motor functioning and dexterity by asking the subject to place metal pegs into holes on a board.
45609375|NCT03208387|Behavioral|PedsQL Multidimensional Fatigue Scale|Designed to measure fatigue in pediatric patients (ages 5-17 years) and is comprised of the General Fatigue Scale (6 items), Sleep/Rest Fatigue Scale (6 items) and Cognitive Fatigue Scale (6 items).
45609376|NCT03208387|Diagnostic Test|MRI|Images will be acquired on a 3.0 Tesla MRI scanner at each of the four study sites. At MSK, resting state fMRI data will be obtained using a 3T GE scanner with an 8-channel head coil (Discovery 750w DV25)
45609377|NCT04676243|Drug|Quizartinib|20 mg coated tablets, orally administered
45609378|NCT04676243|Drug|Treatment according to Physician's Choice|Usually daunorubicin/ cytarabine or idarubicin/Cytarabine plus FLT3 inhibitor (usually midostaurin)
45609379|NCT04676243|Drug|Standard of Care Chemotherapy|Daunorubicin/ Cytarabine or Idarubicin/Cytarabine
45609380|NCT03445741|Other|Supervised treadmill group (%70 VO2 max) (group 1)|An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target heart rate (HR) corresponding to values of 70% VO2max were determined by the submaximal treadmill test. The participants were instructed walking at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port, Washington, NY). During 12 weeks, 3 days in a week and 20 minutes per day walking program was applied.
45445013|NCT01307475|Other|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest.
45445014|NCT03787641|Drug|Protamine Sulfate|Protamine Sulfate will be administered via an infusion pump to administer a 50 mg test doze, then 100 mg after 5 min waiting period. Following blood samples, additional alliquots of 50 mg will be measured to a maximum of 300 mg.
45445015|NCT03790293|Drug|Rituximab|Patient was enrolled into the RITUXIMAB 3 study in the arm Rituximab in association with low corticosteroids'therapy
45445016|NCT03790293|Drug|corticosteroids'therapy|Patient was enrolled into the RITUXIMAB 3 study in the arm Patient was enrolled into the RITUXIMAB 3 study in the arm standard corticosteroid
45609381|NCT03445741|Other|Supervised treadmill group (%50 VO2 max) (group 2)|An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target heart rate (HR) corresponding to values of 50% VO2max were determined by the submaximal treadmill test. The participants were instructed walking at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port, Washington, NY). During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
45609382|NCT03445741|Device|ECE PEDO pedometer group (%50 VO2 max) (group 3)|Target heart rate (HR) corresponding to values of 50 % VO2max were determined by the submaximal treadmill test. The number of steps taken in a minute corresponding to target HR was determined by a criterion pedometer and group 3 was instructed walking in this step range recorded to ECE PEDO giving audible feedback. During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
45609383|NCT03234491|Device|DiAS|Diabetes Assistant (DiAS) hybrid closed loop system.
45609384|NCT03234491|Drug|Afrezza low dose|Afrezza inhaled insulin low dose.
45609385|NCT03234491|Drug|Afrezza high dose|Afrezza inhaled insulin high dose.
45609386|NCT03093961|Device|IASD implant|Single arm for implant
45609387|NCT04285307|Behavioral|Sleep Hygiene tips|Students receive a packet of information on how to improve their sleep habits and hygiene.
45609388|NCT03054961|Device|Near-infrared spectroscopy|Measurement of CCO redox state and cerebral oxygenation during epileptic seizures.
45609389|NCT03445507|Other|Chat bot|Patients in intervention arm will use an evidence-based chat bot as an aid for smoking cessation
45609390|NCT03445507|Other|Usual care|Usual care given by their usual general practitioners and nurses of primary care health centres, as defined in Public Health System Portfolio.
45609391|NCT05089825|Other|Receive routine instructions|Study subjects randomized to this arm will receive a mailed myLab Box kit with instructions on HPV self-collection and postage to be shipped directly to the commercial lab. It should take less than 5 minutes to collect the sample.
45609392|NCT05089825|Other|Telehealth-based instructional visit and receive routine instructions|"Study subjects randomized to this arm will similarly receive a mailed myLab Box kit and also undergo a brief 5-10 telehealth instructional visit via video conference."
45609393|NCT04451629|Behavioral|pelvıc base exercıse, core exercise|Effectıveness of the pelvıc base exercıse on the paın and qualıty of lıfe ın dysmenoral youth 40 minutes exercise intervention 4 times a week for 8 weeks
45609394|NCT01961063|Drug|busulfan|Given IV
45758057|NCT04496726|Other|Pacran and Sapnov P quillaja|Cranberry (450 mg) and quillaja (50 mg) capsules taken orally twice daily (morning and evening) for a total daily dose of 900 mg cranberry and 100 mg quillaja for 14 days. Nitrofurantoin 100 mg taken orally twice daily for five days as a rescue medication if symptoms do not subside.
45445017|NCT05694663|Device|Vivistim|After one month of prehabiliatory training, the patient will then undergo surgical placement of the implantable VNS device (Vivistim System) consisting of an implantable neurostimulator and an implantable lead and electrode per standard of care. The device comes with a controller and software system which allows for control of the stimulation settings during the rehabilitation phase. The PMA number for this device is 210007 and the date of FDA notice of approval occurred on August 27, 2021.
45445018|NCT03790059|Drug|H101|Intraoperative injection of H101 can improve the efficacy of RFA in hepatocellular carcinoma.
45609395|NCT01961063|Biological|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Given IV
45609396|NCT01961063|Other|pharmacological study|Correlative studies
45609397|NCT01961063|Other|laboratory biomarker analysis|Correlative studies
45609398|NCT02951377|Other|Exercise (MDT approach)|Postural or movement exercises of the lower back that aim to centralise and reduce pain intensity.
45609399|NCT02951377|Drug|Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%)|An epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).
45609400|NCT03443089|Drug|Test formulation|Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/mL + estradiol cypionate 5 mg/mL after an overnight fast.
45609401|NCT03443089|Drug|Reference formulation|Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole after an overnight fast.
45609402|NCT05241197|Other|Low Load Training with Blood Flow Restriction|A 12-cm-wide pneumatic nylon tourniquet will be proximally positioned with a snug fit on each thigh. Previously, arterial occlusion pressure (AOP) will be determined using a handheld Doppler Ultrasound in a standing position for each participant. For training routines, cuff pressure will be set to 50% of each individual´s AOP and will be keep inflated during the entire session including the interset rest period of 1 minute. Between the two exercises, the cuff will be deflated for 3 minutes.
45609403|NCT05241197|Other|High Load Training|All participants in this arm will do two exercises, unilateral dynamic standing and sitting calf-raises, with a training load of 70% 1RM, being progressively increased by 5% every four weeks from 70% to 80%. This protocol will consist of three sets of 6-12 repetitions with a interset rest period of 1 minute and 3 minutes rest between exercises.
45609404|NCT03445429|Other|3D-display system|The subjects will perform tasks on a minimal-invasive/laparoscopic training set-up. They will perform the tasks with a 3D-display system or a 4K-display system. The intervention type 3D-display system means that the training-set up is performed first with 3D-display system an after that with the 4K-display system.
45609405|NCT03445429|Other|4K-display system|The subjects will perform tasks on a minimal-invasive/laparoscopic training set-up. They will perform the tasks with a 3D-display system or a 4K-display system. The intervention type 4K-display system means that the training-set up is performed first with 4K-display system and after that with the 3D-display system.
45609406|NCT05239949|Other|Hypopressive exercises|For hypopressive exercises, the patient will be instructed to inhale, then breathe to expand the ribcage, and then exhale completely. Hold the breath out before relaxing core and ribcage.
45609407|NCT05239949|Other|Pelvic floor exercises|For pelvic floor exercises, the patient is instructed to hold each contraction for 6 seconds.
45609408|NCT05082259|Drug|ASTX660|ASTX660 will be supplied as capsules. Each hydroxylpropyl methylcellulose (HPMC) capsule contains either 30 mg or 90 mg of ASTX600 free-base equivalents, suitable for oral administration. Bottles are labelled with the capsule strength (ie, 30 mg or 90 mg) and are further distinguished by different-colored labels. Each bottle contains 14 capsules and an oxygen-absorber (not to be consumed).
45609409|NCT05082259|Drug|Pembrolizumab|"Pembrolizumab Solution for Infusion 100 mg/vial is a liquid drug product supplied as a clear to opalescent solution, essentially free of visible particles, in Type I glass vials and manufactured using the fully formulated drug substance with L-histidine as buffering agent, polysorbate 80 as surfactant, and sucrose as stabilizer/tonicity modifier.~Pembrolizumab Solution for Infusion can be further diluted with normal saline or 5% dextrose in the concentration range of 1 to 10 mg/mL in IV containers made of polyvinyl chloride (PVC) or non-PVC material."
45609410|NCT03445351|Other|Aerobic, resistance and concorrent.|All protocols followed the American College of Sports Medicine (ACSM) guidelines , with frequency of three times per week, duration between 40-50 minutes, low to high intensity, modified according to the physical needs of each participant, respecting the physical training principles.
45609411|NCT03879551|Device|repetitive Transcranial Magnetic Stimulation|By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor digiti minimi (ADM), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for each hemisphere (coil placed tangential over the optimal position of hand motor area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
45758058|NCT03725397|Behavioral|Outpatient|The offered (studied) intervention will be allowing the women with a transcervical Foley catheter in place to spend the night at home.
45758059|NCT03725397|Behavioral|Inpatient|"Women with a transcervical Foley catheter to be admitted to the hospital overnight which has been a standard of care."
45445019|NCT03790059|Procedure|RFA|Treat the samll HCC with the RFA.
45758060|NCT00699491|Biological|Cixutumumab|Given IV
45758061|NCT00699491|Other|Laboratory Biomarker Analysis|Correlative studies
45758062|NCT00699491|Other|Pharmacological Study|Correlative studies
45758063|NCT00699491|Drug|Temsirolimus|Given IV
45445020|NCT03789903|Diagnostic Test|amniotic fluid lactate|AF lactate
45609412|NCT03445117|Other|Educational intervention|a) The educational intervention comprises putting up posters on vaccination in the clinic, as well as provision of a specially designed flyer to the clinic, which will be handed out by the clinic assistants to all patients 65 years and above, at the point of registration. The poster and flyer content will provide simple messaging to encourage patients to receive influenza and pneumococcal vaccinations and inform them of available healthcare subsidies. b) Reminders to physicians: The flyers will also serve as physical prompts to physicians to encourage vaccination for their patients. Doctors and clinic staff will also be updated on the study protocol and the recommended adult vaccination schedule before commencement of the study.
45609413|NCT03203603|Other|No active intervention|This is a follow-up of a randomized trial. No active intervention is being given in the follow-up.
45609414|NCT03445039|Device|traditional TSFE|The TSFE procedure is performed by osteotomes (Straumann AG, Basel, Switzland) and mallet as the traditional ways.
45445021|NCT01307553|Device|Pericardium Covered Stent|Percutaneous implantation of pericardium covered stent
45445022|NCT01305993|Drug|SB injection|Infusion SBinjection of 21.87ml/m^2, IV route, 24times for 4 months
45609415|NCT03445039|Procedure|bone grafting materials|The bone substitute is placed into the siuns under the membrane before the implant placement
45609416|NCT03445039|Device|TSFE by DASK drills|The TSFE procedure is performed by DASK(Dentium Advanced Surgical Kits) drills (Dentium, Korea), the residual cortical plate of the sinus floor is grinded by the drills.
45609417|NCT03445039|Procedure|without bone grafting materials|The bone substitute will not be placed into the sinus before the implant placement.
45609418|NCT04453553|Diagnostic Test|Q16 testing|Nasal swab tested on a rapid near patient device
45609419|NCT04453553|Diagnostic Test|Nasopharyngeal swab and main laboratory|Standard of care testing
45609420|NCT03444883|Drug|Ilaprazole|10mgx2 tablet once daily for weeks
45609421|NCT05206097|Device|Accelerometer|For the following study, each patient will be asked to wear a portable device over a 7-day period. The accelerometer will be previously set up according to anthropometric data of the patient and scheduled to automatically start and stop accelerations registration. The patient will be asked to wear the sensor as frequently as possible, with the exception of sleep period and during aquatic activities. A diary will be delivered to the patient in order to notify any problem/issue observed during the evaluation week (for example forgetting to wear the sensor). The accelerometry assessment will be associated to a questionnaire. Each patient will have to fill in it during the evaluation week. The questionnaire is composed of various questions from three different questionnaires: Ricci & Gagnon for subjective evaluation of PA level, CFQ-14+ for the evaluation of quality of life specifically in CF and EQ-5D for a more generic evaluation of quality of life.
45609422|NCT03443011|Radiation|Low dose CT without intravenous contrast|participants will receive an extra radiation dosage of about 3 milli Sievert (mSv) depending on patients height and weight. This is the radiation amount from the low dose CT protocol without intravenous contrast.
45609423|NCT05201495|Device|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)|Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
45609424|NCT03467399|Device|Nucleus 7 Cochlear Implant System|A new cochlear implant sound processor system.
45609425|NCT03109717|Drug|Monoamine Oxidase Inhibitor (MAOI)|Monoamine Oxidase Inhibitor
45609426|NCT03467321|Other|Physical characteristic assessment|Physical characteristics related to balance, pulmonary function and low back pain were evaluated
45609427|NCT05676229|Dietary Supplement|Probiotic blend|Lactobacillus gasseri CCT 7850 and Bifidobacterium lactis CCT 7858
45445023|NCT03245450|Drug|Eribulin mesilate|IV infusion
45609428|NCT05676229|Dietary Supplement|Placebo|Maltodextrin only (vehicle)
45609429|NCT05439785|Device|Dental floss/Interdental brush|Initially plaque disclosing tablets were used to disclose plaque and plaque and bleeding scores will be recoded. After mechanical plaque debrided, instructions regarding the allocated interdental device given to the patient along with motivation to continue practicing good oral hygiene. After six weeks patients were recalled for reevaluation
45609430|NCT03442621|Drug|Relacorilant Fasted|Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10.5 h fast
45609431|NCT03442621|Drug|Relacorilant with a high fat breakfast|Relacorilant presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a high fat breakfast
45609432|NCT03442621|Drug|Relacorilant with a moderate breakfast|Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a moderate breakfast
45609433|NCT04731545|Device|immediate implant placement|Minimally traumatic tooth extraction, immediate implant placement and hard tissue grafting. loading after 3 months.
45609434|NCT03442543|Device|preoperative localization of SLN detected by CTLG by either methods|50 patients with node negative early breast cancer. The patients were randomized into two groups; SLN localized using CTLG guided injection of liquid charcoal suspended solution (first group) or by placing a 3 cm silver wire using spinal needle (second group). For every patient, SLN biopsy was performed using the traditional method with blue dye. Then dual search for the SLN localized by both the novel & traditional method was performed.
45609435|NCT03444805|Procedure|Autologous HSCT|1st AHSCT
45609436|NCT03467087|Device|Myopuls 2000D|Device: Myopuls 2000D (Curatec Services GmBH, 47443 Moers, Germany)
45445024|NCT03245450|Drug|Irinotecan hydrochloride|IV infusion
45445025|NCT05694585|Drug|Esmolol|Esmolol 50μg/kg /min is intravenously administered before Operation beginning. If HR（heart rate）is greater than 90 beats/min, esmolol 50μg/kg/min is added each time, with interval more than 5 min and the peak value is 200 μg/kg/min. If the heart rate is lower than 60 times/minute, Stop medication.
45445026|NCT05694585|Drug|saline|Saline 50μg/kg /min were iv administered before Operation beginning. If HR（heart rate）is greater than 90 beats/min, saline 50μg/kg/min is added each time, with interval more than 5 min and the peak value is 200 μg/kg/min. If the heart rate is lower than 60 times/minute, Stop medication.
45445027|NCT03787329|Other|Core decompression surgery with bone marrow concentration|Core decompression surgery with bone marrow concentration
45445028|NCT03787329|Other|Core decompression surgery|Core decompression surgery only
45445029|NCT03787407|Behavioral|stress management and meditation|mindfulness training using mobile application
45609437|NCT03444649|Drug|Epacadostat|Epacadostat orally two times daily (BID) for two cycles (28 days each) in combination with standard induction chemotherapy (Idarubicin and Cytarabine)
45758064|NCT04493216|Drug|GSK3640254|GSK3640254 will be available as a 25 mg and 100 mg tablets to be administered via oral route.
45758065|NCT04493216|Drug|ABC/3TC|ABC/3TC will be available as abacavir 600 mg/lamivudine 300 mg tablet to be administered via oral route.
45609438|NCT03444649|Drug|Idarubicin|Standard chemotherapy d1-d3 cycle 1
45609439|NCT03444649|Drug|Cytarabine|Standard chemotherapy d1-d7 cycle 1 and 2
45609440|NCT03444649|Drug|Daunorubicin|Standard chemotherapy d1-3 cycle 2
45609441|NCT04725773|Device|Deep brain stimulation effect on apraxia|We will evaluate the effect of DBS on apraxia
45609442|NCT05439473|Dietary Supplement|Curalin|Supplement capsules, 2 capsules, 3 times a day after meals. Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals.
45609443|NCT02743741|Drug|Lutetium-177 Octreotate|Radiopharmaceutical
45609444|NCT04453241|Biological|NBP615|Intramuscular injection, 0.5ml
45609445|NCT04453241|Biological|Gardasil|Intramuscular injection, 0.5ml
45609446|NCT02717767|Other|Autofluorescence of white corpuscle|Measure of auto-fluorescence of white corpuscles cells harvested from tracheal aspirate and/or bronchoalveolar lavages
45609447|NCT05439239|Other|Repeated sprint training|"Participants will perform 7 weeks of cycling repeated sprint training (2x/week). Inspired oxygen fraction (FiO2) will be set to 14.6% and 20.9% for the hypoxic and normoxic group to simulate an altitude of 3000 m and 300 m, respectively.~The training sessions will consist of a 10-min warm up followed by 3 sets of 5 x 10-s all-out repeated sprints on the cycle ergometer. The number of sets will decrease to two during week 7. Participants will be instructed to try to reach and maintain maximal power output during each sprint. An active recovery at 30% of VO2max will be allowed for 20 s between sprints and for 5 min between sets. The training will end with a 10-min cool down at 30% VO2max. An individual fixed torque of 0.7 will be used during the sprints and it will be reduced to 0.5 Nm/kg at week 7."
45609448|NCT03444571|Procedure|revision surgery|If DNA based diagnosis detects infection, standard revision surgery will be conducted
45609449|NCT03442387|Other|Frame of numerical information|Each group received only one frame of information.
45609450|NCT02583061|Other|There is no intervention. An exposure of interest is glucose tolerance status in pregnancy|
45758066|NCT04493216|Drug|FTC/TAF|FTC/TAF will be available as emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet to be administered via oral route.
45609451|NCT02572765|Other|PET/CT scan|PET/CT scan
45609452|NCT04898803|Other|conventional DGVS training|see above
45609453|NCT04898803|Other|extended simulator training|see above
45609454|NCT03444493|Other|Exercise|Exercises were basically performed in 3 phases in this study. In the first phase; effectively and correctly contraction of TrA and multifidus muscles and how the patients adapted to daily life activities was taught. In the second phase; was aimed that the protection of stabilization by counteracting more muscle activation, in the third phase neutral position along with the activities required high level control.
45758067|NCT04493216|Drug|Dolutegravir|Dolutegravir will be available as a 50 mg tablet to be administered via oral route.
45758068|NCT04493216|Drug|Placebo|Placebo matching GSK3640254 will be administered in the form of tablets via oral route.
45758069|NCT03721965|Drug|Itacitinib|Phase 1: Itacitinib administered orally once daily at the protocol-defined dose according to age cohort, with dose reductions or modifications based on safety assessments. Phase 2: Itacitinib administered orally once daily at the recommended dose from Phase 1.
45758070|NCT03721965|Drug|Corticosteroids|Phase 1 and 2: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose that is appropriate for the severity of disease as outlined per local treatment guidelines as background treatment.
45609455|NCT01328951|Drug|Placebo|Placebo will be administered PO once daily as first-line maintenance until disease progression, death, or unacceptable toxicity.
45609456|NCT01328951|Drug|Erlotinib|Erlotinib will be administered as 150 mg PO once daily until disease progression, death, or unacceptable toxicity, as first-line maintenance or as second-line therapy for those who progress while receiving placebo.
45609457|NCT01328951|Drug|Second-Line Chemotherapy|Participants who progress on first-line maintenance erlotinib may receive an approved second-line therapy (but not EGFR targeted therapies) until disease progression, death, or unacceptable toxicity. The selected chemotherapy will be non-investigational and chosen at the discretion of the Investigator.
45609458|NCT03467009|Behavioral|iPACT Intervention|Brief in-person + tailored, daily 8-week text-message secondary prevention intervention.
45609459|NCT03467009|Other|Control: Enhanced Usual Care (EUC)|EUC group participants will receive standardized information on cyberbullying.
45609460|NCT03467009|Behavioral|iPACT Intervention- app|Brief in-person + tailored, daily 8-week message secondary prevention intervention delivered via app.
45609461|NCT03466931|Other|Milk|Meals containing Milk and Milk
45758071|NCT04483778|Biological|second generation 4-1BBζ B7H3-EGFRt-DHFR|Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR
45609462|NCT03466853|Diagnostic Test|Clinical assessment of nutritional status (CANS) score|Systematized inspection and estimation of loss of SC tissues and muscles of nine superficial physical parameters including hair and buccal fat in the cheeks, chin and neck, arms, back, inter or subscapular skin, buttocks, legs, chest, and abdominal wall skin. These signs will be rated from 1 (worst, severe FM) to 4 (best, well nourished), and the highest and lowest total scores are 36 and 9, 3respectively. A total score of <25 is considered as fetal malnutrition.
45609463|NCT03466853|Diagnostic Test|Anthropometric indices|weight, length and head circumference
45609464|NCT03466853|Diagnostic Test|Proportionality indices|MAC/HC ratio (Calculation for each infant and value will be plotted on and compared with a standard curve). Ponderal index . A PI <2.2 is considered as malnutrition). Body mass index (BMI= weight (kg) / length2 (m). A BMI <11.2 kg/m2 is considered as malnutrition)
45609465|NCT03466775|Diagnostic Test|Anti-angiotensin II type 1 receptor antibody measurement|Anti-angiotensin II type 1 receptor antibodies are assessed using quantitative ELISA in stored serum samples obtained within the first year after transplantation
45609466|NCT03466775|Diagnostic Test|Measurement of ENDAT expression level allograft|Endothelial-associated transcript expression level is assessed using microarray in stored kidney allograft biopsies obtained within the first year after transplantation
45758072|NCT04483778|Biological|second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG|Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
45758073|NCT04399148|Drug|Desloratadine 5 mg|Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
45609467|NCT03466775|Other|Allograft survival|
45609468|NCT03466775|Other|Allograft rejection appearance|
45609469|NCT03466619|Device|inflatable penile prosthesis (IPP)|inflatable penile prosthesis (IPP)
45609470|NCT05438459|Biological|Phase I part|Administration of GAIA-102 as a single agent or GAIA-102 and pembrolizumab in combination.
45609471|NCT05438459|Biological|Phase II part|Randomized into group of administration of GAIA-102 as a single agent or GAIA-102 or pembrolizumab in combination, group of standard treatment
45609472|NCT05438381|Procedure|Atraumatic Restorative Technique (ART)|Glass ionomer capsule (GC, USA)
45609473|NCT05438381|Procedure|SMART Technique|silver diamine fluoride (SDF) then glass ionomer cement capsule (GC, USA)
45609474|NCT03466385|Device|Nasal High Flow|Patients admitted to emergency department with COPD exacerbation combined with mild to moderate acute or acute on chronic hypercapnic respiratory failure will be randomized in one of the two study groups. In case of NHF it will be commence immediately with pre-defined settings
45609475|NCT03466385|Device|Non-Invasive Ventilation|Patients admitted to emergency department with COPD exacerbation combined with mild to moderate acute or acute on chronic hypercapnic respiratory failure will be randomized in one of the two study groups. In case of NIV it will be commence immediately with pre-defined settings
45609476|NCT03466307|Device|Ultrasonography|Ultrasonographic examination of shoulder
45758074|NCT04399148|Drug|Aprepitant 125 mg|Aprepitant (NK1-antagonist): hard capsule (1 x 125 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
45758075|NCT04399148|Drug|Ketotifen 1 MG|Ketotifen (H1-antihistamine and mast cell stabilizer): capsule (1 x 1 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
45609477|NCT03466229|Dietary Supplement|Androferti|
45609478|NCT03466229|Dietary Supplement|Placebo|
45609479|NCT02611817|Drug|Vedolizumab SC 108 mg|Vedolizumab SC Injection.
45609480|NCT02611817|Drug|Placebo|Vedolizumab placebo-matching SC injection.
45609481|NCT02611817|Drug|Vedolizumab IV 300 mg|Vedolizumab IV Injection.
45609482|NCT03465995|Device|NKI i-PAS Diagnostic Protocol|"The NKI i-PAS:~The NeuroKinetics i-PAS system is a mobile assessment device with an integrated display for eye tracking with the following properties: a head mounted display, a sampling rate of 100 frames per second, eye tracking in the horizontal, vertical and torsional axes, and pupil area measurement with a spatial resolution less than 0.1 o. The testing protocol includes: optokinetic tracking, smooth pursuit horizontal, smooth pursuit vertical, saccade random horizontal, saccade random vertical, saccade predictive horizontal, antisaccade (horizontal), self-paced saccade, saccade and reaction times, visual reaction time, auditory reaction time, gaze horizontal, light reflex, subjective visual (vertical) and subjective vertical horizontal. Several quantitative measures are computed from the data acquired in each test, and these measures are then employed in a multivariate diagnostic assessment."
45609483|NCT05433233|Behavioral|Walking|Participants will perform 3,000 additional steps/day on 5 days/week.
45609484|NCT05433233|Other|HAPA Behavior Change Counseling|Structured dialogue for initiating behavior change.
45758076|NCT04672382|Drug|Morphine|During the 1st session, each of the middle forearms of the subject will be divided into two squared areas (4x4 cm) located 3 cm apart. Two areas will be treated with an intradermal injection of morphine (0.05 ml, 0.1 mg/ml), and two areas with an intradermal injection of isotonic saline.
45758077|NCT00699803|Drug|T-PRED|T-PRED sterile ophthalmic solution
45758078|NCT00699803|Drug|Pred Forte|Pred Forte sterile ophthalmic solution
45609485|NCT03465917|Combination Product|Renal Denervation|Bilateral denervation of the renal arteries using extravascular administration of neurolytic alcohol
45609486|NCT05430893|Other|Botulinum Toxin A|100 UI IM in the adductor longus
45609487|NCT02735915|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
45609488|NCT03465839|Behavioral|Education for improving handovers quality|Specific education on the importance of handovers quality will be provided. The educational session will last 4 hours. The program will be divided into the following sections: 1) a structured survey on the perception of the participants on the handovers importance; 2) Key theoretical concepts on the relevance of handovers with case studies of errors related to this critical moment; 3) showing movie clips of nursing handovers to critically interpret the clips by the participants; 4) presentation of the SBAR method recommended by WHO; 5) general presentation of the nursing delivery assessment project of the Valduce Hospital.
45758079|NCT01967433|Drug|Diphenhydramine|
45758080|NCT01967433|Drug|Placebo|
45934981|NCT00212485|Procedure|MRI|Magnetic Resonance Imaging with intravenous gadolinium contrast will be done using a standardized protocol, including a spin echo T2 weighted image and gradient echo images.
45609489|NCT03465839|Behavioral|Education for improving bedside handovers|In addition to the education for improving handovers quality, the following intervention will be implemented for nurses assigned to the study department. The course will be supplemented by a section of the duration of an hour, containing 1) information on the principles underlying bedside handovers; 2) how to handle information in front of the patient and on his / her direct involvement; 3) role-playing of the bedside handover will be performed, assigning the roles of nurse and patient among the participants to bring out impressions linked to the functions.
45609490|NCT03130283|Other|Home Hospitalization|Visit every 24 hours
45609491|NCT03130283|Other|Conventional Hospitalization|No intervention
45758081|NCT03255746|Behavioral|Sleep Enhancement|This regimen combines education and behavioral skills to enable prolonging sleep in chronically sleep deprived subjects so as to better meet participant's sleep needs. This intervention emphasizes plain language communication of cognitive behavioral therapy strategies for initiating and maintaining health behavior change, primarily through using brief action plans (time-limited, personally relevant, behavioral goal setting with confidence), and collaborative problem-solving. Coaching will be provided to modify daily routines and adhere to sleep hygiene practices to allow for extended time in bed.
45609492|NCT03130049|Procedure|Popliteal plexus block|10 mL Marcain-adrenalin 5 mg/mL + 5 microgram/mL. Ultrasound-guided injection into the distal part of the adductor canal
45609493|NCT05420519|Biological|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
45609494|NCT05419973|Other|Anthropometric measurement for pregnant women|Weight, length, upper arm circumference
45609495|NCT05419973|Other|Anthropometric measurement for infants|birth weight, length, head circumference, nutritional status
45609496|NCT05419973|Other|Blood sampling|3 ml of blood will be taken, 1,5 ml each to measure the complete blood count, and other 1,5 ml to measure ferritin, Fe serum, vitamin D levels, vitamin D receptors, IL-6 and IL-10.
45609497|NCT05412095|Other|Ultrasound of the abdominal wall muscles|the measurements will be performed during inspiration and expiration to take into account variability during the respiratory cycle. The examination is performed bilaterally and comparatively and lasts between 3 and 5 minutes.
45609498|NCT05412095|Other|Ultrasound quadricipital|The examination is performed bilaterally and comparatively and takes between 3 and 5 minutes.
45609499|NCT05412095|Other|Ultrasound of the diaphragm|The examination is performed bilaterally and comparatively and takes between 5 and 10 minutes.
45609500|NCT05412095|Other|Ultrasound of the inter-costal muscles|measurements performed bilaterally on a patient in a half-sitting position at 45° and in spontaneous ventilation
45609501|NCT05412095|Other|Ultrasound of the inter-costal muscles|In spontaneous ventilation, lying down, arms by the side of the body, palms up, head down
45609502|NCT02522351|Other|Cereal extract concentration 1|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
45609503|NCT02522351|Other|Cereal extract concentration 2|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
45609504|NCT02522351|Other|Cereal extract concentration 3|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
45609505|NCT02522351|Other|Thicken up clear concentration 1|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
45609506|NCT02522351|Other|Thicken up clear concentration 2|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
45609507|NCT02522351|Other|Thicken up clear concentration 3|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
45609508|NCT02522273|Device|EKF Diagnostics 'SensPoint' Lactate Meter|
45609509|NCT02557139|Drug|Belumosudil Tablet|
45609510|NCT02557139|Drug|Belumosudil Capsule|
45758082|NCT03255746|Behavioral|Health Education|This is a placebo/attention control condition. Participants will receive health education based on NIH information. Number, duration, and frequency of sessions will be identical to those administered to the intervention group.
45758083|NCT01799525|Procedure|Hypercapnia by reduction of respiratory volume|By reduction of the respiratory volume, PaCO2 is raised while paO2 is kept constant by modulation of the oxygen supply through the respirator,
45758084|NCT03888014|Device|GLOW800|The treatment group will consist of patients who require a medically necessary craniotomy. If an investigator deems that it will be useful to see blood vessels better with indocyanine green (ICG) videoangiography (VA), patients may be consented for the use if ICG VA using augmented reality (GLOW800). This will not add additional time or risk to their surgery
45609511|NCT01328717|Device|Contour Link Investigational Blood Glucose Monitoring System|Subjects with diabetes and study staff each performed Blood Glucose tests from the subject's capillary blood obtained from fingerstick using the Contour Link investigational meter.
45609512|NCT05338385|Behavioral|Mental Skills Coaching|Participants will partake in a 1-hour pre-op initial intake, followed by five 30-min follow-up sessions at 2 weeks, 6 weeks, 3 months, 6 months and 9-months post-op. All sessions will be one-on-one with the same master's-level mental skills coach. At each session, the provider will allow time for participants to share their current injury experience to date (i.e. how they are doing, challenges they have encountered). Following this, participants will be introduced to a series of mental skills tools, including but not limited to mindset awareness, motivation, cognitive restructuring, goal setting, and objective performance assessment. Participants will be provided with handouts outlining the strategies addressed to help maintain consistency of mental skills engagement between sessions.
45609513|NCT03465605|Diagnostic Test|frailty test|questionnaire
45758085|NCT03888014|Drug|indocyanine green (ICG)|This is a standard medication which can be given IV during a surgery to better visualize blood vessels under the microscope
45758086|NCT00551447|Drug|MK0653, ezetimibe / Duration of Treatment: 27 Weeks|
45758087|NCT00551447|Drug|MK0733, simvastatin / Duration of Treatment: 27 Weeks|
45758088|NCT00551447|Drug|Comparator: simvastatin / Duration of Treatment: 27 Weeks|
45934982|NCT00212602|Drug|ONO-7436|
45609514|NCT05336903|Behavioral|APP-led model of care for chronic pain management|"The APP will provide an assessment using a biopsychosocial approach. The assessment will include:~taking a comprehensive history~screening for pathologies contributing to the participant's chronic pain~a physical assessment~screening for comorbid health conditions, using the appropriate screening tools, that require specific care (e.g., depression, addiction, post-traumatic stress)~identifying psychosocial risk factors associated with pain and disability~evaluating pain severity and interference~The APP will make recommendations to the participant and the chronic pain clinic health care team based on findings from the comprehensive assessment. These recommendations include, but are not limited to, the need for urgent or emergent referrals, medication management, referral and integration of other health care providers, the need for interventional procedures, or group-based treatment options."
45609515|NCT01677741|Drug|Dabrafenib|Dabrafenib is available as 50 mg or 75 mg capsules and as oral suspension (10 mg/mL for subjects unable to swallow capsules). Dabrafenib (either formulation) will be administered orally as a single dose on Day 1 and twice daily from Day 2, based on weight at the appropriate study dose level.
45609516|NCT02457221|Drug|Tacrolimus capsules|oral
45609517|NCT02457221|Drug|Cyclophosphamide injections|intravenous injection
45609518|NCT02457221|Drug|Prednisone|oral
45609519|NCT03465293|Other|Bacterial composition and activity after bowel preparation|Bacterial composition and activity and patient's symptoms will be assessed pre and post bowel preparation taken as part of the preparation to have a pre-planned colonoscopy
45609520|NCT05302427|Behavioral|Infant Massage|The training will start with a leg massage in the first session and the mother will be asked to do this once a day until the next lesson. The next week, the new massage movement will be shown to the mother and the training will continue, and the mother will be told to do the application throughout the week by integrating it with the previous movement this time, and the four-week training will be completed in this way. After the training, which massage movement was taught to the mothers every week, the application pictures of this part will be sent and at the end of the four-week training, the baby massage video and the baby massage guide will be sent to the mothers by e-mail.
45609521|NCT05265221|Procedure|Endoscopic submucosal dissection|ESD was performed under conscious sedation. For sedation, midazolam and/or propofol were administered intravenously, with cardiorespiratory monitoring. Initially, indigo carmine dye was sprayed onto the tumor to clarify the margin. Then, markings were made 10 mm outside the tumor margin using argon plasma coagulation. After marking, a mixture of sodium hyaluronate with indigo carmine and epinephrine was injected into the submucosa outside the marking dots. Circumferential mucosal incision and submucosal dissection were performed using a Dual and/or IT knife. During the procedure, immediate bleeding was treated by Coagrasper. After ESD, chest and abdominal plain radiography were performed routinely for detection of gastric perforation.
45609522|NCT04660227|Procedure|Exercise Trainning|Participants in the online exercise program group will be given a treatment protocol consisting of aerobic exercise and strengthening exercises in the presence of a physiotherapist for a total of 8 weeks, 2 days a week for 1 hour. Before starting the exercise, the risk of possible injury will be minimized by doing warm-up exercises and preparations will be made to start the exercise. Then, the exercise program will be started with aerobic exercise. Strengthening exercises will be planned for large muscle groups, targeting body parts such as hips, knees, shoulders, abdomen and trunk. In exercises, it is planned to do 2 sets of 10-15 repetitions using elastic band, free weights or body weight. The exercise program will be created according to the condition of the people and progression will be provided every 2 weeks. After the exercises are completed, cool down will be done with relaxation and stretching exercises.
45609523|NCT04660227|Other|Control Group|Participants in the control group will be put on the waiting list after all assessment methods have been applied and will be re-evaluated at the end of 8 weeks. After the final evaluations, they will be directed to the exercise group.
45609524|NCT05375019|Behavioral|Positive discipline program|The intervention group was provided with 8 weekly sessions of a 90 minutes positive discipline program
45609525|NCT05375019|Behavioral|active control group|free interaction group consisting of topics determined by the families.
45609526|NCT05263895|Drug|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single dose orally
45609527|NCT05263895|Drug|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
45609528|NCT05263895|Drug|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
45609529|NCT05263895|Drug|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
45609530|NCT05263895|Drug|PF-07321332|PF-07321332 will be administered as single oral dose orally.
45609531|NCT03134781|Behavioral|DoIT workout|A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management. FFIT was performed 3 times/week with 48 hours recovery between sessions for 40 weeks.
45609532|NCT03134781|Behavioral|DoIT workout - Detraining|A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training, performed according to a periodized model of exercise prescription for a 20-week period (3 times/week). Immediately after a 20-week detraining period (no training was performed) was followed.
45609533|NCT03134781|Behavioral|Control - No training|No training was performed during a 40-week period. Participation only in measurements.
45609534|NCT05233241|Other|in vitro Allergological test Allergological skin tests|"In vitro allergological tests: lymphocyte transformation test, measurement of CD154 membrane expression, ELISPOT-IFNgammma Allergological skin tests (patch tests, prick tests and intradermal tests with European standardised method) in case of negative in vitro tests."
45758089|NCT02299479|Device|Dexcom G4 Platinum CGM|Blood glucose levels will be monitored using continuous glucose monitors (CGMs). Participants will be asked to verify CGM low blood sugars using their home glucometer. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
45609535|NCT03465215|Device|Digital holographic microscopy|Tissue obtained from CD patients will be analyzed using digital holographic microscopy. Results will be compared between non-stenotic and stenotic tissue of the intestinal wall of CD patients.
45609536|NCT03344991|Other|Cardboard Cot Care|When ready to be weaned from radiant warmer, infant will be placed in a reflective film-lined cot for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found < 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
45609537|NCT03344991|Other|Open Crib|When ready to be weaned from radiant warmer, infant will be placed in a standard of care open crib for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found < 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
45609538|NCT04639635|Other|No intervention, this is a natural history progression study|The objective is to better understand the disease process of CNGB1-RP so that we can develop clinical tests to measure the outcomes of treatment.
45609539|NCT01709981|Drug|Colchicine|Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later
45609540|NCT01709981|Drug|Placebo|Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later
45609541|NCT03465137|Behavioral|Coordinated Anxiety Learning and Management (CALM)|Exposure-focused cognitive behavioral therapy
45609542|NCT03268083|Biological|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AI(OH)3] per dose)|Two vaccinations at 28 days apart
45609543|NCT03268083|Biological|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AI(OH)3] per dose)|Two vaccinations at 28 days apart
45609544|NCT03268083|Biological|EV71 vaccine ([1 μg total protein ] per dose)|Two vaccinations at 28 days apart
45609545|NCT04458467|Device|Continuous Infusion|A continuous infusion of ropivacaine 0.2% (6 mL/hr, 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room.
45609546|NCT04458467|Device|Automated Intermittent Boluses|Administration of automated intermittent boluses of ropivacaine 0.2% (8 mL every 2 hr with 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room, but with a 5-hour delay for the first bolus (can be overridden by patients if they would like to initiate their perineural infusion earlier than 5 hours).
45609547|NCT04438239|Other|none, this study is observational|none, this study is observational
45609548|NCT04560543|Procedure|McCall suture|Laparoscopic suture including the uterosacral ligaments and the peritoneum
45609549|NCT04560543|Procedure|Standard cuff closure|Standard laparoscopic barbed suture of the vaginal cuff
45609550|NCT03465059|Drug|Zanubrutinib|A single oral dose of 80 mg Zanubrutinib will be administered.
45609551|NCT04280991|Other|Moderate intensity exercise under mild normobaric hypoxia and normoxia|The participant will perform the exercise interventions consisting of cycling at the heart rate corresponding with 50%WMAX (normoxia) or heart rate corresponding with 50% WMAX (hypoxia) for 30 minutes, twice a day, for 4 consecutive days. 24h glucose concentration will be monitored continuously.
45609552|NCT05185895|Procedure|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
45609553|NCT05185895|Procedure|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
45609554|NCT03170817|Diagnostic Test|Cardiac Perfusion Rest/Stress Digital PET/CT|"Patients with coronary artery disease undergo a N-13 ammonia rest/stress PET/CT scan.~These patients are given:~One 5-10 mCI N13-ammonia (13N-NH3) intravenously and undergo a rest digital PET/CT scan of ~20 minute duration.~A dose of 0.4 mg regadenoson (Lexiscan) intravenously over 10 seconds to increase blood flow to the heart~One 5-10 mCi N13-ammonia (13N-NH3) intravenously and undergo a stress digital PET/CT scan of ~20 minute duration~Total patient time will take approximately up to 120 minutes."
45758090|NCT02299479|Device|Activity monitor|Participants will be asked to wear an activity monitor so that we may assess their daily activity level. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
45758091|NCT01968057|Drug|Baricitinib|Administered orally
45758092|NCT01968057|Drug|Ciclosporin|Administered orally
45609555|NCT03170817|Drug|N-13 ammonia|5-10 mCi intravenous injection of N-13 ammonia radiopharmaceutical at rest and at stress
45609556|NCT03170817|Drug|Regadenoson|0.4 mg/5mL intravenous injection to induce pharmacologic stress (Astellas Pharma US, Inc.)
45609557|NCT04453319|Procedure|Femoral Wound Closure and dressing|Femoral Wound Closure and dressing
45609558|NCT03025425|Device|Trilogy 100 ® (Philips Respironics)|Mouth piece Ventilation (MPV) using Trilogy 100 ® (Philips Respironics).
45609559|NCT05101005|Device|Drug-Coated Balloon|Drug-coated balloon is a fast-exchange balloon dilatation catheter, used to treat coronary artery stenosis lesions.
45609560|NCT05101005|Device|Sirolimus-Eluting Stent|Sirolimus-Eluting Stent is treated for coronary artery stenosis lesions.
45758093|NCT01968135|Drug|Combined Oral Contraceptive Pill|150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
45758094|NCT01968135|Drug|Placebo Sugar Pill|Placebo Sugar Pill
45758095|NCT00658697|Drug|Docetaxel|Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
45758096|NCT00658697|Drug|Bevacizumab|Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
45758097|NCT00658697|Drug|ADT|Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
45758098|NCT00658697|Drug|Bicalutamide|Starting on day 84 orally once daily until hormone therapy is completed
45758099|NCT03873116|Drug|BCX7353 capsules|BCX7353 capsules administered orally once daily
45609561|NCT05100693|Other|Fetoscopic Endoluminal Tracheal Occlusion with the Smart-TO Balloon|Fetal Endoscopic Tracheal Occlusion using the Smart-TO balloon and non-invasive balloon removal by the peripheral magnetic field of an magnetic resonance scanner.
45609562|NCT04437719|Other|Obvio-19 app|"As part of this research, the patient must complete questionnaires daily on the Obvio-19 application, one of 5 minutes.~Evaluation of the proportion of patients with COVID-19 infection's symptoms known to be associated with COVID-19 diagnosis (fever, cough, loss of taste and smell, sore throat, muscle pain, diarrhea, fatigue, difficulty eating and drinking and shortness of breath) followed during a period of 6 months.~To assess the prevalence and course of symptoms of COVID-19 infection of patients followed during a period of 6 months.~To establish the correlation of the COVID-19 infection with the biological and clinical data of patients from the Oncology cohort of the Groupe hospitalier Paris Saint-Joseph in Paris followed during a period of 6 months."
45609563|NCT05100615|Procedure|surgery|applying the graft inside bony defect after surgery
45609564|NCT04387877|Device|Graston|"Graston technique will be applied on the lateral and posterior fascia (tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.~For the first 2 weeks; dorsolumbar stabilization, straight and side leg lifting, gluteal setting, side walking exercises For the second 2 weeks; dorsolumbar stabilization counting on spot, straight and side leg lifting, gluteal setting, side walking exercises with 0.5 kg weight on the ankle, piriformis, tensor fascia lata and hamstring stretching exercises"
45609565|NCT04387877|Other|Sham|"Sham graston technique will be applied on lateral and posterior fascia (tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.~(Sham graston technique will be applied by partially touching the skin overlying the muscle or fascia region via ultrasound gel with the flat part of the Graston instrument so as not to provide any activity of the fascia) For the first 2 weeks; dorsolumbar stabilization, counting on spot, straight and side leg lifting, gluteal setting, side walking exercises For the second 2 weeks; dorsolumbar stabilization counting on spot, straight and side leg lifting, gluteal setting, side walking exercises with 0.5 kg weight on the ankle, piriformis, tensor fascia lata and hamstring stretching exercises"
45609566|NCT04382495|Other|survey|online survey
45609567|NCT04366817|Behavioral|psychological assessment|psychological assessment at D10-12 and 6-8 weeks : Scheduled telephone interview using the assessment scales (EPDS, PPQ, MIBS, DAS-16) on D10-D12 and 6-8 weeks postpartum with a psychologist
45609568|NCT05091983|Other|Sensory Processing Scale Inventory (SPSI)|The Sensory Processing Scale Inventory (SPSI) is the main questionnaire. It allows to define over and under sensitive profiles. It's a self-administrated questionnaire
45609569|NCT05091983|Other|Autism Spectrum Screening Quotient (ASSQ)|"The ASSQ allows to detect autism spectrum disorders (ASD). This quotient is proposed to the group because the investigators know that ASD are often correlated with sensory integration disorders.~It's answered by the participant's parents."
45609570|NCT05091983|Other|GAD 7|"The GAD7 questionnaire allows to detect anxiety disorder. This questionnaire is proposed to the group because the investigators know that anxiety disorders are often correlated with sensory integration disorders.~It's a self-administrated questionnaire."
45758100|NCT03873116|Drug|BCX7353 capsules|BCX7353 capsules administered orally once daily
45758101|NCT03873116|Drug|Placebo oral capsule|Matching placebo capsules administered orally once daily
45758102|NCT01968447|Other|hypocapnia|Hyperventilation to the level of hypocapnia
45758103|NCT01968447|Other|normocapnia|Normal ventilation to the level of nromocapnia
45609571|NCT05091983|Other|Conners abridged|"The Conners abridged questionnaire allows to detect attention-deficit hyperactivity disorder (ADHD). This questionnaire is proposed to the group because the investigators know that ADHD are often correlated with sensory integration disorders.~The questionnaire is answered by the participant's parents."
45609572|NCT05091983|Other|EAT 26|"The EAT 26 questionnaire allows to detect anorexia nervosa. It is proposed to the patient with an eating disorder to establish the level of severity of their disease.~It's a self-administrated questionnaire."
45609573|NCT04452773|Dietary Supplement|Manremyc|Manremyc is composed by 10E5 heat-inactivated Mycobacterium s. manresensis bacilli
45609574|NCT04452773|Dietary Supplement|Placebo|Same excipients than active arm without bacilli.
45609575|NCT04452851|Device|BREATHE|The on-demand handheld portable noninvasive positive pressure airway device unit generates BiPAP by using a built-in blower which intakes air from the nearby ambient. The BiPAP pressure functions as a virtual stent within the lungs of a user with COPD. The virtual stent opens the passageways within the user lungs. Once opened, the virtual stent facilitates gas exchange in order to relieve dyspnea. By temporarily facilitating this gas exchange, the user will quickly recover from dyspnea in order to resume regular activities.
45758104|NCT01795469|Device|Zoex compression garment|5-strap compression of abdomen, thighs and legs
45758105|NCT04399226|Drug|Dexmedetomidine|Group D received 1mg/kg dexmedetomidine+0.5mg/kg propofol intravenous (iv) bolus, 0.5 μg/kg/h dexmedetomidine+ 0.5 mg/kg/h propfol infusion. Group K received 0.125 mL/kg bolus, 0.125 mL/kg/h ketamine+ propofol = ketofol infusion (ketofol was prepared with 4 mg propofol+2 mg ketamine).
45758106|NCT00659165|Drug|Insulin Detemir|Subjects will be given a dose of detemir equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
45758107|NCT00659165|Drug|Insulin Glargine|Subjects will be given a dose of glargine equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
45758108|NCT02299791|Other|ALL|"This clinic-level intervention involves a toolkit of decision support tools. These tools are listed below.~EHR tools to expedite identification~a. EHR automated point-of-care alerts (Best Practice Alerts)~EHR tools to expedite prescribing~EHR order sets~EHR text shortcuts for notation~patient education materials (handout, poster)~EHR-based outreach support tools a. EHR registries"
45758109|NCT02299791|Other|ALL|These clinics got the same exact intervention, but one year later, as this was a staggered randomized trial.
45758110|NCT00700973|Behavioral|Interpersonal Violence Prevention Intervention|This is a cognitive-behavioral approach incorporating cognitive restructuring and behavioral change.
45609576|NCT04452851|Device|BiPAP|BiPAP stands for Bilevel Positive Airway Pressure, and is very similar in function and design to a CPAP machine (continuous positive airway pressure). A BiPAP machine is a non-invasive form of therapy for patients suffering from sleep apnea.
45609577|NCT04452851|Drug|COPD Inhaler|Inhaler medication to support quick relief from COPD symptoms
45609578|NCT05069363|Device|Whole-Body Photobiomodulation Therapy|"All participants entering the trial will receive a course of whole-body PBM therapy~The NovoTHOR Whole-Body PBM therapy device consists of a hinged, clamshell design with light-emitting diodes (LEDs) arranged to emit near-infrared and visible red light therapy is delivered to the entire body at once.~Participants will be expected to lie horizontal in the device with the lid as closed as they are comfortable with.~18 sessions is the currently recommended and widely instituted and accepted practice with the NovoTHOR device.~The LED equipment delivers red and near infrared light therapy to the participant~Session 1 = 6 minutes~Session 2 = 12 minutes~Sessions 3-18 = 20 minutes~Timescale: 3 treatments/week for 6 weeks~The dosage of LED light (also known as 'fluence') will be equivalent to 25J/cm2. The device will supply a dual wavelength of red and near-infrared light with a 50:50 ratio; 660nm and 850nm respectively"
45609579|NCT03130205|Procedure|Core Needle Biopsy|Core Needle Biopsy is performed from liver metastasis.
45609580|NCT03130205|Radiation|Computed Tomography|Computed Tomography
45609581|NCT03130205|Radiation|18F-FDG-PET|18F Fluorodeoxyglucose Positron emission tomography
45609582|NCT03130205|Procedure|Phlebotomy|3 EDTA tubes drawn from peripheral vein
45609583|NCT03130205|Genetic|Molecular genetic analysis|Performed on biomaterial from peripheral vein and core needle biopsy
45609584|NCT05015387|Procedure|Minimally invasive non-surgical therapy|Under local anesthesia subgingival instrumentation with ultrasonic and hand instruments and magnification (4.5x) was performed.
45609585|NCT05015387|Combination Product|Subgingival application of collagen hydrogels with proanthocyanidins|Patients received collagen hydrogel chips with proanthocyanidins from Pelargonium sidoides root extract, placed subgingivally in periodontal pockets with PPD≥4mm after minimally invasive non-surgical therapy.
45609586|NCT05015387|Diagnostic Test|Collection of saliva samples|For MMP-3/TIMP-1 detection, the collection of saliva samples was performed using Salivette (SARSTEDT AG and Co, Germany) saliva sample collection kit. Saliva samples were collected at the baseline for all patients and 8 weeks after treatment. Samples were centrifuged at 3500 rpm (2 min), aliquoted and protease inhibitors cocktail (1 mg/ml) was added to each sample. All samples were stored at -80oC. MMP-3, TIMP-1 concentration in saliva samples was examined using commercial ELISA kits (Elabscience, USA) and Multiskan Microplate Photometer (Thermo Fisher Scientific) at 450 nm wavelength. Saliva MMP-3/TIMP-1 samples were collected before treatment and 8 weeks after treatment.
45609587|NCT03464825|Other|Specific and progressive balance training|Specific and progressive balance training for the intervention group
45609588|NCT03464747|Device|EIRUS system (Maquet Critical Care AB, 17154, Solna, Sweden)|continuous measurement of venous lactate through a central venous catheter by microdialysis
45609589|NCT04984343|Radiation|Radiation Therapy|"Eligible subjects will be randomly assigned to 5 or 2 fraction treatment groups in a 1:1 ratio using a computer-generated randomization scheme.~After consent and eligibility verification, patients will undergo CT/MRI simulation and radiotherapy planning. Patients will receive treatment to the prostate +/- seminal vesicles per treating physician's discretion in either 37.5 Gy in 5 fractions or 25 Gy in 2 fractions. SIB use is at treating physician's discretion and should be concordant with imaging and biopsy findings with no PTV expansion.~Subjects on 5 fraction arm should be treated on non-consecutive days. Subjects on the 2 fraction arm must have >72 hours between beginning of each fraction."
45609590|NCT03464513|Device|Multislice CT Angiography|Multislice CT angiography (MSCTA) provides a relatively non-invasive and effective way of localising the source of bleeding, especially in patients with continuous bleeding.
45609591|NCT00003857|Drug|tamoxifen citrate|
45609592|NCT00003857|Procedure|adjuvant therapy|
45609593|NCT00003857|Radiation|radiation therapy|
45609594|NCT03464435|Drug|Tacrolimus|All the patients will be treated with 0.1% tacrolimus suspension two times daily, LE/T eye drops four times daily for 1 month. 0.1% tacrolimus will be continued for the last 5 months.
45609595|NCT03464357|Radiation|fMRI|"The BOLD (Blood-Oxygen-Level Dependent) signal obtained by fMRI reflects the rate of oxygenation of the blood in the brain. However, the hemodynamic response that corresponds to an inflow of oxygenated blood increases in regions that consume energy. Thus, it is possible, by the study of the BOLD signal, to know with a great precision the regions of the brain specially active during a given task.~The recorded signals reflect a neuronal activation. For each eye, recordings with and without flash visual stimulation are performed alternately."
45609596|NCT03464279|Behavioral|Nudge using Behavioral Economic Interventions|
45609597|NCT03464279|Behavioral|Standard Practices to Reduce Health System Antibiotic Prescription|
45609598|NCT03468647|Other|soles|Volunteer must walk this this connected seamless to measure different walking parameters
45609599|NCT03468647|Other|weighting machine|This weighting machine measure weight evolution and equilibrate of volunteers
45609600|NCT03468647|Other|gripping force|this machine measure the gripping force of volunteer
45609601|NCT03468569|Other|Functional Movement Screen|
45609602|NCT03468491|Other|combined training|The whole intervention period will last for 6 weeks, 2 visits per week, 1 hour per visit in the Research Building Room 630 of National Yang Ming University. All programs will be under the supervision of a physiotherapist with 2-year experience individually. 1. Hallux valgus correction: 1.1 Joint alignment correction (Grade II joint mobilization, 10 times/set, 3 sets/visit) - 1st MTP joint distraction - Proximal talofibular joint anteroposterior glide - (Grade III joint mobilization if any restriction being found) 1.2 Biomechanical taping (using Dynamic taping, 1 time/ visit, keep the taping for 2 days minimum) 1.3 Foot intrinsic muscle strengthening (10 times/set for each exercise, 3 sets/visit): - Short foot exercise - Toespread out exercise - Heel-rise exercises 2. Lower extremity neuromuscular exercises: (10-15 times/set, 3 sets/visit) 2.1 Single lunge 2.2 Stepping down 2.3 Vertical squat 2.4 Vertical jumping
45758111|NCT00700973|Other|Usual care|Substance use disorder usual care
45609603|NCT03468491|Other|Proximal training|1. Lower extremity neuromuscular exercises: (10-15 times/set, 3 sets/visit) 1.1 Single lunge 1.2 Stepping down 1.3 Vertical squat 1.4 Vertical jumping All exercises will first start on firm surface without additional resistance/weight. Later, settings will be gradually shifted into on firm surface with resisted band from random direction, on a cushion with/ without resisted band, on a BOSU balance trainer. Progression are made every 2 weeks ideally, while adjustments may be taken into concern due to individual differences.
45609604|NCT03464123|Other|Standard cardiopulmonary resuscitation|Standard Advanced Life Support based on guidelines 2015, including mechanical chest compression device
45609605|NCT03463967|Dietary Supplement|Lycopene-enriched tomato juice|Energy-restricted diet supplemented with Lycopene-enriched tomato juice
45609606|NCT03463967|Other|Energy-restricted diet|
45609607|NCT03463811|Diagnostic Test|Lactate concentration in vaginal fluid|Lactate concentration in vaginal fluid
45609608|NCT03129971|Procedure|conventional surgery|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to control group, which received conventional surgery.
45609609|NCT03129971|Procedure|autologous platelet-rich plasma|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to experimental group, which are injected with autologous platelet-rich plasma on the basis of conventional surgery.
45609610|NCT03468413|Drug|CP1050 or Placebo|Randomised, double-blinded, placebo-controlled
45758112|NCT03864848|Device|Mitral Touch Implant|The study population for this study will be comprised of patients who are to undergo cardiac surgery with a sternotomy (e.g. CABG) and who present moderate to severe ischemic or functional MR. In order to be considered eligible for the study, each patient must meet the conditions listed in the inclusion and none of the exclusion criteria.
45609611|NCT03463733|Drug|Hydroxyurea|147-94-4/HYDROXYCARBAMIDE/HYDROXYCARBAMIDE/based on myeloproliferative disorders (MPD) record: SUB08076MIG
45609612|NCT03463733|Drug|Temozolomide|85622-93-1 /TEMOZOLOMIDE/TEMOZOLOMIDE/based on myeloproliferative disorders (MPD) record: SUB10889MIG
45609613|NCT03463655|Diagnostic Test|cirrhotic albumin|Ascites puncture
45609614|NCT03463655|Diagnostic Test|serum albumin|blood punctures
45609615|NCT03468257|Behavioral|Pavlovian Conditioning|Imagining a stressful event, engaging in progressive muscle relaxation, and eating fruit
45609616|NCT04258943|Drug|Bosutinib|"Patients with R/I disease are enrolled at a dose of 400 mg/m2 (DL2B) based on tolerability and PK analysis. Once the RP2D for R/I patients (RP2DR/I) is determined in the Phase 1, subsequent patients with R/I disease will be enrolled at the RP2DR/I for this subpopulation for the Phase 2 component of the study (see section 1.6.3 and section 3 for details).~- Patients with newly diagnosed disease are being enrolled on Phase 2 component only, at RP2DND dose of 300 mg/m2. (see section 1.6.3 and section 3 for details)"
45609617|NCT03463343|Other|Cervical spine manual manipulation|In the Manual manipulation group, the thrust was applied in the right side of C3/C4 with neutral flexion/extension, ipsilateral side bending and contralateral rotation. Then, a low amplitude, high velocity thrust in rotation was delivered.
45609618|NCT03463343|Other|Cervical spine mechanical manipulation|In the Mechanical manipulation group, the Activator instrument was applied on the right transverse apophyses of C3.
45609619|NCT03463343|Other|Placebo intervention|The subjects were positioned in the same pre-manipulative position as the manual manipulation group, but the thrust didn't occur. Instead, the position was hold for 3 seconds and then the subject's head returned passively to neutral position.
45609620|NCT03468101|Other|Pulmonary Function Testing|Pulmonary Function Testing, Cardiopulmonary exercise testing, 6 Minute walk test, Thoracic CT
45609621|NCT03463187|Biological|SHR-1314|Administered subcutaneously
45609622|NCT03463187|Drug|Placebo|Administered subcutaneously
45609623|NCT04222595|Other|Fluenz Tetra nasal spray suspension|Prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
45609624|NCT03468023|Procedure|Short arm cast|Application of a below-elbow cast
45609625|NCT03468023|Procedure|Long arm cast|Application of an above-elbow cast
45609626|NCT04176185|Biological|Sublingual allergy immunological tablet|For daily administration (1 tablet per day)
45609627|NCT04176185|Other|Placebo|For daily administration (1 tablet per day)
45609628|NCT04830215|Drug|Brexpiprazole|Brexpiprazole (flexible dose; 0.5 to 2 mg once daily [QD]) as adjunctive therapy to antidepressant therapy (ADT)
45609629|NCT03463109|Other|Electrocutaneous stimulation|Painful electrocutaneous stimuli will be randomly delivered to electrodes positioned in a random order on the participants' back. Participants will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation.
45609630|NCT03463109|Other|Assessment + Electrocutaneous stimulation|"Patients will be asked to provide information about their lifestyle, level of disability, actual pain and general pain, assessment of kinesiophobia and health status.~Subsequently, painful electrocutaneous stimuli will be randomly delivered to electrodes positioned in a random order on the patients' back. Patients will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation."
45609631|NCT04803149|Device|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe
45758113|NCT02299869|Device|Verde (Competitor-control)|contact lens
45758114|NCT02299869|Device|Green (CVI-test)|contact lens
45758115|NCT02299869|Device|Cinza (Competitor-control)|contact lens
45609632|NCT04803149|Device|Conventional Radiofrequency|Delivery of energy to ablate sensory nerves via standard or conventional radiofrequency probe
45609633|NCT04802603|Radiation|Spine stereotactic body radiotherapy|"Cohort 1 - De novo: Spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions.~Cohort 2 - Prior radiotherapy: Risk-adapted spinal cord tolerance based on prior spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions."
45609634|NCT03467711|Other|tidal volume challenge|transiently increasing tidal volume from 6 to 8 mL/kg predicted body weight (tidal volume challenge)
45609635|NCT03467711|Other|volume expansion|give 6ml/kg (predicted body weight) volulyte for 10min
45758116|NCT02299869|Device|Grey (CVI-test)|contact lens
45758117|NCT02299869|Device|Esmeralda (Competitor-control)|contact lens
45758118|NCT02299869|Device|Jade (CVI-test)|contact lens
45609636|NCT03462953|Procedure|Gingival tissue samples will be harvested|"Gingival tissue samples will be harvested during the premolar extraction (Orthodontic ttt) or third molar extraction for the healthy controls and during periodontal surgery or extraction of hopeless teeth with periodontal disease ..~The dissected gingival samples will be washed in saline solution and fixed in 4% buffered formalin for 48 hours, dehydrated in ascending grades of ethyl alcohol, cleared in xylene and embedded in paraffin and will be subjected to the following:.~Sections of 4-5 µm in thickness will be obtained, deparaffinized, rehydrated and subjected to histological staining and histomorphometric analysis.~Real time- PCR for TGF-B1 ,Vimenten , E-Cadherin ."
45609637|NCT04259151|Device|Electric wheelchair with activated assistance module|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance
45609638|NCT04259151|Device|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with no activated assistance
45609639|NCT03467633|Behavioral|High-intensity interval training|Participants in the HIIT group will receive 3-weeks of tri-weekly supervised exercise sessions at the UOHI prior to their scheduled electro-cardioversion. The session will last 23 minutes in duration and consist of a 2-minute warm-up at 50% of peak power output (PPO), 2 x 8-minute interval training blocks of 30 seconds at 80-100% of PPO interspersed with 30-seconds of active recovery and a 1-minute cool down at 25 % of PPO. The sessions will be lead by a Registered Kinesiologist.
45609640|NCT05100303|Drug|Mitoxantrone Hydrochloride liposome injection|Mitoxantrone hydrochloride liposome will be administered by intravenous (IV) injections.
45609641|NCT05100303|Drug|Cytarabine (LoDAC)|Low-dose or high-dose cytarabine (LoDAC) will be administered by intravenous (IV) injections.
45758119|NCT02299869|Device|Azul (Competitor-control)|contact lens
45609642|NCT02522585|Other|Conservative management|Control of CIN-II with cytology and colposcopy to try to avoid unnecessary surgery
45609643|NCT05100147|Procedure|Uterine closure during Cesarean section|The uterotomy is sutured after the delivery of the fetus and the placenta with an appropriate delayed absorbable suture (number 1 polyglactin 910)
45758120|NCT02299869|Device|Blue (CVI-test)|contact lens
45758121|NCT00542087|Drug|MK0663, etoricoxib / Duration of Treatment: 6 Weeks|
45758122|NCT00542087|Drug|Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks|
45609644|NCT05097105|Device|MRI|MRI sequences: TI. T2 and diffusion weighted
45609645|NCT03467555|Device|Class II correction using miniplates in zygomatic region|
45609646|NCT04035759|Behavioral|APPEAL|Three-session, individually administered program, with sessions spaced monthly. Optional weekly contacts with participants to support engagement in program exercises/activities.
45758123|NCT04277624|Drug|fezolinetant - test formulation|Administered orally
45609647|NCT02734823|Other|Cytology Specimen Collection Procedure|Undergo collection of serum
45758124|NCT04277624|Drug|fezolinetant - reference formulation|Administered orally
45758125|NCT00541697|Drug|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
45609648|NCT02734823|Other|Laboratory Biomarker Analysis|Correlative studies
45758126|NCT00541697|Drug|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
45758127|NCT03223376|Combination Product|fruquintinib +paclitaxel|treatment arm(fruquintinib +paclitaxel)- subjects will receive Fruquintinib orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
45758128|NCT03223376|Combination Product|fruquintinib placebo + paclitaxel|control arm(fruquintinib placebo + paclitaxel)- subjects will receive Fruquintinib placebo orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
45758129|NCT00395603|Drug|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
45758130|NCT00395603|Drug|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
45609649|NCT02734823|Other|Questionnaire Administration|Ancillary studies
45609650|NCT02734823|Procedure|Ultrasonography|Undergo transvaginal pelvic ultrasonography
45609651|NCT05096871|Genetic|Genotyping by Real Time PCR|"3 mL of blood will be withdrawn by venipuncture in EDTA tube. DNA extraction will be done after centrifugation and used for genotyping assay of ( BDNF ) gene with the Real- time polymerase chain reaction.~BDNF level in serum will also be analyzed by Sandwich enzyme linked immunosorbant assay kit ( ELISA)."
45609652|NCT03462173|Drug|yimitasvir|Capsule administered orally once daily
45609653|NCT03462173|Drug|placebo|Matching Placebo Capsule
45758131|NCT00659633|Drug|lidocaine|intravenous, effect site concentration: 2mcg/ml, 15-20 min infusion, once
45758132|NCT02300025|Drug|cobimetinib|single oral 10-mg dose of cobimetinib
45758133|NCT00328523|Drug|MK-0653, ezetimibe|
45758134|NCT00328523|Drug|Duration of Treatment: 3 months|
45609654|NCT05096715|Drug|Atezolizumab|Intravenous Infusion
45609655|NCT05096715|Drug|Bevacizumab|Intravenous Infusion
45609656|NCT05096715|Radiation|Stereotactic body radiation therapy (SBRT)|External Beam Radiation
45609657|NCT03462485|Other|Golf|Eight weeks of twice-daily golf training
45609658|NCT05096637|Other|PreventiPlaque App|PreventiPlaque is an app that supports patients with atherosclerotic plaque by strengthening their adherence.
45609659|NCT04984889|Drug|TAK-662|Lyophilized, sterile concentrate of human protein C
45609660|NCT05096559|Device|Microcirculation cytocam|Visualization of tongue microcirculation
45609661|NCT05099601|Combination Product|Silymarin|The patients will use topical silymarin 0.7% cream on the face twice daily(home use).
45609662|NCT05099601|Procedure|Microneedling|Patients will be subjected to microneedling sessions on one side of the face. Three consecutive sessions, 4 weeks apart (0, 4, 8 weeks), will be performed by dermapen. Sessions will be done by well trained physician.
45609663|NCT03462095|Procedure|Autologous HSCT|After the 3rd consolidation, T-cell ALL patients, randomized to auto-HSCT will be mobilised by G-SCF and harvested disregarding MRD-status. After completing the 5th consolidation T-ALL patients will be transplanted after non-myeloablative CEAM (CCNU, Ethoposide, ARA-C, Melphalan) conditioning, and after reconstitution will continue 2-years maintenance
45609664|NCT05099523|Procedure|taking arterial blood sample through the injector|taking blood samples from patients applied with different oxygen concentrations
45609665|NCT05104203|Procedure|Thoracolumbar Interfascial Plane block|Interfascial block done by injection between m. multifidus and m. longissimus
45609666|NCT05104203|Procedure|Modified Thorcolumbar Interfascial Plane block|Injection of local anesthetics between m. longissimus and m. illiocostalis
45609667|NCT04958057|Behavioral|SAIL|6 monthly group sessions with the study nurse with a background in prenatal care and the PI that will include each group will include preeclampsia education, coaching on stress management, resource navigation, and training in problem solving.
45609668|NCT04437147|Dietary Supplement|Placebo|Fibers with vitamins and minerals will be administered for 30 days once a day in sachets
45609669|NCT04437147|Dietary Supplement|3 Billion UFC strains of probiotics|Fibers with vitamins and minerals will be administered for 30 days once a day in sachets with 3 billion CFU strains of probiotics
45609670|NCT04437147|Dietary Supplement|8 Billion UFC strains of probiotics|Fibers with vitamins and minerals will be administered for 30 days once a day in sachets with 8 billion CFU strains of probiotics
45609671|NCT03736629|Drug|Azithromycin|8 weeks of Azithromycin (250 mg) once daily by mouth
45609672|NCT03736629|Drug|Placebo|Placebo
45609673|NCT03461939|Other|ePRIME symptom monitoring tool|ePRIME is an online system for patients to self-report symptoms and AE during cancer treatment. ePRIME allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating notifications for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
45609674|NCT03461783|Device|Zorflex Activated Carbon Dressing|Antimicrobial dressing
45758135|NCT03204266|Drug|Arginine recovery supplement|Participants take 1 ounce (30mls) of Arginine recovery supplement four times daily 5 days preoperatively and 14 days postoperatively.
45758136|NCT03204266|Dietary Supplement|Omega-3 Fatty Acids|Participants given omega-3 fatty acids, 1 gram four times a day, 4 grams total per day. This will be started 7 days preoperatively and continued 14 days postoperatively.
45934983|NCT02966730|Drug|Ibrutinib|Ibrutinib will be administered orally, on a once daily continuous dosing schedule and in an outpatient setting. Treatment will continue for 2 years and there will be no planned treatment breaks. The dose of Ibrutinib will be initiated at 560mg per day, which will remain constant throughout the study period, unless otherwise specified.
45934984|NCT00212641|Drug|ONO-5129|
45609675|NCT03461783|Device|Standard of Care|foam, calcium alginate, hydrogel, or compressive dressings
45609676|NCT01677507|Drug|Variation in eye pressure response to timolol and latanoprost treatment|Arm 1 is to test for variation in eye pressure response to timolol. Arm 2 is to test for variation in eye pressure response to latanoprost.
45609677|NCT04853693|Behavioral|Mom´s Supporting Mom|A preventive peer consultation intervention for Postpartum Depression.
45609678|NCT04853693|Behavioral|Enhanced Treatment As Usual|Referral to treatment in the community, clinical monitoring
45609679|NCT03656367|Dietary Supplement|Cheddar cheese|The reference product is a commercial matured cheddar cheese
45609680|NCT03656367|Dietary Supplement|Blended and homogenized cheddar cheese|A blended and homogenized cheddar cheese (a spread) which, compared to the reference, has a minimal protein network and has smaller fat droplet
45609681|NCT03656367|Dietary Supplement|An analog milk|An anolog milk (i.e. milk with a cheese-like nutritional composition) which, compared to the reference, does not contain a protein network
45609682|NCT03656367|Dietary Supplement|An analog cheese|This analog cheese (a gel/yoghurt) is produced from the analog milk which, compared to the reference, has a protein network, however it is a network that differs from the reference
45609683|NCT04796363|Procedure|Erector Spinae Plane Block with Bubivacaine|Erector Spinae Plane Block with Bubivacaine 0.25% or 0.125% before breast cancer surgery
45609684|NCT04796363|Procedure|Standard General Anaesthesia|Standard General Anaesthesia without ESPB
45609685|NCT03593109|Drug|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
45934985|NCT00212680|Drug|ONO-1101|
45934986|NCT00073242|Drug|Leptin|leptin administration
45934987|NCT00073242|Behavioral|Dietary modification|Subjects lose 10% of body weight via dietary restriction
45934988|NCT00073242|Drug|T3 repletion|administer T3
45934989|NCT00212719|Drug|ONO-5920|
45609686|NCT03566433|Procedure|Tep surgery for inguinal hernia|TEP surgery
45609687|NCT03566433|Procedure|Lichtenstein|Lichtenstein surgery for inguinal hernia
45609688|NCT03522753|Device|Metal skin staples|Routine closure methods/material for surgical wounds
45609689|NCT03522753|Device|Nylon sutures|Routine closure methods/material for surgical wounds
45609690|NCT05103813|Drug|Beraprost Sodium Tablets|Protective effect of Beraprost Sodium Tablets on coronary microcirculation function and ventricular remodeling after reperfusion therapy for acute ST segment elevation myocardial infarction
45609691|NCT03461627|Drug|Salmeterol Xinafoate and Fluticasone Propinate Powder|50ug/250ug 1 puff twice a day for 4 weeks
45609692|NCT03461627|Drug|Seretide|50ug/250ug 1 puff twice a day for 4 weeks
45609693|NCT04452929|Drug|Erenumab|Subcutaneous injection of 140 mg erenumab.
45609694|NCT04452929|Drug|Placebo|Subcutaneous injection of saline placebo.
45609695|NCT04452929|Drug|Calcitonin gene-related peptide|Intravenous infusion of 1.5ug/min calcitonin gene-related peptide over 20 minutes.
45609696|NCT04452929|Drug|Cilostazol|Oral intake of 200 mg cilostazol.
45609697|NCT05095701|Biological|Investigational Live Attenuated Varicella Vaccine|The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0·5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.
45609698|NCT05095701|Biological|Placebo (Freeze Dired Dilution)|The placebo (freeze dired dilution) was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. and contained no active ingredient.It was 0·5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride and phosphate.
45609699|NCT03461471|Behavioral|Exercise Intervention|Exercise intervention
45609700|NCT03099681|Other|Treatment for Epitheloid Sarcoma|Treatment Epitheloid Sarcoma according the disease guideline
45609701|NCT04452539|Procedure|Paediatric cardiac surgery|All patients undergoing paediatric cardiac surgery
45609702|NCT04708223|Device|Direct restorative treatment with fast-curing composites (Tetric PowerFill/ Tetric PowerFlow)|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored. Adhese Universal in self-etch mode, was used to prepare the surfaces for the composite fillings. Tetric PowerFill/ Tetric PowerFlow (test group) was cured for 3 s.
45609703|NCT04708223|Device|Direct restorative treatment with conventionally applied composites (Tetric EvoCeram Bulk Fill/ Tetric EvoFlow Bulk Fill)|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored. Adhese Universal in self-etch mode, was used to prepare the surfaces for the composite fillings. Tetric EvoCeram Bulk Fill/ Tetric EvoFlow Bulk Fill (control group) were conventionally cured for 10 s per increment.
45609704|NCT05103579|Device|MindMics|Patients rhythms was recorded using MindMics device
45934990|NCT00212797|Drug|Org 34517|low dose Org 34517
45934991|NCT00212797|Drug|Org 34517|high dose Org 34517
45609705|NCT05103501|Drug|PF regimen (cis-platinum ; 5-fluorouracil ) combined with PD-1 inhibitors（pembrolizumab）|immunotherapy:PD-1 inhibitor chemotherapy:5-Fu and DDP
45609706|NCT03461393|Device|Medical-Eye-Trainer (MET)|In order to provide a high contrast, dynamic visual stimulus to the patients, we developed an app that allowed the patients to regularly train with this stimulus. The app runs on Android (version 4.2 or later). The display of the screen is divided into 4 rows. In each row, a pattern of black and white squares is moving in one direction. The directions in subsequent rows are opposite to each other. Through the movement in the opposite direction a changing pattern is achieved in vertical and horizontal extension, the pattern alternates between continuous beams and a checkered pattern. The speed of the display on the monitor is 2 cm per second. In a comfortable viewing distance (ca. 40 cm), this leads to an angular velocity of approximately 3°/sec.
45609707|NCT02763111|Drug|BCD-085|
45609708|NCT02763111|Other|Placebo|
45609709|NCT02522117|Drug|Atorvastatin|Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
45609710|NCT02522117|Drug|Placebo|Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
45934992|NCT00212797|Drug|Placebo|placebo
45609711|NCT05103111|Other|No intervention|no intervention
45609712|NCT03461315|Other|Functional assistance model|Preventive home visits carried out by a Team Dedicated Exclusively to the Home Patient.
45609713|NCT02480595|Device|Stent Graft|Endovascular repair of abdominal aortic aneurysm (EVAR)
45609714|NCT04657211|Other|prospective observational cohort study|prospective observational cohort study
45609715|NCT05087199|Diagnostic Test|Rt-PCR.|Nasopharyngeal swab for Rt-PCR for COVID-19
45609716|NCT03947177|Behavioral|GMIT|Six 30-minute sessions delivered virtually in a group format. Each week a group facilitator will elicit adolescents' feedback on important topics related to substance use and provide experiential activities to help adolescents explore their beliefs and practice making healthy choices.
45609717|NCT03947177|Behavioral|GMIT+|Six 30-minute sessions delivered virtually in a group format. Each week a group facilitator will elicit adolescents' feedback on important topics related to substance use and provide experiential activities to help adolescents explore their beliefs and practice making healthy choices. Parents and/or guardians will virtually participate in parent-only support group sessions.
45609718|NCT04628429|Drug|Erenumab|anti-CGRP-receptor monoclonal anti-body
45609719|NCT04628429|Drug|Galcanezumab|anti-CGRP-ligand monoclonal anti-body
45609720|NCT04628429|Drug|Fremanezumab|anti-CGRP-ligand monoclonal anti-body
45934993|NCT00212875|Drug|epoetin alfa|
45934994|NCT02962843|Behavioral|IY TCM|The Incredible Years Teacher Classroom Management program is a manualized program for teachers and staff in school and day-care settings to strengthen teacher classroom management strategies, to reduce negative behavior and promote prosocial behavior, as well as school readiness in children. Two qualified IY TCM group-leaders (facilitators) train teachers and staff in groups through six full-day workshops (a total of 42 hours).Workshop 1: Building Positive Relationships with Students, Workshop 1b: Preventing Behavior Problems -The Proactive Teacher, Workshop 2: The Importance of Teacher Attention, Coaching and Praise, Workshop 3: Motivating Children Through Incentives, Workshop 4 & 5: Decreasing Inappropriate Behavior and Workshop 6: Emotional Regulation, Social Skills & Problem Solving.
45609721|NCT05204589|Biological|Aerosolized Ad5-nCoV|Aerosolized Ad5-nCoV is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
45758137|NCT00295139|Behavioral|Behavioral Treatment for Substance Abuse in SPMI (BTSAS)|Multifaceted treatment for substance abuse in dual disordered patients which contains 6 components: 1) a urinalysis contingency to enhance motivation to change and increase the salience of goals; 2) structured goal setting to identify realistic, short term goals for decreased substance use; 3) motivational interviewing to enhance motivation to reduce use; 4) social skills and drug refusal skills to enable development of relationships with people who do not use drugs, and to provide success experiences that can increase self-efficacy for change; 5) education about the reasons for substance use and the particular dangers of substance use for people with SPMI; and 6) relapse prevention training that focuses on behavioral skills for coping with urges and dealing with high risk situations and lapses. BTSAS is specifically structured to reduce the load on memory and attention, and minimize demands on higher level cognitive processes.
45758138|NCT00295139|Behavioral|Supportive Treatment in Addiction Recovery (STAR)|Manualized substance abuse treatment as usual
45609722|NCT05204589|Biological|Inactivated SARS-CoV-2 vaccine|Inactivated SARS-CoV-2 vaccine is homologous to the priming series which have been administered to the subjects, produced by SinoVac Biotech Co,. Ltd, Beijing Institute of Biological Products Co,. Ltd, Wuhan Institute of Biological Products Co,. Ltd, or Biokangtai.
45609723|NCT05020509|Procedure|medial branch block|lumbar medial branch block
45609724|NCT03461081|Drug|telmisartan/amlodipine and atorvastatin|Telmisartan/Amlodipine(40/5 mg) 2 Tab for 10 days Telmisartan/Amlodipine(40/5 mg) 2 Tab with Atorvastatin 40 mg 1 Tab for 4 days Atorvastatin 40 mg 1 Tab for 4 days
45609725|NCT04601987|Behavioral|Breastfeeding|Counseling about the maternal health benefits of lactation.
45609726|NCT04601987|Behavioral|Smokefree Homes|Counseling about the importance of smoke-free homes.
45609727|NCT04585217|Procedure|Randomized laterality of suture materials for closure (6-0 polypropylene monofilament suture vs fast absorbing gut suture on right eyelid)|"Plain gut suture (6-0 fast absorbing plain gut [Sharpoint Express gut TM]) and polypropylene suture (6-0 polypropylene [Ethicon Prolene TM]) will be used to close blepharoplasty incisions. Each patient will have one eyelid using plain gut suture and the other eyelid with polypropylene suture. Each subject will be randomized as to laterality."
45934995|NCT00069420|Behavioral|Cognitive Motivational Behavior Therapy|
46068602|NCT05832463|Dietary Supplement|Carbohydrate blocking supplement (CBS)|"The CBS is composed of a Hypromellose outer shell, and filled with mulberry leaf extract, berberine HCl, cinnamon bark powder, and cinnamon bark essential oil.~Mulberry leaf extract (Reducose) - 250 mg Berberine HCl (97%)(Berberis aristata root extract)- 25 mg Organic cinnamon powder (Cinnamon (Cinnamomum loureirii) bark powder) - 20 mg Essential oil blend (Grapefruit (Citrus paradisii) peel oil, Lemon (Citrus limon) peel oil Peppermint (Mentha piperita) aerial (leaf/stem) oil), Ginger (Zingiber officinale) root oil, Cinnamon (Cinnamomum zeylanicum) bark oil) - 5 mg"
46068603|NCT05832463|Dietary Supplement|Placebo capsule|The placebo is composed of a Hypromellose outer shell filled with extra virgin olive oil.
45609728|NCT04526301|Device|Tablo Hemodialysis System|Home hemodialysis treatments ~4 times a week.
45609729|NCT04571567|Drug|Secukinumab|Each 300mg dose is given as two subcutaneous injections of secukinumab 150mg, 1mg liquid formulation in a pre-filled syringe.
45609730|NCT04670757|Drug|CPL409116|IMP administration, tablets contain CPL409116 as an active ingredient
45609731|NCT04670757|Drug|Placebo|Placebo comparator
45609732|NCT04557527|Procedure|Pars plana vitrectomy, laser or cryo retinopexy and intraocular gas tamponade|Conventional pars plana vitrectomy procedure is used to treat rhegmatogenous retinal detachment- laser or cryo retinopexy intraocular gas tamponade (SF6, C2F6 or C3F8) are chosen according to the number and size of the causative retinal break(s) and surgeons clinical judgement
45758139|NCT00295139|Behavioral|Critical Time Intervention (CTI)|Case management component
45758140|NCT04277156|Dietary Supplement|Lactobacillus rhamnosus ATCC 53103 & Lactobacillus reuteri DSM 29063|7 drops contain Lactobacillus rhamnosus GG 5x10^9 CFU; and Lactobacillus reuteri 1x10^8 CFU.
45609733|NCT04557527|Device|Suprachoroidal viscobuckle with 2.3% Sodium hyaluronate (Healon 5 Ophthalmic viscoelastic device)|After drainage of subretinal fluid, approximately 0.5 ml of Healon 5 is injected in to the suprachoroidal space underlying the retinal break. Laser retinopexy is applied around the break .
45609734|NCT04525989|Radiation|Radiation therapy|5 x 5 Gy external radiation therapy
45758141|NCT04277156|Dietary Supplement|L rhamnosus ATCC 53103|5 drops contain Lactobacillus rhamnosus 5x10^9 CFU.
45758142|NCT04458584|Procedure|Trapeziectomy with ligament reconstruction (I; LRTI)|Thumb basal joint arthroplasty (surgical) using Trapeziectomy with ligament reconstruction (I; LRTI)
45758143|NCT04458584|Procedure|Trapeziectomy with suture suspensionplasty (II; SS)|Thumb basal joint arthroplasty (surgical) using Trapeziectomy with suture suspension-lastly (II; SS)
45609735|NCT02522039|Drug|Latanoprost|1 drop of latanoprost was given to study eye after washout period of 1 week between drugs
45609736|NCT02522039|Drug|Timolol|1 drop of timolol was given to study eye after washout period of 1 week between drugs
45609737|NCT02522039|Drug|Dorzolamide|1 drop of dorzolamide was given to study eye after washout period of 1 week between drugs
45609738|NCT04950855|Diagnostic Test|Optical Coherence Tomography,Optical Coherence Tomography Angiography(Topcon)|Optical coherence tomography optical coherence tomography angiography
45609739|NCT04505111|Other|Prehabilitation Program + Enhanced Recovery After Surgery|Prehabilitation Program (nutrition + exercise + psychological counseling) + ERAS protocol
45609740|NCT04505111|Other|Enhanced Recovery After Surgery|ERAS protocol
45609741|NCT04522947|Other|Milkshake fMRI|While in the MRI scanner, the participant is shown a cue indicating the impending delivery of either milkshake or tasteless solution, followed by a brief blank screen, then delivery of the sip, and then a swallow cue. This procedure is repeated throughout the task.
45758144|NCT04458584|Procedure|Arthroscopic Trapeziectomy (III; AT)|Thumb basal joint arthroplasty (surgical) using Arthroscopic Trapeziectomy (III; AT)
45609742|NCT04707495|Device|Smartphone Application (SPSRS)|"The experimental group receives video-viewing intervention using the SPSRS application, which is a smartphone application. SPSRS is programmed to present 150 ms of positive words after presenting 17 ms of self-confidence-boosting words in videos.~These words are repeated every 5 s. The words to increase self-confidence are can, let us try, good luck, able, and do not worry. These self-confidence-boosting words randomly appear in the four corners of the screen. The positive words are nice, great, fantastic, satisfactory, and enjoyable. These words are displayed at the center of the screen. Interveners use the SPSRS application according to the operating manual. The participants will use an iPhone managed by interveners to watch a pre-determined 10-minute video."
45609743|NCT04707495|Device|Smartphone Application (YouTube)|The control group uses the same iPhone as the experimental group. The control group uses the YouTube application to receive video-viewing intervention. The control group videos do not show confidence-boosting and positive words. The control group watches the same video as the experimental group for 10 min.
45609744|NCT03460925|Radiation|SBRT plus chemotherapy|Neoadjuvant stereotactic body radiotherapy (SBRT, 30 Gy in 5 fractions) plus chemotherapy with Folfirinox
45609745|NCT05107791|Drug|Stulln Eyedrops|Stulln eyedrops will be applied to the anterior surface of cornea 3 times a day, 6 days a week. Half of participants (46) also receive accommodative training during the second stage (month) of the study while the rest maintains the Stulln eyedrops intervention.
45758145|NCT00701675|Drug|sertraline 50 mg daily|50 mg daily
45758146|NCT00701675|Drug|sertraline 100 mg daily|100 mg daily
45609746|NCT05107791|Drug|Thera Tears|The eyedrops will be used in the identical manner as Stulln eyedrops.
45609747|NCT04430699|Drug|Cisplatin|Participants will be given Cisplatin by intravenous infusion at a predetermined dose 1x weekly up to 8 weeks.
45609748|NCT04430699|Drug|Pembrolizumab|Participants will be given Pembrolizumab by intravenous infusion at a predetermined dose 1x every 3 weeks up to 36 weeks.
45609749|NCT04430699|Radiation|Radiation Therapy|Standard of care radiation therapy 1x daily up to 8 weeks.
45758147|NCT00701675|Drug|Placebo 50 or 100 mg|50mg or 100mg matching placebo
45758148|NCT01987089|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Eight Session CBT-I: Cognitive Behavioral therapy is conducted in 8 individual sessions with the study clinician.
45758149|NCT04458428|Other|SMS|"Patients who are randomized to the intervention arm will be signed up for the automated SMS program. This cohort will receive text messages after surgery, timed from the day of discharge through 14 days post-op. Patients in this cohort will receive text messages each day. The number of text messages varies on patient interest and yes responses to see additional information."
45609750|NCT05107323|Behavioral|Compassionate Mind Training for Teachers|Compassionate Mind Training for Teachers is a biopsychosocial evidence-based approach that aims to foster compassion, affect regulation, prosocial qualities and wellbeing in teachers.
45609751|NCT03460847|Drug|Steroids|Patients with active colitis ulcerosa who need steroids because of their disease course. 1mg/kg bodyweight for one week, followed by a tapping periode.
45609752|NCT05111769|Drug|Recombinant human brain natriuretic peptide|1. To determine the effect of rhBNP on hemodynamics in sepsis based on PiCCO hemodynamic monitoring; 2. To collect and sort out the relevant data to determine the effects of rhBNP on cardiac function and kidney function, including cardiac ultrasound, kidney blood flow index and related laboratory tests. 3. To determine the effect of rhBNP on the final prognosis of patients, including ICU mortality and hospital mortality, ICU time, hospital stay, ventilator use time, kidney replacement therapy time, vasoactive drug dosage and time.
45609753|NCT03460691|Procedure|Bariatric surgery|Bariatric surgery will done to the patients who were morbid obesity
45609754|NCT05107089|Device|Ultrasound|Use of ultrasound at subclavian vein cannulation for visualization
45609755|NCT04358003|Device|Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)|"Subjects will receive one treatment per day with the D2000 Cartridge for up to 4 hours (treatment cycle) for up to seven (7) days. Treatment may extend beyond 7 days, up to 14 days total, if deemed necessary and useful by the principal investigator (PI). Additional cartridges may be used, if needed, to achieve the maximum daily treatment duration of 4 hours. Each day, before initiating the treatment cycle, pre-treatment chemistry and hematology, coagulation status, and disease severity scores (SOFA, APACHE II) will be collected. Then, immediately following the therapy on each treatment day, post-therapy measurements will also be collected.~Study Exit. Subjects will be exited from the study after the Day 28 follow-up visit which will occur 28 days after Study Day 1. Subjects will be included in the study for a total of 28 days. Subjects may also choose to discontinue at any time or conclude participation at the discretion of the PI or the subject's treating physician."
45758150|NCT04444154|Behavioral|Control group|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment.
45758151|NCT04444154|Behavioral|Group with active participation|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with a demonstration of brushing methods in the sink with active participation (use of plate developer and then the Oral B electric toothbrush with special orthodontic head) during the bonding appointment as well than at each check-up appointment.
45934996|NCT00212914|Behavioral|Reminder letter|
45934997|NCT00212953|Procedure|Advanced Life Support|
45934998|NCT00212992|Procedure|fixed versus escalating biphasic defibrillation|
45934999|NCT00213031|Drug|Carraguard (PC-515)|
45935000|NCT02966262|Device|Optical coherence tomography|Intracoronary imaging device which can precisely observe intracoronary structures
45609756|NCT05166603|Other|TeleGRACE|Patients receive a virtual home visit and care from the GRACE team
45609757|NCT03460613|Other|FODMAP diet|Patients with a diagnosed FODMAP intolerance (and a control with no FODMAP intolerance) by prior nutrient challenge testing are going on a FODMAP diet. In a first nutritional visit a specialized nutritionist will inform the patients about FODMAP containing foods and illustrate a FODMAP elimination diet. After 3 weeks of elimination diet another visit will take place and a stepwise reintroduction diet is initiated after successful elimination diet.
45609758|NCT03568409|Device|ABO-GLYC|3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
45445030|NCT03637478|Behavioral|Enhanced Systems of Care Team|E-SOC team will be increasing connections between clinical care and community partners, such as schools, juvenile justice and child-serving state agencies, to reduce disparities in access to mental health/substance use evaluation and treatment. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning. Overall goals are: earlier identification of mental health needs including child trauma; increased treatment access and adherence; care delivered in least restrictive settings; care experience reflecting active youth and family engagement; program sustainability and replicability.
45609759|NCT03568409|Other|ABO-GLYC Placebo|3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
45609760|NCT04642677|Other|healthcare provider's recommended communication with sympathy and printed paper|"Patients and caregivers were received healthcare provider's recommended communication with sympathy and printed paper, Regardless of the patient's outward consciousness, talk with the patient and express empathy. Hearing will be maintained until the end. three times a day (8, 14 and 20 o'clock) during palliative sedation."
45609761|NCT05111067|Genetic|DNA and whole transcriptome mRNA sequencing|DNA and whole transcriptome mRNA sequencing, including total mutational burden and microsatellite instability, will be performed using the TruSight Oncology 500 (TSO500) platform (Illumina Canada, Ulc).
45609762|NCT04519905|Drug|Paclitaxel plus carboplatin|Paclitaxel （45mg/m2) plus carboplatin (AUC=2); five cycles; qw
45758152|NCT04444154|Behavioral|Group with video and quizz|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with have an additional appointment between the device bonding appointment and the first check-up. This is a 15-minute session dedicated to teaching oral hygiene. This session will include watching of an educational video followed by a quiz, as well as the application of the methods taught in the sink (using plate developer and the Oral B electric toothbrush with special orthodontic head).
45609763|NCT04519905|Radiation|radiotherapy|Different radiotherapy dose in different groups.
45445031|NCT03712917|Procedure|Greater Occipital Nerve Block|An enjection to paralyze the occipital nerve.
45609764|NCT04289285|Drug|IBI306 450mg SC Q4W|Subjects will receive IBI306 450mg every 4 weeks subcutaneously.
45609765|NCT04289285|Drug|Placebo SC Q4W|Subjects will receive placebo every 4 weeks subcutaneously.
45609766|NCT04289285|Drug|IBI306 600mg SC Q6W|Subjects will receive IBI306 600mg every 6 weeks subcutaneously.
45609767|NCT04289285|Other|Placebo SC Q6W|Subjects will receive placebo every 6 weeks subcutaneously.
45609768|NCT04477473|Other|Questionnaire-based observational study|"Questionnaire focusing on practical health care issues regarding respiratory support, health status and perception of the COVID-19 issue:~Symptom score (related to noninvasive ventilation: NIV)~Thymic disturbances (score of anxiety and depression)~Compliance to treatment (assessed via tele-monitoring: routine procedure)"
45609769|NCT03460457|Drug|TQB2450|Pharmacokinetics/Dynamics Study
45609770|NCT04474743|Other|No intervention - cross-sectional observational only|No intervention - cross-sectional observational only
45758153|NCT01969539|Drug|Combivent Respimat via tee adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
45445032|NCT03712917|Drug|Topiramate|An antiepileptic agent used for migraine prophylaxis.
45445033|NCT03712917|Drug|Flunarizine|A calcium overload blocker agent used for migraine prophylaxis.
45609771|NCT03129659|Diagnostic Test|Coronary CT Angiography|Coronary CT angiography
45609772|NCT04423341|Drug|Cannabidiol Oral Solution [Epidiolex]|100 mg BID for three months Placebo oral solution for three months
45609773|NCT05106699|Radiation|proton plus carbon ion radiation|All patients received whole pelvis and prostate region proton irradiation of 46 GyE in 23 fractionsfollowed by localized carbon ion irradiation of 32GyE in 8 fractions to the prostate region. The dose to metastatic LN was escalated using simultaneous integrated boost (SIB) technique. The dose was 60-62.1GyE in 23 fractions as much as dose constraints. All patients will be recommened receive 2-3 years endocrine therapy.
45609774|NCT04163367|Behavioral|Safer Kids|A behaviorally based parent training program with the purpose to reduce or prevent child abuse.
45609775|NCT04163367|Other|Intervention as usual (IAU)|Everything that's included in the social service units' regular handling of cases; such as the formal investigation and family treatment. The units cannot offer Safer Kids as a part of IAU.
45609776|NCT03378479|Drug|SOC +Posaconazole 18 MG/ML (milligram/milliliter)|.2*300mg/d IV on day 1, followed by 1*300mg/d IV from day 2 for 7 days (total 7 days)
45609777|NCT03378479|Other|standard of care (SOC)|treatment for influenza pneumonia at the investigators discretion
45445034|NCT03789981|Genetic|Immunogenic profile|RNA sequencing (RNAseq), Whole exome sequencing (WES), NeoAntigens (NeoAg), Immune checkpoints analysis, Gene expression profiling
45609778|NCT04187183|Other|Fresh Platelet Rich Plasma with leukocyte|autologous Platelet Rich Plasma with leukocyte will be infiltrate in the knee joint
45609779|NCT04187183|Other|Fresh Platelet Rich Plasma without leukocyte|autologous Platelet Rich Plasma without leukocyte will be infiltrate in the knee joint
45609780|NCT05101395|Other|Giemsa stain|Giemsa special stain was employed for detection of H. Pylori microorganisms.
45609781|NCT03460223|Biological|MSC|conventional plus MSC or placebo treatment
45609782|NCT04963959|Device|Peripheral blood mononuclear cell apheresis|mononuclear cell donation for tumor immunotherapy study of UCAR-T cells
45609783|NCT03460145|Other|Lavender Oil on Nasal Strip (Lx)|Usage of Aromatherapy for Preoperative Anxiety
45609784|NCT03460145|Other|Strip without Lavender Oil (Px)|Strip without Lavender Oil (Px)
45758154|NCT01969539|Drug|Combivent Respimat via ventilator adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via ventilator adapter
45758155|NCT04277312|Behavioral|Engage|The Engage intervention was developed with input from primary school teachers and includes a range of age-appropriate educational activities related to food. Activities include videos, lesson plans, worksheets, games, talks/visits from experts, visits to industrial partners and other local food-related centres of interest and practical activities such as experiments. All 'Engage' material is mapped to the Northern Ireland School Curriculum. The 'Engage' intervention is structured into three broad topics: Farm to Fork; Pleasure on a Plate and Food Futures. Engage resources were provided to schools electronically and in hard copy and teachers delivered most of the content, with the exception of several sessions which were delivered by visiting scientists.
45609785|NCT03460145|Drug|Propofol 1 % Injectable Suspension|Propofol 1% (10mg/mL)
45609786|NCT04125771|Diagnostic Test|Diclofenac + HBB with hysteroscopy|Giving Diclofenac + HBB with hysteroscopy
45609787|NCT04125771|Diagnostic Test|Diclofenav + placebo|Giving Diclofenac + placebo with hysteroscopy
45609788|NCT03460067|Radiation|Omission of Radiation|No Radiation will be given. 1 year of trastuzumab +/- pertuzumab treatment will be given with 5 years of follow up occurring every 3 months to check for recurrence
45609789|NCT05027997|Drug|Dipraglurant|Oral tablet
45609790|NCT05027997|Drug|Placebo|Oral matching placebo tablet
45609791|NCT03129737|Procedure|Mitral valve surgery|Mitral valve repair is preferred whenever technically feasible over valve replacement. Annuloplasty may be used as sole therapy or in conjunction with other repair maneuvers to support the reconstruction and reinforce the annulus as well as prevent future annular dilatation. The mitral regurgitation secondary to myxomatous degeneration is prolapse of the middle scallop of the posterior leaflet result from chordal rupture or chordal elongation. Quadrangular resection of the involved middle scallop of the posterior leaflet combined with a posterior mitral annuloplasty is the best way to handle this situation. Chordae replacement could be used also to treat flail/prolapse of the anterior leaflet. Annuloplasty is always doing in mitral valve repair to stabilize and reshape the annulus.
45609792|NCT03129737|Procedure|Tricuspid valve annuloplasty|Depending on the extent of the valve disease, there is the possibility to perform valve repair. In mitral valve reference center the rate of repair will reach 100%. In many patients with mitral valve regurgitation, tricuspid valve will be insufficient or the annulus dilated. Tricuspid annuloplasty ring will be helpful to treat dilation by reshaping, or to treat the regurgitant diseases. The ring will be secured and sutured to the native annulus by U-stitches.
45609793|NCT03249077|Behavioral|Digital DPP|The online DPP program is 12 months in duration with 16 core sessions delivered over 16-26 weeks and 6 maintenance sessions delivered over 6 months.
45609794|NCT03249077|Behavioral|In-person DPP|The in-person DPP program is 12 months and consists of weekly sessions for the first 6 months and monthly sessions for the remaining 6 months.
45609795|NCT03249077|Other|DPP not enrolled|Access to usual care services without restrictions.
45758156|NCT04277312|Behavioral|Nourish|The Nourish intervention is a school food environment intervention which included weekly healthy snack provision supplied by food industry partners, enhancement of canteen dining area (café style, tablecloths, centre pieces, bunting and menu boards, healthy eating posters), attendance at Tasting Days held in Higher Education Colleges (children were encouraged to try new foods provided by industry partners and received stamps on 'food passports' in return) and sensory educational and cookery activities.
45758157|NCT04768257|Behavioral|Physical activity|We will assess physical activity patterns of patients at baseline (at discharge from hospital or at patients' home), at 12 weeks and 6 months, through an objective measurement (triaxial accelerometer).
45758158|NCT00659789|Drug|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
45758159|NCT00659789|Drug|Sterile water|Sterile water is used in place of Vacc-4x and in place of Leukine
45758160|NCT04639310|Drug|XEN496|XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child.
45758161|NCT04639310|Drug|Placebo|Placebo sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child.
45609796|NCT04529655|Device|Capillary Refill Assessment|Device to quantify capillary refill time
45758162|NCT03246074|Drug|Fostamatinib and Paclitaxel|"Drug: Fostamatinib (oral; 100 mg, 150 mg, or 200 mg)~Drug: Paclitaxel (60-80 mg/m2)"
45935001|NCT00213070|Drug|Miglitol|
45935002|NCT00213109|Drug|Miglitol|
45935003|NCT00213187|Behavioral|Aerobic and Qi gong Exercise|
45935004|NCT00213226|Drug|dexamethasone|
45609797|NCT05115123|Drug|Duloxetine|60 mg duloxetine
45609798|NCT05115123|Drug|Placebo|Placebo
45609799|NCT04821999|Device|a 940-nm diode laser|a 940-nm diode laser (EPIC™, BIOLASE, www.biolase.com) with an adjustable pain therapy handpiece capable of creating diffuse laser energy patterns ranging from 15 mm to 30 mm in size.
45609800|NCT03209063|Diagnostic Test|polymerase chain reaction|diagnostic test as Polymerase chain reaction for detection of Prothrombin gene and methylenetetrahydrofolate reductase gene polymorphisms
45609801|NCT04636671|Drug|Methylprednisolone|Per-protocol methylprednisolone administration and tapering (see arm description)
45609802|NCT04636671|Drug|Dexamethasone|Per-protocol dexamethasone administration (see arm description)
45609803|NCT03459599|Drug|Prophylactic antibiotics|Amox-clav given to eligible women as per existing protocol, which is 625mg three times a day, for a week
45609804|NCT03459599|Other|No prophylaxis (Amox-clav withheld)|Withholding Amox-clav, which is the current local practice for women with ragged placental membranes. This was replaced with appropriate counselling on signs and symptoms of endometritis, when and where women should present if the symptoms above occur. A follow up phone call was performed at 2 weeks and 6 weeks postpartum to ascertain well-being of patients
45609805|NCT04613583|Other|SAFeR fetuses|NO active intervention performed.
45911417|NCT02007876|Behavioral|Mobility and Activity Training|"Pre-operative: Transfer training: bed and chair transferring exercises rising with and without use of hand assistance including supine to sit in or to the side in bed, and sit to stand from a normal and low height chair. GCS exercises: 1) supine pelvic bracing with transverse abdominal recruitment 2) hip bridges with abductor squeeze 3) supine bent leg abduction with light theraband and 4) supine isometric core and pelvic stabilization with legs flexed and shoulder flexion to raise arms over head with advancement to using theraband. For patients able to stand safely 5) standing mini squats against the wall.~Post-operative: Early mobilization to include standard physical therapy techniques to enhance bed mobility, facilitated sit to stand and walking with therapist assist as needed. All GCS exercises begin 24 hr post op with goal of 5-10 reps and progressing to 3 sets of 10 reps. Participants will be encouraged to move from a roll to the side first supine to sit strategy by week 2."
45911418|NCT02007889|Drug|L-carnitine|50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
45609809|NCT03458507|Device|Switch of nocturnal NIV interface|"test the alternative interfaces (either a nasal mask for the patient used to oronasal mask or inversely an oronasal mask if the usual mask is nasal) during a one-hour diurnal NIV session. SpO2 (polygraphy), PtcCO2 will be monitored continuously during this diurnal session. Patients will use their usual NIV device prescribed at home. NIV settings will be adapted if needed.~Interface switch~unattended nocturnal polygraphy under NIV (cf details below) will be performed at home with SomnoHolter® (Nomics, Liege, Belgium), synchronized with transcutaneous partial pressure in CO2 (PtcCO2) monitoring by SenTec V-Sign™ System.~The PtcCO2 device will be calibrated before and at the end of each night to allow drift correction."
45609810|NCT04867083|Drug|ARV bitherapie|"Dolutégravir 50mg / Lamivudine 300mg per day~Dolutégravir 50mg / Rilpivirine 25mg per day~Darunavir/r 800mg/100mg / Lamivudine 300mg per day"
45609811|NCT03049787|Other|Home Exercise Protocol|Home exercise therapy protocol given to patient to be completed at home.
45609812|NCT03049787|Other|Physical Therapy Protocol|Formal physical therapy protocol to be given to physical therapist working with patient to direct formal intervention along with a home therapy protocol.
45609813|NCT02928185|Behavioral|semi-structured interviews|
45758163|NCT02300727|Drug|Curcumin-MTD|0.33g-3g by ingested mouth wash three times per day for 4-6 weeks until unacceptable toxicity develops- to determine the maximum tolerated does (MTD).
45445035|NCT03787485|Behavioral|LINKS|The primary aim of LINKS is to create community-clinical linkages between three community health centers and their respective county health departments in southern Arizona. This study will also develop and evaluate a chronic disease and emotional well-being intervention that will connect clinic patients to community-centered, county-delivered, community health worker programs.
45445036|NCT03786861|Procedure|corneal WFG group|TransPRK using ESIRIS flying spot excimer laser system (SCHWIND AMARIS®500E, SCHWIND eye-tech-solutions, Kleinhostheim, Germany), with 500 Hz repetition rate for faster treatments and scanning spots and with smart pulse technology. Eye-tracking during laser ablation was achieved using a 1050 Hz infrared eye tracker centered on the pupil. Static cyclotorsion control (SCC) compensation was obtained for all patients in corneal WFG group.
45758164|NCT02300727|Drug|Mouthwash-standard pharmacy preparation|"Standard mouth wash preparation administered by ingested mouth rinse three times per day.~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine."
45445037|NCT03786861|Procedure|aberration free group|TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing aberration free patterns provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
45609814|NCT03645603|Drug|Dexmedetomidine|intravenous infusion
45609815|NCT03645603|Drug|Placebo|intravenous infusion of physiological saline solution to mimic dexmedetomidine infusion
45609816|NCT02878499|Other|polysomnography|
45609817|NCT05059041|Device|Dilated Refraction|The dilated refraction will be a trial spectacle frame composed of lenses based upon a spectacle prescription determined from dilated measures of the eye using a wavefront aberrometer.
45609818|NCT05059041|Device|Non-Dilated Refraction|The non-dilated refraction will be a trial spectacle frame composed of lenses based upon a spectacle prescription determined from non-dilated measures of the eye using a wavefront aberrometer.
45609819|NCT04912323|Device|Percutaneous Implantation of the MAGNITUDE® Bioresorbable Arterial Scaffold|Placement of one or more MAGNITUDE® bioresorbable scaffolds using a percutaneous technique at one or more arterial stenoses.
45609820|NCT04019873|Drug|Dolutegravir (DTG)|DTG is a 2nd generation integrase strand transfer inhibitor. Subjects receiving DTG as a part of 2DR treatment will be included in the study.
45609821|NCT04019873|Drug|Lamivudine (3TC)|3TC is a nucleoside reverse transcriptase inhibitor. Subjects receiving 3TC as a part of 2DR treatment will be included in the study.
45758165|NCT02300727|Drug|Curcumin|After maximum tolerated dose (MTD) is determined, MTD by ingested mouth wash three times per day for 4-6 weeks until mucositis is resolved, disease progression, or unacceptable toxicity develops.
45758166|NCT00250445|Drug|MK0663, etoricoxib|
45758167|NCT00250445|Drug|Comparator: Diclofenac sodium|
45758168|NCT00242489|Drug|MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks)|
45758169|NCT00242489|Drug|Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks|
45758170|NCT03836612|Other|No intervention|Observation of routine clinical practice
45758171|NCT00659945|Drug|Aprepitant plus Ondansetron|Aprepitant plus Ondansetron
45445038|NCT03789435|Diagnostic Test|Questionnaire|"A questionnaire from which the session dedicated to the evaluation of the stump pain, the phantom limb and the sensation of the phantom limb has been extracted will be administered: this is the Prosthetic Evaluation Questionnaire (PEQ) validated in Italian by Ferrero et al. 2005.~In the questionnaire sent to patients will be asked also for anthropometric data (weight, height) in addition to the characteristics of the worn prosthesis and if they have followed a period of rehabilitation.The time of use of the prosthesis will be evaluated through the Houghton Scale of Prosthetic Use in People with Lower- Extremity Amputations (19)"
45609822|NCT04019873|Drug|Rilpivirine (RPV)|RPV is a non-nucleoside reverse transcriptase inhibitor. Subjects receiving RPV as part of 2DR treatment will be included in the study.
45609823|NCT04890639|Procedure|Acute Intermittent Hypoxia|Four hypoxia sessions, consisting of 15 cycles of hypoxia (21%, 17%, 13% or 9% O2), each of which lasts up to 60 seconds, interspersed with up to 90-second normoxic episodes.
45609824|NCT04771689|Drug|Buprenorphine/Naloxone|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for the length of their hospital stay, at least 6 days.
45609825|NCT04879797|Other|Implementation of Maternal Safety Bundles|In the second phase, implementation of the bundles will take place. During this phase investigators will conduct quarterly surveys with the health facilities to measure implementation progress, including an index of evidence-based practices. Investigators will conduct surveys with postpartum women to measure their patient experience. Surveys will be conducted using RedCap software. Participants will be given the opportunity to complete the survey online or if they prefer, a research assistant can call them to conduct the survey over the phone. Data on SMM will be collected through PELL
45609826|NCT04879797|Other|Doula Services|Investigators are evaluating doula services that are offered by two doula organizations at three hospitals.
45609827|NCT04452227|Other|questionnaire|Filling the menstrual distress questionnaire, short-form McGill pain questionnaire, present pain index, visual analog scale
45758172|NCT00659945|Drug|Ondansetron plus placebo|Ondansetron plus placebo
45758173|NCT04442126|Biological|NM21-1480|Trispecific anti-PD-L1/anti-4-1BB/anti-Human Serum Albumin (HSA) single-chain Fv fusion protein
45758174|NCT01534871|Behavioral|Exercise|Subjects will be enrolled in a 12-week community cardiac rehabilitation program. The program consists of two one hour exercise sessions per week and one one hour education session per week. For the exercise sessions the subjects will perform aerobic exercise at 60-80% of heart rate reserve. Education sessions will cover heart healthy eating, setting health-related goals, exercise, nutrition, healthy weight, medication, smoking cessation and stress/coping.
45758175|NCT04387565|Other|magnesium and vanadium measurements and compare|Magnesium and vanadium will be measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).
45758176|NCT03833180|Drug|Zilovertamab vedotin|Zilovertamab vedotin administered via IV infusion per Schedule 1, 2, or 3 according to participant allocation.
45758177|NCT02141555|Drug|Vaginal Misoprostol|Misoprostol inserted into vagina
45609828|NCT04674345|Drug|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity (dose range, 200-800 mg daily).
45609829|NCT03853811|Device|Ankle Foot Orthosis (AFO)|The intervention group will receive the custom AFO to use in their standard Mitchell shoe.
45758178|NCT02141555|Drug|Buccal Misoprostol|Misoprostol placed between the gum and cheek and allowed to dissolve for 30 minutes with the remnants swallowed after this time.
45609830|NCT04165239|Drug|KH176|Oral administration of 50 mg KH176 twice daily
45609831|NCT04165239|Drug|KH176|Oral administration of 100 mg KH176 twice daily
45609832|NCT04165239|Drug|Placebo|Oral administration of matching placebo twice daily
45609833|NCT03329079|Behavioral|Mobile Technology Plus|The intervention group MT+ will receive the premium-version mobile phone app with social comparison group, behavior change text messaging, and daily self-weighing via Wi-Fi scale.
45609834|NCT03329079|Behavioral|Mobile Technology|The comparison group MT will receive the basic-version mobile phone app only to self monitor eating, activity, and weight.
45609835|NCT02732951|Drug|BI 1026706|
45609836|NCT02732951|Drug|Placebo|
45609837|NCT02999373|Other|Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of infection
45609838|NCT03756311|Drug|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|
45609839|NCT04474587|Other|Indirect calorimetry|Measurements of REE by indirect calorimetry
45609840|NCT05106543|Device|Immediate Effect Of Kinesiological Taping On Functionality In Hemiplegic Patients|Kinesiological Taping
45609841|NCT04576767|Other|anaesthetic|different states of consciousness
45758179|NCT03200834|Procedure|Right Hemicolectomy with D2 lymph node dissection|Remove right part of colon with lymph node dissection №201, №202, №211, №212 (if present), №221,№222 (Japanese classification).
45758180|NCT03200834|Procedure|Right Hemicolectomy with D3 lymph node dissection|Remove right part of colon with lymph node dissection №201, №202, № 203, №211, №212 (if present), №213 (if present) №221,№222, №223 (for hepatic flexure and proximal part of transverse colon cancer)(Japanese classification).
45758181|NCT01799057|Drug|Metformin|Participants randomized to metformin will be treated at a maximum dose of 2000mg per day (i.e. 1000mg twice daily for 16-18 weeks; up-titrated from 500mg twice daily for the first 2 weeks). Participants may complete the 16-18 week treatment intervention at the lower dose of 500mg twice daily if limited by side effects.
45758182|NCT01799057|Drug|Placebo|Participants randomized to placebo will take matching oral capsules according to the same dose schedule specified for the metformin intervention.
45758183|NCT02320175|Behavioral|Patient and Family Centered I-PASS|Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
45758184|NCT02421536|Other|Vibrogent Smartphone Application|
45609842|NCT04471311|Procedure|Sub-lay mesh supported closure|A 4 cm space is created between posterior rectus sheath and rectus muscle, widening 2 cm at each side of midline. Both posterior rectus sheath edges are sutured using a running slowly absorbable suture. Above the arcuate line, posterior layer is reinforced suturing the peritoneum and the posterior rectus sheath; below the arcuate line, the posterior layer is reinforced suturing the peritoneum and the trasversalis fascia. Anterior layer is re-established suturing the anterior rectus sheath. A 3 cm BIO-A Mesh strip is sutureless placed between the posterior rectus sheath and the rectus muscle with an overlap of 1,5 cm at each side. In laparotomies >20 cm two stripes of 15 cm each is designed. The midline anterior rectus sheath is closed using a running slowly absorbable suture , covering the mesh.
45445039|NCT05526105|Diagnostic Test|Gastric Ultrasound|Gastric ultrasound in the supine and right lateral decubitus position for patients going for operative intervention with a protected airway.
45609843|NCT04471311|Device|BIO-A (GORE) mesh|3 cm BIO-A Mesh strip
45609844|NCT04454931|Device|Root® with O3® Regional Oximetry|"May help clinicians monitor cerebral oxygenation in situations in which pulse oximetry alone may not be fully indicative of the oxygen in the brain.~It was aimed to determine the appropriate head height that should be given to patients in order to correct the endotracheal suctioning sequence, which is the most important care application of the neurosurgery patients who are followed up in the intensive care unit after surgery, and the possibility of subsequent disruption of cerebral perfusion. Therefore, cerebral oxygenation status, which is the most important parameter that shows the cerebral perfusion status of patients during and after the application, will be followed up by nurses with a non-invasive cerebral oximeter device."
45609845|NCT01377233|Drug|Zicronapine open-label lead-in 10 mg daily|Encapsulated tablet ,10 mg, once daily, open-label
45609846|NCT01377233|Drug|Zicronapine 10 mg daily|Encapsulated tablet, 10 mg, once daily, double-blind
45609847|NCT01377233|Drug|Zicronapine 20 mg once weekly|Encapsulated tablet, 20 mg, once weekly (on day 1 of each 7 day cycle), double-blind
45609848|NCT01377233|Drug|Zicronapine 30 mg once weekly|Encapsulated tablet, 30 mg, once weekly (on day 1 of each 7 day cycle), double-blind
45609849|NCT01377233|Drug|Zicronapine 45 mg once weekly|Encapsulated tablet, 45 mg, once weekly (on day 1 of each 7 day cycle), double-blind
45445040|NCT03787017|Drug|FDC(MP-513 20mg/Metformin XR 1000mg)|
45445041|NCT03787017|Drug|MP-513 20mg|
45445042|NCT03787017|Drug|Metformin XR 1000mg|
45609850|NCT03458273|Procedure|Zero fluoroscopy ablation|Catheter ablation for the treatment of atrial and ventricular arrhythmia - no fluoroscopy guidance
45445043|NCT05524311|Drug|Baricitinib|Oral tablets (2 mg) will be used For children > or = 6 years: 4 mg once a day (2 x 2 mg) during the 24 weeks-period study For children < 6 years: 2 mg once a day during the 24 weeks -period study
45609851|NCT03458273|Procedure|Conventional ablation without 3D|Catheter ablation for the treatment of atrial and ventricular arrhythmia - fluoroscopy guidance only. 3D system (Every Ensite/Carto) is not allowed
45609852|NCT03458273|Procedure|Conventional ablation with 3D|Catheter ablation for the treatment of atrial and ventricular arrhythmia - fluoroscopy guidance + 3D system support (Ensite/Carto)
45609853|NCT02521961|Other|Informational Intervention|Watch a Chair-robics DVD
45609854|NCT02521961|Other|Informational Intervention|Receive community resource booklet
45609855|NCT02521961|Other|Quality-of-Life Assessment|Ancillary studies
45609856|NCT02521961|Other|Questionnaire Administration|Ancillary studies
45758185|NCT00661037|Device|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
45445044|NCT05524311|Biological|pharmacokinetics study|additionnal blood sampling at week 4, 8, 12, and 24
45609857|NCT02521961|Procedure|Support Group Therapy|Attend support group sessions
45609858|NCT03248531|Drug|Bimekizumab|Bimekizumab in different dosages (dose 1 and 2).
45609859|NCT03248531|Drug|Adalimumab|Adalimumab in different dosages (dose 1, 2 and 3).
45609860|NCT03248531|Other|Placebo|Placebo will be provided matching Bimekizumab.
45609861|NCT03456479|Diagnostic Test|skin prick test - specific serum IgE|The study will assess the diagnosis of Cow's milk protein allergy (CMPA) among infant and children in Assiut University Children Hospital using skin prick test and specificserumIgE
45609862|NCT03456167|Other|RecoverWell mobile app for follow-up care|The mobile app follow-up care is an application that can be loaded onto a smartphone. It allows the patient to submit photos of their surgical site, QoR15 scores, and EORTC selected adverse events scores. The information collected is transmitted to members of the surgical team (i.e. the primary surgeon) and used to monitor recovery over the first 6 weeks following surgery.
45609863|NCT03148379|Device|Customized patient instruments|Single use efficiency instruments and cutting blocks specifically made for each patient using pre-op MRI or CT scans to make bone cuts and select implant size.
45609864|NCT03148379|Device|Traditional Metal Instruments|Traditional metal instrument will be used to make bone cuts and size the components in this control group.
45758186|NCT00661037|Device|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
45758187|NCT00588809|Drug|selumetinib|Given PO
45445045|NCT05524311|Biological|dosage of cytokines|additionnal blood sampling at weeks 0, 4 and 24
45445046|NCT05524311|Biological|transcriptomic analysis|additionnal blood sampling at weeks 0, 4 and 24
45609865|NCT03866525|Biological|OH2 injection, with or without irinotecan or HX008|OH2: Oncolytic Type 2 Herpes Simplex Virus Irinotecan: cytotoxic agent HX008: anti-PD-1 antibody
45609866|NCT03129347|Drug|Nalmefene|Comparing pharmacokinetics of intranasal nalmefene to intramuscular nalmefene
45609867|NCT02980679|Drug|CTC|After injection of CTC, a whole body and thyroid scan will be performed.
45609868|NCT02980679|Drug|G-PERT|After injection of G-PERT, a whole body and thyroid scan will be performed.
45758188|NCT00588965|Drug|Placebo|Placebo will be given 1 pill daily for a week, then 2 pills daily, followed by the exercise test.
45758189|NCT00588965|Drug|Propranolol LA|Subjects will receive propranolol LA 80 mg one pill daily for 1 week then 2 pills daily for 1 week followed by exercise test.
45758190|NCT00589277|Behavioral|Gain-Framed counseling & Gain-framed materials|Novel messages for quitting smoking
45758191|NCT00589277|Behavioral|Standard care counseling + standard materials|Standard messages for quitting smoking
45609869|NCT03453437|Behavioral|Mindful Self-Compassion|Mindful self-compassion is a course developed by Kristin Neff and Christopher Germer designed to cultivate self-compassion as measured by three subcategories: self-kindness, mindfulness, and a sense of common humanity. This study will shorten the original 8-week course to 5 sessions, and will include interventions and lectures aimed directly toward addressing evaluative concerns perfectionism.
45609870|NCT02933411|Other|Genetic Analysis|Blood sample will be drawn to assess the number of participants enrolled that have sequence variation in the von willebrand factor gene and other genes affecting bleeding, clotting and blood vessel biology.
45609871|NCT02933411|Other|Medical Record Data Abstraction|"The subject's response to intranasal or intravenous desmopressin (DDAVP) challenge performed as part of standard of care will be recorded. The desmopressin is a drug that increases the clotting factor in blood to prevent bleeding.~Medical and family history including and not limited to age, diagnoses, race/ethnicity, lab values, HMB and low VWF activity diagnoses, and treatment history and outcome will also be recorded."
45609872|NCT02933411|Other|Pictorial Blood Assessment Chart (PBAC) score|PBAC is a pictorial tool to assess menstrual blood loss. Study team will complete the PBAC assessment with each study participant evaluating and measure response to different treatments for menstrual blood loss in the clinic setting between those with VWD versus other bleeding disorders.
45609873|NCT02933411|Other|Complete Bleeding Symptom ISTH Bleeding Assessment Tool|Study participants will complete the ISTH BAT assessment. The ISTH BAT is a questionnaire to aid in the standardized evaluation of the presence and severity of bleeding symptoms.
45609874|NCT02902445|Biological|rotavirus rapid screen test|According to routine care
45609875|NCT02902445|Genetic|polymorphism exploration|from an oral swab collected after parents consent
45758192|NCT00702299|Drug|cisplatin|IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
46068604|NCT05832437|Behavioral|BREATHE-Peds Intervention|BREATHE-Peds utilizes Primary Care Providers (PCPs) to deliver a 4-step script that was created by and tailored to Black adults' asthma and inhaled corticosteroid beliefs, as well as their Asthma Control Questionnaire (ACQ) score, measured just prior to the medical visit. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
45758193|NCT00702299|Drug|paclitaxel|IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
45445047|NCT05524311|Behavioral|Parent version of the Child Health Questionnaire (CHQ)|Evaluate by parents at each visits
46068605|NCT05832437|Behavioral|Control Intervention|The control intervention will be a 9-minute scripted discussion tailored to living a health lifestyle. Step 1: Review of BMI, current diet and exercise (3 minutes). Step 2: Diet/exercise counseling (3 minutes). Step 3: Plan for goal attainment (3 minutes).
46068606|NCT05832385|Radiation|IMRT|anal cancer: chemoradiotherapy, radiation dose>50Gy; rectal cancer: chemoradiotheray, radiation dose=50Gy
46068607|NCT05832359|Radiation|Panoramic rad.|In the study, digital panoramic x-rays of the patients will be evaluated and dental age estimation with Willems method and mandibular bone morphometric measurements will be made.
45758194|NCT00702299|Drug|pemetrexed disodium|Escalate doses in groups of 3 patients to 60mg per m2, 120 mg per m2, 500 mg per m2, 750 mg per m2, 1000 mg per m2
45758195|NCT00702299|Other|biologic sample preservation procedure|Plasma samples will be collected on the 1st course at baseline, 30 minutes, 60 minutes, 2 hours, 4 hours, 6 hours (if possible) and 24 hours after the first IP Alimta® dose.
45758196|NCT00702377|Other|SYSTANE Ultra|SYSTANE Ultra Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
45758197|NCT00702377|Other|Optive|Optive Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
45758198|NCT00703391|Drug|AZD9668|30mg oral tablets twice daily (bid) for 14 days
46068608|NCT05832346|Behavioral|Laughter yoga programme|"Intervention for intervention group:~This is a 4-week laughter yoga programme (8 sessions) to help adolescents with intellectual and physical disabilities bring more happiness, laughter and joy to promote their mental health status. As laughter yoga therapy can reduce people's levels of stress, anxiety, depression, loneliness, strengthen the immune system and keep the mind positive. Each laughter yoga session will last for 15 minutes and in total there will be 8 sessions for four weeks (two sessions per week). Each laughter yoga session consists of hand clapping warming-up exercise, followed by deep breathing exercise, childlike playfulness exercise, and then laughter exercise. The intervention group also receives routine care provided by special school."
46068609|NCT05832333|Biological|VaxigripTetra®|Suspension for injection Injection intramuscular
46068610|NCT05832320|Drug|Etoposide|Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC>4.0×109/L, patients will be given oral etoposide (50mg qd to 50mg tid). Cumulative dosage of etoposide during induction ≤1500mg.
45445048|NCT05524311|Behavioral|Childhood Health Assessment Questionnaire|Evaluate by parents at each visits
45758199|NCT00703391|Drug|Placebo|Matched placebo to 30mg oral tablet twice daily (bid) for 14 days
45758200|NCT00661583|Drug|Ranibizumab|0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed
45758201|NCT00661583|Drug|Ranibizumab and MMC|Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy
45758202|NCT00661583|Drug|MMC|MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.
45445049|NCT05524311|Biological|Pregnancy test|Urine pregnancy test at V4 A dosage of bHCG with current biological analysis is done at each visit (except V4)
45445050|NCT03786705|Other|Massive transfusion|Trauma patients who had received blood transfusion≥10 U
45445051|NCT03786705|Other|Non-Massive Transfusion|Trauma patients who had received blood transfusion<10 U
45445052|NCT01307865|Drug|injectable poly-L-lactic acid|Each patient will receive up to 1 vial of Sculptra Aesthetic total to both midface complexes at each of 3 treatment sessions, spaced 6 weeks apart.
45445053|NCT04730427|Drug|GX-I7|Recombinant human interleukin-7 hybrid Fc
45445054|NCT04730427|Drug|GX-I7 vehicle|Formulation buffer of recombinant human interleukin-7 hybrid Fc
45445055|NCT01307943|Other|Mindfulness-based stress reduction program|Eight MBSR sessions of 2 hrs/week to be held during regular class time plus one 3-hour retreat
45609876|NCT02792855|Device|snifﬁng Position(place a 7-cm cushion under head )|Awake fiberoptic bronchoscope(FOB) orotracheal under snifﬁng position.The snifﬁng position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
45609877|NCT02792855|Device|Simple Head Extension(without cushion)|Awake fiberoptic bronchoscope(FOB) orotracheal under Head Extension position.The Head Extension position was obtained by simple head extension.When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
45609878|NCT03453359|Device|BIS monitor|The investigators will place on the forehead of all patients the sensor BIS quatroTM, that connects with this monitor, and they will guide sedation and will record the values obtained.
45609879|NCT03453359|Device|Ramsay scale|In this group, sedation is guided by the Ramsay monitoring scale. The investigators will talk with the patients and will determine the corresponding level of sedation.
45758203|NCT00661895|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg tablets
45609880|NCT05154929|Behavioral|Dietary and physical activity JITAI delivered through the myBPmyLife app|A Fitbit smartwatch and home blood pressure monitor will be mailed to participants (in both the experimental and control arms). Participants in the intervention arm then will set up and utilize the myBPmyLife app. This app includes push notifications to promote increased physical activity and improve low-sodium food choices, establish goal setting for weekly step count and low sodium food choices, and deliver feedback on achieving the goals using a dashboard visualization within the mobile application.
45609881|NCT05154929|Other|Control Group|Participants will receive the myBPmyLife app, a smartwatch, and blood pressure cuff. The myBPmyLife app will not be fully activated (as they are in the control arm). They will be provided with the option of downloading and installing a mHealth app that is publicly available. In this arm they will also perform the blood pressure monitoring, but do not receive the intervention components through the myBPmyLife app.
45609882|NCT05322395|Diagnostic Test|ESC 0/1 hour troponin pathway|randomisation to 0/1 versus 0/3 hour pathway
45445056|NCT01307943|Other|Usual care|The site provides family centered treatment where adolescents take part in therapy from Sunday evening until Friday afternoon. In addition to a structured day and evening schedule, standard treatment includes: Daily group therapy; ii) Medications; iii) Schooling by Edmonton Public School Board teachers; iv) Physical education and recreation; and v) Weekly Multiple Family Therapy.
45609883|NCT02262923|Drug|metoclopramide|
45609884|NCT03129425|Behavioral|ReNACE Psychoeducational Intervention|9 sessions in groups of 15-20 people at most so as to promote reflection and facilitate the interchange of opinions between participants about issues of interest from their day to day experience of coping with Parkinson's disease.
45609885|NCT03129425|Other|General Educational Program|5 sessions in groups of 15-20 people
45609886|NCT02194595|Drug|Basal insulin and exenatide|
45445057|NCT01308021|Biological|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM, daily , 28 days
45609887|NCT02194595|Drug|Basal insulin only|
45609888|NCT02194595|Drug|Basal insulin and bolus insulin|
45609889|NCT01774409|Genetic|Blood and tumor samples|"Genetic: Establishment of the genetic and immunologic profile~Whole blood sampling :~1 tube for the constitutional DNA extraction;~3 tubes for ancillary studies and research.~Collection of the available archival tumor sample (frozen or FFPE). If there's no available sample, the investigator will prescribe a biopsy of a reachable lesion.~With the established profile, recommendations will be given by a multidisciplinary molecular board."
45609890|NCT05322083|Drug|Doravirine|Doravirine will be given to patients after failure on the first NNRTI regimen.
45609891|NCT02656329|Drug|Iobenguane I -123 Injection|Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.
45609892|NCT02656329|Device|Implantable Cardioverter Defibrillator|In the Iobenguane I-123 Injection group, participants with H/M ratio less or equal to 1.6 underwent ICD device implantation, while those with H/M ratio greater than or equal to 1.6 did not undergo ICD implantation.
45609893|NCT02656329|Drug|Thyroid blocking|Participants received a thyroid blocking agent before the Iobenguane I-123 Injection, AdreView, scan unless medically not indicated, according to local practice.
45758204|NCT00661895|Drug|Lisinopril|Lisinopril 5mg Tablet, 10 mg tablet, 20 mg tablet
45758205|NCT00661895|Drug|Lisinopril and Hydrochlorothiazide|L 10 mg and H 12.5 mg tablets, L 20 mg and H 12.5 mg tablets, L 20 mg and H 25 mg tablets
45758206|NCT00661895|Drug|Nifedipine XL|30 mg extended release tablets, 60 mg extended release tablets
45758207|NCT00661895|Drug|Metoprolol tartrate|50 mg tablets & 100 mg tablets
45758208|NCT00661895|Drug|Atenolol|50 mg tablet
45758209|NCT00661895|Drug|Valsartan|80 mg tablets & 160 mg tablet
45758210|NCT00661895|Drug|Doxazosin|4 mg tablets
45758211|NCT00661895|Drug|Clonidine|0.2 mg tablets
45758212|NCT00661895|Drug|Hydralazine|50 mg tablets
45445058|NCT01308021|Biological|gpASIT+TM|entero-coated capsules containing 800 µg of gpASIT+TM, daily, 28 days
45445059|NCT01308021|Biological|Placebo|Placebo entero-coated capsules
45445060|NCT05693883|Other|Pilates training|Subject participating in 60-min sessions for 10 weeks and Each session consisted of a 10-min warm up (Breathing, Imprint & release, Hip release, Spine rotation, Hip rolls, Scapula isolation, Arm circle, Elevation & depression scapulae, Head nod, Cat stretch), Pilates program 40-min (Toe tap, Ad prep, Breast stroke preps, Heel squeeze prone, Side leg lift, Single leg extension, One leg circle, Shoulder bridge prep, Four point, kneeling, Spine twist, Hundred prep, Roll up prep, shoulder bridge prep2, Breast stroke, Swimming, Half roll back) and 10-min cool down (Spine stretch forward, Shell stretch, Side bending, Cat stretch, Roll down)
45445061|NCT01308177|Drug|Ecabet|comparison between PPI+ ES (lanston 30mg bid+ ES 1g/1.5g/pkg bid) and PPI+placebo (lanston 30mg bid)for 28 days
45758213|NCT00661895|Drug|Metoprolol succinate|50 mg tablet & 100 mg tablet
45758214|NCT00661895|Drug|Amlodipine|5 mg tablets & 10 mg tablets
45758215|NCT02312258|Drug|Placebo|Ixazomib placebo-matching capsules.
45758216|NCT02312258|Drug|Ixazomib|Ixazomib capsules.
45758217|NCT00590369|Device|KCI -VAC|Negative pressure wound therapy device
45758218|NCT00590369|Device|Versatile One (EZCare)|Negative pressure wound therapy device
45609894|NCT02656329|Drug|Iobenguane I -123 Injection|Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.
45758219|NCT00703937|Drug|Ferric Carboxymaltose (FCM)|
45758220|NCT00703937|Drug|Standard Medical Care (SMC) for the treatment of IDA|
45758221|NCT00662207|Device|Vibrator|A vibrator will be applied to the patient's bottom to determine if it will induce a bladder contraction
45609895|NCT02656329|Device|Implantable Cardioverter Defibrillator|All participants allocated to the SoC (control) group underwent ICD implantation.
45758222|NCT00662207|Procedure|Anal dilator|A balloon will be used for anal dilation to determine if it will result in relaxation of the pelvic floor and urethral sphincter. An anal dilator is being conduced with the balloon
45758223|NCT01504373|Device|Neurally Adjusted Ventilatory Assist (NAVA)|Subjects will be placed in the NAVA mode of ventilation.
45758224|NCT04398212|Diagnostic Test|mfERG (multifocal-retinogram)|mfERG will be performed for the students to document the effect of CVS on retina
45758225|NCT02301039|Drug|Pembrolizumab|
45758226|NCT02984540|Other|Low-Carbohydrate Diet|Participants assigned to the Modified Ketogenic-Mediterranean Diet will keep their carbohydrate consumption below 20 grams per day throughout the 6-week intervention.
45758227|NCT02984540|Other|Low-Fat Diet|Participants assigned to the Low-Fat Diet will be encouraged to limit their amount of fat intake to <40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber.
45758228|NCT00662675|Drug|Pancrease MT 10.5, or MT 21|Pancrease MT capsules for maximum dose of 10,000 lipase units / Kg / day
45758229|NCT00662675|Drug|Placebo for Pancrease MT 10.5 or MT 21|Capsules with Pancrease MT excipients without the active enzymes
45758230|NCT04760210|Other|Control Group|Treatment for this group is conventional physical therapy along with the bed rest.
45758231|NCT04760210|Other|Decompression Group|Treatment for this is conventional physical therapy along with the spinal decompression.
45445062|NCT01308099|Device|Blood Pressure and Blood Flow|"A blood pressure cuff will be placed on one arm and small probes on one finger on both hands. The probes also measure blood pressure. After 10 minutes, the arm blood pressure cuff will be inflated. The cuff will stay inflated for 5 minutes, then the air will be let out. A cuff will be place above the left calf and the left knee. The subject will lie quietly for 9 minutes, then blood pressure and calf blood flow will be measured for one minute. the lower leg cuff will be inflated after 1 minute, then the cuff will be deflated. The blood pressure and forearm blood flow will be recorded. Next, the cuff on the upper leg will be inflated for 5 minutes then, it will be released and the measurements of blood pressure and calf blood flow will be repeated.~The study lasts about 2 hours."
45609896|NCT01454843|Procedure|Wavefront-guided LASIK - Allegretto|Wavefront-guided LASIK using the Allegretto excimer laser for myopia.
45609897|NCT01454843|Procedure|Wavefront-guided LASIK - AMO|Wavefront-guided LASIK using the AMO CustomVue excimer laser for myopia.
45609898|NCT02712905|Drug|INCB059872|"Initial cohort dose of INCB059872 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose(s) will be taken forward into expansion cohorts.~INCB059872 tablets to be administered by mouth."
45609899|NCT02712905|Drug|all-trans retinoic acid (ATRA)|
45609900|NCT02712905|Drug|azacitidine|
45609901|NCT02712905|Drug|nivolumab|
45609902|NCT04339803|Other|rehabilitation intervention|we use lower limb mirror therapy after stroke for two weeks
45609903|NCT01166633|Drug|pitavastatin|pitavastatin 2mg per daily
45609904|NCT01166633|Drug|atorvastatin|atorvastatin 10mg per daily
45609905|NCT04025541|Biological|Blood sampling|blood sampling time : cycle 1 day 15 and cycle 2 day 15 : one sample (6ml) by time
45758232|NCT04760210|Other|ELDOA|Treatment for this is conventional physical therapy along with the ELDOA.
45758233|NCT01970787|Device|Radiofrequency Ablation (RFA) using the HALO Ablation System|
45758234|NCT00591305|Dietary Supplement|diindolylmethane (DIM)|3-month DIM
45758235|NCT00591305|Device|585 nm pulsed dye laser|once-time PDL
45758236|NCT01988415|Device|VSS-Rx1 OPM vs Commercial iDesign Treatment|Commercially available iDesign treatment planning software used to calculate the LASIK treatment profile vs VSS-Rx1 OPM (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration).
45758237|NCT01799603|Drug|TMC435|TMC435, 100 milligram oral capsule will be administered on Day 1 of each treatment period, separated by washout period of 9 days.
45758238|NCT04381130|Drug|EF-009|"Subjects who meet the eligibility criteria will have completed following evaluations and assessments before receiving treatment: a) review of medical and medication history; b) physical examination, vital signs and documentation of ECOG; c) ECG; d) routine serum biochemical, hematologic, urine pregnancy (if applicable) and urine laboratory assessments; and e) evaluation of European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 score.~On Day 0, subjects will undergo EF-009 wafer implantation via laparoscopy"
45758239|NCT01970943|Other|Placebo|Placebo will be compared to No Intervention.
45758240|NCT03816176|Drug|Isavuconazonium sulfate|Intravenous (IV) infusion
45758241|NCT03816176|Drug|Isavuconazonium sulfate|Oral capsule
45758242|NCT00666029|Drug|atorvastatin|40 m.g. o.d. tablets for 6 months
45758243|NCT00666029|Drug|placebo|Placebo
45758244|NCT03196778|Radiation|Low Dose Radiotherapy|Patients will receive 10 fractions of very low dose hemi-body radiation, delivered, twice per week, over five weeks
45758245|NCT04372940|Drug|Tranexamic Acid Irrigation|Tranexamic acid (TXA) is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, temporarily inhibiting the degradation of fibrin clots.
45758246|NCT04372940|Other|Saline Irrigation|Saline will serve as the control.
45758247|NCT01971255|Biological|Ca/04/2009/H1N1r Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
45935005|NCT00213265|Biological|7-valent pneumococcal conjugate vaccine|For transplant patients, vaccination will be started at 4 months or greater after transplantation. The second dose will be given 8 weks following the frist, the third dose 8 weeks after the second, and the fourth will be given 8 weeks after the third.
45609906|NCT05321849|Other|Echocardiography guide|Patients with PDA are percutaneously closed with echocardiography guide, without fluoroscopy like classical procedures
45609907|NCT05106075|Procedure|blood sample or joint fluid or gingival exudate|blood sample collected by peripheral blood mobilization joint fluid collected by punction gingival exudate collected with paper strips
45609908|NCT04315311|Drug|CREON|Capsule: Oral
45609909|NCT05321693|Device|Transcranial Pulsed Current Stimulation|Current has a peak pulse amplitude of 2mA, with a frequency range from 6 to 10 Hz. A battery-powered current stimulator will be used. This device provides stimulation through biphasic and alternating square wave pulse, with random pulse width range from 1 to 20 ms
45609910|NCT04245657|Other|Tissue Dielectric Constant Measurement|Sub-tissue fluid proportion will be evaluated via Moisture Meter D (Delfin Technologies, Kuopio, Finland) on both upper extremity (right and left) in predefined reference points on volar side (6 cm distal and 8 cm proximal points from cubital crease, 10 cm inferior side point from axilla and dorsal point of web space in the hand) by using four different probes which can assess 0.5 mm, 1.5 mm, 2.5 mm and 5.0 mm depth. Values taken by 2.5 mm depth probe will be used to calculate the ratio (affected side TDC value/Unaffected side TDC value) to stage lymphedema severity along with the International Society of Lymphology staging system. This device mainly aims to assess the dielectric constant of tissues which is related to the amount of tissue water. In the case of pre-lymphedema or lymphedema, one can assess objectively regarding sub-tissue fluid changes via this device. Triplicate measurements will be taken for each reference point.
45609911|NCT04245657|Other|Muscle strength measurement|Participants' muscle strength of shoulder flexion, abduction, and elbow flexion will be assessed via Handheld digital dynamometer (Lafayette Manual Muscle Tester, Model 01165, LaFayette Instruments, NY, USA). Both upper extremities will be assessed three times and the average value will be recorded.
45758248|NCT04355312|Diagnostic Test|Use of Indocyanine Green in laparoscopic ovarian cystectomy|"During intraperitoneal cystectomy or Plasmajet destruction of the cyst, as a benign organic cyst requiring surgical treatment, peroperatively, at the end of the cystectomy procedure, injection by the anesthetist on a peripheral venous route of a bolus of Indocyanine green diluted 0.2mg / kg. Installation of the SPIES camera system (KARL STORZ GmbH & Co.KG, Tuttlingen, Germany).~Evaluation of the degree of fluorescence at the location of cystectomy or destruction of the cyst.~A fluorescence score between 0 and 4 (on the model of a Likert scale) will be used for the evaluation of fluorescence.~A second reading of the Likert scale results will be carried out by a second inspector so that the score is as objective as possible. Then, second evaluation technique realized by the METAMORPH software, which will assign a raw and objective score according to the fluorescence visualized."
45758249|NCT00592475|Drug|conivaptan|IV
45609912|NCT04245657|Other|Hand-Grip Strength Measurement|Handgrip strength will be assessed with LaFayette Professional Hand Dynamometer, Model 5030L1, LaFayette Instruments, NY, USA). The standard position which can be achieved by 90-degree elbow flexion, shoulder abducted, and hand mid-prone positioned; 90-degree shoulder abduction and 90-degree shoulder abduction positions will be used to assess hang-grip strength. Three measurements will be requested and the maximum value of them will be recorded. 1 minute resting period will be provided between the positions at which handgrip is assessed.
45609913|NCT04245657|Other|Pain Threshold Measurement|The sensitive pain threshold and normal pain threshold will be evaluated by a digital algometer (Wagner FDIX, Greenwich, USA) on reference points as follows: C5-C6 zygapophyseal joints' lateral points, upper trapezius (proximal, middle and distal lateral points, length measured by a tape from C7 Processus spinosus to acromion and this length will be divided equally into three parts for proximal, middle and distal lateral point), deltoid muscle (crista deltoidea), dorsum of the webspace.
45609914|NCT04245657|Other|International Physical Activity Questionnaire-Short Form (IPAQ-SF)|This scale was intended to be filled to assess participants' physical activity levels within the last seven days. Then, MET calculations will be done via a basic Excel Spreadsheet which is pre-defined MET values formulated inside. Scale data then obtained according to the participants' answers and recorded.
45609915|NCT04245657|Other|Fatigue Impact Scale|"This scale has 9 items that can be answered as Strongly Disagree through Strongly Agree by numbered as 1 and 7, respectively. Then total points will be calculated and divided into 9 to achieve the Fatigue Impact Scale score. The higher points will be indicated more perceived fatigue, while lower points indicate less."
45609916|NCT04245657|Other|Disabilities of Arm, Shoulder and Hand Scale (DASH)|"DASH has 30 items related to upper extremity function. Participants will be requested to grade some expressions related to the function within a 5-point Likert scale as follows: No difficulty: 1, Mild Difficulty:2, Moderate Difficulty: 3, Severe Difficulty: 4 and Unable to perform: 5). The symptom score of the DASH will be calculated as dividing filled items total score to filled items' number and minus one from this data then multiplying with 25. The higher points indicate a deteriorated shoulder and hand function while lower points indicate a better upper extremity function."
45609917|NCT04245657|Other|Exercise Benefits/ Barriers Scale|Exercise Benefits/Barriers Scale has 43 items each can be graded within a four-point Likert type scale. Barrier items are reverse coded. 43 items are all related to exercise and exercise beliefs in both in the aspect of health and general. Strongly disagree, disagree, agree, strongly agree will be scored as 1,2,3,4 or vice versa whether the item should de reversely coded, respectively. Total scores ranged between 29 and 172. The barrier scale score is ranged between 14 and 56. The benefits scale is also ranged between 29 and 116. The higher the score of Barriers scale, the greater the perception of barriers to exercise.
45609918|NCT04245657|Other|Beck Depression Scale|Beck Depression Scale has 21 items each can be scored within 0 to 3. All items are related to the depressive mood of a participant. The higher the score of the Beck Depression Scale, the higher the depression level.
45609919|NCT03776357|Device|VERA clinic|A software system used with the Microsoft Kinect intended to support the physical rehabilitation of adults in the clinic and at home.
45609920|NCT03875001|Drug|BI 1358894|tablet
45609921|NCT03875001|Drug|Placebo|tablet
45758250|NCT00592475|Drug|Placebo|IV
45758251|NCT03221426|Biological|Pembrolizumab|IV infusion
45758252|NCT03221426|Drug|Placebo|IV infusion
45758253|NCT03221426|Drug|Cisplatin|IV infusion
45758254|NCT03221426|Drug|Capecitabine|Oral tablets
45758255|NCT03221426|Drug|5-fluorouracil|IV infusion
45758256|NCT03221426|Drug|Docetaxel|IV infusion
45758257|NCT03221426|Drug|Oxaliplatin|IV infusion
45609922|NCT05105373|Behavioral|Parenting for Respectability|"The programme addresses main challenges of Parenting and builds skills in 4 main areas~Poor parental bonding and child attachment;~Harsh parenting~Inequitable socialisation by gender~Parental conflict."
45609923|NCT04256915|Behavioral|Cognitive Behavioural Therapy for Insomnia (CBT-I) + Bright Light Therapy|"CBT-I consists of 6 weekly sessions of CBT-I (90-min, 3-6 adolescents in each group) with elements that address the behavioural, cognitive and physiological factors perpetuating insomnia, including: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.~Participants will additionally undergo daily morning light therapy by wearing Re-timers (a validated portable light emitting device) at home for 30 minutes. Participants will receive constant blue-green light (500 nm, 506 lux)."
45609924|NCT04256915|Behavioral|Cognitive Behavioural Therapy for Insomnia (CBT-I) + Placebo Light Therapy|"CBT-I consists of 6 weekly sessions of CBT-I (90-min, 3-6 adolescents in each group) with elements that address the behavioural, cognitive and physiological factors perpetuating insomnia, including: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.~Participants will additionally undergo daily morning light therapy by wearing Re-timers (a validated portable light emitting device) at home for 30 minutes.Participants will receive red-filtered dim light (<50 lux)."
45609925|NCT05105295|Biological|Inactivated COVID-19 vaccine|receive a third dose of inactivated COVID-19 vaccine
45609926|NCT05105217|Other|Slit2 biomarker|"1.Assessment of slit2 level in SLE patients and its correlation with disease activity.~2-Assessment of slit2 level in SSC patients and its correlation with disease activity"
45609927|NCT03449927|Other|Specialized menu|-Specialized menu that will guide participant food choices if the participant experiences nausea or diarrhea
45609928|NCT03449927|Other|Standard of care menu|-Standard registered dietitian support
45758258|NCT03221426|Drug|Leucovorin|IV infusion
45758259|NCT01989195|Drug|'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT|"EACH SUBJECT UNDERWENT 2 CARDIAC MRI PROCEDURES: ONE WITH MAGNEVIST (GADOLINIUM), ONE WITH SEEMORE (MANGANESE) REAGENT~CARDIAC MRI USING STANDARD DOSE OF 0.2mMOL/KG MAGNEVIST IV (IN THE VEIN)~CARDIAC MRI USING SEEMORE REAGENT, DOSE: 0.35CC/KG IV (IN THE VEIN) 1 WEEK AFTER GADOLINIUM MRI"
45758260|NCT00592943|Drug|armodafinil|tablet, taken by mouth, once each study day
46068611|NCT05832320|Drug|Daunorubicin|Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC>4.0×109/L, patients will be given daunorubicin (20 to 40mg per dose).
45445063|NCT01308255|Drug|Infliximab|"Prior to week 26~Infliximab 3mg/kg standard regime (weeks 0, 2, 6, 14, 22)~Methotrexate commencing at 10mg weekly, progressing to 20mg by week 6.~Folic acid 5 mg daily except the day methotrexate is taken~Patients will be unblinded at week 26 and then treated pragmatically guided by disease activity"
45758261|NCT01973205|Drug|Acetaminophen 250 mg and Aspirin 250 mg|2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg
45445064|NCT01308255|Drug|Methylprednisolone|Steroid
45445065|NCT01308255|Drug|Methotrexate|All patients enrolled are commenced on oral methotrexate 10mg once a week The methotrexate dose should be increased to 15 mg at the week 2 visit. The methotrexate should be increased to 20mg at the week 6 visit.
45758262|NCT01973205|Drug|Placebo|2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
45758263|NCT03220802|Dietary Supplement|OMNI-BiOTiC PPI|The study product consists of a sachet containing 4g of yellowish powder made of corn starch, maltodextrin, fructo-oligosaccharide P6, inulin P2, vegetable protein and 12 bacterial strains (Bacillus coagulans W183, Bacillus subtilus W201, Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Propionibacterium freudenreichii W200, Lactobacillus rhamnosus W71, in a concentration of 2 x 109 cfu/g).
45758264|NCT01990677|Drug|25mg Eplerenone|Patients will be given 25mg Eplerenone (or 50mg Eplerenone) or placebo throughout the study and the dosage will be based on the serum potassium/creatine levels. Patients will be randomized 2:1 such that 36 patients in each group will receive eplerenone and 16 patients in each group will receive placebo
46068612|NCT05832307|Other|Existing Influenza Vaccination Practices|Usual care is defined as the existing inpatient influenza vaccination practices that currently exist at a given site.
45445066|NCT01308255|Dietary Supplement|Folic acid|All patients enrolled are commenced on oral folic acid 5mg daily, except the day methotrexate is taken, and the study infusions.
45445067|NCT05694039|Device|Hearing Aids|The intervention group uses hearing aids, and the intervention group receives hearing aid intervention for 5 years.
45445068|NCT03786159|Other|No intervention|No intervention
45445069|NCT03786393|Diagnostic Test|ACR 1990 fibromyalgia critters|ACR 1990 fibromyalgia critters
45445070|NCT05693961|Device|CART-I plus|CART-I noninvasively measures the oxygen saturation of blood in a local area by screening the bloodstream through the user's finger using PPG signals
45445071|NCT03782025|Drug|Phytomenadione|Blood samples will be taken before and after intravenously prescribed phytomenadione is given. Phytomenadione will be given independently of this study.
45609929|NCT03449927|Other|Self report dietary intake worksheet|-Self report nausea and diarrhea
45609930|NCT03449927|Other|Post study questionnaire|-Completed upon count recovery and prior to discharge
45609931|NCT03449849|Other|Base Diet|Base Diet
45609932|NCT03449849|Other|Kale Treatment|Base Diet plus Kale
45609933|NCT03596073|Drug|Topical Calcipotriene Ointment|Calcipotriene is a form of vitamin D. It works by slowing down the growth of skin cells.
45609934|NCT03596073|Other|Topical Vaseline|Placebo
45609935|NCT05320757|Drug|Olaparib|a PARP inhibitor
45609936|NCT03449693|Dietary Supplement|Magnesium Oxide Supplement|Magnesium Oxide tablet
45609937|NCT04525911|Diagnostic Test|Diagnostic Test: serology test for COVID-19|a serology test will be performed at M3
45609938|NCT03651063|Other|social robot|Reach To Grasp games with a social robot
45609939|NCT03651063|Other|computer group|reach to grasp games with a computer screen
45609940|NCT03449537|Dietary Supplement|extensively hydrolyzed casein formula + LGG|Hypoallergenic formula based on extensively hydrolyzed casein supplemented with the probiotic Lactobacillus rhamnosus GG
45609941|NCT03449537|Dietary Supplement|Hypoallergenic formula based on amino-acid based formula|Hypoallergenic formula for cow milk allergy treatment based on amino acids
45609942|NCT03538119|Other|High intensity interval training program|"The HIIT protocol will consist of four four-minute high-intensity intervals, stimulating 85-95% peak-FC followed by active recovery at 70% peak-FC for a total of 20 minutes. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of maximal HR) and a 3 to 5 minute calm return period was performed at 50% of the HR peak.~The supervised sessions will take place on a cycle ergometer and treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week. Each session will be limited to three participants."
45609943|NCT03538119|Other|Moderate continuous training program|"The MCT protocol consists of continuously exerting moderate intensity, causing a peak FC-70-75% for 27.5 minutes to equal the energy expenditure of the HIIT protocol. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of maximal HR) and a 3 to 5 minute calm return period was performed at 50% of the HR peak.~The supervised sessions will take place on a cycle ergometer and treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week."
45609944|NCT05320523|Device|Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM.|Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM, at the same trajectory.
45609945|NCT05320523|Device|GPi stimulation|Bilateral high-frequency neurostimulation of the GPi using a Vercise neurostimulation system
45609946|NCT05320523|Device|NBM stimulation|Bilateral low-frequency neurostimulation of the NBM using a Vercise neurostimulation system
45609947|NCT05320523|Device|Sham stimulation|Ineffective neurostimulation by setting 0mA output at the Vercise neurostimulation system
45609948|NCT03514563|Diagnostic Test|MRI imaging|MRI recordings of the craniofacial region
45609949|NCT03514563|Diagnostic Test|Optical scan|Optical intraoral scans
45609950|NCT03514563|Diagnostic Test|3D photography|Facial stereophotogrammetry
45609951|NCT03449303|Other|EOI|Topically-applied oil
45445072|NCT05693727|Diagnostic Test|pleural markers|Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}
45609952|NCT03449303|Other|Placebo|Topically-applied oil
45609953|NCT05005065|Drug|IN-C005 X mg|Oral capsule
45609954|NCT05005065|Drug|IN-A001 Y mg|Oral tablet
45609955|NCT05005065|Drug|IN-C005 Y mg|Oral capsule
45609956|NCT05005065|Drug|IN-C005 Z mg|Oral capsule
45609957|NCT03449225|Other|Computer-Aided Genetic Education Module|Subjects will be provided with an electronic device to view Computer-Aided Genetic Education Module (CAGEM) software. This is an interactive software designed to provide subjects with tailored information regarding prenatal screening options for carrier status and aneuploidy.
45758265|NCT01990677|Drug|Placebo|Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.
45445073|NCT03781947|Drug|teverelix TFA|A single s.c. or i.m. injection of teverelix TFA administered on Day 1
45445074|NCT01311219|Other|Non-operative Treatment|A figure-of-8 brace will be applied to afflicted extremity in clinic. The patient will be instructed on proper application of the brace and asked to continue wearing the brace for 2 to 6 weeks, depending on the patient's level of comfort.
45609958|NCT05320055|Procedure|robotic repair|robotic assisted retromuscular hernia repair
45609959|NCT05001633|Behavioral|modified media content paradigm|media content
45609960|NCT05001633|Behavioral|control|media content experience
45609961|NCT05307185|Dietary Supplement|Tritordeum-based food|Diets will last 12 weeks with intermediate nutritional checks every four weeks before returning to the final study visit.
45609962|NCT03479931|Procedure|Without placement of a catheter|Elective cesarean section without preoperative placement of a urinary catheter.
45609963|NCT03479931|Procedure|With placement of a catheter|Elective cesarean section with preoperative placement of a urinary catheter.
45609964|NCT03444909|Device|cardiotocograph|Monitoring of 20 min with the cardiotocograph
45758266|NCT03194750|Other|Share ultrasound measurement of IVC collapsibility to Nephrology Attending|Nephrology attending will be provided with the respiratory variability of IVC diameter as a percent, in addition to a predefined cutoff for responsiveness to volume resuscitation of < 12%. The information will be provided before rounds and before the attending sets the fluid removal goals on dialysis for that day.
45609965|NCT03444909|Device|Toconaute|Monitoring of 20 min withToconaute
45609966|NCT03444909|Device|electrophysiological device (Micromed)|Monitoring of 20 min with the cardiotocograph
45609967|NCT03374943|Drug|KB004|KB004 is a recombinant, non-fucosylated, IgG1κ (human f-allotype) monoclonal antibody targeting the extracellular ligand binding domain of the EphA3 (ephrin receptor) tyrosine kinase
45609968|NCT03448913|Procedure|PECS block|It consists in injection of 20-30 ml of local anesthetic between pectoral minor, pectoral major, and serratus muscles.
45609969|NCT02237183|Drug|Iloprost|Given via inhalation
45609970|NCT02237183|Other|Placebo Administration|Given via inhalation
45609971|NCT02237183|Other|Quality-of-Life Assessment|Ancillary studies
45609972|NCT02237183|Other|Questionnaire Administration|Ancillary studies
45609973|NCT03371979|Drug|Pegzilarginase|Administered IV
45609974|NCT03371979|Drug|Pembrolizumab|Administered IV
45609975|NCT04958577|Device|Ada Waiting Room App (WRA) and Ada Diagnostic Support Application (HDA)|This device is a medical device but will be used only observationally--this device takes a patient's symptoms into account by asking questions and gives a ranked list of likely conditions that the patient might have based on the answers to these questions. The assessment report also includes urgency advice levels, that is, which care the patient should proceed to based on the condition suggestions. The WRA is used by the patient directly and the HDA is used by the doctor to ask the questions to the patient.
45609976|NCT05104593|Other|Intervention tested (CAREPATH)|The intervention tested will be the CAREPATH system. CAREPATH consists of an integrated, patient-centred, flexible and modular system that will provide a viable solution for the improvement of the management of multimorbid elderly patients with Mild Cognitive Impairment or mild dementia, with the help of clinicians. CAREPATH will act on patients and their informal caregivers, and its main objective is to empower multimorbid patients with MCI or mild dementia to manage their health condition together with their informal caregiver by providing assistance and reinforcement to follow their individual care plans, so independence and quality of life will increase for both of them. The intervention will provide a personalized care plan and activities proposal (treatment, activities proposal, lifestyle changes, referrals etc.) to patients and caregivers, considering the various sources of patient data available through the CAREPATH platform, and with the help of clinicians.
45609977|NCT05104437|Biological|Covid-19 vaccine (0-1-4 schedule)|Subjects receive the booster vaccine 3 months after the second dose.
45758267|NCT03194750|Other|Do not share ultrasound measurement of IVC collapsibility to Nephrology Attending|Respiratory variability of IVC diameter will be measured, but the measurement result will not be shared with the treating team.
46068613|NCT05832307|Other|Standardized inpatient influenza vaccination program|Intervention A: The basic intervention is the inpatient influenza vaccination program Intervention B: The intensified intervention is the multifaceted influenza vaccination strategy (Intervention A) plus a learning collaborative
45609978|NCT05104437|Biological|Covid-19 vaccine (0-1-6 schedule)|Subjects receive the booster vaccine 5 months after the second dose.
45758268|NCT00593645|Drug|Clofarabine|
45758269|NCT00593645|Drug|Cytarabine|
45758270|NCT00593645|Drug|Thymoglobulin|
45758271|NCT00593645|Procedure|Stem cell infusion|
45758272|NCT04397822|Biological|Blood samples|Blood samples will be collected in peripheral blood at the admission in intensive care unit or in standard care unit to compare platelet inflammasome NLRP3 and others markers
45758273|NCT03194126|Procedure|Mifepristone + Misoprostol OR oxytocine + laminaria|Three laminaria placed 12 hours prior to administration of misoprostol
45609979|NCT05096793|Dietary Supplement|beta alanine|On day 1, all participants completed the 6-MRT corresponding to baseline. Then, on days 2 and 3, each participant performed the 6-MRT with 30 mg·kg-1 and 45 mg·kg-1 of BA (low and high-dose trials, respectively). BA was purchased in powder format from a factory specializing in sports supplements. BA was colorless when diluted in water and had a characteristic taste. This format of BA (powder) allowed personalized dosing for each participant. The research team performed the personalized dosing before the application of the treatment. Between the evaluation days, there was 72 hours difference. The 30 mg·kg-1 or 45 mg·kg-1 BA administration was done with a double-blind method. Thus, on day 2, 50% of the sample performed the 6-MRT supplemented with 30 mg·kg-1 BA, while the other 50% performed the 6-MRT with 45 mg·kg-1 BA. On day 3, those participants who completed the 6-MRT with 30 mg·kg-1 BA now performed with 45 mg·kg-1 BA and vice versa.
45609980|NCT03338829|Behavioral|Positive incentive|Compensation is paid for each glucose test completed
45609981|NCT03338829|Behavioral|Loss aversion|Fixed compensation is offered to patients and they can earn a range of compensation at the completion of pregnancy depending on overall glucose testing adherence
45609982|NCT05116215|Drug|Hydrogen|Hydrogen supplement
45609983|NCT05090319|Diagnostic Test|complete blood count|Complete blood count will be performed on the patient. Accuracy of micro-hematology analyzer will be assessed.
45758274|NCT03194126|Procedure|Mifepristone + Misoprostol OR oxytocine|standart support
45445075|NCT01311219|Procedure|Operative Treatment-Plate Fixation|Plate fixation of the clavicle fracture will be performed utilizing a 3.5-mm dynamic compression plate.
45445076|NCT01311219|Procedure|Operative Treatment-Intramedullary Pinning|Clavicle fracture will be repaired through intramedullary pinning using The Rockwood Clavicle Pin (DePuy Orthopaedics, Warsaw, IN).
45609984|NCT05115747|Other|weight off-loading aerobic exercise training.|"Mild to moderate intensity weight off-loading aerobic exercise training on the anti-gravity Alter-G treadmill. (speed 8-12 mph, 50%-70% heart rate reserve HRR, 12-16 score on the Borg's scale)"
45609985|NCT03179943|Drug|Atezolizumab|Patients will be administered atezolizumab intravenously on day 1 and day 22 of a 6 week cycle for the period of 8 cycles.
45609986|NCT03179943|Drug|Guadecitabine|Guadecitabine will be administered subcutaneously on days 1 through 5 of the 6 week cycle for the period of 4 cycles
45609987|NCT05115435|Behavioral|neuro linguistic programming|Sub modality Technique: People experience the world with their five senses, and the thoughts that an individual creates in his brain about a situation are coded with these five senses. When these encodings change, the individual's perception of the situation will also change
45609988|NCT02895087|Other|Diurnal Variation Group|This intervention occurs over one 24-hour period. Eligible participants will be required to be admitted into a supervised environment for 24-hours arriving no later than 0730. Blood draws will then be taken every 4 hours (0800, 1200, 1600, 2000, 2400 and 0400). Care will be taken to ensure the total blood draws (including the screening visit) stay within Red Cross Guidelines (less than 500 ml every 8 weeks).
45609989|NCT02895087|Other|External Stress Group|"2 visits will be required, each lasting approximately 2.5 hours in the afternoon.~At both visits participants will rest quietly for 15 minutes, then have 3 blood draws and 4 saliva samples over approximately one hour. Participants will also be required to complete short questionnaires about their mood and experience.~At the second visit, participants will also complete some thinking and talking tasks. In addition the autonomic nervous system of the participant's will be monitored throughout the visit."
45609990|NCT04528173|Drug|Ketorolac|Ketorolac (0.5mg/kg; maximum 15mg intravenously) will be given at end of procedure after evaluation for hemostasis.
45609991|NCT04528173|Drug|Dexmedetomidine|Dexmedetomidine (1ug/kg with maximum 50ug intravenously) will be given at beginning of procedure.
45609992|NCT04528173|Drug|Morphine|Morphine (0.05-0.1 mg/kg intravenously) will be given intra-operatively per institutional standard clinical care.
45445077|NCT03781869|Drug|Anlotinib Hydrochloride; etoposide and cisplatin|etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1 and Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, repeated every 21 days
45609993|NCT04528173|Drug|Fentanyl|Fentanyl (0.5-2 ug/kg intravenously) will be given intra-operatively per institutional standard clinical care.
45609994|NCT05115279|Procedure|breast conservative surgery for post chemotherapy tumour size|"Skin preparation by povidine iodine.~Excision of the mass with safety margin.~Sentinel axillary lymph node or complete axillary clearance depend on axillary lymph node status~All specimens were oriented with sutures~A frozen section examination of the specimen was performed intraoperative~When the margin status was inadequate, a re-excision was performed~Closure as drawn by different oncoplastic technique"
45609995|NCT02789553|Other|First starch meal then meal with glucose syrup|Before bypass surgery, patients will take randomized meal. One day a starch meal and another day a glucose syrup meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
45609996|NCT02789553|Other|First meal with glucose syrup then starch meal|Before bypass surgery, patients will take randomized meal. One day a meal with glucose syrup and another day a starch meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
45609997|NCT02468739|Drug|Ganglioside-monosialic acid|Ganglioside-monosialic sodium is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2). The dosages of GM1 are 80mg per day.
45609998|NCT02468739|Drug|placebo|Placebo is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2).
45609999|NCT05017779|Behavioral|Unstuck & On Target: High School|Unstuck & On Target: High School (UOT:HS) is a group-based curriculum for high school students that targets executive function skills using Cognitive Behavior Therapy (CBT) techniques. UOT:HS focuses on key functions needed for adult success, such as: self-advocacy, flexibility, time management, motivation, goal setting, developing plans, monitoring progress. Guided practice begins with concrete interventionist support and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support. Lessons are delivered by school personnel within the school setting. Home extension activities are provided to parents.
46068614|NCT05832294|Device|Treatment rTMS|Depressed adolescents will undergo emotional processing tasks (within and outside the fMRI scanner) after one session of 1) sham rTMS (n = 15) or 2) active rTMS (n = 15). Prior to stimulation, expectancy for symptomatic benefit will be assessed with a standardized scale and a semi-structured interview conducted regarding their perception of rTMS. After the one-day randomized controlled phase, participants can then enter an open-label active rTMS treatment phase for 4 weeks. Eligible patients who decline the study and open-label treatment phase will be invited to participate in a semi-structured interview to explore their perceptions toward rTMS.
45758275|NCT03219086|Procedure|combined spinal epidural anaesthesia|To give surgical anesthesia for performance of the caesarian section a combined spinal epidural anesthesia will be performed with different spinal solutions according to the appointed study group
45758276|NCT03219086|Drug|Prilocaine|A combined spinal epidural anesthesia with spinal administration of 50 mg hyperbaric prilocaine 2% (Tachipri, Nordic Pharma) + 2,5mcg sufentanyl (5 mcg/ml) (Janssens-cilag)
45445078|NCT03781869|Drug|etoposide and cisplatin|etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, repeated every 21 days
45758277|NCT03219086|Drug|Bupivacaine|combined spinal epidural anesthesia with spinal administration of 7,5 mg hyperbaric bupivacaine 0,5% (Marcaine H) + 2,5mcg sufentanyl ( 5 mcg/ml)( Janssens -cilag) +1 ml nacl0,9%
45445079|NCT05693493|Device|Proprioceptive knee brace|For the intervention group that randomly consisted of 15 subjects will be using a design of knee brace (Reaction Web®; DonJoy, Vista, CA). The elastomeric web design helps to reduce pain by dispersing load across the knee. The web acts like a spring to absorb shock and shifts the peak loads away from the painful area of the knee. Elastomeric web acts to dynamically stabilise the patella on all sides, bringing the patella into proper tracking position to reduce pain for patients with general patellofemoral instabilities. Reaction Web® has dual-axis hinges that are flexible, creating synergy with the elastomeric web for optimal fit and support, and providing energy dispersion to the knee.
45610000|NCT05017779|Other|Treatment as Usual|Participants in schools assigned to the Treatment as Usual (TAU) condition will continue to receive the standard school-based IEP accommodations and school supports that would typically be provided. Data will be collected on the types of supports TAU schools offer, and what supports TAU students receive.
45610001|NCT05114499|Drug|Donepezil|Donepezil 5mg qd
45610002|NCT05114499|Drug|GV-971|GV-971 450mg bid
45610003|NCT04520997|Device|Restylane Defyne|Up to 2 milliliters (ml) of Restylane Defyne per treatment site (chin and surrounding area) with maximum of total 4 ml at baseline, up to 2 ml of Restylane Defyne per NLF and ML at week 3 and optional up to 2 ml of Restylane Defyne per facial half for NLF and ML in combination with a total of 2 ml in the chin and surrounding area at week 6.
45610004|NCT04520997|Device|Restylane Defyne|Up to 2 ml of Restylane Defyne per NLF and ML at baseline, up to 2 ml of Restylane Defyne per treatment site (chin and surrounding area) with maximum of total 4 ml at week 3 and optional touch-up of up to 2 ml per facial half for NLF and ML in combination with a total of 2 ml in the chin and surrounding area at week 6.
45610005|NCT04649385|Drug|BGB-15025|Administered orally once or twice daily (QD or BID)
45610006|NCT04649385|Drug|Tislelizumab|Administered 200 mg intravenous (IV) infusion
45610007|NCT04795323|Device|Self-management support|Self-management support
45610008|NCT04520373|Other|Best Medical Management: Occupational and Physical Therapy|Observation while undergoing Occupational and Physical Therapy for 6 months
45610009|NCT04520373|Biological|Autologous, Adipose Derived Mesenchymal Stem Cells|The mesenchymal stem cells will be collected and expanded from the patients' adipose tissue.
45610010|NCT05114343|Behavioral|Exercise|Participants will perform weight-bearing exercises for 12 weeks. The intervention will be delivered remotely through video calling with an exercise specialist.
45610011|NCT04958499|Behavioral|Bio-healthy Park|Experimental group will receive the exercise program on bio-healthy machinery with a frequency of 2 sessions per week of 55 minutes for 8 weeks. Experimental group 1 will perform the intervention program using machinery designed for self-loading use. The machines used will be rider, low gemini, high gemini, walk, bottoms, flywheels circles, flywheels rotation, twin swing, surf, swing press and rowing. Intensity will be controlled by subjective perception of effort and heart rate (Polar 420). There will be a warm-up 8-10 minutes, a main part 40-45 minutes and a return to calm 5-10 minutes. The intervention programs will be developed by a graduate in Physical Activity and Sport Sciences. The load will be progressed every 2 weeks.
45610012|NCT05114109|Drug|Isatuximab Injection|Isatuximab will be given intravenously at 10mg/kg at day 0, week (W)1, W2, W3, and W4 then every 2 weeks for a total of 12 infusions.
45610013|NCT04450797|Device|US -G VPS placement, done by BK Medical 5000 US with burr hole probe (type 9063 N11C5S, 11-5 MHz).|"US -G VPS placement, done by BK Medical 5000 US with burr hole probe (type 9063 N11C5S, 11-5 MHz).~Head not fixed, placed on horseshoe head holder, no preoperative navigation planning, catheter will be cut in length after positioning under real-time US guidance."
45610014|NCT04450797|Device|Stereotactic navigation for VPS placement (Brainlab Dual Curve System with cranial navigation software version 3.1).|"Stereotactic navigation for VPS placement (Brainlab Dual Curve System with cranial navigation software version 3.1).~Head fixed in head clamp, entry point, trajectory and catheter length planned based on preoperative computer tomography imaging, catheter placed using navigated stylet."
45610015|NCT05109585|Diagnostic Test|assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule willing to receive a 3rd dose of vaccine
45610016|NCT05109585|Diagnostic Test|assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule unwilling to receive a 3rd dose of vaccine
45610017|NCT03949959|Other|Multimodal physiotherapy|Participants will undertake their usual activities for the 5, 8 or 11 day baseline period following PRP. Participants will begin the 6 week intervention period following this period during which time they will participate in 10 sessions with an experienced postgraduate physiotherapist. After these 6-weeks, participants will have no contact with intervention personnel during the 6-week follow-up period.
45610018|NCT02142803|Biological|Bevacizumab|Given IV
45610019|NCT02142803|Other|Laboratory Biomarker Analysis|Correlative studies
45610020|NCT02142803|Other|Pharmacological Study|Correlative studies
45610021|NCT02142803|Drug|Sapanisertib|Given PO
45758278|NCT02998385|Drug|Cisplatin|intravenous, concomitant to irradiation
45610022|NCT04436445|Combination Product|dry cupping|represents the location and clinical importance of each acupoint. First, the position of the patient will be supine lying for SP6, SP9, KI6, GB34 and CV6 acupoints and it will be prone lying for B23 acupoint. Second, the skin will be cleaned by alcohol then cups will be placed on the acupoints. Dry cupping for SP6, SP9, KI6 and GB34 acupoints will be applied using small cups while dry cupping for CV6 and B23 will be applied using large cups. Third, a negative pressure will be applied with a manual handle. Finally, the cups will be removed after 5 to 15 minutes by pressing one side of the skin with a finger to release the vacuum slowly.
45610023|NCT04436445|Other|Life style modification|Life style modification
45758279|NCT02998385|Radiation|radiotherapy|66 à 70 Gy per fractions of 2 Gy, 1 fraction/day, 5 fractions/week
45758280|NCT04398290|Drug|Inhaled nitric oxide (iNO)|iNO Pulse 250 mcg/kg ideal body weight (IBW)/hour
45610024|NCT05283161|Drug|cannabidiol and tetrahydrocannabinol|CBD and THC will be given in the same concentration within a group of 10 participants, while its effects will be compared with the other two groups with 10 participants each and the placebo group.
45610025|NCT05283161|Drug|Placebo|The placebo will match the study drug in odor, taste, color and appearance to ensure proper masking.
45610026|NCT03843489|Device|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because an arterial sample of blood is not required to make the measurement, the pulse oximeter can provide non-invasive real time information.
45610027|NCT03843489|Device|Reference CO-oximetry sensor|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
45610028|NCT03695939|Biological|Xeno-Skin™|3+3 Dose-escalation Study Design; 2 dosage strengths will be utilized during this Phase 1/2 Trial; an expansion cohort (9 patients) receive the highest dose.
45610029|NCT03695939|Biological|Human Cadaver Allograft|HCA is used as a temporary wound dressing between debridement and definitive closure in many well-resourced contexts.
45610030|NCT03691311|Drug|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Two injections on days 1 and 8 previous to surgery breast cancer excision
46068615|NCT05832294|Device|Sham rTMS|Depressed adolescents will undergo emotional processing tasks (within and outside the fMRI scanner) after one session of 1) sham rTMS (n = 15) or 2) active rTMS (n = 15). Prior to stimulation, expectancy for symptomatic benefit will be assessed with a standardized scale and a semi-structured interview conducted regarding their perception of rTMS. After the one-day randomized controlled phase, participants can then enter an open-label active rTMS treatment phase for 4 weeks. Eligible patients who decline the study and open-label treatment phase will be invited to participate in a semi-structured interview to explore their perceptions toward rTMS.
45610031|NCT03448835|Drug|Atezolizumab|atezolizumab 1200 mg 5 cycles
45610032|NCT03448835|Drug|Capecitabine|capecitabine 850 mg /m2 4 cycles
45610033|NCT03448835|Drug|Oxaliplatin|oxaliplatin 100 mg/m2 4 cycles
45610034|NCT03448835|Drug|Docetaxel|docetaxel 50 mg/m2 4 cycles
45610035|NCT03690453|Drug|Ivermectin|single dose of Ivermectin
45610036|NCT03448757|Other|measuring hemodynamic parameters heart beat to heart beat during single-frequency exposure|"This study aims to create a method for non-invasive diagnosis of biofeedback effect exposure to LEEF modulated to specific frequencies in individuals exposed to hepatocellular carcinoma -specific frequencies in increasing sequential manner, frequency to frequency in patients with advanced hepatocellular carcinoma and healthy individuals.~Patients with advanced hepatocellular carcinoma will be exposed to specific LEEF-modulated frequencies (3 to 10 Hz difference) to identify the optimal frequency associated with greater response to the biofeedback effect in patients with advanced hepatocellular carcinoma."
45610037|NCT05234567|Biological|Asfotase Alfa|All participants will receive asfotase alfa subcutaneously per standard of care. Unless otherwise specified per the Physician's standard of care, participants aged < 2 years are recommended for a clinic visit approximately every 3 months after Enrollment until 2 years of age, after which they should have a clinic visit approximately every 6 months. Participants should be followed for 5 years, as possible.
45610038|NCT04931745|Device|Virtual reality|VR headset will be used 5-10 minutes prior to and during port access
45758281|NCT04398290|Drug|Nitrogen gas|250 mcg/kg ideal body weight (IBW)/hour
45758282|NCT04398290|Drug|Oxygen gas|Supplemental oxygen administered via nasal cannula
45758283|NCT04397510|Drug|Heparin|Nebulized Heparin
45758284|NCT04397510|Drug|0.9% Sodium-chloride|Nebulized 0.9% Sodium Chloride
45758285|NCT03742076|Dietary Supplement|High-dose prebiotic|This is a spray-dried powder, yellowish-white in color, that is dissolvable.
45610039|NCT04931745|Device|Tables distraction|Tablet distraction will be used 5-10 minutes prior to and during port access
45610040|NCT04931745|Other|No or non-technologic distraction|This approach will be used 5-10 minutes prior to and during port access
45610041|NCT03487575|Behavioral|Open trial|Integrated electronic support and care support manager contact
45610042|NCT05211635|Dietary Supplement|Vitamin D|One capsule daily for 84 days
45610043|NCT05211635|Other|Placebo|One capsule daily for 84 days
45610044|NCT03464409|Other|Semi-structured interview|Semi-structured interviews to be conducted by a study team member.
45610045|NCT03464409|Other|Spinal Cord Independence Measure (SCIM-SR)|The Spinal Cord Independence Measure - Self Report (SCIM-SR) is a self-report instrument for assessing functional independence of persons with spinal cord injury.
45610046|NCT03464409|Other|SF-36|A health-related quality of life (QoL) self-reported survey.
45610047|NCT03448523|Behavioral|Right To Play's Positive Child and Youth Development program|"Right To Play's Red Ball Child Play manual provided for 60 hours per annum for two years~Training of junior leaders~Related play-based activities such as sports days~Quarterly awareness sessions with community groups and parents~Summer camps for children~training of teachers on Right To Play's foundational resources, positive disciplining, and gender and child protection"
45610048|NCT05184335|Drug|Brilaroxazine|RP5063, a new chemical entity (NCE), is a novel multimodal neuromodulator intended for treating schizophrenia and comorbid conditions. This drug is an investigational drug and has not been approved for treatment or marketing. RP5063 belongs to a class of third generation antipsychotics called Dopamine-Serotonin System Stabilizers. The chemical name of the RP5063 active pharmaceutical ingredient (API) is 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one hydrochloride.
45610049|NCT05184335|Other|Placebo|RP5063 matching Placebo
45610050|NCT03439527|Other|Muscle Precursor Cells (MPCs), ATMP|The advanced therapeutic investigational product, the MPCs, is a living, autologous cell-product isolated from a biopsy of the patient's own musculus soleus.
45610051|NCT05104905|Drug|bexmarilimab|A single neoadjuvant dose will be administered prior to surgery.
45610052|NCT05108727|Device|Diode Laser|DL with a wavelength of 810±5 nm, a 400micron diameter, and a power of 1 watt in continuous mode was applied to the MWF at the test sites.
45610053|NCT05108727|Procedure|Modified Widman Flap|Periodontal Surgery Technique
45610054|NCT05102331|Other|Lavender Oil Aromatherapy|"Participants will be given a dental bib to wear. Three drops of the lavender oil will be placed on the fabric of the bib and the participant will be instructed to relax for 20 minutes.~The lavender oil is produced by doTERRA and has Gas Chromatography Mass Spectrometry analysis showing 35.66% linalool without any contaminants"
45610055|NCT05102331|Other|Placebo oil|"Participants will be given a dental bib to wear. Three drops of the placebo oil will be placed on the fabric of the bib and the participant will be instructed to relax for 20 minutes.~Refined jojoba oil which has no color or smell"
45610056|NCT05102331|Procedure|BMAB procedure|SOC BMAB procedure. The procedure takes approximately 20 minutes to complete and is performed on the posterior superior iliac crest of the pelvic bone. Between 5 and 10 mL of 1% lidocaine will be injected into the site of the BMAB 5 minutes prior to the procedure beginning. No systemic premedications will be allowed including opioids or benzodiazepines. If during the procedure, participants continue to report severe anxiety or pain, the practitioner may consider providing 1mg of lorazepam or morphine as a rescue medication. The aspirate needle and core biopsy needle will be the standard needle provided by the BMAB kit
45610057|NCT04808193|Other|Survey|Participants will fill in the survey
45610058|NCT05058573|Other|Control group (n=22)|Control group will be received only medical treatment
45610059|NCT02734433|Drug|Pexidartinib|
45610060|NCT04741659|Device|Ventimask|The patients will be asked to breathe spontaneously using their actual low oxygen flow
45610061|NCT04741659|Device|High Flow Nasal cannula (HFNC)|The patients will be asked to breathe using high flow nasal cannula (HFNC). Air flow will set up to 60 l/m, temperature according to patient's comfort and FiO2 in order to obtain SpO2 values >/= 92%
45610062|NCT04741659|Device|Helmet CPAP|The patients will be asked to breathe with Helmet. CPAP will set at 10 cmH2O and FiO2 in order to obtain SpO2 values >/= 92%
45610063|NCT04741659|Device|Non Invasive Ventilation (NIV)|the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface
46068616|NCT05832281|Drug|Synthetic CBD|Participants will receive Purysis, or synthetic CBD, which will be compared to placebo
46068617|NCT05832281|Drug|Placebo|Placebo for Purysis
46068618|NCT05832268|Other|Obstetric Anal Sphincter Injury|We will investigate if an obstetric anal sphincter injury affects the function of anal musculature
46068619|NCT05832242|Other|Ultrasound|Point-of-care ultrasound in the emergency department
46068620|NCT05832229|Drug|Rosuvastatin|Patients meeting all eligibility criteria will be assigned to a randomization arm prior to initiation of a 4-week lead-in phase of the study. All participants will undergo a 4-week, open-label active run-in phase to evaluate initial safety and adherence to rosuvastatin. During this active run-phase, all participants will receive target dose rosuvastatin-- 20 mg daily (10 mg daily for participants of East-Asian ancestry). After the active run-in phase, all participants will continue with their pre-assigned randomization (1:1) treatment of rosuvastatin 20 mg daily (10 mg daily for participants of East-Asian ancestry) or matching placebo.
46068621|NCT05832216|Drug|Daratumumab|Daratumumab is a monoclonal globulin targeting the CD38 molecule of immune cells, which can eliminate antigen-presenting cells such as dendritic cells and macrophages, and indirectly reduce the production of autoantibodies. In addition, Daratumumab reduces autoantibody levels by targeting plasma cells, B lymphocytes and T lymphocytes.
46068622|NCT05832203|Other|Counseling on planetary health diet with calorie restriction|Counselling on planetary healthy diet, calorie restriction diet, and healthy lifestyle through mobile application
45610064|NCT04451759|Other|MRI exploration|ultra high field (7T) magnetic resonance imaging
45610065|NCT03129191|Device|Non-invasive bone conduction hearing aid A|The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an elastic headband.
45610066|NCT03129191|Device|Non-invasive bone conduction hearing aid B|The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.
45610067|NCT03443687|Behavioral|Pelvic Floor Physical Therapy|Pelvic floor exercises for 3 months under instruction of physical therapist
45610068|NCT03443687|Device|Home Biofeedback|Pelvic floor exercises for 3 months using biofeedback device
45610069|NCT04696419|Other|Different intensities of contact to dogs|Each subject is exposed to four test situations of 10 minutes. Three situations with increasing intensity of dog contact, and one control test situation with no contact to a dog. The order of the test situations is random and with 30 minute washout in-between
45610070|NCT03448445|Other|Usual care setting|usual care settings without any intervention
45610071|NCT04583319|Diagnostic Test|EasyCov POC|Saliva samples will be collected according to the sampling protocol defined each for EASYCOV test. The EasyCoV test will be performed at the beginning of the study before obtaining the routine RT- PCR test results. The operators performing this test will be blinded from the routine RT-PCR results.
46068623|NCT05832203|Other|Counseling on balanced nutrition diet with calorie restriction|Counselling on balanced nutrition diet, calorie restriction diet, and healthy lifestyle materials through mobile app
46068624|NCT05832190|Other|Standard of care|Patients receiving during 3 months before the surgery usual general dietary recommendations regarding balanced diet comprising legumes and fruits, meat or equivalent, dairy products and starch and bread
46068625|NCT05832190|Dietary Supplement|Biotin supplement|1 capsule per day of Biotin 450µg during 3 months before the surgery.
46068626|NCT05832190|Dietary Supplement|Fiber supplement|3 servings per day of PureLean® Fiber, a powdered blend of fibers and prebiotics, during 3 months before the surgery
46068627|NCT05832164|Other|Multifactorial intervention|"Adherence to a Mediterranean diet.~Progressive aerobic and anaerobic exercise program.~Review of polypharmacy~Group socialization activities"
46068628|NCT05832151|Drug|CIN-102 Dose 1|2 capsules twice daily for 12 weeks
46068629|NCT05832151|Drug|CIN-102 Dose 2|2 capsules twice daily for 12 weeks
45610072|NCT03443609|Diagnostic Test|68Ga-HBED-CC-PSMA PET / CT|Patient will receive a specific PET / CT with PSMA
45758286|NCT03742076|Dietary Supplement|Low-dose prebiotic|This is a spray-dried powder, yellowish-white in color, that is dissolvable.
45758287|NCT03742076|Dietary Supplement|Placebo|Powder fiber supplement, yellowish-white in color, that is dissolvable.
45445080|NCT01311765|Other|Duration of antibiotic therapy limited to 8 days|Initiation of adequate empiric antibiotics for postoperative peritonitis within 24 hours after surgery and up to 8 days. At randomisation performed on day 8, the patients assigned to the 8-day group (short-course group) stop their treatment
45610073|NCT04583163|Diagnostic Test|Transcranial Doppler|Transcranial Doppler is a non-invasive, painless, ultrasound technique that uses high frequency sound waves to measure the rate and direction of blood flow vessels in the brain.
45610074|NCT03448367|Device|FreeStyle Libre Flash Glucose Monitoring System|Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
45758288|NCT00704717|Biological|PegIntron (peginterferon alfa-2b; SCH 54031) pen|PegIntron pen administered in accordance with approved labeling
45610075|NCT04562181|Other|Bispectral index and qCON/qNOX monitoring|This study will characterise the bispectral index data and qCON/qNOX index data in 30 patients during the operation and first postoperative night
45610076|NCT03443531|Drug|Bufei Huatan granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung will be given Bufei Huatan granule, twice daily for 24 weeks for lower dosage.
45610077|NCT03443531|Drug|Yifei Qinghua granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung will be given Yifei Qinghua granule, twice daily for 24 weeks for lower dosage.
45610078|NCT03443531|Drug|Placebo Bufei Huatan granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung will be given placebo Bufei Huatan granule, twice daily for 24 weeks for lower dosage.
45610079|NCT03443531|Drug|Placebo Yifei Qinghua granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung will be given placebo Yifei Qinghua granule, twice daily for 24 weeks for lower dosage.
45610080|NCT04561245|Drug|ALT-801|Injected subcutaneously (SC)
45610081|NCT04561245|Other|Placebo|Injected subcutaneously (SC)
45610082|NCT03448289|Behavioral|RLPT|The Reproductive Life Plan Tool (RLPT) will be self-administered. Pediatricians will use the RLPT to assess women's need for well-woman primary care.
45610083|NCT03443453|Drug|MIV-711|MIV-711 administered as tablets and capsules at four occasions
45758289|NCT00704717|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling.
46068630|NCT05832151|Drug|Placebo|2 capsules twice daily for 12 weeks
45445081|NCT01308411|Other|50% step down reduction in inhaled corticosteroid dose|All participants will have their inhaled corticosteroid dose reduced by 50%
45610084|NCT03448211|Drug|Para-toluenesulfonamide Injection (PTS)|Intratumoral injection
45610085|NCT05098977|Procedure|Heart rate variability measurement|HRV will be measured at the moment of patients' admission to the cardiac catheterization laboratory on the top of therapy guided by European guidelines. Both, time- and frequency-domain parameters (respectively, SDNN, SDANN, RMSSD and LF, HF, LF/HF ratio) of the HRV will be obtained using a validated medical device during 5-minute segments before and after revascularization of the culprit artery. In addition, HRV will be evaluated in ambulatory setting, at 1 month and at 6 months after the index event. Obtained interbeat interval data will be further analysed using a dedicated software in order to derive specified HRV parameters.
45610086|NCT05098977|Procedure|Percutaneous coronary intervention|Coronary angiography and PCI will be performed using femoral or radial approach after local anesthetic infiltration with Lidocaine and arterial sheath placement. Following the culprit lesion detection and guidewire placement, thromboaspiration and glycoprotein IIb/IIIa inhibitors will be left to the operator decision. Also, the choice of coronary stenting technique and stent sizing will be performed according to the operator experience. Antiplatelet and anticoagulant drugs will be administered in concordance with latest European guidelines.
45758290|NCT03708224|Biological|Atezolizumab|Given intravenously (IV)
45758291|NCT03708224|Biological|Tocilizumab|Given IV
45758292|NCT03708224|Biological|Tiragolumab|Given IV
45758293|NCT03632642|Drug|Benzylpenicillin|The study drug will be administered for a minimum of 2 weeks (the minimal currently accepted duration of IV therapy for SAB.) For patients who do not fulfill criteria for 2 weeks of therapy, the duration of treatment will be 4 to 6 weeks and will be made by the treating clinician.
46068631|NCT05832138|Behavioral|ONLOOP program|Participants will receive ONLOOP program intervention materials: a study invitation letter, personalized health information, and a reminder to complete their guideline-recommended surveillance test(s)
45758294|NCT03632642|Drug|Flucloxacillin|The study drug will be administered for a minimum of 2 weeks (the minimal currently accepted duration of IV therapy for SAB.) For patients who do not fulfill criteria for 2 weeks of therapy, the duration of treatment will be 4 to 6 weeks and will be made by the treating clinician.
45758295|NCT05038514|Other|musıc therapy|After the prone position was given to the patients, according to the randomization table, the intervention group was given 30 minutes by the nurse. nature-based music therapy will be applied.
45758296|NCT00594425|Drug|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
45758297|NCT03686384|Drug|SVT-15652|1 vial twice daily
45758298|NCT03686384|Drug|Placebo|1 vial twice daily
46068632|NCT05832099|Radiation|Radiation|The techniques of conformal focal-brain irradiation in the era of modern radiotherapy (i.e., conventionally fractionated VMAT, hypofractionated stereotactic radiotherapy, and proton beam therapy, etc)
45445082|NCT01308489|Procedure|therapeutic conventional surgery|Undergo posterior spinal tumor resection
45445083|NCT01308489|Procedure|therapeutic conventional surgery|Undergo anterior and posterior spinal tumor resection
45610087|NCT03448133|Device|Magstim rTMS|The device is made in London,UK
45610088|NCT05069805|Procedure|PECS II block|Patients will receive standard general anesthesia with sevoflurane and fentanyl associated to PECS II block
45610089|NCT05069805|Procedure|ESP block|Patients will receive standard general anesthesia with sevoflurane and fentanyl associated to ESP block
45610090|NCT03443375|Other|Physical exercise|The interventions proposed in the present trial were based on a safe and well-established exercise training program
45610091|NCT05066529|Procedure|dry-needling|Dry needling is a technique in which a fine needle is used to penetrate the skin, subcutaneous tissues and muscles to mechanically disrupt tissue without the use of anesthesia. Treatment is often used to treat myofascial trigger points.
45610092|NCT03448055|Dietary Supplement|Immunocal|cysteine-rich whey protein isolate
45610093|NCT05059665|Diagnostic Test|Helio Liver Test|De-identified whole blood and serum samples are collected for the purpose of evaluating the performance (sensitivity/specificity) of the HelioLiver Test for the detection of hepatocellular carcinoma (HCC).
45610094|NCT03447977|Other|cervical|cervical spine manual therapy
45758299|NCT04317404|Drug|40 mg Triamcinolone acetonide|Unilateral knee steroid injection
45610095|NCT03447977|Other|thoracic|thoracic spine manual therapy
45610096|NCT03447977|Other|exercises|exercises for pain
45610097|NCT04909905|Dietary Supplement|Standard enteral nutrition|Standard enteral nutrition according to ICU nutrition protocol for 7 days
45610098|NCT04909905|Combination Product|Glutamine|Intravenous glutamine supplementation to enteral nutrition in a dose of dose of glutamine of 0.4 g/kg/day for 7days
45758300|NCT04399070|Drug|S-ketamine|The depression patients received propofol and S-ketamine before ECT
45758301|NCT04399070|Drug|ketamine|The depression patients received propofol and ketamine before ECT
45758302|NCT04399070|Drug|saline|The depression patients received propofol and saline before ECT
45445084|NCT01308489|Procedure|quality-of-life assessment|Ancillary studies
45610099|NCT05057091|Other|Lomber roll techniques group (n=23)|Direct manipulation will be applied to the lumbar region with the lumbar Roll technique. Painful segment will be determined.
45610100|NCT05057091|Other|Posterior- anterior central vertebral manipulation techniques (n=23)|After initial assessments were made, both groups had high velocity and low amplitude (HVLA) or V. Level manipulation will be applied in the form of 2 different direct manipulation techniques
45610101|NCT03443297|Other|breast milk|Feeding with breast milk will be started in early feeding group from 24 to 48 hours of age or in late feeding group, from 48 to 72 hours of age. Initially 4 hourly feeding will be started with 0.5ml and 1 ml expressed breast milk in babies with birth weight <1200 grams and >1200 grams respectively. gradually volume of milk should be increased
45610102|NCT01709123|Drug|chromium niacinate|200ug or 500ug supplementation in pill form
45610103|NCT01709123|Drug|placebo|Placebo pill for chromium niacinate
45610104|NCT03443219|Device|Spritztube®|After preoxygenation, anaesthesia was induced with midazolam, propofol, and fentanyl,Spritztube® was inserted and both cuffs inflated
45610105|NCT03443219|Device|LMA Supreme™|After preoxygenation, anaesthesia was induced with midazolam, propofol, and fentanyl,LMA Supreme™ was inserted and both cuffs inflated
45610106|NCT01301807|Drug|Carfilzomib|Given IV
45610107|NCT01301807|Drug|Panobinostat|Given PO
45610108|NCT04962893|Biological|SARS-CoV-2 VLP Vaccine-Wuhan|Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus
45758303|NCT03650114|Biological|Ofatumumab|subcutaneous injection of 20 mg ofatumumab every 4 weeks
45610109|NCT04962893|Biological|SARS-CoV-2 VLP Vaccine-Alpha (British) variant|Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus
45610110|NCT04962893|Biological|SARS-CoV-2 VLP Vaccine-Wuhan+Alpha variant|Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the Wuhan or Alpha variants
45610111|NCT02521571|Behavioral|Resiliance Alliance|"The intervention is 6 months long & is delivered through weekly sessions held in the participating child protective offices. The sessions follow a 4-week cycle with the participants changing each week of the cycle: (1) CPS alone, by units; (2) CPS/Supervisor units; (3) Child Protective Manager and CPS/Supervisor units; and (4) CPSs & Supervisors/Managers separately.~Participating staff are introduced to a resilience-related topic or skill, and receive a brief didactic training on that topic. Staff then engage in a group activity, which is designed to help them apply the new topic or skill to the workplace. Each module wraps up with a relaxation or exercise to help staff transition back into their work responsibilities; the facilitator can pick among the selection provided based on their sense of what would be helpful for the group. Staff are also given handouts and activities to do during the week."
45758304|NCT03650114|Biological|Tetanus toxoid (TT) containing vaccine (Td, Tdap)|0.5mL Vial/Syringe Containing 5 limit of flocculation (LF) tetanus toxoid
45758305|NCT03650114|Biological|13-valent pneumococcal conjugate vaccine (13-PCV)|0.5mL Vial/Syringe
45758306|NCT03650114|Biological|23-valent pneumococcal polysaccharide vaccine (23-PPV)|0.5mL Vial/Syringe
45758307|NCT03650114|Biological|Seasonal Quadrivalent influenza vaccine|Seasonal 2020-2021 0.5mL Vial/Syringe (trivalent may be used where quadrivalent is not available)
45758308|NCT03650114|Biological|Keyhole limpet hemocyanin (KLH) neo-antigen|1mg Vial
45758309|NCT00667511|Device|NxStage System One|Comparison of Nocturnal (NHD) and Short Daily Hemodialysis (DHD) with the NxStage System One
45758310|NCT00667589|Drug|urea 40% cream|urea 40% cream applied twice per day to affected areas
45758311|NCT00667589|Drug|fluocinonide 0.05% cream|fluocinonide 0.05% cream applied twice per day to affected areas
45758312|NCT00667589|Drug|tazarotene 0.1% cream|tazarotene 0.1% cream applied twice per day to affected areas
45758313|NCT00667589|Drug|bland emollient cream (Udderly smooth® Udder Cream)|bland emollient cream applied twice per day to affected areas
45758314|NCT00667745|Drug|Lithium Carbonate|Lithium was started at 300 mg and then increased to 600 mg after 3 days. Lithium doses were maintained at 600 mg per day for 8 weeks, but may have been adjusted after that time as needed up to a serum level of 1.2 mEq/L.
45758315|NCT00667745|Drug|Optimized Treatment (OPT)|The foundation of OPT was to maintain treatment that will typically include at least one FDA-approved mood stabilizer other than lithium (e.g., divalproex, carbamazepine, risperidone, quetiapine, olanzapine, aripiprazole, ziprasidone) and to follow the recommendations summarized in the evidence-based stages of the Texas Implementation of Medication Algorithm (TIMA) revised guidelines.
45758316|NCT03173612|Drug|Dasatinib|Primary AML includes CBF-AML and non-CBF-AML. Children with a WBC (white blood cell) lower than 4,000/μL and low proliferative bone marrow at diagnosis are treated with CAG. Other children are treated with MAE. The rescue regimen for children who showed M3 marrow after MAE or CAG is IAE. Consolidation therapy consisted of four (for CBF-AML) or five (for non-CBF-AML) courses, and triplein trathecal therapy is given as a part of each course. After the second course of therapy, CBF-AML are stratified into two risk groups, while non-CBF-AML patients in remission are stratified into three risk groups.Consolidation regimen for CBF-AML includes IA, MA, IA, MA. Dasatinib is used in CBF-AML as a part of consolidation therapy. Consolidation regimen for non-CBF-AML includes IAE, MAE, EA, IAE, EA or MAE.
45758317|NCT02990819|Device|Apha/beta T and CD19+ cell depletion using CliniMACS device|Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.
45610112|NCT02521571|Behavioral|Secondary traumatic stress training|"These trainings will take place in two parts (for a total of 3 hours) and include an overview of secondary traumatic stress and its impact on child welfare staff, and some strategies staff can use to protect themselves from STS - essentially a summary version of what the intervention group will receive over the 24 weeks of the intervention. The investigators consider this training to represent treatment as usual, as from our experience it is often how child welfare agencies address the issue of secondary traumatic stress among their staff."
45758318|NCT02998775|Drug|Plasma Sampling|No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
45758319|NCT02999711|Drug|REGN3500|REGN3500 dose
45758320|NCT02999711|Drug|Placebo|Matching placebo
45758321|NCT02999945|Dietary Supplement|SGA-enhanced nutrients|Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
45758322|NCT02999945|Dietary Supplement|IUGR-enhanced nutrients|Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
45610113|NCT03443141|Drug|Vitamin E|The applied dressing will be embebbed in Vitamin E
45610114|NCT03443141|Drug|Standard dressing|The applied dressing is a normal one without adding any product to it.
45758323|NCT02999945|Other|SGA-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
45610115|NCT04937543|Drug|inhaled beclametasone|Adding belcamethasone to standard of care for Covid 19 positive patients
45610116|NCT04937543|Drug|Inahaled beclomethasone / formoterol / glycopyrronium|Adding belcametasone/ formoterol / glycopyrronium to standard of care for Covid 19 positive patients
45610117|NCT03442907|Procedure|24 hour blood pressure measurement, fluids, vasopressors|Targeting individual blood blood pressure values during surgical procedures
45445085|NCT03781635|Drug|bolus of intravenous ketamine|low-dose ketamine (0.25mg.kg-1) is administered intraoperatively as bolus at incision (T0) and for each hour of anesthesia untel the end of surgery.
45610118|NCT03442907|Procedure|Standard of Care|Treatment according to Standard of care at the Department of Anaesthesiology, University Medical Centre Hamburg Eppendorf
45610119|NCT03447899|Behavioral|Attachment and Biobehavioral Catch-up (ABC)|Attachment and Biobehavioral Catch-up (ABC) is an in-home, 10-session, manualized parent-training program for children ages 6 months through 2 years who have experienced early adversity. ABC utilizes parent-child interactions to enhance positive interactions with the child through live coaching with particular focus on nurturing behaviors, following the child's lead, non-frightening behaviors. These behaviors include appropriate soothing and comforting when a child is distressed, responding to or imitating a child in a contingent way, and displaying warmth.
45610120|NCT04928105|Biological|Senl-T7|Patients will be treated with CD7 CAR-T cells
45610121|NCT03447665|Behavioral|Bedtime routine|Tailored bedtime routine
45610122|NCT03447665|Behavioral|Sleep schedule|Tailored sleep schedule, including morning rise time, cut-off for last nap of the day, and bedtime.
45610123|NCT03447665|Behavioral|Intervention (bedtime)|Parents implement behavioral sleep intervention at bedtime.
45610124|NCT03447665|Behavioral|Intervention (after night wakings)|Parents implement behavioral sleep intervention following each night waking.
45610125|NCT04923737|Drug|Dexmedetomidine|patients will receive a loading dose of IV Dexmedetomidine1μg/kg slowly just before induction of anesthesia, then Dexmedetomidine infusion started at a rate of 0.5μg/kg/h.
45610126|NCT04923737|Drug|0.9% sodium chloride|patients will receive an equal volume of 0.9% sodium chloride (both the loading, and the infusion
45610127|NCT02452424|Drug|PLX3397|PLX3397 capsules, 200 mg
45610128|NCT02452424|Biological|Pembrolizumab|Pembrolizumab, 200 mg, IV
45610129|NCT04921943|Drug|Hypertonic saline|Nebulizing with 7% hypertonic saline twice daily for 12 weeks.
45610130|NCT04921943|Drug|Azithromycin|Standard of care
45758324|NCT02999945|Other|IUGR-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
45758325|NCT00595361|Drug|salmeterol|salmeterol 50 micrograms twice daily for 2 weeks
45758326|NCT02998463|Device|skin-to-skin facilitating garment|Fabric garment designed to accommodate term neonates having skin-to-skin contact.
45758327|NCT02999867|Dietary Supplement|triticale and mung bean|subjects are assigned to intake of triticale and mung bean for 30 days
46068633|NCT05832073|Drug|Natural full human monoclonal antibody CBB 1 injection|Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
45610131|NCT04921943|Drug|Ethambutol|Standard of care
45610132|NCT04921943|Drug|Rifampin|Standard of care
45610133|NCT04915859|Other|Hand Cooling at 12-15 degrees celsius|hand cooling at 12-15 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature
45610134|NCT04915859|Other|Hand Cooling at 16-20 degrees celsius|hand cooling at 16-20 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature
45610135|NCT04915859|Other|hand and back cooling at 12-15 or 16-20 degrees celsius|hand and back cooling at 12-15 or 16-20 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature while also wearing the back wrap cooling device set to this temperature
45610136|NCT04915859|Other|Passive cooling|"participants will sit in a chair and passively cool (no active intervention)"
45610137|NCT04904471|Biological|Recombinant COVID-19 vaccine (Sf9 cells)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified by antigen isolation and added with aluminum hydroxide adjuvant for the prevention of COVID-19.
45610138|NCT04904471|Other|Placebo control|Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium dihydrogen phosphate, disodium hydrogen phosphate) are consistent with the study vaccine and have been tested and qualified by National Institutes for Food and Drug Control.
45610139|NCT02419508|Drug|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension|
46068634|NCT05832073|Drug|Rabies Human Immunoglobulin (HRIG)|Active ingredient: Rabid human immunoglobulin
45610140|NCT02419508|Drug|Brinz/brim vehicle|Inactive ingredients used as a placebo for masking purposes
45610141|NCT02419508|Drug|Prostaglandin analogue|
45758328|NCT02999867|Dietary Supplement|adzuki bean|subjects are assigned to intake of adzuki bean for 30 days
45758329|NCT00596453|Drug|Ciprofloxacin hydrochloride|250 mg Ciprofloxacin hydrochloride twice a day for 14 days
45758330|NCT00596453|Drug|Placebo|Placebo twice a day for 14 days
45610142|NCT04926584|Drug|induction therapy|induction immuno-chemotherapy or immunotherapy prior to resection or definitive chemoradiotherapy
45610143|NCT01328249|Drug|eribulin mesylate|Dose dense doxorubicin and cyclophosphamide for 4 cycles during the first 8 weeks followed by eribulin mesylate 1.4mg/m2 for 4 cycles during the next 12 weeks.
45610144|NCT03128801|Procedure|Global Stretching Program|Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active). The GSP will last for a period of 8 weeks. The protocol is based on the study of Lawand et al (2015) who used all postures global therapeutic stretching. The investigators will use six self-management postures in a standardized manner, each of which will last for 10 to 20 minutes.
45610145|NCT03128801|Procedure|Stabilization Exercises|The exercise protocol and criteria to increase exercise progression was previously described by Hicks et al (2005). It will be directed by a single therapist one to one session based on specific criteria (being able to maintain muscle contraction eight seconds during 30 repetitions in bilateral exercises or during 20 repetitions for unilateral exercises). Each session will be conducted weekly for 40 minutes.
45610146|NCT05190575|Drug|TST001|TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.
45610147|NCT01651052|Procedure|Heart Valve Surgery|Implant of an aortic valve, Model 11000
45610148|NCT05188157|Other|mirror therapy|The patients in IG will receive exercise program before mirror theraphy. The patient will continue to do the exercises in front of the mirror for the remaining 20 minutes of the exercise. While doing the exercise with the healthy side in front of the mirror, the patient will try to do the same movement with the shoulder diagnosed with impingement syndrome on the other side of the mirror. The patient will try to do the movement correctly with the reflection in the mirror.
45758331|NCT02998697|Drug|Ferrous Sulfate|Ferrous sulfate 200 mg t.i.d for 90 days
46068635|NCT05832073|Drug|Natural full human monoclonal antibody CBB 1 injection placebo|Composition: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
46068636|NCT05832073|Biological|Lyophilized rabies vaccine for human use (Vero cells)|Active ingredient: inactivated rabies virus fixed poison
46068637|NCT05832034|Drug|Immune Globulin Intravenous (Human)|IVIg is 2 g/kg over 2 to 5 days at baseline, followed by 2 g/kg IV in 2 to 5 days after 4 and 8 weeks. The rate of infusion is controlled by means of an infusion pump. The first dosage (30 grams IVIg) will be administered on the neurology ward.
45758332|NCT02998697|Drug|Placebo Oral Capsule|Lactose 200 mg t.i.d for 90 days
45758333|NCT02998307|Procedure|CPR Training|Brief CPR assessment and training done during working hours with real-time performance feedback
45758334|NCT00597545|Procedure|Carotid endarterectomy|When a shunt is inserted to increase blood flow to the brain
45758335|NCT00597545|Device|Shunt|A tube inserted below and above the surgical area at the time when the carotid artery is clamped to allow the surgeon to work in a bloodless field and to supplement blood flow to the brain.
45758336|NCT00705107|Biological|PegIntron pen (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling.
45610149|NCT05188157|Other|conventional physiotherapy|The conventional physiotherapy program included, wand exercises for shoulder abduction, flexion, hyperextension and internal and external rotation, Codman exercises and isometric and resistive exercises of the shoulder girdle. The exercise program is performed under the supervision of an experienced physiotherapist. The isometric exercises will be used during the painful period, and the resistance exercises will be added after the pain began to relieve.under the supervision of a physician in the first 30 minutes of their exercise.
45610150|NCT03447587|Other|Electroacupuncture|Each subject will be treated with predefined acupoints including bilateral Ear-Shenmen, Touwei (ST8), Sishencong (EX-HN1), and unilateral Yintang (EXHN3) and Baihui (GV20) on the head (total 8 needles). Subject's current symptoms will be ascertained using a Traditional Chinese Medicine symptom checklist and eight additional acupoints will therefore be selected and needled based on their clinical judgements. The acupuncture treatment will consistent of two sessions per week (30 minutes) for 4 consecutive weeks.
45758337|NCT00705107|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
45758338|NCT00240331|Drug|10mg Rosuvastatin|
45758339|NCT00240331|Drug|Placebo|
45610151|NCT03447587|Other|Sham acupuncture|Subjects will be treated at 1 cm posteriorly and laterally adjacent to the same acupoints as the traditional acupuncture group using validated non-invasive sham needles. Subjects will also be assessed with Traditional Chinese Medicine checklist. The acupuncturist, setting, treatment frequency, and duration of the treatment course will be the same as in the traditional acupuncture group.
45610152|NCT02388074|Device|CyPath®|CyPath® diagnostic assay for the early detection of lung cancer using sputum
45610153|NCT03442517|Behavioral|Behavior Lifestyle Intervention|Participants will be involved in group-based counseling. Sessions will be about 1 hour each and comprise up to 10 people. The sessions will be led by a trained health educator. The calls will be a chance for participants to discuss challenges with breastfeeding, problem solving skills, educational information, and discuss balanced diet topics.
45758340|NCT00240097|Drug|Intervention A: Irinotecan; Oxaliplatin; Neulasta|Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
45758341|NCT00240097|Drug|Intervention B: Etoposide; Carboplatin; Neulasta|Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) AUC 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)
45758342|NCT00597935|Procedure|SSLF|sacrospinous ligament fixation (SSLF)
45758343|NCT00597935|Procedure|ULS|uterosacral vaginal vault ligament suspension (ULS)
45758344|NCT00597935|Behavioral|PMT|Pelvic muscle training and exercises (PMT)
45758345|NCT00739765|Behavioral|Interpersonal Psychotherapy|14 weekly 50-minute sessions of interpersonal psychotherapy, a time-limited treatment that focuses on interpersonal functioning and social supports
45758346|NCT00739765|Behavioral|Prolonged Exposure Therapy|Ten 90-minute sessions, distributed over 14 weeks, of prolonged exposure, which involves the repeated, detailed recounting of the trauma to develop a coherent narrative and repeated exposure to reminders of the trauma
45758347|NCT00739765|Behavioral|Relaxation Therapy|Nine 90-minute sessions and one 30-minute session, distributed over 14 weeks, that focus on muscle relaxation to address the physical symptoms of PTSD
45758348|NCT04270721|Behavioral|The EAGLE Safe Anastomosis Quality Improvement Intervention|"The intervention is the same in each arm; the EAGLE Safe Anastomosis Quality Improvement Intervention is an educational programme for behavioural change composed of three parts:~Introduction of a routine patient risk stratification for anastomotic leak~Implementation of the ESCP Safe Anastomosis Checklist~Adoption of a harmonised technique for stapled and handsewn anastomosis based on best evidence."
45758349|NCT04270487|Other|IBS Diet|Patients will be randomized to a diet or a mediation treatment
45758350|NCT04270487|Drug|Otilonium Bromide|Patients will be randomized to a diet or a mediation treatment
45758351|NCT00705653|Drug|PG-11047|PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. A treatment cycle will be defined as 4 weeks of therapy. The planned minimum treatment schedule is 2 cycles of PG-11047 treatment (8 weeks).
45758352|NCT02998073|Behavioral|Stop, Now and Plan|SNAP program was developed to target justice-involved youth (6 years and older) who have problems with aggression, CD, and/or gang affiliation. SNAP focuses on engaging youth in interesting and creative learning modules by providing real life scenarios designed to improve self-control, impulsive behaviors, decision-making skills, and pro-social skills. SNAP treatment is delivered over a 13-week period.
45758353|NCT00739999|Drug|Atorvastatin|6-10 years Tanner Stage 1 will be administered 5-mg daily dose of an atorvastatin pediatric tablet formulation. Dose may be doubled if subjects have not attained target LDL (<3.35 mmol/L) after 4-week treatment.
45758354|NCT00739999|Drug|Atorvastatin|10-17 years Tanner Stage 2 will be administered 10-mg daily dose of atorvastatin tablet formulation. Dose may be doubled if subjects have not attained target LDL (<3.35 mmol/L) after 4-week treatment.
45758355|NCT02999555|Procedure|Ovum pickup|Ovum pickup or Egg retrieval, that is performed not for the purpose of the study, but for the purpose of well known in vitro fertilization indications
45758356|NCT02999321|Other|aspartame|will be given 5mg aspartame or 15 mg aspartame
45758357|NCT02999321|Other|water|control group
45758358|NCT01279525|Device|multifactorial|individual advice, information leaflet, physical exercise workshop and home visits
45758359|NCT00600743|Drug|GSKI181771X (CCK-1R agonist)|Drug one trial vs placebo
46068638|NCT05832034|Drug|Placebo|Placebo infusions, containing sodium chloride 0.9%, at baseline and after 4 and 8 weeks.
45610154|NCT03442517|Other|Usual prenatal care|Participants will receive the standard education given by their OBGYN or other healthcare provider. No additional breastfeeding, nutrition or postpartum weight loss education will be provided to participants by the investigators during pregnancy. After delivery, participants will follow normal pediatric visit schedule.
45610155|NCT03442439|Behavioral|Nutrition and Play Intervention|Mothers and children in the Nutrition and Play group will play educational and nutrition-focused games.
45610156|NCT03442439|Behavioral|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state though sustained physical contact; comfort touch, soothing words, and eye contact.
45610157|NCT03442283|Dietary Supplement|Vitamin mineral supplementation|supplementation with a vitamin or mineral: vitamin A, β-carotene, B1, B2, B3 (niacin), B6, B10 (folic acid), C, D and E, calcium, iron, zinc, magnesium and selenium. Also, multivitamins, antioxidants, B-complex and the combination of calcium and vitamin D.
45610158|NCT01602549|Drug|GSK962040 (25 mg tablet)|25 mg tablet
45610159|NCT01602549|Drug|Placebo|matching placebo tablet
45610160|NCT03447275|Other|Type 2 diabetes|Test if patients with diabetes have different blood concentrations of vitamin biomarkers compared with control subjects and if vitamin levels in the patients will differ according to renal damage.
45610161|NCT03442205|Procedure|LC + LCBDE + ENBD + primary closure of CBD|LC + LCBDE + ENBD + primary closure of CBD
45610162|NCT03442205|Procedure|ERCP technique + LC|ERCP technique + LC
45610163|NCT03442205|Procedure|LC + LCBDE + primary closure of CBD|LC + LCBDE + primary closure of CBD
45610164|NCT03447197|Procedure|The use of extracorporeal circulation|The use or not of extracorporeal circulation during the coronary artery bypass procedure.
45610165|NCT03442127|Behavioral|CaringGuidance™ After Breast Cancer Diagnosis|Web-based, psychoeducational, self-management tool
45610166|NCT02521805|Other|Animal protein|
45610167|NCT02521805|Other|Vegetable protein|
45610168|NCT02521805|Other|Dietary fiber (cereal food matrice)|
45610169|NCT02521805|Other|Dietary fiber (meat food matrice)|
45610170|NCT02521805|Other|Dietary fiber (vegetable food matrice)|
45610171|NCT02521883|Device|Sooma tDCS|2mA current applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).
45610172|NCT02521883|Device|Sham tDCS|sham stimulation (current phased off after 20 secs) applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).
45610173|NCT03442049|Other|Physiotherapy - Study group|Study group : In addition to home program spinal stabilization exercises
45610174|NCT03442049|Other|Physiotherapy - control group|Home exercise program
45610175|NCT03441815|Drug|XC8|
45610176|NCT03441815|Drug|Placebo|
45610177|NCT03446963|Behavioral|Groups for Health|Group sessions, 5 modules x 1.5 hours (once per week). Modules focus on psychoeducation, mapping existing social networks, examining barriers to engagement in existing networks, goal setting and identifying new groups to join.
46068639|NCT05831982|Other|1. Goalsetting conversation before start of training. 2. Strength training two times a week for 15 weeks. 3. Three conversations with dietician. 4. Focus on social relations.|Focus on high intensity strength training and nutrition intervention with focus on energy and protein intake.
46068640|NCT05831982|Other|Standard training|Training as usual when discharged with a rehabilitation plan.
45610178|NCT02427464|Biological|Engensis (VM202)|gene therapy
46068641|NCT05831852|Other|no intervention|no intervention
45610179|NCT02427464|Other|placebo|
45610180|NCT02426918|Drug|Debio 1450 IV|Intravenous (IV) form of Debio 1450 will be supplied in vials containing 50 mg of active pharmaceutical ingredient (API). Intravenous infusions of Debio 1450 (160 mg and 80 mg) will be administered over a 2-hour period BID every 12 hours within a 2-hour window (12 ± 2 hours).
45610181|NCT02426918|Drug|Debio 1450 Oral|Oral forms of Debio 1450 will be provided as white, opaque, hard gelatin capsules containing 50 mg drug substance (equivalent to 40 mg of Debio 1450).
46068642|NCT05831826|Biological|the inactivated COVID-19 vaccines|receive the doses of inactivated COVID-19 vaccines
46068643|NCT05831618|Other|Interactive Visuo-Vestibular training|Dynamic motor activitites aimed to enhance the visuo-vestibular interaction and the sensorial reweighting will be performed for the Interactive Visuo-Vestibular training group.
46068644|NCT05831618|Other|Vestibular rehabilitation training|Dynamic motor activitites aimed to enhance vestibular reflexes will be performed for the vestibular rehabilitation group
45610182|NCT02426918|Drug|Linezolid|Linezolid for oral administration will be provided as 600-mg film-coated compressed tablets.
45610183|NCT02426918|Drug|Debio 1450 Oral Placebo|Debio 1450 placebo will be supplied as white, opaque, hard gelatin capsules.
45610184|NCT02426918|Drug|Linezolid Placebo|Linezolid placebo will be supplied as film-coated compressed tablets.
45610185|NCT02426918|Drug|Vancomycin IV|Vancomycin will be administered BID every 12 ± 2 hours at doses of 1 g or 15 mg/kg as specified in local protocols, with the infusion rate adjusted to 2 hours.
45610186|NCT02387840|Device|Magnetic Resonance Imaging|Patients will have a scan of soft tissue using magnetic field and radio frequency pulses.
45610187|NCT02387840|Device|Magnetic Resonance Fingerprinting|Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2).
45610188|NCT02387762|Drug|acalabrutinib|
45610189|NCT02387762|Drug|Placebo|
45610190|NCT02418182|Drug|Acetaminophen|Acetaminophen total dose of 1000mg
45610191|NCT02418182|Drug|placebo|subjects randomized to this group will be given placebo tablets
45610192|NCT04884191|Drug|Pacritinib|Pacritinib
45610193|NCT03446729|Behavioral|Guided Self-Help Behavioral Weight Loss|Guided self-help Behavioral Weight Loss including 7 visits over 12 weeks. The treatment content includes self-monitoring, healthy eating, stimulus control, increasing physical activity, reducing sedentary activity, planning ahead for high-risk situations, and relapse prevention. The 7 visits are conducted with a behavioral coach to give participants educational materials and to promote accountability. The behavioral coach's role in the gshBWL program is to measure participant weight, collect self-monitoring booklets, clarify materials, and problem-solve barriers to adherence.
45610194|NCT05164835|Other|pharmaceutical follow-up|"Pharmaceutical follow-up over 1 year and pharmaceutical interviews during the various medical consultation appointments.~In addition to the usual care:~Delivery of questionnaire at the time defined in the protocol. The questionnaires will be given during the waiting time of the patients at the University Hospital of Limoges.~Extension of the duration of the usual interview by 10 minutes in order to collect the desired information."
45610195|NCT03441737|Behavioral|Exercise|20 minutes of aerobic exercise (walking on a treadmill) at 2/3 of participant's maximum heart rate (maximum heart rate calculated as 220-age).
45758360|NCT00600743|Behavioral|Instructions to binge eat|Subjects will be instructed to binge eat and will also be given either drug or placebo
45610196|NCT03441737|Behavioral|Non-Exercise|20 minutes of sitting in the laboratory with access to magazines and the internet.
45758361|NCT00600743|Behavioral|Instructions to eat normally|Subjects will be instructed to eat normally and will also be given either drug or placebo
45610197|NCT02387372|Drug|Ceftolozane/Tazobactam - Multiple Doses|"4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:~Participants with CLCR > 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours~Participants with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours~Participants with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours"
45610198|NCT02387372|Drug|Ceftolozane/Tazobactam - Single Dose|Single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion
45610199|NCT05159063|Device|Ultrasound imaging|"Patients scheduled to undergo right heart catheterization (RHC) as their standard of care will be included in the study.~The patient will be positioned supine at 0 degrees with normal restful breathing and patient looking straight up. After the right sternocleidomastoid muscle is identified, internal jugular vein (IJV) will be imaged at the apex of the triangle formed by the sternal and clavicular heads of the muscle. Similarly, the inferior vena cava (IVC) will be imaged at the caudal end of the sternum. The diameters of both the veins will be noted during normal respiration. The patients will then be asked to sniff and collapsibility of the veins will be noted. No pressure will be applied on the neck. The anticipated duration for image acquisition is between 5 to 10 minutes.~The patients will undergo the scheduled RHC within 1 hour as scheduled."
45610200|NCT05156567|Diagnostic Test|Deep Learning System|The multitask DLS with five algorithms detecting five quantitative factors of SINS
45610201|NCT05370170|Behavioral|Acupressure and nutritional advices|Teaching using booklets and application of acupressure
45610202|NCT02426138|Other|Medically Tailored Meal Delivery (MTM)|Patients will receive delivery of medically tailored meals for 12 weeks
45758362|NCT00600743|Drug|Placebo|Drug one trial vs placebo
46068645|NCT05831202|Device|The SEAL™ Saccular Endovascular Aneurysm Lattice System|The SEAL™ Embolization System is a self-expanding, nitinol and platinum wire mesh braided implant as described above; that is available in a broad range of sizes (diameter widths 3mm to 20 mm, and heights; 2mm to 16 mm) and in two configurations with common Base Bridging Component (Base SEAL™, and ARC SEAL™ configurations).
46068646|NCT05830539|Drug|IN10018+PLD|IN10018 orally once daily; PLD 40mg/m2, Q4W
46068647|NCT05830539|Drug|IN10018+PLD+Toripalimab|IN10018 orally once daily; PLD 40mg/m2, Q4W; Toripalimab 3 mg/kg, Q2W
45610203|NCT02426138|Other|Usual Care + Choose MyPlate|Patients will receive usual diabetes care + a Choose MyPlate healthy eating brochure for 12 weeks
45758363|NCT02997995|Drug|Immune-attractant|The first cohort patients will receive tremelimumab (3 mg/kg, single infusion) as immune-attractants combined with exemestane (25 mg daily).
45758364|NCT02997995|Drug|Durvalumab|Durvalumab (lymphocyte activation) will be administrated at a dose of 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months
45758365|NCT02997995|Procedure|Biopsy|After three weeks (+/- 3 days) of immune-attractants, a tumor biopsy will be done. Patients who present >10% CD8+ cells in the tumor after 3 weeks will receive the Durvalumab
45758366|NCT00601367|Drug|flibanserin flexible dose|"Initial dosage:~Patients were to take one 50 mg flibanserin tablet in the evening.~Subsequent dosage titrations:~Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient.~Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY.~Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site."
45758367|NCT03620162|Biological|Prevnar 13™|Prevnar 13™ contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 mL dose given via IM injection.
45758368|NCT03620162|Biological|V114|V114 contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose given via IM injection.
45758369|NCT03620162|Biological|RotaTeq™|RotaTeq™ live, pentavalent Rotavirus vaccine given as background treatment via oral solution.
45610204|NCT04881149|Device|TempSure treatment|Self-controlled, single-arm study using the TempSure device.
45610205|NCT03446495|Drug|Trabectedin + PLD|Combination of Trabectedin + PLD: PLD 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks.
45610206|NCT03441425|Other|Unexpected death|
45758370|NCT03620162|Biological|Pentacel™|Pentacel™ Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine, given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
45758371|NCT03620162|Biological|RECOMBIVAX HB™|RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
45610207|NCT03441347|Behavioral|Specific rehabilitation program|17-week specific and personalised rehabilitation program. The program starts with a visit to the Plexus out patient clinic in week 1. During this visit, the patient will be examined by a multidisciplinary team, consisting of a rehabilitation physician, neurologist, physical therapist and occupational therapist, which will form a rehabilitation treatment plan. This treatment plan is implemented through 4 weekly sessions in week 2-5, 2 biweekly sessions in week 6-9 and 2 monthly sessions in week 10-17 . Each treatment session involves one hour of physical- and one hour of occupational therapy.
45610208|NCT03441347|Other|Usual Care|Participants will receive their usual care for 17 weeks, which may vary for each individual
45610209|NCT03446261|Drug|Rosuvamibe® Tab|Rosuvastatin 5mg/ezetimibe 10mg qd for 8 weeks
45610210|NCT03446261|Drug|Monorova® Tab|Rosuvastatin 10mg qd for 8 weeks
45610211|NCT03441191|Device|Audiovisual Stimulation|A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study
45610212|NCT05116397|Other|Inspired gas|Inspired gas content
45610213|NCT03441035|Other|General anesthesia and surgery (liver transplantation)|The effects of general anesthesia and surgery under the hospital routine of albumin administration during and after liver transplantation is studied with the mass balance of albumin method.
45610214|NCT05105633|Drug|Tenecteplase|Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as an intravenous bolus over 5-10 seconds.
45610215|NCT05105633|Drug|Standard Care (which may include intravenous Alteplase)|Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour.
45610216|NCT03440645|Other|Family-oriented primary cardiovascular prevention|An initial screening visit including a targeted history, physical exam, and investigations as per the Canadian Cardiovascular Society's recommendations for cardiovascular primary prevention. Counselling and informational handouts on improved cardiovascular risk factor and lifestyle habits. All family and household members, as well as the cardiovascular disease proband, are encouraged to attend and participate in all healthcare visits.
45610217|NCT04552275|Diagnostic Test|Proteomics Analysis|Determine a panel of circulating proteins that discriminates between patients with and without Hypo-Attenuated Leaflet Thickening (HALT)
45610218|NCT04807673|Biological|Pembrolizumab|"Neoadjuvant period: pembrolizumab 200mg IV D1, Q3W, and preoperative therapy with three cycles.~Adjuvant period: pembrolizumab 200 mg IV D1, Q3W, up to one year, which should be performed within 3-6 weeks after surgery."
45758372|NCT03620162|Biological|HIBERIX™|HIBERIX™ Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
45758373|NCT03620162|Biological|M-M-R™ II|M-M-R™ II (Measles, Mumps, and Rubella Virus Vaccine Live), given as background treatment via subcutaneous (SC) injection in the opposite limb to V114 and Prevnar 13™ administration.
45758374|NCT03620162|Biological|VARIVAX™|VARIVAX™ Varicella Virus Vaccine Live, given as background treatment via SC injection in the opposite limb to V114 and Prevnar 13™ administration.
45758375|NCT02999165|Other|Breast feeding|Infants on respiratory support will be allowed to attempt to breast feed (with a top up nasogastric tube feed if required).
45610219|NCT04807673|Drug|Paclitaxel|Neoadjuvant period: paclitaxel 135mg/m^2 IV on Day 2 Q3W, and a total of three cycles.
45758376|NCT02999165|Other|Nasogastric feeding|The control intervention is feeding via nasogastric tube
45610220|NCT04807673|Drug|Cisplatin|Neoadjuvant period: cisplatin 80 mg/m^2 IV on Day 2 Q3W, and a total of three cycles.
45610221|NCT04807673|Radiation|neoadjuvant chemoradiotherapy|neoadjuvant chemoradiotherapy 41.4Gy(1.8Gy×23 fractions) with five cycles of TP(Paclitaxel 50mg/m^2 on D1 and Cisplatin 25mg/m^2 D1, repeated every week
45758377|NCT00742573|Drug|Antidepressants through Texas Medication Algorithm (TMA)|Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.
45758378|NCT00742573|Behavioral|Brief Interpersonal Psychotherapy (IPT-B)|IPT-B consists of twelve 50-minute sessions, divided into three phases, focusing on an interpersonal problem or problems.
45758379|NCT02321111|Drug|Eritoran|Eritoran = E5564 Eritoran is a pharmacologic inhibitor of TLR4.
45758380|NCT02321111|Drug|D5W (5% Dextrose in water)|D5W = 5% Dextrose Water Vehicle
46068648|NCT05830461|Behavioral|Online psychological care program to reduce psychological distress in women who attend a breast clinic|"The intervention will be online and self-applied. It will consist of 3 stages, according to the patient's situation: 1) without suspicion of cancer (A1), 2) with suspicion of cancer (A2), and 3) with confirmed diagnosis of cancer (B).~Stage 1 includes modules related to the prevention and timely detection of breast cancer. Stage A2 consists of emotional management in the face of suspicion of breast cancer. In stage B, medical information about breast cancer is provided, as well as psychological strategies to face the diagnosis.~Psychological techniques based on the cognitive behavioral model, mindfulness, acceptance and commitment therapy, and health beliefs are included."
46068649|NCT05830461|Behavioral|Psychological care program to reduce psychological distress in women who attend a breast clinic|"The intervention will be delivered through printed materials. It will consist of 3 stages, according to the patient's situation: 1) without suspicion of cancer (A1), 2) with suspicion of cancer (A2), and 3) with confirmed diagnosis of cancer (B).~Stage 1 includes modules related to the prevention and timely detection of breast cancer. Stage A2 consists of emotional management in the face of suspicion of breast cancer. In stage B, medical information about breast cancer is provided, as well as psychological strategies to face the diagnosis.~Psychological techniques based on the cognitive behavioral model, mindfulness, acceptance and commitment therapy, and health beliefs are included."
45610222|NCT04496817|Other|Docosahexaenoic Acid and Lutein Enriched Eggs|Consumption of 2 docosahexaenoic acid and lutein enriched eggs daily (at least 5 days our week) for 6 weeks
45610223|NCT04496817|Other|Regular Eggs|Consumption of 2 non enriched eggs daily (at least 5 days our week) for 6 weeks
45445086|NCT03781635|Drug|continuous infusion of intravenous ketamine|An infusion of low-dose ketamine (0.25 mg.kg-1.h-1) is started at T0 (incision) with an infusion pump and is kept at the same rate until the end of surgery
45445087|NCT01560897|Drug|Oral C13|Ingestion of C13 and follow up of the ureogenesis
45610224|NCT04803383|Other|Tele-yoga|Tele-yoga training 3 days a week for 8 weeks
45610225|NCT04453215|Device|GaAlAs semiconductor diode laser device|low-level laser therapy
45610226|NCT03446183|Behavioral|Smoking cessation workshops|All the participants took part in smoking cessation workshops. The comparison of metabolic aspects was made between the smokers and non-smokers
45610227|NCT02426684|Drug|IdeS® (Imlifidase)|0.24mg/kg IdeS
45610228|NCT03446105|Behavioral|App-based behavioral intervention|Achieving Wellness After Kancer in Early life (AWAKE) is a behavioral intervention that includes a smartphone app and coaching. AWAKE contains eight modules, and participants will complete the one module every week. App functioning will facilitate weekly homework assignments and include health education messaging, the ability to track progress toward goals over time via self-monitoring and graphical depictions of progress, audio-recordings of guided imagery exercises and relaxation exercises (e.g., progressive muscle relaxation), videos of topic-related inspirational material, and a portal for interacting with the coach. The coach will call each intervention participant weekly. Each coaching session will last roughly 30 minutes and involve four segments that will correspond to the module for the week. The coach will send daily text messages to participants encouraging their goal pursuits and providing other sources of support related to that week's homework.
45758381|NCT03809923|Drug|lidocaine and dexmedetomidine infusion|Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
45610229|NCT03446105|Behavioral|Attention control group|The attention control group will receive the same components as the intervention group, but the educational modules will contain different content than those receiving the AWAKE intervention.
45445088|NCT03781557|Dietary Supplement|Docosahexaenoic acid|High-concentrated DHA
45445089|NCT03781557|Dietary Supplement|Eicosapentaenoic acid|High-concentrated EPA
45445090|NCT03781557|Dietary Supplement|Olive oil|Olive Oil softgels
45610230|NCT05060055|Procedure|Immediate dental implant placement|Immediate dental implant placement
45610231|NCT03445871|Biological|Blood sample|Blood samples will be collected for measuring PG-MTX blood concentration.
45610232|NCT03445871|Diagnostic Test|CRQ|Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.
45610233|NCT03445715|Genetic|ART-I02|Single Intra-articular injection in the wrist joint
45610234|NCT03440489|Diagnostic Test|Six-minute walking test|physical performance of the muscle measured by these tests
45610235|NCT03440489|Diagnostic Test|30 seconds chair stand test|physical performance of the muscle measured by these tests
45610236|NCT03129035|Procedure|Cesarean hystrectomy|Upper segment cesarean section followed by fetal extraction and cesarean hystrectomy started without any attempts of placental removal
45610237|NCT03129035|Procedure|Internal iliac artery ligation|The retroperitoneal space was entered at the level of common iliac bifurcation and followed to the point of division into the external and internal iliac arteries. The ureter was retracted medially by gentle finger dissection, revealing the retroperitoneal anatomy. The fat and loose connective tissue around the IIA and vein were removed and a right-angle clamp was passed beneath the IIA from the lateral to the medial side approximately 4 cm distal to its origin. Using an absorbable suture, the IIA was ligated doubly in all cases . Pulsations of the external iliac and femoral arteries were identified after internal iliac ligation. The procedure was then repeated on the other side
45610238|NCT02656173|Drug|Mirabegron|Oral tablet
45610239|NCT02656173|Drug|Placebo|Oral tablet
45610240|NCT02656173|Drug|Tamsulosin|Oral tablet
45610241|NCT03445403|Other|Offset analgesia|Exposure to a moderate heat-pain stimulus applied for 5 seconds, raised by 1 degree C for 5 seconds, reduced by 1 degree C, and held for 20 seconds using a computerized paradigm in order to evoke endogenous pain modulation.
45610242|NCT03440333|Drug|surfactant|Pulmonary surfactant was administrated if the baby was diagnosed with respiratory distress syndrome
45610243|NCT03440255|Device|Transcutaneous Vagus Nerve Stimulation|"TaVNS will be applied by the TENS 7000 device. The stimulation was set according the group of treatment: (GAD: 20Hz-80µs), (CP: 5Hz-200 µs), (IBS: 3Hz-250µs).~The current intensity was individually established under the pain threshold .The stimulus generates an continous asymmetric biphasic waveform. Ear clip electrodes were plugged in the concha area of the left ear. The stimulation will last 30 min per session (total=8)"
45610244|NCT04452071|Radiation|periapical xray|periapical xray on the middle phalanax of the middle finger
45610245|NCT04724213|Other|Testing of reliability / validity of new questionnaire|Participants will answer new questionnaire and other, established, generic and chronic generic HrQol instruments
45610246|NCT03445247|Other|Extracorporeal low-intensity shockwave|Omnispec device to give a total of 1200 shockwaves, with low energy density at 0.1 mj/mm2 and a frequency of 120 shocks/min per kidney per treatment session, totally 12 times.
45610247|NCT04418895|Other|Chemoradiation|Subjects will receive neoadjuvant chemoradiation per standard of care. This is typically comprised of radiotherapy of 5040 cGy (centigray) with concurrent capecitabine 825 mg/m2 by mouth (po) two times daily (bid) (typically rounded to the nearest 500 mg dose) or infusional 5-fluorouracil (5FU). However, dosing and administration are at the discretion of the treating medical and radiation oncologist.
45445091|NCT03781713|Other|KDIGO|Interventions to prevent renal replacement therapy
45445092|NCT03781713|Other|Delta SOFA|interventions to improve SOFA score
45445093|NCT03781713|Combination Product|Hypoglycemia|Interventions to prevent new episodes of hypoglycemia in the next 24 hours
45445094|NCT03781713|Drug|Drug interaction risk D or X|Intervention in the therapeutic plan in order to avoid adverse drug reactions.
45445095|NCT03781713|Drug|Antimicrobial stewardship|Optimization of anticrobial therapy based on Gram stain, MALDI TOF, MIC and antimicrobial susceptibility
45610248|NCT04418895|Radiation|short course radiation therapy|An acceptable alternative approach is short-course radiation therapy per standard of care, which is typically comprised of radiotherapy of 25 Gy (gray) in 5 fractions, with surgery within 1 week of completion of therapy or delayed for 6-8 weeks. Selection of the optimal radiation therapy approach is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist. However, generally, short-course radiation therapy is not recommended for low-lying tumors less than 5 centimeters (cm) from the anal verge.
45610249|NCT04418895|Drug|mFOLFOX6|possible consolidative neo-adjuvant chemotherapy. This treatment is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist.
45610250|NCT04418895|Drug|CAPOX|possible consolidative neo-adjuvant chemotherapy. This treatment is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist.
45445096|NCT03785535|Device|Vibrotactile stimulation|The active treatment will involve whole-body sensory stimulation with mechanical stimuli of vibrotactile (pallesthetic) type at a relatively high rate, low intensity and long duration administered at sleep time (a total daily duration of 3 h distributed within a period of 2 h at bedtime and 1 h prior to getting up). The intensity will be 30% of power at bedtime and 45% prior to getting up.
45610251|NCT04418895|Drug|fluoropyrimidine +/- oxaliplatin|possible adjuvant chemotherapy regimen. Subjects who do not receive preoperative mFOLFOX6 or CAPOX typically receive postoperative adjuvant chemotherapy with a fluoropyrimidine +/- oxaliplatin for an additional 16-18 weeks of therapy, if permitted based on recovery after surgical resection and post-surgical performance status. This treatment is at the discretion of the treating medical oncologist. Subjects will remain on study regardless of postoperative therapy administration or duration.
45610252|NCT04715633|Drug|PD-1 inhibitor plus VEGF inhibitors|Camrelizumab 200mg IV every 3 weeks; Apatinib 250mg QD day 1-14. Rescue chemotherapy: Oxaliplatin 130mg/m2 IV drip Q3W d1+Capecitabine 1000mg/m2 QD d1-d14 Rescue chemoradiotherapy: Long-course radiotherapy +Capecitabine 825mg/m2 QD d1-d14
45610253|NCT04236999|Behavioral|Yo Sé Lo Que Quiero (YSLQQ)|"This program is organized in 12 sessions around three themes:~Knowledge and attitudes (sessions 1, 3, 5 and 9): Students reflect on their knowledge of legal and illegal drugs, using critical thinking to obtain an objective assessment of this knowledge.~Intrapersonal skills (sessions 4, 6, 8, 10. 11. and 12): Activities are carried out where students can put themselves in everyday situations and develop skills such as assertiveness, problem solving, among others.~Interpersonal skills (sessions 2 and 7): Students are instructed to practice refusal skills, assertiveness, and analyze coping strategies."
45610254|NCT03445091|Device|SANKOM Patent Socks|Using compression socks to ease symptoms of patients with chronic venous insufficiency
45610255|NCT04152915|Drug|Semaglutide|Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 7 weeks
45610256|NCT03109457|Other|oral squamous cell carcinoma|Histological diagnosis of H&E stained sections will be performed according to WHO guidelines by 2 independent pathologists.
45610257|NCT03440021|Drug|ORM-12741|Novel selective alpha2c adrenoceptor antagonist
45610258|NCT03440021|Drug|Placebo|Identical in appearance to experimental drug, not psycho-active
45610259|NCT03445013|Drug|SB414 6%|Twice daily
45610260|NCT03445013|Drug|Vehicle|Vehicle Comparator
45610261|NCT03444935|Behavioral|Follow-up phone call|Please see arm/group description.
45758382|NCT03809923|Drug|Saline infusion|Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
45758383|NCT03809923|Drug|Lidocaine infusion|patients received an IV bolus infusion of lidocaine (2%) 1.5 mg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg made up to 20ml and 20ml normal saline every hour until 30 min before the end of operation, respectively.
45758384|NCT03809923|Drug|Dexmedetomidine infusion|Patients received IV bolus infusion of dexmedetomidine 0.5 μg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4μg/kg made up to 20ml and 20ml normal saline every houruntil 30 min before the end of operation, respectively.
45758385|NCT02997917|Behavioral|Education|
45758386|NCT02997917|Behavioral|Sham|
45610262|NCT03439943|Drug|Lixisenatide|Patients randomized in the Lixisenatide group will receive 10μg/day for 14 days and then 20μg/day administered by once-daily subcutaneous injections during 12 months. If patients are unable to tolerable the dose of 20μg/day, this dose can be reduced to 10μg/day
45610263|NCT03439943|Drug|placebo|Patients randomized in the placebo group will receive the corresponding placebo administered subcutaneously (once daily subcutaneous injection).
45610264|NCT03439787|Drug|Bupivacaine-EPINEPHrine 0.5%-1:200,000 Injectable Solution|10 ml
45610265|NCT03439787|Other|Sodium Chloride 0.9 %|10 ml
45610266|NCT03444857|Device|Continuous positive airway pressure|The optimal continuous positive airway pressure (CPAP, AutoSet S9, ResMed, Sydney, Australia) settings will be determined during 1-2 nights within 7 days after pPCI.
45610267|NCT05082155|Drug|Bupivacaine 0.25%|Bupivacaine 0.25% will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
45610268|NCT05082155|Drug|Normal Saline|Normal saline will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
45610269|NCT02656017|Drug|Metformin|Monitoring of tolerability and symptoms.
45758387|NCT02998853|Other|QFR measurement by dedicated workstation on xrays angio selected runs|The patient undergoes coronary angiography; if at least one stenosis from 40 to 90% in non culprit is present and FFR is indicated by guidelines the patient is enrolled to 3d Angio QFR evaluation; no adjunctive invasive procedures are needed for QFR measurements
45911419|NCT02007902|Other|Evaluation of the relationship plasma protein levels - neonatal hemodynamics|"Patient inclusion at birth~Total plasma protein values measurement on cord blood sample at birth~Hemodynamic evaluation at 6 hours after birth with colour doppler echocardiography and organ blood flow colour doppler~Total plasma protein and albumin values measurement on plasma sample at 12 hours after birth~Blood pressure, heart rate, O2 saturation, capillary refill time, rSO2 [regional (cerebral and somatic) tissue oxygenation by NIRS - near infrared spectroscopy] will be monitored over 24 hours after birth."
45610270|NCT02656017|Other|Placebo|Monitoring of tolerability and symptoms.
45610271|NCT03439709|Radiation|Gamma knife radiosurgery|Minimum 25 Gy of marginal dose is applied for residual tumor or resection cavity. Depending on the size of tumor, the dose can be varied.
45610272|NCT03439709|Drug|Lanreotide 60Mg Solution for Injection|Lanreotide injection.
45610273|NCT03439553|Behavioral|Ads display with target websites|Ads are shown, but users are referred to control websites.
45758388|NCT03802279|Other|Effort test|"Cardiac function:~Echocardiography: left ventricular ejection fraction and global longitudinal strain will be measured.~Cardiopulmonary exercise test (CPET): left ventricular stroke volume was assessed noninvasively using a thoracic bioelectrical impedance device : maximal stroke volume at the peak of effort will be considered.~Peripheral muscle function:~CPET: Oxygen uptake (VO2) (and carbon dioxide) output are measured. The slope of the relationship (dQ/dVO2) will be calculated between cardiac output (Q) and VO2 using measurements of Q (using measure of the stroke volume by thoracic bioelectrical impedance device) and VO2 at rest as well as during submaximal and maximal exercise~Muscle oxygenation is measured using a near-infrared spectroscopy device.~VO2 et Q will be measured : dQ/dVO2 is high in case of oxydation defect; If Q is low because of a concommittant cardiac impairement, the DAV = VO2/Q, and DO = (Q x DAV) / (200 - DAV) will be calculated."
45610274|NCT03439553|Behavioral|Ads display with control websites|Ads are shown, but users are referred to control websites.
45610275|NCT03444545|Device|Capnodynamic method|"Expired carbon dioxide is measured with a mainstream infrared sensor (Capnostat-3, Respironics Inc, Wallingford, CT, USA) and gas flow analysed with the flow sensor incorporated in the ventilator (Servo-i, Maquet Critical Care, Solna, Sweden) which was connected to a computer where all the mathematical analysis is carried out with a software written in Matlab™ (The Mathworks Inc, Natick, MA, USA).~Instead of a fixed ratio between inspiration and expiration, three breaths out of every nine are prolonged with a 3-4 seconds longer expiration creating small changes in end- expiratory CO2"
45610276|NCT03444545|Device|Transpulmonary thermodilution|Each cardiac output measurement comprises an average of three thermodilutions performed successively one after another. TPTD is performed with a PiCCO2 monitor (Pulsion Medical Systems SE, Feldkirchen, Germany)
45610277|NCT04561401|Device|Repeated Transcranial Magnetic Stimulation (rTMS)|rTMS will be applied at 10 Hz. Each train will consist of 40 supra threshold (120% resting motor threshold) pulses over 4 seconds with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3,000 pulses), and occur at the same time of day on every weekday for a period of three weeks (15 days total). During TMS, only passive activities will be allowed (i.e., watching movies or TV, listening to music). Three weeks of treatment was selected based on existing rTMS evidence in youth with treatment resistant major depressive disorder.
45610278|NCT04561401|Other|Intensive Pain Rehabilitation Program (IPRP)|The paediatric Intensive Pain Rehabilitation Program (IPRP) in Canada was established to target youth with severe chronic pain and consequent functional disability who do not respond to standard outpatient pain therapies. The IPRP at the Alberta Children's Hospital (ACH) involves three- to six-weeks of day-treatment rehabilitation, provided by an interdisciplinary team (e.g. Psychology, Physiotherapy, Family Therapy). This rehabilitative program teaches self-management strategies with the goal of helping youth and their families resume normal daily functioning.
45610279|NCT04706039|Diagnostic Test|Performance evaluation (sensitivity and specificity) for COVID-19 diagnosis of the Vocus PTR-TOF process|"Each patient will be sampled to do a systematic respiratory virus infection screening (SARS-CoV-2 and Flu and RSV). Then each patient will be tested using the Vocus PTR-TOF process.~A self-answering questionnaire will be used to collect symptomatology information and date of onset of symptoms."
45610280|NCT04451369|Other|Prehabilitation program|physical, nutritional and psycho-social supports before surgery
45610281|NCT04402515|Drug|TIO/OLO|Tiotropium/Olodaterol
45610282|NCT04402515|Drug|ICS|inhaled cortocosteroids
45758389|NCT03802279|Other|Functional tests on fibroblasts|Functional tests performed on fibroblasts in primary culture, using as tracers of stable isotope-labeled substrates. The metabolites of interest are assayed in mass spectrometry.
45758390|NCT02998931|Drug|Glutamin|Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs
45610283|NCT04451447|Procedure|The White test uses fat emulsion (SMOFLIPID), for localization of bile leakage.|The White test uses fat emulsion (SMOFLIPID), which is a lipid emulsion with a lipid content of 0.2 grams/mL in 100 mL, 250 mL, and 500 Ml that is normally used for parenteral nutrition, for localization of bile leakage.
45610284|NCT04451447|Procedure|Saline test (routine test)|The conventional intra-operative saline test, which involves injecting an isotonic sodium chloride solution through the cystic duct, has been used for detection of leaking points from the transected liver surface.
45610285|NCT04516941|Drug|Edoxaban Tablets|Treatment
45610286|NCT04516941|Drug|Colchicine Tablets|Treatment
45610287|NCT03444467|Drug|NNC9204-1513|"Participants will receive NNC9204-1513 subcutaneous (s.c., in to a skin fold on the stomach) injection as single increasing doses of 0.01 mg, 0.04 mg, 0.10 mg, 0.25 mg, 0.50 mg, 1.0 mg or 2.0 mg. Each participant will only be given one dose.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group."
45610288|NCT03444467|Drug|Glucagon|Participants will receive single dose of 1 mg glucagon s.c. injection.
45610289|NCT03444467|Drug|Placebo|Participants will receive single dose of placebo (for double dummy injections).
45758391|NCT02998931|Other|Maltodextrin|Maltodextrin mixed with water given via NG tube Q 4 hours
45911420|NCT02007915|Drug|Pamidronate Disodium|Pamidronate will be given intravenously over one hour, one day per month for three out of every four months. The initial dose is 0.5mg/kg and subsequent doses are 1mg/kg. Infusions will continue for at least one year with a second year possibly recommended by the surgeon from data on the x-ray and bone scan.
46068650|NCT05829174|Behavioral|Psychoeducation and cognitive modules|Psychoeducation and cognitive modules: what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention.
45610290|NCT02657343|Drug|Ribociclib|
45610291|NCT02657343|Drug|T-DM1|
45610292|NCT02657343|Drug|Trastuzumab|
45610293|NCT02657343|Drug|Fulvestrant|
45610294|NCT03445169|Drug|Belzutifan|Belzutifan Tablets
45758392|NCT01272115|Behavioral|Integrative health care model|The integrative health care model with an empowerment approach will address the care that should be given collaboratively by the health team in cooperation with the active participation of women. The IHCM will be provided under the leadership of the nurse who will coordinate with the health team members, promote preventive care, and incorporate cognitive-behavioral strategies, such as individual and group counseling. The IHCM will be provided for three months to each woman, followed by a three-month follow-up. Each woman will receive: monthly individual counseling by nurse; eight weekly (90-minutes) group counseling sessions and 2-9 consultations with psychologist defined in accordance to women individual needs and characteristics.
45758393|NCT02998619|Radiation|Radiotherapy|Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes
45758394|NCT00719329|Drug|Chlorhexidine 4.0%|Solution (4.0%, 7.1% CHX-D)
45610295|NCT04542837|Biological|KN046|Subjects enrolled in the study will be intravenously administered KN046 5mg/kg every 3 weeks (Q3W), until disease progression, or unacceptable toxicity, or withdrawal of consent, or lost to follow-up, or died, or treatment for 2 years, or the investigator decides to terminate.
45758395|NCT00719329|Behavioral|Dry Cord Care|Educational messages regarding clean cord care
45758396|NCT00602225|Drug|clofarabine|Given IV
45610296|NCT04542837|Drug|Lenvatinib|Subjects enrolled in the study will receive lenvatinib 12 mg (BW≥60 kg) or 8 mg (BW<60 kg) orally once a day (QD) ,until disease progression, or unacceptable toxicity, or withdrawal of consent, or lost to follow-up, or died, or treatment for 2 years, or the investigator decides to terminate.
46068651|NCT05829174|Behavioral|Behavioral module: Starting on Time and Planning Realistically|Learning of realistic planning, and timely starting of work.
45610297|NCT04451603|Procedure|Surgery|Surgical resection of the liver
45610298|NCT04451603|Radiation|Radiation therapy|Y-90 radioembolization therapy is the main treatment
45758397|NCT00602225|Drug|cytarabine|Given IV
45610299|NCT04451603|Drug|Drug treatment|Examples include tyrosine kinase inhibitors and immune checkpoint inhibitors
45610300|NCT04524585|Drug|Neuromuscular blockade|Cisatracurium will be infused to achieve esophageal pressure targets and maintain a Riker Sedation-Agitation Scale (SAS) score of 1-2. Additional boluses of cisatracurium will be delivered as required and adjustment of continuous infusion rate. After establishing a sedation and NMB strategy at which safe spontaneous breathing is achieved, we will seek to determine whether these targets can be maintained over a 24-hour period.
45610301|NCT05072145|Other|Telemedicine|Receiving care in a tele-ED hospital
45610302|NCT04019145|Drug|EverX Posterior|fiber reinforced bulk fill resin composite
45758398|NCT00602225|Biological|filgrastim|Given subcutaneously
45758399|NCT04297748|Combination Product|89Zirconium-M7824|PET imaging agent
45610303|NCT04019145|Drug|Resins, Composite|incremental packing of Nanohybrid Resin composite
45758400|NCT04297748|Drug|M7824|Bifunctional fusion protein intended to block PD-L1 and neutralize TGFbeta simultaneously.
45758401|NCT04286594|Drug|CBD|Participants will be randomized to receive CBD or placebo solution during the double-blind phase of the trial.
45610304|NCT03966495|Other|Sustainability of a research program in risk management|"No intervention will be implemented in the present study.~The investigators will evaluate of the sustainability of a research program in risk management in pluriprofessional primary care offices:~Qualitatively assessed safety culture and Sustainability of the PRisM RM program in the offices by interviews of professional belonging to the offices.~Quantitatively assessed safety climate in the offices measured by the Medical Office Survey on Patient Safety Culture (MOSPS) Questionnaire (fill in by the professionals of the offices)"
45610305|NCT03444311|Dietary Supplement|A: 1 dosis|"1 dosis (3E+09 cfu/d + 6 g of fiber) Two different combinations of fibers (formula A and B) will be tested with the following administration pattern for both groups.~Week 1: Formula A Week 2: Formula A Week 3: Formula B Week 4: Formula B~Composition of an envelope of formula A:~Formula A Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1.75 Inulin of low degree of polymerization 1,5 Polydextrose 1 Guar gum partially hydrolyzed 0,5 TOTAL 6~Composition of an envelope of formula B:~Formula B Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1 Inulin of low degree of polymerization 0.75 Polydextrose 2.5 Guar gum partially hydrolyzed 0,5 TOTAL 6"
45758402|NCT04286594|Drug|Placebo|Participants will be randomized to receive CBD or placebo solution during the double-blind phase of the trial.
45758403|NCT00602771|Drug|tipifarnib|Given orally
45758404|NCT00602771|Drug|etoposide|Given orally
45758405|NCT04278482|Dietary Supplement|Dietary supplement, DHA or Placebo|Consumption of 2 capsules per day of the dietary supplement, DHA or Placebo
45758406|NCT02997683|Device|Body Vibration platform GALILEO|3 month home based training on whole Body Vibration platform GALILEO
45758407|NCT02997683|Other|exercises at home on the floor|exercises at home on the floor
45758408|NCT03598244|Drug|Savolitinib|Given PO
45758409|NCT00742963|Drug|TH-302|"TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Dose escalation dose levels:~Dose level -1 (if needed): 180 mg/m2 Starting dose: 240 mg/m2"
45758410|NCT02997839|Behavioral|sleep disruption|"Group two will have interrupted sleep at time periods of 2 hours post operatively.~Group two will be woken every 2 hours, which is the standard NCCU protocol."
45758411|NCT01279603|Drug|GO-203-2c|GO-203-2c Injection is a non-preserved, sterile, ready-to-use liquid dosage form provided in a glass vial with rubber closure and crimp seal. Injection will be added to the contents of an intravenous bag (of 0.9% NS, D5W or sterile water) to a final concentration of between 0.03 - 0.3 mg/ml (preferable in 100 mls or greater) and administered as a single agent intravenously over 60 minutes. A treatment cycle will consist of a daily IV dose administered for 21 consecutive days followed by a 7 day rest.
45758412|NCT02997527|Device|Intraluminal Impedance|Esophageal impedance testing measures epithelial integrity as reflected through the ability of the mucosa to conduct electric current. Recently, a site specific endoscopically placed impedance probe has been developed that can measure esophageal mucosal impedance at any point of the esophagus.
46068652|NCT05829174|Behavioral|Behavioral module: Working Time Restriction|Restriction of allowed time for work, and gradual increase of allowed time, if previous time windows where effectively used.
46068653|NCT05829174|Behavioral|Behavioral module: Pomodoro Time Management Technique|Working in 25 minutes time intervals
45610306|NCT03444311|Dietary Supplement|B: 2 dosis|"1 dosis (3E+09 cfu/d + 12 g of fiber) Two different combinations of fibers (formula A and B) will be tested with the following administration pattern for both groups.~Week 1: Formula A Week 2: Formula A Week 3: Formula B Week 4: Formula B~Composition of an envelope of formula A:~Formula A Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1.75 Inulin of low degree of polymerization 1,5 Polydextrose 1 Guar gum partially hydrolyzed 0,5 TOTAL 6~Composition of an envelope of formula B:~Formula B Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1 Inulin of low degree of polymerization 0.75 Polydextrose 2.5 Guar gum partially hydrolyzed 0,5 TOTAL 6"
45445097|NCT05399823|Other|Exercise|Strecthing exercises will given for 15-20 minutes everyday for four weeks
45758413|NCT04385485|Procedure|Active rehabilitation|We investigate if active rehabilitation is as good as passive rehabilitation after flexor tendon suture.
45758414|NCT04385485|Procedure|Passive rehabilitation|We investigate if active rehabilitation is as good as passive rehabilitation after flexor tendon suture.
45758415|NCT03579602|Drug|tozuleristide|Tozuleristide will be administered at least 1 hour and no more than 36 hours prior to planned surgical excision of their tumor.
45758416|NCT03579602|Device|Canvas System|All subjects enrolled in the study will have their tissue imaged with the Canvas System.
45758417|NCT03190070|Dietary Supplement|Ingestion of protein|Oral protein load as a physiological stimulus to temporarily increase glomerular filtration rate
45758418|NCT00744211|Drug|1mg/kg sitaxsentan sodium|1mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
45610307|NCT04663529|Other|contact lens|daily disposable soft contact lens
45610308|NCT05073731|Other|Telerehabilitation-based Upper Extremity Training|"Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies.~Synchronized telerehabilitation provides the participant with advantages such as customized treatment, instant feedback, and a social environment such as face-to-face training."
45610309|NCT03439397|Device|Ballon Technique|Ballon Technique
45610310|NCT03439397|Device|SOAI|SOAI
45758419|NCT00744211|Drug|2mg/kg sitaxsentan sodium|2mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
45758420|NCT00744211|Other|Vehicle|Intravenous bolus performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
45758421|NCT04274972|Diagnostic Test|Microbiome evaluation|The oral and rectal microbiome samples will be collected preoperatively. The PDAC tissue from the surgical specimen, the intestinal mucosal tissue from the enteric side of the pancreatic anastomosis, and the bile sample will be collected intraoperatively. On the 30th postoperative day, the oral and rectal samples will be repeated
45758422|NCT02997371|Drug|Anakinra Prefilled Syringe|Administration as initially intravenous injection followed by a intravenous infusion
45758423|NCT02997371|Drug|Isotonic saline|Placebo, administration as initially intravenous injection followed by a intravenous infusion
45610311|NCT03439241|Device|Coloplast ostomy device|the test product is a newly developed Coloplast ostomy device
45610312|NCT02655237|Drug|Relugolix|Relugolix tablets
45610313|NCT02655237|Drug|Relugolix Placebo|Relugolix placebo-matching tablets
45758424|NCT04248998|Dietary Supplement|Fasting-mimicking diet|Cyclic, 5-day, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low protein diet every three weeks
45758425|NCT04248998|Drug|Metformin|Metformin 850 mg twice a day
45758426|NCT04248998|Drug|Preoperative chemotherapy|"Chemotherapy will consist of:~four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by~twelve consecutive cycles of weekly paclitaxel 80 mg/mq"
45758427|NCT00714233|Drug|Metformin|Metformin 425mg. capsules, 2 capsules BID x 24 weeks
45758428|NCT00714233|Drug|Oral Contraceptive Pills (Yasmin)|Yasmin oral contraceptive tabs; 1 tab daily x 24 weeks
45758429|NCT00714233|Behavioral|Lifestyle Modification|weekly classes x 24 weeks for training in diet, exercise and behavior modification skills
45758430|NCT00714233|Drug|placebo|placebo to the active metformin arm. 2 capsules BID x 24 weeks.
45758431|NCT00721357|Behavioral|Treadmill walking|Subjects will perform treadmill walking at a self-selected velocity
45758432|NCT00721357|Other|Magnetic resonance spectroscopy|Muscle oxidative capacity will be assessed via Magnetic resonance spectroscopy (31P-MRS)
45758433|NCT02984306|Dietary Supplement|Cherry powder|
45445098|NCT03781011|Behavioral|Low carnitine/choline diet habit|Patients will received dietary education and supervision by dietician to avoid high carnitine/choline foods including red meat, eggs...etc.
45758434|NCT02984306|Dietary Supplement|Placebo|
45445099|NCT03785613|Drug|Test Product T1: Buprenorphine patch (9 mg)|Buprenorphine transdermal patch formulation, containing 9 milligrams buprenorphine in an active surface area of 25 square centimeters.
45610314|NCT02655237|Drug|Leuprorelin|Leuprorelin injection
45610315|NCT02655237|Drug|Leuprorelin Placebo|Leuprorelin placebo-matching injections
45610316|NCT03444233|Other|Diet|7 days fruit-rich diet, 7 days HFCS-rich diet
45610317|NCT03439163|Device|MRI scan|All participants underwent the MRI scan
45610318|NCT03444077|Diagnostic Test|Use of the Trauma Induced Coagulopathy Clinical Score (TICCS) as a diagnostic tool.|The TICCS will be calculated on the site of injury for the patients taken in charge in the intervention group. Those patients will be classified in two categories regarding their TICCS value. Patients with TICCS ≥ 10 will be classified as in need for DCR; while patients with TICCS < 10 will be classified as not in need for DCR.
45610319|NCT03444077|Diagnostic Test|Regular care|Patients from the control group will be evaluated by clinicians using the local usual clinical Tools.
45610320|NCT03444077|Other|STTTOPPP the bleeding|"Surgical team pre-activation~Trauma team pre-activation~Transfusion team pre-activation~Tranexamic acid (administration of 1 gram of TXA if documented hyperfibrinolysis)~O negative RBC transfusion as soon as possible~Plasma and Platelets transfusion as soon as possible~Permissive hypotension (restrictive use of crystalloids: no more than 500 milliliters before definitive control of the bleeding is achieved)~Prophylaxis (initiate antithrombotic prophylaxis as soon as the bleeding is under control and coagulation tests are normal, first evaluation before the 24th hour after trauma)"
45758435|NCT03809845|Device|High-density surface electromyography|High-density surface electromyography
45610321|NCT03444077|Other|Regular Care|Regular local pre-hospital care.
45610322|NCT03443999|Device|Supraflex Family Sirolimus-eluting Coronary Stent System|Patient implanted with at least one Supraflex Family sirolimus-eluting stent as a part of planned clinical care
45610323|NCT03890133|Behavioral|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-healthcare Qigong exercise that has been practiced by Chinese people for at least eight hundred years.It consists of eight sets of simple movements. By combining meditation with slow, graceful movements,deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear."
45610324|NCT03890133|Drug|Pregabalin capsule|Pregabalin is one of the three medications (pregabalin, duloxetine, and milnacipran) that have been approved by the Food and Drug Administration (FDA) to treat fibromyalgia in US, and the only medicine that has been approved in China.
45610325|NCT03438929|Device|Diode laser|Diolaze XL blended modes diode laser
45610326|NCT03871647|Drug|Beta blocker|perioperative beta blockers
45758436|NCT00714311|Behavioral|Transference-Focused Psychotherapy|Outpatient psychotherapy according to the treatment manual, sessions of 50 minutes twice per week
45758437|NCT00714311|Behavioral|treatment by experienced community psychotherapists|Outpatient psychotherapy in private practices or outpatient units of psychiatric hospitals. Licensed psychotherapists with experience and special interest in the treatment of borderline patients are treating according to the method they have learned.
45610327|NCT03443921|Procedure|Artery Divestment Technique|Tunica adventitia was pick up by forceps and opened by electrocoagulation at 1 cm distal from tumor-artery contact. Space between tunica adventitia and external elastic lamina (EEL) were blunt lifting tumor-invaded adventitia by angled clamp. Adventitia was then sectioned to show EEL. Loose dissect space could be achieve along long the plane between EEL and adventitia as long as tumor invasion outside EEL. Tumor and invaded adventitia were further cut open by electrocoagulation proximally. Circumferentially, separation could be done by blunt dissection around EEL. Nourishing blood vessels of the artery would be secured by electrocoagulation or ultrasonic scalpel while major branch would be ligated or transfixed.
45758438|NCT04213118|Drug|Anlotinib Hydrochloride|Anlotinib 12mg QD PO d1-14, 21 days per cycle.
45758439|NCT04213118|Procedure|TACE|TACE first, followed by anlotinib within day4（+/-1days）
45758440|NCT00746395|Drug|Lubiprostone|24 mcg oral administration
45758441|NCT00746395|Drug|Placebo|Oral administration
45758442|NCT04385615|Other|Fasting Mimicking Diet|Participants will be requested to follow three cycles (of 5 day each), for three consecutive months, of a Fasting Mimicking Diet, a plant-based, low-calorie, low-protein, low-carbohydrate, high-unsaturated fat diet. For the remaining 25 days of each month, participants should continue with their habitual eating habits.
45610328|NCT03443921|Drug|Nab-paclitaxel|After eligibility testing as blood tests, contrast-enhanced CT and MRI scan, 3 cycles were administered (1,000 mg/m2 of gemcitabine and 125 mg/m2 of nab-paclitaxel on days 1, 8, and 15 every 28 days).Patients will be reevaluated and curative operation would be attempted if without disease progression.
45758443|NCT04205786|Dietary Supplement|Vitamin B12|Vitamin B12, orally, 2500 mcg, daily, for 90 days
45758444|NCT04205786|Other|Blood collection|"Blood collection for laboratory testing will occur within 10 days of signing the consent form, on day 45 +/- 10 days, and on day 90 +/- 10 days. It will include:~Serum B12 levels~CRP~Homocysteine level~MMA"
45758445|NCT04205786|Other|Brief Pain Inventory - Short Form survey|Brief Pain Inventory - Short Form survey
45758446|NCT04205786|Other|FACT-ES Trial Outcome Index (Version 4)|FACT-ES Trial Outcome Index (Version 4)
45758447|NCT04205786|Other|Questionnaire to Assess Adherence to Aromatase Inhibitors|Questionnaire to Assess Adherence to Aromatase Inhibitors
45758448|NCT04205786|Other|Demographics Questionnaire|Demographics Questionnaire
45758449|NCT00719966|Drug|anastrozole|Patients receive aromatase inhibition therapy.
45758450|NCT00719966|Drug|exemestane|Patients receive aromatase inhibition therapy.
45758451|NCT00719966|Drug|letrozole|Patients receive aromatase inhibition therapy.
45610329|NCT03781245|Other|All the Right Moves for Subcontractors|"All the Right Moves for Subcontractors aims to improve safety, health and wellbeing, through the development of a communication infrastructure with supplemental tools where construction workers and company mangers work together to collaboratively identify problems and strategies to improve their conditions of work. The intervention is grounded in the key characteristics of integrated organizational interventions to improve workers' health safety and wellbeing detailed in Harvard Center for Work, Health and Wellbeing's Implementation Guidelines (McLellan et al, 2016).~The intervention involves a cyclical approach through which the research team facilitate a participatory process to identify workers' health concerns, prioritize these concerns, use an action planning process to identify and operationalize solutions, and develop a company-specific evaluation plan to measure change."
45610330|NCT03438851|Device|NeuroCatch Platform™|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
45758452|NCT00719966|Procedure|assessment of therapy complications|Endothelial function is measured
45758453|NCT03426644|Behavioral|Mobile Sleep and Growth Study|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
45758454|NCT01275989|Other|Ear acupuncture|
45758455|NCT00591500|Behavioral|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs
46068654|NCT05828940|Drug|Losartan Potassium|oral tablet, over-encapsulated
46068655|NCT05828940|Drug|Placebo|oral tablet, over-encapuslated
45610331|NCT04304703|Device|WHOOP strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks sleep, resting heart rate, and heart rate variability.
45610332|NCT03443843|Drug|loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)|Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally
45610333|NCT03443843|Drug|Placebo tablet|Placebo tablet orally
45610334|NCT03443843|Drug|Fluticasone Propionate|Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril
45610335|NCT03443843|Drug|Placebo spray|Placebo Nasal Spray, 2 sprays per nostril
45610336|NCT04240587|Device|TrueTear™ intranasal neurostimulator (ITN)|"The ITN delivers small electrical currents to the inner cavity of the nose, gently activating nerves that stimulate the body's natural tear production system. Those in the ITN active arm will receive the active tips which contain the current from the base to the nasociliary nerve. Those in the ITN sham arm will receive tips without the current."
45610337|NCT04655651|Other|No intervention|There is no intervention for both groups.
45610338|NCT03756753|Diagnostic Test|Results available to provider|Results of point of care testing are given to provider
45610339|NCT03438305|Other|sonar assessment of gastric volume in Diabetic patients|assessment of gastric volume in Diabetic Patients
45610340|NCT03438305|Other|sonar assessment of gastric volume in Non Diabetic patients|assessment of gastric volume in Non- Diabetic Patients
45758456|NCT00591500|Behavioral|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs.
46068656|NCT05828329|Behavioral|Guided visualization of exams through immersive virtual reality|During 4 weeks (twice per week), students will visualize a 30-minutes 360º video that simulates the experience of an exam, from first person perspective.
45445100|NCT03785613|Drug|Test Product T2: Buprenorphine patch (3.8 mg)|Buprenorphine transdermal patch formulation, containing 3.8 milligrams buprenorphine in an active surface area of 10 square centimeters.
45445101|NCT03785613|Drug|Reference Product R: Transtec patch (20 mg)|Transtec (Registered Trademark) transdermal patch containing 20 milligrams buprenorphine in an active surface area of 25 square centimeters, release rate 35 micrograms per hour.
45445102|NCT03785613|Drug|Matching placebo patch to T1|Placebo patch to T1.
45445103|NCT03785613|Drug|Matching placebo patch to T2|Placebo patch to T2.
45445104|NCT03785613|Drug|Matching placebo patch to R|Placebo patch to R.
45445105|NCT01308645|Drug|SB injection|Infusion SB injection of 21.87 ml/m^2, IV route, 24 times for 4 months
45610341|NCT04181775|Diagnostic Test|ADE-RED scoring tool|The ADE-RED scoring tool will reduce the incidence of future visits to the ED or future admissions by identifying patients who are at high risk for ADE-related readmissions.
45610342|NCT03438227|Drug|Iron dextran|Single intravenous infusion of iron dextran 1000mg.
45610343|NCT03438227|Drug|Ferrous sulfate 325mg|Oral iron supplementation with ferrous sulfate 325mg one to three times daily
45610344|NCT03714633|Behavioral|Stockholm Preterm Interaction-Based Intervention (SPIBI)|Post-discharge intervention to extreme premature infants and their parents
45610345|NCT03438695|Procedure|Motorized Spiral Enteroscopy|Motorized Spiral endoscope will be inserted and advanced with the assistance of motorized clockwise spiral rotation, After reaching the cecum or if no further advancement of the endoscope can be achieved depth of insertion required for patient treatment or diagnosis, the endoscope will be withdrawn using motorized counter-clockwise spiral rotation, also controlled by the foot pedal. If no total enteroscopy was achieved, a submucosal ink dye injection is performed as an endoscopically visible marker of the maximum insertion depth. A retrograde peranal enteroscopy is then performed on one of the following days.
45610346|NCT04318197|Other|Personalized rehabilitation program with electrostimulation|Patient with knee arthroplasty indication. After clinical assessment and a MRI measurement of muscle volume, patients start a 2 hours daily rehabilitation including 2 times 20 minutes of electrostimulation of atrophied muscles, 3 days per week during 4 weeks.
45610347|NCT04318197|Other|Global rehabilitation program|Patient with knee arthroplasty indication. After clinical assessment and a MRI measurement of muscle volume, patient start a 2 hours daily rehabilitation targeting muscles groups with strengthening and stretching exercises, 3 days per week during 4 weeks.
45610348|NCT03438617|Behavioral|Peer Support|The intervention involves monthly education/support groups co-led by a CHC doctor / nurse and peer leaders. These meetings will begin with a general discussion about participants' previous month, what they had been doing, any special events etc. Meetings will devote time to identifying goals and specific plans for reaching them, rehearsal and/or discussion of specific behaviors to execute plans and ways in which the group members can be helpful to each other. This will be organized around a Diabetes Action Plan. Peer leaders will also organize activities to promote healthy lifestyles, such as walking groups, to promote informal contacts among peer leaders and participants.
45610349|NCT03555591|Drug|Trelagliptin|Trelagliptin tablets
45610350|NCT04633187|Drug|EDP-938|"EDP-938 800mg~Dose adjustments will be made for subjects taking azole antifungals."
45610351|NCT04633187|Drug|Placebo|Subjects will take EDP-938 matching placebo tablets once a day orally for 21 days
45758457|NCT02997137|Dietary Supplement|BOT-01|"Amino acid composition with micronutrients, once a day (in the morning) content of a sachet mixed with 200 ml water.~Duration: 12 weeks"
46068657|NCT05828329|Behavioral|Guided visualization of exams through traditional method|During 4 weeks (twice per week), students will listen a 30-minutes audio that explains the experience of an exam from first person.
46068658|NCT05828134|Other|protein-enriched soup|The participants in experimental group have a protein-enriched soup a day and do exercise a week
46068659|NCT05827055|Drug|Gemcitabine|1000mg/m2 IV given days 1, 8, and 15 every 28 days (1 cycle)
46068660|NCT05827055|Drug|Nab paclitaxel|125 mg/m2 given days 1, 8, and 15 every 28 days (1 cycle)
46068661|NCT05827055|Drug|Proglumide Dose level 1|Daily dose of 1200 mg orally given as 400 mg orally (PO), three times a day (TID) (dose level 1)
45610352|NCT04006509|Behavioral|Prenatally Delivered Lactation Educational Program|The support person (SP) of mothers at risk for preterm birth will be educated on how to use a breast pump and instructions regarding breast milk expression and have a pump in their hospital room
45610353|NCT04646213|Behavioral|Managing Cancer and Living Meaningfully (CALM) Therapy|6 sessions of individualized CALM therapy
45610354|NCT03944811|Procedure|piezoelectric device|crestal approach will be used to augment the maxillary sinus with simultaneous implant placement
45610355|NCT03944811|Procedure|Summers technique|Summers technique
45610356|NCT03438461|Drug|Seltorexant 40 mg|Seltorexant 40 mg as two tablets of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 1.
45445106|NCT03785379|Behavioral|Caloric restriction|A structured dietary training will be implemented to educate participants about recommended dietary habits.Patients will follow a caloric restriction (CR) diet, with an energy intake equal to the measured Resting Metabolic Rate (RMR) and with 45% carbohydrate, 20%protein, 35%fat, and 30 g/day fibers. At each follow-up, nutritionist will adjust CR to the latest measured RMR and assess the compliance to the diet.
45610357|NCT03438461|Drug|Seltorexant 20 mg|Seltorexant as a tablet of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 2.
45610358|NCT03433391|Device|Oxiplex|Oxiplex is a clear, viscoelastic gel that is applied to operative site during lumbar spine surgery in order to coat the nerve root with a protective barrier.
45610359|NCT03433391|Other|Surgery Only|Single level partial discectomy as per standard of care procedures.
45610360|NCT04512339|Drug|Dupilumab|Dupilumab injections (blinded labels)
45610361|NCT04512339|Drug|Placebo|Placebo injections (blinded labels), matching the dupilumab injections in quantity and appearance
45610362|NCT03835923|Behavioral|lifestyle intervention|"intervention phase 1 (baseline - month 6): Patients receive an individual exercise plan, nutritional recommendations and advices to increase daily activity. The intervention is accompanied by regular oral and written feedback.~intervention phase 2 (month 6 - month 12): Patients receive an individual exercise plan, nutritional recommendations and advices to increase daily activity without additional oral or written feedback."
45610363|NCT03835923|Behavioral|usual care|Recommendation for lifestyle intervention at baseline and after 6 months (e.g. salt reduction, restricted alcohol consumption and smoking cessation, 10,000 steps/day, 150 minutes/week moderate intensity exercise)
45445107|NCT03785379|Behavioral|Exercise training|Trainers will supervise participants during 12-weeks of structured exercise consisting of 150 min/week workouts, divided in three sessions of progressive mixed (aerobic and resistance) exercise. All aerobic exercise will be performed using treadmill and/or cycle ergo-meter.
45610364|NCT03433235|Drug|Edoxaban|"1-3-6-12 rule*~Anticoagulation in patients with acute ischemic stroke and atrial fibrillation can be initiated from the following days after stroke event.~After 1 day: transient ischemic attacks~After 3 days: mild ischemic strokes (NIHSS <8)~After 6 days: moderate ischemic strokes (NIHSS 8-16)~After 12 days: severe ischemic strokes (NIHSS >16)~- NIHSS: National Institute of Health Stroke Scales"
45610365|NCT03783351|Genetic|CYP2C19 genotype testing|CYP2C19 genotype testing will be conducted in a designated central laboratory.
45610366|NCT03438071|Other|Videoconferencing|Daily videoconference updates using Skype between parents of preterm infants hospitalized in NICU and the nurse taking care of their child, lasting 5 to 10 minutes, to check with her for the daily news and then see their child through the camera.
45610367|NCT03342417|Biological|Nivolumab|Nivolumab 240 mg administered by IV infusion over 30 minutes
45445108|NCT03785223|Drug|Methylphenidate Hydrochloride Controlled-Release Capsules|"25 mg methylphenidate hydrochloride- titrated as tolerated up to a maximum 4 capsules daily (25 mg- 100 mg total dose)~At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. 50 mg of methylphenidate hydrochloride per day (i.e. 2 capsules/day) is the minimum dose that must be achieved. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11, no further dose changes will occur."
45445109|NCT03785223|Drug|Placebo Capsule|At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11 no further dose changes will occur.
45610368|NCT03342417|Biological|Ipilimumab|Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes.
45610369|NCT03437993|Other|Recollect, the game|"Recollect is a working memory training game"
45610370|NCT03437993|Other|Tetris|App-based video game where shapes are rotated and placed to fit a grid
45610371|NCT03437915|Radiation|NIBB: accuboost|28.5 Gy delivered in 5 daily fractions
45610372|NCT03437915|Procedure|Partial mastectomy|4-12 weeks post NIBB
45610373|NCT03234309|Drug|Ferumoxytol|Given IV
45610374|NCT03234309|Procedure|Magnetic Resonance Imaging|Undergo MRI
45610375|NCT04515459|Other|Surgical prehabilitation program.|"This programme will include the practice of general physical activity and the implementation of nutritional and psychological support.~Each patient will have 8 Oncorehabilitation Transdisciplinary Evaluations (OTE):~2 OTE will be performed before the surgery,~6 OTE will be performed after the surgery.~During the program (at each OTE), patients will also be asked to complete the QLQ-C30 questionnaire."
45610376|NCT03433157|Device|Hall technique|Metal Stainless stain crown placed with Hall technique
45610377|NCT03433157|Device|Traditional technique|Metal Stainless stain crown placed with Traditional technique
45610378|NCT03437759|Biological|exosomes derived from mesenchymal stem cells (MSC-Exo)|After air-liquid exchange, 50μg or 20μg MSC-Exo in 10μl PBS was dripped into vitreous cavity around MH, leaving 20% SF6 or air as tamponade .
45610379|NCT03192189|Other|monitoring for progression to chronic kidney disease|Collect clinical information and assess risk factors
45610380|NCT03433079|Diagnostic Test|Neutrophil gelatinase-associated lipocalin (NGAL)|Blood neutrophil gelatinase-associated lipocalin (NGAL) test was performed in all patients.
45610381|NCT03433079|Diagnostic Test|Arterial lactate|Arterial lactate level was assessed in all patients.
45610382|NCT03433079|Diagnostic Test|Interleukin-6 (IL-6)|The level of interleukin-6 was assessed in all patients.
45610383|NCT03433079|Diagnostic Test|Procalcitonin (PCT)|The level of procalcitonin (PCT) was assessed in all patients.
45610384|NCT03433079|Diagnostic Test|Myoglobin|The level of myoglobin was assessed in all patients.
45610385|NCT02657031|Drug|Prochlorperazine|prochlorperazine 10 mg IV
45445110|NCT05691777|Device|Hand and shoulder task|"Hand task: the participant is seated on a chair facing a table, both hands resting on the table. The participant is asked, for each block of 10 seconds, to perform flexion / extension movements of the fingers of the right hand at 0.5 Hz.~Shoulder task: the participant is seated on a chair facing a table, both hands resting on the table. The participant is asked, for each block of 10 seconds, to perform alternating movement of abduction and adduction of the right shoulder at 0.5 Hz with the elbow flexed."
45610386|NCT02657031|Drug|Ketamine|Ketamine 0.3 mg/kg IV
45610387|NCT02657031|Drug|Diphenhydramine|Diphenhydromine 25 mg IV
45610388|NCT02657031|Drug|Ondansetron|Ondansetron 4 mg IV
45610389|NCT02657031|Drug|Normal Saline|Normal Saline 500 cc IV Bolus
45610390|NCT04944953|Drug|Botulinum Toxin Type A Injection [Botox]|Single administration, Day 0, 20 units
45610391|NCT04944953|Drug|Botulinum toxin type A injection [HG-102]|Single administration, Day 0, 20 units
45610392|NCT03437603|Drug|Eltrombopag|Starting Eltrombopag daily on empty stomach (2 hour before breakfast) for 8 weeks.
45610393|NCT03059433|Other|AVID Intervention|Advancement via Individual Determination (AVID) is a college preparatory program that participating high schools have available to students.
45610394|NCT03433001|Drug|Ixazomib|Ixazomib capsules
45610395|NCT03433001|Drug|Lenalidomide|Lenalidomide capsules
45610396|NCT03433001|Drug|Dexamethasone|Dexamethasone tablets
45610397|NCT03437525|Behavioral|Peer Support|The intervention involves monthly education/support groups co-led by a CHC doctor / nurse and peer coaches. These meetings will begin with a general discussion about participants' previous month, what they had been doing, any special events etc. Meetings will devote time to identifying goals and specific plans for reaching them, rehearsal and/or discussion of specific behaviors to execute plans and ways in which the group members can be helpful to each other. This will be organized around a Diabetes Action Plan. Peer coaches will provide education and support for insulin therapy to help reduce barriers around insulin use. Peer coaches will also organize activities to promote healthy lifestyles, such as walking groups, to promote informal contacts among peer supporters and participants.
45758458|NCT02997137|Other|Placebo|"Placebo, once a day (in the morning) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks"
45610398|NCT03797469|Dietary Supplement|Vitamin B3|3 tablets of 1000 mg each will be administered orally.
45610399|NCT03797469|Dietary Supplement|Pyruvate|2 tablets of 1500 mg each will be administered orally.
45610400|NCT03797469|Dietary Supplement|Placebo|Tablets will look identical to the supplements and the number of tablets will equal the amount of supplements provided.
45758459|NCT01276067|Drug|Donepezil|10 mg Tablet
45758460|NCT04183868|Drug|Empagliflozin 10 MG|10 mg tablet daily
45758461|NCT04183868|Drug|Glimepiride 2 mg|starting dose: 2 mg tablet daily, 1 mg for lunch and 1 mg for dinner, can undergo to up-titration of glimepiride to a maximum of 6 mg daily
45758462|NCT02997215|Drug|Lidocaine|lidocaine infusion during surgery
45758463|NCT02997215|Drug|Saline Placebo|saline infusion at same rate as intervention group during surgery
45758464|NCT02990507|Other|AVEED: Arm rotation, video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
45445111|NCT01308723|Drug|RO5323441|escalating doses iv
45445112|NCT01308723|Drug|RO5323441|iv every 2 weeks
45610401|NCT03432923|Drug|Benzocaine 8 mg|Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
45610402|NCT03432923|Drug|Placebo|Placebo, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
45610403|NCT03294993|Device|Ultrasound assess|The investigators designed a study to assess whether there were any blood flow indexes change before and after radial artery puncture with doppler ultrasonography
45610404|NCT04534829|Procedure|Fluoroscopic-guided Radiofrequency Ablation|Radiofrequency ablation of the posterior SIJ complex under fluoroscopic-guidance
45610405|NCT04534829|Procedure|Ultrasound-guided Radiofrequency Ablation|Radiofrequency ablation of the posterior SIJ complex under ultrasound-guidance
45610406|NCT02809989|Drug|Ovaleap®|"About 6-8 weeks of observation per patient from start of the stimulation therapy with Ovaleap® depending on the duration of the required stimulating therapy. Up to 10-11 months per patient for follow-up but only if in case of songraphically intact intrauterine pregnancy to determinate the Baby-Take-Home-Rate (live-births)."
45610407|NCT03432845|Other|compare reversal agents|compare effect of two different approved reversal agents on postoperative and post-discharge nausea and vomiting
45610408|NCT04435899|Other|Physical exercise|Multi-modal exercise protocol
45610409|NCT03437369|Drug|Ivabradine Oral Tablet|The target dose is 10 to 15 mg / day, administered orally in two doses
45610410|NCT03437369|Other|Standard of Care treatment|The study drug will be compared with the standard of Care treatment
45610411|NCT02616081|Other|Clean Intermittent Catheterization|Clean intermittent self catheterization is a standard of care.
45610412|NCT02616081|Other|Indwelling Catheter|Indwelling catheterization is a standard of care.
45610413|NCT02616081|Other|Surgery|Bladder surgery is a standard of care.
45610414|NCT02616081|Other|Voiding|Voiding spontaneously is a standard of care.
45610415|NCT04515095|Other|Water-only Fasting|Participants consume only water for at least 7 days in an in-patient, residential setting with 24 hour medical supervision.
45610416|NCT02384577|Drug|Budesonide, Formoterol Fumarate Dihydrate|
45610417|NCT02521649|Drug|G17DT|
45610418|NCT02215941|Drug|TV-45070|TV-45070 8% ointment
45610419|NCT02215941|Drug|Placebo|Placebo
45758465|NCT02990507|Other|AVEED: Arm rotation, without video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
45758466|NCT02990507|Other|AVEED: Leg rotation, arm-energy input, video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
45758467|NCT02990507|Other|AVEED: Leg rotation, arm-energy input, without video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
45610420|NCT03437291|Procedure|Cesarean section|Lower segment CS with evaluation of Placental site, spontaneous separation, placental invasion into the bladder and other surrounding organs, Uterotonic administration, Bladder , ureteric or bowel injury, blood loss and blood transfusion
45610421|NCT03437291|Device|Transabdominal ultrasound|loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass
45610422|NCT03437291|Device|Transvaginal ultrasound|loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass
45610423|NCT03437213|Drug|Total intravenous anesthesia group|Induction of general anesthesia with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg), intubation. Anesthesia maintained using Propofol (4-6) mg/kg/h, fentanyl (0.5-1) μg/kg/h. to be modified according to analgesic needs and hemodynamics. 10mg atracurium when the 2nd twitch of train of four appears.
45610424|NCT03437213|Drug|Total intravenous plus block group|Ultrasound guidance identifies the paravertebral space using a linear high-frequency (10-12 MHz) probe in the transverse plane in the midline, rotate the probe to the longitudinal plane, and scan in a medial-to-lateral direction. Locate the desired segment shift from the cephalad aspect of the sacrum. The transverse scan will show a hyperechoic outline of the vertebral spinous and transverse processes. Use the loss of resistance technique. Bilaterally inject (5ml) bupivacaine 0.5% for each segment. Induction of anesthesia after 30 minutes with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg),then prone position.
45610425|NCT02030457|Drug|Beclomethasone dipropionate BAI|Breath Activated Inhaler (BAI)
45610426|NCT02030457|Drug|Beclomethasone dipropionate MDI|Metered Dose Inhaler (MDI)
45610427|NCT03991247|Behavioral|Computerized behavioral therapy program delivered by internet for insomnia management|"The online program consists in restriction of time in bed and stimulus control instructions.~First, patient will complete an on-line sleep diary during 2 weeks. The personalized program is then activated by a practitioner (phone interview) who both assesses restriction of time in bed and delivers instructions of stimulus control. Then, restriction of time in bed is administered by the internet-delivered self-help program. The participant still completes his on-line sleep diary every day. Every 7 days, according mean sleep efficiency, a new sleep schedule recommendation is given to the participant. In addition, the program delivers everyday a set of instructions (stimulus control) designed to re-associate the bed/bedroom with sleep and to re-establish a consistent sleep wake schedule. The duration of restriction of time in bed program is 3 weeks (during spa treatment or at home depending on the allocated arm)."
45610428|NCT03991247|Other|Spa treatment|"Spa treatment is harmonized in the different stations. It consists in:~a medical thermal follow-up: weekly medical consultation of 15 minutes during the 3 weeks spa treatment.~an institutional follow-up: support, help and monitoring of patients during spa treatment~Crenotherapy: 18 baths of 10 minutes in running water, 18 spa showers of 3 minutes, 9 massages under water of 20 minutes, 18 baths of 10 minutes in pool. Water temperature of pool is between 31°C and 33°C. Water temperature for other care is 35°C and 38°C."
45610429|NCT01847859|Procedure|Ultrasound examination by nurses|Focused examination of the pleural space and inferior vena cava.Reference method: Cardiologists performed ultrasound examinations.
45445113|NCT01308723|Drug|sorafenib|400 mg orally twice daily to once every other day
45610430|NCT04514133|Behavioral|Participating in Action Civics program|Students in school classrooms participating in Action Civics program
45610431|NCT03437135|Diagnostic Test|Glasgow Hearing Status Inventory questionnaire|"This is a questionnaire of the hearing quality presenting eleven questions. This is allows to determine the quality of the hearing status of the patients. It is enough to answer the various questions yes or no."
45610432|NCT04514055|Procedure|De-epithelialized connective tissue graft wall|A de-epithelialized free gingival connective tissue graft will be used to treat Cairo's recession type 2 and type 3 associated with inta-bony defects
45610433|NCT03980405|Dietary Supplement|Group 1- Control Diet|Oral 5ASA+ Low Residue Diet for 6 weeks and Oral 5ASA+ Free Diet for 6 more weeks
45610434|NCT03980405|Dietary Supplement|Group 2- UCD Diet|Oral 5ASA+ UC Diet for 6 weeks and Oral 5ASA+ UC Diet Stage 2 for 6 more weeks
45758468|NCT03422744|Procedure|trans bronchial biopsy guided by echo-endoscopic miniprobes|We get a sample trough transbronchial biopsy guided by echo-endoscopic miniprobe.
45758469|NCT03422744|Procedure|if first one negative: samples under fluoroscopic control|If no diagnosis with first intervention we get a second sample by cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control
45758470|NCT02990351|Procedure|loco regional therapies for HCC|29 HCC patients received locoregonal therapy as a bridging therapy for those who were within milan and as downstaging for those were initially beyond milan. The main LRT types used for our patients were TACE and or RFA and microwave ablation
46068662|NCT05827055|Drug|Proglumide Dose level 2|Daily dose of 1600 mg orally given as 800 mg orally (PO) twice a day (BID) (dose level 2).
46068663|NCT05826275|Drug|TGN-S11|Small Molecule
46068664|NCT05826275|Drug|Pembrolizumab|PD-1 checkpoint blockade
45445114|NCT01561131|Dietary Supplement|Whey protein|45g protein/d; Dosage 3x15g protein daily
45610435|NCT03432767|Device|Non-invasive hemoglobin monitor|
45610436|NCT03437057|Other|acetylsalicylic acid (below or equal to) 250 mg|Prospective single-arm study to estimate the risk of renal hematoma when performing a session of lithotripsy for renal lithiasis, on a 15-day scanner, in patients treated with acetylsalicylic acid not suspended.
45610437|NCT03579693|Dietary Supplement|CoQ10|CoQ10 tablet
45610438|NCT03579693|Dietary Supplement|Nicotinamide riboside|NR tablet
45610439|NCT03579693|Dietary Supplement|Placebo|Sugar pill designed to mimic coQ10 and NR
45610440|NCT03432689|Device|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
45610441|NCT03432689|Drug|Cycloserine|Cycloserine 100mg
45610442|NCT03432689|Drug|Placebo Oral Tablet|Placebo capsule matched to cycloserine capsule
45610443|NCT02991807|Drug|RAD001|"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."
45610444|NCT02991807|Drug|Placebo|"Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."
45610445|NCT04470869|Other|Phone call|The relatives of both groups will be contacted by phone one month after the discharge of the ICU of the death, three month after, six month after and twelve month after. During these interviews the PTSD symptoms, the anxiety and depression symptoms, the complicated grief symptoms (in case of death) and the satisfaction about the ICU stay will be collected.
45610446|NCT05106933|Other|Plain water|Measure gastric residual volume during upper endoscopic, after given plain water and carborie 2 hours prior upper endoscopy
45610447|NCT05106933|Other|Carborie|carbohydrate drink
45610448|NCT03432611|Other|Self-care information feature|The self-care feature offers information on self-care for menstrual pain. The following topics are shown: exercise, dietary supplementation, heating pad/hot water bottle, yoga, and information on when to consult a doctor and how primary dysmenorrhoea is often treated. Notifications from the app which can be deactivated remind women of surveys and activities.
45610449|NCT03432611|Other|Self-acupressure feature|The acupressure feature offers detailed written and multimedia descriptions of an acupressure used for menstrual pain. Three acupressure points are described, which should be massaged bilaterally twice a day up to five times a day on the 5 days before menstruation and during menstruation. Each point should be massaged for 2 minutes. A timer for the acupressure and notifications from the app which can be deactivated remind women of surveys and acupressure.
45610450|NCT01331187|Procedure|Pocket-size ultrasonography|Routinely adding a ultrasound examination of the heart, pleura, great abdominal vessels, liver/gall bladder and kidneys at patients admittance to hospital
45610451|NCT01331187|Other|Usual care|No intervention, except for usual care (goal-directed diagnostics)
45610452|NCT01081197|Other|Psychiatric and somatic examinations and ,if clinical indicated, treatment|Patients referred to the clinic will be given optimal treatment for revealed psychiatric and/or somatic disease including conversational therapy, and if indicated therapeutic interventions with respect to any kind of disease.
45610453|NCT00829803|Device|SNAP monitor; Bispectral Index Monitor (BIS Monitor)|Intended to monitor the state of the brain by data acquisition of EEG signals.
45445115|NCT01561131|Dietary Supplement|Whey protein enriched with calcium|45g protein/d + 1000mg calcium/d; dosage: 15g protein + 333mg calcium x 3 daily
45610454|NCT05118321|Device|Custom-made upper limb exosuit and hand exoskeleton|Participants go through 3 90-min sessions in a clinic setting and perform a series of functional tasks adapted from motor activity log and bilateral upper limb tasks with and without the device.
46068665|NCT05825521|Other|MRI|During management, patients with hydrocephalus will be subjected to flow MRI and diffusion MRI. Flow parameters and diffusion parameters will be measured and compared to those found in control subjects receiving the same type of imaging
45445116|NCT01561131|Dietary Supplement|Soy protein|45g soy protein/d; dosage 15g soy protein x 3 daily
45445117|NCT01561131|Dietary Supplement|Maltodextrin|48g carbohydrate/d; dosage: 16g carbohydrate x 3 daily
45445118|NCT01313403|Other|Antidepressant (SSRI)|
45445119|NCT03780933|Dietary Supplement|vitamin c|vitamin c IV 10 G
45610455|NCT04380311|Device|Tacrolimus Dosing Support Tool|The tacrolimus dosing support tool is based on a population pharmacokinetic model that incorporates patient specific factors including age, renal function, and concomitant medications.
45445120|NCT03785301|Device|Freestyle Libre Flash Glucose Monitoring|Freestyle Libre Flash Glucose Monitoring will be used in diabetic patients once a month for therr months to monitor glucose level. Patients could scan the sensor to get the glucose level at any time as they want. They could alter thier diet and exercise according to the glucose levels. Patients will be required to keep track of food and exercise during wearing FGM sensor. Physicians would adjust patients' medication according their glucose profile provided by FGM, A1c, and diet and exercise every month.
45610456|NCT05018013|Drug|Ammoxetine hydrochloride enteric-coated tablets|Ammoxetine hydrochloride enteric-coated tablets
45610457|NCT05018013|Drug|Duloxetine hydrochloride enteric-coated capsules|Duloxetine hydrochloride enteric-coated capsules
45610458|NCT05018013|Drug|Placebo to Ammoxetine|Placebo to Ammoxetine
45610459|NCT05018013|Drug|Placebo to Duloxetine|Placebo to Duloxetine
45610460|NCT05118165|Dietary Supplement|Dietary supplement with protein|Will be included protein supplements in the preoperative diet.
46068666|NCT05825040|Behavioral|Online guided transdiagnostic cognitive behavioural therapy|The contents of guided transdiagnostic cognitive behavioural therapy are developed by clinical psychologists and psychological well-being officers. The intervention consists of 8 modules. Contents include emotional awareness, physical sensation, emotion-driven behavior, behavioral activation, worry, cognitive restructuring, behavioral experiment, and relapse prevention. Customized guidance will be provided by coaches once a week based on participants' performance
46068667|NCT05825040|Behavioral|Online self-guided transdiagnostic cognitive behavioural therapy|The contents of self-guided transdiagnostic cognitive behavioural therapy are developed by clinical psychologists and psychological well-being officers. The intervention consists of 8 modules. Contents include emotional awareness, physical sensation, emotion-driven behavior, behavioral activation, worry, cognitive restructuring, behavioral experiment, and relapse prevention. No customized guidance will be provided to participants in the self-guided group.
45758471|NCT03381872|Procedure|Percutaneous coronary intervention for complex lesion|"In patients who have complex coronary lesions, PCI will performed using intravascular imaging or angiography only according to the allocated arms~Intravascular imaging arm~Angiography arm~Definition of Complex Lesions~True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5mm size~Chronic total occlusion (≥3 months) as target lesion~PCI for unprotected left main (LM) disease (LM os, body, distal LM bifurcation including non-true bifurcation)~Implanted stent length ≥38mm~Multi-vessel PCI (≥2 major epicardial coronary arteries treated at one PCI session)~Multiple stent needed (≥3 more stent per patient)~In-stent restenosis lesion as target lesion~Severely calcified lesion (encircling calcium in angiography)~Ostial coronary lesion (LAD, LCX, RCA)"
45610461|NCT03432221|Drug|Desvenlafaxine|Patients included in the study will receive antidepressant treatment with desvenlafaxine. The switch from SSRI to desvenlafaxine will coincide with the baseline visit (Visit 0). The dose of desvenlafaxine will be established based on clinical judgment. As the approach will be naturalistic, the inclusion in this study will not influence the clinical choice, hence changes in the pharmacological strategy will be permitted.
45610462|NCT04678245|Behavioral|Above the Influence-Vaping (ATI-V)|Peer-nominated 8th grade and 9th grade Peer Leaders (PL) will be trained in a half day ATI-V training. Adult Advisors (AA) will attend a half day ATI-V AA training and the PL training. The training day builds leadership skills in the PLs, develops skills for rising above pressure to vape including identification of personal reasons to rise, identification of healthy support people, teaching accurate use statistics, and sharing stories of prior success in rising above negative pressures. The ATI-V team of PLs and AAs then will run four interactive messaging campaigns to reach the rest of the student body. These four campaigns are (1) Introduction to ATI-V and My Reasons to Rise (2) Gain and Loss (3) Who's Got My Back (4) The Facts. Each campaign features a portion in which PLs model healthy norms and behaviors, and a second portion in which all the rest of the students engage in an interactive component to build and demonstrate the target skill.
45610463|NCT02344485|Procedure|OMM treatment|OMM is a gentle hands-on treatment that helps to reduce myofascial restrictions and improve joint range of motion. In doing so, it can address the mechanical, neurologic, and respiratory functions of the body
45610464|NCT04364529|Other|The pit crew model|The pit crew model
45610465|NCT04375397|Drug|Ibrutinib|Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
45610466|NCT04375397|Drug|Placebo|Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
45610467|NCT05112471|Device|Airflow, Perioflow and Erythritol powder and ultrasonic debridement|Airflow and Perioflow combined with Erythritol powder will be used as an adjunct therapy
45610468|NCT05112471|Device|Ultrasonic debridement and curettes|traditional Scaling and Root Planing with curettes and ultrasonic scaler
45610469|NCT05112393|Other|Development of new estimating Glomerular Filtration Rate (eGFR) equation|"Development Cohort:~A new estimating Glomerular Filtration Rate(eGFR) equation will be developed by using a nonlinear regression model utilizing a generalized least squares algorithm."
45610470|NCT05112393|Other|Validation of new estimating Glomerular Filtration Rate (eGFR) equation|"Validation Cohort:~Internal validation will be performed by comparing bias, precision and accuracy of the new equations and the other established equations to the measured GFR."
45610471|NCT05117697|Other|lateral subcutaneous sphincterotomy|"Patients of the main group are treated with a crack by performing a lateral subcutaneous sphincterotomy.~In the control group, the fissure is excised in combination with a lateral subcutaneous sphincterotomy."
45610472|NCT03128333|Other|RunKeeper app + physiotherapy coaching|RunKeeper app for half a year to self-monitor leisure-time PA.
45610473|NCT03128333|Other|Usual care|In the UMCG, patients who receive cancer treatment or in surveillance after treatment are normally advised to live healthy, stay active, and to maintain their weight.
45610474|NCT03436589|Behavioral|Indiana SNAP-Ed|First four Indiana SNAP-Ed nutrition education lessons served as the intervention
45610475|NCT04360421|Drug|Liposomal bupivacaine|"Patient's undergoing major extremity amputation and enrolled in the study as part of the experimental arm will, during their amputation operation, receive liposomal bupivicaine per recommended manufacturing dosing and administration in a field block for long-acting local anesthesia."
45610476|NCT02387216|Drug|MM-121|Investigational, fully human antibody targeting and inhibiting ErbB3
45610477|NCT02387216|Drug|Docetaxel|approved chemotherapy treatment for NSCLC
45758472|NCT03381872|Device|Drug-eluting stent|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
46068668|NCT05825040|Behavioral|Online self-guided mindfulness-based intervention|The contents of online self-guided mindfulness-based intervention are developed by clinical psychologists and psychological well-being officers. The intervention consists of 6 modules. Contents include mindfulness and auto-pilot, react and respond, aversion, craving, equanimity, and 'suffering', thoughts and letting go, starting with loving kindness, and mindfulness in life.
45445121|NCT03780855|Device|nerve scaffold|It is a new kind of nerve scaffold with the microstructure of longitudinally oriented microchannels. It's made of collagen as the main raw material.
45445122|NCT03780621|Dietary Supplement|Andrographis and Withania|Combination of Andrographis paniculata and Withania somnifera
46068669|NCT05825014|Other|No intervention|No intervention
46068670|NCT05820035|Device|Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter|All subjects will be ablated using the Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the management of their Paroxysmal Supraventricular Tachycardia
46068671|NCT05818423|Behavioral|Brain Health Academy|The Brain Health Academy group will review online content about brain health (1 hour, 2 days/week for 12 weeks) and will complete a brief survey after each module to assess compliance (30 hours total).
45610478|NCT03128489|Biological|Infanrix-IPV/Hib|Subjects will receive (Infanrix-IPV/Hib) as three-dose primary vaccination course at 6, 10 and 14 weeks of age. The vaccine will be administered intramuscularly, at a 90-degree angle into the anterolateral side of the thigh on the right side. The vaccine should not be administered in the buttock.
45610479|NCT03431909|Drug|Human urinary kallidinogenase (HUK)|Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
45610480|NCT03431909|Drug|aspirin® , clopidogrel® , atorvastatin®|Patients in control group will receive foundation treatment, including aspirin® (100 mg/d), clopidogrel® (75 mg/d), and atorvastatin® (20 mg/d) for 14 days
45610481|NCT03436355|Behavioral|Physical activity|"The Active school study was a 10-month randomized controlled trial.The weekly interventions were 2×45 minutes physically active academic lessons, 5×10 minutes physically active breaks, and 5×10 minutes physically active homework."
46068672|NCT05818423|Behavioral|Brain Health Together|The Brain Health Together group will participate in online, live-streaming, group-based Moving Together classes (1 hour/week); Brain Health education group classes (1 hour/week) and individual brain health coaching sessions (0.5 hours/week) for 12 weeks (30 hours total).
46068673|NCT05818423|Behavioral|Maintain Brain Health Together|The Maintaining Brain Health Together group will participate in the full Brain Health Together program (30 hours) for 12 weeks followed by weekly group classes and six individual coaching for an additional 12 weeks (additional 15 hours).
45610482|NCT03436277|Drug|L-Carnitine|L-Carnitine oral solution 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
45610483|NCT03436277|Dietary Supplement|Sucralose|Sucralose 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
45610484|NCT03941717|Other|Mindfulness-Based Condition|Each script for the mindfulness-based intervention was slightly modified to fit the context of a venipuncture, and begins with instructions to take deep breaths. Both scripts aim to cultivate present moment awareness of experiences, curiosity, nonjudgement, and acceptance of experiences as they unfold. In particular, the scripts ask that the participant visualize their worries and feelings as a cloud in the sky, and probes for curious thoughts about these experiences. The temporary nature of sensations is described, and the participant is asked to keep this openness and curiosity during the venipuncture.
45610485|NCT03941717|Other|Unfocused attention Condition|Each script for the unfocused attention task instructs participants to allow their mind and thoughts to roam. The aim is to encourage the participant to continue thinking and mind wandering as they typically would.
45610486|NCT03929081|Behavioral|Inference Based Approach (IBA)|The Inference Based Approach aims at strengthening reality testing in patients with Obsessive-Compulsive Disorder, by teaching the patient to actively rely on sensory information.
45610487|NCT03929081|Behavioral|Cognitive Behavioural Therapy (CBT)|CBT teaches the patient with Obsessive-Compulsive Disorder to refrain from compulsive acts.
45610488|NCT03436121|Drug|Ketamine|"Ketamine is a medication approved by the US Food and Drug Administration (FDA) for anesthesia, sedation, and post-surgical pain treatment. It is not approved for emergency patients complaining of pain but is often used off-label. Ketamine may be useful for acute pain management and in treatment of depressed mood. The purpose of this study is to determine whether a single low dose of ketamine can relieve pain and reduce negative mood for 2 weeks after emergency department (ED) treatment."
45610489|NCT03436121|Drug|Midazolam|In this study, all patients will also receive midazolam. Midazolam is a sedative that typically makes people feel relaxed and is intended to increase comfort with ketamine and reduce anxiety.
45610490|NCT03436121|Drug|Placebo|In this study, patients in the active comparator group will receive midazolam first, then placebo. A placebo is an inactive solution that looks like the study drug, but contains no active ingredients.
45610491|NCT04899635|Other|In-vitro contractile fatigue protocol|Using contractility assays for muscle slices or the work-loop assay for isolated heart cells, the tissue preparation will undergo a series of contraction and relaxation under varying levels of preload, afterload, stimulation frequency and under other experimental conditions such as drug-induced inotropism.
45445123|NCT03780621|Dietary Supplement|Placebo|Visually identical placebo capsule
45445124|NCT05688891|Other|Virtual reality|"5 minutes before the burn dressing procedure, virtual reality glasses were put on the patient's head by the researcher and a 360° VR video with submarine and nature content pre-loaded on the glasses was opened.~Audio and video settings were made and started to be watched. Video monitoring with Virtual Reality continued throughout the entire dressing. This procedure was performed during 2 consecutive dressing changes. A 1-week period was given between 2 dressings."
45610492|NCT03436043|Device|Transmural Plastic stenting|After metal stent removal in patients of disconnected pancreatic duct syndrome, transmural plastic- double pig tail stent will be placed into the residual necrotic cavity with the standard duodenoscope.
45610493|NCT02417246|Drug|brand name metoprolol ER|This medication will be taken for 7 to 28 days
45610494|NCT02417246|Drug|Generic A|This medication will be taken for 7 days
45610495|NCT02417246|Drug|Generic B|This medication will be taken for 7 days
46068674|NCT05817929|Other|blood sample|5 ml blood sample will be withdrawn at the surgery start and at the surgery end
46068675|NCT05817890|Drug|Fadraciclib|Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-CYC065 Following a Single Oral Dose in Healthy Male Subjects
46068676|NCT05816785|Drug|Cetuximab|Week 1: loading dose of 400mg/m2; Week 2: 250mg/m2
46068677|NCT05816785|Drug|Imatinib|400 mg orally daily
46068678|NCT05813912|Drug|Insulin Icodec|Participants will receive subcutaneously insulin icodec once weekly for 52 weeks.
46068679|NCT05813912|Drug|Semaglutide|Participants will receive once weekly semaglutide subcutaneously starting from 0.25 mg and dose increased up to 1 mg for 26 weeks.
45610496|NCT03431753|Diagnostic Test|PSA, STHLM3 and mpMRI for PC detection|"Men who request a prostate specific antigen test from their general practitioner will be offered study participation.~Men with increased PC risk as judged from the STHLM3 test and/or an elevated PSA test will be offered an mpMRI examination."
45610497|NCT04902092|Behavioral|High Intensity Interval Training|Exercise sessions will commence with an initial 3-week accustomization period whereby training load will increase incrementally from 2 x 45min sessions with effort peaking at 60% VO2 max (week 1) increasing to 3 x 45minute with effort peaking at 80% VO2max (week 3). Participants will transition to the full HIIT protocol for the remaining weeks. The HIIT component will comprise a work-rest ratio of ≥1:1minutes, with alternating exertion epochs at >80% VO2max and <60% VO2max. As VO2max is likely to increase as fitness improves toward the end of the 3-month program, adjustments to HIIT will be made by the exercise physiologist based on real-time heart rate monitoring, ensuring greater accuracy in participants achieving their heart rate targets.
45610498|NCT04902092|Behavioral|Strength and Resistance Training|Exercise sessions will comprise a combination of strength, coordination and mobility exercises. The strength component will consist of 2-3 sets of resistance exercises at ≤70% of a predicted 1 repetition maximum, targeting all body segments. Heart rate tracking will occur to ensure participants do not exceed 70% v02 (or exceed Lactate Threshold).
45610499|NCT04309487|Diagnostic Test|ShuntCheck|The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
45610500|NCT03431675|Drug|Ciprofloxacin|Single-dose oral ciprofloxacin
45610501|NCT02424734|Drug|Ceftaroline Fosamil|Ceftaroline fosamil will be given at a dose of 6 mg/kg IV over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour).
45610502|NCT02424734|Drug|Ampicillin|Ampicillin IV is required for the first 48 hours if the presence of an organism that requires treatment with ampicillin cannot be excluded. Will be given as per local standard of care.
45610503|NCT02424734|Drug|Aminoglycoside|Optional, will be given as per local standard of care.
45758473|NCT03381872|Device|Intravascular imaging (IVUS or OCT)|"IVUS Reference site: Largest lumen, Plaque burden <50% Stent sizing: By measuring vessel diameter (external elastic membrane) at proximal and distal reference sites. The averaged value of the proximal and distal reference external elastic membrane diameter will be used as stent diameter~OCT Reference site: Most normal looking segment, No Lipidic plaque Stent sizing: [1] By measuring vessel diameter at the distal reference sites (in case of ≥180° of the external elastic membrane can be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25 mm.~[2] By measuring lumen diameter at the distal reference sites (in case of ≥180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25 mm."
46068680|NCT05813418|Biological|blood retriewal|blood retriewal for cytokine concentration measurement
46068681|NCT05812131|Behavioral|COPEWeb online training|COPE training delivered via online COPEWEb to providers
45445125|NCT05688891|Other|Music|"5 minutes before the burn dressing procedure, the patient was asked about the type of music he preferred in the introductory patient information form. Then, the patient was started to listen after putting on headphones and adjusting the volume. The patient was asked to keep his eyes closed while listening to music. Music listening was continued throughout the entire dressing.~After the process was finished, the music was turned off and the headphones were removed.~This procedure was performed during 2 dressing changes in accordance with clinical treatment and protocols.~A 1-week period was given between 2 dressings."
45445126|NCT03780777|Behavioral|Home Hazard Removal|Removal of home barriers or hazards
45610504|NCT03431597|Dietary Supplement|novel micronutrient|The supplements will be supplied to participants on a daily basis. The novel micronutrient supplement will be provided in powder form with instructions to dissolve one sachet in 250ml of clean water
45445127|NCT02748694|Drug|TAK-041|TAK-041 tablets or oral suspension.
45445128|NCT02748694|Drug|TAK-041 Placebo|TAK-041 placebo-matching suspension or tablet.
45610505|NCT03431597|Dietary Supplement|existing micronutrient supplement, UNIMMAP|UNIMMAP will be provided in tablet form and given one daily
45610506|NCT03435965|Diagnostic Test|AmnioQuickDuo+|AmnioQuickDuo+ kit for detection of PROM
45610507|NCT04283981|Device|Control group without use of VSP|The control group will include patients that undergo mandibular reconstruction via open reduction internal fixation (intraoral or extraoral approach) in standard fashion (without virtual surgical planning assistance and occlusal splint)
45610508|NCT04283981|Device|Treatment Group with use of VSP|The treatment group corresponds to patients undergoing mandibular reconstruction via open reduction internal fixation (intraoral or extraoral approach) utilizing virtual surgical planning via 3D Systems, bite registration and fabrication of occlusal splint via intraoral digital scanner, and mandibular hardware
45610509|NCT02424578|Drug|Diclofenac Capsules low dose|
45610510|NCT02424578|Drug|Diclofenac Capsules high dose|
45610511|NCT03435887|Behavioral|Alere q HIV-1/2 Detect for point of care infant testing|The investigators will pilot the Alere q HIV-1/2 Detect mobile system for point of care (POC) infant testing at two of the study hospitals. A blood sample will be collected from each HIV-exposed infants at birth (before discharge from Maternity or at first follow-up MCH visit within 14 days postnatal) and at 6-week EID visit (4-8 weeks postnatal) for analysis with Alere q HIV-1/2 Detect, with results available within 1-2 hours to enable mother notification at the same clinic visit.
45610512|NCT03435887|Behavioral|GeneXpert HIV-1 Qual for point of care infant testing|The investigators will pilot the GeneXpert HIV-1 Qual mobile system for point of care (POC) infant testing at two of the study hospitals. A blood sample will be collected from each HIV-exposed infants at birth (before discharge from Maternity or at first follow-up MCH visit within 14 days postnatal) and at 6-week EID visit (4 to <24 weeks postnatal) for analysis with GeneXpert HIV-1 Qual, with results available within 1-2 hours to enable mother notification at the same clinic visit.
46068682|NCT05812131|Behavioral|COPE In Person|COPE training provided in person to providers
45445129|NCT03785067|Drug|telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg|1 capsule taken orally once daily for 36 months
45445130|NCT03785067|Drug|Placebo oral capsule|1 capsule taken orally once daily for 36 months
45445131|NCT03780699|Procedure|Diagnostic hysteroscopic examination|The hysteroscopic criteria of the cesarean scar defect will be observed with comment on different niche features
45758474|NCT03381872|Device|Drug-coated balloon|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
45610513|NCT03435887|Behavioral|HIV DNA PCR testing (Standard of Care)|This is the standard of care for infant HIV testing. A dried blood spot sample will be collected from the infant and shipped to a central laboratory for HIV DNA PCR testing. Results will then be returned to the hospital.
45610514|NCT03431519|Procedure|VP|Percutaneous Injection of Strontium Containing Hydroxyapatite versus Polymethacrylate plus Short Segment Pedicle Screw Fixation
45610515|NCT03431285|Drug|Morphine Group|Patients will receive standard dose of morphine (0.1 mg/kg) in 100 ml normal saline infused over 30 min in addition to standard IV hydration.
45610516|NCT03431285|Drug|Ketamine Group|Patients will receive low dose ketamine 0.3 mg/kg in 100ml N.S. infused over 30 min in addition to standard IV hydration
45610517|NCT03431285|Other|standard IV hydration|IV hydration as per our institutional protocol (Lactated Ringer's or NaCl 0.9% solution will be infused at a rate of 2-3 ml/kg/h)
45610518|NCT02416934|Drug|Treatment 1; Dexamethasone|Dexamethasone IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
45758475|NCT02990585|Other|Back school|
45758476|NCT04158128|Other|non-intervention|non-interventional, prospective cohort study
45758477|NCT03331484|Drug|Ticagrelor|Ticagrelor 90 mg twice daily
45758478|NCT03331484|Drug|Rivaroxaban|Rivaroxaban 15 mg once daily (10mg for patients with moderate renal impairment, creatinine clearance: 30-50 mL/min by the Cockcoft Gault method)
45758479|NCT00721513|Biological|cetuximab|
45758480|NCT00721513|Drug|cisplatin|
45758481|NCT00721513|Drug|docetaxel|
45758482|NCT00721513|Drug|fluorouracil|
45758483|NCT00721513|Procedure|computed tomography|
45610519|NCT02416934|Drug|Treatment 0; Saline placebo|Saline (placebo) IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
45610520|NCT02819635|Drug|Placebo|Film-coated tablet for oral administration
45610521|NCT02819635|Drug|Upadacitinib|Film-coated tablet for oral administration
45610522|NCT03435809|Procedure|Intrauterine insemination|Obligatory use of a Pozzi forceps tenaculum during intrauterine insemination
45610523|NCT04912544|Device|Noninvasive Ventilation Mask Microphone|Noninvasive Ventilation Mask Microphone is turned on to enhance speech intelligibility during the intervention portion of the crossover feasibility study
45758484|NCT00721513|Procedure|positron emission tomography|
45758485|NCT00721513|Procedure|quality-of-life assessment|
45758486|NCT00721513|Radiation|3-dimensional conformal radiation therapy|
46068683|NCT05807399|Drug|Sutezolid|"STZ belongs to the oxazolidinone class of antibiotics and is currently under development for the indication treatment of TB.~Sutezolid is not licensed yet and will be dosed at 1200 mg once daily in arm 4"
45445132|NCT05688111|Drug|Tranexamic acid injection|Active group will receive 1gm Tranexamic acid 12 hourly for 48 hours
45610524|NCT03435731|Combination Product|Dual Therapy|Concomitant use of Continuous Positive Airway Pressure (CPAP) and Mandibular Advancement Splint (MAS) therapeutic devices.
45610525|NCT04914572|Other|Therapeutic rainforest mindful walking|A two-kilometer trail curated by the National Parks Board, Singapore. The walk will be led by Mindfulness Practitioner who volunteered to be guides for this study.
45610526|NCT04914572|Other|Therapeutic rainforest walk|A two-kilometer trail curated by the National Parks Board, Singapore. The walk will be led by volunteer guides recruited by the research team.
45610527|NCT04914572|Other|Campus Green walk|A two-kilometer trail curated by the Office of Facility Management, NUS. The walk will be led by volunteer guides recruited by the research team.
45610528|NCT03435653|Other|OFD with DFDBA|Control Group Open flap debridement with DFDBA Periodontal surgery will be performed in the form of open flap debridement along with placement of demineralized freeze dried bone allograft at the defect site.
45610529|NCT03435653|Other|OFD with decortication and DFDBA|Test Group Open flap debridement with decortication and demineralised freeze dried bone allograft Open flap debridement with decortication and placement of demineralized freeze dried bone allograft at the defect site.
45610530|NCT04914416|Dietary Supplement|Verum T1|Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
45758487|NCT00721513|Radiation|intensity-modulated radiation therapy|
45758488|NCT04139642|Device|SimpleSway|"During the 9-month period each practitioner who receives the balance + weight device is asked to provide anonymous feedback via a kiosk regarding if the balance data influenced clinical decision making after every patient. The kiosk has four marked buttons indicating a 4-point Likert Scale, so the practitioner just presses one of the four buttons to indicate their agreement with the statement, The balance measurement influenced my clinical decision making with this patient. After 9 months, the devices are switched so that every practitioner who had a weight only device receives balance + weight device and vice versa. After the second 9-month period concludes all devices will be retrieved by study personnel, and participants will be asked to complete surveys regarding their experience and attend group feedback sessions regarding their experiences."
45758489|NCT03314558|Other|pulmonary rehabilitation|a pulmonary rehabilitation program of 30 sessions, (3X1h/ week), will be followed by the COPD patients
45758490|NCT00706121|Drug|Vitamin E|400 IU daily by mouth for 7 - 12 years
45758491|NCT00706121|Drug|Selenium|200 mcg daily for 7 - 12 years
45758492|NCT00706121|Drug|Vitamin E placebo|1 pill by mouth daily for 7 - 12 years
45758493|NCT00706121|Drug|selenium placebo|1 pill by mouth daily for 7 - 12 years
45758494|NCT03251612|Drug|Based on sensitivity analysis|"5FU, infusional~Capecitabine~Oxaliplatin (FOLFOX)~Irinotecan (FOLFIRI)~FOLFOXIRI (triplet)~Bevacizumab~Panitumumab~Cetuximab~Regorafenib~Tas-102~Ramucirumab~Aflibercept~Pembrolizumab~Nivolumab~Vinorelbine and capecitabine~Sorafenib~Gemcitabine and capecitabine~Olaparib~Epirubicin"
46068684|NCT05807399|Drug|Rifampicin|Rifampicin will be dosed in a fixed high-dose (2100 mg for arms 1 and 2) or a weight-banded regular dose (10 mg/kg) in arm 3.
46068685|NCT05807399|Drug|Isoniazid|Isoniazid will be dosed at fixed dose of 300mg in arms 1 and 2, and regular dose of 5 mg/kg in arm 3.
45610531|NCT04914416|Dietary Supplement|Verum T2|Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
45610532|NCT04914416|Dietary Supplement|Verum T3|Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules
46068686|NCT05807399|Drug|Pyrazinamide|Pyrazinamide will be dosed in a fixed regular dose in arm 1 (1600 mg), a weight banded high dose in arm 2 (2000/2400 mg) or a weight-banded regular dose (25 mg/kg) in arm 3.
45610533|NCT04914416|Dietary Supplement|Verum T4|Verum T4 is a 17500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
45758495|NCT00746863|Drug|0.125% Marcaine|Patients randomized to the intervention arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
45610534|NCT04914416|Dietary Supplement|Verum T5|Verum T5 is a 17500AAIU/g white kidney bean extract. Daily dosage is 371 mg in 3 capsules
45610535|NCT04914416|Dietary Supplement|Verum T6|Verum T6 is a 34200AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
45610536|NCT04914416|Dietary Supplement|Verum T7|Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules
45758496|NCT04121156|Device|HD-tDCS treatment|2 milli Amp dose of HD-tDCS treatment for for 20 minutes, for 5 consecutive twice daily sessions
45610537|NCT04914416|Dietary Supplement|Verum T8|Verum T8 is a 34200AAIU/g white kidney bean extract. Daily dosage is 190 mg in 3 capsules.
45610538|NCT04914416|Dietary Supplement|Verum T9|Verum T9 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 1000 mg in 3 capsules
45758497|NCT04121156|Device|sham (placebo) HD-tDCS|Participants will receive sham (placebo) HD-tDCS for 20 minutes, for 5 consecutive twice daily sessions
45610539|NCT04914416|Dietary Supplement|Verum T10|Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules
45610540|NCT04914416|Dietary Supplement|Verum T11|Verum T11 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 900 mg in 3 capsules
45610541|NCT04914416|Dietary Supplement|Verum T12|Verum T12 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 600 mg in 3 capsules
45610542|NCT04914416|Dietary Supplement|Verum T13|Verum T13 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
45610543|NCT04914416|Dietary Supplement|Verum T14|Verum T14 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract. Daily dosage is 900 mg in 3 capsules.
45610544|NCT04914416|Dietary Supplement|Verum T15|Verum T15 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, Zinc, and, black currant leaf extracts. Daily dosage is 1000 mg in 3 capsules.
45610545|NCT04914416|Dietary Supplement|Verum T16|Verum T16 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, and Zinc. Daily dosage is 1000 mg in 3 capsules.
45610546|NCT04914416|Dietary Supplement|Verum T17|Verum T17 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
46068687|NCT05807399|Drug|Moxifloxacin|Moxifloxacin will be dosed at 600 mg orally once daily in arms 1-2, and 400 mg orally once daily in arm 4.
45610547|NCT03431207|Other|Standardized video recording for behaviors|"A standardized apparatus, scenario, and procedure was applied to record all the behavioral phenotypes with minimized background interference and stimulation.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the stage. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for over 5 minutes to ensure that behavioral phenotypes could be completely recorded."
45610548|NCT03435575|Device|Boosth|Boosth activity tracker which measures steps
45758498|NCT04115384|Drug|Novolin-R insulin|Insulin (Novolin-R) 20 IU/IN (0.1ml/10 units IN in each nostril), twice per day, once in the morning and again in the evening (at least 8 hours between doses) for 4 weeks.
45758499|NCT04385563|Drug|TQ-B211|Participants will receive TQ-B211 8 milligrams/kilogram (mg/kg) intravenously(iv.) on day 1 in Cycle 1 followed by 6 mg/kg iv.on day 1 in Cycles 2 to 8.
45758500|NCT04385563|Drug|Herceptin®|Participants will receive Herceptin® 8 milligrams/kilogram (mg/kg) intravenously(iv.) on day 1 in Cycle 1 followed by 6 mg/kg iv.on day 1 in Cycles 2 to 8.
45758501|NCT04385563|Drug|docetaxel|Participants will receive docetaxel 75 milligrams/square meter (mg/m^2) iv.on day 2 in Cycle 1 followed by 75mg/m^2 iv.on day 1 in Cycles 2 to 8.
45758502|NCT01279837|Behavioral|Pharyngocise|swallowing intervention by a speech language pathologist, consisting of the battery of isometric / isotonic exercises
46068688|NCT05807399|Drug|Bedaquiline|Bedaquiline will be dosed as 200 mg orally once daily for the first 8 weeks, thereafter 100 mg once daily in arm 4.
45610549|NCT03874325|Drug|Durvalumab|1500 mg Durvalumab will be administered intravenously every 4 weeks for 6 months.
45610550|NCT03874325|Drug|Anastrozole 1mg|Participants will self administer 1 mg anastrozole by mouth daily for 6 months.
45610551|NCT03874325|Drug|Letrozole 2.5mg|Participants intolerant to anastrozole will self administer 2.5 mg letrozole by mouth daily for 6 months. Exemestane may be substituted.
45610552|NCT03874325|Drug|Exemestane 25 MG|Participants intolerant to anastrozole will self administer 25 mg exemestane by mouth daily for 6 months. Letrozole may be substituted.
45610553|NCT02424344|Drug|Aclidinium/Formoterol|Aclidinium bromide/Formoterol fumarate FDC 400/12μg dry powder for oral inhalation twice daily via Genuair inhaler
45610554|NCT02424344|Drug|Placebo|Dose-matched placebo dry powder for oral inhalation twice daily via Genuair inhaler
45610555|NCT03435419|Diagnostic Test|LoopampTM Leishmania Detection Kit|LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection
45610556|NCT03435419|Diagnostic Test|CL DetectTM Rapid Test|CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection
45610557|NCT04914338|Other|Health Promotion|Participate in MDT-intervention
45610558|NCT04914338|Other|Quality-of-Life Assessment|Ancillary studies
45610559|NCT04914338|Other|Questionnaire Administration|Ancillary studies
45610560|NCT02423798|Device|Glucose sensor (Enlite)|This is a postmarket, interventional, open-label, non-randomized, single center clinical research trial. The trial will adopt a prospective single-sample design using the Yellow Spring Instruments (YSI) plasma glucose reference sampling procedure in the clinic and selfmonitoring of blood glucose (SMBG) plasma glucose reference sampling procedure at home. The trial will consist of 6 visits to the investigational site: a visit for informed consent procedures (Visit 0), a screening visit (Visit 1), 3 study visits (Visit 2-4) and a final examination (Visit 5).
45610561|NCT03861611|Drug|Ketorolac|Participants may be randomized to receive Ketorolac oral medication 10 mg, every 8 hours for 5 days as needed
45610562|NCT03861611|Drug|Ibuprofen|Participants may be randomized to receive Ibuprofen oral medication 600 mg, every 8 hours for 5 days as needed
45610563|NCT03861611|Drug|Diclofenac|Participants may be randomized to receive Diflofenac oral medication 50 mg, every 8 hours for 5 days as needed
45610564|NCT03861611|Behavioral|Educational Intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information
45610565|NCT01651208|Behavioral|Motivational Interviewing (MINT)|"We will hire a Latino and an AA nurse to deliver the interventions and will match their race/ethnicity with that of the subject. Past experience suggests that at 4-7 calls per subjects each lasting about 30-45 minutes, a nurse can carry a caseload of about 125-150 subject (we propose 125 per nurse) Each telephone encounter will have a patient centered approach having the following basic structure and goals:~a)Establishing a connection and reinforcing autonomy b)Empathizing with ambivalence and rolling with resistance.c)Coach the subject towards expressions of commitment."
45610566|NCT01651208|Behavioral|Mailed DVD|The DVD will have a documentary format that will engage subjects as the portrayed real patients relate their struggles and successes, that will entertain and ultimately motivate subjects to succeed in a similar way as the role models in the video. That personal connection will activate patients to address their own adherence issues and will show real life ways to deal with the health behaviors recommended post PCIS. Key concepts regarding adherence to medications and other behaviors will be imbedded in the story telling. The DVD will also feature a humanistic perspective of a cardiologist talking about his concerns for his patients that do not adhere to the antiplatelet therapy, the difficulties that his patients face, and the merit of the success stories he witnesses.
45758503|NCT03082898|Device|Indego Exoskeleton|Regular dosing of Indego Exoskeleton walking.
45610567|NCT03841409|Other|Collection of blood samples|Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.
45610568|NCT03128983|Device|Participants wear a sensor bracelet for collecting physiological data and conducted urine tests to estimate the day of ovulation|
45610569|NCT03435263|Other|home management|pregnant women presented with PROM will be randomized into 2 groups group a will be discharged home after initial assessment and group B will be admitted to hospital as usual
45610570|NCT03430817|Drug|Citicholine|Patients will receive 1 gram (2 vials of citicholine; each 500 mg) every 12 hours given slowly intravenous over 10 minutes for 7 days then oral form of the drug will be used. Participants who can swallow will receive 500-mg (5ml volume; 100mg/ml) oral drops (syrup) twice a day. Participants who cannot swallow will receive the same dose as oral drops syrup of citicoline through a nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG) tube in a total dose of 1000 mg/day for the remainder of the 30 days study period.
45610571|NCT03430817|Drug|Amantadine|Patients will receive 200 mg of amantadine sulphate in a 500 ml solution every 12 hours by slow intravenous infusion over a period of 4 hours for 7 days then oral form will be used. Participants who can swallow will receive two 100-mg tablets twice a day. Participants who cannot swallow will receive the tablets of amantadine through a NG tube or PEG tube as 400 mg via crushed tablets with a 25-mL saline or water flush for the remainder of the 30 days study period.
45758504|NCT03568838|Drug|Enoxaparin|Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin (0.75 mg/kg) pre PPCI followed by an infusion of 0.75 mg/kg over a 6-hour period to be started as soon as possible when PPCI starts.
45758505|NCT00726713|Other|Metanx (a medical food)|Metanx one tablet twice a day
45758506|NCT00726713|Other|Metanx placebo|Metanx placebo one tablet twice a day
45758507|NCT01272349|Other|Acute intermittent hypoxia|30 minutes of intermittent breathing low oxygen followed by walking on a body-weight support treadmill
45610572|NCT02383940|Drug|Sotagliflozin|Sotagliflozin 400 mg, once daily before the first meal of the day
45610573|NCT02383940|Drug|Placebo|Placebo, once daily before the first meal of the day
45610574|NCT03430739|Other|No intervention|No intervention
45610575|NCT03444415|Other|Motivational interviewing in groups|Intervention consists of six 90 minutes workshops, two of those during pregnancy and the other four within the following two years after the birth of the children.
45610576|NCT03444415|Other|Usual care|Parents will receive information about height, weight, and BMI percentile provided by a health professional during usual well child visits
45610577|NCT03799835|Drug|BCG|Intravesical administration OncoTice wil be used only under two conditions : BCG Medac® unavailable and the patient has received at minimum one instillation of BCG Medac®
45610578|NCT03799835|Drug|Atezolizumab|IV perfusion
45758508|NCT01272349|Other|Room air|30 minutes of breathing room air followed by walking on a body-weight support treadmill
45758509|NCT03089684|Other|No intervention|No intervention
45758510|NCT03087344|Device|Fibroscan and Acoustic Radiation Force Impulse|Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
45758511|NCT03087344|Device|Fibroscan|Liver stiffness will be measured before and after a standard meal is administered
45758512|NCT03087344|Device|Acoustic Radiation Force Impulse|Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
45758513|NCT00759187|Drug|Fluoride|Brush twice daily
46068689|NCT05807399|Drug|Delamanid|Delamanid will be dosed as 200 mg orally once daily in arm 4.
46068690|NCT05807386|Behavioral|Home-based exercise programme|A 12 week, online delivered, home-based exercise programme.
45610579|NCT02383862|Other|Feedback Group|The intervention will consist of feedback provided to clinicians in the form of patients' baseline PROMIS scores
45610580|NCT02521675|Behavioral|Usual algorithm|"The patient will be fitted with a CGMS (continuous glucose monitoring system) (data not shown) and it will be given the booklet to collect events + food survey~The patient goes home and he must perform 3 physical activities during the week (30-60 minutes) using its usual algorithms (glucose administration or adaptation of the BR), in the afternoon, and spacing them at least 24 hours :~Moderate activity 3 hours after lunch~Intense activity 3 hours after lunch~Moderate activity 90 min after lunch These activities should not exceed 1 hour in wherever possible"
45610581|NCT02521675|Behavioral|Diabrasport algorithm|"The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey~The patient goes home and he must perform 3 physical activities during the week (identical to those carried out during the week test algorithms usual and during comparable periods) using DIABRASPORT algorithms, the afternoon and in the spacing at least 24 hours:~Moderate activity 3 hours after lunch~Intense activity 3 hours after lunch~Moderate activity 90min after lunch These activities shall not exceed one hour"
45610582|NCT02521675|Behavioral|Rest|"The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey.~The patient goes home and he will not perform any physical activity during the week"
45610583|NCT02521675|Device|Holter Glycemic Ipro2, Medtronic|
45758514|NCT00759187|Drug|Triclosan/Fluoride|Half mouth toothbrushing twice daily for 4 days
46068691|NCT05805020|Procedure|cellvizio|During surgery an intravenous injection of fluorescein will be performed. The surgeon will, then, evaluate the ileal section margins on the mucosa, the serosa and the mesentery to evaluate if the section margin in microscopically inflammatory or not. She/he will then evaluate (in cm) the length between this section margin and the theorical section margin to be on a non-inflammatory tissue on the mucosa, serosa and mesentery. The data will be filled during surgery, blind from the pathological analysis. The pathological analysis will also be blind from the Cellvizio data. A video collection will be performed anonymously.
45758515|NCT00759187|Drug|Chlorhexidine Gluconate|Mouth rinsing twice a day for 4 days
45610584|NCT03784235|Other|18F NaF-PET/CT and cone beam CT scans|Cross sectional measures of 18F NaF-PET/CT and cone beam CT scans
45610585|NCT03442153|Dietary Supplement|Solgar No7 Complex|Solgar No7 Capsules
45758516|NCT04387175|Device|Carriere Motion 3D Class III Appliance|The device made of stainless steel consists of a flexible bar with two pads at the end which are bonded bilaterally with composite resin to the lower second deciduous molar or the lower first permanent molar at the rear and the lower deciduous canine at the front. The base on the lower deciduous canine has a hook to which bilaterally elastic latex bands are connected with the vestibular tubes of the cemented bands on the upper deciduous second molars (Force 2 elastics ) or on the first permanent upper molars (Force 1 elastics), on whose palatine surface the a rapid maxillary expander is welded.
45758517|NCT04387175|Device|Facial mask|The facial mask consists of a chin pad and frontal pad connected by a central steel bar. On the central bar there is a horizontal steel bar to which latex elastic bands are attached which develop 14 ounces of force. The elastics are connected to the rapid maxillary expander by means of two hooks welded on the bands of the second upper deciduous molars or the first upper permanent molars.
45758518|NCT03085940|Drug|Hydroxychloroquine|Hydroxychloroquine 400mg once daily initially
45758519|NCT03085940|Drug|Placebo|Placebo
45758520|NCT04100564|Device|Supraglottic airway device|Initial advanced airway management with a supraglottic device
45758521|NCT04100564|Other|Standard airway management|Initial advanced airway management with standard care method
45758522|NCT00727337|Behavioral|LACE-computer|Computerized Auditory Training
45758523|NCT00727337|Behavioral|PLACEBO-Directed listening|Subjects will be asked to listen to books on tape for 20 minutes a day and answer questions as they go along
45758524|NCT00727337|Behavioral|CONTROL|No specialized treatment will be provided in addition to standard of care audiology treatment provided with the provision of hearing aids
45758525|NCT00727337|Behavioral|Lace-DVD|DVD based Auditory Training
45758526|NCT01279915|Drug|ASP0456|oral
45610586|NCT03442153|Dietary Supplement|placebo|Placebo tablets Cellulose
45610587|NCT04896307|Other|Survey|Survey
45610588|NCT02383472|Device|MedX Health Console model 1100|"All treatments will be administered using the MedX Health Console model 1100. These units were cleared by the FDA as non-significant risk in 2003 and approved for home treatment use in 2005 for temporary increase in local blood flow circulation . . . for temporary relief of minor muscle and joint aches. Cluster heads are 2 inches in diameter. Each contains 9 red (633nm wavelength) diodes and 52 near infrared (870 nm wavelength) diodes. LED cluster heads would be applied to the frontal, parietal and temporal areas, as well as the mid sagittal suture line"
45758527|NCT01279915|Drug|Placebo|oral
45758528|NCT03809455|Drug|Fentanyl citrate|"Fentanyl citrate arm (FAR Arm): one intake of fentanyl citrate 100 µg (intranasal or buccal).~Placebo Arm: one intake of placebo (intranasal or buccal) The administration route will be left to the discretion of the investigator taking into account the patient's profile (capable of maintaining the sublingual tablet without swallowing, absence of nasal discharge…), and/or the patient's choice.~Medication Commercial name Formulation Administration route Dose Fentanyl citrate Pecfent® Nasal spray Intranasal 100 µg Fentanyl citrate Abstral® Sublingual tablet Buccal 100 µg For the cohort the choice of treatment by FAR is at the centres discretion, according to standard of practice.~Treatment duration: 1 day"
45758529|NCT03809455|Drug|Placebo|one intake of placebo (intranasal or buccal)
45758530|NCT02990273|Biological|Blood transfusion|
45758531|NCT01272427|Dietary Supplement|water with glucose|0.75 g/kg body weight of glucose added to water
45758532|NCT01272427|Dietary Supplement|water and whey protein|0.75 g/kg body weight of whey protein added to water
45758533|NCT01272427|Dietary Supplement|water with noncaloric sweetener|0.15 g of sucralose added to water
45758534|NCT03618134|Biological|Durvalumab|Given IV
45758535|NCT03618134|Procedure|Modified Radical Neck Dissection|Undergo modified radical neck dissection
45758536|NCT03618134|Other|Quality-of-Life Assessment|Ancillary studies
45758537|NCT03618134|Other|Questionnaire Administration|Ancillary studies
45610589|NCT02383472|Device|MedX Health Console model 1100-placebo|The placebo machine is identical in appearance as the treatment machine; It vibrates, warms, and does everything the treatment machine does except it does not have LED lights on the marker, therefore it cannot emit light. Subjects enrolled in the placebo group will be on the same schedule as the treatment group. They will have two, 10 minute treatments, three times a week totaling 18 visits. The placebo allows the researchers to isolate the effect of the study treatment. If patient's in the LED treatment group fare significantly better than those in the placebo treatment group, the study helps support the conclusion that the LED therapy is effective.
45758538|NCT03618134|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45610590|NCT03729947|Device|Subfascial closed suction drain|Ch 14 closed suction drain
45610591|NCT02412553|Other|Specific carbohydrate diet|
45610592|NCT02412553|Other|Elemental diet|
45610593|NCT05370638|Other|Rounding on discharging patients first|Rounding on discharging patients meant that the attending physician and accompanying team (i.e. if they were working with advanced practice providers or learners) would prioritize seeing any patients that were going to discharge that day. The attending could break protocol if needed for patient care purposes and this was tracked each day.
45610594|NCT03430583|Drug|MZ101|Drug
45610595|NCT03435029|Behavioral|Cognitive Remediation Program (REHACOP)|The REHACOP group received cognitive remediation sessions 3 times per week for 3 months in 60 minute per session. The rehabilitation consisted of 39 sessions divided into: attention and concentration unit (sustained, selective, alternating, and divided attention) 4 weeks; learning and memory unit (verbal and visual memory and learning strategies) 3 weeks; language (verbal fluency, syntax, grammar, vocabulary, and comprehension) 3 weeks; and executive functioning (objectives planning and attainment, verbal reasoning, categorization, and conceptualization). In addition, processing speed was trained transversely during all the sessions.
45610596|NCT03435029|Other|Occupational Therapy|The control group received occupational group activities (reading the newspaper, drawing, singing or doing crafts) with the same frequency and format as the experimental group.
45610597|NCT03430505|Device|Bilevel|Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, IPAP 12 and EPAP 8 bilevel applied for 10 minutes, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
45610598|NCT03430505|Drug|Albuterol|Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, 400 micrograms inhaled Albuterol, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
45610599|NCT03434951|Drug|Bupivacaine Hydrochloride, Spinal|Intrathecally administered 12,5mg bupivacaine for spinal anaesthesia
45610600|NCT03434951|Drug|Morphine hydrochloride, Spinal|Intrathecally administered morphine 0,2mg (2mg/ml, 0,1ml)
45610601|NCT03434951|Drug|Placebo - Concentrate|Intrathecally administered saline solution 0,9% 0,1ml to match morphine volume
45610602|NCT04450589|Dietary Supplement|ALRV5XR|"ALRV5XR oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
45610603|NCT04450589|Other|ALRV5XR Shampoo|"ALRV5XR Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
45758539|NCT03618134|Procedure|Transoral Robotic Surgery|Undergo TORS
45758540|NCT03618134|Biological|Tremelimumab|Given IV
45758541|NCT02997059|Drug|Fluconazole|200 mg/ day
45758542|NCT02997059|Other|Placebo|
45758543|NCT01279993|Procedure|Kerato refractive Surgery|This interventional case series was performed on 297 eyes of 150 patients who were candidates for PRK. Complete ophthalmic evaluations focusing on orthoptic examinations were performed before and 3 months after PRK.
45758544|NCT02990117|Other|No Intervention|No Intervention
45758545|NCT03162536|Drug|Nemtabrutinib|Nemtabrutinib will be orally administered once per day under fasted conditions (1 hour prior to or 2 hours after a meal) and is available in tablets in strengths of 5 mg or 20 mg. For Expansion Food Effect Cohort I, nemtabrutinib will be orally administered once per day under fasted and non-fasted condition.
45758546|NCT00759811|Drug|Methotrexate|"Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks."
45758547|NCT00759811|Drug|Placebo|"Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks."
45758548|NCT03085628|Drug|Oxytocin|40IU
45758549|NCT03085628|Drug|Placebo|40IU
45758550|NCT00694577|Radiation|Partial Breast Irradiation using 32 Gy / 8 fractions|32 Gy-8 Treatments, 4 Treatment Days
45758551|NCT00694577|Radiation|Partial Breast Irradiation using 36 Gy / 9 fractions|36 Gy- 9 Treatments, 4 1/2 Treatment Days
45758552|NCT00694577|Radiation|Partial Breast Irradiation using 40 Gy /10 fractions|40 Gy-10 Treatments, 5 Treatment days
45610604|NCT04450589|Other|ALRV5XR Conditioner|"ALRV5XR Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
45758553|NCT02990039|Behavioral|Counseling letter|The intervention is based on the Health Action Process Approach. The first letter provides information on knowledge regarding sedentary time and physical activity as well as intervenes on self-efficacy depending on the mindset of participants (non-intender, intender, actor). The second letter focuses on benefits and barriers of physical activity as well as the role of social support for physical activity. In case of actional stage, the third letter intervenes on self-efficacy again and suggests action and coping planning. Otherwise, the letter includes ipsative feedback according to the second letter.
45758554|NCT02996747|Procedure|curettage (intralesional surgery)|comparison of two different tumors treated by curettage
45758555|NCT04397666|Diagnostic Test|conjunctival RT PCR|conjunctival sample in covid-19 patients
45758556|NCT01276613|Drug|Gemcitabine|Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min.
45610605|NCT04450589|Other|ALRV5XR Hair Follicle Serum (Nutriment)|"ALRV5XR topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
45610606|NCT04450589|Dietary Supplement|Placebo|"Placebo oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
45610607|NCT04450589|Other|Placebo Shampoo|"Placebo Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
45758557|NCT01276613|Drug|Losartan|50 mg by mouth daily for one week and 50 to 100 mg of Losartan by mouth daily for at least 1 week and at most 3 weeks prior to surgical resection.
45758558|NCT03077594|Device|Mucosal Impedance|Aim 1: Mucosal impedance will be measured by an endoscopic probe 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Mucosal impedance will be measured 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
45610608|NCT04450589|Other|Placebo Conditioner|"Placebo Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
45610609|NCT04450589|Other|Placebo Hair Follicle Serum (Nutriment)|"Placebo topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
45758559|NCT03077594|Other|Research Biopsies|Aim 1: Research biopsies will be obtained at 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction, and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Aim 2: Research biopsies will be taken 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
45758560|NCT03077594|Device|Volumetric Laser Endomicroscopy|Aim 2: Volumetric laser endomicroscopy will be done and marked at 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
45758561|NCT02428205|Drug|Propranolol|Participant will receive Propranolol prior to each EIBI session
45445133|NCT05688111|Other|Glucose water 5%|Placebo group 30ml will be received 12 hourly for 48 hours
45445134|NCT02059018|Drug|COX-inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
45758562|NCT02428205|Drug|Placebo|Participant will receive placebo prior to each EIBI session
45758563|NCT01276691|Drug|81 mg enteric coated aspirin|81 mg enteric coated aspirin will be provided both as an acute dosage immediately prior to firefighting (1 hour pre-activity) and as a 14 day dosage prior to firefighting
45610610|NCT03430271|Other|Physical Activity Intervention|Participants in this arm will complete exercise sessions 1 time per week for 24 weeks. An optional, second PA session will also be offered to PA participants. The exercise sessions will be multimodal and involve walking, lower extremity strengthening exercises, flexibility and balance training.
45758564|NCT04398836|Dietary Supplement|Exclusive Enteral Nutrition|Mulnourished patients will drink an enteral polymeric formula suited to their energy expenditure calculated by 25-30 kcal/kg and at least 1 gr/kg of protein, a minimum of 1500 ml (1500 kcal, 54 gr of protein). The amount of formula to achieve nutritional requirements are based on body weight, but the average intake is of 6-8 cups of formula (36-48 scoops of formula mixed with 1260-1680 ml of water to achieve a concentration of 1 kcal per ml). During this period patients will be guided to avoid eating and drinking anything but the enteral formula. The formula will be supplied to the patients by the investigators. The formula used for this study will be VITAL - suitable for people with disease-related malnutrition and malabsorption. Vital 1.5kcal is peptide-based, nutritionally complete formulation for the dietary management of active phase of Crohn's disease. VITAL includes all the nutritional macro and micronutrients and can serve as a sole source of nutrition.
45610611|NCT03430271|Other|Healthy Aging Intervention|Participants will attend health education workshops on topics of relevance to older adults. Workshops will be offered weekly in a group setting, and participants will be required to attend biweekly.
45610612|NCT02234323|Biological|rFVIIIFc|Administered as specified in arm description
45610613|NCT03434873|Other|magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks
45610614|NCT03430193|Other|FIRM|"FIRM program consisted of total 10 days session including PT, in two times twenty-minute sessions per day and 4 times OT during admission initiated before transfer to rehabilitation ward.~PT (Weight bearing exercise, strengthening exercise, gait training, aerobic exercise and functional training) progressed gradually based on individual functional level and OT of activities of daily life (ADL) training (transfer, sit to stand, bed mobility, dressing, self-care retraining and using adaptive equipment) was provided."
45445135|NCT02059018|Drug|Nitroglycerin|Oral administration of tablet nitroglycerin 0,5mg 5 minutes before recordings of diameter changes of retinal vessels are initiated
45610615|NCT03430193|Other|Conventional rehabilitation|Conventional rehabilitation program consisted of total 10 days session of PT focused on simple standing and gait training, in one time twenty-minute sessions per day.
45610616|NCT05078203|Behavioral|Exercise|36 minutes of Exercise
45610617|NCT03128255|Other|Assessment of already preacquired I-124 PET/US|Assessment of preacquired I-124 PET/US by review of anonymous digital case files
45610618|NCT03128645|Device|Abdominal Corset|The patient's colonoscopy procedure in group 2 after randomization will be performed with the abdominal corset.
45610619|NCT03429959|Device|SOCKNLEG|Donning and doffing success compared with the two study stockings, wearing the assigned study stocking for a day, Patient Quesationnaire on donning and doffing success and wearing comfort of each study stocking
45610620|NCT03429959|Device|SIGVARIS Cotton|SIGVARIS Cotton
45758565|NCT04398836|Other|High energy / protein diet.|Mulnourished patients will receive a high energy / protein diet.
45758566|NCT04398836|Other|Standard nutrition|Well nurished patients will receive a standard nutrition
45758567|NCT04398602|Behavioral|behavior of the leader|A study investigator, expert in both PPH and simulation debriefing, not involved in the simulation, observed each scenario to record and check the team's technical skills according to the established 23 PPH key tasks. The behavioral scores were assigned by two independent observers, experts in communication and evaluation in simulation, who reviewed the videos of each simulation each simulation all participants were asked to complete a survey related to the leader and the team behaviors. Questions required a yes/no answer or an answer based on an ordinal scale (1=poor, 5=excellent).
45758568|NCT03081416|Drug|Ketamine|Intranasal ketamine administration
45758569|NCT03081416|Drug|Normal saline|
45758570|NCT03081416|Drug|Metoclopramide|Standard therapy
45758571|NCT03081416|Drug|Ketorolac|standard therapy
45758572|NCT03081416|Drug|Dexamethasone|Standard therapy
45758573|NCT03081416|Drug|Benadryl|Standard therapy
45758574|NCT00706589|Drug|aripiprazole|Initial dose : 2mg, Maximum dose : 20mg
45758575|NCT00706589|Drug|placebo|Initial dose: 2mg, Maximum dose:20mg
45758576|NCT03080402|Device|Mechanical Perturbation Training|The training program will consist of three stages and subjects will progress through each neuromuscular training stage.The training will consist of double- to single-limb movements with progression of jumping, hopping, and pivoting maneuvers on the perturbation device with an emphasis on proper technique and landing. The initial four sessions will focus on primarily on jumping and hopping maneuvers on double- and single-limb in the sagittal plane. The intermediate four sessions will incorporate additional medial and lateral maneuvers with the plyometric tasks. The final four sessions will incorporate rotational and pivoting activities with the maneuvers. The resultant protocol has been derived and optimized from previous published research studies and prevention techniques.
45758577|NCT01276769|Drug|Paclitaxel plus carboplatin|"Paclitaxel 175 mg/m2 D1 i.v., carboplatin AUC=5 D2 i.v.~1 cycle = 21days 2-6cycles"
45758578|NCT01276769|Drug|Paclitaxel and epirubicin|"Paclitaxel 175 mg/m2 D3 i.v.,Epirubicin 75mg/m2 D1，2 i.v.~1 cycle = 21days~2-6cycles"
45758579|NCT01279681|Biological|bevacizumab|Given IV
45758580|NCT01279681|Drug|capecitabine|Given PO
45758581|NCT01279681|Drug|fluorouracil|Given IV
45758582|NCT01279681|Drug|leucovorin calcium|Given IV
45758583|NCT01279681|Drug|oxaliplatin|Given IV
45445136|NCT02059018|Drug|COX-inhibitor + Nitroglycerin|Combination of COX-inhibitor and nitroglycerin interventions.
45445137|NCT03780465|Drug|Oral idronoxil suspension|Idronoxil powder up to 150 ml ORA-BLEND® flavoured syrup
45445138|NCT03780465|Drug|NOX66 (A)|Idronoxil formulated in suppository base A
45445139|NCT03780465|Drug|NOX66 (B)|Idronoxil formulated in suppository base B
45445140|NCT02059096|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
45610621|NCT03434639|Diagnostic Test|Spectroscopic gut permeability test|"The spectroscopic gut permeability test first involves patients receiving an oral dose of one or more fluorescent dyes. A wearable sensor will then be attached to the patients' skin and this will be used to monitor the leakage of the fluorescent dyes from the intestine into the blood stream in a non-invasive manner. In this way, a measure of the permeability of the intestine will be obtained.~Note that patients in Group 1 (ophthalmology patients) will not receive oral doses of contrast agents. Instead, the wearable sensor will simply be used to detect the presence of fluorescent dyes that were administered intravenously as part of planned ophthalmic procedures.~Complete details of the spectroscopic gut permeability test can be found in the attached protocol."
45610622|NCT03128177|Dietary Supplement|Dietary sodium|High (6 g) versus low (1.5 g) sodium diet
45610623|NCT03434483|Procedure|Assessment of the atherosclerotic plaque in a moderate lession.|"In patients who have been successfully revascularized the artery responsible for AMI and also present an intermediate lesion (40-80%) in another coronary territory, the clinical care protocol of the Cardiology Service stipulates the need for a physiological assessment with guidance of pressure (FFR).~The thickness of the fibrous cap shall be measured using optical coherence tomography.~In addition to the FFR measurement, a complete physiological assessment with a Doppler-pressure guide. This will allow the procedure to be performed without additional risk to the patient. The physiological study will include the analysis of endothelium-dependent vascular function and endothelium-independent vascular function."
45610624|NCT03434483|Genetic|Gene variants in atherosclerosis|From the blood samples of the patients, the total DNA will be extracted and the main functional variants identified in the literature will be genotyped
45610625|NCT03434483|Other|Microbiota analysis|From the samples of blood, feces, oral cavity and blood, the DNA of the microbiota will be extracted using specific extraction kits and the microbiome will be analyzed through the study of 16S ribosomal RNA amplicons.
45610626|NCT03434483|Other|Immunological analysis|A study of immunological cell populations and cytokines will be carried out from fresh blood samples using antibody panels and flow cytometry
45610627|NCT03434483|Other|Clinical evaluation|Clinical evaluation including hemostasis and biochemical studies and questionaries for diet and exercice registration
45610628|NCT03434405|Behavioral|SocialMind|SocialMind is a mindfulness-based intervention including elements such as radical acceptance, decentering or meditation-techniques. It is designed to target social cognition, defined as the ability to recognize, understand and benefit from social stimuli.
45610629|NCT03434405|Behavioral|Psychosocial treatment|Treatment as usual delivered by patient's practitioner
45758584|NCT01276925|Drug|Ropivacaine|7,5 mg/ml. 10 ml for the femoral nerve, 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
45911421|NCT02007928|Other|Rispéridone, aripiprazole, olanzapine|"Study:~We propose a prospective, interventional multicenter study.~Method:~Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.~The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug."
46068692|NCT05800028|Behavioral|Learning new information|The purpose of this study is to test the effects of different social contexts when learning new information. Participants in the AD, SPPA, and HC experimental groups will be given tests to learn verbal information (location of drawings in a grid). The learning phases of these tests are presented in the form of a memory game in which participants are asked to make pairs of drawings by finding the second copy of the proposed pair by trial and error in a grid. After learning, a task of recognizing the position of the drawings in the grid is performed. Each participant will carry out this learning in three different conditions: 1) learning alone, 2) learning by observation of the reconstruction of the pairs of images by a partner, and 3) collaborative learning in which the two game partners discover and reconstruct the pairs together.
45610630|NCT03434405|Drug|Psychotropic treatment|Treatment as usual delivered by patient's practitioner
45610631|NCT03434327|Other|Strength Training|Eleven resistance training exercises performed on pneumatic resistance training machines using 2 second concentric and 3 second eccentric contractions at 75-80% of each subjects maximal strength. Subjects will perform 3 sets per exercise, two times per week for 12 weeks.
45610632|NCT03434327|Other|Power Training|Eleven resistance training exercises performed on pneumatic resistance training machines using maximum speed concentric and 3 second eccentric contractions at the load that produces the highest power for the individual. Subjects will perform 3 sets per exercise, two times per week for 12 weeks.
45758585|NCT01276925|Drug|Ropivacaine|7,5 mg/ml. 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
45758586|NCT01276925|Device|Ultrasound|All nerve blockades will be performed with ultrasound guidance.
45758587|NCT01276925|Procedure|Peripheral nerve blockade|All patients will receive injections around the three nerves before surgery.
45911422|NCT02007941|Drug|CKD-501|From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .
46068693|NCT05798390|Drug|Bempedoic acid and/or its fixed dose combination with ezetimibe|This is a non-interventional study. No study medication will be provided as part of this protocol to the patients. Medications will be as prescribed by the treating physician in line with clinical practice.
46068694|NCT05796401|Behavioral|Cognitive training|"Cognitive reinforcement using digital applications (PSYCARE application) during 12 weeks~+/- virtual reality based cognitive remediation application : 24 sessions over 12 weeks (only for patients who have a higher cognitive deficits (TMTB score >110s))"
45610633|NCT04449419|Other|There is not intervention.|There is not intervention
45610634|NCT03429881|Procedure|Stripping versus laser CO2|Patients were randomly selected to undergo either CO2 laser vaporization (L group) or laparoscopic stripping (S group) of OE.
45610635|NCT03650699|Device|Electropalatography Biofeedback Training|The study agent is electropalatography (EPG). The LinguaGraph EPG device is a biofeedback technology that creates a digital visualization of tongue function during speech. The visualization is accomplished by a custom made mouthpiece that fits over the hard palate with 62 sensors that capture tongue position. The information from the sensors in the mouthpiece, as well as the audio output, is processed in an EPG Unit that converts the information from mouthpiece to a visual representation on a computer screen. The visual information with respect to tongue position can be used to provide biofeedback training.The computer can be used in the clinic during a patient visit or it can be seen over the internet with the patient at home and the speech and language pathologist at the clinic.
45445141|NCT01308801|Device|active rTMS + rehabilitation exercise|14 weeks program of active repetitive transcranial magnetic stimulation associated with rehabilitation exercise
45610636|NCT03434171|Behavioral|Aerobic excercise|practiced treadmill exercise program for 30 minutes at 60% to 70% of maximum heart rate. The treatment sessions will be repeated 3 times per week for 12 weeks
45610637|NCT03434171|Dietary Supplement|soy products|diet modification contains soy products (phytoestrogen) such as soy milk and soy beans every day for 12 weeks only
45610638|NCT03434093|Device|Transcranial Magnetic Stimulation (TMS)|Description: This will comprise single and repeated paired-pulses delivered over motor and non-motor areas.
45610639|NCT03434093|Behavioral|Working Memory Task|This will consist in remembering an item presented 1 to 5 steps before the inquiry. This task will span the whole duration of the functional MRI acquisition.
45610640|NCT04247399|Other|Simulation-based learning|Pre-clinical simulation-based learning at Simbionix GI-mentor II virtual reality simulator and OGI CLA 4 phantom.
45610641|NCT03642587|Other|There is no intervention in this study.|There is no intervention in this study.
45610642|NCT03429725|Other|Online prime (statements writing)|Participants to write statements describing themselves or their similarities to their community.
45610643|NCT03429725|Other|Online prime (circling)|Participants to circle either pronouns denoting themselves or pronouns denoting others.
45610644|NCT03429725|Other|Online prime (Sumarian Warrior)|Participants read a passage which described the factors that led to his success in a war.
45610645|NCT03429725|Other|Online prime (all)|Participants wrote statements, circled pronouns, as well as read the Sumarian Warrior passage.
45610646|NCT03128567|Device|Stimulation of the subthalamic nucleus|Stimulation of the subthalamic nucleus
45610647|NCT03429647|Diagnostic Test|visible light spectroscopy|Sigmoid perfusion was assessed using visible light spectroscopy
45610648|NCT02414828|Biological|Placebo|This is the identical buffer solution in which AERAS-402 is formulated. The placebo (1.0 mL volume) was administered by intramuscular (IM) injection to the deltoid area on Study Day 0 for groups 1 and 2 and Study Day 0 and 42 for group 3.
45610649|NCT02414828|Biological|AERAS-402 3 x 10^8 vp|AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0
45610650|NCT02414828|Biological|AERAS-402 3 x 10^9 vp|AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0
45610651|NCT02414828|Biological|AERAS-402 3 x 10^10 vp|AERAS-402 was administered by intramuscular (IM) injection to the deltoid area on Study Days 0 and 42.
45610652|NCT04450433|Diagnostic Test|aortic dissection and healthy people|Differential expression of metabolites in patients with aortic dissection and healthy people
45610653|NCT02413346|Drug|Sarecycline|Administered based on participant's body weight.
45758588|NCT01276925|Drug|Saline|Isotonic. 10 ml for the femoral nerve.
45758589|NCT01276925|Procedure|Total hip arthroplasty|All patients undergoes total hip arthroplasty.
45758590|NCT01276925|Drug|Bupivacaine|5 mg/ml. 3 ml for spinal anaesthesia.
45758591|NCT01272505|Procedure|converntional SILC|
45758592|NCT01272505|Procedure|Harmonic scalpel Single incision laparoscopic cholecystectomy|
45758593|NCT00728507|Drug|Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid|Rifapentine:150mg tablets, dose = 300mg for subjects <= 45kg and 450mg for those >45kg by mouth once a day for 8 weeks; Moxifloxacin 400mg tablet by mouth once a day for 8 weeks, Isoniazid and Pyrazinamide per standard of care for TB treatment.
45758594|NCT00728507|Drug|Isoniazid, Rifampin, Pyrazinamide, Ethambutol|Administered per standard of care for TB treatment
45911423|NCT02007993|Other|PDT|"A single session of PDT will be performed with the Chimiolux® photosensitizer at a concentration of 0.005% applied over the middle and posterior thirds of the dorsum of the tongue.~Nine points will be irradiated, the device will be previously calibrated with a wavelength of 660 nm, power of 100 mW, energy of 9 joules for 90 seconds per point in Groups 2 and 4 and 12 joules for 120 second per point in Groups 3 and 5"
45911424|NCT02007993|Other|Tongue Scraper|The pacient will scrap the tongue 10 times.
45445142|NCT01308801|Device|placebo rTMS+ rehabilitation exercise|14 week program of placebo repetitive transcranial magnetic stimulation associated with rehabilitation exercise
45758595|NCT03056534|Device|R3 Biolox Delta Ceramic Acetabular System|All study related procedures with the R3 delta Ceramic Acetabular System must be performed according to the recommended surgical technique described in the labeling and in the instructions for use (IFU).
45758596|NCT01279057|Drug|Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals)|Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
45758597|NCT01279057|Drug|Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray|Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
45758598|NCT01279057|Drug|Placebo|Placebo nasal spray administered once daily (4 actuations) for 14 days.
45445143|NCT01561209|Drug|Amitryptiline|Amitryptiline 5 mg before bedtime for 2 months
45610654|NCT04450121|Device|Patients will be intubated using Air-Q airway|"Both groups:~Grade 1: Split airway provides an unobstructed path for bronchoscope from mouth to glottis.~Grade 2: Tongue rests against posterior pharyngeal wall causing partial obstruction to bronchoscope.~Grade 3: Epiglottis rests against posterior pharyngeal wall causing partial obstruction to bronchoscope.~Grade 4: Tongue and epiglottis rest against posterior pharyngeal wall, both causing partial obstruction to bronchoscope.~Grade 5: Tongue rests against posterior pharyngeal wall causing total obstruction to bronchoscope (failure).~Grade 6: Epiglottis rests against posterior pharyngeal wall causing total obstruction to bronchoscope (failure)"
45445144|NCT01561209|Drug|Placebo|"Placebo pill~1 before bedtime"
45445145|NCT01308879|Behavioral|Contextualized Feedback Systems (CFS)tm|After clinical questionnaires are entered, an automated feedback report is available online weekly to clinicians (and supervisors) in the experimental group. The report shows current mental health status of youths, alerts, and trends over time. Reports also show some clinical data on youths' caregivers.
45610655|NCT03585257|Biological|25% IV albumin|"Intravenous 25% albumin infusion 1.0 g/kg body weight (maximum 100gm) once a week for five weeks for a maximum of 5 infusions. These infusions will be administered over sixty minutes per clinical treatment protocols for this population. Patients and investigators will be blinded as to the characteristic of the infusion. Pre-infusion serum albumin will be checked and if >4.0gm/dl, then normal saline will be given instead as mentioned in the blinding section above. Samples will be collected before and one hour after the infusion for all patients.~The total grams of albumin infused over the 4 weeks during and outside the study will be collected and compared between groups."
45610656|NCT03585257|Other|Placebo|"Normal saline infusion 1.0g/kg body weight once a week for five weeks for a maximum of 5 infusions. These infusions will be administered over sixty minutes per clinical treatment protocols for this population. Patients and investigators will be blinded as to the characteristic of the infusion. Pre-infusion serum albumin will be checked and if >4.0gm/dl, then normal saline will be given instead as mentioned in the blinding section above. Samples will be collected before and one hour after the infusion for all patients.~The total grams of albumin infused over the 4 weeks during and outside the study will be collected and compared between groups."
45610657|NCT03433937|Device|Negative pressure wound therapy|Wound dressing
45445146|NCT03780231|Other|non-ischemic scar|"non-ischemic LGE with no underlying labelled cardiomyopathy is detected on CMR"
45445147|NCT02800642|Drug|Aflibercept (Eylea, BAY86-5321)|The recommended dose for intravitreal aflibercept was 2 mg equivalent to 50 μL. Study treatment was administered at baseline and at monthly intervals until stabilization of disease. When stability was achieved, the treatment interval could be extended based on visual and anatomic outcomes as judged by the treating investigator.
45610658|NCT03433937|Other|Micropore tape|Wound dressing
45610659|NCT03433859|Drug|OnabotulinumtoxinA|OnabotulinumtoxinA in intradermal Injections on residual lower limb : 100 Units - 1 dose
45610660|NCT03433859|Other|Topical Aluminium Chloride (cosmetic product)|Topical Aluminium Chloride (cosmetic product) : 1 quantity sufficient on the lower limb
45610661|NCT03558893|Behavioral|Forced Desynchrony|All sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
45610662|NCT03429569|Drug|Cross linking|Accelerated cross-linking procedure: (Total duration: 40 minutes)
45610663|NCT03429491|Dietary Supplement|Placebo|Protein-free, LC n-3 PUFA-free juice based supplement
45610664|NCT03429491|Dietary Supplement|Leucine-enriched protein|Leucine-enriched whey protein
45610665|NCT03429491|Dietary Supplement|LC n-3 PUFA|LC n-3 PUFA
45610666|NCT03429257|Other|Exposures of interest: Maternal EED and Aflatoxin Exposure|Maternal EED, measured via lactulose: mannitol (L:M) ratios and serum concentrations of antibodies to the bacterial components flagellin and lipopolysaccharide (LPS); Maternal aflatoxin exposure, measured via serum concentration of AFB1-lysine adduct
45610667|NCT03429179|Drug|Butorphanol|intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
45610668|NCT03429179|Other|Physiological saline|intravenous infusion of the same volume of 0.9% saline
45610669|NCT03429101|Drug|Poziotinib|Poziotinib is a tablet for oral administration.
45610670|NCT03429101|Drug|T-DM1|T-DM1 (ado-trastuzumab emtansine) is a HER2-targeted therapy for I.V. administration.
45911425|NCT02008006|Drug|BeEAM|"High Dose Chemotherapy (HDT) containing :~Bendamustine 160 mg/m2 for 2 days (D-8 and D-7)~Etoposide 200 mg/m2 and Cytarabine 400 mg/m2 for 4 days (D-6 to D-3)~Melphalan 140 mg/m2 on D-2~HDT will be followed by an Autologous Stem Cell Transplantation on D0"
45911426|NCT02008019|Drug|Everolimus 2.5 mg/day|Comparison between 2,5 mg/day of Everolimus per os to 10 mg/day, or to no treatment, taken during 30 days before chondrosarcoma surgery
45911427|NCT02008019|Drug|Everolimus 10 mg/day|Comparison between 10 mg/day of Everolimus per os to 2.5 mg/day, or to no treatment taken during 30 days before chondrosarcoma surgery
45445148|NCT01308957|Dietary Supplement|Omega-3 fatty acids|4 grams per day for 24 weeks
45445149|NCT01308957|Dietary Supplement|corn oil|4 grams per day for 24 weeks
45445150|NCT02056600|Drug|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
45445151|NCT02056600|Drug|gemigliptin/metformin HCl sustained release|Administration of combination of gemigliptin 50mg/metformin HCl sustained release 1000mg, for 1day.
45445152|NCT03780309|Behavioral|Exercise Self-Monitoring|Participants engaged in exercise self-monitoring utilizing a traditional calendar recording method and heart rate monitor.
45445153|NCT03780309|Behavioral|Blood Pressure Self-Monitoring|Participants engaged in blood pressure self-monitoring by measuring blood pressure twice daily and before and after exercise.
45758599|NCT01277003|Device|Aculife Magnetic Wave Therapist|two therapeutic points, each for 15 minutes
45610671|NCT03525431|Diagnostic Test|Whole Exome Sequencing|Whole Exome Sequencing is a form of Next Generation Sequencing allowing investigators to assess the coding regions of many thousands of genes to find variants implicated in disease.
45758600|NCT01277003|Device|TENS|tow therapeutic points, each for 15 minutes
45610672|NCT04173689|Device|Threshold IMT|7 days a week, 2 times a day 15 min each
45610673|NCT04173689|Other|breathing exercises combined with upper extremity and trunk|upper extremity and trunk exercises combined with breathing exercises for 7 days a week, 2 times a day for 15 minutes each
45758601|NCT05249738|Diagnostic Test|Measuring tongue cross-sectional area by submental ultrasonography|The tongue cross-sectional areas of both groups were measured with submental ultrasonography to detect tongue edema.
45445154|NCT01313793|Drug|Treatment A-B|Subjects to receive 3 X 15 mg tablets of the clinical formulation in first period then 1 x 45 mg tablet of the commericializable formulation in 2nd period.
45610674|NCT03433625|Behavioral|Behavioural experiments for intolerance of uncertainty (BE-IU)|CBT
45610675|NCT04449575|Other|eSwabs|from skin
45610676|NCT03433547|Procedure|Buckle|Surgical procedures of macular buckling
45610677|NCT03433547|Procedure|Vitrectomy|Surgical procedures of small gauge vitrectomy
45610678|NCT03433547|Other|Limbal paracentesis|Drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis
45610679|NCT03433547|Other|Gas injection|Inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous cavity through pars plana.
45610680|NCT03433547|Other|Peeling internal limiting membrane|Peeling internal limiting membrane with forceps
45610681|NCT03433547|Other|Gas tamponade|Filling the vitreous cavity with gas (C3F8, 14%)
45610682|NCT04449107|Behavioral|Android based mobile phone application|An android based mobile application will be developed. The application will have features and capacity for text messages, voice messages, pictorial messages and video messages. The content of the messages will be according to the findings of Paigham e sehat project and the four messages domains would be educational, reminder, religious and adverse effects. In addition, pictorial and video messages would be used as per freely available through EPI programme Pakistan.
45610683|NCT04048343|Drug|Biological: Experimental: Tezepelumab|Tezepelumab subcutaneous injection every 4 weeks
45610684|NCT04016753|Drug|BMS-986256|30 mg(6ml)
45610685|NCT04016753|Drug|Loestrin|1.5 mg Norethindrone and 30ug ethinyl estradiol
45758602|NCT04384783|Drug|growth hormone|growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.
46068695|NCT05796401|Drug|Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC|"Personalised neuroprotective medication adapted to the individual's biological profile :~Vitamin B12 : 500 micrograms per day~Folinic acid : 50 mg per day~Omega 3 : 1380 mg EicosaPentaenoic Acid (EPA) + 1140 mg DocosaHexaenoic Acid (DHA) per day~N-acetyl-cysteine (NAC) : 2400 mg per day~duration of supplementation(s) : 12 weeks"
45610686|NCT04449887|Drug|Xiangsha Liujunzi granules|A traditional Chinese medicine compound, taken three times a day, one bag at a time, for a total of 28 days
45610687|NCT03428789|Procedure|Sensory nerve coaptation|A recipient sensory nerve of the abdomen was reattached to a donor nerve in the chest area. The sensory branch of usually the 11th intercostal nerve was used as recipient nerve for nerve coaptation and the anterior cutaneous branch of the third intercostal nerve was used as donor nerve. Direct, end-to-end nerve coaptation was performed with two stitches.
45610688|NCT04449809|Behavioral|Exercise program|3x per week group monitored group exercise sessions
45610689|NCT03390101|Drug|BCD-085 Q2W|"In Arm 1, the test drug BCD-085 will be used at a dose of 120 mg given as two SC injections according to the following schedule: once a week for the first 3 weeks (induction treatment) and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label patients will receive BCD-085 through week 50. The follow-up will continue through week 54."
45610690|NCT03390101|Drug|BCD-085 Q4W|In Arm 2, and then once every 4 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will be given BCD-085 once every 4 weeks through week 50. The follow-up will continue through week 54.
45610691|NCT03390101|Drug|Placebo|"In Arm 3, patients will be given two SC injections of placebo (1.0 mL each) according to the following schedule: on Day 1 of weeks 0, 1, 2 and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 at weeks 12, 13, 14 and then once every 4 weeks through week 50. The follow-up will continue through week 54."
45610692|NCT02732639|Drug|Pegylated Interferon (PEG-IFN) alfa-2a|Participants received pegylated interferon (PEG-IFN) alfa-2a 180 microgram (mcg) subcutaneously (SC) weekly for 48 weeks.
45610693|NCT05063747|Other|No intervention.|Observational study. No intervention.
45610694|NCT03232151|Diagnostic Test|C-Arm Cone Beam Computed Tomography|C-ARM CBCT angiogram and CBCT perfusion imaging using prototype software (SMART-RECON) can rapidly and accurately assess the cerebral blood flow maps in the setting of decreased blood flow to the brain (ischemic cerebrovascular events). This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the angiography suite.
45758603|NCT03186560|Device|gekoTM|The geko™ W devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg. The W device has a fixed 27mA current. The devices are self-adhesive and are applied to the outer/posterior aspect of the knee. This positioning enables integral electrodes to apply a stimulus to the lateral popliteal nerve (often additionally termed the common peroneal) which branches from the sciatic nerve. This nerve controls the contraction of several muscles in the lower leg.
45758604|NCT03186326|Drug|FOLFOX regimen|"A course of treatment every 14 days~Oxaliplatin: 85 mg/m² IV over 2 hours Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours"
45758605|NCT03186326|Drug|FOLFIRI Protocol|"A course of treatment every 14 days~Irinotecan: 180 mg/m² IV over 1H30 Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours"
45610695|NCT05045495|Diagnostic Test|Sucrose Hydrogen Methane Breath Test|Subjects will collect 2 buccal swabs for the sucrase genetic test and then subjects will simultaneously conduct the sucrose challenge test, sucrose hydrogen methane breath test, and the 13C-sucrose following ingestion of 50-grams of sucrose (table sugar) mixed with 8 ounce of water.
45610696|NCT02732561|Device|Alpha Stim device|cranial electrotherapy stimulation device
45610697|NCT02732561|Device|Sham device|Sham device
45610698|NCT03423563|Device|Flexible fiberoptic bronchoscopy|Flexible fiberoptic bronchoscopy versus flexible intubation video endoscope regarding intubation time in obese patients
45610699|NCT03423563|Device|Fexible intubation video endoscopy|Fexible intubation video endoscopy
45610700|NCT03428633|Drug|Ropivacaine|Paravertebral block using ropivacaine preoperatively and postoperatively
45610701|NCT03428633|Drug|Morphine|Morphine intraoperatively and postoperatively
45610702|NCT03428555|Behavioral|Integrated Care Pathway|The intervention is a integrated care pathway based on the NICE Clinical Practice Guidelines and measurement-based care in the form of a flow chart. Each decision point on the pathway is guided by results of self-report measures for depression (the Mood and Feelings Questionnaire), functional impairment (Columbia Impairment Scales) and family functioning (the McMaster Family Assessment Device). The results of these scales and protocol recommendations are fed back to the patients, families and clinicians in order to make further treatment decisions
45610703|NCT03428555|Behavioral|Treatment As Usual|Treatment As Usual represents what clinicians would typically do when presented with an adolescent with depression. There is no algorithm provided to guide clinical decision-making and no systematic measurement-based care.
45610704|NCT02521337|Other|observation|observation
45610705|NCT02412878|Drug|Carfilzomib|Carfilzomib was administered as an IV infusion
45610706|NCT02412878|Drug|Dexamethasone|Commercially available dexamethasone was obtained by the investigational site.
45610707|NCT03428399|Other|Psychosocial variables|The investigators will assess mental health history and self-reported psychosocial variables as hypothesized risk and protective factors for body image and depression severity in breast reconstruction patients, before and after their mastectomy and breast reconstruction surgery. Mastectomy and breast reconstruction will be received in the context of routine medical care. Thus, this is not a psychological intervention, but rather observational measures assessed pre- and post routine care for breast reconstruction patients.
45610708|NCT03428243|Device|truSculpt|Device comparison of Circumference measurement at Baseline vs 18 months post treatment
45610709|NCT03423485|Device|CG-100 Intraluminal Bypass Device|Intended to reduce contact of fecal content with an anastomotic site , following colorectal surgery.
45610710|NCT03423329|Drug|Brufen|Brufen Syrup
45610711|NCT03423329|Drug|Cital|Cital Cyrup
45610712|NCT03423329|Drug|Placebo for Brufen|Sansovit Syrup
45610713|NCT02380742|Drug|lidocaine-prilocaine cream|The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of EMLA cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
45610714|NCT02380742|Drug|Placebo cream|The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of placebo cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
45610715|NCT02944019|Drug|Edoxaban|Prescribed according to approved label
45610716|NCT03423095|Behavioral|Active Jaw Exercise with Relaxation|This is the control group that will complete exercises unrelated to the primary outcome measures.
45610717|NCT03423095|Behavioral|Active Tongue Exercise|This is the active comparator group that will complete exercises already shown to increase tongue strength measures.
45610718|NCT03423095|Behavioral|Active Tongue Exercise + Mental Practice|This is an experimental group that will complete active tongue and mental tongue exercises to assess effect on tongue strength measures.
45610719|NCT03423095|Behavioral|Mental Practice Tongue Exercise|This is an experimental group that will complete mental tongue exercises only to assess effect on tongue strength measures.
45610720|NCT03422939|Other|there was no intervention, only separate analyses|We only conducted separate analyses to see if responses differed according to level of experience.
45610721|NCT03422783|Device|Standardized tetanic stimulation|"The intervention is not a drug, but it is standardized electrical stimulus applied with a muscle relaxation monitor on the forearm of the anesthetized patient. The NoL index is registered in response to this stimulus in an observational manner.~Device: Device PMD200TM offering intraoperative NoL Index"
45610722|NCT03422783|Diagnostic Test|Catastrophizing score|Pre-operative catastrophizing score is correlated with post-operative pain and opioid consumption
45610723|NCT03422783|Diagnostic Test|Nociceptive threshold|Nociceptive threshold for pressure, heat and electrical stimulation are associated with post-operative pain and will be assessed preoperatively to see if there is correlation between them and the NOL index response to the nociceptive stimulus (see intervention 1)
45610724|NCT03422783|Biological|Biomarkers|Some biomarkers of inflammation and endogenous opioids are associated with post-operative pain. Blood samples will be withdrawn at D0 before surgery starts, D1 (H24) and D2 (H48) after surgery to see if they correlate with NOL changes after the stimulus described in intervention 1 above
45610725|NCT02022059|Drug|Lidocaine = group A|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by spray of lidocaïne during the insertion (group A = lidocaine)
45610726|NCT02022059|Drug|Group B placebo|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by placebo during the insertion
45610727|NCT03422549|Device|Drager VN500 Ventilator|This ventilator is capable of providing both CPAP and NHFOV support.
45610728|NCT02922725|Drug|5-hydroxytryptophan and Creatine|
45610729|NCT02922725|Other|Placebo control|
45610730|NCT03422315|Drug|Propofol|injection;2mg/kg;single-dose
45758606|NCT03186326|Drug|Avelumab|"A course of treatment every 14 days. Premedication obligatory with antihistamines and paracetamol (example: 25-50 mg diphenhydramine and 500-650 mg paracetamol) IV, approximately 30 to 60 minutes before each dose of avelumab.~Then:~Avelumab: 10 mg/kg IV in 1 hour diluted with 0.9% saline solution; alternatively a 0.45% saline solution can be used if needed"
45758607|NCT03186326|Drug|Panitumumab|Administered at 6 mg/Kg
45758608|NCT03186326|Drug|Cetuximab|Administered at 500 mg/m²
45758609|NCT03186326|Drug|Bevacizumab|Administered at 5 mg/Kg
45445155|NCT01313793|Drug|Treatment B-A|Subjects to receive 1 x 45 mg tablet of the commericializable formulation in first period then 3X 15 mg tablets of the clinical formulation in 2nd period.
45610731|NCT03427853|Drug|LY06006|LY06006 18mg, 60mg, 120mg subcutaneous injection
45610732|NCT03427853|Drug|Placebos|Placebo subcutaneous injection
45610733|NCT03422081|Diagnostic Test|arterial doppler ultrasound|doppler ultrasound
45610734|NCT03127475|Device|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
45610735|NCT03427775|Combination Product|multimodal perioperative pain protocol (MP3)|administration of gabapentionoid, acetaminophen, non steroidal anti-inflammatory drugs around the clock in addition to the peripheral nerve block offered before surgery
45610736|NCT03127553|Dietary Supplement|Low-sodium diet with standard bread|low-sodium diet (2300 mg Na/die) with use of standard bread (750 mg Na/100g) for 6 months
45610737|NCT03127553|Dietary Supplement|Low-sodium diet with low-sodium bread|low-sodium diet (2300 mg Na/die) with use of low-salt bread (280 mg Na/100g) for 6 months
45610738|NCT03127241|Device|Assistive device (Armon Ayura) test|"Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.~Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported."
45610739|NCT03127241|Device|Assistive device (Jaeco Wrex) test|"Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.~Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported."
45610740|NCT03427697|Device|Virtual reality and accommodation relax techniques in combination|The children will be given head-mounted video display to watch video at break of classes, 40 minutes per day in total. The video will be shown by virtual reality and accommodation relax techniques in combination.
45610741|NCT03427541|Procedure|Surgeries|Surgeries
45610742|NCT03427385|Drug|Ropivacaine 0.5%|The volume of local anesthetic Ropivacaine 0.5% will be determined by the response (success or failure of block, 30 minutes after local anesthetic injection) of the previous patient in that group. Block success is defined as an absence of ice sensation in the knee within 30 min of ropivacaine administration accompanied by tolerance to tetanic electrical stimulation (TES) at 60 mA(milliamp) for 5 seconds.
45610743|NCT03427229|Biological|Single-infusion FMT|Patients will receive a single fecal infusion by colonoscopy
45610744|NCT03427229|Drug|Vancomycin (before randomization)|Vancomycin is administered in all patients for 3 days before randomization. Then vancomycin is stopped and patients are randomized to single-infusion FMT or multiple-infusion FMT.
45610745|NCT03427229|Biological|multiple-infusion FMT|Patients will receive multiple fecal infusions by colonoscopy
45610746|NCT04449185|Drug|Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days|Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days
45610747|NCT03427151|Drug|IPP-201101|200 mcg of IPP-201101 will be administered subcutaneously every 4 weeks for 24 weeks.
45610748|NCT03426839|Diagnostic Test|Coagulation tests|
45610749|NCT02837159|Other|mHealth application|Dietary and physical activity recommendations trough a mobile application
45758610|NCT03186326|Drug|Aflibercept|Administered at 4 mg/Kg
45758611|NCT02999633|Drug|Isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
45758612|NCT02999633|Drug|dexamethasone|Pharmaceutical form:pills Route of administration: oral
45758613|NCT02999633|Drug|dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
45758614|NCT02999633|Drug|acetaminophen|Pharmaceutical form:pills Route of administration: oral
45758615|NCT02999633|Drug|ranitidine|Pharmaceutical form:solution Route of administration: intravenous
45758616|NCT02999633|Drug|diphenhydramine|Pharmaceutical form:solution Route of administration: intravenous
46068696|NCT05796401|Other|Treatment as usual (TAU)|Treatment as usual (TAU), including a standardised psycho-education program with a group cognitive behavioural therapy (e.g. I_Care - You Care) and, in FEP only, second generation antipsychotic from a restricted list (following the recommendations www.orygen.org.au)
46068697|NCT05794191|Biological|Vaccine Administration|PCV13 administration
46068698|NCT05792917|Drug|tafolecimab (a modified manufacturing process)|450mg，SC，single dose
45758617|NCT04749797|Drug|Liposomal bupivacaine|Used as cranial block for craniotomy surgery
45758618|NCT04749797|Drug|Bupivacaine Injection|Used as cranial block for craniotomy surgery
45758619|NCT04749797|Drug|Saline|Used as cranial block for craniotomy surgery
45610750|NCT03426761|Drug|Dalbavancin|Dalbavancin 1,500mg intravenously every fourteen days for two to four infusions
45610751|NCT03426761|Drug|Vancomycin|Examples of standard of care arm; infusions one to three times per day depending on the antibiotic for a total of three to eight weeks
45610752|NCT03426683|Other|Intestinal Microbiota Transplantation|the bacteria will be transplanted to mid-gut by nose-jejunum nutrition tube. Patients in this study will be assigned to receive standardized IMT three times or traditional medicine and would be followed up for at least 3 year.
45610753|NCT03426527|Drug|Levobupivacaine|Following induction of anaesthesia, patients will receive ultrasound guided bilateral superficial cervical plexus block with levobupivacaine
45610754|NCT03426527|Drug|Levobupivacaine-Dexmedetomidine|Following induction of anaesthesia, patients will receive ultrasound guided bilateral superficial cervical plexus block with levobupivacaine in conjunction with dexmedetomidine
45610755|NCT03426527|Other|General Anaesthesia|Using propofol, fentanyl and atracurium
45610756|NCT03426449|Procedure|posterolateral sphincterotomy|Fissurectomy and limited division of internal anal sphincter at 5 o'clock position for 8-10 mm
45610757|NCT03426449|Procedure|lateral sphincterotomy|Fissurectomy and limited division of internal anal sphincter at 3 o'clock position for 8-10 mm
45610758|NCT03426371|Drug|KL-140|"KL-140 will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m^2) at 5 milligram per minute (mg/min) and 250 mg/m^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to KL-140.~Drug: Oxaliplatin Oxaliplatin 85 mg/m^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m^2/day intravenously followed by 2400 mg/m^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity."
45610759|NCT03426371|Drug|Placebo|"Placebo will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m^2) at 5 milligram per minute (mg/min) and 250 mg/m^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity Drug: Oxaliplatin Oxaliplatin 85 mg/m^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m^2/day intravenously followed by 2400 mg/m^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity."
45610760|NCT03426215|Diagnostic Test|Magnetic Resonance Imaging (MRI)|Changes in size and severity of the main herniated disc causing radiating pain will be evaluated by radiology specialists and Korean medicine doctors (KMDs) and categorized into three groups (improved, worse or no discernible change) in comparison with the immediate previous MRI to track long-term changes and assess for correlations in subjective clinical symptoms and objective physical evaluation and MRI results.
45610761|NCT02805257|Drug|Mitomycin-C|Intraoperative and postoperative injections of mitomycin-c/Mitosol
45610762|NCT02805257|Other|Balanced Salt Solution|Intraoperative and postoperative injections of BSS
45610763|NCT02805257|Procedure|Ahmed Glaucoma Valve Implant|Implantation of Ahmed Valve in study eye
45610764|NCT02781935|Procedure|DW-MRI|DW-MRI combined with Contrast Enhanced MRI will be used to confirm the status of disappearing liver metastasis prior to surgery and will be compared to findings from either histopathology of resected lesions (Rubbia-Brandt Classification of Tumor regression grading) or follow-up imaging of lesions left behind (either CT scan or MRI) after surgery. MRI will be used during the follow-up period to confirm recurrences from a previous site of DLM.
45610765|NCT02734589|Other|Fecal transplantation|Transplantation of fecal bacteria from a healthy individual into a recipient- ulcerative colitis patient via colonoscopy and enemas
45610766|NCT02734589|Other|Unique novel Diet for UC and Unique novel Diet for the donor + FMT|A developed unique diet that is geared to induces remission and decreases inflammation in patients with active UC. Also a conditioning diet for healthy subjects to be used by the donor prior to transplantation- a developed unique diet for two weeks.
45610767|NCT02734589|Other|Unique novel Diet for UC|A developed diet that is geared to induces remission and decreases inflammation in patients with active UC.
45610768|NCT02684903|Behavioral|Parent Child Interaction Therapy|PCIT is a 16-20 session live-coaching parenting intervention. PCIT for Child Welfare families is delivered in two sequential treatment phases following a motivational enhancement training: Phase 1, Child-Directed Interaction (CDI) to enhance positive parenting and interrupt harsh aversive parenting, and Phase 2, Parent-Directed Interaction (PDI) to coach effective parent commands and a consistent time-out protocol when child disobeys.
45610769|NCT03426059|Other|No Intervention|No Intervention. This is an observational study.
45610770|NCT03127787|Diagnostic Test|CMV Assay|Molecular diagnostic test to detect CMV
45610771|NCT03425981|Other|Whole-Body Electromyostimulation Training|"The WB-EMS training program consisted of six WB-EMS training sessions (one per week) and six running training sessions (also one per week).~This intervention programme followed a within-day undulating periodization model. The training sessions were divided into four parts: warm up (A), strength (B), high intensity interval power training (c), and high intensity interval training (HIIT) (D)."
45610772|NCT03425903|Device|Whole body cryotherapy sessions|Whole body cryotherapy (WBC) 10 sessions of 3 minutes at a temperature of -196ºC (point of evaporation of liquid nitrogen), on the basis of three sessions a week.Fills in questionnaires.
45610773|NCT02636387|Drug|Desmopressin|Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if <50 % improvement
45610774|NCT02333435|Dietary Supplement|EPA|3g/day of purified EPA , capsules, taken once daily, for 14 months
45610775|NCT02333435|Dietary Supplement|Placebo|3g/day of placebo (high oleic sunflower oil) , capsules, taken once daily, for 14 months
46068699|NCT05792917|Drug|tafolecimab (a original manufacturing process)|450mg，SC，single dose
46068700|NCT05792813|Drug|LGYY|LGYY = Linggui Yangyuan paste
46068701|NCT05792813|Drug|LGYY mimetic|LGYY = Linggui Yangyuan paste
46068702|NCT05792813|Drug|WZYZ|WZYZ= Wuzi Yanzong oral solution
45610776|NCT03425747|Drug|Calcium Carbonate|subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
45610777|NCT03425747|Drug|Calcium Citrate|subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
45610778|NCT03425669|Device|Stochastic Vestibular Stimulation|Stochastic vestibular stimulation will be given by electric stimulation through electrodes place over the mastoid processes behind each ear. Auditory stimulation with stochastic white noise will be administrated through ear phones.
45610779|NCT03425669|Device|Sham stimulation|Patients will receive sham stimulation in place of active vestibular stimulation.
45610780|NCT03425669|Drug|Active medication|Patients will be examined with and without medication.
45610781|NCT03425513|Diagnostic Test|Hepatitis B serology|A serum specimen will be taken and assessed for hepatitis B serology (HBsAg and anti-HBc antibodies).
45610782|NCT03425513|Other|Questionnaire|Participants will be asked to fill in a questionnaire regarding demographic characteristics, known viral hepatitis status and risk factors for HBV infection.
45610783|NCT03425357|Other|Low Load Exercises|"All rotator cuff and scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
45610784|NCT04815161|Behavioral|Adherence|Adherence to medication using an electronic pillbox
45610785|NCT04794803|Drug|Reparixin|Reparixin was administered via oral tablets 1200 mg TID for 7 days. In case of improvement, treatment can be prolonged at discretion of the investigator up to a maximum of 21 days of treatment in total or live discharge from the hospital, whichever comes first.
45610786|NCT04794803|Drug|Standard of care|Standard of care
45610787|NCT04756349|Other|composite resin restoration|All patients will receive adhesive composite resin restorations. There will be 3 groups (different adhesives): Clearfil SE, Optibond All-in-One and Prime & Bond Universal.
45610788|NCT03425123|Other|Regenerative Endodontic Procedure (REP)|Regenerative Endodontic Procedure (REP) involves disinfection of the root canal with the use of acombination of three antibiotics including ciprofloxacin, metronidazole, minocycline. At the second visit, the patient is evaluated for resolution of signs or symptoms of an acute infection and if none then bleeding is induced, the site covered with a plug and the patient is evaluated at follow up.
45610789|NCT03425045|Procedure|Repetitive Transcranial Magnetic Stimulation|Patients randomised in Arm 1 will receive stimulation of the dorsolateral prefrontal cortex (frequency 25 Hz; 300 pulses; 80% resting motor threshold=RMT) and primary auditory cortex on both sides (1 Hz; 1000 pulses; 110% RMT) will be stimulated in patients in rTMS stimulation group for 5 consecutive days. No medication therapy will be provided for patients in this arm.
45610790|NCT03425045|Procedure|Sham stimulation|Sham stimulation will be performed in patients randomised in Arm 2 of the study for 5 consecutive days. No medication therapy will be provided for patients in this arm.
45610791|NCT03425045|Drug|Ginkgo Biloba Extract|Patients randomised in Arm 3 of the study will receive medication therapy with Ginkgo biloba extract EGb 761 once a day for 6 months.
45610792|NCT03424967|Behavioral|ABM|Participants are trained with a dot-probe task including angry-neutral faces. In 80% of trials the probe appears in place of the neutral face, and in 20% of trials in place of the angry face.
45610793|NCT03424889|Drug|Xylometazoline|Nasal administration of Xylometazoline
45610794|NCT03424889|Drug|Saline|Nasal administration of 0.9% Saline
46068703|NCT05792813|Drug|WZYZ mimetic|WZYZ= Wuzi Yanzong oral solution
46068704|NCT05771909|Other|NeurodigitX|"The NeurodigitX Group receiving this program will follow the recommendations for a period of three months (2 sessions of 2 minutes per day)."
45610795|NCT03424811|Device|Mobile Health Intervention|Mobile health intervention to promote healthy eating.
45610796|NCT03424733|Drug|Plegridy|Self injection into area of high adipose content. Injections include 63 and 94 microgram titration doses, and the full 125 microgram dose
45610797|NCT03424733|Drug|Prednisone|Take one 20 milligram prednisone tablet four to five hours prior to injections two through six of the full 125 microgram Plegridy dose.
45610798|NCT03424733|Drug|Tylenol Pill|Take two 325 milligram Tylenol tablets 1 hour prior to each Plegridy injection, irregardless of dosage.
46068705|NCT05771909|Other|Control|"The Control Group does not receive the NeurodigitX application."
46068706|NCT05771402|Drug|Anti-PD-1 antibody|Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection
46068707|NCT05771402|Drug|NAs|Once/day, 1 capsule/time, oral
46068708|NCT05771402|Drug|Peg-IFNα|Once/week, 180μg/time, subcutaneous injection
45445156|NCT02054650|Other|Osteopathic Manual Treatment (OMT)|Osteopathic Manual Treatment (OMT) is a system of hands-on techniques used by osteopathic physicians to increase function and reduce pain.
45610799|NCT03424655|Procedure|Twisted File Adaptive|Twisted file adaptive SM1 (size 20, .04 taper) and SM2 (size 25, .06 taper) were used serially with a single controlled motion according to the manufacturer's instructions.
45610800|NCT03424655|Procedure|Balance Force|Flex-R files sizes 15-45 taper .02 were used according to the technique
45610801|NCT03424655|Procedure|WaveOne|"WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL."
45610802|NCT03424655|Procedure|Reciproc technique|Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
45610803|NCT03424577|Drug|H3B-6527|Oral capsule
45610804|NCT03424031|Procedure|Verticalization|To allow the verticalization of hemiplegic patients, we will use a device commonly used in rehabilitation: the standing (or standing) brand Thera Trainer . This device makes it possible to keep the patient standing despite the motor and postural deficits thanks to knee, buttocks and an anterior support for the upper limbs. Verticalization with this device requires the presence of one or two caregivers (including at least one re-educator), depending on the possibilities of participation of the patient.
45758620|NCT02991599|Biological|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
45610805|NCT03421925|Procedure|Laparoscopic totally extraperitoneal procedure for inguinal hernia|Laparoscopic totally extraperitoneal procedure for inguinal hernia is a technique that is done by not entering the peritoneal cavity
45610806|NCT03423875|Diagnostic Test|PrEDICT game score|PrEDICT game score will be shared with the emergency physicians and health care professionals
45610807|NCT03423797|Drug|25% AgNO3 solution followed by 5% NaF|Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF: 11.6mg (F-)/0.5ml (max dose).
45610808|NCT03423797|Drug|25% AgNO3 solution followed by 5% NaF with fTCP|Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF with fTCP: 11.6mg (F-)/0.5ml (max dose).
45610809|NCT03421847|Diagnostic Test|Rotatory vestibular test|We will measure Depression and Healthy subjects vestibular activity by Rotatory Vestibular tests
45610810|NCT03423719|Dietary Supplement|Fiit-ns®|Fiit-ns® is a blend of polyphenol-rich extracts from grapefruit, grape, green tea, guarana and black carrot. It also provides Vitamin B3. Daily dosage is 900 mg in two 450 mg-capsules for 16 weeks.
45610811|NCT03423719|Dietary Supplement|Placebo|Placebo product is 100% maltodextrin. Daily dosage is 900 mg in two 450 mg-capsules of identical appearance than the supplement capsule for 16 weeks.
45610812|NCT03421769|Procedure|EA and AMLK|A 7-9mm diameter corneal epithelial tissue will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).
45610813|NCT03421769|Procedure|LA and AMLK|A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
45610814|NCT03417323|Other|Compression|Participants in the treatment group wear compression garment after intense WB-EMS application for 24 h, and 12 h for day 2, 3, 4 post WB-EMS.
45610815|NCT03421691|Device|excel V Laser|excel V Laser Genesis procedure utilizing 1064 nm Nd:YAG laser
45610816|NCT03421613|Drug|3VM1001|Self treatment 3 times daily for 10 days
45610817|NCT03421613|Other|Placebo|Cream without investigational drug. Self treatment 3 times daily for 10 days
45610818|NCT02064803|Procedure|Gastro-entero anastomosis only|Gastro-entero anastomosis only
45610819|NCT02064803|Procedure|Gastric partitioning Plus Gastro-entero anastomosis|Gastric partitioning Plus Gastro-entero anastomosis
45610820|NCT03417167|Other|US-guided synovial biopsy|Needle Synovial biopsy performed using a Tru-cut® device.
45610821|NCT01791595|Drug|AZD3965|"Day -7: single dose of 5 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 5 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
45610822|NCT01791595|Drug|AZD3965|"Day -7: single dose of 10 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
45610823|NCT01791595|Drug|AZD3965|"Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 20 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
45610824|NCT01791595|Drug|AZD3965|"Day -7: single dose of 30 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 30 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
45610825|NCT01791595|Drug|AZD3965|"Day -7: single dose of 30 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 15 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
46068709|NCT05769816|Drug|Anti-PD-1 antibody|Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection
46068710|NCT05769816|Drug|NAs|Once/day, 1 capsule/time, oral
45445157|NCT02054650|Other|Sham OMT|Sham OMT involves hand contact, active and passive range of motion, and sham techniques that simulate OMT, but that utilize such maneuvers as light touch, improper patient positioning, purposely misdirected movements, and diminished provider force.
45610826|NCT01791595|Drug|AZD3965|"Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
45610827|NCT01791595|Drug|AZD3965|"Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment (first 3 trial participants in the Expansion Cohort only; subsequent patients started treatment at Cycle 1, Day 1).~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
45610828|NCT05061433|Other|Mobile Integrated Healthcare/Community Paramedicine (MIH/CP) Support|MIH/CP provider and their team will offer additional support and connection to resources after patient is discharged from hospital.
45610829|NCT04451941|Device|Experimental: RecoveriX with individual EEG calibration|RecoveriX applied FES according to individual brainwave by individual EEG calibration for 5 times a week for 4 weeks
45610830|NCT04451941|Device|RecoveriX without individual EEG calibration|RecoveriX applied FES according to the brainwave of other subjects regardless of the individual brainwave for 5 times a week for 4 weeks
45610831|NCT03441997|Other|Mind-body exercise|Exercise program.
45610832|NCT03441997|Other|Light mobility exercises|Modified mind-body program.
46068711|NCT05764265|Drug|LTP001|LTP001 will be administered orally once daily in the morning
45610833|NCT03441919|Radiation|PET-CT (positron emission tomography - computer tomography)|PET-CT to determine vascular inflammation
45610834|NCT03441919|Diagnostic Test|Blood drawn|Blood drawn
45610835|NCT03441841|Drug|Lidocaine + Prilocaine|Single topical dose of 2g lidocaine + prilocaine 2.5 % formulation.
45610836|NCT03441841|Drug|Lidocaine|Single topical dose of 2g lidocaine 2.5 % formulation.
45610837|NCT03441841|Drug|Prilocaine|Single topical dose of 2g prilocaine 2.5 % formulation.
45610838|NCT02692339|Drug|Lenalidomide|Standard of Care doses for relapsed/refractory multiple myeloma: 25 mg/day lenalidomide 21 of 28 days cycle
45610839|NCT02692339|Drug|Dexamethasone|Standard of Care doses for relapsed/refractory multiple myeloma: dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
45610840|NCT03444103|Drug|Clazakizumab / Clazakizumab|Humanized monoclonal anti-IL-6 antibody
45610841|NCT03444103|Drug|Placebo / Clazakizumab|0.9% Saline
45610842|NCT03444025|Drug|Goserelin|Goserelin is Luteinizing hormone releasing hormone (LHRH) analogue.
45610843|NCT03443947|Device|Tongue depressor group|using a tongue depressor to assess airway score without tongue protrusion
45610844|NCT03443947|Procedure|control group|airway assessment after tongue protrusion
45610845|NCT04890145|Device|RW-Precision-Coupler|Implantation of the RW-Precision-Coupler together with FMT-VORP 503
45610846|NCT02667067|Device|Simplify Disc|Simplify Disc at one level in the cervical spine.
45610847|NCT02667067|Device|Anterior Cervical Discectomy & Fusion|"This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm (N=133) of the recently completed Kineflex®|C Disc trial."
45610848|NCT02636881|Procedure|Autologous Chondrocyte Implantation|Implantation of the patients own cartilage cells in a chondral defect of the knee
45610849|NCT02636881|Procedure|Arthroscopic Debridement|Arthroscopic diagnosis and debridement of the lesion, without cartilage therapy. Removal of lose bodies etc.
45610850|NCT02615275|Procedure|Bioelectric Impedance Analysis|Undergo BIA with seca mBCA
45610851|NCT02615275|Procedure|Computed Tomography|Undergo CT
45610852|NCT02615275|Procedure|Positron Emission Tomography|Undergo PET
45610853|NCT02615275|Other|Quality-of-Life Assessment|Ancillary studies
45758621|NCT02991599|Biological|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
45610854|NCT02615275|Other|Questionnaire Administration|Ancillary studies
45610855|NCT02615275|Radiation|Radiation Therapy|Undergo RT
45610856|NCT03438253|Procedure|spinal anaesthesia|
45610857|NCT02594215|Drug|MK-7075 (miransertib)|MK-7075 or miransertib (formerly ARQ 092) is small molecule that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a phase I study to determine a recommended dose for subsequent trials, which will determine the efficacy of miransertib in Proteus syndrome.
45610858|NCT03441763|Device|Emed foot device|foot pressure will be measure by using emed foot pressure system
45610859|NCT02535325|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-D conformal RT
45610860|NCT02535325|Drug|Cisplatin|Given IV
45610861|NCT02535325|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45610862|NCT02535325|Drug|Methoxyamine|Given PO
45610863|NCT02535325|Drug|Methoxyamine Hydrochloride|Given PO
45610864|NCT02535325|Drug|Pemetrexed|Given IV
46068712|NCT05760898|Behavioral|Blood pressure intervention arm|The intervention will focus on empowering patients to actively participate in their HTN care, facilitating patient-provider communication, and creating a cohesive care team to close the coordination loop for HTN management. This pilot intervention will help achieve these goals by providing participants with home blood pressure monitors and teaching, improving patient-provider communication regarding blood pressure and RA management, and initiating care coordination between rheumatology and primary care providers.
46068713|NCT05745142|Drug|Sunitinib|as provided in real world practice
45610865|NCT02535325|Drug|Pemetrexed Disodium|Given IV
45610866|NCT03441685|Behavioral|Semantic cues (perform action), syntactic cues (sentence frame), or combined semantic and syntactic cues|"Verb Learning Session Teaching phase. The examiner labels each target word and performs the action 6 times in each condition. She elicits the target word from the participant 2 times per word per condition and provides feedback on accuracy.~Testing phase. Receptive probes are administered after every 2 words are taught. Expressive probes are at the end of the condition. For receptive probes, the examiner asks the participant to identify novel verbs and for expressive probes, the examiner asks the child to label the novel action. Testing after 2 items is designed to decrease memory load. Participants have a brief break between conditions.~Data are collected on: a) child responses on standardized assessments, (b) responses to verb learning probes, (c) parent responses to intake form, and (d) relevant medical history from electronic medical record.~None of the above procedures present more than minimal risk to participants or research staff. Vanderbilt IRB approved all procedures."
45610867|NCT04881175|Device|Non-Invasive Treatment|Single-arm group using the FlexSure Applicator device.
45610868|NCT03438175|Behavioral|Enhanced communication by brochure, website and posters|Several instruments to improve communication toward ICU patients' families were prepared for this study: a brochure of 12 pages, a website with 80 webpages, 8 posters for the waiting room, 1 sign for the ICU door. All these instruments are made to have more correct comprehension and to legitimize emotions of ICU patients' families.
45610869|NCT03441607|Drug|mHACMb|Active ingredient
45610870|NCT03441607|Other|placebo|inactive ingredient
45610871|NCT03441529|Drug|Lumicitabine|Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
45610872|NCT03441529|Drug|Piperacillin/Tazobactam|Participants will receive three IV infusions of piperacillin/tazobactam combination product (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1.
45758622|NCT00706823|Device|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
45758623|NCT00706823|Device|Laryngeal Mask Airway-Unique|supra-glottic airway device
45758624|NCT04348058|Behavioral|Telephone recruitment to screening colonoscopy|Utilisation of dedicated call center for recruitment to screening program instead of traditional, paper invitation
45610873|NCT03438019|Device|PrO2|The PrO2 device is linked to a tablet via Bluetooth and provides the user with a graphic representation of their inspiratory effort throughout all of inspiration and real-time biofeedback. This device incorporates a standard 2mm leak to avoid glottal closure during maximal inspiration. The PrO2 provides measures of MIP (cmH2O), SMIP (PTU) and ID (seconds).
45610874|NCT03438019|Device|Threshold Inspiratory Muscle Trainer|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
45610875|NCT03449875|Device|TREOVANCE® Stent-Graft with Navitel® Delivery System|Endovascular repair of abdominal aortic aneurysms.
45610876|NCT04547569|Behavioral|Speech adaptation|Sensorimotor adaptation in speech
45610877|NCT04547569|Behavioral|Vibrotactile Discrimination|Vibrotactile Discrimination
45610878|NCT04547569|Other|fMRI|fMRI measurement of brain activity
45610879|NCT04547569|Behavioral|Speech production|Speech production task
45610880|NCT03441373|Drug|XC8 20 mg|once daily during 5 days.
45610881|NCT03441373|Drug|XC8 100 mg|once daily during 5 days.
45610882|NCT03441373|Drug|XC8 200 mg|once daily during 5 days.
45610883|NCT03441373|Drug|Placebo|once daily during 5 days.
45610884|NCT03449797|Procedure|AVS performed with no intraprocedural rapid cortisol assay|AVS performed plus intraprocedural rapid cortisol assay
45610885|NCT03449797|Procedure|AVS performed plus intraprocedural rapid cortisol assay|Adrenal vein sampling performed according to usual clinical practice without intraprocedural rapid cortisol assay
45610886|NCT03441295|Procedure|Dynamic Intraligamentary Stabilization|DIS, Ligamys
45610887|NCT03441295|Procedure|Internal Brace Ligament Augmentation|IBLA
45610888|NCT03441295|Procedure|ACL Reconstruction|Conventional
45610889|NCT03449719|Radiation|SBRT - Ablative radiation Therapy|"The current phase II randomized trial,Ablative Radiation Therapy in patients with Oligometastatic castration resistant prostate cancer (ARTO trial) aims to evaluate the difference in PSA response rate between the experimental arm (AA+SBRT) and control arm (AA) in metastatic castration-resistant prostate cancer patients."
45610890|NCT03449719|Drug|Abiraterone Acetate|systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist
45610891|NCT03449641|Device|Positive airway pressure (PAP)|Positive airway pressure (PAP) is a mode of respiratory ventilation used in the treatment of sleep apnea.
45610892|NCT02521519|Other|Medial branch block in one side|MBB: Using sterile conditions, 25G needles will be placed in the desired position. In its final position for the L3 and L4 vertebrae the needle tip should reside at the junction of the superior articular process and the transverse process. At the L5-S1 level the needle tip should reach the junction between the sacral ala and the superior articular process of S1. Following a negative aspiration 0.5ml of injectate will be injected into each site.
45610893|NCT02521519|Other|paravertebral deep intramuscular (PDI) injection|injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.
45610894|NCT03437785|Drug|CKD-495 75mg|CKD-495 75mg Tab.
45610895|NCT03437785|Drug|CKD-495 150mg|CKD-495 150mg Tab.
45610896|NCT03437785|Drug|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
45610897|NCT03437785|Drug|Rebamipide 100mg|Rebamipide 100mg Tab.
46068714|NCT05737069|Drug|Ibuprofen arginine granules 400 mg|Experimental- Ibuprofen arginine granules 400 mg, one sachet administration containing 400 mg ibuprofen granules.
46068715|NCT05737069|Drug|Ibuprofen arginine granules 400 mg (Spedifen)|Marketed drug- Ibuprofen arginine granules 400 mg (Spedifen), one sachet administration containing 400 mg ibuprofen granules.
45610898|NCT03437785|Drug|Placebo of the CKD-495 75mg|Placebo of the CKD-495 75mg Tab.
45610899|NCT03437785|Drug|Placebo of the CKD-495 150mg|Placebo of the CKD-495 150mg Tab.
46068716|NCT05732311|Device|intermittend theta burst stimulation|intermittend theta burst stimulation
45610900|NCT03437785|Drug|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
45610901|NCT03437785|Drug|Placebo of the Rebamipide 100mg|Placebo of the Rebamipide 100mg Tab
45610902|NCT03449563|Combination Product|Open TPVB|In Group E,the thoracic paravertebral block was performed under the direct vision with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
45610903|NCT03449563|Combination Product|Ultrasound-guided TPVB|In Group U, thoracic paravertebral block was performed on the operated side under ultrasound guidance with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
45610904|NCT03449563|Other|placebo|In Group G,patients were just received Patient-controlled intravenous analgesia after the surgery.
45610905|NCT03437707|Drug|Morphine Sulfate|Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
45610906|NCT03437707|Drug|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
45758625|NCT04348058|Behavioral|Combined methods recruitment to screening colonoscopy|Utilisation of dedicated call center for recruitment to screening program in participants, who did not respond to traditional, paper invitation
46068717|NCT05732103|Drug|CTX-712|CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 weekly, depending on their dose level assignment, during each 28-day cycle.
45445158|NCT03779919|Device|extracorporeal shock wave|Extracorporeal shock wave therapy uses acoustic waves to fragment calcific deposits. Variables of the settings include dose (low or high energy), duration (impulses), and the interval of administration.
45445159|NCT02056678|Drug|acetaminophen, IV preparation|
45610907|NCT03437707|Drug|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
45610908|NCT03437629|Procedure|Temporary cement based on Calcium Hydroxide|Confection of a temporary crown with acrylic resin; Finishing and polishing; relative isolation with cotton and gauze; Manipulation of the temporary cement based on Calcium Hydroxide; Cement insertion on the internal surface of the temporary crown; Excess cement removal; Occlusal Adjustment.
45610909|NCT03437629|Procedure|MTA temporary cement|Confection of a temporary crown with acrylic resin; Finishing and polishing; relative isolation with cotton and gauze; Manipulation of the temporary cement based on Mineral trioxide aggregate; Cement insertion on the internal surface of the temporary crown; Excess cement removal; Occlusal Adjustment.
45610910|NCT03437551|Other|cross-sectional observation|cross-sectional ophthalmic examination
45610911|NCT03437473|Device|SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System|Active Implantable Vagus Nerve Stimulation device.
45610912|NCT03441217|Drug|Hyoscine Butylbromide 20Mg/1mL Injection|Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide upon arrival in the Labor and Delivery Unit (4-5 cms).
45610913|NCT03441217|Drug|Saline Solution|Nulliparous women with gestations at term receive 20 mg of saline solution upon arrival in the Labor and Delivery Unit (4-5 cms).
45610914|NCT03128515|Drug|Hydroxyurea|Administered once a day in tablet form (100mg or scored 1000mg) for 24 months
45610915|NCT02521441|Biological|F-627|F-627 at doses of 10 mg/dose or 20 mg/dose, s.c. on Day 3 of each cycle for up to 4 cycles.
45610916|NCT02521441|Biological|Filgrastim|Filgrastim at dose of 5 mcg/kg/day for up to 2 weeks, s.c. start from Day 3 of each cycle for up to 4 cycles.
45610917|NCT03440983|Device|MRI data acquiring in healthy volunteers|The quality of the images, cartographies or spectres will be compared to standard acquisitions. This evaluation will be based on qualitative visual criteria assessed by expert radiologists or on quantitative criteria assessed by data processing tools
45610918|NCT03440827|Behavioral|Focus Group|First (phase 1), collect experiences, perceptions, difficulties, needs and expectations of patients with slow-flow malformations (for the age group of 11 to 15 years-old), carried out with 3 categories of participants and then (phase 2) development and validation of the specific scale of life's quality of slow-flow vascular malformation in children aged 11 to 15 years-old.
45610919|NCT03440749|Other|luminous stimuli|The child is placed in front of a screen on which 4 luminous stimuli are presented on a horizontal plane. Four buzzers are placed in front of him, each buzzer corresponds to the position of a stimulus. Child had to push the buzzer corresponding to the place of the luminous stimuli.
45610920|NCT03437317|Behavioral|Perceptual Retraining|"Participants viewed faces varying in their expression of anger and were asked to identify if the face was angry or neutral via button press. Participants were provided with feedback if their categorization of the face as neutral or angry was correct. Each participant was assigned 4 levels of angry faces based on their decision point of anger detection in faces. Faces were selected based on the closest existing anger morph to the category boundary; for example, a decision point of 40% anger was closest to the 38% anger face, and so the faces used would have been 17%, 31%, 45%, and 59% anger. For this example, responses of neutral to the 31% angry face would be marked as correct, whereas a similar response to the 45% angry face would be incorrect, as it was above their decision point."
45610921|NCT03437317|Behavioral|Gender Discrimination|Participants viewed faces varying in their expression of anger and were asked to identify if the face was male or female via button press.
45610922|NCT03437239|Device|Delfi PTS II Portable Tourniquet System|This is a portable tourniquet system that allows for occlusion of venous outflow without inhibiting arterial blood flow. This portable tourniquet system allows for rapid cuff inflation and deflation with a battery. The Delfi PTS is a purpose-built system that allows for precise control of pressure throughout training, despite the natural changes in muscle shape and length. The device has advanced pressure leak detection that monitors the tourniquet cuff, tubing, and connectors for air leaks and safely alerts staff to hazards or follow-up actions required. The device has visual and audio alarms for over and under pressure and elapsed time as well as a large, easily visible display of tourniquet pressure and elapsed time. The Delfi PTS II calibrates and self-tests on startup. It has a safety interlock that limits the normal maximum pressure and integrated tourniquet cuff testing as recommended in current AORN Standards and Recommended Practices
45610923|NCT03437083|Drug|Eribulin mesylate|intravenous infusion
45610924|NCT03436927|Other|Nintendo Wii Fit Balance exercises|Nintendo Wii Fit' training protocol consisted of 'Penguin Slide', 'Table Tilt', 'Ski Slalom', 'Heading' and 'Balance Bubble' games that selected from the Wii Fit Plus balance games section
45610925|NCT03436927|Other|Balance Trainer Balance Exercises|Balance Trainer' training protocol consisted of 'Collect Apples', 'Outline', 'Paddle War' and 'Evaluation of Movement' games which were included in the device software and allowed the patients to done balance exercises in different directions.
46068718|NCT05723432|Drug|KD6001|KD6001 will be administered intravenously.
46068719|NCT05723432|Drug|Toripalimab|Toripalimab will be administered intravenously.
46068720|NCT05723328|Behavioral|Group Music Therapy Advocacy Recording Intervention (MTAR)|Music Therapy Advocacy Recording Intervention (MTAR) is a sequence of group music therapy song-writing and recording sessions framed as a mental health awareness project to be shared with the general public.
45445160|NCT04662567|Drug|acetaminophen|compare the postoperative pain 1 hour and ~24h post surgery
45445161|NCT02799784|Drug|UMEC/VI|ELLIPTA dry powder inhaler (DPI) will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5 mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
45610926|NCT03433027|Drug|BB-401|BB-401 1.92ug/mL Intratumoral Injections, every week for up to 8 weeks
45610927|NCT03432871|Dietary Supplement|Nicotinamide Riboside|Nicotinamide Riboside is a member of the Vitamin B family which acts as a precursor to NAD+, an enzyme involved in energy production.
45610928|NCT04415281|Device|THOR® laser system|We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.
45610929|NCT04415281|Device|sham THOR® laser system|sham THOR® laser system
45610930|NCT04451239|Drug|topical steroids and cyclosporin-A|All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .
45610931|NCT04406935|Device|treatment with the study device (NuEra)|"Multi-arm, prospective, multi-center, baseline-controlled study:~Arm 1: NuEra treatment using 475 KHz Arm 2: NuEra treatment using 1 MHz Arm 3: NuEra treatment using 2 MHz"
45610932|NCT03440671|Biological|Hutox Inj|Hutox Inj(Clostridium botulinum type A)
45610933|NCT03440671|Biological|Botox Inj|Botox Inj(Clostridium botulinum type A)
45610934|NCT03440593|Other|Caloric delivery will target results of IC measurement.|The prescribed calories to be delivered will be set to target the measurement obtained from performing indirect calorimetry (IC). IC measures the gas exchange of oxygen consumption and carbon dioxide production to determine the true metabolic needs for cellular respiration. The expenditure of calories will be measured utilizing the gas module incorporated within the General Electric Carescape R860 ventilators.
45610935|NCT03440515|Drug|Prednisone|Prednisone treatment for severe skin rash induced by imatinib
45610936|NCT02521597|Device|Cellscope|The CellScope Oto, is a portable video-otoscope that allows residents and staff to share diagnostic-quality images
45610937|NCT02521597|Device|Traditional otoscope|Use of a regular otoscope
45610938|NCT03432793|Drug|TD-9855|oral tablet, QD
45610939|NCT03432793|Drug|Fluvoxamine|oral tablet, QD
45610940|NCT03432793|Drug|Itraconazole|oral tablet solution, QD
45610941|NCT03432793|Drug|Caffeine|oral solution, single dose
45610942|NCT05121025|Diagnostic Test|Analysis of gut microbiome and immune signatures|The investigators will analyse the microbiome composition (16S rDNA-sequencing and metagenomics), microbiome activity (RNA-sequencing of stool bacteria and metabolite sampling) and immune cell activity (leukocyte RNA-sequencing) of all study groups.
45610943|NCT03436849|Drug|ESN364|ESN364 will be administered orally.
45610944|NCT03436849|Drug|Placebo|Placebo will be administered orally.
45610945|NCT03436771|Genetic|JCAR017|No drug is administered in this study. Patients who received JCAR017 in a previous trial will be evaluated in this trial for long-term safety and survival.
45610946|NCT03436771|Genetic|JCARH125|No drug is administered in this study. Patients who received JCARH125 in a previous trial will be evaluated in this trial for long-term safety and survival.
45610947|NCT03436693|Drug|Canagliflozin|Canagliflozin 100mg orally once daily
45610948|NCT03436693|Drug|Placebo|Placebo orally once daily
45610949|NCT03432637|Procedure|spontaneous ventilation|thoracoscopic lobectomy under spontaneous ventilation
45610950|NCT03432637|Procedure|intubated anesthesia with single-lung mechanical ventilation|undergoing thoracoscopic lobectomy under intubated anesthesia with single-lung mechanical ventilation
45610951|NCT03436537|Other|Periodontal Aesthetic Perception Scale|Patients answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale
45610952|NCT03436459|Device|Extracorporeal Shock Wave Therapy|shock wave therapy once a week for three weeks, total of 1000 shock waves for each treatment at the frequency of 10Hz, with 2 Bar pressure and energy flux density (EFD) of 0.25 mJ/mm2 per minute using a BTL-6000 SWT Topline Power® device
45610953|NCT03436459|Device|Low Level Laser Therapy|LLLT once a day for three weeks (altogether 15 working days) using a PR999 4W scanning laser device; around trigger points with 3 J/cm2, power 800 mW, frequency 2000Hz, on trigger points with 9 J/cm², power 2000mW, frequency 5000Hz for total of 2 minutes on each spot
45610954|NCT03432559|Diagnostic Test|endoscopy|endoscopy of pharynx, upper esophagus, mid esophagus, cardia, gastric fundus, und gastric body
45610955|NCT03436381|Other|Questionaire|We will provide two sleep apnea screening questionnaire, Stop-bang questionnaire and Epworth sleepiness scale
45610956|NCT03432403|Device|Ambu LMA|Will be randomized to either the new Gastro LMA or old Ambu LMA for EGD procedure and the intracuff pressure will be measured
45610957|NCT03432403|Device|Gastro LMA|Will be randomized to either the new Gastro LMA or old Ambu LMA for EGD procedure and the intracuff pressure will be measured
45610958|NCT03436303|Drug|CEE 0.625 mg/MP 100mg|CEE 0.625 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years
45610959|NCT03436303|Drug|CEE 0.3 mg/MP 100mg|CEE 0.3 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years
45610960|NCT03436303|Drug|CEE 0.625mg/dydrogesterone|CEE 0.3 mg/dydrogesterone 10mg daily for the last 12 days of every 28 days for two years
46068721|NCT05722964|Drug|SHR-1906|Intravenous injection
45610961|NCT03432169|Other|Yoga (stretching plus mindfulness)|Stretching plus mindfulness
45610962|NCT03432169|Other|Stretching|Stretching alone
45610963|NCT03436225|Drug|Dexamethasone orally.|Administered orally (0.15mg /kg / dose) twice daily for 3 to 5 days.
45610964|NCT03436225|Drug|Dexamethasone parenteral.|Administered parenteral (0.15mg /kg / dose) twice daily for 3 to 5 days.
45610965|NCT03436225|Drug|Inhaled nebulized Budesonide.|Administered for inhalation (1 mg/ 2ml) twice daily for 3 to 5 days.
46068722|NCT05722964|Drug|SHR-1906|Intravenous injection
46068723|NCT05722964|Drug|Placebo|Placebo，Intravenous injection
46068724|NCT05716165|Device|proprioceptive knee braces|The patient will perform the tests with the knee braces.
45610966|NCT03436225|Drug|Inhaled nebulized salbutamol.|Administered for inhalation (0.15mg /kg / dose) daily every 6-8hrs
45610967|NCT03440359|Drug|Progesterone Vaginal Gel 8%|progesterone supplementation for luteal phase support administered with vaginal applicators and used instead of progesterone intramuscular injections or progesterone vaginal suppositories.
45610968|NCT03440359|Drug|Letrozole Oral Tablet|letrozole oral tablet 2.5 mg or 5 mg administered cycle day 3-7 for ovulation induction
45610969|NCT03440359|Diagnostic Test|pelvic ultrasound|pelvic ultrasound performed at cycle day 11 or 12 and repeated as necessary until leading follicle size is >17 mm in diameter
45610970|NCT03440359|Drug|Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe|ovidrel 250 mcg given when leading follicle size is > 17 mm in diameter
45610971|NCT03440359|Other|Intrauterine insemination or timed intercourse|Intrauterine insemination or timed intercourse (depending on semen parameters) performed 36-40 hours after Ovidrel
45610972|NCT03128749|Behavioral|Mindfulness Based Intervention|"The mindfulness based intervention protocol used in this project is adapted from the original and validated MBCT program for depression (Segal, Williams & Teasdale, 2002). Two more sessions, focused on obsessive symptoms specfic to each participant, will be included. Those two sessions will be adapted from the manual The Mindfulness Workbook for OCD (Hershfield and Corboy, 2013)."
45610973|NCT03128749|Drug|Treatment as Usual|The psychiatric referee will follow OCD guidelines modifying or potentiating drug treatments if needed.
45610974|NCT03432013|Behavioral|CUD-AMT|Participants will be trained to manage their negative thoughts and emotions while also receiving treatment for cannabis misuse
45610975|NCT03432013|Behavioral|SUD-CBT|Participants will receive traditional cognitive behavioral therapy for substance use disorder
45610976|NCT03431779|Procedure|Adipose derived stem cell transplantation via lipofilling|Liposuction of 60cc abdominal fat with its adipose derived stem cells which will be reinjected (10-20 cc) in the vestibular area after centrifugation for 3 minutes at 1000 rpm and decantation of oil and red blood cells.
45610977|NCT03431779|Procedure|Surgical excision|Excision of painful areas
45610978|NCT03440281|Diagnostic Test|Uterine artery doppler|Uterine artery Doppler pulsatility indices
45610979|NCT03440281|Diagnostic Test|Maternal serum homocysteine estimation|
45610980|NCT03440203|Other|difficult activities of daily living in each group|Compare the severity of pain by the severity of diabetic peripheral neuropathy. Compare the difficulties in ADLs in three group of diabetic patients
45610981|NCT03440125|Drug|Cayenne Pepper topical|20min topical Cayenne Pepper Cataplasm application containing 5% Cayenne Pepper nd 95% Kaolin mixed with water
45610982|NCT03440125|Device|Electrical stimulation|Electrical stimulation 10min 60Hz biphasic rectangular neuromuscular electrical Stimulation (NMES)
45610983|NCT03440125|Procedure|Massage|10 minutes of classical massage of low back pain area.
45610984|NCT03435991|Other|Validation Experience Sampling Method 'Uromate'|In a period of 7 days, participants will fill out an electronic ESM assessment at 10 random moments during the day. Moreover, they will fill out a sensation-related bladder diary (SR-BD) during the last three consecutive days of filling out the ESM and several symptom questionnaires at the end of the study period.
45610985|NCT03435913|Other|Standard PEEP ventilation|During mechanical ventilation a fixed PEEP (5 mcH2O) is set at all IAP levels during pneumoperitoneum insufflation
45610986|NCT03435913|Other|Matched PEEP ventilation|During mechanical ventilation PEEP is matched to IAP level
46068725|NCT05716165|Device|No knee brace|The patient will perform the tests without the knee brace.
45610987|NCT03435757|Procedure|OFD+IMP+CPS|open flap debridement (OFD) and intramarrow penetration (IMP) plus calcium phosphosilicate putty
45610988|NCT03435757|Procedure|OFD+IMP|open flap debridement (OFD) and intramarrow penetration (IMP)
45610989|NCT03435679|Procedure|one-stage|one-stage surgery
45610990|NCT03435679|Procedure|two-stage|two-stage surgery
45610991|NCT03435601|Drug|Anifrolumab|"IV Administration of Anifrolumab 300 mg every 4 weeks from week 0 to week 20 for a total of 6 doses.~At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period)."
45445162|NCT02799784|Drug|TIO/OLO|TIO/OLO inhalation spray will be supplied as an inhalation spray delivered using a RESPIMAT inhaler. Each actuation from the RESPIMAT inhaler delivers 3.124 mcg tiotropium bromide monohydrate (equivalent to 2.5 mcg tiotropium) and 2.736 mcg olodaterol hydrochloride (equivalent to 2.5 mcg olodaterol)
46068726|NCT05709483|Drug|Aspirin|Platelet assays including VerifyNow Aspirin assay, VerifyNow Base assay, platelet aggregometry, Thromboxana A2 levels- will be measured at baseline and 1 hour after administration of single-dose enteric-coated 81 mg aspirin
45610992|NCT03435601|Drug|Placebos|"Placebo IV administration Q4W, a total of 6 doses At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period)."
45610993|NCT04855825|Device|Robotic Exoskeleton Rehabilitation|Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.
45610994|NCT04855825|Other|Conventional Gait Therapy|Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.
45610995|NCT03902821|Other|XR-NTX and Certified Recovery Mentor|All consented participants will be offered an injection of extended-release naltrexone 3-7 days prior to release from prison. All consented participants will also be introduced to Certified Recovery Mentors one month prior to release.
46068727|NCT05709197|Procedure|Braun anastomosis|Participants will undergo open pancreatoduodenectomy (PD). The reconstruction technique will not be standardized. In addition to the reconstruction technique used, a side-to-side anastomosis will be created between the afferent and efferent jejunal limbs of the gastrojejunostomy (GJ) at 20 cm distance from the GJ. The anastomosis will be hand-sewn with monofilament PDS 3-0 one-layer running suture.
45610996|NCT03435523|Procedure|Recruitment maneuver|"the ventilator was switched to pressure-control ventilation with a driving pressure of 20 cmH2O. After a 3 min equilibration, PEEP was applied in steps of 5,10,15 and 20 cmH2O every five respiratory breaths; subsequently, after setting a driving pressure of 15 cmH2O, PEEP was stepwise reduced, starting from 15 cmH2O, by 2 cmH2O every 2 minutes. The recruiting pressure of 20/20 was applied for six breaths. During the decremental PEEP trial, CRS was measured at every step. The PEEP level corresponding to highest CRS during the decremental trial was identified as the best PEEP. Subsequently, the lungs were recruited again and the best PEEP was applied."
45610997|NCT03435445|Behavioral|Online platform group|The online platform has social network, gamification and short-text sessions.
45610998|NCT03435445|Behavioral|Online dietitian coaching|Dietitian coaching refers to individual online sessions between a dietitian and participants to strengthen dietary recommendations
45610999|NCT03435445|Behavioral|Control group|Minimal intervention with four videos with diet, physical activity and behavior change recommendations
45758626|NCT02996513|Other|Retinol Isotope Dilution (RID)|13C-retinyl acetate will be administered to subjects in order to assess their body retinol pools
45611000|NCT03435367|Device|Virtual Reality Program|VR with head mounted display (HMD) and headphones.
45611001|NCT03435367|Device|iPad Tablet|iPad with headphones
45611002|NCT03439969|Device|Mobile Text Messages|Dental inter-proximal control with floss holder and receiving 16 SMS during 4 months.
45611003|NCT03439969|Device|Intra Oral Camera|"SPT - Appointment with Intra-Oral Camera~Examination and diagnosis (15 min) using Intra-oral camera.~Motivation, discussion about desired outcomes and treatment needs (using Intra-oral camera) followed by instrumentation (scaling, polishing) (30 min)."
45611004|NCT03431701|Other|Chlorhexidine|Vaginal cleansing will be performed in conjunction with the abdominal preparation with foam sponge that contains chlorhexidine. A sponge soaked with chlorhexidine will be inserted into the vagina and rotated 360 degrees in the vaginal cavity for about 30 seconds
45611005|NCT03431701|Other|Iodine|Vaginal cleansing will be performed in conjunction with the abdominal preparation with foam sponge that contains iodine. A sponge soaked with iodine will be inserted into the vagina and rotated 360 degrees in the vaginal cavity for about 30 seconds
45611006|NCT03431701|Other|Antibiotics|All participants will receive a single body mass index (BMI) based antibiotic dose of cefazolin or clindamycin within 30 minutes prior to the incision.
45758627|NCT05248412|Other|COVID-19 outbreaks|The intervention of the study is the COVID-19 outbreaks in Hong Kong. The pre-and post-COVID-19 outbreak periods will be defined as 1 January 2010 - 31 December 2019 and 1 January 2020 - 31 December 2024, respectively.
45611007|NCT03431623|Biological|CKD-11101(Darbepoetin alfa)|
45611008|NCT03431623|Biological|NESP(Darbepoetin alfa)|
45611009|NCT04451395|Dietary Supplement|Multiple micronutrients (UNIMMAP composition)|"The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.~Other Name: UNICEF, Micronutrient tabs, pregnancy/PAC-1000"
45611010|NCT03439813|Behavioral|TASK-CBT|.Web and telephone-delivered cognitive behavioural therapy designed for anxiety after stroke and TIA. Six personalized telephone CBT sessions, one week apart by a trained and supervised medical professional using the TASK Therapist's Manual. Treatment website contains multimedia content to cover key CBT skills with weekly online tasks.
45611011|NCT03439813|Behavioral|TASK-Relax|Web and telephone-supported relaxation therapy. Treatment website contains five relaxation exercises: i) audio- and visually-guided breathing exercise, ii) relaxing imagery and sounds, iii) music for relaxation, iv) audio-guided progressive muscle relaxation, and v) a selection of sounds of nature. Telephone instruction given and treatment website contains multimedia content to explain to participant how to practice relaxation regularly during the trial period.
45758628|NCT01270061|Behavioral|HIV testing|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test.
45611012|NCT04451005|Other|0|Elderly patients with sarcopenia
45611013|NCT04451083|Drug|FOY-305|Multiple-dose of FOY-305 will be administered orally at 4 times/day.
45611014|NCT04450849|Procedure|guided tissue regeneration with using an absorbable collagen membrane associated with inorganic bovine bone associated.|Dental surgical procedures that use barrier membranes to direct the growth of new bone and gingival tissue at sites with insufficient volumes or dimensions of bone or gingiva for proper function, esthetics or prosthetic restoration. Using an absorbable collagen membrane (Bio-Gide® Perio) associated with inorganic bovine bone associated with collagen matrix (Bio-Oss® Collagen).
45758629|NCT01270061|Behavioral|General Health Screen|A video will provide health education on diabetes, hypertension, and HIV. The video will then offer free blood pressure check, blood glucose measuring, and a free, rapid oral HIV test.
45758630|NCT01277237|Drug|Omacor|Active comparator: omacor 4g/day
45758631|NCT01277237|Drug|lactose tablet|placebo: lactose tablet 4g/day
45758632|NCT04276688|Drug|Lopinavir/ritonavir|400mg/100mg twice daily for 14 days
45758633|NCT04276688|Drug|Ribavirin|400mg twice daily for 14 days
45758634|NCT04276688|Drug|Interferon Beta-1B|0.25mg subcutaneous injection alternate day for 3 days
45758635|NCT02996435|Behavioral|Mobile Application Intervention|Mobile phone application that sends reminders and allows participants to self-manage their medication adherence. Monitoring of participant adherence from this tool will be performed by the central coordinating center, which will send notifications or contact the participant based on the adherence history in accordance with the study protocol.
45758636|NCT02996435|Other|No Intervention|Participants will receive physician- or nurse-guided standard of care.
45445163|NCT02799784|Drug|Albuterol/salbutamol|Albuterol/salbutamol will be supplied as an inhalation spray via metered dose inhaler and will be issued for reversibility testing at Visit 1. Albuterol/salbutamol will be permitted throughout the study for use as-needed
45611015|NCT04450849|Procedure|guided tissue regeneration with using an absorbable collagen membrane associated or not with inorganic bovine bone associated with collagen matrix.|dental surgical procedures that use barrier membranes to direct the growth of new bone and gingival tissue at sites with insufficient volumes or dimensions of bone or gingiva for proper function, esthetics or prosthetic restoration. Using an absorbable collagen membrane (Bio-Gide® Perio) alone.
45611016|NCT03431389|Device|Tracheostomy tube|Tracheostomy done to all patients by open surgical technique and was done in ICUs without need to transfer to theatre.
45611017|NCT03435289|Drug|CPI 613 in Combination With Gemcitabine and Nab-paclitaxel|"Day 1,15 CPI-613: IV infusion at a rate of 4 mL/min via a central venous catheter starting at 500 mg/m2 (with concurrent D5W infusing at a rate of 125-150 cc/hr). The CPI dose will be determined based on cohort. Day 2,16 Neulasta as clinically indicated~Nab- paclitaxel 125mg/m2 iv over 30 min followed by Gemcitabine 1000mg/m2 iv over 30 min"
45611018|NCT03435133|Drug|Prasugrel|60 mg oral bolus plus oral 10 mg once daily
45758637|NCT04275986|Procedure|Intensity modulated radiotherapy (IMRT)|Intensity-modulated radiation therapy (IMRT) with a total dose of 45Gy in 25 fractions
45611019|NCT03435133|Drug|Ticagrelor|180 mg oral bolus plus oral 90 mg every 12 hours daily
45611020|NCT03431311|Biological|Adoptive Cell Therapy (ACT)|T cell receptor based therapy of metastatic colorectal cancer with mRNA-engineered T cells targeting mutant transforming growth factor beta receptor type II (TGFβII)
45758638|NCT04275986|Drug|Chemotherapy|Nedaplatin 25 mg/m2 and Paclitaxel liposome 45mg/m2, day 1, every week, 5 weeks
45758639|NCT05246150|Behavioral|nursing care practices|To determine the effect of nursing care practices on Near Infrared Spectroscopy (NIRS) levels in premature babies
45758640|NCT01277627|Drug|Nevirapine|nevirapine: 400 mg a day.
45758641|NCT01277627|Drug|efavirenz, protease inhibitors|efavirenz: 600 mg a day
45758642|NCT04397744|Behavioral|Unidas por Vida y Salud prevention program|The Unidas por Vida y Salud (United for Life and Health) prevention program is led by the El Paso Cancer and Chronic Disease Consortium (CCDC), the only Breast and Cervical Cancer Services (BCCS) provider in El Paso. This prevention program will use a well-integrated network of community organizations and health service providers to connect medically underserved women to services. To reach the most underserved women and increase preventive cancer screening and timely follow-up, diagnosis, and treatment, the multi-method approach uses evidence-based strategies, including face-to-face educational sessions led by promotoras (community health workers), client reminders, and provision of community-based navigation services to affordable and free screening services. The program also includes clinic-based navigation for those requiring diagnostics or treatment delivered by trained nurses and case workers.
45758643|NCT02996201|Other|Completion of PRO-CTCAE items before consultation|Patients report PRO-CTCAE symptoms on a tablet computer before each cycle of chemotherapy
45758644|NCT03009890|Procedure|Surgery (Open Reduction Internal Fixation)|Either volar of dorsal plating or both
45758645|NCT03009890|Procedure|Cast treatment|Hospitals may use their preferred protocol
45758646|NCT00728819|Device|Tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
45758647|NCT00728819|Device|Non-tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
45445164|NCT03779685|Procedure|General anesthesia|Sevoflurane and morphine
45445165|NCT03779685|Procedure|Regional anesthesia|Paravertebral block
45445166|NCT03779607|Other|Celtra Press|"new class of zirconia-reinforced lithium silicate material available to labs for pressing. This unique material provides top aesthetics and is virtually impossible to tell apart from a natural tooth.~Celtra Press is a multiphase ceramic consisting of a glass matrix and lithium disilicate crystals having a crystal length of about 1.5 µm plus nano-scale lithium phosphate . In addition to Li2O and SiO2, Celtra Press contains about 10% zirconia (ZrO2), which is dissolved completely in the glass phase rather than in crystalline form. Celtra Press is characterized by a high strength of about 500 MPa and excellent flow properties during pressing."
45445167|NCT02059252|Device|SmartMatrix dermal replacement scaffold|SmartMatrix dermal replacement scaffold
45611021|NCT03439579|Behavioral|Home weight loss program|Patient remote self-monitoring of diet, activity, and weight with clinician feedback provided remotely based on self-monitored data.
45611022|NCT03431233|Dietary Supplement|Protein-enriched bar, commercial cereal bar, or water|Protein enriched bar, commercial cereal bar, or water will be provided 15 minutes before breakfast.
45611023|NCT03431155|Other|Nursing intervention|Nursing Intervention: Protocol and education booklet were developed according to literature and Theory. There were six modules (10 session) which aimed to personal education for every care givers. Every session took 20 minutes and total 200 minutes. First 5 modules finished within 3 days and aafter one week last module completed (to summarize process). Also individual counseling were made.
45611024|NCT03434899|Behavioral|Physical exercise and online support|Person-centered design of a health care plan including individually adjusted physical exercise. Online support for management of health care plan.
45611025|NCT03434899|Behavioral|Physical exercise|Person-centered design of health care plan individually adjusted physical exercise.
45611026|NCT03431077|Drug|Angiotensin II|Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption. LJPC-501 (angiotensin II) is being developed for the treatment of hypotension in patients who do not respond to fluids and vasopressor therapy.
45611027|NCT03430999|Drug|Calmangafodipir|Single ascending doses of 2 μmol/kg, 5 μmol/kg, and 10 μmol/kg
45611028|NCT03430999|Drug|Placebo|Placebo
45611029|NCT04450615|Other|Core stability|"The exercise protocol consists of the following sets and repetitions, with a total duration of 5 weeks and a frequency of 3 sessions per week.~Dynamic exercises: 2 sets of 10 to 15 repetitions (each side) Isometric exercises: 2 sets of 5 to 15 seconds (each side) Week 1- As mentioned above Week 2- Add 1 set Week 3 - Add 5 seconds and 5 repetitions Week 4 - Add 1 set Week 5- Add 5 seconds and 5 repetitions"
45611030|NCT03430921|Device|Enlighten™ Laser and a MLA Attachment|Subjects will receive up to six treatments with the Cutera enlighten laser with the Micro-Lens Array handpiece attachment, and may undergo a 2mm punch biopsy before, immediately after, and up to 72 hours after treatment. Subjects may receive a biopsy per Investigator discretion either at one of the follow-up visits (6 weeks or 12 weeks) or 3 months post initial treatment.
45611031|NCT04450537|Behavioral|Vape Messaging Intervention|Participants will be exposed to 10 vape education messages
45611032|NCT03860311|Device|Bladder Ultrasound|"Bladder fullness will be assessed upon enrollment and if not full, the patient will receive hydration, determined by treating physician, and the bladder ultrasound will be repeated every 30 minutes until the patient states that the bladder is full, or until bladder is deemed full based on a previously validated bladder fullness qualitative scale, at which point patients in this group will proceed to undergo pelvic ultrasound."
45445168|NCT03779451|Drug|17-OHPC|received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 26-28 week and up to 37-weeks' gestation or delivery.
45611033|NCT03860311|Other|Standard of Care|Per institution protocol, patients in the standard of care group will have urethral (bladder) catheter placed immediately after the order for pelvic ultrasound and will undergo retrograde bladder filling as determined by the radiologist/ultrasonographer to the point necessary to fully visualize pelvic structures.
45611034|NCT03434743|Other|Rehabilitative|Non-nutritive sucking on emptied breast
45611035|NCT03434743|Other|Active Comparator|Non-nutritive sucking on pacifier
45611036|NCT03434665|Procedure|Transradial celiac artery angiography|"After completion of transradial diagnostic coronary angiography and/or PCI, before removal of the radial arterial sheath, selective angiography of the celiac artery will be performed.~Technically, a 0.35-inch wire is advanced into the descending aorta. A 125 cm 5-French Judkins right catheter is inserted over this wire, which is then removed. The distal tip of the catheter is brought in front of the ostium of the celiac artery and positioning is confirmed with angiography of the celiac artery. Two or three views will be obtained to determine the optimal view to visualize the left gastric artery anatomy. All material is removed and hemostasis is obtained as per clinical routine for coronary angiography."
45611037|NCT04689295|Other|exercise programme 1|Schroth three dimensional scoliosis therapy method
45611038|NCT04689295|Other|exercise programme 2|Traditional scoliosis exercises
45611039|NCT03856723|Other|Renal Replacement Therapy|"Indications for RRT were defined as previously reported.~Kidney Disease: Improving Global Outcomes (KDIGO) stage 2 ;~severe sepsis, persistence of hypotension (for more than 6 h) despite preload optimization and use of vasopressors or catecholamines (norepinephrine or epinephrine >0.1 μg/kg/min),~refractory fluid overload (worsening pulmonary edema, PaO2/FiO2 <300 mm Hg or fluid balance >10% of body weight),~low probability of rapid renal recovery according to the judgment of the intensivists and nephrologists."
45611040|NCT03434587|Procedure|Syndactyly|Syndactyly
45611041|NCT03434587|Procedure|Reduction and inmobilization|Closed reduction and inmobilization with splint
45611042|NCT03848299|Other|Experimental: Single Arm|"All participants will have to consume the same standardized breakfasts from the second to the seventh day, except the ones that are intolerant or allergic to lactose or/and gluten. In those cases, they will follow an adapted diet for their intolerance or allergies.~Day 2 and 3: 110 g white bread.~Day 4 and 5 : 110 g white bread and 30 g butter or 55 g white bread, 50 g dark chocolate for lactose intolerant.~Day 6 and 7: Glucose drink (50g).~The bread will be replaced by gluten-free bread for gluten intolerant participants."
45611043|NCT03430765|Behavioral|Acceptance and Commitment Therapy|Single 2-hour individual Acceptance and Commitment Therapy coping skills session.
45611044|NCT03439501|Drug|avelumab|"Study drug: Avelumab (PD-L1 inhibitor; MSB0010718C)~Dosage: 10 mg per body weight (kg) of a subject every two weeks~One cycle consists of two injection of avelumab (28 days).~The treatment cycle will be repeated until progression of disease or unacceptable toxicity and dose adjustments are permitted for patients who are unable to tolerate the side effects of drugs within each cycle."
45611045|NCT03430687|Other|Laboratory Biomarker Analysis|Correlative studies
45611046|NCT03430687|Biological|Talimogene Laherparepvec|Given intravesically
45611047|NCT03434431|Other|Reverse dieting|
45611048|NCT04255381|Device|Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)|Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)
45611049|NCT03757897|Drug|Dexmedetomidine|The standard dosing of 1mcg/kg will be implemented over 10 minutes followed by a maintenance infusion of 0.2-1.0 titrated to a the target BIS (60-70) during the 20 minutes prior to MRI.
45611050|NCT03434197|Drug|Esflurbiprofen|A plaster containing 40 mg of Esflurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per patch (10 × 14 cm)
45758648|NCT05245214|Diagnostic Test|Magnetic Resonance Imaging|Muscle analysis by Magnetic Resonance Imaging
45758649|NCT01270217|Behavioral|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
45758650|NCT05241470|Drug|ST-100 Ophthalmic Solution|One drop in each eye twice a day
45758651|NCT05241470|Drug|Placebo Ophthalmic Solution|One drop in each eye twice a day
45445169|NCT03779451|Drug|vaginal progesterone|vaginal progesterone suppositories (Cyclogest vaginal suppository) in a dose of 400 mg daily starting at 26-28 weeks of gestation till 37 weeks of gestation or delivery
45445170|NCT02059330|Drug|Palbociclib 75mg|In Period 1, Japanese subjects will receive a single oral 75mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
45445171|NCT02059330|Drug|Palbociclib 125mg|In Period 2, Japanese subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
45611051|NCT03434197|Drug|Diclofenac diethylamine|A gel containing 11.6 mg of Diclofenac diethylamine (equivalent to 10 mg of diclofenac sodium) per 1 g (1 tube contains 20 g)
45758652|NCT05245838|Biological|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg
45611052|NCT03439111|Dietary Supplement|Standardized Lycium chinense Fruit Extract (LCF) capsules|All dried water extracts and capsules of the Standardized Lycium chinense Fruit Extract (LCF) and Standardized Lycium chinense Fruit Extract (LCF)-matched placebo capsules used in the present study were manufactured and provided by the BIOMIX Company (Ilsan City, Korea).
45611053|NCT03757429|Other|RS-virus infection|The intervention consists of lower respiratory tract infection due to RS-virus
45611054|NCT03430609|Procedure|Laparoscopic treatment for endometrioma Astus©|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In the hemostasis , the investigators will use coagulation with bipolar tweezers Astus Medical© in this group.
45611055|NCT03430609|Diagnostic Test|AMH Level|"The AMH levels will be quantitatively measured via ELISA, Enzyme-Linked Immunosorbent Assay (Diagnostic Systems Laboratories, Webster, TX), with a detection sensitivity of 0.006 ng/mL.~The participants' sera will be obtained from blood samples after centrifugation for 10 minutes to separate the cell contents and debris. Each serum sample will be transferred to polypropylene tubes and stored at -70ºC. Venous blood samples will be collected before surgery (on the day ultrasound is performed for antral follicle count, approximately 1 month before surgery) and 1, 3 and 6 months after surgery."
45611056|NCT03430609|Diagnostic Test|Transvaginal ultrasound for antral follicle count|The participants will be subjected to transvaginal ultrasound for antral follicle count before surgery (1 month before surgery) and 1, 3 and 6 months after surgery. This test will be performed during the early proliferative stage (days 3 to 6 of the menstrual cycle); the size of the endometrioma and the ovary volume will be recorded, and functional cysts or suspected malignant cysts will be ruled out. For measurement of cysts, the average diameter of the three perpendicular ovary dimensions will be considered. For antral follicle count, the total number of follicles with diameters under 9 mm will be considered.
45611057|NCT03430609|Procedure|Laparoscopic treatment for endometrioma Vicryl®|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In the hemostasis , the investigators will perform suture with 2-0 Vicryl® in this group.
45611058|NCT03430609|Procedure|Laparoscopic treatment for endometrioma Surgicel®|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In this group, for hemostasis , the investigators will use matrix Surgicel®
45611059|NCT03438955|Drug|Omacor|Omacor soft capsule 4000mg for 16days
45611060|NCT03438955|Drug|Pritor|Pritor tablet 40mg for 7days
45611061|NCT03438955|Drug|Omacor + Pritor|Omacor soft capsule 4000mg + Pritor tablet 40mg for 7days
45611062|NCT03438955|Drug|Pritor + Omacor|Pritor tablet 40mg + Omacor soft capsule 4000mg for 16dyas
45611063|NCT03433963|Dietary Supplement|L-Arg supplement|L-Arg supplement will be prepared as pills, administered 9g each day in 3 times for 2 weeks.
45611064|NCT03433963|Dietary Supplement|Placebo|Placebo will be prepared as pills (the same size, color and shape as of L-Arg), administered 3 times daily for 2 weeks.
45611065|NCT03128437|Behavioral|Aerobic Exercise|At each of the six exposure sessions, participants will be invited to engage in 2-minute warm-up on the treadmill. Following this warm-up period, participants will be asked to briskly walk or jog on the treadmill at a speed that maintains their heart rate at 60-80% of maximum age-predicted heart rate for 20 minutes using the formula: (220-age) x (0.60 [lower bound] or 0.80 [upper bound]). Participants will be fitted with a heart rate monitor, which will be checked by a research assistant at 5-minute intervals in order to ensure adherence to this prescription; participants will be asked to adjust treadmill speed in order to remain in this range. Following each 20-minute exposure, participants will complete 5 minutes of cool down walking on the treadmill. Assessments will take place at baseline, week 2 (post-intervention), week 4, and week 8.
46068728|NCT05709197|Procedure|Standard Child reconstruction|Participants will undergo open pancreatoduodenectomy (PD). The reconstruction technique will not be standardized. The surgeon is able to perform the PD as normally would be done (antecolic, retrocolic, pylorus-preserving or with distal gastric resecting).
46068729|NCT05706441|Other|Point-of-Care Ultrasound|Ultrasonographic scans of the lung and right hemidiaphragm were acquired after 30 min from the beginning of the SBT, or immediately before reconnecting the patient to the ventilator in the case of SBT failure occurring before
46068730|NCT05697198|Diagnostic Test|OmniSeq Test|Genomic and immune profiling assay for all solid tumors
46068731|NCT05696561|Device|Canaloplasty Device|Canaloplasty
46068732|NCT05692323|Other|PREHAB|6-week supervised PREHAB program. Each week of the program consists of 3 x 1 hour supervised training sessions made up of moderate intensity aerobic training and resistance training. In addition to the supervised sessions, patients will be instructed to accumulate a total of 150 minutes per week of moderate aerobic training at home which is measured by a wrist worn FitBit device.
46068733|NCT05683418|Drug|TOS-358|Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor
46068734|NCT05683119|Other|Exercise and blood draw|This project intends to investigate the effects of circulating fluctuations in oestradiol and progesterone, experienced during the menstrual cycle [MC] and oral contraceptive pill [OCP] use, on aspects of exercise physiology and athletic performance in female athletes. This research aims to determine if a particular hormonal profile affects physiological functioning (e.g., muscle strength, maximum oxygen uptake) and/or athletic performance in female athletes. The intervention will include a stretching regimen, balance test, push-ups, agility test, handgrip muscle test, vertical jump, flexibility test, cycling protocol, blood sample and height/ weight measurements.
45611066|NCT04240249|Behavioral|Constructive self-assertiveness program via the internet|"Participants will get one chapter a week to work with. All chapters are presented on web pages and include information and exercises and end with homework assignments."
45611067|NCT04655911|Biological|ABO-101|Gene therapy rAAV9.CMV.hNAGLU
45611068|NCT03430453|Procedure|Measure of the minimal intensity of stimulation during ultrasound guided peripheral nerve blockade|A needle is placed at the target under ultrasound guidance, the nerve stimulator is turned on and the intensity increased until motor response is observed. The Minimal Intensity of Stimulation is recorded before injection of local anesthetic
45611069|NCT04450303|Behavioral|Telehealth CBT|The Coordinated Anxiety Learning and Management (CALM) program is an evidence-based, computer-assisted protocol for cognitive behavioral therapy (CBT) for anxiety, depression, and/or post-traumatic stress. CALM will be implemented via secure and HIPAA compliant video-conferencing software (enterprise Zoom), following modifications to address obstacles associated with physical distancing and the tele-health medium.
45611070|NCT03430375|Device|Alternating air wheelchair cushion|The Ease alternating air cushion has longitudinal air bladders which alternately inflate and deflate at 3 minutes intervals in order to change the areas of pressure to the skin for areas in contact with the wheelchair cushion/seat (buttock and posterior thighs). The Ease Alternating Pressure wheelchair cushion is 510(k) exempt.
45611071|NCT03430375|Device|Static air cushion|The Roho static air cushion is composed of multiple air bladders that are inflated to proper levels according to the individual's weight. This cushion is commonly used for individuals post spinal cord injury and sometime for individuals post stroke. The Roho wheelchair cushion is 510(k) exempt.
45611072|NCT03438799|Device|Cordio System|App, cloud and web device
45611073|NCT03430297|Biological|JS001 240mg Q2W|"recombinant humanized anti-PD-1 monoclonal antibody injection (JS001) will be provided by the sponsor. Strength: 240mg/6ml/vial. 240mg, once every two weeks.~Control drug: dacarbazine (1000mg/m2, d1, intravenously, once every three weeks). The dose will be given intravenously over 180 minutes (the infusion time can be prolonged according to the institutional criteria), starting from Week 1, once every 3 weeks, until progression of disease."
45611074|NCT03430297|Drug|Dacarbazine 1000mg/m2 Q3W|"The dose of DTIC will be calculated according to the following formula, where the 'X' represents the total mg dose of DTIC: X (mg) = [body surface area (BSA) x (1000mg/m2)].~The body surface area (BSA) is defined by Dubois formula: BSA (m2) = 0.007184* (cm0.725) * (kg0.425)"
45611075|NCT04224883|Procedure|Continuously feeding|Daily amount of feeding were continuously pumped for 24 hours. EN preparation pumping scheme was as follows: The initial pumping speed was average pumping volume of total enteral nutrition in one day, and gastric residual volumes is checked every 4 hours. If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV<200mL were considered markers of good tolerance.Feeding intolerance was defined as GRV>200 mL. If GRV>500mL, EN was stopped and reassessed after 4 hours.
45611076|NCT04224883|Procedure|16-hours feeding|Daily amount of feeding were continuously pumped for 16 hours.EN preparation pumping scheme was as follows: The initial pumping speed was average pumping volume of total enteral nutrition in one day, and gastric residual volumes is checked every 4 hours.If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV>200 mL. If GRV>500mL, EN was stopped and reassessed after 4 hours.
45611077|NCT04224883|Procedure|intermittent feeding|Daily amount of feeding were divided into four meals, each meal are pumped within 60mins or 120mins through stomach tube. EN preparation pumping scheme was as follows: If the volume of each meal is less than or equal to 250ml(≤250ml), pump in within 60min, if volume is greater than 250ml(>250ml), pump in within 120min and gastric residual volumes is checked before each intermittent feeding. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV>200 mL. If GRV>500mL, EN was stopped and reassessed after 4 hours.
45611078|NCT03430141|Other|Nutritarian Diet-style|Nutritarian Diet-style: Daily consumption of greens, beans/legumes, a variety of other vegetables, fresh or frozen fruits, nuts, seeds and whole grains. Participants are encouraged to minimize consumption of refined grains, vegetable oils, processed foods, and to limit animal products.
45611079|NCT03433729|Other|Patient agenda form|On arrival at the clinic patients are given an agenda form to prompt them to think about what issues they wished to discuss with their doctor. The form contains a prompt list of items they can tick, free space to write their own items, and a prompt to consider what is the most important issue for them and what they would like to happen before they leave their clinic appointment.
45611080|NCT04219735|Drug|Minocycline|Minocycline 100mg BID
45611081|NCT04219735|Drug|Placebos|Placebo
46068735|NCT05678478|Other|semi-directed interview concerning the experience of adolescents and their parents on Lyme borreliosis and on the tick.|"semi-structured interview on the experience of adolescents and their parents on Lyme borreliosis and the tick.~The interviews will be semi-directed in physical presence. Three interviews will be conducted.~The minor will be questioned first, then the parent(s). And finally, the whole family in one interview. All interviews will be audio recorded with parallel note taking in order to best transcribe the visual expressions. The interviews will be transcribed in writing and pseudonymised."
45611082|NCT03433651|Drug|Creatine monohydrate|Subjects will take by mouth 5 grams a day of creatine monohydrate powder.
45611083|NCT03433651|Drug|Placebo|Subjects will take by mouth 5 grams a day of placebo powder.
45611084|NCT03438565|Device|Asahi Chikai Black 18 neurovascular guidewire|"The Asahi Chikai Black 18 microguidewire employs a reverse tapered shaft with 0.018 tip and 0.014 proximal shaft, which provides additional support and tactile feedback."
45611085|NCT04450147|Behavioral|Tai Chi/Qigong vs. Walking/Stretching|Both interventions can be thought of as a form of movement and exercise.
45611086|NCT03438409|Other|Robotic gait training|Robotic gait training
45758653|NCT05245838|Biological|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg with aluminum hydroxide (alum)
46068736|NCT05672134|Diagnostic Test|Iohexol measurement|Invasive renal hemodynamic measurement of mGFR through the administration of Iohexol.
46068737|NCT05672134|Drug|Geranylgeranylacetone (GGA)|13 weeks of treatment with GGA/placebo orally, followed by a wash-out period of 6 weeks, then reversal of the treatment arms.
45611087|NCT03433573|Device|Abbott Sensor Based Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring System and will be asked to perform 4 blood glucose tests per day (pre-meal and before bedtime). Subjects will be asked to scan the sensor when each blood glucose test is performed.
45611088|NCT03128125|Other|clinical examination in neurology|This examination is based on the movement of the child in a standing position (forward and backward on a straight line, jumping on a foot ...), seated (visual continuation ...) and elongated (tone, patellar and achillian reflexes, superficial sensitivity ...) . This makes it possible to evaluate all the neurological systems.
45611089|NCT03128125|Other|neuropsychological examination|This examination is based on the use of standardized psychometric tools and validated with children, usually used in clinical practice.
45611090|NCT03128125|Other|anamnestic elements|Several elements will be collected during the clinical interview to inform the history of the child's development, such as neonatal data (term of pregnancy, APGAR score ...), age of appearance of the first words , seating, walking, possible care, level of education ans level of education of the parents.
45611091|NCT03433495|Other|Melodic Intonation Therapy|
45611092|NCT04070365|Device|FLEX Vessel Prep System followed by angioplasty|Eligible Arteriovenous Fistula (AVF)/Arteriovenous Graft (AVG) will be treated with the FLEX Vessel Prep system followed by angioplasty.
45611093|NCT03375853|Behavioral|Computer Based Response Training Weight Loss Intervention|Participants complete four computer based training tasks each visit, over the course of a few lab visits. Participants then perform weekly booster sessions in a more natural home or community environment over the internet using the same computer based training tasks.
45611094|NCT03375853|Behavioral|Generic Response Training Control Intervention|Participants complete four computer based training tasks each visit, over the course of a few lab visits. Participants then perform weekly booster sessions in a more natural home or community environment over the internet using the same computer based training tasks.
45611095|NCT03128281|Behavioral|Questionnaires|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~Questionnaires ask about pain level and any drugs taken for it. It should take about 5 minutes to complete."
45611096|NCT03128281|Device|Conventional Insufflation System (CIS)|CIS with pressure target of 15±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
45611097|NCT03128281|Device|ConMed AirSeal Insufflation System (AIS) at Low Pressure|AIS with an insufflation pressure target of 9±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
45611098|NCT03128281|Device|ConMed AirSeal Insufflation System (AIS) at Higher Pressure|AIS with an insufflation pressure target of 15±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
45611099|NCT03429751|Drug|30 ml/Kg/h crystalloid|Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 30 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
45611100|NCT03429751|Drug|10 ml/Kg/h crystalloid|Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 10 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
45611101|NCT04012723|Device|MY01 Continuous Compartmental Pressure Monitor|The MY01 Continuous Compartmental Pressure Monitor is intended for real-time and continuous measurement of compartmental pressures.
45611102|NCT04449757|Drug|Bicarbonated Ringer's solution|Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.
45611103|NCT04449757|Drug|Lactated Ringer's solution|Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.
45611104|NCT04008745|Other|Educational and home-based physical therapy by foot-related exercises|The booklet is divided in 2: educational and exercise protocol. The aim of the first part is to guide the individual for a change in his/her health behavior, and comprises info about diabetic neuropathy, foot care, shoes, and benefits of exercising. The second part is the foot protocol, composed by 6 exercises. The maximum duration of a session is 20min and should be performed 3 times/week. The subject should warm-up the foot-ankle and then start exercising in the order suggested by the booklet, filling a table with the effort perceived (effort likert scale). The foot exercises progresses from one set with 30 repetitions in a sitting position, to exercising standing, then performing the exercise on one foot only. Other progression criterion is to increase the number of sets performed. The effort scale regulates the individual effort for his/her progression, which is also registered by the participant in the monthly table at the booklet.
45611105|NCT03429673|Procedure|Surgeries|Lobectomy or segment/wedge dissection
45611106|NCT04449601|Other|clinical assesment|Comparison of Hypertensive group and normotensive group
45611107|NCT03621553|Drug|Ergocalciferol|Vitamin D2 50,000 units
45611108|NCT03621553|Drug|Placebo|Sugar pill manufactured to mimic ergocalciferol 50,000 units
45758654|NCT05245838|Biological|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg
46068738|NCT05672134|Diagnostic Test|Echocardiography|The investigators will perform echocardiography to find changes in cardiac function.
46068739|NCT05672134|Diagnostic Test|6-minute walking distance test|6 minute walking distance test to compare exercise tolerance in participants.
45611109|NCT03621553|Drug|Calcium Citrate with Vitamin D2|To meet the recommended minimum daily dietary requirements
45611110|NCT03423667|Drug|N-acetylcysteine|N-acetylcysteine (1200 mg) administered twice a day during 5 days
45611111|NCT03423667|Drug|Lactose powder|Placebo comparator.
45611112|NCT03423511|Device|MiStent II coronary artery stent|Implantation of a coronary stent patient with stable and unstable coronary artery disease including non-ST-Elevated Myocardial Infarction
45611113|NCT03423511|Device|Xience or Promus coronary artery stents|Implantation of a coronary stent patient with stable and unstable coronary artery disease including non-ST-Elevated Myocardial Infarction
45611114|NCT01559363|Drug|Tesevatinib|Pharmaceutical form: Tablets Route of administration: Oral
45758655|NCT05245838|Biological|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg, with aluminum hydroxide (alum)
45758656|NCT05245838|Biological|Shingrix|a suspension for injection supplied as a single-dose vial of 50 mcg varicella zoster virus (VZV) glycoprotein E (gE) antigen and AS01B adjuvant
45758657|NCT02996123|Other|cad/cam maxillary dentures|patients wearing cad/cam designed and milled dentures
45611115|NCT03423433|Behavioral|Heel raise intervention|A daily heel-raise programme for ten weeks to determine any chronic effects of heel raises on the previously mentioned variables.
45611116|NCT03127969|Other|Fluidotherapy treatment|fluidotherapy and joint protection and exercise
45611117|NCT03127969|Other|Joint protection and exercise|joint protection and exercise
45758658|NCT01270451|Other|Lifestyle intervention to prevent weight regain|To study if subjects receiving extra guidance in diet and physical activity experience less weight gain compared to a control group.
45758659|NCT01270607|Procedure|Acupuncture|Treatment given twice per week for 4 weeks
45611118|NCT03569839|Drug|Propofol|Patients undergoing surgery, TIVA (total intravenous anaesthesia)
45611119|NCT01504919|Behavioral|Health Education|Brief counseling at baseline, at 6 months and again at 12 months, and self-help materials addressing smoking cessation, diet, physical activity, referrals to available resources, and a home-based exercise kit (e.g., pedometer, exercise ball, strength training cables).
45611120|NCT01504919|Behavioral|Questionnaires|Computer-based questionnaires completed at baseline, then every 6 months taking 60-90 minutes to complete.
45611121|NCT01504919|Behavioral|Telephone Counseling Sessions|9 proactive, telephone counseling sessions over 18 months. Each of these phone calls should last about 20-30 minutes.
45611122|NCT01504919|Drug|Nicotine Patches|6-week supply of nicotine patches given to participants ready to quit smoking.
45611123|NCT03540121|Behavioral|Video education + adherence contract|Participants will receive standard education along with the home-based video education plus an adherence contract. Following the baseline assessment, access to videos will be provided electronically so that the patient can watch them at home. The videos will be initially viewed in the following order: Video 1: Introduction, Video 2: Medications, Video 3: Your New Life. Approximately one month after transplant, after the video series has been viewed in its entirety, participants will receive an email link inviting participants to reflect on their goals about transplantation and pledging to taking their medications as directed. The contract will be non-enforceable, but it will provide patients with the opportunity to formally commit to a goal of taking the medications as prescribed. At 3 months, and 12 months, the participant will have the opportunity to reflect and modify adherence goals as desired.
45611124|NCT02732327|Drug|CAZ-AVI|Ceftazidime-Avibactam (2 g ceftazidime and 0.5 g avibactam)
45611125|NCT02732327|Drug|Vancomycin|15 mg/kg
45611126|NCT02732327|Drug|Linezolid|600 mg
45611127|NCT02732327|Drug|Cefepime|2 g
45611128|NCT02732327|Drug|Meropenem|1 g
45611129|NCT02732327|Drug|Piperacillin/tazobactam|4.5 g
45611130|NCT03428503|Drug|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solutionBristol-Myers Squibb_UK) intravenous (IV) was given 100patients
45611131|NCT03428503|Drug|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
45611132|NCT03421535|Procedure|Sleeper Stretch|Internal Range of motion of dominant shoulder
45611133|NCT03421535|Procedure|Opposite SI joint Stretch|Internal range of motion of dominant shoulder
45611134|NCT03428425|Drug|paclitaxel apatinib S-1|"HIPEC: 43℃, 60min. the drug is paclitaxel : 70mg/m2 d1 d3 d5, The interval is not less than 24h , A total of three times.~apatinib：500mg qd po, 28 days is a cycle.preoperative 2 cycles, 2 cycles after surgery.~S-1： According to the body surface area, BSA <1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA >1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery"
45611135|NCT03417089|Procedure|Falciform ligament suspension|routine of falciform ligament suspension during Mini gastric bypass
45758660|NCT01277939|Behavioral|Therapeutic Education System (TES)|Therapeutic Education System (TES) is an interactive, computer-based, psychosocial treatment program. TES is theoretically grounded in evidence-based psychosocial treatments (Community Reinforcement Approach and Cognitive Behavioral Therapy).
45611136|NCT03417089|Procedure|no suspension|working without of falciform ligament suspension during Mini gastric bypass
45611137|NCT03534583|Other|Sudarshan Kriya Yoga|Participants in the SKY group will undergo an oline 12-week training course conducted by certified teachers of the Art of Living Foundation
45758661|NCT01277939|Behavioral|Standard Care|Psycho-educational and psycho-social approaches to substance use disorders (commonly offered in prison settings) delivered by counselors in group formats.
45611138|NCT03534583|Other|Health Enhancement Program|Participants in the online HEP will learn about health promotion, healthy diet, music, and exercise, but will not learn breathing techniques, or meditation. HEP will be delivered by trained staff.
45758662|NCT00729053|Drug|IMO-2055|immunostimulatory oligonucleotide
45611139|NCT03416777|Behavioral|Meat-based diet|Diet including 4 servings per week of red meat (1 serving = 150 g), 3 servings per week of processed meat (1 serving = 50 g), and 1 servings per week of poultry (1 serving = 150 g), for a total amount of 900 g per week of meat.
45611140|NCT03416777|Dietary Supplement|Meat-based diet supplemented with alpha-tocopherol (MBD-T)|Dietary intervention like the MBD with supplementation of alpha-tocopherol at a dosage of 100 mg/die. Available evidence suggests that alpha-tocopherol may help prevent colon cancer by decreasing the formation of mutagens arising from the oxidation of faecal lipids, by decreasing oxidative stress in the epithelial cells of the colon and by molecular mechanisms that influence cell death, cell cycle and transcriptional events (Pierre 2013, Bastide 2016, Bastide 2017, Diallo 2016). It is important to note that 200 mg/day of tocopherol was administered to 20,000 women for 10 years without side effects (Lee et al.,2005).
45611141|NCT03416777|Behavioral|Pesco-vegetarian diet|Diet excluding fresh and processed meat, poultry but including 3 servings per week of any type of fish, excluding shellfish (1 serving = 150 g), for a total amount of 450 g per week. Diet will contain other sources of proteins (e.g. eggs, dairy, legumes/beans). There is suggestive evidence that fish and vegetable consumption has protective effects against CRC (Vieira et al., 2017).
45758663|NCT00706979|Other|Practice Quit Attempt plus nicotine lozenge|nicotine lozenge, 2 mg or 4 mg
45758664|NCT00706979|Behavioral|Practice Quit Attempt only|Practice Quit Attempts (PQA) message aided by brief advice and self-help materials
45758665|NCT01278017|Drug|ceftriaxone|ceftriaxone ,parenteral route, 50mg/kg/day divided twice
45758666|NCT01278095|Drug|GLPG0555 solid dispersion|solid dispersion capsules, 50 mg, single dose
45758667|NCT01278095|Drug|GLPG0555 nanosuspension|Nanosuspension, 50 mg, single dose
45611142|NCT03533725|Other|Breastfeeding counseling and education services|Breastfeeding counseling and education by educated and trained peer counselors using mHealth tools
45611143|NCT03429595|Drug|ATx201|ATx201 GEL
45611144|NCT03429595|Other|ATx201 GEL Vehicle|Vehicle
45611145|NCT03428347|Biological|GamEMab|drug for emergency prevention of Ebola based on recombinant monoclonal antibodies
45611146|NCT03423043|Radiation|Low Dose CT Scan of the Wrist|A low dose CT scan will be obtained in patients with a distal radius fracture of the wrist.
45611147|NCT02521129|Device|Biopsy Track Ablator (STARmed, Goyang, Korea)|After percutaneous ultrasound guided biopsy for hepatic masses is performed, biopsy track is ablated with a new track ablation device.
45611148|NCT03429517|Diagnostic Test|Lipogram|liporgram samples
45611149|NCT03429439|Other|intestinal microbiota transplant|Participants in experimental group take 6 times IMT with 2-week intervals.
45611150|NCT03429439|Drug|Antiviral Agents|All participants continue present antiviral therapy over 12 months.
45611151|NCT03422965|Diagnostic Test|Optical Coherence Tomography Angiography|Optical Coherence Tomography Angiography images capture.
45611152|NCT03422965|Diagnostic Test|Blood test|Blood test, systemic markers
45611153|NCT03422965|Diagnostic Test|Urine test|Urine test, systemic markers
45611154|NCT03422887|Drug|Nalbuphine|Nalbuphine administration during surgery
45611155|NCT03422887|Drug|Flurbiprofen Axetil|Flurbiprofen axetil administration during surgery
45611156|NCT03422887|Drug|Nalbuphine and Flurbiprofen Axetil|Nalbuphine and Flurbiprofen Axetil administration during surgery
45611157|NCT03428269|Other|simulation by gaming (LabForGames Warning)|comparison of the efficacy of two educational methods to improve the clinical reasoning skills of nursing students facing patient deterioration
45611158|NCT03428269|Other|traditional education|comparison of the efficacy of two educational methods to improve the clinical reasoning skills of nursing students facing patient deterioration
45611159|NCT02521207|Drug|Ibuprofen|
45611160|NCT03179605|Drug|DFD06|Apply twice per day for 15 days
45611161|NCT03173053|Drug|Doxycycline|tablet
45611162|NCT03173053|Drug|Trimethoprim|tablet
45611163|NCT03173053|Drug|Sulfamethoxazole/trimethoprim|tablet
45611164|NCT03173053|Drug|Clindamycin|tablet
45611165|NCT03173053|Drug|Clarithromycin|tablet
45611166|NCT03173053|Drug|Ciprofloxacin|tablet
45611167|NCT03173053|Drug|Fusidic Acid|tablet or ointment
45611168|NCT03173053|Drug|Rifampin|tablet
45611169|NCT03173053|Drug|Chlorhexidine|Mouthwash or bodywash
45611170|NCT03173053|Drug|Mupirocin|Nasal ointment
45611171|NCT03173053|Drug|Betadine|Shampoo
45611172|NCT03429361|Other|Health by Mindstrong|Health by Mindstrong is a smartphone application that collects data on a participant's smartphone usage patterns.
45611173|NCT03429283|Other|descriptive retrospective epidemiological study|descriptive retrospective epidemiological study
45611174|NCT03109795|Drug|Clonidine Pill|sympathetic nerve activity blockade
45611175|NCT03109795|Drug|Hydrochlorothiazide|Blood pressure-lowering control condition
45611176|NCT03429127|Other|Normal saline|Plasma osmolality, acid base status and electrolytes after application up to 2000 ml of normal saline during neurosurgical operation
45611177|NCT03429127|Other|Balanced fluid|Plasma osmolality, acid base status and electrolytes after application of up to 2000 ml balanced fluids during neurosurgical operation
45611178|NCT03428191|Drug|Remifentanyl+Dexmedetomidine|In all patients, dexmedetomidine was injected at a bolus of 0.6 mg/kg and then continuously infused at 0.6 ug/kg/h using the conventional continuous microinfusion pump. the target Effect-site concentration of remifentanil was determined by sequential method.
45611179|NCT03422575|Drug|Etoricoxib 120Mg Film-coated Tablet|One tablet of the Test drug was given orally (swallowed with 200 mL of water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.
45611180|NCT03422575|Drug|Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp & Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk)|One tablet of the Reference drug was given orally (swallowed with 200 mL of water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.
45611181|NCT03428971|Procedure|cardioversion|Direct current (DC) cardioversion for sinus rhythm restoration
45611182|NCT03422497|Other|Male sex|Male sex-as listed in the discharge abstract database
45611183|NCT03422497|Other|Female sex|Male sex-as listed in the discharge abstract database
45611184|NCT02412722|Drug|Sapanisertib|Sapanisertib capsules
45611185|NCT02412722|Drug|Paclitaxel|Paclitaxel injection
45611186|NCT03422419|Drug|Heparin|The choice of the anticoagulant medication in terms of duration and dose will be determined by the treating physician.
45611187|NCT03422419|Device|TIPS|transjugular intrahepatic portosystemic shunt deployment
45611188|NCT03077815|Other|Systematically intermittent arm exercise|While holding a rubber ball for 5 minutes a day, together with strappy elastic compression arm veinElastic bandages defined for using this research provides of standard bandages, according to research personnel Guide, reached hand elbow near heart end 4 (2~6) cm at of arm local pressure strong 50 mm-Hg (+/-10 mm-Hg) (about equivalent to provides pressure strong 6.67 thousand PA (kPa), also about equivalent to 0.97 PSI (pound per square inch)), to reached 5 minutes arm movement Shi short reduced vein return, promotion pathway vein extended of effect
45611189|NCT03428893|Device|Mobile Application|Participants will receive usual care physical therapy guided by Clinical Practice Guidelines and based on individual symptoms and need over 7 in-person visits. Measures will be collected by the physical therapist related to leg strength, balance, fitness, and mobility as part of the usual care physical therapy evaluation and follow-up. The treating physical therapist will negotiate the physical therapy intervention based on patient preferences and goals and assessment findings. Using clinical practice guidelines, the intervention for the research participants is expected to address deficits in strength, mobility, balance, and cardiovascular endurance. Exercise prescription will be provided using the Wellpepper physical therapy exercise prescription mobile app.
45611190|NCT04449289|Drug|Intravenous lidocaine|Intraoperatively and postoperatively a standard intravenous infusion of lidocaine will be used for analgesia
46068740|NCT05672134|Diagnostic Test|EndoPAT|Use of EndoPAT to measure endothelial function.
45611191|NCT04449289|Drug|Epidural ropivacaine|Intraoperatively and postoperatively an epidural infusion of ropivacaine will be used for analgesia
45611192|NCT03074695|Procedure|Dural puncture epidural (DPE)|Epidural with spinal needle placed to confirm cerebral spinal fluid (CSF) position. No intrathecal dosing
45611193|NCT03074695|Procedure|Standard Epidural (EPL)|Standard epidural placement
45611194|NCT03074695|Drug|Dural puncture epidural (DPE)|Epidural with spinal needle placed to confirm CSF position. No intrathecal dosing. Ropivacaine 0.1% and Fentanyl 2mcg/mL.
45611195|NCT03074695|Drug|Standard Epidural (EPL)|Standard epidural placement. Ropivacaine 0.1% and Fentanyl 2mcg/mL.
45611196|NCT03128203|Drug|Oxytocin|Oxytocin, intranasally administrated
45611197|NCT03128203|Drug|Placebos|Saline, intranasally administrated
45611198|NCT03422341|Device|Comparison between GenePOC CR and Reference Method|The collected swab will be tested with both the GenePOC Strep A, C/G assay and the Reference Method defined as standard microbiology culture and strain identification using a MALDI TOF.
45611199|NCT03422185|Other|No intervention|No intervention
45611200|NCT03469999|Drug|Dysport Injectable Product|Selected dose of medication will be determined by affected muscle(s), severity of spasticity, and the patient's body weight. We will follow the recommended total Dysport dose of 10-15 units/kg per limb, not to exceed 15 units/kg for unilateral lower limb, 30 units/kg for bilateral lower limb, or a total of 1000 units, whichever is lower in a given session.
45611201|NCT02379728|Device|PrenaBelt|"The PrenaBelt (PB) is a belt-like, positional therapy (PT) device designed for pregnant women. While the PB does not prevent the user from lying on her back during sleep, it is expected to significantly decrease the amount of time a user spends supine via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PB is worn at the level of the waist or thorax. By design, the PB affects subtle pressure points on the user's back while supine, activating her body's natural mechanism to reposition itself to relieve discomfort, thereby reducing the amount of time spent supine."
45611202|NCT02379728|Device|Body Position Sensor|The Body Position Sensor (BPS) is for research purposes only. The BPS can be securely integrated into a pocket on the PrenaBelt (PrenaBelt with BPS Arm) or sham-PrenaBelt (Control with BPS Arm). The BPS is a small, electronic data acquisition device. The BPS uses a three axes accelerometer to detect orientation of the PrenaBelt, and thus the user (right, left, prone, supine), in three-dimensional space. The accelerometer data is collected continually with time stamping and stored on the BPS hard drive and can be accessed via connecting it to a computer. The BPS is not expected to affect the body position of the user.
45611203|NCT02379728|Device|sham-PrenaBelt|The PrenaBelt can be easily converted into a sham-PrenaBelt for research purposes by removing the hard balls from its pockets or exchanging these hard balls for soft balls so it cannot provide pressure points, i.e., positional therapy function. The sham-PrenaBelt looks, fits, and feels like the PrenaBelt but cannot provide positional therapy.
45611204|NCT02935309|Drug|Lenvatinib|Pre-surgery Lenvatinib, days 1 - 5. Dose Escalation Levels: 1.) 10 mg by mouth (PO) daily (QD); 2.) 14 mg PO QD; 3.) 20 mg PO QD; 4.) 24 PO QD.
45611205|NCT02935309|Drug|Capecitabine|Pre-surgery Capecitabine, 850 mg/m^2, twice a day (BID) on days 1-5 for 5½ -6 weeks.
45611206|NCT02935309|Radiation|External Radiation Therapy (XRT)|Pre-surgery RT: Participants will receive 6 weeks of radiation therapy. The radiation sessions will be daily, Monday through Friday, except for holidays.
45611207|NCT03428113|Other|Bladder Volume Measurement bladder scanner RN|Measure Urine Volume with Bladder Scanner by RN
45611208|NCT03428113|Other|Bladder Volume Measurement Ultrasound APRN|Measure Urine Volume with Point of Care Ultrasound by APRN
45611209|NCT03428113|Other|Bladder Volume Measurement bladder scanner APRN|Measure Urine Volume with Bladder Scanner by APRN
45611210|NCT03428113|Other|Bladder Volume Measurement Ultrasound MD|Measure Urine Volume with Point of Care Ultrasound by MD
45611211|NCT03428113|Other|Intermittent Straight Catheterization|Measure Urine Volume with Intermittent Straight Catheterization
45611212|NCT04900922|Device|isokinetic dynamometer|We will use an isokinetic dynamometer to conduct the concentric isokinetic fatigue protocol. The start position is shoulder abduction 90°, elbow flexion 90°and range of motion is set from 0 ° (internal rotation) to 90 ° (external rotation) under 120°/s. To calculate maximum torque of shoulder external and internal rotation, the subject will perform maximum isokinetic test 5 times before fatigue. Fatigue protocol include 10 sets, and each set include 32 repetitions with 30 seconds of rest between sets. The fatigue protocol will be stopped under three conditions: 1. the torque decreases 50% of maximum torque three times in one set or 2.rating of perceived exertion (RPE) abrove 15 and players can not perform the fatigue protocol or 3. finish the whole test.
45611213|NCT04900064|Behavioral|Brief interventions|'Brief Interventions' (BI) is a generic term for a multitude of tools and interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. As such, there is no separation between assessment and intervention. The interventions within BI often have their foundation in CBT, ACT or Motivational Interviewing (MI). The common theme is that they are principle-based rather than manual-based and focus on behavioural change in relation to a problem, rather than focusing on a specific diagnosis. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. A BI treatment usually consists of 1-4 appointments with several weeks apart and has an open ending, where the patient easily can schedule a new appointment. Clinicians delivering brief interventions will have had 3 days of training as well as regular supervision.
45758668|NCT02995811|Other|Observational Cohort|Ultrasound assessment of 4 muscles, activity monitoring, daily global peripheral skeletal muscle strength
46068741|NCT05672134|Diagnostic Test|Para-amino Hippuric Acid test|PAH-measurement to measure ERPF.
46068742|NCT05672134|Diagnostic Test|Electrocardiogram|12-lead Electrocardiogram
46068743|NCT05668091|Drug|Nirmatrelvir|Two 150 mg tablets taken by mouth every 12 hours.
46068744|NCT05668091|Drug|Ritonavir|One 100 mg capsule taken by mouth every 12 hours.
46068745|NCT05668091|Drug|Placebo|Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours.
46068746|NCT05664100|Drug|FX-345|Single intratympanic injection of FX-345
46068747|NCT05664100|Drug|Placebo|Single intratympanic injection of placebo
45611214|NCT04900064|Behavioral|Self-help CBT|The patient receives a previously scientifically evaluated CBT-based self-help book for one of the following conditions: depression, generalized anxiety disorder, panic disorder, social anxiety, health anxiety, insomnia, or stress/burnout. The therapist support consists of 3-6 contacts throughout the 6-12 weeks long intervention period as decided by the clinician and patient together, as long as at least one and not more than three are physical visits at the center and the rest via phone, video conferencing, or secure internet messages. Clinicians delivering self-help CBT will need four days of reading and two days of training as well as regular supervision to be able to make initial assessments and problem profiling and use the self-help books.
45611215|NCT03463993|Drug|Tranexamic Acid|TXA (10mg/kg) solution for injection from the vial will be diluted with 100 - 200ml electrolyte solution such as Normal Saline, Ringers solution, dextrose/water for injection on the same day it is to be used (i.e. when anaesthetist notes the patient has been randomized to receive TXA). Intravenous administration should be at a rate of 100mg or fraction thereof over at least 1 minute - usually at least 5 minutes. Standard practice is to administer over 20 minutes. Administration is to be done at least 10 minutes prior to skin incision.
45611216|NCT03463993|Drug|Oxytocin|5IU of oxytocin are administered intravenously slowly once the baby has been delivered at caesarean section.
45611217|NCT04899440|Device|Water Flosser|A pressurized stream of water to reduce gingivitis and remove adherent plaque
45758669|NCT00729521|Other|facilitative system|The facilitative system links communities with academic partners to provide communities with the skills and resources needed to help facilitate the community health improvement process. The system identifies what assets are available within communities, as well as the skills and resources needed to work through the community health improvement process. The facilitative system will then provide technical assistance, best practices guides, and direct consultation in carrying out all phases of the community health improvement process. This information is designed to increase community capacity in community assessment, coalition development, accessing and interpreting local injury prevention data, searching and selecting evidence-based research, and program planning and evaluation.
45611218|NCT04899440|Other|Control|No Oral Irrigator Control
45611219|NCT02412488|Other|Out of cathlab insertion|"Insertion of the Reveal LINQ device in the out-of-cathlab setting (out of the operating room, cardiac catheterization or electrophysiology laboratory)."
45611220|NCT03417271|Device|Deep brain stimulation|The different stimulation pulse widths are made possible by the use of a Medtronic XBP flashcard used with the conventional Medtronic 8840 programmer.
45611221|NCT04910984|Behavioral|Chatbot messages|Automated personalized messages containing HIV testing-related information, motivation and skills
45611222|NCT04910984|Behavioral|Attention-matched educational materials|Attention-matched educational materials manually sent by our research assistant. These educational materials will be retrieved from CDC and WHO websites and curated into short articles (<200 words) and pictures. All educational materials will be screened by HIV experts from University of Malaya to ensure accuracy before being sent to participants.
45611223|NCT03422029|Drug|177Lu-Dotatate PRRT|"PRRT using 177Lu-Dotatate 100-150mCi will be performed 8-weekly. A maximum of 8 cycles will be administered.~Other: Amino-Acid Solution The Amino-Acid Solution (AAS) to be used in this study, infused over 4-6 h, starting 30 min before PRRT"
45611224|NCT03421873|Other|0h/1h hs-cTnT protocol|Implementation of a 0h/1h hs-cTnT protocol in routine care
45611225|NCT03417037|Drug|BMS-986205|Administered orally daily, 100 mg
45611226|NCT03417037|Biological|Nivolumab|Specified dose on specified days
45611227|NCT03417037|Drug|Chemotherapy|Platinum-based doublet chemotherapy
45611228|NCT02378480|Drug|Omadacycline|Injection for IV dosing; Tablets for oral dosing
45611229|NCT02378480|Drug|Linezolid|Infusion solution for IV dosing; Tablets for oral dosing
45611230|NCT03109639|Device|Conventional EUS FNA needle|Participants randomised to Group A will undergo tissues acquisition using the Conventional EUS FNA needle and then crossed over to receive the experimental Acquire EUS- FNB device.
45611231|NCT03109639|Device|Acquire FNB device|Participants randomised to Group B will undergo tissue acquisition using the experimental Acquire EUS FNB device and then crossed over to receive the conventional EUS FNA needle
45611232|NCT03421795|Other|Let's Talk About Pain Training|See arm/group descriptions.
45611233|NCT03421795|Other|Family Centered Care Training|See arm/group descriptions.
45611234|NCT03421717|Device|Chitosan brush|If inflammation (Bleeding on probing) and deep pockets (4 mm or more) is present at the control - maintenance is performed according to allocation
45611235|NCT03428035|Other|Package Insert|Modified package insert of Ibuprofen given postprocedural as pain medication
45611236|NCT03427957|Diagnostic Test|Endometrial biopsy with the new hysteroscopic grasper with knurled terminal end and cutting jaws|Hysteroscopic endometrial biopsy performed through the new grasper with knurled terminal end and cutting jaws.
45611237|NCT03427957|Diagnostic Test|Endometrial biopsy with the hysteroscopic spoon grasper|Hysteroscopic endometrial biopsy performed through the spoon grasper.
45611238|NCT03427957|Diagnostic Test|Endometrial biopsy with the hysteroscopic alligator grasper|Hysteroscopic endometrial biopsy performed through the alligator grasper.
45611239|NCT03427879|Drug|Low flavonoid beverage|A low flavonoid, sports nutrition recovery beverage will be prepared from milk (78%), sugar (8.6%), maltodextrin (8.6%), placebo blueberry powder (2.4%), alkalized cocoa powder (1.6%), and whey protein isolate (0.6%). The beverage will contain approximately 5mg flavonoids per serving.
45611240|NCT03427879|Drug|High flavonoid beverage|A high flavonoid, sports nutrition recovery beverage will be prepared from milk (78%), sugar (8.6%), maltodextrin (8.6%), blueberry powder (2.4%), cocoa powder (1.6%), green tea extract (0.1%) and whey protein isolate (0.6%). The beverage will contain approximately 620 mg flavonoids per serving.
45611241|NCT03427801|Drug|Erythropoiesis-Stimulating Agent|erythropoiesis-stimulating agent: Mircera or Darbepoietin
45758670|NCT00729521|Other|Standard Program|"a Standard Program group receiving modest funding to implement an evidence-based fall prevention program in their local community;"
45758671|NCT01278251|Procedure|Distal Biceps Re-Insertion|
45758672|NCT01270763|Behavioral|Intensive lifestyle intervention|Lifestyle intervention focused on weight loss through diet and physical activity
45611242|NCT03421561|Device|"Stellarex 0.035 OTW Drug-coated Angioplasty Balloon"|"The Stellarex 0.035 OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm."
45611243|NCT03421561|Device|EverCross™ 0.035 PTA Balloon Catheter|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).
45611244|NCT03416803|Radiation|Radiotherapy|Radiotherapy
45611245|NCT03416725|Device|Otoscope|Otoscopic examination will be done to find the presence or absence of perforation, granulation tissue and cholesteatoma.
45611246|NCT01483105|Behavioral|DVD Self-Hypnosis Training Program|The DVD training program contains instructional materials developed by an experienced psychiatrist and psychologist at the Department of Psychiatry at Stanford University School of Medicine. Parents will be instructed to review these materials, watch the DVD, and practice the self-hypnosis exercises every day for a week with their child prior to the upcoming procedure. Parents are encouraged to practice self-hypnosis during their child's VCUG procedure.
45611247|NCT01329757|Drug|GH|Administration of a subcutaneously injected daily dose of GH (0.4mg)for 1 year
45611248|NCT01329757|Drug|Placebo|Administration of a subcutaneously injected daily dose of placebo for 1 year
45611249|NCT03427723|Device|Accuvein®400|The intervention comes down to the randomization of the standard treatment versus Accuvein for peripheral intravenous cannulation
45611250|NCT03427723|Other|Standard care|The intervention comes down to the randomization of the standard treatment versus Accuvein for peripheral intravenous cannulation
45611251|NCT03416647|Procedure|Duodenojejunostomy|Duodenojejunostomy with or without duodenal resection
45611252|NCT03427645|Behavioral|Decision tool|A tailored web-based stroke decision support intervention. This web-based tool will be developed for use by the surrogate decision maker during the acute stroke hospitalization and will be designed to facilitate high quality patient-centered decisions and minimize adverse effects on the surrogate.
45611253|NCT03416569|Drug|Placebo|placebo skin patch + placebo capsule
45611254|NCT03416569|Drug|Nicotine|nicotine patch (7 mg/24 hrs) + placebo capsule
45611255|NCT03416569|Drug|Prazosin|placebo patch (7 mg/24 hrs) + prazosin capsule (1 mg)
45611256|NCT03416569|Drug|Nicotine + Prazosin|nicotine patch (7 mg/24 hrs) + prazosin capsule (1 mg)
45611257|NCT01004029|Drug|Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL|1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
46068748|NCT05662982|Device|Northwestern University Flexible Subischial Suction Socket (NU-FlexSIS)|A custom-made prosthetic socket for transfemoral amputation that consists of proximal trimlines that do not interact with the pelvis.
45611258|NCT01004029|Drug|Vehicle|Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
45611259|NCT03416491|Drug|KW-136|KW-136 30 mg was provided in 3 capsules, 10 mg each, and KW-136 60 mg in a single capsule of 60 mg.
45611260|NCT03416491|Drug|Sofosbuvir|Sofosbuvir was provided in a single tablet of 400 mg.
45445172|NCT02059330|Drug|Palbociclib 100mg|In Period 3, Japanese subjects will receive a single oral 100mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
45611261|NCT03427567|Procedure|Sublobar dissection|Sublobar dissection plus lymphadenectomy
45611262|NCT03416257|Other|No intervention|
45611263|NCT03427333|Device|The Rook® Epicardial Access Kit|Use of the Rook Epicardial Access Kit to gain access to the normal, non distended pericardial space.
45611264|NCT03421405|Device|NeuroCatch Platform™|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
45611265|NCT03421249|Other|Exercises|Muscle strengthening exercises of the hip and knee muscles
45611266|NCT03421249|Other|Electromagnetic field therapy|Electromagnetic field therapy with Magnetron®
46068749|NCT05654870|Drug|Valbenazine|Oral treatment
46068750|NCT05654870|Drug|Placebo|Placebo matching valbenazine
46068751|NCT05647057|Combination Product|A: gelofusine + ringers|750 milliliter (mL) modified fluid gelatin (Braun Melsungen, Germany), 650 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands)
45611267|NCT03421171|Other|no intervention|Qualitative research through semi-structured interviews
45611268|NCT04596475|Drug|glecaprevir/pibrentasvir (GLE/PIB)|The study intervention consists of a single daily dose of GLE/PIB 100/40 mg (one dose consists of 3 tablets) administered orally; or crushed and administered via a feeding tube if participant is unable to swallow by mouth, for example in the immediate post-operative period. First dose will be administered in the pre-operative period within 4 hours of surgery followed by once daily doses for 7 days total.
45611269|NCT03421093|Procedure|Surgeries|Surgeries or surgeries plus adjuvant therapies
45611270|NCT03420937|Drug|Sugammadex|Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
45611271|NCT03420937|Drug|Neostigmine, Atropin Biotika|Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
45611272|NCT02900443|Drug|Mycophenolate mofetil|
45611273|NCT02900443|Drug|Azathioprine|
45611274|NCT02881255|Device|Implantable Cardioverter Defibrillator|Patients will be randomized to receive either a subcutaneous or transvenous ICD.
45611275|NCT04449445|Dietary Supplement|Isocaloric and iso-nitrogenous standard enteral tube feeds|Dietary supplement
45611276|NCT04449445|Dietary Supplement|Nestle IMPACT AR|Dietary supplement
45611277|NCT04594213|Drug|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
45611278|NCT04594213|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
45758673|NCT01270763|Behavioral|Diabetes support and education|Behavioral intervention focused on diabetes support and education
45758674|NCT00716963|Drug|Fluticasone propionate (Flovent Diskus) 250 mcg|Flovent Diskus 250 mcg
45611279|NCT03416101|Procedure|Total Gastrectomy|The esophagus was resected at the arch level of the azygos vein, a frozen section of the resection margin was routinely performed to achieve a proximal clean resection margin. The surgical specimen was comprehensive of distal esophagus, stomach and omentum. Digestive tract continuity was established with Roux-en-Y esophagojejunostomy. Lymphadenectomy was extended to the thoracic stations R 2-4, 7-8-9, and L 4, numbered according to the Mountain's classification [39] (Suppl. File 2 Figure A) and to the abdominal stations 1-12, numbered according to the Japanese Research Society for Gastric Cancer (JRSGC) 1998 classification.
45611280|NCT04449367|Procedure|ultrasound guided erector spinae plane block|bilatral block given to patients under general anaesthesia for thoracic spine sugery to contorl post operative pain
45611281|NCT04449133|Drug|AD128|Oral administration of two capsules before sleep for 7 days.
45611282|NCT04449133|Drug|Placebo|Oral administration of two capsules before sleep for 7 days.
45758675|NCT00716963|Drug|budesonide 400 mcg|budesonide 400 mcg
45611283|NCT03420703|Other|erector spinae plane block|ultrasound guided erector spinae plane block will be administered to this group.
45611284|NCT03420703|Device|Intravenous morphine patient controlled analgesia device|Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
45611285|NCT03416023|Device|TIES® (Transcutaneous Implant Evacuation System)|Transcutaneous Implant Evacuation System
45611286|NCT03415945|Device|Cardiac resynchronization therapy (CRT)|All study participants have a clinical indication for CRT and will receive CRT implantation as part of their routine medical care. Additionally, participants will receive temporary left and right ventricular septal pacing electrodes and a temporary PressureWire to investigate the acute hemodynamic effect of left ventricular septal pacing, using patients as their own controls.
45611287|NCT03420547|Behavioral|RISE|Intervention will consist of 3 sessions over 6 weeks. Each session will last 2 hours and be conducted with a clinical psychologist or medical social worker. The intervention content include psycho-education, communication training between the couple, and exercises to foster intimacy. A therapy manual will be developed to ensure program delivery fidelity. A folder with session summaries will be provided to the participants.The intervention content include psycho-education, communication training between the couple, and exercises to foster intimacy. A therapy manual will be developed to ensure program delivery fidelity. A folder with session summaries will be provided to the participants.
45611288|NCT03109171|Other|Laryngopharyngeal sensory test|The sensory measurements will include thresholds for psychophysical sensory thresholds at the velopharynx, hypopharynx and aryepiglottic folds
45611289|NCT03420469|Drug|Bupropion|Phase 1: Baseline CYP2D6 activity, using dextromethorphan (30 mg single dose PO) as a probe drug Phase 2: Single dose bupropion pharmacokinetics and its effect on CYP2D6 activity (determined by dextromethorphan 30 mg single dose PO) Phase 3: Steady state disposition of bupropion and its interaction with CYP2D6 activity (30 mg single dose PO)
45611290|NCT03415789|Diagnostic Test|Doppler echocardiogram exam|A complete echocardiographic study will be performed at enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
45611291|NCT03415789|Diagnostic Test|Cardiac Magnetic Resonance|"A cardiac MR will be acquired within 10 days after the enrollment. The protocol includes the following sequences: cine mode of short axis from LV base to apex and 2-3-4 chambers. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 3 min and 10 min of the administration of a total of 0.2 mmol / kg of Prohance®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ) and sphericity index will be measured."
45611292|NCT03415789|Diagnostic Test|Brain Magnetic Resonance|A brain MR will be acquired within 10 days after the enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
45611293|NCT03415789|Diagnostic Test|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment.
45611294|NCT03420391|Device|Photobiomodulation Therapy (PBMT)|Phototherapy device - Multi Radiance Medical® (Solon, OH, EUA)
45611295|NCT03427021|Drug|Oxaliplatin|Infusion
45758676|NCT00716963|Other|Placebo|Placebo
45758677|NCT01270997|Biological|Etanercept|Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
45758678|NCT01270997|Biological|Etanercept|Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
45758679|NCT01271075|Drug|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
45758680|NCT01271075|Drug|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
45758681|NCT01278745|Biological|Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|
45758682|NCT01278745|Drug|Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|
45758683|NCT02995655|Drug|CX-01|CX-01 at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle.
45758684|NCT02995655|Drug|Azacitidine|Azacitidine at a dose of 75mg/m^2 on Days 1-7 of each 28-day cycle.
45758685|NCT02995655|Procedure|Bone marrow biopsy|-Baseline, day 28 of even-numbered cycle through Cycle 6, and end of study
46068752|NCT05647057|Combination Product|B: albumine + ringers|200 mL human albumin (20%, Sanquin, Amsterdam, Netherlands), 1200 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands)
45611296|NCT03415711|Dietary Supplement|VSL#3®|VSL#3® 450 billion sachets
45758686|NCT02995655|Procedure|Peripheral blood draw|-Day 1 of each cycle, day 3 of each cycle, day 7 of each cycle, day 28 of every even-numbered cycle through Cycle 6, and end of study
45611297|NCT03415711|Drug|Mesalamine|Mesalamine 2.4 g/day in once daily administration.
45611298|NCT03415711|Drug|Placebo|sachets with maltose, cornstarch and dioxide
45611299|NCT03420313|Drug|Buprenorphine/naloxone sublingual tablets|24-week maintenance with buprenorphine/naloxone sublingual tablets (plus other technology-assisted components described previously)
45758687|NCT01271153|Drug|Dobutamine|Dobutamine at 5 mcg/kg/min will be administered for 2.5 hours each. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
45758688|NCT01271153|Drug|Placebo|A 5% dextrose solution will be administered for 2.5 hours. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
45611300|NCT03415633|Other|Home Respiratory Polygraphy (APNIA)|Randomizing to start with home respiratory polygraphy (APNIA)
45611301|NCT03415633|Other|Standard Polysomnography (PSG)|Randomizing to start with Standard Polysomnography (PSG)
45611302|NCT03415633|Other|Home Respiratory Polygraphy (APNIA)|Randomizing for therapeutic decision taken with home respiratory polygraphy (APNIA)
45611303|NCT03415633|Other|Standard Polysomnography (PSG)|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
45611304|NCT03420235|Other|Home monitoring program|The home monitoring program consists of 1) the use of an interactive internet tool to coach patients and enhance self-management 2) home-based pulmonary function testing with a handheld spirometer and 3) recording of patient-reported outcomes (PROs).
45611305|NCT03415555|Procedure|Erector Spinae Plane blockade|Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.2 mL per patients' KG. The maximum dose is 40 mL.
45611306|NCT03415555|Drug|Oxycodone|Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
45611307|NCT03415555|Procedure|general anesthesia|Each patient will generally anesthetized and endotracheal tube will be inserted
45611308|NCT03415555|Drug|paracetamol|Paracetamol will be given i.v. every 6 hours.
45611309|NCT03420157|Other|Focus Group|Focus Group of 2 hours. Women will be asked to give their opinion about the communication media of the vaginal self-sampling kit.
45611310|NCT03415477|Drug|Denosumab (Xgeva)|Denosumab (Xgeva) 120 mg was given subcutaneously (abdomen wall or upper arms) every 4 weeks (Q4W), with a loading dose on both Day 8 and Day15 of the first cycle， perioperatively.
45611311|NCT03127735|Drug|BAY1436032|"BAY1436032 administered continuously as a single agent dosed twice a day orally on Days 1 to 28 of a 28-day cycle.~Patients may continue treatment with BAY1436032 until disease progression, development of other unacceptable toxicity or Investigator discretion."
45611312|NCT02345252|Drug|FTC/RPV/TAF|200/25/25 mg FDC tablets administered orally once daily
45611313|NCT02345252|Drug|FTC/RPV/TDF Placebo|Tablets administered orally once daily
45611314|NCT02345252|Drug|FTC/RPV/TDF|200/25/300 mg FDC tablets administered orally once daily
45611315|NCT02345252|Drug|FTC/RPV/TAF Placebo|Tablets administered orally once daily
45611316|NCT03415399|Biological|ET190L1 ARTEMIS™ T cells|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct
45611317|NCT03415321|Device|Postpartum Mobile Support Application|"Women in the experimental group will use the Postpartum Mobile Support Application during six weeks after birth.~Women will be evaluated three times in total, one for the first day after birth, second for the seventh day after birth and the last for the sixth week after birth.~Short messages and calls will be remind of women's Postpartum Mobile Support Application use"
45611318|NCT03420079|Drug|FCN-411 Dose-escalation|"FCN-411 is a pan EGFR inhibitor, which has strong activity against wild type (WT), HER2, HER4 and EGFR sensitive mutations (including but not limited to T790M and L858R mutation).~FCN-411 shows significant antitumor activity in a dose-dependent manner in in vivo models of lung cancer, esophageal cancer and pharyngeal squamous cell carcinoma mediated by EGFR."
45611319|NCT03420079|Drug|FCN-411 Dose-expansion|"FCN-411 is a pan EGFR inhibitor, which has strong activity against wild type (WT), HER2, HER4 and EGFR sensitive mutations (including but not limited to T790M and L858R mutation).~FCN-411 shows significant antitumor activity in a dose-dependent manner in in vivo models of lung cancer, esophageal cancer and pharyngeal squamous cell carcinoma mediated by EGFR."
45611320|NCT03415165|Drug|green tea buccal tablet|buccal tablet for 8 hrs 3 times aday
45611321|NCT03415165|Drug|Corticosteroids Topical|kenacort in orabase 4 times aday
45611322|NCT03419923|Drug|two stage regional citrate|4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.
45611323|NCT03419923|Drug|one stage regional citrate|4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.
45611324|NCT03419845|Device|Step Right Buddy|The Step Right Buddy, which is under investigation in this clinical study, is an elasticated band that attached by Velcro to the back legs of a standard walking frame. The purpose of the Step Right Buddy is to provide sensory feedback to standard walking frame users of how far to step in to the frame and to encourage them to move the frame forward.
45611325|NCT03426553|Biological|Riboflavin+UV RBC|35 patients who met all inclusion and exclusion criteria received transfusion with RBC suspension from whole blood, treated with riboflavin and ultraviolet pathogen reduction technology
45758689|NCT03809065|Drug|Nitroglycerin|Nitroglycerin is a direct vasodilator and its main action is through venodilation. Nitroglycerin will be diluted by adding 3 mL (3 mg) to 47 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr to have a starting dose of 0.5 μg/Kg/min. The rate of nitroglycerin infusion will be 0.5-2 μg /kg/min .The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) <3}.
45611326|NCT03426553|Biological|irradiated RBC|35 patients who met all inclusion and exclusion criteria received transfusion with irradiated RBC suspension
45611327|NCT03415087|Procedure|sequential intrathecal injection|intrathecal injection of fentanyl and hyperbaric bupivacaine
45611328|NCT03415087|Drug|hyperbaric bupivacaine|intrathecal injection of intrathecal bupivacaine
45611329|NCT03415087|Drug|fentanyl|intrathecal injection of fentanyl
45611330|NCT02833753|Drug|Oxaliplatin|"Intraperitoneal oxaliplatin will be given along with standard chemotherapy FOLFIRI.~Level 1: Oxaliplatin 25mg/m2 IP every 2 weeks on day #1 of chemotherapy . Level 2: Oxaliplatin 55mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 3: Oxaliplatin 85mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 4: Oxaliplatin 55 mg/m2 IP every 2 weeks on day #1 of chemotherapy (due to DLTs found)"
45611331|NCT03419767|Drug|Melatonin|Patients under carotid revascularization surgery taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
45611332|NCT03419767|Other|blank|Patients under carotid revascularization surgery without taking melatonin
45611333|NCT03414931|Drug|NMDA|Use of an NMDA enhancer for the treatment of MDD in late life
45611334|NCT03414931|Drug|Sertraline|Use of SSRI as an active comparator
45611335|NCT03414931|Drug|Placebo - Cap|Use of placebo as a comparator
45611336|NCT03414853|Diagnostic Test|Free text prediction algorithm for appendicitis|A free-text prediction software that predicts the probability of acute appendicitis
45611337|NCT03426319|Diagnostic Test|Cardiovascular evaluation|Cardiovascular evaluation includes anamnesis, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, echocardiography and cardiac MRI.
45611338|NCT03426241|Other|no intervention|this is cross-sectional study
45445173|NCT02059330|Drug|Palbociclib|In Period 4, Japanese subjects will receive a single oral dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours. The amount of the dose will be determined based on an interim analysis of the PK data from Periods 1 and 2.
45611339|NCT03033823|Drug|Magnesium|Usual care (i.e. without any restriction of drug therapy) plus oral tablet magnesium supplementation: 426.6mg of magnesium per day three times daily (i.e. 142.2 mg for each shot) throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used (i.e. 189.6mg).
45611340|NCT03033823|Drug|Placebo Oral Tablet|Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.
45611341|NCT04699591|Drug|Domperidone|Domperidone taken 4 times a day, dose based on body weight
45758690|NCT03809065|Drug|Labetalol|Labetalol is an α and β - adrenergic receptors competitive antagonist. Labetalol will be diluted by adding 10 mL (50 mg) to 40 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr. The rate of Labetalol infusion will be 0.5-2 mg/kg/h.The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) <3}.
45758691|NCT03006926|Drug|lenvatinib|4 mg capsules
45758692|NCT03006926|Drug|pembrolizumab (200 mg)|30-minute intravenous infusion
45445174|NCT02059330|Drug|Palbociclib 125mg|In Period 1, healthy non-Asian subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
45445175|NCT03561142|Radiation|Radiotherapy|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
45445176|NCT03561142|Drug|Chemotherapy|chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29. After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of: Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv
45611342|NCT04669639|Other|Block procedures for shoulder surgery analgesia|"The patients in group (a) will be placed in lateral decubitus. Then, an ultrasound-guided aseptic technique with a high-frequency linear transducer will be used to locate the transverse process of T2, where a needle will be inserted in a cephalocaudal direction until reaching the space between the fascia of the erector spinae and the transverse process of T2 and 30 ml of local anesthetic of bupivacaine 0.5% will be injected.~In group (b), SSC nerve block will be done as follow: In the suprascapular notch, an ultrasound-guided aseptic technique with a high-frequency linear transducer will be used. The linear probe, enveloped in a sterile sheath, will be placed parallel to the spine of the scapula to visualize it and then will be moved cephalic to the supraspinatus fossa. The probe will then be moved laterally up to the scapular notch, where the nerve will be identified by its round hyperechogenic shape 4 cm deep.~control group: patients will receive only general anesthesia"
45758693|NCT01271387|Drug|tasimelteon|20 mg tasimelteon capsules, PO single dose
45445177|NCT03561142|Other|Deep regional hyperthermia|"Deep regional hyperthermia to the pelvis, total time 90 min, target temperature 41-42°C. Twice weekly, up to a total of 10 sessions within d1 and d38.~Deep regional hyperthermia is offered at the centers in Tübingen and Erlangen."
45611343|NCT03414697|Other|Control group|The control group received routine rehabilitation treatments including acupuncture, massage, Bobath therapy, and Vojat therapy.
45611344|NCT03414697|Procedure|UC-MSCs|Injection of umbilical cord-derived mesenchymal stem cells (UC-MSCs) (at least 1×10^7), once every 2 weeks, one course of treatment including two injections within 4 weeks, a total of two courses of treatment.
45611345|NCT03419611|Behavioral|Multi-Modal|Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 3 times per week.
45611346|NCT03419611|Other|Treatment as Usual|Teacher provided with word list and teacher intervening as usual.
45611347|NCT03419611|Behavioral|High Intensity Multi-Modal|Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 5 times per week.
45611348|NCT04448821|Drug|Metformin|Single administration of metformin
45611349|NCT04448821|Drug|Metformin + Nilotinib|Coadministration of metformin and nilotinib
45611350|NCT03414619|Behavioral|Cognitive Control Tasks and Script Driven Imagery|All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors and anxiety/mood symptoms. They then will complete a battery of neuropsychological executive functioning tasks on the computer, each of which measures a different facet of cognitive control (i.e., response inhibition, cognitive flexibility, and attentional control). Finally, they will be guided through a standardized script-driven imagery paradigm that involves generating and listening to an individualized imaginal script associated with a moderately distressing intrusive thought. Self-report and psychophysiological data will be collected during this exercise.
45611351|NCT04448509|Other|Peripheral blood mononuclear cell apheresis|Peripheral blood mononuclear cell collection for tumor immunotherapy study of UCAR-T cells
45611352|NCT03414541|Drug|DS102|DS102
45611353|NCT03414541|Other|Placebo|Placebo
45611354|NCT04448899|Drug|Ivabradine Oral Tablet|Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability plus their standard treatment.
45611355|NCT04448899|Drug|Blacebo plus standard treatment|Blacebo plus standard treatment
45611356|NCT03419377|Other|Standard care and sexological counseling|6-8 sexological consultants in a period of six months
45611357|NCT03414307|Procedure|Intracerebral catheter placement|Image guided stereotactic placement of intra-hemorrhage catheters to evacuate intra-cerebral hemorrhage
45611358|NCT03414307|Device|Robot-assisted intracerebral catheter|ROSA is a robotic device with trajectory planning software that can be used to aid in planning multiple trajectories to large, irregular clots, and aids in navigating into and out of the cerebral hematoma with minimum human error.
45611359|NCT03419299|Other|Tube Feeding Application|A smart device application was developed and used to help residents determine the best enteral nutrition prescription for patients admitted to the ICU
45611360|NCT03414151|Other|Observation|No intervention administered.
45611361|NCT03419065|Behavioral|Relaxation Intervention|Relaxing Music combined with Progressive Muscle relaxation and guided imagery
45611362|NCT04649047|Behavioral|Goal-oriented episodic future thinking|All participants will receive a 3-week web-based intervention plus individual health coaching. The intervention topics include stress management, healthy eating, and physical activity
45611363|NCT03418987|Other|Medical File data analysis|Analysis of the 2D/3D spine images (performed with the sterEOS software and the MATLAB software)
45611364|NCT02835157|Drug|Balanced crystalloid solution|Multiple electrolyte solution as boluses would be administered.
45611365|NCT02835157|Drug|0.9%sodium chloride|saline as boluses would be administered
45611366|NCT04448977|Drug|Ocrevus|"Participants with MS will be divided into two treatment groups: those who will begin to take Ocrevus (the early Ocrevus group (EO), and those who plan to be begin treatment with Glatimer acetate SC (Copaxone) (EC). Both groups will be matched to the EO group for age, gender and education. The HC group will be free of neurological disease or injury and will be matched to the EO group for age, gender, and education."
45611367|NCT03418831|Drug|Raloxifene Hydrochloride|60 mg per capsule (1 tablet daily) for 12 weeks
45611368|NCT03418831|Other|Placebo|1 tablet daily for 12 weeks
45611369|NCT04448587|Drug|Sitagliptin 100mg|Oral sitagliptin will be commenced at a dose of 100 mg BID. The dose will be increased by 100 mg every three days up to a maximal dose of 300 mg BID. In the case of significant drug related side effects or drug intolerance, the last tolerated dose will be resumed. Patients responding well to lower doses of sitagliptin, will not be given higher doses of the drug. Sitagliptin will be provided as long as deemed effective by the treating physician up to three months.
45611370|NCT02770183|Device|Imacor|"In ICU, the doctors in charge places the probe in the esophagus, executing a series of morphological evaluations and semi-quantitative evaluations. Each image is saved as a video loop or a static image, to have a basic data for each patient and perform an off-line analysis. At the end of the first recording, the esophageal probe is left in the neutral position in the stomach, to eliminate any risk associated with a local increase of pressure.~During the stay in the intensive care unit until the end of the study, the esophageal probe will be left in the neutral position, to run every two hours a new echocardiographic assessment on the main window, similar to the first evaluation, always recording loop-video and photographs, to have a time course of recovery of cardiac contractile function. All images will be stored in a digital archive."
45611371|NCT02737189|Procedure|Mechanical embolectomy|Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration
45445178|NCT03784443|Drug|Iluvien 0.19 MG Drug Implant|Fluocinolone Acetonide Sustained Release Intravitreal Implant at Baseline Visit
45611372|NCT02737189|Drug|Medical Treatment|Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
45611373|NCT03426163|Device|Virtual reality|Application of knee MRI transformed virtual reality system
45611374|NCT03426085|Drug|Liraglutide 6 mg Solution for Injection|
45611375|NCT03426085|Other|Placebo|
45611376|NCT03127657|Drug|Cock's comb extract 0.01%|Applied topically twice daily for 12 weeks
45611377|NCT03127891|Behavioral|pranayama yoga|providing short term pranayama yoga for 5 sessions before surgery patients under going cardiac surgery.
45611378|NCT03127891|Other|control group|no intervention should be given to patients allocated to this group
45611379|NCT03426007|Procedure|Uterine lavage|embryo recovery from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).
45611380|NCT03418597|Procedure|Deep local anesthesia + Virtual reality|Biopsy performed according to current practice (deep local anesthesia with premedication and lidocaïne). Patient will have a 3-D immersive experience, created using a visual and audio headset and a software labelled as medical device.
45445179|NCT03784443|Drug|Ranibizumab Injection [Lucentis]|Monthly PRN intravitreal injections
45758694|NCT01272739|Dietary Supplement|IHBG-10|500 mg of IHBG-10 taken 15 minutes prior to the three main meals of the day
45445180|NCT03784443|Procedure|Sham Intravitreal Injection|Sham injection without penetrating needle and without drug delivery at baseline visit.
45611381|NCT03418597|Procedure|Deep local anesthesia alone|Biopsy performed according to current practice (deep local anesthesia with premedication and lidocaïne).
45611382|NCT03414073|Device|Knotted floss technique|The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)
45611383|NCT03414073|Device|Conventional flossing technique|"The subject will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
45911428|NCT02008032|Device|Stationary Breast Tomosynthesis|The patient will have the SDBT study performed in a similar manner as conventional mammography in the mediolateral oblique and cranio-caudal plane. The participant will stand up and the mammography research technologist, ensuring patient comfort, will assist in positioning their breast in the breast tomosynthesis unit with standard compression. Once positioned, the total scan time is approximately 10 seconds. Both the left and right breast will be imaged. The length of time for the positioning and examination of a subject's breast may vary but it is expected that the entire imaging procedure will take about 5-10 min, including positioning time.
45611384|NCT03414073|Device|Conventional Interdental Brushing|The subject will gently insert the interdental brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
45611385|NCT04637971|Other|Coaching|Participants will receive 4 sessions of group coaching intervention within 6 weeks. Each session is in a group of 3-4 women and lasts for approximately 1.5 hours. The sessions will be conducted by experienced social workers.
45611386|NCT04637971|Other|Self-help tips plus telephone support|Participants will receive 4 self-help tips sent via SMS and 4 phone call from a social worker in 6-week of time. During the telephone call, the social worker will advise the client to make use of the tips we sent to her.
45611387|NCT03425929|Drug|Oxytocin|Intranasal administration, 24 international units (IU) oxytocin.
45611388|NCT03425929|Drug|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself.
45611389|NCT03127189|Drug|Rilpivirine|Rilpivirine 25 mg immediate release oral solution.
45611390|NCT03127189|Drug|Rilpivirine Long-acting Parenteral Formulation|RPV LA 600 mg extended-release suspension for IM injection.
45611391|NCT02521051|Drug|Alectinib|
45611392|NCT02521051|Drug|Bevacizumab|
45611393|NCT03413917|Other|Analysis of genomic markers in uterine atony|No intervention will be performed. We will be analyzing tissue and blood samples only to identify potential association of genomic markers with uterine atony.
45445181|NCT03561064|Behavioral|CBT-I|Eligible participants will receive CBT-I by a licensed clinical psychologist.
45611394|NCT01239797|Drug|Lenalidomide|Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
45611395|NCT01239797|Drug|Dexamethasone|Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
45611396|NCT01239797|Drug|Dexamethasone (Oral)|"On weeks without Elotuzumab dosing: Tablets, Oral, 40mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug.~On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
45611397|NCT01239797|Drug|Dexamethasone (IV)|"On weeks without Elotuzumab dosing: Not Applicable (N/A)~On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
45611398|NCT01239797|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
45611399|NCT02639065|Drug|Durvalumab|1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
45611400|NCT03418519|Other|Constraint Induced Movement Therapy|Constraint-induced movement therapy (CIMT) is a high-dosage, efficacious, rehabilitation approach used for children with hemiplegic cerebral palsy
45611401|NCT01236521|Drug|Pharmacological (MED)|"During the baseline assessment, the nurse care managers will determine current and past treatments for chronic lower back pain and establish whether or not patients have had an adequate trial (i.e., were analgesics sufficiently dosed). If not, the nurse care manager in conjunction with study doctors will recommend an adjustment of the patients' opioid or initiate treatment with a co-analgesic with appropriate dosing and scheduling.~The Patients in the MED arm will be asked to sign an opioid treatment agreement at enrollment."
45611402|NCT01236521|Behavioral|Behavioral treatment (CBT)|There will be 8 sessions of pain self-management and coping skills.
45611403|NCT01092143|Drug|BI 671800|BI 671800
45611404|NCT01092143|Drug|Fluticasone propionate placebo|Placebo matching Fluticasone propionate
45611405|NCT01092143|Drug|Fluticasone propionate|Fluticasone propionate
45611406|NCT01092143|Drug|BI 671800 Placebo|Placebo matching BI 671800
45758695|NCT01272739|Dietary Supplement|Placebo|Placebo taken 15 minutes prior to the three main meals of the day
45758696|NCT02995577|Other|Feeding tolerant|
45758697|NCT02995577|Other|Feeding intolerant|
45758698|NCT02995577|Other|Necrotizing enterocolitis|
45611407|NCT03421457|Procedure|Uterus-preserving laparoscopic lateral suspension with mesh|V-shaped 2cm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3-4 cm superoposterior to the anterosuperior iliac spine.A grasper is introduced retroperitoneally through the sub-peritoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Round ligament is lifted upward and tunnel is practiced horizontally.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba-Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level.
45611408|NCT03421457|Procedure|Uterus-preserving laparoscopic sacrocervicopexy with mesh|The peritoneum over the sacral promontory is incised until the anterior longitudinal ligament is reached and ureters are identified. Peritoneal relaxing incision is made medial to the right ureter, down into the pelvis, posterior to the cervix and rectovaginal fascia, laterally to the rectum. The arm of the mesh is sutured to the posterior cervix by 2.0 prolene and fixated to the sacral promontory by either Tacker (Covidien) and/or 2.0 prolene as tension-free. Complete peritonisation of the mesh is performed.
45611409|NCT02377466|Drug|Retosiban IV infusion|Retosiban for IV administration will be supplied as solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram per milliliter (mg/mL).
45611410|NCT02377466|Drug|Placebo IV infusion|0.9% NaCl matched for the retosiban loading dose and continuous infusion rates
45445182|NCT05652075|Procedure|pericapsular nerve group and lateral femoral cutaneous nerve block|Will undergo pericapsular nerve group block (PENG) combined with lateral femoral cutaneous nerve under ultrasound guided block with 20 mL of 0.25% bupivacaine.
45611411|NCT03416465|Behavioral|medical questionnaire|The patient will complete a questionnaire of 10 questions before leaving hospital. This questionnaire concerns the care pathway for hospitalized patients.
45611412|NCT03418363|Dietary Supplement|DHEA Oral Capsule|Daily 100mg DHEA supplement
45611413|NCT03418363|Other|Placebo Oral Capsule|Daily oral capsule
45611414|NCT03421301|Dietary Supplement|dietary portfolio|The dietary intervention was a combination of functional foods (dehydrated nopal, chia seed, soy protein and inulin) that was provided in dehydrated form in packages of 17.3 g dissolved in 250 ml water for breakfast and 34.7 g in 300 ml water for dinner.
45611415|NCT03421223|Other|No intervention|No intervention
45611416|NCT00816491|Device|conventional white light colonoscopy|conventional white light colonoscopy
45611417|NCT00816491|Device|FICE (Fujinon Intelligent Chromoendoscopy)|chromoendoscopy
45611418|NCT03416387|Device|3D PRINTING|A 3D digital image reconstruction and a 3D printing model were performed in all patients with complex liver tumors.
45611419|NCT00950989|Drug|Brodalumab|3 single subcutaneous (SC) injections at day 1 and weeks 1, 2, 4, 6, 8, and 10
45611420|NCT00950989|Drug|Placebo|3 single SC injections at day 1 and weeks 1, 2, 4, 6, 8, and 10
45758699|NCT05137418|Biological|COVID-19 Vaccine,Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection
45445183|NCT05652075|Procedure|lumbar plexus block|Will undergo Lumbar plexus block (LPB) under ultrasound guided block with 20 mL of 0.25 % bupivacaine.
45445184|NCT01309035|Procedure|Total Knee Arthroplasty|Surgery for OA knee pains
45445185|NCT02056912|Genetic|Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene|
45445186|NCT02056912|Biological|Perform blood cells and fibroblasts biochemical and immuno-labeled investigations|Performed only in the two index patients enrolled in the sub-study
45445187|NCT01314885|Drug|PF-03715455|20mg, Inhaled, single dose
45445188|NCT01314885|Drug|PH-797804|30mg, Oral, single dose
45445189|NCT01314885|Drug|Placebo for PF-03715455|Single dose, inhaled, Placebo for PF-03715455
45611421|NCT00950989|Drug|Methotrexate|Two methotrexate dose adjustments were allowed in the event of methotrexate toxicity, however, doses < 7.5 mg/week necessitated discontinuation from study.
45611422|NCT00950989|Dietary Supplement|folic acid|at least 5 mg per week
45611423|NCT03420911|Drug|dexketoprofen trometamol|
45611424|NCT03420911|Drug|Midazolam|
45611425|NCT03416231|Drug|Apatinib|apatinib, at a dose of 250 mg daily,Treatment was continued until disease progression.
45611426|NCT03416231|Drug|Docetaxel|Docetaxel, at a dose of 75mg/m2 on days 1 and 22, repeat every 4 weeks for 4~6 cycles.
45611427|NCT03420755|Behavioral|Mothers and Babies 1-on-1|MB 1-on-1 is a 12-session intervention divided into five modules. An introductory 2-session module establishes key concepts related to stress, monitoring of one's mood, and ways in which one's mood influences one's internal thoughts and external environment; three 3-session modules correspond with key cognitive-behavioral elements: pleasant activities, thoughts, and social support/contact with others; a 1-session summary reviews content and identifies areas for future use of MB skills. Throughout MB, mood management skills are integrated using psycho-educational activities that encourage participants to understand connections between their mood and their activities, thoughts, and contacts with others.
45758700|NCT04278209|Other|Breakfast 1|Participant will receive Breakfast 1
45758701|NCT04278209|Other|Breakfast 2|Participant will receive Breakfast 2
45758702|NCT04278209|Other|Water|Participant will receive water
45445190|NCT01314885|Drug|Placebo for PH-797804|Single Dose, Oral, Placebo for PH-797804
45445191|NCT02054728|Other|RHC and IMT|"Eligible patients subjected to RHC will be instructed on how to do RMT using the Threshold IMT® two days in advance. RMT will be conducted with 20-30% of individual inspiratory muscle strength, which will be measured beforehand. A single training session consists of 7 cycles with 2 min inspiratory training each, followed by a 1 min break (total duration 21 min).~The actual intervention consists of inspiratory muscle training (IMT) during right-heart catheterization for at least 2 min or as long as is necessary to measure all specified parameters."
45758703|NCT05244434|Other|Best Practice|Given standard of care ribociclib + AI or palbociclib + AI
45758704|NCT05244434|Procedure|Biopsy|Undergo biopsy of tumor tissue
45758705|NCT05244434|Procedure|Biospecimen Collection|Undergo blood sample collection
45758706|NCT05244434|Other|Laboratory Biomarker Analysis|Undergo analysis of previously collected tumor tissue
45611428|NCT03420755|Behavioral|Mothers and Babies Plus Text|MB 1-on-1 along with text enhancements, both in English and Spanish. These texts focus on: a) skill reinforcement (e.g., Some thoughts just come to us, but we can make a conscious effort to think of positive thoughts.); b) homework reminders (e.g., What pleasant activity will you try today?), and c) self-monitoring (e.g., On a scale of 1-9, how would you rate your mood?). These texts will be linked with the 12 MB sessions. Specifically, after completing each in-person session, 3 texts will be sent by a home visitor to her client; one text will focus on skill reinforcement, one will be a homework reminder, and one will focus on self-monitoring.
45611429|NCT03420677|Device|Application of tones|During NREM sleep, tones (max. 60 dB) will be played using a portable, safe, in-home device. This device records biosignals (e.g. brain activity) and precisely times the tones during NREM sleep. It was developed and produced by the ETH Zurich and approved for use in this study by Swissmedic
45611430|NCT03420677|Device|No application of tones|This is the sham-control intervention; The device will only record biosignals but will not play tones.
45611431|NCT03420599|Procedure|splenectomy|Traumatic patients who performed total splenectomy
45611432|NCT03416075|Device|Mechanical ventilation|Noninvasive and/or invasive mechanical ventilation were performed when patients had respiratory failure.
45611433|NCT03420443|Dietary Supplement|Oat bran|45 g oat bran.
45611434|NCT03420443|Dietary Supplement|Oat bran and blueberry husks|13 g freeze dried blueberry husks and 22 g oat bra + probiotic bacteria.
45611435|NCT03420443|Dietary Supplement|No oral supplementation|No oral supplementation.
45611436|NCT03415997|Drug|Iohexol|Iodinated contrast media
45611437|NCT03420365|Behavioral|Aerobic exercise|30 minutes of either aerobic, or balance and coordination, or reading magazines
45611438|NCT03415919|Other|no intervention will be given to patients.|samples are collected at the time of a scheduled procedure that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
45611439|NCT03415841|Device|mHealth remote monitoring devices|"Blood Pressure and wearable vital signs monitor, Biovotion and Kardia mobile application"
45611440|NCT03415763|Drug|Capecitabine|According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
45611441|NCT03415763|Drug|mFOLFOX6 or CAPOX|According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
45611442|NCT03415685|Device|PicoPlus laser system|Laser treatment using specific pulse durations and wavelengths for selective pigment photothermolysis.
45611443|NCT03415451|Device|Fiberscope-Guided Nasogastric tube insertion|Fiberscope-Guided Nasogastric tube insertion
45611444|NCT03420287|Combination Product|MPM Prepared From Allogenic Bone Graft|patients will receive a sticky bone which prepared by mixing the the growth factors of the patient with allogenic bone graft for cleft closure
45611445|NCT03420287|Other|Autogenous bone|patients will receive an autogenous bone graft from anterior iliac crest for cleft closure
45611446|NCT03415373|Device|Microneedle Adapter (Model UAR-2S)|Investigational device
45611447|NCT03415373|Device|Hypodermic needle + syringe|Control device
45611448|NCT03415295|Other|Plasma TMAO concentration|Plasma TMAO concentrations were determined by stable isotope dilution liquid chromatography with online electrospray ionization tandem mass spectrometry on an AB SCIEX 4500 triple quadrupole mass spectrometer
45611449|NCT00593567|Drug|gentamicin-collagen sponge|Inserted daily into open ulcer
45611450|NCT00593567|Drug|Levofloxacin|750mg oral levofloxacin daily
45611451|NCT00575081|Device|Stereotactic brain procedures|Stereotactic brain procedures
45611452|NCT03415217|Other|Neighbourhood Team Development Program|The Neighbourhood Team Development Program aims to both enhance team development and resident centredness in LTC. The Program has three components, designed to modify the physical environment, the organization and delivery of services, and the alignment of staff members, to function independently and collaboratively in providing resident-centred care.
45611453|NCT03109613|Device|Positive end-expiratory pressure (PEEP)|level changes as per arm description
45611454|NCT03420131|Diagnostic Test|QFR and iFR|"iFR® (CE-Marked) is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option.~QFR® (CE-Marked) is an angio-based FFR estimation using the analytical Software QAngio XA 3D from Medis medical imaging B.V., The Netherland"
45611455|NCT03420053|Biological|PfSPZ Vaccine|Aseptic, purified, metabolically active, non-replicating, radiation-attenuated, cryopreserved Pf sporozoites.
45611456|NCT03420053|Other|Normal Saline Placebo|0.9% sodium chloride solution
45611457|NCT03420053|Biological|PfSPZ Challenge|Aseptic, purified, live, infectious, cryopreserved Pf sporozoites.
45611458|NCT03419975|Drug|TJO-002|Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
45611459|NCT03419975|Drug|Latanoprost|Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
45611460|NCT03109535|Behavioral|Fitbit + Maptrek|Users receive a Fitbit Zip to wear daily. Users aslo receive the mHealth MapTrek game that places users in weekly walking races and sends automated text messages to users on a daily basis for the purpose of increasing daily physical activity.
45611461|NCT03109535|Behavioral|Fitbit only|Users receive a Fitbit Zip to wear daily.
45611462|NCT03419819|Dietary Supplement|PKU Sphere|PKU Sphere is a glycomacropeptide based alternative to amino-acid based products for the dietary management of phenylketonuria.
45611463|NCT03414749|Procedure|Lower Extremity First (LEF)|The intervention for the LEF group was a non-specific long-axis distraction to the ankle, knee, and hip or shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
45611464|NCT03414749|Procedure|Upper Extremity First (UEF)|The intervention for the UEF group was a non-specific long-axis distraction to the shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
45611465|NCT03419663|Dietary Supplement|cereal or grain consumption|intake of cereal, whole grain, refined grain, and other grain of every day
45611466|NCT00006455|Drug|cyclophosphamide|
45758707|NCT02995265|Device|Exoskeleton Program|Subjects will wear the exoskeleton device at each physiotherapy session to work on improving mobility and walking ability.
45611467|NCT00006455|Drug|cytarabine|
45611468|NCT00006455|Drug|dexamethasone|
45611469|NCT00006455|Drug|doxorubicin hydrochloride|
45758708|NCT02995265|Other|Usual Care Program|Subjects will receive hands-on physiotherapy to improve their mobility and walking ability. Physiotherapy session will be tailored to subject individually by their therapist.
45611470|NCT00006455|Drug|etoposide|
45611471|NCT00006455|Drug|ifosfamide|
45611472|NCT00006455|Drug|leucovorin calcium|
45611473|NCT00006455|Drug|methotrexate|
45758709|NCT05244044|Other|Pulmonary rehabilitation in primary care|Pulmonary rehabilitation consists breathing exercises, exercise capacity, muscle strength and change towards an active lifestyle.
45758710|NCT02995187|Drug|Apatinib Mesylate tablet|Apatinib 500 mg in tablet once daily
45445192|NCT02054806|Biological|Pembrolizumab|IV infusion
45611474|NCT00006455|Drug|therapeutic hydrocortisone|
45611475|NCT00006455|Drug|vinblastine sulfate|
45611476|NCT03414593|Drug|Ultrasound guided popliteal sciatic nerve block with 0.2% ropivcaine|Ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml
45611477|NCT03414281|Procedure|TMQLB group 1|"The patient is placed in the lateral position. The curved (C1-5) probe of Philip CX50 Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 4 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
45611478|NCT03414281|Procedure|TMQLB group 2|"The patient is placed in the lateral position. The curved (C1-5) probe of Philip CX50 Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
45611479|NCT03414281|Procedure|TPVB|"The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe of Philips CX50 is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the paravertebral space of T10.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
45611480|NCT03419507|Device|Endotracheal tube introducer|The doctors that drawed envelop number 2 will be asked to intubate with laryngoscope by the adult size, endotracheal tube introducer with using No. 3 Macintosh blade
45611481|NCT03419507|Device|Macintosh laryngoscopy|The doctors who drawed envelope number 1 will asked to intubate with using No. 3 Macintosh blade
45611482|NCT02411084|Biological|Begelomab|BEGEDINA® (Begelomab) is a murine immunoglobulin G (IgG) 2b monoclonal antibody against CD26 (dipeptidyl peptidase-4; DPP4) and is produced by biotechnological means.
45758711|NCT01278329|Other|"Garbh Sanskar audio cassette (Times Music Inc., Mumbai, India)"|Approximate playing time = 50 minutes. Mothers advised to listen to it once every day.
45758712|NCT01271621|Device|Intubation|Endotracheal intubation
45758713|NCT02394704|Other|Sensory attention training|"Participants will be instructed to attend to sensory stimuli and to press a button as quickly and accurately as possible while ruminating. Stimuli will consist of vibration via a wearable subwoofer or non-painful electrical muscle stimulation (10Hz biphasic current with a pulse width of 200us with rectangular 2 electrodes placed on the back near the shoulders) or vibratory stimulation with a vibroacoustic element placed on the back near the shoulders. Up to four sessions will be approximately 45 minutes, over the course of two weeks."
45758714|NCT02995109|Drug|BAY987521|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code: Z11-004)"
45758715|NCT02995109|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
45758716|NCT03554330|Other|Radiofrequency catheter ablation|(1) In control group: only graded balloon atrial septostomy will be carried out and there is no radiofrequency catheter ablation. (2) In single-RFA group: after graded balloon atrial septostomy identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration. (3) In double-RFA group: the first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (BAS and RFA around the rim of fenestration).
45758717|NCT03554330|Other|Balloon atrial septostomy|Graded balloon atrial septostomy is performed in all patients.
45445193|NCT03779529|Dietary Supplement|Olive oil|Intervention includes dosage and amount of biophenols administered daily
45445194|NCT02054884|Drug|Arm A: F16IL2 in combination with paclitaxel|"Intravenous (i.v.) 1 hour infusions of paclitaxel 90 mg/m^2 followed, after 30 min pause, by 3 hour i.v. infusions of F16IL2 35 Mio IU on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
45445195|NCT02054884|Drug|Arm B: Paclitaxel|"Intravenous (i.v.) 1 hour infusions of Paclitaxel 90 mg/m^2 on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
45611483|NCT02411084|Biological|Conventional Second-line Treatment|"There are no approved second-line treatments for aGvHD and due to the life-threatening nature of the disease it was agreed with the FDA and EMA that BEGEDINA® would be compared with best conventional second-line treatments which will be chosen by each center, based on the clinical conditions of the individual subject and according to the standard practice at the study center and which may vary between centers. Treatments are generally biological products and could include anti-thymocyte globulin, monoclonal antibodies, such as anti-CD147, basiliximab, daclizumab and alemtuzumab; mycophenolate mofetil; anti-TNF-alpha; pentostatin; dinileukin diftitox; N-acetyl-cysteine; sirolimus; and visulizumab."
45611484|NCT03413839|Behavioral|Physiotherapeutic Scoliosis Specific Exercises (PSSE)|Exercises with emphasis on trunk extensor strengthening, and teaching patient better postural strategies in supine, sidelying, sitting, standing, and dynamic movements (walking, squatting), led by a PSSE-trained physical therapist.
45611485|NCT03413839|Behavioral|Conventional Physical Therapy (PT)|Conventional PT includes generalized pelvis, and trunk strengthening, lower extremity (LE) stretching, and use of modalities (ice and heat), iontophoresis and E-Stim.
45611486|NCT01602315|Drug|BYL719 as film-coated (FC) whole tablets|Oral alpha-specific PI3K inhibitor
45611487|NCT01602315|Drug|BYL719 as dispersible tablets (DT)|New formulation of the oral alpha-specific PI3K inhibitor
45611488|NCT01602315|Biological|cetuximab|Recombinant chimeric monoclonal antibody driven against EGFR
45611489|NCT01602315|Drug|BYL719 drink suspension|Oral alpha-specific PI3K inhibitor
45611490|NCT02537197|Drug|Naltrexone|Regular opioid antagonist dosing of disordered gamblers
45611491|NCT02525185|Other|Diagnostic interventions; PET, MRI, cardiac ultrasound.|
45611492|NCT03418207|Procedure|trans-perineal template-guided mapping biopsy|new super saturation of prostate biopsy technique
45611493|NCT03413605|Behavioral|A Multilevel CBPR Intervention|The intervention will be implemented through a group-based education workshop. The education session is a curriculum-based group education; each group will be having about 15-20 participants. All group education sessions will take place at collaborating Viet community partners sites, and delivered in Vietnamese language, with offering of refreshment. We will allow 5-7 minutes for participants to get to know each other and to get comfortable talking to the group. Education will have two major topics--- (a) CDC's standard Clinical Preventive Services Guidelines for adults 50+ (CPS). (b) culturally tailored CRC information discussion.
45611494|NCT03413527|Device|rTMS|rTMS Treatment
45611495|NCT03127345|Drug|Omegaven|Intravenous omega 3 fatty acid administration
45611496|NCT03127345|Drug|Intralipid|Standard of care
45611497|NCT05117541|Other|Interview|Participate in interviews
45611498|NCT05117541|Procedure|Biospecimen Collection|Undergo collection of hair samples
45611499|NCT05117541|Other|Electronic Health Record Review|Medical records are reviewed
45611500|NCT05112159|Drug|IPG1094|The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094.
45611501|NCT05112159|Drug|placebo|Matching placebo tablets to IPG1094 50mg and 100mg
45611502|NCT02316457|Biological|IVAC_W_bre1_uID|vaccination
45611503|NCT02316457|Biological|IVAC_W_bre1_uID/IVAC_M_uID|vaccination
45611504|NCT04145895|Other|Postoperative activity restrictions|Recommendations for return to full activity including return to school, sports, exercise, etc.
45611505|NCT03413371|Drug|paracetamol|in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
45611506|NCT03413371|Drug|0,5 % bupivacaine with of 2% lidocaine|in group BL patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
45611507|NCT03413371|Drug|1 % ropivacaine with of 2% lidocaine|in group RL patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
45445196|NCT01309113|Drug|VAC BNO 1095 film coated tablets|3 dosages: Placebo, 10 mg of VAC BNO 1095 once daily in the morning, 10 mg of VAC BNO 1095 twice daily in the morning and in the evening
45445197|NCT01315197|Other|Massage|Massage Anmá: 7-8 sessions, twice per week, kneading and pressure points on the bladder meridian
45445198|NCT02056990|Other|Advice|
45445199|NCT02057146|Procedure|Duodenoscopy, pancreatoscopy, cholangioscopy, confocal microscopy|The intervention consists of mother-baby endoscopy of the bile and/or pancreatic duct with visual inspection, confocal laser microscopy, collection of fluid for cytology, and eventually biopsy.
45611508|NCT03413371|Drug|1 % Ropivacaine|in group R patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (5 ml)
45611509|NCT03413371|Drug|0,5 % bupivacaine|in group B patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)
45611510|NCT05116995|Drug|Rivaroxaban|rivaroxaban 2.5 mg twice a day for 7 days
45611511|NCT05116995|Drug|Ticagrelor|Ticagrelor 60 mg twice a day for 7 days
45611512|NCT03425851|Other|Diapers|Receive 600 diapers.
45611513|NCT03425851|Other|Resources of diaper banks|Caregivers will receive resources of diaper banks.
45445200|NCT03779373|Other|Use of a decision support system on the EV1000 monitor (AFM mode)|The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical deicsion support system for fluid administration called AFM (assisted fluid management)
45611514|NCT03425773|Biological|BVAC-B|Autologous B cell and monocyte presenting HER2/neu antigen
45611515|NCT03992001|Biological|Blood component A|PRBCs obtained from whole blood after separation of plasma, buffy coat, and RBCs and successive leukoreduction of RBCs
45611516|NCT03992001|Biological|Blood component B|PRBCs obtained by leukoreduction of whole blood, and successive separation of plasma and RBCs
45611517|NCT03417973|Device|dorsal root ganglion neuromodulation|stimulation for neuromodulation of the dorsal root ganglion
45611518|NCT02344004|Drug|LAI (Liposomal Amikacin for Inhalation) 590 mg|LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes.
45611519|NCT03417817|Device|Bravo|wireless pH monitoring over 96 hours
45611520|NCT03677115|Drug|Dexmedetomidine|combination of ropivacaine and dexmedetomidine 20 ug every time
45611521|NCT05116449|Behavioral|Quality of life questionnaires|Different quality of life questionnaires : FACT-B, EORTC QLQ-C30, QIC, BRIEF COPE, HADS, QSSS-C
45611522|NCT03413293|Diagnostic Test|Diagnosis of bacterial infections|Cultures
45611523|NCT05116371|Drug|150 mcg levonorgestrel/30 mcg ethinyl estradiol|concurrent use of COC with Nexplanon
45611524|NCT03417661|Drug|HEXI-PREP By Clinell Wipes|Sterile single sachet wipe containing 3ml solution.
45611525|NCT03417661|Drug|Chloraprep|Sterile applicator containing 3ml solution.
45611526|NCT03417661|Drug|Placebos|Sterile saline (0.9% w/v) wipe, containing 3ml of solution.
45445201|NCT02057224|Procedure|Renal denervation using Medtronic Symplicity System (mono-electrode)|Secondary hypertension is excluded by an extensive preoperative clinical investigation and the renal artery anatomy is visualized by computer tomography (with contrast). By cannulating the femoral artery both renal arteries are treated by a radiofrequency-catheter, 4-6 ablations in each artery.
45611527|NCT03008811|Procedure|Pulmonary vein isolation with cryoballoon catheter.|Device: Arctic Front Advance™ cardiac cryoablation catheter system.
45611528|NCT03008811|Procedure|Pulmonary vein isolation with radiofrequency ablation.|Device: TactiCath™ Quartz irrigated ablation catheter (St. Jude Medical) with aid of 3-D mapping system (EnSite Precision, St. Jude Medical).
45611529|NCT03425695|Device|CheseeTM Diode Laser|low level laser therapy was utilized adjunct with free gingival graft.
45611530|NCT03425695|Other|Clinical examination|"The shrinkage of the graft area was calculated according to the differences between the graft area at baseline, 1st, 3rd, and 6th months.~Epithelization was determined via bubbling test by using 3% hydrogen peroxide (H2O2) at 7, 14, 21, and 28 days after surgery."
45611531|NCT05171413|Other|Prediction model|We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with soft tissue sarcoma.
45611532|NCT04436211|Procedure|Total Knee Arthroplasty|The common procedure of Total Knee Arthroplasty is investigated in order to compare the techniques of implantation (kinematic vs mechanical alignment)
45611533|NCT01328093|Drug|LY2140023|Administered orally
45611534|NCT01328093|Drug|Aripiprazole|Administered orally
45611535|NCT03417427|Drug|Decitabine and Ara-C|Decitabine in combination with high-dose of Ara-C is used to improve the effect of consolidation chemotherapy. It is expected to make minimal residual disease (MRD) become negative in more patients with intermediate-risk AML.
45758718|NCT02995031|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z09-177)
45758719|NCT02995031|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
45611536|NCT03417427|Drug|Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
45611537|NCT04262505|Behavioral|Mediterranean Diet Group|Participants will be advised to follow a traditional Mediterranean diet
45611538|NCT04262505|Behavioral|Healthy Eating Group|Participants will be advised to follow the Healthy Eating Guidelines in Ireland
45611539|NCT05089305|Drug|Ozone plasma|Patients will be provided with an ion-laden cold atmospheric plasma administration equipment from the company Fulgur Vitae Model 9000, they will also be given the necessary indications, as well as recommendations on the use of the equipment, which they must use for 5 minutes three consecutive times a day, every 6 hours, for two weeks. They will also be provided with an atmospheric oxygen meter, with the indication to keep the ppb below 0.07. You must record in your diary the start time, end and eventualities (in case of presenting them).
45611540|NCT04448275|Other|Neurodynamics Nerve flossing|"Neurodynamics Nerve flossing for femoral nerve that includes two techniques inform of:~slider technique and the second is the tensioner technique"
45611541|NCT04448275|Other|conventional selected exercise program|Ultrasound therapy The flexibility exercises for iliopsoas & quadriceps The iliopsoas & quadriceps muscles strength exercise
45611542|NCT05059197|Dietary Supplement|AP collagen peptide|Health functional food
45611543|NCT05059197|Dietary Supplement|Placebo|placebo
45611544|NCT03425617|Drug|Tiotropium + Olodaterol|tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose
45611545|NCT03425617|Other|PLACEBO|PLACEBO via Respimat® single dose
45611546|NCT04448353|Diagnostic Test|vascuCAP|adverse event and phenotype classification model
45611547|NCT03419429|Drug|Simvastatin|Simvastatin is a drug used orally for treatment of hypercholesterolemia. It assists in bone regeneration and has anti-inflammatory effect when applied locally in intrabony defects for periodontal therapy.
45611548|NCT03419429|Other|EDTA|EDTA is a demineralizing agent used for root surface conditioning.
45611549|NCT03419429|Device|Occlusive membrane|Occlusive membrane is the traditional collagen resorbable membrane used in guided tissue regeneration.
45611550|NCT03419429|Device|Modified perforated membrane|Modified perforated membrane is the traditional collagen resorbable membrane but modified to be perforated. It is used in guided tissue regeneration
45611551|NCT04448041|Other|Malnutrition screening|Primary comparison: Prevalence of malnutrition and impact on 30-day outcomes in patients undergoing surgery for cancer
45611552|NCT02654145|Drug|Mepolizumab 100mg SC|At Visit 2 (Week 0) eligible subjects will receive mepolizumab 100mg SC into the upper arm or thigh every 4 weeks over a period of 28 weeks.
45611553|NCT02654145|Drug|Albuterol/salbutamol MDIs|Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
45611554|NCT02654145|Drug|Omalizumab|Subjects receiving omalizumab will enter in a run-in period and will continue to receive omalizumab throughout the run-in period. At Visit 2 (week 0) subjects will discontinue omalizumab.
45758720|NCT01272089|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once a day for one week
45758721|NCT01278563|Behavioral|Low glycemic index diet|dietitian interview and counselling for the low glycemic index diet group
45758722|NCT02396810|Other|intra-operative MRI|Intra-operative magnetic resonance imaging under general anesthesia
45445202|NCT05265429|Genetic|Data and Specimen Collection|"Provide research team access to relevant medical records~Answer two (2) short questionnaires at time of consent~Provide up to 5 tubes (37 ml) of blood at or near the time of consent, and/or saliva sample~Consider consenting to other optional parts of the research such as:~Providing additional blood or tissue samples in the future (optional)~Providing permission for obtainment of stored tissue specimens from lung cancer surgeries or biopsies from the pathology departments where they have been stored (optional)"
45611555|NCT03414203|Other|tDCS|Transcranial Current Stimulation equipment consists of an ammeter (measured with current intensity), a potentiometer (voltage controller between the electrodes), a generator (two 9-volt batteries) and two electrodes (anode and cathode). The direct low-amplitude currents released by the electrodes reach the cortex and modify the neuronal potentials.
45611556|NCT04447885|Device|weighted blanket|A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
45611557|NCT03413215|Behavioral|Intensive|"Patients are provided with a BP machine, glucometer and test strips, and instructed how to use either a written or smartphone logbook, photograph their meals and use smartphone apps to measure daily activity. DNEs will contact patients in between visits to reinforce adherence and self-monitoring.~MSWs will conduct at least 6 face-to-face sessions, at 3 weeks then less frequently, on essential self-care behaviours in people with diabetes: healthy eating; being physically active; monitoring of blood sugar; compliance with medications; problem-solving; healthy coping skills; and risk-reduction behaviour.~Renal pharmacists will see patients at 2-4 week intervals for 3 months after the first clinic visit, and subsequently every 3-6 months. They will review patient's compliance, laboratory results and home BP, educate patient and titrate antihypertensives to meet BP goal. Physician referrals will be made for severe hypertension or hypotension, or intolerable side effects."
45611558|NCT05122455|Drug|ASA|During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.
45611559|NCT05122455|Drug|Clopidogrel|During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.
45611560|NCT05122455|Drug|Edoxaban|During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.
45611561|NCT03413137|Procedure|Transperineal mpMRI-US Fusion prostate biopsy|mpMRI-US Fusion prostate biopsy in a transperineal approach to direct the needles towards an area in the prostate that was found as suspicious of malignancy by previous MRI imaging, defined as region of interest (ROI).
45611562|NCT03413137|Procedure|Transrectal mpMRI-US Fusion prostate biopsy|using the same system and MRI imaging, a transrectal approach would be used to sample a few more cores from the ROI as defined by the MRI imaging.
45611563|NCT03413059|Drug|Morphine Sulfate|Thoracic Epidural morphine
45611564|NCT03413059|Drug|Triamcinolone Acetonide|thoracic epidural triamcinolone acetonide
45611565|NCT05120817|Behavioral|"Personal intervention"|Participants will receive a link with an invitation to watch a 10-minute educational video about the personal benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
45758723|NCT02396810|Procedure|Transsphenoidal resection of pituitary macroadenoma|Routine transsphenoidal resection of pituitary macro adenomas
45758724|NCT00748657|Biological|Bevacizumab|Given IV
45758725|NCT00748657|Other|Laboratory Biomarker Analysis|Correlative studies
45758726|NCT02994953|Drug|Avelumab|Subjects will receive avelumab intravenous (IV) infusion once a week on Day 1 and Day 15 of each cycle.
45758727|NCT02994953|Drug|M9241|Subjects will receive Subcutaneous (SC) injection of M9241 in escalating doses on Day 1 of each cycle.
45758728|NCT02994953|Drug|Avelumab (Once weekly)|Subjects will receive avelumab once weekly in combination with M9241 every 4 weeks at M9241 maximum tolerated dose (MTD) for first 12 weeks followed by avelumab once every 2 weeks plus M9241 once every 4 weeks at M9241 MTD until a criterion for treatment discontinuation has been met.
45758729|NCT02994953|Drug|M9241 (MTD)|Subjects will receive M9241 at M9241 MTD once every 4 weeks until a criterion for treatment discontinuation has been met.
45758730|NCT02994953|Drug|Avelumab (Expansion cohort)|Subjects in the expansion cohorts will receive Induction Therapy (Avelumab once weekly + M9241 once every 4 weeks) through Cycle 3 (for 12 weeks) then starting at Cycle 4, Continuation Therapy (Avelumab once every 2 weeks + M9241 once every 4 weeks).
45611566|NCT05120817|Behavioral|"Social intervention"|Participants will receive a link with an invitation to watch a 10-minute educational video about the social benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
46068753|NCT05647057|Combination Product|C: ringers + retrograde autologous priming|"1400 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands) with retrograde autologous priming.~Retrograde autologous priming (RAP) is applied using clinical parameters such as Central Venous Pressure, Mean Arterial Pressure (MAP), and intra cardiac filling pressure based on Trans Esophageal Echo as guidance to the amount of fluid displaced. RAP is applied to a maximum volume of 475 mL provided that systolic blood pressure will remain >90 millimeter of mercury (mmHg). Phenylephrine can be administered up to 200 mcg to keep the system hemodynamics stable during RAP. In case of a body surface area <1.7m2, a maximum volume of 375 mL is desired. Once the desired amount of prime is displaced, the transfusion bag is clamped and CPB is started. If additional fluids are needed during CPB to maintain optimal perfusion, the displaced prime is used prior to the vasoplegia protocol."
45611567|NCT05120817|Behavioral|"Personal + Social intervention"|Participants will receive a link with an invitation to watch a 10-minute educational video about both personal and social benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
45611568|NCT05122377|Drug|3M GnRHa|This was a real world, observational study of adjuvant endocrine therapy with GnRHa for OFS in postoperative, premenopausal women with endocrine responsive breast cancer. Patients will receive treatment per GnRHa commercial label instruction: leuprorelin, goserelin, leuprorelin from local like: acetate microspheres sustained for injection(boennuokang), leuprorelin acetate microspheres for injection(beiyi).
45611569|NCT05122377|Drug|1M GnRHa|This was a real world, observational study of adjuvant endocrine therapy with GnRHa for OFS in postoperative, premenopausal women with endocrine responsive breast cancer. Patients will receive treatment per GnRHa commercial label instruction: leuprorelin, goserelin, leuprorelin from local like: acetate microspheres sustained for injection(boennuokang), leuprorelin acetate microspheres for injection(beiyi).
45611570|NCT03425461|Biological|Anti-SEMA4D Monoclonal Antibody VX15/2503|Given IV
45611571|NCT03425461|Biological|Ipilimumab|Given IV
45611572|NCT03425461|Other|Laboratory Biomarker Analysis|Correlative studies
45611573|NCT03425461|Biological|Nivolumab|Given IV
45611574|NCT03425461|Other|Pharmacological Study|Correlative studies
45611575|NCT05122299|Procedure|Negative control group|No intervention after extraction then delayed implant insertion at the site of extraction after three months
45611576|NCT05122299|Procedure|Postive control|Application of collagen only in the socket after extraction then delayed implant insertion at the site of extraction after three months.
45611577|NCT05122299|Procedure|Study group|Application of acombination of CoQ10 and collagen hydrogel in the socket after extraction then delayed implant insertion at the site of extraction after three months.
45611578|NCT03412981|Other|pregnant mothers|we will be collecting data on a cohort of pregnant mothers
45611579|NCT03425383|Diagnostic Test|FMD and c-IMT|"The diameter of the target artery (right brachial artery) will be measured from two- dimensional ultrasound images, with a 70 MHz linear array transducer and a standard 128XP/10 system (Acuson, Mountain View, California, USA).~c-IMT will be assessed by M-mode ultrasonography via a vivid 7 MHz linear array transducer and a standard 128XP/10 system (Acuson, Mountain View, California, USA) with participants in the supine position."
45611580|NCT04865601|Other|resectomy of the colon|The patient scheduled for colon resectomy are included in the study
46068754|NCT05646082|Drug|Dostarlimab in Combination Antiretroviral Therapy|Patients will receive dostarlimab at the fixed dose of 500 mg dose Q3W for the first 4 doses followed by a fixed 1000 mg dose Q6W until week 48 of treatment.
45611581|NCT05120115|Other|Weight belt|Wearing belt around waist with various weights attached.
45611582|NCT04753437|Drug|Clarithromycin|Clarithromycin tablets.
45611583|NCT04753437|Drug|Amoxicillin|Amoxicillin capsules.
45611584|NCT04753437|Drug|Bismuth potassium citrate|Bismuth potassium citrate tablets.
45611585|NCT04753437|Drug|Esomeprazole|Esomeprazole tablets.
45611586|NCT04753437|Drug|Vonoprazan|Vonoprazan tablets.
45611587|NCT02520973|Other|Sputum sample|
45611588|NCT03411187|Device|used of the Pressure adjustable foot-control method|Whether The Pressure adjustable foot-control method is used.
45611589|NCT03411187|Device|direct exhaust|direct exhaust through the trocar.
45611590|NCT04616079|Drug|REGN6490|Single dose of REGN6490
45611591|NCT04616079|Drug|Placebo|Placebo matching single dose of REGN6490
45611592|NCT03411109|Drug|Hydromorphone Hydrochloride|All intrathecal injections were performed preoperatively using a 22g or 25 g Whitacre or 24g Sprotte spinal needle. The IA regimen, medication(s) and dose(s), was at the discretion of the attending anesthesiologist, and consisted of one of the following regimens: (1) hydromorphone + local anesthetic (IA-L), or (2) hydromorphone only (IA-O). In patients receiving IA, no other interventional locoregional analgesic techniques (such as rectus sheath blocks or transversus abdominis plane blocks) were utilized.
45611593|NCT05121987|Procedure|Erector Spinae Plane block|An ultrasound linear probe is going to be placed in a longitudinal orientation 3 cm lateral to the T6 spinous process corresponding to the T5 transverse process. . Local infiltration with 2% of lignocaine at the site of needle insertion is going to be administered. Using in plane approach an 18 G Tuohy needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane, and on injection of 5 ml of normal saline.
46068755|NCT05645835|Behavioral|intervention|the intervention app will be installed on participants iPad or android. Lonely older adults will use the app five days a week for eight weeks total. Neuroimaging will be performed before and after the intervention.
46068756|NCT05645835|Behavioral|Active placebo|Participants will engage for 15 min with the control app five days a week for 8 weeks
46068757|NCT05643794|Drug|rozanolixizumab|Study participants will receive rozanolixizumab during the dosing periods as pre-defined.
46068758|NCT05643794|Other|Placebo|Study participants will receive Placebo during the dosing periods as pre-defined.
45611594|NCT05121987|Procedure|Continuous Wound Infusion|Towards the end of surgery, a multiholed 15-cm Anesthesia catheter will be placed in the preperitoneal space (the subfascial space between the peritoneum and posterior fascia) under direct vision and to be tunneled via the rectus sheath to the skin, rolled out and exiting laterally and stabilized with an adhesive tape on skin.
45611595|NCT03425227|Other|FRED EXERGAME|biofeedback with physiological constants as follows: systolic blood pressure, diastolic blood pressure, heart rate and blood oxygen saturation
45611596|NCT05121753|Dietary Supplement|Survey investigating Infant formula feeding in newborns|A database will be created that allows individuals to register and enter information about the premature infant's feeding history and symptoms/ medical history.
45611597|NCT03425149|Biological|VLA1601|purified inactivated ZIKV vaccine candidate adsorbed on alum
45611598|NCT03425149|Biological|Placebo|Phosphate buffered saline (PBS)
45611599|NCT05119725|Device|continous 3 day EKG monitoring with S-Patch Cardio|continous 3 day EKG monitoring with S-Patch Cardio
45611600|NCT03412825|Dietary Supplement|Egg supplementation|Participants will required to consume 2 eggs per day, 5 days a week (a total of 10 eggs per week).
45611601|NCT01111565|Drug|Escitalopram|Escitalopram capsule administered orally, once daily without regard to meals.
45611602|NCT01111565|Drug|Aripiprazole|Aripiprazole capsule administered orally, once daily without regard to meals.
45611603|NCT03412669|Other|Supporting Addiction Affected Families Effectively|Counselling
45611604|NCT03412669|Other|Enhanced Usual Care|Information sheet
45611605|NCT04564365|Drug|beta-blocker|To investigate the relationship between the use of beta blockers and prognosis in patients with normal ejection fraction after acute myocardial infarction
45611606|NCT04448665|Diagnostic Test|microbiological investigation|a microbiological tests, including isolation of the pathogen and analysis of their susceptibility/resistance to antimicrobial agents
45611607|NCT04523571|Biological|BNT162b1|Intramuscular injection
45611608|NCT04523571|Other|Placebo|Intramuscular injection
45611609|NCT02520895|Biological|blood samplings|patients will have blood samplings at different time : D0: day of inclusion = day of the first course of chemotherapy or the 1st day of the confirmation of the diagnosis (group 8) M3: 3 months (+/- 1 month) after the start of treatment (except for group 8) M6: 6 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) M12 : 12 months after the start of treatment (group 6 and 7) M18: 18 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) R: to relapse if it occurs before 18 months or at the time of first treatment if it occurs before 18 months (group 8)
45611610|NCT02521025|Other|Intermittent feeding pattern|Intermittent feeding
45611611|NCT02521025|Other|Continuous feeding pattern|Continuous feeding
45611612|NCT02520583|Dietary Supplement|Lactic acid bacteria and bifidobacteria|
45611613|NCT02520583|Other|Placebo|
45611614|NCT04170933|Procedure|Magnetic recanalization|"Establish a percutaneous transhepatic cholangio drainage (PTCD) fistula.~Perform endoscopic sphincterotomy (EST).~Place one magnet above the stricture through the PTCD fistula.~Introduce another magnet below the stricture through the common bile duct with ERCP.~Place the magnets at the appropriate point to attract each other.~The patient will be strictly followed, and the magnets will be taken out out of the mouth by the thread connected with the magnets.~A plastic stent will be placed in the bile duct for lasting support."
45611615|NCT05121207|Device|Terahertz scanning|Short scans using Terahertz device
45611616|NCT03412513|Drug|Mirabegron|Mirabegron 50mg po daily for 12 weeks to Active Comparator group, and 4 weeks(from visit 4 to visit 5) to Placebo comparator group.
45611617|NCT03412513|Drug|Placebo|Placebo po daily for 8 weeks to Placebo comparator group.
45611618|NCT03419351|Diagnostic Test|Smartphone|Smartphone based measurement of refractive error and visual acuity testing using these measurements.
46068759|NCT05641363|Drug|Ketorolac Tromethamine|ketorolac tromethamine, an NSAID belonging to a group of non-opioid analgesics that inhibit the synthesis of prostaglandins and thromboxanes with strong analgesic and anti-inflammatory properties. It is the only non-opioid parenteral non-sedating analgesic available for use to treat acute pain in the emergency department.
46068760|NCT05640583|Device|Hygieacare System|The device is an FDA cleared colon irrigation device, it will be used according to clearance. The sampling of the colon effluent sampled is the are of study.
45611619|NCT03419351|Diagnostic Test|Autorefractor|Autorefractor based measurement of refractive error and visual acuity testing using these measurements.
46068761|NCT05639322|Drug|Ketamine Hydrochloride|Ketamine-HCL IV 1mg/kg (up to 100 mg) over 2 hours, on weeks 2, 7, and 12.
46068762|NCT05639322|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioural Therapy/ Mindfulness Based Meditation therapy (CBT/MM) remotely for 16 hours between weeks 1 to 16 inclusive + in-person sessions on weeks 2, 7 and 12
46068763|NCT05639322|Other|Ketamine + Cognitive Behavioral Therapy|Ketamine-HCL + CBT/MM according to the same directions specified in Arm 1 and Arm 2.
46068764|NCT05635799|Other|Analysis of walking on flat ground|Analysis of walking on flat ground under different environmental conditions (visit 1)
46068765|NCT05635799|Other|Hospital Anxiety Disorder Questionnaire|performed during the inclusion visit
45611620|NCT03419351|Diagnostic Test|Individual|Individual, human measurement of refractive error and visual acuity testing using these measurements.
45611621|NCT05119491|Device|uitrasonography and spirometry|chest uitrasonography and spirometry
45611622|NCT04797091|Other|Retrospective data collection|Retrospective data collection to overcome the lack of knowledge on epidemiology, clinical course including diagnostic and therapeutic approaches and prognostic factors for SARS-CoV-2-infections and their complications among nephrology and elderly patients, as well as to serve as a platform for future studies and outbreak situations.
45611623|NCT03413969|Behavioral|CREATION|The physician-oriented intervention will consist of a two-day weekend retreat that focuses on the application of CREATION Health principles in order to reduce burnout and perceived stress and improve well-being and empathy. There will be one four-hour session about each of the following CREATION Health principles: Choice, Trust, Interpersonal Relationships, and Outlook.
45611624|NCT04482699|Biological|RAPA-501-Allo off-the-shelf Therapy of COVID-19|Allogeneic off-the-shelf RAPA-501 cells
45611625|NCT04482699|Other|Placebo|RAPA-501-Allo cell placebo
45611626|NCT03410719|Other|Hi GI|subjects will consume the same quantities of metabolizable CHOs (270 g/d) with 135 g of CHOs assigned to the GI intervention foods. The 135 g of CHOs will be distributed as 35 g GI breakfast product, 40 g GI lunch product, and 60 g GI dinner product. Assuming an average 2400 kcal/d total energy requirement among subjects, the 270 g/d metabolizable CHO equates to 40% of total energy intake (1080 kcal/d). One-half of daily CHO intake (135 g/d) will be the same between the Hi-GI and Low-GI groups, including CHOs in fruits, vegetables, and other foods that all subjects will consume. The other one-half of daily CHO intake (135 g) will be different between the Low-GI and Hi-GI groups. Specifically, the GI values of these foods will either be <55 (Low-GI group) or >70 (Hi-GI group).
45611627|NCT03419273|Procedure|bariatric surgery|We are recruiting only those going through bariatric surgery
45611628|NCT04457817|Device|CRI|Monitoring via CRI
45611629|NCT03412357|Procedure|pleurectomy/decortication|"VAT-PD is a type of keyhole surgery performed under general anaesthesia using a telescope and instruments put inside the chest. Through small incisions, or keyholes made between the ribs, the thoracic surgeon removes the hard rind of the tumour over the surface of the lung, thereby allowing the 'trapped' lung to fully expand again. Simultaneous removal of mesothelioma from the outer pleural membrane allows pleurodesis to occur."
45611630|NCT03412357|Procedure|indwelling pleural catheter|A soft silicone catheter (IPC) with a one-way valve at the end is inserted a few centimetres under the skin under local anaesthesia. The inside end of the catheter is inserted into the pleural space and the outside end is connected to a vacuum drainage bottle. The IPC permits regular fluid drainage.
45611631|NCT03419117|Procedure|ESP block|An ESP block will be performed prior to surgery for postoperative pain control
45611632|NCT03419117|Procedure|Placebo|A sham ESP block will be performed before surgery in the placebo group
45611633|NCT04370379|Drug|IBI302 (the first dose level)|q4week (3 injections) followed by PRN dosing
45611634|NCT04370379|Drug|IBI302 (the second dose level)|q4week (3 injections) followed by PRN dosing
45611635|NCT04370379|Drug|Aflibercept|2mg, q4week (3 injections) followed by q8week
45611636|NCT03413891|Drug|Tranexamic Acid|Mouthwash
45611637|NCT03413891|Other|Placebo|Mouthwash
45611638|NCT03410641|Behavioral|Diet and antismoking advice|Dietary advice with the aim of reducing participant's serum cholesterol levels, including reduction in the intake of saturated fat and cholesterol, and increased intake of polyunsaturated fat, fish, vegetables and fruit. Weight reduction was recommended for overweight men, as well as reduced consumption of sugar rich foods and drinks, and alcoholic beverages. Smokers were advised to stop smoking. The advice was given both individually and in group sessions during a five-year time period from 1972/3 until 1977/8.
45611639|NCT03419039|Dietary Supplement|Anthocyanins|Medox tablet containing 80 mg anthocyanins.
45611640|NCT03419039|Dietary Supplement|Placebo|Identically appearing capsules.
45611641|NCT05109819|Radiation|Esophagus sparring radiotherapy treatment|A radiotherapy plan for metastatic spinal cord compression is conducted with specific constrains sparring the esophagus.
45611642|NCT03126955|Diagnostic Test|Pre-Operative CISS-MRI Sequences|Compare pre-operative MRI diagnosis to intra-operative findings on if both are in agreement
46068766|NCT05635799|Other|Analysis of walking on slopes|All assessments will be identical to the flat walking analysis: flat walking will be replaced by slope walking for all environmental conditions
46068767|NCT05635799|Other|Group interview with a sociologist|Virtual reality feedback, accompanied by a confrontation of the patients' subjective experiences (group of 5 to 10 people)
45611643|NCT03126955|Diagnostic Test|Pre-Operative Interictal Laryngoscopy|Compare pre-operative laryngoscopy diagnosis to intra-operative findings on if both are in agreement
45611644|NCT03126955|Diagnostic Test|Pre-Operative Unilateral and Contralateral Botox|Compare pre-operative diagnosis using Botox to intra-operative findings on if both are in agreement
45611645|NCT03413813|Device|Magmaris|Severe stenosis de novo, in native coronary arteries, treated with percutaneous coronary intervention with scaffold implantation.
46068768|NCT05631470|Diagnostic Test|MR screening|This study is to compare the results of MR-FFR with pressure-wired-based FFR measurement.
46068769|NCT05630547|Drug|SAR443820|Tablet by oral administration
46068770|NCT05630547|Other|Placebo|Tablet by oral administration
46068771|NCT05629702|Drug|Sativex|Oromucosal spray
46068772|NCT05629702|Drug|Temozolomide|Oral capsule
45611646|NCT03127397|Behavioral|Praise message phone call|Praise message phone calls after each completed ART appointment, up to two calls per month.
45611647|NCT03127033|Other|Soft liner telescopes|"Soft liner telescopes: Overdenture will be adjusted by relieving acrylic opposite to the abutment about 2 mm using a metal stone. The relieved areas will be painted with an adhesive and the rest of the fitting surface of the denture will be painted with a separating medium.~The soft liner (Silicone based soft liner, mollosil, chairside soft relining-long term, DETAX, Germany) will then be applied in the relieved areas to act as a secondary coping The base and catalyst will be mixed according to the manufacturer's instructions on a glass slab. The mix will be placed on the relieved area, seated in the patient's mouth, the patient is asked to bite in centric relation and the excess liner is removed with a lancet."
45611648|NCT03412279|Behavioral|Application of the initial evaluation|Initial evaluation involves the application of Hausa ODI, NPRS, RMDQ, SF-12, PCS, GROC, BBQ, VAS for pain and disability, and FFD.
45611649|NCT03412279|Behavioral|Final application of instruments|Application of the Hausa versions of ODI, NPRS, RMDQ, SF-12, PCS, GROC and BBQ one week after initial evaluation
45611650|NCT03413657|Procedure|Increase in intrathoracic pressure|Will transiently increase intrathoracic pressure for 60 seconds and monitor for changes in hemodynamics during this time.
46068773|NCT05629702|Drug|Sativex-matched placebo|Sativex-matched placebo oromucosal spray
45611651|NCT03317613|Drug|Qutenza|Patients suffering from neuropathic pain will receive patch of capsaicin (qutenza) on the painful zones. Three months after the first application, patients will be allowed to receive another patch if necessary. They will be able to receive one every three months. They will be followed in the study during one year after the first patch application.
45611652|NCT03410563|Behavioral|Auditory inputs|Three different auditory inputs
45611653|NCT03311763|Behavioral|EIM Fitness Practitioners|Exercise is Medicine Practitioners will facilitate peer groups that attend twice-weekly exercise classes for 8 weeks, with clinical monitoring and advise regarding increasing physical activity.
45611654|NCT03311763|Behavioral|Counseling and wearable device|Brief exercise counseling session and provision of a wearable fitness tracking device to promote physical activity.
45611655|NCT03126877|Drug|Mitomycin C|The surgical procedure includes a low dose, short duration mitomycin C (MMC) treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.
45611656|NCT03126877|Device|Raindrop Near Vision Inlay|The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominante eye for the improvement of uncorrected near vision.
45611657|NCT03412201|Other|Usual Care|Follow-up and management of heart failure medications provided by the patient's general physician and/or cardiologist according to local medical standards
45611658|NCT03412201|Other|High Intensity Care|Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 2 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses.
45611659|NCT04260477|Drug|6EH³R³Z|"A triple dose is defined as the triple of the routine dose used for a specific WHO weight band. Hence, the mg/kg within a weigh-band varies, as is the case in routine practice.~Dosing takings into consideration the fixed dose combination (FDC) tablets (one tablet: 150 mg R + 75 mg H + 400 mg Z + 275mg E). Dosage relies on tables with dosage by weight-bands used by WHO for the Cat. 1 regimen. The dosage used for the intensive phase of the Cat. 1 regimen applies for the whole treatment duration. A double dose of H and R is added to the recommended normal dose for adults (WHO,2003)"
45611660|NCT04260477|Drug|6EHRZ|"Recommended normal dose adults (WHO, 2003)~H: 5 (4-6) mg/kg/day~R: 10 (8-12) mg/kg/day~Z: 25 (20-30)mg/kg/day~E: 15 (15-18)mg/kg/day"
45611661|NCT02343458|Drug|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
45611662|NCT02343458|Drug|FF MDI (PT005)|Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
45611663|NCT02343458|Drug|GP MDI (PT001)|Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
45611664|NCT02343458|Drug|Placebo MDI|Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
45611665|NCT02964377|Drug|(+)- Epicatechin|
45611666|NCT03126045|Device|Standard needle|"Patients will perform a spinal punction with a standard needle, used in the usual practice. The standard needles have the following characteristics : BD 22 G x 3 ½ in, 90mm, Quincke spinal needle, Black hub.~When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture."
45611667|NCT03126045|Device|Atraumatic needle|"Patients will perform a spinal punction with an atraumatic needle, used in the hematological service of the CHU of Saint-Etienne. The atraumatic needles have the following characteristics : Vygon 24 G × 3 ½ in, 90mm, Whitacre Pencil Point Spinal Needle, Purple hub.~When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture."
45611668|NCT03424837|Behavioral|ASCENT|"ASCENT includes the following components:~Survivorship care plan created through the ASCENT tool~Online tool which assesses health care needs and facilitates receipt of care~A national-level navigator who helps the participant to access support services~Periodic reminders for the participant to pursue recommended survivorship care"
45611669|NCT05171023|Device|ROTEM and standard coagulation tests|ROTEM and standard coagulation tests assessment
45611670|NCT05230407|Other|Visual analog scale (VAS) assesment of pain|Post operation VAS score will be assessed before discharge from hospital and 24 hours post operation
45611671|NCT03424759|Drug|AZD9291|Patients will be treated 80 mg/day of AZD9291 orally (1 cycle for 21 days).
45611672|NCT02839811|Procedure|Immediate hypersensitivity to BLC|immediate hypersensitivity to BLC by In vitro diagnosis
45611673|NCT05230329|Procedure|right sided hemicolectomy, laparoscopy|Comparison of CME
45611674|NCT03127813|Other|Application of continuous positive airway pressure (CPAP)|CPAP will be delivered at 4 different pressure levels (6, 10, 13 and 16cmH2O) in a randomly allocated order
45611675|NCT03413579|Biological|Nimotuzumab ( h-R3)|Humanized monoclonal antibody
45611676|NCT03413579|Other|Placebo|
45611677|NCT04824807|Other|Yoga|"The yoga classes included a progression of low-impact, modified poses, stretching and isometric exercises focused on the shoulders, arms, and chest, and meditation. Breathing and poses to drain the lymphatic system were incorporated throughout the yoga practice to assist with lymphatic flow.~Exercises: sitting down badrasana, ardha navasana, dhanurasan, setu bandhasana, Urdhva Dhanurasana, Urdhvamukha Svanasana, Virabhadrasana, Warrior Virasana, Supta Virasana, Surya Namaskar, Mayurasana, Padmasana, Bharadvajasana."
45611678|NCT04824807|Other|Clinical Pilates|"before starting the clinical Pilates exercise program, the patients were trained on Pilates exercises and postures. During training, the patients were taught how to create lumbopelvic stability (core stabilization), which is the basis for Pilates exercises, and spinal stabilization and appropriate posture techniques.~Exercises: cork screw, toy soldier, kleopatra, the saw,breast stroke preparation, swimming, diamond press - arm openings, scapula isolations, open book, scissors, shoulder bridge."
45611679|NCT04824807|Other|An educational booklet|Only educational booklets will be given to the control group
45611680|NCT03413501|Behavioral|MUD-PI|
45611681|NCT03410485|Device|BIS index/NoL index|"Remifentanil i.v. infusion will be run between 0.03 and 0.15 mcg/kg/min and boluses (0.4mcg/kg) will be given to keep a NoL index between 10-20.~Once intubated, the maintenance of anesthesia will be achieved with: desflurane set at 1 MAC to start, then adapted to the BIS between 45-55."
45611682|NCT03410485|Device|Variation of baseline mean arterial pressure|"Remifentanil i.v. infusion will be run between 0.03 and 0.15 mcg/kg/min and boluses (0.4mcg/kg) will be given to keep a baseline mean arterial pressure between 10% of variation.~Once intubated, the maintenance of anesthesia will be achieved with: desflurane set at 1 MAC to start, then ajusted to 0.8 MAC."
45611683|NCT04814745|Drug|intrathecal infusion|morphine 150 mcg will be used by intrathecal administration
45611684|NCT04814745|Drug|Intravenous Infusion|tramadol administration
45611685|NCT04814745|Drug|Ropivacaine injection|bilateral transversus abdominis plane block by using ropivacaine 80 mg
45611686|NCT03412123|Behavioral|group lifestyle-integrated functional exercise|Manualized teaching of balance and strength principles and integration of exercises and physical activity into daily routine during 7 sessions in a group of 8 to 10 participants with 2 trainers. The pilot intervention group will undergo the same strength and balance exercises and learn about the same physical activity enhancement strategies as described in the LiFE programme by Clemson et al. (BMJ 2012;345:e4547). However, instead of 7 home visits, gLiFE participants will attend seven group sessions (1 session/week). In these, LiFE contents are adapted to the group setting and enhanced by health psychological and behaviour change strategies fitting to the social structure and modalities of a group.
45611687|NCT03410329|Other|Resistance training|Physical activity
45611688|NCT04757103|Procedure|Resection of the retrorectal tumor|Surgical resection of the retrorectal mass
45611689|NCT04448093|Procedure|dental treatment|Dental treatment of adequacy of oral environment and assessment of quality of life and self-esteem through questionnaires comparing a group that received treatment with another that did not.
45611690|NCT03410251|Procedure|Socket preservation|"Teeth were extracted atraumatically and without flap release in patients who have received prophylactic antibiotherapy and local anaesthesia. After checking the integrity of the buccal and palatal bone plate, biomaterial (Bio-Oss®) was introduced into the socket. A connective tissue graft harvested from the palate was inserted and sutured in buccal and palatal pouches in order to cover the socket.~chlorhexidine spray (0.12%) twice a day and Ibuprofen 600 mg three times/ day were prescribed whereas antibiotics were continued for 5 days. Tooth brushing was banned at the extraction site for 10 days and sutures were removed 10 days after surgery."
45611691|NCT04640571|Drug|pravastatin and chenodeoxycholic acid, after metformin and placebo|single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg
45611692|NCT04640571|Drug|valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo|single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg
45611693|NCT02801825|Procedure|Real-time ultrasound-guided in-plane infraclavicular axillary artery cannulation.|Real-time ultrasound-guided in-plane infraclavicular axillary artery cannulation.
45611694|NCT02801825|Procedure|Real-time ultrasound-guided out-of-plane femoral artery cannulation.|Real-time ultrasound-guided out-of-plane femoral artery cannulation.
45611695|NCT04593147|Other|BBN|BBN to be fed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
45611696|NCT04593147|Other|Brand|Brand to be fed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks
45611697|NCT04448405|Behavioral|Questionnaire for evaluation of confinement on deviant sexual fantasies|Questionnaire for evaluation of confinement on deviant sexual fantasies. Population already followed for deviant fantasies
45758731|NCT05249660|Other|Soft tissue release technique|Patient sat on a chair. The therapist stood behind the participant and held one hand over head as the support, with the thumb of the other hand scan to detect the painful area of the latent TP of the upper trapezius muscle along the fibers. Then, pressure was applied by the thumb and the participant was asked to simultaneously actively change the muscle from shorted position to elongated state (ipsilateral side flexion of the cervical to the opposite side). This technique was repeated 3-5 times per session, and each repetition was maintained for 40-60 s till release is felt, with a 15-second rest interval. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
45611698|NCT04431141|Drug|Teneligliptin|Teneligliptin alone
45611699|NCT04431141|Drug|Empagliflozin|Empagliflozin alone
45611700|NCT04431141|Drug|Teneligliptin and Empagliflozin|Teneligliptin and empagliflozin
45611701|NCT03418883|Other|Mirror therapy|
45611702|NCT05229627|Drug|MPH|the drug would be prescribed to patients without any contraindication
45611703|NCT05229627|Drug|ATX|the drug would be prescribed to patients without any contraindication
45611704|NCT03413267|Other|Custard|Food matrix: custard (liquid emulsion)
46068774|NCT05627492|Behavioral|Dialectical behavioral therapy|DBT will be conducted over 1 year. Participants and their treatment providers will decide on the frequency of sessions collaboratively. This may include individual and/or skills sessions in addition to phone coaching for those who attend individual sessions at least once per month. DBT consultation will also remain a component of the treatment. Participants may choose skills training, conducted in approximately 60 minute meetings, and individual therapy conducted in approximately 60 minute sessions. Family participation in skills training is highly encouraged. Skills training may include: psychoeducation, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the youth in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets.
46068775|NCT05623943|Procedure|Endovascular treatment|Patients treated with endovascular treatment, including balloon angioplasty alone and balloon angioplasty plus stenting.
46068776|NCT05623267|Drug|Sugemalimab|Recombinant anti-PD-L1 fully human monoclonal antibody
46068777|NCT05623267|Drug|Placebo|Placebo of Sugemalimab
46068778|NCT05622864|Drug|HRS-9821|HRS-9821
46068779|NCT05622864|Drug|HRS-9821|HRS-9821
46068780|NCT05622201|Drug|Rituximab|Infusion
45611705|NCT03413267|Other|Flan|Food matrix: flan (soft gel)
45611706|NCT03413267|Other|Sponge cake|Food matrix: sponge cake (porous and spongy)
45611707|NCT03413267|Other|Biscuit|Food matrix: biscuit (thick and crunchy)
45611708|NCT01976169|Drug|PD-0332991 and T-DM1|"The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.~A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.~Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)"
45611709|NCT04448639|Diagnostic Test|Echocardigraphy (ECHO)|Standar 12 lead electrocardiogram
45611710|NCT04448639|Diagnostic Test|Bloodtest|cardiac biomarkers
45611711|NCT04298151|Drug|Zirconomer Improved|glass ionomer restoration reinforced with nano-zirconia particles to improve strength and esthetics
45758732|NCT05249660|Other|Comparator: Instrument assisted soft tissue mobilization|Patient lied prone; the treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers with the instrument at a 45º angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45º angle for an additional 20-second, resulting in a total treatment time of approximately 40 s. This technique was applied 3-5 times per session with 20 s rest between each time. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
45611712|NCT04298151|Drug|Ketac Molar Aplicap|highly viscous glass ionomer with improved mechanical properties than the conventional GI
45758733|NCT01272895|Device|Coronary Intervention (GENOUS stent)|GENOUS stent (Coronary Intervention)
45611713|NCT03413111|Procedure|Modified double wire technique|For experimental arm, a tiny cut of papilla orifice, with the length of 5mm, was performed by sphincterotome before the double wire cannulation.
45611714|NCT00148629|Drug|multivitamin, mebendazole|
45611715|NCT04448015|Other|Perinatal Opioid Use Disorder Education and Enhanced Perinatal Care|University of Utah clinicians will provide face-to-face, online, and written training materials for health, mental health, and substance use service providers in Carbon and Emery Counties, UT.
45758734|NCT05244902|Drug|5% Dextrose|All the patients will receive oral 3mL/kg 5%Dextrose
45758735|NCT00717977|Device|Continuous glucose monitor|Daily use of a continuous glucose monitor for 3-7 days
45758736|NCT05242250|Device|Catheter Ablation|Ablation RF technologies manufactured by Abbott.
45445203|NCT05212701|Drug|Reparixin|The oral tablets of the investigational product (IP) will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack (it is preferable that reparixin is taken with food).
45611716|NCT03413033|Other|Resonance tube|Participants will phonate into a tube (10cm length 4mm inner diameter) during 5 minutes. They will produce series of the vowel /u/ into the tube. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
45611717|NCT03413033|Other|Tongue trill|Participants will produce series of a similar /r/ Spanish sound during 5 minutes. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
45611718|NCT04511325|Other|Potato Regimen|100 grams cooked white russet potato with the skin
45611719|NCT04511325|Other|Refined Grain Regimen|75 grams of cooked long-grain white rice
45758737|NCT01272973|Drug|semaglutide|Semaglutide (oral) administered once daily for 10 weeks.Individually adjusted dose investigated up to maximum level.
45758738|NCT01272973|Drug|placebo|Placebo (oral) administered once daily for 10 weeks.
45758739|NCT01272973|Drug|semaglutide|Administered s.c. (under the skin) once weekly for 10 weeks. Individually adjusted dose investigated up to maximum level.
45611720|NCT03412955|Drug|Eribulin Mesylate|1.4mg/m2/dose on days 1 and 8 of a 21-day treatment cycle.
45611721|NCT05229237|Drug|Conbercept|Intravitral injection of Conbercept (0.5 mg/0.05 mL, Chengdu Kanghong Biotech, Inc.)
45611722|NCT03418493|Drug|LY3316531 - IV|Administered IV.
45758740|NCT02924636|Behavioral|ePPOP-ID program|This is a personalized and online program. The website will provide secure communication with dietician and lifestyle coaches.
45758741|NCT01273051|Drug|Capecitabine|Capecitabine will be administered at a dose of 825 mg/m2 bid during radiotherapy treatment
45758742|NCT01273051|Radiation|radiotherapy|radiation 25x2 Gy
45758743|NCT01273051|Procedure|TME resection|All patients undergo a MRI of the pelvis and a rectoscopy and endorectal ultrasound 6 weeks after chemo radiation. Patients who do not respond or clinically have a T3 tumour either on visual measurements or post therapy MRI or endoanal ultrasound will be operated on with a TME resection 8 - 10 weeks after the last chemo radiation treatment.
46068781|NCT05617092|Other|Physiotherapy treatment|physiotherapy individualized treatment according to the needs of the patient and clinical findings and symptoms
45611723|NCT03418493|Drug|LY3316531 - SC|Administered SC.
45611724|NCT03418493|Drug|Placebo - IV|Administered IV.
45611725|NCT03418493|Drug|Placebo - SC|Placebo - SC.
45611726|NCT05229159|Diagnostic Test|Bioelectrical impedance analysis|Segmental multi-frequency bioelectrical impedance analysis are carried out at all patient admitted to our ICU for postoperative care after cardiac surgery with cardiopulmonary bypass. Our objective is to evaluate the relevance of phase angle to predict mortality or a prolonged hospital length of stay. Phase angle is evaluated at ICU admission and will be compared to well-known prognostic scores computed in preoperative (EuroSCORE II) and at day one after surgery (SOFA, CASUS and SAPS II).
45611727|NCT01328041|Drug|dolutegravir|50 mg twice daily
45611728|NCT03412721|Procedure|Laser analgesic procedure|"Water mist spray set to maximum, non-contact handpiece with sapphire tip. Tip-to-tissue distance 10 mm from the tooth neck, achieved by using a spacer. Energy is delivered to the enamel above the gingival margin adjacent to the cemento-enamel junction (perpendicularly towards the dental pulp) on each of the four line angles of the tooth for 30s, moving the laser handpiece in a sweeping action. Pulse energy - 0.2 W/ 10 Hz/ 20 mJ. Follows increase of energy and repetition of protocol - 0.6 W/ 15 Hz/ 40 mJ. Total duration of LA-induction - 240s."
45611729|NCT03412721|Procedure|Placebo analgesic procedure|Performing imitation of laser analgesic procedure. No pulse energy applied, non-contact handpiece with sapphire tip. Moving the laser handpiece in a sweeping action towards the cemento-enamel junction (pointing perpendicularly towards the dental pulp) on each of the four line angles of the tooth. Total duration of placebo analgesia induction - 240s.
45611730|NCT05229081|Behavioral|vaccine education|The educational content was developed based on research and expert perspectives and included general information about immunization, pneumonia, and pneumococcal vaccines, as well as vaccine myths. This information was first conveyed to the patients verbally, and then booklets with the same material were handed to them. The Pneumococcal Conjugate Vaccine 13 (PCV13) vaccination was recommended based on Infectious Disease Society of America (IDSA), Advisory Committee on Immunization Practices (ACIP), and national adult immunization guidelines.
45611731|NCT03418415|Device|Renal denervation|multi-electrode catheter-based renal denervation
45611732|NCT05029557|Behavioral|Education and telephone follow ups based on the Chronic Care Model|The effects of Chronic Care Model-based education and telephone follow-up given to patients with COPD on self-efficacy and patient-reported outcomes.
45611733|NCT03418337|Drug|dexilansoprazole (Dexilant 60 mg)|evaluate the response rate (symptom free) during the 8-week PPI therapy for atypical GERD between dexlansoprazole group and lansoprazole group
45611734|NCT03418337|Drug|lansoprazole (Takepron OD 30 mg)|lansoprazole group
45611735|NCT03412487|Procedure|laparoscopy|under general anesthesia. CO2 pneumoperitoneum, the laparoscope inserted through the umbilicus and a thorough evaluation of the abdominal cavity and pelvis was performed. a grasper was inserted; the utero-ovarian ligament was stabilized with the round biopter will be introduced. The tip of the biopsy instrument was placed on an area of the ovary free of cysts; the hilar area was avoided because it is deficient in small follicles. After correct placement was verified, the inner protecting trocar was removed to expose the sharp leading edge of the round sheath. Gentle circular movements were made cutting through the ovarian cortex to produce a 5-mm disk of 2-3 mm in thickness.
45611736|NCT04435977|Drug|Cabozantinib 60 MG|"• The assigned dose for study treatment is 60 mg qd. Two dose reductions will be permitted (Table 2):~60 mg qd to 40 mg qd (level 1)~40 mg qd to 20 mg qd (level 2)"
45611737|NCT03414125|Other|FIT Screening Strategy|"Mailed outreach invitation to complete FIT. FIT Strategy invitation includes: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
45611738|NCT03414125|Other|Choice Screening Strategy|"Mailed outreach invitation offering patients the choice to complete either a FIT or schedule a colonoscopy.~Letter will discuss advantages and disadvantages of FIT vs. colonoscopy but will not recommend a particular test, allowing patients to choose a screening option based on their own preferences. Outreach includes: 1) invitation letter, 2) choice grid 3) telephone number for scheduling colonoscopy, and 4) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
45611739|NCT03418181|Procedure|Standard Haemodialysis|Thrice weekly dialysis.
45611740|NCT03418181|Procedure|Incremental dialysis|Individualised dialysis dose according to native kidney function.
45611741|NCT03424447|Procedure|efferent limb stimulation|
45611742|NCT04510857|Device|MOVE-IT Intervention|The MOVE-IT device comprises a custom smart toy and therapy game software to enable repetitive task practice involving the arm and hand.
45611743|NCT04510857|Behavioral|UCT Control|Participants assigned to the UCT control group will continue to receive their previously prescribed therapy services.
45611744|NCT03411967|Drug|Apatinib|apatinib mesylate tablets 500mg, po, qd, continued until the next cycle, taking on an empty stomach (daily taken at the same time), every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment, apatinib has been taken until the disease progresses, intolerable toxicity.
45611745|NCT03411967|Drug|Docetaxel|Docetaxel, 60 mg / m2, d1, iv ,every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment
45611746|NCT04236843|Dietary Supplement|Feces|Feces from healthy donor
45611747|NCT03418103|Device|Thermal imaging analysis of participant position in a hospital bed|The SAFE sensor system will use thermal imaging to detect and identify a participant's position relative to the edges of the hospital bed. If a dangerous position is identified, an alarm notification will be sent to the ward staff to allow them to take pre-emptive action to prevent the participant's situation from evolving into a fall event.
45611748|NCT03410173|Drug|Taurine|
45611749|NCT03410173|Drug|Placebo|
45611750|NCT05228925|Other|Maternal vitamin D status|Maternal vitamin D status (serum 25-hydroxyvitamin D) was collected during the GraviD study, while the woman was pregnant with the child now being followed-up in the GraviD-child study
45611751|NCT03412409|Drug|Cytarabine|RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).
45611752|NCT05168293|Other|Detection of HBV-DNA in Peripheral Blood Mononuclear cells|Detection of HBV-DNA level in Peripheral Blood mononuclear cells
45611753|NCT02410772|Drug|rifapentine|Regimen 2: Rifapentine is substituted for rifampin as the basis of 4-month treatment
45611754|NCT02410772|Drug|rifapentine and moxifloxacin|Regimen 3: In addition to the single substitution described for regimen 2, a second substitution is added, of moxifloxacin for ethambutol.
45611755|NCT02410772|Drug|control|standard six-month treatment
45611756|NCT03814317|Drug|Inhaled Treprostinil|"Inhaled treprostinil causes dilatation of the pulmonary arteries and may help reduce the pulmonary pressures in this studied population.~All subjects will initiate inhaled treprostinil at a dose of 3 breaths (18 mcg) four times daily. Study drug doses escalations (additional one breath four times daily) can occur every three days with a maximum dosing regimen of up to 12 breaths (72 mcg) four times daily, as clinically tolerated."
45611757|NCT03127319|Drug|apatinib docetaxel zoledronic|apatinib 500 mg qd p.o.docetaxel 60mg/m² iv q3w;zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
45611758|NCT03127319|Drug|docetaxel zoledronic|docetaxel 60mg/m² iv q3w;zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
45611759|NCT03411811|Other|Usual Care|Therapeutic ultrasound, myofascial release of extensor and flexor muscles of forearm and stabilization exercises for the wrist.
45611760|NCT03411811|Procedure|Dextrose|Injection of 1 ml of 12.5% dextrose in 1% lidocaine at 0, 3 and 6 weeks in 5 locations: Origin of ulnar collateral ligament, insertion of ulnar collateral ligament on the triquetrum, insertion of the extensor carpi ulnaris on the base of the 5th metacarpal, triquetral hamate ligament and ulnotriquetral joint space.
45611761|NCT04505163|Procedure|Standard Cryoballoon Pulmonary Vein Isolation (PVI)|Arctic Front Advance cryoballoon ablation system to ablate the pulmonary veins to achieve PVI alone
45611762|NCT04505163|Device|Cryoballoon PVI + Posterior Wall Isolation|Arctic Front Advance Cardiac Cryoballoon Ablation System to ablate the pulmonary veins and the left atrial posterior wall to achieve PVI + posterior wall isolation within the region of the pulmonary venous component
45611763|NCT03412331|Device|Ultrasonic|Cavitron® BOBCAT® Pro, Dentsply International, USA
45611764|NCT03412331|Device|Hand Instruments|Gracey, SG 5/6, 7/8, 11/12, 13/14, Hu-Friedy Ins. Co., USA
45611765|NCT03412331|Device|LED Source|LED source (625-635 nm wavelength) (FotoSan®, CMS Dental, Denmark)
45611766|NCT03424369|Procedure|Tympanoplasty|Tympanoplasty
45611767|NCT03418025|Behavioral|Exercise Intervention|Undergo Exercise Together intervention
45611768|NCT03418025|Other|Questionnaire Administration|Ancillary studies
45611769|NCT03418025|Other|Survey Administration|Ancillary studies
45611770|NCT03410095|Diagnostic Test|Brain MRI, cognitive testing, bloodwork|"Participants will undergo 3-Tesla MRI. Scan time will be about 1 hour and 15 minutes per subject per session at the Sunnybrook site. The protocol is designed to image SVD burden by quantifying PVS and WMH volumes, and image various physiological estimates on the brain.~Participants will undergo the following cognitive tests: Behavioural Neurology Assessment-R (BNA-R), Montreal Cognitive Assessment (MOCA), Center for Epidemiologic Studies Depression Scale (CES-D), and BrainScreen.~Blood samples will be assayed for inflammatory and endothelial function. Classical vascular risk factors will also be assessed. Once data collection is complete, DNA will be extracted from the frozen PBMC fraction and will be genotyped for APOE genotype and a panel of other single nucleotide polymorphisms known to be associated with cognition and cerebrovascular disease."
45611771|NCT03417947|Dietary Supplement|Vitamin D bolus|One single oral liquid vitamin D3 supplement of 300 000 IU
45611772|NCT03417947|Dietary Supplement|Placebo|Placebo identical in taste and appearance to the vitamin D bolus
45611773|NCT03905811|Drug|Terazosin 5 MG|5 milligrams by mouth daily at bedtime
45758744|NCT01273051|Procedure|TEM surgery|"All patients undergo a MRI of the pelvis and a rectoscopy and endorectal ultrasound 6 weeks after chemo radiation.Patients with a significant downsizing of the tumour (T0-T2) will be operated on by TEM surgery 8 -10 weeks after the last chemo radiation treatment.~After TEM surgery, pathological assessment will dictate further treatment. Conservative treatment with careful follow-up will be performed in patients with a complete resection of a ypT0-1 rectal tumour. Patients with lymphangio invasion, an incomplete resected ypT1 (<2 mm margin), an ypT2 or ypT3 tumour after TEM will subsequently undergo TME surgery to remove the rectum within 4 weeks."
45758745|NCT02994875|Dietary Supplement|N-acetylcysteine|NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications.
45758746|NCT02994875|Other|Placebo|Sugar pill
45758747|NCT03809143|Drug|RBP-6000|All study participants are scheduled to receive monthly subcutaneous injections of depot BPN, RBP-6000. RBP-6000 (BPN in the ATRIGEL® Delivery System) contains buprenorphine (200mg/mL) in the ATRIGEL® Delivery System, which provides sustained plasma level of BPN over a minimum of 28 days.
45758748|NCT02390960|Drug|Sildenafil Cream|Patients will be instructed to apply pre-weighed SST-6006 to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
45758749|NCT02390960|Drug|Placebo Cream|Patients will be instructed to apply the pre-weighed placebo cream to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
45758750|NCT02390960|Device|Penile Plethysmography (RigiScan)|During each dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. Each plethysmography session will be approximately 75 minutes.This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
45758751|NCT03808831|Device|Fall detection and prevention system|The fall detection and prevention system records near-fall and fall events; meanwhile, it alarms subjects while detecting near-fall events and alarms caregivers while detecting fall events.
45758752|NCT03808831|Device|Sham fall detection and prevention system|The sham system with record but no alert function
45758753|NCT04270331|Other|PADS protocol|Assessment and management per PADS protocol
45611774|NCT03905811|Drug|Placebo oral capsule|1 capsule by mouth daily at bedtime
45611775|NCT01648790|Drug|Prasugrel ODT1 - Tablet|Administered orally as tablet.
45611776|NCT01648790|Drug|Prasugrel ODT2 - Tablet|Administered orally as tablet.
45611777|NCT01648790|Drug|Prasugrel ODT2 - Suspension|Administered orally as suspension.
45611778|NCT03127163|Device|Intraestromal corneal ring|The patients underwent surgery to implant the intrastromal corneal ring (Ferrara Ophthalmics, Belo Horizonte, Brazil) using a manual technique. The procedures were performed by a single surgeon with extensive training in corneal surgery. All patients received the same ring, and the number (1 or 2 segments), thickness, and arc size were calculated using the nomogram provided by the manufacturer.
45445204|NCT05212701|Drug|Placebo|The oral tablets of masked placebo will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack
45611779|NCT03411733|Other|Blood and stool samples collection|Collection of blood and stool samples from each participants for H.pylori antigen/ antibody detection
45611780|NCT03417869|Device|QuickVue Influenza A+B|Rapid diagnostic test with IVD, QuickVue Influenza A+B
45611781|NCT03771885|Drug|BI 705564|Film-coated Tablet
45611782|NCT03771885|Drug|Placebo|Film-coated Tablet
45611783|NCT03409393|Other|The COPUS intervention|The COPUS intervention consists of 8 weeks of High-Intensity Functional Training (HIFT). The frequency of the training is 3 sessions per week and the duration is one hour per session. The intervention is group-based and supervised. Each training session includes warm-up (15 min), followed by 30 minutes of HIFT based on a range of varied functional exercises, including elements of strength training and aerobic exercise. The sessions are supervised by a trained physiotherapist and exercise physiologist supported by 2 two trained bachelor students in Sports Science.
45611784|NCT03409393|Other|Usual Care (OPUS treatment)|Usual care include specialised early intervention treatment (OPUS treatment) and consists of three main pillars: modified assertive treatment, family involvement, and social skill training. OPUS treatment is delivered via multidisciplinary teams include psychiatrists, psychologists, nurses, social workers, physiotherapists, and vocational therapists. All team members, except for the psychiatrist, function as case managers. The ratio of patients to case managers must not exceed 12:1.
45611785|NCT03652077|Drug|INCAGN02390|Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation in 7 total cohorts to determine the maximum tolerated dose or PAD.
45611786|NCT03417791|Other|no intervention|no intervention
45611787|NCT03409315|Procedure|Centralized Therapeutic Drug Monitoring|Plasma samples will be drawn at peripheral centres en shipped to a central laboratory for analysis. Results and dosing advice will be returned by email to local physician.
45611788|NCT04470687|Device|contrast enhanced ultrafast ultrasound imaging|"Ultrasound contrast medium: SonoVue 8µL/mL (Bracco International BV) Ultrasound scanner: Aixplorer® device marketed by SuperSonic Imagine©, CE Doppler UltraFast™Doppler, contrast ultrasound (CEUS), color Doppler and ultra-sensitive energy Doppler, high-performance directional energy Doppler, Elastography ShearWave™ UF-Doppler (UltraFast-Doppler) and microbubble injection (SonoVue) Apparatus for performing the UF Doppler sequence: Aixplorer, manufacturer : Supersonic Imagine, Aix-en-Provence, France, CE Marking.~3D RCA dedicated vascular probe with dedicated Doppler sequences"
45611789|NCT05171309|Drug|Apatinib|250 mg once daily (QD) oral dosing.
45611790|NCT05171309|Drug|Camrelizumab|200 mg intravenously every 2 weeks.
45611791|NCT05171309|Drug|NK cell|Cord blood derived NK cells 4 cycles, one cycle is defined as: total cells ≥1×109 per time, continuous intravenous infusion for 2 days every 14±2 days
45611792|NCT03409237|Drug|Mannitol|Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity <320.
45611793|NCT03409237|Drug|Hypertonic saline solution|Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity <320.
45611794|NCT03570489|Behavioral|Exercise|Patients will bicycle for 20 minutes per day for 5 days per week for 6 months
45611795|NCT03570489|Behavioral|Relaxation|Patients will listen to a relaxation tape 20 minutes per day 5 Days a week for 6 months
45611796|NCT03417635|Behavioral|Guided focused attention|Participants will meet for 20 minute group sessions with 6-10 participants in each group. There will be three meetings a week for a four week period. The focused attention practice itself will last for 20 minutes with instructions being given during the 20 minute period. All sessions will occur in the retirement home in a community room to ensure the sessions are easily accessible to the participants.
45611797|NCT03417635|Behavioral|Acoustic music|Participants will meet for 20 minute group sessions with 6-10 participants in each group. There will be three meetings a week for a four week period. The acoustic music track itself will last for 20 minutes with instructions being given during the 20 minute period. All sessions will occur in the retirement home in a community room to ensure the sessions are easily accessible to the participants.
45611798|NCT03408847|Combination Product|Beclomethasone dipropionate in addition to MC-EVOO|Oral beclomethasone dipropionate at dose of 10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks plus MC- EVOO for 12 weeks at a dose of 2 tablespoons per day (1 before lunch and 1 before dinner). Each spoon will contain 10 grams of oil containing 5 mg of biophenols.
45611799|NCT03408847|Combination Product|Beclomethasone dipropionate in addition to refined oil|Oral beclomethasone dipropionate (10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks) plus placebo consisting of refined olive oil with low biophenols.
45611800|NCT03412253|Procedure|Single-Anastomosis Gastric Bypass surgery (SAGB).|We checked the effect of SAGB on patients suffered from T2DM with BMI 25-30
45611801|NCT03332121|Biological|B001|4 times intravenous injection totally,dosing at Day1,Day35,Day56,Day77
45611802|NCT03424291|Drug|Apatinib plus chemoradiation|Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)
46068782|NCT05617001|Device|Kardia 12L|The purpose of this study is to collect clinical validation data to support an FDA submission for a 510(k) for the Kardia 12L hardware which enables the simultaneous diagnostic quality recording of all 6 limb leads and any chest lead. We will be recording both Leads V1 and V2 in a sequential fashion along with the V4 and Limb leads and a simultaneous 12-lead ECG to validate the hardware and a Deep Neural Network model which expands the 5 leads into a complete 12-lead ECG. The 12-lead ECG used for validation of the recordings and the 12-lead synthesis model is the GE Cardiosoft System which is FDA cleared.
46068783|NCT05612581|Drug|VIR-3434|VIR-3434 given by subcutaneous injection
46068784|NCT05612581|Drug|VIR-2218|VIR-2218 given by subcutaneous injection
45611803|NCT03412175|Behavioral|Behavioral Intervention|The CREATION Health Specialist (CHS) will review with the participant his/her biometrics, assessments, and surveys. The CHS will identify the participant's strengths and weaknesses thereby tailoring the intervention care plan to the participant. Together the participant and CHS will work on goal-setting, action plans, self-monitoring, identification of personal and social barriers to change, and self-regulatory techniques.
45611804|NCT03412097|Other|active surveillance|Provides a structure to systematically gather adverse event information from healthcare providers and sometimes directly from patients.
45611805|NCT03411655|Device|Ambu Aura GainTM|Time and success rate
45611806|NCT03411655|Device|Ambu® Aura-ITM|Time and success rate
45611807|NCT05170451|Drug|CBD|Topical CBD 50 mg/ml applied in 1mL amounts twice daily
45611808|NCT03408691|Dietary Supplement|Fresh fermented dairy drink containing probiotic strain|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) BID for 6 weeks.
45611809|NCT03408691|Other|Acidified dairy drink without ferment|Acidified dairy drink without ferment consumed as follows: one bottle (100g) BID for 6 weeks.
45611810|NCT05228379|Procedure|Small Bowel Capsule Endosocopy|A wireless capsule is ingested by the patient. It moves passively along with the peristaltic movements to capture images of the small intestine. The images are processed and recorded by data recorder worn on a belt. The recorded images are downloaded and analyzed by the computer software.
45611811|NCT05170373|Procedure|ESP block|Before general anesthesia, ESP block was applied from the T12 vertebra level with 10 ml 0.5% bupivacaine HCL 5 ml 2% lidocaine HCL 5 ml 0.9% isotonic NaCl mixture
45611812|NCT03408535|Other|Eriksholm Guide to Better Hearing|Online rehabilitation program.
45611813|NCT04413513|Other|Integrated Attention Training Program (IATP)|Integrated attention training program (IATP) is a newly developed cognitive training programs that combined relaxation technique with integrated attentional training into daily life activity.
45611814|NCT04413513|Other|Health Education|Health educational sessions on health concerns and physical diseases commonly found in old age
45611815|NCT04447859|Drug|Semaglutide|Slow semaglutide titration group vs. label recommended titration group (16-week flexible vs. 8-week semaglutide titration)
45611816|NCT04447859|Other|label recommended titration|label recommended titration
45611817|NCT03411577|Other|Behavioral Intervention|
45611818|NCT04412889|Biological|BCMA/CD19 dual-target CAR-T cell immunotherapy|The intervention is a CAR-T cell immunotherapy targeted CD19 and BCMA. The dosage ranges from 2×10^5 to 1×10^6 CAR+T/Kg.
45611819|NCT04447937|Other|No Interventions|There are no interventions associated with the study.
45611820|NCT03407521|Drug|Misoprostol|induction of abortion using misoprostol
45611821|NCT03407521|Drug|isosorbide mononitrate|isosorbide mononitrate
45611822|NCT03407521|Drug|Placebo|Placebo
45611823|NCT03255993|Drug|SPH3127 50mg|SPH3127 50mg
45611824|NCT03255993|Drug|SPH3127 100mg|SPH3127 100mg
45611825|NCT03255993|Drug|Placebo matching to SPH3127 50mg|Placebo matching to SPH3127 50mg
45611826|NCT03255993|Drug|Placebo matching to SPH3127 100mg|Placebo matching to SPH3127 100mg
45611827|NCT03424135|Drug|Naproxen sodium and diphenhydramine hydrochloride soft capsules|Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)
45611828|NCT03424135|Drug|Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)|Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
45611829|NCT03411941|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|IVT(Intravitreal) aflibercept treatment in routine clinical practice.
45611830|NCT03249753|Drug|SPH3127 200mg Panel A|Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg after a high-fat breakfast.
45611831|NCT03249753|Drug|SPH3127 200mg Panel B|Participants who are in panel B will receive a single dose of a SPH3127 tablets 200mg after a high-fat breakfast, then 72 hours later participants take the second dose of SPH3127 200mg when limosis.
45611832|NCT03424057|Procedure|Asymmetric Primary Closure and Additional Skin Excision Technique|In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method, but an advancement tissue flap was performed using additional skin excision, in order to reduce the dead-space volume.
45611833|NCT03424057|Procedure|Standard Karydakis technique.|In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method
45611834|NCT03411785|Other|CPC+ model|CPC+ practices receive a monthly care management fee and prospective performance-based incentive payment on top of traditional payments. Some practices will also receive some payment that shifts away from fee-for-service. In addition, CPC+ practices will receive learning and health IT support and data feedback to implement processes to meet care delivery requirements and achieve five primary care functions.
45611835|NCT04413435|Other|File Scanning|The patients' epidemiological, clinical, laboratory, and radiological characteristics and treatment and outcomes data will accessed from Hospital Data Management System (HDMS) of Konya Training and Research Hospital and Public Health Management System (PHMS) of Ministry of Health.
45611836|NCT05170555|Drug|68Ga-PSMA|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-PSMA. Tracer doses of 68Ga- PSMA will be used to image lesions of Renal Cell Carcinoma by PET/CT.
45611837|NCT05170555|Drug|1.85GBq (50 mCi) of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
46068785|NCT05612581|Drug|TDF|TDF given orally
45611838|NCT03423901|Other|Blood sampling|Descriptive analysis of clinical, biological and histological of 3 arms: ABO incompatible, HLA incompatible, and ABO/HLA incompatible kidney transplantation (1 and 5 years posttransplantation in each groups)
45611839|NCT05228223|Diagnostic Test|Neuromuscular monitoring|TOF monitoring
45611840|NCT05228223|Other|reverse of NMB with sugammadex|Patients reversed with Sugammadex 2mg/kg after TOF count is 1-2.
45611841|NCT05228223|Other|reverse of NMB with Sugammadex and neostigmin low dose|Patients reversed with Sugammadex 1mg/kg + Neostigmin 0.02 mg/kg
46068786|NCT05612581|Drug|PEG-IFNα|PEG-IFNα given by subcutaneous injection
46068787|NCT05611801|Drug|marstacimab|marstacimab
45611842|NCT05228223|Other|reverse of NMB with Sugammadex and neostigmin high dose|patients reversed with sugammadex 1.5 mg/kg + Neostigmin 0.02 mg/kg
45611843|NCT03406819|Drug|Nitroprusside Sodium|Intracoronary infusion 50~100μg each time (repeated)
45611844|NCT03406819|Drug|Tirofiban Hydrochloride|Intracoronary infusion 10μg/kg for single time
45611845|NCT03406819|Drug|Heparinized saline|Intracoronary infusion 2ml for single time
45611846|NCT05170217|Drug|THC|Inhaled cannabis containing 10mg THC
45758754|NCT00759967|Procedure|Microneurography|Muscle sympathetic nerve activity measurement will be obtained using microneurography. Approximately 10-20% of microneurography recordings are not interpretable due to technical problems. For this reason, blood samples will be collected at the same time that the microneurography is to be done. These test will be done at 3 time points throughout the study.
45445205|NCT01333072|Drug|Aripiprazole|The starting dosage will be 2.0 mg/day. The dosage will be allowed to increase to 5.0 mg/day on day 4 and can be increased thereafter as judged clinically appropriate until the maximum dosage of 15 mg/day. The dosage will only be increased in 5.0 mg intervals. No dosage adjustments will be allowed for either drug after 4 weeks.
45611847|NCT05170217|Drug|Cannabidiol|Inhaled cannabis containing 10mg CBD
45611848|NCT05170217|Drug|Cannabidiol|Inhaled cannabis containing 20mg CBD
45611849|NCT05170217|Drug|Cannabidiol|Inhaled cannabis containing 30mg CBD
45611850|NCT04356105|Drug|Minimal stimulation protocol|Letrozole, Recombinant FSH, GnRH antagonist
45611851|NCT04356105|Drug|Microflare protocol|OCP, GnRH agonist, Recombinant FSH
45611852|NCT04356105|Procedure|IVF/ICSI cycle|Involving ovum pickup and embryo transfer
45611853|NCT03411551|Procedure|regional anesthesia|The analgesic effectivity of the forearm intravenous regional anesthesia and the ultrasound-guided peripheral nerve block will be investigated in patients undergoing carpal tunnel release
45611854|NCT03406195|Device|Transcranial magnetic stimulation (TMS)|TMS paradigm called theta burst stimulation
45611855|NCT04347681|Other|convalescent plasma from recovered COVID 19 donor|After obtaining informed consent, Eligible Patients who have severe COVID-19 and have not recovered yet will be infused with the donated convalescent plasma (10-15 ml/kg body weight of recipient)19 at least once & if possible, daily, for up to 5 sessions.
45611856|NCT05170061|Drug|Valsartan|Valsartan 160 mg PO daily for 1 week followed by 320 mg daily for 3 weeks, followed by 1 week down-titration to 160 mg daily
45611857|NCT05170061|Drug|Nebivolol|Nebivolol 20 mg daily for 1 week followed by 40 mg daily for 3 weeks, followed by 1 week down-titration to 20 mg daily
45611858|NCT05170061|Drug|Nebivolol/valsartan|Valsartan/Nebivolol, 160/20 mg daily for 1 week followed by 320/40 mg daily for 3 weeks, followed by 1 week down-titration to 160/20 mg daily
45611859|NCT03411499|Procedure|Early surgery|Surgery within 72 hours from endocarditis diagnosis
45611860|NCT03411499|Procedure|Conventional therapy|Delayed surgical intervention or medical treatment according to the current guidelines
46068788|NCT05608057|Other|Vitamin C mesotherapy|Vitamin C intra-mucosal injection; in which the site of interest will be anesthetized using a topical anesthetic agent (lidocaine gel or xylocaine gel) or infiltration anesthesia, followed by intra-mucosal field injections of 1-1.5 ml Cevarol (L-Ascorbic acid 1000 mg/5 ml
45445206|NCT01333072|Drug|Risperidone|Children weighing 20-45 kg will receive an initial dose of 0.5 mg daily that will be increased to twice daily on day 4 (morning and bedtime). The dosage will be gradually increased in 0.5 mg increments to a maximum dose of 2.5 mg per day (1.0 mg in the morning and 1.5 mg at bedtime) by the fourth treatment week. A slightly accelerated dosage will be allowed for children who weigh more than 45 kg for a maximum dosage of 3.5 mg /day (McCracken et al 2002).
45758755|NCT00759967|Procedure|Bioimpedance testing|bioimpedance measurement of extracellular fluid volume will be measured at the end of each 3 month period. This test will be done at 3 time points throughout the study.
45758756|NCT02394548|Radiation|Contralateral Esophageal Sparing Technique (CEST)|Determine whether CEST decreases rate of severe acute esophagitis
45758757|NCT04385953|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
45758758|NCT02769806|Procedure|MRI|
45758759|NCT03808519|Dietary Supplement|n3 PUFA-enriched fish oil|3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
46068789|NCT05608057|Radiation|Diode laser|Diode laser ablation: in which the site of interest will be anesthetized using infiltration anesthesia, followed by laser ablation. 980nm Diode laser will be applied using the following setting parameters: continuous mode with 980nm wavelength at 1.5 W output power.
46068790|NCT05602402|Other|CAEP-01|Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
46068791|NCT05602402|Other|Placebo|Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
45445207|NCT03784365|Drug|One dose of Cefo-perazone Sulbactum|Antibiotic
45611861|NCT04235205|Drug|Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)|Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g) for 16 weeks
45611862|NCT04235205|Drug|Elobixibat 10mg + cholestyramine powder placebo|Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg+ cholestyramine powder placebo for 16 weeks
45611863|NCT04235205|Drug|Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g)|Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder 9g (cholestyramine 4g) for 16 weeks
45611864|NCT04235205|Drug|Elobixibat placebo + cholestyramine powder placebo|Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder placebo for 16 weeks
45611865|NCT02520635|Drug|supra-early TEMODAL® chemotherapy|
45611866|NCT02520635|Drug|standard TEMODAL® chemotherapy|
45611867|NCT02520635|Radiation|Radiotherapy 60Gy|
45611868|NCT03411421|Drug|AL-794|AL-794 will be administered as tablets orally on Day 1 to Day 5.
45611869|NCT03411421|Drug|Placebo|Matching placebo tablets will be administered.
45611870|NCT03404947|Dietary Supplement|Ethanol|For one exercise session, participants will be asked to ingest a quantity of ethanol (in the form of vodka) sufficient to maximally stimulate liver alcohol metabolism.
45611871|NCT03411473|Biological|AGEN1884 in combination with pembrolizumab|AGEN1884 in combination with pembrolizumab in subjects with stage IV NSCLC whose tumors have high PD-L1 expression and no EGFR or ALK genomic tumor aberrations
45758760|NCT03808519|Dietary Supplement|Placebo|Organic Sunflower Oil 5000mg per day
45445208|NCT02059486|Behavioral|Teen Choice|The curriculum provides sexual education on topics such as anatomy, puberty, sexually transmitted infections, and contraceptive methods (including abstinence). It also covers topics such as gender and sex roles, sexual orientation, decision making and conflict resolution, adult-teen relationships, rape and sexual assault, and coping with stress.
45445209|NCT01560663|Drug|Docetaxel- Carboplatin|Docetaxel 75mg/m2 day 1 and Carboplatin(AUC6)day 1, each 21 days for 6 cycles.
45611872|NCT03867981|Behavioral|Internet-based weight loss program|12-month, Internet-based weight loss/maintenance program.
45611873|NCT03867981|Behavioral|Brief phone coaching|Some individuals will receive 3 weeks of phone coaching. Coaching calls will occur 1x/week, starting at week 5. Once coaching calls are completed, the participant will not have any other contact with their coach.
45611874|NCT03867981|Behavioral|Extended phone coaching|Some individuals will receive 12 weeks of phone coaching. Coaching calls will occur 1x/week, starting at week 5. Once coaching calls are completed, the participant will not have any other contact with their coach.
45611875|NCT03404869|Drug|ORL-1M - D-mannose|Oral ORL-1M
45611876|NCT04184349|Drug|LA group|In the LA group, only the local anesthetic infiltration will be performed by injecting the numbing medicine ropivacaine into the surgical site.
45611877|NCT04184349|Drug|B Group|In the B Group,pectoral (PECS) and transversus thoracic plane(TTP) blocks will be performed by injecting the numbing medicine ropivacaine near the nerves.
45611878|NCT05169749|Procedure|Control-Service Nurse Group|"Processing Steps~The State-Trait Anxiety Inventory was applied before the patient education~The State Anxiety Inventory was applied after the education.~The pain was monitored in accordance with the surgical patient follow-up protocol for 24 hours postoperatively~The State Anxiety Inventory was applied again 24 hours after surgery."
45611879|NCT05169749|Procedure|Nursing Visiting Group|"Processing Steps~The State-Trait Anxiety Inventory was applied before the patient education~The State Anxiety Inventory was applied after the education.~The pain was monitored in accordance with the surgical patient follow-up protocol for 24 hours postoperatively~The State Anxiety Inventory was applied again 24 hours after surgery."
45611880|NCT02520739|Dietary Supplement|Virgin Olive Oil (VOO)|VOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of VOO distributed over 3 meals. Daily doses of VOO were blindly prepared in special containers, with the corresponding 30 mL VOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed VOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
45611881|NCT02520739|Dietary Supplement|Optimized High Phenolic Content Oil (OHPCO)|OHPCO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of OHPCO distributed over 3 meals. Daily doses of OHPCO were blindly prepared in special containers, with the corresponding 30 mL OHPCO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed OHPCO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
45611882|NCT02520739|Dietary Supplement|Functional Olive Oil (FOO)|FOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of FOO distributed over 3 meals. Daily doses of FOO were blindly prepared in special containers, with the corresponding 30 mL FOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed FOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
45611883|NCT03864003|Behavioral|Community Health Workers and Teleaudiology as a Culturally-Relevant Approach to Improving Access to Hearing Health Care|In this project, remote hearing aid fittings will be delivered by an audiologist with patient-site support from a local facilitator for a cohort of older adults (>50 years) from a rural area that has been identified as under-resourced for hearing health care.
45611884|NCT03411395|Dietary Supplement|5AA+CrPic Water|Dietary supplement drink with carbonation, aroma, amino acids and chromium picolinate
45445210|NCT02059564|Drug|HM11260C|doses of 6 mg, 16 mg
45611885|NCT03411395|Other|Placebo drink|Placebo water with carbonation and aroma
45611886|NCT03423823|Drug|Ziv-Aflibercept 25 MG/ML [Zaltrap]|Anti-VEGF injection
45611887|NCT03423823|Drug|Ranibizumab|Anti-VEGF standard of care injection
45758761|NCT03139838|Behavioral|EHR-Based Intervention A|Intervention A will be a prompt for clinicians to document an estimated prognosis for patients at 6 months, and an assessment of predicted functional outcome if expected to survive.
45758762|NCT03139838|Behavioral|EHR-Based Intervention B|Intervention B will entail a prompt for clinicians to provide a reason for not offering patients and their families the alternative of care focused entirely on comfort despite recommendations from critical care professional societies to do so for patients at high risk for death or severely impaired functional recovery.
46068792|NCT05602389|Other|VL-G-A57|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
45445211|NCT02059564|Drug|Placebo|Normal saline solution
45445212|NCT02059564|Drug|Victoza|doses of 1.8 mg
46068793|NCT05602389|Other|VL-G-E12|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
46068794|NCT05602389|Other|Placebo|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
46068795|NCT05594693|Other|Questionnaire|Electronic self-report questionnaires before and after integrative interventions, and monthly.
45611888|NCT03411161|Drug|Combination therapy (S81694 + paclitaxel) phase I|Dose escalation S 81694 (IV); paclitaxel started at 80 mg/m²,(IV)
45611889|NCT03411161|Drug|Paclitaxel|Paclitaxel (IV) at 80 mg/m²/week
45611890|NCT03411161|Drug|Combination therapy (S81694 + paclitaxel) phase II|S 81694 (IV) at RP2D; paclitaxel (IV) at 80 mg/m²/week
45611891|NCT05228067|Device|anodal transcranial direct current stimulation|anodal tDCS of the hypothalamus resting-state functional connectivity network using 12 Electrodes of the Starstim device by Neuroelectrics. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.
45611892|NCT05228067|Device|cathodal transcranial direct current stimulation|anodal tDCS of the hypothalamus resting-state functional connectivity network using 12 Electrodes of the Starstim device by Neuroelectrics. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.
45611893|NCT05228067|Device|sham transcranial direct current stimulation|Double blind sham stimulation of the hypothalamus resting-state functional connectivity network (ramp-up ramp-down stimulation will be applied for 30 seconds)
45611894|NCT03411343|Procedure|Interscalene Block|Injection with ultrasound guidance of 20mL of levobupivacaine 0.5% with 5 micrograms of epinephrine per mL in the interscalene groove of the brachial plexus.
45611895|NCT03411343|Procedure|Costoclavicular Infraclavicular Block|Ultrasound guided brachial plexus block injecting 20mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in between the cords of the brachial plexus at the costoclavicular infraclavicular space.
45611896|NCT05227911|Procedure|Abdominal Surgery|Abdominal surgery (laparotomy or laparoscopy) ,which includes proper inspection of the abdominal cavity.
45611897|NCT04833933|Other|Phone survey about smoking cessation process since intervention in DISCO trial|We will conduct a phone survey at 2 years follow-up with a random sample of smoking patients at inclusion in DISCO trial, to know the evolution of their smoking habits, the quit attempts since the intervention and the modalities of these attempts.
45611898|NCT03411005|Dietary Supplement|Metabolic availability of lysine in sorghum|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from sorghum and 1 level from sorghum with lentils.
45445213|NCT03778749|Diagnostic Test|TOF measurements|The investigators will determine how the TOF% values vary in each individual patient, over time, in ICU.
45611899|NCT04447573|Biological|BCMA CAR-T|Biological: BCMA CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
45611900|NCT04841759|Other|Exercise|8 week exercise program, nutritional & psychological consultation
45611901|NCT03972579|Behavioral|Graded exposure therapy|Gradually increased contact with avoided sensory stimuli (e.g., light, noise, movement) and activities (e.g., mental exertion, physical exercise, stressful activities) in order to increase tolerance.
45611902|NCT03972579|Behavioral|Pacing + mindfulness|Shifting from symptom-contingent to time-contingent activity stopping rules, minimizing activity level peaks (excessive endurance behavior) and valleys (prolonged periods of recuperative rest) to improve overall functioning.
45758763|NCT00720473|Drug|Lamotrigine|Lamotrigine with dosage range from 25 mg to 200 mg per day.
45611903|NCT03411265|Other|self-administered, e-health application|"RETAIN is a self-administered, e-health application and includes short videos in which patients who are successfully engaged in MAT discuss what they wish they had known about MAT and its benefits when they started treatment. The intervention is designed to maximize scalability - the administration would entail handing an electronic device (e.g., tablet, laptop, etc.) to an individual who would then self-administer the intervention."
45611904|NCT04737603|Drug|ED-Initiated treatment with buprenorphine / naloxone|A Clinical Opiate Withdrawal Score (COWS) score will be administered, and an induction dose of buprenorphine when COWS scores >=8. Participants who weigh > 70 kg and/or reported using ≥ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg. After 1 hour an additional 4 mg will be administered for a total of 8 mg. Participants who weigh <= 70 kg and/or reported using ≤ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg of buprenorphine. After 1 hour, an additional 2 mg will be administered for a total of 6 mg. Patients will be prescribed sufficient take-home daily doses (one-week supply) to ensure that the patient has adequate medication to receive 12-16 mg buprenorphine sublingual once daily. Parents of adolescents will also receive appropriate education on how to administer medication. Home induction instructions will be provided to patients and parents that arrive to the ED after an opioid overdose.
45758764|NCT00637832|Biological|rituximab|
45758765|NCT00637832|Drug|cyclophosphamide|
45758766|NCT00637832|Drug|doxorubicin hydrochloride|
45758767|NCT00637832|Drug|prednisolone|
45758768|NCT00637832|Drug|vincristine sulfate|
45758769|NCT00637832|Radiation|yttrium Y 90 ibritumomab tiuxetan|
45758770|NCT01277887|Behavioral|Cognitive-Behavioral Counseling|The cognitive-behavioral intervention integrates standard smoking counseling adapted from the American Lung Association Freedom from Smoking program along with cognitive-behavioral techniques for improving insomnia.
45758771|NCT01277887|Behavioral|Smoking Cessation Counseling|The smoking cessation counseling intervention will incorporate standard psychoeducational and behavioral smoking counseling techniques adapted from the American Lung Association Freedom from Smoking program.
45611905|NCT03410849|Diagnostic Test|Gastroscopy|in both arms intervention 'gastroscopy' will be carried out
45611906|NCT03394183|Other|Cardiac Rehabilitation|Cardiac rehabilitation is a 6 month program in which patients enrolled attend weekly classes which consist of individualized exercise and risk factor education lectures. This intervention is consistent with standard care procedures for the Cardiovascular Prevention and Rehabilitation Program at the Toronto Rehabilitation Institute Rumsey Centre.
45758772|NCT04276454|Device|Flexitouch Plus system|A single treatment for external lymphedema using the FDA-approved Flexitouch Plus device.
45758773|NCT00720629|Drug|Visilizumab|3 mg/m^3, IV (in the vein) on day 0, prior to hematopoietic cell infusion (transplant).
45758774|NCT00720629|Drug|Tacrolimus|0.02 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 4 after transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
45758775|NCT00720629|Drug|Methotrexate|15 mg/m^2 intravenously (IV) on Day 1 after transplant; 10 mg/m^2 IV on Days 3, 6 and 11 after transplant.
45611907|NCT03918369|Procedure|Laparoscopic right hemicolectomy with intracorporeal anastomosis.|Intracorporeal anastomosis group The laparoscopic right hemicolectomy with intracorporeal mechanical side-to-side isoperistaltic anastomosis. In this procedure, intracorporeal division of the mesoileum and transverse colon is performed, as shown in the animation. The ileum and transverse colon are divided with the Endopath® Echelon Flex ™ 60 stapler. The specimen is inserted in a plastic bag. Side-to-side isoperistaltic mechanical anastomosis is performed using the same endostapler. A running suture is performed of the mechanical suture orifice, with another reinforcing suture with Monocryl ™ (poliglecaprone 25) or with STRATAFIX ™ Spiral Knotless barbed suture. The specimen is extracted through a Pfannestiel minilaparotomy (3.5-4 cm) Wound Protector
45611908|NCT03918369|Procedure|Laparoscopic right hemicolectomy with extracorporeal anastomosis.|Laparoscopic right hemicolectomy with extracorporeal anastomosis with the technical features of each center
45611909|NCT05168137|Drug|Low-dose colchicine|prescribed colchicine 0.6 mg/day
45611910|NCT05168137|Drug|Placebo|Placebo of colchicine
45611911|NCT03410771|Drug|Monitor antibiotic exposure (PK profile)|several plasma samples to measure drug exposure
45611912|NCT03410771|Device|Bioelectrical impedance analysis to measure body composition|non invasive analysis (electrodes) to measure extra- and intracellular, and total body water.
45611913|NCT05168059|Drug|Clevidipine 0.5 MG/ML Intravenous Emulsion|Effectiveness and safety of clevidipine
45611914|NCT05226819|Drug|PPI quadruple therapy|Among these outpatients, H. pylori-negative patients don't give any intervention. But H. pylori-positive patients are given rabeprazole 10mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT is performed.
45611915|NCT03397901|Procedure|Transverse colostomy|Transverse double-cavity colostomy
45611916|NCT03126253|Diagnostic Test|Anemia|"Hemoglobin level will be used as the parameter for diagnosing anemia. The HemoCue system was used to estimate the concentration of hemoglobin in capillary blood. WHO guidelines for the diagnosis of anemia that were adopted by the Demographic Health Surveys will be used in this study. Briefly, a hemoglobin concentration of less than 70 g/L will be consider to define severe anemia, 70-99 g/L for moderate anemia, and 100-109 g/L will be presumed to correspond to mild anemia. The above-mentioned classification of anemia as severe moderate and mild categories is based on blood hemoglobin cutoffs (will be adjusted for altitude and smoking) recommended by the Center for Disease Prevention of United States; this classification has also been adopted by the World Health Organization."
45611917|NCT05216757|Drug|Iguratimod|iguratimod, 25mg bid po.
45611918|NCT05216757|Drug|placebo|placebo 1 tablet bid po.
45611919|NCT03126409|Procedure|No-Touch vein harvesting technique|The No-Touch technique focuses on saphenous vein graft harvesting, featured by preserving the surrounding tissue of the vein while at the same time avoiding manual distension.
45611920|NCT03126409|Procedure|Conventional vein harvesting|During saphenous vein harvesting, surrounding tissue of the vein is stripped off, and manual distension is routinely performed
45611921|NCT05206227|Behavioral|Exercise|Subjects will perform one-legged knee extension exercise while seated on a purpose-built ergometer. Subjects will exercise for 60 minutes, which includes 5-minute warm-up at 30% of peak power and 55 minutes at 60% of peak power.
45611922|NCT02520869|Procedure|swim-up technique|swim-up technique used
45611923|NCT02520869|Procedure|zeta test technique|zeta test technique used
45611924|NCT05214781|Procedure|modified radical mastectomy|excision of the whole breast tissue including nipple and skin with axillary clearance
45611925|NCT02375295|Drug|ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin|Approved antibiotics used routinely will be given at the physician's discretion with the patient: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin
45611926|NCT03397745|Device|BIS|All patients applied BIS on both side (Left and Right)
45611927|NCT05167747|Dietary Supplement|Dietary Supplement|"Dietary supplement formulated with magnesium, standardized extract of orthosiphon, standardized extract of hawthorn and standardized extract of hibiscus. Each tablet contains: 0.1 g magnesium, 0.25 g standardized extract of orthosiphon (Orthosiphon stamineus Benth), 0.16 standardized extract of hawthorn (Crataegus curvisepala Lind.) and 0.08 g standardized extract of hibiscus (Hibiscus sabdariffa L.).~Oral administration: 2 tablets/day at evening meal"
45445214|NCT05622058|Drug|ALRN-6924|ALRN-6924 administered in every chemotherapy treatment cycle as an IV infusion over 1 hour on Days 0 (approximately 18 hours prior to chemotherapy administration), 1 (approximately 1 hour prior to chemotherapy administration), and 2 (approximately 24 hours after the second infusion of ALRN-6924).
45611928|NCT05167747|Other|Placebo|Oral administration: 2 tablets/day at evening meal
45758776|NCT00720629|Drug|Antithymocyte globulin (ATG)|1 mg/kg IV over 6 hours on Day 3 before transplant; 3.25 mg/kg IV over 4 hours on days 2 and 1 before transplant.
45445215|NCT05622058|Drug|TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)|TAC will be administered as an IV infusion on Day 1 of every 3-week treatment cycle
45445216|NCT02057302|Drug|Xuezhikang capsule|
45445217|NCT02055196|Biological|carboxylesterase-expressing allogeneic neural stem cells|Given via intracerebral catheter
45611929|NCT04736147|Biological|JNJ-64300535|JNJ-64300535 injection will be administered intramuscularly.
45758777|NCT00720629|Drug|Tacrolimus|0.03 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 3 before transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
45611930|NCT05167357|Biological|COVID19|"Intervention in experimental group (COVID+ group) is the disease itself, compared to the control group (COVID- group). At inclusion, subjects have been asked if they have suffered COVID19 in the 12 months before inclusion, during whichever wave, attested by a positive PCR, positive serology test or positive chest CT scan.~Moreover, the Richalet test is a cardiorespiratory exercise test on an ergocycle (an electrically braked cycloergometer), whilst continuous measurement by a 12-lead ECG, a blood pressure cuff, a metabograph and an ear pulse oximeter. This, to assess cardiac response, ventilatory response and relevant metabolic parameters (CF, RR, SpO2, volume, BP). Subjects breathes through a mask connected to a gas mixer, which provides a gas mixture with 11,5% oxygen (corresponding to ambient air at an altitude of 4800m) in the hypoxia phases."
45758778|NCT00720629|Drug|Methotrexate|15 mg/m^2 IV on Day 1 after transplant; 10 mg/m^2 IV on Days 3, 6 and 11 after transplant.
45611931|NCT05169281|Other|Medication Disposal Packet|The disposal packet (DisposeRx Inc.) contains a powder that sequesters unused opioids in a polymer gel. The kits reached patients four days following their surgery based on prior data to leverage availability bias, or a tendency to think or act on things that are most present in one's mind, and provided patients with a disposal technique when they were likely to be finished with their opioids. The process of mailing the disposal packet is simple, low cost (~$1.50/ mailed packet) and scalable.
45611932|NCT03397511|Behavioral|Financial Incentives|Baseline Interview, 2 Counseling Sessions at baseline and 2 weeks post baseline, and one follow up survey at one month
45611933|NCT04787809|Behavioral|Living Well|Living Well is a single session digital intervention that aims to decrease experiential avoidance and increase engagement in values-consistent behavior.
45611934|NCT02356575|Other|Acupuncture|
45611935|NCT02356575|Other|Cognitive Behavior Therapy|
45611936|NCT03410537|Drug|Taurine|
45611937|NCT03410537|Drug|Placebo|
45445218|NCT02055196|Drug|irinotecan hydrochloride|Given IV
45611938|NCT03394105|Drug|intrapleural docetaxel administration|intrapleural docetaxel administration using medical pleuroscopy in malignant effusion with lung cancer
45611939|NCT03126773|Drug|BAY86-4891|Drospirenone 0.25 mg + estradiol hemihydrate 0.5 mg (Angeliq Micro, G03FA17).Dosage form is one tablet a day.
45611940|NCT03393949|Drug|Methylprednisolone 1 mg•kg-1|Patients in Group M received methylprednisolone 1mg•kg-1
45611941|NCT03393949|Drug|isotonic saline 1mg•kg-1|Patients in Group C received isotonic saline 1mg•kg-1
45611942|NCT03126929|Diagnostic Test|Coma Recovery Scale-Revised and Glasgow Coma Scale|Patients have been assessed with both the Coma Recovery Scale-Revised(CRS-R) and the Glasgow Coma Scale(GCS)
45611943|NCT04678947|Behavioral|Baxter Retching Faces (BARF) scale|"Pictorial scale that was developed for use by pediatric patients in self-reported assessments of nausea severity~A patient will respond by choosing a picture or a number on the scale that best represents how they feel. The patient may speak or simply point to their response. While the numbers 0-2-4-6-8-10 are listed alongside the pictures, patients are also allowed to choose in between or odd numbers. If a patient is unwilling to participate, the patient's parent or guardian may serve as their proxy and choose a number for them, based off of their symptoms.~The BARF scale has 6 faces with assigned scores ranging from 0 to 10 with a score difference of 2 between each face (a higher score indicates more nausea)."
45611944|NCT04707677|Device|Titanium and ceramic dental Implants|Two types of implant placement and follow-up to compare the esthetic, clinical and radiographic parameters between them.
45611945|NCT03397849|Behavioral|Intervention using mobile technology|Each study patients that are randomized to IMT plus usual care group will receive a group of smart devices including mobile phone (Vestel Venus e2) (Vestel, Manisa, Turkey), wristband (Xiaomi band 2) (Beijing Xiaomi Technology Co., Beijing, China), weight scale (Bluecat, Yongkang Tiansheng Electronic Co., Zhejiang, China) and blood pressure monitor (Clever Chek TD-3250) (TaiDoc Technology Co., Taipei County, Taiwan)
45611946|NCT04447365|Diagnostic Test|device interrogation|All patients will have a pre-existing ICD and a diagnosis of cardiomyopathy with left ventricular systolic function of 35% or less by echocardiogram done within 3 years of the time of enrollment.
45611947|NCT03393871|Diagnostic Test|absolute blood flow measurement|Absolute maximum flow will be measured, using the RayFlow® multifunctional monorail infusion catheter. (This measurement takes a few minutes per artery, does not require any additional drug, but only 50-100 ml of saline per artery, and is not associated with any additional risk for the patient compared to the regular invasive procedure.
45611948|NCT03836937|Drug|Obeticholic acid|Farnesoid X receptor ligand which is a semi synthetic bile acid analogue
45611949|NCT05169125|Procedure|standard hemodialysis|patients who will undergo standard hemodialysis (dialysate sodium concentration 143 mmoL/L)
45445219|NCT02055196|Other|laboratory biomarker analysis|Correlative studies
45445220|NCT02057536|Other|Arm A Directed exercise program|
45445221|NCT02057536|Other|Observation|
45611950|NCT05169125|Procedure|lower dialysate sodium dialysis|patients who will undergo hemodialysis with lower dialysate sodium concentration (140 mmoL/L)
45611951|NCT03397433|Other|Information Technology physician assist|The intervention hospitals will have a progress note placed in the electronic health record by a reviewing Infectious Disease specialist that comments on the initial antibiotic choice. The comment is based on an electronic prediction tool (Information Technology physician assist) as to what the best therapy is for the individual patient whose health record is reviewed.
45611952|NCT03818061|Drug|Atezolizumab|Patients will receive the combination of Atezolizumab 1200 mg and Bevacizumab 15 mg/kg by IV infusion every 3 weeks.
45611953|NCT03818061|Drug|Bevacizumab|Patients will receive the combination of Atezolizumab 1200 mg and Bevacizumab 15 mg/kg by IV infusion every 3 weeks.
45611954|NCT03402529|Diagnostic Test|Contrast Enhanced Spectral Mammography|Pilot study
45611955|NCT04447391|Other|Combined exercise program|Combined exercise programme, consisting of warm-up, aerobic exercise, resistance training, and cool-down, 3 days a week after school for 50 minutes from 17;30 under supervision by a trainer plus 300 kcal deficit diet
45611956|NCT04447391|Other|Control|300 kcal deficit diet only
45611957|NCT03410459|Diagnostic Test|DEXA (= Dual-energy x-ray absorptiometry)|measurement of vertebral bone and hip bone mineral density
45611958|NCT03759015|Behavioral|Health education|All subjects are tasked to create an original 10-minute theater about physical activity and diet/nutrition.
45611959|NCT03397615|Behavioral|Betadine douches|subjects received a vaginal preparation with povidone-iodine solution immediately prior to caesarean delivery
45758779|NCT03808441|Other|ctDNA analysis|Regular ctDNA analysis, which upon a decrease in mutant BRAF VAF (variant allele frequency) level of ≥80% the switch to N+I is triggered.
45445222|NCT02059720|Procedure|HSCT|Patients randomly assigned in to either of groups will receive either autologous SCT or haplo-SCT after CR1 is achieved.
45445223|NCT01315353|Procedure|Cervical Cryotherapy|Participants had cervical cryotherapy within 7 days after study entry. The cryotherapy consists of two 3-minute freezes separated by 5 minutes of thawing.
45758780|NCT04759820|Drug|injecting Carbon Nanoparticles Suspension|injecting Carbon Nanoparticles Suspension for lymph node detection
45758781|NCT04759820|Drug|Injecting indocyanine green|Injecting indocyanine green for lymph node detection
45611960|NCT04435743|Drug|Lenalidomide|"Lenalidomide is given as any following dosage:~25mg, PO QD, Day 1-10 in every 21 days for 6 cycles;~15mg, PO QD, Day 1-14 in every 21 days for 6 cycles;~25mg, PO QD, Day 1-10 in every 21 days for 1 year;~25mg, PO QD, Day 1-21 in every 28 days for 1 year;~25mg, PO QD, Day 1-10 in every 28 days for 12 cycles;~20mg, PO QD, Day 1-21 in every 28 days for 12 cycles."
45611961|NCT04447079|Behavioral|Assertive Community Treatment (ACT)|"Assertive Community Treatment (ACT) is part of a 6-month program ARFAs will undergo.~ACT teams will engage with ARFAs on a dedicated schedule. Each visit would last an average of 60 minutes. There will not be a re-arrangement of no-show visits. ACT teams will re-engage the ARFA over the phone to plan for the next visit as per the schedule.~In keeping with principles of ACT, ARFA's will be assertively sought out in the community and provided intensive engagement, with holistic and supportive care alongside a harm reduction approach. Care will also involve case management and involvement of SSA's.~Each interaction during the treatment period will focus on various aspects covering physical health, mental health, and addiction"
45611962|NCT03393715|Drug|Perindopril Oral Tablet|Perindopril oral tablet morning versus evening
45611963|NCT03410381|Other|Application EMMA|Emma proposes four types of assessments during 6 months:1) 5 times a day during 3 days, every month (5 minutes): patients can assess their emotions, their thoughts, their behavior and their occurrence context. 2) Weekly (7 minutes): consists of a summary of the week, about their emotions, thoughts, behavior, their relationships (family, work, friends, and their quality of life.3) Monthly (5 minutes): assessment of the usefulness and satisfaction about the application.4) Assessment available at any time An action plan is designed to support the participants, to help them facing difficult emotions and feelings, and to encourage them to ask for help. They can contact a relative or call the psychiatric emergency service directly by clicking on a button.
45611964|NCT02064309|Device|Beta-Air device for encapsulation of transplanted human islets|
45611965|NCT03397537|Drug|Letrozole 2.5Mg Tablet|letrozole 2.5mg p.o.qd
45611966|NCT03397537|Drug|GnRH analogue|3.75 mg triptorelin im. q28d
45611967|NCT03612921|Drug|oral Amantadine sulfate|oral amantadine
45611968|NCT03612921|Drug|i.v Amantadine Sulfate|intra venous amantadine
45611969|NCT03612921|Drug|placebo tablet|placebo tablet
45611970|NCT03410303|Diagnostic Test|Intraoperative ultrasound and 2 months post-operative ultrasound ( ± 1 month)|An ultrasound of the position of the prosthesis during surgery, under general anesthesia, is performed. A follow-up visit will be carried out 2 months (± 1 month) after the surgery as part of the usual care. An ultrasound of the position of the prosthesis is performed without anesthesia, either as part of the treatment or as part of the research. This measurement is performed without the intraoperative measurement by an independent sonographer.
45611971|NCT03393559|Procedure|leg elevation|Patients' leg will be raised by a pillow under both legs and the hip and knee joints will be flexed 45 degrees to position both knees at the heart level.
45758782|NCT01272167|Behavioral|Long-term grapefruit juice consumption|The main goals of this project are (1) to characterize the effect of a long-term grapefruit juice consumption on both vascular and bone protections and (2) to assess the specific role of naringin, in these potential protective effects.
45758783|NCT01276327|Drug|Linagliptin + Pioglitazone|Medium doses, oral administration
45758784|NCT01276327|Drug|Linagliptin + Pioglitazone|Medium doses, oral administration
46068796|NCT05594693|Other|Physical Exam|Physical measures before and after integrative interventions, and monthly. Thoracic kyphosis will be measured with a non-invasive gravity dependent inclinometer (Isomed Inc.).
45611972|NCT03716037|Other|Physical Activity for Life (PAL)|The eight-week exercise program (The PAL Study) will incorporate balance, strength, endurance, and flexibility training. The duration of each exercise session, which will be offered three times a week, will be one hour. The supervised exercise session will include 30 minutes of moderate-intensity aerobic exercise, 15 minutes of resistance training, and 15 minutes of stretching and balance training
45611973|NCT03397277|Behavioral|Safety behaviour promoting video|A 7 min. video which teaches 15 different safety behaviours to reduce violence or the effect of violence
45758785|NCT01276327|Drug|Linagliptin/Pioglitazone|Medium dose oral administration
45758786|NCT01276327|Drug|Linagliptin/Pioglitazone|Medium dose oral administration
45758787|NCT03183830|Dietary Supplement|Nitrate-rich Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
45758788|NCT03183830|Dietary Supplement|Nitrate-deplete Beetroot Juice|"See description of placebo juice in Arms for comparative information. The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day."
45758789|NCT00721175|Device|biliary stent (self expandable metallic stent)|metallic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
46068797|NCT05594615|Drug|EDP-235|Subjects will receive EDP-235 once daily on Days 5-15
46068798|NCT05594615|Drug|Midazolam|Subjects will receive midazolam once daily on Days 1 and 12
46068799|NCT05594615|Drug|Rosuvastatin|Subjects will receive rosuvastatin once daily on Days 2 and 13
46068800|NCT05594615|Drug|Caffeine|Subjects will receive caffeine once daily on Days 1 and 12
46068801|NCT05594602|Drug|EDP-235|Subjects will receive EDP-235 on Days 1 and 14
46068802|NCT05594602|Drug|EDP-235|Subjects will receive EDP-235 on Days 1 and 23
46068803|NCT05594602|Drug|EDP-235|Subjects will receive EDP-235 on Days 1 and 8
46068804|NCT05594602|Drug|Itraconazole|Subjects will receive itraconazole QD Days 5-18
46068805|NCT05594602|Drug|Carbamazepine|Subjects will receive carbamazepine BID Days 5-23 and Days 24-27
46068806|NCT05594602|Drug|Quinidine|Subjects will receive quinidine BID Days 5-12
46068807|NCT05594056|Procedure|Transorbital ultrasound of the optic nerve sheet|Measurement of the optic nerve sheet with a linear transducer (7,5 MHz).
46068808|NCT05591014|Device|Novel ROTEM interpretation software|Clinicians will be asked to interpret ROTEM studies before and after exposure to a novel ROTEM interpretation software.
45758790|NCT00721175|Device|PS|plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
45758791|NCT05245760|Drug|Intravenous Tislelizumab|Participants will receive 200mg, every three weeks for up to 51 weeks
45758792|NCT05245760|Drug|Chemotherapy|Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks
45758793|NCT05245760|Radiation|Fractionated radiation|Concurrent with chemo, x5 weeks
45611974|NCT03397277|Behavioral|Control video|A 7 min. video which teaches women about safety regarding food, alcohol, smoking, medication and physical activity during pregnancy
45611975|NCT04413045|Other|Prevalence of COVID-19|All COVID-19 cases to be admitted in the assigned hospital with positive results of nasopharyngeal swab for SARS-CoV-2 during one-month duration.
45611976|NCT03401437|Behavioral|SF-36|Evaluation of the quality of life with an auto-questionnaire validated, with 8 dimensions: physical activity ; limitations due to physical condition; physical pain; perceived health; vitality; life and relationship with others; limitations due to physical condition; psychic health as well as the assessment of perceived health compared to a year ago. Evaluation done pre-operatively, at M1 and M3
45611977|NCT03401437|Behavioral|HAD|Evaluation of anxiety and depression with a scale validated with 14 items assess between 0 and 3. Evaluation done pre-operatively and at M3.
45611978|NCT03401437|Other|ANSM|Additional information requested by the ANSM (french National Agency for Medicines and Health Products Safety) following a materiovigilance report. Evaluation done pre-operatively and at M3.
45611979|NCT03410225|Behavioral|CAMI-TPP|The TPP group will receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; the sessions will be guided by personalized feedback aimed at increasing condom use, supporting female partners in contraceptive use, and obtaining reproductive health services and STI testing. MI counseling sessions will be conducted by phone or video call.
45611980|NCT03410225|Behavioral|CAMI-Fitness|The Fitness group will also receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; these sessions will be guided by personalized feedback aimed at healthy diet, physical activity and tobacco avoidance. MI counseling sessions will be conducted by phone or video call.
45611981|NCT03400891|Behavioral|Program based on the theory of planned behaviour|14 sessions of one hour to work TPB constructs: attitude, subjective norms, perceived behavioural control and intention.
45611982|NCT03393481|Drug|MAA868|MAA868 dose 1 and dose 2, single administration, subcutaneous,
45611983|NCT03393481|Drug|Enoxaparin|Enoxaparin 40 mg, o.d X 10 days
45611984|NCT05168345|Other|Course and web information|"The interventional phase of the study will be conducted on IBD patients only. Patients will undergo two interventional periods which will include:~Self-selected information from the internet - patients will be asked to independently search the web for information regarding the categories of information which are discussed in the online course.~An online, interactive IBD course. Lectures will be passed by the multidisciplinary team of the IBD Center which includes IBD gastroenterologists, an IBD nurse, an IBD dietitian, and a social worker."
45611985|NCT01936857|Drug|Buprenorphine/naloxone|Buprenorphine/naloxone induction begins with a 2-4mg test dose followed by additional doses on the day of induction to relieve withdrawal symptoms, and then titrated to a maintenance dose between 8-24 mg/day over 1 to 3 days. Doses will be directly observed and occur daily. After a minimum of 2 weeks, dosing may be changed to 3 or 4 times per week, as determined clinically appropriate by the HIV clinic study physician. Dosing will remain flexible to a maximum dose of 24mg for daily dosing and 32mg for every other day dosing, as deemed clinically appropriate by the study physician.
45758794|NCT05245760|Procedure|Esophagectomy|Surgical resection of cancer after chemoradiation therapy when no disease progression found.
45758795|NCT03808285|Other|mandibular osteomylitis|
45611986|NCT01936857|Drug|Methadone Maintenance Therapy|Subjects randomized to methadone maintenance therapy (MMT) referral will meet with an HIV clinic case manager who will facilitate referral to MMT. Methadone dosing will be managed by MMT staff, who dispense methadone according to Ministry of Health guidelines for MMT.
45611987|NCT03393403|Drug|Dexmedetomidine|0.5mcg/kg intravenous(IV)continuous infusion for 30 minutes, or 0.5mcg/kg adding to local anesthetic for subcostal TAP block
45611988|NCT03393403|Drug|0.9% Sodium-chloride|0.125ml/kg intravenously infusion in Dexmedetomidine_adj group and control group
45758796|NCT03808363|Other|High Intensity Interval Training|Participants assigned to this group will perform a very mild 5-minute warm-up (0 resistance, and 60 rpm), followed by 5 one-minute bouts of high intensity exercise, with 90 seconds between each bout. These bouts will be followed by a 3-minute cool down (0 resistance, and 60 rpm). The high-intensity exercise will be performed at an intensity of 17 on the Borg rating of perceived exertion (RPE) scale (very hard), and the 90 second active rest intervals will be performed at an intensity of 7-9 (very, very light - very light). The exercise will be performed on the NuStep machine 3 times a week for 6 weeks.
45758797|NCT01278641|Behavioral|Graded strength resistance training program|Graded strength resistance training, 75 minutes, twice a week for 12 weeks.
46068809|NCT05590260|Drug|IV iron infusion|single-dose IV iron infusion
46068810|NCT05590260|Drug|Oral iron tablets|60 mg of elemental iron
45758798|NCT01278641|Behavioral|Temperate pool exercise program|Temperate pool low intensive exercise, 50 minutes, twice a week for 12 weeks.
46068811|NCT05589844|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo standard of care allogeneic hematopoietic stem cell transplant
46068812|NCT05589844|Procedure|Biospecimen Collection|Correlative studies
46068813|NCT05589844|Biological|CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine|Given intradermally
46068814|NCT05589285|Biological|Injection of autologous whole blood to the plantar fascia|Patients assigned in this group will have 2 ml of blood withdrawn from a peripheral vein, then mixed with 1 mL Lidocaine 2% for a total of 3mL volume in one syringe. The patient will be asked to lie down in the clinic bed, and the injection will be administered to the plantar fascia by the principal investigator using a sterile technique.
45758799|NCT02674958|Drug|Aspirin|Aspirin 325mg bolus followed by 162mg daily until day 7 post alcohol septal ablation
45611989|NCT03410147|Diagnostic Test|13C-octanoate breath test for gastric emptying|"The 13C-octanoate breath test for gastric emptying will be performed to assess gastric emptying rate of a liquid meal that is infused continuously over a period of 8 hour.~13C-labeled sodium octanoate (food adjective) is mixed with liquid nutrients used for enteral feeding. The concentration of 13C-labeled sodium octanoate is according to the randomized treatment order. This mixture is infused at 20 ml/h for 8 hours (hourly dose of 13C-octanoate differs between treatment arms). In order to estimate gastric emptying rate quantitatively throughout the infusion period, the appearance of 13CO2 in the breath, relative to 12CO2, will be monitored by sampling the exhaled breath at a 15 minute interval.~The aim is to induce a steady state hourly 13C-recovery. This would allow to implement the prolonged breath test protocol in future clinical investigations."
45611990|NCT03399955|Drug|Paromomycin|Paromomycin (20 mg/kg/d) IM for 14 days
45611991|NCT03399955|Drug|Ambisome|AmBisome® (20 mg/kg total dose) IV over 7 days
45611992|NCT03399955|Drug|Miltefosine|Miltefosine oral (allometric dosing) for 42 days (arm 1) or 28 days (arm 2)
45611993|NCT03397199|Drug|Apatinib + S-1|Apatinib 250mg/d,q.d.,p.o. A course of treatment need 21days. S-1 40-60mg（40mg bid BSA <1.4, 60mg bid BSA>1.4），bid,from day1-day 14.
45611994|NCT04708327|Drug|STAT-205|naltrexone hydrochloride capsules 4.5 mg each
45611995|NCT04651361|Drug|Dinalbuphine sebacate|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
45611996|NCT04651361|Drug|Placebo solution|Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
45611997|NCT03397043|Other|Protein intake (dose)|Protein intake, in the form of crystalline amino acids, will range between 0.2-3.0 g/kg/d
45611998|NCT03397459|Diagnostic Test|Spine teleradiography EOS|
45611999|NCT05188053|Drug|HTX-011|Single dose administration periarticular 400mg bupivacaine and 12mg meloxicam extended release solution
45612000|NCT05188053|Drug|ropivacaine , epinephrine , ketorolac diluted in sodium chloride|Single dose administration in 100cc of standard formulation, there is 225mg of ropivacaine 5mg/mL, 0.6mg epinephrine 1mg/mL, 30mg ketorolac 30mg/mL diluted in sodium chloride
45612001|NCT03396965|Other|Mini-c-arm|Fluoroscopy used to aid reduction of distal radius fracture
45612002|NCT05193721|Drug|SHR-1901|SHR-1901 dose escalation at 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg or 3 mg/kg or 10 mg/kg
45612003|NCT05184309|Other|ConventioanalExercises|Wand exercises and shoulder wheel exercises to increase the range of motion of the shoulder joint with 10 repetitions will be applied in CEG. Finger ladder exercises will be performed in the abduction and flexion position with 5 repetitions, holding the endpoint for 5 seconds. Stretching exercises with 5 repetitions will be applied in all directions for the limitation of movement, holding it for 20 seconds at the endpoint. Individuals performed conventional exercises twice a week for 6 weeks.
45612004|NCT05184309|Other|Serious games|A Serious game program will be applied to the individuals twice a week for 6 weeks in this group. Armrotate, Uball, Balance Surf and Balance Adventure games will be developed by Becure company for shoulder rehabilitation. These games developed for shoulder rehabilitation will be applied to individuals under the supervision of a physiotherapist. Each game will be played for 10 minutes, for a total of 40 minutes.
45612005|NCT03396887|Other|U Control Drink Smartphone Application|The smartphone application comprises five recovery focused features: supportive messages, Computerised-Cognitive Behavioural Therapy, a drinking log, craving management and gamification.
45612006|NCT03396887|Other|Control group|The control group will receive treatment as usual.
45612007|NCT03399877|Biological|Combining electromyography with uroflowmetry (group A)|Children who assigned group A perform uroflowmetry-electromyography for the first and subsequently perform uroflowmetry-electromyography again.
45612008|NCT03399877|Biological|Uroflowmetry(Group B)|Children who assigned Group B perform uroflowmetry-electromyography for the first, and subsequently perform sole uroflowmetry.
45612009|NCT03399877|Biological|Uroflowmetry-Combining electromyography with uroflowmetry (Group C)|Children who assigned Group C firstly perform sole uroflowmetry and subsequently perform uroflowmetry-electromyography.
45612010|NCT03396809|Device|Punctal plug|Punctal plugs are FDA approved for the treatment of dry eye. They increase lubrication of the eye by blocking the drainage of tears into the lacrimal sac. The nose portion of the plug has a larger diameter which is designed to fit in the canaliculum in order to retain the plug in the punctum. The plugs will be used on-label, as it is FDA approved in the treatment of dry eye. The purpose of punctal plugs are to increase tear volume by preventing drainage of tears into the lacrimal sac. The plugs are removable if necessary. Investigators are not testing this device for effectiveness or safety.
45612011|NCT05110807|Drug|TQB3617|TQB3617 is a BET inhibitor.
45612012|NCT03399721|Device|Chordate S101|Active treatment: The controller creates air-mediated kinetic oscillations with regulated pressure and frequency during a preset treatment time
45758800|NCT04385771|Device|vv-ECMO + cytokine adsorption (Cytosorb adsorber)|in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)
45758801|NCT04385771|Device|vv-ECMO only (no cytokine adsorption)|COVID-19-diseased treated with vv-ECMO
45758802|NCT00760435|Drug|Infliximab|5 mg/kg IV over 2 hours once
45758803|NCT00760435|Drug|Placebo|Placebo (same volume as active drug)
45758804|NCT02144597|Dietary Supplement|Liquid formula low-calorie diet (LCD)|The liquid formula low-calorie diet (LCD) will provide 800kcal/day from powdered milkshakes and soups. The diet will be provided by Cambridge Weight Plan.
45758805|NCT02144597|Procedure|Roux-en-Y gastric bypass (RYGB)|Participant went through Roux-en-Y gastric bypass (RYGB) surgery
45758806|NCT02144597|Other|Control diet|
45612013|NCT03399721|Device|Chordate S101 Placebo|Placebo treatment: Placebo treatment is similar to active treatment, but with no oscillations. It is difficult to discern any difference between active and placebo treatment.
45612014|NCT04566965|Diagnostic Test|SARS-CoV-2|"Testing weekly samples from nasal swabs to promptly diagnose acute COVID-19 infection.~Testing monthly serum samples to document post-viral infection."
45445224|NCT01315353|Procedure|Loop Electrosurgical Excision Procedure (LEEP)|Loop Electrosurgical Excision Procedure (LEEP): Participants found to have CIN2+ by biopsy had LEEP, an electro-surgical procedure used to treat high-grade cervical dysplasia.
45612015|NCT03393325|Other|Observation of treatment with Tadalafil-Delivra|Tadalafil 2% in a Delivra base (Transdermal Application)
45612016|NCT04353765|Drug|Cabozantinib monotherapy|Intervention description (FDA Label): kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
45612017|NCT04353765|Drug|All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC|As per authorized FDA label in advanced RCC
45612018|NCT03410069|Device|IKORUS UP system|Continuous assessment of the urethral microcirculation
45612019|NCT03399643|Drug|Atezolizumab|Atezolizumab is administered via IV 1200 mg every 3 weeks
45612020|NCT04010097|Other|chewing gum|The test involves chewing a chewing gum for 4 minutes
45445225|NCT02055274|Drug|LY03003|
45612021|NCT03407573|Biological|Administration of Red Cell|Transfusion of red cells dependent on haemoglobin level. Either transfused at haemoglobin of 7 or 9.
45612022|NCT04533581|Drug|ME-401|In the first 2 cycles (1 cycle is 28 days), subjects will be administered 60 mg of ME-401 orally once a day on a continuous schedule (CS). After that, subjects will be administered 60 mg of ME-401 orally once a day for the first 7 days, followed by rest for 21 days on an intermittent schedule (IS).
45612023|NCT03268473|Other|Non-surgical periodontal therapy|Experimental: Non-surgical periodontal therapy (scaling and root planing) and supportive periodontal therapy
45445226|NCT02055274|Drug|Neupro|
45445227|NCT02055508|Behavioral|Exercise Intervention|
45612024|NCT03268473|Other|Delayed non-surgical periodontal therapy|Delayed non-surgical periodontal therapy (scaling and root planing) after the 3 month visit
45612025|NCT03393247|Drug|infliximab and azathioprine combination at week 0|All enrolled CD patients will schedule on IF X (week 0, 2, 6 and then every 8 weeks at 5mg/kg).Experimental group will receive azathioprine at week 0.
45758807|NCT03808129|Drug|Bupivacaine and Lidocaine|ESP block was administered under general anesthesia before the surgery. Patients with ESP block, 1: 1 ratio of 0.25% bupivacaine and 0.4 ml / kg of 1% lidocaine
45612026|NCT03393247|Drug|infliximab and azathioprine combination at week 14|All enrolled CD patients will schedule on IF X (week 0, 2, 6 and then every 8 weeks at 5mg/kg).Control group will receive azathioprine at week 14.
45758808|NCT01273285|Device|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
45758809|NCT00749125|Drug|Lexapro|10 mg by mouth once per day for first 2 weeks, with psychiatric re-evaluation every 2 weeks to determine if any change in dosage is required, with a maximum of 20 mg per day
46068815|NCT05589285|Device|Injection of normal saline to the plantar fascia|This will be the control group receiving sham injection. Patients will have 2 ml of blood withdrawn from a peripheral vein for blinding proposes. They will be asked to lie down on the clinic bed, 1 ml of normal saline will be administered under sterile technique by the principal investigator. The blood that was withdrawn initially will be discarded.
46068816|NCT05584280|Device|Orsiro stent on shelf|Cluster randomization to Orsiro stent on shelf vs. control
46068817|NCT05584280|Device|Promus stent on shelf|Cluster randomization to Promus stent on shelf vs. treatment
45612027|NCT03407027|Drug|Quadratus triamcinolone|40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
45612028|NCT03407027|Drug|Gluteus triamcinolone|40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
45612029|NCT03407027|Drug|quadratus without triamcinolone.|10ml of levobupivacaine 0,25%.
45612030|NCT03397303|Other|elastography measurements|elastography measurements
45612031|NCT03343197|Drug|AG-120|Prior to surgery subjects will receive AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects without residual disease following surgery will have the option to receive treatment for up to a year, until disease progression or unacceptable toxicity, whichever occurs first. Subjects with residual disease following surgery will have the option to receive treatment, until disease progression or unacceptable toxicity.
45612032|NCT03343197|Drug|AG881|Prior to surgery subjects will receive AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects without residual disease following surgery will have the option to receive treatment for up to a year, until disease progression or unacceptable toxicity, whichever occurs first. Subjects with residual disease following surgery will have the option to receive treatment, until disease progression or unacceptable toxicity.
45612033|NCT04512989|Diagnostic Test|Cognitive assesment using MOCA test|Cognitive assesment using MOCA test
45445228|NCT02055508|Other|Care-Management-Phone-Calls|
45445229|NCT03778905|Other|Rehabilitation|The stroke patients who admitted to post acute care(PAC) institution would undergo regular rehabilitation.
45445230|NCT03783897|Drug|EDP-305|Subjects will receive EDP-305 on on Days 11 through 21 of cycle 3
45445231|NCT03783897|Drug|Oral Contraceptive|Subjects will receive active Oral Contraceptive on Days 1-21 and inert OC on Days 22-28 of cycles 1, 2 and 3
45758810|NCT02144675|Drug|choline magnesium trisalicylate|Given PO
45758811|NCT02144675|Drug|idarubicin|Given IV
45758812|NCT02144675|Drug|cytarabine|Given IV
45758813|NCT02144675|Other|laboratory biomarker analysis|Correlative studies
45445232|NCT01315821|Drug|Saccharomyces boulardii|5 million units/day for 3 months
45445233|NCT01315821|Drug|Placebo|Placebo for 3 months
45445234|NCT03779061|Drug|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary
45445235|NCT03779061|Drug|Propofol|Initial dose plus supplemental doses as necessary
45758814|NCT00721253|Device|ReSTOR|Implantation of the ReSTOR Aspheric +4 (SN6AD3) multifocal intraocular lens (IOL)
45758815|NCT00721253|Device|Tecnis|Implantation with the Tecnis multifocal (ZM900) intraocular lens (IOL)
45758816|NCT00721253|Device|Acri.LISA|Implantation with the Acri.LISA 366D multifocal intraocular lens (IOL)
45758817|NCT00749515|Drug|Deferoxamine|After a 3-day washout period from all chelation, all patients have a 12 hour infusion of 50mg/kg of deferoxamine with urine collection and pre and post blood sampling to assess iron and Total Iron Binding Capacity (TIBC) by atomic absorption.
45612034|NCT03189459|Behavioral|Home Visit Program|RC: Informed consent discussion, documentation RN: UPDRS I-II, vitals, medication reconciliation, patient medical history and comorbidities RN and SW: Home safety assessment SW: Psychosocial assessment of dyad, HADS, assessment of mobility and homebound status, needs assessment of dyad, caregiver medical history and comorbidities RC: patient and caregiver short MoCA, PD-Rx, health literacy assessment, satisfaction surveys; patient PDQ-39/PDQ-8
45612035|NCT03189459|Behavioral|Caregiver Mentorship Program|"Both mentors and mentees will be completing this program:~Mentors will be asked to complete: 1) a Mentor Training - One 5-hour session at Rush University Medical Center; and 2) two 16-week periods of mentoring someone who is currently a caregiver for a patient with Parkinson's Disease~Caregivers mentees will be asked to complete a 16 week mentorship program with their assigned mentor"
45612036|NCT01602224|Drug|Placebo|Administered IV
45612037|NCT01602224|Drug|Dexamethasone|Administered orally
45612038|NCT01602224|Drug|Bortezomib|Administered SQ
45612039|NCT01602224|Biological|Tabalumab|Administered IV
45612040|NCT03399487|Drug|LDK378(Ceritinib)|"This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.~This clinical study is targeted for the patients who harbor ROS1 rearrangement and all patients will be treated with LDK378 750mg daily. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days."
45612041|NCT04504097|Behavioral|m-Health|Participants receive a weekly bidirectional text message (SMS) asking how they are doing. They are requested to reply fine, or not fine, in which case they will be contacted with support by a peer navigator. If they do not reply to the message within the specified timeframe a peer navigator will follow up with them.
45612042|NCT04504097|Diagnostic Test|HIV self-testing|Participants will receive HIVST kits so that they can perform their HIV testing.
45758818|NCT00749515|Drug|Deferasirox|After a 3-day washout period from all chelation, patients had a desferal challenge which was followed by a single dose of deferasirox, 35mg/kg orally with blood sampling taken pre-deferasirox and at intervals for 24 hours after the dose.
45612043|NCT05161429|Drug|DPP4|Dipeptidyl peptidase-4 inhibitors (DPP4) including alogliptin, linagliptin, sitagliptin, and saxagliptin
45612044|NCT05161429|Drug|GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonists (GLP1-RA) including dulaglutide, exenatide, liraglutide and semaglutide
45612045|NCT05161429|Drug|Basal Insulin|degludec, detemir, glargine and NPH
45758819|NCT00749515|Radiation|HIDA|All patients had a HIDA scan to assess physiologic liver clearance capacity.
45758820|NCT00707447|Behavioral|PREDIAS|Group programme aiming at modification of lifestyle: lifestyle changes, 12 lesson a 90 minutes, delivered in a group setting, consists of analysis of barriers against lifestyle changes, behavior analysis of eating and exercise behavior, modification of unhealthy lifestyle and relapse prevention
45758821|NCT00707447|Behavioral|Control|Written Information about diabetes risks. Brochure about the value of a healthy lifestyle, calorie table, suggestions for healthy food and daily exercise
45758822|NCT03807895|Behavioral|REBT Career Intervention|Eight sessions of regular career intervention with rational emotive behavioral therapy (REBT) methods.
45758823|NCT03807895|Behavioral|Regular Career Intervention|Eight sessions of regular career intervention.
45758824|NCT00749671|Device|Bispectral index monitoring|The monitoring of the EEG signal is designed to determine if the sedation is adequate.
45758825|NCT00749671|Other|Ramsey Sedation Scale|The determination of the degree of sedation is accomplished using an established sedation scale.
45612046|NCT05161429|Drug|SLGT2|Sodium-glucose cotransporter-2 inhibitors (SLGT2) including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin
45612047|NCT05161429|Drug|SU|Sulfonylurea (SU) including glimepiride, glipizide, and glyburide
45612048|NCT03984045|Drug|Lidocaine topical|Intranasal 2% lidocaine delivered directly to SPG
45612049|NCT03984045|Drug|Prochlorperazine Injection|intravenous prochlorperazine at 0.15mg/kg max 10 mg
45612050|NCT05154799|Behavioral|Proprioception and tactile localization with manual or ocular response and/or free hand grasp|"In the first part of the study, the subject must designate a target in 2 ways: manual pointing or ocular saccadic response.~In the second part of the study the subject will have to reach and grasp a rectangular block of wood placed on the table at a distance of 35 cm. He will have to catch the wooden block, lift it a few centimeters and put it back on the table. Tool use and control phases: the subject grasps the wooden block with a tool or without the tool but with a weighted bracelet loading his wrist by the same amount as the tool."
45612051|NCT03895359|Radiation|Stereotactic Body Radiation|For patients randomized to the SMRT arm, SBRT is to be delivered over 5 fractions delivered over 5 to 15 days.
45612052|NCT03895359|Drug|Transarterial Chemoembolization|Transarterial chemoembolization is a standard treatment for patients with hepatocellular carcinoma (liver cancer). Chemotherapy is injected into the arteries of the liver and liver cancer.
46068818|NCT05574062|Device|MiniMed 780G Automode|"Subjects will start using the MiniMed™ 780G system in Auto Mode.~The 780G system consists of:~MiniMed™ 780G Insulin Pump with auto mode enabled Guardian™ 4 Sensor Guardian™ 4 Transmitter"
46068819|NCT05574062|Device|MiniMed 780G Manual Mode + Suspend Before Low|Subjects will start using the MiniMed™ 780G system in Manual Mode. The 780G system consists of: MiniMed™ 780G Insulin Pump with manual mode + Suspend before Low enabled Guardian™ 4 Sensor Guardian™ 4 Transmitter
46068820|NCT05571410|Behavioral|HTN Chat bot|Remote monitoring via automated messaging program
45612053|NCT05134753|Biological|Advanced PRF|Advanced PRF will be placed for patients undergoing sinus augmentation
45612054|NCT05134753|Biological|Control|PRF will be placed for patients undergoing sinus augmentation
45758826|NCT01272323|Biological|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
46068821|NCT05569174|Drug|secukinumab|AIN457 300 mg subcutaneously for 12 weeks
46068822|NCT05569174|Other|Placebo|Placebo to match AIN457 subcutaneously for 12 weeks
45612055|NCT03661047|Drug|AMR101 (VASCEPA, icosapent ethyl)|Oral administration, 4 grams per day
45612056|NCT05125861|Procedure|remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg. All patients underwent dynamic cerebral autoregulation on days 1-2 and 7-10 after onset, and intravenous blood was collected by a nurse and stored in the laboratory 0-6 hours after thrombolysis and 24 hours after thrombolysis.
45612057|NCT05125861|Procedure|sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg. All patients underwent dynamic cerebral autoregulation on days 1-2 and 7-10 after onset, and intravenous blood was collected by a nurse and stored in the laboratory 0-6 hours after thrombolysis and 24 hours after thrombolysis.
45758827|NCT01272323|Biological|Cat-PAD Dose 1|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
45612058|NCT05060991|Drug|Reduction in antimetabolite immunosuppression|Reduction in dose in mycophenolate mofetil/mycophenolic acid (MMF) or azathioprine before and after receiving 3rd dose vaccination
45758828|NCT01272323|Biological|Cat-PAD Dose 2|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
45612059|NCT05115253|Behavioral|HAPA behavioural counselling + SMS text message boosters|Behavioural counseling grounded in the Health Action Process Approach (HAPA; i.e., action planning and coping planning) paired with daily personalized HAPA guided SMS text message boosters to reduce consecutive workplace sedentary behaviour.
45612060|NCT05115253|Device|JITAI|EMA monitoring mobile phone application that uses a phone's on-board accelerometer to monitor a participant's sedentary behaviour and deliver a push notification once a set condition has been met. This intervention will be utilized to reduce consecutive workplace sedentary behaviour.
45612061|NCT03397225|Behavioral|Lifestyle intervention|The educational sessions and individual sessions including dietary management and physical activity advices.
45612062|NCT03399409|Behavioral|Motivational Interviewing|Motivation techniques
45612063|NCT03399409|Behavioral|Anti-inflammatory Information|Provision of information on anti-inflammatory products
45612064|NCT03399331|Dietary Supplement|Manuka honey|5 for children or 10cc of honey for adults was ordered directly from a New Zealand company
45612065|NCT03399331|Dietary Supplement|olive oil|5 cc of extra virgin olive oil for adults and 2 cc for children directly from a local distributor in south Lebanon will be given.
45612066|NCT03399331|Combination Product|Control group|Control at our institution is 5cc sodium bicarbonate, 5cc rinsidin and 5cc of mycostatin 4 times daily for children. For adults it is Caphosol in the BMT unit and in the Basile inpatient unit it is the magic solution (without xylocaine).
45612067|NCT03399253|Procedure|surgery|D2 gastrectomy + metastasectomy
45612068|NCT03399253|Drug|chemotherapy|capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
45612069|NCT03397147|Behavioral|Sleep Coach Jr.|A brief sleep education program for parents of school-aged children with type 1 diabetes, with a focus on resolving sleep disturbances with parent education and positive bedtime routines.
45612070|NCT04498247|Biological|V591|1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.
45612071|NCT04498247|Other|Placebo|Placebo (0.9% sodium chloride) administered via IM injection.
45758829|NCT01272557|Drug|Doxorubicin|Doxorubicin 60 mg/m2 i.v. on day 1 every 21 days Sorafenib 400 mg bid (oral) from day 3-19 every 21 days. Maximum accumulative dose of doxorubicin: 360 mg/m2 (thereafter sorafenib monotherapy continuously until progression or unacceptable toxicity).
45758830|NCT01272557|Drug|Sorafenib|Sorafenib 400 mg bid (oral) continuously
45758831|NCT01272713|Other|Oxygen therapy|"Pre-hospital supplemental oxygen administered via Hudson mask at a flow rate of 8L/min~In-hospital oxygen as per hospital protocol"
45758832|NCT01272713|Other|No oxygen therapy|No oxygen pre-hospital or in-hospital unless the oxygen saturation falls below 94% in which case oxygen will be administered via nasal cannulae (4L/min) or Hudson mask (8L/min) and titrated to achieve oxygen saturation of 94%.
45758833|NCT00762307|Device|Zeltiq Dermal Cooling Device|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
45758834|NCT01273025|Dietary Supplement|Lime powder regime|1 sachet of lime powder regimen with 200 ml of water
45758835|NCT00639002|Drug|Ruxolitinib 25 mg|Ruxolitinib was supplied as 5 and 25 mg tablets.
45758836|NCT00639002|Drug|Dexamethasone 40 mg|Dexamethasone was obtained commercially by Investigators in tablet strengths of 20 or 40 mg.
45758837|NCT00761137|Drug|0.3 mg tropicamide|0.3 mg tropicamide in intra-oral thin film
45758838|NCT00761137|Drug|1 mg tropicamide|1 mg tropicamide in intra-oral thin film
45758839|NCT00761137|Drug|3 mg tropicamide|3 mg tropicamide in intra-oral thin film
45758840|NCT00761137|Drug|0 mg tropicamide|0 mg tropicamide (placebo) in intra-oral thin film
45758841|NCT01273103|Drug|200mg [14C]- GSK2248761|single oral suspension dose of [14C]- GSK2248761 200 mg
45758842|NCT04386161|Other|Scheduled exercise program|45 minutes of stretching, strengthening, and balance-coordination exercises and 20 minutes of balance training on the Balance Master® device twice a week for six weeks
45758843|NCT02575118|Device|Restoration of dental caries with dental composite|
45758844|NCT02145247|Drug|hCG|"3. On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~4. Blood samples will be obtained at T = -0.5, 0, and +24 hours."
45758845|NCT00722111|Device|lingual press|lingual press (high-intensity, oral, non-swallowing)
45758846|NCT00722111|Behavioral|effortful swallowing|effortful swallowing (high-intensity swallowing)
45758847|NCT00722111|Behavioral|natural swallowing|natural swallowing (high frequency, low intensity swallowing)
45758848|NCT00722111|Behavioral|non-oral sham (control) exercise|non-oral sham (control) exercise
45758849|NCT00638846|Device|senofilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
45758850|NCT00638846|Device|balafilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
45612072|NCT03397069|Procedure|Peribulbar block (control)|"The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture."
45758851|NCT01273493|Drug|Trabectedin|Trabectedin 0.58 or 1.3 mg/m^2 (or adjusted dose) i.v. will be administered on Day 1.
45612073|NCT03397069|Procedure|Peribulbar block(M1)|"The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 50 µg/ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture."
45612074|NCT03397069|Procedure|Peribulbar block(M2)|"The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 100 µg/ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture."
45612075|NCT03396497|Drug|LYC-55716|Continuous twice daily administration of LYC-55716 in 28 day treatment cycles.
45612076|NCT03396497|Drug|Pembrolizumab|Pembrolizumab administered every 3 weeks as prescribed as standard of care by the investigator in accordance with the package insert.
45612077|NCT03392857|Other|Assessment by caregivers of the quality of the end of life in intensive care units|Quality of the end of life in intensive care units perception will be explore from the side of the caregivers, trough the CAESAR scale.
45612078|NCT03405623|Procedure|Dynamic needle tip positioning under ultrasound-guidance|The tip of needle is positioned under ultrasound-guidance using dynamic short-axis view.
45612079|NCT03405623|Procedure|Conventional long-axis view|The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
45612080|NCT03405467|Other|general and specific data|General and specific data collected
45612081|NCT03405233|Procedure|Double vein cuffed ePTFE graft both at the inflow and outflow ends|Vein cuff is obtained from a segment of one of the arm veins (cephalic or basilica) after incising it longitudinally and wrapped around both ends of PTFE Graft
45612082|NCT03405233|Procedure|single vein cuffed eTFE graft both at the inflow and outflow ends|Vein cuff is obtained from a segment of one of the arm veins (cephalic or basilica) after incising it longitudinally and wrapped around the venous end of PTFE Graft
45612083|NCT03405233|Procedure|ePTFE graft without any cuff|anastmosis between arterial and venous side usinf non cuffed ePTFE graft
45612084|NCT03399019|Drug|Dexmedetomidine|initial loading dose (0.5 ~ 1㎍/kg for 10 minutes) and maintenance infusion (0.2-0.7㎍/kg/hr)
45612085|NCT03399019|Drug|Propofol|continuous infusion (0.75-3mg/kg/hr)
45612086|NCT03399019|Drug|Midazolam|0.05mg/kg bolus injection and if not OAA/S ≤ 3 within 5 minutes, add 0.01mg/kg at intervals of 1~2 minutes
45612087|NCT04452383|Drug|Ketamine + propofol|effect of adding ketamine to propofol for patients undergoing DISE surgery
45758852|NCT01273493|Drug|Dexamethasone|Dexamethasone will be administered as 20 mg/m^2, 30 minutes prior to trabectedin.
45758853|NCT00638456|Drug|Budesonide plus Prevacid|Budesonide is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
45758854|NCT00638456|Drug|placebo plus Prevacid|Placebo is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
45758855|NCT01273571|Drug|Canagliflozin/Metformin|Two 1000-mg tablets of metformin on Day 1 followed by one 300-mg tablet of canagliflozin once daily on Days 4 through 8, followed by two 1000-mg tablets of metformin and one 300-mg tablet of canagliflozin on Day 8.
45758856|NCT02147899|Drug|SYM-1219|Oral
45758857|NCT02147899|Drug|Placebo|Oral
45758858|NCT01273649|Device|cryotherapy|cryotherapy is given with other physical training
45758859|NCT02565992|Biological|CAVATAK|Maximum dose of CVA21 is 3 x 10E+08 TCID50 (about 4.5 x 10E+06 TCID50/kg for a 70-kg patient) by intratumoral administration.
45758860|NCT02565992|Drug|Pembrolizumab|Intravenous pembrolizumab at 2 mg/kg solution.
46068823|NCT05566951|Other|Psychosocial program|A technology-based model-based psychosocial empowerment program will be implemented for parents and children in the control group.
46068824|NCT05566951|Other|Standart care|Parents and children in the intervention group will be applied standard support approaches to be applied in the center where they receive treatment.
46068825|NCT05564104|Drug|Cagrilintide|Cagrilintide will be administered subcutaneously in the abdomen in the form of a solution for injection.
46068826|NCT05554601|Behavioral|gamification with collaboration|participants receive a FitBit and set goals, then are assigned to a group of other participants who will play a game to gain points based on collaboration
46068827|NCT05554601|Behavioral|gamification with competition|participants receive a FitBit and set goals, then are assigned to a group of other participants who will play a game to gain points based on competition with each other
46068828|NCT05546164|Other|Assessment of hand grip strength|Assessment of hand grip strength
46068829|NCT05546164|Other|Assessment of pinch strength|Assessment of pinch strength
46068830|NCT05546164|Other|Assessment of upper limb dexterity|Assessment of upper limb dexterity
45758861|NCT03548558|Behavioral|Group sessions|"Mother-child dyads in Arm 1 households will receive biweekly ECD sessions for a total of 16 sessions over 7 months. CHVs will record attendance at each session. To maximize participation, prior to each session the CHVs will send a short message service (SMS) mobile phone reminder of the session's topic, time and location to all participants.~After the end of the 16 biweekly sessions, we will re-randomize across the 40 intervention villages, stratified by Arms 1 and 2, and half of each of Arm 1 and Arm 2 villages will receive bimonthly booster visits for the period between end-line and follow-up surveys."
45758862|NCT03548558|Behavioral|Group+Home sessions|"Households in Arm 2 will receive a total of 16 sessions with identical content similar to Arm 1, but 4 of those sessions will replace group sessions held at the level of villages for personalized home visits, in which the CHV will visit each participant household to deliver these sessions. These home visits will cover identical material and topics as the group sessions in Arm 1 villages, but will be delivered on a personalized basis in the home of the mother and child. Personal barriers to the practices will be discussed and an active resolution strategy developed in concert with the CHV.~After the end of the 16 biweekly sessions, we will re-randomize across the 40 intervention villages, stratified by Arms 1 and 2, and half of each of Arm 1 and Arm 2 villages will receive bimonthly booster visits for the period between end-line and follow-up surveys."
45612088|NCT04452383|Drug|propofol|effect of IV propofol alone for patients undergoing DISE surgery
45612089|NCT05036941|Device|Acteev™ Masks|Participants will wear the mask on every shift for 8 consecutive weeks. Participants in Arm 1 will be supplied adequate number of Acteev™ N95 masks YQD8008 during 8-hour shift and Acteev™ fabric masks for community use.
45612090|NCT05036941|Device|Comparison Masks|Participants will wear the mask on every shift for 8 consecutive weeks. Participants in Arm 2 will be supplied with adequate number of standard N95 masks during 8-hour shift and fabric mask for community use.
45612091|NCT04447547|Biological|CD19 CAR-T|Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
45612092|NCT03396757|Procedure|Standard strategy|"RRT is initiated within 12 hours after documentation of serum urea concentration >40 mmol/l and/or an oliguria/anuria for more than 72 hours. The timing of its initiation will be recorded and RRT will continue until criteria for cessation are observed. This arm corresponds to the delayed strategy in the published AKIKI trial (NEJM 2016),"
45612093|NCT03396757|Procedure|Delayed strategy|"RRT will be initiated only if one or more of above-mentioned potentially severe situations occur (identical to those used during the observational study) or if serum urea concentration reaches 50 mmol/L (this level being chosen in order to avoid extreme elevations of serum urea levels as mentioned above). The physician in charge will be allowed to try a medical treatment. Patients will not receive RRT whatever the duration of anuria/oliguria if any above-mentioned indication for RRT is not present. When required, RRT will be performed with the same modalities and stopped according to the same criteria as in the no further delayed RRT strategy, with special care to avoid dialysis disequilibrium syndrome (see below).~The decision to initiate RRT in the delayed strategy arm of the trial will have to be approved by the attending physician(s) involved in patient's care in order to make sure that it corresponds to her/his usual practice."
45612094|NCT03396263|Behavioral|Non-personalised advice|Provision of online non-personalised advice on dietary intake, weight and physical activity levels. Non-personalised dietary advice for improved food choice based on standard population health guidelines.
45612095|NCT03396263|Behavioral|Online personalised advice|Provision of online personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
45758863|NCT03807583|Drug|Aminoven 10%|"After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~group A: RENORAL® product~group B: AMINOVEN® 10% product~group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month (Day 90, Day 120, Day 150). Protocol visits are included in the patient's course of care."
45612096|NCT03396263|Behavioral|Face-to-face personalised advice|Provision of face-to-face personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
45612097|NCT03392779|Drug|ZSP1601 25 mg|ZSP1601 tablet administered orally once daily under fasted condition
45612098|NCT03392779|Drug|Placebo 25mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
45612099|NCT03392779|Drug|ZSP1601 50 mg|ZSP1601 tablet administered orally once daily under fasted condition
45758864|NCT03807583|Dietary Supplement|RENORAL|"After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~group A: RENORAL® product~group B: AMINOVEN® 10% product~group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month ( V3, V4, V5). Protocol visits are included in the patient's course of care."
45758865|NCT03802123|Drug|⁸⁹Zr-Df-IAB22M2C|⁸⁹Zr-Df-IAB22M2C CD8 T cell tracer for Positron Emission Tomography (PET)
45758866|NCT00733343|Device|Europe: AutoSet CS (USA: VPAP Adapt SV)|At least 3 hours average daily usage time
45758867|NCT00638378|Drug|Ruxolitinib|Ruxolitinib 25 mg tablets taken with water twice a day.
45758868|NCT03807661|Procedure|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
45758869|NCT03807661|Device|LimFlow System|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
45758870|NCT03132116|Drug|gentamicin|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of gentamicin .~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
45612100|NCT03392779|Drug|Placebo 50 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
45612101|NCT03392779|Drug|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily in the fasting state
45612102|NCT03392779|Drug|Placebo 100 mg|Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
45758871|NCT03132116|Drug|placebo|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of placebo.~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
45758872|NCT00762619|Drug|Fluoride|Brush twice daily
45612103|NCT03392779|Drug|ZSP1601 175 mg|ZSP1601 tablets administerekd orally once daily under fasted condition
45612104|NCT03392779|Drug|Placebo 175 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
45612105|NCT03392779|Drug|ZSP1601 275 mg|ZSP1601 tablets administered orally once daily in the fasting state
45612106|NCT03392779|Drug|Placebo 275 mg|Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
45612107|NCT03392779|Drug|ZSP1601 350 mg|ZSP1601 tablets administered orally once daily under fasted condition
45612108|NCT03392779|Drug|Placebo 350mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
45612109|NCT03392779|Drug|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition
45612110|NCT03392779|Drug|Placebo 100mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition
45445236|NCT03784053|Other|Immersive virtual reality|At the start of every session, the participants' top five occupational problems will be reviewed, and a list of apps corresponding to the desired occupational problem will be offered through the immersive virtual reality device (Oculus Go). There will be eight 30-minute virtual reality sessions.
45612111|NCT03392779|Drug|ZSP1601 50 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
45612112|NCT03392779|Drug|Placebo 50 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
45612113|NCT03392779|Drug|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
45612114|NCT03392779|Drug|Placebo 100 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
45612115|NCT02520557|Other|Blood or Saliva|To screen for HLA genotypes that may place patients at high risk of SCAR when they use ESL.
45612116|NCT02520479|Drug|P-CHOP|Two cycles of P-CHOP:cyclophosphamide, 750 mg/m2 day 1; vincristine,(maximal dose 2 mg),adriamycin , 50 mg/m2 day 1; dexamethasone,10mg days 1-8; Pegaspargase, 2500IU/m2 day 1 are given before radiotherapy
45612117|NCT02520479|Radiation|Radiotherapy|Radiotherapy was scheduled after 2 cycles of P-CHOPregimen. Involved field radiotherapy(IFRT) is delivered using 6-Million electron Volts linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions.
45445237|NCT01316445|Drug|nasal Midazolam|Intranasal and buccal administration of the standard IV formulation of midazolam (5mg/mL), administered via a metered dose sprayer at 0.1mL/spray (i.e. 0.5mg/spray). Administration will be via three sprays in each nostril (for nasal) or three sprays between the cheek and the gum per side (for buccal).
45612118|NCT02520479|Drug|P-CHOP|"Two consolidation cycles of P-CHOP are given after radiotherapy"
45612119|NCT03396679|Other|Ultrasound examination|Evaluation of the Psoriatic Arthritis remission according to patient and physician's global assessment of disease activity are in agreement (CASPAR criteria agreement) or in disagreement (CASPAR criteria disagreement)
45758873|NCT00762619|Drug|Triclosan, fluoride|Brush twice daily
45758874|NCT05248568|Device|Core training|Core training lasts for 12 weeks, three times a week, one hour each time
45445238|NCT03712449|Device|JUVÉDERM®|Facial filler injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) from Month 6 to Month 8 (BELKYRA Treatment) and Month 0 to Month 2 (Non-BELKYRA Treatment).
45612120|NCT02520947|Device|BIS|Bispectral index monitoring
45612121|NCT02520947|Drug|Desflurane|volatile agent for maintenance of anesthesia
46068831|NCT05545514|Drug|One out of 140 predefined homeopathic medical products (HMP) in potency C200 or C1000,|To investigate the efficacy of individualised homeopathic treatment (potency C200 and/or C1000) in comparison to placebo regarding the number of UTI treated with antibiotic agents.
45612122|NCT05002153|Other|Fecal microbiota transplantation (FMT)|FMT is the process of transferring stool from a healthy donor to another.
45612123|NCT05002153|Other|Placebo|Placebo capsules consist a combination of agarose in normal saline/glycerol (the same vehicle as in a FMT capsules)
45612124|NCT03396185|Drug|Icotinib|Patients who have EGFR-mutant stage IIIA-IIIB and unresectable lung adenocarcinoma will receive Icotinib with a dose of 125 mg three times per day orally till progressive disease or unaccepted toxicity as consolidation therapy after synchronous or sequential chemoradiotherapy.
45612125|NCT03392701|Biological|LPS infusion|infusion of LPS 2 ng/kg over 5 minutes
45612126|NCT05168189|Drug|Ivabradine|follow up chronic coronary syndrome patients receiving Ivabradine for ( 6 months ) if the participants develop atrial fibrillation using 24 hours holter .
45612127|NCT05168189|Diagnostic Test|transthoracic echo|performing baseline transthoracic echo for all patients to exclude any chamber dilatation
45612128|NCT05168189|Device|24 hours holter|perform 24 hours Holter monitoring for all patients at the start of the study and follow up after 6 months
46068832|NCT05541393|Behavioral|Active Intervention Group|The intervention will involve meetings with the church health ministers to discuss COVID-19 vaccines and booster shots.
45612129|NCT03398941|Drug|Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide|Long-Period Octreotide 20mg one week before operation combine Short Period Octreotide 0.3mg during postoperative five days.
45612130|NCT05168111|Diagnostic Test|Detect the serum sample|Detect the serum sample
45612131|NCT05000671|Drug|STC314 injection or Placebo(rate=58.3 mg/hr)|To receive continuous infusion of STC314/Placebo injection at rate 58.3mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.
46068833|NCT05535257|Device|Sequential Compression Device|Calf size lower extremity sequential compression device sleeve will be placed on the weak upper extremity blow the cubital fossa and may include the hand if necessary. The device will inflate and deflate.
45612132|NCT05000671|Drug|STC314 injection or Placebo(rate=87.5 mg/hr)|To receive continuous infusion of STC314/Placebo injection at rate 87.5mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.
45612133|NCT04413773|Other|Treatment as usual + Video|Additionally to treatment as usual a video is shown to participant about procedures on the ward before, during and after surgery
45758875|NCT02521142|Other|Non-invasive OCT based optical angiography|This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
45758876|NCT02521142|Other|Oxymap T1|The Oxymap system T1 is installed on a conventional fundus camera (Topcon TRC-50DX), which is operated as for color photography. The Oxymap T1 simultaneously acquires two images of the same area of the fundus at two different wavelengths of light. One of the two wavelengths is sensitive to oxygen saturation, i.e. the light absorbance changes with the oxygen saturation, while the other is insensitive to oxygen saturation and is used to calibrate the light intensity. The two spectral images are automatically processed by the Oxymap Analyzer software. Oxymap Analyzer detects blood vessels and estimates the light absorbance (optical density) at each point along the vessels at each wavelength. The ratio of the optical densities (optical density ratio or ODR) has been shown to be linearly related to hemoglobin oxygen saturation.
45758877|NCT02521142|Other|OCT|non-invasive imaging of retinal and choroidal structures.
45758878|NCT02521142|Other|FLA/ICG angiography|Fluorescein Angiography and Indocianine Angiography
45758879|NCT00734903|Behavioral|A Woman's Path to Recovery|WPR is a gender-specific therapy model for women with substance use disorder. It uses A Woman's Addiction Workbook to provide education and coping skills. In this trial it was conducted in 12 weekly individual sessions.
45758880|NCT00734903|Behavioral|12-Step Facilitation|12SF is an evidence-based therapy designed to facilitate early recovery from substance addiction. It is an individual model consisting of 12 sessions that use the principles of 12-step groups such as Alcoholics Anonymous, and strongly emphasizes participation in those. In this trial the model was conducted weekly.
45758881|NCT01273753|Other|Intradialytic exercise|Patients will exercise using a stationary foot pedal cycle for 20 minutes at the beginning of hemodialysis.
45758882|NCT00735449|Drug|Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%|1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
45758883|NCT00735449|Drug|timolol maleate 0.5%|1 drop of timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
45758884|NCT00735449|Drug|latanoprost 0.005%|1 drop of latanoprost 0.005% once nightly.
45445239|NCT03712449|Drug|BOTOX Cosmetic®|BOTOX Cosmetic, 20 U to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U injected to forehead lines at Month 9 and Month 10 (BELKYRA Treatment) and at Month 3 and Month 4 (Non-BELKYRA Treatment).
45758885|NCT04386343|Drug|CH1701 for prevention and treatment of radiation burns.|Ch1701 is used for cancer patients who are treated with radiotherapy, then assess the safety and treatment effectiveness of the product.
45758886|NCT04386343|Drug|Safety assessment of CH1701|Safety assessment of CH1701 after 14 days of use on volunteers
45758887|NCT04386343|Drug|Placebos|The placebo was used on patients as a control for the doses of CH1701
46068834|NCT05525377|Behavioral|Better living with non-memory led dementia course|Caregivers online training and educational phenotype-specific programme on how to support people with non-memory-led dementia.
46068835|NCT05519540|Drug|Xevinapant (Debio 1143)|All participants (Japanese and non-Japanese East Asian) will receive single oral dose of xevinapant (Debio 1143) on Day 1.
45445240|NCT03712449|Drug|BELKYRA®|BELKYRA, subcutaneous injection for maximum of 6 treatments, 1 month apart from Month 0 to Month 5. Maximum dose = 100 mg (10mL).
45612134|NCT04413773|Other|Treatment as usual|Explanation of standard procedures before, during and after surgery by nurse
45612135|NCT03398863|Procedure|Cleaning of uterine cavity|Procedure: Cleaning the uterine cavity These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
45612136|NCT05167799|Device|Cardiac Contractility Modulation (CCM)|Patients will be implanted with CCM device according to indications, to improve Heart Failure symptoms and then enrolled in the Registry if they fullfil Inclusion and Exclusion Criteria (First of all if they are diagnosed with TTR Amyloidosis)
45612137|NCT03396601|Drug|Ketamine Hydrochloride|Ketamine HCl will be infused intravenously at a dose of 0.5 mg/kg over 40 minutes
45612138|NCT03396601|Drug|Placebo|Normal Saline placebo will be infused IV over 40 minutes
45612139|NCT04369547|Device|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation.
45612140|NCT04369547|Drug|Roflumilast|Roflumilast 250mcg
45612141|NCT04369547|Drug|Placebo oral tablet|Placebo capsule matched to roflumilast capsule
45612142|NCT03392623|Drug|Retinoic acid|topical administration in melasma lesions
45612143|NCT03392623|Device|colorimetry measurement|Measurement of erythema and luminosity through a colorimeter
45612144|NCT03392623|Drug|sunscreen|topical administration in melasma lesions
45612145|NCT03392623|Drug|Niacinamide|topical administration in melasma lesions
45612146|NCT03396107|Drug|Dexamethasone|Dexamethasone 6mg, IM, 48 hours before cesarean section
45612147|NCT03396107|Drug|Placebo|Placebo 6mg, IM, 48 hours before cesarean section
45612148|NCT04976491|Dietary Supplement|CD-C-Food|CD patients combined with the characteristics of Chinese diet, remove the refined food, and combined with food intolerance detection method to check the corresponding food
45612149|NCT04976491|Dietary Supplement|EEN|EEN goup received EEN continuously for 6 moths
45612150|NCT04359797|Other|Prone|Provider-recommended guidance on prone positioning of patients
45612151|NCT04359797|Other|Usual Care|No provider-recommendation, patients will remain in their natural choice of position
45612152|NCT03398785|Procedure|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.
45612153|NCT03392545|Combination Product|Combined immune adjuvants and radiation|24 hours before the radiation, patients will be administrated poly I:C or CAR-T or TCR-T intratumorally and receive granulocyte macrophage colony stimulating factor 5 days after the radiation.
45612154|NCT03396029|Behavioral|Individually tailored lifestyle feedback|The written, standardized individually tailored lifestyle feedback includes feedback on consumption of fruit, berries and vegetables and alcohol, physical activity, smoking and body mass index.
45612155|NCT03396029|Behavioral|Standard leaflet|The leaflet is The Norwegian Cancer Society's one-page information brochure on healthy lifestyle behaviours for low cancer risk, including non-smoking, healthy body weight, physical activity, diet, moderate alcohol consumption, moderate sun exposure etc.
45612156|NCT03126695|Drug|Ticagrelor granule|A P2Y12 receptor inhibitor provided as granule for suspension.
45612157|NCT03126695|Drug|Ticagrelor pediatric tablets|A P2Y12 receptor inhibitor provided as pediatric tablets to be swallowed whole.
45612158|NCT03126695|Drug|Ticagrelor pediatric tablets suspended in water|A P2Y12 receptor inhibitor provided as pediatric tablets suspended in water.
45612159|NCT03126695|Drug|Ticagrelor immediate release (IR) tablets (Commercial tablet)|A P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (unstable angina, non-ST (S and T waves) elevation MI or ST elevation MI) and in patients with a history of MI
45612160|NCT04616443|Biological|OH2 injection|Oncolytic Type 2 Herpes Simplex Virus
45612161|NCT04616443|Biological|HX008 injection|Recombinant humanized anti-PD-1 monoclonal antibody of injection
45445241|NCT03712449|Other|SkinMedica|SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 6 to Month 11 (BELKYRA Treatment) and Month 0 to Month 5 (Non-BELKYRA Treatment).
45612162|NCT04615039|Device|PROFEMUR® Preserve Classic Femoral Stem|Single study group of subjects, either newly or previously implanted with the PROFEMUR® Preserve Classic Femoral Stem combined with any type of polyethylene and ceramic acetabular shells, acetabular liners and femoral heads.
45612163|NCT03403907|Other|Probiotic|twice a day for 4 months (Streptococcus thermophilus, Lactobacillus acidophilus, L.plantarum, L. paracasei, L. delbrueckii subs bulgaricus, Bifidobacterium breve, B.longus y B.infantis. y CD2).
45612164|NCT04300595|Procedure|Combination of General anesthesia and local anesthesia in dacryocystorhinostomy surgery|"all patients were assigned randomly to receive either general anesthesia with intravenous opioids and local infiltration of saline (Group G) or general anesthesia with intravenous saline and local infiltration of a mixture of lidocaine/epinephrine (Group L).~In both groups, general anesthesia was induced with 2 mg/kg propofol and tracheal intubation was facilitated by 0.1 mg/kg cisatracurium. All patients underwent mechanical ventilation with 100% oxygen. Anesthesia was maintained with isoflurane, and muscle relaxation was provided by an injection of cisatracurium 0.02 mg/kg every 20 minutes."
45612165|NCT04610593|Behavioral|Mindfulness-based Intervention|A mindfulness-based intervention will be developed for chronic hemodialysis patients to be performed during hemotherapy sessions. This is an integrative mind-body program, which is based on the MBRP (Bowen et al., 2014) and BMT (T. Russell, 2015) protocols. The program will be conducted in eight weeks, with a weekly individual session of up to 60 minutes facilitated by an instructor, at the bedside during the HD session. The program aims to develop awareness of bodily sensations, emotions and thoughts, with an attitude of openness, curiosity, kindness and non-judgment. During the sessions will be worked four main techniques of mindfulness meditation: mindfulness in breathing, body scanning, conscious movements and practice of compassion. Participants are invited and encouraged to practice Mindfulness using audios made available during the other HD sessions they undergo during the week, in addition to daily home practice.
45612166|NCT04608019|Other|Immediate Antibiotics|increase airway clearance/start oral antibiotics right away
45612167|NCT04608019|Other|Tailored Treatment|increase airway clearance and start oral antibiotics later if symptoms get worse or do not get better
45612168|NCT04647643|Drug|Paclitaxel|Paclitaxel to treat peripheral arterial disease
45612169|NCT05166941|Behavioral|creative drama|In the training program, a total of six games were played about the experiences of psychiatric patients. The program was designed to be two game per week for four weeks.
45612170|NCT04167761|Drug|Ertugliflozin|Consenting participants in the Ertugliflozen group will be supplied with 2-week course of medication prior to cardiac surgery. Participants will be educated on use and have blood glucose monitored during the medication course. The surgeon will then collect a small amount of fat near the heart during surgery.
45612171|NCT04167761|Drug|Glipizide|Consenting participants in the Glipizide group will be supplied with 2-week course of medication prior to cardiac surgery. Participants will be educated on use and have blood glucose monitored during the medication course. The surgeon will then collect a small amount of fat near the heart during surgery.
45758888|NCT01273831|Drug|atracurium|atracurium, Drop,0.5 mg/kg, one time, one day
45758889|NCT01273831|Drug|cisatracurium|cisatracurium, drop,0.15mg/kg,one time, one day
45758890|NCT00735839|Biological|V710|V710 vaccination (60 mcg, 0.5 ml) single injection on Day 1
45758891|NCT00735839|Biological|Placebo|Saline placebo (0.5 ml) single injection on Day 1
46068836|NCT05506124|Device|airbag-type stretchable electrode array (ASEA) device|Propose a novel airbag-type stretchable electrode array (ASEA) device for electrical stimulation for training of the female pelvic floor muscle (PFM) for the treatment of UI
45445242|NCT03517540|Drug|Tropifexor (LJN452)|Comparison with monotherapy and different combination doses
45445243|NCT03517540|Drug|Cenicriviroc (CVC)|Comparison with monotherapy and different combination doses
45612172|NCT04567381|Other|Enhanced Services|In enhanced services, the provision of services go beyond just referring a patient and leaving them to follow-through on their own accord. ES varies based on resources, model of service delivery, philosophy, and role and responsibilities of team members. Enhanced services usually includes longer-term case management which can then facilitate the connection to clinical counseling, victim assistance, familial assistance, legal assistance, emergency financial funding, transportation for subsequent appointments related to a patient's medical condition, employment assistance, and assistance in educational program enrollment.
45612173|NCT04567381|Other|Treatment as Usual|Individuals randomized to TAU will receive a list of resources which provides participants with community agency information that they can engage on their own. The list of resources will include contact information for various services such as housing, employment, mental health and legal services. Patients randomized into this condition receive little to no assistance from program staff and must navigate the vast terrain of social service providers on their own.
45445244|NCT03778359|Drug|Leuprorelin|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Leuprorelin.
45612174|NCT03401177|Drug|Naproxen 500 Mg|Naproxen is used as a tool to dampen the inflammation thought to be present in early phase Tendinopathy
45612175|NCT03401177|Drug|Placebo Oral Tablet|Placebo is used, to provide a control to the active group.
45612176|NCT03401177|Other|Heavy resistance training|Heavy slow resistance training - used in both groups subsequent to the initial week of NSAID or placebo treatment.
45758892|NCT03805711|Device|HLT® Transcatheter System|Transcatheter aortic valve replacement using The HLT® Transcatheter System (HLT System) in patients with symptomatic heart disease due to severe aortic stenosis who are judged by the Heart Team to be at Intermediate or High Risk for aortic valve replacement surgery (Heart Team agrees that the risk of 30-day mortality is ≥ 3%).
45445245|NCT03778359|Device|Levonorgestrel|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Levonorgestrel.
45758893|NCT00735917|Drug|saracatinib|Given PO
45758894|NCT00735917|Other|pharmacogenomic studies|Optional correlative studies
45758895|NCT00735917|Other|pharmacological study|Optional correlative studies
45758896|NCT00735917|Procedure|positron emission tomography|Optional correlative studies
45758897|NCT00735917|Radiation|fludeoxyglucose F 18|Optional correlative studies
45612177|NCT04152785|Behavioral|Information regarding GHG and/or nutrition|Participants will have to select a meal from a menu.
45612178|NCT04446715|Drug|sufentanil|Patients will receive sufentanil in spinal anesthesia
45612179|NCT04446715|Drug|meperidine|Patients will receive meperidine in spinal anesthesia
45612180|NCT04446715|Drug|Bupivacaine|Patients will receive 0.5% heavy bupivacaine in spinal anesthesia
45612181|NCT04079387|Device|ENDOTRACHEAL TUBE + STYLET|"The experimental group consists in intubating the trachea with an endotracheal tube + stylet with a straight-to-cuff shape and a bend angle of 25° to 35°"
45612182|NCT04079387|Device|ENDOTRACHEAL TUBE ALONE|intubating the trachea with an endotracheal tube alone
45612183|NCT04069247|Behavioral|ECBT-I|The eCBT-I will be delivered through a mobile application (eSleep) with a personal password.
45612184|NCT04069247|Behavioral|HE|The HE will be delivered in control though a mobile application (eSleep) with a personal password.
45758898|NCT00735917|Other|laboratory biomarker analysis|Optional correlative studies
45445246|NCT03778359|Drug|Dienogest|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Dienogest.
45612185|NCT03398473|Drug|Epoetin Hospira SDV|Epoetin Hospira Single Dose Vial
45612186|NCT03398473|Drug|Epoetin Hospira MDV|Epoetin Hospira Multi-Dose Vial
45612187|NCT04559035|Other|Nasal lavage|Twice daily nasal lavage.
45612188|NCT03395951|Drug|Diuretics|Observation of hemodynamics during diuretics treatment within clinical indication.
45612189|NCT04535791|Drug|Cholecalciferol|4,000 IU orally daily for 30 days
45612190|NCT03395873|Drug|Avelumab|"Decitabine 20mg/m2 IV day 1-5, every 28 days~Avelumab 10mg/kg IV, day 1, every 14 days"
45612191|NCT04529629|Other|surgery or drug|pheochromocytoma and adrenocortical carcinoma need surgery and primary aldosteronism need drug according to the genetic results
45612192|NCT03916835|Device|Pain evaluation ( FLACC scale) before and during the cleaning care with and without music therapy.|"Each child will benefit two cleaning cares during hospitalization. One with music therapy and the other without music therapy.~Every time, the preparation will be the same with an equipment installation in order to keep comparability and blind.~Child will be videotaped without sound during the care. The order of music therapy intervention will be randomized."
45612193|NCT04447625|Drug|Oral antibiotic administration|per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day for 14 days and metronidazole of 500mg twice a day for 14 days
45758899|NCT00779155|Device|The Resonator|active magnetic field therapy
45758900|NCT00779155|Device|The Resonator control|inactive magnetic field therapy with placebo fields
45758901|NCT00736073|Drug|aprepitant|one dose of aprepitant (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
45758902|NCT00736073|Drug|Placebo|one dose of placebo (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
45758903|NCT00736229|Drug|Exenatide|0.05 µg/min bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours
45758904|NCT00737243|Drug|Paclitaxel|175 mg/m2, 1-3 hour IV infusion Day 1
45758905|NCT00737243|Drug|Carboplatin|AUC 6.0 IV Day 1
45758906|NCT00737243|Drug|Bevacizumab|15 mg/kg IV infusion Day 1
45758907|NCT00737243|Drug|Erlotinib|150 mg PO
45758908|NCT00737243|Other|Treatment determined by physician|Patients Assigned a Specific Diagnosis by the Molecular profiling Assay will have physician's choice therapy
46068837|NCT05506124|Device|two-channel hard electrode device|Propose a two-channel hard electrode device for electrical stimulation for training of the female pelvic floor muscle (PFM) for the treatment of UI
45612194|NCT04447625|Drug|Intrauterine antibiotic infusion|intrauterine infusion of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml
45612195|NCT03392389|Biological|mRNA-1653|Escalating dose levels
45612196|NCT03392389|Other|Placebo|Saline
45612197|NCT03398317|Other|PICSI|sperm selection using PICSI dish for selecting sperm with lower DNA fragmentation index
45612198|NCT03398317|Other|MACS|sperm selection using MACS for selecting sperm with lower DNA fragmentation index
45612199|NCT03398239|Device|Noninvasive mechanical ventilation|
45612200|NCT03126175|Device|Below elbow immobilization|20cm wide gypsum in the forearm cut to fit the thumb.
45612201|NCT03126175|Device|Above elbow immobilization|20cm wide gypsum in the forearm cut to fit the thumb associated a elbow splint made with a 15cm width on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
45612202|NCT03396523|Drug|Losartan|administration of losartan (50 mg) (oral)
45612203|NCT03396523|Drug|Placebo Oral Tablet|administration of placebo (oral)
45612204|NCT03126097|Drug|JNJ-64155806 150 mg|JNJ-64155806 150 mg (3*50 mg tablet) twice daily will be administered under fed conditions on Days 1 to 7 [JNJ-64155806 Alone Phase] and on Days 60 to 66 [JNJ-64155806 + COCP Coadministration Phase].
45612205|NCT03126097|Drug|Ethinylestradiol/drospirenone 0.02 mg/3 mg|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol administered as combined oral contraceptive pill (COCP) given on Days 18 to 41 (lead-in phase), Days 46 to 69 (coadministration phase - Days 59 to 66 under fed conditions).
45612206|NCT03126097|Drug|COCP Placebo|Participant will receive COCP placebo tablets once daily on Days 42 to 45 (lead-in phase) and Days 70 to 73 (JNJ-64155806 + COCP coadministration phase).
45612207|NCT03398083|Drug|THC|THC capsule
45612208|NCT03398083|Drug|Alprazolam|Alpraxolam capsule
45612209|NCT03398083|Drug|Placebo oral capsule|Sugar pill capsule
45612210|NCT03398083|Drug|CBD|CBD capsule
45758909|NCT00707759|Drug|Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + Withdrawal Prednisone|"Arms A: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + withdrawal steroids over a six-days following randomization.~1°day: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~2ºday: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~3°day: Prednisone 2 mg/kg/d in 2 doses~4ºday: Prednisone 1 mg/kg/d in 2 doses~5ºday: Prednisone 0.5 mg/kg/d in 2 doses~6ºday: Prednisone 0.25 mg/kg/d in 2 doses~7ºday: Stop Prednisone"
46068838|NCT05494788|Drug|CardiolRx|Pharmaceutically produced Cannabidiol
45612211|NCT03392311|Drug|Calcipotriol ointment|The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
45758910|NCT00707759|Drug|Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone|"Arms B: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone (see schedule)/day~10°days after Tx: 2 mg/kg/d~Day 11 - 20: 1 mg/kg/d~Day 21 - 30: 0.5 mg/kg/d~Day 31 - 60: 0.3 mg/k/d~Week 8 - 12: 0.25 mg/k/d~Week 12 - 16: 0.20 mg/k/d~Week 16 - 20: 0.15 mg/k/d~Month 6 - 12: 0.10 - 0.12 mg/k/d"
45758911|NCT01273727|Drug|Dexamethasone|intravitreal implant 0.7 mg 6 month duration
46068839|NCT05494632|Device|Treatment-modifications to CI speech processor program|We will modify the CI speech processor program to reduce interaural loudness and pitch mismatches.
46068840|NCT05485519|Drug|Dexmedetomidine|Infusion start at 0.5 mcg/kg/hour. Titrate to effect (up to1.5 mcg/kg/hour)
46068841|NCT05485519|Drug|Midazolam|(1 mcg/kg/minute. up to a maximum of 5 mcg/kg/minute.
45612212|NCT03392311|Biological|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg.
45612213|NCT03398005|Drug|CaPre|4 x 1 g capsules administered orally once a day for 26 weeks
45612214|NCT03398005|Drug|Placebo|4 x 1 g capsules administered orally once a day for 26 weeks
45612215|NCT03397927|Device|orthosis|
45612216|NCT03392233|Radiation|Stereotactic Body Radiation Therapy|Eligible patients will receive Stereotactic body radiation therapy (SBRT) for spinal metastatic lesion in 24Gy/3f(cervical vertebra) or 30Gy/3f (thoracic vertebra/lumbar vertebra) every other day and receive relevant system treatment at same time
45612217|NCT03126721|Drug|midazolam|a single oral dose of 2 mg midazolam
45612218|NCT03126721|Drug|PF-06751979|multiple oral doses of PF-06751979 100 mg a day
45612219|NCT03392155|Behavioral|Training & Nutrition|Exercise at moderate to high intensities and diet education/counseling
45612220|NCT04928521|Procedure|bilateral erector spinae plane block with 30 mL 0.25 % bupivacaine|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 30 mL 0.25 % bupivacaine
45612221|NCT04928521|Procedure|bilateral erector spinae plane block with 20 mL 0.25 % bupivacaine|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 20 mL 0.25 % bupivacaine
45612222|NCT03126565|Other|Lifeline CareSage Flagging|Patients in the intervention group will receive active monitoring by the CareSage risk assessment platform and clinical interface, including nurse triage calls and tailored PHH interventions. Beginning at month 4, the CareSage algorithm will assess patients' risk for emergency transport every 30 days. Patients identified as high risk will receive nurse triage calls and, depending on their needs, tailored care according to a stepped-care approach. The principal goals will be to reinforce the patients' education, ensure compliance with medications and diet, and identify recurrent symptoms amenable to treatment on an outpatient basis to avoid readmissions
45612223|NCT03392077|Procedure|Caesarean section|Caesarean section will be done to deliver the baby
45612224|NCT03392077|Other|cervical dilatation|Cervical dilatation will be done by double gloves digital dilatation postpartum
45612225|NCT03392077|Other|No cervical dilatation|after delivery of the baby cervix will be remain closed
45612226|NCT02823847|Behavioral|Screening Interview|Participants asked about demographic information, and questions about history of tobacco, alcohol, and mouthwash use. Interview lasts about 7 minutes.
45612227|NCT02823847|Device|Carbon Monoxide Test|Carbon monoxide testing given to participants at baseline. Participants blow into a device that measures the amount of carbon monoxide in the lungs.
45612228|NCT02823847|Behavioral|Self-Help Materials|"Participants who want to stop smoking are given referral information for a tobacco cessation program at baseline.~Participants with premalignant and malignant oral lesions [PMOL]) given printed materials and web-based programs for tobacco and alcohol cessation."
45612229|NCT02823847|Procedure|Visual Oral Screening Examination|Intraoral exam performed under incandescent (white light) conditions at baseline, and again two weeks later.
45612230|NCT02823847|Procedure|Direct Fluorescent Oral Visualization Examination|Intraoral exam performed under reduced room lighting with a handheld autofluorescence imaging device at baseline, and again two weeks later.
45612231|NCT02823847|Procedure|Oral Biopsy|Premalignant and malignant oral lesions [PMOL]) still present 2 weeks after oral exam are biopsied.
45612232|NCT03396289|Other|Conventional physiotherapy including balance exercises|Programme will include balance exercises with balance board and swiss ball, weight shifting exercises on board, one-legged balance, balance on unstable surface, balance on tilting surface and balance with Biodex Balance System. Biodex Balance System Biodex will only be used during sessions under physiotherapist supervision.
45612233|NCT03396289|Other|Inspiratory muscle training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
45612234|NCT03391999|Other|A questionnaire; CHU9D|Measuring Health Related Quality of Life
45612235|NCT03396133|Diagnostic Test|Snap|screen, transmission, and analysis ECG automated
45612236|NCT03389815|Drug|WX-0593 Tablets|tablets, dosage ranged from 30 mg to 300 mg, quaque die（QD）
45612237|NCT03887117|Other|IQOS + Exercise Training Program|Switch to IQOS use + participation in a training program
45612238|NCT03887117|Other|IQOS without Exercise Training Program|Switch to IQOS use only, without participation in a training program
45612239|NCT03887117|Other|Cigarette Smoking + Exercise Training Program|Continue to smoke cigarettes + participation in a training program
45612240|NCT03887117|Other|Smoking Abstinence + Exercise Training Program|Switch to smoking abstinence + participation in a training program
45612241|NCT03389737|Behavioral|Counseling|Counseling on healthy behaviors with in person meetings.
45612242|NCT03389737|Behavioral|Counseling|Counseling on healthy behaviors with emails.
45612243|NCT03391843|Drug|FOLFOXIRI+Cetuximab regimen|FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h +Cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle
45612244|NCT03389659|Drug|vitamin D3|vitamin D3 400IU*5pills po. qd continue to disease progression
45612245|NCT03389659|Drug|Placebo|placebo 5 pills po. qd continue to disease progression
45612246|NCT02819791|Other|Optimized conventional therapy alone|Patients will benefit from a traditional follow-up as provided for this type of patients at 3 months and 1 year
45612247|NCT02819791|Behavioral|Optimized conventional therapy with therapeutic education|"The objectives of this therapeutic education program involve:~learning objectives and acquisition of knowledge and self-care skills making the patient more autonomous and facilitating its adherence.~the objectives of acquiring coping skills ( self-confidence , stress management , setting projects ) to improve their quality of life .~the development objectives respects the relevant criteria of quality , realism and principle of educational progress."
45612248|NCT04447495|Diagnostic Test|iAMP test|The low-cost Atila BioSystems iAMP® COVID-19 Detection kit consists of a reaction buffer mix, primer mix, three sample buffer components, a positive and negative control, nasopharyngeal swabs, and sample collection vials. Each kit is suitable for 100 tests.
45612249|NCT03395561|Dietary Supplement|green coffee|2 capsuls
45612250|NCT03395561|Other|control|2 capsuls
45612251|NCT04244773|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
45758912|NCT01273727|Drug|dexamethasone|intravitreal implant 0.7 mg duration 6 months
45758913|NCT00707915|Drug|Drug: Benzodiazepine (listed out below)|"The benzodiazepine (BZD) dose will be discontinued in 4 weeks by a weekly 25% reduction. BZD-derivative hypnotics will include brotizolam, flunitrazepam, etizolam, quazepam, estazolam, nitrazepam, flurazepam, and diazepam.~All psychotropic agents other than the BZD-derivative hypnotics will be kept constant throughout the study. In addition, the use of trazodone (25-100 mg/day) will be allowed anytime throughout the study period. Subjects will be observed for 8 weeks."
45612252|NCT04244773|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
45612253|NCT03399695|Procedure|preoxygenation|spontaneous breathing
45612254|NCT03395483|Other|Haemodynamic monitoring|see Group description
45612255|NCT04414189|Diagnostic Test|HostDx Sepsis|Blood collection for mRNA analysis
45612256|NCT03395327|Other|quality of life questionnaire|QLQ-C30 and BR23 (Quality of Life Questionnaire and Breast 23) Questionnaire FSFI (Female Sexual Function Index)
45612257|NCT04388293|Other|Exposure of interest|Very Low Birth Weight infants admitted to tertiary NICUs in Canada.
45612258|NCT03399461|Other|Patient Interview guide|The interviewer will conduct the interview for subjects with WAS using a semi-structured patient interview guide.
45758914|NCT02994407|Drug|turoctocog alfa pegol|"Part A: Participants will receive a single dose of turoctocog alfa pegol, administered subcutaneously (under the skin), at a dose of 12.5, 25 or 50 U/kg.~Part B: Participants will receive a daily dose of turoctocog alfa pegol, as identified in Part A, as a subcutaneous (under the skin) injection for a period of 3 months."
45758915|NCT00708071|Biological|Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)|Each subject received fibrin sealant with 4 IU/mL thrombin, vapor heated, solvent detergent treated containing synthetic aprotinin (FS VH S/D 4 ) to one side of the face. The dosing volume to be applied is 0.02 mL/cm2 to 0.04 mL/cm2. The study product will be applied to the subcutaneous plane in both the neck and the face area. The product will be applied using the spray device provided by the sponsor. (The other side of the face will be treated using standard of care.)
45612259|NCT03399461|Other|Caregiver interview guide|The interviewer will conduct the interview for caregivers of subjects with WAS using a semi-structured caregiver interview guide.
45612260|NCT03399461|Other|Sociodemographic questionnaire|At the end of interview, subjects will be required to complete subject or caregiver versions of country-specific sociodemographic questionnaire.
45612261|NCT03399461|Other|Pediatric quality of life (PedsQL) questionnaire|The PedsQL is a validated generic measure of health-related quality of life (HRQOL) in children, adolescents, and young adults with acute and chronic health conditions. At the end of interview, subjects will be required to complete subject or caregiver versions of PedsQL questionnaire.
45612262|NCT03399461|Other|Clinical questionnaire|At the end of interview, subjects will be required to complete subject or caregiver versions of clinical questionnaire.
45612263|NCT03389581|Behavioral|awareness and anxiety|before operation awareness and anxiety will recorded with STAIX-I score
45612264|NCT04446637|Drug|Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI|Ipratropium/Levosalbutamol 20 mcg/50 mcg Aerosol Inhalation, Suspension 2 inhalations in the morning (single day)
45612265|NCT04446637|Drug|Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI|Salbutamol 100 mcg Inhaler, 2 inhalations + Ipratropium 20 mcg Inhalation Aerosol,2 inhalations in the morning (single day).
45612266|NCT02520401|Other|Probiotic - BioGaia|Use of a probiotic tablet
45612267|NCT02520401|Other|Placebo|Use of a placebo tablet
45612268|NCT03389503|Procedure|Radial approach|Approach site for coronary angiography and coronary intervention
45612269|NCT02520323|Other|Blood draw|
45612270|NCT02520323|Procedure|Bronchoscopy|
45612271|NCT02520323|Behavioral|Questionnaires|
45612272|NCT03389425|Behavioral|simplified intervention to modify physical activity, lifestyle, and eating behavior|16 week, behavioural weightloss intervention.
45612273|NCT03395249|Drug|SPR994|"SAD: Double-blind dosing will occur in all SAD Cohorts except for Cohort 12. In each cohort, six subjects will receive one of five different timed release formulations of SPR994 and 2 subjects will receive placebo. Subjects in SAD Cohorts 2, 3, 6, 16 and 17 will receive a single dose following a 10-h fast. Subjects in SAD Cohorts 1, 8-15 will receive one dose of SPR994 or placebo following a 10-h fast on Day 1 and a second dose following consumption of a standardized meal on Day 7. The dose escalation steps may be altered following review of the safety data of each cohort.~MAD: Double-blind dosing will occur in all MAD Cohorts. Subjects will receive multiple doses of an optimal timed release formulation of SPR994 in MAD Cohort 4 (300 mg) and Cohort 5 (600 mg) or placebo for 14 consecutive days at either BID or TID dosing beginning on Day 1."
45758916|NCT02994641|Procedure|COMA Score Assessment|
45612274|NCT03395249|Drug|Placebo Oral Tablet|Mannitol 200SD SAD: Two subjects in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
45612275|NCT03395249|Drug|Orapenem®|Tebipenem pivoxil granules
45612276|NCT03396055|Other|specific rehabilitation exercise|specific rehabilitation exercise for patients with cervical myelopathy
45612277|NCT03395171|Dietary Supplement|Cholecalciferol (Vitamin D3)|Supplementation of subjects who meet the inclusion criteria and test to have below the threshold of vitamin D in their blood.
45612278|NCT03395977|Drug|Placebos|Lactose placebo for pills and saline for perfusion.
45612279|NCT03395977|Drug|Febuxostat|Febuxostat tablet.
45612280|NCT03395977|Drug|Rasburicase|Rasburicase injectable solution.
45612281|NCT03126487|Procedure|HIGH INTENSITY FOCUSED ULTRASOUND|HIGH INTENSITY FOCUSED ULTRASOUND GUIDED BY MRI AS THERMIC DESTRUCTION
45612282|NCT03821519|Biological|donor-derived CIK cells|Treatment plan will be based on three infusions of donor derived CIK cells given by 3 weeks intervals at increasing dose levels. No dose changes are allowed and the following planned dose levels will be administered to each patient enrolled: 5x106, 5x106 and 10x106 cells/Kg according to the dose escalating program
45612283|NCT03125551|Dietary Supplement|Ginger|Ginger dosage at daily recommended allowance
45612284|NCT03125551|Dietary Supplement|Garlic|Garlic dosage at daily recommended allowance
45612285|NCT03125551|Dietary Supplement|Ginkgo Biloba|Ginkgo Biloba dosage at daily recommended allowance
45612286|NCT03125551|Dietary Supplement|Ginseng|Ginseng dosage at daily recommended allowance
45612287|NCT03125551|Other|Placebo|Daily dosage strategy
45612288|NCT03391687|Diagnostic Test|Amylase Test|body fluid amylase will be tested after radical gastrectomy in scheduled interval
45612289|NCT03399383|Other|Patient education|Participation in the standardized education program (90min patient education). During sessions of 90-120 minutes duration, patients are educated in basic knowledge on adrenal insufficiency including the correct behaviour in emergency settings. Participants are provided with emergency cards and sets and are trained in self-injection of glucocorticoids.
45612290|NCT05239325|Behavioral|World Cancer Day Walk|Health literacy education (cancer prevention and healthy lifestyle) and free breast, prostate, cervical cancer screening
45758917|NCT02994485|Drug|Simvastatin|Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks plus the routine treatment
45758918|NCT02994173|Drug|Oxycodone|Current clinical practice, used as a control in this study
45758919|NCT02994173|Drug|S-Ketamine 0.25|dosage
45758920|NCT02994173|Drug|S-Ketamine 0.5|dosage
45758921|NCT02994173|Drug|S-Ketamine 0.75|dosage
45758922|NCT01273961|Device|AuraLevée treatment|A single treatment, on day 0, on each of no more than two treatment sites, using the AuraLevée device. Treatment sites are the face, abdomen, upper arm, thigh or neck.
45758923|NCT00723749|Drug|Buprenorphine/Naloxone|"Sublingual combination tablet containing buprenorphine and naloxone at a ration of 4:1, respectively. It is available in two tablet strengths: 2 mg buprenorphine & 0.5 mg naloxone and 8 mg buprenorphine & 2 mg naloxone.~The only effective and safe use is sublingual administration. SUBOXONE® use will occur on the basis of SPC and is solely aimed at medical-therapeutic necessity."
45758924|NCT00723827|Drug|Temozolomide|Administration of temozolomide based on the product labeling.
45758925|NCT00723827|Radiation|Radiotherapy|Radiotherapy given concomitantly with temozolomide for newly diagnosed glioblastoma multiforme.
45612291|NCT02678143|Drug|Alemtuzumab|
45612292|NCT02678143|Drug|Cyclophosphamide|
45758926|NCT02995343|Procedure|Hypogastric and/or uterine artery ligation|
45758927|NCT02993861|Other|Anti-epileptics|
45758928|NCT00779311|Drug|sorafenib|Sorafenib will be administered daily starting day 1 at 200mg QOD at Dose Level 1; 200mg/day at Dose Level 2; 200mg BID (5 days on/ 2 days off) at Dose Level 3; 200mg BID at Dose Level 4; and 400mg BID at Dose Level 5.
45758929|NCT00779311|Drug|bevacizumab|Bevacizumab will be administered as 5mg/kg IV on Day 1 of each treatment cycle.
46068842|NCT05501236|Device|Grass S88 Muscle Stimulator|The Grass S88 nerve and muscle stimulator is a widely-used tool in electromyography and nerve conduction studies. During the DISE and second sleep study, fine-wire electrodes will be placed into the hypoglossal nerve or genioglossus muscle. Two more electrodes are placed transcutaneously, proximate to the bilateral branches of the cervicalis innervating the sternothyroid muscle in the anterior neck.
46068843|NCT05471414|Behavioral|Whole-food, Plant-Based Diet|Pre-packaged, plant-based meals (prepared by Plantable) will be delivered weekly to participants' homes for 8 weeks. Meals are made with whole ingredients including whole grains, vegetables, legumes, nuts and seeds. Added sugar, animal-based products, refined grains, and processed foods are not used in any meal. Participants will be coached via phone calls, SMS, emails, and the app throughout the intervention to prepare meals in accordance with the diet. Participants will have access to a Registered Dietitian. During the first 4 weeks, 12 meals/week will be provided to participants; followed by 6 meals/week for the next 4 weeks; followed by 18 weeks where participants will continue to receive coaching, but will be expected to make all their own whole-food, plant-based meals using Plantable's assistance.
45612293|NCT02678143|Drug|Mycophenolate mofetil|
45612294|NCT02678143|Drug|Sirolimus|
45612295|NCT02678143|Drug|Fludarabine|
45612296|NCT02678143|Radiation|Total body irradiation|
45612297|NCT02678143|Procedure|Hematopoietic stem cell transplant|
45612298|NCT03389269|Other|Meal test|240 min mixed meal test with aspiration using AspireAssist.
45612299|NCT03395093|Drug|Fentanyl|Five minutes before the patients is done the flexible bronchoscopy, fentanyl will be intravenous injected.
45612300|NCT03395093|Drug|Midazolam|Five minutes before the patients is done the flexible bronchoscopy, midazolam will be intravenous injected.
45612301|NCT03395093|Drug|Propofol|Propofol will be intravenous injected as soon as the flexible bronchoscopy begins.
45612302|NCT03395093|Device|Bispectral Index monitoring|Bispectral Index monitoring will be used in the process of the flexible bronchoscopy.
45612303|NCT03389191|Drug|Acyclovir|
45612304|NCT05100797|Device|Vyntus CPX|To study the validity, precision and accuracy of the Vyntus CPX metabolic cart using both, in-vitro and in-vivo (i.e., human study) measures.
45612305|NCT04330183|Drug|Ketamine|0.3mg/kg of ketamine
45612306|NCT04330183|Drug|Normal Saline|3cc of normal saline
45612307|NCT05097053|Biological|MVC-COV1901(3 Months)|MVC-COV1901 vaccine after a 3-month Interval
45612308|NCT05097053|Biological|MVC-COV1901(6 Months)|MVC-COV1901 vaccine after a 6-month Interval
45445247|NCT03778359|Drug|Progestins|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Progestins.
45445248|NCT03560908|Drug|Dasatinib|Dasatinib 70mg twice a day will be administered orally for 2 weeks along with re-induction chemotherapy from day 1 of chemotherapy. Recommended re-induction regimens include (1)FLAG: Fludarabine 30mg/m2/d,d1-5;cytarabine 1g-2g/m2/d,d1-5;±G-CSF;(2)IA/DA:idarubicin 8-12mg/m2/d,d1-3 or daunorubicin 45-60mg/m2/d，d1-3;cytarabine 100-200mg/m2/d，d1-7;(3)CAG:Aclarubicin 20mg/d,d1-4；cytarabine 15mg/m2/Q12h,d1-14; ±G-CSF.The chemotherapy regimen is not limited to recommended regimens. Patients will be recommended to receive allogeneic hematopoietic stem cell transplantation (HSCT) once complete remission is achieved. Otherwise, they will continue the consolidation chemotherapy.
45612309|NCT04323475|Biological|Bacteriophage cocktail spray|Study intervention consists of a dosage-metered airless spray containing a cocktail of 14 bacteriophages at a concentration of 1.4 x 10^8 PFU/mL for an effective dosage of 2.5 x10^5 PFU/cm^2 of burned area. The study intervention will be applied in conjunction with standard of care.
45758930|NCT00779311|Drug|mFOLFOX6 regimen|The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days continuous infusion.
45758931|NCT01274039|Drug|Acetazolamide for glaucoma patients to lower eye pressure|Acetazolamide tablets 3 times daily for 3 to 4 weeks
45612310|NCT04323475|Drug|Xeroform|Standard of care will consist of Xeroform primary dressing and Kenacomb topical antibiotic cream (for wounds with signs of localized infection)
45445249|NCT02038426|Biological|BLOOD SAMPLES|
45445250|NCT02038426|Device|Radiographs of the sacroiliac joints|
45612311|NCT03398993|Drug|Clomiphene Citrate|50 mg twice daily from3rd day of cycle till 7th day of cycle
45612312|NCT03398993|Drug|Human chorionic gonadotropin|75 IU dail;y from 6th day of cycle till 8th of cycle once daily
45612313|NCT03398993|Device|Endometrial scratch|"The procedure was carried out in preovulatory day (known when dominant follicle reached 18_20 mm in diameter), usually, done around day 14-day of the cycle.~In the theatre, Patients put in a lithotomy position, sterilization was performed with the presence of good source of light., the procedure was carried out using a thin pipelle tube as follow :- A cuscoe's speculum was inserted into the vagina in order to visualize the cervix.~Cervix was grasped by vollselum upwards backwards, then pipelle tube passed through the cervix and uterine cavity, then moved up and down to make a single induced scratch two times in the lining endometrium of posterior wall of uterus.~The procedure took approximately 15minutes to complete"
45612314|NCT03395015|Other|VAS scale (from 1 to 10) esthetic assessment of facial 3-D images|The rating process is biphasic: firstly a 3-D model is showed to the raters, who can orientate the vultus, familiarize with the 3-D technology and have a first glance evaluation. Secondly, the judges are asked to rate each of the following patient views: right profile, left profile, frontal, neck hyperextension and hyperflexion views Two weeks after the first assessment, the same judges assessed the same number of pictures, once again in random order.
45445251|NCT02038426|Device|Radiographs of heels|
45758932|NCT03802201|Drug|PTG-300|Subcutaneous (SC)
45758933|NCT01274117|Procedure|Transposition of the basilic vein and anastomosis with the brachial vein|One-stage vs two-stage transposition of the basilic vein
45758934|NCT00725153|Device|Balafilcon A contact lenses (PureVision)|Commercially marketed, soft contact lenses worn bilaterally for 10 hours
45758935|NCT00725153|Device|Etafilcon A contact lenses (Acuvue2)|Commercially marketed, soft contact lenses worn bilaterally for 10 hours
45758936|NCT03807349|Device|N-Force Screws Augmented with N-Force Blue|N-Force Fixation System 7.3 mm (Non-fenestrated/fenestrated) applied with washers; N-Force Blue (Bone Substitute Material)
45758937|NCT04387019|Diagnostic Test|blood sampling|blood sampling from peripheral vein
45758938|NCT01274195|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
45758939|NCT00779701|Drug|Insulin|Insulin infusion titrated to patients blood glucose to maintain blood glucose between 80-110mg/dL
45758940|NCT04345055|Other|Treatment of the lumbar fasciae|Treat the lumbar facial with a manual technique
45758941|NCT04345055|Other|Placebo intervention|Introduce in a machine off
45758942|NCT01279031|Device|Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound|Comparison of vision after cataract surgery based on two different types of equipment.
45758943|NCT01279031|Device|Alcon Infiniti wiht the OZIL Torsional Handpiece|Comparision of vision after cataract surgery based on two different types of equipment.
45445252|NCT02038426|Device|SCAN|
45445253|NCT02057770|Drug|busulfan|
45758944|NCT03802825|Behavioral|Diabetes Self-Management Training|The Decision-making Education for Choices in Diabetes Everyday (DECIDE) program is a nine-module, literacy adapted diabetes and cardiovascular disease education and problem-solving training program. Participants are taught the five steps of problem solving with each module going in depth on a single step: 1) identify the problem; 2) brainstorm possible strategies for problem resolution; 3) select the most appropriate strategy; 4) apply the strategy; 5) evaluate the effectiveness of the strategy. During the six months, CHWs will have weekly or bi-weekly contact with participants in-person or by phone to deliver the DECIDE modules and address social and economic needs.
45445254|NCT02057770|Drug|fludarabine phosphate|
45445255|NCT02057770|Radiation|total-body irradiation (TBI)|
45445256|NCT02057770|Procedure|Stem cell transplant|
45445257|NCT02057770|Drug|cyclophosphamide|
45445258|NCT02057770|Drug|tocilizumab|
45445259|NCT05615025|Drug|Sevoflurane|Anesthesia will be maintained by sevoflurane.
45612315|NCT04249297|Drug|Duphaston® (Dydrogesteron)|No intervention. Description of routine practice only. Prescribed Duphaston® according local marketing authorization and international and Russian In-Vitro Fertilization guidelines for luteal phase support as part of an Assisted Reproductive Technology (1 tablet 3 times a day starting at the day of oocyte retrieval).
45612316|NCT05063825|Behavioral|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
45612317|NCT05063825|Behavioral|Attention placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
45612318|NCT05063123|Drug|Flotetuzumab|Flotetuzumab will be given after at least 2 intensive chemotherapy cycles and before the start of the conditioning regimen prior to allo-HCT.
45612319|NCT03391609|Drug|placebo infusion|Caesarian section will be performed under standard general anesthesia plus pre and intra operative saline infusion (placebo) in the same rate as dexmedetomedine starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
45612320|NCT03391609|Drug|Dexmedetomidine infusion|Caesarian section will be performed under standard general anesthesia plus pre and intra operative Dexmedetomidine infusion in a dose of 0.5mic/kg/hour starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
45612321|NCT05238077|Procedure|Visible Light-Ultraviolet A Light or Narrowband-Ultraviolet B phototherapy|Patients will have different kinds of light shined on different areas
45612322|NCT03391531|Procedure|Bilateral subcostal TAP block|Echo-guided infiltration of a local anesthetic solution in the plane located between the transversus abdominis muscle and the rectus abdominis muscle
45612323|NCT03394937|Biological|ECI-006|ECI-006 consists of TriMix and 5 tumor associated antigens mRNA. TriMix is a mixture of mRNAs that encodes potent immune stimulating molecules
45612324|NCT04177381|Procedure|Cesarean section|"Abdominal Incision: Pfannenstiel incision Sharp dissection will be continued through the subcutaneous layer to the fascia.~The fascia will be then incised sharply at the midline~The transversalis fascia and pre peritoneal fat will be dissected carefully~The peritoneum will be then incised.~Low Transverse Cesarean Incision. Bladder flap creation effectively moves the bladder away from the planned hysterotomy site~Delivery of the Fetus and placenta.~Uterine Repair in two layers of continuous 0-or No.1 absorbable suture."
45612325|NCT04177381|Procedure|subcutanous sutures|suture closure of subcutaneous tissue with interrupted 2-0 polyglactin 910 (Vicryl).the stitch interval is 1cm
45612326|NCT04177381|Device|subcutanous drain|Inthedraingroup,aclosednonvacuum drain willbeinsertedin thetissueandexitefrom theskinthroughaseparateopeningandstitchto theskin
45612327|NCT03126305|Other|OC-Go|OC-Go, a HIPAA-compliant web-based clinician portal and patient-side mobile application that allows clinicians to create and push tailored treatment assignments to patients on their mobile devices
45612328|NCT03391375|Biological|DNA-HIV-PT123 & AIDSVAX B/E|DNA-HIV-PT123 encodes clade C ZM96 Gag and gp140, CN54 Pol-Nef; AIDSVAX®B/E is a subtype B (MN) and subtype E (A244) HIV gp120 glycoprotein adsorbed onto aluminium hydroxide gel adjuvant
45612329|NCT03398915|Procedure|Transpedicular Instrumentation|Transpedicular screw placement and instrumentation
45612330|NCT03391297|Behavioral|Prolonged Exposure Therapy|PE consists of 10-15 treatment sessions. Treatment includes psychoeducation, in vivo exposure (i.e., confronting trauma-related situations and objects that are being avoided), imaginal exposure (i.e., revisiting and recounting traumatic memory) followed by processing (discussing the experience of revisiting the trauma memory, with a focus on new learning and changed beliefs or perspectives).
45612331|NCT04042285|Device|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy will be given at 120 pulses/cm2, penetration 5mm at a dose of 0.1mJ/mm2 at 5 pulses/second. Participants will receive 3 sessions of shockwave therapy in a 7-day period.
45612332|NCT04042285|Other|Standard Wound Care|dressing changes, negative pressure wound therapy, offloading footwear, debridement, glycaemic control and antibiotics as necessary
45612333|NCT03398837|Drug|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily.
45445260|NCT05615025|Drug|Propofol|Anesthesia will be maintained by propofol.
45758945|NCT03802825|Other|Standard Patient Navigation|Once the participant has completed the YCLS assessment with study staff, the navigator will receive the referral and follow-up with the participant to address the social and economic needs identified. The patient navigator will follow-up with the participant 2-3 times over the 6 months by phone or in-person about progress with the referral and help address additional needs that may develop during the 6-month intervention.
45758946|NCT00738023|Drug|Rosiglitazone|Diabetic subjects will be receive rosiglitazone for 6 weeks
45758947|NCT00738023|Drug|Normal saline 0.9%|Normal saline 0.9% intravenous infusion at 40ml/hr for 48 hours
45758948|NCT00738023|Drug|Intralipid 20%|Intralipid 20% at 40ml/hr intravenously for 48 hours
45758949|NCT03808909|Other|Continuous Labor Support|Participants in the intervention condition will be assigned a doula who is a lay person trained to provide emotional and practical support to individuals throughout labor and delivery.
45758950|NCT04385849|Biological|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
45758951|NCT04385849|Other|Saline|Sterile saline solution
45758952|NCT00708851|Other|LCD Solution with NB-UVB Phototherapy|"LCD Solution: 2 applications / day~NB-UVB Phototherapy: 3 light sessions / week"
45758953|NCT00708851|Device|NB-UVB Light Device (311-315 nm)|NB-UVB Phototherapy: 3 light exposures / week
45758954|NCT03809221|Drug|Triptorelin acetate|Achieve pituitary down regulation with triptorelin acetate and start controlled ovarian stimulation after complete pituitary down regulation
45758955|NCT02993627|Dietary Supplement|Spirulina|2 g(4* 500 mg tablets) daily intake of Spirulina Platensis
45445261|NCT02057848|Other|low amount of carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
45612334|NCT03398837|Drug|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily.
45612335|NCT03398837|Other|Placebo oral capsule|Subjects will receive placebo twice daily.
45612336|NCT04038385|Behavioral|Multilevel Behavioral Intervention|Behaviorally-focused intervention grounded in the Social Ecological Model and Social Cognitive Theory to promote vegetable intake and the redemption of seasonal Farmers' Market Nutrition Program vouchers and monthly Cash Value Vouchers at farmers' markets.
45612337|NCT05237921|Behavioral|Combined Exercise and Dietary Intervention (CEDI)|"Intervention aimed at conveying a supervised combined moderate aerobic and resistance training, once a week with a duration of 40-60 minutes plus daily home exercise, personalized according to patients' age and functional status.~Dietary intervention aimed at a one-on-one nutritional counseling. In the first visit a dietary plan is designed and one daily oral nutritional supplement (Forticare®, Nutricia) is given to meet the European Society of Parenteral and Enteral Nutrition (ESPEN) recommended intake."
45612338|NCT05237921|Behavioral|Standard Care|Standard Care
45612339|NCT03398759|Drug|Butorphanol|IV injection during induction
45612340|NCT03398759|Drug|Placebos|IV injection during induction
45612341|NCT03391219|Drug|injection bevacizumab|1.25 mg/0.05 cc bevacizumab
45612342|NCT03391219|Drug|injection Combined Bevacizumab and Fasudil|1.25 mg/0.05 cc bevacizumab and 0.15mg/0.05 cc fasudil
45612343|NCT04446923|Drug|Hand antisepsis by scrub|Surgical Hand scrubbing using P-1 of both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side.
45612344|NCT04446923|Drug|Hand antisepsis by scrub|Surgical Hand rubbing using P-1 of both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side.
45612345|NCT04447001|Behavioral|Tai-chi prime (TCP)|TCP is a 6-week twice-weekly simplified tai chi class of 1.5 hr per session with two components: (a) Tai-chi fundamental Adapted Program, and (b) home practice coaching.
45445262|NCT02057848|Other|high amount of carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
45612346|NCT03953053|Device|Femtosecond Laser Assissted Cataract Surgery|During routine Catarct Surgery the Femtolaser cuts a ACCC (Anterior Continous Curvilinear Capsulotomy) into the lensbag and fragmentise the cataract affilited lens body
45612347|NCT05237843|Drug|Hydroxychloroquine|Besides anti-thrombotic effects, hydroxychloroquine have immunoregulatory properties and can block the production of pro-inflammatory cytokines ( Mekinian A et al ,2015 ) , Few in vitro studies showed a potential benefit of hydroxychloroquine in early trophoblastic migration and implantation. Hydroxychloroquine restored trophoblastic fusion and differentiation and restored the annexin A5 expression.( Guller S et al ,2011 )
45612348|NCT03389113|Device|Whole body vibration|Whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.
45612349|NCT03389113|Other|Exersice|Exercise maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees.
45612350|NCT03391063|Other|polyamide|metal reinforced polyamide denture base material
45612351|NCT03391063|Other|heat cured acrylic resin|conventional heat cured acrylic resin denture base material
45612352|NCT03394625|Procedure|Socket shield technique|Socket shield technique is a recent technique which is by sectioning the root and extraction of palatal part and leaving buccal part of the root with its attachment of periodontal ligament and vascularization still intact then placing implant in palatal socket.
45612353|NCT03394625|Procedure|using Xenograft material|placing xenograft material in gap between the implant and the buccal plate of bone
45612354|NCT04447105|Drug|total intravenous anesthesia with propofol|In the TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using infusion pump (Orchestra®; Fresenius Vial, Brezins, France). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
45612355|NCT04447105|Drug|inhalation anesthesia with desflurane|In the desflurane group, anesthesia is induced with propofol 1-2 mg/kg and maintained with desflurane (5-7 vol %). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
45612356|NCT03398681|Drug|Ferric carboymaltose|Ferric Carboxymaltose solution [Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)]
45612357|NCT03398681|Drug|Placebo (Normal saline)|Normal saline (0.9% weight/volume (w/v) NaCl)
45758956|NCT02993627|Other|diet therapy|low calorie diet (-500 or -300 kcal) composed of 55% carbohydrate, 15% protein and 30% fat
45758957|NCT02993315|Biological|nDC vaccination|
45758958|NCT02993315|Biological|placebo injection|
45758959|NCT00739583|Drug|CHG 2% w/v and IPA 70% v/v|Skin preparation of the surgical site per label of the product. The area for surgery will be prepared for 30 seconds
45445263|NCT02057848|Other|Rapid-acting carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
45445264|NCT03778281|Drug|Baclofen|Oral baclofen 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
45612358|NCT03398681|Diagnostic Test|Cardiac magnetic resonance|Cardiac magnetic resonance including T2* and T1-mapping sequences
45612359|NCT04447261|Drug|BI 1356225|BI 1356225
45612360|NCT04447261|Drug|Placebo|Placebo
45612361|NCT03394547|Device|Allay|pulsed shortwave therapy treatment for painful periods
45612362|NCT03394547|Device|Placebo|A placebo device is given which is identical to the Allay device but emits no pulsed shortwave therapy.
45612363|NCT03394469|Other|collection|Blood, urinary and faecal samples
45612364|NCT03398603|Procedure|blood sample and ultrasound|When included in the study blood samples and ultrasound are taken every second day of the first and third menstrual cycle after inclusion.
45758960|NCT00739583|Drug|Iodophor 0.7% and IPA 74% w/w|Skin preparation of the surgical site per product labeling. The area will be painted with the solution.
45758961|NCT04385459|Other|Coronary artery disease|Exposure
45758962|NCT01274741|Behavioral|Creating Change (CC)|Creating Change is a past-focused, integrated, cognitive-behavioral therapy for PTSD/SUD. It has 17 topics, which in this study were delivered in weekly one-hour sessions, in individual format. The treatment explores how PTSD and SUD arose and interacted across the patient's life, including constructing a narrative of its meaning, processing associated emotions and memories, and exploring themes related to these.
45612365|NCT05237765|Other|controlled (automatic) massage|Massage methods that are performed with mechanical methods are called automated massage. Automated massage is also individual-controlled massage. This is because in automated massage, to relax, solve or reduce their pain, the individual applies the massage under their own control or under the control of someone else through a controller in a way where the duration and intensity of the massage in the body part of application vary. Individual-controlled massage devices may be in the form of chairs, cushions, beds and mattresses. These massage devices have functions such as vibrating, applying vacuum, imitating manual massage motions and applying heat.
45612366|NCT03398525|Other|usual care|usual care following local standard operational procedures
45612367|NCT03398525|Other|Musical intervention|Musical intervention using a marketed music program validated for music therapy
45612368|NCT05237375|Other|The MIDWIZE model|"So-called MIDWIZE ambassadors are planned to be appointed to lead the clinical implementation of the quality improvement components.~Initial training workshops will be held with the ambassadors on practical aspects of the chosen components and how to explain their benefits to the units' staff. Training will also be provided on how to enhance interdisciplinary teamwork and coordinate quality improvements. The workshops will be held onsite at Naguru hospital and online via the project's MIDWIZE virtual platform. The ambassadors will themselves hold training workshops to support midwives and other healthcare providers at the clinics during the implementation of the quality improvements components. The virtual MIDWIZE platform will contain videos, posters, presentations, and other training material that the ambassadors can utilise to enhance the units' capacity and engage their colleagues."
45612369|NCT03398369|Diagnostic Test|CMR/CTA Guidance for CRT|The intervention is the use of CMR and CTA to determine the optimal pacing site in the left ventricle for cardiac resynchronization therapy (CRT) and guide left ventricular lead placement.
45612370|NCT03398291|Procedure|Synchronous resection of primary pancreatic cancer and liver oligometastasis|Patients undergo surgical exploration. If no extensive metastatic sites are found, the synchronous resection of primary pancreatic cancer and liver metastatic sites will be performed. Adjuvant chemotherapy was recommended, and the regimen selection is recommended to be based on the preoperative chemotherapy.
45612371|NCT03398291|Drug|Standard chemotherapy|Patients continue to receive standard chemotherapy including folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), gemcitabine plus nab-paclitaxel, or gemcitabine plus S-1
45612372|NCT05216315|Device|Transcranial direct current stimulation (tDCS)|10 sessions of tDCS stimulation on dorsolateral prefrontal cortex with the apparatus HDC stimulator (Newronika TM)
45612373|NCT05216315|Device|Sham stimulation|The sham group received direct current only on the ramps to generate a sensation of the effect.10 sessions
45612374|NCT03394235|Device|Long-pulsed, 1064nm Nd-YAG laser|This long-pulsed Nd-YAG laser is commonly used for laser hair removal and vascular lesions, but in this study it is used to reduce the size of the hair shaft at the occipital area.
45612375|NCT03398057|Other|Health education|SHEP included a comprehensive lecture about BC, with a generally deep focus on detection and screening tools, which were illustrated by a PowerPoint presentation with pictures and videos. The program also included a practical session about BSE (on breast silicon model). At the end of SHEP, a focused group discussion was conducted to answer participants' questions, and to discuss important barriers regarding BSE practice and visiting primary health care centers or clinics to undergo CBE and mammography. Different scientific and administrative solutions were discussed. SHEP materials were distributed as a hard copy (booklet) and in electronic format (CD) for all participants in the health education group at the end of training.
45612376|NCT03398057|Other|Control group|Placebo health education (pamphlets) will be applied to this group participants during study.
45612377|NCT03126461|Radiation|SAbR|"For patients treated on the GRID A regimen, a dose of 15-20 Gy will be delivered with the GRID device in either a single field, with prescription to dmax, or with parallel opposed GRID fields (matching beamlets from the opposed directions). For patients treated on the GRID B regimen, this same dose will be delivered, with a subsequent regimen of 3 Gy X 10 fractions, with the first of these fractions following the GRID dose."
45612378|NCT03126461|Drug|Ipilimumab|ipilimumab 3mg/kg IV q3wk x 4
45612379|NCT03126461|Drug|Nivolumab|nivolumab 1 mg/kg IV q3wk x 4
45612380|NCT03397979|Behavioral|Infrequent versus Frequent Soaking Baths|Submersion of skin, affected by atopic dermatitis, in a bathtub filled with luke-warm water, where the frequency and duration of these baths are varied, to look for any differential effect.
45612381|NCT03394157|Other|metabolic surgery|operation to cure type2 diabetes
45612382|NCT03389789|Other|Oral glucose solution + maternal holding|Infant will receive both the oral glucose solution and the contact with the mother
45612383|NCT03389789|Other|Breastfeeding|Infants will be breastfed
45612384|NCT03389789|Other|Oral glucose solution|Infant will receive only oral glucose solution without contact with the mother
45758963|NCT01274741|Behavioral|Seeking Safety (SS)|Seeking Safety is a present-focused, evidence-based cognitive-behavioral therapy for integrated treatment of patients with PTSD/SUD. It is a cognitive-behavioral therapy comprising 25 topics, each a coping skill relevant to both disorders. In this study 17 of the 25 topics were conducted, one per weekly, one-hour, individual session.
45758964|NCT02993237|Drug|DRV/COBI FDC placebo tablet|Participants will receive 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC
45758965|NCT02993237|Drug|D/C/F/TAF FDC placebo tablets|Participants will receive 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC.
45758966|NCT03808597|Other|Digital health promotion intervention|Digital health promition related to HIV, Tuberculosis and TSCT in a digital format.
45758967|NCT03808207|Other|Dietary counseling and DHA dietary increase in breastfeeding mothers|Specific dietary advices in order to increase the daily/weekly intake of docosahexaenoic acid of breastfeeding mothers for the first 3 months after delivery
45758968|NCT02993159|Drug|Afimoxifene|Applied to the breast
45758969|NCT02993159|Other|Laboratory Biomarker Analysis|Correlative studies
45758970|NCT02993159|Other|Placebo|Given PO
45758971|NCT02993159|Other|Placebo|Applied to the breast
45758972|NCT02993159|Drug|Tamoxifen Citrate|Given PO
45612385|NCT03389789|Other|Oral expressed breastmilk|Infant will receive only oral expressed breast milk without contact with the mother
45612386|NCT03394001|Procedure|Wound infiltration|Before skin closure,the subcutaneous tissue and skin all around the wound will be infiltrated by 20 mL of the drug then closure of the skin will be done.
45612387|NCT03394001|Drug|Lidocaine Hydrochloride|20 ml of 1% Lidocaine solution
45612388|NCT03394001|Drug|Ketorolac tromethamine|20 mL of saline with 30 mg ketorolac
45612389|NCT03389633|Other|rehabilitation|
45612390|NCT03393923|Other|Application of the anterior wedge|Application of anterior wedge in tennis
45612391|NCT03125681|Procedure|Remote ischemic conditioning|In the RIC group, RIC is performed before and after coronary anastomoses by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
45612392|NCT03125681|Procedure|Control|In the control group, all the procedures will be same with RIC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
45758973|NCT03807505|Procedure|Interscalene brachial plexus nerve block|An interscalene brachial plexus nerve block (single shot or catheter, depending on surgical procedure) will be placed under ultrasound guidance and all patients will receive 10cc 0.5% ropivacaine during block placement. Patients with a nerve catheter will receive a bolus of 5cc 0.5% ropivicaine postoperatively, on arrival to the recovery unit.
45612393|NCT03126149|Drug|PF-06667272|Single ascending dose of PF-06667272
45612394|NCT03126149|Other|Placebo|Single dose of placebo
45612395|NCT03393767|Drug|Ranibizumab|Intravitreal injection
45612396|NCT03393689|Drug|One injection of 68Ga-NODAGA-E[c(RGDyK)]2|One injection of 68Ga-NODAGA-E[c(RGDyK)]2
45612397|NCT03393533|Procedure|Group I|Extraction third molar without the application of therapeutic bandaging in the face and with evaluation of edema, pain and trismus
45612398|NCT03393533|Procedure|Group II|Extraction third molar with the application of therapeutic bandaging in the face and with evaluation of edema, pain and trismus
45612399|NCT03389321|Drug|Riociguat (Adempas)|Riociguat film-coated tablets for oral administration at a strength of 1 mg
45612400|NCT03389321|Drug|Macitentan (Opsumit)|Macitentan film-coated tablets for oral administration at a strength of 10 mg
45612401|NCT03393455|Other|not accurate|not accurate
45612402|NCT03393377|Drug|fluvastatin 10 mg and valsartan 20 mg|
45612403|NCT03393377|Drug|placebo|
45612404|NCT05181527|Drug|Selective Serotonin Reuptake Inhibitors|Patients in both the study arms will receive SSRI for 8 weeks.
45612405|NCT05181527|Drug|Dextromethorphan|Patients in the test group will get Dextromethorphan 30 mg once daily orally as an add-on to ongoing SSRI treatment for 8 weeks.
45758974|NCT03807505|Procedure|Erector spinae plane block|An erector spinae plane block (single shot or catheter, depending on surgical procedure) will be placed under ultrasound guidance and all patients will receive 10cc 0.5% ropivacaine during block placement. Patients with a nerve catheter will receive a bolus of 5cc 0.5% ropivicaine postoperatively, on arrival to the recovery unit.
45758975|NCT03802513|Other|Physical Therapy|Individualized physiotherapy including exercises to be performed by the Veteran at home.
45612406|NCT05181527|Drug|Placebo|Patients in the control group will get placebo tablet once daily orally as an add-on to ongoing SSRI treatment for 8 weeks.
45612407|NCT02421263|Drug|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
45758976|NCT02993003|Device|Nasopharyngeal probe|nasopharyngeal probe insertion
45758977|NCT01279421|Behavioral|Social Network HIV Testing|Crack users will be recruited for HIV testing and receive 3 coupons to recruit other crack users for HIV testing.
45758978|NCT01279421|Behavioral|Peer Network Intervention|Peer leaders will recruit small networks of crack users and facilitate a three-day prevention intervention.
45758979|NCT02992847|Other|Unenhanced MRI|
45758980|NCT00723931|Biological|Peginterferon alfa-2b (SCH 54031)|Surveillance will be conducted after administration of peginterferon alfa-2b (administered according to the directions on the products' labeling). PegIntron Injection for surveillance is a weight-based dosing product administered at a dose of 0.5/1.0 ug/kg or 1.5 ug/kg. Administration of treatment is not part of this study.
45612408|NCT01889303|Drug|DC|"Docetaxel plus cisplatin chemotherapy regimen was delivered as chemotherapy and concurrent chemoradiotherapy.~chemotherapy regimen: Docetaxel（Qilu Pharma. China） 75mg iv D1, Cisplatin（Qilu Pharma. China） 75mg iv D1 ,Q3W for 2 cycles, then Docetaxel 35mg iv D1, Cisplatin 25mg iv D1,QWx4 cycles(but rest in the 4th week during RT) + RT 45Gy( 5weeks) for concurrent chemoradiotherapy→ Rest for 4 weeks → Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W for 2 cycles."
45612409|NCT01889303|Drug|concurrent chemoradiotherapy with 5-FU/CF|"FOLFOX6 regiment was delivered as adjuvant chemotherapy and 5-FU/CF as concurrent chemotherapy treatment.~Adjuvant chemotherapy: FOLFOX6 regiment : Oxaliplatin（Hengrui Medicine Co., Ltd，China） 85mg/m2 IV d1, Leucovorin （Hengrui Medicine Co., Ltd，China）400mg/m2 IV d1, 5-FU（Hengrui Medicine Co., Ltd，China） 400mg/m2 IV bolus d1, followed with 2400mg/m2 over 46h continuous infusion Q2Wx3 cycles of chemotherapy Concurrent chemotherapy : 5-FU 400mg/m2 IV and Leucovorin 20mg/m2 IV were given on the first four and the last three days in the period of radiotherapy. After radiation, patients will have a rest lasting for 4 weeks and then given Folxof6 regiment chemotherapy for 3 cycles."
45612410|NCT01889303|Radiation|radiation|Therapy plan system was formulated by CT simulation. Radiation was delivered with 15MV photons in both Arm A and Arm B. Radiotherapy consisted of 45Gy of radiation at 1.8Gy/day, five days per week for 5 weeks, to the tumor bed, to the margins of resection, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.
45612411|NCT00783263|Drug|Comparator: rosuvastatin 5 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
45612412|NCT00783263|Drug|Comparator: rosuvastatin 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
45612413|NCT00783263|Drug|Comparator: rosuvastatin 10 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
45612414|NCT00783263|Drug|Comparator: rosuvastatin 20 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
45612415|NCT00664937|Drug|montelukast sodium|single oral dose, before exercise challenge, of montelukast 10mg; 7 week duration.
45612416|NCT00664937|Drug|Comparator: placebo (unspecified)|single oral dose, before exercise challenge, of Pbo; 7 week duration.
45612417|NCT03389165|Device|Wearable hip assist robot|All participants climbed stairs from the first basement level to the fourth floor of the Proton Therapy Center, Samsung Medical Center, Korea with and without a wearable hip assist robot. During climbing stairs, the metabolic energy expenditure of all participants was measured using a portable cardiopulmonary metabolic system (Cosmed K4b², Rome, Italy).
45758981|NCT00740129|Drug|Zoledronic Acid|Zoledronic acid 5 mg intravenous infusion once
45758982|NCT00762853|Drug|Fluoride|Brush half mouth once with assigned study treatment
45612418|NCT04951661|Device|Virtual Reality|Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
45612419|NCT00540839|Drug|Montelukast sodium|Montelukast 4 mg OG or montelukast 4 mg CT
45612420|NCT00540839|Drug|Placebo to montelukast|Placebo OG or CT
45612421|NCT00540839|Drug|Fluticasone propionate|Fluticasone 50 mcg inhalation aerosol metered dose inhaler
45612422|NCT00540839|Drug|Placebo to fluticasone|Placebo inhalation aerosol metered dose inhaler
45612423|NCT03389087|Drug|Apatinib and Etoposide Capsule|Apatinib 250mg/qd，po, A course of treatment need 28 days. Etoposide Capsule 25mg/d，po, from day 1-day 21.
45758983|NCT00762853|Drug|Fluoride and triclosan|Brush half mouth once with assigned study treatment
45758984|NCT00740207|Drug|VISIPAQUE 270|VISIPAQUE 270 (Iodixanol Injection) is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
45758985|NCT00740207|Drug|Isovue 250|ISOVUE-250 (Iopamidol Injection) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
45758986|NCT00724009|Drug|Clofarabine|Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line.
45758987|NCT04384081|Drug|BI 456906|Solution for injection
45758988|NCT04384081|Drug|Placebo|Solution for injection
45758989|NCT01279499|Drug|Sevoflurane|Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR > 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes
45758990|NCT01279499|Drug|Sevoflurane|Intraoperatively sevoflurane will be guided by a target BIS of 40 - 50. If a positive sympathetic response occured (an elevation of the HR and/or MAP greater than 15% above baseline) a bolus SEVO 8 MAC will be administered for 2 minutes.
45758991|NCT01279499|Drug|Propofol- Remifentanyl|"Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (doses based on ideal body weight).~Every rise of BP or HR > 15% of baseline will be followed by a Remifentanyl bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remifentanyl from 0.1 to 1.0 μg/kg/min"
45758992|NCT01279499|Drug|Propofol, Remifentanyl|"Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW). General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (ideal body weight).~The depth of anesthesia will be adjusted so as to accomplish a BIS score between 40 and 50 Every rise of BP or HR > 15% of baseline will be followed by a Remi bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remi from 0.1 to 1.0 μg/kg/min"
45758993|NCT04384237|Procedure|Er,Cr:YSGG laser-aided CSF|After injection 2% lidocaine with 1:80.000 epinephrine concentration in labial and lingual vestibule the fiberotomy is carried out by inserting a 9 x 0.5 mm laser tip into the gingival sulcus with an angle of 10-15º to the radicular surface
46073634|NCT04240782|Behavioral|Nutrition and hands on cooking classes for parents and their children|The adults and children will learn how to prepare the fresh produce during an age appropriate, evidence-based, family cooking school. The class will provide participants with a no-cost, low-risk incentive to try new vegetables, and will empower them to build healthier lives through nutrient-rich, locally sourced meals. Participants will also receive nutrition education and information on how they can integrate local produce into their food budget. One of the class sessions will focus solely on how to budget for healthy food, comparison shop, and make the most of their food dollars. Participants will learn how to use their SNAP benefits at local farmers markets.
45612424|NCT04446299|Drug|Bowel Prep|Orally ingested liquid bowel preparation
45612425|NCT03393299|Procedure|STOPP/START criteria|software which helps to do the drug reconciliation
45612426|NCT03389009|Diagnostic Test|Ultrasound Biomicroscopy of anterior segment of the eye|5150 Vumax (Sonomed, USA) under standard illumination
45612427|NCT03388931|Radiation|Radiation Therapy|Increased radiation therapy dose
45612428|NCT03388931|Combination Product|Chemotherapy|Standard-of-care chemotherapy with treatment regimen to be determined by the treating physician
45612429|NCT03393221|Behavioral|ER|Emotion regulation content
45612430|NCT03393221|Behavioral|SBWC|
45612431|NCT03388853|Drug|Acetylcysteine/Doxofylline|Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily for four weeks.
45612432|NCT03388853|Other|Placebo|Placebo once daily for four weeks.
45612433|NCT04746521|Diagnostic Test|Multitest 6 color TBNK and BD Lyotubes|The Multitest 6 color TBNK allows us to count the population-specific B, T, NK cells
46068844|NCT05471414|Behavioral|General Nutritional Counseling|"All study participants will receive consult with a Registered Dietitian at the Baseline visit and visit 1 study assessments. After visit 1, study participants assigned to the general nutritional counseling arm will receive an additional in-person or telehealth consultation with a Registered Dietitian that will consist of identification and counseling to improve diet quality and achieve a healthy body weight consistent with American Cancer Society guidelines.~Study participants in the control group will continue to receive general nutritional counseling and education with weekly scheduled telephone consultations with a Registered Dietitian for the first 4 weeks of the study period. For the remainder of the study period, they will receive counseling and education from Registered Dietitians via monthly scheduled phone calls."
45612434|NCT04746521|Biological|genomicDNA extraction|Peripheral blood biospecimens (about 10-15 mL) will be collected through venipuncture in EDTA tubes. Peripheral blood mononuclear cells (PBMCs) will be isolated using Ficoll® Paque Plus (Sigma-Aldrich) centrifugation gradient and genomic DNA will be extracted from fresh PBMCs using DNeasy Blood & Tissue kit (QIAGEN), according to manufacturer protocols
45612435|NCT00380705|Drug|MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks|
45612436|NCT03388697|Diagnostic Test|Quantose IR and Quantose IGT analysis|Testing using Quantose IR and Quantose IGT: The blood draws will be timed to coincide with clinically indicated blood tests as much as possible (e.g. first visit labs, aneuploidy screening, gestational diabetes screening).
45612437|NCT03388697|Diagnostic Test|HOMA IR the standard testing for insulin resistance|Testing using HOMA IR: Investigators will be measuring fasting insulin and glucose levels (last meal more than 8hrs before testing i.e. overnight fasting) from EDTA-plasma samples. After collection, the samples will be spun and plasma obtained. Samples will be stored until testing. The investigators will be using the following computation to calculate HOMA.
45612438|NCT03987919|Drug|Tirzepatide|Administered SC
45612439|NCT03987919|Drug|Semaglutide|Administered SC
45445265|NCT03778281|Drug|Methoxyclopramide|Intramuscular injection of metoclopramide 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
45612440|NCT03388957|Drug|Propranolol|This drug will be given before the extraction procedure
45612441|NCT03388957|Drug|Midazolam|This drug will be given before the extraction procedure
45612442|NCT03904069|Drug|AMG 553|AMG 553 is a chimeric antigen T-cell receptor (CAR-T) therapy
45612443|NCT03395821|Behavioral|Conventional training|traditional training according to residency program
45612444|NCT03395821|Behavioral|Virtual Reality+conventional training|virtual reality training+traditional training using virtual reality
45612445|NCT03390829|Other|semi-directed interviews|semi-directed interviews
45612446|NCT03395743|Biological|AB-PA01|AB-PA01 is an investigational bacteriophage therapeutic for treatment of Pseudomonas aeruginosa infections
45758994|NCT04384237|Procedure|Conventional CSF|After injection 2% lidocaine with 1:80.000 epinephrine concentration in labial and lingual vestibule the fiberotomy is carried out by inserting a surgical blade (#11)into the gingival sulcus at an angle of 10-15º to the radicular surface
45758995|NCT01274975|Other|Autologous Adipose Derived Mesenchymal Stem Cells|Intravenous infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4 x 10e8 cells
45758996|NCT02992925|Biological|DPT-IPV-Hib-High（Combined Vaccine）|
45758997|NCT02992925|Biological|DPT-IPV-Hib-Low（Combined Vaccine）|
45758998|NCT02992925|Biological|Hib vaccine|
46068845|NCT05462262|Drug|Intensive lipid-lowering control|The initial recommended therapy is 10-20mg atorvastatin plus Ezetimibe, and the type and dosage of drugs can be adjusted according to the situation.
45612447|NCT02520271|Behavioral|Behavioral Activation|BA consists of at least 4 intervention sessions with a focused, active working style by the therapist. The therapy initiation includes a focused interview targeting at determining 1-2 main problems, on which the therapy will be focused. Specific therapeutic methods for BA include the use ABC analysis, targeting at hitting the negative consequences of current problematic behavior and motivating for change. Further, recognizing the obstacles for change (TRAP) is the next method to be used. The therapist encourages the client for active behavioral monitoring through assigned homework during the therapy process. The final step and method used is strengthening the gained change (ACTION).
45758999|NCT02992925|Biological|DPT-IPV|
45445266|NCT02055586|Other|fluorine F 18 fluorothymidine|Undergo FLT-PET/MRI
45445267|NCT02055586|Device|positron emission tomography|Undergo FLT-PET/MRI
45759000|NCT00762931|Device|Resolve Stimulator and Proximity Lead|An electrical neurostimulation signal will be applied to the neck via subcutaneous lead placement for vagal nerve stimulation
45759001|NCT01275209|Drug|HCD122|
45759002|NCT00780715|Drug|Gliclazide MR|30mg daily increased to 60mg if HbA1c > 7% at 3 months
45759003|NCT00780715|Drug|Sitagliptin|Sitagliptin 100mg daily for 6 months
45759004|NCT00780715|Drug|Pioglitazone|Pioglitazone 30mg daily , increased to 45mg daily if HbA1c >7% at 3 months. 6 months duration
45445268|NCT02055586|Device|magnetic resonance imaging|Undergo FLT-PET/MRI
45445269|NCT03778593|Drug|5-Fluorouracil|D1-2 5-Fluorouracil 1000 mg/m2 + 5DW 1L continuous IV over 23 hours q 2 weeks
45445270|NCT03778593|Drug|Leucovorin|D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours q 2 weeks
45445271|NCT03778593|Drug|Irinotecan|D1 Irinotecan 135 mg/m2 + 5DW 500 mL mix IV over 2 hours (concurrent with the leucovorin infusion) q 2weeks
45759005|NCT00780715|Drug|Metformin|Metformin 500 mg od for 1 week, bd for 1 week, 1g mane 500 mg nocte 1 week, 1g bd there after. Total of 6 months treatment
45759006|NCT03807193|Behavioral|Self-selected treatment|The participants will select their own treatment material with the help of a written manual. The interventions possible to choose are all interventions used in standard cognitive behavior therapy for anxiety and depression.
45759007|NCT03807193|Behavioral|Predetermined treatment|The participants will be given a treatment program designed to address worry and generalized anxiety disorder. The program are based on newer forms of cognitive behavior therapy and include mindfulness and acceptance.
45759008|NCT03807193|Behavioral|Weekly support|The participants will have scheduled weekly support, once a week, during the treatment. The support till be delivered by students in clinical psychology.
45612448|NCT02520271|Behavioral|Motivational Interview|"Motivational interview (MI) is a therapeutic intervention that focuses on resolving client ambivalence towards changing problematic behavior. MI involves a client-centered approach that encourages the client to develop his or her own motivation. The therapeutic alliance in MI is predominantly a partnership, rather than an expert/client dynamic.~MI has been studied primarily in addiction problems, but there are numerous reports of its efficacy in several chronic somatic conditions, and lifestyle problems."
45612449|NCT03395665|Other|Estradiol level|Estradiol level measured at previous day of embryo transfer procedure
45612450|NCT03395665|Other|Progesterone level|Progesterone level measured at previous day of embryo transfer procedure
45612451|NCT03395665|Other|Endometrial thickness|Endometrial thickness measured at previous day of embryo transfer procedure
45612452|NCT03388879|Device|Taylor Spatial Frame|Circular external fixator
45759009|NCT03807193|Behavioral|Support on demand|The participants will have support if and when they ask for it by themselves. If asked for the support will be delivered by students in clinical psychology.
45612453|NCT03388879|Device|Intramedullary nail|Antegrade intramedullary nail
45612454|NCT03388801|Other|Spa therapy|Spa treatment was applied during a session lasting 120 to 150 minutes a day. Spa treatment lasted 3 weeks, including treatments from Monday to Friday (15 days of treatment). As a part of comprehensive spa treatment, all the patients benefited from kinesiotherapy, physical agent modalities (electrotherapy, phototherapy), massage and balneotherapy (peloid therapy, hydrotherapy with mineral waters, crenotherapy).
46068846|NCT05462262|Drug|Moderate-intensity lipid-lowering control|The initial recommended therapy is 10-20mg atorvastatin, and the type and dosage of drugs can be adjusted according to the situation.
46068847|NCT05461950|Procedure|Extrauterine placental transfusion and physiology-based umbilical cord clamping|Placenta is delivered prior to umbilical cord clamping to facilitate placental transfusion. Infant and placenta are transferred to a warmer in an adjacent room, the umbilical cord is clamped and cut when the cord is white, pulsations have ceased and the infants is breathing regularly (within 10 minutes after delivery)
45612455|NCT03125707|Other|Registry study|
45759010|NCT03806881|Device|reversed glenoid prothesis|All patients will undergo a primary or revision arthroplasty with Glenius according to the routine practice at the investigation site and will be followed at specified visiting moments, during which radiological and clinical data will be gathered.
45759011|NCT03800485|Device|IMT|A training protocol of the inspiratory muscles that goes from the 15% of the maximal inspiratory muscle preassure until the 60% of the maximal inspiratory muscle preassure during 8 weeks
45759012|NCT01273987|Procedure|rONB|Neobladder posterior wall suspended with round ligament of uterus after radical cystectomy in female with bladder cancer
45759013|NCT03806725|Diagnostic Test|Intravenous administration of iodinated contrast medium for coronary CT angiography|Administration of iodinated contrast medium for coronary CT angiography
45759014|NCT01274143|Behavioral|TeleCARE|Personalized telephone-delivered cancer risk assessment.
45612456|NCT03390751|Other|Data collection|The collection of data will be done by interrogation of the patient and his family / entourage and rereading of medical records
45612457|NCT00535405|Drug|Atorvastatin 10 mg|Atorvastatin 10 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
45759015|NCT01274143|Behavioral|Pamphlet intervention|Mailed pamphlet about familial colorectal cancer risk and screening.
45759016|NCT05318443|Drug|SIBP04|SIBP04, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.
45759017|NCT05318443|Drug|Avastin|Avastin, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.
45612458|NCT00535405|Drug|Ezetimibe 10 mg/simvastatin 20 mg|Ezetimibe 10 mg/simvastatin 20 mg and Placebo for atorvastatin once daily for 12 weeks
45612459|NCT00535405|Drug|Atorvastatin 20 mg|Atorvastatin 20 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
45612460|NCT00535405|Drug|Ezetimibe 10 mg/simvastatin 40 mg|Ezetimibe 10 mg/simvastatin 40 mg and Placebo for atorvastatin once daily for 12 weeks
45612461|NCT00535405|Drug|Atorvastatin 40 mg|Atorvastatin 40 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
45759018|NCT05318443|Drug|Paclitaxel|Paclitaxel, 175mg/m2, intravenous infusion, every 3 weeks/cycle, administered on the first day of each treatment cycle.
45759019|NCT05318443|Drug|Carboplatin|Carboplatin, AUC=5.0, (upper limit 800mg), intravenous infusion, 3 weeks/cycle, administered on the first day of each treatment cycle.
45759020|NCT00740831|Drug|PGL4001|tablets
45759021|NCT00740831|Drug|leuprorelin|solution for injection
45759022|NCT03806569|Behavioral|MAC-cbt group treatment for adult ADHD|Psychotherapeutic intervention to treat adult patients with ADHD to be mindful, accept the symptoms and disturbances and commit with the situation or the possibility to change.
45759023|NCT03806569|Behavioral|Jacobson|Relaxation treatment in technique of Jacobson in 8 sessions
45759024|NCT03806413|Other|Open heart surgery|The study will be done on patients undergoing open heart surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6 9 and 12 months after surgery.
45759025|NCT01275287|Drug|Standard of care treatment|"induction : pulse methyl prednisolone (7 mg/kg/day x3) then prednisone 1 mg/kg/day (not to exceed 60 mg/day) for 4 weeks, then taper over the following 12 weeks. Cyclophosphamide starting at 0.75 gm/m2 IV (decreased to 0.5 gm/m^2 for patients > than 70 or with estimated Glomerular Filtration Rate (eGFR) < 20 ml/min) to be titrated up to 1 gm/m^2 depending on the 2 week white blood count (WBC) nadir > 3000 cell/μL. Subsequent cyclophosphamide will be given every 4 weeks for at least 2 more doses. Once complete remission for 2 months, patient may be switched from cyclophosphamide to maintenance therapy with azathioprine 1.5-2 mg/kg/day for 6-9 months (to a total of 12 months of therapy) .~For patients who cannot tolerate cyclophosphamide, or who have received it in large doses previously, another medication called rituximab may be used instead. However, if rituximab is indicated for the patient, he cannot participate in the study."
46073635|NCT04240782|Behavioral|Produce allocations|Participants will also receive a produce allocation from a local farm during each session of the class.
46073636|NCT00834847|Drug|pravastatin|40 mg tablet
45612462|NCT03390595|Combination Product|avelumab 10mg/kg with carboplatin/gemcitabine|"Dosage and schedule:~Avelumab 10mg/kg will be administered over 60 minutes in the experimental arm as follows:~Intravenously every 2 weeks for two cycles.~During carboplatin-gemcitabine treatment, on day +15 (carboplatin will be administered on day 1; gemcitabine on days 1 and 8), for six cycles. Intravenously every 2 weeks until progressive disease o intolerance.~Intravenously every 2 weeks until progressive disease or intolerance.~Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC~Carboplatin 5AUC day +1.~Gemcitabine 1000mg/m2 day +1 and +8."
45612463|NCT03390595|Combination Product|carboplatin/gemcitabine alone|"•Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC~Carboplatin 5AUC day +1.~Gemcitabine 1000mg/m2 day +1 and +8."
45612464|NCT03395431|Other|Fingerprick autologuos blood (FAB)|Intervention involves the instillation of whole blood obtained from the prick of a clean finger 4 times a day.
45612465|NCT03125863|Device|AquaBeam System|The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
45612466|NCT03390517|Device|Fluorescence angiography with indocianyne green|The fluorescence angiography was performed after mobilization of the bowel, transection of the rectum, division of the rectal and colon mesentery and central vessels, before specimen extraction or resection and creation of the anastomosis. This site was selected by the surgeon using his or her best judgment and typical standard of care assessment. After this selection, the anesthesiologist administered a bolus of 1 to 2 ml indocianyne green intravenously. Perfusion of the colon was visualized and assessed via fluorescence angiography and the line of demarcation between perfused and nonperfused tissue was noted and compared with the initial planned transection point.
45612467|NCT00271817|Drug|Comparator: ezetimibe/simvastatin + niacin (ER)|ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be ~24 weeks
45612468|NCT00271817|Drug|Comparator: Placebo to ezetimibe/simvastatin|ezetimibe/simvastatin (Pbo) tablet. Treatment time will be ~24 weeks.
45612469|NCT00271817|Drug|Comparator: niacin (ER) tablet|niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be ~24 weeks
45612470|NCT00271817|Drug|Comparator: ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20mg tablet. Treatment time will be ~24 weeks.
45612471|NCT00271817|Drug|Comparator: Placebo to Niacin (ER)|Niacin (ER) (Pbo) tablet. Treatment time will be ~24 weeks.
45612472|NCT00271817|Drug|Comparator: ezetimibe/simvastatin and niacin (ER)|ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet 2g, po qd. Treatment time will be ~40 additional weeks for a total of 64 weeks
45612473|NCT00271817|Drug|Comparator: ezetimibe and simvastatin|ezetimibe/simvastatin 10/20mg tablet. Treatment time will be ~40 additional weeks for a total of 64 weeks
45612474|NCT00271817|Drug|Comparator: Placebo to niacin (ER)|Niacin (ER) (Pbo) tablet. Treatment time will be ~40 additional weeks for a total of 64 weeks
45612475|NCT03388567|Other|Staff pharmacy whith intervention|Pharmacists who will receive continuous education through technology and communication tools, as well as accompaniment and advice from a pharmaceutical chemist
45612476|NCT03390439|Device|Nd-Yap 1340nm laser|Each part of the abdomen will be treated with a therapeutic modality. The ND-yap 1340-nm laser will be used in the following parameters: 90 mtz / cm2 nozzle, 90 mJ / mtz power, 2.5 Hz frequency, 3 ms pulse duration, 1 pass.
45612477|NCT03390439|Device|Microneedling|In the other segment of the abdomen, the dermaroller 2.5 mm will be applied, with ten to fifteen passes in the same direction and at least four crosses in the rolling areas.
45612478|NCT03390361|Device|Femtosecond Laser-assisted|Laser cataract surgery will be performed in one eye
45612479|NCT03390361|Procedure|Manual Cataract Surgery|Manual cataract surgery will be performed in contralateral eye
45612480|NCT03388541|Drug|Dexmedetomidine|Dexmedetomidine will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.
45612481|NCT03388541|Drug|Placebo|A continuous infusion of NaCL 0.9% will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.
45612482|NCT00092989|Drug|montelukast sodium|Duration of Treatment: 1 dose
45612483|NCT00092989|Drug|placebo|Duration of Treatment: 1 dose
45612484|NCT03388463|Drug|Omeprazole|Omeprazole 80 mg continues infusion
45612485|NCT03388463|Drug|Placebo group|Omeprazole 40 mg single daily dose.
45612486|NCT03388489|Behavioral|Mind-Body Walking|walking, breathing, and mindfulness
45445272|NCT03778593|Drug|Oxaliplatin|D1 Oxaliplatin 65 mg/m2 + 5DW 200 mL mix IV over 2 hours q 2 weeks
45445273|NCT03778593|Drug|5% dextrose water|mix fluid with 5-FU, leucovorin, irinotecan, and oxaliplatin
45612487|NCT03388307|Procedure|unilateral laminotomy|minimally invasive technique
45612488|NCT03388307|Procedure|decompressive laminectomy|classic surgery
45612489|NCT03388411|Diagnostic Test|Gut microbiome profiling|Gut microbial profiling will be done with next-generation sequencing targeting bacterial 16s rRNA genes.
46068848|NCT05461950|Procedure|Extrauterine placental transfusion, intact cord stabilisation and physiology-based umbilical cord clamping|Placenta is delivered prior to umbilical cord clamping to facilitate placental transfusion. Infant and placenta are transferred to a warmer in an adjacent room and necessary respiratory support is initiated (CPAP or PPV) by a neonatal team. The umbilical cord is clamped and cut when the cord is white, pulsations have ceased and the infant is breathing regularly with or without support (at maximum 10 minutes after delivery)
46073637|NCT00834847|Drug|Pravachol®|40 mg Tablet
46073638|NCT02823132|Biological|blood sample|
45445274|NCT02055664|Drug|Ropivacaine 0.2%|
45445275|NCT02055664|Drug|Chlorure de sodium 0.9%|
45445276|NCT02055742|Device|illumigene CT and NG assays, illumipro-10|
45445277|NCT03778437|Procedure|subclavian vein catheterization|Here we introduced a new freehand method, named as Aiming Method, which facilitated the alignment of injection needles with ultrasound beams. During this aiming method, patient is still positioned in Tredelenburg with the arm abducted to 90° and no needle guidance will be used.
45612490|NCT04702529|Device|Treatment of hypertrophic scars (Soliton's Rapid Acoustic Pulse (RAP) Device)|Administration of 3 Rapid Acoustic Pulse (RAP) treatments
45612491|NCT03388229|Behavioral|not an intervention|it was observation not intervention
45612492|NCT03388333|Procedure|Catheter Ablation|
45612493|NCT04685993|Drug|LPCN 1144|Oral LPCN 1144, total daily dose of 450 mg testosterone undecanoate administered as BID (225 mg testosterone undecanoate per dose).
45612494|NCT03858049|Drug|Crinone|Participants will receive 90 milligram (mg) of intravaginal Crinone gel daily in the morning in the treatment period for approximately 75 days.
45612495|NCT03858049|Drug|Duphaston|Participants will receive 10 mg of Duphaston orally twice a day in the treatment period for approximately 70 days.
45612496|NCT03388151|Drug|Midazolam|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg till reaching satisfactory level of sedation
45612497|NCT03388151|Drug|Propofol|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v till reaching satisfactory level of sedation
45612498|NCT03838939|Other|Therapeutic education|"Individual and group therapeutic education sessions will consist of :~acquisition by patient of self-care skills such as performing subcutaneous injection,~acquisition by patient of safety skills such as identifying symptoms that should lead to consult general practitioner, and stop treatment ..."
45612499|NCT03388073|Other|Berry extract I|Seabuckthorn berry proanthocyanidin extract 250 mg single dose
45612500|NCT03388073|Other|Berry Extract II|Seabuckthorn berry proanthocyanidin extract 500 mg single dose
45612501|NCT03388073|Other|Berry extract blend|Seabuckthorn berry blend with other berry-based antioxidants
45612502|NCT03388073|Other|Placebo|Placebo
45612503|NCT03390205|Diagnostic Test|Optical coherence tomography angiography under dark and light adaptation|Optical coherence tomography angiography under dark and light adaptation with pupil dilatation
45612504|NCT03797911|Combination Product|Active resistive capacitive monopolar radiofrequency with physiotherapeutic techniques and pain education|Activated resistive capacitive monopolar radiofrequency is applied to the patient along with the conventional treatment of physiotherapeutic techniques and pain education.
45612505|NCT03797911|Combination Product|Inactive resistive capacitive monopolar radiofrequency with physiotherapeutic techniques and pain education|Disactivated resistive capacitive monopolar radiofrequency inactived is applied to the patient along with the conventional treatment of physiotherapeutic techniques and pain education.
45612506|NCT03393065|Other|Fluid management guided by BLS|We propose a randomized study where in the interventional arm the fluid management (volume replacement, diuretics, use of vasopressors) will be guided using the BLS as a sign of pulmonary congestion.
45612507|NCT03388255|Drug|Polydeoxyribonucleotides|"Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use i.m.~The study period consists of the following phases:~Treatment period: 3 months (daily i.m. treatment with PLACENTEX ® Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use, one vial per day for intra-muscular administration).~Follow up period: 3 months after end of active treatment, without study medication."
45612508|NCT03392987|Genetic|OTL-200|OTL-200 is an autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human ARSA cDNA sequence
45612509|NCT03390127|Other|PEEP|After LMA Supreme™ insertion, it's proper position is confirmed. Then, PEEP of 7 cmH2O is applied during mechanical ventilation.
45612510|NCT03392909|Drug|Gentamicin|Short-term intravenous gentamicin therapy should have the advantage of treating all of the patient's multiple skin wounds simultaneously. Six patients (three adults and 3 children) will receive intravenous gentamicin (7.5 mgs/kg) daily for 14 days and then stopped. Three adult patients will receive intravenous gentamicin (7.5mg/kg) biweekly for three months and then stopped.
45612511|NCT03388177|Behavioral|Yoga-based therapy|
45612512|NCT03388177|Other|Treatment as usual|
45612513|NCT03392831|Other|Peripherally inserted central catheter (PICC)|The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established. In the case of children the procedure may be performed at the Ambulatory Surgical Center
45612514|NCT03392831|Other|Central venous catheter|The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.The decision of the caliber depends on the clinical evaluation and need for multiple infusional therapy.
45612515|NCT05239273|Other|Complex Decongestive Therapy|Phase 1 of CDT will be applied. This application consists of manual lymph drainage, skin care, compression bandage and exercises.
45612516|NCT05239273|Other|Control|No intervention
45612517|NCT02731157|Drug|Rejuvesol|
45612518|NCT02731157|Procedure|Blood transfusion|Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
45612519|NCT03387995|Device|LVIS stent|The group has 80 patients.
45612520|NCT03387995|Device|Solitire stent|The group has 80 patients.
45612521|NCT03387995|Device|Enterprise stent|The group has 80 patients.
45612522|NCT03387995|Device|Neuroform stent|The group has 80 patients.
45612523|NCT03387995|Device|Pipeline stent|The group has 80 patients.
45612524|NCT03392675|Behavioral|Self-monitoring of BF and intervention|"Self-Monitoring: At discharge, mothers will complete daily diaries for self-monitoring to stimulate cognitive reframing on the occurrence, duration, and characteristics of nipple and breast pain, infants' latch and sucking pattern, positioning, length of each BF session, and the MAIBB.~Self-Regulation: To support self-regulation skills, mothers will be provided with several 5-minute video modules on pain and BF pain SM with additional resources links. After discharge mother will receive text message from a nurse 2X/week for BF support. Mothers may text the nurse for emergent BF support."
46068849|NCT05461950|Procedure|Delayed umbilical cord clamping|Umbilical cord is clamped and cut minimum 60 seconds after delivery to facilitate placental transfusion. Placenta is delivered after cord clamping. Infants needing respiratory support or other stabilisation are transferred to a warmer in the adjacent room where a neonatal team is waiting.
46068850|NCT05453695|Drug|Intravenous DNase I|Dose-escalating intravenous infusion of DNase I
45759026|NCT01275287|Drug|eculizumab|In addition to conventional therapy, patients randomized to eculizumab will receive 600 mg by IV infusion over 35 minutes every 7 days for the first 4 weeks, then 900 mg by IV infusion for the fifth dose 7 days later (week 5), then 900 mg every 14 days thereafter, for a total of 9 doses (about 3 months of treatment). This dosing scheme is based on that used for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The length of treatment is shorter than for PNH, based on a desire to target the addition of eculizumab to the period of maximal disease activity, while limiting the risks of infectious complications in this first pilot study.
45759027|NCT05744245|Other|Swallow Strength and Skill Training|Practice swallowing exercises with biofeedback and strength and skill targets
46068851|NCT05436665|Procedure|DSAEK|"The main incision (3.5-5mm) is created at the corneal limbus or via a cornea-scleral tunnel with 2-3 smaller (approx. 1mm) paracentesis incisions. An ophthalmic viscosurgical device (OVD) or a continuous infusion of water or air can be used to maintain the stability of the anterior chamber, according to the surgeon's preference. The corneal endothelium is scored using a scoring instrument and the central diseased corneal endothelium is removed. Once the anterior chamber is prepared, OVD or air has been removed, then the eye is ready for the new corneal graft.~The pre-cut corneal tissue delivered by the bank is then gently rinsed and may be stained with 0.06% trypan blue if required. The tissue is loaded into a glide or injector, and pulled into the anterior chamber using a smooth-tipped micro-forceps (e.g., Busin forceps). Once the graft enters the eye, it is lifted to the posterior cornea. The graft is further centred using air (or SF6 Gas) in the anterior chamber."
45445278|NCT03778437|Procedure|landmark techniques|The patient is positioned in Tredelenburg with the arm abducted to 90°. Venipuncture should occur 1 cm lateral to the curvature of the middle third of the clavicle with the needle pointing horizontally directed at the sternal notch. If subclavian vein is missing at the first try, withdraw the needle and direct horizontally at the cricoid cartilage at the second try.
45445279|NCT03778437|Procedure|Ultrasound-guided plus needle guide techniques|Subclavian vein catheterization is performed under ultrasound guidance with in-plane technique. The patient is positioned in Tredelenburg with the arm abducted to 90°. During the needle insertion, the needle is secured in the needle guidance device which keeps the alignment of needle and ultrasonic beam.
46068852|NCT05436665|Procedure|DMEK|"The main incision (2.8-3mm) is created superior or temporally at the corneal limbus and is accompanied by 2-3 smaller paracentesis incisions. An ophthalmic viscosurgical device (OVD) or a continuous infusion of water or air can be used to maintain the stability of the anterior chamber. The corneal endothelium is scored using a scoring instrument and the central diseased corneal endothelium is removed.~The DMEK roll is poured into a basin and rinsed. The graft is then stained with 0.06% trypan blue to aid in graft visualization. The graft is loaded into an injector and introduced into the anterior chamber. The graft is unrolled using external manoeuvres and once unrolled, it is lifted to the back of the cornea. The eye is then pressurised with a full air fill from 10 to 120 minutes. The pressure is then reduced and the case is completed by suturing any incisions required."
45445280|NCT03804346|Diagnostic Test|Acceleromyography|At the End of Surgery, shortly before Extubation, the TOF-Ratio is measured by an independent investigator using Acceleromyography.
45445281|NCT03778047|Drug|Enzalutamide|oral
45612525|NCT03387839|Other|Stress X-Ray|Antero-posterior stability of the knee measured with stress x-rays using the TELOS Stress device in 45° and 90° flexion
45612526|NCT03392597|Behavioral|Brothers as Allies|Strengths-based group approach to promote boys' and young men's safe and healthy passage through the pre-teen and adolescent years.
45759028|NCT02992535|Device|Intense Pulse Light Energy delivery (IPL)|
45759029|NCT05744167|Behavioral|BFRT|Following a warm-up of 10 min, subjects in the experimental group will undergo BFRT for two times per week, consisting of lower extremity exercises (leg press, knee extension, knee flexion). BFRT will be at 40% of 1 repetition maximum (1RM); The volume % (V% = number of repetitions x number of sets x number of exercises x % 1 repetition max) = 57.6%. Progression during the 12 week program will be attained by a 1RM test every 4 weeks.
45759030|NCT05744167|Behavioral|MDRT|Following a warm-up of 10 min, subjects in the experimental group will undergo MDRT for two times per week, consisting of lower extremity exercises (leg press, knee extension, knee flexion). The exercise will be at 80% of 1RM concentric-only or 120% of 1RM eccentric-only in a 3:1 ratio. The volume % (V% = number of repetitions x number of sets x number of exercises x % 1 repetition max) = 57.6%. Progression during the 12 week program will be attained by a 1RM test every 4 weeks.
45759031|NCT01275443|Drug|300mg TMC278LA|300mg TMC278LA intramuscular injection
45759032|NCT01275443|Drug|150mg TMC278LA|150mg TMC278LA intramuscular injection
45759033|NCT01275443|Drug|1200mg TMC278LA|1200mg TMC278LA intramuscular injection
45759034|NCT01275443|Drug|600mg TMC278LA|600mg TMC278LA intramuscular injection
46068853|NCT05430919|Drug|REGN5713|Administered subcutaneously (SC)
45612527|NCT03392597|Behavioral|Programming-as-Usual|Usual afterschool programming.
45612528|NCT04586621|Device|Atoldys/ Lexilens - SHAM|Atoldys/ Lexilens: glasses with specific light frequency SHAM: glasses with no frequency
45612529|NCT04586621|Device|SHAM- Atoldys/ Lexilens|SHAM: glasses with no frequency Atoldys/ Lexilens: glasses with specific light frequency
45612530|NCT03387605|Drug|Ivabradine|ivabradine or placebo given orally 2 times daily for 72 hours
45759035|NCT01274221|Drug|SPD489|1 capsule per day throughout the open-label treatment phase and for one week of the double-blind crossover phase
45759036|NCT01274221|Other|Placebo|1 capsule per day for one week of the double-blind crossover phase
45445282|NCT03778047|Drug|HC1119|oral
45445283|NCT03560830|Other|2 submaximal exercise stress tests|
45445284|NCT03777891|Combination Product|phonophoresis with different material|phonophoresis with Silicone gel for group A, , Group B: 15 patients (8 males and 7 females) received phonophoresis with Contractubex gel and Group C: 15 patients (9 males and 6 females) received Corticosteroid phonophoresis.
45445285|NCT03804112|Diagnostic Test|Ultrasound exam with Doppler|Ultrasound exam of the neck to search a perivascular inflammation at the level of the carotid bifurcation.
45445286|NCT03804112|Biological|Blood samples|blood count , CRP and viral serologies (herpes virus, chlamydia, mycoplasma),
45445287|NCT01309425|Drug|tapentadol (CG5503) ER two 100-mg TRF|200mg TRF single oral dose
45612531|NCT03387605|Drug|Placebo|matching placebo given 2 times daily for 72 hours
45759037|NCT03806023|Device|hand movements (signals from thumb muscle) triggered PNS and TMS|"PNS, TMS or PNS+TMS will be delivered while the participant performs specific finger tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
45445288|NCT01309425|Drug|tapentadol (CG5503) ER 50-mg TRF|50mg TRF single oral dose
45612532|NCT03387527|Behavioral|Prostate cancer decision aid|Patients will undergo standardized counseling and individualized counseling with the screening decision aid. The screening decision aid is a computer program that provides individual patients estimates of their risks of prostate cancer diagnosis, prostate cancer related death, or death from any cause
45612533|NCT04562363|Procedure|Suturing of a laparotomic wound with modified methods|Suturing the white line of the abdomen with the help of developed techniques aimed at preventing hernias and eventrations
45612534|NCT03387371|Device|Ultrasonics|ultrasonic scalers
45612535|NCT03387371|Device|Gracey Curettes|Spesific gracey curettes
45612536|NCT03387371|Device|Er:YAG Laser|2940 nm wavelenght Er:YAG laser
45612537|NCT04506983|Biological|GPC3-CAR-T cells|Patients with hepatocellular carcinoma will be enrolled, and GPC3-CAR-T cells will be intravenously infused with a escalated dose of 1×106 /3×106/10×106GPC3-CAR-T cells.
45612538|NCT04506593|Other|no intervention|
45612539|NCT04501211|Drug|Granisetron|transdermal sancuso patch
45612540|NCT04465331|Other|Questionnaires|completion of Exercise Adherence Rating Scale (EARS)
45612541|NCT03392363|Device|Recordings of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease.
45612542|NCT03125993|Behavioral|>10000 steps brisk walking|This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: > 10000 steps, > five days, per week brisk walking.
46068854|NCT05430919|Drug|REGN5714|Administered SC
46068855|NCT05430919|Drug|REGN5715|Administered SC
45445289|NCT01309425|Drug|tapentadol (CG5503) ER 25-mg TRF|25mg TRF single oral dose
45612543|NCT03126071|Drug|Raltitrexed|Raltitrexed:3mg/m2,iv 15min,d1,q3w.
45612544|NCT03126071|Drug|Irinotecan|Irinotecan:250mg/m2,iv 90min,d1,q3w.
45612545|NCT03126071|Drug|Oxaliplatin|Oxaliplatin:130mg/m2,iv 120min,d1,q3w.
45612546|NCT03126071|Drug|Bevacizumab|Bevacizumab:75mg/kg,iv 30min,d1,q3w.
45612547|NCT03392285|Device|Internal fixation or hip arthroplasty|Patients treated according to the routine at the orthopedic department with screw fixation of an undisplayed femoral neck fracture or hip arthroplasty for a displaced femoral neck fracture.
45612548|NCT03392207|Biological|Seasonal Influenza Vaccine|Trivalent, Fragmented, Inactivated Seasonal Influenza Vaccine (2018 Southern Hemisphere Season) produced at Butantan Institute
46068856|NCT05430919|Other|Placebo|Administered SC
45612549|NCT03387293|Other|LGI-LII Breakfast|This test meal with low GI and low FII amounts were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.
45612550|NCT03387293|Other|LGI-HII Breakfast|In crossover design, this test meal with low GI and high FII amounts were served as a breakfast to compare the LGI-LII Breakfast.
45612551|NCT03392129|Other|Ai Chi|Children in the intervention group will perform 12 sessions (twice a week 40 minutes each session) of treatment with the Ai Chi Method, and educational intervention in relation to asthma.
45612552|NCT03392129|Other|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
45612553|NCT03387215|Drug|ITI-214|Oral
45612554|NCT03387215|Other|Placebo|Oral
45612555|NCT03392051|Drug|ISIS 681257|Xmg dose administered as a subcutaneous injection
45612556|NCT03392051|Drug|Clopidogrel|75mg tablet administered orally
45612557|NCT03391895|Other|Home based exercise program|Program will include deep diaphragmatic breathing exercises, local expansion exercise on the collapsed areas in scoliosis concave sides with elastic exercise bands, dynamic lumber stabilization exercises for core stabilisation, strengthening of interscapular muscles with elastic bands and stretching exercises for lumbar extensor, hip flexor and hamstring muscles. Exercises will be applied 2 sets of 10 repetitions and once a day.
46068857|NCT05429788|Drug|Low dose RLS103|3 mg CBD inhaled powder administered before public speaking challenge
46068858|NCT05429788|Drug|High dose RLS103|6 mg CBD inhaled powder administered before public speaking challenge
46068859|NCT05429788|Drug|placebo inhaled dry powder|placebo inhaled powder administered before public speaking challenge
46068860|NCT05411744|Drug|1 month Rifapentine, Isoniazid and Vitamin B6|Participants will be treated with one month (4 weeks) of daily Isoniazid, Rifapentine and Vitamin B6.
46073639|NCT00841477|Biological|hepatitis B vaccine 3 dose schedule (0,1,2 month)|hepatitis B (HB) vaccine: Engerix-B (GlaxoSmithKline) (20 µg/dose) accelerated HB vaccine schedule (0,1,2 month),vs, standard HB vaccine schedule (0,1,6 m)
45445290|NCT01309425|Drug|tapentadol (CG5503) ER 100-mg TRF|100mg TRF single oral dose
45445291|NCT03561298|Drug|BGB-3111 and Drug Cocktail|BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)
45445292|NCT04476537|Device|OncoTreat|OncoTreat is a computational pipeline that begins with a tumor expression profile and ends with a list of several candidate regimens.
45445293|NCT05648422|Dietary Supplement|Probiotics|Saccharomyces Boulardii 200 mg every 12 hours for 6 days at week 1, 5 and 9
45445294|NCT05648422|Dietary Supplement|NSS Nutritional Support System|Nutritional Support System consists in NSS envelope (glutamine, arginine, folic acid, PUFA-n3, vegetal protein, nicotinic acid, cobalamin, thiamine, pyridoxine, magnesium, zinc, selenium, cholecalciferol, resveratrol, ascorbic acid, Spirulina Máxima, glycine, tryptophan, and inuline) every 12 hours for 12 weeks.
45445295|NCT05648422|Drug|Deworming|nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days
45612558|NCT03391895|Other|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure after assessment of respiratory muscle strength for each patient every week.
46073640|NCT00841477|Behavioral|HBV Vaccination Self-Efficacy Intervention|HB Vaccination Intervention consists of 4 sessions - Sessions 1, 2: at screening and enrollment after intake, vs regular risk reduction education Sessions 3, 4: coincide with the vaccination schedule ions 4 before 3rd dose
45759038|NCT00741455|Procedure|Stem Cell Transplant|"Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be > 5 x 106 CD34+cells/kg of recipient.~Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.~Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml."
45759039|NCT00741455|Drug|G-CSF|10 mcg/kg/day on days 5, 6, and 7
45612559|NCT03386981|Other|blood and saliva tests|Blood and saliva will be tested for: bone turnover markers, cytokines, chemokines, adipokines, myokines and hormones regulating bone and energy metabolism
45759040|NCT00741455|Drug|Fludarabine|25 mg/m2/d IV over 30 minutes on days -6 to -2
45612560|NCT02520167|Behavioral|Dietary and Lifestyle Counseling|Dietary and lifestyle education; Peer group support.
45612561|NCT04253483|Radiation|High-Dose Rate Brachytherapy|Undergo HDR
45612562|NCT04253483|Other|Quality-of-Life Assessment|Ancillary studies
45759041|NCT00741455|Drug|cyclophosphamide|1 g/m2/d IV on days -3 and -2
45759042|NCT00741455|Drug|Cyclosporine|used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
45759043|NCT00741455|Drug|Methotrexate|used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
45759044|NCT01274299|Procedure|Digital camera picture|A digital camera will be used to take a 3D picture the face of each infant. Off line measurements of landmarks on the face will be marked and dimensions will be calculated using a special analysis software.
45759045|NCT01274377|Biological|CMV Specific T Cell donor lymphocyte infusion|Donor Lymphocyte Infusion (DLI)
45759046|NCT00742313|Biological|FloSeal Matrix|10 ml of FloSeal Matrix will be applied to the endoscopic wound bed.
45759047|NCT05744011|Other|Tango intervention|"The interventions will be implemented by ABB Reportages and will be carried out by nursing staff who had previously received training in therapeutic tango at the University of Burgundy.~A dance movement therapist and a musician will accompany the interventions twice a month.~Participants will attend a 1-hour tango session, twice a week for twelve weeks."
45911429|NCT02008058|Behavioral|Survey|Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study. Patients will remain on study for up to 26 months (slightly longer than the expected median survival in this population based on data from docetaxel, abiraterone, and MDV3100 pivotal phase 3 trials).
45911430|NCT02008071|Behavioral|Daily step goal financial incentive|Participants' daily activity was incentivized. Reaching a predetermined/individualized step goal each day resulted in 1.00 per day.
45911431|NCT02008071|Behavioral|Standard of Care|Standard payment of 70.00 at the beginning of the study. Participants' daily activity was not incentivized.
45612563|NCT04253483|Other|Questionnaire Administration|Ancillary studies
45612564|NCT04253483|Procedure|Stereotactic Ablative Radiotherapy|Undergo SABR
45612565|NCT04236791|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
45612566|NCT04236791|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
45612567|NCT03386903|Device|Ture acupuncture|"Patients receive true acupuncture treatment by Zhoushi coordinated points at the Bai-hui (DU20), Shen-ting (DU24), bilateral Ben-shen (BG13), Shen-men (HT7), San-yin-jiao (SP6) with Deqi sensation. The needles are retained for 20 minutes in every course, three times per week and last for 3 months."
45612568|NCT03386903|Device|Sham acupuncture|Patients receive sham acupuncture stimulation by non-acupoint points (superficial insertion, 0.2 cun, No needle sensation (de qi) is elicited) at the bilateral mid-point between Shuaigu(GB8) and Touwei(ST8), Touwei(ST8) and Yangbai(GB14), front tibia, the junction of biceps and triceps.
45911432|NCT02008084|Drug|TRIA-662|Following Baseline randomized to active TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then active TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
45759048|NCT05744011|Other|Adapted Physical Activity|"The intervention will be carried out by an Adapted Physical Activity professor and by nursing staff.~Music is prohibited during the sessions. Participants will attend a 1-hour APA, twice a week for twelve weeks."
45759049|NCT00742469|Drug|Rifaximin|
45759050|NCT00742469|Drug|Placebo|
45759051|NCT00763243|Behavioral|Cogmed Working Memory Training Program|The Cogmed Working Memory Training program is a 5-week program of computer-based exercises that require the user to complete tasks involving verbal, visual, or combined verbal-visual memory skills. In addition to memory skills, Cogmed tasks demand attention, concentration, and reasoning skills. Users are expected to practice Cogmed exercises at home for 40 minutes/day, 5 days/week, during the 5-week training period. The program uses an adaptive algorithm that presents users with problems of increasing difficulty at a level slightly higher than that at which they have recently achieved success.
45759052|NCT02992613|Procedure|total knee arthroplasty with ultra-congruent (UC) insert|
45911433|NCT02008084|Drug|Placebo|Following Baseline randomized to placebo TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then placebo TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
45612569|NCT04167371|Behavioral|Biofeedback|Three sessions by biofeedback will be performed during the first 3 weeks of the intervention period. In each session patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
45612570|NCT04167371|Dietary Supplement|Placebo|Three sessions will be performed during the first 3 weeks of the intervention period. In each session abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
45612571|NCT03386825|Drug|Regorafenib (Stivarga, BAY73-4506)|Antineoplastic agents, protein kinase inhibitor (L01XE21)
45612572|NCT03386747|Behavioral|Home visits to improve parenting behaviors|Caregivers will be visited twice per month starting from the third trimester in pregnancy up to age three to discuss important health and development behaviors.
45612573|NCT03386747|Behavioral|Center based parenting groups|Caregivers will be invited to early childhood development groups. Groups will meet at nearby centers twice per month. Caregivers will be invited to participate starting from the third trimester up to age 3 of the child.
45612574|NCT04446767|Radiation|polarized light|bioptron light therapy sessions, about 12 minutes on the foot ulcer 3 sessions per week for about 8 weeks
45612575|NCT04446767|Other|Medical Care|Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
45612576|NCT03386669|Drug|F-18|Totally 60 subjects age 20-80 including 20 subjects with a diagnosis of PD,PSP,and CBS. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
45612577|NCT03416543|Other|Puncture|Puncture necessary for daily practice in patients with acute arthritis of RA or Gout or osteoarthritis
45612578|NCT04446533|Drug|Hydrogen Peroxide and Hyaluronic acid filming formulation|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with BMG0703 by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of BMG0703 will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
45612579|NCT04446533|Drug|Chlorhexidine 0.2%|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with Chlorhexidine 0.2% by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of Chlorhexidine 0.2% will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
45612580|NCT04446533|Drug|Placebo|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with a placebo product by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of the placebo product will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
45612581|NCT03386591|Drug|Naloxone|Comparing pharmacokinetics of naloxone
45612582|NCT03386591|Device|Mucosal atomization device and syringe|Injection
45612583|NCT03386591|Device|Narcan|Nasal Spray
45612584|NCT03386591|Device|Intramuscular Auto Injector|Intramuscular injection
45612585|NCT04446689|Behavioral|Biofeedback|This intervention will be measured by the Software Emwave Pro Plus during 4 weeks, which send out a sign captured by a non-invasive sensor such as an ear lobe fixed photoplethysmograph.
45612586|NCT04446455|Other|InVEST: Increased Velocity Exercise Specific to Task|Functional Power Training
45612587|NCT04446455|Other|TAPAT: Tonic and Phasic Alertness Training|Computerized cognitive training.
45612588|NCT03391817|Other|Fecal microbiota transplantation|Fecal microbiota transplantation administered in gastroscopy
45612589|NCT03391739|Biological|CART-19 cells|CART-19 cells treat
45612590|NCT03386279|Drug|PF-04965842|one single dose of 600 mg by mouth
45612591|NCT03386279|Drug|Moxifloxacin|one single dose of 400 mg by mouth
45612592|NCT03386279|Drug|Placebo|one single dose by mouth
45612593|NCT03391661|Behavioral|Pain neuroscience education patient exercise|Patients complete a 15 to 20-minute on-line exercise that inquires about 5 domains: the degree of central sensitization symptoms, catastrophizing and kinesiophobia, personality factors, stressors that triggered or exacerbated the pain, and adverse childhood experiences.
45612594|NCT03391661|Behavioral|Health behavior control intervention|Patients engage in a 15 to 20-minute on-line exercise examining their health behaviors in five domains: exercise, sleep, diet, hygiene, and social connections.
45759053|NCT02992613|Procedure|total knee arthroplasty with posterior-stabilized (PS) insert|
45759054|NCT01279577|Drug|Low dose TSO|Low dose TSO suspension
45759055|NCT01279577|Drug|Medium dose TSO|Medium dose TSO suspension
45759056|NCT01279577|Drug|High dose TSO|High dose TSO suspension
45612595|NCT03391583|Other|Education|Participants in the education arm of the study will be provided with three PowerPoint presentations. Material for these slides has been adapted from material developed by the Ontario Neurotrauma Foundation. Topics to be addressed will surround post-traumatic headache and will include information regarding common symptoms, timeline for improvement, red- flags and when to seek medical attention
45612596|NCT03386201|Drug|Intravenous Methylene blue|Methylene blue fluorescence cholangiography during laparoscopic cholecystectomy
45612597|NCT03386123|Behavioral|Cognitive Behaviour Therapy for Insomnia|Continuous maintenance of sleep diary, cognitive behaviour therapy, including cognitive restructuring, and behavioural change focusing on sleep restriction and safety behaviours.
45612598|NCT03386123|Behavioral|Standard Audiological Care|Maintenance of sleep diary at key times. Psycho-education, provision of bedside sound generator.
45612599|NCT03386123|Behavioral|Sleep Support Group|Maintenance of sleep diary at key times. Social support focused on tinnitus and sleep problems.
45612600|NCT03391505|Behavioral|Small-sided soccer game|The small-sided soccer game consists of a single bout (two times ten minutes) of small-sided soccer game (3v3) interspersed with a five minutes break.
45612601|NCT03391505|Behavioral|Walking soccer game|The walking soccer game consists of a single bout (two times ten minutes) of small-sided walking soccer game (3v3) interspersed with a five minutes break.
45612602|NCT03391505|Behavioral|Rest group watching soccer|The rest group watching soccer consists of watching a soccer game on a laptop (two times ten minutes) interspersed with a five minutes break.
45612603|NCT03298217|Device|Measurement of the peak tidal inspiratory flow (PTIF)|"In patients with bronchiolitis sverity mWCAS / 3-5 :~Nasopharyngeal aspiration and comfortable placement of the infant upon admission; Clinical evaluation: respiratory rate, respiratory distress scores rating (Silverman and m-WCAS); If the patient is eligible: information and collection of parental consent; If signed parental consent obtained: progressive (on at least 10 min) withdrawal of HFNC support and maintenance if necessary of conventional oxygen therapy (maximum 1 L/min); Application of the spirometer for the recording of 20 consecutive spontaneous respiratory cycles for PTIF measurements; Respiratory support with HFNC; flow adapted to the need of the patients (equal to the measured PTIF)."
45612604|NCT03391427|Drug|Lidocaine|This group will receive lidocaine infusion
45612605|NCT03391427|Drug|Ketamine|This group will receive Ketamine infusion
45612606|NCT03391427|Drug|Lidocaine+ketamine|This group will receive mixture of ketamine and lidocaine infusion
45612607|NCT03391427|Drug|Saline|This group will receive saline infusion
45612608|NCT03268811|Drug|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
45612609|NCT03391271|Other|photobiomodulation therapy (PBMT)|"Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)~• The PBMT-group will receive twice-weekly laser sessions starting at first until the last week of chemotherapy (9-12 weeks depending on the type of chemotherapy)"
45612610|NCT03391271|Other|sham laser sessions|• The control group will undergo twice-weekly sham laser sessions starting at first until the last week of chemotherapy (9-12 weeks depending on the type of chemotherapy). The laser device will be placed on the same manner and for the same period of time on the identified body sites, but the device will not be switched on.
45612611|NCT03385967|Drug|Dexmedetomidine|Addition of Dexmedetomidine in block .25mcg/kg of dexmedetomidine
45612612|NCT03385967|Drug|ropivacaine|Standard of care 0.5%ropivacaine
45612613|NCT03391037|Diagnostic Test|Internal Jugular Vein Distensibility|. 40 donor candidates for right lobe hepatectomy for living donor liver transplantation were enrolled. During period of hypovolemia (T0) left IJV scanned and measured. After a given fluid bolus in the form of ringer acetate 5 ml / Kg. ultrasonic and hemodynamic measurements were reassessed 10 minutes (T 10) after the fluid resuscitation
45612614|NCT03131531|Other|Patient registry|Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
45612615|NCT03390959|Other|Proprioceptive Training|"Individuals in the Trained Group will perform the training twice a week for 45 minutes and perform for a period of 12 weeks.~The training is divided into a pre-training phase where general hip dissociation exercises and simple stretching of the hip flexor and extensor muscle groups, knee, foot and paravertebral are performed.~The second phase is the proprioceptive training, where it will involve training of balance, sensitivity and proprioception, being used a circuit composed of 15 stations, whose time of stay in each station is 2 minutes.~And finally the third stage are relaxation exercises, performed with breathing exercises associated with slow active movements of the joints."
45612616|NCT03390959|Other|Control Group|Will not be submitted to any physical intervention. It continues in your daily life with only phone monitoring.
45612617|NCT03390881|Other|Fasting condition|Subjects will fast over the whole experimental period (480 min)
45612618|NCT03390881|Other|Sugar condition|After a 2-h fasting state, subjects will ingest every hour a drink containing 70% carbohydrate, 15% fat and 15% protein and providing 1.5 X hourly resting energy requirement.
45759057|NCT01279577|Drug|Placebo|Placebo solution
45911434|NCT02008097|Device|GE LOGIQ E9 Ultrasound System|"Subjects will have an ultrasound exam using the GE LOGIQ E9 Ultrasound System which has computer software that combines the color-flow image and B-mode image to produce the new B-Flow method of ultrasound."
45911435|NCT02008110|Drug|CA125 guided strategy|Up titration of loop diuretics according to plasma levels of CA125 in the active arm
45612619|NCT03390881|Other|Fat condition|After a 2-h fasting state, subjects will ingest every hour a drink containing 70% fat, 15% carbohydrate and 15% protein and providing 1.5 X hourly resting energy requirement.
45612620|NCT03390803|Other|effect of hemifacial spasm on intraocular pressure|To evaluate the effect of Hemifacial spasm on Intraocular pressure measurement.
45612621|NCT03390647|Drug|E6130|Oral dose
45612622|NCT03390647|Drug|Placebo|E6130-matched placebo
45612623|NCT03390179|Drug|Steroid Drug|mesure of the glucose concentration
45612624|NCT02732015|Drug|Dexamethasone|Given IV
45612625|NCT02732015|Drug|Doxorubicin|Given IV
45612626|NCT02732015|Drug|Fosaprepitant Dimeglumine|Given IV
45911436|NCT02008110|Drug|CA125 guided strategy|Consider statins in all patients in the active arm
45911437|NCT02008110|Drug|CA125 guided strategy|Consider omega-3 polyunsaturated fatty acids in the active arm
45612627|NCT02732015|Drug|Ifosfamide|Given IV
45612628|NCT02732015|Other|Laboratory Biomarker Analysis|Correlative studies
45612629|NCT02732015|Drug|Mesna|Given IV
45612630|NCT02732015|Drug|Ondansetron|Given IV
45612631|NCT02732015|Other|Questionnaire Administration|Ancillary studies
45612632|NCT02732015|Drug|Rolapitant Hydrochloride|Given PO
45612633|NCT02732015|Drug|Vincristine Sulfate|Given IV
45612634|NCT03093701|Drug|TLC399 (ProDex)|2-vial system: TLC399-DSP and TLC399-Lipid
45612635|NCT03789461|Procedure|Fecal Microbiota Transplantation|FMT infusion (100-200ml) and Mucosal Microbiota Assessment (To assess the fecal and mucosal microbiota before and after FMT)
45612636|NCT03048461|Device|Platelet Rich Plasma Prep System|intradermal injections of platelet rich plasma to an area of alopecia
45612637|NCT03048461|Drug|Placebo|intradermal injections to an area of alopecia
45612638|NCT03708419|Other|Optimal diet|Based on a 7-points OGTT, participants will be classified as MIR or LIR. The hypothesized optimal diet for MIR has a moderate fat content which is high in mono- unsaturated fatty acids (HMUFA) with a macronutrient breakdown of 38 E% from fat (20% MUFA, 10% polyunsaturated fatty acids (PUFA), 8% saturated fatty acids (SFA)), 48 E% from carbohydrates (CHO, 35% complex), and 14 E% from protein (35-40% plant protein). The hypothesized optimal diet for LIR is low in fat, high in protein (LFHP) and increased fiber with a macronutrient breakdown of <28 E% from fat (10% MUFA, 10% PUFA, 8% SFA), 48 E% from CHO (35% complex), and 24 E% from protein (35-40% plant protein), and an additional supplement of 6g of soluble fiber per day. Participants wil be randomly allocated to one of the two diets.
45612639|NCT03708419|Other|Suboptimal diet|"The optimal diet for the other metabolic phenotype will be considered as suboptimal/ control diet. For the MIR phenotype this is the high protein, high fiber, low fat diet; for the LIR phenotype this is the high monounsaturated fatty acid diet. See the description above."
45612640|NCT02950961|Behavioral|Collaborative Care for Women Veterans|This is a collaborative care model that focuses on identifying need for depression and/or anxiety care. Patients with possible anxiety and/or depression are referred to a care manager in primary care-mental health integration. The care manager then conducts a thorough assessment, offers the patient a variety of appropriate treatment options, and works with the patient to determine a care plan. One of the key options the investigators will be offering in this study is the Calm Tools for Living (CALM) intervention, which is focused on anxiety and which is rooted in patient preferences. Patients can choose web-based cognitive behavioral therapy (CBT) and/or pharmacologic treatment. In this study the investigators will be training appropriate MH providers in CALM and studying the ways in which the intervention needs to be tailored to women Veterans. The investigators will also examine the relative importance of patient preference with regard to engagement and retention in care.
45612641|NCT02922881|Other|Ulcerative Colitis Diet (UCD)|The primary study intervention is a novel dietary intervention, the UC Diet. The UC Diet is a structured 12-week diet with a step down phase designed to remove products that allow harmful bacteria to thrive and add products that can change the bacteria in the gut to induce remission
45612642|NCT03702257|Procedure|bronchoscopy.|gDSAs are studied on cryopreserved biopsies obtained during bronchoscopy. The technique is the one described by Visentin J.
45612643|NCT02520245|Drug|REGN2810|Patients will receive REGN2810 by intravenous (IV) infusion
45612644|NCT02864303|Other|Saliva samples|saliva specimens were collected using a neutral or citric acid impregnated Salivette cotton swabs on Alzheimer patients to quantify the level of amyloid peptides
45612645|NCT03390023|Behavioral|Focus Group|Groups will last 60 to 90 minutes. Focus groups will be moderated by KUMC Juntos staff who are formally trained to conduct focus groups. General topics to be covered in focus groups include: attitudes, preferences and knowledge about prenatal care, clinical trial participation, and nutritional supplement use. Focus groups will be conducted in Spanish.
45612646|NCT03385889|Procedure|Cervical Spine Mobilization|C1/2 graded mobilizations (Grade III/IV) provided to C1/2 segment on ipsilateral side of unilateral headache. Mobilizations will be completed for 3 sets of 30 seconds.
45612647|NCT03385889|Procedure|Cervical Spine Manipulation|C1/2 manipulation (Grade V) provided to C1/2 segment on ipsilateral side of unilateral headache. The goal of the manipulation technique is to elicit an audible cavitation. If no cavitation is achieved upon the first attempt, a second and final attempt will be completed. No more than two attempts will be utilized per each subject in this allocated group.
45612648|NCT03389945|Procedure|25G Dural Puncture Epidural Block|"Dural puncture epidural analgesia using a 25G pencil point spinal needle at a lumbar interspace.~Then 20ml of bupivacaine 0.125% + fentanyl 2ug/ml will be injected in the epidural space."
45759058|NCT01275599|Drug|telaprevir|Two 375 mg tablets administered every 8 hours on Day 1 through Day 7, inclusive.
45759059|NCT01275599|Drug|buprenorphine/naloxone|Buprenorphine/naloxone sublingual tablets or films contain buprenorphine HCl and naloxone HCl dihydrate at a ratio of 4:1 buprenorphine:naloxone (ratio of free bases). In this study buprenorphine/naloxone will be dosed from Day -14 through Day 38, inclusive. From Day -14 through Day -1 all subjects will receive a maximum of 24 mg/6 mg of buprenorphine/naloxone. Subjects will not be permitted to change their dose during the telaprevir co-administration period (Day 1 through Day 7) unless warranted by the investigator's clinical judgment of subject safety. After Day 8, the dose of buprenorphine/naloxone may be adjusted if deemed necessary by the investigator.
45759060|NCT02992457|Drug|Sofosbuvir|Sofosbuvir 400 mg daily.
45759061|NCT02992457|Drug|Ribavirin|Ribavirin 1000-1200 mg daily
45612649|NCT03389945|Procedure|27G Dural Puncture Epidural Block|"Dural puncture epidural analgesia using a 27G pencil point spinal needle at a lumbar interspace.~Then 20ml of bupivacaine 0.125% + fentanyl 2ug/ml will be injected in the epidural space."
45612650|NCT03385811|Other|no intervention, only questionnaires survey|questionnaires survey
45612651|NCT03603353|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|"Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling.~Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit."
45612652|NCT03603353|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
45612653|NCT03385733|Other|inspiratory muscle training|The treatment group received IMT. Patients were trained using an inspiratory threshold-loading device
45612654|NCT03537833|Other|pemetrexed-related hematological toxicity|hematological toxicity will be found on biologic data the day or the day before chemotherapy. Classification will based on NCI-CTCAE criteria
45612655|NCT03439085|Biological|DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457|Given IM and via electroporation
45612656|NCT03439085|Biological|Durvalumab|Given IV
45759062|NCT02992457|Drug|Pegylated-interferon alfa-2a|Pegylated interferon alfa-2a once weekly for 3 months
45911438|NCT02008110|Other|CA125 guided strategy|Frequency of monitoring according plasma evolution of CA125 in the active arm.
45911439|NCT02008110|Drug|Standard treatment strategy|All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone antagonists, diuretics, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, statins, omega-3 polyunsaturated fatty acids, digoxin, nitrates and vasoactive group).
45911440|NCT02008110|Drug|CA125 guided strategy|All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, digoxin, nitrates and vasoactive group).
45445296|NCT05648422|Other|Specific diet|This diet focuses on meeting caloric needs according to age, weight, height, and stress factor dividing total caloric value in 50% carbohydrates, 30% lipids, and 20% proteins. It consists of smoothies at breakfast and dinner, high consumption of fish, five meals during the day, 70% of meals eaten during the day will consist on vegetables, fruits, roots, cereals, and legumes. Red meat, gluten, lactose, junk food, sugar, salt, fast food free.
45612657|NCT03389867|Dietary Supplement|Kaempferia parviflora extract|
45612658|NCT02581709|Behavioral|Countering cognitive impairment|The intervention will include education about cancer-related cognitive impairment, instruction on relaxation techniques, compensatory techniques, goal-setting and lifestyle advice. Each session will last between 90 and 120 minutes, once a week for six weeks. The intervention will be delivered in a group setting, in a non-clinical environment by the investigators.
45612659|NCT02554331|Radiation|FP-CIT single-photon emission computed tomography|FP-CIT radiolabeled is used as a surrogate marker to examine the integrity of the dopaminergic nigrostriatal neurons.
45612660|NCT02554331|Behavioral|neuropsychological evaluation|"Assessment of:~overall cognitive function~executive functions~visuospatial functions~Nonverbal memory~verbal memory~Evaluation of hearing ability of time perception and sensorimotor synchronization from selected tasks the Battery of assessment of auditory sensorimotor and timing abilities~Beck Depression Inventory"
45612661|NCT02554331|Other|Gait recording with sensors|Gait recording with sensors
45612662|NCT01999595|Device|Control TENS|Control TENS was the application of electrical stimulation via skin with no current
45612663|NCT01999595|Device|Sham TENS|"Sham TENS was the application of electrical stimulation via skin with no current on the participant, who was told TENS is at a turn-on level whether or not you feel it"
45612664|NCT01999595|Device|High frequency TENS with large pads|High frequency TENS was delivered on large electrodes
45612665|NCT01999595|Device|Low frequency TENS with large pads|Low frequency TENS was delivered on large electrodes
45612666|NCT01999595|Device|High frequency TENS with small pads|High frequency TENS was delivered on small electrodes
45612667|NCT01999595|Device|Low frequency TENS with small pads|Low frequency TENS was delivered on small electrodes
45759063|NCT02992457|Drug|Simeprevir|Olysio once daily.
45759064|NCT02992457|Drug|Daclatasvir|Dakla once daily for three months.
45759065|NCT02992457|Drug|Ritaprevir, paritaprevir, ombetasvir|Querevo for three months
45445297|NCT05648422|Other|Conventional diet (WHO)|This diet focuses on meeting caloric needs according to age, weight, height, and stress factor dividing total caloric value in 50% carbohydrates, 30% lipids, and 20% proteins. It consists of general nutricional recommendations.
45759066|NCT02992457|Drug|Sofosbuvir and Ledipasvir|Once daily for three months
45759067|NCT02992457|Drug|Salvage therapy|three months in repeated treatment failure
45759068|NCT01279655|Device|tDCS|20 min, 1mA, 8 weeks (5 days a week, 20 min a day)
45759069|NCT01279655|Behavioral|Bimanual Training|The training program consisted of a bimanual etch-a-sketch task. By rotating two wheels subjects have to match a line presented on the screen with the cursor. 8 weeks (5 days a week, 20 min a day)
45759070|NCT00782821|Drug|Rabbit Antithymocyte Globulin|rATG will be given 1.5mg/kg intravenous (IV) per dose.
45759071|NCT00782821|Drug|Velcade|Velcade will be given 1.3mg/m2 via intravenous push (IVP) per dose.
45759072|NCT00782821|Drug|Rituxan|Given via IV per group assignment.
45612668|NCT02370797|Radiation|Single Fraction IOeRT|A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
45612669|NCT01964807|Other|Cigarette, NIDA test type with 16.6 mg nicotine|Smoke a single cigarette for up to 10 minutes
45911441|NCT02008123|Drug|Primidone|Primidone is an antiepileptic used for the management of generalized tonic-clonic seizures and for the management of complex partial seizures. One of primidone's active metabolite is phenobarbital, which is a potent cytochrome P450 inducer. In this study, primidone will be used to induce CYP 1A2 in order to provide more efficient metabolism of clopidogrel to its active form
45612670|NCT01964807|Other|Cigarette, NIDA test type with <0.45 mg nicotine|Smoke a single low-nicotine cigarette for up to 10 minutes
45612671|NCT01964807|Other|Electronic cigarette with 18 mg/ml nicotine|Use electronic cigarette with 18 mg/ml nicotine for 30 minutes
45612672|NCT01964807|Other|Electronic Cigarette with no nicotine|Use electronic cigarette with no nicotine for 30 minutes
45612673|NCT01964807|Other|Moist snuff|Use moist snuff for 30 minutes
45612674|NCT01964807|Other|Sham Smoking|Sham smoking or e-cigarette use consists of puffing on a drinking straw for 10 minutes
45612675|NCT01964807|Other|Secondhand cigarette smoke (SHS)|180-minute exposure to SHS generated by controlled dilution of smoke from machine-smoked cigarettes
45612676|NCT01964807|Other|Conditioned, filtered air|Exposure to conditioned, filtered air for 180 minutes
45612677|NCT01964807|Other|Sham Moist Snuff|Chew gum for 30 minutes
45612678|NCT02317289|Device|Detection of freezing|single wireless inertial sensor placed on the patients's lower limbs to detect freezing of gaitin Parkinsonian patients
45612679|NCT02263235|Biological|administration of stable isotope-labelled leucine-|- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
46068861|NCT05400603|Combination Product|Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate|"The cell dose will be based on the subject's body weight. Subjects will receive a single infusion of third party, ex vivo expanded, frozen then thawed γδ T cell product at a dose of 3 x 106 cells/kg on Day 6 and then if they meet criteria for subsequent γδ T cell dose will receive a second dose of 3 x 106 cells/kg on Day 13. The dose will be escalated to 1 x 10^7 and then 3 x 10^7 cells/kg. In absence of any dose limiting toxicity, 3 x 10^7 cells/kg will be accepted as the maximal dose.~Dinutuximab (17.5 mg/m2), temozolomide (100 mg/m2),irinotecan (50 mg/m2) and zoledronic acid (0.0125 mg/kg/dose) will be consistent across all dose levels."
46068862|NCT05392751|Drug|EA-2353|EA-2353 Ophthalmic Suspension
45612680|NCT02263235|Other|collection of CSF, blood, urine, saliva|- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
45612681|NCT01441115|Procedure|Radiation Therapy|
45612682|NCT01441115|Drug|ECI301|
45612683|NCT02006147|Drug|TLC399|Dose-escalation Study from 100 mM PL (20 µL) with 0.24 mg DSP to 100 mM PL (20 µL) with0.36 mg DSP to 100 mM PL (20 µL) with 0.6 mg DSP to 50 mM PL (10 µL) with 0.6 mg DSP.
45612684|NCT03385499|Biological|blood additional samples|additional samples of mother's blood and umbilical cord at delivery
45612685|NCT01164995|Drug|MK-1775 and carboplatin|Carboplatin will be administered in a dose resulting in AUC5 (i.v. 30 min) at day 1 of each cycle. Concomittantly with the start of the carboplatin infusion 225 mg of MK-1775 will be administered as an oral capsule, followed by 4 additional doses at 12 hour increments ( = 5 BID doses of MK-1775 in 2.5 days in total). One cycle will last 21 days.
45612686|NCT03380741|Diagnostic Test|Tumour markers detection|Lab on a chip detection of tumour markers measured from vaginal/cervical cytology swab
45612687|NCT03385187|Device|NightOwl HSAT|Patient wears the NightOwl sensor device
45759073|NCT00743093|Drug|acetaminophen|500 mg caplets; 2 caplets (1 g)/dose; 4 doses (4 g)/day, 4 hours apart for 16 to 40 days.
45612688|NCT03385109|Device|Surgery|Patients are approached surgically with the Senhance Surgical System
45612689|NCT03380663|Procedure|Remote Ischemic Conditioning (RIC)|"Remote Ischemic Conditioning (RIC) is a new treatment modality to attenuate reperfusion injury. Organ protection by RIC can be achieved simply by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet or simple blood pressure cuff Ischemic resistance exercise training conducted as low-intensity blood flow restricted resistance exercise (BFRE), with a low occlusion pressure stimulus, which only compromises venous but not arterial blood flow. Much like RIC, BFRE is conducted as 3-5 cycles (sets of exercise) interspaced by short duration of recovery.~High intensity traditional resistance training (TRT) is performed by sets of 10-12 repetitions are performed in the knee extensor machine - load equaling 15RM and rest for 3 minutes)."
45759074|NCT00743093|Drug|placebo|placebo caplets, 2 caplets per dose, 4 doses per day, 4 hours apart for 16 to 40 days
45759075|NCT03805945|Drug|dexmedetomidine group|After the fetus was delivered, low-dose dexmedetomidine intraoperative infusion, postoperative low-dose dexmedetomidine patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min).
45759076|NCT03805945|Drug|control group|After the fetus was delivered, saline intraoperative infusion, postoperative patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min) without dexmedetomidine.
45911442|NCT02008136|Drug|Botulinum Toxins|intramuscular injections
45911443|NCT02008162|Drug|Bronchodilators|Administration of both albuterol and tiotropium bromide after a 48h period of washout from all bronchodilators, followed by spirometry and plethysmography
45911444|NCT02008175|Radiation|Conventional CXL|Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin (<0.1%) to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/cm2 with riboflavin and distilled water alternated every 2 minutes was used for the procedure..
45911445|NCT02008201|Dietary Supplement|vitamin D|
45911446|NCT02008214|Drug|Pentoxifylline|Addition of pentoxifylline to current HCV treatment
45612690|NCT03380585|Procedure|Reciprocating single-file system|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.The device in the experimental group moves in CW and CCW direction with different angles. It is a single-file endodontic file system. The intervention is reciprocating single-file system. A Reciproc single-file will be used for enlarging apical foramen. In the active comparator group, a continuous rotational multi-file system, ProTaper Next, will be used in enlarging apical foramen.
45612691|NCT03380585|Procedure|Rotational multi-file system.|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged. In this group, a continuous rotational multi-file system, ProTaper Next, will be used in enlarging apical foramen.
45612692|NCT04715321|Other|CT perfusion examination|CT perfusion was performed with a 64-section multidetector CT scanner. The following CT parameters were used to acquire dynamic data: blood flow (BF), blood volume (BV), mean transit time (MTT), permeability-surface area product (PS), hepatic artery ejection fraction (HAF), hepatic artery perfusion (HAP), and hepatic portal vein perfusion (PVP). And we used these parameters to predict the vascular pattern.
45612693|NCT00999401|Drug|sapacitabine and seliciclib|sequential or concomitant administration of sapacitabine and seliciclib
45612694|NCT04446065|Drug|Previfenon®|Every capsule of Previfenon® (patent pending) provides 250 mg EGCG ≥ 98% purity with a carefully selected set of excipients to improve flowability, stabilize EGCG against early auto-oxidation, and increase its hepatoprotective activity with prolonged use.
45612695|NCT04446065|Drug|Placebo|Participants will receive placebo starch capsules (250 mg plus excipients) identical in appearance and taste to Previfenon® capsules in a double-blind manner.
45612696|NCT03385031|Other|CBCT imaging|CBCT imaging at first and last fraction of radiotherapy treatment
45612697|NCT00225095|Drug|Mesenchymal Stem Cells|
45612698|NCT00225095|Drug|Hyaluronan|
45612699|NCT05174429|Behavioral|Risk-Targeted Behavioral Activation|"The behavioral activation component of the treatment program focused on goal setting, structuring and scheduling activities, increasing success and achievement experiences, and problem-solving. In order to maximize the impact of behavioral activation on disability reduction, goal setting and scheduling of activities focused primarily on resumption of discontinued activities as opposed to focusing on the scheduling of pleasant activities. One objective of goal setting and activity scheduling was to reduce the discrepancy between the client's pre-injury activity repertoire and the client's current activity repertoire.~Behavioral activation was supplemented by a collection of techniques designed to reduce catastrophic thinking and perceptions of injustice, two psychosocial risk factors that have been shown to contribute to prolonged work-absence."
45612700|NCT04682873|Drug|Enisamium Iodide|"Capsule formulations of the active product (enisamium iodide 500 mg; Investigational medicinal product 1 [IMP-1]).~1 capsule Amizon® Max contains: enisamium iodide 500 mg.~Amizon® Max (active ingredient: enisamium iodide; IMP-1 will be administered as 1 capsule 4 times a day, every 6 hours (total dose 2,000 mg per day). Capsule will be taken orally (swallowed whole), together with a sufficient amount of liquid (preferably water).~Treatment will start on Day 1 (randomization) and for up to 168 hours after the first dose administration i.e. Day 7 or Day 8. The site staff will ensure that the IMP (1 capsule) is taken every 6 hours by the study subjects.~For documentation purposes, the IMP-1 packs (empty blister / blister with unused capsules) will be kept at the site and drug accountability forms are completed."
45612701|NCT04682873|Drug|Placebo|"Capsule formulations of the reference product placebo Amizon® Max (IMP-2), will be identical in appearance (size, shape, and color), taste, and smell as the active formulation capsule.~1 capsule placebo Amizon® Max contains: placebo (no active substance).~Amizon® Max placebo (IMP-2), will be administered as 1 capsule 4 times a day every 6 hours. Capsule will be taken orally (swallowed whole), together with a sufficient amount of liquid (preferably water).~Treatment will start on Day 1 (randomization) and for up to 168 hours after the first dose administration i.e. Day 7 or Day 8. The site staff will ensure that the IMP (1 capsule) is taken every 6 hours by the study subjects.~For documentation purposes, the IMP-2 packs (empty blister / blister with unused capsules) will be kept at the site and drug accountability forms are completed."
45612702|NCT02732119|Drug|Ribociclib|supplied in 50 mg, 200 mg capsules/tablets taken orally and dosed daily for 28 day cycle
45612703|NCT02732119|Drug|Everolimus|supplied in 2.5 mg tablets taken orally, daily for 28 day cycle
45911447|NCT02008214|Drug|Placebo|Placebo matching pentoxifylline dosage
45911448|NCT02008240|Procedure|Needle aspiration of hydrosalpinx|Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
45911449|NCT02008240|Procedure|Salpingectomy|laparoscopic surgical removal of affected tube is done with bipolar electrocoagulation for hemostasis. The mesosalpinx is coagulated as close a possible to the fallopian tube to avoid any compromise in the ovarian blood supply . In cases with marked adhesion, proximal ligation and a distal fenestration is done .
45911450|NCT02008253|Procedure|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Main outcome measures included UCVA, BCVA, refraction, keratometry and computerized analysis of corneal topography.
45911451|NCT02008279|Biological|100 mg CNTO 3157|A single subcutaneous (SC) (under the skin) injection of 100 mg CNTO 3157
45612704|NCT02732119|Drug|Exemestane|supplied in 25 mg tablets taken orally, daily for 28 day cycle
45612705|NCT04529915|Diagnostic Test|Exosome sampling|"Centrifugation of blood plasma~Size exclusion chromatography~ELISA assay, Western blotting~Deep-learning analysis"
45612706|NCT03384719|Dietary Supplement|35 g protein (30% milk + 70% rapeseed)|"The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)~Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day."
45612707|NCT03384719|Dietary Supplement|35 g protein (54% milk + 46% rapeseed)|"The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)~Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day."
45612708|NCT03384719|Dietary Supplement|35 g protein (100% milk)|"The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day."
45612709|NCT04476329|Drug|Regorafenib 40 MG|Regorafenib (BAY 73-4506) is an oral small molecule tyrosine kinase inhibitor (TKI) that potently blocks multiple protein kinases, including kinases involved in tumor angiogenesis (vascular endothelial growth factor receptor [VEGFR] 1, 2, 3, Tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 [TIE2]), stem cell growth factor receptor (KIT, rearranged during transfection [RET], p38-alpha, a member of the mitogen activated protein kinase [MAPK] family, proto-oncogene c-RAF [c-RAF], proto-oncogene BRAF [BRAF], BRAFV600E), metastasis (VEGFR3, platelet-derived growth factor receptor [PDGFR], fibroblast growth factor receptor1 [FGFR1]) and tumor immunity (colony stimulating factor 1 receptor [CSF1R]).
45612710|NCT04448717|Diagnostic Test|COVID-19 Antibody testing|COVID-19 Antibody testing in venous blood and/or saliva samples.
45612711|NCT03850951|Device|Lingual appliances|Patients with moderate crowding will be treated without extraction using lingual appliances.
45612712|NCT03850951|Device|Labial appliances|Patients with moderate crowding will be treated without extraction using labial appliances.
45612713|NCT05174195|Drug|Desogestrel 0.075 milligram|Inserted after 3 months use of DESOGESTREL
45612714|NCT05174195|Drug|Implanon NXT® subdermal implant|Inserted immediately
45612715|NCT05238727|Drug|1.8 ml mepivacaine hydrochloride|1.8 ml mepivacaine IANB
45612716|NCT05238727|Drug|3.6 ml mepivacaine hydrochloride|3.6 ml mepivacaine IANB
45612717|NCT05238727|Drug|1.8 ml mepivacaine hydrochloride IANB plus 1.8 ml articaine hydrochloride BI|1.8 ml mepivacaine IANB plus 1.8 ml articaine BI
45612718|NCT05174117|Combination Product|single irradiation|46-48h irradiation after photosensitizer injection: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2
45612719|NCT05174117|Combination Product|Double irradiation|46-48h, 72h after photosensitizer injection, divided into two irradiation times: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2;Power density: 200mW·cm-2, irradiation time: 300s, volume density: 60 J·cm-2.
45612720|NCT05173571|Combination Product|Comprehensive patient support program (educational, physiotherapy, nutritional, emotional)|Identification of patient needs and non-pharmacological holistic approach, including education, emotion and nutrition (nurse) and optimization of physical activity (respiratory physiotherapist)
45612721|NCT03754153|Device|Balanced Binocular Viewing (BBV)|The dose of BBV therapy will be one hour a day or 2x30 min/day (depending on child's attention span and/or need to implement the treatment around the family daily routine).
45612722|NCT03754153|Other|Standard Therapy - Occlusion (patching) or blurring (atropine)|The prescribed dose of occlusion treatment / patching (parental choice) will depend on the severity of amblyopia, as by current clinical practice based on PEDIG studies
45911452|NCT02008279|Biological|300 mg CNTO 3157|2 SC injections of CNTO 3157 providing a total dose of 300 mg
45911453|NCT02008279|Biological|600 mg CNTO 3157|4 SC injections of CNTO 3157 providing a total dose of 600 mg
45911454|NCT02008279|Biological|300 mg CNTO 3157|300 mg of CNTO 3157 as an intravenous (IV) infusion (into a vein) administered over a period of 30 minutes
45911455|NCT02008279|Drug|Placebo|SC injections of placebo (number of injections to equal number of injections of CNTO 3157)
45911456|NCT02008305|Device|protocol of optimization ALARA|
45911457|NCT02008305|Device|protocol of optimization Philips|
46068863|NCT05392556|Dietary Supplement|Probiotic|Cerebiome (Lallemand Health Solutions): probiotic supplement containing Bifidobacterium longum R0175, Lactobacillus helveticus R0052, and maltodextrin. Dosing: Oral, 3.6 g/d containing 3x10^9 CFU/d (powder form)
46068864|NCT05392556|Dietary Supplement|Prebiotic|Bimuno-GOS (Clasado Biosciences): Dosing: Oral; 3.6 g/d containing 2.75 g active GOS/d (powder form)
46068865|NCT05392556|Other|Placebo|Maltodextrin 3.6 g/d (powder form)
46073641|NCT00830037|Drug|IV Iron|IV iron sucrose 200 mg over 2 hours baseline visit, week 2, week 4, week 6 and week 8 for a total of 1000mg total dose. Further cycles of iv iron may be used based on periodic monitoring of iron stores.
46073642|NCT00830037|Drug|Ferrous Sulfate|Oral ferrous sulfate 325mg three times daily over 8 weeks. Further cycles of oral iron may be used based on periodic monitoring of iron stores.
45612723|NCT04371887|Other|Local Tailoring|"The guided local tailoring approach will employ a standard structured process, including (1) convening a project team, (2) conducting a local diagnostic process to identify likely barriers using provider/patient survey and interviews with providers/administrators, (3) selecting from a pre-developed menu of implementation strategies categorized by core function (form and function menu), and (4) deploying the selected strategies in collaboration with local implementation and improvement consultants."
45445298|NCT03783663|Behavioral|Misfit Shine 2|The intervention group was given a Misfit Shine 2 to monitor sleep throughout the 12-week intervention period. Participants were instructed to wear the device on the wrist, which is better for capturing sleep than the other wear locations. Participants were instructed on how to self-monitor total sleep time and select a goal for that behavior. Further, participants were asked to view feedback on their sleep time daily on the Misfit smartphone app, which they used to monitor their progress toward achieving their behavioral goals.
45445299|NCT02057926|Drug|The effect of tetracycline in degradation and permeability of collagen membranes.|
45612724|NCT05173181|Device|Flexible intramedullary nail|Fixation of distal ulna fracture with flexible intramedullary nail
45612725|NCT03785275|Radiation|gallium-68-exendin PET/CT|PET/CT scan after injection with gallium-68-exendin
45612726|NCT03380117|Behavioral|eBridge Online Counseling|In eBridge, students take an online screen and receive personalized feedback about their self-reported depression, alcohol/substance use, and level of functioning. Students are randomly assigned to either the eBridge or control condition. In the eBridge condition, personalized feedback is provided in a graphic format that is accompanied by motivational-interviewing-adherent statements. In this condition, students' communications with eBridge counselors will occur via online dialogues, in which students and counselors exchange messages using a secure website. In the control condition, personalized feedback will also be delivered online to students, highlighting their personal data and specify links between key screening variables and negative outcomes. However, in the control condition, this is provided in a straightforward graphic, informational format, which is consistent with standard practice in online screening programs for college students.
45612727|NCT03712267|Behavioral|Electronic Media Enhanced|Research assistants will provide participants' therapists with information from participants' electronic messaging prior to typically scheduled clinical appointments.
45612728|NCT03712267|Behavioral|Treatment as Usual|Research assistants will not review or provide participants' therapists with information from participants' electronic media and will compare with the Electronic Media Enhanced cohort to see if there was a difference in therapy outcomes.
45445300|NCT01561287|Procedure|Dermal Autograft|Patients in the dermal autograft group will undergo harvest of a dermal autograft from the lower abdomen at the time of mastectomy, which will be used to cover the lower pole of the tissue expander.
45612729|NCT03384485|Diagnostic Test|antiphospholipid syndrome|blood test for enzyme test,plasma and Lys-3-3 plasma
45612730|NCT02520349|Device|MarkTen and e-Go e-cigarettes|
45612731|NCT03380039|Genetic|CAR-BCMA T cells|"Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied."
45612732|NCT03380039|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
45612733|NCT03380039|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
45612734|NCT05238259|Device|kinesiotaping|Kinesio tape is the name of an adhesive tape created by Kenzo Kase in Japan in 1973. Kinesiotaping is latex-free with 100% cotton fibers that has no pharmaceutical effect, designed to mimic the elasticity properties of the muscle, skin, and fascia. These properties make it resistant and wearable for a long period, in general, 3 to 5 days at a time; it is even water resistant.
45612735|NCT05238259|Device|wrist wheel|Wrist wheel is a therapy aid that exercises muscles in the wrist, forearm and shoulder. It utilizes exercises known as pronation and supination moving from pronation to supination exercises is made easy because of the wheel. It allows the pateint to easily roll wrist back and forth focusing on the wrist and arm
45612736|NCT03125213|Drug|AL-3778|AL-3778 tablets
45612737|NCT03125213|Drug|Peginterferon Alfa-2A|Peginterferon Alfa-2A for subcutaneous injection
45612738|NCT03125213|Drug|Placebo Oral Tablet|Placebo to Match AL-3778 tablet
45612739|NCT05238181|Diagnostic Test|Assess pyloric or pseudopyloric metaplasia of corpus by H&E stains|"The pathologists assess pyloric or pseudopyloric metaplasia. Pyloric or pseudopyloric metaplasia of corpus is defined as the presence of torturous deep glands in a pseudo-pylori pattern with focal or complete loss of parietal cells. The score of pyloric or pseudopyloric metaplasia of the corpus mucosa is ranging from 0 to 3. Score 0 is no loss of parietal cells with normal fundus gland patterns. Score 1 presents focal loss of parietal cells and scattered patterns of pyloric or pseudopyloric metaplasia with few forming pylorus-like glands. Score 2 presents focal loss of parietal cells and scattered patterns of pyloric or pseudopyloric metaplasia mixed with >= 4 pylorus-like glands. Score 3 was clusters of pylorus-like glands; the metaplasia involves > 60% of mucosa and extends to the lower third of mucosa."
45612740|NCT05238181|Diagnostic Test|Assess pyloric or pseudopyloric metaplasia of corpus by TFF2 immunohistochemistry stains|"Mouse anti-human TFF2 monoclonal antibody (R&D Systems) is used to stain gastric corpus tissues to assess the presence and degree of SPEM. The score of TFF2 staining of the corpus mucosa is ranging from 0 to 3. Score 0 is not stained. Score 1 is a scattered pattern of TFF staining between parietal cells; the staining is limited in the middle third of the mucosa. Score 2 is TFF2-expressing cells distributed over both the middle and lower third of the glands. Score 3 is torturous gastric oxyntic glands with a diffuse expression of TFF2 into the whole glands over both the middle and lower third of the glands of the mucosa."
46073643|NCT00834925|Drug|low dose diltiazem|Low dose diltiazem: 0.15mg/kg over 2 minutes Standard dose diltiazem: 0.25mg/kg over 2 minutes
45445301|NCT01561287|Procedure|AlloDerm|The acellular dermal matrix used in our study is AlloDerm (LifeCell Corp., Branchburg, N.J.) The AlloDerm group will consist of patients without a suitable abdomen for autografting and those who declined the dermal autograft procedure. Patients in the dermal allograft group will have placement of AlloDerm over the lower pole of the tissue expander. Patients with a lower abdominal scar and sufficient abdominal laxity for autograft harvest will be offered this technique.
45445302|NCT02058004|Procedure|Cricoid pressure|Firm pressure on the cricoid cartilage with the goal of occluding the esophagus during endotracheal intubation.
45445303|NCT02058082|Procedure|Intracytoplasmic sperm injection|
45612741|NCT05238181|Diagnostic Test|The assessment of corpus-predominant gastritis index (CGI), Operative Link for Gastritis Assessment (OLGA), and Operative Link on Gastric Intestinal Metaplasia assessment (OLGIM)|"We take five gastric mucosal biopsies in each patient under gastroscopy, including two from the antrum (at the lesser and greater curvature, 2 cm within the pylorus, respectively), two from the corpus (at the lesser curvature of the lower corpus and the greater curvature of the middle corpus, respectively), and one from the lesser curvature of the high corpus.~The pathologists assess the gastric pathology according to the updated Sydney system. Accordingly, the histological findings are translated into CGI, the Operative Link for Gastritis Assessment (OLGA), and the Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) stages."
45612742|NCT05173025|Drug|Fimasartan|- Fimasartan group: fimasartan, 60 mg once a day, oral administration
45612743|NCT03395119|Drug|Ozone|After the four-week supplementation period, each subject will be blindly exposed on consecutive days to filtered air for 2 hours and to 0.3 ppm ozone for 2 hours, while undergoing intermittent moderate exercise (minute ventilation of 20 L/min/m²).
45612744|NCT03395119|Dietary Supplement|Fish Oil|3 (1-gram) soft-gels daily Commercially available, enteric-coated, soft-gels formulated to deliver >60% eicosapentaenoic/docosahexaenoic acids (EPA/DHA)
45612745|NCT03395119|Dietary Supplement|Olive Oil|3 soft-gels daily Commercially available soft-gels containing 1 gram of USDA organic certified, cold pressed, extra virgin, olive oil
45612746|NCT03384407|Device|Red cell survival in INTERCEPT treated red cells|Red cell recovery/survival analysis of untreated and INTERCEPT treated RBC concomitantly
45612747|NCT02520817|Dietary Supplement|175 mg zinc gluconate, 50000 IU vitamin A, 500 mg vitamin C and 100 mg vitamin E once daily plus lactulose; dose 30-60 ml/day for 3 months|
45612748|NCT02520817|Dietary Supplement|Lactulose|
45612749|NCT02520193|Procedure|Protocolized early mobilization in ICU|
45612750|NCT03379883|Procedure|Pulsed radiofrequency (P-RF)|"Intra articular RF~Insertion of the RF cannula within the joint. The recommended parameters are a pulse width of 20 msec and a rate of 2 Hz at 42°C for 10min.~Genicular nerve RF ablation.~The RF probe will be placed. A 50 Hz-frequency sensorial stimulation will be applied with a threshold of < 0.6 V"
45612751|NCT03379883|Procedure|Platelet rich plasma (PRP)|Under ultrasound guidance while the patients in a sitting position. In total, 3 to 8 mL of PRP will be injected via the inta-articular route
45612752|NCT03388021|Procedure|completion angiography followed by endovascular treatment of residual or underlying lesions|completion angiography followed by endovascular treatment as thromboembolectomy under fluoroscopic guidance using Fogarty over the wire, angioplasty, stenting, or Intraarterial thrombolysis to treat residual or underlying lesions
45612753|NCT03379805|Diagnostic Test|Near Infrared Fluorescence Imaging|The functional state of lymphatics is investigated using near infrared fluorescence imaging, NIRF.
45612754|NCT03379805|Diagnostic Test|Non-contrast MRI|The anatomy is described using non-contrast MRI.
45612755|NCT03379805|Diagnostic Test|Strain Gauge Plethysmography|The capillary filtration rate is measured using plethysmography
45612756|NCT03387943|Drug|PLD|intravenous infusion of liposomal doxorubicin 35 mg/m2, d1,once every 21days, for 6 cycles.
45612757|NCT03387943|Drug|Cisplatin|cisplatin 75 mg/m2, drip, total dose should be carried out on d1-3; once every 21days, for 6 cycles.
45612758|NCT03384251|Behavioral|comprehensive sex education|A comprehensive sex education program to be delivered in approximately six (6) sessions comprising of an introductory lesson on susceptibility and severity of teenage pregnancy, personal and community values, female reproductive system, contraception and decision-making skills.
45612759|NCT03390049|Device|Fractional CO2 Laser Treatment|After obtaining a negative urine pregnancy test, each subject assigned to the fractional CO2 laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe with the following settings: dot power 26 Watts, dwell time 1000 μs, dot spacing 1000 μm, and smart stack parameter from 1 to 3. Stack 1 is used at baseline; stack 3 is used 6 and 12 weeks after.
45612760|NCT03390049|Device|Sham Laser Treatment|After obtaining a negative urine pregnancy test, each subject assigned to the sham laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe. However, these sham laser sessions will administer no fractional CO2 laser energy. To increase the likelihood that subjects assigned to sham laser remain blinded to treatment arm assignment during the study, MonaLisa Touch will provide a software package with settings that allow for reproduction of the sounds generated during a regular fractional CO2 laser session but using 0 Watts of power.
45612761|NCT03379493|Biological|ET190L1 ARTEMIS™ T cells|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct, administered by intravenous (IV) infusion
45612762|NCT03384095|Drug|Hyaluronic Acid (HA)|Dosage form: hyaluronic capsules; Dose: 100 mg; Frequency: twice daily; Duration: 26 weeks
45612763|NCT03384095|Other|Placebo|Dosage form: microcrystalline cellulose (MCC) capsules; Dose: approx. 100 mg (determined by weight of HA counterpart); Frequency: twice daily; Duration: 26 weeks
45612764|NCT03379415|Device|Footwear|Different types of footwear will be tested to see if these can be used to help slow the progression of osteoarthritis in meniscectomy patients or even stop it from occurring.
45759077|NCT04270019|Drug|Polyethylene Glycol 3350|In order to prepare PEG 3350 50% weight/volume, 25 grams of the sterilized PEG 3350 will be measured out and placed into a sterilized glass bottle then 25 mL of sterile water will be added. The solution will be allowed to rest for 10 minutes so that dissolution may occur. More sterile water will then be added so the total volume is 50mL. This solution will then be sterilized by the Halifax Health Infirmary pharmacy department using a liquid autoclave cycle of 120 degrees Celsius for 20 minutes in a glass vial. The 50 mL solution will be portioned into 2mL sterilized glass vials using a standard aseptic technique. The solutions will be kept at a solid frozen state between negative 25 degrees Celsius and negative 10 degrees Celsius for a maximum of 45 days. The solutions will be removed from storage on the day of surgical utilization in order to ensure storage guidelines are kept to the highest standards.
45759078|NCT04270019|Drug|Normal Saline|Standard solution of sterile normal saline.
45612765|NCT03379415|Procedure|Gait analysis|Gait analysis will be done during several different tasks wear the footwear
45612766|NCT03660865|Device|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Primary eye will receive Light adjustable lens with Light delivery Device treatments
45612767|NCT03660865|Device|Control IOL|Fellow eye will receive control IOL
45612768|NCT03379337|Diagnostic Test|Dental imaging|The target teeth positions for imaging included 4 incisors and all 4 canines. Only the vestibular and interproximal regions were of interest. Images were taken of these target teeth positions regardless of whether or not they exhibited plaque, consisted of full or partial restorations, contained major cracks/fractures, chips, or were missing. Other captured images included any abnormality of the tooth or gum exhibiting red fluorescence physically accessible by the devices.
45612769|NCT03394963|Behavioral|Food-based dietary guidelines for healthier diet|Develop and validate food-based dietary guideline and a healthy eating index
45612770|NCT03384017|Other|Transcutaneous Spinal Cord Stimulation and Gait Training|"TSCS will be applied using a midline electrode placed on the skin between spinous process T11 -T12 and two electrodes placed symmetrically on the skin over the lower abdomen as anodes. A symmetrical biphasic rectangular waveform, at 50 Hz and 1 millisecond, is used to provide 30 continuous minutes of stimulation.~Subjects will participate in 24 two-hour sessions of physical therapy over eight weeks. In each session, subjects will receive TSCS continuously for 30 minutes, using the parameters outlined above. During stimulation, subjects will participate in strengthening, segmental task practice, and gait-based interventions. Participation in gait training will continue following the stimulation period for the duration of the session."
45612771|NCT03379181|Drug|Propranolol|Patients receive a single dose of 80 mg propranolol p.o.
45612772|NCT03389971|Procedure|catheter-directed thrombolysis|catheter-directed thrombolysis with commercially available multi-sidehole catheter or USAT catheter
45612773|NCT03383939|Drug|Group A|one nebulization with 250mg alpha-1-antitrypsine diluted in 10ml injectable solution once a day during 1 month. A CR-60 high flow compressor and Ventstream nebulizer were used for nebulization.
45612774|NCT03383939|Drug|Group B|10ml of 0.9% NaCl saline solution nebulised once daily for 1 month. A CR-60 high flow compressor and Ventstream nebulizer were used for nebulization.
45612775|NCT03379103|Drug|Sevoflurane|Patients will receive 1 MAC sevoflurane for 15 minutes before the installation of member ischemia by tourniquete
45612776|NCT03379103|Drug|Propofol|Patients will receive propofol for 15 minutes before the installation of member ischemia by tourniquete
45612777|NCT03383861|Diagnostic Test|Dual-Energy X-ray Absorptiometry (DXA)|BMD t-score derived from DXA scan
45612778|NCT03387709|Behavioral|Pistachio-enriched diet|Composition of prescribed diets will be based on individual preferences, with the goal of consuming 1.5 oz of pistachios per day and increased energy expenditure. During the 4-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Pistachios will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
45612779|NCT03387709|Behavioral|General dietary guidance diet|During the 4-month group intervention, study subjects will participate group sessions, receive telephone, email and/or text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
45612780|NCT03383705|Device|VBeam Prima|Up to four treatments will be performed every 4-6 (±1) weeks.
45612781|NCT03387631|Drug|Artemether-Lumefantrine|
45612782|NCT03383549|Other|Tele-rehabilitation|Each subject undergoes a combined rehabilitation protocol, which will be administered on a daily basis, designed to alternate physical exercises and cognitive training. Each daily session lasts between 30 and 45 minutes. The complete protocol lasts 8 weeks.
45612783|NCT03383471|Biological|Invossa K Inj.|Invossa K Inj.
45612784|NCT03383471|Drug|Placebo|Placebo control
45612785|NCT03383393|Drug|Intracoronary bolus of adenosine (adenocor), Integrilin (eptifibatide) or nitroglyzerin (nitronal)|intracoronary drugs
45612786|NCT03394807|Drug|Levobupivacaine|Levobupivacaine injection to Transversus abdominis plane and rectus sheath
45612787|NCT03394807|Drug|Placebo|Saline injection to Transversus abdominis plane and rectus sheath
45911458|NCT02008331|Dietary Supplement|SYNBIOTIC|"INTERVENTION: Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.~PLACEBO: Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water."
45612788|NCT03383315|Drug|Tramadol|One dose of intravenous tramadol 50mg
45612789|NCT03383315|Drug|Metoclopramide|One dose of intravenous metoclopramide 10mg
45612790|NCT03383315|Drug|Placebo|Sodium chloride 0.9%
45612791|NCT03394729|Drug|Propolis tablet to limit dental biofilm|The tablets will be offered in an exact number of days of use. Collection of total stimulated saliva and dental biofilm will be performed at the beginning of the study (before tablet consumption) and 7 days after the intervention. Saliva samples from each individual will be collected in separate containers as well as the biofilm samples, both at baseline and after 7 days
45612792|NCT03394729|Drug|Xilytol tablet to limit dental biofilm|The tablets will be offered in an exact number of days of use. Collection of total stimulated saliva and dental biofilm will be performed at the beginning of the study (before tablet consumption) and 7 days after the intervention. Saliva samples from each individual will be collected in separate containers as well as the biofilm samples, both at baseline and after 7 days.
45759079|NCT02992301|Drug|Alirocumab|Injectable prescription medicine called a PCSK9 inhibitor.
45612793|NCT04446949|Other|Register follow-up|Number of adverse pregnancy outcomes
45612794|NCT04445285|Drug|Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)|2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses
45612795|NCT04445285|Drug|0.9%sodium chloride|Placebo of 0.9% sodium chloride every 24 hours for five (5) consecutive days; a total of 5 doses
45612796|NCT03379025|Other|Electronic cigarette|electronic cigarette and cartridge refills (also known as pods)
45612797|NCT03252925|Drug|N-Acetylcysteine|50mg/Kg.d, oral
45612798|NCT03252925|Drug|Placebo Oral Tablet|50mg/Kg.d, oral
45612799|NCT05171543|Procedure|Periapical surgery with placement of an allograft and a membrane|Periapical surgery will be done followed by placement of an allograft into the defect and a membrane over the defect before closure of the flap.
45612800|NCT03383237|Drug|Apatinib|500mg/d,q.d.,p.o.
45759080|NCT00743717|Device|zirconia femoral component|total knee arthroplasty performed using implant with zirconia femoral component
45759081|NCT00743717|Device|cobalt chrome femoral component|total knee arthroplasty performed using implant with cobalt chrome femoral component
45759082|NCT00744965|Drug|Glyburide|Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.
45759083|NCT00744965|Drug|Placebo|Sham dose adjustments of the placebo will be made.
45759084|NCT04385225|Other|Longitudinal follow-up|Longitudinal hearing, vestibular and cognitive follow-up
45759085|NCT00763867|Drug|Placebo|
45759086|NCT00763867|Drug|Sildenafil|
45759087|NCT00749879|Drug|Proellex|25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting
45759088|NCT04385147|Other|Endoscopic management according to standard of care|Endoscopic management according to standard of care by ERCP or EUS according to the indication in each case
45759089|NCT00711347|Device|DisCoVisc|Use of Alcon's DisCoVisc Ophthalmic Viscosurgical Device(4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery with intraocular lens implantation.
45759090|NCT00711347|Device|Healon5|Use of Abbott Medical Optics (AMO) Healon5 Ophthalmic Viscosurgical Device (2.3% Sodium Hyaluronate) during cataract surgery with intraocular lens implantation.
45759091|NCT01276223|Drug|Difluprednate 0.05% ophthalmic emulsion|Topical ocular steroid
46068866|NCT05381610|Device|Peristeen|The Peristeen system will be handled by Coloplast trained personnel. The investigator and a trained nurse will participate in all the investigation related procedures. The nurse is trained in the handling of the investi-gational product as well as this is described in detail in the Instruction for Use (IFU). Subjects (and their caregivers, if appropriate) will also be trained on the use of Peristeen prior to independent use at home.
45612801|NCT03048799|Device|Radiofrequency|The radiofrequency application protocol will be used in the form of capacitive electrical transfer, bipolar configuration, with CAPENERGY device (Figure 1), which has two electrodes: an active one, which will be introduced into the anal region, using a condom and gel to The emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The active electrode has at its end a sensor capable of capturing the temperature. The temperature used in the treatment will be 41 ° C, which this parameter will be placed in the equipment. Upon reaching the desired heating, the apparatus maintains the temperature and thus the application of the radiofrequency will be maintained for 2 minutes.
45612802|NCT03125057|Drug|Hemoporfin PDT|Photodynamic therapy is performed using hemoporfin. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
45612803|NCT03387241|Drug|Fluticasone/ Formoterol|See above
45612804|NCT03387241|Drug|fluticasone/ salmeterol|See above
45612805|NCT03378947|Other|clinical and pathological data EBV-related GZL and DLBCL|"Invesrigators will retrospectively collect clinical and pathological data of all EBV-related GZL and DLBCL in immunocompetent patients diagnosed in the pathology department Centre Hospitalier Lyon Sud.~Investigators will analyze their clinical feature and prognosis."
45612806|NCT05152121|Other|Carb and fat counting|In the 7 days leading up to the study, participants were contacted to review blood glucose levels with CGMS, food and activity diary. basal rates and insulin carbohydrate ratio and sensitivity factor were changed according to the CGMS values and normoglycemia was achieved.In the study day same meals were served which included high fat, high energy density test meal containing 80 gram carbohydrate (34%), 70 gram fat (66%) and 35 g protein (14%).The participants had to have no glucose fluctuations 2 hours before study entry based on CGMS, no correction boluses for at least 4 hours before the test meal consumption and fasting glycemia in the range of 70-180 mg/dL on both study days.The participants received the test meal calculating insulin dose by CC on the first study day and calculating insulin dose by and fat/protein counting in the second study day. The test meal consumption was completed in 20 minutes under supervision by a caregiver and a dietician of the research team
45759092|NCT01276223|Other|Difluprednate vehicle|Inactive ingredients used as Run-In and placebo comparator
45759093|NCT01275833|Device|Cardiac resynchronization therapy-defibrillator|Device programming that modifies AV timing
45759094|NCT01279733|Genetic|Microarray analysis|"Microarray performed on prenatal specimen:~Fluorescence in-situ hybridization (FISH) or other standardized tests such as qPCR or MLPA will be performed on the fetal sample to confirm abnormal MA findings of known and unknown clinical significance which are discordant with CC findings, including anomalies normally detected by karyotyping.~Microarray analysis of DNA from parental blood samples will be used to determine whether CNVs detected in a fetal sample are also present in a healthy parent, in which case no further evaluation will take place, moreover any finding in a fetus which is duplicated in a parental microarray is considered to be confirmed."
45759095|NCT01275755|Drug|Placebo|
45759096|NCT01275755|Drug|ADL5945 0.25 mg|
45759097|NCT00784225|Drug|selenium|200 mcg daily for 7-12 years
45759098|NCT00784225|Drug|vitamin E|400 IU daily by mouth for 7-12 years
45759099|NCT00784225|Drug|vitamin E placebo|daily for 7-12 years
45612807|NCT03378869|Procedure|esophagectomy|all the included participants had received esophagectomy, either Ivor Lewis or tri-incision, or more complex procedures.
45612808|NCT03378791|Drug|Iron bisglycinate Oral Tablet|
45759100|NCT00784225|Drug|selenium placebo|daily for 7-12 years
45445304|NCT03777579|Drug|JS001，an engineered anti-PD-1 antibody|JS001 at a fixed dose of 240 milligrams via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
45612809|NCT03378791|Drug|Ferrous Fumarate Oral Tablet|
45612810|NCT03383003|Drug|Nexium|Esomeprazole ( Nexium )40 mg tid daily for 14 days in the high dose dual therapyarm and 40 mg bid daily for 7 days in the non-bismuth quadruple therapy
45759101|NCT02991989|Behavioral|Exercise Snacking|"Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are; sit-to-stand from a chair, marching on the spot, seated knee extensions alternating legs, standing knee bends alternating legs, and standing calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.~Two exercise snacks are completed each day for 28 days; once in the morning and once in the evening, or at least separated by 2 hours."
45759102|NCT02991989|Dietary Supplement|Yogurt|Participants are asked to consume 150 g of yogurt (Arla, Skyr- natural flavour) with their breakfast meal. Participants may substitute the yogurt for another part of their regular breakfast, or add the yogurt to their regular breakfast, with participants asked to record a log book of daily yogurt consumption and to complete a three day food diary during the last week of the 28 day intervention period.
45759103|NCT02991911|Biological|MEDI3726 Post-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, with a prior taxane-based chemotherapy in the mCRPC setting
45759104|NCT02991911|Biological|MEDI3726 Pre-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, without a prior taxane-based chemotherapy in the mCRPC setting
45759105|NCT02991911|Biological|MEDI3726 & Enzalutamide Combo|MEDI3726 in combination with Enzalutatmide after prior treatment with abiraterone, with or without a prior taxane-based chemotherapy in the mCRPC setting
45759106|NCT01275131|Drug|Insulin aspart|
45759107|NCT01275131|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
45759108|NCT00749957|Biological|rAAV2-CB-hRPE65|Recombinant adeno-associated virus vector expressing RPE65
45759109|NCT01274429|Drug|Peanut flour|Peanut flour that is ingested daily and administered in gradually increasing amounts up to a maximum maintenance dose.
45759110|NCT04272671|Other|Educational Intervention|The intervention has the following components: 1) alerts given to providers to identify patients taking opioids or benzodiazepines (BZD) and therefore at risk for falls; 2) educational materials to inform providers on best practices for de-prescribing opioids and BZDs in patients at risk; and 3) recommendations on de-prescribing provided by a consultant pharmacist. Impact of the intervention will be evaluated using pre-post surveys evaluating changes in providers' knowledge, confidence, and skills as well as information from the EHR to evaluate impact of the intervention on de-prescribing opioids and BZDs.
45759111|NCT01273883|Dietary Supplement|Magnesium|Magnesium 532 mg a day
45759112|NCT01273883|Other|Placebo|matching form/dosage
45759113|NCT01273805|Drug|Hydroxychloroquine|
45759114|NCT01273181|Biological|PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes|
45759115|NCT01273181|Drug|Aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses
45759116|NCT01273181|Drug|Cyclophosphamide|60 mg/kg/day x 2 days intravenous (IV)over 1 hour.
45759117|NCT01273181|Drug|Fludarabine|25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
46068867|NCT05378113|Drug|Ondansetron|Ondansetron (Zofran) is a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist commonly used to treat postoperative nausea and vomiting.
45445305|NCT03777579|Drug|Nab-Paclitaxel|Nab-Paclitaxel at a starting dose of 125mg per square meter via IV infusion on Days 1, 8 of each 21-day cycle. Nab-Paclitaxel will be administered until disease progression or unacceptable toxicity.
45612811|NCT03383003|Drug|Amolin|Amoxicillin 750 mg qid daily for 14 days in the high dose dual therapy and amoxicillin 1 g bid daily for 7 days in the non-bismuth quadruple therapy
45612812|NCT03383003|Drug|Klaricid|clarithromycin 500 mg bid daily for 7 days in the non-bismuth quadruple therapy
45612813|NCT03383003|Drug|Flagyl|Metronidazole (Flagyl) 500 mg tid daily for 7 days in the non-bismuth quadruple therapy
45612814|NCT03378713|Drug|GROUP 1: Long testosterone|Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application
45612815|NCT03378713|Drug|GROUP 2: Short testosterone|Application of testosterone in transdermal gel begins on day 21 of menstrual cycle, from the luteal phase of the cycle prior to initiation of controlled ovarian stimulation and until menstruation (approximately 10 days). The COS begins the day after the last testosterone application.
45612816|NCT03378713|Drug|GROUP 3: Control|The COS starts directly on the second day of the cycle without prior medication.
45612817|NCT04445675|Other|Support for breastfeeding and the feeding of infants' with breast milk|The content of the support for breastfeeding and the feeding of infants' with breast milk consists of the titles of the importance of breastfeeding and breast milk, the effect of breast milk on preventing jaundice, the importance of early start of breastfeeding, breastfeeding techniques and positions in infants, milking, storage and later use of milk, increasing the quantity and quality of milk, and nutrition of the mother during breastfeeding.
45759118|NCT01272947|Drug|Diclofenac sodium|Topical gel 1%- 4 times daily
46068868|NCT05378113|Drug|Lidocaine|Lidocaine is a local anesthetic agent used intravenously prior to the propofol injection. Currently the standard of care to help decrease the severity of pain in the injection site, a common side effect of propofol.
45612818|NCT04079465|Device|O2matic|O2matic controls oxygen supply with a closed-loop feedback from a pulse oximeter. The aim is to maintain SpO2 within a predefined target interval according to guidelines for the specific condition causing hypoxemia, with the lowest possible supplementation of oxygen.
45612819|NCT04967963|Procedure|HAM|Transplantation of HAM
45612820|NCT03378401|Drug|Octenidinedihydrochlorid|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
45612821|NCT03378401|Other|Placebo|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
45612822|NCT03378323|Drug|Multiple injection local anesthetic|Multiple injection local anesthetic
45612823|NCT03378323|Drug|Single injection local anesthetic|Single injection local anesthetic
45612824|NCT03382691|Device|blood pressure check|Check blood pressure using new device and conventional device alternatively. Compare blood pressure measured with new device and conventional device.
45612825|NCT03378245|Behavioral|Behavioral modification and education on pharmacologic treatments.|Education and counseling of care-giving staff on behavioral modification strategies, as well as education about current standard of care best practices for pharmacologic interventions.
45612826|NCT03378089|Behavioral|Music Therapy|No narcotic or anti-emetic therapy will be administered for at least 2 hours prior to music therapy session. Music therapy sessions will be administered by a board certified music therapist (MT-BC) and last approximately 45 minutes. Involvement in sessions will be based on therapist and patient availability.
45612827|NCT03378089|Behavioral|No Music Therapy|Participants will fill the same 45 minute period in any way they choose; however, they will be asked to refrain from listening to recorded music during this time.
45612828|NCT03378011|Other|phototherapy|phototherapy either UVA1 or topical PUVA on acral vitiligo
45612829|NCT03125525|Device|Cefaly device|Use of Cefaly based upon the protocol of the approval study of the device, in which it is used once every day on the migraine prevention program
45612830|NCT03125603|Other|Consultation of the patient's medical files at the hospital|Gradation of the adverse events according to CTCAE scale 4.03 (June 2010).
45612831|NCT04923815|Device|THERMOCOOL SMARTTOUCH® Diagnostic/Ablation Deflectable Tip Catheter|THERMOCOOL SMARTTOUCH® catheter is a pressure catheter irrigated with cold saline, contact force sensing catheter. When used with Carto ®3 system, this catheter can provide a real time measurement for contact force. The magnitude and direction of the contact force can be displayed visually in the form of vector arrow on the top of catheter in Carto®3 system. It can be used for electrophysiological mapping and ablation of the heart.
45612832|NCT03382535|Behavioral|Voice therapy|Voice therapy with direct and indirect therapy elements.
45612833|NCT03382535|Behavioral|Voice therapy with carryover strategies|Voice therapy with direct and indirect therapy elements and supplementary tasks and reminders.
45612834|NCT03382535|Other|Control group|No therapy during eight weeks. After the control period half of the group will be provided with Voice therapy and half with Voice therapy with carryover strategies.
45612835|NCT03382379|Device|Active transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) as a device-based technology is employed by applying a very weak (2 mAmp) direct current over the skull for 1200 seconds with 30 seconds ramp up to 2 mAmp, and 30 seconds ramp down at the end.
45612836|NCT03382379|Device|Sham transcranial Direct Current Stimulation (tDCS)|Sham Transcranial Direct Current Stimulation (tDCS) as a device-based technology is employed by applying a very weak direct current over the skull. Sham mode will have just 30 seconds ramp up to 2 mAmp, 40 seconds on 2 mAmp stimulation and, 30 seconds ramp down with 1160 seconds no stimulation (just impedance control).
45612837|NCT03993197|Behavioral|Psychological and corporal group management|"After inclusion, patient will be divided into groups of 6 or 8 patients either in pre-operative or post-operative phase. Patient care will take place entirely in pre-operative or post-operative phase.~Each group will benefit of six one hour and a half sessions.~The frequency is established as follows:~First week a session of Body Strategy ©~Second week a psychological session with group of speech (Photolanguage ©).~Third week is a break Then the cycle currently described is repeated, for a total of 6 alternate sessions"
45612838|NCT03382067|Dietary Supplement|High Epicatechin/ Melissa|Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa chocolate + 7.2g caster sugar + 5g Melissa
45612839|NCT03382067|Other|Low Epicatechin/ Oat bran|Single consumption of a 55g bar of white chocolate containing: 50g Lindor chocolate + 5g oat bran
45612840|NCT03377933|Other|Compound Lactobacillus acidophilus|Compound Lactobacillus acidophilus Tablet
45612841|NCT03377855|Other|Default Prescribing Change|In the e-prescribing system, the default opioid dosage/duration is changed to the minimum recommended dosage from the CDC guidelines for short acting opioids.
45612842|NCT01327885|Drug|Eribulin mesylate 1.4 mg/m^2 intravenous|Administration of eribulin mesylate at a dose of 1.4 mg/m^2 as an intravenous (IV) bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
45612843|NCT01327885|Drug|Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV|Administration of dacarbazine at a dose of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 selected by the Principal Investigator [PI] or designee according to the subject's clinical status as an IV infusion over 15-30 minutes on Day 1 of every cycle, where the duration of each cycle is 21 days.
45759119|NCT01272947|Other|Placebo|Topical gel - 4 times daily
45759120|NCT01279343|Device|Foley bulb|This is a randomized trial comparing foley bulb with the use of misoprostol versus use of misoprostol alone for cervical ripening and labor induction.
46068869|NCT05366296|Biological|A Lyophilized COVID-19 mRNA Vaccine|Active substance: NTD-RBD derived from S protein of Omicron variant Excipient: ALC-0315 (4- hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2- hexyldecanoate), ALC-0159 (2-[(polyethylene glycol)-2000]-N, N-ditetradecylacetamide), DSPC [1,2- distearoyl-sn-glycero-3-phosphocholine], Cholesterol, Trometamol and Sucrose
46068870|NCT05366296|Biological|Placebo|Normal saline (0.9% sodium chloride solution
46068871|NCT05363839|Drug|ACH-000029|ACH-000029 will be administered orally via a capsule.
46068872|NCT05363839|Drug|Placebo|Placebo will be administered orally via a capsule.
45759121|NCT03830645|Biological|Platelet Rich Plasma|Application of platelet rich plasma through the intercostal tube into the pleural space
45759122|NCT02991833|Other|A New Incontinence Care Product|The novel incontinent care product is dressed and removed removed by opening both sides. In the part surrounding the waist and thights of the novel incontinent care product flexibility is achieved by planting rubber bien. When developing new incontinence care products was taken counselling from a faculty member from Department of Textile Engineering of one University Faculty of Engineering. The insurance policies was prepared for each patients attended to the study (Number: 481360).New care product is put on the experimental group. Perineal care was made to patients twice a day and after each defecation. After each perineal care, the novel incontinent care product was changed.
45759123|NCT02991833|Other|Diaper|In patients of the diaper group was used the optimum adult diaper (Pads, Linea TENA, SCA, Hygiene, Goteborg, Sweden) which was available in the market. Perineal care was made to patients twice a day and after each defecation. After each perineal care, the diaper was changed.
45759124|NCT01278797|Drug|Telmisartan/Amlodipine Combination Tablet|Combination Tablet
45612844|NCT03381911|Other|Embodied Conversational Agent|The Embodied Conversational Agent (ECA) is a computer generated character that can interact with study subjects through a touch screen computer. The ECA is programmed to respond with relevant speech and body language to a subject's responses.
45612845|NCT03377777|Other|No intervention|
45612846|NCT03377621|Device|Whole Body Vibration|Whole Body Vibration Machine from the company Confidence Fitness
45612847|NCT03381833|Drug|LJPC-401|subcutaneous injection, up to 20 mg per week from week 26 to 52
45612848|NCT03381833|Drug|LJPC-401|subcutaneous injection, up to 20 mg per week from week 1 to 52
45612849|NCT02976337|Drug|Naloxone|active drug infusion
45612850|NCT02976337|Drug|Normal Saline|placebo comparator
45612851|NCT03377465|Diagnostic Test|ADMA (asymmetric dimethylarginine) , NTproBNP (N-terminal pro b-type natriuretic peptide), IL-6 (Interleukin 6), Adiponectina, Leptine, Syndecan, Resistin|ADMA, NTproBNP, IL-6, Adiponectina, Leptine, Syndecan, Resistin
45612852|NCT02929849|Dietary Supplement|300 mg SC|Salacia (T1) capsule given with breakfast (mixed meal tolerance test)
45612853|NCT02929849|Dietary Supplement|500 mg SC|Salacia (T2) capsule given with breakfast (mixed meal tolerance test)
45612854|NCT02929849|Dietary Supplement|Placebo|Placebo capsule given with breakfast (mixed meal tolerance test)
45612855|NCT03381755|Drug|half-dose ticagrelor|To observe the effectiveness and safety of ticagrelor 45mg bidpo. in Chinese ACS patients undergoing PCI.
45759125|NCT01278797|Drug|Amlodipine Monocomponent|Active Comparator
45612856|NCT03381755|Drug|standard-dose ticagrelor|To observe the effectiveness and safety of ticagrelor 90mg bidpo. in Chinese ACS patients undergoing PCI.
45612857|NCT03387163|Drug|Sacubitril/Valsartan|commercially available Sacubitril/Valsartan: 24/26; 49/51 ; 97/103
45612858|NCT03381677|Device|Pedicle Lengthening Osteotomy with Altum® Device|Decompressive surgery via Pedicle lengthening osteotomy using Altum Device. Altum is intended for pedicle lengthening to correct degenerative lumbar spinal stenosis in the presence of a grade 1 degenerative spondylolisthesis. The Altum bone saw is designed for creating an osteotomy at the base of each pedicle. The Altum implant is designed for distraction of the pedicle osteotomy and for lengthening of the pedicles. Altum is appropriate for skeletally mature adults with symptomatic stenosis at one or two levels between L2-L5.
45612859|NCT03381677|Device|Control|"Decompressive surgery via open surgical decompression and Transforaminal Lumbar Interbody Fusion (TLIF) using either a midline or paramedian incision with implantation of bilateral pedicle screws (4 screws) and rods (2 rods) and an interbody fusion cage (1 PEEK fusion cage, coated or uncoated):~DePuy Synthes Expedium® 5.5 System, Stryker Xia 5.5 System, Medtronic CD Horizon Solera 5.5 Systemor Innovative Surgical Designs True Spinal Fixation System; and~DePuy Synthes Concord TLIF cage, Stryker UniLIF TLIF cage, Medtronic Capstone TLIF cage or Meditech Talos TLIF cage."
45612860|NCT03394651|Drug|Oral medications to treat lower urinary tract symptoms|Patients in this group will receive oral medication(s) depending on doctors' prescriptions.
45612861|NCT03394651|Procedure|Minimal invasive transurethral prostate procedures|Patients in this group will receive surgical treatment.
46073644|NCT05659680|Device|WiSE-CRT|Participants undergo pre-procedural CT, implantation of the WiSE-CRT system targeting the left bundle branch area, and post procedural non-invasive electro-anatomical mapping using electrocardiographic imaging and haemodynamic assessment.
46073645|NCT02611557|Procedure|Manual lymphatic drainage therapy|Patients will undergo a 50 min manual lymphatic drainage (MLD) therapy session by a certified lymphedema therapist. MLD therapy is performed routinely for standard of care in these patients and consists of light massage to facilitate lymphatic fluid mobility.
45612862|NCT03377309|Drug|Fycompa|Dose will be increased by 2mg/day increments every one week to reach a maximum dose of 8 mg/day. Treatment phase will be stable dose for 12 weeks then followed by washout period over 2 weeks.
45612863|NCT04446403|Procedure|Suprascapular Nerve Block|The patient will be put in sitting down position with upper limbs pending beside the body then a high-frequency linear ultrasound probe will be positioned transversely above the spine of the scapula. The suprascapular nerve often appears as hypereccoic structure at the suprascapular notch. A 20-gauge spinal needle will be advanced in-plane from medial to lateral 10mL of bupivacaine 0.25% into the suprascapular notch deep to the superior transverse scapular ligament (STSL) and adjacent to the suprascapular artery (SSA) .
45759126|NCT04277273|Other|Questionnaire|Questionnaires WHOQOL-BREF and GOHAI
45759127|NCT01272869|Device|SenSura|The ostomy bag filter will be tested for a period of 14 days
45759128|NCT01272869|Device|Morfeus|The new ostomy bag filter will be tested for a period of 14 days
45759129|NCT01272635|Drug|Azithromycin|Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
45759130|NCT01272635|Drug|Prednisolone|Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
45759131|NCT01272635|Other|Placebo Azithromycin|Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
45759132|NCT01272635|Drug|Placebo Prednisolone|Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
45612864|NCT04446403|Procedure|Axillary Nerve Block|Patient will be put in sitting position, with the shoulder in full adduction. linear transducer (8-14 MHz) will be positioned in the short axis orientation at the neck of humerous to identify the axillary artery about 1 to 3 cm from the skin surface.The artery is the most reliable landmark, then a 21-gauge 90 mm needle will be advanced in-plane and 10 mL of bupivacaine 0.25% will be injected adjacent to the artery.
45612865|NCT04446403|Procedure|posterior cord block|Patient will be put in supine position with head turned away from side that will be blocked with the arm abducted 90 and flexed at the elbow then linear transducer (8-14 MHz) will be positioned in short-axis just medial to coracoid process.Once the artery will be identified, an attempt will be made to identify the hyperechoic cords of the brachial plexus and their corresponding positions relative to the artery, although these may not always be identifiable. The needle will be inserted in plane from the cephalad end of the probe. 10 mL bupivacaine 0.25% will be injected at the posterior cord.
45612866|NCT04446403|Procedure|General anesthesia|General anaesthesia will be induced after giving nerve block in a standardized way with propofol 1.5-2.5mg/kg, fentanyl 2-3 µ/kg and atracurium 0.5mg/kg. maintenance of anaesthesia with isoflurane and atracurium 0.1mg/kg/20min.
45612867|NCT03377231|Device|Stratamark®|Film-forming dressing for the prevention and treatment of stretch marks.
45612868|NCT05237791|Drug|Magnesium sulfate|magnesium sulphate 50mg/kg (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
45612869|NCT05237791|Drug|Placebo|normal saline 100ml (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
45612870|NCT03381599|Drug|Filgrastim Injection|Filgrastim of 10 ug/kg/day will be given for four serial days.
45612871|NCT03385447|Behavioral|Physical Activity|Participants underwent 12-weeks of exercise prescription aimed at the federal guidelines (3 days/week).
45612872|NCT03377153|Dietary Supplement|hesperidin and flaxseed|2 capsuls hesperidin and 30 g flaxseed
45612873|NCT03377153|Other|control|no supplementation
45612874|NCT03394573|Other|OCT guided treatment arm|Intravitreal injection of Aflibercept for DME OCT guided
45612875|NCT03394573|Other|VA guided treatment arm|Intravitreal injection of Aflibercept for DME VA guided
45612876|NCT03381443|Other|different assessments|coded survey about NTS and assessment
45612877|NCT03387007|Behavioral|Psychosocial support training for school teachers|The intervention for this study was schoolteachers' training on psychosocial support.A clinical psychologist provided 2-day training (a total of 16 hours) training on psychosocial support for the schoolteachers
45612878|NCT03898817|Other|taking of cutaneous cells|Taking of cutaneous cells by biopsy Sample of blood
45612879|NCT03385369|Drug|MEDI0382|Single dose of MEDI0382
45612880|NCT03385369|Drug|Placebo|Single dose of placebo
45612881|NCT03381365|Device|CuraSeal Percutaneous Intraluminal Closure System|
45612882|NCT03381209|Drug|Sugammadex|sugammadex given based on 3 measurements of body weights
45612883|NCT03461887|Behavioral|Exercise|"Home-based exercise training program that requires only minimal equipment, and is individually adaptable to the participant's exercise level (6 times per week; 15-20 min; 38 exercise cards and one interactive training agenda booklet). After randomization, a health care professional (HOMEX coach) will visit the intervention group participants at their home to set up the training location, to instruct the exercises and to establish individualized goals. Follow-up visits are planned after 3 and 8-9 weeks. Regular telephone calls will be conducted by the same HOMEX coach to motivate the patients, to discuss training progress and concrete benefits and barriers, and to adapt goals and the training program. Additional intervention elements are that a relative or friend is involved as a sparring partner to support the participant. The general practitioner is informed about the participation of his/her patient in the intervention."
45612884|NCT03124433|Drug|Apalutamide|Participants will receive oral apalutamide 240mg daily for 12 weeks
45612885|NCT03394495|Other|BCE Combination group|The combination intervention programme consists of a weekly exercise training sessions and 6 sessions of Behavioral Change Enhancement (BCE) programme.
45612886|NCT03124589|Behavioral|Online Gambling Internet Intervention|CAMH's online gambling intervention which includes self-help materials as well as a personalized feedback component.
45612887|NCT03381053|Drug|Imatinib 400mg|The NIH assessment of patients with surgical excision of GIST with moderate to high risk of recurrence was recommended imatinib 400mg treatment.
45612888|NCT03394417|Device|StrataXRT|randomized patient allocated to this group will receive 2 50g tubes of StrataXRT for application during the treatment and 4 weeks further after the treatment ends.
45612889|NCT03380975|Drug|Montelukast 10mg|Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis. Montelukast should be taken once daily in the evening
45612890|NCT01913587|Device|Acupuncture|Acupuncture points are ST36, GB34 (bilateral), BL60 (bilateral), BL40 (bilateral), and 2 Back-su points (bilateral). Back-su points are selected as close as possible to pain region. Electroacupuncture will be performed at only 2 Back-su points (bilateral).
45612891|NCT01913587|Procedure|Nerve block|Epidural nerve block uses the mixture (10ml) of dexamethasone (10 mg) and bupivacaine (10 mg) dissolved in saline solution. Medial branch block uses mepivacaine (10 mg).
45612892|NCT03377075|Device|AL measurement|IOL Master 500 (Carl Zeiss AG, Germany)
45612893|NCT03377075|Device|OCT|Choroidal and retinal thickness measurement (DRI OCT-1 Model Triton (plus), Topcon, Tokyo, Japan)
45612894|NCT03376997|Drug|Perampanel|IV infusion
45612895|NCT03376997|Drug|Perampanel|Oral tablet
45612896|NCT03460015|Drug|Sevoflurane|"During the first 30 minutes after randomization, patients will be treated with propofol (same dosage as the propofol group).~Once the AnaConDa® system is installed, sevoflurane administration will begin (propofol is stopped)."
45612897|NCT03460015|Drug|Propofol|"In the control group, sedation will be maintained with the above objective (RASS between -4 and -5, BIS between 40 and 60) until the patient is extubated.~In the sevoflurane group, propofol is administrated during the first 30 minutes after the randomization and when the AnaConDa® system is installed propofol is stopped."
45612898|NCT03376919|Device|CLs++ gait training|CLs++ gait training
45612899|NCT03380897|Other|Intervention for outpatient group was to go home|Intervention for outpatient group was to go home and assess the the pain
45612900|NCT03380897|Other|Intervention for inpatient group was to stay at ward|Intervention for inpatient group was to stay at ward and assess the pain
45612901|NCT03376841|Drug|Cenicriviroc|1 tablet; single-dose oral administration
45612902|NCT03125135|Device|MightySat RX Pulse Oximeter Sensor|Noninvasive pulse oximeter finger sensor.
45612903|NCT03376685|Behavioral|Endurance Exercise Training (END)|Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 5 days a week for 30 minutes (Week 1-2); 35 minutes (Weeks 3-4); or 40 minutes (Weeks 5-6) at 60% VO2 peak.
45612904|NCT03376685|Behavioral|Sprint Exercise Training (SIT)|Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 3 days a week involving a 3-minute warm-up, followed up 4 repetitions (Week 1-2); 5 repetitions (Weeks 3-4); or 6 (Weeks 5-6) repetitions of 30 seconds at a maximal intensity with 2 minutes' rest in between. Exercise will conclude with a 2-minute cool-down.
45612905|NCT03376607|Other|HBCP programme|The newly-established Home-Based Community Practitioners (HBCPs) programme will enable frontline workers to offer monthly health assessments, disease management and lifestyle advice to diabetic patients, and referral to the district hospitals when needed.
45612906|NCT03376607|Behavioral|mobile health application|"HBCPs will actively encourage the use of a mobile app by assisting patients to access it (this process is known as facilitated access). The app will enable: (i) the registration of measurements, such as blood glucose and weight; (ii) the registration of concerns and questions in a diary; (iii) the reception of alerts and notifications for the appointments to the health facilities, and; (iv) access to advice on lifestyle improvement and other patient educational material."
45612907|NCT03812159|Device|iCSPlan|"The Investigator will acquire a routine pre-operative CT-scan to help assess the synostosis severity. A week before the surgery a routine preoperative visit will be done. If the potential subject agrees to participate in the study, a presurgical plan will be built, and based on the CT scan, it will (1) quantify shape differences between pathological and healthy cranial shapes; (2) compensates for brain and cranial growth during the months between diagnosis, treatment and recovery; and (3) guides bone-cuts and bone-placement for the simplest and optimal surgical procedure.~Finally this plan will be recorded in a software, iCSPlan, which will be reviewed by the surgeon. If it is accepted, it will be available during the surgery as a rely-on tool which may or may not be followed."
45612908|NCT03125291|Behavioral|Bridges 4-week Program|Participants receive 4, 2-hour sessions over a 6-week period.
45612909|NCT03125369|Procedure|Sleeve gastrectomy + duodeno-jejunal bypass|
45612910|NCT03125369|Procedure|Roux-Y gastric bypass|
45612911|NCT03375515|Drug|Hydromorphone|"For opioid-intolerant patients: continuous infusion of hydromorphone 0 mg per hour, and a demand dose of 0.5 mg with a lockout interval of 15 minutes.~For opioid-tolerant patients: basal rate 0 mg per hour, and a demand dose of 10% of the hydromorphone dose equivalent to the total opioid taken in the previous 24 hrs with a lockout interval of 15 minutes."
45612912|NCT03375515|Device|PCA pump|"For opioid-intolerant patients: initial dose 0.5 mg intravenous hydromorphone.~For opioid-tolerant patients: intravenous hydromorphone with a initial dose equivalent to 10%(5-15%) of the total opioid taken in the previous 24 hrs."
45612913|NCT03375281|Procedure|RFA|thermal ablation using radiofrequency for HCC
45612914|NCT03449771|Other|self-administered questionnaire|The newsletter and a self-questionnaire will be systematically given in the waiting room to any PrEP consultant to evaluate the consumption of psychoactive substances (ASSIST questionnaire) and to identify anxio-depressive disorders (HAD questionnaire - Hospital Anxiety and Depression). scale).
45612915|NCT03371615|Other|Anti-regurgitation infant formula|Anti regurgitation infant formula
45612916|NCT03124667|Behavioral|Games|The game training will emphasize general and exercise-specific dual task processing, self-priming and certainty training.
45612917|NCT03124667|Behavioral|Videos|The video training will emphasize health and educational information.
45612918|NCT03124277|Dietary Supplement|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
45612919|NCT03124277|Other|Control Group|Best local diet
45612920|NCT03124511|Procedure|Surgery for breast cancer|Breast cancer resection performed via lumpectomy or mastectomy with or without sentinal node biopsy and axillary lymph node dissection.
45612921|NCT03270917|Procedure|Parenchymal preserving postero-superior liver segment resection|Parenchymal preserving liver segment resection of one or two of the postero-superior liver segments (4A, 7 or 8).
45612922|NCT03375125|Dietary Supplement|Probiotic|L. reuteri DSM 17938 & L. reuteri ATCC PTA 5289 ) will be given at a dose of 2x10^8 Colony Forming Units (CFU). One lozenges is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.
45612923|NCT03375125|Other|Placebo|Placebo will have identical appearance, taste, and flavor, except for lacking the bacteria. One lozenges will be taken twice per day (one in the morning and one in the afternoon)
45612924|NCT03099863|Drug|Cystoscopic Fluid containing Neosporin G. U. Irrigant|Normal saline cystoscopic fluid containing Neosporin G. U. Irrigant 1mL/1000mL
45759133|NCT01272011|Other|Intermittent Hypoxia|Individuals received exposure to intermittent hypoxia for 10 days, and placebo for 1-2 days.
45759134|NCT01272011|Other|Locomotor Training|Individuals received 10 days of locomotor training, intense walking training on a treadmill with body weight support. Manual assistance was provided at the legs to optimize stepping patterns.
45759135|NCT00750191|Device|The Transdiscal Radiofrequency Annuloplasty|Adjustment in dosage form, frequency and or duration.
46068873|NCT05359627|Drug|Polymyxin B|Polymyxin B acts against gram-negative bacteria (GNB) only, via three known mechanisms of action: First, polymyxin B can electrostatically interact with the outer membranes of GNB to compete against and displace calcium and magnesium divalent cations from membrane lipids, thereby disrupting lipopolysaccharide (LPS) molecules on the outer membrane and triggering their release. This leads to changes in the permeability of the bacterial membrane and subsequently causes cell content leakage, cell lysis, and death. Second, polymyxin B can act as a surfactant, as it is amphipathic and contains both lipophilic and lipophobic groups; this allows it to penetrate cell membranes, interact with the phospholipids within, and rapidly disrupt membranes to kill bacteria. Third, polymyxin B can bind to the lipid A portion of bacterial endotoxin or LPS molecules, thus neutralizing their toxicity.
45445306|NCT03777579|Drug|Placebo|Placebo administered via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
45759136|NCT00750191|Device|The Transdiscal Radiofrequency Annuloplasty|interventions include adjustment to dosage form,frequency,duration or switching to treatment arm A
45759137|NCT04387097|Drug|remifentanil|postoperative drip-infusion of remifentanil
45445307|NCT02059876|Drug|carboplatin and paclitaxel and or without trastuzumab|dose-dense(biweekly) carboplatin and paclitaxel and or without trastuzumab as neoadjuvant treatment in early breast cancer
45759138|NCT01270841|Drug|Placebo|Placebo capsule 1x daily for 3 months
45445308|NCT03777423|Device|PEEK framework partial dentures|Polymer-based framework recently introduced made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
45759139|NCT01270841|Drug|topical testosterone|testosterone gel applied 1x daily for 3 months
45759140|NCT01270841|Drug|Androxal|Capsule of either 12.5 mg or 25 mg Androxal, 1x daily for 3 months
45759141|NCT04345523|Other|Blood and derivatives.|Administration of fresh plasma from donor immunized against COVID-19
45759142|NCT04345523|Drug|Standard of Care|Standard of care for the treatment of COVID-19 in hospitalized patients
45759143|NCT01270139|Procedure|Transplantation of nanoparticles|60 patients into nanogroup with the use of 60/15-70/40 nm silica-gold nanoparticles (NPs) transplanted by endoscopic cardiac surgery in the composition of bioengineered on-artery patch grown on the basis of biopolymeric scaffold and host circulating CD45-CD34-CD73+CD105+ progenitor cells
45759144|NCT01270139|Procedure|Transplantation of iron-bearing nanoparticles|60 - into ferro-magnetic group with 60/15-70/40 nm silica-gold iron-bearing NPs with delivery in hand of magnetic navigation system
45445309|NCT03777423|Device|Cobalt- chromium framework partial dentures|It's a bio-compatible metal used in thin sections so less bulky, provide high strength and stiffness ,conduct heat and cold for a more natural experience, enable designs that minimize the covering of the gingival margins, allow for a stable denture base, and resistance to corrosion.Drawbacks of metal frameworks can include hypersensitivity, aesthetics because of metal metal display, oral galvanism, adverse tissue reactions, osteolysis of abutment teeth, and biofilm production
45445310|NCT05617924|Procedure|Physical Therapy|Therapy methods using physical agents in treatment
45612925|NCT03099863|Procedure|Cystoscopy|Diagnostic cystoscopy performed during pelvic floor surgery
45612926|NCT03099863|Drug|Cystoscopic Fluid/Placebo|Normal saline cystoscopic fluid
45612927|NCT03375047|Drug|MRT5005|Nebulization of MRT5005
45612928|NCT03375047|Drug|Normal saline|Normal Saline for Inhalation
45612929|NCT03374969|Behavioral|Attachment and Biobehavioral Catch-Up|Attachment and Biobehavioral Catch-up (ABC) is a 10-session, weekly intervention delivered in the family's home. ABC addresses three primary issues. First, young children who have experienced early adversity are especially in need of nurturance and parents who behave in synchronous ways and delight in them. Next, when parents behave in frightening ways, it is difficult for children to look to them for reassurance when distressed. This can be particularly difficult for children who have experienced early adversity. Therefore, this intervention helps parents learn how to: 1) behave in nurturing ways when children are distressed; 2) behave in synchronous, delighted ways when children are not distressed; and 3) avoid behaving in frightening or intrusive ways. Interventionists are provided with a manualized protocol, but tailor specific session content to each family's needs. Sessions are videotaped, both for playback to families, and for supervision.
45759145|NCT01270139|Device|Stenting|60 - in sirolimus-eluting stenting control
45759146|NCT01278407|Drug|Donepezil 5 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg
45759147|NCT01278407|Drug|Donepezil 10 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg and then the dose was increased to 10 mg
45759148|NCT01278407|Drug|Donepezil matched placebo|
45759149|NCT01278173|Drug|Sabril|Sabril: 500 mg tablets, orally. Physicians will dose their patients according to guidance provided in the product label.
45759150|NCT00784303|Drug|Lenvatinib (DTC Cohort)|24 mg lenvatinib (two 10 mg tablets and one 4 mg tablet) given orally, once daily, or 10 mg lenvatinib orally twice daily (20 mg total). Out of 58 participants in the DTC cohort, 56 participants received 24 mg lenvatinib once daily and 2 participants received 10 mg lenvatinib twice daily (total 20 mg daily), given continuously in 28-day treatment cycles.
45759151|NCT00784303|Drug|Lenvatinib (MTC Cohort)|24 mg lenvatinib (two 10 mg tablets and one 4 mg tablet) given orally, once daily given continuously in 28-day treatment cycles.
45759152|NCT00750815|Drug|Cyclophosphamide|Enroll patients into 4 different dose levels. The dose of Cyclophosphamide they receive will depend on how many patients have been treated.
45759153|NCT00750815|Drug|Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)|Patients will receive Bortezomib, Pegylated Liposomal Doxorubicin and Dexamethasone at standard doses.
45759154|NCT00784849|Drug|Methylene blue|1 mC1
45759155|NCT04386707|Biological|Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age|Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age
45759156|NCT04386707|Biological|Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age|Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age
45759157|NCT04386707|Biological|Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age|Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age
45759158|NCT04386707|Biological|Three doses control wIPV at the schedule of 2,3,4 months of age|Three doses control wIPV at the schedule of 2,3,4 months of age
45759159|NCT00786019|Behavioral|Exercise program|Three month exercise program located at the Anschutz Medical Campus at I-225 and Colfax. The program runs three times per week for about an hour each session. Gym is open Monday - Saturday during specific hours (morning, noon, evening).
45612930|NCT03374969|Behavioral|Developmental Education for Families|Developmental Education for Families (DEF) is a 10-session, weekly intervention delivered in the family's home. DEF focuses on enhancing gross and fine motor skills, cognition and language development. The age-based protocols (i.e., 6-24 months,) provide information about the developmental themes of focus for each week and suggest activities to enhance the target skills for that week. However, the protocols do not provide a direct script with which to conduct the sessions. Interventionists tailor the developmental program session to the needs of the child and family by considering the child's current gross, fine, cognitive and language skills and creatively preparing several activities that will address the session topics.
45612931|NCT03374813|Device|MimetikOss (bone grafting surgery)|Ridge preservation bone grafting after dental extraction.
45612932|NCT03374813|Device|Bio-Oss (bone grafting surgery)|Ridge preservation bone grafting after dental extraction.
45612933|NCT03374735|Device|SETALUM™ Sealant|SETALUM™ Sealant to be applied on the suture line
45612934|NCT03374579|Diagnostic Test|Fluid challenge|Fluid challenge and measure change in co2 gap
45612935|NCT03374501|Dietary Supplement|Sugardown™|Test food #2: 495.0 g Sprite™ soft drink plus 2 Sugardown™ tablet consumed with 250 mL water (repeated twice) Test food #3: 495.0 g Sprite™ soft drink plus 4 Sugardown™ tablet consumed with 250 mL water (repeated twice)
45612936|NCT03374501|Dietary Supplement|Soft drink|Test food #1: 495.0 g Sprite™ soft drink consumed with 250 mL water (repeated twice)
45612937|NCT03374423|Procedure|radiofrequency|"The procedure will be done under propofol sedation, under fluoroscopic guidance. The image intensifier will be rotated in a cephalo-caudal direction until the endplates of the thoracic vertebrae are aligned and the transverse processes became discernable from the ribs.~For the intercostal nerve group, the radiofrequency needle 10 cm with 10 ml active tip will then inserted to contact the lower edge of the transverse process of (T2-T5), the needle is walked off to obtain sensory stimulation between 0.3-0.6 mv and motor stimulation less than 1.2 mv .five cycle of pulsed radiofrequency will be delivered."
45612938|NCT03374423|Procedure|radiofrequency|The procedure will be done under propofol sedation, under fluoroscopic guidance.for dorsal root ganglion group, radiofrequency needle 10 cm with 10 ml active tip will inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walked into the thoracic intervertebral foramen. Once correct needle position is confirmed, test stimulation will be performed at 50 Hz, during which time the needles will slightly redirected to optimize stimulation, the point of maximum stimulation will be designated to be the location of the dorsal root ganglion. five cycle of pulsed radiofrequency will be delivered.
45612939|NCT03374345|Drug|Sipjeondaebo-tang Granule|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
45612940|NCT03374345|Drug|Placebo|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
45759160|NCT00786019|Drug|Ascorbic Acid (Vitamin C)|"During one exercise study visit, 0.06 grams of Vitamin C per kilogram fat-free mass per 100 milliliters (mL) of normal saline administered; Subjects will receive a bolus of 100mL Vitamin C solution given at 5ml/minute over 20 minutes followed by a drip-infusion given at 1.7ml/minute."
45759161|NCT01277861|Drug|Fentanyl|FENTANYL PRETREATMENT DURING INDUCTION OF ANESTHESIA
45759162|NCT00786487|Drug|20% lipid infusion|1.5 ml/min for 6 hours
45759163|NCT00786487|Drug|glycerol|glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,
45612941|NCT04175873|Other|music|Patients will listen to music with MP3 headphones for 1 hour preoperatively and throughout the operation.
45612942|NCT02872727|Other|Respiratoy health, biological investigations|Once the subjects have agreed to participate, self-surveys on their lifestyle habits will be filled and EACand urine samplings will be taken during one same consultation, in addition to exhaled CO and No measurements. This consultation will also include a spirometry test. The employees' workstation data (and their evolution since the first study) will be collected. Therefore, the volunteers' participation is limited to one single visit including non-invasive examinations and self-surveys.
45612943|NCT03374111|Drug|Colla corii asini|15 g Colla corii asini granule daily for 8 weeks
45612944|NCT03374111|Drug|a Simulate Agent of Colla corii asini granule|15 g a Simulate Agent of Colla corii asini granule daily for 8 weeks
45612945|NCT03373955|Drug|pembrolizumab|anti-programmed death 1 (PD-1) antibody
45612946|NCT02814695|Dietary Supplement|Vit E|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (2 mg/ml) Vitamin E and incubated at 37o C for 30 minutes.
45759164|NCT02991443|Behavioral|Mindfulness based stress reduction|Mindfulness based stress reduction consisted of 8 group sessions for parents of children with IBD
45759165|NCT01277549|Device|Mononuclear cell collection.|Each donor will undergo one apheresis procedure to collect mononuclear cells from their peripheral blood.
45612947|NCT02814695|Dietary Supplement|Yeast|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (20 mg/ml) yeast extraction and incubated at 37o C for 30 minutes.
45612948|NCT02814695|Dietary Supplement|Vit C 1|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.02 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
45612949|NCT02814695|Dietary Supplement|Vit C 2|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.04 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
45612950|NCT02814695|Dietary Supplement|Vit C 3|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.06 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
45612951|NCT03420781|Drug|Placebo|Placebo injected twice daily
45612952|NCT03420781|Drug|Relamorelin|Relamorelin 10 μg injected twice daily
45612953|NCT03385291|Device|music,name,and noise sound|A 5-minute baseline silence was followed by the presentation of three contrasting auditory stimuli(music,name,and noise), with a 2-minute washout silence separating each stimulus
45612954|NCT03386695|Other|Education by Pamphlets|Distribution of pamphlets with information of prevention and early detection of cervical cancer and written as well as pictorial depiction on how to collect cervical self sample for HPV detection.
45612955|NCT03386695|Other|Health education programme|Health education program explaining about prevention and early detection of cancer and education on method of collection of cervical self sample for HPV.
45612956|NCT03386461|Behavioral|Exercise training|Combined aerobic and resistive training 3 times a week for 4 months. The strength training will be performed at moderate intensity (i.e., 50-60% of RM), and moderate volume (i.e., 2 to 3 sets per exercise). Endurance training will be performed at moderate- to high-intensity (i.e., 60-85% of VO2max) in the form of continuous and interval training (for high intensities), respectively. The training intensity will be prescribed individually on the basis of the initial exercise testing. Subjects will be thoroughly instructed on effective home-based exercise and advised to exercise in total 5 days a week.
45612957|NCT03386461|Dietary Supplement|omega 3 supplementation|Capsules with high content of omega 3 fatty acids (Calanus oil) will be taken every day with lunch meal. The content of omega-3 fatty acids (EPA, DHA) per day should reach 250 mg.
45612958|NCT03386461|Dietary Supplement|placebo|Capsules with content of omega 6 fatty acids (sunflower oil) will be taken every day with lunch meal.
45911459|NCT02008383|Biological|Panitumumab|The FDA approved dose for panitumumab is 6mg/kg IV, every two weeks. This is the dose and schedule that will be used in this study.
46068874|NCT05357625|Behavioral|Feedback Informed Treatment|FIT is based on two simple questionnaires and aims to assess and improve the effectiveness of therapeutic treatment. Treatment outcomes are assessed with the Outcome Rating Scale (ORS), a four-item self-report instrument measuring client functioning in the area of quality of life. Therapeutic alliance is assessed using the four-item Session Rating Scale (SRS). In FIT the feedback from the client is used to continuous adjustment and improvement of therapy
45612959|NCT03386305|Drug|EnvarsusXR|Patients randomized to study drug will be converted to EnvarsusXR once daily.
45612960|NCT03386305|Drug|Tacrolimus|Patients continue to take Tacrolimus BID, as a part of routine care.
45612961|NCT03386227|Other|Withholding antibiotic prophylaxis|Our intervention will be a deviation from our current standard of care which is universal antibiotic prophylaxis, even in low risk populations. Our intervention will be withholding antibiotic prophylaxis in low risk populations.
45612962|NCT05237635|Other|descriptive case-scenarios|Each case-scenario will include: (1) a GRADE Summary of Finding (SoF) table providing information about the Population, Intervention, Comparator, Outcome (PICO), the relative and absolute anticipated effects of the intervention, and the certainty in the evidence; (2) a Health Outcome Descriptor describing key attributes of the outcome under consideration including symptoms, time horizon, testing and treatment, and consequences; a measure of the impact on health of the outcome (also known as 'value' of the outcome or 'health utility' in health economics).
45612963|NCT05237323|Drug|mycophenolate mofetil 2 g per day|mycophenolate mofetil 2 g per day and methylprednisolone in an average starting dose 24 [24; 32] mg per day and standard drug therapy for heart failure.
45612964|NCT05237323|Drug|azathioprine of 150 [75; 150] mg per day|azathioprine at an average dose of 150 [75; 150] mg per day and methylprednisolone in an average starting dose 24 [24; 32] mg per day and standard drug therapy for heart failure.
45612965|NCT05226715|Other|chiropractic manual therapy|high velocity low amplitude thrust into a human joint
45612966|NCT03394261|Behavioral|Patient Decision Aid|PtDA-MAT will provide information on MAT treatment options and pros and cons of each treatment option, and will assess patients' preferred options.
45612967|NCT02520505|Drug|Supraovulation clomiphene citrate|Treatment with clomiphene citrate during day 3 to 7 of the menstrual cycle.
45612968|NCT02520505|Behavioral|Timed intercourse|Timing intercourse during the fertile window in the menstrual cycle. Patients may also utilize an ovulation predictor kit to determine time of ovulation.
45759166|NCT01274455|Genetic|Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes|Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumor injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every two weeks. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume 30 days after the first administration followed by Three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose.
45612969|NCT02520505|Procedure|Intrauterine Insemination|Intrauterine insemination will be performed ~36 hours after the time the woman ovulates, as determined by an ovulation predictor kit.
45612970|NCT03380767|Procedure|Trauma-induced coagulopathy treatment|Transfusion as needed according to the assay methodology
45612971|NCT03380689|Drug|S-1|- S-1 is administered orally on days 1 to 7 of a 14-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).
45612972|NCT03380689|Drug|Irinotecan|- CPT-11 was administrated as a 90-min intravenous infusion on day 1 of a 14-day cycle. Five escalating dose levels of CPT-11 were prepared, at an initial dose of 75mg/m2/day (level 1), stepping up to 100 (level 2), 125 (level 3), 150 (level 4) or 175 (level 5) mg/m2/day.
45612973|NCT03380689|Drug|Bevacizumab|- Bevacizumab (5 mg/kg) is administered by intravenous infusion over the course of 30 to 90 min on day 1 of each 2-week cycle.
45612974|NCT03380611|Dietary Supplement|Wakame|Consumption of 4.8 grams wakame per day for 17 days
45612975|NCT03380611|Dietary Supplement|Spirulina|Consumption of 4.8 grams spirulina per day for 17 days
45612976|NCT03380611|Dietary Supplement|Control|Consumption of microcrystalline cellulose for 17 days
45612977|NCT03380533|Drug|Buprenorphine|Buprenorphine 10mg transdermal patch used during the first five postoperative days after arthroscopic rotator cuff repair
45612978|NCT03380533|Drug|Placebo Patch|Adhesive patch with the same macroscopic characteristics to the buprenorphine patch, without drugs.
45612979|NCT03380533|Drug|Multimodal Oral Scheme|Diclofenac 75mg c 12h Tramadol 50mg c 12h. Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)
45612980|NCT03380533|Drug|Tramadol|Tramadol 50mg tablet that the patient consumes every 8 hours during the first five days
45612981|NCT03380533|Drug|Placebo Tablet|Placebo tablet that the patient consumes every 8 hours during the first five days
45612982|NCT03386149|Drug|Bosinji|"Product name : Bosinji Granule Manufacturer : Tsumura & Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)~Bosinji extract is composed of following proportion of ingredient~Rehmannia Root 1.7g~Achyranthes Root 1.0g~Cornus Fruit 1.0g~Dioscorea Rhizome 1.0g~Psyllium Husk 1.0g~Alisma Rhizome 1.0g~Hoelen 1.0g~Moutan Root Bark 1.0g~Cinnamon Bark 0.3g~Pulvis Aconiti Tuberis Purificatum 0.3g"
45612983|NCT03386149|Drug|Loxonine tab.|Product name : Loxonine tab. Manufacturer : Dong Wha Pharm. Co., Ltd Ingredient : Loxoprofen Sodium 68.1mg (Loxoprofen 60mg)
45612984|NCT03386149|Procedure|Acupuncture|"Acupuncture treatment will be performed on 20 predefined acupoint using 0.25mm x 40mm acupuncture needle. The time for needle retaining is 15 minutes.~Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints)~Both side BL24, BL25, BL26, EX-B7, BL28 (10 acupoints)~Symptomatic side GB30, GB34, BL57, ST36 (4 acupoints)"
45759167|NCT03805633|Diagnostic Test|Venous blood sample|Venous blood samples will be obtained for hemoglobin A1c, C peptide, insulin level, and 2-hour fasting glucose tolerance test.
45759168|NCT03805633|Diagnostic Test|Ultrasound of pancreas|Ultrasound of pancreas will be obtained on all study participants.
45759169|NCT01274845|Other|Heliox mechanical ventilation|Mechanical ventilation (MV) with air-oxygen at baseline, then 1 hour of heliox (helium-oxygen) MV and then return to MV with air-oxygen.
46068875|NCT05612490|Drug|Furosemide stress test|The FST corresponds to the intravenous single-dose administration of 1 mg/kg (1.5 mg/kg in previously exposed patients) of furosemide and the assessment of resulting diuresis in the following two hours. In the 12 hours following the first RRT liberation, a FST will be performed. The test will be considered positive if urinary output is ≥200 mL in the two hours following furosemide administration.
46068876|NCT05354024|Biological|NDV-HXP-S 10μg|NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), 1 dose (booster)
46068877|NCT05354024|Biological|BNT162b2 30μg|Vaccine against COVID-19 BNT162b2 30μg/0.3mL intramuscular (deltoid), 1 dose (booster)
46068878|NCT05348317|Behavioral|VetReach|Telehealth-delivered MI-CBT substance use disorder care model
45445311|NCT03777501|Behavioral|non-random whole body vibration|Each participant will receive the treatment about one hour after the administration of medicine. For non-random whole body vibration group, participants will be required to maintain the erect standing position on the vibratory platform and the frequency and amplitude of vibratory stimuli will be 6Hz and 3mm respectively. Each treatment includes five sessions and each session is composed of one minute whole body vibration and one minute rest.
45445312|NCT03777501|Behavioral|occupational therapy|Participants will receive the occupational therapy including dynamic balance training and functional ambulatory training.
45445313|NCT05654662|Drug|Corsodyl Original Dentifrice|It contains 67% weight/weight (w/w) Sodium Bicarbonate and 0.310% w/w Sodium Fluoride (1400 parts per million [ppm] Fluoride ion [F])
45612985|NCT03301441|Other|questionnaire ef-ID Migraine|"All consecutive patients eligible to the study will be included within 7 days of their initial admission, and evaluated with a short questionnaire classifying them as migrainers whose status will undergo a detailed validation at 3 months by a migraine expert, and non-migrainers whose status will be validated by repeating the short questionnaire at the follow-up visit at 3 months.~Initial multimodal imaging, done routinely in any stroke patient, will acquire the raw data necessary to calculate the mismatch ratio (MRI DWI/PWI or CT rCBF/CTP). All radiological data will be analyzed centrally after the end of the recruitment, by investigators blinded to the migraine status."
45612986|NCT03386071|Drug|Trametinib 2 mg|The dosage of trametinib for oral administration is 2mg once daily.
45612987|NCT03269695|Drug|PF-06687234|SC QW
45612988|NCT03269695|Drug|Placebo|SC QW
45612989|NCT01098331|Procedure|Radical Prostatectomy|
45612990|NCT01098331|Procedure|Brachytherapy|
45612991|NCT03231085|Drug|Ferrous fumarate or ferrostrane|Young children operated with craniosynostosis and treated with EPO and ferrous fumarate or ferostrane per os or intravenous ferric carboxymaltose.
45612992|NCT03118921|Device|Virtual reality|The first session aims to present the virtual reality material that will be used. The second session will take place 2 weeks after the first session and will consist of the use of the immersion software.
45612993|NCT03385135|Drug|Allopurinol|300 mg for 4 weeks then 600 mg for 4 weeks in the active group
45612994|NCT00462943|Drug|Omacetaxine mepesuccinate|"Induction: 1.25mg/m^2 subcutaneously twice daily for 14 consecutive days, every 28 days.~Maintenance: 1.25mg/m^2 subcutaneously twice daily for 7 consecutive days, every 28 days.~Response targets during induction vary by chronic myeloid leukemia (CML) subclass (chronic, accelerated, or blast phase). Participants will complete at least one cycle (14 days treatment of a 28 day cycle) of induction therapy before changing to maintenance therapy. Participants not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study."
45612995|NCT04475185|Device|MakAir|MakAir artificial ventilator
45612996|NCT04436965|Other|Standardized nutrition therapy|Standardized nutrition therapy with ONS, nasal feeding tube, PEG or parenteral nutrition
45612997|NCT04436965|Drug|Cisplatin|Patients in both arms received concurrent cisplatin chemotherapy:100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy.
45612998|NCT04436965|Radiation|Intensity Modulated Radiation Therapy|Patients in both arms received Intensity Modulated Radiation Therapy:All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose was 70-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-70 Gy to PTVnd (Planning target volume of the cervical lymph node),60- 64Gy to PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
45612999|NCT04420741|Drug|Iloprost|Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min
45613000|NCT04420741|Drug|Isotonic saline|Continuously infusion for 72 hours at 3 ml/hours
45613001|NCT04409041|Drug|Low-Dose Naltrexone|Based on the promising evidence, we propose using low-dose naltrexone at a daily dose of 3mg to treat lichen planopilaris and frontal fibrosing alopecia. The patients would be continued on their other medications for these conditions. The study would be open-label, so all participants would receive the low-dose naltrexone. Patients would be seen at 0,3,6 and 12 months to monitor their progress.
45613002|NCT03090997|Dietary Supplement|vitamin C (500 mg / day) + placebo|Adminstration of vitamin C (500 mg / day/orally) + placebo (same presentation like resveratrol)
45613003|NCT03090997|Dietary Supplement|resveratrol (500 mg / day) + placebo|Adminstration of resveratrol (500 mg / day/orally) + placebo (same presentation like vitamin C)
45613004|NCT03090997|Dietary Supplement|vitamin C (500 mg / day) and resveratrol (500 mg / day)|Adminstration of resveratrol (500 mg / day/orally) + vitamin C 500 mg/day/orally)
45613005|NCT03069469|Drug|DCC-3014|CSF1R inhibitor
45759170|NCT01276847|Drug|Ustekinumab|Ustekinumab 45 mg per dose, administered subcutaneously for participants weighing ≤ 100 kg, and ustekinumab 90 mg per dose administered subcutaneously for participants weighing > 100 kg on Day 1, and Weeks 4 and 16
45445314|NCT05654662|Drug|Colgate Cavity Protection Dentifrice|It contains 0.76% w/w Sodium Monofluorophosphate (1000 ppm F) and 0.1% w/w Sodium Fluoride (450 ppm F)
45445315|NCT03783819|Other|Hypericum perforatum oil|Ointment containing Hypericum perforatum oil
45445316|NCT03783819|Other|Placebo|Ointment containing plant oils used in Hypericum perforatum oil production and dye
45613006|NCT03062995|Other|Infant Formula with added synbiotics|Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.
45613007|NCT03062995|Other|Standard Infant formula|Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).
45613008|NCT03009331|Procedure|Lungrecruitment manoeuver in prone position.|Postoperative lungrecruitment in prone position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
45613009|NCT03009331|Procedure|Lungrecruitment manoeuver in supine position.|Postoperative lungrecruitment in supine position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
45613010|NCT03385915|Procedure|Aortic valve replacement|Transcatheter or surgical aortic valve replacement for severe aortic valve stenosis
45613011|NCT03374033|Dietary Supplement|NUTR +|one extra g/kg/d of protein and lipids starting before 48 hours after birth until 36 weeks postmenstrual age
45759171|NCT01276847|Drug|Etanercept|Etanercept 50 mg twice weekly by self-administered subcutaneous injection for 12 weeks, then once weekly for 4 weeks
45759172|NCT03830879|Other|No intervention|This cohort study have any no intervention.
45759173|NCT03805555|Procedure|Radiofrequency ablation|Pulmonary vein isolation by radiofrequency ablation
45759174|NCT03805555|Procedure|Cryoballoon ablation|Pulmonary vein isolation by cryoballoon ablation
45759175|NCT00945269|Biological|therapeutic autologous lymphocytes|Given IV
46068879|NCT05336435|Diagnostic Test|Implementation of the new population and sex-specific 99th percentile URL for cardiac troponin|The new population and sex-specific 99th percentiles URLs will be implemented at all Danish hospitals receiving patients with chest pain for initial diagnostics for possible acute MI. This will take place as a randomized step-by-step introduction of population and sex-specific 99th percentile URLs for troponin in all hospital centers with a monthly start time interval. Each center is randomized to shifting from the sex-uniform manufacturer provided 99th percentile URL of cardiac troponin currently used nationwide to the new population and sex-specific 99th percentiles URLs provided by the DANSPOT study's first phase.
46068880|NCT05318092|Device|AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE|The AngioDynamics' AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE has five main components, a flexible cannula (F1885), sheath, tapered obturator, aspirator handle, and waste bag.
46068881|NCT05316584|Behavioral|Remote monitoring|See prior description of the intervention.
46068882|NCT05298774|Device|G-tech WPS|G-tech WPS patches applied and activated within 4 hours of surgery
46068883|NCT05295784|Drug|Caffeine citrate|A single dose of intravenous caffeine citrate will be administered to neonates with hypoxic ischemic encephalopathy to determine the pharmacokinetics and tolerability.
46068884|NCT05283018|Device|Electroencephalogram recording|Brain function monitoring using a Sedline® module (Masimo corporation) to evaluate the state of the brain under anesthesia
46068885|NCT05283018|Other|Auditory stimulation|Monotonous sounds are sent via binaural headphones: a standard item and a distractor item (rough sound). Each stimulus lasts about 300 ms and they are separated by 1.5 to 2 seconds between them; the deviant sound/standard sound ratio is fixed between 1/5 and 1/6.
45613012|NCT03374033|Behavioral|STIMUL +|Physical activity stimulation consists in flexion/extension of the 4 limbs and other motion exercises of the shoulder girdle and of the hips. This stimulation will take place before the feed for a mean of 30 times a week (minimum 24- maximum 36 times a week, 10 minutes each time) and will start within the 10th day of life until 36 weeks postmenstrual age
45613013|NCT04446169|Diagnostic Test|SARS-CoV 2 RNA PCR Urine|Search for SARS-CoV 2 RNA in urine through PCR
45613014|NCT04446169|Diagnostic Test|SARS-CoV 2 RNA PCR Semen|Search for SARS-CoV 2 RNA in Semen through PCR
45613015|NCT04446169|Diagnostic Test|Semen Qualitative Analysis|Search for Semen Alterations in patients with past SARS-CoV 2 infection
45445317|NCT03783819|Procedure|SLS induced irritation|60 uL of 1% w/v sodium lauryl sulphate (SLS) will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis. Procedure will be performed to specified skin sites, according to randomization protocol.
45445318|NCT03783819|Procedure|Tape-stripping|Skin barrier disruption will be induced by tape-stripping. Procedure will be performed to specified skin sites, according to randomization protocol.
45445319|NCT03783819|Procedure|UV radiation|UV radiation will be used to induce skin erythema and damage. Procedure will be performed to specified skin sites, according to randomization protocol.
45613016|NCT04446169|Diagnostic Test|IIEF-5 questionnaire|IIEF-5 assessment in patients with past SARS-CoV 2 infection
45613017|NCT04446169|Diagnostic Test|Male Sexual Health Questionnaire (MSHQ)|Male Sexual Health Questionnaire (MSHQ) assessment in patients with past SARS-CoV 2 infection
45613018|NCT04446169|Diagnostic Test|IPSS questionnaire|IPSS assessment in patients with past SARS-CoV 2 infection
45613019|NCT04446169|Diagnostic Test|SECRET questionnaire|SECRET questionnaire assessment in patients with past SARS-CoV 2 infection
45759176|NCT00945269|Biological|aldesleukin|Given SC
45759177|NCT00945269|Biological|denileukin diftitox|Given IV
45759178|NCT00945269|Procedure|biopsy|Optional correlative studies
45759179|NCT00945269|Other|immunohistochemistry staining method|Correlative studies
45759180|NCT00945269|Other|laboratory biomarker analysis|Correlative studies
45759181|NCT00945269|Genetic|polymerase chain reaction|Correlative studies
45759182|NCT00765193|Other|Inspection of covered areas|Clinicans performed a two-step examination for skin cancer, with clinical examination of individual lesions was aided by the use of dermoscopy, as needed. In the first step, physicians performed inspection of problem areas and uncovered areas only, and lesions suggestive of melanoma or non-melanoma skin cancer were noted. In the second step, TBSE was performed. Following both examinations, lesions suggestive of melanoma or non-melanoma skin cancer were excised or biopsied. Histopathologic diagnosis was recorded for each of the biopsied or excised lesions.
45759183|NCT02991287|Procedure|Inguinal hernia repair|
45759184|NCT02991287|Procedure|Abdominal hysterectomy|
45759185|NCT02991287|Procedure|Vaginal hysterectomy|
45759186|NCT02991287|Procedure|Thoracotomy|
45911460|NCT02008383|Drug|Cabozantinib|"There will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort.~Cabozantinib will start at a dose of 60 mg daily with reductions to 40 and 20 mg daily possible in the dose finding cohort. The combination expansion cohort dose will determined by the dose finding cohort. The Monotherapy MET Amplified cohort will recieve 60 mg Cabozantinib daily."
45759187|NCT01272791|Biological|bavituximab|Patients who qualify for enrollment into the study will be randomized in a 1:1 ratio to receive study treatment of gemcitabine alone or gemcitabine with weekly 3 mg/kg bavituximab. Treatment for each patient will begin on Study Day 1. Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will be treated weekly beginning on Day 1 of each cycle. Study visits are scheduled to occur every 7 (± 2) days for bavituximab administration (for patients randomized to receive bavituximab); gemcitabine administration will occur every 7 (± 2) days for the first 3 weeks of each 4-week cycle
45759188|NCT01272791|Drug|Gemcitabine|Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities
45759189|NCT00765661|Drug|Tacrolimus (Tacro™)|"The initial dose at 0.14 mg/kg (daily dose for African-American is 0.17 mg/kg), oral in the morning (before noon) within 12 hours after transplantation. Subsequent doses adjusted to maintain a target tacrolimus trough level of 7 - 20 ng/mL for (PK) phase of the study (through Study Day 14). Post PK maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other Names:~Tacrolimus modified-release"
45759190|NCT00765661|Drug|Prograf|"Prograf® capsules, twice daily: Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other name: tacrolimus"
45759191|NCT01274923|Device|"MEDISPEC treatment probe"|shock wave treatment
45759192|NCT00765895|Drug|Nortriptyline Hydrochloride|Nortriptyline; 10 mg, one capsule, po qhs (by mouth at bedtime each night) x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks, f06 visit, 50 mg, two capsules, po qhs x 3 weeks, f09 visit, 75 mg, three capsules, po qhs x 6 weeks, f15 visit: taper study drug by one capsule a week, off study drug for the last week
45759193|NCT00765895|Drug|Placebo (for nortriptyline)|Placebo (for nortriptyline), 10 mg, one capsule, po qhs x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks;
45759194|NCT03805087|Procedure|Transarterial coil embolization|Transarterial coil embolization of the superior rectal arteries via a transradial left arterial access.
45759195|NCT05743309|Behavioral|Video call sessions|Investigators made video call sessions with the participants.
45759196|NCT01275157|Drug|LY2452473|Administered orally as a liquid suspension
45613020|NCT04446169|Diagnostic Test|Interleukin assessment in semen|Assessment of Interleukin presence and quantitative analysis in semen, to study if a previous inflammation/infection due to SARS-CoV 2 in testis was present
45613021|NCT02615951|Other|blood sampling|Blood sample retrieval for biological and genetic analysis and comparison
45613022|NCT04446013|Other|Optic Nerve Sheath Diameter Measurement|The change in intracranial pressure via optic nerve sheath diameter measurement
45613023|NCT03373799|Other|Video-Based Rehabilitation Program|In both groups, a program consisting of exercises used in conservative treatment of rotator cuff tears was performed. A video record was made by the physiotherapist to a patient where each exercise was described in detail and the patient correctly performed the exercises according to the verbal and visual commands of the physiotherapist. This video record watched by the patients who come to the clinic and patients were asked to do the exercises in the video. Patients did the exercises under control of the physiotherapist in the clinic.
45613024|NCT03373799|Other|Physiotherapist-Supervised Rehabilitation Program|In both groups, a program consisting of exercises used in conservative treatment of rotator cuff tears was performed. Program was carried out by teaching the same exercises individually by the physiotherapist.
45759197|NCT05743231|Procedure|interpectoral area block + serratus anterior area block group|The interpectoral and serratus anterior area blocks will be applied immediately after general anesthesia is given to the participants under ultrasound guidance. 30 ml of 0.25% bupivacaine will be used for two blocks.
45445320|NCT03783819|Procedure|Intact skin|Healthy, intact skin. Procedure will be performed to specified skin sites, according to randomization protocol.
45445321|NCT02059954|Procedure|Hysterectomy|
45445322|NCT03777111|Other|Exercise|Single Task Training: Single task training includes exercises that require only one task or stimulation. For this study the task consists of motor tasks (walking or balance) Dual Task Training: Dual task training includes exercises simultaneous performance of two tasks that can be performed independently, measured separately and with different goals. In the study motor tasks will combine with cognitive tasks.
45445323|NCT02058316|Device|Lateral Flow Device Test|Testing of leftover BAL samples from clinical routine by the lateral flow device test
45445324|NCT03783585|Behavioral|Cognitive behavioral therapy for insomnia|The web-based CBT-I program is a 6-week interactive, online program that delivers typical CBT-I treatment techniques of stimulus control, sleep restriction, behavioral modifications, and cognitive restructuring.
45445325|NCT03783585|Behavioral|Cognitive behavioral therapy for insomnia + biweekly support|Individuals randomized into the CBT-I + biweekly support will participate in CBT-I as described as well as a biweekly phone call or video call with research personnel for motivational interviewing.
45445326|NCT02058394|Procedure|Phacoemulsification|Subjects will be recruited serially from eligible candidates on the basis of presentation for cataract evaluation and subsequent cataract surgery with phacoemulsification.
45445327|NCT03777189|Behavioral|Cognitive-Behavioral Therapy|Cognitive-behavioral therapy will be delivered in line with recommendations (e.g., NICE 2017). Format will be guided self help with added content related to physical activity.
45613025|NCT04446091|Drug|Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)|Observe the efficacy of immune checkpoint inhibitors combined with anti-angiogenic drugs for colorectal mucinous adenocarcinoma
45759198|NCT01276457|Drug|Everolimus 0.25 and 0.75 mg tablets|The dose of everolimus for each patient was adjusted to achieve the target everolimus blood level range. Everolimus blood trough level was measured 5 days after any dose adjustment to verify that the blood level was within the desired target level range.
45445328|NCT01561365|Behavioral|Ottawa ankle rules|Ottawa ankle rules implementation
45613026|NCT04446091|Drug|Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan|Observe the efficacy of immune checkpoint inhibitors combined with anti-angiogenic drugs and chemotherapy for colorectal mucinous adenocarcinoma
45613027|NCT04445935|Drug|Bivalirudin Injection|The patients will receive iv Bivalirudin according to the institutional HIT protocol.
45759199|NCT01276457|Drug|Cyclosporine very low dose (150-300 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
45759200|NCT01276457|Drug|Cyclosporine low dose (350-500 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
45613028|NCT04445935|Drug|Standard treatment|This group will receive standard anticoagulation with LMWH/UFH
45613029|NCT03373643|Diagnostic Test|OSA screening|Full night polysomnography
45613030|NCT03385057|Drug|Ibuprofen|Grape-flavored ibuprofen 100mg/5mL (Leader®) will be dispensed. Ibuprofen will be dosed at 10mg/kg (max dose 600mg) QID (roughly Q6 hours, however we left dosing QID to allow for some flexibility in the dosing schedule to accommodate patient sleeping schedules). The pharmacy will manipulate the volume of each medication using Ora Blend suspension so that for each child, weight-based dosing of each medication will be equivalent in volume. The first dose of study medication will be dispensed 4 hours after the preoperative acetaminophen dose. Thereafter, medication will be dosed QID (or roughly 6 hours apart). Surgeons, nursing staff, and patients and their families will be blinded regarding the type of medication administered.
45613031|NCT03385057|Drug|Acetaminophen|Grape-flavored acetaminophen 160mg/5mL (Leader®) will be dispensed based upon the arm to which each participant has been randomized. Acetaminophen at 15mg/kg (max dose 650mg), dosing will be QID (roughly Q6 hours, however we left dosing QID to allow for some flexibility in the dosing schedule to accommodate patient sleeping schedules). The pharmacy will manipulate the volume of each medication using Ora Blend suspension so that for each child, weight-based dosing of each medication will be equivalent in volume. The first dose of study medication will be dispensed 4 hours after the preoperative acetaminophen dose. Thereafter, medication will be dosed QID (or roughly 6 hours apart). Surgeons, nursing staff, and patients and their families will be blinded regarding the type of medication administered.
45613032|NCT02051309|Drug|Guanfacine|6mg/day ER with 3-week lead-in period. Maintained at steady state throughout 8 week treatment phase. After treatment phase, given taper supply of medication. Follow up at 1 month, 2 months and 6 months.
45613033|NCT02051309|Drug|Placebo|
45613034|NCT03373565|Procedure|Radial|Coronary angiography using radial approach
45613035|NCT03373565|Procedure|Palmar|Coronary angiography using radial approach
45613036|NCT00372073|Drug|seliciclib|1200 mg bid x 3 days every 2 weeks
45613037|NCT00372073|Drug|placebo|1200 mg bid x 3 days every 2 weeks
45613038|NCT03373487|Behavioral|The cognitive rehabilitation program ReMind|Cognitive rehabilitation, i.e. psychoeducation, strategy training & retraining
45613039|NCT03373409|Drug|Albuterol DPI 90mcg|Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90mcg will be given on one of the 3 treatment days. One inhalation from the DPI will be used.
45613040|NCT03373409|Drug|Albuterol DPI 180mcg|Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the DPI will be used to deliver the 180mcg dose
45759201|NCT03804931|Procedure|Fecal microbiota transplantation|200 mL of prepared fecal microbiota suspension from healthy donors' fresh feces was injected into the intestine
45759202|NCT03804931|Procedure|Infusion of Saline|Infusion of Saline
45759203|NCT03804931|Drug|5-Aminosalicylic acid(5-ASA) and/or Prednisone|Mesalazine and/or Prednisone
45759204|NCT02991131|Drug|Tedizolid (Sivextro, BAY1192631)|Antibiotic
45613041|NCT03373409|Drug|Albuterol HFA MDI|Albuterol HFA MDI delivers 90mcg of albuterol with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the MDI will be used to deliver the 180mcg dose
45613042|NCT03380065|Device|Late deflation of TR band|"First 3ml of air is removed after TWO hour of sheath removal. Then, 3ml of air is removed every 15minutes.~Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 3ml of air is pushed back into the device until bleeding stops. Then a gap of 15minutes is observed for the next deflation."
45759205|NCT02991131|Drug|Linezolid|Antibiotic
46068886|NCT05283018|Device|Transcranial Doppler|Measurement of cerebral blood flow velocity (CFV) with use of Transcranial Doppler ultrasonography. For all patients, CFV (unit cm/s) will be collected over four distinct periods: 1/ baseline or during pre-oxygenation at inspired oxygen fraction (FiO2) of 21% in awake patients; 2/ during anesthetic induction; 3 /deep sleep; 4/ recovery period.
45759206|NCT00748865|Other|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
46068887|NCT05283018|Device|Near-infrared spectroscopy|"Continuous measurement of cerebral oxygen saturation (SO2) with Near-infrared spectroscopy (NIRS).~For all patients, SO2 (%) will be collected over four distinct periods: 1/ baseline or during pre-oxygenation at FiO2 of 21% in awake patients; 2/ during anesthetic induction; 3 /deep sleep; 4/ recovery period."
46068888|NCT05274074|Behavioral|Social LEAF|Social LEAF is an adaptation of the Life Enhancing Activities for Family Caregivers program to focus on social relationships and loneliness. Social LEAF is a six-session group program provided by video-conference that teaches caregivers coping skills to improve social relationships and social connection. Social LEAF is delivered in groups of up to 10 caregivers via videoconference and will consist of six weekly hour-long discussion-based classes to teach positive coping skills around improving social relationships. Each week will focus on a skill from the original LEAF study adapted to the group and social context.
45613043|NCT03380065|Device|Early deflation of TR band|"First 2ml of air is removed from the band ONE hour after sheath removal. Then, 2ml of air is removed every 30minutes.~Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 2ml of air should be pushed back into the device until bleeding stops. Then wait for another 30minutes for the next deflation."
45613044|NCT03384979|Drug|Iopamidol|Contrast agent will be adrministered intravenously using total body weight or lean body weight, calculated with bioelectrical impedance analysis balance.
45759207|NCT00748865|Other|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye one time
45613045|NCT03379987|Drug|PVB morphine|The PVB was performed under ultrasonographic guidance in the sitting position. Surgical disinfection of thoracoabdominal paravertebral area was done. A linear high-frequency transducer (10-12 MHz, Sonosite, Bothell, WA, USA) was used. The scanning process (Longitudinal out-of-plane technique) was started at 5-10 cm lateral to the spinous process of thoracic vertebrae to identify the rounded ribs and parietal pleura underneath. The transducer is then moved progressively more medially until the transverse processes are identified as more squared structure deeper to the ribs. A 100 mm needle was inserted out-of-plane to contact the transverse process of thoracic vertebra and then, walked off above the transverse process 1-1.5 cm deeper searching for loss of resistance injecting 10 ml of 0.25% bupivacaine + 3 mg morphine for group PVB morphine in incremental doses of 3 ml.
45613046|NCT03379987|Drug|PVB bupivacaine|the same steps mentioned in group PVB morphine but the solution used for paravertebral block contain bupivacaine only 10 ml of 0.25% bupivacaine injected in in incremental doses of 3 ml.
45613047|NCT02730793|Drug|Oral Aztreonam|Standard Therapy Comparator (Oral Cayston 75mg three times a day)
45613048|NCT02730793|Drug|Nasal Aztreonam|Study Therapy (nasal Aztreonam 75mg twice per day)
45613049|NCT02730793|Drug|Nasal Placebo|Placebo (nasal saline twice per day)
45613050|NCT03384901|Procedure|vitrectomy|Pars plana vitrectomy and ILM (internal limiting membrane) peeling
45613051|NCT02855125|Drug|TAS-114|TAS-114 was a modulator of 5-fluorouracil (5-FU).
45613052|NCT02855125|Drug|S-1|S-1 was designed to provide oral delivery of 5-FU and to reduce the rate of degradation of 5-FU in vivo.
45759208|NCT00766753|Biological|Dendritic vaccine pulsed with multiple peptides|Subjects will receive four (4) injections of the vaccine into the lymph nodes. Injection is guided by ultrasonography. Subjects will receive the first cycle of vaccine in the right groin. Two weeks after the first vaccine, subjects receive the same vaccine at the left groin, followed by the 3rd and the 4th vaccines in the left and right armpits, respectively, with two-week intervals. Each injection contains 0.2cc (less than 1/20th of a teaspoon) of a saline solution containing the vaccine cell mixture.
45759209|NCT00766753|Biological|The first booster vaccine phase:|This phase will begin at week 13. These subjects will be treated with additional vaccinations every 4 weeks to a maximum of 5 vaccine injections and, if poly-ICLC is available from the supplier starting on the day of the first additional vaccine and twice/week for 8 injections following each additional vaccine. If poly-ICLC supply is not available from the supplier, DC vaccines only will be given in the booster phases.
46068889|NCT05273151|Device|KOS (Intranasal kinetic oscillation stimulation)|Treatment is 10 minutes in each nasal cavity. Totally 2 x 10 minutes per treatment.
45445329|NCT02038582|Other|POC CD4 Testing|Point of Care CD4 testing
45445330|NCT02038582|Other|CD4 Referral|Referral to CD4 testing
45445331|NCT02038582|Behavioral|Lay Counselor Follow-up|Follow-up from a lay counselor
45445332|NCT02038582|Behavioral|Clinic Accompaniment|Accompaniment to the clinic by a counselor
45445333|NCT02038582|Behavioral|Clinic Referral|Referral to clinic
45445334|NCT02038582|Behavioral|SMS Reminder|SMS reminder for male circumcision
45613053|NCT02845531|Device|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator and Optimal Medical Therapy
45613054|NCT02845531|Drug|Optimal Medical Therapy|
45613055|NCT02827279|Other|emotional induction|The eye-tracking mesure the reaction at emotional induction using of sound stimuli in a group of children with or without ASD, in a context of
45613056|NCT02791321|Other|ADS severity|Evaluation of the ADS severity with the CARS scale
45613057|NCT02791321|Other|Adaptative and intellectual functioning|Evaluation with IQ and Vineland II scale
45613058|NCT02791321|Other|Psychiatric and somatic comorbidities|Evaluation with the Reiss, DSQIID and CIRS Scales
45613059|NCT02781025|Other|Blood draw|A blood sample of 10mL- 25mL will be collected before the start of radiation treatment.
45613060|NCT03379909|Drug|Metformin|Metformin orally at doses up to 1500 mg twice daily for 3 months.
45613061|NCT02678533|Drug|G-CSF|D1 to D4 : Injection of 12 µg/kg of G-CSF twice a day . D5 : injection of 12 µg/kg of G-CSF (once/ twice a day according to cytapheresis's realization)
45613062|NCT02678533|Drug|Plerixafor|D5 : injection of 24mg/kg of plerixafor once a day until cytapheresis has be done (maximum of 4 days)
45613063|NCT02601937|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
45613064|NCT03384667|Drug|Maekmoondong-tang|MMDT is a Herbal medicine consist of six herbs.
46068890|NCT05270694|Behavioral|Public Health Intervention Package|"The intervention package consists of two components:~To make COVID-19 testing more acceptable, there will be a communication campaign that aims to promote COVID-19 testing and is designed based on qualitative formative research (N.B. the campaign is currently being developed; the investigators will update the registration with details of campaign activities and messages once they are finalized)~To make COVID-19 testing more accessible, participants will be provided five at-home COVID-19 testing kits per month throughout the course of the study"
46068891|NCT05264337|Other|Self-reported lymphedema|Lymphedema as reported by LymQOL questionnaire.
46068892|NCT05264337|Other|Dielectric constant ratio|Measurement of percentage tissue water content of lower extremities by dielectric constant ratio measured by MoistureMeter D.
45759210|NCT00766753|Biological|The second booster vaccine phase:|"At week 33, following the completion of 5 additional vaccines, if participants demonstrate stable disease or positive clinical response, if poly-ICLC supply is still available, participants will be offered additional DC-vaccines and poly-ICLC treatment. The second phase booster vaccines can be continued as long as the patient shows continued positive response or stable disease (both radiological and clinically) with no major adverse events, and as long as funding is available for the study. DC vaccines in this phase will be administered every 6 months+/- 2 weeks.~2). Poly-ICLC at 10µg/kg and up to 1640 µg/injection will be administered intramuscularly (i.m.) on the day of each booster DC vaccine. Poly-ICLC will be administered weekly thereafter for twice (at one week and two weeks after each vaccine) (e.g. if the previous DC vaccine was administered on a Thursday, subsequent poly-ICLC will be administered on the next two Thursdays"
45759211|NCT03804775|Diagnostic Test|Serum lipid profile|Blood samples drawn from the patients and controls will be analyzed for serum cholesterol, serum triglycerides, serum LDLs and serum HDL levels. All the results will be recorded on a performa
45613065|NCT03384667|Drug|Placebo|The granules do not contain any active ingredients.
45613066|NCT02557477|Dietary Supplement|Omega 3/6 fatty acids|Three Omega 3/6 capsules twice daily
45613067|NCT02557477|Dietary Supplement|Placebo|Three placebo capsules twice daily
45613068|NCT03379597|Drug|Bifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral)|Bifico 840mg Bid
45613069|NCT03379597|Dietary Supplement|Dietary fiber|dietary fiber compound powder 30g bid
45613070|NCT05173909|Device|BIS closed-loop target controlled infusion|BIS was monitored by connecting the BIS monitor (BISXP, Aspects Medical Systems, USA). The corresponding value was set on the BIS detector and connected to the targy-controlled infusion pump to automatically adjust the plasma drug concentration of propofol
45613071|NCT03379519|Behavioral|Multi-domain Attention Training (MAT)|The training content emphasis three concept of attention include: intensity of attention, executive attention, and spatial orienting attention.
45613072|NCT03379519|Behavioral|Passive information activities (PIA)|The active control group (Passive information activities) training content included reading online e-books and playing online games.
45759212|NCT03804697|Drug|selective anticoagulation|Selective anticoagulation group used anticoagulant once thromboelastography indicated hypercoagulable state. Conventional anticoagulation group used anticoagulant until one month after surgery routinely. The main difference was that the experimental group did not use anticoagulation if the thromboelastography indicated that the blood coagulation status was normal while the control group use anticoagulation routinely.
45759213|NCT00767767|Drug|Placebos|IV Saline infusion for 2 hours.
45759214|NCT00767767|Drug|Propofol 0.45mcg/mL|IV Propofol infusion for 2 hours.
45759215|NCT00767767|Drug|Propofol 0.90mcg/mL|IV Propofol infusion for 2 hours.
45759216|NCT00767767|Drug|Thiopental 1.5mcg/mL|IV Thiopental 1.5mcg/mL infusion for 2 hours
45759217|NCT00767767|Drug|Thiopental 3mcg/mL|IV Thiopental 3mcg/mL infusion for 2 hours
45759218|NCT00761345|Drug|gemcitabine|gemcitabine 1000mg/m2 days 1 and 8 of each 21 day cycle.
45759219|NCT00761345|Drug|Erlotinib|Erlotinib 100mg or 150mg daily of each 21 day cycle
45911461|NCT02008409|Device|EndoLift Liver Retractor|"During the surgery, the surgeon will use the new internal liver retractor device. The device will retract the liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is clipped onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends."
45911462|NCT02008422|Drug|Oxaliplatin|130mg/m2 , iv, 3-4h, d1, 21 d as a cycle.
45445335|NCT02038582|Behavioral|Circumcision Promotion|Promotion of male circumcision at the time of HIV testing
45911463|NCT02008422|Drug|Gimeracil and Oteracil Potassium Capsule|40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
45445336|NCT02038582|Other|POC VL|POC VL testing for HIV infected persons on ART
45911464|NCT02008422|Drug|Endostar injection|7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10, 21 d as a cycle.
45445337|NCT02038582|Other|Laboratory based VL assay|Laboratory based viral load testing for HIV infected persons on ART
45445338|NCT03777033|Drug|Prophylactic protocol with Ca and Vit D|"3g calcium /day for 5 days and then 2g/day for 10 days 2 Micrograms Alfacalcidol/day and then 1 microgram /day for 10 days~the Prophylactic protocol with Ca and Vit D will be given in the form of Alfacalcidol 0.5 Micrograms Capsule and CALCIUM CARBONATE + CALCIUM GALACTOGLUCONATE 1000mg tablet"
45445339|NCT05654584|Procedure|laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy surgery will be performed by a single surgeon.
45445340|NCT02058472|Drug|G3041|
45445341|NCT02058472|Drug|SEVIKAR®|
45445342|NCT02058550|Other|survey administration|Receive reminder email survey
45613073|NCT03379441|Drug|Pembrolizumab Injectable Product|Pembrolizumab Injectable Product 200 mg Q3W Intravenous
45613074|NCT02479321|Other|GDT based on noninvasive monitoring|"Before entering the operating room, hemodynamic optimization start by optimizing preload with Fluid Challenge according to evidence-based GDT protocols. Once stabilized the cardiovascular system after induction of anesthesia, hemodynamic optimization continue with Mini Fluid Challenge.~In the intraoperative period, hemodynamic optimization is based on maintaining systolic blood pressure and stroke volume. A Mini Fluid Challenge is administered to patients who respond to volume or a vasoactive drug according cardiac index for non-responders."
45613075|NCT02479321|Device|System ClearSight® and Platform EV Clinic 1000®|Hemodynamic control is held by non-invasive continuous monitoring techniques (system ClearSight® and Platform EV Clinic 1000®). Monitored variables: blood pressure, heart rate, oxygen saturation, cardiac output, cardiac index, stroke volume and stroke volume index.
45911465|NCT02008435|Behavioral|Enriched GLB|Habit formation techniques, namely if-then plans and their mental practice are being added to the standard Group Lifestyle Balance program.
45445343|NCT02058550|Other|computer-assisted intervention|Receive reminder email survey
45445344|NCT02058550|Behavioral|telephone-based intervention|Receive reminder phone call
45613076|NCT02464345|Behavioral|HAPIFED|HAPIFED is adapted from CBT to promote a positive relationship with food, eating and activity, appetite awareness, and weight loss to be achieved over a longer and more intensive period of therapy, thus recognizing the importance of longer-term therapy in weight loss (Casazza et al., 2013). Notably, HAPIFED is also multidisciplinary. Clinical practice and consensus views are to utilize the special expertise of dietitians and other allied health professionals (Robinson, 2009).
45613077|NCT02464345|Behavioral|CBT-E|CBT-E therapy
45613078|NCT02345005|Device|The Gore® EXCLUDER® ILIAC BRANCH Endoprosthesis.|The Gore IBE device is a newly designed iliac branched device, that is used in combination with the widely accepted C3 Excluder endograft, for the exclusion of common iliac aneurysms and aorto-iliac aneurysms.
45613079|NCT03384511|Drug|Apatinib|Patients will accept apatinib therapy and undergo baseline 18F-ALF-NOTA-PRGD2 PET/CT scans of the whole body after having met all eligibility criterias.
45613080|NCT03385603|Device|Dilator|Both groups will have a home program consisting of dilators which are progressive in size. The standard care group will use manufacturer instructions to progress in size of dilators, while the experimental group will use self-reported levels of fear to progress in size of dilators.
46068893|NCT05264337|Other|Limb volume|Measurement of lymphedema by limb volume of lower extremities by multiple measurements of circumference.
45613081|NCT03385603|Behavioral|Fear-Based Questionnaires|Series of questionnaires used to facilitate emotional awareness associated with vaginal and decreased sexual arousal.
45613082|NCT03385525|Drug|BIIB074|Administered as specified in the treatment arm
45613083|NCT03385525|Drug|Valproic Acid|Administered as specified in the treatment arm
45613084|NCT03384433|Biological|exosome|allogenic mesenchymal stem cells derived exosome enriched by miR-124
45613085|NCT05172895|Other|Presence, prevalence, severity, and morphological characteristics of anemia|Evaluation of the presence, prevalence, severity, and morphological characteristics of anemia, trying to define, when possible, the underlying pathogenetic mechanisms, paying particular attention to the characteristics of menstrual cycles, the iron, folate and vitamin B12 metabolism, any chronic inflammatory state, and thyroid hormones.
45613086|NCT05172895|Other|Effect of gluten-free diet on anemia|Evaluation of the therapeutic responses (i.e., improvement/regression) of anemia after at least one year of GFD.
45613087|NCT05172739|Drug|Opioid-Based Anesthesia-Analgesia Strategy|"A perioperative Opioid-Based multimodal Anesthesia- Analgesia strategy will be implemented that incorporates the following pharmacological agents:~Premedication: Midazolam, Anaesthesia induction & maintenance: Midazolam, Propofol, Fentanyl, Cisatracurium or alternatively Rocuronium, Desflurane, Morphine, Paracetamol, Dexketoprofen trometamol, Ondansetron or Droperidol, Ropivacaine Surgical ward: Morphine, Paracetamol, Dexketoprofen trometamol Rescue therapy only: Tramadol"
45613088|NCT05172739|Drug|Opioid-free Anesthesia-Analgesia Strategy|"A perioperative Opioid-Based multimodal Anesthesia- Analgesia strategy will be implemented that incorporates the following pharmacological agents:~Premedication: Pregabalin, Midazolam, Anesthesia induction & maintenance: Midazolam, Dexmedetomidine, Lidocaine, Propofol, Ketamine, Hyoscine, Cisatracurium or alternatively Rocuronium, Magnesium sulphate, Dexamethasone, Desflurane, Paracetamol, Dexketoprofen trometamol, Ondansetron or Droperidol, Ropivacaine, Surgical ward: Ketamine, Lidocaine, Clonidine, Droperidol and Midazolam, Pregabalin, Paracetamol, Dexketoprofen trometamol Rescue therapy only: Tramadol"
45613089|NCT03375463|Drug|Tirzepatide|Administered SC
45613090|NCT03375463|Drug|Tirzepatide|Administered IV
45613091|NCT03375463|Drug|Placebo|Administered SC
45613092|NCT04445623|Drug|Prasugrel Hydrochloride 10 MG Oral Tablet|administration of prasugrel daily for 15 days
45613093|NCT04445623|Drug|Placebo|administration of placebo daily for 15 days
45613094|NCT04445311|Drug|Ivermectin|3 successive days ttt of ivermectin started within 48 hours of symptoms
45613095|NCT05172583|Behavioral|Control|The control groups will receive the nursing interventions that are performed daily in the adult ICU. These are orientation in time, space, and place, accompaniment of the family for two hours in the morning and two hours in the afternoon, physical therapy once a day according to the patient's condition, medication with conscious sedation, and progressive reduction analgesics. opioids and benzodiazepines.
45613096|NCT05172583|Behavioral|Interventions to reduce delirium based on DSM and scientific evidence|The interventions are designed from the structure of the Dynamic Symptoms Model (DSM), taking into account the antecedents of delirium, physiological such as the medical condition of mechanical ventilation and pain, and drug treatment with sedatives and analgesics; the psychological, social, and spiritual antecedents with stimulation in the values, life experience, personality and spirituality, and the environmental antecedents with an adaptation of the physical conditions of the ICU. In addition, previous experience with identification and care of concomitant symptoms such as fear, confusion, restlessness, loneliness, and discomfort, and with the measurement and classification of the trajectory of delirium when it occurs, will also be considered. The interventions follow the scientific evidence, mainly from the ABCDEF bundle. All interventions are non-pharmacological.
45911466|NCT02008435|Behavioral|Standard GLB|This arm is the standard Group Lifestyle Balance program
45911467|NCT02008448|Procedure|Pulmonary vein isolation|
45911468|NCT02008448|Procedure|Linear Lesion Ablation|
45911469|NCT02008448|Drug|BT injection|
46068894|NCT05262374|Procedure|Procedure/Surgery: Laparoscopic|Surgeon
46068895|NCT05262374|Procedure|Robotic|Versius system.
46068896|NCT05262023|Drug|DNL593|Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
46068897|NCT05262023|Drug|Placebo|Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
46068898|NCT05259163|Device|LFR-260 portable phoropter|Portable unit to evaluate visual refractive state of the patient
46068899|NCT05259163|Device|Traditional phoropter (Standard of Care)|Standard unit for evaluating visual refractive state of the patient
46068900|NCT05246293|Drug|Tofacitinib|"Tofacitinib in doses of 5 mg BID, in RA-ILD patients at stable doses of prednisone ≤ 10 mg/day during the last three months.~Patients who met the inclusion criteria of the study protocol will received tofacitinib 5 mg BID for 12 months"
46068901|NCT05246267|Biological|Dupilumab|Standard of care treatment with dupilumab
46068902|NCT05243147|Device|nasal stents|using nasal stents after septoplasty
46068903|NCT05243147|Device|merocel|using merocel after septoplasty
45613097|NCT05172427|Behavioral|14 days of EMI|Following the intervention, participants will receive personalized prompts whenever they report elevated stress or anxiety. These prompts will be generated at the end of the intervention session, and will only be sent to individuals in the EMI condition.
45613098|NCT05172427|Behavioral|Uncertainty reappraisal training|CLUE consists of an hour long intervention, followed by a 2-week long EMI. During the hour long intervention session, participants will receive psychoeducation (i.e., defining uncertainty), discuss myths associated with uncertainty (e.g., if I do not plan things, they will go poorly), and discuss behavioral experiments that can be done to challenge uncertainty beliefs.
45613099|NCT03497455|Device|Barco NV Digital Dermatoscope device images|Images taken by Clinician in consultation OR in Dermatology department theatres OR images taken in medical photography suite - in the latter case, images can be taken by medical photographer or Research nurse or Dermatologist
45613100|NCT03497455|Device|Standard medical photographs including dermoscopy images|Images taken by medical photographer as part of standard care in the medical photography suite.
45613101|NCT03497455|Other|Clinic proforma completion|This is part of standard care and will be undertaken by the clinician who is responsible for the patient
45613102|NCT03384199|Radiation|Dose escalation to prostate focal lesion|For each patient the radio-opaque marker (used for treatment verification) will be inserted by ultrasound guidance & local anaesthetic with an 17ga x 30cm brachytherapy needle that has 1.2mm x 3mm one gold marker. The ultrasound probe (as used for transrectal biopsy) will be introduced rectally with the patient in the left lateral position. After measuring the volume of the prostate and determining the desired position (preferably in the corpus of prostate), three gold markers will be inserted as follows: one into right side, one into left side of the base and the third in the apex of the prostate
45613103|NCT03384823|Drug|EDP-938|Subjects will receive either a single dose of EDP-938 on Day 1 only (SAD) or a single dose of EDP-938 starting on Day 1 through Day 7 (MAD).
45613104|NCT03384823|Drug|Placebo|placebo to match EDP-938
45613105|NCT03375229|Other|Dry Needling|"It will be used acupuncture needles, individually packaged and sterilized, with 0.25 mm of thickness and 0.40 mm of length. The therapist will perform the grip in upper trapezius on the site of one of the two previously marked locations, according to the subject group allocation, and will insert the needle in the skin with help of a guide tube and will deepen the needle approximately 10 to 15 mm inside the trigger point. The needle will be moved up and down as in the fast-in and fast-out technique described by Hong and the movement will be repeated during 30 seconds in a cadence of approximately 1 Hz. The protocol will be the same for the groups that will receive the application directly on the trigger point and for the group that will receive the application away from the trigger point"
45613106|NCT03375229|Device|Low-Level Laser Therapy|The laser protocol used the PainAway Laser™ cluster equipment composed of one pulsed infrared laser of 905 nm, four red LEDs of 640 nm, and four infrared LEDs of 875 nm, with full device aperture of 4 cm2, total delivered energy of 39,8 J, a magnetic field of 35 Mt and treatment time of 300 seconds. The equipment was turned on only for the DNP group and it remained in slight contact with the skin during 300 s for all groups.
45613107|NCT03378895|Behavioral|online questionnaire|Risk assessment identified by online questionnaire
45613108|NCT03384121|Drug|Rifampin 150 mg, 300 mg capsules and 25 mg/mL oral suspension|Starting Dose (V2): 5 mg/kg/day (max 600mg/day) orally for 2 months followed by a 2 month washout period V4: After washout period, only Non-responders will escalate dose to 10 mg/kg/day (max 600mg/day) orally for 2 months
45613109|NCT03378817|Procedure|HOPE|HOPE for 1 hour via the renal artery in a recirculating and pressure controlled system, Belzer (UW) machine perfusion solution, perfusate temperature 0-4 °C, perfusate oxygenation pO2 of 60-80 kPa Other Name: Hypothermic machine perfusion (HMP)
45445345|NCT01315899|Drug|ORM-12471 30mg|Given as a single dose once during the crossover study as per Williams design
45445346|NCT01315899|Drug|ORM-12471|Given as a single dose once during the study as per Williams crossover design
45445347|NCT01315899|Drug|placebo|Given once as a single dose during the study as per Williams crossover design
45445348|NCT01317147|Procedure|Roux-en-Y gastric bypass (RYGBP)|
45613110|NCT03378817|Other|Conventional cold storage|No intervention
45613111|NCT03124225|Drug|DMARD|
45759220|NCT00761345|Radiation|low dose fractionated radiotherapy|low dose fractionated radiotherapy day 1 and 2, day 8 and 9 of each 21 day cycle
45759221|NCT05743153|Behavioral|Multimodal intervention program|"Exercise intervention: combined endurance and resistance training three times a week using workout video's which patients can do at home. Advice to exercise at low-intensity for at least 30 minutes per day.~Nutritional intervention: Patients are advised to aim for optimal energy and protein intake (by registered dietician) and to avoid red meat, processed foods and sweetened drinks. Aiming for a mainly plant based diet.~Psychological intervention: screening for psychological risk factors and if present, patients are referred to a general practitioner or psychologist for psychological support."
45759222|NCT04385381|Device|URECA CTO device|facilitating guidewire re-entry into the true lumen after passing occlusion(s) in the peripheral vasculature with the URECA CTO device.
45911470|NCT02008461|Procedure|radiofrequency ablation|
45911471|NCT02008461|Drug|botulinum toxin injection|
45445349|NCT02060968|Device|Promus PREMIER|
45445350|NCT05121519|Other|Consume coffee|Drink coffee regularly (recommend at least 1 cup of coffee per day)
45445351|NCT05121519|Other|Avoid coffee|Abstain from coffee and other caffeinated beverages
45445352|NCT02060032|Drug|1.2% Atorvastatin local drug delivery|
45445353|NCT02060032|Drug|1.2% simvastatin local drug delivery|
45445354|NCT02060032|Drug|Placebo local drug delivery|
45445355|NCT03783273|Dietary Supplement|Vitamin D3|Single dose vitamin D3
45445356|NCT03783273|Combination Product|Whey protein-complex|Whey protein complex-bound vitamin D3
45445357|NCT03783273|Other|Water|500 mL water
45445358|NCT03783273|Other|Milk|500 mL milk
45759223|NCT01273337|Biological|ALD-401|3 mL ALDHbr cells isolated from autologous bone marrow given as a one-time infusion via intracarotid infusion.
45759224|NCT01273337|Procedure|Sham Procedure|Sham bone marrow harvest and sham product infusion procedures.
45759225|NCT00761813|Device|Open reduction internal fixation (ORIF) with single sliding hip screw|The ORIF will be performed using a single large diameter partially threaded screw that is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixations. Surgeons will use any commercially available sliding hip screw implant and will insert implants as per the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
45613112|NCT03384043|Behavioral|Smartphone Personal Assistant|Electronic memory aids (e.g., pagers) are known to support memory for goals and intentions (prospective memory) in individuals with cognitive impairment. Smartphone technology has the potential to enhance the benefits of previous electronic memory aids because they can provide reminders not only at the correct time, but also at the correct location.
45613113|NCT03384043|Behavioral|Implementation Intention|Verbally specifying when and where one intends to complete a goal or action (prospective memory) is known to improve the likelihood of later completing that prospective memory. The implementation intention is the best known memory strategy for prospective memory in patients with mild cognitive impairment.
45613114|NCT03383965|Biological|ICAR30 T cells|T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD30 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.
45613115|NCT03367429|Drug|Botox|THE PROTOCOL DESCRIPTION ATTEMPTED TO OUTLINE A CONTINGINECY PLAN- MOVING TO ONE OF TWO METHODOLOGOIES DPENDING ON PRELIMINARY FINDINGS. UNFORTUNATLEY, OVER 2 YEARS RECRUITMENT WAS GROSSLY INADEQUATE PREVENTING ANY TYPE OF EVEN CURSURY PRELIMINARY DATA ANALYSIS AND FORCING THE EARLY TERMINATION OF THIS STUDY. MICHAEL W. O'DELL, MD
45613116|NCT03378661|Drug|Benznidazole|Benznidazole tablet
45613117|NCT03378661|Drug|E1224|E1224 capsules
45613118|NCT03378661|Drug|E1224 Placebo|E1224 matched placebo capsules
45613119|NCT03378661|Drug|Benznidazole Placebo|Benznidazole matched placebo tablets
45613120|NCT03383809|Dietary Supplement|Strawberry juice with Inulin|Mixture of polyphenols and non digestible carbohydrates
45613121|NCT03383809|Dietary Supplement|Strawberry Juice|Source of Polyphenols
45445359|NCT03783273|Other|Juice|500 mL juice
45613122|NCT03383809|Dietary Supplement|Inulin|Source of non digestible carbohydrate
45759226|NCT00761813|Device|ORIF with multiple cancellous screws|ORIF will be performed using multiple small diameter threaded screws (with a minimum of two screws and a minimum diameter of 6.5 mm). Surgeons will use any threaded screw or hook pin and will follow the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
45759227|NCT03803423|Other|The Donor App|The Donor app is a web-based application that helps transplant candidates tell the candidate's story via social media in the hopes of identifying an appropriate living donor. Sample stories created using the Donor App can be found at www.thedonorapp.com.
45759228|NCT03809351|Drug|[F-18]AV-1451-PET|All study participants will undergo brain imaging with [F-18]AV-1451-PET/MRI. [F-18]AV-1451 is a PET imaging agent used primarily to measure the amount of abnormal tau protein deposition the brain.
45759229|NCT03807791|Procedure|Blood sample|"A blood sample will be taken by the nurse of our unit within a week after their consent. It consists as a simple blood sample and it will be taken during the normal analysis planed by the chief of the service in order to avoid to collect two different samples.~The measurement method will use equipment from the Lyon Sud hospital laboratory. The samples need a pre-treatment in the 3 hours after taking the blood to avoid the oxidation of vitamin C and a result lower than expected."
45911472|NCT02008474|Behavioral|Online weight loss + incentives for behavior 3 months|Participants will receive monetary incentives for submitting their behavior change information into a study website
45445360|NCT02060110|Device|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study|
45613123|NCT03375151|Device|EEG based feedback|Participants will participate in cognitive training sessions. The therapist will use feedback from the EEG analyzed data to direct the cognitive therapy based on the therapist's guidance to maximize the intensity and duration of the patient's high brain engagement Index (BEI) during exercise.
45613124|NCT03375151|Behavioral|Standard practice based feedback|Participants will participate in cognitive training sessions. The therapist will give feedback to the participants during the exercise based on their performance only according to the his therapist standard practice.
45613125|NCT03375151|Behavioral|No feedback|Participants will participate in cognitive training sessions. The therapist will not guide them during the sessions.
45613126|NCT03383731|Procedure|Group 1|the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + air-fluid exchange + silicone oil infusion
45613127|NCT03383731|Procedure|Group 2|the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + inverted internal limiting membrane insertion + air-fluid exchange
45613128|NCT03375073|Other|Positive communication during medical transmission|Use of positive communication for medical transmission to the anaesthetic team who takes over the patient.
45911473|NCT02008474|Behavioral|Online weight loss + incentives for weight loss at month 3|Participants will receive an incentive for meeting their weight loss goal at month 3.
45445361|NCT02060110|Device|MADIT-CRT ICD ONLY ARM|
45613129|NCT03378505|Behavioral|Mobile App|Purposeful Living Mobile App JOOL to be used daily
45613130|NCT03378505|Behavioral|Reflection|Bi-weekly online reflection question
45613131|NCT03378427|Drug|Tedizolid Phosphate 200 MG [Sivextro]|Antibiotic treatment (monotherapy or combination) targeting bacteria cultured from per operative samples.
45613132|NCT05172115|Procedure|Conventional catheter-directed thrombolysis (CDT) with recombinant tissue plasminogen activator (rtPA)|Conventional catheter-directed thrombolysis with fixed-dose of 24 mg tissue plasminogen activator infusion over 24 hours
45613133|NCT05172115|Drug|Enoxaparin|Subcutaneous enoxaparin twice-daily (1mg/kg)
45911474|NCT02008474|Behavioral|Online weight loss + Incentives for behavior 12 months|Participants will receive incentives for submitting behavior change information over the course of 12 months.
45445362|NCT02060266|Drug|semaglutide|Subjects will receive a single dose subcutaneously (s.c., under the skin).
45613134|NCT03378349|Behavioral|Internet-delivered cognitive behavior therapy|The intervention lasts for 10 weeks and include: Education, Interoceptive exposure, exposure in-vivo, combining in-vivo exposure with interoceptive exposure, behavioral activation and relapse prevention. Include the guidance of a minimum weekly contact with a CBT psychologist.
45613135|NCT03378349|Behavioral|Treatment as usual|Consist of standardized AF information that emphasizes that an active physical and social lifestyle is necessary to maintain good health, without the guidance of a psychologist or any CBT interventions.
45613136|NCT03374917|Drug|ABBV-951|powder for solution
45445363|NCT03777345|Device|cobalt-chromium framework partial dentures|It's a biocompatible metal alloy used in thin sections and are less bulky, provide high strength and stiffness ,conduct heat and cold for a more natural experience, enable designs that minimize the covering of the gingival margins, allow for a stable denture base, and is resistant to corrosion. Disadvantages include hypersensitivity, esthetic issues with metal display, oral galvanism, adverse tissue reactions, osteolysis of abutment teeth, and biofilm production .
45445364|NCT03777345|Device|PEEK framework partial dentures|It's a promising polymer-based framework material has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
45613137|NCT03383341|Dietary Supplement|Cricket Protein Powder|Cricket powder was supplied by Entomo farms and consists of roasted and milled whole crickets.
45613138|NCT03383341|Other|Placebo control|Placebo controls consisted of intervention foods (muffin and smoothie powder packet) that were visually and organoleptically similar to cricket-containing foods but contained no cricket powder.
45613139|NCT03374761|Other|Families First Home Visiting Program|10 group sessions and 4 home visits with community facilitators emphasizing positive parenting
45613140|NCT05171803|Other|No intervention|No intervention, prospective, cohort study.
45613141|NCT03378037|Procedure|Acupuncture|20 minutes of acupuncture treatment, twice a week for 2 weeks. Acupoints will be manually stimulated every 10 minutes.
45613142|NCT03374605|Device|active tDCS|15 minutes of active (2mA) high definition tDCS will be applied to the participant's skull. The anodal electrode will be placed over 10-20 EEG coordinate AF7 and cathodal electrode over coordinate Fz.
45613143|NCT03374605|Device|sham tDCS|15 minutes of sham high definition tDCS will be applied to the participant's skull. The anodal electrode will be placed over 10-20 EEG coordinate AF7 and cathodal electrode over coordinate Fz.
45613144|NCT03374527|Other|blood sample collection|Blood samples are collected from patients with psoriasis vulgaris and patients with psoriatic arthritis following the routine procedure. Blood samples will also be collected from healthy control subjects.
45613145|NCT03374527|Procedure|Synovial Fluid collection|Synovial fluid is collected when prescribed in patients with psoriatic arthritis
45613146|NCT03980743|Behavioral|iOTA text messaging intervention|Over 6 months, participants in the iOTA arm will have monthly in-person visits with a health coach who will work with the participant to set goals for the upcoming month related to healthy eating and activity. The participant will receive daily text message health tips related to their goals, and will be prompted once a week to respond with a text indicating their weight and how they are doing with their goals. Following the 6-month active treatment phase, participants will receive text messages only for another 3 months.
45613147|NCT03980743|Behavioral|Health Education text messaging intervention|Over 6 months, participants in the Health Ed arm will also have monthly in-person visits with a health coach who will provide education on energy balance and problem-solving. Specific goals will not be set, but the health coach will assist participants in problem-solving any challenges. Participants will receive a weekly automated motivational text message health tip from the study related to what they learned in their health coaching sessions. Following the 6-month active treatment phase, participants will receive text messages only for another 3 months.
45613148|NCT03377959|Other|Pilates Mat Classes|The intervention, the exercises, and their progressions were systematized based on protocol proposed by Siler (2008).
45911475|NCT02008474|Behavioral|Online weight loss + Incentives for weight loss 12 months|Participants will be receive monetary incentives for reaching their weight loss goal at months 3 and 12.
45911476|NCT02008487|Other|Wound powder application|Powder application to wound per protocol.
45911477|NCT02008500|Other|placebo mouthwash|15 ml placebo mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
45613149|NCT03377959|Other|Ballet Classes|The intervention is ballet classes three times a week, 1 hour and 30 min. The ballet classes consists in barre work and center work with specific ballet exercises.
45613150|NCT03383185|Device|Intrauterine device|Use of Intrauterine device during the follow-up period
45613151|NCT03383185|Drug|Combined Oral Contraceptive|Use of combined oral contraceptive during the follow-up period
45613152|NCT03383185|Drug|Progestin-only pills|Use of progestin-only pills during the follow-up period
45613153|NCT03383185|Drug|Depot-Medroxyprogestereone Acetate|Use of depot-medroxyprogesterone acetato during the follow-up period
45613154|NCT03377881|Procedure|MRI/Fusion biopsies|The intervention in the experimental arm is an MRI with targeted biopsies using fusion technique to prostate lesions.
45613155|NCT03377881|Procedure|Systematic biopsies|The intervention in the control arm is traditional systematic biopsies of the prostate.
45911478|NCT02008500|Other|Herbal Mouthwash|15 ml Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
45911479|NCT02008500|Other|Non Herbal Mouthwash|15 ml Non Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
45613156|NCT04177849|Procedure|ACDF|A 4-cm anterolateral transverse incision is made over the index level, on either the right or left side. Platysma is sectioned transversal to its fibers and the anterior aspect of the spinal column is bluntly exposed between the carotid sheath and the esophagus. The disk is excised, including the posterior longitudinal ligament. Disk fragments and/or osteophytes from the uncovertebral joint on the affected side are removed until the root is fully decompressed. Reconstruction is typically done with an interbody spacer, autologous bone graft and a stabilizing plate screwed to the adjacent vertebral bodies. A fusion cage with integrated screws may also be used according to the surgeon's preference.
45613157|NCT04177849|Procedure|PF|A 4-cm longitudinal midline incision exposes the spinous processes of the adjacent vertebrae. The facet joint covering the index foramen is exposed through intermuscular planes. The root canal is opened as the medial third of the facet joint is removed with a high-speed diamond burr. The affected nerve root is decompressed by laterally undercutting the facet joint throughout its length.
45613158|NCT04161859|Dietary Supplement|Nutraceutical|Nutraceutical with action on glycemia, dsylipidemia or hypertension will be considered.
45613159|NCT05153473|Device|Total Hip Arthroplasty Revision|Hip revision surgery is performed to repair an artificial hip joint (prosthesis) that has been damaged over time due to an infection, or due to normal wear and tear of the prosthetic hip. Revision surgery helps to correct the problem so the hip can function normally again.
45759230|NCT03807557|Other|Robotic Constraint-induced movement therapy|"i.Robotic repetitive task-specific training followed by task-oriented practice: during each session, participants first receive 60 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 30 minutes of functional practice using shaping technique.~ii.Restraint of the unaffected limb: Patients will wear a mitt to restrict the unaffected hand during training at clinic for 0.5 hours of functional practice each session, 3 sessions per week for 8 weeks.~iii. Transfer package: The transfer package aims at transferring the therapy gains to the participant's real world by use of a set of behavioral techniques. This is intended to have the participant responsible for adhering to the treatment requirements and encourage active engagement in the functional practice outside of the clinic setting. The participants will be given appropriated home assignment practicing daily activities outside of the clinic."
45759231|NCT03807557|Other|conventional UE rehabilitation training|focusing on UE training and including neuro-developmental techniques(Bobath, 1990), trunk-arm control (ie, practice UE tasks during standing), weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
45759232|NCT03801083|Biological|Tumor Infiltrating Lymphocytes (TIL)|TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
45613160|NCT03377725|Drug|Decitabine|20mg/m^2,d1-5,ivgtt,28days as a duration
45613161|NCT03377725|Drug|Arsenic Trioxide|0.16mg/kg,d1-5,ivgtt,28days as a duration
45613162|NCT03383029|Behavioral|iEAT Program|The iEAT Program is a six-month long behavioral intervention consisting of 10 biweekly outpatient appointments of about 1 hour in length. The iEAT manual will guide behavioral intervention targeting severe feeding disorders and will involve some combination of escape extinction, reinforcement, and antecedent manipulation of food presentation to lessen the aversive quality of the meal.
45613163|NCT03374293|Radiation|Radiation|RT to 45-50.4 Gy, 5 x per week, 1.8Gy/fx. Radiation begun the day after the first dose of anti-PD-1 antibody .
45613164|NCT03374293|Drug|Anti-PD-1 Antibody|Anti-PD-1 antibody (every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 30 minutes.
45613165|NCT02730871|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
45613166|NCT02730871|Drug|Brinzolamide/brimonidine vehicle|Inactive ingredients used as placebo comparator
45613167|NCT02730871|Drug|Travoprost 0.004%/timolol 0.5% solution|1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for up to 10 days during the Screening/Eligibility Phase and 42 days during the Treatment Phase
45759233|NCT01279967|Drug|ADI-PEG 20|36.8mg/m2 based on BSA, weekly treatment for 6 months
45759234|NCT03807635|Device|ergoLance safety lancet|The ergoLance contact activated safety lancets type 450 are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.
45759235|NCT03807635|Device|Acti-Lance safety lancet|The Acti-Lance safety lancet type 610 is a sterile, single use device used to carry out skin punctures for the purpose of collecting capillary blood samples.
45759236|NCT00762515|Drug|Fluoride|Brush teeth two times daily for 6 weeks
45759237|NCT00762515|Drug|Triclosan|Brush two times daily for 6 weeks
45759238|NCT00762515|Drug|Fluoride|Brush two times daily for 6 weeks
45759239|NCT03806933|Drug|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
45759240|NCT00753935|Drug|enteric-coated aspirin|enteric-coated aspirin 81mg daily for 2 weeks
45445365|NCT03776721|Procedure|Liposuction|Liposuction is performed on the abdomen or thighs.
45445366|NCT03776721|Procedure|Fat graft|30mL harvested lipoaspirate is injected at the affected axillary site.
45445367|NCT03776721|Procedure|Sham graf (Saline injection)|30mL saline is injected at the affected axillary site.
45911480|NCT02008513|Biological|AFFITOPE® AD02|
45911481|NCT02008513|Biological|Placebo|
45911482|NCT02008539|Drug|MSC_apceth_101|
45445368|NCT03776721|Biological|Stem cell injection|4mL stem cell suspension injected at the affected axillary site.
45445369|NCT03776721|Procedure|Saline injection|4mL saline injected at the affected axillary site.
45911483|NCT02008578|Biological|Intravenous hyperimmune immunoglobulin (Flu-IVIG)|
45911484|NCT02008578|Biological|Placebo|
45445370|NCT01318005|Drug|Oral Contraceptive: Ortho-Novum® 1/35|Oral Contraceptive: Ortho-Novum® 1/35, pill, 2-3 mos, daily.
45445371|NCT01318005|Drug|Oral Contraceptive: Ovcon® 35|Oral Contraceptive: Ovcon® 35, pill, 2-3 mos, daily.
45445372|NCT01318005|Drug|Oral Contraceptive: Microgestin Fe® 1/20|Oral Contraceptive: Microgestin Fe® 1/20, pill, 2-3 mos, daily.
45759241|NCT00753935|Drug|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
45613168|NCT03377335|Drug|Dapagliflozin 10mg|"The subjects in this arm will receive dapagliflozin (10mg daily) as add-on to metformin therapy (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: >87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment."
45613169|NCT03377335|Drug|Metformin|"All the subjects in this arm will be on metformin therapy only (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: >87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment."
45759242|NCT00779285|Drug|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.
45759243|NCT00786643|Drug|5-Fluorouracil|5-FU bolus was administered at 400mg/m^2 on day 1 and day 2 of each cycle. 5-FU at 600 mg/m^2 infusion was administered over 22 hours on day 1 and day 2 of each cycle.
45613170|NCT03377257|Drug|zolmitriptan by sublingual administration|Experimental group
45613171|NCT03377257|Drug|zolmitriptan by oral|Active group
45759244|NCT00786643|Drug|Leucovorin (LV)|Leucovorin 200mg/m^2 was administered over 2 hours on day 1 and day 2 of each cycle.
45613172|NCT03374059|Other|Exercise program|
45759245|NCT00786643|Drug|Gamma-Interferon-1b (IFN-γ)|Gamma-Interferon 150 mcg/m^2 was administered by subcutaneous injection on day 1 of each cycle immediately before treatment with 5-FU and LV, and on day 3 of each cycle immediately after treatment with 5-FU and LV.
45759246|NCT00786643|Drug|Bevacizumab|Bevacizumab 5mg/kg was only added to the treatment regimen of patients in stratum 1 who demonstrated stable disease on imaging repeated prior to the 5th cycle of treatment. Bavacizumab was administered on day 4 of each cycle.
45759247|NCT01275469|Drug|GFT505 80mg|Hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast.
45759248|NCT01275469|Drug|Placebo|Hard gelatin capsules, oral administration, 4 capsules per day before breakfast.
45759249|NCT05742997|Device|PartoSure|Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1
45759250|NCT05742997|Device|Fetal Fibronectine|Diagnostic Kit for the Detection of Fetal Fibronectine
45759251|NCT03804463|Procedure|endometrial cancer radical surgery|Take hysterectomy and bilateral adnexectomy.
45613173|NCT03374059|Other|Life modification|
45613174|NCT03373903|Other|Placebo|oral
45613175|NCT03373903|Drug|BEZ235|oral
45759252|NCT03804463|Procedure|fertility-sparing surgery|Take endometrectomy , preserve uterus and bilateral ovaries.
45759253|NCT03804463|Procedure|ovarian preservation surgery|Take hysterectomy,preserve bilateral ovaries.
45759254|NCT01276379|Drug|FOLFIRI (m)|"FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:~Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.~l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.~One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.~5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours."
45759255|NCT01276379|Drug|FOLFOX-6 (m)|"FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:~Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.~l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.~One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.~5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours."
45759256|NCT01276379|Drug|Cetuximab|- 500 mg/m2 i.v. Every 2 weeks.
45613176|NCT03373903|Drug|BEZ235 plus everolimus (RAD001)|Oral
45613177|NCT05089279|Drug|D113|QD, PO
45911485|NCT02008591|Procedure|Epidural Technique versus Dural Puncture Epidural Technique versus Combined Spinal Epidural Technique|Three different techniques, using the same medications (bupivacaine and fentanyl)
45613178|NCT05089279|Drug|CKD-349|QD, PO
45613179|NCT02775409|Procedure|Subcutaneous placement|The tissue expander will be placed above the muscle.
45613180|NCT02775409|Procedure|Submuscular placement|The tissue expander will be placed below the muscle
45759257|NCT01275547|Drug|s-ketamine & midazolam|s-ketamine 6 mg intranasal midazolam 0.75 mg intranasal
45759258|NCT01275547|Drug|Morphine PCA|2 mg Morphine i.v. all 12 minutes as a patient controlled system
45759259|NCT03804385|Procedure|intercostal tube|surgical operation
45759260|NCT03804307|Radiation|standard treatment|3000 cGy in 10 daily fractions
45759261|NCT03804307|Radiation|short course treatment|2000 cGy in 4 fractions administered twice a day
45759262|NCT03804151|Behavioral|FitSpirit intervention|The study evaluates the effects of the FitSpirit intervention on divers health markers of adolescents. Participants freely register to the intervention via their school. Physical activities and event are organized by the schools with the help of the FitSpirit organization.
45759263|NCT00789685|Drug|Interferon Beta|Interferon Beta administered intravenously daily for 6 days. Doses of 0.12 MIU, 1.2 MIU, 2.7 MIU or 6.0 MIU (dose escalation phase) or 2.7 MIU (dose expansion phase) were administered.
45759264|NCT03804229|Drug|Butylphthalide soft capsule|700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills(100mg each) of Butylphthalide soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
45759265|NCT03804229|Drug|Placebo soft capsule|700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills of placebo soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
45759266|NCT05742607|Drug|IPH5201 + durvalumab + standard chemotherapy|"Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy.~Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab."
45759267|NCT03804073|Radiation|standard treatment|3000 cGy in 10 daily fractions
45759268|NCT03804073|Radiation|short course treatment|2000 cGy in 4 fractions administered twice a day
45911486|NCT02008630|Other|Animal-assisted activity|
45759269|NCT05742529|Procedure|TIP|TIP An 8F straight sound is passed into the hypospadiac meatus to assess skin coverage over the urethra., a circumscribing incision is made 2 mm proximal to the meatus, a U-shaped incision is extended proximally to healthy skin The key step in the operation is a midline relaxing incision made from within the meatus to the distal extent of the plate. This incision extends through the epithelial surface of the plate deeply into underlying connective tissues down to the corpora cavernosaNext, a 6F stent is passed into the bladder for postoperative urinary diversion. Then the urethral plate is tubularized. , stitches are ever taken further distally to ensure the neomeatus has a generous oval openingticular closures. .
45613181|NCT05068999|Device|shear wave elastography|"Shear wave elastography (SWE) is an emerging technology that provides information about the inherent elasticity of tissues by producing an acoustic radiofrequency force impulse, sometimes called an acoustic wind, which generates transversely-oriented shear waves that propagate through the surrounding tissue and provide biomechanical information about tissue quality. Although SWE has the potential to revolutionize bone and joint imaging, its clinical application has been hindered by technical and artifactual challenges. Many of the stumbling blocks encountered during musculoskeletal SWE imaging are readily recognizable and can be overcome, but progressive advances in technology and a better understanding of image acquisition are required before SWE can reliably be used in musculoskeletal imaging."
45613182|NCT05048329|Other|Non-invasive continuous remote monitoring with structured escalation pathway|Continuous patient monitoring through non-invasive biosensors coupled with machine learning algorithms, with a structured escalation and communication pathway for home health providers and colorectal clinical team
45613183|NCT05048329|Other|Affective Analysis of Participant Response to Continuous Remote Patient Monitoring|Surveys and interviews with enrolled participants
45613184|NCT05019547|Behavioral|Determining Barriers and Facilitators of Physical Activity|Determining Barriers and Facilitators of Physical Activity
45613185|NCT02440945|Device|Collection of blood|Blood test on blotting paper DBS (for the patients recruting)
45613186|NCT03872089|Other|Infrared Thermography|Measurements of the temperature of the plantar arch by thermal imaging (Infrared Thermography)
45613187|NCT03860935|Drug|acoramidis|TTR stabilizer administered orally twice daily (BID)
45613188|NCT03860935|Drug|Placebo Oral Tablet|Non-active control administered orally twice daily (BID)
45613189|NCT04445857|Drug|Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml)|coadministration of calcitonin and a single-shot hyperbaric bupivacaine prolongs the length of the sensory block (min) of SA in tramadol-abuse patients independent of the route of calcitonin administration intrathecally or i.v.
45911487|NCT02008630|Other|Animal-assisted therapy|
45613190|NCT04445857|Other|normal saline (NS)|1ml NS intrathecally OR injection of 10 ml NS slowly IV over 5 min.
45613191|NCT03373825|Behavioral|Take home rapid drug test|The Rapid Response fentanyl test strips will be offered as take-home rapid drug tests to all participants to assess the willingness to use take-home rapid drug tests and the feasibility of using such an intervention at home. Arm 1 will be offered one method of using the take-home rapid drug test (urine testing). Arm 2 will be offered a second method of using the take-home rapid drug test (testing drug residue).
45613192|NCT03382873|Behavioral|Group Lifestyle Balance (GLB)|"The intervention includes the following key features: 1) individual case managers or lifestyle coaches; 2) frequent contact with participants; 3) a structured, state-of-the-art, 16-session core-curriculum that teaches behavioral self-management strategies for weight loss and physical activity; 4) a more flexible maintenance intervention, combining group and individual approaches and motivational campaigns; 6) individualization through a toolbox of adherence strategies; and 7) tailoring of materials and strategies utilizing a network of training, feedback, and support."
45613193|NCT03382873|Behavioral|Group Lifestyle Balance Plus (GLB+)|The GLB+ intervention arm will include participants who did not achieve the targeted percentage of weight loss by week 5, and will add enhanced training to the program that will focus on values clarification, mindful decision making, planning, and problem solving.
45613194|NCT04445779|Dietary Supplement|Coenzyme Q10|Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before surgical procedure.
45759270|NCT05742529|Procedure|STITCH BY STITCH|SBS in brief Operative technique :starts with penile degloving, preparation of the flap (Site of hypospadic meatus is determined after degloving). Creation of a narrow strip of the urethral plate with wide glanular wings is done using bilateral incisions which are extended to the tip of the glans. The width of the urethral plate is about 3 mm then we suture the flap to the narrow urethral plate in two layers in continuous manner using vicryl 6/0 over a suitable plastic catheter. Triangular (Vshape) area of the distal part of the flap is excised a the midline. After this we anastomose the flap to thetip of the glans. The glans appears opened in the midline as inverted V shape. Closure of the glans is finished in the midline using three mattress interrupted sutures with another three simple stitches are used in between
45911488|NCT02008643|Other|filling questionnary to quality of life|filling questionnary to quality of life
45911489|NCT02008669|Procedure|Blood sampling|A blood sample will be taken from each patient and the following parameters will be assessed : magnesium, albumin, Vitamin B12, Vitamin D, Calcium, Iron.
45445373|NCT02799082|Drug|Vehicle|topical treatment for photodynamic therapy combining vehicle application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
46068904|NCT05230524|Device|DiamondTemp™ Ablation System|Pulmonary vein isolation will be performed with the DiamondTemp™ Ablation System
46068905|NCT05229224|Other|Osteo fluidic Sensitive méthod|Manual therapy, without manipulative treatment, based on rebalancing of the body with manual pressures on specific body areas.
46068906|NCT05229224|Other|Placebo method|Soft Manual pressures at specific points that are defined as non-effective and non-deleterious for patients.
45613195|NCT03377101|Drug|Copanlisib|Given IV
46068907|NCT05227053|Device|Arctic Front™ Cardiac Cryoablation Catheter|Pulmonary vein isolation will be performed with the Arctic Front™ cardiac cryoablation catheter system
45613196|NCT03377101|Drug|Fulvestrant|Given IM
45613197|NCT03377101|Other|Laboratory Biomarker Analysis|Correlative studies
45613198|NCT03377101|Drug|Palbociclib|Given PO
45759271|NCT03803917|Procedure|Injection with freshly collected autologous adipose tissue|
45759272|NCT04276987|Biological|MSCs-derived exosomes|5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).
45759273|NCT00769015|Behavioral|BA-LVR|Low vision clinic-based optometry plus 6 in-home occupational therapy visits
45613199|NCT03373747|Diagnostic Test|Reliability of IET|The participants will be do three sessions: familiarization, test and retest to assess the reliability inter and intra rater of the test.
45613200|NCT03373747|Diagnostic Test|Physiological analysis of IET|The participants will be submitted two sessions, familiarization session and test session. In the test session there will be the physiological analysis by means of gas analysis, blood lactate concentrate and activation muscular percentage.
45759274|NCT00769015|Behavioral|ST-LVR|Clinic-based low vision optometry plus 6 in-home sessions of Supportive Therapy
45613201|NCT04445467|Drug|Favipiravir|Favipiravir
45613202|NCT03382795|Drug|EGFR|Gefitinib 250mg or Erlotinib 150mg medication, Once-Daily.
45613203|NCT03373669|Biological|Oral Cholera Vaccine|Shanchol is a bivalent (O1 and O139 serotypes) vaccine using a heat-killed classical Inaba strain and a formalin-killed classical Ogawa strain produced by Sanofi. Shanchol requires no oral buffer for administration, is approved for persons greater than 1 year of age, and requires 2 doses at two-week intervals. It became World Health Organization (WHO) prequalified in 2011.
45613204|NCT03373669|Biological|Adjusted Dose Oral Cholera Vaccine|The Adjusted Dose Oral Cholera Vaccine is given in two doses, with the second dose given at six months, rather than the manufacturer described 2 week interval between first and second dose.
45613205|NCT03124615|Drug|Enzalutamide|Enzalutamide is a FDA and Therapeutic Goods Administration (TGA, Regulatory Authority of therapeutic goods in Australia) approved treatment for castration resistant prostate cancer
45613206|NCT03382717|Device|Excilor Forte|1 application per day during 6 months
45613207|NCT03382717|Drug|Loceryl 5%|1 application per week during 6 months
45613208|NCT03373513|Procedure|Robotic single-site Hysterectomy|Robotic assisted Periumbilical single incision hysterectomy
45613209|NCT03373513|Procedure|Laparoscopic hysterectomy|Multiport laparoscopic hysterectomy
45613210|NCT03125473|Biological|VXA-G1.1-NN Oral Vaccine|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high total doses.
45613211|NCT03373357|Other|Patient not SAHOS|"Phone consultation in 1 month, 3mois, then every 6 months, and an annual visit.~Cardiovascular events arisen during the duration of the study~Modifications of the lifestyle: alcohol, physical activity~Weight~Clinical measure of the PA~Clinical examination~The collection of the cardiovascular events arisen during the duration of the study will be realized for all the inclusive patients"
45613212|NCT03373357|Other|Patient SAHOS sailed by the ventilation in PPC and not sailed|"Questionnaire of subjective evaluation of diurnal slumber: scale of Epworth and search for appearance of at least 2 of the following symptoms: sleep not salvage dealer, night-breathlessnesses, multiple awakenings, fatigue, disordersconfusions, nycturie, snore.~Questionnaire of evaluation of the global quality of life of the SAHOS~Appearance of new cardiovascular risk factors~Cardiovascular events arisen during the duration of the study~Modification of the current treatments~Modifications of the lifestyle: alcohol, physical activity~Weight~Clinical measure of the PA~Clinical examination~The collection of the cardiovascular events arisen during the duration of the study will be realized for all the inclusive patients"
45445374|NCT02799082|Drug|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
45613213|NCT03376945|Drug|trail cohort|"Drug: Omega-3 Fatty Acid-Based Parenteral Nutrition Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid [FA] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
45613214|NCT03376945|Drug|control cohort|"Drug: Structolipid Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
45613215|NCT03376789|Drug|MYL-1501D product using manufacture process V|MYL-1501D product using manufacture process V
45613216|NCT03376789|Drug|MYL-1501D product using manufacture process VI|MYL-1501D product using manufacture process VI
45613217|NCT03376711|Behavioral|Online Peer Support Program|"The online peer support program will entail: 1) Informational links; 2) A discussion forum (open to all participants and allowing for asynchronous contact between caregivers & peer mentors); 3) A weekly live chat; 4) Private messaging (audio, video, and text options); and 5) Ask-a-mentor (A short video/blurb profiling each caregiving mentor will be posted including details such as gender, age, duration of care, relationship to care-recipient, and illness that care-recipient suffers from). Caregiving participants can then self-match to a peer mentor they feel is best-positioned to address their support needs."
45613218|NCT03125239|Drug|Merestinib|Oral, once a day, Merestinib Only- Lead in period on week. The followed by cycles on combination therapy with Merestinib and LY2874455 (28 days long)
45759275|NCT02991677|Behavioral|aerobic exercise intervention|Exercise physiologist supervised walking or running on the treadmill 3 times weekly for 12 weeks.
45759276|NCT02991677|Other|control group|weekly contact by study staff with survivorship information offered not related to neuropathy.
45759277|NCT02991677|Behavioral|resistive training|Exercise physiologist supervised upper and lower extremity resistive training 3 times weekly for 12 weeks
45759278|NCT04384549|Biological|BCG GROUP|One intradermal injection of 0.1 ml of BCG vaccine (AJ Vaccine).Each 0.1 ml vaccine contains between 2 to 8 x 105 colony forming units.
45759279|NCT04384549|Other|PLACEBO GROUP|One intradermal injection of 0.1ml NaCl
45759280|NCT02149303|Drug|Dabigatran 75 mg|PO BID
45759281|NCT02149303|Drug|Dabigatran 150 mg|PO BID
45759282|NCT03803527|Procedure|Esophageal String Test|An EST will be performed for a 1hour sampling period on the same day as the scheduled clinic visit. Subjects will be asked to swallow a capsule and the attached EST string will be taped to the cheek with tegaderm tape. At the completion of the 1-hour sampling period, the EST will be removed and it will immediately be processed and cryopreserved for metabolomics profiling.
45613219|NCT03125239|Drug|LY2874455|This will be followed by cycles of combination therapy with merestinib and LY2874455. Each of these cycles are 28 days long. • LY2874455 will be taken by mouth twice a day. You may take LY2874455 twice daily for 14 days, 21 days, or 28 days each cycle depending on the dose level you are assigned.
45759283|NCT03803449|Drug|50-200mg propofol|participants in both groups are given standard regimen including 50-200mg propofol.
45759284|NCT03803449|Drug|50ug fentanyl|participants in fentanyl group are given intervention regimen: 50ug fentanyl.
45759285|NCT03803449|Drug|1 mg midazolam|participants in both groups are given standard regimen including 1 mg midazolam.
45759286|NCT03803839|Drug|Clodronate|
45759287|NCT03803839|Drug|Saline|
45759288|NCT03803293|Diagnostic Test|Pharmacogenomic testing|A comprehensive PGx interpretive report created by OneOme (www.oneome.com) provides information on how an individual patient's genes may affect medication response. OneOme utilizes algorithms and curated clinical PGx knowledge to generate a highly intuitive personalized report based on a patient's genomic results.
45759289|NCT03803137|Other|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry
45613220|NCT03382483|Device|Low intensity pulsed ultrasound|bone growth stimulator
45613221|NCT03376555|Drug|Acetylcholine (ACh) Dose Response|Probe 1. Lactated Ringer's only (control) Probe 2. Lactated Ringer's + N-G-nitro-L-arginine methyl ester (LNAME) Probe 3. Lactated Ringer's + Ascorbate Probe 4. Lactated Ringer's + Tempol Probe 5. Lactated Ringer's + Apocynin
45613222|NCT03376555|Drug|Local Heating (LH)|Probe 1. Lactated Ringer's only (control) Probe 2. Lactated Ringer's + Ascorbate Probe 3. Lactated Ringer's + Tempol Probe 4. Lactated Ringer's + Apocynin
45613223|NCT03376555|Drug|Flow Mediated Dilation with nitroglycerin|"BP cuff on a forearm, gel on the upper arm just above the elbow, and a Doppler ultrasound probe on the gel. The ultrasound measures vessel size and blood velocity. After a 3-minute resting measurement, the cuff inflates for 5 minutes to occlude forearm blood flow (BF). After the cuff deflates, we perform a second reading.~Sublingual nitroglycerin: The subject is supine. We measure blood pressure. Also, we perform ultrasonography at the brachial artery at the elbow during the procedure. Nurse places a 0.4 mg nitroglycerin tablet under the subject's tongue. The subject remains supine for 20 minutes following the nitroglycerin administration."
45613224|NCT03373201|Drug|Tasimelteon|Oral capsule
45613225|NCT03373201|Drug|Placebo|Oral capsule
45759290|NCT00771277|Behavioral|Support Teams|Use of volunteers organized into teams with a coordinator to provide services to TBI family
45759291|NCT00789997|Drug|Prednisone|prednisone 40 mg daily for 10 days or placebo prednisone
45759292|NCT00789997|Drug|Etanercept|etanercept 50 mg subcutaneous given on the day of randomization and one week later or placebo subcutaneous injection
45759293|NCT00789997|Drug|levofloxacin|Levofloxacin 750 mg daily for 10 days.
45759294|NCT03832855|Biological|pING-hHER3FL|Plasmid vaccine containing HER3
45759295|NCT00771745|Drug|Thymoglobulin|Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
45759296|NCT00771745|Drug|Thymoglobulin|Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
45759297|NCT02148835|Other|Sausage: Triomeg|Commercial sausages enriched with 330 - 510 mg EPA+DHA / 100 g Approximate average composition of active product per 80 g Sausage (Triomeg): 250 mg EPA+DHA as ethyl-ester Energy content 500 kJ (120 kcal), protein 12 g, Carbohydrates 0.8 g, total fat 9 g, of which 2.8 g saturated fatty acids, 4.5 g monounsaturates, 1.4 g polyunsaturates. sodium 0.66 g.
45759298|NCT02148835|Other|Sausage: Control|Control sausage: as active, but no EPA+DHA ethyl-ester.
45759299|NCT00790699|Device|I-PORT|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
45759300|NCT00790699|Other|standard injections|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
45759301|NCT03803215|Drug|Theophylline|Oral theophylline initially 600 mg bid and then titrated at the maximum tolerated dose
45759302|NCT00790855|Drug|Bendamustine|Starting dose of 50 mg/m^2 through a needle or catheter in vein over 2 hours twice on Days 1-4 of every 4 week study cycle. A new study cycle may begin when blood cell counts have returned to an appropriate level or a new study cycle may begun earlier if disease gets worse or does not improve.
45759303|NCT03802747|Drug|Durvalumab|Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity.
45759304|NCT03802747|Drug|Durvalumab and Tremelimumab|Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity. Tremelimumab will be dosed at 75 mg every 4 weeks (same day as durvalumab infusion) for a maximum of 4 doses.
45759305|NCT03802747|Drug|Y-90 Selective Internal Radiation Therapy (SIRT)|Yttrium-90 microsphere therapy consists of resin beads loaded with Yttrium, a pure beta emitter with a 64.2 hour half-life. Radioembolization will be performed as standard of care therapy per current NCCN guidelines.
45759306|NCT03802747|Drug|Stereotactic Body Radiation Therapy (SBRT)|High-dose hypofractionated conformal external beam radiation therapy that is considered a standard of care. SBRT will also be considered for metastases that are persistent and/or progressive after Y-90 based on MR imaging and pathology from tissue biopsies.
45759307|NCT00791089|Drug|LOVAZA Omega 3-acid ethyl esters|Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.
45759308|NCT00791089|Drug|LOVAZA|(EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
45613226|NCT03382405|Biological|mRNA-1647|Escalating dose levels
45613227|NCT03382405|Biological|mRNA-1443|Escalating dose levels
45613228|NCT03382405|Other|Placebo|Saline
45759309|NCT00791089|Other|placebo|Control group will receive placebo before & after ablation.
45759310|NCT03802903|Device|Remo-Wax|topical treatment
45759311|NCT03802669|Other|oral mutans streptococcus|quantitative assessment of mutans streptococcus of each group by using PCR and protein pattern
45759312|NCT04384315|Other|Questionnaires|Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
45613229|NCT03373123|Procedure|Endoscopy|Endoscopy
45613230|NCT03373123|Procedure|CTA|Radiomic features were extracted from CTA images.
45613231|NCT03372967|Biological|Vaccine administration by a pharmacist|Administration, number and types, of vaccines by a pharmacist
45759313|NCT00791323|Drug|Ketorolac 0.4%|One drop 4 times a day in the pre-operative eye beginning day 0 for 4 days
45759314|NCT00791323|Drug|Lubricating Eye Drop|One drop 4 times a day in the operative eye beginning one day prior to the peripheral iridotomy and continuing until the day of IOL implantation
45759315|NCT03802357|Procedure|Exercise training|Patients perform an exercise Training program of 3 weeks Duration including endurance Training, resistance Training and squat Training. This program is part of an inpatient pulmonary Rehabilitation.
45759316|NCT05691595|Other|Online survey data collection|The data will be collected via a web-survey created with the SurveyMonkey® software. The web-survey will be distributed among nurses at IRCCS Policlinico San Donato (San Donato Milanese, Italy) and ASST Grande Ospedale Metropolitano Niguarda (Milan, Italy).
45759317|NCT00772915|Drug|dexamethasone|"Dose: -40 mg once weekly (days 1, 8, 15, & 22) orally with food until progression.~If after 3 cycles, a partial response is not achieved on lenalidomide alone, dexamethasone 10 mg weekly will be added, and the weekly dexamethasone dose will be increased by 10 mg each cycle to a maximum of 40 mg weekly, as long as a partial response is not achieved. If a partial response is achieved at a dose of dexamethasone less than 40 mg weekly, patients will continue on that dose. If progression at any time, increase dexamethasone to 40 mg weekly. Patient will go off study only when progression is documented while receiving 40 mg/week of dexamethasone or the maximum tolerated dose of dexamethasone (if prior dose reductions have been implemented for toxicity). Increases in dexamethasone dose are to be made only at the initiation of a cycle.~If progression at any time while on lenalidomide alone (first 3 cycles), add dexamethasone 40 mg weekly."
45759318|NCT00772915|Drug|lenalidomide|"25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.~Lenalidomide alone will be administered for the first 3 cycles, then in combination with dexamethasone as needed (described)."
45759319|NCT00774163|Biological|Lactobacillus reuteri|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
45613232|NCT03372967|Behavioral|Unmet vaccination needs identified and met|Identification of unmet vaccination needs and having those needs met
45613233|NCT03372967|Behavioral|Vaccination forecast review and patient education|Pharmacist review of the vaccination forecast and patient education on his/her vaccine needs
45613234|NCT03717727|Other|Exergame|16-week home-based exercise intervention with exergaming system and usual treatment.
45613235|NCT03717727|Other|Control|16-week home-based exercise by standard protocol and usual treatment.
45613236|NCT02519881|Procedure|Microfracture|simple microfracture of ankle
45613237|NCT02519881|Device|CartiFill|add collagen when doing microfracture
45613238|NCT03382327|Procedure|Surgical planning|Two surgical plans will be established preoperatively. The first plan will be based on standard preoperative images (CT-scan, MRI) review. The second plan will be based on the 3D model review. Both will be compared to the actual surgery performed in the operating room.
45613239|NCT03372889|Behavioral|Patient educaiton materials - Print based|Print (paper) based materials
45613240|NCT03372889|Behavioral|Patient educaiton materials - Media based|Media (electronic) based materials
45613241|NCT03372811|Drug|TC cream|A well-characterized botanical drug for topical treatment of psoriasis vulgaris
45613242|NCT03372811|Drug|Vehicle|Vehicle
45759320|NCT00774163|Other|Placebo|5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period
45759321|NCT03801967|Drug|AZD9977|Randomized participants will receive oral dose of AZD9977.
45759322|NCT03801967|Drug|Placebo|Randomized participants will receive oral dose of matching placebo.
45759323|NCT05497453|Drug|OTX-2002|OTX-2002 is a lipid nanoparticle (LNP) that contains a biscistronic mRNA that codes for 2 independent epigenomic controllers.
45613243|NCT03382171|Other|FoodforCare at home|Five small protein rich meals that will be delivered twice a week for 3 weeks.
45613244|NCT03382093|Behavioral|Personalized Feedback Intervention|Personalized Feedback Intervention for smoking and anxiety.
45613245|NCT03382093|Behavioral|Smoking Information Control|Smoking Information with no personalized feedback.
45613246|NCT03376399|Other|Gastroparesis Cardinal Symptom Index Questionnaire|Patients with an established diagnosis of Diabetic Gastroparesis that are interested in a sleeve gastrectomy for weight loss will be asked to participate in the registry. Once the consent process is complete the patient will be asked to complete the Gastroparesis Cardinal Symptom Index Questionnaire prior to weight loss surgery and 30 days, 3 months, 6 months and 12 months after surgery.
45613247|NCT03382015|Other|BKR-013 or Placebo|Encapsulated L-glutamine
45613248|NCT03715231|Other|NIDEK Gonioscope GS-1|To determine inter-observer repeatability when using this device, two observers will examine each image obtained from NIDEK Gonioscope GS-1 and separately determine the iridocorneal angle. Inter-observer repeatability will be tested using Pearson correlation.
45613249|NCT03715231|Other|Standard Digital Gonioscopic Images|To determine inter-observer repeatability when using this device, two observers will examine each image obtained from NIDEK Gonioscope GS-1 and separately determine the iridocorneal angle. Inter-observer repeatability will be tested using Pearson correlation.
45613250|NCT03376243|Other|LIPIKAR BAUME AP+ emollient|Structured education on prevention guidelines
45613251|NCT03381937|Other|speech trial|speech trial during different ventilation conditions
45613252|NCT03700411|Drug|Morphine|Morphine intravenous
45613253|NCT03700411|Drug|Piritramid|Piritramid intravenous
45911490|NCT02008669|Other|Gustatory sensitivity test using Taste strips|"16 Taste Strips impregnated with 4 flavors (sweet, sour, salty, bitter, each flavor present at 4 different concentrations), are offered to the patient one after the other in a so-called pseudorandomized sequence. The task of the patient is to choose one of the following answers: sweet / sour / salty / bitter / no taste.~Each correct answer is granted one point. In addition to the impregnated strips, two tasteless strips can be integrated in the examination at any point of time (no point)"
45911491|NCT02008669|Other|Questionnaires|"Evaluation of the following parameters by validated questionnaires (name of the questionnaire in bracket):~Fatigue (EMIF-SEP)~Dysphagia (DYMUS)~Food intake (semi-structured questionnaire)~Depression (BDI-II)~Daily energy expenditure (NAP)~Visual analog scale to study quality of sleep"
45613254|NCT03700411|Drug|Epidural|Perioperative epidural analgesia
45613255|NCT03691051|Drug|Pyrotinib plus Capecitabine|Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days.
45911492|NCT02008695|Behavioral|adult microfinance|"Female piglet provided to household member. Participants agrees to repay participants' loan by giving two piglets (one to repay the loan and one for the interest on the loan) to the association from the first litter of piglets (on average 6-12 piglets). These piglets are then given to other village member households"
45613256|NCT03372577|Behavioral|Mindfulness-Based Sex Therapy|It is based on an integration of psychoeducation, sex therapy, and mindfulness-based skills. the intervention will be delivered by a group of facilitators on a group based weekly.
45613257|NCT03372577|Other|Treatment as usual|Routine discharge counseling
45613258|NCT03381859|Drug|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]|Hepatitis C Virus direct-acting antiviral
45613259|NCT03372499|Dietary Supplement|diet management strategy for encephalopathy|diet management strategy for encephalopathy means diet management strategy from the nutritional management consensus of hepatic encephalopathy.
45613260|NCT03381781|Drug|Decitabine|20mg/m^2,d1-5,ivgtt,28days as a duration
45613261|NCT03381781|Drug|Arsenic Trioxide|0.16mg/kg,d1-5,ivgtt,28days as a duration
45613262|NCT03381781|Drug|Cytarabine|15mg/m^2,hypodermic injection,q12h,d1-7
45613263|NCT03372421|Other|Social Story|A short story written in the third person about what it's like to attend an assessment for ASD.
45613264|NCT03372421|Other|Standard Information|Information the host site currently sends out to patients informing them about what to expect from the assessment
45613265|NCT03381703|Drug|YH12852|YH12852 administration
45613266|NCT03381703|Drug|14C-labeled YH12852|14C-labeled YH12852 administration
45613267|NCT03372265|Drug|Ropivacaine 0.2%|Perineural infusion using a peripheral nerve block catheter and a portable infusion pump.
45613268|NCT03376009|Diagnostic Test|Blood sample for serum and plasma biomarkers:|Serum/plasma biomarkers: Approximately 10ml (3 teaspoons) of blood will be extracted to measure pre-specified biomarkers of renal injury including kidney injury molecule-1 (KIM-1), cystatin C and neutrophil gelatinase-associated lipocalin (NGAL). Samples will then be stored to facilitate measurement of additional biomarkers in the future.
45613269|NCT03376009|Diagnostic Test|Urine sample for biomarkers|Urinary biomarkers: A random urine sample will be obtained to measure urinary protein to creatinine ratio (uPCR), KIM-1 and liver-type fatty acid binding protein (L-FABP)
45759324|NCT05497453|Drug|Tyrosine kinase inhibitor One|Tyrosine Kinase Inhibitor
45759325|NCT05497453|Drug|Tyrosine kinase inhibitor Two|tyrosine kinase inhibitor
45759326|NCT05497453|Drug|Checkpoint Inhibitor, Immune|monoclonal antibody that binds to PD-1 or PD-L1
45759327|NCT03801889|Drug|SP-420|Self-administered by mouth
45759328|NCT03801577|Dietary Supplement|Hepaxa|High concentrate EPA and DHA
45613270|NCT03376009|Diagnostic Test|Cardiac bio-impedance (Cardioscreen Medis)|Cardiac bio-impedance - a non-invasive assessment of cardiac output, cardiac index and systemic vascular resistance index using the bio-impedence technique (Cardioscreen 1000 Medis) Cardiac bio-impedance is performed by attaching sticky electrodes to the participant's neck and thorax. These electrodes pass a very low, constant and alternating current (1.5 mA, 86 kHz) across the thorax, which is imperceptible to the patient. This provides beat by beat data on cardiac output and haemodynamic measurements.
45613271|NCT03376009|Diagnostic Test|Aortic pulse wave velocity (APWV) (TensioMed and SphygmoCor)|"Aortic pulse wave velocity (APWV) a non-invasive measure of arterial function using oscillometric recordings to detail peripheral and central haemodynamics. This will be measured using two different techniques:~TensioMed Arteriograph: After a rest period a blood pressure cuff inflates and deflates twice on the arm. This takes ~3 minutes and should cause only mild, temporary discomfort. The test will routinely be performed in duplicate to ensure accuracy of results.~SphygmoCor: A pressure sensor is held over the radial pulse at the wrist to analyse the pulse wave. Then held over the carotid artery and/or femoral artery to assess the speed of the pulse wave through the body. The probe is similar to an ultrasound probe and should not cause any discomfort."
45613272|NCT03376009|Diagnostic Test|Optical Coherence Tomography (Spectralis OCT)|"OCT is a non-invasive imaging test which uses light waves to take cross sectional images of the back of the eye. Examination of the retinal and retinal nerve fibre layer thickness, macular volume, and choroidal thickness provides an assessment of generalised systemic microvascular injury. A strong correlation between choroidal thickness and renal dysfunction has previously been shown in patients with chronic kidney disease (Balmforth C et al, JCI Insight 2016).~The participant is asked to sit in front of the OCT machine and rest their chin on a support to keep it motionless. The equipment will then scan the eye without touching it. Scanning takes about 5 - 10 minutes."
45613273|NCT03376009|Diagnostic Test|Arterial Spin Labelling Magnetic Resonance Imaging|"Magnetic resonance imaging using arterial spin labelling (ASL-MRI) This promising quantitative technique has the potential to identify dysregulated renal perfusion, stratify risk of AKI in pre-OLT patients, and to monitor alterations in renal haemodynamics in the post transplantation setting.~We aim to recruit 5 participants with 'normal' renal function (eGFR≥60ml/min/1.73m2) and a further 5 participants with 'abnormal' renal function (eGFR<60ml/min/1.73m2)~ASL-MRI will be performed in this subgroup during the week of OLT assessment and then repeated at 6-weeks post transplantation in those participants who undergo OLT during the study period."
45613274|NCT03381625|Drug|BMX-010|Safety and efficacy of BMX-010 in topical treatment of psoriasis and/or atopic dermatitis.
45613275|NCT03381625|Drug|Placebo|Topical administration of placebo in patients with psoriasis and/or atopic dermatitis.
45759329|NCT03801811|Procedure|Study of the efficacy of using skin glue in the application of Port a cath|The use of glue as a device in the implantation of central venous catheters has recently been introduced into European clinical practice. It is possible that the surgical incision created for the insertion of the PORT may be subject to complications such as: local bleeding, which if not properly treated may last even a few days, infections or surgical wound outbreaks. This possibility of bleeding occurs more easily in patients suffering from coagulation problems or when appropriate preventive measures have not been taken at the time of implantation of the device. A solution to this problem could be the application of the cyanoacrylate dermal glue on the edges of the surgical wound, after intradermal suture. The glue would have the purpose of sealing the surgical wound so as to immediately seal the skin incision with hemostatic effect and create a potential barrier against bacterial infections.
45759330|NCT03801733|Drug|Vadadustat|Oral dose of 600 mg QD
45759331|NCT03801733|Drug|Simvastatin|Oral Simvastatin
45759332|NCT03801733|Drug|Rosuvastatin|Oral Rosuvastatin
45759333|NCT03801733|Drug|Atorvastatin|Oral Atorvastatin
45759334|NCT03801733|Drug|Pravastatin|Oral Pravastatin
45759335|NCT03801733|Drug|Sulfasalazine|Oral Sulfasalazine
45759336|NCT03801421|Procedure|Mass continous suture with PDS|The surgical incision will be treated by mass continous suture with PDS.
45759337|NCT03801421|Procedure|Interrupted suture with thread|The surgical incision will be treated by interrupted suture with thread.
45759338|NCT03801343|Dietary Supplement|Nutrakos®|"Nutrakos® Amino Acid Food Supplement supplies a specific mixture of amino acids that has been proven to induce synthesis of collagen and elastin, the main proteins of derma structure in fibroblasts and keratocytes."
45759339|NCT04383535|Other|Convalescent SARS COVID-19 plasma|Convalescent SARS COVID-19 plasma from a pool of 10 donor plasma. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.
45759340|NCT04383535|Other|Placebo|Single infusion of saline solution, in addition to standard care. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.
45759341|NCT04383613|Other|Prone positioning|The intervention is prone positioning (i.e., instructing a patient to lie on their stomach while they are in bed) for 7 days or until the first of study hospital discharge or not requiring supplemental oxygen for >24 hours or study outcome. Patients will be asked to aim for prone positioning four times per day for at least two hours each time, and will be encouraged to sleep on their stomach at night.
45759342|NCT00775411|Drug|dexamethasone|700 µg dexamethasone intravitreal injection at Day 1 in the study eye.
45759343|NCT00775411|Biological|ranibizumab|Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.
45759344|NCT03801655|Dietary Supplement|Bio-Kult|4 capsules/day
45759345|NCT03801655|Other|Placebo|4 capsules/day
45759346|NCT03801499|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
45613276|NCT03372187|Behavioral|DIET-MS|Following the completion of testing, all 20 participants will be placed into the DIET-MS group and will follow the prescribed diet plan for 12 weeks. At the end of the 12 weeks, the participants will return to complete follow up testing.
45613277|NCT03381547|Biological|Pegilodecakin|Pegilodecakin Alone
45613278|NCT03372109|Dietary Supplement|Meal replacement shake|Meal replacement shake taken two days per week during the modified fasting periods
45613279|NCT03372109|Dietary Supplement|Multivitamin and mineral capsules|Multivitamin/mineral supplement
45613280|NCT03372109|Dietary Supplement|Fish oil with sesame lignans and olive extract softgel|Wild Fish Oil Concentrate 2000mg, Olive Extract 300mg, Sesame seed lignan extract 10mg/2 softgels
45613281|NCT03372109|Dietary Supplement|Prebiotic Chewable tablet|Prebiotic Fiber 1,400 mg/tablet
45613282|NCT03372109|Dietary Supplement|Clove Extract and Maqui Berry extract capsule|Clove extract 250mg and maqui berry extract 200mg/capsule
45613283|NCT03372109|Dietary Supplement|.Whole Food Blend capsule|Whole food blend 1000mg/3 capsules
45445375|NCT03783117|Device|Magnetic field treatment|The MBPL device for clinical trials is made with modification of an electromagnet: A bore of 10cm diameter was made to go through the frame and poles. The device can produce a magnetic field close to 1.0 T inside the bore, which is along the axis direction. The trial for each subject takes about 20-30 minutes. To start with, the subject's blood pressure is measured first as the baseline. Afterwards, the subject places his/her right arm into the bore of the electromagnet for treatment while the blood pressure is monitored with the left arm. The magnetic treatment lasts about 15 minutes and will lower the subject's blood pressure. In order to see how long the effect lasts, the subject needs to return and measure the blood pressure again 24 hours after the treatment. The clinical trials are non-invasive. There is no medicine or surgery involved.
45613284|NCT03372109|Dietary Supplement|Turmeric extract capsule|Turmeric 25:1 extract 400mg/capsule
45613285|NCT03372109|Dietary Supplement|European White Kidney Bean capsule|White kidney bean extract 100mg/capsule
45613286|NCT03372109|Dietary Supplement|Saffron extract capsule|Saffron extract 88.25mg/capsule
45613287|NCT03372109|Dietary Supplement|Ubiquinol with Fulvic acid complex softgel|Ubiquinol 100mg and Fulvic Acid complex 100mg/softgel
45613288|NCT03372109|Dietary Supplement|Calcium with Hesperidin and gynostemma extract tablet|Calcium 130mg. hesperidin 500mg and gynostemma extract 450mg/ tablet
45613289|NCT03372109|Dietary Supplement|Multivitamin and mineral supplement|Multivitamin and multimineral supplement
45613290|NCT03372031|Behavioral|Piano training (Active)|Piano Curriculum. Participants were all trained on one of four 88-key pianos located in the assisted living facility. Piano instructors were 6 undergraduate Music Education and Music Performance majors. Each lesson of the week had a different focus: right and left hands separately, bimanually coupled, and bimanually uncoupled (Loehrer et al., 2016). Each week of the module had a different focus as well: notes played one step apart, notes played multiple steps apart (intervals), and tones played together (two-note chords) (van Vugt et al., 2016; Villeneuve et al., 2014). Each session began with skill exercises and ended with learning a simple, recognizable song. Two participants with extensive piano experience progressed to playing duets with the instructor and hymns out of a hymnal after mastery of the study curriculum. These training protocols were based on those of Schneider and colleagues' 2007 study.
45613291|NCT03372031|Behavioral|Piano Training (Passive)|Participants listened to their research partner complete 8 active piano training sessions across 2 weeks.
45613292|NCT04417387|Other|Observational|
45613293|NCT03381469|Procedure|Comprehensive periodontal treatment|The Case group participants will receive non-surgical periodontal therapy that will be completed by the end of week 20-21 of gestation. This will consist of oral hygiene instruction with comprehensive periodontal treatment which will include excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth followed by supragingival and subgingival scaling and root planing (SRP) of sites with PDs > 4 mm and polishing of all the teeth. Participants will be offered treatment under local anesthetic when necessary. No limits will be imposed on the number of dental visits needed to accomplish periodontal therapy.
45613294|NCT03381469|Procedure|single visit supragingival scaling|The control and Placebo group participants will receive oral hygiene instruction and supragingival cleaning of all teeth at their baseline visit.
45759347|NCT00808405|Drug|acyclovir|400mg taken orally three times daily for 5 days
45613295|NCT03371953|Drug|Vecuronium|A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
45613296|NCT03371953|Drug|Atracurium|A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
45613297|NCT03371953|Drug|Vecuronium + Atracurium|A top-up dose of vecuronium + atracurium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
45759348|NCT00808405|Drug|matching placebo|matching placebo taken orally three times daily for 5 days.
45759349|NCT00775645|Dietary Supplement|acetyl-L-carnitine hydrochloride|Given orally
45759350|NCT00775645|Other|placebo|Given orally
45759351|NCT04902781|Drug|AT-007|Treatment with AT-007 given orally
45759352|NCT04902781|Other|Placebo|Placebo given orally
45759353|NCT01974687|Drug|Uprifosbuvir|Uprifosbuvir 5 mg, 25 mg, or 50 mg capsule, or 150 mg tablet, administered by mouth.
45759354|NCT01974687|Drug|Placebo|Matching placebo to uprifosbuvir capsule administered by mouth.
45759355|NCT01974687|Drug|Itraconazole|Itraconazole is supplied as 10 mg/mL oral solution or 100 mg capsules administered by mouth.
45759356|NCT00795145|Drug|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
45759357|NCT00795145|Drug|Linezolid 900 mg|Intravenous, 900 mg linezolid, single dose
45759358|NCT00795145|Drug|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
45759359|NCT00795145|Drug|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
45759360|NCT00795145|Drug|Linezolid 600 mg|Intravenous, 600 mg linezolid, single dose
45759361|NCT00795145|Drug|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
45613298|NCT03381391|Behavioral|Personalized Feedback Intervention|The current intervention included personalized feedback regarding their alcohol consumption, alcohol-related consequences, gender-specific normative drinking comparisons, personal risk factors (e.g., dependence symptoms, family history of alcoholism), and alcohol expectancies. The intervention also included didactic material related to alcohol (e.g., effects at different BAC levels, tolerance) and drinking moderation strategies. The feedback was presented graphically in a feedback report with the individual's information.
45613299|NCT03375931|Behavioral|Prayer|If the patient wishes to pray, the anesthesiologist will pray for one minute before anesthesia.
45613300|NCT03375931|Behavioral|non-prayer|If the patient does not want to pray, the anesthesiologist does anesthesia without praying.
45613301|NCT03550183|Biological|mesenchymal stem cells|Patients with PD in the therapy group were given UC-MSCs by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1 month, 3 months, 6 months and 12 months were evaluated respectively the curative effect.
45613302|NCT03381313|Behavioral|Conditioned word repetition training|In the classical conditioning training the onset of the visual stimulus preceded that of the auditory stimulus with a short onset asynchrony, and both stimuli co-terminated. By contrast, in the training without conditioning the auditory stimulus was administered first and the visual stimulus appeared short after the off-set of the auditory one.
45613303|NCT03371797|Drug|Valsartan, Amlodipine -|"Valsartan is a non-peptide, orally active, and specific angiotensin II receptor blocker acting on the AT1 receptor subtype used as an antihypertensive agent.~Amlodipine besylate is a dihydropyridine long-acting calcium channel blocker."
45613304|NCT02520115|Drug|Dexamethasone|Given PO
45613305|NCT02520115|Other|Laboratory Biomarker Analysis|Analysis of serum and tissue samples
45613306|NCT02520115|Drug|Valproic Acid|Given PO
45613307|NCT03375775|Drug|Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy|According to standardized clinical protocol
45613308|NCT03375775|Other|No immunotherapy, symptomatic treatment|These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.
45613309|NCT03381235|Other|Spin exercise|Each exercise class will consist of 20 minutes of progressive, interval based Spin exercise 2 times a week for 6 months on stationary exercise cycles and will be led by a qualified instructor. The Duration of each session is lengthened based on the progression of the participant and the recommendation of the instructor by 1-2 minutes as needed to a maximum time of 60 minutes per session. Exercise intensity will begin at low levels (50% of maximal heart rate reserve (HRR) and increase by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
45613310|NCT03371641|Behavioral|ASQ parental questionnaire|ASQ parental questionnaire
45613311|NCT03371641|Behavioral|Development scales|WPPSI - IV and NEPSY development scales
45613312|NCT03371641|Behavioral|Scale of Conners|Scale of Conners
45613313|NCT03371641|Behavioral|SCQ Questionnaire|SCQ questionnaire
45613314|NCT03371641|Procedure|Blood sample (mother)|Blood sample (mother) before delivery
45613315|NCT03371641|Procedure|Cord blood sample|Cord blood sample after delivery
45613316|NCT03371641|Procedure|Placenta sample|Placenta sample
45613317|NCT03381157|Other|Observational General Movements Assessments|GMs assessment has been increasingly used to predict motor dysfunction, especially the Cerebral Palsy (SP), since its introduction 25 years ago. The GMs assessment is based on the visual holistic perception of normal and abnormal movements of the body. This approach focuses on spontaneous movements of the baby rather than reflexes, tonus, and reactions
45613318|NCT04527133|Drug|Aprotinin|Intravenous or inhalation
45613319|NCT03371563|Drug|Antibiotics|Patients were treated with antibiotics for Lyme disease.
45613320|NCT03371563|Other|no intervention|controls were not given antibiotics
45613321|NCT03381079|Procedure|Posterior scleral reinforcement|Posterior scleral reinforcement (pPSR) is a procedure applied with autologous or biological material or synthetic materials reinforcing pole of the sclera after eyeball, in order to prevent or alleviate myopic development.
45613322|NCT03375541|Other|Risk Aversion Calculator|The calculator asks the participant to rate their level of aversion to having a set list of potential medication side effects (0 = no concern; 1 = mild concern; 2 = moderate concern; 3 = moderate to severe concern; 4 = severe concern)
45613323|NCT03371329|Biological|MSC|bone marrow derived cultured MSC (mesenchymal stem cell)
45613324|NCT03381001|Procedure|embryo transfer after thaw and culture|embryos will be kept in culture after thawing for one day before transfer for the uterus
45759362|NCT00795145|Drug|Moxifloxacin 400 mg|Oral, 400 mg moxifloxacin, single dose
45759363|NCT03801187|Procedure|chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
45759364|NCT03801187|Procedure|Er:YAG laser|Er.YAg laser treatment will be provided on the implant surface.
45613325|NCT03381001|Procedure|embryo transfer with no culture|embryos will be transfer with no culture after thaw
45613326|NCT03380923|Behavioral|Moderate Intensity|Exercise prescription intensity is moderate
45613327|NCT03380923|Behavioral|High Intensity|Exercise prescription intensity is high
45613328|NCT03125161|Drug|HAI|HAI
45613329|NCT03125161|Drug|chemotherapy ± target therapy|chemotherapy ± target therapy
45613330|NCT03370081|Device|CAPNOGRAPHY|MONITORING OF CAPNOMETRY USING ETCO2 METHOD
45613331|NCT03370003|Other|Standard medical care|All children will receive nutritional treatment and standard medical care in accordance with the nutritional guidelines of the national protocol, with the exception of the routine distribution of antibiotics.
45613332|NCT03125317|Other|Music|a kind of music which the participant likes will be listened using speakers
45613333|NCT03125317|Other|Valsalva maneuver|Participant will be asked to take a deep breath and exhale the air out in 15 seconds
45613334|NCT03125317|Other|control|No intervention
45613335|NCT03369925|Dietary Supplement|Placebo supplement|Cellulose
45613336|NCT03369925|Dietary Supplement|Citicoline supplement|Cognizin
45759365|NCT03801187|Procedure|Air-Powder|An air powder device will be treatment will be provided on the implant surface.
45613337|NCT03369847|Drug|budesonide, beclomethasone|The inhaled corticosteroids we are using for this study are budesonide nebulized solution and beclomethasone metered-dose inhaler. Low-doses for these medications are 0.5mg/day for budesonide and 160 mcg/day for beclomethasone. Patients under 5 years of age will receive low dose budesonide solution 0.25mg/respule to be given twice a day via nebulizer. Budesonide is FDA approved for children under 5 years of age. Patients 5 years and older will receive one beclomethasone metered-dose inhaler (MDI) 40mcg/puff two puffs twice a day via spacer. Beclomethasone is FDA approved for children 5 years and older.
45613338|NCT04526743|Behavioral|Questionnaire|Psychological and behavioral variables will be collected using questionnaires that have been validated in our setting and will be completed by the patients themselves online.
45759366|NCT00809185|Drug|everolimus|Patients will receive monotherapy with RAD001(everolimus)for 21 days within the 28 day cycle.
45759367|NCT00809185|Other|laboratory biomarker analysis|Laboratory correlates (cytotoxic t cell populations, S6K1 levels, GSTT-1 mutations, and the presence or absence of HLA-DR15) will be assessed to see if any of these correlates correspond to response.
45759368|NCT00809185|Procedure|Bone marrow aspirate/biopsy|Bone marrow aspirate and biopsy with cytogenetics should be obtained within 4 weeks prior to starting drug and at week 33. A bone marrow aspirate and biopsy should also be obtained for patients going off study prior to week 33 (including cytogenetics). The percentage of blasts on the aspirate should be used to determine the IPSS score.
45759369|NCT03800953|Drug|Avelumab|The study treatment comprises two phases, the concurrent immune-chemoradiotherapy (Ave-PF-CRT) phase and the immune-chemotherapy (Ave-PF) phase. All the subjects will receive Avelumab at both phases.
45759370|NCT03809663|Drug|Tezepelumab|Solution for injection
45613339|NCT04526431|Drug|Dosage Forms Oral|Dosage form of tacrolimus (extended release tacrolimus or immediate release tacrolimus)
45613340|NCT04526353|Drug|Oxybutynin 1 mg/ml Syrup|"The Investigational Medicinal Product of this study is Oxybutynin 1 mg/ml Syrup (see Annex 1 for the Monograph of PMS-Oxybutynin provided by ANSM under the ATU.). It will be administered at the dose of 0.1 mg/kg/twice a day to patients randomized to the study treatment group. The dose will be adapted to the child's weight to the nearest kilogram.~The recommended dosage for older children with neurologic bladder is 0.3 to 0.4mg/kg/day, whilst the dosage we will be using is effectively 0.2mg/kg/day. This is because we are taking into account the absence or pharmacological studies of oxybutynin use in children <1 year of age, as well as their specific liver metabolism. Furthermore, the dose of 0.1mg/kg twice daily is the dose used in children within the same age group in the study by Casey et al, 2012"
45613341|NCT03363607|Procedure|Digital indirect bonding|Indirect bonding of orthodontic attachments using digital 3D printed transfer tray
45613342|NCT03363607|Procedure|Conventional indirect bonding|Indirect bonding of orthodontic attachments using thermoformed transfer tray
45613343|NCT03363607|Procedure|Intraoral scanning|Intraoral Scanning of the bonded brackets
45613344|NCT03363607|Procedure|Superimposition and evaluation|superimposition of the brackets' positions before and after bonding and evaluation of the transfer accuracy
45613345|NCT03369769|Other|Activity|10 minutes interaction with therapy dog and adult handler in small group (2-4 participants).
45759371|NCT03809663|Other|Placebo|Placebo solution for injection
45759372|NCT04349787|Other|Computer-aided diagnosis (CADx)|Optical diagnosis of colorectal polyps made with computer-aided diagnosis (CADx) using state-of-the-art machine learning methods and deep learning architectures.
45613346|NCT03371173|Drug|Ferric maltol 30 mg (Feraccru®)|Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
45613347|NCT03363529|Device|Dynamic light|Dynamic lighting is light that changes in intensity and spectral distribution during the day
45613348|NCT03363529|Device|Standard|Standard lighting is non-dynamical light corresponding to standard hospital lighting.
45445376|NCT02062138|Other|continuous passive motion (CPM)|standard-of-care therapy (control intervention); Patients receive three 30 minutes CPM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.
45613349|NCT03371095|Drug|Infliximab|Use of infliximab instead of cyclophosphamide
45613350|NCT03371095|Drug|Cyclophosphamide|Use of cyclophosphamide
45613351|NCT03363451|Drug|Antibiotics|This is an observation study, no specific antibiotics will be indicated during treatment
45613352|NCT04525963|Other|Preoperative visit of the operating room nurse and patient education|The operating room nurse, who is given intervention training, will visit the patient before the operation. After the oral training of the operating room nurse, a printed booklet will be left for the patient to read.
45613353|NCT03369535|Other|CARB rich diet|Consumed CARB rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
45613354|NCT03369535|Other|MUFA rich diet|Consumed MUFA rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
45759373|NCT04349787|Other|BLI Adenoma Serrated International Classification (BASIC)|Optical diagnosis of colorectal polyps made with BLI Adenoma Serrated International Classification (BASIC), both by exert endoscopists and novices.
45759374|NCT00795769|Drug|ondansetron|Given IV
45759375|NCT00795769|Other|survey administration|Correlative studies
45759376|NCT00795769|Procedure|management of therapy complications|Ondansetron IV
45759377|NCT00796627|Genetic|Healthy volunteers|Comparison of healthy volunteers to burn wounded volunteers
45759378|NCT00796627|Other|Burn volunteers|Comparison of burn wounded volunteers to healthy volunteers
45445377|NCT02062138|Other|controlled active motion (CAM I)|Patients receive three 30 minutes CAM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.
45445378|NCT02062138|Other|controlled active motion (CAM II)|Patients receive three 30 minutes CAM applications (bilateral alternating) each day from the second postoperative day until 1 day prior to discharge.
45759379|NCT01975935|Drug|Amlexanox|25 mg amlexanox tablets blinded by encapsulation
45759380|NCT01975935|Drug|Placebo|placebo sham blinded by encapsulation in the same capsules as the study drug arm
45759381|NCT04345679|Biological|anti-SARS-CoV-2 convalescent plasma|Infusion of one unit of anti-SARS-CoV-2 convalescent plasma ~200 mL over 4 hours
45759382|NCT02305017|Drug|BIA 9-1067|BIA 9-1067 50 mg
45759383|NCT02305017|Drug|Paracetamol|Paracetamol 1g
45613355|NCT03369535|Other|PROT rich diet|Consumed PROT rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
45613356|NCT03363295|Drug|Moxifloxacin Injection|One group will receive moxifloxacin injection (0,03ml) in the anterior chamber by the end of phacoemulsification surgery
45613357|NCT03370861|Biological|Immunotherapy|Medications that increase the activity of the immune system.
45445379|NCT03710889|Drug|Abaloparatide|Abaloparatide is a novel, synthetic, 34 amino acid peptide designed to be a potent and selective activator of the PTH/PTH-related protein (PTHrP) type 1 receptor (PTHR1) signaling pathway with 41% homology to PTH[1-34] and 76% homology to human PTHrP[1-34].
45613358|NCT03369457|Biological|Isolation of multipotent cells|Isolation of multipotent cells from patient's cells. Analysis of CFU and differentiation potential
45613359|NCT03370705|Drug|Sulodexide|Sulodexide 250 ULS twice daily per oral route
45613360|NCT03370705|Drug|Statin|Statin 20mg once daily per oral route,
45613361|NCT03370705|Drug|Antiplatelet Agents|Antiplatelet therapy 75mg once daily per oral route
45613362|NCT03370705|Drug|ACE inhibitor|ACE inhibitor 20mg once daily per oral route
45613363|NCT03363139|Drug|Tirosin Kinase Inhibitors|Patients that received Tyrosin Kinase inhibitors and progressed
45613364|NCT04525807|Diagnostic Test|Multi-omics|Use multi-omics to analyze
45613365|NCT04445077|Other|Dementia Competence Education for care home setting|The intervention is a competency-based education program for care home staff who provide dementia care in Mainland China.
45613366|NCT04445077|Other|Printed educational materials|The educational materials will be delivered to the participants in the control group for their self-study.
45613367|NCT03370549|Behavioral|AWARE intervention|Group psychotherapy for Asian-American women
45613368|NCT03369379|Drug|D3 Vitamin|Subjects will receive a capsule of 50,000 units of vitamin D3 echa week for 12 weeks, basal levels of vitamin D will be taken and again at week 12.
45613369|NCT03369379|Other|Placebo|Placebo pill
45613370|NCT03123991|Behavioral|UP-A adapted as a preventive intervention|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a school-based anxiety and depression preventive intervention. The UP-A (Ehrenreich-May et al., 2016) is a transdiagnostic anxiety and depressive disorders treatment protocol that implement a set of core principles to address common factors underlying youth anxiety and depressive symptoms in an individual setting. Core modules of the UP-A include: (1) Building and Keeping Motivation; (2) Getting to Know Your Emotions and Behaviors; (3) Behavioral Activation; (4) Sensational Awareness; (5) Being Flexible In Your Thinking; (6) Awareness of Emotional Experiences; (7) Situational Emotion Exposures and (8) Keeping it Going - Maintaining Your Gains.
45613371|NCT03123991|Behavioral|Same than experimental group (EG), after EG finishes|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a school-based anxiety and depression preventive intervention. The UP-A (Ehrenreich-May et al., 2016) is a transdiagnostic anxiety and depressive disorders treatment protocol that implement a set of core principles to address common factors underlying youth anxiety and depressive symptoms in an individual setting. Core modules of the UP-A include: (1) Building and Keeping Motivation; (2) Getting to Know Your Emotions and Behaviors; (3) Behavioral Activation; (4) Sensational Awareness; (5) Being Flexible In Your Thinking; (6) Awareness of Emotional Experiences; (7) Situational Emotion Exposures and (8) Keeping it Going - Maintaining Your Gains.
45613372|NCT03369145|Dietary Supplement|High-fat diet|The high-fat diet will provide 7 days of overfeeding comprising of: +50% extra calories above the daily required intake, 65% of which is fat.
45613373|NCT03362983|Other|CareHND|Multidisciplinary, integrated, person-centered care at the integrated HND-clinic
45445380|NCT02061046|Device|CPAP therapy|8 weeks of CPAP therapy
45613374|NCT02519569|Other|Internet-based cognitive-behavioral therapy|The intervention consists of ten writing assignments
45613375|NCT03362905|Drug|Lidocaine topical|Local anesthetic for reduction of IUD associated pain
45613376|NCT02519647|Device|Tracheal intubation with Gliderite|Tracheal intubation with Gliderite
45759384|NCT00249821|Drug|Saizen®|Saizen® [somatropin (recombinant deoxyribonucleic acid [rDNA] origin) for injection], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
45759385|NCT00249821|Drug|Saizen®|Saizen® [somatropin (rDNA origin) for injection], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
45445381|NCT01318473|Device|ActiSight™ Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
45613377|NCT02519647|Device|Tracheal intubation with S-guide|Tracheal intubation with S-guide
45613378|NCT04525651|Device|Digital Acupuncture Manipulation Therapeutic Instrument|The device is based on the characteristics of traditional acupuncture manipulation of Shanghai School of Traditional Chinese Medicine, and absorbs the information of the techniques of famous experts, modulates the stimulation waveform of the electroacupuncture device by modulating the signal, and realizes the digitization of acupuncture technique information.
45613379|NCT04525651|Other|Manual Acupuncture|Manual acupuncture to acheive de qi.
45613380|NCT04525651|Other|Sham Acupuncture|Sham acupuncture to avoid de qi.
45759386|NCT01976871|Drug|Rotigotine|Rotigotine is FDA approved for the treatment of Restless Legs Syndrome at doses of 1 mg/24h, 2 mg/24h, and 3 mg/24h. The prescribed dose of rotigotine may be achieved using single or multiple patches. Subjects will titrate the dose based on discussions with the investigator.
45759387|NCT03602781|Drug|Placebo|Placebo at a dose setting of 75 mcg/kg IBW/hr
45759388|NCT03602781|Drug|iNO|iNO at a dose setting of 75 mcg/kg IBW/hr
45613381|NCT03370315|Other|Dance Program|The dance program consists of dance classes inspired by the rhythm of Forró and Samba. The sessions are divided into four stages: 1) stretching and sensitization of the body, with the support of chairs; 2) balance and rhythm exercises, with the support of the bar; 3) dance inspired by the genres worked - Forró and Samba; 4) Fun activities that stimulate socialization or with visual clues, working displacements, motor coordination, rhythm, improvisation and creativity. 24 sessions, twice a week, which session take 60 min.
45445382|NCT03782961|Device|sodium lactate and combination of polymers|sodium lactate and combination of polymers (polycarbophil, carbomer and PVM / MA copolymer)
45613382|NCT03370315|Other|Walking Program|The walking program consists of 3 moments: 1) a brief warm-up of free walking for 3 minutes in the comfortable velocity; 2) then walking according to the training cycle, the intensity will be between 60 and 80% of the reserve heart rate; 3) a relaxation. 24 sessions, twice a week, which session take 60 min.
45613383|NCT03362827|Other|Chronic low back pain patients|People must have experienced low back pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
45613384|NCT03362827|Other|Subjects without chronic low back pain|These participants must not have presented episodes of low back pain for more than 7 days in the last 12 months.
45613385|NCT03370159|Drug|6,8-Bis(benzylthio)octanoic Acid|Given IV
45445383|NCT02061124|Drug|Sevelamer 1600 mg TID for 7 days|
45613386|NCT03370159|Drug|Docetaxel|Given IV
45613387|NCT03370159|Other|Pharmacological Study|Correlative studies
45613388|NCT02519725|Other|ICU diary|The intervention is the elaboration of an ICU diary by caregivers and families The first pages of the diary is standardized to include an explanation of the purpose of the diary. The diary is maintained by the family and ICU staff. The only instruction given to the families and staff members about diary entries is to refrain from writing about confidential matters that could not be shared among the patients, the staff and the relatives. Staff members are free to express compassion and their hope, or absence thereof, that the patient would recover. Relatives can speak freely with the patients without receiving guidance from the ICU staff. At the minimum, the ICU staff write a brief entry at each weekly staff meeting. For patients discharged to wards and if he can receive the diary, the diary is given to the patient. If the patient died, the diary is given to the family.
45613389|NCT03362593|Drug|MEDI7219|Experimental Drug
45613390|NCT03362593|Drug|Placebo|Placebo
45613391|NCT03362593|Drug|Formulation without Active Drug|Formulation without Active Drug
45613392|NCT03358459|Other|non|non
45613393|NCT03358381|Procedure|the gap balance type of total knee arthroplasty|A gap balance type of total knee arthroplasty surgery will be performed.The gap balance group will receive this kind of intervention.
45613394|NCT03358381|Procedure|the measured resection type of total knee arthroplasty|A measured resection type of total knee arthroplasty surgery will be performed.The measured resection group will receive this kind of intervention.
45613395|NCT04522297|Drug|Midodrine/Octreotide|oral midodrine plus octreotide as subcutaneous injection
45613396|NCT04522297|Drug|Nor-epinephrine|Intravenous infusion norepinephrine
45613397|NCT03358225|Procedure|anterior cervical discectomy and fusion|The patients undergoing anterior cervical discectomy and fusion sugery
45613398|NCT03358225|Procedure|cervical artificial disc replacement|The patients undergoing cervical artificial disc replacement surgery
45613399|NCT03358225|Procedure|hybrid surgery|The patients undergoing 1-level C-ADR plus 1-level ACDF surgery
45613400|NCT03369067|Device|Tandem t:slim X2 with Control-IQ Technology + Dexcom G6|Subjects will use the Tandem t:slim X2 with Control-IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor [CGM].
45613401|NCT03369067|Device|Dexcom CGM G5|"The Dexcom G5 CGM is a subcutaneous glucose sensor that provides an estimate of the prevailing blood glucose concentration approximately every 5 minutes.The Dexcom G5 sensor alerts the user if the prevailing glucose concentration is higher or lower than predetermined thresholds, or if it is changing too fast. In addition, the Share/Follow functionality of the Dexcom G5 allows up to 5 people (followers) to receive in real-time information about the current blood glucose concentration and rate of change.~The Dexcom G5 system will be used by participants and clinical study staff to monitor glucose levels 24h/day during the camp, ensure participants safety, and compute glycemic control outcomes"
45759389|NCT02280239|Drug|Acetaminophen|one-time dose of acetaminophen 650mg given via the enteral route (via the gut)
45759390|NCT02280239|Drug|Placebo|one-time dose of placebo (identical capsule) given via the enteral route (via the gut)
45759391|NCT01993875|Drug|Lubiprostone|Liquid formulation, 12 mcg x 2 pumps administered orally twice daily (BID)
45759392|NCT01993875|Drug|Placebo|Matching liquid placebo, 0 mcg x 2 pumps administered orally twice daily (BID)
45759393|NCT03809741|Other|Bundled L&D Infection Prevention Interventions|"The following bundle of infection prevention interventions will be implemented at each study site for 12 weeks:~Education: 2 day module of Infection Prevention and Control (IPC) training and education at the beginning of the period, with specific information pertaining to labor and delivery. A refresher course will be administered at week 6.~Feedback: Monthly feedback sessions detailing IPC practices~Reminders: Visual poster reminders on hand hygiene and daily SMS reminders on best practices for peripartum and postnatal care.~Alcohol Hand Rub (AHR) supply: Provision of AHR, produced by WHO standards and guides in collaboration with district pharmacy"
45759394|NCT00796705|Drug|Adalimumab|40 mg injection of adalimumab administered subcutaneously
45911493|NCT02008695|Behavioral|Youth microfinance only|One child (10-15 years) receive rabbits loan. The child is mentored by microfinance and community mentors. The child repays the loan to program and other children in the family and community are provided a loan from the repayment.
45445384|NCT02061124|Drug|Placebo 1600 mg TID for 7 days|
45445385|NCT01318941|Drug|Ranibizumab|
45445386|NCT01318941|Other|Ranibizumab|
45445387|NCT02060422|Behavioral|Mindfulness-based therapy|Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.
45613402|NCT03369067|Device|Continuous Subcutaneous Insulin Infusion|Subjects will use a subcutaneous pump to deliver insulin and control their glycemia.
45613403|NCT03368989|Drug|Radium-223 dichloride|Previously known as Alpharadin, Radium-223 dichloride is a calcium-mimetic, alpha emitting radiopharmaceutical, which introduces double-stranded DNA breaks in metastatic cancer cells.
45613404|NCT03368911|Device|Oral/Nasal Endotracheal Tube, Reinforced (Covidien)|Use Oral/Nasal Endotracheal Tube, Reinforced (Covidien) for endotracheal intubation
45613405|NCT03368911|Device|TaperGuard oral tracheal tube (Covidien)|Use TaperGuard oral tracheal tube (Covidien) for endotracheal intubation
45613406|NCT04525729|Drug|Rituximab|To evaluate the efficacy and safety of HLX01 combined with RASi in patients with IgAN.
45613407|NCT04525729|Drug|RAS 2410|To evaluate the efficacy and safety of RASi in patients with IgAN.
45613408|NCT03362437|Drug|BMS-986177|Form A
45613409|NCT03362437|Drug|BMS-986177|Form B
45613410|NCT04525495|Drug|Dopamine|Dopamine treatment
45613411|NCT03362359|Drug|Ga-68-PSMA-11|Single administration of 150 MBq (± 50 MBq), corresponding to a mass dose of ≤ 6 µg. A 2nd administration of 150 MBq (± 50 MBq), corresponding to a mass dose of ≤ 6 µg is possible in the unlikely case of a negative histological result (i.e. no prostate-specific membrane antigen (PSMA) expression in dissected lymph nodes) to verify if PSMA PET-positive tissue as seen on day 1 has not been removed during RP with EPLND.
45613412|NCT04525417|Diagnostic Test|AAZ Covid-19 rapid test|To assess the immune status
45613413|NCT03358069|Diagnostic Test|Emergence agitation scale|Emergence agitation scale: PAED scale > 10 defined as positive for Emergence agitation (EA) Post hospitalize behavioral questionnaire (PHBQ) positive Post operative behavioral changes defines as 10 % change from sum score of PHBQ
45613414|NCT03362281|Drug|Ilaprazole|10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling.
45613415|NCT03362281|Drug|Omeprazole|40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min.
45613416|NCT03362281|Drug|Ilaprazole tablet|Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
45613417|NCT03362281|Drug|amoxicillin and clarithromycin|The Patients who with helicobacter pylori infection were provided amoxicillin and clarithromycin as complimentary therapy for two weeks
45613418|NCT04521985|Procedure|thoracolumbar kyphosis surgery|patients receiving surgery or not
45613419|NCT03362203|Other|Patients with chronic neck pain|Patients,aged 21-80 years, must have experienced neck pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
45613420|NCT03362203|Other|Subjects without chronic neck pain|Subjects,aged 21-80 years, must not have presented episodes of chronic neck pain for more than 7 days in the last 12 months.
45613421|NCT04032093|Biological|RSV vaccine|RSV vaccine
45613422|NCT04032093|Biological|Placebo|Normal saline solution for injection (0.9% sodium chloride injection)
45613423|NCT03357913|Other|Lung transplantation|To estimate the incidence of non-respiratory co-morbidities after lung transplantation between 2004 and 2014 in the cohort of patients with cystic fibrosis grafted in the Rhône-Alpes region
45613424|NCT03357835|Other|Trauma Decision System|At the time of application, color codes indicating the urgency of the patients will be given according to the demographic data of the patients, the type of trauma and the vital signs were directed by the software program. As a result of the software program's direction, patients will be coded as green-yellow-orange-red area and patient care will be made in accordance with these codes.
45613425|NCT03368755|Diagnostic Test|Cardiopulmonary Exercise Testing|Pimax, Pemax, airway pressure at 100 msec after occlusion (P0.1), and Ti and Ttot will be measured by the Micro 5000 device (Medisoft, Sorinnes, Belgium). TTImus will be calculated as (Pimean / Pimax) x (Ti / Ttot), where Pimean is the mean airway pressure resulting from the formula Pimean = 5 x P0.1 x Ti9. RM function will be determined a) prior to CPET, b) during CPET when the anaerobic threshold (AT) will be reached, and c) after CPET, when heart rate (HR) and oxygen consumption will be normalized.
45911494|NCT02008695|Behavioral|youth and adult micro finance|One child and adult member of household receive animal loan. The child and adult are mentored and repayment of the loan to the program is provided and the repayment animal is provided to other members of the community
45613426|NCT03368755|Diagnostic Test|Respiratory Muscle Strength and Endurance|CPET will be performed by the Ultima CPX system (Medgraphics, St. Paul, USA), using a cycle ergometer and according to a standardized protocol. The following parameters will be recorded: total work in Watts, maximum HR, maximum oxygen consumption (VO2max), AT indices (work, HR, VO2 ) and duration of recovery.
45613427|NCT03368599|Procedure|Bronchoscope guided advancement|"During the anesthetic induction for thoracic surgery, Lt. DLT is intubated using the bronchoscope-guided method. The method is as follows.~Lt. DLT is intubated through vocal cord using the direct laryngoscopy.~Pass the fiberoptic bronschoscope through a bronchial lumen of Lt. DLT.~Secure the pathway into the Lt. main bronchus by advancing the bronchoscope into the Lt. main bronchus.~Lt. DLT can be advanced through the guide of the bronchoscope into Lt. main bronchus.~After the advancement, the position of Lt. DLT can be confirmed using the fiberoptic bronchoscope. If necessary, the depth and direction of Lt. DLT should be modified."
45613428|NCT03368599|Procedure|Conventional advancement|"During the anesthetic induction for thoracic surgery, Lt. DLT is intubated using the conventional method. The method is as follows.~Lt. DLT is intubated through vocal cord using the direct laryngoscopy.~Rotate Lt. DLT 90 degrees to the left side.~Advance Lt. DLT blindly to main bronchus level.~After the advancement, the position of Lt. DLT can be confirmed using the fiberoptic bronchoscope. If necessary, the depth and direction of Lt. DLT should be modified."
45613429|NCT02518789|Drug|Low-dose Dexmedetomidine|Pretreatment：Intravenous injection dexmedetomidine 0.5 µg/kg ，completed within 15 minutes.
45613430|NCT02518789|Drug|High-dose dexmedetomidine|Pretreatment：Intravenous injection dexmedetomidine 1 µg/kg ，completed within 15 minutes.
45613431|NCT02518789|Drug|normal saline|Pretreatment：Intravenous injection normal saline equal quantity，completed within 15 minutes.
45911495|NCT02008708|Behavioral|Livestock Microfinance|Participants randomized to the microfinance group receive the pig loan.
45911496|NCT02008708|Other|Delayed Control Group|Participants enrolled in delayed control receive their pig loan 12 months after the intervention group.
45911497|NCT02008721|Drug|EGCG as putative neuroprotective agent|Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent
45613432|NCT02518789|Drug|Etomidate|"After 90 seconds of Pretreatment，intravenous infusion of etomidate fat emulsion 0.3mg/kg.~-Does not offer any other drugs within 5 min after completion of etomidate."
45613433|NCT02518789|Drug|midazolam，fentanyl，rocuronium|Anesthesia induction：Intravenous injection midazolam 0.03 ~ 0.05 mg/kg, fentanyl 5 ~ 8 g/kg, rocuronium 0.6 mg/kg
45613434|NCT02518789|Drug|propofol，remifentanil，cis atracurium|Anesthesia maintenance：Intravenous infusion of propofol 4 ~ 6 mg/kg/h, remifentanil 0.1 ~ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 ~ 0.1mg/kg
45613435|NCT03357757|Drug|Valproic Acid|The target serum level for VPA will be between 75 and 100 mcg/mL checked every 2 weeks for the first 6 cycles.
45613436|NCT03357757|Biological|Avelumab|10 mg/kg IV
45613437|NCT03361969|Drug|Estetrol|estetrol formulated in tablets
45613438|NCT03361969|Drug|Placebo Oral Tablet|placebo tablets
45613439|NCT03368521|Other|Back pain screening test|The care giver use the screening tool in order to score the back patient to three levels of risk. For each level of risk, one suggested type of care is provided; 1) simple advise; 2) physiotherapy; 3) multimodal rehabilitation. highest risk level includes multimodal intervention.
45613440|NCT02994225|Drug|Indocyanine Green|"Subcutaneous injection (1 ml) of the indocyanine green into the ipsilateral upper extremity 10 min before the surgery.~Near Infra-red images acquisition is performed during surgery"
45759395|NCT00796705|Drug|Adalimumab placebo|1.0 ml .9% saline placebo administered subcutaneously
45759396|NCT00796705|Drug|Etanercept|50 mg dimeric fusion protein administered subcutaneously
45613441|NCT03361891|Behavioral|WalkMORE Group|Hospitalized Internal Medicine patients will walk with trained volunteer coaches twice daily until hospital discharge
45613442|NCT03357679|Procedure|Tracheal intubation|Intubation of the trachea with endotracheal tube
45613443|NCT03357679|Device|Glidescope assisted tracheal intubation|With the use of the Glidescope video laryngoscope, the trachea will be intubated with the endotracheal tube
45613444|NCT03357679|Device|Bed up head elevated tracheal intubation|Use of the Macintosh laryngoscope blade size 3
45613445|NCT02983695|Drug|TIL-TC150|The active ingredients in TIL-TC150 are tetrahydrocannabinol (THC) and Cannabidiol (CBD), isolated from the Cannabis sativa L. strains produced by Tilray, and formulated into an oral liquid drug product.
45613446|NCT02549781|Other|Go-Nogo test|"In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
45613447|NCT03361813|Other|trans-cutaneous ultrasound guided peritonsillar infiltration|Preoperative peritonsillar infiltration of bupivacine in tonsillectomy surgery by using the ultrasound through a transcutaneous route
45613448|NCT03361813|Other|trans-oral ultrasound guided peritonsillar infiltration|Preoperative peritonsillar infiltration of bupivacine in tonsillectomy surgery by using the ultrasound through a trans-oral route
45759397|NCT03800875|Drug|27-hour inpatient intervention|Subjects will be admitted at the research facility at 19:00. Each 27-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (22:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The infusion rate of either insulin alone or insulin and pramlintide will be changed manually based on the computer generated recommendation. The computer generated recommendations are based on a predictive algorithm.
45759398|NCT02148523|Behavioral|Comparison to peers|
45759399|NCT02148523|Behavioral|Adherence feedback|
45445388|NCT02060422|Behavioral|Social support group|Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
45759400|NCT02148523|Device|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
45911498|NCT02008721|Drug|Placebo|Placebo
45445389|NCT02060500|Procedure|Cardiaplication|
45445390|NCT02060578|Other|Questionnaire and interview|Questionnaire completed by the parents Interview with the parents and the psychologist (University Rennes 2)
45445391|NCT03560440|Other|Plasma exposure vancomycin|Investigation of plasma exposure of vancomycin.
45759401|NCT00809809|Drug|Zicam (Ionic zinc)|33mmol/l of ionic zinc
45759402|NCT00809809|Drug|placebo|placebo swab
45759403|NCT04384471|Other|Online survey|Participants are invited to answer an online questionnaire including both close-ended and open-ended questions about their experience during this sanitary crisis
45759404|NCT03839797|Behavioral|Cadet Healthy Personal Skills|7.5 hour skills training group intervention
45759405|NCT03839797|Behavioral|Standard Health Education|Standard Health Education
45759406|NCT00248651|Drug|Amitriptyline|25 mg capsule by mouth at bedtime for two weeks, then 50 mg capsule by mouth at bedtime for 10 weeks. The drug will be provided in blister packs.
45759407|NCT00248651|Drug|Escitalopram|10 mg tablets by mouth at bedtime for 12 weeks. The drug will be provided in blister packs.
45911499|NCT02008734|Drug|PD0332991|
45445392|NCT02797678|Device|Powersleep|Participants will receive 5 nights of stimulation
45445393|NCT02797678|Device|Sham Powersleep|Participants will receive 5 nights of no stimulation
45445394|NCT03776955|Drug|Carvedilol|Oral tablet
45759408|NCT00248651|Drug|Placebo|Placebo escitalopram and placebo amitriptyline will be manufactured to ensure all tablets and capsules will be indistinguishable, and provided in blister packs.
45613449|NCT04203069|Device|Control group : Day-time compression sleeve|"In the control group, patients wear only day-time compression garment : lymphatrex during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)."
45759409|NCT03839719|Procedure|Group PI|Before rinsing with the mouthrinse, Ultrasonic scaling was done in the 1st and 4th quadrant without any mouth rinse (placebo mouthrinse) and fall out samples were collected in the blood agar plates kept at a distance of 0.5 m and 1 m from the oral cavity.
45759410|NCT03839719|Procedure|Group OC|After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.
45759411|NCT03839719|Procedure|Group CHX|After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.
45759412|NCT03800251|Dietary Supplement|Nutricia PreOp - a clear, non-carbonated, lemon flavoured, carbohydrate drink that provides 0.5kcal/ml|Fasting parturients at term, admitted for elective cesarean section and consent to partake in the study, will be given the intervention drink
45759413|NCT05464381|Drug|allo-APZ2-OTS|Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
45759414|NCT05464381|Drug|Placebo|Placebo
45759415|NCT03800797|Drug|Loxoprofen sodium hydrogel patch|100 mg per day
45759416|NCT03800797|Drug|Loxoprofen sodium tablet|60 mg t.i.d.
46068908|NCT05221606|Behavioral|Nurse AMIE|Supportive Care Platform (behavioral interventions that are offered based on answers to daily symptom rating questions). Interventions offered include walking, balance, strength exercise, guided relaxation, mindfulness, CBT, DBT, soothing music.
45613450|NCT04203069|Device|Intervention group : Day-time compression sleeve and Night-time MOBIDERM® Autofit|"In the intervention group, patients wear a day-time compression garment : lymphatrex and the night-time compression garment : MOBIDERM AUTOFIT during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)."
45613451|NCT03357601|Behavioral|HIIT|The participant will perform HIIT where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 20 seconds of high intensity interval exercise at an all out intensity separated by 2 minutes of active recovery at 30% MHR. The interval will be repeated six times. Once completing all six intervals, participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
45613452|NCT03357601|Behavioral|MCEET|The participant will perform MCEET, where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 14 minutes of moderate, continuous endurance exercise at 70% MHR. Participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
45613453|NCT02929485|Drug|Tolcapone|Tolcapone 200mg (single dose) administered at study visit
45613454|NCT02929485|Drug|Placebo|Placebo (200mg) administered at study visit
45613455|NCT02929485|Drug|Bromocriptine|Drug: Bromocriptine 1.25 mg (single dose) administered at study visit
45613456|NCT03368443|Behavioral|treadmill training and overground gait training|The participants will be randomized into two different groups, and they will receive treadmill and overground gait training in one or two rooms.
46068909|NCT05221606|Behavioral|Usual Care|Binder of written supportive care materials
45445395|NCT05102721|Drug|Avelumab and Pepinemab|IV Infusions every two weeks.
45445396|NCT03308942|Drug|Niraparib|Niraparib is an orally available, potent, highly selective poly adenosine diphosphate- ribose (poly ADP-ribose) polymerase-1 (PARP-1) and PARP-2 inhibitor. It will be available as 100 milligrams (mg) capsules and will be administered as 2 X 100 mg capsules (200 mg per day) orally once daily (QD).
45613457|NCT04523623|Drug|Oxycodone|oxycodone 0.2mg/kg, max 10mg to be administered, randomized between that and Ibuprofen
45759417|NCT04383067|Procedure|Tumor Infiltrating Lymphocytes (TIL)|Patient with metastatic urothelial carcinoma will undergo a autologous lymphocyte transplantation. Patient will undergo surgery to remove either the primary tumor or a tumor metastasis. The cells collected in this surgey will be cultured and reintroduced to the patient. Following the cell infusion, patient will receive a high-dose bolus of IL-2.
45759418|NCT04383067|Drug|Proleukin|high-dose (720,000 IU/kg) IL-2 will be administered every 8 hours, to tolerance. A maximum of 10 doses will be administered
45911500|NCT02008747|Drug|Magnesium sulphate|Continuous application of magnesium sulphate applied 40 mg/kg ideal body weight by bolus before the operation started, followed by a continuous infusion of 10 mg/kg ideal body weight/h for 24 hours
46068910|NCT05215652|Other|adherence monitoring package (AMoPac)|"AMoPac is a tool that consists of~an electronic monitoring device,~data management and data analysis,~feedback on patient's performance,~clinical-pharmaceutical evaluation of medication adherence,~transmission of an adherence report."
45613458|NCT04523623|Drug|Ibuprofen|ibuprofen 10mg/kg, max 800mg, randomized between that and Oxycodone
45613459|NCT03368365|Device|Ventilotel ®|Using of the spirometer of Aqsitania company, Ventilotel ®, to analyse the respiratory function at rest and to predict unplanned hospitalizations.
45613460|NCT02510079|Biological|Autologous human Schwann cells|Schwann cells harvested from the sural nerve will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
45613461|NCT04521595|Behavioral|Weigh Smart Telehealth intervention|Trial of the group program (nutrition, exercise) delivered via telehealth through fruit street on the Eastern Shore and Western Maryland with use of noninvasive lifestyle tracking options (drink water aquarium app for water consumption and fitbit - steps, sleep monitoring) provides novel options for expansion of family- based lifestyle intervention to underserved areas. We plan as a pilot study to assess the sensitivity of noninvasive measures for the detection of sleep apnea (pediatric sleep questionnaire (PSQ) and fitbit sleep data) in comparison to clinically indicated polysomnography among children with clinical suspicion for sleep apnea.
45613462|NCT04977063|Device|Atmo gas capsule|The Atmo Gas Capsule measures the capsules location and motility/transit times through gas sensing capabilities
45613463|NCT04977063|Device|SmartPill|The SmartPill measures the capsules location and motility/transit times through pH sensing
45613464|NCT03357289|Biological|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
45613465|NCT03368287|Device|Fitbit One, the activity tracker|Activity tracker, Fitbit One, will be used for a week to evaluate the steps of daily life before the surgery and at the time of follow up.
45613466|NCT03368209|Device|WM3.4|Investigational Medical Device collecting spectral raman data from tissue.
45613467|NCT02518867|Other|high intensity iTBS|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (high intensity , 100% of active motor threshold) TBS for 3 days.
45613468|NCT02518867|Other|low intensity iTBS|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low intensity, 80% of active motor threshold) TBS for 3 days.
45613469|NCT02518867|Other|sham iTBS|In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment.
45613470|NCT03368131|Drug|Trastuzumab|intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle
45613471|NCT03368131|Drug|Capecitabine|825~1000mg/m2 bid d1-14
45613472|NCT03368131|Drug|Oxaliplatin|130 mg/m2 Ivgtt d1 q3w
45613473|NCT03368131|Radiation|Radiotherapy|45 Gray (unit) Gy/25f （1.8Gy/f/d，5 f/w）
45613474|NCT04521751|Drug|EMP16-02 120 mg orlistat/40 mg acarbose|EMP16-02 capsules are composed of three pharmaceutical fractions (granules denoted G1, G2 and G3). G1= Prolonged release of acarbose, G2= Enteric-coated granule fraction containing orlistat and acarbose, G3= Orlistat with a delayed on-set release mechanism.
45613475|NCT04521751|Drug|EMP16-02 150 mg orlistat/50 mg acarbose|EMP16-02 capsules are composed of three pharmaceutical fractions (granules denoted G1, G2 and G3). G1= Prolonged release of acarbose, G2= Enteric-coated granule fraction containing orlistat and acarbose, G3= Orlistat with a delayed on-set release mechanism.
45613476|NCT04521751|Drug|Placebo|Matching oral placebo capsules
45613477|NCT02518711|Behavioral|Behavioral Teacher Program|This program was based on the evidence-based Summer Treatment Program (MTA Cooperative Group, 1999), involving psycho-education for the teacher and universal and individual behavioral techniques that focused on classroom structure and contingency management
45613478|NCT04521517|Behavioral|pamphlet describing the timing of family planning during postpartum with methods advantages and disadvantages of family planning|a pamphlet describing the timing of family planning during postpartum with methods advantages and disadvantages of family planning
45613479|NCT03367975|Other|near infrared spectroscopy|
45613480|NCT03361579|Other|Education|c.p. intervention description
45613481|NCT03361501|Drug|CaPre|4 x 1 g capsules administered orally once daily for 26 weeks
45613482|NCT03361501|Drug|Placebo|4 x 1 g capsules administered orally once daily for 26 weeks
45613483|NCT04444765|Other|Collection of clinical and biological data during renal replacement therapy sessions|Collection of clinical and biological data during renal replacement therapy sessions. Two additional blood samples collected during and after RRT session (critically ill patients all have arterial catheter thus additional samples will not need additional puncture).
45613484|NCT03123523|Diagnostic Test|Echocardiography at T0|
45613485|NCT03123523|Diagnostic Test|Exercise test|
45613486|NCT03123523|Biological|Biological assays|Creatinin, hematocrit and BNP assays
45613487|NCT03123523|Device|MRI with contrast agent injection|With injection of gadolinium
45613488|NCT03123523|Device|MRI without contrast agent injection|Without injection of gadolinium
45613489|NCT03123523|Diagnostic Test|Echocardiography at M24|
45613490|NCT01675167|Drug|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 150-900 mcg twice daily
45613491|NCT01675167|Drug|Placebo|Matching Placebo Buccal Film twice daily
45613492|NCT03370627|Biological|Monoclonal anti-cd303 antibody|Addition of monoclonal anti CD303 antibodies or not (control) on 2 blood samples of the same patient, to which 10 μl of CpG (20 μg / ml) are added in order to activate plasmacytoid Dendritic Cells and to induce the secretion of Type I interferons.
45613493|NCT04521205|Drug|fecal microbiota capsule|a capsule full of fecal microbiota extracting from the health
46068911|NCT05212610|Biological|Pfizer-BioNTech mRNA COVID-19 vaccine|Participants will receive an initial or additional dose of a highly protective COVID-19 mRNA vaccine for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in an environment where the investigators and staff are experienced in the care of patients with allergic reactions.
45759419|NCT01994109|Drug|MYOBLOC|"MYOBLOC (rimabotulinumtoxinB) Injection, or botulinum toxin type B, is the B serotype of botulinum toxin. It is the only commercially available B serotype, and also the only available botulinum toxin that does not require reconstitution for use."
45759420|NCT01994109|Other|PLACEBO|
45911501|NCT02008760|Dietary Supplement|Omega Krill with D3|
45613494|NCT03367663|Drug|Prednisone 20 Mg|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
45613495|NCT03367663|Drug|Prednisone 40 Mg|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
45613496|NCT03123601|Device|Risk sign displays|"Set of sign displays designed to communicate fall, dehydration and pulmonary aspiration risks and reflect on tailored interventions to manage these events in nursing homes. Risk sign displays are:~Small, lightweight rubber coloured bracelets with phrases related with the different risks: prevent rather than fall, contain to protect, drink to hydrate and avoid choking.~Small and coloured signposts next to head of patients bed that are believed to offer some key advantages and increase technically the quality of immediate communication of information and data regarding procedures. It is expected to have greater subject compliance once they will have discrete messages with thoughtful design and colour."
45613497|NCT02265939|Drug|NPO-13|
45445397|NCT03308942|Biological|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G-4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands (PD-L1 and PD-L2). It will be available as 50 mg lyophilized powder single-use vials or 100 mg/4 milliliters (mL) (25 mg/mL) solution in a single-dose vial. It will be administered at a dose of 200 mg intravenous (IV) using a 30-minute IV infusion
45613498|NCT03123289|Drug|68-Gallium citrate PET/CT scan|After establishment of an intravenous access, approximately 5 mCi of 68Ga-citrate (Zevacor Molecular, Somerset, NJ, USA) will be administered intravenously. Whole body PET/CT scan will be performed after 60 minutes of uptake phase.
45613499|NCT03123289|Drug|18F FDG PET/CT scan|Subjects will undergo FDG PET/CT scan using the same imaging parameters either on the same day or within the next 24-48 hours. The subjects will be requested to fast for a minimum of 4 h prior to PET acquisition. After confirmation of a blood glucose level ≤200 mg/dl, technologists will establish the intravenous access and the subject will receive approximately 10 mCi of 18F-FDG (Zevacor Molecular, Somerset, NJ, USA) intravenously. The subject will be placed in uptake room for 60 minutes to allow for optimal localization of the compound. The subjects will be requested to void prior to administration of 18FDG and again prior to image acquisition.
45613500|NCT02459847|Behavioral|Mindfulness Training|
45613501|NCT02459847|Behavioral|Sonographic Biofeedback|
45613502|NCT02459847|Other|Standard Care|
45613503|NCT04521049|Drug|Saxagliptin 5mg|Patients would be assigned to saxagliptin (Onglyza® AstraZeneca Pharmaceuticals LP, Indiana, USA), either received a dose of 5 mg or 2.5 mg daily if patients had eGFR <50 mL/min/1.73 m2
45613504|NCT02267343|Drug|ONO-4538|
45613505|NCT02267343|Drug|Placebo|
45613506|NCT03123445|Drug|Endostar|Endostar,30mg continuous intravenous injection pump, d1-d7,21 days as one cycle, 4 cycles in total
45613507|NCT03123445|Drug|Gemcitabine|Gemcitabine,1000mg/m2, i.v, d1 and d8 in each cycle, 21 days as one cycle, 4 cycles in total
45759421|NCT03800095|Drug|Early palliative care integration|The follow-up time for each patient is 12 months with evaluation of the main objective by a standardized questionnaire: The Functional Assessment of Cancer Therapy-Anaemia (FACT-An) Scale at 6 months. Throughout the study, patients included will receive conventional haematological care and the interventional arm will benefit in addition to a monthly consultation by a palliative care team.
45759422|NCT01978509|Drug|Low volume prep (Prepopik)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
45759423|NCT01978509|Drug|Moderate volume prep (Moviprep)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
45759424|NCT01978509|Drug|High volume prep (Golytely)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
45445398|NCT03308942|Biological|TSR-042 (Dostarlimab)|TSR-042 (Dostarlimab) is a humanized mAb of the IgG4/kappa isotype that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. It will be administered at a dose of 500 mg for every 3 weeks (Q3W) for first 4 cycles followed by 1000 mg for every 6 weeks (Q6W) for all subsequent cycles using a 30-minute IV infusion. TSR-042 (dostarlimab) will be supplied as a solution of 160 mg (20 mg/mL) or 500 mg (50 mg/mL) in a single-dose vial.
45445399|NCT01319019|Drug|GSK961081|Comparison of different doses and dosing regimens of the drug
45445400|NCT01319019|Drug|Salmeterol|Positive control
45759425|NCT00248495|Drug|cisplatin|Given IV
45445401|NCT01319019|Drug|Placebo|Placebo arm
45613508|NCT03123445|Drug|Cisplatin|Cisplatin,75mg/m2, i.v, d1 in each cycle, 21 days as one cycle, 4 cycles in total
45759426|NCT00248495|Drug|pemetrexed disodium|Given IV
45759427|NCT00248495|Procedure|adjuvant therapy|Metastasis prevention/control
45759428|NCT00248495|Procedure|conventional surgery|Undergoing tissue removal
45613509|NCT04520581|Other|"group O"|"Endotracheal tube was made O shape by assistants."
45613510|NCT03361267|Diagnostic Test|Helicobacter pylori PCR test|Clarithromycin resistance (-) Triple therapy (rabeprazole 20 mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid) for 7 days Clarithromycin resistance (+) Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 500 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) for 7 days
45613511|NCT03361267|Diagnostic Test|CLO test|CLO test : negative --> drop out CLO test : postive --> bismuth containing quadruple therapy
45613512|NCT04914819|Behavioral|Online Behavioral Weight Loss Program|Participants will be enrolled in a 16-week online behavioral weight loss program based on the Diabetes Prevention Program (DPP). The program involves weekly brief videos, a self-monitoring platform, automated feedback, and access to a health coach.
45613513|NCT04914819|Behavioral|Virtual weigh-in|Participants will be sent a digital scale and will be asked to complete a virtual weigh-in at home at the start of the study and again after 16 weeks.
45613514|NCT03357133|Drug|Tirofiban|Tirofiban Injection after the alteplase intravenous thrombolysis
45613515|NCT03357133|Drug|Alteplase|Only alteplase intravenous thrombolysis
45613516|NCT05128305|Drug|traditional Chinese medicine1 and traditional Chinese medicine 2|We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS
45613517|NCT03357055|Drug|Ketamine|IV infusion of 0.25mg/kg of ketamine over 10 minutes before pneumatic tourniquet inflation. Throughout procedure patient will receive 0.25mg/kg of ketamine infusion.
45613518|NCT03357055|Drug|Normal saline|Control group will receive an intravenous (IV) infusion of 10 ml of normal saline in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure, patients will receive 10ml/hour normal saline infusion until the end of operation
45613519|NCT04909047|Device|parassacral transcutaneous electrostimulation|Use of parassacral transcutaneous electrostimulation
45613520|NCT03367585|Dietary Supplement|Physical exercise + Vitamin D3|Strength exercise + Supplementation of vitamin D3 50,000 IU / week
45613521|NCT03367585|Other|Physical exercise|Strength exercise
45613522|NCT04885101|Procedure|LISWT Group|The treatment consists of a weekly session and 4,000 pulses will be emitted each of the eight sessions totaling 32,000 pulses with a frequency of 18Hz and 100mJ of energy.
45613523|NCT04885101|Procedure|NARFT Group|The device used will be with an intensity of 350 Wpp; 75% pulsed operation mode; frequency of 640 kHz, 1200 kHz and 2400 kHz. Eight radio frequency sessions will be held with an interval of seven days between them.
45613524|NCT04885101|Procedure|Sham Group|In the RNA group, radiofrequency will be applied, the device used will be the Nèartek Esthetic Ibramed - Tecarterapia e Radiofrequency Apparatus, with an intensity of 350 Wpp; 75% pulsed operation mode; frequency of 640 kHz, 1200 kHz and 2400 kHz. The radiofrequency will be applied with the patient in the supine position on both sides of the penis with an opposite dispersion plate against the radiofrequency emitter. To perform the procedure, the therapist will use a glove. Eight radio frequency sessions will be held with an interval of seven days between them.
45613525|NCT03367507|Behavioral|Sub-symptom aerobic exercise|Both groups will be instructed to perform their respective aerobic exercise program the following day after completing their first treadmill test. Participants will be instructed to exercise at their prescribed intensity for a maximum of 30 minutes a day, 4-5 days a week. They will be asked to postpone the exercise until the next day if they experience significant increases in symptoms from usual resting levels. Exercise type will be the participant's choice, however we will ask the participant refrain from contact/high risk activities including any modalities that might induce rapid and aggressive head movements.
45613526|NCT04796259|Dietary Supplement|Malt ingredient|Solution with malt-derived ingredient
45613527|NCT04796259|Dietary Supplement|Non-alcoholic beer solids|Solution with non-alcoholic beer solids
45613528|NCT03360955|Procedure|Anesthesia|Different anesthesia technique will be compared to find out which one offers better outcome to perform ultrafast track extubation
45613529|NCT00584025|Drug|levetiracetam|100 - 500mg IV q 15 min
45613530|NCT00584025|Drug|Placebo|Placebo equivalent of 100 - 500 mg levetiracetam IV q 15 min
45613531|NCT02519179|Behavioral|Opaque, weighted bottle|This is the experimental condition; mothers will be asked to feed their infants from an opaque, weighted bottle.
46068912|NCT05212610|Biological|Moderna mRNA COVID-19 vaccine|Participants will receive an initial or additional dose of a highly protective COVID-19 mRNA vaccine for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in an environment where the investigators and staff are experienced in the care of patients with allergic reactions.
45445402|NCT05079945|Procedure|Spinal cord Tractography in order to differentiate spinal tracts.|Spinal cord tractography using DTI MRI sequences of the brain and spinal cord, in order to differentiate tracts at the spinal cord level; and by performing a stitching process between Brain and Spinal cord DTI sequences.
45613532|NCT02519179|Behavioral|Clear, conventional bottle|This is the control condition; mothers will be asked to feed their infants from a clear, conventional bottle.
45613533|NCT04520893|Procedure|ventilator setting vcv with pause|ventilator setting vcv with pause
45613534|NCT04520893|Procedure|ventilator setting vcv|ventilator setting vcv without pause
45613535|NCT04520893|Procedure|ventilator setting pcv-vg|ventilator setting with pcv-vg
45613536|NCT01735461|Dietary Supplement|Calcium Carbonate|There is a regimen for dietary supplement intake that will be provided to study participants.
45613537|NCT04520737|Behavioral|Physical Prehabilitation|The prehabilitation program consists of the following interventions: in-hospital high-moderate intensive exercise training, nutritional assessment and high-protein supplementation, smoking cessation, psychological support and Comprehensive Geriatric Assessment.
45613538|NCT01595841|Drug|Sirolimus|3 mg po od loading dose for two days, then 2 mg po od for thirty days
45759429|NCT00248495|Procedure|neoadjuvant therapy|Tumor Reduction
45613539|NCT03360877|Other|Health-care associated infection (HCAI)|Cleaning of the child with soap and water administered by the child's accompanying person in a structure or - a cleaning of the child with chlorhexidine gluconate administered by the child's accompanying person in the other structure
45613540|NCT05405049|Drug|Morphine hydrochloride|Group M will be given a 0.5% Bupivacain Dosage Regimen with weight and height adjustment+15 μg fentanyl +150 μg morphine intrathecally.
45759430|NCT04739371|Drug|Insulin, Regular, Human|The spray will last a few seconds and then the participant will be asked to sniff to aid the drug into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
45613541|NCT05405049|Drug|Bupivacain|Group LWI+IPLA will given 30 ml %0,5 bupivacaine+%2 lidocaine infiltration and instillation
45613542|NCT04520503|Drug|Propofol|The dose of propofol required for loss of consciousness and the total induction dose of propofol will be recorded for every patients.
45613543|NCT04520503|Device|EEG monitoring|The processed EEG spectrogram and indices, such as patient status index, 95% spectral edge frequency, and suppression ratio, will be obtained from Sedline monitoring device. The raw pre-induction EEG will be extracted from Sedline at the end of induction and it will be analyzed by an external software to calculate the mean frequency, frequency band power and its distribution.
45613544|NCT04698369|Device|Vibration Massage Therapy|WearUL is a patent pending wearable rehabilitation technology that targets localized vibration massage therapy directly onto the body. The frequency and amplitude combinations to be delivered by WearUL are safe and effective in clinical and research settings based on previous studies on focal vibration.
45613545|NCT03360799|Other|Questionnaire Administration|Complete questionnaires
45613546|NCT02871843|Drug|RRx-001 dose escalation with TMZ + RT|Dose escalation of RRx-001. Dose levels of 0.5, 1.0, 2.0 and 4.0 mg, once weekly.
45613547|NCT02871843|Radiation|Radiation|Conformal or intensity-modulated radiotherapy (60 Gy in 2 Gy fractions) given 5 days a week for 30 fractions (about 6 weeks)
45613548|NCT02871843|Drug|Fixed dose Temozolomide (75 mg/m2)|Oral temozolomide 75 mg/m2 daily for 6 weeks
45613549|NCT02871843|Drug|TMZ Maintenance|TMZ maintenance at 150-200 mg/m2
45613550|NCT03356899|Drug|Low dose bupivacaine 0.5% (8mg)|8 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.1 ml
45613551|NCT03356899|Drug|High dose bupivacaine 0.5% (10mg)|10 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.5
45613552|NCT03356821|Biological|Mesenchymal Stem Cells|One dose of 50x10^6 bone marrow-derived allogeneic MSCs via the nasal route as soon as possible after confirmation of the stroke (in the middle cerebral artery), but within the first week of onset of presenting clinical symptoms. Within 30 minutes after cleaning the nose with saline, using standard procedures operative at the Neonatal Intensive Care Unit, the MSC will be delivered.
45759431|NCT04739371|Drug|Placebo|The spray will last a few seconds and then the participant will be asked to sniff to aid the saline into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
45759432|NCT03809767|Drug|CS1003 monoclonal antibody|CS1003 will be administered intravenously every 3 weeks.
45759433|NCT03806465|Other|Feasibility survey|A survey questionnaire will be administered at each household. At the baseline household survey, each child aged less than 5 years will be tested for malaria using a rapid malaria test.
45613553|NCT04525105|Genetic|SMAD2|a family of structurally related cytokines
45759434|NCT03806465|Other|Sentinel hospital surveillance|Cerebrospinal samples will be collected from all children hospitalised and suspected of having meningitis.
46068913|NCT05207501|Behavioral|Exercise|Participants will perform 3 times a week for 4 weeks a moderate intensity interval training.
45613554|NCT02846103|Other|Biological samples|blood and tumor tissue samples
45613555|NCT04523467|Drug|Anti-angiogenic Targeted Drugs|A tyrosine kinase inhibitor inhibits vascular endothelial growth factor (VEGF) receptors 1-3, showed efficacy in hepatocellular carcinoma
45613556|NCT04523467|Drug|Ginsenoside Rg3|An active ingredient extracted from ginseng leachate, which can restrain angiogenesis and reduce the expression of programmed cell death ligand 1 (PD-L1) on the tumor cell surface and block the binding of programmed cell death 1 (PD-1) and PD-L1
45613557|NCT04523467|Procedure|TACE|A specific type of chemoembolization that blocks the hepatic artery to treat liver cancer
46068914|NCT05207280|Combination Product|Noradrenaline plus Terlipressin|Comparison Norepinephrine plus placebo versus Terlipressin plus Norepinephrine for the Treatment of Septic Shock
46068915|NCT05203835|Drug|Acebilustat|By mouth, once a day, 100 mg capsule
45613558|NCT02837757|Other|Biological samples|blood and tumor tissue samples
45613559|NCT03367351|Behavioral|Web-Based Education|Completion of a CGM specific web-based educational intervention that includes a series of online learning modules.
45613560|NCT03367351|Behavioral|Social Support|Engagement in peer-led CGM specific discussion boards
45613561|NCT03367351|Behavioral|Standard of Care|Standard of Care - serves as the control group for the treatment arm
46068916|NCT05203835|Drug|Placebo|Placebo to match acebilustat by mouth, once a day
46068917|NCT05200923|Device|Sacral Neuromodulation|Sacral neuromodulation delivers electrical stimulation to a sacral nerve
46068918|NCT05196854|Other|Group 1. Standard Home Blood Pressure Measurement|Measurement of Blood Pressure using Home blood pressure monitor
45613562|NCT03360643|Diagnostic Test|Point-of-care ultrasound prior to radiology ultrasound|Point-of-care ultrasound performed by pediatric emergency medicine physicians prior to radiology-performed ultrasound
45613563|NCT03360643|Diagnostic Test|Radiology-performed ultrasound|Ultrasound performed an ultrasound technician and/or radiologist, and interpreted by a radiologist
45613564|NCT02801097|Drug|RRx-001|
45613565|NCT02801097|Drug|Irinotecan|
45613566|NCT04636983|Drug|BV100|Rifabutin IV
45613567|NCT04636983|Drug|Placebo|Saline
45613568|NCT03367273|Other|skin biopsy|Lesional skin biopsy was taken from every patient. Also a skin biopsy was taken from every control subject
45613569|NCT04601805|Device|Observation|We will record the vascular changes that follow the inflammatory bowel diseases
45613570|NCT04520269|Drug|Pacritinib|3+3 design Dose Level 1 :200mg BD every 4 weeks Dose Level -1 :200mg OM, 100mg ON every 4 weeks Dose Level -2 :100mg BD every 4 weeks
45613571|NCT04589091|Other|Refractive surgery|Refractive surgery for correction of error of refraction
45613572|NCT03356743|Device|Spectrum Analysis|The ultrasound probe will be placed on the lung surface in several different directions to obtain the cross section with maximum diameter. Three spectral parameters including midband-fit (dB), intercept (dB), and slope (dB/MHz) will be calculated and compared between the tumor and the lung.
45613573|NCT05404659|Other|Oscillatory Mobilization|conventional physical therapy treatment, postural correction and maitland's oscillatory mobilizitions.
45613574|NCT05404659|Other|Mckenzie Retraction Exercises|conventional physical therapy treatment, postural correction and Mckenzie retraction exercises.
45613575|NCT03367195|Drug|Omeprazole|1 Omeprazole 20 mg capsules twice daily
45613576|NCT03367195|Drug|DLBS2411|1 DLBS2411 caplet 250 mg, twice daily
45613577|NCT03367195|Drug|Placebo capsule of Omeprazole|1 placebo capsule of omeprazole, twice daily
45613578|NCT03367195|Drug|Placebo caplet of DLBS2411|1 placebo caplet of DLBS2411, twice daily
45613579|NCT04579653|Device|transcutaneous electrical nerve stimulation devices|electrical stimulation through surface electrodes
45613580|NCT03360487|Radiation|Photobiomodulation in the sublingual region|In the group submitted to sublingual irradiation, disposable plastic wrap will cover the application pen for the purposes of hygiene, and irradiation will take 10 minutes.
45613581|NCT03360487|Radiation|Photobiomodulation in the spinal cord|Transcutaneous irradiation of the spinal cord will be performed on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be irradiated for 30 seconds (total treatment time: 10 minutes).
45613582|NCT03360487|Radiation|Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific bracelet of the DMC laser Therapy EC model.
45613583|NCT04213911|Radiation|low-dose chest CT scan|The low-dose chest CT scan is now commonly used as a quick, painless, and non-invasive approach to screen for lung cancer. The radiation exposure from one low-dose CT scan of the chest (1.5 mSv) is comparable to 6 months of natural background radiation for a person living in the US.
45613584|NCT04213911|Device|insertion of esophageal balloon|The esophageal catheter is a flexible thin plastic tube with an air-filled balloon at the distal end. The tube will be placed through the nasopharynx after local anesthesia.
45613585|NCT03356665|Diagnostic Test|Rapid diagnostic test (RDT)|The 4 rapid diagnostic tests (RDT) will be carried out on fresh blood from clinical suspects. Only those subjects that are positive in at least 1 RDT will 1) undergo tests on DBS (immune trypanolysis, ELISA and DNA detection); 2) undergo parasitological confirmation (reference standard) at inclusion.
45613586|NCT03356665|Diagnostic Test|Serological and molecular tests on DBS|Serological and molecular reference tests on dried blood spots (DBS) are carried out on RDT positive clinical suspects, which also undergo parasitological examination at inclusion (reference standard). If at least one of the serological or molecular reference tests on dried blood spots is positive, parasitological examination is repeated 3 and 6 months after inclusion. The combined results of parasitological examinations (at inclusion and if applicable at 3 and 6 months) serve as reference standard
45613587|NCT04523389|Biological|analysis (protein, lipid, RNA ...) of circulating exosomes, size and number|use of blood samples stored at the Ferdinand Cabanne Biological Resource Centre
45613588|NCT04523389|Other|Gathering additional information about the patient's cancer|Gathering additional information about the patient's cancer, its treatment and its sequelae from the patient's medical record.
45613589|NCT04523389|Diagnostic Test|Diagnostic test|Diagnostic test
45613590|NCT05123781|Drug|Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)|One tablet of the test product was administered orally with 240 ml of water
45613591|NCT05123781|Drug|Glucophage® XR 1000 mg Prolonged Release Tablets (Merck Serono Ltd, UK)|One tablet of the Reference product was administered orally with 240 ml of water
45613592|NCT04523233|Diagnostic Test|Amniocentesis|Amniocentesis is a procedure in which amniotic fluid is removed from the uterus for testing or treatment.
45613593|NCT05127447|Device|ES application|Electrical stimulation (ES) application will be given to the ES group
45613594|NCT05127447|Other|Sham application|Only vacuum was applied and no current was given from the applied device
45613595|NCT03356587|Drug|Abemaciclib|Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day
45613596|NCT05123625|Procedure|Reduce surgical procedures|In the intervention group, investigators used a reductive approach. That is, for radical cystectomy, investigators did not perform pelvic lymph node dissection.
45613597|NCT04444375|Diagnostic Test|balance test|balance test
45613598|NCT05127369|Drug|Dental pulp mesenchymal cell injection|Dental pulp mesenchymal cell injection was administered intravenously on D1, D15 (2 weeks), D29 (4 weeks) and d43 (6 weeks); Fluoxetine hydrochloride capsule / simulant was administered orally daily.
45613599|NCT05127369|Drug|Dental pulp mesenchymal cell vehicle|Dental pulp mesenchymal cell vehicle was administered intravenously on D1, D15 (2 weeks), D29 (4 weeks) and d43 (6 weeks); Fluoxetine hydrochloride capsule / simulant was administered orally daily.
45613600|NCT05127369|Drug|fluoxetine hydrochloride capsule|fluoxetine hydrochloride capsule
45613601|NCT05127213|Procedure|Intragastric balloon system|Intragastric balloon system (PA450) developed and produced by Changzhou Zhishan Medical Technology Co., Ltd. It is a swallowable capsule intragastric balloon.The degradable material on the intragastric balloon can be degraded naturally, and the balloon is naturally discharged from the body through the gastrointestinal tract
45613602|NCT05127213|Procedure|Sleeve gastrectomy|Sleeve gastrectomy is the use of laparoscopy to cut out the greater curvature of the stomach, mainly for weight loss.
45613603|NCT03360409|Procedure|ACD|Undertake anterior cervical discectomy without fusion
45613604|NCT03360409|Procedure|ACDF|anterior cervical discectomy with fusion
45445403|NCT05076903|Drug|OFA|Dexmedetomidine and lidocaine are administered during anesthesia, and opioid is not used. For induction, 1 μg/kg of Dexmedetomidine is administered over 10 minutes and 1mg/kg of lidocaine is administered intavenously (bolus). This is followed by continuous intravenous infusion of dexmedetomidine at a rate of 0.2-0.7 μg/kg/h and infusion of lidocaine at the rate of 1 mg/kg/h.
45613605|NCT03360409|Procedure|ACDA|anterior cervical discectomy with arthroplasty
45613606|NCT05123469|Device|Electroencephalography|Simultaneous recording of electroencephalogram by conventional EEG device and the Zeto EEG device
45911502|NCT02008786|Drug|ramipril|5-10mg (starting dose 5mg titrating up to 10mg if tolerated after 1 week)
46068919|NCT05196854|Other|Group 2. Hypnosis script prior to home blood pressure measurement|Pre-recorded clinical hypnosis script (approx 5 mins long) used prior to standard home blood pressure measurement. Clinical Hypnosis is used as a non-pharmacological technique for reducing procedural anxiety, distress and discomfort with patients.
45613607|NCT04096963|Device|The WATCHMAN FLX Delivery System|WATCHMAN FLX Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium
45613608|NCT05127135|Biological|ThisCART7 cells|0.5-6 x 10^6 CAR T cells per kg body weight
45613609|NCT03356509|Behavioral|Exercise|Exercise will be performed on a stationary bicycle ergometer.
45613610|NCT05126901|Drug|Ferric Maltol|"Ferric maltol oral suspension: 150 ml amber glass bottle with graduated syringe and adaptor. Oral suspension containing 30 mg elemental iron, in the form of 231.5 mg ferric maltol, in 5 ml suspension~Study dosage: The dose of ferric maltol oral suspension that will be administered for children aged 1 month to < 2 yrs: 0.1 ml/kg BID, 2 to - 11 yrs: 2.5 ml BID, 12-17 yrs: 5 ml BID."
45613611|NCT05126901|Drug|Ferrous sulfate|"Ferrous sulfate 125 mg/ml (25 mg/ml elemental iron) oral liquid : 15 ml glass bottle.~Study dosage: For ferrous sulfate oral liquid, the dose administered will be for children and adolescents aged 2 years to 17 yrs: 6 mg/kg to the maximum of 4 ml BID."
45613612|NCT03360253|Dietary Supplement|L. reuteri DSM 17938 in drops|L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle
45613613|NCT03360253|Other|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
45613614|NCT03356353|Drug|Sildenafil Citrate|20 mg tablets
45613615|NCT04520035|Drug|camrelizumab|Carilizumab 200 mg, every 3 weeks, 2 cycles.Paclitaxel 175 mg / m2, D1, every 3 weeks, 2 cycles
45613616|NCT04520035|Drug|Paclitaxel|Cisplatin 75mg / m2 D1, conventional hydration for 3 days, every 3 weeks, 2 cycles
45613617|NCT04520035|Drug|Neoadjuvant Chemotherapy|Neoadjuvant Chemotherapy
45613618|NCT05404269|Device|AGC mode|Automated Gas Control mode at Maquet FLOW-i anesthesia machine
45613619|NCT04519801|Other|Blood Flow Restriction (BFR) therapy|BFR therapy beginning 1-week after ACL reconstruction with quadriceps tendon autograft.
45613620|NCT04519801|Other|Standard REHAB|Standard post-operative rehabilitation regimen (REHAB) beginning 1-week after ACL reconstruction with quadriceps tendon autograft.
45613621|NCT04519567|Biological|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
45613622|NCT04519567|Biological|Placebo|Placebo Comparator
45613623|NCT01675011|Device|Embozene® Microspheres|
45445404|NCT05076903|Drug|Control|Remifentanil is infused during anesthesia, and target-controlled infusion (TCI) is performed according to the Minto model. During indcution of anestheisa, target concentration of remifentanil is set within 3-5 ng/mL. After intubation, target concentration is adjusted within the range of 2-8 ng/mL.
45445405|NCT03308786|Drug|Recombinant Interleukin-2|Subcutaneous recombinant interleukin-2 (rIL2), 5 MIU twice daily for four consecutive days(cycle) every 8 weeks for 8 cycles
45445406|NCT03776565|Other|Ultrasound|Ultrasound of antrum of stomach
45613624|NCT01675011|Device|Embosphere®|
45613625|NCT03356275|Behavioral|Mindfulness for Resilience in Illness: Support for Parents|Mobile application focusing on emotional coping skills for parents of children and adolescents with chronic pain. Components of the module include: library of mindfulness meditations/relaxations; peer support videos; and psychoeducational information related to pain, stress, and mindfulness.
45613626|NCT05123157|Other|NO intervention|"N/:~NO intervention"
45613627|NCT03356119|Device|RemovAid device|The contraceptive implants of the subjects in this arm are removed by the new IMD.
45613628|NCT03356041|Other|Diabetic patients with neuropathy|Lifestyle modification will be assessed using summary of diabetes self-care activity
45613629|NCT04208997|Drug|Antiarrhythmic drug|Continuation of amiodarone or sotalol.
45613630|NCT03124147|Device|Neuroconn Eldith stimulator by Magstim|Transcranial direct current stimulation to the ipsilesional hemisphere, contralesional hemisphere, or both, paired with task-oriented therapy.
45613631|NCT05126667|Procedure|Breast-conserving surgery|Breast conserving surgery plus whole breast irradiation
45613632|NCT05126667|Procedure|Mastectomy|Breast mastectomy
45613633|NCT03355963|Other|saline injection|The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.
45613634|NCT03355963|Biological|Botulinum toxin type A 50 units|The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.
45911503|NCT02008786|Drug|rosuvastatin|10-20mg (suggested dose 10mg for Asians, 20mg for everyone else)
45911504|NCT02008786|Drug|placebo|Placebo
45911505|NCT02008799|Procedure|Bone marrow stem cell injection|Injection should be in testis and testicular artery
45911506|NCT02008812|Device|Ad sensor|"Ad sensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-Adenovirus and its Adenovirus antigen present in patients and normal samples.~The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens."
45613635|NCT03355963|Biological|Botulinum toxin type A 100 units|The treatment group C: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test.
45613636|NCT05122923|Device|Serious Game S'TIM|Video Game S'tim : the patient is inside a bedroom and he has to find a friend outside. this game will study the orientation, the memory of the patient
45613637|NCT04414683|Procedure|staging surgery|laparoscopic or laparotomic staging surgery
45613638|NCT03360175|Other|No intervention - observational study|No intervention - observational study
45613639|NCT05122845|Biological|Blood sample|"Blood test (10 tubes of 5mL) :~- 6 tubes for : complete blood count, platelets, reticulocyte count, TP-INR, AST, ALT, GGT ferritin, serum iron, CRP, transferrin, soluble transferrin receptors, transferrin saturation coefficient enzymatic creatinine, MDRD, ionogram calcemia, phosphoremia, PTH, 25 (OH) D3, 1.25 (OH) 2D3.~2 dry tubes 2 tube EDTA"
45613640|NCT02518633|Device|Continuous positive airway pressure devices|overnight use of CPAP device
45613641|NCT05126043|Diagnostic Test|Triglycerides/high density lipoprotein ratio|Lipid profile
45613642|NCT04519489|Device|PAP therapy with telemonitoring|This study intends to investigate effect of PAP therapy on reducing AF recurrence rate in the patients in co-morbidity of OSA. The study will use 2 investigational devices: Philips DreamStation and Philips EncoreAnywhere. Philips DreamStation is used as the PAP therapy device to provide PAP therapy on the study subjects; Philips EncoreAnywhere is used as a telemonitoring service to provide monitoring by physicians that ensure good adherence to PAP. In addition, subjects in the intervention group will also receive AFib standard management and OSA general care.
45613643|NCT04519489|Other|AF standard management and OSA general care|Subjects in the control group will receive AF standard management and OSA general care. The treatment, medical care, and AF management for the subjects will be performed at the study hospitals following the newly updated Chinese AF management guideline 'Current knowledge and management recommendations of atrial fibrillation: 2018'.All subjects including the intervention group and the control group will receive the education materials to understand the disease, risk, and management of OSA. All subjects will also receive the general intervention for OSA, including suggestions for body weight control, smoking cessation, alcohol limiting, lateral position sleep, etc.
45613644|NCT05122611|Other|no intervention, imaging study only|Imaging study only
45613645|NCT03360097|Procedure|Frozen Embryo Transfer|Patient's embryos are cultured to day 6, vitrified and transferred in a cryo-synthetic cycle
45613646|NCT05114889|Biological|BSI-045B|BSI-045B will be administered weekly, subcutaneously
45613647|NCT04518475|Drug|eltrombopag combining rituximab|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the eltrombopag will stop until the platelet count <30×10^9/L.~All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
45613648|NCT04518475|Drug|eltrombopag|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the eltrombopag will stop until the platelet count <30×10^9/L.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
45613649|NCT05114811|Procedure|Self-provided perineal massage|External massage should be applied with pump of the perineum central core. Internal massage should be applied intracavitary with longitudinal glides, myofascial trigger points of pelvic diaphragm and streching.
45613650|NCT05114811|Procedure|Physiotherapist perineal massage: manual and instrumental (with EPI-NO)|"The treatment sequence included external massage with two manouvres: vulvar drainage and pump of the perineum central core. Intracavitary techniques were then applied through three maneuvers: massage with longitudinal glides, myofascial trigger points of pelvic diaphragm and streching.~After this, instrumental massage was applied with the EPI-NO® device."
45613651|NCT02518399|Other|Heat therapy|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
45759435|NCT03806465|Other|Community mortality surveillance|A verbal autopsy will be performed
45759436|NCT02307123|Procedure|Intubation|HEMS physician prehospital intubation
45759437|NCT03800641|Drug|Dexmedetomidine|oral, intravenous and nasal administration of Dexmedetomidine
45759438|NCT03807011|Drug|fentanyl group|fentanyl 2 μg/kg
45759439|NCT03807011|Drug|remifentanil group|remifentanil 0.2 μg/kg/min
45759440|NCT02986503|Drug|Doxorubicin+cisplatin+ifosfamide|Chemotherapy for Good responder high grade osteosarcoma
45759441|NCT02986503|Drug|Doxorubicin+cisplatin+ifosfamide+methotrexate|Chemotherapy for Poor responder high grade osteosarcoma
46068920|NCT05177679|Dietary Supplement|Active supplement|Carotenoid supplement comprised of 10mg lutein and 2mg zeaxanthin.
46068921|NCT05177679|Dietary Supplement|Placebo control|Placebo control supplement
46068922|NCT05174832|Drug|Cisplatin|75 mg/m2 IV days 1 of each 21-day cycle
46068923|NCT05174832|Drug|Nab-paclitaxel|125 mg/m2 IV days 1 and 8 of each 21-day cycle
46068924|NCT05174832|Drug|Pembrolizumab|200 mg IV every 21 days
46068925|NCT05174832|Drug|Olaparib|300 mg PO BID
46068926|NCT05165394|Drug|Placebo|Tablets for oral administration
46068927|NCT05165394|Drug|NBI-1065846|Tablets for oral administration
46068928|NCT05157672|Dietary Supplement|Cinnamon (2 g)|oral capsules, 2 g
46068929|NCT05157672|Drug|Nicotine gum (2.5 mg)|gum, 2.5 mg
46068930|NCT05157672|Drug|Letrozole (2.5 mg)|tablet, 2.5 mg
46068931|NCT05156372|Other|High Intensity Interval Training|Participants will perform high-intensity aerobic and resistance exercise
46068932|NCT05153252|Behavioral|Morning Exercise|Morning Exercise will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
45445407|NCT05061303|Other|Assessment of the drug concentration in the blood|The material in the study will be blood, in which tacrolimus concentrations will be measured at the following time points: 0, 2hours, 6hours, 12hours after drug administration, without taking omeprazole/famotidine and then the next day after taking the protective drug in same time points, without 12hours. Sequentially routinely in the so-called point T0 before taking the drug (12 hours after the last dose) during follow-up visits at the Transplant Outpatient Clinic.
45613652|NCT02518399|Other|Thermoneutral water immersion|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
45613653|NCT05109663|Drug|SKLB1028|SKLB1028, capsule, oral
45613654|NCT04517539|Drug|rhGM-CSF，Peginterferon alfa-b2，radiation|"Radiation:~If there are two measurable lesions totally, One lesion received radiotherapy for 30 Gy in 5 fractions and rested for one week; If there are three measurable lesions totally, two lesion received radiotherapy for 30 Gy in 5 fractions separately.~drug: Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy. Peginterferon alfa-b2 90 ug in d8 in each cycle.~And the 1 month after the end of all radiotherapy courses, 4 weeks as a course of treatment, once per course of treatment, each dose is 90μg until desease progress."
45613655|NCT05101863|Behavioral|Motivational interviewing|MI is a goal-oriented style of communication, and focuses on resolving a patient's ambivalence, while eliciting his/her own reasons to change addictive behavior, also known as change talk.
45613656|NCT03359941|Procedure|acupuncture|Acupuncture points: Examples of acupuncture points to be used include BL23 (Sinsu, bilateral), BL24(Gihaesu, bilateral), BL25(Daejangsu, bilateral), BL40(Wijung, bilateral), BL60(Gollyun, bilateral), BL65(Sokgol, bilateral), LI11(Gokji, bilateral), LI4(Hapgok, bilateral), ST36(Joksamni, bilateral), GB41(Jogimeup, bilateral), LR3(Taechung, bilateral). Electrical stimulation with alternating frequency of 2-100 Hz will be applied to the selected points (e.g., BL 23-25, bilateral). Treatments will be provided by qualified Korean traditional medicine doctors with more than 2 years of clinical experience.
45613657|NCT04444219|Other|Breakfast meals|Fifteen volunteers will undergo a medical and dietary assessment and their health status will be evaluated through a complete blood count. Then, they will come after overnight fasting and will consume one of two breakfast meals, including 114g bread, 40g cheese and 15g dry mushrooms (meal 1) or 114g bread, 40g cheese and 200g tomatoes (meal 2). Blood samples will be obtained on timepoints 0h, 30min, 1h, 1,5h, 2h, 2,5h and 3h after breakfast intake. Two weeks later, the same volunteers will consume the other breakfast meal.
45613658|NCT03367039|Procedure|ProDisc-C vivo|Total Disc Replacement using ProDisc-C vivo.
45613659|NCT03367039|Procedure|Anterior cervical discectomy fusion|Anterior Cervical Discectomy and Fusion
45613660|NCT04278651|Drug|Ferumoxytol|510mg infusion x 2 doses 3-8 days apart
45613661|NCT04278651|Drug|Ferrous Sulfate|325mg oral twice daily
45759442|NCT04727983|Device|Electrotherapy|The first group will be given Neuromuscular Electrical Stimulation (NMES) and lifestyle suggestions (LSS) (NMES group)
45759443|NCT04727983|Device|Sham Electrotherapy|The second group will be given sham NMES in addition to LSS (SHAM ES group)
45759444|NCT02986191|Procedure|Mucograft|This method of grafting will be used to treat the gingival recession using coronally advanced flaps.
45613662|NCT03366961|Procedure|Conversion surgery|Palliative chemotherapy followed by radical gastrectomy
45613663|NCT05125965|Other|additional time for the MRI|3 additional minutes to perform the MRI
45613664|NCT04523155|Dietary Supplement|Medically tailored meals|10 meals per week for 3 months
45613665|NCT03975465|Behavioral|Expiratory Muscle Strength Training|8 weeks of EMST at 75% maximum expiratory pressure (MEP)
45613666|NCT03975465|Behavioral|Pharyngeal Muscle Strengthening Exercises|8 weeks of exercises designed to increase pharyngeal muscle strength for swallowing
45613667|NCT03359707|Other|survey|no intervention just survey
45613668|NCT05125575|Drug|Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)|One tablet of the Test (T) product was administered orally with 240 mL of water.
45759445|NCT02986191|Procedure|Connective Tissue Graft|This will be used in the traditional manner to correct gingival recession
45613669|NCT05125575|Drug|Glucophage® XR 1000 mg Prolonged Release Tablets|One tablet of the Reference (R) product was administered orally with 240 mL of water.
45613670|NCT03366883|Combination Product|Paclitaxel, Cisplatin Plus 5-FU (TCF)|preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks)
45759446|NCT03806699|Biological|Placebo|Sterile normal saline
45759447|NCT03806699|Biological|ID93+GLA-SE|ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
45759448|NCT01978743|Drug|Raltegravir|Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks
46068933|NCT05153252|Behavioral|Evening Exercise|PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.
46068934|NCT05149378|Drug|Venetoclax combined with azacitidine regimen|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7 .
45759449|NCT00763061|Drug|Travoprost 0.004% Ophthalmic Solution (Travatan)|Travoprost at 9 AM + Placebo & 9 PM
45759450|NCT00763061|Drug|Timolol 0.5% Ophthalmic Solution (Timoptic)|Timolol in each eye, twice daily at 9 AM & 9 PM
45759451|NCT03806335|Other|Infiltration|The infiltration will be performed by the anesthetist using a 25G- 3.5cm curved needle. A total of 2.5 ml of local anesthetic mixture will be used for each tonsil. The mixture will contain: 10 ml xylocaine 2% an d10 ml bupivacaine 0.5%
45759452|NCT03806335|Other|Placebo|Patients will receive 2.5 ml normal saline in each tonsil
45759453|NCT03806335|Other|General anesthesia|All patients will receive general anesthesia prior to infiltration
45759454|NCT03806777|Drug|Dexmedetomidine|Highly selective alpha-2 adrenergic agonist with sedative properties.
45613671|NCT03366883|Radiation|radiochemotherapy|preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week)
45613672|NCT03971799|Biological|CD33CART|"The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by CD33CART infusion:~LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).~Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable."
45613673|NCT03123367|Device|Group 1: Nella VuSleeve|Sleeve
45613674|NCT03123367|Device|Group 2: Nella NuSpec|Speculum
45613675|NCT03123367|Device|Group 3: NellaSpec|Speculum
45613676|NCT03123367|Device|Group 4: Nella Insert|Sleeve
45613677|NCT04444297|Other|3D Telemedicine|A consultation performed with a 3D form of telemedicine
45613678|NCT04444297|Other|2D Telemedicine|A consultation performed with 2D (standard) telemedicine
45613679|NCT02550093|Procedure|Intervention 1|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 1 (Day 1).
45613680|NCT02550093|Behavioral|Washout Period|The wash-out period will be between intervention 1 and intervention 2. 13 days in length.
45613681|NCT02550093|Procedure|Intervention 2|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 2 (Day 14).
45613682|NCT04444063|Procedure|Non-Incised Papilla Surgical Approach|"Horizontal or oblique incision is done on the buccal mucosa as far as possible from the marginal keratinized tissue and the inter dental papilla The horizontal/oblique incision is extended mesio-distally enough to allow proper visualization of the defect A full thickness flap is elevated apico- coronally to expose the coronal limit of the defect Scaling and root planning are done using mini-curettes and power driven ultrasonic tips with care trying to maintain fibers attached to the cementum Granulation tissue is removed with mini-curettes detached from the bony walls and removed from the base of the papilla carefully with microblades and microscissors .~1ry soft tissue closure will be performed by horizontal mattress suture 2mm from the edges of the incision as a first line of closure and then simple interrupted suture as a second line of closure using (5-0, 6-0) polypropylene suture."
45613683|NCT03366805|Behavioral|Pain Management Patient Education Video|Patient education video that were created in-house specifically for this project.
45613684|NCT03366805|Behavioral|Wound Care Patient Education Video|Patient education video that were created in-house specifically for this project.
45613685|NCT03355807|Drug|Magnesium|The magnesium group (group Mg, n _ 40) received an additional infusion of MgSO4
45613686|NCT02512107|Dietary Supplement|Juice Plus+|Dried fruit and vegetable juice capsule.
45613687|NCT02512107|Other|Placebo|Placebo capsule
45613688|NCT03359317|Behavioral|jogging|Jogging as instructed for 1 year
45613689|NCT02494791|Behavioral|Questionnaire, Educational Material|Participants in this study will be given educational material about Lynch Syndrome and genetic testing for this condition. They will be asked to complete questionnaires about their family cancer history, personal health history and attitudes toward genetic testing.
45613690|NCT03355651|Dietary Supplement|PROGEN|Dietary supplement based on plasma proteins, hydrolyzed collagen, a complex of Hyaluronic Acid - Chondroitin Sulfate (HC-15), and vitamin C
45613691|NCT04186455|Device|proseal|laryngeal mask proseal
45613692|NCT04186455|Device|baska-mask|laryngeal mask baska-mask
45613693|NCT03366571|Drug|Nucleos(t)ide Analogues|Entecavir 0.5mg daily, Lamivudine100mg qd daily, Adefovir Dipivoxil 10mg daily, telbivudine 600mg qd daily, their combination therapy, tenofovir 300mg qd daily.
45445408|NCT03776409|Drug|vancomycin plus piperacillin/tazobactam|Patients in intensive care unit who received the combination of VAN(vancomycin) and PTZ (piperacillin/tazobactam) for at least 48 hours, had a serum creatinine level measured in the 24-hour of hospital admission.The dosage and frequency of VAN and PTZ was adjusted based on clinical practice and patient characteristics.
45445409|NCT03776409|Drug|vancomycin plus other beta-lactams|Patients in intensive care unit who received the combination of VAN (vancomycin) and other beta-lactams (cefoperazone/sulbactam, meropenem, imipenem/siastatin, ceftriaxone, ceftazidime, et al) for at least 48 hours, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and other beta-lactams were adjusted based on clinical practice and patient characteristics.
45445410|NCT05534607|Behavioral|Ola Mau i ka Hula|"The first 3 months of the hula-based intervention program was designed and standardized as a culturally-based physical activity (PA) that includes 15 minutes of ADRD education and intervention orientation with 12 weeks of hula lessons.~These hula lessons consist of two 60-minute classes per week over 12 weeks. Each hula lesson will consist of 8 participants, providing them with the opportunity to engage-in this social support network.~For the remaining 5 months of the Ola Mau i ka Hula Program, hula lessons led by the kumu hula will be reduced to once a month for 60 min. In addition, the intervention group will meet with a community-peer educator weekly over this 5-month period. Each meeting will be 90 minutes in length with 60 minutes of hula practice following the same format as previous classes, and 30 minutes will cover the PILI Lifestyle Plan curriculum and cultural-based cognitive exercises, alternating weekly."
45613694|NCT05125107|Device|Quantitative Flow Ratio derived PPG and dQFR/ds|"From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2~Physiologic local severity of coronary atherosclerosis was assessed by instantaneous QFR gradient per unit length (dQFR/ds)"
45613695|NCT04523311|Behavioral|Hypnosis.|Online, group-based, single session hypnosis workshop followed by 2 weeks of self hypnosis.
45759455|NCT03809689|Other|68Ga-NODAGA-RGD PET/CT|intravenous injection of 200 Megabecquerel (MBq) 68Ga-NODAGA-RGD followed by a whole-body acquisition after injection and one hour after injection
45759456|NCT03809689|Diagnostic Test|82-Rb PET/CT as part of standard care, not a comparator|2 intravenous injections of standard dose of 82-Rb : the first followed by an at-rest acquisition, the second followed by a pharmacological myocardial stress acquisition
45759457|NCT03806621|Procedure|Rotational Atherectomy|Patients with severe calcified lesions will receive rotational atherectomy during index PCI
45613696|NCT04523311|Other|Usual care|Participants will be asked to continue with whatever interventions they are already receiving/employing to manage their migraine and tension-type headaches.
45613697|NCT05055765|Procedure|Microneedling|MN will be carried out 1mm below of the gingival margin on the gingiva of the tooth to be treated with thirty-gauge (0.255 mm) lancet needles.
45613698|NCT05055765|Procedure|injectable- platelet rich fibrin|I-PRF will be prepared according to Choukroun PRF method.
45613699|NCT03366493|Combination Product|FRD|The Folate Receptor-Mediated Staining Solution is a dye solution that stains for medical purposes used in staining cells and tissues for detecting neoplastic diseases. After inserting a speculum into your vagina, the FRD™ staining solution will be applied to the cervix using an applicator. After removal of the applicator, the doctor will inspect the applicator for color changes and note any changes. The physician will then remove any excess stain from the cervix using distilled water.
45613700|NCT03366493|Other|Cytology|Cytology testing done by collecting samples of cells, and smearing those samples across a glass microscope slide in order to detect abnormal cells that may develop into cervical cancer.
45613701|NCT03366493|Other|HPV testing|HPV tests will detect HPV infections, which can lead to cervical cells to become cancer cells.
45613702|NCT03366493|Procedure|Colposcopy|During the colposcopic examination, the physician will insert a speculum into the vagina and then apply a vinegar solution to the cervix. The vinegar solution causes any potential abnormal cells to turn white. These white regions are best seen using the colposcope, which magnifiesthe skin.
45613703|NCT03366493|Procedure|ECC|If the examination is not satisfactory and the doctor is not able to see the entire cervix, he may perform an endocervical curettage, or ECC. This sample is collected by placing a long, thin instrument into the cervical canal and a sample is scraped from that area. The sample will be sent to the laboratory for a pathologist to review.
45759458|NCT01979133|Drug|Icariin|Participants will receive 20% icariin (100 mg/day) in a commercially available over-the-counter Horny Goat Weed supplement. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
45759459|NCT03800069|Device|Group K Diagnostic point of care device|Arm 1 will have a finger prick sample collected to test the ability of Group K Diagnostic point of care device and app to identify liver function values.
45759460|NCT04675879|Device|Shoulder arm bandage|Three different shoulder-arm bandage types
45759461|NCT03806387|Drug|Alemtuzumab|Alemtuzumab will be given two times, separated by 1 year.
45613704|NCT03366493|Procedure|Biospy|"According to the colposcopy assessment, if the doctor sees a white area, or an area of abnormal cells, a tiny sample of tissue, called a biopsy will be taken from the cervix. About half of women do not feel the biopsy being taken.~Others may feel a quick pinch. After the biopsy, the wound will be treated to stop bleeding.The biopsy will be sent to the laboratory for a pathologist to review."
45759462|NCT04645069|Biological|ADG126 Mono|ADG126 will be administered as an IV infusion over 30-60 minutes ± 15 minutes.
45759463|NCT04645069|Biological|ADG126-anti PD1|ADG126-toripalimab combination regimen will receive of toripalimab 15 to 30 minutes after the end of the ADG126 infusion
45759464|NCT04645069|Biological|ADG126-ADG106|ADG126-ADG106 combination regimen will be receive of ADG106 15 to 30 minutes after the end of the ADG126 infusion
45759465|NCT05432713|Drug|LP-168 tablet|Lp-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
45759466|NCT05432713|Drug|LP-168 Placebo tablet|LP-168 placebo tablets contain excipients for LP-168 tablets, but do not contain the active ingredients of the drug, and are used for comparison in clinical trials with the same usage and dosage as LP-168 tablets
45911507|NCT02008825|Device|Utilization of ViSiGi calibration tube|Utilization of ViSiGi calibration tube
45613705|NCT03355495|Procedure|Colonoscopy - Position Change|Colonoscopy is the gold standard for detecting precancerous lesions. We are proposing that changing positions will provide better visualization for detecting such lesions. We will test our intervention of patients positioned in the Right Lateral Decubitus Position to the gold standard of Left Lateral Decubitus Positioning, hypothesizing better visualization in the right lateral decubitus position.
45759467|NCT00754247|Drug|0.5% hydrocortisone, silicone, vitamin E lotion|0.5% hydrocortisone, silicone, vitamin E lotion will be applied topically to cover the selected scar twice daily for 16 weeks. The lesion will be cleansed with soap and water and dried thoroughly. The medication will be applied with a brush and allow it to dry for one minute before contact with clothing.
45759468|NCT00754247|Drug|Onion extract gel|Onion extract gel is applied and massaged into the selected scar 3 to 4 times daily according to product instructions for 16 weeks.
45759469|NCT00754247|Drug|Cetearyl alcohol lotion|Placebo is cetearyl alcohol lotion with no steroids, silicone, vitamin E, or onion extract and will be applied 2 times a day to the lesion.
45911508|NCT02008825|Device|Usual non suction Bougie|Usual non suction Bougie
45911509|NCT02008838|Dietary Supplement|Synbiotic|
45911510|NCT02008838|Dietary Supplement|Placebo|
45445412|NCT03776331|Diagnostic Test|Flow mediated dilation|Measurement of the change in the vasodilatative reserve of the brachial artery
45613706|NCT05124951|Radiation|Whole-ventricle irradiation|Whole-ventricle irradiation will be applied in patients with localized basal ganglia germ cell tumors after induction chemotherapy
45613707|NCT05124951|Drug|Carboplatin/etoposide|Carboplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia germinoma
45613708|NCT05124951|Drug|Ifosfamide/cisplatin/etoposide|Ifosfamide/cisplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia non-germinomatous germ cell tumors.
45613709|NCT05124951|Procedure|Second-look surgery|Second-look surgery would be applied to patients who presented residue disease after induction chemotherapy.
45613710|NCT03359083|Other|Correlation|Correlation between assesment parameters
45613711|NCT03355417|Other|OT-SI|Occupational therapy using a sensory integration approach (OT-SI) 3x per week for 10 weeks. A typical session will be 1 hour (total of 3 hours per week).
45613712|NCT04375449|Dietary Supplement|Pep2dia|what is the effect of Pep2dia on postprandial glycemia after a meal rich in carbohydrates (75g)
45613713|NCT04375449|Dietary Supplement|maltodextrin|maltodextrin
45759470|NCT05422339|Device|The MapHabit system|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
45759471|NCT02305329|Drug|BIA 9-1067|
45613714|NCT04523077|Diagnostic Test|determination of thyroid hormones and antibodies|TSH, fT3, fT4, anti-TPO and anti-Tg were determined from blood sample
45613715|NCT05124717|Drug|Metformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine)|One tablet of the Test product was administered orally with 240 mL of water.
45613716|NCT05124717|Drug|Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)|One tablet of the Reference product was administered orallyn with 240 mL of water.
45613717|NCT03355339|Device|Binasal occlusion|Binasal occlusion glasses
45613718|NCT03355339|Device|No binasal occlusion|Non-occluded glasses
45613719|NCT05116839|Device|the first 15 minutes with pressure support ventilation|PSV pressure support ventilation:triggered by minute volume < 3 Liter ,with no frequency
45613720|NCT05116839|Device|the following 15 minutes ventilation will be changed to continous positive air way pressureCPAP mode|continous positive air way pressure CPAP mode at 10 cm H2o .
45759472|NCT01979445|Drug|Cangrelor|Cangrelor intravenously (IV) administered as a 30 microgram (µg)/kilogram (kg) bolus, followed by 4 µg/kg/min infusion for 2 hrs on Day 1.
45759473|NCT01979445|Drug|Clopidogrel|Clopidogrel 600 mg single oral dose
45759474|NCT01979445|Drug|Prasugrel|Prasugrel 60 mg single oral dose
45759475|NCT03802565|Drug|Tolperisone|TID
45613721|NCT05116839|Device|i gel air way|supraglottic air way device
45613722|NCT03358927|Behavioral|Immediate Fast-Track Care|Eligible for fast-track care at enrollment
45613723|NCT03358927|Behavioral|Deferred Fast-Track Care|Eligible for fast-track care after 6 months on ART
45613724|NCT04139655|Drug|Colchicine 0.6 mg|Oral colchicine given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
45613725|NCT04139655|Drug|Placebo oral tablet|Placebo oral tablet given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
45759476|NCT03802565|Drug|Placebo|Placebo
45759477|NCT02308371|Device|Automated Pulse Pressure Variation|Based on standard of care, the physician will give fluid as needed based on standard clinical data (heart rate, central venous pressure if available, blood pressure, urine output, physical exam, lactate level) and pulse pressure variation. PPV should be elevated consistently greater than 15 minutes before giving fluid without other symptoms of patient instability (low blood pressure, elevated lactate, tachycardia). Pulse pressure variation will be followed for 48 hours.
45613726|NCT03355261|Procedure|complete remission (CR) group|According to the RECIST 1.1, 32 patients were allocated into the complete remission (CR) group based on their responses to neoadjuvant chemotherapy (NAC).
45613727|NCT03355261|Procedure|partial remission (PR) group|According to the RECIST 1.1, 61 patients were allocated into the partial remission (PR) group based on their responses to neoadjuvant chemotherapy (NAC).
45613728|NCT03355261|Procedure|stable disease (SD) group|According to the RECIST 1.1, 12 patients were allocated into the stable disease (SD) group based on their responses to neoadjuvant chemotherapy (NAC).
45613729|NCT03355261|Procedure|progressive disease (PD) group|According to the RECIST 1.1, 5 patients were allocated into the progressive disease (PD) group based on their responses to neoadjuvant chemotherapy (NAC).
45613730|NCT04113057|Other|Remote Coaching|In patients randomized to the remote coaching arm, study staff will provide feedback on home-based supplemental exercise based on heart rate and walking distance measurements from the LIVMOR health monitoring system.
45613731|NCT04515511|Other|4% gelatin|Pulmonary artery catheter insertion is prepared before fluid challenge. Baseline hemodynamic value and each time after 5 sequential intravenous boluses of 100 mL colloid are recorded.
45613732|NCT04109547|Drug|Oral semaglutide|Tablets to be taken once-daily for 26 weeks
45613733|NCT04109547|Drug|Placebo|Tablets to be taken once-daily for 26 weeks
45613734|NCT03366259|Drug|Misoprostol 200Mcg Tab|administration of 200 Mcg of misoprotol rectal
45613735|NCT03366259|Procedure|elective cesarean section|elective cesarean section for full term patients
45613736|NCT03366181|Device|internal cardioverter defibrillator implant (ICD)|to implant ICD in failing heart subjects with reduced left ventricle ejection fraction (LVEF < 35%).
45613737|NCT03366181|Procedure|percutaneous catheter ablation|to perform catheter ablation in patients with heart failure and reduced left ventricle ejection fraction (LVEF < 35%).
45613738|NCT03358849|Biological|Natural killer cell|Patients who received natural killer cell injection
45613739|NCT05403411|Other|Distance education for nursing students on critical thinking|The students in the intervention group were trained with distance education method for the first 4 weeks, and in the following weeks, with theoretical and case presentations. Critical thinking techniques were used during the trainings. A total of 8 weeks of training was given. Training was given for the first 5 weeks without interruption, and for the next three weeks with a two-week break. Critical thinking disposition scale was applied in the pre-test and post-test.
45613740|NCT03366025|Diagnostic Test|Serum progesterone measure|Serum Progesterone will be measured in all donors on the day triggering at 8:00 am, 12:00 p, 16:00 pm and 20:00 pm
45613741|NCT05403333|Drug|utidelone|Utidelone Injection: 65 mg/m2/day, IV on day 1, 8, and 15 every 28 days
45613742|NCT04514887|Other|mild intraoperative hyperventilation|Intraoperative mechanical ventilation of patients was adjusted so that end-tidal CO2 readings lie between 30-32 mmHg
45613743|NCT05115591|Diagnostic Test|Spinal Ultrasound|Spinal Ultrasound is performed by an observer who records ultrasound characteristics of the intervertebral space chosen by the anesthetist who will practice spinal anesthesia
45613744|NCT05115591|Procedure|Spinal Anesthesia|Spinal anesthesia is performed by an anesthetist after the observer recorded ultrasound characteristics of the intervertebral space chosen by the anesthetist, who is blinded to the ultrasound evaluation.
45613745|NCT03358771|Other|COPD discharge care bundle|As a part of RHSCN quality improvement initiative, the elements of the COPD discharge bundle were integrated into a standardized COPD admission order set and are being implemented province-wide. The discharging physician/team will complete the COPD bundle (with reminders facilitated by clinical decision support tools) prior to patient discharge. A copy of the bundle is retained in the patient's medical record, and another copy is sent to the patient's primary care provider detailing the components of the bundle that were completed prior to discharge, and those still needing to be addressed. The patient will also receive a patient-focused discharge checklist detailing discharge bundle items
45613746|NCT03358771|Other|COPD discharge care bundle & coordinator|The coordinator will be health professional associated with a Primary Care Network, ED or AHS with access to patient information. Patients will be informed that care coordinator may contact them for follow up after discharge. At 48-72 hours after hospital/ED discharge and then at intervals to be determined, the care coordinator will contact the patient by phone. The care coordinator will identify specific needs or problems that patient may have encountered after discharge, which could potentially affect the successful transition from acute to community care setting. Specifically, the care coordinator will seek information on any follow up with family doctor visit, pulmonary rehabilitation and smoking cessation referrals
45445413|NCT01560741|Device|Telemonitoring tools|Patients will go home with telemedicine tools to monitor efficacy and compliance of non-invasive home mechanical ventilation
45613747|NCT05403255|Other|evaluation of the quality of life with questionnaires|"Questionnaire data will be collected among patients and their parents during follow-up consultations.~Children's quality of life will be evaluated using the Kidscreen-10 questionnaire (for children and parents) and PedsQL multidimensional fatigue scale. Psychosocial indicators (standard of living, schooling, recreation activities, social and family relationships, perceived health status and physical appearance) will be gathered using a questionnaire based on the HBSC (Health Behaviour in School-Aged Children) questionnaire (INPES 2010), and compared with data from the general population of elementary-, middle-and high-school children in France."
45613748|NCT04513405|Diagnostic Test|Blood sampling|"a peripheral venous blood sample will be analyzed to measure the levels of estrone and estradiol.~The sample of the blood sample will be deposited in the red cap tube with a polymeric gel."
45613749|NCT04513405|Procedure|Shave Biopsy|in the tissues, of the related estrogenic receptors, estrogen α receptors, estrogen β receptors (ER- α, ER-β) and G protein-coupled estrogen receptor 1 (GPER) correlates with the functional status of these receptors
45613750|NCT05403099|Other|Hyaluronic acid|immediate placement of dental implant after topical application of hyaluronic acid on implant surface
45613751|NCT05403099|Other|conventional implant placement|immediate placement of dental implant without application of hyaluronic acid on implant surface
45759478|NCT03800017|Biological|Hyperoxia|Participants breathe 60% oxygen during exercise
45759479|NCT04382443|Drug|Colchicine|At the moment of BMS implantation intervention will mean that this group will receive colchicine as described.
45759480|NCT01980771|Behavioral|BTWB intervention|Men work in groups to complete a intervention that takes approximately two hours to complete.
45759481|NCT01980771|Behavioral|Cancer prevention and screening|Men are provided health education about cancer screening and prevention
45759482|NCT04633213|Drug|HBM9036 0.25% Ophthalmic Solution|Ophthalmic Solution
46068935|NCT05142605|Behavioral|Meaning-Centered Grief Therapy|Meaning-centered grief therapy is a therapy that focuses on helping participants find a sense of meaning or purpose in their life after their loss. Parents will be provided (via mail or email) a workbook. This support program will involve 16 sessions that will take place about once a week. Each session will last 60 to 90 minutes and will be delivered through videoconferencing.
45759483|NCT04633213|Drug|Placebo|Ophthalmic Solution
45759484|NCT01981863|Drug|Epsilonaminocaproic acid|One group receives Epsilonaminocaproic acid, 10 gr IV bolus, followed by 1 gr/hr. Second group receives placebo.
45911511|NCT02008851|Biological|Neo-kidney augment|Injection of 3.0 x 10e6 selected renal cells into the left kidney of the patient
45445414|NCT01560741|Device|Usual Care|The assessment of efficacy and compliance will be monitor at the end of third month. This is the date of the scheduled hospital visit.
45759485|NCT01981863|Drug|Placebo|Placebo administered in same volume as in experimental arm.
45759486|NCT00245765|Drug|Certolizumab Pegol|"Pharmaceutical Form: solution for injection in pre-filled syringe~Route of Administration: subcutaneous use"
45759487|NCT00245765|Other|Placebo|Matching Placebo to Certolizumab Pegol
45759488|NCT01995045|Drug|Triamcinolone|Retrobulbar anesthesia
45911512|NCT02008864|Drug|Senna|(7.5 mg of sennosoides A and B) Senna tablet/ 2 times per day
45911513|NCT02008864|Drug|Placebo|Placebo tablet/ 2 times per day
45613752|NCT03355183|Other|Isokinetics|Isokinetics, or accommodating resistance, is a form of exercise where a person provides a maximum muscle contraction against a resistance or lever arm, (isokinetic dynamometer) at a fixed speed through a given range of motion. This type of muscle action can be done either concentrically or eccentrically at the given joint.
45613753|NCT05404035|Behavioral|Family Connections for relatives of people with eating disorders and personality disorders|"The FC program (Fruzzetti and Hoffman, 2005) is divided into 7 modules:~Introduction to the intervention program. Program objectives, guidelines, criteria, and symptoms of ED and PD.~Psychoeducation on the development of ED and PD, explanatory theories, available treatments, comorbidity with PD.~Emotional regulation skills and awareness, and to decrease emotional reactivity.~Skills to improve the quality of relationships in family interactions (letting go of guilt and anger, acceptance skills in relationships).~Communication skills and effective self-expression, such as validation.~Problem management and making safe plans for crisis management.~Making new sense of my relationship with my family member, an opportunity to grow together.~All the modules include practice exercises, video viewing, and homework assignment."
45613754|NCT05404035|Behavioral|Optimized Treatment As Usual|"Family members with this condition will continue to receive the usual treatment provided by their referral care center. In addition, we will optimize the treatment, following the recommendations of the international guidelines for the treatment of ED (NICE, 2017). There will be 3 two-hour session in group format each week, with the following components: Up-to-date information and research on ED and PD; Psychoeducation on the development of ED and PD; Explanatory theories; Available treatments and comorbidity.~In both conditions, after each face-to-face session, the participant will be asked to review the contents addressed during the session as homework (independently of the homework corresponding to the specific module being addressed). All interventions carried out with family members will be performed by clinical psychologists or general health psychologists with at least a master's degree or a doctoral degree and previous training in the application of the programs."
45613755|NCT03358615|Procedure|cesarean section|assessment of the indications of cesarean section according to Robson criteria
46068936|NCT05142605|Behavioral|Supportive Psychotherapy|Supportive psychotherapy will help participants cope with their loss by giving them a place to express their feelings and providing them with support during the sessions. Supportive counseling will involve 16 sessions that will take place about once a week. Each session will last 60 to 90 minutes and will be delivered through videoconferencing.
45613756|NCT05403957|Other|TID video|"Main intervention: A video introducing the tobacco industry's marketing tactics to attract children and adolescents to smoke and their manipulation of tobacco control policy formation.~Booster intervention: 6 screenshots from the video and 6 true or false questions."
45613757|NCT05403957|Other|TID worksheet|"Main intervention: A worksheet using pictures and texts to introduce the tobacco industry's marketing tactics to attract children and adolescents to smoke and their manipulation of tobacco control policy formation.~Booster intervention: 8 pictures from the TID worksheet in the main intervention and 6 true or false questions."
45613758|NCT05403957|Other|SSB worksheet|"Main intervention: A worksheet using pictures and texts to introduce the beverage industry's marketing tactics to attract children and adolescents to drink SSBs and the health risks of SSBs.~Booster intervention: 8 pictures from the SSB worksheet in the main intervention and 6 true or false questions."
45613759|NCT04512469|Device|Low molecular weight mesh|Following liver implantation, the subcostal incision will be closed using a running fascial closure with absorbable 1-0 Polydioxanone (PDS) suture and staples, with the treatment group also receiving a mesh.
46068937|NCT05142605|Behavioral|Enhanced Usual Care|Enhanced usual care includes any support or resources participants may receive as part of their standard care (for example, therapy sessions with a local therapist), enhanced with additional resources.
45613760|NCT05399979|Procedure|Labor Neuraxial Analgesia|Labor Neuraxial Analgesia
45613761|NCT04512157|Behavioral|Promoting Alternative Thinking Strategies (PATHS), Preschool Edition|PATHS® is a universal teacher implemented, and school-based intervention that aims to give preschool children a strategically timed boost in social emotional competence. Specifically, PATHS® encourages the use of interactive techniques to bolster children's ability to self-regulate, increase their adeptness at social cognitive problem solving, as well as to gain insight into their emotions and emotions of others.
45613762|NCT03707301|Other|Questionnaires|Questionnaires of satisfaction and the Hospital Anxiety and Depression scale.
45613763|NCT03365869|Drug|Sirolimus|Sirolimus or placebo were added to patients every day
45613764|NCT04932213|Drug|Tropicamide Ophthalmic|Tropicamide eye drops are used for dilating pupils (mydriasis) to do comprehensive fundus examination.
45613765|NCT03684213|Drug|Control (Norepinephrine)|This intervention is aimed at assessing the vascular responsiveness to norepinephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.
45613766|NCT03684213|Drug|Norepinephrine + Ascorbic Acid|This intervention is meant to globally assess the impact of oxidative stress on vasoconstrictor responses by scavenging numerous oxidative molecules.
45613767|NCT03684213|Drug|Norepinephrine + L-NAME|This intervention is meant to assess the impact of endothelium-derived nitric oxide on vasoconstrictor responses by inhibiting production of this source of nitric oxide.
45613768|NCT03684213|Drug|Norepinephrine + L-NAME + Ascorbic Acid|This intervention is meant to assess the combined impact of scavenging oxidative stress and inhibiting endothelium-derived nitric oxide on vasoconstrictor responses.
45911514|NCT02008929|Biological|MG4101|Ex vivo expanded allogeneic NK cell
45911515|NCT02008955|Dietary Supplement|Lysine intake provided as a milkshake|There are 7 different lysine test levels ranging from 10 to 80 mg of lysine per kilogram body weight per day (10 - 80 mg/kg/d)
46068938|NCT05140382|Drug|AZD4573|AZD4573 will be given intravenously
45613769|NCT03365557|Procedure|Airway peak pressure|Air was injected into LMA cuff during expiration phase to make intracuff pressure achieve the level of airway peak pressure. If there's any leakage, increase 5 cmH2O every time till there's no air leakage from the mouth.
45613770|NCT04049097|Drug|Arimoclomol|1200 mg/day arimoclomol citrate (400 mg t.i.d.)
45613771|NCT03365479|Drug|Iloprost|Single administration of inhaled iloprost 2.5 μg delivered via Breelib nebulizer
45613772|NCT04032795|Dietary Supplement|Lycium barbarum polysaccharide|Experimental group takes Lycium barbarum polysaccharide (LBP) tablet (300mg/day)for 6 weeks
45613773|NCT04032795|Dietary Supplement|Placebo|Placebo-controlled group take he placebo capsules that are identical in shape, color, and taste to LBP tablet.
45613774|NCT03365401|Procedure|decompression surgery|undertake decompression surgery
45613775|NCT03365401|Procedure|nonsurgical treatment|complete on bed with prevention of complication
45613776|NCT04925271|Device|X-Tack|The mucosal or submucosal defect is closed with X-Tack.
45613777|NCT04925271|Device|Overstitch|The mucosal or submucosal defect is closed with Overstitch.
45613778|NCT03355027|Drug|Alirocumab 150 MG/ML|Dosing to be performed by subcutaneous injection in clinic
45613779|NCT03355027|Drug|Ezetimibe 10Mg Tablet|Patients will be instructed to take once daily at night.
45613780|NCT03355027|Drug|Atorvastatin 40Mg Tablet|Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR < 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
45613781|NCT03355027|Drug|Atorvastatin 80Mg Tablet|Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR < 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
45613782|NCT03355027|Drug|Rosuvastatin 20Mg Tablet|Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
45613783|NCT03355027|Drug|Rosuvastatin 40Mg Tablet|Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
45613784|NCT03355027|Drug|Simvastatin 80mg|Patients will be instructed to take once daily at night. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
45613785|NCT04923165|Device|robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
45613786|NCT04923165|Diagnostic Test|biochemical analyses|ematochemical and biochemical serum analyses at T0 and at T1; oxidative stress analyses;
45613787|NCT04923165|Device|BIA, hand grip|bioimpedentiometric analyses of muscular mass (T0 and T1) , muscular force with hand grip
45613788|NCT04923165|Diagnostic Test|nutritional assessment, MNA|nutritional status assessment with MNA, body mass index measurements, weight loss detection, food income detection
45613789|NCT03354949|Other|Measurement of sitting postural control of the adult (MCPAA)|"The Adult Seated Postural Control Measure 2.0 (MCPAA 2.0) is a clinical evaluation tool for sitting postural control of adult clients using a locomotion aid. It thus allows the evaluation of the two variables inherent to the postural control sit, the alignment of body segments and the influence between movement and posture.~It can also be used to evaluate the changes in seated postural control due to changes over time or to an adaptation of the sitting posture.~Assessment of wheelchair pain in the spine and ischia by a self-evaluation scale (EVA).~the speed of propulsion by a wheelchair."
45613790|NCT04905927|Other|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
45613791|NCT04182867|Other|Dietary intervention|Dietary modification (provision of diet).
45613792|NCT03828045|Drug|Apremilast|Apremilast
45613793|NCT03354793|Other|Survey on first pregnancy after endometriosis diagnosis|Obstetric complications were noted
45613794|NCT03354793|Other|Survey on first pregnancy|Obstetric complications were noted
45613795|NCT03365323|Other|Periprosthetic Joint Infection|Periprosthetic Joint Infection is diagnosed according to the diagnosing criteria from the Workgroup of the Musculoskeletal Infection Society.
45759489|NCT01995045|Drug|Bupivicaine Hydrochloride|Retrobulbar anesthesia
45759490|NCT04937725|Diagnostic Test|eye tracking|Eye tracker will be used to evaluate study parameters
45759491|NCT03806075|Behavioral|Second generation sequencing|Firstly, all Peutz-Jeghers patients accept second generation gene sequencing with their blood specimen
45759492|NCT03806075|Behavioral|16s rRNA gene sequencing|Secondly, All patients and Health persons accepted 16s rRNA gene sequencing with their feces specimen
45759493|NCT04894123|Drug|Trifluridine/Tipiracil|"Trifluridine/tipiracil : 35 mg/m² orally twice a day from day 1 to day 5 every 14 days.~If oxaliplatin is stopped or it is not indicated, trifluridine/tipiracil in monotherapy 35 mg/m² orally twice a day between days 1-5 and days 8-12; repeated every 28 days."
45911516|NCT02008968|Drug|allopurinol 300 mg./day|
45911517|NCT02008968|Other|No intervention|
45911518|NCT02008968|Drug|Normouricemic|
45613796|NCT03365323|Other|Non-Periprosthetic Joint Infection|PJI can not be diagnosed for the lack of clinical evidence according to the diagnosing criteria from the Workgroup of the Musculoskeletal Infection Society.
45613797|NCT03123679|Radiation|pulmonary perfusion/reserve with Tc-99m-MAA SPECT/ Low dose CT|"Patient referred to radiotherapy treatment are evaluated with a baseline PFT [Forced expiratory volume in 1 second (FEV1), Forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide (DLCO), Alveolar gas volume (VA)].~RT simulation at the radiotherapy department and treatment planning.~Baseline evaluation of pulmonary perfusion/reserve with Tc-99m-MAA SPECT/ Low dose CT.~Radiotherapy."
45613798|NCT02519413|Drug|dimethyl fumarate|delayed release capsules
45613799|NCT04522609|Device|Neuromuscular electrical stimulation (NMES)|"NMES will carried out with four-channel myostimulator Beurer EM80 (Germany). Self-adhesive electrodes locates above the quadriceps, the duration of the NMES session was 60 minutes, including 5-minute periods of warm-up and warm-down. Throughout the series, rectangular pulses with a frequency of 45 Hz will modulate. As a result, tonic contraction of these muscles will induce for 12 seconds, followed by a pause of 5 seconds. The amplitude of electrical exposure will select separately for each of the four channels until good muscle contraction (visually or by palpation) without pain. Electrical stimulation: 5-6 session per week, for 12 weeks, with 60-minuite session."
45613800|NCT03358537|Dietary Supplement|Clear Liquid Diet|Clear liquid diet was compared with low-residue diet, in combination with Poliethylene Glycol in each group
45613801|NCT03358537|Dietary Supplement|Low-residue Diet|Clear liquid diet was compared with low-residue diet, in combination with Poliethylene Glycol in each group
45613802|NCT03123757|Other|6 Minute Walk Test|The 6 minute walk test measures the distance walked in 6 minutes without sitting and without the use of a walker or the help of another person (a cane may be used). The walk was conducted in a wide hallway, specifically designed for this type of assessment, with a defined 20-meter course. The subject walked back and forth in the hallway for six minutes and the distance covered was recorded.
45613803|NCT03123757|Other|EQ-5D Survey|The EQ-5D is a self-reported questionnaire that describes a respondent's health using a descriptive system comprised of five items, each representing a different health dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, respondents state whether they have no problems, slight problems, moderate problems, severe problems, or are unable to perform the activity.
45613804|NCT03123757|Other|Short Physical Performance Battery|The SPPB is a brief performance battery based on timed short distance walk, repeated chair stands and balance test administered by trained examiners. The measurement goal for this battery is to assess lower extremity functional limitations, which indicate functional abilities and are a strong measure of risk for future disability.
45613805|NCT02519335|Drug|Dexrazoxane|Dose escalation every 4 subjects from 200mg/m2/dose; 300mg/m2/dose to 400mg/m2/dose
45613806|NCT03354715|Device|Rapid prototyping Denture base|The introduction of rapid prototyping (RP)Stereo lithography (SLA) technology, which mainly depends on addition of layers of materials which would be polymerized using a light curing unit. It consists of a bath of photo polymerized liquid and ultraviolet unit for curing these layers, that would bond to each other till forming the full object. SLA has many advantage as high accuracy, high mechanical strength, smooth surface finish with close tolerance and fine details printing, but it has some limitation as it is only limited Material, in addition to the high material and equipment cost.
45613807|NCT03354715|Device|Heat Cured Conventional Complete Denture|it is the main treatment for most of completely edentoulous Cases
45613808|NCT03365245|Device|Microperimetry|Microperimetry is performed at three different days
45613809|NCT03365245|Device|automated visual field|Automated visual field ist performed at three different days
45613810|NCT03365167|Radiation|LANAP (Laser Assisted New Attachment Procedure)|radiation of Nd:YAG laser in periodontal pocket
45613811|NCT03365167|Radiation|LANAP off|radiation of Nd:YAG laser in off mode in periodontal pocket
45613812|NCT03365089|Procedure|Collateral vein ligation|Collateral venous flow will be interrupted by ultrasound-guided ligation of venous side branches.
45613813|NCT03364933|Behavioral|Primary intensivist and nurses|"Primary intensivist will have no active role in the daily management of patients. The primary intensivist should facilitate decision-making, be a liaison between the patient/family and PICU team, and be a resource of information for all. Responsibilities of primary intensivist:~Weekly check-in with and availability to patient/family~Attendance at family meetings~Availability to PICU team~Primary nurses will be a team of up to 7 ICU nurses who will provide as much of the bedside care as possible. Responsibilities of primary nurses:~Maintain a primary nurse binder (paper format) for on-going communication about the patient among the team members; it will be their discretion what is information is communicated.~The Primary Nurse or delegate will be involved in all team/family meetings and will be expected/given an opportunity to speak during these meetings."
45613814|NCT04509895|Procedure|Lateral extensile approach in calcaneal fractures fixation|The standard extended lateral approach with L-shaped incision was made in this group, which originated vertically from 5 cm over lateral malleolus or the midpoint between the fibula and Achilles tendon and ended on the base of the fifth metatarsal . The incision is made directly to the bone at the corner to create a full-thickness flap. Attention must be paid to protect the sural nerve and peroneal tendons as well.
45613815|NCT04509895|Procedure|Minimally invasive sinus tarsi approach in calcaneal fractures fixation|An incision is made from the tip of the lateral malleolus toward the base of the fourth metatarsal bone. The incision lies in a plane between the superficial peroneal nerve and the sural nerve. Care is taken to bluntly dissect after the skin incision to protect the sural nerve or branches of the superficial peroneal nerve. By mobilizing the sinus tarsi fat pad dorsally, the incision was deepened. The extensor digitorum brevis muscle is sharply elevated off of the anterior process with the lateral root of the inferior extensor retinaculum and reflected dorsally and distally. The peroneus brevis and peroneus longus tendons are split, allowing exposure to the sinus tarsi and visualization of the posterior facet of the subtalar joint.
45759494|NCT04894123|Drug|Oxaliplatin|Oxaliplatin : 85 mg/m² intravenous at day 1 every 14 days.
45911519|NCT02008981|Drug|Curcuma longa|Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
45911520|NCT02008981|Drug|Angelica sinensis|Angelicae sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
45613816|NCT04509817|Device|Acupuncture+Usual care|"Acupuncture intervention Disposable, sterilized needles (0.25×40 mm and 0.30×50 mm) will be used and selected acupoints will include GV20, CV4, and bilateral BL32, ST25, ST29, EX-CA1, LI4, LR3, SP6, SP9. Subject will be prone position first and BL32 will be inserted with an angle of 30-45° in an inferomedial direction and a depth of 30-50 mm. Once the subject has a needle sensation ('De-qi'), the needle will be removed immediately. Then the subject will be supine position, and GV20, CV4, ST25, ST29, EX-CA1, LI4, LR3, SP6, SP9 will be needled with a depth of 10-40mm. After subject feel 'De-qi', the needles will be placed for 20 min to maintain the stimulation.~Usual care intervention The subjects will receive the health advice including diet with regular meal, enough sleep, and appropriate exercise.~Behavioral: Usual care Usual care intervention The subjects will receive the health advice including diet with regular meal, enough sleep, and appropriate exercise."
45613817|NCT04509817|Behavioral|Usual care|Usual care intervention The subjects will receive the health advice
45613818|NCT04509583|Dietary Supplement|PROFortil|Multi-micronutrient supplement (PROfortil™, twice daily) plus Vitamin E (Enat 400, once per day) in 3 months
45613819|NCT04509583|Other|Vitamin E|Only Vitamin E (Enat 400, once per day) in 3 months
45613820|NCT04509661|Drug|LABA/LAMA or Placebo inhalation|Inhaled LABA/LAMA for one year.
45613821|NCT03122977|Procedure|FM-SRP|Supra- and sub-gingival mechanical instrumentation of the root surface of the whole dentition within 24 hours.
45613822|NCT03122977|Procedure|Q-SRP|"Supra- and sub-gingival mechanical instrumentation of the root surface will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
45613823|NCT04509271|Diagnostic Test|MicRNAs battery kits|Novel peripheral blood diagnostic biomarker for MCI due to AD.
45613824|NCT03350737|Other|Physical rehabilitation|Standard treadmill exercise session
45613825|NCT03350737|Drug|Heparin|Heparin i.v.
45613826|NCT03350737|Other|Placebo|Sodium Chloride 0.9% i.v.
45613827|NCT03350659|Drug|Midodrine|Midodrine single 5mg/day
45613828|NCT03350659|Drug|Atomoxetine|Atomoxetine single 18mg/day
45613829|NCT03350581|Procedure|FAM 3D map group|Radiofrequency catheter ablation using the 3D map which is constructed by FAM alone.
45613830|NCT03350581|Procedure|FAM-CT 3D map group|Radiofrequency catheter ablation using the 3D map which is constructed by the integration of the FAM with CT or MRI.
45613831|NCT04524793|Other|Questionnaires|Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
45613832|NCT04524793|Other|Physical examinations|GSV/SSV/AASV reflux, CEAP Classification (Clinical, Aetiological, Anatomical and Pathophysiology), Venous Clinical Severity Score (VCSS) and duplex ultrasound
45613833|NCT03364855|Other|Star excursion balance test|Star excursion balance test,
45613834|NCT03364855|Other|Kinesthetic Ability Trainer 2000|Kinesthetic Ability Trainer 2000
45613835|NCT03364855|Other|SEBT and KAT 2000|Star excursion balance test and Kinesthetic Ability Trainer 2000
45613836|NCT03364777|Other|emotional state|anxiety or depression state evaluated by emotional scale
45759495|NCT04539457|Behavioral|Desktop helper|The 'Desktop Helper (version 10)' is a user-friendly information sheet developed by the IPCRG. This 'Desktop Helper (version 10)' has been developed in co-operation with several clinicians and experts in the field of COPD. These practical guidance and support are a tool for clinicians working in primary care. The 'Desktop Helper (version 10)' contains specific advice to prevent clashes. The specific advice of the 'Desktop Helper (version 10)' will be elaborated in decision trees. These will be integrated and implemented into the MedicomSmart system by Stichting Healthbase. Subsequently, these decision trees will provide GPs to conduct case-finding of COPD patients with 'medication-comorbidity clashes'. These are based on the 'Desktop Helper (version 10)' . Case finding will be done by the GP or the practice nurse (POH).
45911521|NCT02008981|Drug|Siwu Tang|"TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after."
45911522|NCT02008981|Drug|Aspirin|Aspirin (enteric-coated) at 100mg daily will be given one of the actual herb or placebo herb, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
45613837|NCT04443517|Procedure|Alpha Optimization|Intraoperative oscillatory EEG alpha optimization involves real-time acquisition of oscillatory alpha power from the frontal EEG with individualized titration of desflurane and opioid.
45613838|NCT04443517|Behavioral|Emergence from anesthesia with propofol|Infusion of 400 mg/h of propofol during the final 10-20 minutes of surgery. Total doses of propofol administered are likely to be in the range of 1-3 mg/kg.
45613839|NCT04524559|Other|conventional physical therapy training|"The program focused on regaining typical movement, prohibiting abnormal muscle tone, promoting postural reactions and enhancing postural mechanisms. The program was applied via certified physical therapists five days/week for 4 successive months. The intended goals of the treatment program were achieved through:~Neurodevelopmental based training (NDT)~Functional stretching exercises to preserve muscle and soft tissues elasticity~Sequenced trunk co-activation (STA) exercises~Righting and protective reactions It is worth mentioned that the exercises applied in each session was influenced by the age and the specific functional abilities within the selected activity."
45613840|NCT04524559|Other|oral motor training.|"Children in the experimental group received 30 minutes of oral motor training five days week. The training included oral stimulation (facilitation) conducted before the child's actual meal time.~The designed protocol comprised modified perioral and intraoral maneuvers based on Fucile's protocol. The utmost aims of the protocol were to decrease hypersensitivity of oral structures, increase jaws movement, and reinforce muscle strength, improve tongue movement and enhance oral motor organization"
45613841|NCT03364699|Dietary Supplement|dietary supplementation|The volunteers ingested 3 g daily of Soybean lecithin or fish oil rich in docosa-hexanoic acid (DHA) containing 1.5 g DHA and 0.3 g EPA (DHA:EPA = 5:1) or fish oil rich in eicosapentaenoic acid (EPA) containing 1.6 g EPA and 0.3 g DHA (EPA:DHA = 5.4:1) during 60 days.
45613842|NCT03364699|Other|Exercise|All volunteers performed two half-marathons. In the first half-marathon, all participants were not supplemented. In the second half-marathon, all participants were supplemented. Blood samples were collected before and after both half-marathon race.
45613843|NCT03364543|Other|Access to the Medical-Legal Partnership Group|The Medical-Legal Partnership Group are lawyers in clinics who address health-harming legal needs.
45613844|NCT03364543|Other|Access to social worker and a community worker|Access to social worker and a community worker, but no systematic process for addressing health-harming legal needs.
45613845|NCT02519257|Procedure|CAD|Patients with CAD diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
45613846|NCT02519257|Procedure|VHD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
45613847|NCT04443595|Procedure|Dual-scopic pancreatic necrosectomy（DPN）|Treatment of Acute Severe Pancreatitis with DPN
45613848|NCT04509349|Device|transcranial Altering Current Stimulation|The participant will wear an electrode cap with 5 gel-filled cup HD electrodes arranged in a 4 x 1 montage.
45613849|NCT04509349|Device|Sham tACS|2 saline sponge electrodes will be attached to the upper arm contralateral to hand attached to the accelerometer.
45613850|NCT03350347|Drug|Molidustat (BAY85-3934)|Starting dose of 25 mg or 50 mg molidustat once daily (OD) will be titrated based on the subject's Hb response
45613851|NCT03350347|Drug|Darbepoetin alfa|Starting dose and frequency of darbepoetin alfa are based on previous ESA. The dose will be titrated based on the subject's Hb response
45613852|NCT03350191|Drug|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
45613853|NCT03350191|Drug|[68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
45613854|NCT03350191|Drug|[68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
45613855|NCT03364465|Other|change of ventilatory settings|change of tidal volume during one-lung ventilation
45613856|NCT04508569|Behavioral|Big Decisions|Big Decisions is a promising teen pregnancy prevention intervention that consists primarily of abstinence-plus sexual health education curriculum. The intended dosage for students is 10 classroom-based sexual health lessons.
45613857|NCT02519101|Device|continuous noninvasive blood pressure monitoring ClearSight-Device|Noninvasive continuous blood pressure monitoring using the volume clamp method (ClearSight-Device)
45613858|NCT02649231|Drug|Ketamine|0.8 mg/kg ketamine
45613859|NCT02649231|Drug|Placebo|0.9% saline
45613860|NCT02649231|Behavioral|Psychological Therapy|Manualised relapse prevention based CBT
45911523|NCT02008994|Other|Genomic and Proteomic Profiling|Following review of targets by the Treatment Selection Committee, the treating physician will decide whether to continue with planned therapy or alter the course of treatment based on the genomic results.
45613861|NCT02649231|Behavioral|Alcohol Education|Simple education about alcohol effects
45613862|NCT03364075|Drug|Duloxetine|30 mg for seven days, then increased to 60 mg for seven days
45613863|NCT03364075|Drug|Propranolol|40 mg for seven days, then increase to 60 mg for seven days
45911524|NCT02009007|Drug|dopamine|continuous infusion during operation
45613864|NCT03364075|Genetic|Genotype for SNPs associated to Serotonin and COMT|DNA and RNA extraction from blood samples to identify genetic variants associated to pain pathways
45613865|NCT03364075|Drug|Placebo Treatment|1 capsule BID for two weeks
45613866|NCT03363997|Drug|Estriol 0.125 mg/day|Application of one vaginal ring
45613867|NCT03363997|Drug|Estriol 0.250 mg/day|Application of one vaginal ring
45613868|NCT03363997|Drug|Estriol 0.500 mg/day|Application of one vaginal ring
45613869|NCT05378295|Dietary Supplement|Fermentable oligosaccharide|Supplementation period 12 weeks
45613870|NCT05378295|Dietary Supplement|Personalized fiber mixture|Supplementation period 12 weeks
45613871|NCT03350113|Device|Blood sampling for analysis|Blood Sampling for Analysis
45613872|NCT02518477|Other|exercise|progressive resistance training
45613873|NCT03547869|Device|Active tDCS|Active tDCS will be adminestered
45613874|NCT03547869|Device|Sham tDCS|Sham tDCS will be administered
45613875|NCT04504279|Biological|FB-401|Topical application
45613876|NCT04504279|Biological|Placebo|Vehicle
45613877|NCT04176939|Biological|HZ/su vaccine (GSK1437173A)|2 intramuscular (IM) doses of the HZ/su vaccine administered- first dose at month 24 and second dose at month 25
45613878|NCT03354481|Behavioral|Arithmetic facts solving|The experiment will contain several tasks. The main one will be a computerized task on arithmetic facts where participants will have to solve simple additions. There will also be three additional tasks: a processing speed task where the participant will have to tell the orientation of an arrow as fast as possible, a visuo-spatial task where the participant will have to reproduce a tapping block sequence and an arithmetic task where the participant will try to solve a maximum of operations in a limited time.
45613879|NCT03349957|Drug|Transarterial chemoembolization using TANDEM and idarubicin|Transarterial chemoembolization using TANDEM and idarubicin
45613880|NCT04175301|Drug|Hydrogen|Each hydrogen tablet contains 80 mg magnesium
45613881|NCT04175301|Drug|Placebo oral tablet|Matching placebo tablet also contains 80 mg magnesium
45911525|NCT02009007|Drug|phenylephrine|continuous infusion of phenylephrine during operation
45445415|NCT03782805|Dietary Supplement|cholecalciferol (Euro-Pharm International, Canada)|The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months
45445416|NCT03782805|Dietary Supplement|Placebo tablet|The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months
45613882|NCT04174989|Other|Plasma treated with ClearPlasma (Extra-corporeal plasma filtration device)|ClearPlasma is designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma is a non-pyrogenic, sterile, single-use medical device that is indicated for use in conditions where massive bleeding situations exist.
45613883|NCT04174989|Other|Regular fresh-frozen plasma (not treated)|Regular fresh-frozen plasma (not treated)
45613884|NCT04524169|Drug|Thymosin Alpha1|Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.
45613885|NCT03568929|Drug|Idelalisib|Tablets administered according to the product information and treatment guidelines in routine clinical practice
45613886|NCT03354247|Behavioral|Lifestyle Intervention|Participants randomized to the Lifestyle Intervention will receive an intensive, state-of-the-art weight loss intervention based on a Mediterranean diet and physical activity. The intervention will focus on changing both eating and exercise habits with a goal of producing a 7-10% weight loss within the first 6 months and then maintaining this weight loss. Participants will be evaluate using validated questionnaires and adherence scores to assess food intake and physical activity, and will then be closely followed during the intervention period.
45613887|NCT04503967|Drug|Anlotinib Hydrochloride With Nivolumab|Anlotinib Hydrochloride Combined With Nivolumab in the second line Treatment of Gastric and Esophageal Cancer patients
45613888|NCT04841499|Drug|BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)|take 2 capsules orally each day for 7 days
46068939|NCT05134857|Drug|Zonisamide|The ZON will be supplied in 100 mg capsules and deposited directly into the TAD device by research staff every 2 weeks. All participants will be told to take 100 mg/day for the first three weeks (Week 1-2 single-blind, placebo-only, induction; end of Week 2, active treatment begins) and increasing by 100 mg/day every other week (Week 4: 200 mg/day; Week 6: 300 mg/day; Week 8: 400 mg/day) up to the target dose of 500 mg/day by Week 10. The participants will be maintained on this dose through Week 14 of active treatment and then tapered off ZON (2 weeks). This dosing schedule is consistent with best practices for ZON. All TAD devices will only dispense the prescribed medication between 4pm and 11pm each night. Participants will be instructed to take the medication at or near bedtime.
45613889|NCT04503889|Device|Transauricular electrical vagal nerve stimulation|transauricular electrical vagal nerve stimulation will be applied to the cymba conchae of both ears using ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany) with currency intensity of max 10 mA and current frequency 2/100 Hz.
45613890|NCT04503889|Device|taVNS sham|ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany)
45613891|NCT04822935|Procedure|Vertebral Body Tethering|VBT surgery is a surgery performed by thoracotomy in adolescent idiopathic scoliosis patients.
45613892|NCT04808817|Diagnostic Test|calorimetry, impedance measurement at baseline and after 3 months of treatment|biobanking (30ml) for cytokines and complement dosages at baseline and after 3 months of treatment calorimetry and impedance measure will be collected at baseline and after 3 months of ICI treatment
45613893|NCT04522999|Device|Photobiomodulation|The Valeda™ Light Delivery System
45613894|NCT05028465|Procedure|Endoscopic Papillectomy|A snare devicewas inserted via the working channel, and the endoscopist adjusted the snare to securely grasp the lesion, which was then excised by using standard electrocautery.
45613895|NCT05028465|Procedure|Endobiliary Radiofrequency Ablation|The RFA catheter was then placed under fluoroscopic guidance across the distal common bile duct. An ERBE VIO200D generator (ERBE Elktromedizin, Tubingen, Germany) was connected for RFA at 10 W for 90 seconds.
45613896|NCT04773405|Drug|a 1: 1 mixture of 2% lidocaine with 5ug/ml epinephrine and 0.5% levobupivacaine|"This study adopts a Modified Narayana rule (MNR), a sequential up-and-down pharmacodynamics method (UDM) to estimate the minimum effective local anesthetic volume of 90% (MELAV90) of cases of the aforementioned local anaesthetic (LA) mixture, in order to produce the surgical anaesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries. Based on the principal investigator's clinical experience, the initial volume of 21ml will be used. Depending on the success or failure of the SeTB, which is defined as the readiness for surgery at 30 minutes after the block, the volume for the next patient will be adjusted up or down by 3ml (1ml for each trunk of brachial plexus located above the clavicle). The upper dose limit of the study to minimize the potential for local anaesthetic systemic toxicity will be 30ml and the lower dose limit will be 12ml, which will be of no clinical importance."
45613897|NCT04991571|Drug|Zibotentan (Treatment A)|Zibotentan capsule will be administered orally as multiple doses in Part 1 and as single dose in Part 2.
45613898|NCT04991571|Drug|Dapagliflozin (Treatment A)|Dapagliflozin tablet will be administered orally as single dose in Part 2.
45445417|NCT03776097|Other|observational study|Observational study
45445418|NCT05533203|Biological|Prodencel; an autologous dendritic cell therapeutic tumor vaccine|Subcutaneous injection, each injection point should not exceed 1ml.
45445419|NCT03776019|Device|AVWF device|The AVWF method utilizes sound modulated music, which is thought to regulate the vagus nerve.
45613899|NCT04991571|Drug|Zibotentan/Dapagliflozin - Formulation 1 (Treatment B)|Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.
45613900|NCT04991571|Drug|Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)|Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.
45613901|NCT03191019|Behavioral|Mobile-phone app for smoking cessation|Android App for smoking cessation
45613902|NCT03176979|Other|Contrast Agent|Given IV
45613903|NCT03176979|Procedure|Digital Tomosynthesis Mammography|Undergo CESM with DBT
45613904|NCT03176979|Procedure|Dual-Energy Contrast-Enhanced Digital Spectral Mammography|Undergo CESM with DBT
45613905|NCT01376245|Drug|fluticasone furoate/vilanterol|Inhaled corticosteroid/long acting beta-agonist
45613906|NCT01376245|Drug|Placebo|matching placebo
45613907|NCT04754061|Drug|Psilocybin|"Phase 1 (week 1): all enrolled participants will take a single 1mg oral dose of psilocybin once per day on Monday and Thursday. If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 2 for week 2.~Phase 2: The participant will take a single 1mg oral dose of psilocybin once per day for 5 consecutive days (Monday to Friday). If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 3 for week 3.~Phase 3: The participant will take two 1mg oral doses (2mg total) of psilocybin once per day for 5 consecutive days (Monday to Friday). If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 4 for week 4.~Phase 4 (maximum allowable dose): The participant will take three 1mg oral doses (3mg total) of psilocybin once per day for 5 consecutive days (Monday to Friday)."
45613908|NCT04508881|Device|Ahmed Glaucoma Valve|To compare the prevalence of postoperative hypotony between the 2 arms
45613909|NCT05403645|Diagnostic Test|Movement With Mobilization|with the help of Movement With Mobilization technique
45613910|NCT05403645|Diagnostic Test|Exercise Therapy|with the help of Exercise Therapy technique
45613911|NCT04508491|Other|Rhythm control|Rhythm control with medications or any procedure
45613912|NCT04508491|Other|Rate control|Rate control
45613913|NCT04728477|Device|OPti BP measurements|measurement of blood pressure with the new smartphone App ( OPTIBP)
45613914|NCT03349489|Other|Exercise 1|Participants will be admitted at the research center at 14:00. At 14:30, participant's insulin basal rate will be reduced by 80%. At 16:00, participants will perform a 60-minute exercise on a stationary bicycle at 60% of their maximal cardiorespiratory capacity (VO2 max). During the exercise period, muscle oxygenation and muscle oxygen extraction will be measure by near infrared spectroscopy. Glucose levels will be measured every 10 minutes during the exercise period. At 17:30, the participant will be discharged.
45613915|NCT03349489|Other|Exercise 2|Participants will be admitted at the research center at 14:00. At 15:20, participant's insulin basal rate will be reduced by 80%. At 16:00, participants will perform a 60-minute exercise on a stationary bicycle at 60% of their maximal cardiorespiratory capacity (VO2 max). During the exercise period, muscle oxygenation and muscle oxygen extraction will be measure by near infrared spectroscopy. Glucose levels will be measured every 10 minutes during the exercise period. At 17:30, the participant will be discharged.
45613916|NCT03349489|Device|Dexcom G4 Platinum|The Dexcom G4 Platinum will be used to measure continuous glucose levels.
45613917|NCT03349489|Drug|Insulin|Participant's usual fast-acting insulin analog will be used.
45613918|NCT03349489|Device|Insulin pump|Participant's insulin pump will be used to infuse insulin.
45613919|NCT04936581|Procedure|Open Total Mesorectal Excision|Open approach for Total Mesorectal Excision
45613920|NCT04936581|Procedure|Laparoscopic Total Mesorectal Excision|Laparoscopic approach for Total Mesorectal Excision
45613921|NCT04936581|Procedure|Robotic Total Mesorectal Excision|Robotic approach for Total Mesorectal Excision
45613922|NCT04936581|Procedure|Transanal Total Mesorectal Excision|Transanal approach for Total Mesorectal Excision
45613923|NCT03349411|Diagnostic Test|Confusion Assessment Method|This test is used for delirium assessment. The CAM consists of a series of questions, measuring attention (digits forward and backwards, days of the week and months of the year backwards), orientation (person, place, time), memory (immediate and delayed recall of 3 concrete nouns); and probing for any sleep, perceptual, or thinking disturbances. It was designed to incorporate DSM-III criteria for delirium.
45613924|NCT03349411|Diagnostic Test|Behavioral Inattention Test|This test is used for neglect assessment. The BIT consists of 6 tasks: figure and shape copying; line, star, and letter cancellation, and representational drawing. Such tasks were shown to be appropriate in patients within 48 hours of stroke onset. Scoring of each test will include proportion of error responses on each test or deviation from midpoint on line bisection. Figure and shape copying and representational drawing will be scored based on each item completed.
45613925|NCT03349411|Diagnostic Test|Magnetic Resonance Imaging|Structural, functional and diffusion weighted scans will be obtained or acquired, depending on the cohort. Subacute sample participants will undergo a research MRI scan, whereas acute sample participants will allow the release of their clinical MRI scans.
45613926|NCT03349411|Diagnostic Test|Florida Mental Status Examination|This test is used for mental status assessment, and it will be conducted in our subacute sample only. The FMSE tests memory, attention, language, visuospatial processing, and executive function. It will help to establish patients' mental status profile, including any deficits.
45613927|NCT03349411|Diagnostic Test|Montreal Cognitive Assessment|MoCA is a brief cognitive screening tool for individuals with mild cognitive impairment and will be used in the acute sample.
45613928|NCT03349411|Diagnostic Test|Geriatric Depression Scale|Because depression has been previously associated with delirium, patients will be evaluated for depression with the GDS. The GDS is a self-report measure consisting of 30 yes/no questions to measure depression in the elderly. It will be used as a covariate in data analysis.
45613929|NCT03349411|Diagnostic Test|Kessler Foundation Neglect Assessment Process|This is a 10-category scale for spatial neglect based on observation of activities of daily living (e.g., eating, dressing, grooming, gaze orientation). Thee test is based on the Catherine Bergego Scale (CBS) and administered via the standardized KF-Neglect Assessment Process developed within our program.
45613930|NCT04896957|Behavioral|Interview|Face to face semi-directed interviews about perceptions, representations and experiences of Covid-19 vaccination, including six opened-questions
45613931|NCT04724577|Radiation|carbon ion radiotherapy|dose escalation radiotherapy with five levels of dose from 54GyE/12Fx to 58.8GyE/12Fx
45613932|NCT03349255|Biological|autologous ET1402L1-CART cells|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1)-CAR expression construct
45911526|NCT02009033|Drug|Lactated Ringer|When normovolæmic status of the patient is secured, 35 ml/kg of the allocated fluid is infused during the operation (estimated time for this type of operation is 180 minutes), however max. 3500 ml.Lactated Ringer is the interventional medication.
45911527|NCT02009033|Drug|Hydroxyethylstarch|
45911528|NCT02009059|Device|Non-invasive temperature in hypothermia|accuracy of non-invasive temperature measurement in deep hypothermia compared to core temperature
45613933|NCT04861155|Device|SIVA-P3|Digital cough recording: Participants receive a small, wearable data recorder, wear it during waking hours and keep it on the nightstand during sleep for 7x24 hours. The data is sent to a smartphone application, where a cough detection algorithm converts it into time-stamped cough events. Participants respond to questions on their smartphone once a day for additional context data. The cough events and context data are sent to a secure online database for further evaluation. For the first 24 hours, segments of audio data are sent to be able to validate the performance of the cough detection algorithm. Afterwards, only cough events and context data are sent from the participant's smartphone.
45613934|NCT05477719|Device|Wearing of specific compression stockings|The patient will wear specific compression stockings prevent the accumulation of fluids during the day in the lower part of the body and thus limiting the nocturnal drainage effect from the lower part of the body to the upper part of the body
45613935|NCT05452525|Drug|CKD-379 I|1 tablet administration under fed condition
45613936|NCT05452525|Drug|CKD-379 II|1 tablet administration under fed condition
45759496|NCT04539457|Behavioral|E-learning|The e-learning module will be explanatory to the 'Desktop Helper (version 10)' how to perform the case-finding and in what way the case-finding can be beneficial to the patients with COPD and their (co)morbidities. This e-learning module will include several example cases and how to deal with the case-finding and the next steps in the process to reduce the (co)morbidity clashes with the medications of COPD. Together with the decision trees as inferred from the 'Desktop Helper (version 10)', the e-learning module is aimed at inducing a behavioral change in prescribing medication to a patient suffering from COPD and one or more (co)morbidities.
45613937|NCT05452525|Drug|D759+D745+D150|3 tablet coadministration under fed condition
45613938|NCT04584567|Drug|Doxycyclin|daily (100mg)
45613939|NCT04508257|Dietary Supplement|Oral feeding of Investigational Formula (Stage 1&2)|Participants will receive stage 1 formulas up to 180 days of age and then switch to stage 2 formulas though 365 days of age.
45613940|NCT04508257|Dietary Supplement|Oral feeding of Control formula (Stage 1&2)|Participants will receive stage 1 formulas up to 180 days of age and then switch to stage 2 formulas though 365 days of age.
45613941|NCT04508257|Dietary Supplement|Breast feeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
45759497|NCT03805997|Device|Dietary advice|participants will benefit of dietary device 30-minute dietary advice carried out by a doctor at the University Hospital of Rennes, in order to provide nutritional advice adapted to pregnant women.
45445420|NCT03782649|Device|Working Model 3.4NR|Investigational Medical Device collecting spectral Raman data from tissue
45445421|NCT04929249|Drug|Inclisiran|284 mg liquid in prefilled syringe (PFS), 1.5 ml inclisiran sodium (300 mg)
45759498|NCT03805997|Other|Consumption of Bleu-Blanc-Coeur products|consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day
45445422|NCT05518227|Device|The Clareon™ PanOptix™ Trifocal (toric and non-toric models)|Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
45445423|NCT03775863|Procedure|Liver transplantation|Liver transplantation for patients with hepatocellular carcinoma
45445424|NCT03274076|Drug|Tofacitinib|Oral medication tofacitinib 5 mg twice a day for 24 weeks.
45445425|NCT03274076|Drug|Placebo Oral Tablet|Oral Placebo 5 mg twice a day for 24 weeks
45445426|NCT03775707|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
45445427|NCT03775707|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
45445428|NCT03775551|Behavioral|Improvement cycle|at least 6 workshops (sessions) will be held with the members of the care system, in order to identify opportunities for improvement oriented to the design and application of an innovative intervention based on best practices.
45445429|NCT01320501|Drug|Erlotinib|All patients will receive: TarcevaTM 150mg/day PO.
45445430|NCT04442607|Device|artificial intelligence image processing|Patients will undergo a standard colonoscopy performed by a trained endoscopist. A second observer, who is not a trained endoscopist, will follow the procedure on a bedside AI-tool to count the number of detections made by the AI system and categorize the results into positive or negative results as follows (1) true positive, (2) false negative or (3) false positive.
45445431|NCT02764268|Drug|Apatinib|
45445432|NCT01320111|Drug|Paclitaxel and Sorafenib|"intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15~AND~pills (200mg), cycle 1: 400 mg / day cycle 2: 600 mg / day from cycle 3: 800 mg / day"
45445433|NCT01320111|Drug|Paclitaxel|intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15
45445434|NCT03773601|Other|Sleep Profiler|A 4-days sleep monitoring with the use of the Sleep Profiler. Data on objective sleep behavior will be collected.
45445435|NCT03773601|Other|PSQI|Fill the Pittsburgh Sleep Quality Index (PSQI) for the subjective evaluation of sleep.
45445436|NCT03773601|Other|TQR|Fill the Total Quality of Recovery Scale (TQR), every morning for 4 consecutive days, to collect data on subjective perception of recovery,
45613942|NCT04814901|Procedure|Curing small and medium sized oronasal fistula|"Flap will be marked medial to the duct, which limits posterior extent of flap. Anterior flap marking starts 1cm posterior to oral commissure.~Width of flap was kept to about 2-2.5cm.~An initial incision will be made 1cm posterior to oral commissure.~Incision will be deepened through buccal mucosa, submucosa, & underlying muscles into layer of buccal fat.~Flap will be dissected in a retrograde or antegrade manner depending on fistula site, maintaining vessels in a central position in the flap.~Once completely raised, flap inserted & sutured in place while donor site be closed primarily with 4-0 polyglactin (Vicryl) interrupted sutures.~Patient's comparator group will be treated by raising a palatal pedicled flap.~Flap will be outlined extending from palatal mucosa against permanent 2nd molar till permanent canine anteriorly.~It is rotated towards oronasal fistula & secured in place using 4 -0 Vicryl interrupted sutures."
45613943|NCT03354091|Device|FitBit Flex 2|Participants in the intervention Group will wear the FitBit Flex 2 for Three months.
45613944|NCT04777461|Other|Survey on patient's perspectives on the development of an structured education programme for PCOS|The outcome of this survey will help with developing curriculum for the structured education programme.
45613945|NCT04777461|Other|Pre-pilot questionnaire|The questionnaire is aimed to capture the knowledge and expectations of the participants from taking part in the educational sessions.
45613946|NCT04777461|Other|Piloting the structured education programme for PCOS|Piloting the education program through 2 educational group sessions
45613947|NCT04777461|Other|Post-pilot questionnaire|The questionnaire aimed to capture participant's satisfactions and knowledge gained by taking part in the pilot study
45613948|NCT04777461|Other|cognitive outcomes outcome evaluation form|This aimed to capture skills developed, knowledge gained and changes in participants behaviour and perceptions by taking part in the pilot study.
45613949|NCT03349177|Drug|Epirubicin|100mg/m2
45613950|NCT03349177|Drug|Fluorouracil|500mg/m2
45613951|NCT03349177|Drug|Docetaxel|75mg/m2(TC), 100mg/m2(EC-T)
45613952|NCT03349177|Drug|Cyclophosphamide|500mg/m2(FEC), 600mg/m2(EC-T and TC)
45613953|NCT04775667|Other|questionnaires for clinical assessments|questionnaires for clinical assessments
45613954|NCT02518321|Device|Technology-Assisted Toileting|
45445437|NCT01320579|Drug|Cis-UCA 2.5% emulsion cream|2.5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
45613955|NCT04691505|Drug|Methotrexate|Methotrexate is used as the reference group.
45613956|NCT04691505|Drug|Hydroxychloroquine|Hydroxychloroquine is used as the exposure group.
45613957|NCT04507945|Drug|Nutritional Therapy, Metabolic Disorder, Regular|According to the result reported by Byrne, Wilmore, etc. in 1992 ~ 1995, the use of growth hormone, glutamine, modified diet and other measures proposed intestinal rehabilitation treatment. Then, check the patient's quality of life survey, nutritional status, inflammation indicators and other changes every three months, and use metabolomics and microbiomic tools to detect changes in the patient's nutritional metabolism, intestinal microecology, etc., and adjust the patient's nutritional treatment and microecological treatment based on the results Program.
45613958|NCT04653363|Other|assessments|All assesments will be done by the first physiotherapist. But only 3m backward test will be done by the first and second physiotherapist in the first day and second day.
45613959|NCT05400265|Drug|HLX26|Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
45445438|NCT01320579|Drug|Cis-UCA 5% emulsion cream|5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
45445439|NCT01320579|Drug|Placebo for cis-UCA emulsion cream|The placebo for cis-UCA product (emulsion cream base) twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area on of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
45613960|NCT05400265|Drug|HLX10|Humanized Anti-Programmed Death-1 Monoclonal Antibody
45613961|NCT05364619|Drug|Qingre Huashi Granules combined the modified dual therapy|Qingre Huashi Granules combined the modified dual therapy for 14 days
45613962|NCT05364619|Drug|Bismuth containing quadruple therapy|Bismuth containing quadruple therapy for 14 days
45613963|NCT03349021|Device|Bougiecap|Treatment of esophagel Stenosis by Bougiecap
45613964|NCT04433013|Drug|Lianhua Qingwen|The LHQW capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
45613965|NCT04433013|Drug|Placebo|The placebo capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
45613966|NCT03353935|Other|Validated questionnaires|Patients were administered pre- and post-operatively the three validated questionnaires ((FSFI, ICIQ-UI short form Italian, NBD score) investigating sexual, urinary, and fecal function, respectively.
45445440|NCT01320579|Drug|Protopic® 0.1% ointment|0.1% Protopic® twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
45613967|NCT03353857|Drug|levonorgestrel/ Microlut|In Period 1, 0.03 mg single dose administered as 1x0.03 mg tablet on Study Day 1, In Period 2, 0.03 mg single dose administered as 1x0.03 mg tablet on Study Day 15 In Period 3, 0.03 mg single dose administered as 1x0.03 mg tablet at Study Day 26
45613968|NCT03353857|Drug|Norethindrone/ Noriday|In Period 1, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 1, In Period 2, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 15 In Period 3, 0.35 mg single dose administered as 1x0.35 mg tablet at Study Day 26
45613969|NCT03353857|Drug|Desogestrel/ Cerazette|In Period 1, 0.075 mg single dose administered as 1x0.075 mg tablet on Study Day 1, In Period 2, 0.075 mg single dose administered as 1x0.075 mg tablet on Study Day 15 In Period 3, 0.075 mg single dose administered as 1x0.075 mg tablet at Study Day 26
45613970|NCT03353857|Drug|Dienogest/ Visanne|In Period 1, 2 mg single dose administered as 1x2 mg tablet on Study Day 1, In Period 2, 2 mg single dose administered as 1x2 mg tablet on Study Day 15 In Period 3, 2 mg single dose administered as 1x2 mg tablet at Study Day 26
45613971|NCT03353857|Drug|Drospirenone, Ethinylestradiol/ Yasmin|In Period 1, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 1, In Period 2, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 15, In Period 3, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 26,
45613972|NCT03353857|Drug|Midazolam/ Midazolam-ratiopharm|In Period 1, 1 mg single dose administered as 1x0.5 ml oral solution on Study Day 1, In Period 2, 1 mg single dose administered as 1x0.5 ml oral solution on Study Day 15 In Period 3, 1 mg single dose administered as 1x0.5 ml oral solution at Study Day 26
45613973|NCT03353857|Drug|Rifampicin|In period 2, 10 mg (suspension, 0.5 ml) for 11 days at 10 mg/day In period 3, 600 mg (film-coated tablets) for 11 days at 600 mg/day
45613974|NCT04499859|Drug|Ezetimibe 10mg + Rosuvastatin 5mg|Initial use of 10mg of ezetimibe combined with 5 mg of rosuvastatin
45613975|NCT04499859|Drug|Rosuvastatin 20mg|20mg of Rosuvastatin as a standard treatment for AMI patients
45613976|NCT03348943|Behavioral|Right hemiparesis, right upper limb.|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
45613977|NCT03348943|Behavioral|Right hemiparesis, left upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
45613978|NCT03348943|Behavioral|Left hemiparesis, left upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
45613979|NCT03348943|Behavioral|Left hemiparesis, right upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
45613980|NCT03348865|Behavioral|Fertility Life Counselling Aid (FeLiCiA)|The FeLiCiA study is a pilot randomised control trial study of an intervention that uses cognitive behavioral therapy (CBT) method to provide counselling for infertility patients within low resource settings. this intervention is designed for management of the psychological problems associated with having infertility. It is based on the Thinking Healthy Programme by WHO.
45613981|NCT05306899|Drug|Ketamine|Bolus of IV Ketamine 1 mg.kg-1 (= 0.1 ml.kg-1) followed by Infusion of Ketamine 1 mg.kg-1.hour-1 (= 0.5 mL.kg-1.hour-1) for 6 hours. All patients will receive IV midazolam 0.04 mg.kg-1 (maximum 3 mg) and subsequently 0.01-0.02 mg.kg-1 every hour to keep participants in a sedated but arousable state (Ramsay Sedation Scale score 3 or 4) to blind the participants and assessors to group allocation. Ondansetron 8 mg and 8 mg of dexamethasone will be administered to prevent nausea, 5000 units of heparin will be given subcutaneously to prevent thrombo-embolic events.
45613982|NCT05306899|Other|0.9% Saline|Bolus of IV Saline 0.9% of 0.1 ml.kg-1 followed by Infusion of Saline 0.9% of 0.5 mL.kg-1.hour-1 for 6 hours. All patients will receive IV midazolam 0.04 mg.kg-1 (maximum 3 mg) and subsequently 0.01-0.02 mg.kg-1 every hour to keep participants in a sedated but arousable state (Ramsay Sedation Scale score 3 or 4) to blind the participants and assessors to group allocation. Ondansetron 8 mg and 8 mg of dexamethasone will be administered to prevent nausea, 5000 units of heparin will be given subcutaneously to prevent thrombo-embolic events.
45613983|NCT03348787|Behavioral|Behavioral and Cognitive Therapies|"Group intervention of 6 weekly sessions of one hour and 30 minutes based on the psychoeducational therapeutic principles and CBT type 3 wave Accept Voices applied to HAV"
45613984|NCT00807651|Procedure|AHSCT|All study participants given written informed consent will perform autologous hematopoietic stem cell transplantation(AHSCT) and be treated with immunosuppression.
45613985|NCT00807651|Drug|Insulin therapy|All study participants not accepted written informed consent will received insulin therapy with consistent or multiply subcutaneous injection.
45613986|NCT03353623|Device|Serious Game|"Serious Game (SG) refers to the use of immersive virtual environments and wearable haptic devices during the treatment. Two SG were specifically developed to allow a playful training of different, targeted Upper Limb (UL) movement based on typical rehabilitation exercises (reach-to-grasp, linear path tracking, hand orientation). The child interacts directly with a virtual environment through haptic feedback provided to his/her fingertips. In particular, moneybox game focused on pincer grasp and reaching tasks with pronation/supination od the hand while marble labyrinth game focused on pointing and tracking movements requiring both eye-hand and upper limb inter-joint coordination."
45613987|NCT03353623|Other|Conventional Therapy|Conventional therapy (CONV) refers to the neurocognitive rehabilitation approach, with the purpose of improving pointing, tracking, reaching and grasping, and pronation/supination of the forearm. The therapeutic sessions were performed with the exception of the visual channel to ensure that the child focused his/her attention on tactile/kinesthetic information to complete the task. In particular, five different tasks have been proposed during the sessions: 1) recognize trajectories; 2) arm proprioception; 3) object manipulation; 4) recognize surfaces; 5) forearm orientation.
45613988|NCT00752193|Other|Probiotic lactobacilli|Probiotic lactobacilli in combination with antibiotic therapy
45613989|NCT00752193|Other|Placebo|Placebo in combination with antibiotic therapy
45613990|NCT05272267|Other|AI-assisted models providing diagnosis and prognostic information|AI-assisted models providing diagnosis and prognostic information in the ED, including triage, ICD coding, chest x ray alerts, critical event alerts, readmission prediction, and post-cardiac arrest prognostication.
45613991|NCT05272267|Procedure|Critical treatment|Critical treatment of the emergency room
45613992|NCT00700791|Dietary Supplement|Natural Vitamin E Tocotrienol supplement (TCT)|Oral Vitamin E Tocotrienol Supplement (TCT)
45613993|NCT00700791|Device|Natural Vitamin E Tocotrienol Cream (TCT)|Natural Vitamin E Tocotrienol(TCT)Topical Cream
45613994|NCT00700791|Other|Placebo|Oral Placebo
45613995|NCT00700791|Other|Placebo Cream|Topical Placebo Cream
45613996|NCT04502329|Other|Diet|Energy Restriction Intermittent Fasting Diet
45613997|NCT05344365|Drug|Iloperidone|oral tablet
45613998|NCT03348709|Dietary Supplement|Isoosmolar|48 hours, 800 ml per 24 hours
45613999|NCT03348709|Dietary Supplement|Hyperosmolar|48 hours, 800 ml per 24 hours
45614000|NCT05129553|Device|Béa Applicator and Béa Cervical Cap Device|Single-use of the investigational device
45614001|NCT03348553|Dietary Supplement|control group|no supplements given for 16 weeks, after 4 week washout of all supplements and dietetic products
45614002|NCT03348553|Dietary Supplement|Omega2|2 capsules of JP+® Omega/d for 16 weeks, after 4 week washout of all supplements and dietetic products
45614003|NCT03348553|Dietary Supplement|Omega4|4 capsules of JP+® Omega/d for 16 weeks, after 4 week washout of all supplements and dietetic products
45445441|NCT05669001|Biological|TCD601|Investigational Product
45614004|NCT03348553|Dietary Supplement|Omega2+OGV|2 capsules of JP+® Omega/d plus 2 capsules each of an encapsulated fruit, vegetable and berry-juice concentrate (6 capsules) for 16 weeks, after 4 week washout of all supplements and dietetic products
45614005|NCT05343273|Diagnostic Test|taking a blood sample|blood collection for routine biochemical analysis
45614006|NCT04467333|Other|All lung cancer patients.|There will be no specific interventions. All patients will receive guidelines based therapy of lung cancer and their comorbidities.
45614007|NCT05129007|Device|Oura ring|Photopletysmography based noninvasive device
45614008|NCT05128851|Procedure|HTO|Hight Tibial Osteotomy
45614009|NCT05128851|Procedure|Arthroscopy treatment|Arthroscopy treatment
45614010|NCT05128851|Procedure|Micro fractures|Micro fractures
45445442|NCT05669001|Biological|belatacept|Study Product
45445443|NCT05669001|Drug|ATG|Comparator
45445444|NCT05669001|Drug|TAC|Comparator
45445445|NCT05669001|Drug|MPA|Immunosuppression Therapy
45614011|NCT05128695|Other|there is no intervention; the study is observational|there is no intervention; the study is observational
45614012|NCT04501419|Procedure|US-guided breast biopsy|During this study, women with undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.
45445446|NCT05669001|Drug|Corticosteroids|Immunosuppression Therapy
45614013|NCT04501419|Other|Ultrasound-guided breast biopsy training program|This program, developed by experts in Nigeria and the United States of America, certifies that they have the skills required to safely perform these biopsies on patients
45614014|NCT04457115|Procedure|Thoracic paravertebral block|Thoracic paravertebral block performed at T2-T3 and T4-T5 levels with administration of Ropivacaine 0.7% 8 ml for each level
45614015|NCT04457115|Procedure|Erector spinae plane Block|Erector spinae plane block performed at T2 and T5 levels with administration of Ropivacaine 0.5% 12 ml for each level
45614016|NCT05120583|Other|Pilates exercises|Side kick internal/ external rotation with Pilate's band
45614017|NCT05120583|Other|Traditional physical therapy program|strength, flexibility
45614018|NCT04400877|Diagnostic Test|Diagnostic examination for venous thromboembolism|Patients who have done a diagnostic examination for suspected VTE (pulmonary embolism och deep venous thrombosis) within the health care system of Region Östergötland. Patients without matching diagnostic examination but with a new diagnosis of pulmonary embolism or deep venous thrombosis during the same time periods will also be taking into account.
45614019|NCT04373733|Drug|Favipiravir|Anti-viral
45614020|NCT04373733|Other|Standard of care management|Standard of care management for COVID-19
45614021|NCT05403489|Procedure|Bronchoalveolar lavage|In cases approved for bronchoscopy, bronchoalveolar lavage was performed and culture analysis was performed.
45614022|NCT05403489|Procedure|endotracheal aspirate culture|In cases where consent for bronchoscopy could not be obtained, tracheal secretions were aspirated and culture analysis was performed.
45614023|NCT05032521|Biological|collection of biological data|collection of biological data
45614024|NCT05032521|Other|collection of demographic, ventilatory, cardiac echocardiography, arterial and venous gas data|These data are usually measured continuously (monitoring of the resuscitation patient) and recorded on recorded on the resuscitation software.
45614025|NCT05032521|Procedure|Standard treatment|usual management based on the use of drugs according to international recommendations
45614026|NCT05032521|Procedure|stratified treatment according to algorithm|management based on arteriovenous CO2 gradient Stratification of drug use
45614027|NCT05039385|Other|Exercise Program focused on resistance training|"The program will be carried out by a personal trainer. To ensure correct execution, given that the groups will be of a maximum of 5 people. Each session will include:~A) Warm up: movility exercises and coordination games B) Main part: 3 exercises will be included to strengthen different muscle groups (pull , bench press and back squat). Velocity based training (VBT) will be used to control load. 3 sets of 16-30 repetitions mantaining the speed between Light (estimated loss of speed of the series 5-10%).~C) Cool down: feedback with patients based on the work of Stiles-Shields (2015).~Specific training content will focus on safety, while re-educating patients on proper exercise methods, motivation-related attitudes, and transparency on health benefits and potential harms as a result of increased exercise."
45614028|NCT04987515|Procedure|fenestration decompression combined with secondary curettage|First，fenestration decompression was performed. then, patients return every 3 months for follow up. If the cystic cavity area was gradually reduced after one year of follow-up, patients should be considered for secondary curettage surgery.
45614029|NCT04969731|Drug|Immuncell-LC|IV
45614030|NCT04969731|Drug|Gemcitabine|IV
45614031|NCT04921761|Procedure|Conventional epidural|In this group, a 20-gauge multi-orifice catheter was threaded through the cephalic-directed tip of the epidural needle 5 cm into the epidural space.
45614032|NCT04921761|Procedure|Dural puncture epidural|In this group, the dura was punctured by 25G Whitacre needle. After confirmation of CSF flow, the needle was removed and the epidural catheter was threaded.
45614033|NCT03058653|Procedure|Small fluid boluses of 50 ml|Participants will receive small 50ml boluses of fluid up to 250ml in total. The remainder will be given as infusion pump method at a rate of 1000ml/hour which will complete in 15 minutes. In total, the 500ml will be given over 25 minutes.
45614034|NCT03058653|Device|LIDCORapid Monitor|Addition of the LIDCORapid Monitor to measure stroke volume
45614035|NCT04807647|Other|"Orhan OSMAN's track Don't Let Your Baby Cry in the Kolik album will be played on the music player."|white noise will be played while breastfeeding
45614036|NCT04839315|Biological|mRNA COVD19 vaccine|Subjects will receive two doses of mRNA based COVID19 vaccines.
45614037|NCT04489251|Diagnostic Test|Protein Elisa analysis, microRNA analysis, whole exome sequencing|"ELISA Testing Procedure: The circulating levels of BMP 2, 4, 6, 7, 9 and 10, together with activin A and TGF-β as well as CHIP will be measured using streptavidin ELISA assays.~Micro-RNA analysis: From 100µL of plasma, we will prepare small RNA libraries using TruSeq Small RNA Sample Preparation kit (Illumina Inc).~TGF-B mutation evaluation: Blood from subjects with PH will also be analyzed for known genetic mutations in TGF-B pathway using whole exome sequencing."
45445447|NCT01320189|Dietary Supplement|Differences in protein content of meals|Differences in protein content (energy percent) of meals
45614038|NCT05301231|Diagnostic Test|Genomics (DNA Extraction)|"Blood samples for detection of:~Genes for Dyslipidemia BY WES and NGS (4 GWA) (30 cases) Genes polymorphism for NAFLD/NASH BY TaqMan SNP Genotyping Assay on 10 GWAS"
45614039|NCT05301231|Diagnostic Test|Epi-genomics|"blood samples for detection of Expression profiling of plasma microRNAs~PCR array to determine the altered miRNAs for 168 plasma miRNAs (12 cases)~Expression analysis of top 5 altered miRNAs (All)"
45614040|NCT05301231|Diagnostic Test|Proteomics (Glycoproteomics)|blood samples for Identifying glycosylation pattern of five glycoproteins linked with NAFLD/NASH (transferrin, apoC III, haptoglobin, Mac2 binding protein, IgG)
45614041|NCT05301231|Diagnostic Test|Salivary Metabolomics|"Salivary Samples for detecting Salivary Metabolomics~Genome analysis (Identification of microbial strains common among Egyptians BY apid RT-PCR (DNA sequencing: 16S rRNA gene amplicons)~Microbiome related Metabolites Identification using GC-MS Analysis (the top 5 identified microbial-related metabolites) as metabolomics~Meta-genomic assess of three microbiome-related metabolites; lactoferrin, (LPS), (IgA) BY Commercial ELISA kits"
45614042|NCT05301231|Behavioral|Individualized counselling for behavioural modification|"Individualized counselling for behavioral modification (3 sessions):~Nutritional education, Promotion of physical activities and Cognitive & Psychological support"
45614043|NCT02045901|Drug|Diclegis|On Day 1, all participants will take 2 tablets of Diclegis at bedtime. On Days 2 to 14, participants will take 2 tablets of Diclegis at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
45614044|NCT02045901|Drug|Placebo (Sugar Pill)|On Day 1, all participants will take 2 tablets of Placebo at bedtime. On Days 2 to 14, participants will take 2 tablets of Placebo at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
45614045|NCT04899219|Drug|ACT-1014-6470 40 mg|ACT-1014-6470 will be available as soft gelatin capsules for oral administration formulated at a dose strength of 20 mg.
45614046|NCT04888143|Other|questionnaires|evaluation of hearing performance and quality of life questionnaires
45614047|NCT04888143|Other|Evolutionary algorithm|application of the evolutionary algorithm and customized frequency allocation on a separate program.
45614048|NCT04478409|Biological|one additional blood sample during a planned blood test|The study does not change the usual course of care. Only an additional blood sample (4 ml for children under 12 and 10 ml for children 12 and over and adults) during a planned blood test is specific to research (no risk added). The benefit / risk balance therefore remains unchanged with regard to the usual care of patients.
45614049|NCT04473885|Other|Perturbation-based balance training|Participants in the experimental group will receive the balance training under perturbation on Balance SystemTM SD, including limits of stability training, maze control training, random control training. The intervention is 40 min/session, 3 sessions/week for 6 weeks.
45614050|NCT04458363|Biological|Convalescent Plasma (CP)|Once the patient meets criteria for CP infusion (severity of disease and risk factor determination and absence of exclusion criteria), an ABO compatible product will be identified. The CP dose administered will be 10mL/kg/dose (up to 2 units per dose) times two doses per patient for a total dose of 20 mL/kg. Patients will be followed for adverse events and clinical response. Research blood testing will be obtained prior to infusion (baseline) and serially weekly afterwards until clinical resolution. Patients will receive 2 doses equaling 20 mL/kg (if available) of ABO compatible CP over 24-48 hours if they do not experience grade 3-5 adverse events that are possible, probably, or definitely attributed to CP after the first dose. Patients will be followed for adverse events for a minimum of 28 days after the last infusion of CP.
45614051|NCT04458363|Drug|Standard COVID-19 therapies|If clinical status permits, administration of additional COVID-19 therapies should be delayed 48 hours or more from CP infusion completion. Supportive care will be administered by best clinical practice.
45614052|NCT04662411|Dietary Supplement|Placebo|acute intake of 0 mg butyrate and hexanoate
45614053|NCT04662411|Dietary Supplement|butyrate and hexanoate amount 1|acute intake of 650 mg butyrate and hexanoate
45614054|NCT04662411|Dietary Supplement|butyrate and hexanoate amount 2|acute intake of 1325 mg butyrate and hexanoate
45614055|NCT04662411|Dietary Supplement|butyrate and hexanoate amount 3|acute intake of 2000 mg butyrate and hexanoate
45614056|NCT04332861|Other|Initial clinical and laboratory evaluation|"Initial evaluation, prior to administration of any antibiotics if possible, includes history, physical exam, and labs including:~Urinalysis~Urine culture~Blood cultures~Complete blood count with differential~Comprehensive metabolic panel~Lactate~Procalcitonin~Other inflammatory markers"
45614057|NCT01674621|Drug|Abaloparatide Transdermal (50 mcg)|Abaloparatide Transdermal Microneedle Active Patch
45614058|NCT01674621|Drug|Abaloparatide Transdermal (100 mcg)|Abaloparatide Transdermal Microneedle Active Patch
45614059|NCT01674621|Drug|Abaloparatide Transdermal (150 mcg)|Abaloparatide Transdermal Microneedle Active Patch
45614060|NCT01674621|Drug|Abaloparatide Injection (80 mcg)|Abaloparatide Subcutaneous Injection
45614061|NCT01674621|Drug|Abaloparatide Placebo|Abaloparatide Transdermal Microneedle Placebo Patch
45614062|NCT04651179|Other|observation|not applicable, observational study
45614063|NCT04644705|Drug|Niclosamide|Niclosamide will be applied in various dosage steps, galenic preparations and in combination with camostat
45614064|NCT04644705|Drug|Placebo|placebo to the interventional drug
45614065|NCT04248855|Drug|KAN-101|Intravenous (IV) infusion
45614066|NCT04248855|Drug|Placebo|Intravenous (IV) infusion
45614067|NCT04412733|Device|Therapeutic Pulsed Ultrasound|Patients in pulsed ultrasound group received pulsed ultrasound treatment (frequency: 1000 kHz, intensity: 0.5w/cm2, on-off ratio: 1:2). Pulsed ultrasound treatment were applied with 5-cm2 head Enraf-Nonius Sonopuls 434 ultrasound device.
45614068|NCT04412733|Device|Sham Ultrasound|Control group received sham ultrasound treatment
45614069|NCT04095975|Dietary Supplement|Baking Soda|Standard baking soda that can be bought from stores.
45759499|NCT03805997|Other|No consumption of Bleu-Blanc-Coeur products|no consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day. This group will receive Système U vouchers.
45759500|NCT03805997|Biological|Blood sample|the fatty acid profile of the women red blood cells of the woman wil be test at the inclusion and at 21 days post-partum
45614070|NCT04095975|Dietary Supplement|LithoLyte|LithoLyte is considered a medical food and consists of: potassium citrate, magnesium citrate, sodium bicarbonate, and erythritol.
45614071|NCT04038489|Drug|Aspirin|325 mg aspirin daily during AC-T chemotherapy
45614072|NCT04038489|Drug|Tamoxifen Pill|Tamoxifen (either 20 mg daily or 10 mg twice a day) during AC-T chemotherapy
45614073|NCT04038489|Drug|Doxorubicin|Doxorubicin (60 mg/m2) Given by IV with cyclophosphamide
45614074|NCT04038489|Drug|Cyclophosphamide|Cyclophosphamide (600 mg/m2) Given by IV with doxorubicin
45614075|NCT04038489|Drug|Paclitaxel|Paclitaxel 80 mg/m2 or 175 mg/m2 based on provider preference. Given by IV after completion of doxorubicin/cyclophosphamide therapy
45614076|NCT05134077|Procedure|CT scan with contrast|CT scan with contrast is necessary to determine the position of renal cysts, their location, and size (determine volume of atrophic parenchyma will be calculated).
45614077|NCT05134077|Radiation|Nephroscintigraphy|Nephroscintigraphy is necessary to determine the renal function
45614078|NCT04468425|Drug|Tofacitinib Citrate|Period 1: Xelijanz® 5 mg tablet (tofacitinib citrate) for single oral dosing. Period 2: Tofacitinib Citrate Topical Gel 3.2% for repeat topical dosing BID for 14 days.
45614079|NCT05133843|Procedure|Assession of complete coronary physiology|Assession of complete coronary physiology in TAVI candidates with intermediate coronary artery stenosis before and 6 months after TAVI.
45614080|NCT03891771|Device|Telemonitoring sensors|This complex platform entails several sensors aimed at detecting falls, nocturia and environmental variables in the participant's home. Sensors are non-intrusive and its only wearable component is the panic button which must be carried by the participant.
45614081|NCT03830619|Diagnostic Test|collect samples|collect serum samples and clinical features
45614082|NCT04438863|Diagnostic Test|home spirometry|portable hand-held spirometer to collect and store daily spirometric data (including FVC, FEV1, forced expiratory flow after 25 to 75% of vital capacity has been expelled, and peak flow).
45614083|NCT04287855|Drug|Isatuximab|Isatuximab by IV route - Cycle 1 : 10mg/kg on days 1, 8, 15 and 22 per 28 days cycle. After cycle 1 : 10mg/kg on days 1 and 15 per 28 days cycle
45614084|NCT04287855|Drug|Carfilzomib|Carfilzomib by IV route - Cycle 1 : 20/27 mg/m² on days 1-2, 8-9, 15-16 per 28 days cycle. Cycle 2-13 : 56mg/m² on days 1, 8, 15 per 28 days cycle. After cycle 13 : 56mg/m² on days 1 and 15 per 28 days cycle.
45614085|NCT04287855|Drug|Pomalidomide|Pomalidomide by oral route - Cycle 1-2 : 3mg on days 1 to 21 per 28 days cycle. After cycle 2 : 4mg on days 1 to 21 per 28 days cycle.
45614086|NCT04287855|Drug|Dexamethasone|Dexamethasone by oral route - Cycle 1-13 : 40/20 mg on days 1, 8, 15 and 22. Cycle 2-13 : 56mg/m² on days 1, 8, 15 per 28 days cycle. After cycle 13 : 56mg/m² on days 1 and 15 per 28 days cycle.
45614087|NCT03710265|Drug|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
45614088|NCT03640455|Device|Placebo|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; placebo (dummy stimulation), according to the patient's randomization arm.
45614089|NCT03640455|Device|Anodal|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; intensity 2 mA, in anodal polarity, according to the patient's randomization arm.
45614090|NCT03640455|Device|Cathodal|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; intensity 2 mA, in cathodal polarity, according to the patient's randomization arm.
45614091|NCT03531099|Procedure|treatment with focal HIFU|HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
45614092|NCT03531099|Biological|PSA dosage|PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
45614093|NCT03531099|Device|MRI|MRI exam will be regularly performed during patient follow up.
45614094|NCT03531099|Other|Questionnaires|Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function), STAI-YB (State-Trait Anxiety Inventory)
45614095|NCT03531099|Procedure|Prostatic biopsies|Prostatic biopsies will be regularly performed during patient follow up.
45614096|NCT05133609|Biological|ChAdOx1 nCoV-19 vaccine (AZD1222)|ChAdOx1 nCoV-19 vaccine (AZD1222) in a standard 3-dose schedule with an interval of 12 weeks (first-second dose) and 24 weeks (second-third dose).
45759501|NCT03805997|Other|Contact|Participants of the group A will be contacted by phone,sms, mail by a technician every 15 days from 7th month of pregnancy to the 8th month of pregnancy and then every week from the 9th month of pregnancy to the 45th postpartum day (except the week of childbirth), in order to collect their consumption data of the delivered food products.
45759502|NCT03805997|Other|food questionnaire|Participants will have to complete a food questionnaire at the inclusion and at 21 days post-partum
45759503|NCT03805997|Other|newborn faeces sample|Newborn faeces sample will be collected at 21 Days post partum
45759504|NCT03805997|Other|breast milk sample|Breast milk sample will be collected at 21 days and 45 days post partum
45911529|NCT02009072|Procedure|Sutureless and glue free limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 50 eyes of 50 patients (group 1)
45614097|NCT05133375|Procedure|Tracheal Intubation|Before reporting to Operation theatre, a detailed pre anesthesia assessment was done in all patients, all necessary laboratory investigations were collected. On OT table pulse and systolic blood pressure was checked by non-invasive method. 18G cannula was passed and ECG was attached. A pillow was placed under the head to obtain classical sniffing position for intubation. All the patients were pre medicated with injection midazolam 0.08mg/kg, injection nalbuphine 0.1 mg/kg, injection dexamethasone 0.08mg/kg and injection metoclopramide 0.1 mg/kg. Pre oxygenation was done with 100% oxygen for 3 mins. Induction was done with injection propofol2 mg/kg, muscle relaxation achieved with injection atracurium 0.5mg/kg. Laryngoscopy was started after 3 minutes by a qualified anesthetist. Pulse and systolic blood pressure was recorded by non-invasive measures before laryngoscopy and at 30 seconds, 2 and 3 minutes after intubation.
45614098|NCT04258761|Drug|10XB-101 Solution for Injection|Active test article
45614099|NCT04154553|Diagnostic Test|Buccal swab|Pharmacogenetic panel testing is conducted by Stratipharm with the DNA of the buccal swab. TaqMan® polymerase chain reaction is proceeded to express the genetic information. Stratipharm is a product offered by Humatrix Aktiengesellschaft (AG). It consists of a laboratory analysis of approximately 100 pharmacological relevant genetic variations (polymorphisms) in over 30 different genes, which code for transport proteins, metabolizing enzymes, or drug targets.
45614100|NCT04154553|Diagnostic Test|EDTA Blood sample (4.9mL)|Genetic testing of potentially relevant genetic variants using the DNA extracted from the EDTA blood sample.
45614101|NCT04154553|Diagnostic Test|Serum sample (7.5mL)|blood sample to determine the actual levels of the compound in patients on medication assumed to be associated to an observed ADR (phenotype).
45614102|NCT04154553|Other|communication of test results|Certified study pharmacist evaluates and communicates clinically relevant test results to the subject and to the responsible physician
45614103|NCT04154553|Other|unstructured interview|One and six months after the communication of test results, the study center will make a phone call to the patient for an unstructured interview in order to gather information about potential outcomes
45614104|NCT02952885|Drug|Pegvisomant|Study medications will be prescribed as per clinical practice with PEGV being added, or optimally dosed, at the Month 0 visit. Subjects who are naïve to PEGV should start their injections from 10 mg twice a week to 10 mg daily if used as combination therapy or 10 to 20 mg daily if used as monotherapy. Maximum dosing should not exceed 40mg/day. Dosing of PEGV can be adjusted as per clinical judgement to meet the normalization of IGF-1 levels (<1.0 ULN) in increments of 5-10mg/day. In the event of a reduction in IGF-1 below the LLN, the dose of PEGV could be decreased by 5-10 mg/day.
45614105|NCT02183727|Device|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
45614106|NCT02183727|Procedure|Hamstring Autograft|The gold-standard treatment for ACL reconstruction is autograft tissue. Autograft is a piece of tendon harvested from another part of the patient's body, such as the hamstring or kneecap. In this study, the hamstring tendon from the back of the thigh of the injured (target) leg will be harvested and surgically transferred to replace the torn ACL. The attachment of the autologous tendon in the femoral and tibial bone tunnels will utilize techniques that are similar to those for the L-C Ligament. Over time the replacement tendon resorbs and a new ACL is regenerated.
45614107|NCT02113917|Biological|Identification of biological markers|
45614108|NCT01959087|Procedure|single port surgery|Single port surgery can be converted in multiport surgery if necessary
45614109|NCT01959087|Procedure|Multiport surgery|
45614110|NCT04082481|Drug|TAK-988|TAK-988 tablets.
45614111|NCT04082481|Drug|TAK-988 Placebo|TAK-988 placebo-matching tablets.
45614112|NCT04435587|Drug|Ivermectin Pill|3 days of once daily oral ivermectin 600mcg/kg/d
45614113|NCT04435587|Drug|Combined ART/hydroxychloroquine|"Day 1 hydroxychloroquine 400mg bid, Day2-5 hydroxychloroquine 200mg bid~Darunavir/ritonavir (400/100mg) q 12 hours for 5 days"
45759505|NCT01995123|Behavioral|Behavioral Activation Therapy|Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding.
46068940|NCT05134857|Drug|Placebo|The PLO will be supplied at the same schedule and in the same manner (TAD device) as the ZON.
46068941|NCT05120843|Behavioral|Care coordination and motivational interviewing|Interventionist will engage participants in care planning, health education, health care navigation, screening for unmet health needs or social needs, and motivational interviewing. The final intervention is expected to be six months in duration. However during this single-arm open testing phase, some participants may receive only key components of the intervention in order to assess feasibility, reach, adoption, and fidelity of those components.
46068942|NCT05116254|Combination Product|AZD1390 + radiotherapy|AZD1390 combined with preoperative radiotherapy
45911530|NCT02009072|Procedure|Sutured limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutured limbal conjunctival autograft in 100 eyes of 100 patients (group 2).
46068943|NCT05114590|Drug|Insulin glargine/Lixisenatide|Solution for injection in a pre-filled pen by subcutaneous injection
45614114|NCT03849105|Radiation|4-L-[131I]iodo-phenylalanine (131I-IPA)|"Study participants will receive by intravenous infusion an escalating activity of 4-L-[131I]iodo-phenylalanine (131I-IPA).~Additional therapy is received in the form of externally administered radiotherapy"
45614115|NCT04499391|Other|Project ECHO|Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation. This differentiates ECHO from traditional learning and facilitates rapid dissemination of medical knowledge and increased capacity to deliver best-practice care.studying innovative approaches.
45614116|NCT04498221|Procedure|Imaging procedure|During routine examination under anaesthetic 4 x peritumoural injection of Lymphoseek (lymphatic mapping tracer) followed by freehand SPECT scan
45614117|NCT04498221|Procedure|Surgical procedure|Excision of contralateral nodes identified on imaging *(fhSPECT or SPECT/CT*) during routine examination under anaesthetic. Serial sectioning of excised (sentinel) nodes to identify micrometastasis.
45614118|NCT04498065|Biological|Biological data|Biological data
45614119|NCT04498065|Other|Clinical data|Clinical data
45614120|NCT04497909|Behavioral|Mindfulness|Mindfulness online training
45614121|NCT04497363|Device|Brainsonix Pulsar 1002|Each participant will undergo 8 consecutive weekly sessions (each session is 10 minutes long) of focused ultrasound with the Brainsonix Pulsar 1002 device.
45614122|NCT05132751|Device|Machine Learning Ventilator Decision System|Artificial intelligence ventilator system for personalized mechanical ventilation
45614123|NCT03685929|Procedure|Punch skin biopsy|Two punch biopsies will be performed in each patient, one at the border of the skin lesion, and one at the adjacent healthy skin. A disposable biopsy punch of 4 mm will be used. A biopsy punch is a small circular blade (like an apple corer) which is rotated into the skin to obtain a cylindrical specimen. Local anaesthesia will be applied and the circular wound will be closed by a single suture. Sutures will be removed after one week.
45614124|NCT05131893|Drug|Tamoxifen|endocrine therapy
45614125|NCT05131893|Drug|Goserelin|endocrine therapy
45614126|NCT05131893|Drug|Letrozole 2.5Mg Tab|endocrine therapy
45614127|NCT05131893|Drug|Epirubicin|chemotherapy
45614128|NCT05131893|Drug|cyclophosphamide|chemotherapy
45445448|NCT03775083|Drug|Currently approved medications|subjects will be treated according to current Department of Health and Human Services (DHHS) Center for Disease control and prevention (CDC), Society for Healthcare Epidemiology of American (SHEA guidelines for nPEP
45614129|NCT05131893|Drug|Docetaxel|chemotherapy
45614130|NCT05131893|Drug|paclitaxel|chemotherapy
45614131|NCT05131893|Drug|trastuzumab|biological treatment
45614132|NCT05131893|Drug|pertuzumab|biological treatment
45614133|NCT05131893|Drug|Capecitabine|chemotherapy
45614134|NCT03522519|Behavioral|Real world performance of physical activity and arm use|Patients will be assessed by using movement sensors and standard clinical assessments
45614135|NCT03343041|Dietary Supplement|low-carbohydrate nutrition|low-carbohydrate enteral nutrition
45614136|NCT03343041|Dietary Supplement|Standard enteral nutrition|standard enteral nutrition
45614137|NCT05130879|Behavioral|BRAW|"Sessions~Happiness and positivity Understanding strengths and resilience and positive attitude~Cognitive restructuring Identification dysfunctional automatic thoughts in problematic and emotional arousing situations Usage of cognitive -behavioural techniques to evaluate and modify dysfunctional thoughts and beliefs~Behavioural activation Initiation and utilization of behavioural activation techniques for positive change by increasing pleasant events Healthy interpersonal relationships Importance of peer support~Emotion regulation Preventing and managing conflict Emotion regulation abilities~Positive work climate Building supportive work environment Development of supportive collegial relationships Promotion of coworker support~Problem solving Problem-solving work-life problems Work-life balance Bringing it together"
45614138|NCT03222921|Procedure|High tibial osteotomy|Patients undergoing high tibial osteotomy are investigated by a pressure insole for post-operative weight bearing behavior
45614139|NCT03069807|Other|Community/Primary Care|The treatment of Latent Tuberculosis Infection (LTBI) in the community by General Practitioners (Family Doctors) and Pharmacists
45614140|NCT03069807|Other|Hospital/TB Clinic|The treatment of Latent Tuberculosis Infection (LTBI) in the Hospital TB Clinic by specialist doctors and nurses
45614141|NCT03014583|Device|Precision Spectra™ system|Neurostimulation procedures
45614142|NCT05128461|Other|Exercise|M-CIMT-based telerehabilitation will be implemented.
45614143|NCT05128461|Other|Home program|Lower and upper extremity exercises and gait training exercises selected according to the Bobath approach will be given as a home program consisting of 10 same exercises.
45614144|NCT05096013|Other|individual nutritional therapy|Intervention arm: Usual care + individualized nutritional therapy. Patients at risk for malnutrition and sarcopenia will receive a counselling by the nutritional therapist twice a week. The therapists will assess the patient's energy and protein demand in order to develope appropriate individual measures (e.g additional meals or supplements) to increase patients' energy and protein intake. Individual nutritional therapy is already usual care in patients with high risk for malnutrition, but not for patients with only light to moderate risk of malnutrition and risk of sarcopenia.
45759506|NCT01995123|Behavioral|Health and Smoking Education|Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health.
45445449|NCT03775317|Procedure|Video Laryngoscopy|The direct, or conventional, laryngoscopy group will undergo the planned nasotracheal intubation utilizing a Macintosh or Miller laryngoscope for direct visualization of the larynx.
45614145|NCT02901405|Device|Negative Pressure Wound Therapy (ActivVAC, KCI)|
45614146|NCT02901405|Device|Standard dressings|Current absorbent dressing is 'tegaderm with absorbent pad' (3M)
45614147|NCT02889237|Dietary Supplement|Calcium|Immediate administration of daily calcium supplementation for 12 weeks
45614148|NCT02889237|Dietary Supplement|Calcium + low dose vitamin D|Immediate administration of daily calcium and low dose vitamin D (1 sachet CaD 1000/880) supplementation for 12 weeks
45614149|NCT02889237|Dietary Supplement|Calcium + high dose vitamin D|Immediate administration of daily calcium and high dose vitamin D (2 sachets CaD 500/880) supplementation for 12 weeks
45614150|NCT02689167|Drug|Sunitinib|
45759507|NCT01995123|Behavioral|Standard Smoking Cessation Therapy|Standard smoking cessation therapy will be delivered in eight, 20-minute individual sessions over an 8-week period.
45614151|NCT02582697|Drug|Bleomycin (active name: Bleomycin Sulfate)|"Standard Arm: Bleomycin 30,000 international units IV weekly for 3 doses (eg. days 1, 8 and 15 or days 2, 9 and 16 of a 21-day cycle) for 4 cycles.~Accelerated Arm: Bleomycin 30,000 international units IV weekly for 2 doses (eg. days 1 and 8 or days 2 and 9 of a 14-day cycle) for 4 cycles. Followed by Bleomycin 30,000 international units IV weekly for 4 doses."
45614152|NCT02582697|Drug|Etoposide|"Standard Arm: Etoposide 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.~Accelerated Arm: 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles."
45614153|NCT02582697|Drug|Cisplatin|"Standard Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.~Accelerated Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles."
45614154|NCT02582697|Drug|Pegylated G-CSF (Pegfilgrastim)|Standard Arm: 6 mg SCI on day 6 of a 21-day cycle for 4 cycles. Accelerated Arm: 6 mg SCI on day 6 of a 14-day cycle for 4 cycles.
45614155|NCT02582697|Drug|Filgrastim|"Standard Arm: 10 mcg/kg/day on day6, until post-nadir absolute neutrophil count ≥ 1.0 x 10^9/L, of a 21-day cycle for 4 cycles.~Accelerated Arm: 10 mcg/kg/day on day 6, until post-nadir absolute neutrophil count ≥ 1.0 x 10^9/L, of a 14-day cycle for 4 cycles."
45614156|NCT05009511|Behavioral|Learning through feedback|The goal of this investigation is to examine the influence of feedback timing on learning and brain function.
45614157|NCT05292417|Radiation|hypofractionation Radiotherapy|Patients will receive radiation to the target lesion at a dose of 5Gy, 5 fractions a week, or a dose of 8Gy, 3 fractions a week. The course last once or twice depending on the investigator.
45614158|NCT05292417|Drug|sintilimab|200 mg per IV infusion every 21 days until disease progression or participant withdrawal from study or last for two years
45614159|NCT05292417|Drug|GM-CSF|200µg given 7-14 days(until WBC≥40x109/L), every 21 days until disease progression or participant withdrawal from study or last for two years.
45614160|NCT05292417|Drug|Fruquintinib|Fruquintinib will be given 5mg qd for 2 weeks on and 1 week off, Q3W.
45445450|NCT03775317|Procedure|Direct Laryngoscopy|The video-assisted laryngoscopy group will undergo the planned nasotracheal intubation utilizing a Storz C-MAC S Video Laryngoscope to allow for indirect visualization of the larynx.
45445451|NCT01320267|Procedure|Single port laparoscopic right hemicolectomy|above procedure using Roticulating instruments (from Covidien)
45614161|NCT05285241|Other|Multidirectional stepping exercises|These exercises included stepping of the legs in different directions i.e. sideways, sideways and forefoot (forward), sideways and heel (backward).
45614162|NCT05285241|Other|Conventional physiotherapy group|Conventional physiotherapy included a one-to-one range of motion exercises (10min), Strengthening exercises (10 min), Functional mat exercises (10 min), Stretching exercises (5 min), and Gait exercises (10 min)
45614163|NCT02137473|Other|Human milk-based fortifier|
45614164|NCT02137473|Other|Bovine protein-based fortifier|
45614165|NCT01503489|Drug|Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor( SNRI), and Tricyclics.|Risk for antidepressant-associated switch from depression to hypomania, mania, or mixed episode during the 8 weeks after the introduction of an antidepressant or after increasing the dosage of baseline antidepressant.
45614166|NCT04492683|Combination Product|DBV1605|"Ready-to-use atopy patch test for diagnostic use containing 2 distinct patches:~One active patch containing a dry deposit of 180 μg of cow's milk proteins~One control patch with the same design as the active patch but devoid of any formulation."
45614167|NCT04490655|Behavioral|Active somatosensory training|Patients in the experimental group will be required to move the robotic handle using their paretic arm from the start position to a visual target shown on screen. However, patients' paretic arm will be occluded from vision throughout the training session. They will make the reaching movement by depending on their proprioception of the arm position in space, without relying too much on the vision of their arm. Haptic guidance will be provided as somatosensory cues while participants are actively moving. Positive reinforcement will also be given for each successful movement that reaches the target in the form of a pleasant audio tone, visual feedback, and a running score. Assessment will be performed before and after the completion of the whole 15 training sessions.
45614168|NCT04490655|Behavioral|Motor-based training|Patients in the control group will also be required to propel the robotic handle using their paretic arm to a target location. This training covers the same centre-out reaching movements but without any emphasis on proprioception, where the view of the paretic arm will not be occluded. However, no haptic guidance will be provided during the reaching movement. Positive reinforcement will still be given to inform the participants of their trial outcomes. Assessment will be performed before and after the completion of the whole 15 training sessions.
45614169|NCT05137977|Procedure|Intensive Care|Invasive ventilation more than 24hs.
45614170|NCT05250609|Other|"Endocrown composite."|It is a type of restoration has been shown a great success in adult and recently has been suggested for children
45614171|NCT05092737|Procedure|Prone positioning|Prone position during invasive mechanical ventilation
45614172|NCT05137821|Device|Er: YSGG laser|Er: YSGG laser decontamination of infected implant surfaces to simulate peri-implantitis therapy
45614173|NCT05137821|Other|no therapy|new sealed implant without any surface treatment
45445452|NCT03775395|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
45445453|NCT03775395|Drug|Sorafenib|400mg BID daily oral dosing
45445454|NCT03775395|Procedure|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
45445455|NCT03775005|Radiation|standard treatment|3000 cGy in 10 daily fractions
45614174|NCT05059587|Drug|MBA-P01|MBA-P01 will be injected into the Glabellar line.
45614175|NCT05059587|Drug|BOTOX|Botox will be injected into the Glabellar line.
45614176|NCT05137509|Device|Computerized Tomography|Using Computerized Tomography for diagnosis COVID -19 patients
45614177|NCT05137197|Device|Predictix Genetics Antidepressant|Predictix Genetics Antidepressant (PGA) is a software tool that is intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with MDD.
45614178|NCT04560309|Drug|L-alanyl-L-glutamine dipeptide|Intravenous infusion of 0.5 mg/kgbw L-alanyl-L-glutamine dipeptide diluted in normal saline to volume of 500 mL, started after induction of anesthesia for 24 hours.
45614179|NCT04560309|Drug|Placebo|Intravenous infusion of 500 mL normal saline, started after induction of anesthesia for 24 hours.
45614180|NCT05192031|Behavioral|Smoking cessation support|Training healthcare professionals to deliver smoking cessation support as part of hospital-based lung cancer workup.
45614181|NCT05135715|Drug|RC48-ADC|2.0 mg/kg IV every 2 weeks
45614182|NCT05185167|Drug|Anesthetics, General Desflurane Maintenance|Comparison of dna damage of desflurane maintenance with propofol maintenance according to comet analysis
45614183|NCT05185167|Drug|Anesthetics, General Propofol Maintenance|Comparison of dna damage of propofol maintenance with desflurane maintenance according to comet analysis
45614184|NCT04474119|Drug|KN046|In combine therapy stage, KN046 is 5 milligram per kilogram, every 3 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.
45614185|NCT04474119|Drug|KN046 placebo|"In combine therapy stage, KN046 placebo is 5 milligram per kilogram, every 3 weeks.~In maintain stage, KN046 placebo is 5 milligram per kilogram, every 2 weeks."
45614186|NCT05134389|Procedure|One Anastomosis Gastric Bypass|Exposure to One Anastomosis Gastric Bypass
45614187|NCT05133453|Drug|Pirfenidone|drug intake three times daily for one year
45614188|NCT05165823|Behavioral|Sodium restriction|Participants will be guided in minimizing sodium intake. Guidance will be both oral and written. Bread with low sodium content will be offered to the participants.
45614189|NCT05125185|Other|The Effectiveness of USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in Improving Insulin Adherence, Glycemic Control and Inflammation|To study the effect of counseling using USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in improving Insulin Adherence, Glycemic Control and Inflammation
45614190|NCT05008341|Drug|Solriamfetol 150 mg Oral Tablet|Single-dose 150 mg tablet orally administered.
45614191|NCT05121363|Drug|TQB2858 injection|TQB2858 is an anti-programmed death receptor 1(anti-PD-1) /Transforming growth factor-β(TGF-β )bi-functional fusion protein
45614192|NCT05121363|Drug|Anlotinib Hydrochloride capsules|Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
45614193|NCT04244877|Drug|Rifaximin|Drug: Rifaximin tablet
45614194|NCT05129319|Drug|prabotulinumtoxinA|Injection of glabellar rhytids
45614195|NCT05305833|Biological|Stem Cells|ATMP
45614196|NCT04495179|Drug|AZD4635|Subjects will receive AZD4635 orally daily
45614197|NCT04495179|Drug|Durvalumab|Subjects will receive intravenous durvalumab every 4 weeks for Arm A and every 3 weeks for Arm B.
45614198|NCT04495179|Drug|Cabazitaxel|Subjects will receive intravenous cabazitaxel every 3 weeks
45614199|NCT04494945|Procedure|Biospecimen Collection|Undergo collection of saliva sample
45614200|NCT04494945|Other|Genetic Counseling|Receive genetic counseling if testing results are positive
45759508|NCT00781079|Behavioral|Consumer Provider|Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
45445456|NCT03775005|Radiation|short course treatment|1800 cGy in 4 fractions administered twice a day
45445457|NCT02797522|Drug|ARC-521 Injection|
45445458|NCT02797522|Other|Placebo|0.9% normal saline
45614201|NCT04494945|Other|Genetic Testing|Undergo genetic testing
45445459|NCT02797522|Drug|antihistamine|Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with an oral antihistamine, selected by the investigator from the list of approved antihistamines that is available in that country. Approved antihistamines are: diphenhydramine 50 mg by mouth (PO), chlorpheniramine 8 mg PO, or hydroxyzine 50 mg PO.
45614202|NCT04494945|Other|Survey Administration|Complete a survey
45614203|NCT05118945|Device|Insulin pump Tandem: t:slim X2|"Insulin pump with Hybrid-Closed Loop - Modus. The insulin pump t:slim X2 from the manufacturer Tandem, in cooperation with the glucose sensor DexCom G6, has the option of using an algorithm called control IQ, which controls the insulin delivery semi-automatically by means of an MPC algorithm. For this purpose, the insulin basal delivery can be increased or decreased by the system. Furthermore, automatic bolus deliveries, which are possible in the amount of up to 60% of a manual correction, can be delivered."
45614204|NCT05114655|Other|Herbaceous Essential Oil Blend|Participants are given a diluted proprietary oil blend of aromatic extracts from resins, bark, and flowers to apply three times daily for the purposes of inhalation.
45614205|NCT05114655|Other|Citrus Essential Oil Blend|Participants are given a diluted proprietary oil blend of aromatic extracts from citrus peel, and flowers to apply three times daily for the purposes of inhalation.
45614206|NCT05114655|Other|Inert Oil|Participants are given an inert vegetable based oil blend to apply three times daily for the purposes of inhalation.
45614207|NCT02730169|Drug|BGS649|Capsules were taken weekly for a maximum of 24 weeks
45614208|NCT02730169|Drug|Placebo|Capsules were taken weekly for a maximum of 24 weeks
45614209|NCT05105763|Other|Sequential switched feedback training on the knee and the hip (Condition A)|Condition A will include four 6-mins training blocks: 2-mins knee joint feedback-on, 2-mins hip joint feedback-on, and 2-mins feedback-off. Training with feedback on will occur as follows: The subject will walk on the treadmill and try to achieve the target hip and/or knee flexion pattern shown on the feedback interface. Training with feedback off will occur as follows: The subject will walk on the treadmill and try to maintain the pattern without any form of visual or verbal feedback.
45614210|NCT05105763|Other|Feedback training on the knee alone (Condition B)|Condition B will include four 6-mins training blocks: 4-mins knee joint feedback-on and 2-mins feedback-off. Training with feedback on will occur as follows: The subject will walk on the treadmill and try to achieve the target hip and/or knee flexion pattern shown on the feedback interface. Training with feedback off will occur as follows: The subject will walk on the treadmill and try to maintain the pattern without any form of visual or verbal feedback.
45614211|NCT05305131|Drug|cisplatin and gemcitabine|Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2
45614212|NCT05305131|Drug|induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab.|Day -7 (+/-1 day): IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2+ IV pembrolizumab 200mg over 30 minutes Day 8: IV Gemcitabine 1000mg/m2 Day 15 (for cycles 1 and 2 only): IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes
45911531|NCT02009098|Drug|Cefuroxime|iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
45614213|NCT03353467|Procedure|Endoscopic surgery|Endoscopic nasopharyngectomy included endoscopic resection, with or without posterior pedicle nasal mucoperiosteal flap resurfacing the nasopharyngeal defects.
45614214|NCT03353467|Radiation|Intensity-modulated radiotherapy|All of the patients were received irradiation by IMRT. The target volumes were delineated according to a previously described institutional treatment protocol, which is in accordance with the International Commission on Radiation Units and Measurements reports 50 and 62.
45614215|NCT05101317|Drug|HMI-115|HMI-115 is human monoclonal antibody
45614216|NCT05101317|Drug|Placebo|Placebo
45614217|NCT03122665|Drug|Nefopam Low dose|Continuous intravenous infusion at 0.5 mg/ml for three hours.
45614218|NCT03122665|Drug|Nefopam High dose|Continuous intravenous infusion at 1.0 mg/ml for three hours.
45614219|NCT05099913|Drug|Deanxit|Central neuromodulators was applied in refractory FD patients for different time
45614220|NCT03346993|Drug|Bupivacaine Hydrochloride 5 MG/ML|Ultrasound guided infraclavicular brachial plexus block with warmed bupivacaine
45614221|NCT05304975|Behavioral|diet|Participants will be provided with written dietary education, meal plan, recipe ideas, tips and suggestions at their baseline visit. Participants will then meet online with the study nutritionist for around 90 minutes for personal dietary advice which will be based on the latest evidence from the MIND (Mediterranean-DASH diet Intervention for Neurodegeneration Delay) diet tailored for the target population. The nutritionist will support participants to set personal dietary goals and to monitor progress in changing towards the MIND diet. If weight loss is indicated, the nutritionist will also advise energy intake to facilitate 5-10% body weight reduction. Following the initial appointment, review meetings with the nutritionist will take place monthly in the first four months, either online or by telephone and lasting up to 60 minutes
45614222|NCT05304975|Behavioral|cognitive stimulation|Cognitive stimulation will be delivered using Brain HQ® (Posit Science), a computer based cognitive training platform, which utilises games to enhance attention, mental processing speed, learning, memory, and low mood. On 2 occasions during the first month participants will receive a 30-60min training. The aim is to familiarise participants with games and program processes to optimise engagement with the programme.The cognitive training application is available to download on a range of devices. Following training, participants will be asked to log in and complete the training session at least 4 days per week. Each session is expected to last 30 minutes. Individual cognitive training performance will be recorded centrally. Participants will receive feedback of percentage improvement in performance. The program allows remote monitoring of frequency of use and engagement. Therefore, performance, frequency, duration, and type of use will be recorded centrally throughout the study period
45614223|NCT05304975|Behavioral|physical activity|The exercise intervention will be delivered remotely. Participants will undergo a physical performance assessment at baseline and receive a home exercise written resource that has been designed for older adults and adapted for the current study. It is expected that participants will begin with a basic level of exercise that will increase in frequency and intensity over the first 4 weeks to reach a core required level. In week one, participants will meet online with the trained exercise instructor for around 60 minutes to plan a personalised exercise programme. The instructor will explain the basics of exercise prescription, the foundations of the personal home programme and safety aspects. The instructor will facilitate appropriate exercise goal setting and demonstrate the exercises within the personal programme. Participants will be advised to wear the study pedometer to record their walking activity and complete the exercise diary to record overall step count and daily exercise.
45614224|NCT05304975|Other|risk factor management|Metabolic and vascular risk factor management. At each study visit (baseline, month 4, month 6 and month 9), participants will be informed by the research nurse about their blood results, weight and blood pressure and will receive recommendations to visit their GP to change treatment as necessary
45759509|NCT01982643|Drug|naltrexone plus bupropion|Participants will receive a monthly injection of extended-release depot naltrexone (XR-NTX; as Vivitrol®) plus once-daily bupropion extended-release tablets (BRP; as Wellbutrin XL®) for 8 weeks.
45759510|NCT01996839|Drug|Loteprednol Etabonate Gel (BID)|One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
45759511|NCT01996839|Drug|Loteprednol Etabonate Gel (TID)|One drop of LE gel instilled into the study eye three times per day (TID) for 14 days.
45759512|NCT01996839|Drug|Vehicle (BID)|One drop of vehicle instilled into the study eye two times per day (BID) for 14 days
45759513|NCT01996839|Drug|Vehicle (TID)|One drop of vehicle instilled into the study eye three times per day (TID) for 14 days
45759514|NCT00797797|Drug|No Treatment Added|No added treatment
45759515|NCT00797797|Drug|Milnacipran Added|Milnacipran 100 mg/d added
45759516|NCT01996917|Device|Prineo|After a Wise pattern breast reduction, one breast will have final layer closure with Prineo, while the other breast will be closed in the standard fashion with sutures.
45759517|NCT03496233|Drug|Elbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier]|Treatment with EBR/GZR Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients, with non- severe fibrosis, with or without IR and/or DM
45935006|NCT00213265|Biological|Pneumococcal 7-valent Conjugate Vaccine|"Healthy infants: The Prevnar schedule for healthy infants consists of 3 doses of 0.5 ml each, at approximately 2 month intervals, followed by a fourth dose of 0.5 ml at 12-15 months of age (i.e., 2, 4, 6, and 12-15 months)~Previously unvaccinated older infants and children, who are beyond the age of the routine infant schedule, should receive the follwong schedule:~7-11 months of age: 3 doses (2 doses at least 4 weeks apart with the third dose after the first birthday and separated from the second dose by at least two months)~12-23 months of age: 2 doses (at least 2 months apart)~≥24 months through 9 years of age: 1 dose"
45935007|NCT00213304|Biological|varicella vaccine (VARIVAX)|
45445460|NCT02797522|Drug|acetaminophen|Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).
45759518|NCT04482673|Drug|Daily Vitamin D3|6000 IU vitamin D3 daily
45759519|NCT04482673|Drug|Daily placebo|Placebo daily
45759520|NCT04482673|Drug|Bolus vitamin D3|Bolus 20,000 IU vitamin D3 daily for 3 days
45759521|NCT04482673|Drug|Bolus placebo|Bolus placebo daily for 3 days
45614225|NCT03346915|Behavioral|WoW and BNI|The Text/web based health information technology system, WoW, will provide educational resources for participants and their families to learn more about HPV vaccination and cervical cancer screening. WoW will be tailored to the participant and will be based on the participant's cancer screening and HPV vaccine health needs; It will then send custom text messages based their concerns and will remind them to schedule and attend their doctor's appointment. The brief negotiated interview will encourage and empower participants to have positive behavioral changes in regards to their health.
45614226|NCT05060601|Procedure|Gracey micro-curettes|Mechanical debridement will be performed by means of ultrasonic scalers with specific thin tips and micro-curettes, in order to minimize trauma for gingival tissues.
45614227|NCT05060601|Procedure|Standard Gracey curettes|After local anaesthesia, non surgical subgingival debridement will be performed by standard Gracey curettes
45614228|NCT03346837|Drug|BMS-986205|BMS-986205
45614229|NCT03346837|Drug|Itraconazole|Oral solution
45614230|NCT03346837|Drug|Rifampin|Tablet
45614231|NCT04987905|Other|Mindfulness|"In the study, for 60 minutes once a week for 8 weeks MIND-BE program will be applied to nurses. The program includes formal and informal practices of mindfulness (Getting started, Introduction to MIND-BE, Noticing the autopilot, Power of attention, Simple awareness, Eating awareness, Body awareness, Breath awareness, Sitting awareness, Stress and reactions, Vision awareness, Challenging emotions and situations in business life, Awareness in business life, Awareness and communication, Awareness and compassion, Developing your own practice)."
45614232|NCT04564521|Drug|Nitroglycerin|Intravenous nitroglycerin (0.5mcg/kg/min) is infused after the induction of general anesthesia and during intra-arterial chemotherapy to reduce the cardio-respiratory side effects.
45614233|NCT04564521|Drug|Normal saline|Intravenous normal saline is infused after the induction of general anesthesia and during intra-arterial chemotherapy as an active comparator.
45614234|NCT05158621|Procedure|blood collection for research (next generation sequencing [NGS])|participants will have whole blood collected for NGS
45614235|NCT05158621|Procedure|blood collection for research (HLA typing)|participants will have whole blood collected for HLA typing
45614236|NCT05158621|Procedure|blood collection for research (circulating tumor DNA [ctDNA])|participants will have whole blood collected for ctDNA detection
45614237|NCT05035797|Procedure|Cardiopulmonary rehabilitation|Cardiopulmonary rehabilitation program which encompasses six evidence-based components according to literature review: 1) positioning; 2) passive range of motion (PROM) training; 3) neuromuscular electronic stimulation (NMES); 4) surface electrical phrenic nerve stimulation (SEPNS); 5) PNF techniques; and 6) airway clearance techniques; Usual care normally comprises pharmacotherapy, mechanical ventilation, continuous renal replacement therapy (CRRT), intra-aortic balloon pump (IABP), and specific nursing for ECMO therapy and their original injuries, as appropriate.
45614238|NCT05035797|Procedure|Usual care|Control group will be treated with usual care and ECMO therapy. Usual care normally comprises pharmacotherapy, mechanical ventilation, continuous renal replacement therapy (CRRT), intra-aortic balloon pump (IABP), and specific nursing for ECMO therapy and their original injuries, as appropriate.
45614239|NCT05304429|Behavioral|nutrition education|Educational sessions with topics that will address the management and prevention of frailty syndrome focusing on protein intake and physical activity
45614240|NCT05304429|Behavioral|nutritional counseling|nutritional counseling system based on the com-b model through three strategies: goal setting, self-monitoring and social support
45614241|NCT03348891|Other|Tumor biopsy specimens and blood samples|Tumor biopsy specimens (if feasible) and blood samples will be collected at Baseline, Week 6 Day 1 (blood sample only) and Week 12 Day 1.
45614242|NCT05304117|Behavioral|Advance Care Planning|Community Information Session and Private Sharing Session with trained social worker
45614243|NCT03348475|Behavioral|Binge Focused Therapy (BFT) Intervention|The intervention, Binge Focused Therapy, is a 3-session, 8-week, non-expert guided self-help program. Participants will attend sessions at Week 1, Week 2, and Week 8 at the Nova Scotia Health Authority Eating Disorder Clinic. Each session will be approximately 2 hours in length.
45614244|NCT03348397|Procedure|right ventricular outflow tract reconstruction with contegra|Contegra pulmonary valved conduit is an animal jugular vein that contains a valve with three leaflets that are similar to a human heart valve.
45614245|NCT03348397|Procedure|right ventricular outflow tract reconstruction with pulmonary homograft|cryopreserved pulmonary homografts
46068944|NCT05109325|Behavioral|IntERact|The IntERact intervention includes: (1) three remotely delivered Health Coach therapist sessions that integrate behavioral therapy (motivational interviewing [MI] + cognitive behavioral therapy [CBT] and strengths-based care management (CM); as well as, (2) an APP supporting and enhancing the therapist intervention by: (a) conducting automated daily assessments; (b) delivering daily MI/CBT messages tailored by the daily surveys; (c) delivering GPS-enabled alert notifications and immediate one-touch pro-social support; (d) providing access to reminders regarding goals/strengths from the ED session, CBT tools/skills (e.g., infographics, coping strategies, harm reduction strategies), and other psychoeducation (e.g., safe storage); (e) facilitating one-touch contact with pro-social support, including the health coach and others; (f) providing easy linkage to care management resources (web links, phone numbers, contact information).
45614246|NCT02956317|Drug|STP705|The Cotsiranib drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and Cox-2 mRNA respectively, and formulated in nanoparticles with Histidine-Lysine co-Polymer (HKP) peptide at a ratio of 1:4 in mass weight (siRNA:peptide), which is further formulated into a dry powder drug product. The administration route would be intra-dermal injection.
45614247|NCT02956317|Drug|Placebo|Normal Saline
45614248|NCT03353155|Behavioral|Usual Care|
45614249|NCT03353155|Behavioral|CareHub|
45614250|NCT02517931|Procedure|Sphenopalatine Ganglion Block|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1mL of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
45614251|NCT02517931|Procedure|Placebo|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e. K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
45614252|NCT05303961|Drug|SA001 240mg + Rebamipide 200mg or Placebo|Cohort 1 in the Part1(Single dose): Study drug(SA001 240mg + Rebamipide 200mg), Comparator: Placebo
45614253|NCT05303961|Drug|SA001 480mg or Placebo|Cohort 2 in the Part1(Single dose): Study drug(SA001 480mg), Comparator(Placebo)
45614254|NCT05303961|Drug|SA001 710mg + Rebamipide 600mg or Placebo|Cohort 3 in the Part1(Single dose): Study drug(SA001 720mg + Rebamipide 600mg), Comparator(Placebo)
45614255|NCT05303961|Drug|SA001 1,080mg or Placebo|Cohort 4 in the Part1(Single dose): Study drug(SA001 1,080mg), Comparator(Placebo)
45614256|NCT05303961|Drug|SA001 360mg or Placebo|Cohort 5 in the Part2(Multiple dose): Study drug(SA001 360mg), Comparator(Placebo)
45614257|NCT05303961|Drug|SA001 720mg or Placebo|Cohort 6 in the Part2(Multiple dose): Study drug(SA001 720mg), Comparator(Placebo)
45614258|NCT05303961|Drug|SA001 1,080mg or Placebo|Cohort 7 in the Part2(Multiple dose): Study drug(SA001 1,080mg), Comparator(Placebo)
45614259|NCT03353077|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
45614260|NCT04974333|Device|Mobile health application on phone|Patients will use a mobile app on their smart phones
45614261|NCT03122353|Drug|Calcipotriene and betamethasone suspension|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
45614262|NCT03122353|Drug|Taclonex|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
45614263|NCT03122353|Drug|Placebo|vehicle used as placebo
45614264|NCT04970433|Procedure|Electroacupuncture (EA)|Acupuncture at Hegu (LI4), Neiguan (PC6), Zusanli (ST36), Sanyinjiao (SP6) and Sishencong (EX-HN1). Electrical stimulation with a pair of electrodes connecting on LI4/PC6 and ST36/SP6.
45614265|NCT04970433|Procedure|Laser acupuncture (LA)|The laser applies to each point for 40 seconds, which delivers 3 J of energy at each of the acupoints as those in electroacupuncture group.
45614266|NCT04970433|Procedure|Sham laser acupuncture (SLA)|The laser device without any laser output applies on the acupoints the same as those in the LA group.
45614267|NCT03122275|Other|Customized text message invitation ( Step 1a)|Personalized text messages, automatically sent by Smart Message v.3.1 software. These text messages intend to invite women to cervical cancer screening
45614268|NCT03122275|Other|Customized automatic phone call invitation (Step 1b)|Personalized phone call, not operator dependent, automatically sent by Smart-Interactive Voice Response v.1.1 software These phone calls intend to invite women to cervical cancer screening
45614269|NCT03122275|Other|Secretary phone call (Step 2)|Manual phone call, performed by a trained secretary. These phone calls invite women to cervical cancer screening, but will only be used after automatic strategies (customized text messages and phone calls)
45614270|NCT03122275|Other|Health professional face-to-face appointment (Step 3)|"Women randomized to experimental arm, who do not undergo cervical cancer screening after automatic invitation or manual phone call, receive this intervention. First, women are contacted through a phone call, performed by a health professional, inviting them for a face-to-face appointment at her primary care unit.~During appointments, the health professional understands possible barriers felt by women for not undergoing cervical cancer screening. Health professionals will try to overcome these barriers, using pre-defined arguments and facts. Finally, women are invited to perform screening."
45614271|NCT03122275|Other|Written Letter|"A written letter will be used to invite eligible women to cervical cancer screening.~This intervention will be used only for women randomized to active comparator arm."
45614272|NCT05303259|Drug|Bevacizumab|Bevacizumab 2.5mg/kg, q2w, 4 cycles.
45614273|NCT03121963|Drug|Oxycodone|oxycodone tablet
45614274|NCT03121963|Drug|Acetaminophen|acetaminophen tablet
45614275|NCT03121963|Drug|Gabapentin|gabapentin tablet
45614276|NCT03121963|Drug|Celecoxib|celecoxib tablet
45614277|NCT03121963|Drug|Hydrocodone-Acetaminophen|hydrocodone 5 mg/acetaminophen 325 mg tablet
45614278|NCT05051787|Biological|Blood and milk samples|"2 types of samples will be taken over the same time slots in breastfeeding mothers treated with amoxicillin for at least 2 days:~3 breast milk collections of about 20 ml each made using an electric breast pump provided to the participant.~3 blood samples of approximately 5 ml each."
45614279|NCT04507789|Other|exercise intervention|Exercise protocol will consist of the recommended special exercise sets for upper extremity problems on mastectomy patients. The upper extremity protocol has published in 2018 by Richmond and friends called prevention of musculoskeletal shoulder problems after breast cancer treatment UK-PROSPER protocol.this special protocol has unique exercise sets for to restore shoulder range of motion, to maintain good force level of upper extremity muscles and stretch exercises especially to the muscles around the radiotherapy area. Exercises will be done under the supervision of a specialized physiotherapist about upper extremity disorders.
45614280|NCT04507789|Other|routine radiotherapy protokol|This intervention is only an observation to patients during their routine radiotherapy protocol. There will be no exercise intervention for the upper extremity for the patient in this group.
45614281|NCT04502251|Drug|Low-Dose Naltrexone|4.5mg daily dose, orally, during 26 days
45614282|NCT04502251|Device|Transcranial Direct Current Stimulation|An anodal electrode was placed on the scalp above the primary motor cortex (M1), contralateral to the dominant cortex. The cathodal electrode was placed on the supraorbital contralateral area. The current used was 2mA during 20 minutes.
45614283|NCT04502251|Drug|Placebo|The capsule presented the same format, size and color as LDN capsules, however the excipient used was starch.
45445461|NCT02797522|Drug|entecavir|Participants take entecavir OR tenofovir daily throughout the study.
45614284|NCT04502251|Device|Sham Transcranial Direct Current Stimulation|Sham-tDCS stimulation consists of an active current during 30 seconds
45911532|NCT02009111|Behavioral|Couple CARE for Parents|Couple CARE for Parents is a skill-based relationship enhancement program based on a self-regulatory model. It consists of seven sessions and two follow-up booster sessions that occur over the baby's first eight months of life. The first home visit is scheduled 7 - 14 days following recruitment. The next two sessions are scheduled in two week intervals. Sessions 4 through 7 are scheduled in three week intervals. Home visits are expected to last 1.5 to 2 hrs. Out-of-session viewing of the video and completing the exercises typically requires 45 min to 1 hr. The typical phone consultation lasts 15- to 30- min per person. Thus, the program lasts a minimum of 8 to 12 hours. The program will also include two booster sessions (beyond the 8 - 12 hrs).
45911533|NCT02009124|Biological|Autologous bone marrow mononuclear cell transplantation|Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
45911534|NCT02009137|Device|EVERA|EVERA apply for 12 weeks
45614285|NCT04962087|Behavioral|Experimental: Health enSuite Insomnia|Health enSuite: Insomnia has been designed based on established cognitive behavioural treatments for insomnia and adapted to fit an automated interactive platform available via an internet enabled device. The program is divided into a series of treatment modules or levels that will be delivered over the course of 6-8 weeks. The content of these 6 levels includes the following components, a sleep diary, sleep restriction clock, sleep hygiene, relaxation techniques, sleep related thoughts and beliefs, and involving a support person.
45614286|NCT04962087|Behavioral|Experimental: Health enSuite Insomnia - Deprescribing|All participants in Trial 2 will be initiating a gradual medication tapering schedule recommended to them by their physician. The module physicians use to refer their patients to the study includes a section where they fill out a brief drug history for sleep medications. This information is then used to generate a tapering schedule that the health care provider will review with their patient. Health care providers are responsible for providing appropriate medication counselling and follow-up care to supervise deprescribing. This study does not place any restriction on the usual care participants will receive.
45614287|NCT03348319|Other|radiation|Scanning cadaver organs
45614288|NCT03348241|Drug|Gum Arabic|Gum acacia, also known as Gum Arabic is exuded from acacia trees; mainly from Acacia Senegal (gum Hashab or Kordofan gum) which was used in this study.
45614289|NCT03348241|Drug|Chemotherapy|Patients of control group and study group (Gum Arabic group) received chemotherapy according to type and stage of cancer.
45614290|NCT03348241|Behavioral|Lifestyle counseling|Lifestyle counseling pertaining to the optimal nutrition and daily routine for oral hygiene.
45614291|NCT02648217|Drug|insulin degludec/insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
45614292|NCT02648217|Drug|biphasic insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
45614293|NCT04507399|Behavioral|Liquid Model|"To study the perception of whey beverages using sensory methods (rating drying as well as discrimination tests which is the stronger in drying)~Measuring mucoadhesion via protein content remaining in saliva following swallowing of whey protein and whey permeate beverages."
45614294|NCT03122041|Drug|Sitagliptin|
45614295|NCT03122041|Behavioral|Lifestyle intervention|
45614296|NCT04943679|Drug|Anti-PD-1/PD-L1|Intravenous injection for up to 2 years
45614297|NCT04943679|Drug|PEG-Interferon Alfa|3 µg/kg every week by subcutaneous injection for up to 2 years
45614298|NCT04507165|Procedure|Paravertebral block+Anterior serratus plane block|"Paravertebral block will be performed at T3 and T7 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.5% ropivacaine 10ml at each injection site. Anterior serratus plane block will be performed at the 4th rib level on the surgical side under ultrasound-guided, with 0.5% ropivacaine 15ml. The blocking range is measured by ice cube method 15 minutes after the procedure."
45911535|NCT02009137|Device|ESTES|ESTES apply for 12 weeks
45614299|NCT04507165|Drug|opioid free anesthesia|"Anesthesia induction: Dexmedetomidine 1µg/kg (intravenous infusion within 10min), propofol 1.5-2mg/kg (intravenous bolus), lidocaine 1.5-2mg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus), and 0.5% tetracaine 5ml for surface anesthesia of the throat.~Maintenance of anesthesia: Continuous infusion of propofol and dexmedetomidine [0.4μg/(kg.h)]. The infusion rate of propofol was adjusted according to bispectral index value. Cisatracurium besylate was given as needed. Flurbiprofen 50mg was given intravenously before the skin incision and suture respectively.~Remedy: If blood pressure rises (more than 30% of the mean arterial pressure after induction), and heart rate increases (more than 30% of heart rate after induction) during skin incision, lidocaine 1.5mg/kg will be given intravenously and then be continuously infused at a rate of 1.5mg/(kg.h)."
45911536|NCT02009189|Drug|2% Taurolidine Lock|Catheter lock with 2% Taurolidine
45911537|NCT02009189|Drug|1.35% Taurolidine|Catheter lock with 1.35% Taurolidine + citrate
45911538|NCT02009202|Drug|polyethylene glycol|
45911539|NCT02009202|Drug|picosulphate|
45911540|NCT02009215|Drug|Dihydroartemisinin-piperaquine (DP)|Intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be delivered to participating students monthly, for up to 6 rounds of treatment during one school year. DP will be given once a day for 3 days, using full strength tablets (40/320mg) according to weight-based guidelines. Treatment will be directly observed, and will not be blinded.
45911541|NCT02009228|Procedure|Ovarian cystectomy|
45911542|NCT02009241|Other|Pulmonary Rehabilitation|
45911543|NCT02009254|Other|Dietary treatment|
45911544|NCT02009267|Device|Patient controlled analgesia|A programable electronically controlled infusion pump that delivers an amount of intravenous analgesic when the patient presses a button.
45911545|NCT02009267|Procedure|Continuous thoracic epidural infusions|Continuous thoracic epidural infusions (TE) involves continuous infusion of drugs through a catheter placed into the epidural space, resulting in a loss of sensation-including the sensation of pain-by blocking the transmission of signals through nerve fibers in or near the spinal cord.
46068945|NCT05108935|Drug|Suboxone|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
45614300|NCT04507165|Drug|opioid based anesthesia|"Anesthesia induction: Propofol 1.5-2mg/kg (intravenous bolus), sufentanil 0.3μg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus).~Maintenance of anesthesia: Continuous infusion of propofol and remifentanil. The infusion rate of propofol was adjusted according to BIS value. The infusion rate of remifentanil was 0.1-0.5µg/(kg.min) and adjusted according to the change of heart rate and blood pressure. Cisatracurium besylate was given as needed. Sufentanil 0.1μg/kg and flurbiprofen 50mg were given intravenously before the skin incision and suture respectively."
45614301|NCT02315469|Other|Comprehensive Geriatric Assessment|Complete pre-operative geriatric assessment
45614302|NCT02315469|Other|Questionnaire Administration|Ancillary studies
45614303|NCT05585437|Procedure|gastric cancer specialist training program|The gastric cancer specialist training program includes technical training and non-technical training. The technical training includes 1. The whole process of laparoscopic gastric cancer surgery technical teaching 2. Operation practice 3. Operation video review, non-technical training includes 1. Difficult case discussion 2. Specialists Session 3. Lymph node sorting training.
45614304|NCT04507087|Behavioral|Documentary|A 20-minute documentary about the health, environmental, and animal welfare consequences of eating meat and animal products
45614305|NCT04507087|Behavioral|Control|"A 20-minute unrelated video (a motivational talk entitled Listening to shame)"
45614306|NCT05585359|Other|injectable platelet rich fibrin augmented with Vitamin C|According to the amount of the injectable platelet rich fibrin that will be obtained after the centrifugation of blood, the amount of Vitamin C will be calculated to be; for each 1 ml of injectable platelet rich fibrin, 250 μg of Vitamin C will be mixed with the i-PRF and injected inside the canals using a plastic syringe with a 25-gauge needle that was placed 1mm short of the working length and will be withdrawn gradually while injecting till reaching the canal orifice
45614307|NCT03348085|Other|No intervention|No intervention.
45614308|NCT05060575|Other|Education and Telephone Counceling|"Drug use and rational drug use training will be given to hypertension patients in the experimental group.~The patients in the experimental group twice in the 1st month (2nd and 4th weeks), once in the 2nd month (8th week) and once in the 3rd month (12th week) phone call counseling will be providedved an average of 10-15 minutes."
45614309|NCT04503421|Other|Blood Flow Restriction Therapy|Use of a tourniquet set to 50% of limb occlusion pressure while performing post operative physical therapy
45614310|NCT03352999|Procedure|Fast track access to vaECMO|"ROHCA must be witnessed with onset of bystander CPR and an immediate call to Emergency Dispatch. Furthermore, to minimize any loss of time, all qualified geographical locations are directly incorporated in the regulation software of the center for medical emergency control.~Patients suitable for vaECMO implantation were identified as early as possible by the Medical Dispatcher at the Emergency Call Dispatch Center.~Bystanders pursued CPR until Mobile Intensive Care Unit (MICU) arrival. OHCA was considered refractory after 10 min of CPR initiating the transport by MICU to the hospital such that the vaECMO intervention could be performed. The resuscitation was pursued during the transfer to hospital. An automated chest compression device was used in order to minimize interruption periods.~The intensivists and cardiac surgeons stood ready to implant the vaECMO surgically in the catheterization laboratory where a percutaneous coronary intervention was subsequently performed."
45614311|NCT05043337|Behavioral|Maternal voice|"The recordings were made in a quiet and separate consultation room. For infants in the maternal voice group, mothers were recorded what they wanted to say to their baby and read an independently published children's book, Xiao Qi's yellow persimmon which describes how mothers with premature babies care for their infants. After reviewing the quality of the recordings, the maternal voice recordings were edited for 13 minutes using a sound organizer. Respiration, heart rate, oxygen saturation, and Neonatal Infant Pain Scale (NIPS) were measured and recorded 3 minutes before, during, 1 minute, 3 minutes, and 10 minutes after the puncture."
45614312|NCT05043337|Behavioral|Lullaby|The Brahms Lullaby recordings are compiled for 13 minutes. Measuring with the Respiration, heart rate, oxygen saturation, and neonatal infant pain scale (NIPS ) were recorded 3 minutes before, during, 1st, 3rd, and 10th minutes after the heel lance puncture.
46068946|NCT05108935|Drug|Truvada|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
45614313|NCT05043337|Behavioral|Maternal voice combined with lullaby|"The recordings were made in a quiet and separate consultation room. For infants in the  Maternal voice combined with lullaby group,  mothers were recorded what they wanted to say to their baby and read an independently published children's book-Xiao Qi's yellow persimmon , and giving mother listening to the Brahms Lullaby at the same time, the maternal voice recordings were edited for 13 minutes using a sound organizer. Measuring with the Respiration, heart rate, oxygen saturation, and neonatal infant pain scale (NIPS ) were recorded 3 minutes before, during, 1st, 3rd, and 10th minutes after the heel lance puncture."
45614314|NCT02164695|Procedure|PPCI plus RIPC|All patients will be prepared with an upper-arm blood pressure cuff before arterial puncture (contralateral in case of radial access). In patients allocated into PPCI plus RIPC group, the protocol will be started immediately after cuff preparation. Upper-arm will be exposed to 4 cycles of ischemia/reperfusion, each obtained by 5 min cuff inflation at 200mmHg, followed by 5 min complete deflation.
46068947|NCT05108935|Drug|Mavyret|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
45445462|NCT02797522|Drug|tenofovir|Participants take entecavir OR tenofovir daily throughout the study.
45445463|NCT01320813|Procedure|Robot-assisted thyroidectomy|Patients will have a thyroidectomy via a robot-assisted (da Vinci robot) endoscopic (subclavical entry)surgical technique.
45614315|NCT02164695|Procedure|PPCI only|All patients randomized to PPCI only arm, the blood pressure cuff will be applied to the arm or the calf but will not be inflated.
45445464|NCT01320813|Procedure|Open thyroidectomy|Patients will have a conventional (non-endoscopic) thyroidectomy using an open surgical technique
45614316|NCT04506697|Procedure|Uroflowmetry|The patient is given a portable uroflowmeter for performing uroflowmetry at home, and the NetHealth app is installed on his smartphone. The patient registers his account in the app. A personal uroflowmeter is paired with the patient's smartphone using the installed app via a Bluetooth connection. The investigator trains the patient how to use the app and how to conduct uroflowmetry at home. The patient within 1 day (24 hours) at home performs uroflowmetry during all urination, including night urination.
45614317|NCT03352921|Other|clinical pilates exercises|servikal, deep flexor muscles, posture exercsises
45614318|NCT03352921|Other|home exercises program|stretching, strengthening, and posture exercises to reduce functional disability, to relieve the pain and to provide postural straightening.
45614319|NCT05303181|Device|Russian Current|"The patient will be placed in sitting position, hip at 90-degree flexion, knee at 60°, the upper body supported by the backrest, cross belt support the trunk and cross belt support the pelvis. The dynamometer rotating axis will be aligned with knee joint axis and the resistance lever arm will place in the distal leg above the malleolus. The angle of the joints adjustment considering the joint's range of motion and the device's user's manual, any movement other than the range of motion determined by the mechanical limit will be not allowed~All electrical induced contraction will last 4 second each, with characteristics of 75 bursts; 4 second time on, 400 μs pulse width and 10 second time off. The greatest electrically induced torque by the quadriceps muscle at the maximum current output from the stimulator will be recorded for each subject to be used in data analysis. The same procedure will be done on the 3rd week and after 6th week."
45614320|NCT04506541|Other|Kangaroo Care|Kangaroo care application started in the first minute after giving birth in mothers who were in the kangaroo care group and came to the delivery room.
45614321|NCT05011903|Behavioral|Cross-tailored Dynamic Feedback|Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to alcohol use and related sexual behaviors.
45614322|NCT05011903|Behavioral|Personalized Feedback Intervention|Technology-delivered personalized feedback on first-year college student behavior related to alcohol use and related sexual behaviors.
45614323|NCT05011903|Behavioral|Dynamic Feedback on General Health Behaviors|Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to general health behaviors.
45614324|NCT04475991|Drug|Maraviroc + Currently used therapy|"Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)"
45614325|NCT04475991|Procedure|Curently used therapy for COVID-19 non-critical patients|"Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga"
45614326|NCT04475991|Drug|Favipiravir + Currently used therapy|"Favipiravir tablets 200 mg. given orally for a 7 day period. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)."
45614327|NCT04475991|Drug|Maraviroc+Favipiravir+CT|"Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND Favipiravir tablets 200 mg. given orally for the first 7 days. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)"
45614328|NCT03387475|Drug|Deferasirox|iron chelation
45614329|NCT05010265|Other|Clinician Questionnaire|Surveys will serve to identify preferences, expectations and concerns among clinicians and researchers surrounding data-sharing of uncertain diagnostic data generated through investigative neurotechnologies which will then be systematically evaluated.
45614330|NCT05010265|Other|Semi Structured Interviews|Semi-structured interviews will further serve to identify preferences, expectations and concerns among patients, surrogates, clinicians and researchers surrounding data-sharing of uncertain diagnostic data generated through these investigative neurotechnologies which will then be systematically evaluated.
45614331|NCT04502017|Drug|ASA plus Clopidogrel|OAC (6 weeks) + DAPT (until 6 months) + ASA
45614332|NCT04502017|Drug|Genetic-Tailored AntiThrombotic Strategy|Half-Dose OAC or Clopidogrel in combination with ASA on the basis of CYP2C19 Genotype
45614333|NCT04502017|Drug|Half-Dose of novel OAC|Half Dose of novel OAC post-device Implantation
45614334|NCT05302713|Dietary Supplement|Ionic Calcium|Ionic calcium (IC), a calcium in a free ionic state (i.e., non-protein bound), is purported to improve calcium uptake and homeostasis leading to improved cellular signaling that may have been disrupted through environmental and lifestyle stressors.
45614335|NCT05302713|Dietary Supplement|Calcium Carbonate|Calcium carbonate supplementation in a solution identical in appearance, consistency, and taste to the intervention supplement.
45911546|NCT02009267|Procedure|Continuous paravertebral blockade|Continuous paravertebral blockade (PVB) is the technique of injecting local anesthetic adjacent to the thoracic vertebra that anesthetizes the spinal nerve roots after they exit the spinal canal.
45445465|NCT03773367|Drug|Fluorouracil|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
45445466|NCT03773367|Drug|Oxaliplatin|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
45445467|NCT03773367|Drug|Irinotecan|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
45445468|NCT02060656|Drug|Gemcitabine|1000mg/m2 IV D1, D8, D15 every 28 days
45445469|NCT02060656|Drug|Methylprednisolone|1000mg/m2 IV or PO D1-5 every 28 days
46068948|NCT05104307|Device|Cardiac Performance System (CPS) Device|CPS is a passive measurement system that acquires signals from multiple sensor sources that monitor cardiac heart sounds. The passive sensor systems measure sound only and do not produce energy. The CPS system also includes a Patient Monitor device that acquires data from the sensors as well as from three standard ECG electrodes. The CPS system does not acquire or store any protected health information or any subject characteristics. The CPS system has received FDA clearance K173156. Note that the CPS system was previously named Integrated CardioRespiratory (ICR) system. The CPS is FDA cleared for the ejection fraction (EF) assessment which will be its intended use for this study.
45445470|NCT02060656|Drug|Rituximab|375mg/m2 IV D1, D15 every 28 days
45614336|NCT04992949|Drug|CPX-351|"Induction : patients will receive induction treatment with CPX-351 100 U/m2 on days 1, 3, and 5. Patients who fail to achieve CR/CRi after the induction cycle will be offered a second induction course of CPX-351 100 U/m2 on days 1 and 3, at the investigators' discretion. If CR/CRi is not achieved following the second induction cycle, patients will go off study~Consolidation : patients in CR/CRi after induction cycle will receive up to 2 course of consolidation therapy with CPX-351 65 U/m2 on days 1 and 3. CPX351 doses could be reduced to 65 U/m2 on day 1 in case of unacceptable toxicity following the previous course.~Allo-SCT : patients for whom an allo-SCT is planned will receive a maximum of one consolidation cycle"
45614337|NCT05584969|Behavioral|Peer-led integrated nutrition education intervention delivered through Care Groups|The intervention comprised a peer-led integrated nutrition education training using the Care Group model developed by the TOPS program [13]. In the treatment arms, topics trained in the peer support groups included 1) group dynamics and social support, 2) infant feeding 3) adequate basic hygiene, 4) child growth and development, and 5) fathers' involvement. The training modules were adopted and modified from the community health extension workers (CHEWs) handbook [14] and the UNICEF IYCF counseling cards for community workers [15, 16]. Over the study, the intervention participants also engaged in cooking demonstrations targeting infant complementary foods preparation and backyard kitchen gardening.
45614338|NCT05136027|Other|Concurrent training|Low intensity interval training and resistance exercise
45614339|NCT05584891|Procedure|mastoidectomy and mastoid oblitration|Forty pediatric patients with cholesteatoma indicated for radical mastoidectomy or modified radical mastoidectomies will be enrolled in our study and we will be grouped into two groups: one will undergo radical mastoidectomy alone and their operation results will be compared to other group which includes twenty pediatric patients with mastoid obliteration operation.
45614340|NCT05302557|Other|Ileostomy stimulation|Daily stimulation of the efferent loop will be performed during the two weeks prior to the surgery.
45614341|NCT05584813|Other|Hypobaric Hypoxia|The Waggoner Computerized Color Vision Test (WCCVT) and the Waggoner D-15 (WC-D15) were performed by 54 healthy volunteers in a decompression chamber.
45614342|NCT03352687|Procedure|anterior SSAX|block of the suprascapular nerve block for shoulder surgery by anterior way
45614343|NCT03352687|Procedure|posterior SSAX|block of the suprascapular nerve block for shoulder surgery by posterior way
45614344|NCT04922853|Drug|Capox chemotherapy|oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals
45614345|NCT03348007|Other|Taking two kinds of mineral water|1.5L of low-mineral water (Vittel Bonne Source, control group) or 1L of Hépar + 0.5L of low-mineral water (Hépar group).
45614346|NCT05302401|Behavioral|intrapartum uninterrupted midwife support|Prenatal women will be trained about the birth process and psychological and physical support will be provided to women during childbirth. Among these supports, healthy women will be exercised during the labor action, given positions that facilitate childbirth, their hands will be held when they need them, their oral intake will not be restricted, and warm showers will be applied according to their wishes. (These applications can be increased.)
45614347|NCT04921033|Dietary Supplement|EEN (Nestle Modulen®)|35kcal/kg/day for every patient
45614348|NCT04921033|Drug|Standart of care|"Budesonide 9mg/day for mild disease~Prednisolone 1mg/kg, maximum 40mg/day in decreasing doses (40mg for 4 weeks followed by a fixed taper for 6 weeks) for moderate-to-severe disease for 12 weeks.~Patients with moderate to severe disease in the steroid group will also receive 2mg/kg azathioprine. The dose of azathioprine will be adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase [ALT], aspartate transaminase [AST], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine."
45614349|NCT03352375|Device|Orotracheally intubation|Interventions used for airway safety and ventilation during surgical procedures
45614350|NCT03352375|Device|Laryngeal Mask Airway|Interventions used for airway safety and ventilation during surgical procedures
45614351|NCT04915833|Diagnostic Test|Standard high-definition colonoscopy|"Evaluation of the colonic mucosa with a high definition colonoscope (EPKi7010 video processor).~The endoscopy images will be seen on a 27inch, flat panel, high-definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) only by one expert endoscopist, randomly assigned.~The number, location and polyps' features (Paris classification) will be recorded by the operator. If a polyp is detected, the endoscopist will remove the polyp endoscopically with a cold snare and forceps biopsy."
45614352|NCT04915833|Diagnostic Test|Colonoscopy with real-time AI assisted automated polyp detection|The same patient will be submitted to a second, same session, computed aided real-time colonoscopy using the DISCOVERY, AI assisted polyp detector. Colonoscopy will be performed by a same-level-of-expertise operator in comparison to the initial procedure. Any polyp or lesion detected with the AI system will be recorded and endoscopically removed and considered as a missed lesion from standard colonoscopy.
46068949|NCT05101668|Device|Intracranial Thrombosis Aspiration Catheter|Direct Aspiration
45445471|NCT02060656|Drug|Cisplatin|100mg/m2 IV D15 every 28 days
45445472|NCT02060656|Drug|Lenalidomide|25mg PO D1-21 every 28 days
45445473|NCT03773211|Drug|Renaparin|50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
45445474|NCT03773211|Drug|Placebo|50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
45445475|NCT03774849|Device|PicoWay™ 532nm fractional handpiece|PicoWay™ Laser System is picosecond 532/1064/785 laser
45614353|NCT03346681|Drug|N-acetyl cysteine|The procedure involved would be the administration of N-acetylcysteine via nebulization, which would be administered to the patient by respiratory therapy in the dosage of 2 mL 20% solution acetylcysteine (or 4 mL of 10% solution) along with inhaled albuterol via endotracheal tube every six hours for 72 hours total. The control arm will have saline administered with the albuterol every six hours. Both arms will have additional bronchodilators administered as indicated clinically (bronchospasm, COPD, peak airway pressure elevation, etc.).
45759522|NCT01984515|Behavioral|Referral Management System|"Referral Management System (RMS) will address patient-level barriers with the delivery of a 1-session cognitive behavioral therapy (CBT) intervention to identify and change treatment seeking beliefs that serve as an barrier to treatment engagement, including specific negative beliefs about EBP (e.g., talking about past trauma will be too difficult for me). RMS will address system-level barriers by tracking the progress of RMS referrals and contacting Veterans who have not followed thought on their chosen referral options. Primary Care staff will also be trained with simple scripts on how to address PTSD symptoms and make appropriate referrals based on VA/DoD Clinical Practice Guidelines for PTSD."
45445476|NCT03774849|Device|PicoWay™ 730nm wavelength|PicoWay™ Laser System is picosecond 532/1064/785 laser
45614354|NCT05136573|Behavioral|Combined Exercises|Combined Exercises
45614355|NCT05136495|Other|caffeinated coffee - decaffeinated coffee|Drink caffeinated coffee one morning and drink decaffeinated coffee the other morning
45614356|NCT03347851|Other|MRI|Enrolled patients will complete a non-contrast cardiac MRI
45614357|NCT03347851|Other|Transthoracic echocardiography exam|Enrolled patients will complete a transthoracic echocardiography exam.
45759523|NCT00245063|Drug|cediranib maleate|Given PO
45759524|NCT00245063|Other|laboratory biomarker analysis|Correlative studies
45614358|NCT03347773|Dietary Supplement|ReGen 18%|ReGen 18% is a kind of oral nutritional supplement, designed for patients under regular hemodialysis. One can of ReGen 18% contains 237ml, 425 Kcal, 19.1g protein, 22.7g lipid and 37.9g carbohydrate.
45759525|NCT00245063|Other|pharmacogenomic studies|Optional correlative studies
45759526|NCT02151487|Drug|Ropivacaine|Ropivacaine alone
46073646|NCT00841633|Drug|Induced hypertension with norepinephrine|Hypertension will be induced with norepinephrine. Administration of norepinephrine results in vasoconstriction, leading to an increase in blood pressure. The normal blood pressure of the patient will be calculated as the average MAP of the day before the start of the study. To achieve the intended hypertension (30 mmHg above the normal MAP for patients allocated to index group 2) in most cases a dose of 100-300 ng/kg/minute must be administered. Norepinephrine will be started on a dose of 100 ng/kg/minute, after which the dosing will be adjusted to achieve the desired blood pressure level. The maximum dose to be used in the study is 1000 ng/kg/minute. Norepinephrine is administered through the central venous catheter.
45614359|NCT05301777|Device|Computed tomography|Computed tomography
45445477|NCT03774849|Device|PicoWay™ 1064nm fractional handpiece|PicoWay™ Laser System is picosecond 532/1064/785 laser
45614360|NCT04853121|Procedure|Tapered Implants|Tapered Implants are placed in fresh socket via dynamic navigation
45614361|NCT04853121|Procedure|Straight Implants|Straight Implants are placed in fresh socket via dynamic navigation
45614362|NCT05584735|Biological|Influenza vaccine|Observe effects of flu vaccine on microbiome
45614363|NCT05136261|Device|Ceradan ® Advanced Cream|Ceradan ® Advanced Cream
45614364|NCT05136261|Device|Basic cream|Basic cream
45614365|NCT04503187|Behavioral|Visuomotor leg reaching task|Similar to a hand reaching task in which participants were asked to reach to a tea-cup, in a visuomotor leg reaching task, participants will be seated and given real-time visual feedback about their leg movements via a cursor display on a computer screen. The task is to control a foot mouse/marker attached to the foot and move the cursor from a start location to the target displayed on a wall screen. Three different targets, equidistant from the start location at top, top-left, and top-right screen positions, will be used for leg reaching. In each trial, one of three targets will be randomly presented and subjects will be instructed to make forward, or rightward, or leftward foot reaches to guide the cursor to one of the targets. Throughout the entire experiment, subjects are blocked from viewing leg movements by a cardboard.
45614366|NCT04488315|Drug|Dexamethasone lipid microsphere plus ropivacaine|Local scalp infiltration solution will consist of 30ml miscible liquids containing 8 mg dexamethasone lipid microsphere, 150mg ropivacaine and normal saline.
45614367|NCT04488315|Drug|Ropivacaine alone|Local scalp infiltration solution will consist of 30ml miscible liquids containing 150mg ropivacaine and normal saline
45614368|NCT03352297|Biological|Unfiltered Nanofat Graft|Nanofat created from microfat, skipping the filtration step. Intradermal and subdermal injections in post burn scars on the face.
45614369|NCT04506307|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
45614370|NCT05136183|Device|HA-330 Disposable Hemoperfusion Cartridge (Jafron, China)|"If no appropriate vascular access available, a double lumen catheter is placed by treating physicians, under ultrasonographic guidance.~Two sessions of hemoperfusion using HA-330 Disposable Hemoperfusion Cartridge are performed 24 hours apart.~Hemoperfusion is performed using either hemoperfusion or continuous renal replacement therapy machine. The optimal blood flow rate is 150-200 mL/min. The duration for each session in 2 hours. No systemic anticoagulant is given except for priming of the cartridge according to manufacturer recommendations.~The first hemoperfusion session is recommended to be initiated within 12 hours after randomization."
45759527|NCT02151487|Drug|Ropivacaine and dexamethasone|Ropivacaine combination with dexamethasone
45759528|NCT02151487|Drug|Ropivacaine and clonidine|Ropivacaine combination with clonidine
45759529|NCT02151487|Drug|Ropivacaine, dexamethasone and clonidine|Ropivacaine combination with dexamethasone and clonidine
45759530|NCT02148809|Radiation|1mL of I-131 Human Serum Albumin is injected prior to the measurements|
45759531|NCT05377489|Drug|RTX-GRT7039|RTX-GRT7039 monoarticular injections or bilateral intra-articular injections.
45759532|NCT03805763|Procedure|Large extent of ILM Peeling|The extent of ILM peeling is 4DD
45759533|NCT03805763|Procedure|Small extent of ILM Peeling|The extent of ILM peeling is 2DD
45445478|NCT02062372|Device|7 T MRI|Overview Technical DetailsField strength: 7 Tesla Bore size: 60 cm System length: 317,5 cm RF power: 7,5 kW / 8x1 kW Gradient strength: SC 72 Gradients (max. 70 mT/m @ 200 T/m/s) Helium Consumption: Zero Helium boil-off technology
45614371|NCT05584579|Procedure|laparoscopic surgery|laparoscopic surgery
45614372|NCT05135793|Drug|Topoprazan|1 tablet contains 20 mg vonoprazan
45614373|NCT05135793|Drug|Takecab|1 tablet contains 20 mg vonoprazan
45614374|NCT04841889|Diagnostic Test|Associated factors with decannulation|All factors potentially associated with successful tracheostomy removal will be prospectively collected: severity factors related to the ICU stay, ventilatory factors, respiratory and extra-respiratory factors. Lung and diaphragm ultrasound, swallowing, muscles and functional assessment will be performed.
45614375|NCT00709735|Drug|Propranolol|0.67 mg/kg short-acting propranolol combined with 1 mg/kg long-acting propranolol
45614376|NCT00709735|Drug|Placebo|Placebo (matching propranolol) short-acting and long-acting capsules
45614377|NCT04568811|Biological|Adenovirus Type-5 Vectored COVID-19 Vaccine|Low dose adenovirus type-5 vectored COVID-19 vaccine (5E10 vp)
45614378|NCT04503031|Device|TaperGuard endotracheal tube|TaperGuard endotracheal tube is intubated
45614379|NCT04503031|Device|cylindrical endotracheal tube|endotracheal tube is intubated
45614380|NCT04806555|Diagnostic Test|Compression ultrasound examination|After successful revascularisation for acute ischemia and clinical suspicion of acute compartment syndrome, compression ultrasound (CU) will be performed in OR followed by standard intra-compartmental measurement. Two physicians will perform two subsequent measurements of the affected limb after revascularisation. The unaffected limb will be examined once to obtain baseline elasticity ratio values. All CU examinations will be documented in PACS (picture archiving and communication system) and evaluated after ICP measurement, and if necessary, fasciotomy is performed.
45614381|NCT05135637|Other|Mobile health services|Mobile health services (MHS) will be deployed with one team per UC. MHS will focus on underserved areas to provide basic health services, immunization, & health and nutrition counseling for under-five children & WRAs.
45614382|NCT05135637|Other|Private practitioner engagement for immunization|Private healthcare providers (HCPs) will be taken on board to increase coverage of immunization. HCPs will offer routine vaccination to all under-five children visiting their clinics. Project team will liaison with EPI to arrange vaccines for them.
45614383|NCT05135637|Other|Community engagement and mobilization|Community engagement & mobilization will focus on immunization, breastfeeding practices, & optimal care-seeking for both pregnant women and young children. Opinion leaders will be engaged to gain support for activities.
45614384|NCT05135637|Other|Sehat Nishani - a health, nutrition and immunization app|Sehat Nishani App will be launched to assess feasibility of a health, & immunization app to capture information on birth, nutrition, immunization & growth records. Lady health workers (LHWs), lady health visitors (LHVs) in government health facilities, EPI vaccinators & HCPs will be engaged to use app.
45614385|NCT03121885|Behavioral|30-minute movement activity|The subjects arrive in the CRU after a 12 hours overnight fast to perform a 30-minute movement activity with individually adapted exercise intensity on the treadmill.
45614386|NCT03121885|Other|Hypoxia|The 30-minute movement activity on the treadmill will be completed by each subject once under normobaric normoxic and once under normobaric hypoxic conditions (equivalent to approximately 3000 meters above sea level) in a randomized episode.
45614387|NCT03352219|Behavioral|Reality Check|
45614388|NCT03352219|Behavioral|Physical Activity Attention Control|
45614389|NCT04561713|Procedure|Virtual reality task|Virtual reality application in an immersive room (CAVE) in three dimensions to assess child's sustained attention in a dynamic environment that is as close as possible to everyday situations.
45614390|NCT04548063|Other|6,000 word consent form|Mock consent form with consistent content in approximately 6,000 word length.
45759534|NCT05318339|Drug|Trastuzumab|"A loading dose of trastuzumab 8mg/kg IV over 90 minutes will be administrated on day 1 of week 1.~For all subsequent doses, trastuzumab 6mg/kg IV over 30 minutes will be administrated every three weeks.~Pyrotinib 400mg PO daily will be administrated at the same time."
45614391|NCT04548063|Other|4,000 word consent form|Mock consent form with consistent content in approximately 4,000 word length.
45614392|NCT04548063|Other|2,000 word consent form|Mock consent form with consistent content in approximately 2,000 word length.
45614393|NCT04664257|Behavioral|e-CBT|e-CBT will be administered with weekly modules. See arm/group descriptions for more information.
45614394|NCT05584501|Other|Care Navigator|The Dental Team will have a Care Navigator as an added resource to assist with offering, implementing, and counseling for HIV testing; providing PrEP education and linkage; and providing linkage and re-linkage to HIV care.
45614395|NCT05584501|Other|Health Information Supported Ending the HIV Epidemic (ETE) Activities in Dental Setting|Dental Teams will receive a Best Practice Alert (BPA) when they have a patient who should be offered HIV testing. Dental Teams will also be notified when they have a patient known to be HIV positive but out of HIV care.
45614396|NCT04502953|Procedure|Vertical plication|Vertical plication of the rectovaginal septum was done
45614397|NCT04502953|Procedure|Horizontal plication|Horizontal plication of the rectovaginal septum was done
45614398|NCT02647905|Device|Continuous Glucose Monitoring System|Accuracy and safety assessment of a continuous glucose monitoring device
45614399|NCT04502875|Drug|PRP|Platelet Rich Plasma (PRP) is an autologous blood component derivate from the own patient blood, with a high concentration in platelets. The liquid fraction obtained after the soft centrifugation of Whole Blood (WB) collected with anticoagulant, in a way that most of the red cells and leukocytes are sedimented and removed, but most of the platelets are kept in the supernatant plasma. The platelet concentration in PRP is not well defined.
45614400|NCT04502875|Drug|PPP|PPP is the liquid fraction obtained after the hard centrifugation of WB collected with any anticoagulant. PPP does not contain cells. (Hematocrit lower than 1% and leukocytes below 1 x 109/L) x but contains WB proteins (including clotting factors), ions, microelements and water. PPP can be also being collected using an apheresis technique.
45614401|NCT03352141|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
45614402|NCT04546971|Behavioral|Brief Intervention|Brief alcohol intervention delivered by telephone or videoconferencing focusing on advising participants to reduce drinking
45614403|NCT04546971|Behavioral|Telehealth Counseling|5 sessions of counseling on alcohol use based on Motivational Interviewing.
45614404|NCT04546971|Behavioral|Text messaging|A daily and then monthly text messaging program designed to help participants monitor drinking, set goals, and reinforce successful reduction or abstinence.
45614405|NCT04502797|Behavioral|Electronic Patient Visit Assessment (ePVA)|The ePVA is an mHealth clinical support tool. The ePVA consists of a patient-reported measure that focuses on symptoms common to HNC (i.e. pain, eye, ear, nasal, mouth, voice, fibrosis, edema, skin, gastrointestinal, fatigue, limitation in movement, sleep, breathing, difficulty eating or drinking, swallowing, communication, social activities, anxiety, depression, and daily activities). PROMIS® questionnaires (pain intensity 3a, fatigue 6a, sleep disturbance 6a, anxiety 6a, depression 6a) are embedded within the ePVA.
45614406|NCT04541121|Behavioral|3D printed model|Mother is given 3D printed model of fetus' face
45614407|NCT04541121|Behavioral|Placebo|Mother is given a picture of 3D ultrasound of fetus
45614408|NCT04316481|Device|AngelMed Guardian System|The AngelMed Guardian System detects potential ongoing ACS events, characterized by sustained ST segment changes, and alerts the patient to seek medical attention for those potential ACS events. The Guardian System is indicated as an adjunct to patient recognized symptoms.
45614409|NCT04506229|Genetic|Whole exome sequencing|MoCA survey to evaluate cognitive function in COVID-19 positive cases with vs without neurological symptoms
45614410|NCT04804839|Other|First research arm|Patients in this group were given 8-week PFMT (including knack maneuver) and lifestyle recommendations for the treatment of urinary incontinence symptoms.
45614411|NCT04804839|Other|Second research arm|Patients in this group were given only 8-week PFMT (including knack maneuver) for the treatment of urinary incontinence symptoms.
45614412|NCT04804839|Other|Third research arm|It is the control group and patients in this group were given alone8-week PFMT (without knack maneuver).
45614413|NCT04582357|Behavioral|Physical activity program|The physical activity program is a suite of several exercises which intend to improve muscular mass of targeted muscles.
45614414|NCT05584189|Device|Rapid SARS-CoV-2 Antigen Test|Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person.
45614415|NCT04536519|Other|osteoarthritis management|"The conventional physical therapy will be consisted of an array of protocols being deployed in parallel. This will consist of~Patient education regarding deforming forces, strategies of prevention and home exercise program~Decreasing stiffness by controlled active range of motion and mobilization techniques involving join play.~Mechanical stresses will be controlled in form of support provided by foot wear modification~Range of motion will be increased muscle stretches and manual mobilization techniques~Muscle performance and neuromuscular control will be addressed by gentle exercises of low intensity and repetitive exercises.~Balance improvement by employing balance training activities as part of treatment~Physical conditioning low impact or non-impact aerobics This conventional exercise will be given as baseline treatment to both of groups."
45759535|NCT00763919|Behavioral|Psychoeducation module|The psychoeducation module will use psychological and medication education to address opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes toward drugs in general, lack of information about mood stabilizers, and stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments.
45759536|NCT00763919|Behavioral|Substance abuse module|The substance abuse module will address problematic substance abuse, particularly as it relates to medication adherence.
45614416|NCT04505995|Drug|Azacitidine and homoharringtonine|Concommitant use of azacitidine and homoharringtonine
45614417|NCT04486911|Drug|Pyrotinib maleate, SHR6390, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor SHR6390, and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
46073647|NCT02823678|Procedure|Pancreatectomy|Patients will undergo pancreatectomy as part of routine care for their pancreatic neoplasms.
46073648|NCT02823912|Drug|Capsaicin|
45445479|NCT02062372|Procedure|Biopsy|During surgery patients will receive standard biopsies plus one study biopsy from a region of interest. The neuro-surgeon will determine the feasibility of the extra biopsy and the optimal biopsy tract. A screen capture from the neuronavigation system will be saved for each biopsy to relate the findings on 3T and 7T MRI to histopathology.
45445480|NCT03774537|Drug|Transplantation of hUC-MSCs|Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs through intravenous infusion. Dose A - 1 million cells per kg; Dose B - 5 million cells per kg
45445481|NCT03774537|Drug|No transplantation of hUC-MSCs|Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs
45614418|NCT05584033|Diagnostic Test|Mansora Arabic test battery for childhood apraxia of speech|Searching of apraxia of speech in children with Specific Language Impairment in able to better management of these cases.
45614419|NCT05135247|Other|Exercise|3 different types of training or control
45614420|NCT04526977|Diagnostic Test|Immune response study|"ACE2 and CD26 receptor study~Cytokine profile: Quantification of plasma cytokine levels~SARS-CoV-2 CD4/CD8 T cell response~TLR7/8 activation~KIR characterization"
45614421|NCT03352063|Behavioral|Prolonged sitting with exercise|Subjects will commit to sitting more than 11 hours per day and taking less than 5000 steps per day while participating in exercise training.
45614422|NCT03352063|Behavioral|Active walking with exercise.|Subjects will commit to sitting less than 5 hours per day and taking more than 10000 steps per day while participating in exercise training.
45614423|NCT04374175|Biological|Blood sample|Blood sample will be performed
45614424|NCT02518165|Dietary Supplement|Proprietary spearmint extract|Water extracted spearmint extract
45614425|NCT02518165|Other|Placebo|Microcrystalline Cellulose
45614426|NCT05135013|Drug|Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol|"History of hormonal use as follows:~Reason for hormonal use: contraception, fertility promotion, Polycystic ovary syndrome (PCOS)~Duration of hormonal use~Type of hormonal drug used: dose, hormone type, route of administration"
45614427|NCT04522713|Behavioral|Behavioral activation, evidence-based sleep strategies including sleep restriction, exposure-based strategies, promotion of physical activity and recuperating activities, psychoeducational material|Primarily standard cognitive-behavioral strategies to reduce common psychiatric symptoms
45614428|NCT02518243|Other|Patient's answer with non pharmacological therapeutic|"Installation at patient's home of :~aromatherapy~music therapy~cognitive training in multimedia application offering cognitive games"
45614429|NCT04516161|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Receiving Ra-223 either alone or in combination with other cancer therapies at any time after diagnosis of mCRPC
45614430|NCT03351985|Device|quantitative electroencephalogram (qEEG)|the patients receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
45614431|NCT04509609|Other|Exon 3 truncating mutation|Any patient affected by LGMD 2E with a genetic diagnosis carrying the truncating mutation c.377_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis
45614432|NCT04509609|Other|Any other mutation in SGBC gene|Any patient affected by LGMD 2E with a genetic diagnosis other than the truncating mutation c.377_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis
45759537|NCT00763919|Behavioral|Improved communication/rapport with provider module|The provider communication and rapport module will improve health care provider communication to address fear of side effects, concern regarding change in appearance, or side effect-related distress.
45445482|NCT03774771|Drug|Cinacalcet|Capsule for oral administration
45445483|NCT03774771|Drug|Placebo|Capsules for oral administration
45445484|NCT01320891|Behavioral|balanced solutions|during the general anaesthesia until 8 o'clock of the day after the operation the subject will receive only balanced fluids that means balanced crystalloid and colloids dissolved in balanced solution. 12 ml /Kg/h during operation time. ratio 3:1 between crystalloid and colloid.
45614433|NCT04505917|Drug|dinoprostol|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
45614434|NCT04505917|Drug|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
45614435|NCT04505917|Drug|placebo|2 tablet of placebo inserted by the study nurse 3 hours before IUD insertion
45614436|NCT04412967|Device|Dynamic ultrasound-guided short-axis needle tip navigation|placement of peripheral venous catheters using ultrasound guided technique
45614437|NCT04412967|Other|Standard technique of placing a PVC|Standard technique with palpation or Visual inspection of the pvc placement site
45614438|NCT04234971|Drug|Intervention group (DBM/BMP)|All patients will undergo a standard procedure for exposure of the cleft alveolar defect and closure of all oronasal fistulae. After induction of general anesthesia, the patient will be intubated with an oral ray tube and prepped and draped in sterile fashion. Pre-operative antibiotics will be given to cover oral flora (i.e. Unasyn or clindamycin if penicillin allergy exists). The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed. For the treatment group, 10cc of crushed DBM will be mixed with the micro-sized sponge of rh-BMP-2 (Infuse Bone Graft, Medronic, Minneapolis, MN). The sponge and DBM will then be packed into the defect to completely fill the bony space (FIGURE 3). The anterior mucosa will then be closed.
45614439|NCT04234971|Drug|Control group(autologous ICBG)|The patient will be induced with anesthesia, prepped, and draped. The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed.In the control group, the ICBG will be harvested percutaneously using the Accumed bone graft harvesting system. Briefly, an incision will be made in iliac crest and drill bit inserted. Multiple passes of the drill be used to harvest as much autograft bone as possible from the cancellous region of the iliac crest.Following harvest, fibrin glue will be instilled for hemostasis and a Ropivicaine On-Q pain pump inserted for post-operative pain control. The harvest bone graft will be packed into the alveolar defect in a similar fashion and the mucosa closed anteriorly.
45614440|NCT04495959|Drug|68Ga-HTK03149|PET/MRI scan with radiotracer 68Ga-HTK03149
45614441|NCT04505761|Device|Virtual Reality|Participants will use a Virtual Reality headset with a range of applications applicable for rehabilitation after COVID-19. Applications target physical, psychological, and cognitive rehabilitation. VR headset will be used for six weeks first at the physiotherapist's practice, and when possible, at home.
45614442|NCT04266457|Other|No Intervention|No Intervention
45614443|NCT04185909|Device|Renuvion Dermal System|The Renuvion® Dermal System consists of an electrosurgical generator unit, a handpiece with detachable standoffs, and a supply of helium gas. Radio Frequency (RF) energy is delivered to the handpiece by the electrosurgical generator unit and used to energize an electrode. When helium gas is passed over the energized electrode, a helium plasma is generated which allows for conduction of the RF energy from the electrode to the subject in the form of a precise helium plasma beam.
45445485|NCT01320891|Behavioral|not balanced|during the operation time until the 8 o'clock of the day after the operation, the subjects will receive only normal saline and colloid dissolved in normal saline.
45614444|NCT04505683|Drug|Benapenem|Benapenem for IV injection administered as a 1-gram IV infusion
45614445|NCT04505683|Drug|Ertapenem|Ertapenem for IV injection administered as a 1-gram IV infusion
45614446|NCT03351829|Genetic|Gene-modified autologous stem cells|1 infusion for 5x10^6~1x10^7 gene-modified cells; or more infusions depending on the circumstances
45614447|NCT05580055|Diagnostic Test|Affinity|Blood Analyser
45614448|NCT05576155|Drug|Compound 21|Compound 21 + Ringer's is perfused at 10 doses increasing serially for 10 minutes each from 10^-12 M to 10^-3 M
45614449|NCT05576155|Drug|Compound 21 + losartan|Compound 21 + losartan (43 µM) is perfused at 10 doses increasing serially for 10 minutes each from 10^-12 M to 10^-3 M.
45614450|NCT04505215|Other|Mulligan Technique|"First, the painless application angle was determined for each patient. The lateral condyle of the humerus was fixed by the web range of the physiotherapist. The elbow joint was glided until the elbow joint and the hand tightening position were not able to cause pain.~The patients were asked to repeat the motion of the elbow joint and the ball squeezing motion given to their hands 10 times without pain. For pain control, the same procedure was performed with three sets, each containing 10 repetitions of the exercise. The interval between sets was 15 to 20 seconds, and the interval between repetitions within each set was 30 seconds."
45614451|NCT04505215|Other|Muscle Energy Technique|Firstly, 5-7 sec opposite isometric muscle contraction was requested from the patient in the barrier by passively stretching by the physiotherapist until the barrier of the related muscle or dysfunctional joint. After a short rest period of 2-3 seconds, the physiotherapist continued to stretch passively until the second barrier. The application continued until the tension of the muscle or dysfunction of the joint disappeared.
45614452|NCT04505215|Other|Only Exercise (Control)|Eccentric training for the extensor Carpi Radialis Brevis (ECRB) muscle, the most affected wrist extensor tendon, and static stretching exercise for the EKRB muscle were given as home exercise program. The best stretching position for the EKRB tendon is provided when the elbow joint is in extension, forearm pronation, when the wrist is flexed with ulnar deviation (Mills maneuver). Each exercise was taught to patients in 10 repetitions and 10 seconds, and one day of the week, participants in the control group performed their exercises under the supervision of a physiotherapist.
45614453|NCT04443855|Behavioral|Water quality|"Hardware: Free supplies chlorine tablets (Aquatabs; NaDCC) and a safe storage vessel to treat and store drinking water.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children < 36 months of age."
45614454|NCT04443855|Behavioral|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
45614455|NCT04443855|Behavioral|Hand washing|"Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
45759538|NCT00763919|Behavioral|Medication routines management module|The medication routines management module will develop strategies and behaviors that help create medication adherence routines for those who have difficulties with medication routines or experience outside opposition to medications.
45759539|NCT04703335|Drug|Antimicrobial efficacy of gel ZHCK4 as a patient preoperative skin preparation|Evaluate the antimicrobial efficacy of two concentrations of one patient preoperative skin preparation product compared to a positive control (2.0% chlorhexidine gluconate) and negative control (physiological saline 0.9% solution). Following a 14-day restriction period, subjects will be sampled for baseline, 10-minutes, 6-hours, and 24-hours microbial reduction evaluations post-product application. Subjects will not be sequestered for the 6-hour or 24-hour evaluations. Test day baseline criteria will be set at: abdomen: ≥ 3.0 log10 CFU/cm2, and inguen: ≥ 5.0 log10 CFU/cm2.
46073649|NCT02823912|Drug|Magnesia calcinada|
45445486|NCT03774927|Device|10 Hz treatment group|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
45445487|NCT03774927|Device|20 Hz treatment group|20 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 20 intervals with 28s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
45445488|NCT03774927|Device|Control Group|all procedures were identical to 10Hz group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
45614456|NCT04443855|Behavioral|Water quality, Sanitation, Hand washing (Combined WASH)|"Hardware: Free supplies Aquatabs; (NaDCC) and a safe storage vessel to treat and store drinking water. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of drinking water for children < 36 months.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.~Hardware: Hand washing stations, soapy water bottles, detergent soap to supply soapy water bottles. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times as food preparation, defecation, and contact with feces."
45614457|NCT04443855|Behavioral|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) delivered daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices.General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
45614458|NCT04443855|Behavioral|Nutrition, Water quality, Sanitation, Hand washing|Each of the interventions described above for Water Quality, Sanitation & Hand washing (Combined WASH) Plus the intervention described above for nutrition.
45445489|NCT01320969|Behavioral|Mindfulness-Based Stress Reduction course|an eight-week mindfulness-based stress reduction course
45445490|NCT03774693|Other|General anesthesia with fentanyl boluses|Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1
45614459|NCT04443127|Device|Virtual Reality Training Session|VR based motor priming intervention will be given for 16 sessions, comprising of 45 minutes, 4 times/week for the duration of 4 weeks on two VR environments.
45614460|NCT04443127|Behavioral|Motor-Relearning Program|Motor-Relearning Program intervention will be given for 16 sessions, comprising of 45 minutes, 4 times/week for the duration of 4 weeks on two VR environments.
45445491|NCT03774693|Procedure|Regional block|Patients will receive trans-oral bilateral sphenopalatine ganglion block and trans-oral bilateral infraorbital nerve block.
45614461|NCT04501783|Drug|Favipiravir|TL-FVP-t will be administered orally
45614462|NCT04501783|Drug|Standard of care (SOC)|SOC will include standard etiotropic therapy (umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine) according to MoH of Russian Federation recomendations for COVID-19
45614463|NCT04501783|Drug|standard concomitant therapy|Standard of care according to MoH of Russian Federation recomendation for COVID-19
45614464|NCT04501471|Behavioral|SAAF-T|Parents and youth meet separately during first hour to engage in activities then meet in family groups during the second hours of each session.
45614465|NCT04501471|Behavioral|Fuel for Families|Parents and youth meet separately during first hour to engage in activities then meet in family groups during the second hours of each session.
45614466|NCT04439643|Device|vascuCAP|time to event and phenotype classification model
45614467|NCT04505137|Drug|GMA301 Injection|GMA301 Injection administered as a single dose of 1500 mg
45614468|NCT04505137|Other|GMA301 Placebo Injection|GMA301 Injection without GMA301 administered as a single intravenous dose
45614469|NCT04505137|Drug|GMA301 Injection|GMA301 Injection administered as a single dose of 2000 mg
45759540|NCT04382989|Device|Analysis of human milk composition by mid-infrared spectrophotometry|"Analysis of human milk macronutrient content was performed by mid-infrared spectrophotometry using a Miris Human Milk Analyser.~An immune-enzymatic ELISA assays were used to estimate lysozyme and lactoferrin concentrations in human milk."
45445492|NCT04873401|Behavioral|Chain-referral|"In the chain-referral intervention, a discrete number of seeds will be recruited from the community partners, trained and incentivized to recruit and refer members of their social networks to receive COVID-19 testing. The peer recruiters are paid for each suvcessful and eligible recruit who enrolls to be tested. Those individuals are then themselves trained to recruit peers from their social networks to receive COVID-19 testing. This is repeated over a period of 4-6 months."
45445493|NCT04873401|Behavioral|Credible Messenger|In the credible messenger intervention, peers noted to be popular and socially influential individuals with lived experience will be trained to engage within community settings and areas to encourage community members to receive COVID-19 testing at the community partnering agencies. Peers will recruit community members over a period of 4-6 months.
45614470|NCT05125419|Diagnostic Test|Homocysteine level|diagnostic test
45614471|NCT04501549|Procedure|percutaneous coronary intervention|PCI will be performed according to local practice.The bifurcation lesion will be imaged by OCT on at least two time-points for each patient. Plaque morphology will be characterized by OCT. Off-line quantitative coronary angiography (QCA) will be performed before and after PCI and the following QCA parameters will be computed: reference vessel diameter (RVD), lesion length and diameter stenosis (DS) of Main Vessel (MV) and side branch (SB). Blood samples will be taken prior to PCI and 8-12 hours later to determine peri-procedural myocardial injury and infarction following PCI by measuring serum Troponin.
45614472|NCT04424745|Other|Simultaneous Attention Bias Modification Training and Transcranial Direct Current Stimulation (tDCS)|Participants will receive 10 sessions of computerised attention bias modification training with either real or sham tDCS. Participants will self-administer tDCS at home, with research supervision, and complete attention bias modification training on a laptop or desktop computer while receiving stimulation. Sessions will be completed week daily for 2-3 weeks.
45614473|NCT03351751|Drug|Placebo|Placebo
45614474|NCT03351751|Drug|PF-06372865|PF-06372865
45614475|NCT04501315|Diagnostic Test|Blood, cerebrospinal fluid and urine samples|In all subjects, blood (4 mL), cerebrospinal fluid (4mL) and urine (4mL) samples were collected daily as part of the clinical routine at 6:00 AM.
45445494|NCT03774615|Drug|Ferric maltol 30 mg (Feraccru®)|Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
45445495|NCT01321047|Drug|Propofol|propofol (0.5 mg/kg body weight; 10 mg if age > 70 or ASA class III-IV)
45614476|NCT04407585|Diagnostic Test|Covid-19 swab PCR test|Participants satisfying machine learning test criteria will be asked to take a swab test for Covid-19.
45759541|NCT03806153|Other|Morphokinetic|The embryos will be observed at a fixed time and according to morphological criteria (Alpha Specialist Group in Reproductive Medicine and ESHRE, 2011). and all the films obtained will be analyzed. Embryos will be classified according to morphokinetic criteria (Ciray et al., 2014).
45759542|NCT04695301|Other|Rehabilitation protocol through a digital platform|During 3 months the patients will participate in a rehabilitation program through a digital platform
45759543|NCT04691635|Other|evaluation of movements with sensors|evaluation of movements with sensors
45759544|NCT05352529|Device|The MapHabit system|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application was made available to families through compatible smartphones and tablets.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
45759545|NCT05352529|Device|Dementia educational videos|Investigators collected publicly available educational videos regarding dementia-related caregiving and support. The videos were made available to participants through compatible tablets.
45759546|NCT00764309|Drug|dasatinib|Tablets, Oral, 100 mg, once daily, 6 months
45759547|NCT04430725|Procedure|Computed Tomography with Contrast|Undergo contrast-enhanced CT
45759548|NCT04430725|Procedure|Microwave Ablation|Undergo microwave ablation
45759549|NCT04430725|Other|Questionnaire Administration|Ancillary studies
45759550|NCT04430725|Procedure|Wedge Excision|Undergo wedge resection
45759551|NCT04656379|Procedure|spine surgery|Risk factors for postoperative delirium in elderly patients underwent spine surgery will be evaluated.
45759552|NCT02151877|Drug|Inhaled Nitric Oxide|delivering inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery
45759553|NCT02151877|Drug|placebo|inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
45759554|NCT03970837|Biological|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
45759555|NCT03970837|Drug|Tofacitinib|Tofacitinib cap (over encapsulated 5mg tablet) to be administered orally.
45759556|NCT03970837|Drug|Placebo to GSK3196165 (Otilimab)|Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/pre-filled syringe (PFS) to be administered SC.
45759557|NCT03970837|Drug|Placebo to Tofacitinib|Placebo cap (containing lactose) to be administered orally.
45759558|NCT03970837|Drug|csDMARDs|Stable dose of csDMARD(s) as SoC.
45759559|NCT04382833|Other|HOT APPLICATION|HOT APPLICATION
45759560|NCT04382833|Other|MASSAGE|
45759561|NCT00798577|Drug|Vigamox Ophthalmic Solution|Moxifloxacin 5mg/mL 3 times daily for 7 days
45759562|NCT00798577|Drug|BSS placebo|Balanced Saline Solution for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days
45759563|NCT00799435|Drug|Exenatide|5 μg of exenatide subcutaneously twice a day for 4 weeks, followed by 10 μg of exenatide subcutaneously twice a day for an additional 8 weeks
45445496|NCT01321047|Drug|BPS|midazolam (0.05 mg/kg body weight; 1 mg if age > 70 or ASA class III-IV) fentanyl (50 µg; 25 µg if age > 70 or ASA class III-IV) propofol (0.5 mg/kg body weight)
45445497|NCT01320423|Procedure|Surgical Trial|Surgical Trial in Lobar Intracerebral Haemorrhage
45614477|NCT04381533|Behavioral|Internet-delivered Adolescent Community Reinforcement Approach (I-A-CRA)|The intervention is a behavioral internet-based intervention based on the Adolescent Community Reinforcement Approach. The program encompasses text, pictures, videos, and written as well as practical assignments (skills training). The main components of the treatment for the young adult with problematic alcohol use consist of psychoeducation and functional analysis, goal formulation, increasing prosocial behaviors, relapse prevention, problem solving, and communication training. The accompanying significant other receives modules containing information focusing on gaining an understanding of the treatment components aimed at the young adult, as well as communication training to improve communication between the young adult and the significant other.
45759564|NCT04634227|Drug|Ascorbate|Following 15g test dose, 75g administered 75g dose on days 1 and 2. Further doses of ascorbate will be determined by serum ascorbate levels measured by the end of the week to reach a target serum concentration between 20 -30 mM. Ascorbate doses will continue to be escalated until either the target serum concentration or maximum dose of 125 g is administered.
45759565|NCT04329091|Drug|Dexmedetomidine|All subjects will receive Dexmedetomidine to induce sedation between their pre-sedation and post-sedation perceptual learning tests.
45759566|NCT00244751|Drug|GI262570 0.5 mg|GI262570 0.5 mg
45759567|NCT00244751|Drug|GI262570 1.0 mg|GI262570 1.0 mg
45759568|NCT00244751|Drug|Placebo|Placebo
45759569|NCT04382209|Procedure|Erector spinae plane block|The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. Bilateral ultrasound guided erector spinae plane block with 20 mL of 0.375% bupivacaine each using an in-plane, cranial-to-caudad approach to contact the bony shadow of the transverse process (TP) with the tip deep to the fascial plane of the erector spinae muscle. The correct location of the needle tip was confirmed by injecting 0.5-1 cc of normal saline 0.9% and observing linear fluid spread lifting the erector spinae muscle off the tip of the TP.
45759570|NCT04382209|Device|Intravenous meperidine patient controlled analgesia device|Intravenous meperidine patient controlled analgesia device will be given to the patients postoperatively and 24 hour meperidine consumption will be recorded
45614478|NCT04381533|Behavioral|Psychoeducation, information on use of alcohol and its effects|The intervention is a behavioural internet-based intervention including psychoeducation focusing on providing information on alcohol, alcohol use, and its effects. The psychoeducation is provided via texts and pictures, and there is a possibility of asking questions to a therapist if needed however no therapist contact is mandatory. There are separate programs directed towards the young adult and the accompanying significant other. The programmes give brief self-help tips at the end. The intervention approximately corresponds to the information given in a primary care setting for someone with problematic alcohol use.
45759571|NCT04634071|Drug|Varenicline|Varenicline therapy will be 12-week course. On days 1-3 participants will receive 0.5mg once daily; days 4-7 receive 0.5mg twice daily and day 8 until the end of treatment receive 1mg twice daily.
45614479|NCT03347461|Drug|Otiprio|Otiprio is a single-dose, physician-administered, sustained-exposure otic fluoroquinolone antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement surgery. Otoprio (6% ciprofloxacin, 60 mg/mL) will be administered through the tube lumen by the otolaryngologist immediately after tympanostomy surgery.
45614480|NCT03347461|Drug|Ciprodex|Ciprodex is a combined antibiotic and steroid ear drop used to treat otitis media with tympanostomy tubes. Four drops of Ciprodex (0.14mL) instilled by the otolaryngologist into the affected ear immediately after tympanostomy surgery. Each mL of Ciprodex contains ciprofloxacin hydrochloride 0.3 % (equivalent to 3 mg ciprofloxacin base) and dexamethasone 0.1 % equivalent to 1 mg dexamethasone
45614481|NCT03351673|Diagnostic Test|endometrial volume 2D TVS|calculation the endometrial volume using 2D ultrasound and correlation the results with the pathological findings of endometrial biopsy
45614482|NCT03346603|Other|urine culture and susceptibility testing|All patients will have a urine culture and susceptibility test ordered per standard care. Results of tests will identify which patients have antimicrobial-resistant organisms.
45614483|NCT03351517|Drug|Tapentadol 100 MG|100 mg of oral extended release tapentadol will be given to the patients undergoing total knee replacement surgery on spinal anesthesia to evaluate its efficacy in the management of post-operative pain.
45614484|NCT03351517|Drug|Placebo Oral Tablet|A matching placebo will be given to the patients undergoing total knee replacement surgery on spinal anesthesia to evaluate its efficacy in the management of post-operative pain.
45614485|NCT04351659|Other|Blood donation from convalescent donor|Donation of 1 unit of blood or leukapheresis
45759572|NCT04634071|Drug|Bupropion|Patients will begin with a dose of 150 mg every morning for 3 days. Then dosage will increase to 150 mg twice daily (morning and evening), for a total daily dose of 300 mg, for 7 to 12 weeks.
45759573|NCT04634071|Drug|Long-acting nicotine replacement therapy|Nicotine replacement therapy (NRT) patches will be used daily from 1-10 weeks depending on participant's smoking history.
45759574|NCT04634071|Behavioral|Low-intensity counseling|A study coordinator or a member of the treatment team will provide a minimum level of initial counseling, approximately 10-20 minutes in length.
45759575|NCT04634071|Behavioral|High-intensity counseling|A counselor will provide eight sessions in the first 8 weeks of the study. Up to three follow up sessions over the next 4 months of study will be encouraged, but not required.
45759576|NCT04634071|Other|No nicotine replacement therapy|Participants in this group will not receive per required need nicotine replacement therapy.
45759577|NCT04634071|Drug|Nicotine Replacement Products|Participants in this group will receive per required need nicotine replacement therapy.
45759578|NCT03417921|Drug|ABTL0812|ABTL0812 in combination with gemcitabine and nab-paclitaxel
45759579|NCT03417921|Drug|Gemcitabine and nab-paclitaxel|Gemcitabine and nab-paclitaxel as standard pattern
45759580|NCT03028935|Behavioral|Exercise Intervention|Undergo instructor-led exercise program
45759581|NCT03028935|Behavioral|Nutritional Intervention|Undergo instructor-led nutritional education program
45759582|NCT03935425|Device|FitMi Plus|A set of common objects that couple with a wireless sensor platform to allow the performance of functional exercises to be measured by a motivating software platform.
45759583|NCT03935425|Device|FitMi Basic|A wireless sensor platform that allows movement subcomponents and point-to-point exercises to be measured by a motivating software platform.
45759584|NCT03389997|Diagnostic Test|nasal swabs|Iterative nasal swabs will be performed to screen for virus shedding
45759585|NCT03381183|Drug|Durvalumab|Phase 1 and Phase 2: 1500 mg every 4 weeks (Q4wks).
45759586|NCT03381183|Drug|IRX-2 Regimen|"Phase 1 and Phase 2 - Every 12 weeks - IRX-2 Regimen:~Cyclophosphamide 300 mg/m^2 - intravenously.~IRX-2: 460 units daily (4 injections of 115 units)."
45759587|NCT00799981|Device|A=SpeediCath Compact 7 cm and B=POBE 10 cm|Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
45759588|NCT03378297|Drug|Metformin|Metformin tablets 850 mg x 2 orally
45759589|NCT03378297|Drug|Acetylsalicylic acid|Acetylsalicylic acid tablets 160 mg x1 orally
45759590|NCT03378297|Drug|Olaparib|Olaparib capsules 300 mg x 2 orally
45759591|NCT03378297|Drug|Letrozole|Letrozol tablets 2.5 mg x 1 orally
45759592|NCT03933475|Device|Virtual reality game|Use of virtual reality games on television screens
45759593|NCT03372057|Drug|Duvelisib|Duvelisib PO 25 mg BID or 50 mg BID or 75 mg BID in 28-day cycles.
45759594|NCT03372057|Drug|Duvelisib|Duvelisib PO 75 mg BID in 28-day cycles.
45759595|NCT03372057|Drug|Duvelisib|Duvelisib PO BID in 28-day cycles (dose determined in Optimization Phase)
45614486|NCT03346525|Drug|intramuscular benzathine penicillin G (BPG) prophylaxis|Intramuscular BPG prophylaxis (600,000 IU for children <30kg, 1.2 million IU for children ≥30kg), every 28 days.
45614487|NCT05070273|Diagnostic Test|Hypoglossal nerve conduction study|"NCS of nervus hypoglossus (evaluation of M-response parameters) was carried out using a 4-channel electromyographic machine. The stimulation will be carried out from three points:~angle of the lower jaw (proximal point),~the area of the carotid triangle (distal point),~directly from the electrode of St. Mark when it is localized on the muscles of the tongue.~The initial stimulation parameters: strength of an electric current 20 mA, stimulus duration 0.2 ms, and frequency 1 Hz. To achieve supramaximal stimulation, the stimulation strength will be increased with a step of 1-2 mA to a maximum of 35 mA, the duration of the stimulus will be increased to 0.3 ms."
45614488|NCT05070273|Diagnostic Test|Transcranial magnetic stimulation of hypoglossal nerve|"TMS will be carried out using a Magstim 200 magnetic stimulator connected with a BiStim module (Magstim Co. Ltd., Whitland, Wales, UK). The generated magnetic pulses will be delivered by the coil 65 mm in diameter tangentially located relative to the scalp in the F7 projection - T3 and F8-T4 (according to the international scheme 10-20). The area of cortical stimulation will be localized by supplying single pulses with gradual increase, with a coil displacement with a step of 1 cm, until the contraction of the facial muscles will be obtained, followed by the determination of the MEP threshold value. Analysis of conduction by cortical-lingual pathway will be performed at TMS with magnetic stimulus intensity 20-30% above the MEP threshold."
45614489|NCT05060523|Drug|Tolvaptan Tablets|• Tolvaptan15 mg once a day for 7 days, stat with 7.5 mg and titrate to 15 mg in 24 hours max30 mg
45614490|NCT05060523|Drug|Midodrine Oral Tablet|"• Midodrine 5 mg at 0 hours and then 5 mg every 8 hours to maintain Target MAP-80"
45614491|NCT05060523|Other|Placebo|Placebo of Midodrine
45614492|NCT04502641|Drug|Docetaxel|60mg/m2 on day 1, 3 weeks as one cycle, for 3 cycles.
45614493|NCT04502641|Drug|5-fluorouracil|600 mg/m² per day as a continuous 120 h infusion on days 1-5, 3 weeks as one cycle, for 3 cycles.
45614494|NCT04502641|Drug|Cisplatin|60mg/m2 on day 1, 3 weeks as one cycle, for 3 cycles.
45614495|NCT04502641|Radiation|Intensity Modulated Radiation Therapy|The treatment consisted of definitive radiotherapy with conventional fractionation, a total dose of 68-70 Gy to PTVp, 62-68 Gy to PTVn, 60-62 Gy to PTV-HR, and 50-54 Gy to PTV-LR.
45614496|NCT04502641|Drug|Platinum|100mg/m2 on day 1, 3 weeks as one cycle, during radiotherapy.
45614497|NCT05555797|Device|308nm Excimer laser|Excimer laser will be (1-2 sessions/ week for 12 sessions according to induration protocol)
45614498|NCT05555797|Drug|Tazarotene Topical Gel|Tazarotene gel 0.1%(finger tip unit of the gel) will be applied once daily for weeks
45614499|NCT05555797|Drug|Betamethasone Valerate|.Betamethasone valerate ointment 0.1% will be applied twice daily for 12 weeks.
45614500|NCT04504513|Drug|Trilaciclib|"Trilaciclib is a highly potent, selective, and reversible cyclin-dependent kinase 4/6 inhibitor administered intravenously prior to chemotherapy for chemotherapy-induced myelosuppression (CIM).~In patients being treated for SCLC, trilaciclib transiently maintains G1 cell cycle arrest of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow, thus protecting the cells from damage by cytotoxic chemotherapy (myelopreservation). This can reduce chemotherapy-related toxicity, making chemotherapy safer and more tolerable, and also reduce the need for rescue interventions that address the effects of myelosuppression, such as growth factors or blood and platelet transfusions."
45614501|NCT04502485|Procedure|Gastric water exchange|Upon entering the fundus of the stomach the air button will be turned off. Air pocket and gastric fluids will be removed by suctioning. Distilled water, delivered by a 50-ml syringe in 10ml-to-20 ml increments, will be infused to dislodge debris and air bubbles adhering the gastric mucosa and open the lumen. The infused water will be removed to keep the lumen almost completely collapsed before the scope advance further.
45614502|NCT04502485|Procedure|traditional air insufflation|Air will be minimally insufflated and residual fluid suctioned during the entire insertion process. Usually, no water will be infused to cleanse the mucosa until the withdrawal phase.
45614503|NCT03347305|Behavioral|automated DP|Energy expenditure measurement
45614504|NCT03347305|Behavioral|Calorimetric chamber|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
45614505|NCT04076943|Drug|Roxadustat|Roxadustat will be administered per schedule specified in the arm description.
45614506|NCT04219033|Other|EEG(Electroencephalogram) change|patients are found to have characteristic EEG change
45614507|NCT04325763|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
45614508|NCT04325763|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
45614509|NCT04325763|Drug|TQB2450(blank)|Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
45614510|NCT04325763|Drug|Anlotinib(blank)|Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
45614511|NCT00708643|Device|Habitual Silicone Hydrogel Contact Lens|contact lens
45614512|NCT00708643|Device|narafilcon A|contact lens
45614513|NCT03955575|Drug|Liraglutide 6 MG/ML|Liraglutide as injections.
45614514|NCT03955575|Drug|Colesevelam|3 x 625 miligram 2 times a day.
45614515|NCT04204759|Device|Transcranial direct current stimulation|Non-invasive stimulation will be conducted using a tDCS device (StarStim, Neuroelectrics, Spain).
45614516|NCT04204759|Device|Sham transcranial direct current stimulation|The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
45614517|NCT03762603|Device|Robotic exoskeleton device|It is a non invasive and non significant risk medical device which wraps around operated knee to support motion.
45614518|NCT04163419|Drug|Tanezumab|Tanezumab 10 mg SC
45614519|NCT04163419|Drug|Placebo|Placebo 10 mg SC
45614520|NCT03347149|Device|Alarm Advisor Software|Providing advice on alarm limits as part of routine medical care
45614521|NCT03351205|Device|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.
45614522|NCT03351205|Procedure|dried biological amnion graft|"Uterine application of dried biological amnion graft following hysteroscopic adhesiolysis.~Other Name: Human amnion membrane"
45614523|NCT03351205|Drug|estradiol valerate tablets+dydrogesterone tablets|oral estradiol valerate tablets+dydrogesterone tablets
45614524|NCT04698057|Drug|Placebo|The aim of the study is to validate the desescalation of the treatment to stop ciprofloxacin prescription that may not impact the outcome of the patients but add toxicity and antibiotics selection. Placebo will be administred in the experimental arm
45614525|NCT04698057|Drug|Amoxicillin Clavulanate|Will be administred to all patients
45614526|NCT04698057|Drug|Ciprofloxacin|Will be administred to patients in the standard of care arm
45614527|NCT03351127|Radiation|Carotid ultrasound examination|Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's Aixplorer ultrasound system.
45614528|NCT04257045|Other|Interview|Participate in semi-structure, in-depth qualitative interviews
45614529|NCT04257045|Other|Questionnaire Administration|Complete questionnaires
45614530|NCT04257045|Other|Survey Administration|Complete survey
45614531|NCT02449005|Biological|BM-MSCs/fibrin glue/collagen fleece|Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
45614532|NCT02449005|Other|Fibrin glue/collagen fleece|The biocomplex of autologous fibrin glue and collagen fleece devoid of stem cells will fill the osseous defect
45614533|NCT02449005|Procedure|Open flap debridement|Group C will receive minimally invasive surgery employing papilla preservation techniques in addition to retaining the soft tissue wall of the pocket. There will be no use of grafting materials
45614534|NCT04217109|Diagnostic Test|Odour sampling|"Upon receipt of the samples at the Institute Curie-Paris, the compresses will be packed in jars and then transmitted to the dog center and analyzed by the study dogs.~Positive marking is characterized by a sitting position of the dog in front of the sample."
45614535|NCT03049111|Biological|Der f|Inhalation of Der f in mild asthmatics who are sensitive to Der f.
45759596|NCT04559659|Other|Respiratory muscle strength|Pimax and Pmax will be performed according to the (ATS) and (ERS). A Manovacuometer (Analog M 120, GlobalMed) with a range between 0-120cmH2O will be used. The elderly should undergo forced inspiration after maximal expiration and forced expiration after maximal inspiration through a mouthpiece with a hole to prevent closure of the glottis to evaluate Pimax and Pmax. The elderly should sustain the inspiration for 1 second. Three measurements will be performed, with a one-minute interval between them, with less difference equal to 10% between them, the higher value will be used.
45614536|NCT04485507|Other|Nature-VR|Viewing 360 degree nature pictures delivered by a virtual reality headset for 10 minutes/day, 5 days/week for 4 weeks (total of 200 minutes).
45614537|NCT04485507|Other|Urban-VR|Viewing 360 degree urban pictures delivered by a virtual reality headset for 10 minutes/day, 5 days/week for 4 weeks (total of 200 minutes).
45614538|NCT04274049|Genetic|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
45614539|NCT04274049|Other|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
45614540|NCT04204707|Other|PROMS|Patient Reported Outcomes after different types of surgery for rectal endometriosis
45614541|NCT02929069|Behavioral|ESTEEM|ESTEEM is a 10-session intervention based on the Unified Protocol, an individually-delivered CBT intervention with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation skills; reducing avoidance patterns; and improving motivation and self-efficacy for behavior change.
45614542|NCT02929069|Behavioral|CMHT|CMHT is the current standard of care for LGB individuals who seek mental, behavioral, or sexual health care is LGB-affirmative therapy.The practice of LGB-affirmative therapy is outlined across 21 guidelines published by the American Psychological Association.
45614543|NCT02929069|Behavioral|VCT|Voluntary Counselling and Testing (VCT).
45614544|NCT04132791|Other|placebo after awakening + aspirin before bedtime|determine the difference in major adverse cardiovascular events between the group with aspirin after awakening and placebo before bedtime and the group with placebo after wakening and aspirin before bedtime.
45614545|NCT04132791|Other|aspirin after awakening + placebo before bedtime|determine the difference in major adverse cardiovascular events between the group with aspirin after awakening and placebo before bedtime and the group with placebo after wakening and aspirin before bedtime.
45614546|NCT04263987|Procedure|Moses laser enucleation of prostate|Using the moses settings with the Lumenis laser system to evaluate outcomes for enucleation of the prostate; hypothesis is that it leads to faster operative time
45614547|NCT04662879|Other|Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score|ENDPAC is a model to risk-stratify patients with new onset diabetes and hyperglycemia for PDAC. Score is calculated using i) age, ii) change, over past year, in body weight and iii) change, over past year, in glucose/HbA1c values obtained from the electronic medical record.
45759597|NCT03367689|Drug|Olaparib|Olaparib 300 mg twice a day (orally) beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
45614548|NCT04662879|Other|Abdominal imaging|Using computerized tomography (CT) scan or magnetic resonance imaging (MRI), if CT scan is contra-indicated, patients with a high ENDPAC score (>0) are approached for informed consent to participate in the imaging intervention. Imaging (CT scan) is performed at up to two time points, study baseline and approximately 3-9 months following the first imaging study.
45614549|NCT03350971|Other|Virtual reality training|training with Wii games, ergometer exercise, ambulation, standing exercises
45614550|NCT03350971|Other|Control|chest physical therapy exercises
45614551|NCT04065009|Drug|Ropivacaine|Experimental drug will be administered intraperitoneally
46068950|NCT05096260|Behavioral|Motivational Interviewing based SMS/MMS and web content|Our primary framework that will guide the web content is Self-Determination Theory (SDT). SDT differentiates between autonomous (conscious choice and are personally relevant) and controlled behavioral regulation (performed due to pressure or coercion by external or internal forces). Messages that enhance autonomy and perceived competence and are consistent with a person's values and goals will be more effective in changing behavior than messages focusing on external rewards. To link vaccination to broader values and goals, participants will select 3-4 goals from approximately 20 values/goals. Individually tailored messages will link each of these values to vaccination. We will also tailor testimonials based on member values and communication style preference.
45614552|NCT04065009|Drug|Saline Solution|Placebo will be administered intraperitoneally
46068951|NCT05070130|Device|dPR and FFR|OpSens non-hyperemic dPR and/or OpSens FFR
45614553|NCT02860741|Behavioral|REJOICE|Small groups led by lay leaders undergo an 8-session faith-based behavioral activation protocol that provides individuals with education about: identifying depressive symptoms, identifying pleasurable activities, scheduling pleasurable activities, and identifying and addressing avoidant behaviors that act as barriers to completing pleasurable activities
45614554|NCT02860741|Other|Control|Churches in the control arm will receive an educational materials about identifying depressive symptoms and self-management options for addressing depressive symptoms.
45614555|NCT04250493|Biological|Homeostasis Model Assessment of insulin resistance (HOMA)|Fasting blood sample for : glucose, insulinemia, hemoglobin and lipid test to determine the Homeostasis Model Assessment of insulin resistance (HOMA) index
45614556|NCT04250493|Behavioral|MOntreal Cognitive Assessment (MoCA)|Cognitive evaluation with MOntreal Cognitive Assessment (MoCA)
45614557|NCT04250493|Behavioral|Clinical characteristics of AMS patients|Severity and progression of motor disorders assessed by the UMSARS scale, severity of dysautonomia assessed by the COMPASS31 scale ; quality of life questionnaire (AMS-Qol) for the level of difficulty experienced by the patient (on activities such as : move; walk; maintain balance; talk; feed)
45614558|NCT04250493|Procedure|Brain Magnetic Resonance Imaging (MRI)|Brain Magnetic Resonance Imaging (MRI) : putamen imaging, bridge and cerebellum; white substance hypersignals volume
45614559|NCT04250493|Biological|Blood sampling|Optional blood sampling for the constitution of a biological collection
45614560|NCT04501003|Device|Bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen)|With the bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen. Germany), a single incision was made from the bottom of the ostium onto the lateral walls up to the isthmus, with both lateral horns perpendicular to myometrium. The depth of the incision was between 5 and 7 mm. The cavity was widened to be triangular and symmetrical. Both tubal ostium surgeries were clearly observed at the end of the surgery. All patients were discharged on the day of surgery and no hormonal therapy and intrauterine balloon was applied after surgery. Approximately 3 months after the hysteroscopic T-shaped operation, an office hysteroscopy operation was planned to control patients in the secretory phase, to perform uterine cavity and post-operative fly control and to receive post-operative control endometrial biopsy specimens.
45614561|NCT04064229|Device|ivWatch Model 400 with SmartTouch Sensor|The ivWatch Model 400 with SmartTouch Sensor monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
45614562|NCT04064229|Device|ivWatch Model 400 with Fiber Optic Sensor|The ivWatch Model 400 with Fiber Optic Sensor monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
45614563|NCT04501159|Other|blood sample pre, during and post HD|Assessment of ABG pre, during and post HD
45614564|NCT04501159|Device|Non invasive cardiac output assessment|Four ECG style electrodes are placed on the thorax which indirectly measures cardiac output.
45614565|NCT04218591|Other|PRP|Platelet rich plasma
45614566|NCT04218591|Other|Placebo|Saline
45614567|NCT03350893|Combination Product|Emulsion base with probiotics|Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide, Heat-killed L. plantarum powders (1x10^9 cells/ g-cream)
45614568|NCT03350893|Other|Emulsion base|Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide
45614569|NCT01868451|Drug|Brentuximab vedotin (SGN-35)|
45614570|NCT01868451|Drug|Doxorubicin HCL|
45759598|NCT00813319|Behavioral|Girls OnGuard|Using the Information-Motivation-Behavioral Skills Model (IMB) as a framework, Girls OnGuard is an interactive,culturally-appropriate, computer-delivered program design to enhance initial uptake of GARDASIL by addressing three major components: (1) information about GARDASIL; (2) motivation to obtain GARDASIL vaccination; and (3) behavioral skills to enhance self-efficacy of obtaining GARDASIL vaccination.
45759599|NCT00243659|Biological|ReFacto AF|
45614571|NCT01868451|Drug|Vinblastine Sulfate|
45759600|NCT00814177|Drug|warfarin|No change: Continue without any change in spite of prothrombin time outside the therapeutic range.
45614572|NCT01868451|Drug|Dacarbazine|
45759601|NCT00814177|Drug|warfarin|Change: Increase one dose in case prothrombin time is below the therapeutic range; delete or reduce one dose in case prothrombin time is above the therapeutic range.
45614573|NCT01868451|Radiation|Involved-Site Radiation Therapy (ISRT)|
45614574|NCT01868451|Procedure|Interim PET|
45614575|NCT01868451|Radiation|consolidation volume RT (CVRT)|
45614576|NCT04501237|Behavioral|Bruxers with sleep hygiene instructions|the test group will receive instructions of sleep hygiene, limited use of screens and a relaxation audio.
45614577|NCT01591707|Behavioral|ISC+PRT Intervention|Teachers will be trained to implement an intervention in preschool ASD classrooms that provides a learning environment in which social and communication skills are focused on.
45614578|NCT04500925|Procedure|UNILATERAL THYROIDECTOMY|
45614579|NCT04645329|Device|shoulder immovilization sling|immobilization of the arm after surgery
45445498|NCT01321125|Biological|Bacterial culture of the prepared skin's areas|Cultures were taken with a scrub-cup of 5cm2 of internal area pressed over the skin previously prepared, then it was added a 3mL of culture broth (C/E neutralizing broth (D/E Neutralizing Broth, DIFCO TM) containing a neutralizing agent and a detergent agent (1% solution tween-80) as washing solution. The skin was scrub with a sterile rubber policeman for 2 minutes, and the procedure was conducted once again. Both aliquots were gathered together in a sterile tube, and a sample of 50mL was spread in a plate containing a neutralizing agar (D/E neutralizing Agar, DIFCO TM) and incubated at 35°C for 72 hrs. After incubation, the colonies were counted.
45614580|NCT02513017|Behavioral|Stimulus Control Instructions and Sleep Restriction Therapy|Please refer to arm/group descriptions.
45614581|NCT03346447|Other|Artificial Fecal Enzyme|Artificial Fecal enzyme Trypsin/Chymotrypsin mixture
45614582|NCT04619355|Device|NIRS-IVUS|Near-infrared spectroscopy-intravascular ultrasound can be implemented in parallel with intravascular ultrasound and provides important information for predicting prognosis by measuring the lipid component of atherosclerotic plaques.
45445499|NCT01321125|Other|Preparing skin's areas to be tested|Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 10% sodium hypochlorite) and two controls were tested as skin antiseptics. The intervention consisted of preparing four skin's areas with the antiseptic or the control, two in each arm of the volunteer. These ones were approximately 25cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was kept on the skin for 60 seconds before the bacterial culture was conducted. Every volunteer were studied in three separate occasions, alternating the four areas in every subsequent test, so every area was studied with each control or antiseptic.
45614583|NCT01210365|Drug|Diurisa®|Furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow onde tablet per day in whole form on an empty stomach with some liquid during 4 weeks.
45614584|NCT01210365|Drug|Lasix ®|One group of patients will receive furosemide 40mg .The patient will swallow the tablet in whole form on an empty stomach with some liquid.
45614585|NCT03833479|Other|No Further Treatment|No further treatment
45614586|NCT03833479|Drug|TSR-042|Fixed 500 mg TSR-042 dose Q3W for the first 4 doses followed by a fixed 1000 mg TSR-042 dose Q6W for up to 24 months
45614587|NCT01119807|Device|Intravenous access during OHCA|First attempt will be a peripheral IV in the AC. If this fails, second attempt will be a tibial IO, followed by a humeral IO when indicated.
45614588|NCT01119807|Device|Humeral IO insertion|First attempt will be a humeral IO. Second attempt should occur at the tibia if the first humeral IO fails. Subsequent attempts will be for a peripheral IV or additional IOs as determined by the paramedic.
45614589|NCT01119807|Device|TIbial IO insertion|First attempt will be a tibial IO. Second attempt should occur on the opposite tibia if the first IO fails. Subsequent attempts will be for a humeral IO or peripheral IV as selected by the paramedic.
45614590|NCT01137643|Other|biologic sample preservation procedure|All samples collected during routine clinical care.
45759602|NCT00243347|Drug|AZD2171|oral tablet
45911547|NCT05778890|Other|Intervention Group: Physiotherapy program + home exercises program|Physiotherapy program: The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Treatment for control group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education. In addition to the treatment for control group, intervention group received home exercises program.The intervention group was also taught home exercises program and asked to do 6 repetitions 6 times a day. This exercise program was given to the patients in brochure form.
45614591|NCT01137643|Other|cytology specimen collection procedure|All Samples collected during routine clinical care.
45614592|NCT05583331|Procedure|Cataract surgery|Cataract surgery will be performed as per local practice and standard guidelines.
45614593|NCT05583331|Procedure|Vitrectomy|Vitrectomy will be performed as per local practice and standard guidelines.
45614594|NCT04615689|Other|The collection of feces|When the infants will be diagnosed with urinary tract infection, feces will be collected. Feces will be collected from healthy infants with informed consent.
45614595|NCT02517853|Device|Posterior tibial nerve stimulation|
45614596|NCT02517853|Device|Sham posterior tibial nerve stimulation|
45614597|NCT04147221|Drug|Imipenem-relebactam|After receipt of imipenem-relebactam, participants will have six blood samples collected over 6 hours for determination of imipenem and relebactam concentrations.
45614598|NCT03432429|Other|REIMS iKnife|Use of REIMS iKnife in breast conserving surgery
45614599|NCT04499365|Drug|68Ga-DOTA/NOTA-FAPI-04|Each patient receive a single intravenous injection of 68Ga-DOTA/NOTA-FAPI-04, and undergo PET/CT scan within specified time.
45614600|NCT04499365|Diagnostic Test|PET/CT scan|PET/CT scan
45614601|NCT04435509|Dietary Supplement|1000+ Greek Mountain Tea|Dietary Supplement: Greek Mountain Tea dietary intake of the content of 12 grams (4 grams 3 times per day ) 50 grams per month
45614602|NCT04435509|Other|Mediterranean Diet|a Mediterranean dietary protocol
45614603|NCT01037907|Drug|Pleneva TM BGC20-0134|Placebo or 5 g dose
45614604|NCT01037907|Drug|Placebo|Placebo or 5 g dose
45614605|NCT02517775|Dietary Supplement|Cranberry 320|Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily)
45614606|NCT02517775|Dietary Supplement|Cranberry 640|Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily)
45614607|NCT02517775|Dietary Supplement|Cranberry 960|Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily)
45614608|NCT02517775|Dietary Supplement|Cranberry 1280|Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)
45614609|NCT02517775|Dietary Supplement|Cranberry 1600|Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily)
45614610|NCT02517775|Dietary Supplement|Cranberry deprived supplement|Cranberry deprived supplement Acute intake of 500 mL (1x daily)
45614611|NCT02517697|Drug|14 Nitrogen (N) Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times daily for 12 weeks
45614612|NCT02517697|Drug|Placebo|oral formulation of matching placebo three times daily for 12 weeks
45614613|NCT04130529|Behavioral|Adjusted group CBT-i for Bipolar disorder|CBT-i includes sleep scheduling/sleep compression, stimulus control, relaxation, cognitive interventions and sleep hygiene advice. In addition components targeting circadian rhythm problems and problems with very high or very low levels of activity are included.
45614614|NCT04130529|Other|Sleep lectures|Lectures on the topic of sleep.
45614615|NCT02517619|Drug|Dexamethasone Phosphate Ophthalmic Solution|40 mg/mL
45614616|NCT02517619|Drug|Prednisolone Acetate Ophthalmic (1%)|Prednisolone Acetate (1%)
45614617|NCT03968913|Drug|Anakinra injection|anakinra 150mg in 5milliliters of sterile saline will be injected into the knee joint
45614618|NCT03968913|Procedure|sterile saline injection|5 milliliters of sterile saline will be injected into the knee joint
45614619|NCT03504943|Other|Early Intradialytic Exercise|Timing of intradialytic exercise first half of HD
45614620|NCT03504943|Other|Late Intradialytic Exercise|Timing of intradialytic exercise second half of HD
45614621|NCT03892395|Dietary Supplement|B-vitamin supplementation on bone health|An intervention study to investigate the effect of B-vitamin supplementation for 2-years on bone health
45614622|NCT03892395|Dietary Supplement|Control group; Vitamin D, a daily capsule containing 10 µg/day vitamin D|Vitamin D, a daily capsule containing 10 µg/day vitamin D
45614623|NCT04481451|Procedure|Erector spinae block with ropivacaine 0.2%|Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.
45614624|NCT04481451|Procedure|Quadratus lumborum block with ropivacaine 0.2%|Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.
45614625|NCT04481451|Drug|Ropivacaine|ropivacaine 0.2% nerve block injection
45614626|NCT03376659|Drug|Durvalumab|750mg IV q2 weeks
45614627|NCT03376659|Biological|CV301|"MVA-BN-CV301 (prime) - two priming doses of 1.6 x 109 infectious units/0.5 mL (Inf.U) given subcutaneously (s.c.)~FPV-CV301 (boost) - dosed at 1 × 109 Inf.U/0.5 mL given s.c."
45614628|NCT03376659|Drug|Capecitabine|1000mg orally twice a day, Monday - Friday Weekly
45614629|NCT03376659|Drug|Bevacizumab|5mg/kg IV q2weeks
45614630|NCT03335553|Drug|BMS-986235|Specified dose on specified days
45759603|NCT05335681|Behavioral|WARM SHOWER APPLICATION|Experimental group; At least when the cervical opening is 4 cm (Latent phase) and 7 cm (Active phase) While the 20-minute hot shower (37 °C) intervention was performed, the control group only will receive standard care. hot shower; sacrum, lower abdomen and groin areas will be applied. Since possible complications may be encountered, pregnant women The researcher will be accompanied and sit safely in the chair. will be provided. VAS scale twice, before and after the intervention will be applied. Birth satisfaction scale before discharge will be applied.
45759604|NCT04332601|Behavioral|Fatigue Management Therapy|14 sessions of 1h CBT intervention
45759605|NCT04332601|Other|TAU (Treatment as usual)|No CBT intervention
46068952|NCT05067569|Behavioral|SleepFix mobile application|The SleepFix app is a novel, innovative way to deliver digital brief behavioural therapy for insomnia for adults.
46068953|NCT05067569|Behavioral|Sleep Health Education|These internet-based modules provide an active control intervention consisting of 3 modules provided bi-weekly. The participant will receive a link to this information as each module is made available. Control participants will have full access to these modules for the duration of the study. They reflect basic educational information regarding sleep health for poor sleepers that is otherwise easily accessible on the internet.
45614631|NCT03335553|Other|Placebo|Specified dose on specified days
45614632|NCT04120467|Other|Dance|"One group will receive a 60-minute dance class weekly over a 6 weeks period. A physiotherapist - dance teacher will lead the classes, supported by at least one volunteer.~The class structure will consist of five components: warm up (10 minutes), technical exercises (10 minutes), improvisation (15 minutes), a short routine (15 minutes) and a cool down/feedback time (10 minutes). Dance exercises will be targeting flexibility, balance, endurance, upper and lower limbs functions, interaction between dancers, perception and memory. Using choreography or short routine, the class will include repeating the dance moves - which fosters memorization - and also the additional challenge of remembering a sequence of moves.~Given the great variability of each participant's functional ability, the complexity and the intensity of the dance exercises will progress according to each participant's capacity, in order to fulfill an appropriate challenge at moderate treatment intensity."
45614633|NCT04120467|Other|Standard rehabilitation|The control group will have conventional rehabilitation as usually planned in the rehabilitation center: 45 to 60 minutes of physiotherapy per day integrating sensory stimulation, motor activation, strengthening, coordination, balance and exercise training. Patients also receive 45 to 60 minutes of occupational therapy per day.
45614634|NCT03300921|Drug|Paricalcitol|"Product: Paricalcitol~Dose/Route/Regimen:~Arm A: 50mcg IV weekly Arm B: 12mcg PO daily"
45614635|NCT03888339|Procedure|Commercially available high abutments placement|Patients will be randomly selected for the commercially available high abutments option. Two or three implants will be placed following the drilling protocol suggested by the manufacturer. Implants will be placed 0.5mm subcrestal. Once the implants have been placed, periapical radiographs and clinical pictures will be taken. Implants will be uncovered 10 weeks after being placed. After performing the incision and elevation a minimal flap, conventional high transmucosal abutments will be screwed using the torque recommended by the manufacturer. Once the abutments have been screwed, periapical radiographs and clinical pictures will be taken. The abutments will not be unscrewed thereafter throughout the study.
45445500|NCT01321125|Biological|Antiseptic substantivity|Three antiseptics will be tested: 2% chlorhexidine gluconate in 70% isopropyl alcohol, 10% sodium hypochlorite and 10% povidone-iodine, each one will be applied on the surface of one fingertip each, and will be allow to dry for 60 seconds, then the remaining antiseptic on the skin will be wash out with distilled water. The evaluated zones will be dried with sterile gauze, and then will be covered with sterile gauze for two hours. After this period, each finger will be placed for 30 seconds on an agar plate, which will be inoculated whit an ATCC E. coli. The plate will be incubated at 35ºC for 72 hrs. After incubation, a blinded technician will report the presence or absence of bacterial growth
45614636|NCT03888339|Procedure|Modified shape abutments|Patients will be randomly selected for the modified shape abutments option. Two or three implants will be placed following the drilling protocol suggested by the manufacturer. Implants will be placed 0.5mm subcrestal. Once the implants have been placed, periapical radiographs and clinical pictures will be taken. Implants will be uncovered 10 weeks after being placed. After performing the incision and elevation a minimal flap, modified high transmucosal abutments will be screwed using the torque recommended by the manufacturer. Once the abutments have been screwed, periapical radiographs and clinical pictures will be taken. The abutments will not be unscrewed thereafter throughout the study.
45614637|NCT04116099|Other|Conservative care|May include graduated compression, MLD performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
45614638|NCT04116099|Device|Flexitouch Plus|Flexitouch Plus treatment.
45614639|NCT03882021|Procedure|A specific electrophysiology mapping protocol is applicable with the GRID catheter.|The procedure will be done according to a standard ablation approach. During the electrophysiology study, additional mapping data will be collected to support the study endpoints using the GRID catheter.
45614640|NCT03852615|Diagnostic Test|Pre operation Blood sample for AMH|Blood sample for Anti Mullarian Hormone (AMH) analysis will be taken during preparation for surgery, while inserting vein line and taking the customary blood samples.
45614641|NCT03852615|Diagnostic Test|3 month post operation blood sample for AMH|Additional blood sampling that will include a single tube containing 3 cc of blood for analysis of AMH will be taken three month from operation.
45614642|NCT03259815|Procedure|P.I.O.S.|Physiologically-Guided Incremental Optimisation Strategy
45614643|NCT03259815|Diagnostic Test|Pre and post-PCI coronary physiology measurements|Pre and post-PCI coronary physiology measurements will be performed but not disclosed to the operator
45614644|NCT03222999|Other|No intervention planned|No intervention planned
45614645|NCT04102371|Drug|Lactated Ringer|"LR is a sterile, nonpyrogenic balanced solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5)."
45614646|NCT04102371|Drug|Normal Saline|"Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride."
45614647|NCT04102371|Drug|Plasma-lyte|PL is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration. Each 100 mL contains 526 mg of Sodium Chloride, USP (NaCl); 502 mg of Sodium Gluconate (C6H11NaO7); 368 mg of Sodium Acetate Trihydrate, USP (C2H3NaO2•3H2O); 37 mg of Potassium Chloride, USP (KCl); and 30 mg of Magnesium Chloride, USP (MgCl2•6H2O). It contains no antimicrobial agents. The pH is adjusted with sodium hydroxide. The pH is 7.4 (6.5 to 8.0).
45614648|NCT04094103|Dietary Supplement|Active strawberry powder|Participants will drink a strawberry beverage with active ingredients once a day during the 4-week intervention period.
45614649|NCT04094103|Dietary Supplement|Placebo strawberry powder|Participants will drink a strawberry placebo beverage once a day during the 4-week intervention period.
45614650|NCT04094103|Dietary Supplement|Mixed strawberry powder|Participants will drink a mixed strawberry beverage with active ingredients and placebo once a day during the 4-week intervention period.
45759606|NCT00243269|Behavioral|Acupressure expectancy enhancement|"This study hypothesizes that patients receiving efficacy enhancing information about the acupressure bands will expect less treatment-related nausea, which will subsequently result in less treatment-related nausea compared to patients who do not receive such information.~This study extends prior research by utilizing a randomized controlled trial in a clinical environment to examine the efficacy of an intervention that is specifically designed to reduce patients' response expectancies concerning nausea development from cancer treatments, and, thereby, reduce nausea."
45759607|NCT05329987|Other|Rehabilitation|Intervention focused on balance, gait and postural transfers rehabilitation. 20 session of 90 minutes (60 minutes of physiotherapy and 30 minutes of occupational therapy), 2 times a week, for 10 weeks.
45759608|NCT03364491|Drug|Tranexamic Acid|A single dose of Tranexamic Acid (1 gram) in normal saline for a total of 50cc, administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
45759609|NCT03364491|Drug|Placebo|50 cc normal saline administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
45759610|NCT04311307|Biological|[6,6-2H2]glucose|Each subject will be administered two oral [6,6-2H2]glucose loads (pre-prandial, fed) in the hospital setting and one oral [6,6-2H2]glucose load at home setting (random time). Capillary blood samples will be collected on filter paper 10 times at specific time points after each oral [6,6-2H2]glucose load.
45759611|NCT04294069|Drug|Azithromycin 500 mg|500mg azithromycin PO for seven days starting on admission
45759612|NCT04294069|Drug|Azithromycin Oral Product|1000mg azithromycin PO once at admission
45759613|NCT00782639|Drug|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
45614651|NCT04086147|Drug|Low dose tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
46068954|NCT05064839|Procedure|Bony scintigraphy|Bony scintigraphy (99mTc-Hydromethylene diphosphonate) will be performed in all patients with hypertrophy of the left ventricle
46068955|NCT05061446|Drug|Etrasimod|Etrasimod tablet by mouth, once daily for 12 weeks
45614652|NCT04086147|Drug|High dose tenecteplase|Intravenous (IV) tenecteplase 0.32 mg/kg (single bolus; maximum dose 32 mg)
45614653|NCT03179397|Device|Model SC9|Experimental
45614654|NCT03179397|Device|Model LI61SE|Active Comparator
45614655|NCT03161223|Drug|Durvalumab|"Durvalumab is an investigational human monoclonal antibody that works to inhibit (block) a protein called programmed cell death-1 ligand 1 (PD-L1). Durvalumab has not been approved by the FDA for the treatment of PTCL but has been given to patients other types of cancers. Given intravenously (through the vein).~Starting dose: 1500 mg"
45614656|NCT03161223|Drug|Pralatrexate|"Pralatrexate is an antimetabolite drug. Pralatrexate alone is FDA-approved for the treatment of PTCL. Given intravenously (through the vein).~Starting dose: 25 mg/m2"
45614657|NCT03161223|Drug|Romidepsin|"Romidepsin is another type of chemotherapy known as histone deacetylase (HDAC) inhibitors. Romidepsin has not been approved for use in lymphoma other than Cutaneous T cell lymphoma (CTCL) by the FDA. Given intravenously (through the vein).~Starting dose: 12 mg/m2"
45614658|NCT03161223|Drug|5-Azacitidine|"Oral 5-azacitidine is used for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Azacitidine prevents the body from making DNA and RNA that cells need to grow. This stops the growth of cancer cells and causes them to die. Given by mouth (orally).~Starting dose: 300 mg daily"
45614659|NCT03105921|Device|NanoKnife|The aim of the treatment is to sourround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
45614660|NCT03735927|Other|Spot monitoring device, excl. Sham|During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
45614661|NCT03660813|Diagnostic Test|Follicle measurment|Follicle will be measured before aspiration
45614662|NCT03660813|Drug|Ovitrelle ( Hcg 250 mcg)|Drug used for triggering
45614663|NCT03660813|Drug|Decapeptyl ( GnRH Agonist 0.1 mg*2 )|Drug used for triggering
45614664|NCT05431959|Other|balneotherapy|immersion in Lake Hévíz, 36℃ sulphur, carbonate, calcium, magnesium, hydrogen carbonate and very light radon-content thermal-mineral water 15 times in 3 weeks 30-minute therapy sessions. The total mineral substance of the water is 754 mg/l.
45614665|NCT01285557|Drug|S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)|25 mg/m² body surface area (BSA) orally 2 times daily from Days 1 through 21 followed by a 7 day rest period, plus cisplatin 75 mg/m2 BSA on Day 1 each 28 day cycle Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles.
45614666|NCT01285557|Drug|Fluorouracil/cisplatin (control arm)|"5-FU: 800 mg/m2 BSA/24 hours by continuous intravenous infusion (CIV) from Days 1 through 5 plus cisplatin 80 mg/m2 BSA on Day 1 each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles."
45614667|NCT03351283|Other|Severe sodium restriction|Patients will be assigned to a diet with sodium restriction of two grams.
45614668|NCT03351283|Other|Moderate sodium restriction|Patients will be assigned to a diet with sodium restriction of three grams.
45614669|NCT01032603|Procedure|Bilateral lateral rectus recession (BLRc)|Bilateral lateral rectus recession surgery
45614670|NCT01032603|Procedure|Unilateral lateral rectus recession with medial rectus resection (R&R)|A unilateral lateral rectus recession combined with a medial rectus resection in the same eye. Choice of eye at investigator discretion based on any interocular difference, position under anesthesia, fixation preference, or forced duction testing. Reason for choice of eye will be recorded.
45614671|NCT03083067|Drug|Budesonide/formoterol|On the foundation of basic treatment strategies, inhaled budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug for patients in PIC group. When air quality index (AQI) is above 200, they will temporary add one inhalation of budesonide/formoterol（160ug/4.5ug）twice a day until the third day after AQI drops below 200.
45614672|NCT03083067|Drug|tiotropium bromide|Inhaled tiotropium bromide(18ug) will be used as routine medicine according to doctor's advice.
45614673|NCT03406975|Device|Overstitch Endoscopic Suture System|Endoscopic Sleeve Gastroplasty (ESG), an endoscopic minimally-invasive weight loss procedure, utilizing a suturing device to reduce the stomach volume by 80% through the creation of sleeve. This is accomplished by a series of endoscopically placed stitches through the stomach wall.
45614674|NCT03406975|Behavioral|Lifestyle Intervention|Standard low-calorie diet plan and moderate intensity life-style intervention of 150 minutes of aerobic exercise per week for 12 months.
45614675|NCT03023241|Procedure|biopsy|cold cup bladder biopsies and bladder washings under anesthesia, blood and urine collection
45614676|NCT05431569|Drug|6MW3211|6MW3211 injection ,30mg/kg,iv drip，Q2W
45614677|NCT02994771|Drug|Lymfactin® [1 x 10E10 vp]|Lymfactin® [1 x 10E10 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
45614678|NCT02994771|Drug|Lymfactin® [1 x 10E11 vp]|Lymfactin® [1 x 10E11 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
45614679|NCT02512549|Other|Pulmonary Rehabilitation|
45614680|NCT02512627|Behavioral|Cognitive training|visuospatial, attention, memory, and executive abilities
45614681|NCT02512627|Behavioral|Physical exercise|endurance, balance, and mobility
45614682|NCT02992431|Behavioral|Participatory patient care planning|Intervention includes the patient activation questionnaire form, a visit to the nurse who conducts the measurements (blood pressure, waist measurement, weight and length) and a visit to the general practitioner who discusses and agrees with the patient about the treatment goals and follow-up resulting in the written PPCP.
45614683|NCT02992431|Other|Usual care|Usual care including standard disease specific follow-up with visit to general practitioner.
45614684|NCT03218137|Drug|Adenosine|Adenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes) Verapamil 0.15 mg/kg
45614685|NCT03346291|Behavioral|counseling|individual, weekly, smoking cessation counseling + over-the-counter nicotine patch
45759614|NCT00782639|Drug|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
45759615|NCT03805295|Other|BOKS Program|12-week physical activity program, occurring 3x/week, lasting 30-60 minutes per session.
46068956|NCT05061446|Drug|Etrasimod|Etrasimod tablet by mouth, once daily for 12 weeks
46068957|NCT05061446|Drug|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 12 weeks
45614686|NCT03346213|Drug|MonoFer|Anaemic patients undergoing major surgery who would routinely be receiving intravenous iron 'MonoFer' will get this as part of routine care. They will then have a CPET repeated at least 10 days afterwards.
45614687|NCT03345043|Biological|VAL-339851|Escalating dose levels
45614688|NCT03345043|Other|Placebo|Saline
45759616|NCT05744219|Drug|Ferric carboxymaltose|Active drug
45759617|NCT05744219|Drug|Placebo|Placebo
45759618|NCT01997229|Biological|Eculizumab|Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every 2 weeks during Weeks 4-26
45614689|NCT05638399|Drug|Denosumab 60 mg/ml [Prolia]|60 mg subcutaneously per 6 month
45759619|NCT01997229|Drug|Placebo|Placebo
45759620|NCT00800839|Drug|Busulfan|Starting dose of 32 mg/m^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3.
45759621|NCT00800839|Drug|Fludarabine|Dose of 40 mg/m^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan.
45759622|NCT00800839|Drug|Cyclophosphamide|Dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
45759623|NCT02000583|Other|Aerobic Exercise|Aerobic group participants will engage in 150 minutes of aerobic exercise over 4-5 days per week for 52 weeks
45759624|NCT02000583|Other|Standard of Care|Control group participants will be provided educational materials on starting an exercise program, but will receive no formal support for their exercise program.
45759625|NCT00814255|Drug|Adalimumab|Adalimumab 24 mg/m^2 (maximum dose 40 mg) sc q 14 days
45759626|NCT00814255|Drug|Lisinopril, losartan, and atorvastatin|Lisinopril PO 10-20 mg per day Losartan PO 25-50 mg per day Atorvastatin PO 10-20 mg per day
45759627|NCT00814255|Drug|galactose|galactose 0.2 g/kg/dose (maximum dose 15 g)po BID
45759628|NCT02000973|Drug|Lidocaine|General anesthesia combined with thoracic epidural 1% lidocaine
45759629|NCT02000973|Drug|Bupivacaine|General anesthesia combined with thoracic epidural 0.25% bupivacaine
45614690|NCT05638399|Drug|Zoledronate|5mg, intravenous infusion once a year
45911548|NCT05778890|Other|Control Group : Physiotherapy program|Physiotherapy program: The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Treatment for control group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education.
46068958|NCT05056870|Device|ACUVUE Oasys 1-Day with HydraLuxe Technology for Astigmatism|TEST
45614691|NCT03346369|Drug|Lanthanum Carbonate|Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period
45614692|NCT02512471|Drug|Ropivacaine|brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB (young group) brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB (middle-aged group)
45759630|NCT02000973|Drug|Ropivacaine|General anesthesia combined with thoracic epidural 0.3% ropivacaine
45759631|NCT02000973|Drug|Normal Saline|General anesthesia combined with thoracic epidural 0.9% normal saline
45759632|NCT02002767|Drug|Velpatasvir|Velpatasvir 100 mg (2 x 50 mg tablets) administered orally
45759633|NCT00815035|Drug|Peanut OIT|Peanut flour that is orally ingested in a graded fashion.
45759634|NCT00815035|Drug|Placebo|Oat flour used as a placebo that is orally ingested a graded fashion
45759635|NCT01985685|Drug|Thiamine|200 mg IV thiamine
45759636|NCT00815347|Drug|bosentan|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
46068959|NCT05056870|Device|ACUVUE Oasys 1-Day with HydraLuxe Technology|CONTROL
45614693|NCT02517385|Drug|Phosphatidylcholine|Pharmaceutical form:Paste Route of administration: Oral
45614694|NCT04499443|Drug|GST-HG131 tablets|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.
45614695|NCT04499443|Drug|Placebo|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.
46068960|NCT05055401|Procedure|Direct Laryngoscopy|The participant will perform a direct laryngoscopy on a Laerdal SimMan 3G under healthy conditions and under limited cervical range of motion.
45614696|NCT02992119|Biological|RTS,S/AS01B Fractional dose|RTS,S/AS01B standard dose at Month 0 and Month 1 + RTS,S/AS01B fractional dose (1/5th dose) at Month 2.
45759637|NCT00815347|Drug|placebo|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
45759638|NCT04196101|Drug|EDP-938|Four tablets daily for 5 days
45759639|NCT04196101|Drug|Placebo|Four tablets daily for 5 days
45759640|NCT01985763|Drug|Genistein|Genistein combined with FOLFOX or FOLFOX-Avastin
45759641|NCT04149301|Diagnostic Test|3D gait analysis|Children will have their walking measured in the gait laboratory to record their kinematics and kinetics along with electromyography (EMG) from key muscle groups.
45759642|NCT04149301|Diagnostic Test|MRI scan|The children will have two MRI scans taken - one with the foot loaded and one with no load applied.
45759643|NCT02061969|Drug|linagliptin|5mg linagliptin tablets
45759644|NCT02061969|Drug|insulin glargine|
45759645|NCT02003625|Drug|GCSF|
45759646|NCT02003625|Drug|meloxicam|
45759647|NCT02003625|Drug|Placebo|
45911549|NCT05778825|Drug|Oral Minoxidil|minoxidil at a dose of 0.01 (<40kg) and 0.02 (≥40kg) mg/kg/day
45911550|NCT05778825|Other|Placebo|placebo for 4 months
46068961|NCT05055401|Procedure|Laryngeal Mask Airways|The participant will perform LMA placement on a Laerdal SimMan 3G under healthy conditions and under full tongue edema.
45614697|NCT02992119|Biological|Double RTS,S/AS01E Fractional dose|A double dose of RTS,S/AS01E standard dose at Month 0 and Month 1 + a double dose of RTS,S/AS01E fractional dose (1/5th dose) at Month 2.
45759648|NCT04037683|Drug|Misoprostol Oral Tablet|Misoprostol 25mcg orally given 2-hourly
45759649|NCT04037683|Drug|Oxytocin|Oxytocin infusion
45614698|NCT02992119|Biological|RTS,S/AS01E Standard dose|RTS,S/AS01E standard dose at Month 0, Month 1 and Month 2.
45614699|NCT02992119|Biological|RTS,S/AS01E + DHA-PIP+PQ Standard dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0, Month 1 and Month 2
45614700|NCT02992119|Biological|RTS,S/AS01E Fractional dose|RTS,S/AS01E standard dose at Month 0 and Month 1 + RTS,S/AS01E fractional dose (1/5th dose) at Month 2.
45614701|NCT02992119|Biological|RTS,S/AS01E + DHA-PIP+PQ Fractional dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0 and Month 1 + RTS,S/AS01E fractional dose (1/5th dose) + DHA-PIP+PQ at Month 2.
45614702|NCT02992119|Biological|RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0 + RTS,S/AS01E fractional dose (1/5th dose) + DHA-PIP+PQ at Month 2
45614703|NCT04500691|Other|pain intensity reporting|pain intensity reporting
45614704|NCT02507479|Drug|Thiotepa|Chemotherapy given prior to allogeneic stem cell transplantation
45614705|NCT02512705|Device|Pinel Restraints|
45614706|NCT02512705|Behavioral|Seclusion Room|
45614707|NCT03394365|Biological|tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
45614708|NCT02512315|Drug|Docetaxel (DOC)|Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Docetaxel is given at a dose of 75mg/m2 on the first day of every cycle.
45614709|NCT02512315|Drug|Cisplatin (DDP)|Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Cisplatin is given at a dose of 75mg/m2 on the first day of every cycle.
45614710|NCT02512315|Radiation|Concurrent chemoradiation (CCRT)|"The technology of radiotherapy is intensity-modulated radiation therapy (IMRT). A total dose of 66-72Gy is given to gross tumor of nasopharynx (GTVnx), 60-70Gy to positive neck lymph nodes (GTVnd), 60Gy to high-risk region (CTV1), and 50-54Gy to prophylactic irradiation region (CTV2).~The regimen of concurrent chemotherapy is single-agent cisplatin 40mg/m2 weekly."
45614711|NCT02507323|Drug|ticagrelor|A platelet aggregation inhibitor
45614712|NCT02507323|Drug|prasugrel|a thienopyridine class inhibitor of platelet activation and aggregation
45614713|NCT02507323|Drug|Placebo|placebo
45614714|NCT05431413|Drug|Control group: Fluoxetine and Placebo|Fluoxetine and 0.9% sodium chloride was administered intravenously.
45614715|NCT05431413|Drug|Experimental group: Fluoxetine and ATP|Fluoxetine and ATP was administered intravenously.
45614716|NCT05431413|Drug|Experimental group: Fluoxetine and Phosphocreatine|Fluoxetine and Phosphocreatine was administered intravenously.
45614717|NCT02507245|Drug|Growth Hormone-Releasing Hormone|From Baseline Visit (T0) to 6th Month Visit 0,025 mg/kg Growth Hormone/die. From 6th Month Visit to 12th Month Visit 0,030 mg/Kg Growth Hormone/die.
45759650|NCT04251247|Diagnostic Test|D-dimer/fibrinogen ratio|The ratio of D-dimer (ng/ml) to fibrinogen (mg/dl)
45759651|NCT04768413|Other|Teleconsultation either by phone or by computer consultation. Quantitative and qualitative approaches to analysis|A group of patients who have voluntarily adhered to the clinic's tele-assisted consultation and who receive remote, multidisciplinary team care without requiring physical displacement.
45614718|NCT05431335|Other|Structured exercise program|"It consists of aerobic exercise combined with breathing, strengthening exercises, and stretching exercises. Aerobic exercise will be performed similarly to the other group, only consisting of a five-minute warm-up period and a 15-minute aerobic load period.~Strengthening exercises consist of deep cervical flexor muscles and shoulder region resistive exercises. Each exercise will be repeated as 15 repetitions, 2 sets.~Stretching exercises are neck region stretching exercises. Each exercise will be performed with 10 seconds of stretching and 5 repetitions."
45759652|NCT04768413|Other|Care modalities. Quantitative and qualitative approaches to analysis|Group of patients who wish to continue with the usual face-to-face consultation, since for these patient's isolation measures allow trips to the care centers and who receive care from a multidisciplinary team on a regular basis.
45759653|NCT04383301|Procedure|Intracorneal ring segment implantaion as the first stage|Intracorneal ring segment (ICRS)
45759654|NCT04383301|Procedure|ACXL and wafe front guieded TPRK as the second stage|Accelerated corneal cross linking (ACXL) and wafe front guided transepithelial photorefractive keratotomy (TPRK)
45759655|NCT04631029|Biological|Atezolizumab|Given IV
45759656|NCT04631029|Drug|Carboplatin|Given IV
45759657|NCT04631029|Drug|Entinostat|Given PO
45759658|NCT04631029|Drug|Etoposide|Given IV
45759659|NCT03356431|Other|Supervised group exercise|"Quadriceps muscle isometric contraction in sitting position 1 set of 3-3 reps × 1 min hold.~Isotonic quadriceps contraction with resistance band 3 sets of 10 reps x 1min hold.~Isotonic hamstring contraction with resistance band 3 sets of 10 reps x 1min hold.~Sit to stand exercise during 1 min.~Dynamic stepping exercise (walking up and down one step/stair during 1 min).~Standing calf stretch 3 x 20 sec.~Standing quadriceps stretching 3 x 20 sec.~Supine hamstring stretching 3 x 20 sec."
45759660|NCT03356431|Other|Home-based exercise|"Quadriceps muscle isometric contraction in sitting position 1 set of 3-3 reps × 1 min hold.~Isotonic quadriceps contraction with resistance band 3 sets of 10 reps x 1min hold.~Isotonic hamstring contraction with resistance band 3 sets of 10 reps x 1min hold.~Sit to stand exercise during 1 min.~Dynamic stepping exercise (walking up and down one step/stair during 1 min).~Standing calf stretch 3 x 20 sec.~Standing quadriceps stretching 3 x 20 sec.~Supine hamstring stretching 3 x 20 sec."
46068962|NCT05055401|Procedure|Video Laryngoscopy|The participant will perform video laryngoscopy on a Laerdal SimMan 3G under healthy conditions and under half tongue edema with pharyngeal obstruction.
46068963|NCT05053321|Drug|Valbenazine|All participants will be treated with Valbenazine for 7 weeks.
45614719|NCT05431335|Other|Aerobic exercise program|Aerobic exercise intensity will be determined by the Perceived Fatigue Scale (Borg scale). It consists of a ten-minute warm-up period (Borg 11), a 15-minute aerobic load (Borg 13-14), and a five-minute cool-down period(Borg 11). The warm-up and cool-down periods include brisk walking combined with breathing, and calisthenic exercises involving the upper and lower extremities; the loading period consists of exercises using a step-dance board accompanied by music. The number of repetitions will be increased progressively to keep the exercise intensity constant.
45759661|NCT03211221|Device|rTMS (repetitive transcranial magnetic stimulation)|rTMS is a non-invasive neuromodulation technique that is able to modulate cortical and subcortical function with the use of rapidly changing electromagnetic fields generated by a coil placed over the scalp (George and Post, 2011). Depending on the parameters of stimulation, rTMS can either decrease or increase cortical excitability in relatively focal areas, with frequencies < or = 1 Hz (low frequency rTMS or LF-rTMS) being usually inhibitory and higher frequencies (> or = 5 Hz; high frequency rTMS or HF-rTMS) being usually excitatory (Rosa and Lisanby, 2012). Moreover, rTMS has proven to have long-lasting effects on brain neuroplasticity through different mechanisms (e.g. by inducing long-term potentiation, increasing several neurotrophic factors etc.) (Chervyakov et al., 2015).
45759662|NCT05280613|Behavioral|Family Check-Up|See arm/group description
45759663|NCT05280613|Behavioral|Treatment as Usual|See arm/group description
45759664|NCT02395185|Other|Milk bottle administration|Patients are given a bottle of milk during the casting process.
45759665|NCT02395185|Other|Water bottle administration|Patients are given a bottle of water during the casting process.
45759666|NCT02395185|Other|Sucrose bottle administration|Patients are given a bottle of sucrose during the casting process.
45614720|NCT02517307|Drug|Intralipid/Heparin|Co-infusion of intralipid and heparin solutions during a hyperinsulinemic euglycemic clamp
45614721|NCT02517307|Drug|Glycerol/Saline|Co-infusion of a glycerol/saline solutions during a hyperinsulinemic euglycemic clamp
45759667|NCT02396511|Biological|TRC105|weekly i.v. TRC105 in combination with every 2 weeks i.v.bevacizumab, until progression or unacceptable toxicity develops
45759668|NCT02396511|Biological|Bevacizumab|Every 2 weeks i.v.bevacizumab in combination with weekly i.v. TRC105, until progression or unacceptable toxicity develops
45759669|NCT02396745|Device|Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex))|"TECR will be performed to resect the entire length and area of BE lesion.~ECM PLACEMENT:~Following resection, the exposed area will be covered with a 6 ply sheet of ACell MatriStem® Surgical Matrix PSMX ECM (ACell Inc., Columbia, MA). The ECM will be placed and held in position for 14 days (±4 days) using a Boston Scientific WallFlex™ Fully Covered Esophageal Stent (Boston Scientific, Boston, MA)."
45759670|NCT00816829|Drug|Placebo|Fenofibrate-matching placebo tablet
45759671|NCT00816829|Drug|Fenofibrate|145 mg NanoCrystal tablet
45759672|NCT02062359|Biological|Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells|"Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T cell receptor (TCR) CD62L+ cells and high dose aldesleukin.~On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes."
45614722|NCT02517307|Drug|Hyperinsulinemic euglycemic clamp|Infusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.
45759673|NCT02062359|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
45759674|NCT02062359|Drug|Cyclophosphamide|On days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
45759675|NCT02062359|Drug|Fludarabine|On days -5 to -1: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
45759676|NCT02397291|Drug|Mannose|A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
45614723|NCT02517229|Other|Parabolic flight|
45614724|NCT02517229|Other|balance control measurements|
45614725|NCT02517229|Device|electromagnetic maneuverable postural platform|
45759677|NCT02397291|Drug|Myoinositol|A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
45759678|NCT02397291|Drug|Placebo|placebo
45759679|NCT00816907|Drug|Metformin|500 mg to 1,000 mg taken twice daily for 16 weeks
45759680|NCT00816907|Drug|Placebo|1 to 2 placebo capsules taken twice daily for 16 weeks
45759681|NCT00817219|Drug|Calcipotriene plus betamethasone dipropionate ointment|Once daily application for 4 weeks
45759682|NCT02007369|Behavioral|WhatsApp|Intervention arm with relapse prevention intervention in the social group via the social networking service WhatsApp and the duration of the intervention will be 8 weeks.
45759683|NCT02007369|Behavioral|Facebook|Another intervention arm with the same intervention content, but the platform for the participants to share and receive quitting advice is Facebook and the duration of the intervention will be 8 weeks.
45759684|NCT00817843|Drug|Simvastatin|6 weeks of treatment with simvastatin 80 mg
45759685|NCT00817843|Drug|Simvastatin/Ezetimibe|6 weeks of treatment with simvastatin 10 mg / ezetimibe 10 mg combination
45614726|NCT02903667|Device|Bone grafting|
45614727|NCT02516917|Behavioral|Attention Training Technique|
45614728|NCT05431257|Drug|Venetoclax|"Standard azacytidine treatment (AZA; D1-D7, 75mg/m2 qd) in combination with a short duration of low-dose venetoclax treatment (LD-VEN; D1-D14 before CR and D1-D7 after CR, 400mg qd) per 28 days cycle for elderly/unfit (arm 1) and relapsed/refractory (arm 2) patients with acute myeloid leukemia."
45614729|NCT02516995|Device|Functional magnetic resonance imaging|
45614730|NCT02516995|Device|Ultrasound|
45759686|NCT02008149|Other|Rowing exercise|Individuals with SCI will use the rowing exerciser to see if there is a benefit to skeletal health in the lower limbs.
46068964|NCT05053243|Device|Kardia 12L|The purpose of this study is to collect clinical validation data to support an FDA submission for a 510(k) for the Kardia 12L hardware which enables the simultaneous diagnostic quality recording of all 6 limb leads and any chest lead. We will be recording both Leads V2 and V4 in a sequential fashion along with the Limb leads and a simultaneous 12-lead ECG to validate the hardware and a Deep Neural Network model which expands the 7 leads into a complete 12-lead ECG. The 12-lead ECG used for validation of the recordings and the 12-lead synthesis model is the GE Cardiosoft System which is FDA cleared.
45759687|NCT00817999|Dietary Supplement|Grapefruit juice|Participants received grapefruit juice during 1 of the 2 periods.
45759688|NCT00817999|Drug|Clopidogrel 75 mg/day|
45614731|NCT05431023|Drug|Lactoferrin|Lactoferrin binds to and blocks glycosaminoglycan viral receptors, especially heparan sulfate (HS). The binding of LF and HS prevents the first contact between virus and host cell and therefore prevents the infection
45614732|NCT05431023|Drug|Pneumonia treatment|Antibiotics for pneumonia
45614733|NCT02512081|Other|No intervention applied|No intervention applied
45614734|NCT05430945|Biological|BCMA Targeted CAR T-cells|Each subject receive BCMA Targeted CAR T-cells by intravenous infusion
45614735|NCT02517151|Drug|Ferric carboxymaltose|
45614736|NCT02517151|Drug|Placebo|
45759689|NCT00817999|Drug|Clopidogrel 300 mg|
45759690|NCT03839485|Drug|Endodontic treatment using Guedes-Pinto Paste|Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste is applied
45614737|NCT02507089|Behavioral|Tailored sleep health education materials.|Tailored sleep health materials.
45614738|NCT02507089|Behavioral|Generic sleep health education materials.|
45759691|NCT03839485|Drug|Endodontic using Guedes-Pinto Paste without antibiotic|Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste without antibiotic is applied
45759692|NCT02008617|Drug|Bupivacaine|30mL of Bupivicaine 0.20% with epinephrine 1:300,000
45759693|NCT02008617|Drug|Preservative free normal saline|Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
45759694|NCT03839251|Drug|abilify maintena|aripiprazole 400mg or 300mg, IM, Once a month
45614739|NCT04484727|Other|PEEP-step method|By changing PEEP in one or two steps up and down, transpulmonary pressure and the lung P/V curve can be determined using a dedicated software collecting data on tidal-volume changes and pressure changes during the PEEP-changes from the standard monitoring equipment or ventilator.
45614740|NCT02507167|Dietary Supplement|mixed meal|250 ml Fortimel compact (chocolate)
45445501|NCT03773055|Drug|NPC-06|Patients will receive once a day for 7 days.
45614741|NCT02507167|Drug|Rifampin|oral rifampin administration (600 mg EREMFAT®)
45759695|NCT00819403|Drug|simvastatin|Subjects will receive 6 weeks of simvastatin 40 mg, after which atherothrombotic biomarker assessment will be studied.
45759696|NCT00819403|Drug|ezetimibe/simvastatin|Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
45759697|NCT02062593|Procedure|Coronary angioplasty|Percutaneous coronary intervention with drug-eluting stents and modern techniques
45614742|NCT02512159|Procedure|drenovac handcrafted|under local anesthesia, sepsis and antisepsis, place sterile field, prepared area go out all devitalized or necrotic tissue using liquid soap surgical and irrigation back saline 0.9%. We introduce a device to distribute the negative pressure or vacuum on ulcer; conducted margins make recommendations 5-12 mm over the edge of the wound, applying negative pressure or vacuum retracted sponges, likewise for the spare fewer gauze was placed Sterile adhesive film covering the defect to seal the system cover adequately the probe output nelaton not to submit drain the system. Connect the probe to the sterile nelaton this hose and a suction system with pressure gauge, pressure -80-125 mmHg. Change it every 72 hours.
45759698|NCT03286387|Other|Functional brain imaging without any contrast agent|"During the fMRI protocol, the subject will perform the retrieval tasks while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (TE) = 30 ms, Repetition Time (TR) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min)."
46068965|NCT05051657|Dietary Supplement|PKU express plus|PKU express plus is a powdered protein substitute for the dietary management of PKU. It is formulated in a variety of flavours to provide a convenient, low volume, lower calorie, pre-measured protein substitute, containing a full micronutrient profile.
45614743|NCT02512159|Procedure|Healing|"Were handled as follows:~Under local anesthesia, prior asepsis and antisepsis of the skin ulcer with iodinepovidone sterile fields are placed, we proceeded to debridement of all necrotic tissue or devitalized then a cure with liquid soap surgery was performed and was irrigated with 1000 cc of solution physiological 0.9%, and finally the ulcer was covered with sterile gauze.~healing of skin ulcers were performed every 24 hours.~the evolution of skin ulcers was evaluated every 3 days, requesting a differential valuing of clinical and biochemical form the aforementioned variables."
45759699|NCT02010021|Drug|Letrozole|Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
46068966|NCT05051527|Drug|Legalon® 140 mg|Legalon® 140 mg as per the Summary of Product Characteristics (SPC) and as per treating Investigator's decision
45614744|NCT02516839|Behavioral|Regulation of Cues (ROC)|Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger,satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.
45614745|NCT02516839|Behavioral|Behavioral Weight Loss (BWL)|All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
45614746|NCT02516839|Behavioral|BWL + ROC|BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments. All participants will be taught to decrease caloric intake and increase physical activity, and to use all of the behavioral skills provided in BWL. However, they will also be taught models of hunger and satiety and about food cue reactivity, and will learn skills to manage these. This arm will include an experiential component, including hunger monitoring during dinner and participating in exposure sessions in the clinic.
45614747|NCT02516839|Behavioral|Nutrition Education, Stress Management and Social Support|Topics included will be stress management/relaxation, social support, and nutrition education. There will be a strong mindfulness component to this group.
45614748|NCT02512237|Drug|ARX788|ARX788, an antibody drug conjugate
45614749|NCT01376167|Drug|Chloroquine 600mg|600mg Chloroquine given to each subject on Day 1 and Day2 of the trial
45759700|NCT03272737|Procedure|1RM Test|The dynamic force of the lower limb muscles will be evaluated by the maximal repetition of knee extension and leg press exercise, according to the protocol presented in a previous study [37]. The elderly will perform a warm up consisting of 1 series with 10 unloaded repetitions. After the warm up, the mass to be lifted will be progressively increased until the maximum load that can be lifted is reached, with a maximum limit of 5 attempts and a 3 to 5 minutes interval between them. The test will be conducted by a physical education professional who will verbally encourage participants throughout these steps and perform the load adjustment at week 5 and 10 (Radaelli, 2014).
45614750|NCT01376167|Drug|Chloroquine 300mg|300mg Chloroquine given to each subject on Day 3 of the trial
45614751|NCT01376167|Drug|Tafenoquine 50mg|single dose 50mg Tafenoquine given to subject on treatment arm 1 on Days 1 or 2
45614752|NCT01376167|Drug|Tafenoquine 100mg|single dose 100mg Tafenoquine given to subject on treatment arm 2 on Days 1 or 2
45614753|NCT01376167|Drug|Tafenoquine 300mg|single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2
45614754|NCT01376167|Drug|Tafenoquine 600mg|single dose 600mg Tafenoquine given to subject on treatment arm 4 on Days 1 or 2
45614755|NCT01376167|Drug|Primaquine 15mg|15mg Primaquine given once daily to subject on treatment arm 5 on Days 2 to 15.
45614756|NCT01376167|Drug|Chloroquine 600mg (Part 2 )|600mg Chloroquine given to each subject on Day 1 and Day2 of the trial.
45614757|NCT01376167|Drug|Chloroquine 300mg (Part 2 )|300mg Chloroquine given to each subject on Day 3 of the trial.
45614758|NCT01376167|Drug|Tafenoquine 300mg (Part 2)|single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2.
45614759|NCT01376167|Drug|Primaquine 15mg (Part2 )|15mg Primaquine given once daily to subject on treatment arm 3 on Days 2 to 15.
45614760|NCT02511769|Behavioral|WEB-MAP Educational Control Group|OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
45759701|NCT03272737|Procedure|Speed gait test|To measure the gait speed of participants they will walk 4.6 metres and the time needed to cover this distance is measured. The mean of three attempts is recorded and divided by the distance. The participants included must achieve in the walking test an average of < 0.,9 m/s (Guralnik, 1994).
46068967|NCT05041062|Drug|Nivolumab|Nivolumab is an immunotherapy drug (a type of drug that helps your immune system fight cancer) that is often used with ipilimumab as the first treatment in adults with mesothelioma whose disease cannot be removed by surgery. The drug will be given as an IV infusion.
46068968|NCT05041062|Drug|Ipilimumab|Ipilimumab is a type of immunotherapy drug known as a checkpoint inhibitor, which helps your own immune system attack cancer cells.
46068969|NCT05037266|Biological|COVID-19 Vaccine Janssen (Ad26.COV2-S)|one dose (0.5mL) at D1 and one dose (0.5mL) at D57
46068970|NCT05034419|Device|Parasym|Stimulation will be done under anesthesia for 30 minutes. Stimulation parameters include a pulse width of 200 μs, amplitude of 20 mA and a pulse frequency of 20 Hz. The Parasym devise (Parasym Health, London, UK) will be used for stimulation. The device will be connected to a clip electrode that will be attached to the external ear. In the active group, the ear clip electrode will be attached to tragus in the active stimulation group. This device has been deemed non-significant risk by the FDA. In the control group, no stimulation will be done.
46068971|NCT05034419|Device|Sham stimulation|Sham stimulation
46068972|NCT05030987|Procedure|Renal Denervation|Renal denervation in patients with HFpEF and uncontrolled hypertension
46068973|NCT05030987|Procedure|Sham|Sham Treatment. After six months, cross-over is planned in all sham-treated patients and this patients will also receive a renal denervation.
46068974|NCT05006092|Device|ENDOMIND|CADe system for Polyp detection
45614761|NCT02511769|Behavioral|WEB-MAP CBT|Web-MAP Group: Participants will have access to the full version of the web program. They will be asked to log in to the website using their own personal computer at home, work, school, or a public library. Participants in the Web-MAP group will have access to treatment modules and daily diaries on the web site. The online treatment will take between 8 and 9 weeks for participants to complete. Children and parents will be asked to log onto the web site, read through the treatment modules, and complete practice assignments to learn new skills (e.g., relaxation). Adolescents and parents will be asked to complete a total of 8 modules each.
45614762|NCT02516761|Other|Low-impact aerobic exercise combined with music therapy|Intervention consists in working the muscles which are mostly affected by fibromyalgia through group exercises, which are dynamic, smooth and aim functionality. Each session consists of 60 minutes with 3 parts: initial warming up time, main part through games, group dynamics and pure aerobic workout, and final cool down with stretching. This exercise is done to the rhythm of melodic music, adapted to the tastes of the participants and also adapted on the way to perform the exercise. For this, they were shown a list of 100 music compositions from which participants choose a minimum of 20 preferences. All exercises are performed with proper postural control both dissociated and global and within a framework of therapeutic proprioceptive gymnastics.
45614763|NCT02516761|Other|Low-impact aerobic exercise|Low-impact aerobic exercise. Then intervention is like the previous group but with the difference that physical activity is not performed to the rhythm of chosen melodic music. Therefore, exercises are done with general chill-out music throughout the session, without adaptation of the exercise to the music.
45614764|NCT02516761|Other|Control group|With this group no intervention is done, but they are assessed like the other groups.
45614765|NCT02511613|Drug|Squalamine Lactate Ophthalmic Solution, 0.2%|Squalamine Lactate Ophthalmic Solution, 0.2% administered BID
45614766|NCT02511613|Drug|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution, administered BID
45614767|NCT02511613|Drug|ranibizumab|ranibizumab intravitreal injection
45614768|NCT02516683|Other|Shigella sonnei infection|A Shigella-exposed cohort of 124 hospital employees who had been infected by Shigella sonnei due to contaminated food in the employee-cafeteria in Gangnam Severance Hospital, Seoul, Korea, at December 2001.
45614769|NCT02506699|Other|analgesic effect of rTMS|
45614770|NCT02506777|Drug|metformin|
45614771|NCT02506777|Drug|Fluoruracil|
45614772|NCT02506777|Drug|Doxorubicin|
45614773|NCT02506777|Drug|Cyclophosphamide|
45614774|NCT02506777|Drug|melatonin|
45614775|NCT04497571|Procedure|Piezoelectric osteotomy.|Implants placed using the ultrasonic technique.
45614776|NCT04497571|Procedure|Conventional drilling|Implants placed using drilling technique
45614777|NCT02516527|Drug|Ipilimumab|
45614778|NCT02511847|Drug|Afatinib|"Afatinib 40 mg per day for 14 days, then evaluation, every subject will go into the following phase no matter whether she had response or not~Afatinib 40 mg per day, day 1 to day 21, in combination with paclitaxel 80 mg/m² on days 1, 8, 15 in a 3-weekly course."
45614779|NCT02511691|Drug|18F-PSS232|Diagnostic PET Tracer
45614780|NCT02516449|Other|Patient decision aid|"The patient decision aid is a 12-page A3 size color-printed booklet entitled Should I take asthma inhaled controller medication to optimize asthma control?"
45614781|NCT02511925|Other|Weekly poster of unit performance|Weekly feedback is provided to the ICU about current levels of hand hygiene compliance amongst doctors, nurses, and allied healthcare professionals
45759702|NCT03272737|Device|Venous occlusion plethysmography protocol|A mercury-filled silastic tube, connected to a low-pressure transducer and a plethysmograph (D.E. Hokanson), will be placed around the largest circumference of the calf region. One cuff will be placed around the ankle and another around the thigh. The ankle cuff will be inflated to a supra-systolic pressure 30 seconds before starting the measurements. At 15-second intervals, the cuff around the thigh will be inflated above the venous pressure for a period of seven to eight seconds. Increased tension in the silastic tube reflects an increase in leg volume and vasodilation. The signal of the muscle blood flow wave will be recorded on a polygraph and analysed every minute, averaging three records per minute. The protocol will be performed during 5 minutes of rest, 3 minutes isometric exercise and 2 minutes of recovery (Bahia, 2006).
46068975|NCT04999709|Device|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
46068976|NCT04992845|Device|Anterior Vertebral Body Tethering|The SCOLI-TETHER (MIScoli) System is intended for anterolateral vertebral body fixation and internal fastening of the convex side of the thoracic curvatures thereby reducing the deformity and preventing the progression of idiopathic scoliosis in growing children/adolescents at high risk for curve progression while preserving motion.
46068977|NCT04987255|Other|Free visit|The persons with sedentary (healthy) in this group will have to visit the museum freely (without a guide) for a period of 75 minutes.
45614782|NCT02511925|Other|Daily email of personal feedback|Healthcare workers receive private and personal feedback via email regarding their individual performance benchmarked against the average performance for their professional grouping.
45614783|NCT02511925|Other|Active reminder from badge|The badge the healthcare worker is wearing vibrates if opportunities to perform hand hygiene are missed
45614784|NCT02506621|Device|R test|
45614785|NCT02506621|Device|Nuubo|
45614786|NCT02506621|Device|TECHNOMED pocket ECG|
45614787|NCT02506621|Device|ZIO xt patch|
45614788|NCT02506621|Device|MoMe|
45614789|NCT04497805|Biological|ALLO-ASC-SHEET|Hydrogel sheet containing Allogenic Mesenchymal Stem Cells
45614790|NCT02506855|Drug|Ropivacaine|
45614791|NCT02506855|Other|Placebo|
45614792|NCT02506855|Procedure|Transversus Abdominis Plane Block|
45614793|NCT02506543|Behavioral|COMPASS|COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 13-19 year old girls in three refugee camps in Ethiopia. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
45614794|NCT02506543|Behavioral|No intervention|Wait list control group will not receive an intervention. After the follow-up study, the wait-list control group will receive the regular COMPASS program
45445502|NCT03815253|Other|acupuncture|"Body electro-acupuncture will choose eight acupoints as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), Sanyinjiao(SP-6).Disposable acupuncture needles (verum acupuncture needles asia-med Special No. 16 with 0.30 x 0.30mm matching the Streitberger sham-needles) will be inserted at a depth of 10-25 mm into the points.~We will also deliver electrical stimulation with dense-disperse waves with 50Hz at 10 volts through electrical acupuncture stimulation instrument (ES-160 6-Channel Programmable Electro-acupuncture) to the abdominal points. The bodily needles will be retained for 30 minutes."
45445503|NCT03774303|Other|Mobile application|A mobile application that will be used to prepare families for day surgery
45614795|NCT02516371|Other|lymphocyte|To evaluate the subpopulation of lymphocytes in cancer patients
45614796|NCT02516293|Behavioral|Exercise, nutritional and pharmaceutical counseling|Physical exercise intervention protocol was performed three times per week, 60 minutes per session, during 8 months. Exercise sessions consisted of 30 minutes of aerobic exercise on a treadmill or on a cycle ergometer, 20 minutes of strength exercises for the major muscle groups (sit-ups, push-ups, and pull-ups), and 10 minutes of stretching exercises. Nutritional and pharmaceutical consisted on general guidance about adequate eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
45614797|NCT02516215|Other|No intervention|
45614798|NCT02516137|Procedure|Dry needling|Dry needling will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. A Seirin L- type 50 mm needle will be inserted into each of the two points to a depth no greater than three-quarters length of the needle into the hamstring muscle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
45614799|NCT02516137|Procedure|Sham needling|Sham dry needling will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. The plastic tube of a Seirin L- type 50 mm needle will be placed against the skin and the needle will be tapped once so that it is inserted subcutaneously no deeper than 5 mm for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes in each location.
45614800|NCT02516137|Procedure|Blunt needle placement|Blunt needle placement will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. A blunt needle handle is inserted into a plastic tube which will be placed over the identified points for 30 seconds and then for an additional 10 minutes each. The blunt needle handle only touches the skin without puncturing it.
45614801|NCT02516137|Other|Standard hamstring stretching exercise|Subjects will be instructed to stretch the back of their thighs, once a day for 3 repetitions, holding for 30 seconds each time performed bilaterally.
45614802|NCT02511223|Drug|OLAPARIB|Olaparib 300 (mg) twice a day per os given every day until disease progression or toxicity
45445504|NCT03774303|Other|current practice|the current practice used to prepare families for day surgery
45614803|NCT02516059|Drug|oxycodone/naloxone|Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.
45614804|NCT02516059|Drug|Oxycodone|Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.
45614805|NCT02516059|Drug|Placebo|Placebo (Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
45614806|NCT02516059|Device|epidural catheter|
45614807|NCT02515981|Behavioral|NH Medicaid Incentives Program|
45614808|NCT02506231|Drug|Folinic acid|
45614809|NCT02506231|Drug|Placebo|
45614810|NCT02511145|Other|occlusive bandage|
45614811|NCT02511145|Device|ablative fractional CO2 laser pretreatment|
46068978|NCT04987255|Other|Guided visit|The persons with sedentary (healthy) in this group will have to visit the museum with a guide for a period of 75 minutes.
46068979|NCT04987255|Other|Guided visit (stroke)|The persons with motor disability after stroke in this group will have to visit the museum with a guide for a period of 75 minutes.
46068980|NCT04984629|Device|HYDRAFIL|The HYDRAFIL System contains the following items: the Delivery System and the Pressure Gauge. The HYDRAFIL implant is contained within a pre-filled syringe that is inserted into the delivery system housing during the manufacturing process. The implant is heated within the delivery system prior to use to ensure a flowable implant that can be injected through a standard coaxial needle.
45614812|NCT02511145|Device|Microneedles pretreatment|
45614813|NCT02511145|Drug|METVIXIA Cream|
45614814|NCT04499287|Other|15-minute walk at preferred walking speed.|
45614815|NCT04499287|Dietary Supplement|Fiber|9 grams soluble fiber
45614816|NCT04499287|Other|control|control
45614817|NCT02511301|Device|Cyrcadia CBR™ device placement for abnormality screening|Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis. There are no interventions after the CBR™ is removed from the Study Subject.
45614818|NCT02505997|Drug|Midazolam|Single 5 mg oral dose of midazolam syrup given in the AM on Day 1 and Day 8.
45614819|NCT02505997|Drug|Delafloxacin|Oral 450 mg delafloxacin tablets given twice daily (Q12h) on Days 3 to 8
45614820|NCT02511067|Drug|Tocilizumab|Intravenous Infusion of Tocilizumab ( 8.0 mg/kg)
45614821|NCT02511067|Drug|Ranibizumab|Intravitreal injection of Ranibizumab (0.3mg)
45614822|NCT02506075|Device|Transcranical direct current stimulator|approved by Conformity European as safe treatment device for stroke patients
45614823|NCT02506075|Behavioral|Visual inattention training|
45614824|NCT02505841|Other|TAP block with Ropivacaine|Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg
45614825|NCT02505841|Drug|Curare|Atracurium injection at 0.5 mg/kg at least 3 minutes before the surgical incision
45614826|NCT04500457|Behavioral|Exposure-based Treatment for Perfectionism (ETP)|Three tasks focused on exposures are completed. Each treatment session is approximately twenty minutes.
45614827|NCT04500145|Radiation|SIB-IMRT|60Gy given to the tumor area，50Gy to the CR lesion or high-risk field at the same time
45614828|NCT04500145|Radiation|routine IMRT|patients received IMRT or VMAT，with the prescription of 60Gy/2Gy/30F to the planning tumor volume ，concurrent or sequential with EP chemotherapy
45614829|NCT02510755|Other|MRI|
45911551|NCT05778812|Behavioral|Full Sleep|"Daily lessons about sleep and skills that can help with sleep. Participants also record information about each night's sleep in their sleep log. Every seven nights, they also complete the Sleep Needs Questionnaire. At the beginning, middle, and end of the study, they complete the Insomnia Severity Inventory in the app. At the end of every week, a sleep schedule and weekly summary are calculated via automated formulas. The app also contains access to messaging a coach, for participants to ask questions about their daily lessons and application of the skills and to feel supported and accountable.~The REST device in the Full Sleep program uses radar to passively track sleep patterns and nighttime awakenings. It also offers white noise options and audio guidance for relaxation techniques and stimulus control."
45445505|NCT03774459|Drug|High dose ANAVEX2-73|Active oral capsule
45614830|NCT02510677|Other|myocardial perfusion scintigraphy|
45614831|NCT03345745|Diagnostic Test|salivary samples|Salivary Hs-CRP, Fetuin-A and S100A12 levels and salivary flow rates were evaluated at baseline and a month after the treatments
45614832|NCT03345667|Drug|lucentis|Use of lucentis and other anti-vegf in patients with diabetic retinopathy
45614833|NCT03345589|Drug|18-22mg/kg/d Ursodeoxycholic|18-22mg/kg/d Ursodeoxycholic
45614834|NCT03345589|Drug|13-15mg/kg/d Ursodeoxycholic|13-15mg/kg/d Ursodeoxycholic
45614835|NCT04499989|Drug|INH|3 vaginal tablet of isonicotinic acid hydrazide self inserted 12 hours before IUD insertion.
45445506|NCT03774459|Drug|Mid dose ANAVEX2-73|Active oral capsule
45445507|NCT03774459|Drug|Placebo oral capsule|Placebo oral capsule
45614836|NCT04499989|Drug|Placebo Comparator|3 vaginal tablet of Placebo Comparator self inserted 12 hours before IUD insertion
45614837|NCT02515903|Procedure|Intra-endoscopic surgery|Intra-endoscopic surgery for evacuation of ICH
45614838|NCT02515903|Procedure|Placebo:stereotactic aspiration surgery|Placebo:stereotactic aspiration surgery for evacuation of ICH
45614839|NCT04500067|Drug|IVIG|Patients in the study group receive the drug Bioven, 10% solution for infusions produced by LLC Biopharma Plasma 0,8-1,0 g/kg once a day for 2 days (total course dose - 1.6-2.0 g/kg) as well as base treatment recommended by the protocol of COVID-19 coronavirus infection treatment depending on the severity of their condition according to the prescription sheet.
45614840|NCT03345511|Procedure|Ultrasound Guided Caudal Block|Using an external ultrasound probe, the investigators guided a 18 gauge epidural needle into the caudal space and injected a local anesthetic solution consisting in bupivacaine 0.25%, lidocaine 1% and dexamethasone 8mg in the caudal space.
45614841|NCT02515747|Procedure|percutaneous coronary intervention|elective percutaneous coronary balloon angioplasty and/or stenting
45614842|NCT02515747|Procedure|coronary artery bypass grafting|elective surgical myocardial revascularisation
45614843|NCT02505763|Procedure|Strategy with thoracic ultrasound|This strategy involves the systematic use of thoracic ultrasound for the treatment of pleural effusion, treatment and follow up care.
45614844|NCT04497649|Drug|Sofosbuvir|Sofosbuvir once daily
45614845|NCT04497649|Drug|Daclatasvir|daclatasuvir once daily
45614846|NCT02505451|Drug|dobutamine|In each participant, dobutamine will be administered via intravenous infusion in doses of 10, 20, 30 and 40 lg/kg/min during 3-min stages and 2D strain echocardiography will be performed at each stage.
45614847|NCT02505529|Other|Resistance Exercise Training|Behavioral interventions of resistance exercise
45614848|NCT02505529|Other|Mental Imagery|Behavioral intervention of mental imagery
45614849|NCT02505373|Behavioral|Attempted Suicide Short Intervention Program (ASSIP)|"The brief therapy ASSIP consists of three to four sessions, which are ideally administered within a period of 2 to 4 weeks. Therapy sessions are scheduled for 60 to 90 minutes.~Session 1: A narrative interview is conducted, in which the patient is asked to tell his or her personal story which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behaviour is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years."
45614850|NCT02505373|Behavioral|Control Group (CG)|Participants assigned to the control group underwent a single clinical interview that included a structured assessment of suicide using the SSF (Jobes, 2006).
45614851|NCT02505607|Other|Overactive Bladder Care Plan counseling|"Use of a printed Overactive Bladder Plan of Care information sheet."
45614852|NCT02505295|Dietary Supplement|Selenium|4 vials selenase stat and 2 vials daily for 5 days
45614853|NCT02505295|Drug|normal saline|Normal saline infusion like intervention group
45614854|NCT02510833|Behavioral|Exercises oriented, manual and monitoring by phone|Individual meeting to guide therapeutic exercises (stretching, mobility, balance and strength), manual with these exercises for support in practice at home and weekly monitoring by phone. Patients will be oriented to do exercises three times per week for twelve weeks.
45614855|NCT02510833|Behavioral|Exercises oriented, manual and without monitoring by phone|Lectures (optatives) about therapeutic exercises (stretching, mobility, balance and strength) in days of medical consultation, manual with these exercises for support in practice at home, without weekly monitoring by phone. Patients will be oriented to do exercises three times per week for twelve weeks.
45614856|NCT04500223|Other|Cervical Cranioflexion exercise plus cardiopulmonary exercise|Intervention:Cervical Cranioflexion exercise plus cardiopulmonary exercise
45614857|NCT04500223|Other|Cervical stretch exercise plus cardiopulmonary rehabilitation|control:Cervical stretch exercise plus cardiopulmonary rehabilitation
45614858|NCT02510911|Drug|Caffeine (100 mg)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 100 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
45614859|NCT02510911|Drug|Caffeine (200 mg)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 200 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
45614860|NCT02510911|Drug|corn starch (250 mg approx.)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 250 mg corn starch together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
45614861|NCT02510911|Other|Radiopaque marker|"On the morning of the first, second and third day after surgery patients will take 1 capsule each day with radiopaque markers .~On day 4 after surgery an abdominal X-ray will be performed to localize the markers.~Each gelatin capsule contains 10 markers consisting of polyurethane encapsulated barium sulfate (40%)."
45614862|NCT04499911|Drug|Isotonic dextrose 5% in water solution|The isotonic dextrose 5% in water solution (a total volume of about 5 ml). Subcutaneous perineural injection of dextrose (5%) in sterile water was given once. The injection was administered by using the Lyftgot technique of neural prolotherapy on the lateral aspect of the thigh along the tender areas.
45614863|NCT03343951|Other|Examination|"Patients will be examined twice the same day by an extended scope physiotherapist (ESP) and an orthopaedic surgeon (OS) in random order. They will independently and blinded to each other's opinion register~diagnosis and treatment plan (including need for further diagnostic examinations - i.e. imaging)~if the patient needs a new appointment at the shoulder clinic~if they under usual conditions would discuss their results with the opposite health professional before deciding diagnosis and treatment plan.~After the individual examinations the ESP and OS discuss their results and come to an agreement (common decision) regarding the patient's diagnosis, treatment plan and need of a new appointment. Patients will be informed only of the common decision of the ESP and OS."
45614864|NCT03121807|Other|Oliclinomel N4 Per bag 1.5 L|Home parenteral nutrition with 910 kcal/day , including 33 g amino acid/day, 120 g glucose/day, 30 g lipid/day and electrolyte, micro-element and vitamin according to the nutritional status of subjects and followed the standard procedure of the hospital (Oliclinomel N4 Per bag 1.5 L), was infused continuously daily in an infusion time ranged between 18-24 hours.
45614865|NCT03121807|Drug|Oxaliplatin|
45614866|NCT03121807|Drug|5Fluorouracil|
45614867|NCT03121807|Drug|Leucovorin|
45614868|NCT03121729|Procedure|enhanced recovery after surgery|Undergo an enhanced recovery after surgery program
45614869|NCT03343873|Drug|Midazolam|Midazolam was administered intravenously at a dose of 0.1 mg / kg followed by continuous intravenous injection at 0.03 mg / kg / h and maintained until the course of the scan.
45614870|NCT03343873|Drug|Propofol|Propofol group 1mg / kg intravenous injection, followed by 2mg / kg / h continuous intravenous injection, and maintained to the scanning process;
45614871|NCT03343873|Drug|Dexmedetomidine|Dexmedetomidine group with total amount of 1μg / kg, infusion time 15min, followed by 0.6μg / kg / h, and maintained to the scanning process;
45614872|NCT02647281|Drug|GSK3389404|GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.
45614873|NCT02647281|Drug|Matching Placebo|Placebo is supplied as solution for injection vial. It's physical appearance is clear colourless solution.
45614874|NCT03343795|Drug|oral progesterone|daily
45614875|NCT03343795|Drug|intramuscular progesterone|every week
45614876|NCT03343717|Other|Rehabilitation|physical therapy exercise
45614877|NCT03343717|Other|Chest physical therapy|chest physical therapy exercise
45614878|NCT02510365|Biological|Functional collagen scaffold|Patients will receive functional neural regeneration collagen scaffold and patients will undergo a comprehensive rehabilitation and psychological measures after surgery.
45614879|NCT02505139|Other|the number of circulating tumor cells|
45614880|NCT04499755|Drug|Nucleo CMP Forte|Nucleo CMP Forte twice daily for 6 weeks
45614881|NCT02515513|Procedure|Muscle Tissue Biopsy Sample|During surgical resection, to enter the abdominal cavity, anterior muscle groups such as the rectus abdominous muscle. This group of muscle is divided. During division, muscle fibers are released from fascial group and discarded off the operative field. This will be the target for specimen collection.
45614882|NCT03345433|Behavioral|interactive group drumming sessions|interactive group drumming sessions
45759703|NCT03272737|Device|Measurement of Arterial Stiffness - Pulse Wave Analysis and Velocity|"Arterial stiffness will be estimated from the carotid-femoral aortic pulse wave velocity [33]. Carotid-femoral aortic pulse waves will be recorded by tonometry (SphygmoCor, AtCor Medical, Australia). At the same time, an electrocardiogram will be obtained to calculate the wave transit time. Two distances will be measured: the recording point of the carotid artery and the sternal furcula (distance 1) and the sternal furcula and the recording point in the femoral artery (distance 2). The distance travelled by the pulse wave will be calculated as distance 2 - distance 1. The carotid-femoral aortic pulse wave velocity will be calculated as: carotid-femoral aortic pulse wave velocity = ¼ * distance travelled by the pulse wave (m) / transit time(s)."
45614883|NCT02510287|Drug|Bupivacaine and Fentanyl Initial Dose|10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution)
45759704|NCT03272737|Device|Isometric handgrip exercise protocol|In a supine position, the maximal voluntary handgrip force will be determined as the highest force in 3 consecutive attempts using a Jamar hydraulic palmar dynamometer (Asimow Engineering, CAL, USA). For activation of the central command, mechanoreceptors and muscular metaboreceptors the individual will perform, after 5 minutes of rest (baseline records), 3 minutes of exercise at 30% MVC. This manoeuvre isolates the activation of muscle metaboreceptors, observing the selective activation of these. After the isometric handgrip exercise, 2 minutes of recovery will be performed. Throughout the protocol muscle blood flow, blood pressure and heart rate will be recorded.
45614884|NCT02510287|Drug|Bupivacaine and Fentanyl: Continuous Epidural Infusion|0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour)
45911552|NCT05778812|Behavioral|Path to Better Sleep|Path to Better Sleep is a self-management tool for insomnia. It is available as a web-based program at https://www.veterantraining.va.gov/apps/insomnia/index.html#dashboard. Path to Better Sleep is intended to be completed over six weeks, and includes weekly educational lessons about sleep which include videos, visual depictions, and interactive activities, in addition to sleep check-ins (e.g., knowledge checks, self reflections about sleep). It also includes sleep logging. Participants in this condition will be asked to share their sleep log weekly via email, as Stanford and Koko Labs do not receive access to the data.
45614885|NCT02510287|Drug|Bupivacaine and Fentanyl: Programmed Intermittent Epidural Bolus|A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour
45614886|NCT02510287|Drug|Rescue Bolus|Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.
45614887|NCT02510287|Drug|Lidocaine|If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered.
45614888|NCT02510443|Device|ESS305 (Essure, BAY1454032)|Bilateral insert placement
45614889|NCT03345355|Diagnostic Test|Imaging|Coronal oblique T1, Coronal oblique and axial STIR, Coronal oblique T1 Dixon, Coronal oblique and Axial T2 Dixon and T1 Dixon post Gadolinium
45614890|NCT02505061|Behavioral|Hospital-based Program|"The research team will discuss with the clinical therapists who will provide training program in a hospital for 120 minutes/per session, 2 sessions/per week for a total of 9-week intervention. In addition, the research team will videotape the childs natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase. The treatment program of the two sessions will be preplanned and adjusted by the occupational therapist through clinical observation of participant's performance in the previous session. Training will still concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person), and upper limb use in functional tasks with driving in a hospital,discussed by the family, the treating therapist and the research team."
45614891|NCT02505061|Behavioral|Regular Therapy Program|"The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the childs natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase"
45614892|NCT02510521|Device|acute muscle exercise by NMES|
45614893|NCT02510521|Device|daily workout sequence with NMES in one week|
45614894|NCT02510521|Other|rest situation|
45614895|NCT03345277|Other|Continuous Temperature monitoring|Residents in a long term care facility will wear a thermometer continuously for 3 months, measuring their body temperature
45614896|NCT02510209|Behavioral|Teen Outreach Program|TOP® is a youth development and service learning program for youth ages 12 to 17 designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP® program model consists of three components implemented in school, after school, or in community settings over nine consecutive months: (1) weekly curriculum sessions, (2) community service learning (CSL), and (3) positive adult guidance and support. The TOP® Changing Scenes® curriculum is separated into four age- and stage-appropriate levels, which range from Level 1, typically for youth ages 12 or 13, to Level 4, typically for youth age 17.
45614897|NCT02515357|Behavioral|Mediterranean lifestyle|Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean lifestyle (food and food group consumption according to the Mediterranean diet, beneficial culinary practices, seasonality and locality of foods consumed, socialization during meals, adequate rest during the day through night sleep and siesta nap, sleep hygiene recommendations and adoption of a physically active lifestyle) and at achieving a 5-10% weight loss.
45614898|NCT02515357|Behavioral|Standard care|General written instructions regarding the adoption of a healthy lifestyle.
45614899|NCT02515357|Behavioral|Mediterranean diet|Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean dietary pattern (food and food group consumption according to the Mediterranean diet, beneficial culinary practices and seasonality and locality of foods consumed) and at achieving a 5-10% weight loss.
45614900|NCT02515435|Drug|apatinib single agent|For those heavily treated non-squamous non-small cell lung cancer, treat with apatinib single agent, 500mg or 750mg Qd, p.o based on the status of patient, continue until disease progression, dose reduction was admitted
45614901|NCT02515201|Drug|Taurolidine|taurolidine in central catheter lumen
45614902|NCT02515201|Drug|Heparin|heparin in central venous catheter lumen
45445508|NCT03815409|Other|Treadmill with partial weight unload|10-minute treadmill walk with a support corresponding to 20% of his/her own weight, followed by a 5-minute rest and a second 10-minute session on the treadmill with a support corresponding to 10% of his/her own weight. In the initial treadmill session, the starting speed of the treadmill was set to 0.5 km/h, subsequent increments of 0.5 km/h per minute were added to reach the maximum speed that was comfortably tolerated by the patient. This latter was used for the entire training period.
45445509|NCT03815409|Other|Traditional PT rehabilitation treatment|Every 40-minute treatment session consisted in isotonic and isometric exercises for the major muscles of the limbs and trunk including cardiovascular warm-up exercises (5 minutes), muscle stretching exercises (10 minutes), muscle stretching exercises for functional purposes (10 minutes), balance training exercises (10 minutes), relaxation exercises (5 minutes)
45445510|NCT03773991|Diagnostic Test|Lung MRI|Proton Lung Magnetic Resonance Imaging
45445511|NCT03773991|Diagnostic Test|Sodium MRI|Sodium Soft Tissue Magnetic Resonance Imaging
45614903|NCT02515123|Device|E-Motion System|"E-Motion Tube: A disposable oro/nasogastric feeding tube fitted with stainless steel electrodes along its length that delivers the stimulation to the esophageal mucosa.~E-motion EPG 1000: a durable, touchscreen operated, bedside control unit that generates the electric stimulation pattern and sends it via the feeding tube to the esophagus.~By applying predetermined sequences of electrical stimulation to various locations along the esophagus asynchronous esophageal motion is induced, resulting is reduction of reflux and increased GI motility, enabling safer and better feeding."
45614904|NCT02515123|Device|Sham E-Motion System|The sham EPG will resemble the investigational EPG. The external shape, interface, lights, and switches will be exactly the same. The Sham device will emit a low intensity pulsation so that, it will not unblind the patient nor health care professional. In the event that unblinding does occur, we will take steps to mask the identity of the EPG by covering the number of the device with tape to prevent members of the clinical team becoming aware of which device is active or sham.
45614905|NCT02504983|Drug|sorafenib|sorafenib is an oral, multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma
45614906|NCT02504983|Procedure|TACE|Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor.
45614907|NCT02504749|Procedure|general anasthesia,spinal anasthesia|"Randomization done by computer generated random number in sealed opaque envolopes.Each patient was given a study information sheet and a consent was signed. Sample size was calculated to prevent type II error. Based on these data, we would need to study 225 cases in each arm to be able to reject the null hypothesis that the rates for the experimental and control groups are equal with a probability of 80%. The type I error probability associated with this test for the null hypothesis is 0.05. We used an uncorrected chi-squared statistic to evaluate this null hypothesis. Additionally, to compensate for discontinuations, we recruited 225 women in each arm.~450-pregnant women with an indication for caesarean section were randomly allocated ."
45614908|NCT02509975|Device|Prostate artery embolization.|Embolization of the prostatic vasculature with OCL 503 using a microcatheter.
45614909|NCT02504593|Device|mHealth platform employing Fionet Deki Readers to ensure quality of community-based malaria diagnosis|The investigators propose to implement a new mobile interface that automatically reads and troubleshoots malaria rapid diagnostic test (RDT) cassettes. This device, called a Deki reader (DR), will allow the investigators to establish an extensive quality assurance program of malaria diagnosis performed by trained community health volunteers (CHVs). To ensure high-quality diagnosis by CHVs, the study team will deploy 10 Fionet DRs and rotate them amongst 200 CHVs who have been trained to do RDTs. In the first phase, each CHV will use the device for 10 successive clients presenting themselves for malaria diagnosis to the CHV, and then the device will be rotated to another CHV.
45614910|NCT02504515|Other|World Health Organization Quality of Life Bref Questionnaire|"The World Health Organization Bref (WHOQOL-BREF) questionnaire will be applied in three different moments: Baseline, after 6 months, and after 12 months.~The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment. The WHOQOL-BREF is a shorter version of the original instrument that may be more convenient for use in large research studies or clinical trials."
45614911|NCT02510053|Drug|Caspofungin|40 patients with suspected/preoperation/confirmed IFI in ICU received Caspofungin
45614912|NCT02504437|Biological|BMMSCs|
45759705|NCT03272737|Device|Vasodilatory capacity|The vasodilatory capacity will be calculated as the percentage of increase of the diameter of the brachial artery and femoral post occlusion in relation to its basal values.
45759706|NCT03272737|Device|Basal blood flow and vasodilatory capacity - Flow mediated dilation (FMD)|Images of the brachial artery will be recorded by a two-dimensional ultrasonography device with a spectral Doppler and linear transducer (Ultra-0122, Philips, The Netherlands).
45759707|NCT03272737|Diagnostic Test|Quality of Life EuroQol-5 Domain|This questionnaire is used to estimate the quality of life in participants before and after the study.
45759708|NCT03272737|Other|Anthropometric Assessment|Anthropometric measurements will be made before and after the training program following the standardization of the International Society for Anthropometric Assessments. The body mass will be measured with an accuracy of 0.1 kg (Filizola). The stature will be obtained by means of the stadiometer with an accuracy of 0.5 cm. The BMI will be calculated as body mass divided by height squared. The circumference of the quadriceps will be measured with a tape measure (Seca) with a precision of 0.1 cm.
45759709|NCT02062905|Drug|Dexamethasone|
45759710|NCT02062905|Other|Placebo Vehicle|
45759711|NCT03201757|Drug|ALKS 3831|Olanzapine + samidorphan, daily oral dosing
45759712|NCT00820573|Drug|Sitagliptin|tablet, 100 mg/day, 6 weeks
45445512|NCT03773991|Diagnostic Test|Chest CT|High-resolution Quantitative Chest CT
45445513|NCT03773991|Diagnostic Test|Echocardiography|Transthoracic 2D Speckle-Tracking Echocardiography
45445514|NCT03773991|Diagnostic Test|Fractional Exhaled Nitric Oxide|Fractional Exhaled Nitric Oxide testing
45445515|NCT03773991|Diagnostic Test|Pulmonary Function Tests|Spirometry and Plethysmography
45445516|NCT03773991|Diagnostic Test|Blood Sampling|Blood testing for: standard-of-care, inflammatory biomarkers, uremic toxins
45614913|NCT02510131|Behavioral|Exercises|To compare Hyacinth exercise with Kegel's exercise in improving urinary incontinence
45614914|NCT02504359|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
45614915|NCT02504359|Drug|Carmustine|Given BEAM chemotherapy
45614916|NCT02504359|Drug|Cytarabine|Given BEAM chemotherapy
45614917|NCT02504359|Drug|Etoposide|Given BEAM chemotherapy
45614918|NCT02504359|Drug|Ixazomib Citrate|Given PO
45614919|NCT02504359|Drug|Melphalan|Given BEAM chemotherapy
45614920|NCT02504359|Drug|Methotrexate|Given IV
45614921|NCT02504359|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
45614922|NCT02504359|Other|Quality-of-Life Assessment|Ancillary studies
45759713|NCT00820573|Drug|Metformin|tablet, 1000 mg/ bid, 6 weeks
45759714|NCT00820573|Drug|Sitagliptin + Metformin|tablet, Sitagliptin (100mg/day) + tablet, Metformin (1000 mg/bid), 6 weeks
45759715|NCT00820573|Drug|Placebo|Placebo 6 weeks
45759716|NCT00821041|Behavioral|Cognitive Behavioral Therapy|6 weeks of relaxation training, cognitive therapy, sleep restriction, stimulus control, sleep hygiene, psychoeducation, hypnotic tapering and mindfulness training
45759717|NCT00821119|Device|nasal intermittent positive pressure ventilation|Nasal intermittent positive airway pressure will be compared are the nasal continuous positive pressure as an initial ventilatory mode in preterm infants with respiratory distress syndrome
45759718|NCT05217355|Drug|MBA-P01 (Botulinum toxin A)|MBA-P01 will be injected into the Glabellar line
45759719|NCT05217355|Drug|Placebo|Placebo will be injected into the Glabellar line
45614923|NCT02504359|Drug|Tacrolimus|Given IV or PO
45614924|NCT02729545|Other|Tung's acupuncture|The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).
45614925|NCT02729545|Drug|Cyproterone acetate/ethinylestradiol (CPA/EE)|Cyproterone acetate/ethinylestradiol (CPA/EE) contains 2mg cyproterone acetate (an anti-androgenic progestin) and 0.035mg ethinylestradiol (CPA/EE). The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
45614926|NCT02509819|Device|Heel Cushion Material Bulk (foam)|The heel wedge is made of a rubber style urethane foam. Heel wedges of specified heights and durometers will be inserted into the standard shoes, one at a time, during the test session only. The heel wedges used during the test session are made of the same foam as the heel wedges that are used clinically.
45614927|NCT01376089|Drug|Iodixanol|Iodixanol 320 mg I/mL as a single iv. administration.
45614928|NCT01376089|Drug|Iopamidol|Comparator agent iopamidol (Isovue) 370 mg I/mL as a single iv. administration.
45614929|NCT02509741|Behavioral|Education|
45759720|NCT05236855|Diagnostic Test|Spectoscropy testing of urine specimen|Urine samples will be independently tested by I R Spectroscopy and those results are to be compared with standard testing procedures for HPV
45759721|NCT04382599|Behavioral|Text warning with square background|The warning message is in white text on a black square background
45759722|NCT04382599|Behavioral|Text warning with octagon background|The warning message is in white text on a black octagon background
45759723|NCT04382599|Behavioral|Icon warning|The warning message in in white text on a black background, below an icon that conveys the topic the warning is about
45759724|NCT04382599|Behavioral|Graphic warning|The warning message in in white text on a black background, below a graphic that conveys the topic the warning is about
45759725|NCT05236699|Combination Product|DEB-TACE combined with Surufatinib and Camrelizumab|"All patients will be treated with standard DEB-TACE on the first day (D1).~After DEB-TACE, if the liver function is Child-PughA grade, they will be treated with Camrelizumab on the same day, 200mg/ times, intravenous injection, once every 3 weeks.~Surufatinib capsule will be given orally to 250mg within 1 hour after breakfast on the second day (D2) after the first DEB-TACE. The drug will be given continuously once a day and stopped on the same day of each DEB-TACE.~The combination of drugs for 3 weeks is a cycle.The treatment will continue until the patient developed the disease or met the other criteria for terminating the study."
45759726|NCT02010645|Drug|Eltrombopag|Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.
45759727|NCT02010645|Drug|Decitabine|Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle.
45759728|NCT02944747|Behavioral|Education & paper based calendar|The participants will be counseled on importance of remembering LMP. In addition, they will be provided a free calendar to record their LMP dates.
45445517|NCT03773991|Diagnostic Test|Six-Minute Walk Test|Six-Minute Walk Test
45445518|NCT03773991|Diagnostic Test|Dyspnea Questionnaires|Modified Medical Research Council; University of California, San Diego Shortness of Breath Questionnaire; Borg Scale
45445519|NCT03774147|Device|24-hour Ambulatory Blood Pressure Monitoring (ABPM)|
45614930|NCT02509741|Dietary Supplement|Food replacement|
45445520|NCT01560195|Drug|Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve[AUC] 5 or cisplatin 75 mg/m2.
45614931|NCT02509741|Behavioral|IOT monitoring|
45614932|NCT02514967|Drug|Blisibimod|Administered via subcutaneous injection once per week
45614933|NCT02514967|Drug|Placebo|Administered via subcutaneous injection once per week
45614934|NCT02504125|Drug|Tranexamic Acid|1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision
45614935|NCT02504125|Drug|Normal saline|100 mL of normal saline intravenously approximately 15 minutes before incision
45614936|NCT02504047|Procedure|T-Cell replete haplo-transplant|Infusion of haploidentical related donor peripheral blood stem cells following myeloablative conditioning (fludarabine 200 mg/m2, busulfan 12.8 mg/kg and total body irradiation (TBI) 400 centigray -or- fludarabine 200 mg/m2, busulfan 9.6 mg/kg). GVHD prophylaxis will be with cyclophosphamide 50 mg/kg/day x 2 on days 3 & 4, mycophenolate mofetil 1 gm p.o. bid days 5 - 35 and tacrolimus (5-15 ug/ml) days 5 - 100.
45614937|NCT02503813|Procedure|venous blood gas|Venous blood gas will be measured at the time of arterial blood gas measurement.
45614938|NCT02503969|Other|Exposure to having a long-term condition.|"Long-term conditions are self-reported: twelve named conditions are recorded, along with an other condition - these shall all be considered with the exception of the named condition cancer."
45614939|NCT02509663|Procedure|Functional Endoscopic Sinus Surgery|Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.
45614940|NCT02509663|Procedure|Functional Endoscopic Sinus Surgery using rigide instrumentation|"FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.~The procedure works by cutting to remove bone and tissue to enlarge the sinus opening."
45614941|NCT02509663|Device|Sinuplasty balloon|Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.
45614942|NCT02509663|Device|Endoscope|"FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.~The procedure works by cutting to remove bone and tissue to enlarge the sinus opening."
45614943|NCT02514811|Behavioral|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
45614944|NCT02503891|Device|MP-1 Polymer on Ceramic Articulation system|MP-1 Polymer liner on Ceramic head
45759729|NCT02944747|Behavioral|Education & SMS system|The participants will be counseled on importance of remembering LMP. They will be asked to send the LMP date via SMS. Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
45759730|NCT02944747|Behavioral|Education & smart-phone application|The participants will be counseled on importance of remembering LMP. Participants will be asked to record the LMP on a calendar app. This will be transferred to central server via internet Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
45759731|NCT02833207|Drug|Drug Trial 1 (EDD)|"Drugs that increase blood flow and test EDD are: ACh, ISO, BK, ATP. Remaining drugs used to test mechanisms of EDD: L-NMMA, ketorolac, and BaCl2.~Details under study description."
45759732|NCT02833207|Drug|Drug Trial 2 (ROV)|"Tools used to increase blood flow: muscle contractions and ATP. Remaining drugs used to test mechanisms of ROV: L-NMMA, ketorolac, and BaCl2.~Details under study description."
45759733|NCT02065479|Drug|Prasugrel|Comparison of platelet reactivity between prasugrel and ticagrelor
45759734|NCT02065479|Drug|Ticagrelor|Comparison of platelet reactivity between prasugrel and ticagrelor
45759735|NCT05236621|Drug|Pomalidomide|4 mg pomalidomide capsules administered orally
45759736|NCT05236621|Drug|Dexamethasone|40 mg dexamethasone tablets administered orally
45445521|NCT01560195|Drug|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve[AUC] 5 or cisplatin 75 mg/m2.
45614945|NCT02509429|Device|Insulin therapy (aspart, lispro ou glulisine) with Control-to-Range algorithm|The insuline used is usual patient insuline. There is no specific insulin for this protocol
45614946|NCT02509429|Device|Insulin therapy ((aspart, lispro ou glulisine) withThreshold Low Glucose Suspend|The insuline used is usual patient insuline. There is no specific insulin for this protocol
45614947|NCT04497181|Device|Coil embolization surgery|Embolization of aneurysms with various coils system
45614948|NCT02509273|Drug|Clonidine|
45614949|NCT02509273|Drug|Midazolam|
45614950|NCT03344653|Device|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by 1 month DAPT
45614951|NCT03344653|Device|Biosensors BioFreedom BA9 Drug Coated Coronary Stent|Biosensors BioFreedom BA9 Drug Coated Coronary Stent Followed by 1 month DAPT
45759737|NCT02066727|Drug|Dexmedetomidine|Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.
45759738|NCT02066727|Drug|Normal Saline|Normal Saline is administrated as an adjuvant of lidocaine.
45759739|NCT05235997|Dietary Supplement|Hydrolized Collagen Peptide|Dietary Hydrolized Collagen Peptide sourced from bovine
45759740|NCT05235997|Other|Placebo|Placebo look alike the experimental product
45614952|NCT02514343|Drug|Magnesium Sulfate|1ml of 10% magnesium sulfate with 1.5 ml of sterile water
45614953|NCT02514343|Drug|Bupivacaine|1.5 ml of Bupivacaine 5mg/ml plus 1 ml of 10% magnesium sulfate
45759741|NCT04349241|Drug|favipiravir|pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), a new type of RNA-dependent RNA polymerase (RdRp) inhibitor
45759742|NCT04349241|Drug|Standard of care therapy|oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10
45911553|NCT05778773|Procedure|TAVR (Transcatheter Aortic Valve Replacement)|Percutaneous aortic valve replacement, also known as percutaneous aortic valve implantation, transcatheter aortic valve implantation or transcatheter aortic valve replacement, is the replacement of the aortic valve of the heart through the blood vessels.
45614954|NCT02514499|Other|Questionnaires|
45614955|NCT03344575|Procedure|Conventional defect closure|Laparoscopic suturing of the defect prior to placing an intraperitoneal Onlay Mesh
45614956|NCT03344575|Procedure|Peritoneal bridging|Laparoscopic closure of the defect by using a peritoneal flap prior to placing an intraperitoneal Onlay Mesh
45614957|NCT03344497|Other|VC Group|VC (Conventional Consultation/Video) Group
45614958|NCT02514421|Device|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
45614959|NCT02514421|Drug|gemcitabine|The chemotherapy schedule will include administration of gemcitabine 1000mg/m2 IV infusion over approximately 30 minutes on days 1, 8, and 15 of each 28 day cycle.
45614960|NCT02514421|Drug|nab-paclitaxel|The chemotherapy schedule will include administration of nab-paclitaxel 125mg/m2 intravenous (IV) over approximately 30 to 45 minutes on Days 1, 8, and 15.
45614961|NCT04499209|Drug|XG005|XG005 Capsule
45614962|NCT04499209|Drug|Combination of Naproxen and Pregabalin|Naproxen and Pregabalin are commercially available products with trade names of Aleve and Lyrica
45614963|NCT04499209|Drug|Placebos|Placebo Capsule
45614964|NCT02514109|Other|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS)) and 2 blood collection tubes for antibody screening
45614965|NCT04497259|Other|Teleevaluation|Patients will answer to a questionnaire filled through a chatbot link
45614966|NCT04497259|Other|Teleconsultation|A teleconsultation (skype-like connection) at 6 and 9 months after surgery
45614967|NCT04497259|Other|Classical consultation|Patients in the consultation arm will benefit from a classical face to face consultation at 6 and 9 months after surgery.
45614968|NCT02503579|Behavioral|physical training|physical activity program, 30 minutes
45614969|NCT04497103|Other|control|The traditional therapy included immersing the hand in paraffin for 10 min; soft massaging with a moisturizing gel for 5 min; passive mobilization of the wrist, MP, PIP, and DIP joints; active/passive ROM and stretching exercises; strengthening exercises (done in static mode initially and progressed in the second month to dynamic strengthening using elastic bands); desensitizing sensory stimulation of hypertrophic scars, occupational therapy.
45614970|NCT04497103|Other|Xbox kinect|The traditional plus Xbox Kinect games were related to five target activities determined according to the person-centered analysis results were chosen for each patient.
45614971|NCT04497103|Other|task oriented training|The traditional plus the target activities involved training with the materials (clothes, spoons, pencils, buttons, rope, etc) needed for the activity as well as Velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools.
45614972|NCT02509351|Drug|misoprostol|400 microgram of misoprostol is given preoperatively in patients undergoing elective cesarean section
45614973|NCT02509351|Drug|placeboo|women will recive 2 identical tablets as placeboo
45614974|NCT02513953|Procedure|Laparoscopic|Four Port Laparoscopic cystectomy
45614975|NCT02509195|Drug|Triumeq|Subjects will take the last dose of their current antiretroviral combination at its usual time on the day before the baseline visit (day 1) and will switch on day 1 to Abacavir/lamivudine/dolutegravir 600mg/300mg/50mg (Triumeq) fixed dose combination once daily between day 1 and day 180.
45614976|NCT04496791|Device|RIC (Receiver in Canal) hearing aid/ hearing instrument (HI)|HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
45614977|NCT02508961|Behavioral|Exercise|web-based physio exercise programme
45614978|NCT02503345|Drug|ALLN-177 low dose|ALLN-177 1,500 units (1 capsule)/meal PO 3 times per day
45614979|NCT02503345|Drug|ALLN-177 mid dose|ALLN-177 3,000 units (2 capsules)/meal PO 3 times per day
45614980|NCT02503345|Drug|ALLN-177 high dose|ALLN-177 7,500 units (5 capsules)/meal PO 3 times per day
45614981|NCT02503345|Drug|Placebo|Placebo: 1, 2 or 5 capsules with meals PO 3 times per day
45614982|NCT04496635|Other|Implementation of a bundle of care|
45614983|NCT03345199|Other|Inspiratory Muscle Trainer (IMT)|During the 10-week training period, participants will perform exercises using a Threshold Inspiratory Muscle Trainer (IMT) at 3 sets of 15 repetitions per day. The initial resistance of the IMT unit will be at 30% of participants' maximum inspiratory pressure (MIP). Resistance for the IMT unit will be increased progressively and adjusted weekly by a licensed physical therapist based on participant's MIP at baseline, Borg perceived rate of exertion, and symptoms.
45614984|NCT03121651|Device|RL-adaptive application|"Up to 6 dyads of individuals with disabilities and their caregivers will be recruited to collaborate in defining the features and content of the RL-adaptive support. The steps in developing the RL-adaptive support include having the dyads use for approximately 6 weeks each:~young adult uses an electronic medication pillbox that sends its pillbox openings within one hour of opening to the research team,~young adult uses the electronic medication pillbox + both use a commercially available medication reminder app + caregiver uses a pillbox opening notification app, and~young adult uses the electronic medication pillbox + the RL-adaptive support including push notifications in the form of text messages + caregiver uses the pillbox opening notification app.~The goal is to reduce the number of caregiver prompts necessary for the medication pillbox to be opened."
45614985|NCT03121495|Diagnostic Test|Second forward view (SFV) examination of the right colon|The colonoscope will be advanced to the cecum again when hepatic flexure was reached the first time, where a second forward view (SFV) examination of the right colon will be performed
45614986|NCT02508805|Drug|Neuromultivit|
45614987|NCT02508805|Drug|Voltaren|
45614988|NCT02508805|Drug|Sirdalud|
45614989|NCT03121573|Drug|Duloxetine|duloxetine 30 to 60 mg tablets by mouth, QD to BID per day,
45614990|NCT03121417|Biological|Nivolumab|240 mg given IV
45614991|NCT02513797|Device|LARIAT + PVI|Left Atrial Appendage ligation with the LARIAT System initially performed followed by adjunctive pulmonary vein isolation catheter ablation in staged procedures
45614992|NCT02513797|Device|Pulmonary Vein Isolation|Perform pulmonary vein isolation (PVI) catheter ablation procedure using a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
45614993|NCT02503267|Other|none intervention|
45614994|NCT02503033|Drug|HMPL-523|Oral administration, once daily
45614995|NCT02503189|Drug|KCT-0809 ophthalmic solution|
45614996|NCT02503189|Drug|Placebo|
45614997|NCT02502955|Procedure|Comparison autopsy methods|Comparison of post-mortem angiography/virtual autopsy and medical autopsy
45614998|NCT02508727|Other|MRI|
45614999|NCT02508727|Other|3D cardiac ultrasound|
45615000|NCT02502721|Drug|DWC20151|
45615001|NCT02502721|Drug|DWC20152|
45615002|NCT04498975|Other|Rurality; Ethnicity; Exercise; Hopelessness|Observational study exploring rurality, ethnicity, exercise and hopelessness patterns cross-sectionally and longitudinally
45911554|NCT05778773|Procedure|AVR (Aortic Valve Replacement)|Aortic valve replacement is a procedure whereby the failing aortic valve of a patient's heart is replaced with an artificial heart valve through an open-heart surgery.
45615003|NCT02502643|Drug|OK-432 pleurodesis|1.Pain medications (if no contraindications) Before half hour; Bain (IM ,0.15mg / kg). 2. Make the patient supine position 3. Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.4. 20 cc of 2% lidocaine hydrochloride (400 mg) was instilled into the pleural cavity through the chest tube 5. A solution of 30 cc of normal saline containing 5 KE of OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci).6. Inject air 20 cc 7. The injection site will cover with op site and the rubber tube that connecting the chest tube and chest bottle was raised 40-60 cm above the patient to trap the sclerosing agent but allow air to pass 8. Patients will reposition (left and right side)every 30 minutes in 2 hours
45759743|NCT05212129|Device|Percutaneous vagal nerve stimulation (pVNS) device|Subjects in Treatment Arm B will enter a six-week, prospective open label treatment trial with the FDA-approved and commercially available device IB-Stim. This is an ambulatory, neurostimulation device which consists of a battery powered, externally affixed generator with 4 wire leads attached to electrode/needle arrays affixed to the outer ear. The device delivers low voltage (3.2V) stimulation in alternating frequencies for a total of 5 days (around the clock).
45911555|NCT05778760|Other|Retinol|Topical retinol (0.5%) applied to the face
45615004|NCT02502643|Drug|normal saline pleurodesis|Make the patient supine position , Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.injected a solution of 30 cc of normal saline , and then injected into 20 cc air to the rubber chest tube , so that normal saline can completely into the chest, the injection site will cover with op site, use a rubber band to the rubber chest tube for hanging from the patient's body 40-60 cm high.Patients will reposition (left and right side)every 30 minutes in 2 hours
45615005|NCT02502565|Other|Uric acid level|
45615006|NCT02508415|Other|Non Surgical Periodontal Therapy|OHE, scaling root planing, mouth wash
45615007|NCT02501551|Drug|regorafenib|160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
45615008|NCT02501395|Other|No intervention, observational|
45615009|NCT02501317|Behavioral|Active Perineal Rehabilitation protocol|Active Perineal Rehabilitation Protocol available in http://www.perineo.info/wordpress/book-active-perineal-rehabilitation/
45615010|NCT02501317|Behavioral|Kari Bo protocol|Group exercises to pelvic floor rehabilitation
45615011|NCT04498897|Drug|Vortioxetine|"Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate"
45615012|NCT04498897|Drug|Acamprosate|"Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate"
45615013|NCT02502877|Drug|Midazolam|The investigators will administer 0,05mg/kg of midazolam, being 2/3 administered before the neuraxial block and 1/3 after.
45615014|NCT02502877|Drug|Propofol|The investigators will administer 0,033mg/kg of midazolam before the neuraxial block, and immediately after installation of the block the investigators will start a propofol TCI pump (Schnider model) with an effect concentration set at 1mcg/mL. This pump will be turned off at the end of the surgery.
45615015|NCT02502877|Drug|Standard|The investigators will administer to every patient: cefazolin 2g iv bolus, ketorolac 30 mg iv bolus, pantoprazole 40 mg iv bolus, paracetamol 1g iv perfusion (initiated 30 minutes before the end of surgery).
45615016|NCT02502877|Device|SpotOn|Central temperature will be monitored with the SpotOnTM3MTM device from entering till leaving the operating room, through a sensor placed in the patient's forehead
45615017|NCT02508181|Device|I-gel|supraglottic airway device without cuff
45615018|NCT02508181|Device|LMA Supreme|supraglottic airway device with cuff
45615019|NCT03343561|Behavioral|Nutrition Advice|Intervention diet for 8 weeks for intervention group. Detailed 30 mins consultation in week 1 (provided by dietitian) and 15 min consultation (provided by RA) in week 4 to enhance subject adherence to the diet for intervention group. Control group subjects will receive 1 detailed 30 mins nutrition consultation from dietitian after the study.
45615020|NCT02502409|Other|Standard care with blood and urine sample collection|
45615021|NCT04498819|Behavioral|Wearable Activity Trackers, Exercise Prescription and Virtual Care|"The intervention is merging wearable activity trackers and tailored aerobic exercise prescriptions into the PCDSP's virtual STAND (a biweekly, evidence based, lifestyle medicine) program.~Participants will wear activity trackers for a week to collect baseline step data (used to create tailored step prescriptions). Biweekly, new step prescriptions will be tailored to each participant based on the previous two week's step count data. The intervention will add onto STAND classes by using activity tracker data into the class discussion for learning opportunities, as well as goal setting and action planning. The day of class, participants will receive a summary email new prescription and encouragement to continue to work hard, using the previous weeks' data to reinforce motivation. The activity tracker will provide instant feedback about step goals, sedentary behaviour and exercise minutes. Individual calls every other week will ensure adherence to exercise regime."
45615022|NCT02502331|Biological|Test Oral Cholera Vaccine|Thimerosal free, manufactured at 600 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
45911556|NCT05778760|Other|Adapinoid|Topical Adapinoid (0.5%) applied to the face
45911557|NCT05778734|Behavioral|CM-PST|CM-PST is a tailored behavioral intervention that enables young adults with AUD to successfully manage and overcome everyday life challenges influencing their alcohol intake.
45911558|NCT05778734|Behavioral|CM only|CM is a behavior therapy that rewards individuals for evidence of positive change (alcohol abstinence).
45911559|NCT05778721|Other|respond to questionnaires by telephone|Seasonal Pattern Assessment Questionnaire (SPAQ) questionnaires and Sachs bipolarity index and Idiopathic Hypersomnia (IH) severity score
45911560|NCT05778695|Dietary Supplement|Ketone Ester (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate|Ketone ester (KE) dietary supplement (KetoneAid)
45445522|NCT01560195|Drug|placebo and rhG-CSF 5ug/kg/d|Patients receiving chemotherapy and placebo in cycle 1 and rhG-CSF 5ug/kg/d in cycle 2 to 4. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve[AUC] 5 or cisplatin 75 mg/m2.
45445523|NCT03772665|Drug|Emixustat|Once daily oral tablet taken for 24 months
45615023|NCT02502331|Biological|Euvichol®|Licensed, manufactured at 100 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
45615024|NCT02501239|Behavioral|Accept Yourself!|
45615025|NCT02501239|Behavioral|Weight Watchers|
45615026|NCT03121339|Biological|VXA-A1.1 H1 Tablet Vaccine (small)|Tableted oral H1 vaccine (~140 mg tablet)
45615027|NCT03121339|Biological|VXA-A1.1 H1 Tablet Vaccine (large)|Tableted oral H1 vaccine (~275 mg tablet)
45615028|NCT03343327|Drug|Chronocort®|Single dose of 20mg Chronocort® administered in one treatment period
45615029|NCT03343327|Drug|Cortef®|Single dose of 20mg Cortef® administered in one treatment period
45615030|NCT03343249|Behavioral|Smart Phone Based Smoking Cessation|The Samsung Galaxy Light Smart phone uses the Android 4.2 operating system. The phone has a 4.0 inch (480x800-pixel resolution) touch screen display, a built in microphone, earphone jack, audio speaker, and a rechargeable battery with 12.5 hours of talk time. The phone has 4G and is Wi-Fi and GPS capable. Participants navigate through the EMA program and enter data simply by touching the screen, similar to a pen-and-paper questionnaire. Thus, computer/typing skills are not required. Participants have the ability to call and receive calls from research staff through the smart phone free of charge. All phones will be equipped with Global Positioning Systems (GPS) capability. The smart phones are also equipped with a Secure Digital card to store data as it is collected.
45759744|NCT05212129|Other|Acoustic vagal nerve stimulation (aVNS) treatment|All subjects receiving acoustic therapy via active VNS (aVNS; n=30) or sham VNS (sVNS; n=30) will enter a four-week, randomized, double-blind clinical trial during which they will listen to either computer altered/filtered vocal music (active treatment) that has been designed to stimulate vagal calming vs. regular non-filtered music (sham treatment). The stimuli will mirror the acoustic intervention known as the Safe and Sound Protocol. This protocol has been found to reduce auditory hypersensitivities and calming the autonomic nervous system by increasing vagal regulation of the heart via brainstem ventral vagal complex. The acoustic intervention may be played by an electronic device (i.e. smartphone, tablet, laptop, mp3) and delivered virtually with the help of trained coaches.
45759745|NCT02012283|Other|Food consumption|Cooked vegetables with spices or without spices
45759746|NCT02812615|Dietary Supplement|Egg|After enrollment, participants will receive one large egg 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
45759747|NCT02812615|Dietary Supplement|Milk|After enrollment, participants will receive 150ml of milk 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
45615031|NCT03121183|Device|Laser sheath|Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
45615032|NCT03121183|Behavioral|Implantable Cardiac Device lead extraction|Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
45615033|NCT02502175|Drug|opium|Opium tincture (10mg/ml), manufactured by Daroupakhsh.co, Tehran, Iran.
45615034|NCT02502175|Drug|methadone|Methadone (5mg/ml), manufactured by Daroupakhsh.co, Tehran, Iran.
45759748|NCT02812615|Drug|Albendazole/Pyrantel Pamoate|As per the national guidelines, treatment will be provided based with 200 mg of Albendazole or 10mg/kg Pyrantel Pamoate single dose if the participants have not been treated for helminths in the preceding three months.
45759749|NCT02812615|Behavioral|Nutritional counselling|Parents/caregivers will be given nutritional counselling
45759750|NCT02812615|Dietary Supplement|Micronutrient sprinkles|For the child cohort, one sachet of multiple micro-nutrient sprinkles per day to be administered with the mid-day meal for two months
45759751|NCT02665117|Drug|Potassium Magnesium Citrate (KMgCit)|KMgCit will be administer for 4 months with chlorthalidone.
45615035|NCT04496323|Other|EE Golf|Exercise in Golf and Playing 9 holes
45615036|NCT02508025|Other|Functional Capacity Evaluation|Assessment of work related physical capacity
45615037|NCT03343405|Behavioral|Online Mind/Body Program for Fertility|The Mind/Body intervention involves (1) reducing physical symptoms of stress, (2) enhancing lifestyle behaviors related to fertility, (4) self-nurturing and coping skills, and (5) relaxation methods.
45615038|NCT02501941|Drug|ketamine|Ketamine will be used as a sedative alternative to other more conventional sedatives (such as propofol, versed, or dexmedetomidine) in 6 hour blocks of time. Ketamine will be titrated at the bedside based on clinically desired Riker Sedation-Agitation Scale target. Both groups will receive the drug in this multiple crossover design. The only difference between groups is which sedation regimen is started first to minimize any bias related to differences in physiology in the early post-operative phase.
45615039|NCT02501785|Behavioral|Caregiver Reaction Assessment (CRA)|
45615040|NCT02501785|Behavioral|The Caregiver Quality of Life - Cancer (CQOLC)|
45615041|NCT02501083|Other|no intervention|The study will not include any intervention.
45759752|NCT02665117|Drug|Potassium Chloride (KCl)|KCl will be administer for 4 months with chlorthalidone.
45759753|NCT02665117|Drug|Chlorthalidone|Chlorthalidone will be administered for 2-3 weeks. Then either KCL or KMgCit will be added to Chlorthalidone and the combination will be taken for 4 months.
45759754|NCT02402127|Device|Narafilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
45759755|NCT02402127|Device|Stenfilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
45759756|NCT02402127|Device|Somofilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
45759757|NCT05195749|Drug|101-PGC-005 ('005) + SOC|Three consecutive days of '005 administration
45445524|NCT03772665|Drug|Placebo|Once daily oral tablet taken for 24 months
45615042|NCT04495387|Drug|Chemotherapy|standard adjuvat chemotherapy for reast and colo cancer
45615043|NCT02501005|Procedure|VT ablation|Catheter ablation of ventricular tachycardia
45615044|NCT04495075|Other|Visuomotor Therapy|"The use of visual feedback informing internal physiological processes, such as muscle activation, torque, and joint position, has been termed visuomotor therapy. Visuomotor therapy encompasses completion of sub-maximal motor control tasks accompanying real-time visual biofeedback."
45615045|NCT04495075|Other|Passive Motion|The knee is passively moved through a range of motion.
45615046|NCT02500927|Drug|ASP8273 Capsules|oral
45615047|NCT02500927|Drug|ASP8273 Capsules A|oral
45615048|NCT04495309|Radiation|Metastases-directed Radiotherapy|Ablative radiotherapy (radiosurgery, stereotactic radiotherapy, hypofractionated image-guided radiotherapy (IGRT)) with few high-dose fractions
45615049|NCT02507869|Behavioral|Positive affective response|Participants adjust the intensity of their exercise to maintain a pleasant affective response.
46068981|NCT04980677|Device|Tangiball|"To enable baseline scores comparison, children will be matched according to age and score on the four-strand Hands-On assessment tool which takes 30 minutes to complete. Children will then play with the Smart Toy during a 20 minute session. Sessions will be recorded using an SD card within the Smart Toy which captures information on user speed and accuracy of placement of the detachable segments of the toy when placed into the main hub of the toy, allowing comparison between neuro-typical children and children with Autism. The intervention will run either in clinic (preferred option) or in children's homes-and in this case will be sent to them via post with the Standard Operating Procedure which can then be employed when children are taking part in the intervention via online video link (not recorded)."
45615050|NCT02507869|Behavioral|Moderate-intensity heart rate|Participants adjust the intensity of the exercise to maintain a heart rate in the moderate range (64-76% of their HRmax).
45615051|NCT02501863|Drug|Femoral nerve block with ropivacaine+fentanyl|Ropivacaine+fentanyl are used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
45615052|NCT02501863|Drug|Femoral nerve block with ropivacaine|Ropivacaine is used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
45615053|NCT02500771|Behavioral|ABA therapy enhanced with V-Motive software|Tutors will use the V-Motive software to enhance their delivery of Applied Behavioral Analysis therapy.
45615054|NCT02500693|Biological|Isolation of circulating tumor cells (CTC) from veinous blood|Thirty ml of peripheral blood will be collected in buffered EDTA, maintained at 4°C, and processed within 1 hour for filtration. After blood filtration, the membrane will be gently washed with PBS, disassembled from the filtration module, and allowed to air-dry. The determination of CTC number present on filters will be carried out by combining four color immunofluorescent (anti-pancytokeratins/anti-vimentin/DAPI/anti-CD45) staining and cytomorphological examination after Diff-quick and Mayer Hemalun staining in three spots per patient sample. Imaging of immunofluorescent and cytological staining will be performed at x20 magnification using the automated Ariol system. CTCs are identified by relocating images of immunofluorescent and cytological staining.
45445525|NCT03774225|Other|Virtual Reality with Manual and Verbal Guidance|Participants will perform 4 balance games during 8 sessions with a manually and verbally assisted by a experient physiotherapist.
45615055|NCT03344185|Dietary Supplement|Low Glycaemic Diet|This intervention consisted of three low GI meals.
45615056|NCT03344185|Dietary Supplement|High Glycaemic Diet|This intervention consisted of three meals, all with a high GI value.
45615057|NCT02500615|Other|ECIG liquid vehicles|The ratio of propylene glycol and vegetable glycerin will be changed while all other factors of the electronic cigarette provided to participants will be held constant.
45615058|NCT04496011|Other|Aerobic training with cycle ergometer|Patients start with an initial warm-up of 2 minutes, with rotations per minute free, without load. Progressively, the load of the exercise cycle increases every minute up to the supported limit or up to 60% - 70% of maximum heart rate (HRmax). The training will be carried out for 20 continuous minutes, being interrupted whenever the heart rate (HR) reaches 90% of the maximum expected for the age and / or the loss of effort perceived in the BORG scale, above 8 on a scale of 0 to 10.
45615059|NCT03344107|Other|USSQ questionnaire administration after RIRS.|USSQ symptoms questionnaire administration after RIRS
45615060|NCT02500459|Drug|topotecan|intraparenchymally-administered topotecan will use the Cleveland Multiport Catheter to directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). This drug is already FDA approved to be administered intravenously.
45615061|NCT02500459|Device|Cleveland Multiport Catheter|The Cleveland Multiport Catheter will directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). Standard treatment is to adminsiter the drug intravenously.
45615062|NCT04498507|Diagnostic Test|HADS questionnaire|Patients will be asked to answer to 3 questionnaires about anxiety and depression, post-traumatic stress disorder and health-related quality of life
45615063|NCT02500225|Drug|Etomidate|0.2 mg/kg etomidate
45615064|NCT02500225|Drug|Sevoflurane|8% Sevoflurane
46068982|NCT04972097|Device|Irreversible Electroporation|IRE of the prostate is typically performed with the subject in the lithotomy position, with 2-6 monopolar probes placed through the perineum using a brachytherapy grid and ultrasound or CT guidance. IRE supplies the targeted tissue with high voltage (2-3 kV) direct current pulses lasting up to 100 microseconds through the electrode probes.
45445526|NCT03774225|Other|Virtual Reality with No Manual and Verbal Guidance|Participants will perform 4 balance games during 8 sessions in the presence of a experient physiotherapist that will ensure patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game.
45759758|NCT05195749|Drug|Placebo + SOC|Three consecutive days of placebo administration
45759759|NCT02067039|Device|OraQuick in home & Sure Check HIV tests|Provision of OraQuick in home & Sure Check HIV tests
45759760|NCT05182489|Device|Medtronic Adaptix™ titanium implants|Patients who will be having a spinal fusion procedure as part of their standard of care treatment will be randomized to receive either the Medtronic titanium or the PEEK cage supplemented with a pedicle screw system and milled local autograft bone supplemented with GRAFTON DBM DBF. In order to assess fusion, patients will undergo a research-only CT Scan at 6 months post-surgery.
45759761|NCT05182489|Device|Medtronic CAPSTONE® PEEK cage|Medtronic CAPSTONE® PEEK cage
45759762|NCT02067273|Device|Transcranial Magnetic Stimulation (TMS)|
46068983|NCT04970875|Other|Questionnaire|QoL questionnaire
46068984|NCT04965753|Drug|FHD-609|FHD-609 as a single, intravenously administered agent given twice-weekly (BIW). Alternative dosing regimens may be evaluated.
46068985|NCT04939753|Drug|Sevoflurane|Sevoflurane administration to sedate the patient
46068986|NCT05471401|Device|Balloon-tipped catheter|Gastric balloon
45445527|NCT03774225|Other|Physical Therapy|Patients of the control group will be trained with balance exercises by a experient physiotherapist.
45615065|NCT04496557|Device|PROCESS-INSTRUCTED SELF NEURO-MODULATION (PRISM)|"Neurofeedback sessions targeting down-regulation of deep limbic structures, specifically the amygdala, delievered via PRISM: a non-significant risk device (software) intended to be used in research studies testing the clinical efficacy of an innovative paradigm for EEG-based neurofeedback.~The study will include 12 EEG-NF sessions, administered twice per week for a duration of 6 active weeks in total. Twice weekly sessions will be held on non-consecutive days. Each session will last 30 minutes.~EFP-EEG-NF training: Each NF training session consists of 5 consecutive sequences of NF presentations. During a watch condition (60 seconds) participants are instructed to passively view the animation, and are told that that the scenario does not influence their brain activity. In the regulate phase (60 seconds) participants are instructed to lower the room's unrest level. A rest phase (15 seconds) follows each sequence, allowing participants to relax."
45759763|NCT02151253|Drug|Armodafinil|Armodafinil 50 - 250 mg pills Subjects took armodafinil once daily, before 8 am. Armodafinil was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
45759764|NCT02151253|Drug|Placebo|Subject given placebo tablets to match Armodafinil pills. Subjects took placebo once daily, before 8 am. Placebo was initiated as 1 tablet and titrated to 3 tablets after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 5 tablets or reduced back to 1 tablet based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
45759765|NCT02151331|Behavioral|External Facilitation|Non-responding sites randomized to receive external facilitation
45759766|NCT02151331|Behavioral|External + Internal Facilitation|Non-responding sites randomized to receive both internal and external facilitation
45615066|NCT02507635|Drug|Levocetirizine|administration of Levocetirizine 5 mg/day for 4 weeks
45615067|NCT02507635|Drug|Desloratadine|administration of Desloratadine 5 mg/day for 4 weeks
45615068|NCT04495933|Biological|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg
45615069|NCT04495933|Biological|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg
45615070|NCT04495933|Biological|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg
45615071|NCT04495933|Other|Placebo|sterile saline
45615072|NCT04496089|Diagnostic Test|89Zr-girentuximab|A single dose of 37 MBq (±10%) is administered. The dose per dose is equivalent to girentuximab 10 mg (±10%).
45615073|NCT04495465|Other|Radial Shock Wave Therapy|2000 shots of extracorporeal radial shock waves therapy on neck muscles at 4bars and 10 Hertzs
45615074|NCT04495465|Other|Manual Therapy|25 minute massage to neck muscles
45615075|NCT04495465|Other|placebo shock waves|3 minutes of placebo extracorporeal radial shock waves therapy on painful points of neck muscles.
45759767|NCT02067585|Dietary Supplement|Standardized Lipid meals|Standardized Lipid meals: 240 ml of Hormel Great Shake Plus liquid nutritional supplement, 203 Kcal/100mL; 49% calories from fat, mostly unsaturated fatty acids of soy origin; 38% calories from carbohydrates, 13% calories from proteins.
45759768|NCT02308839|Device|GORE® EXCLUDER® Endoprosthesis|Endovascular therapy to treat abdominal aortic aneurysms
45759769|NCT02314689|Drug|Intravenous (IV) citrulline|
45759770|NCT02403999|Other|Test shampoo|Participants used Oilatum Soothe & Protect Shampoo at home in place of their usual wash product at least twice weekly for a two week period.
45911561|NCT05778682|Procedure|Suctioning based protocol|cf. arm The necessity of suctioning will be assed continuously by the nurses, respiratory therapist and the medical team. If the patient require 2 or less aspiration each 8 hours for 24 hours straight, an attempt of decanalution will be done.
45911562|NCT05778682|Procedure|Usual Care|Usual care in our center is tolerance to a capping trial.
45445528|NCT03772821|Other|Data collection|Between D0 and D90: local and general complications, demographic, clinical, paraclinical and biological data
45615076|NCT02500069|Other|placebo|infusion of tap water in all regions (duodenum, jejunum and ileum)
45615077|NCT02500069|Other|Casein (in duodenum)|infusion of protein in duodenum
45615078|NCT02500069|Other|Casein (in jejunum)|infusion of protein in jejunum
45615079|NCT02500069|Other|Casein (in ileum)|infusion of protein in ileum
45615080|NCT02499991|Behavioral|memory|keep track of social events in diary for memory recall. Used by treatment group
45615081|NCT02499913|Behavioral|breath alcohol monitoring|Daily breath alcohol monitoring
45615082|NCT02499913|Behavioral|contingency management|Participants can earn chance to win prizes for negative breath alcohol samples.
45911563|NCT05778669|Other|Monitoring of medical, health and psychosocial conditions|"Questionnaires will be used to collect information including children's health and psychosocial conditions, academic performance, and family demographics.~On-site assessments including general health and learning assessments.~Tracking of medical and health-related events of participants will be performed through the existing health care system."
45445529|NCT03772821|Other|Incision/scar measurement|Between D0 and D90
45615083|NCT04498039|Device|Portable Neuromodulation Stimulator|Examining the effect of targeted physical therapy with and without cranial nerve non-invasive neuromodulation (CN-NINM), on the walking ability of people with MS who exhibit a dysfunctional gait. Adopting a rehabilitative strategy using neuromodulation of the cranial nerves via electrical stimulation of the tongue to enhance the plasticity of the brain.
45615084|NCT03343015|Procedure|complete dentures|therapy with maxilla and mandible dentures
45615085|NCT04498195|Behavioral|increased exercise and physical activity|Participants were encouraged to increase physical activity for 12-week study duration and wear an activity tracker for a minimum of 12 hours a day.
45615086|NCT03344029|Biological|SP Shz TIV|0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0
45615087|NCT03344029|Biological|Hualan TIV|0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0
45615088|NCT04494997|Other|Survey Questionnaire|"This Cross sectional study uses Questionnaire with Closed ended questions. The survey form is designed using Google forms program. Survey initial question seeks CONSENT from the respondent. Survey collects data under 4 sections.~Section I: Demographic details Section II: 6 Questions regarding use of your Social Media for Professional activities.~Section III: 7 Questions regarding the advantages of your Social Media use. Section IV: 5 Questions regarding the disadvantages of your Social Media use.~The Google form questionnaire survey link will be shared with the Dentists in internet via Social Media &/Or email to seek responses. The link will be available for single response for a single respondent."
45615089|NCT05460637|Behavioral|No BS just Fitness|The participants receive lessons on the physical activity guidelines, goal setting, physical activity planning, habit development, identity formation, and how to apply all these tools together. In addition, there are numerous resources provided to other existing web resources, including exercise videos and other informational webpages (e.g., USDA nutritional recommendations).
45615090|NCT03120637|Drug|Methylene Blue|
45615091|NCT02496169|Device|eucaLimus|Percutaneous Coronary Intervention (PCI)
45445530|NCT05435313|Procedure|HAIC|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.
45445531|NCT05435313|Drug|Fruquintinib|3mg, qd, po, 21 days for a cycle, Suspend medication on the day of HAIC
45615092|NCT02496013|Drug|68Ga-NEB|68Ga-NEB were injected into the patients before the PET/CT scans
45615093|NCT02499757|Device|flavor and sweetener|maltol added as sweetener to e-cigarette with flavor
45615094|NCT02499757|Device|flavor and nicotine|12 mg of nicotine added to e-cigarette with flavor
45615095|NCT02499757|Device|flavor, nicotine and sweetener|12 mg nicotine and maltol (sweetener) added to e-cigarette with flavor
45615096|NCT02499757|Device|flavor|flavored e-cigarette stand alone without added nicotine and maltol (sweetener)
45615097|NCT02499601|Device|CORolla™ TAA device|
45615098|NCT02499523|Procedure|THR with conventional technique|THR with conventional technique.
45615099|NCT02499523|Procedure|THR with Acetabular Cup Orientation Guides (ACOG)|THR with the ACOG System.
45615100|NCT03120559|Device|New Floss Holder - Gum Chucks|Dental inter-proximal control with GumChucks floss holder
45759771|NCT02403999|Other|Test bath foam|Participants used Oilatum Soothe & Protect Bath Foam at home in place of their usual wash product at least twice weekly for a two week period.
45759772|NCT02403999|Other|Test head to toe wash|Participants used Oilatum Soothe & Protect Head to Toe Wash at home in place of their usual wash product at least twice weekly for a two week period.
45759773|NCT02405325|Behavioral|Physical Activity|intervention activities will remain at the daily level, including using pedometers, having daily goals, attendance at Peer lead group walks and recognition of efforts through monthly celebrations and bi-weekly goal tracking with peer Health Coaches.
45759774|NCT02069847|Drug|Budesonide|"Participants will be instructed to swallow budesonide 3mg twice daily for eight consecutive weeks following endotherapy with EMR or ESD. Budesonide will be provided in a capsule containing 3mg budesonide only by Mayo Clinic Pharmacy with full 8 weeks supply.~The patient will require opening the capsule and mixing the budesonide powder in 10ml (2 teaspoons) honey, or pancake syrup.~Patients will be instructed not to ingest any solid or liquids for 30 minutes before and after taking the budesonide. For purposes of this study, budesonide is used off-label but according to the same dose and efficacy as has been demonstrated in other esophageal inflammatory conditions. Patients will receive a handout with exact instructions how and when to take Budesonide."
45759775|NCT02070237|Drug|Enoxaparin|Enoxaparin will be given in either once daily or twice daily doses. One arm will receive 40 mg enoxaparin subcutaneous injection daily. The other arm will receive 0.5 mg/kg dosed subcutaneously twice daily. This medication will be started 8-12 hours after cesarean section and will be continued while the patient is admitted. It will be stopped at the time of discharge.
45759776|NCT02406495|Device|filcon IV 1|contact lens
45445532|NCT05435313|Drug|Tislelizumab|200mg, ivgtt, d1, 21 days for a cycle
45445533|NCT05435313|Drug|Raltitrexed|2 mg/m2, hepatic artery infusion for 15 min, d1, 4-6 Cycles
45445534|NCT05435313|Drug|Oxaliplatin|85 mg/m2, hepatic artery infusion for 2 h, d1, 4-6 Cycles
45615101|NCT03120559|Device|New Floss Holder - Gum Chucks/SMS|Dental inter-proximal control with GumChucks floss holder and receiving 16 SMS during first 4 months.
45615102|NCT00706849|Drug|mipomersen sodium|200 mg /mL
45615103|NCT00706849|Drug|placebo|1 mL matching placebo
45759777|NCT02406495|Device|ocufilcon D|contact lens
45615104|NCT02499445|Drug|Remifentanil|administering remifentanil for anesthesia maintenance
45615105|NCT02499445|Drug|sevoflurane 1|administering sevoflurane 1 for anesthesia maintenance
45445535|NCT05435313|Drug|Irinotecan|120mg/m2, hepatic artery perfusion for 30-90min, d1, 4-6 Cycles
45445536|NCT05419791|Other|Robot Asisted Gait Training with Lokomat (Endurance)|"Faster application (using for Endurance) : 3 days in a week for 6 weeks,very season was 40 min.~Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
45445537|NCT05419791|Other|Robot Asisted Gait Training with Lokomat (Attention and Motivation)|"Smile application (using for Attetion and Motivation) : 3 days in a week for 6 weeks,very season was 20 min.~Gabarello application (using for Attetion and Motivation) : 3 days in a week for 6 weeks,very season was 20 min.~Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
45615106|NCT02499445|Drug|sevoflurane 2|administering sevoflurane 2 for anesthesia maintenance
45615107|NCT02499445|Drug|propofol|administering propofol for anesthesia maintenance
45615108|NCT02499445|Drug|sufentanil|administering sufentanil for anesthesia maintenance
45615109|NCT03336775|Procedure|acupuncture|Acupuncture for 30 minutes per day for up to 20 sessions (over 4 weeks).
45615110|NCT04443049|Drug|Lenvatinib|Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is < 60 kg and 12 mg if body weight is > 60 kg
45615111|NCT04443049|Drug|Mebendazole|mebendazole will be given at dose of 100 mg orally twice a day (BD) daily
45615112|NCT04443049|Other|Placebo|Placebo (Tab Mecovit) orally twice a day (BD) daily
45615113|NCT02499133|Other|language and cognitive tests|The participants will undergo seven different. The tests will include different cognitive and language examinations. The main test of the study will be The Hebrew Focused Stress Test (HFST). The HFST includes three subtests. The first subtest requires identification of the stressed word in a sentence based on psychoacoustic abilities alone. The second and the third subtests require understanding the meaning of focused stress in different contexts - lexical grammatical and pragmatic/social. The test includes forty eight recorded sentences. In each sentence one word is stressed. The participants will be asked to listen to the recordings and answer a closed question regarding the stressed word.
45445538|NCT05419791|Other|Robot Asisted Gait Training with Lokomat (Activity Timing)|"High Flyer application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 20 min.~Treasures application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 10 min.~Curve Pursuit application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 10 min.~Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
45615114|NCT02495935|Device|OkuStim®|Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany
45615115|NCT02495935|Device|Sham-OkuStim®|Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany
45445539|NCT05419791|Other|Conventional Physiotherapy|-Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min.
45615116|NCT02495545|Procedure|CSFD and elevation of MAP|Lumbar drain placement with CSFD with elevation of MAP
45615117|NCT02495545|Procedure|Maintenance of MAP|Lumbar drain placement without CSFD and with maintenance of MAP
45615118|NCT03336697|Diagnostic Test|Nasal swab|a nasal swab will be performed by a trained physician by gently passing of a cotton swab in the nasal passage to get samples from middle meatus. This will be performed under guide of nasal anterior endoscopy to visualize the location of sampling. The cotton swab heads will be placed in sterile tubes and frozen at -80°C until DNA extraction.
45615119|NCT02495155|Behavioral|PROSPECT|PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms through non-pharmacologic approaches.
45615120|NCT02499211|Other|Intervention stores|"In-store marketing strategies will focus on placement and promotion of healthier items (lower calorie options) in the milk, frozen food, beverage checkout cooler, bread, salty snacks, and cheese sections of the store.~Intervention efforts in the dairy section promote lower calorie milk (skim, 1%, and 2%), while diminishing the presence of whole milk. The visual order of the milk displays will be changed, and the number of facings, or the fronts of packages the consumer can see, of whole milk will be decreased by 30% while increasing the facings of the lower calorie milk. In the other product categories, target products will be moved to eye level and the number of facings will be increased.~Call-out signs will be placed by the target products that list the name and price of the product. No health information or claims will be included. Signage will be rotated monthly to increase the chances that customers will notice them."
45615121|NCT02498899|Behavioral|Questionnaires|Participants complete questionnaires at baseline, after watching a video, and after reading a story about the patient in the video.
45615122|NCT02498899|Behavioral|Video|Participants watch a video lasting about 4 minutes.
45615123|NCT02499055|Behavioral|FearFighter|FearFighter™ is a nine session cognitive behavioural self-help therapy program delivered over the internet during nine weeks. Each session on FearFighter excluding the homework takes about 30-40 minutes to finish. A support person will make a weekly contact of 10 minutes in average to secure understanding of the program and compliance.
45615124|NCT03120793|Device|Esophageal balloon catheter|Measurements obtained from mechanically ventilated patients with ARDS in the supine, upright and prone positions
45615125|NCT02494999|Biological|13-valent pneumococcal conjugate vaccine|0.5ml vaccine produced by Beijing Minhai Biotechnology Co., Ltd.,three doses with 2 month interval, a booster dose 10 months after the first dose
45615126|NCT02494999|Biological|Prevnar 13|0.5ml vaccine produced by Wyeth,three doses with 2 month interval, a booster dose 10 months after the first dose
46068987|NCT04924036|Drug|glycopyrronium cloths|Qbrexza is an anticholinergic indicated for topical treatment of axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
45615127|NCT03341845|Drug|Axitinib|axitinib in combination with avelumab
45615128|NCT03341845|Drug|Avelumab|axitinib in combination with avelumab
45615129|NCT03336385|Dietary Supplement|Naxus|Non-digestible polysaccharides arabinoxylan (Naxus)
45615130|NCT03336385|Dietary Supplement|Oatwell|Non-digestible polysaccharides oat beta-glucan (Oatwell)
45911564|NCT05778630|Other|Focus group meetings|Focus group meetings with different experts in the domain of CPCs (health care professionals) and/or parents or family members of a child with CPC. Focus group meetings will be facilitated by one or two study investigators. Group discussions will be audio-recorded.
45911565|NCT05778630|Other|Individual interviews|Individual qualitative interviews (semi-directive), conducted by one or two study facilitators.
45911566|NCT05778604|Behavioral|Physio-feedback|"The researcher presents the BTrackS software to display the participant's BBS score (s) with interpretations including: (1) baseline, post-baseline, percent of changes; (2) comparison to sex and age group; and (3) levels of fall risk. The researcher will categorize participants into four groups (irrational | incongruent | congruent | rational) based on the fall risk appraisal (FRA) matrix and plots the position on one of the four quadrants in the FRA matrix chart. The researcher will provide physio-feedback to participants at baseline and week 9."
46068988|NCT04924036|Drug|Placebo|Placebo for this study are cloths that look like the qbrexza cloths but do not have any active ingredient.
46068989|NCT04917744|Procedure|Biospecimen Collection|Undergo collection of blood samples
46068990|NCT04917744|Other|Laboratory Biomarker Analysis|Ancillary studies
46068991|NCT04917744|Other|Medical Chart Review|Review of medical charts
46068992|NCT04914923|Device|Muse|Muse is an EEG headset device created by Interaxxon to track brain waves during mindfulness sessions.
45615131|NCT03336385|Dietary Supplement|Placebo|Maltodextrin as placebo
45615132|NCT03336307|Other|Rehabilitation program|"all patients received a rehabilitation program planned according to the European Physiotherapy guideline for Parkinson's disease and focus on:~endurance, strength, flexibility and balance with functional practice for all H/Y stage~endurance also for H/Y stage 1,~motor learning principles and cue functional for H/Y stage 2-3~external cues and self-instruction strategies and attention H/Y for stage 2-3 The rehabilitative program comprised 60-minute sessions a day (3d/wk)."
45615133|NCT02494765|Device|I-gel TM|Airway management with I-gel
45759778|NCT02071095|Drug|Arm A: Poly-ICLC|Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
45759779|NCT02071095|Drug|Arm B: Normal Saline|Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
45615134|NCT02494765|Device|Ambu AuraOnce (AO)|Airway management with Ambu AuraOnce (AO)
45759780|NCT02406573|Device|Crest® Sensi-Stop™ Strips|
45759781|NCT02071173|Device|ACUITY X4 quadripolar coronary venous lead and RELIANCE 4-FRONT defibrillation lead|"The ACUITY X4 leads are intended for chronic left ventricular pacing and sensing. The leads have 3 tip configuration designs (straight tip, short tip spiral, and long tip spiral), which is intended to provide choices for patients with different anatomies.~The RELIANCE 4-FRONT leads are designed for right-side heart applications within the ventricle, atrium, and superior vena cava. It is intended for permanent sensing, pacing, and defibrillation when used with a compatible implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D).~Subjects were allowed to receive both the ACUITY X4 and RELIANCE 4-FRONT lead."
45759782|NCT02348359|Drug|X-82|
45759783|NCT02348359|Drug|Anti-VEGF|
45759784|NCT02348359|Drug|Placebo|
45759785|NCT02406885|Drug|Apixaban|New Oral Anticoagulants (NOACs) are currently available for prophylaxis against venous thromboembolism in patients undergoing total hip or knee replacement surgery.
45759786|NCT02407041|Drug|GR-MD-02|IV infusion
45759787|NCT05235841|Other|acupressure|Acupressure is a complementary and supportive approach used in symptom management.
45759788|NCT02206945|Behavioral|neurofeedback|Subject provided with feedback of activity in target brain area in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
45759789|NCT02206945|Behavioral|control feedback|Subject provided with a control/placebo type of feedback in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
45759790|NCT05235607|Biological|Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration|subcutaneous administration
45445540|NCT03773913|Other|ICBHSS model|"Bundle of evidence-based interventions that include the following 5 components:~Community engagement meetings and feedback;~Elimination of public sector facility user fees for children under five and pregnant women;~Pro-active community based IMCI using trained, equipped, supervised, and salaried Community Health Workers (CHWs) with additional services including linkage to family planning and counseling, HIV testing & referrals;~Clinical mentoring and enhanced supervision by a trained peer coach at public sector facilities;~Basic infrastructure improvements and supply chain management training of pharmacy managers"
45445541|NCT03774381|Dietary Supplement|Bifidobacterium breve B-3|160 mg of Bifidobacterium breve B-3 is orally administered per day for 12 weeks.
45615135|NCT02494843|Other|online Hemodiafiltration|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
45615136|NCT02494843|Other|Hemodialysis|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
45615137|NCT02498977|Genetic|Biomarker|Real time polymerase chain reaction (PCR) gene expression measurement
46068993|NCT04914923|Behavioral|Cognitive Behaviour Therapy (CBT)|Cognitive behavioural therapy (CBT), incorporating exposure/response prevention (ERP) and cognitive therapy, is considered the gold-standard treatment for OCD. The efficacy of CBT has been well established, with numerous studies demonstrating that it leads to significant and lasting reduction in OCD symptoms for the majority of completers.
46068994|NCT04914923|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|Mindfulness-based interventions (MBIs) including MBCT, are interventions that incorporate formal and informal mindfulness practice in order to treat mental health concerns.
46068995|NCT04902885|Drug|Trilaciclib|Group 1: Trilaciclib, carboplatin, etoposide，or Topotecan Group 2: Trilaciclib, Topotecan Group 3: Placebo, carboplatin, etoposide，or Topotecan
45615138|NCT02498977|Drug|Tacrolimus, cyclosporine and/or mycophenolic acid, mycophenolate mofetil or azathioprine|Immunosuppression drugs as per protocol
45615139|NCT02498743|Procedure|echocardiography|TV was connected to display the cartoon video during the echocardiography: the episode number 125 of 'Dora the Explorer': 'Baby Winky Goes Home!' was reproduced during the echocardiography.
45615140|NCT02498743|Behavioral|Watching Animated cartoons|
45615141|NCT03336229|Behavioral|Exercise intervention|Graduated walking programme, strengthening exercises and respiratory muscle training.
46068996|NCT04896632|Drug|INE 963|Part A: Single ascending dose with 4 planned cohorts> Part B: multiple dose with 1 planned cohort q24x3 days
46068997|NCT04896632|Other|Placebo|Part A: single ascending dose with 4 planned cohorts. Part B: multiple dose with 1 planned q24x3 days.
46068998|NCT04891640|Other|Standard TNFi Therapy|Participants randomly assigned to this arm will continue taking their TNFi medication as currently prescribed.
45615142|NCT02494687|Drug|Oral Domperidone|10 mg of oral domperidone administered (four times a day) for two weeks
45615143|NCT02494687|Drug|Oral Domperidone|Increased to 20 mg four times a day for 2 weeks at the Investigator's discretion
45615144|NCT02494687|Drug|Oral Domperidone|Increased to 30 mg four times a day at the Investigator's discretion
45615145|NCT02494609|Drug|sotagliflozin|400 mg sotagliflozin
45615146|NCT02494609|Drug|oral contraceptive|0.25 mg norgestimate/0.035 mg ethinyl estradiol
45615147|NCT02494609|Drug|oral contraceptive + sotagliflozin|0.25 mg norgestimate/0.035 mg ethinyl estradiol + 400 mg sotagliflozin
45615148|NCT03336151|Behavioral|Front-of-pack labelling Nutri-Score|Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
45615149|NCT03341767|Drug|Clofazimine|50 or 100 mg micronized Clofazimine suspended in an oil-wax base in a gelatin capsule
45615150|NCT03341767|Drug|Placebo|Oil-wax in gelatin capsule
45615151|NCT02498353|Radiation|preoperative short-course radiotherapy with local boost|Except the clinical target volume(CTV),a gross tumour volume（GTV）is delineated，and give a dose of PTV-GTV:30Gy/5F
45615152|NCT02498353|Radiation|preoperative short-course radiotherapy without local boost|Preoperative short-course radiotherapy without local boost,the dose of radiotherapy is PTV-CTV 25Gy/5F
45615153|NCT02498353|Procedure|TME surgery|both study group and control group received surgery under TME principle after radiotherapy
45615154|NCT02498431|Procedure|percutaneous coronary intervention|a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease
45615155|NCT02498431|Procedure|coronary angiography|is a procedure performed along with cardiac catheterization that uses X-ray imaging to see your heart's blood vessels
45615156|NCT02498431|Device|Stent, Medronic Resolute Integrity|A stent is placed in an artery as part of a procedure called percutaneous coronary intervention (PCI) to restore blood flow through narrow or blocked arteries. A stent helps support the inner wall of the artery in the months or years after PCI.
45615157|NCT03335917|Other|Hypoxia|Participants will be exposed to hypoxia by reducing barometric pressure or by reducing oxygen concentration
45615158|NCT03335917|Other|Exercise|Graded cycling exercise to volitional fatigue
45615159|NCT02498509|Drug|CKD-342|treatment for 4 weeks after randomization
46068999|NCT04891640|Other|TNFi fixed longer dosing intervals|"Participants randomly assigned to this arm will increase the time between TNFi medication doses.~Adalimumab- from every 2 to 3 weeks~Certolizumab- from every 2 to 4 weeks~Etanercept- from every 1 to 2 weeks~Golimumab- from every 4 to 6 weeks~Infliximab- from baseline to baseline + 2 weeks"
45445542|NCT03774381|Dietary Supplement|Control group|160 mg of placebo is orally administered per day for 12 weeks.
45615160|NCT02498509|Drug|Mometasone furoate|treatment for 4 weeks after randomization
45445543|NCT05472675|Procedure|Botulinum toxin and bupivacain|Botulinum toxin A AND bupivacain( local anesthetic)
45615161|NCT02498509|Drug|Levocabastine HCL|treatment for 4 weeks after randomization
45615162|NCT02498665|Drug|DSP-7888 Dosing Emulsion|"Dose escalation cohort: Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.~MDS cohort 1: Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.~MDS cohort 2: Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks."
45615163|NCT03341611|Behavioral|Neuro-imaging during behavioral decision-making task|All participants will make simple decisions while in a scanner.
45615164|NCT03335683|Drug|Lenidase|drug per os twice day for 7 days, or for 10 days
45615165|NCT03341455|Behavioral|Capacity building to support families affected by IPV & substance misuse|Training targeted groups (mothers, fathers, preschool teachers, community officers managing preschools) separately with the aim to identify and support high-risk families early enough to arrest the cycle of violence that results in children themselves becoming victims and perpetrators of such violence.
45615166|NCT04494919|Device|Ultrafine Endoscope|The reversal of the normal colonoscope (CV-260SL; Olympus, Tokyo, Japan) along the guidewire to replace the UFE (GIF-XP260NS; Olympus, Tokyo, Japan).
45615167|NCT04494685|Device|Intervention group (Robotic rehabilitation)|Robotic rehabilitation with Erigo® equipment (Hocoma, Volketswil, Switzerland). The training protocol has a progression of the board inclination up to 90º associated with flexion/extension movements of the knees and hips, with time evolution of up to 40 minutes. Such equipment is associated with electrostimulation of the quadriceps, hamstrings, sural triceps and anterior tibialis.
45759791|NCT02093455|Dietary Supplement|Chardonnay Seed Flour (CSF)|CSF is made from wine grape skins and seeds.
45759792|NCT02093455|Dietary Supplement|Placebo|
46069000|NCT04891640|Other|Stop TNFi treatment|Participants randomly assigned to this arm will stop TNFi medication.
45445544|NCT03773835|Drug|HSK3486|Mmanual IV bolus injection completed in 1 minute.
45759793|NCT05235529|Procedure|Aortic valve replacement|Surgery replacement od the aortic valve
45759794|NCT05235529|Device|TAVI|Transcatheter aortic valve implantation
45759795|NCT05164237|Other|nerve flossing technique|subjects will receive NFT with conventional physical therapy modalities in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
45615168|NCT04494685|Other|Control group (Conventional physiotherapy)|Knee and hip flexion and extension movements, hip adduction, and abduction, respecting the articular physiology of each joint. Weight transfer will also be performed in the sitting and standing position, mini squat, and gait training. All exercises will have a total of 10 repetitions in three sets. In the end, stretching of the upper and lower limbs will be performed.
45615169|NCT04494607|Dietary Supplement|lowest Glycemic Index for a selected type fo cereal product|determination of lowest Glycemic Index for a selected type fo cereal product
45615170|NCT03342859|Drug|Vilaprisan, BAY1002670|Daily single oral doses of 2 mg vilaprisan over 8-12 weeks
45615171|NCT03342859|Drug|Ulipristal|Daily single oral doses of 5 mg ulipristal over 8-12 weeks
45615172|NCT03342781|Device|high flow nasal oxygen therapy|Oxygen therapy using a high-flow nasal cannula (HFNC) is a high-flow oxygen delivery system that enhances the efficiency of respiration by using high flow rates to clear dead space and provide fresh oxygen. This system supplies oxygen at a high flow rate through a loose nasal cannula.
45615173|NCT03342781|Device|Diffuser oxygen mask|diffuser mask is a low-flow delivery system, which is capable of delivering up to 90% of the fraction of inspired oxygen (FiO2) with low CO2 retention. In this system, the FiO2 can be adjusted by modifying the flow velocity to deliver the quantity of oxygen that the patient requires. Oxygen is supplied to the patient in a jet that flows from a device mounted on the oxygen mask. This ensures that a high concentration of oxygen is provided at a low flow rate.
45615174|NCT02494453|Procedure|Research Cardiac MRI|Cardiac MRI has increasing utility in evaluating structural and functional cardiac pathologies. For detection of coronary artery disease, MRI outperforms SPECT and dobutamine stress echocardiography for the detection of ischemia. MRI also can detect wall-motion abnormalities and other dysfunction. Dynamic contrast-enhanced MRI (DCE-MRI) can evaluate microvascular parameters such as vessel permeability and fluid volume fraction as an assessment of tissue perfusion. Thus, cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiotherapy and could potentially identify patients for intervention to prevent cardiac events. All patients will follow the protocol calendar requiring research MRIs, but will receive standard radiation treatment determined by their treating physician. In this study, treatment will not be altered based on the data collected from these MRIs.
45615175|NCT02494453|Procedure|Biomarkers|"Scant data exist on potential biomarkers of cardiac radiation exposure and damage. However, we have identified potential candidates based on other processes affecting heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis and left ventricular dysfunction, these include galectin-3 and N-terminal-Pro brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15. Additional blood will be collected and stored for future assessment of other candidate biomarkers.~All patients will follow the calendar of protocol required research blood draws for biomarker collection, but will receive standard radiation treatment as clinically indicated by their treating physician. In this study, treatment will not be altered based upon the data collected from these samples."
45615176|NCT02493283|Drug|Dapsone single dose|Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration), urine (0-24 h, 24-48 h, 48-72 h, 72-96 h, 96 -120 h) and feces (on treatment days 1-5)
45615177|NCT02493283|Drug|Dapsone multiple dose|Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) s.i.d. for 7 days and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration), urine (last treatment day 0-24 h) and feces (on treatment days 12-15)
45615178|NCT02493283|Biological|leucocytes|sampling for leucocytes collection: study days -1, 1, 14 and 15
45615179|NCT02493283|Biological|Met-Hb|sampling before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration, before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration and sampling for additional safety analyses (Met-Hb): study days 10, 12, 14 and hematology on study day 12
45615180|NCT03342703|Diagnostic Test|Ultrasound|Patients will undergo a standard liver US protocol for approximately 15 minutes.
45615181|NCT03335527|Drug|Dexmedetomidine|Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.1-0.2 ug/kg/h (0.025-0.05 ml/kg/h) from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.
45615182|NCT03335527|Drug|Placebo (normal saline)|Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025-0.05 ml/kg/h from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.
45615183|NCT03342625|Device|High Instensity Focused Ultrasound|High Intensity Focused Ultrasound guided by MRI
45615184|NCT03341065|Device|exoskeleton type robot|
45615185|NCT03341065|Device|end-effector type robot|
45615186|NCT02493049|Drug|Domperidone|Addition of Domperidone to current Disease Modifying Therapy.
45615187|NCT03120715|Drug|estrogen|The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.
45759796|NCT05164237|Other|multimodal electrotherapy|subjects will receive multimodal approach of electrotherapy (LLLT , US and IFC) with conventional physical therapy modalities in the form of ( splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
45759797|NCT05164237|Other|exercises|subjects will receive with conventional physical therapy modalities only in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
45759798|NCT02341599|Drug|MK-6183|MK-6183 (CB-238,614) is supplied as lyophilized powder 500 mg vial and mixed into solution for 100 mL intravenous (IV) administration over 1 hour.
45759799|NCT02408445|Drug|testosterone cypionate 200mg/ml|Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.
45759800|NCT01889329|Dietary Supplement|RUTF-1|Made from local food ingredients
45759801|NCT01889329|Dietary Supplement|RUTF-2|Made from local food ingredients
45759802|NCT01889329|Dietary Supplement|Plumpynut|Commercially made from peanut paste
45615188|NCT03120715|Drug|Low Molecular Weight Heparin|If the endometrial thickness is greater than 9 mm, hCG 10000 IU will be administered via intramuscular injection.And low molecular weight heparin (LMWH) will be injected subcutaneously 4100 IU (WHO) every other day before FET.Then on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
45615189|NCT03120715|Drug|hCG|If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.
45615190|NCT03120715|Drug|progesterone|on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
45615191|NCT03120403|Procedure|intrathecal morphine|
45615192|NCT02497963|Procedure|Foreskin Graft-Tubularized Incised Plate|TIP Urethroplasty with foreskin graft in primary hypospadias
45615193|NCT02497963|Procedure|Tubularized Incised Plate|TIP Urethroplasty without foreskin graft in primary hypospadias
45615194|NCT03342547|Procedure|Duodenal biopsy|Two duodenal biopsy samples will be collected from each participant
45615195|NCT03342547|Procedure|Saliva|Saliva (1-2 mL) will be collected from each participant for secretor status testing
45615196|NCT03340987|Procedure|vestibular incision subperiosteal tunnel access|vertical vestibular incision will be made down to the periosteum followed by creating a tunnel without reflecting the interdental papilla. Then a free gingival graft will be optained from the palate and de-epithelialized extraorally. The connective tissue graft will then be applied through the tunnel and the gingival margin will be sutured and the sutures will be fixed to the tooth surface by flowable composite. Then the vestibular incision will be sutured.
45615197|NCT03340987|Procedure|Coronally advanced flap|Two horizontal incisions will be made mesial and distal to the recession area followed by two oblique incisions extended to the alveolar mucosa and a full-split thickness flap will be elevated. De-epithelialization will be done to receive the connective tissue graft obtained from the palate by de-epithelializing a free gingival graft. Then the flap will be advanced coronally aand sutured without tension
45615198|NCT02492893|Other|Hatha yoga|
45615199|NCT02492737|Drug|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
45615200|NCT03340831|Device|Continuous Glucose Monitoring (CGM)|Use of CGM to compare incidence of diabetes events compared to use of a blood glucose meter (BGM)
45615201|NCT03120481|Other|no intervation|no intervention
45615202|NCT03335449|Other|Protective ventilation group|Application of a protective ventilation strategy in order to improve gas exchange and respiratory mechanics during Robotic surgery in deep Trendelenburg position.
45615203|NCT03335293|Drug|100 mcg Epinephrine|This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.
45615204|NCT03335293|Other|normal saline|placebo comparator
45615205|NCT03335293|Drug|200 mcg Epinephrine|This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.
45615206|NCT02498197|Behavioral|Participatory Intervention|
45615207|NCT02498197|Behavioral|Control|
45615208|NCT02498041|Procedure|Transnasal Endoscopy|Experimental procedure with transnasal endoscopy for the first 80% of the patients (n=90). The examination is limited to the esophagus and the proximal stomach.
45759803|NCT00426205|Biological|GM-CSF secreting leukemia vaccine|Vaccine given subcutaneously or intradermally on the leg, arm, or abdomen 6 times. The first three vaccines will be given once a week for three weeks. The last three vaccines will be given once every other week for three doses.
45759804|NCT05235217|Drug|Test product (T) 40 mg Hard Gelatin Capsules|Hard Gelatin Capsules products containing 40 mg Esomeprazole
45615209|NCT02498041|Device|Office-based disposable transnasal endoscopy Endosheath|Experimental procedure with portable, disposable transnasal endoscopy for the last 20% of patients only (n=25). The examination is limited to the esophagus and the proximal stomach.
45759805|NCT05235217|Drug|Reference product (R) 40 mg Hard Gelatin Capsules|Reference product (R) 40 mg Hard Gelatin Capsules
45615210|NCT02498041|Device|Standard upper GI endoscopy|Upper GI endoscopy with standard gastroscope.
45615211|NCT02498041|Procedure|Esophageal biopsies|2 research biopsies taken if endoscopic evidence of columnar-lined esophagus
45615212|NCT03340753|Drug|KBP-5074 mineralocorticoid receptor antagonist|KBP-5074 (0.5 mg or 1.0 mg) in either capsule or tablet formulation, single dose, in a 2-period crossover design with a 2-week washout/follow-up period
45615213|NCT02494531|Radiation|Fluorodeoxyglucose-PET|Fluorodeoxyglucose-PET performed within 2 months
45759806|NCT00388921|Drug|Vitamin A|
45759807|NCT02016885|Drug|glycopyrrolate, 1.0%|glycopyrrolate Topical Wipes, 1.0%
45759808|NCT02016885|Drug|glycopyrrolate, 2.0%|glycopyrrolate Topical Wipes, 2.0%
45759809|NCT02016885|Drug|glycopyrrolate, 3.0%|glycopyrrolate Topical Wipes, 3.0%
45759810|NCT02016885|Drug|glycopyrrolate, 4.0%|glycopyrrolate Topical Wipes, 4.0%
45759811|NCT02016885|Other|Vehicle|Vehicle Topical Wipes
45615214|NCT02494531|Radiation|florbetapir F 18-PET|florbetapir F 18-PET performed within 2 months
45615215|NCT03335215|Other|cognitive remediation|The innovative nature of this program is that it integrates both neuropsychological psychoeducation, the principles of reeducation of altered cognitive functions and the setting in addictological context benefiting from the interactions of the group situation. Thus, during the three months of REMED management, six modules corresponding to six altered cognitive domains that may have an impact on the maintenance of the therapeutic contract will be offered to patients. The REMED group will benefit from cognitive remediation of episodic memory disorders, executive and attentional functions, and the theory of the mind integrating psychoeducation, training and systematic situations related to an alcoholic context. The different procedures of neuropsychological management (facilitation, use of preserved capacities and compensation) will help to integrate the concepts and addictological strategies necessary to maintain the therapeutic contract taking into account cognitive impairments.
45615216|NCT03340597|Drug|F901318|F901318 tablet
45615217|NCT03342391|Other|Transnasal esophagoscopy|single food antigen introduction OR removal of topical swallowed steroid therapy followed by surveillance utilizing TNE
45615218|NCT03335137|Diagnostic Test|Drug Level Monitoring|Free (unbound) drug concentration 1 hour, 4 hours and 7.5 hours after primary load of piperacillin/tazobactam on day 1 and day 3 after admission
45615219|NCT00707161|Radiation|Radiation Therapy|Radiation therapy will be delivered concurrent with cisplatin chemotherapy as outlined in table 2. Radiation therapy dose will be 50 Gy (2.5 Gy per day, 5 days per week, for 20 treatments).
45759812|NCT00802633|Device|Stapling device during radical cystectomy|Hemostasis
45759813|NCT00802633|Device|Ligasure tissue sealing device|Efficacy of tissue sealing device during hemostasis
45759814|NCT00244777|Drug|Hypo-osmolar ORS|
45759815|NCT05139121|Drug|MR-100A-01|Transdermal contraceptive delivery system
45759816|NCT02016963|Biological|Raxibacumab|Raxibacumab will be supplied in 50 milliliter (mL) sterile, single-use vials containing 34.9 mL of liquid formulation per vial. Each vial contains 50 milligram (mg)/mL raxibacumab in 0.13 mg/mL citric acid, 2.8 mg/mL sodium citrate, 10 mg/mL sucrose, 18 mg/mL glycine, 0.2 mg/mL polysorbate 80, pH 6.5
45615220|NCT00707161|Drug|Cisplatin|Cisplatin dose will be 100 mg/m2 given i.v. every 3 weeks for a total of 2 doses (days 1 and 22) during radiation.
45759817|NCT00142285|Drug|Zinc sulphate (20 mg)|
45759818|NCT02018445|Procedure|Posterolateral Fusion|
45445545|NCT04673721|Dietary Supplement|Fortified eggs|Average 12 eggs consumed per week
45759819|NCT02342379|Drug|Bevacizumab|10mg/kg
45759820|NCT02342379|Drug|TH-302|670mg/m2
45759821|NCT02019069|Drug|liposomal cytarabine-daunorubicin CPX-351|Given IV
45445546|NCT04673721|Behavioral|Intermittent fasting|16-hour fast and then an 8-hour nutritional window with aim for energy needs to be consumed during an 8 hour eating window (e.g., 11 am - 7 pm) with fasting for 16 hours (e.g., 7 pm - 11 am the next day).
45759822|NCT00821821|Drug|MCI-186|"Cohort 1: Edaravone: circa 1000 mg / 72-hour infusion~Cohort 2: Edaravone: circa 2000 mg / 72-hour infusion"
45759823|NCT00821821|Drug|Placebo|"Cohort1:circa 1000mg / 72-hour infusion matching placebo~Cohort2:circa 2000mg / 72-hour infusion matching placebo"
45445547|NCT04673721|Dietary Supplement|Non-egg supplemented|2 or less eggs consumed per week
45445548|NCT04673721|Behavioral|Usual care diet|Consistency with current diet without consideration of intermittent fasting
45445549|NCT03773679|Procedure|Daily Exercise|Daily Exercise Programme
45445550|NCT03815097|Procedure|Mapleson circuit and nasal trumpet|The Mapleson Circuit is a breathing system used to deliver oxygen and remove carbon dioxide during anesthesia. It consists of fresh oxygen flow, a reservoir bag, an expiratory valve, tubing, and a connection to the patient. There are different types of Mapleson circuits depending on the different arrangements of its components. We plan to use a Mapleson D circuit attached to a nasal trumpet via a connector.
45445551|NCT04720053|Device|Wearable brain sensing wellness device headband system|Brain sensing headband that measures brain activity by detecting electrical impulses created by the brain.
45759824|NCT03839875|Drug|Gynomax® XL Vaginal Ovule|tioconazole, tinidazole, lidocaine
45759825|NCT02409459|Drug|Injectafer|
45759826|NCT02409459|Drug|Placebo|Normal saline solution
45759827|NCT05198167|Other|Hyperoxygenated fatty acids|Application of hyperoxygenated fatty acids in pressure zones for prevention of prone position pressure ulcers
45759828|NCT05198167|Other|Hydrocolloid dressings|Protection of pressure areas with hydrocolloid dressings for the prevention of prone pressure ulcers
45759829|NCT02409927|Dietary Supplement|MCT oil 10g|10 g of pure MCT oil mixed with skim milk in a standardized breakfast
45759830|NCT02409927|Dietary Supplement|MCT homogenate 10g|10g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
45759831|NCT02409927|Dietary Supplement|Control|vehicule (skim milk) with a standardized breakfast
45759832|NCT02409927|Dietary Supplement|MCT oil 20g|20g of pure MCT oil mixed with skim milk in a standardized breakfast
45759833|NCT02409927|Dietary Supplement|MCT homogenate 20g|20g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
45759834|NCT02409927|Dietary Supplement|MCT oil 30g|30g of 100% pure MCT oil mixed with skim milk in a standardized breakfast
45759835|NCT02409927|Dietary Supplement|MCT homogenate 30g|30g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
45759836|NCT00816751|Procedure|Paracervical block|The paracervical block was administered using 20 ml of buffered lidocaine and a 5/8 inch, 25-gauge needle. A small amount was injected at the tenaculum site, and the remainder equally distributed around the cervicovaginal junction at 3, 5, 7, and 9 o'clock. The depth was standardized at 5/8 inch by inserting the needle to the hub.
45445552|NCT03763461|Device|HFNC|High flow nasal humidified oxygen HFNC is an air-oxygen blender, which provides high flow (up to 60 L/min) of warmed (36°C) and humidified gas through nasal cannula, allowing tighter control of FiO2 from 0.2 to 1.0.
45615221|NCT00707161|Procedure|Surgical resection|Surgical resection of residual (or recurrent) melanoma for cure or for palliation may be performed following chemoradiation if deemed appropriate by the treating physicians (surgical resection may be planned following pre-operative chemoradiation or may be performed for salvage due to inadequate response to chemoradiation or for relapse following chemoradiation). Surgical resection will not be performed until at least 4 weeks following chemoradiation (unless deemed emergent by the treating physicians).
45615222|NCT03120247|Drug|OTM Dexmedetomidine 1µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
45615223|NCT03120247|Drug|OTM Dexmedetomidine 0.75µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
45615224|NCT03120247|Drug|OTM Dexmedetomidine 0.5µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
45615225|NCT04443205|Other|Data record|Data record
45615226|NCT02497651|Dietary Supplement|Liquid mixed meal|The subjects will ingest a 400 ml chocolate drink, rich on carbohydrates, fat and lipids. In the following 4 hours, blood samples will be drawn from a PVC for the measurement of plasma glucose, gut- and pancreatic hormones, acetaminophen etc. After the 4 hours, the subjects will be offered an ad libitum meal.
45615227|NCT02497651|Other|Skin Biopsy|All subjects will undergo a skin biopsy procedure. Two small (3 mm) biopsies will be taken from the hip area under local anaesthesia. Standard wound treatment will follow.
45615228|NCT05465473|Other|Distalization|Group I: will include 10 patients undergo distalization according to a standardized protocol. Group II: will include 10 patients undergo distalization assisted with low level laser therapy according to a standardized protocol.
45615229|NCT02497573|Other|Diffuse Weighted MRI|The DW MRI scans will be used to measure ADC and to calculate change in ADC between the 2 scans. Each scan will take approximately 30 minutes. Images will be acquired and analysed as per the separate scanning protocol.
45615230|NCT03340441|Device|Prizma|sensor unit with mobile application installed on smartphone
45615231|NCT02494375|Other|Sleep and glucose assessments|Sleep characteristics, glycemic control, salivary amylase and body composition will be assessed 3 times, at 3-4 months intervals
45615232|NCT03335059|Combination Product|Synergo® RITE + MMC|Subjects will receive a series of induction followed by a series of maintenance bladder instillations of Synergo® RITE + MMC
45615233|NCT02497729|Procedure|Written Checklist|Use of a written checklist pre and peri-intubation
45615234|NCT02497729|Procedure|Head of Bed Up|Raising the patient's head of bed to 25 degrees
45615235|NCT02497495|Other|immersion cold water|immersion cold water at different temperatures and exposure times
45615236|NCT03334981|Procedure|Concentrations in Meconium of Buprenorphine and Methadone|buprenorphine or methadone concentration measurement
45615237|NCT03340363|Behavioral|environmental change|"Offer kid-friendly, low-cost recipes in a prominent, high-traffic location.~Offer healthy default ingredients (bundled ingredients promoted with recipes).~Promote recipe ingredients with prominently displayed signage and images.~Promote recipes in multiple locations throughout the store."
45615238|NCT03340363|Behavioral|messaging|Short, behavioral messages sent to participants via text message or email each week to promote the in-store environmental changes
45615239|NCT02492503|Drug|Paclitaxel and carboplatin|Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour, and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly
45615240|NCT02492503|Drug|Paclitaxel and carboplatin|Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly
45615241|NCT03340285|Dietary Supplement|AkP06|first 2 weeks: Placebo + Diet then 4 weeks AkP06 two tablet/day before meals + Diet
45615242|NCT03340285|Dietary Supplement|Placebo|first 2 weeks: Placebo + Diet then 4 weeks placebo two tablet/day before meals + Diet
45615243|NCT03334669|Behavioral|Parents Connect for Healthy Living (PConnect)|Parents Connect for Healthy Living (PConnect) parent curriculum: This 10-week program (20 hours total) engages Head Start parents in a wide range of topics related to health and empowerment and is designed to foster a safe, open forum through which parents can connect with other parents and mobilize resources to support their family's health; NOTE: The PConnect program was not implemented in 2019-2020 due to the coronavirus pandemic. In 2020-2021, PConnect was implemented virtually; these are pilot data and not part of the main trial.
45615244|NCT03334669|Behavioral|Enhanced Nutrition Support|Enhanced Nutrition Support: Existing nutrition resources within Head Start (e.g., Biannual child health letters) are expanded and improved to ensure parents are aware of their child's weight status and are linked with age-appropriate weight management services if their child has overweight or obesity. NOTE: Enhanced nutrition support was not implemented in spring 2020 due to the pandemic. In 2020-2021, it was moved to a virtual format in what will be a pilot virtual trial.
45615245|NCT03334669|Behavioral|Media Resources|Media Resources: Print and online resources that employ consistent messaging to reach parents and ensure that behavior change messages are accessible to families. NOTE: Due to the pandemic, media resources were not shared in spring 2020. They were implemented in virtual format in 2020-2021 in a pilot virtual trial.
45615246|NCT02497339|Behavioral|Mindfulness training|Using mindfulness training (Thinking and Yoga class) to help women smokers in workplaces to quit smoking
45615247|NCT02497183|Device|ultrasound|A repeat ultrasound exam following oral contrast material consumption
45615248|NCT02497183|Other|iodine based solution of oral contrast material|A solution of oral contrast material that is routinely used in our institution prior to performing a computed tomographic (CT) examinations of the gastrointestinal tract will be given prior to performing the repeat ultrasound/
45615249|NCT02497105|Other|Ketogenic Diet|Dietary
45759837|NCT00816751|Procedure|Intracervical|The intracervical block was administered using 20 ml of buffered lidocaine and a 1-1/2 inch, 20 gauge needle in order to overcome the increased resistance to injection caused by the cervical stroma. A small amount was injected at the tenaculum site, and the remainder into the cervical stroma at 12, 3, 6, and 9 o'clock, at a depth of 1-1/2 inch by inserting the needle to the hub.
45759838|NCT00816751|Drug|Buffered Lidocaine, vasopressin, sodium bicarbonate|The buffered lidocaine preparation for both block techniques consisted of 50 mL of 1% lidocaine, 5 units of vasopressin, and 5 mL 8% sodium bicarbonate.
45615250|NCT02497027|Other|pharmacogenetic testing|pharmacogenetic testing report released to physician at 4 weeks post enrollment
45615251|NCT02497027|Other|pharmacogenetic testing|pharmacogenetic testing report released to physician at 12 weeks post enrollment
45615252|NCT03339973|Biological|allo-APZ2-PAOD|Suspension of ABCB5-positive mesenchymal stem cells in pre-filled syringe
45759839|NCT00822523|Drug|Botulinum Toxin, Type A|20 units, single dose, intramuscular in right EDB muscle
45615253|NCT03339973|Drug|Placebo|Solution for injection in pre-filled syringe
45615254|NCT03334591|Drug|Apatinib|Apatinib 500mg with Docetaxel 60mg/m2
45615255|NCT03339895|Other|pvı-guided|pvı- guided total amount of crystalloid volume of fluid infused during colorectal surgery pvı-guided(according to pvi value) fluid infused during whole procedure 2 ml/kg/h infusion during surgery If PVI value <%13 and if MAP>65mmHg continue with 2 ml/kg/h cristalloid infusion If PVI value <%13 and if MAP>65mmHg 5 mcg efedrin intravenous bolus till MAP>65 mmHg If PVI value >%13 and MAP>65 mmHg infuse 250 ml Gelofusine bolus up to PVI value lowers to %13 every 5 minute If PVI value >%13 and MAP <65 mmHg infuse 250 ml Gelofusine bolus and 5 mcg efedrin intravenous up to PVI value lowers to %13
45615256|NCT03339895|Other|traditional-guided|traditional-guided total amount of crystalloid volume of fluid infused during colorectal surgery traditional-guided fluid infused during whole procedure 4-8 ml/kg/h infusion during surgery If MAP <65 mmHg or <30%of basal value, infuse 250 ml Gelofusine bolus and 5 mcg efedrin If MAP>65 mmHg no intervention
45615257|NCT03339817|Diagnostic Test|Polysomnography|During polysomnographia and functional pulmonary testing, signs of diaphragmatic dysfunction responsible for respiratory disorders will be searched.
45615258|NCT03334513|Drug|Bevacizumab|intravitreal injection of bevacizumab
45615259|NCT03334513|Drug|Ranibizumab|intravitreal injection of ranibizumab
45615260|NCT02496949|Drug|Icaritin|600mg,800mg two doses, Bid, continuous dosing for 56 days, to assess the safety,tolerance,pharmacokinetics and efficacy of icaritin
45615261|NCT03339739|Other|Isometric mandibular exercises|daily video guided three-minutes routine in 21 days (days of OC consumption) of soft clenching over three millimeters silicone bars bilaterally on molars
45615262|NCT03339739|Other|Isotonic mandibular exercises|daily video guided three-minutes routine in 21 days (days of OC consumption) of isotonic dynamic contraction over calibrated cloth pegs on central incisors
45615263|NCT03339739|Behavioral|Counseling group|subjects included in this group get an education brochure about the disorder and receive no further interventions
45615264|NCT02130466|Biological|Pembrolizumab|IV infusion
45759840|NCT00822523|Drug|Botulinum Toxin, Type A|2 units, single dose, intramuscular to right EDB muscle
45759841|NCT00822523|Drug|Saline|Single Dose, Intramuscular into right EDB muscle
45759842|NCT02410707|Drug|Nitrous Oxide arm|Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
45759843|NCT02410707|Drug|Propofol|The loading dose of propofol will be administered immediately after nitrous oxide discontinuation. All sedations in this trial will use propofol 1.0 mg/Kg initial dose, with 0.5 mg/Kg doses titrated to deep sedation. Once the patient is deeply sedated, the procedure will begin.
45615265|NCT02130466|Drug|Dabrafenib|oral capsule
45615266|NCT02130466|Drug|Trametinib|oral tablet
45615267|NCT02130466|Drug|Placebo|IV infusion
45615268|NCT03334357|Other|PAR|
45759844|NCT02410707|Drug|Oxygen|If pulse oximetry declines to less than 92%, subject will be placed on nasal cannula with administration of 2 liter flow of oxygen and titrated in increments of 1 L flow to maintain pulse oximetry greater than 92%
45759845|NCT00822757|Biological|Comparator: V710|Single dose V710 (60 Mcg/0.5 mL) by intramuscular injection.
45759846|NCT00822757|Biological|Comparator: placebo|Single dose of buffered saline placebo (0.5 mL) by intramuscular injection.
45615269|NCT03334357|Other|HIIT|
45759847|NCT02343081|Drug|Temozolomide|
45759848|NCT02343081|Drug|Temozolomide|
45615270|NCT03334357|Other|WB-EMS|
45615271|NCT03339661|Drug|Group 1_No proph treatment|After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, expansion of γδ T cell at the end curative treatment was detected, so secondary prophylaxis will not be started.
45615272|NCT03339661|Drug|Group 2A_Proph treatment and γδ T cell expansion|After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum. The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A.
45759849|NCT03839329|Behavioral|Acceptance and Commitment Training|Acceptance and Commitment Therapy is an acceptance- and mindfulness-based psychotherapy that aims to foster psychological flexibility.
45759850|NCT02343627|Drug|NVXT Solution|NVXT Solution, applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
45759851|NCT02343627|Drug|Vehicle of test product|Vehicle of test product applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
45759852|NCT00823069|Device|Perlane and Perlane-L|This is a split face design and each subject received both Perlane-L and Perlane. Treatments were blinded, randomized, and successive.
45759853|NCT00823303|Drug|Paricalcitol|1 mcg daily, adjusted to achieve 40-60% PTH suppression
45615273|NCT03339661|Drug|Group 2B_Proph treatment and no γδ T cell expansion|After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum. Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
45615274|NCT03334279|Other|Cigarette smokers|frequent cigarette smoking for not less than 5 years
45615275|NCT03334279|Other|Simultaneous cigarette and cannabis smokers|frequent cigarette and cannabis smoking for not less than 5 years
45615276|NCT02492659|Procedure|femtosecond laser-assisted cataract surgery|the femtosecond laser platform was used to generate capsulotomy with a diameter as described above in the control group, and lens fragmentation into 6 segments.
45615277|NCT02492659|Procedure|conventional phacoemulsification|continuous curvilinear capsulorhexis was performed with capsulorrhexis forceps. Following hydrodissection, phacoemulsification of the nucleus, aspiration of the residual cortex and capsular polishing were performed using a phacoemulsification machine
45615278|NCT02493829|Biological|AML Cell Vaccine|
45615279|NCT03342313|Other|Food - Sandwich|Sandwich as a breakfast for testing chewing activities.
45615280|NCT03334123|Other|Functional training and cycling|"First 8 weeks: patients will perform 20 minutes of functional training before their dialysis procedure. The exercise program will be run by kinesiologists, who will also teach patients how to perform exercises on their own at home. During intradialysis cycling 3 times weekly participants will cycle on adapted ergometer. Participants will start with 10 - 15 minutes of cycling and then gradually increase time and intensity up to 45 minutes of duration.~Second phase of 8 weeks: participants will no longer perform functional training before dialysis but will be motivated, monitored and advised to perform functional exercise at home on non-dialysis days for 20-30 minutes and continue with cycling sessions during the dialysis procedures three times weekly."
45615281|NCT03334123|Other|Cycling|"First 8 weeks: cycling on an adapted ergometer during dialysis; starting with 10 - 15 minutes of cycling and then gradually increasing time and intensity up to 45 minutes of duration.~Second 8 weeks: continue with cycling at the target duration and intensity during dialysis."
45615282|NCT02496793|Behavioral|Peer-facilitated community support group|Support groups were composed of up to 20 women from community. Peer facilitator facilitated a total of 6 groups of a maximum of 20 women each. Women were exposed to 8 two hour sessions. Facilitators gave activities in support of MCH/PMTCT. Group met twice a month for four months. The support group meetings took place in the community at a convenient location for those attending (e.g. village meeting point, churches, schools or individual households). With local support through community leaders, the intervention involved trained peer facilitators working with pregnant and post-partum women to form ANC and PNC support groups through which they will present information on general maternal and child health and PMTCT specific topics using participatory learning and problem-solving approaches.
45615283|NCT03339427|Other|vitamin D|different doses of vitamin D supplementation
45615284|NCT03339427|Other|control|control group
45615285|NCT03339349|Drug|Enoxaparin|Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
45615286|NCT03339193|Device|Left atrial appendage closure|Percutaneous insertion of a Watchman FLX left atrial appendage closure device under general anesthesia with transesophageal echo guidance.
45615287|NCT02163538|Device|articulating Enseal|Vessel-sealing device used for laparoscopic hysterectomy.
45615288|NCT02163538|Device|Ligasure device|Vessel-sealing device used for laparoscopic hysterectomy.
45615289|NCT02496637|Behavioral|Appetite Awareness|Appetite Awareness Training (AAT) is an approach to increasing eating regulation through training individuals to eat in response to their appetite cues rather than external or emotional cues
45615290|NCT02496637|Behavioral|Nutrition Education|Nutrition education provides information about energy balance, dietary guidelines, portion and serving sizes, and other general dietary information.
45615291|NCT02496715|Drug|Fluticasone propionate 100 mcg / salmeterol 50 mcg|Brand inhaler containing pMDI containing fluticasone and salmeterol
45615292|NCT02496715|Drug|Generic fluticasone propionate 100 mcg / salmeterol 50 mcg|Generic inhaler containing pMDI containing fluticasone and salmeterol
45615293|NCT02496715|Drug|Placebo|Placebo inhaler
45615294|NCT02496871|Behavioral|Group Phone Calls|University of Kansas Weight Management Program - Group Phone calls
45759854|NCT00823303|Drug|Calcitriol|0.25 mcg daily, adjusted to achieve 40-60% PTH suppression
45759855|NCT02344251|Device|MEMS Cap|MEMS Track Cap records when the medication bottle is opened and closed
45615295|NCT02496871|Behavioral|Social Media|University of Kansas Weight Management Program - Social Media (Facebook)
45615296|NCT02163226|Radiation|Hypofractionated Radiation Treatment|Participants receive standard hypofractionated regimen of 3 Gy x 10 fractions, 1 radiation treatment a day for 5 days in a row.
45615297|NCT02163226|Radiation|One Radiation Treatment|12 Gy x 1 fraction or 16 Gy x 1 fractions adaptively depending on the size of the metastases or gross tumor volume (GTV).
45615298|NCT02163226|Behavioral|Questionnaire|Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
45615299|NCT02496481|Behavioral|Motivational Interviewing|Motivational interviewing (MI) in the ED has been used to encourage a variety of health behaviors among at-risk patients. In this study, researchers will employ motivational interviewing with half of the study participants to investigate the effects of the technique on child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
45615300|NCT02496481|Behavioral|Tailored brochure|Tailored Print materials will be mailed to half of participants to investigate the effects of using patient-centered educational materials compared with generic educational materials to influence child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
45615301|NCT02496559|Procedure|Pre-consultation CRP|Use of CRP test on all children with fever before the consultation (intervention) compared to where the doctor requests a CRP test (no intervention)
45615302|NCT02496325|Procedure|Ultrasound guided transperineal pudendal nerve block|Children under general anesthesia were positioned supine, flexed legs and balls of the feet joined. A 12 MegaHertz (MHz) (38 mm) ultrasound probe was positioned on a horizontal axis passing through the ischial tuberosity, previously palpated.The probe was then moved medially on the axis, until the rectum appeared. Pudendal artery was identified if possible, using colour Doppler. The needle (22 Ga, 50 mm) was then introduced at the middle of the superior edge of the probe, in an out-of-plane approach. Tip of the needle was identified by direct vision, through displacement of adjacent anatomical structures or with saline injection. Nerve stimulation was started after placement of the tip of needle in the ischiorectal fossa, before local anaesthetic injection. After a negative aspiration test, a mix of Ropivacaine 2 % and clonidine 0.2µg/kg was injected in the ischiorectal fossa under ultrasound guidance.
45615303|NCT02193178|Device|comfilcon A Toric|Contact lenses
45615304|NCT03342235|Procedure|Photorefractive Keratectomy (PRK)|Subjects randomized to refractive surgery will be referred to one of six study surgical centers (surgical centers are listed in Appendix B) to have photorefractive keratectomy (PRK) in the affected eye within 60 days after randomization.
45615305|NCT03342235|Other|Patching 2 hours per day|Patching prescribed 2 hours per day with continued refractive correction (with spectacles and/or contact lenses) as able.
45615306|NCT03342235|Device|Excimer Laser System|Excimer Laser System for use in photorefractive keratectomy.
45615307|NCT03333889|Other|Vita Enamic hybrid crown|hybrid ceramic material in the form of mesoblocks where the ceramic block is attached to a ti base .The whole assembly is screw retained superstructure.
45615308|NCT03333889|Other|emax hybrid crown|high srength glass ceramic that can be milled in sections up to 1mm .
45615309|NCT02492581|Drug|Nalmefene|No intervention on the use of Selincro. The physician will prescribe Selincro following its usual practice.
45615310|NCT02129608|Device|LLLT|The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.
45615311|NCT02129608|Drug|Lorcaserin|10 mg pills twice daily for 12 weeks.
45615312|NCT03342079|Drug|Local Anesthetics,Topical|topical anesthetic
45615313|NCT03342079|Drug|Nitrous Oxide|inhaled nitrous oxide
45615314|NCT03342079|Drug|Placebos|placebo topical anesthetic
45615315|NCT02496403|Behavioral|Standard Medical Management (SMM)|SMM is designed to provide basic advice about opioid dependence and encouragement to adhere to treatment recommendations. Sessions provide support and monitoring of medication compliance, dose, withdrawal, adverse effects, and discussion of medical complications of opioid and other drug use. Early in treatment, the focus will be on helping patients adjust to the medications (e.g., monitoring withdrawal or other adverse symptoms, tolerating discomfort, curtailing illicit drug use, and referral to self-help). As treatment progresses, the practitioner may focus more on educating the patient about the social and behavioral factors perpetuating addiction and encourage behavioral and lifestyle change to support recovery.
45445553|NCT03763461|Device|Oxygen Mask|Application of oxygen during conscious sedation
45445554|NCT03769779|Dietary Supplement|FloraGLO Lutein|Lutein (FloraGLO™) in safflower oil
45615316|NCT04755790|Device|Point Digit|Patient is fit with Point Digit partial hand prosthetic system
45615317|NCT03338725|Other|Clinical pharmacy model|Patients who are being monitored by a clinical pharmacy model
45615318|NCT01631188|Procedure|Minimally Invasive Aortic Valve|Patients having minimally invasive aortic valve surgery will have a pacing wire placed through the endovent catheter. The anesthesiologist will attempt to pace the ventricle with this wire if needed to wean from bypass.
45615319|NCT01631188|Procedure|Minimally Invasive Aortic Valve Surgery|The Anesthesiologist will advance a pacing wire through the Endovent Catheter under TEE in order to pace the heart when the subject is coming off the Cardiopulmonary bypass machine
45615320|NCT01631188|Device|Manipulation in OR surgical technique|Endovent and pacing wire when coming off cardiopulmonary bypass
45615321|NCT03333733|Behavioral|HENRY|"HENRY is an 8-week programme delivered in Children's Centres, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. It is currently delivered in ~ 35 local areas across England and Wales by trained health and community practitioners. Training includes:~Centre Level Training: to equip staff with knowledge and skills to promote and provide healthy nutrition within early years settings and support parents to provide healthy family lifestyles and nutrition for their families. The theoretical underpinning combines proven models of behaviour change including the Family Partnership Model, motivational interviewing and solution-focused support.~Practitioner Level Training: to deliver the 8-week HENRY programme, which aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition for their young children."
45759856|NCT02344251|Device|ID-Cap|ID-Cap Tag is an ingestible medical device for detecting the presence of an ingested capsule inside the gastrointestinal (GI) tract.
45445555|NCT03769779|Dietary Supplement|Safflower Oil|Safflower Oil
45615322|NCT02492347|Procedure|Electrocardiogram|The ECG is a non-invasive screening tool. It will be performed when the neonate is settled and comfortable. The electrodes used are made with soft jelly adhesive which is stored at room temperature. The procedure will be conducted in a timely manner, taking no longer than 15 minutes. The electrodes are easily removed, and the neonate redressed.
45615323|NCT02129062|Drug|Ibrutinib|Given orally 560 mg daily (dispensed as 4 x 140-mg capsules)
45615324|NCT02129062|Other|Laboratory Biomarker Analysis|Correlative studies
45615325|NCT02496247|Other|Canned Herring|Families with children in this study arm will receive a weekly ration of herring throughout the 8-10 week study period (2 cans herring/day per study child).
45615326|NCT04494763|Drug|Propanolol|Non-selective Beta-blocker
45615327|NCT04494763|Other|Placebo|Inactive drug
45759857|NCT02344407|Biological|VSVG-ZEBOV|The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)
45759858|NCT02344407|Biological|ChAd3-EBO Z|The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.
45759859|NCT02344407|Biological|Placebo|
45759860|NCT00823459|Drug|Everolimus|Given PO
45759861|NCT00823459|Other|Archival Tissue Analysis|Correlative studies
45759862|NCT02411565|Drug|Fermented Wheat Germ Extract (FWGE)|5.53 grams of FWGE combined with natural orange flavor and stevia Reb-A sweetener to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
45759863|NCT02411565|Drug|Placebo|Dried and pulverized, white and black rice, 5.53 grams, combined with natural orange flavor and stevia Reb-A sweetener, to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
45759864|NCT02411565|Other|Standard of Care: Planned Surgery|Participants will undergo their planned surgery during the 2nd to 4th week after entry into the study. However, if there are delays, patients can continue to take drug/placebo for a time period no greater than 2 months. If surgery has not occurred after this 2-month period, the patient will be removed from the study. Participants will take the study drug up until the day prior to surgery. The minimum amount of time on study drug is 2 weeks. A separate consent form will be obtained for the surgical procedure.
45759865|NCT02411565|Other|Quality of Life (QoL) Surveys: FACT-O|Quality of life questionnaire (FACT-O) at the time of enrollment, then weekly and the day of surgery.
45759866|NCT03839407|Device|MUSE Meditation Device|The MUSE Meditation Device guides users in mindful meditation using real-time feedback on brain wave activity.
45759867|NCT02020785|Other|Higher phosphorus period|"Commercially-available unaltered food/beverage products containing phosphorus additives (~1gm/d of phosphorus) will be given for 3 weeks.~All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of ~1gm/d by receiving education on avoiding phosphorus-based additives."
46069001|NCT04889027|Diagnostic Test|Standardized Infant NeuroDevelopmental Assessment|The neurological scale of SINDA is designed as a screening tool as follows: (1) in the first year of life after the neonatal period, that is, in the corrected age range of 6 weeks to 12 months; (2) covers all infant neurological areas; (3) it is standardized, that is, it has a set of items and criteria identical to that age range; (4) results in a score that is largely independent of the baby's age; (5) general pediatricians are easy to use and take about 10 minutes to do (including recording scores); (6) contains a substantial part of items assessing the quality of spontaneous movements; and (7) helps predict developmental outcome (Hadder-Algra et al., 2018).
45759868|NCT02020785|Other|Lower phosphorus period|"Commercially-available unaltered food/beverage products without phosphorus additives (<10mg/d of phosphorus) will be given for 3 weeks.~All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of ~1gm/d by receiving education on avoiding phosphorus-based additives."
45759869|NCT04974775|Diagnostic Test|Blood collection|Sampling on admission to ICU (all patients)
45759870|NCT04974775|Diagnostic Test|Blood collection, serial sampling|"Additional sampling to admission samples in~the Cardiac Arrest group after 12 and 48 hours~the Covid-19 group on day 2 and 7 while in the ICU~the Covid-19 group after 3 and 12 months."
45759871|NCT00825565|Drug|Alwextin cream|Alwextin cream contains active ingredient, allantoin 3%. Use 1 application daily for 3 month duration.
45759872|NCT02345031|Drug|AUT00063|600 mg, orally, once a day, for 4 weeks
46069002|NCT04886310|Diagnostic Test|Peabody Developmental Motor Scale II (PDMS-2)|is composed of six subtests (reflex, stationary, locomotion, object manipulation, grasping, and visual-motor integration) that measure inter-related abilities in early motor development. It was designed to assess gross and fine motor skills in children from birth through 5 years of age.
45615328|NCT03338491|Behavioral|Induction of Implemental Mindset|"This induction of a psychological state was extensively studied in basic cognitive science. Gollwitzer & Keller (2016, p.3): The implemental mindset is evoked by asking participants to think of a personal project for which they have already made the decision to act but did not initiate any action yet. Subsequently, participants are asked to list the steps necessary for successful goal attainment and to plan out in detail when, where, and how they intend to act on each of these steps."
45615329|NCT03338491|Behavioral|Induction of Deliberative Mindset|"This induction of a psychological state was extensively studied in basic cognitive science. Gollwitzer & Keller (2016, p.3): The deliberative mindset is evoked by asking participants to (a) name an unresolved, important personal problem that is causing rumination but for which they have not made a decision yet and (b) reflect on whether to take action or not. Further, to enhance the depth of reflection, participants are requested to list a number of positive and negative, short- and long-term consequences of both deciding to act and deciding not to act; indicating the probability of the occurrence of each of these consequences is required."
45615330|NCT02162758|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsules
45615331|NCT02162758|Drug|Dexlansoprazole Placebo|Dexlansoprazole placebo-matching capsules
45615332|NCT03333499|Drug|YanXinShi placebo pills|participants will take matched 1800 mg YXS placebo pills TID in addition to the optimal combination drug treatment of heart failure
45759873|NCT02345031|Drug|Placebo|orally, once a day, for 4 weeks
45445556|NCT01321905|Dietary Supplement|Supplementation with vitamin D2/D3|"Patients younger than 16 years of age are administered 35,000 IU ergo-/chole-calciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring. The intervention time is 3 months, followed by 2-months wash-out period when patients do not take any more extra vitamin D but they are still monitored.~Patients 16 or more years of age are administered 50,000 IU ergo-/chole-calciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
45445557|NCT02659514|Drug|Poziotinib|8 mg oral tablets, administered QD.
45615333|NCT03333499|Drug|YanXinShi pills|participants will take 1800 mg YXS pills TID in addition to the optimal combination drug treatment of heart failure
45615334|NCT03333499|Drug|Trimetazidine pills|participants will take 20mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure
45615335|NCT03333499|Drug|YanXinShi and Trimetazidine pills|participants will take 1800 mg YXS and 20 mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure
45759874|NCT00803647|Biological|cetuximab|500 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles. Cetuximab dose will be escalated by 100 mg/m2 every 2 weeks to a maximum dose of 800 mg/m2 if, at the time of retreatment, skin rash is less than or equal to grade 1, diarrhea is grade 0 (defined as less than or equal to 3 stools per day over baseline), and the patient is not experiencing any other greater than or equal to grade 2 toxicity attributed to cetuximab.
45759875|NCT00803647|Drug|5-FU|3000 mg/m2 IV continuous infusion over 46 hours every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
45759876|NCT00803647|Drug|oxaliplatin|85 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
45759877|NCT00803647|Drug|leucovorin|400 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
45759878|NCT00827983|Drug|Progesterone|25 mg, s.c., once à day
45759879|NCT00827983|Drug|Progesterone|90 mg, vaginally, once à day
45759880|NCT02412501|Device|Resolute Onyx Stent - 2.0 mm|Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent
45759881|NCT02346903|Drug|Capsaicin|one inch ribbon of Capzasin -HP applied to forearm for 30 minutes
45759882|NCT05056207|Other|Cohort I (patients receiving annual lymphedema screening|patientns who previously underwent preoperative perometer lymphedema screening
45759883|NCT05056207|Other|Cohort II (patients followed intensively for lymphedema)|patients who have recently undergone ALND
45759884|NCT00844051|Biological|School-based influenza vaccination program|School-based influenza vaccination program
45759885|NCT02347605|Drug|Nicotine lozenge 4 mg|
45759886|NCT02347605|Drug|Placebo lozenge|
45445558|NCT04600791|Device|BATwire Implant Kit|The BATwire Implant Kit is a delivery system for the placement of the Barostim Carotid Sinus Lead.
45445559|NCT03769623|Device|Biolimus|103 subjects with small coronary artery disease who met the inclusion/exclusion criteria were enrolled, subjects were assigned to the treatment group of Biolimus
45445560|NCT03769623|Device|Powerline|103 subjects with small coronary artery disease who met the inclusion/exclusion criteria were enrolled, subjects were assigned to the treatment group of Powerline
45445561|NCT03763383|Procedure|Lateral Arm Flap|Its a kind of flap that is harvested from the lateral aspect of the arm to cover defects in different parts of the body
45615336|NCT03338413|Behavioral|Goal Management Training|9 GMT modules will be administered in 9X2 hour sessions (ten groups). Manualized intervention; metacognitive strategies for improving attention and problem solving.
45615337|NCT03338413|Behavioral|Computerized Cognitive Training|9 modules will be administered in 9x1 hour session (ten groups). Computerized Cognitive Training using commercially available web-based platforms based on neuroplasticity, developed to target skills such as attention, memory, speed of processing and executive functioning. Homework assignment between sessions.
45759887|NCT02410161|Dietary Supplement|alpha-linolenic acid-rich supplement|each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).
45759888|NCT02348619|Drug|JZP-110|
45759889|NCT02153671|Biological|A(H5N1) inactivated influenza vaccine (IIV)|Prepared from the NIBRG-23 vaccine virus strain. One vaccine dose (0.5 ml) contained 15 mg of influenza A(H5N1) virus hemagglutinin (HA), adjuvanted with aluminum hydroxide. Two doses were administered intramuscularly 28 days apart.
45759890|NCT02153671|Biological|A(H5N2) live attenuated influenza vaccine (LAIV)|Two doses of A(H5N2) live attenuated influenza vaccine (LAIV) administered 28 days apart, approximately 1.5 years prior to receiving A(H5N1) IIV
45445562|NCT01561599|Drug|BB3|Daily intravenous administration of 2mg/kg for 4 days
45445563|NCT01561599|Drug|Normal Saline|Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
45445564|NCT04570670|Drug|monomethyl fumarate 190 mg|
45445565|NCT04570670|Drug|dimethyl fumarate 240 mg|
45759891|NCT02413203|Drug|Celecoxib|Blood and urine collections before and 3 hours after celecoxib administration.
45759892|NCT02413203|Drug|Placebo|Blood and urine collections before and 3 hours after placebo administration.
45759893|NCT04382365|Other|Sleep Health Using the Internet for Older Adult Sufferers of Insomnia and Sleeplessness|Cognitive-Behavioral Treatment for insomnia (CBT-I) is a non-pharmacological intervention that is effective in treating insomnia in older adults, even when present with comorbid medical and psychological conditions.25 CBT-I focuses on the maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems, and typically consists of five primary treatment components: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
45759894|NCT02021955|Behavioral|guideline treatment recommendations|Primary care clinicians receive guideline concordant treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
46069003|NCT04868058|Drug|Ropivacaine injection|Ropivacaine : 0.4 ml/kg (ideal body weight!) of 5mg/ml (20 to 30 ml bolus dose (100-150 mg), maximum dose 200 mg ropivacaine
45615338|NCT02192164|Behavioral|smoking questionnaire|patients fill in a smoking questionnaire about their smoking habits
45615339|NCT04494529|Drug|12 mg betamethasone + placebo|"After the first intramuscular injection of 12 mg of betamethasone, participants randomized to the Placebo Comparator group will receive 1 intramuscular injection of placebo."
45911567|NCT05778604|Behavioral|Cognitive reframing|Cognitive reframing will be based on the fall risk appraisal (FRA) matrix. We will present the FRA matrix and activities will be tailored based on the quadrant that participant fits. Quadrant 1 (Irrational) focus on increasing balance confidence and maintaining exercise. Quadrant 2 (Incongruent) focus on individual fall risk factors from the CDC fall risk checklist, enhance fall risk awareness, and participate in the exercise. Quadrant 3 (Congruent) focus on individual fall risk factors from the CDC fall checklist and participate in the exercise. Quadrant 4 (Rational) encourage to maintain exercise.
46069004|NCT04862247|Behavioral|Imaginal Exposure Condition|Participants will be asked to think and write about an eating related fear or anxiety. Specifically, they will be asked to spend 20-30 minutes writing about a specific fear or anxiety they have, then another 20-35 minutes re-reading and imagining that what they have written is happening.
46069005|NCT04862247|Behavioral|Writing and Thinking Condition|Participants will be asked to think and write about their eating disorder using specific prompts designed to help them process their eating disorder. Specifically, they will be asked to spend 20-30 minutes writing their eating disorder, then another 20-35 minutes re-reading what they wrote.
45615340|NCT04494529|Drug|24 mg betamethasone|"After the first intramuscular injection of 12 mg of betamethasone, participants randomized to the Active Comparator group will receive the standard 2nd intramuscular injection of 12 mg of betamethasone."
45615341|NCT04494139|Behavioral|Behavioral and Canteen intervention|Behavioral intervention: 16 weeks
46069006|NCT05192434|Behavioral|Expressive Writing|Expressive writing (EW) is a safe, acceptable, and effective intervention for improving psychological adjustment. Via brief directed writing sessions, EW facilitates disclosure of traumatic events. At a basic level, emotional expression and disclosure are important because they reduce the need to unconsciously direct psychological energy towards suppressing emotions from traumatic events.
45615342|NCT04494139|Other|Canteen|Canteen changes to introduce health foods
45615343|NCT03333187|Procedure|Allogeneic stem cell transplantation|
45445566|NCT03763227|Drug|Intravitreal ranibizumab (IVR) injection|Intravitreal ranibizumab (IVR) injection in patients with retinal dystrophy and macular cysts who have not responded to treatment with carbonic anhydrase inhibitors
45615344|NCT03333187|Drug|Ruxolitinib continuous therapy|
45615345|NCT02191618|Device|WEB|The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.
45615346|NCT03331159|Device|NanoBone|Cage was filled with nanocrystalline hydroxyapatite embedded in a silica gel matrix
45615347|NCT03331159|Device|Homologous Bone|Cage was filled with homologous bone
45615348|NCT02491957|Other|LOFT Therapy|"LOFT Therapy™ will be performed 2 times a week for 4 weeks a total of 8 sessions. The patient will be wrapped with fabric cuffs, on up to four limbs. The cuffs are applied to the widest part of the biceps and upper thighs at pressures between 80-100 mmHg with minimal venous encroachment. The patients will ride a recumbent bike for 18 total minutes of sub-maximal exertion (up to 70% repetition maximum ), with the option of up to 2 periods of 15-second higher intensity exertions as tolerated, followed by individualized respiratory recovery periods determined by the relative decrease in breathing effort.~The 18-minute session will be preceded by a two-minute compression check, where the wraps will be adjusted based on any signs or symptoms of nerve or vessel impingement."
45615349|NCT03331081|Other|Bladder Training|The patient will participate in a class in which the physiotherapist will provide the following information: on the anatomy and function of the MAP, using figures; on bladder function; guidelines on the positioning and voiding habits and the definition and main risk factors responsible for urinary incontinence. The bladder training will consist of a program of time micturition to increase bladder capacity and the interval between urinations. Urge suppression strategies will be targeted, and include distraction, relaxation, breathing, and MAP contraction (quick flicks).
45615350|NCT03331081|Other|TMAP|There will be 36 monthly series of home training (totaling at the end of the 3 months of treatment 108 series) performed 3x / week, 3x / day. The training protocol consists of three daily TMAP series. One series consists of 8 maximum voluntary contractions, with maintenance of the contraction of 6 to 10 seconds (type I muscle fibers), with twice the rest time between contractions, followed by three to five rapid contractions (muscle fibers type II ). The protocol will total 24 contractions of MAP per day performed, which will be divided in the morning (8 contractions), late (8 contractions) and night (8 contractions).
45615351|NCT03331081|Other|Bladder Training + TMAP|Will perform the exercises of the bladder training group and the TMAP in an associated way.
46069007|NCT05192434|Behavioral|Contingency Management|Contingency management (CM) is a proven strategy to reduce drug use and HIV risk behavior. Also known as a conditional cash transfer, CM reinforces positive behavior with tangible rewards. In the context of substance use treatment, monetary incentives are typically used to reinforce drug-negative urine specimens.
46069008|NCT04860466|Drug|CC-96673|IV Infusion
46069009|NCT04850105|Other|Data Collection|"Data on each patient will be collected at study enrollment and at each follow-up visit.~No mandatory visits, tests, or assessments are required for this study. All visits will be scheduled and conducted according to the clinical site's normal clinical practice."
46069010|NCT04844060|Other|Lumbar punction|Lumbar punction
46069011|NCT04841447|Other|Study sample collection|Peripheral blood draws and bone marrow aspiration will be done during clinic visit and hospital stay.
46069012|NCT04830137|Drug|NX-2127|Oral NX-2127
46069013|NCT04828993|Drug|tafamidis meglumine|Tafamidis meglumine 20 mg, once daily, oral administration, for 72 weeks (18 months).
45445567|NCT03763227|Drug|Carbonic Anhydrase Inhibitor (CAI) therapy|Carbonic anhydrase therapy (Oral or Topical) in patients with retinal dystrophy and macular cysts
45445568|NCT03769389|Dietary Supplement|Birhi|"Birhi which contain the following:~43.6g of Freeze-dried date powder+ 150g of 0% fat yoghurt"
45445569|NCT03769389|Dietary Supplement|Khassab|34.6g of freeze-dried date powder+ 150g of 0% fat yoghurt
45445570|NCT03769389|Dietary Supplement|placebo|50g of pure glucose dissolved in 100ml of water
45615352|NCT02491645|Other|Sensory interventions|"Tactile stimulation: Brushing technique , handling materials of various textures, bear hug and rug , play dough and find in rice techniques to be done.~Proprioception technique : Joint compression , popping bubbles, lifting weights of different measures and scooter board push activities to be done.~Movement/vestibular techniques :Bear hug and rug , swinging or rocking motion, jumping or spinning to be done.~Visual stimulation : picture recognition, dot colouring , lighting balls and toys , familiarisation of emotions to be done.~Auditory stimulation : Sound familiarisation and music time will be done."
45615353|NCT02491879|Drug|Ketoprofen|2.5% Ketoprofen gel with a 2 g local use
45615354|NCT02491879|Other|Placebo|Placebo gel with a 2 g local use
45615355|NCT03338335|Drug|prolonged DAPT|Dual antiplatelet therapy will be prescribed for more than 12 months
45615356|NCT04494451|Drug|Vit C|vitamin C (25 mg/kg or max. 1.5 gram every 6 hourly) for maximum 5 day
45615357|NCT04494451|Drug|Standard medical Treatment|iv antibiotics alone
45615358|NCT02493985|Other|0.5% CO2|The subjects will be randomized to breath 0.5% carbon dioxide during one of the -12 degree head down tilt body position periods in crossover design
45615359|NCT02493985|Other|ambient air|The subjects will be randomized to breath ambient air during one of the -12 degree head down tilt body position periods in crossover design
45615360|NCT03332953|Other|E-cigarettes with varying concentrations of nicotine & flavor|Subjects will be asked to vape various e-cigarettes containing e-liquids at three concentrations of nicotine and sweet flavor (9 stimuli per subject).
45615361|NCT02494219|Procedure|Rapid Immunochromatographic streptococcal test|Throat swab obtained for rapid strep test in addition to throat culture,in order to check the accuracy of Rapid Immunochromatographic streptococcal test in detection of streptococcal pharyngitis
45615362|NCT03338179|Behavioral|Judgement of learning evaluation|The hardware consists of two lists of 30 pairs of French words, each pair of words being composed of a word index and a target word (names of concrete objects). Among the 60 word pairs, 30 are strongly associated items (or easy items, the other 30 being weakly associated or difficult items.
45615363|NCT02491723|Drug|Azithromycin|Patients with bronchiectasis treated with Azithromycin for three to five days.
45615364|NCT02492191|Device|Smartphone app Recovery Assessment by Phone Points (RAPP)|An e-assessed follow-up of day surgery patients postoperative recovery measured via smartphone app
45615365|NCT03332875|Behavioral|OurRelationship Online Program|OurRelationship.com is an online program designed to improve distressed romantic relationships.
45615366|NCT02493673|Device|Continuous positive airway pressure device|(ResMed Spirit S8)
45615367|NCT04494373|Drug|HS-20090|A human IgG2 monoclonal antibody with affinity and specificity for human RANKL
45615368|NCT04494373|Drug|Xgeva®|A human IgG2 monoclonal antibody with affinity and specificity for human RANKL
45615369|NCT05464849|Diagnostic Test|Evaluation of systemic skin microvascular endothelial function|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
45615370|NCT03332719|Biological|Etanercept|
45615371|NCT03332719|Drug|Methotrexate|
45615372|NCT03331003|Device|low level light therapy|iRestore low-level light therapy on androgenetic alopecia
45615373|NCT03331003|Device|non-LLLT wavelength group|A LED light device is non-curative for the patients.
45615374|NCT03332641|Dietary Supplement|Citron peel extract|Citron peel extract for 12 weeks
45615375|NCT03332641|Dietary Supplement|Placebo|Placebo for 12 weeks
45615376|NCT03337867|Device|Magstim Super Rapid2 System|Intermittent theta-burst-stimulation (iTBS) protocol
45615377|NCT03337867|Device|Magstim Super Rapid2 System|Sham stimulation
45615378|NCT03330925|Device|ElastiMed's SACS|A wearable medical device that improve circulation using smart materials
45615379|NCT03332563|Behavioral|Cognitive-behavioral intervention for chronic pain|WebMAP is a technology-based cognitive-behavioral intervention program that teaches relaxation skills, pain coping strategies and parent behavioral and communication techniques to youth with chronic pain and their parents.
45615380|NCT03330769|Drug|New course of treatment|Prescription of new course of NSAIDs (monotherapy), steroid intra-articular injections (monotherapy), conventional DMARDs, biologic DMARDs, including switches or dose augmentations, indicated by the treating rheumatologist according to usual clinical practice.
45615381|NCT03330613|Diagnostic Test|PAEDS|pediatric emergency delirium scale
45615382|NCT03330613|Procedure|TIVA|Total intravenous anesthesia with propofol
45615383|NCT03330613|Procedure|Inhalational anesthesia|Inhalational (volatile) anesthesia with sevoflurane
45615384|NCT03337789|Dietary Supplement|Polygonatum sibiricum|Polygonatum sibiricum 800mg, 30-60 minutes before sleep, once a day for 4 weeks
45615385|NCT03337789|Dietary Supplement|Placebo|Placebo 800mg, 30-60 minutes before sleep, once a day for 4 weeks
45615386|NCT03332485|Drug|ECP Colon Prep Kit|ECP Colon Prep Kit
45615387|NCT03332485|Drug|MoviPrep®|MoviPrep®
45615388|NCT03330535|Behavioral|Reminders once a week|Participants in this group will receive active oral hygiene reminders through text messaging once a week.
45615389|NCT03330535|Behavioral|Verbal oral hygiene instructions|Participants in this group will receive verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.
45615390|NCT03330535|Behavioral|Reminders three times a week|Participants in this group will receive active oral hygiene reminders through text messaging three times a week.
45615391|NCT03330535|Behavioral|Daily reminders|Participants in this group will receive active oral hygiene reminders through text messaging on a daily basis.
45615392|NCT03332329|Drug|Entecavir|Entecavir is used for 96 weeks
46069014|NCT04781465|Device|Immersive Virtual Reality|"Dedicated virtual reality sessions.~Duration 20 minutes per session.~The virtual reality session will be supervised by a health professional trained in this tool after 1.5 hours of training by the team responsible for the equipment (use of the equipment, and use of the 20 minutes of VR). This supervising professional may be a doctor, an occupational therapist, a caregiver or any other health professional trained in the tool under this protocol.~The exercises proposed will be standardized virtual reality exercises with the same exercises for all, but adapted to the level and abilities of each patient."
45615393|NCT03332329|Drug|Granulocyte Macrophage Colony Stimulating Factor|Granulocyte-macrophage colony stimulating factor is used intermittently from baseline to week 16 and from 60 to week 84
45615394|NCT03332329|Drug|Y peginterferon alfa-2b|Y peginterferon alfa-2b is used for 96 weeks
45615395|NCT03332329|Drug|HBV vaccine|60ug HBV vaccine is used every four week for 24 weeks
45615396|NCT03337633|Behavioral|Menu design|Participants were given 5 minutes to order a hypothetical meal from the assigned test menu by circling all items they wanted to order.
45615397|NCT03337555|Device|McGrath|McGrath videolaryngoscope
45615398|NCT03337555|Device|Pentax|Pentax videolaryngoscope
45615399|NCT03337555|Device|Macintosh|Macintosh direct laryngoscope
45615400|NCT03330379|Device|Tracoe Smart CuffmanagerTM|In patients randomly assigned to the continuous adjustment strategy, in addition to standard care, the Tracoe Smart CuffmanagerTM will be connected to the tracheal cuff. Within the 2 days following the inclusion, all the intermittent Pcuff measurements will be collected as well as the incidence of Pcuff manual adjustments
45615401|NCT03330301|Other|D-tect|"This study is based on a unique Danish social experiment that took place during a well-defined period between 1937 and December 1985, when it was mandatory to fortify all margarine with vitamin D (1.25 μg/100 g). This well-defined vitamin D fortification period makes it possible to investigate the impact of fetal exposure to extra vitamin D from food fortification on the risk of developing diseases later on. This study is possible due not only to the well-defined adjacent time window but also to the complete registration of every citizen via a civil registration number. This number can be linked, on an individual level, to Danish birth, patient and medical registries; social and ethnic registries; and clinical and other large databases~Case-cohort study: vitamin D measurements from dried blood spots and the risk of diseases later on"
45615402|NCT02492113|Procedure|Positive end-expiratory pressure (PEEP)|"Titrated-PEEP. After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at Titrated-PEEP, with the PSV=0 and FiO2 unchanged."
45615403|NCT02492113|Procedure|ZEEP|"After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at PEEP = 0-5 cmH2O, with the PSV=0 and FiO2 unchanged."
45615404|NCT03331939|Other|no stimulation|Vagal nerve stimulator will be set to no stimulation
45615405|NCT03331939|Other|beta (25-30 Hz)|Vagal nerve stimulator will be set to beta (25-30 Hz)
45615406|NCT03331939|Other|Theta (5 Hz)|Vagal nerve stimulator will be set to beta (5 Hz)
45615407|NCT03330223|Device|Clopidogrel group;Ticagrelor group|A total of 60 patients with ESRD and under dual-antiplatelet treatmen for at least 5 days will be enrolled and divided into the Clopidogrel group (clopidogrel 75mg qd;aspirin 100mg qd, n=30) and the Ticagrelor group (ticagrelor 90mg bid; aspirin 100mg qd, n=30). All included patients will receive haemodialysis by two different types of dialysis membrane.Platelet aggregation of venous blood from all patients will be detected by LTA and VerifyNow immediately before and after haemodialysis.
45615408|NCT03330145|Behavioral|Scales, questionnaires and inventory|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
45615409|NCT05232721|Diagnostic Test|The new instrument and colonoscopy with pathological examination|Detect hemoglobin in stool by the point-of-care testing instrument before colonoscopy, detect colon lesion using colonoscopy and pathological examination.
45615410|NCT03329833|Behavioral|Motivational Interviewing|Motivational interviewing will consist of weekly phone calls for two months, bi-weekly phone calls for two months, and monthly phone calls for two months.
45759895|NCT02022111|Behavioral|Patient Education and Behavioral Activation|To stimulate and motivate sustained, effective self-care, patient education materials and behavioral activation techniques that are adapted for the Indian population will be used by care coordinators. Behavioral activation strategies are brief, structured psychological interventions that are based on extensive theoretical and clinical literature, can be delivered by non-specialist providers, can be combined with antidepressant medications, and emphasize reinforcing behaviors to produce improvements in thoughts, mood, and quality of life.
45615411|NCT03329833|Behavioral|Web-based application|Web-based application participants will be asked to log activity at least on a daily basis.
45615412|NCT02493439|Behavioral|Best Possible Self|
45615413|NCT02493439|Behavioral|Daily Activities|
45615414|NCT03337243|Procedure|HAM and HUMCWJ Injections|SURGENEX SurForce® (1cc) allograft placental based tissue matrix, will be injected using a 22 gauge, 2-inch needle. The injection site (medial, lateral, patellar) will be determined based on the side with the most joint space from the findings of the most recent x-rays. The Physician will insert the needle fully into the joint space and begin to expel the fluid. He will achieve a continuous injection flow as he withdraws the needle back out of joint space. Immediately following the SURGENEX SurForce® injection, an injection of Predictive Biotech CORECYTE(TM) (1 cc) allograft umbilical cord-derived Warton's Jelly tissue matrix will be administered. This will be done using the exact same protocol as the SURGENEX SurForce® injection.
45615415|NCT03331861|Drug|Metformin hydrochloride|Metformin starting at 500mg twice a day and increasing to 1000mg twice a day for a total of 6 months
45615416|NCT03331861|Drug|Placebo|Similar dosing regime as active comparator
45615417|NCT03337165|Biological|tolerogenic dendritic cells|dose-escalation
45615418|NCT03329755|Other|Dedicated and coordinated e-follow-up during the treatment period|"Completion of questionnaires using an electronic tool~Telephone follow-up between the nurse and the patient~Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30)"
45615419|NCT03329755|Other|Standard follow-up during the treatment period|- Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30)
45615420|NCT03329443|Drug|Spironolactone|each patient will receive 200 mg of spironolactone as per his/her angiography premedications
45615421|NCT03329443|Drug|Placebo Oral Tablet|Each patient will receive a placebo tablet as per his/her angiography premedications
46069015|NCT04763759|Drug|TRL1068, a human monoclonal antibody|A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
45615422|NCT03329287|Behavioral|SCBT|SCBT, one hour per session.
45615423|NCT03329287|Drug|SSRIs and/or SNRIs|SSRIs and/or SNRIs at a recommended dosage.
45615424|NCT03329287|Behavioral|Psychological Placebo|Supportive and relaxation therapy, one our per session.
45615425|NCT03329053|Behavioral|The EAPC Exercise Prescription (EXPERT) Tool|"During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, except recommendations for physical activities. This domain will be consulted exclusively through the digital training and decision support tool.~The EXPERT tool is an interactive digital training and decision support system for optimized exercise prescription in cardiovascular disease patients. The EXPERT tool was designed to provide optimized exercise prescription based on detailed overview of patient´s diagnosis, prognostics, complications and medication."
45615426|NCT03329053|Behavioral|Standard Cardio-Care Lifestyle Counselling|During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions also in the domain of recommendations for physical activities. The exercise prescription process during consultation will be constructed in accordance with published guidelines and recommendations for secondary prevention of cardiovascular diseases.
45615427|NCT03325075|Biological|VAL-181388|Escalating dose levels
45615428|NCT03325075|Other|Placebo|Saline
45615429|NCT03324997|Drug|Restylane Silk|Restylane Silk is a temporary hyaluronic acid filler currently approved for the lips and fine lines around the mouth.
45615430|NCT03324997|Drug|Saline|Saline as placebo
45615431|NCT03324997|Device|Optical Coherence Tomography|An FDA-cleared non-invasive imaging device
45615432|NCT02646891|Biological|Trivalent P2-VP8 Subunit Rotavirus Vaccine|Manufactured and supplied by the Walter Reed Army Institute of Research (WRAIR) Pilot Bioproduction Facility (BPF). The trivalent P2-VP8 vaccine was formulated as a sterile suspension containing a total of 360 µg of protein (120 µg of each P type) per mL adsorbed to aluminum hydroxide (1.125 mg of aluminum per mL in a phosphate buffer, pH 7).
45615433|NCT02646891|Biological|Placebo|Sodium Chloride 0.9%, USP for Injection
45615434|NCT03109405|Device|Stimulation-assisted venous access|Stimulation-assisted venous access
45615435|NCT03109405|Other|20 guage cannula for IV, tourniquet optional|Standard IV cannulation using 20 ga needle, and use of tourniquet at discretion of nurse performing IV cannulation
45615436|NCT02492035|Behavioral|Lifestyle intervention|
45615437|NCT03324919|Behavioral|HRQL|Intervention of patient centered care situation and health-related quality of life of patients with Psoriasis, Urticaria or Lupus erythematodes from non-urban practices vs urban practises. Identification of relevant health-related quality of life parameters of these patients.
45759896|NCT02022111|Behavioral|Supporting Self-Care (care coordinators)|Care coordinators will: (a) meet with intervention arm patients and collaboratively set treatment goals; (b) provide verbal education regarding diabetes and depression self-care ;(c) will use motivational interviewing and self-efficacy enhancement strategies to promote monitoring of depressive symptoms, glucose, BP; (d) will proactively follow-up to externally monitor depression symptoms and CVD indicators; (e) will enter updated patient indicators into decision-support electronic health record and utilize software outputs to prioritize patients for review; (g) will convene case review meetings with supervising physicians; and (h) will communicate physician-recommended treatment changes to patients and their routine providers.
45615438|NCT03324841|Diagnostic Test|Caris MI Profiling|Customized comprehensive biomarker testing
45615439|NCT03328975|Drug|Dexamethasone|The overall purpose of this study is to evaluate the effect of a corticosteroid shoulder injection on glucose levels in insulin-dependent diabetic men and women.
45615440|NCT03328975|Other|Placebo|the placebo group will not receive the corticosteroid medication in their injection to treat the inflammation and pain in their shoulder. Instead, they will receive an injection of 5 mL lidocaine only.
45615441|NCT04484415|Combination Product|Cevira®|The device is a single-use, disposable, LED-based red light source. The device will automatically switch on the light 5 hours after administration, and provide continuous photoactivation of 125 J/cm2 over 4.6 hours before automatically shutting down.
45615442|NCT04484415|Combination Product|Placebo|The placebo device is identical in appearance as the Cevira® device, but does not provide light.
45615443|NCT02491801|Other|Dietary intervention|All arms are given to all participants, in a randomized order
45615444|NCT03102957|Other|functional MRI|
45615445|NCT03324763|Other|stool sampling|A stool sample will be collected to perform the H. pylori antigen test
45615446|NCT05430711|Drug|Dinoprostone|After randomization, participants will receive dinoprostone 10 mg vaginal delivery system which will remain in place up to 24 hours or until the labour begins. At the onset of labor or after 24h it will be removed and participant transferred to labour room for further standard procedures.
45615447|NCT03331783|Other|Standard hydrocolloid adhesive patch|This patch is made of a standard hydrocolloid adhesive
45615448|NCT03331783|Other|LT-2|This patch is made of a new adhesive
45615449|NCT03331783|Other|LT-21|This patch is made of a new adhesive
45615450|NCT03331783|Other|33-20|This patch is made of a new adhesive
45615451|NCT03102567|Drug|GLPG1205 50mg q.d.|oral gelatin capsule containing 50mg GLPG1205 for q.d. administration - compared to placebo
45615452|NCT03102567|Drug|Placebo oral capsule|oral gelatin capsule containing placebo to match study arm 1 - q.d. administration
45615453|NCT03102567|Drug|GLPG1205 250 loading dose and 50mg q.d. maintenance dose|Open label - oral gelatin capsule containing 50mg GLPG1205 for one time 250mg loading dose and subsequent q.d. administration
45615454|NCT03331705|Device|Uro-C (Use of new cystoscope)|Diagnostic cystoscopic procedure of the urethra and bladder
45615455|NCT03324685|Drug|BIIB074|BIIB074 is administered as specified in the treatment arm.
45615456|NCT03324685|Drug|OC (ethinyl estradiol and levonorgestrel)|OC is administered as specified in the treatment arm.
45615457|NCT03331627|Drug|STR001-IT and STR001-ER|STR001-IT intrataympanic injection and STR001-ER tablet
45615458|NCT03324295|Diagnostic Test|cortical cataract|Blood urea
45615459|NCT03328585|Behavioral|CBT-I in person|6 weeks of CBT-I in person, one 1-hour long session per week
45615460|NCT03328585|Behavioral|CBT-I via Telemedicine|6 weeks of CBT-I via telemedicine, one 1-hour long session per week
45615461|NCT03328585|Other|No intervention|Patients in this arm will receive no intervention but will receive CBT-I treatment after conclusion of the study
45615462|NCT03324217|Other|Mental Practise|They made a mental task to produce a neurophysiological activation of the brain areas related to the planning and execution of voluntary movement in a manner that resembles how the action is performed in reality in combination with real exercises.
45615463|NCT03331471|Procedure|alveolar recruitment maneuver|applying alveolar recruitment maneuver using the anesthesia machine
45615464|NCT03331471|Procedure|conventional ventilation|conventional ventilation using the anesthesia machine
45759897|NCT02022111|Other|Psychiatrist and Diabetologist Reviews|Senior psychiatrist and endocrinologist/diabetologist will be involved in weekly offline case review meetings with care coordinators. Case review meetings will be structured: the decision-support electronic health record will help prioritize cases that are new (within 3 weeks of randomization); have moderate/severe depression symptoms (based on Patient Health Questionnaire (PHQ)-9) ≥6 weeks after most recent treatment changes, or continued poor HbA1c, home glucose, BP, or LDL-c control in past 4 weeks; or have not been reviewed for 3 months. Based on patient indicators and current therapies, physicians will recommend treatment changes (initiation, increases, or simplification of medication regimens) which will be communicated by care coordinators to patients and their usual care providers.
45759898|NCT02022111|Other|Decision-support Electronic Health Record System|The decision-support electronic health record will store patient indicators entered by the Nurse Case Managers (NCM) and provide diabetes and depression care prompts based on an evidence-based treatment algorithm developed from recommended guidelines for control of diabetes and depression, Indian formularies, and TeamCare investigators. The decision-supported electronic health record (DS-EHR) will prioritize patients (new; poorly-controlled; or well-controlled but not reviewed ≥3 months) for case review meetings and promote accountability (physicians must justify rejecting electronic care prompts).
45759899|NCT02022111|Other|Standard of Care|Participants randomized to the control arm will receive the existing standard care and treatment for their diabetes that is provided routinely at each Clinic Site and their care provider will be notified regarding their depressive symptoms. The physicians treating the control arm will also be provided with trainings regarding identification and care for people with depression. The control participants will have no contact with care coordinators and will only be contacted at 6-monthly intervals for assessment by the blinded outcomes assessor.
45759900|NCT02022735|Device|Deep Brain Stimulator|DBS will provide brain stimulation.
45615465|NCT02491489|Other|Glenohumeral mobilization|Participants will then be placed supine on a standard plinth. The investigators will then proceed to provide a mobilizing force to the participant's glenohumeral joints. Each of two investigators will, in sequence perform a 15 second longitudinal distraction, followed by a 15 second posteriorly directed glenohumeral glide with the shoulder placed in the open pack resting position (~50 degrees abduction, slight horizontal adduction, external rotation).
45615466|NCT03331237|Procedure|scalene block|scalene block using 5ml of ropivacaine
45759901|NCT02153983|Drug|Colchicine 0.6Mg Cap|Colchicine 0.6 mg given twice daily
45759902|NCT02153983|Drug|Placebo capsules given|Placebo capsules given twice daily
45759903|NCT02153983|Drug|Colchicine 0.6Mg Tab|Open-label colchicine
45615467|NCT03331237|Procedure|ISO block|ISO block is a combined block of suprascapular nerve and brachial plexus cords using a single puncture
45615468|NCT03328429|Other|Excision|Bartholin gland will be excised
45759904|NCT02348775|Dietary Supplement|GlyNAC (combination of glycine and n-acetylcysteine)|HIV patients will be studied before and after receiving GlyNAC
45759905|NCT00828061|Drug|Placebo|Single dose of 5 tablets matching placebo (5 x 0 mg) to prednisone. The washout between treatment periods will be approximately 4 weeks
45759906|NCT00828061|Drug|prednisone|Single dose of 5 tablets prednisone totaling 10 mg (3 x 0 mg + 2 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
45759907|NCT00828061|Drug|prednisone|Single dose of 5 tablets prednisone totaling 25 mg (5 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
45615469|NCT03328429|Other|Marsupialization|Bartholin gland will be marsupialised
45615470|NCT03328351|Other|manual therapy|"Manual therapy: One of the following techniques was used for the treatment group based on the patients' response (i.e centralization and reduction of symptoms).~Cervical postero-anterior vertebral mobilization glides:~a central posteranterior (PA) or unilateral PA oscillatory pressure of grade III on the patient's most symptomatic level for 2 minute and 3 sets .~Cervical lateral vertebral glides :at grade III for 1 minute and 3 sets.~Strengthening Exercises:~for deep neck flexor muscles for 10 seconds and repeating it for 10 times."
45615471|NCT03328351|Other|Superficial soft tissue massage|"1. Superficial soft tissue massage: The researcher applied a superficial effleurage massage without moving the deeper tissue for 2 minutes for 3 sets~Strengthening Exercises:~for deep neck flexor muscles for 10 seconds and repeating it for 10 times"
45615472|NCT05430633|Procedure|Appendectomy|Appendectomy - laparoscopic or open
45615473|NCT03324139|Drug|Low molecular weight heparin|Patients included in this study group will receive 3,500 IU / 0.2 ml / day of Bemiparina sc, from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
45615474|NCT03324139|Drug|Placebos|Patients included in this study group will placebo (same presentation as the active drug), from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
45615475|NCT05430321|Other|Assessment of physiological parameters|FT implementation begins 3 minutes before the procedures and 10 minutes continuous. After the end of the procedures further 3 minutes was given . Physiological parameters were simultaneously recorded on the registration form
45615476|NCT05430321|Other|Assessment of Stress|Newborn Stress Scale (NSS) was used end of the all procedures which means 13th minute.
45615477|NCT05430321|Other|Assessment of Comfort|Neonatal Comfort Behavior Scale (NCBS) was used end of the all procedures which means 13th minute.
45615478|NCT03324061|Drug|Fulvestrant for Injectable Suspension|Test drug is administered as a single 5mL intramuscular injection in the right or left dorsogluteal muscle area
45615479|NCT03324061|Drug|Faslodex (Reference)|Reference drug is administered as two 5mL intramuscular injections, one in each of the right and left dorsogluteal muscle areas
45615480|NCT03323983|Other|data collection|data collection
45615481|NCT02488603|Behavioral|Decision aids (tamoxifen-related educational materials in brochure or mobile app)|Decision aids (tamoxifen-related educational materials in brochure or mobile app)
45615482|NCT02488603|Drug|tamoxifen|
45615484|NCT02640105|Other|Neurological clinical examination|Diagnostic and description of cluster headache
45615485|NCT02640105|Other|Psychological clinical examination|Scale and questionnaires
45615486|NCT02640105|Other|Questionnaires|Psychopathological and cognitive questionnaires
45615487|NCT02640105|Other|Blood sample|Blood sample for DNA collection
45615488|NCT02640105|Other|Endothelial function measurement|Endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
45615489|NCT03328117|Drug|Imatinib|Over-encapsulated 100 mg imatinib mesilate tablets
45615490|NCT03328117|Drug|Placebo oral capsule|Matching placebo oral capsule
45615491|NCT03328039|Device|Garmin wearable device|Physiological data capture only
45615492|NCT04492657|Other|no intervention|Natural exposure of iodine.
45615493|NCT05430087|Drug|Observe the clinical outcome and inflammatory cytokines levels in patients with systemic lupus erythematosus (SLE) after being supplemented with Cholecalciferol (Vitamin D3) and Curcumin-Piperine.|All patients and physicians were blinded to group assignment and treatment allocation. All subjects received the tablets for three months. All subjects were still required to consume their routine medications during the supplementation according to the disease activity. Patients were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters. Adherence to therapy was assessed by monthly pill counts of returned tablets and biweekly phone calls to the patients.
45759908|NCT00849121|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for 6 total doses, followed by pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. every 3 months until radiographic disease progression
45615494|NCT05424159|Radiation|Carbon ion radiotherapy|Patients with locally advanced unresectable pancreatic cancer without invasion of gastrointestinal tract will received ablative carbon ion radiotherapy. The prescription dose for primary pancreatic lesion, positive lymph node, and retroperitoneal high-risk recurrence area is 67.5 Gy (RBE weighted dose) in 15 fractions for 3 weeks; Pancreatic primary lesion and positive lymph node SIB to 75 Gy (RBE weighted dose) in 15 fractions for 3 weeks.
45615495|NCT03327727|Drug|Investigational Agent: VL-2397|VL-2397
45615496|NCT03327727|Drug|Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B|Voriconazole, Isavuconazole, or Liposomal amphotericin B
45759909|NCT00849121|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for a minimum of 6 total doses, and continuing biweekly until evidence of T-cell immune response, and then following a booster schedule as defined by evidence of T-cell immune response.
45759910|NCT02023125|Drug|Alectinib|A single 600-mg oral dose of alectinib will be administered in a fasted or fed condition.
45615497|NCT03102489|Drug|BP101|Nasal spray
45615498|NCT03102489|Drug|Placebo|Nasal spray
45615499|NCT02522637|Other|Exercise training|"The workout will start with a workload of 50% of the theoretical maximum Watts indirectly assessed by the 6-Minutes Walking Test (6MWT) with equation of Luxton et al. Each training session will begin with three minutes of warm-up and cool-down with a low load.~At the end of each session, the physiotherapist will administer the Borg Scale (i.e. for dyspnea and muscle fatigue) and detect the oxygen saturation. The sessions will be conducted at constant load for 25 minutes and increase following the Maltais protocol (the workload increase in the next session will be 10 W, if dyspnea and muscle fatigue, evaluated at the Borg Scale, were each < 5 ).~The patients will perform a supervised 20-min light warm-up gym exercise before the endurance training session. The training will be carried out with the oxygen level necessary to maintain the saturation level ≥ 91%."
45615500|NCT03323671|Drug|preemptive mefenamic acid|preemptive analgesia before menstrual pain
45615501|NCT03323671|Drug|mefenamic acid|mefenamic acid given only during menstruation
45615502|NCT02503527|Other|Diben 1.5 kcal HP|Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) > 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
45759911|NCT02023125|Drug|Esomeprazole|Esomeprazole 40 mg will be administered orally once daily for 6 days prior to alectinib administration.
45759912|NCT02023125|Other|High Fat and Calorie Meal|High fat and calorie meal served prior to alectinib administration
45759913|NCT02023125|Other|Standard Meal|Standard meal served prior to alectinib administration
45759914|NCT00803959|Other|Office evaluation|Office evaluation
45759915|NCT00803959|Other|UDS|Urodynamics
45759916|NCT02349477|Drug|Gabapentin|gaba potentiating medication
45759917|NCT02349477|Drug|Placebo|a pill that looks exactly like the active medication but does not contain medication
45759918|NCT00828295|Drug|palonosetron|palonosetron IV 1 mcg/kg
45759919|NCT00828295|Drug|palonosetron|palonosetron 3mcg/kg IV
45759920|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.5 mL, Subcutaneous
45911568|NCT05778604|Behavioral|Peer-led exercises|The peer-led exercise is focused on balance, strength training, and incorporating exercises into daily activities. A trained peer coach (PC) will lead the group-based exercises for 60 mins (8-10/group). Exercise training consists of four sets: a) warm-up (seated), b) strength for upper and lower body (seated and standing), c) balance (standing and moving), and d) stretching of the lower and upper body. We will provide an exercise booklet (English/Spanish version) with illustrations that highlight steps for each set of exercises and a wide variety of exercises to integrate into daily activities (e.g., cooking). Participants will be instructed to complete a weekly exercise log to record types and duration of activity performed at home.
45911569|NCT05778604|Behavioral|CDC older adults fall prevention|Participants will receive an information pamphlet about falls (English or Spanish version) developed by the CDC (Stopping Elderly Accidents, Deaths, and Injuries (STEADI)-Older Adult Fall Prevention). The pamphlet contains information on fall risk, how to prevent falls, check for safety, postural hypotension and chair rise exercise including what you can do to prevent falls. The participants will be encouraged to discuss fall prevention with a primary care provider and continue normal activities (treatment-as-usual) for 6 months. Participants will receive monthly follow-up phone calls from the study team to record a monthly fall incidence log.
45911570|NCT05778552|Device|Home-based pelvic muscle training devices or traditional PFMT at hospital|Performed home-based pelvic muscle training devices at home or traditional PFMT at hospital
45759921|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.1 mL, Subcutaneous
45911571|NCT05778539|Procedure|Lateral retinacular release|During the implantation of a total knee arthroplasty a lateral retinacular release is performed in the intervention group
45911572|NCT05778526|Behavioral|Virtual reality|There are a total of 12 training sessions for 3 weeks (4 sessions per week). Each session of the Social VR intervention lasts for a maximum of 20 minutes. The intervention contains three real-life virtual scenarios, including (1) a classroom and playground, (2) an MTR station and compartment, and (3) a supermarket and restaurant.
45911573|NCT05778526|Behavioral|Traditional social skills training|There are a total of 12 training sessions for 3 weeks (4 sessions per week). Each session lasts for a maximum of 20 minutes. Four modules will be covered in the 3-week training: (1) how to introduce yourself and basic social skills; (2) how to listen to others; (3) how to share with others; (4) learn to know how people feel and how to empathise.
45615503|NCT02503527|Other|Fresubin HP Energy Fibre (1.5 kcal)|Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) > 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
45615504|NCT03323593|Drug|Dexmedetomidine|blood is sampled for quantification of plasma concentration after intravenous, intranasal by atomisation and intranasal by drops.
45615505|NCT02499003|Drug|Obinutuzumab and Pixantrone|Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles, Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
45615506|NCT03320551|Behavioral|Immersion program|Evaluate the impact of an already established one week long lifestyle immersion program sponsored by Whole Foods, Inc for their employees on anthropomorphic, clinical labs such as lipid levels, blood sugar and other markers of nutrition, quality of life and activity levels at baseline, at the end of the program and at 3 and 6 months
45615507|NCT02279979|Device|HeartMate PHP|The HeartMate PHP system is a catheter-based heart pump and console designed to provide hemodynamic left ventricular support for up to 3 days to stabilize patients by maintaining adequate systemic cardiac output.
45615508|NCT04492813|Drug|Pharmacokinetic of propofol and remifentanil|Pharmacokinetic of propofol and remifentanil in both population: Obese and non Obese patients
45615509|NCT01236807|Procedure|MR perfusion guidance|Coronary revascularization guided by MR perfusion imaging
45452261|NCT02269618|Other|Home-based telehealth program|"Home-based telehealth program~Scheduled calls initiated by nurse performed weekly; the nurse carried out a standardized interview on general clinical condition of the patients.~Unscheduled calls initiated by patients or caregivers through the service centre(24h/24h) to report any clinical problems. in case of signs or symptoms~Telemonitoring: during calls, patients can transmit via landline or mobile phone the recordings from the 1-lead ECG to a service centre, and talk to the nurse or doctor~Home visit performed by therapist seven days after hospital discharge by setting the daily physical activity and other home visits in case of need~Scheduled calls initiated by therapist performed weekly aimed at increasing workload and evaluating the proper execution of exercises."
45615510|NCT01236807|Procedure|FFR guidance|Coronary revascularization guided by invasive angiography and FFR
45615511|NCT03323359|Device|Hemopatch|Hemopatch is applied upon the verification made by the surgeon of the presence of an appropriate target bleeding site in the hepatic parenchyma. At the time point of application a stopwatch starts simultaneously. Time to hemostasis is defined as the time required to obtain successful haemostasis in a single bleeding site. At 3 minutes the inspection will be made and, if haemostasis is not achieved, the treatment is considered failed and the Principal Investigator and/or his delegates is allowed to use additional haemostatic measures.The time to haemostasis will be recorded in the patient's medical record and in the electronic Case Report Form. The bleeding site will be observed for 1 additional minute at the end of the haemostatic procedure and, of the surgery to confirm the haemostasis.
45759922|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.05 mL, Intradermal
45759923|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.1 mL, Intradermal
45759924|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.15 mL, Intradermal
45759925|NCT02350569|Drug|LDV/SOF|90/400 mg FDC tablet administered orally
45759926|NCT02023515|Behavioral|Emotional brain training|Stress management based program
45759927|NCT02023515|Behavioral|Behavioral weight loss|Standard behavioral weight loss
45759928|NCT00355017|Procedure|BNP-guided care in addition to multidisciplinary management|
45759929|NCT02350647|Device|Suture Anchor HEALOCOIL|Rotator cuff tears will be repaired intraoperatively using suture anchors
45759930|NCT02350647|Device|Suture anchor Twinfix Ultra HA|
45615512|NCT03323359|Procedure|Common Surgical Techniques|Patients undergoing liver resection for any underlying disease and with resectable mass. The list of the underlying diseases is the following (but might not be limited to): Hepatocellular carcinoma, Hilar cholangiocarcinoma, Adrenal cancer metastasis, Breast cancer metastasis, Colorectal cancer metastasis, Ovarian cancer metastasis, Biliary carcinoma, Hemangioma, Hepatic adenoma, Focal nodular hyperplasia, Unilocular hydatid cyst, Multilocular, hydatid cyst.
45615513|NCT02441751|Procedure|intra-operative blood loss|surgery in the urology and orthopedics
45615514|NCT05406687|Other|Health Navigator Model|The Health Navigator Model will be a longitudinal, person-centered and community-based intervention focused on addressing both primary and secondary cancer prevention, as well as reducing wider barriers to healthcare. Health Navigators (HNs) will be professionals who have a background in social care and an understanding of the local user population, and will be embedded in settings familiar and accessible to people experiencing homelessness. The primary aspects of the HN role will be to identify the health needs and barriers of users, promote cancer awareness and education, facilitate timely access to healthcare services and cancer screening, provide practical assistance, delivered through regular in-person meetings, and utilize wider stakeholders, including healthcare professionals, to deliver the intervention. A comprehensive training package will be delivered to the HNs, covering population specific knowledge, interpersonal skills, cancer education and local resources.
45615515|NCT02491255|Device|Lotus Valve System|Device: Lotus Valve System
45615516|NCT02488369|Device|PET / CT|
45615517|NCT02405169|Device|4 vs 6 implant treatment in the maxilla|
45615518|NCT03320395|Device|Small bowel RFA treatment|"The samples will be spread and fixed using needles. The prototype RFA-SB ablation catheter will be applied by the PI as follows to each section of duodenum, jejunum and ileum.~The treating paddle of the prototype RFA-SB catheter will be pushed on the small bowel mucosa exerting the same pressure that would be applied endoscopically.~12 J/cm2 will be applied every time with a 20 second interval between applications to simulate clinical practice.~There will be two single applications to two separate specimen sites. There will be two double applications to two separate specimen sites. There will be two triple applications to two separate specimen sites. There will be two quadruple applications to two separate specimen sites."
45615519|NCT03102801|Drug|Humulin S|Humulin S used to induce hypoglycaemia
45615520|NCT02646423|Behavioral|Prior CD Decision App|The Prior CD Decision App begins with an explanation that its goal is to help the user better understand the two approaches to delivery she is eligible for (trial of labor after cesarean (TOLAC) and elective repeat cesarean delivery (ERCD)), and that its goal is to help her engage with her provide in making an informed, shared decision regarding which approach to undergo. It includes four sections: a calculator to estimate the likelihood of having a vaginal delivery if she undergoes TOLAC, a series of information pages that include graphical presentations of the chances of various potential outcomes of the two options, a series of values clarification exercises to help the user think through what's important to her, and a summary print out for her to keep.
45615521|NCT03327337|Procedure|Arthroscopic Assisted Balloon Tibioplasty|Under arthroscopy, the balloon supports the articular surface, with additional bone graft and necessary internal fixation
45615522|NCT03327259|Behavioral|Activity Planning|The therapist will work with the participant to select a challenging, yet rewarding or value-driven activity that he/she can engage in 5x and monitor daily over the upcoming week.
45615523|NCT03327259|Behavioral|Therapist Guided Activity Practice|The therapist will work with the participant to plan and carry out a brief in-vivo version of their goal/target activity. The therapist will guide the participant through the activity for approximately 15 minutes.
45615524|NCT03323203|Device|FORE-SIGHT Elite, CASMED, Inc., Branford, Connecticut, USA|Tissue oxygenation was monitored using a tissue oximeter based on near-infrared spectroscopy (FORE-SIGHT Elite, CASMED, Inc., Branford, Connecticut, USA). The oximeter had four cables with each cable connected to an adhesive probe.
45615525|NCT04412577|Drug|TQB3473|TQB3473 tablets administered orally once. Then TQB3473 tablets administered orally, once daily in 28-day cycle after 3 days of first administration.
45615526|NCT02488057|Drug|Liraglutide|Active comparator. See arm descriptions.
45615527|NCT02488057|Behavioral|Weight loss|Active comparator. See arm descriptions.
45615528|NCT04044495|Other|Multimodal brain imaging (MRI)|Multimodal brain imaging (MRI)
45615529|NCT04044495|Other|Actimetry|7 days actimetry
45615530|NCT04044495|Other|Sleep Diary|7 days Record of sleep and wake cycle
45615531|NCT03323125|Other|Self-Assessment Questionnaire|Self-assessment questionnaire with sun exposition, sun protection, vitiligo severity and vitiligo outbreaks, will be suggested to patient during medical consultation.
45615532|NCT04039347|Drug|Liposomal Cyclosporine A 5 mg|delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
45615533|NCT04039347|Drug|Liposomal Cyclosporine A 10 mg|delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
45615534|NCT03327181|Dietary Supplement|short chain fatty acid tracers|stable tracer infusion of acetate, propionate, and butyrate
45615535|NCT05253573|Drug|Nicotine patch|Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.
45615536|NCT05253573|Behavioral|Self-help materials (to support smoking cessation)|"Our team has translated and validated the World Health Organization's A guide for tobacco users to quit into Lao language for use as the self-help material in this study."
45759931|NCT02350881|Device|Primus FGTI (Flexible Great toe Implant)|Great toe arthroplasty consists of replacing the first Meta-Tarso-Phalangeal (MTP1) joint by a two hinged prosthesis made of silicone : the Primus FGT implant (FGTI). The Primus is designed with an axially offset hinge to align with the anatomy of the MTP joint. This results in less implant stresses and improved toe function.
45759932|NCT02023983|Other|Early discharge|Early discharge (within 72 hours) of selected patients with low risk of complications after myocardial infarction with ST segment elevation, treated with successful percutaneous coronary intervention
45759933|NCT02023983|Other|Standard discharge|Discharge after myocardial infarction with ST segment elevation in a standard way accordingly with present practice and physician´s decision (usually 4th-7th day)
45759934|NCT02351115|Drug|A=Placebo|
45759935|NCT02351115|Drug|B=Inhaled Alprazolam 0.5 mg|
45759936|NCT02351115|Drug|C=Inhaled Alprazolam 1 m|
45615537|NCT05253573|Behavioral|Smartphone-based automated treatment for smoking cessation|The automated treatment(AT) include text messages, images, and videos. The AT content is designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The AT will begin immediately after enrollment and continue for a 12-week period. The AT approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.
45615538|NCT03320239|Behavioral|HIV risk assessment and tailored suggestions|The intervention contains: HIV risk investigation, tailored suggestions and free HIV testing link
45759937|NCT02351115|Drug|D= Inhaled Alprazolam 2 mg|
45759938|NCT02351115|Drug|E=Placebo|
45759939|NCT02351271|Device|Femto LDV Z8|Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification
45759940|NCT02351271|Device|Manual capsulorhexis&lens fragmentation|Control treatment where the capsulorhexis is performed manually and the lens fragmentation is performed by the stop and chop technique with the phaco emulsification device
45759941|NCT02025075|Drug|Rocuronium|Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).
45759942|NCT02351505|Drug|Selinexor|Given PO
45759943|NCT02351505|Other|Laboratory Biomarker Analysis|Correlative studies
45759944|NCT02351505|Other|Pharmacological Study|Correlative studies
45759945|NCT00242567|Drug|Zoledronic Acid|"Zoledronic acid was provided by Novartis in vials containing 4 mg/5 mL liquid concentrate. Prior to administration, the liquid concentrate from one vial was to be further diluted with 100 mL of calcium-free infusion solution (0.9 % weight by volume sodium chloride solution or 5 % weight by volume glucose solution). If refrigerated, the solution had to be allowed to reach room temperature before administration.~After addition of the liquid concentrate to the infusion media, the infusion solution was to be used as soon as practicable to reduce the risk of microbiological hazard. If storage of the solution was necessary, it had to be refrigerated at temperatures between 2-8 degrees C and was to be used within 24 hours.~The infusion solution containing 4 mg zoledronic acid was to be administered every 4 weeks as an i.v. infusion over no less than 15 minutes."
45615539|NCT03320239|Behavioral|HIV risk behavior assessment|It only contains HIV risk behavior assessment and routine education
45615540|NCT03320239|Behavioral|placebo control|It only contains HIV/AIDS knowledge assessment and routine education
45615541|NCT03327103|Behavioral|CHAMPION|An interactive mHealth decision aid that includes immediate and over time quality of life (QL) graphical summaries for advanced prostate cancer patients to enhance informed, shared decision making and will also be used to assess the CPNs' role in the decision-making process.
45615542|NCT02488291|Drug|0.25 sufentanil|with different dosage
45759946|NCT00242567|Drug|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) was to be administered according to institutional protocols, in accordance with relevant prescribing information. The type and duration of androgen deprivation was at the discretion of the treating specialist, and could include orchiectomy where this would normally have been performed. Androgen deprivation therapy was provided by the investigational center, or obtained by the patient from usual sources. Anti-androgen monotherapy and intermittent ADT were excluded in the first 12 months of the study.
45759947|NCT00241631|Drug|Fluticasone Propionate|500 u
45759948|NCT00241631|Drug|placebo|
45759949|NCT00241631|Drug|Theophylline|Theophylline placebo capcule
45615543|NCT02488291|Drug|0.5µg/ml sufentanil|0.5µg/ml sufentanil
45759950|NCT05744141|Procedure|Relaxation Exercises|"Relaxation exercises consist of voluntary, rhythmic and regular stretching and relaxation of large and small muscle groups until the whole body relaxes. For this exercise application, the Relaxation Exercises CD prepared by the Turkish Psychological Association will be used. The CD consists of 30 minutes and relaxation exercises are explained with the sound of a stream accompanied by verbal instructions. This exercise includes rhythmic breathing, muscle relaxation exercises and music (stream sound)."
45759951|NCT02351739|Drug|pembrolizumab|
45759952|NCT02351739|Drug|ACP-196 in combination with pembrolizumab|
45759953|NCT05744063|Drug|Emapalumab-Lzsg 5 MG/ML [Gamifant]|iv
45615544|NCT02488291|Drug|0.1% ropivacaine|0.1% ropivacaine
45615545|NCT03102255|Procedure|Sniffing position|All procedure is done under sniffing position.
45615546|NCT03102255|Procedure|Nasal tip lifting|Before inserting the endotracheal tube to patient's nose, the researcher lift up the nose tip.
45615547|NCT03327025|Behavioral|Health education counseling|Health education counseling
45615548|NCT05226039|Behavioral|Moderate intensity acute exercise bout|The treatment/intervention will consist of 20 minutes of moderate intensity aerobic exercise on a stationary bike. Intensity will be prescribed based off of heart rate reserve.
45615549|NCT03320083|Behavioral|Educational care derived from POSSUMS|Intervention group were offered a sleep education session on healthy practices for parent-baby sleep which included information on sleep needs, sleep hygiene, training in strategies to remove obstacles that get in the way of healthy sleep. Information were provided to guide the parent in forming an action plan based on cued care which included aligning the circadian clock with real time, removing the obstacles that get in the way of healthy sleep, physical activity, mindfulness, and relaxation techniques for mothers derived from the POSSUMS approach. However, we could not use Acceptance and Commitment Therapy, because none of the investigators had sufficient training on ACT at the time the study was conducted.
45615550|NCT03102333|Device|Variable-rate Feedback Infusion mode|The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time. It can increment or decrement rate(0.2ml/hr) by press bolus button during a 48 h period
45615551|NCT03102333|Device|Constant-rate Infusion mode|The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time during a 48 h period
45615552|NCT03323047|Drug|Acetaminophen|Oral acetaminophen (15 mg/kg) 1 hr pre-operatively
45615553|NCT03323047|Drug|Low-dose Dexamethasone|Intravenous low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia
45615554|NCT03323047|Drug|Placebo Oral Tablet|Oral placebo 1 hr pre-operatively
45615555|NCT03323047|Drug|High-Dose Dexamethasone|Intravenous high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia
45615556|NCT03102099|Procedure|contrast-enhanced ultrasound group|The contrast-enhanced ultrasound patients will undergo biopsy with contrast-enhanced ultrasound guidance.
45615557|NCT03102099|Procedure|conventional ultrasound group|The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
45615558|NCT03102177|Drug|Administration of stable Isotope labeled levothyroxine|Administration of single dose of stable isotope carbon-13 labeled levothyroxine and measurement of blood levels of stable isotope-labeled levothyroxine
45615559|NCT03322969|Drug|Paclitaxel/DDP|receiving the modified chemotherapy
45615560|NCT03322969|Drug|XELOX/SOX|receiving the original chemotherapy
45615561|NCT03320005|Other|Resistance training group|Resistive exercises for legs and arms
45615562|NCT05187975|Procedure|Acupuncture|"Acupuncture:~Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees.~Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Qimen (LR14), Taixi (KI3).~Traditional Chinese medicine:~Chaihushugan Power: Chaihu 12g, Chenpi 12g, Chuanxiong 9g, vinegar Xiangfu 9g, Zhike 9g, Shaoyao 9g, roasted Gancao 3g.~Repetitive transcranial magnetic stimulation:~The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 10Hz.~Standard care:~The same as the standard care group."
45615563|NCT05464303|Drug|Intravenous Antibodies|Treatment is usually performed with sensitive third-generation cephalosporins, and medication is adjusted according to blood culture results
45615564|NCT02352129|Other|CMR using T1 mapping technique|the level of myocardial fibrosis for patient suffering of cardiomyopathy dilated will be quantified using CMR T1 mapping technique
45615565|NCT03319771|Behavioral|Treadmill Walking Exercise Training|12-weeks of supervised, progressive treadmill walking exercise training
45615566|NCT03319771|Behavioral|Stretching-and-toning Exercise Training|12-weeks of supervised, stretching-and-toning exercise training
45615567|NCT05042427|Other|Pregnancy Weight Management Health Literacy Questionnaire|Give questionnaires to check the weight management health literacy level of primigravida women.
45759954|NCT00240071|Drug|Avastin|All patients will received Avastin 15 mg/kg IV every three weeks. The first evaluation will be done at Week 6. Patients with objective response or stable disease will continue therapy with restaging every 6 weeks until evidence of disease progression. Patients with progression of disease will be taken off study.
45759955|NCT00240071|Drug|Hormonal therapy|aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or Selective Estrogen Receptor Modulator (SERM) (tamoxifen 20mg/d PO)
45759956|NCT00240383|Drug|Muraglitazar|
45759957|NCT02352363|Drug|CVT-301|
45759958|NCT02352363|Other|Observational cohort|
45759959|NCT03805139|Dietary Supplement|Ajwa Date (phoenix dactylifera)|Effect of Ajwa on Dyslipidemia
45759960|NCT00765947|Drug|Aliskiren|Aliskiren 150 or 300 mg
45615568|NCT04443283|Other|No intervention|This is a observation study, with no intervention
45615569|NCT03322891|Other|Educational Supplement|Participants will receive education about prostate cancer and treatments using models and props during a face-to-face interview. During the interview, participants will also be asked about medical terms and treatments regarding prostate cancer. The interview will last 45 to 60 minutes.
45615570|NCT03322891|Other|Standard Practice Education|Participants will receive traditional standard of care education regarding prostate cancer treatments and side effects provided by their physician.
45615571|NCT03319693|Genetic|Somatic Genetic|NGS analysis
45615572|NCT04435275|Other|Virtual Assistant first, then Human Coach|Instructions to aid healthcare worker adherence to proper PPE and intubation and extubation procedure is given by a VA (e-coach) in place of a safety officer (a human coach).
45615573|NCT04435275|Other|Human Coach first, then Virtual Assistant|instructions to aid healthcare worker adherence to proper PPE and intubation and extubation procedure is given by a safety officer (a human coach).
45615574|NCT04000269|Device|Soterix MxN Neuromodulation device|Up to 2 mA stimulation to primary motor cortex for 10 sessions at 20min per session
45615575|NCT04000269|Device|Sham Stimulation|Uses slight stimulation initially then turns of and provides no stimulation after a few seconds.
45615576|NCT02488213|Other|Nutritional Counseling|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive nutritional counseling from the diet quality assessment with adopting some techniques of motivational interviewing, and delivery of educational support material. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
45615577|NCT02488213|Other|Usual Diet Guidance|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive usual diet guidance from the current nutritional recommendations for diabetes, according to the routine performed. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
45615578|NCT03992235|Other|Chest physiotherapy|"All patients will receive chest physiotherapy including Breathing exercise, intensive spirometry use, coughing, ambulation."
45615579|NCT03992235|Other|Educational material|Exercise brochure with photos and explanations
45615580|NCT02491021|Other|Rehabilitation Class|A 6 week programme of exercise and education in an out patient setting
45615581|NCT03319615|Behavioral|Dietary energy restriction|
45615582|NCT02491177|Behavioral|cMM|Home visits from community mentor mothers
45615583|NCT02491177|Behavioral|Text Messaging|Text messages received on mobile phone
45445571|NCT04570124|Device|Home Blood Pressure Telemonitoring|Women will complete a 9-question survey (pre-education) prior to discharge and will go over an education video a study team member. Once discharged, women will be asked to measure their blood pressure daily for the first postpartum week, and then weekly until postpartum week 6. Women who have a doctor's visit scheduled during the first 10 days, a member of the study team will meet them there to assess blood pressure and answer any questions. Women who do not have a visit scheduled they will have a telehealth visit during days 8-10 to complete the same assessments. At the final visit, participants will measure their blood pressure via HBPT, prior to returning the unit, complete a post-education questionnaire, a post-study questionnaire and have any questions or concerns addressed.
45615584|NCT03322735|Drug|Fludarabine|25-30mg/m2/day IV for 3 days
45615585|NCT03322735|Drug|Cyclophosphamide|cyclophosphamide 0.6-0.8g/m2/day IV for 2 days
45615586|NCT03322735|Biological|BCMA CAR-T|BCMA CAR-T cells will be administered after completion of the chemotherapy.
45759961|NCT00765947|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 or 25 mg
45759962|NCT00765947|Drug|Amlodipine|Amlodipine 5 or 10 mg
45445572|NCT04929548|Drug|Pyrotinib Maleate Tablets|Addition of Pyrotinib in the EC phase to the standard treatment EC-THP regimen recommended by the guidelines.
45615587|NCT03953625|Other|delivery of the low back pain booklet|"When a patient arrives at the GHPSJ emergency room or in general medical consultation at the CMT and a diagnosis of common acute low back pain is made, the physician verifies the study selection criteria.~If it is randomized in the arm 2 with booklet group, the management will be the same as for the without booklet group but with the hand delivery of the booklet in addition.~All patients will be informed about the existence of the booklet. A link to the digital version on the ameli.fr website is included in the information note The patient will be contacted 3 months later by a Clinical Research Associate (CRA) to conduct a data collection."
45615588|NCT03109327|Diagnostic Test|Melanoma Detection System -MDS|Imaging of lesion using the MDS test.
45615589|NCT02487901|Device|ultrasonic osteotome|making gutter with ultrasonic osteotome
45615590|NCT02487901|Device|drill|making gutter with drill
45615591|NCT02487667|Device|Therapeutic exercise by fitness machines|Therapeutic exercise program by using 8 exercise machine circuit
45615592|NCT02490709|Procedure|Local excision|Local excision for rectal cancer with good response
45615593|NCT05418205|Other|Families with FGP support|Non-randomized controlled trial with four points of measurement ( in 18 months)
45615594|NCT03326635|Other|Frailty in elderly (≥70 y) patients in ICU|Determine the prevalence of frailty in elderly patients (≥ 70 year old) in a group of French ICUs. The frailty is measured by a score (Fried score) at the admission of the patient
45615595|NCT02487823|Drug|BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide|BKM 120, LH-RH agonists and Bicalutamide
45759963|NCT05743907|Drug|DA-2811|DA-2811 Group: DA-2811 + Forxiga placebo
45759964|NCT05743907|Drug|Forxiga|Forxiga Group: Forxiga + DA-2811 placebo
45759965|NCT03805061|Other|'aerobic exercise'|The aerobic exercise group by using treadmill their walking speeds were adjusted according to the maximum speed at which the person could walk was performed a period of; 8 weeks, 3 days a week, 30-45 minutes each patient.
45759966|NCT03805061|Device|'isokinetic exercise'|Patients in the isokinetic exercise group pedaled a bicycle ergometer for warming with low exercise and exercise was applied for 5-10 minutes to cool down at the end of the study. were included in a rehabilitation program that they would apply for 3 days per week for 8 weeks.The measuring of isokinetic muscle strength, CSMI Humac Norm isokinetic dynamometer's commonly used angular velocities of 60 ° and 180 ° / sec was used.
45759967|NCT00766649|Drug|Sirolimus|Participants receive a 20 μL (440 μg) subconjunctival injection of sirolimus in the study eye at baseline and every three months thereafter.
45759968|NCT02352831|Drug|Tosedostat|
45759969|NCT02352831|Drug|Capecitabine|
45759970|NCT02352831|Procedure|Fresh tissue biopsy|Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
45445573|NCT04150029|Drug|MBG453|Solution for intravenous infusion
45445574|NCT04150029|Drug|Venetoclax|Tablet for oral administration
45445575|NCT04150029|Drug|Azacitidine|Solution for subcutaneous injection or intravenous infusion
45445576|NCT04205474|Diagnostic Test|graded bicycle test|the subjects perform an exercise test on a reclining bicycle, and perform against increasing afterload
45615596|NCT03326557|Procedure|Membrane Sweeping versus Transcervical Foley Catheter for Induction of Labour in Women with Previous Caesarean Delivery|Subjects undergoing induction of labour (IOL) will be randomly assigned to two interventional arms (Group 1: membrane sweeping or Group 2: transcervical Foley catheter insertion). Before IOL, modified Bishop score will be assessed for cervical favourability. After 24 hours of IOL, improvement of modified Bishop score will be reassessed. If the cervix is favourable, amniotomy will be performed followed by augmentation with intravenous oxytocin. If the cervix is still unfavourable and amniotomy is impossible, membrane sweeping will be continued for one more day in Group 1 whereas conservative management will be undertaken for one day in Group 2. Suitability for amniotomy will be reassessed on the next day. After amniotomy, subsequent intrapartum management will be based on the hospital protocol. If amniotomy is still impossible after 2 days of IOL, the ward Obstetrician will discuss with women regarding option of Caesarean section.
45445577|NCT04182620|Device|renal denervation|Renal denervation using the Paradise renal denervation system - a dedicated RDN catheter that delivers a circumferential ring of ablative ultrasound energy
45445578|NCT04182620|Device|Catheter ablation|Catheter ablation - one of the most common procedures performed by Cardiac Electrophysiologists for atrial fibrillation
45445579|NCT03769233|Behavioral|Mindfulness-based Intervention|MBI will be delivered in group format, 90 minutes per week, for 5 consecutive weeks with 6-15 participants per group.
45445580|NCT03769077|Device|Exergaming|This study involves the use of multiplayer exercise video games or 'exergames' that incorporate an avatar powered by pedaling a recumbent stationary bicycle. The Liberi suite of exergames contains six mini-games, including a combination of cooperative games, competitive games and individual games designed to be fast-paced, action-oriented, and enjoyable for youth with special needs.
45445581|NCT03768921|Other|PEEP Titriation|The alveolar recruitment maneuver PEEP reaches a maximum of 25 cmH2O, with recruitment being performed progressively, where the pressure variation is maintained at 15 cmH2O and the PEEP increase progressively occurs at 2 cmH2O every 2 minutes and Ventilatory mode with Controlled Pressure Ventilation. After the alveolar recruitment maneuver, the PEEP titration or determination will be performed, where the PEEP of 2 cmH2O will be reduced every 2 minutes and the variables after the alveolar recruitment maneuver and PEEP maintenance will be checked in the TIMPEL brand equipment at the point where the patient has better alveolar recruitment, with fewer alveolar collapsing points and pulmonary hyperdistension.
45445582|NCT02797132|Drug|LUM/IVA|
45445583|NCT02519270|Biological|IGN002|IGN002 is a monoclonal antibody fusion protein.
45445584|NCT03768843|Procedure|Harms technique|Atlantoaxial fusion
45445585|NCT03768765|Procedure|Holmium Laser Prostate Surgery|Patients will undergo standard of care holmium laser prostate surgery
45615597|NCT03326479|Diagnostic Test|Caris Molecular Intelligence Profile|A comprehensive biomarker testing
45615598|NCT02487511|Other|Duration of HP therapy|the comparison of HP eradication rate between 7 days and 14 days
45615599|NCT03319381|Behavioral|Following new SOPs|The new SOPs comprised early whole-body CT, damage control surgery, and the use of goal-directed coagulation management and are based on the ATLS® concept, which was the strictly followed protocol before implementation of the new SOPs
45759971|NCT00766727|Device|GLYDe Dressing|Wound dressing intended to minimize scar formation
45445586|NCT02060734|Procedure|Lidocaine|Lidocaine injection 3-5 points in experimental group( using 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point).
45445587|NCT02060734|Other|Saline|The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.
45445588|NCT03270644|Drug|Lasmiditan|Administered orally
45445589|NCT03270644|Drug|Propranolol|Administered orally
45445590|NCT02062528|Dietary Supplement|omega-3 fatty acids|highly dosed in EPA
45445591|NCT02062528|Dietary Supplement|placebo|
45445592|NCT03772275|Diagnostic Test|New york Heart Association Class II-IV|"New york Heart Association Class II-IV  study of markers"
45445593|NCT03772275|Diagnostic Test|New york Heart Association Class I|New york Heart Association Class I
45445594|NCT02062684|Drug|Blisibimod|
45445595|NCT02062684|Drug|Placebo|
45759972|NCT04275479|Diagnostic Test|Oral Glucose Tolerance Test|This is a two step process. Subjects will be asked to fast overnight,(no food and only water to drink for at least 8 hours). Then when subjects arrive for the visit,participants will have blood drawn and be asked to drink a sugary liquid. One hour later, another blood sample will be drawn and after two hours a final blood sample will be drawn.
45759973|NCT04275479|Other|Modified Oral Glucose Tolerance Test|The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). There will be no blood drawn during this test, participant will be asked to drink a sugary liquid and to remaining fasting (water only) for the two hour after finishing the drink.
45615600|NCT03322579|Device|Balloon dilatation Eustachian tuboplasty|Eustachian tuboplasty by balloon dilation involves the recanalization of the cartilaginous portion of the ET via the nasopharynx with a balloon catheter. This catheter is inflated to multiple atmospheres of pressure for a short amount of time and then removed.
45615601|NCT03322501|Behavioral|Provider Advice, Framed Messaging|The purpose of the study is to determine if an Ask, Advise, Connect (AAC) intervention model benefits tobacco control outcomes for pediatric primary care providers (pPCP's) and their young patients.
45615602|NCT03326089|Procedure|Pulmonary rehabilitation|Endurance training for 30 minutes, 3 times/week for 2 months followed by resistance training
45615603|NCT02487589|Other|Telephone support, telemonitoring and tele-exercise|"The care model will provide 24/24 h assistance for six months and include:~Telephone Support: a nurse-tutor (NT) will follow-up the enrolled patients weekly mainly through scheduled appointments. NTs duties will be: 1 education (patients and family ' s health education on how to prevent falls, verification of the adherence to the pharmacological therapy, teaching on how to recognize problems that can conduct to falls) and 2. management. Occasional appointments will be required by patients on duty and managed by a nurse .~Telemonitoring: all patients will send proper biological traces and data will be registered on a personal health record.~Tele-exercise: Home exercises sessions will be provided by a DVD and monitored through a videoconference by a physiotherapist."
45445596|NCT04535102|Drug|Polatuzumab Vedotin|Polatuzumab vedotin is an ADC designed for the targeted delivery of MMAE(mono-methyl auristatin E), a potent microtubule inhibitor to lymphoma cells expressing CD79b. MMAE has a mechanism of action that is similar to that of vincristine.
45615604|NCT05463913|Drug|18F-FDG|Patients will receive a single intravenous injection of 3 MBq/kg 18F-FDG
45445597|NCT02062762|Behavioral|Online-MBSR|8 week mindfulness based stress reduction online
45759974|NCT04275479|Other|Modified Mixed Meal Tolerance Test|The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). The participant will be given a meal supplement to drink in place of breakfast, for example Boost Plus. The participant will be asked to drink the meal supplement and to remaining fasting (water only) for the next two hours.
45615605|NCT05463913|Radiation|PET/CT imaging|Patient will undergo 2 CT acquisitions and multiple PET emission scans.
45615606|NCT05463835|Dietary Supplement|RubusElite|Each 500ml serving of this beverage will contain approximately 30g of milk protein alongside 750mg of polyphenols derived from blackberry puree. The study participant will consume 2 x 500ml per day which will contribute 60g protein and 1500mg polyphenols. No adverse effects associated with the consumption of dairy protein or berry fruits at the proposed intake levels have been reported to date.
45615607|NCT05463835|Dietary Supplement|'Protein rich' dairy beverage|This dairy beverage will contain approximately 30g of milk protein /500ml serving and will not contain polyphenols.
45615608|NCT05463835|Dietary Supplement|'Low Protein' dairy beverage|This product also contains no polyphenols and negligible protein.
45615609|NCT03322189|Genetic|pharmacogenomic|Standard Operating Procedures on Pharmacogenomic testing and changes made to specific SOP
45615610|NCT03319147|Dietary Supplement|Active|4g of essential amino acids
45615611|NCT03319147|Dietary Supplement|Placebo|4g of maltdextrin
45615612|NCT03322111|Diagnostic Test|measurement of the cyclofusion|Measurement of the maximal cyclofusion competence with a dynamic 3-D Random-Dot Landolt-C stimulus
45615613|NCT03326011|Device|Samsung Hip Assist v1|All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
45615614|NCT03325933|Other|High Load/Low Rep Resistance Training|Participants will be prescribed High Load/Low Rep resistance training.
45615615|NCT03325933|Other|Low Load/High Rep Resistance Training|Participants will be prescribed Low Load/High Rep resistance training.
45615616|NCT02487433|Drug|Tofacitinib MR 22 mg (Fed)|A single dose of tofacitinib modified release 22 mg tablet after receiving the standard FDA high-fat/high-calorie meal
45759975|NCT04275479|Device|Continuous Glucose Monitor|The participant will be provided a CGM device to wear for 10 days during the study period. The CGM will be blinded (meaning that the participant will not be able to see the results).
45615617|NCT02487433|Drug|Tofacitinib MR 22 mg (Fasted)|A single dose of tofacitinib modified release 22 mg tablet after an overnight fast of 10 hours
45615618|NCT03319069|Radiation|Hypofractionated radiotherapy|"Hypofractionated radiotherapy 43,5 GY/15 fractions (f)/3ws. to chest wall and supraclavicular nodal region.~."
45615619|NCT03319069|Radiation|Conventional fractionated radiotherapy|50 Gray(GY)/ 25f/5 weeks(5w) to chest wall and supraclavicular nodal region
45615620|NCT04493125|Drug|Mosapride citrate|Patients receive mosapride citrate (5mg/T) three times a day from the first day after surgery.
45759976|NCT04275479|Other|Food Diary|The participant will be asked to maintain a detailed food diary for 3 days during the 10 day study period.
45445598|NCT02062762|Behavioral|Expressive Writing Online|Online distributed expressive writing intervention as active control
45759977|NCT04275479|Other|Medical History Questionnaires|The participant will be asked to provide detailed medical history
45615621|NCT04493125|Drug|Placebo|Placebo
45615622|NCT04442893|Behavioral|Rumination-Focused Cognitive Behaviour Therapy|Rumination-Focused Cognitive Behavioural Therapy(RFCBT) is based on a differentiation between functional and dysfunctional styles of perseverative thinking with the helpful style characterized as a concrete, process-focused and specific style of thinking and the idea that rumination is a habit maintained by negative reinforcement. In line with the theoretical assumptions, RFCBT combines strategies from behavioral activation with strategies to foster concrete, process-focused and specific thinking.
45615623|NCT04442893|Other|Health Education programme|Health education programme would be any planned activity or set of activities aimed at increasing health literacy and developing life skills conducing to health (e.g. decision making, problem solving, critical thinking, interpersonal skills, stress management, coping with emotions).
45759978|NCT02353299|Drug|Silenor 6 mg|Silenor 6 mg single nighttime dose.
45759979|NCT02353299|Drug|zolpidem 10 mg|Zolpidem 10 mg single nighttime dose
45759980|NCT02353299|Drug|Placebo|placebo single nighttime dose-1.5 hours
45615624|NCT03318991|Procedure|Laser prostatectomy|Patients with symptomatic benign prostate obstruction (BPO) will be assigned under randomisation to treat with GreenLight laser or thulium laser.
45615625|NCT04493983|Procedure|laparoscopic salpingo-oophorectomy|Laparoscopic bilateral salpingo-oophorectomy
45615626|NCT04493983|Procedure|Laparoscopic bilateral salpingo-oophorectomy|Unilateral oophorectomy was performed immediately after abdominal entry, and the remaining contralateral ovary was excised at the end of the hysterectomy in order to compare the effect of these surgical procedures on ovarian tissue.
45615627|NCT04493593|Behavioral|SilverCloud|"'Space for Sleep' is a seven-module online CBT-based intervention for sleep. The structure and content of the programme modules follow evidence-based CBT principles for insomnia. Each module is structured to incorporate introductory quizzes. videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.~As per normal service provision, each participant will be assigned a clinician (PWP) who will monitor participants' progress through the program. Every one to two weeks, the PWP will login and review participants' progress, leaving feedback for them and responding to the work they have completed."
45615628|NCT03318913|Other|Placebo|5g of the sucralose administered as white plastic capsules
45615629|NCT03318913|Other|Fish protein hydrolysates|5g of the FPH dissolving in 100 mL of water
45615630|NCT03318835|Drug|Thalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Thalidomide 200mg PO QN D1-21
45615631|NCT03318835|Drug|R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
45615632|NCT03318757|Drug|Bupivacaine Extended Release Liposome Injection|Bupivacaine Extended Release Liposome Injection (Exparel TM) 133 mg diluted in 10ml of normal saline (13.3 mg/ml) will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
45615633|NCT03318757|Drug|Bupivacaine HCl|10ml of Bupivacaine HCl 0.5% will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
45615634|NCT03325699|Device|SMART4MD Health Application|"SMART4MD is a general health application which has been adapted specifically for people with mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal carers. The application is optimized for tablet devices running on Android operating system (OS). Participants will be provided with a tablet with the SMART4MD health application.~The core functionalities of the application are based on reminders (medication, appointments with healthcare providers), brain supporting activities (clock, calendar, brain games, photos) and optional status and health information sharing with family and informal carers (including daily feeling status, specific health problems, and quality of life). An important feature of SMART4MD is its personalization facility: main users (PWD and informal carers) will be able to switch off/on various features and information sharing possibilities."
45615635|NCT03325621|Biological|PRS-080#022-DP|Biological/Vaccine: PRS-080#022-DP Hepcidin antagonism to mobilize iron and to treat anemia
45615636|NCT03325621|Biological|PRS-080-Placebo#001|Placebo Comparator
45615637|NCT02487355|Drug|Dexmedetomidine|Dexmedetomidine 1 μg/ kg
45615638|NCT02487355|Drug|Magnesium Sulphate|Magnesium Sulphate 50 mg
45615639|NCT02487355|Drug|Bupivacaine|1ml/kg of 0.25%of bupivacaine
45615640|NCT02487355|Drug|Dexmedetomidine + Magnesium Sulphate + Bupivacaine|Dexmedetomidine 1 μg/ kg + Magnesium Sulphate 50 mg + 1ml/kg of 0.25%of bupivacaine
45615641|NCT02487121|Behavioral|variable interval schedule|12 group-based extended care treatment sessions scheduled in 3, 4-week periods over a 12-month period
45615642|NCT02487121|Behavioral|self-directed treatment|provision of treatment materials with instruction to work through materials at participant's own pace
45615643|NCT03325465|Drug|Pembrolizumab|Patients will receive pembrolizumab alone or pembrolizumab in combination with epacadostat. Pembrolizumab will be administered at 200 mg IV every 3 weeks for up to 3 doses for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
45615644|NCT03325465|Drug|Epacadostat|Patients will receive epacadostat in combination with pembrolizumab. Epacadostat will be administered orally at a dose of 100 mg twice a day starting on day 1 for the duration of pembrolizumab treatment. Patients will continue on this combination for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
45615645|NCT03325387|Drug|LY3305677|Administered SC
45615646|NCT03325387|Drug|Placebo|Administered SC
45615647|NCT03325309|Other|Home-based cycling|A single outpatient supervised session followed by a 3-month home-based cycling program tailored to patients' preferences
45615648|NCT01876953|Drug|cytarabine|Given IV
45615649|NCT01876953|Drug|idarubicin|Given IV
45615650|NCT01876953|Drug|dasatinib|Given PO
45615651|NCT01876953|Other|laboratory biomarker analysis|Correlative studies
45615652|NCT04493359|Drug|Renin-angiotensin system inhibitors|switch anti-hypertensive class
45615653|NCT03321955|Drug|Ziconotide 100 MCG(microgram)/ML Intrathecal Solution|Initial dose at time of the implant will be 1.2 mcg/day with dose increases of no more the .4 mcg/day planned for 3, 6, 8, 9, 10, 12 weeks and 4, 5, 6 and 12 months.
45759981|NCT02353299|Drug|Placebo|placebo single nighttime dose-4 hours
45759982|NCT00756977|Drug|BLI850|multi-dose preparation for oral administration prior to colonoscopy
45759983|NCT00756977|Drug|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
45759984|NCT02354781|Biological|rAAV1.CMV.huFollistin344|Six DMD patients will receive rAAV1.CMV.huFollistatin344 to both limbs by multiple injections to gluteal muscles, quadriceps and tibialis anterior muscles.
45759985|NCT03808961|Dietary Supplement|Niacin|100mg tablets twice daily
45759986|NCT03808961|Dietary Supplement|Niacinamide|100mg tablets twice daily
45759987|NCT03808961|Other|Placebo|Placebo tablet twice daily
45759988|NCT02027883|Device|Nominal T shock setting|Nominal Parameter Set 1 Programming Values for EnTrust
45759989|NCT02027883|Device|Educated T shock setting|Experimental Parameter Set 2 Programming Values
45759990|NCT00783965|Drug|tazarotene|Applied to the skin
45759991|NCT00783965|Other|placebo|Applied to the skin
45759992|NCT02354859|Drug|Gallium nitrate|Study subjects will receive an infusion of either placebo or gallium nitrate.
45759993|NCT02354859|Drug|Normal Saline|Study subjects will receive an infusion of either placebo (normal saline) or gallium nitrate.
45759994|NCT00421551|Drug|Darunavir|during the 48 first weeks of the trial, (2x300mg) twice a day between W48 and W96, (2x400mg) once a day
45759995|NCT00421551|Drug|ritonavir|during the first 48 weeks, 100mg twice a day between W48 and W96, 100mg once a day
45615654|NCT03321955|Diagnostic Test|Quantitative sensory testing|Quantitative sensory testing will be done using different types of sensory stimulation to objectively quantify sensation and pain tolerance. VonFrey fibers of various widths are used to detect sensation, a Neuropen pin prick iutilized to detect pain, along with a tuning fork to measure vibrationand a pressure guage to measure pressure felt on the skin. Cold/hot sensation is tested with Medoc Pathway system to quantitatively measure the temperature felt by patients to be done at baseline, 6 months and 12 months,
45615655|NCT03321955|Diagnostic Test|Serum markers: Interleukin-1, Interleukin-6, and tumor necrosis factor|Increases in these biomarkers indicate nerve pain as they are released from macrophages in patients with damaged nerves.
45615656|NCT03318679|Other|No intervention is planned.|None is planned
45615657|NCT04493437|Device|Telerehabilitation|Blood pressure (iHealth Neo), weight (iHealth Lina), step counters(Fitbit Inspire & Charge 3), sleep sensor (Emfit QS), tablet (iPad Air 2), and ECG recorder (AliveCor KardiaMobile).
45615658|NCT03318601|Procedure|Blood taking|"Blood taking in 2 times :~J0 : 15 mL~J14 : 5 mL 20 mL in total volume"
45615659|NCT04493281|Drug|MT-1186|Oral suspension
45615660|NCT04493281|Drug|MCI-186|Intravenous formulation
45615661|NCT01764711|Drug|Cosyntropin administration|After 30 minutes of rest in the seated position, participants will be given cosyntropin intravenously. Blood samples will be taken 30 minutes pre-drug administration, 30 minutes post and 60 minutes post drug administration.
45615662|NCT04493047|Behavioral|Mobile health (mHealth) for pneumonia|Audiovisual mobile based application will be used to counsel caregivers of children under five on pneumonia and its prevention. This will be coupled with text and voice message dissemination to the cell phones of caregivers.
45759996|NCT02356107|Drug|5-hydroxytryptophan and Creatine monohydrate|
45759997|NCT00767507|Drug|cangrelor|
45759998|NCT00767507|Other|Placebo|Placebo IV infusion administered in the same fashion as the active study drug in order to maintain the blind in the study.
45759999|NCT02029755|Procedure|transversus abdominis plane block|bilateral ultrasound-guided transversus abdominis plane block, with 20 ml of 0.25% ropivacaine at each side after the induction of general anesthesia
45760000|NCT02029755|Procedure|local infiltration|local anesthetics infiltration at surgical wound with 20 ml of 0.5% ropivacaine before wound closure
45760001|NCT02029755|Procedure|Patient controlled analgesia|postoperative analgesia with intravenous patient controlled analgesia with morphine
45760002|NCT05743829|Procedure|Tissue excision as part of routine clinical care|Tissue excision
45760003|NCT03804749|Drug|suramin sodium|The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.。
45760004|NCT03804749|Other|placebo|Placebo is 0.9% sodium chloride injection.
45760005|NCT03804515|Drug|14C-labeled poziotinib|a single capsule containing 12 mg of 14C-labeled poziotinib (approximately 90 to 110 μCi) will be administered orally
45760006|NCT02029911|Device|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
45760007|NCT05621213|Other|Teleconsultation assisted by a physiotherapist or nurse|"A home health care provider (with expertise in NIV) will be asked to attend the 2 home teleconsultation sessions.~This assistance will make it possible to help, if necessary, the patient to settle in and connect, collect the elements necessary for the doctor's consultation and adjust, if necessary, the NIV settings. He will also be responsible for administering the questionnaires to the patient as well as to his family caregiver."
45615663|NCT01737255|Other|Whole body MRI|Individuals will undergo whole body and brain MRI
45615664|NCT01737255|Other|Psychological questionnaires|All recruits will complete questionnaires at 6 time points to assess psychological impact
45615665|NCT04493515|Drug|Oral Oxytocin|Administration of oxytocin orally (24 IU)
45615666|NCT04493515|Drug|Oral Placebo|Administration of placebo orally (24 IU)
45615667|NCT04493749|Diagnostic Test|ECG measurement|Simultaneous recording of a single-lead ECG signal with the Withings Move ECG and ECG signal for the reference 12-lead ECG
45615668|NCT01644669|Radiation|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
45615669|NCT03318445|Drug|Rucaparib|All participants will take rucaparib by mouth
45615670|NCT03318445|Drug|Irinotecan|Patients in the dose escalation phase, and patients in the dose expansion phase who have received prior PARP inhibitor therapy, will be given irinotecan by in combination with rucaparib.
45615671|NCT01627821|Device|Jarvik 2000 VAS|Jarvik 2000 LVAD
45615672|NCT01627821|Device|HeartMate II|HeartMate II LVAD
45615673|NCT03321877|Drug|Change to dose of patient's regular medication|Dose reduction of the drug each patient was already taking
45760008|NCT04384757|Procedure|Distal gastrectomy|Distal gastrectomy and standard D2 lymphadenectomy
45760009|NCT02357043|Device|Dario Blood Glucose Monitoring System|Finger-stick obtained with BGMS
45760010|NCT02357043|Device|YSI|Finger-stick sample obtained by nurse/technician to be tested with YSI
45911574|NCT05778513|Other|Passive knee flexion-extension + Cycle ergometer exercise + 3-week body weight reduction program|Passive knee flexion-extension movements + Incremental cycle ergometer exercise + Multidisciplinary body weight reduction program with a duration of 3 weeks
45615674|NCT01556139|Device|Spirotiger|"The Training group perform 20 sessions of a specific training with Spirotiger, a device allowing respiratory muscle training with isocapnic hyperpnea.~The setting is the following:~volume/size of the breathing bag: 50% of the vital capacity (VC) and ventilation (VE= Tidal volume x respiratory rate) at 66% of the MVV aiming to reach 15 minutes of training without breaks. During the initial sessions, the patient can interrupt training every 5 minutes and recover.~increase in training: after 15 minutes of exercise VE is increased up to 75% of the MVV through modification of the volume of breathing bag or respiratory rate.~At the end of 15 minutes of exercise, further increases in ventilation are 10% of each previous step."
45615675|NCT03318367|Other|Educational Intervention|Complete virtual reality education module
45615676|NCT02485015|Biological|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells are used to treat advanced gastric cancer patients with Apatinib.
45615677|NCT02485015|Drug|Apatinib|Advanced gastric cancer patients take Apatinib 850mg qd by mouth.
45615678|NCT01137123|Drug|adjuvant chemotherapy|Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.
45615679|NCT01137123|Procedure|standard two field Lymphadenectomy|Standard two field lymphadenectomy is standard mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
45615680|NCT01137123|Procedure|Total two field Lymphadenectomy|Total two field Lymphadenectomy is total mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
45615681|NCT01137123|Procedure|three field Lymphadenectomy|Three field Lymphadenectomy includes abdominal,mediastinal and cervical lymphadenectomy.
45615682|NCT02484781|Other|Gait analysis on a trendmill|"Gait analysis on a trendmill GRAIL to analyse spatio-temporal kinetics and kinematics when flat walking and inclining"
45615683|NCT03318289|Behavioral|Ving Tsun|The VT training regimen is designed to improve reactive balance control, lower extremity muscle strength and balance confidence in the elderly. It comprises 9 VT sticking-hand drills that must be practised with a partner. Participants will be trained to respond rapidly to upper body perturbations and to maintain body balance. Those joined the VT training group will attend a one-hour supervised VT training session at an elderly community centre 2 times per week for 12 weeks.
45760011|NCT05743751|Device|Normothermic machine perfusion|XVIVO (perfusion company, Gothenburg, Sweden), functions to be included in perfusion equipment, cardiopulmonary bypass machine and neonatal cardiopulmonary bypass machine, including polyethylene pipeline, heating equipment (perfusion temperature 37 ℃), venous pool (venous pressure is 0 mmHg, adjust the height of perfusion pool), centrifugal pump (arterial pressure is set at initial 75 mmHg, maintain 65 mmHg). The perfusion solution contains 215ml of dextran/albumin solution and 400ml of hematocrit, 2ml of 10% calcium gluconate, 1300u/L heparin and 400mg of cefazolin sodium. The oxygen/carbon dioxide ratio is (95%/5%, 2L/min) for continuous perfusion, and pO2 is maintained at 650mmHg during perfusion. During perfusion, continue to use verapamil, amino acid, glucose and insulin. Lactic acid Ringer solution (10ml/h) was used to supplement the lost circulation volume due to urine production during perfusion.
45760012|NCT05743751|Device|Hypothermic machine perfusion|LifePort Kidney Transporter is designed to integrate with the clinical environment by using readily available supplies, requiring minimal user intervention, and by being easy to use. LifePort Kidney Transporter is a portable, isolated kidney perfusion and transport system, designed to support a donated kidney and to maintain the organ in a near-normal physiologic state under hypothermic aseptic conditions. An insulated plastic housing encloses the kidney and perfusate within a LifePort Kidney Transporter Disposable Perfusion Circuit. LifePort Kidney Transporter components include an Ice Container, Pump Deck, Control Panel, Outer Display, Bubble Detectors, External Connections Panel, sensors, and four lithium-ion batteries. Two handles make the unit easy to lift and carry
45760013|NCT03804671|Drug|BI 730357|Oral dose
45760014|NCT03804671|Drug|BI 730357 mixed with [C-14] BI 730357 BS|Intravenous dose
45760015|NCT02031627|Device|pneumatic compression - 1 hour per day|Pneumatic compression treatment once per day (1 hour)
45760016|NCT02031627|Device|pneumatic compression - 2 hours per day|pneumatic compression treatment twice per day in the AM & PM (2 hours)
45760017|NCT02031627|Device|pneumatic compression - 4 hours per day|pneumatic compression treatment twice per day consisting of 2 consecutive 1 hour treatments in the AM & PM (4 hours)
45760018|NCT05743595|Biological|Personalized Neoantigen DNA vaccine|The sites of immunization may be rotated for each of the immunizations.
45760019|NCT05743595|Biological|Retifanlimab|Retifanlimab will be supplied by Incyte.
45760020|NCT05743595|Device|TDS-IM v 2.0 electroporation device|Each DNA vaccination will be 1 mL vaccine administered intramuscularly using an integrated electroporation administration system
45760021|NCT04273295|Other|Abdominal massage|The patients lying in comfortable relaxed supine position and physiotherapist performed slow circular clockwise movements on the abdomen, throw tangential pushing, with digital pulp, slow and gradual pressure, with fingers inclination 45 degree. The pressure applied to the abdomen on each point for 1 min, beginning with the ascending colon, transverse colon, descending colon and sigmoid; this sequence was repeated approximately 15 min. The therapist teaches the parents this technique and asked them to apply at home 3 times / day for 15 min.
45760022|NCT02358135|Other|Collaborative Connected health, (CCH)|CCH is an asynchronous, secure online platform where patients can upload images of psoriasis lesions and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
45760023|NCT02358135|Other|Control|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or UV therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from PCPs or dermatologists, just as they would in the real world.
45760024|NCT02032641|Device|Laser treatment|Non-ablative, non-fractional, microsecond-pulsed Nd:YAG laser 500-1000 pulses, 0.3 msec pulse duration, 10-14 J/cm2, 5 mm spot size
45911575|NCT05778513|Other|Passive knee flexion-extension + Cycle ergometer exercise|Passive knee flexion-extension movements + Incremental cycle ergometer exercise
45760025|NCT02312739|Procedure|In-office Transcervical Sterilization (Essure®)|The standard transcervical sterilization procedure is not being evaluated in this study, and will be performed in the same manner in the two study arms. The procedure includes a standardized paracervical block with 1% lidocaine. A 5mm operative hysteroscope is passed through the cervix and into the uterine cavity using normal saline for uterine distention. Each tubal ostium is identified, followed by deployment of the device into each fallopian tube. A confirmatory test, hysterosalpingogram, is required at 90 days post procedure to demonstrate successful sterilization.
45760026|NCT02312739|Drug|Standard Oral pain medications|one 5/325mg hydrocodone/acetaminophen (Vicodin) tablet and one 1mg Lorazepam tablet given to patients randomized to the active comparator arm at least 30 minutes before the procedure
45445599|NCT04529720|Biological|Biological/Vaccine: Pertagen (aP BioNet)|"Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region."
45615684|NCT03933423|Device|Home based phototherapy and referral|CHWs will visit the household twice in a month and will counsel mother and families on use of preventive care such as routine antenatal check care and newborn care. The investigators will conduct blood grouping and rhesus (Rh) typing. If the mother is Rh negative, investigators will also measure the Rh status of the father prior to delivery to determine the risk of Rh disease in the newborn. The investigators will establish an emergency contact system both in intervention and comparison arm where mothers and family members contact and inform the research team about delivery. The trained phlebotomist will collect cord blood for measuring glucose 6-phosphate dehydrogenase and infant blood type, Rh status, direct antigen testing. The investigators will develop a protocol for treating infants at home based on the ETAT (Emergency Triage Assessment AND Treatment) AAP (American Academy of Paediatrics) guidelines and treat with LED based phototherapy
45615685|NCT02486887|Device|telemonitoring of weight, pulse and blood pressure|
45615686|NCT04941573|Combination Product|Hyperpolarized 129-Xenon (MagniXene) MRI of the lung|Hyperpolarized xenon is a contrast imaging agent for lung MR imaging. Inert noble gas xenon is hyperpolarized using Xemed developed technology. The gas is administered to the human subjects as a short seconds-long breath-hold while inside the MRI scanner. Once the gas is inhaled, lung images of HP Xenon distributed within the lung spaces can be acquired. Additionally, xenon follows a similar path to oxygen, dissolving in lung tissue and further in bloodstream.
45760027|NCT02312739|Drug|Intramuscular Ketorolac|30mg of intramuscular ketorolac given to all patients at least 30 minutes before the procedure
45760028|NCT02312739|Drug|Placebo pills|Two placebo bills given to patients randomized to the experimental arm at least 30 minutes prior to the procedure
45760029|NCT02312739|Other|Oxygen|Oxygen at 5L/min given to patients randomized to the active comparator arm
45760030|NCT02312739|Other|Nitrous Oxide|Nitrous oxide with a maximum titration of up to 70% given to patients randomized to the experimental arm
45615687|NCT03316339|Drug|Dexmedetomidine|Opioid-free anesthesia
45615688|NCT03316339|Drug|Remifentanil|Opioid anesthesia
45615689|NCT02484625|Other|Potato chips|Commercially available potato chips, 180 kcal
45615690|NCT02484625|Other|Greek yogurt|Commercially available Greek yogurt, 180 kcal
45615691|NCT02484625|Other|Cookies|Commercially available cookies, 180 kcal
45760031|NCT05718765|Behavioral|PACES intervention|"The exercise perception intervention program is divided into three stage, and every four weeks is a stage. The theme of the first stage is to make the patient have the intention to exercise. The theme of the second stage is to provide effective support for the patient, so that the patient can take the initiative to start exercise. The theme of the third stage is to enable patients to keep exercising.~The exercise intervention is a 12-week progressive intradialytic combined cycling exercise which proceed in the first HD 2 hours for safety. Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE."
45760032|NCT05718765|Other|Usual care with sham intervention|Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 hemodialysis hours.
45760033|NCT02351037|Drug|Ibrutinib|Subjects will receive ibrutinib 560 mg once daily on a continuing basis.
45760034|NCT02351037|Drug|Ibrutinib + LD-AraC|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
45760035|NCT02351037|Drug|Ibrutinib+Azacitidine|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75 mg/m2 IV once daily on Days 1-7 of a 28-day cycle (with an option to increase to 100 mg/m2 after 2 cycles).
45760036|NCT05718687|Drug|GBT021601|Single oral dose of 200 mg GBT021601, containing ~74 kBq (~2 µCi) of [14C]-GBT021601
45911576|NCT05778500|Device|COMPACS|We will modify the current version of the COMPACS software package to implement several guideline-derived algorithms to help the clinician to reduce diagnostic errors and increase the adherence to current guidelines
45760037|NCT02358603|Diagnostic Test|Chronotropic Incompetence Diagnostic Algorithm|
45760038|NCT05718609|Drug|Rabeprazole|proton-pump inhibitor (PPI)
45760039|NCT05718609|Drug|Colloidal Bismuth Pectin Granules|Gastric mucosal protective drug with anti-H. pylori effect
45760040|NCT05718609|Drug|Amoxicillin|Antibiotic for H. pylori eradication
45760041|NCT05718609|Drug|Furazolidone|Antibiotic for H. pylori eradication
45760042|NCT05718609|Drug|Clarithromycin|Antibiotic for H. pylori eradication
45760043|NCT02359305|Drug|Acetaminophen|Acetaminophen given by IV
45760044|NCT02359305|Drug|Acetaminophen|Acetaminophen suppository given rectally
45760045|NCT02360319|Drug|Any FDA approved antipsychotic agent|Investigators are free to choose the most appropriate treatment for their clients
45760046|NCT02360319|Drug|aripiprazole long acting injectable formulation|
45615692|NCT02484625|Other|Cheese|Commercially available cheese, 180 kcal
45615693|NCT02484625|Other|Milk|Commercially available milk, 180 kcal
45615694|NCT02490865|Drug|RNS60|RNS60, 4 ml dose nebulized twice daily
45615695|NCT02490865|Drug|Normal saline|Normal Saline, 4 ml dose nebulized twice daily
45615696|NCT02486809|Drug|Lebrikizumab|Participants will receive a single SC dose of lebrikizumab, delivered via needle and syringe or PFS-NSD.
45615697|NCT02490787|Drug|Concizumab|Administered subcutaneously (s.c., under the skin) at five different dose levels (ranging from 0.25 to 1.5 mg/kg)
45615698|NCT02490787|Drug|placebo|Administered subcutaneously (s.c., under the skin)
45615699|NCT02490553|Other|heteroevaluation scale by a nurse or doctor|
45615700|NCT02484703|Drug|Placebo|Participants will receive matching placebo PO BID. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
45615701|NCT02484703|Drug|RO5186582|Participants will receive 1 of 3 dosages of RO5186582 PO BID, including 40 mg, 60 mg, or 120 mg. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
45760047|NCT05718531|Drug|Rivaroxaban 2.5 Mg Oral Tablet twice daily|effect of rivaroxaban 2.5 mg twice daily on MACE and quality of life in coronary artery ectasia patients.
45760048|NCT05718531|Drug|Clopidogrel 75 Mg Oral Tablet|Used as control group in 2nd arm and 5th arm
45760049|NCT05718531|Drug|Aspirin tablet 75 mg|Used as control group in 2nd arm and 5th arm
45760050|NCT05718453|Combination Product|Laboratory Tests|Measurement of serum level of CRP, tumor necrosis factor, zinc, copper, potassium, sodium, and magnesium in patients with stable COPD and during exacerbation.
45760051|NCT02360631|Drug|Chantix|A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.
45760052|NCT02360631|Drug|Placebo|Health education counseling will be provided to all participants.
45760053|NCT02033499|Behavioral|SMBG|Blood glucose levels are tested once daily.
45760054|NCT02362191|Device|Alternating Current Stimulator|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
45760055|NCT05718375|Drug|CU01-1001|CU01-1001
45760056|NCT05718375|Drug|Placebo|Placebo
45760057|NCT00355095|Drug|Erythropoietin|intravenous daily 3.3 *10^4 Units, duration 3 days
45615702|NCT02484469|Device|The Virtual Human Project|Virtual Human educational videos about leprosy
45615703|NCT03316183|Other|Perioperative and postoperative management|Cerebral oximetry informed perioperative management
45760058|NCT02366871|Drug|Oral apixaban|To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
45760059|NCT02366871|Drug|Subcutaneous enoxaparin|To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
45760060|NCT05718219|Drug|SIM0348|Several dose levels will be evaluated for SIM0348 administered as a single agent . SIM0348 will be given via IV infusion on Day 1,Day 8,Day 15,Day 22 of each cycle (28-day or depending on study cohort and phase) until disease progression or loss of clinical benefit.
45615704|NCT02484313|Other|dietary treatments|commercially available food products
45615705|NCT02486497|Biological|hENT1|hENT1 is a membrane transporter for gemcitabine. According to the hENT1 staining, patients will be treated with gemcitabine or 5-FU.
45615706|NCT02486575|Other|Self-learning|Every resident will train following the video instruction included in the FLS course material and related written instruction only
45615707|NCT02486575|Other|Mentoring|A tutor will follow each resident during learning, giving instruction, examples and any kind of suggestions.
45615708|NCT03318211|Drug|Magnesium Sulfate|Intravenous ampules of MgSo4 was given to only to control group after delivery
45615709|NCT04492579|Other|Gentle-UHT donor human milk supplementation|Providers referred mothers with newborns that fit the following criteria: exhibited insufficient milk supply, an infant with early weight loss born >36 weeks gestation. Mother was given Gentle-UHT donor milk for supplementation, in addition to mother's own milk for the first week of the infant's life after hospital discharge.
45615710|NCT02484235|Other|HIIT|Group training with HIIT 3 times per week during 10 sessions
45615711|NCT02484235|Other|Strength|Group training with strength exercises 3 times per week during 10 sessions
45615712|NCT03321565|Other|Behavioral counseling and optional meal replacement program|Medical assessment and medical supervision of weight loss Measurements of metabolism and body composition Individualized exercise programs Personal training Support group meetings Individual psychotherapy A variety of nutritional plans including meal replacement options Nutrition education Long-term weight maintenance and relapse prevention programs
45615713|NCT03321487|Device|Blood-Brain Barrier opening with MRgFUS|ExAblate Transcranial MR-guided Focused Ultrasound to temporarily open the Blood-Brain Barrier
45760061|NCT05718219|Drug|SIM0348|Several dose levels will be evaluated for SIM0348 administered as a single agent . SIM0348 will be given via IV infusion on Day 1,Day 8,Day 15,Day 22 of each cycle (28-day or depending on study cohort and phase) until disease progression or loss of clinical benefit.
45760062|NCT02036541|Device|AqueSys XEN 45 Glaucoma Implant|Placement of the AqueSys XEN 45 Glaucoma Implant in the study eye
45760063|NCT02368431|Drug|Zonisamide|Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
45760064|NCT02368431|Drug|Placebo|Placebo
45760065|NCT00757601|Drug|MK1006|"MK1006 capsules: 1 mg, 10 mg, and 20 mg.~Panel A: MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: MK1006 capsules in five doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose"
45615714|NCT02484157|Device|Hemochron|Activated coagulation time was checked serially by Hemochron Jr.
45615715|NCT02484157|Device|ACT Plus|Activated coagulation time was checked serially by ACT Plus.
45615716|NCT02490397|Other|Day Light|Patients are exposed to day light for 2 weeks after a heart attack. At the end of 2 weeks they will have blood drawn.
45615717|NCT02490397|Other|Room Light|Patients will be exposed to only room or natural light for 2 weeks after heart attack. At the end of 2 weeks they will have blood drawn.
45615718|NCT02486419|Other|Outdoor weather|Seasonal changes in temperature
45615719|NCT02483767|Drug|goserelin|Gonadotropin-Releasing Hormone Agonist
45615720|NCT02483767|Drug|standard chemotherapy|(Anthracyclines/cyclophosphamide) followed by paclitaxel or doxetaxel; doxetaxel/cyclophosphamide; doxetaxel or paclitaxel/Anthracyclines; fluorouraci/Anthracyclines/cyclophosphamide followed by doxetaxel or paclitaxel; doxetaxel/Anthracyclines/cyclophosphamide; Anthracyclines/cyclophosphamide;
45615721|NCT03317665|Device|Mesh for hernia repair|Permacol, Parietex, Progrip, Strattice Perforated, and Surgimend.
45615722|NCT02483845|Drug|Natalizumab|
45615723|NCT02486341|Drug|Insulin|Continuous glucose monitoring system over 120-hour period.
45615724|NCT02484001|Drug|ESL 800 mg|one (1) tablet of 800 mg (QD).
45615725|NCT02484001|Drug|ESL 1200 mg|one (1) and a half tablets of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
45760066|NCT00757601|Drug|Placebo|"Placebo capsule to match MK1006 1, 10, and 20 mg.~Panel A: Placebo to MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: Placebo to MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: Placebo to MK1006 capsules in 5 doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose"
45760067|NCT03809975|Other|Multidisciplinary Community Program|"Patient will undergoes 12 weeks of structured and personalized multidisciplinary community-based program, which consists of Physiotherapy, Dietetics and Psychology sessions. Patients will also attend 2 educational sessions. Physiotherapy and educational sessions are mandatory for all participants, while the need for dietetics and psychological interventions are determine using individual's BMI measurements and psychological questionnaires.~Inclusion criteria:~Dietetics: 23.5 < BMI <32.5; Psychology: PEG > 4 or PHQ-4 > 5 or PAM level < 3"
45615726|NCT02484001|Drug|ESL 1600 mg|two (2) tablets of 800 mg (QD).
45615727|NCT02484001|Drug|ESL 400 mg|half tablet of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
45615728|NCT02483923|Drug|Ultrasound guided serratus anterior block with ropivacaine|After induction of anesthesia, patients take ultrasound guided serratus anterior plane block with 0.5ml/kg of ropivacaine 0.375%. 30minutes before the end of operation, intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient.
45615729|NCT02483923|Drug|intravenous PCA only|same dose of intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient only.
45615730|NCT02647359|Drug|Ataluren|Ataluren oral suspension will be administered as per the dose and schedule specified in the respective arms.
45615731|NCT02647359|Drug|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
45615732|NCT02483689|Drug|Pre Incisional Local Anesthetic|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
45615733|NCT02483689|Other|Pre-Incisional Saline|Patient will be given a max of 30 cc injected through a 22g needle to area of incision.
45615734|NCT02483689|Drug|Post-Closure Local Anesthetic|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
45615735|NCT02483689|Other|Post-Closure Saline|Patient will be given a max of 30 cc injected through a 22g needle after closing sutures were made.
45615736|NCT02490085|Other|24-hour intervention with multiple daily injections|Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. The subjects will carry on with their normal insulin therapy. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.
45615737|NCT02490085|Other|24-hour intervention with closed-loop strategy|Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing subject's usual fast acting insulin analog will be placed in the insulin pump. Closed-loop strategy will start at 21:00 until 21:00 the next day. Neither basal nor prandial insulin injections will be given. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.
45911577|NCT05778487|Dietary Supplement|Gatorade Thirst Quencher|Gatorade Thirst Quencher, 710ml (45g of carbohydrates, 6.3% carbohydrates, 25.4kcal/100ml)
45615738|NCT02490085|Drug|Insulin|Subject's usual insulin analog will be used.
45445600|NCT04529720|Biological|Biological/Vaccine: Boostagen (TdaP BioNet)|"Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TdaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region."
45445601|NCT04529720|Biological|Biological/Vaccine: Adacel|"Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region."
45615739|NCT02490085|Device|Insulin pump Accu-Chek Combo|During closed-loop intervention, the Accu-Chek Combo (Roche) insulin pump will be used
45615740|NCT02490085|Device|Dexcom G4 Platinum|In both visits, glucose levels will be measure with the Dexcom G4 Platinum (Dexcom)
45615741|NCT03102021|Drug|erythropoietin|500 units/kg daily for 3 days at onset of acute kidney injury
45615742|NCT03102021|Drug|saline|saline 10 ml for 3 days
45615743|NCT03317587|Behavioral|INSPIRE|Eight week program of weekly group sessions with homework assignments addressing beauty ideals, establishing a healthy relationship with food and exercise, and tolerating and managing uncomfortable emotions. Participants will complete questionnaires are separate time points (one week before the program, one week after the program, and 1 month after the program) to evaluate the impact of the program on various behavioral and psychological outcomes.
45615744|NCT04916691|Procedure|EPSB for rib fractures|EPSB for rib fractures
45615745|NCT04916691|Drug|Ropivacaine|Standard of care weight-based optimal Ropivacaine dosing for ESPB
45615746|NCT02486185|Other|SCREENING TEST|"Skeletal muscle mass, which will be estimated by calculating values for the mid-arm muscle circumference (MAMC) from brachial perimeter (BP) and triceps skinfold thickness (TSF).~Muscle force will be measured using a hydraulic dynamometer~Physical performance will be estimated from the subject's Gait speed using a 4 meter gait test (Gait speed 4-m)"
45615747|NCT04904835|Diagnostic Test|Access HBV serological marker assays on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays|All samples will be tested with both CE-marked HBV serological predicate assays (HBsAg, HBsAb, HBcT, HBc IgM, HBeAb, and/or HBeAg assays) and Access HBV serological assays (HBsAg, HBsAb, HBcT, HBc IgM, HBeAb, and/or HBeAg assays) according to respective Instructions For Use to determine non-reactive (NR), initially reactive (IR), repeatedly reactive (RR), or confirmed or not confirmed Positive.
45615748|NCT03321409|Diagnostic Test|The general population|After recruiting participants, collecting the baseline data, the SSS-CN and PHQ-15 will be carried out. Then validating the reliability, validity of the SSS-CN will be compared with the PHQ-15.
45615749|NCT03321409|Diagnostic Test|Patients with suspected CAD|In patients with suspected CAD, after recruiting participants, collecting the baseline data, the SSS-CN and PHQ-15 will be carried out before undergo coronary angiography. Then the prevalence of somatic symptoms will be investigated.
45615750|NCT02490163|Device|Spectra Optia|"The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself, 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software.~Terumo BCT developed a completely automated apheresis system: the Spectra Optia MNC and CMNC based on an automatic interface-controlled technology that allows MNCs collection without the intervention of an operator. The optical sensors continuously control and adjust the buffy coat layer by adjusting the plasma flow.~The Spectra Optia MNC collects MNCs by intermittent flow: MNCs accumulate and are flushed from a secondary chamber at intervals during the procedure. On the other hand, the very recently released Spectra Optia CMNC (developed especially to collect stem cells that reside in the MNCs layer) is able to collect MNCs by continuous flow."
45615751|NCT05117385|Dietary Supplement|Botanical extract|1 capsule per day
45615752|NCT02483455|Drug|2014-ALC-919-US|A topical solution to be applied twice daily for the treatment of Common Warts
45615753|NCT02483455|Drug|Vehicle-Control Topical Solution|A topical solution to be applied twice daily for the treatment of Common Warts
45615754|NCT05105139|Other|Allantoin/ Coal Tar/ Clioquinol|Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 5.0 g/ Clioquinol 3.0 g Administration way: For scalp use
45615755|NCT05105139|Other|Allantoin/ Coal Tar/ Clioquinol/ Triclosan|Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 3.0 g/ Clioquinol 3.0 g/ Triclosan 0.3 g. Administration way: For scalp us
45615756|NCT04492423|Diagnostic Test|VerifyNow PRUTest|VerifyNow PRUTest for platelet aggregation
45615757|NCT03317509|Procedure|repetitive transcranial magnetic (rTMS)|Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days. Sham rTMS is the same pulse as the first group but with the coil placed perpendicular to the scalp.
45615758|NCT03317353|Device|Vestibular rehabil.: CDP|Vestibular rehabilitation, ten sessions
45615759|NCT03317353|Device|Vestibular rehabil.: optokinetic stimuli|Vestibular rehabilitation, ten sessions
45615760|NCT03317353|Other|Vestibular rehabil.: home exercises|Exercises performed twice a day for two weeks. Approximate duration of each session: 15 minutes
45615761|NCT03865173|Other|Telephone Interview|Telephone Interview
45615762|NCT03862833|Drug|IL2|"Three IL2 levels will be tested:~Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion 4 weeks, 5 days per week from day + 15 post graft to day + 40"
45615763|NCT03862833|Drug|Zoledronic Acid|4 mg at day +15 post graft
45615764|NCT03315637|Procedure|Fetoscopic repair of spina bifida|Fetoscopic intrauterine repair of open spina bifida
45615765|NCT03843255|Other|Part 1: DCM Cohort|Patients with a confirmed diagnosis of DCM will have samples that undergo whole genome sequencing and biomarker analysis
45615766|NCT03843255|Other|Part 2: Heritable CV Diseases and Family Members|Biomarker analysis will be undertaken on samples
45615767|NCT03317275|Device|18F-Fluoride-PET/MRI|facet joint injection guided by the anatomical localization of causative structures by PET/MRI compared to standard assessment techniques.
45615768|NCT03317275|Procedure|facet injection|facet joint local anesthetic and corticosteroid injection according to the 18F-Fluoride-PET/MRI result or based on current standard clinical practise (MRI and clinical correlation) respectively
45615769|NCT03317275|Other|pain assessment by VAS|VAS questionnaire immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
45615770|NCT03325543|Other|Verbal instruction and Vaginal palpation|The experimental group will receive verbal instructions on the anatomy and function of PFMs associated with the use of body awareness techniques and vaginal palpation to learn the correct PFMs contraction. The control group will receive only verbal instructions on the anatomy and function of PFMs associated with the use of body awareness techniques.
45615771|NCT03835689|Behavioral|Strongest Families Intervention (formerly Family Help)|Distance HEALTH education intervention focused on skill learning for parents
45615772|NCT02483377|Other|Quality-of-Life Assessment|Ancillary studies
45615773|NCT02483377|Other|Questionnaire Administration|Complete questionnaires
45615774|NCT05463445|Other|Only observation|No intervention is needed.
45615775|NCT04435353|Device|VibroLUNG|Lungs intensive therapy
45615776|NCT05386927|Other|Questionnaire survey and specimen collection|A questionnaire survey was conducted when pregnant women were enrolled in the first trimester, and blood, urine, saliva and other specimens were collected.
45615777|NCT02645409|Drug|OTL38|OTL38 is a folate analog conjugated with a fluorescent dye that emits light in the near infrared spectrum. This longer wavelength allows for deeper penetration of the fluorescent light through tissues with the potential to better image tumors beneath adipose tissue or deeper into organ parenchyma.
45615778|NCT02645409|Device|Intraoperative fluorescence imaging system|
45615779|NCT03321331|Combination Product|Lark (JITAI)|Lark works as a just-in-time adaptive intervention (JITAI), providing interactive counseling through a chat-style interface. The app prompts users to self-monitor, set goals, review them, provides feedback, and social support.
45615780|NCT03321331|Combination Product|MyFitnessPal (no JITAI)|MyFitnessPal (MFP) is a calorie counting app, which relies on user input for food tracking, but automatically tracks activity through the phone or through integrations with wearable devices. This app provides allows to set weight and caloric goals, review them and to receive feedback, but it has limited social support, a feature that is generally lacking in calorie-counting apps.
45615781|NCT03104829|Behavioral|Motivational interviewing|
45615782|NCT03104829|Drug|DSME participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later|
45615783|NCT03317197|Drug|Control Group|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) only
45615784|NCT03317197|Drug|Experimental Group 1|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle)
45615785|NCT03317197|Drug|Experimental Group 2|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
45615786|NCT03317197|Drug|Experimental Group 3|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle), Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
45615787|NCT03317041|Other|Capacitive-resistive electric transfer (Tecar) therapy|The Tecar treatment group will receive 45 minutes of Tecar therapy treatment. Subjects will lay down with the face down and two metallic plaques situated under each quadriceps muscle all over all the treatment. The treatment will start with the automatic capacitive energy transfer for 10-min where the capacitive plaque is situated on the sole of each foot with an elastic band. After that, the capacitive plaque will be pulled out. Then, the resistive electrode will be moved longitudinally through different muscles with massage lotion during 15-min per each lower extremity. The treatment will conclude with the automatic capacitive energy transfer for 10-min and the capacitive plaque situated on the sole of each foot with an elastic band.
45615788|NCT02483299|Drug|Metformin|
45615789|NCT02483299|Drug|Glucophage tablets and Victoza|
45615790|NCT01597479|Drug|Levobupivacaine|In dPNBs group, we performed ultrasound guided dPNBs on radial and median nerves using low concentration and low volume of long acting local anesthetic (0.125% levobupivacaine, 5 ml per nerve). Using low concentrations of levobupivacaine on target nerves could achieve a prolonged sensitive block in the surgical area without motor block of the hand.
45615791|NCT03316963|Drug|Neostigmine Methylsulfate|After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate with co-administration of intravenous glycopyrrolate 0.2mg. At each of 5 injection sites on the soft palate , 0.5 mL (0.5mg) of neostigmine methylsulfate will be administered, yielding a total of 2.5mg (2.5mL) of neostigmine methylsulfate. The medication will be administered using five 1 mL syringes filled with 0.5 mL neostigmine each. Following administration of neostigmine, the patient will be observed for an additional 4 minutes to examine both vibration and sound emanating from the soft palate. The anticipated time under sedation will be 14 minutes.
45615792|NCT03101943|Behavioral|Family Spirit Nurture (FSN)|The FSN intervention will be conducted over a 6-month period. Participants in the intervention group will receive 6- 45 minute lessons in their home or a private place of their choosing. The lessons focus on elimination or reduction of Sugar Sweetened Beverages (SSBs) among infants while teaching mothers complementary feeding and responsive parenting practices
45615793|NCT03101943|Other|Control Program|The control group will receive three home-based lessons with home safety information.Lessons will be delivered monthly (at 3, 4 and 5 months postpartum) in the same format as the FSN lessons, by trained FHCs in the home of the participant or in a private place of their choosing.
45615794|NCT03101943|Other|Water Delivery|Drinking water will be delivered to the household of each participant (both in the FSN intervention and control groups) from 6 to 9 months postpartum. The amount of water will be determined by the number of children and adults living in the household at the time of water delivery. The first delivery of water will occur at the time of the 6-month evaluation and the last delivery will occur at the time of the 9-month evaluation. Water will be delivered as often as weekly. Those families who do not need weekly water delivery (based on their preference and their usage of the first delivery of water) will receive water less frequently.
45615795|NCT03315481|Procedure|SAX catheter insertion|Suture-method catheter inserted in the short axis of the adductor canal
45615796|NCT03315481|Procedure|LAX catheter insertion|Suture-method catheter inserted in the long axis of the adductor canal
45615797|NCT03101865|Device|FlorenceM|The automated closed loop system (FlorenceM) will consist of: Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature. An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.
45615798|NCT02489929|Other|blood samples|This clinical study aims at correlating the values in CDA levels with the risk of drug-related toxicities and to the clinical response to azacytidine treatment for patient suffering of MDS or Myeloid leukemia
45615799|NCT02489929|Drug|azacytidine|
45615800|NCT04548141|Other|Questionnaire|Scoring of the IPAQ is performed according to references. Scoring of the SAPHIR has been submitted for copyright protection (involves a series of 23 additions)
45615801|NCT03316885|Device|Clareon® IOL|Foldable, single-piece posterior chamber IOL intended for long-term use over the lifetime of the cataract patient. This device is CE-marked (European Conformity) in the countries with participating Investigators.
45615802|NCT05154903|Drug|Citicoline 500 MG|Citicoline will be administered in continuous iv infusion in a dose of 2000 mg per day for the first week following AIS then by oral route for the next 5 weeks.
45615803|NCT03315325|Biological|Human kisspeptin-10 (metastin 45-54)|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) is a potent HPG-axis stimulator and control reproduction.
45615804|NCT02486107|Procedure|surgical procedure|
45760068|NCT03809975|Other|Current model of care|No controlled set of treatment assigned to patient. It is based totally on the discretion of the attending clinicians. It will generally contain an unspecific number of physiotherapy sessions. Other allied health involvement such as dietetics and psychological interventions will be on an ad hoc basis. In some cases, the orthopaedic surgeon may recommend for surgery.
45615805|NCT04888611|Biological|Camrelizumab plus GSC-DCV|Prior to scheduled surgery, patients need to receive Camrelizumab IV (3mg/kg, up to 200mg). After surgery, patients receive Camrelizumab IV (3mg/kg, up to 200mg) and GSC-DCV IH every 3 weeks in the absence of disease progression or unacceptable toxicity.
45615806|NCT04888611|Biological|Camrelizumab plus Placebo|Prior to scheduled surgery, patients need to receive Camrelizumab IV (3mg/kg, up to 200mg). After surgery, patients receive Camrelizumab IV (3mg/kg, up to 200mg) and Placebo IH every 3 weeks in the absence of disease progression or unacceptable toxicity.
45615807|NCT02483143|Drug|NAC|3 gr NAC was made up to 1000 ml with NS; a 1 ml/3 mgr NAC solution was obtained and 3 ml/kg NAC+NS solution was administered for 1 h before CTPA and a 1 ml/kg per hour NAC+NS solution was administered for a minimum 6 h after CTPA.
45615808|NCT02483143|Drug|NaHCO3|132 mEq NaHCO3 was made up to 1000 ml with NS; and 3 ml/kg NaHCO3+NS solution was administered for 1 h before CTPA and 1 ml/kg per hour NaHCO3+NS solution was administered for a minimum of 6 h after CTPA.
45615809|NCT02483143|Drug|Normal Saline|3 ml/kg NS was administered for 1 h before CTPA and 1 ml/kg per hour was administered for a minimum of 6 h after CTPA.
45615810|NCT04828239|Device|laser acupuncture|400 mW, near-infrared, continuous wavelength, 810 nm. about 24J/cm2
45615811|NCT04828239|Other|acupuncture|Needle type: C&G, gauge and size: 0.25x40mm
45615812|NCT04828239|Device|Sham laser acupuncture|This laser pen is the same device with a red light was pasted on the acu-points in the same way, using the same protocol as for the active laser stimulation, but the laser apparatus was not switched on.
45615813|NCT02483221|Drug|Hydromorphone|Hydromorphone is given intravenously by TCI-PCA. The TCI-PCA system steer the hydromorphone infusion pump to achieve plasma and effect-site concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma and effect-site concentration range, lockout times and infusion speed.
45615814|NCT02483221|Drug|Morphine|Morphine is given intravenously by PCA. The PCA pump administers a predefined bolus dose on patient request considering the predefined lockout time and infusion speed.
45615815|NCT02489851|Procedure|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
45615816|NCT02489851|Procedure|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
45615817|NCT04766697|Behavioral|Risk-Reduction Sessions|The 8-session intervention protocol emphasizes cognitive-behavioral interventions for anger management, conflict resolution, reducing sexual risk behavior, substance use, and enhancement of couple functioning.
45615818|NCT02485951|Procedure|Central air injection|Air was injected inside the trephination site in the central injection group.
45615819|NCT02485951|Procedure|Peripheral air injection|Air was injected at the corneal periphery outside the trephination site.
45615820|NCT03104595|Drug|EC-18|oral administration
45615821|NCT02489461|Drug|VM-1500|VM-1500 up to 96 weeks
45615822|NCT02489461|Drug|Efavirenz|Efavirenz up to 48 weeks
45615823|NCT02489461|Drug|Antiretroviral therapy (ART)|Antiretroviral therapy up to 96 weeks
45615824|NCT05129475|Drug|PF-07321332/ritonavir|Single oral dose of PF-07321332 300 mg (2 × 150 mg tablets)/ritonavir 100 mg under fed or fasted conditions at 0 hour on Day 1
45615825|NCT05129475|Drug|Ritonavir|Single oral dose of ritonavir 100 mg at -12 hours prior to PF-07321332/ritonavir dosing, and ritonavir 100 mg will be dosed at 12 hours after PF-07321332/ritonavir dosing.
45615826|NCT04762095|Other|mindfulness stress reduction program|mindfulness stress reduction program
45615827|NCT03315169|Other|External dressing|Application of external dressing whilst perianal abscess cavity heals.
45615828|NCT03315169|Other|Packing of perianal abscess cavity|Internal packing of perianal abscess cavity - standard treatment.
45615829|NCT05048043|Behavioral|Computer-assisted Behavior Intervention|"The CABI includes a serious game called ATHEMOS that is designed to help students rehearse skills that ameliorate impairments associated with ADHD, including organization, scheduling, and note taking strategies. Once students have some experience with the game, a teacher consultee will help students actively transfer skills learned in the game to real-world classroom demands."
45615830|NCT05048043|Behavioral|Challenging Horizons Program|The Challenging Horizons Program is an established psychosocial intervention package for young adolescents with ADHD, focusing on academic and behavioral impairments.
45615831|NCT02838381|Other|Additional biological samples|blood and tissue samples
45615832|NCT03104361|Biological|Platelet-Rich Plasma|Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
45615833|NCT02485795|Other|Observational|This study will evaluate the impact of genetic testing information on medical regimen plans and whether this information results in benefits to patient care.
45615834|NCT03104907|Procedure|Prostatic Artery Embolization|The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
45615835|NCT05457907|Device|Ultrasound device|Low energy ultrasound therapy will be administered to the spleen
45615836|NCT04572165|Drug|Ozempic®|Patients have been treated with commercially available Ozempic® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Ozempic® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
45615837|NCT04572165|Drug|Active Comparator|Patients have been treated with commercially available active comparators according to local label and to routine clinical practice at the discretion of the treating physician. Active comparators will include the following antidiabetic agents: sulphonylureas, sodium-glucose co-transporter 2 inhibitors, and insulin. The decision to initiate treatment with commercially available active comparators had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
45615838|NCT04572165|Drug|Rybelsus®|Patients have been treated with commercially available Rybelsus® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Rybelsus® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
45615839|NCT04569123|Device|real stimulation|Participants will undergo standardized hand task practice therapy (3 sessions/week for 6 weeks) with the watch worn on the paretic wrist. Participants will be randomized into two groups: The device will deliver vibration for the treatment group.
45615840|NCT04569123|Device|No stimulation|Participants will undergo standardized hand task practice therapy (3 sessions/week for 6 weeks) with the watch worn on the paretic wrist. Participants will be randomized into two groups: The device will deliver no vibration for the control group during therapy.
45615841|NCT04568031|Drug|AZD1222|For subjects in part 1 will have that route of Administration as Intramuscular, 5 × 1010 vp (nominal, ± 1.5 × 1010 vp) on V2
45615842|NCT04568031|Drug|0.9% (w/v) saline|For subjects in placebo will have that route of Administration as Intramuscular 0.9% (w/v) saline on V2 and V6.
45615843|NCT02489383|Other|Continuous Exercise Training|The continuous training (CT) will be held in two weekly sessions lasting total of 40 minutes and 5 minutes for heating and 5 to slowdown, and the duration will be 24 sessions (3 months). The exercise sessions will be will be performed on a stationary bicycle, with the initial intensity of 70% of VO2max. If the subject sustain continuously training intensity for 2 consecutive sessions without symptoms breathing, exercise intensity will be increased by 5% of heart rate. The patient may stop the activity if he has any symptoms or respiratory distress, returning it as soon present improvement. Throughout the training, will be monitored heart rate and the level of perception subjective effort (modified Borg scale).
45760069|NCT03836651|Other|Dietary Antioxidant (V8® Low Sodium 100% vegetable juice)|Following completion of baseline data collection, participants will be randomized to one of two groups. Participants randomized to the intervention group will receive a month's supply of the V8® 100% Low-Sodium Vegetable juice as the dietary antioxidant intervention. Participants will be asked to drink one V8® juice each day for 30 days. Each V8® juice can is 11.5 ounces and can be consumed in divided amounts or all at once. The average daily intake of lycopene is estimated to be 5mg, one can of V8 juice provides 24 mg of lycopene. Thirty days duration for the intervention of V8® juice is based on previous data that indicates plasma antioxidant concentrations rise significantly within a two-week period and a plateau effect is reached within 4 weeks.
45615844|NCT02489383|Other|Interval Exercise Training|The interval training (IT) will be held in two weekly sessions. The IT is individualized and will be performed on a stationary bicycle. Training sessions will be performed with total duration of 40 minutes consisting of 5 minutes extender, 30 minutes from the main part (IT), finishing with five minutes back to calm. In the main part (of 5 to 30 minutes), the patient will perform the exercise with high intensity in the first two weeks, the exercise will be conducted with an intensity 80% of maximum capacity obtained in cycle ergometer test and will cycle for 30 seconds followed by a 30 second recovery period. In the 3rd and 4th weeks, the intensity will be increased to 100% of the maximum obtained. After this period, the intensity will be increased by 5% charge.
45760070|NCT03836651|Other|Control group|The control group will continue to be medically managed by their health care provider as usual. The control group will have the same visit and call schedule as the intervention group.
45615845|NCT02489383|Behavioral|Education Program|The education program will discuss issues related to asthma and physical activity. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peak flow meter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
45615846|NCT02485873|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
45615847|NCT02485873|Drug|Vitamin K antagonists|As prescribed by treating physicians
45615848|NCT04847271|Behavioral|Physical activity on prescription (PAP)|The intervention in this study will comprise the 3 PAP components. Participants will take part in all components and perform one or several physical activities of their choice in accordance to the written prescription, at the prescribed frequency and duration, for a period of 4 months.
45445602|NCT02060812|Procedure|Group I, SSNB & ANB|Suprascapular nerve block (SSNB) and axillary nerve block(ANB) were performed by one anesthesiologist under sono-guidance. 23 gauge spinal needle was used. SSNB was done at first and the entry site was the mid point between an anterolateral angle of acromion and medial end of scapular spine. With the linear probe, the suprascapular notch was identified and the block was performed penetrating the transverse scapular ligament because the scapular nerve and artery were located at the suprascapular notch. Just after the SSNB, ANB was performed and the entry site was the point 1.5 cm medial and 2cm inferior to posterolateral angle of acromion. With the linear probe, posterior circumflex artery was identified and the block was done at just above the artery.
45760071|NCT05743439|Behavioral|Early Augmentative and Alternative Communication (AAC) Intervention|Caregivers will receive 24, 50 min intervention sessions twice a week for three months. During each intervention session, the therapist provides instruction and coaching on using AAC and a set of evidence-based language support strategies. Strategies are taught sequentially in three phases: (1) Responding to all Communication, (2) Teaching Words, and (3) Creating Communication Opportunities. Caregivers practice using the AAC intervention strategies during three, five-minute routines with their children. Therapists coach the caregiver on using the targeted strategies during these routines, encouraging caregivers to reflect on their implementation, and developing a plan to use the AAC strategies during activities not practiced during the intervention session. The AAC intervention is provided to families using an evidence-based service delivery model, Family Guided Routines Based Intervention.
45760072|NCT02037555|Biological|AT-III (Human)|AT-III (Human) is an antithrombin concentrate prepared from pooled human plasma. AT-III (Human) is provided as a freeze-dried preparation for intravenous use. The AT-III (Human) preparation is reconstituted in 10 or 20 mL of sterile water for injection prior to intravenous administration.
45760073|NCT02037555|Other|Placebo|0.9% Sodium Chloride for Injection, United States Pharmacopeia
45760074|NCT03809819|Procedure|laparoscopic Vecchietti vaginoplasty|Patients who underwent laparoscopic Vecchietti vaginoplasty
45615849|NCT02485639|Biological|Influenza Virus Vaccine Inactivated|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. All participants will receive vaccine IM on day 1.
45760075|NCT03809819|Diagnostic Test|FSFI questionnaire|Completion of FSFI questionnaire
45760076|NCT03809819|Diagnostic Test|UDI-6 questionnaire|Completion of UDI-6 questionnaire
45760077|NCT03809819|Diagnostic Test|IIQ-7 questionnaire|Completion of IIQ-7 questionnaire
45760078|NCT03804359|Drug|Rituximab|"In the personalized arm, the patient will be treated in function of the CysR activity result during the inclusion visit."
45760079|NCT05743361|Diagnostic Test|Blood sampling|Detection of ANA, AMA, anti-dsDNA, anti-ENA, anti-MPO, anti-PR3, aPL, RF, ACPA, anti- TPO, anti-TG
45615850|NCT04412421|Procedure|Gastric Bypass, Sleeve Gastrectomy|Lifelong vitamin and Mineral supplementation
45760080|NCT02369211|Drug|Acetaminophen (Ofirmev)|The patient was administered IV Ofirmev during anesthesia and then 3 more IV doses (1g each) every 6 hours up to 24 hrs.
45760081|NCT02369211|Other|Placebo|The patient was administered IV Placebo during anesthesia and then 3 more doses of IV Placebo every 6 hours up to 24 hrs.
45760082|NCT03804281|Procedure|Test group|The surgery will be done with the use of 4x magnification loop, the knives are micro blades and micro-sutures 7//0 used with the microsurgical instruments kit
45760083|NCT03804281|Procedure|Control group|esthetic crown lengthening with conventional approach with an internal bevel incision, following CEJ anatomy, this will be followed by an intra-sulcular incision, removal of the strip of outlined marginal gingiva and elevation of a mucoperiosteal ﬂap to the level of the alveolar bone crest.
45760084|NCT00759161|Drug|AN2728|AN2728 Ointment, 5%, twice daily for 4 weeks
45760085|NCT00759161|Drug|AN2728 Ointment Vehicle|AN2728 Ointment Vehicle, twice daily for 4 weeks.
45760086|NCT02038023|Drug|Intravaneous iron(low molecular weight iron dextran)|1000 mg of Iron dextran administered over one hour
45760087|NCT04384133|Diagnostic Test|Impulse oscillometry|Impulse oscillometry is a pulmonary function test. During the test, the participant is told to breathe normally.
45615851|NCT02483065|Other|mortality at discharge and 3-months after the admission in patients with and without dementia|Patients diagnosed of dementia who ingresed the hospital were informed of the goals of the study and invited to voluntarily participate. In order to take part in the study, patients were required to provide informed consent. All participants were first screened with the Alzheimer's Disease Test. A diagnosis of dementia was generated by an independent clinician experienced in old age psychiatry using a structured clinical assessment based on operationalized DSM-IV criteria. Clinical data were gathered from hospital notes. Information on sociodemographic data, premorbid basic and instrumental activities of daily living, quality of life and burden of the caregiver was gathered from carers and review of hospital notes. In both cohorts, participants were telephoned 3 months after hospital admission to respond the follow-up questionnaires. Patients who decided not to answer them were considered lost to follow-up. All information was kept confidential.
45760088|NCT04384133|Diagnostic Test|Spirometric pulmonary function test|In the spirometric pulmonary function test, the participant is asked to perform respiratory maneuvers such as breathing deeply.
45615852|NCT03104127|Device|Alter G Bionic Leg|Participants are randomized to a 10 week, community-based bionic leg programme. Participants must use the leg for a minimum of 1 hour per day and continue to have active physical therapy sessions.
45615853|NCT03104127|Other|Normal therapy (physiotherapy)|Participants are randomized to a normal therapy (physiotherapy) only program. Participants are also advised to undertake 1 hour a day of physical activity and have active physical therapy (physiotherapy) sessions.
45615854|NCT03316729|Drug|DS-9231|DS-9231 in saline solution for intravenous infusion
45615855|NCT03316729|Drug|Placebo|Placebo is matching saline solution for intravenous infusion
45615856|NCT04758741|Behavioral|Acceptance and Commitment Therapy|Investigating the impact of Acceptance and Commitment Therapy on Resiliency in women affected by domestic violence
45615857|NCT04758741|Other|placebo|This rct has one arm and health education is done only for the purpose of blinding the study so that the participant does not know which of the control or intervention groups it is in and has no comparative aspect and has nothing to do with resilience
45615858|NCT03315091|Drug|Treatment A - AZD1775 administered under fasted conditions|Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules. Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fasted conditions. The drug class of AZD1775 is Wee-1 kinase inhibitor.
45615859|NCT03315091|Drug|Treatment B - AZD1775 administered under fed conditions.|"Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules.~Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fed conditions.~The drug class of AZD1775 is Wee-1 kinase inhibitor."
45615860|NCT04666467|Device|Transcatheter mitral valve repair|Transvenous approach with a transeptal puncture to place the study device
45615861|NCT02482987|Device|dense polytetrafluoroethylene (dPTFE) membrane Cytoplast|ridge preservation intervention using the dPTFE membrane device
45760089|NCT04384133|Diagnostic Test|Fractional exhaled nitric oxide (FENO) test|In the FENO test, the participant is asked to perform respiratory maneuvers such as breathing deeply.
45760090|NCT04384133|Diagnostic Test|Thorax Computed Tomography|Computed tomography is a radiological examination.
45445603|NCT02060812|Procedure|Group II, SSNB alone|This is same as the Group I, SSNB & ANB, but ANB was performed with placebo(10mL normal saline).
45760091|NCT04384133|Diagnostic Test|Chest X Ray|Chest X ray is a radiological examination.
45760092|NCT04384133|Diagnostic Test|Blood eosinophil level|A tube of blood will be drawn from the participant.
45445604|NCT04445558|Dietary Supplement|oral nutritional supplementation|Adjunction of oral nutritional supplementation
45445605|NCT04445558|Dietary Supplement|intradialytic parenteral nutrition|Adjunction of intradialytic parenteral nutrition
45445606|NCT05654272|Diagnostic Test|MRI|Cardiac MRI
45615862|NCT02482987|Device|human amniotic-tissue derived membrane BioXclude|ridge preservation intervention using the dPTFE membrane device
45615863|NCT02482987|Procedure|Ridge Preservation with overlay graft|ridge preservation intervention with additional freeze dried bone allograft (FDBA) placed buccal to the socket
45615864|NCT02482987|Procedure|Ridge Preservation without overlay graft|ridge preservation without overlay graft / traditional FDBA placement into the socket only
45615865|NCT04519203|Device|SPI|Either standard monitoring alone or added with SPI
45615866|NCT04519203|Device|Standard|Standard monitoring alone
45615867|NCT02482909|Procedure|Hepatic resection|Anatomical surgical resection of the liver including the tumor
45615868|NCT02482909|Procedure|Radiofrequency ablation|Percutaneous ablation using radiofrequency under the imaging guidance
45615869|NCT04475055|Diagnostic Test|Diagnostisches Interview bei psychischen Störungen (DIPS)|The DIPS is a structured interview which assesses the most frequent psychological disorders. It can be delivered by trained clinicians and takes between 50-120 minutes. Its acceptance with patients is very good.
45615870|NCT02482831|Procedure|Subgluteal sciatic nerve block|All patients (either diabetic or non-diabetic patients) received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml.
45760093|NCT04384133|Other|CAT|It consists of 8 questions.
45760094|NCT04384133|Other|mMRC|It is the scale used to measure the severity of shortness of breath.
45760095|NCT02038179|Drug|Allopurinol|Participants who received allopurinol as urate lowering therapy, at a daily dose of 300 mg once daily by mouth for a 4 week duration.
45760096|NCT02038179|Drug|Placebo|Participants who received placebo tablet (matching Allopurinol 300 mg) daily by mouth for a 4 week duration.
45760097|NCT00768287|Biological|IB1001|Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa; Study Part 2: Non-randomized, open-label evaluation of prophylaxis and on demand IB1001; Surgical Sub-study: Open-label evaluation of IB1001 during major surgery
45615871|NCT02489149|Other|Multi-sector interventions|"Multi-sector interventions to enhance food security: Agricultural interventions are matched with field training for government sectors working with quilombolas communities on best agronomic practices to promote technical assistance for this communities. Stimulate the participation in the Program of Food Acquisition, supporting quilombolas agriculture.~For quilombolas participants: nutritional counseling based on traditional healthy cooking practices, using traditional recipes.~For health professionals: to strengthen food and nutrition actions at all levels of health care. Food and nutritional education training for primary care health professionals.~Helping families to have more knowledge about your citizen rights."
45615872|NCT02489149|Other|Control|Placebo Comparator: Conventional approach of current public food and nutrition policies.
45615873|NCT03321175|Other|subcutaneous saline irrigation|200 cc saline irrigation
45615874|NCT04644003|Drug|STP1|STP1 is a combination of two drugs, a PDE inhibitor and an NKCC1 inhibitor
45615875|NCT04644003|Drug|Placebo|Placebo medication (capsule and tablet) identical in appearance to active medication
45615876|NCT04554927|Other|WEB-Application|The patients of the Web-application arm will be trained on the devices and the application will be installed either on their smartphone or on another support (computer, tablet).
45615877|NCT04554927|Other|Standard accompaniment|Personalized schedule of medical follow-up given to the patient
45615878|NCT03316651|Drug|GM-CSF|"After the patients were randomly divided into two groups, they will receive whole lung lavage (WLL), and then one of the two groups with continue the next step as follows:~Induction period: The time of beginning is 1 week after whole lung lavage, aerosolized GM-CSF was given for 7 days (150ug bid), and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle, a total of 6 cycles (3 months) were known as the induction period.~Maintenance period: maintenance period came up after the induction period. The dose of aerosolized GM-CSF was reduced to 150ug/d for three times a week, and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle and maintenance period lasted for 9 months."
45615879|NCT03315013|Procedure|SLATE II|The SLATE II algorithm is a series of questions and procedures that allow a study clinician to determine if antiretroviral therapy for HIV can be started immediately (same-day) or if additional care or services are needed before ART initiation.
45615880|NCT02485405|Other|Trier social stress test|Volunteers perform Trier social stress test
45760098|NCT00768287|Biological|nonacog alfa|Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa
45615881|NCT02489071|Behavioral|Brain Training Program|
45615882|NCT02489071|Behavioral|Brain Health Program|
45760099|NCT02369835|Drug|Dakin's solution|Apply modified Dakin's solution (0.005 to 0.01%) topically
45760100|NCT02369835|Other|Placebo|Applied topically
45760101|NCT00768521|Drug|tolterodine tartrate|"Part I: tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose tolterodine tartrate 4 mg capsule"
45615883|NCT02488993|Other|Prospective Phase Rifaximin-α 550mg|Prospective data collection of all patients receiving rifaximin-α 550 mg from the point of study entry.
45615884|NCT02488993|Other|Prospective Phase No Rifaximin-α 550mg|Prospective data collection of all patients not receiving rifaximin-α 550 mg from the point of study entry.
45615885|NCT02488993|Other|Retrospective Phase|Review of medical records and electronic hospital admissions data for patients with HE who have not received rifaximin-α 550 mg during the previous 12 months.
45615886|NCT03316495|Behavioral|PAMPHLET|EXPOSURE TO PAMPHLETS
45615887|NCT03320863|Device|Enso device|An active Enso device that delivers neuromodulation therapy.
45615888|NCT02485327|Drug|Technosphere Insulin SAR439065 Afrezza®|"Pharmaceutical form: dry powder~Route of administration: oral inhalation"
45615889|NCT03314701|Device|Biphasic Intermittent Positive Airway Pressure (BIPAP)|"Following endotracheal intubation BIPAP mode will be started with:~Inspiratory positive airway pressure [IPAP] at 20 cmH2O~Expiratory positive airway pressure [EPAP] at 5 cmH2O~PRESSURE SUPPORT is difference between these two pressures [IPAP]- [EPAP]~Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed"
45760102|NCT00768521|Drug|Comparator: Placebo to tolterodine tartrate|"Part I: placebo to tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: placebo to tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose placebo to tolterodine tartrate 4 mg capsule"
45760103|NCT02038569|Drug|LEO 80185 gel|
45760104|NCT00768599|Drug|Econazole Nitrate Cream 1%|Topical cream, applied once daily for 4 weeks.
45760105|NCT00768599|Drug|Econazole Nitrate Foam 1%|Topical foam, applied once daily for 4 weeks.
45760106|NCT00768599|Drug|Vehicle Foam|Topical foam, applied once daily for 4 weeks.
45760107|NCT03804203|Radiation|standard treatment|3000 cGy in 10 daily fractions
45760108|NCT03804203|Radiation|short course treatment|2000 cGy in 4 fractions administered twice a day
45760109|NCT03803891|Procedure|Endoscopic full-thickness resection|Endoscopic full-thickness resection (EFTR) with Over-The-Scope-Clip in colorectal lesions
45760110|NCT02370693|Drug|Bortezomib|Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
45615890|NCT03314701|Device|Airway Pressure Release Ventilation (APRV)|"high airway pressure (Phigh) will be set at 20 cmH2O~low airway pressure ( Plow) will be set at 5 cmH2O~the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min~T high at 4.5-6 seconds~T low at 0.5 to 0.8 second"
45615891|NCT02485249|Drug|Dexamethasone Phosphate Ophthalmic|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
45760111|NCT02370693|Drug|Placebo|Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
45760112|NCT02370693|Drug|Mycophenolate mofetil|Mycophenolate mofetil 1.5 g twice a day orally for 24 weeks
45760113|NCT03809507|Other|Qualtrics survey questions|"Qualtrics Survey:~For each of the scenarios, practitioners will be asked whether opioids are prescribed or not, and the type(s) of other analgesic medications that would be prescribed, the strength in mg, and the number of doses for each medication"
45615892|NCT02482441|Drug|OMP-131R10|There are 5 planned dose cohorts of OMP-131R10. Dose escalation will follow a traditional 3+3 framework. Treatment will be continued until progressive disease or unacceptable toxicity.
45615893|NCT02482441|Drug|FOLFIRI|Treatment will consist of OMP-131R10 and the FOLFIRI chemotherapy regimen.
45615894|NCT03320707|Drug|Daratumumab|Single SC dose of daratumumab will be administered in each of 8 dose cohorts.
45760114|NCT02039115|Drug|prednisone|6 weeks of prednisone and placebo therapy will be given over 6 weeks after both the first and second stage complete Barretts Excision.
45760115|NCT02039115|Drug|placebo|6 weeks of placebo therapy will be given in the same manner as the prednisone arm after the first and second stage complete Barretts excision.
45760116|NCT00759473|Drug|D-Cycloserine (DCS)|50 mg d-cycloserine or placebo taken orally
45760117|NCT00759473|Drug|Placebo|
45760118|NCT02371395|Other|Realtime amplification (RealAmp)|Molecular assay for the diagnosis of malaria.
45615895|NCT03320707|Drug|Placebo|Placebo liquid will be administered as SC dose in each of first 7 dose cohorts.
45615896|NCT03320707|Drug|rHuPH20|Participants in Cohort 8 will receive single SC dose of rHuPH20 as a part of daratumumab formulation.
45615897|NCT02485093|Device|Septal ventricular pacing|Ventricular pacing must be at least 90%, from the septum and with optimized AV delay
45615898|NCT02485093|Device|VIP|Ventricular pacing must be less than 10%.
45615899|NCT03320629|Combination Product|apatinib S-1 radiotherapy|apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
45760119|NCT00759707|Drug|L-N^G monomethyl arginine (L-NMMA)|L-NMMA was infused at a dose of 1 mg/kg over 10 minutes to competitively inhibit the production of nitric oxide. Ultrasound imaging of the saphenous vein [arterial] bypass at baseline, and following an ischemic stimulus, administration of sublingual nitroglycerin, and intravenous administration of L-NMMA.
45760120|NCT02039817|Drug|IDN-6556|
45760121|NCT04275089|Device|Reia Vaginal Pessary|Reia Vaginal Pessary
45760122|NCT05743049|Other|Obtaining blood for analysis of various circulating biomarkers|4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period
45760123|NCT02371785|Device|CorPath 200 System|Remote delivery of guide wires and balloon catheters for use in percutaneous vascular interventions (PVI).
45760124|NCT03809273|Drug|Yangxinshi|Yangxinshi pill 3 pills /tid
45760125|NCT03809273|Drug|Trimetazidine|Trimetazidine 20mg/tid
45760126|NCT03809273|Drug|Yangxinshi mimic|Yangxinshi mimic tablets 3 pills /tid
45760127|NCT03809273|Drug|Trimetazidine mimic|Trimetazidine mimic tablets 20mg/tid
45760128|NCT02372097|Drug|SYR-472|SYR-472 25mg, 50mg
45760129|NCT05742971|Device|Virtual reality intervention performed through the Oculuc Go VR glasses|The participants randomised into this group are offered a VR intervention during the external version for 5-10 minutes in addition to the standard care of an ECV. The VR is performed through the Oculus Go VR glasses. These women can choose for an immersive guided relaxation VR experience or an interactive VR experience (see descriptions below). The ECV expert executing the ECV will register immediately after the ECV which option the patients has chosen. Immediately after the external version, a pain measurement is taken with regard to the pain during the ECV by means of the NRS score. After the ECV procedure, participants of the VR-group receive a structured questionnaire in which tolerability, feasibility and satisfaction of VR use is evaluated.
45760130|NCT04384991|Drug|HU007|Cyclosporine 0.02% with Trehalose 3%
45760131|NCT04384991|Drug|Restasis eye drop|Cyclosporine 0.05%
45445607|NCT03763071|Other|Patient-reported scales to measure sleep disorders|"Patient-reported scales to measure sleep disorders include below mentioned scales:~Pittsburgh Sleep Quality Index; measures the quality of sleep Berlin Questionnaire; measures the obstructive sleep apnea Stop-Bang questionnaire; measures the obstructive sleep apnea Insomnia Severity Index; measures the insomnia and related parameters"
45615900|NCT03320629|Combination Product|S-1 radiotherapy|S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
45615901|NCT02488525|Drug|Prophylactic treatment with Wilfactin|Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
45615902|NCT03314623|Behavioral|Weight bearing as tolerated|If fracture is deemed stable the subjects will be allowed to weight bear immediately after surgery.
45615903|NCT02482597|Device|Whole Body Periodic Acceleration|A bed that translates back and forth at different frequencies while the subject lies supine
45615904|NCT02482363|Radiation|UVA radiation|20 minutes of low dose UVA from a phototherapy unit
45615905|NCT02482363|Radiation|Sham Control|20 minutes of sham control exposure
45615906|NCT03314545|Procedure|laminate veneer with coronal post|laminate veneer with coronal post
45615907|NCT03314545|Procedure|post,core and crown|post,core and crown
45615908|NCT03316417|Other|Renal Tolerance to Immunotherapy|The main objective is to describe the renal tolerance of these innovative therapies within a population homogeneous of patients.
45760132|NCT05742893|Diagnostic Test|Measurement of pragmatic and discourse test scores in the two scales.|The aim of this study is to compare the effectiveness of a newly developed speech-language assessment tool for pragmatic and discourse skills for patients suffering from schizophrenia .
45760133|NCT00354627|Drug|TMC125|200 mg b.i.d. till commercially available.
45615909|NCT02482207|Drug|Rosuvastatin|
45760134|NCT03803501|Other|condensed functional restoration program|The condensed functional restoration program (CFRP) is a complex multidisciplinary intervention proposed as usual care according to international guidelines. The program takes place in our department of rheumatology, 6 hours per day, 1 day a week, for 4 weeks. Patients are included during consultation or Hospitalisation and are in groups of 6 maximum per FRP. The CRFP was developed on the basis of therapeutic patient education programs and physical exercises (Van Wambeke 2017, Desthieux 2014). Three hours per day are devoted to physical exercises which were divided into three periods: warming, stretching, and muscular strengthening. Specific exercises adapted to work circumstances (like manutention) are taught. Muscular strengthening is based on isotonic contraction on fitness devices. Education is based on 1 hour long educative session adapted from back school programs once a week. Educative booklets are also given to the patients.
45760135|NCT05742815|Other|No intervention|This is an observational collection of data from purchased donor milk samples
45615910|NCT02482207|Behavioral|Life style modification|
45615911|NCT02485171|Device|SAFEWALKER|Medical device walking aids.
45760136|NCT00770861|Drug|Nebivolol|Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets , oral administration Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
45615912|NCT05534191|Other|Experimental, comparator and control|"To quantify the effect of a strength intervention for footballers on improved range of motion, balance, speed, jump height, and technical football skills compared to a training group from the Danish football strength and conditioning concept Fodboldperformance and a control group."
45615913|NCT02480179|Device|H.E.G. (hematoencephalography) based neurofeedback|H.E.G. is a relatively new neurofeedback technique which, similar to fMRI is based on differential oxygenated blood supply according to regional brain activity.
45615914|NCT02480101|Biological|H7N9 live influenza vaccine|H7N9 live influenza vaccine
45615915|NCT02480101|Biological|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers
45760137|NCT00770861|Drug|Placebo|Matching placebo tablets, oral administration
45615916|NCT02476981|Drug|Remifentanil|Patients given remifentanil received continuous infusion of the drug at 1-5 µg/kg/h
45760138|NCT03808805|Drug|Aprepitant 80 mg|oral therapy - daily dose - 14 days
45760139|NCT03808805|Drug|Hydroxyzine 25mg|oral therapy - daily dose - 14 days
45760140|NCT03808805|Drug|Placebo of Hydroxyzine|oral therapy - daily dose - 14 days
45760141|NCT03808805|Drug|Placebo of Aprepitant|oral therapy - daily dose - 14 days
45760142|NCT05717829|Procedure|Modified hip capsular incision|modified incision to make re -suturing of the capsule easier with multiple stitches.
45760143|NCT00355173|Device|Lubo cervical collar|
45760144|NCT03803267|Other|Erector spinae plane block|For each side, the eighth thoracic transverse process will be identified by a linear US transducer (HFL38_10-5 MHz), puncture will be performed in the plane in the craniocaudal direction until the needle contacts the transverse process, and 20 ml of bupivacaine 0.25% and 4 mg dexamethasone will be injected visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesirable motor weakness will be recorded as a side effect.
45760145|NCT03803267|Other|Quadratus lumborum block|For each side, shamrock sign with three leaves (psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process of the L4 vertebral body) will be identified by a curved array US transducer (6-2MHz), puncture will be performed in-plane, the needle will be advanced through the quadratus lumborum muscle penetrating the ventral proper fascia of the quadratus lumborum muscle, and 20 mL of bupivacaine 0.25% and 4 mg dexamethasone will be injected in that space visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesired motor weakness will be recorded as a side effect
45760146|NCT03803267|Drug|Propofol|Propofol (2 mg/kg)
45615917|NCT02476981|Drug|Dexmedetomidine|Patients receiving dexmedetomidine were given that drug at 0.3-0.4 µg/kg over 10 min, followed by continuous infusion of 0.2 1 µg/kg/h
45615918|NCT02476981|Drug|midazolam|All patients were premedicated with midazolam 0.02 mg/kg before induction.
45615919|NCT02476981|Drug|propofol|All patients in both groups received a bolus dose of propofol 0.3 mg/kg for sedative effect.
45615920|NCT02476981|Drug|ephedrine|Ephedrine 5 mg was injected when systolic blood pressure decreased below 90 mmHg
45615921|NCT04248465|Drug|Placebo|Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
45615922|NCT04248465|Biological|Ravulizumab|Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
45615923|NCT02480335|Drug|bosentan|62.5 mg oral twice daily for 4 weeks, then 125 mg oral twice daily.
45615924|NCT05456269|Drug|Bisantrene Dihydrochloride (high dose)|Induction monotherapy cycle: IV bisantrene daily on Days 1 to 7, starting at 250 mg/m2 then adjusted to either 275 mg/m2 or 225 mg/m2 based on confirmed dose (Run-in) Consolidation combination cycle/s: IV bisantrene daily on Days 1 to 2
45615925|NCT05456269|Drug|Bisantrene Dihydrochloride (low dose)|IV bisantrene at escalating doses for 3 dose levels of 50, 65, 85 mg/m2 on Days 3 and 5 until Maximum tolerated dose (MTD) reached.
45615926|NCT05456269|Drug|Cytarabine Hydrochloride|Consolidation cycles: continuous IV cytarabine (100mg/m2) on Days 1 to 5
45615927|NCT05456269|Drug|Decitabine and cedazuridine|PO fixed-dose decitabine/cedazuridine 35/100 mg tablet daily for 5 days (Days 1 to 5), 1 hour prior bisantrene infusion
45615928|NCT05245383|Other|ten products (S01~S10) and two blank (BK1, BK2)|"S01 Functional Peptides Recovering Essence EX S02 Advanced Revitalizing Eye Cream S03 Advanced Revitalizing Lotion S04 NB-1 Anti-Sensitive Repair Activator S05 NB-1 Anti-Sensitive Repair Toning Extract S06 Ginseng Vitality Serum S07 Ginseng Revitalizing Age-defense Essence Cream S08 Ginseng Age-defense Eye Cream S09 Revital Energy Balance Gel S10 Revital Energy Tightening Body Lotion BK1 Water BK2 Blank ten products and two blank, 24 hours single application patch test on the back."
45760147|NCT03803267|Drug|Fentanyl NCS|Fentanyl (1µg/Kg)
45760148|NCT03803267|Drug|Atracurium Injectable Product|atracurium (0.5mg/kg)
45615929|NCT03314467|Diagnostic Test|polysomnography|"classical polysomnography~non invasive measurement of blood pressure~blood test: determination of HbA1c, glucose, C-peptide, hemoglobin, white blood cell count, trombocytes"
45615930|NCT05245305|Other|Mindfulness Based Stress Reduction Program|The intervention was structured as 11 weeks, taking into account the group. The program takes 2-2.5 hours per week. The program includes raisin exercise, body scanning meditation, breath awareness meditation, sitting meditation, mindfull movement, walking meditation, vision meditation, compassion meditation,mindfulness communication and day of silence.
45615931|NCT02481973|Other|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy prescribed according to their characteristic symptoms.
45615932|NCT02479945|Other|Obtaining biospecimen|
45615933|NCT02476825|Drug|Fluticasone propionate|Flixotide Accuhaler 500 micrograms b.i.d.
45615934|NCT02476825|Device|Accuhaler|Flixotide Accuhaler 500 micrograms b.i.d.
45615935|NCT05245227|Drug|Sublingual Misoprostol|Misoprostol 400 mcg sublingual
45760149|NCT03803267|Other|Endotracheal intubation|endotracheal intubation
45760150|NCT03803267|Drug|Anesthesia Maintenance|Inhalational isoflurane in oxygen/air mixture
45760151|NCT03803267|Drug|Muscle Relaxation|atracurium boluses (0.2 mg/Kg/20 minutes) will be used for maintenance of general anesthesia
45760152|NCT02041221|Drug|SPARC1316 Dose 1|The subjects will receive SPARC1316.
45760153|NCT02041221|Drug|Placebo|
45615936|NCT05245227|Drug|IV Oxytocin|40 units IV Oxytocin in 1000 mL normal saline
45615937|NCT02479867|Drug|Cefadroxil|1 tablet from test vs 1 tablet from reference
45760154|NCT02041221|Drug|SPARC1316 Dose 2|
45760155|NCT02041221|Drug|SPARC1316 Dose 3|
45760156|NCT02041221|Drug|SPARC1316 Dose 4|
45760157|NCT02041221|Drug|SPARC1316 Dose 5|
45615938|NCT05245149|Diagnostic Test|Cardiac CTA on a photon-counting detector CT (PCD-CT)|Cardiac CTA will be performed on a dual-source photon-counting CT
45615939|NCT05245149|Diagnostic Test|Cardiac CTA on a regular CT with Energy-Integrating Detector (EID-CT)|Cardiac CTA was performed on a dual-source CT with regular energy-integrating detector (EID-CT)
45760158|NCT02041377|Device|Karajishi TS Investigational Blood Glucose Monitoring System|Subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi TS Investigational Blood Glucose Monitoring System with no training. All BG results were compared to reference method results obtained from subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
45760159|NCT00787943|Drug|Topical benzoyl peroxide 10.0% cream - Formulation 1|Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
45760160|NCT00787943|Drug|Topical benzoyl peroxide 10.0% cream - Formulation 2|Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
45760161|NCT00354705|Behavioral|Questionnaire|Two questionnaires taking 30 minutes to complete.
45760162|NCT03803033|Other|Clinical pharmacy-based home medication management review service|A baseline interview by the clinical pharmacist was conducted with patients at their homes to assess their use of treatment and to collect all relevant information needed to identify TRPs. Upon TRP identification at baseline, the clinical pharmacist generated a written report of findings and recommendations, which was delivered directly to the patient's physician in a sealed envelope. Patients were asked to refer back to their physicians if they required confirmation of any changes in treatment. Physicians maintained the blinding of patients with regard to whether changes were based on recommendations by the pharmacist. In both the intervention and the control groups, the clinical pharmacist performed a follow-up interview with patients 3 months after the initial interview, during a regular follow-up visit to their physician at the hospital. Assessments in the follow-up interview, regardless of the study group, involved changes in treatment and number of TRPs.
45760163|NCT05717751|Procedure|surgical staging|para-aortic lymphadenectomy from the inferior mesenteric artery cranially to the aorta caudally via laparoscopy or laparotomy
45615940|NCT04533399|Biological|SARS-CoV-2 rS/Matrix-M1 Adjuvant|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.
45760164|NCT00771173|Drug|phenazopyridine HCl|Phenazopyrdine HCl 200 mg q8h x 24
45445608|NCT03768609|Drug|Pimodivir|Participants will be administered pimodivir 600 mg orally as two tablets of 300 mg each.
45445609|NCT03768609|Drug|Cyclosporine|Participants will be administered cyclosporine 400 mg orally as 4 capsules of 100 mg each.
45445610|NCT03269552|Drug|Carfilzomib|Given IV
45615941|NCT04533399|Other|Placebo|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.
45615942|NCT03314389|Device|Cochet bonnet esthesiometer|Cochet bonnet esthesiometer- To examine sensation
45615943|NCT02476591|Behavioral|Charge Transparency|"Providers caring for patients in the Charge Transparency cohort will be given access to patient specific charge data on a daily basis via an interactive dashboard which allows for full charge transparency to patients admitted to the Vanderbilt ICUs"
45615944|NCT02476747|Other|EMR|performing EMR for patients with small polyp
45615945|NCT02476747|Other|CSP|performing CSP for patients with small polyp
45615946|NCT05244837|Drug|Tislelizumab 200 mg|Tislelizumab 200mg IV Q3W + Followed by adjuvant treatment for 1 year (Tislelizumab 200 mg IV Q3W for 2 cycles and Tislelizumab 200 mg Q4W for 12 cycles)
45615947|NCT05244837|Drug|Carboplatin AUC 5|Carboplatin AUC 5 IV Q3W
45615948|NCT05244837|Drug|pemetrexed 500mg/m2|Pemetrexed 500mg/m2 IV Q3W if non-squamous lung cancer
45615949|NCT05244837|Drug|Paclitaxel 175mg/m2|Paclitaxel 175mg/m2 IV Q3W if squamous lung cancer
45615950|NCT05244837|Drug|Nab-paclitaxel 260 mg/m2|nab-paclitaxel 260 mg/m2 Q3W if squamous lung cancer
45615951|NCT03103893|Drug|Rapamycin|topical formulation
45615952|NCT05497375|Diagnostic Test|The amount of intraoperative bleeding|Total amount of intraoperative bleeding will be calculated in milliliters after the end of surgery.
45615953|NCT05497375|Diagnostic Test|Quality of the intraoperative surgical field|Quality of the intraoperative surgical field will be measured on a grade of 0-10 (0-1. no bleeding, 2-3. mild bleeding, 4-5. Mild to moderate bleeding, 6-7. moderate bleeding, 8-9. moderate to severe bleeding, 10. Severe bleeding)
45615954|NCT05497375|Diagnostic Test|Surgeon Satisfaction|Surgeon Satisfaction will be measured on a grade of 0-5 (1= very bad, 2= bad, 3= moderate, 4= good, 5= very good).
45615955|NCT05497375|Diagnostic Test|Heart rate|From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
45615956|NCT05497375|Diagnostic Test|Mean arterial pressure|From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
45615957|NCT05497375|Diagnostic Test|Peripheral oxygen saturation|From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
45615958|NCT05244759|Drug|[14C]-BLU-5937|Each subject will receive a single oral administration of [14C]-BLU-5937 capsule, in the fasted state.
45615959|NCT03314311|Behavioral|Rehabilitation programme|The RESTORE trial is a 12 week multi-disciplinary intervention involving exercise, nutrition advice and education sessions
45615960|NCT04281225|Behavioral|Attention to Variability (ATV)|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and behavior that occur throughout the day, and to notice changes they experience with their hearing loss symptoms; noticing if it is better or worse and to ask why it may be.
45615961|NCT04281225|Other|Placebo|Participants are told that the device they will be testing will improve their hearing, when in fact the device is not a hearing aid but just a metallic earring.
45615962|NCT02481661|Procedure|segmentectomy|segmentectomy in Arm I and lobectomy in Arm II
45615963|NCT05244603|Behavioral|Ideal binary mask|Speech in noise processed by ideal binary mask to reduce background noise
45615964|NCT05714293|Radiation|CT scan with contrast medium|Multislice CT scan (if possible retrospectively EKG-gated) with contrast medium injection of nonionic contrast agent. All CT datasets will be analysed for the qualitative and quantitative assessment of the aortic root. The coronary height will be assessed at baseline in relation to the aortic annulus and in relation to the stent of the bioprostheses after aortic valve replacement.
45615965|NCT03103815|Drug|Amivita|In each course, Amivita solution (500ml) will be administrated i.v. once daily for 4 weeks. After an interval of 2 weeks, the participants will be treated again. A total of 7 courses will be given,
45615966|NCT02479789|Drug|Lidocaine|
45445611|NCT03269552|Other|Laboratory Biomarker Analysis|Correlative studies
45615967|NCT02479789|Drug|Placebo|
45615968|NCT03103737|Behavioral|Virtual Reality (VR) and Reminiscence Intervention|First and third sessions are dedicated to remember positive and meaningful personal experiences. Second and fourth sessions are oriented to positive emotions by the use of VR. Participants can choose the virtual environment to work with.
45615969|NCT04266639|Device|Remote Ischemic Conditioning|RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion
45615970|NCT04266639|Device|Sham Remote Ischemic Conditioning|Sham Comparator (Sham-RIC)
45615971|NCT05374681|Other|Medical treatment|Medical treatment alone
45615972|NCT05374681|Other|Surgical treatment|Surgical treatment alone
45615973|NCT05374681|Other|embolization of the MMA|The middle meningeal artery will be catheterized then embolized by cyanoacrylates until the occlusion of the MMA.
45615974|NCT02481895|Behavioral|E-neurocognitive module|The experimental group will take part of a 12-week extension with a total of 36 hours training with the e-neurocognitive module tailored for bipolar patients
45615975|NCT02481739|Other|retrospective study|
45615976|NCT02643693|Other|P3L|"Ad libitum use for a maximum of three hours.~P3L delivers, on average, 80 µg of nicotine per puff under Health Canada Intense smoking regime."
45615977|NCT02643693|Other|VUSE|"Ad libitum use for a maximum of three hours.~VUSE delivers, on average, 80 µg of nicotine per puff based on the CORESTA e-cigarette recommended smoking regime."
45615978|NCT02643693|Other|CC|Ad libitum use of the subject's own brand of non-menthol CC for a maximum of three hours.
45615979|NCT05361733|Drug|XFB-19|XFB-19 is a first-in-class synthetic tetra-peptide (Acetyl-Lys-D-Ala-D-Val-Asp-NH2) that inhibits the activation of the human CCAAT-enhancer binding protein beta (C/EBPβ) thus mediating the activation of lung myofibroblasts. Activation of myofibroblasts is responsible for the development of lung fibrosis in idiopathic pulmonary fibrosis (IPF).
45760165|NCT00771173|Other|Placebo|Placebo tablet administered q8 hours for 24 hours postop.
45615980|NCT05361733|Drug|Placebo|No active ingredient drug use to blind participants and investigators
45615981|NCT04227951|Device|Avoid drain placement|In No Drain arm (experimental) no abdominal drain is placed at the end of the operation.
45615982|NCT04227951|Device|Drain placement|In Drain arm (sham comparator) an abdominal drain is inserted in the abdomen from the right flank, passing below the liver (close to the duodenal stump) with the apex behind the esophago-jejunal (in total gastrectomy) or gastro-jejunal (in subtotal gastrectomy) anastomosis.
45615983|NCT02476435|Device|Active rTMS|Strong electromagnetic fields (~2Tesla) generated briefly but repetitively (1Hz) applied for 30mins, in five sessions per week for 3 weeks
45615984|NCT02476435|Device|Placebo rTMS|Placebo electromagnetic fields generated briefly but repetitively applied for 30mins, in five sessions per week for 3 weeks
45615985|NCT02726113|Drug|cholecalciferol|softgels 4000 IU daily for approximately two months prior to surgery (prostatectomy).
45760166|NCT05717673|Device|Specular microscopy|Specular microscopy is a noninvasive photographic technique that analyze the corneal endothelium. Using computer-assisted morphometry, modern specular microscopes analyze the size, shape and population of the endothelial cells. The instrument projects light onto the cornea and captures the image that is reflected from the optical interface between the corneal endothelium and the aqueous humor. The reflected image is analyzed by the instrument and displayed as a specular photomicrograph
45760167|NCT05717595|Dietary Supplement|fructose|oral ingestion of fructose vs dextrose
45760168|NCT05717517|Device|anterior segment oct|ant segment oct before and after corneal collagen cross-linking
46069016|NCT04762706|Behavioral|CRUTCH Pathway|Patients will be offered referral to a behavioral medicine specialist in the novel Combined Rehabilitation Using Team Centered Help (CRUTCH) Pathway. Once enrolled, these patients will meet virtually with a psychiatrist. The psychiatrist will complete a 30-minute intake visit where he will review the patient's DT scoring, discuss contributing factors to current distress level, and assess for psychiatric comorbidities. Following this assessment, psychotherapy, psychotropic medication, and referral for social work/financial services will be offered to the patient as indicated. If more frequent behavioral health follow-up is clinically indicated, it will be provided to the patients.
45445612|NCT03269552|Biological|Rituximab|Given IV
45615986|NCT02726113|Other|placebo|softgel containing no active ingredient daily for approximately two months prior to surgery (prostatectomy).
45615987|NCT04140903|Drug|Early transition to oral antibiotics|Patients will be treated with an oral antibiotic regimen (e.g. amoxicillin + metronidazole) based upon pharmacokinetic and pharmacodynamic properties of the drugs, pathogen susceptibility, and any existing drug allergies or interactions
45615988|NCT04140903|Drug|Standard treatment of intravenous antibiotics|Patients will continue standard intravenous antibiotic therapy for brain abscess (e.g. 3rd generation cephalosporin + metronidazole) according to international guidelines and pathogen susceptibility patterns.
45615989|NCT02481583|Drug|Levosulpiride|different formulations of levosulpiride
45615990|NCT05243667|Other|Wearable wrist Smart Device of Huami|"All enrolled patients underwent continuous monitoring by wearing huami blood oxygen testing equipment, and signed the informed consent for the clinical trial.Smart wrist wristbands will be issued, and patient information will be bound to the Migang Health platform, and clinical trial doctors will improve relevant personal information and clinical data.After binding to the APP Migu Health, you can start collecting and recording dynamic data such as peripheral blood oxygen saturation, heart rate, exercise steps, sleep data, etc., and upload the data once a day."
45760169|NCT02044419|Drug|lomitapide|
45760170|NCT02045277|Drug|IDP-118 Lotion|Lotion
45760171|NCT02045277|Drug|IDP-118 Monad HP Lotion|Active Comparator
45760172|NCT02045277|Drug|IDP-118 Monad Taz Lotion|Active Comparator
45760173|NCT02045277|Drug|IDP-118 Vehicle Lotion|Vehicle
45760174|NCT02045511|Behavioral|Baltimore HEARS|Tailored aural rehabilitation for participant and communication partner
45760175|NCT02045511|Device|Baltimore HEARS|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
45760176|NCT02378025|Behavioral|Yoga Group|A 10-week yoga course designed to treat pain.
45760177|NCT02378025|Behavioral|Pain Management Wellness Group|A 10-week behavioral therapy course designed to treat pain.
46069017|NCT04735016|Device|DiamondTemp™ Ablation System|A cardiac ablation will be performed using the DiamondTemp™ Ablation System.
46069018|NCT04730869|Other|Standard Treatment Plus Metabolic Therapy Program|"See description under Arms."
46069019|NCT04710043|Drug|BNT152|IV
45445613|NCT03771729|Drug|LCZ 696|LCZ696 200mg twice daily
45445614|NCT02796664|Dietary Supplement|Ginseng|Korean Red Ginseng extract tablet (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months.
45445615|NCT02796664|Dietary Supplement|Placebo|Placebo (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months.
45760178|NCT00771407|Device|Strattice Reconstructive Matrix|Strattice will be placed as a fascial inlay to support stoma sites
45760179|NCT00771407|Other|Standard ostomy creation|Ostomy will be created as routinely performed
46069020|NCT04710043|Drug|BNT153|intravenous (IV)
45452262|NCT02269618|Other|Home-based rehabilitation|"Home-based rehabilitation Individual rehabilitative program including at least 3 sessions/week of mini-ergometer and exercises and 2 sessions/week of walking with pedometer~Mini-ergometer: The personalized protocol will be structured at the beginning on the basis of data obtained from the assessment of the baseline exercise test, trying to get a training activity to the maximum value of around a Borg dyspnoea and motor equal to 6 (according to the protocol of Maltais)~Walking: The patient will be encouraged to walk every day. Will be given a pedometer and will be asked to try to increase the amount of steps up to the maximal for the patient."
45615991|NCT02480023|Radiation|calcaneal quantitative ultrasound assessment|QUS for calcaneus bone of right foot will be done for this group of Pregnant women at the third trimester
45615992|NCT05243589|Other|Proprioceptive training|"Proprioceptive training included exercises on different floor textures composed of 10 stations of exercises with the objective of stimulating the sole of the foot where participants had to coordinate gait by stepping with alternate feet on markers placed on the ground and the progression was manipulated through modifications of speed and direction.~Sequence of materials was 10 cm-thick foam, wood box with beans, two-cm thick mat with a density lower than the foam, wood box with cotton, two-cm thick mat volunteers sat on a bench and trained feet flexors by grasping with the toes a towel put on the floor, Two proprioception balls was used with an eight cm diameter with external projections resting on the floor a box with grains and sandpaper. After that joint Positional Sense Exercises were performed."
45615993|NCT05243589|Other|routine physical therapy|Routine physical therapy included range of motion exercises for bilateral ankle joints (5 min.), functional balance training (15 min.) involving sit to stand (5 times); standing weight shift (5 times each); functional reach- sideway and anterior for touching targets set by the therapist (5 times each); bipedal heel rise for 20 seconds (5 times); unipedal standing for 15 seconds (5 times each) and unipedal standing with knee bending for 15 second (5 times each). Other exercises was practiced as wobble board training (6 min).
45615994|NCT02479633|Other|Coronally advanced flap with connective tissue graft|"Two oblique, divergent releasing incisions extending beyond the mucogingival junction were performed. An intra-sulcular incision was performed at the buccal aspect of the involved tooth. Subsequently, a partial-thickness flap was raised beyond the MGJ. The papilla adjacent to the involved tooth were then de-epithelialized.~The CTG was harvested using a single incision approach from the palate. The graft was positioned on the instrumented root surface immediately apical of the CEJ and then stabilized using a sling compressive crossing suture. The flap was coronally displaced 1-2 mm above the CEJ. A sling suture was placed to stabilize the flap in a coronal position, followed by interrupted sutures on the releasing incisions with an apico-coronal direction."
45452263|NCT02269618|Other|Usual care|Usual care All patients will be followed also in usual care manner by their GPs.
45615995|NCT05243355|Drug|"Envafolimab and Chemotherapy and Recombinant Human Endostatin"|"Envafolimab: 300 mg，D1，Q3W,until PD or intolerable toxicity Chemotherapy: Paclitaxel / NAB-Paclitaxel, 175 / 260mg / m2, D1, Q3w; Cisplatin: 75mg / m2, 1-3 days, or carboplatin: AUC 5, D1, Q3w, 4-6 cycles in total.~Recombinant Human Endostatin：210mg，CIV 72h，d1-3，Q3W，4-6 cycles in total."
45615996|NCT02479711|Other|composite restoration|The tooth will be isolated with cotton rolls and the caries will be removed. Enamel and dentin conditionings were performed with a self-etching adhesive system (Adhese One F, Ivoclar Vivadent, Liechtenstein). Bulk fill composite (Tetric EvoCeram® , Ivoclar Vivadent, Liechtenstein) will be injected in a single bulk increment of less than 4 mm to fill the preparations. The material was condensed with a flat instrument. Once set, it will be polished with finishing cups (Enhance® , Dentsply , Milford, USA). An interproximal strip will be used to finish the final contour.
45615997|NCT02479711|Other|glass ionomer cement|The tooth will be isolated wit cotton rolls and the caries will be removed. The dentist will mix and handle the materials in accordance with the manufacturers' instructions. The material was condensed with a flat instrument. Once set, it will be polished. An interproximal strip will be used to finish the final contour. G-Coat Plus (GC, America) will be applied to the surface and margins of the restoration.
45615998|NCT05334511|Other|Functional Electrical Stimulation|functional electrical stimulation with Frequency 20 pps with Pulse width of 300 msec.
45615999|NCT05196945|Drug|vonoprazan fumarate + amoxicillin|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral
45616000|NCT05196945|Drug|Esomeprazole +Amoxicillin+Clarithromycin+Bismuth potassium citrate|Esomeprazole 20mg/ time, 2 times/day, oral Amoxicillin 1g/ time, 2 times/day, oral Clarithromycin 0.5g/ time, 2 times/day, oral Bismuth potassium citrate 220mg/ time, twice a day, orally
45616001|NCT02481427|Procedure|Unicondylar Knee Replacement|UKA involves only the replacement of affected medial compartment. In the study, the operation will be performed through standard medial parapatellar incision with midline skin incision, but the knee joint and fascia will be opened like in standard Oxford minimally invasive incision. The procedure will be performed by using Oxford Microplasty instrumentation and following Microplasty surgical technique (Biomet Orthopedics). Intraoperative local infiltration analgesia is used for postoperative pain management. Drain is not used.
45616002|NCT02481427|Procedure|Total Knee Replacement|TKA is performed through a standard medial parapatellar incision, which provides easy access to the knee joint. Skin incision is done to midline. Intramedullary guide is used for alignment of femoral and tibia saw cuts and component positions. Components will be cemented in position. The patella will not be resurfaced. Intraoperative local infiltration analgesia (LIA) is used for postoperative pain management. Drain is not used.
45616003|NCT03804021|Genetic|ADVM-043|Long term follow-up of subjects that received ADVM-043
45616004|NCT05715151|Other|CQI intervention|Activity 1: Reflective sessions and problem prioritisation. Activity 2: PDSA cycles. Activity 3: Group mentoring.
46069021|NCT04708769|Behavioral|Smartphone App Participants (APP)|Participants will receive calorie, fat, and physical activity goals, a Smartphone application for self-monitoring their diet, activity and weight, online educational readings, and brief bi-weekly remote health sessions with a Health Promotionist. They will also be provided with a wireless bluetooth scale and portable blood pressure machine.
45616005|NCT05715151|Other|Audit and Feedback|Audit and Feedback on six key AA indicators, patients reported experience about access and selected AA processes.
45616006|NCT03800979|Drug|Tofacitinib|Tofacitinib is an oral medicine in Janus kinase inhibitor 3 group which has been approved by FDA in treating Rheumatoid Arthritis. It has ability to inhibit nerve signal Interferon-ɣ and Interleukin-15 between white blood cell(WBC) and the nucleus of hair follicle cell causing the production of WBC type CD8+NKG2D+ T cell to slow down which this type of WBC is one of the cause of hair loss.
45616007|NCT02476123|Biological|Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)|i.v. administration
45616008|NCT02481271|Behavioral|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice"
45760180|NCT03808649|Drug|1500ml of 2.5% mannitol|1500ml of 2.5% mannitol was used in experimental group
45452264|NCT01023880|Drug|CEP-18770|CEP-18770 beginning at a dose of 1.5 mg/m2. Patients will receive I.V. administration on days 1, 8, 15 (up to 8 cycles of 28 days each). When the MTD is established, additional patients will be treated at the MTD.
45452265|NCT02650804|Drug|BPM31510 Nanosuspension Injection|
45616009|NCT02481271|Behavioral|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
45616010|NCT03794661|Device|Clinician programmer electrode screening mode tool|Provides a standardized workflow to guide clinicians or trained healthcare providers through the deep brain stimulation monopolar review screening process
45616011|NCT02481037|Other|Primary care clinical pathway|Installing a primary care clinical pathway for managing childhood asthma into clinicians' electronic medical record (EMR) to facilitate the use of best-evidence by practitioners.
45616012|NCT02481037|Other|Asthma education|Physicians will receive web-based education through an interactive learning module regarding best management for childhood asthma and use of the primary care clinical pathway. Chronic disease management (CDM) health professionals in practices will attend asthma education sessions delivered by an asthma educator. This training will be then used by the CDM professional to provide targeted and timely asthma education to parents and children with asthma.
45616013|NCT02481037|Other|EMR embedded dashboard|An EMR embedded dashboard will deliver real-time feedback to clinicians.
45616014|NCT02481193|Drug|Cisatracurium|Different doses of cisatracurium pretreatment
45616015|NCT03101709|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
45616016|NCT03101709|Drug|Fludarabine|Fludarabine 25 mg/m2/day IV for 3 days (Day-5 to day-3).
45616017|NCT03101709|Biological|CART-19|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
45760181|NCT03808649|Drug|different volume of 2.5% mannitol|different volume of 2.5% mannitol based on BMI was used in active comparator group
45760182|NCT03808571|Other|cord blood specimen during the delivery|The cord blood will be taken during the delivery of baby.
45760183|NCT00788255|Drug|Final exogenous oxytocin concentration=22.5 μU/mL|Citrated whole blood 1mL + 23μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
45445616|NCT03752619|Device|Contracting Producing Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for Peripheral Nerve Stimulation (PNS). The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed.
45445617|NCT03752619|Device|Non Contracting Producing Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for Peripheral Nerve Stimulation (PNS). The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed.
45452266|NCT02650804|Drug|Gemcitabine|
45452267|NCT02269696|Drug|Metoprolol|Intraoperative metoprolol infusion.
45452268|NCT02269696|Drug|Normal saline|Equal of volume compared to metoprolol.
45616018|NCT03101631|Diagnostic Test|Comprehensive Geriatric Assessment (CGA)|"CGA includes a set of evaluations to determine therapeutic decision based on mortality risk, toxicity risk and frailty group. Evaluations includes:~Nutritional Assessment: Mini Nutritional Assessment (MNA)~Functional Assessment: Get up and Go, Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Karnofsky Scale, Walking one Block, Number of Falls in last 6 months and Hearing Loss.~Cognitive Assessment: Mini-Mental State Examination (MMSE-30)~Psychological status: Geriatric Depression Scale (GDS)~Social Support: Medical Outcomes Study Social Support Survey (MOS-SSS)~Comorbidity and Severity of Comorbidities: Charlson Comorbidity Index and Adult Comorbidity Evaluation (ACE-27)~Age~Haemoglobin~CrCl~Presence of geriatric syndromes"
45616019|NCT02480959|Procedure|Surgical treatment for recurrent patellar instability|Either medial plication or MPFL reconstructuion surgery
45616020|NCT03101553|Behavioral|Interpretation Bias Modification|Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to negative evaluation.
45616021|NCT03101553|Behavioral|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR).
45616022|NCT05452759|Device|high-flow oxygen therapy device for Severe pneumonia patients with artificial airway|Using NTHF, adjust the MR850 humidifier to invasive automatic gear, the temperature sensor automatically adjusts and maintains the gas temperature at the entrance of the tracheal tube at 37°C according to the feedback temperature, and monitors and maintains SpO2 between 94% and 100%. The monitored pulse oxygen saturation (SpO2) is used to adjust the concentration of the venturi valve and the corresponding oxygen flow rate. At the preset gas flow rate levels of 40L/min, 50L/min and 60L/min, the test pipeline is connected to optimize the breath. The actual gas flow rate value and the gas flow rate loss difference before and after the gas joint (screw joint), and at the corresponding gas flow rate, measure the gas temperature and humidity at the near-patient end of the pipeline.
45616023|NCT05452759|Device|AIRVOTM2 device for Severe pneumonia patients with artificial airway|Use AIRVOTM2 (Fisher & Paykel, Auckland, New Zealand), select the output gas temperature of 37°C, monitor and maintain SpO2 between 94% and 100%, and adjust the output gas flow rate of the therapy device to 40L/min, 50L/min and 60L/min, respectively. min, measure the actual gas flow rate value and the gas flow rate loss difference before and after each flow rate horizontal pipeline is connected to the conventional exhalation joint (matching special exhalation joint), and measure the gas temperature and humidity near the patient end of the pipeline at the corresponding gas flow rate.
45616024|NCT03101319|Drug|Vitamin D3 cholecalciferol|As mentioned in the description of the study arm
45616025|NCT03101319|Drug|B Complex Oral Tablet|As mentioned in the description of the study arm
45616026|NCT02479555|Drug|Dexamethasone sodium phosphate injection, USP, 4 mg/mL|"Post-balloon angioplasty revascularization, the unblinded Pharmacist will prepare a sterile 20 mL syringe (Luer locking) with 16 mL of investigational drug or placebo per assignment. The unblinded Pharmacist provides syringe to investigator. Syringe shall only be labeled with the study number, patient number, randomization number and Investigational Drug.~Investigational Drug will be administered via Bullfrog Micro-Infusion Device."
45616027|NCT03103659|Other|personalised care plan|Quality of life assessement in elderly cancer patients
45616028|NCT02476045|Drug|5-fluorouracil,leucovorin,panitumumab|Maintenance treatment (ARM A)
45616029|NCT02476045|Drug|panitumumab|Maintenance treatment (ARM B)
45616030|NCT02476045|Drug|Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab|Induction treatment
45616031|NCT02479399|Drug|ipragliflozin|Tablets
45616032|NCT03885921|Drug|Ezetimibe|oral tablet
45616033|NCT03885921|Drug|Atorvastatin|oral tablet
45616034|NCT03885921|Drug|Simvastatin|oral tablet
45616035|NCT02475889|Procedure|Hepatic RFA|Hepatic RFA was performed under guidace of ultrasonography (US) or computed tomography (CT) before primary tumor resection.
45616036|NCT02475889|Procedure|Primary tumor resection|Primary tumor resection were performed pre- or post-RFA for liver metastases.
45616037|NCT01230879|Other|EFR and TDM|EFR : Pulmonary function test TDM : tomodensitometry
45616038|NCT02475811|Radiation|3D ultrasonography|The angle of volume sampling varied throughout gestational age with a maximum limit of 75° in the third trimester. After scanning the volume, multiplanar imaging in the 3 orthogonal ultrasonographic sections was analyzed to reconstruct the 3D ultrasound image. Before its volume was analyzed, each lung was carefully identified on the 3 orthogonal multiplanar imaging sections. We used the rotational technique that entails the VOCAL imaging program to measure lung volume. A transverse section of the multiplanar imaging was chosen as the reference image for volume analyses
45445618|NCT03752619|Other|Physical Therapy|All participants receive eight 1.0 hr. sessions of physical therapy (PT) over a 4-wk period from a therapist blinded to Peripheral Nerve Stimulation (PNS) treatment assignment. Each participant also performs home exercises. The primary objective of physical therapy (PT) and the home exercise program is to prevent re-injury by educating and training participants in the biomechanics and proper use of the shoulder and upper limb. During each in-lab session, participants are trained in the implementation of these exercises, which are individually adjusted and progressed with increasing external loads by using weights and elastic rubber bands.
45616039|NCT03750747|Device|Pulse Oximeter|SpO2 will be measured using a handheld PO device (selected for this study) applying the low noise cabled sensor. For patients weighing <10 kg, the sensor will be placed on the big toe. For patients weighing >10 kg, the sensor will be placed on an index finger. In case of failure in the first attempt, the alternate toe or index finger will be tried (second attempt). First, the sensor will be placed on toe or index finger and then the PO will be powered-on. A stable Sp02 reading will be considered to be obtained if SpO2 reading is stable by ±1 % for at least 10 seconds and the device signal strength is displayed to be adequate (green signal). Second attempt will be warranted if a stable reading is not obtaining within 1-2 minutes.
45616040|NCT02475967|Other|Intervention group|The intervention group patients have access to the eLearning platform in addition to conventional cardiac care.The content of platform will be gathered from a multidisciplinary input of both medics (e.g. cardiologists) and paramedics (e.g. psychologists). Patients will also contribute to platform content.
45616041|NCT02475967|Other|Control group|The control group patients receive conventional cardiac care alone.
45616042|NCT02475577|Device|Peripherals with HealthInterlink technology|home remote monitoring
45616043|NCT01361919|Procedure|Feedback During CPR Training and Testing|"Students in this group will receive training in BLS skills according to the 2005 AHA/ILCOR guidelines, using the ZOLL R Series™ defibrillator with an attached accelerometer pad that will be placed on the sternum of the manikin and visible to the user. Participants will be taught to use and follow the audio and visual feedback provided by the accelerometer and defibrillator to optimize their CPR performance (depth, rate, and minimal hands-off time). After the simulated cardiac arrest scenario, a data card containing the raw data collected from the accelerometer and defibrillator will be downloaded onto a laptop and used as a demonstration and training tool."
45616044|NCT01361919|Procedure|No Feedback Group|"A standard no feedback defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur."
45616045|NCT01361919|Procedure|Feedback during CPR Training Not Testing|Students in this group will be tested using a five minute basic vfib arrest scenario and an R-series defibrillator and told to perform compressions on top of the accelerometer pad. The hexagonal icon will be visible but no prompting on its usage will be delivered during testing.
45445619|NCT04163198|Device|Insufflation|Patients will receive different inspiratory (Ti) and expiratory (Te) times and inspiratory flows, at a fixed insufflation and exsufflation pressure. Optimum insufflation pressure will be determined by measuring maximal inspiratory capacity.
45445620|NCT04163198|Device|Exsufflation|Patients will receive different exsufflation pressures at fixed insufflation pressure.
45616046|NCT05714917|Other|Observational study with no interventions|This is an observational study and there will be no clinical interventions.
45445621|NCT01561677|Device|Continuous Positive Airway pressure-RESPIRONICS|obstructive sleep apnea syndrome survival ischemic stroke continuous positive airway pressure handicap
45616047|NCT02480881|Drug|BMS-663068|Investigational product
45616048|NCT02480881|Drug|Oral Contraceptive|Subject's existing combination OC tablet containing EE and progestin
45616049|NCT02480881|Drug|Loestrin 1.5/30|OC containing EE and norethindrone acetate (NEA)
45616050|NCT05073159|Biological|Allocating head-of-bed position|Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
45616051|NCT05713591|Behavioral|Transition care model|The transition care model (TC) consists in multidisciplinary standardized interventions to educate and support adolescents with congenital heart disease, representing a key element in the adequate delivery of care to these individuals during their transition from childhood to adulthood. This model encompasses three main pillars previously described.
45616052|NCT02480647|Drug|Levonorgestrel|20μg/day.
45616053|NCT02480647|Drug|Etonogestrel|20μg/day.
45445622|NCT01561677|Device|Sham Continuous Positive Airway pressure-RESPIRONICS|inefficient Continuous Positivie Airway pressure
45760184|NCT00788255|Drug|Final exogenous oxytocin concentration=30.1μU/mL|Citrated whole blood 1mL + 31μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
45616054|NCT05072925|Other|Tobacco products|Products will be used under defined (10 puffs, 30 seconds apart) and ad libitum puffing conditions
45616055|NCT02479477|Other|kinesio therapy|during for fifteen minutes the nursing assistants will perform stretching exercises and muscle relaxation of large muscle groups the orthostatic position
45616056|NCT05384509|Diagnostic Test|solid organ malignancies treatment|Major inclusion criteria for this cohort of the study included: (1) age above 20 years; (2) presence of solid organ malignancies treated with immunotherapy, chemotherapy, Target therapy irrespective of the treatment phase; and (3) eligibility for vaccination.
45616057|NCT03100071|Drug|Apixaban|Patients will be treated with Low Molecular Weight Heparin (LMWH) for 1 week and then with apixaban 5 milligram (mg) twice daily for 11 weeks.
45616058|NCT02479165|Drug|Ibuprofene|The Ibuprofene group is given an ibuprofen based analgesic regimen, to be compared with the standard opiod based regimen.
45616059|NCT02479165|Drug|Oxycodone|The opioid group is given an oxycodone based analgesic regimen.
45616060|NCT05072769|Dietary Supplement|Date Fruit|Within the first hour after birth, 100gr (5-6 pieces) dates will be eaten.
45616061|NCT02479087|Drug|Plasma-derived FVIII/VWF concentrate|"The investigational treatment is with lyophilized plasma-derived Factor VIII. The product belongs to the factor VIII concentrates class, containing also VW Factor in an average ratio VW/VIII of > 1: 4.5.~The product is as a powder and a solvent solution for continuous infusion of Factor VIII. The specific activity of Factor VIII is of approximately 80 IU/mg protein.~The number of units of FVIII administered is expressed in International Units (IU), which are consistent with current WHO standards for products containing Factor VIII. The activity of Factor VIII in plasma is expressed either as a percentage (compared to normal human plasma) or in International Units (compared to the international standard for FVIII in plasma)."
45616062|NCT05072691|Diagnostic Test|CSF immunoglobulin (Ig) free light chains (FLC) dosage|CSF immunoglobulin (Ig) free light chains (FLC) dosage in the peripheral blood and cerebrospinal fluid.
45616063|NCT05071989|Behavioral|Sleep Education|A single-blind school- based randomized controlled design
45616064|NCT05714839|Drug|Bela|Bela will be administered.
45616065|NCT05714839|Drug|Belamaf|Belamaf will be administered.
45616066|NCT05714839|Drug|Lenalidomide|Lenalidomide will be administered.
45616067|NCT05714839|Drug|Dexamethasone|Dexamethasone will be administered.
45445623|NCT03560362|Drug|Bupivacaine liposome|
45445624|NCT03560362|Drug|Bupivacaine / Epinephrine|
45616068|NCT05714839|Drug|Standard of Care|Either standard of care (SoC) or an emerging treatment for Multiple Myeloma will be administered
45616069|NCT03103269|Behavioral|Challenge! Small Group Intervention|The Challenge! Small Group intervention consists of curriculum related to health behavior goal setting, healthy eating, and staying active, working out with Health Educators, and receiving a year-long membership to the YMCA.
45616070|NCT03103269|Other|Challenge! Environmental Intervention|The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier.
45616071|NCT05378425|Drug|NTX-1088|IgG4 mAb targeting the poliovirus receptor (PVR, CD155).
45616072|NCT05378425|Drug|Pembrolizumab|IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
45616073|NCT05377255|Combination Product|16 mg naloxone AP003|4 doses of 4 mg each (total: 16 mg) of naloxone through the AP003 device
45616074|NCT05377255|Combination Product|8 mg naloxone NARCAN Nasal Spray|2 doses of 4 mg each (total: 8 mg) of the naloxone through the NARCAN Nasal Spray device
45616075|NCT03719547|Procedure|Abdominal radical hysterectomy|Radical hysterectomy (type B or C according to the Querleu&Morrow classification) with pelvic lymphadenectomy
45616076|NCT03719547|Procedure|Robot-assisted radical hysterectomy|Radical hysterectomy (type B or C according to the Querleu&Morrow classification) with pelvic lymphadenectomy
45616077|NCT03719547|Diagnostic Test|Sentinel lymph node biopsy|Assessment of sentinel lymph nodes using either radiotracer or indocyanine green (ICG)
45616078|NCT02475499|Drug|DPP-4 inhibitors|Ever-use of DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
45616079|NCT02475499|Drug|GLP-1 analogs|Ever-use of GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
45760185|NCT00788255|Drug|Final exogenous oxytocin concentration=32.9μU/mL|Citrated whole blood 1mL + 34μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
45760186|NCT02379195|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg are administered i.v on day -7 and -6
45445625|NCT03771807|Dietary Supplement|Beauty From Within|one scoop of product mixed in 8-16 ounces of water consumed once daily
45445626|NCT03771807|Other|Placebo|one scoop of product mixed in 8-16 ounces of water consumed once daily
45616080|NCT02475499|Drug|Sulfonylureas|Ever-use of sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
45616081|NCT02475499|Drug|Biguanides|Ever-use of biguanides (ATC A10BA) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
45616082|NCT02475499|Drug|Thiazolidinediones|Ever-use of thiazolidinediones (ATC A10BG) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
45616083|NCT02475499|Drug|Alpha-glucosidase inhibitors|Ever-use of alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
45616084|NCT02475499|Drug|Meglitinides|Ever-use of meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
45616085|NCT05072223|Procedure|Pericapsular nerve group block|A new nerve block guided by ultrasound that aims to block articular branches of the shoulder.
45616086|NCT05072223|Procedure|Interscalene block|A common and rapid-onset nerve block method guided by ultrasound for pain control of patients undergoing shoulder surgery.
45616087|NCT03375645|Drug|Any oral opioid|Emergency department patients who receive a prescription for an oral opioid
45616088|NCT05071443|Other|Negative pressure wound therapy (NPWT)|"The therapeutic intervention being tested is the use of a negative pressure wound therapy (NPWT) device. Several medical devices are currently being used and are based on the same principle. They involve applying negative pressure, generally between -100 and -150 mmHg, to a wound using a dressing (mostly a polyurethane foam dressing with hydrophobic pores), which hermetically covers the wound's surface and is connected to a container for collecting the fluids drained off. These devices are widely available and used to treat post-operative wounds.~Duration of treatment: the use of NPWT will be maintained until the recovery of the skin has been achieved by the skin graft. An average duration of 3 weeks' treatment is expected in the intervention group."
45616089|NCT05071443|Other|Conventional dressing|"Conventional dressings will be performed from randomization to skin grafting and applied every day based on the methods normally used in the participating centres, and also until the recovery of the skin has been achieved by the skin graft.~This generally involves local care provided on a daily basis, ensuring gentle mechanical and chemical debridement by covering the wound with alginate type or other dressings, according to the condition of the wound. The methods used to apply these conventional dressings will be recorded."
45616090|NCT02479009|Device|Fluoroscopy|Each patient will undergo fluoroscopy-imaging evaluation in the office to determine whether the fracture moves (instability). The investigators will deviate the wrist from ulnar to radial and back in posteroanterior, oblique and lateral views with the wrist in neutral flexion. Any angulation or translation at the fracture site or more than one millimeter displacement or gap will be considered as a sign of instability. The fluoroscopy will be viewed and an image showing the largest gap will be saved. The diagnosis of instability (which is the same as displacement with this test) will be made by consensus of the research team.
45616091|NCT05071521|Other|The Body Project: A Dissonance-Based Eating Disorder Prevention Intervention|The Body Project is a a selective dissonance-based prevention program that targets women with body image concerns. It has been developed with University and similar populations in mind, making it appropriate to the current research.The Body Project is based on a protocol, and aims to create cognitive dissonance that encourages participants to reduce pursuit of the thin-ideal. It involves the use of a scripted manual, covering four interactive weekly sessions. These involve role play, behavioural, verbal and written exercises.
45616092|NCT03136809|Drug|Cu(II)ATSM|copper-containing synthetic small molecule
45616093|NCT02475421|Biological|Glucagon|One hour glucagon-clamp followed by one hour of blood sampling
45616094|NCT03646617|Radiation|Hypofractionated Radiation Therapy (HFRT)|The dose of HFRT will be 8 Gy x 3 fractions, given over a maximum of 7 days timespan.
45616095|NCT03646617|Drug|Nivolumab|Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses. After these 4 doses, the patient and investigator will decide to continue with nivolumab (240 mg) every 2 weeks or Nivolumab (480mg) every 4 weeks as monotherapy for up to one year as an IV infusion over 30 minutes.
45616096|NCT03646617|Drug|Ipilimumab|Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses.
45616097|NCT02163525|Procedure|Global Fibroid Ablation (GFA)|GFA is radiofrequency ablation of fibroids. This is a laparoscopic procedure whereby a radiofrequency probe is inserted into the fibroid under laparoscopic and ultrasound guidance. Each fibroid is heated to temperatures averaging 95 deg C. The fibroid undergoes coagulative necrosis and shrinks and/or disappears.
45616098|NCT02163525|Procedure|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which an incision is made into the uterus and the fibroids are surgically removed from the uterus. The uterine incision is closed with sutures. This procedure can be performed through an abdominal incision or via laparoscopy.
45760187|NCT02379195|Drug|Fludarabine|Fludarabine 25 mg/m2 are administered i.v on day -5 to -1
45760188|NCT02379195|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 min on day 0
45760189|NCT02379195|Drug|Interleukin-2|Interleukin-2 are administered as a continuous i.v. infusion in a decrescendo regimen (18 MIU/m2 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU IL-2 over 24 hours followed by 4.5 MIU/m2 IL-2 over another 24 hours for three days)
45760190|NCT02379195|Drug|Peginterferon alfa-2b|Peginterferon alpha-2b, 3 microgram/kg are administered as subcutaneous injection on day -2, day 7 and day 14.
45760191|NCT02379273|Device|Nucleus Hybrid L24 Implant|Subjects have already been implanted with the Nucleus Hybrid L24 implant.
45760192|NCT05715567|Other|Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)|Following the intervention of the Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)
45616099|NCT02163525|Procedure|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids. An embolic material is injected into the uterine artery(ies) to block blood flow to one or more fibroids. This procedure is performed by an interventional radiologist.
45616100|NCT05713513|Other|Leukapheresis|Leukapheresis to isolate 1x10e9 cells, examined for purity and specificity under Good Manufacturing Practice (GMP)
45616101|NCT03641859|Device|virtual reality|"The virtual reality headset can be used for 45 minutes with the need to pause for 5 minutes if the gesture lasts longer. The VR sequence will be complete when the end of the programmed time is reached to preserve the patient's immersion. The patient will be able to see the final sequence at the end of the gesture in order to get used to the real world again. The programs and their durations will be adjusted to the duration of the gesture concerned. Regarding the pain, anxiety and satisfaction visual analogue scales, they will be performed just after the removal of the VR helmet.~Virtual reality videos are from Healthy Mind® software. The videos are contemplative with three kinds of relaxing landscapes accompanied by a sound universe specifically composed to relax the patient. The patient can choose one of three interactive worlds (an Asian garden, a forest or a mountain)."
45616102|NCT02475343|Device|Schiotz tonometer|The corneal biomechanical properties will be measured using a Schiotz tonometer with routine manipulation protocol.This measurement will be used in normal people, keratoconic patients, patients received keratoplasty.
45616103|NCT02475343|Device|UVA/riboflavin|The UVA/riboflavin corneal crosslinking will be applied using a UV-X lamp (Peschke Meditrade GmbH, Switzerland) with routine manipulation protocol (3mW/cm2, 365nm, 30 minutes).This treatment will be used in keratoconic patients.
45616104|NCT02475343|Device|femto-LASIK|The keratoplasty mainly include femto-LASIK (Laser in situ keratomileusis), which will be applied using a Wavelight FS200 and Wavelight EX500 Excimer Laser (Alcon Inc. USA.).The keratoplasty will be applied in patients who would like to receive the surgery.
45616105|NCT02475343|Device|Tomey SP-100 Pchymeter , Topolyzer Vario|Cornea thickness will be measured with a pachymeter (Tomey SP-100 Pchymeter, Japan); cornea topography will be measured with Topolyzer Vario (Allegro, Wavelight GmBH, Germany); anterior chamber depth, white to white, and ocular axis length will be measured using a IOL master (Carl Zeiss Meditec, Germany). These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
45760193|NCT05714319|Other|Data collection|"Variables collected will include:~demographics (sex, age)~comorbidities (type 2 diabetes mellitus, familiar history of CAD, smoke habit, dyslipidaemia, hypertension, history of CAD)~echocardiographic (left ventricle ejection fraction at admission, the presence and grade of diastolic dysfunction, and the presence and grade of any valvulopathies)~angiographic data (presence of non-obstructive CAD (any coronary lesion <50% diameter stenosis), the presence of myocardial bridge and, if this latter is present, its localization and length)~laboratory measurements (hematologic variables (haemoglobin and white blood cells), creatinine, high sensitivity cardiac troponin I (hs-cTnI), and C-reactive protein (CRP) at the time of admission)~medical therapy at admission~response to intracoronary provocative test with ACh."
45760194|NCT05714319|Other|Clinical follow-up|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 6, 12, 24, 36, 48 and 60 months from hospital discharge, during which the incidence of MACCE in the past months will be investigated and collected.
45616106|NCT02475343|Device|Topcon CT-80, Topcon, Japan|Vision acuity will be measured with a decimal visual chart; IOP (Intra-ocular pressure) will be measured with a tonometer (Topcon CT-80, Topcon, Japan) , fundoscopy examination will be apllied with a direct ophthalmoscopy, slit lamp examination will be applied with a slit lamp. These examinations will be used in normal people, keratoconic patients, patients received keratoplasty.
45616107|NCT02475343|Device|Corvis-ST|Cornea biomechanical properties will be measured with a ocular response analyzer (Reichert, USA.) and/or a Corvis-ST (Oculus, Germany).These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
45616108|NCT05070897|Other|Questionnaires|"Approved French version of the FCCHL scale~Questionnaire on the use of digital tools adapted from the questionnaire on digital tools"
45760195|NCT00771875|Drug|Rabbit Antithymocyte Globulin (RATG)|All patients will receive Thymoglobulin dosed based on CD3 count. Patients will be redosed when the CD3 count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily.
45760196|NCT00771875|Drug|Rituximab|Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care.
45760197|NCT00771875|Drug|Bortezomib|Patient will receive 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Consolidation course of bortezomib will be dosed at 1.3 mg/m2 IVP X 4 doses administered on days 1, 4, 7 and 10.
45760198|NCT00771875|Drug|Acetaminophen|Patients will be premedicated with acetaminophen prior to dosing per institution standard of care.
45911578|NCT05778474|Other|Healthy subjects|"Participants' ground spontaneous speed overground will be tested by means of the 10-meter walking test. Participants will be tested for their foot dominance by means of the Waterloo footedness questionnaire-revised. Participants will walk on a treadmill mounted on force sensors. The test sequence will be the following:~Familiarization. Participants will walk on the treadmill with the belt running at increasing velocities up to their spontaneous walking velocity . Speed will be increased of 0.2 m s-1 every 30 s. A brief pause of around 1 minute will follow.~Walking. Participants will walk at 0.4 m s-1 and 1.2 m s-1 for at least 30 seconds.~Walking with a rigid ankle-foot orthosis. Participants will walk at 0.4 m s-1 and 1.2 m s-1 for at least 30 seconds with an ankle-foot orthosis on the dominant lower limb.~Participants will repeat the last point (n°3) with the ankle-foot orthosis on the non-dominant lower limb. A 3-min pause will follow each section."
45616109|NCT02478619|Other|IMT group|"Patients will be instructed to do a daily inspiratory muscle training at home with the preset load at 50% of the maximal inspiratory pressure, during 30 minutes for 4 weeks before bariatric surgery.~They will also receive the routine physical therapy in the post operative period."
45760199|NCT00771875|Drug|Antihistamine|Patients will be premedicated with an antihistamine prior to dosing per institution standard of care.
45616110|NCT02478619|Other|Control group|Patients will be instructed to do a daily inspiratory muscle training at home with the minimal inspiratory load of the respiratory resistance device, during 30 minutes for 4 weeks before bariatric surgery. They will also receive the routine physical therapy in the post operative period.
45616111|NCT02088333|Behavioral|mCRC intervention|a multilevel intervention consisting of tablet-based patient education about CRC screening, post-visit patient electronic messaging, and clinic protocols to facilitate ordering of screening tests
45616112|NCT02088333|Behavioral|Healthy Lifestyles video|a brief video about healthy lifestyle habits displayed on a tablet device
45616113|NCT02480725|Procedure|collect CSF (Cerebrospinal fluid) sample|collecting CSF samples for thrombin activity assay
45616114|NCT05070507|Dietary Supplement|Enzyme containing lozenge|Subjects are instructed to take one lozenge three times daily, at least 30 minutes after a meal, for seven days. No oral health care procedures are allowed during the intervention period.
45445627|NCT03771807|Other|Facial cleansing|All subjects will use a cosmetic instrument to clean on one half of their face daily
45616115|NCT05070507|Dietary Supplement|Placebo lozenge|Subjects are instructed to take one lozenge three times daily, at least 30 minutes after a meal, for seven days. No oral health care procedures are allowed during the intervention period.
45616116|NCT02475109|Drug|PAN-90806 Ophthalmic Solution|
45616117|NCT02480569|Other|FFR Measurement|
45616118|NCT04492501|Procedure|Therapeutic Plasma exchange|1-1.5 plasma volume exchange, 2/3rd plasma should be replacing with FFP to avoid coagulopathy, adequate dieresis to prevent volume overload, 1-5 sessions in total, 1 session daily
45616119|NCT04492501|Biological|Convalescent Plasma|"Convalescent plasma as part of replacement therapy (200-400ml) if reported within 14 days of illness. An IgG titer of > 1.320 will be considered suitable for use. It will be Collected from person previously infected with Covid-19 and meet following criteria;~After 28 day of illness till 3 months~Symptom free 2 weeks prior to donation~Negative two consecutive PCRs any time between initial positivity and before donation~Anti SARS-CoV2 IgG positive, IgM negative~Fulfills healthy donor criteria as per WHO/AABB guidelines~Volume of plasma to be collected: 900-1200 ml through Apheresis OR plasma separated from phlebotomy donation"
45616120|NCT04492501|Drug|Tocilizumab|A predefined number of patients having evidence of cytokine release storm with normal procalcitonin level for three consecutive days, a normal blood culture and IL-6 level > 3 times ULN will be given 1-2 doses of Tocilizumab (80mg IV) . Following contraindications to Tocilizumab will be considered (Allergy to any monoclonal Ab, ANC < 1000, Platelets < 50, ALT or AST > 5 times ULN, Pregnancy and breast feeding, Post TB lung). Some patients will receive it alone in addition to standard treatment whereas in few patients where indicated it will be given in combination with MSC or Remdesivir or both
46069022|NCT04708769|Behavioral|Diabetes Prevention Program Participants (DPP)|In accordance with the Center for Disease Control curriculum, participants will receive a participant log for tracking physical activity, food intake, and weight, a paper participant guide with worksheets, logs, and psycho-educational materials, and 16 hour long remote sessions with a Health Promotionist. They will also be provided with a wireless bluetooth scale and portable blood pressure machine.
45616121|NCT04492501|Drug|Remdesivir|It will be given to selected patients who have evidence of hypoxemia and presented with in 14 days of illness. For adults requiring invasive mechanical ventilation the dosage of remdesivir is a single loading dose of 200 mg sta on Day 1 followed by once daily maintenance doses of 100 mg IV for 9 days (days 2 through 10). For adults not requiring invasive mechanical ventilation 5 standard doses will be used. However, patients with known hypersensitivity to Remdesivir, multi organ failure, ALT > 5 times ULN and GFR < 30ml/minute will not be given Remdesivir. In some patients, where indicated other novel treatments including MSC therapy, Tocilizumab and therapeutic plasma exchange will be given.
45445628|NCT02061670|Biological|Ragweed-SPIRE|Intradermal injection
45616122|NCT04492501|Biological|Mesenchymal stem cell therapy|Single Dose of 2 x 106 cells/kg will be administered either alone or in combination with other novel therapies. At Armed Forces Bone Marrow Transplant Centre (AFBMTC), MSCs will be isolated from bone marrow harvested cells. About 50ml bone marrow will be collected from iliac crest using aseptic technique in syringes primed with anticoagulant. The collected sample will be diluted with Phosphate Buffer Saline (PBS) and MSCs will be separated using density gradient centrifugation. After resuspension the cells will be seeded at a fixed concentration of 100,000 cells/cm2 in specially designed flasks and incubated at 37Oc in 5% CO2. Medium will be changed after every third day till harvesting of MSCs from the flasks. Once confluent (approximately day 20) the cells will be harvested with sterile techniques using Trypsin- EDTA solution.
45616123|NCT03101085|Drug|S-equol|S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules
45616124|NCT03101085|Other|Placebo|Placebo capsules matched in size and color to S-equol capsules
45616125|NCT02480491|Other|measuring cell freeDNA|measuring cell free DNA using PCR
45760200|NCT00771875|Drug|Methylprednisolone|Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
45760201|NCT02046525|Biological|Autologous fecal microbiota therapy|
45760202|NCT02046525|Other|Placebo|Saline enema
45445629|NCT02061670|Biological|Placebo|
45445630|NCT03762837|Other|Benigh gallbladder diseases|We aim to observe the relationship between the benigh gallbladder diseases and gallbladder cancer, and we will not take any actions to interrupt.
45760203|NCT05742737|Other|Frailty Index|The mFI-5 scoring system used in the current study was developed by Saxton and Velanovich by comparing the five variables in the original CSHA-FI with NSQIP database
46069023|NCT04703439|Behavioral|Medication-taking reminders & educational materials|The intervention has been described in arm/group descriptions, which lasted for 60 days for each participants.
45445631|NCT03560596|Behavioral|Adherence Intervention|9 sessions with bilingual health coaches who will utilize a culturally tailored adherence checklist to identify patients specific medication adherence barriers.
45445632|NCT03560596|Behavioral|Usual Care|standard hypertension treatment recommendations as determined by PCP
45445633|NCT03768531|Drug|Nivolumab|Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes every 2 weeks. (Cycle length 2 weeks).
45452269|NCT03135184|Device|HDL Therapeutics PDS-2 System|Delipidation of plasma HDL to reduce coronary atheroma
45760204|NCT02047305|Device|Radiofrequency Ablation|Patients with a histopathological diagnosis of moderate-grade intra-epithelial neoplasia (MGIN), high-grade intra-epithelial neoplasia (HGIN) and/or early flat-type SCCA of the esophagus, are treated with radiofrequency ablation, with repeat endoscopy and follow-up treatment at 3 month intervals.
45616126|NCT03606759|Procedure|Weekly assessment|"Weekly assessment during 3 months :~Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours)"
45616127|NCT03606759|Procedure|Weekly assessment ajusted|"Weekly assessment during 3 months :~Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours) Individually Adjusted Therapy scale (ATI)"
45616128|NCT02480413|Other|Accuracy of an algorithm and the pediatric emergency tape.|No intervention
45616129|NCT05070195|Drug|SKLB1028|SKLB1028, capsule, oral
45616130|NCT05070195|Drug|Midazolam|Midazolam Maleate, tablet, oral
45616131|NCT05714449|Device|eye patch|standard amblyopia treatment
45616132|NCT05714449|Device|After-image and MIT trainer|Common clinical training for foveation
45616133|NCT04412655|Device|Percutaneous Coronary Revascularization for STEMI|Percutaneous Mechanical Reperfusion for STEMI
45616134|NCT02478307|Other|Cognitive Therapy|
45760205|NCT00760019|Drug|salsalate|1.5 grams orally 3 times daily
45760206|NCT00760019|Drug|placebo|matching placebo
45760207|NCT02383719|Device|Oro-nasal Mask|
45760208|NCT00789113|Drug|Extended Release Lamotrigine|
45760209|NCT05714241|Other|Data extraction|"After routine coronary function testing using a diagnostic pressure-temperature sensor guidewire in order to assess Coronary Flow Reserve (CFR) and the Index of Microvascular Resistance (IMR); and/or the acetylcholine (Ach) provocative test to assess the presence of coronary vasomotion disorders, patients will be stratified, accordingly to coronary function testing and Ach provocative test, in four groups/endotypes:~MVA (evidence of CMD defined as any of abnormal CFR [<2.0], IMR [≥25], or microvascular spasm);~VSA (CFR ≥2.0, IMR <25 and epicardial spasm);~both MVA and VSA (evidence of CMD and epicardial spasm);~none/non-cardiac chest pain (CFR ≥2.0 and IMR <25 and neither microvascular nor epicardial spasm)."
45760210|NCT05714241|Other|Blood sampling|At the time of this coronary angiography, arterial blood samples through the radial sheath will be collected. If collected at the time of any follow-up visit, venous blood samples will be collected by venipuncture with the same modalities to obtain whole blood, serum and plasma samples after centrifugation.
45760211|NCT05714241|Other|Clinical Follow-up|"All patients will undergo a final follow-up visit at 12 months from the date of enrollment.~During the visit, the incidence of MACE in the past months will be investigated, the Seattle Angina Questionnaire (SAQ) will be administered and the SAQ summary score will be collected."
45760212|NCT03808259|Drug|(S)-ketamine Oral Thin Film|(S)-ketamine OTF sublingual formulation at a dose of 7 mg, 14 mg, and 28 mg will be administered in sequential cohorts.
45445634|NCT03768531|Drug|Cabrilizumab|Cabiralizumab 4 mg/kg given IV for 30 minutes, 30 minutes after Nivolumab infusion is completed, every 2 weeks. (Cycle length 2 weeks).
45445635|NCT01321983|Other|Inspiratory muscular training - IMT|
45616135|NCT02478307|Other|Mindfulness Meditation|
45616136|NCT02478307|Other|Mindfulness-Based Cognitive Therapy|
45616137|NCT05069883|Drug|Steroid Drug|In this group Oral steroid medication after Direct Vision Internal Urethrotomy
45616138|NCT05069883|Drug|No steroid|In this group no Oral steroid medication (palcebo medication) after Direct Vision Internal Urethrotomy
45616139|NCT02478385|Other|Supportive care in a specially designed labour room|Light and sound effects, homelike design in furniture and wall paper, sound insulation of walls, covering medical devices in walls, apparatus, and cupboards
45616140|NCT03100929|Diagnostic Test|Ultrasound|Pre-operational ultrasound for the detection of fetal heart rate, fetal presentation and presence of nuchal cord.
45616141|NCT02474953|Dietary Supplement|Proprietary Curcumin Formulation|
45616142|NCT02474953|Dietary Supplement|Unformulated Comparator Curcumin Product|
45616143|NCT05069571|Other|Endoangel|Collecting the colonoscopy videos and analyzing the correlation between withdrawal overspeed proportion and adenoma detection rate.
45616144|NCT05713435|Device|intravaginal laser|application of intravaginal laser
45616145|NCT05069025|Other|music|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
45616146|NCT05069025|Other|no-music|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
45616147|NCT05713279|Drug|VV116+SOC|"In this study, the standard treatment plan (SOC) for COVID-19 in the Department of Respiratory and Critical Care Medicine was used as the best accessible treatment, and the treatment plan principle was based on the latest national guidance document (Expert Recommendations for Clinical Treatment of Severe Novel Coronavirus Infection Caused by Omicron Variant; Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 10); Diagnosis and Treatment Plan for Severe Cases of Novel Coronavirus Infection (Trial Fourth Edition)). In this study, the drug flunotinib maleate (FM) 100mg is a class of JAK inhibitors of anti-inflammatory therapy of SOC as standard clinical treatment regimen, and will be used in combination with SOC according to the judgment of the investigator."
45760213|NCT03808259|Drug|(S)-ketamine IV Infusion|(S)-ketamine IV solution will be infused at a dose of less than or equal to 14mg.
45760214|NCT03808259|Drug|Placebo|Participants will receive matching placebo.
45760215|NCT05742659|Other|A mobile-based interactive simulation scheme (MISS)|A mobile-based interactive simulation scheme (MISS) was proposed and developed to investigate its effects on facilitating hands-on learning of NG insertion in undergraduate medical students.
45616148|NCT05713279|Drug|SOC|"In this study, the standard treatment plan (SOC) for COVID-19 in the Department of Respiratory and Critical Care Medicine was used as the best accessible treatment, and the treatment plan principle was based on the latest national guidance document (Expert Recommendations for Clinical Treatment of Severe Novel Coronavirus Infection Caused by Omicron Variant; Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 10); Diagnosis and Treatment Plan for Severe Cases of Novel Coronavirus Infection (Trial Fourth Edition)). In this study, the drug flunotinib maleate (FM) 100mg is a class of JAK inhibitors of anti-inflammatory therapy of SOC as standard clinical treatment regimen, and will be used in combination with SOC according to the judgment of the investigator."
45616149|NCT05714371|Drug|Nivolumab|Patients receiving nivolumab
45616150|NCT05714371|Drug|Ipilimumab + nivolumab|Patients receiving ipilimumab + nivolumab
45616151|NCT05714371|Drug|Pembrolizumab|Patients receiving pembrolizumab
45616152|NCT05714371|Drug|Dabrafenib + trametinib|Dabrafenib + trametinib
45616153|NCT03103191|Diagnostic Test|KL-6 levels|Measure of KL-6 in serum
45616154|NCT02472613|Device|acupuncture|"Patients will be treated at Renzhong（Du26）, Yintang（EX-HN3）、accupuncture Shangxing（DU23）penetrate to Baihui（DU20）,Sishencong（EX-HN1）; Neiguan（PC6）,Sibai（ST2）,Fengchi（GB20）and Sanyinjiao（SP6）in bilateral;Jianyu（LI15）,Quchi（LI11）,Shousanli（LI10）,Hegu（LI 4）, Fengshi (GB31),Xuehai（SP10） ,Zusanli（ST36）、Taichong（LR 3） of the hemiplegia side. There are another six groups of acupoints in bilateral. The acupuncturist will choose one group acupoints according to patients syndrome:Zhigou (SJ6),Qimen (LR14);Xingjian (LR2),Xiaxi(GB43);Fenglong (ST40),Lianquan(RN23);Tongli (HT5),Xinshu (BL15);Xinshu (BL15),Pishu(BL20);Shenshu (BL23),Taixi (KI3).~The acupoints are inserted at the depth of 20-30mm except Renzhong（Du26）, Sibai（ST2）, Sishencong（EX-HN1）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks."
45616155|NCT02472613|Drug|placebo|Placebo was given for 12 consecutive weeks.
45616156|NCT02472613|Device|sham-acupoint acupuncture|"Jianliao（SJ14）,Tianquan（PC2）,Xiabai (LU4),Xiaoluo (SJ12),Shouwuli (LI13),Sidu (SJ9),Huizong (SJ7),Wenliu (LI7),Zhouliao (LI12),Quze（PC3）,Kongzui（LI6）,Zhigou（SJ6）,Zhongzhu（SJ3）,Futu（ST32）,Jimen (SP11),Yinshi (ST33),Liangqiu（ST34）,Shangjuxu（ST37）,Xiajuxu（ST39）,Xiyangguan（GB33）,Ligou（LR5）,Pucan (BL61),Jinggu (BL64),Rangu (KI2),Ligou (LR5),Neiting （ST44） of the hemiplegia side.~• The acupoints are inserted at the depth of 20-30mm,except Pucan (BL61),Jinggu (BL64),Rangu (KI2) ,Neiting （ST44）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks."
45911579|NCT05778474|Other|Pathologic group|"Participants will walk on a treadmill mounted on force sensors. They will walk freely, under tight supervision, but without hanging to any support. The test sequence will be the following:~4. Familiarization. Participants will walk on the treadmill with the belt running at increasing velocities up to their spontaneous walking velocity . Speed will be increased of 0.1 m s-1 every 30 s. A brief pause of around 1 minute will follow.~5. Walking. Participants will walk at 0.4 m s-1 for at least 30 seconds. Participants will be informed a few seconds before the changes in belts' velocities with a verbal warning."
45616157|NCT02472613|Drug|Fluoxetine|Fluoxetine was given at a dose of 20 mg/day for12 consecutive weeks.
45911580|NCT05778461|Drug|L-ornithine L-Aspartate|LOLA will be administered via continuous intravenous infusion at a dosage of 0.75g/kg/day for 72h (maximum 30g/day). High volume plasma exchange (2x plasma volume) will be started at least 8 hours after initiation of LOLA, and will be completed within 4-5 hours depending on the volume of exchange. Three consecutive cycles of HVPE will be performed, starting at 8h, 32h and 56h respectively.
45911581|NCT05778461|Drug|Placebo|Placebo will be administered via continuous infusion for 72h, along with HVPE (2x plasma volume) starting at 8h, 32h and 56h respectively.
45445636|NCT02061904|Radiation|DEXA: dual energy X-ray absorptiometry|Bone mineral density development measured with dual energy X-ray absorptiometry
45616158|NCT03100851|Dietary Supplement|Lactobacillus casei strain Shirota|a bottle of 100 mililiter probiotic dairy beverage containing 10^8 CFU Lactobacillus casei strain Shirota every day after lunch.
45760216|NCT03808181|Device|ChloraSolv|Weekly application of ChloraSolv for 6 weeks
45760217|NCT02386605|Behavioral|Motivational Interviewing and Cognitive Behavioral Therapy|group-based recovery-oriented Motivational Interviewing combined with cognitive-behavioral therapy to target the negative symptoms of schizophrenia
45445637|NCT02061904|Other|Short Form Health Survey 12|questionnaire for general health monitoring
45445638|NCT02061904|Other|VAS-satisfaction|questionnaire for intervention satisfaction monitoring
45445639|NCT02061904|Other|VAS-pain|questionnaire for pain monitoring
45616159|NCT05047783|Drug|Masitinib Mesylate|3CL-protease inhibitor
45616160|NCT05047783|Drug|Placebo|Placebo
45616161|NCT03100695|Other|Concentrated autologous PRP-BMA|Injection of autologous, concentrated platelet-rich plasma and bone marrow aspirate at the site of fixation.
45616162|NCT02472535|Other|Run-In Period: Placebo|2 capsules, once a day for two weeks
45760218|NCT02386605|Behavioral|Relaxation Skills|Relaxation and mindfulness skills training group for comparison condition for negative symptoms of schizophrenia
45760219|NCT03807947|Procedure|Radial TAE - Bland embolization with 40-100 Microparticles|TAE - Bland embolization with 40-100 Microparticles performed via left transradial access
45911582|NCT05778448|Device|Brain Computer Interface/ Functional Electrical Stimulation/ Virtual Reality|A BCI system involves 3 main components - (1) brain activity collection, (2) external devices triggered by specific features of brain activity, and (3) a processor which decodes the brain activity signal and then translates it into computerized commands to control external devices such as virtual games and functional electrical stimulation (FES).
45445640|NCT02061904|Other|Harris Hip Score|questionnaire for hip function monitoring
45452270|NCT05613400|Drug|Simvastatin 10mg|One simvastatin 10mg-tablet
45760220|NCT03807947|Procedure|Transfemoral TAE - Bland embolization with 40-100 Microparticles|TAE - Bland embolization with 40-100 Microparticles performed via right transfemoral access
45760221|NCT02387853|Drug|LEO 90100|
45760222|NCT03802331|Drug|BI 1323495,|single oral doses
45616163|NCT02472535|Drug|MBX-8025 50 mg (Dose Escalation Period 1)|"1 capsule once a day for 4 weeks~(MBX-8025 50 mg capsule)"
45616164|NCT02472535|Drug|MBX-8025 50 mg or 100 mg (Dose Escalation Period 2)|"1 capsule once a day for 4 weeks~(MBX-8025 50 mg or 100 mg capsule)"
45760223|NCT05742581|Other|Computed Tomography|In our study, computerized tomography of 24 rotator cuff tears (rotator cuff tear group) and 20 Bankart lesions, and no rotator cuff tears (control group) were examined. CSA and AI were measured on three-dimensional glenohumeral joint models obtained by three-dimensional reconstructions of computed tomography examinations.
45760224|NCT05708079|Procedure|Endovascular thrombectomy|An endovascular thrombectomy is the removal of a thrombus (blood clot) under image guidance. A thrombectomy is most commonly performed for an arterial embolism, which is an arterial blockage often caused by atrial fibrillation, a heart rhythm disorder.
45616165|NCT02472535|Drug|MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)|"1 or 2 capsules once a day for 4 weeks~(MBX-8025 50 mg, 100 mg or two (2) 100 mg capsules)"
45760225|NCT02145299|Device|TruePath CTO Device|"The TruePath CTO Device is composed of a 0.018 guidewire and a motor housing with a connector cable along with a sterile, disposable battery-powered Control Unit for manipulation of the device during operation. The TruePath CTO Device is indicated to facilitate the intra-luminal placement of conventional guidewires beyond peripheral artery chronic total occlusions."
45760226|NCT02145299|Device|CROSSER CTO Device|
45616166|NCT00783237|Drug|Mometasone|Mometasone Furoate Nasal Spray, single dose of 200 mcg (2 sprays per nostril)
45616167|NCT00783237|Drug|Placebo|Placebo nasal spray, single dose of 2 sprays per nostril
45760227|NCT02051595|Other|Vancomycin concentrations|Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.
45760228|NCT02146001|Other|Reducing sedentary behavior group|This intervention will use individual counseling and the the BodyMedia armband to self-monitor sedentary behavior. The goal will be to decrease time spent in sedentary behavior by 60 minutes each day.
45616168|NCT02478541|Other|Sugar study|Subjects are given a single test meal on two study days that has a sugary drink that varies in the amount of fructose and glucose it contains. They consume the same amount of fat on both study days.
45760229|NCT02146001|Other|Moderate-to-vigorous activity group|This group will be administered an individual, behavioral intervention using the BodyMedia armband to self-monitor physical activity. The prescription will be 150 minutes of moderate exercise (e.g. brisk walking) each week.
45760230|NCT02313597|Procedure|SETON|In seton treatment, initially Hydrogen peroxide will be applied to the external opening with a 10-cc syringe, and the internal opening will be located by direct visualization of the anal canal via proctoscope. A probe will be inserted into the external opening and carefully maneuvered through the internal opening. Silk 1/0 suture will be then tied to the tip of the probe, which will be then squeezed out of the external opening. The suture will be then tied around the sphincter and through fistula tract. Later, the seton will be tightened at four-week intervals under local anesthesia until the suture cut through the sphincter.
45616169|NCT03099915|Other|completion of self-reported questionnaires|Single completion: Participants will have to complete self-reported questionnaires based on gina criteria and 12-item general health questionnaire
45616170|NCT02474875|Other|Educational program|Patients in experimental groups will receive different educational sessions (contents and duration)
45616171|NCT03103035|Other|Blog|Participants randomised to the experimental group are exposed to one blog post each week for a period of 6 months. Blog posts focus on the improvement of fruits and vegetables consumption targeting four main determinants of the behavior: (1) knowledge; (2) attitude; (3) self-efficacy; and (4) motivation/goals. Each post included a step-by-step recipe developed by the research team and featuring fruits and vegetables. Recipes were described textually and also using pictures and/or video. Twenty-six posts were created over the six-month intervention.
45616172|NCT03109249|Drug|SPARC1613|Single intravenous infusion of 260 mg/m2 of SPARC1613 delivered over 25 minutes in either of two periods (Period 1 or 2)
45616173|NCT03109249|Drug|Reference1613|Single intravenous infusion of 260 mg/m2 of Reference1613 delivered over 30 minutes in either of two periods (Period 1 or 2)
45616174|NCT02478229|Drug|Sofosbuvir (SOF) and Ledipasvir (LDV)|
45760231|NCT02313597|Procedure|VAAFT|Patients assigned to the VAAFT group will receive the following procedure. The external opening will be widened with a probe, and a fistulascope will be inserted to delineate the primary and secondary tracts and locate the internal opening. The internal opening will be then stitched with Vicryl™ (Polyglactin 910) 2-0 suture through the anal route with the help of a proctoscope. The tract of the fistula will be washed and debrided through the scope and cauterized. Finally, the external opening will be excised and will be sent for biopsy.
45760232|NCT05742503|Other|Depo-Provera|Injectable progesterone
45760233|NCT05742503|Other|Implanon|Etonogestrel implant
45760234|NCT05742503|Other|Norgestrel|Pill containing progesterone
45445641|NCT01322061|Drug|Ascorbic Acid|Effervescent,1000mg/tablet, 2000 mg dissolved in 50ml water, the drug will be given once, one hour prior to surgery
45445642|NCT02062918|Device|Abdominal belt|
45445643|NCT03768375|Biological|conventional chemotherapy(FORFIRINOX) combined with target agents|Drug: FORFIRINOX Conventional chemotherapy:gemcitabine and oxaliplatin Drug: Cetuximab Drug: Trastuzumab Drug: Gefitinib Drug: Lapatinib Drug: Everolimus Drug: Sorafenib Drug: Crizotinib
45760235|NCT05742503|Other|Mirena|Levonorgestrel-releasing intra-uterine drug (IUD)
45760236|NCT02388321|Drug|Ketamine|intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
45760237|NCT02388321|Drug|Fentanyl|intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
45911583|NCT05778435|Device|wireless fetal monitoring system|The wireless fetal monitoring system shortens the period of labor by enabling the woman to be more mobile during the intrapartum period.
45445644|NCT03768375|Biological|conventional chemotherapy(FORFIRINOX)|conventional chemotherapy(FORFIRINOX)
45760238|NCT03802253|Behavioral|Time Restricted Feeding(TRF)|Participants will receive a diet of 1200-1500kcal/d and be instructed to eat only during a window of 8 hours (Finishing the last meal before 4pm) in the first 6 months. 6 months later, Participants will receive a diet of 1200-1500kcal/d without a restriction of feeding time.
45616175|NCT04491799|Diagnostic Test|Fecal calprotectin|Fecal calprotectin is a protein found in human neutrophils, and it is released during active periods of inflammation of intestine. The sensitivity and specificity has been reported at 93% and 96%, respectively in differentiating inflammatory bowel disease from irritable bowel syndrome in outpatient setting.
45616176|NCT05002387|Device|NanoScope™ Operative Arthroscopy (Arthrex, Inc)|Needle arthroscopy will be performed in the operating room to visual the medial, lateral, and patellofemoral compartments prior to undergoing either unicompartmental or total knee arthroplasty
45616177|NCT05272423|Diagnostic Test|FoundationOne® Liquid CDx|The FoundationOne® Liquid CDx is an FDA-approved companion diagnostic that analyzes guideline-recommended genes from a simple blood draw.
45760239|NCT03802253|Behavioral|Reduced Calorie Diet (RCD)|Participants will receive a diet of 1200-1500kcal/d and keep their usual eating pattern.
45616178|NCT04887025|Biological|RGV004|a genetically-engineered vaccinia virus (encoding CD19/CD3 bispecific antibody)
45616179|NCT04879615|Drug|Alteplase|Patients will receive standard dose intravenous alteplase (0.9 mg per kilogram, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)
45616180|NCT05068947|Drug|GV101|GV101 administered once orally.
45616181|NCT05068947|Drug|Placebo|Matched placebo
45616182|NCT05713123|Other|A SPECT-CT whole body is added in VERITON-CT camera|A SPECT-CT whole body in VERITON-CT camera is added after the conventional procedure recorded in Anger camera
45616183|NCT05069103|Device|Intervention|"Similar to the original TWIST trial , patients will receive access to the online tool hosted on the ISLA platform until postoperative day 30 which is composed of two parts:~A series of simple questions related to the detection of surgical wound infection (e.g. redness, swelling, fluid leakage, etc). These questions would be expected to be routinely asked during in-person assessment, and these questions have been previously developed and tested within the TWIST trial (the only change being the addition of questions specifically relating to the change in these symptoms).~At least one image of their surgical wound(s)."
45616184|NCT05713045|Dietary Supplement|Konakion|Comparing 4 different regimen of Vitamin K administration in newborn
45616185|NCT00653835|Drug|Ezetimibe + Simvastatin|oral tablets: ezetimibe 10 mg + simvastatin 20 mg once daily for 6 weeks
45616186|NCT00653835|Drug|Simvastatin|oral tablets: simvastatin 20 mg + ezetimibe placebo once daily for 6 weeks
45616187|NCT05068557|Dietary Supplement|Dietary plan along with fish oil capsules (3 capsules daily. Containing EPA+DHA: 1.8 g).|Subects within the Intervention group will be provided with a dietary plan along with fish oil capsules. Subjects will be asked to consume three capsules per day. Every capsule contains: EPA+DHA: 1.8 g.
45616188|NCT05068557|Dietary Supplement|Dietary plan along with chia/linseed oil capsules (3 capsules daily. Containing ALA 1.6 g).|Subects within the Intervention group will be provided with a dietary plan along with fish oil capsules. Subjects will be asked to consume three capsules per day. Every capsule contains: ALA 1.6 g).
45616189|NCT03099759|Dietary Supplement|Vitamin D|Vitamin D2/D3
45616190|NCT03535311|Procedure|Measurement of sternal-notch to umbilicus distance|"The sternal notch to upper border of umbilicus length measurement in centimetres.~The length of the umbilical stump in centimetres.~The length of the UVC and/or UAC inserted in centimetres which will be identified using the printed markers on the catheter. The marker which is closest to the end of the umbilical stump will be the recorded value.~The length of the UVC and/or UAC in centimetres when the umbilical stump length is subtracted."
45616191|NCT03100773|Other|Oral health educational strategy|Oral health educational strategy consisted of four consecutive sessions (once a week) about etiological factors of caries (using visual aids), oral hygiene instructions (using models), supervised toothbrushing and explanation of atraumatic restorative treatment (indications and stages).
45616192|NCT03100773|Procedure|Atraumatic Restorative Treatment|Atraumatic Restorative Treatment was performed using hand instruments for opening and cleaning the cavities and a high-viscosity glass-ionomer for restoration.
45760240|NCT05742425|Drug|Serplulimab Combined With FOLFIRI and Bevacizumab|For patients with confirmed failure to reach CC0/1, they should be treated with sullizumab combined with FOLFIRI+bevacizumab for 4-8 cycles within 3 weeks after the exploration operation. After the end of the 4th and 8th cycles, they should be evaluated with imaging and MDT. If the conversion is successful, they should be treated with a second exploration operation within 3-4 weeks, The patients with CC0/1 can be evaluated for tumor reduction surgery (CRS) combined with intraperitoneal hyperthermic perfusion chemotherapy (HIPEC), and the follow-up treatment plan will be selected according to the clinical situation of the patients after surgery; If CC0/1 cannot be evaluated after the second exploration surgery and CC0/1 cannot be performed after the imaging evaluation, other chemotherapy and optimal supportive treatment will be performed according to the situation.
45911584|NCT05778409|Biological|Cordyceps cicadae extract|500mg/ day for one month
45616193|NCT05712811|Drug|CRYOTHERAPY|Group A had their warts treated once every two weeks for a total of twelve weeks, with liquid nitrogen using cryoget method for 10 to 15 seconds on each lesion (depending on size, until a narrow white rim of around 1 mm developed around it).
45616194|NCT05712811|Drug|Tricholoracetic acid|Group B were treated with liquid TCA 90% by an applicator every two weeks for a total of twelve weeks. After 20 minutes, patients were instructed to remove the solution by washing their warts with water or regular saline.
45616195|NCT05711797|Drug|ZX-7101A 80mg|ZX-7101A a drug to treatment influenza in Chinese adults
45616196|NCT05068245|Behavioral|Preselected classical music|Preselected classical music
45911585|NCT05778383|Dietary Supplement|Zinc Acetate|Each participant allocated in the intervention arm will be treated as Standard of Care and will be supplemented with 240mg of Zinc Acetate
45911586|NCT05778370|Device|Swept Source Optical Coherence Tomography(Topcon DRI Triton)|Topcon DRI Triton
45616197|NCT05244577|Drug|Olanzapine Tablets|Olanzapine,Ondansetron,Dexamethasone,Fosaprepitant
45616198|NCT05244577|Drug|Placebo|Placebo,Ondansetron,Dexamethasone,Fosaprepitant
45616199|NCT05068167|Diagnostic Test|Kidney function test|Creatinine twice the baseline and urine output of fewer than 0.5 ml/kg per hour for 12 hours
45616200|NCT05710237|Drug|Psilocybin 25 mg|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with either risperidone 1 mg or place. It will also be administered in conjunction with supportive therapy.
45445645|NCT03768297|Procedure|dual zone concept|immediate implant with bone fill till soft tissue level
45616201|NCT05710237|Drug|Risperidone 1 MG|The risperidone is encapsulated using a cellulose capsule and contains 1 mg of risperidone. The risperidone will be administered once during the trial in combination with either psilocybin 25 mg or placebo. It will also be administered with supportive therapy.
45616202|NCT05710237|Drug|Placebo|The placebo will be administered once during the trial in combination with either risperidone 1 mg or psilocybin 25 mg.
45616203|NCT05068323|Diagnostic Test|Digital electroencephalography (EEG) for an hour (16 channels)|Digital electroencephalography (EEG) for an hour (16 channels)
45616204|NCT02472379|Behavioral|Writing: Group 1|Writing about experiences with familiar individuals in their lives, once a week for 6 weeks.
45616205|NCT02472379|Other|Writing: Group 2|Writing about experiences with familiar places, once a week for 6 weeks.
45616206|NCT04215003|Drug|A|"Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle. Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle,6 cycles.~Pertuzumab: 420-mg ( loading dose 840mg) ivgtt d1, 21 days per cycle,6 cycles."
45616207|NCT04215003|Drug|B|Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle.
45616208|NCT04215003|Drug|CL1|"Drug:~SHR6390（CDK4/6 inhibitor）150 mg qd(three week on one week off) Fulvestrant 500mg IM Q4W； Premenopause：Goserelin 3.6mg IM IM Q4W."
45616209|NCT04215003|Drug|CL2|"Drug:~SHR6390（CDK4/6 inhibitor）150 mg qd(three week on one week off); Alpelisib 300mg PO QD； Premenopause：Goserelin 3.6mg IM IM Q4W."
45616210|NCT04215003|Drug|CLH1|"Drug:~SHR6390（CDK4/6 inhibitor）150 mg qd(three week on one week off) Fulvestrant 500mg IM Q4W； Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle； Pertuzumab: 420-mg ( loading dose 840mg) ivgtt d1, 21 days per cycle； Premenopause：Goserelin 3.6mg IM IM Q4W."
45616211|NCT04215003|Drug|CLH2|"Drug:~SHR6390（CDK4/6 inhibitor）150 mg qd (three week on one week off) Alpelisib 300mg PO QD； Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle； Pertuzumab: 420-mg ( loading dose 840mg) ivgtt d1, 21 days per cycle； Premenopause：Goserelin 3.6mg IM IM Q4W."
45616212|NCT04215003|Drug|CH1|"Drug:~pyrotinib(EGFR-TKI) 400mg qd； Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle； capecitabine 1000mg/m2 bid(d1-d14)"
45616213|NCT04215003|Drug|CH2|"Drug:~Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle.Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle； Alpelisib 300mg PO QD； Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle； Pertuzumab: 420-mg ( loading dose 840mg) ivgtt d1, 21 days per cycle； Premenopause：Goserelin 3.6mg IM IM Q4W."
45616214|NCT04215003|Drug|CT1|"Drug:~SHR6390（CDK4/6 inhibitor）150 mg po.qd(three week on one week off) SHR3680（AR inhibitor）240 mg po. qd."
45616215|NCT04846387|Diagnostic Test|Magnetic Resonance Imaging (MRI)|"A T1-weighted Anatomical Image, Diffusion Weighted Image, and functional MRI (fMRI) of empty bladder image will be obtained.~Additionally, fMRI image during full bladder state and voiding/holding tasks will be obtained."
45616216|NCT04846387|Diagnostic Test|Post-Void Residual|The patient's post-void residual is determined using a portable ultrasound machine after emptying the bladder just prior to entering the MRI scanner and immediately after the MRI scan.
45616217|NCT04846387|Diagnostic Test|Uroflowmetry|Patients will urinate into a funnel connected to an electric flow meter to record urine flow rates in mililters per second. This is used as part of the screening process.
45911587|NCT05778357|Other|Group1|75 healthy infants were included. Neuromotor development was evaluated with the Denver II Developmental Screening Test and Alberta Infant motor scale.
45616218|NCT04846387|Behavioral|Questionaire - AUA Symptom Score|Subjects will fill out questionnaire asking about urinary symptoms. The range is 0-35.
45616219|NCT05067699|Diagnostic Test|Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)|The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).
45616220|NCT02474797|Device|Diaphragmatic ultrasonography|"Daily Measure of Diaphragmatic Thickening Fraction (DTF) will be performed by a trained physiotherapist. Physiotherapist (A. LE NEINDRE). The patient will be then instructed to perform breathing to total lung capacity and then to exhale to residual volume, when it is possible (awaken patient). Awakening status will be recorded. Mechanically ventilated patients will be evaluated in Pressure Support (PS) mode (during daily PS mode research for patients with Controlled Ventilation), with the lower PS level tolerated. PS level will be recorded.~Thickening fraction (TF) measure is performed in B-mode using the following formula: TF (%) = [(end-inspiration thickness - end-expiration thickness)/(end-expiration thickness) x 100]. Diaphragmatic dysfunction is defined like a DTF < 20% (7)."
45616221|NCT04191993|Device|Total hip arthroplasty|Surgical intervention designed to replace arthritic joint with artificial implant
45760241|NCT02313675|Drug|Acetaminophen|
45760242|NCT02313675|Drug|Ketorolac Tromethamine|
45760243|NCT02313675|Drug|Saline|
45760244|NCT02388633|Procedure|Plasmapharesis|Clinically-indicated LDL apheresis
45760245|NCT02389101|Other|68Ga-DOTANOC PET/CT; Diffusion weighted MRI|PET/CT: Radionuclide imaging using short-lived isotope Ga-68; MRI imaging w/o gadolinium contrast
45445646|NCT03762525|Radiation|ECG gated CTA|"Routine care consists of a preoperative and several postoperative CTA scans. In A. The preoperative and first postoperative CTA will be replaced by ECG-gated CTA imaging and in B. the scheduled imaging will be replaced by an ECG-gated CTA.~General information: The protocol is based on the ECG gated cardiac protocol using abdominal parameter settings."
45445647|NCT02063308|Dietary Supplement|Oxaloacetate (OAA)|
45445648|NCT03768219|Biological|APVO210|APVO210
45445649|NCT03768219|Biological|Placebo|Placebo is saline based IV infusion, and is identical in appearance to active study drug.
45445650|NCT02063386|Drug|AZD1722|Single oral dose 15 mg of [14C]AZD1722
45616222|NCT02474719|Other|comparison of two regimens in peritoneal dialysis|Dialysate samples (8 by scheme, volume of 10 mL) are collected at each cycle (one at the beginning and one at the end of the cycle). A blood sample (5 mL) is collected at the beginning of the second scheme and a 24-hour urine sample at the end of the second scheme.
45616223|NCT05067153|Drug|Fragmin 5000 UNT in 0.2 ML Prefilled Syringe|30 days postoperative prophylactic treatment.
45616224|NCT02642679|Device|Opticell Ag|Opticell Ag+ applied to STSG donor site
45616225|NCT05224921|Other|Not applicable (cohort study)|This is a prospective observational study and does not include interventions. The exposure is peripheral perfusion index and the outcome is the incidence of late onset sepsis. From the day when the very low birth weight infant is admitted into hospital, PPI monitoring should be recorded once a day, and continuous monitoring would be recorded until 1 month after birth. Before collection, the infant will be confirmed to be in supine position with neutral temperature, and at the same time, the infant will be in a quiet state, without the contact and operation of medical personnel.
45616226|NCT03100461|Other|I2|"A touch screen computer delivered implementation intentions (I2) intervention on CRC screening. Implementation intentions are the exact steps (the when, what, where, how) one will take to complete a test (the date and time, at home or at the doctor's office, with what supplies, etc.)."
45616227|NCT03100461|Other|Health Education|Standard of care approach that will provide basic information on CRC screening.
45616228|NCT02472301|Dietary Supplement|cowpeas complementary food|cowpeas supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
45616229|NCT02472301|Dietary Supplement|corn-soy flour|Corn-soy flour supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
45616230|NCT02472301|Dietary Supplement|common bean complementary food|common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
45616231|NCT05067309|Drug|Letrozole 2.5mg|Missed abortion received letrozole then misoprostol
45616232|NCT03099603|Drug|HTD1801|A small molecular compound for the treatment of primary sclerosing cholangitis
45616233|NCT02474563|Drug|Bortezomib|Participants receiving Bortezomib 1.3 milligram per square meter (mg/m2) will be observed in this study.
45616234|NCT02474563|Drug|Melphalan|Participants receiving Melphalan 9 mg/m^2 will be observed in this study.
45760246|NCT02389725|Device|disposable elastic tourniquet|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
45760247|NCT02389725|Device|blood pressure cuff|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
45760248|NCT05568797|Biological|RSVPreF3 OA investigational vaccine|One dose of RSVPreF3 OA investigational vaccine administered intramuscularly.
45760249|NCT05568797|Biological|FLU vaccine|One dose of FLU vaccine administered intramuscularly.
45760250|NCT03801629|Drug|High Morphine Dose|Subjects will receive an intramuscular morphine injection (0.07mg/kg) in the non-dominant deltoid muscle. Metoclopramide (10mg; oral) will be administered PRN to reduce nausea.
45616235|NCT02474563|Drug|Prednisone|Participants receiving Prednisone 60 mg/m^2 will be observed in this study.
45616236|NCT04092153|Device|Total knee arthroplasy|Surgical implantation of prosthetic knee using robotic-arm assist
45616237|NCT05066841|Drug|CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)|CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang) for 12 weeks
45616238|NCT05066841|Drug|10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)|10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang) and 90% starch for 12 weeks
45760251|NCT03801629|Drug|Low Morphine Dose|Subjects will receive an intramuscular morphine injection (0.04mg/kg) in the non-dominant deltoid muscle. Metoclopramide (10mg; oral) will be administered PRN to reduce nausea.
45616239|NCT04090515|Behavioral|Project Health|This intervention involves a one-hour group meeting for six consecutive weeks.
45760252|NCT03801551|Diagnostic Test|Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).|Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).
45760253|NCT05741021|Drug|F520|F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).
45760254|NCT05741021|Drug|Pemetrexed|A chemotherapy medication used to treat a number of types of cancer.
45760255|NCT05741021|Drug|Carboplatin|A chemotherapy medication used to treat a number of types of cancer.
45760256|NCT05741021|Drug|Paclitaxel|A chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC).
45760257|NCT04383977|Drug|Apatinib and Etoposide capsule|Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
45760258|NCT04383977|Drug|Apatinib|Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity
45445651|NCT02062996|Drug|Oxymetazoline|
45445652|NCT03762369|Drug|CKD-351|twice a day
45616240|NCT04090515|Other|Educational Video Control|This intervention involves a one-hour educational video control viewing for six consecutive weeks.
45616241|NCT03099525|Other|ILD|This is an observational study without any intervention.
45616242|NCT03100227|Other|PET [18F] FDG|Measurement of carbohydrate metabolism at the individual level. Standardization of the individual imaging data in a standard anatomical space and then calculation of an average image through the group-level controls.
45760259|NCT03801239|Diagnostic Test|Urodynamic Study|during visit Week 0 patients had urodynamic study
45760260|NCT03801239|Diagnostic Test|OABSS questionnaire fulfilment|during visit Week 0 and Week 2 patients fulfilled OABSS
45760261|NCT03801239|Diagnostic Test|UDI-6 questionnaire fulfilment|during visit Week 2 patients fulfilled UDI-6 questionnaire
45760262|NCT03801239|Diagnostic Test|IIQ-7 questionnaire fulfilment|during visit Week 2 patients fulfilled IIQ-7 questionnaire
45445653|NCT03762369|Drug|Latanoprost|once a day
45616243|NCT03100227|Other|Anatomical MRI|All subjects will benefit from a 3D anatomical MRI to control the normality of their MRI and an automatic segmentation of 73 brain regions by multi-atlas segmentation.
45616244|NCT02474641|Radiation|Standard Radiation|"Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or~Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or~Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially"
45616245|NCT02474641|Radiation|Hypofractionation with SIB|Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed
45616246|NCT03099447|Other|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
45616247|NCT03099447|Other|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
45616248|NCT03099447|Other|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
45616249|NCT03098901|Diagnostic Test|Tc99m-labeled pyrophosphate scan|Intravenous injection of Tc99m-labeled pyrophosphate with consecutive whole body scan using gamma ray scanner for assessment of radioactive uptake in the heart. The results of the scan will be evaluated by a specialist in the field. The uptake will be graded using Perugini scale (0- no uptake, 1- uptake in heart less intense than in bones, 2-uptake in heart as intense as in bones, 3-uptake in heart more intense than in bones).
45616250|NCT03108781|Drug|Lavender Oil|Lavender Oil twice a day; one month on the face and one month on the legs
45616251|NCT03108781|Drug|sunflower oil|placebo twice a day (sunflower oil); one month on the face and on month on the legs
45616252|NCT03993951|Device|ICT System|Update the Information and Communications Technology System in Family Service Agencies
45616253|NCT05419609|Procedure|Limited facelift|A limited procedure under local anesthesia that addresses signs of aging in the lower face and neck
45616254|NCT05419609|Procedure|Full facelift|A full face and neck lift that addresses signs of aging in the face and neck
45616255|NCT05419609|Other|"FACE-Q | Aesthetics - Satisfaction With Lower Face and Jawline"|"Completed by patients. The FACE-Q | Aesthetics - Satisfaction With Lower Face and Jawline is a 5-item questionnaire. Each item is rated 1-4, with 1 being Very Dissatisfied and 4 being Very Satisfied. Lower scores suggest the person may be less pleased with the appearance of their lower face and jawline."
45616256|NCT05419609|Other|"FACE-Q | Aesthetics - Recovery Early Symptoms"|"Completed by patients. The FACE-Q | Aesthetics - Recovery Early Symptoms is a 17-item questionnaire. Each item is rated 1-4, with 1 being Not at all and 4 being Extremely. Lower scores suggest the person may be experiencing fewer symptoms early in their recovery following an aesthetic facial procedure."
45616257|NCT05419609|Other|"FACE-Q | Aesthetics - Satisfaction with Outcome"|"Completed by patients. The FACE-Q | Aesthetics - Satisfaction with Outcome is a 6-item questionnaire. Each item is rated 1-4, with 1 being Definitely disagree and 4 being Definitely agree. Lower scores suggest the person may be less pleased with their final appearance following surgery and the decision to have an aesthetic facial procedure."
45616258|NCT05419609|Other|"FACE-Q | Aesthetics - Adverse Effects: Cheeks, Lower Face, Neck"|"Completed by patients. The FACE-Q | Aesthetics - Adverse Effects: Cheeks, Lower Face, Neck is a 15-item questionnaire. Each item is rated 1-3, with 1 being Not at all and 3 being A lot. Lower scores suggest the person may be experiencing fewer chronic symptoms following an aesthetic facial procedure."
45616259|NCT05066763|Other|Non-interventional|non-interventional
45616260|NCT02477995|Biological|DTaP Vaccine A|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml, three doses, 28 days interval
45616261|NCT02477995|Biological|DTaP Vaccine B|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B(Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
45616262|NCT03098823|Drug|RAYOS|FDA approved RAYOS for indication of fatigue in Lupus.
45616263|NCT03098823|Drug|Prednisone|FDA approved corticosteroid frequently used for SLE.
45760263|NCT03801161|Biological|Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).|Pentavalent vaccine is being recommended to provide infants at 6wk, 10wk and 14wk of age. This vaccine also induces plasma CRP >5 mg/L in infants within 24 hours of immunization.
45445654|NCT03762369|Drug|D930|three times a day
45616264|NCT05703919|Drug|Titrated Oxygen|Titrated oxygen strategy - a mix of supplemental oxygen and compressed atmospheric air as driver for inhaled bronchodilators to target SpO2 88-92%
46069024|NCT04703439|Behavioral|Educational materials|The intervention has been described in arm/group descriptions, which lasted for 60 days for each participants.
45445655|NCT03762369|Drug|Placebo of CKD-351|once a day
45445656|NCT03762369|Drug|Placebo of CKD-351|twice a day
45616265|NCT05703919|Drug|Standard Oxygen|Standard care using compressed oxygen (100%) as driver for inhaled bronchodilators
45616266|NCT04788277|Procedure|Biospecimen Collection|Undergo collection of urine samples
45616267|NCT04478487|Dietary Supplement|Medolac human milk based human milk fortifier (MHMHMF)|MHMHMF is admixed with expressed or donor human milk in graded doses according to tolerated feed volume according to established guidelines and maintain adequate micronutrient levels.
45445657|NCT03762369|Drug|Placebo of D930|three times a day
45445658|NCT03762057|Diagnostic Test|Intraabdominal pressure monitoring|Classic manometry technique measurement once daily
45452271|NCT05613400|Drug|Ezetimibe 10mg|One ezetimibe 10mg-tablet
45616268|NCT03108937|Drug|Dexmedetomidine|Patients in the experimental group will receive Dexmedetomidine during surgery.
45616269|NCT03108937|Drug|saline|Patients in the control group will receive saline but not Dexmedetomidine during surgery.
45616270|NCT05689099|Drug|Semaglutide B, 1.34 mg/mL|Participants will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
45616271|NCT05689099|Drug|Semaglutide B, 0.68 mg/mL|Participants will receive single dose of 0.5 mg Semaglutide B, 0.68 mg/mL subcutaneously.
45616272|NCT03913845|Drug|lidocaine with epinephrine|One of the most commonly used local anesthetic agents in surgical practice is lidocaine. Lidocaine as a local anesthetic is characterized by a rapid onset of action (typically within 2-5 minutes of injection) and intermediate duration of efficacy and thus is often favored in the outpatient setting for pre-incisional injections. Of note, however, its effects general only last up to 2 hours. Epinephrine (adrenaline) vasoconstricts arteries, delaying the resorption of lidocaine, and thus almost doubles the duration of anesthesia.
45616273|NCT03913845|Drug|Normal saline with epinephrine|Several mechanisms could explain the inability to void postoperatively, including nerve conduction impairment from anesthesia. Multiple studies have investigated the use of various types of anesthesia and downstream effects on postoperative urinary retention. It is postulated that denervating the regional pelvic nerves for pain control may lead to denervation of the bladder for a transient period of time, block both the afferent and efferent pathways of the voiding mechanism, affect the urethral retro-resistance pressure and impact urethral length thereby contributing to voiding dysfunction postoperatively. The use of normal saline in this setting may have a reduction in rates and duration of postoperative urinary retention following retropubic midurethral sling placement.
45616274|NCT03098667|Device|LMA Protector|After induction of general anesthesia, the LMA Protector will be applied for airway management. The size of the laryngeal mask will be chosen according to the manufacturer's instructions. Lubricant gel will be applied to the dorsal side of the mask to ease the insertion to the oropharynx. The cuff of the mask will be filled with air by syringe until the indication of the integrated cuff pressure indicator is appropriate according to the manufacturer (green indication). If the indication changes during surgery, air will be added or removed accordingly. If the ventilation of the patient is inadequate at the beginning or anytime during the operation, the mask will be removed and the patient will be intubated.
45616275|NCT03098667|Device|Endotracheal tube|After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
45616276|NCT00705523|Drug|varenicline|1.0 mg BID for 12 weeks
45616277|NCT00705523|Drug|placebo|BID 12 weeks
45616278|NCT03903939|Drug|Iloprost|continuously infusion for 72 hours 1 ng/kg/min
45616279|NCT03903939|Drug|Isotonic saline|continuously infusion for 72 hours equal volume to Iloprost
45616280|NCT03749499|Other|HTN Educational Video|The video will educate participants in arm 2 about high BP, how it is diagnosed, and the importance of treating it to prevent secondary complications.
45760264|NCT05561777|Other|Physician-targeted CDS tool for PCN allergy delabeling|This intervention will provide access to a best-practices alert (BPA) containing the patient's risk-stratification status and a link to the local standard of care protocol, oral amoxicillin challenge order set and written consent form (same resources as used in pharmacist -led electronic health record dashboard). If the provider opts to perform the oral challenge and it is successfully passed, a second BPA will prompt them to update the allergy status in the medical record.
45760265|NCT02389881|Drug|TAK-058|TAK-058 Solution
45760266|NCT02389881|Drug|TAK-058 Placebo|TAK-058 placebo-matching solution
45760267|NCT02389959|Drug|Bevacizumab|Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose
45616281|NCT03749499|Other|Visual Echocardiogram Image Clips|Visual clips of age/gender-matched echocardiograms will be used to educate and motivate patients to change their behavior and improve their BP. We have found that real time visualization of cardiac ultrasound images with active discussion of findings is a significant patient motivator and empowerment tool, and was a significant factor in the success of our previous pilot study.
45616282|NCT03749499|Other|Mobile Health and Remote BP monitoring|All participants randomized to the intervention group will receive an FDA-approved HBPM kit that includes the Nokia wireless (self-inflating) BPM+ monitor and Health Mate mobile app. The app automatically launches when the patient slips on the cuff and turns on the monitor to measure his/her BP. Synced data are automatically uploaded from the mobile app to the iCardia server of our study.
45616283|NCT03749499|Other|Post-Acute Care HTN Transition consultation (PACHT-c)|All participants randomized to the E2 intervention will have a focused consultation with either a clinical pharmacist or an APN. During this consultation, the pharmacist/APN repeats the BP measurement; reviews the screening assessments; and reviews general principles of BP control including nutrition, exercise, and smoking cessation. BP will be managed according to the current published guidelines available at the time of funding regarding initiation of first-line antihypertensive medications. Patients with BP ≥160/100 mmHg may be started on antihypertensive medications by the provider during the consultation if appropriate.
45760268|NCT02389959|Drug|Placebo (Saline)|4mL of saline will be mixed by the Stanford Hospital Pharmacy as a control
45760269|NCT05518487|Biological|Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine|0.5 mL per dose of the Sanofi-GSK COVID-19 Vaccine will be administered intramuscularly in the deltoid muscle of the upper arm
46069025|NCT04695210|Behavioral|Virtual peer-to-peer support|See arm description
46069026|NCT04676906|Drug|NNC0113-6861|Study compound 1 - Each participant will receive a single intravenous (i.v) dose of [14C]-NNC0113-6861
46069027|NCT04676906|Drug|NNC0113-6860|Study compound 2 - Each participant will receive a single i.v dose of [14C]-NNC0113-6860
46069028|NCT04676906|Drug|NNC0113-6891|Study compound 3 - Each participant will receive a single i.v dose of [14C]-NNC0113-6891
46069029|NCT04652596|Other|Produce prescription program|A monthly $150 stipend will be provided to participants for 6 consecutive months to purchase fresh food items at mobile markets and independent farmers markets across Boston.
45616284|NCT05065905|Drug|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10*7 Units per mg of protein
45616285|NCT03718221|Other|Usual Care FIT Screening Strategy|Patients in usual care neighborhoods will receive FIT kits randomly throughout the year.
45616286|NCT03718221|Other|GeoMail FIT Screening Strategy|Patients in treated neighborhoods will receive kits at the same time.
45616287|NCT03703323|Other|Rotative thromboelastometry analysis|Obtaining blood sample (one tube of blood)
45616288|NCT03100305|Other|Collection of blood and urine|Collection of blood and urine before nutritional support, during total parenteral nutrition, during partial parenteral nutrition and during enteral nutrition
45616289|NCT05064969|Behavioral|Blended intervention based in acceptance and commitment therapy|"Blended intervention includes completing 9 e-modules consist of written material, videos, and assignments (one e-module per week) that can be completed over 9 to 12 weeks AND 9 (to 12 ) coaching sessions (telephone call). Weekly coaching will be offered by a motivational coach based in Maastricht University.~After the post-intervention assessments, individuals will receive monthly calls from the motivational coach as booster sessions. Booster sessions will be received on monthly basis for a period of 6 months (one session per month) and until the last follow-up assessment. Communication with participants will take place online or via telephone."
45616290|NCT05059275|Procedure|modified ostium obstruction surgery|An ostium at the end of the site where the nerve root enters the dural sac, from which CSF could flow continuously along the subarachnoid space, was identified An appropriate amount of autologous soft adipose tissue was removed under the skin of the incision or deep in the upper part of the buttock (Iliac spine incision, for less subcutaneous fat patients). It was then trimmed to resemble a gourd or dumbbell, with a relatively small middle section and two relatively large end sections. Trimmed graft was inserted into the neck of the sac and subarachnoid space below the dural sac so that it plugs the ostium inside and outside After filling the graft, Prolene 6-0 was used to continuously suture and close the ostium and dural sac starting from the lower part of the nerve root sheath and the ostium.The residual cyst cavity filled with autologous fat and gelatin sponge
45616291|NCT04434573|Other|Observation study|French-speaking digestive surgeons are invited to respond to an online survey consisting of 13 common clinical situations concerning primary or asymptomatic incisional hernia pathology where a therapeutic decision is requested.
45616292|NCT05019027|Drug|Beta blocker|"The intervention is a single-arm crossover withdrawal/reversal design (On vs Off) with up to 4 total periods, each period lasting between 2-6 weeks. During the On period, subjects will be on their beta blocker. During the Off period, their beta blockers will be down titrated and subsequently discontinued.~Other Names:~atenolol~betaxolol~bisoprolol~metoprolol~nebivolol~nadolol~propranolol~acebutolol~penbutolol~pindolol~carvedilol~labetalol~sotalol~metoprolol succinate~metoprolol tartrate"
45616293|NCT03099057|Other|follow-up of patients after interventional rhythm operation|The follow-up will take place at 3 months postoperatively, then at 1 year and then annually for 5 years.
45616294|NCT05005221|Behavioral|Automated text messages|Automated text messages will be used to facilitate blood sample collection at home for therapeutic drug monitoring of tacrolimus and mycophenolate. Participants will collect dried blood samples on 4 occasions. Two days in the clinical with simultaneous venipuncture (one sample) and two days at home with 4 samples collected at specified time points over 8 hours.
45616295|NCT05010915|Device|Transcranial magnetic stimulation|Transcranial magnetic stimulation
45616296|NCT05010681|Drug|Sintilimab|Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
45616297|NCT05010681|Drug|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
45616298|NCT05009823|Dietary Supplement|Standard F75|F-75 contains 75 kcal and 0.9 g protein per 100 ml.
45616299|NCT05009823|Dietary Supplement|Alternative F75 With CMV|Cereal flour, oil, sugar, powdered milk with complex mineral-vitamin.
45760270|NCT00775931|Procedure|umbilical cord blood transplantation|Umbilical cord blood will be collected, processed and shipped according to existing protocols. 2 cord blood units will be utilized if available. The choice of units will be based on the HLA typing standards of the University of Minnesota Blood and Marrow Program. If 2 units are not available, a single unit may be used. If a single unit is used, the unit should provide at least 10 x 107 nucleated cells/kg recipient body weight.
45760271|NCT00775931|Drug|Campath-1H|Campath-1H will be administered 0.3 mg/kg subcutaneously per day for three days starting on Day -21 through Day -19.
45760272|NCT00775931|Radiation|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior(PA) fields (250 cGy AP and 250 cGy PA).
45760273|NCT00775931|Drug|Cyclophosphamide|Cyclophosphamide (50 mg/kg/dose) will be given IV on day -4, -3, -2 and -1 over 2 hours. The total dose to be given over 4 days is 200 mg/kg for cord blood grafts-receiving patients only.
45445659|NCT03768141|Procedure|Liver surgery|"All indications (including benign and living donor resections), all co-morbidities, open, laparoscopic or robotic, single wedge resections to extended liver resections, single or two-stage hepatectomies, procedures with liver volume enhancement such as portal vein embolization (PVE), portal vein ligation (PVL), Associating Liver Partition and Portal vein Ligation for Staged hepatectomy (ALPPS), resections involving cold perfusion (ex-situ and ante-situ)"
45760274|NCT00775931|Drug|Busulfan|patients<12 kg: 1.1 mg/kg/dose IV every 6 hours for 8 doses total; patients >12 kg: 0.8 mg/kg/dose IV every 6 hours for 8 doses. on Day -8 to -7 for donor grafts-receiving patients, and on Day -9 to -6 for cord blood grafts-receiving patients.
45760275|NCT00775931|Drug|Fludarabine monophosphate|Fludarabine (35 mg/m2 daily for 5 days, 175 mg/m2 total) will be administered IV over 30 minutes on days -6, -5, -4, -3, and -2 for donor grafts-receiving patients only.
45760276|NCT00775931|Procedure|marrow graft transplantation|Related donor marrow will be collected, processed and shipped according to existing protocols of the National Marrow Donor Program or other URD registry, with the goal of achieving a cell dose of ≥ 6.0 x 108 nucleated cells/kg. The proportion of cells that are CD34+ will be determined prior to the administration of the graft. This will allow a portion of the graft (2 x 106 CD34+ cells) to be frozen for a subsequent infusion on day +42.
45760277|NCT02148107|Drug|BI 691751|BI 691751 Dose 1
45760278|NCT02148107|Drug|BI 691751|BI 691751 Dose 2
45760279|NCT02148107|Drug|BI 691751|BI 691751 Dose 3
45760280|NCT02148107|Drug|BI 691751|BI 691751 Dose 4
45616300|NCT05009823|Dietary Supplement|Alternative F75 Without CMV|Cereal flour, oil, sugar, powdered milk without complex mineral-vitamin.
45616301|NCT05009823|Dietary Supplement|F100|100 kcal and 3 g protein per 100 ml if the test of appetite at the end of the stabilization phase is negative (the child does not accept the Plumpynut)
45616302|NCT05009823|Dietary Supplement|Standard F75 + RUTF|Standard F75 with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive
45616303|NCT05009823|Dietary Supplement|Alternative F75 with CMV + RUTF|Alternative F75 + CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 + CMV during the stabilization phase
45616304|NCT05009823|Dietary Supplement|Alternative F75 without CMV + RUTF|Alternative F75 - CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 - CMV during the stabilization phase
45445660|NCT02061982|Dietary Supplement|Coffee consumption|Coffee is consumed before cognitive tests. One cup of instant coffee with 75 mg of caffeine or 0 mg caffeine and will be prepared with 150-200 mL of hot water.
45760281|NCT02148107|Drug|BI 691751|BI 691751 Dose 5
45760282|NCT02148107|Drug|BI 691751|BI 691751 Dose 6
45760283|NCT02148107|Drug|Placebo|Placebo
45760284|NCT02052141|Biological|CINRYZE 500|500 Units of CINRYZE administered by IV injection
45760285|NCT02052141|Biological|CINRYZE 1000|1000 Units of CINRYZE administered by IV injection
45445661|NCT01321515|Drug|famciclovir|500 mg tablet
45445662|NCT03771573|Other|Physical exercise|Participants will perform physical exercises with constant, or intermittent professional supervision or will interrupt the exercise after ambulatorial physical therapy
45616305|NCT03439917|Dietary Supplement|L-Carnitine tartrate|2g L-Carnitine tartrate as a powder consumed twice a day
46069030|NCT04652596|Other|Grocery store gift cards|A monthly value of $150 in grocery store gift cards redeemable at conventional grocery stores will be provided to participants for 6 consecutive months.
46069031|NCT04628988|Drug|CC-90011|Capsule
45616306|NCT03439917|Dietary Supplement|Meal Replacement Drink|325ml dairy-based meal replacement drink ('Slimfast' trademark of KSF Acquisition UK Ltd) consumed twice a day
45760286|NCT02391987|Device|Tele-monitoring and health coaching|"Tele-monitoring involves a personal monitoring system used to analyze data to provide relevant health information back to the treating clinician and the user. The monitoring system remotely monitors electrocardiographic (ECG) signals, heart rate, breathing rate, and activity levels. Additional devices will be integrated with the monitoring device to assess blood pressure and weight.~Health Coaching involves a team of health care professionals including a registered nurse (RN) . The health care team creates a plan specific to the patient and provides guidance on nutrition' medications, and exercise. The data collected by the remote monitoring device will assist the care team in patient management."
45760287|NCT00777179|Drug|Vandetanib|Tablet, oral, daily
45760288|NCT00777179|Drug|Placebo|Placebo
45760289|NCT05507177|Other|communication training programme for healthcare providers|the communication training programme is specifically designed to help Dutch primary care healthcare providers facilitate adequately deprescribing cardiometabolic medication in older patients
45760290|NCT05734235|Dietary Supplement|Vitamin C|Two Vitamin C tablets daily for 8 days.
45760291|NCT05734235|Dietary Supplement|Vitamin E|One Vitamin E tablet daily for 8 days.
45760292|NCT02392767|Dietary Supplement|Verum|2400 mg L-arginine, 80 mg Pycnogenol, 45µg vitamine K2, 10 mg R (+) alpha lipoic acid, 8 mg vitamine B6, 500 µg vitamine B12, and 600 mg folic acid.
45760293|NCT02392767|Dietary Supplement|Placebo|corn starch
45760294|NCT04384289|Procedure|Nursing care based on the Transitonal Care Model|Nursing care carried out in collaboration with a multidisciplinary team in line with Transitonal Care Model for elderly patients who have undergone open heart surgery
45760295|NCT05732129|Drug|Fluzoparib|150mg,orally, bid (days 1-7) every 2 weeks
45760296|NCT05732129|Drug|Irinotecan|30-90min continuous infusion 180mg/m2 Irinotecan on day 1, q2w
45760297|NCT04384601|Drug|Chemotherapy|Perioperative chemotherapy will be administered according to description in two arms.
45760298|NCT02394951|Drug|Pregabalin|Anticonvulsant
45760299|NCT02394951|Drug|Placebo|Identical, matching inactive substance
45760300|NCT03838367|Drug|350 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
45760301|NCT03838367|Drug|525 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
45445663|NCT03771573|Other|monitoring|the patients will be under monitoring to investigate the evolution of the disease
46069032|NCT04628988|Drug|Abiraterone|Tablet
46069033|NCT04628988|Drug|Prednisone|Tablet
45616307|NCT03439917|Dietary Supplement|Maltodextrin|2g Maltodextrin powder packaged to mimic carnitine powder consumed twice a day
45616308|NCT05064891|Procedure|Ultrasound guided injection|Subdeltoid bursa injection, suprascapular nerve block, or posterior glenohumeral joint injection. The participants should only receive one type of the injection mentioned above.
45616309|NCT03106701|Procedure|Ablation|Epicardial Radiofrequency ablation
45760302|NCT03838367|Drug|700 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
45616310|NCT05064189|Device|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
45616311|NCT05064033|Other|Pragmatic Set of intervention and posterior capsular stretch|Group 1 will receive a pragmatic set of interventions, including Serratus Anterior Stretch,Rotator Cuff Facilitation,Acromilcalavicular joint Mobilization,Stretch of Pectoralis Major and Minor,Thoracic Manipulation and posterior capsular stretch.
45760303|NCT03838367|Drug|AUC 5 Carboplatin|Carboplatin is an anticancer drug chemotherapy drug.
45445664|NCT03761979|Dietary Supplement|Strontium L-lactate|The Study Product was a highly pure form of SrLac, the strontium salt of L-lactic acid. SrLac was manufactured in compliance with current Good Manufacturing Practices. SrLac was thoroughly tested and met rigorous purity specifications. It was free from contamination by D-lactic acid and trace metals known to harm human health.
45616312|NCT05064033|Other|Pragmatic Set of intervention and Sleeper Stretch|Group 2 will receive a pragmatic set of interventions, including Serratus Anterior Stretch, Rotator Cuff Facilitation, Acromilcalavicular joint Mobilization, Stretch of Pectoralis Major and Minor, Thoracic Manipulation and sleeper stretch.
45760304|NCT03838367|Drug|Maximum Tolerated Dose (MTD) of leronlimab|The decision on the MTD will be made following the results obtained from Phase I studies
45911588|NCT05778331|Procedure|Antagonist protocol for induction of ovulation|Full labs will be revised to exclude women with any chronic disease. Ultrasound to exclude any anatomical uterine problem.HSG.Women who will be categorized as Poseidon group 3 and Poseidon group 4.They will be given after that antagonist protocol with dose of HMG/FSH 300-450 I.U. per day: (Gonapure 150 I.U -follicle stimulating hormone FSH preparation of recombinant DNA technology- MinaPharm pharmaceuticals-Egypt) will be given from 2nd day of menstruation per day as starting dose then on 7th day (Cetrotide 0.25 -Cetrorelix, an anti-gonadotropin releasing hormone- MERCK SORONO-Germany) will be given daily till triggering . US will be done to evaluate follicular size from 7th day if it will be 1.8 cm or more for at least 2 follicles then (Chorimon 5000 i.u-Choriogonadotropin Alfa-IBSA-Switzerland )of total dose 10000 I.U. will be given then ovum pick up with be done after 35 h of triggering ovulation .Assessment of embryo quality
45911589|NCT05778305|Drug|Dexmedetomidine|a central sympatholytic drug
45445665|NCT02065414|Other|Listerine Advance Gum Defense|
45445666|NCT02065414|Other|Mouth rinse containing Chlorhexidine|
45445667|NCT02065414|Other|Mouth rinse containing 5% Hydroalcohol|
45760305|NCT04384211|Other|Computer Assisted Detection Software For Vertebral Fractures|A device named Smart Bone that is using CT image retrospectively acquired to entails a second review of CT images with Vertebral Compression Fractures through an interactive AI program developed by Quanta Computer Inc. was applied to the CT images. The device is a computer-aided detection (CADe) software application and is designed to assist radiologists to analyze Spine CT images. The device uses deep learning methods to perform vertebrae detection and classification of images.
45760306|NCT05680155|Drug|Ecnoglutide|Subcutaneous Injection
45760307|NCT05680155|Drug|Placebo|Subcutaneous Injection with matched volume
45760308|NCT00354861|Biological|hepatitis B antigen (without alum) plus IMP321|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with IMP321
45760309|NCT00354861|Biological|hepatitis B antigen alone (without alum)|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with physiological saline
45760310|NCT00354861|Biological|Engerix B|20 µg hepatitis B antigen absorbed on alum
45760311|NCT04345445|Drug|Tocilizumab|IV infusion
45760312|NCT04345445|Drug|Methylprednisolone|IV infusion
45911590|NCT05778305|Other|normal saline|saline is given to control group
45445668|NCT03771339|Procedure|Continuous Epidural analgesia|Continuous Epidural catheter is inserted at the Thoracic 11-T12 level, using Ropivacaine 0.375% 3 mL bolus followed by Ropivacaine 0.2% with rate 6 mL/hour for 24 hours after laparoscopic nephrectomy
45445669|NCT03771339|Procedure|Bilateral Quadratus Lumborum block|Bilateral anterior Quadratus Lumborum block using Ropivacaine 0.375% 20 mL each injection as postoperative analgesia treatment for 24 hours
45445670|NCT03767985|Other|Dichoptic video game therapy|Dichoptic video gaming for 1 hour per week, viewed through the Oculus Rift.
45445671|NCT03767985|Other|Occlusion therapy|Occlusion therapy for 2 hours per day, 7 days a week
45445672|NCT03761901|Drug|1L treatment|chemotherapy, EGFR TKI, immunotherapy, other
45445673|NCT03761901|Drug|2L Treatment|Chemotherapy, EGFR TKI, immunotherapy, other
45445674|NCT03761901|Drug|3L treatment|chemotherapy, EGFR TKI, immunotherapy, other
45760313|NCT02056431|Behavioral|IVR Intervention Group|Participants will receive 3 interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) to collect information on medication use, side effects, rating of side effects, and pain symptoms to be fed back to their physicians.
45760314|NCT03800459|Behavioral|family empowerment program|The empowerment program-nursing interventions were given in 6 sessions in the experimental group Session 1: Individualized training: General information about CF, respiratory system involvement and treatment process, airway cleaning in CF, drug applications (45-50 min) Session 2:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the first individual training (15 min).Session 3:Phone calls:Motivational and reminder interviews were carried out in order to reinforce the content of the first individual training (15 min) Session 4:Individualized training:protection from infections, nutrition and psychosocial support (45 min) Session 5:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the second individual training. (10 min) Session 6:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the second individual training. (10 min)
45760315|NCT00354939|Drug|Insulin glargine|
45616313|NCT05058495|Other|Mobile Lymphedema Self-Care Support Program|The Mobile Lymphedema Self-Care Support Program is composed of three section. First section includes the information about lymphedema and lymphedema self care. Second section includes the exercises videos which women can concurrently exercise with application and an alarm to remind to exercise. Last section is a social network form the women could chat and share anything with eachother. Patients will be told how to use the Mobile Lymphedema Self-Care Support Program and a contact number will be provided to ask questions about the program at any time.
45616314|NCT05058495|Other|standart lymphedema education|The control group will be received standart lymphedema education. The standart lymphedema education is an oral education that composed of informations about lymphedema and lymphedema self-care.
45616315|NCT05058183|Diagnostic Test|ctDNA|Patients with stage 1 HER2 positive and triple negative breast cancer will receive ctDNA test after surgery. Treating clinicians will receive results and may change treatment plans in event of negative test.
45616316|NCT05063799|Other|pulmonary rehabilitation|pulmonary rehabilitation programs
45760316|NCT04919031|Device|Inspiratory muscle trainer|POWER breathe IMT is a drug-free, hand-held breathing training device. The medical term for this type of breathing training is Inspiratory Muscle Training, or IMT. POWER breathe IMT exercises the main muscles you use to breathe in, primarily your diaphragm and intercostal
45616317|NCT03099993|Other|Measurement of maximal forces of elbow pronosupination and flexion-extension|Maximal forces of elbow pronosupination and flexion-extension will be measured with a portable dynamometer.
45616318|NCT05063721|Biological|autologous mesoangioblasts|intra-arterial administration of autologous mesoangioblasts in lower leg (50x10E6/kg)
45760317|NCT04919031|Other|diaphragmatic release|diaphragmatic release is a manual technique use for restoring the ability of the diaphragm to go through a full range of motion
45760318|NCT05713877|Drug|Melatonin|Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.
45616319|NCT02725411|Drug|Celecoxib|Orally administered Celecoxib 100 mg twice daily for 56 weeks
45445675|NCT03767829|Drug|ALN-AAT02|ALN-AAT02 will be administered subcutaneously (SC) at dose levels planned for Part A.
45616320|NCT02725411|Biological|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
45616321|NCT02725411|Biological|Tanezumab 10 mg|Subcutaneous injection of tanezumab 10 mg every 8 weeks for 56 weeks
45616322|NCT02725411|Drug|Placebo for celecoxib|Orally administered the placebo twice daily for 56 weeks
45445676|NCT03767829|Drug|Placebo|Sterile normal saline (0.9% NaCl) matching volume of ALN-AAT02 doses will be administered SC.
45760319|NCT05713877|Drug|Placebo|Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.
45760320|NCT05545371|Biological|immunization procedures|The subjects were vaccinated with rabies vaccine according to different immunization procedures
45760321|NCT05664945|Behavioral|pulmonary tele-rehabilitation (PTR)|"PTR is delivered from promoter hospital to a group of 4-6 patients who exercise at home and communicate via tablet-camera.~Each session is 60 min; 35 min exercise/ 25 min patient education, two times per week for a duration of 10-weeks (primary endpoint).~Specific exercises are evidence-based; been used in several intervention studies on patients with COPD.~Exercises involves larger muscle groups with 50/50 exercises for upper and lower extremities. Volume, intensity and content exercise protocol follow both national and international exercise recommendations.~The education sessions consist of dialogue, reflections around empowerment and better living with COPD.~Every fourth education session consists of 25 min Mindfulness exercises developed for COPD patients.~After 10-weeks of PTR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline)."
45911591|NCT05778253|Diagnostic Test|WES and ctDNA detection|WES and ctDNA detection
46069034|NCT04625205|Biological|NEO-PTC-01|Administered via intravenous infusion.
45445677|NCT03767829|Drug|ALN-AAT02|ALN-AAT02 will be administered subcutaneously (SC). Part B dose levels to be determined upon review of data from Part A.
45445678|NCT04233879|Drug|DOR/ISL|100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
45445679|NCT04233879|Drug|BIC/FTC/TAF|BIC/FTC/TAF 50/200/25 mg FDC tablet taken once daily by mouth.
46069035|NCT04625205|Drug|IL-2|Administered via intravenous infusion.
45616323|NCT02725411|Biological|Placebo for tanezumab|Subcutaneous injection of the placebo every 8 weeks for 56 weeks
46069036|NCT04625205|Drug|αPD-1 therapy|Administered via intravenous infusion.
45445680|NCT04233879|Drug|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF taken by mouth.
45445681|NCT04233879|Drug|Placebo to DOR/ISL|Placebo tablet matched to DOR/ISL taken by mouth.
45616324|NCT02435511|Other|HealtheRx|The HealtheRx is an informational intervention. The HealtheRx is generated and administered at the point of care. It includes a list of community resources, tailored to a patient's needs based on diagnoses, that are located near the patient's home. A health care provider and/or administrative staff administers and reviews the HealtheRx with the patient.
45616325|NCT05058105|Drug|FL058 500mg and Meropenem 1000mg（ IV 120min）|"D1 qd;~D2~ D8 q8h;~D9 qd"
45616326|NCT05058105|Drug|FL058 Placebo and Meropenem 1000mg（ IV 120min）|"D1 qd;~D2~ D8 q8h;~D9 qd"
45616327|NCT05058105|Drug|FL058 1000mg（ IV 120min）|D1 qd;
45616328|NCT05058105|Drug|FL058 Placebo （ IV 120min）|D1 qd;
45616329|NCT05058105|Drug|Meropenem 1000 mg （ IV 120min）|D4 qd;
45616330|NCT05058105|Drug|Meropenem Placebo （ IV 120min）|D4 qd;
45616331|NCT05058105|Drug|FL058 1000mg and Meropenem 1000mg （ IV 120min）|"D7 qd;~D8~ D14 q8h;~D15 qd;"
45616332|NCT05058105|Drug|FL058 Placebo and Meropenem 1000mg （ IV 120min）|"D7 qd;~D8~ D14 q8h;~D15 qd;"
45616333|NCT05058105|Drug|FL058 1000mg and Meropenem 2000mg （ IV 120min）|"D1 qd;~D2~ D8 q8h;~D9 qd"
45616334|NCT05058105|Drug|FL058 Placebo and Meropenem 2000m（ IV 120min）|"D1 qd;~D2~ D8 q8h;~D9 qd"
45616335|NCT05058105|Drug|FL058 1000mg and Meropenem 2000mg （ IV 180min）|"D1 qd;~D2~ D8 q8h;~D9 qd"
45616336|NCT05058105|Drug|FL058 Placebo and Meropenem 2000m（ IV 180min）|"D1 qd;~D2~ D8 q8h;~D9 qd"
45616337|NCT05058105|Drug|FL058 2000mg and Meropenem 2000mg（ IV 180min）|"D1 qd;~D2~ D8 q8h;~D9 qd"
45616338|NCT05058105|Drug|FL058 Placebo and Meropenem 2000mg（ IV 180min）|"D1 qd;~D2~ D8 q8h;~D9 qd"
45616339|NCT05058027|Device|GUARDIX-SG®|GUARDIX-SG® 6g prefilled syringe
45616340|NCT05058027|Device|Medicurtain®|Medicurtain® 5ml prefilled syringe
45616341|NCT05063643|Other|High altitude|High altitude is defined as >2000m.
45616342|NCT05063409|Other|Treatment|Blood product transfusion at a ratio of 1:1 FFP to PRBC or 1:4 FFP to PRBC during the operative period (start of surgery to 12 hours post operatively)
45616343|NCT05046405|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) has been suggested to the peripartum period combining antidepressant eﬀects with low risks. In tDCS a low intensity constant current is delivered to the scalp with sub-threshold eﬀect on neurons' resting membrane potential. Long stimulation sessions lead to lasting eﬀects and neuroplastic changes. Local tDCS eﬀects target calcium-dependent synaptic plasticity and distal eﬀects alter the networks' connectivity, synchronicity and oscillatory patterns. tDCS applications aim to counteract the hypoactivity of the frontoparietal network and the left sided hyperactivity of the default mode network associated with depressive symptoms.
45616344|NCT02477917|Biological|Allergovac depot with Parietaria judaica pollen extract|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
45616345|NCT05063253|Drug|TG103|TG103 injection, SC, once weekly
45616346|NCT05063253|Drug|Placebo|Placebo, SC, once weekly
45616347|NCT02477761|Dietary Supplement|Nutrient preload|Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
45616348|NCT05062941|Other|Conventional physiotherapy|Conventional therapy (CT) included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation, 5 minutes of ultrasound, 20 minutes of interference current with vacuum electrodes, and exercises.
45616349|NCT05062941|Device|High-intensity laser therapy (HILT)|"HILT stimulates oxidation of mitochondria and ATP creation by delivering high energy output inside the tissues and with this photochemistry effect, metabolism and blood circulation is increased resulting HILT to cause quick absorption of edema and removal of exudates.~HILT (BTL 6000, BTL Industries, Inc., USA) application was to the shoulder area in the analgesic mode of the device at a frequency of 25 Hz with a power of 10 W and a dosage of 12 j/cm2 for 2 minutes: 5 sessions a week for 3 weeks and 15 sessions in total."
45616350|NCT05057325|Other|Pulpectomy using single file system ( One Shape file)|Rotary file instrument for pulpectomy of primary molars ( One shape file)
45616351|NCT05057325|Other|Pulpectomy using single file system ( WaveOne Gold file)|Rotary file instrument for pulpectomy of primary molars ( WaveOne Gold file)
45616352|NCT05649943|Drug|APA + ADT|"All participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily. Apalutamide is distributed in Italy under the trade name of Erleada® 60 mg.~All patients not undergoing surgical castration should also continue medical castration by taking a gonadotropin-releasing hormone (GnRHa) analogue during treatment."
45616353|NCT05649943|Procedure|Local Treatmetn RT or RP|"Patients who will undergo radiotherapy as a local treatment must be treated according to the following scheme:~External beam radiotherapy administered at 36 Gy in six consecutive weekly fractions of 6 Gy, or 55 Gy in 20 daily fractions of 2・75 Gy over 4 weeks.~Radiation therapy will be given with the patient supine and with a full bladder and an empty rectum. The planned target volume is prostate only, with an 8 mm margin posteriorly and a 10 mm margin elsewhere.~No RT on lymph nodes is foreseen. RT should begin 6 months after the first dose of apalutamide (+/- 2 weeks).~Radical prostatectomy should be performed 6 months after the first dose of apalutamide (+/- 2 weeks)."
45616354|NCT05045781|Drug|Eptinezumab|single iv infusion
45616355|NCT02472067|Behavioral|Psychologically - Based Physical Therapy|Psychologically - Based Physical Therapy targeting risk factors for disability.
45616356|NCT05045859|Behavioral|CBCT for PTSD|CBCT for PTSD is a 15-session, manualized therapy developed by Monson and Fredman, designed to simultaneously improve PTSD symptoms and enhance relationship functioning. It assumes that PTSD exists within the couple's relationship and that partners can join together to reduce the presence of PTSD in their relationship. Sessions are organized into three phases of treatment: (1) psychoeducation about PTSD and relationships; (2) behavioral interventions to enhance relationship functioning; and (3) dyadic cognitive intervention designed to contextualize trauma memories and address trauma-relevant cognitions held by either partner that keep the PTSD and/or relationship distress alive. Out-of-session assignments are designed to assist the couple in reinforcing skills learned in the sessions.
45616357|NCT02471989|Dietary Supplement|Low-FODMAP diet|
45616358|NCT02471989|Dietary Supplement|GERD diet|
45804032|NCT05717192|Device|InterVapor®-System|"The InterVapor System uses heated water vapor to ablate the airways and parenchyma within targeted regions of the lung. Lung remodeling occurs after an initial localized inflammatory response and a subsequent healing and repair. The remodeling of the tissue results in reductions in tissue and air volume in the targeted regions of the lung. The remodeled lung tissue does not re-inflate as a result of collateral ventilation.~The lung volume reduction of diseased hyper-inflated lung segments after InterVapor treatment is expected to increase elastic recoil by reducing the most compliant segments of the lung, decompressing segments of healthier lung allowing for alveolar recruitment, and improving the mechanical efficiency of the respiratory muscles. These mechanical changes are anticipated to improve pulmonary function, exercise capacity and quality of life."
45616359|NCT05046015|Other|10% Urea foot lotion|"During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 Lipolotion 10% Urea once daily in the evening by themselves."
45445682|NCT01370356|Drug|Varenicline Tartrate|Varenicline Tartrate oral tablets 2 (0.5mg) tablets twice a day for 24 weeks (first week titration)
45445683|NCT01370356|Drug|Placebo|Matching placebo 2 oral tablets twice a day for 24 weeks (first week titration)
45445684|NCT03767751|Biological|Dual Specificity CD38 and bcma CAR-T Cells|1) Biological: Dual Specificity CD38 and BCMA CAR-T Cells,2)1-5X10E6/Kg
45445685|NCT03770949|Device|3-D Printed Orthotic (Ankle Foot Orthosis)|Participants will receive a custom individual 3-D printed ankle foot orthosis (AFO).
45445686|NCT03792334|Device|depth of anesthesia|monitoring of depth of anesthesia
45616360|NCT05046015|Other|10% Urea foot ointment|"During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 ointment10% Urea once daily in the evening by themselves."
45616361|NCT04652557|Drug|Fampridine SR|Fampridine SR is an inhibitor of voltage gated potassium channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
45616362|NCT04652557|Drug|Placebo|no active component
45616363|NCT05062551|Procedure|three steps hysteroscopic resection of an isthmocele|removing the distal edge of the niche then the proximal edge and lastly ball cauterization of the floor of the pouch of the isthmocele. Post-operative trans vaginal ultrasound and follow up for 2 menstrual cycles.
45616364|NCT05185297|Other|Recreational Futsal|Participants will participate in 2-3 weekly one hour sessions of Recreational Futsal, during 3 months, while maintaining standard care provided by the family physician.
45616365|NCT04474353|Device|Optune|Noninvasive, portable device which generates tumor treating fields (TTFields) manufactured by Novocure
45616366|NCT04474353|Drug|Gadolinium|Gadolinium contrast medium
45616367|NCT04474353|Drug|Temozolomide|Chemotherapy agent
45616368|NCT04474353|Radiation|Stereotactic radiosurgery (SRS)|Standard of Care: SRS (35 Gy in 5 fractions of 7 Gy), 5-day treatment from Day 2
45616369|NCT05639569|Device|Ankura™ TAA Stent Graft Systems|All patients will be implanted with Ankura™ TAA Stent Graft Systems in accordance with the instructions for use (IFU).
45616370|NCT05045469|Drug|dian dao san|dian dao san and placebo will be used in the rosacea lesions twice a day for 6 weeks
45616371|NCT03099213|Drug|RAMIPRIL HOE498|Pharmaceutical form:Tablet Route of administration: Oral
45616372|NCT02474485|Device|BVS Absorb implantation.|Absorb bioresorbable vascular scaffold will be implanted to treat in stent restenosis in target vessel.
45616373|NCT02474485|Device|DEB Sequent Please inflation.|Inflation of drug eluting balloon Sequent Please will be performed to treat in stent restenosis in target vessel.
45616374|NCT02474485|Procedure|Control coronary angiography.|Control coronary angiography will be performed at 9 month follow-up.
45616375|NCT02474485|Procedure|OCT visualization.|OCT visualization will be performed during index procedure and at 9 month follow-up.
45616376|NCT02474485|Other|Clinical observation.|Patients will be informed that Investigator will contact them at 12, 24 and 60 months after the procedure. Investigator will collect information regarding clinical status of Patients, cardiac medications and any adverse events that occurred since the last follow-up.
45616377|NCT05056935|Drug|LB1148|A total of 700 mL of LB1148 will be administered orally as a split dose before surgery.
45616378|NCT05056935|Drug|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
45616379|NCT05056701|Other|annual follow-up during 10 years|an annual follow-up is carried out systematically for a total of 10 years in order to detect the subsequent occurrence of CKD
45616380|NCT02190604|Drug|Placebo|Capsule- oral dose
45804033|NCT01863446|Device|Lighting1|Ocular light exposure to a red wavelength light for one or two nights
45804034|NCT01863446|Device|Lighting2|Ocular light exposure to a blue/green wavelength light for one night
45804035|NCT01863446|Device|Lighting3|Ocular light exposure to a red wavelength light (Device 1) on night 1 and to a blue/green wavelength light (Device 2) on night 2
45804036|NCT01863446|Device|Lighting4|Ocular light exposure to a red wavelength light (Device 1) on day 1 and to a blue/green wavelength light (Device 2) on day2
45616381|NCT02190604|Drug|QBW251|Capsule - oral dose
45616382|NCT05062005|Drug|Induction Chemotherapy|Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.
45616383|NCT05062005|Drug|Concurrent Chemotherapy|Cisplatin 100 mg/m², Q3w.
45616384|NCT05062005|Radiation|Definitive Radiotherapy|For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).
45616385|NCT05061459|Genetic|circANKRD36 as a new biomarker|expression levels of circANKRD36 in the development and progression of DN
45616386|NCT05061225|Behavioral|Physical activity counselling|Educational content on several topics regarding physical activity and its implementation in daily living
45616387|NCT05061147|Drug|MAX-40279-01|"Drug: AZA AZA will be administered at 75 mg/m^2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.~Other Name: Azacitidine~Drug: Max-40279-01 Max-40279-01 will be administered as a combination of multiple oral capsules containing 5 and 25 mg. An alternate combination of 35 mg, 50 mg and 60 mg Max-40279-01 twice a day may be utilized.~Other Name: NA"
45616388|NCT04434651|Procedure|SPGB|Sphenopalatine Ganglion Block using 2% lidocaine in block group. Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge a syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril SPGB using normal saline is performed in the control group
45445687|NCT04545411|Drug|Dapagliflozin 10 MG [Farxiga]|4-Week, double-blind, once daily oral 10mg dapagliflozin
45616389|NCT05177107|Biological|Phage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
45616390|NCT05177107|Other|Placebo|Placebo (normal saline)
45616391|NCT02127970|Drug|Dalbavancin|Dalbavancin IV infusion over 30 minutes.
45616392|NCT02127970|Drug|Dalbavancin-matching Placebo|Dalbavancin-matching placebo IV infusion over 30 minutes.
45616393|NCT03097887|Procedure|Omega Loop Gastric Bypass|Bariatric/metabolic surgical procedure
45616394|NCT03097887|Device|Bilitec 2000™|The Bilitec 2000™ device will be used to measure the intensity of biliary reflux in the pouch.
45616395|NCT03097887|Device|V-Loc|Sewing device to perform the anti-reflux sutures.
45616396|NCT02474251|Other|Continuous positive airway pressure device|GROUP B ONLY will be evaluated on two randomized counterbalanced nights, on one they will undergo a full night of therapeutic CPAP; on the other the investigators will withdraw CPAP during SWS only. A morning LP will be performed approximately 10 hours after sleep onset in both visits
45616397|NCT05056389|Drug|Oxaliplatin|Administration of oxaliplatin intraperitoneally
45616398|NCT02473861|Other|Exercise|Moderate intensity aerobic and resistance training. Five minutes each of warm-up, cool-down, balance and flexibility will also be performed.
45616399|NCT02548299|Other|Nutrition Education|Nutrition classes will be led by a registered dietician.
45616400|NCT02548299|Other|Cooking Lecture|
45616401|NCT02548299|Other|Cooking Demo|
45616402|NCT02548299|Other|Hands-on Cooking|
45911592|NCT05778240|Behavioral|Phone call|"Participants were given the vaccination appointment card and participants received a telephone call every month two days before their appointment. Participants were reminded that they have a set appointment and were asked to plan the day of their appointment as detailed below. The standard script used in the telephone call in every hospital was as follows:Hello, we are calling you because you are enrolled in the palivizumab prophylaxis research program. As you know, you have a vaccination appointment on [enter date] at [enter time]. To help you plan your day of appointment, we have a few short questions.~At your appointment day, will you be coming to the hospital from home, or will you need to get permission from your workplace?~What kind of transportation do you plan to take to come to the hospital at your appointment day?~At what time do you plan to leave home or work to come to the hospital?"
45760322|NCT05664945|Behavioral|home-based pulmonary rehabilitation (HPR)|"HPR is an individual self-initiated home-based PR aiming to achieve 20 min of self-initiated muscle-endurance based exercise; 3-days/weekly for 10-weeks (primary endpoint).~Exercises are evidence-based; used in several intervention studies on patients with COPD and involves larger muscle groups with 50/50 exercises for upper/lower extremities.~First session is a home visit by a respiratory physiotherapist. During the visit the physiotherapist and patient establish exercise goals, exercise prescription and provision of mindfulness exercises and educationbook.~The home visit is followed by one weekly session for 10-weeks. A menu of topics relevant to COPD and self-management is discussed. A session is delivered from promoter hospital via tablet-camera or telephone call (patients' preference).~After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline)."
45616403|NCT02548299|Other|e-Coaching|
45616404|NCT04759612|Other|Action Observation|Participants will watch an upper extremity functionality test.
45616405|NCT02471677|Drug|Elonva|corifollitropin alfa (Elonva): a single injection 100 or 150 ug (depending on patient body weight) on Day 2/3 of menstrual cycle
45445688|NCT04545411|Drug|REMD-477|4-Week, double-blind, once weekly subcutaneous injection with 35mg REMD-477 in 1mL solution.
45445689|NCT04545411|Drug|Placebo|4-Week, double-blind, once weekly subcutaneous injection with placebo in 1mL solution.
45445690|NCT02065492|Drug|Standard Chelation|This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).The dosage and drug used will depend on ferritin levels and individual requirement, as determined by the treating hematologist and will be in accordance with the Iron chelation guidelines from Pakistan Thalassemia Society.
45616406|NCT02471677|Drug|Puregon|follitropin beta (Puregon): daily injections 150 IU from Day 2/3 of menstrual cycle until adequate follicle development is achieved
45616407|NCT04755634|Device|Hyaluronic Acid|Injectable
45616408|NCT03097809|Other|SEEG Recordings|To directly record brain activity from the frontal-limbic circuitry of subjects in the resting state and while they engage in behavioral tasks designed to assess emotional response to negative stimuli and different aspects of impulse control and emotional processing
45616409|NCT02471599|Procedure|tonsillectomy|The tonsillectomy will be performed by the otolaryngologist. In addition, all subjects will receive the conventional drug treatments, defined as treatment of participants using the angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB), anticoagulants, antihypertensives, corticosteroids so on, according to individual status.
45616410|NCT02471599|Other|non-tonsillectomy|The non-tonsillectomy group received conventional drug treatments defined as treatment of participants using the ACEi/ARB,Anticoagulants, Antihypertensives, corticosteroids and so on, according to individual status.
45760323|NCT05664945|Behavioral|Control|"Receive usual care; medication, scheduled follow-up visit and possible phone contact with GP and the outpatient respiratory department.~Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered.~If a patient changes his/her mind and wishes to participate in a conventional hospital- or community-based PR program, it will be granted as this is a highly recommended treatment (e.g. rehabilitation after hospital admitted exacerbation)."
45760324|NCT03800147|Drug|"Mutaflor Suspension (E. coli Nissle 1917)"|"Inoculation of Mutaflor Suspension (E. coli Nissle 1917)"
45616411|NCT05060757|Diagnostic Test|biotax|patients who are scheduled to undergo colonoscopy will be asked to participate and give a stool sample
45616412|NCT05405179|Procedure|Simultaneous dental implantation|To perform dental implantation simultaneously in free vascularized bone flaps for jaw reconstruction using patient-specific surgical guides and titanium plates
45616413|NCT03099135|Drug|No Treatment|No treatment will be given tp participants during this follow-up study of previous phase II and Phase III in which they have received Odalavir and AL-335 with or without Simeprevir.
45616414|NCT05395507|Drug|Recombinant Interferon Alpha|Recombinant Interferon Alpha, with an initial dose of 300 wu three times a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available.
45616415|NCT05395507|Drug|Pegylated interferon alfa-2b|Pegylated Interferon Alfa-2b, with an initial dose of 135 ug at week 0 , and then 180 ug once a week from week 1 to week 52.
45616416|NCT05055687|Drug|FL058|2500mg、3000mg
45616417|NCT05055687|Drug|Placebo|empty bottle
45616418|NCT05055687|Drug|FL058|500mg、1000mg、2000mg
45616419|NCT05055687|Drug|Placebo|empty bottle
45616420|NCT02473939|Drug|VR942 delivered via a Vectura Dry Powder Inhaler|
45616421|NCT02473939|Drug|Placebo delivered via a Vectura Dry Powder Inhaler|
45616422|NCT03097419|Procedure|Remote post-ischemic conditioning|"A manual sphygmomanometer will be inflated over the brachial artery of the participants' arm that does not have an intravenous catheter actively infusing medications. If both arms are in use, then the participant's non-dominant arm will be used.~The sphygmomanometer will be inflated to a pressure at least 20 mmHg greater than the participants' last recorded systolic blood pressure.~The sphygmomanometer will be inflated for 5 minutes then rapidly deflated for 5 minutes, thereby concluding one iteration.~Five (5) total iterations constitute the treatment.~The left arm will be preferentially used instead of the right arm, unless the left arm is receiving medication administration."
45616423|NCT02477449|Drug|istaroxime|8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).
45616424|NCT02477449|Drug|9% Saline (NS)|infusion for 24 hours
45616425|NCT04470843|Drug|Acetazolamide|Being that adequate pain control is essential to recovery in the post-operative setting, efforts have been made to address this pain at its root. Prior studies have demonstrated that preoperative administration of acetazolamide decreased post-operative referred pain in the immediate post-surgical period.
45760325|NCT03800147|Other|Blood samples|Blood samples will be collected and analyzed at different study time points
45760326|NCT03800147|Other|Stool samples|Stool samples will be collected and analyzed at different study time points
45760327|NCT03800147|Other|Clinical information|Clinical information will be collected at different study time points using questionnaires
45616426|NCT04470843|Other|Placebo|Group 2 (placebo): Patients undergoing RALP with the peri-operative use of 10 mL normal saline as placebo.
45760328|NCT03800303|Behavioral|Family-based treatment|2-week family-based treatment
45760329|NCT05663463|Drug|Fluzone High-Dose Quadrivalent- 2 doses|2 doses of the High-Dose (HD) influenza vaccine separated by 4-6 weeks
45760330|NCT05663463|Drug|Fluzone High-Dose Quadrivalent- 1 dose|1 dose of the HD dose influenza vaccine
45760331|NCT03800225|Procedure|Repair|Anterior ligament repair with internal brace.
45760332|NCT00795275|Drug|Sitagliptin Phosphate|Januvia 100 mg po qd x 28 days for all subjects after baseline measures made
45616427|NCT04566601|Drug|BI 1358894|Film-coated tablet
45616428|NCT04566601|Drug|Placebo|Film-coated tablet
45616429|NCT03097263|Other|Physical Rehabilitation program|
45616430|NCT05055141|Other|Care to Share poster|The Care to Share poster enabled patients to share written information about who they are as people with their hospital caregivers.
45616431|NCT05036811|Other|data collection|data collection
45616432|NCT05161741|Drug|Insulin|Human rDNA Insulin (Insuget, local brand of Getz Pharma)
45616433|NCT05036889|Diagnostic Test|Mind.Px Report|Use of Mind.Px report as a reference for potential better matching of biologics to patients.
45616434|NCT02471443|Procedure|Surgery for severe endometriosis|Consecutive patients undergoing excisional surgery for severe endometriosis with bowel involvement
45616435|NCT05044143|Other|Monitoring the length of the uterine cervix using transvaginal ultrasound|Cervical length is measured with a 7-9 MHz transvaginal probe by trained obstetricians-gynecologists following the same standardized approach (Berghella 2003). Transvaginal CL measurement is largely used in current obstetric practice, and it is considered the 'gold standard' measurement when assessing the uterine cervix. In contrast to transabdominal US, the transvaginal approach is highly reproducible, and measurements are unaffected by maternal obesity, cervical position, and shadowing from fetal parts (Berghella 2003, Hassan 2000, ACOG 2012, Berghella 2012).
45616436|NCT02477371|Procedure|Fractional flow reserve-guided CABG|Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting and where FFR-measurements are made, only receive grafting if FFR-value is ≤ 0,8. Arteries with FFR-values > 0,8 are deferred.
45616437|NCT02477371|Procedure|Angiography-guided CABG|Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting all receive grafting. FFR-measurements are still made, but not used for guidance of grafting.
45760333|NCT05713565|Device|A digital care solution for patients with Coronary Artery Disease|A digital care solution that provides remote patient monitoring and a patient support program specifically developed for CAD patients. The digital care solution empowers self-assessment of CAD symptoms as well as positive lifestyle change by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.
45616438|NCT05055375|Other|questionnaire survey|We will conduct a questionnaire survey of outpatients.
45760334|NCT05713565|Other|Standard of care for patients with Coronary Artery Disease|Follow-up and continuous care as usual in outpatient care (i.e., Standard of Care). The participants in the Standard of Care - control group will also receive an information leaflet about relevant lifestyle modifications for CAD.
45616439|NCT02477293|Drug|Hyeonggaeyeongyo-tang|
45760335|NCT00777335|Drug|Panobinostat - LBH589|Solution for infusion - 25mg/5ml
45616440|NCT02473627|Drug|DS-1971a|200mg tablet
45616441|NCT02473627|Drug|midazolam hydrochloride|2.5mg oromucosal liquid
45616442|NCT02473627|Drug|Omeprazole|20mg gastro-resistant capsule
45616443|NCT02473627|Drug|Pioglitazone hydrochloride|15mg tablet
45616444|NCT02473627|Drug|Buproprion|150mg Prolonged release tablet
45616445|NCT02473627|Drug|Tolbutamide|500mg tablet
45616446|NCT02477137|Device|smartphone or tablet|Patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
45616447|NCT03095703|Drug|Sirolimus|Participants will be given sirolimus tablets. The starting dose is 2 mg once daily which will be given in 1mg tablets. On day 7 the first trough level is measured (using the LC-MS/MS method) and if not within the target range of 5-8ng/ml, dosing adjustments are made. In case of dosing adjustments, the next trough level is measured seven days later and this is repeated weekly until the target range is achieved. In case trough levels are within the target range, the next trough level measurement is at month 3, after which dosing adjustments are made if necessary, and at month 6. The maximum daily dose is 40mg. No placebo is given.
45616448|NCT05035953|Drug|Edaravone Dexborneol|Edaravone Dexborneol 37.5 mg (containing Edaravone 30 mg and Dexborneol 7.5 mg), BID, 14 days, addition to thrombolysis
45616449|NCT05035953|Drug|Placebo|Edaravone Dexborneol matching injection, addition to thrombolysis
45616450|NCT05583487|Other|Nurse-led progressive mobility protocol|The nurse-led mobility progression protocol incorporates a checklist for four primary team members belonging to each discipline to follow before, during, and after providing mobility for each patient. It outlines steps to progress patient mobility from in-bed mobility activities to out-of-bed activities as tolerated. This protocol intervention was created and designed based upon a review of previously conducted studies' interventions and findings, as well as expert guidelines established in the literature. Furthermore, multidisciplinary experts at the medical center who work with ventilated neurosurgery patients were consulted to form the protocol to further establish hemodynamic, neurological, respiratory, and physiological patient safety parameters. This intervention has not been implemented in previous studies and will be piloted for this study.
45760336|NCT00777335|Drug|Panobinostat - LBH589|Hard gelatine capsules - 5mg and 20 mg
45760337|NCT04902573|Other|Non-interventional|As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
45760338|NCT04896645|Device|Digihaler Albuterol Device by TEVA|Patient with asthma will have their regular albuterol rescue inhaler replaced with Digihaler, they will also be asked to perform gamified spirometry (Aluna) at home
45760339|NCT00790673|Drug|CF 102|Oral capsules
45760340|NCT00790673|Drug|Placebo|Matching placebo capsules
45760341|NCT05644587|Drug|buprenorphine/naloxone|Buprenorphine/naloxone will be used to begin each patient's treatment for opioid use disorder.
45760342|NCT03801863|Procedure|Ultrasound-guided Erector Spinae Plane Block with Ropivacaine 0.375%|Ultrasound-guided Erector Spinae Plane Block will be done at L4 interspace. Ropivacaine 0.375% will be used.
45760343|NCT03801863|Drug|Ropivacaine|Using 0.375% Ropivacaine in the nerve block
45760344|NCT00355329|Procedure|Tongue Acupuncture (Procedure)|
45760345|NCT00355407|Drug|Darbepoetin alfa|
45760346|NCT00355251|Drug|Atorvastatin 40 mg/Atorvastatin 80 mg|Atorvastatin 40 mg/80 mg
45760347|NCT03832127|Drug|18F-Fludarabine|Two PET with 18F-Fludarabine : one at Baseline, the second one at the end of treatment of myeloma
45760348|NCT04880265|Device|BraveHeart wearable life sensors|Collection of EKG data
45760349|NCT04876131|Drug|Benzylpenicillin - single dose|"Participants will receive a single dose of IV antibiotic (benzylpenicillin).~Benzylpenicillin dosing: 1 month - 18 years, IV or Intramuscular (IM) 30 mg/kg (maximum 1.2 g) every 6 hours."
45760350|NCT04876131|Drug|Benzylpenicillin - three days|"Participants will receive three days of this IV antibiotic (benzylpenicillin).~Benzylpenicillin dosing: 1 month - 18 years, IV or Intramuscular (IM) 30 mg/kg (maximum 1.2 g) every 6 hours. For severe infections, use up to 60 mg/kg (maximum 2.4 g) every 4-6 hours."
45616451|NCT05583487|Other|Standard of Care|For the purposes of the current study, the control group of multidisciplinary teams requested to mobilize the ventilated neurosurgery patient, may also consist of the primary nurse, RT, PT, and PCT. They will be asked to progressively mobilize the patient to the best of their ability according to standard of care procedures, incorporating any resources the medical center provides including, but not limited to, written information, equipment, ThinkLift, etc.
45616452|NCT05044299|Device|Isoped|Isoped is a mechanical device allowing movement of lower extremities in a forward and backward motion, with phone-based app to control resistance load
45616453|NCT02477059|Drug|tocilizumab|Le tocilizumab is administered by intravenous infusion at a dose of 8 mg / kg.
45616454|NCT02477059|Drug|saline solution|La saline solution is administered by intravenous infusion.
45616455|NCT02471209|Drug|Sevoflurane|general anesthesia with 2% followed by 3% sevoflurane
45616456|NCT05043987|Drug|CPO102|Anti-claudin 18.2 Antibody-MMAE Drug Conjugate
45616457|NCT02470819|Genetic|Genetic profiling|genetic profiling
45616458|NCT02471131|Device|WATCHMAN Device implantation|The implantation of the device will be done into the left atrial appendage according to the guidelines.
45760351|NCT04876131|Drug|Gentamicin - single dose|"Participants will receive a single dose of IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children >10 years old: 6-7 mg/kg (maximum dose 560 mg)"
45616459|NCT02473705|Dietary Supplement|Fish Oil and Bicarbonate|1280mg of fish oil per day and 1mg of bicarbonate per Kg of body weight per day
45760352|NCT04876131|Drug|Gentamicin - three days|"Participants will receive three days of this IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children >10 years old: 6-7 mg/kg (maximum dose 560 mg)"
45616460|NCT02473705|Dietary Supplement|Fish Oil and Bicarbonate Placebo|1280mg of fish oil per day and bicarbonate placebo (Methylcellulose)
45616461|NCT02473705|Dietary Supplement|Fish Oil Placebo and Bicarbonate|Fish oil placebo (soybean oil) and 1mg of bicarbonate per Kg of body weight per day
45616462|NCT02473705|Dietary Supplement|Fish Oil Placebo and Bicarbonate Placebo|Fish oil placebo (soybean oil) and bicarbonate placebo (Methylcellulose)
45616463|NCT02476903|Drug|Monovisc|
45616464|NCT02473237|Drug|indacaterol|Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
45760353|NCT04876131|Drug|Cefalexin - post single dose of IV antibiotics for the remaining two days|Oral antibiotic will be as per local guidelines. i.e. Cefalexin 25mg/kg (maximum dosage 500mg) 4 times a day or 33mg/kg (maximum dosage 500mg) 3 times a day
45760354|NCT04852497|Procedure|Ventricular tachycardia ablation|patients having undergone ventricular tachycardia radiofrequency ablation using of pace mapping strategy to identify the critical isthmus
45760355|NCT00355875|Procedure|titration of oxygen during resuscitation|
45616465|NCT02473237|Drug|Tiotropium|Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
45616466|NCT04347811|Behavioral|Death Cafe|Death Cafés are a specific form of debriefing that focuses on discussing death, dying, loss, and illness. Nourishment in the form of cake is provided. These sessions may allow for reflection on distressing patient events while developing a sense of community and collaboration among hospital employees.
45616467|NCT02473159|Drug|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
45760356|NCT04825275|Drug|Posaconazole Pill|300 mg (three 100 mg tablets) orally
45760357|NCT05627349|Device|wrist splinting|standard wrist splinting at night for 2 weeks
45760358|NCT05627349|Device|FSN|FSN is a single-use disposable needle(Trocar Acupuncture Needle, Nanjing FSN Medical Co. , Ltd, China.). The needle body is solid, and covered with a plastic tube. The needle penetrates the skin with insertion device. Under the guidance of ultrasound, the needle enter the loose subcutaneous layer obliquely without penetrating into the muscle. This is the difference from traditional acupuncture. The insertion point is midpoint of the anterior forearm. The needle tip is toward the carpal tunnel. After the needle is inserted, SM and RA are performed. The frequency of SM is 200 times in two minutes. The method of SM is to make a horizontal fan swaying with the base of the needle as the fulcrum. RA is performed while SM-slowly make a fist for 10 seconds and then relax for 5 seconds. Eight times of RA in two minutes. After the FNS treatment, the needle was withdrawn.
45616468|NCT02473081|Behavioral|Minimal psychological intervention|Minimal psychological intervention (MPI) was used to help adults with chronic illness to manage their psychological burden by breaking through a negative spiral between thoughts and behaviors.
45616469|NCT02473081|Other|Usual care|Usual care was given by their family physicians.
45616470|NCT04273243|Genetic|AT-GTX-501|No study drug is administered in this study. Subjects who received AT-GTX-501 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
45616471|NCT03549871|Drug|Fitusiran|Pharmaceutical form: solution for injection Route of administration: subcutaneous
45911593|NCT05778240|Behavioral|Text message|Participants were given the vaccination appointment card and participants were included in a messaging group (on Whatsapp or SMS, depending on the participant's preference) where, twice a month they received a message informing them on RSV, on the additional risks caused by RSV infection in children with congenital heart diseases and on the benefits of adherence to the prophylaxis program. These messages also involved statements about the high number of patient families that kept their appointments in the previous month.
45911594|NCT05778240|Behavioral|Control|Participants were given the vaccination appointment card.
45760359|NCT00791219|Drug|SUBA-itraconazole|100 mg approximately 30 minutes prior to breakfast for 12 weeks of SUBA™-Itraconazole 50 mg capsules (HalcyGen Ltd)
45760360|NCT00791219|Drug|Itraconazole|200 mg taken with breakfast of SPORANOX® (itraconazole) 100 mg capsules (Janssen Pharma).
45760361|NCT00791219|Drug|Placebo|Two placebo capsules taken approximately 30 minutes prior to breakfast
45760362|NCT04825041|Diagnostic Test|Patency test|Successive flow test, bubble flow test and peristalsis test
45616472|NCT03549871|Drug|BPA prophylaxis|Pharmaceutical form: solution for injection Route of administration: Intravenous
45616473|NCT03549871|Drug|Factor (FVIII or FIX) prophylaxis|Pharmaceutical form: solution for injection Route of administration: Intravenous
45616474|NCT03108703|Radiation|SBRT|35-40 Gy delivered in 5 fractions
45616475|NCT03403621|Drug|Pentamidine Isethionate|Pentamidine isethionate prepared in a silicone base will be applied topically
45616476|NCT03403621|Drug|Silicone Gels|Silicone base will be applied topically
45616477|NCT04238455|Procedure|Sham serratus anterior plane block|The serratus anterior plane block will be performed by the anesthesiology team just prior to emergence from general anesthesia.
45616478|NCT04238455|Procedure|Serratus anterior plane block|The serratus anterior plane block will be performed by the anesthesiology team just prior to emergence from general anesthesia.
45911595|NCT05778227|Drug|Ethylene Diamine Tetra Acetic acid|Final irrigation will be done with 5ml of EDTA for 1min which is the gold standard and compare it with experimental irrigants.
45616479|NCT04220125|Drug|Ketamine Group|Ketamine intravenous administration 0.5 mg/kg over 40 minutes.
45616480|NCT04220125|Drug|Midazolam injection|Midazolam intravenous administration 0.045 mg/kg IV over 40 minutes.
45616481|NCT03108547|Other|Determination of scalp hair steroids|
45760363|NCT04822545|Other|referral to comprehensive weight management clinic|"Patients will receive a referral for outpatient CWM clinic, with a message sent to the CWM clinic scheduler, prior to hospital discharge.~At six months after discharge, the patient will receive a phone call from the investigators to ascertain whether they were able to go to the CWM clinic and about their experience."
45760364|NCT04818489|Drug|Colchicine 0.5 MG|colchicine 0.5 mg (2 tablets: 1 mg) twice per day as a loading dose, followed by one tablet 0.5 twice per day for three weeks in addition to the standard protocol
45760365|NCT04818489|Other|the standard protocol only|the local standard protocol for COVID19
45760366|NCT05494671|Procedure|conjunctival limbal autologous transplant|"Patients with unilateral chemical ocular injury will be included in the study. All selected patients will receive a thorough explanation of the study design and aims and informed consent will be obtained in all patients. Eyes of all participants will be subjected to: Best corrected visual acuity, Slit lamp examination and ocular ultrasound if no fundus view.~Staging of degree of limbal stem cell deficiency is done by Roper Hall classification and then the patient will have conjunctival limbal autologous transplant (CLAU)"
45760367|NCT00797459|Device|Restylane and Restylane-L|This is a split face design and each subject received both Restylane and Restylane-L. Treatments were double blind, randomized, and successive.
45616482|NCT03305185|Combination Product|Schroth SSE with Bracing|Patients in this group will be prescribed an outpatient-based Schroth exercise program, as per our preliminary study. It consists of an individualised eight-week outpatient program that includes four initial private training sessions, once every two weeks, where exercises will be taught to the patient and their caregivers. A home exercise program will be instituted thereafter and patients will be required to return for supervised sessions once every two months.
45760368|NCT05614401|Other|functional and medical information|1) functional outcomes(mRS scoring), 2)survival status, 3) date of death in those who died (based on information of the treating physicians), 3) mRS score at the time of the interview, 4) recurrent stroke/TIA, 5) new onset atrial fibrillation, 6) other cardiovascular events, including myocardial infarction, pulmonary embolism, deep venous thrombosis, peripheral arteriopathy.
45760369|NCT04817553|Other|exposure to COVID19|Observational study of IgG4 patients with pancreatobiliary involvement who were diagnosed with COVID19
45760370|NCT04807101|Drug|midazolam alone|elimination of fentanyl from conscious sedation
45616483|NCT03305185|Device|Bracing alone|Patients in the control group will receive standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will only attend study assessments with no extra physiotherapy sessions.
45804037|NCT05717114|Procedure|Pecs block|(Pecs block):the block will be performed with the patients in the supine position.The infraclavicular and axillary regions will be cleaned with antiseptic solution. the inplane technique will be used from proximal and medial to distal and lateral in an oblique manner at dermatome level T2and T3.The puncture site was infiltrated with 2%lidocaine and once the structures is identified with ultrasound.
45804038|NCT02415439|Drug|VBP15|
45804039|NCT02415439|Drug|Placebo|
45616484|NCT02472769|Drug|IBP-9414|
45616485|NCT02472769|Drug|Placebo|Sterile water
45616486|NCT03268603|Drug|Autologous Adipose-derived Mesenchymal Stromal Cells|The investigational product consists of autologous adipose-derived Mesenchymal Stromal Cells (MSCs), suspended in 5-10 mL Lactated Ringer's. The MSC are provided in a sterile syringe labelled with appropriate patient and product identifiers ready for intrathecal injection.
45616487|NCT03247309|Biological|IMA201 Product|The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
45616488|NCT03247309|Diagnostic Test|IMADetect®|IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials with investigational IMA201 therapy. IMADetect® is intended for investigational use only.
45616489|NCT04089943|Procedure|Revascularization operation|Participants will be randomized into an endovascular or open bypass procedure.
45616490|NCT04089943|Other|Control group|Healthy non-PAD participants will be recruited for the study.
45616491|NCT02472691|Drug|Lenalidomide|Lenalidomide (investigational drug) will be added to standard of care (Aza and DLI) starting from day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.
45616492|NCT02472691|Drug|Azacitidine|Starting on day 1 all patients will receive Azacitidine (standard of care) 75 mg/m2/d for 7 days every 28 days for up to 8 cycles.
45760371|NCT04793217|Behavioral|Improving AIDS Care After Trauma +|ImpACT+ integrates skills for HIV treatment adherence and coping with trauma, tailored to the South African context. This includes exploration of values informing care engagement, recognizing the synergistic stress of sexual trauma and HIV, understanding the contribution of stressors to maladaptive coping, and developing adaptive methods for coping as alternatives to avoidance. ImpACT+ will be delivered in private spaces at the primary care clinic and will consist of 6 individual sessions followed by 6 maintenance check-ins. Individual sessions focus on coping, adherence, and care engagement during an early critical period, while maintenance check-ins reinforce positive change and support ongoing implementation of skills. Evidence supports a 6-session format in low-resource settings. Individual sessions will begin within 2 weeks after the baseline survey and be completed by the 4-month assessment. Maintenance check-ins will begin following the 4-month assessment.
45616493|NCT02472691|Biological|Donor Lymphocyte Infusions|DLIs will be given after cycle 4, 6 and 8 at a dose of 0.5-1x10^6 CD3/kg (1st DLI), 1-5x10^6 CD3/kg (2nd DLI) and 5-15x10^6 CD3/kg (3rd DLI).
45616494|NCT03202069|Other|Even protein|Intake of even protein 5 day rotating menu
45616495|NCT03202069|Other|Skewed protein|Intake of skewed protein 5 day rotating menu
45760372|NCT04793217|Behavioral|Adapted Problem-Solving Therapy|Participants will receive three weekly individual sessions of adapted PST. The goal of PST is to identify problems that interfere with daily activities and address them through problem-orientation work. We anticipate stressors will include (a) relationship difficulties, including family stress, (b) financial stress and unemployment, (c) general impact of HIV infection, and (d) overall chronic stress. Thus, PST may indirectly address stressors that may impact care engagement, but will not address the intersection of HIV and trauma specifically.
45760373|NCT05452031|Behavioral|Care2Sleep|A multicomponent behavioral sleep program, consisting of sleep hygiene, stimulus control, sleep compression, pleasurable activity, daily walking, and light exposure.
45616496|NCT03311035|Procedure|Seton|The identification of the primary tract of the fistula and the placement of the thread can be performed in one single step. a non-absorbable, braided thread is inserted . After excision of the external opening and the extrasphincteric parts of the fistula, the thread is grasped and is pulled out of the anus .The thread is cut in two parts. The mucosa is incised over the muscular bridge . One thread is tied snugly around the muscle; the other is tied loosely .The snugly tied seton has to be replaced after 14 days to provide appropriate tension to cut slowly trough the muscle. This can easily be achieved with the second loosely tied seton . A new thread is folded in the middle and connected to the opened sling of the loose seton using a special knot shown in.The old thread is removed and in the same maneuver two new setons are placed. Again, one thread is tied snugly around the remaining portion of the sphincter muscle; the other is tied loosely .
45760374|NCT05452031|Behavioral|Sleep Education|This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations
45760375|NCT05685251|Other|Health Coaching|Participants will receive a health coach telehealth/video visit or phone call every 2 weeks for 4 months, for a total of 8 calls. After these initial 8 calls, at approximately 6 months postpartum, the health coach will schedule maintenance calls 1 per month until approximately 12 months postpartum, for a total of 6 additional calls.
45616497|NCT03311035|Procedure|LIFT technique|The internal opening was identified . The intersphincteric plane was entered via a curvilinear incision corresponding to the site of the internal opening at the intersphincteric groove. The intersphincteric plane was developed by meticulous scissor and diathermy dissection up to the tract. Once identified, a small, right-angled clamp was hooked underneath or a tape passed round it. the tract was then transfixed close to the internal sphincter with 2/0 polyglactin suture . Saline was gently injected through the external opening to confirm that the tract was no longer patent and it was then divided distal to the point of ligation . After light traction, a segment of the distal tract was excised and, if needed, any defect in the external sphincter was closed. The intersphincteric incision wound was re-approximated loosely with interrupted 2/0 Vicryl. Partial core-out of the fistula tract was performed from the external opening to the external sphincter.
45616498|NCT02470663|Dietary Supplement|DENSITYTM caplets (marketed as Amorphical)|supplementation
45760376|NCT05685251|Other|Home Blood Pressure Monitoring|Participants will be provided an A&D UA-651 (BT) home blood pressure monitor with an appropriate cuff size, they will be asked to take their blood pressure at least three days a week, 2 measurements each time
45616499|NCT02470663|Dietary Supplement|Calcium carbonate 600 mg once daily|supplementation
45760377|NCT00355953|Drug|Genistein|
45760378|NCT05419193|Drug|Propranolol Hydrochloride|"Day of randomization:~propranolol IV vp for 7 days after randomization"
45760379|NCT05419193|Other|control group|Patients will receive usual care and drug use in hospital
45760380|NCT05416073|Drug|Esketamine|"PCIA formula：100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline.~30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h.~The target value of analgesia in this study was NRS (Numerical Rating Scale)< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition."
45911596|NCT05778227|Drug|smearOFF|Final irrigation of root canal treatment procedure will be done with 5ml of smearOFF for 1min.
45911597|NCT05778227|Drug|Etidronic acid /sodium hypochlorite|During whole procedure of cleaning and shaping combination product of HEBP/NaOCl will be used
45445691|NCT02065492|Drug|Amlodipine|doses of 0.2 to 0.25 mg/kg/day PO would be given during this trial
45616500|NCT00705367|Drug|Placebo|Infusion, Intravenous, single dose, Day 1
45616501|NCT00705367|Drug|Abatacept|Infusion, Intravenous, 30mg/kg, single dose, Day 1
45616502|NCT00705367|Drug|Abatacept|Infusion, intravenous, 10 mg/kg, administered on Days 15 and 29 followed by doses every 4 weeks until the end of the study
45616503|NCT03310801|Procedure|ACP or Watchman|Left atrial appnedage occlusion using ACP or Watchman
45616504|NCT03055429|Other|Full Scale Unit|Pre-test, usability, post-test
45616505|NCT03043729|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2, as 2h infusion on Day 1 (Arm A + Arm B)
45616506|NCT03043729|Drug|5-FU|5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusion q2w (Arm A + Arm B)
45616507|NCT03043729|Drug|Leucovorin|Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 (Arm A + Arm B)
45616508|NCT03043729|Biological|Aflibercept|Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (Arm B, Cycles 1 to 5)
45616509|NCT03310645|Drug|BAY1817080|4 different doses over the course of study
45616510|NCT03310645|Drug|Matching Placebo|Matching placebo for BAY1817080
45616511|NCT05306431|Drug|Polyhexamethylene biguanide|Polyhexamethylene biguanide (PHMB), is a disinfectant solution having a broad spectrum of antimicrobial activity and is investigated as an endodontic irrigant
45616512|NCT05306431|Drug|Sodium Hypochlorite|A number of irrigant solution has thus been proposed to serve the purpose, the most popular being sodium hypochlorite (NaOCl) because of its excellent antimicrobial activity but also the ability to dissolve organic matter
45616513|NCT02970955|Procedure|Inoperable thoracic nodes metastases|The radiation treatment will be delivered with three possible schedules, with a risk adaptive scheme according to number, site and size of metastatic nodes and based on the possibility to respect the constraints of healthy tissues
45616514|NCT03905707|Drug|glepaglutide|Glucagon-Like Peptide-2 (GLP-2) analog
45616515|NCT03108313|Drug|aloe vera toothpaste|herbal toothpaste used to decrease salivary streptococcus bacterial count
45616516|NCT03108313|Drug|fluoride toothpaste|chemical toothpaste used to decrease salivary streptococcus bacterial count
45616517|NCT03108625|Drug|Vortioxetine|Target dose is 10 mg/day; the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
45616518|NCT03310567|Drug|Epacadostat + pembrolizumab|Each patient would be administered epacadostat orally twice a day and pembroluzimab by infusion once in a cycle of 21 days
45616519|NCT03900949|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic SCT
45616520|NCT03900949|Drug|Cytarabine|Given IV
45616521|NCT03900949|Drug|Daunorubicin Hydrochloride|Given IV
45616522|NCT03900949|Drug|Gemtuzumab Ozogamicin|Given IV
45616523|NCT03900949|Drug|Midostaurin|Given PO
45616524|NCT02864251|Biological|Nivolumab|Specified dose on specified days
45616525|NCT02864251|Biological|Ipilimumab|Specified dose on specified days
45616526|NCT02864251|Drug|Pemetrexed|Specified dose on specified days
45616527|NCT02864251|Drug|Cisplatin|Specified dose on specified days
45616528|NCT02864251|Drug|Carboplatin|Specified dose on specified days
45616529|NCT02757859|Procedure|Pancreatectomy|Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
45616530|NCT02757859|Other|Lavage|Receive EIPL-S
45804040|NCT05717036|Device|Serum Total Protein Measurement with TS Meter-DSP and Refractix DSP|The two blood samples will be centrifuged and hematocrit measured per the plasma center's standard operating procedures. One participant sample will be dispensed onto the cleared TS Meter-DSP for a serum total protein measurement. This measurement will be used, along with other pre-screening information, to determine if the participant can donate plasma. The second participant sample will be dispensed onto the investigational Refractix DSP for a serum total protein measurement. It will be compared to the sample measurement taken on the cleared TS Meter-DSP.
45804041|NCT00358280|Drug|Ropivacaine|
45804042|NCT00358280|Drug|Bupivacaine|
45616531|NCT02757859|Procedure|Pancreatectomy|Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
45616532|NCT02757859|Other|Lavage|Receive EIPL-D
45616533|NCT02757859|Procedure|Pancreatectomy|Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
45616534|NCT03310489|Behavioral|Digitalized cognitive-behavioral intervention for anxiety|An internet-based CBT, including telephone coaching
45616535|NCT03310489|Behavioral|Psychoeducation about anxiety|Psychoeducative material about anxiety in internet
45616536|NCT02468791|Drug|Rituximab|
45616537|NCT02470195|Behavioral|workshop|workshop for procedural simulation for education in difficult airway situation
45616538|NCT02693821|Drug|Gabapentin|gabapentin 300 mg per day, orally during 30 days
45616539|NCT02693821|Drug|Placebo|Placebo 300 mg per day, orally during 30 days
45616540|NCT02468713|Drug|Combiflex® lipid peri|total parenteral nutrition solutions containing glucose, amino acids, electrolyte, soybean oil
45616541|NCT02468713|Drug|Winuf® peri|total parenteral nutrition solution containing glucose, amino acids, electrolyte, soybean oil, medium chain triglyceride, olive oil and fish oil
45616542|NCT02470117|Drug|Alginate-based reflux suppressant|
45616543|NCT02470117|Drug|magnesium-aluminium antacid gel|
45616544|NCT03310333|Drug|Propess® (dinoprostone)|"The inclusion begins after 12 hours of PROM for a pregnant woman who has an unfavourable cervix and no B streptococcus. The case is discussed during the obstetric staff every morning.~If the cervix is unfavourable (cervical Bishop's score <6), the information of the study is given to the patient and the consent collected.~An antibiotic is started at the beginning of the inclusion by amoxicillin (or clindamycin in case of allergy of amoxicillin) to prevent choroamnionitis."
45616545|NCT03310333|Device|cook cervical pipening balloon|• In dinoprostone vaginal group: the device is placed in vaginal fornix by the midwife for maximum 24 hours. If Propess ® is fallen before the first 12 hours, another one could be introduce if the cervix stayed unfavourable.
45616546|NCT03310255|Diagnostic Test|H pylori Faecal Antigen|All patients will be screened for H. pylori using fecal Ag and positive patients will do endoscopy and biopsy.
45616547|NCT02299999|Drug|AZD2014|Target: m-TOR
45616548|NCT02299999|Drug|AZD4547|Target: EGFR
45616549|NCT02299999|Drug|AZD5363|Target: AKT
45616550|NCT02299999|Drug|AZD8931|Target: HER2, EGFR
45616551|NCT02299999|Drug|Selumetinib|Target: MEK
45760381|NCT05416073|Drug|Sufentanil|"PCIA formula：100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline.~30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h.~The target value of analgesia in this study was NRS (Numerical Rating Scale)< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition."
45760382|NCT02979171|Device|Laryngeal Mask Airway Classic|
45760383|NCT05481801|Biological|Covid-19 vaccination|"Correct Covid19 vaccination status was considered in the following situation:~Received at least two Covid-19 vaccine doses being the last in the last 6 months."
45760384|NCT05481801|Biological|Influenza vaccination|"Correct influenza vaccination status was considered in the following situation:~- Received at least one Influenza vaccine dose in the last year."
45760385|NCT05481801|Biological|Pneumococal vaccination|"Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~One pneumococcal conjugate vaccine (PCV) 13 dose in the last year. One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~One PPSV 23 dose in the last 5 years. One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year."
45760386|NCT05481801|Biological|Hepatitis B Virus (HBV) vaccination|"Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months."
45760387|NCT05601687|Procedure|Direct Endoscopic Necrosectomy|Endosonography-guided, transmural drainage of the WONs shall be performed using a lumen-apposing metal stent (LAMS).After placement of the LAMS, EN shall be performed during the same procedure (Direct EN). After DEN, a 7-Fr/4cm double pigtail and a 7-Fr nasocystic irrigation catheter shall be placed through the LAMS. Endoscopic necrosectomy and VARD shall be repeated as often as clinically indicated and logistically possible with a minimum of one day between procedures
45760388|NCT05601687|Procedure|Step-up Approach|"Endosonography-guided, transmural drainage of the WONs shall be performed using a lumen-apposing metal stent (LAMS). After placement of the LAMS, a 7-Fr/4cm double pigtail stent and a 7-Fr nasocystic catheter shall be placed through the LAMS.~The effect of the index drainage procedure shall be evaluated every 72 hours and next treatment step will depend on whether the patient's condition improves.~If clinical improvement is observed, the drainage regime continues, and no further therapeutic action shall be taken.~In absence of clinical improvement after 72 hours and if supplementary drainage is impossible, the patient shall proceed to endoscopic necrosectomy (EN) or video-assisted retroperitoneal debridement (VARD). Absence of clinical improvement due to causes not related to the WON treatment, e.g., urinary tract or pulmonary infection or iv catheter sepsis, shall not influence the treatment algorithm of the WON."
45616552|NCT02299999|Drug|Vandetanib|Target: VEGF, EGFR
45616553|NCT02299999|Drug|Bicalutamide|target: Androgen receptor
45616554|NCT02299999|Drug|Olaparib|Target: PARP
45616555|NCT02299999|Drug|Anthracyclines|DNA intercalation
45760389|NCT05664971|Biological|Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection|200mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
45760390|NCT05664971|Biological|Toripalimab|240mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
45760391|NCT05664971|Drug|Docetaxel|60 or 75mg/m2 via IV infusion on Day 1 of a 21-day cycle, which may be maintained until disease progression
45760392|NCT05664971|Drug|Pemetrexed|500mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles; Subjects who have disease progression after 4 cycles may continue to receive maintenance treatment with pemetrexed
45760393|NCT05664971|Drug|Cisplatin|75mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
45760394|NCT05664971|Drug|Carboplatin|AUC 5 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
45760395|NCT05664971|Drug|Paclitaxel|175mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
45760396|NCT05664971|Drug|Etoposide|100mg/m2 via IV infusion on Days 1, 2, and 3 of a 21-day cycle for 4 cycles
45760397|NCT05594667|Drug|Psilocybin|25mg of psilocybin provided by Filament Health
45804043|NCT05719285|Drug|Single-Dose Antibiotic|"Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.~First line:~Arm 1: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure~Second line:~Arm 1: cefalexin 500 mg once pre-procedure~Third line:~Arm 1: nitrofurantoin 100 mg once pre-procedure~Fourth line:~Arm 1: ciprofloxacin 500 mg once pre-procedure"
45616556|NCT02299999|Drug|Taxanes|Target: mitotic tubulin and microtubules
45616557|NCT02299999|Drug|cyclophosphamide|Alkylating agents
45616558|NCT02299999|Drug|DNA intercalators|DNA intercalators
45616559|NCT02299999|Drug|Methotrexate|DNA intercalators
45616560|NCT02299999|Drug|vinca alkaloids|Target: mitotic tubulin and microtubules
45616561|NCT02299999|Drug|Platinum based chemotherapies|Platinum based chemotherapies
45616562|NCT02299999|Drug|Bevacizumab|Target: VEGF
45616563|NCT02299999|Drug|Mitomycin C|Alkylating agents
45616564|NCT02299999|Drug|Eribulin|Microtubule modulator
45616565|NCT02299999|Drug|MEDI4736|Target: PD-L1
45616566|NCT00705289|Biological|Infliximab|Infliximab used in line with current clinical practice and local guidelines.
45616567|NCT02469805|Drug|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
45616568|NCT02469805|Drug|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL.
45616569|NCT02469805|Procedure|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
45616570|NCT02469805|Procedure|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
45616571|NCT02469805|Device|Shepherd catheter|Processes semen will be drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
45616572|NCT03310099|Behavioral|Increasing daily unsaturated fatty acid consumption|Investigators will provide participant with detailed information about the consumption of food rich in unsaturated fatty acids (UFA) like extra-virgin olive oil, canola oil or mixed nuts, and they will provide specific recommendations based on the participant's diet. The investigators will follow up with a weekly phone call to assure that the dietary recommendations are clear and that the participants can integrate the suggestions into their daily diets.
45616573|NCT02263729|Drug|Losartan|
45616574|NCT02263729|Drug|placebo|
45616575|NCT03309865|Dietary Supplement|semi-vegetarian diet|semi-vegetarian dietary intervention: Duration of Therapy: 14 weeks;
45616576|NCT03309865|Drug|Vedolizumab Injection|vedolizumab (300mg) IV infusions at week 0, 2, 6, 14; Duration of Therapy: 14 weeks
45616577|NCT02469571|Dietary Supplement|Winclove 607|multispecies probiotic
45616578|NCT02469571|Dietary Supplement|Placebo|Placebo
45616579|NCT02111941|Other|Laboratory Biomarker Analysis|Correlative studies
45616580|NCT02111941|Biological|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
45616581|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
45616582|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
45616583|NCT02038777|Drug|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
45616584|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
45616585|NCT02038777|Drug|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days.
45616586|NCT02038777|Drug|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7.
45760398|NCT04848077|Behavioral|Step count increase with the use of a motivational smartphone application|All participants will be given access to an application installed on the participants' own smartphone: the STEPWISE app. The STEPWISE app will encourage participants to increase their long-term physical activity (1 year). Different treatment arms will receive different physical activity goals. Participants will get feedback and support via the smartphone app, that stimulates them to reach their individual physical activity goal (i.e. target percentage increase in stepcount).
45616587|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
45616588|NCT02038777|Drug|Azacitidine|Azacitidine Combination Cohort; Azacitidine 75 mg/m2 for 7 days.
45616589|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
45616590|NCT02038777|Drug|LDAC|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
45616591|NCT03744793|Drug|Avelumab|Given IV
45616592|NCT03744793|Drug|Pemetrexed|Given IV
45616593|NCT03713593|Drug|lenvatinib|Administered orally once a day
45616594|NCT03713593|Biological|pembrolizumab|Administered as an IV infusion on Day 1 Q3W
45760399|NCT04785963|Behavioral|Music with Suggestion|A nonpharmacological, short-term treatment that poses minimal risk and places very limited burden on patients seems ideal for this population, and music with suggestions is one such treatment option.
45760400|NCT04785963|Behavioral|Pain Information|The comparison condition of informational recordings about chronic pain are structured to account for non-specific effects of general time and attention and to evaluate whether the treatments of music alone, and music in combination with suggestion are effective in the reduction of pain intensity more than an appropriate control group.
45616595|NCT03713593|Drug|saline placebo|Administered as an IV infusion on Day 1 Q3W
45616596|NCT03309709|Drug|subcutaneous progesterone|25mg daily for 7 days
45616597|NCT01720147|Drug|Quercetin (dietary supplement)|"Quercetin will be given orally on a twice a day schedule starting with weight adjusted dose for a maximum total daily dose of 1500 mg/day, for 4 months (16 weeks). Pharmacokinetics (PK) data will be analyzed after each cohort of 3 patients and will be used to optimize the dosing schedule (if required)for subsequent patients.~An expansion cohort has been added to the study protocol. Up to 20 patients may be enrolled. The dose utilized will be the same as the max weight adjusted dose that showed biological activity in our last cohort of patients (subjects #10-12 from above)."
45616598|NCT02469883|Drug|Sinotecean|
45616599|NCT02468635|Other|upper limb exercises|HEATING PHASE: diagonals for upper and lower limbs (5-10 minutes). AEROBIC PHASE: aerobic exercise on a treadmill or bicycle between 5 - 30 minutes and rest 1-2 minutes according to the Borg scale and patient tolerance (Borg scores for dyspnea 4-5); RESISTANCE STAGE: upper limb exercises with weight training equipment or dumbbells (the patient's adaptation) with 50% of maximum load reached the maximum repetition test. Series 2 minutes and rest interval between sets 1-2 minutes. RESPIRATORY TRAINING : Strengthening of the respiratory muscles 5-15 minutes with Threshold with load of 50% of the affected MIP (measure maximal inspiratory pressure) evaluation. RELAXATION: Stretching and muscle massage therapy group involved in the 5-10 minute workout.
45616600|NCT02468635|Other|without training for upper limb|HEATING PHASE: diagonals for upper and lower limbs (5-10 minutes). AEROBIC PHASE: aerobic exercise on a treadmill or bicycle between 5 - 30 minutes and rest 1-2 minutes according to the Borg scale and patient tolerance (Borg scores for dyspnea 4-5); RESPIRATORY TRAINING: Strengthening respiratory muscles 5-15 minutes with Threshold with load of 50% of MIP hit in the evaluation. RELAXATION: Stretching and muscle massage therapy group involved in the 5-10 minute workout.
45616601|NCT02469727|Behavioral|Fitbit|Participants will use the FitBit device to track their physical activity
45616602|NCT02469727|Behavioral|Facebook group|Participants will receive and post messages and receive badges on the Facebook group
45616603|NCT03309631|Diagnostic Test|In vitro Diagnostic|
45760401|NCT04785963|Behavioral|Music|The comparison condition of the music only is structured to account for the effect of music listening, and to evaluate whether the addition of suggestion optimizes its effectiveness in the reduction of pain intensity.
45760402|NCT05591313|Behavioral|LI-40|Participants were asked to complete a volume-matched light-intensity exercise for 30-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
45616604|NCT05190055|Device|bone graft delivery system/wiltrom interbody fusion system/wiltrom spinal fixation system|After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted, exposing the lumber vertebras encompassing the facet joints. The facet joints were removed, and decompression was performed. The diseased disc nucleus was then excised before filling in the bone substitutes. In the case of the device group, a novel filler tube with an integrated threaded rod, which can be connected to a surgical drill, A PEEK interbody fusion cage was then placed into the disc space followed by fixation with pedicle screws.
45616605|NCT05190055|Device|wiltrom interbody fusion system/wiltrom spinal fixation system|After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted, exposing the lumber vertebras encompassing the facet joints. The facet joints were removed, and decompression was performed. The diseased disc nucleus was then excised before filling in the bone substitutes. For the control group, the bone substitutes were filled in the disc space manually using a bone grafting funnel. A PEEK interbody fusion cage was then placed into the disc space followed by fixation with pedicle screws.
45616606|NCT03304951|Device|Sinopsys® Lacrimal Stent|The Sinopsys® Lacrimal Stent is indicated for use in creating a transcaruncular ethmoid access.
45616607|NCT01141309|Drug|sorafenib with everolimus|"Treatment will be with sorafenib 400 mg orally twice a day and everolimus 5 mg orally daily. Restage every 2 cycles *Cycle = 4 weeks of treatment.~Subjects may consent to allowing blood to be drawn for DNA. Two blue top tubes will be required. Approximately 5-6 ml will be needed. This may be done at anytime, including before, during, or after treatment. This is not required to participate in the study."
45616608|NCT00806065|Drug|ENMD-2076|
45616609|NCT03309553|Other|Current Primary Care Referral Process|Children who screen positive for hearing loss will receive the same method each school had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.
45616610|NCT03309553|Other|Telemedicine Referral Process|In villages randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made same-day or next-day, with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children screening positive will be transported to clinic for their appointment with adult chaperones. Parents are encouraged but not required to attend, except for children grades 2 and younger, for whom parental participation will be required. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
45616611|NCT03304561|Other|Traditional rehabilitation|traditional ACL rehabilitation program
45616612|NCT03304561|Other|Cross-over training|Cross-over training addition to the traditional rehabilidation
45616613|NCT03314077|Other|GOLD 2017|Standard COPD management according to GOLD 2017, and control the quality of management in one-year follow-up.
45760403|NCT05591313|Behavioral|MI-30|Participants were asked to complete a volume-matched moderate-intensity exercise for 20-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
45616614|NCT03304483|Other|246-km running|Spartathlon 2017
45616615|NCT03304405|Diagnostic Test|Gait Analysis|All patients will undergo gait analysis using reflective surface markers placed at different locations on the head, trunk, upper and lower extremities, and pelvis. All patients will complete an analog pain scale, Oswestry, and SRS-22 questionnaires. These are health-related quality of life questionnaires that provide subjective assessment.
45616616|NCT03309319|Drug|Rosiglitazone|rosiglitazone is added to the primary treatment
45760404|NCT05591313|Behavioral|HI-16|Participants were asked to complete a volume-matched high-intensity exercise for 16-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
45760405|NCT05590299|Other|Fish oral immunotherapy (codfish)|Codfish in mixture of potato prepared under food manufacturing regulations provided in varying doses
45760406|NCT05590299|Other|Placebo oral immunotherapy|Placebo in potato mixture prepared under food manufacturing regulations provided in varying doses
45760407|NCT05458713|Device|Laser acupuncture|Irradiate acupoints with low power laser
45760408|NCT00355485|Device|microdermabrasion|"Device: Bellamed microdermabrasion system produced by Bella products or the Altair Diamondtome System.~Subjects will receive a series of microdermabrasion treatment sessions (up to 6) spaced one to two weeks apart."
45760409|NCT05660915|Procedure|Intermediate approach|The area between superior mesenteric vein and superior mesenteric artery was defined as the intermediate area and dissection was performed in this area to achieve the removal of the uncinate process of pancreas.
45760410|NCT05660915|Procedure|Standard approach|The key point of surgery in the standard approach group was to first reveal portal vein-superior mesenteric vein and gradually complete the the resection of the uncinate process of pancreas based on the reference of portal vein-superior mesenteric vein.
45760411|NCT04812509|Drug|MW032|The active ingredient of MW032 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
45760412|NCT04812509|Drug|Xgeva|The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
45760413|NCT05647655|Device|Ultrasonography|Bedside thoracic ultrasound for patients complaining of acute dyspnea.
45760414|NCT00810095|Device|MindFrame System|Thrombectomy Catheter designed to rapidly restore blood flow in patients experiencing an ischemic stroke
45616617|NCT03304327|Behavioral|Mindfulness and Yoga Training|"Centering and Breathing- Practice begins by turning attention to the breath to help participants make the transition from the busy, doing, outward focus of daily life into the mindful, balanced, internal focus central to yoga practice.~Practices:Breath awareness, the relaxed abdominal breath. Posture Practice-Warm up with the range-of-motion sequence to take the major joints of the body through their full range of motion.This is done lying down with the head on the floor; the head can be supported by a small, folded towel if desired.~Practices: Knee-to-chest sequence, Arms and Shoulders, Gentle Spinal Twist, Apanasana.~Standing Poses for Strength and Balance, to enhance function and confidence. Practices: Mountain Pose, Flying Crane Sequence, Tree Pose, Warrior 2 and Side Angle.~Relaxation- Practice concludes with guided relaxation to quiet the mind and calm the body.~Practices: Seated Mountain Pose, even breath, extended exhalation,Yoga Nidra."
45616618|NCT03309241|Drug|PF-06882961|Single Ascending Doses of PF-06882961 from 3mg to TBD mg.
45616619|NCT03309241|Other|Placebo|Placebo Single Dose
45616620|NCT03313921|Diagnostic Test|Online Manifest Refraction|"The online manifest refraction is performed with a web-based application and consists of an assessment of visual acuity, an assessment of spherical refractive error, and an assessment of cylinder refractive error. The software is a class 1 CE-approved medical device.~The automated refraction is measured with a regular office-based autorefractor device; TOPCON RM-8000."
45616621|NCT02469493|Device|acupuncture (Huatuo)|The needles used were Huatuo brand (Suzhou, China) sterile disposable stainless steel filiform; needles sized 0.25*25 mm. After disinfection, needles were inserted 0.5 to 0.8 inches into the skin and were manipulated manually to obtain Deqi. An electric stimulator (Huatuo SDZ-V, Suzhou, China) was connected to the needles and delivered a constant-current, 0.2-ms, density-wave, stimulus of 2 to 10-Hz frequency, level of intensity was as much as tolerable, but not painful to the subjects. The needles were left for 30 minutes and then removed.
45616622|NCT03309163|Drug|Tramadol|Patient-controlled intravenous analgesia with Tramadol
45616623|NCT03309163|Drug|Hydromorphone|Patient-controlled intravenous analgesia with Hydromorphone
45616624|NCT03309163|Drug|Ropivacaine (Epidural analgesia)|Patient-controlled epidural analgesia with Ropivacaine.
45616625|NCT03309085|Procedure|Repeated CT scan|CT scan of chest on different PEEP levels, 4 in total
45616626|NCT03309085|Device|CT scan|CT scan
46069037|NCT04624139|Behavioral|Internet-based cognitive behavioral therapy + physiotherapy|"Combined intervention of stress reducing I-CBT and physiotherapy. The intervention consists of two components; I-CBT and physiotherapy aiming to reduce symptoms of stress.~I-CBT: Designed to reduce stress, during 8 weeks. Physiotherapy: A total of three visits with a physiotherapist (at start, after 4 weeks and after 12 weeks). Visit 1 (at start): The participant and the physiotherapist design together an individual plan of physical activity, based on the recommendations for stress as suggested in the Physical Activity in the Prevention and Treatment of Disease (FYSS in Swedish): Physical activity on moderate intensity 150 min/week and a strengthening exercise program performed at twice a week.~The physical activity is performed outside health care - in the participant´s home or in other exercise premises outside health care Visit 2 and 3 (after 4 and 12 weeks): Follow up and revision of the Physical activity plan."
46069038|NCT04624139|Behavioral|Physiotherapy only|"A total of three visits with a physiotherapist (at start, after 4 weeks and after 12 weeks). Visit 1 (at start): The participant and the physiotherapist design together an individual plan of physical activity, based on the recommendations for stress as suggested in the Physical Activity in the Prevention and Treatment of Disease (FYSS in Swedish): Physical activity on moderate intensity 150 min/week and a strengthening exercise program performed at twice a week.~The physical activity is performed outside health care - in the participant´s home or in other exercise premises outside health care Visit 2 and 3 (after 4 and 12 weeks): Follow up and revision of the Physical activity plan."
45616627|NCT03308851|Procedure|Piezocorticision|The piezocorticision is a procedure that aims to accelerate the movement of teeth during an orthodontic treatment. It consists of a local anaesthesia followed by an incision of the buccal mucosa and an incision in the alveolar bone with a piezotome.
45616628|NCT03308851|Procedure|Osteoperforation|The osteoperforation is a procedure that aims to accelerate the movement of teeth during orthodontic treatment. It consists of a local anaesthesia followed by perforations of the buccal mucosa and alveolar bone using a specific osteoperforation tool.
45616629|NCT03304015|Behavioral|Behavioral Change Communications|HERrespect is developed by Business for Social Responsibility (BSR) and Change Associates. HERproject is one of BSR's numerous initiatives for improving women's lives through enhancement of access and knowledge (BSR, 2015). The factory-based component of HERrespect will be implemented by Change Associates. The intervention group will receive training (group session), research and consultancy services to the corporate and development sectors. HERrespect proposes to use the workplace as an incubator of dialogue among men and women to tackle underlying issues which allow violence against women and girls. Workplace offers a unique platform and environment to engage women who are gaining financial independence to reduce intimate partner violence and workplace violence.
45616630|NCT03174847|Procedure|Adrenalectomy|Adrenalectomy for unilateral adrenal hyperplasia / adenoma
45616631|NCT03174847|Drug|Mineralocorticoid Receptor Antagonists|Medical treatment with MRA / amiloride
45616632|NCT03313765|Behavioral|Motivational interviewing (MI)|Brief MI intervention
45616633|NCT03313765|Other|Standard-of-care|Standard-of-care education and counseling
45616634|NCT02468479|Other|No relevant intervention.|No relevant intervention.
45911598|NCT05778227|Drug|Maleic acid|Final irrigation of root canal treatment procedure will be done with 5ml of maleic acid for 1min.
45616635|NCT04442035|Behavioral|5-element music therapy|participants were treated by TCM five-phase music therapy for not less than 30 minutes per day, and group music therapy was performed every three weeks. In addition, the therapeutic schedule is composed of treatment time (1pm-2pm, 9pm-11pm), frequency treatment (two times a day), intervention (10-15 minutes in the afternoon, 30 minutes in the evening) and content (individuals: dialectical selection of music; groups: community singing, every three weeks).
45616636|NCT04441723|Device|Osteosynthesis with Gamma 3 nail , using a dynamic lag screw as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Gamma 3 nail , with dynamic lag screw as proximal fixation
45616637|NCT04441723|Device|Osteosynthesis with Gamma 3 nail , using a static lag screw as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Gamma 3 nail , with static lag screw as proximal fixation
45616638|NCT04441801|Other|stretching exercise|Static stretching consists of stretching a muscle (or group of muscles) to its farthest point and then maintaining or holding that position
45616639|NCT03303859|Diagnostic Test|Bacterial vaginosis|
45616640|NCT03313609|Behavioral|Investigating Burnout in Intensive Care in Middle Incoming Turkey|single-group studies
45616641|NCT03313531|Diagnostic Test|Thrombin Generation Assay|Inter lab variation and level of agreement will be determined
45616642|NCT03313531|Drug|Treatment with recombinant coagulation factor|To obtain a wide range of thrombingeneration levels, one person (Treated HA person) will recieve one injection of Advate and one injection of Adynovate respectively
45616643|NCT03308539|Radiation|echocardiography and cardiac magnetic resonance|transthoracic echocardiography and magnetic resonance imaging of the heart
45616644|NCT03313453|Device|PuriCare (HEPA Air Cleaner)|The active comparator group is a group that uses machines that have the same functions as those on the market. In intervention group, two air-cleaners will be activated, one in the living room (covers 91 m2) and the other in the bedroom (covers 58 m2). The air cleaner will be operated continuously for 6 weeks. Inside the air cleaner, a device for measuring the quality of the indoor air is built in. It will be used to compare indoor air quality before and after air cleaner operation. In order to maintain the double-blind setting, a label for 'prohibition of opening' will be attached to the joint of the outer case, and a sticker to cover the air quality measurement display part built in the air cleaner itself will be attached.
45616645|NCT03313453|Device|Mock device of PuriCare|The Control group operates the air-cleaner with the same appearance as the experiment group. However, all the filters including HEPA filter will not be inserted in this group (mockup devices). Two mockup air-cleaners will be activated, one in the living room (covers 91 m2) and the other in the bedroom (covers 58 m2). The mockup devices will be operated continuously for 6 weeks. Same as active comparator group, a device for measuring the quality of the indoor air is built in the mockup air cleaner. It will be used to compare indoor air quality before and after air cleaner operation. In order to maintain the double-blind setting, a label for 'prohibition of opening' will be attached to the joint of the outer case, and a sticker to cover the air quality measurement display part built in the air cleaner itself will be attached.
45616646|NCT03303781|Other|Cardiac Rehabilitation|phase II center-based cardiac rehabilitation
45616647|NCT03308461|Drug|Fecal Microbiota suspension|The prepared microbiota suspension was infused into mid-gut.
45616648|NCT05067907|Procedure|Early physiotherapy|"Respiratory physiotherapy included:~early and functional mobilization: passive and active mobilization, muscle strengthening, improving independence in activities of daily living (ADL), sitting out of bed, standing, walking;~patient positioning to achieve better ventilation/perfusion ratio and gas exchange;~airway clearance;~aerosol administration;~invasive mechanical ventilation weaning;~use of non-invasive mechanical ventilation (NIMV) and continuous positive airway pressure (CPAP);~tracheostomy management and weaning;~swallowing assessment;~management of oxygen delivery;~lung expansion;~patient assessment and functional scale administration."
45616649|NCT03313375|Other|Continuous Exercise|Subjects will be asked to perform a 45 min exercise bout. 10 minutes will be a warmup (at a work rate associated with 50% heart rate max), 30 minutes at a wattage that elicits 75-80% heart rate max, and a 5 minute cool down period, returning them to approximately 50% heart rate max.
45616650|NCT03313375|Other|Aerobic Interval Exercise|Subjects will be asked to complete a 43 minute exercise session. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax.
45760415|NCT05446623|Drug|Dexmedetomidine|Opioid free anesthesia (OFA) consists in the simultaneous administration of alpha2-agonist (for example the dexmedetomidine), sodium channel blocker (lidocaine), and NMDA antagonists receptors (Ketamine). Its aim is to control de cardiovascular nociceptive response to the surgical stimulation.
45760416|NCT05446623|Drug|Sufentanil|The one in the OA group will be given a bolus of Sufentanil before and during the surgery.
45760417|NCT04383899|Other|Questionnaire|All patients testing positively for COVID-19, with completed questionnaires. As appropriate, the duration of the study will be at least the time to complete the questionnaire for non-hospitalized patients, and for those who are hospitalized, they will be followed until hospital discharge or death to ascertain outcome.
45616651|NCT03308383|Other|DOING TRANSTHORACIC ECHOCARDIOGRAM|TRANSTHORACIC ECHOCARDIOGRAM WILL BE DONE IN THE PARTICIPANTS WHICH IS NON-INVASIVE
45616652|NCT05289973|Device|TruNatomy Files|Newly introduced endodontic file with high flexibility.
45616653|NCT05289973|Device|HyFlex EDM Files|Endodontic files
45760418|NCT00792077|Drug|Lenalidomide|5 mg daily for 56 days.
45760419|NCT04712175|Diagnostic Test|Nasopharyngeal sampling|Swabs will be taken of nasopharyngeal samples for RT-PCR
45760420|NCT04712175|Diagnostic Test|Saliva sampling|A 10ml saliva sample will collected in a sterile 60ml bottle for mass spectrometry and RT-PCR
45760421|NCT02979015|Drug|alirocumab SAR236553 (REGN727)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
45760422|NCT02979015|Drug|placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
45760423|NCT04696263|Device|Da Vinci ® Xi system - MP Robotic Radical Prostatectomy|After pneumoperitoneum is established, four 8mm, one 12 mm, and one 5 mm trocars are placed for instrumentation. After the robot is docked, radical prostatectomy is performed with the SOC approach.
45616654|NCT03303703|Other|RENEwS|The intervention participants will meet with a trained interventionist for five 60-minute sessions as a group (two groups of five participants each). In the sessions time will be divided between didactic presentation of material, active practicing of techniques, group work focused on case studies, and worksheets for further practice at home. Topics covered within the intervention include emotional awareness, balancing emotional and physical wellbeing, selecting and implementing emotion regulation strategies (such as situation selections, mindfulness, engagement/avoidance, reappraisal, and emotional sharing), and emotional monitoring.
45616655|NCT02468167|Procedure|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
45616656|NCT02468167|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
45616657|NCT02468167|Drug|N-butyl-2-cyanoacrylate|
45616658|NCT02468167|Drug|Lauromacrogol|
45616659|NCT03303547|Diagnostic Test|MRI mapping to guide pathological sampling of extranodal tumour deposits|Radiologist to mark areas where extranodal disease is identified on MRI. The pathologist will use this to take additional samples for analysis. This will allow better pathological staging and will affect treatment decisions for patients.
45616660|NCT03313297|Drug|AZD4017|AZD4017 is a novel orally bioavailable small molecule inhibitor of 11β-HSD1 enzyme activity. It is potent and highly selective in vitro and in vivo. The half maximal inhibitory concentration (IC50) for inhibition of 11β-HSD1 activity (cortisone to cortisol conversion) is 2nM. AZD4017 is selective (> 2000x) for 11β-HSD1 over human recombinant 11β-HSD2 and the closely-homologous enzymes 17β-hydroxysteroid dehydrogenase 1 and 17β-hydroxysteroid dehydrogenase 3 in vitro.
45616661|NCT03313297|Drug|Placebo|Matching placebo
45616662|NCT03308149|Drug|infiltration with triamcinolone and bupivacaine|facet joint infiltration
45616663|NCT03308071|Behavioral|Hypnosis|Hypnotic induction, relaxation, and guided imagery specific to perioperative symptoms will be administered.
45616664|NCT03313219|Drug|Gentuximab Injection|Gentuximab Injection (Recombinant anti-VEGFR2 human-mouse chimeric monoclonal antibody injection)
45616665|NCT03303313|Drug|Cemdisiran|Subcutaneous (sc) injection of Cemdisiran
45616666|NCT03303235|Drug|Methylergonovine|IV vs IM
45616667|NCT03307993|Drug|Idalopirdine|Idalopirdine 60-120 mg daily dose
45616668|NCT04442113|Procedure|Pulmonary vein isolation plus ablation guided by novel STAR mapping™|Catheter ablation for persistent AF consisting of pulmonary vein isolation plus additional ablation guided by the novel STAR mapping™ software on a computer device.
45616669|NCT04442113|Procedure|Pulmonary vein isolation|Catheter ablation for persistent AF consisting of pulmonary vein isolation (the standard treatment for AF)
45616670|NCT03303157|Other|no intervention|not relevant
45616671|NCT05127499|Other|progressive relaxation exercises|progressive relaxation exercises will do
45616672|NCT03303001|Procedure|Subacromial high volume infiltration|This group will receive a high volume dose of a mix of methylprednisolone (40 mg in 2 mL) plus ropivacaine at 7.5% plus simple lidocaine plus saline solution for a total of 50 mL
45616673|NCT03303001|Procedure|Subacromial conventional infiltration|This group will receive a mix of solution of 2 mL of 40 mg of methylprednisolone plus 5 ml of ropivacaine at 7.5% plus 3 mL of lidocaine simple for a total of 10 ml
45616674|NCT03302923|Behavioral|Brisk walking|Prospective randomized clinical trial with 2 intervention groups and 1 control group.
45452272|NCT03134950|Behavioral|ADAPT|Aim to Decrease Anxiety and Pain Treatment is a tailored CBT ranging from 4 sessions (pain-focused) to 6 sessions (blend of pain and anxiety coping strategies depending on the needs of the individual patients. The first 2 sessions will be in person with a trained psychologist and the following 2-4 sessions will be web-based. Each web-based session will be followed by phone support.
45616675|NCT04490629|Device|Lyoplant Onlay|Lyoplant Onlay is a kind of latest artificial Dura Mater
45616676|NCT04490629|Device|DURAFORM|DURAFORM is a kind of conventional artificial Dura Mater
45616677|NCT03302845|Drug|Omeprazole 40 MG|Omeprazole 40 mg capsule
45616678|NCT03302845|Drug|Famotidine 40 mg|Famotidine 40 mg tablet
45616679|NCT03302845|Drug|Telotristat ethyl 250 mg|Telotristat ethyl 250 mg tablet
45616680|NCT03313141|Diagnostic Test|Ultrasound|Volitional and non volitional respiratory tasks
45616681|NCT05104411|Other|Rehabilitative intervention|Active rehabilitation programs were done for all patients. Participants were asked to attend exercise program at PT room or bedside. Exercise program was offered once or twice daily on weekdays, by trained kinesiologists. In PT programs, most patients performed strengthening exercise of lower extremities, balance training, sit-up training, sit-to-stand training and gait training for about 30 minutes. Each program was individualized to participants' current physical function. In bedside programs, patients also underwent strengthening exercise and balance training without gait training for about 10 minutes. The duration of exercise program at PT room depends on the patient's condition(upto 1 month).
45760424|NCT04696263|Device|Da Vinci ® SP system - SP Robotic Radical Prostatectomy|After induction of general anesthesia and supine participant positioning, a 3.5 cm infraumbilical incision will be made for single-port access into the space of Retzius. Radical prostatectomy is then performed with the SOC approach
45616682|NCT03312985|Procedure|ACAF surgery|The main surgical procedures include discectomy of the involved levels, thinning of the anterior part of the involved vertebrae, intervertebral cages, anterior plate and screws installation, bilateral osteotomies of the vertebrae, and antedisplacement of the vertebrae-OPLL complex
45616683|NCT03312985|Procedure|ACCF surgery|Removal of the vertebral body，exposed ossification of the posterior longitudinal ligament，and then removed
45616684|NCT03302689|Drug|Levobupivacaine Solution|TAP-block with Levobupivacaine 0,3% - 25 ml from each side
45616685|NCT03302689|Drug|Ropivacaine Solution|TAP-block with Ropivacaine 0,3% - 25 ml from each side
45616686|NCT03108235|Behavioral|HOM-HEMP|a 6-week nurse-led, home-based self-management psychosocial education programme comprising of a specifically developed HF education and self-management toolkit, three biweekly home visits by the research nurse.
45760425|NCT04693767|Other|Mechanical thrombectomy|"Clot specimen collection~Extracranial blood collection"
45760426|NCT04693767|Other|Minimally invasive surgery|"Clot specimen collection~Arterial blood collection"
45760427|NCT05583123|Device|restored abutment (OPZAs)|The restorations will be restored by the OPZAs
45760428|NCT05583123|Device|restored abutment (TPZAs)|The restorations will be restored with the TPZAs with friction-fitted titanium bases.
45760429|NCT04647435|Drug|APSCTC|APSCTC + Toragesic® placebo + Tramal® placebo
45616687|NCT03108235|Behavioral|HOM-HEMP with smartphone app|"a 6-week nurse-led, home-based self-management psychosocial education programme comprising of a specifically developed HF education and self-management toolkit, three biweekly home visits by the research nurse. In addition, participants will receive a smartphone app.~The smartphone will be used to monitor their health data (such as weight, and blood pressure). The data will be synchronized to a web-connected portal on a remote server. The research nurse would be able to access your data through the web-connected portal and provide consultation through scheduled tele or video conference."
45616688|NCT03108235|Behavioral|Standard Care|standard care provided by the hospital. It consists of all nursing, medical, and follow-up services as needed.
45616689|NCT03307681|Other|White bread|Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.
45616690|NCT03307681|Other|Baked potato with skin|Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).
45616691|NCT03307681|Other|Mashed potato served hot|Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.
45616692|NCT03307681|Other|Fried French fries|Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.
45616693|NCT03307681|Other|Meal skipping|No food given
45616694|NCT03307603|Radiation|yttrium-90 radioembolization|Yttrium-90 will be given as biocompatible resin-based microspheres and will be introduced to the tumor(s) on one side of the liver through a catheter placed in the right or left hepatic artery. The dose of radiation will be determined by a radiologist and will be based on body surface area and tumor burden.
45616695|NCT03307603|Drug|Phase Ib - nivolumab|240 mg intravenously
45616696|NCT03307603|Drug|Phase II - nivolumab|nivolumab will be administered as determined during the phase Ib portion of the study. Nivolumab will be administered on an every 2 week basis for a total of 48 weeks or until disease progression, unacceptable toxicity or discontinuation due to patient/physician preference.
45616697|NCT03302533|Procedure|Total elbow arthroplasty|Implantation of a total elbow arthroplasty after distal humerus fracture
45616698|NCT00703963|Device|INRatio monitor by Hemosense|Home testing monitor to test patients INR by placing a capillary drop of blood from the finger onto a test strip. The test strip is then inserted into the INRatio point-of-care self-testing coagulometer. After approximately 2 minutes of analysis, the INR value will be presented on the meter's display.
45760430|NCT04647435|Drug|Toragesic®|APSCTC placebo + Toragesic® + Tramal® placebo
45760431|NCT04647435|Drug|Tramal®|APSCTC placebo + Toragesic® placebo + Tramal®
45760432|NCT04382417|Other|Observational study|Not required
45616699|NCT00703963|Other|Usual Care|Usual care is defined as that care currently received by patients into whom mechanical heart valves are placed. Typically, these patients undergo frequent checks of their INR level until the therapeutic range is achieved. Then periodic INR levels are drawn at the discretion of the managing physician.
45616700|NCT02468323|Drug|Placebo|Patients will receive regular spinal anesthesia
45760433|NCT04637529|Drug|S (+) - Ibuprofen|S (+) - Ibuprofen + placebo of Ibuvix®
45760434|NCT04637529|Drug|Ibuvix® - ibuprofen|Ibuvix® + placebo of S(+) - Ibuprofen
45760435|NCT00799643|Drug|Salsalate|Salsalate 3.5 g/d orally, divided dosing
45616701|NCT02468323|Drug|Ondansetron|Patients will receive slow intravenous injection of ondansetron 4 mg after cord clamping
45616702|NCT02468323|Drug|Palonosetron|Patients will receive slow intravenous infection of palonosetron 75 mcg after cord clamping
45616703|NCT03307447|Drug|Secukinumab|Secukinumab 300 mg subcutaneous injection
45760436|NCT00799643|Drug|Salsalate Placebo|
45760437|NCT03835013|Drug|Saline 0.9%|Intravenous infusion of 0.9% saline
45760438|NCT03835013|Drug|Glucagon (25ng/kg/min)|Intravenous infusion of glucagon 25ng/kg/min
45760439|NCT03835013|Drug|Glucagon (50ng/kg/min)|Intravenous infusion of glucagon 50ng/kg/min
45760440|NCT03835013|Drug|Exenatide|Intravenous infusion of Exenatide (loading 50ng/min for 30 minutes followed by 25ng/min for 30 minutes
45760441|NCT05568303|Behavioral|CBT techniques|through CBT sessions , the participants apply problem solving process in managing their stressors . examining the role of cognitions, emotions, and behaviors to form cause and effect relationship of participants psychological distress
45760442|NCT04546737|Other|Magnetic Resonance Spectroscopy (MRS).|This is a Nuclear Magnetic Resonance (NMR) technique which can detect the NMR signal allowing to measure under curves areas, amplitudes, ratios and concentrations of various metabolites contained in a biological tissue, in addition to water and lipids. This offers the possibility, in addition to the contribution of MRI imaging, to better characterize pathological processes (inflammatory, infectious, etc.) through spectral and metabolic changes that can be quantitatively evaluated. Spectroscopic measurements will be carried out with a mono-voxel spectroscopy using a PRESS [Point RESolved Spectroscopy] sequence with a short Echo Time (TE) of 35 ms, an intermediate TE of 144 ms and a long TE of 288 ms.
45760443|NCT05555823|Drug|ATR-002|300 mg tablets for oral intake
45760444|NCT05555823|Drug|Placebo|matching tablets for oral intake
45760445|NCT05555823|Drug|Repaglinide|0,5 mg tablets for oral intake
45760446|NCT05555823|Drug|Celecoxib|100 mg capsules for oral intake
45616704|NCT03312673|Other|Interview and tests of drawing.|The intervention will take place with patients followed for asthma at the Croix Rousse hospital. Patients agreeing to participate in the study will come to the hospital for one hour and a half. They will answer questionnaires and tests of drawing. Results Restitution Session (optional) is proposed to patients within the next 4 weeks during a routine consultation.
45616705|NCT02469259|Drug|Oxytocin|
45616706|NCT02469259|Other|Placebo|
45616707|NCT03302455|Behavioral|eCBTI|The brief eCBTI contains a one-week core course: sleep hygiene education, sleep restriction, stimulus control, relaxation audios, cognitive components, information about sleeping pills, and a brief overview. In addition, individual customized sleep restriction and stimulation control treatments were provided according to the subject's previous 2-week sleep status.
45452273|NCT02261662|Drug|Ribavirin|"A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.~It will be used along with Topical steroids; Betamethasone"
45616708|NCT02467933|Other|Placebo letter|The placebo letter describes a new rule in Medicare that requires prescribers to enroll in Medicare
45616709|NCT02467933|Other|Initial Informative letter|The intervention is a letter that describes the Seroquel prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
45616710|NCT02467933|Other|Followup Informative Letter|The followup informative letter is identical to the initial informative letter except it provides an update on more recent prescribing rather than a description of earlier prescribing.
45616711|NCT03302377|Behavioral|physical activity counseling & Fitbit|Participants will receive individual counseling & guidance in goal setting, then will receive a Fitbit wrist monitor and guidance in personalizing the Fitbit features
45616712|NCT03307213|Device|BioFreedom™ CoCr Biolimus A9™ stent|Stent implantation
45616713|NCT03307213|Device|BioFreedom™ SS Biolimus A9™ stent|Stent implantation
45616714|NCT03302299|Drug|Isoniazid 300 Mg ORAL TABLET|The study intervention will include a single arm given (1) 6H: 300 mg INH daily by mouth for 6 months.
45760447|NCT05553561|Procedure|IPRL device|Intense pulsed light therapy (IPL) is a non-coherent large wavelength high-intensity light in the range of 500-1200nm. It has been used by many investigators for the treatment of evaporative dry eye safely and effectively.
45760448|NCT05553561|Procedure|pharmacological therapy & Eyelid hygiene|traditional methods of MGD treatment as Eyelid hygiene, topical preservative free lubricant, topical & systemic antibiotics & anti-inflammatory agent
45760449|NCT00421629|Behavioral|After-sales service and supportive supervision (AfterSS)|
45760450|NCT00421629|Behavioral|Prospective reimbursement (PR)|
45452274|NCT02261662|Drug|Betamethasone|Topical Steroids alone will be used; Betamethasone
45616715|NCT03302299|Drug|Pyridoxine 25 Mg Oral Tablet|All participants will also receive 25 mg pyridoxine (vitamin B-6) daily by mouth for 6 months for the treatment duration to reduce the risk of INH-induced peripheral neuropathy.
45616716|NCT03302221|Drug|0.5% ropivacaine paravertebral block|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography after 0.5% ropivacaine paravertebral block
45616717|NCT03302221|Drug|0.25% ropivacaine epidural block|A 4-5 ml bolus of 0.25% ropivacaine was administered 1 h after the initiation of TEB.
45616718|NCT03302221|Drug|0.5% ropivacaine local anaesthesia|local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.
45616719|NCT02469337|Drug|Dichloroacetate|Dichloroacetate, an analog of acetic acid has been shown to increase the activation of PDC by inhibiting PDK4 in humans. This drug is expected to shift the metabolism of pyruvate from glycolysis and towards oxidative pathway in the mitochondria
45760451|NCT00421629|Behavioral|Both (AfterSS and PR)|
45760452|NCT04499157|Drug|MEMOPTIC|Patients will receive their usual treatment of glaucoma adding 1 tablet of MEMOPTIC per day during 2 years of following
45616720|NCT02469337|Dietary Supplement|Carbohydrate drinks|preoperative carbohydrate drinks
45616721|NCT02469337|Behavioral|Moderate intensity exercise|30 min exercise using a semi-recumbent exercise bike, at about 70% of their age estimated heart rate
45616722|NCT03307135|Device|single assessment with the MSPMI|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
45616723|NCT03307135|Device|double assessment with the MSPMI with 7 days of interval|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
45616724|NCT03307135|Device|double assessment with the MSPMI before and after treatment|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
45616725|NCT02469103|Device|C2|C2 and colonoscopy will be performed one after another on the same day
45616726|NCT02469103|Procedure|colonoscopy|
45616727|NCT03312439|Behavioral|Given advice|Based on results of testing the participants will be give advice with the general aim to decrease the future risk of non-communicable disease by increasing physical activity,
45760453|NCT04499157|Drug|usual treatment of glaucoma|Patients will receive only their usual treatment of glaucoma.
45760454|NCT04481061|Genetic|Electronic Decision Tool|Adolescents and a parent, if applicable, will use an electronic decision tool to make categorical choices of types of diseases (treatable, preventable, adult-onset, and carrier status) they want to learn about the adolescent. Granular choices can be made within each category.
45760455|NCT05364879|Behavioral|Prehabilitation Exercise Intervention|The exercise intervention will consist of light-to-moderate intensity aerobic, resistance, and mobility exercises. These exercises will be performed in a circuit type manner. Participants will perform similar exercises that are modified to meet their individual abilities. Exercise intensity, modifications and substitutions will be determined for each participant based on their medical history, 6 minute walk test results, and baseline frailty scores. Exercise sessions will be performed 3x/wk beginning at 30 min and progressing to 60-min as tolerated for a minimum of four weeks but will continue up until the time of the participants surgery. A hybrid approach will be used for the exercise sessions whereby the participant must attend the first exercise session in person and subsequent sessions will be delivered virtually. Sessions will be overseen by the study Clinical Exercise Physiologist.
45616728|NCT03302143|Procedure|Guided bone regeneration with Bovine Bone Mineral|Guided bone regeneration with Bovine Bone Mineral
45616729|NCT03302143|Procedure|Guided bone regeneration with freeze dried bone allograft|Guided bone regeneration with freeze dried bone allograft
45616730|NCT03053791|Procedure|Deep brain stimulation in mesencephalic locomotor region|Implantation of Electrodes in the Mesencephalic Locomotor Region for improvement of Locomotion and Gait
45616731|NCT03053791|Device|Implantation of a Deep brain stimulation system|Implantation of a Medtronic Activa SC Impulse Generator for chronic Stimulation of the selected target.
45616732|NCT03302065|Drug|Tiotropium|
45616733|NCT03306745|Dietary Supplement|Profertil female|"For micronutrient ingredients please see details above. PROfertil ® female is approved in Austria by the Austrian Ministry of Health and has a Free Sales Certificate."
45616734|NCT03306745|Dietary Supplement|Folic acid 400 mg|Folic acid 400 mg
45616735|NCT03301987|Other|Therapeutic exercise|30 minutes per day of therapeutic exercise
45616736|NCT02469025|Other|Manual caudal traction mobilization in resting position|
45616737|NCT02469025|Other|Manual caudal traction mobilization in end range position|
45616738|NCT02469025|Other|Selftreatment|Each subject is advice to do some exercises at home
45616739|NCT03306667|Drug|FYU-981|Oral single dosing
45760456|NCT00800345|Drug|Oral Topotecan|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of topotecan administered by mouth.
45760457|NCT00800345|Drug|Pazopanib|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of pazopanib administered by mouth.
45760458|NCT04479111|Procedure|laparoscopic ileocecus-sparing right hemicolectomy|The ileocecal artery(ICA) is skeletonized. The colic branch of ICA is divided and ligated. Preserve anterior cecal artery, posterior cecal artery and ileocecal branch of ICA. Divide and ligate the right colic artery(RCA) and middle colic artery(MCA) at their roots. Dissect the lymph nodes surrounding the ICA, RCA and MCA accordingly. Head-to-Head colocolic anastomois is done, with circular stapler via making an opening at the bottom of cecum.
45616740|NCT03312361|Drug|15% oxygen|Participants will inhale 15% oxygen for 2 hours to see how it affects them.
45616741|NCT03306511|Other|Repeated-sprint test|6x30-meter sprint interspersed with 90-s rest
45616742|NCT03312283|Drug|lucentis|intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
45616743|NCT03312283|Drug|QL1205|intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
45616744|NCT03312205|Biological|Autologous CAR-T cells|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
45616745|NCT03301597|Biological|NLA101|"NLA101 is a universal donor off-the-shelf ex-vivo expanded hematopoietic stem and progenitor cell (HSPC) product that is cryopreserved and ready for immediate use."
45760459|NCT03847467|Drug|2'-Fucosyllactose|Human milk oligosaccharide prebiotic dietary supplement
45760460|NCT03847467|Other|Placebo|Dextrose
45760461|NCT04789655|Drug|CC-96191|CC-96191
45760462|NCT04471779|Other|Disclosure of APOE genotype|Information about risk of Alzheimer's disease will be given to participants based on their APOE genotypes, in addition to Latino ethnicity and family history.
45760463|NCT04788797|Drug|Prolyl Endopeptidase|Two capsules three times a day.
45760464|NCT04788797|Other|Placebo|Two capsules three times a day
45616746|NCT03301597|Drug|Standard of Care (SOC) chemotherapy|The SOC chemotherapy regimen for each patient will be determined by local PI. Regimen must be a standard AML regimen that will result in moderate to severe myelosuppression and have curative intent.
45616747|NCT02721355|Dietary Supplement|GastimunHP|Health food supplement containing specific IgY against urease of H. pylori
45616748|NCT03312127|Device|ILIAC ENDOPROSTHESIS GORE EXCLUDER|Set up of GORE ® Excluder Iliac Branch Endoprosthesis in endovascular barring of complex aneurysms without distal neck. In the immediate post-operating follow-up visit and at the 3 months visit and the 12 months visit after surgery, an ultra-sound scan, a tomodensitometric exam and a walking test on a treadmill with oximetric gluteal region exploration will systematically be performed.
45616749|NCT02468401|Procedure|Percutaneous coronary intervention|Patients planned for coronary angiography or percutaneous coronary intervention will be managed using a protocol that allows us to use minimal volumes of contrast dye
45616750|NCT03301285|Drug|Zoledronic Acid|Treatment of osteoporosis
45616751|NCT04491565|Other|educational video|an interactive educational video was viewed by participants in the intervention arm.
45616752|NCT03249493|Other|Blood sample on DBS|"We will take 5 mL of whole blood at ART initiation, 6, 12 and 24 months of follow up after ART initiation. Blood will be transferred on DBS cards.~HIV Viral Load measurements will be done and HIV Drug Resistance measurements will be performed in case of 2 consecutive VL results > 1000 cp/mL"
45616753|NCT02467855|Other|No Intervention|No intervention was administered in this study.
45616754|NCT03301207|Drug|Ibrutinib|Ibrutinib capsule (at dose of 420 or 560 mg) will be taken orally QD.
45616755|NCT03301207|Drug|OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg|Single dose of oral contraceptives (OC) (1 tablet containing 30 mcg EE and 150 mcg LN) will be taken orally on Study Days 1 and 22.
45911599|NCT05778214|Device|Interventional Robotic System|Cerebral angiography was performed by using the interventional robotic system
45911600|NCT05778201|Biological|Baby Drink group|1 packge (20 ml)/ day for 1 month
45911601|NCT05778188|Drug|RLS-0071|RLS-0071 (unit strength 10 mg/mL) will be administered by infusion for a dose level of 3, 10, or 20 mg/kg. Planned infusion duration is 10 minutes for all dose levels.
45616756|NCT03301207|Drug|Bupropion|Bupropion 75 mg tablet as a part of CYP cocktail will be taken on Study Days 3 and 24.
45616757|NCT03301207|Drug|Midazolam|Midazolam 2 mg (1 milliliter [mL]) oral solution will be taken on Study Days 3 and 24 (as a part of CYP cocktail) and on Study Day 8 (alone).
45616758|NCT03301129|Behavioral|Smoke|See arm/group descriptions.
45616759|NCT03311971|Device|Virtual reality glasses|Patients will be treated with virtual glasses
45616760|NCT03311971|Device|No VR glasses|Patients will not use VR glasses
45616761|NCT03311893|Procedure|natural orifice surgery|evaluation of the awareness of the use of transvaginal, transoral and transcranial approach in surgical excision and the difference between the health staff and the pathology
45616762|NCT03305965|Behavioral|Patient navigation|Consultations with a specifically trained oncology nurse (i.e. patient navigator), who assesses patients' needs for supportive cancer care, provides information on supportive cancer care, and guides patients through the supportive cancer care system. Consultations with the patient navigator take place at the start, halfway through, and at the end of treatment.
45616763|NCT03311815|Diagnostic Test|NGS techniques|Using NGS techniques we will detect the recurrently mutated genes in AML to establish the biological role of each mutation
45616764|NCT03311737|Combination Product|general anesthesia|The investigators used general anesthesia preoperatively in uniportal VATS lung surgery
45616765|NCT03311737|Combination Product|epidural anesthesia|The investigators used general anesthesia combined with epidural anesthesia preoperatively in uniportal VATS lung surgery
45616766|NCT03300973|Procedure|sling surgery|transoburator vaginal tape ,inside out procedure under spinal anathesia
45616767|NCT03300895|Other|High-intensity interval training|21.5 minutes of high-intensity interval exercise at an intensity between 90-95 of HRmax (15x30 s), with recoveries at 50-60% of HRmax (14x60 s). 24 sessions, 3x weekly of walking and running outdoors on a sports field in a supervised manner.
45616768|NCT03300895|Other|Comparator: Moderate-intensity continuous exercise|30 minutes of continuous exercise at an intensity between 65-75% of HRmax. 24 sessions, 3x weekly of walking and jogging outdoors on a sports field in a supervised manner
45616769|NCT04491019|Other|Balance exercise group|Balance exercises will be carried out with a physiotherapist
45616770|NCT03300661|Behavioral|Mediterranean Style|After completion of a Food Frequency Questinnaire (FFQ) and the International Physical Activity Questionnaire (IPAQ), patients enrolled in the study undergo a personalized educational intervention by a registered dietician. During the intervention the dietician advice about the main errors in diet and physical activity (by FFQ and IPAQ) and chooses three aims in diet modification and one aim in physical activity improvement. Patients adherence is assessed by the same dietician every three months, using FFQ and IPAQ, and futher supports are provided. Total intervention lenght is twelve months.
45616771|NCT03300583|Behavioral|Focus groups|Focus group discussion led by the PI and facilitated by another researcher.
45616772|NCT03300583|Behavioral|Semi-structured interviews|1:1 semi-structured interviews led by the PI
45616773|NCT02467543|Other|20% Ethanol|Unmedicated 20% Ethanol
45616774|NCT02467543|Other|Viburnum opulus 3X|Viburnum opulus 3X in a vehicle of 20% ethanol.
45616775|NCT03311581|Drug|Propofol|Propofol works by increasing GABA-mediated inhibitory tone in the CNS. Propofol decreases the rate of dissociation of the GABA from the receptor, thereby increasing the duration of the GABA-activated opening of the chloride channel with resulting hyperpolarization of cell membranes.
45616776|NCT03311581|Device|Sevoflurane|sevoflurane inhalation 2~4%
45616777|NCT03311425|Drug|Methylprednisolone|Application of 40mg Depomedrol (methylprednisolone acetate) suspension into the retropharyngeal space prior to incision closure
45616778|NCT03311425|Drug|Dexamethasone|Administration of 10mg Dexamethasone IV intraoperatively
46069039|NCT04622683|Procedure|Ultrasound|To determine whether ultrasound exposure at the porta hepatis will affect plasma glucose levels. To also determine whether porta hepatic ultrasound exposure will affect plasma glucose levels as well as insulin sensitivity among overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance (as defined by OGTT.
45616779|NCT05195281|Procedure|Fine Needle Biopsy or Aspiration|A new sampling of the tumor will be performed after 4-6 months of neoadjuvant chemotherapy
45616780|NCT03305497|Behavioral|Mobile Phone Application|110 persons will be equipped with a mobile phone application, trained in overdose prevention, and equipped with naloxone. The mobile phone app will allow persons witnessing an overdose to signal persons in the vicinity to respond with naloxone.
45616781|NCT02468089|Drug|Carbepenem|
45616782|NCT02468089|Drug|Albumin|
45616783|NCT02468089|Drug|GMCSF (of Granulocyte-Monocyte Colony-Stimulating Factor) .|
45616784|NCT03311347|Other|+Gz accelerations and positive pressure breathing|
45616785|NCT03300349|Other|Fulfillment of a preventive programme|Information about risk factors for breast cancer-related lymphedema and home-based exercise programme for shoulder
45616786|NCT03300349|Other|No fulfillment of a preventive programme|No fulfillment of the preventive programme: Information about risk factors for breast cancer-related lymphedema and home-based exercise programme for shoulder
45616787|NCT04491097|Device|Panavia V5 resin cement|Missing lateral incisor teeth will be restored by zirconia ceramic RBFDs and adhesively bonded with Panavia V5 resin cement.The preperation and restoration of the tooth will be done according to to the guidelines for ordinary prosthetic techniques.
45911602|NCT05778188|Drug|Placebo|Placebo control (commercial sterile saline) will be administered by infusion at a volume matched to RLS-0071 (3, 10, or 20 mg/kg). Planned infusion duration is 10 minutes for all matched dose levels.
46069040|NCT04614363|Drug|68Ga-PSMA|All subjects enrolled in the study will receive a single IV dose of 3-7 mCi of 68 Ga-PSMA (study drug) followed by PET/CT imaging for detection of tumor location.
45616788|NCT04491097|Device|Panavia F2.0 resin cement|Missing lateral incisor teeth will be restored by zirconia ceramic RBFDs and adhesively bonded with Panavia F2.0 resin cement.The preperation and restoration of the tooth will be done according to to the guidelines for ordinary prosthetic techniques.
46069041|NCT04582409|Drug|HSY244|HSY244 concentrate solution for injection via intravenous infusion
46069042|NCT04582409|Other|Placebo|Placebo concentrate solution for injection via intravenous infusion
46069043|NCT04569903|Device|Computer algorithm for ATTR|Patients will be evaluated for the identification of ATTR Amyloidosis through a claims-based algorithm
45616789|NCT02468011|Other|vibration|vibration will be applied at 35 Hz
45616790|NCT03311191|Device|Measurement of skin oxygenation and oxygen consumption|Oxygenation properties will be measured using a transparent paint-on bandage formulation that consists of New-Skin liquid bandage, an oxygen-sensing metallo-porphyrin exhibiting bright red phosphorescence, and the green-fluorescing reference dye fluorescein.
45616791|NCT02733991|Device|MiniMed™640G and Suspend before low|"All enrolled subjects will start a run in phase, receive training and start pump therapy with the MiniMed™640G insulin pump and usage of blinded Continuous Glucose Monitoring. Eligible subjects that meet the randomization criteria assessed after the running phase will be randomized into the treatment or control arm. Treatment Arm: training and start of Sensor Augmented Pump therapy with Suspend before Low feature of SmartGuard turned ON.~Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks during the treatment phase."
45616792|NCT02733991|Device|MiniMed™640G|Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks.
45616793|NCT02468869|Behavioral|"Communication skills training empathy skills"|
45616794|NCT02468869|Behavioral|"Communication skills training information structuring skills"|
45616795|NCT03311113|Other|Drug adherence questionnaire|Adherence to oral antibiotic therapy will be assessed by means of a questionnaire adapted from the French standardized self-assessment questionnaire of Girerd et al. This questionnaire has six questions, each question being associated with a score. Patient's drug adherence is classified into three groups based on the total score: of high, moderate and poor adherence. The questionnaire will be carried by a phone call to the patient.
45616796|NCT03300271|Other|Mobile application for self monitoring|Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.
45616797|NCT03300271|Other|Education|Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).
45616798|NCT03300271|Other|Mobile application for personal coaching|Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
45616799|NCT03305263|Drug|Hydroxychloroquine|One tablet a day from inclusion until end of pregnancy or gestational age 28
45616800|NCT03305263|Drug|Hydroxychloroquine placebo|One tablet a day from inclusion until end of pregnancy or gestational age 28
45616801|NCT03300115|Drug|AC0010|After subjects prove eligible after screening and are enrolled, they are given AC0010 300 mg Bid (the two doses are advised to be administered at an interval of 12 hours), receive evaluation of safety indicators every 3 weeks, efficacy evaluation every 6 weeks until disease progression or intolerable toxicities or withdrawal from the trial. (If the investigator suspects disease progression, CT or MRI may be performed in advance; if the patient does not have disease progression, subsequent efficacy evaluation will proceed still according to the protocol).
45616802|NCT03305107|Other|Exercise and Chocolate Milk|High intensity interval exercise Chocolate Milk
45616803|NCT03305107|Other|Exercise and Water|High intensity interval exercise Water
45616804|NCT03305107|Other|Sitting and Chocolate Milk|Sitting Chocolate Milk
45616805|NCT03305107|Other|Sitting and Water|Sitting Water
45760465|NCT04466865|Other|Best Case/Worst Case communication tool training|"The communication tool promotes dialogue and patient deliberation, and supports shared decision making in the context of kidney disease. Building on a conceptual model of shared decision-making proposed and the practice of scenario planning the intervention is designed to lead to a discussion of participants preferences and consideration of outcomes.~The nephrologist verbally describes the best case, worst case, and most likely outcomes for each treatment option-incorporating rich narrative from clinical experience and translation of probabilistic information-while drawing a diagram of those options. The nephrologist also writes details about each option on the diagram. The narrative and graphic help family and patients formulate and express preferences."
45616806|NCT03300037|Device|Kinesthetic stimulation|The kinesthetic actuator is placed on the skin near the ear and emits vibrations.
45616807|NCT04442191|Biological|Convalescent plasma|This study will use convalescent plasma collected from those who have previously had COVID-19 and have been shown to have cleared the infection and made antibodies against the virus.
45616808|NCT04442191|Biological|Placebo|The placebo arm of this study will use fresh frozen plasma that presumably does not contain antibodies against COVID-19.
45616809|NCT03305029|Drug|SCNT-hES-RPE Cells|Pars Plana Vitrectomy and Sub-retinal Transplantation of Human Somatic cell nuclear transfer Embryonic Stem Cell Derived Retinal Pigmented Epithelial(SCNT-hES-RPE) Cells in Patients with Advanced Dry Age-related Macular Degeneration
45760466|NCT04020029|Other|Mindset|Mindset Intervention will include watching three brief ~10-25 minute films
45760467|NCT04020029|Other|Reflection activities|Reflection activity include exercises to internalize the message
46069044|NCT04567615|Biological|Nivolumab|Specified dose on specified days
45452275|NCT02269774|Procedure|Standard pulmonary vein isolation|The MM will be carried out during a elective standard pulmonary vein isolation procedure. The MM will be performed using an occluded mouthpiece with a small air leak to prevent complete closure of the glottis during inspiration and thus assure negative pressure throughout the entire airway. After expiration, inspiration with a target negative intrathoracic pressure of -40mmHg will be carried out against the mouthpiece.
45616810|NCT05478265|Device|RS-4i Plus|RS-4i Plus in an FDA-regulated prescription TENS medical device that outputs and INF signal and a NMES signal and Intersperse signal, which combines INF and NMES into a single treatment.
45760468|NCT03806751|Drug|[O-15]Water|All study participants with undergo brain imaging with [O-15]water-PET/MRI without and with administration of the carbonic anhydrase inhibitor acetazolamide. The PET tracer will be used to measure regional cerebral perfusion, and the administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
45760469|NCT03806751|Drug|Acetazolamide|The administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
46069045|NCT04567615|Biological|Relatlimab|Specified dose on specified days
45760470|NCT04383275|Drug|capecitabine and trastuzumab|In IRIS-A cohort, patients who met the inclusion criteria(ER，PR<10%, T≤2cm or ER,PR ≥10% 1cm<T≤2cm）would be given capecitabine for 6 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
45616811|NCT05728021|Behavioral|Recovery Record Aftercare|"Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of Recovery Record at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (eating disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 5-8 and every other week in weeks 9-16."
45616812|NCT05728021|Behavioral|Treatment as usual (TAU)|Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2. Patients from the CG are also assessed at all assessment points.
45616813|NCT02916979|Drug|Fludarabine|Fludarabine: 30 mg/m2 daily for 5 days
45616814|NCT02916979|Drug|Busulfan|Busulfan: 100 mg/m2 daily for 4 days
45616815|NCT02916979|Biological|Rabbit ATG|"Rabbit ATG:~Related donors: 1.5 mg/kg daily x 2 days (on days -6 and -5) Unrelated donors: 1.5 mg/kg on day - 6 2 mg/kg on day -5 2.5 mg/kg on day -4"
45616816|NCT02916979|Drug|Methotrexate|"Methotrexate:~Related donors: 5 mg/m2 on days 1, 3 and 6 Unrelated donors: 5 mg/m2 on days 1, 3, 6 and 11"
45760471|NCT04383275|Drug|endocrine therapy and trastuzumab|In IRIS-B cohort, patients who met the inclusion criteria(ER,PR ≥10% T≤1cm) would be given endocrine therapy (premenopausal: tamoxifen or toremifene; postmenopausal: letrozole or anastrozole or exemestane) combined with standard trastuzumab for 1 year and complete endocrine therapy for 5 years.
45616817|NCT00702949|Drug|pregabalin|Given orally
45616818|NCT00702949|Other|placebo|Given orally
45616819|NCT05476237|Behavioral|Group Interpersonal Therapy for Adolescents (IPT-AG)|IPT-AG is a ten session, group therapy for adolescents. Each group contains 6-8 adolescents who attend weekly sessions together. The goals of IPT-AG are: 1) to reduce depression symptoms, and 2) to improve interpersonal relationships. Another aim of the group format is to increase adolescents' experience with positive social interactions and to reduce social isolation.
45616820|NCT05476237|Behavioral|Treatment as Usual (TAU)|Adolescents will be administered unstructured psychotherapy in individual sessions with a trained mental health specialist (i.e., psychologist or psychiatric technician).
45760472|NCT00355563|Device|PAS-Port Automated Proximal Anastomosis System|
45616821|NCT04791475|Procedure|adding Dexmedetomidine and dexamethasone to bupivacaine in USG guided supraclavicular brachial plexus block.|The linear transducer probe (frequency 4 -12 Hz) of USG machine will be used. A superficial skin wheal will be made by 2ml of 1% lignocaine subcutaneously at the point of needle insertion. USG guided Brachial plexus block will be performed by supraclavicular route via the subclavian perivascular approach in in-plane technique from lateral to medial using 22 gauge spinal needle. Study Drug will be administered via Pressure Monitoring line connected to syringe according to the allocated group with repeated aspiration and incremental dosing. • Intercostobrachial nerve block will be performed to alleviate the tourniquet pain. A 25 G needle will be inserted at the level of axillary fossa. The entire width of the medial aspect of arm, starting at the deltoid prominence and proceeding inferiorly, will be infiltrated with 5ml of 1% Lignocaine with Epinephrine (1:4,00,000) to raise a subcutaneous wheal. •
45616822|NCT03299803|Behavioral|Men's Healing Pathways|Peer implemented group self management program to reduce depressive symptoms in men with physical disabilities
45616823|NCT03299725|Drug|colloidal bismuth sub-citrate|colloidal bismuth sub-citrate administered as an adjunctive therapy in combination with esomeprazole, amoxicillin and metronidazole
45616824|NCT04490551|Diagnostic Test|Risk-based logistic regression model|The intervention will be a risk-based logistic regression model that takes multiple variables into account to calculate the risk of advanced neoplasia as an outcome.
45616825|NCT04490551|Diagnostic Test|FIT|FIT is a stool-based test that detects human blood in faeces.
45616826|NCT05727943|Drug|Clioquinol|add on clioquinol to concomitant ASM
45616827|NCT02466997|Drug|tacrolimus|tacrolimus 0.1% ointment applied twice a day for the experimental group during 24 weeks placebo ointment applied twice a day for the control group during 24 weeks
45616828|NCT02466997|Drug|Placebo|
45616829|NCT05445427|Device|vagal nerve stimulator|Non-invasive vagus nerve stimulator
45616830|NCT05441683|Procedure|horizontally extending incision|An intrasulcular incision will be made on the labial side of the front teeth with a thin alveolar bone or dehiscence and/or fenestration. Then horizontally extending incisions will be added to each side of the Intrasulcular incision, extending one to two teeth beyond the defected area, before a full-thickness flap is lifted.
45616831|NCT05441683|Procedure|vertical releasing incision|An intrasulcular incision will be made on the labial side of the front teeth with a thin alveolar bone or dehiscence and/or fenestration. Vertical releasing incisions will be made on each side of the intrasulcular incision before a full-thickness flap is lifted.
45616832|NCT05727787|Radiation|Stereotactic Body Radiation Treatment|Single fraction SBRT 27 Gy
45760473|NCT04453059|Drug|Iopamidol|Previously administered Isovue-300 (300 mgI/mL) PO at a dilution of 2-3% (6-9 mgI/mL)
45760474|NCT04383197|Behavioral|Endurance exercise training|Ergometer cycling at 70 % of VO2 max, 45 minutes, 3 times a week
45760475|NCT04383197|Drug|Semaglutide|3 months of therapeutic treatment with semaglutide
45760476|NCT04445493|Device|MindRhythm Harmony|Passive recording of the head pulse
45760477|NCT04009811|Device|Suersen and membraneous obturators evaluation|"The patient will wear one month each obturator prothesis (Suersen and membraneous obturators). The order of evaluation will be randomized in two arms.~Half of patient will first wear one month the membranous obturator then one month the Suersen, the other half of patient will first wear one month the Suersen obturator and one month the membranous obturator."
46069046|NCT04556734|Drug|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily
45616833|NCT00702715|Drug|sugammadex|"Each subject will receive an~intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After~this dose, maintenance doses of 0.1 - 0.2 mg.kg-1~rocuronium may be given. In case of maintenance dosing, the target depth of~neuromuscular blockade has to be maintained at 1-2 post-tetanic counts (PTC). After the last dose of rocuronium has been administered, the subject will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC."
45760478|NCT03796065|Behavioral|FSI-R Treatment|The FSI-R involves a series of separate and joint meetings with parents and children to discuss challenges the family has faced and the strengths that helped them make it through past challenging times. Additional psychoeducation on mental health and promoting resilience along with coaching to enhance parenting skills is provided throughout and may be tailored to family needs. The FSI-R provides a shared space for refugee families both to recognize their strengths and to problem-solve in a more collective way on family challenges and shared hopes for the future. The FSI-R is delivered in the home, by a trained interventionist, over the course of 10-modules.
45445692|NCT02062840|Device|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
45616834|NCT05727631|Other|gentle human touch|Mother will apply gentle human touch touch technique during venous blood collection from preterm babies between 32-37 weeks of gestation
46069047|NCT04556734|Drug|Etrasimod|Etrasimod 3 mg (1 mg and 2 mg tablets) by mouth, once daily
45760479|NCT04441983|Diagnostic Test|7 Tesla MRI of the foot|7 Tesla MRI
45616835|NCT03299491|Other|MWA intervention|The MWA intervention will involve upgrading existing maternity waiting areas to ensure that essential supplies and services are available to create a comfortable environment for women to temporarily reside in and have easy access to skilled obstetric services.
45616836|NCT03299491|Other|IEC intervention|"Community and religious leaders will each attend one-day workshops designed using participatory, adult learning methods to help participants better understand the importance of maternal health care services, identify barriers to accessing care and to strategize how to promote utilization of services. Half-day workshops will conducted in subsequent years to build on shared experiences.~Health extension workers will attend 3-day workshops to identify enablers and barriers to implementation of the safe motherhood components of the health extension program and strategize on how to engage community and religious leaders to support access to maternal health care services in their communities.~Half-day workshops will conducted in subsequent years for each of the participant groups to build on shared experiences."
45616837|NCT03299413|Biological|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be injected intravenously
45760480|NCT03973229|Drug|Estradiol patch|Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.
45760481|NCT03973229|Other|Placebo patch|Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.
45616838|NCT04939909|Drug|Botulinum toxin type A|Patients were treated with Botulinum toxin type A applications on the Orbicularis oculi and glabellar complex
45616839|NCT02466295|Other|Volume-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the volume-controlled mode with tidal volume 8 ml/kg during surgery.
45616840|NCT02466295|Other|Pressure-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the pressure-controlled mode with tidal volume 8 ml/kg during surgery.
45616841|NCT03299257|Drug|donepezil treatment|30-day donepezil treatment
45616842|NCT02466373|Drug|Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml|clonidine intravenous
45616843|NCT05727397|Drug|RC28-E|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
45616844|NCT05727397|Drug|Aflibercept|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
45616845|NCT05378269|Drug|Tamoxifen|Tamoxifen vaginal insert
45760482|NCT05236595|Other|Individualized drug matching per genetic disease|Patient phenotype and samples will be evaluated for individualized therapeutic drug development
45445693|NCT02062840|Device|Low intensity whole-body infrared heating|Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
45760483|NCT03782103|Drug|ZuraPrep Clear Solution|Apply topically.
45616846|NCT05378269|Other|Placebo|Placebo vaginal insert
45616847|NCT05728099|Device|Expiratory muscle strength training + SpiroGym application|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations coupled with SpiroGym app. per training session for 8 weeks (intensive training period). For another 16 weeks (maintenance period) participants will be instructed to perform, at least twice per week, five sets of five forceful expirations coupled with SpiroGym app. per training session .
45760484|NCT03782103|Drug|ChloraPrep|Apply topically.
45760485|NCT03782103|Drug|ZuraPrep Vehicle|Apply topically.
45760486|NCT05319015|Drug|Neoadjuvant Lenvatinib|20 mg PO daily for 12 weeks prior to surgery
45760487|NCT05319015|Drug|Neoadjuvant Pembrolizumab|200 mg IV every 3 weeks for 4 doses prior to surgery
46069048|NCT04556734|Drug|Placebo|Etrasimod matching placebo tablet by mouth, once daily
46069049|NCT04555967|Device|SAPIEN 3 Ultra System|Transcatheter aortic valve implantation
46069050|NCT04544904|Device|PAARx|Prescription Physical Activity Programming Application
46069051|NCT04544904|Device|JM|Joint Management (JM) web-based joint management resource.
45616848|NCT05728099|Device|Expiratory muscle strength training|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations per training session for 8 weeks (intensive training period). For another 16 weeks (maintenance period) participants will be instructed to perform, at least twice per week, five sets of five forceful expirations per training session. Participants will be given the practice log to track training adherence.
45445694|NCT02062840|Device|Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG)|A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain. An standard EKG (compatible with the fMRI machine) will be used to take measurements of cardiac vagal control.
45616849|NCT05367973|Device|IVR Dose 1|Estradiol 80 ug/day + progesterone 4 mg/day
45616850|NCT05367973|Device|IVR Dose 2|Estradiol 160 ug/day + progesterone 8 mg/day
45616851|NCT02466451|Other|Questionnaires|"For not collaborative patients, under the age of 4 years:~Standardized questionnaire collecting anamnestic-clinical data~Stress Parenting Index questionnaire and COPE brief questionnaire(Questionnaire assessing adaptation strategies of parents).~For collaborative patients, over the age of 4 years:~Standardized questionnaire collecting anamnestic-clinical data~Fractional exhaled nitric oxide (FeNO) assessment (oral and alveolar )~Spirometry~6-minutes walk test (WT 6')~Prick tests~Children Quality of life questionnaire (KINDL questionnaire)~Psychological test (Raven Matrices)~Stress Parenting Index questionnaire and COPE brief questionnaire (Questionnaire assessing adaptation strategies of parents)"
45616852|NCT04794595|Procedure|CBP|continuous blood purification can prevent or treat fluid overload in children with septic shock or other sepsis-associated organ dysfunction who are unresponsive to fluid restriction and diuretic therapy management of septic AKI patients, particularly those with hemodynamic instability or fluid overload. Also, it can remove cytokines
45616853|NCT05319535|Other|Implementation Strategy: Foundational REP|Among Caregivers FIRST sites that do not meet implementation adoption benchmarks, the goal is to test implementation intensification approaches, specifically Foundational REP vs. Enhanced REP. The investigators propose that low intensity implementation support that promotes adapting Caregivers FIRST for context and provides tools for ongoing Caregivers FIRST evaluation (defined as foundational REP), will be sufficient for some but not all sites to successfully incorporate Caregivers FIRST into routine practice.
45616854|NCT05319535|Other|Implementation Strategy: Enhanced REP|Among Caregivers FIRST sites that do not meet implementation adoption benchmarks, the goal is to test implementation intensification approaches, specifically Foundational REP vs. Enhanced REP. The investigators posit that higher intensity strategies (defined as Enhanced REP) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
45616855|NCT02466919|Drug|Pantoprazole|H. pylori eradication therapy
45616856|NCT02466919|Drug|Amoxicillin|H. pylori eradication therapy
45616857|NCT02466919|Drug|Metronidazole|H. pylori eradication therapy
45616858|NCT02466919|Drug|Levofloxacin|H. pylori eradication therapy
45616859|NCT02466919|Drug|Clarithromycin|H. pylori eradication therapy
45616860|NCT05727163|Drug|Dexamethasone|25mg via HAI (Pre-chemotherapy)
45616861|NCT05727163|Drug|Anisodamine|10 mg via HAI (Pre-chemotherapy)
45616862|NCT05727163|Drug|Oxaliplatin|85 mg/m2 via HAI over 3 hours
45616863|NCT05727163|Drug|Leucovorin|200 mg/m2 via HAI
45616864|NCT05727163|Drug|Fluorouracil|400 mg/m2 via HAI and 2.4g/m2 via HAI over 48 hours
45616865|NCT05727163|Drug|Irinotecan|150 mg/m2 intravenously
45616866|NCT05727163|Drug|Bevacizumab|5 mg/kg intravenously
45616867|NCT05727163|Drug|Oxaliplatin|85 mg/m2 intravenously over 3 hours
45616868|NCT05727163|Drug|Leucovorin|200 mg/m2 intravenously
45616869|NCT05727163|Drug|Fluorouracil|400 mg/m2 intravenously + 2400 mg/m2 continuous intravenous infusion over 46 hours
45616870|NCT05727085|Other|All pregnant women with a twin pregnancy and the offspring|No intervention
45616871|NCT05259709|Drug|89Zr˗DFO˗REGN5054|Administered by intravenous (IV) infusion during Part A and B.
45616872|NCT05259709|Drug|cemiplimab|Administered by IV infusion every 3 weeks (Q3W).
45616873|NCT05727007|Diagnostic Test|MRI in colon cancer|The MRI protocol will include the following imaging series: T1 and T2 in axial and coronal plane before the administration of intravenous contrast, diffuse weight imaging in axial plane and T1 after the administration of intravenous contrast
45616874|NCT05727007|Diagnostic Test|CT in colon cancer|The CT scan protocol will include the following: per os and intravenous administration of contrast, axial slices of 0.3mm thickness and reconstruction per 1mm, multi-planar reformation and three-dimensional volume rendering
45616875|NCT05302531|Drug|Amoxicillin|Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally
45616876|NCT05302531|Drug|Levofloxacin|Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally
46069052|NCT04539002|Behavioral|Aerobic exercise|Aerobic exercise performed on a stationary ergometer for 30 minutes, thrice weekly, with graded supervision. Participants will participate in the intervention over 24 weeks.
46069053|NCT04539002|Behavioral|Education Group Control|A monthly, hour-long, class over various MS topics and symptoms, led by a trained facilitator.
46069054|NCT04526899|Biological|BNT111|IV injection
46069055|NCT04526899|Biological|Cemiplimab|IV infusion
45445695|NCT02062840|Other|Questionnaires|Weekly questionnaires to assess changes in depression, mood, perceptions of self and quality of life will be administered.
45616877|NCT05302531|Drug|Ofloxacin|Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally
45616878|NCT05302531|Drug|Sulfamethoxazole trimethoprim|Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally
45616879|NCT00702403|Drug|nilotinib|Given PO
45616880|NCT00702403|Drug|imatinib mesylate|Given PO
45616881|NCT00702403|Other|pharmacological study|Correlative studies
45760488|NCT05319015|Procedure|Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection|Resection of locally advanced RCC with IVC tumor thrombus
45616882|NCT05302453|Other|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), which is among the body-mind approaches, is also frequently used in the rehabilitation of patients with psychiatric disorders, pain, and chronic musculoskeletal system problems.
45616883|NCT05293951|Device|Mirror Strengthening Device|"Participants will perform resisted task-specific upper limb exercises. During the exercises, participants will pull a resistance cord with their non-affected arm, Participants will complete the exercises while looking at its reflection in a mirror covering their affected arm.~The initial resistance will be chosen based on the participants initial outcome measure results.~Repetitions of these exercises will be prescribed according to patient function and strength, and will be increased each week as their ability improves. Sessions will start with 20-minute durations, and should increase in length as the therapy progresses due to the increased repetitions, but are not expected to exceed 30 minutes.~Training duration & frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
45616884|NCT05293951|Device|Mirror Therapy|"Participants will perform non-resisted task-specific upper limb exercises. During the exercises, participants will be watching their non affected arm reflected in a mirror covering their affected arm.~Repetitions of these exercises will be prescribed according to patient function and strength, and will be increased each week as their ability improves. Sessions will start with 20-minute durations, and should increase in length as the therapy progresses due to the increased repetitions, but are not expected to exceed 30 minutes.~Training duration & frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
45616885|NCT04691947|Biological|ERUCOV-VAC|Vaccination on Day 0 and Day 21
45616886|NCT04691947|Other|Placebo Vaccine|Placebo Vaccination on Day 0 and Day 21
45616887|NCT00702325|Drug|Budesonide / formoterol fumarate (SYMBICORT)|160/4.5 μg x 2 actuations twice daily (bid)
45616888|NCT00702325|Drug|Budesonide|inhalation powder 180 μg x 2 inhalations bid (PULMICORT)
45616889|NCT02719171|Drug|risankizumab|Risankizumab administered by SC injection
45616890|NCT02719171|Drug|placebo for risankizumab|Placebo for risankizumab administered by SC injection
45616891|NCT02464813|Drug|Pregabalin|Patients will receive pregabalin twice preoperatively and twice daily for 5 days after surgery.
45616892|NCT02464813|Drug|Sugar pill|Patients will receive placebo twice preoperatively and twice daily for 5 days after surgery.
45616893|NCT02464813|Drug|Oxycodone|All patients will receive oxycodone as analgetic treatment administered by PCA. Oxycodone consumption will be measured.
45616894|NCT05270707|Radiation|Stereotactic radiosurgery|HyperArc is a radiotherapy treatment with a structured workflow to plan and deliver stereotactic radiosurgery (SRS).
45616895|NCT05726929|Other|Osteopathic treatment|Osteopathic Manual Treatment
45616896|NCT05726929|Other|Capsaicin QUTENZA Patch (TAU)|Capsaicin QUTENZA Patch is the treatment as usual (TAU) delivered in the medical algology service
45616897|NCT04682353|Drug|TV-46046|SC injection of 300 mg/mL (120 mg/0.4mL; 180 mg/0.6mL; 240 mg/0.8mL)
45616898|NCT04682353|Drug|DeposubQ Provera|SC injection of 104 mg/0.65 mL
45616899|NCT05266495|Other|Brolucizumab|There is no treatment allocation. Patients administered brolucizumab by prescription will be enrolled.
45760489|NCT05319015|Drug|Adjuvant Pembrolizumab|200 mg IV every 3 weeks for up to 13 doses after surgery
45445696|NCT03767673|Diagnostic Test|Initial Spirometry|Determination of Vital Capacity by spirometry before (within 30 minutes) spiroergometry. Measurements will be performed in both groups.
45616900|NCT05220241|Biological|Nasopharyngeal swab for RT-PCR SARS-CoV-2|2 nasal swabs (one per nostril) of olfactory mucosa cells under local anesthesia for SARS-CoV-2 RT-PCR and pathological analysis
45616901|NCT02722525|Procedure|Magnetic Resonance Imaging|Undergo treadmill stress CMR
45616902|NCT02722525|Behavioral|Exercise Intervention|Complete treadmill exercise
45616903|NCT02722525|Procedure|Perfusion Magnetic Resonance Imaging|Undergo gadopentetate dimeglumine perfusion MRI
45616904|NCT02722525|Behavioral|Exercise Intervention|Complete resistive lower extremity exercise
45616905|NCT02722525|Procedure|Spectroscopy|Undergo skeletal muscle PMRS
45616906|NCT02722525|Other|Laboratory Biomarker Analysis|Correlative studies
45616907|NCT04490473|Other|survey work|Survey forms will be sent to individuals online. Information about the study will be given to individuals with the informative text at the beginning of the questionnaire form. Individuals who agree to participate in the study will fill in the questionnaire and send it back online.
45616908|NCT05726695|Diagnostic Test|microRNA test|Laboratory analysis for the detection of microRNA in blood samples.
45616909|NCT05726695|Diagnostic Test|Heart ultrasound examination|Heart ultrasound examination will be performed as a standard cardiology examination.
45616910|NCT05726539|Behavioral|Group-based peer support|Receipt of semi-structured curriculum based group peer support that addresses common concerns of military spouses
45616911|NCT04755907|Procedure|surgical resection|Surgical resection will be performed for locoregional lesions or liver metastases.
45616912|NCT04755907|Other|adjuvant chemotherapy|Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.
45616913|NCT04755907|Other|neoadjuvant therapy|Regimens of neoadjuvant chemotherapy are directed by clinical guidance and experience.
45616914|NCT02466607|Device|RETeval color flicker ERG|Flicker ERGs obtained to 56 CIE 1931 (created by the International Commission on Illumination (CIE) in 1931) colors series. White flash of 0,33, 0,33 was used for comparison.
45616915|NCT02466607|Device|RETeval dilated versus un-dilated flicker ERG|Two series of white flashes: 3,0 cd/m2/sec and Trolands equivalent assuming 3,7 mm pupil size, delivered at 3 min interval over 30 min.
45616916|NCT02466607|Other|pupil dilation|Pupil will be dilated using Proparacaine 0.5% and Tropicamide 0.5%
45616917|NCT05275231|Behavioral|Intensive lifestyle interventions (ILIs)|Intensive lifestyle interventions (ILIs) is a group-based programs designed to promote weight loss through a combination of diet, activity, and behavior change, decrease Type 2 Diabetes (T2D) incidence in people with prediabetes and reduced complications among people with T2D.
45760490|NCT00810719|Drug|Erlotinib|Erlotinib will be administered at 150 mg once daily by mouth on the following schedule: days 2-5, 9-12,16-26.
45760491|NCT00810719|Drug|gemcitabine|The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.
45616918|NCT04590079|Device|Conventional pain treatment with daily sessions with innovative medical device, Remedee One, for pain management by Millimeter Band Radiation|Conventional pain treatement with daily sessions with innovative medical device for pain management (radiation in millimeter band) at the rate of 1 to 3 sessions by day of 40 minutes for 3 months.
45616919|NCT04740385|Diagnostic Test|Lung auscultation|auscultation of air entry through chest wal
45616920|NCT04740385|Device|Fiberoptic bronchoscopy|Checking correct double lumen position through direct vision using fiberoptic bronchoscopy
45616921|NCT04740385|Device|Lung Ultrasound|real time visualization of air entry to the lungs using trans-thoracic lung ultrasound
45616922|NCT04522219|Diagnostic Test|Contrast enhanced ultrasound|Acquisition of contrast enhanced ultrasound. Contrast agent: SonoVue®: Hexafluoride (SonoVue®, injectable solution to solubilisate, 8µg/mL) is injected in all patients
45616923|NCT04491175|Device|DuoTherm|New combination device comprising a sculpted low back plate with multiple sensory modalities held in place with a neoprene belt capable of being tightened with patient control of variations in sensory modalities.
45616924|NCT04491175|Device|TENS|LG SMART TENS stimulator is a portable electgrotherapy devcie featuring transcutaneous electrical nerve stimulation (TENS) therapeitud devcie, which is used for pain relief. The stimulator sends a gentle electrical current to underlying nerves and muscle groups via electrodes applied on the skin. The parameters of the device are controlled by buttons on a controller with an adjustable intensity level.
45616925|NCT05722873|Behavioral|Fasting arm|Study participants will fast one day per week for 12 weeks
45616926|NCT05722873|Behavioral|Weight maintenance|Study participants will be counseled to maintain body weight
45616927|NCT05722873|Behavioral|Counseling|Study participants will be counseled on optimal diet and activity recommendations for maintaining/achieving a normal BMI
45616928|NCT02718625|Biological|Santyl|Collagenase ointment applied topically
45616929|NCT02718625|Biological|SoloSite®|SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.
45616930|NCT05123911|Other|Investigational Shampoo|Parent/LAR will bathe the child participant with the investigational shampoo at least 3 times a week for up to 28 days.
45616931|NCT05123911|Other|Investigational Conditioner|Parent/LAR will bathe the child participant with the investigational conditioner at least 3 times a week for up to 28 days.
45616932|NCT05123911|Other|Investigational Combing Cream|Parent/LAR will apply investigational combining cream to wet and previously moistened hair at least 3 times a week for up to 28 days.
45616933|NCT05719987|Other|Biodentine|After the endodontic procedure, Biodentine will be placed into the apical portion of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha and AH Plus. The coronal restoration will be completed with GIC, composite, and stainless-steel crown.
45616934|NCT05719987|Other|MTA|After the endodontic procedure, MTA will be placed into the apical portion of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha and AH Plus. The coronal restoration will be completed with GIC, composite, and stainless-steel crown.
45445697|NCT03767673|Diagnostic Test|Final Spirometry|Determination of Vital Capacity by spirometry after (within 30 minutes) spiroergometry. Measurements will be performed in both groups.
45445698|NCT03767673|Diagnostic Test|Pulmonary microbiome (16S rDNA profiling)|Harvesting of deep induced sputum and determination of the airway microbiome by 16S ribosomal RNA (rRNA) pyrosequencing. Evaluation of alpha and beta diversity and relative bacterial abundance at the genus level. Measurements will be performed in both groups (samples will be harvested within 30 minutes after spiroergometry).
45445699|NCT03767673|Diagnostic Test|Maximum oxygen uptake|Determination of the maximum oxygen uptake (ml/kg/min) corrected for gender, age and body weight by bicycle spiroergometry. Measurements will be performed in both groups.
45445700|NCT03767673|Diagnostic Test|Maximum performance|Determination of the maximum performance (W/kg) corrected for body weight by bicycle spiroergometry. Measurements will be performed in both groups.
45445701|NCT03767673|Diagnostic Test|weight|Determined by Kilogram on a medical weight scale
45616935|NCT05122351|Drug|Bupivacaine infiltration at the Quadratus Lumborum muscle Versus Paracetamol injection as analgesia in post operative Open Inguinal Hernia surgeries|Comparative Study Between The Efficacy Of Quadratus Lumborum Block VS Conventional Analgesia In Patients Undergoing Open Inguinal Hernia Surgical Repair
45616936|NCT05118919|Biological|BGP-014|Oral capsule containing lyophilised Lactobacillus reuteri
45616937|NCT05118919|Biological|Placebo|Oral capsule
45616938|NCT05716789|Procedure|CPR|CPR in cardiac arrest patients
45616939|NCT02466061|Behavioral|Telemedicine Weight Management plus Wi-Fi Scale (Arm A)|Telephonic weight loss counseling by trained interventionists, with guided digital scale measurements of weight, lean mass, and fat mass. Counseling sessions and digital weight recording occur at regularly scheduled intervals over a six-month intervention period.
45616940|NCT02466061|Behavioral|Text for Diet (Text4Diet) Group (Arm B)|Short Message Service (SMS) text messaging in which participants receive 3-5 text messages each day during a six-month intervention period. The text messages provide tips and reminders to encourage healthy eating and weight loss. Participants on this arm also receive a digital scale to track and report weight as prompted once per week through the text program.
45616941|NCT02466061|Behavioral|Enhanced Usual Care Group (Arm C)|Participants are provided with handouts based on American Cancer Society guidelines for healthy eating and exercise.
45616942|NCT05713903|Procedure|Laparoscopic right colectomy|Resection of the ascending colon via a laparoscopic approach, adhering to the CME principles
45616943|NCT05713903|Procedure|Open right colectomy|Resection of the ascending colon via an open approach, adhering to the CME principles
45616944|NCT05232331|Dietary Supplement|Intake of nitrate rich vegetables|Nutritional intervention for 10 weeks to increase the consumption of vegetables rich in nitrate. At the beginning of the NSPT on visit 1 (week 2), the first of 5 nutritional interventions will begin with the objective of consuming ~ 350 mg of NO3 daily from vegetables
45760492|NCT04394559|Behavioral|Discharge Order Sets|Discharge order sets will be implemented in the electronic health record and will provide surgeons a guideline for a recommended dose and duration of opioids for each commonly performed orthopedic surgery.
45616945|NCT02464501|Other|Paclitaxel administration using the OPC|
45616946|NCT02465827|Drug|nerve block with ropivacaine|Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with ropivacaine 0.75% for both nerve branches
45616947|NCT02465827|Drug|nerve block with ropivacaine and with saline|nerve blocks of the saphenous nerve with ropivacaine 0.75% and obturator nerve, posterior branch with saline
45616948|NCT02465827|Drug|nerve block with saline|Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with saline for both nerve branches
45616949|NCT04368403|Drug|KHK4827|210 mg every 2 weeks (Q2W), subcutaneous (SC) injection
45616950|NCT04358185|Drug|Itacitinib (INCB039110)|Novel and small molecule selective inhibitor of JAK1
45616951|NCT05241847|Behavioral|PeLTQL delivery via electronic means|Delivery of PeLTQL scoring information to clinicians via electronic means.
45616952|NCT02716987|Drug|TAK-831|TAK-831 oral suspension.
45616953|NCT02716987|Drug|[18F]PGM299|[18F]PGM299 injection
45616954|NCT04331977|Device|Maxillary Expansion|2 appliances to expand the maxillary arch
45616955|NCT04298203|Drug|Phentermine-Topiramate|The study medication to be tested for this study is a combination of phentermine and topiramate.
45616956|NCT04298203|Dietary Supplement|Meal Replacement Therapy|The first six weeks of the study, subjects will receive meal replacement therapy in an effort to reduce their BMI by at least 5%.
45616957|NCT04298203|Other|Placebo|A pill that looks like Phentermine-Topiramate but has no active medication.
45616958|NCT02464423|Behavioral|Trauma-Informed Cognitive Behavioral Therapy enhanced (TI-CBTe)|
45616959|NCT02464189|Other|Q-Kap|
45616960|NCT05709067|Dietary Supplement|Probiotic|6 Billion CFU per day
45616961|NCT05709067|Dietary Supplement|Placebo|0 CFU per day
45760493|NCT04394559|Behavioral|Pharmacist-Led Discharge Counseling and Communication|Two visits by a trained inpatient pharmacist, including an intake visit to determine previous barriers to safe medication use, and a discharge counseling session with patients and caregivers regarding safe and effective opioid use after discharge; pharmacist communication with providers regarding the post-discharge pain management plan.
45760494|NCT04394559|Behavioral|Post-discharge Pain Management Follow-up|An outpatient pharmacist pain management follow-up visit (with additional contact as needed) embedded within routine post-operative care for managing pain and opioid use.
45760495|NCT04394559|Behavioral|Patient Engagement Pain Management App|A mobile patient-reported outcomes application for assessing pain, function, and possible development of opioid use disorder.
46069056|NCT04525274|Drug|normal saline|"At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of 40 ml bupivacaine 0.25% + 5 ml normal saline will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure."
45616962|NCT05686759|Biological|Undiluted I.V.-Hepabig inj(GC5103)|undiluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
45616963|NCT05686759|Biological|Diluted I.V.-Hepabig inj(GC5103)|Diluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
45616964|NCT05679895|Biological|CD1a-CAR T|Autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express CD1a chimeric antigen receptor administered by intravenous infusion following a dose-escalation approach
45616965|NCT05679661|Dietary Supplement|immunonutrition|Patients in the intervention group will receive additional immunonutrition supplementation, which is oral intake of ORAL IMPACT™ 2 servings per day from the day of allocation at the preoperative anesthesia clinic until the day before surgery.
45616966|NCT05679661|Behavioral|oral chlorhexidine decontamination|Patients in the intervention group will receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
45616967|NCT05678179|Behavioral|Telehealth|Patients will participate in standard clinical practice for bariatric surgery preparation with 50% of visits occurring via telehealth.
45616968|NCT05678179|Behavioral|In Person (Face-2-Face)|Patients will participate in standard clinical practice for bariatric surgery preparation with face-2-face clinic visits.
45616969|NCT04813315|Other|Kendall exercise|consist of stretch of pectoralis major and neck extensor strengthening of deep neck flexors and scapular retractor
45616970|NCT04813315|Other|Gong's mobilization|it is combination of glide along the facet joint and concurrent movement of cervical spine
45616971|NCT02466763|Procedure|Cochlear implant surgery|Surgical placement of a cochlear implant device.
45616972|NCT02464111|Other|Treatment 1: Control|No supplement provided.
45616973|NCT02464111|Dietary Supplement|Treatment 2: Bolus (LNS)|One LNS supplement provided in a single bolus dose in the morning
45616974|NCT02464111|Dietary Supplement|Treatment 3: Divided Dose (LNS)|One LNS supplement provided in 3 separate portions throughout the study visit
45616975|NCT05044039|Drug|Duvelisib|Patients should take duvelisib at approximately the same time every day, with or without food.
45616976|NCT02465983|Biological|CART-meso-19 T cells|A single dose of CART-meso-19 cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting. Patients will receive CART cell treatment on an outpatient basis.
45616977|NCT02465983|Drug|Cyclophosphamide|A single dose of chemotherapy to be administered prior to dosing of the CART-meso-19 cells
45616978|NCT02465749|Drug|Continuous oxygen|Continuous oxygen intake at a concentration of 93±3%, 3L/min flow-rate, 2h/bid, five days a week;
45616979|NCT02465749|Device|blue light-absorbing sunglasses|Wearing blue light-absorbing sunglasses at daily time;
45616980|NCT02465749|Drug|Compound thrombosis capsule sig: 1.5g/tid|Compound thrombosis capsule sig: 1.5g/tid
45616981|NCT02465749|Drug|Ginkgo biloba pills sig: 300mg/tid;|Ginkgo biloba pills sig: 300mg/tid;
45616982|NCT02465749|Drug|Vitamin B sig: 10mg/tid|Vitamin B sig: 10mg/tid
45616983|NCT02465749|Drug|Vitamin AD sig: 1 tablet/tid|Vitamin AD sig: 1 tablet/tid
45616984|NCT00701779|Drug|Tamsulosin|Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
45445702|NCT03767673|Other|age|Determination of age by patient's Report and past medical history
45445703|NCT02063620|Drug|Ketamine HCL|ketamine HCL is using as adjuvant agent with local anesthetic agent in regional intravenous anesthesia procedure routinely
45616985|NCT02465905|Other|raw milk|
45616986|NCT02465905|Other|Heated milk|
45445704|NCT03761667|Other|Endoscopy using Narrow band imaging|Inspection of resection margin of SSA/P for the evaluation of complete resection or the presence of remnant lesion using NBI method
45616987|NCT04950127|Drug|Linerixibat|Participants will receive linerixibat.
45616988|NCT04950127|Drug|Placebo|Participants will receive placebo.
45616989|NCT05618587|Drug|Lithium|Lithium has multiple mechanisms of action including anti-inflammatory actions, which may be relevant for treating long COVID.
45616990|NCT05618587|Drug|Placebo|Inactive pill
45616991|NCT05617807|Procedure|Nanoscopic partial meniscectomy|Patients will have a partial meniscectomy performed using the arthrex nanoscope and it will be compared to partial meniscectomy performed using standard arthroscopic equipment
45616992|NCT05617807|Procedure|Standard Partial Meniscectomy|Patients will have partial meniscectomy performed using standard arthroscopic equipment
45616993|NCT05599711|Behavioral|Transitioning Together (TT) / Juntos en la Transicion (JET)|"One individual family joining session when each family dyad meets with group therapists to establish rapport and share their own unique family's background, goals, and supports.~A series of four 2.5-hour multi-family group psychoeducation intervention sessions focused on problem-solving education and psychoeducational autism transition-to-adulthood content which can include independence in adulthood, community involvement, guardianship and legal issues, employment and education, health and well-being."
45616994|NCT05599711|Behavioral|Usual autism transition care|An expedited referral will be made for participants to establish care with a BMC Autism Program Transition/Resource Specialist. Data will be abstracted from the electronic medical record on how many visits each family completes with a BMC Autism Program Transition/Resource Specialist or other BMC Developmental and Behavioral Pediatrics provider throughout the study period.
45760496|NCT03835845|Device|PICO7Y|The PICO 7Y pump maintains NPWT at -80 mmHg (nominal) to two wound surfaces simultaneously. Exudate is managed by the dressings through a combination of absorption and evaporation of moisture through the outer film. The PICO 7Y kit is intended to be used for up to 7 days on low exuding wounds. For moderately exuding wounds the system is intended to be used for up to 4 days without a dressing change. For 7 days use on moderately exuding wounds additional dressings will be supplied.
45616995|NCT05599009|Procedure|remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg. All patients underwent dynamic cerebral autoregulation before treatment, immediately after treatment, 6 hours after treatment and 24 hours after treatment.
45616996|NCT05599009|Procedure|sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg. All patients underwent dynamic cerebral autoregulation before treatment, immediately after treatment, 6 hours after treatment and 24 hours after treatment.
45616997|NCT04169815|Diagnostic Test|Access Immunodiagnostic Products|Access Natriuretic Peptide Assay
45616998|NCT04166851|Behavioral|PrEP campaign messages developed via open contest|PrEP campaign messages will be developed via an open contest in Baltimore.
45616999|NCT04166851|Behavioral|PrEP campaign messages developed via social marketing approach|PrEP campaign messages developed with a traditional social marketing approach.
45617000|NCT04162171|Radiation|Stereotactic Body Radiotherapy (SBRT) ablation of VT|"Additional imaging for SBRT planning and implementation:~Planning CT (pCT) - CT simulator that utilizes a respiratory positioning monitoring (RPM) optical tracking system and SBRT immobilization setup to provide necessary data to allow for monitoring of the patient's deep inspiration breath-hold (DIGH) maneuver during treatment delivery.~SBRT treatment - 30 min procedure on a TrueBeam 1 linear accelerator using SBRT fixation. Patient alignment and DIBH maneuver from the pCT will be replicated using the on-board cone-beam CT (CBCT) guidance and RPM systems."
45617001|NCT02463565|Other|no intervention|
46069057|NCT04525274|Drug|dexmedetomidine|"At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of the study drug(40 ml bupivacaine 0.25% + 1 µg/kg dexmedetomidine diluted in 5 ml normal saline) will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure."
45617002|NCT05029141|Drug|CAHAG regimen|"Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC > 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial."
45911603|NCT05778162|Diagnostic Test|Synovasure® RISC™ Panel|The Synovasure® RISC™ Panel is a laboratory-developed test (LDT) panel (CD Laboratories, Clinical Laboratory Improvement Amendments [CLIA] Registration No.: 21D0216863) intended to provide indications for diagnosing different types of arthritis that may correspond to higher risk levels for postoperative complications in patients experiencing knee pain and/or inflammation prior to primary knee arthroplasty.
45452276|NCT02261740|Behavioral|Yoga Therapy|"A 90-minute orientation session led by the yoga class instructors, followed by 90-minute group yoga classes twice weekly for 6 weeks. Classes will be led by an experienced instructor. Women will also be taught to avoid any habits that may worsen their genito-pelvic pain (e.g., straining their pelvic floor muscles).~Participants will also be asked to practice yoga at home an additional hour per week throughout the 6-week yoga therapy program. Participants will be given a detailed written manual to use for home practice."
45617003|NCT05029141|Drug|Placebo regimen|"Chidamide 0mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC > 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial."
45617004|NCT02463643|Drug|Z-215 10mg|Z-215 10mg, capsules
45617005|NCT02463643|Drug|Z-215 20mg|Z-215 20mg, capsules
45617006|NCT02463643|Drug|Z-215 Placebo|Z-215 placebo-matching capsules
45617007|NCT02463643|Drug|Rabeprazole Sodium|Rabeprazole Sodium 10mg tablets
45617008|NCT02463643|Drug|Rabeprazole Sodium Placebo|Rabeprazole Sodium Placebo placebo-matching tablets
45617009|NCT04927975|Drug|Upadacitinib|Oral tablets
45617010|NCT04927975|Drug|Placebo|Oral tablets
45617011|NCT02463721|Other|ascitic fluid culture and microbiological testing|ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP
45617012|NCT04924933|Diagnostic Test|Computerised associative memory task using abstract words and landscape photographs|Two test sessions using the computerised associative memory task will be performed by the two groups (patients and control subjects). The first session will consist of the encoding of 56 associations between a word and a photograph and the recall of half of them (28) 30 minutes later by the mean of a matching task and a recognition task. The second session consists of the recall of the other half of the associations (28) 72 hours after the encoding phase, using the same procedure (matching task and recognition task). Performance obtained by patients and by healthy volunteers will then be compared.
45617013|NCT04913467|Other|Groningen Anti-Inflammatory Diet (GrAID)|Specially designed diet based on the most recent scientific evidence of the inflammatory characteristics of food and food groups. Basically, subjects will be instructed to increase uptake of food components that hold potential anti-inflammatory proportions and to avoid food components that may showcase potential pro-inflammatory proportions.
45617014|NCT04913467|Dietary Supplement|ColoVit capsule|Vitamin B2/B3/C supplement in a ColoPulse-coated capsule
45617015|NCT04913467|Other|ColoPulse-placebo capsule|A capsule containing microcrystalline cellulose which is coated using the same ColoPulse technology as is used with the ColoVit
45617016|NCT02463955|Device|flexible video endoscope|Thoracoscopy is done using flexible video endoscope
45617017|NCT02463955|Device|video-rigid thoracoscope|Thoracoscopy is done using video-rigid thoracoscope
45617018|NCT04889833|Behavioral|hypnosis therapy|Pre-recorded hypnosis therapy audio recording with accompanying visual of a calm ocean to be played at least once daily for 7 preoperative days, the day of surgery, and for 7 days postoperatively.
45617019|NCT04150861|Drug|Follitropin Delta|Solution for Injection, subcutaneous administration
45617020|NCT04150705|Device|FDG PET/MRI|-All patients will undergo a simultaneous list mode PET and MR acquisition beginning 55-65 minutes after administration of FDG according to a standard weight-based scale.
45617021|NCT04143295|Drug|Diiodothyropropionic acid|Drug Administration
45617022|NCT04490083|Procedure|Extra corporeal shock wave lithotripsy|ESWL will be performed with a third generation electromagnetic lithotripter (Delta Compact, Dornier Med Tech, Germany) This has both fluoroscopy and ultrasound imaging facility. Radio opaque calculi will be targeted directly while a naso pancreatic tube (NPT) was placed for all radiolucent calculi and contrast was passed through this to localize the calculi. Between 5000 and 6000 shocks were delivered per session with frequency of 90 shocks per minute. The aim will be to fragment the calculi to <3 mm or demonstrate a decrease in heterogeneity or density of the calculi in the main pancreatic duct. Shocks will be delivered on consecutive days till fragmentation is achieved. If there is no fragmentation after four sessions of ESWL the procedure will be labeled as unsuccessful and patient will be advised surgery. Procedures will be performed under epidural anesthesia.
45617023|NCT02465359|Drug|Immune Globulin Subcutaneous (Human)|Patients who have CIDP and are on IVIG will be allowed in the study to try subcutaneous immune Globulin (SCIG) as part of an open label study.
45760497|NCT04369443|Procedure|Large volume Acute Normovolemic Hemodilution|Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
45911604|NCT05778149|Drug|Aumolertinib,Anlotinib|Aumolertinib 110mg p.o QD; Anlotinib 12mg, oral for 2 weeks, three weeks a cycle, until disease progression.
45452277|NCT01016782|Drug|0444|A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
45617024|NCT05491603|Biological|DBI-001|Topically administered
45617025|NCT05491603|Biological|DBI-002|Topically administered
45617026|NCT05491603|Biological|Aqueous Gel|Topically administered
45617027|NCT02465281|Other|Device: 3T scanner with MRI-compatible robot|
45617028|NCT04857229|Device|Histolog Scanner|Confocal Microscope
45617029|NCT02463019|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate
45617030|NCT02462941|Drug|Adenosine|Testing escalating doses of adenosine in pediatric heart transplant patients
45617031|NCT02462941|Procedure|Cardiac catheterization|(non-experimental) standard procedure
45452278|NCT02269852|Biological|trivalent seasonal influenza vaccine|"Infants: 0.25 ml/ dose;~Adults: 0.5 ml/ dose;~Seniors: 0.5 ml/ dose;"
45617032|NCT02462707|Drug|PF-03084014|gamma-secretase inhibitor, formulated in tablets for oral administration containing 10 mg, 50 mg and 100 mg. Patient will receive 80 mg, 100 mg or 150 mg twice daily of PF-03084014 with continuous dosing schedule
45617033|NCT03714451|Dietary Supplement|onyx sorghum|The diet intervention will last a total of 28 days. Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat. In the Onyx Group, 25% of carbohydrate will come from the onyx sorghum, and at least three foods per day (including cereals, bread, muffins, pasta, and smoothie boosters) will contain this.
45617034|NCT03714451|Dietary Supplement|whole wheat flour|Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat.
45617035|NCT04096885|Diagnostic Test|Blood and urine samples, skin and stool swabs|Blood samples will be collected before surgery, on the first postoperative day and after 3-8 weeks. Urine samples will be collected after surgery and after 3-8 weeks. Stool and skin swabs will be collected before surgery.
45617036|NCT02465047|Other|Self-help booklet|See Arm/Group Description
45911605|NCT05778097|Drug|Apalutamide 60mg Tab|Apalutamide 60Mg Tab (4 x 60 mg) once daily on days 1-28 of a 28-day cycle
45911606|NCT05778097|Drug|Androgen deprivation therapy(ADT)|The choice of ADT will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
45617037|NCT04042831|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
45760498|NCT03761277|Device|Medtronic SynchroMed™ II infusion system|Implanted infusion system consisting of a pump and catheter, as well as external components of a clinician programmer, refill and catheter access port kits, and the Personal Therapy Manager (myPTM™).
45760499|NCT03761277|Drug|Preservative-free morphine sulfate (PFMS)|The pharmacological agent used in the pump for this study is limited to a preservative-free morphine sulfate (PFMS).
45452279|NCT02269930|Drug|peginterferon beta-1a|Administered as subcutaneous injection
45452280|NCT02269930|Drug|Rebif|Administered as subcutaneous injection
45617038|NCT04042831|Procedure|Computed Tomography|Undergo CT
45617039|NCT04042831|Procedure|Magnetic Resonance Imaging|Undergo MRI
45617040|NCT04042831|Drug|Olaparib|Given PO
45617041|NCT02463175|Drug|Plasmalyte|Boluses of 5ml/kg of plasmalyte
45617042|NCT02463175|Procedure|Goal-directed fluid therapy (GDT)|Intraoperative goal-directed fluid therapy (GDT)
45617043|NCT02462395|Device|tDCS|"Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.~A first group of CCH patients will have to apply the neurostimulation outside of an attack every day for 20 minutes during 4 weeks. A second group will use the tDCS device everyday for 8 weeks.~Adherence to the treatment will be evaluated by monitoring the time during which the device is switched on via an in-built software."
45617044|NCT03707977|Drug|ART|ART will not be provided by the study. Participants will continue to receive their ART regimen they were receiving prior to enrolling in the study.
45617045|NCT03707977|Biological|VRC01LS|Administered by intravenous (IV) infusion
45760500|NCT04348929|Other|Self-administered questionnaires|Self-administered questionnaires once during the post-natal hospitalization and a second time 7 to 9 weeks after the delivery (at home)
45617046|NCT03707977|Biological|10-1074|Administered by intravenous (IV) infusion
45617047|NCT03670615|Other|tDCS|All study participants randomized to tDCS will receive active tDCS.
45617048|NCT03670615|Other|Exercise|Participants will exercise at TRI according to an individualized exercise prescription.
45617049|NCT03670615|Other|Exercise Education|Exercise education/ treatment as usual will include routine advice about physical activity for older adults.
45617050|NCT03670615|Other|Sham tDCS|The same procedure for tDCS will be used for the sham condition, except without active current.
45617051|NCT02465125|Biological|red blood cell transfusion|
45617052|NCT02464891|Drug|CCX168|
45760501|NCT03729999|Device|Portable, Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
45911607|NCT05778084|Drug|Empagliflozin 10 MG|Blood samples will be collected as a baseline to test for N-terminal Pro-B-type Natriuretic Peptide, followed by administration of empagliflozin for 6 months, and then another blood samples will be collected after 6 months.
45911608|NCT05778058|Device|Unilateral Stimulation|With the Vagustim device, vagus nerve stimulation will be applied in one ear for 20 minutes, with a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current that the participant will feel the current comfortably.
45911609|NCT05778058|Device|Bilateral Stimulation|With the Vagustim device, vagus nerve stimulation will be applied in one ear for 20 minutes, with a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current that the participant will feel the current comfortably.
45911610|NCT05778058|Device|Bilateral Sham Stimulation|Participants were shown that the device was working, but no current was given.
45911611|NCT05778058|Diagnostic Test|Bicycle Ergometer Test|Participants in this group were asked to perform bicycle exercise with maximum performance under 30 watts for 30 minutes.
45911612|NCT05778058|Diagnostic Test|Lactat Scout|For lactic acid analysis measurement, the middle fingertip of the athlete is disinfected with an alcohol swab and a blood sample is taken by puncturing the finger.The measuring range is 0.5 - 0.25 mmol/L.
45445705|NCT03761589|Behavioral|AFL Intervention|The AFL intervention consisted of two 90-minute sessions per week for 12 months for both children and parents. The child physical activity sessions, held separately from the parent sessions, aimed to achieve 60 minutes of moderate-to-vigorous physical activity during each session through structured play activities, athletic drills, and sport exercises. Child dietary behaviors were taught through educational activities in small groups. For the parent program, behavior modification techniques were used to guide parents toward changing their own and their child's behavior. Take-home materials for self-monitoring of behaviors were used for both the child and the parent in order to reinforce concepts discussed in class.
45617053|NCT02462551|Device|Focal Electrically Administered Seizure Therapy|A focal administration of the right unilateral configuration of electro-convulsive therapy for the treatment of recurrent and treatment-resistant depression.
45617054|NCT04824391|Biological|ERUCOV-VAC 3 µg/0.5 ml Vaccine|Two IM applications on Days 1 and 28
45617055|NCT04824391|Biological|ERUCOV-VAC 6 µg/0.5 ml Vaccine|Two IM applications on Days 1 and 28
45617056|NCT04824391|Other|Placebo|Two IM applications on Days 1 and 28
45617057|NCT02464735|Device|Polysomnography|
45617058|NCT03297151|Dietary Supplement|CONTROL|"Food grade mixture of non-essential amino acids in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Product Reference Number 10955"
45617059|NCT03297151|Dietary Supplement|Whey Protein Concentrate|"Whey protein concentrate in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Trade name of product is Carbelac80 Instant Product Reference Number 10431"
45617060|NCT03297151|Dietary Supplement|Whey Protein Hydrolysate|"Whey protein concentrate hydrolysate (degree of hydrolysate 27%) in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Product Reference Number 10468"
45617061|NCT03297073|Drug|paracetamol|"Paracetamol 1000 mg will be administered 30 minutes before the end of the procedure and then every 6 hours systematically at the following times: 6h / 12h / 18h / 00h.~The analgesic treatment after hepatectomy with paracetamol will be maintained for at least 5 days in all patients in parenteral form"
45617062|NCT03297073|Procedure|hepatic surgery|
45617063|NCT03296995|Device|Flash glucose monitoring system|Flash glucose monitoring systems in critically ill patients may improve glycemic control and reduce glucose variability.
45617064|NCT03296917|Drug|PrEP-001|A spray dried powder for intranasal administration formulated from an aqueous mixture of pre-gelatinized waxy maize starch and the drug substance delivered using a single dose nasal powder device.
45617065|NCT03296917|Drug|G-004|A spray dried pre-gelatinized waxy maize starch powder (G-001) in the single dose nasal powder device
45617066|NCT02462317|Drug|botulinum A toxin|botulinum toxin injection
45617067|NCT02462317|Drug|Baclofen|baclofen oral tablet
45452281|NCT02261896|Drug|Placebo|Evaluate usefullness of antibiotic prophylaxis
45760502|NCT03720795|Behavioral|Stepped Care CBT|"Stepped Care CBT is a multi-method, parent-led approach, consisting of two main steps. Step one involves a low-intensity delivery of CBT, consisting of more flexible, parent-led, at-home treatment. Participants who do not show improvement in symptom severity at the end of Step One, are then stepped up to receive Step Two. Step two involves a high intensity delivery of CBT, consisting of therapist-led, parent-assisted weekly treatment sessions."
45452282|NCT02261896|Drug|Ciprofloxacin|Ciprofloxacine 400 mg intravenous one dose followed by ciprofloxacine oral each 12 hours (complete 3 days)
45617068|NCT02462317|Drug|Placebo toxin|placebo injection
45617069|NCT02462317|Drug|placebo baclofen|placebo oral tablet
45617070|NCT03296683|Device|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
45617071|NCT03402685|Device|ClearSight|Patients in the intervention group receive management of volume and vasopressor settings according to the non-invasive ClearSight system.
45617072|NCT02462785|Behavioral|In-person Carbohydrate Counting Class|An in-person carbohydrate counting class led by a registered dietician. The in class session covers topics including the role of CHO in nutrition and diabetes, sources of CHO, different CHO and non-CHO foods, resources for CHO counting, label reading, and meal planning. This is the standard procedure for CHO counting education at SickKids.
45617073|NCT02462785|Behavioral|Online Carbohydrate Counting Tutorial|A web-based CHO counting tutorial that covers the same concepts reviewed during the standard in-person instructional session held at SickKids. A teen delivers the educational messages in short segments using techniques designed to maintain the viewer's attention (e.g., visuals of food portions and short segment highlights to emphasize important points). The online module includes brief interactive question/answer components for reinforcement. The secure online tutorial will be accessible for one week through a link provided by REDCap. Users will be able to repeat sessions, log on and off during sessions, and choose specific modules for repetition/review. The investigators will be able to capture the number of times patients log on and detail frequency and specifics of usage.
45617074|NCT02462863|Dietary Supplement|Arginine and fish oil|Dietary supplements
45617075|NCT02461069|Drug|Dimethyl fumarate|Dimethyl fumarate (Tecfidera®) treatment is initiated by daily administration of 120 mg Tecfidera® p.o. in the morning in week 0. At week 1, the dose is increased to 120 mg Tecfidera® p.o. twice daily, split into a morning and an evening dose. At week 2, the daily dose is further increased to 240 mg Tecfidera® p.o. in the morning and 120 mg Tecfidera® p.o. in the evening. Finally at week 3, the dose will be increased to the final daily dose of 240 mg Tecfidera® p.o. in the morning and 240 mg Tecfidera® p.o. in the evening and maintained throughout the study.
45617076|NCT03332095|Drug|Doravirine (DOR)|100 mg of DOR administered orally
45617077|NCT03332095|Drug|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)|DOR/3TC/TDF administered orally as a fixed-dose combination (as a tablet, 100 mg/300 mg/300 mg) once daily
45760503|NCT00810797|Drug|exemestane|Given orally
45760504|NCT00810797|Other|laboratory biomarker analysis|One year after completion of study treatment
45760505|NCT00810797|Procedure|quality-of-life assessment|One year after completion of study treatment
45760506|NCT00810797|Other|immunohistochemistry staining method|Correlative studies
45760507|NCT04340505|Drug|Fluocinolone Acetonide|Injection of fluocinolone acetonide implant will be injected as standard of care treatment for patients with active uveitis.
45617078|NCT03332095|Drug|Antiretroviral (ARV) medications|Participants in Cohort 1 received a combination of dolutegravir (DTG) or raltegravir (RAL) plus two nucleoside reverse transcriptase inhibitors (NRTIs). The ARV drugs were prescribed by participants' own health care providers and were not provided by the study.
45617079|NCT04489381|Drug|Nitazoxanide|Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days
45617080|NCT04489381|Drug|Placebo|Two placebo tablets administered orally twice daily with food for 5 days
45617081|NCT04489381|Dietary Supplement|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
45617082|NCT05241223|Other|Behavior change intervention|This is an online intervention based on the transtheoretical model, along with self-determination theory strategies. This intervention will take place weekly summing up 12 online individual and/or group sessions of approximately 20 minutes. The sessions will be made through a platform and/or application that makes video calls privately. Each session will address a topic. In addition, in all sessions, the patients gain during the previous week will be recognized, as well as new goals will be set for the next week. The goals will always be individualized, realistic and achievable, based on the identification of each person's capacity and motivation. A Fitbit Zip will be used to propose objective goals aimed at increasing physical activity and reduce sedentary behavior. Additionally, a complex practice environment will be created around this device, such as the visualization of the number of steps evolution and competitions/games with other participants, among others.
45617083|NCT05241223|Other|Educational program|The educational program will be delivered similarly to both groups through videos and booklets, which will be sent in all weekdays during de first week after the initial assessment. Later, one educational material will be sent every two weeks until de 11th week. In the first day, patients will receive a quick welcome video call, in which information will be provided on how this program will work. In the subsequent days, the material will be sent daily and the participants will be able to ask questions, if they want to. The program will cover information regarding the respiratory system, pathophysiology of asthma, asthma treatment, prevention strategies and medication instructions. It will also be briefly addressed the subjects: understanding physical activity and sedentarism, as well as the importance and benefits of being physically active and less sedentary.
45617084|NCT04489849|Drug|Apixaban 2.5 MG|apixaban 2.5mg BID for 3 months in experimental group
45617085|NCT04489849|Other|Active Control|Medication other than anticoagulation
45617086|NCT03296449|Procedure|CPAP|A recruitment maneuver will be applied to the ventilated lung. Immediately continuous positive airway pressure, at a pressure of 2-3cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP).
45617087|NCT03296449|Procedure|HFJV|A recruitment maneuver will be applied to the ventilated lung. Immediately, high-frequency jet ventilation, with a driving pressure of 0.5 atm and a respiratory rate of 100 cycles per minute will applied to the non-ventilated lung for 20 minutes using the Monsoone III Jet Ventilator (Acutronic, Hirzel, Switzerland). Monsoone III is a recognised ventilator design for HFJV.
45617088|NCT04488367|Drug|Tranexamic acid|10 mg/kg IV TXA in the ED, repeat doses before skin incision and in PACU
45617089|NCT04488367|Drug|Normal Saline|100 mL 0.9% normal saline in the ED, 10 mg/kg IV TXA before skin incision and in PACU
45617090|NCT03265873|Other|Systematic consideration of the advice of the ENT surgeon in the determination of the radiotherapy target volumes in head and neck cancers.|The contouring of the different target volumes will be first performed by the radiotherapists. During the Head and Neck Tumor Board, the volumes initially determined by the radiotherapists will be analyzed jointly by the radiotherapists and the patient's ENT surgeon to carry out, if necessary, modifications, taking into account clinical observations, intraoperative findings (if any) and endoscopy findings. Concordance parameters will be calculated in a second time with the determined volumes (in particular, index of concordance, coefficient of similarity).
45617091|NCT03296293|Other|PEEP at 5cmH2O|Effect of PEEP at 5cmH2O on ICP
45617092|NCT03296293|Other|PEEP at 10cmH2O|Effect of PEEP at 10cmH2O on ICP
45760508|NCT04724447|Drug|Valganciclovir|2 x 450mg VGCV tablets
45760509|NCT04724447|Drug|Placebo|Placebo equivalent of 900mg/day VGCV
45617093|NCT03296293|Other|PEEP at 15cmH2O|Effect of PEEP at 15cmH2O on ICP
45760510|NCT03695601|Other|Standard of Care|Other Standard measures for monitoring rejection: Endomyocardial Biopsy, Echocardiogram, Angiography, Intravascular Ultrasound, Donor-specific HLA Antibody
45760511|NCT04693715|Drug|RNS60|RNS60 injection solution
45760512|NCT04693715|Drug|Placebo|Placebo injection solution
45760513|NCT04679675|Other|Usual Care|Subjects will receive Kaiser Permanente Washington standard of care.
45760514|NCT04679675|Behavioral|Education|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening.
45760515|NCT04679675|Behavioral|Direct Mail|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will also receive an insert describing the home-based cervical cancer screening option and that a kit will be sent within 1 week. An HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.
45911613|NCT05778058|Diagnostic Test|Polar H10|RR times transferred to computer with Polar H10 are used in heart rate variability analysis. Heart rate data will be transferred to the Kubios program and heart rate variability parameters will be calculated and data on the autonomic nervous system (RMSSD, PNS index, Stress index, SNS index, pNN50, Power LF, Power HF and LF/HF ratio) will be obtained.
45911614|NCT05778058|Device|Vagustim Device|Vagustim Health Technologies Vagus stimulator device is used for this experiment.
45452283|NCT02262052|Other|MRDTI|MRDTI is primary diagnostic test for management of suspected ipsilateral DVT
45617094|NCT03734653|Drug|Transdermal Testosterone|Patients will be prescribed 2 packets of testosterone gel 1% containing 50mg per packet to apply transdermally daily.
45617095|NCT03734653|Drug|Standard of Care, Enzalutamide|Patients will take four 40mg capsules of enzalutamide for a total daily dose of 160mg.
45617096|NCT03296215|Other|Observational|To determine different patterns of admission and their Outcome
45617097|NCT03108391|Device|Ambu AuraGain|
45617098|NCT03108391|Device|LMA Supreme|
45617099|NCT04489459|Drug|Colistin|Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h
45617100|NCT04489459|Drug|Meropenem|Intravenous meropenem 2 g IV infusion over 30 minutes q8 h
45617101|NCT04489459|Drug|Tigecycline|Intravenous Tigecycline 100 mg IV infusion over 1 hour loading dose followed by maintenance dose 50 mg IV infusion over 1 hour q12
45617102|NCT03296137|Biological|Autologous tumor-infiltrating lymphocytes|Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion.
45445706|NCT03761589|Behavioral|Wait-List Control|Families that were randomly assigned to the wait-list control group were asked not to change their normal physical activity or dietary behaviors for the duration of the 12-week waiting period. They were asked to participate in the baseline and 12-week evaluations and then they were enrolled to receive the 12-week intervention.
45617103|NCT03296137|Drug|Ipilimumab|One treatment with ipilimumab (3 mg/kg) prior to tumor resection.
45445707|NCT02065726|Dietary Supplement|Whey protein|Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician + 20 g (2 x 10 g) of whey proteins
45617104|NCT03296137|Drug|Nivolumab|4 doses of nivolumab. Starting 2 days prior to TIL infusion and every 2 weeks hereafter.
45617105|NCT03296137|Drug|proleukin|2 MIE s.c. injection, after TIL infusion and continuing for 2 weeks
45760516|NCT04679675|Behavioral|Opt-in|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will receive an Opt-in Insert describing the home-based cervical cancer screening option and how to request a kit. Individuals can request a kit by phone or through a webpage. Individuals who request a kit will receive the HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.
45760517|NCT03677739|Other|Informational Intervention|Receive information focusing on skin cancer
45760518|NCT03677739|Other|Informational Intervention|Receive information on healthy lifestyle
45617106|NCT03296137|Drug|Cyclophosphamide|2 doses (60 mg/kg) prior to TIL infusion
45617107|NCT03296137|Drug|Fludara|5 doses (25 mg/m2) prior to TIL infusion
45617108|NCT03295903|Dietary Supplement|Cannabidiol supplement|Subjects will be administered in a double-blinded, randomized and cross-over design
45617109|NCT03290833|Device|Robotic|Participants will be placed in the robot and practice common hand tasks involving single finger range of motion exercise, grasping, and pinching objects.
45617110|NCT03290833|Other|Conventional therapy|An occupational therapist will provide one-on-one individualized programs focused on arm and hand function. Treatment will include function-oriented specific tasks, such as reach, grasp, transport and release of various objects between different targets.
45617111|NCT03290755|Behavioral|semi-directed interviews|semi-directed interviews in order to collect socio-behavioral data
45617112|NCT03290677|Procedure|Cryoablation|This involves passing a special needle into the body (cryoprobe) to freeze tumor and kill a small part (not all) of the cancer. The immune system will respond to the damage caused by freezing part of the tumor.
45760519|NCT03677739|Other|Survey Administration|Ancillary studies
45760520|NCT03955913|Other|Archival Tumor Tissue Sample|Percentage of participants with UC and selected FGFR aberrations will be assessed through molecular testing of their archival tumor tissue.
45760521|NCT00355641|Drug|Ropinirole Extended Release (XR)|Dose range of Ropinirole XR of 0.5mg to 6.0mg daily
45911615|NCT05778032|Other|Multidisciplinary metabolic rehabilitation program|Multidisciplinary metabolic rehabilitation program with a duration of 3 weeks
45445708|NCT02065726|Other|Nutritional counseling|Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician
45445709|NCT03767439|Drug|Vismodegib|150 mg PO daily
45617113|NCT03290677|Procedure|Biopsy|Removing a small piece of the affected area to confirm cancer
45617114|NCT03192007|Device|Magnetic Resonance Imaging|Investigate anatomic and functional characteristics of transplant kidneys using MRI
45617115|NCT02460913|Procedure|Acupuncture|Acupuncture session of 20 to 30 minutes. Treatment protocols were determined through review of major clinical manuals and textbooks, literature review, and a panel of specialist acupuncturists from Chinese medicine backgrounds.
45617116|NCT02460913|Drug|Morphine titration|Patients in this group received IV titrated morphine. Morphine was prepared onsite and diluted in a manner to obtain a dose of 1mg in each ml of normal saline. The initial dose was 0.1 mg per kg and a titration dose of 0.05 mg per Kg was repeated every 5 minutes until reaching objective. The maximum allowed dose was 1.5 mg/kg.
45617117|NCT04444999|Procedure|Carbon Dioxide Angiography|• Automated carbon dioxide angiography: Patients are placed in the Trendelenburg position with the feet elevated of 10 º degrees. Carbon Dioxide automatic injection will be performed by digital Angiodroid injection system
45617118|NCT02973997|Other|Laboratory Biomarker Analysis|Correlative studies
45760522|NCT04624763|Procedure|Left bundle branch pacing|"LBBP is defined if fulfilling criterion 1 and at least one in criteria 2:~Paced morphology of RBBD in surface lead V1 (QR, Qr, rSr', rSR' or Qrs);~One of the following should be met:~Selective LBBP with an iso-electrical window between the pacing spike and QRS onset;~If using dual-lead method with one at His-bundle and the other at LBB region, a retrograde His-bundle potential is recorded from His-bundle lead during LBBP;~LVATs at lead tip pacing of 1.5V/0.5ms and 10V/0.5ms are ≤ 80ms and the difference is < 10ms;~A discrete LBB potential is recorded from lead tip and LVAT at tip pacing of 3V/0.5ms is ≤ 80ms19.~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be left ventricular septal pacing (LVSP)."
45760523|NCT04624763|Procedure|Right ventricular pacing|Implantation of a RV pacing lead is attempted using the standard-of-care technique first.
45760524|NCT05268237|Drug|Liraglutide|Sublingual or subcutaneous liraglutide
45760525|NCT05268237|Drug|Placebo|Sublingual placebo
45617119|NCT02973997|Drug|Lenvatinib|Given PO
45617120|NCT02973997|Drug|Lenvatinib Mesylate|Given PO
45617121|NCT02973997|Biological|Pembrolizumab|Given IV
45617122|NCT01174225|Device|Flexi T 380(+) IUD|The intrauterine device is placed in the uterus immediately post-abortion. Participant is counseled that she may leave the device in for up to five years.
45617123|NCT01174225|Device|Nova T IUD|The intrauterine device is placed in the uterus immediately post-abortion. Participant is counseled that she may leave the device in for up to five years.
45445710|NCT03767439|Drug|Nivolumab|480 mg IV every 4 weeks
45760526|NCT00356733|Drug|Erythropoietin administration|50 IU/kg/week EPO to a target haemoglobin level of 13.7 g/dL for men and 13.4 g/dL for women (group A) or to a target comparable to starting hemoglobin level (group B)
45760527|NCT04591925|Device|Control Device insulin infusion devcie|Control Device - Commercially available insulin infusion device using a soft Teflon indwelling cannula
45760528|NCT04591925|Device|Investigative insulin infusion devcie|Investigative insulin infusion device with coil-reinforced soft polymer indwelling cannula
45760529|NCT03642795|Other|Questionnaire|Patients are asked to complete several questionnaires
45617124|NCT04331119|Drug|Duvelisib|SecuraBio will supply duvelisib
45617125|NCT04331119|Procedure|Peripheral blood draw|-Prior to transplant, cycle 1 day 1 of duvelisib, and at the time of all imaging studies
45617126|NCT04326049|Device|LLETZ with videocolposcope|Loop procedure using a videocolposcope in order to see and remove the abnormal cervical tissue
45760530|NCT04542473|Drug|Pancreatic Enzyme|CREON micro 5000
45760531|NCT04542473|Drug|Ursodeoxycholic acid|Ursodiol C24H40O4 suspension
45760532|NCT04542473|Other|Pancreatic Enzyme placebo|Microcrystalline Cellulose,Macrogel 4000, Iron Oxide Yellow, Iron Oxide Red, Activated Charcoal.
45760533|NCT04542473|Other|Ursodeoxycholic acid placebo|Sodium Citrate Dihydrate, Aspartame, Carboxymethylcellulose Sodium, Citric Acid Monohydrate, Dispersible Cellulose, Glycerol, Polysorbate-80, Saccharin Sodium,Sodium Benzoate, Sodium Methylparaben, Sodium Propylparaben
45760534|NCT04166019|Behavioral|Peer-led self-management program|The program based on completion of a self-management workbook, consisting of the main components: personal recovery goals, plans to re-establish community functioning and support networks following a crisis, identifying early warning signs and creating a relapse prevention plan, and strategies and coping resources to problem-solving and maintain well-being.
45760535|NCT04166019|Behavioral|Psycho-education group|The psycho-education group program is comprised of six components: introduction and goal-setting; basic understanding of psychosis and symptom and emotion self-care; education workshop of psychosis care, treatment and community support services; learning about self-care skills; establishing social support and effective coping skills; and skills practices, review and future plan.
45760536|NCT04166019|Behavioral|Usual care|Routine care services consist of monthly psychiatric consultation and treatments prescribed by psychiatrist, nursing advice on community care, brief education (1-2 hourly sessions) about mental illness/treatments by psychiatric nurses, home visits by case managers, and/or referrals to community/welfare services.
45617127|NCT04326049|Device|LLETZ with binocular colposcope|Loop procedure using a binocular colposcope in order to see and remove the abnormal cervical tissue
45760537|NCT05249907|Other|Massage|"Stroking (stroking) movement will be performed on the soft tissue parallel to the muscle fibers on the origo and insertion lines. Vaseline will be preferred as an intermediate to increase the lubricity of the instrument. The frequency of patting and friction movements will be 60 repetitions per minute.~Starting from the medial side of the gastrocnemius (calf) muscle in both legs and moving it longitudinally from distal to proximal and from back to distal in a straight line within 20 seconds, for 2.5 minutes. Then this treatment will be applied to the lateral side of the gastrocnemius muscle for 2.5 minutes."
45617128|NCT03290599|Other|Mini Mental and Modified Mini Mental Test|Mini Mental Test was used for literate patients and Modified mini mental test was used for illiterated patients
45617129|NCT03295825|Diagnostic Test|Biomarker|Measument of heparin-binding protein in the serum of patients
45617130|NCT03290443|Drug|Enasidenib|100 mg enasidenib (CC-90007)
45617131|NCT03290365|Drug|platelet rich plasma + Hyaluronic acid|Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee.
45617132|NCT03290365|Drug|platelet rich plasma + normal saline|The normal salin as the placebo intervention was injection control group.
45617133|NCT02832505|Other|No intervention but only observational|This study is a cross-sectional and observational MRI study with three cohorts of patients, and no interventions will be applied.
45617134|NCT02831335|Other|MRI|Perform MRI studies
45617135|NCT02831335|Other|MRI|Perform MRI studies
45617136|NCT02831335|Other|MRI|Perform MRI studies
45617137|NCT02831335|Other|Group 4|Perform MRI studies
45617138|NCT04489069|Diagnostic Test|MRI|Magnetic Resonance Imaging (sturctural MRI, fMRI resting state and task related, DTI)
45445711|NCT03767439|Drug|Ipilimumab|1 mg/kg IV every 6 weeks
45445712|NCT02063932|Other|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
45617139|NCT04489069|Diagnostic Test|Clinical and Neuropsychological evaluations|Clinical interviews and neuropsychological tests (paper/pencil and computer based)
45617140|NCT04489069|Diagnostic Test|Drawing DNA sample|Saliva sample
45617141|NCT02764489|Biological|FEIBA|Anti-inhibitor Coagulant Complex Nanofiltered (activated prothrombin complex concentrate [APCC]), FEIBA NF.
45617142|NCT04488991|Other|Cervical Cancer Rate|In the end of the Research, we will compare cervical cancer rates between groups
45617143|NCT02462161|Drug|Insulin aspart|Participants will administer 20 IU insulin aspart two times per day with an intranasal delivery device.
45617144|NCT02462161|Drug|Placebo|Participants will administer placebo two times per day with an intranasal delivery device.
45617145|NCT03290053|Drug|SonoVue|SonoVue-infusion over 1 hour
45617146|NCT03290053|Drug|Sodium chloride|Placebo
45617147|NCT03290053|Procedure|Transcranial Ultrasound|Transcranial ultrasound aimed at the blockage
45617148|NCT03290053|Procedure|Sham Transcranial Ultrasound|Placebo - machine is attached, but not active
45617149|NCT04441645|Other|Acupressure|acupressure once per day, five times per week, a total of 12 weeks
45617150|NCT03295591|Diagnostic Test|Circulating tumor cell|Circulating tumor cell enumeration and sequencing
45617151|NCT03289975|Other|pulmonary ultrasound|Collect the aeration profile for each lung quadrant: profile A, profile B1, profile B2, profile C. Calculate the aeration score from O to 36 (LUS (Lung ultrasound) score).
45617152|NCT03289897|Diagnostic Test|LiverMultiScan|LiverMultiScan is an imaging technique which is able to identify early liver disease.
45617153|NCT03289819|Drug|Pembrolizumab|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w. After the 25th patient has started trial treatment, all further included patients will receive 1 cycle of pembrolizumab i.v. 200 mg q3w monotherapy followed by 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w.
45617154|NCT03289819|Drug|nab-paclitaxel|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
45617155|NCT03289819|Drug|Epirubicin|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
45617156|NCT03289819|Drug|Cyclophosphamide|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
45617157|NCT02001623|Drug|Tisotumab Vedotin (HuMax-TF-ADC)|
45617158|NCT03373331|Behavioral|Emotional Processing Training|Participants in the experimental group will receive computerized exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
45617159|NCT03373331|Behavioral|Placebo Control Exercises|Participants in the control group will receive computerized control exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
45617160|NCT02713867|Biological|Nivolumab|
45617161|NCT03123965|Drug|glecaprevir|Glecaprevir will be administered orally.
45445713|NCT03771495|Other|Joint Mobilization|Manual Therapy Intervention, commonly used by physiotherapists
45445714|NCT03771495|Other|Laying on of Hands|Sham Hip Joint Mobilization
45445715|NCT04539405|Device|To evaluate sevoflurane consumption when using Memsorb|Sevoflurane administration at 0.2L.min-1 (minimal gas flow)
45445716|NCT04539405|Device|To evaluate sevoflurane consumption when using classical Dräegersorb|Sevoflurane administration at 2L.min-1 (classical gas flow)
45445717|NCT03767361|Biological|packed red blood cells transfusion|packed red blood cells transfusion
45445718|NCT03761433|Device|SPI group|All patients applied surgical pleth index at the time of surgical incision, under End tidal Sevoflurane 3%
45445719|NCT01321281|Dietary Supplement|AquaCal|"AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.~The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg)."
45617162|NCT03123965|Drug|pibrentasvir|Pibrentasvir will be administered orally.
45617163|NCT03373175|Device|Basal record|Basal EMG record will be performed during 5 minutes. This record must be the same in both ventilators.
45617164|NCT03373175|Device|PS 10 record|PS 10 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
45617165|NCT03373175|Device|PS 15 record|PS 15 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
45445720|NCT01321281|Dietary Supplement|AquaPT|"AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.~The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract."
45617166|NCT03373175|Device|PS 20 record|PS 20 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
45617167|NCT03373019|Drug|Chidamide combined with R-GDP|Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
45617168|NCT03372785|Drug|aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
45617169|NCT03372785|Device|coronary wires. stents or coronary balloons|all species of drug-eluting stent ((such as Xience, Endeavor, Resolute) implantation or balloon expansion (POBA)
45617170|NCT03295513|Other|Veneered zirconia|he use of veneered zirconia is well documented in the literatures as successful restoration modality. A two Clinical performance of two different CAD/CAM-fabricated ceramic crowns revealed no chipping for veneered zirconia
45617171|NCT03295513|Other|Monolithic zirconia|Monolithic zirconia product presented a new generation of polycrystalline material by which full anatomical crowns and bridges can be produced
45617172|NCT00985205|Dietary Supplement|Enteral Glutamine|0.5g/kg/day powdered glutamine to be mixed in with water and given via nasogastric or feeding tube q4 hrs or TID or QID if po.
45617173|NCT00985205|Dietary Supplement|Placebo|Maltodextrin mixed with water given via NG or feeding tube Q 4 hours or TID or QID if po.
45617174|NCT03295435|Other|Composition of functional tooth units|"Composition of functional tooth units measured by trained oral health therapists and was categorised into 3 groups:~Group A: Natural units only Group B: Natural & Prosthetic units present Group C: No natural units present"
45617175|NCT04526873|Behavioral|Postcard|Mailed
45445721|NCT03761199|Other|whole body cryostimulation|In this research project will be performed 15 treatments in cryogenic chamber (1 once a day, every day, with a break on Saturdays and Sundays). Cryostimulation will be conducted in a cryochamber located in the Małopolska Cryotherapy Centre in Kraków, Poland (Polish: Małopolskie Centrum Krioterapii). The whole body cryostimulation (WBC) exposure will be administered in a special temperature-controlled unit which consists of two rooms (-60° and -120°C). Throughout the session, the participants will be under direct supervision of qualified doctor.
45617176|NCT04526873|Behavioral|Phone call|May be automated or by human
45760538|NCT04139733|Procedure|Prone positon|Prone position within 6 hours after randomization. Prone position for at least conservative hours per days during a minimum of 5 days.
46069058|NCT04525274|Drug|Ketamine|"At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of the study drug(40 ml bupivacaine 0.25% + 0.5 mg/kg ketamine diluted in 5 ml normal saline) will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure."
46069059|NCT04513483|Device|continuous positive airway pressure|CPAP treatment at night. Treat AF as cardiologist's discretion.
46069060|NCT04513483|Device|Placebo|Observation. Treat AF as cardiologist's discretion.
45617177|NCT04526873|Behavioral|Humor/Salience|Funny cartoon + health risk examples
45617178|NCT04526873|Behavioral|Telehealth|Information about video visit
45617179|NCT03289663|Drug|synergistic combination of insecticides|third generation insecticide -treated bednets
45617180|NCT03289663|Drug|Pyrethroids|Conventional insecticide
45760539|NCT04139733|Procedure|Supine positon|Conventional supine position ventilation, no prone position.
45760540|NCT05158595|Other|Exergaming low intensity group|wobble board-based Exergame balance training, the game intensity will be low for this group (Size of goal will be kept small for 3 times a week, 30 minutes per day for 8 weeks.
45760541|NCT05158595|Other|Exergaming moderate intensity group|Wobble board-based Exer- game balance training, the game intensity will be moderate for this group (size of goal will be kept medium).for 3 times a week, 30 minutes per day for 8 weeks.
45760542|NCT05158595|Other|Exergaming high intensity group|Wobble board-based Exer- game balance training, the game intensity will be moderate for this group (size of goal will be kept high).for 3 times a week, 30 minutes per day for 8 weeks.
46069061|NCT04507503|Drug|TAS-120|Futibatinib 20mg QD orally on a 28 days cycle
46069062|NCT04503668|Drug|Ondansetron|8 mg IV or 16 mg by mouth on day 1 pre-chemotherapy; then 8 mg by mouth twice a day on days 2-4 of chemotherapy
45445722|NCT02794870|Biological|RSV LID ΔM2-2 1030s vaccine|10^5.0 PFU; administered as nose drops
45445723|NCT02794870|Biological|Placebo|Isotonic diluent, administered as nose drops
45617181|NCT03372629|Drug|ID-085|Hard gelatin capsules for oral administration formulated in strengths of 10 mg, 100 mg, and 200 mg
45617182|NCT03372629|Drug|Placebo oral capsule|Placebo capsules matching ID-085 capsules
45760543|NCT05158595|Other|control group exergaming|Exer games training with soccer heading and penguin slide games(Wii Fitt balance games) for 3 times a week, 30 minutes per day for 8 weeks.
46069063|NCT04503668|Drug|Dexamethasone|20 mg IV on day 1 pre-chemotherapy
46069064|NCT04503668|Drug|Neurokinin-1 Receptor Antagonist (NK1-RA)|150 mg IV on day 1 pre-chemotherapy
46069065|NCT04503668|Drug|Olanzapine|5 mg by mouth on days 1-4 of chemotherapy (taken at night)
46069066|NCT04503668|Drug|Compazine|5-10 mg by mouth, available as needed, every 6 hours, days 1-5
45617183|NCT02519933|Procedure|mNT-BBAVF|mNT-BBAVF was performed under local anesthesia. A transverse incision of approximately 4 cm was made in the antecubital area. The basilic vein was isolated, and its side branches were ligated; followed by the isolation of brachial artery. A venotomy of 5 mm was performed, followed an arteriotomy of 5 mm. The two vessels then had a side-to-side anastomosis, followed by the ligation of the vein above anastomosis. All the perforating veins located in an area 2-4 cm down the antecubital fossa from anastomosis were separated and ligated carefully. After surgeries, all patients will be followed up for 12 months. The outcomes are patency (primary unassisted patency and secondary), complications and hemodynamic parameters (diameters, blood velocities and blood volume) detected by Ultrasound.
45617184|NCT02519933|Procedure|BCAVF|BCAVF was performed under local anesthesia. A transverse incision of approximately 4 cm in length was made in the medial antecubital area. The cephalic vein was isolated, followed by the isolation of brachial artery. The distal end of cephalic vein was ligated and dissected. Patency of the proximal vein was verified by the warmed saline injection. The artery was then incised after clamping, and an end-to-side anastomosis (4-0 silk suture) between the cephalic vein and the brachial artery was performed. At last the skin is sutured (1-0 silk suture). At last the skin is sutured. After surgeries, all patients will be followed up for 12 months. The outcomes are patency (primary unassisted patency and secondary), complications and hemodynamic parameters detected by Ultrasound.
45617185|NCT04488835|Other|Electromagnetic field therapy and transcutaneous electrical nerve stimulation|Both groups received conventional physical therapy treatment protocol. Moreover, group (A) has an additional TENS application and group (B) had PEMFS application. TENS and the PEMFT were applied once daily, three times per week for 20 minutes for each session. Assessment performed pre and post intervention using visual analogue scale (VAS) and estimation of the carbamazepine intake (CMI).
45617186|NCT03372473|Drug|Montelukast mixed with Loratadine|Montelukast 5mg mixed with Loratadine 5mg, one dose per day
45617187|NCT03372473|Drug|Montelukast|Montelukast 5mg
45617188|NCT03289429|Drug|Atorvastatin|Atorvastatin in a dose of 80 mgs, twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
45617189|NCT03289429|Drug|Magnesium Sulfate|Magnesium sulfate: ( 3 grams dissolved in 100 mL of isotonic saline to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
45445724|NCT03767205|Device|Ankle Assist Robot|"overground walking in three conditions (with robot-torque on/with robot-torque off/without robot). During overground walking, gait function was measured using motion analysis, sEMG, and force plate~treadmill waking in three conditions (with robot-torque on/with robot-torque off/without robot). During treadmill walking, the metabolic energy expenditure was measured using a portable cardiopulmonary metabolic system (Cosmed K4b², Rome, Italy)."
45617190|NCT03289429|Other|intravenous placebo|100 mL of isotonic saline (to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
45617191|NCT03289429|Other|tablets placebo|Placebo tablets: twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
45617192|NCT03372395|Other|Lactobacillus rhamnosus BMX 54|Given once a day for 10 days, once every 3 days for 20 days and then once every 5 days for other 2 months in all patients (probiotics implementation for 3 months comprehensively).
45617193|NCT03372239|Drug|Indoximod base formulation|Specified dose on specified days
45617194|NCT03372239|Drug|Indoximod HCL (salt) formulation|Specified dose on specified days
45617195|NCT03372239|Other|Placebo|Specified dose on specified days
45617196|NCT03289117|Device|Novel gel installation device procedure|Catheter change with novel device Each subject will undergo catheter change with novel gel instillation device
45617197|NCT03289117|Device|Standard procedure|Catheter change with standard procedure Each subject will undergo catheter change with standard procedure
45617198|NCT03372005|Behavioral|Floorball|This intervention will have one week of testing before the first 12 weeks of floorball, followed by one week of testing before the last 27 week training period.
45617199|NCT03371927|Other|SINC Feeding Protocol|Safe individualized nipple-feeding competence protocol for premature infants
45617200|NCT03294967|Dietary Supplement|Caffeine|As in group descriptions
45617201|NCT03294967|Dietary Supplement|Vitamin E|As in group descriptions
45617202|NCT03371849|Drug|montelukast and levocetirizine FDC|HCP1102
46069067|NCT04503278|Biological|CLDN6 CAR-T/CLDN6 CAR-T(A)|administered as an i.v. infusion.
45445725|NCT02065804|Drug|Bupivacaine|injection, once, 5 min
45617203|NCT03371849|Drug|Singulair + xyzal|HGP0813 + HGP1408
45760544|NCT04290689|Drug|Botulinum Toxin-A injection|Botulinum Toxin-A injection to be administered by the surgeon to the subject's calf muscle as per normal clinical protocol to help improve muscle tone.
46069068|NCT04503278|Biological|CLDN6 RNA-LPX|administered as an i.v. injection at protocol-specified intervals.
45760545|NCT04290689|Procedure|Serial casting stretching|Stretching cast intervention to be carried out in clinic as per normal clinical protocol.
45445726|NCT05423691|Drug|CK0804|CK0804 is a cryopreserved, allogeneic T-regulatory cell product that is manipulated to traffic to the bone marrow.
45445727|NCT02064712|Other|Low CPAP Wean|Infants receive NCPAP by Hudson nasal prongs.
45760546|NCT00801827|Drug|F-18 (fallypride)|Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET)scans of their brains using the radioligand fallypride before and after the operation.
46069069|NCT04502446|Biological|CTX130|CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
45445728|NCT02064712|Other|High CPAP Wean|Infants receive NCPAP by Hudson nasal prongs.
45445729|NCT03767049|Other|Colection of clinical data|Colection of clinical data
45445730|NCT02064010|Drug|SNC-102|Acamprosate calcium (SNC-102) tablet, administered orally for 4 weeks
45445731|NCT02064010|Drug|Placebo|Placebo tablet, administered orally for 4 weeks
46069070|NCT04501445|Behavioral|Written Summary of Rounds|The summary was organized as follows for each of the most important ICU problems: 1) Description of the problem, 2) Ways the ICU team is addressing the problem i.e. consultations, diagnostic tests, and treatments. 3) An assessment of whether the problem is improving or worsening.
45617204|NCT03371771|Behavioral|Volunteer-delivered Behavioral Activation|Behavioral Activation as delivered by trained volunteers
45617205|NCT03371771|Behavioral|MSW-delivered Behavioral Activation|Behavioral Activation as delivered by trained MSWs
45617206|NCT03294889|Radiation|Stereotactic body radition (SBRT)|"Ultra-hypofractionated single-fraction SBRT with urethra-sparing with image-guidance and intra-fractional control motion with the Calypso® system.~19 Gy in a single fraction to the whole prostate gland ± proximal seminal vesicles~17 Gy in a single fraction to the urethra planning-risk volume (PRV)"
45617207|NCT03371693|Device|HIPEC|Patients consenting to this protocol will undergo their scheduled surgical procedure. After cytoreductive surgery (CRS) to a residual disease ≤ 2.5 mm, a single dose of lobaplatin (30 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen technique. HIPEC will be continued for 60 minutes in the hyperthermic phase (43℃±0.5℃). And HIPEC will be repeated at the 3 and 5 day after the day of CRS plus HIPEC.
45617208|NCT03371693|Device|CRS|cytoreductive surgery (CRS) to a residual disease ≤ 2.5 mm.
45617209|NCT03371693|Device|IVCT|platinum-based intravenous chemotherapy
45617210|NCT03288883|Device|Photothermal Non-ablative Erbium:YAG-laser|Laser treatment of the vagina for GSM
45617211|NCT03288883|Device|Fractional Microablative CO2-laser|Laser treatment of the vagina for GSM
45617212|NCT03371537|Procedure|Liver debit measure|Mesure of liver debit during hepatectomy
45617213|NCT02085421|Device|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that has been shown to enhance learning. tDCS is applied with current intensity of 1-2 mA of direct current and can be applied both before and during each cognitive remediation treatment session. Two saline soaked electrode sponges will be applied to the scalp.
45617214|NCT03371303|Other|collection of prescription data|collection of prescription data before and after a hospitalization
45617215|NCT03294811|Device|Telemonitoring|The telemonitoring interference in the telemonitoring arm consists of a smartphone application that helps the patient to take their medication in time and to take their blood pressure and weight on a daily basis in order to improve the medication uptitration and medication compliance.
45617216|NCT03123887|Other|salvage therapy|VDC(L)P regimen or High-dose cytarabine based regimen or High-dose methotrexate based regimen or Hyper-CVAD regimen or FLAG (Flu, Ara-C, G-CSF) ± anthracyclines based regimen or Repeated original induction regimen or VDP or other
45617217|NCT03124043|Other|Livongo for Diabetes program|See description in arm/group description.
45617218|NCT03294733|Procedure|Ultrasound|This ultrasound machine is owned by the department of orthopaedic surgery and is capable of up to 15 MHz image definition with its linear transducer
45617219|NCT04307329|Biological|Monalizumab|Monalizumab 750 mg every two weeks
45617220|NCT04307329|Biological|Trastuzumab|Trastuzumab 4 mg/kg every two weeks
45760547|NCT04112823|Drug|Dexamethasone 4mg|Dexamethasone 4mg + metoclopramide 10mg, intravenously
45760548|NCT04112823|Drug|Dexamethasone 16mg|Dexamethasone 16mg + metoclopramide 10mg, intravenously
45760549|NCT00802685|Drug|Early ibuprofen|"IBUPROFEN SCHEDULE: initial dose 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy is blinded. At PDA diagnosis, infants randomized to early treatment receive blinded ibuprofen. Infants randomized to late treatment receive blinded placebo. Hemodynamically significant PDA criteria: SIGNS OF PDA + pulmonary hemorrhage OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV. Once hemodynamically significant PDA criteria met, if echo is positive, infants from both groups can receive open label ibuprofen."
45445732|NCT02065960|Radiation|Stereotactic body radiotherapy (SBRT)|
45617221|NCT03290209|Procedure|Laparoscopic D1 Lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic D1 Lymphadenectomy will be performed in the experimental group.
45617222|NCT03290209|Procedure|Laparoscopic D2 Lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic D2 Lymphadenectomy will be performed in the comparator group.
45617223|NCT04526483|Device|Laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D Endoscopic Imaging System|Laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D Endoscopic Imaging System
45617224|NCT04526717|Drug|MPT0B640|Each dose of MPT0B640 will be administrated per Cohort. (15, 30, 60, 80, 100 mg of MPT0B640)
45617225|NCT04295707|Device|orthokeratology|Nightly wear of orthokeratology lenses to correct vision in the daytime
45617226|NCT04295707|Device|Menicon Progent A+B|Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.
45617227|NCT04526327|Other|exercise|the combination of aerobic and resistive exercise, three time a week
45617228|NCT03294655|Behavioral|Pilot Resilience Building Intervention|The intervention will include a brief one-on-one visit in which psychoeducational information on building resilience will be given via a PowerPoint presentation, which will include exercises for the participants to engage in over the following four weeks in their daily lives. After the presentation participants will also develop a personalized intervention plan where they will choose at least five areas of the American Psychological Association 10 Strategies for Building Resilience on which to specifically focus. Participants will also receive a pamphlet of abbreviated information from the PowerPoint presentation.
45617229|NCT03371147|Other|CancerLife|CancerLife is a patient facing messaging app that gives cancer survivors and caregivers the ability to update family and friends of their health status through their existing social networks and at the same collect psychosocial and symptom reports that can be shared with the patients care team.
45617230|NCT03371069|Other|users of methylphenidate|Children and adolescents who are users of methylphenidate, 2010 to 2015
45617231|NCT03294577|Drug|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
45617232|NCT03294577|Drug|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
45617233|NCT03294577|Other|D5W Placebo|Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W
45617234|NCT03294577|Drug|Docetaxel, doxorubicin, and cyclophosphamide (TAC)|Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
45617235|NCT04526015|Procedure|Iliohypogastric and ilioinguinal nerve block|Each patient will receive spinal anesthesia plus bilateral ultrasound-guided IL/IH nerve block. The abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualized between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side
45617236|NCT04526015|Procedure|Controlled Group|Each patient will receive spinal anesthesia alone with no block.
45617237|NCT03370835|Drug|Metoprolol succinate ER|Cardioselective beta-blocker
45617238|NCT03370835|Drug|Carvedilol|Non-cardioselective beta-blocker
45617239|NCT03288571|Biological|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be injected in the renal parenchyma
45617240|NCT04525859|Biological|Safety|See previous Safety group description
45617241|NCT04525859|Biological|Expansion Cohort|See previous Expansion Cohort
45617242|NCT03294421|Procedure|combined access tympanomastoidectomy|Trans canal surgery with the use of a surgical microscope with a rigid endoscope measuring 14cm of length with 0º and 30º angulation allowing better visualization and removal of the cholesteatoma before mastoid debridement. In this surgery, mastoid debridement is conducted only if there was no full endoscopic removal of the cholesteatoma. The other procedures of this type of surgery are similar to the standard tympanomastoidectomy technique.
45617243|NCT03294421|Procedure|standard closed tympanomastoidectomy|"Supine position and general anesthesia with orotracheal intubation~Antisepsis and placing of sterile fields~Local anesthesia of the external auditory canal with lidocaine 2% and adrenaline 1:100. 000 UI~Retroauricular incision~Removal of the temporal muscle fascia~Elevation of the surgical flap of the tympanic meatus~Visualization and exploration of the cholesteatoma~Exploration of the ossicular chain~Mastoid debridement~Conservation of the upper posterior wall of the auditory conduct~Removal of the cholesteatoma~Tympanoplasty with the temporal fascia~Retroauricular suture with vycril 3.0 and mononylon 4.0"
45617244|NCT04526171|Behavioral|Vaparshun|Participants in the intervention clusters were encouraged to improve their existing toilets.
45617245|NCT02460367|Drug|Docetaxel|
45617246|NCT02460367|Biological|Tergenpumatucel-L|
45617247|NCT02460367|Drug|Indoximod|
45617248|NCT03370601|Drug|Infliximab|Infliximab 10mg/kg every 8 weeks
45617249|NCT03370601|Drug|Mercaptopurine|6-mercaptopurine 1 à 1,5 mg/kg
45617250|NCT03370601|Drug|Azathioprine|Azathioprine 2 à 2.5mg/kg/j
45617251|NCT03370601|Drug|Infliximab|Infliximab 5mg/kg every 8 weeks
45617252|NCT03370523|Other|No intervention is planned in our study|No intervention is planned in our study
45760550|NCT00802685|Other|Late ibuprofen expectant group (placebo)|"Drug: Late ibuprofen expectant group (placebo): DOSING SCHEDULE: At PDA diagnosis infants randomized to late ibuprofen expectant group will receive blinded placebo. If hemodynamically significant PDA develops, infants now receive open label ibuprofen at an initial dose of 10 mg/kg, then two doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Signs of a hemodynamically significant PDA include: SIGNS OF PDA + pulmonary hemorrhage ALONE OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due PDA) defined as at least 2 of the following settings: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV."
45617253|NCT03370211|Other|resistance training|Participants from TG performed program, executed in 3 sets of 10-15RM, 3 times per week on Mondays, Wednesdays, and Fridays. The RT program was composed of 8 exercises comprising one exercise with free weights and seven with machines performed in the following order: chest press, horizontal leg press, seated row, knee extension, preacher curl (free weights), leg curl, triceps pushdown, and seated calf raise. All participants were personally supervised by physical education professionals with substantial RT experience to help ensure consistent and safe exercise performance. Participants were instructed to inhale during the eccentric phase and exhale during the concentric phase while maintaining a constant velocity of movement at a ratio of approximately 1:2 seconds (concentric and eccentric phases, respectively). Participants were afforded 1 to 2 min of rest between sets and 2 to 3 min between each exercise. The average duration of each session lasted approximately 50-60 minutes.
45617254|NCT03376529|Drug|SPR741|400 mg IV over 1 hour
45760551|NCT03535857|Device|PTNS|Use of PTNS on the ankle for 30 minutes
45760552|NCT03496623|Drug|Inhaled treprostinil solution|Treprostinil inhalation solution
45760553|NCT03496623|Drug|Placebo solution|Placebo solution
45760554|NCT00802919|Drug|Varenicline|Varenicline 1-2 mg/day
45760555|NCT00802919|Drug|Placebo for varenicline|Placebo
45760556|NCT00802997|Device|Sinergy|radiofrequency denervation
45760557|NCT00802997|Device|Placebo sham|sham procedure
45760558|NCT04537013|Procedure|Microfracture|Debridement of cartilage followed by placement of small holes in the effected area to fill the debrided area with marrow and cells.
45617255|NCT03376529|Drug|Ceftazidime|1.0 gram IV over 1 hour
45617256|NCT03376529|Drug|Piperacillin/tazobactam|4.5 grams IV over 1 hour
45617257|NCT03376529|Drug|Aztreonam|1.0 gram IV over 1 hour
45617258|NCT03370055|Device|LeucoPatch®|LeucoPatch® is an elastic membrane produced by the patients own venous blood by centrifugation, and one or two is placed on the wound once a week The LeucoPatch® consist of the fibrin Leucocytes and growth factors from the patients own blood
45617259|NCT03370055|Other|Control,|Usual wound care in a specialized clinic
45617260|NCT04132661|Drug|Bisacodyl 5 milligram|one single dose
45617261|NCT04132661|Drug|Placebo oral tablet|one single dose
45617262|NCT03369977|Device|BioGlue Surgical Adhesive|BioGlue (produced by CryoLife in Kennesaw, GA) is a surgical adhesive with two components respectively purified bovine serum albumin (BSA) and Glutaraldehyde (their proportions are 4:1). Crosslinked bonds (covalent bonds) of Glutaraldehyde cross-link the protein on the surface of the tissue and the amino residue of the bovine serum albumin. BioGlue also adheres to the synthetic matrix material by a mechanical interlocking mechanism in the space of graft matrix.
45617263|NCT03369977|Other|Traditional Surgical Repair|Traditional surgical repair as determined by the surgeon
45617264|NCT03376373|Behavioral|neurofeedback|real-time feedback on accuracy of emotion recognition
45617265|NCT03369899|Device|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
45617266|NCT03700541|Drug|Morphine|Morphine intravenous
45617267|NCT03700541|Drug|Piritramid|Piritramid intravenous
45617268|NCT01854775|Drug|E/C/F/TAF|Tablets administered orally with food.
45617269|NCT01854775|Drug|E/C/F/TAF (Low Dose)|90/90/120/6 mg STR administered once daily orally with food.
45617270|NCT02460211|Dietary Supplement|Vitamin D3|Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
45617271|NCT02460211|Dietary Supplement|Placebo|Those randomized to the control arm will receive three placebo doses. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
45760559|NCT04537013|Device|Microfracture plus placement of Chondro-Gide® ACC|Debridement of cartilage followed by placement of small holes in the effected area to fill the debrided area with marrow and cells, followed by affixing Chondro-Gide® with fibrin glue.
45760560|NCT04383041|Other|No intervention|Completing questionnaires via ePRO app from their own mobile devices
45617272|NCT03294343|Procedure|salpingo-oophorectomy only by laparoscopy|Salpingo-oophorectomy are provided for carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome). Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
45617273|NCT03294343|Procedure|salpingo-oophorectomy with hysterectomy by laparoscopy|Salpingo-oophorectomy with hysterectomy are provided for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11. Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
45617274|NCT03294343|Other|Follow-up|Detailed multi-disciplinary counseling, decision-making analysis and long-term follow-up are provided for carriers with any mutation genes but refusal to any risk-reducing gynecologic surgeries
45617275|NCT03288259|Procedure|transnasal endoscopy|Transnasal endoscopy without sedation with ultra-thin endoscopes in patients who are candidates for bariatric surgery
45617276|NCT03288259|Drug|Local Anesthetics,Topical|Will be carried out topical anesthesia of the pharynx with lidocaine spray (10%) 6 puffs and instillation of nasal vasoconstrictor 4 drops.
45617277|NCT03288181|Device|Muscle Stretch|The splint will be applied to the affected leg as per the protocol for 30 minutes per day, 5 days per week for 4 weeks.
45617278|NCT03294265|Behavioral|Peer support sessions|"Stages of mourning and motivation Patients introduce themselves, share their experience and mention a strategy on moving on to the next stage Reminder of metabolic control goals Leaders write on the board metabolic variables and ask everybody the goal values. Patients share their results and mention plans to improve them Self-care activities Leaders ask who owns a glucometer, how regularly they use it, its importance and consequences of not doing so.~Simplified meal plan Everyone brings a snack. Leaders ask if each snack is appropriate, how everyone carries out their meal plan, barriers and possible strategies Activities to increase physical activity Everyone compares who achieves 10 thousand steps/day and who doesn't, then mention benefits of exercise"
45617279|NCT03294265|Behavioral|Reminders|"Creation of a group on WhatsApp to send leaders and patients a weekly reminder on the different areas of self-care, such as foot care, self-monitoring, adherence to meal plan, medication and exercise.~This intervention will be applied to both groups."
45760561|NCT04480385|Other|Remote Automated Monitoring System|The patient will be monitored with conventional monitoring devices as well as the MultiSense patch
45760562|NCT04467905|Drug|Etripamil|The formulation of etripamil Nasal Spray will consist of MSP-2017 (etripamil), water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg.
45617280|NCT03294031|Other|Pilates|"Warm-up exercises included Abdominal and costal breathing and Pelvic Clock. Some exercises included in the main part of the mat session were Arm arcs, Curls up, Femur arcs, Shoulder bridge, Leg circles, among others. The main part of the sitting/standing session included in standing position exercises like Standing on one leg with support, Neck rolls, Side leg lift with support and in sitting position Spine stretch 5, Elbows back with hands behind his head, Heel/knee slides, Shoulder drops, Knee folds, among others. In mat sessions, cooling exercises included in standing position Hamstring stretch and Abdominal Breathing and Rest position and in sitting/standing session Stretching and Abdominal Breathing."
46069071|NCT04493606|Other|SCI ProACTIVE Coaching (objective 1)|Peer coaches will conduct an assessment to understand patient's readiness, goals, barriers, preferences, and access to physical activity resources and mutually select tailored physical activity-enhancing strategies based on the assessment. These strategies include education (SCI exercise guidelines, safety, benefits, basics of physical activity, behaviour change techniques) and referral to appropriate peers, programs, and organizations. Goals will be based on the SCI Fitness Guidelines (targeting a goal of 20min of moderate to vigorous intensity aerobic exercise + 3 sets of strength training exercises for each major functioning muscle group at a moderate to vigorous intensity each 2x/week) and if ready, the Canadian SCI Physical Activity Guidelines (30 min 3x/week of moderate to vigorous intensity aerobic exercise + strength training 2x/ week). Ten 15-minute, video-conference or telephone sessions will be scheduled in accordance with patient needs and readiness with the peer coaches.
46069072|NCT04493606|Behavioral|Implementation Intervention (objective 2)|"A training on how to deliver the ProACTIVE intervention will be delivered. Day 1 training will include an overview of the intervention, demonstration of the delivery of the intervention, and behavioural practice. Interventionists will practice delivering the intervention and record issues or questions to bring to the day 2 training. Day 2 training will include a refresher on intervention content, barriers identified during in-clinic/community practice will be addressed, and further behavioural practice with volunteer clients with additional feedback provided.~The trainer (Dr. Jasmin Ma) will provide monitoring and feedback during the first two months of implementation. Community of practice meetings will be held as needed to discuss challenges and facilitators to implementation. Feedback provided during community of practice meetings will be collected and used for iterative quality improvement of the intervention approaches."
45617281|NCT03294031|Other|Conventional Exercise|All sessions started with a 15-minute warm-up phase based on walking performance and joint mobility exercises. It was followed by a 35-minute second phase, which included low-impact aerobics (music tempo was set at 120 beats per minute), gross motor coordination tasks and balance activities. The final 5-minute phase focused on gentle stretching exercises.
45617282|NCT01653925|Other|Dietary intervention first|The dietary intervention will be aimed to increase intake of ω-3 long chain fatty acids and to reduce intake of saturated and trans fatty acids. Three consultations with a nutritionist experienced in clinical trials will be planned over a 6-month period. An additional 2 consultations in the last 6 months with the study nutritionist will be planned for men allocated to the dietary fat intervention arm first. Then, after the 6 months of diet intervention, drug intervention with 5α-Reductase Inhibitor will be add to diet for the 6 following months.
45617283|NCT01653925|Drug|Drug (Dutasteride) intervention first|5α-Reductase Inhibitor will be taken daily in tablet dosage form (0.5 mg) taken orally for 12 months depend of the group. After 6 months of drug intake, dietary fat intervention will be add to treatment for the following 6 months. Three consultations with a nutritionist experienced in clinical trials will be planned over this 6-month period.
46069073|NCT04491071|Diagnostic Test|Generalized Anxiety Disorder-7 (GAD 7)|test that will evaluate persistent and excessive worry about a number of different things. People with Generalized Anxiety Disorder may anticipate disaster and may be overly concerned about money, health, family, work, or other issues. Individuals with Generalized Anxiety Disorder find it difficult to control their worry.
45617284|NCT03287713|Drug|oxygen therapy|conventional nasal prongs vs nasal high flow oxygen during Pulmonary Rehabilitation in Interstitial Lung Disease.
45617285|NCT02730455|Drug|natalizumab|Administered as specified in the treatment arm
45617286|NCT02730455|Drug|Placebo|Matched placebo
45617287|NCT02460757|Other|Laryngoscopy|Observation of glottic width in different arms
45617288|NCT03287479|Procedure|Gavi® Vitrification|A closed, semi-automated vitrification system
45617289|NCT03287479|Procedure|Cryotop® Vitrification|An open, manual vitrification system
45617290|NCT03287401|Device|Electroencephalography|Patients electroencephalogram will be recorded
45617291|NCT03376217|Other|IPTp delivered by HSAs|Pregnant women will have the option to receive IPTp-SP from Health surveillance assistants (HSAs). SP is recommended in Malawi for prevention of malaria during pregnancy, but currently it is only available at antenatal clinics.
45617292|NCT03369587|Behavioral|Handwriting Practice|Self-directed home handwriting practice daily for 6 weeks
45617293|NCT02460523|Procedure|conservative|1- Patients in conservative treatment group will receive medical treatment in the form of antibiotics (3rd generation cephalosporine), analgesics (NSAID eg Ibuprofen) and antispasmodics for 3 days. These patients will be followed up for improvement on the ground of clinical symptoms and serum bilirubin level and abdominal US for CBD stones.
45617294|NCT02460523|Procedure|ERCP|2- Patients in ERCP group will undergo ERCP and wide papillotomy and stone extraction directly then laparoscopic cholecystectomy (LC) within 3 days.
45617295|NCT03376139|Drug|Zonisamide|Zonisamide capsules titrated to a maximum tolerated dose of 400 mg/day for 35 days +/- 4 days, followed by a 14 day down-titration period.
45760563|NCT04467905|Drug|Placebo|The formulation of placebo will consist of water, sodium acetate, disodium, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid to reproduce the same pH as the etripamil formulation.
45617296|NCT03376139|Drug|Placebo Comparator|Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
45760564|NCT04447313|Other|Survey Administration|Ancillary studies
45760565|NCT04447313|Behavioral|Telephone-Based Intervention|Receive ACT telephone coaching
45760566|NCT04447313|Behavioral|Telephone-Based Intervention|Receive SBT telephone coaching
45760567|NCT04429919|Drug|AP-325|During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
45617297|NCT03369275|Biological|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|Cryopreserved Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
45617298|NCT03369275|Other|Placebo|Placebo, with excipients, will be administered intravenously.
45617299|NCT03293875|Behavioral|Encuentro|a behavioral intervention designed to increase HIV testing rates and reduce behaviors that place individuals who use drugs at risk of contracting HIV
45617300|NCT03287323|Other|Proactive Palliative Care|In the intervention part of the study, enrolled patients will be offered a set of different palliative care interventions, including symptom management, advance care planning, palliative physiotherapy, social and spiritual support, communication with patients and caregivers, in addition to standard intensive care.
45617301|NCT03287167|Drug|1 month DAPT|Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 1 month, after which patients will be given ASA and placebo in next 5 months and then continue on monotherapy with ASA only, unless contraindications for ASA emerge.
45617302|NCT03287167|Drug|6 months DAPT|Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 6 months, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
45617303|NCT04440449|Behavioral|Lifestyle App|A mobile app used to assist with lifestyle changes
45617304|NCT04440449|Behavioral|Look AHEAD behavior lifestyle intervention|A modified Look AHEAD behavior lifestyle intervention with smartphone-based self-monitoring of diet and physical activity
45617305|NCT04440449|Behavioral|Abbreviated Look AHEAD behavior lifestyle intervention|An abbreviated Look AHEAD behavior lifestyle intervention with smartphone-based self-monitoring of diet and physical activity
45617306|NCT03293797|Behavioral|Abbreviated-Mindfulness-based Therapy|A-MBT will be delivered in group format, 120 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
45617307|NCT04403789|Other|Exercise Time|Employees will be provided with exercise time of 2 hours per week. The 2 hours should be used in two days. The intervention duration is 12 weeks.
45617308|NCT04403789|Behavioral|Supervised Group Exercise|The intervention group will receive 2-hours of exercise sessions per week under the supervision of a certified trainer in the gym workplace. The intervention duration is 12 weeks.
45617309|NCT03299023|Other|Medibyte Portable Monitor|Patients will be provided with the portable monitor in order to measure their apnea/hypopnea index.
45617310|NCT03293719|Device|BPK-S Integration UC|Primary Knee Endoprosthesis
45617311|NCT03369119|Drug|Montelukast 4 Mg Oral Granule|
45617312|NCT03369119|Drug|Placebos|
45617313|NCT03287011|Other|Shoplaq toothpaste|"ACTIVE INGREDIENT Sodium Monofluorophosphate 1000 PPM INGREDIENTS Precipitated Calcium Carbonate, Sorbitol, Glycerin, Precipitated Silica, Sodium Carboxy Methyl Cellulose, Sodium Benzoate, DM Water, Colour CI-45410, Holy Basil Oil, Neem Oil, Citrus Oil, Thymol Oi, Clove Oil, Piper Betel Leaf Oil, Tea Tree Oil, Eucalyptus Oil, Peppermint Oil, Spearmint Oil.~Dye containing tooth paste for disclosing plaque and efficient brushing for better oral health."
45617314|NCT03287011|Other|Colgate toothpaste|fluoridated
45617315|NCT04385537|Dietary Supplement|PECAN|Raw pecan halves without other changes to their habitual diet.
45617316|NCT03286933|Behavioral|yoga|75 minute weekly group yoga classes for 8 weeks. Home program online.
45617317|NCT03375983|Biological|Blood-stage infection of P.vivax|The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
45617318|NCT03293641|Dietary Supplement|Zinc Sulfate Tablets|Zinc Sulfate Tablets 3 times every 7 days for 6 months.
45617319|NCT03293641|Drug|Standard of Care|Folic Acid, Proguanil, Penicillin V, Hydroxyurea over 6 months
45617320|NCT03375905|Device|cNEP|subjects with OSA will be treated with the cNEP device with the goal of reducing the number of apneas and hypopneas
45617321|NCT02460601|Drug|Qizhiweitong granule|
45617322|NCT02519543|Drug|Placebo|Placebo to be given twice daily, once with breakfast and once with supper
45617323|NCT02519543|Drug|Metformin|Active experimental drug to be given twice a day, 1000 mg with breakfast and 1000 mg with supper
45617324|NCT03286855|Device|Vibrating Mesh Nebuliser|The Aerogen Ultra vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.
45617325|NCT03286855|Device|Standard Hospital Care|"The standard hospital care refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications. This is the Hudson micromist small volume nebuliser."
45617326|NCT03293407|Drug|Iloprost (Ventavis, BAYQ6256)|Using Breelib device
45617327|NCT03293407|Device|Breelib nebulizer|Used for inhalation of Ventavis
45760568|NCT04429919|Drug|Placebo|During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
45617328|NCT02519699|Drug|norepinephrine|Increase in mean arterial pressure using norepinephrine
46069074|NCT04491071|Diagnostic Test|Background questionnaire|questionnaire on the living conditions, socio-professional contexts and environmental conditions of the participants
46069075|NCT04491071|Diagnostic Test|Impact of COVID-19 questionnaire|status of the patient with regard to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus)
46069076|NCT04491071|Diagnostic Test|Confinement and Communication During the COVID-19 Pandemic|know the experience of containment and isolation during the pandemic
45617329|NCT03286777|Dietary Supplement|Placebo|Mannitol and silicon dioxide capsules
45617330|NCT03286777|Dietary Supplement|Native 6-prenylnaringenin|250 mg native 6-PN plus mannitol and silicon dioxide capsules
45617331|NCT03286777|Dietary Supplement|Micellar 6-prenylnaringenin|250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant capsules
45617332|NCT02519465|Other|10l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher & Paykel healthcare, New Zealand) and nasal cannula (Fisher & Paykel healthcare, New Zealand) with flow 10l/min
45617333|NCT02519465|Other|30l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher & Paykel healthcare, New Zealand) and nasal cannula (Fisher & Paykel healthcare, New Zealand) with flow 30l/min.
45617334|NCT02519465|Other|50l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher & Paykel healthcare, New Zealand) and nasal cannula (Fisher & Paykel healthcare, New Zealand) with flow 50l/min.
45617335|NCT00701311|Drug|CC-10004|CC-10004 20 mg per day
45617336|NCT03368885|Other|Maternal dietary diversity|Counsel pregnant women for proper dietary intake and create awareness among family members and community to support her on maternal nutrition
45617337|NCT03368885|Other|Diet diversity in complementary feeding|Counsel mothers of children of 6-23 months on diet diversity in complementary feeding by demonstration during home-visits and seek support from father and family members
45617338|NCT03368885|Other|Exclusive Breast Feeding|Counselling on exclusive breast feeding among children under 6 months-Provide information to mothers of children of 3-6 months for exclusive breast feeding through home visits, and mothers meetings
45617339|NCT03368885|Other|Community mobilization|Engagement of local/religious leader, husbands to support diet diversity for pregnant women and doctors and fathers to support diet diversity for complementary feeding
45617340|NCT03368885|Other|Capacity Building|Capacity Building-Training of Community mobilization coordinator and mentoring for knowledge enhancement on nutrition for pregnant women and children below 2 years
45617341|NCT03368885|Other|Use of existing platforms VHSND|Convergence- Strengthen Village Health Sanitation and Nutrition Day for creating awareness on diet diversity for maternal nutrition and complementary feeding
45617342|NCT03368885|Other|Strategic use of data|Strategic use of data-Data analysis for concurrent monitoring,planning and decision making to improve the performance of CMCs
45617343|NCT03293329|Other|Diaphragm manual therapy techniques|3 diaphragm manual therapy techniques performed by a physical therapist are employed in this experimental group during 10 minutes. The participants are situated in a seated, supine and side bending position.
45617344|NCT03293329|Other|Diaphragm mobilization through active hipopressive gymnastic exercise|Diaphragm mobilization through active hipopressive gymnastic exercise in two different postures: standing and standing bending forward.
45911616|NCT05778019|Other|Case Scenarios of complications to be ranked / classified according to classifications (for the severity grading of events)|Test the feasibility, applicability and logic of a novel instrument for the grading of unexpected events in pediatric surgery (Clavien-Madadi classification) compared to the Clavien-Dindo classification for the grading of postoperative complications in general surgery
45617345|NCT03293329|Other|Ischemic compression techniques in shoulder myofascial trigger points|Ischemic compression techniques in infraespinatus and supraespinatus myofascial trigger points during one minute each muscle. The pressure increases gradually until the individual feels a tolerable pain.
45617346|NCT03375749|Behavioral|Standing desk intervention|Standing desk converter
45617347|NCT03375749|Behavioral|Waitlist control|Control
45617348|NCT03293251|Procedure|Trabeculectomy with MMC|glaucoma surgeries
45617349|NCT03375671|Drug|Ketalar|single administration of 5 mg/kg, IM
45617350|NCT03375671|Drug|Midazolam injection|single administration of 5 mg, IM
45617351|NCT03375671|Drug|Haloperidol|single administration of 5 mg, IM
45617352|NCT03298789|Other|Activation exercise|Two series of 4 activation exercise will be included in the intervention.
45617353|NCT03298789|Other|7 series of static stretching|7 series of 4 20 seconds static stretches will be conducted.
45617354|NCT03375593|Drug|Hydrocodone 5Mg/Acetaminophen 500Mg Tab|tablet
45617355|NCT03375593|Drug|Acetaminophen 500Mg Tab|tablet
45617356|NCT03375593|Drug|Ibuprofen 600 mg tab|tablet
45617357|NCT04257955|Behavioral|Interview and evaluation of Engagement|(i) the completion of the scheduled outpatients visit (ii) filling of the PHE-Scale® questionnaire by the patient to investigate the level of engagement and (iii) the completion of a semi-structured interview to assess the rate of understanding of the information received from the doctor.
45617358|NCT04525235|Combination Product|phenotyping cocktail|A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach
45617359|NCT04525235|Drug|rifampicin|A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach
45911617|NCT05777967|Biological|human autologous synovial stem cells|A single injection of 1.5 to 9.0 x 10^7 human autologous synovial stem cells under arthroscopy
45445733|NCT03761043|Behavioral|Professional Behavior Change Intervention|IV to PO antimicrobial conversion guidelines for nurses, nurse in-services and internet education sessions, IV to PO antimicrobial conversion health record reminder, endorsement from antimicrobial stewardship program, prescribers, and nurse educators.
45617360|NCT03363815|Drug|CC-90001|CC-90001
45617361|NCT03363815|Drug|Omeprazole|Omeprazole
45617362|NCT03363815|Drug|Midazolam|Midazolam
45617363|NCT03363815|Drug|Warfarin|Warfarin
45617364|NCT03363815|Dietary Supplement|Vitamin K|Vitamin K
45617365|NCT03363815|Drug|Rosuvastatin|Rosuvastatin
45617366|NCT03363815|Drug|Metformin|Metformin
45617367|NCT03363815|Drug|Digoxin|Digoxin
45617368|NCT03363815|Drug|Nintedanib|Nintedanib
45617369|NCT03286621|Other|Administration of five eye-tracking paradigms|All subjects will undergo the battery of five eye-tracking paradigms to determine potential markers for autism.
45617370|NCT03363737|Behavioral|Transtheoretical Model|Exposure to content on Facebook, either daily (dynamic) or just at one time period (static).
45617371|NCT03293173|Combination Product|R-CHOEP|rituximab, cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone
45617372|NCT03293173|Combination Product|DA-EPOCH-R|dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab
45617373|NCT03363659|Drug|Disulfiram|Disulfiram is taken orally, twice daily.
45617374|NCT03363659|Dietary Supplement|Copper gluconate|Copper gluconate is taken orally, twice daily
45617375|NCT03363659|Drug|Temozolomide|Temozolomide is taken once daily
45617376|NCT03293095|Procedure|Standard Care|The guidelines for the management according to the musculoskeletal disorder in primary care will be the treatment guidelines for the Standard Care.
45617377|NCT03368651|Procedure|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
45445734|NCT02064088|Drug|Injection of 0,2 ml/kg of 0,2% levobupivacaine for small volume group|Ultrasound guided administration of 0,2 ml/kg of 0,2% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
45617378|NCT03298633|Other|ICSI|All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo routine ICSI procedure according to the result of randomization in each study site.
45617379|NCT03298633|Other|Conventional IVF|All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo conventional IVF procedure according to the result of randomization in each study site.
45617380|NCT03363581|Behavioral|Food Preference|Buffet meal to assess food preference
45617381|NCT03368573|Device|QbTest|QbTest is a computerised assessment which takes approximately 20mins. The test combines a continuous performance test alongside an infrared camera which measures the participant's movements. The infrared camera measures motor activity of the participant whilst they undertake the task. During the test, the participant is presented with continuously changing stimuli. Embedded within these stimuli is a given target. Participants have to respond by pressing a hand-held button only when the target appears. Attention is measured through omission errors and reaction time to response. Impulsivity is assessed through commission errors and anticipatory errors. Motor activity is measured through head movements during the task. The test is approved by the FDA (Ref: K133382) and CE marked.
45617382|NCT03292939|Diagnostic Test|A complete Doppler ﬂow assessment of the maternal and fetal circulation|A complete Doppler ﬂow assessment of the maternal and fetal circulation was conducted by an independent investigator blinded to the treatment, 48 hours after receiving 400mg of vaginal progestrone .Voluson E8 (GE Healthcare, Zipf, Austria) ultrasound machine ,equipped with a 3.5-MHz curvilinear abdominal transducer with color imaging capabilities, was used in all cases.
45617383|NCT03363425|Drug|Lidocaine Iv|Lidocaine Iv
45617384|NCT03363425|Drug|Dexmedetomidine|dexmedetomidine iv
45617385|NCT03363425|Drug|Normal saline|placebo
45617386|NCT03292783|Drug|NOV1501 (ABL001)|VEGF/DLL4 targeting bispecific antibody
45617387|NCT03368495|Biological|Co-administration of MMR/YF|Both MMR & yellow fever vaccines administered on Day 0.
45617388|NCT03368495|Biological|MMR followed by YF|MMR vaccine administered on Day 0 and yellow fever vaccine administered on Day 28.
45617389|NCT03368495|Biological|YF followed by MMR|Yellow fever vaccine administered on Day 0 and MMR vaccine administered on Day 28.
45617390|NCT03298555|Behavioral|Mobile phone based intervention|Participants in the intervention group will receive a 6-month mobile phone based program via a mobile phone application specifically designed for this study. The program will include information, advice and strategies to promote healthy gestational weight gain.
45617391|NCT03363347|Drug|Redifferentiation with retinoid acid|In this retrospective study, patients with radioiodine refractory papillary thyroid cancer routinely received (clinical indication, no study medication was given) retinoid acid for redifferentiation prior to further course of radioiodine therapy.
45617392|NCT03286231|Diagnostic Test|CT imaging|Contrast-enhanced CT imaging of the pelvis in prone and jackknife positions
45617393|NCT03286153|Other|Ideal Body Weight First|Randomized to receive 50 U/kg (+/- 20%) of the factor product participants routinely use based on ideal body weight. For participants age 12-19, ideal weight is calculated using the McLaren method. For participants age 20 and over, ideal weight is calculated using the following equation: [50kg + (2.3kg*every inch over 5 feet)].
45617394|NCT03286153|Other|Actual Body Weight First|Randomized to receive 50 U/kg (+/- 20%) of the factor product participants routinely use based on actual body weight.
46069077|NCT04491071|Diagnostic Test|Mental Health questionnaire|welfare effect
46069078|NCT04491071|Diagnostic Test|Patient Health Questionnaire (PHQ-9)|assess depression during the pandemic
46069079|NCT04491071|Diagnostic Test|Post Traumatic Stress Disorder questionnaire (PTSD-8)|Assessing the trauma of subjects during the pandemic
46069080|NCT04491071|Diagnostic Test|Experiences in Close Relationship Scale questionnaire (ECR-S)|Measuring social ties and attachment of subjects
45445735|NCT02064088|Drug|Injection of 0,4 ml/kg of 0,1% lévobupivacaine for high volume group|Ultrasound guided administration of 0,4 ml/kg of 0,1% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
45445736|NCT03760887|Other|Home exercise program only|After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program only
45445737|NCT03760887|Other|Home exercise program and home program of sensory discrimination|After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program and two 5 minutes sessions of sensory training at home each day.
45617395|NCT03368417|Other|Usual Care|"Participants will be advised to measure their BP at least 3 times a week and record their results on a form. The participants will be educated on how to interpret their BP according to standard self-monitoring practice guidelines.~As part of the study, participants without a HBPM will be provided with the Omron HEM 7130. Adherence to hypertensive medicines will be monitored using the medication event monitoring system eCAP™. In addition, the participants will be asked to undertake ambulatory blood pressure monitoring (using the Welch Allyn ABPM 7100 monitor) at Baseline and Month 6 for a duration of 12 hours, during their waking hours."
45617396|NCT03368417|Other|Wireless HBPM System|"BP will be monitored using the iHealth KN-550BT wireless HBPM and transmitted to the study application via the iHealth mobile application.~The Wireless HBPM System consists of:~i) Instant BP feedback: Classification of each BP reading with feedback SMS. CRC will call the patient in case of alarming BP readings.~ii) Weekly HBPM adherence feedback: Participants receive praise, encouraging, or reminder SMSes.~iii) Continuous assessment: Based on average BP over the last 4 weeks, participants will be categorized and flagged for the CRC to follow clinical protocols. Protocols include asking patients to immediately come to the clinic, checking for alarm symptoms and discussing adherence over the phone, remote titration, and cancelling 1 clinic visit in case of good BP control."
45617397|NCT03368417|Behavioral|BP Monitoring Incentives|"Participants will receive an intervention identical to those in the Wireless HBPM System, with financial incentives for BP monitoring. This arm is further randomly subdivided into the Instant Reward and Health Capital arms in a 1:1 ratio.~Instant Reward sub-arm:~Participants receive SGD 3 for each day they measure their BP, up to three times per week.~Participants do not receive financial incentive if they do not measure their BP.~Health Capital sub-arm:~Participants receive an initial health capital of SGD 72~Participants' health capital increases by SGD 6 on each week where they measure their BP on at least 3 different days and decreases weekly by 10% per missing BP reading."
45617398|NCT03292705|Behavioral|PEP|The PEP system is built on a picture-based touch-screen interface on tablet computers. PEP allows users to explore and participate in entertainment, educational, spiritual, and other recreational activities and content personalized according to their interests and preferences. It provides easy access to the Internet and communication applications, and has hundreds of modules spanning music, travel, trivia, games, and religious and inspirational domains. For instance, if music is among a person's lifelong interests, the system provides access to multiple music genres through jukebox, karaoke and therapeutic music applications that can be tailored to a particular activity and by individual interest (for instance, a preference for classic jazz). As another example, for someone who likes travel or visiting new places, the interface offers access to Google Earth, guided tours, slide shows and regional facts and history.
45617399|NCT03292705|Behavioral|CCI|VSOP training will use five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All exercises share visual components and focus on accuracy and fast reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
45617400|NCT03368339|Drug|PR013 (0.045%)|PR013 topical Ophthalmic Drops (0.045%)
45617401|NCT03368339|Drug|PR013 (0.06%)|PR013 topical Ophthalmic Drops (0.06%)
45617402|NCT03368339|Drug|Vehicle|Vehicle
45617403|NCT03286075|Device|tDCS Anode session|"The aim of this unique anode tDCS session is to study the possibility of enhancing emotional processing, attentional resources and physiological responses in healthy subjects.~The arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)."
45760569|NCT04382729|Other|Neuromuscular Electrical Stimulation|The intervention group, in addition to the daily routine physical therapy, receives NMES for 15 days (5 days per week for 3 weeks). NMES is applied bilaterally using an electrical stimulator with pairs of electrodes placed transversally on the quadriceps muscles and on the gastrocnemius muscles. The stimulation protocol consists in the application of symmetrical biphasic rectangular pulses with a frequency of 30 Hz (pulse duration: 400 µs). Stimulation intensity is adjusted daily by the physical therapist to elicit a visible twitch in each muscle. The total duration of the NMES session is 30 min for the first week and 45 min for the second and third week. Stimulation (on) time is 5 s and relaxation (off) time is 15 s, thus eliciting a total of 90 evoked contractions per day during the first week and 135 contractions per day during the second and third week.
45760570|NCT04382729|Other|Physical Therapy Exercise|The control group is subjected to a protocol of physical therapy exercises, applied once a day for 30 minutes (5 days per week for 3 weeks) by the staff physical therapists. It starts with global passive range of motion exercises, followed by active and resistive exercises (including controlled breathing exercises and respiratory muscle training), transfer to the edge of the bed or to a chair, standing and walking.
45760571|NCT00803543|Drug|Valacyclovir|500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks
45760572|NCT00803543|Drug|Placebo|Dosage: Two tablets once a day for 24 weeks
45760573|NCT04099641|Drug|Bavituximab|Bavituximab IV infusion
45760574|NCT04099641|Drug|Pembrolizumab Injection|Pembrolizumab IV Infusion
45760575|NCT05051735|Drug|Paracetamol|Paracetamol 500 mg
45760576|NCT05051735|Drug|Placebo|Placebo
45760577|NCT05220033|Other|Informational intervention|Receive information focusing on coping skills for patients diagnosed with gynecologic cancer
45760578|NCT05220033|Other|survey administration|Ancillary studies
46069081|NCT04488822|Drug|Pexidartinib|400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)
45452284|NCT02270008|Other|Pelvic floor training|Baseline muscle strength will be measured with the modified Oxford scale. The intervention group will undergo an in-person standardized pelvic strength training session by a trained nurse practitioner.
45452285|NCT00035555|Drug|Belatacept|Solution, intravenous
45452286|NCT00035555|Drug|Cyclosporine|Oral, capsule
45452287|NCT00035555|Drug|Mycophenolate mofetil (MMF)|Oral, capsule
46069082|NCT04488484|Other|Serology test follow-up|"The enrolled participants will be invited to visit ESS. They will then meet the occupational physician, who wil obtain their free, informed and written consent. The information and consent will be recorded in the personal medical follow-up file.The staff will then complete the self-questionnaire and the ESS physician will provide a prescription for the blood samples to be taken.~In case of positive answers to one or more of the questions in this self-questionnaire, the enrolled participant will be contacted in order to schedule another post-COVID-19 consultation with additional examinations if needed (new COVID PCR, scanner, etc.)."
45617404|NCT03286075|Device|tDCS Cathode session|"The aim of this unique cathode tDCS session is to study the possibility of inhibiting or altering emotional processing, attentional resources and physiological responses in healthy subjects.~This arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Cathode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and anode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)."
45617405|NCT03286075|Device|tDCS Placebo session|"This arm will help compare the effects of stimulation versus no stimulation on emotional processing, attentional resources and physiological responses.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)"
45617406|NCT03363269|Drug|ID1201|
45617407|NCT02459977|Drug|Basiliximab|Basiliximab induction therapy
46069083|NCT04481113|Drug|Abemaciclib|Given PO
45617408|NCT02459977|Drug|No basiliximab|No basiliximab induction therapy
45617409|NCT02459977|Procedure|Kidney transplantation|kidney transplantation
45617410|NCT02519075|Other|No intervention|Observational study
45617411|NCT03298477|Device|Nellix® System|Endovascular Abdominal Aortic Aneurysm Repair using the Nellix® System
45617412|NCT02519153|Drug|Sildenafil|placebo will take nitrofuratoin once daily for 4 weeks . sildenafil arm will take sildenafil 50 mg once daily for 4 weeks
45617413|NCT03285997|Biological|GC3110A|A single 0.5mL dose intramuscular injection
45617414|NCT03285997|Biological|GCFLU Pre-filled syringe inj.|A single 0.25mL dose intramuscular injection
45617415|NCT04523987|Drug|Ciprofloxacin|Subjects enrolled will be administered oral ciprofloxacin twice a day throughout the course of each 28-day cycle of gemcitabine and nab-paclitaxel chemotherapy.
45617416|NCT03292627|Device|Portable Noninvasive Hemodynamic Monitor|A non-invasive monitor for estimating patient's heart contractility and cardiac output by the change of thoracic electrical bioimpedance.
45617417|NCT03368261|Other|HTAP/ clinical complications in the sickle cell disease|At the inclusion in our study the diagnosis of PAH will be performed by transthoracic Doppler-echocardiograms in a group of 306 children (aged between 8 to 16 years old) with either SS or SC genotype with similar medical caring, to avoid a known selection bias. These patients will be followed during a 3 years longitudinal period. The occurrence of the clinical specific complications associated with SCD (acute chest syndrome, painful vaso occlusive crisis, septicemia and stroke) and the observed mortality rate of our children group, will be compared in patients groups stratified according to the occurrence of PAH. The expression of several molecular and cellular genetic biomarkers potentially associated with this complication will also be studied.
45617418|NCT03298399|Biological|Autologous MSCs|Participants at dose level 1 receive four infusions of MSCs, given once per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
45617419|NCT03298399|Biological|Autologous MSCs|Participants at dose level 2 receive four infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
45617420|NCT03298399|Biological|Autologous MSCs|Participants at dose level 3 receive six infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
45617421|NCT03363191|Drug|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol will be supplied as inhalation powder in ELLIPTA DPI. It will contain 2 strips with 30 blisters per strip. First strip will contain fluticasone furoate 100 mcg dry white powder blended with lactose. Second strip will contain vilanterol 25 mcg dry white powder blended with lactose and magnesium stearate.
45617422|NCT03363191|Drug|Fluticasone Furoate|Fluticasone furoate will be supplied as inhalation powder in ELLIPTA DPI. It will contain a single strip with 30 blisters, containing fluticasone furoate 100 mcg dry white powder blended with lactose.
45617423|NCT03363191|Drug|Salbutamol/Albuterol|Salbutamol/albuterol will be provided to subjects to use as rescue medication on an as-needed basis.
45617424|NCT03285919|Device|Balance Assessment Robot (BAR™)|"The BAR™ has got six degrees of freedom (DOF) that interface to the pelvis of a walking subject. Five DOFs (translation of pelvis in sagittal, lateral and vertical directions; pelvic rotation and pelvic list) are actuated and admittance-controlled, providing transparent haptic interaction with negligible power transfer; the remaining DOF (pelvic tilt) is passive. The BAR™ is capable of delivering perturbations in the directions forward/backward and left/right, but for the purpose of this study only outward perturbations in the frontal plane were considered."
46069084|NCT04481113|Drug|Niraparib Tosylate Monohydrate|Given PO
46069085|NCT04472611|Drug|Standard of Care (SOC) and Colchicine+Rosuvastatin|Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization
46069086|NCT04472598|Drug|Navitoclax|Tablet; Oral
45617425|NCT03368105|Dietary Supplement|Prevention of C. difficile infections using LP299v strain|"Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.~We will divide participants into two group. Group 1 will receive one capsule of LP299v orally per a day during the entire period of antibiotic therapy. Group 2 will receive one capsule of placebo during the entire period of antibiotic therapy."
45617426|NCT03292549|Procedure|Robotic partial surgery|Robotic partial surgery
45617427|NCT03368027|Behavioral|A cognitive-behavioral intervention program|In this program, participants receive a training of assertive skills, social skills, acceptance, among other psychological aspects.
45617428|NCT03368027|Other|Standard intervention|Participants receive different activities conducted by a psychologist in the association where the attend.
45617429|NCT03292393|Behavioral|Financial reward|In contingency management, financial rewards are contingent upon an individual changing behavior. In our study, financial incentives are contingent upon group behavioral changes.. In the intervention phase participants will be randomly assigned to one of the three treatment arms and they will receive the financial incentive that corresponds to their treatment arm. Data will be collected for four months and all participants will continue receiving a compensation for participation
45617430|NCT03292393|Behavioral|Social norms|To build social norms the study adds a group component to a contingency management model. In contingency management, financial rewards are contingent upon an individual changing behavior. Social norms are expected to emerge as a result of the designed group contingency management, monthly-facilitated meetings at a local clinic, and daily basis interaction through social media. The intervention will build social norms that improve medication adherence of each member of a group. A three-arm randomize trial is designed to test this hypothesis. Hypertensive patients will be randomly assigned to a group contingency management (GCM) arm, an individual contingency management (ICG) arm, or a control arm.
45617431|NCT03292393|Device|Home Blood Pressure Monitoring|Participants will be reminded that they will receive and learn how to use a Home Blood Pressure Monitor (HBPM) device that participant will keep for the duration of the study
45617432|NCT03292393|Device|Medication adherence assessment|Participants will be informed that they will receive and learn how to use eCap, a medication event monitoring system that participants will return after completing the study. The project nursing student will count the number of pills the participant currently has and make a record of it on the Data Collection form.The participant will provide the project nursing student with his/her antihypertension prescription records so that the dosage amount and number of pills can be recorded on the Data Collection form.
45617433|NCT03367949|Other|Surgical guide designed from Impression inversion with markers|Rather than using optical scan of the cast , We will use impression inversion technique with VPS impression and adding CBCT Markers on the tray
45617434|NCT03285841|Device|OCT-AFI|Both groups will be imaged with the OCT-AFI device. Imaging will not influence standard of care biospies, treatment and procedures.
45617435|NCT03363113|Drug|Botulinum Toxins|Injection of botulinum toxin in the muscles affected by oromandibular dystonia
45617436|NCT02461303|Other|Counseling|Subjects will be counseled on the impact of KS on the reduced fertility potential, and about providing a semen sample for semen analysis. Semen analysis is the gold standard for fertility preservation in adult patients, but is only rarely considered by post-pubertal adolescent and young adult patients and their families. Only the semen analysis parameters will be used by the study for the comparison with physical and endocrine measures to assess whether spermatogenesis in these patients coincides with pubertal development. All potential frozen samples will be stored for the patient's future use, and samples will not be used for research experiments.
45617437|NCT02518841|Device|ThermaWedge TM|ThermaWedge TM is a foam wedge device that is designed to be used in the treatment of plantar fasciopathy.
45617438|NCT02518841|Other|Achilles Tendon Stretching|Participants will be asked to perform achilles tendon stretching exercises which will be demonstrated at the initial orientation.
45617439|NCT03108079|Device|Cystosure Urinary Access System|"Demonstrate the 3D bladder wall anatomy with 300 cc of fluid infused with each of the following bladder drainage mechanisms~The traditional Foley catheter (Catheter A)~The novel FDA approved Cystosure catheter (Catheter B)~Compare the fluid flow pattern during bladder drainage for~The traditional Foley catheter (Catheter A)~The novel FDA approved Cystosure catheter (Catheter B)~Compare the 3D bladder wall anatomy after emptying the bladder with~The traditional Foley catheter (Catheter A)~The novel FDA approved Cystosure catheter (Catheter B)"
45617440|NCT03108079|Device|Foley Catheter|"Demonstrate the 3D bladder wall anatomy with 300 cc of fluid infused with each of the following bladder drainage mechanisms~The traditional Foley catheter (Catheter A)~The novel FDA approved Cystosure catheter (Catheter B)~Compare the fluid flow pattern during bladder drainage for~The traditional Foley catheter (Catheter A)~The novel FDA approved Cystosure catheter (Catheter B)~Compare the 3D bladder wall anatomy after emptying the bladder with~The traditional Foley catheter (Catheter A)~The novel FDA approved Cystosure catheter (Catheter B)"
45617441|NCT03367559|Biological|ROTAVAC®|Rotavac® is in frozen form and is thawed till fully liquid prior to administration.
45617442|NCT03285685|Device|active tDCS|Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left M1 and cathodal over supraorbital contralateral area
45617443|NCT03285685|Device|active tDCS|Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left DLPFC and cathodal over supraorbital contralateral area.
45617444|NCT03285685|Device|sham tDCS|The procedure is the same as for active tDCS anodal over left M1 and cathodal over supraorbital contralateral area, but the in the placebo tDCS the stimulation is non-active / sham.
45617445|NCT03367481|Device|Toothbrush type|In this cross-over study, the participants will use either a soft brush (control) and the medium brush (test).
46069087|NCT04472598|Drug|Ruxolitinib|Tablet; Oral
46069088|NCT04472598|Drug|Placebo for Navitoclax|Tablet; Oral
46069089|NCT04460885|Drug|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 78 weeks.
46069090|NCT04460885|Drug|Insulin glargine|Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 78 weeks
46069091|NCT04450550|Device|VeNS device|VeNS treatment
46069092|NCT04450550|Device|Sham VeNS device|Sham treatment of VeNS
46069093|NCT04446000|Biological|CSL730|solution for injection and infusion
45617446|NCT03292159|Device|Active RAVANS concurrent with arm motor training|Patient receives non-painful, sensory-level stimulation to the skin of left outer ear, where nerve endings of the auricular branch of the vagus nerve reside, while participating in arm motor training
45617447|NCT03292159|Device|Inactive RAVANS concurrent with arm motor training|Patient does not receive stimulation delivered to the skin of left outer ear while participating in arm motor training
45617448|NCT03367325|Device|CDS-NVAF|The CDS-NVAF is intended for patients diagnosed with NVAF and treated with VKA. This tool calculates the time in the therapeutic range (TTR) using the Rosendaal method considering the last International Normalized Ratio (INR) data. The INR data are found in the clinical history of NVAF patients. The CDS-NVAF will be activated when the physician introduces the last INR value. At this time the TTR will be calculated automatically. If the TTR value is < 65%, a pop up screen with a warning text will open suggesting a change to DOAC therapy. The physician can decide whether to change or not the previous prescription. If the TTR value in > 65% the pop up screen will not appear. The TTR value will remain registered on the screen of the follow up of oral anticoagulant use and can be consulted in future queries. The diffusion of the CDS-NVAF will be made by an announcement on the first day of the intervention when the health care professional opens the electronic clinical history.
45617449|NCT03285607|Biological|MCS110|-MCS110 is an IgG1/κ humanized monoclonal antibody directed against human macrophage colony stimulating factor
45617450|NCT03285607|Drug|Doxorubicin|-Standard of care
45617451|NCT03285607|Drug|Cyclophosphamide|-Standard of care
45617452|NCT03285607|Drug|Paclitaxel|-Standard of care
45617453|NCT03285607|Procedure|Bone marrow aspirate|-Time of enrollment and at time of surgery
45617454|NCT03285607|Procedure|Peripheral blood samples|-Time of enrollment and at time of surgery
45617455|NCT03285607|Procedure|Tumor tissue|-Time of enrollment and at time of surgery
45617456|NCT03362801|Diagnostic Test|sarcopenia and mobility measurement|"walking speed, grip strength and BIA. QAPPA questionnaire (validated in French in the elderly) and the objective measurement of the time of activity and rest on a week per wrist actimeter.~Comprehensive Geriatric Assessment"
45617457|NCT03298321|Other|Effect of Vidaza treatment|The goal of this study is to evaluate the effects of azacytidine on arrhythmia and left atrium fibrosis.
45617458|NCT03362723|Drug|Idasanutlin|Participants will receive one 300-mg dose of each of the four different oral tablet formulations of idasanutlin (tablet A [reference], B, C, D) during Cycle 1, in the order specified for their assigned treatment arm (Treatment Sequence 1-4). Participants who enter the optional treatment extension phase will receive the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
45617459|NCT04527055|Drug|Bismuth Subcitrate 120 MG Oral Tablet|Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
45617460|NCT04527055|Dietary Supplement|Lactobacillus acidophilus and Bifidobacterium lactis Bb12|"The probiotic powder per oral twice daily for 24 weeks. The probiotic powder is named as President AB powder, which contains an approximately equal mixture of Lactobacillus acidophilus and Bifidobacterium lactis Bb12 at a concentration of >= 10E9 CFU/mL (President Corp., Tainan, Taiwan)."
45617461|NCT04527055|Drug|Esomeprazole 40mg|Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
45617462|NCT04527055|Drug|Metronidazole 250 MG|Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
45617463|NCT04527055|Drug|Tetracycline Pill|Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
45617464|NCT03123653|Drug|Peg IFN 2b|Peg IFN 2b 1.5mcg/kg once every week for 48 weeks
45617465|NCT03292081|Device|OFDI|PCI under OFDI guidance
45617466|NCT03292081|Device|IVUS|PCI under IVUS guidance
45617467|NCT02518763|Drug|Vitamin D3, 100 000 IU weekly, 4 times|
45617468|NCT02518763|Biological|25 OH vitamin D serum concentration measurements|
45617469|NCT03285451|Diagnostic Test|submental ultrasonography|Submental ultrasound, the noninvasive and convenient tool, has been widely applied to measure the tongue base thickness in patients with obstructive sleep apnea, so as to predict the severity and relationship with upper airway collapse.
45617470|NCT03362567|Other|Sustained Natural Apophyseal Glides|Subjects in SNAGS group were treated with sustained natural apophyseal glides, twice weekly for six weeks
45617471|NCT03362567|Other|Mechanical Cervical Traction|subjects in MCT received mechanical cervical traction, for 15 minutes each session twice in a week for six weeks
45617472|NCT03292003|Device|Journey II BCS Total Knee System|
45617473|NCT04019093|Drug|Ethanol|A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
45617474|NCT04019093|Other|Placebo|A beverage that does not meaningfully increase breath alcohol concentration.
46069094|NCT04446000|Drug|Placebo|A solution matching the excipient profile of CSL730 without the active substance
46069095|NCT04437446|Diagnostic Test|Case Group|The additional examination corresponds to an OCTA which is a non-invasive examination, without potential risks, without radiation, using infrared light.
46069096|NCT04437446|Diagnostic Test|Control Group|"The additional examinations correspond to:~OCTA which is a non-invasive examination, without potential risks, without radiation, using infrared light.~OCT: non-invasive examination, without potential risks, without radiation, using infrared light. The patient must sit in front of a screen and a contact is taken without contact in about ten seconds.~Visual field"
46069097|NCT04428489|Other|Observation and necessary supportive care|For patients with ICUS and CCUS, necessary supportive care could be given. No addtitional treatment is administrated.
45617475|NCT03285217|Dietary Supplement|Ensure Plus Advance|Supplements, labeled only with the name of the participant and his/her identification number, will be provided to the participants in the Translational Research Unit of the Miguel Servet Hospital. Every 2 weeks, changes in body composition, in particular in fat and muscle, will be assessed by bioelectrical impedance analysis (BIA). Likewise they will be asked about compliance and their diets will be controlled by a nutritionist. Fresh stool samples, urine and blood will be collected pre- and post treatment. An extensive bloodwork will be performed at the Clinical Biochemistry Service at the Miguel Servet Hospital (plasma HMB, total cholesterol, triglycerides, LDL&HDL-cholesterol, free fatty acids, glucose, insulin, β-hydroxybutyrate, hs-CRP, and liver transaminases (AST, ALT, GGT).
45617476|NCT03285217|Dietary Supplement|Ensure High Protein|Supplements, labeled only with the name of the participant and his/her identification number, will be provided to the participants in the Translational Research Unit of the Miguel Servet Hospital. Every 2 weeks, changes in body composition, in particular in fat and muscle, will be assessed by bioelectrical impedance analysis (BIA). Likewise they will be asked about compliance and their diets will be controlled by a nutritionist. Fresh stool samples, urine and blood will be collected pre- and post treatment. An extensive bloodwork will be performed at the Clinical Biochemistry Service at the Miguel Servet Hospital (plasma HMB, total cholesterol, triglycerides, LDL&HDL-cholesterol, free fatty acids, glucose, insulin, β-hydroxybutyrate, hs-CRP, and liver transaminases (AST, ALT, GGT).
45617477|NCT03362411|Drug|BMS-986205|Single 100 mg dose on Day 1 and Day 15
45617478|NCT03291925|Procedure|Selective invasive angiography based on CT/CCTA imaging.|
45617479|NCT03291925|Procedure|Procedure/Surgery: Invasive angiography|
45617480|NCT03362333|Other|Exercise|Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular stabilizer muscles.
45617481|NCT03362333|Other|Pain neuroscience education|Pain neuroscience education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
45617482|NCT03362255|Other|thoracic epidural catheterization|thoracic epidural catheterization with different speed of injection
45617483|NCT03362021|Procedure|transvaginal oocyte retrieval|sedation for oocyte retrieval
45617484|NCT02460289|Drug|Treatment: Minoxidil 5% / Botanical Hair Solution for Men|
45617485|NCT03367091|Other|Ekso GT gait training with high swing assistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high assistance"
45617486|NCT03367091|Other|Ekso GT gait training with neutral swing assistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at neutral"
45617487|NCT03367091|Other|Ekso GT gait training with high swing resistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high resistance"
45617488|NCT03298165|Device|diode laser|diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation
45617489|NCT02461381|Other|not intervention|This is a cross-sectional study for estimation of diagnostic performance.
45617490|NCT03361787|Behavioral|"Parentship- a multi dimensional intervention program to improve parental resilience"|"Parentship is a multi dimensional intervention program to improve parental resilience and adolescent participation using the OPC model."
45617491|NCT04524065|Other|Early rehabilitation protocol for children hospitalized in the PICU|The early rehabilitation protocol was developed by a collaborative multidisciplinary team approach in Samsung Medical Center, and the central components include the involvement of physical therapy/occupational therapy (PT/OT).
45617492|NCT03284983|Other|Suture spacing for wound closure|The wound was divided in half and sutures were spaced 5mm or 10mm apart depending on side. The sutures were removed at 2-week follow-up appointment and photographs were taken. The Patient and Observer Scar Assessment Scale (POSAS) was then performed by both patient and physician.
45617493|NCT03291457|Drug|Tocilizumab|For intravenous (IV) tocilizumab, the recommended dosage is 8 milligrams per kilogram (mg/kg) once every 4 weeks. For subcutaneous (SC) tocilizumab, the recommended dosage is 162 milligrams (mg) once weekly. However, because of the observational nature of the study, dosing and treatment duration is at the discretion of the physician in accordance with local clinical practice and local labeling.
45617494|NCT03291457|Drug|Glucocorticoid Agent|Because of the observational nature of the study, the choice of glucocorticoid agent, as well as dosing and treatment duration, is at the discretion of the physician in accordance with local clinical practice and local labeling.
45617495|NCT03361709|Drug|Dexamethasone|Dexamethasone will be injected intracamerally at the conclusion of Phacoemulsification
45617496|NCT03361709|Drug|Saline Solutions, Intraocular|Only saline will be injected intracamerally at conclusion of Phacoemulsification
45617497|NCT03284905|Dietary Supplement|Probiotic supplement|Capsule containing freeze dried probiotic bacteria together with maize starch
45617498|NCT03284905|Dietary Supplement|Placebo supplement|Capsule containing maize starch
45617499|NCT03366935|Other|EPL and CEI|"Procedure: Standard epidural placement(EPL)~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA)."
45617500|NCT03366935|Other|DPE and CEI|"Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA)."
45617501|NCT03366935|Other|DPE and PIEB|"Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA)."
45617502|NCT03284749|Other|Copper impregnated wound dressing|Copper impregnated wound dressing
45617503|NCT03284749|Other|Normal wound dressing|Normal wound dressing
45617504|NCT03284749|Other|Copper impregnated maternity pads|Copper impregnated maternity pads
45617505|NCT03284749|Other|Normal maternity pads|Normal maternity pads
46069098|NCT04423718|Drug|Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)|Solution in Vial, intravitreal (IVT) injection
46069099|NCT04423718|Drug|Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)|Solution in Vial, 2 mg, intravitreal (IVT) injection
45617506|NCT04523675|Dietary Supplement|N-acetylcysteine|Orally in three daily dosages (morning-midday-evening), at 20 mg/kg/day, for seven consecutive days.
45617507|NCT04523675|Dietary Supplement|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder. Orally in three daily dosages (morning-midday-evening), for seven consecutive days.
45617508|NCT03298009|Drug|Canagliflozin 100mg|2-week intervention
45617509|NCT03298009|Drug|Placebo oral capsule|2-week intervention
45617510|NCT03298009|Radiation|PET imaging|1 day postprandial metabolic protocol at the end of treatment: CT scan followed by dynamic and pancorporel imaging
45617511|NCT03366857|Drug|Oxygen 30 %|The oxygen concentration will be set at 30%.
45617512|NCT03366857|Drug|Oxygen 80 %|The oxygen concentration will be set at 80%.
45617513|NCT03291301|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia including psychoeducation, sleep restriction, stimulus control, cognitive restructuring, and relaxation.
45617514|NCT03291301|Other|Acupressure|Acupressure, a non-invasive therapy, is commonly used in Traditional Chinese Medicine
45617515|NCT03284671|Other|bifocal stimulation with tDCS|Patients will receive an active Treatment with tDCS (10 sessions of 30 mn with an intensity of 2 mA)
45617516|NCT03361631|Drug|Autologous Bone Marrow derived Mesenchymal Stem Cells|Information visit (time 1) Inclusion visit (time 2) Bone marrow extraction (time 3) Treatment and culture of MSC (time 4) Intra-cavernosal injection of autologous MSC (time 5) Follow-up 1 (time 6): control / tolerance visit (andrological clinical examination, EHS and and IIEF-5), 2 weeks after injection; Follow-up 2 (time 7): 12-week evaluation of treatment response: andrological clinical examination, IIEF-5 and EHS score determination & Pharmaco-Doppler; Follow-up 3 (time 8): 24-week evaluation of the response to treatment: andrological clinical examination, determination of IIEF-5 and EHS scores & Pharmaco-Doppler
45617517|NCT03291145|Drug|Beta Blockers|With and without Beta Blockers
45617518|NCT03291145|Drug|Spironolactone|Brisk Standing before and after seven days treatment with Spironolactone
45760579|NCT00803777|Device|Investigational Blood Glucose Monitoring System|Subjects with diabetes used a new blood glucose monitoring system with capillary blood. Certain results were compared to a laboratory glucose method.
45760580|NCT04098237|Drug|Pancrelipase|Pancrelipase delayed-release capsules
45760581|NCT00356343|Device|NMES Strength Training|Subjects will complete 12 weeks of NMES isometric strength training using implanted electrodes in bilateral quadriceps and triceps surae muscles.
45760582|NCT00356343|Other|Volitional Strength Training|Subjects will complete 12 weeks of volitional isometric strength training of bilateral quadriceps and triceps surae muscles.
45760583|NCT05217693|Drug|BB-1705|BB-1705 is an ADC consisting of an engineered humanized IgG1κ monoclonal antibody conjugated to the cytotoxic agent eribulin via a cathepsin-cleavable valine-citrulline linker. BB-1705 has a molecular weight of approximately 152 kDa, including two molecules of eribulin via the linker.
46069100|NCT04419428|Device|BiPAP A40 Expiratory Flow Limitation (EFL)|All participants in the observational registry will be using the BiPAP A40 EFL noninvasive ventilator as part of standard of care and will be participating in the same follows up and data collection. The BiPAP A-40 EFL ventilator is intended to provide non-invasive ventilatory support to treat adult patients with Respiratory Insufficiency with the primary cause being COPD. It is intended to be used within the home, institution/hospital, and diagnostic laboratory environments.
46069101|NCT04417842|Diagnostic Test|Respimetrix flow-volume monitoring device|The Respimetrix flow-volume monitoring device is being tested to validate its ability to measure Inspiratory Capacity
46069102|NCT04391790|Procedure|Cystectomy and modified urinary conduit|The modified retrosigmoid conduit is extended aorund 5 cm, so the left ureter does not have to cross under the mesentery wheras the presumed more robust ileal segment does.
46069103|NCT04391790|Procedure|Cystectomy and standard urinary conduit ad modum Bricker|The conduit is constructed using approximately 15 cm of terminal ileum and placed in the right side of the abdomen. In order for the left ureter to reach the conduit, it is mobilized behind the sigmoideum to the conduit.
45617519|NCT03366701|Other|Rehabilitation|The intervention (routine care) correspond to five weeks rehabilitation program
45617520|NCT03297931|Dietary Supplement|Corn Chips + Onion Dip|Non-pulse chip + non-pulse dip
45617521|NCT03297931|Dietary Supplement|Yellow pea chip + hummus|Novel pulse chip + pulse spread
45617522|NCT03297931|Dietary Supplement|Pinto bean chip + hummus|Commercial pulse chip + pulse spread
45617523|NCT03297931|Dietary Supplement|Pinto bean chip + onion dip|Commercial pulse chip + non-pulse spread
45617524|NCT03297931|Dietary Supplement|Yellow pea chip + onion dip|Novel pulse chip + non-pulse spread
45617525|NCT03297931|Dietary Supplement|Corn chips + hummus|Non-pulse chip + pulse spread
45617526|NCT03366623|Behavioral|Hospital clown|Presence of the hospital clown
45617527|NCT03366623|Behavioral|No hospital clown intervention|Presence of pediatric nurses and biomedical laboratory technologists in the venipuncture procedure.
45617528|NCT03361475|Behavioral|SME App|"The features in the App could be used in the future by linking with some platforms / existing services so that more SME messages can be sent to the students for sharing. One school workshop will be held to promote SME and introduce the function of SME App for students to download and use immediately to connect family members.~SME App promotes SME via:~Express gratitude to family members (sharing)~Deliver positive messages regularly (mind)~Record physical and other joyful activities (enjoyment)~Increase knowledge and understanding of adolescent mental health problem (in particular the anxiety disorders)"
45617529|NCT03284593|Drug|intensive chemotherapy|
45617530|NCT03284593|Drug|Azacitidine|
45617531|NCT03366311|Procedure|holding position|two types of holding positions plus two types of shapes of stylet, with or without epiglottis lift
45617532|NCT03284515|Biological|Vaccination with a pertussis containing vaccine|Vaccination with a pertussis containing vaccine
45617533|NCT03361397|Drug|Lidocaine Hydrochloride|Lidocaine hydrochloride will be used via mask nebulizer before LMA insertion
45617534|NCT03361397|Drug|Distilled Water|Distilled Water will be used via mask nebulizer before LMA insertion
45617535|NCT03283423|Device|Image-guided Lymphadanectomy in AMIGO|Image guided laparoscopic lymph node biopsy
45617536|NCT03366233|Other|Mental fatigue|A modified Stroop task of 90 min, partitioned in 8 blocks of 252 stimuli, will be used as mentally fatiguing task. The Stroop task requires inhibition and sustained attention on controlled processes.
45617537|NCT03366233|Other|Control|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content.
45617538|NCT03284437|Behavioral|Early Cognitive Training|Choose level of activity (e.g., coloring, holding objects) based on occupational therapist assessment.
45617539|NCT03123497|Other|completion of questionnaire|completion of questionnaire for patient and parent
45617540|NCT03283345|Procedure|modified radical mastectomy|systemic responses to trauma are compared with evaluating inflammatory cytokine levels between premenopausal and postmenopausal patient groups with different estrogen levels who underwent modified radical mastectomy.
45617541|NCT03123419|Behavioral|Appointment reminders|The purpose of the Gardasil study is to increase the rates of Gardasil vaccination in the Maternal Fetal Care Center. This will be done by reminding patients via text to come for their follow up vaccine appointments.
45804044|NCT05719285|Drug|Multi-Dose Antibiotic|"Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.~First line:~Arm 2: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure plus 800/160 mg every twelve hours for 6 total doses~Second line:~Arm 2: cefalexin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses~Third line:~Arm 2: nitrofurantoin 100 mg once pre-procedure plus 100 mg every twelve hours for 6 total doses~Fourth line:~Arm 2: ciprofloxacin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses"
45617542|NCT03284281|Device|Tragus stimulator|Tragus nerve stimulation for at least 8 hours per day for 1 week post discharge.
45617543|NCT03284281|Device|Sham Tragus stimulator|No stimulation will be performed
45617544|NCT03366077|Dietary Supplement|Probiotic|Probiotic
45617545|NCT03283267|Drug|Sodium Zirconium Cyclosilicate (ZS)|Sodium zirconium cyclosilicate (ZS) is a non-absorbed, inorganic crystalline compound that selectively captures potassium ions in exchange for sodium and hydrogen ions in the gastrointestinal tract after oral administration.
46069104|NCT04373811|Diagnostic Test|Lung ultrasound|"Lung ultrasound will be performed in 12 thorax area: anterior, lateral and posterior, each area divided in superior and inferior area, for each hemithorax.~Lung Ultrasound Score (lung aeration) will be recorded using a convex probe with a transverse view. Presence of pleural thickening and subpleural consolidations will be recorded."
45445738|NCT03560050|Behavioral|Nutrition assistance|Participating family child care home providers in and around the Oklahoma City (OKC) area will be randomized to either the Nutrition (n=26), or an environmental health comparison group (n=26). Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with the intervention team: two home-based, 90-minute visits scheduled at the convenience of the family child care home provider and a 3-hour group class session that will be conducted on a weekend. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention over a period of three months.
45617546|NCT03109379|Drug|Trospium-Releasing Intravesical System (TAR-302-5018)|TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
45617547|NCT03361319|Drug|Vargatef|small molecule triple kinase inhibitor
45617548|NCT03361319|Drug|Abraxane|Paclitaxel formulated as albumin bound nanoparticles
45617549|NCT03361319|Other|placebo|Placebo in place of Ninedanib
45617550|NCT04489147|Drug|Metformin|metformin 850 mg orally twice daily along the cycle of ICSI
45617551|NCT03365999|Drug|Oral Tranexamic Acid|Patients undergoing total knee replacement who will receive three doses of tranexamic acid administered orally (1 prior to surgery and 2 subsequent to surgery).
45617552|NCT03365999|Drug|Oral Aminocaproic Acid|Patients undergoing total knee replacement who will receive three doses of aminocaproic acid administered orally (1 prior to surgery and 2 subsequent to surgery).
45617553|NCT02460055|Device|endotracheal tube|This study will determine if the placement of an ETT will lead to dysphagia.
45617554|NCT02460055|Drug|propofol|propofol 3mg/kg will be administered to facilitate endotracheal intubation
45617555|NCT02460055|Drug|Fentanyl|Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation
45617556|NCT02460055|Drug|Dexamethasone|Dexamethasone 0.15mg/kg up to 20 mg will be used for anti-emesis prophylaxis
45617557|NCT02460055|Drug|Ondansetron|Ondansetron 0.15mg/kg up to 4mg will be used for anti-emesis prophylaxis
45617558|NCT02460055|Drug|sevoflurane, nitrous oxide and oxygen|Inhalational agents will be used to induce general anesthesia
45617559|NCT03361241|Other|No Physiotherapeutic Intervention|"Experimental group will perform a balance training program in a virtual environment (using a gaming system with balance board device - eight games of Nintendo Wii Fit®, for 14 sessions) without verbal/manual physiotherapeutic intervention.~Initially, instructions about the rules and strategies of how to play the game and control the avatar will be provided.~Then the patient will be invited to start the game, and in the two attempts of the training no manual or verbal assistance will be provided. Physiotherapist participation during training will be restricted to ensuring patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game at the end of each attempt."
45617560|NCT03361241|Other|Physiotherapeutic Intervention|Control group will perform a balance training program in a virtual environment (gaming system with balance board device - eight games of Nintendo Wii Fit®, for 14 sessions) with verbal and manual physiotherapeutic intervention. Initially, instructions about the rules and strategies of how to play the game and control the avatar will be provided. Then the patient will be invited to start the game, and in the first attempt of the training physiotherapist will provide manual and verbal assistance, providing corrections on movement (avoiding compensatory movements). In the second attempt, no manual or verbal assistance will be provided (only ensuring patient safety, providing motivational verbal stimuli), allowing the patient to organize his or her performance.
45617561|NCT03297619|Behavioral|Mindfulness and Acceptance Workbook for Social Anxiety and Shyness|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
45617562|NCT03297619|Behavioral|The Shyness and Social Anxiety Workbook|Participants assigned to this condition will be asked to read this self-help book over an 8-week period (with some chapters omitted).
45617563|NCT03361163|Biological|emm75 Streptococcus pyogenes (GAS M75, strain 611024)|Direct oropharyngeal application by swab following immersion in a solution containing a specified concentration (dose) of GAS M75.
45617564|NCT03284125|Other|Swallowing disorders evaluation|Self-administered questionnaires and non-invasive clinics tests
45617565|NCT03365921|Biological|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
45617566|NCT03283189|Other|Group discussions|The focus group discussions will be conducted in a private room in the maternity of the women. They will last approximately 2 hours and will be led by an interviewer using an interview grid. All interviews will be audio-recorded.
45617567|NCT03361085|Procedure|nvHAP Prevention Bundle|oral care, (early) mobilization, diagnosis and treatment of dysphagia, respiratory physiotherapy, stop Proton pump Inhibitors (PPI) if reasonable
45617568|NCT02461147|Procedure|Cholecystectomy with intraoperative cholangiogram|cf. arm/group description. This intervention is not assigned by the investigators: it is the standard treatment at the investigators institution.
45617569|NCT03365843|Device|Montage bone putty|Application of bone putty on cut sternal surfaces prior to application of conventional wires for closure of sternum during cardiac surgery.
45617570|NCT03365843|Other|Conventional Sternal Closure|Closure of sternum with standard wire cerclage.
45617571|NCT03283111|Biological|autologous stem cell transplantation|autologous stem cell transplantation
45617572|NCT03361007|Device|Transcatheter Aortic Valve Implantation (TAVI)|Patients who were disqualified from surgical cortical valve replacement by decision of the Heart Team.
45617573|NCT03282877|Behavioral|iCST web-application|The iCST web-application will be delivered by a carer in regular contact with the person with dementia (family carer, a close friend, or a volunteer befriender) for 1.5 hours a week. It is up to the carer to distribute the time in a matter that is convenient to them (e.g. two long sessions of 45 minutes or 3 shorter sessions of 30 minutes). Participants will be asked to use the web-application for a duration of 11 weeks at their homes. Each session will consist of structured cognitive stimulation aided by the use of multimedia. After completing each session, participants will be guided to a new screen on the web-application in which they will be asked to briefly reflect on the session and provide us with feedback.
45617574|NCT03365765|Drug|Apatinib|Apatinib tablet
45617575|NCT03365765|Drug|Oxaliplatin|Oxaliplatin Intravenous
45617576|NCT03365765|Drug|5-fluorouracil|5-fluorouracil Intravenous
45617577|NCT03297463|Drug|Interleukin-2 & Ipilimumab (P-Ib)|"Phase Ib:~- Ipilimumab will be administered in a 3 + 3 dose escalation design.~The starting dose will be 0.3 mg/kg administered within 7 days of day 1 cycle 2 ALdesleukin (IL-2).~If dose limiting autoimmune toxicities (DLTs) are not observed, the next cohort will receive 1.5 mg/kg.~The final cohort will receive 3 mg/kg, in the event that cohort 2 does not exhibit DLTs.~In the event of excessive toxicity in cohort 1, then a -1 dose level of 0.1 mg/kg may be evaluated in subsequent cohorts. Cohort sizes will increase to 6 patients if 1 of 3 patients in a cohort experience a DLT.~Once the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) is declared, no staggering of enrollment is required for accrual."
45617578|NCT03297463|Drug|Interleukin-2 & Ipilimumab (P-II)|"Phase II:~- Interleukin-2 & Ipilimumab will be administered at the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D)."
45617579|NCT03365531|Other|Alternate Daily Fasting (ADF)|See ADF arm for details
45617580|NCT03365531|Other|Caloric Restriction (CR)|See CR arm for details
45617581|NCT03283891|Other|Educational intervention - humanistic nursing practice|"Four educational sessions:~Acquisition of core concepts of caring practice (I)~Acquisition of core concepts of caring practice (II)~Search for meaning: Influencing hope in persons through humanistic practice~Enacting different caring attitudes and behaviours in an intermediary simulation exercise with actor"
45617582|NCT03360851|Diagnostic Test|low-dose CT|see arm/group description
45804045|NCT05719207|Device|Balloon dilation of eustachian tube (Stryker XprESS LoProfile ENT dilation system)|Patients in the intervention group would undergo balloon dilation of the eustachian tube under local anesthetic in clinic. The Stryker XprESS LoProfile ENT dilation system will be used. Participants may undergo dilation under general anesthesia if a contraindication to in-clinic dilation exists.
45804046|NCT05719207|Other|Sham procedure|Patients in the sham group will undergo the motions of an in-office dilation of the eustachian tube, without actually dilating the eustachian tube.
45804047|NCT02363803|Drug|lidocaine|lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.
45617583|NCT03360851|Diagnostic Test|PoC-PCR|see arm/group description
45617584|NCT03283735|Behavioral|Elderly Enablement|The information given in this group will result from the knowledge obtained in previous phase of the study in the shape of small leaflets and other information materials to be made according to the best practice, to be given and remembered at scheduled times to the intervention group
45617585|NCT03365375|Behavioral|MBSR Referral|Referral for mindfulness-based stress reduction (MBSR), a structured meditation training program consisting of 8 weekly group sessions.
45617586|NCT03365375|Other|Usual Care Referral|Referral to PCP or Psychiatry
45617587|NCT03360617|Device|Syringe IV Push over 2-3 minutes|IV antibiotics will be administered by Syringe IV Push over 2-3 minutes
45617588|NCT03360617|Device|Piggyback over 30 minutes|IV antibiotics will be administered by IV Piggyback over 30 minutes.
45617589|NCT03297385|Drug|Enzalutamide|Men with localized prostate cancer will undergo an additional set of targeted tumor biopsies and will be subsequently treated with 3 months of enzalutamide. The prostatectomy specimen will be additionally sampled, ex vivo.
45617590|NCT03365297|Drug|Apalutamide|240mg (4x60mg) oral tablets daily over a max. of 90 days
45617591|NCT02459821|Other|GE-O SYSTEM|The first group will be subjected to RAGT for 9 weeks (2 sessions/ week) with a total of 18 sessions by mean of GE-O System (9). During each session, the patients will practice 15 to 20 min of simulated floor walking followed by 5 to 10 min of repetitive simulated stair climbing up and down. Breaks will be optional, but uninterrupted training intervals of at least 5 min for simulated floor walking and 3 min of simulated stair climbing will be required. When the patient reaches the maximum amount of time, speed of gait will then be progressively increased. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
45617592|NCT02459821|Other|Conventional training|The conventional walking group will be subjected to a conventional gait training for 9 weeks (2 sessions/week) with a total of 18 sessions. Each session will last altogether 50 minutes, the first 30 minutes will be dedicated to gait and stair climbing up and down training while the last 20 minutes to stretch the lower limb's muscles.
45617593|NCT03283501|Procedure|PCI after TAVI|Any patient undergoing PCI after TAVI, irrespective of clinical indications and irrespective of whether planned or not at the time of TAVI
45617594|NCT03282721|Procedure|precise location of commissure|
45617595|NCT04479319|Diagnostic Test|Thorax CT|Subjects in all arms have a Thorax CT and RT-PCR for SARS-CoV-2.
45617596|NCT04412941|Behavioral|Myofunctional exercises|"Myofunctional exercises: Respiratory rehabilitation exercises with diaphragmatic breathing, thoracic mobilization exercises and manual pompage techniques, followed by manual trigger point therapy techniques, that were identified by palpation following the guidelines provided by Travell and Simons trigger point manual, the accessory inspiratory muscles like pectoralis minor muscle, scapula elevator muscle, Sternocleidomastoid muscle.~Home oropharyngeal exercises: at every patient will be taught oropharyngeal exercises to perform at home twice a day (the duration of 15 minutes each session) involving in particular exercises for soft palate, tongue, facial and genio-glosso muscle.~The rules of sleep hygiene: a list of behaviours that physiologically promote a good night's sleep."
45617597|NCT04412941|Behavioral|The rules of sleep hygiene|The rules of sleep hygiene: a list of behaviours that physiologically promote a good night's sleep.
45617598|NCT04350541|Other|High-intensity interval training|Exercise with high-intensity intervals followed by active rest
45617599|NCT04350541|Other|Continuous aerobic training|Interval Moderate-intensity aerobic training without intervals
45617600|NCT03282643|Drug|Rivaroxaban 10 MG|Rivaroxaban pill 10mg qd, day1 and day2 after femoral venepuncture
45760584|NCT04095221|Drug|Prexasertib|"DOSE LEVELS FOR PATIENTS > 21 YEARS OF AGE, Dose Level -1, prexasertib 105 mg/ m2 once every 14 days in 28 day cycles Dose Level 0, 60 mg/m2 prexasertib once every 21 days Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days Dose Level 2, 105 mg/m2 prexasertib once every 21 days Dose Level 3, 105 mg/m2 prexasertib once every 21 days~DOSE LEVELS FOR PATIENTS ≤ 21 YEARS OF AGE Dose Level -1, prexasertib 150 mg/ m2 once every 14 days in 28 day cycles, Dose Level 0, 60 mg/m2 prexasertib once every 21 days, Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days, Dose Level 2, 150 mg/m2 prexasertib once every 21 days, Dose Level 3, 150 mg/m2 prexasertib once every 21 days"
45760585|NCT04095221|Drug|Irinotecan|15 mg/m2 IV daily x 10 days in 21 day cycles
45617601|NCT03282643|Drug|Rivaroxaban 20 MG|Rivaroxaban pill 10mg bid, day1 and day2 after femoral venepuncture
45617602|NCT03282643|Drug|Low-molecular-weight heparin|0.4 ml once daily, before femoral venepuncture(day1) and the following day (day 2)
45617603|NCT03282487|Drug|Modified release hydrocortisone|Patients will switch from their usual conventional immediate release hydrocortisone to daily dose equivalent of modified release hydrocortisone (Plenadren®)
45617604|NCT04068805|Behavioral|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
45617605|NCT02458651|Other|No intervention|No intervention administered in this study
45617606|NCT02458729|Drug|Tranexamic Acid 5%,5ml/amp (intraoperative)|tranexamic acid 1g administered intravenously five minutes before deflation of the tourniquet
45617607|NCT02458729|Drug|Tranexamic Acid 5%,5ml/amp (3 hours after operation)|tranexamic acid 1g administered intravenously 3 hours after operation
45617608|NCT02458729|Drug|0.9% Normal Saline (intraoperative)|0.9% Normal Saline 20ml administered intravenously five minutes before deflation of the tourniquet
45617609|NCT02458729|Drug|0.9% Normal Saline (3 hours after operation)|0.9% Normal Saline 20ml administered intravenously 3 hours after operation
45760586|NCT03466125|Procedure|Cardiac surgery|Retrospective cohort study
45804048|NCT02363803|Drug|Placebo|Normal saline, approved for hypovolemia, and homeostasis.
45804049|NCT02364271|Other|Thrombolysis in myocardial infarction score|An English- and Cantonese-speaking research nurse obtained the TIMI scores which consists of seven variables from each eligible patient.
45617610|NCT02458729|Drug|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14
45617611|NCT04229173|Diagnostic Test|MRI acquisition|MRI acquisition
45617612|NCT04229173|Diagnostic Test|DAT-SPECT|Imaging with DAT SPECT (Dopamine Transporter, Single Photon Emission Computed Tomography)
45617613|NCT04229173|Diagnostic Test|blood sample, cerebrospinal fluid (optional)|blood sample, cerebrospinal fluid
45617614|NCT04229173|Behavioral|Evaluations about motor abilities, depression, cognition and lifestyle|Evaluations about motor abilities (UMSAR scale), depression (BDI scale), cognition (MoCA scale) and lifestyle (MSA- QoL)
45617615|NCT04229173|Behavioral|Evaluation about depression cognition|Evaluations about depression (BDI scale), cognition (MoCA scale)
45617616|NCT02457871|Behavioral|Ecological Nurse Case Management|The Ecological Nurse Case Management (ENCM) intervention allows for individualized case management based on client preferences through mutual goal setting and client choice points, nursing assessments, the nurse's analytic decision-making process and critical thinking, and nursing actions.
45617617|NCT03282331|Procedure|Standard oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
45617618|NCT03282331|Procedure|High flow nasal oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
45617619|NCT03282331|Procedure|noninvasive ventilation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
45617620|NCT03920527|Drug|Itraconazole 400 mg|Duration of itraconazole
45617621|NCT03764995|Other|Standard bowel management|Lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.
45617622|NCT03764995|Other|Abdominal massage|Abdominal massage will be performed three days a week for four weeks. Each session will last around 15-20 minutes.
45617623|NCT03764995|Other|Placebo Ultrasound|Placebo ultrasound (US) will be applied to the abdominal region for four weeks, 2 days of the week and 15 minutes per day.
45617624|NCT03698539|Behavioral|hand gestures|We observe the use of spontaneous hand gestures in all the groups.
45617625|NCT03626311|Dietary Supplement|AKBM-3031|"Krill are shrimp-like small crustaceans (up to 6 cm) found in all the world's oceans, but mostly in the Arctic and Antarctic polar seas. Krill are rich in the long-chain omega-3 polyunsaturated fatty acids or LC-PUFAs eicosapentaenoic acid (EPA, C20:5n3) and docosahexaenoic acid (DHA, C22:6n3). The lipid pool of krill is composed of phospholipids and triglycerides and the LC-PUFAs are primarily in the phospholipid fraction.~The product is produced under food Good Manufacturing Practice (GMP) regulations and has status as GRAS or Generally Recognized As Safe. GRAS is defined by the US Food and Drug Administration (FDA) as a substance that is generally recognized, among qualified experts, to be safe under the conditions of its intended use."
45617626|NCT03626311|Other|Placebo|The placebo will be provided in capsules looking exactly as the krill oil capsules and will contain a fatty acid mixture (olive oil, corn oil, palm oil and medium chain triglycerides) which has the same composition as the average European diet (26.0% C16:0, 4.6% C18:0, 35.8% C18:1n9, 16.7% C18:2n6, 2.1% C18:3n3, 0% C20:4n6 and 14.8% other compounds) and contains no EPA or DHA.
45617627|NCT03265327|Dietary Supplement|Oral supplement containing omega-3 and omega-6|An oral supplement containing omega-3 and omega-6
45617628|NCT03265327|Dietary Supplement|Oral supplement containing coconut and olive oil|An oral supplement containing coconut oil and olive oil
45617629|NCT03611569|Drug|Lu AF82422|Lu AF82422 - concentrate for solution for infusion; vials containing 50mg/ml, single dose
45617630|NCT03611569|Drug|Placebo|placebo - concentrate for solution for infusion, single dose
46069105|NCT04373811|Diagnostic Test|Muscle ultrasound|"Diaphragm ultrasound will be performed using intercostal view with a linear probe at the zone of apposition for assessing diaphragm thickness and thickening and subcostal anterior view with convex probe to assess diaphragm excursion.~Thickness of vastus intermedius, rectus femori and tibialis anterior will be measured using ultrasound linear probe. Cross-sectionnal area and echogeneicity of rectus femori and tibialis anterior will be measured using ultrasound linear probe. Penation angle of rectus femori will be assessed using ultrasound linear probe."
46069106|NCT04367233|Other|General anesthesia|General anesthesia with fentanyl, propofol and remifentanil.
45617631|NCT03107845|Behavioral|Cognitive Behavior Therapy|Treatments are conducted by cognitive-behavioral therapists in training with different levels of experience as well as licensed cognitive-behavioral therapists with several years of experience. The treatment approach is based on cognitive-behavioral manuals and principles.
45617632|NCT03107845|Behavioral|CBT plus Feedback|Therapists of the IG1 are provided with information about the initial status concerning symptoms (BSI & OQ-30), interpersonal functioning (IIP-32 & OQ-30) as well as diagnoses specific symptoms (GAD-7 or PHQ-9). Beside the status measures, also individual progress information on the symptom level (HSCL-11 each session) is provided to the therapist. Randomized controlled trial to evaluate the effects of personalized prediction and adaptation tools on treatment outcome in outpatient psychotherapy. This group is a matched sample.
45804050|NCT02364271|Biological|routine blood test for hs-cTnT|Patient had routine venipuncture blood taking for hs-cTnT measurement in the central laboratory of the hospital. Normal level of hs-cTnT is below 14ng/L.
45804051|NCT02364271|Other|HEART score|The modified HEART score of each patient was determined retrospectively by a research assistant.
45804052|NCT02366611|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
45617633|NCT03107845|Behavioral|CBT plus Feedback plus CST|"Additional to the intervention group CBT and Feedback therapists will be provided with additional clinical support tools (CST) which are designed to facilitate treatment selection and treatment adaptation. The causes of deterioration will be assessed and therapists will be provided with additional treatment recommendations and material to help preventing treatment failure for a specific patient. During treatment the clinical support tools will be provided in the problem fields: risk/suicidality, motivation / treatment goals, therapeutic relationship, social support / critical life events, and emotion regulation / self regulation."
45445739|NCT03560050|Behavioral|Children's environmental health|Participating family child care home providers in and around the OKC area will be randomized to either the Nutrition (n=26), or an environmental health intervention (n=26) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Intervention will consist of three encounters with the intervention team: two home-based, 90-minute visits scheduled at the convenience of the family child care home provider and a 3-hour group class session that will be conducted on a weekend. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention over a period of three months.
45445740|NCT02066038|Drug|Erlotinib|150mg po on days 2-15 of each 3 week cycle for 4 cycles and 150mg po per day after 4 cycles until disease progression
45445741|NCT03766893|Drug|Buprenorphine / Naloxone Oral Product|To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly (buprenorphine/naloxone) basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
45617635|NCT03264937|Behavioral|Social-software management|Using Wechat application, a social platform, to manage warfarin therapy in patients with mechanical valve replacement.
45617636|NCT03282175|Other|Exercise|Exercise session consisted of general warm-up of 10 min, followed by 35-40 min of resistance exercises (chair squats, band seated: biceps curl, seated row, knee extension, leg press and hip abduction; standing behind the chair: knee flexion, and calf rise), and general cool down of 10 min.
45617637|NCT03282175|Other|Training|Each training session consisted of general warm-up of 10 min, followed by 35-40 min of resistance exercises (chair squats, band seated: biceps curl, seated row, knee extension, leg press and hip abduction; standing behind the chair: knee flexion, and calf rise), and general cool down of 10 min.
45760587|NCT03839147|Behavioral|Education and counseling|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale were applied to both groups by face to face interview during the day giving appointment for HSG. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher was repeated briefly on the morning of the HSG procedure and any questions of the patients were answered.
45617638|NCT03282175|Other|Control group|The control group did not receive any treatment.
45617639|NCT03282019|Device|High-flow nasal cannula therapy|Subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current Home oxygen therapy (HOT). The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
45617640|NCT03282019|Device|Home oxygen therapy (HOT)|All subjects will continue their current Home oxygen therapy (HOT) which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
45617641|NCT03536455|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
45617642|NCT03536455|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
45617643|NCT03529825|Drug|Rifaximin|Rifaximin will be administered twice a day orally or by nasogastric tube, at a dose of 15 mg/kg divided BID with a maximum dose of 1,650 mg, day -7 to day +28 or discharge (maximum duration 36 days).
45617644|NCT03281941|Other|Inhaled capsaicin cough challenge|
45617645|NCT02459509|Drug|Dexmedetomidine|Either 2mcg/kg or 4mcg/kg of intranasal dexmedetomidine will be given to assess efficacy of preoperative sedation
45617646|NCT03264859|Diagnostic Test|NGAL levels early and post STEMI|NGAL levels early and post ST elevation MI (STEMI)
45617647|NCT03264781|Drug|Cyclofem|Intramuscularly injection 0.5 ml of Cyclofem or placebo
45760588|NCT03929393|Behavioral|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social suppo
45617648|NCT03281863|Diagnostic Test|C reactive protein, anti streptolysin o antibody test ,erythrocyte sedimentation rate|Throat culture to detect the causative organism
45617649|NCT03272581|Other|Functional Training|Functional training has been defined as emphasizing multiple muscle and joint activities, combining upper and lower body movements, and utilizing more of the body in each movement. The primary goal of functional training is to transfer improvement achieve in one movement to enhancing the performance of another movement by affecting the entire neuromuscular system.
45617650|NCT03281785|Other|Pressure controlled mandatory ventilation mode (P-CMV)|Pressure controlled mandatory ventilation mode (P-CMV)
45760589|NCT03929393|Other|Keys to Health & Wellbeing|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
45617651|NCT03281785|Other|Pressure synchronized intermittent mandatory ventilation|Pressure synchronized intermittent mandatory ventilation
45617652|NCT03281785|Other|Pressure support mode (PS)|Pressure support mode (PS)
45617653|NCT03272269|Drug|IMCY-0098|Small synthetic peptide for SC admin. Solvent: alum hydroxide
45617654|NCT03272269|Other|Placebo|Solvent: alum hydroxide
45617655|NCT03281707|Procedure|NIRS|NIRS devices patch will be applied on patients' head in order to measure the cerebral saturation of each cerebral emisphere
45617656|NCT03281707|Other|DO2i|Oxygen delivery standardized to the body surface area will be calculate in order to optimize tissue perfusion
45617657|NCT02458495|Behavioral|Diabetes MAP Intervention|
45617658|NCT03264625|Drug|Cholecalciferol (2000iu qd)|Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD
45617659|NCT03264625|Other|Routine therapy for PD|Patients randomized to the placebo group will receive routine therapy for PD.
45617660|NCT03281551|Drug|PZ01 CAR-T cells|Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma. The CAR consists of a CD19 targeting antibody scFv with two intracellular signaling domains derived from CD3 zeta and 4-1BB. Autologous T cells will be gene-engineered with the CAR gene using a lentivirus vector. Prior to T cell infusion, the patients will be subjected to preconditioning treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of CAR T cells and efficacy.
45617661|NCT03271645|Behavioral|Space from Depression|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
45617662|NCT03271645|Behavioral|Space from Anxiety|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
45760590|NCT05209269|Other|Work of breathing observation|We will place soft elastic bands around the infant's chest and abdomen to assess their work of breathing.
45804053|NCT03417193|Drug|opioid free Anesthesia vs Opioid based Anesthesia|Compare the opioid based anesthesia with Fentanyl and Remifentanyl to opioid free anesthesia with dexmedetomidine and lidocaine and their effect on postoperative pain.
45804054|NCT02366845|Biological|Fresh Frozen Plasma|An INR dose-response curve with associated transfusion algorithm was generated for plasma in bleeding patients with chronic liver disease. In the intervention arm we will determine the plasma transfusion dose using the algorithm dosing table based on the pre-transfusion INR and the clinician chosen INR target. In the usual care group the dosing will be determined by the clinician.
46069107|NCT04367233|Other|Transverse abdominal block|Transverse abdominal block with ropivacaine 0,25% 0,2 ml/kg at the end of general anesthesia with fentanyl, propofol and remifentanil
46069108|NCT04367233|Other|Quadratus lumborum block|At the end of general anesthesia with fentanyl, propofol and remifentanil, patients will receive quadratus lumborum block with ropivacaine 0,25% 0,2 ml/kg
46069109|NCT04362072|Drug|Lorlatinib|25 milligram (mg) tablet
45617663|NCT03271645|Behavioral|Space from Stress|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014).The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
45760591|NCT05205369|Behavioral|10-week home-based Yi Jin Bang exercise program|Each participant in this group will do a home-based Yi Jin Bang exercise program four times a week for ten consecutive weeks, which consists of ten minutes of warm-up, 18 minutes of Yi Jin Bang exercise (ten exercises), and ten minutes of cool-down. To learn how to conduct the home-based exercise session, each participant will be invited to one introductory session before starting the prescribed exercise program. Two experienced Yi Jin Bang instructors will lead the introductory session. Besides, in order to monitor participants' adherence and help them to conduct self-training, we will use the Zoom Meeting application. Zoom can capture and record participants' movements through the webcam. During the introduction sessions, we will teach participants how to use Zoom. Furthermore, we will provide support for adherence to the home exercise sessions through telephone calls or e-mail every two weeks.
45617664|NCT03271645|Behavioral|Face-to-face counselling|Face-to-face counselling
45617665|NCT03281473|Other|Strategy 1|PEEP titration according to transpulmonary-end-expiratory pressure
45617666|NCT03281473|Other|Strategy 2|PEEP titration according to chest wall elastance measurement
45617667|NCT02458573|Other|continuous epidural analgesia|the continuous epidural analgesia group: epidural analgesia started from induction of anesthesia and continued for 48 h.
45617668|NCT02458573|Other|continuous intravenous analgesia|the continuous intravenous analgesia group: intravenous analgesia started from induction of anesthesia and continued for 48 h.
45617669|NCT03281395|Procedure|Rapid ventricular pacing (RVP)|Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short period of time during dissection of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. RVP technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations and can be lifesaving in the case of an intraoperative bleeding or rupture.
45617670|NCT03281395|Procedure|No rapid ventricular pacing|
45617671|NCT03269929|Other|Music therapy|Subjects listened to music for 30 minutes before undergoing brachytherapy with spinal anesthesia
45617672|NCT03269929|Drug|Midazolam|Subjects received intravenous midazolam 0,02 mg/kgBW injection before undergoing brachytherapy with spinal anesthesia
45617673|NCT02457481|Device|Embryo Culture medium|Two step sequential embryo culture medium system
45760592|NCT05205369|Behavioral|10-week home-based usual exercise therapy program|Among exercise therapy in the treatment of SAPS, stretching and strengthening protocols are often used . Therefore, participants in this group will do a standardized home-based stretching and strengthening exercise program four times per week for ten weeks, which is set up according to a previous study. This program has been demonstrated that can be effective in reducing pain and improving function in patients with SAPS. For strengthening exercises, elastic bands will be used. To learn how to conduct the self-training program, each participant in this group will also be invited to one introductory session before starting the prescribed exercise training. Two certificated physiotherapists will lead the introductory session. In addition, a video demonstration clip will be given to each participant to provide a home reference, and the Zoom Meeting application will be used to help monitor the exercise.
45617674|NCT02730377|Drug|liraglutide|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
45760593|NCT05202873|Diagnostic Test|Gait analysis|Gait assessment will be performed using a non-invasive device. It is the BTS G-sensor inertial sensor (BTS Bioengineering, Garbagnate Milanese, Italy). The spatiotemporal variables of gait will be studied from the 6 'gait test, mobility, dynamic balance, gait ability and risk of falling through the Up and Go test.
45617675|NCT02730377|Drug|alpha-glucosidase inhibitors|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
45617676|NCT02730377|Drug|DPP-4 inhibitors|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
45617677|NCT02730377|Drug|meglitinides|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
45617678|NCT02730377|Drug|SGLT-2 inhibitors|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
45617679|NCT02730377|Drug|sulphonylurea|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
45617680|NCT02730377|Drug|thiazolidinediones|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
45617681|NCT03269773|Biological|FURESTEM-AD Inj.|"0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5 mL).~Treatment group: FURESTEM-AD® inj. 5.0 X 107 cells/1.5 mL"
45760594|NCT03454347|Dietary Supplement|Profile Perform|The dietary supplement includes 1.5 grams of fat, 19 grams of carbohydrate, and 25 grams of protein per serving. Participants in the experimental group will consume 3 servings per day.
45760595|NCT03454347|Other|Lower Limb Suspension|This group will complete two weeks of lower limb suspension.
45760596|NCT03867305|Device|MOBIDERM|Use of a MOBIDERM mobilizing band after total knee prosthesis
45617682|NCT03269773|Other|Placebo|0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5mL)
45617683|NCT03264547|Drug|Pertuzumab|Every 3 weeks
45617684|NCT03264547|Drug|Trastuzumab|Every 3 weeks
45617685|NCT03264547|Drug|Docetaxel|Every 3 weeks
45617686|NCT03264547|Drug|Paclitaxel|Every week
45617687|NCT03264547|Drug|Eribulin|Administered for 2 weeks and is then stopped to be administered for 1 week
45617688|NCT03360461|Drug|EMI-137|EMI-137 - a fluorescent c-Met receptor targeted peptide
45617689|NCT03365219|Device|Alexis O-Ring Wound Retractor|A flexible self-retaining plastic Alexis retractor was used in place of standard surgical retractors.
45617690|NCT03365219|Other|Standard Surgical Retractors|Routine hand-held metal retractors as needed by the surgical team
45617691|NCT03360383|Procedure|percutaneous vertebroplasty|Undertake Percutaneous vertebroplasty with polymethylmetacrylate bone cement.
45617692|NCT03360383|Procedure|conservative treatment|complete on bed with prevention of complications
45617693|NCT03360305|Behavioral|GAPcare intervention|Subjects will receive PT and pharmacist evaluation. PT will help determine whether subject may benefit from doing exercises to improve strength or balance. PT may also supply subject with an assist device. A pharmacist will ask patient about any medication they are taking and will make recommendations on how their medication could be changed to prevent falls. Pharmacists will communicate this information to subject's doctors. Subjects will receive a fall calendar for home, where they will record any falls they have after their discharge from the ED. They will receive a phone call at home asking about any recent falls and health care interactions. Study personnel will call subjects every 2 weeks for 6 months. Subjects may receive a referral for outpatient or home-based physical and occupational therapy at the end of the visit.
45617694|NCT03360227|Device|implantation of cardiac devices|implantation of cardiac devices
45617695|NCT03365141|Drug|Triamcinolone acetonide 0.4mg/cc|"Intralesional injection of dilute triamcinolone acetonide with 2% lidocaine (400mg/20 mL) would be performed to reduce pain when injecting the drug.~Once weekly, for a total of 12 weeks"
45617696|NCT03365141|Device|Phototherapy (NBUVB or excimer laser)|NBUVB or excimer laser treatment weekly
45617697|NCT03365141|Drug|Topical tacrolimus|Application of topical tacrolimus ointment twice a day
45617698|NCT03364985|Drug|DWP16001|DWP16001 tablets
45760597|NCT03994887|Device|Experimental group|EEG acquisition system BioSemi (Amsterdam, the Netherlands), enabling real-time measurement and continuous recording of EEG on up to 128 leads.
45760598|NCT04940897|Other|Use of CareSens ketone meter|Use of CareSens ketone meter to identify blood ketone levels and delivery of fluid therapy to those patients at high risk of DKA
45760599|NCT04938869|Other|Educational Intervention|Receive basic diabetes mellitus education
45760600|NCT04938869|Other|Medical Device Usage and Evaluation|Use CGM device and app
45760601|NCT04938869|Other|Survey Administration|Ancillary studies
45617699|NCT03364985|Drug|Placebo|DWP16001 placebo-matching tablets, Active control placebo-matching tablets
45760602|NCT05192655|Other|Observation|Observation Study
45760603|NCT05186337|Behavioral|FROA-BD programme|The experimental group (n=42) will receive a 4-month intervention consisting of 32 sessions of treatment.
45760604|NCT03361371|Device|Battery operated nasal aspirator|Suctioning prior to every feed with battery operated nasal aspirator for three days in addition to the routine standard of care.
45760605|NCT03361371|Device|Suction bulb|Suctioning prior to every feed with bulb nasal aspirator for three days in addition to the routine standard of care.
45760606|NCT03359733|Drug|TAK-659|TAK-659 tablet.
45617700|NCT03364985|Drug|Dapagliflozin|Forxiga®
45617701|NCT04523441|Other|Focus group|Holding of a focus group by a sociologist
45617702|NCT04523441|Other|Semi-directive interview|Conducting a semi-directive interview by a sociologist after discharge from hospital
45617703|NCT03364907|Other|HIPEC with flushing afterwards|flushing with saline fluid after HIPEC
45760607|NCT03357627|Drug|TAK-659|TAK-659 tablets.
45617704|NCT03364907|Other|HIPEC without flushing afterwards|NO flushing with saline fluid after HIPEC
45617705|NCT03359915|Behavioral|COPD Self-Management Plan|Patient education in use of a COPD self-management action plan supported by monthly visits from, and access to, a CHW who has been trained in the use of a COPD self-management action plan.
45617706|NCT03364829|Drug|Indacaterol/Glycopyrronium|
45617707|NCT03359837|Drug|INSULIN GLARGINE (HOE901)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
45617708|NCT03359837|Drug|Insulin Glulisine|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
45617709|NCT03359837|Drug|Biphasic insulin aspart 30|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
45617710|NCT03359837|Drug|Repaglinide|"Pharmaceutical form: tablet~Route of administration: oral administration"
45617711|NCT03359837|Drug|Acarbose|"Pharmaceutical form: tablet~Route of administration: oral administration"
45617712|NCT03359837|Drug|Metformin|"Pharmaceutical form: tablet or capsule~Route of administration: oral administration"
45760608|NCT03357627|Drug|Venetoclax|Venetoclax tablets.
45760609|NCT03834701|Device|EUS guided radiofrequency ablation|The EUS-RFA system (Taewoong, Seoul, Korea) utilized for EUS-RFA consists of an 19-gauge needle electrode (140-cm long), a radiofrequency generator, and an inner cooling system that circulates chilled saline solution during the RFA procedure. The inner metal part is insulated over its entire length, with the exception of the terminal 5 to 20mm for energy delivery. The needle electrode is attached to a radio frequency current generator (VIVA RF generator; Taewoong) and to a cooling pump. The generator, in addition to providing radio frequency current, allows the control of physical power and impedance parameters.
45617713|NCT04523285|Drug|TQB3728|TQB3728 tablets is a small molecule oral drug.
45617714|NCT04524923|Other|visual motor integration|investigate the relation between touch screen usage and visual motor integration in preschoolers
45617715|NCT04524923|Other|Quality of life assessment|investigate the relation between touch screen usage and Quality of life assessment in preschoolers
45617716|NCT04524923|Other|Cognitive Functioning|investigate the relation between touch screen usage and Cognitive Functioning assessment in preschoolers
45617717|NCT03359759|Other|Conected objects|"Every week, each patient report her symptoms and answer ten questions on the i-PAD. The connected watch reports the performance status (activtiy and time spent in bed or sitting), and the falls.~If nurses or doctors detect any problem, they ask the patient for a telemedicine to try to help her. During the same time, nurses or doctors send a message on a secure plateform to the local team (nurse, General Practitioner, and pharmacists) and they reserve a place for an hospitalization if necessary."
45617718|NCT03359681|Drug|Metformin Hydrochloride|metformin 500mg three times a day 20 days before colon cancer surgery and 10 days after.
45617719|NCT03359681|Drug|Placebo oral capsule|placebo 500mg three times a day 20 days before colon cancer surgery and 10 days after.
45617720|NCT03359603|Device|Electro-acupuncture|"Patients will be treated by use of 5 obligatory and 3 customized acupoints. Obligatory points (ST35, EX-LE5, LR8, GB33 and Ashi) will be used in all patients. Other 3 customized acupoints should be chosen by the physicians on the basis of traditional Chinese medicine diagnosis for acupuncture channels related to the individual pain area, with the intent of optimizing efficacy. ST34, ST36, ST32, ST40 and EX-LE2 will be used for pain at stomach meridian. GB31, GB36, GB34, GB39 and GB41 will be used for pain at gallbladder meridian. BL39, BL40, BL57 and BL60 will be used for pain at bladder meridian. LR7, SP9, SP10, KI10, SP4, SP6, LR3 and KI3 will be used for pain at three yin meridians of foot. Needles will be stimulated manually for 10 seconds to achieveDe Qi. Paired alligator clips will be attached transversely to the needle holders at LR8-GB33 and two other customized acupoints. Other needles will be manipulated for 10 seconds during the treatments."
45617721|NCT04171063|Device|Thoracic compressor|The intervention is the use of the thoracic compressor for the conservative treatment of pectus carinatum
45617722|NCT04524845|Device|Unloading brace|"Participants underwent one session of gait analysis. The experimental protocol was divided in four conditions, the control condition without brace (NO), and then three conditions with the different braces tested in a randomized order.~For each condition, the participant was fitted with the brace by the same experimenter and equipped with 19/20 retro-reflective markers (without/with brace) on the pelvis and the investigated leg for motion analysis. After a short recording in a fixed standing position (static trial), each participant carried out at least three barefoot walking trials of a few meters long at a self-selected pace. The walking trial was validated if a complete gait cycle occurred on the two 90cm x 90 cm force plates recording the ground reaction forces. After each condition, the participant had to assess knee pain."
45617723|NCT04524845|Device|Rebel Reliever (RR)|Rebel Reliever (RR) (Thuasne, Levallois Perret, France)
45617724|NCT04524845|Device|Action Reliever|Action Reliever (AR) (Thuasne, Levallois Perret, France)
45617725|NCT03364595|Procedure|plate fixation|ORIF of the radial head fracture
45617726|NCT03364595|Procedure|replacement|replacement of the radial head fracture
45617727|NCT03364361|Procedure|Acupuncture|Participants will receive a six-point standardized stress acupuncture (SSA) treatment once a week for 4 weeks. The SSA consists of GV- 20, GV-24.5 (Yin Tang), bilateral LI-4, and bilateral LR-3. This acupuncture protocol has been used as an effective treatment for stress-related symptoms in the operational theater.
45617728|NCT03364205|Behavioral|solution-focused interview technique|This approach helps an individual make decisions about behavioral change, focusing particularly on his or her past achievements and looking forward to a time when the problems cease to exist.
45617729|NCT03363971|Drug|Zhi Kang Capsule|0.3g/capsule, oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery; treatment for 6 weeks.
45617730|NCT03363971|Drug|Simulant agent for Zhi Kang Capsule|0.3g/capsule,oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery; treatment for 6 weeks.
45617731|NCT04524377|Procedure|Deep Brain Stimulation|"Deep brain stimulation involves implanting electrodes within certain areas of the brain. These electrodes produce electrical impulses that regulate abnormal impulses. Or the electrical impulses can affect certain cells and chemicals within the brain.~The amount of stimulation in deep brain stimulation is controlled by a pacemaker-like device placed under the skin in the upper chest. A wire that travels under the skin connects this device to the electrodes in the brain."
45617732|NCT03359525|Drug|Tranexamic Acid|intravenous versus Intraarticular versus intravenous
45617733|NCT03359447|Drug|Weekly Ferrous Sulfate|Drops
45617734|NCT03359447|Drug|Daily Ferrous Sulfate|Drops
45617735|NCT04524299|Radiation|chest radiation(IMRT)|Patients will receive intensity modulated radiotherapy (IMRT) once a day, 5 days a week. The first stage: DT 3000 cGy / 6 FX; the second stage, DT 3500 cGy / 7 FX. Or: the first segment: DT 4000 cGy / 10 FX; the second segment DT 2400 cGy / 6 FX. The interval between two stages of radiotherapy was 4 weeks.
45804055|NCT02366845|Diagnostic Test|Pre-Transfusion International Normalized Ratio (INR)|INR result prior to Fresh Frozen Plasma (FFP) transfusion determined by clinical lab testing performed within 6 hours to 1 day before transfusion start time.
45804056|NCT02366845|Diagnostic Test|Post-Transfusion International Normalized Ratio (INR)|INR result after Fresh Frozen Plasma (FFP) transfusion completed, determined by clinical lab testing performed within 1 hour after transfusion completed.
45804057|NCT02367391|Behavioral|Motivational Text Messages|Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.
45804058|NCT02367391|Behavioral|Control|Usual Care. All participants receive the active medication, Varenicline.
45617736|NCT04524299|Drug|Concurrent chemotherapy twice a week|"During the same period of radiotherapy, 30 mg / m2 albumin bound paclitaxel was intravenously infused twice a week for 0.5 hours, and nedaplatin 10 mg / m2 twice a week for 0.5 hours.~When the radiotherapy dose was 3000 cGy / 6 FX + DT 3500 cGy / 7 FX, the infusion time was D1, D4, D8 of the first stage of radiotherapy; D1, D4, D8 of the second stage of radiotherapy.~When the radiotherapy dose was 4000 cGy / 10 FX + DT 2400 cGy / 6 FX, the infusion time was D1, D4, D8, D11 of the first stage of radiotherapy; D1, D4, D8 of the second stage of radiotherapy"
45617737|NCT04524299|Drug|Concurrent chemotherapy once a week|During the same period of radiotherapy, albumin bound paclitaxel (50 mg / m2) was intravenously infused once a week for 0.5 hours; nedaplatin (25 mg / m2) was intravenously infused once a week for 0.5 hours. The infusion time was D1, D8 of the first radiotherapy and D1, D8 of the second radiotherapy.
45617738|NCT03358433|Other|Exercise|
45617739|NCT03359369|Diagnostic Test|level of serum cholesterol and triglyceride|other
45617740|NCT03359291|Drug|Rosuvastatin|Single oral dose of 10 mg rosuvastatin (film-coated tablet) on Day 1 and Day 10
45617741|NCT03359291|Drug|Macitentan|Single oral dose of 30 mg macitentan (film-coated tablet) on Day 5 and 10 mg macitentan administered orally from Day 6 to Day 16
45617742|NCT04522583|Diagnostic Test|Diagnosis of Myocardial Ischemia|Discharge diagnosis of myocardial ischemia
45617743|NCT03358277|Drug|MPH + APZ|MPH was administered with either Ritalin (from 10mg/day to 40mg/day) or Concerta (from 18mg/day to 36mg/day) according to clinical judgement for six weeks. APZ was administered with dose from 2.5mg/day to 5mg/day according to clinical judgement for six weeks.
45617744|NCT03359135|Other|Rehabilitation|Rehabilitation during 4 weeks
45617745|NCT03359135|Device|Compression Garment|Rehabilitation associated to wearing CG during 4 weeks
45760610|NCT03839225|Other|Community intervention|"Community intervention will be built depending on contextual factors and will contain the following elements:~Cross-sector intervention, including sectors to define the intervention as primary health care services, education services (language, knowledge to prevent health problems and resilience strategies), family welfare units, Integral Care and Reparation Unit for Victims (UARIV), Ministry of Labour, national and international social support network, among others.~The leader will be chosen by the community, with the capabilities to coordinate the community-based network.~Mental health providers at the local level, who must develop psychosocial and mental diagnoses and interventions, based on experience and evidence, respectively. This team will include psychiatry, psychologists (one an expert in clinical psychology) and a community team involved in the implementation of mental interventions."
45804059|NCT02367859|Drug|Dabrafenib|Given PO
45804060|NCT02367859|Drug|Trametinib|Given PO
45804061|NCT02368093|Drug|Dextromethorphan hydrobromide|120mg per day with once daily dose taken after breakfast for 6 months
45445742|NCT03766893|Drug|injectable naltrexone|To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
45617746|NCT04522193|Device|Glycemic Holter|Continuous glycaemia monitoring,
45617747|NCT04522193|Radiation|gastric emptying scintigraphy|Fasting administration of a Technecium-labelled milk bottle and quantification of the remaining radioactivity by a camera every 30 minutes for 4 hours.
45617748|NCT04522193|Device|Holter ECG|continuous cardiac monitoring
45617749|NCT03359057|Drug|ethinyl estradiol + levonorgestrel + folic acid|One coated tablet of ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg for 21 days in 3 cycles (12 weeks).
45617750|NCT03359057|Drug|Folic Acid|One coated tablet of folic acid 0.4 mg for 7 days in 3 cycles (12 weeks).
45617751|NCT04522115|Other|exercises|"Group(1) aerobic training: Each exercise training session included 3 to 5 minutes of warm-up, range-of-motion exercises, interval training(aerobic training), cool-down, and post-exercise range-of-motion exercises. Patients exercise at 40 to 60% of maximum heart rate.~Group(2) resistance exercise: training of the lower extremities was performed three times per week. Starting weights for knee extension and hip abduction and flexion were determined from a three-repetition maximum (3RM) using ankle weights that can be adjusted in 1 lb. increments. A 3RM is the maximum weight that can be lifted three times with proper technique. Training started at approximately 60% of 3RM for two sets of 10 repetitions and was increased to three sets as tolerated."
45617752|NCT03358199|Procedure|LOD|Women underwent LOD in the preceding 3 months prior to IVF/ICSI
45617753|NCT03358121|Diagnostic Test|Clamp study|Clamp study to achieve high, normal, and lower glucose levels to study the dynamics of Asprosin.
45617754|NCT03358901|Drug|YC-6|
45617755|NCT03358901|Drug|Vehicle|
45617756|NCT03358043|Device|mechanical ventilation|Consecutive intubated pateints receiving mechanical ventilation with a PaO2/FiO2≤300 mmHg on positive end-expiratory pressure (PEEP) of 5 cmH2O or more and FiO2 of 0.3 or more.
45617757|NCT02714569|Drug|LY3202328|Administered orally
45617758|NCT02714569|Drug|Placebo|Administered orally
45617759|NCT02714569|Drug|Atorvastatin|Administered orally
45617760|NCT02714569|Drug|Simvastatin|Administered orally
45617761|NCT03358745|Other|Standard meal, bread/butter as starter|Reference lunch. Bread and butter are eaten during the first 15 min. Soup, cheese and salad are eaten within the following 15 min.
45617762|NCT03358745|Other|Standard meal with soup as starter|Lunch meal in which soup is eaten during the first 15 min. Bread, butter, cheese and salad are eaten within the following 15 min.
45617763|NCT03358745|Other|Standard meal with cheese as starter|Lunch meal in which cheese is eaten during the first 15 min. Bread, butter, soup and salad are eaten within the following 15 min.
45617764|NCT03358745|Other|Standard meal with salad as starter|Lunch meal in which salad is eaten during the first 15 min. Bread, butter, soup and cheese are eaten within the following 15 min.
46069110|NCT04341350|Drug|Propofol + analgesic drug|sedation according to a written, standardized Nurse management protocol using at least one sedative drug (propofol) and one analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl
45617765|NCT03358667|Procedure|augmentation peri-implant soft tissue|the implant was cover with a 2 mm cover screw for a tent effect or with a dermal membrane after implant insertion
45617766|NCT03357965|Other|Questionnaire|Women who had gave birth in 6 weeks
45617767|NCT03357887|Other|Analysis of cerebrospinal fluid and serum|Analysis of biomarkers in patient biological samples
45617768|NCT03269851|Radiation|computed tomography|ct will be done to detect radiological risk factors for neurological deficits after thoracolumbar fractures
45617769|NCT04522817|Biological|CLBS119|Peripheral blood derived autologous CD34+ cells
45617770|NCT03281161|Behavioral|Sun Safe Workplaces Program|A follow-up analysis of sun safe practices by employees and an economic evaluation of the SSW intervention was conducted with the work-sites who received occupational sun protection policy promotion materials in the prior trial. The analysis of sun safety practices of employees was done by preparing the protocols and measures for surveying employees and front-line supervisors by online and paper methods. The economic evaluation was a retrospective collection of cost information from the prior project ledgers and an in depth interview with the key contact manager at each work-site. No additional treatment was provided and the groups were evaluated based on their prior condition assignment.
45617771|NCT03281161|Behavioral|Attention Control|A follow-up analysis of sun safe practices by employees and an economic evaluation of the SSW intervention was conducted with the work-sites who received occupational sun protection practice promotion materials in the prior trial. The analysis of sun safety practices of employees was done by preparing the protocols and measures for surveying employees and front-line supervisors by online and paper methods. The economic evaluation was a retrospective collection of cost information from the prior project ledgers and an in depth interview with the key contact manager at each work-site. No additional treatment was provided and the groups were evaluated based on their prior condition assignment.
45617772|NCT03357809|Procedure|Endoscopic mucosal resection|"Mucosectomy performed at day 1. Endoscopic mucosal resection (EMR) and or endoscopic submucosal dissection (ESD), is at least 3 cm long. The mucosal resection is carried out along the side of the small curvature of the stomach, in order to preserve a valve of the cardia at the level of the large curvature of the stomach.~A coloured solution is injected into the submucosa following markers. The correct submucosal injection is confirmed by the lifting of the mucosal surface. A submucosal dissection is carried out using the dual knife. The mucosectomy is repeatedly performed until the mucosal zone is completely resected. The choice of the resection technique will depend on the anatomy of the patient."
45617773|NCT03281083|Drug|Levothyroxine Sodium|
45617774|NCT04445129|Device|Portable EEG Device|Portable EEG device is lightweight and designed for nighttime wear.
45617775|NCT04445129|Device|Portable ECG Device|Portable ECG device is waterproof and will be adhered to the chest of the participant.
45617776|NCT04445129|Device|Accelerometry|Portable accelerometry device is noninvasive and will capture data on participant activity level, including intensity of movement, rest, and sleep.
45617777|NCT04521959|Procedure|Blood flow restricted and normal aerobic exercise and resistance exercise|Interventions of the same duration and intensity will be applied to two groups.
45617778|NCT04522037|Other|No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups|Respiratory rate is analyzed with the scope (approved by the French national medical authorities)
45760611|NCT04923113|Diagnostic Test|Histology，13C urea breath test，Stool antigen test，Serological antibody test for H.pylori and Serologic test with a current infection marker of H.pylori|The above 5 detection methods will be performed in patients who meet the inclusion criteria to detect H. pylori infection
45760612|NCT04923113|Drug|Rabeprazole，Minocycline，Amoxicillin and Colloidal bismuth pectin|Helicobacter pylori positive patients will be treated with rabeprazole10mg,minocycline 100mg,amoxicillin1000mg,and colloidal bismuth pectin 200mg,all twice daily for 10 days
45760613|NCT05143047|Behavioral|Medication counseling|"Participants will receive a customized written medication instruction sheet which includes a picture of an oral dosing syringe indicating the patient's dose as well as a chart showing medication name, dose, route, frequency, duration, next dose due, side effects, and storage information. In addition, participants will be shown how to draw up their child's dose using an oral syringe and then will be asked to practice this task (show-back). Teach-back will be used to ensure participant's understanding of medication details."
46069111|NCT04341350|Drug|Isoflurane + analgesic drug|sedation by inhalation of halogenated gas (Isoflurane) delivered by the Anesthetic-Conserving Device (ACD) system ANACONDA ™ associated with the administration of a analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl.
46073650|NCT00841711|Behavioral|Intensive Case Management|Transitions involves the integration of evidence-based interventions, intensive case management that incorporates outreach elements similar to assertive community treatment (ACT). Intensive case management goes beyond the tenets of case management and incorporates community outreach. This model of case management has its roots in assertive community treatment (ACT) and has demonstrated a 37% greater reduction in homelessness and a 26% greater improvement in psychiatric symptom severity compared with standard case management treatments. As such, intensive case management is likely to result in important outcomes for the target population, is evidence-based and has been validated in prison-release programs.
45617779|NCT03357653|Drug|Losartan group|Losartan 50 mg daily
45617780|NCT03357653|Drug|Placebo group|Placebo 1 pill daily
45617781|NCT02713789|Drug|hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)|
45617782|NCT02713789|Drug|Placebo (PBS-20% sucrose)|
45617783|NCT04522661|Procedure|Vitrectomy|Vitrectomy within 48 hours of randomisation
45804062|NCT05719129|Behavioral|Date With Destiny (DWD) Seminar|6 days of immersive seminar
45617784|NCT04522661|Procedure|Intravitreal antibiotics|Intravitreal Antibiotics at 48 hours
45617785|NCT04445051|Device|New intermittent catheters variation 1 and 2 for both male and females|The new catheters are not named at this point but are intended for intermittent drainage of the bladder.
45617786|NCT04522349|Device|Greifer then Axon-Hook|Each participant is fitted with a Greifer and assessed after two weeks home-trial. Then he is fitted with Axon-Hook and assessed after two weeks home trial.
45617787|NCT04522349|Device|Axon-Hook then Greifer|Each participant is fitted with a Axon-Hook and assessed after two weeks home-trial. Then he is fitted with Greifer and assessed after two weeks home trial.
45617788|NCT03358589|Diagnostic Test|FDG-PET/CT|Scans
45617789|NCT03264313|Device|Deep Transcranial Magnetic Stimulation|Patients undergoing of Deep Transcranial Magnetic Mtimulation (dTMS) for smoking cessation
46069112|NCT04316663|Behavioral|Well-Being Intervention|The main aim of the well-being intervention is to reduce levels of distress through the promotion of psychological well-being. Key components of the intervention are self-monitoring of instances of well-being and what leads to their interruption (i.e., thoughts and behaviors), cognitive restructuring of interfering thoughts, and homework assignments to address dysfunctional behaviors and increase exposure to optimal experiences. Participants will become aware of their functioning based on six different dimensions of psychological well-being (i.e., self-acceptance, positive relations with others, autonomy, environmental mastery, purpose in life, and personal growth), and will be guided in finding a balance within each dimension.
46069113|NCT04316663|Behavioral|Sleep Hygiene|The main aim of sleep hygiene education is to provide participants with a set of behavioral and environmental recommendations intended to promote healthy sleep. During the intervention, participants will become aware of their own sleep patterns, will learn about healthy sleep habits, and will be encouraged to follow a set of recommendations to improve their sleep. Key components of the intervention are sleep hygiene and education.
46069114|NCT04264403|Device|Renal denervation|The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
45617790|NCT03357575|Biological|Mesenchymal Stem Cells from adipose|inject mesenchymal Stem Cells from adipose
45617791|NCT03357575|Biological|Hyaluronic Acid|inject hyaluronic acid
45617792|NCT03269461|Device|Angiography and Optical Coherence Tomography evaluations|coronary stent implantation followed by Angiography and Optical Coherence Tomography evaluations
45617793|NCT03358511|Dietary Supplement|Probiotic|Primal Defense Ultra® Probiotic Formula is an over-the-counter probiotic that provides 15 billion colony forming units of 13 species of beneficial bacteria, including Saccharomyces boulardii, Lactobacillus plantarum, Bacillus subtilis, Bifidobacterium lactis, Bifidobacterium bifidum, Lactobacillus rhamnosus, Bifidobacterium breve, lactobacillus casei, Lactobacillus salivarius, Lactobacillus acidophilus, Lactobacillus brevis, Bifidobacterium longum, and Lactobacillus paracasei.
45617794|NCT03269617|Dietary Supplement|Bacteriophage mixture|Four bacteriophage strains: LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae.
45617795|NCT03269617|Other|Placebo Control|Placebo control capsule consisting of rice maltodextrin
45617796|NCT03357497|Other|Very early mobilization|The patient will be mobilized by a physiotherapist in our postoperative care unit. The intervention uses the SOMS protocol.
45617797|NCT03280927|Drug|Jublia®|Jublia® topical solution
45617798|NCT03357263|Biological|GC3114|High-dose Quadrivalent influenza vaccine
45617799|NCT03357263|Biological|GCFLU Quadrivalent|Quadrivalent influenza vaccine
45617800|NCT03269383|Drug|Bupivacaine|Patients will receive a stellate ganglion block using 10 ml of 0.5% bupivacaine
45617801|NCT03269383|Other|Saline|Patients will receive a stellate ganglion block using 10 ml of 0.9% saline
45617802|NCT04522427|Device|Use Multifocal and Extended Depth-of-Focus Intraocular Lenses(IOLs)|IOLs include AT LISA tri 839MP, AcrySof IQ PanOptix IOL, TECNIS Symfony EDOF
45617803|NCT04522427|Device|Use Monofocal intraocular lenses(IOLs)|Monofocal IOLs include 409(Zeiss), AcrySof, TECNIS IOLS
45617804|NCT03280849|Other|Implant of bilaminar chitosan scaffold|The patient underwent endoscopic endonasal transsphenoidal surgery for resection of the sellar lesion, under the direct visualization, the lesion appeared redish and soft with moderately bleeding, a sample was taken for pathology and the remaining is extracted without complications, then the scaffold is implanted in the site of the bone defect in the sphenoid sinus, due to its moldable nature, it was easily set, covering the entire extension of the defect, a fat graft was set in the sphenoid sinus covering the bilaminar chitosan membrane, then fibrin sealant was used for hemostatic control and a nasal packing was set in both nostrils for finalize the procedure.
45617805|NCT04521491|Drug|FOLFOX4(infusional fluorouracil [FU], leucovorin [LV], and oxaliplatin [OXA]).|FOLFOX4 (OXA 85 mg/m2 intravenously [IV] on day 1; LV 200 mg/m2 IV from hour 0 to 2 on days 1 and 2; and FU 400 mg/m2 IV bolus at hour 2, then 600 mg/m2 over 22 hours on days 1 and 2, once every 2 weeks.All patients in the treatment group will receive FOLFOX4 at most 12 times beginning from the 4th week after liver resection.
45617806|NCT04509635|Drug|Cetuximab|Cetuximab is used for only patients with ctDNA test RAS wild type.
45617807|NCT04509635|Drug|Chemotherapy|The detailed regimen is determined by a multi-disciplinary team according to the previous use of chemotherapy.
45617808|NCT03967717|Other|Characterization of parameters of medical history, examination and diagnostics.|Patients receive standard of care diuretics. The study only collects data to characterize parameters of medical history, examination and diagnostics.
45617809|NCT03357185|Procedure|Femoral eversion|"The purpose of this database is to compile the data of patients followed at the René Dubos Hospital Center with symptomatic lower extremity arterial disease (AOMI) (Rutherford 2 to 5) who were operated on by the femoral tripod eversion technique.~The database will include data on the operation, possible complications, clinical course of patients and medical and surgical follow-up."
45617810|NCT03280771|Combination Product|Hope Soap|HOPE SOAP© is a colourful, translucent bar of soap with a toy embedded in its centre.
45617811|NCT03280771|Combination Product|Control group soap|A colourful, translucent bar or soap with the toy alongside it
45617812|NCT03269539|Other|MRI Imaging|
45617813|NCT04521023|Drug|Cantabell Tab|Patients assigned to experimental group are treated with Cantabell Tab
45617814|NCT04521023|Drug|Candemore Plus Tab|Patients assigned to experimental group are treated with Candemore Plus Tab
45617815|NCT03269071|Drug|human fetal-derived Neural Stem Cells (hNSCs)|"The Drug Product (DP) can be classified as an ATIMP belonging to the class of Cell Therapy Medicinal Products (EU law). The ATIMP consists of human fetal-derived Neural Stem Cells (hNSCs) re-suspended in their final formulation medium as defined in the Investigational Medical Product Dossier (IMPD).~For dosage indications, see specific Treatment Cohorts (TC), from A to D.~The product will be administered intrathecally through lumbar puncture."
45617816|NCT04521101|Other|VAST Course|Educational course to teach non-technical skills
45617817|NCT02518529|Biological|G17DT|
45617818|NCT02457169|Behavioral|Parent Preschool Engagement intervention|This 1-2 session intervention (2-4 hours total) will involve one-on-one session(s) for parents whose children (all of whom have received a diagnosis of ASD through our study) are turning 3 and therefore transitioning from the Early Intervention system to the public school special education system. The intervention will utilize motivational interviewing (MI) principles to equip parents with the skills, knowledge, and clarity of goals necessary to collaborate effectively with school special education staff and teachers, to advocate for their children's needs, and to be empowered to navigate the special education system.
45617819|NCT02457169|Behavioral|Attention Control|The attention control condition is parallel in format (one-on-one between parent with interventionist) and intensity (1-2 sessions, or 2-4 hours total). It involves open-ended interviews with parents about their child's development and plans for school.
45617820|NCT04444817|Drug|Tacrolimus|Similar to the clinical routine, as soon as a patient is able to swallow and has a sufficient gastrointestinal activity, Tacrolimus-based immunosuppression using Prograf®, Advagraf® or Envarsus® will be started. Furthermore, calcineurin inhibitors-based immunosuppression will be used (initial dose based on the patients' body weight) with the goal of tough levels of 3-7 ng/mL in the first seven days after liver transplantion, depending on immune status and indication for transplantation. Further tough levels will be determined based on factors such as patients' history and indication for liver transplant.
45617821|NCT05234827|Other|Virtual Reality|Total time duration for session is 40 minutes which includes 5 min of warm exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 minutes of VR session and 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing.
45760614|NCT03925311|Procedure|endometrial biopsy and blood sampling|patient will be performed endometrial biopsy and collected blood samples at particular time points
45760615|NCT03923907|Behavioral|EIM intervention group|As in arm description
45911618|NCT05777954|Other|Possible Klotho effects on SSc clinical conditions, namely skeletal, fibrotic and microangiopathic damage|"Female patients with a diagnosis of Systemic Sclerosis ( EULAR/ACR 2013 criteria ) attending the FPG Department of Rheumatology will be recruited after exclusion criteria are ruled out and informed consent is signed. DXA bone mineral density determination (Lunar Prodigy ) will be performed and bone metabolism parameters, according to routinary clinical practice, will be collected. Immunological and SSc-related disease features will also be recorded. Fibrosis will be determined by the extent of cutaneous involvement (limited or diffuse) and modified Rodnan Skin Score. Microangiopathy will be assessed by videocapillaroscopy and presence of acral ulcers or acrosteolysis; Presence of calcinosis will also be assessed .~Upon recruitment each SSc patient will undergo blood sampling, which will be centrifuged and stored at -80° until the day of the processing. Biomarkers (Klotho, OPG, DKK, and sclerostin) will be determined using commercial kit of the ELISA Immunoenzyme techniques"
46069115|NCT04254939|Drug|CS3007 (BLU-285)|"A modified 3+3 dose escalation design will be adopted. Each group will enroll 3-6 subjects. Avapritinib will be administered orally at the starting of 200 mg QD. A cycle consists of 28 consecutive days."
45617822|NCT05234827|Other|Control|Control group receive endurance exercise testing in which stationary cycle is used for 30 min per session. It includes lower extremity strengthening i.e., increases hamstring and quadricep strength. Total time duration for session is 40 minutes in which 5 min of warm up exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 min of bicycling and after that 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing.
45617823|NCT04520945|Biological|Chondrogen|Mesenchymal stem cell-derived from umbilical cord Wharton Jelly and hyaluronic acid
45617824|NCT04520945|Biological|Placebo|Consist of saline and hyaluronic acid
45617825|NCT03354689|Radiation|Scintigraphy|Scintigraphy
45617826|NCT02459431|Other|21 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 21 G needle, by random assignment
45617827|NCT02459431|Other|22 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 22 G needle, by random assignment
45617828|NCT04509089|Device|Suremedix Device|Performing measurements using the Suremedix Device by applying gradually ascending air pressure to the subject lungs through a mouse piece while measuring respiratory chest motion, PPG and ECG.
45760616|NCT02152085|Device|Narrow pulse|Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises narrow (0.4 ms) stimulus pulses.
45760617|NCT02152085|Device|Wide pulse|Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises wide (1 ms) stimulus pulses.
45760618|NCT03250923|Drug|silver citrate complex and acemannan|Oral rinse solution with each dose containing 100μg silver citrate complex and 40mg acemannan
45760619|NCT00805493|Drug|Riluzole|
45760620|NCT05723133|Device|Electric toothbrush|Patients will receive oral hygiene instructions and an electric toothbrush with or without daily personal feedback using the brushing app (Oral-B app).
45760621|NCT05723133|Behavioral|Oral hygiene instructions|The same oral hygiene instructions are given to all patients. It is important for the patient to scrupulously follow these oral hygiene instructions at home and carry them out daily.
45760622|NCT03236649|Drug|Icaritin|600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
45760623|NCT03236649|Drug|Sorafenib Tosylate Tablets|400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
45617829|NCT03264079|Drug|Bardoxolone methyl capsules 10 mg|One 10 mg capsule of bardoxolone methyl administered on Study Day 1 (Period 1) of the trial and one 10 mg capsule of bardoxolone methyl administered on Study Day 18 (Period 2) of the trial
45617830|NCT03264079|Drug|Itraconazole capsules 100 mg|Two 100 mg capsules of itraconazole administered once daily during Study Days 15 - 27 (Period 2) of the trial
45617831|NCT03357107|Procedure|Transoral robotic surgery (TORS)|All patients underwent primary tumour resection with transoral robotic surgery (TORS) using the daVinci robot (Intuitive Surgical, Sunnyvale CA)
45617832|NCT04509323|Drug|Huperzine A for Injection|Give the patient one intramuscular injection (0.2mg) of Huperzine A of injection once a day for 14 days
45617833|NCT03280693|Diagnostic Test|Diagnostic test|Body balance was assessed using Berg Balance Scale (BBS), while BMD of the lumbar spine was measured by dual energy X-ray absorptiometry (DEXA) scan.
45617834|NCT04520789|Diagnostic Test|RPE cell collection and single cell heterogeneity study|Study of initiating proliferative vitreoretinopathy (PVR)cell subtype (PVR initiating cells (PVR-IC) in RPE cells of rhegmatogenous retinal detachment (RRD) patients, the percentage of which decides the risk of serious PVR occurring after surgery.
45617835|NCT04520789|Procedure|Postoperative intervention|Early local steroids drug intervention in patients with severe postoperative PVR
45617836|NCT04520789|Procedure|Conventional Surgery for Retinal Detachment|Conventional Surgery for Retinal Detachment
45617837|NCT03356951|Procedure|TAR through anterior approach and subtalar fusion|Simultaneous total ankle replacement through anterior approach and subtalar fusion
45617838|NCT03356951|Procedure|TAR through lateral approach and subtalar fusion|Simultaneous total ankle replacement through lateral approach and subtalar fusion
45617839|NCT03280459|Procedure|robot-assisted cystectomy|Removal of urinary bladder in oncologic or functional setting using a assistance of a operation robotic for laparoscopy
45617840|NCT04443647|Drug|Oxytocin|Syntocinon nasal spray
45617841|NCT04443647|Drug|Placebo|Placebo nasal spray
45617842|NCT04443881|Drug|Anakinra 149 MG/ML Prefilled Syringe [Kineret]|Anakinra (100 mg/ 6 hours) i.v infusión during 15 days
45617843|NCT02458339|Procedure|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
45617844|NCT02458339|Drug|Methotrexate|4, 6, or 8 mg into fourth ventricle of the brain via the Ommaya Reservoir for 2 days a week for 3 weeks with week 4 is a rest week. Each patient will undergo three cycles.
45760624|NCT00807209|Drug|Low Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 75mg SKY0402 (25 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
45617845|NCT03280225|Other|External facilitation|"Facilitation is an evidence-based implementation strategy to support sites that have difficulty implementing innovative programs. Facilitation is a multi-faceted process of interactive problem solving and support that occurs in the context of a recognized need for improvement and a supportive interpersonal relationship (Powell et al., 2015). Facilitation has been used nationally across VA to implement a number of different clinical interventions. The current project will examine this minimally intensive version of implementation facilitation, virtual external facilitation."
45617846|NCT03268915|Diagnostic Test|3 minutes sit-to-stand test|3 minutes sit-to-stand test, 1 minute sit-to-stand test, 6 minutes walk test will be performed 2 times for each patients 3 minutes sit-to-stand test with oxygen uptake measurement will be performed one time for each patient
45617847|NCT03356795|Biological|Cervical cancer-specific CAR-T cells|1 infusion, for 1x10^6~1x10^7 cells/kg via IV
45617848|NCT03268759|Other|fMRI|Observation of neural markers of reward processing
45617849|NCT03354533|Drug|L-fucose|Oral ORL-1F
45617850|NCT03268525|Drug|Marcaine 0.5 % Injectable Solution|Local infiltration by Marcaine 0.5% Injectable Solution prior to incision
45617851|NCT03268525|Drug|Sodium Chloride 0.9%|Local infiltration by Sodium Chloride 0.9% prior to incision
45617852|NCT03356717|Behavioral|educational intervention with observer tool|To assess if the use of an observer tool by observers during high fidelity simulation improves learning outcomes
45617853|NCT03356717|Behavioral|educational intervention|without observer tool
45760625|NCT00807209|Drug|High Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 150 mg (50 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
45617854|NCT04520243|Diagnostic Test|Visual acuity assessment by ETDRS charts|All participants must complete VA measurement of both eyes using 2 charts including the ETDRS letters chart and ETDRS numbers chart.
45617855|NCT02456935|Drug|CJ-12420 100 mg QD|CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100 mg.
45617856|NCT02456935|Drug|Esomeprazole 40 mg QD|Esomeprazole 40 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40 mg.
45617857|NCT03354455|Device|Repetitive transcranial magnetic stimulation|"Frequency: 1 Hz., Pulse shape: biphasic, Duration: 30 minutes (1800 pulses).~Neuronavigation: MRI-guided and robot-assisted neuronavigation using Localite software and an Axilum robot."
45617858|NCT02457013|Device|HFNC|Hygh flow nasal canula HFNC
45911619|NCT05777954|Other|Evalution in healthy patients of bone mineral density, Klotho level and key bone-related cytokines|Healthy female control patients undergoing bone mineral density determination will be recruited upon exclusion criteria are ruled out. A detailed clinical history will be assessed and blood sempling will be processed for detection of bone-related cytokines
45617859|NCT02457013|Device|nCPAP|nasal nCPAP
45617860|NCT04520321|Drug|TTHX1114(NM141)|engineered FGF-1 delivered intracamerally
45617861|NCT04520321|Other|Vehicle (placebo)|Placebo
45617862|NCT04520399|Other|none intervention|there is no intervention in this study
45617863|NCT03280147|Drug|7-day course of antibiotics|"Subjects in the 7-day course of antibiotics arm of the study will receive no further antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned."
45617864|NCT03280147|Drug|14-day course of antibiotics|"Subjects in the 14-day course of antibiotics arm of the study will receive 7 more days of antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned."
45617865|NCT03356639|Drug|ASP6981|Oral
45617866|NCT03356639|Drug|Placebo|Oral
45617867|NCT03263689|Drug|Intrathecal morphine|ITM group were given 100 micrograms of preservative-free morphine in addition to the local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia
45617868|NCT03354299|Dietary Supplement|coconut milk|50 cc of coconut milk supplementation plus 25 gram sugar (pudding) was given to cirrhosis patients as late night snack
45617869|NCT03264001|Behavioral|Negative energy balance|20% and 40% reduction of daily energy needs for weight maintenance
45617870|NCT03356561|Biological|Ad26.ZIKV.001 5*10^10 vp|Participants will receive Ad26.ZIKV.001 at a dose of 5*10^10 vp via IM route.
45617871|NCT03356561|Biological|Ad26.ZIKV.001 1*10^11 vp|Participants will receive Ad26.ZIKV.001 at a dose of 1*10^11 vp via IM route.
45760626|NCT00807209|Drug|Placebo|Bupivacaine, 15 mg/mL per epidural PLUS administration of 4 mL Placebo to each of three nerves for a total of 12 mL (intercostal)
46069116|NCT04242186|Other|Injury Liaison Service|The Injury Liaison Service nurse will coordinate deprescribing of fall-related medications, osteoporosis management, staff support of behavior management using video case conferencing, and shared decision making with residents and/or families.
45617872|NCT03356561|Biological|Placebo|Participants will receive placebo via IM route.
45617873|NCT03268369|Radiation|MRI of the brain|to eliminate a structural intra-cerebral lesion
45617874|NCT03268369|Radiation|PET scan [18F]F-A-85380|exam performed after iv injection of 200 MBq [18F]F-A-85380
45617875|NCT03268369|Radiation|PET scan [18F]FDG|exam performed after iv injection of 200 MBq [18F]FDG
45617876|NCT03356327|Drug|Actitan F|A molecolar complex of Tannins and Flavonoids used for acute diarrhea in children
45617877|NCT03356327|Drug|Standard Oral Rehydration|Standard oral rehydration as suggested by ESPGHAN guidelines
45617878|NCT03268447|Dietary Supplement|Lactobacillus plantarum P8|This project aims to study the benefits of probiotics namely Lactobacillus plantarum P8 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years.
45617879|NCT03268447|Dietary Supplement|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus plantarum P8 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years.
45617880|NCT03354221|Device|Cytosponge|Patients undergoing the six food elimination diet will be monitored during the initial elimination period at 2, 4 and 6 weeks with swallowing the cytosponge. This is a ten minute procedure in the office. The cytosponge will be sent to the lab for histology reading of the eosinophilic count.
45617881|NCT03354221|Other|Diet|During the initial 6 week elimination period, participants will eliminate the 6 most common food allergens from their diet (fish, nuts, eggs, soy, wheat, dairy). Participants will return for the cytosponge during this time at 2, 4 and 6 weeks of elimination.
45617882|NCT03354221|Other|EEsAI Pro|This is a short questionnaire to assess the participants swallowing. This will be completed at baseline and during each cytosponge visit during the initial elimination period (2, 4, 6 weeks).
45617883|NCT03354221|Other|Likert Scoring Scale|"This is a short questionnaire for patients to compare their experiences swallowing the cytosponge versus completing an upper endoscopy. The scale is rated from worst experience to best experience."
45617884|NCT02458417|Device|ReCell|A split-thickness skin biopsy will be taken from the hip region of the patient. The skin biopsy that is obtained will be treated in the ReCell kit (Avita Medical Europe Ltd, Cambridge, UK): it will be placed in the heated enzyme solution, containing trypsin, in the device for 15-20 minutes to allow cell disaggregation. After that period, the biopsy will be taken from the enzyme solution and will be dipped in sodium lactate buffer solution. The biopsy will then be scraped to disaggregate the cells from the dermal epidermal junction. The epidermal cells are drawn up in a syringe. The prepared suspension will be dripped on both donor and acceptor site.
45760627|NCT00807209|Drug|Fentanyl via PCA|Fentanyl via PCA
45760628|NCT00807209|Drug|Bupivacaine via epidural|Bupivacaine via epidural
45760629|NCT03220035|Other|Laboratory Biomarker Analysis|Correlative studies
45760630|NCT03220035|Drug|Vemurafenib|Given PO
45760631|NCT03372317|Drug|18F-MK-6240|Results of the 18F-MK-6240 PET scan will be correlated with other observations.
45760632|NCT00807989|Drug|Carbamazepine|
45617885|NCT02458417|Device|Full surface CO2 laser 200 mJ|Full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 200 mJ (depth 144 µm) and density 3
45760633|NCT00807989|Drug|Lamotrigine/Valproate|
45760634|NCT05131191|Diagnostic Test|CT-FFR measurement|Patients were scanned with ≥ 64 row CT according to standard operating specifications. The software obtains the coronary CT angiography image file through the data communication interface. Based on the image processing algorithm, the centerline and contour of the target vessel can be extracted, and then the target vessel can be reconstructed to obtain the three-dimensional size information of the vessel; Based on hydrodynamics calculation and analysis, the fractional flow reserve (FFR) of each position of the target vessel is measured.
45617886|NCT02458417|Device|Full surface CO2 laser 150 mJ|Full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 150 mJ (depth 144 µm) and density 3
45617887|NCT02458417|Device|Fractional CO2 laser 7.5 mJ, 20%|Pretreatment with the fractional CO2 laser (Ultrapulse, DeepFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 7.5 mJ/microbeam (depth 225 µm) and 20% density.
45617888|NCT03356171|Procedure|Cardiac Coherence|"10 sessions of HRV-BF (45mn) weekly over 12 weeks. HRV-BF is a cognitive behavioural therapy consisting on stress management training based on breathing. We use the SYMBIOLINE PC software to record the heart rate variability biofeedback, with an infrared plethysmograph sensor. The sensor is put on the finger, and the patient's HRV pattern is displayed in real time.~24 APA sessions (1.5h) bi-weekly over 12 weeks. Each session includes aerobic exercises (walk, step) and resistant exercises (muscular reinforcement). This program is built on previous cancer studies to make it effective."
45617889|NCT03356171|Procedure|Adapted Physical Activity|- 24 APA sessions (1.5h) bi-weekly over 12 weeks. Each session includes aerobic exercises (walk, step) and resistant exercises (muscular reinforcement). This program is built on previous cancer studies to make it effective.
45617890|NCT04508387|Procedure|Group HH (heated-humidified)|Group CD patients were administered dry CO2 via insufflator at room temperature (21°C), while Group HH patients were administered 95% humidified CO2 insufflation at 37°C. The study was planned as a randomized and double-blind study, where patients were not informed of their group. During the operation and in the postoperative period, the patients were followed up by two different anesthetists. All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia device and the visual analog scale the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form. Both groups received the standard general anesthesia protocol. Laparoscopic surgery was performed in the same manner for all cases by AA.
45617891|NCT03280069|Device|THERMIeyes® 20 RF System|The masked evaluating physician will be blinded as to which eye is treated. The evaluation on all visits will be performed on both eyes by the masked physician who will not know which eye has been treated with the THERMIeyes® 20 RF System. The treating technician will be aware of the treated eye so as to ensure all treatments are performed to the same eye.
45617892|NCT03268291|Other|Standard outpatient observation|Outpatient management according to Ministry of health standards
45617893|NCT03268291|Behavioral|"Communicational program Trust"|"The developed program is based on the experience of international research studies and includes the following sections:~daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials; service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators; questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services."
45617894|NCT03356093|Other|complete questionnaire|Patients were asked to complete a questionnaire at baseline, and week 1, 2, 3, 4, 5 and 6 after starting of radiotherapy.
45617895|NCT03356015|Drug|4L Polyethylene Glycol|4L group received double-dose PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes.
45617896|NCT03356015|Drug|3L Polyethylene Glycol|3L group were instructed to drink 1L PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes
45617897|NCT03279679|Procedure|costoclavicular infraclavicular block|Infraclavicular brachial plexus block will be performed through new costoclavicular space approach under realtime ultrasound guidance with 0.5% ropivacaine
45617898|NCT03279679|Procedure|paracoracoid infraclavicular block|Infraclavicular brachial plexus block will be performed through traditional paracoracoid approach under realtime ultrasound guidance with 0.5% ropivacaine
45617899|NCT03279679|Device|Ultrasound|All the nerve blocks will be performed under realtime ultrasound guidance
45617900|NCT03279679|Drug|Ropivacaine|0.5% ropivacaine will be used for the brachial plexus block in both groups.
45617901|NCT03354065|Dietary Supplement|TIME OF FEEDING|Liquid ( Re Feeding 8 h ) OR Enteral Feeding ( re feeding 48 h)
45617902|NCT03263377|Dietary Supplement|The school feeding intervention|The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium.
45617903|NCT02518607|Drug|MGB-BP-3|Treatment of CDI
45617904|NCT02518607|Other|Placebo|Placebo
45617905|NCT03279211|Other|Whey Protein Isolate 894 Fonterra|30 g of protein powder diluted in water
45617906|NCT03279211|Other|Zein Sigma-Aldrich W555025|30 g of protein powder diluted in water
45617907|NCT03279211|Other|Protein-free test-meal|No protein included in the drink made of water and flavour/sugar
45760635|NCT05131191|Procedure|invasive FFR|Insert the pressure guide wire into the finger guide tube and push the pressure guide wire until the pressure sensor just comes out of the orifice of guiding catheter; Equalize PD and PA values;Push the pressure guide wire to the distal end of the lesion, and record the measured blood vessel and position;Record the resting Pd / PA of the pressure guide wire;Nitroglycerin and adenosine triphosphate were administered intravenously according to standard catheter laboratory specifications to achieve maximum hyperemia;Record the FFR value of the in-stent lesions.
45760636|NCT05124327|Other|QI project- usage of RPM|close monitoring through RPM to analyze feasibility and compare readmission rates
45760637|NCT05124249|Diagnostic Test|Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment|Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment
45760638|NCT05124249|Procedure|PCI|Patients who undergoing PCI
45617908|NCT03278353|Other|Exercise|"A prescription of progressive rehabilitation exercises designed to strengthen weakened muscle groups and stretch joint movements that demonstrate range of motion limitations will be provided as a home program. Treatment is based on clinical presentation and identification of impairments by the treating clinician. Participants will be seen for 3 visits over 6 weeks and a final visit 1 year post-surgery for those electing to undergo surgery.~The interventions will consist of progressive exercise (PE) in two phases with general instruction guidelines. The assigned program will be tailored per each participant's clinical presentation and progressed based on response to exercise load. The researcher will instruct, review and supervise each program initially and, at follow-up visits; as well as monitor progress, re-enforce treatment strategies and modify the respective program accordingly. Each participant will receive a home program manual as well as a program log."
45617909|NCT03278353|Other|Manual Therapy|Hip joint and spine manual therapy techniques applied toward the impairments of the subject.
45617910|NCT02518451|Drug|Valsartan 160 mg film-coated caplets (test formulation)|In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
45617911|NCT02518451|Drug|Valsartan 160 mg film-coated caplets (reference formulation)|In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
45617912|NCT03263611|Drug|Placebo|single intradiscal injection
45617913|NCT03263611|Drug|AMG0103|single intradiscal injection
45617914|NCT04516811|Biological|COVID-19 convalescent plasma (CCP) plus standard of care (SOC)|A single unit of approximately 200-250 mL of CCP that contains anti-SARS-CoV-2 collected by plasmapheresis from a volunteer who recovered from COVID19 with SOC as determined by local practice and guidelines.
45617915|NCT04516811|Biological|Standard of care (SOC) plus placebo|A single unit of 200 mL normal saline with SOC as determined by local practice and guidelines
45617916|NCT03263299|Drug|cabergoline|Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer
45617917|NCT03263299|Drug|Aspirin|Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
45617918|NCT03263299|Drug|GnRH agonist|Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.
45617919|NCT03355937|Procedure|Sperm Chip|Sperm selection using by conventional or with sperm chip
45617920|NCT02457091|Behavioral|Resistance exercise|strength training consists of 1-3 sets , 10-15 repetitions of 10 exercises targeting lower body, upper body and core muscle groups
45617921|NCT02457091|Behavioral|Stretching exercise|The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
45617922|NCT04444271|Drug|Mesenchymal stem cells|1. Frozen MSCs will be resuspended in 100ml normal saline for immediate use and given intravenously. The patients should be pre-medicated to avoid allergic reactions to third party MSCs. Each patient in Experimental arm will be given 2 x 106 cells/kg will be administered on day 1,7 in addition to supportive care
45617923|NCT04444271|Other|Placebo|100 ml of normal saline will be given intravenously to control arm
45617924|NCT03263455|Other|Kinesio taping group|"The tape in the KT group will be applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension). KinesioTape will be applied over the SCM dystonic muscle by means of 2 I-strips: the first strip will be placed on the medial (sternal) head and the second will be applied on the lateral (clavicular) head of the SCM muscle. KinesioTape was applied from the mastoid bone to the clavicle (rostrocaudal direction) with the SCM placed in a position of maximum stretching."
45617925|NCT03263455|Other|Sham Taping|"Patients in the ST group, smaller I-strips of KinesioTape will be used and they will be applied, with no tension and without stretching the muscles, perpendicularly to the muscle belly (starting from the middle and progressing to each side) over the same dystonic muscles as in the experimental group. Although the specific therapeutic elements of KinesioTaping (ie, longitudinal stretch, start and ending point tape application) will be removed"
45617926|NCT04444349|Drug|Coenzyme Q10|Coenzyme Q10 is a cardiovascular health supplement. It is a component of the electron transport chain and participates in aerobic cellular respiration, which generates energy in the form of ATP. The ingredients in Coenzyme Q10 help regulate the body's production of free radicals, strengthen the arteries and heart, and reverse oxidation.
45911620|NCT05777941|Other|eccentric arm-cranking training|Over the twenty training sessions, able-bodied participants will exercise on the KREHA device. An arm-crank has to be decelerated, which will be rotated by a prematurely defined revolution rate and training duration. During this intervention a certain power has to be applied. During the whole time of training a continous progression in power and training duration is applied.
46069117|NCT04233164|Drug|SOLU-MEDROL|Methylprednisolone sodium succinate for injection, United States Pharmacopeia grade (USP), sold as SOLU-MEDROL sterile powder by Pfizer, Inc, is an antiinflammatory glucocorticoid that occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol, but is insoluble in chloroform and is very slightly soluble in acetone. The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg or 250 mg of methylprednisolone.
45617927|NCT04444349|Dietary Supplement|Placebo|placebo that looks and tastes identical to Coenzyme Q10
45617928|NCT03263533|Drug|Vorinostat Oral Capsule Group 1|Following the initial washout and first 4-week period of the trial, all patients will enter a second 1-week washout. After the washout, all patients will then enter a second 4 week alternate treatment (vorinostat or placebo). During the vorinostat sequence, doses will be increased over the first 2 weeks in each phase of the crossover study, starting by 100 mg per day, and increasing to 200 mg by week 2 and 300 mg per day at the start of week 3 until the end of week 4.
45617929|NCT03263533|Drug|Vorinostat Oral Capsule Group 2|Following the initial washout and first 4-week period of the trial, all patients will enter a second 1-week washout. After the washout, all patients will then enter a second 4 week alternate treatment (vorinostat or placebo). During the vorinostat sequence, doses will be increased over the first 2 weeks in each phase of the crossover study, starting by 100 mg per day, and increasing to 200 mg by week 2 and 300 mg per day at the start of week 3 until the end of week 4.
45617930|NCT03355859|Biological|JWCAR029|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with JWCAR029 by intravenous (IV) injection.
45617931|NCT03267745|Dietary Supplement|Amino Acid|23.7 g amino acid 3 times daily for 28 days
45617932|NCT03267745|Device|Breg Brace single-leg immobilization|7 days of single leg immobilization; randomized to leg; knee brace will be worn in a fixed flexion position at 140°.
45617933|NCT03267745|Other|Placebo|Excipient-matched placebo 3 times daily for 28 days
45617934|NCT03122951|Diagnostic Test|ovulation test use|Normal use of The Clearblue® Advanced Ovulation Test according to Information for use instructions
45617935|NCT03267823|Diagnostic Test|International Normal Ratio (INR)|Blood test for INR using laboratory and point of care methods
45617936|NCT03123107|Drug|Ascorbic Acid|Ascorbic acid doses will be mixed in 100 mL normal saline and infused over 60 minutes. The postoperative dose will be given on postoperative day #1.
45617937|NCT03267979|Other|Video-pupillometer|Video-pupillometer will be performed. In this study data will be collected and analyzed.
45617938|NCT03267979|Other|Electrocardiogram|Electrocardiogram will be performed. In this study data will be collected and analyzed.
45617939|NCT04516655|Drug|chidamide combined with rituximab and high-dose methotrexate|chidamide 20 mg biw PO day1-14 and rituximab 375 mg/m2 IV given on day 1 and methotrexate 3.5g/m2 IV given on day 2 of every 21-day cycle for 6 cycles in untreated patients with primary central nervous system lymphoma
45617940|NCT02458183|Biological|DTaP-IPV combination vaccine|0.5-mL IM
45617941|NCT02458183|Biological|DTaP vaccine and IPV vaccine|0.5-mL IM
45911621|NCT05777928|Procedure|Sleeve gastrectomy|Sleeve gastrectomy involves vertical resection of a major part of the stomach, and a tubular remnant is retained along the lesser curvature.
45617942|NCT04444193|Drug|Durvalumab|Anti-PD-L1 Monoclonal Antibody
45617943|NCT04444193|Drug|Lenvatinib Oral Product|Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT
45617944|NCT03267901|Other|food|45 g of walnut / iso-caloric white bread
45617945|NCT02457949|Other|Non-synchronized social assistance receipt|Social assistance disbursement outside government cheque issue week
45617946|NCT02457949|Other|cheque divided into two equal disbursements|Social assistance disbursement divided into two equal payments
45617947|NCT04444037|Device|OCT-guided PCI|using optical coherence tomography imaging to help PCI procedure
45617948|NCT03984955|Device|Sodium hyaluronate with mannitol (Ostenil Tendon)|1ml isotonic solution contains 20.0mg sodium hyaluronate and sodium chloride, disodium phosphate, sodium dihydrogen phosphate, mannitol and water for injections.
46069118|NCT04221139|Behavioral|Virtual Reality games|Participants will play the following four virtual reality games for 15 minutes each: Beat Saber, Holopoint, Hot Squat, and Relax Walk.
45617949|NCT03984955|Device|Platelet-Rich Plasma Injection|Platelet-rich plasma (PRP) describes an autologous blood plasma fraction enriched with platelets which is then injected at the site of tendon injury.
45617950|NCT03984955|Other|Subcutaneous sham injection|Sham injection will penetrate the skin, but no therapeutic substance will be injected
45617951|NCT03355547|Other|questionnaire about the severity of their symptoms of upper respiratory tract infection|Before the operation, the researcher interviews the parents of the pediatric patients to check whether they have the upper respiratory tract infection and asks them to fill out a questionnaire about the severity of their symptoms. The questionnaire consists of 8 types of symptom about upper respiratory infections and each symptom was checked from 0 to 3 according to severity by their patients.
45617952|NCT03946969|Drug|Sintilimab|Sintilimab (200mg) will be given intravenously on day 1 in 3-week cycles for two cycles.
45617953|NCT03946969|Drug|Liposomal Paclitaxel + Cisplatin + S-1|Liposomal Paclitaxel (135mg/m2), ivd, d1 + Cisplatin (25mg/m2), ivd, d1-3 + S-1 capsule (40mg), po, d1-14, repeated every 3 weeks for two cycles.
45617954|NCT03277573|Drug|Salsalate|Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a non-steroidal anti-inflammatory drug (NSAID). Salsalate has been commercially available in the US as a prescription drug for the relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and related rheumatic disorder for decades.
45617955|NCT03277573|Drug|Placebo|Inactive ingredient
45617956|NCT03355313|Radiation|Low level Light therapy|Laser will be administered for 10 seconds on four intraoral points and four extraoral points in the region of the parotid glands bilaterally as well as one intraoral point and one extraoral point in the regions of the submandibular and sublingual glands.
45911622|NCT05777928|Procedure|OverStitch™ Endoscopic Suturing System|Overstitch endoscopic procedure makes a review of gastro-jejunal anastomosis reducing surgical complications
46069119|NCT04220190|Biological|RAPA-501 Autologous T cells|TREG/Th2 cells
46069120|NCT04218448|Other|Hypnorelaxation|"Hypno-relaxation is induced by following VAKOG: external sensory identification, fixation of attention, bodily sensation, breathing, sensory perceptions, closing of the eyes.~The work phase follows induction and allows deepening of the hypnotic trance. It corresponds to a metaphorical narrative associated with post-hypnotic suggestions and is fueled by the construction of adapted suggestions and metaphors, adapted to each patient. The investigator who remains present throughout the duration of the examination, maintains a hypnotic, empathetic, attentive attitude, and makes it possible to recover this material. Using the elements previously supplied by the patient, the investigator tells a story which allows the patient to focus his attention on something other than the performance of the somatosensory evoked potentials examination. The investigator, thanks to hypnosis, allows the development"
45617957|NCT03267667|Diagnostic Test|2D Echocardiography and cardiac MRI|imaging of right ventricle by both modalities to assess right ventricle function accurately
45760639|NCT04744558|Other|Low carb high fat ketogenic dieting|Macronutrient ratios for low carb high fat ketogenic diet were 20 %, 5 %, 75 % of protein, carbohydrates and fat, respectively. Caloric intake for experimental phase was set to cover basal metabolism and sedentary activities (BMR times 1.2) for every participant using the Mifflin St Jeor equation.
45911623|NCT05777915|Other|Usability testing|Usability testing
46069121|NCT04213261|Biological|FCX-007 (dabocemagene autoficel; see below for FCX-007 description)|FCX-007 is comprised of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.
45617958|NCT03353987|Behavioral|Cognitive training|"Procedure~A therapist will go through the daily routine of the participants at home before starting the intervention~Selections of exercise items based on familiar items/ activities at home~Given a memory logbook with list of household items, names and numbers and newspaper cuttings from the previous week~Taught on how to perform the exercises~Perform at least one hour per day~Both spatial and visual memory strategies will be used for memory training: simple mnemonics, associations, visualisations, rhymes~Advised to follow-up with the therapist to review on the progress and compliance of exercises weekly~The difficulty of the exercise will be adjusted weekly~List of exercises:~Memorizing a set of lists, household items, names and numbers~Summarising the contents of newspaper cuttings within a set of time~Searching and listing sets of words from newspaper cuttings"
45617959|NCT03263221|Procedure|reduction and fixation|Surgical procedures, as plating, Proximal Femoral Nail , Dynemic Hip screw and others procedures according to needed for each types
45617960|NCT03262831|Other|Yoga|The yoga practice, Gentle Hatha and Restorative Yoga, will be based on protocols that have been found to decease fatigue and weight gain by helping the participant gain insight in recognizing stress responses and ways to relax
45617961|NCT03262831|Procedure|Blood draw|"Baseline and end of treatment~To evaluate change in inflammatory markers (CRP, IL-6, and TNF)"
45617962|NCT03262831|Behavioral|FACT-G questionnaire|"7 statements that other people with breast cancer have said are important, the patient is to circle or mark one number per line to indicate the response as it applies in the last 7 days~Answers range from 0=not at all to 4=very much"
45617963|NCT03262831|Procedure|Weight measurement|-Weight will be taken at baseline, on day 1 of each cycle, and the end of treatment
45617964|NCT03262831|Behavioral|Recent Physical Activity Questionnaire|-To assess physical activity, the RPAQ will be completed at baseline and at the end of treatment.
45617965|NCT03262831|Behavioral|NHANES Food Questionnaire|-To assess diet, the NHANES Food Questionnaire will be completed at baseline and at the end of treatment.
45617966|NCT03353909|Device|new crosslinked hyaluronan gel|At the end of the dilatation and curettage, new crosslinked hyaluronan gel was applied to the uterine cavity.
45617967|NCT03267355|Device|Endoscopic Ultrasound|Indication of EUS
45617968|NCT04514705|Other|Exercise|Exercise with treadmil and weight training station
45617969|NCT02459353|Drug|Dapagliflozin|
45617970|NCT02459353|Drug|Placebo|
45617971|NCT04508231|Other|Gender-affirming hormone therapy|Gender-affirming hormone therapy according to the recommendations of the Endocrine Society
45617972|NCT04514627|Device|Auricular percutaneous neurostimulation|The BRIDGE/PENFS device manufactured by Key Electronics, consists of a battery activated generator and wire harness that connects to the generator. Four leads are also attached to the generator, each with a sterile 2 mm, titanium needle. The BRIDGE device settings are standardized and deliver 3.2 volts with alternating frequencies (1 ms pulses of 1 Hz and 10 Hz) every 2 s. This stimulation targets central pain pathways through branches of cranial nerves V, VII, IX, and X, which innervate the external ear. The PENFS device generator has a battery life of 5 days and delivers almost continuous stimulations throughout the 120 hours.
45617973|NCT03263065|Dietary Supplement|Bran|220g rice pudding meal with raspberry jam with added bran flakes
45617974|NCT03263065|Dietary Supplement|Nopal|220g rice pudding meal with raspberry jam with added nopal flakes
45617975|NCT03263065|Dietary Supplement|Psyllium|220g rice pudding meal with raspberry jam with added psyllium flakes
45617976|NCT03274531|Behavioral|Referral of hypertensive patients to the attending physician|Immediate referral to the treating physician in case of elevated automated office blood pressure measurements
45617977|NCT04513613|Device|Procedure/Surgery: Robotic-PVI|Robotic-assisted (CorPath GRX System) percutaneous vascular interventions.
45617978|NCT02518373|Biological|G17DT|G17DT is a therapeutic immunogen, formulated as a white, sterile, semi-viscous, water-in-oil emulsion (30:70 weight for weight). It was manufactured and supplied by Nova Laboratories Ltd., in glass ampoules containing 0.5 mL at a concentration of 1.25 mg/mL, as a single dose to be administered by intramuscular injection.
45617979|NCT02518373|Drug|Omeprazole|Proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome.
46069122|NCT04193215|Biological|V114|IM injection
45617980|NCT03263143|Other|Palliative Care|Palliative Care Consultation within 24 to 48 hours after admission
45617981|NCT03353597|Biological|Plasma Transfusion|All subjects will receive monthly, 2-unit transfusions of young healthy male donor plasma for total of 6 treatments. The plasma will be administered at a transfusion services facility in a manner consistent with generally accepted and standard guidelines for plasma transfusions.
45617982|NCT04512833|Radiation|Cyberknife stereotactic body radiation therapy|A total dose of 45-54 Gy in 5-10 fractions was given according to the location of lesions for small HCC patients with decompensated cirrhosis.
45617983|NCT03266965|Drug|Carbidopa|All subjects will receive a fixed dose of 50mg of Lodosyn twice daily.
45617984|NCT03266965|Dietary Supplement|L-Histidine|Sequential Dose Escalation of 250mg to 500mg to 1000mg twice daily.
45617985|NCT03353519|Other|Primary care model|"Specifically, the intervention will comprise the following components:~Structured review of patient needs;~A self-management programme (MLAS) for stroke survivors and their carers;~A direct point of contact for stroke survivors and carers at the GP surgery;~Optimised communication between General Practice staff and specialist services;~Service mapping for stroke related needs;~Training for General Practice staff."
45617986|NCT04512677|Device|Timed Inspiratory Effort (TIE index)|Conventional clinical treatment and using the Timed Inspiratory Effort (TIE index), which guided the decision to ventilate weaning and extubation.
46069123|NCT04193215|Other|Pediatric vaccines|Standard of care vaccines administered according to the local recommended schedule.
46069124|NCT04183894|Behavioral|Personalized Intervention|Participants will receive a personalized intervention based on their personalized network.
45617987|NCT03266731|Drug|Aspirin|evaluates the safety and efficacy of clopidogrel and aspirin as an alternative treatment in patients not eligible for recombinant tissue plasminogen activator or any other acute reperfusion therapy with acute ischemic stroke (AIS) and transient ischemic attack (TIA) within 24 hours of symptoms onset
45617988|NCT04507529|Other|Peer-mentoring|Patients (mentees) are matched with a peer-mentor. Throughout the intervention period (24 weeks), the mentee and the mentor will have informal telephone contact and meet face-to face approximately 8 times during the intervention period.
45617989|NCT02458963|Procedure|IVF|Women will undergo one IVF cycle
45617990|NCT02458963|Drug|Gonadotropin|Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol
45617991|NCT03262597|Other|enterade|Subjects will consume enterade, which is an amino acid-based oral rehydration solution.
45617992|NCT03262597|Other|Pedialyte|Subjects will consume Pedialyte
45617993|NCT03262597|Other|Gatorade|Subjects will consume Gatorade
45617994|NCT03262597|Other|Water|Subjects will consume water as the control beverage
45617995|NCT04511819|Drug|Losmapimod oral tablet|This study includes a 14-day treatment period. Patients will receive losmapimod 15 mg twice daily given as two 7.5 mg tablets per dose by mouth: for a total of 4 pills or 30 mg daily. The study drug should be taken with food when possible.
45617996|NCT04511819|Drug|Placebo oral tablet|This study includes a 14-day treatment period. Patients will receive Placebo twice daily given as two tablets per dose by mouth: for a total of 4 tablets daily. The study drug should be taken with food when possible.
45617997|NCT03273517|Procedure|Elective surgery|Elective surgery in children aged 0-15 years ASA I and II
45617998|NCT03355079|Drug|SmofKabiven® E|In the intervention arm, SmofKabiven® E, with or without addition of Suppliven®, Vitalipid® Adult and/or Soluvit®, will be administered in addition to standard of care oral nutrition as per dietary counseling, whereas in the control arm, oral nutrition as per dietary counseling is the primary nutritional support.
45617999|NCT03262753|Procedure|Surgery|Primary end-to-end surgical treatment of coarctation of the aorta
45618000|NCT03262753|Procedure|Balloon dilation|Primary balloon dilation treatment of coarctation of the aorta
45618001|NCT03262753|Procedure|Stent|Primary stent dilation treatment of coarctation of the aorta
45618002|NCT04507607|Drug|Tenofovir Alafenamide 25 MG|TAF was administered to pregnant women with CHB during pregnancy for mother-to-child interention.Women with chronic hepatitis B who are not pregnant receive TAF for antiviral treatment.
45618003|NCT03353441|Dietary Supplement|Microencapsulated Sublingual Glycine (MSG)|Glycine (MSG) tablet
45618004|NCT03353441|Dietary Supplement|Placebo|Lactose tablet manufactured to mimic Glycine (MSG) tablet
45618005|NCT03273205|Device|Anodal tDCS|This group gets a real stimulation
45618006|NCT03273205|Device|Sham tDCS|This group gets a sham stimulation
45618007|NCT03353363|Drug|Bupivacaine|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of bupivacaine 0.5% plain will be infiltrated into the wound by the obstetrician team in a standardized fashion.
45618008|NCT03353363|Drug|Liposomal bupivacaine|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of one liposomal bupivacaine will be infiltrated into the wound by the obstetrician team in a standardized fashion.
45760640|NCT04744558|Other|Low carb high fat non-ketogenic dieting|Macronutrient ratios for low carb high fat non-ketogenic diet were 20 %, 15 %, 65 % of protein, carbohydrates and fat, respectively. Caloric intake for experimental phase was set to cover basal metabolism and sedentary activities (BMR times 1.2) for every participant using the Mifflin St Jeor equation.
46069125|NCT04171440|Procedure|robotic pancreaticoduodenectomy|The robotic pancreaticoduodenectomy is performed through small incisions using robotic-assisted technology. Pancreaticoduodenectomy is the operation that is necessary to remove tumors of the head and neck of the pancreas, lower portion of the bile duct, and the ampulla of Vater.
46069126|NCT04146870|Other|not have|not have
45618009|NCT03353363|Drug|Placebos|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of normal saline will be infiltrated into the wound by the obstetrician team in a standardized fashion.
45618010|NCT03266185|Other|Shorter PICT|Shorter post-infusion cooling time
45618011|NCT03354923|Behavioral|PEERS intervention|PEERS is a 14-week manualized social skills treatment program that targets the friendship skills of adolescents with ASD. In the Israeli adaptation of PEERS, two meeting were extended. An adolescents group will be held concurrently with the parents group in different rooms. Both groups will begin the session with homework review, followed by a didactic social skills lesson, utilizing the teaching methods of modeling and role-playing. In order to practice the newly learned social skills,a behavioral rehearsal interaction will be assigned in the adolescents group. Finally,Socialization homework assignments designed to address further mastery and generalization of newly learned skills within the natural social environment will be assigned too.
45760641|NCT04745247|Procedure|RSS|"Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours~Sham Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours : the number of stimuli is reduced compared to the effective RSS"
45760642|NCT05111392|Biological|Placebo|Ingestion of one (1) liter of beverage with observation for 2 h
45760643|NCT05111392|Biological|Oral Rehydration Solution 1|Ingestion of one (1) liter of beverage with observation for 2 h
46069127|NCT04142385|Other|Cytology Specimen Collection Procedure|Undergo blood, urethral swab, penile skin cell, and anal swab collection
46069128|NCT04142385|Other|Laboratory Biomarker Analysis|Correlative studies
45618012|NCT03353285|Procedure|intracytoplasmic sperm injection (ICSI)|All eggs will be fertilized by ICSI
45618013|NCT04086121|Drug|Spesolimab|Solution for SC injection
45618014|NCT03354845|Other|Deprescribing intervention|Pharmacists assessed the appropriateness of target symptomatic medications and potential for discontinuation. After discussion with pharmacists and consideration of patients' and caregivers' preferences regarding discontinuation or dose reduction, doctors would deprescribe these symptomatic medications. Symptom recurrence, adverse drug withdrawal events (ADWEs), and the need for drug re-initiation or initiation of new symptomatic control medications after deprescribing were monitored and documented in the 1st, 2nd and 6th weeks.
45618015|NCT05234905|Drug|Recombinant human adenovirus type 5＋Camrelizumab|"Recombinant human adenovirus type 5: one lesion was selected for intratumoral injection.Intratumoral injection of H101 was performed on day 1 and day 4 of each cycle, and was repeated once every 3 weeks. H101 dose:~① Tumor maximum diameter ≤5cm, 1.5×1012vp (3 injections) on day 1, 1.0×1012vp (2 injections) on day 4.~② Tumor maximum diameter >5cm but ≤10cm, 3.0×1012vp (6 injections) on day 1 and 2.0×1012vp (4 injections) on day 4.~③ Tumor maximum diameter >10cm, 4.5×1012vp (9 injections) on day 1 and 3.0×1012vp (6 injections) on day 4.~H101 intratumoral injection until the tumor is completely regressed to stop the drug, but not more than 5 cycles at most.~Camrelizumab: administered after H101 on day 1 of each cycle and repeated for 3 weeks. Camrelizumab dose: 200 mg IV."
45618016|NCT03266263|Device|automatic computer-led feedback|automated feedback software for CPR quality, including compression depth, rate, recoil, hands-off time, and ventilation volume
45618017|NCT03266263|Other|instructor-led feedback|feedback for CPR quality by instructors
45618018|NCT03354767|Procedure|Aortic and aortic valve surgery|
46069129|NCT04142385|Procedure|Medical Examination|Undergo anal and penile clinical exam
45618019|NCT04511195|Dietary Supplement|Standardized extract of Sphaeralcea angustifolia|Each patient will be treated topically with a gel containing the Sphaeralcea angustifolia extract three times a day for 4 weeks. Sphaeralcea angustifolia extract is standardized in its active compounds content: Sphaeralcic acid and scopoletin
45618020|NCT04511195|Drug|Diclofenac Sodium Gel|Each patient will be treated topically with a gel containing 2% diclofenac three times a day for 4 weeks.
45618021|NCT05075473|Other|Segmental stabilization|Physiotherapist will perform activation of multifidus in prone position. It also includes activation of transverse abdominas in crook lying position, in sitting as well as in point kneeling position to re-establish simultaneous contraction of deep muscles synergy.
45618022|NCT05075473|Other|Generalized Lumber stabilization exercsies|It can by performed by patient him or her self under physiotherapist's assistance. Lumber neutral position is maintained. Bridging in prone as well as supine position will be maintained.
45618023|NCT03353051|Other|Observational study|Observational study
45618024|NCT03262207|Other|Extraction genomic DNA|
45618025|NCT03262207|Other|Analysis of methylation profiles of numerous GSI and TE|
45618026|NCT03262207|Other|Analysis of methylation for the whole genome (sub-population of 15 samples from group 1)|
45618027|NCT03262207|Other|Method of protein detection by immunostaining and flow cytometry|
45618028|NCT04443725|Drug|Hydroxychloroquine , Sofosbuvir, daclatasvir|Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days (dose reductions for weight < 45 kg or GFR (glomerular filtration rate) <50ml/min) alone; as provided by the MOHP protocol), Sofosbuvir 400 mg once daily for 14 days and daclatasvir 90 mg for 14 days.
45618029|NCT04443725|Drug|Standard of care treatment|Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days (dose reductions for weight < 45 kg or GFR (glomerular filtration rate) <50ml/min) alone; as provided by the MOHP protocol),
45618030|NCT03266341|Diagnostic Test|Cultures|Take different samples anddetection of anaerobes on enriched blood agar and other selective anaerobic cultures
45618031|NCT04507451|Procedure|inspiratory and expiratory muscle training|inspiratory muscle training using threshold IMT device expiratory muscle training using a bottle filled of water
45760644|NCT05111392|Biological|Oral Rehydration Solution 2|Ingestion of one (1) liter of beverage with observation for 2 h
46069130|NCT04142385|Procedure|Physical Examination|Undergo targeted physical exam
45618032|NCT04507451|Procedure|inspiratory and expiratory exercises|inspiratory exercise using fractionated inspirations expiratory exercise using a bottle filled with water at a minimum level
45618033|NCT05074927|Diagnostic Test|diaphragm ultrasonography|For all patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France) : diaphragm ultrasonography at 3 (M0) and 6 months (M3) after the end of his hospitalisation
45618034|NCT04510805|Device|NextDose (nextdose.org)|"NextDose guided warfarin management taking into consideration covariates (sex, age, weight, height CYP2C9 (rs1057910) and VKORC1 (rs9923231), the dosing and INR history of each patient to predict an individualized dose in accordance with the theory-based warfarin model and target concentration intervention principles.~Initial recommended warfarin dose, up to the first INR, will be the maintenance dose predicted from group values, subsequently the NextDose predicted maintenance dose will be recommended. The treating clinician will also be provided with the NextDose report to inform the choice of the prescribed dose."
45618035|NCT03266029|Device|Cordio App|
45618036|NCT03265951|Drug|Ramelteon|8 mg once daily administered within 30 minutes of bedtime
45760645|NCT05112627|Procedure|Biospecimen Collection|Undergo blood collection
45760646|NCT00364234|Device|Low magnitude mechanical stimuli|20 minutes standing on low magnitude high frequency vibrating platform
45760647|NCT03210675|Diagnostic Test|Polysomnography (PSG)|PSG will be perfomed every 6 months in the Study group from the age of 6 months to 3 years
45618037|NCT03265951|Other|Usual Care|education brochure about sleep hygiene
45618038|NCT04507295|Device|cerebral oximetry ( INVOS 5100 )|"in case of critical cerebra desaturation occurred which is defined as decrease in cerebral saturation by 20% from the base line the following will be done~Increase FIO2 up to 100%~Increase PEEP up to 5 cmH2O~Decrease insufflation pressure"
45618039|NCT03265717|Biological|INVAC-1|Patients are treated by INVAC-1 for 6 cycles at 4-week intervals
45618040|NCT02456779|Other|in vitro diagnostic test (Peptest)|saliva samples obtained and tested in laboratory conditions for the presence of pepsin using Peptest
45618041|NCT02456779|Other|Questionnaire|all recruited subjects to complete the RDQ as a determinant of inclusion criteria
45760648|NCT04928872|Combination Product|Predefined meal|Nine predefined meals are administered in a randomized fashion, one meal per one study day, 2-3 study days per week. Meals have a form of drinks with different compositions of protein, carbohydrates and fat in relation to the US diet
46069131|NCT04142385|Procedure|Proctoscopy with Biopsy|Undergo HRA
46069132|NCT04142385|Other|Questionnaire Administration|Ancillary studies
46069133|NCT04125563|Drug|Capsicum Oleoresin|The soft gel capsules used in the study are easily digested in the stomach and contain standardised doses of 0,4 mg Capsicum oleoresin with the main component capsaicin (8-methyl-N-vanillyl-6-nonenamide) (from chili extract).
45618042|NCT02456779|Other|Questionnaire|control subjects to complete RSI as a determinant of inclusion criteria
45618043|NCT04510493|Drug|Canakinumab|Body weight adjusted dose in 250 ml 5% dextrose solution i.v. over 2 hours
45618044|NCT04510493|Drug|Placebo|Aqua ad injectabilia in 250 ml 5% dextrose solution i.v. over 2 hours
45618045|NCT04509869|Procedure|varicocelectomy|operation for varix ligation
45618046|NCT03262363|Combination Product|Curcumin/NFE2L2 A>G|The administration will be orally and the patient will be instructed to take two capsules per day for one week, one in the morning 15 minutes before breakfast and another at night 15 minutes before dinner, accompanied by a cup of 240 mL of pure water. It will be indicated to continue with their usual medical treatment.
45618047|NCT03262363|Combination Product|Placebo/NFE2L2 A>G|The administration will be orally and the patient will be instructed to take two capsules for 24 weeks, one in the morning 15 minutes before breakfast and another in the evening 15 minutes before dinner, accompanied by a 240 mL cup of pure water. They will be advised to continue their usual medical treatment.
45618048|NCT04509713|Behavioral|Collection of odour samples|Samples of breath odours will be passively collected while participants wear the mask while breathing naturally, for at least 3 h. Skin odours will be passively collected by participants wearing the shirt and nylon socks for at least 12 h.
45618049|NCT02459041|Other|Elastography, contrast enhancement|"Elastography is an ultrasound method used for the reconstruction of tissue elasticity distribution in real-time. The main intended use is to differentiate between benign and malignant focal lesions based on the significantly smaller strain of the latter real time. Tissue elastography can be easily performed with conventional probes, including the linear EUS probes used for the examination of the pancreas and/or lymph nodes.~Contrast-enhancement Ultrasound contrast agents in conjunction with contrast specific imaging techniques are increasingly accepted in clinical use for diagnostic imaging. Pancreatic adenocarcinomas are usually hypovascular tumors."
45618050|NCT03352973|Other|active tDCS on the dlPFC|During active tDCS session, participants will perform the regulation of craving (ROC) and emotion regulation (ER) tasks. In the ROC task, participants will downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. In the ER task, participants will downregulate and upregulate aversive feelings by negative pictures using cognitive reappraisal. After the active tDCS session, participants will complete a cognitive task assessing inhibitory control of attentional bias, in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. During the task, reaction times (RTs) wil be recorded.
45618051|NCT03352973|Other|sham tDCS on the dlPFC|During the sham tDCS session, participants will perform the regulation of craving (ROC) and emotion regulation (ER) tasks. In the ROC task, participants will downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. In the ER task, participants will downregulate and upregulate aversive feelings by negative pictures using cognitive reappraisal. After the sham tDCS session, participants will complete a cognitive task assessing inhibitory control of attentional bias, in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. During the task, reaction times (RTs) wil be recorded.
45618052|NCT04506827|Procedure|Maxillary Sinus Augmentation|Biomaterial Graft into the Maxillary Sinus
45618053|NCT04506827|Device|Maxillary Sinus Graft with ABBM|The maxillary sinuses in the control group are grafted with ABBM
45618054|NCT04506827|Device|Maxillary Sinus Graft with TCP|The maxillary sinuses in the test1 group are grafted with TCP
45618055|NCT04506827|Device|Maxillary Sinus Graft with TCP + HA|The maxillary sinuses in the test1 group are grafted with TCP + HA
45618056|NCT03262285|Procedure|phacoemulsification|removal of cataract using ultrasound waves
45618057|NCT03262285|Procedure|extracapsular cataract extraction|removal of cataract using surgical corneal incision
45618058|NCT03352895|Dietary Supplement|resveratrol|Grape seed extract 100mg Microcrystalline Cellulose 90mg Magnesium Stearate 2mg Gelatin 100mg
45618059|NCT03352895|Dietary Supplement|Placebo|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
45618060|NCT03265483|Dietary Supplement|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
45618061|NCT03265483|Dietary Supplement|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
45760649|NCT00357591|Device|Continuous Aortic Flow Augmentation|1.0-1.5 lpm augmented blood flow
45911624|NCT05777902|Drug|Ozanimod Oral Capsule|We propose to integrate measurements obtained using multiple tools. Patients will undergo MRI and hdEEG procedures, and blood samples will be obtained for the immunological and biochemical studies on the same day. The study of the immune system's status will include an extensive immunophenotypic analysis, a functional characterization following ex vivo stimulation of innate immune cells, and the measurement of soluble products in the serum, such as cytokines. Cellular traits of interest include the absolute numbers and relative proportions of specific cell subsets, transcriptional states, secretory functions, proliferative capacity or cytolytic potential. Specifically, the following antibody combination will constitute the core of the immunophenotypic analysis: HLADR CD11c, CD38, CD14, CD123, lineage (CD3, CD56, CD19).
46069134|NCT04125563|Drug|Placebos|Soft gel capsules filled with placebo - sorbitol and colorant.
46069135|NCT04113161|Other|Standard Care|Standard care will consist of 1) community-based screening and referral conducted by HomeGrown St. Louis (HomeGrown StL) network members and supported by HomeGrown StL coordinator; and 2) monthly contacts by a case manager, who will track attendance in mental health services and provide referrals upon request.
45618062|NCT04504643|Other|Technology-assisted circuit training|Circuit training assisted by Fitlight™ 3 times a week for one hour during 8 weeks
45618063|NCT04504643|Other|Conventional circuit training|Conventional circuit training including single and dual task 3 times a week for one hour during 8 weeks
45618064|NCT04504643|Other|Nordic walking|Classic nordic walking 3 times a week for one hour during 8 weeks
45760650|NCT04905628|Device|Dexcom CGM System|Dexcom CGM System
45804063|NCT04345081|Procedure|Skin Reducing Nipple Sparing Mastectomy and Implant Based Breast Reconstruction|Skin Reducing Nipple Sparing Mastectomy is performed from Inverted T incisuion and nipple is preserved.
45804064|NCT04345081|Procedure|Skin- Sparing Mastectomy and Implant- Based Breast Reconstructive Surgery|Classic Skin- Sparing Mastectomy
45804065|NCT05719051|Drug|Albumin infusion|Albumin infusion was administrated according to the standard clinical practice
45618065|NCT05074147|Drug|Reduction in the duration of antibiotic therapy 3 weeks or 6 weeks|"Drugs :~Rifampin (IP an PO) : 10mg/Kg/12h~Ofloxacin (PO) : 200Mg/8h~Levofloxacin (PO) : 500mg ot 1g/ twice a day~Ciprofloxacin : IV : 400mg/8h if Pseud spp ; 400mg/12h for others Gram-negative bacilli strains; PO : 1gr/12h if Pseud spp ; 750mg/12h for others Gram-negative bacilli strains~Clindamycin : 600-900mg/8h~Fusidic Acid : 500mg/8h~Teicoplanin : 10mg/kg/12h for 5 dosis in combination, then in monotherapy.~Ceftasidim : 2g/8h if Pseud spp ; 2g/12h for others Gram-negative bacilli strains~Trimethoprim-sulfamethoxazole (800mg/160mg) : once per day if patient < 80Kg ; one and a half per day if patient > 80Kg.~Doxycyclin : 200mg/day~Minocyclin : 100mg/8h to 12h~Ceftriaxon : 1g to 2g/day in IV, IM or SC~Cefotaxim : 1g to 2g/day in IV~Pristinamycin : 1g thrice a day"
45618066|NCT03350633|Drug|Tocilizumab Injection|Tocilizumab Injection will be intravenously administered with a dose of 8 mg/kg every 4 weeks.
45618067|NCT03350633|Drug|Azathioprine|Azathioprine will be orally given at a dose of 2-3 mg/kg/d
45618068|NCT03265795|Device|Poly Ether Ether Ketone PSI (patient specific implant).|reconstruction of the bone and the original volume of maxillary sinus accurately (in terms of clinical and radiographic parameters).
45618069|NCT03350555|Device|Additioned Endoscopy|To evaluate the use of additioned endoscopy in ERCP treatment.
45618070|NCT03265561|Device|Bone allograft|All patients will undergo the same surgical procedure consisting of open surgery, more debridement of infected and devitalized tissue, as well as corresponding bone resection. For the identification of the microorganism, biopsies will be performed by puncture guided by CAT and / or fluoroscopy, and culture and antibiogram will be performed in case of not obtaining enough material for this, at the time of the surgery samples will be sent to perform the same procedure. We will use the appropriate antibiotics, according to infecting microorganism and result of antibiogram. We will include patients with infections with gram positive and negative microorganisms only. This patients will go stabilized with bone allograft only.
45618071|NCT03265561|Device|Bone auto and allograft group|All patients will undergo the same surgical procedure consisting of open surgery, more debridement of infected and devitalized tissue, as well as corresponding bone resection. For the identification of the microorganism, biopsies will be performed by puncture guided by CAT and / or fluoroscopy, and culture and antibiogram will be performed in case of not obtaining enough material for this, at the time of the surgery samples will be sent to perform the same procedure. We will use the appropriate antibiotics, according to infecting microorganism and result of antibiogram. We will include patients with infections with gram positive and negative microorganisms only. This patients will go stabilized with bone autograft plus bone allograft
45618072|NCT03350477|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
45618073|NCT03350477|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
45618074|NCT03265639|Dietary Supplement|P-inulin|
45618075|NCT04504409|Other|Rehabilitation|Training
45618076|NCT03262051|Diagnostic Test|CYP phenotyping|Phenotyping using a simplified version of the Geneva cocktail
45618077|NCT03352817|Other|Cardiac rehabilitation|A questionnaire and an information sheet are provided. The questionnaire had to be completed anonymously and individually by the patient, to avoid any influence.
45618078|NCT04506749|Dietary Supplement|Dietary supplement consumption|The consumption time was 56 days. Consumed 100 grams daily to consume during the day.
45618079|NCT02458105|Behavioral|Acceptance & Commitment Therapy|A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
45618080|NCT02458105|Behavioral|Attention|Supportive conversation at a frequency and length corresponding to the experimental condition.
45618081|NCT04506671|Procedure|Renal biopsy|Renal biopsy will be performed prior to the cryoablation on the basis of the center and according to the current protocols
45760651|NCT03218891|Behavioral|Cardiac Rehabilitation|"The physical training program will start shortly after the initial exams have been completed. The physical training protocol will consist of a 12-week duration, with a frequency of 3 weekly sessions of 60 minutes duration each. The intensity will be prescribed from the echocardiogram with effort and cardiopulmonary test. All sessions will be monitored by telemetry and will be distributed as follows:~5 minutes warm up~30 to 40 minutes of aerobic exercise (treadmill). The training intensity will be prescribed individually, based on the results of the test results;~10 minutes of localized exercises;~5 minutes of relaxation."
45618082|NCT04506671|Procedure|Cryoablation|Cryoablation under CT guidance will be performed on the basis of the center and according to the current protocols
45760652|NCT05722977|Drug|Surufatinib + envafolimab|Surufatinib: oral, fix dose 250mg, once a day; Envafolimab: subcutaneous injection, fix dose 300mg, once every three weeks
45618083|NCT04506671|Procedure|Partial nephrectomy|Partial nephrectomy will be performed on the basis of the center and according to the current protocols
45618084|NCT04982497|Behavioral|Video game based intervention|The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated prevention program based on the model by Lewinsohn et al. (1985). The cognitive stimulation component is based on cognitive reserve (Tucker & Stern, 2011) and neuroplasticity (Shapiro, 2001), the cognitive stimulation model by Spector et al. (2006), and the causes of age-related memory failures (Light, 1991) (e.g., decrease in the processing resources, semantic coding deficit, difficulties in deliberate information retrieval). The healthy habits promotion component is based on the social learning and social cognitive theories (Bandura, 1986; Spiegler, 2016).
45618085|NCT04982497|Other|Control group|The active control group will have access to a platform of online therapeutically inactive information related to active aging.
45618086|NCT03352739|Device|DBS of the fornix, power on|"DBS of bilateral columns of the fornix is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on .~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
45760653|NCT00843713|Drug|raltegravir|For patients assigned to the raltegravir group, subjects will receive raltegravir 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
45618087|NCT03352739|Device|DBS of the NbM, power on|"DBS of bilateral NbMs is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on .~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
45618088|NCT03352739|Device|DBS of the fornix, power off|"DBS of bilateral columns of the fornix is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation.~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
45618089|NCT03352739|Device|DBS of the NbM, power off|"DBS of bilateral NbMs is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation.~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
45618090|NCT03350399|Diagnostic Test|placenta growth factor|estimation level of derum placenta growth factor
45618091|NCT03265093|Other|Platelet Rich Fibrin Injection|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge. I- prf will be injected on one side and corticosteroid will be injected on the other side in patients with bilateral oral lichen planus. Once a week in the first month after treatment and one time at the end of the second month, the patient will be called to the control.
45618092|NCT03265093|Drug|Corticosteroid|Corticosteroid injection
45618093|NCT03122483|Diagnostic Test|blood biomarker|
45618094|NCT03261583|Other|Thoracis Surgery - Common care|Observational study. It is only a matter of collecting clinical data.
45760654|NCT00843713|Drug|Placebo|For the patient assigned to the placebo group, subjects will take a matching placebo pill 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
45760655|NCT04845490|Drug|Mitomycin|Mitomycin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Mitomycin 30mg/m2. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
45618095|NCT03352661|Other|Collect retrospectively data|Collect retrospectively data
45618096|NCT03261739|Biological|RYI-018|Anti-CB1 monoclonal antibody
45618097|NCT03261739|Biological|Placebo|Placebo
45618098|NCT03352583|Dietary Supplement|Protein|40g calcium caseinate
45618099|NCT02456623|Behavioral|Intervention|Home-based session targeting the parent
45618100|NCT02456623|Behavioral|Attention Control|Attention condition with newsletters and support phone calls
45618101|NCT03350321|Drug|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
45618102|NCT03350321|Drug|Darbepoetin alfa|Starting dose of darbepoetin alfa once every 2 weeks will be titrated based on the subject's Hb (Hemoglobin) response
45618103|NCT04956679|Diagnostic Test|carbon 13 breath test|Patients with positive Helicobacter pylori infection were determined by carbon 13 breath test ,The diagnosis and treatment of positive patients were followed up without other intervention.
45618104|NCT03261895|Behavioral|Nurse-led Integrative health and wellness programme|Participants in the intervention group will go through a eight-session structured education programme. The education programme was designed by incorporating the evidences of diabetes care from the western medicine and the philosophy of traditional Chinese medicine.
45618105|NCT03350165|Drug|K-877|0.2mg tablet
45618106|NCT03350165|Drug|Placebo|K-877 matching placebo tablet
45618107|NCT03352349|Drug|Terlipressinum|If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
45618108|NCT03265171|Biological|Plasminogen (Human)|
45618109|NCT04933669|Drug|Imatinib|Imatinib neoadjuvant therapy
45618110|NCT03352271|Procedure|Individualized Incremental hemodialysis|Individualized Incremental hemodialysis program (twice/week, once/week, once/10days or less frequent) will be provided to incident ESRD patients according to their symptom presentation, clinical examination, investigations and daily urine volume measurement.
45618111|NCT03352271|Procedure|Conventional thrice weekly hemodialysis|Thrice weekly hemodialysis program, the current standard of care for all patients, as a control
45618112|NCT04889287|Drug|Elinzanetant (BAY3427080)|Once daily over 12 days
45618113|NCT04889287|Drug|Rosuvastatin|Single doses on Day 1, Day 8, and Day 13
45618114|NCT03350087|Device|intermittent theta burst stimulation|"In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s repeated 2 times for a total of 40 times (low pulse: 1200 pulses in total)~Other Names:~intermittent theta burst stimulation"
45618115|NCT03350087|Device|continuous theta burst stimulation|"In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times(low pulse: 1200 pulses in total).~Other Names:~continuous burst stimulation"
45618116|NCT03350087|Device|iTBS+cTBS group|In iTBS+cTBS pattern, continuous cTBS will be followed by intermittent iTBS (low pulse; 1200 pulses in total)
45618117|NCT03350087|Device|sham theta burst stimulation|"In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 1200 pulses in total).~Other Names:~sham theta burst stimulation"
45760656|NCT04845490|Drug|Lobaplatin|Lobaplatin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Lobaplatin 50mg/m2. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
45760657|NCT00356967|Drug|dianicline|
45760658|NCT03143621|Dietary Supplement|Coffee|Brewed, caffeinated coffee, 100 cc's each dose
45760659|NCT03143621|Other|Water|Tap water heated to same temperature as coffee
45760660|NCT00357045|Drug|Paroxetine|
45760661|NCT04819360|Drug|VESIcare 10Mg Tablet|"Vesicare® 10 mg per day for 12 weeks~Vesicare 10mg 12 weeks"
45760662|NCT04819360|Drug|Botox 100 UNT Injection|1 injection of Botox® 100 UNT
45618118|NCT03350087|Device|VCT|"The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.~Other Names:~The upper extremity programs virtual cycling training program"
45618119|NCT03350087|Device|VCT+optimal rTMS group|In VCT+optimal rTMS group, VCT will be combined with optimal rTMS, which has the best outcome in phase 1.
45618120|NCT04870255|Device|Left Dorsolateral Prefrontal Cortex (L-DLPFC)|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
45618121|NCT04870255|Device|Dorsomedial Prefrontal Cortex (DMPFC)|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the DMPFC. Stimulation intensity will be standardized at 100% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
45618122|NCT04870255|Device|Sham Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system."
45618123|NCT04669561|Drug|Lifitegrast 5% Ophthalmic Solution|Open label, self-controlled, single group study of the efficacy of Lifitegrast 5% in improving higher order aberrations, ocular scatter index, and best corrected visual acuity in patients with dry eye. All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days.
45760663|NCT05103189|Other|4D-flow sequence|all patients will be referred for a complete cardiac MRI exam with the addition of a 4D Flow sequence (does not require supplementary injection of a contrast agent and does not extend the duration of the examination) followed promptly (within the same hour) by a Doppler-echocardiography.
45618124|NCT03904927|Other|Radiation, Surgery or Radiofrequency ablation|Patients with no more than 4 metastases located in less than 2 organs/ lymphatic drainage regions treated with combined chemotherapy and radiation, surgery or radiofrequency.
45618125|NCT03904927|Drug|Chemotherapy|"First-line chemotherapy (previously without chemotherapy), paclitaxel 175mg/m2, d1+cisplatin 25mg/m2, d1-3, repeated every 28 days, intravenous infusion, a total of 4 cycles.~If patients have a history of chemotherapy, use a regimen of docetaxel 75mg/m2, d1, intravenous infusion, repeated every 21 days for a total of 4 cycles. If previously use docetaxel but not irinotecan, then use a regimen of irinotecan 180mg/m2, d1, d15, repeated every 28 days for a total of 4 cycles. If both docetaxel and irinotecan have been used, the investigator could decide the chemotherapy regimen."
45618126|NCT03259399|Genetic|detection of genotype|detection of genotype by next generation sequencing
45618127|NCT02729909|Drug|Lubiprostone|Lubiprostone capsules
45618128|NCT02729909|Drug|Placebo|Lubiprostone placebo-matching capsules
45618129|NCT03259633|Drug|Selumetinib|open-label, single-arm, multicenter intermediate access protocol
45760664|NCT04585204|Diagnostic Test|Oral glucose tolerance test|Oral glucose tolerance test
45760665|NCT05722899|Other|Football training|10-week progressive football training with small-sided games, 2x/week, 45min-1h sessions
45618130|NCT04506203|Diagnostic Test|Air test|Patients will breathe 0.21 < FiO2 < 0.25 during 5 min and have a lung ultrasound perfomed at the end of the 5 min trial.
45618131|NCT03352193|Dietary Supplement|Wheat spaghetti|Wheat oral immunotherapy
45618132|NCT03252769|Other|Self-sampling|
45618133|NCT03352115|Drug|Prednisolone|5 day course of oral prednisolone
45618134|NCT03352115|Drug|Placebos|Placebo syrup
45618135|NCT05723861|Device|VR|We will use the Pico Headset, a three-dimensional Gear with a connected tablet, and will be positioned on the head with elastic straps. Patients will be instructed about the VR device before their procedure and virtual experiences will initiate just before colonoscope insertion and continuously delivered throughout the procedure for max of 20 minutes. Patients will experience max of 20 minutes of VR and if colonoscopy lasts longer than 20 min, the remaining time of colonoscopy will be performed without using VR. The visualized content of VR will be chosen by the participants among three available contents including beach, nature, or mountain with relaxing music. Participants could opt out and/or request standard medications for pain at any time before or during the procedure.
45760666|NCT04341220|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation.
45760667|NCT04341220|Other|Balance exercises|Specific balance exercises, focused on balance, postural control and control of the center of gravity within the support base.
45760668|NCT00357123|Drug|Rosuvastatin|20 mg 10 days daily since abdominal sepsis diagnosis
45760669|NCT04436458|Drug|Niclosamide Oral Tablet|Continued SOC therapy together with niclosamide TID for 14 days
45760670|NCT04436458|Drug|Placebo|Continued SOC therapy together with placebo tablets matching niclosamide for 14 days
45760671|NCT03834753|Biological|bevacizumab|1.25 mg, intravitreal injection
45760672|NCT03834753|Biological|ranibizumab|0.5mg, intravitreal injection
45804066|NCT05718895|Drug|ATG-022|"Dose Escalation Phase:~A treatment cycle of ATG-022 will be defined as 21 days. Dosing will begin at 0.3 mg/kg once every 3 weeks (Q3W) with 1 subject ,the following dose cohorts (0.9, 1.8, 2.4, 3.0, and 3.6 mg/kg Q3W) will require at least 3 and up to 6 evaluable subjects by using dose escalation plan of 3+3 design."
45911625|NCT05777889|Other|Forward Looking InfraRed Camera|"Forward Looking InfraRed Camera:~We will use a FLIR T420 or T62101 camera with a resolution of 320*240.~Each image will be captured perpendicularly with a 1-inch gap on all four sides.~A Myler blanket placed in the background will separate the feet from the background.~The camera will be normalized to a temperature range of 15°C to 40°C.~The images will be saved in radiometric JPEG format.~Once the images have been transferred to a computer, we will remove the background.~Next, we'll make a temperature histogram with 0.1°C temperature bin resolution.~The before and after histograms (IB, IA) will be compared to see which one indicates more extreme temperature distributions.~Those who improve by 30% or more are considered to have had a successful spinal cord stimulation."
45618136|NCT02456077|Behavioral|Multimodal Vaccine Program|Efforts will be made to collaborate with pediatric and family medicine offices to utilize a multimodal intervention to improve adolescents' HPV immunization rates. As part of the overall intervention, four intervention strategies will be used: 1) a tailored website, iVac -HPV , 2) Motivational Interview Training for providers, 3) HPV Fact Sheets and 4) The Decision Aid for HPV Vaccines
45618137|NCT03349931|Diagnostic Test|DNA extraction and detection of Aspergillus fumigatus in serum samples|Performances diagnostic test of the real-time PCR ADEMTECH kit of DNA extraction and detection of Aspergillus fumigatus in serum samples in patients at high-risk for invasive aspergillosis (IA).
45618138|NCT03252457|Drug|Decitabine|given intravenously at a dose of 3.5mg/m2/d for 4 consecutive days as a cycle and repeated every 2 weeks for 3cycles
45618139|NCT03252457|Drug|Dexamethasone|given 40mg/d for 4 consecutive days as a cycle , If platelet count remained below 30 × 109/L or there were bleeding symptoms by day 10, an additional cycle of dexamethasone was given.
45618140|NCT03258931|Drug|Crenolanib|Crenolanib will be administered orally
45618141|NCT03258931|Drug|Midostaurin|Midostaurin will be administered orally
45618142|NCT03258931|Drug|Cytarabine|100 mg/m² IV continuous infusion over 24 hours
45618143|NCT03258931|Drug|Duanorubicin|90 mg/m2 IV
45618144|NCT04506281|Drug|neoadjuvant treatment|PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
45618145|NCT04506125|Other|Haemoglobin 9.5 g/dL|transfusion of red blood cell concentrate if the haemoglobin level is less than 9,5 g/dL
45618146|NCT04506125|Other|Haemoglobine 7.5g/dL|transfusion of red blood cell concentrate if the haemoglobin level is less than 7,5 g/dL
45618147|NCT03261349|Drug|Ledipasvir and sofosbuvir|To assess whether Harvoni® (ledipasvir and sofosbuvir) could eradicate HCV and lead to durable complete remission of these lymphomas.
45618148|NCT04488211|Other|Survey|The IVM survey will be structured as a series of open questions and multiple-choice questions.
45618149|NCT02455609|Procedure|intrathecal drug administration|pre-emptive intrathecal administration of analgesic medications for control of postoperative pain.
45618150|NCT02455609|Drug|Dexmedetomidine|
45618151|NCT02455609|Drug|ketamine|
45760673|NCT04271878|Other|RespirAct™ system (Thornhill Research Inc., Toronto, Canada)|"HUTT with Normal Breathing in Room Air (No gas interventions will be applied)~HUTT with Normal Breathing and ETCO2 clamped at baseline levels~HUTT with Normal Breathing and Mild Hypercapnia (the ETCO2 will be clamped at 45mmHg )~HUTT with Normal Breathing and High Hypercapnia (the ETCO2 will be clamped at 55mmHg)~HUTT with Fast, Deep Breathing and resultant Hypocapnia Participant will be coached to breath around 15 breath per min.No gas interventions will be applied~HUTT with Fast, Deep Breathing and ETCO2 clamped at baseline levels. Participant will be coached to breath around 15 breath per min, with ETCO2 clamped to baseline levels."
45760674|NCT00845039|Biological|Cetuximab|Cetuximab 500 mg/m² every 14 days until disease progression or participant intolerance
45760675|NCT00845039|Drug|Irinotecan|180 mg/m² every 14 days until disease progression or participant intolerance
45618152|NCT02455609|Drug|Bupivacaine|
45760676|NCT00845039|Biological|IMC-A12 (cixutumumab)|IMC-A12 10 mg/kg every 14 days until disease progression or participant intolerance
45760677|NCT05098821|Other|not applicable, observational study|Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study
45760678|NCT03879616|Behavioral|An Enhanced Reminder|"This study will be a randomized trial over a 6-month period (March 8 through September 7, 2019) in 3 GI endoscopy clinics (Franklin, Rock Creek, and Lone Tree). All members currently receive a text reminder 7 days prior to their procedure, which rolls over to a telephone reminder if the text cannot be delivered or the member's phone is not text-enabled. Members will be randomized either to receive this standard IVR-T protocol (control) or to receive an enhanced reminder (intervention) protocol.~Data from the randomized trial, for both intervention and control participants, will be analyzed to develop a statistical prediction rule that identifies members at highest risk of missing their procedure."
45760679|NCT00845195|Drug|Olopatadine HCl Nasal Spray, 0.6%|2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
45618153|NCT04504019|Device|USCTR|Ultrasound guided CTR via a single < 1 cm wrist or palmar incision. The procedure will be performed using the SX-One MicroKnife®
45618154|NCT04504019|Procedure|mOCTR|Mini-open CTR via a single 1-3cm palmar incision
45618155|NCT03352037|Diagnostic Test|PET scan|Patients with known pancreatic cystic lesions requiring MR imaging for lesion characterization for clinical evaluation will be recruited to undergo 18F-FDG PET/MR imaging after written informed consent.
45618156|NCT03349697|Dietary Supplement|Phyllantus amarus|
45618157|NCT03349697|Other|Placebo|
45618158|NCT04505579|Device|Anterior Vertebral Body Tethering|Anterior Vertebral Body Tethering (AVBT) is a technique that utilizes growth modulation to remodel the shape of the vertebra and straighten scoliotic curves in skeletally immature individuals. In this technique, screws are inserted at each vertebral level for the length of the convex side of the curve. A strong cord is connected through the screw tulip heads and used to initially straighten the curve as each level is fixed with a set screw. Following surgery and during the growth period the spine begins to remodel according to the Hueter-Volkmann Law, bone growth is relatively inhibited in areas of increased pressure (convex or tethered side) and relatively stimulated in areas of decreased pressure or tension (concave side).
45618159|NCT05723627|Drug|Remimazolam besylate|Patients in this group receives 0.1mg/kg of remimazolam to induce sedation prior to endoscope insertion.
45618160|NCT05723627|Drug|Propofol|Patients in this group receives 0.5mg/kg of propofol to induce sedation prior to endoscope insertion.
45618161|NCT02713243|Drug|LJN452|Capsules containing LJN452
45618162|NCT02713243|Drug|Placebo to LJN452|Capsules containing placebo to LJN452
45618163|NCT03349619|Drug|Resveratrol plus Carboxymethyl-β-Glucan|Patients in this arm will receive Resveratrol plus Carboxymethyl-β-Glucan, two sprays (100µL/spray) per nostril three times/day for 4 weeks
45618164|NCT03349619|Drug|Placebo|Patients in this arm will receive nasal saline solution 0.9%, two sprays per nostril, three times/day for 4 weeks
45618165|NCT04505657|Drug|celecoxib plus lidocaine|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
45618166|NCT04505657|Drug|Celecoxib|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +Sterile water 4 puffs during the procedure
45618167|NCT04505657|Drug|lidocaine|placebo to celecoxib administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
45618168|NCT03259243|Drug|Bupivacaine Hydrochloride|0.5 Bupivacaine hydrochloride were port site infiltration preincision and preclosure injection
45618169|NCT03351959|Radiation|neo-adjuvant treatment|long-course radio-chemoradiation; short-course radiation with immediate/delayed surgery
45618170|NCT03349541|Other|Complex Care Curriculum|"A well-established approach to curriculum development was utilized to develop competency-based objectives aligned with the Canadian CanMEDS Physician Competency Framework, identify appropriate educational strategies and design relevant evaluations."
45618171|NCT03258775|Other|water intake|After an overnight fast participants' RMR will be measured by indirect calorimetry for 30 minutes after which either a low (250ml) or high (500ml) dose of water will be consumed followed by an additional 90 minutes of indirect calorimetry. The test day will be repeated after 7-10 days with the second dose of water. The order in which the dose of water will be consumed will be randomized
45618172|NCT03258697|Drug|Levobupivacaine Hydrochloride|Different way of LevoBupivacaine injection
45618173|NCT03530891|Procedure|Computer guided lag screw fixation|Under general anaesthesia: Patient specific pre operative prefabricated surgical guide will be used intra operative for open reduction and internal fixation for anterior mandibular fracture using lag screws.
45618174|NCT03530891|Procedure|Conventional lag screw fixation|Under general anaesthesia: Open reduction and internal fixation for anterior mandibular fracture utilising lag screws.
45618175|NCT02456155|Procedure|placing nasal jejunal tube with ultrasound|bedside placing nasal jejunal tube with ultrasound confirmation versus placing endoscopically
45618176|NCT02456155|Procedure|placing nasal jejunal tube endoscopically|
45618177|NCT03349463|Drug|Fluciclovine F18|All study participants will receive 10 mCi of 18F-Fluciclovine (Axumin) one time administered through injection through the catheter into participant's arm immediately before PET/CT scan.
45618178|NCT03530813|Other|Ebook Asthma First Aid in School Training|Technology assisted, self-directed learning eBook resource
45618179|NCT03530813|Other|Face-To-Face Asthma First Aid in Schools Training|School Asthma First Aid Management Program 3 Hour Face to Face Training
45618180|NCT02455297|Drug|Copanlisib (BAY80-6946)|Starting dose 60 mg (dose reduction due to toxicities to 45 mg allowed). Administered in slow IV bolus on days 1, 8 and 15 of each 28 day cycle until disease progression or until another criterion is met for withdrawal from study treatment.
45618181|NCT03351881|Other|Description of Organ Donation Policy|Participants will read about an organ donation policy type (opt-out, opt-in, or opt-neutral) and rate what they think or feel about it.
45618182|NCT02456701|Biological|KTN3379|IV every 2 weeks
45618183|NCT02456701|Drug|vemurafenib|960 mg po bid
45618184|NCT03258619|Biological|Aldosterone / renin dosage|Plasma levels of aldosterone and renin
45618185|NCT03258619|Biological|Natriuresis|natriuresis levels
45618186|NCT03252379|Procedure|hepaticojejunostomy|"Under general intubation anesthesia, a generous right subcostal incision is performed and could be extended on demand upward to the xiphoid process and/or to the left subcostal area. Thorough dissection and adhesiolysis is performed to reach the CBD and prepare the unaffected proximal part for anastomosis. The Roux jejunal loop is prepared and passed retrocolic to reach the porta hepatis.~Then, the hepaticojejunostomy is done via end to side anastomosis using interrupted sutures of polyglactin of 3-0 or 4-0 size. The anastomosis is done 10-15 cm away from the free distal end of the Roux jejunum loop to allow anastomosis without tension to the stomach. A biliary stent may be optionally placed according to operative circumstances and is brought out through the anterior abdominal wall."
45618187|NCT03252379|Procedure|modified hepaticojejunostomy with subcutaneous access loop|"In the subcutaneous access loop, the same steps are done for performing roux-en-Y hepaticojejunostomy.~The closed free end of roux loop is passed through the anterior abdominal wall in the right subcostal area and then fixed to the wall in a subcutaneous position using 3/0 polyglactin sutures. The limb between the hepaticojejunal anastomosis and the subcutaneous fixation should be short and straight.~Four Ligaclips are used to mark the jejunal loop by clipping the sutures holding the access loop in place."
45618188|NCT03252379|Procedure|modified hepaticojejunostomy with gastric access loop|"In the gastric access loop, the same steps are done for performing roux-en-Y hepaticojejunostomy.The end of the Roux jejunal loop taken up for hepaticojejunostomy is not closed but is anastomosed to the anterior wall of the gastric antrum near the pyloric orifice.~All the enterogastrostomies and enteroenterostomies were in the form of single-layer continuous sutures of polyglactin of 3-0 size. An intraperitoneal drain was left in the hepatorenal pouch before closing the incision."
45618189|NCT03122795|Procedure|Microbiome transplant|A raw microbiome, collected from a donor without any sinonasal health problems, as a nasal lavage.
45618190|NCT03258541|Device|TraceIT®|This pilot study wishes to investigate feasibility and efficacy of the injected hydrogel spacers TraceIT® in sparing vagina/prostate in the treatment of rectal cancer patients.
45618191|NCT03258541|Radiation|Volumetric Arc Therapy (VMAT)|VMAT - fractionation Schedule : 1.8 Gy per fraction, one fraction per day, 5 fractions per week for the elective PTV and 2 Gy per fraction, one fraction per day, 5 fractions per week for the PTV-boost using a simultaneous integrated boost technique.
45618192|NCT03258541|Procedure|Surgery|Low anterior resection of the rectum: 8-10 weeks post-radiotherapy
45618193|NCT03349307|Device|Thin Convex Probe Endobronchial Ultrasound (TCP-EBUS)|Patients scheduled for a lobectomy will be recruited to this study and approached for informed consent. At the time of surgery, once the lobe has been removed, the TCP-EBUS will be inserted through a bronchial stamp for brief operability evaluations and image acquisition. Once this data has been captured standard of care will continue.
45618194|NCT03258229|Dietary Supplement|Angelica gigas N. extract|capsules(2cap/d, 1,000mg/d) for 8 weeks.
45618195|NCT03258229|Dietary Supplement|Placebo|Placebo for 8 weeks
45618196|NCT05550623|Device|Tourniquet|Tourniquet use in transfemoral amputation.
45760680|NCT00845195|Drug|Azelastine HCl Nasal Spray, 0.1%|2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
45760681|NCT00845507|Drug|Exenatide|The dosage of study medication will be 5 mcg injection of exenatide twice daily for 28 days. On day 28 the dosage may be increased, as tolerated, to 10 mcg twice daily.
45618197|NCT02456545|Other|≥ 1 potential risk factor for BD|exposure to ≥ 1 potential risk factors for BD (e.g. (sub)threshold affective symptomatology, anxiety, sleep disturbances, family history, episodic substance misuse)
45618198|NCT02456545|Other|depressive syndrome|in- and outpatients with depressive syndrome
45618199|NCT02456545|Other|ADHD|in- and outpatients with ADHD
45618200|NCT03252301|Device|PMD 200|finger sensor which estimate objectively the pain level
45618201|NCT03252067|Drug|azithromycin eyedrop|Tear samples will be collected using the strips.
45618202|NCT04505033|Drug|HB0017|HB0017 at 100 mg/mL (1 mL/vial) in 2 mL glass vial with a rubber stopper. HB0017 will be administered in the abdominal area by a subcutaneous injection in the mornings. A maximum volume of 1 mL is injected per site.
45760682|NCT00845507|Drug|Placebo|Placebo: Sterile solution in equivalent doses as Exenatide
45618203|NCT04505033|Drug|placebo|A matching injection solution containing a specific volume of normal saline (0.9%, Sodium Chloride Injection USP) and no active substance will be prepared for the subjects who will be assigned to placebo according to the dose schedule.
45618204|NCT03258307|Other|Preoperative level|Blood sample
45618205|NCT05550545|Other|cohort study|Please note that this is an observational study; not applicable
45618206|NCT03258073|Other|Medical simulation using scenario execution|Each team of students will be exposed to simulation two times in a semester totaling to four times a year. In a scenario execution, participants are placed in a simulated experience of a medical emergency. Participants are required to respond and their reactions are observed by the investigators. After the experience, participants will have a debriefing session to learn from their experience of handling this emergency.
45760683|NCT03782506|Behavioral|Interactive Music Therapy|Ten 45-minutes individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. Each session involves learning and practicing music-based techniques for the self-management of pain, anxiety, stress, mood, fatigue, and sleep disturbance as these are common opioid withdrawal symptoms. Psychoeducation about opioid tapering is provided and tapering challenges experienced by the patient will be actively addressed through music-based interventions.
45760684|NCT03782506|Behavioral|Verbal-based support|Ten 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears. As in the IMT protocol, psychoeducation about opioid tapering will be included and will be considered the only active treatment factor for this intervention.
45760685|NCT05078541|Procedure|Ultrasound-guided Radiofrequency Ablation of Parotid Warthin's Tumor|"The Procedure~Injection of local subcutaneous and pericapsular anaesthesia~Needle radiofrequency ablation under ultrasound guidance~Patients should communicate with operating surgeon upon excessive heat or pain~The procedure usually lasts 30-45 minutes"
45760686|NCT03761914|Biological|galinpepimut-S|Galinpepimut-S will be administered as monotherapy, then galinpepimut-S will be co-administered with pembrolizumab. After that, there will be un-paired administration of pembrolizumab and galinpepimut-S according to the schedule described in the protocol and described in the arm/group descriptions on ClinicalTrials.gov.
45911626|NCT05777876|Device|non-invasive transcranial deep brain stimulation|A new non-invasive transcranial deep brain stimulation, Temporal Interference Stimulation (TIS), can focus the stimulation region specifically on the deep brain region without affecting the upper level of the target region. At present, the safety of this method has been preliminarily verified in animals and healthy people, but the brain target of TRD treatment is not clear.
45618207|NCT05545787|Procedure|Cold snare endoscopic mucosal resection|During CS-EMR, methylene blue-tinted epinephrine saline will be injected into the submucosal space around the lesion to lift the lesion. The polyp and 1-2mm of surrounding mucosa will then be closely snared and transected mechanically.
45618208|NCT05545787|Procedure|Hot snare endoscopic mucosal resection|During HS-EMR, methylene blue-tinted epinephrine saline will be injected into the submucosal space around the lesion to lift the lesion. The snare will be placed around the lesion, and then cautery will be applied using the electrosurgical generator.
45618209|NCT03252223|Drug|Recombinant Follicle Stimulating Hormone|A modified dose-response study will be done using recombinant FSH (r-FSH), injected sc for 3 days at any one dose. r-FSH will be administered at weight-adjusted doses equivalent to 37.5, 75, and 150 IU based on an average weight of 70 kg, which approximates the weight of the average woman in the United States according to the Centers for Disease Control. Therefore, the actual dose of r-FSH will be 0.53 IU/kg for the 37.5 dose group. Accordingly, r-FSH will be repeated at doses of 1.1 IU/kg and 2.2 IU/kg that are equivalent to 75 and 150 IU for a 70 kg subject. Each FSH stimulation test will be assigned randomly and be separated by an interval of 8 weeks.
45618210|NCT05513807|Drug|Nicotinamide treatment|3g Nicotinamide orally (1g immediately pre transplant, then 1g post-transplant in the recovery room and 1g 24 hours later)
45618211|NCT05513807|Drug|Placebo treatment|3g Placebo orally (1g immediately pre transplant, then 1g post-transplant in the recovery room and 1g 24 hours later)
45618212|NCT02518217|Behavioral|Weight Loss Apps|Provision of commercially available smartphone applications for healthy eating, physical activity, and weight loss.
45760687|NCT03761914|Drug|Pembrolizumab|Galinpepimut-S will be administered as monotherapy, then galinpepimut-S will be co-administered with pembrolizumab. After that, there will be un-paired administration of pembrolizumab and galinpepimut-S according to the schedule described in the protocol and described in the arm/group descriptions on ClinicalTrials.gov.
45445743|NCT03766893|Other|Pharmacy maintenance addiction care|Patients on a stable dose of buprenorphine/naloxone or naltrexone will receive maintenance care at the pharmacy for one month. Patients will visit weekly for check-ins with a pharmacist. Patients on buprenorphine/naloxone will be dispensed their medication at study visits, whereas patients taking injectable naltrexone will be dispensed it once by the pharmacist during the pilot. All patients will visit the pharmacy at least weekly for addiction care (assessment, toxicological testing).
45618213|NCT02518217|Behavioral|ShapeUp Empower|Online intervention with training in behavioral strategies for healthy eating, physical activity, and weight loss. Includes periodic feedback on weight loss progress and engagement with the intervention platform.
45618214|NCT02518217|Behavioral|Financial Incentives for Engagement|Financial incentives for completing tasks such as viewing instructional information and reporting self-monitored body weights via the study website.
45618215|NCT03258151|Genetic|detection of genotype|detection of genotype by next generation sequencing
45445744|NCT02066116|Procedure|Kinect-based rehabilitation plus occupational therapy|The developed kinect-based rehabilitation system will be used for 30min/session. Conventional 30min occupational therapy also will be applied for the patient enrolled.
45618216|NCT03349151|Behavioral|Early feeding|Feeding on postoperative 2nd hour on return to the ward
45618217|NCT03349151|Behavioral|On- Demand feeding|Feeding whenever the patient asks for on return to the ward
45618218|NCT03813433|Other|Revascularization|a procedure used to regenerate pulp dentin complex that restores the functional properties of this immature anterior teeth, prevent and resolves apical periodontitis
45760688|NCT00845663|Drug|Certolizumab pegol|Auto-injection device (test) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
45760689|NCT00845663|Drug|Certolizumab pegol|Pre-filled syringe (reference) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
45445745|NCT02066116|Other|sham virtual rehabilitation education plus occupational therapy|For the sham virtual rehabilitation, computer-based cognitive rehabilitation program will be used. Patients will be encouraged to use their affected arm to push the button but the motion will be minimal and not related to the concept of upper extremity rehabilitation.
45445746|NCT03766815|Dietary Supplement|BCAA 200mg/kg/day|BCAA supplement based on 200mg/kg/day for 18 days.
45445747|NCT03766815|Dietary Supplement|Placebo|Fiber supplement jelly for 18 days.
45445748|NCT03766815|Dietary Supplement|BCAA 400mg/kg/day|BCAA supplement based on 400mg/kg/day for 18 days.
45445749|NCT03766815|Behavioral|Muscle damaging exercise|Participants will be asked to perform muscle damaging elbow eccentric contraction exercise at 120% of 1RM for three sets of 15 repetitions with the dominant arm at maximal effort on a Biodex machine with a 3 minute rest period between each set.
45445750|NCT02066194|Procedure|Electroacupuncture|
45445751|NCT02064244|Other|Ultrasound for measurement of Inferior Vena Cava size.|Focused bedside ultrasound will be performed for each patient as part of their routine care and initial assessment. The IVC size will be measured at the subcostal window, during inspiration and expiration, using the Sonosite cardiac probe P-21 (5-1 MHZ). The measurement is obtained by applying the M-mode, perpendicular to the IVC axis and 2 cm caudal from its junction with the right atrium.
45445752|NCT03766737|Device|An intelligent visual acuity diagnostic system for children|An artificial intelligence to make evaluation and of children's vision.
45760690|NCT00364312|Behavioral|diet and physical activity|
45760691|NCT00364390|Drug|Anginera, a human tissue replacement therapy|
45760692|NCT03500380|Drug|RC48-ADC|RC48-ADC 2.0 mg/kg IV every 14 days
45760693|NCT03500380|Drug|Lapatinib|Lapatinib 1250 mg orally once daily during each 21-day cycle.
45445753|NCT04354467|Drug|Acute kidney Injury due to nephrotoxic medications in the NICU|AKI will be defined using the KDIGO AKI definition
45618219|NCT03251677|Procedure|Surgical procedure, Hysterectomy|Surgical removal of the uterus
45618220|NCT03791749|Other|Breastfeeding Support|12-minute simple technique
45618221|NCT03351725|Device|peripheral venous catheter (PVC)|No intervention is made only in situ swab from the PVC
45618222|NCT03261661|Behavioral|Reading|Students are taught the processes involved in hearing, seeing, and feeling sounds as well as differences between sounds in words. New knowledge is built on previous knowledge in a step-by-step manner. Sounds build to letter-sound relationships to reading of words and syllables. Students learn the connection between reading of words (decoding) and writing/spelling words (encoding) building from simple words to multisyllabic words to text reading with fluency and understanding.
45760694|NCT03500380|Drug|Capecitabine|Capecitabine 2000 mg/m^2 orally daily on Days 1-14 of each 21-day treatment cycle.
45760695|NCT03416998|Other|phototherapy|Phototherapy will be performed using clusters of 12 diodes (Table 1); four 905 nm diodes (mean power of 0.3125 mW and peak power of 12.5 W for each diode; 250 Hz), four 875 nm diodes (mean power of 17.5 mW for each diode) and four 640 nm diodes (mean power of 15 mW for each diode). The device manufactured by Multi Radiance Medical® (Solon, OH, USA) will be used due to its high quality, ample use in clinical practice and due to the fact that no national companies manufacture diode clusters with the characteristics required for the proposed project.
45760696|NCT03267238|Biological|Fecal Microbial Transplantation|Fecal Microbial Transplantation via will be offered to eligible Crohn's patient
45804067|NCT03342937|Drug|Oxaliplatin+Capecitabine+Pembrolizumab|"For each cycle: Oxaliplatin 130 mg/m2 IV on Day1, Capecitabine 825 or 1000 mg/m2 PO, BID Days on Days1-14, Pembrolizumab 200 mg IV on Day 1.~This study has 2 parts:~Safety validation part: all Cycles are 21 days in length.~Dose Expansion part: Cycle 1 is 28 days in length. Cycle 2 and beyond are 21 days."
45618223|NCT03261661|Behavioral|Mindset|Blended learning program with online and teacher-directed activities related to how the brain functions, learns, and remembers, and how it changes in a physical way when we exercise it. Instruction in how students are in control of their brain and its development, and how to apply this to their schoolwork with practical strategies for tackling academic challenges.
45618224|NCT03261661|Behavioral|Reading Embedded with Mindset|Mindset training explicitly linked to the reading content through lesson openers, feedback prompts, and self-monitoring of mindset during reading work.
45445754|NCT03760809|Drug|Dexmedetomidine 0.5μg／kg|Group A received dexmedetomidine 0.5μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.
45618225|NCT03261661|Behavioral|Business as Usual|Reading interventions already provided to students with reading difficulties as per typical procedures at the participating school
45445755|NCT03760809|Drug|Dexmedetomidine 1μg／kg|Group B received dexmedetomidine 1μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.
45618226|NCT04504877|Drug|Cannabidiol|Cannabidiol 300 mg daily for 4 weeks
45618227|NCT03251755|Behavioral|Yoga|Exercise promotion using Chinese Yoga
45618228|NCT02518295|Other|Positive control|200ml milk containing 18g lactose
45618229|NCT02518295|Other|Probiotic S. thermophilus|200ml milk containing 18g lactose + probiotic S. thermophilus
45618230|NCT02518295|Other|Probiotic B. longum|200ml milk containing 18g lactose + probiotic B. longum
45618231|NCT02518295|Other|Negative control|200 ml of UHT Lactose free milk
45618232|NCT03261271|Behavioral|Weight Loss Program|Program involves one-on-one coaching, diet meal plan, and physical activity plan.
45618233|NCT03261271|Behavioral|Standardized educational flyer|"The American Institute for Cancer Research handout Nutrition and the Cancer Survivor will be provided to participants."
45618234|NCT03261271|Behavioral|Weight Maintenance Program|Post-surgery program involves group support sessions, phone check-ins, and diet and exercise monitoring.
45618235|NCT05501717|Drug|ALXN2030|ALXN2030 will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
45618236|NCT05501717|Drug|Placebo|Placebo will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
45618237|NCT03260959|Behavioral|Interview by hierarchical evocation's Method|Interview to describe the experience of the man during the announcement of a pregnancy that it is expected or not.
45618238|NCT03257683|Drug|Ranolazine|Study group will receive additional therapeutic dosing of drug.
45618239|NCT02518061|Other|No intervention|This is a retrospective study
45618240|NCT03251521|Other|pain rating during injection with botulinum toxin|The pain intensity was rated verbally on a numeric scale. The pain was rated after each phase of injection
45618241|NCT03351569|Drug|Intravenous immunoglobulin|Intravenous drip.
45618242|NCT03257839|Device|Routine Full-Field Digital Mammography|Routine screening mammography exam, CC + MLO views.
45618243|NCT03257839|Device|Routine Digital Breast Tomosynthesis|Routine screening tomosynthesis exam, CC + MLO views.
45618244|NCT03257839|Device|Automated Whole Breast Ultrasound|Bilateral breast ultrasound performed as an adjunct to mammography.
45618245|NCT03348917|Drug|7.5% Povidone-Iodine [PVP-I]|Betadine® 7.5% skin cleanser (PVP-I 7.5%)
45618246|NCT03348917|Drug|4% chlorhexidine skin cleanser|Unity antiseptic hand wash (no alcohol)
45618247|NCT03348917|Drug|Plain non antibacterial soap|Guardian gel hand wash (not medicated),
45911627|NCT05777876|Device|Sham stimulation|Electrodes will be placed in the same location on the head as that for the TI intervention; 30 seconds of electrical current will be delivered to the brain (compared to 30 minutes in the experimental intervention arm), therefore it is expected to elicit no changes in neural activity.
45618248|NCT03260803|Drug|Oligopin|Oligopin ,150 mg ,once daily, 12 week
45618249|NCT03260803|Drug|Placebo|Placebo,150 mg ,once daily, 12 week
45618250|NCT03251599|Drug|Glyceryl trinitrate 0.2|These patients will receive glyceryl trinitrate infusion at a rate of 0.2 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
45618251|NCT03251599|Drug|Glyceryl trinitrate 0.5|These patients will receive glyceryl trinitrate infusion at a rate of 0.5 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
45618252|NCT03348839|Device|NeLLY service|Telesurveillance and therapeutic support
45618253|NCT03251365|Drug|HIPEC-gemcitabine|• Group II.After a R0 cytoreductive surgery, HIPEC is performed with gemcitabine, 120mg / m2 for 30' + adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
45618254|NCT03348761|Device|rTMS group|
45618255|NCT03257527|Behavioral|ENHANCE group|The ENHANCE program includes an initial 3-month treatment of 12 weekly sessions (including an introductory session, a final session, and 10 content sessions) followed by a 3-month maintenance phase intervention with bi-weekly sessions. Over the course of the program, participants will learn about 10 evidenced-based principles of happiness and how these principles can be applied effectively in their lives. At the final session, participants will receive feedback outlining the happiness principles and activities that fit them best, and will then be asked to work on creating a plan for integrating those principles into their daily lives.
45618256|NCT03257527|Behavioral|MBSR group|"The MBSR program is based on the self-help workbook entitled, A Mindfulness-Based Stress Reduction Workbook. This workbook is authored by Drs. Bob Stahl and Elisha Goldstein - who are both certified MBSR trainers. The workbook is written to help everyday people learn how to replace stress-promoting habits with mindfully-based ones to improve overall well-being. The workbook begins by providing a thorough introduction to the basic tenets of mindfulness, and improving well-being through the use of mindfulness-based skills. The workbook outlines, in detail, several skills-based exercises for practicing mindfulness across different aspects of a person's life. The MBSR group will be provided with a recommended weekly schedule for the initial 3-month treatment and a list of additional resources to be completed over the 3-month maintenance phase."
45618257|NCT03251443|Drug|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
45804068|NCT05718739|Device|AX6 6-axis logging accelerometer|The device is collecting longitudinal movement data.
45760697|NCT03006016|Drug|Omega-3 Fatty Acid|The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
45618258|NCT03348605|Device|Phantom Stimulator, Cort X Sensorics, Spaichingen, Germany|"This system consists of a pressure sensing insole connected to regular TENS-Electrode patches which are applied to the receptive fields of the patients (evoking the sensation of heel and forefoot). The individually adjusted stimulation intensity on the systems regulatory box through a socked screw is set at the beginning of the testing phase, and not changed anymore.~The current is applied to mimic the roll-off-sensation while walking. This is done by locating two sets of electrodes on the receptive fields representing the heel and the ball of the foot respectively. Now the current is applied in an alternating manner coordinated with the walking of the participant. The coordination is made able through the pressure sensing insole."
45618259|NCT03251287|Drug|Sodium Nitrate|Single dose of 14mmol oral inorganic sodium nitrate
45760698|NCT03006016|Other|Placebo|The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
45760699|NCT04292561|Drug|Low MAC|To maintain a target of sevoflurane inhalation concentration 0.8 MAC.
45618260|NCT03251287|Drug|Placebo|Single dose of oral matching placebo
45760700|NCT04292561|Drug|High MAC|To maintain a target of sevoflurane inhalation concentration 1.0 MAC.
45760701|NCT02871934|Genetic|SLCO1B1 Genotype|Polymerase chain reaction (PCR) assay for SLCO1B1 rs4149056, with possible results T/T, T/C, or C/C.
45760702|NCT03123393|Drug|TAK-659|TAK-659 Tablets
45760703|NCT04340830|Procedure|Free gingival graft|Following recipient site preparation, free gingival graft obtained from palatal mucosa was applied to buccal sites of dental implants having inadequate keratinized attached mucosa.
45760704|NCT04743076|Procedure|Endovascular treatment|Endovascular treatment
45618261|NCT03251287|Diagnostic Test|Phosphorous Magnetic Resonance Spectroscopy|On the first visit day of this arm, participants will be lie inside an MRI scanner to take pictures of the heart. The thigh muscle will then be imaged before, during, and after kicking exercises.
45760705|NCT04743076|Other|Standard medical treatment|Standard medical treatment
45760706|NCT00848237|Device|Radiofrequency Ablation (HALO Ablation Systems)|Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.
45760707|NCT03115203|Other|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis
45760708|NCT03115203|Other|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in healthy subjects|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle in healthy subjects (data obtained from the SIMOVI project being published).
45618262|NCT03251287|Diagnostic Test|Exercise Stress Transthoracic Echocardiogram|On the second visit day of this arm, participants will be asked to lie, semi-erect, on an exercise bed for up to 90 minutes. The echocardiogram will be performed at rest and during peak exercise. The exercise will be in the form of a pedal bike. The exercise levels will be worked out from an upright bicycle exercise test completed by the participants prior to randomization.
45618263|NCT04502303|Diagnostic Test|18F-FDG and 68Ga-FAPI PET/CT|Participants will undergo 18F-FDG (0.12-0.15mCi/kg) and 68Ga-FAPI (3-6mCi) PET/CT on two consecutive days. At least 6 hours of fast is required for 18F-FDG PET scan, while no dietary control is necessary for 68Ga-FAPI PET scan. If the patients are on metformin, discontinuation of 48 hours is required before 18F-FDG injection to minimize the bowel uptake. If the patient is planned for surgical resection of one or more stricture (s), the scans have to be completed within a maximum period of 30 days before the surgery.
45760709|NCT00534430|Drug|busulfan|
45760710|NCT00534430|Drug|cyclosporine|
45760711|NCT00534430|Drug|etoposide|
45760712|NCT00534430|Drug|mycophenolate mofetil|
45760713|NCT00534430|Procedure|allogeneic bone marrow transplantation|
45760714|NCT00534430|Procedure|allogeneic hematopoietic stem cell transplantation|
45760715|NCT00534430|Procedure|peripheral blood stem cell transplantation|
45760716|NCT00534430|Radiation|total-body irradiation|
45760717|NCT03092895|Biological|SHR-1210|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
45760718|NCT03092895|Drug|Apatinib|Subjects receive Apatinib orally every day with a dose escalation
45760719|NCT03092895|Drug|FOLFOX4|Subjects receive FOLFOX4 treatment every 2 weeks
45760720|NCT03092895|Drug|GEMOX|Subjects receive GEMOX treatment every 2 weeks
45760721|NCT03084731|Dietary Supplement|Microbiota Directed Complementary Food (MDCF)|"For Study 1: Investigators will test 3 prototype MDCFs and the current RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 2: From study 1 Investigators will select most efficacious MDCF and compare with 2 additional MDCF prototypes to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 3: Investigators will select the lead MDCF from study 2 and examine the effects between the final MDCF versus current RUSF and also examine the impact dispensing of the lead MDCF once versus twice per day with a 4 week post-intervention period."
45760722|NCT02589808|Device|Full TTE|Full transthoracic echocardiogram, with Doppler.
45760723|NCT02589808|Device|GE Vscan|Handheld echo.
45760724|NCT03839771|Drug|AG-120|250mg tablets
45760725|NCT03839771|Drug|Placebo for AG-120|250mg tablets
45760726|NCT03839771|Drug|AG-221|100mg tablets
45760727|NCT03839771|Drug|Placebo for AG-221|100mg tablets
45760728|NCT03033225|Procedure|Endoscopic Ultrasound|Undergo EUS-guided PDT
45760729|NCT03033225|Procedure|Fluorescence Imaging|Undergo fluorescence imaging
45618264|NCT05350943|Procedure|HAIC|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.
45618265|NCT05350943|Drug|Gemcitabine|1000 mg/m^2 in 100ml saline solution IV, d1, Q3W
45618266|NCT05350943|Drug|Oxaliplatin|85 mg/m^2 in 500ml 5% glucose solution over 2 hours IV, d1, Q3W
45618267|NCT05350943|Drug|Toripalimab|3mg/kg (body weight < 60kg) or 240 mg（body weight>= 60kg）in 250 saline soluation, IV, Q3W
45618268|NCT05350943|Drug|Donafenib|0.2mg. P.O, BID, continuously
45618269|NCT03257449|Dietary Supplement|Viscous Fibre|Meta-analysis of Randomized Controlled Trials
45618270|NCT03351413|Other|LIVE-LiFE to Prevent Falls Among Older Fallers|"LIVE-LiFE Intervention: Individually tailored program at the participant's home spaced across 12 weeks including:~Home safety assessment and risk reduction strategies; incorporating strength and balance training into daily habits vision screening and referral; and education about fear of falling and falls~Home repairs, modifications, and low cost assistive devices to address unsafe home environments increasing fall risk~Medication review and feedback concerning medications with increased fall risk~Measurement intervals: Baseline, 4 months, 8 months (with $25 gift card given at each visit for your time)"
45618271|NCT03251053|Device|Electronic cigarette use|Replacement of tobacco smoking with electronic cigarette vaping
45618272|NCT03251053|Other|Control regular cigarette smokers|
45618273|NCT04503785|Diagnostic Test|Manometry|Transnasal Esophageal manometry and Endoflip Balloon distensibility
45618274|NCT03261427|Drug|Lyrica 150Mg Capsule|150 mg oral administered (BID)
45618275|NCT03261427|Drug|YNP-1807 330Mg Tablet|330 mg oral administered (QD)
45618276|NCT05329571|Behavioral|Low-FODMAP diet|Participants will be instructed to maintain their usual diet, while eliminating all dietary gluten.
45618277|NCT05329571|Behavioral|Gluten-free Diet|Participants will be instructed to maintain their usual diet, while eliminating all dietary gluten.
45618278|NCT05329571|Behavioral|Control group|Patients of this group will have dietary consultation but will not change their regular diet for the period of the study.
45618279|NCT03261115|Procedure|No topical anesthesia|Lack of use of topical anesthesia application prior to infiltration injection intra-orally
45618280|NCT03348527|Drug|2-Hydroxyflutamide Depot|Liproca® Depot is a depot formulation containing a bioresorbable, controlled-release,formulation of the nonsteroidal antiandrogen 2-hydroxyflutamide
45618281|NCT03251131|Other|Restrictive fluid management|Daily fluid input is restricted to drugs and nutrition. Fluid boluses and blood products can be given if clinically indicated. Matching fluid output to fluid input whenever possible using diuretics if needed, and additionally, if clinically necessary and plausible, commencing renal replacement therapy. If renal replacement therapy is not deemed clinically desirable, acceptance of a less than targeted fluid balance.
45618282|NCT05320133|Drug|JWC containing quadruple therapy|Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and Jinghua Weikang Capsule 240mg twice daily for 14 days.
45618283|NCT05320133|Drug|Bismuth-containing quadruple therapy|Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and bismuth potassium citrate 220mg twice daily for 14 days.
45618284|NCT03257293|Behavioral|Modified Cystoscopy|The objective of this study is to examine whether a non-pharmacologic modification in procedure of cystoscopies improves patient perception of pain and discomfort.
45618285|NCT03257293|Behavioral|Routine Cystoscopy|Routine cystoscopy as done as part of routine clinical practice
45618286|NCT02455219|Device|Prototype UHRSZ (UltraHigh Resolution Smart Zoom) Collimator|In DATScan SPECT scans, the UHRSZ collimator will be exchanged for the standard collimator following completion of the clinically ordered scan. A scanning sequence will be repeated with the prototype collimator in place. Images from the two scanning sequences will be compared.
45760730|NCT03033225|Drug|Photodynamic Therapy|Undergo EUS-guided PDT
45760731|NCT03033225|Other|Quality-of-Life Assessment|Ancillary studies
45760732|NCT03033225|Other|Questionnaire Administration|Ancillary studies
45618287|NCT03347045|Combination Product|Trimodal Prehab & ERP|"1-hr daily exercise will be completed a total of 5d/week, of which 2 of these sessions are completed through a community fitness center. Following these sessions, the participant will consume a high-protein oral supplement.~Additionally, during the program, participants will be given the option of attending a stress-reduction group and will receive a take-home anxiety-reduction program. They will have access to a physiotherapist, kinesiologist, registered dietitian, and physician throughout the program.~The total length of this program is 8-weeks and is timed to occur in the waiting period between the consent for surgery and operation date."
45618288|NCT03347045|Other|No Prehab; ERP Alone|1-hr daily exercise with a self-completed home-exercise program. The participant will be given nutritional education material and a take-home anxiety-reduction program. They will be responsible for maintaining a journal of their activity.
45760733|NCT03033225|Drug|Verteporfin|Given IV
45760734|NCT02591056|Device|Erchonia® Verju™ Laser|There are 12 procedure administrations with the Erchonia® Verju™ Laser across 6 weeks: 2 procedures per week. For each procedure administration, the Erchonia Verju is applied to the midsection for 30 minutes: 15 minutes to the front and 15 minutes to the back. All subjects receive the active Erchonia Verju Laser treatment for all 12 procedure administrations.
45911628|NCT05777876|Device|Motor cortex stimulation|Receive stimulation in the motor cortex stimulation instead of deep brain.
45911629|NCT05777876|Device|non-invasive transcranial deep brain stimulation with closed-loop|Non-invasive transcranial deep brain stimulation devices based on closed-loop regulation of EEG can improve the accuracy of treatment.
45618289|NCT03257917|Other|Understanding value in Metastatic Breast Cancer|The overall objective of this project is to gain knowledge about out-of-pocket (OOP) expenses and lost opportunity costs among metastatic breast cancer (MBC) patients. To achieve this objective, MBC patients will be asked to participate in a short, 37-question survey asking questions about the financial burden, OOP expenses, and opportunity costs related to their cancer care.
45618290|NCT03122561|Drug|Paracetamol 500 mg tablet at morning|Single dose oral paracetamol will be administered at 8.00 am
45618291|NCT03122561|Drug|Paracetamol 500 mg tablet at midday|Single dose oral paracetamol will be administered at 2.00 pm
45445756|NCT03760497|Procedure|Restorative treatment|For all groups, first the patients will be submitted to the anesthetic technique indicated with Lidocaine + Epinephrine 1: 100,000 (New DFL, Rio de Janeiro, Brazil), followed by absolute isolation with rubber sheet and metal clamp; then prophylaxis of the selected tooth will be performed with Robson's brush and pumice stone and water, surface washing and drying with cotton balls, removal of carious tissue or affected enamel without dentin support with sharp curettes or low-speed spherical drills. Subsequently, each group will follow the treatment protocols suggested by the manufacturer of restorative materials.
45445757|NCT01370590|Drug|Atorvastatin|20 mg tablet administered orally once daily
45445758|NCT01370590|Drug|Ezetimibe|10 mg tablet administered orally once daily
45618292|NCT03122561|Drug|Paracetamol 500 mg tablet at night|Single dose oral paracetamol will be administered at 8.00 pm
45618293|NCT03260335|Behavioral|Anxiety management strategy|Anxiety management strategy as per standard care plan
45618294|NCT03351257|Other|observation of surface patterns and colors of polyps|examination of the surface patterns and colors of polyps using Linked color imaging and white-light
45618295|NCT03351179|Combination Product|clinical characteristics, previous history, laboratory bio-markers, echocardiographic measurements, angiographic findings,clinical outcomes|The differences of data(clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic characteristics and clinical outcomes) in two groups were conducted. The differences between two groups were compared (clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic characteristics and clinical outcomes) in two groups were compared, and then found the risk factors. Following,the incidence of clinical outcomes and mortality were compared. Then, univariate logistic regression and multivariate logistic regression analysis adjusted for significant risk factors were performed to find out the independent predictive factors. Finally, the ROC was constructed, and the area was evaluated to assess the predicted probability of regression model.
45618296|NCT02454829|Other|questionnaire|A questionnaire will be send concerning the patient's ovarian function since the cryopreservation procedure i.e: progression of puberty, menstrual cycle, hormonal treatment, desire for pregnancy, occurence of pregnancy, details of pregnancy, need for ART (Artificial Reproductive Techniques), and about the patient's satisfaction concerning the cryopreservation procedure. Data collected will be correlated with treatments received.
45618297|NCT04503629|Drug|Anaprazole Sodium|Anaprazole Sodium 20mg
45618298|NCT04503629|Drug|Anaprazole Sodium|Anaprazole Sodium 40mg
45618299|NCT04503629|Drug|Rabeprazole sodium|Rabeprazole sodium 10mg
45618300|NCT03257059|Other|Breakfast|Glutinous rice (75 grams of available carbohydrate)
45618301|NCT03257059|Other|No Breakfast|No food to be served in the morning
45618302|NCT05305001|Genetic|Invitae Multi-Cancer Panel ®|Participants will have genetic testing.
45618303|NCT04487509|Other|THROMBOLYSE|the treatment delivered to the emergency room, in particular the nature of the treatment for obstruction (primary angioplasty or thrombolysis)
45911630|NCT05777850|Procedure|Conventional cavotricuspid isthmus ablation|Point-by-point 25-40 W applications at the CTI of unlimited duration until achieving the pre-established Ablation Index.
45445759|NCT01370590|Drug|Ezetimibe/atorvastatin|Ezetimibe/atorvastatin 10 mg/20 mg combination tablet administered orally once daily
45911631|NCT05777850|Procedure|High-power short-duration ablation|Point-by-point 90W applications at the CTI ablation during 4 seconds.
45445760|NCT01370590|Drug|Placebo to atorvastatin|Administered orally once daily
45618304|NCT03256981|Radiation|SBRT|SBRT dose and fractionation dependent on site of metastasis and proximity to critical normal tissues.
45618305|NCT03256981|Drug|TKI|Continued background TKI alone
45618306|NCT03348449|Other|Collection of data|Outcome of patients will be collected from charts to evaluate primary and secondary objectives
45618307|NCT03256903|Drug|Methoxyflurane|Up to two inhalers containing 3 mL methoxyflurane. Treatment duration: 1 administration in 1 day.
45618308|NCT03256903|Drug|Standard of care|Any kind of analgesia, administered by any route for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain
45618309|NCT03260725|Behavioral|Parent-Child Interaction Therapy (PCIT)|PCIT is a short-term intervention that incorporates principles of play therapy into behavioral parent training, drawing on attachment and social learning theories to emphasize positive attention, consistency, problem solving, and communication. Treatment is delivered in the clinic.
45618310|NCT03260725|Behavioral|Internet-delivered PCIT (I-PCIT)|I-PCIT is a short-term intervention that incorporates principles of play therapy into behavioral parent training, drawing on attachment and social learning theories to emphasize positive attention, consistency, problem solving, and communication. Treatment is delivered to families in their own home in real-time via videoconferencing over the Internet by a remote therapist.
45911632|NCT05777837|Procedure|laparoscopic repair of cesarean scar niche|Intentional perforation of the niche will be done using uterine sound and excision of the fibrotic edges then suturing the uterine incision using 2-0 absorbable suture.
45445761|NCT01370590|Drug|Placebo to ezetimibe|Administered orally once daily
45445762|NCT01370590|Drug|Placebo to ezetimibe/atorvastatin|Administered orally once daily
45445763|NCT03770871|Drug|Indirect pulp treatment using Dycal (TM)|Partial caries removal and protection of the dental pulp with biocompatible material
45445764|NCT03770871|Drug|Indirect pulp treatment using Vitrebond (TM )|Partial caries removal and protection of the dental pulp with biocompatible material
45445765|NCT03771027|Other|The low FODMAP diet.|The low FODMAP group had reduced the intake of FODMAP. Children received 3 main meals and 2 snacks daily prepared by the catering company according to the Human Nutrition Recommendations for Polish Population. The dietary intervention lasted four weeks.
45618311|NCT03256747|Device|NMES|NMES will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time application will be 60 minutes. Intensity will be adjusted individually, taking into account the patient's ability to promote the full knee extension and comfort during contractions.
45618312|NCT03256747|Device|NMES-placebo|NMES-placebo will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time of application will be 60 minutes. Intensity will be adjusted with minimal intensity, utilized to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
45618313|NCT03256669|Procedure|umbilical incision|exploration through umbilical incision
45618314|NCT03256825|Diagnostic Test|Rapid diagnostics alone|Urine samples present at the laboratory at opening on weekdays will be screened using urine flow cytometry and microscopy of centrifuged gram stained urine. Samples found positive for significant mono microbial bacteriuria will be investigated further by using direct automated phenotypic identification and antimicrobial susceptibility determination.
45618315|NCT03256825|Other|Real-time antimicrobial stewardship decision support|"A clinical microbiologist will be give RADS by phone to a designated clinician with the aim of:~Switch to active treatment if non-working empirical treatment~De-escalate broad spectrum empiric treatment when feasible~Promote early intravenous to per oral switch~Shorten treatment duration"
45618316|NCT03351023|Other|no intervention-this was an observational study|
45618317|NCT03259945|Other|Data collection|demographic and clinical data
45618318|NCT03259945|Other|Review of ECGs|nature and frequency of proven conduction disorders
45618319|NCT03260179|Drug|AL3810|Fasting，oral ，4w on or 3w on/1w off
45618320|NCT03260179|Drug|AL3810|Fasting，oral ，4w on or 3w on/1w off
45618321|NCT03260179|Drug|AL3810|Fasting，oral ，4w on or 3w on/1w off
45618322|NCT04504565|Diagnostic Test|99mTc-3PRGD2|intravenous injection of 0.3 mCi/kg of 99mTc-3PRGD2
45618323|NCT03250819|Other|SNP analysis|The collected blood samples will be used to investigate the occurrence of SNPs (single nucleotide polymorphisms) in both study groups
45618324|NCT03350945|Procedure|Device: tumor localization|At present, three dominant methods can be available to locate tumor: preoperative endoscopic clip placement, intraoperative endoscopy and endoscopic tattooing
45618325|NCT03256513|Other|model controlling|control blood pressure by statistical l model with anticipate lowest peri-procedure risk
45618326|NCT03256513|Other|conventional controlling|control blood pressure by conventional strategy
45618327|NCT03348371|Other|Ethanol|The intervention is two different administrationforms of ethanol, orally and i.v.
45618328|NCT03251209|Other|Physical practice|Physical Practice: reproduce through the motor execution (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles), the activities assisted in the video (5 minutes / task).
45618329|NCT03251209|Other|Mental practice|Mental practice: think about the tasks watched in the videotherapy (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles) for 5 minutes / task.
45618330|NCT03251209|Other|Videotherapy|Videotherapy, being 2 minutes per task (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles)
45618331|NCT05231603|Drug|Ivermectin|0.4 mg/kg/day-maximum dose is 24 mg.
45618332|NCT05231603|Other|Placebo|Similar to drug in term of tablets
45618333|NCT03256591|Other|HBB facilitators with simulation training|HBB training from facilitators with simulation skills. Standard HBB facilitators do not have simulation skills
45618334|NCT03250429|Procedure|Sinus surgery|Standard Clinical Sinus Surgery
45618335|NCT03256279|Device|".014 NiTi heat-activated archwire"|".014 NiTi heat-activated archwire In the lower arch during the first three months of the orthodonci treatment"
45618336|NCT03256279|Device|".014 NiTi Superelastic archwire"|".014 NiTi superelastic archwireIn the lower arch during the first three months of the orthodonci treatment"
45618337|NCT02517749|Device|Chest Drain Insertion and Talc Pleurodesis|
45618338|NCT02517749|Device|Indwelling Pleural Catheter Insertion and Talc Pleurodesis|
45618339|NCT02914483|Behavioral|Enhanced Usual Care|"Participants randomized into the EUC group will complete 8 weekly individual sessions by phone. Each weekly session consists of: brief check-in and review of AHA brochure- Women, Heart Disease and Stroke."
45618340|NCT02914483|Behavioral|Stress Management|Participants randomized into the stress management group will complete 8 weekly group sessions by phone. The intervention is a telephone adaptation of mindfulness-based cognitive therapy (MBCT) and focuses on building cognitive-behavioral and mindfulness skills to help manage and cope with stress. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and home-based practice assignment.
45618341|NCT02914483|Diagnostic Test|Actigraph|The Actigraph (wGT3X-BT) will monitor sleep activity and will be worn by participants for 7 days, pre- and post stress based intervention.
45618342|NCT05196191|Biological|VIAGENEX Max|Collagenous membrane derived from umbilical cord
45618343|NCT05196191|Procedure|Hibiclens wash|Antiseptic skin cleanser
45618344|NCT03256123|Dietary Supplement|red palm shortening group|Biscuits made of red palm shortening will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. The biscuits for each subject will contain ~200 kcal with 10 g of red palm shortening/day (630 µg RE/day). This biscuit would be given four days a week on schooling days for a duration of 6 months. On average in a week, subject is expected to receive 630 µg RE of vitamin A/day. This would fulfill ~70% of the RNI of vitamin A for children aged 7-11 years old.
45618345|NCT03256123|Dietary Supplement|palm shortening group|Biscuits made of palm shortening (control group) will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. The palm shortening biscuits contain corresponding fatty acids as red palm shortening group.
45618346|NCT03350867|Other|Personalized Insole Group|Personalized Insole Group
45618347|NCT03350867|Other|Placebo Group|Placebo Group
45445766|NCT03771027|Other|The diet based on NICE guidelines.|The control group based on NICE guidelines received diet contained products with different FODMAP content. Children received 3 main meals and 2 snacks daily prepared by the catering company according to the Human Nutrition Recommendations for Polish Population. The dietary intervention lasted four weeks.
45618348|NCT03256357|Behavioral|Constraint-induced movement therapy|In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.
45445767|NCT02064322|Device|SImmetry Implant|"The SImmetry system is commercially available. The implanted devices consist of a range of thread-tapping cannulated implants designed to transfix the sacrum and ilim, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
45618349|NCT03256357|Behavioral|Action observation training|Action observation training consists of 15 sessions of 1 hour. Children watch 3 minute video clips of unimanual goal-directed actions followed by 3 minutes of execution of the actions.
45618350|NCT03256357|Behavioral|Placebo observation training|Placebo observation training consists of 15 sessions of 1 hour. Children perform the same actions as the AOT training after watching computer games without biological movements.
45618351|NCT03350789|Device|Real acupuncture|manual acupuncture(0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) (unilateral GB30) + electroacupuncture(0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) (unilateral EX-B2 (L4 & L5), BL25, BL23, BL40, GB34), twice a week, for 4 weeks, common approaches for the treatment of chronic sciatica used by doctors of Korean medicine in Korea today
45618352|NCT03350789|Device|Sham acupuncture|sham acupuncture without skin penetration(0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) (unilateral GB30) + placebo electroacupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) without electrical stimulation (unilateral EX-B2, BL25, BL23, BL40, GB34), twice a week, for 4 weeks
45618353|NCT03467113|Drug|ZX008 0.2 to 0.8 mg/kg/day|ZX008 drug is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free.
45618354|NCT03467113|Drug|Cannabidiol|Cannabidiol
45618355|NCT02517983|Other|epidemiology|Relative prevalence of different chronic respiratory disease phenotypes
45618356|NCT03438331|Behavioral|Cognitive Behavioural Therapy for Insomnia (CBT-I)|The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-I delivered within a 10-week window. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
45618357|NCT03438331|Behavioral|Cognitive Behavioural Therapy for Depression (CBT-D)|The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-D delivered within a 10-week window. The main treatment elements of CBT-D include: psycho-education about depression, self-monitoring, behavioural activation, improving social skills, communication skills and problem solving skills, cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
45618358|NCT05585489|Other|Gait training with musical cue|Entraînement de 20 minutes de marche à vitesse confortable sur un parcours ovale de 20 mètres au laboratoire ARM avec la technique d'indiçage musical personnalisé de la longueur de pas.
45618359|NCT03346967|Combination Product|adipose-derived mesenchymal stem cells|Collect adipose-derived mesenchymal stem cells from the patients. Adipose-derived mesenchymal stem cells will be isolated, expanded and characterized in vitro under the GMP- grade procedure
45618360|NCT03348293|Procedure|3D printing|Scope of tumor resection was simulated according to the MR imaging data. After meticulous design, we created the personalized porous biodegradable scaffold and printed by 3D printer, using porous PCL biomaterials. During operation, the biodegradable scaffold was implanted into the defective cavity after tumor resection.
45618361|NCT03036683|Device|Transcranial direct current stimulation|Transcranial direct current stimulation will be administered for 20 minutes using a CE approved stimulator (NeuroConn, Ilmenau, Germany).
45618362|NCT03036683|Device|Sham transcranial direct current stimulation|The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
45618363|NCT03348215|Other|Enhanced Treadmill Training|6 week programme of treadmill training with addition of an immersive environment (virtual reality projection), body weight support, orthotics and functional electrical stimulation
45618364|NCT02888249|Other|Altered composition cigarette|This double-blind study will systematically determine the abuse liability of altered composition cigarettes using a behavioral economics abuse-liability approach. Altered composition cigarettes (e.g., cigarettes differing in casings, sugars, tar levels, moisture) may result in decreased intake and decreased dependence, although critical questions remain regarding the abuse-liability of altered composition cigarettes, whether exposure to these cigarettes reduces use, and whether altered composition cigarettes will substitute for standard cigarettes. The addictive effects and abuse liability of altered composition cigarettes, therefore, are not well understood, and will be tested in this study.
45618365|NCT03348137|Other|Questionnaire Administration|Ancillary studies
45618366|NCT03434041|Drug|Esketamine 56 mg|Participants will self-administer 56 mg of esketamine as intranasal spray.
45445768|NCT03770793|Procedure|Lung-sono guided|"The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, alveolar recruitment is performed to the non-surgical side of lung under examination with ultrasound just after anesthesia induction.~During the gradual increment in the pressure of recruitment, the anesthesiologist can find the opening pressure that means the minimal pressure at which observed atelectasis starts to disappear.~Then, alveolar recruitment is performed with the opening pressure until the atelectasis is not visible."
45618367|NCT03434041|Drug|Esketamine 84 mg|Participants will self-administer 84 mg of esketamine as intranasal spray.
45618368|NCT03434041|Drug|Placebo|Participants will self-administer matching placebo as intranasal spray.
45618369|NCT03434041|Drug|Duloxetine (Oral Antidepressant)|Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The minimum therapeutic dose is 60 milligram per day (mg/day).
45618370|NCT03434041|Drug|Escitalopram (Oral Antidepressant)|Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. Escitalopram will be started at a dose of 10 mg/day and up-titrated to a maximum dose of 20 mg/day.
45618371|NCT03434041|Drug|Sertraline (Oral Antidepressant)|Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. Sertraline will be started at a dose of 50 mg/day and up-titrated to a maximum dose of 200 mg/day.
45618372|NCT03434041|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine XR can be selected as the oral antidepressant medication based on investigator's discretion. Venlafaxine XR will be started at a dose of 75 mg/day and up-titrated to a maximum dose of 225 mg/day.
45618373|NCT02680067|Drug|Indocyanine Green|A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
45618374|NCT02680067|Device|MultiSpectral Imaging System|Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
45618375|NCT05585411|Procedure|Left bundle branch area pacing|"LBBAP success is defined if ventricular lead is successfully placed at interventricular septum and RBB configuration observed during unipolar tip pacing.~LBB capture is defined if fulfilling criterion 1 and at least one in criteria 2.~RBBB configuration observed during unipolar tip pacing~One of the following should be met:~Abrupt shortening of Stim-LVAT (stimulus to peak of the R wave in V6 [LV activation time]) of >10ms during increasing output~Short and constant stim-LVAT and the shortest stim-LVAT <75ms in non-LBBB and <85ms in LBBB~Programmed stimulation by pacing lead changes QRS morphology from nonselective LBB to LV septal capture~LBB potential (LBB-V interval of 15 to 35ms)~Transition from nonselective LBB capture to selective LBB capture at near threshold outputs~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be deep septal pacing (DSP)."
45618376|NCT05585411|Procedure|Right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. Implantation of a RV pacing lead (apex or septum of right ventricle) will be attempted using the standard-of-care technique first
45618377|NCT03346811|Drug|Icotinib|Patients with plasma EGFR mutation-positive are arranged to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
45618378|NCT03250585|Diagnostic Test|Exhaled Breath Condensate (EBC)|Serial EBC samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up
45618379|NCT03250585|Diagnostic Test|Plasma Sample|Serial plasma samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up
45618380|NCT04503239|Device|G6|Wear 9 wear periods of the 10-day CGM
45618381|NCT03250741|Drug|Rotigotine transdermal patch|Rotigotine transdermal patches 4mg/24hr
45618382|NCT03250741|Other|Placebo|Placebo transdermal patches of the same size as for Rotigotine transdermal patches
45618383|NCT03255811|Drug|apatinib|Apatinib mesylate tablets treatment and to maintain the actual benefit in progression free survival.
45618384|NCT03255889|Drug|Glyceryl Tridecanoate|Glyceryl Tridecanoate (GT) is the triglyceride form of decanoic acid (DA), a C10 fatty acid. GT belongs to the class of medium chain triglycerides (MCT), which has been accepted as a Generally Recognized As Safe food product by FDA. Decanoic acid, also known as capric acid, occurs naturally in coconut oil (8 - 10%) and palm kernel oil (4%).
45618385|NCT03255889|Other|Placebo|Sunflower oil emulsion of equal calories.
45618386|NCT03250351|Other|Neurodynamic techniques|See arm/group descriptions
45618387|NCT03250351|Other|Early physical therapy plus educational strategy|See arm/group descriptions
45618388|NCT01842035|Drug|regadenoson|Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.
45618389|NCT03260101|Other|non intervational|Subjects who completed ApoGraft-01 study (through 180 days post-transplantation) and have signed informed consent for this follow-up study will be eligible to enroll. Subject will attend 4 in-clinic visits, once every 6 months up to 2 years post transplantation, and will undergo the following evaluations: acute and chronic graft versus host disease (GvHD) assessments, survival status (overall, relapse-free), disease status (disease relapse/recurrence)
45618390|NCT03249805|Device|Steenbeek Foot Abduction Brace (SFAB)|The FAB will be equipped with discretely hidden sensors; subjects and their families will not be aware of the actual function of the sensor in order to avoid increased compliance due to the sensor. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
45618391|NCT03249805|Device|MiracleFeet Foot Abduction Brace (mFAB)|Sensors in the mFAB will measure whether the shoe is on, the foot is in contact with the sole of the shoe and the shoes are clipped into the bar. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
45618392|NCT03122249|Behavioral|Advanced Cancer Symptom Management|For a period of eight weeks patients will use the OASIS web-application daily to help them get better control of their cancer symptoms. In addition, to daily symptom and strategy tracking, participants will have eight e-visits with the nurse-coach via the Zoom application through the UIHC eHealth and eNovation Center to evaluate their progress with managing their symptoms, assess for barriers to implementing strategies, and offering coaching on how to improve symptom management. Questionnaires and blood samples will be collected at baseline (week 0) and follow-up (weeks 4, 8, and 12).
45618393|NCT03348059|Drug|Direct-acting antiviral therapy|HCV patients received direct-acting antiviral treatment for 12 or 24 weeks
45618394|NCT03255421|Other|Pressure measurement|Observational study No intervention, only fragmenting the emptying of the bladder
45618395|NCT03122327|Other|Questionaires|Questionaires of cGA assessment. No other interventions would be carried out aside from the standard treatment for MM.
45618396|NCT03255343|Device|IMDENDRIM|In situ and intra tumoral injection of non removal nanodevice IMDENDRIM
45760735|NCT02591056|Device|Green PRESS 8|There are 12 procedure administrations with the Green PRESS 8 across 6 weeks: 2 procedures per week. For each procedure administration, the Green PRESS 8 is applied to the midsection for 30 minutes. All subjects receive the active Green PRESS 8 treatment for all 12 procedure administrations. Each Green PRESS 8 procedure administration occurs right after each procedure administration with the Erchonia Verju Laser.
45760736|NCT03007095|Behavioral|Evaluation of the children's social cognitive development|standardized neuropsychological tests
45760737|NCT02997033|Other|No intervention|No intervention
45760738|NCT02953587|Procedure|Oral Glucose Tolerance Test (OGTT)|Subjects will have glucose administered enterally and blood will be drawn to measure its kinetics.
45760739|NCT02953587|Drug|Human Ghrelin|Human ghrelin will be administered by IV at two of the four study visits in conjunction with the OGTT.
45760740|NCT02953587|Drug|Saline|Saline Infusion will be administered by IV at two of the four study visits in conjunction with the OGTT to serve as a placebo comparator for the human ghrelin infusions.
45760741|NCT00814697|Device|Repetitive Transcranial Magnetic Coil Stimulation (rTMS)|The first six patients were administered rTMS at 10Hz in 20 trains of 5 seconds with 20 second intervals between trains in each hemisphere. The total number of pulses for each session was set at 1000 pulses. The second six enrolled patients were administered rTMS at 15 Hz in 20 trains of 5 seconds with 25 second intervals between trains in each hemisphere.
45760742|NCT00814775|Device|Fastrach Laryngeal Mask|Intubation of difficult airway using Fastrach Laryngeal Mask
45760743|NCT00814775|Device|CTrach Laryngeal Mask|CTrach Laryngeal Mask intubation
45760744|NCT02593396|Drug|Bupropion hydrochloride sustained-release|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)The study drug will be repacked in the standard capsules by the research assistant who is not involved in the assessment of the study. The study drug and placebo will be packaged in sets of 11 (1 tablet per day for 3 days, followed by 2 tablets per day for 4 days.) for the first week. Subsequently, the study drug and placebo will be packaged in sets of 14 (2 tablets per day for 7 days.).
45760745|NCT02593396|Drug|placebo|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)
45760746|NCT02593630|Device|Unicirc circumcision|Unicirc circumcision under topical (EMLA) anaesthesia, wound sealing with cyanoacrylate tissue adhesive
45760747|NCT00848783|Drug|Irinotecan|
45445769|NCT02064400|Other|Musculoskeletal Ultrasound|7-joint musculoskeletal ultrasound scan
45760748|NCT00848783|Drug|Cisplatin|
45911633|NCT05777837|Procedure|Combined hysteroscopic and laparoscopic repair of cesarean scar niche|Hysteroscopic resection of the niche under laparoscopic guide will be done to avoid perforation of the niche. After completion of the hysteroscopic approach, laparoscopic plication of the niche without opening it will be done using multiple interrupted 2-0 absorbable suture.
45445770|NCT02064400|Other|Semi-structured patient interview|Semi-structured patient interview
45445771|NCT03766503|Other|Daily|The main study intervention is the daily witnessing of participants while they self-administer their medications by trained pharmacy staff to ensure compliance. The staff in question will be provided by Leila pharmacy and will in addition provide support so that individuals can transition back into living independently through reminders to attend regularly scheduled medical appointments and counseling on correct use of prescribed medications.
45618397|NCT03249961|Device|Sham TDCS|Placebo stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.
45618398|NCT03249961|Device|Anodal TDCS|Excitatory stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.
45760749|NCT00848783|Procedure|Surgery|
45760750|NCT00848783|Drug|Floxuridine|
45760751|NCT00848783|Drug|Capecitabine|
45804069|NCT05718661|Behavioral|Watching video with virtual glasses|Using Mobile Virtual Glasses; In the preoperative period, after the patient is taken to the surgical service, a virtual reality video will be watched with mobile virtual glasses at the specified time (before going to the operating room on the day of surgery). Measurements will be made before and after the application. Necessary hygiene will be provided before the use of glasses, and the researcher will ensure hand cleaning before entering the patient's room.
45618399|NCT03249961|Device|Transcranial Magnetic Stimulation (TMS)|Participants will receive Transcranial Magnetic Stimulation (TMS) to allow research investigators to determine the location of the left motor cortex.
45760752|NCT05372536|Other|parent-led home-administered low-dose Cytarabine|Parents to the included participants are offered to administer the protocolized low-dose bolus (injection) Cytarabine in their children's CVCs at home. The administration procedure is developed as a simple and safe non-touch technique. The parents receive a video and paper-based guideline and information material followed by a 3-step nurse-led education program. The parents can administer the Cytarabine at home when they (and the child/adolescent) feel safe and comfortable managing the procedure and when the nurses are sure that the parents can manage the procedure at home. The first dose of Cytarabine is always administered at the hospital.
45760753|NCT05371990|Other|Determination of Eating habits|Questionnaire
45760754|NCT00849251|Drug|cyclophosphamide|Given IV or PO
45760755|NCT00849251|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
45618400|NCT05585255|Diagnostic Test|enzyme-linked immunosorbent assay(ELISA)|After allowing to stand at room temperature for 2h, blood samples are centrifuged at 4 ℃ for 15 min (12000 rpm) to collect the supernatant. Then, the levels of DKK2, IL-6, IL-1β, TNF-α, and IL-10 in the supernatants are tested by ELISA detection.
45618401|NCT02455999|Drug|SYL1001|SYL1001 eye drops dose C administration for 10 consecutive days
45618402|NCT02455999|Drug|SYL1001|SYL1001 eye drops dose D administration for 10 consecutive days
45618403|NCT02455999|Drug|Placebo|Placebo eye drops administration for 10 consecutive days
45760756|NCT00849251|Drug|bortezomib|Given IV
45760757|NCT00849251|Drug|dexamethasone|Given IV or PO
45618404|NCT04488445|Behavioral|Strength training|3 sets of 3 to 5 repetitions with 4 minutes of rest between sets. 90% load of 1 maximum repetition of a resistance exercise
45618405|NCT04488445|Behavioral|Stretch and balance training|3 sets of 3 exercises of stretching and balance of one minute each. One minute of resting time between sets.
45445772|NCT01567683|Drug|Imiquimod (topical use)|
45445773|NCT03766425|Drug|Aflibercept|subconjunctival injection
45445774|NCT03766425|Drug|Mitomycin|subconjunctival injection
45618406|NCT04502459|Procedure|Tourniquet|A tourniquet is often used in total knee arthroplasty to achieve better visualization, reduce intra-operative bleeding and facilitate cement interdigitation
45760758|NCT05371912|Device|Trans Cranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neurostimulation technique that alters cortical excitability by repeated induction of electromagnetic activity. FDA approved for depression, rTMS is a promising tool in the field of neuropsychiatry with an excellent safety profile.
45760759|NCT00364468|Drug|pegfilgrastim|
45760760|NCT00850031|Device|AcuFocus Corneal Inlay|Inlay implanted in cornea for improvement of near vision
45760761|NCT05371678|Other|Therapeutic motor control interventions|Treatment duration will be 8 weeks, two sessions a week. Each session will take approximately 60 minutes. This intervention includes education, dietary advices, core stabilization exercises and pelvic floor muscle training with surface Electromyographic-Biofeedback. In the education will be taught to the child and their parents in the first session. Dietary advices will be given by specialist dietitian. Core stabilization exercises will be performed 2 days a week with a physiotherapist and the session will be approximately 50 minutes. Diaphragmatic breathing will be taught to children in breathing exercises. The pelvic floor muscles exercises will be do by surface Electromyographic-Biofeedback. The Electromyographic-Biofeedback teaches the child how to relax the external anal sphincters with visual and auditory feedback techniques.The child will learn to relax the pelvic floor muscles during defecation by monitoring the recorded electromyographic activity.
45445775|NCT03913065|Diagnostic Test|CT|"Head computed tomography on patients still unconscious 48 hours after cardiac arrest.Visual evaluation of generalized oedema (eye-balling). Manual and automated measurement of the differentiation of gray and white matter (GWR) using circular regions of interest (ROI)."
45452288|NCT00035555|Drug|Corticosteroids|Corticosteroids given daily, orally or intravenously (IV). Day of transplant (Day 1): methylprednisolone, 500 mg, given IV on arrival in operating room; Day 2: methylprednisolone, 250 mg, given IV once daily; Day 3: prednisone, 100 mg, given orally once daily; Day 4: prednisone, 50 mg, given orally once daily; Days 5 through 30: prednisone, 25 mg, given orally once daily; Days 31-44: prednisone, 22.5 mg, given orally once daily; Days 45-58: prednisone, 20 mg, given orally once daily
45618407|NCT03259711|Drug|Hormonal therapies L02 in the ATC classification|Hormonal therapies L02 in the ATC classification
45618408|NCT05585177|Drug|Growth hormone|3 months of growth hormone treatment (2 units daily)
45618409|NCT03249883|Device|SACH prosthetic foot, 1M10 prosthetic foot|"In the SACH first group - the amputees will wear the SACH feet for three weeks and then switch to 1M10 feet for another three weeks.~In the 1M10 first group - the amputees will wear the 1M10 feet for three weeks and then switch to SACH feet for another three weeks."
45760762|NCT05371678|Other|Conventional treatment|Treatment duration will be 8 weeks. This intervention includes education, dietary advices and laxative therapy. In the education will be taught to the child and their parents in the first session. Dietary advices will be given by specialist dietitian. Laxative therapy will be adjusted at different doses according to the child's age and weight. Laxative therapy will be administered to children by a specialist doctor.
45760763|NCT05371522|Radiation|[18F]DPA-714 positron emission tomography (PET) scan|60 minute dynamic brain [18F]DPA-714 positron emission tomography (PET) scan followed by a 30 minute static whole body positron emission tomography (PET) scan
45760764|NCT02153099|Drug|TAK-058 (ENV8058)|TAK-058 (ENV8058) oral solution
45760765|NCT02153099|Drug|Placebo|TAK-058 (ENV8058) placebo-matching oral solution
45618410|NCT04501835|Other|Diagnostic and treatment evaluation|No intervention, description of the diagnostic evaluation and the treatment
45760766|NCT00850889|Device|Hyaluronic acid gel (24 mg/mL) with 0.3% lidocaine|Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
45760767|NCT00850889|Device|A gel of hyaluronic acid (concentration of 20 mg/mL)|Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
45760768|NCT05254288|Other|Chlorhexidine|In-office and domiciliary use of chlorhexidine for 14 days.
46069136|NCT04113161|Other|Child Behavioral Health Navigator (cbhN)|CbhNs will engage in a series of contacts in person and by phone/text to coordinate needed appointments at mental health care sites, as well as a range of human service support organizations (e.g. housing, food, financial, legal assistance). Over time, contact may decrease as the youth/family make ongoing connection with mental health care and other resources. However, over the course of the study (twelve months), twice per month check-ins will be routine between cbhNs and families. In addition, the cbhN will be expected to actively engage with the range of service providers and mental health resources as needed and preferred by the family. These contacts include telephone linkage calls, in-person advocacy meetings and at time, accompanying the youth and families to meetings at each organization.
46069137|NCT04106232|Other|No change in procedure except for specimen collection throughout procedure|Stool specimens will be taken before and during the HyGIeaCare procedure. Microbiome comparisons will be made across all specimens
45618411|NCT03250039|Drug|PF-04965842|14C labeled PF-04965842
45618412|NCT03250039|Drug|Absolute Bioavailability|Oral dose of unlabeled PF-04965842 and an IV dose of 14C labeled PF- 04965842
45618413|NCT03259477|Procedure|precise segmental renal arterial clamping|Precise segmental renal artery clamping eliminates global renal ischemia by performing highly selective clamping of single or multiple segmental arteries.
45452289|NCT01087463|Device|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
45618414|NCT03259477|Procedure|laparoscopic partial nephrectomy|Laparoscopic partial nephrectomy (LPN) has been widely adopted as a minimally invasive nephron-sparing surgery for clinical T1 renal cell carcinoma(RCC).
45618415|NCT03122015|Other|Therapeutic clown distraction|The presence of the therapeutic clown, which can adapt his interventions of distraction to the state of health of the patient and the culture of the child, is a multimodal and multi sensorial distraction intervention and can have an impact on health status, procedures, family and multidisciplinary team members. The results of five studies evaluated the effects of distraction by the clown therapy demonstrate a decrease in pain and anxiety in children aged 2 to 17 years, as well as parental anxiety in painful procedures involving needles such as venipuncture.
45618416|NCT03249649|Behavioral|Comprehensive Healthcare Needs Assessment|Questionnaire focused on existing healthcare communication, treatment and services plus community needs in those three areas.
45618417|NCT02517827|Device|Atherectomy and paclitaxel-coated balloon angioplasty|Directional atherectomy and paclitaxel-coated balloon angioplasty (optional with stentimplantation) of the common femoral artery
45618418|NCT02517827|Procedure|Open, surgical endarterectomy|open, surgical endarterectomy of the common femoral artery
45618419|NCT02456311|Device|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in open lobectomy in humans
46069138|NCT04101357|Drug|BNT411|intravenous
45618420|NCT05584865|Other|Digital occluar prosthesis|Each patient will receive the full digital fabricated ocular prosthesis. DICOM data from the Computerized Tomography (CT) will be imported into Materializes Interactive Medical Image Control System (MIMICS) software++++ tool for visualizing and segmenting medical images (such as CT and MRI)
45618421|NCT05584865|Other|Conventional occluar prosthesis|An accurate impression of the patient's eye socket will be obtained to prepare a suitable wax mod. The wax model will be flasked and processed into heat cured acrylic resin of the same colour of the sclera of the other healthy eye of the patient
45618422|NCT03255499|Behavioral|Exercise|Exercise
45618423|NCT03255499|Behavioral|Cognitive|Cognitive
45618424|NCT03255499|Behavioral|Active control|Active control, including a blend of computer games, board games, quizzes, trivia
45618425|NCT05082779|Drug|CS0159|Tablets administered orally
45618426|NCT03255265|Other|no interventions|no interventions
45618427|NCT03347981|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
45618428|NCT03347981|Device|IOL implantation active comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
45618429|NCT02880319|Drug|Stereotactic Body Radiation Therapy (SBRT)|
45618430|NCT02880319|Device|Stereotactic Linear Accelerator|
45618431|NCT05045183|Device|SoC Adhesive Bandage|On the randomized wound site, a SoC adhesive bandage will be applied.
45618432|NCT05045183|Drug|Antibiotic Ointment|On the randomized wound site, a antibiotic ointment will be applied.
45618433|NCT05045183|Drug|Antiseptic Wash|On the randomized wound site, a antiseptic wash will be applied.
45618434|NCT05045183|Device|Hydrocolloid Pad|On the randomized wound site, hydrocolloid pad will be applied.
45618435|NCT04487977|Other|Survey|Answering a survey on airway management in COVID-19 patients
45760769|NCT05254288|Other|Ozoral gels|In-office administration of Ozoral Pro and domiciliary use of Ozoral gel for 14 days.
45760770|NCT04742998|Other|Acoustic-phonetic decoding task (DAP)|Completion of speech-related quality of life autoquestionnaires Routine speech assessment Acoustic-phonetic decoding task (DAP) two lists of 16 pseudo-words
45760771|NCT00851279|Device|Magnetic irrigated ablation catheter|Magnetic irrigated catheter to be used with the magnetic navigation system
45760772|NCT04742764|Combination Product|Standard medical therapy|Standard medical therapy (according to the Surviving Sepsis Campaign) will include standard monitoring (pulseoximetry, 5-lead ECG, continuous invasive blood pressure monitoring, central venous cannulation and 24 with PiCCO-technology. Norepinephrine as a vasopressor and dobutamine - if needed - as an inotrope will be administered by the attending physician.
45911634|NCT05777824|Combination Product|anti-PD-1 or PD-L1 antibody|immunotherapy maintenance with anti-PD-1 or PD-L1 antibody every three weeks for 13 cycles after radiotherapy
46069139|NCT04101357|Drug|Atezolizumab|intravenous
46069140|NCT04101357|Drug|Carboplatin|intravenous
46069141|NCT04101357|Drug|Etoposide|intravenous
45618436|NCT02517671|Device|Enhanced External Counterpulsation (EECP)|EECP is a non-invasive therapy that has been approved by the United States Food and Drug Administration (FDA) for the management of refractory angina and heart failure. This study is using the device to potentially improve 1.5 mile run times and VO2max in healthy volunteers.
45618437|NCT03246451|Drug|Placebo Oral Tablet|2-4 tablets in 14 days
45618438|NCT03246451|Drug|Metformin|1000-2000 mg in 14 days
45618439|NCT03246451|Drug|Saline|9 mg/ml saline infusion during experimental days
45618440|NCT03246451|Drug|Exendin (9-39)|Infusion of GLP-1 receptor antagonist used as a tool during experimental days
45760773|NCT04742764|Device|Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 12 hours|Standard medical therapy, as discussed above will be applied. Furthermore, Cytosorb will be administered as soon as it is possible after randomization but not later than 2 hour (start of the treatment, T0). In a blood pump circuit in pre-haemofilter position, using a kidney replacement device of Fresenius Multifiltrate as a solo therapy or in combination with renal replacement therapy. It will be run in CVVHD, CVVHDF or CVVH mode with a 150 and 200 ml/min blood flow. Anticoagulation will be applied intravenously with heparin, low molecular weight heparin or citrate. The aim of the pump flow rate will be 100-400 mL/min, and the flow rate will be recorded. Possible shock reversal will be assessed by the physician attending. Adsorber cartridges will be changed in every 12 hours. End of the study period (Te): 12 hours after shock reversal, death of the patient, or maximum of five days, whichever happens first.
45760774|NCT04742764|Device|Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 24 hours|The standard medical therapy and method of Cytosorb treatment as detailed above will be applied. Adsorber cartridges will be changed in every 24 hours.
45760775|NCT00851357|Drug|Nicotine Patch|Subjects are randomized into 1 of 3 conditions: active, placebo or usual care. Usual care subjects are not mailed patches; however, we facilitate their use by providing a certificate that can be used by the State Medicaid program and some insurance companies to obtain free patches. For those mailed patches directly, we will mail 8 weeks of patches. Dosage depends on the number of cigarettes per day (cpd). Light smokers (6-10 cpd) will receive 6 weeks of 14 mg and 2 weeks of 7 mg patches. Heavy smokers (11+ cpd) will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg patches. Placebo patches will have no nicotine, but will be packaged to mimic the active patches.
45618441|NCT02517593|Genetic|Polygenic Risk Score|A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 77 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (>40%).
45760776|NCT00851357|Behavioral|Telephone Counseling|"Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Telephone counseling includes a comprehensive pre-quit session (to include motivation, planning, and setting of a quit date and discussion of nicotine patch use) plus up to 5 proactive follow-up calls. Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling."
45760777|NCT00851357|Drug|Placebo|Placebo nicotine patch
45618442|NCT00708461|Behavioral|weight gain prevention|"Changes in the food environment that increase the availability of healthy foods and beverages, reduce food and beverage portion sizes, reduce prices on healthy food items, and increase prices on less healthy food items.~Changes in the activity environment that increase cues and incentives for walking at work and at home, using stairs, and to increase exposure of employees to information about active recreational opportunities at work and at home.~Changes to the environment to increase cues and incentives for regular weight monitoring by providing scales at convenient locations.~Changes in the informational environment that increase frequency of exposure of the employee population to accurate information about healthy food and activity choices."
45618443|NCT03246607|Device|MicroEye & ContinuMon|Continuous intravascular glucose monitoring using MicroEye/ContinuMon system, peripherally inserted via a peripheral venous catheter.
45618444|NCT03249571|Dietary Supplement|Flavonoid supplement|2-weeks ingestion of flavonoid supplement
45618445|NCT03249571|Dietary Supplement|Placebo|2-week ingestion of placebo supplement
45618446|NCT05013437|Drug|Evomela|16 mg/m^2 Evomela administered one time via a central line
45618447|NCT05013437|Device|Next Generation Sequencing|Next Generation Sequencing
45618448|NCT05013437|Drug|Prochlorperazine|10mg once intravenous (IV) within 30 minutes before Evomela
45618449|NCT05013437|Drug|Acetaminophen|650 mg once orally within 30 minutes before Evomela
45618450|NCT05013437|Drug|Diphenhydramine|50 mg once intravenously within 30 minutes before Evomela
45445776|NCT01561911|Drug|Chi Lob 7/4 (A chimeric monoclonal antibody)|3 patients will receive treatment at each dose level. Escalation from one treatment dose level to another will only be permitted once at least 3 patients have completed treatment without any DLTs. Starting weekly dose of Chi Lob 7/4 will be 0.5mg (giving a total dose per patient of 2mg divided over 4 weeks). Subsequent individual, weekly dose levels of 1.6mg, 5mg, 16mg, 50mg and 160mg (resulting in total patient doses of 6.4mg, 20mg, 64mg 200mg and 640mg respectively). Further dose escalation can continue to 240mg and 320mg dose per week (resulting in 960mg and 1280mg. Patients may be treated at a lower or intermediate dose level to define the MTD/BAD.
45618451|NCT03246295|Other|lifestyle intervention or insulin treatment|Firstly，the gestational diabetes mellitus（GDM） women were treated with lifestyle intervention.Those women were treated with insulin if their blood glucose was not well Controled.
45618452|NCT03347825|Procedure|Robotic-assisted lobectomy using da Vinci Surgical System|Robotic-assisted lobectomy
45618453|NCT03347825|Procedure|VATS (video assisted thoracic surgery)|VATS (video assisted thoracic surgery)
45618454|NCT03347825|Procedure|Open lobectomy|Open lobectomy
45618455|NCT02455765|Other|Rice and Amino Acid mixtures|Rice and amino acid mixture
45618456|NCT03346733|Dietary Supplement|Psyllium Fibre|Viscous soluble psyllium fibre
45760778|NCT00851357|Other|Self-Help Materials|"Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Reading materials and written consent will be mailed to all study subjects the next business day."
45618457|NCT03254875|Behavioral|Individually tailored nurse navigation|The intervention consists of systematic report of symptoms to the nurse and up to six individual, manual-based, face-to-face or telephone nurse navigator sessions depending on individual needs.
45760779|NCT05105074|Drug|Intrathecal Morphine|Group 1 - Patients will receive intrathecal morphine 100 mcg in addition to the standard dose of bupivacaine and 15 mcg of fentanyl for spinal anesthesia.
45760780|NCT05105074|Drug|Placebo|Group 2 - Patients will not receive intrathecal morphine. Patients will receive only bupivacaine and 15 mcg of fentanyl for spinal anesthesia.
45760781|NCT00815087|Device|Functional electrical stimulation|15 sessions of VitalStim® therapy, 60 minutes per session
45760782|NCT00815087|Behavioral|Exercise home program|Daily exercise training
45760783|NCT04978324|Biological|leukocyte platelet rich fibrin (L-PRF)|Participants blood will be spun to obtain L-PRF strips and liquid L-PRF. Pockets will receive insertion of small L-PRF strips followed by liquid L-PRF injections to fill the 5-8mm pockets of the test side.
45618458|NCT05584787|Procedure|Soractelite Echolaser Transperineal focal laser ablation|US/MRI fusion laser ablation of low- and intermediate risk prostate cancer
45760784|NCT04978324|Procedure|Scaling and Root Planing|Scaling and root planing, which is the standard of care, will be performed on the control side using Cavitron and hand scalers on test and control sides under local anesthesia.
45760785|NCT04946968|Drug|Oral Dacomitinib|All subjects will receive the open-label Dacomitinib as tablets for oral self-administration on a continuous daily basis at a dose of 30 mg for one cycle. For subjects eligible for dose titration after Cycle 1, and after shared patient and investigator decision, these subjects will receive Dacomitinib 45 mg orally on a continuous daily basis.
45760786|NCT02856269|Dietary Supplement|Zinc gluconate|Participants will take a daily dose of zinc gluconate.
45760787|NCT03663023|Procedure|Intestinal obstruction|
45760788|NCT03643991|Other|Weighted Blanket|Weighted blanket will be given to patients based on the patient weight (10% of patients body weight) for three nights while on inpatient unit.
45618459|NCT03249337|Drug|Ripasudil hydrochloride hydrate 0.4% ophthalmic solution|"the ophthalmic solution will be administered three or six per times per day in the eye designated as the Study Eye upon study enrollment"
45618460|NCT03346265|Other|Treatment A combined exercise program and gait training with sensory cues|Treatment A consisted in a combined exercise program of 40 min duration RMP
45618461|NCT03346265|Other|Treatment B Conventional physiotherapy|Conventional physiotherapy was composed of 4 sections of exercises, chiefly oriented to different body structures appropriate to movement (International Classification of Functioning, Disability and Health code)
45760789|NCT04839250|Procedure|heads-up method|3D surgical video system, which includes Alcon NGENUITY 3D visualization system (Alcon, Fort Worth, TX) and Leica M822 and M844 microscopes (Leica Microsystems, Wetzlar, Germany),can be used to perform head-up phacoemulsification combined with intraocular lens implantation surgery.
45445777|NCT03770481|Behavioral|nurse-led communication strategy|Nurse-led communication strategy (NLCS) applies 'COMFORT' framework that research nurses use the framework to engage one communication session per day with surrogates and two discussions with bedside nurses or attending physician during the ICU stay.
45618462|NCT04487821|Other|Cawthorne Cooksey Exercises|"Activity sitting on the Exercise Ball swing (eye movements, first slow and then fast)~Swing sitting activity (head movements, first slow then fast - eyes open and eyes closed)~Trunk activities focusing on balance~Dynamic balance activity focusing on standing"
45618463|NCT03346187|Drug|Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate)|Lipitor(Atorvastatin Calcium Trihydrate 20mg/tablet) + Lipidil supra(Fenofibrate 160mg/tablet)
45760790|NCT04382573|Genetic|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
45760791|NCT00364702|Drug|methylphenidate|
45760792|NCT00852137|Drug|PEP005 (ingenol mebutate) Gel, 0.05%|PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
45445778|NCT03760341|Procedure|adenoidectomy - cold method|a surgery for adenoid removal or reduction under general anesthesia using surgical curretes
45445779|NCT03760341|Procedure|adenoidectomy - hot method|a surgery for adenoid removal or reduction under general anesthesia using suction diathermy
45618464|NCT03346187|Drug|Test drug(CKD-337)|CKD-337(Atorvastatin calcium trihydrate 20mg+choline fenofibrate 178.8mg/capsule)
45760793|NCT00852137|Drug|Vehicle Gel|Vehicle Gel once daily for 2 consecutive days
45760794|NCT04765306|Device|Traditional Direct Fascial Closure|Fascial closure using traditional surgical instruments and suture without laparoscopic guidance.
45760795|NCT04765306|Device|Fascial Closure Device|Fascial closure using a fascial closure device under direct laparoscopic guidance.
45760796|NCT04702672|Dietary Supplement|100% wheat (control)|Intake of 250 ml of tap water and 100 g of bread baked with 100% wheat flour (regular commercial available wheat flour). Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.
45911635|NCT05777824|Radiation|postoperative radiaotherapy|postoperative radiotherapy (60Gy or 50Gy)
45911636|NCT05777785|Device|VIZO Glasses|Eyeglasses with personalized peripheral retinal stimuli
45445780|NCT03310983|Dietary Supplement|Docosahexaenoic acid|The main study, ADORE, includes providing DHA to participants during pregnancy. No intervention is included as part of this study.
45618465|NCT04487743|Drug|Liraglutide|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
45618466|NCT04487743|Drug|placebo|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
45618467|NCT05010629|Drug|9-ING-41|Intravenous infusion
45760797|NCT04702672|Dietary Supplement|50% HIAMBA®|"Intake of 250 ml of tap water and 100 g of bread baked with 50% HIAMBA® flour and 50% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~HIAMBA® are naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flou"
45618468|NCT05010629|Drug|Carboplatin|Intravenous infusion
45618469|NCT03246217|Behavioral|Therapeutic Instrumental Music Performance|Participants will play a variety of instruments (acoustic and electronic) to facilitate retraining of everyday functional movements.
45618470|NCT03246217|Behavioral|Therapeutic Performance with Sensory-Enhanced Motor Imagery|Participants will listen to a metronome set to their preferred pace for previously practised movements while engaging in motor imagery.
45618471|NCT03246217|Behavioral|Therapeutic Performance with Motor Imagery|Participants will engage in motor imagery of previously practised movements.
45618472|NCT05584631|Drug|Intravenous immune globulin G|Intravenous immune globulin G dosed based on the subjects's current dose received for the treatment of CIDP.
45618473|NCT05584631|Drug|Subcutaneous immune globulin G|Subcutaneous immune globulin G converted from the subject's current IVIG dose 1:1.
45618474|NCT03249259|Drug|Choline alfoscerate|Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
45618475|NCT03249259|Drug|Placebo|Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
45618476|NCT04503005|Other|Time Restricted Eating|Effect of 16, 14 or 12 hours of daily fasting
45760798|NCT04702672|Dietary Supplement|75% HIAMBA®|"Intake of 250 ml of tap water and 100 g of bread baked with 75% HIAMBA® flour and 25% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~HIAMBA® are naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour."
45760799|NCT04702672|Dietary Supplement|50% nude barley|"Intake of 250 ml of tap water and 100 g of bread baked with 50% nude barley flour and 50% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~Ancient nude barley naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour."
45618477|NCT04487587|Drug|Cediranib, Olaparib|Cediranib film coated tablet, Olaparib film coated tablet
45618478|NCT05584397|Procedure|Venipuncture|Draw of peripheral blood (about 20 ml and 40 ml, during the screening and procedure visits, respectively).
45760800|NCT04652362|Behavioral|Growth Mindset Online Single-Session Intervention|During the self-administered single session intervention participants are provided with basic information about the brain and are introduced to the concept of neuroplasticity. The concept of neuroplasticity is applied to personal traits, such as shyness, anxiety and sadness, and young people are taught that these traits are the result of thoughts and feelings in our brain and are amenable to change. Participants are presented with scientific information and research evidence to support the idea that people have the potential to change and are given vignettes from older children detailing how they have used a growth mindset to overcome difficulties. The intervention takes approximately 20-30 minutes to complete.
45760801|NCT04652362|Behavioral|Supportive Therapy Online Single-Session Intervention (Control)|The single session supportive therapy intervention was designed to be structurally comparable to the growth mindset intervention, including the same number of reading and writing activities. Participants were provided with information about emotions and the benefits of expressing emotions. Vignettes from older children described times they had shared their emotions with friends and family members.
45760802|NCT04742530|Behavioral|Fasted Evening Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 18:30, after a 7-hour period of fasting. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
45911637|NCT05777772|Behavioral|STOP Falls D Educational Intervention|This is one-arm, health-system embedded pragmatic pilot trial
45618479|NCT05584397|Procedure|Targeted physical medical exam|"Study participants will be undergoing a physical exam where vitals will be recorded (e.g. temperature, blood pressure, heart rate). The registered nurse (RN) will also perform auscultation of heart and lungs.~Study participants will be also asked to fill out a survey with questions related to his/her medical history, current use of medications, sexual history and substance abuse."
45618480|NCT05584397|Procedure|Urine pregnancy test|Women of childbearing potential will be asked to run an urine pregnancy test during the second (procedure) visit. Pregnant women will not be allowed to participate in the study.
45618481|NCT05584397|Procedure|Anoscopy|The anoscopy is an examination using a small, rigid, tubular instrument called anoscope (also called an anal speculum). This is inserted a few inches into the rectum in order to collect some small samples of mucosal tissue. We will collect 5 rectum biopsy samples and one cytobrush.
45618482|NCT05584397|Procedure|Esophagogastroduodenoscopy (EGD)|The EGD involves looking at the esophagus, stomach, and first and second portion of the duodenum. This procedure involves the use of an endoscope to remove small tissue samples. This procedure uses conscious sedation drugs given by a vein in the arm. The procedure takes about 1½-2 hours, including time for recovery. We will collect 5 duodenal biopsies and one cytobrush.
45618483|NCT03254797|Other|Stepping training with feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells, look at the displayed section which will be positioned at their eye level. Then subjects will be instructed to shift/take their body-weight onto the trained leg until the green zone of the displayed section is lightened. When the subjects can take a proper level of their body-weight onto the trained leg, the beep sound will be alarmed to trigger the subjects and therapist that the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
45445781|NCT03770637|Drug|Glucagon RTU|Glucagon RTU is a sterile subcutaneous injectable non-aqueous solution formulation supplied in a vial and administered via syringe.
45618484|NCT03254797|Other|Stepping training without feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells. Then subjects will be instructed to shift/take their body-weight onto the trained leg as most as they can. If the subjects can take a proper level of their body-weight onto the trained leg, the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
45618485|NCT04833413|Drug|Continuous intensive insulin therapy|After initial intensive insulin therapy in hospital, patients were grouped according to different treatment regimens within 6 months of discharge
45618486|NCT02454751|Drug|fentanyl|One time dose of 50mcg of fentanyl administered intranasally
45618487|NCT02455921|Drug|neostigmine - atropine|Efficacy, safety and effect on cognitive and behavioural function
45618488|NCT02455921|Drug|Sugammadex|Efficacy, safety and effect on cognitive and behavioural function
45618489|NCT03347747|Other|Study Photography + Personal & Medical History Collection|3D facial images taken and complete a detailed study questionnaire
45618490|NCT04786613|Other|Intra-articular 20 mg, 1.0% Hyaluronic Acid Injection|"Intra-articular 2 ml linearly linked 20 mg 1.0% hyaluronic acid injection in 5 sessions will be applied.~As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions."
45618491|NCT04786613|Other|Intra-articular 32 mg, 1.6% Hyaluronic Acid Injection|"Intra-articular 2 ml linearly linked 32 mg 1.6% hyaluronic acid injection in 3 sessions will be applied.~As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions."
45618492|NCT04786613|Other|Intra-articular 48 mg, 2.0% Hyaluronic Acid Injection|"Intra-articular 2,4 ml linearly linked 48 mg 2.0% hyaluronic acid injection in single session will be applied.~As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions."
45618493|NCT04767191|Drug|artemether lumefantrine|The drugs are approved and in use by the Kenya Ministry of Health as the 1st and 2nd line treatment for malaria. The study is to assess the continued efficacy of the two drugs in the treatment of uncomplicated malaria.
45618494|NCT04767191|Drug|dihydroartemisinin piperaquine|Antimalarial Combinations
45618495|NCT03254953|Behavioral|self-monitoring of body weight|- weigh daily for 3 months and track their weight using the MyFitnessPal mobile app
45618496|NCT03254953|Behavioral|self-monitoring of diet|"track their diet (food and drinks) daily using the MyFitnessPal mobile app~when they are asked to track diet will vary based on the arm"
45618497|NCT03254953|Behavioral|weekly personalized feedback + lessons + action plans|- these are additional evidence-based intervention components
45618498|NCT04502069|Drug|Opaganib|500 mg Q12 hours orally
45618499|NCT03246139|Behavioral|Action observation, imagery & execution|The participants will be asked to observe movements through a video clip, practice motor imagery, and executing the movements that the participants observed.
45618500|NCT03246139|Behavioral|Action observation|The participants will be asked to observe videos and then practice what the participants observed.
45618501|NCT03246139|Behavioral|Control treatment|The participants will receive UE training without watching videos or imagining movements/tasks.
45618502|NCT02517359|Drug|RV6153 single dose|Safety and tolerability of single doses
45618503|NCT02517359|Drug|RV6153 matching placebo single dose|Safety and tolerability of single doses
45618504|NCT02517359|Drug|RV6153 14 day repeat dose|Safety and tolerability of repeat doses
45618505|NCT02517359|Drug|RV6153 matching placebo 14 day repeat dose|Safety and tolerability of repeat doses
45618506|NCT02517359|Drug|RV6153 28 day repeat dose|Safety and tolerability of repeat doses
45618507|NCT02517359|Drug|RV6153 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
45618508|NCT02517281|Procedure|Biopsy|
45618509|NCT02517437|Drug|Suprascapular & axillary blocks|After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots to achieve circumferential spread around the nerve.The axillary nerve block will be performed next in the posterior aspect of the operative arm. The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle.
45618510|NCT02517437|Drug|Interscalene block|After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a 5 cm 22 G insulated needle is then inserted and local anesthetic solution (20 mL of 0.5% ropivacaine) will be injected in 5 mL aliquots after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.
45618511|NCT00700999|Drug|Paroxetine|Paroxetine 20-40mg po QD for 12 weeks
45760803|NCT04742530|Behavioral|Fed Evening Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 18:30, after having consumed a carbohydrate-containing meal (20% estimated energy requirements) 2 hours prior. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
45760804|NCT04742530|Behavioral|Fed Morning Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 10:30, after having consumed a carbohydrate-containing meal (20% estimated energy requirements) 2 hours prior. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
45760805|NCT04479826|Device|Advanced hybrid closed loop system|Free living follow-up of meal handelling
45760806|NCT00852761|Drug|Olux-E Foam|Olux-E (clobetasol propionate 0.05%) foam. Starting at baseline, subjects were to apply twice daily Olux-E foam to the affected elbows and/or knees up to day 15.
45618512|NCT03347669|Device|Sudoscan®|Sudoscan® is a new device that provides rapid, non-invasive and reproducible quantitative assessment of sweat function. It makes it possible to measure the ability of the sweat glands to release chloride ions in response to electrochemical activation and thus to detect the presence of a neuropathy with small fibers. This new device therefore makes it possible to detect an SFN in a much simpler and faster way than the technique of ophthalmology, or biopsy. Sudoscan® has been tested to assess the neuropathies of small nerve fibers in several diseases, in particular diabetes, chemotherapy-induced polyneuropathy, familial amyloid polyneuropathy or Fabry disease. The interest of Sudoscan® lies in the fact that this device is non-invasive and rapid. Its diagnostic value has been compared with other neurophysiological tests.
45618513|NCT02454595|Behavioral|Registry|Physician will complete a series of four questionnaires to capture the treatment decisions based upon standard clinical-pathological information and with the addition of the result of genomic testing (Prolaris test).
45618514|NCT03121937|Behavioral|Mobile App|"The mobile app mConnect is an app designed to facilitate psychotherapy for depression and includes mood tracking, goal setting, and communication"
45760807|NCT00852761|Drug|Clobex lotion|Clobetasol propionate 0.05% lotion. Starting at baseline, subjects were to apply twice daily Clobex lotion to the affected elbows and/or knees up to day 15
45618515|NCT03248869|Other|Current Daily Survey|need description
45618516|NCT03248869|Other|Mobile Health App|Participants recruited, consented and enrolled via the AMHA and complete assessments using the app
45618517|NCT03121859|Other|Neck stabilization exercise|Exercise
45618518|NCT03121859|Other|TENS|Transcutaneous electrical nerve stimulation (TENS)
45618519|NCT03121859|Other|IFC|Interferential current therapy(IFC)
45618520|NCT04502771|Drug|Antifungal treatment|Treatment by fluconazole, voriconazole,posaconazole or caspofungin during the patient stay in Intensive Care Unit
45618521|NCT02454361|Drug|KBP-7072|KBP-7072
45618522|NCT02454361|Drug|Placebo|Placebo
45618523|NCT04502849|Procedure|Bypass surgery|Creating a bypass with graft or vein.
45618524|NCT04502849|Procedure|Endovascular angioplasty/stenting|Performing an angioplasty with or without stenting in stenosis.
45618525|NCT04502849|Procedure|Hybrid surgery|Performing an angioplasty with or without stenting in stenosis and creating a bypass with graft or vein.
45618526|NCT04502849|Drug|Vitamin E|100 mg Vitamin E per os 1 per day (1 month).
45618527|NCT04502849|Diagnostic Test|Duplex ultrasound|Duplex ultrasound of lower limbs arteries.
45618528|NCT04502849|Diagnostic Test|Blood sampling|Blood sampling for apoptosis and endothelial dysfunction markers.
45618529|NCT04502849|Diagnostic Test|Arterial wall sampling|Arterial wall sampling for apoptosis markers.
45618530|NCT02455843|Other|Microwave ablation|Patients assigned to the combination group will be treated with microwave in the primary tumor site
45618531|NCT04761887|Drug|Cool Ropivacaine Block|Ropivacaine is cooled.
45618532|NCT04761887|Drug|Room Temp Ropivacaine Block|Room Temp Block
45618533|NCT03249025|Drug|Lidocaine|Initial dose of 5.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45-60 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, to a maximum total dose of 600 mg. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience
45618534|NCT03249025|Drug|Ketamine|initial dose of 0.25 mg/kg (based on actual weight) over 45-60 minutes (rounded to nearest 5 mg), increased by 10mg each infusion based on tolerability of side effects. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience
45618535|NCT02729831|Behavioral|Interactive decision aid|The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
45618536|NCT02729831|Behavioral|Video decision aid|Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
45618537|NCT02729831|Behavioral|Provider Report|A short report that includes the patients' goals and treatment preferences
45618538|NCT03245905|Drug|Chidamide|Chidamide 30mg orally BIW. Treatment cycles are repeated every 3 weeks.The maximum duration of treatment is 2 years.
45618539|NCT03248713|Drug|Mifepristone|Mifepristone 600mg 2 tablets will be compared to the placebo
45618540|NCT03248713|Drug|Placebo|Placebo sugar 2 tablets will be compared to mifepristone
45618541|NCT03245671|Drug|Kenalog Injectable Product|80 mg of Kenalog will be used.
45618542|NCT03245671|Drug|Decadron Phosphate, Injectable|15 mg of Decadron will be used.
45618543|NCT03245671|Procedure|Epidural Steroid Injection|Patient will receive epidural steroid injections of either Kenalog or Decadron.
45618544|NCT03254641|Drug|human chorionic gonadotropin|5000 IE times one
45618545|NCT02729753|Device|CryoBalloon™ Full Ablation System|Tissue Ablation using CryoBalloon™ Full Ablation System
45618546|NCT02729753|Device|CryoBalloon™ Swipe Ablation System|Tissue Ablation using CryoBalloon™ Swipe Ablation System
45618547|NCT03254407|Other|Screening medical record|Communicating possible IV/PO switch to prescriber by phone or e-note in medical record
45618548|NCT02516891|Device|Drug-Eluting Stents implantation in bifurcation lesions|
45618549|NCT04487197|Procedure|blood sample for seroepidemiological investigation|blood sample for seroepidemiological investigation
45618550|NCT04627571|Drug|Cenegermin Ophthalmic Solution [Oxervate]|An 8-week course of topical cenegermin eye drops given 6 times daily would be started in the affected eye, in conjunction with the pre-existing medical treatment for neurotrophic keratopathy. Patients will be followed-up at 4 weeks, 6 weeks, 8 weeks, 3 months, 6 months, 9 months and 12 months (±2 weeks at each time point) after treatment. At each visit, patients will be assessed to determine the corneal epithelial defect and corneal sensation.
45618551|NCT03245515|Drug|BMS-986195|specified dose on specified days
45618552|NCT03363503|Drug|Salmeterol/Fluticasone Capsair®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Capsair® for 8 weeks
45760808|NCT03839537|Other|Exposure measurement|"2 measurements per subject (in warm season and in cold season)~Devices placed inside taxi vehicles on the passenger seat in a sampling bag"
45760809|NCT03839537|Other|Spirometry test|"2 measurements per subject - before and after the work shift - in warm and cold seasons~Subject will inhale and exhale in the device"
45618553|NCT03363503|Drug|Salmeterol/Fluticasone Diskus®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for 8 weeks
45618554|NCT03248791|Drug|Phenylephrine|Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
45618555|NCT03248791|Drug|Norepinephrine|Norepinephrine variable infusion with a starting rate of 0.1 mcg/Kg/min.
45618556|NCT03248791|Drug|Bupivacaine|Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg
45618557|NCT05582603|Behavioral|CCT Long COVID|A 15-day training protocol in which every 48 hours participants' complete a series of different cognitive tasks in the form of games selected among a pool of 12 games from CogniFit (CogniFit Inc., San Francisco, USA) whose difficulty level is tailored to each individual by the a patented Individualized Training System™ (ITS) software that automatically chooses the activities and difficulty levels for each person in every session.
45618558|NCT03254251|Behavioral|Stair climbing|Stair climbing (SC) training was 12 weeks of progressive SC program. Each training session consisted of a general warm-up (5 min: slow and fast skipping, stretching) followed by the SC training and was supervised by experienced personnel. The program began with two bouts of stair climbing four days a week in weeks 1 and 2, increasing by one climb a day every three weeks. By the last three weeks (10-12) of the study, all subjects were completing 5 climbs four days a week. During each climb participants ascended 12 flights (192 steps) divided into 3 sets of 4 flights, with a 2 min rest period between each set. There was a 5 min rest period between climbs that allowed the participants to reach the ground floor using an elevator. Subjects in the non-exercising control group did not participate in a supervised exercise program for the duration of the study.
45618559|NCT04585685|Behavioral|Cognitive Processing Therapy|A 12-session cognitive behavioral therapy for posttraumatic stress disorder
45760810|NCT03839537|Diagnostic Test|Exhaled carbon monoxide test|"2 measurements per subject - before and after the work shift - in warm and cold seasons~Subject will exhale in the device"
46069142|NCT04100148|Device|SyncAV programmed ON|For those subjects randomized to SyncAV programmed ON, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF), at BiV pacing nominal settings, with various SyncAV programmed offsets, and at LV first 30 ms, RV first 30 ms and LV-only pacing with optimal SyncAV offsets. The site will then program the subject's device using the SyncAV offset that provided the narrowest QRS duration.
46069143|NCT04100148|Device|Fixed AV delay|For those subjects randomized to the fixed AV delay arm, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF) and at BiV pacing nominal settings. Sites will then program the subject's device using BiV pacing nominal settings.
45618560|NCT04585685|Behavioral|Self-Compassion Therapy|A 6-session mindfulness based therapy for posttraumatic stress disorder aimed at enhancing self-compassion
45618561|NCT03254173|Drug|Mirtazapine 30 mg oral tablets|Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets) , half tablet before sleep for 8 weeks
45618562|NCT03254173|Drug|Placebo oral tablets|Placebo oral tablets , half tablet daily before sleep for 8 weeks
45618563|NCT02516735|Device|I-scan with magnification|
45618564|NCT02516735|Device|Standard endoscopy|
45618565|NCT03248323|Radiation|dyna-pbv|
45618566|NCT03254329|Other|Assessment of human milk nutrient composition|Observational study to measure nutrients in human milk during lactation and their relationship to maternal and infant nutritional status.
45618567|NCT03248401|Drug|Cilostazol|Cilostazol 200 mg/day
45618568|NCT03248401|Drug|Aspirin|Aspirin 100 mg/day
45618569|NCT04502927|Procedure|Passive extension mobilization of the hand and wrist joints|"The physiotherapist will proceed with the passive mobilization of the spastic hand of the stroke patient or the dominant hand for healthy volunteers.~Two mobilizations will be performed for each participant, i.e. one for each type of medial or lateral grip. The order of mobilization will be determined by randomization."
45760811|NCT03839537|Diagnostic Test|Skin allergy test|- Performed by a physician during the inclusion clinical examination
46069144|NCT04078295|Drug|E7389-LF|E7389-LF Intravenous infusion.
46069145|NCT04078295|Drug|Nivolumab|Nivolumab Intravenous infusion.
45445782|NCT03770637|Other|Placebo|The placebo is a non-active version of Glucagon RTU formulation, containing the same solvent and excipients (i.e., vehicle).
45618570|NCT03254017|Procedure|Bilateral surgical implantation of DBS system to Habeluna|The SceneRay DBS device utilized in the present study is a double-channel device designed and manufactured by Suzhou Scene-Ray Medical Co., Ltd. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead (diameter =1.27 mm) contains four stimulating contacts made of platinumiridium alloy. The length of each contact is 1.5 mm, and interval spaces are 0.5 mm. This device shares the same basic principles utilized by Medtronic products, with unique wireless programming and electrode fixing designs. The amplitude (0-10 V), pulse width (60-960 ms), and frequency (1-1,600 Hz) can be programmed, and different frequencies may be utilized in the left and right hemispheres using this type of dual-channel IPG.
45618571|NCT03254017|Other|Follow-up Period|The researchers will remotely program the DBS biweekly after opening the stimulator and face to face test the patients' cognitive function every half year. Montgomery-Asberg Depression Rating Scale will be tested biweekly until the Programmed parameter has stable therapeutic efficacy and then tested after 3 months, 6 months, 9 months and 12 months.The other neuropsychological scales will be test on 3 months, 6 months, 9 months and 12 months.
45618572|NCT03253939|Procedure|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
45760812|NCT03839537|Diagnostic Test|Spirometry test|- Performed by a physician during the inclusion clinical examination
45760813|NCT03839537|Diagnostic Test|Fractional Exhaled Nitric Oxide Testing|- Performed by a physician during the inclusion clinical examination
45760814|NCT04268992|Other|Long-term exercise|All patients randomised to long-term exercise will perform exercise training at least three times a week for three months. The exercise is supervised and individualised.
45760815|NCT00364936|Procedure|Palliative care service|
46069146|NCT04074044|Behavioral|BHmApp|Use of BHmApp for bladder education and training in pregnancy
46069147|NCT04072367|Device|NeVa Stent Retrievers|thrombus removal
45445783|NCT03766269|Drug|Dronabinol|Dronabinol coadministered with patient's existing Baseline Opioid.
45760816|NCT04222751|Device|Ankle Splint|Ankle splint will be slightly modified from the commercial form to include a pneumatic air cell secured under the forefoot below the splint's padded lining. This replaces the foam wedge provided by the manufacturer, allowing a gradual adjustment of the forefoot/toe region.
45760817|NCT04084756|Behavioral|Couples Crisis Response Plan|The CCRP is a single session therapist-facilitated suicide prevention intervention conducted with a dyad
45618573|NCT03253939|Procedure|Cytoreductive surgery alone|Exclusively Cytoreductive surgery approach
45618574|NCT03346031|Procedure|music therapy|patients will listen to music with an MP3 headset
45760818|NCT04084756|Behavioral|Mental Health Education|The Mental Health Education session is a single session therapist-facilitated mental health psychoeducation session conducted with a dyad
45618575|NCT03245203|Procedure|FOLFIRI+beacizumab|Eligible patients received bevacizumab 5.0 mg/kg followed by irinotecan 125mg/m2 combined with LV 200mg/m2 followed by 5-FU bolus 400mg/m2,then 5-FU infusion 2.4~3.0g/m2 over a 46-h period.Those agents were given for a 2-week cycle.Treatment was administered for six cycles. LARC was reevaluated and operated after 4~8 weeks.
45618576|NCT03245203|Procedure|CRT|total dose of radiotherapy was 40~50Gy, a subdose of 1.8~2Gy for continuous 5 weeks, 5 times/week.Then,5-FU infusion 400mg/m2 combined with LV 200mg/m2 over 24 h for 4 days/week during the first and fifth weeks of radiotherapy.Whereas,Capecitabine was administered orally at a dose of 825mg/m2 twice a day for 5 days of a week. Second staging and operation were performed in the sixth week after chemoradiotherapy.
45618577|NCT02516423|Drug|ixazomib|oral
45618578|NCT02516423|Drug|lenalidomide|oral
45618579|NCT02516423|Drug|dexamethasone|oral
45618580|NCT02516423|Drug|zoledronic acid|IV
45618581|NCT03245281|Drug|Diuretic Suspension (DS)|Stop diuretic consumption in the 48h before the follow-up visit
45618582|NCT03245281|Drug|Diuretic Increase (DI)|Double diuretics dosage in the 48h before the follow-up visit
45760819|NCT04082806|Drug|GHB|50 mg/kg GHB at one experimental night
45618583|NCT03245281|Drug|Diuretic and Medication Suspension (DMS)|Stop diuretic and MRA medication consumption in the 48h before the follow-up visit
45618584|NCT02454439|Other|CRT implantation|
45618585|NCT03253783|Behavioral|Pulse|
45760820|NCT04082806|Drug|Trazodone|1.5 mg/kg trazodone at one experimental night
45760821|NCT04082806|Drug|Placebos|placebo oral solution (placebo for GHB) and placebo pills (placebo for trazodon)
45445784|NCT03894891|Drug|Nivolumab|Nivolumab is a type of immunotherapy that tries to enhance participants own immune system to fight cancer
45445785|NCT03894891|Drug|Cisplatin|Cisplatin is a chemotherapy medication used to treat a number of cancers
45618586|NCT03248011|Other|Stretching|Lower extremity flexibility exercises will be performed
45618587|NCT03248011|Other|Strengthening|Eccentric hamstring strengthening exercises will be performed
45618588|NCT03248011|Other|Neuromuscular|Dynamic lower extremity balance and movement control exercises will be performed
45618589|NCT03253861|Other|No intervention|No intervention
45618590|NCT04487275|Drug|MLC901 or Placebo|groups randomly assigned to receive either MLC901 or placebo capsules three times per day over 6 months
45618591|NCT03245359|Device|Short-term ON-Q|single port, select-a-flow pump connected to saphenous nerve block catheter until medication in initial balls are depleted (usually 2-4 days)
45618592|NCT03245359|Device|Short-term ON-Q|single port, fixed flow pump connected to posterior knee catheter until medication in initial balls are depleted (usually 2-4 days)
45760822|NCT05656222|Drug|VIA combination treatment|a 90-minute intravenous infusion of irinotecan at a dose of 50 mg/m2/d for 5 days every 3 weeks, vincristine given at a dose of 1.4 mg/m2 (maximum 2 mg) on days 1 and 8, and oral administration of Anlotinib once daily on days 1-14 within a 21-day cycle.
45760823|NCT05635786|Drug|Alteplase (0.9mg/kg)|Intravenous thrombolysis with Alteplase (0.9 mg/kg, maximum 90 mg) with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes.
45760824|NCT05635786|Drug|Tenecteplase (0.25mg/kg)|Intravenous thrombolysis with Tenecteplase (0.25mg/kg, maximum 25 mg) with 100% of the dose given as a bolus.
45760825|NCT00854087|Drug|Fuzheng Huayu|The subjects will be taking 2 tablets three times a day for 48 weeks.
45760826|NCT00854087|Drug|Placebo|The subjects will be taking 2 tablets three times a day for 48 weeks.
45760827|NCT00365950|Drug|Duration of anticoagulation|
45760828|NCT00365950|Drug|Warfarin duration|
45760829|NCT02487797|Drug|Oxytocin|
45618593|NCT03245359|Drug|Short-term ON-Q|Bupivacaine 0.125%
45618594|NCT03245359|Device|Long-term ON-Q|single port, select-a-flow pump connected to saphenous nerve block catheter until day 7 post-operative
45618595|NCT03245359|Device|Long-term ON-Q|single port, fixed flow pump connected to posterior knee catheter until day 7 post-operative
45618596|NCT03245359|Drug|Long-term ON-Q|Bupivacaine 0.125%
45618597|NCT03245047|Dietary Supplement|Oral Nutritional Supplement with AN 777|Oral Nutritional Supplement with AN 777, 2 servings a day
45618598|NCT03245047|Other|Oral Nutritional Supplement|Oral Nutritional Supplement, 2 servings a day
45760830|NCT02487797|Other|Sodium Chloride 0.9%|
45760831|NCT00422266|Drug|Omega 3 fatty acids and plant sterol enriched drink|
45760832|NCT00422266|Dietary Supplement|Omega 3 fatty acids and plant sterols|Capsules and Yoghurt based minidrink
45618599|NCT02516345|Device|Fitbit|Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
45618600|NCT02516345|Behavioral|Incentives|Incentives will be awarded to participating children for meeting step targets as measured by the Fitbit pedometer.
45760833|NCT01733693|Drug|Buprenorphine|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
45760834|NCT01733693|Drug|Methadone|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
45760835|NCT00855413|Drug|Darunavir|800 mg orally once daily
45760836|NCT00855413|Drug|Ritonavir|100 mg orally once daily
45760837|NCT00855413|Drug|Etravirine|200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen
45760838|NCT05599984|Drug|ABBV-706|Intravenous (IV) Infusion
45760839|NCT05599984|Drug|Cisplatin|Intravenous infusion
45618601|NCT03248245|Other|LOG-model|"Besides the LOG-manual, school owners and leaders receive economic compensation and the intervention team will supervise the implementation. School-owners, school leaders and teachers will participate in dialogue-seminars at the municipal level and the school level respectively. The aim is to discuss and agree on the goal and content of the work and discuss the experiences from the implementation. The main arena for discussing and practical implementation will be in local collaborating teams or resource teams in each school. The resource teams at schools will consist of various interprofessional competences in addition to the school leader. The main method in the LOG-model is the interchange and feedback process between the discussion of measures and the execution of these measures."
45618602|NCT03248245|Other|TAU|Ordinary practices related to interprofessional team collaboration
45618603|NCT05565131|Device|Guided placement with PYTHEAS® ODYSSEE|Pre-surgery, the surgeon generates a 3D model of the spine from a preoperative CT scan During the perforation and insertion of the implant, the system indicates the orientation of the pedicle path and the current orientation of the instruments (perforation tool) with the orientation sensor (inertial sensor). The system also displays the position of the entry point of the planned pedicle path on the views.
45618604|NCT03248089|Diagnostic Test|Guardant360|Cell-free circulating tumor DNA (cfDNA) targeted next-generation sequencing (NGS) panel.
45618605|NCT02516267|Device|Multiplate ADP®|Patients will be evaluated by platelet function testing (Multiplate ADP®) daily until the value obtained> 46 AU, when they will be immediately released to CABG
46069148|NCT04072367|Device|Solitaire Stent Retrievers|thrombus removal
45760840|NCT05599984|Drug|Budigalimab|IV Infusion
45445786|NCT03894891|Drug|Docetaxel|Docetaxel (Taxotere®) is a chemotherapy drug. It is used to treat many types of cancer including head and neck
45760841|NCT05599984|Drug|Carboplatin|Intravenous infusion
45760842|NCT05599204|Other|schroth exercise|the patients will receive the Schroth three-dimensional exercise. patient first assumes a posture in the cervico-cranial and shoulder girdle and the thoracic region is held in the correct posture. The patient inspires air into the concave side and during the exhalation phase isometric and isotonic muscle tensing occur. While the patient is breathing, the therapist should observe the posture and movement of the thoracic cage and diaphragm. Basic posture correction in sitting and walking and Sensorimotor training by the ball will be applied
45760843|NCT05599204|Other|postural correction exercise|the patients will receive postural correction exercises, stretches, and exercises to the pectoralis major, elevator scapulae, upper trapezius, serratus anterior, rhomboids, and deep neck flexors. The stretches included sitting chair stretches, Brugger's, wall angels, and doorway stretches. The exercises included push up- plus, head-neck-retraction, and Kibler squeeze
45760844|NCT05553340|Other|Education for caregivers|The intervention will aim to equip the family caregiver to assist the elderly in activities of daily living after discharge, and will be carried out by two researchers, through an online course. The course includes the skills required and included in the scales that assess the caregiver's knowledge and performance. The course is divided into 12 modules that can be accessed as many times as needed by caregivers, in random order, according to the care needs of the elderly and the caregiver.
45760845|NCT00816101|Other|Procellera™ Antimicrobial Dressing|Dressing indicated for partial and full-thickness wounds.
45911638|NCT05777746|Behavioral|12-week plant-based dietary program|a 12-week plant-based dietary program consisting of information via an online platform, online guidance by dieticians and in online peer support groups. Patients will aim to maximize their intake of plant-based products while reducing their of animal products as much as possible.
45760846|NCT00816101|Other|Mepilex® Border Lite|Self-adherent foam dressing
45760847|NCT00816101|Device|Adhesive Bandage|Adhesive bandage
45911639|NCT05777746|Behavioral|Usual Diet|Patients in the control group continue with their usual diet and/or usual dietary care. Patients in the control group will be offered access to the online platform at 24 weeks.
45760848|NCT05504434|Device|Single-use gastroscope|Adults patients are treated with a single use gastroscope instead of a reusable gastroscope
45760849|NCT00366262|Drug|PLA-695|
45911640|NCT05777733|Drug|n-acetylcystine|Single daily oral administration of N_acetylcystein on dose 10mg /kg/day
45911641|NCT05777720|Device|Filtration Fan|Investigators are using box fans with attached MERV16 filters, a design that has been tested and published in the scientific literature.
46069149|NCT04068597|Drug|CCS1477|Oral capsule
46069150|NCT04068597|Drug|Pomalidomide|oral capsule
46069151|NCT04068597|Drug|Dexamethasone|oral tablet
46069152|NCT04068597|Drug|Azacitidine|Powder suspension for Injection
45445787|NCT03894891|Radiation|Radioimmunotherapy|Radiation Therapy to shrink or kill tumors.
45760850|NCT00366262|Drug|Naproxen|
45760851|NCT00366262|Drug|Placebo|
46069153|NCT04068597|Drug|Venetoclax|Oral tablet
45618606|NCT03245125|Behavioral|High-intensity interval training|Patients warmed up for 3 min at 30% of peak oxygen consumption (VO2peak). Five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak. All subjects used a EKG and BP monitors as indicators of the assigned exercise intensity. Borg 6-to-20 scale was used to assess the rate of perceived exertion during and after each exercise session. Patients suffering unstable hemodynamic, ischemic cardiac symptoms/signs, and uncontrolled arrhythmia were instructed to immediately terminate exercise training.
45618607|NCT02516189|Other|Strength training program|"Strength Training program applied twice a week for sixteen weeks. Each training exercises has a total time of 50 minutes. Warm-up: 5 minutes of stretching. Training: Leg press; Leg Curl; Vertical traction; Chest press; Abdominal crunch; Lower back. Gametherapy.~Relaxation: 5 minutes of stretching."
45618608|NCT02516111|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
45760852|NCT05452018|Other|Intervention group|In healthy volunteers, activity measurement of muscles of interest by intramuscular electromyography during predefined swallowing tasks
45760853|NCT00818363|Drug|SABER-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER-Bupivacaine/Once
45760854|NCT00818363|Drug|SABER-Placebo|Injectable Solution; 5.0 mL SABER-Placebo/Once
45760855|NCT00828841|Drug|Cetuximab|Cetuximab will be administered at a loading dose of 400 mg/m2 on Day 1, Cycle 1 and at a dose of 250 mg/m2 weekly during chemotherapy. During the maintenance period, cetuximab will be dosed at 500 mg/m2 every two weeks.
45760856|NCT00828841|Drug|Paclitaxel|Paclitaxel 200 mg/m2 Day 1 every 21 days
45760857|NCT00828841|Drug|Carboplatin|Carboplatin AUC 6 Day 1 every 21 days
45618609|NCT02516111|Biological|OFD with PRF|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
45618610|NCT02516111|Drug|OFD with ALN|Oral prophylaxis followed by Open flap debridement (OFD) with 1% ALN gel placement into the bone defect
45618611|NCT02516111|Drug|OFD with ATV|Oral prophylaxis followed by Open flap debridement (OFD) with 1.2% ATV gel placement into the bone defect
45618612|NCT03253471|Drug|AL-611|AL-611 tablets
45618613|NCT03253471|Drug|Placebo|Placebo to Match AL-611
45760858|NCT00828841|Drug|Gemcitabine|Gemcitabine 1,000 mg/m2 Days 1 and 8 every 21 days
45618614|NCT02515955|Drug|JNJ-54175446|Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.
45618615|NCT02515955|Drug|Minocycline|Participants will receive minocycline 100 mg as capsule twice daily.
45618616|NCT02515955|Drug|JNJ 54175446 Matching Placebo|Participants will receive placebo matching with JNJ 54175446 once daily orally.
45618617|NCT02515955|Drug|D Amphetamine|Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
45760859|NCT00828841|Drug|Cisplatin|Cisplatin 75 mg/m2 Day I every 21 days
45760860|NCT00486551|Behavioral|Anger control training|
45760861|NCT05445310|Drug|Furmonertinib|Furmonertinib 80mg/d
45618618|NCT02515955|Drug|D Amphetamine Matching Placebo|Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
45618619|NCT03247933|Device|Telemedicine: Maintenance Respiratory Rehabilitation|"Telemedicine: Maintenance Respiratory Rehabilitation. Patients will receive a personal program of maintenance respiratory rehabilitation supported by telemedicine (TeleRR).~A personal program of Respiratory rehabilitation consists on: 20-30 minutes of static bicycle exercises + 3 series of ten repetitions from 4 different types of exercises with weights / cufflinks. 3 days a week, every week for a year.~They will be in their homes doing the program of treatment prescribed by the physician. They will be provided with the material that is needed: 1 static bicycle, 2-weights / cufflinks, 3-device mobile (smartphone/PDA) + Pulse Oximeter.~The patient must send the exercises every day that are scheduled training exercises once have been completed."
45618620|NCT03244813|Other|Personalized activity program|Targeted physical activity
45618621|NCT03345953|Drug|BP 1.4979|Double blind versus placebo
45618622|NCT03345953|Drug|Placebo|Double blind versus placebo
45618623|NCT03244891|Other|Increase of central volume|"Mild hypovolemia will be induced in healthy volunteers by 12 hours fasting. Three conditions will be considered for the analysis, each of them both during spontaneous breathing and positive pressure ventilation:~baseline~after fluid shift induced by passive head down position at 15 degrees~after fluid challenge with Ringer acetate 15ml*kg in head down position~A total of six steps will be considered for the analysis"
45618624|NCT03244891|Other|Ventilation mode|"Each previous step will be done in two respiratory conditions:~spontaneous breathing~noninvasive ventilation via facial mask in pressure support mode at 8 cmH2O above positive end expiratory pressure of 5 cmH2O, inspiratory fraction of oxygen of 0.25 In both conditions respiratory rate will be set at 18 breaths per min following a metronome"
45760862|NCT03611621|Drug|Imlifidase|This is a five year, long-term follow up, observational study. The study will primarily determine the time of graft survival in subjects who have received imlifidase prior to kidney transplantation. Subjects who have participated, or are currently participating, in the imlifidase kidney transplantation studies (called feeder studies) 13-HMedIdeS-02, 13-HMedIdeS-03, 14-HMedIdeS- 04 and 15-HMedIdeS-06 will be included. The subjects will attend 4 follow up visits, 1, 2, 3 and 5 years after imlifidase administration.
45760863|NCT05443906|Behavioral|Home exercise|Exercise to address limitations impacting walking
45760864|NCT05442346|Biological|γ-globin reactivated autologous hematopoietic stem cells|gene edited autologous hematopoietic stem cells with γ-globin expression; BRL-103
45760865|NCT00858689|Drug|Minocycline|50-100 mg PO BID for 8 weeks with an option for a 1 year extension.
45760866|NCT05415592|Device|DePuy Synthes Radial Head Replacement System|DePuy Synthes Radial Head Replacement System will be used for radial head replacement or partial replacement of the elbow joint.
45760867|NCT00830791|Drug|MK-0941 20 mg|Two 10-mg tablets of MK-0941 administered as a single oral dose.
45760868|NCT00830791|Drug|MK-0941 5 mg|MK-0941 administered as one single 5-mg tablet.
45760869|NCT04741360|Other|Modified Story Memory Technique|10-session computerized program to improve new learning and memory
45760870|NCT00820235|Device|OsseoSpeed™|OsseoSpeed™ implant
45618625|NCT03345875|Diagnostic Test|HPV self collection, followed by visual assessment of the cervix for treatment (VAT) and treatment|Women who test HPV positive are offered visual assessment for treatment, with treatment method (cryotherapy, LEEP, or biopsy) based on visual assessment findings.
45760871|NCT00820235|Device|NobelSpeedy™ Replace®|NobelSpeedy™ Replace® implant
45760872|NCT00820235|Device|NanoTite™ Certain® PREVAIL®|NanoTite™ Certain® PREVAIL® implant
45760873|NCT05353816|Device|Intervention/treatment:|Implantation of left ventricular assist device for hemodynamic support.
45760874|NCT05026099|Other|Boxing training|Boxing training: warm-up. Mitt hitting, sandbag hitting, in sitting, cool down, Assessment after 4 weeks boxing training: warm-up. Mitt hitting, sandbag hitting, below hips, cool down, Assessment after 6 weeks Boxing training: warm-up. Mitt hitting, sandbag hitting, both inn sitting and standing, cool down, Post assessment
45760875|NCT05026099|Other|Task Oriented Training|Task-oriented training: 6 tasks in sitting and standing position for both upper and lower limb Assessment after 4 weeks Task oriented training: 6 tasks in sitting and standing position for both upper and lower limb Assessment after 6 weeks Task oriented training: 6 tasks in sitting and standing position for both upper and lower limb Post assessment
45618626|NCT03244735|Other|Atkins diet|A nutritional regimen characterized by high fat low carbohydrate intake.
45618627|NCT03345797|Drug|Testosterone Nasal Gel [Natesto]|nasal gel containing 4.5% w/w testosterone
45618628|NCT03247855|Procedure|minimal invasive coronary artery bypass graft surgery|coronary artery bypass grafting surgery by using a minimal invasive technique
45618629|NCT04500743|Drug|Dienogest|Group B (n=67) who had daily oral Dienogest 2 mg/d for 3 months before starting standard long protocol for IVF
45618630|NCT04500743|Drug|leuprorelin acetate|Group A (n=67) who had monthly depot GnRHa for 3 months before ovarian stimulation in IVF treatment (Ultra-long protocol)
45760876|NCT03625765|Device|SmartGoggles|the system is wearable and simulates natural binocular human vision, which minimizes the training curve for new users. The wide-field stereoscopic imaging allows clinicians to rapidly determine the extent of lesions and the hand-held microscopy probe assist clinician to visualize the lesions with high resolution.
45760877|NCT00821795|Drug|NPH/Regular 70/30 mix|injectable solution, subcutaneous,0.3-0.5 units/kg/day divided into twice per day dosage, 16 weeks duration
45760878|NCT00821795|Drug|insulin aspart protamine/insulin aspart 70/30 mix|injectable solution, subcutaneous, 0.3-0.5 units/kg/day divided into twice per day dosage, for 16 weeks
45760879|NCT05322304|Dietary Supplement|Almond|Intervention (almond supplementation) and Isocaloric diets (control)
45760880|NCT04382131|Other|NaCl Solution|NaCl Solution prepared by participants at home using water and salt
45760881|NCT05316142|Procedure|AGV implantation|This method will use Ahmad FP7 model valved shunt (New World Medical, LA), which is one of the most commonly used shunts in the world
45760882|NCT04382261|Procedure|Scaling and root planing|Full mouth or quadrant SRP
45760883|NCT00833365|Drug|Ibuprofen|Ibuprofen 10 mg/kg/dose for one dose, then repeated 24 hrs later at 5 mg/kg/dose and repeated 24 hrs later at 5 mg/kg/dose
45760884|NCT00833365|Drug|Ibuprofen|Initial dose of ibuprofen is 10 mg/kg and then repeated every 24 hours times two with doses of 5 mg/kg
45760885|NCT00821951|Drug|Vorinostat|200 mg, 300 mg, 400 mg, once per RT fraction
45760886|NCT00821951|Radiation|Radiotherapy|Standard fractionation of 3.0 Gy per day over 2 weeks, to a total dose of 30 Gy, will be utilized for all patients. All patients will be treated one time per day, 5 days per week unless interruption is clinically indicated.
45618631|NCT03247699|Other|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
45618632|NCT03247699|Other|"Basel phenotyping cocktail individual components"|"Oral intake of Basel phenotyping cocktail individual components and PK sampling"
45618633|NCT04500431|Biological|Targeting CD269 chimeric antigen receptor engineered T cells|Targeting CD269 chimeric antigen receptor engineered T cells, single infusion intravenously
45760887|NCT00852631|Drug|Quetiapine fumarate (Seroquel)|600mg Extended release tablet, oral, once daily
45760888|NCT00860015|Drug|Alimta|"500 mg/m2 via IV over 10 minutes~A chemotherapy drug with indications to treat pleural mesothelioma and non-small cell lung cancer."
45618634|NCT02623699|Drug|BIIB067|Part A, B and C
45618635|NCT02623699|Other|Placebo|Part A, B and C
45618636|NCT03345719|Diagnostic Test|3D Cone-Beam Imaging|
45618637|NCT04303715|Procedure|No SLNB|BCS only. Ommission of SLNB by axilla ultrasonography among selective breast cancer patients
45618638|NCT04303715|Procedure|SLNB|BCS with SLNB(+/-ALND)
45618639|NCT03253159|Behavioral|Hypnosis|The conversational hypnosis (10-15 min) is standardized and performed just before intravenous general anesthesia induction in the operative room.
45618640|NCT03253237|Device|continuous glucose monitoring (CGM)|A CGM device is to be set and take of by the GP. Before the study start all GPs will have a short education on CGM device by the diabetologist who use CGM on a daily base. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard home blood glucose monitoring (SHBGM) along with the data on eating, physical exercise, drugs. Bayer's Contour® glucometer is used for the SHBGM. On Day 7, CGM device is took of and the data from iPro2 is uploaded to PC. At the end, each patient fill a short query on satisfaction while wearing CGM.
45618641|NCT03247621|Behavioral|Whatsapp|
45618642|NCT03247621|Behavioral|Article|
45760889|NCT00860015|Drug|Gemcitabine|"1000 mg/m2 via IV over 90 minutes~A nucleoside analog used as chemotherapy."
45760890|NCT00853333|Drug|dexmedetomidine|
45760891|NCT00853333|Drug|midazolam|
45760892|NCT00853333|Drug|propofol|
45760893|NCT05237063|Biological|Blood and urine samples|Additional Blood and urine samples will be collected at inclusion, 1, 3 and 5 years follow up visits
45760894|NCT00853645|Device|Subcutaneous Implantable Defibrillator (S-ICD) System|
45760895|NCT05227612|Drug|Psilocybin|Participants will receive two doses of psilocybin (10mg, 25mg) as well as 12 sessions of CBT.
45618643|NCT03247621|Behavioral|No Phone|
45618644|NCT04501991|Other|antidiabetic treatment|Every kind of antidiabetic treatment, oral or injective, were considered including patients treated only with diet
45760896|NCT00822107|Drug|Hydrochlorothiazide|50 mg one time
45760897|NCT05218408|Biological|CYNK-001 systemic and Intra cavity administration|"Phase 1 Lymphodepletion Days -5,-4 and -3 Cyclophosphamide 900 mg/m2, Fludarabine 30 mg/m2 and Mesna per SOC~IL 2 at 6M IU subcutaneous administration:~For IV cycle ( cycle1) rhIL2 will be administered on Days 1,3,5,8,9,11 and 15 . On days 1, 8 and 15 rhIL-2 will be administered 1 to 3 hours prior to CYNK-001 infusions For IC cycles rhIL2 will be administered 1 to 3 hours prior to each CYNK-001 IC dose.~CYNK-001 : for IV at 2.4 x10^9 or 3.6 x10^9 cells Days 1,8 and 15~Tumor resection will take place 7 to 14 day follow by first IC cycle ( Cycle 2) at 100 Million cells or 200 Million cells~IC cycles 3,4,5 once a week for three weeks , 28 days cycle at100 Million cells or 200 Million cells only for Phase 1 cohort 4 and Phase 2a"
45760898|NCT05236907|Drug|Melatonin|The patients were assessed using the Memorial Delirium Assessment Scale (MDAS) after the operation at 30, 60, and 90 min. Melatonin was shown to reduce delirium from 41.6% to 16.6% at 60 minutes, and the significant reduction was at 90 minutes (0%) when compared to both groups. Thus, melatonin was found to be successful in decreasing postoperative delirium when administered preoperatively.
45760899|NCT05236907|Other|No intervention|No intervention was used.
45618645|NCT03247777|Other|Traditional strengthening|dead lifts, bench press, wrist curls, and lat pulldowns as examples
45618646|NCT03247777|Other|Functional Strengthening|diagonal chops, one leg deadlifts, lateral plyometrics as examples
45618647|NCT04501601|Dietary Supplement|Fruit and vegetable solid drink|weight loss program supplement
45618648|NCT03247465|Other|Image Fusion|Addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
45760900|NCT05236907|Drug|Midazolam|7.5 mg of Midazolam orally.
45760901|NCT05217706|Drug|Ketamine|The treatment group will receive Ketamine 0.2mg/kg IV once
45618649|NCT03346577|Device|stent or balloon|Endovascular treatment with stent or balloon according to current practice
45618650|NCT03244657|Drug|conbercept ophthalmic injection （0.5mg）|"The target eye receives intravitreal injection of 0.5mg conbercept ophthalmic injection once every 12 weeks; if a subject meets additional drug administration criteria within 12 weeks between treatments, the subject can receive additional injection treatment"
45618651|NCT03244657|Drug|conbercept ophthalmic injection （0.5mg）|"In principle, the first administration time of the target eye uses the time determined by the assessment at end of STAR study; later, based on treatment-extension drug administration criteria, an investigator determines next visit time/treatment interval according to assessment result at each visit.When a subject's visit/treatment interval extends to 12 weeks, an additional safety visit can be arranged if an investigator considers that there is suspicious active lesion; if assessment result at the safety visit meets additional drug administration criteria, additional injection treatment can be given."
45618652|NCT03346499|Biological|NK cells and IL-2|Natural Killer Cells
45618653|NCT03244579|Behavioral|Dietary Intervention|Adjusting the quantity and quality of food intake to improve glycemic control, maternal and newborn health outcomes of women with gestational diabetes.
45618654|NCT03244267|Behavioral|Standard Education|Participants will receive the usual verbal education and printed information provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery, medication dosage and scheduling.
45618655|NCT03244267|Behavioral|Medication Reminder App|Participants will use a medication reminder app that is set in collaboration with the participants for times that fit into their daily lifestyle. The app will alert participants when it is time (selected by the participant) to take their medication.
45618656|NCT04164563|Device|Even-Up|Orthotic shoe lift worn on contralateral foot to increase leg length
45618657|NCT03253003|Device|Line extension of the Phonak Audéo B product family|The line extension of Phonak Audéo B product family will be fitted to the participants individual hearing loss.
45618658|NCT03247387|Device|MC10 BioStampRC|"Subjects will fill out electronic diaries on a provisioned iPhone to capture On versus Off time on a daily basis while at home. In addition, subjects will be asked to wear three actigraphy devices."
45618659|NCT03247387|Device|APDM actigraphy device|"Subjects will fill out electronic diaries on a provisioned iPhone to capture On versus Off time on a daily basis while at home. In addition, subjects will be asked to wear three actigraphy devices."
45618660|NCT03247387|Device|GENEActiv watch|"Subjects will fill out electronic diaries on a provisioned iPhone to capture On versus Off time on a daily basis while at home. In addition, subjects will be asked to wear three actigraphy devices."
45618661|NCT03345641|Other|describe precocious maternal impressions when confronting the premature birth of her infant|
45618662|NCT03247153|Diagnostic Test|Echocardiography|Imaging of the heart using ultrasound
45618663|NCT04156919|Behavioral|fooya!™|fooya!™ is a science/evidence-based AI-enabled neuromodulation and Cognitive Behavior Therapy (CBT) technology. fooya!™ has been shown to deliver statistically significant outcomes concerning food choices during randomized-controlled clinical trials conducted at the Baylor College of Medicine's Children's Nutrition Research in the United States of America as well as India. In the game, children make several decisions with split-second timing, such as food choices, destroying bad/unhealthy food robots using the bad foods that are thrown at the player, and saving themselves. If the children collect good/healthy foods, they are in fit-zone for a while, which shields them from bad food robots.
45618664|NCT04156919|Other|WordSearch|We will have an active control group that will play a WordSearch game. The intention is to have the children play a familiar video game through the same modality (IPAD) that is unrelated to diet or lifestyle choices.
45760902|NCT05217706|Drug|normal Saline|The placebo group will receive normal saline IV in a matched syringe
45804070|NCT05718661|Behavioral|watching video without virtual glasses|The plain version of the video, which was shown to the intervention group by the researcher (SŞ) to the placebo group, will be watched over the phone with the naked eye and the stress level on the smart bracelet will be recorded.
45618665|NCT03239353|Drug|Entecavir|Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.
45618666|NCT03347591|Genetic|WES|136 bleeding related OMIM (Online Mendelian Inheritance in Man)-proved genes involved in haemostasis will be selected from Whole Exome Sequencing (WES)
45618667|NCT03347591|Diagnostic Test|Several assays|Patients will be approached by their own treating physician. Data will be collected through questionnaires, a clinical interview, a blood and saliva sample obtained from each participant, and thorough review of electronic patient records. All procedures are study related. In case a physician visit with the treating physician is already planned, or in case a venepuncture for regular diagnostics or treatment is already planned, this can be combined with the study procedures to prevent an extra visit.
45618668|NCT03239119|Biological|rE-4 5 mcg|Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 5 mcg for 26 weeks - All are subcutaneously injected twice daily
45618669|NCT03239119|Biological|rE-4 10 mcg|Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 10 mcg for 26 weeks - All are subcutaneously injected twice daily
45618670|NCT03239119|Biological|Placebo 5 mcg|Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 5 mcg for 26 weeks - All are subcutaneously injected twice daily
45618671|NCT03239119|Biological|Placebo 10 mcg|Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 10 mcg for 26 weeks - All are subcutaneously injected twice daily
45618672|NCT03239275|Procedure|Biocreative therapy|
45618673|NCT04130243|Other|Blood test|Withdrawal of (extra) blood to measure serum biomarkers with a blood test
45618674|NCT04486651|Drug|Irinotecan Hydrochloride Injection|160 mg/m² administered as IV infusion on Day 1 of each 14-day cycle.
45618675|NCT04486651|Drug|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
45618676|NCT04486651|Drug|Placebo|Administered as IV infusion on Day 1 of each 21-day cycle.
45618677|NCT03347513|Drug|triple attack therapy|eradication of H-pylori using triple attack therapy.
45618678|NCT03347513|Drug|Ferrous(II)-glycine-sulphate complex 567.7 mg capsules|Iron therapy will be given to both groups twice daily for one month.
45618679|NCT04088591|Drug|Ascorbic Acid 500Mg/Ml Inj|Ascorbic acid 200mg/kg/day administered upon suspicion or confirmation of sepsis every 6 hours for a total duration of 96 hours
45760903|NCT00833443|Drug|Bupropion|Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days. The medication treatment phase is for 12 weeks.
45618680|NCT04088591|Drug|Dextrose in Water|50 ml of 5% dextrose in water every 6 hours for a total duration of 96 hours
45618681|NCT04501289|Drug|Low dose magnesium sulphate|Participants in this arm will receive 4g of 20% intravenous (I.V.) MgSO4 (Magphate®) given over 10 minutes, followed by 3g of 50% intramuscular (I.M.) MgSO4 in each buttock statim. Then, maintenance doses will be given as 2.5g of 50% MgSO4 administered intramuscularly 4 hourly for 24 hours, for participants with severe preeclampsia and for 24 hours post delivery or post last seizure episode, whichever occurs last, for cohorts with eclampsia.
45618682|NCT04501289|Drug|Pritchard regimen|Participants in this arm will receive loading dose as 4g of 20% MgSO4 I.V. over 10 minutes, followed by 5g of 50% MgSO4 I.M. in each buttock. Maintenance doses will be given as 5g of 50% MgSO4 I.M. 4 hourly in alternate buttock until 24 hours for patients with eclampsia and for 24 hours after delivery or after last fit, whichever occurs later, for cohorts with eclampsia.
45618683|NCT03244345|Behavioral|Self-measurement scale of sensitivity to stress/emotion|Patient will answer self-questionner on Depression
45618684|NCT03247075|Behavioral|Cognitive Behavior Therapy|Guided Internet-delivered CBT includes exposure training, coping techniques and cognitive components, intended to reduce social anxiety symptoms
45618685|NCT03247075|Behavioral|Support and Counseling|Guided Internet-delivered support and counseling includes educative material about social anxiety and health related issues such as physical activity, nutritious diet, sleep habits etc.
45760904|NCT05215912|Drug|TNB-738|TNB-738 is an investigation drug. Other: Matching placebo
45760905|NCT05215912|Drug|TNB-738|TNB-738 is an investigation drug. Other: Matching placebo
45760906|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 5 mcg/kg
45760907|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 10 mcg/kg
45618686|NCT03347435|Genetic|genetic tests for CYP2C19*2, CYP2C19*17 and ABCB1 3435|The CYP2C19*2 (10q24.1-q24.3; rs4244285), CYP2C19*17 (10q24.1-q24.3; rs12248560) and ABCB1 3435 (7q21.1; rs1045642) genetic variants will be genotyped using an ST Q3 system. The conventional genotyping methods so far used for diagnostic purposes will not be used in this study because appropriate labs may not be readily available and the processing time is prohibitive. Q3 is a compact platform enabling the classical laboratory analysis of DNA by means of real-time PCR. The Q3 has been designed as a low entry-cost, portable, point-of-care instrument for foolproof use by unskilled personnel. Antiplatelet therapy will be choose on the basis of clinical and genetic algorithm.
45618687|NCT03347435|Other|clinical algorithm|Antiplatelet therapy will be choose on the basis of clinical algorithm alone
45618688|NCT02453971|Other|German Version of eCHECKUP TO GO|It is an online prevention program targeting alcohol consumption.
45760908|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 20 mcg/kg
45760909|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 30 mcg/kg
45760910|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 5 mcg/kg
45618689|NCT05559047|Device|Eclipse novel CPAP mask|"Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring).~Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly."
45618690|NCT05559047|Device|Phillips Respironics Nuance|Participants will follow instructions to set up and put on the Respironics Nuance, traditional nasal mask. Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.
45618691|NCT03244423|Drug|Normal saline at induction|0.5 ml/kg
45618692|NCT03244423|Drug|Normal saline infusion|1ml/kg/hr. during surgery for six hours
45618693|NCT03244423|Drug|Intravenous tranexamic acid|50 mg/kg
45618694|NCT03244423|Drug|infusion tranexamic acid|1mg/kg/hr infusionfor 6 hours
45618695|NCT03244423|Drug|topical tranexamic acid|50 mg/kg added to the normal saline 2 ml/kg into the pericardial cavity before sternal closure
45760911|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 10 mcg/kg
45760912|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 20 mcg/kg
45760913|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 30 mcg/kg
45760914|NCT05213338|Device|Wear-documentation microchip|Microchip embedded in the appliance
45618696|NCT03244423|Drug|topical normal saline|2 ml/kg into the pericardial cavity before sternal closure
45911642|NCT05777720|Behavioral|Safe-home pamphlet|The pamphlet has information on how the filtration fans work through visual images; and images of ventilation improvements in the home through opening windows.
45911643|NCT05777720|Behavioral|Mid-week phone call|On day 3-4 of the study, the study coordinator assigned to the house will call and check in regarding the filtration fan usage and remind families about the importance of filtration and ventilation.
45911644|NCT05777707|Drug|PD-1 blockade|PD-1 blockade (Sintilimab/Camrelizumab/Toripalimab/Tislelizumab), 200 mg, IV., every 3 weeks, 2-3 cycles.
45618700|NCT03347357|Drug|Tacrolimus|Tacrolimus was administered orally at a dose of 0.05 mg/kg/dose twice daily (bid) for children with nephrotic syndrome.
45760915|NCT00835003|Procedure|Elective caesarean section|Procedure performed at 38 weeks and 3 days of gestation (+/- 2 days)
45760916|NCT00835003|Procedure|Elective caesarean section|Procedure performed at 39 weeks and 3 days of gestation (+/- 2 days)
45760917|NCT05207722|Biological|CYNK-101|CYNK-101 is a human placental hematopoietic stem/progenitor cell derived NK cell product, that is genetically modified to express a variant of CD16, Fc gamma receptor III (FcγRIII).
45760918|NCT05207722|Drug|Pembrolizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion.
45760919|NCT05207722|Drug|Trastuzumab|8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.
45760920|NCT05207722|Drug|Recombinant Human Interleukin-2|6 million (M) international units (IU) of rhIL-2 administered subcutaneously (SC) on each CYNK-101 infusion day.
45760921|NCT05207722|Drug|Cyclophosphamide|Cyclophosphamide: 900 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.
45760922|NCT05207722|Drug|Fludarabine|Fludarabine: 30 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.
45760923|NCT05207722|Drug|Mesna|MESNA: shall be administered as part of a 3-day lymphodepletion regimen for the inhibition of hemorrhagic cystitis induced by cyclophosphamide. Route of administration, dosage, and frequency of Mesna should be based on institutional standards.
45760924|NCT00860171|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Autologous stem cells given via central catheter
45760925|NCT00860171|Radiation|Iodine I 131 Monoclonal Antibody BC8|Given IV
45911645|NCT05777707|Drug|Albumin paclitaxel|Albumin paclitaxel, 300 mg/m2, IV., every 3 weeks, 2-3 cycles.
45760926|NCT00860171|Other|Laboratory Biomarker Analysis|Correlative studies
45760927|NCT05206240|Other|Radial extracorporeal shock wave therapy and conventional physical therapy|"The conventional physical therapy program will consist of verticalization strategies, range of motion exercises, muscle stretching and strengthening exercises, stance and balance training, core stability exercises, gait training, functional training, cryotherapy or local heat for 1h/day, 5 days/week for 2 weeks.~Regarding the rESWT delivery, 2000 shots will be applied on the triceps surae myotendinous junction with a frequency of 10 Hz and an energy density of 60 mJ, 7 min/session, 1 session/week for 2 weeks."
45760928|NCT00366418|Drug|Rituximab|
45760929|NCT03839303|Device|Infra-zygomatic Mini Implant Supported Appliance|"leveling and alignment of the four maxillary incisors~infra zygomatic mini-implant will be placed bilaterally~wire frame work that is designed resembling the inner bow of headgear will be adapted to the upper arch~a heavy arch wire engaging the 4 incisors will be attached to the wire frame work~orthopedic force will be delivered from the mini-implants to the wire frame work"
45760930|NCT03839303|Device|high pull head gear|"acrylic maxillary splint is made with flying tubes~high pull head gear is adapted to be inserted in the flying tubes"
45760931|NCT05184088|Drug|[18F]florbetaben|All enrolled patients will undergo [18F]florbetaben PET imaging.
45760932|NCT00860795|Biological|Echinacea purpurea|Echinacea purpurea 100 mg/ml, 25 ml daily in 2 divided doses for 10 days
45760933|NCT00860795|Drug|placebo|placebo 25 ml daily in 2 divided doses for 10 days
45760934|NCT00823043|Drug|timolol hemihydrate|timolol hemihydrate 0.5% solution
45911646|NCT05777707|Drug|Carboplatin/Nedaplatin|Carboplatin/Nedaplatin, area under the curve = 5, IV., every 3 weeks, 2-3 cycles.
45618701|NCT03239509|Procedure|bioprosthesis implantation between 2000-2015|Implantation of a bioprosthesis in aortic position with cardiopulmonary bypass
45618702|NCT03239509|Procedure|mechanical prosthesis implantation between 2000-2015|Implantation of a mechanical prosthesis in aortic position with cardiopulmonary bypass
45618703|NCT03346421|Behavioral|diet and physical activity|
45618704|NCT02325349|Drug|radiopharmaceutical (Flotegatide (18F) or RGD (68Ga)|PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
45618705|NCT02515877|Radiation|External radiotherapy + curietherapy|External radiotherapy: 45 Gy in 5 weeks Curietherapy: 15Gy
45618706|NCT02515877|Drug|Vistide|VISTIDE® (mg/kg) Level 1: 1mg/kg Level 2: 2,5 mg/kg Level 3: 5 mg/kg Level 4: 6,5 mg/kg
45618707|NCT02515877|Drug|Carboplatin|AUC= 2,5 (Calvert formula)
45760935|NCT00823043|Drug|timolol maleate|timolol maleate in sorbate
45618708|NCT03952091|Drug|TJ202, Lenalidomide and Dexamethasone|One dose of TJ202 will be given on Day 1 and Day 4 of Week 1, respectively, every week from Week 2 to Week 12, every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter.Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.
45760936|NCT05115760|Dietary Supplement|Dietary Supplement|Given Kate Farms pea protein oral nutrition supplement PO
45760937|NCT05115760|Other|Quality-of-Life Assessment|Ancillary studies
45760938|NCT05115760|Other|Questionnaire Administration|Ancillary studies
45760939|NCT03885167|Other|Specimen Collection|No interventions take place as part of study participation- only specimen collection occurs for both cohorts.
45760940|NCT05103514|Other|Online Survey|There are no interventions planned for this study. This is an observational study only.
45760941|NCT00861263|Device|overtube use during enteroscopy|use of overtube for the regular scheduled enteroscopy
45760942|NCT05083390|Drug|norUrsodeoxycholic acid|500 mg norUrsodeoxycholic acid or placebo film-coated tablets; 3 tablets/day
45618709|NCT03952091|Drug|Lenalidomide and Dexamethasone|Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg weekly will be administered.
45618710|NCT02234557|Behavioral|Tai Chi|"6-8 students will be enrolled in 8 weeks of Tai Chi instruction, with two 1-hour sessions per week. Students will be requested to practice from recorded materials at home three times a week for 15-30 minutes each session, and parents will be asked to keep a log of at-home practice.~Class sessions will consist of warm up (qi k'ong), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Practice will consist of warm up, followed by practice of selected pieces of the form.~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing pre-, mid- and postintervention)."
45618711|NCT03244501|Other|Active tSMS|A cylindrical neodymium magnet is placed above the scalp.
45618712|NCT03244501|Other|Sham tSMS|A cylindrical piece of nonferrous metal (brass). This is not attracted to magnets, and is identical in weight and appearance to active magnets.
45618713|NCT05555537|Diagnostic Test|MiRNA223 and High mobility group box1(HMGB1)|Measure tye 2 biomarkers miRNA223 and HMGB1 in drug resistant and in medically controled epilepsy
45618714|NCT03246919|Drug|Oxytocin|Oxytocin is administered after delivery of the fetal anterior shoulder, rather than being administered after delivery of the placenta
45760943|NCT05074030|Behavioral|Personalized Normative Feedback|Normative Feedback on drinking behaviors.
45760944|NCT05074030|Behavioral|Coping-Motive Specific Personalized Feedback Intervention plus an Ecological Momentary Intervention (PFIcope+EMI)|An EMA plus EMI intervention to decrease drinking to cope behaviors among emerging adults receiving psychiatric treatment.
45760945|NCT00862745|Drug|Fesoterodine|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
45760946|NCT00862745|Drug|Matching Placebo|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
45618715|NCT03246919|Drug|Placebo|Placebo will be administered after delivery of the placenta
45618716|NCT04502537|Drug|Roxadustat|Oral
45618717|NCT04502537|Drug|erythropoietin|injection
45760947|NCT05045404|Drug|Poziotinib Hydrochloride|"1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE~Given PO"
45911647|NCT05777694|Procedure|Patients who underwent cesarean section under spinal anesthesia with 25 gauge spinal needle|the investigators performed spinal anesthesia with 25 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
45618718|NCT03246997|Other|Autumn Group|The intervention is participating in a fruit and vegetable farm share for 6 months.
45618719|NCT03246997|Other|Spring Group|The intervention is participating in a fruit and vegetable farm share for 6 months.
45618720|NCT03347201|Device|HMS Plus|Subjects randomized to the intervention group will have their dose of Heparin and Protamine calculated by the HMS Plus.
45618721|NCT02453659|Behavioral|Distress Tolerance Treatment for Weight Concern (DT-W)|
45618722|NCT02453659|Behavioral|Health Education (HE)|
45618723|NCT02453659|Behavioral|Smoking Cessation counseling|
45618724|NCT02453659|Drug|Transdermal Nicotine Patch|
45618725|NCT02515799|Drug|Tacholiquine|Inhaled Tacholiquine ®1% - 5ml
45618726|NCT02515799|Other|Placebo|Inhaled Placebo
45618727|NCT02796313|Behavioral|DASH Groceries + Weekly Sessions|Intervention group participants will receive 1 hour of in-person nutritional counseling and a personalized prescription for the low-salt DASH diet based on estimated calorie needs at baseline, followed by weekly 20-minute phone calls in weeks 1-8 to provide extra support.
45618728|NCT02796313|Behavioral|Groceries + Brochure|Control group participants will receive a printed brochure about the health benefits of a low-salt diet. They will place an unrestricted $35 grocery order for 8 weeks.
45618729|NCT03802955|Drug|ADG106|IV infusion over 60 minutes on Day 1 of each cycle, at 7 doses depending on cohort at enrollment.
45618730|NCT03239431|Other|asthmatic exacerbation|evaluate the risk factors, frequency and nature of asthma exacerbations
45618731|NCT02513225|Behavioral|Project EMPWR|Participants will receive both Adapted Project EMPWR and Optimized Standard Care (OSC).
45760948|NCT05045404|Biological|1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE|"Biological/Vaccine Ramucirumab 947687-13-0, anti-VEGFR-2 fully human monoclonal antibody IMC-1121B, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2, ramucirumab, RAMUCIRUMAB~Given IV"
45445788|NCT03760107|Behavioral|Connect Smokers to Treatment 1|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
45618732|NCT02513225|Other|Optimized Standard Care (OSC)|Participants will receive Optimized Standard Care (OSC) alone.
45618733|NCT02515643|Other|Endothelial dysfunction|"One month before surgery and one year after, the following procedures will be performed in donors and recipients:~Blood samples will be obtained for the measurement of endothelial dysfunction and low grade inflammation markers.~Atherosclerotic burden: carotid ultrasound to determine the number of plaques and intima-media thickness, carotid-femoral pulse wave velocity (m/s) will be performed by pulse tonometry.~Ambulatory blood pressure monitoring with overnight-automated ABPM monitor~Estimation of glomerular filtration rate by Iohexol method"
45618734|NCT03246763|Behavioral|Integrated community-healthcare childhood obesity treatment|"The intervention will include nutrition and fitness programming at a local community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
45618735|NCT02512991|Other|Helicopter Emergency Medical Service|May 1st 2010, the first Danish Helicopter Emergency Medical System (HEMS) was implemented in Region Zealand and the Capital Region of Denmark.
45618736|NCT02513147|Drug|Dolutegravir|
45618737|NCT02513147|Drug|PI|(Fosamprenavir, atazanavir, lopinavir or darunavir) boosted with 100 mg of ritonavir, or atazanavir (400 mg / d) not boosted with ritonavir,if the 2 NRTIs are abacavir + Lamivudine
45618738|NCT02513147|Drug|2 NRTI|
45618739|NCT02513147|Drug|2 NRTI|
45618740|NCT02714881|Drug|certolizumab|Subjects who are about to start TNFi therapy as part of usual therapy will be enrolled. In this study we will provide the drug, certolizumab.
45618741|NCT02714881|Radiation|Stress myocardial perfusion PET|We will measure coronary flow reserve (CFR) using cardiac PET before the patients starts TNFi and 24 weeks after starting TNFi.
45760949|NCT03611309|Other|Surgeon-palliative care team co management|Surgeon-palliative care team co management includes surgeon alone care and palliative care specialist team
45760950|NCT03611309|Other|Surgeon team alone management|The surgeon and surgical team will manage
45760951|NCT02150759|Drug|Dexmedetomidine|dexmedetomidine infusion during spinal anesthesia
45760952|NCT02150759|Drug|Fentanyl|add dexmedetomidine during position change
45760953|NCT02150759|Drug|Ketamine|add dexmedetomidine during position change
45618742|NCT03121781|Other|respiratory support- interface|change interface to RAM cannula
45618743|NCT03121781|Other|respiratory support- interface|change interface to binasal prongs
45618744|NCT03246685|Biological|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
45618745|NCT03246685|Drug|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
45618746|NCT03121625|Biological|Autologous CAR-T|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
45760954|NCT05011864|Behavioral|Behavioral Activation|In BA, depressive symptoms are viewed as depressive behaviors. Compared to those without depression, people with depression engage in fewer overt behaviors that provide positive reinforcement and pleasure/enjoyment and in more behaviors that function to escape or avoid aversive stimuli (e.g., staying in bed all day).55-59 Thus, BA is aimed at increasing and reinforcing meaningful, healthy, and enjoyable behaviors while decreasing depressive behaviors and is well-suited to help depressed, disabled older adults increase mood-enhancing activities, self-care management skills, and social connectedness.
45760955|NCT05011864|Behavioral|Fall Prevention|Following FP psychoeducation based on the Centers for Disease Control and Prevention (CDC)'s STEADI tool kits, lay coaches will assist clients in implementing evidence-based FP strategies that have been adapted for low-income homebound seniors. These include referrals to healthcare providers as needed, home safety checks, practice of safe ambulation/transfer and mobility aid use, medication review, and in-home exercise routines with an innovative, gamified tablet-based exercise app for balance and strength building.
45760956|NCT05011864|Other|Telephone support|Subjects in this arm will receive 9 weekly support calls last 30 minutes each. These calls are intended to provide an opportunity for social support and check safety.
45618747|NCT02453893|Drug|Iloperidone|
45618748|NCT02453893|Drug|Risperidone|
45760957|NCT05003674|Device|Focused stimulation strategy|Investigational focused stimulation strategy
45760958|NCT05003674|Device|ACE stimulation strategy|Standard of care stimulation strategy
45760959|NCT02150837|Other|5 & 2 & 2 Plan|Medifast has developed the 5 & 2 & 2 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 5 & 2 & 2 Plan consists of 5 Medifast meal replacements, 2 Lean & Green meals, and 2 healthy snacks and provides 1,200-1,400 kcal, >72g protein, >100g of carbohydrate, and <30% of calories from fat. The Lean & Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack(s) included in this plans consists of a consumer selected serving of grain/starch, dairy, or fruit.
45618749|NCT03707093|Drug|ADG106|IV infusion over 60 minutes on Day 1 of each cycle, at doses of 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg,10 mg/kg or 300mg flat dose depending on cohort at enrollment.
45760960|NCT02150837|Other|4 & 2 & 1 Plan|Medifast has developed the 4 & 2 & 1 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 4 & 2 & 1 Plan consists of 4 Medifast meal replacements, 2 Lean & Green meals, and 1 healthy snack, providing 1,000-1,200 kcal, >72g protein, >100g carbohydrate, and <30% of calories from fat. The Lean & Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack included in this plans consist of a consumer selected serving of grain/starch, dairy, or fruit.
45618750|NCT03664895|Drug|Leuplin or zoladex|OFS(Leuplin or zoladex) add on to TMX
45618751|NCT03238885|Diagnostic Test|pelvic MR examination|All patients will take pelvic MR examination within 1 week before CRT and within 1 week before surgery.Pre- and post-CRT MRI examinations will be performed using a 3.0 T unit (Discovery 750) using an 8-channel phased array body coil in the supine position. To reduce colonic motility, 20mg of scopolamine butylbromide will be injected intramuscularly 30 min before MRI.
45618752|NCT02513069|Other|Nicotine gum|"Participants will be prescribed one form of nicotine replacement rescue treatment (i.e., gum, lozenge), and may choose nicotine gum as the preferred rescue treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings."
45618753|NCT02513069|Behavioral|mobile contingency management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided reinforcement for videos that suggest smoking abstinence.
45618754|NCT02513069|Behavioral|Telephone counseling|Participants receive five sessions of cognitive-behavioral telephone counseling, and a participant manual. The telephone counseling protocol included in this application is based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation and is informed by behavioral treatment principles .
45618755|NCT02513069|Other|Nicotine patch|Participants will be prescribed nicotine patches to be used during the post-quit phase of the study.
45618756|NCT02513069|Other|Nicotine lozenge|"Participants will be prescribed one form of nicotine replacement rescue treatment (i.e., gum, lozenge), and may choose nicotine lozenge as the preferred rescue treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings."
45618757|NCT02513069|Other|Smart phone|Participants in the experimental condition will be loaned a smart phone to use during the mobile contingency management intervention period. The phone will be used to record videos of carbon monoxide readings to determine smoking abstinence.
45618758|NCT02513069|Other|Carbon monoxide monitor|Participants in the experimental condition will be loaned a CO monitor to use during the mobile contingency management intervention period. The monitor will be used to determine carbon monoxide content in the breath as a measurement of smoking.
45618759|NCT03244111|Behavioral|simple memory tool|The goals may be implemented using the simple memory tool. Simple memory tool involves using materials such as checklists or diaries to assist with memory.
45618760|NCT03121703|Other|lumbar stabilization exercise|lumbar stabilization exercise
45618761|NCT03121703|Other|trunk muscle strengthening exercise|trunk muscle strengthening exercise
45618762|NCT02512835|Other|Community vital signs|We will present clinicians with information about their patients' communities
45760961|NCT04991350|Drug|Intravitreal ranibizumab|Intravitreal injection of 0.3 mg/0.05 ml ranibizumab will be performed monthly for 3 months.
45760962|NCT04991350|Drug|Intravitreal bevacizumab|Intravitreal injection of 1.25 mg/0.05 ml bevacizumab will be performed monthly for 3 months.
45760963|NCT00366496|Device|Acrysof single piece (SA60AT)|
45760964|NCT00366496|Device|Acrysof IQ (SN60WF)|
45760965|NCT00857545|Other|Laboratory Biomarker Analysis|Correlative studies
45760966|NCT00857545|Biological|Polyvalent Antigen-KLH Conjugate Vaccine|Given SC
45760967|NCT00857545|Biological|Saponin-based Immunoadjuvant OBI-821|Given SC
45760968|NCT04952194|Drug|Stalevo|The dose of Stalevo initially ranges from (Levodopa/Carbidopa/Entacapone) 50/12.5/200 mg 3 times a day to a target dose of 100/25/200 mg 5 times a day, with an interval of 3 hours. No other anti-Parkinson's disease drugs are added.
45760969|NCT04952194|Drug|Carbidopa and Levodopa Controlled Release Tablets|The dose of Carbidopa and Levodopa Controlled Release Tablets initially ranges from (Levodopa/Carbidopa) 50/12.5mg 3 times a day to a target dose of 100/25 mg 5 times a day, with an interval of 3 hours. No other anti-Parkinson's disease drugs are added.
45760970|NCT04930354|Drug|ECP-1014|Patients will be selected who (1) have failed all standard of care therapy (relapsed/refractory) or (2) have relapsed and are not a candidate for an available standard of care therapy as assessed by the investigator (such as, but not limited to, colorectal cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), head and neck, etc.) with COX-2 overexpression, ultimately resulting in elevated production of prostaglandin E2 (PGE2).
45760971|NCT00835159|Drug|Rivastigmine Patch|Rivastigmine Patch 4.6 mg/24 hours: 5 cm2 size containing 9 mg rivastigmine applied to upper back preoperatively for a period of 24 hours
45760972|NCT00835159|Other|Placebo Patch|A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.
45760973|NCT04927156|Device|BALT medical devices|"Includes, but is not limited to, the following:~Access devices~Aneurysm treatment devices~Ischemic Stroke and peripheral occlusive diseases treatment devices~Arterio-Venous Malformations/fistulas treatment devices"
45760974|NCT04860856|Drug|0.5% ropivacaine|The maximal single dose of ropivacaine without vasoconstrictor is 2-3 mg/kg.9 0.5% ropivacaine has 5 mg/mL of ropivacaine. 20 mL of 0.5% ropivacaine has 100 mg of ropivacaine. 100 mg of ropivacaine can be toxic to a patient less than 33-50 kg or 73-110 lb. If a patient weighs less than 110 lb, the ropivacaine dose will be scaled down below 2 mg/kg.
45760975|NCT04860856|Drug|Normal Saline|20ml of normal saline
45760976|NCT00827099|Biological|anti-thymocyte globulin|anti-thymocyte globulin
45760977|NCT00827099|Drug|fludarabine phosphate|fludarabine phosphate
45760978|NCT00827099|Drug|Melphalan|melphalan
45760979|NCT00827099|Drug|mycophenolate mofetil|mycophenolate mofetil
45618763|NCT02454205|Drug|Linezolid|600mg Linezolid po daily, reduced to 300mg po daily if toxicity occurs.
45618764|NCT02454205|Drug|Bedaquiline|400mg po daily for 2 weeks, followed by 200mg three times per week .
45618765|NCT02454205|Drug|Levofloxacin|750mg (<50kg) 1000mg (>50kg)
45618766|NCT02454205|Drug|Pyrazinamide|1000-1750mg (40-50kg) 1750-2000mg (51-70kg) 2000-2500mg (71-90kg)
45618767|NCT02454205|Drug|Isoniazid|high dose Isoniazid 500mg (40-50kg) 750mg (51-70kg) 750-1000mg (71-90kg)
45618768|NCT02454205|Drug|Ethionamide|15mg/kg (max 900mg)
45618769|NCT02454205|Drug|Terizidone|750mg (40-70kg) 750-1000mg (71-90kg)
45618770|NCT02454205|Drug|Moxifloxacin|400mg po daily.
45618771|NCT02454205|Drug|Kanamycin|500-750mg (40-50kg) 1000mg (51-90kg) intramuscular daily during 6-8 month intensive phase.
45618772|NCT03243877|Other|MammoAlert Screening Test|Plasma obtained from blood samples will be analyzed with the MammoAlert Screening Test for the presence of known breast cancer bio-markers.
45760980|NCT00827099|Drug|tacrolimus|tacrolimus
45760981|NCT00827099|Procedure|umbilical cord blood transplantation|umbilical cord blood transplantation
45760982|NCT00366574|Device|Amadeus Microkeratome|
45760983|NCT00366574|Device|IntraLase|
45760984|NCT00366652|Drug|desvenlafaxine SR|
45760985|NCT00366652|Drug|desipramine|
45760986|NCT00366652|Drug|duloxetine|
45760987|NCT00366730|Drug|Nitazoxanide|
45760988|NCT02617888|Radiation|CCTA ~ BREAST SHIELDS|Breast shield placement (randomized) among women.
45760989|NCT02618512|Drug|SBC-103|SBC-103 is a recombinant human alpha-N-acetylglucosaminidase (rhNAGLU). Patients were started with low dose of SBC-103 for 12 weeks and then will escalate to a higher dose.
45760990|NCT02620774|Drug|Ceftolozane/tazobactam|3 or more doses of ceftolozane/tazobactam intravenously administered over 60 minutes every 8 hours
45760991|NCT02620774|Procedure|Microdialysis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
45445789|NCT03760107|Behavioral|Connect Smokers to Treatment 2|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
45618773|NCT02515721|Device|pCLE-TB|Patients will receive white-light endoscopic imaging, followed by probe-based Confocal Laser Endomicroscopy scanning on suspected lesions and 5 standardized locations. Then targeted Biopsies will be performed on locations with intestinal metaplasia, intraepithelial neoplasia, and carcinoma.
45618774|NCT02515721|Device|virtual chromoendoscopy-TB|Patients will receive virtual chromoendoscopy using iScan. Standard biopsies will be performed on all suspected lesions and standardized loctaions.
45618775|NCT03238729|Behavioral|Heart Failure Education and Management App|Patients will be provided with an app on a smartphone that provides a daily checklist with items like reminders for logging weight and food, as well as educational components about heart failure and it's management.
45618776|NCT03238729|Behavioral|Heart Failure Literature|Patients will be provided standard literature about heart failure and the management of heart failure.
45618777|NCT03489707|Behavioral|Home-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 1 will receive an HPV DNA home-based collection kit in the mail at 0 and 12 months.
45618778|NCT03489707|Behavioral|Clinic-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 2 will attend a clinic where a clinician will collect the DNA specimen at 0 and 12 months.
45618779|NCT02515409|Device|HHHFNC|After the treatment with CPAP fails, the participants will use HHHFNC as a treatment for OSAS.
45618780|NCT02515409|Device|CPAP|CPAP, as a first line treatment in OSAS.
45618781|NCT03235063|Other|routinely care- no intervention|routinely care- no intervention
45618782|NCT02515487|Other|Brain Fitness Program (BFP)|The program is designed to improve processing speed of auditory information and attention. The BFP is comprised of six computerized subtests that continuously adjust in the level of difficulty to maintain an 85% correct response rate. The subtest exercises include discrimination of confusable syllables, recognition of sequences of syllables, matching pairs of confusable syllables, reconstruction of sequences of verbal instructions and identification of details in a verbally presented story. Participants will participate in 40 one-hour training sessions over a 12 week period to complete all cognitive remediation training sessions. Since this intervention is presented both visually and verbally, noise cancelling headphones will be provided to the participants.
45911648|NCT05777694|Procedure|Patients who underwent cesarean section under spinal anesthesia with 26 gauge spinal needle|the investigators performed spinal anesthesia with 26 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
45618783|NCT04486339|Radiation|Stereotactic Radiotherapy|Stereotactic radiotherapy targets on the pulmonary vein ostium aiming to achieve pulmonary vein electrial isolation
45618784|NCT03243799|Behavioral|Group psychoeducation|Educational group sessions for patients with depression and physical comorbidities in order to improve the degree of control of their illnesses
45618785|NCT03345251|Device|Hydrotubation|
45445790|NCT03760107|Behavioral|Connect Smokers to Treatment 3|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
45445791|NCT03760107|Behavioral|Connect Smokers to Treatment 4|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
45445792|NCT03760107|Behavioral|Connect Smokers to Treatment 5|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
45618786|NCT03235141|Drug|azithromycin eye drops by essex|azithromycin eye drops,2.5ml/25mg,by ZHUHAI ESSEX BIO-PHARMACEUTICAL),
45618787|NCT03235141|Drug|azithromycin eye drops|azithromycin eye drops,2.5ml/25mg ,by Oak Pharmaceuticals, Inc subsidiary of Akorn, Inc
45760992|NCT00857857|Drug|GW870086X|Investigational product
45760993|NCT00857857|Drug|FP|Positive control
45760994|NCT00857857|Drug|Placebo|Placebo control
45760995|NCT02622178|Diagnostic Test|Optical Coherence Tomography|Optical coherence tomography (OCT) is a noninvasive imaging modality that provides micrometer-scale resolution.It has been revolutionized in recent years by exploitation of Fourier domain (FD) techniques, which have a significant sensitivity advantage over traditional time domain (TD) OCT. In spectral-domain (SD-OCT) the reference mirror is stationary, and OCT signal is acquired using a spectrometer as detector or by varying the wavelength of the light source.
45911649|NCT05777694|Procedure|Patients who underwent cesarean section operation under spinal anesthesia with 27 gauge spinal needle|the investigators performed spinal anesthesia with 27 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
45911650|NCT05777681|Procedure|Aortic Surgery|open surgical repair with resection of infected aortic segment, debridement of surrounding tissue and in situ graft replacement.
45911651|NCT05777668|Radiation|Volumetric modulated radiotherapy|
45618788|NCT03403361|Device|Siemens Somatom Definition Edge|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study. These additional scans will be acquired utilizing the FDA-approved workflow and scanner operating modes. Sinogram data will be exported in raw, minimally processed form utilizing proprietary data export and processing tools provided to the investigators by the scanner vendors. In no case, will the additional local imaging dose (in terms of CTDIvol) given to the patients by the two or three additional scans exceed 6 cGy per session
45618789|NCT03403361|Device|Philips Brilliance Big Bore CT/simulator|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study. These additional scans will be acquired utilizing the FDA-approved workflow and scanner operating modes. Sinogram data will be exported in raw, minimally processed form utilizing proprietary data export and processing tools provided to the investigators by the scanner vendors. In no case, will the additional local imaging dose (in terms of CTDIvol) given to the patients by the two or three additional scans exceed 6 cGy per session
45618790|NCT03234751|Drug|Continous IV infusion of Nesiritide|Nesiritide (fhBNP) administered by continuous IV infusion during 48 hours.
45618791|NCT03234751|Drug|Hyperinsulinemic euglycemic clamp|48 hours IV infusion of nesiritide on insulin sensitivity (IS) measured by two-step hyperinsulinemic euglycemic clamp in obese nondiabetic insulin resistant subjects.
45618792|NCT03234751|Drug|Placebo|48 hours of placebo.
45760996|NCT02622178|Diagnostic Test|Visual evoked potential|Visual evoked potential is a means of objectively testing visual field by viewing a computer monitor at 1 meter with a square black/white checkerboard pattern reversal stimulus. Electrodes are placed on the head and face to monitor Electroencephalogram (EEG) activity during testing. Output parameters from VEP system include amplitude and latency measures for each stimuli.
45760997|NCT02623348|Behavioral|pedometer|pedometer-based physical activity recommendations
45760998|NCT02625298|Device|ProRoot MTA|Apical thirds of the root canals obturated with ProRoot MTA (Dentsply Tulsa Dental Specialties, Tulsa, OK USA).
45760999|NCT02625298|Device|MTA+ Cerkamed|Apical thirds of the root canals obturated with MTA + (Cerkamed, Stalowa Wola, Poland).
45761000|NCT02625844|Other|No intervention|No intervention administered in this study.
45761001|NCT00858013|Drug|Nateglinide|Nateglinide 90~120mg three times a day
45445793|NCT03760107|Behavioral|Connect Smokers to Treatment 6|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
45618793|NCT03397589|Behavioral|Community Health Worker (CHW) services|CHWs are non-clinical people who provide education, care coordination, and support to families.
45761002|NCT00858013|Drug|Glimepiride|Glimepiride 1~2mg once a day
45761003|NCT02626156|Device|Cooling gel pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cooling gel pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
45761004|NCT02626156|Device|Cooling cotton pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cotton filled pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
45761005|NCT00835861|Drug|Metformin|Women randomized to the Experimental arm will receive standard diet and glucose self-monitoring education. They will be initiated on Metformin 500 BID if they were medication naïve, or will be continued on their current dosage of Metformin if they were taking it prior to pregnancy. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to a maximum of 2250mg/day to achieve target glycemic control. If glycemic control can not be achieved with Metformin as a single agent insulin will be added.
45761006|NCT00835861|Drug|Insulin|Women randomized to the Insulin group will receive standard diet and glycemic monitoring education. They will be initiated on weight based Regular and NPH insulin at a total dosage of 0.7units/kg in the first trimester or 0.8units/kg in the second trimester divided as 2/3 of the total dosage (with 2/3 given as NPH and 1/3 given as Regular) administered before breakfast and 1/3 of the total dosage (with 1/2 given as NPH and 1/2 given as Regular)administered with dinner. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to achieve optimal glycemic control with fasting values <90 and one hour post prandial values <130.
45761007|NCT04339660|Biological|UC-MSCs|1*10E6 UC-MSCs /kg body weight suspended in 100mL saline
45761008|NCT04339660|Other|Placebo|100mL saline intravenously
45761009|NCT02627794|Device|Restora™ Steroid eluting spacer|The Restora™ Steroid eluting spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
45761010|NCT02627794|Device|Silastic Silicone Spacer|The Silastic Silicone Spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
45761011|NCT00804973|Drug|LY2590443|200 milligrams (mg) as four 50-mg capsules, oral, once
45445794|NCT03878979|Drug|Nivolumab 480mg and surgical resection|One dose of Nivolumab 480mg given four weeks prior to surgical resection.
45761012|NCT00804973|Drug|Placebo injection|saline solution, injection, once
45761013|NCT00804973|Drug|Sumatriptan|6 milligrams (mg) injection (0.5 milliliter [mL] of 12 mg/mL solution), once
45761014|NCT00804973|Drug|Placebo capsule|4 capsules, once
45618794|NCT03243565|Biological|OM-85|OM-85 is an oral bacterial lysate of 21 different strains of 8 species and sub-species of the most common respiratory tract pathogens.
45618795|NCT03243565|Biological|Placebo|Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate
45618796|NCT04486105|Dietary Supplement|sucrose|pure sucrose in water in addition to habitual diet
45618797|NCT03369197|Device|Nasal Mask|Nasal anesthesia mask which covers the nose and attaches to the anesthesia circuit, allowing for variable positive pressure by setting the pop-off valve
45761015|NCT02628106|Drug|Lipo-PGE1|all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days
45761016|NCT02628964|Device|e-cigarettes|Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.
45618798|NCT03369197|Device|Control: Nasal Cannula|Nasal cannula as per usual care
45618799|NCT03107689|Other|administration of intravenous lipid emulsion|all patients receive intravenous lipid emulsion at the discretion of the treating provider. This registry prospectively collects detailed information on such patients
45618800|NCT03234673|Drug|Tacrolimus ointment|3 sessions of fractional CO2 laser one month apart Patients will start treatment Tarolimus ointment twice daily for 3 months.
45618801|NCT03234673|Drug|calcipotriol ointment|3 sessions of fractional CO2 laser one month apart Patients will start treatment Calcipotriol ointment twice daily for 3 months.
45761017|NCT00836017|Other|No Intervention|No intervention was administered as part of the study.
45445795|NCT03765957|Biological|Mesenchymal Stem Cells|After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjetcts of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. Besides MSCs, moisturizers such as boric acid ointment will be given to all subjects.
45761018|NCT02629354|Drug|Ibuprofen|
45761019|NCT02629354|Drug|Caffeine|
45761020|NCT02629354|Drug|Ibuprofen|
45761021|NCT02834247|Drug|TAK-659|TAK-659 Tablets.
45761022|NCT02834247|Drug|Nivolumab|Nivolumab intravenous infusion.
45761023|NCT00859027|Drug|risedronate|35 mg/week by mouth
45761024|NCT00859027|Drug|Placebo risedronate oral tablet|One tablet by mouth every week as directed
45618802|NCT03234673|Drug|NB-UVB|3 sessions of fractional CO2 laser one month apart Patients will start treatment NB-UVB phototherapy twice weekly for 3 months
45618803|NCT03148613|Device|Carbon Monoxide Breath Sensor System (COBSS)|Carbon Monoxide Breath Sensor System (COBSS): Device to measure carbon monoxide levels in one's breath and inform the user.
45618804|NCT03148613|Device|Bedfont - Micro+™ Smokerlyzer®|Bedfont - Micro+™ Smokerlyzer® : Predicate Device to measure carbon monoxide levels in one's breath.
45618805|NCT03243643|Drug|HS-10241|HS-10241 is provided as white, film-coated,immediate release tablets containing HS-10241 at dosage strengths of 20mg/50mg/100 mg. Multiple tablets of HS-10241 will be administered daily to achieve targeted doses of HS-10241: 200 mg-1200 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
45618806|NCT03243643|Drug|Apatinib|Apatinib is provided as white, film-coated,immediate release tablets containing aptinib at dosage strengths of 250mg. Apatinib will be administered daily to achieve targeted doses of 500 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
45618807|NCT03243487|Behavioral|structured adherence management program|Structured adherence management service (PAMS) program and a web-based information program designed for participants beginning positive airway pressure therapy
45618808|NCT03243487|Behavioral|Standard of care|Standard care provided at a VA Sleep Center for participants beginning positive airway pressure therapy
45618809|NCT03238261|Radiation|Chemotherapy and concomitant radiotherapy|Radiotherapy (teletherapy + high or low rate brachytherapy)
45618810|NCT03237949|Behavioral|Phone counseling|Four telephone counseling sessions using a motivational interviewing approach
45618811|NCT03237949|Behavioral|Text message|30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages follows the self efficacy theory. The messages follows the self efficacy theory.
45761025|NCT02630992|Drug|Amoxicillin-Clavulanate potassium|
45761026|NCT05072067|Procedure|the sleeve gastroplasty with the endoscopic system Overstich SX|the sleeve gastroplasty with the endoscopic system Overstich SX
45761027|NCT05071131|Dietary Supplement|Inulin|1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days
45761028|NCT05071131|Dietary Supplement|Placebo|1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days
45761029|NCT00836407|Drug|Ipilimumab|Ipilimumab (10mg/kg) will be administered intravenously at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
45761030|NCT00836407|Biological|Pancreatic Cancer Vaccine|The Pancreatic Cancer Vaccine (5E8 cells) will be administered intradermally at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
45618812|NCT04485793|Dietary Supplement|Dietary supplement|"Dietary supplement formulated with 400 mg Bergamot d.e. obtained from different parts of the Citrus Bergamot whole fruit (Citrus bergamia Risso et Poiteau, fructus), specifically from fresh fruits collected from November to February (Brumex TM).~Oral administration: 1 tablet/day at evening meal"
45761031|NCT02631772|Drug|Sofosbuvir/Ledipasvir x 12 weeks|
45761032|NCT02631772|Drug|Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks|
45761033|NCT02633488|Drug|Placebos|A 12 week single blind placebos
45761034|NCT02633488|Drug|metformin|A 12 week single blind metformin
45761035|NCT05722353|Other|Biocollection|Collection of blood samples and feces specimen at inclusion visit; clinical and biological assessment at each visit.
45445796|NCT03770247|Procedure|Intraoperative celiac plexus neurolysis|neurolysis of celiac plexus by intraoperative techniques
45618813|NCT04485793|Other|Placebo|Oral administration: 1 tablet/day at evening meal
45618814|NCT03234517|Drug|Vaginal Clindamycin Cream|Vaginal Clindamycin Cream
45618815|NCT03234517|Drug|Vaginal Probiotic|Vaginal Probiotic
45618816|NCT02453815|Procedure|non-cardiac surgery|all surgical procedures except cardiac
45618817|NCT02453815|Other|arterial catheter|arterial catheter
45618818|NCT03238105|Drug|Thioglycolic Acid|Monthly sessions for 3 months with progressive increase of the duration of contact time of the drug with the skin, 3, 6 and 9 minutes.
45618819|NCT03238105|Device|Intense Pulsed Light|Monthly sessions for 3 months.
45618820|NCT03243721|Diagnostic Test|7T MRI|A high field MRI that will take approximately one hour.
45618821|NCT03243721|Diagnostic Test|Neurocognitive testing|A series of tests to assess memory, verbal skills, and visuospatial skills.
45618822|NCT03234439|Behavioral|myStrength|myStrength is a digital self-care behavioral and wellness platform
45761036|NCT00859339|Drug|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
45761037|NCT00859339|Drug|Cisplatin|Cisplatin (70 mg/m2) IV day 1
45761038|NCT00859339|Drug|Sunitinib Malate|Sunitinib malate (37.5 mg) oral daily for days 1-14
45761039|NCT00859339|Procedure|Radical Cystectomy|Radical cystectomy performed no sooner than 2 weeks but within 6 weeks of the last dose of sunitinib malate.
45761040|NCT05032599|Biological|CD5 CART|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m^2/day and cyclophosphamide at 250 mg/m^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.
45761041|NCT00859495|Drug|Doxorubicin|A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.
45761042|NCT00859495|Drug|Cisplatin|Platinum-based antineoplastic
45761043|NCT00859495|Drug|Pemetrexed|Folate Analog Metabolic Inhibitor
45618823|NCT03243253|Other|all the data collection have done by CDC.|In this study there was no intervention, just simple data collection via CDC.
45911652|NCT05777655|Other|Medication management app (mediteo m+, Mediteo GmbH, Heidelberg)|Free access to a study version of the medication management app mediteo m+ for reminders and documentation of statin therapy in addition to usual care
45911653|NCT05777642|Dietary Supplement|Oxygen Nanobubble|This contains oxygenated nanobubbles made from lecithin and natural flavourings (Liquorice, glycerol, and citric acid)
45445797|NCT03770247|Procedure|CT guided celiac plexus neurolysis|Neurolysis of celiac plexus percutaneously by CT guidance
45911654|NCT05777642|Dietary Supplement|Placebo|This does not contain nanobubbles and is made from natural flavourings (Liquorice, glycerol, and citric acid)
45911655|NCT05777590|Drug|Indocyanine Green Angiogram|Angiogram using ICG dye the occurs directly after conventional angiogram in assessment of frostbite patients undergoing thrombolysis
45911656|NCT05777577|Dietary Supplement|probiotic therapy|probiotic including bifidobacterium
45445798|NCT03240003|Behavioral|GC-MRT|Group 1 will receive a 4-week (8-sessions) course of GC-MRT
45445799|NCT03240003|Behavioral|modified GC-MRT|group 3 will receive a 4-week (8-sessions) course of GC-MRT, modified
45445800|NCT03240003|Behavioral|Non-GC-MRT|Group 2 will receive a 4-week (8-sessions) course of non-GC-MRT
45445801|NCT03770325|Drug|Berberine|Purified berberine (500 mg orally twice a day) in tablets for 12 weeks
45445802|NCT03770325|Drug|Placebo|Placebo tablets, prepared with the same appearance, for 12 weeks
45445803|NCT03765801|Drug|GRTA9906 60 mg PR tablet|GRTA9906 60 mg PR tablet
45618824|NCT03238183|Drug|dextrose|compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
45618825|NCT03238183|Device|hyaluronic acid|compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
45618826|NCT02729051|Drug|FF/UMEC/VI|This intervention is provided in two strips. First strip contains FF blended with lactose. It is available as dry white powder, 100 mcg per blister. Second strip contains UMEC and VI blended with lactose and magnesium stearate. It is available as dry white powder, 62.5 mcg per blister UMEC, 25 mcg per blister VI. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (2 strips with 30 blisters per strip).
45618827|NCT02729051|Drug|FF/VI|This intervention is provided in two strips. First strip contains FF blended with lactose. It is available as dry white powder, 100 mcg per blister. Second strip contains VI blended with lactose and magnesium stearate. It is available as dry white powder, 25 mcg per blister. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (2 strips with 30 blisters per strip).
45618828|NCT02729051|Drug|UMEC|This intervention is available in one strip. The strip contains UMEC blended with lactose and magnesium stearate. The formulation is available as dry white powder, 62.5 mcg per blister. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).
45618829|NCT02729051|Drug|Placebo|This intervention is available in one strip. The strip contains lactose. The formulation is available as dry white powder. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).
45618830|NCT02729051|Drug|Albuterol/salbutamol|This is a rescue medication administered via metered-dose inhaler (MDI) with a spacer which will be used when needed during the study.
45761044|NCT00859495|Radiation|Radiotherapy|Standard procedure given 3 weeks after last dose of chemotherapy
45761045|NCT05722041|Procedure|Immediate dental implant placement|Placement of one dental implant immediately after tooth extraction.
45761046|NCT05029635|Drug|HMPL-523|HMPL-523 will be oral administrated once daily for 24 weeks
45761047|NCT05029635|Drug|Placebo|HMPL-523 matching placebo will be oral administrated once daily for 24 weeks .
45761048|NCT00355719|Drug|Atazanavir (Reyataz)|Atazanavir (Reyataz): capsules 150 mg (2 capsules/24h)
45761049|NCT00355719|Drug|Ritonavir (Norvir)|Ritonavir (Norvir): capsules 100 mg (1 capsule/24h)
45761050|NCT00355719|Drug|Nevirapine (Viramune)|Nevirapine (Viramune): tablets 200 mg (1 tablet/12h*)
45618831|NCT03234283|Device|IRRIS InfraRed - Red Intubation System|IRRIS will be attached to the patient's neck skin just beneath the laryngeal prominence. Tracheal intubation will be performed by using a video-laryngoscope in a standardized Fashion and by guiding the tracheal tube into the Larynx by following the visual Signal on the Screen that is caused by IRRIS. The handling of IRRIS and the Performance of tracheal Intubation will be recorded. Patients will be monitored for safety parameters and possible adverse events during the study until recovered and released from the postoperative care unit.
45618832|NCT03234205|Device|MRI scan|"MRI standard protocol with addition of:~a second clinical respiratory belt besides belt usually installed for clinical examination~a second clinical electrocardiogram sensor besides sensor usually installed for clinical examination~12 sequences during free respiration are added lasting supplementary 15 minutes~Use of cardiac antennae usually used for cardiac MRI scans"
45618833|NCT03237637|Drug|oral propranolol|oral propranolol 1-2mg/kg/day as crushed tablets in two divided doses
45618834|NCT03237637|Drug|oral atenolol|oral atenolol 0.5-1mg/kg/day as crushed tablets in a single dose
45618835|NCT03243331|Drug|Gedatolisib|Gedatolisb will be intravenously administered on Day 1, Day 8 and Day 15 of every 21 day cycle at a dose of 110 mg or 180mg depending on cohort assignment.
45618836|NCT03243331|Drug|PTK7-ADC|PTK7-ADC will be administered on Day 1 of every 21 day cycle at a dose of 1.4mg/kg or 2.8 mg/kg depending on cohort assignment.
45618837|NCT03237715|Other|Assessment of unbound bilirubin levels|Collection of residual blood for measurement of unbound bilirubin
45618838|NCT02453035|Device|PTCA - Desolve Scaffold|Percutaneous Coronary Artery Intervention with a DESolve bioresorbable coronary scaffold
45618839|NCT05621603|Behavioral|Training|"The proposed intervention for the school workforce draws on a mental health integrated disaster preparedness model, emphasizing peer support, developed and used successfully by our team working with communities experiencing multiple disasters.~The 3 hour training is comprised of 4 modules - Module 1: Emergency Preparedness Module 2: Psychological Preparedness Module 3: Peer Support Module 4: Shared Leadership and Feedback Session"
45445804|NCT03765801|Drug|GRTA9906 60 mg IR capsule|GRTA9906 60 mg IR capsule
45618840|NCT03237793|Procedure|Fluorosed Group|A single episode of laser therapy with without potassium nitrate (RA Thermoseal*) desensitising agent application was administered to the patients, A group only with desensitising paste and A group with desensitising paste and laser treatment depending on the study group they were assigned
45618841|NCT03237793|Procedure|Non Flourosed Group|A single episode of laser† therapy with or without potassium nitrate (RA Thermoseal*) desensitising agent application was administered to the patients, depending on the study group they were assignedGROUP 2B: Patients with healthy non fluorosed teeth receiving diode laser treatment$. (n=15)GROUP 2C: Patients with healthy non fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA thermoseal**) treatment.
45618842|NCT02507453|Other|parabolic flight|
45618843|NCT02507453|Other|mass/weight perception estimation|estimate the mass/weight perception, expressed by verbally report the absolute and relative mass of the object using a scale from 1 to 10 (1 being light and 10 being heavy)
45618844|NCT02507453|Device|ESA short-arm human centrifuge (SAHC)|
45618845|NCT02515565|Drug|cephalosporin with or without erythromycin|Second- or third-generation cephalosporin (cefuroxime, cefotaxime, or ceftriaxone) with or without erythromycin, given parenterally; parenteral therapy should continue until the patient has been afebrile for more than 24 hours and oxygen saturation exceeds 95 percent.
45618846|NCT02515565|Other|Physiotherapy program|The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes added to the standard medical treatment. I will include breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
45618847|NCT03234049|Other|Checklist|The Alberta Children's Hospital Trauma Checklist was developed by the ACH Resuscitation Council Trauma Committee in response to a quality assurance review of high-acuity trauma activations. It is a cognitive aid and focuses in particular on pre-arrival preparation and a pre-departure review prior to patient transfer to diagnostic imaging or the operating room.
45618848|NCT05600075|Drug|microneedling with topical glycolic acid 35%.|15 patients will be subjected to microneedling with topical glycolic acid 35%. Selected patients will receive one session of microneedling combined with a topical agent, with two weeks interval till complete clearance or up to 6 sessions.
45761051|NCT00859651|Drug|Cholecalciferol|"Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each."
45618849|NCT05600075|Drug|microneedling with topical human insulin solution.|15 patients will be subjected to microneedling with topical human insulin solution. Selected patients will receive one session of microneedling combined with a topical agent, with two weeks interval till complete clearance or up to 6 sessions.
45618850|NCT03234127|Genetic|Whole Genome Sequencing|Whole Genome Sequencing Biomarkers analyses
45618851|NCT02512601|Drug|Sulodexide|Sulodexide (two capsules of Sulodexide 15 mg twice daily).
45761052|NCT00859651|Drug|Placebo capsule|Matching placebo capsules
45761053|NCT02815761|Other|NO intervention, just observation|No intervention.
45445805|NCT03765645|Drug|Piperacillin + Tazobactam|Antibiotic used will be Piperacillin + Tazobactam Dose: 4.5 g, thrice a day at regular intervals Route: Intra-venous
45445806|NCT03223935|Other|Corn nuts|Roasted corn nut snack
45445807|NCT03223935|Other|Chickpeas|Roasted chickpea snack
45445808|NCT03223935|Other|Yellow peas|Roasted yellow pea snack
45445809|NCT03223935|Other|Pinto beans|Roasted pinto bean snack
45445810|NCT03223935|Other|Soybeans|Roasted soybean snack
45445811|NCT03223935|Other|Almonds|Roasted almond snack
45618852|NCT02512601|Other|Compression therapy|"Compression:~With an orthosis: Compression 22-29 mmHg, length of 20 cm above the DVT area.~With a bandage: 7-10 m long and 10 cm wide.~Both strategies (orthosis vs bandage) are equally applicable."
45761054|NCT02811705|Other|Quality of life|Quality of life
45761055|NCT02633956|Drug|Obeticholic Acid|Once a day (QD) by mouth (PO)
45911657|NCT05777564|Other|High intensity exercise|High intensity exercise on a indoor aerobic exercise device.
45618853|NCT03233815|Drug|Propofol|Propofol anesthesia Dose: 4-6mg/kg/h
45618854|NCT03233815|Drug|Sevoflurane|Inhaled anesthesia with sevoflurane. Dose: 1-2.5 Minimum Alveolar Concentration(MAC)
45618855|NCT02507609|Other|Moderate neuromuscular blockade|TOF count is maintained to 1 to 2 by intermittent intravenous injection of rocuronium bromide 5 mg during operation
45618856|NCT02507609|Other|Deep neuromuscular blockade|PTC is maintained to 1 to 2 degree by continuous infusion of rocuronium bromide intravenous route
45761056|NCT02633956|Drug|Atorvastatin|"Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).~Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.~Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated."
45911658|NCT05777538|Other|hydrotherapy|Hydrotherapy will be performed by immersing the women's foot in a container filled with 3 liters water with a temperature of 30-32°C. The water level must cover the women's feet up to ankle. During the immersion the therapist will ask the women to perform exercise with legs being fully supported, then alternatively stretch and flex the ankle for 30 times. which will be followed by circling each foot at ankle in clock wise and anticlock wise direction, 30 times each. The duration of water immersion session will be (30 min) for 5 consecutive days.
45445812|NCT03765489|Device|electrical muscle stimulation|electrical muscle stimulation: The parameters used in biceps were: 35 Hz, 250 μs and in quadriceps were: 50 Hz, 400 μs. In both, biphasic wave was used, 45 minutes of total work, 5 seconds of contraction and 10 seconds of relaxation and the intensity was adjusted to present a visible contraction
45618857|NCT03233971|Other|rPATD Questionnaire|A 5-point Likert scale questionnaire consisting of 22 questions for older adults, and 19 questions of caregivers.
45618858|NCT02512367|Other|Dental care education program|Dental care education program
45618859|NCT02512367|Other|Surveillance|Surveillance
45618860|NCT03237403|Other|observational study|observational study between clinical criteria collected at SAMU regulation centre call and hospital orientation
45618861|NCT02512523|Drug|Teneligliptin|
45618862|NCT02512523|Drug|Sitagliptin|
45618863|NCT03233893|Other|light activated calcium silicate|"for the first group light activated calcium silicate can be easily placed by a 20 second light cure and ability to be syringed directly on to the cavity preparation and restore the cavity by composite restoration.~for the second group using light activated calcium hydroxide is placed by placing a disposable tip securely on to the syringe then light cure for 20 seconds depending on the light cure unit and restore the cavity with composite restoration."
45618864|NCT05597813|Procedure|microneedling|15 patients will be subjected to microneedling alone. Selected patients will receive one session with two weeks interval till complete clearance or up to 6 sessions.
45618865|NCT05597813|Procedure|microneedling with topical timolol 0.5%|15 patients will be subjected to microneedling with topical timolol 0.5%.Selected patients will receive one session with two weeks interval till complete clearance or up to 6 sessions.
45761057|NCT02633956|Drug|Placebo|Once a day (QD) by mouth (PO)
45761058|NCT02802423|Drug|BLEX 404 Oral Liquid|BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.
45761059|NCT02800161|Drug|Trehalose|Trehalose 70g/die
45761060|NCT02800161|Drug|Maltose|Maltose 70g/die
45761061|NCT00836641|Biological|prevenar|7-valent pneumococcal conjugate vaccine
45761062|NCT00836641|Biological|pneumovax|23 valent pneumococcal polysaccharide vaccine
45618866|NCT03233581|Behavioral|Fitbit + Facebook + Coaching Group|Participants will use the FitBit device to track their physical activity (PA). Participants will receive and post messages and receive badges on the Facebook group. Weekly a research staff member will call them to provide brief health coaching. Participants will select an adult family member or friend to also receive a Fitbit during the intervention period to provide support.
45618867|NCT03233581|Behavioral|Fitbit only|Participants will receive a Fitbit device only, and will not receive health coaching, join the Facebook group, or select an adult family member or friend to receive a Fitbit to provide them with support.
45618868|NCT04499261|Procedure|laparoscopic surgery|Patients were supine in a reverse Trendelenburg position and received intravenous inhalation combined with anesthesia. The patients' legs were spread apart. A carbon dioxide pneumoperitoneum was established. The intermittent Pringle's maneuver was carried out when necessary. Five trocars were placed in a fan shape around the lesion. Cholecystectomy was performed routinely. First, the liver was mobilized. Then, the liver parenchyma was transected and the branches of the hepatic veins and pedicles encountered were clipped and divided. The lesion was meticulously separated from the vascular structures and liver parenchyma and completely resected. The raw surface was treated with bipolar coagulation to achieve hemostasis and repeatedly washed until no bleeding or bile leakage was confirmed. Finally, the specimens were packed in a specimen bag and removed. The raw surface was packed with biological hemostatic materials, and drainage tubes were routinely placed.
45761063|NCT05721963|Diagnostic Test|No interventions.|No interventions.
45761064|NCT02693067|Drug|Rose bengal disodium|Percutaneous intralesional injection to NET tumor
45761065|NCT00806221|Drug|emollient (Cetaphil cream)|Cetaphil cream applied daily from birth
45618869|NCT04499261|Procedure|Open surgery|Patients were placed in the supine position and received intravenous inhalation combined with anesthesia. The intermittent Pringle's maneuver was carried out when necessary. Routinely, a reversed L-shape incision was performed. Cholecystectomy was performed routinely. First, the liver was mobilized. Then, the liver parenchyma was transected and the branches of the hepatic veins and pedicles encountered were clipped and divided. The lesion was meticulously separated from the vascular structures and liver parenchyma and completely resected. The raw surface was treated with bipolar coagulation to achieve hemostasis and repeatedly washed until no bleeding or bile leakage was confirmed. Finally, the specimens were packed in a specimen bag and removed. The raw surface was packed with biological hemostatic materials, and drainage tubes were routinely placed.
45618870|NCT02512133|Device|MIGS Hydrus Ivantis|implant of the micro stent in the nasal Schlemm's canal
45618871|NCT02512133|Procedure|360 degrees SLT|Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ
45618872|NCT02512289|Device|tDCS (ELDITH) and RAT (REAplan)|Transcranial direct-current stimulation( ELDITH) and Robot-assisted therapy by using REAplan
45618873|NCT03107767|Procedure|PRO-malleol algorithm|An evidence based algorithm for ankle fractures
45445813|NCT03765489|Procedure|conventional physical therapy|"conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al"
45618874|NCT02507063|Procedure|ultrasound|Ocular ultrasound to look at the optic nerve sheath diameter in patients with an intracranial monitoring device or with a ventriculoperitoneal shunt malfunction requiring revision
45618875|NCT03233503|Diagnostic Test|Basic taste, fat sensation and texture perception|"This is an observational Sensory study methodologically similar to Astringency and bitterness perception clinicalTrials.gov identifier NCT03171402 Participants are first involved in sensory training sessions that train how they recognise between different basic tastes and differentiate perceived intensity in solutions and foods. After 6 months of training, the trained participants are involved in tasting a wide array of commonly consumed foods. At this study phase, participants will rate for the foods' taste, fat sensation perception and texture"
45618876|NCT04497623|Device|Invasive mechanical ventilation using the Unisabana-Herons Ventilator during 24 hours|Recruited patients will receive volume-controlled mechanical ventilation (assist-control mode) using the Unisabana-Herons ventilator for 24 hours. Information on clinical, hemodynamic, and respiratory variables will be recorded from 30 minutes before the start of mechanical ventilation with the Unisabana-Herons ventilator. Recordings will be made in the first 4 hours every 15 minutes in the CFR, except for arterial blood gases which will be taken every 30 minutes. In the following 20 hours, arterial blood gas controls will be taken at hour 12 from the start of the ventilator and at hour 24. Other hemodynamic and respiratory variables will be recorded every hour from hour 4 of ventilator start until hour 24.
45618877|NCT03242785|Other|Self-monitoring/Self-titration|"The intervention of the ADAMPA trial is not pharmacological but an intervention that modifies usual clinical practice. The intervention of self-monitoring and self-titration of the medication is composed of 3 elements:~Education of the patient: information and training on hypertension, its risks, management, the benefits of an adequate control and the generic measures for an optimal control.~Training for self-monitoring: Patients will be trained to perform the self-measurement of blood pressure correctly (and recording their values in the sheet enabled for this purpose)~Training for self-titration: patients will be instructed on the target BP numbers, individualized for each patient, on the mode of action against specific figures, including self-adjustment of drug treatment."
45618878|NCT03242707|Biological|Autologous adipose tissue injection|"20ml to 40ml of subcutaneous adipose tissue will be aspirated from the abdomen. Adipose tissue will be processed using the Lipogems device, a closed-loop processing device used in medical procedures involving the harvesting, concentrating and transferring of autologous adipose tissue.~The resulting fat product will be delivered locally via ultrasound-guided, intra-articular injection."
45618879|NCT03242707|Drug|Hyaluronic Acid|Synvisc-One® is a high molecular weight sodium hyaluronate.
45618880|NCT02511977|Other|peri-implant examination|The prostheses were removed and all implants were evaluated: probing depth, plaque index and bleeding index.
45618881|NCT03242629|Drug|oral chloral hydrate|Chloral hydrate syrup was available in a concentration of 100 mg×ml-1.The children assigned to receive 0.8 ml×kg-1 of chloral hydrate (80 mg×kg-1) by oral.
45618882|NCT03242629|Drug|enema chloral hydrate|Chloral hydrate syrup was available in a concentration of 100 mg×ml-1 at our hospital.The children assigned to receive 0.8 ml×kg-1 of chloral hydrate (80 mg×kg-1) by enema.
45618883|NCT02452723|Biological|ISC-hpNSC|
45618884|NCT02512055|Drug|Ketamine|Repeated ketamine 2 mg/kg administration intravenously for sedation during each radiotherapy sessions
45618885|NCT02514941|Drug|paracetamol|Administration of 5 ml Paracetamol Saft Hexal (= 200 mg paracetamol)
45618886|NCT02514941|Drug|amoxicillin|Administration of 5 ml Amoxypen® 250 mg Saft (= 250 mg amoxicillin)
45618887|NCT02514941|Drug|talinolol|Administration of 1 tablet Cordanum® 50 (= 50 mg talinolol) dissolved with 40 ml tap water
45445814|NCT03765411|Procedure|Proctectomy|Resection of the rectum
45618888|NCT02514941|Procedure|gastroduodenoscopy with biopsy|Gastroduodenoscopy with biopsy of the lower duodenum before the first pharmacokinetic study period
45618889|NCT02514941|Procedure|gastrojejunoscopy with biopsy|Gastrojejunoscopy with biopsy of the jejunum about one year after proximal Roux-en-Y gastric bypass
45618890|NCT02514941|Procedure|proximal Roux-en-Y gastric bypass|sampling of a tissue specimen from the jejunum during the operation
45618891|NCT02511743|Other|physicians|physicians taking care of patients with chronic Hepatitis B Virus infection, without intervention
45445815|NCT03759483|Diagnostic Test|AI diagnostic algorithm|The visual fields collected would be assessed by the algorithm and ophthalmologists independently. The performance of the algorithm and the ophthalmologists would be compared, including accuracy, AUC, sensitivity and specificity.
45618892|NCT02515019|Device|Bispectral index Monitoring|In group SevoBIS, the sevoflurane concentration was titrated to maintain a target BIS value between 40 and 60.
45618893|NCT02511665|Drug|Metformin|Given metformin
45618894|NCT02511665|Radiation|PET-MRI Scan|Patients will under go 2 PET-MRI scans in the PET-MRI substudy arm one before treatment with metformin and one after
45618895|NCT02511665|Drug|Placebo|Given placebo
45618896|NCT03233269|Behavioral|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment via a prerecorded video. The Music Therapist will then engage the patients in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
45618897|NCT03242551|Drug|Chemotherapy|"AC followed by T Chemotherapy with or without trastuzumab, i.e. Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days."
45618898|NCT02511821|Other|Computer-Assisted Intervention|Complete online surveys
45618899|NCT02511821|Device|Vivofit watch|Wear Vivofit watch
45618900|NCT02511821|Other|Quality-of-Life Assessment|Ancillary studies
45618901|NCT02511821|Other|Questionnaire Administration|Ancillary studies
45618902|NCT03242473|Other|Fluid Management|The patient will remain NPO for at least the first 24 hours. The following studies will be obtained at the time of admission if not previously obtained in the ED: CMP, GGT, Amylase, Lipase, Triglycerides, CBC, and CRP, along with an abdominal ultrasound. CBC, CRP, BMP, amylase and lipase levels will be obtained at 24 and 48 hours (+/- 2 hours). SIRS status will be evaluated with vital sign checks every 4 hours and the leukocyte counts every 24 hours.
45618903|NCT02514629|Drug|Placebo|
45618904|NCT02514629|Drug|Metformin|
45618905|NCT02514629|Drug|Testosterone Undecanoate|
45618906|NCT02514629|Drug|Metformin + Testosterone Undecanoate|
45618907|NCT03237091|Other|bihemispheric transcranial pulsed current stimulation (tPCS)|Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
45618908|NCT03237091|Other|unihemispheric transcranial pulsed current stimulation (tPCS)|One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
45618909|NCT03237091|Other|bihemispheric transcranial direct current stimulation (tDCS)|Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
45618910|NCT03237091|Other|unihemispheric transcranial direct current stimulation (tDCS)|One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
45618911|NCT03237091|Other|sham-control|Sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply stimulation to the scalp via the sponges for 1-2 minutes. The stimulator will then be turned off.
45445816|NCT03765255|Other|In the Know: sexual health education|The in-person sessions include modules on: sexual and reproductive health (2 hours - anatomy, gender and sexual orientation, pregnancy, contraception, sexually transmitted infections); healthy relationships and life skills (2 hours - communication and negotiation, consent, violence, online dating, goal setting, strengths); and educational and career success (2 hours - educational and career options, applying for scholarships and financial aid, job readiness, resume preparation, interview skills). The app includes: online referrals, personal life plans/goal setting, text message reminders, quizzes, and other resources.
45618912|NCT02511899|Dietary Supplement|Mango fruit powder|Dietary supplement; Mango fruit powder
45618913|NCT02511509|Device|Bifrontal electroconvulsive therapy|The centre of each electrode will be placed 4-5 cm above the outer canthus of the eye along a vertical line perpendicular to a line connecting the pupils.
45618914|NCT02511509|Device|Bitemporal electroconvulsive therapy|The centre of the stimulus electrodes will be applied 2-3 cm above the midpoint of the line connecting the outer canthus of the eye and the external auditory meatus on each side of the individual's head.
45761066|NCT02634814|Device|Transcutaneous Electrical Nerve Stimulation|TENS is FDA approved for the purposes in which we will be applying the modality (21CFR882.5890; http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=882.5890, these TENS Units have been acquired by the PI, who is a licensed Allied Health Professional in the state of North Carolina).
45911659|NCT05777538|Other|foot exercises|The therapist will ask the women to perform exercise with legs being fully supported, then alternatively stretch and flex the ankle for 30 times. which will be followed by circling each foot at ankle in clock wise and anticlock wise direction, 30 times each.
45761067|NCT02634814|Other|Therapeutic Exercise|Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program. The intervention will consist of 10 45-minute sessions.
45761068|NCT02634814|Device|Sham Transcutaneous Electrical Nerve Stimulation|"Sham TENS+TE patients will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN) specifically configured to cease TENS current output 20 seconds after the participants initiation. For blinding purposes, patients will be told that they should feel a brief stimulation (~20 seconds) that will become sub-sensory in nature. The participants will wear the Sham TENS for 8 hours per day."
45911660|NCT05777525|Combination Product|"application of cream La Chinata"|application of cream enriched with essential oil
45445817|NCT01321671|Drug|Pregabalin controlled release, 330 mg, 600- 750 calorie|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
45761069|NCT04345029|Dietary Supplement|Dietary supplement consumption|"The experimental product consumption time was 60 days and the control consumption time was 60 days.~Each subject must consume both products, with a washing period of 30 days."
45618915|NCT04485715|Other|AI system|The real-time assistance of AI system
45618916|NCT02511353|Drug|ivermectin|
45618917|NCT02511353|Drug|placebo|Placebo for ivermectin.
45618918|NCT02511353|Drug|dihydroartemisinin-piperaquine|
45618919|NCT03242317|Drug|Mitomycin C|The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.
45618920|NCT03242317|Device|Raindrop Near Vision Inlay|The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominant eye for the improvement of uncorrected near vision.
45618921|NCT02514317|Procedure|percutaneous treatment|
45618922|NCT02514317|Device|Ultrasound|
45618923|NCT02453503|Drug|Licorice|licorice mucoadhesive films evey 6 hours for two weeks
45618924|NCT02453503|Drug|Triamcinolone Acetonide|Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
45618925|NCT04499651|Behavioral|Navigation|Trained study navigators will provide one-on-one learning sessions and accompaniments to criminal-justice involved people to help link them to HIV/Hepatitis C care
45618926|NCT02514395|Other|disability index administration -self report form|Final T12 version of KOOS was given to the participants by an assistant who was not involved with any prior procedure. At the same time SF- 36 v2[32] generic health measure was also handed over. Filled forms were collected by the same assistant. Next day participants were given another blank copy of Marathi KOOS T12 versions. Hence each participant filled three forms.
45618927|NCT03233425|Behavioral|multiprofessional group therapy|Behavioural therapy of lifestyle including activity, family and eating habits
45618928|NCT03242161|Diagnostic Test|LabPatch-alcohol|a wearable, non-invasive biosensor Band-Aid like patch that is designed to detect real-time changes in interstitial alcohol concentrations in human subjects after they have consumed alcohol
45618929|NCT03242083|Other|quality of life questionnaire|quality of life questionnaire
45618930|NCT04499885|Device|Paraffin oil gastric lavage|Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution
45618931|NCT04499885|Device|Gastric lavage with saline and sodium bicarbonate 8.4%|Gastric lavage with saline and sodium bicarbonate 8.4%
45618932|NCT03233113|Behavioral|Exposure therapy|"Exposure therapy (i.e., exposure-based cognitive behavioral therapy) for spider phobia according to condition-specific, scripted treatment manuals inspired by evidence-based exposure programs for anxiety/phobias (for both arms: Abramowitz, Deacon, & Whiteside, 20011; Antony, Craske, & Barlow, 1995) as well as the seminal account of the judicious use of safety behaviors thesis (for the experimental arm only: Rachman, Radomsky, & Shafran, 2008). Exposure and response prevention involves confronting a live spider while resisting safety-seeking behaviors; exposure with judicious safety behaviors involves strategically using safety behaviors while confronting a live spider."
45618933|NCT02511275|Procedure|Renal microdialysis|Renal microdialysis is an innovative and promising technique in the monitoring of renal ischemia. Its sterile nature enables intraoperative use to give us real-time reflection of the in situ metabolism. In Patients who participated in clinical research with this microinvasive technique, no complications including bleeding has been reported.
45618934|NCT02453425|Other|MAP 60 mmHg|Norepinephrine adjusted to reach MAP 60 mmHg
45761070|NCT02635828|Drug|Palonosetron 0.075 mg IV|At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.
45761071|NCT02635828|Drug|Dexamethasone 10 mg IV|At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.
45911661|NCT05777499|Behavioral|Music Therapy|Music Therapy will comprise individual and group sessions 20-45 minutes. Participants usually have 1-2 individual sessions, and 1 group session/week. Group sessions include 2-6 participants. On average, participants receive an average 1 hour 30 minutes Music Therapy/week, timetabled when they would not otherwise be undergoing any therapy sessions. The Music Therapist will use the Nordoff Robbins approach and work flexibly as a musician. Techniques include (but are not limited to) empathic listening, musically matching, turn taking and sequencing, call and response. Sessions may also involve songwriting, singing familiar songs, listening to, sharing and discussing music, developing specific musical skills of interest to the participant, structured musical games and activities, joint working with other members of the therapy team in sessions focused on functional development and communication skills.
45445818|NCT01321671|Drug|Pregabalin controlled release, 330 mg, fasted|A single oral dose of 330 mg controlled release tablet administered fasted in the evening
45618935|NCT02453425|Other|MAP 75 mmHg|Norepinephrine adjusted to reach MAP 75 mmHg
45618936|NCT02453425|Other|MAP 90 mmHg|Norepinephrine adjusted to reach MAP 90 mmHg
45618937|NCT02511197|Drug|68Ga-NOTA-PRGD2|68Ga-NOTA-PRGD2 were injected into the patients before the PET/CT scans
45618938|NCT02511197|Device|PET/CT|
45761072|NCT02635828|Drug|Promethazine 25 mg IV|At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.
45761073|NCT00836719|Drug|Polyphenon E|Polyphenon E capsules containing 200 mg of Epigallocachin-galleate. Two capsules twice a day.
45445819|NCT01321671|Drug|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered in the evening
45618939|NCT02453269|Behavioral|Transdisciplinary program|
45618940|NCT04499105|Drug|Mesenchymal Stem Cell + NaCl 0,9% 2ml|Patients enrolled in Cipto Mangunkusumo Hospital with degenerative disc disease with no promising result after conventional treatment.
45618941|NCT03236701|Other|Egg White replacement|Nutritional intervention: the meat or fish of two meals will be replaced twice a week with an equivalent amount (in protein content) of egg white.
45618942|NCT02511041|Drug|N-Acetylglucosamine (GlcNAc)|N-acetylglucosamine (GlcNAc), 2-acetamino-2-deoxy- <=-Dglucose, or 2- acetylamino)-2- deoxy-D-glucose, is a monosaccharide derivative of glucose. It is classified as dietary supplement in the United States. In general, it is a white and slightly sweet powder that melts at 221 degrees C. The solubility of GlcNAc is 25% in water, and 1% aqueous solutions are colorless and clear. GlcNAc is contraindicated for patients receiving warfarin, chemotherapy or diabetes drugs. As GlcNAc may interfere with blood sugar control during and after surgery, it is contraindicated during the two weeks prior to major surgery.
45618943|NCT02511041|Drug|Uridine|Uridine 5 -monophosphate (UMP) disodium salt is a water soluble colorless crystalline powder which melts at 202oC.
45618944|NCT03233035|Drug|Ketamine|25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril is received
45618945|NCT03233035|Drug|Placebo|0.5 mL of normal saline solution as a placebo in one pulverisation per nostril
45618946|NCT02514161|Other|Inspiratory Muscle training|This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)
45618947|NCT02514161|Other|IMT + Manual Therapy and Motor Control Exercise|The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
45618948|NCT03236467|Behavioral|Progressive Exercise Training|Designed to ease primarily sedentary individuals into exercise training, increasing in intensity up to 80% of maximum Heart Rate Range over time.
45618949|NCT03242239|Biological|ALT02|
45618950|NCT03242239|Biological|EU-licensed Herceptin|
45618951|NCT03242239|Biological|US-licensed Herceptin|
45618952|NCT02514005|Other|Manual therapy|- Manual Therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.
45618953|NCT02514005|Device|Dry needling|"Manual therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.~Dry needling (DN). Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps."
45618954|NCT03232957|Procedure|50 ug IT morphine|Spinal block with bupivacaine and intrathecal morphine 50 ug
45618955|NCT03232957|Procedure|100 ug IT morphine|Spinal block with bupivacaine and intrathecal morphine 100 ug
45618956|NCT03232957|Procedure|No IT morphine|Spinal block with bupivacaine and intrathecal morphine 0 ug
45618957|NCT03232957|Drug|Morphine|intrathecal morphine
45618958|NCT03232957|Drug|Bupivacaine|0.5 isobaric bupivacaine
45618959|NCT02513849|Drug|Tamoxifen|Daily tamoxifen tablet for approximately 4 weeks
45618960|NCT03232879|Behavioral|Motor Imagery|Two consecutive 30 seconds imagery tasks were performed, both based on two movements that are recorded in the Revised Movement Imagery Questionnaire (MIQ-R).
45618961|NCT03232879|Behavioral|Action Observation|Two consecutive 30 seconds imagery tasks were performed, both based on two movements that are recorded in the Revised Movement Imagery Questionnaire (MIQ-R). Before the subjects performed the mental MI practice, they were presented with a 30 seconds video that displayed the task that they ought to imagine later. A video was played prior to the first practice of imagination and after the second mental practice, a second video was shown.
45618962|NCT02513927|Drug|metoprolol|Metoprolol was given orally in a dose of 95 mg/day to treat patients in the metoprolol group for 12 weeks.
45618963|NCT02513927|Drug|Nifedipine|Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
45618964|NCT03241849|Procedure|Modified surgical technique for placenta accreta|suturing of the myometrium splitted by the placenta in cases presented by placenta accreta
45618965|NCT03242005|Device|MiniMed® Pro-set®|Utilization of the MiniMed® Pro-set® to administer the subject's current insulin therapy.
45618966|NCT03242005|Device|MiniMed® Quick-set®|Utilization of the MiniMed® Quick-set® to administer the subject's current insulin therapy.
45618967|NCT03236623|Other|Menthol Popsicle|The menthol popsicle composed of 0.05% menthol, 0.05% saccharin, 30ml ultrafiltered water and 2% cereal alcohol. The popsicle will have a support that will assist the patient in the administration of the intervention, giving him autonomy and safety in the application of the intervention.
45618968|NCT05560841|Device|topical treatment|Topical application of Nailner brush 2in1 for toenail onychomycosis
45618969|NCT03320837|Dietary Supplement|Infant formula|Breast milk substitute containing synbiotics
45618970|NCT03320837|Other|Breast milk|Breast milk
45618971|NCT03107221|Behavioral|"Smart Eating internet-based self-help programme"|An internet-based self-help programme using cognitive behavioural therapy principles to treat individuals receiving input from a specialist eating disorders service. The programme takes 3 months to complete.
45618972|NCT02510651|Procedure|Melanocyte-keratinocyte suspension|Treatment of non-segmental vitiligo by CO2 laser followed by melanocyte-keratinocyte suspension.
45618973|NCT03236389|Device|Q Collar|measuring changes in brain during MRI while wearing the Q collar
45618974|NCT03121313|Drug|tegafur-uracil|
45618975|NCT03236233|Drug|PC786 - Single doses|Safety and tolerability of single doses
45618976|NCT03236233|Drug|Placebo - Single doses|Safety and tolerability of single doses
45618977|NCT03236233|Drug|PC786 - Repeat doses|Safety and tolerability of repeat doses
45618978|NCT03236233|Drug|Placebo - Repeat doses|Safety and tolerability of repeat doses
45618979|NCT02510729|Device|Neurostimulation|
45618980|NCT02510729|Device|Sham stimulation|
45618981|NCT02513693|Drug|Standard neuromuscular blockade|Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
45618982|NCT02513693|Drug|Deep neuromuscular blockade|Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
45618983|NCT03241615|Other|Dysphagia evaluation|Dysphagia evaluation is performed in a clinical setting by an eating assessment tool. Swallowing related quality of life is also assessed.
45618984|NCT03232723|Diagnostic Test|Whole-cortex MEG System (with optional EEG)|"Whole-Cortex MEG System non- invasively measures the magnetoencephalographic (MEG) signals (and, optionally, electroencephalographic EEG signals) produced by electrically active tissue of the brain. These signals are recorded by a computerized data acquisition system, displayed, and may then be interpreted by trained physicians to help localize these active areas. The location may then be correlated with anatomical information of the brain. MEG is routinely used to identify the locations of visual, auditory, somatosensory, and motor cortex in the brain."
45618985|NCT03121547|Drug|Tapentadol 50 mg Oral Tablet|1 tablet administered
45445820|NCT03770013|Drug|bupivacaine|bupivacaine 0.25% a total volume of 40 ml (20 ml each side
45618986|NCT03121547|Drug|Tramadol Hydrochloride 100 mg Extended Release Oral Tablet|1 tablet administered
45618987|NCT03121547|Drug|Placebo Oral Tablet|calcium tablet
45618988|NCT03241381|Diagnostic Test|vitamin D serum assay study and control groups|Serum- vitamin D assay
45618989|NCT03241381|Diagnostic Test|Photometry|Serum- Hemoglobin assay
45618990|NCT03241381|Other|Russels periodontal index|Clinical examination for periodontitis
45618991|NCT02510807|Other|Pedometer|The use of a pedometer will demonstrate improvement in the following health outcomes in patients with PAD by acting as a method of surveillance to improve compliance with a walking regimen
45618992|NCT02454049|Dietary Supplement|beetroot juice|6mmol nitrate
45618993|NCT02454049|Dietary Supplement|sodium nitrate|6mmol sodium nitrate
45445821|NCT03770013|Drug|Dexmedetomidine|Dexmedetomidine 0.5 mcg/kg
45445822|NCT03770013|Drug|clonidine|1ug/kg clonidine
45445823|NCT03770013|Drug|placebo|add placebo 9normal saline)
45445824|NCT03759249|Other|Sleep medical treatment|"The participant ungo Standard Sleep medical diagnostics. If a sleep disorder is diagnosed in the interventional Group the applicable therapy is conducted.~If the participant is randomized in the waiting Group the applicable Therapy is initiated after study completion."
45618994|NCT02454049|Dietary Supplement|water|plain water
45618995|NCT03241303|Drug|Acarbose|Glucobay tablets on experimental day.
45618996|NCT03241303|Drug|Placebo Oral Tablet|Placebo tablets on experimental day.
45618997|NCT03241303|Drug|Exendin (9-39)|Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.
45618998|NCT03241303|Drug|Placebo Saline|9 mg/ml placebo saline infusion on experimental day.
45618999|NCT02510963|Drug|Tenofovir Disoproxil Fumarate|Use Tenofovir at 24week of gestation
45619000|NCT02510963|Drug|Tenofovir Disoproxil Fumarate|Use Tenofovir at 28week of gestation
45619001|NCT02510963|Drug|Tenofovir Disoproxil Fumarate|Use Tenofovir at 32week of gestation
45619002|NCT03241147|Drug|Lu AF35700|Single dose, 10 mg film coated tablet
45619003|NCT02513381|Other|Vitamin D3, 3200IU|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
45619004|NCT02513381|Other|Placebo|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
45619005|NCT03236155|Drug|opioid pain pills|patient will receive their pain pill prescription
45619006|NCT04499417|Device|Electromyostimulation Whole-Body-Workout|Electromyostimulation - intensity 5 (muscle stimulation)
45619007|NCT04499417|Device|Electromyostimulation Sham Whole-Body-Workout|Electromyostimulation - intensity 0 (no muscle stimulation)
45619008|NCT03235921|Drug|Nitroglycerin patch 5mg|application of the nitroglycerin patch 5 mg to each patient in nitroglycerin group
45619009|NCT03235921|Other|placebo|no drug given to the control group
45619010|NCT02510339|Other|Observation|Administration of two questionnairs during post operative visits.
45619011|NCT03232021|Drug|Placebo oral capsule|Placebo oral capsule administered 1 hour prior to the surgical operation
45619012|NCT03232021|Drug|Pregabalin Oral Capsule [Lyrica] 75mg|Pregabalin Oral Capsule [Lyrica] 75 mg administered 1 hour prior to the surgical operation
45619013|NCT03232021|Drug|Pregabalin Oral Capsule [Lyrica] 150 mg|Pregabalin Oral Capsule [Lyrica] 150 mg administered 1 hour prior to the surgical operation
45619014|NCT04499183|Dietary Supplement|fructo- and galacto-oligosaccharides|15 gram/day fructo- and galacto-oligosaccharides
45761074|NCT05721885|Behavioral|nutrition management|Nutritional management was performed by clinical pharmacists and registered dietitians to develop nutritional intervention strategies based on patient clinical assessment and nutritional assessment. PG-SGA score was 0-3 points, and diet guidance was given. PG-SGA score > 4 points, artificial nutrition intervention was carried out, and the way and amount of nutritional intervention were clarified to achieve the final daily energy and protein target requirements. Nutritional interventions and assessments were adjusted over time.
45619015|NCT02510495|Procedure|"30 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 30 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
45619016|NCT02510495|Procedure|"60 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 60 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
45619017|NCT02510495|Procedure|"180 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 180 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
45619018|NCT02510495|Procedure|"300 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 300 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
45619019|NCT03235843|Device|AAIR pacing|Rate adaptive pacing using a MV sensor.
45619020|NCT03235843|Device|DDI-pacing|Rate adaptive pacing OFF
45619021|NCT04486183|Other|capillary blood samples|The patient's finger was wiped with alcohol, left to dry, and the first and second blood drops were read The patient was asked to wash their hands, their finger was perforated with a strip, and the first and second blood drops were read The finger of the patient whose hands had been washed was wiped with alcohol, left to dry, and the first and second blood drops were read Venous blood was collected for blood sugar measurement 2 hours after the patient had a beverage containing 75 gr sugar for OGTT The patient was ensured to wash their hands, their finger was wiped with alcohol, and the first and second blood drop glucose values were measured and recorded
45619022|NCT02510183|Device|Acupressure Wrist Band|Acupressure wrist band is a knitted elasticated wrist band, which operates by applying pressure on the P6 acupressure point on each wrist by means of a plastic stud.
45761075|NCT02638168|Drug|Immediate Release Methylphenidate|The medication assessment procedure will be a double-blind, within-subject evaluation of placebo and matching evening dose of IR MPH rounded to the nearest 2.5mg increment with a max IR MPH dose of 0.3mg/kg. Expected evening dose range will be from 2.5mg to 20mg with most participants receiving between 5 to 15mg per evening dose. Dose will be determined based on current dose of their morning extended release stimulant
45619023|NCT02510183|Device|Placebo Acupressure Wrist Band|Placebo Acupressure Wrist Band is a knitted elasticated wrist band without a plastic stud.
45619024|NCT03235609|Drug|Fentanyl|fentanyl used with propofol for sedation
45619025|NCT03235609|Drug|Ketamine|ketamine used with propofol for sedation
45761076|NCT02638168|Drug|Placebo|inert placebo ingredient
45761077|NCT00837031|Drug|Lenalidomide|The starting dose of lenalidomide for the lead-in portion will be 25 mg orally daily on Days 1-21, followed by a 7-day rest period (28-day cycle). If the 25-mg dose of lenalidomide is found to be intolerable or unsafe (i.e., if more than one of the 6 patients experience a DLT), then the dose will be reduced to 20 mg orally daily, and 6 additional patients will be treated. All patients will receive lenalidomide at the confirmed tolerable dose (either 25 mg or 20 mg given orally daily on Days 1-21 of a 28-day cycle) until disease progression. If the 20-mg daily dose is found to be intolerable or unsafe, enrollment will be put on hold.
45761078|NCT00837031|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV will be administered on Days 1, 8, and 15 for a 28-day cycle.
45445825|NCT03769935|Drug|cis Platinum, etoposide, S1|"cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.~S1 25 mg/m2 oral, everyday until progression disease"
45619026|NCT02509871|Other|Body composition measurement|DXA, impedance
45761079|NCT02973880|Drug|NETILDEX™ ophthalmic gel|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) ophthalmic gel immediately after the surgery then 1 drop twice daily (b.i.d.) from Day 1 until Day 14 after surgery + 1 drop of XANTERGEL™ ophthalmic gel twice daily (b.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
45619027|NCT02510105|Device|VDR4 ventilator (Intrapulmonary Percussive Ventilation)|
45619028|NCT02510105|Device|CT scan|
45619029|NCT02510105|Device|Servo-i|
45619030|NCT02510105|Device|- Intubation|
45619031|NCT02510105|Device|Ventilation ( with an ICU conventional ventilator)|
45619032|NCT02509949|Drug|Dexmedetomidine|
45619033|NCT02509949|Drug|Saline|
45619034|NCT02510027|Other|HPV screening and triage tests|All cervical and/or vaginal specimens are tested for hrHPV using the Cobas® 4800 HPV test. Triage testing will be performed on all participants with a positive HR-HPV test declared consent at recruitment visit: HPV16/18 genotyping, Cobas® 4800 HPV test, HPV16/18/45 genotyping, BD OnclarityTM HPV Assay, OncoE6 Cervical Test, Liquid based cytology with Papanicolaou stain and p16INK4a/ Ki-67 immunostain.
45619035|NCT02509715|Procedure|Intraoperative nerve monitoring|Intraoperative nerve monitoring during thyroid surgery
45935008|NCT00213421|Drug|Dermoval|group 1 elevated corticosteroids : attack treatment 2 tubes of 10g (4t/d) decreasing treatment : one month: 2 tubes/J (2t/d); 2 months : 2 tubes 1d sur 2 (1d/j); 4 months : 2 tubes 2 fois /week (0,6t/d); 4 months : 2 tubes 1 fois /week (0,3t/d)fois /week (0,3t/d) group 2 low corticosteroids : for paucibullous form with weight < 45kg attack treatment 1 tubes of 10g (1t/d)decreasing treatment 1 month : 1 tube every 2d (0,5t/d; 1 month : 1 tubes 2 fois /week (0,3t/d) 1 month : 1 tubes 1 fois/week (0,15t/d); for paucibullous form with weight > 45kg or for multibullous form with weight < 45kg attack treatment 2 tubes of 10g (2t/d)decreasing treatment 1 month : 2 tubes every 2j (1t/d; 1 month : 2 tubes 2 fois /week (0,6t/d) 1 month : 2 tubes 1 fois /week (0,3t/d)and for multibullous form attack with weigth > 45kg treatment 3 tubes of 10g (3t/d)decreasing treatment 1 month : 3 tubes every 2days (1,5t/d) 1 month : 3 tubes 2 fois /week (1t/j)1 mois : 3 tubes 1 fois /week (0,45t/d)
45619036|NCT03344783|Other|PUFA and R-TFA|PUFA and R-TFA exposure were assessed mainly from maternal dietary, blood sample or breast milk. Exposure period was restricted to early life. Dietary PUFA and R-TFA were measured by food-frequency questionnaire (FFQ) or diet history questionnaire (DHQ). The profile of PUFA and R-TFA in the blood sample and breast milk were examined by using gas chromatography
45619037|NCT02509637|Device|Flutter|Flutter is a small device, simple, like a plastic pipe with a mouthpiece at one end and a perforated cover on the other, containing a steel ball resting in a plastic cone inside. When the patient exhales through the flutter expiratory flow causes movement of the ball, creating an oscillatory positive pressure.
45445826|NCT03769857|Dietary Supplement|NEM® + BIOCURC®|Dietary supplement combination for the support of joint health.
45619038|NCT02509637|Other|Chest Compression|Manual chest compression is based on the application of forces resulting from the action of respiratory muscles or physiotherapist manual action in order to increase the alveolar pressure creating a pressure gradient to promote change in pulmonary flow and volume.It consists of vigorous compression of the chest at the beginning of expiration or during expiration.
45445827|NCT03769857|Dietary Supplement|Placebo|Placebo
45619039|NCT02509637|Other|Control|
45619040|NCT02509637|Other|Impulse Oscillometric|"For this measure will be used IOS Jaeger (Jaeger, Wurzburg, Germany). to minimize the effect of the bad positioning of the tongue will use a mouth free-flow, which contains a depressant for keeping the tongue in the mouth soil, stabilizing it and reducing oral resistance. Volunteers will support hands firmly on the cheeks to reduce the effect of oscillation thereof. The measures will be carried out with the volunteer sitting, using nasal, relaxed and your head in neutral clip, breathing normally through the mouthpiece to his lips tightly sealed to prevent air leaks."
45619041|NCT02509637|Other|Dyspnea scale|Dyspnea will be evaluated across the range Medical Research Council (MRC) for use in patients with chronic obstructive pulmonary disease in Brazil.
45619042|NCT02509637|Other|Acceptability and tolerance|patients will complete scales 1-7, 1: extremely and 7: none) on usefulness, ease to understand the instructions, easy to perform the exercises, degree of fatigue and discomfort
45619043|NCT02509637|Device|Pulse oximetry|During therapy the patient will remain monitored with digital oximeter and the information will be recorded before and after the procedures
45761080|NCT02973880|Drug|NETILDEX™ eye drops solution|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) eye drops solution immediately after the surgery then 1 drop four times a day (q.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
45445828|NCT03765021|Drug|Tranexamic Acid|One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will prepared under sterile conditions. Injections will be applied intradermally on hyperpigmented areas at 1cm intervals. The injection will be repeated every two weeks for three months.
45619044|NCT02509637|Other|Difficulty sputum|Patients inform the ease or difficulty sputum according to a scale of 1 to 5, where 1 = no difficulty and 5 = extremely difficult.
45619045|NCT03344705|Biological|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days. Two days later, Cells Expressing an Anti-CD19 Chimeric Antigen Receptor will be infused.
45619046|NCT03344705|Drug|Fludarabine|Two days before cell infusion,all patients will be treated with fludarabine for 3 days
45619047|NCT03344705|Drug|Cyclophosphamide|Two days before cell infusion,all patients will be treated with cyclophosphamide for 3 days
45619048|NCT02501525|Device|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
45619049|NCT02501525|Device|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
45619050|NCT02501603|Drug|afatinib|Afatinib 40mg daily oral administration
45619051|NCT02501603|Drug|paclitaxel|Paclitaxel 80mg/m2 IV weekly (day 1,8,15)
45619052|NCT03344627|Drug|Meropenem standard dose|"Empirical with 1 g meropenem intravenous infusion in 30 minutes then 1 g intravenous infusion in 3 hours every 8 hours.~Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection."
45619053|NCT03344627|Drug|Meropenem high dose|"Empirical with 2 g meropenem intravenous infusion in 30 minutes then 2 g intravenous infusion in 3 hours every 8 hours.~Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection"
45619054|NCT02501369|Behavioral|Self-directed Teen Triple P|Manualised parenting programme that parents will complete at home. This involves reading weekly modules of the manual and completing small exercises to practice the skills taught. These include strategies to help build positive relationships between parent and child, helping parents to effectively manage challenging childhood behaviours, and providing parents with the skills to support their child's independence and independent management of their cystic fibrosis.
45619055|NCT03344549|Behavioral|Renal nutrition teleconsultation|Renal Nutritional teleconsultation for patients with diabetic kidney disease without dialysis, monthly for 4 months.
45761081|NCT04344483|Drug|2% Lidocaine and 1:100,000 Adrenaline|Topical application of 2% Lidocaine and 1:100,000 Adrenaline in the form of dressing will be applied over skin graft donor site of thigh for 10 minutes.
45761082|NCT04344483|Drug|Normal saline|Topical application of Normal saline will be applied over skin graft donor site of thigh as a control group.
45761083|NCT02639494|Device|Self-Centering Guide Catheter|
45619056|NCT03344549|Behavioral|Face-to-face consultation of renal nutrition|Face-to-face consultation of renal nutrition for patients with diabetic kidney disease without dialysis, monthly for 4 months.
45619057|NCT02501213|Drug|Spironolactone (+/- Furosemide)|Administration of spironolactone alone 100 mg/day each morning, increased in increments of 100 mg / week to a maximum of 400 mg / day in the absence of efficiency. In case of ineffectiveness or hyperkalemia: addition of Furosemide 40 mg / day increased in increments of 40 mg / week to a maximum of 160 mg / day in the absence of efficiency.
45619058|NCT02509403|Drug|Essential oils infused Perineal Hygiene wipe|Each participant will be asked to complete a treatment period of one month's duration. At the start of the study, the participants will be asked to fill-out a baseline questionnaire and will be given a month's supply of the perineal hygiene towel with instructions about its use. At day 15, 30 and 45 follow-ups will be conducted.
45761084|NCT02154763|Drug|Ropivacaine|
45761085|NCT02154763|Drug|Normal Saline|
45761086|NCT05721807|Other|functional magnetic stimulation|"When applying functional magnetic stimulation, the stress urinary incontinence program P2 stress was chosen. The first 20 min. current frequency was 35 Hz, modulation - rising amplitude (from 0 to maximum per second), total wave duration 12 s. active time 6 s., pause time 6 s. After 20 min. current frequency changed to 5 Hz, modulation and wave remained the same. After 2 min. current frequency changed to 35 Hz, modulation - amplitude, one-sided sinusoidal, wave remained the same. The total duration of the procedure was 30 min. A magnetic spring is installed at the bottom of the chair. During the treatment, each subject was instructed to sit on a chair so that the perineum was centered on the spring and that the subjects felt the contraction of the muscles. The intensity of the magnetic field was adjusted so as to feel comfortable during the study procedure (Vadalà et al., 2017)."
45761087|NCT05721807|Other|pelvic floor muscle training program|The program consisted of two parts. From procedures 1 to 6, 6 exercises were performed, after 6 times the exercises were adjusted, and from procedures 7 to 12, another 5 exercises were performed. The program consists of breathing, pelvic floor muscle strength, endurance, speed training exercises and exercises to strengthen the thighs, buttocks, deep back and deep abdominal muscles. Exercises were performed in 2 sets of 10 repetitions at an intensity from various positions: lying on the back, side, sitting, quadruped (Oliveira et al., 2017; Walton et al., 2019).
45761088|NCT02629731|Device|custom orthoses with varying degrees of hindfoot posting|The base orthotic design will be altered for one foot (most symptomatic in the case of patients or randomly chosen for controls) to give variations from 5-degree lateral hindfoot posting to 10-degree medial in 2.5-degree increments.
45935009|NCT00213499|Procedure|non invasive ventilation|
45445829|NCT03765021|Device|Fractional CO2 laser|The other side of the face will be randomly assigned to low power fractional CO2 laser with a power of 12 watts, spacing 700 micrometers (low density), and dwell time 300 microsecond every four weeks for three months.
45761089|NCT02639884|Device|SedLine EEG|
45761090|NCT02639884|Device|RRa monitoring|
45761091|NCT02641522|Drug|Siltuximab|Single infusion of siltuximab (11 mg/kg)
45935010|NCT00213538|Drug|Response to anakinra associated with methotrexate|
45445830|NCT03764787|Combination Product|Radiation+PD-1 Ab|combination of proton radiotherapy with PD-1 antibody
45619059|NCT02501291|Drug|Thalidomide|
45619060|NCT02509559|Drug|propranololhydrochloride|oral administration of one capsule Propanolol-CT 80 mg Filmtabletten (propranololhydrochloride, film-coated tablet encapsulated, 80 mg, single dose) together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3 with subsequent measuring of propranolol and its clinically relevant metabolites
45619061|NCT02509559|Drug|placebo|oral administration of one placebo capsule together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3
45619062|NCT02509559|Device|Net Station® System and compatible Geodesic Sensor Nets®|Electrocortical activity will be assessed by continuous EEG recording using Net Station® System and compatible Geodesic Sensor Nets® (Electrical Geodesics Incorporated, Eugene, OR, USA), measured at days 1, 3 and 10 of the study. Event related potentials at encoding (late positive potential, LPP) and at retrieval (ERP memory old/new effect) will be computed off-line after acquisition of the data.
45761092|NCT02641834|Other|Vegetarian diet|7-days dietary profile with an isocaloric Vegetarian diet for 3 months
45761093|NCT02641834|Other|Mediterranean diet|7-days dietary profile with an isocaloric Mediterranean diet for 3 months
45761094|NCT05721495|Other|freeze all strategy embryo transfer|criopreservation of all viable embryos in order to transfere the best one in a posterior cycle
45935011|NCT00213577|Drug|type A botulinum toxin|
45761095|NCT05721495|Other|fresh embryo transfer strategy|transfer of the best embryo two or three days after the fecundation technique
45761096|NCT04967001|Diagnostic Test|PSMA PET|68Ga-PSMA PET
45619063|NCT02509559|Device|VITAPORT|Measurement of the skin conductance by VITAPORT (Vitaport EDV Systeme GmbH, Erftstadt, Germany) on study days 1 and 3 at the time points before administration of the study medication, during the psychophysiological measurement and at 4 h. Furthermore, the skin conductance responses will be measured on day 10 during the psychophysiological measurement.
45619064|NCT02509559|Device|ergoselect II 100/200|Performance of an ergometry by ergoselect II 100/200 (ergoline GmbH, Bitz, Germany) on study days 1 and 3 at 120 min. The burden will be the same wattage over 4 min, that corresponds to that of reaching 80% of the maximal heart frequency in the prestudy examination.
45619065|NCT02509559|Device|SpiroScout|Performance of a spirometry (SpiroScout, Ganshorn Medizin Electronic GmbH, Niederlauer, Germany) with measuring of the forced expiratory volume in 1 second (FEV1) on study days 1 and 3 before administration of the study medication and at 120 min.
45619066|NCT02509559|Device|Mobil-O-Graph® PWA|Measurement of pulse waves by Mobil-O-Graph® PWA (I.E.M., Stollberg, Germany) on study days 1 and 3 at the time points -10 min, 20, 40, 60, 80, 120 min, 3, 5, 7, 11 h.
45619067|NCT02509559|Procedure|Saliva collection|Saliva collection will be performed on study days 1 and 3 at time points -10 min, 80 min, 120 min with subsequent measuring of the concentration of α -amylase
45619068|NCT00707993|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and glipizide placebo matching tablets, orally, once daily for up to 52 weeks.
45619069|NCT00707993|Drug|Glipizide|Alogliptin placebo-matching tablets, orally, once daily and glipizide 5 mg to 10 mg, tablets, orally, once daily up to 52 weeks.
45619070|NCT02509247|Device|Telemonitoring|Wireless telemonitoring
45619071|NCT02501057|Behavioral|Clinician's Guide|An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings.
45619072|NCT02501057|Behavioral|Enhanced Motivational Interviewing|Brief motivational interview plus the use of a smart phone application to monitor alcohol use and health behaviors.
45619073|NCT02501057|Behavioral|Enhanced Clinician's Guide|An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings plus the use of a smart phone application to monitor alcohol use and health behaviors.
45619074|NCT02509091|Drug|Bronchoalveolar Lavage and Local Amikacin Injection|injecting 0.4g of AK in 100 ml to 250 ml, not exceeding 300 ml. And generally, repeat it for 3 to 5 times.
45619075|NCT04495361|Other|E-learning portal|An online learning portal for the identification and management of pneumonia in under five children
45619076|NCT03343223|Behavioral|Intervention Group|"The goal of this research study is to evaluate the preliminary impact of a public-health-partnered tele-pharmacist model for pre-exposure prophylaxis (PrEP) delivery in a rural state (TelePrEP). In brief, PrEP involves daily use of a medication (i.e. Truvada) to prevent HIV infection among people at risk for infection due to sexual exposure or needle sharing."
45619077|NCT03343145|Biological|Leucostim 5µg/kg/day|5µg/kg/day (based on actual body weight) Leucostim®, subcutaneously, once a day, for up to 14 days or until the target ANC of 10,000/mm3 following the expected chemotherapy-induced ANC nadir
45619078|NCT03343145|Biological|Neupogen 5µg/kg/day|5µg/kg/day (based on actual body weight) Neupogen®, subcutaneously, once a day, for up to 14 days or until the target ANC of 10,000/mm3 following the expected chemotherapy-induced ANC nadir
45619079|NCT02508857|Drug|Ketorolac|Patients received intravenous injection of ketorolac (30 mg) in bolus; then, saline solution was continuously infused during the entire procedure (Group K),
45761097|NCT04964427|Drug|Methylphenidate|A single dose of 5-10 mg of immediate release MPH (Ritalin®) will be administered in line with NICE and AIFA (Agenzia Italiana del Farmaco) guidelines for ADHD treatment.
45761098|NCT04964427|Device|anodal tDCS|Anodal electrode will be positioned over the left dlPFC, according to the 10-20 EEG on the sites corresponding F3, whereas the reference electrode will be placed above the contralateral supraorbital area, corresponding to Fp2. In the active tDCS condition, the current will increase slowly during the first 30 seconds to 1 mA (ramp-up) and, at the end of the stimulation, the current will decrease slowly to 0 mA during the last 30 seconds (ramp-down). Between the ramp-up and ramp-down constant current will be delivered for 20 minutes, with a density of 0.04 mA/cm2.
45761099|NCT04964427|Device|sham tDCS|In the sham tDCS condition, the stimulation will be delivered by using the same active tDCS montage, respectively left-anodal dlPFC and right-reference electrode over Fp2. Stimulation intensity will be set at 1 mA, but the current will be applied for 30 seconds and will be ramped down without the participants' awareness.
45761100|NCT05721417|Procedure|Tricuspid valve surgery|Surgical treatment of tricuspid regurgitation, that may be performed by repair or replacement
45935012|NCT00213616|Procedure|surgical reinnervation|laryngeal reinnervation with a phrenic nerve root
45935013|NCT00213655|Biological|bladder tumor recurrence|bladder tumor recurrence assessed by clinical and biological exams
45935014|NCT00213694|Drug|docetaxel and celecoxib|
45935015|NCT00213811|Behavioral|clinical, biological, and radiological|
45619080|NCT02508857|Drug|Magnesium|Patients received intravenous magnesium sulfate (20 mg/kg) in bolus, then magnesium sulfate (2 mg/kg/h) was continuously injected during the procedure (Group M)
45619081|NCT02508857|Drug|Saline solution|intravenous saline solution (20 ml) was injected in bolus, followed by continuous infusion of saline solution during the entire procedure (Group S).
45619082|NCT02509169|Drug|TAE plus P53 gene|Trans-catheter embolization combined with recombinant adenoviral human p53 gene therapy
45619083|NCT02509169|Other|TAE|Trans-catheter embolization
45935016|NCT00213850|Procedure|EFR|
45935017|NCT00213889|Other|None: molecular genetics diagnosis procedure only|None: molecular genetics diagnosis procedure only
45935018|NCT00213928|Drug|Horse Chestnut Seed Extract|Control (no intervention) vs Horse Chestnut Seed Extract
45445831|NCT03759171|Other|Guitars for Vets Intervention|This was an active intervention providing veterans with an acoustic guitar, guitar pick, tuning instruments, a music book, practice CDs, and individual and group sessions of music instruction during a 6-week intervention period. Six tailored 1-hour individual guitar instruction sessions were scheduled (1 session per week). In addition to the 6 tailored individual lessons, the intervention provided 3 group sessions. Veterans were given a guitar that they could keep upon completion of the program. The same instructor was assigned to a subject for the duration of the study, and group sessions were supervised by the Education Director of Guitars for Vets.
45619084|NCT02508779|Behavioral|Bump2be|Bump2be is an internet intervention focusing on six topics (called cores) psycho-educational in nature with the goals of improving individuals' ability to: a) anticipate extreme BG levels, b) detect the presence of extreme BG levels, c) address current extreme BG levels, and d) prevent future extreme BG levels. The program includes didactic information, self-assessment tools, and active learning exercises.
45761101|NCT05721339|Behavioral|Acceptance and Commitment Therapy|"ACT will be applied through 8 sessions by the psychological flexibility processes, which were grouped into three response styles: open, aware, and active. Openness is reflected by acceptance, which means the conscious embrace of psychological events without unnecessary attempts to change their frequency. Defusion means untangling unhelpful thoughts and responding to mental experiences as experiences rather than guides to action. The awareness set, which is reflected by applying self-as-context, which means a continuous and secure I from which events are experienced but distinct from those events. A present moment means ongoing, nonjudgmental contact with internal and external events as they occur in the present moment. The active set, which was reflected by making the intern nurses embrace their desired and chosen life values directions, and commit action to selected values."
45761102|NCT02460783|Other|Boost (R) 5-2 diet|Regular diet for 5 days/week; Calorie Restriction (480 Kcal in the form of a shake) for 2 days/week. Supplement providing 240 Kcal per shake. Participant takes 2 shakes per calorie restriction day.
45761103|NCT02460783|Other|Healthy Living Diet|Counseling and educational material on diet portion, consistency
45911662|NCT05777499|Behavioral|Control Therapy|Control Therapy sessions will be carried out by a member of the clinical team, matched in duration and number to Music Therapy sessions as closely as possible. Participants will usually have 1-2 individual sessions and 1 group session/week. Group sessions include 2-6 participants. The Control Therapy intervention will continue throughout participant's rehabilitation program until participants have completed a total of 15 hours intervention, which will usually take 10 weeks to complete. The content of sessions is designed to reflect 'usual care' however control therapy sessions will not include access to specific specialist equipment such as MOTOmed, therabike or neuro-muscular electrical stimulation, to ensure the control group does not get additional specialist intervention beyond usual care. Content of control therapy sessions will therefore be restricted to the following five domains: gaming, education, mindfulness, current affairs discussions, and passive and dynamic stretching.
45761104|NCT00357669|Drug|Brivaracetam 25 mg|"Active Substance: Brivaracetam~Pharmaceutical Form: Tablet~Concentration: 25 mg~Route of Administration: Oral use"
45761105|NCT00357669|Drug|Brivaracetam 50 mg|"Active Substance: Brivaracetam~Pharmaceutical Form: Tablet~Concentration: 50 mg~Route of Administration: Oral use"
45761106|NCT00357669|Other|Placebo|"Active Substance: Placebo Pharmaceutical Form: Tablet~Concentration: 25 mg and 50 mg~Route of Administration: Oral use"
45911663|NCT05777486|Behavioral|TikTok Ads - With Food|TikTok posts from influencers promoting food.
45911664|NCT05777486|Behavioral|TikTok Ads - Without Food|TikTok posts from influencers who are not promoting food.
45911665|NCT05777460|Device|Thoracic endovascular aortic repair (TEVAR)|The TEVAR procedure involves the placement of a covered stent (a metal mesh tube with a layer of fabric) into the weakened area of the artery.
45911666|NCT05777447|Procedure|Mycotic aortic-iliac aneurysms and in situ reconstruction|Surgical treatment of mycotic aortic-iliac aneurysms and in situ reconstruction
45911667|NCT05777434|Procedure|Conventional Physical Therapy for Chronic Neck Pain|Conventional physical therapy for Chronic Neck Pain will include hot pack and TENS for pain relief, axial elongtion exercises to correct posture, cervical isometrics and cervical stabilization exercises. After 2 weeks, functional training will be added. Sets and repetitions will be increased progressively.
45911668|NCT05777434|Procedure|Scapulothoracic Stabilization Exercises|• Scapulothoracic stabilization exercises in addition to conventional physical therapy will include scapular adduction and shoulder external rotation, B/L shoulder extension with scapular retraction, Eccentric scapular retraction, Brügger exercise and Forward punch. Exercises would be given using latex Thera-Band, or acc. to patient strength for mild to moderate resistance. After 2 weeks, functional training will be added. Sets aand repetitions will be increased progressively.
45935019|NCT00213967|Device|22 gauge 1 1/2 inch needles on a 3 ml syringe|cold needles or needles kept at room temperature
45619085|NCT02508779|Other|Routine Care|Participants will continue to receive care from their clinician.
45761107|NCT00861601|Drug|eltrombopag 12.5 milligrams (mg) tablet|eltrombopag 12.5 mg tablet once a day
45761108|NCT00861601|Drug|eltrombopag 25 mg tablet|eltrombopag 25 mg tablet once a day
45619086|NCT02508623|Drug|Rifaximin|Rifaximin 550 mg tablet BID for 60 days
45619087|NCT02508623|Drug|Placebo|Placebo 1 tablet BID for 60 days
45619088|NCT02508545|Other|perceived egocentric distance (PED) measurements|
45619089|NCT02508545|Other|Parabolic flight|
45619090|NCT04498637|Other|'Attitudes towards people with disability Scale'|The scale 'Attitudes towards people with disability' was completed by the participants. This scale allows the analysis of the attitudes towards disability trough a score whose lower values indicate a more negative attitude and higher values indicate more positive attitudes.
45619091|NCT02500667|Drug|N91115|200 mg BID
45619092|NCT02500667|Drug|Rifampin|600 mg QD
45619093|NCT02500511|Biological|NmVac4-A/C/Y/W-135-DT™|no intervention in this study, received test vaccine in trial JN-NM-002
45761109|NCT00357747|Drug|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
45761110|NCT00357747|Drug|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
45761111|NCT05715723|Drug|Reamberin|Reamberin® in the average daily dose of 10 ml/kg daily
45761112|NCT02641912|Other|Biotene mouthwash|During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.
45761113|NCT02641912|Other|Mineral Water|"During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.~At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use."
45761114|NCT05721261|Device|Temporary Peripheral Nerve Stimulation System|Single use medical device. Therapy consists of single, 1 hour dose of electrical stimulation delivered proximal to injury site.
45619094|NCT02500355|Procedure|Carpal Tunnel Release via limited approaches|Carpal tunnel release with partial excision of the flexor retinaculum via two small incisions.
45619095|NCT02500355|Procedure|Carpal Tunnel Release via standard approach|Carpal tunnel release with partial excision of the flexor retinaculum via the standard incision.
45445832|NCT05418699|Device|closed-loop insulin pump|Follow up of patients with real-time closed-loop insulin delivery systems
45619096|NCT02500355|Procedure|Endoscopic Carpal Tunnel Release|Carpal tunnel release under endoscope.
45619097|NCT02500355|Device|endoscope or an arthroscopic device|
45761115|NCT05721261|Device|Sham Temporary Peripheral Nerve Stimulation System|Single use medical device. Sham treatment consists of single, 1 hour dose of sham stimulation.
45619098|NCT02500433|Other|Device: Kinect-Xbox 360TM|Based around a webcam-style add-on peripheral for the Xbox 360 console, it enables users to control and interact with the Xbox 360 without the need to touch a game controller, through a natural user interface using gestures and spoken commands. Participants were asked to practice 30 minutes per day, 2 days per week for 2 months, added to their conventional treatment. The games used were Kinect Sports ITM, Kinect Joy RideTM and Kinect Disneyland AdventuresTM and involved balance and trunk movements, general and visual-manual coordination and limb tasks. Each subject followed instructions on the screen with the help of his physiotherapist, with points awarded based on degree and speed of movement and level of difficulty.
45761116|NCT00861913|Other|Laboratory Biomarker Analysis|Correlative studies
45761117|NCT00861913|Drug|Pazopanib Hydrochloride|Given orally
45761118|NCT00861913|Other|Pharmacological Study|Correlative studies
45761119|NCT00862537|Device|Resonator Device|active pico-tesla magnetic fields treatment for Parkinson's disease individuals
45619099|NCT02500433|Other|Conventional therapy|
45761120|NCT02421705|Other|Sample collection|Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon
45761121|NCT00863551|Drug|Trospium Chloride|Extended release, 60 mg, oral daily
45452290|NCT01093157|Drug|Adrenocorticotrophic hormone ACTH|There will be two arms to the study: one arm receive 40 units and the second arm 80 units of the ACTH gel subcutaneously both given in a dose escalating frequency beginning at once every two weeks escalating to a maximum of twice per week over a total of three months exposed.An ammendment(approved by Health Canada and the UHN IRB allows an additional 1 month of the perscribed therapy of ACTH )if there is an improvement in proteinuria at the end of the 3 month exposure.
45452291|NCT03953105|Device|ePER|usind the ePER for weight estimation and suggestion of the defined parameter
45452292|NCT03953105|Device|BT|usind the BT for weight estimation and suggestion of the defined parameter
45452293|NCT01093235|Biological|bevacizumab|
45761122|NCT03838575|Drug|2% alcoholic chlorhexidine skin prep (SKIN PREP)|This intervention describes the preparation of the intact skin incision site immediately prior to incision, using chlorhexidine gluconate (CHG) in an alcohol-based solution, providing durable sterilisation of the surgical field. Pre-prepared applicators will be available for use in this trial (ChloraPrep™ sticks, 2% CHG with 70% isopropyl alcohol, BD Infection Prevention).
45761123|NCT03838575|Device|Iodophor Antimicrobial Incise Drapes (DRAPE)|"Please note: In January 2022, following the first interim analysis, arms including intervention 2 - Iodophor-impregnated incise drape (arms C, E, G and H) were closed to recruitment.~This intervention describes the application of a single Iodophor Antimicrobial Incise Drape to be applied topically onto the prepared and draped surgical field by sterile, gloved members of the surgical team before the surgical incision is performed. Only after the skin preparation solution has dried completely can the incise drape be applied."
45761124|NCT03838575|Device|Gentamicin-impregnated implants/ sponges (SPONGE)|This intervention describes the implantation of Gentamicin-impregnated collagen implants at the time of fascial closure. Each sponge (10 by 10 cm) contains 280mg of collagen and 130mg of gentamicin. The sponges gradually degrade and the gentamicin solution permeates into surrounding tissues to create a high local antimicrobial concentration within the surgical wound.
45761125|NCT03838575|Other|NONE (Control)|"Any skin preparation of the surgeon's choice may be used in the control arm apart from 2.0% Alcoholic Chlorhexidine Skin Prep.~No drapes or sponges of any kind may be used."
45935020|NCT00214084|Drug|Allopurinol|
45619100|NCT02506595|Behavioral|ERRT-M for Nightmares|Exposure, Relaxation, and Rescripting Therapy Military version (ERRT-M) - Five 60-90 minute sessions administered once weekly. ERRT-M includes psychoeducation, sleep habit modification, relaxation training, written exposure to and rescription of nightmare content and imagery rehearsal of rescripted dream content.
45619101|NCT02508155|Biological|MEDI7352 for IV infusion|MEDI7352 for IV infusion
45911669|NCT05777421|Procedure|Conventional Physical Therapy for Knee Osteoarthriths|Participants of Group A will receive the conventional physical therapy for Knee Osteoarthistis for a duration of 6 weeks atleast 2 times a week
45911670|NCT05777421|Procedure|Virtual Reality-Based Therapeutic Exercise regimes|"Participants of Group B will receive Virtual Reality Based therapeutic exercises on the Xbox. The difficulty level of the games will progess each week. The duration of training will also also progress at treatment week progresses.~Frequency: 2-3 times a week for 6 weeks. Minimum 12 sessions in total."
45911671|NCT05777408|Procedure|Conventional Physical Therapy|"15 mins of TENS (frequency 100 Hz, phase duration 50 μs) with moist heat over the area of pain~Isomeric Stretching of neck muscles followed by neck isometrics"
45911672|NCT05777408|Procedure|Natural Apophyseal glides|-Will be applied in sitting position Therapist right hand would cradle the head such that the little finger would rest on the spinous process of the vertebra that is to be mobilized. The other hands thumb would be used to apply over pressure. Direction of force will be parallel to highly irritable-grossly restricted cervical facet joints. Intervention would involve 3 sets of 20 repetitions in 15minutes, 3 days a week for 2 weeks comprising of total 6 session.
45619102|NCT02508155|Biological|Placebo for IV infusion|IV Placebo infusion
45911673|NCT05777408|Procedure|Cranial Base Release|Will be performed in lying position. therapist fingers will contact the sub occipital muscles and upward pressure would be given until the tissues and muscles relax. it will be given once daily for 3 days a week and will continue for 2 weeks
45911674|NCT05777395|Procedure|Maitland Oscillatory Mobilization|Maitland Posteroanterior unilateral vertebral pressure and Maitland cervical rotation technique will be used.3 sets of 15 repetitions. Each set is of 30 seconds and each repetition is given for 2 seconds.
45911675|NCT05777395|Procedure|Kaltenborn Sustained Stretch Mobilization|"Kaltenborn sustained stretch mobilizations. 3 sets of 15 repetitions for 3 seconds.~Frequency: 3 times a week for 2 weeks. 6 sessions in total.~Mobilizations will be performed in Grade 1 and then progressed to 2 and 3.~Kaltenborn technique used will be atlas-axis rotation"
45445833|NCT03764709|Device|Vital signs wireless monitoring system|WIN@Hospital wireless remote monitoring is a modern light monitoring medical device with no need for continuous presence of a dedicated person. WIN@Hospital is based on an innovative modular and wearable device laid out for remote monitoring of several vital parameters 24/7. Dexcom G6 is a continuous glucose monitoring system which measures interstitial fluid glucose levels in people with diabetes from a sensor applied to the skin as an alternative to routine finger-prick blood glucose testing, and can produce a -continuous record of measurements which can be checked using an App. It can also indicate glucose level trends over time. Monitoring devices will be applied to all patients randomly assigned to the wireless monitoring arm, with a continuous monitoring setting over the first 5 days after the initiation of monitoring, corresponding to the starting of the observation (i.e. transition to subacute unit for GROUP A, discharge for GROUP B).
45619103|NCT02508155|Biological|MEDI7352 for Subcutaneous Injection|MEDI7352 for subcutaneous injection
45619104|NCT02508155|Biological|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
45911676|NCT05777395|Procedure|Conventional therapy|Moist heat, TENS, Neck Muscle Stretching, Neck muscle isometrics
45911677|NCT05777382|Other|inquiry to postnatal mothers|structured questionnaires was asked to postnatal mothers
45911678|NCT05777369|Drug|Rituximab|375 mg/m2, d0
45452294|NCT01093235|Drug|cyclophosphamide|
45619105|NCT03344393|Drug|Ketamine Hydrochloride|intravenous ketamine infusion intraoperatively
45619106|NCT03344393|Drug|Normal saline|intravenous normal saline infusion intraoperatively
45911679|NCT05777369|Drug|Mitoxantrone hydrochloride liposome|18 mg/m2, d1
45619107|NCT04498793|Biological|Tislelizumab|On Day 1 of the last seven cycles in the neoadjuvant and each cycle in the adjuvant phases of the study for a total of 21 cycles; intravenous (IV) infusion.
45619108|NCT04498793|Drug|Nab paclitaxel|On Days 1 and 8 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.
45911680|NCT05777369|Drug|Cyclophosphamide|750 mg/m2, d1
45911681|NCT05777369|Drug|Vincristine/Vindesine|Vincristine: 1.4 mg/m2, d1(The maximum dose was 2 mg) Vindesine: 3 mg/m2, d1
45911682|NCT05777369|Drug|Prednisone|60 mg/m2, d1~d5
45911683|NCT05777343|Other|Experimental|Cognitive training combined with the recommended non-pharmacological intervention (Exercise and Pain Neuroscience Education).
45452295|NCT01093235|Drug|docetaxel|
45619109|NCT04498793|Drug|Doxorubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
45619110|NCT04498793|Drug|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
45619111|NCT04498793|Device|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.
45619112|NCT03344315|Device|experimental: collagen matrix|Mucograft collagen matrix combined with coronal advanced flap
45935021|NCT00214123|Radiation|radiation therapy (radiotherapy)|Bin assignment based on tumor volume
45452296|NCT01093235|Drug|epirubicin hydrochloride|
45452297|NCT01093235|Drug|fluorouracil|
45452298|NCT01093235|Procedure|assessment of therapy complications|
45911684|NCT05777343|Other|Exercise and PNE|Recommended non-pharmacological intervention (Exercise and Pain Neuroscience Education).
45911685|NCT05777343|Other|Cognitive training|Online sessions of cognitive training.
45911686|NCT05777304|Device|wearable device|IMU sensors and EMG sensors
45911687|NCT05777291|Device|Activity watch monitoring|Patients will be using activity devices during the study period
45619113|NCT03344315|Other|Active Comparator: autologous connective tissue graft|Soft tissue harvesting from patient palate with coronal advanced flap
45911688|NCT05777291|Device|Sleep mattress monitoring|Patients will be using sleep mattress during the study period
45911689|NCT05777291|Behavioral|Physical activity counseling|Physical activity counseling in accordance to the Swedish model
45911690|NCT05777278|Drug|Savolitinib|Savolitinib (300mg or 200mg according to safety run-in recommendation, p.o., BID)
45911691|NCT05777278|Drug|Docetaxel|Docetaxel (60 mg/m2, ivgtt, q3w)
45911692|NCT05777265|Other|Circuit Training|CT will be applied to the participants, taking into account the recommendations of the American College of Sports Medicine (ACSM), 3 days a week, an average of 40 minutes a day, for a total of 16 weeks. Warm-up and cool-down protocols will be applied before and after each CT, and each exercise will be performed as 15 repetitions and an average of 40 seconds of rest will be given between exercises. Also, the intensity of CT will be determined according to the Borg scale (between 11 and 14). CT will include 'mini squat', 'step up', 'sit ups', 'reverse sit ups', 'leg press', 'leg curl', 'leg extension', 'crunches', 'lunge', 'prone bridge', and 'side bridge' exercises.
45911693|NCT05777252|Other|Circuit Training|Warm-up and cool-down protocols will be applied before and after each CT, and each exercise will be performed as 15 repetitions and an average of 40 seconds of rest will be given between exercises. Also, the intensity of CT will be determined according to the Borg scale (between 11 and 14). CT will include 'mini squat', 'step up', 'sit ups', 'reverse sit ups', 'leg press', 'leg curl', 'leg extension', 'crunches', 'lunge', 'prone bridge', and 'side bridge' exercises.
45911694|NCT05777239|Procedure|Dental Implant Approach for Crestal Sinus Elevation|Crestal Sinus Elevation by elevating the sinus membrane with a blunt ended dental implant approach
45911695|NCT05777213|Biological|Secretome|The interventions given in this study were Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) as much as 0.1cc / 1cm intracutaneously with a flexpen device in the wound area every 2 weeks. The variables in this study were divided into two, namely the independent variable was the use of Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) were administered intracutaneously, and the dependent variables were wound healing and side effects caused by the interventions given. Wound healing or repair in this study was assessed from several variables, namely the presence of granulation tissue growth, reduced edema, reduced erythema and improvement in wound size both in terms of length, width, and area measured by using a standard ruler and digital photo.
45911696|NCT05777148|Device|super high-flux hemodialysis|Super high-flux hemodialysis (SHF-HD) is hemodialysis using Super high-flux dialyzer for 24 week then crossover to post dilution online HDF (wash out period 4 weeks)
45911697|NCT05777148|Device|postdilution online hemodiafiltration|hemodialysis by post dilution online HDF technique for 24 week then crossover to super high-flux HD (wash out period 4 weeks)
45911698|NCT05777122|Drug|lignocaine gel|pharmacological ,topical anesthetic gel
45452299|NCT01093235|Procedure|neoadjuvant therapy|
45452300|NCT01093235|Procedure|quality-of-life assessment|
45452301|NCT01093235|Procedure|therapeutic conventional surgery|
45619114|NCT02507999|Device|Flotrac|Flotrac guided intervention
45619115|NCT04498325|Drug|NT-I7|Supplied by study
45619116|NCT04498325|Drug|Placebo|Supplied by study
45619117|NCT04498325|Procedure|Blood for research purposes|Prior to injection (Day 0), Day 7, and Day 14
45619118|NCT04498325|Procedure|Blood for pharmacokinetic samples|-Phase I only: 1-2 hours prior to dosing, 6 hours after dosing, 24 hours after dosing, Day 7, Day 14, and Day 21
45619119|NCT04498325|Procedure|Nasopharyngeal, oropharyngeal, or saliva swab|-Prior to study treatment, Day 4(optional), Day 7, and Day 14
45619120|NCT04498325|Procedure|Blood for anti-drug antibody (ADA)|Baseline, Day 7, Day 14, Day 21, Day 60, and Day 90. Participants with ADA positivity on Day 90 will be monitored every 90 days until antibody level returns to baseline
45619121|NCT02507843|Drug|Cholecalciferol|Oral Cholecalciferol(100000 IU) will be administered in Vitamin D group monthly for 6 months.
45619122|NCT02507843|Drug|Placebo|Placebo will be administered in placebo group monthly for 6 months.
45619123|NCT02500277|Device|Cryoprobe pleural biopsy first|Four pleural biopsy specimens will be obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm) followed by 6-10 pleural biopsy specimens obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter).
45911699|NCT05777122|Other|sugar free chewing gum|non pharmacological
45911700|NCT05777109|Drug|HS-20090|A human IgG2 monoclonal antibody with affinity and specificity for human RANKL
45911701|NCT05777109|Drug|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
45911702|NCT05777096|Diagnostic Test|Standardised Nordic questionnaires|participants will complete the SNQ online. Estimated time of participation per person: 15 minutes to fill in the questionnaires
45935022|NCT00214162|Behavioral|Comprehensive Health Enhancement Support System|Full CHESS
45935023|NCT00214162|Behavioral|computer with internet|computer with internet use x 1 year
45935024|NCT00214240|Drug|CMV Immune globulin|CMV IvIg 150mg/kg x 6 doses
45452302|NCT01097525|Procedure|WFG PRK|
45452303|NCT01097525|Procedure|WFG LASIK|
45452304|NCT01097525|Procedure|WFO PRK|
45452305|NCT01097525|Procedure|WFO LASIK|
45452306|NCT01097681|Drug|ASP1941|oral
45452307|NCT01087697|Device|Neo-Urinary Conduit|Implantation with the autologous Neo-Urinary Conduit
45452308|NCT01087853|Drug|Crystalloid|2 litres intravenous infusion in 60 minutes
45619124|NCT02500277|Device|Flexible forceps biopsy first|Six to ten pleural biopsy specimens will be obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter) followed by four pleural biopsy specimens obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm)
45452309|NCT01087853|Drug|Colloid|1 litre intravenous infusion over 30 minutes
45452310|NCT01088009|Drug|lamivudine|patients in this arm will receive oral lamivudine 100mg,daily for 24 weeks; if patients with HBV DNA higher than 1000 copies/ml at week 24, add on adefovir to week 104; otherwise, keep lamivudine monotherapy to week 104
45619125|NCT02500199|Drug|Pyrotinib|Pyrotinib maleate, is provided as yellow, film-coated, immediate release tablets containing pyrotinib maleate at dosage strengths of 80 and 160 mg. Multiple tablets of pyrotinib will be administered daily to achieve targeted doses of pyrotinib: 320 mg, 400 mg, 480 mg, 560 mg and 640 mg. Tablets will be orally administered with water, once daily, 30 min after a meal.
45619126|NCT04498091|Biological|Biological data|Biological data
45619127|NCT04498091|Other|Clinical data|Clinical data
45761126|NCT02642536|Behavioral|MH MOVE|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions
45619128|NCT02425891|Drug|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
45619129|NCT02425891|Drug|Nab-Paclitaxel|Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle. Nab-Paclitaxel was administered for a target of at least 6 cycles, with no maximum in the absence of disease progression or unacceptable toxicity.
45761127|NCT02642536|Behavioral|Enhanced Usual Care|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
45761128|NCT03540355|Drug|Cipros 20 association|oral, once a day
45761129|NCT03540355|Drug|Crestor 20 mg|Oral, once a day
45761130|NCT00357201|Drug|Food supplement (T1675)|
45761131|NCT04339816|Drug|Azithromycin|orally or into nasogastric tube for 5 days
45761132|NCT04339816|Drug|Hydroxychloroquine|orally or into nasogastric tube for 5 days
45761133|NCT04339816|Drug|Placebo|orally or into nasogastric tube for 5 days
45761134|NCT02978703|Drug|COPD Pharmacologic Substance|COPD patients treated by Fluticasone / Salmetrol via Elpenhaler device
45761135|NCT02643004|Device|Senofilcon A|contact lens
45761136|NCT02643004|Device|Stenfilcon A|contact lens
45761137|NCT05588986|Other|ultrasonography|Umbilical artery Doppler evaluation by ultrasonography just before the first dose of antenatal corticosteroid, 24 hours and 48 hours after the last dose.
45761138|NCT05588908|Drug|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)|100 mg subcutaneous (s.c) once
45761139|NCT05588908|Drug|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib)|200 mg subcutaneous (s.c) once
45761140|NCT05588908|Drug|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib)|300 mg subcutaneous (s.c) once
45761141|NCT05588908|Drug|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II)|one s.c. injection of SSGJ-613 once, on Day 1.
45761142|NCT05588908|Drug|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II)|one s.c. injection of SSGJ-613 once, on Day 1.
45761143|NCT05588908|Drug|Compound Betamethasone Injection (phase II)|1 mL i.m. once on Day 1
45761144|NCT05588908|Other|Placebo (phase II)|Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.
45761145|NCT05588830|Drug|Belimumab|Belimumab, 10mg/kg, was administered intravenously on the 0, 14 and 28 days, and then once every 28 days until the 24th week
45619130|NCT02425891|Drug|Placebo|Placebo administered via IV infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
45935025|NCT00214279|Drug|Corticosteroid withdrawal|prednisone withdrawal, with maintenance mycophenolate mofetil therapy and either cyclosporine or tacrolimus
45935026|NCT00214318|Drug|Terbutaline plus Metoprolol or carvedilol|
45619131|NCT04495205|Biological|PRF under non-eugenol containing periodontal pack|Platelet Rich Fibrin under non-eugenol containing periodontal pack
45761146|NCT05588830|Drug|Telitacicept|Telitacicept is injected subcutaneously, 160mg/time, once a week, for a total of 24 weeks
45761147|NCT05588752|Other|TAP block|TAP block under ultrasound
45761148|NCT04740190|Drug|Talazoparib|low dose whole brain radiation, followed by combination talazoparib and carboplatin
45761149|NCT00865969|Drug|Belinostat|
45761150|NCT05588674|Dietary Supplement|Probiotic Supplement|8.5 week supplementation period. One capsule daily.
45761151|NCT05588674|Other|Placebo Capsule|8.5 week supplementation period. One capsule daily.
45761152|NCT05588596|Behavioral|Trauma Resiliency Mindfulness-Informed Intervention|The total duration of the intervention was once a week for eight weeks. The aim of the intervention was to teach patients a range of trauma recovery mindfulness skills
45761153|NCT05588518|Combination Product|desensitizing agents -10% Propolis|"10% propolis was prepared after mixing with 70% ethanol and distilled water based on the method described previously. Propolis and ethanol mixture was allowed to stay in dark place for two weeks. The mixture was stirred everyday intermittently for two weeks. Later the mixture was strained twice using filter paper to remove impurities.~Propolis in general are fairly stable without losing its antibacterial properties for over 12 months when stored without direct sunlight and at cool temperatures. Alcohol based extracts will have extended shelf life and hence ethanol-extracted propolis prepared was stored in dark amber colored bottle without any preservatives."
45761154|NCT05588362|Other|Fitz Frames 3-D Printed Glasses|The intervention group will order glasses directly in the office following their exam and consent using an iPad with the help of the research assistant. The iPad will be e-connected to a 3D printed glasses manufacturer (Fitz Frames) through their application, allowing the child (with assistance from the doctor or research assistant) to take various measurements in real time. Sixteen different measurements will be taken including interpupillary distance, face length, face width, and temple measures. The child will be able to choose frame style and order it directly from the manufacturer immediately following the exam. Glasses will be shipped directly to the patient's home (shipping address will be input to the app by the family).
45761155|NCT04339894|Other|Duplex ultrasonography (data collection by extra-corporeal non-invasive sensors)|Search for venous thrombosis and description of thrombosis
45619132|NCT04495205|Other|Non-eugenol containing periodontal pack|Non-eugenol containing periodontal pack after gingival depigmentation
45619133|NCT02499809|Other|Recovery mode|After the gradual maximal exercise the subjects will use different recovery modes (vibration therapy or passive and active recovery).
45619134|NCT04498013|Drug|Cyclodynon|Cyclodynon 1 tablet a day during 6 menthes period.
45619135|NCT04498013|Behavioral|Lifestyl modification|Measures to normalize the hygiene of work and rest. A diet aimed at achieving an optimal body mass index. Teaching relaxation techniques to increase resistance to chronic stress.
45619136|NCT04497935|Drug|PLENVU|Bowel preparation for a colonoscopy
45619137|NCT04497935|Drug|MoviPrep|Bowel preparation for a colonoscopy
45619138|NCT02507531|Device|NeXsys Embolization System|Woven metallic mesh placed in aneurysm fundus
45619139|NCT02499965|Drug|Ethyl Chloride Topical Aerosol Anesthetic|Sprayed on the skin for 5-8 seconds immediately before IV cannulation
45619140|NCT02499965|Drug|Nature's Tears Sterile Water|Sprayed on the skin for 5-8 seconds immediately before IV cannulation
45619141|NCT05504057|Drug|Antihistamine|Observation of the rate of COVID19 infection, the rate of hospitalization and the rate of survival among patients previously treated with
45619142|NCT05504057|Drug|Amantadine|Observation of the rate of COVID19 infection, the rate of hospitalization and the rate of survival among patients previously treated with amantadine
45619143|NCT03241225|Behavioral|EM/PROTECT|EM/PROTECT is a behavioral intervention for depressed elder mistreatment (EM) victims designed to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services
45619144|NCT03241225|Behavioral|EM/MH|EM/MH provides individuals experiencing elder mistreatment with support services from staff trained in linking elder mistreatment victims to community mental health services.
45619145|NCT03344003|Drug|Wilate or Nuwiq|Wilate or Nuwiq administered via intravenous injection
45619146|NCT02506751|Drug|liothyronine|All eligible subjects will be treated with the study drug as per the standardized dose-escalation protocol. Subjects will be required to report to the study site every six weeks for the duration of the study in order to receive their study drug and to monitor drug safety and tolerability.
45619147|NCT03235531|Drug|Valproate|Valproate is an anti-epileptic medication that can influence the chemical changes in the brain that result from alcohol withdrawal syndrome (AWS) via three mechanisms of action: (1) an increase in GABA activity, (2) inhibition of glutamate binding to NMDA, and (3) restoration of the balance between dopamine and acetylcholine activity. VPA may be effective in the prevention of AWS, and could serve as efficacious adjuvant to traditional benzodiazepine (BZD) therapy for AWS, both decreasing symptoms of AWS and decreasing the use of BZDs.
45619148|NCT03235531|Drug|Lorazepam|Lorazepam is a benzodiazepine used to treat symptoms of AWS. Standard of care at CAMC is monitoring by CIWA tool and administration of lorazepam according to CIWA score.
45619149|NCT05472701|Behavioral|Diet order: WFPB, PBMA, Animal|Participants followed the WFPB, PBMA, and Animal diets (in this order) for 4 weeks each.
45619150|NCT05472701|Behavioral|WFPB, Animal, PBMA|Participants followed the WFPB, Animal, and PBMA diets (in this order) for 4 weeks each.
45619151|NCT05472701|Behavioral|PBMA, WFPB, Animal|Participants followed the PBMA, WFPB, and Animal diets (in this order) for 4 weeks each.
45619152|NCT05472701|Behavioral|PBMA, Animal, WFPB|Participants followed the PBMA, Animal, and WFPB diets (in this order) for 4 weeks each.
45619153|NCT05472701|Behavioral|Animal, WFPB, PBMA|Participants followed the Animal, WFPB, and PBMA diets (in this order) for 4 weeks each.
45619154|NCT05472701|Behavioral|Animal, PBMA, WFPB|Participants followed the Animal, PBMA, and WFPB diets (in this order) for 4 weeks each.
45619155|NCT03232255|Other|Mouthrinse (IQP-OLP-101)|Rinse/gargle 10mL of Mouthrinse for 60 seconds after tooth brushing, twice a day.
45445834|NCT03764397|Behavioral|Prehabilitation for behavioural change|The 4-week prehabilitation educational programme will consist of a meeting for one session (approximately 1 - 1.5 hours) per week. This behavioural change programme will involve a mixture of interactive and didactic sessions, facilitated by a physiotherapist, psychologists, and other health professionals. The purpose of the initial prehabilitation programme is to gain participant 'buy-in' to the programme, to assist participants engage with exercise, to help participants overcome barriers to exercise and improve self-efficacy for exercise. The prehabilitation phase will also enable participants to understand why and how to perform gentle self-paced exercise. After the prehabilitation programme, participants will be advised to engage in a 6-week gentle self-paced walking programme; i.e., a simple pedometer-driven walking programme with weekly telephone support.
45445835|NCT03758859|Other|sodium hyaluronate eyedrops|sodium hyaluronate eyedrops administered - route ocular -topical
45761156|NCT05588206|Radiation|Hypofractionated Stereotactic Radiotherap|A standard 3+3 statistical design was employed. Three patients will initially be treated at dose level 1, 6 Gy in 5 fractions, 3 fractions a week. Dose limiting toxicities (DLT) were defined as any grade 3-5 radiation injury or any non-hematologic toxicity felt to be possibly, probably, or definitely related to radiation, identified within the evaluation period of 3 months following the completion of radiotherapy.
45935027|NCT00214357|Behavioral|Mindfulness-based stress reduction|
45619156|NCT02506829|Behavioral|Smoking cessation counseling (Quitline)|
45619157|NCT02506829|Behavioral|Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)|
45619158|NCT02506829|Behavioral|Financial incentives|
45619159|NCT03232177|Drug|Anagre Cap.|from 0.5mg twice a day to maximally increase total10mg in 8 weeks and maintain maximal tolerable dose to 104 weeks
45619160|NCT02499731|Behavioral|Strong Hearts, Healthy Communities|"We will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized controlled intervention trial. We will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 8 intervention and 8 control communities. In addition, we will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
45619161|NCT02499731|Behavioral|Strong Hearts, Healthy Women|"The Strong Hearts, Healthy Women (minimal intervention) will meet once per month for an hour each time for 6 months.~Participants will learn and discuss techniques and strategies to improve personal health."
45935028|NCT00214435|Drug|once daily minimum 3-drug regimen of anti-retroviral medications|
45619162|NCT03232099|Dietary Supplement|Red Wine consumption|After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.
45619163|NCT03232099|Other|Period without alcohol consumption|After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
45619164|NCT02499653|Behavioral|Psychological Intervention|
45445836|NCT03764319|Other|Ultra-protective ventilator settings|4-5 Breaths per minute; 14-16 cmH2O Positive endexpiratory pressure (PEEP) (adjust PEEP to 23 < Plateau pressure < 25 cmH2O); 23-25 cmH2O Plateau pressure (adjust to not exceed Tidal volume > 4 mL/kg Predicted body weight (PBW)); < 4mL/kg PBW Tidal volume; 1:5 Inspiration:Expiration (I:E)
45619165|NCT02499653|Behavioral|Videos|
45619166|NCT03231865|Diagnostic Test|Non-invasive measurement of ZincProtoporphyrin IX|Within 30 seconds, a measurement is performed on the lip of a patient to determine a ZincProtoporphyrin value
45619167|NCT05467163|Device|Biventricular pacemaker implantation|Implantation of permanent pacemaker with biventricular stimulation with or without defibrillator lead placement using standard techniques. The right ventricle lead will be positioned in the RV apex or septum, while the left ventricle lead will be delivered to the most appropriate coronary sinus tributary, preferably posterolateral or lateral vein.
45619168|NCT05467163|Device|Conduction system pacing device implantation|Left bundle branch pacing (LBBP) will be the preferred pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory. If LBBP will be unobtainable, His bundle pacing (HBP) implantation will be attempted. His bundle potential mapping will be performed with the use of the electrophysiological system and under fluoroscopic guidance. Distal HB potential with a large ventricular signal and a small atrial signal will be targeted before the pacing lead will be screwed into position. Backup RV lead will be mandatory for all patients receiving HBP devices.
45619169|NCT05467163|Procedure|AV node ablation|Atrioventricular node ablation (AVNA) will be performed following pacemaker implantation (preferably during the same hospitalization). After femoral vein access will be obtained, the ablation catheter will be positioned to the presumed area of the AV node in the mid-septum under fluoroscopy. The location will be optimized according to the intracardiac electrograms. Ablation will be performed in a temperature-controlled mode. Successful AVNA will be recognized with an abrupt drop of heart rate to 40 bpm and will continue for 60 seconds thereafter.
45619170|NCT02496143|Drug|EC-18|EC-18 will be supplied as 500 mg Softgel capsules. The study will include up to four sequential dose cohorts. Six subjects in each cohort will be randomized to receive EC-18: 500, 1000, 2000, or 4000 mg by oral administration of 1, 2, 4, and 8 EC-18 capsules, for Cohorts 1, 2, 3 or 4, respectively.
45619171|NCT02496143|Drug|Placebo|Placebo will be supplied as Softgel capsules. The study will include up to four sequential dose cohorts. Two subjects in each cohort will be randomized to placebo and will receive 1, 2, 4 or 8 placebo capsules for Cohorts 1, 2, 3 or 4, respectively.
45619172|NCT02499107|Dietary Supplement|Rice treatment|All arms are given to all participants, in a randomized (cross over) order
45619173|NCT02499107|Dietary Supplement|Pasta treatment|
45619174|NCT02499107|Dietary Supplement|Boiled and mashed potato treatment|
45619175|NCT02499107|Dietary Supplement|Baked french fries treatment|
45619176|NCT02499107|Dietary Supplement|Fried french fries treatment|
45619177|NCT02506283|Device|Zamar Therapy CT clinic|Zamar Therapy is a certified medical product (directive 93/42/EEC and ISO 134 85:2012) (www.zamarmedical.com)
45761157|NCT05587972|Other|survey|Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic PRO surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks.
45761158|NCT00866749|Drug|Daunorubicin|Starting Dose 25 mg/m^2 by vein weekly
45761159|NCT00866749|Drug|Vincristine|Starting Dose 2 mg by vein weekly
45761160|NCT00866749|Drug|PEG-asparaginase|Starting Dose 2000 International units/m2 by vein in week 1
45619178|NCT02506439|Dietary Supplement|10 mcg Vitamin D3|Once daily, 10mcg (400IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
45619179|NCT02506439|Dietary Supplement|20 mcg Vitamin D3|Once daily, 20mcg (800IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
45619180|NCT02506439|Dietary Supplement|Placebo|Once daily, placebo capsule containing 0mcg (0IU) of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
45619181|NCT04497701|Drug|PEG-rhG-CSF group|Patients received a single dose of 100 ug/kg of PEG-rhG-CSF（Jinyouli®）, on the basis of actual body weight. Peg-rhG-CSF can be used prophylactically only when the interval between two chemotherapy regimens is no less than 12 days.
45911703|NCT05777083|Diagnostic Test|KardiaMobile 6L|Before coronary angiography, all participants will contact both fingers on the two probes at the front side of portable 6-leads electrocardiogram recorder (KardiaMobile 6L), and be recorded all six leads by contacting the other side of probe at lower extremities (left hip bone ridge, thigh, knee, lower abdomen, etc.).
45911704|NCT05776641|Device|GENUS|Participants will use the GENUS light and sound device at home for 60 minutes daily for 12 months
45619182|NCT04497701|Drug|rhG-CSF group|Patients received 5μg/kg/d of rhG-CSF, on the basis of actual body weight.
45911705|NCT05775367|Device|Cochlear Implant|A cochlear implant is a surgically implanted device that provides access to sound in people cannot get enough access to sound for communication with traditional hearing aids.
45911706|NCT05775250|Drug|giomer varnish|Giomer varnish containing surface pre-reacted glass-ionomer (PRG) filler, will be administrated once.
45619183|NCT02496065|Drug|BLZ-100|
45619184|NCT02495675|Device|High flow nasal cannulas|Comparison of different flow levels
45619185|NCT02495675|Device|Conventional flow via nasal prongs|Low flow of air delivered through conventional nasal prongs
45619186|NCT02495753|Procedure|Vaginal Cleansing|The vagina will be prepped in two passes with sponge sticks soaked in 1% povidone-iodine solution from a prepackaged sterile pouch.
45619187|NCT02495753|Procedure|Abdominal Cleansing|The abdomen will be cleansed using chlorhexidine or betadine according to surgeon's preference prior to cesarean.
45619188|NCT02495597|Other|no intervention - just observational|
45619189|NCT03341897|Procedure|endovasculer embolization of varicocele|"Step 1: Vascular Access~Access can be achieved via the internal jugular or femoral veins. Step 2: Left Renal Vein Injection Step 3: Left Spermatic Vein Catheterization Step 4: Spermatic Vein Occlusion Step 5: Right Spermatic Venography POSTPROCEDURE CARE~The patient is kept in bed for 1 hour postprocedure. The patient is advised to take anti-inflammatory agents as needed and to avoid any activity involving the Valsalva maneuver, such as lifting, vigorous, or hitting type sports for 3 full days beginning the day after the proce¬dure. Most patients report a minor dull ache in the back or groin lasting < 2 to 5 days. Fewer than 5% of patients will develop more severe pain lasting up to 14 days, requiring oral analgesics and anti-inflammatory agents and avoidance of vigorous exercise."
45619190|NCT02495519|Drug|Imatinib|Imatinib 400 mg/day until disease progression
45619191|NCT02495207|Device|Piezosurgery|This intervention is dependent on use of piezosurgery to conduct the required bone cuts to remove third molars.
45619192|NCT02499341|Drug|Tramadol|Tramadol administered intravenously (1mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of tramadol (0.2mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
45619193|NCT02499341|Drug|Ketamine|Ketamine administered intravenously (0.5mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of ketamine (0.12mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
45619194|NCT02499185|Device|Nephro Check Test|Urine sample
45619195|NCT02499185|Other|serum creatinine measurement|Blood sample
45619196|NCT02495285|Drug|Gelofusine 4%|
45619197|NCT02495285|Drug|Gelaspan 4%|
45619198|NCT02495363|Procedure|PECS Block|"As standard departmental protocol ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .~The concentration is determined by the upper dose limit to 2 mg / kg 11"
45619199|NCT02495363|Drug|Bupivacaine 0.25-0.5%|"Ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .~The concentration is determined by the upper dose limit to 2 mg / kg 11"
45619200|NCT03121079|Drug|Interferon-alpha|patients in Interferon-alpha group will receive Interferon-alpha injection since the third month after transplantation for six months.
45619201|NCT03120845|Procedure|One visit RCT|Root canal treatment in one vist
45619202|NCT03120845|Procedure|Post operative pain in two-visits RCT|Root canal treatment in Two visits
45619203|NCT02495441|Other|Use of Rapid Immunoassay Tests for the Detection of PROM|"After informed consent , both the ROM Plus®, ActimProm Amnioquick® Complete and AmniSure® bedside tests (without the use of a speculum) will be performed.~The patient will then undergo the standard clinical assessment, which includes a sterile speculum exam (SSE). If either 1) amniotic fluid is seen leaking from the cervical os, or 2) if at least two of the following three clinical signs are present: visual pooling of fluid in the posterior fornix, positive nitrazine test, and microscopic evidence of ferning, then the patient will be considered positive for ROM.~Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of IGFBP-1/AFP tests and Amnisure®."
45619204|NCT02495129|Drug|VAY736 lower dose|Patients will receive a total number of 3 monthly subcutaneous injections with the lower dose of VAY736
45619205|NCT02495129|Drug|VAY736 higher dose|Patients will receive a total number of 3 monthly subcutaneous injections with the higher dose of VAY736
45619206|NCT02495051|Procedure|esophageal biopsies|
45619207|NCT02498795|Other|Group of Dry Needling|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
45619208|NCT02498795|Other|Group of Electrolysis|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
45619209|NCT02498795|Other|Control Group|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
45619210|NCT02494973|Drug|Oxaliplatin HAI|Oxaliplatin 85 mg/m² in 2 hours HAI day (D)1,
45619211|NCT02494973|Drug|Oxaliplatin IV|Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,
45619212|NCT02494973|Drug|mFOLFOX6|Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours.
45911707|NCT05774730|Other|Emphysema quantitative analysis software based on chest image AI technology|The participants would undergo lung CT, and the integrity of interlobar fissure will be quantitatively analyses by software based on chest image AI technology.
45619213|NCT02494973|Drug|LV5FU2|Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours.
45619214|NCT02494895|Drug|Ticagrelor monotherapy|Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to stop aspirin at 3 months after PCI.
45761161|NCT00866749|Drug|Intrathecal Methotrexate|Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid
45761162|NCT00866749|Drug|Cyclophosphamide|Starting Dose 1g/m2 by vein in weeks 1 and 5
45761163|NCT00866749|Drug|Cytarabine|75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months
45761164|NCT00866749|Drug|Mercaptopurine|Starting Dose 60 mg/m2 by mouth on days 1-14 of each month
45761165|NCT00866749|Drug|Methotrexate|"Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10~+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3"
45761166|NCT00866749|Drug|Doxorubicin|25 mg/m2 by vein in weeks 1, 2 and 3
45619215|NCT02494895|Drug|Ticagrelor with Aspirin DAPT(dual antiplatelet treatment)|Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to continue DAPT (aspirin+ticagrelor) up to 1 year.
45619216|NCT02498873|Behavioral|Linear Periodization|Linear Intensity Periodization Running
45761167|NCT00866749|Drug|Thioguanine|60 mg/m2 by mouth daily for two weeks
45761168|NCT04740112|Other|Foods with beta-glucan from oats and barley|Breakfast bars made with varying levels of total dietary fiber and beta-glucan, with or without claims on package image
45761169|NCT05587660|Procedure|Fully threaded cannulated screws|The most popular method in undisplaced neck of femur fracture include internal fixation by cannulated screws in which screws can be inserted relatively simply and atraumatically as compared to other methods. Screws can be used partially threaded or fully threaded; however studies on fully threaded screw fixation method are inconclusive.
45761170|NCT00866905|Drug|Ixabepilone|40 mg/m2 IV infusion over 3 hours on day 1 of a 21 day cycle for 6 cycles
45761171|NCT00866905|Drug|Cyclophosphamide|600 mg/m2 IV infusion per institutional guidelines on day 1 of a 21 day cycle for 6 cycles
45761172|NCT05587426|Dietary Supplement|SFF|Ingestion of 20g of SFF after 10-14 hours of fasting
45761173|NCT05587426|Dietary Supplement|Glucose|Ingestion of 20g of glucose after 10-14 hours of fasting
45761174|NCT05587426|Dietary Supplement|SFF chocolate chips|Ingestion of 50g of chocolate chips made with SFF after 10-14 hours of fasting
45445837|NCT03764319|Other|Standard ventilator settings|12-25 Breaths per minute; 8-12 cmH2O PEEP; max. 35 cmH2O Plateau pressure
45452311|NCT01088009|Drug|lamivudine|Patients will receive oral lamivudine 100mg,daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
45619217|NCT02498873|Behavioral|Non Linear Periodization|Non Linear Periodization Running
45619218|NCT02498717|Device|GameReady|Cryotherapy and compression
45619219|NCT02498717|Other|RICE|SOC ice and elevation
45761175|NCT05587426|Dietary Supplement|Regular chocolate chips|Ingestion of 50g of regular chocolate chips after 10-14 hours of fasting
45761176|NCT05582980|Device|HD-tDCS|See detail in arm/group descriptions regarding the intervention.
45761177|NCT00867139|Drug|TCAD|TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
45761178|NCT00867139|Drug|Zanamivir or Oseltamivir|Zanamivir or Oseltamivir
45761179|NCT00867139|Other|Open label treatment with TCAD|TCAD(amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
45761180|NCT05441878|Drug|20% albumin|Albumin arm for resuscitation fluid
45761181|NCT05441878|Drug|Balanced salt solution|Only Balanced salt solution will be used.
45761182|NCT05370430|Biological|BAFFR-CAR T cells|First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-NHL
45761183|NCT05342818|Drug|Neostigmine|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
45761184|NCT05342818|Drug|Ondansetron 8mg|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
45761185|NCT05342818|Drug|Metoclopramide Injection|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
45761186|NCT05342818|Other|Enteral feeding nutrition|The type and rate of enteral feeding nutrition will be the same for all patients (180ml/3h). All patients have a 30-degree head-up position
45761187|NCT05342818|Other|Sequential Organ Failure Assessment (SOFA) score|SOFA score will be performed on all patients before the beginning of the study
45761188|NCT00867217|Dietary Supplement|High Dose Vitamin D|High Dose Vitamin D3 (3 capsules of 10,000 IU) weekly for 24 weeks.
45761189|NCT00867217|Dietary Supplement|Placebo|Placebo comparator
45761190|NCT00867217|Dietary Supplement|Standard Dose Vitamin D3|Standard Dose Vitamin D3 (600 IU of vitamin D3 daily)
45761191|NCT00867217|Drug|Letrozole 2.5mg|All subjects received letrozole as standard of care.
45761192|NCT05337592|Drug|BI 1815368 formulation 1|BI 1815368 formulation 1
45761193|NCT05337592|Drug|Placebo|Placebo
45761194|NCT05337592|Drug|BI 1815368 formulation 2|BI 1815368 formulation 2
45761195|NCT00867451|Behavioral|Sleep Intervention|A structured sleep protocol is taught to parents, use of a white noise generator
45761196|NCT00867451|Drug|Melatonin|Body Weight <40mg will be given 3mg at bedtime for two weeks Body Weight >40mg will be given 6 mg at bedtime for two weeks
45761197|NCT05302414|Other|board game-based teamwork training|Using board game-based learning to develop resuscitation teamwork competency in PGY doctors and nurses.
45619220|NCT02498639|Procedure|percutaneous balloon aortic valvuloplasty|"Percutaneous BAV is performed according to the standard retrograde technique. The measurement of the trans-aortic gradient is given by two catheters placed one in the left ventricle, the other in ascending aorta. An extra stiff wire is placed in the left ventricular cavity. A balloon (size fitting the valve annulus) is inserted over the wire and a series of three inflations is performed at nominal pressure.~The procedure terminates in case of:~Reduction of the mean aortic gradient ≥50%.~Aortic pressure drop during the inflations, indicative of valve orifice sealing.~Intraprocedural complication.~Poor compliance of the patient. If none is met, the balloon is changed with a bigger one and a new series of three inflations performed. Aortic gradient is finally recorded."
45619221|NCT02494739|Other|Yogurt enriched with polyphenols|Yogurt enriched with polyphenols extracted from grape seeds
45619222|NCT02494739|Other|Yogurt not enriched with polyphenols|Yogurt not enriched with polyphenols
45619223|NCT02494661|Behavioral|Healthy Cart and Stress Management Videos|Healthy Cart and Stress Management Videos: educational videos on healthy food shopping and stress reduction.
45619224|NCT02494661|Behavioral|Healthy Cart Video|Healthy Cart Video: educational video on healthy food shopping
45619225|NCT02494427|Device|CAD/CAM manufactured fixed unitary dental prostheses|
45619226|NCT02494427|Device|Conventionally manufactured unitary dental prostheses|
45619227|NCT03341819|Procedure|Total knee arthroplasty|A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)
45619228|NCT03341819|Procedure|Urinary Catheterization|Urinary catheterization is a latex, polyurethane, or silicone tube known as a urinary catheter is inserted into a patient's bladder via the urethra. Catheterization allows the patient's urine to drain freely from the bladder for collection.
45619229|NCT03341741|Drug|Tobramycin Powder|TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off);
45619230|NCT03341741|Drug|Colistin|Colistin solution 2 x daily 1 Mega continuously
45619231|NCT02498327|Other|Gelatine Capsule|Gelatine capsules containing only the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
45619232|NCT02498327|Other|Venavine Intensive®|Gelatine capsules containing 360 mg Red Vine Leaf extract, 60 mg of Horse Chestnut extract, 35 mg of Butchers Broom extract and 3,2 mg of Vitamin B6 as well as the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
45619233|NCT03341663|Combination Product|Coronary angiography,Canadian Cardiovascular Society angina pectoris classification for the severity of angina and electronic Von Frey instrument for testing the degree of acupoint sensitization|All the interventions were tested for only once
45619234|NCT04494581|Other|questionnaire|Questionnaire survey
45619235|NCT02498561|Procedure|nonsurgical periodontal therapy|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
45619236|NCT02498561|Procedure|oral hygiene instructions|Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush
45619237|NCT02498561|Procedure|nonsurgical periodontal therapy|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
45619238|NCT02498561|Procedure|oral hygiene instructions|Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush
45619239|NCT01597245|Drug|80 mg ixekizumab Dosing Regimen|Administered SC
45761198|NCT05302414|Behavioral|simulation-based teamwork training|Using board simulation-based learning to develop resuscitation teamwork competency in PGY doctors and nurses.
45761199|NCT05302414|Other|lecture-based teamwork training|Using board lecture-based learning to develop resuscitation teamwork competency in PGY doctors and nurses.
45761200|NCT05239156|Device|Janesse|"Device: Janesse® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation.~The subjects will receive at baseline the first investigational medical device by the Investigator in accordance with the clinical investigation plan."
45619240|NCT01597245|Drug|50 mg etanercept|Administered SC
45761201|NCT00867529|Biological|rituximab|Given IV
45761202|NCT00867529|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation
45445838|NCT03759093|Drug|Bortezomib|Dose in the range of 0.7,1.0,1.3 or 1.5 mg/m2 subcutaneous (SC) injection on Day 1, 8, 15 ,22 for cycles 1 to 4 , as determined by the clinical care team according to standard of care
45619241|NCT01597245|Drug|Placebo|Administered SC
45619242|NCT03341585|Other|expiration lente prolongée|l'Expiration Lente Prolongée (ELPr) is a passive technique to enhance the expiration used in infants, obtained by a slow and increasing manual thoraco-abdominal pression applied at the end of a spontaneous expiration till the residual volume. The aim is to obtain a bigger expired volume compared to a normal expiration and drain the mucus out of the airways (Postiaux 2003). This technique has been invented by Guy Postiaux and is used in the Chest Physiotherapy (CPT).
45619243|NCT03341429|Drug|Liraglutide Pen Injector [Saxenda]|Daily injection of GLP-1 agonist (liraglutide 3.0 mg) for obese patients presenting poor weight loss (<20%) after bariatric surgery and suboptimal GLP-1 levels.
45761203|NCT00867529|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation
45761204|NCT00867529|Other|pharmacological study|Correlative studies
45761205|NCT00867529|Other|laboratory biomarker analysis|Correlative studies
45761206|NCT05199220|Other|Questionnaire|Participant must complete a questionnaire about injury during crossfit practice
45761207|NCT05197270|Biological|4D-150 IVT|4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept
45619244|NCT03341429|Drug|Placebo|Daily subcutaneous injection
45619245|NCT03342833|Device|Blood flow restriction|Occlusion of venous flow between bouts of HIIT training exercise
45619246|NCT04494659|Drug|Famitinib capsule|single dose and co-administrated with Rifampicin capsule
45761208|NCT05197270|Biological|Aflibercept IVT|Commercially available Active Comparator Other Name: Eylea
45619247|NCT04494659|Drug|Rifampicin capsule|repeated doses of Rifampicin capsule
45911708|NCT05774730|Other|artificial analysis of chest image|The participants would undergo lung CT, and the integrity of interlobar fissure will be artificially analyses.
45911709|NCT05774730|Procedure|imported Chartis detection system|The participants would undergo imported Chartis detection system.
45619248|NCT03341351|Other|Instructional video|Instructional video using the modified beef tongue model
45619249|NCT03341351|Other|Instructional workshop|Instructional workshop using the modified beef tongue model.
45619250|NCT03341195|Behavioral|SMS messages and automated calls|The intervention consists of SMS and automated calls based messages
45619251|NCT03342677|Diagnostic Test|Primovist MRI|Utility of Gd-EOB-DTPA (Primovist) enhanced Liver MRI in HCC detection and characterization in cirrhotic patients will be studied.
45619252|NCT03342599|Dietary Supplement|Alpha Lipoic Acid Supplement|Alpha lipoic acid ingestion (600mg/daily) for 8 weeks with no change in lifestyle.
45619253|NCT03342599|Dietary Supplement|Placebo|Cellulose fiber ingestion (600mg/daily) for 8 weeks with no change in lifestyle.
45761209|NCT02417779|Device|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
45445839|NCT03759093|Drug|Cyclophosphamide|Dose in range of 100, 150, 200, 250, 300, 350, 400, 450 or 500 mg per os (PO) on Day 1, 8, 15, 22 for cycles 1 to 4 as determined and guided by the clinical care team according to standard of care
45911710|NCT05774483|Procedure|Sentinel Node Biopsy|The Sentinel node will be localized after injecting peritumoral nano colloid followed by dynamic lymphoscintigraphy and SPECT localization. Methylene blue or indocyanine green may be used but not mandatory as an adjunct for lymphoscintigraphy for node localization. Intraoperatively the node will be identified using a hand-held gamma probe. The sentinel node will be processed on a frozen section, histopathological processing with serial step sectioning, and immunohistochemistry. If reported as metastatic, then a single-stage or second-stage completion neck dissection will be performed.
45911711|NCT05774483|Procedure|Limited Elective Neck Dissection|Patients who are allocated to the limited END arm will undergo dissection of level I, IIa and III/IV nodes sparing level IIb. Level IIa will be subjected to a frozen section and if reported as metastatic will mandate clearance of level IIb.
45911712|NCT05774301|Behavioral|simulation-based training|the training will include a theoretical & practical parts
45911713|NCT05773248|Procedure|ERAS protocol|The main concepts of the ERAS protocol compared to standard care included the following aspects: preoperative counselling with a specially trained nurse, restrictive use of preoperative sedation, intraoperative fluid and opioid administration and drain placement, strict antiemetic prophylaxis, early mobilisation, bowel stimulation and removal of any catheters as well as early food intake. Additionally, the ERAS protocol included a 30-day telephone follow-up.
45911714|NCT05764551|Diagnostic Test|Serum DNA methylation|Serum DNA methylation
45911715|NCT05755672|Drug|Chemotherapy|Neo-adjuvant and adjuvant chemotherapy with curative intent, according to the current clinical practice guidelines
45911716|NCT05755672|Procedure|Resection of the primary tumor|Surgical resection of the primary tumour, according to the current clinical practice guidelines
45619254|NCT03341117|Drug|Acetylsalicylic acid|Acetylsalicylic acid 300 mg per capsule
45619255|NCT03341117|Drug|Calcined magnesia|Calcined magnesia 300 mg per capsule
45619256|NCT05035719|Device|non-invasive cardiac output monitor|Equivalence of Caretaker cardiac output reading to reference standard
45619257|NCT02498249|Device|low level laser therapy|Will be performed irradiation with low-intensity laser in upper trapezius muscle
45619258|NCT02498249|Device|Placebo low level laser therapy|Will be not performed irradiation with low-intensity laser in upper trapezius muscle
45619259|NCT02498171|Drug|Intrathecal morphine with fentanyl|"Parturients in this arm underwent a single shot spinal following standard procedure. the drug mixture was then introduced into the subarachnoid space following free flow of csf. the parturient was the monitored fo labour progression using the standard partogram, vital signs and the visual analogue scale score for pain recorded every 5 min.~The fetus was monitored with an ultrasonic aided fetal Doppler until delivery"
45619260|NCT02498171|Drug|Intrathecal morphine with bupivacaine|"Parturients in this arm underwent a single shot spinal following standard procedure. the drug mixture was then introduced into the subarachnoid space following free flow of csf. the parturient was the monitored fo labour progression using the standard partogram, vital signs and the visual analogue scale score for pain recorded every 5 min.~The fetus was monitored with an ultrasonic aided fetal Doppler until delivery"
45619261|NCT05035875|Device|ultrasonography|ultrasound assessment of diaphragm function
45619262|NCT03342521|Diagnostic Test|optical coherence tomography and VerifyNow|optical coherence tomography Imaging P2Y12 and Aspirin reaction units quantification by the VerifyNow
45619263|NCT03120533|Drug|Iontophoresis of treprostinil|the participant will receive 10 days of iontophoresis of treprostinil on a first site
45619264|NCT03120533|Drug|Iontophoresis of placebo|the participant will receive 10 days of iontophoresis of NaCl on a second site, but the same time than treprostinil; it's like a design of cross-over study
45619265|NCT03096951|Behavioral|Prehabilitation|Prehabilitation group will receive a 4-week tele-supervised prehabilitation and a 8-week tele-supervised postoperative rehabilitation.
45761210|NCT02417779|Device|Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
45911717|NCT05755672|Procedure|Resection of tumour metastases|Surgical resection of tumour metastases, according to the current clinical practice guidelines
45911718|NCT05755672|Procedure|Blood sampling during chemotherapy|Drawing of blood samples several times during patient visits for chemotherapy regimen
45911719|NCT05753306|Procedure|Biospecimen Collection|Undergo stool and blood sample collection
45911720|NCT05753306|Drug|Cisplatin|Given via HIPEC
45911721|NCT05753306|Procedure|Computed Tomography|Undergo CT scan or PET/CT
45911722|NCT05753306|Drug|Docetaxel|Given via HIPEC
45911723|NCT05753306|Procedure|Gastrectomy|Undergo robotic gastrectomy
45911724|NCT05753306|Drug|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
45619266|NCT03096951|Other|Rehabilitation|Rehabilitation group will receive World Health Organization recommendations on physical activity for health before surgery and a 8-week tele-supervised postoperative rehabilitation.
45619267|NCT03120767|Behavioral|Risk and Resilience|"The Risk and Resilience course is a 14-week undergraduate seminar that is grounded in the current understanding of adolescent and young adult development, neuroscience, and positive psychology. Students will learn about key areas proven to enhance wellness, including communication, executive functioning, social support, self-efficacy, emotion regulation, and sense of purpose. Students will learn about healthy exercise, nutrition, and sleep habits, and develop skills in core components of cognitive-behavior therapy, mindfulness, and organizational skills."
45619268|NCT03120767|Behavioral|Coordinated Wellness Programming|"During the Fall of 2017, wellness activities will be provided within Founders Hall that support the theories and skills being taught in the Risk and Resilience course occurring in the same semester."
45619269|NCT05043909|Behavioral|VR-based training|Students simulate the different physical and oral conditions of the elderly through virtual situations and provide suitable oral care methods. The whole training session took approximately two hours for each student; First, students were first given a short introduction to the VR system's use (10 minutes). Second, they were able to carry out oral care for the elderly while wearing VR goggles and using hand-controllers with the teaching and audio guides during the process (90 minutes), and an evaluation was taken after the intervention (20 minutes).
45619270|NCT03340649|Other|taking peripheral blood|taking peripheral blood of no more than 3ml
45619271|NCT05035563|Behavioral|Intervention. Early and integral communication strategy (EICS)|"This intervention will be implemented in patients since they are hospitalized in the ICU where is expected:~Facilitate contact and communication between patients, families and the health team.~Respond to the communication needs of family members.~Reduce equipment overload and facilitate communication with families and patients, providing tools and timely support.~Build a positive and trusting relationship of relatives and patients with health teams.~The intervention considers the following actions:~- Training in communication to the health team~- Written material~- Family website~- Standardized and daily telephone information~- Health Team Support Strategy~- Weekly multidisciplinary virtual meeting with the family~- ICU diaries for family members"
45619272|NCT03342443|Drug|Memantine|Patients receive memantine with a dosage of 5 microgram at 8 am daily for one week (Week 1), then 5 microgram at 8 am and 5 microgram at 5 pm for one week (Week 2), then 10 microgram at 8 am and 5 microgram at 5 pm for one week (Week 3), then 10 microgram at 8 am and 10 microgram at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
45619273|NCT03342443|Drug|Placebo|Patients receive placebo with a dosage of one halfpill at 8 am daily for one week (Week 1), then one halfpillat 8 am andone half pill at 5 pm for one week (Week 2), then one pillat 8 am and one half pill at 5 pm for one week (Week 3), then one pill at 8 am and one pill at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
45619274|NCT05035485|Drug|Phenylephrine|A rescue phenylephrine (75μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia
45619275|NCT05035485|Drug|Norepinephrine|A rescue norepinephrine (6μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia
45619276|NCT02498093|Behavioral|Maximal strength training|
45619277|NCT02498093|Behavioral|conventional rehabilitation|
45619278|NCT05035329|Other|Outcome measurements|Outcome measurements were applied.
45619279|NCT02498015|Drug|"3D regimen"|"The 3D regimen contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily for genotype 1b without cirrhosis."
45911725|NCT05753306|Procedure|Magnetic Resonance Imaging|Undergo MRI
45911726|NCT05753306|Procedure|Positron Emission Tomography|Undergo PE/CT
45911727|NCT05753306|Other|Questionnaire Administration|Complete questionnaire
45911728|NCT05751655|Other|Prehospital care following drowning accident|Prehospital care provided by the emergency medical service 83 (SAMU 83)
45911729|NCT05744973|Other|No intervention|This is an observational study
45911730|NCT05742685|Behavioral|Reinforcement Learning|Participants in the intervention arm will receive up to daily, tailored text messages based on their electronic pill bottle-measured adherence. Given the participants' baseline characteristics and time-varying responses to the messages, a reinforcement learning algorithm will deliver different text messages and adapt over time to determine which type of messaging works best for each individual participant.
45445840|NCT03759093|Drug|Dexamethasone|8, 12 , 16, 20, 24, 28, 32 , 36 or 40 mg PO on Day 1 ,8 , 15, 22 for cycles 1 to 4, as determined and guided by the clinical care team according to standard of care
45445841|NCT03759093|Other|CURATE.AI-Guided dosage modulation|CURATE.AI-guided modulation of Velcade and Cyclophosphamide dosages
45445842|NCT03759093|Drug|Thalidomide|Dose in a range of 50, 100, 150, 200 mg PO on day 1-28 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
45619280|NCT02498015|Drug|"3D regimen with ribavirin"|"The 3D regimen with ribavirin contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily, and ribavirin (1000 mg regardless of weight) daily in two divided doses for genotype 1a and genotype 1b with cirrhosis."
45619281|NCT05054517|Dietary Supplement|Glutamine|Oral Supplement
45619282|NCT05043753|Other|Point of care ultrasound to measure the fetal abdominal circumference (POC-US-AC)|"Midwives perform a POC-US to measure the fetal abdominal circumference (AC) and evaluate the quantity of amniotic fluid.~In order to identify the appropriate sonographic plane the following markers need to be identified on POC-US~Fluid filled fetal stomach on the left.~Umbilical vein~Umbilical portion of left portal vein within liver, as it meets the pars transversa (horizontal portion of left portal vein) seen as a right sided  L  or  C  shape.~Fetal spine seen in cross section Amniotic fluid volume will be evaluated determining the deepest vertical pocket (DVP). Measurement is performed by assessing a pocket of maximal depth of amniotic fluid free of umbilical cord and fetal parts. The transducer is held perpendicularly to the patient's abdomen. The absence of a pocket measuring at least 2 cm in depth and 1 cm in width is indicative of oligohydramnios, while detection of a pocket measuring 8 cm or larger is suggestive of polyhydramnios (ACOG bulletin 175, 2016)."
45619283|NCT05043597|Procedure|Thrombus aspiration|Thrombus aspiration
45619284|NCT02494505|Drug|Mycophenolate Mofetil|2g/day per os
45619285|NCT02494505|Drug|placebo|
45619286|NCT03340493|Drug|Tenecteplase|Tenecteplase 0.25mg/kg and 0.4mg/kg are being used
45445843|NCT03759093|Drug|Bortezomib|Dose in a range of 0.7,1.0,1.3 or 1.5 mg/m2 subcutaneous (SC) injection on Day 1, 8, 15 ,22 for cycles 1 to 4 , as determined and guided by CURATE.AI and approved by the clinical care team
45619287|NCT03096795|Drug|MEDI3506|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 1 or Dose 2 or Dose 3 or Dose 4 or Dose 5 or Dose 6 subcutaneously and Dose 6 intravenously in Part 1. Participants with COPD will receive 3 administration of MEDI3506 Dose 4 or Dose 5 or Dose 6 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of MEDI3506 Dose 6 intravenously in Part 3.
45619288|NCT03096795|Drug|Placebo|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously in Part 1. Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously in Part 3.
45619289|NCT03098199|Drug|300IU Gonal-F|<1.5 AMH group
45619290|NCT03098199|Drug|150IU Menopur|<1.5 AMH group
45619291|NCT03098199|Drug|225IU Gonal-F|1.6-2.5 AMH group
45619292|NCT03098199|Drug|75IU Menopur|1.6-2.5 AMH group 2.6-6.9 AMH group >7.0 AMH group
45619293|NCT03098199|Drug|150IU Gonal-F|2.6-6.9 AMH group
45619294|NCT03098199|Drug|75IU Gonal-F|>7.0 AMH group
45619295|NCT00707057|Drug|Ibuprofen 600 mg Extended-Release Tablets|Ibuprofen 600 mg Extended-Release Tablet: One 600 mg tablet taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
45911731|NCT05741892|Device|Fracture reposition with 3D printed patient specific repositions guides|Comminuted tibial- or/and femur shaft fractures will be treated using 3D printed patient-specific repositions guides.
45911732|NCT05740995|Drug|neoadjuvant anti-PD-1 plus chemotherapy|"Patients will be given preoperative treatment as below once recruited:~Chemotherapy is delivered and composed of two cycles of Nab-paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 3 weeks;~PD-1 antibody is delivered 200 mg (iv, in 30 minutes) every 3 weeks;~After neoadjuvant therapy of 3-4 cycles, esophagectomy is performed. We advise starting 4 cycles of identical chemoimmunotherapy in 6w after surgery."
45911733|NCT05735678|Device|Single-Use Duodenoscopes|Single-Use Duodenoscopes
45911734|NCT05734417|Dietary Supplement|Probiotic|Oral administration of Bifidobacterium lactis subsp. infantis B8762 at 0.5x10 log colony forming unit (CFU)/day for 4-weeks
45619296|NCT00707057|Drug|Placebo|Placebo: One matching placebo tablet was taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
45619297|NCT05034705|Device|Conventional suction system|This is the conventional method of using the dental high volume suction to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
45619298|NCT05034705|Device|Dental aerosol box with modified high volume evacuation system|The dental aerosol box will be equipped with an exit for the high volume suction to be attached to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
45619299|NCT03096561|Diagnostic Test|blood draw from three different vessels|Patient in cardiac-arrest and cold exposure, diagnostic test: blood draw from three different vessels (central vein, artery, peripheral vein) and measuring of PR
45619300|NCT02494349|Drug|JLP-1207|The subjects will receive JLP-1207 under fed(high fat meal) condition. After washout period, the subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition.
45619301|NCT02494349|Drug|Solifenacin 5mg+Tamsulosin 0.2mg|The subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition. After washout period, the subjects will receive JLP-1207 under fed(high fat meal) condition.
45619302|NCT05034237|Device|ND;YAG 1064NM LASER|laser hair removal sessions
45619303|NCT02497859|Behavioral|Egg Breakfast (EB)|The EB will receive a breakfast of higher quality protein, but similar in macronutrient and energy density than the active comparator. The EB will have the following energy density, macronutrient composition, and protein score: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.5%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.
45911735|NCT05734417|Dietary Supplement|Placebo|Intervention consists of daily administration of 2g/sachet of excipient administered daily for 4-weeks
45619304|NCT02497859|Behavioral|Cereal Breakfast (CB)|The CB will receive a breakfast of lower quality protein, but similar in macronutrient and energy density than the experimental treatment. The CB will have the following energy density, macronutrient composition, and protein score: weight 293 g, energy 398 kcal, energy density 1.3 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
45619305|NCT02497859|Behavioral|Weight Loss Counseling|Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics including portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, will be discussed. Self-monitoring, motivational interviewing, goal setting, and problem solving will be the behavioral strategies used during counseling.
45619306|NCT02497859|Behavioral|Weight Loss Diet|Energy intake for study duration will be prescribed at 1,200-1,500 kcals adjusted for each individual's body weight.
45761211|NCT05169190|Procedure|Stellate Ganglion Block|After procedure informed consent, the procedure will be done using an ultrasound guided technique with a high frequency (6 to 13 MHz) linear transducer and confirmation of placement by fluoroscopy at sites who do this in clinical practice. The subject will be prepped and draped and placed in supine position in a suite with continuous vital sign monitoring and advanced cardiac life support equipment and IV placement. Local anesthesia with 1% buffered lidocaine will be achieved. After visualization of Chassaignac's tubercle of C6 is identified along with the carotid artery, internal jugular vein and longus colli and capitus muscles, a 25-gauge echo-enhanced needle will be inserted to inject anesthetic over 2 minutes anterior to the prevertebral fascia at the ventral aspect of the longus colli muscle, medial to Chassaignac's tubercle. The needle will be withdrawn and the subject will be monitored for a minimum of 30 minutes.
45761212|NCT05169190|Procedure|Sham Stellate Ganglion Block|"The Sham protocol is identical to the SGB protocol except After needle tip confirmation and negative aspiration, normal saline (0.9%) + contrast (unlabeled to keep treater blinded) will be slowly injected over 2 minutes while closely monitoring the subject."
45619307|NCT05043519|Drug|FAM-NP41|The patients will be injected with FAM-NP41 in one dose intravenously 2 hours prior to the dural incision.
45619308|NCT05034315|Other|Whole egg consumption|The participants in the whole egg group consumed two whole eggs immediately after exercise.
45619309|NCT05430347|Combination Product|Neoadjuvant therapy: TCbHPy|Pyrotinib combined with docetaxel, carboplatin and trastuzumab (TCbHPy) for neoadjuvant therapy of HR+/HER2+ breast cancer
45619310|NCT05430347|Combination Product|Neoadjuvant therapy: TCbHP|Pertuzumab combined with docetaxel, carboplatin and trastuzumab (TCbHP) for neoadjuvant therapy of HR+/HER2+ breast cancer
45619311|NCT03095469|Drug|Dexmedetomidine|when the operation begin,dexmedetomidine will be pumped at 0.4μg/kg•h for 15 minutes ,then reduce the dose to 0.2μg/kg•h until 24h after PCI.
45619312|NCT03095469|Drug|0.9%NaCl solution|when the operation begin,0.9%NaCl solution will be pumped at 0.1ml/kg•h until 24h after PCI.
45619313|NCT02497703|Device|Knee robot|
45761213|NCT00367588|Behavioral|Low bacterial diet|
45911736|NCT05728866|Procedure|VR immersive therapy|Participants will be asked to participate in 5 consecutive, 1-hour, 1:1 therapy sessions focused on rehabilitation of their weakened arm. Each session will involve use of a Virtual Reality (VR) system to deliver an immersive environment to encourage movement of the arm. The system also relies on 6 body-worn sensors that will detect movements of participant's arms and trunk. VR use will encompass 30-minutes of the therapy session, the remainder of the session will involve working with the therapist in addressing the functional tasks that are most meaningful for the participant and that involve the upper extremities.
45911737|NCT05726396|Drug|RMT|A single loading dose of RMT capsules containing ~5 x 10 11 bacteria on day 1 followed by 2 x 10 11 bacteria daily for 6 days. The RMT capsule preparation (~2-5 capsules, size 00) is self-administered on an empty stomach with at least one glass of water. Clear liquids are allowed, and food can be resumed 2 hours after administration.
45911738|NCT05726396|Drug|Placebo|Participants will receive an identical looking placebo capsules daily for 7 days (i.e 5 placebo capsules on day 1), followed by 2 placebo capsules daily from Day 2-7. The placebo capsule preparation is self-administered on an empty stomach with at least one glass of water. Clear liquids are allowed, and food can be resumed 2 hours after administration.
45445844|NCT03759093|Drug|Cyclophosphamide|Dosing in a range of 100, 150, 200, 250 ,300, 350 ,400, 450 or 500 mg PO on Day 1, 8, 15, 22 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
45445845|NCT03759093|Drug|Thalidomide|Dose in a range of 50, 100, 150, 200 mg PO on day 1-28 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
45619314|NCT05034549|Device|Noninvasive ventilation|The non-invasive ventilator at home (≥5h/ night)
45619315|NCT02497625|Behavioral|Positive Therapeutic Alliance|Intervention involving reassurance and information related to the return to daily activities, advice on dealing with the pain and clear explanation of signs and symptoms. The session will take 60 minutes and will be structured to increase the therapeutic alliance and empathy. Patients will be instructed to return in a week for further consultation to clarify doubts.
45619316|NCT02497625|Behavioral|Usual care|Information about low back pain based on Back Book. The therapy will be performed with limited interaction between patient and therapist and the information will be transmitted in a clear and direct way. The limited interaction between patient and therapist in this group will be established at the first session lasting 45-60 minutes. Patients will be instructed to return for a visit after a week to clarify questions.
45619317|NCT02497625|Other|Control group|Patients will not receive intervention in the first month in which they are enrolled. After a year, the treatment offered to the Positive Therapeutic Alliance or Usual Care group will be available for patients who are interested.
45452312|NCT01088009|Drug|lamivudine, adefovir|patients in this arm will receive oral lamivudine 100mg daily and adefovir 10mg for 104 weeks
45619318|NCT05054673|Other|universal adhesive|PALFIQUE universal adhesive
45619319|NCT05054673|Other|universal adhesive|3M™ ESPE™ single bond Universal Adhesive
45761214|NCT05037292|Other|PAUSE Intervention|Standardized frailty screening and utilization of a frailty review board (PAUSE Board)
45761215|NCT05028946|Drug|Foralumab|Foralumab will be administered per dose and schedule specified in the arm description.
45619320|NCT03340259|Procedure|Exposure(s) of interest: enterostomy|Newborn infants with congenital malformations of the gastrointestinal tract, necrotizing enterocolitis, and spontaneous intestinal perforation commonly require surgery and enterostomy. In these infants samples of the enterostomy effluent will be collected and DNA extracted for microbiota identification.
45619321|NCT05054205|Behavioral|Motivational İnterviewing|"The most current version of Motivational İnterviewing (MI) is described in detail in Miller and Rollnick (2013) Motivational Interviewing: Helping people to change (3rd edition). Key qualities include:~MI is a guiding style of communication, that sits between following (good listening) and directing (giving information and advice).~MI is designed to empower people to change by drawing out their own meaning, importance and capacity for change.~MI is based on a respectful and curious way of being with people that facilitates the natural process of change and honors client autonomy."
45619322|NCT02497547|Drug|Oxytocin|
45619323|NCT02497547|Drug|Placebo|
45619324|NCT05043363|Device|LumenEye X1 digital rectoscope|The LumenEye X1 is a novel digital rectoscope that introduces digital HD imaging and improved ergonomics to conventional rigid sigmoidoscopy.
45619325|NCT05043129|Biological|Biological/Vaccine: SARS-COV-2 VACCINE|The antibody titer and adverse reactions were observed.
45619326|NCT03340181|Other|RIPC|4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb before skin incision.
45619327|NCT03340103|Dietary Supplement|LUTEIN ofta 0,5 gocce|LUTEIN ofta 0,5 gocce, containing a solution of 5% Lutein and 2,5% Zeaxanthin with excipients (Corn starch, glucose, potassium sorbate, xanthan gum, citric acid)
45619328|NCT03340103|Drug|Placebo|Placebo solution with unique excipients (Demineralised water, potassium sorbate, xanthan gum, citric acid)
45619329|NCT05054283|Diagnostic Test|Inflamatory biomarkers|laboratuary parameters of within 24 hours of admission (levels of white blood cell (WBC), lymphocyte neutrophil, hemoglobin (Hb), platelet, fasting glucose, glycated hemoglobin, aspartate aminotransferase (AST) , c-reactive protein (CRP), ferritin, and procalcitonin) were recorded from medical records and collected by two trained fellow geriatricians.
45761216|NCT04814212|Device|Percutaneous coronary intervention using drug-coated balloon|"SeQuent Please (BBraun) + tailored antithrombotic regimen:~Stable patients without OAC: perioperative SAPT (preferably) or perioperative DAPT followed by lifelong SAPT~Stable patients with OAC: perioperative SAPT (preferably) or perioperative DAPT and lifelong OAC~ACS patients without OAC: 1-month DAPT followed by lifelong SAPT~ACS patients with OAC: perioperative DAPT followed by 1-month SAPT and lifelong OAC"
45619330|NCT04473183|Diagnostic Test|Specimen Collection|"Blood: Two tubes of blood (up to 10 ml each) will be drawn from participants and will be collected by experienced phlebotomists.~Nasal, oral, and rectal swabs: Nasal, oral, and rectal swabs are optional specimens that patients may be asked to donate. If prospective consent is provided, swabs will be self-collected by participants after receiving clear instructions from the team and collected in the dedicated container.~Saliva: Saliva is an optional specimen that patients may be asked to donate. If prospective consent is provided, whole saliva samples will be self-collected by participants using a pad placed between the cheek and gum for 2-5 minutes or collecting the saliva directly to a sterile container."
45619331|NCT04473183|Diagnostic Test|Surveys|Participants will be asked to fill out a brief online survey that will investigate symptoms consistent with SARS-CoV-2 infection in the past 3 months and the geographic location of the clinic(s) they work in (if a resident of a medical school) and their comorbidities related to SARS-CoV-2.
45619332|NCT03342365|Diagnostic Test|Evaluation of microbial translocation and microbiota|Blood test from catheter already in place to determine microbial translocation and stool sample taken for microbiota analysis
45619333|NCT02497313|Drug|Isotonic saline|
45935029|NCT00214474|Behavioral|ATSM Intervention|Participants randomized to ATSM Intervention received weekly, automated (pre-recorded) telephone calls over 39 weeks (9 months). Patient responses triggered either immediate, automated health education messages and/or subsequent nurse phone follow-up.
45619334|NCT02497313|Drug|Metformin placebo|
45619335|NCT02497313|Drug|Cholecystokinin|
45935030|NCT00214474|Behavioral|GMV Intervention|GMV Intervention involved 90-minute monthly sessions over 9 months, involving 6-10 participants, co-facilitated by a primary care physician and health educator.
45935031|NCT00214513|Behavioral|Home-based exercise training|
45935032|NCT00214552|Drug|rabeprazole|
45935033|NCT00214591|Drug|GALIDA|
45445846|NCT03759093|Drug|Dexamethasone|8, 12 , 16, 20, 24, 28, 32 , 36 or 40 mg PO on Day 1 ,8 , 15, 22 for cycles 1 to 4, as determined and guided by the clinical care team according to standard of care
45445847|NCT02646969|Dietary Supplement|Formula regimen 1|
45445848|NCT02646969|Dietary Supplement|Formula regimen 2|
45452313|NCT03894046|Drug|Sulbactam|1.0 g sulbactam IV infused over 3 hours every 6 hours (q6h).
45619336|NCT02497313|Drug|Metformin|
45619337|NCT03095391|Device|VFI|The IV administered visible fluorescent injectate (VFI)™ agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
45619338|NCT03095391|Device|Iohexol|Iohexol is a contrast enhancement agent which, following intravascular injection, is distributed in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
45619339|NCT03339947|Other|Questionnaire|
45619340|NCT05033691|Radiation|Stereotactic surgery|At two month (8 weeks) post Osimertinib start, patients will be randomized into one of the two study arms. Arm A patients will be treated with stereotactic surgery (SRS). In both arms Osimertinib treatment will continue.
45619341|NCT03339869|Other|Blood sample|The blood samples will be taken from the patient's bed and then sent to the clinical pharmacology laboratory of Prof. Blin (DRC, Bat F, Timone Hospital).
45619342|NCT02497157|Drug|Oxaliplatin (L-OHP)|
45619343|NCT02497157|Drug|Irinotecan hydrochloride hydrate (CPT-11)|
45619344|NCT02497157|Drug|Continuous intravenous infusion of fluorouracil (CIV 5-FU)|
45619345|NCT02497157|Drug|Levofolinate calcium (l-LV)|
45619346|NCT02497157|Drug|Bevacizumab (Bmab)|
45619347|NCT03096717|Diagnostic Test|colonoscopy and histology|colonic biopsies for detection of dysplasia
45761217|NCT04814212|Device|Percutaneous coronary intervention using drug-eluting stent|"Biofreedom (Biosensors), Synergy (Boston Scientific), Ultimaster Tansei (Terumo) and Integrity Onyx (Medtronic), Xience Pro S (Abbott) or Promus Elite (Boston Scientific) or any other DES can also be used provided that it has a CE mark for 1-month DAPT, combined with tailored antithrombotic regimen:~Stable patients without OAC: 1-month DAPT followed by lifelong SAPT~Stable patients with OAC: perioperative DAPT followed by 6 months SAPT (ADP receptor blocker) and life-long OAC~ACS patients without OAC: 3-month DAPT followed by lifelong SAPT~ACS patients with OAC: perioperative DAPT followed by 6 months SAPT (ADP receptor blocker) and lifelong OAC"
45761218|NCT00889915|Drug|Methylphenidate transdermal system|Not specified in protocol; determined by local standard of care.
45761219|NCT00889915|Drug|Lisdexamfetamine dimesylate|Not specified in protocol; determined by local standard of care.
45761220|NCT00889915|Drug|Osmotic-release oral system methylphenidate (OROS MPH)|Not specified in protocol; determined by local standard of care.
45761221|NCT00889915|Drug|Mixed amphetamine salts extended release|Not specified in protocol; determined by local standard of care.
45619348|NCT03095235|Dietary Supplement|Dietary riboflavin|Dietary riboflavin is vitamin B2. It has been shown to be safe in children in the treatment of migraines at doses of 400 mg per day. There are no known documented side effects
45619349|NCT03339791|Procedure|Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy. Technique: complete mobilization of the greater curvature and gastric fundus up to the angle of Hiss; stapling beginning at 3 to 4 cm away from the pylorus; bougie size 32 French; oversuture of the staple line; hiatoplasty in selected cases; routine drainage of the abdominal cavity
45761222|NCT00841087|Drug|insulin degludec|The insulin NN1250 (insulin degludec) injected subcutaneously at bedtime
45761223|NCT00841087|Drug|insulin detemir|Injection subcutaneously at bedtime
45761224|NCT00841087|Drug|insulin aspart|Injection subcutaneously immediately before each meal.
45761225|NCT04700488|Diagnostic Test|6D-MRI|Six-Dimensional Quantitative Dynamic Contrast Enhanced MRI
45761226|NCT04601818|Procedure|Experimental: Preserving of Donor Lungs|lung transplants that have a proposed after hours start time will be delayed until 6am and the donor lungs will be preserved for no more than 12 hours at 10 degrees celsius cold static
45761227|NCT02685436|Drug|Omeprazole and domperidone|wheezy infants with abnormal MII-pH or reflux esophagitis will be given omeprazol(10mg/once/day) and domperidone (0.2mg/kg/day t.d.s)
45761228|NCT04338958|Drug|Ruxolitinib|2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days with clinical and/or radiographic response assessment
45761229|NCT00841555|Drug|temozolomide|"Chemotherapy will be given for 5 weeks; it will start 1 week before Radiotherapy, will continue for the 3 weeks of Radiotherapy, and will continue for 1 week post-Radiotherapy.~Dose Level 1: 50 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 2: 65 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 3: 75 mg/m2 over the entire 5 weeks of treatment"
45761230|NCT00841555|Radiation|Hypofractionated radiation therapy|Patients will undergo HIMRT
45761231|NCT00841555|Radiation|Intensity-modulated radiation therapy|Patients undergo HIMRT
45761232|NCT02686138|Drug|Tenapanor|
45761233|NCT02686138|Drug|Placebo|
45761234|NCT00842023|Drug|Nesiritide|Bolus 2 mcg/kg followed by 0.01 mcg/kg/min
45761235|NCT00842023|Drug|Nitroglycerin|5-10 mcg/min titrating per protocol based on blood pressure
45619350|NCT03339791|Procedure|Gastric Bypass|Laparoscopic Gastric Bypass. Technique: Pouch size 30 to 40 ml, biliopancreatic limb 70 to 100 cm, alimentary limb 100 to 120 cm, antecolic, routine closure of the mesenterial defects, routine drainage of the abdominal cavity
45761236|NCT00868309|Biological|Anavip|Anavip, 10 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 4 vials every 6 hrs
45761237|NCT00868309|Biological|CroFab|CroFab, 5 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 2 vials every 6 hrs
45761238|NCT02688868|Device|FirehawkTM 2.25mm|Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems
45761239|NCT02693704|Device|Hearing Aids|The only intervention consists in applying a specific processing on some recorded speech signals, and comparing the performance obtained with such processed samples with ones that have not been processed. The applied processing is a binaural spatialization method that consists in filtering an original audio signal to get a left and right versions (for the two ears). The binaural rendering gives the impression that the speech signal (and thus the speaker) is located in a desired position in the environment.
45761240|NCT00368134|Drug|Vildagliptin|
45761241|NCT02696200|Device|Q Collar|The device is fitted to the neck to provide a comfortable and precise jugular compression that potentially mitigates cerebral slosh. The device will be worn inside the collar of an athletic compression shirt.
45761242|NCT02697214|Device|Fitbit Charge HR|Fitbit Charge HR heart rate monitoring device compared to ECG and Polar H7
45761243|NCT02697214|Device|Apple Watch|Apple Watch heart rate monitoring device compared to ECG and Polar H7
45761244|NCT02697214|Device|Mio Fuse|Mio Fuse heart rate monitoring device compared to ECG and Polar H7
45761245|NCT02697214|Device|Basis Peak|Basis Peak heart rate monitoring device compared to ECG and Polar H7
45761246|NCT02697292|Drug|Intravenous Immunoglobulin|GAMUNEX-C is a clear a ready-to-use sterile solution of human immune globulin protein for intravenous administration. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day [week 1 day 1], then will receive 1g/kg not exceeding 80 grams daily for 1 day [week 1 day 2]. Then once every 2 weeks subjects will receive 0.6g/kg IVIG for 4 weeks [week 3 and 5] for 2 infusions.
45619351|NCT03095079|Drug|recombinant human endostatin|"Cisplatin:dose was based on patient's weight and could be adjusted for weight change,75 mg/m^2 by IV infusion separated in 3 different days Dacarbazine:250mg/m2,administered by intravenous (IV) infusion on the 1 to 5 day of each cycle~Hr-endostatin:dose based on body surface area as 15mg/m2,continuous intravenous infusion from day 1 to day 14"
45619352|NCT03120923|Drug|Lidocaine 3 cc|
45619353|NCT03120923|Drug|Lidocaine 9 cc|9mL of 1% lidocaine plus 1mL of 40mg triamcinolone acetonide
45619354|NCT03120923|Drug|Triamcinolone Acetonide|
45619355|NCT03095157|Dietary Supplement|fractionated marine lipid concentrate derived from anchovy and sardine oil|Patients will be randomized to receive perioperative treatment versus placebo
45619356|NCT02497079|Device|Nested PCR for formalin-fixed tissues|For nested PCR, formalin-fixed paraffin-embedded tissues were incubated in 1 mL of xylene at 60°C for 30 min and then centrifuged for 10 min. Paraffin and the supernatant were removed from the samples after centrifugation. The same procedures were repeated until deparaffinization was complete. After adding 1 mL of alcohol, the samples were centrifuged for 5 min, and the supernatant was removed. The sample was then air-dried as a pellet. DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
45619357|NCT02497079|Device|Nested PCR for fresh tissues|For nested PCR with specimens in sterile saline, DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
45911739|NCT05726214|Other|Exercise|"The face-to-face multicomponent program will entail:~Strength training of upper and lower limbs. Familiarization phase will include 2-3 exercises of 1-2 series and 8-12 repetitions per session. During the acquisition phase, 2-3 exercises of 2-3 series and 8-12 repetitions at a higher velocity. The resting time between sets will be of 1-3 minutes.~Balance exercises will include proprioception, agility and weight transfer exercises. Difficulty will progressively increase by reducing the base of support, by including multidirectional displacements, walking on tiptoe or heels, body-weight transfer, dynamic exercises modifying the centre of gravity, and stressing postural muscles and by sensorial reductions.~Flexibility exercises: Static stretching maintained during 20-30s carried out at the end of each session.~The Vivifrail exercise wheel corresponding to each participant will be given according to their functional level type."
45619358|NCT02497079|Device|Real-time PCR for fresh tissues|For real-time PCR, specimens in sterile saline were filtered and 1 mL of phosphate based saline was added. After centrifugation for 3 min, the supernatant was removed. Next, 50 μL of extraction buffer was added to the sample, and the sample was heated at 100°C for 20 min. After centrifugation for 3 min, the supernatant was used in PCR. Real-time PCR was performed using the AdvanSure TB/NTM real-time PCR kit. Three channels were used in the real-time PCR reaction (Mycobacterium tuberculosis complex, mycobacteria, and internal control). Signals for FAM, HEX, and Cy5 were measured in each channel. Mycobacterium tuberculosis was considered present if the cycle threshold of rpoB was less than 35 on each signal and greater than or equivalent to that of IS6110.
45619359|NCT04135677|Drug|Rivaroxaban|Drug: Rivaroxaban 20mg Duration of treatment: 12 weeks(12 weeks for DAPT afterwards)
45619360|NCT04135677|Drug|DAPT|Drug: Aspirin 100mg and clopidogrel 75mg Duration of treatment:24 weeks
45619361|NCT02494193|Other|Partial caries removal|The caries infected dentin will be removed mantaining the affected caries tissue.
45619362|NCT02494193|Other|Provisional restoration - control|After partial caries removal, a provisional restoration will be performed using a layer of calcium hydroxide paste covered by a layer of calcium hydroxide cement and resin-modified glass ionomer.
45619363|NCT02494193|Other|Provisional restoration - experimental|After partial caries removal, a provisional restoration will be performed using only resin-modified glass ionomer.
45619364|NCT02494193|Other|Total caries removal|After two months of their placement, the provisional restoration will removed followed by tota caries tissue removal.
45619365|NCT02494193|Other|Definitive restoration|Definite restoration will be performed using composite.
45619366|NCT05042739|Diagnostic Test|CAARMS;SIPS; BSABS;|Comprehensive Assessment of At Risk Mental State (CAARMS); Structured Interview for Psychosis-Risk Syndrome (SIPS); Bonn Scale for the Assessment of Basic Symptoms (BSABS);
45619367|NCT03339557|Device|NexGen|Comparing two conventional designs and one novel design
45761247|NCT02697292|Drug|Placebos|Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Dose will be determined based on ideal wt. with not to exceed 80 grams. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day [week 1 day 1], then will receive 1g/kg not exceeding 80 grams daily for 1 day [week 1 day 2]. Then once every 2 weeks subjects will receive 0.6g/kg for 4 weeks [week 3 and 5] for 2 infusions.
45761248|NCT02697292|Drug|Normal Saline|Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Subjects will receive 500 ml normal saline before and after the higher dose infusion of 1g/kg
45761249|NCT00842335|Drug|JI-101|JI-101, 50 mg capsules, will be administered daily for up to 112 days (four 28-day cycles); treatment may be extended if, in the opinion of the investigator, a patient has tolerated the treatment and appears to be benefitting from receiving study medication
45761250|NCT02700334|Drug|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
45761251|NCT02700334|Drug|Placebo|one per day before breakfast during 12 weeks.
45761252|NCT00868699|Drug|lurasidone|lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day
45761253|NCT00868699|Drug|lurasidone|lurasidone 20 mg/day for Days 1-7
45761254|NCT00868699|Drug|Placebo|Placebo Comparator
45761255|NCT02701270|Dietary Supplement|Experimental Dietary Fibre 1|22.17 g of product diluted in 250 ml of water taken once orally.
45761256|NCT02701270|Dietary Supplement|Experimental Dietary Fibre 2|21.84 g of product diluted in 250 ml of water taken once orally.
45761257|NCT02701270|Dietary Supplement|Polydextrose|21.48 g of product diluted in 250 ml of water taken once orally.
45761258|NCT02701270|Dietary Supplement|Dextrose|23.89 g of dextrose diluted in 250 ml of water taken once orally.
45619368|NCT03339557|Device|Persona|Comparing two conventional designs and one novel design
45761259|NCT02701582|Drug|Phenylephrine|if Mean arterial pressure (MAP) is < = 65, Stroke volume variation (SVV) < 13 and Cardiac Index is >=2.2 Phenylephrine is administered
45761260|NCT02701582|Drug|Epinephrine|if Mean arterial pressure (MAP) is < = 65, Stroke volume variation (SVV) < 13 and Cardiac Index is < 2.2 Epinephrine is administered
45761261|NCT02701582|Other|Albumin|if Mean arterial pressure (MAP) is < = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is <2.2 fluids are administered.
45445849|NCT03764241|Drug|Rivaroxaban|Rivaroxaban 15mg/QD will be applied for 3 months unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
45445850|NCT03764241|Drug|Vitamin K Antagonist|warfarin (INR 2.0-2.5) will be applied for 3 months unless severe safety outcome occur. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
45619369|NCT03339557|Device|PFC|Comparing two conventional designs and one novel design
45619370|NCT05033925|Dietary Supplement|FADA (active fraction of Ficus septica leaf) 800 mg/day|FADA is given twice a day (total dose of 800 per day per patient)
45445851|NCT03764163|Diagnostic Test|Pulmonary Function Test|Spirometry, Diffusing Capacity of the Lungs (DLCO), Lung Volumes
45619371|NCT05033925|Dietary Supplement|FADA (active fraction of Ficus septica leaf) 2000 mg/day|FADA is given twice a day (total dose of 2000 per day per patient)
45619372|NCT05033925|Other|Placebo capsule|Placebo capsule is given twice a day
45619373|NCT02496923|Device|High flow nasal oxygen therapy (Optiflow™)|
45619374|NCT02496923|Device|Standard oxygen therapy (Hudson Type face mask or nasal prongs)|
45619375|NCT05033613|Other|heart rate、arrhythmia、blood pressure、central body temperature (ear temperature) and blood oxygen saturation level.|heart rate、arrhythmia、blood pressure、central body temperature (ear temperature) and blood oxygen saturation level.
45761262|NCT02701582|Other|Voluven|if Mean arterial pressure (MAP) is < = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is <2.2 fluids are administered.
45761263|NCT02701582|Other|Normal Saline|if Mean arterial pressure (MAP) is < = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is <2.2 fluids are administered.
45761264|NCT02701582|Other|Packed Red Blood Cells|if Mean arterial pressure (MAP) is < = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is <2.2 fluids are administered.
45761265|NCT02701582|Device|FloTrac Monitor|FloTrac monitor is connected for all patients, but only visible to the anesthesiologist for half. Based on a decision tree and the data from monitor, choices of interventions are used.
45761266|NCT00869167|Drug|Ramelteon|melatonin agonist
45761267|NCT02013583|Other|No intervention|This is an observational registry. No interventions are required or provided.
45761268|NCT00843349|Drug|Lanthanum Carbonate|Phosphorus binder
45761269|NCT00843349|Other|900 mg Phosphate Diet|Amount of phosphorus consumption in a day kept below 900 mg.
45761270|NCT00843349|Drug|LC Placebo|Placebo for Lanthanum Carbonate
45761271|NCT00843349|Other|Ad Libitum Diet|Patients continued to eat their usual diet.
45761272|NCT03839017|Device|SIMMAXMARCHERYAN2|Digital cognitive aid during the management of simulated war wounded.
45761273|NCT00869791|Drug|IPX066|experimental drug product: extended-release carbidopa-levodopa capsules
45761274|NCT00869791|Drug|IR CD-LD|active comparator: immediate-release carbidopa-levodopa capsules
45761275|NCT02704702|Drug|Fimasartan|
45761276|NCT02704702|Drug|Rosuvastatin|
45761277|NCT02704702|Drug|Fimasartan + Rosuvastatin|
45761278|NCT04382287|Procedure|Remin Pro® and MI Paste Plus®|Te toothastes were applied at home twice a day over the six anterior upper primary teeth
45911740|NCT05726214|Other|Recommendations for active lifestyle|After the baseline assessments, all participants will receive individualized counseling for following physically active lifestyle and reducing sedentary behaviors. Participants will be encouraged to increase the physical activity time and intensity, and to hourly break the sedentary time while at home. The recommendations will be transmitted verbally and through written material.
45761279|NCT00869947|Device|Powered ankle-foot prosthesis|The powered ankle-foot prosthesis is comprised of a series-elastic actuator (SEA) and an elastic leaf spring. This technology has been previously developed for robotic and human rehabilitation applications. The SEA allows for precise force control of the ankle joint, thus mimicking the spring-like behavior of the human ankle, as well as providing adequate energy for forward progression of the body. From the early stance period to the mid-stance period of walking, the SEA will be controlled so that the ankle joint behaves like a spring. During the late stance period, the SEA will be employed to power the forward movement of the body. The elastic leaf spring will provide shock absorption during foot strike, energy storage during early stance, and energy return during late stance.
45761280|NCT00869947|Other|No device|
45761281|NCT02707432|Behavioral|Heart Matters|"Heart Matters is an intervention adapted from PREMIER, an evidence-based, comprehensive lifestyle intervention that focuses on blood pressure as the primary outcome. To assess the feasibility and efficacy of adapting PREMIER for rural African Americans, Heart Matters will be delivered to multiple intervention groups, but at two different stages."
45761282|NCT03216655|Other|phone call|Investigators give a regular follow-up to participants: phone call monthly
45761283|NCT03216655|Other|wechat group|Investigators give a regular follow-up to participants: wechat follow up. Investigators send useful information and answer their questions monthly.
45761284|NCT01622335|Drug|Nitrous oxide|General anesthesia with Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
45619376|NCT02496689|Biological|asfotase alfa|Patients participating in this program will receive 6 mg/kg/week asfotase alfa (administered at a dosage regimen of 1 mg/kg 6 times per week or 2 mg/kg 3 times per week at the discretion of the Investigator) by SC injection. During follow-up visits, dose adjustments to account for changes in body weight will be made. Additional incremental dose adjustments for lack of efficacy or safety reasons may also be decided upon by the Investigator in consultation with the Alexion Medical Monitor.
45619377|NCT02496845|Drug|VL#FIA3-30|Vasoactive dual treatment (MH30-01 & IS045-01)
45619378|NCT02639247|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
45619379|NCT02639247|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily without regard to food
45911741|NCT05718791|Diagnostic Test|blood sample|blood sample to check CXCL9 and EASIX at day 28 post stem cell transplant
45619380|NCT03339479|Diagnostic Test|dielectric property test|Test the dielectric property of resected lung nodules/mass through a touching probe after the lung tissue with nodules/mass has been resected and cut open, which usually takes only 1-5 minutes.
45619381|NCT03339479|Diagnostic Test|frozen pathological examination|And after the dielectric property test, the lung tissue will be sent for frozen pathological examination.
45619382|NCT03339479|Diagnostic Test|final pathological examination|All of the lung nodules/mass will be diagnosed by final pathological examination and recognized as the final diagnosis after surgery.
45619383|NCT03339323|Other|Exercise|TKA patients do the exercise intervention
45619384|NCT03342287|Other|questionnaires|Questionnaires rating IBS symptoms, constipation, anxiety and depression
45619385|NCT03342287|Other|cognitive evaluation|Administration of online cognitive battery
45761285|NCT01622335|Other|General anesthesia with oxygen|General anesthesia with(Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
45761286|NCT02708212|Procedure|EGD and colonoscopy|Cold forceps biopsy, cold snare polypectomy, and/or hot snare polypectomy will be performed for stomach and/or colon polyps during EGD and colonoscopy examinations will be performed whenever indicated.
45761287|NCT00871819|Device|Precision Spinal Cord Stimulation (SCS)|Various SCS device programming parameters
45761288|NCT02708290|Other|MITA Prefrontal Synthesis exercises - each activity adapts to deliver the exercise that is at the exact level of difficulty appropriate for a child at any given point in time|"Mental Imagery Therapy for Autism (MITA) is an early-intervention application for children with Autism Spectrum Disorder (ASD). MITA app uses adaptive-learning technologies, with fun, educational exercises that adapt to a child's abilities, resulting in a highly-customized learning experience. The MITA application is available for free in the Apple Store, Google Play, and Amazon App Store.~MITA verbal activities start with simple vocabulary-building exercises and progress toward exercises aimed at higher forms of language, such as noun-adjective combinations, spatial prepositions, recursion, and syntax. All exercises are deliberately limited to as few nouns as possible since the aim is not to expand a child's one-word vocabulary, but rather to teach him/her to integrate mental objects in novel ways by utilizing prefrontal synthesis (PFS). MITA activities outside of the verbal domain aim to provide the same PFS training visually through implicit instructions."
45761289|NCT00895531|Drug|Depodur|7.5 mg Depodur via the epidural catheter
45911742|NCT05692882|Device|Drug-Eluting Stents|The NOVA stent is a sirolimus-eluting stent system designed for intracranial artery stenosis with a rapid exchangeable balloon
45445852|NCT03764163|Diagnostic Test|CT Scans|volume scans, perfusion scan, ventilation scan
45445853|NCT03764163|Behavioral|Questionnaires|Human Subjects Questionnaire, Baseline Dyspnea Index, Chronic Respiratory Questionnaire
45445854|NCT03764163|Diagnostic Test|MRI|proton scans, hyperpolarized 3-Helium scan
45619386|NCT03342287|Other|Blood|Measurement of cytokines/inflammatory biomarkers
45619387|NCT03342287|Other|Fecal sample|Measurement of the gut microbiome
45911743|NCT05680129|Drug|Ecnoglutide high dosage|Administered subcutaneously
45911744|NCT05680129|Drug|Ecnoglutide low dosage|Administered subcutaneously
45911745|NCT05680129|Drug|Dulaglutide|Administered subcutaneously
45911746|NCT05680129|Drug|Metformin|Administered orally
45911747|NCT05668858|Drug|SI-B001|Administration by intravenous infusion
45619388|NCT05033457|Procedure|unilateral biportal endoscopy technique or percutaneous endoscopic transforaminal discectomy|Treatment of lumbar intervertebral disc herniation with unilateral biportal endoscopy technique in unilateral biportal endoscopy technique group.Treatment of lumbar intervertebral disc herniation with percutaneous endoscopic transforaminal discectomy in percutaneous endoscopic transforaminal discectomy group.
45761290|NCT00895531|Procedure|sciatic nerve block|The sciatic nerve will be identified at the subgluteal level with ultrasound. A point 3 cm lateral and 4 cm caudad will be marked. Patients will be placed in the lateral position. A 18 G Tuohy needle will be inserted at a 45° angle until a peroneal or tibial twitch is obtained at 1.5 mA. Once the current can be reduced to obtain a twitch less than 0.5 mA, a catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.
45761291|NCT02709694|Other|No intervention|No drug or device intervention. However, participants will receive MRI of their spine, answer questionnaires, provide clinical history as well as blood and stool sample. Joint exams will also be performed on all participants.
45761292|NCT02710240|Drug|Indocyanine Green (ICG)|
45761293|NCT02710240|Radiation|Intraoperative near-infrared (NIR)|
45761294|NCT01603225|Procedure|Transcranial Direct Current Stimulation (tDCS)|Delivery of transcranial direct current stimulation for 30-60 minutes or sham stimulation.This will be administered by two or more similar devices.
45761295|NCT03215875|Drug|Fed- 60mg ER Torsemide|60mg ER Torsemide will be given after high fat, high-calorie meal
45911748|NCT05668858|Drug|SI-B003|Administration by intravenous infusion
45911749|NCT05639374|Behavioral|BASICS_HealthyClassroom|First, they will complete a 22-item online questionnaire, collecting all the variables of the research. After completing it, the students in the intervention group will receive personalized feedback by mail that visually summarizes the content of the questionnaire. Students will receive a motivational intervention with the aim of increasing the university's awareness of their alcohol consumption. In the intervention session of the program, the following aspects may be addressed, whenever the participant wishes: 1) Pattern of alcohol consumption of the student; 2) Social norm of alcohol consumption; 3) Negative consequences of alcohol; 4) Costs of alcohol consumption; 5) The change; 6) Specific education on alcohol; and 7) Advice and recommendations.
45911750|NCT05638386|Procedure|Bone plug|The investigational treatment is the use of a bone plug in the two drill-holes in the tibia, made by two pins for securing the tibial array to the bone. The pins that are used for this, are 4.0mm wide. The bone plug that is used to fill the drill-holes of tibia, is obtained from the bone that is removed during the operation to make place for the new prosthesis. A piece as wide as the drill-hole is cut off the recessed bone and put into this hole. After this, the wound is closed using surgical staples.
45911751|NCT05635487|Drug|SHR-A1811|SHR-A1811
45911752|NCT05635487|Drug|Pyrotinib|Pyrotinib
45911753|NCT05627856|Drug|GNC-038|Administration by intravenous infusion
45911754|NCT05623982|Drug|GNC-038|Administration by intravenous infusion
45911755|NCT05620355|Drug|BG2109|BG2109 100mg film coated tablet for oral administration once daily.
45619389|NCT03120455|Behavioral|Almond Group|Obese or overweight female adults will be randomly allocated to have almond as afternoon snacks, while they have a hypoenergetic diet.
45619390|NCT03120455|Behavioral|Pistachio Group|Obese or overweight female adults will be randomly allocated to have Pistachio as afternoon snacks, while they have a hypoenergetic diet.
45761296|NCT03215875|Drug|Fasting- 60mg ER Torsemide|60mg ER Torsemide will be given after overnight fasting
45761297|NCT02710630|Drug|Dabigatran etexilate tablet E1|
45761298|NCT02710630|Drug|Dabigatran etexilate tablet D1|
45761299|NCT02710630|Drug|Dabigatran etexilate tablet C1|
45761300|NCT02710630|Drug|Dabigatran etexilate tablet B1|
45761301|NCT02710630|Drug|Dabigatran etexilate tablet A1|
45761302|NCT02710630|Drug|Dabigatran etexilate capsule|
45761303|NCT02715076|Other|Ambient Temperature 19°C|Ambient Temperature 19°C
45761304|NCT02715076|Other|Ambient Temperature 21°C|Ambient Temperature 21°C
45761305|NCT02715076|Other|Ambient Temperature 23°C|Ambient Temperature 23°C
45761306|NCT02715076|Device|Forced-air cover (Bair hugger 63500, 3M)|Patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
45761307|NCT02715076|Other|Passive insulation|Patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
45761308|NCT00873457|Drug|perifosine|Perifosine 50 mg will be taken orally twice a day for a maximum of six 28-day cycles
45761309|NCT02715700|Drug|Methadone|Methadone 20 to 200 mg (10 mg/mL if oral solution concentrate) oral tablet once per day.
45911756|NCT05620355|Drug|Placebo for BG2109|Placebo for BG2109 100mg tablet for oral administration once daily.
45911757|NCT05620355|Drug|Placebo for add-back therapy|Placebo for add-back therapy tablet for oral administration once daily.
45911758|NCT05620355|Drug|Add-back therapy|Estradiol 1 mg / Norethindrone Acetate 0.5 mg for oral administration once daily.
45445855|NCT03764163|Biological|Xenon gas|ventilation CT scans
45619391|NCT03120455|Behavioral|Nut free group|Obese or overweight female adults will be asked to avoid nuts, seeds and nut products, while they have a hypoenergetic diet.
45761310|NCT02715700|Drug|Doravirine|Doravirine 100 mg oral tablet once per day.
45761311|NCT03215953|Device|cast shoe|ankle-high, custom-made, well-moulded cast shoe
45761312|NCT03215953|Device|removable walker|Prefabricated especially designed for relieving load on the foot
45911759|NCT05616390|Drug|Sintilimab|200mg IV d1,Q3W
45911760|NCT05616390|Drug|Bevacizumab|7.5mg/kg IV d1,Q3W
45911761|NCT05616390|Combination Product|Liver Protective Support Therapy|Medical treatment such as liver protection therapy, antiviral therapy, platelet and granulocyte upgrading therapy
45911762|NCT05614817|Drug|CBP-201|CBP-201 subcutaneous(SC) injection
45911763|NCT05614817|Drug|Placebo|subcutaneous(SC) injection
45445856|NCT03764085|Drug|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
45619392|NCT05033535|Drug|Sacubatril Allisartan medoxomil|Sacubatril Allisartan medoxomil ：A randomized, double-blind, placebo and positive drug parallel controlled, multi-center phase II clinical study on the effectiveness and safety of treating mild and moderate essential hypertension
45911764|NCT05613413|Drug|Cabozantinib 40 MG|Cabozantinib is taken my mouth
45619393|NCT05033535|Drug|Olmesartan Medoxomil|Efficacy for lowering blood pressure of Olmesartan medoxomil
45619394|NCT03339167|Dietary Supplement|Metabolic availability of lysine in millet|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from millet and 1 level from millet with lentils.
45619395|NCT04434495|Biological|PRP|PRP injection into uterine cavity
45619396|NCT03339011|Behavioral|Motivational SMS text message|Motivational text messages delivered to the participants' mobile phones. The text messages contain motivational text and advice on physical activity.
45619397|NCT05053893|Drug|Roxadustat;Sacubitril Valsartan Sodium Tablets;|Select the appropriate dose according to the patient's situation
45619398|NCT05053893|Drug|EPO; ACEI / ARB|Select the appropriate ACEI /ARB according to the subject's situation or follow its previous medication
45619399|NCT03120299|Drug|Omega-3 fatty acid|Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
45619400|NCT03120299|Drug|Placebos|Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
45619401|NCT03096327|Drug|Montelukast|Montelukast sodium is a selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.
45619402|NCT03096327|Drug|Placebo|Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured
45619403|NCT03338777|Biological|Suicide plus immunogene therapy|"Intra and peritumoral infiltrates with multiple injections of 0.1 ml/cm2 or 0.2 ml/cm3 of lipoplexes bearing the HSVtk suicide gene (1: 1; 1 mg/ml, according to tumor size), co-administered with GCV (12.5 mg/ml). Patients start with a minimum of 0.5 ml and at the 3rd week, the maximum dose is scaled according to the tumor size up to 2 ml maximum.~Treated simultaneously with a subcutaneous vaccine produced with:~Formolized allogeneic tumor extracts and,~Lipoplexes carrying hIL-2 and hGM-CSF genes (0.5 mg each)."
45619404|NCT03098121|Drug|grazoprevir and elbasvir|For patients with chronic genotype 1a, with or without resistance associated variant (RAV) of NS5A, are expected to receive grazoprevir and elbasvir in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and for patients with chronic genotype 1b are expected to receive grazoprevir and elbasvir in a fixed-dose combination tablet once daily for 12 weeks.
45619405|NCT03342209|Device|Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy|"A high flow nasal cannula will be implemented to the CO-poisoned patients. In the meantime, intravenous access and cardiac monitorization will have been establishing. When the high flow nasal cannula becomes ready, the first venous blood sample will be taken and the treatment will be started without any delay. The gas flow rate will be started at the rate of 30 liters per minute and will be increased to the max flow rate which patient can tolerate and FiO2 of 1.0. If the first COHb level is lesser than 10%, the patient will be excluded and will receive standard emergency care.~The blood sample will be drawn from existing IV access every 10 minutes until the COHb levels become %50 or lesser of the initial level.~Once the COHb level becomes 50% of initial measurement, following blood samples will be taken in every 30 minutes."
45761313|NCT02716324|Behavioral|Care Manager CM)|The CM was an individual responsible for communicating and coordinating ADHD care. The CM established rapport with families and communicated with them every 3 months or more frequently if needed to assess treatment use, identify new concerns, and help problem-solve. The CM also communicated with the patient's ADHD care team (pediatrician, teacher, mental health providers) to clarify family goals, communicate information, and coordinate treatment.
45761314|NCT02716324|Other|ADHD Portal|The ADHD portal was a web-based platform that permits access to parts of the hospital's electronic health record. The portal permits (1) capture and sharing of patient and family treatment preferences and goals, (2) monitoring of ADHD symptoms, treatment receipt, and side effects, and (3) assessing goal attainment. The system prompts for completion of periodic check-in surveys (bi-weekly to 3 months) with parents and teachers. Within the portal, preferences and goals for ADHD treatment were measured using the ADHD Preference Goal Instrument (PGI) (Fiks et al., 2012). Parents were encouraged to consult with their children when completing the tool.
45761315|NCT00875641|Other|Health Insurance Database|Review of two health insurance databases in the US to determine the safety outcomes among infants who have received Rotarix or IPV vaccination.
45761316|NCT04338724|Drug|CS1002|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
45761317|NCT03216031|Behavioral|Gardening programme|3 groups with up to 10 patients and 2-4 students/staff members each should meet once per week for about 1 hour to engage in gardening activities at the falls prevention growing site. Each participant will attend the programme 8 times.
45761318|NCT00338377|Biological|Dendritic Cell Immunization|1x10^7 to 2.5x10^8 MART-1 peptide-pulsed Dendritic Cells given by vein over 20-30 minutes approximately 4 hrs after receiving T cells.
45911765|NCT05613413|Drug|Pembrolizumab 200mg|Pembrolizumab is given intravenously
45911766|NCT05612412|Other|Morning Exercise|Standardized treadmill exercise session starting at approximately 0700
45911767|NCT05612412|Other|Evening Exercise|Standardized treadmill exercise session starting at approximately 1800
45445857|NCT03764085|Drug|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
45911768|NCT05605054|Behavioral|UCSD RELINK|UCSD RELINK coach-guided health literacy intervention and in-person service navigation assistance
45911769|NCT05605054|Behavioral|Self-study|Self-studying of programmatic information and list of service referrals
45911770|NCT05597150|Dietary Supplement|Magnesium Citrate|Each participant should receive a high-magnesium diet for 1-3 weeks and take magnesium supplements for 4-6 weeks.
45911771|NCT05595460|Drug|RYZ101 Dose Level 1|6.5 MBq/175 μCi administered by IV for up to 6 infusions once every 4 or 6 weeks
45619406|NCT03342131|Other|Circulating wnt 2 and wnt 4 concentration|"Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA. Continuous wnt2 and wnt4 concentration are measured in all patients with STEMI at 0 , 7days and 12 months after admission. Other patients with acute syndrome system are measured Wnt 2 and wnt4 only once within 24h after admission.~Wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission."
45761319|NCT00338377|Drug|Cyclophosphamide|60 mg/kg/d by vein over 2 hours on Days -7 and -6 before T cell infusion
45761320|NCT00338377|Drug|Fludarabine|25 mg/m^2 by vein daily over 30 minutes on Days -5 to -1 before T cell infusion.
45761321|NCT00338377|Biological|T-Cells|On Days 0, up to 1.5 x 10^11 T-cells by vein infusion over 30-60 minutes.
45761322|NCT00338377|Biological|Interleukin-2|12-16 hours after completing the T cell infusion, all will receive high dose IL-2 on an inpatient basis at the standard dose of 720,000 IU/kg as an intravenous bolus over approximately a 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26 (+/- 7 days), as tolerated.
45761323|NCT00338377|Drug|Mesna|60 mg/kg with D5W or NS at 125 ml/hr infused intravenously over 24 hours on Day -7 and -6.
45761324|NCT00338377|Biological|Intrathecal T-Cells|5.0x10^9 T-cells administered on Day 1, and 10x10^9 T-cells on Day 15. 1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated.
45761325|NCT00338377|Biological|Intrathecal Interleukin-2|1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated. Then, patient receives twice weekly IL-2 that will be gradually changed to weekly IL-2. After 4-6 weeks patients switched to IL-2 maintenance.
45761326|NCT00895921|Drug|Olanzapine|Single intramuscular 10-mg dose
45761327|NCT00895921|Drug|Aripiprazole|Single intramuscular 9.75-mg dose
45761328|NCT02716714|Drug|ingenol mebutate gel 0.015%|-Face or Scalp arm (Referred to Face/Scalp arm): Apply ingenol mebutate gel 0.015% once daily for 3 consecutive days
45761329|NCT02716714|Drug|ingenol mebutate gel 0.05%|-Trunk or Extremities arm (Referred to Trunk/Extremities arm): Apply ingenol mebutate gel 0.05% once daily for 2 consecutive days
45445858|NCT01322451|Drug|GLPG0259 fumarate|single oral dose, two capsules each containing 25 mg of GLPG0259 fumarate
45619407|NCT03095001|Drug|Bevacizumab|Bevacizumab 5mg/kg intraperitoneal administration every 3 weeks for 4-6 cycles
45761330|NCT02719366|Device|comfilcon A Extended Range test lens|contact lenses
45761331|NCT02719366|Device|comfilcon A control lens|contact lenses
45619408|NCT03095001|Drug|Carboplatin|carboplatin AUC=5 intraperitoneal administration every 3 weeks 4-6 cycles
45761332|NCT05315479|Drug|N1539|Once daily
45761333|NCT00368212|Behavioral|Relaxation response training|The control treatment is relaxation training or attention control. This will be taught in three, 1-hour sessions with a trained therapist.
45761334|NCT00368212|Behavioral|Psychoeducational counseling|Patients will receive five sessions of psychoeducational counseling from the nurse who works with the primary care physicians. Patients who are interested in continuing treatment or who have not responded to this first treatment step will then be referred for the second step, cognitive behavioral therapy (CBT), for more intensive treatment.
45761335|NCT05319457|Other|The radon app|Participants will be asked to use the radon app.
45761336|NCT05319457|Other|Print brochure|Participants will receive print brochures.
45911772|NCT05595460|Drug|RYZ101 Dose Level 2|8.3 MBq/225 μCi administered by IV for up to 6 infusions once every 4 or 6 weeks
45445859|NCT01322451|Drug|GLPG0259 free base|single oral dose, GLPG0259, 50 mg solid formulation
45445860|NCT02556099|Drug|Hydroxyurea|drug to be administered
45619409|NCT03095001|Drug|paclitaxel|paclitaxel 175mg/m2, iv d1, every 3 weeks for 4-6 cycles
45619410|NCT03338699|Device|ShangRing|Topical anesthesia based, no-flip ShangRing circumcision.
45619411|NCT03338699|Device|Mogen clamp|Mogen clamp circumcision
45619412|NCT05042271|Drug|meropenem|each patient received a 1 hour infusion of a single dose of 1 g of meropenem diluted in 100 ml of normal saline solution, at the same time as the start of the first TPE and meropenem PK studies were carried out after the administration of meropenem. Blood samples (3 ml) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hours after the start of the meropenem administration.
45619413|NCT03094767|Other|Cardiovascular Rehabilitation|Aerobic and anaerobic exercises performed for 12 weeks, 3x/week, of 60 minutes each.
45619414|NCT03094767|Other|Initial and Final assessment|Measuring blood preassure, heart rate, Borg scale, respiratory rate, oxygen saturation and HbA1C in the first day of assessment and after 12 weeks.
45619415|NCT03338543|Device|PENS|percutaneous electrical nerve stimulation
45619416|NCT03338543|Device|TENS|transcutaneous electrical nerve stimulation
45761337|NCT03215329|Procedure|abdominal or vascular surgery|Intermediate or high risk abdominal or vascular surgery
45761338|NCT02720224|Drug|Estetrol|15 mg [14C]-estetrol containing approximately 2.8 MBq (76 μCi) 14C
45761339|NCT05310799|Other|Shared Decision Making (SDM)|The intervention is a structured SDM discussion between physician and family, occurring at the time of the child's JIA diagnosis and clinic visit. Discussion will be guided by a discussion guide and the PERSON-JIA Report, which is generated in real time on the physician's smartphone.
45761340|NCT05312827|Behavioral|Training Intervention and Program of Support (TIPS) for fostering the adoption of family-centred telehealth interventions in pediatric rehabilitation|The proposed pre-post study will evaluate the implementation and effectiveness of a Training Intervention and Program of Support (TIPS) to enhance the adoption of family-centred telehealth in pediatric rehabilitation centres across Canada. TIPS is a multifaceted intervention, comprised of the following: 1) a 10-hour intensive training program offered to participating therapists at each site over a one-month period, including 4 hours of self-paced learning modules and a 6-hour mandatory interactive webinar; and 2) an 11-month program of support which is composed of monthly mentoring meetings at each site led by the local therapist champion, and a national virtual community of practice facilitated by 3 national knowledge brokers - an occupational therapist, a physiotherapist and a speech-language pathologist - experienced in family-centred telehealth in pediatric rehabilitation, offered simultaneously to all participating therapists across Canada.
45911773|NCT05595460|Drug|RYZ101 Dose Level 3|10.2 MBq/275 μCi administered by IV for up to 6 infusions once every 4 or 6 weeks
45761341|NCT02722330|Device|Baha 5 SuperPower on Baha Attract System|The Investigational device involves the following parts: the sound processor unit, an actuator unit and a cable that connects the sound processor and actuator units. The actuator unit is attached to the Sound Processor Magnet (SP Magnet) of the Baha Attract System which is pulled towards the BIM400 Baha Implant Magnet that is fixated to the BI300 Implant. The actuator unit can also be connected to the Baha Softband via a snap coupling.
45619417|NCT05054049|Device|Interventional Diagnostic Device Arm|Point of care testing venous blood diagnostic device.
45619418|NCT05054049|Other|Usual care|Usual care provided to patient without use of point of care testing device
45619419|NCT03338465|Device|Duolith SD1, STORZ Medical, Switzerland with F-SW applicator|The procedure will be performed with the patient in lateral positioning of the decubitus. The treatment area will be prepared with a coupling ultrasound gel to minimize the loss of shockwave energy at the interface between the tip of the applicator and the skin. The inline ultrasonic guide will be used to concentrate the shockwaves on the pain area in the trochanteric region. No local anesthesia will be applied.
45619420|NCT02138955|Drug|Liposomeal curcumin|
45619421|NCT02494115|Procedure|subcutaneous drainage|
45761342|NCT05314777|Procedure|Low dose ESWT application|Patients trained for low dose ESWT application.
45761343|NCT05314777|Procedure|High dose ESWT application|Patients trained for high dose ESWT application.
45619422|NCT05032911|Diagnostic Test|sensorimotor control analysis using inertial sensor technology|Inertial Measurement Unit (IMU) sensors will measure sensorimotor control variables including active range of motion, movement speed, acceleration, smoothness of motion, head repositioning accuracy and motion coupling patterns
45619423|NCT02493881|Device|intraoperative neuromonitoring|NIM-Response 3.0 Intraoperative Neuromonitoring System (Medtronic Xomed, Jacksonville, FL, USA) was used to record the EMG amplitude signal for the anterior and/or posterior branches of recurrent laryngeal nerves (RLNs).
45619424|NCT03096405|Diagnostic Test|Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus|Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus
45619425|NCT05032989|Procedure|Extraction of mandibular 3rd molar via Cowhorn forcep technique|Cowhorn forceps technique used to extract the tooth results in less post operative pain and swelling also it makes the extraction easier.
45619426|NCT05032989|Procedure|Extraction of mandibular 3rd molar via conventional technique|Conventional method of extraction uses dental elevator and forceps resulting in post operative pain and swellig.
45619427|NCT02493803|Behavioral|Dietary Advice|Detailed dietary advice and planning, complete with dietary information sheets which were developed with a dietitian and a dental psychologist
45619428|NCT05032287|Drug|Tamsulosin|Tamsulosin 0.4 mg once daily
45619429|NCT05032287|Drug|Placebo|Placebo once daily
45619430|NCT02493959|Biological|PYY1-36 infusion|Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs.
45761344|NCT05314777|Procedure|Sham ESWT|Patients trained for sham ESWT.
45911774|NCT05595460|Drug|RYZ101 Dose Level -1|4.6 MBq/125 μCi administered by IV for up to 6 infusions once every 4 or 6 weeks
45619431|NCT02493959|Biological|PYY1-36 + sitagliptin|Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs. Two doses of 100 mg sitagliptin are administered 10 and 1 hour before start of infusion, respectively.
45619432|NCT02493959|Biological|PYY3-36 infusion|0.8 pmol/kg/min infusion of PYY3-36.
45761345|NCT05314777|Procedure|Exercise Training|Patients trained for exercise training.
45761346|NCT00881647|Other|Cognitive Behavioral Treatment for Insomnia (CBT-I)|CBT-I includes strategies and instructions targeted toward improving the quality of sleep and resolving problems falling and staying asleep
45761347|NCT00882661|Device|SECURE-C Cervical Artificial Disc|Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc
45761348|NCT00882661|Device|ASSURE Cervical plate and an allograft interbody spacer|Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion
45761349|NCT00883675|Drug|Docetaxel-Carboplatin|Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin AUC 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses
45911775|NCT05595460|Drug|Atezolizumab|1200 mg administered IV for 4 x 21-day cycles, followed by 1680 mg every 28-days (maintenance)
45911776|NCT05595460|Drug|Carboplatin|AUC 5-6 administered IV for 4 x 21-day cycles
45911777|NCT05595460|Drug|Etoposide|80-100 mg/m2 administered IV on 3 consecutive days for 4 x 21-day cycles
45911778|NCT05593471|Other|high intensity exercises|resistance training progressively increasing according to specific criteria (10 repetitions maximum). for the major muscles of the body
45911779|NCT05593471|Other|low intensity aerobic exercises|low-intensity exercises performed using arm or leg ergometer machines
45911780|NCT05592236|Other|Dynamic compression garments|Dynamic compression garments for 2 hours a day in addition to standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
45911781|NCT05592236|Other|Standard therapy|Standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
45619433|NCT02493959|Biological|placebo|Infusion of saline for 2 hrs.
45619434|NCT05032209|Other|follow-up of children with severe asthma in adulthood|follow-up of children with severe asthma in adulthood
45619435|NCT02496377|Drug|ferrous glycine sulfate Tardyferon|
45619436|NCT02496377|Drug|Epoetin Alfa|
45619437|NCT02496377|Drug|ferric carboxymaltose Ferinject|
45619438|NCT03096171|Behavioral|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 16 weeks, with trainings of 20 minutes, four times a week.
45619439|NCT02496455|Procedure|cesarean section|Women in 36 to 40 weeks of pregnancy undergoing cesarean section by Pfannenstiel technique
45619440|NCT02496455|Drug|Opioid Tramadol|Tramadol will be administered via patient controlled analgesia (PCA) pump in the postoperative period
45619441|NCT03094689|Other|Cold water immersion|
45619442|NCT03094689|Other|Water immersion|
45619443|NCT02496299|Drug|Dexamethasone|Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
45761350|NCT00884065|Other|Diacutaneous Fibrolysis|The implementation of the technique consists of three consecutive stages: The first stage involves manual palpation, which is carried out by the hand that is not holding the hook, with the objective to find the area to be treated; the second, or instrumental palpation stage, is carried out by introducing the spatula of the hook together with the index finger of the palpatory hand to locate with precision the adherent connective fibers or fibrous corpuscles; the third, or fibrolysis stage, is the actual treatment. Here, a brief supplementary traction is carried out with the hook.
45761351|NCT00884065|Other|Diacutaneous Fibrolysis (placebo)|The placebo was designed for this study and the stages of manual and instrumental palpation occur strictly at a superficial level. In the third stage, instead of fibrolysis a pinch of skin is hold with the thumb of the palpatory hand and the tip of the spatula, so that the patient feels the hook distinctly but without any action taking place on the deep tissular planes.
45761352|NCT03215407|Drug|Intra-articular Tocilizumab|Patients will be randomly chosen to be intra-articular injected of tocilizumab injection
45761353|NCT03215407|Drug|Intra-articular Compound Betamethasone|Patients will be randomly chosen to be intra-articular injected of compound betamethasone injection
45761354|NCT02722408|Drug|Gemcabene|300 mg tablet orally once daily for four weeks followed by 600 mg tablet orally once daily for four weeks followed by 900 mg tablet orally once daily for four weeks.
45619444|NCT02496299|Drug|Bupivacaine|Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
45619445|NCT03096015|Behavioral|Intensive Comprehensive Aphasia Program|
45619446|NCT02493725|Drug|Eculizumab|
45911782|NCT05587894|Drug|Paxlovid 5 days|"Nirmatrelvir/r 300mg/100 mg bid will be given for 5 days, orally.~Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role.~Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19."
45619447|NCT02493725|Drug|Placebo|
45911783|NCT05587894|Drug|Paxlovid 10 days|Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally.
45619448|NCT03095859|Other|Physical rehabilitation.|Early mobility, aerobic exercise, upper and lower limb strength and flexibility training, trunk mobility and core strengthening, inclusive of respiratory therapy and education.
45619449|NCT04467957|Drug|Initiation of CFTR Modulator|Inhaled contrast for MRI occurring at each visit
45619450|NCT04467957|Drug|Hyperpolarized Xenon 129|Inhaled contrast for MRI occurring at each visit
45619451|NCT02493647|Behavioral|Love, Sex, & Choices|Investigators propose to conduct a two-arm clinical trial of guide enhanced LSC impact on reducing unprotected sex with high risk partners and increasing HIV testing in Black women in high HIV prevalence neighborhoods. Undiagnosed HIV is a significant factor fueling the epidemic. Recruitment into the study will be via Facebook or traditional on the ground.
45619452|NCT04467879|Device|Zona Plus Device|Zona Plus 3.0 Individualized Isometric Handgrip Therapy Device
45619453|NCT04467879|Device|Control Device|Zona Plus control sham device, with a nominal weaker grip
45761355|NCT00884611|Device|Predictive Low Glucose Suspend Algorithm ON|The algorithm uses a Kalman filter-based model to predict whether the sensor glucose level will fall below 80 mg/dL within a given time period and suspends the insulin pump if this event is predicted.
45761356|NCT00884611|Device|Predictive Low Glucose Suspend Algorithm OFF|
45761357|NCT05310331|Combination Product|Donafenib combined with paclitaxel and platinum ± PD-1 antibody|Patients will receive Donafenib (200mg, bid) combined with paclitaxel (135mg/m2) and cisplatin (creatinine clearance rate > 60ml/min, 50 mg/m2) or paclitaxel (175 mg/m2) and carboplatin AUC=5 (40ml/min < creatinine clearance rate < 60ml/min) ± PD-1 antibody every 3 weeks.
45761358|NCT00891319|Device|Electrical stimulator|"• 12-week intervention~Therapist-guided task practice performed twice a week in the research laboratory. (Device used for CCFES group but not for cNMES group during these sessions.)~Self-administered CCFES or cNMES-mediated hand opening exercise performed 10 sessions per week at home."
45761359|NCT04381117|Drug|Previously Treated with EN3835|No treatment to be administered - Observational only
45761360|NCT00885079|Drug|OPC-12759 Ophthalmic suspension|OPC-12759 Ophthalmic suspension 2%
45761361|NCT00885079|Drug|Hyalein Mini Ophthalmic solution|Hyalein Mini Ophthalmic solution 0.1%
45761362|NCT00896779|Drug|ranibizumab|"Group 1 - 0.5mg intravitreal injection every month for 3 months then as needed for 12 months~Group 2 -0.5mg intravitreal injection every month for 6 months then as needed for 12 months"
45761363|NCT03214939|Biological|Immunotherapy based on dendritic cells|Intravenous injection of cells
45911784|NCT05587894|Drug|Veklury|"Remdesivir flash, 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound."
45911785|NCT05587751|Diagnostic Test|Spirometry|Pulmonary function test to measure lung function
45911786|NCT05587751|Diagnostic Test|Plethysmography|Pulmonary function test to measure lung volume
45619454|NCT03337061|Other|Mindfulness Meditation|Mindfulness Meditation delivered through a mobile application
45619455|NCT02493569|Procedure|The radical mastectomy of breast cancer|The radical mastectomy of breast cancer could be used for the treatment of breast cancer during the observation.
45619456|NCT03120689|Other|Live Surgery using VITOM|The vaginal operative field will be filmed with a VITOM® camera and the image from the VITOM® camera will be projected live within the operating room, so that the operating team can reference the image during the surgery.
45619457|NCT03120689|Other|Live Surgery without VITOM|The vaginal operation will not be filmed and learner observation will take place in the traditional way, with them looking at the physical surgical field.
45619458|NCT03120689|Other|Video viewing with VITOM|They will view the 10-minute standardized video filmed with the VITOM® camera.
45619459|NCT03120689|Other|Video viewing with standard handheld high-definition camera|They will view the 10-minute standardized video filmed with the standard, handheld high-definition camera.
45619460|NCT04974645|Device|W-SUDs|Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
45619461|NCT04974645|Other|Education|The education arm will receive digitally delivered psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.
45619462|NCT03094923|Other|Inspiratory Muscle Training|"The inspiratory muscle training (IMT) will be carried out in the IG with Threshold® IMT (Respironics New Jersey, Inc) consisting of a unidirectional flow control valve which assures the constant resistance (linear load) between 7 and 41cmH20.~The IMT will be carried out in the sitting position with a load of 30% of the MIP during the two weeks preceding the surgery, seven days a week, twice daily in three series of ten repetitions with a 30 second interval between series, under the supervision of a physiotherapist. A load of 15% of the MIP was used only on the first day of training in order for the individual to adapt to the equipment. Subsequently, the 30% MIP load will be applied and readjusted according to the new MIP values determined every four days."
45445861|NCT01321827|Drug|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
45619463|NCT03120611|Other|Virtual Reality Exercise|Game developed by the Kinect, adapted to the lying position of participants.
45619464|NCT03120611|Other|Conventional exercise intradialysis|Aerobic exercise (cycling) and strengthening exercise for lower limbs using elastic bands and gravity
45619465|NCT05041881|Device|Trifocal lens AT LISA TRI, Zeiss|lens is made of hydrophilic acrylic material with square edge technology and having diffractive optic design
45619466|NCT05041881|Device|Accommodating Tetraflex HD lens, Lenstec inc.|lens is made of hydrophilic acrylic material with square edge technology and having monofocal optic design
45619467|NCT05041881|Device|Monofocal lens, Softec HD|lens is made of hydrophilic acrylic material with square edge technology and having monofocal optic design
45619468|NCT04494191|Drug|Flibanserin 100Mg Tab|One tablet contains 100 mg Flibanserin
45619469|NCT04494191|Drug|Flibanserin 100 MG [Addyi]|One tablet contains 100 mg Flibanserin
45619470|NCT05041725|Drug|Remimazolam Injection [Byfavo]|Remimazolam injection and continuous infusion for postoperative sedation, 0.2 mg/kg for 1 min and continuous infusion of 1-2 mg/kg/hour
45619471|NCT03338075|Radiation|fractionated stereotactic radiotherapy|The regular prescription doses were 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.
45619472|NCT02121405|Procedure|Rectectomy|Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).
45619473|NCT02121405|Radiation|Radiotherapy|45-50 Gy in 25-28 fractions to the pelvis. After 45 Gy a tumor bed boost with a 2 cm margin of 5.4 Gy in 3 fractions for preoperative cancers or 5.4-9.0 Gy in 3-5 fractions for postoperative cancers could be considered. Radiotherapy is used only for patients with pathological confirmed positive circumferential margin in Group primary surgery. Radiotherapy is used to all of the patients in Group preoperative radiochemotherapy.
45619474|NCT02121405|Drug|Capecitabine|Capecitabine 825 mg/m2 twice daily 5 or 7 days/week with concurrent radiotherapy in Group primary surgery and Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 weeks after preoperative radiochemotherapy in Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 months postoperative therapy for a part of stage II patients in Group of primary surgery. Capecitabine 1000 mg/m2 twice daily 1-14 every 3 weeks with oxaliplatin day 1 to a total of 6 months postoperative therapy for stage III patients in Group of primary surgery.
45619475|NCT02121405|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 over 2 hours, day 1, with capecitabine every 3 weeks. Repeat every 3 weeks to total of 6 months postoperative therapy.
45619476|NCT03336905|Other|Physical activity program and prevention after cancer|Providing a supervised and non-supervised physical activity program for adolescent and Young adult with cancer and improve awareness on cancer prevention recommendations (second cancer risk, healthy lifestyles...)
45619477|NCT03337997|Procedure|Irreversible Electroporation|Open Irreversible Electroporation by ultrasound guidance for tumors under 3 cm in diameter. Goal is to obtain an Amp rise of 12 or more
45761364|NCT03376477|Biological|GM-CSF vaccine|Each vaccination will consist of three total intra-dermal injections, on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Vaccine injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each vaccination injection is approximately 0.7-0.8ml.
45761365|NCT03376477|Drug|Lenalidomide|Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5-25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
45761366|NCT03376477|Drug|Prevnar13|Prevnar will be administered at the same time points as the GM-CSF vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine.
45619478|NCT05030883|Behavioral|Source of news|The main intervention was the source of the news that was shown to participants
45619479|NCT03336827|Behavioral|Cognitive-Behavioral Group Therapy and Hypnosis|The intervention consists in a pre-group interview and eight 2,5 h-session extended over 4 months. The intervention is based on cognitive-behavioral group therapy and hypnosis. To promote use of hypnosis at home, patients will receive audiorecordings of the hypnosis exercises. Starting immediately after the pre-group interview, the group will receive 3 app prompts a day promoting self-awareness and modulation of internal states, orientation of attention toward positive stimuli and inviting them to increase physical activity. Patients will be given a patient manual to promote an active approach to changes.
45911787|NCT05584111|Drug|STC-15|STC-15 oral capsules once a day in 3-week cycles
45445862|NCT01321827|Drug|Itraconazole|Itraconazole 200 mg BD for 6 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach
45619480|NCT03336827|Behavioral|Cognitive-Behavioral Group Therapy and Hypnosis|The intervention consists in a pre-group interview and eight 2,5 h-session extended over 4 months. The intervention is based on cognitive-behavioral group therapy and hypnosis. To promote use of hypnosis at home, patients will receive audiorecordings of the hypnosis exercises. Starting immediately after the pre-group interview, the group will receive 3 app prompts a day promoting self-awareness and modulation of internal states, orientation of attention toward positive stimuli and inviting them to increase physical activity. Patients will be given a patient manual to promote an active approach to changes.
45619481|NCT05052177|Device|Edge to edge repair in systemic tricuspid valve regurgitation|Edge to edge repair of severe tricuspid regurgitation on a right systemic ventricle with a Mitraclip device.
45619482|NCT05052489|Other|registy|Children with diarrhea were registered in the hospital. Baseline information of the children was recorded and followed up to observe the distribution of disease types, clinical manifestations, treatment plans and clinical outcomes
45761367|NCT03376477|Other|Placebo Prevnar13|Saline will be used for placebo. Placebo prevnar will be administered at the same time points as the GM-CSF vaccine or Placebo GM-CSF Vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine or placebo GM-CSF vaccine.
45619483|NCT03094845|Biological|Placebo solution|15 injections over 7 weeks
45619484|NCT03094845|Biological|hdmASIT+TM|15 injections over 7 weeks
45619485|NCT03337841|Drug|Pembrolizumab|Each subject will receive administration of pembrolizumab 200mg IV once only before curative treatment such as hepatic resection or radiofrequency ablation, and will receive curative treatment after administration of pembrolizumab. After curative treatment, each subject will receive pembrolizumab 200mg IV every 3 weeks. Treatment will continue until tumor recurrence, occurrence of an unacceptable adverse event, or the 16th treatment with pembrolizumab.( The setting of 16 times administration is the period of adjuvant therapy of this trial is 12 month(=48weeks), administration of pembrolizumab is Q3W, so 16 times administration comes to 48 weeks.)
45619486|NCT05041413|Behavioral|Moms Quit|Participants will receive text messages tailored on (1) current smoking status and (2) intention to quit/remain quit. Message content includes supportive messaging for child and self-care, relapse prevention, and smoking cessation. Women who are ready to quit will receive messages from the SmokeFreeText library.
45619487|NCT05041413|Behavioral|Text4Baby|Text4Baby is a free, publicly available text messaging program that provides information about nutrition, safe sleep tips, baby's milestones, signs and symptoms of labor, doctor visit and appointment reminders, breastfeeding advice, car seat safety, information on health insurance, urgent health alerts, and resource hotlines and websites.
45619488|NCT03336749|Behavioral|Sensory group|The sensory re-learning consists of touch detection practice, i.e., touch discrimination to identify different materials, shapes, textures, weights and temperatures, proprioception and tactile object recognition in combination with task-specific training.
45619489|NCT03336749|Other|Control group|Traditional task-specific training
45619490|NCT05052021|Other|Recent or Peri-Operative Covid19 Infection|No intervention will be done. The groups will be differentiated based on whether they had recent or peri-operative Covid19 infection (group 1), or whether they have had no or previous Covid19 infection (Group 2)
45619491|NCT02493335|Drug|Budesonide 0.5mg orodispersible tablet twice daily|
45619492|NCT02493335|Drug|Budesonide 1mg orodispersible tablet twice daily|
45619493|NCT02493335|Drug|Placebo orodispersible tablet twice daily|
45619494|NCT05040945|Procedure|Traditional corticotomy|Adult patients will be treated by extraction of maxillary first premolars with applying mini-screws between maxillary second premolar and first molar as temporary skeletal anchorage devices (TSADs). Then en-masse retraction associated with traditional corticotomy will be applied.
45619495|NCT05040945|Procedure|Flapless corticotomy|Adult patients will be treated by extraction of maxillary first premolars with applying mini-screws between maxillary second premolar and first molar as temporary skeletal anchorage devices (TSADs). Then en-masse retraction associated with flapless corticotomy will be applied.
45619496|NCT04494269|Drug|Tegoprazan 50mg|Oral administration once daily
45619497|NCT03336593|Biological|Quadrivalent Influenza Vaccine|1 or 2 doses of Quadrivalent Influenza Vaccine depends on age
45619498|NCT03336593|Biological|Trivalent Influenza Vaccine|1 dose of Trivalent Influenza Vaccine
45619499|NCT05030727|Diagnostic Test|record of pNGAL|Preoperative (0.hour baseline), postoperative 24.,48. BUN, Creatinine, Lactate values in the blood of the patients at 1 hour, and for plasma NGAL, blood samples will be taken at the preoperative, postoperative 6th and 24th hours. And the results will be recorded.
45761368|NCT03376477|Other|Placebo GM-CSF Vaccine|Saline will be used for placebo. Each placebo vaccine will consist of three total intra-dermal injections on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Placebo injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each injection is approximately 0.7-0.8ml.
45761369|NCT04381663|Procedure|conservative treatment|conservative treatment for patients with cervical spine stenosis without myelopathy
45761370|NCT04381663|Procedure|surgical treatment|surgical decompress the spinal canal in patients with moderate to severe degenerative cervical spine myelopathy
45911788|NCT05564754|Device|Feedback-controlled temperature device|If core body temperature exceeds 37.7°C a feedback controlled-device will be used and set at 37.5°C.
45445863|NCT03758937|Procedure|volume-controlled ventilation|
45619500|NCT03120377|Other|Platform|Whole body vibration training will consist of 12 consecutive weeks with two sessions per week on alternate days. Initially, before training with the vibratory platform, stretches lasting 5 to 10 minutes will be performed, with a series of 60 seconds for each of the following muscle groups: pectorals, sternocleidomastoids, scalenes, quadriceps and ischiatibial muscles. Patients will be monitored through vital signs for follow-up.
45619501|NCT03120377|Other|Platform sham|will receive the treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display lit and a sound device coupled with a noise recording generated by the vibration, but without therapeutic purposes.
45619502|NCT05040789|Biological|CoVLP formulation|"The Coronavirus-Like Particle (CoVLP) COVID-19 Vaccine is composed of recombinant spike (S) glycoprotein expressed as virus-like particles (VLPs).~The 3.75 µg dose of CoVLP will be administered with the adjuvant AS03 (manufactured by GlaxoSmithKline)."
45619503|NCT03337607|Device|rESWT|"rESWT will be performed as follows:~Four rESWT sessions~One rESWT session per week~4 × 1000 radial extracorporeal shock waves (rESWs) per session (1000 rESWs each applied to the left and the right paravertebral muscles above L3 to S1 using the 36-mm applicator, plus 1000 rESWs each applied to the left and the right sacroiliac joint using the 15-mm convex applicator, in prone position of the patient.~rESWs applied at 15 Hz~Air pressure of the rESWT device gradually increased during the first 200 rESWs each until the maximum discomfort the patient can tolerate will be reached, followed by 800 rESWs at this air pressure / energy flux density.~No application of local anaesthetics"
45619504|NCT03337607|Drug|Celecoxib|1 x 200 mg per day for moderate pain (Numerical Rating Scale score 4-6 on an 11-point scale where 0 indicates no pain and 10 indicates worst imaginable pain), or 2 x 200 mg per day (Numerical Rating Scale 7-10), respectively, for four weeks
45619505|NCT03337607|Drug|Eperisone|3 x 50 mg per day for four weeks
45619506|NCT03336515|Device|Group C-Postural device activated|General recommendation not sleeping in supine position and the postural device activated (intervention group).
45619507|NCT03336515|Device|Group B-Postural device no activated|General recommendation not sleeping in supine position and the postural device without any activation (placebo)
45761371|NCT02726620|Procedure|Attending real-time decision support|Near real-time decision support elements will notify the attending anesthesiologists of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the pager system. The page will also display the associated increased risk of organ injury due to organ ischemia.
45761372|NCT02726620|Procedure|In-room real-time decision support|Near real-time decision support elements will notify the in-room anesthesia provider of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the anesthesia information management system. The decision support system will display the associated increased risk of organ injury due to organ ischemia.
45761373|NCT02726620|Procedure|Attending feedback emails|Attending anesthesiologists will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.
45761374|NCT02726620|Procedure|In-room provider feedback emails|In-room anesthesia providers will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.
45911789|NCT05564754|Other|High MAP|A MAP target of >85mmHg will be used. Vasopressors will be titrated to this target during 36h.
45911790|NCT05564754|Other|Deep sedation|Deep sedation for at least 36h
45911791|NCT05564754|Other|Fever control without a device|Management of fever in the ICU without a device
45911792|NCT05564754|Other|Low MAP|A MAP target of >65mmHg will be used. Vasopressors will be titrated to this target during 36h.
45619508|NCT03336515|Behavioral|Group A-General Recommendation|General recommendation not sleeping in supine position
45619509|NCT05030181|Other|kinesiotaping and exercise|kinesiotaping group, ''I'' strip kinesiotape will be applied with the space correction technique for the upper trapezius muscle, for a total of 4 sessions, 2 days a week, and the patients will be included in the 1-month home exercise program.
45619510|NCT05030181|Other|exercise|exercise
45619511|NCT02493179|Drug|Serodase 5 mg|Serodase 5mg two tablets three times per day
45619512|NCT02493179|Drug|Placebo|Placebo two tablets three times per day
45619513|NCT05030259|Procedure|fasciotomy|To perform fasciotomy
45619514|NCT03336437|Drug|Estradiol vaginal ring|Estradiol 2mg vaginal ring
45761375|NCT02726620|Device|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
45761376|NCT02726620|Device|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the postoperative feedback emails.
45761377|NCT02726620|Procedure|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
45761378|NCT02726620|Device|Pager system|The mobile pager system through which alerts can be sent
45911793|NCT05564754|Other|Minimal sedation|A strategy of minimal sedation in the ICU, used only as needed to facilitate transport, imaging and invasive procedures.
45911794|NCT05563051|Device|i-ED COIL|The i-ED COIL System (i-ED COIL and detachment box) are intended for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.
45911795|NCT05548270|Drug|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel or Placebo
45911796|NCT05548270|Drug|Placebo|Subjects will self-administer DPI-386 Nasal Gel or Placebo
45911797|NCT05546814|Procedure|Sodium algorithm|Infants will receive sodium and follow a sodium supplementation schedule or algorithm. This means that based on the sodium levels collected from the samples (stool and urine) they will receive an increase or maintain the same amount to help
45911798|NCT05546450|Behavioral|Diet|"Patient in Diet Group and Cornus mas L. and Diet Group will be given a personalized diet and be followed up by a dietician."
45445864|NCT03758937|Procedure|pressure-controlled ventilation|
45619515|NCT03336437|Other|Placebo vaginal ring|Silicone vaginal ring without any active estradiol
45619516|NCT05040867|Other|Physical exercise program|"The physical exercise programme will last 16 weeks where participants will do three weekly sessions of 60 minutes, approximately. In these training sessions, cardiovascular and strength components will be worked out, planned from moderate to high intensity in the TEG and unique high intensity in the HRVG. The training programme will be divided into three mesocycles from neuromuscular adaptation to reach, in last period, the highest loads and cardiovascular levels. Each session will include a warm-up, a main part and a cool-down with stretching and mobility exercises.~The difference between the interventions of the HRVG and TEG will be in the planning of the intensity of the cardiovascular exercises and the weight to be lifted in the strength exercises. The first session of both programmes will have the same intensity but depending on how the heart rate variability of the HRVG patients reacts to, the weight and the intensity will be individualised each day."
45619517|NCT03337529|Other|Vitamin C|200 mg Vitamin C will be given on daily basis for 8 weeks
45911799|NCT05546450|Dietary Supplement|Cornus mas L.(Cornelian Cherry)|"Patients in Cornus mas L. Group and Cornus mas L. and Diet Group will receive 30 g/day freeze-dried Cornus mas L. fruit powder supplement."
45619518|NCT03337529|Other|Placebo|200 mg placebo will be given on daily basis for 8 weeks
45619519|NCT03336359|Diagnostic Test|Tandem colonoscopy|Different image enhanced endoscopy systems
45619520|NCT03097965|Dietary Supplement|PROGRAM|
45619521|NCT03097965|Other|DIET|
45619522|NCT05041179|Dietary Supplement|Pruvin R|Combination of N-acetylcysteine an glycine
45619523|NCT05041179|Other|Isomaltulose|Placebo as comparator to intervention
45761379|NCT02726620|Procedure|Central neuraxial anesthesia|Regional anesthesia effectuated through the placement of local anesthetics around the nerves of the central nervous system, e.g. spinal anesthesia and epidural anesthesia.
45761380|NCT02726620|Procedure|Non-cardiac surgery|Any surgical intervention that is not aimed at surgical correction of the heart
45445865|NCT04294251|Drug|DWP450|Botulinum toxin type A(DWP450) will be administered intramuscularly to the bilateral masseter muscles on Day 1.
45619524|NCT00706901|Behavioral|Arm 1 GMI|Participants randomized to GMI received four structured, back-to-back, 75-minute sessions in one week consistent with the central principles and spirit of MI (Miller & Rollnick 2013) and based on a manualized protocol (Martino & Santa Ana 2013; Santa Ana & Martino, 2009). Designed for dually diagnosed patients, a focus of the intervention is to examine the relationship between the substance use and the co-existing psychiatric disorder(s) and the importance of proactively treating both conditions.
45619525|NCT00706901|Behavioral|Arm 2 IHMD|Participants randomized to IHMD received a 27 day VA Care Coordination Home Telehealth (CCHT) program targeting acute recovery from alcohol and other drug disorders. IHMD consisted of daily assessment combined with dialogues consisting of motivational interviewing, cognitive behavioral therapy, and 12-step (mutual self-help) facilitation.
45619526|NCT00706901|Behavioral|Arm 3 TCC|TCC consisted of a 4-session psychoeducational group (75 minutes per session). Material was delivered using a power point presentation on topics
45619527|NCT05040399|Other|Locking Compression Plates|Plates and screws for sternal fixation
45619528|NCT05040399|Other|Sternal Wires|sternal wires used for fixation of sternum
45619529|NCT05051709|Procedure|Corrective osteotomy|First metatarsal distal corrective osteotomy
45619530|NCT05051709|Procedure|Fusion of First ray|Fusion of first ray with soft tissue procedure
45761381|NCT02726620|Drug|Propofol|Anesthetic drug used to maintain general anesthesia
45911800|NCT05536076|Other|Hypercapnia treatment|Intermittent hypercapnia treatment five days per week for two weeks.
45911801|NCT05536076|Other|Sham treatment|Intermittent pressurized air five days per week for two weeks.
45445866|NCT04294251|Drug|Placebo|Placebo(Normal Saline) will be administered intramuscularly to the bilateral masseter muscles on Day 1.
45445867|NCT01756365|Procedure|Surgical transplantation of ACCE|The culture of corneal epithelium strives to produce a reconstructed tissue with the therapeutical aim of treatment of limbal stem cell deficiency.
45445868|NCT02402517|Other|Control|Non pulse extruded snack
45445869|NCT02402517|Other|Small particle size pea flour|Pulse extruded snack
45445870|NCT02402517|Other|Large particle size pea flour|Pulse extruded snack
45761382|NCT02726620|Drug|Sevoflurane|Anesthetic drug used to maintain general anesthesia
45761383|NCT02726620|Drug|Desflurane|Anesthetic drug used to maintain general anesthesia
45761384|NCT02726620|Drug|Isoflurane|Anesthetic drug used to maintain general anesthesia
45761385|NCT02726620|Drug|Ephedrine|Cardiovascular drug used to treat intraoperative hypotension
45445871|NCT02402517|Other|Lentil flour|Pulse extruded snack
45445872|NCT02402517|Other|Navy bean flour|Pulse extruded snack
45445873|NCT02402517|Other|Pinto bean flour|Pulse extruded snack
45619531|NCT03337373|Drug|cisatracurium|A single dose of 0.2 mg/kg intravenous bolus cisatracurium will be administered and blood samples will be taken before and at least 7 occasions post dose (at 1, 5, 10, 12, 15, 20, 30, and/or 60 minutes after a single bolus).
45619532|NCT05040555|Combination Product|R-CDOP|Rituximab 375mg/m2, D0; Cyclophosphamide 750mg/ m2, D1; Doxorubicin hydrochloride liposome 30-35mg/ m2, D1; Vindesine 3mg/ m2, D1; Prednisone 60mg/ m2, D1~5.
45619533|NCT03336281|Drug|Ustekinumab|All participants will receive ustekinumab at study entry. Ustekinumab will not be provided by the sponsor. The treatment decision must have been taken by the investigator prior to, and independently of the participant's inclusion into the study following the standard clinical practice. Only data available from a participant's source medical records will be collected.
45911802|NCT05534620|Drug|Treosulfan|IV infusion
45911803|NCT05534620|Drug|Fludarabine|IV infusion
45911804|NCT05534347|Biological|Blood sample|Addtional tube of blood needed for follow up of patients
45911805|NCT05534347|Biological|Joint puncture|Joint puncture if needed according to routine care of the patients
45911806|NCT05524597|Behavioral|Writing Intervention|Participants will be asked to write about different kinds of experiences.
45911807|NCT05521516|Device|Active Percutaneous Auricular Neuromodulation with NSS-2 Bridge|Application of 5 days of percutaneous auricular neuromodulation with NSS-2 Bridge device
45911808|NCT05521516|Device|Sham Treatment|Application of 5 days of a nonfunctional sham device
45619534|NCT03336125|Dietary Supplement|Vitamin D|Vitamin D (40µg/day) will be compared with placebo
45761386|NCT02726620|Drug|Phenylephrine|Cardiovascular drug used to treat intraoperative hypotension
45619535|NCT03336125|Dietary Supplement|Placebo|120 mg olive oil
45619536|NCT05051163|Drug|Ceftriaxone Sodium|7 days of once daily dosing
45619537|NCT05051163|Drug|Ampicillin|7 days of 6 hourly dosing
45619538|NCT05051163|Drug|Gentamicin|7 days of once daily dosing
45619539|NCT05050851|Dietary Supplement|Measurement of nutritional parameters in children with pneumonia|measurement of Body Mass Index, head circumference, weight, length
45761387|NCT02726620|Drug|Norepinephrine|Cardiovascular drug used to treat intraoperative hypotension
45761388|NCT02726620|Drug|Epinephrine|Cardiovascular drug used to treat intraoperative hypotension
45761389|NCT02726620|Drug|Dobutamine|Cardiovascular drug used to treat intraoperative hypotension
45761390|NCT02726620|Drug|Dopamine|Cardiovascular drug used to treat intraoperative hypotension
45761391|NCT02726620|Drug|Isoproterenol|Cardiovascular drug used to treat intraoperative hypotension
45761392|NCT02726620|Drug|Milrinone|Cardiovascular drug used to treat intraoperative hypotension
45761393|NCT02726620|Drug|Atropine|Cardiovascular drugs used to treat intraoperative hypotension
45935034|NCT00069459|Drug|Extended-release Bupropion Hydrochloride|Bupropion hydrochloride will be available in dose strength of 150 and 300 milligram (mg). Subjects will receive one tablet of 150 mg bupropion hydrochloride from Day 1 to 7, from Day 8 to Week 27 will receive one tablet of 300 mg bupropion hydrochloride and from Week 28-29 one tablet of bupropion hydrochloride
45445874|NCT03756675|Other|haplotype PBSCT|"haplotype peripheral blood stem cell transplantation (PBSCT) of GIAC system"
45619540|NCT03337217|Procedure|Position during colonoscopy|Position during colonoscopy
45619541|NCT05029791|Other|Tumor biopsy|2 cutaneous tumor biopsies before treatment initiation (D-28 to D-1) and under treatment (Month 1)
45761394|NCT02726620|Drug|Glycopyrrolate|Cardiovascular drug used to treat intraoperative hypotension
45761395|NCT02726620|Drug|Vasopressin|Cardiovascular drug used to treat intraoperative hypotension
45761396|NCT02726620|Drug|Terlipressin|Cardiovascular drug used to treat intraoperative hypotension
45761397|NCT02726620|Drug|Sodium Chloride 0.9%|Intravenous fluid used to treat intraoperative hypotension
45761398|NCT02726620|Drug|Ringer's lactate|Intravenous fluid used to treat intraoperative hypotension
45619542|NCT05029791|Other|Blood sample|1 EDTA blood sample (8mL) before treatment initiation (D-28 to D-1)
45619543|NCT03336047|Behavioral|personal activity intelligence|"Participants randomized to the PAI intervention will receive a Mio Slice fitness bracelet and asked to install the Mio Pai 2.0 app on their smart phone. This tracks their fitness score based on the PAI algorithm where the goal is to maintain 100 PAI points a week. PAI is earned incrementally based on time spent in three different heart rate zones, low, medium and high intensity. PAI is recorded every day and added to the weekly total and the PAI earned on the same day the previous week is deleted (on Tuesday, the PAI earned the previous Tuesday will disappear).~Participants will be encouraged to maintain 100 PAI during the 8 weeks intervention by telephone messages (sms)."
45619544|NCT03336047|Behavioral|10,000 steps daily|Participants randomized to the 10,000 step intervention will receive a fit bit zip step counter and asked to obtain 10.000 steps per day. Participants will be encouraged to obtain 10.000 steps per day by telephone messages (sms).
45935035|NCT00214630|Drug|rosuvastatin calcium|
45445875|NCT03765099|Behavioral|Animal-Assisted Interactions|Child and caregivers randomly assigned to the intervention group will spend approximately 15 min with a registered canine and its owner during potentially anxiety-producing visits to the hospital.
45445876|NCT03763851|Radiation|Active PPP005|Group assigned to active PPP005 in the randomized placebo-controlled trial
45445877|NCT03763851|Radiation|Radiotherapy|Palliative RadioTherapy to the symptomatic site
45445878|NCT03756519|Behavioral|Exercise|A standardized exercise program tailored to the individual based on their directional preferences and current functional abilities.
45445879|NCT03756519|Behavioral|Advice to stay active and engaged in usual activities.|Participants will be advised that staying physically active and continuing to participate in usual activities improves recovery. This verbal advice will be reinforced with a written handout.
45619545|NCT05029323|Diagnostic Test|Fast HUTT|Fast HUTT protocol stabilization phase of 5 min in the supine position; passive phase of 10 min at a tilt angle of 60 degrees; provocation phase of further 10 min after 300 micrograms NTG sublingual spray.
45619546|NCT05029323|Diagnostic Test|Conventional HUTT|Conventional HUTT protocol stabilization phase of 5 min in the supine position; passive phase of 20 min at a tilt angle of 60 degrees; provocation phase of further 15 min after 300 micrograms NTG sublingual spray.
45619547|NCT03335969|Device|colon irrigation|Study is to compare bowel movement patterns before and after colon irrigation.
45761399|NCT02726620|Drug|Hydroxyethyl starch solutions|Intravenous fluid used to treat intraoperative hypotension
45761400|NCT02726620|Drug|Fresh Frozen Plasma|Intravenous fluid used to treat intraoperative hypotension
45761401|NCT02726620|Drug|Packed Red Blood Cells|Intravenous fluid used to treat intraoperative hypotension
45761402|NCT02726620|Drug|Albumin solutions|Intravenous fluid used to treat intraoperative hypotension
45761403|NCT02726620|Drug|Plasma-Lyte|Intravenous fluid used to treat intraoperative hypotension
45761404|NCT02726620|Drug|Lidocaine|Local anesthetic used for central neuraxial anesthesia.
45761405|NCT02726620|Drug|Bupivacaine|Local anesthetic used for central neuraxial anesthesia.
45761406|NCT02726620|Drug|Levobupivacaine|Local anesthetic used for central neuraxial anesthesia.
45761407|NCT02726620|Drug|Ropivacaine|Local anesthetic used for central neuraxial anesthesia.
45761408|NCT02726620|Drug|Mepivacaine|Local anesthetic used for central neuraxial anesthesia.
45761409|NCT02726620|Drug|Tetracaine|Local anesthetic used for central neuraxial anesthesia.
45761410|NCT02726620|Drug|Prilocaine|Local anesthetic used for central neuraxial anesthesia.
45761411|NCT02726620|Drug|Procaine|Local anesthetic used for central neuraxial anesthesia.
45761412|NCT02726620|Drug|Chloroprocaine|Local anesthetic used for central neuraxial anesthesia.
45761413|NCT02726620|Drug|Benzocaine|Local anesthetic used for central neuraxial anesthesia.
45619548|NCT05040477|Other|Muscle energy Technique|"Muscle Energy technique was used to increase the strength of weak muscles,relaxation of tightened muscles in result mobilizes the restricted joint segments.MET's group received 3-5 repetition of post isometric relaxation (PIR).~Treatment through Facet Joint Mobilization based on 3 sets of 15 repetitions of unilateral poster-anterior glide (UPA) using initially grade I & II mobilizations followed by grade III of mitland glides on selected tender segments and 5 repetitions of extension sustained natural apophyseal glides (SNAGs) on hypo mobile segments.~Conventional therapy comprising of stretching and isometric strengthening exercises in combination with TENS and heat therapy."
45935036|NCT00214630|Drug|atorvastatin|
45761414|NCT02726620|Drug|Articaine|Local anesthetic used for central neuraxial anesthesia.
45619549|NCT03094455|Other|Experimental group|Observation of video sequences showing uni¬manual or bimanual goal-directed actions followed by the execution of the observed actions either with plegic upper limb for unimanual or with both upper limbs for bimanual actions.
45619550|NCT03335891|Procedure|Core Stabilization Exercises|Volunteers received an asthma education program and trained for diaphragmatic, pursed lip breathing exercises as well as participated in the core stabilization exercises program.
45619551|NCT03335891|Procedure|Control|Volunteers received an asthma education program and trained for diaphragmatic andpursed lip breathing exercises
45619552|NCT03094377|Other|Multisensory therapy|Sensory stimulation, motor training and ADL training
45619553|NCT03094377|Other|Conventional training|Motor training and ADL training
45619554|NCT03331211|Drug|TKIs|Dasatinib combined with Chematherapy
45619555|NCT05040165|Device|Iceform liner and sleeve|Subjects will be asked to use the investigational device as their primary prosthesis for up to 6 months. TPE material durability evaluated through monthly online questionnaires.
45619556|NCT03335735|Behavioral|Loss-framed text message|Participants in the intervention group will receive loss-framed text messages related to drinking and driving on days during the week with a higher likelihood of alcohol consumption (Thursday-Saturday). Loss aversion refers to people's tendency to prefer avoiding losses to acquiring equivalent gains: it's better to not lose $5 than to find $5, so the content of the messages will be related to loss of personal freedom, loss of money, and loss of future employment opportunities due to Driving Under the Influence (DUI) convictions.
45761415|NCT04381585|Device|A MINI DISTRACTOR WITH A SUBMERGED ACTIVATION COMPONENT|Mini distractor is used to regenerate alveolar bone which is resorbed due various reasons. The distractor uses a winch-like submucosal activation component which is buried in the tissue; Flicking the winch turns the screw which moves the segment upwards in the direction of black arrow increasing height.
45761416|NCT00887575|Drug|Paclitaxel|IV infusion per institutional guidelines on Days 1, 8 and 15 of a 28 day cycle as follows depending on dose level (DL): DL1- 70 mg/m2, DL2- 80 mg/m2, DL3- 80mg/m2, DL4- 80mg/m2, DL-1- 70mg/m2, DL-2- 60mg/m2
45619557|NCT03335735|Behavioral|Gain-Framed text message|Participants in the intervention group will receive gain-framed text messages related to drinking and driving on days during the week with a higher likelihood of alcohol consumption (Thursday-Saturday). Gain-framed messages have been shown to have a positive effect on preventative healthcare and include content framed in a manner that the participant gains something from taking preventative action. Message content will be related to saving lives, gaining control, and making loved ones happy.
45761417|NCT00887575|Drug|Carboplatin|IV infusion per institutional guidelines Day 1 of a 28 day cycle as follows depending on dose level (DL): DL1- AUC=5, DL2- AUC=5, DL3- AUC=6, DL4- AUC=6, DL-1- AUC=4, DL-2- AUC=4
45619558|NCT01929915|Procedure|Epidural patient controlled analgesia|Patient controlled epidural analgesia with marcaine(1mg/ml)+ fentanyl(1.25mcg/ml)for postoperative pain control
45619559|NCT01929915|Drug|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia with morphine(1mg/ml)for post operative pain control
45619560|NCT05039697|Other|oxygen|deliver high flow oxygen (10L/min)
45445880|NCT03756519|Behavioral|Advice on use of ice or heat|Participants will be advised on the appropriate use of ice or heat to manage pain. This verbal advice will be reinforced with a written handout.
45619561|NCT05029245|Biological|Comirnaty®|intradermal injection or intramuscular injection
45619562|NCT02491931|Dietary Supplement|Supplement/placebo intake|Patients will receive either GLN or placebo prior to cardiovascular surgery under extracorporeal circulation, during 3 days and one final dose 4 hours prior to anesthesia.
45619563|NCT05050461|Other|Immunological analyses|Immunological analyses will be performed at inclusion in both arms
45619564|NCT05039853|Behavioral|Brief cognitive task-based intervention|Memory reminder procedure, playing the computer game, Tetris , on a smart-device using mental rotation.
45619565|NCT05039853|Behavioral|Placebo activity|Listening to a pod-cast on a smart-device for approximately 15 minutes.
45761418|NCT00887575|Drug|Sunitinib|By mouth (PO) once daily on days 1-21 of a 28 day cycle as follows depending on dose level (DL): DL1- 25mg, DL2-25mg, DL3- 25mg, DL4- 37.5mg, DL-1- 25mg, DL-2- 25mg. Maintenance therapy of 25mg daily
45761419|NCT03214783|Other|Facial characteristics|The exposures are facial characteristics which differ significantly in exposure rates between coronary artery disease (CAD) group and no CAD group.
45452314|NCT03894046|Drug|Durlobactam|"1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h).~Sulbactam-Durlobactam: Treatment for 7 days up to 14 days if clinically indicated."
45761420|NCT03352843|Drug|Primaquine|All patients will be administered with a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen, and then followed-up for 28 days for clinical and laboratory assessment to assess safety and efficacy.
45761421|NCT03215173|Behavioral|Fit After Baby|Mobile application
45761422|NCT03215173|Behavioral|Text4Baby Control Group|Receive free text messages
45761423|NCT03214549|Procedure|gull wing preparation of laminates veneers|preparation involving mesial and distal extension further lingualy.
45761424|NCT03214549|Procedure|conventional preparation of laminates veneers|preparation not involving mesial and distal extension further lingualy.
45761425|NCT03238027|Drug|SNDX-6352|Humanized IgG4 mAb that blocks colony stimulating factor 1 receptor (CSF-1R)
45935037|NCT00397163|Procedure|Remote ischemic preconditioning|Blood pressure cuff inflation
45935038|NCT00397163|Procedure|Placebo|Deflated cuff on upper arm and thigh for 20 min
45761426|NCT03238027|Drug|Durvalumab|Durvalumab (MEDI4736) is a humanized IgG1 kappa mAb that blocks the interaction of PD-L1 with PD-1 CD80 (B7.1) molecules
45619566|NCT02491853|Device|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator
45619567|NCT02491385|Procedure|thoracic epidural analgesia|In a sitting position, an 18-gauge Tuohy needle is introduced at T6-7 or T7-8 intervertebral space using a paramedian approach. An epidural catheter is advanced 5 cm beyond the tip of the needle and secured with a sterile dressing. For TEA regimen, hydromorphone (8 mcg/ml) was added to 0.15% ropivacaine. TEA setting was bolus/lock out time/basal, 3 ml/15 min/5 ml.
45619568|NCT02491385|Drug|iv-PCA|iv-PCA setting was fentanyl 20 mcg/ml, bolus/lock out time/basal, 0.5 ml/15 min/0.5 ml.
45619569|NCT03331055|Device|PENS|percutaneous electrical nerve stimulation
45619570|NCT03331055|Device|TENS|transcutaneous electrical nerve stimulation
45619571|NCT05028543|Procedure|Conventional TLH|"Procedure: conventional Total laparoscopic hysterectomy the uterine artery will be identified close to the isthmus then coagulated at this level, close to the uterus , using bipolar diathermy. The utero-vesical fold will be dissected and the bladder will be pushed down done.. The vasculature of the uterus will now secured and this will be evidenced by the pale color of the fundus.~Using either bipolar diathermy , the cornual pedicles on one side will be desiccated and cut. Also, both the uterosacral and cardinal ligaments will be coagulated and cut. So that, the opposite side pedicles can be taken care of.. The infundibulopelvic ligaments will be coagulatd and cut if it is necessary to remove both ovaries. A vaginal cuff was inserted into the vagina to identify the vault, which will then cut laparoscopically using a monopolar hook, where the specimen will be completely detached."
45619572|NCT05028543|Procedure|Clipping of utrine artery at its origin before bginning of TLH|"the uterine artery will be dissected using posteriorly and medially to the infundibulopelvic ligament, the ureter should be first identified. The surgeon may grab the obliterated umbilical artery at the anterior abdominal wall and retract it. The movement of the umbilical artery may be Seen at the ovarian fossa perpendicular to the ureter~The uterine vessels will be clipped at their origin from the hypogastric vessels using aclip applier which will be introduced through 10mm trocar. clipping of the artery will be performed through application of two 5 mm size metallic clips in continuity and complete the laparoscopic hysterectomy with the same steps of the conventional method."
45619573|NCT05464745|Drug|PERINDOPRES® DUO 8 mg perindopril tert-butylamine / 2.5 mg indapamide tablets|Oral, generic fixed-dose combination of perindopril tert-butylamine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure) and indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure)
45619574|NCT05464745|Drug|Noliterax® 10 mg/2.5 mg 10 mg perindopril arginine / 2.5 mg indapamide film-coated tablets|Oral, innovative fixed-dose combination of perindopril arginine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure) and indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure)
45619575|NCT03094533|Drug|TIVA|total intravenous anesthesia with propofol
45619576|NCT03094533|Drug|VIMA|volatile induction and maintenance anesthesia with sevoflurane
45619577|NCT03330977|Device|Compression garments|"Patients will wear the compression garments since 4 months after inclusion in order to have a comparison before and after use.~Usual practice would give to the patient the compression garments at inclusion."
45619578|NCT05028231|Procedure|Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy|Each patient will complete 2 cycles of neoadjuvant therapy. After evaluating the curative effect, decide whether to operate or not. Patients with and without surgery enter the survival follow-up period.
45619579|NCT03335579|Combination Product|inhalation or propofol ,epidural or general anesthesia, remifentanil or sufentanil|Different combination of opioids and anesthetics
45761427|NCT00887653|Drug|raltegravir|This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.
45761428|NCT00887965|Drug|Previous denosumab|Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
45761429|NCT05312749|Other|progressive relaxation exercises|progressive relaxation exercises
45761430|NCT02729038|Drug|Gepotidacin|Gepotidacin after reconstitution is a clear, dark brown to dark brownish-yellow solution, free from visible particulate matter. Subjects will receive gepotidacin 750 mg single IV dose over 2 hours.
45761431|NCT05311813|Drug|Enoxaparin, Hydroxychloroquine|To compare efficiency and safety of Enoxaparin and Hydroxychloroquine as monotherapy versus Polytherapy
45761432|NCT03214627|Device|Anemia Control Model (ACM)|The ACM is mainly composed of 2 sub-Systems - predictor model which, depending on the input data, forecasts the response to anaemia drug therapy for a specific patient. The predictor model is implemented as a feed-forward artificial neural network. The ACM is an algorithm that extracts the optimal policy to achieve the established clinical outcome for anaemia management using the predictor model.
45761433|NCT03214627|Drug|IV iron|IV iron given monthly as required - dose determined by the ACM and as agreed by the investigator
45761434|NCT03214627|Drug|Erythropoiesis-Stimulating Agent (ESA)|ESA given monthly as required over 6 months - dose determined by the ACM and as agreed by the investigator
45761435|NCT00888511|Drug|Tarceva|Tarceva 150 mg/day
45761436|NCT00888511|Radiation|Radiotherapy|66 Gy/33 F/5 F per week for 5 weeks
45911809|NCT05517850|Behavioral|Therapist-guided cognitive behavioral therapy administered online|This intervention consists of 10 modules of education and interventions and lasts 12 weeks. An introduction provides information about CBT and AD. Step by step, the participants are introduced to the proposed active treatment components: mindfulness training, and exposure with response prevention. Through this whole process, the participant is guided by a therapist. The therapist may be contacted through a secure internet platform at any time and responds within 48 hours. Participants reads the education material, construct exercises to perform, describes their progress in homework assignments, and receives feedback from their therapist.
45445881|NCT03756519|Other|Advise regarding use of medications|Participants will receive education regarding the use of non-steroidal anti-inflammatory medications (NSAIDs) for pain relief, if needed and if the patient is appropriate for NSAIDs. Information regarding specific recommended doses, potential benefit and risk will be discussed.
45761437|NCT05311111|Procedure|distal radial artery approach|Procedure: Use of radial artery for access for a coronary angiography or intervention After preparation and local anesthesia, the operator will puncture the distal radial artery in the dorsum of the hand or the anatomical snuff-box. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
45761438|NCT05311111|Procedure|conventional radial artery approach|Procedure: conventional radial access for a percutaneous coronary intervention After preparation and local anesthesia, the operator will puncture the proximal radial artery at the conventional site in distal forearm. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
45761439|NCT03214393|Diagnostic Test|Doppler|Doppler will be done to pregnant women with Pre-Eclampsia
45619580|NCT05050071|Drug|Allium Sativum|Sixty-six permanent mature necrotic incisors associated with apical periodontitis in male children were selected. Teeth were randomly divided into three groups (n=22) according to intra canal medications used; group I: Ca OH2, group II: garlic extract and group III: mixture of Ca OH2 and garlic extract. After access preparation, four microbiological samples (S) were as follows; (S1): were taken before canal instrumentation and irrigation. (S2): after cleaning and shaping, Then, the third samples (S3) and forth samples (S4) were taken after placement of the tested intracanal medications into the corresponding canals, for 7 and 14 days respectively. Total DNA was extracted from microbiological samples and relative quantitive real time PCR reactions were done to quantify the relative gene expression levels (FC) for Streptococcus and Enterococcus faecalis species.
45619581|NCT05050071|Device|Polymerase chain reaction|Change in the bacterial load in response to different treatment procedures
45619582|NCT03330899|Biological|H7N9 antigen + adjuvant IB160|H7N9 monovalent (fragmented and inactivated)
45619583|NCT03330899|Biological|H7N9 antigen + adjuvant SE|H7N9 monovalent (fragmented and inactivated)
45619584|NCT03330899|Biological|H7N9 antigen without adjuvant|H7N9 monovalent (fragmented and inactivated)
45619585|NCT03330899|Biological|Placebo (PBS)|Placebo (Phosphate Buffered Saline -PBS)
45619586|NCT03335501|Device|Insulin pump|The participant's insulin pump will be used to infuse insulin
45761440|NCT03214393|Diagnostic Test|serum antibodies|serum antibodies will be measured for pregnant women with Pre-Eclampsia
45911810|NCT05517850|Behavioral|Self-guided digital intervention based on cognitive behavioral therapy|Participants will access a digital platform, read information, and perform exercises in their everyday life. The main treatment components are mindfulness and exposure with response prevention, with a specific focus on itch. Participants will be able to practice mindfulness with the help of instructions and examples. Participants will receive detailed instructions and guidance, and get to choose exposure exercises from a long list of examples. Participants will also be free to create their own relevant exposure situations within the intervention. Digital self-care consists of 8 modules. The only active interventions, mindfulness and exposure are introduced week 1 and 2, respectively. From week 3-7, no new interventions are introduced and participants are advised to continue practicing the interventions, but there is a new theme of education each week, to act as inspiration for exercises. The last 4 weeks, the participant is merely advised to continue practice.
45911811|NCT05517226|Combination Product|Cotadutide|Participants will receive cotadutide subcutaneously.
45911812|NCT05514197|Drug|Ascorbic acid 5000mg|Intravenous loading of 5000mg ascorbic acid with normal saline, totally 100ml Completed before surgical incision
45619587|NCT03335501|Device|Continuous glucose monitoring system|The Dexcom G4 Platinum will be used to measure glucose levels
45619588|NCT03335501|Other|11-hour intervention with the single-hormone artificial pancreas|"Subjects will be admitted at IRCM at 9:30. An intravenous catheter will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing rapid-acting Aspart or faster acting Aspart will be placed in the insulin pump. Closed-loop strategy will start at 10:00 until 21:00. A glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pumps' parameters will then be changed manually to implement the computer generated recommendations.~At 12:00, a lunch meal will be served. An insulin bolus will be given 15 minutes before the meal. At 17:00, a dinner meal will be served. As recommended, an insulin bolus will be given at the time of the meal. Each subject will ingest the same meals during both visits.~Venous blood samples will be obtained for the measurement of plasma glucose and insulin concentrations. Blood samples will be taken every 20 minutes."
45619589|NCT03330431|Behavioral|Progressive Muscle Relaxation (PMR)|"All groups undergo a PMR session, but they differ regarding the treatment before the PMR session. Two groups watch a video before undergoing PMR, the control group reads a text before undergoing PMR.~Progressive muscle relaxation (PMR) is a technique for learning to monitor and control the state of muscular tension. It was developed by American physician Edmund Jacobson in the early 1920s.~The technique involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation."
45619590|NCT05049915|Device|bioglass (S53P4)|surgical procedure: Masquelet defect augmentation with bioglass
45619591|NCT05049915|Device|RIA and TCP|surgical procedure: Masquelet defect augmentation with RIA and TCP
45619592|NCT02492789|Biological|INCSHR01210 injection|"Part1: INCSHR01210 injection at a dose of 1, 3 or 10 mg/kg is administered every 2 weeks (3+3,q2w, except in the first cycle, in which subjects will be only dosed once on Day 1 for PK samplings and dose limiting toxicity observation). Response is assessed by every 2 cycles (4 weeks each cycle) by using irRECIST.~Part2: Additional patients (200mg dose cohorts will be enrolled in Part 2, depending on the data outcomes in Part 1, to further explore preliminarily clinical benefits of INCSHR01210 as well as the other objectives of the study."
45619593|NCT02492945|Drug|3ml-Rejuvinex|They take the three times of the ultrasonography-guided 3ml-Rejuvinex as a PDRN group for four weeks(0,2,4 weeks) under double-blind.
45911813|NCT05514197|Drug|Control Rx|Intravenous loading 100ml normal saline
45619594|NCT02492945|Drug|3ml-15%-dextrose solution|They take the three times of the ultrasonography-guided 3ml-15%-dextrose solution injections as a Dextrose group for four weeks(0,2,4 weeks) under double-blind.
45619595|NCT03335423|Drug|Oral metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
45761441|NCT02730988|Behavioral|Weight Stable Group|The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 & 2 & 1 Plan.
45761442|NCT03214315|Procedure|Visceral adipose tissue specimen|specimen
45761443|NCT02731300|Device|tDCS|brain stimulation by cathodal electrode at motor cortex
45619596|NCT03335423|Drug|Intravenous metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
45619597|NCT03335423|Drug|Oral codeine and oral metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
45619598|NCT03335423|Drug|Oral codeine and intravenous metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
45619599|NCT03330353|Diagnostic Test|Pupillometry|Use of pupillometry to assess melanopsin-light pathway in patients with neurodegenerative diseases
45619600|NCT02491307|Other|Ginger.io Smartphone Application|Daily use of the Ginger.io smartphone application
45619601|NCT01673373|Device|iCAST™ Rx Stent System|All enrolled subjects will undergo primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.
45619602|NCT03335189|Device|ASyMS-Can|Data reported by the participants will be sent to a secure, encrypted clinical central server hosting the risk-alerting algorithms. The web interfaces will provide a clinical portal for the nurses to screen and follow any alerts being triggered, as well as review patient-specific information. Based on these back-end computations, participants will receive automated self-care notifications on their mobile phones. If incoming symptom reports indicate severe adverse effects a designated clinic nurse will receive an 'amber alert', or 'red alert', that will require response within 30 minutes. Nurses will handle alerts during business hours (9 am to 5 pm). After-hour alerts will be sent to the oncologist or nursing supervisor on call as per usual care. Patients will be instructed that clinicians will not receive alerts during the evening hours or night and instructed to follow usual practice of contacting their family physician, or oncologist on call, or call 911, as required.
45619603|NCT02493023|Device|navigated bronchoscopy|
45761444|NCT05315089|Other|Virtual reality games +conventional exercises|Virtual reality games +conventional exercises
45761445|NCT05315089|Other|Conventional exercises|Conventional exercises
45761446|NCT00368368|Drug|GK Activator (2)|100mg po
45911814|NCT05510193|Device|Aktio prosthesis|Transradial myoelectric prosthesis
45761447|NCT00888979|Drug|Nicotrol Inhaler|10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
45761448|NCT02734498|Device|Electroconvulsive Treatment (ECT) Right Unilateral|Intervention is electroconvulsive treatment (ECT) involves a brief electrical stimulation of the brain while the patient is under anesthesia. Performed unilateral on the right side.
45761449|NCT02734498|Device|Electroconvulsive Treatment (ECT) - Bilateral|Intervention is electroconvulsive treatment (ECT) involves a brief electrical stimulation of the brain while the patient is under anesthesia. Performed Bilateral.
45761450|NCT03142867|Other|non-applicable|non-applicable
45911815|NCT05507749|Procedure|cryoballoon ablation|Cryoballoon ablation for the treatment of atrial fibrillation
45911816|NCT05507749|Device|implantable loop recorder insertion|The device called a implantable loop recorder, is placed just under the skin of one's chest during a minor surgery.
45445882|NCT03763695|Other|Measures for the VAP prevention in the PICU|Oral hygiene care (i.e chlorhexidine swab); clean and dry ventilator circuits; head positioning at 45 degrees.
45619604|NCT03335111|Other|Remote Ischemic Conditioning Equipment|BAIPC is admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation up to 50 mmHg higher than baseline, followed by 5-minute cuff deflation) for one week.
45619605|NCT03335111|Procedure|Intravenous blood collection|Nurses will collect 5 ml intravenous blood with anticoagulant and 5ml total blood at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
45619606|NCT05038605|Drug|Topical metronidazole|Topical application of metronidazole cream on the anal verge every 8 hours after surgery
45619607|NCT05038605|Drug|oral metronidazole|Patients received oral metronidazole 500 mg tablets every 8 hours after surgery
45619608|NCT03329807|Device|Transcranial Magnetic Stimulation|The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the somatosensory cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 10Hz on the injured hemisphere by stroke; 1500 pulses with an intensity of 120% of MT 10 sessions of rTMS, one per day, always before conventional sensory therapy. rTMS it will be applied for about 20 minutes, five days per week.
45619609|NCT03329807|Behavioral|conventional sensory therapy|Behavioral: conventional sensory therapy All patients will receive the same protocol of Sensory Therapy that will consist of the behavioral methods of Active Sensory Reeducation, Mirror Therapy and passive method that will consist in the administration of electric current by TENS (sensitive threshold). Participants will be instructed not to perform active muscular contraction during Interventions. The protocol it will be applied for about 60 minutes, five days per week.
45619610|NCT02491229|Other|Hepafast|Two weeks of Hepafast three times a day and additionally 200 kcal followed by 10 weeks of Hepafast two times a day and a meal according to LOGI diet
45619611|NCT02491229|Other|LOGI diet|For twelve weeks, this group eats meals according to the Low Glycemic and Insulinemic Diet (LOGI).
45619612|NCT03329729|Other|Rosuvastatin|Hyperlipidemic patients treated with rosuvastatin
45619613|NCT05038683|Behavioral|Holbæk Obesity Treatment|"Obesity is a chronic, progressive, severe, recidivistic, and complex disease, which mandates that children and adolescents with overweight or obesity have access to a professional medical healthcare service as other pediatric chronic diseases, implying a lifelong course of treatment. The HOT method is further based on the physiological insight into the endocrine regulation of fat mass; especially on how the body adapts when it is challenged by weight loss. These insights include an understanding where the body shifts into an energy-preserving mode when the individual is initiating weight-reducing actions, such as a reduced caloric intake or an increased level of physical activity, which has numerous impacts on communication and pedagogy.~HOT is administered by healthcare nurses and dietitians at healthcare centers in Danish municipalities. Each treatment will be conducted as face-to-face sessions totalling a range of six to 12 hours for 12 months."
45619614|NCT05038683|Behavioral|Conventional Obesity Treatment|"Obesity is viewed as a chronic disease that is ultimately thought to result from an imbalance between energy intake and energy expenditure. However, multiple factors, both environmental and genetic, are thought to influence the disease as well. As obesity reflects energy imbalances, the treatment plan should be designed to induce a slightly negative energy balance by focusing on diet, physical activity, and inactivity through behavior change. Taking one step at a time, will in the end lead to the same energy balance result (i.e. weight loss) and will be more sustainable for the participant whose motivation is absolutely pivotal in this process.~COT is administered by healthcare nurses and dietitians at healthcare centers in Danish municipalities. Each treatment will be conducted as face-to-face sessions totalling a range of six to 12 hours for 12 months."
45619615|NCT02492477|Procedure|evaluation of PORT-A-CATH®|in patients in curative setting, clinical assessment, PORT-A-CATH® testing of possibility of saline-administration and blood withdrawal with vacutainer, laboratory assessment
45619616|NCT02492477|Drug|blocking with Medunasal®-Heparinblock|blocking of the functioning PORT-A-CATH® with heparinized 0,9% NaCl solution
45619617|NCT02492477|Drug|restoration of PORT-A-CATH® with Alteplase|by malfunction of the PORT-A-CATH® attempting of restoration with Actilyse® according to guidelines
45619618|NCT05049759|Behavioral|Confident, Active and Happy Youth|The three target goals of the intervention (confident, active and happy) link closely to the core symptoms of internalizing disorders. Thus, a core symptom of anxiety is a lack of confidence in one's ability to cope with a given fearful situation. The ensuing behavioral reaction is avoidance of the situation and/or enduring it with excessive discomfort. Similarly, a core symptom of a depressive disorder is lowered mood. Regarding both depression and anxiety, both disorders are associated with less physical activity, and low levels of physical activity conversely help maintain the disorders. As such, the aim is to alleviate symptoms and supplement ongoing treatment in CAMHS.
45619619|NCT03095547|Drug|cyclosporine A|Pharmacokinetic assessment Area Under the plasma concentration: time Curve (AUC) 0-t
45619620|NCT03095547|Drug|Posaconazole|Pharmacokinetic assessment AUC 0-tau
45619621|NCT03095547|Drug|Pantoprazole|Pharmacokinetic assessment AUC 0-tau
45619622|NCT03095547|Drug|F901318|Pharmacokinetic assessment AUC 0-tau
45619623|NCT03095547|Drug|Tacrolimus|Pharmacokinetic assessment AUC 0-t
45619624|NCT03329651|Drug|Metformin treatment|"Daily treatment with metformin tablets for 24 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-24: Metformin tablet 1000 mg x 2"
45445883|NCT03763695|Other|Evaluation of VAP incidence before the protocol introduction|evaluation of VAP incidence in our pediatric population of intensive care patients before the implementation of the protocol for VAP prevention
45445884|NCT03763617|Device|d-ptfe membrane|Socket preservation using d-ptfe membrane to inhibit the formation of osteoclasts
45445885|NCT03763539|Procedure|SWL|Shock wave lithotripsy
45445886|NCT03758703|Other|Pre-recorded music intervention group|Refer to the arm/group descriptions.
45445887|NCT03758703|Other|Pre-recorded soothing poetry group|Refer to the arm/group descriptions.
45452315|NCT03894046|Drug|Colistin|Treatment for 7 days up to 14 days if clinically indicated.
45619625|NCT03329651|Drug|Placebo treatment|"Daily treatment with placebo tablets for 24 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-24: Placebo tablet 1000 mg x 2"
45619626|NCT03334955|Procedure|Laparoscopic ovarian drilling|A specially designed monopolar electrocautery probe was used to penetrate the ovarian capsule at 4 points, with the aid of a short burst of monopolar diathermy. The probe (which has a distal stainless steel needle measuring 10 mm in length and 2 mm in diameter) was applied to the surface of the ovary at a right angle to avoid slippage and to minimize surface damage. A monopolar coagulating current at a 40 W power setting was used. The needle was pushed through the ovarian capsule for about 4 mm depth into the ovarian tissue and electricity was activated for 4 seconds.
45619627|NCT05049447|Drug|Pascoflair|1 x 2 tablets (single-dose)
45619628|NCT05049447|Other|Placebo|1 x 2 tablets (single-dose)
45619629|NCT03334877|Diagnostic Test|β -human chorionic gonadotropin|Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation.
45619630|NCT04969107|Procedure|taTME|Resection of rectal cancer with preparation of the mesorectal plane along the TME-plane in a rendezvous procedure of an abdominal and a transanal approach.
45619631|NCT04969107|Procedure|abdTME|Resection of rectal cancer with preparation of the mesorectal plane along the TME-plane in an abdominal Approach.
45619632|NCT03334799|Device|sacroiliac belt|standing and walking with the belt on and with the belt off
45445888|NCT03756441|Behavioral|Mindfulness meditation|This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol
45619633|NCT05028387|Drug|medical abortion|medical abortion
45619634|NCT05465447|Device|subjective refraction|Short-term postoperative (1-3 months) and long-term postoperative (3-5 years) subjective optometry results were measured by subjective refraction.
45619635|NCT05027841|Other|Proprioseption in hemiparetics|Proprioception on balance and gait functions in hemiparetic individuals
45619636|NCT03334643|Dietary Supplement|Fiber mix|Participants will test white bread or fiber mix over a span of 2 weeks. During each testing block, each food will be tested twice over two consecutive days. There are 4 testing blocks in total (one for white bread and three for fiber mix).
45619637|NCT04968951|Drug|Metronidazole|Antibiotic treatment - 250 mg every 6 hrs for 5 days
45619638|NCT04968951|Drug|Placebo|Placebo treatment
45619639|NCT04968951|Drug|Vancomycin|Antibiotic treatment - 125 mg every 6 hrs for 5 days
45619640|NCT04968951|Biological|Fecal Microbiota Transplantation|Encapsulated biologically active human fecal material (donor stool) is provided in capsule form. The fecal material is homogenized with sterile saline, then pelleted and re-suspended in sterile saline/40% glycerol. Participants will receive 15 FMT capsules per day for 3 consecutive days. Capsule are to be swallowed under direct supervision.
45761451|NCT02734576|Device|Venous Sinus Stenting with the Precise Pro Stent|Enrolled patients will undergo a minimally invasive procedure that involves placement of a stent in the cerebral venous sinuses (large veins of the brain).
45445889|NCT03756441|Behavioral|Psychotherapy group|Caregivers will learn the technique of group problem solving
45445890|NCT03756363|Procedure|Non-solvent|Root canal filling removal using ProTaper retreatment instruments. Single session retreatment procedures.
45445891|NCT03756363|Procedure|Solvent|Root canal filling removal using ProTaper retreatment instruments in combination with a gutta percha solvent. Single session retreatment procedures.
45445892|NCT04660383|Device|Inspiratory Muscle Training|Patients will be submitted to three weekly IMT sessions in three different intensities for a period of twelve weeks, totaling 36 sessions.
45445893|NCT03758547|Device|in-exufflator technique|application through a device of 10 cycles using positive pressure (30 cmH20) during inspiration and negative pressure (-30 cmH20) during exhalation
45619641|NCT03334565|Device|Low efficiency air filtration systems|Subjects were exposed to low-efficiency filtered air.
45619642|NCT03334565|Device|High efficiency air filtration systems|Subjects were exposed to high-efficiency filtered air.
45619643|NCT03334565|Device|Air filtration systems without filters (sham)|Subjects were exposed to unfiltered air.
45619644|NCT05049681|Drug|Camrelizumab|SHR-1210（Camrelizumab） 200 mg，Intravenous injection， q2W ，A course of treatment need 28 days.
45619645|NCT05049681|Drug|Apatinib|Apatinib 250mg, q.d.po
45619646|NCT03334487|Drug|Dexamethasone|Oral
45619647|NCT03334487|Drug|Rovalpituzumab tesirine|Intravenous
45761452|NCT03214237|Other|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
45761453|NCT03214159|Drug|Ritonavir Tablet 100mg|Ritonavir Tablet 100mg is a generic product manufactured by Ascletis Pharmaceutical Co., Ltd.
45761454|NCT03214159|Drug|NORVIR tablet 100mg|NORVIR Tablet is a generic product manufactured by AbbVie. NORVIR Tablet 100mg will be used as a comparator drug for the BE study.
45445894|NCT03758547|Device|percussion technique|sliding venturi system (phasitron), powered by compressed gas that can be changed from 0.8 up to 3.5 bar and that generates the oscillations in the range of 80-650 cycles/min
45445895|NCT03753633|Other|Speech therapy|Oropharyngeal exercises will be performed under the supervision of a speech therapist.
45445896|NCT03753633|Other|Control|Inspiratory and expiratory exercises recruiting diaphragmatic muscles
45452316|NCT03894046|Drug|Imipenem/Cilastatin 500 mg/500 mg|1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. Treatment for 7 days up to 14 days if clinically indicated.
45452317|NCT02271490|Other|Acrosome Reaction induction|
45452318|NCT02271490|Other|capacitation in incubation medium prior to ICSI|
45452319|NCT04475614|Dietary Supplement|BioGaia Prodentis lozenges|oral probiotics
45452320|NCT04475614|Procedure|low level laser treatment with Ga-Al-As laser|low level laser treatment
45761455|NCT03213925|Radiation|Radiation therapy|"Radiation therapy to the breast with or without regional nodal area is performed within 12 weeks after completion of chemotherapy with conventional dose (25x200cGy). Additional boost of 16 Gy in the primary involved tumor region.~Techniques: 3D conformal radiation therapy or intensity modulated radiation therapy (IMRT).~Standard systemic treatment for patients with hormonal positive receptor (hormone therapy for at least 5 years) and HER2 positive (trastuzumab for 1 year)"
45619648|NCT05038215|Behavioral|adherence promotion techniques|The experimental group will receive adherence promotion techniques in addition to routine care, including 1-additional information tailored for the spouse/partner, persons living with the patient. 2- Educational material delivered at follow up appointments and by mail at intervals agreed upon by the patient and the clinician. 3- Electronic reminder/communication system established by patient and provider. 4-Follow up communication from the dental provider of the oral appliance to the primary care physician and with patient's approval, their general dentist. 5- After the 3 month follow up visits the patient will be provided with reports about their appliance wear per week. 6-Gift card delivery, $25, at 6 month follow up if a follow up with sleep physician is scheduled.
45619649|NCT05038215|Procedure|Routine Care|The control group will receive routine care
45619650|NCT05038449|Drug|Colchicine Tablets|Colchicine Tablets (Each tablet contains colchicine 0.5mg)
45445897|NCT05377203|Drug|Quadruple combination of half doses therapy→Dual combination of standard dose therapy|"Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day.~Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day."
45619651|NCT05038449|Drug|Standard therapy|Standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition)
45619652|NCT03334331|Other|Six-minute step test|Volunteers will be instructed to go up and down one step for six minutes
45761456|NCT03043573|Behavioral|PATH-MCI|Problem Adaptation Therapy for Mild Cognitively Impaired Adults (PATH-MCI) differs from standard of care psychotherapy by offering a combination of emotion regulation techniques with the provision of environmental adaptation tools (notes, checklists, calendars, etc.), the use of the WellPATH app, and the participation of a willing and available caregiver.
45761457|NCT03043573|Behavioral|Supportive Therapy|ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
45761458|NCT03213847|Device|Superb microvascular imaging (SMI) (Toshiba)|to determine whether there is a correlation between the increased intraneural flow as measured using Doppler US and SMI methods and the severity of CTS as measured by nerve conduction studies, we designed this study
45911817|NCT05502094|Other|Heart Rate Variability Measurement|The heart rate variability of the participants will be measured with the Polar H10 device with a measurement time of 5 minutes.
45452321|NCT04475614|Dietary Supplement|B vitamin injections (Neurobion, Merck, Darmstadt, Germany)|intra muscular vitamin injections
45619653|NCT03334331|Other|Six-minute walk test|Volunteers will walk the longest distance possible by performing turns in a 30 meter corridor for six minutes
45619654|NCT05038059|Drug|ethanolic extract of sapindus mukorossi|ethanolic extract will be used as final endodontic irrigant during root canal procedures in extracted teeth.
45619655|NCT05038059|Drug|ethylene diamine tetra acetic acid|used as final endodontic irrigant in root canal therapy
45619656|NCT05232695|Diagnostic Test|metabolically healthy obese|Obese individuals will be divided into 2 groups as metabolic healthy and unhealthy obese, and their batokine concentrations will be compared.
45619657|NCT01236547|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45761459|NCT03838705|Procedure|hypoxia|It was accepted that hypoxia developed in patients with SpO2< 92 or falling over 20% compared to preoperative values.
45761460|NCT03838705|Procedure|normooxy|It was accepted that patients with SpO2 between 100-92 mmHg
45619658|NCT01236547|Drug|Paclitaxel|Given IV
45619659|NCT01236547|Drug|Pazopanib Hydrochloride|Given PO
45619660|NCT01236547|Other|Placebo Administration|Given PO
45911818|NCT05499052|Drug|REKOVELLE®|"Subjects must be treated according to the routine clinical practice and REKOVELLE® must be prescribed in accordance with the terms of the marketing authorisation of each participating country.~According to the label the REKOVELLE® dose should be based on a recent determination of body weight and a recent determination of Anti-Müllerian Hormone (AMH) (i.e. within the last 12 months) measured by the following diagnostic tests: ELECSYS AMH Plus immunoassay from Roche or alternatively the ACCESS AMH Advanced from Beckman Coulter or LUMIPULSE G AMH from Fujirebio."
45911819|NCT05493735|Drug|Lidocaine Hcl 2% Jelly|Participants in the experimental arm will undergo pessary removal and reinsertion after the application of lidocaine topical gel.
45619661|NCT03329495|Procedure|SMA-orientated right hemicoloectomy|Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMA. The left boundary of resection is the left side of SMA, and artery sheath is not necessarily being opened.
45619662|NCT03329495|Procedure|SMV-orientated right hemicoloectomy|Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMV. The left boundary of resection is the left side of SMV, and SMA is not exposed.
45619663|NCT05048745|Procedure|interval appendectomy|interval appendectomy
45619664|NCT03329339|Procedure|1 L PEG with ascorbic acid with prepackaged, low residue diet|Participants who were allocated to the 2 L PEG with ascorbic acid (PEGA) group took 250 ml of PEG with ascorbic acid at 15-min intervals, completing 1 L of the PEG with ascorbic acid protocol at 8:00 PM on the day prior to the procedure. The remaining 1 L of the PEG with ascorbic acid solution was administered in the same manner at 6:00 AM on the day of the procedure. Participants assigned to the 1 L PEG with ascorbic acid with PLD (PLD) group consumed a prepackaged, low residue diet (ZeroCol, Korea Medical Food Inc., Seoul, Korea) which consisted of a breakfast, lunch and dinner, the day prior to colonoscopy. The Participants took 1 L PEG with ascorbic acid solution at 6:00 AM on the day of the colonoscopy in the same way as described above. All of the subjects ingested 500 mL of water for every 1 L of 1 L PEG with ascorbic acid solution consumed. The Participants completed all of the administrations at least 2 hours before the colonoscopy.
45761461|NCT03213613|Behavioral|Adaptive Attention Training|The training is comprised of a time-based titration of rich audiovisual and sparse audio interactive environments. Training progressively transitions the participants from an immersive and rapid reward setting to a less immersive, sensory impoverished, and slower reward setting. Further, the participants' actions require delayed gratification decisions to accomplish play in the sparse setting, building fronto-parietal control through sustained attention and suppression of ventral-striatal reward impulses.
45761462|NCT03213613|Behavioral|Active Control|Participants in the expectancy-matched active control group will play a visuo-spatial iPad game, in which players use their finger to move an object to different successive square platforms. Expectancy matching to the adaptive attention training was pre-confirmed in 121 participants (18-20 years of age), using targeted surveys on MTurk about their expectations of either training exposure on our specific outcome measures. To balance expectations of potential benefits, this group will receive identical recruitment and experimental instructions as the adaptive attention training group.
45761463|NCT03213613|Behavioral|Low-dose Adaptive Attention Training|Participants in the low-dose training group will play a reduced number of sessions as the Adaptive Attention Training group. Specifically, they will train for two 30-minute sessions at the start and middle of a six-week period. To balance expectations of potential benefits, this group will receive identical recruitment and experimental instructions as the adaptive attention training group.
45761464|NCT03838315|Other|Neural Mobilization with Soft Tissue Mobilization|"Cervical Traction for 10mints 7%of body weight with 7 second hold time and 5 second rest time.~Hot Pack for 10mints. Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization. Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 10minute.~•Post isometric relaxation technique"
45761465|NCT03838315|Other|Neural Mobilization without Soft Tissue Mobilization|"Cervical Traction for 10mints 7%of body weight with 7 second hold time and 5 second rest time.~Hot Pack~Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 10minute."
45761466|NCT02737072|Drug|LY2510924|Administered SQ
45761467|NCT02737072|Drug|Durvalumab|Administered IV
45761468|NCT02834065|Device|Cardiopulmonary bypass machine|Routinely used cardiopulmonary bypass machine (standard of care) will be used to initiate circulatory arrest
45761469|NCT05446558|Procedure|Intracorporeal anastomosis|"Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.~Device:~Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis."
45761470|NCT05446558|Procedure|Extracorporeal anastomosis|"A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.~Device:~Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis."
45761471|NCT04739176|Other|One-on-one rehabilitation program including computerized mirror therapy in addition to standard rehabilitation.|atients will be admitted to the day hospital 2 days a week for 9 weeks. They will participate in a one-on-one rehabilitation program conducted by a multidisciplinary team including a physiotherapist, psychomotor therapist, occupational therapist and a physical activity monitor. Patients will also participate in 12 computerized mirror therapy sessions (twice a day, 2 days a week, from week 4 to 6 of the program).
45761472|NCT03213379|Device|Actimetry measures|The patient will wear actigraphy bracelet during a week that will enable to record patients' movements. The report based on the recording will provide an assessment of daytime somnolence and an indication of propensity for impulsive behaviours.The intervention consisted in 2 supplementary actimetry measures and sending of the actimetry reports to the investigator.
45761473|NCT05446480|Drug|Desloratadine|Oral ingestion 10mg pill 2 hours prior to heat strain trial. Second 10mg dose 24-hours later.
45761474|NCT05446480|Drug|Placebo|Oral ingestion 10mg inert pill 2 hours prior to heat strain trial. Second dose 24-hours later.
45761475|NCT05446480|Other|No Intervention|No pill ingestion during the trial - to discern the presence of a placebo effect from baseline inflammatory response
45761476|NCT03213145|Drug|intraconazole|Subjects will receive itraconazole once daily from Day 5 through Day18
45452322|NCT02262208|Other|Aerobic Exercises|"Exercise intensity for each individual by a heart rate monitor (Polar F1 TM, Polar Electro Oy, Helsinki, Finland), and a Borg 0-10 scale used to register individuals' perceived exertion every 5 minutes throughout the experimental sessions.~Aerobic session will consist of 40 min of lower limb bicycle at 70% of the peak heart rate, as determined in the incremental exercise test."
45452323|NCT02262208|Other|Eccentric Exercise|Eccentric session will consist of 40 min of one lower -limb exercises (leg press) with 6 sets of 10 repetitions at 120% of 1-RM.
45445898|NCT05377203|Drug|Dual combination of standard dose therapy→ Quadruple combination of half doses therapy|"Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day.~Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day."
45445899|NCT03753477|Drug|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin)|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin) X 1 tablet followed by Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet (after washout period)
45619665|NCT05037591|Drug|Sea grapes extract 1.68 g/70kg BW|Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.
45761477|NCT03213145|Drug|Rifampin|Subjects will receive rifampin once daily from Day 5 through Day 16
45761478|NCT03213145|Drug|EDP 305|Subjects will receive EDP 305 once daily on Day 1 and Day 14
45619666|NCT05037591|Drug|Placebo|placebo lactose powder (1.68 g/70kg BW day-1).
45761479|NCT02722564|Behavioral|self estimation of breath alcohol content|
45761480|NCT02722564|Device|breath alcohol content as measured by Alco Sensor IV device|
45761481|NCT02722564|Other|drink a beer|drink a beer, repeat until breath alcohol content 0.1
45761482|NCT05446246|Procedure|Bariatric surgery|Sleeve gastrectomy
45761483|NCT02598817|Other|Standard Infant Formula|Standard Infant Formula containing High Sn-2
45761484|NCT05446090|Diagnostic Test|Spirometry including peak flow|Spirometry including peak flow to assess the degree of airway obstruction. Spirometry will be conducted according to a study SOP. The Global Lung Function (GLI) 2012 equations will be used. Reversibility testing will not be routinely performed. Thus, asthma medications will not normally be withheld for study visits and patients should take their inhalers as usual. The same type of device will be used at each visit.
45761485|NCT05446090|Diagnostic Test|Fractional Exhaled Nitric Oxide (FeNO)|Fractional Exhaled Nitric Oxide (FeNO) to assess the degree of airway inflammation. FeNO will be measured using a standard device (NIOXX Vero®) in accordance with the manufacturer's guidelines. The same type of device will be used at each visit. FeNO should be performed prior to any other respiratory assessment if possible.
45761486|NCT05446090|Diagnostic Test|Forced Oscillation Technique (FOT)|FOT is a non-invasive method that evaluates resistance and reactance in the respiratory system during tidal breathing. It should be performed after FeNO, but prior to Spirometry and will be conducted according to a study SOP.
45761487|NCT05446090|Procedure|Sputum Induction|Sputum Induction for the assessment of airway inflammation and microbiology. Sputum induction will be performed according to an SOP, which includes measures to protect the safety of participants. These consist of pre-treatment with Salbutamol, a short acting bronchodilator, stipulated levels of lung function in order to perform the test and stopping criteria. If the participant is unable to undergo the procedure, due to safety reasons, they will be asked to produce a spontaneous sputum sample. Sputum samples will be collected for a differential cell count, bacterial culture and sensitivity and storage for future research. Procedures for sampling and processing will be detailed in a study SOP.
45761488|NCT05446090|Diagnostic Test|Bloods|Blood will be collected for laboratory analysis, including Vitamin D, Haematology, WCC differential, C-Reactive protein.
45761489|NCT05446090|Diagnostic Test|Nasal lavage|Nasal lavage samples will be taken at the baseline (attack) visit. Samples will be obtained by injecting 5ml of sterile normal saline into the participant's nostrils via a nasal adaptor and then immediately aspirated. These will be placed in a sterile container and transported to the laboratory for viral identification. This procedure will be detailed in a study SOP.
45761490|NCT05446090|Diagnostic Test|Throat swab|A throat swab will be taken at the baseline (attack) visit for viral identification.
45911820|NCT05493735|Drug|Placebo Jelly|Participants in the control arm will undergo pessary removal and reinsertion after the application of lubricating jelly.
45619667|NCT03334097|Other|Prenatal education|"Education intervention will consist of a total of six sessions one week apart, with two hours of duration each one. The sessions that are exclusively oriented towards preparation for childbirth are session 1 and session 2. The content of each session is:~St. Birth: Start of childbirth, Symptoms and Signs, Delivery schedules, Phases of childbirth, Normal childbirth, Other circumstances (Obstetrical pathology / previous pathology, Induction of labor, Instrumental birth, Caesarean section).~nd:methods for relieving birth pain: Alternative Methods of Pain Relief, Pharmacological analgesia, Regional analgesia. Local and regional anesthesia, General anesthesia, breathing training and accompaniment during childbirth-~rd: Puerperium.~rd :Breastfeeding~rd : Newborn care~rd :Positive parenting."
45761491|NCT05446090|Diagnostic Test|Nasal Brush.|Nasal brushings samples may be taken at baseline (attack) and at second visits for RNA and DNA extraction. This will be optional and specific consent from participants will be sought. Procedures for sampling and processing will be detailed in a study SOP.
45761492|NCT05446090|Diagnostic Test|Nasal absorption|Nasal absorption will be used to collect mucosal lining fluid from the respiratory tract for cytokines profiling at baseline (attack) and at second visits.
45761493|NCT05446090|Other|Medical History, Demographic, and Concomitant Medications|Medical history will include clinically significant diseases and prior surgeries and smoking history. A specific respiratory history will also be recorded. Demographic data will include age, sex and self- reported race/ethnicity. Medication use will also be collected.
45761494|NCT05446090|Other|Sino-nasal Outcome Test|The incidence of upper airway symptoms will be assessed using Sino-nasal Outcome Test (SNOT).
45761495|NCT05446090|Other|Gastroesophageal Reflux Disease Questionnaire|The incidence of Gastroesophageal Reflux Disease will be assessed using GERDQ questionnaire.
45761496|NCT05446090|Other|Pittsburgh Vocal Cord Dysfunction Index|The incidence of vocal cord dysfunction will be assessed using Pittsburgh Vocal Cord Dysfunction (VCD) Index
45911821|NCT05493293|Drug|NBI-921352|Tablets for oral administration
45761497|NCT05446090|Other|Nijmegen Questionnaire.|The incidence of dysfunctional breathing will be assessed using Nijmegen dysfunctional questionnaire.
45619668|NCT02492399|Procedure|extended myectomy|The scheme of extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.
45619669|NCT02492399|Procedure|myectomy by Morrow|A first myotomy is made into the septum just below the base of the right coronary leaflet at a point 2-3 mm to the right of the commissure between the left and right coronary leaflets. A second myotomy is made in the same manner, parallel to the first one and about 1 cm to the right of it. The two vertical myotomies are made and cornnected transversely in the interventricular septum. The muscle bar is then grasped with the angled rongeur and the instrument is pushed firmly toward the apex, peeling the mtusele from its anterior septal attachments. After completion of the resectioni, a rectangular channel about 1 X 1.5 cm is palpable from the valve ring toward the apex for a dis- tance of about 4 cm.
45619670|NCT02492633|Behavioral|Control|The Standard Intervention will be offered to residents at all of Beacon Communities properties, regardless of the presence of this study. The standard intervention will be implemented as part of the smoke-free initiative roll out and will consist of: monthly articles in newsletters, re-usable shopping bag giveaways touting cessation messages, information provided via the property websites, and training of Residential Service Coordinators (RSCs) using the 8-session smoking cessation group training provided by the American Lung Association. The RSCs will offer group cessation counseling sessions for residents who would like support to quit smoking.
45619671|NCT02492633|Behavioral|Intervention|"At a subset of 6 Beacon Communities properties, residents will receive an 'enhanced intervention' in addition to the 'standard intervention' that Beacon Communities is already providing. The enhanced intervention will consist of the following:~A web-based smoking cessation intervention via Facebook~Enhanced gain-framed messaging communicated via several channels. Gain framed messages will incorporate themes of smoking cessation and policies which aim to distinguish from the vast 'library' of traditional messages which focus on loss-framing.~A behavioral nudge designed to enhance public support for the smoke free policy, through personal adoption and adherence to the policy. This will be done by promoting a publicly viewable pledge program."
45445900|NCT03753477|Drug|Sevikar and Crestor|Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet followed by FDC Amlodipine/Olmesartan/Rosuvastatin X 1 tablet (after washout period)
45619672|NCT03329261|Drug|Clopidogrel|COPIGREL® - clopidogrel dosed at 75 mg per tablet
45619673|NCT05037435|Biological|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Group 1 (20 participants) - received the pentavalent live vaccine to prevent rotavirus infection Single-use orally 2.5 ml (1 dose).
45761498|NCT05446090|Other|Hospital Anxiety and Depression Scale|The incidence of anxiety and depression will be assessed using Hospital Anxiety and Depression Scale (HADS).
45761499|NCT05446090|Other|Compliance and adherence|In order to assess adherence as a factor in exacerbations, a participant's beliefs and attitudes towards medicines will be explored using the Medicines Adherence Report Scale (MARS) questionnaire. Non-intentional non-compliance with usual treatment will be assessed by checking inhaler technique; poor inhaler technique will be reported to the participant's clinical team. Also, GP records will be reviewed for information on medications prescribed in the last 12 months.
45761500|NCT05446090|Other|Acute Asthma Quality of Life Questionnaire|The impact of acute asthma on quality of life will be assessed using Acute Asthma Quality of Life Questionnaire at baseline and follow up.
45761501|NCT02547883|Drug|Cessation of statin|The intervention evaluated is the cessation of statin
45761502|NCT05445700|Device|Patient-controlled analgesia pump (PCA)|Each patient will receive a PCA pump with intravenous (i.v.) morphine.
45761503|NCT04381975|Behavioral|Move in Mind Program|Each of the six Move in Mind sessions will take place once a week for approximately 1.5 hours, with 12-17 individuals participating per class. The material and exercises taught will include physical floor exercises, breathing exercises, as well as awareness training.
45761504|NCT04381975|Behavioral|6 Week Waitlist Control|The waitlist control group will receive the Move in Mind program after 6 weeks.
45761505|NCT05445622|Other|learning spinal mobilization with a force sensor|Experimental group will use a force sensor (Active5) while learning spinal mobilization during the practice lab portion of the class. The force sensor will provide objective feedback to the students. Each student will be instructed on how to use the Active 5 device prior to utilization it in the classroom setting.
45761506|NCT05312203|Other|the App|The App provides content for mobile-based stress relief that can be used on most Android and iOS-based mobile devices. Content for stress relief consists of three modules; meditation, cognitive approach, and relaxation sounds. Additionally, the App includes the module for objective stress monitoring. The APP was originally designed and developed in Korean, but English, Chinese, and Japanese versions are also available. For use in the treatment environment, the manufacturer also provides a service that allows therapists to check their patients' application usage and their stress level measured by the stress monitoring module.
45761507|NCT05445388|Device|Aurisvue|OCT imaging of the middle ear
45761508|NCT03213301|Drug|Lurbinectedin|3.2 mg/m2 i.v. every 3 weeks
45761509|NCT05445154|Drug|SKLB1028 Dose Escalation|Drug :SKLB1028 ;Drug: Cytarabine ;Drug: Daunorubicin
45761510|NCT04381819|Diagnostic Test|SARS-CoV-2 PCR|SARS-CoV-2 E gene
45445901|NCT05236647|Drug|Morphine|Intravenous morphine infusion compared to subcutaneous morphine infusion
45445902|NCT03756207|Procedure|multidisciplinary bladder-preservation therapy|Maximal transurethral resection followed by radiotherapy with concomitant radio-sensitizing chemotherapy
45445903|NCT03758469|Drug|HSK3486|Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
45619674|NCT05037435|Other|Placebo|Group 2 (20 participants ) - received placebo orally once of 2.5 ml (1 dose).
45619675|NCT03329183|Drug|Irinotecan|High-dose FOLFIRI regimen (Irinotecan 260mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
45619676|NCT03235453|Other|Binary rhythm|The binary rhythm intervention will be performed using the dance modalities, Forró, Merengue and Bolero. It will occur twice a week for 12 weeks with 45 minutes of sitting.
45619677|NCT03235453|Other|Quaternary rhythm|The quaternary rhythm intervention will be performed using the modalities of dance, Tango, Salsa, Zouk. It will occur twice a week for 12 weeks with 45 minutes of sitting.
45619678|NCT05027373|Drug|SSGJ-613|SSGJ-613 injection is 200mg/2mL solution in a single vial.The solution is a clear to slightly opalescent, colorless to a slightly yellow tint.
45619679|NCT05027373|Drug|Placebo|Placebo injection is 2mL excipient solution in a single vial.The solution is clear and colorless.
45619680|NCT02492555|Other|SI|A routine scheduled (SI) screening of FC and DA every 3rd month
45619681|NCT02492555|Other|OD|A screening of FC and DA on demand (OD)
45619682|NCT03235765|Diagnostic Test|MACROGEN Pan Cancer Panel (Tier 2)|This study will utilize a MACROGEN Pan Cancer Panel (Tier 2), which is a hybrid capture-based NGS assay interrogating the coding regions of 170 cancer-related genes.
45619683|NCT03235375|Drug|MEDI0382|MEDI0382 administered subcutaneously
45445904|NCT03758469|Drug|rifampin , HSK3486|Sequence 2: Orally take 600 mg rifampin once a day for 8 consecutive days in the morning on an empty stomach, followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
45619684|NCT03329105|Other|Sea Salt Mouth Rinse|Rinsing mouth with a tablespoon of sea salt mouth rinse without any dilution, for 30 seconds, once in the morning and once before bed, in addition to Standardized Oral Health Practices.
45619685|NCT03329105|Other|Standardized Oral Health Practices|Brushing teeth for two minutes using the modified Bass technique, twice per day with the provided dentifrice, and flossing once daily using the spool method
45619686|NCT05048823|Other|Visceral Osteopathic Techniques|Generalized Discharge Technique of the Peritoneum and Intestinal Wings, Mobilization of the Cecum, Technique for the Root of the Mesentery, Release of the D1-D2 Angle, Technique for the Sigmoid Colon
45619687|NCT05048823|Other|Simulated visceral techniques|Simulated visceral techniques in the region of the gastrointestinal system
45619688|NCT03334019|Other|blood test|Data collected on general population, farmers and veterinarians though questionnaires and blood samples.
45619689|NCT05048511|Biological|vitamin D estimation|Serum samples to estimate vitamin D status were collected on the sixth day of stimulation
45619690|NCT03333863|Other|descriptive study which reviewed the data of patients hospitalized with positive bacterial cultures|A retrospective, descriptive study was conducted at shengjing hospital of China Medical University between 2015- 2017. Data regarding bacterial culture isolates, antimicrobial susceptibility spectrum, and the general data of patients with fever or suspicion of sepsis were collected.
45619691|NCT03329027|Device|Vibrating Capsule|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
45619692|NCT03329027|Device|Sham capsule|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
45619693|NCT05048277|Behavioral|Single Session Consultation|"Single-Session Consultation (SSC) is a low-intensity, goal-directed, solution-focused counseling service used for treatment of mental health problems. The intervention consists of a 60-minute session conducted through NYU ZOOM, a HIPAA compliant teleconferencing platform. Sessions will be conducted between a parent and a study consultant. The consultant will 1) identify the participant's specific modifiable goal (and associated hope); 2) the smallest-possible step taken to overcome their problem; and 3) work collaboratively in creating an Action Plan, drawing on their inner abilities and external resources. This intervention does not act as therapy but instead, to potentially jumpstart progress and facilitate hope and agency. Following completion, participants will receive their Action Plan. Additional personalized resources will be provided following completion of the follow-up assessment, which includes referrals for further services and online resources."
45619694|NCT05025969|Other|Glioma data collection|Glioma data collection
45619695|NCT05025969|Other|Brain metastasis data collection|Brain metastasis data collection
45619696|NCT02491541|Biological|Changchun Werersai|"A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.~1.0 ml experimental vaccine on day 0,3,7,14,28"
45619697|NCT02491541|Biological|Jilin Maifeng|"A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.~1.0 ml comparator vaccine on day 0,3,7,14,28"
45619698|NCT02167945|Drug|ABT-450/r/ABT-267|Tablet for oral use
45619699|NCT02167945|Drug|ABT-333|Tablet for oral use
45619700|NCT02167945|Drug|Ribavirin (RBV)|Ribavirin was provided as 200 mg tablets, and dosed based on weight, 1000 to 1200 mg divided twice daily per local label. For example, for participants weighing < 75 kg, RBV may have been taken orally as 2 tablets in the morning and 3 tablets in the evening which corresponds to a 1000 mg total daily dose. For participants weighing ≥ 75 kg, RBV may have been taken orally as 3 tablets in the morning and 3 tablets in the evening which corresponds to a 1200 mg total daily dose.
45619701|NCT05048355|Device|Power Knee Mainstream Dynamic|Powered Microprocessor controlled prosthetic knee. The Power Knee Mainstream - Dynamic, was designed to provide powered swing dynamics to restore muscle activity and thereby attempting to mitigate this increase in metabolic cost that individuals living with TF amputation face.
45619702|NCT05048355|Device|Passive microprocessor controlled knee|Any passive microprocessor controlled prosthetic knee on the market
45619703|NCT03328871|Device|Fractional CO2 Laser|Fractional Carbon Dioxide Laser will be treated once every three months for 2 times.
45619704|NCT03328871|Procedure|Nanofat grafting|Nanofat grafting will be applied once every three months for 2 times.
45619705|NCT03328871|Procedure|Platelet-rich plasma (PRP) Injection|PRP Injection will be applied once a month for 6 times.
45619706|NCT05464589|Other|Transcutaneous tibial nerve stimulation along with pelvic floor muscle srengthening|"Pelvic floor muscles strengthening:~Pelvic floor muscles training involves Kegel's exercises. Kegel exercises improve the function and tone of the pelvic floor. Kegel exercises represent the voluntary contraction and relaxation of the levator ani muscle (principally the pubococcygeus and puborectalis portions), which supports the vagina, bladder, and urethra. The slow contractions help with muscle strengthening.~Transcutaneous electrical stimulation of Tibial Nerve:~Transcutaneous Tibial nerve stimulation is a form of treatment technique that involves the use of electrical impulses to address urinary symptoms and target the lower urinary tract."
45619707|NCT05464589|Other|Pelvic floor muscles strengthening|"Pelvic floor muscles strengthening:~Pelvic floor muscles training involves Kegel's exercises. Kegel exercises improve the function and tone of the pelvic floor. Kegel exercises represent the voluntary contraction and relaxation of the levator ani muscle (principally the pubococcygeus and puborectalis portions), which supports the vagina, bladder, and urethra. The slow contractions help with muscle strengthening."
45619708|NCT03094221|Device|Rhythmia Mapping System|Arrhythmia mapping will be performed using the Rhythmia mapping system, including its mapping catheter, either in the atria or ventricles depending on the clinical arrhythmia being treated. Detailed mapping will be performed to determine tissue voltage and arrhythmia mechanism/location according to standard clinical practice. This part of the study will take approximately 90-120 minutes. The catheter position and contact will be visualized with intra-cardiac echocardiography, which is also routinely used during these procedures, and to monitor for potential clinically related complications. Images will be recorded to establish criteria for mapping.
45619709|NCT03328793|Behavioral|Mood Assessment|Prior to and after the session, the patients will be asked to fill a VAMS (Visual Analog Mood Scale).
45619710|NCT03328793|Behavioral|Emotion Assessment|During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the Observed Emotional Rating Scale (OERS), the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).
45619711|NCT03328793|Behavioral|Communication Assessment|During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the CODEM Scale, the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).
45619712|NCT03328793|Other|Mobility assessment|If deemed to be safe, the patients will undergo a gait speed assessment as well as a TUG (timed-up-and-go) prior to and after the sessions
45619713|NCT03328793|Other|Music Intervention|The participants will listen to a 30 minute live music sessions which will be given by musicians (who is a volunteer)
45619714|NCT03328793|Other|Documentary watching|The patients will watch a documentary for 30 minutes in the presence of a volunteer
45619715|NCT03093831|Drug|Ibrutinib|560mg administered orally once daily.
45619716|NCT03328637|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) consisting of weekly 12 sessions will focus on moderated and controlled use of smartphone instead of abstinence model.
45619717|NCT05025891|Other|Teleconsultation|Patients are randomized into groups in which there are either teleconsultations alone or with the help of a mediator to carry out their follow-up care
45619718|NCT03328559|Diagnostic Test|ISET® - Isolation by Size of Tumor cells|early stage bronchial cancer patient will have a blood collection
45619719|NCT03328559|Diagnostic Test|ISET® - Isolation by Size of Tumor cells|advanced stage bronchial cancer patient will have a blood collection
45761511|NCT05444998|Drug|Intuzumab, pyrrolidone, nab-paclitaxel|"Pyrrolidone 400 mg, qd; nab-paclitaxel 125 mg/m2, qw, D1/8/15; inituzumab 6 mg/kg (first dose 8 mg/kg) q3w, D1; 4 cycles in total (q3w as 1 cycle).~The patient's postoperative adjuvant therapy was 4 cycles of epirubicin + cyclophosphamide + physician's choice of anti-HER2 targeted therapy.~Multiple drug interruptions for adverse events were allowed throughout."
45761512|NCT05444842|Other|insulin iontophoresis|All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent). after cleaning the wound the insulin ions and oleic acid will be injected into the electrode of iontophoresis device (Phoresor_ IIAuto, ModelPM850, IOMED) then The device was set to the required dose of 40 mA-min, and the current intensity was gradually increased based on the subject's tolerance (ranging from 1 to 4 mA). The device computed the required time for the selected dose automatically.
45619720|NCT03093987|Other|Critical care ultrasound|Circulateory will be managed according to the result of critical ultrasound joint clearance of lactic acid in patients with shock
45761513|NCT05444842|Other|topical insulin|All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent) after cleaning the wound For each 10cm2 of the wound, patients will get ten units (0.1 mL) of insulin crystal in solution with 1mL saline (0.9 percent). An insulin syringe needle was used to spray the solution twice daily on the wound area.
45761514|NCT05444842|Other|conventional treatment|All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent) after cleaning the wound For each 10cm2 of wound 1mL 0.9 percent saline was given.
45761515|NCT04381741|Biological|CD19-7×19 CAR-T plus PD1 monoclonal antibody|Three different doses of CD19-7×19 CAR-T (1×106/kg、2×106/kg、3×106/kg) plus 200mg Tislelizumab every 3 weeks for 6 times
45761516|NCT03838003|Procedure|ERIC protocol|ERIC protocol is an aerobic exercise protocol with 5 levels of intensity
45761517|NCT05444686|Diagnostic Test|99mTc-FAPI|inject the tracer to subjects and perform SPECT/CT scans
45761518|NCT05444452|Device|Implanatation of Genoss DES sirolimus-eluting coronary system|Percutaneous coronary intervention will proceed as per clinical guidelines, under operator's discretion. Genoss stent will be implanted if the lesion is deemed necessary to be revascularized by stenting
45761519|NCT05444452|Device|Implanatation of Xience DES everolimus-eluting coronary system|Percutaneous coronary intervention will proceed as per clinical guidelines, under operator's discretion. Xience stent will be implanted if the lesion is deemed necessary to be revascularized by stenting
45619721|NCT03328481|Procedure|Loss-of-resistance Quadratus lumborum block|"ِA blunted 22-G, 11 mm, short-bevel facet needle will be introduced in the paravertebral line at the level of L3 or L4, in 30-45 degree to the skin directing it laterally. Once the skin barrier is breached, the needle will be withdrawn back so that the tip lies just under the skin. The needle will be advanced through the posterior thoracolumbar fascia and a first fast pop sensation will be felt when the needle pierced it. With further advancement of the needle, a second deep pop will be felt after it pierces the middle thoracolumbar fascia. At this point, the needle will be in the plane of the quadratus lumborum block type II. After careful aspiration, the 30 mLs of local anaesthetic will be injected. The needle will be visualized by the ultrasound by another physician to ensure safety."
45619722|NCT03328481|Procedure|Ultrasound-guided Quadratus lumborum block|A broadband (5-8 MHz) convex transducer will be placed transversely in the abdominal flank above the iliac crest to identify the external oblique, internal oblique, transversus abdominis muscles and aponeurosis. Then the external oblique muscle will be followed posteriorly until its posterior border is visualized (hook sign), and the posterior aspect of the Quadratus lumborum muscle is confirmed. A 22-G, 11-mm, short-bevel facet needle will be advanced under direct ultrasound visualization in-plane from anterolateral to postero-medial. Then the 30 ml of local anesthetic (bupivacaine 0.25 %) will be injected into the lumbar inter-facial triangle (LIFT) behind the quadratus lumborum muscle using hydro-dissection.
45619723|NCT03328481|Procedure|General anesthesia|Patients will receive 2 mg of midazolam and 8 mg of dexamethasone IV; then, they will be transferred to the operating room to receive a standard general anesthetic. Perioperative monitoring will include ECG, non-invasive arterial blood pressure, and pulse oximetry (SpO2) and end-tidal carbon dioxide. Anesthesia will be induced by propofol 1.5-2.5 mg/kg, atracurium 0.5 mg/kg, and fentanyl 2 mcg/kg to facilitate the insertion of an endotracheal tube. Anesthesia will be maintained by isoflurane 1-2% end-tidal concentration to maintain systolic arterial blood pressure and heart rate within + 20% of the baseline values. Ventilation will be adjusted to maintain normocapnia.
45619724|NCT02452801|Drug|ALKS 5461|Single dose, given orally
45619725|NCT03094065|Other|News items with spin|Interpretation of news items with spin
45619726|NCT03094065|Other|News items without spin|Interpretation of news items without spin
45619727|NCT02491619|Procedure|orthodontic decompensation|Evaluation of the correlation between bone thickness and tooth inclination previously and after orthodontic treatment of decompensation due to orthognathic surgery
45619728|NCT02452879|Device|Electroacupuncture|For the deep needling acupoint group, needle on bilateral BL33 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V Hua Tuo Brand electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day The treatment period lasts eight weeks. totally 24 times.30min/time.
45619729|NCT02452879|Device|Sham Electroacupuncture|with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.
45619730|NCT02452879|Drug|Solifenacin Succinate|made by the Anse Tailai Pharmaceutical (China) R & D limited company) 5mg / tablet
45619731|NCT05048121|Other|Cosmetic Active Ingredient CLS02021|Topical, face application of the cream base with the CLS02021, two times a day in a period of 30 days
45911822|NCT05491213|Behavioral|TELESCOPE, Remote Decision Coaching with Navigation Intervention|The TELESCOPE intervention involves three complementary components: 1) decision aid and coaching for LCS, 2) referral of current smokers to evidence-based smoking cessation services, and 3) for participants interested in screening, navigation to complete LCS and diagnostic testing and oncology care as needed
45619732|NCT05048121|Other|Placebo PLC01021|Topical, face application of the cream base, two times a day in a period of 30 days
45619733|NCT03328403|Device|Aspiration First|Use aspiration system (mainly Penumbra) first, other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.
45911823|NCT05489575|Device|Active CPAP|Continuous positive airway pressure (CPAP) is applied at 8, 10, or 12 cm H20. The active CPAP level will be determined during a CPAP titration trial
45911824|NCT05489575|Device|Sham CPAP|Sham continuous positive airway pressure applied at <4 cm H2O
45911825|NCT05489575|Other|Sleeping in a head-up tilt (HUT) position|Sleeping with the whole bed tilted head-up by 10 degrees or with the head elevated by 13-14 inches.
45911826|NCT05485753|Drug|GNC-038|Administration by intravenous infusion
45911827|NCT05477524|Biological|VLA15|Shot in the deltoid muscle (preferable in the nondominant arm)
45911828|NCT05477524|Other|Saline|Shot in the deltoid muscle (preferable in the nondominant arm)
45911829|NCT05472441|Behavioral|Mid-Ohio Food Farmacy|The Food Farmacy arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective.
45911830|NCT05472441|Behavioral|Mid-Ohio Food Farmacy + Cooking for Diabetes|The Food Farmacy + Cooking for Diabetes Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention.
45619734|NCT03328403|Device|Stent retriever first|Use one of the stent retrievers (Trevo / Solitaire) first, other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.
45619735|NCT05026515|Behavioral|Parents|To observe the influence of the parents/caregivers behavior on their child during dental treatment
45619736|NCT03241069|Other|Reference position|patient is put in a 30 degree supine position during 5 minutes
45445905|NCT03753399|Procedure|acupuncture|Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combining with electro-acupuncture at fixted acupoints.
45619737|NCT03241069|Other|sitting position|patient is put to a 90 degree sitting position during 1 to 2 minutes then the CO is measured
45619738|NCT03241069|Other|Valsalva maneuver|patients are asked to perform the Valsalva maneuver by executing a forced blow into a manometer for 30 seconds and the CO is calculated during this test.
45619739|NCT03241069|Other|a passive leg rising maneuver|we make a passive leg rising and we measure the cardiac output by BIOPAC system (45 degree passive leg rising was done for 1 to 2 minutes and CO was measured during the maneuver.)
45619740|NCT03333785|Behavioral|eOncoNote|"Diagnosis phase: The patient's nurse navigator will initiate an eOncoNote to the patient's PCP, inviting them to send any questions related to the patient's diagnostic process. The nurse navigator will initiate case closure after the diagnostic process has been completed (case will be open up to 4 months).~Treatment phase: The patient's medical or radiation oncologist will initiate an eOncoNote to the patient's PCP inviting them to ask questions related to the patient's cancer treatment and/or request information related to the patient's co-morbidities. The oncologist will initiate case closure after the treatment has been completed.~Survivorship phase: The patient's registered nurse within the Wellness Beyond Cancer Program will send an eOncoNote invitation to the patient's PCP inviting them to ask any questions as the patient transitions back to their care. The nurse will initiate case closure after one year."
45619741|NCT05025579|Other|Aerobic Exercise|"Since up in 2 min 10 repetitions active joint movement (while seated knee flexion and extension the ankle plantar and dorsal flexion , standing the hip flexion , extension the , abduction and adduction ) , treadmill for 3 minutes, 0.5 m / sec speed walk with and to adapt both warming bike 5 minutes, RPE ( Rating of Perceived exertion discoverable by exertion rate) will be 2/10 in a way was built.~As aerobic exercise, the first week will be RPE 4/10 for 10 minutes, the second week with RPE 4/10 12 minutes, the third week with RPE 4/10 14 minutes, the fourth week with RPE 4/10, 16 minutes, the fifth week with RPE 5/ 2 0 will be as 18 minutes sixth week RPA 10.6 will form was done 20 minutes of exercise .~Cooling period in the RPE 2.10 will be the 5 minute turning cycling, 5 min active range of motion exercises and stretching was done."
45619742|NCT03240991|Other|Quality of life|Dermatology Life Quality Index, Angioedema Quality of Life Questionnaire, Angioedema Activity Score
45761520|NCT04380571|Device|Biofeedback|Biofeedback therapy in addition to the conventional measures done in the control Group. It was performed in the same position used for baseline manometry. The used protocol included strength and sensory training, twice weekly for 3 months. Strength training was performed by a double-lumen rectal PVC balloon clothed catheter (MMS U-72210).
45761521|NCT04380571|Device|Electrical stimulation|A positive auto adhesive electrode was applied above the medial malleolus over the S3 dermatome. A second negative electrode was applied just below the same malleolus. Both electrodes were linked to an electrical stimulation device ( EMS physio Ltd, OX129 F, England) with a low frequency current (10 Hz), and adjustable intensity.
45761522|NCT04380571|Other|Traditional treatment|Conventional treatment through Kegal exercises and dietetic regulation where they had received bulky food including vegetables, fruits bran and cereals. Fast foods, spicy drinks and caffeine should be limited in child's diet. Local hygiene and zinc oxide application to the perianal skin were advised to prevent skin excoriation.
45761523|NCT05444374|Drug|Serplulimab|Recombinant anti-PD-1 humanized monoclonal antibody injection
45761524|NCT05444374|Drug|Bevacizumab|Humanized anti-VEGF monoclonal antibody injection
45761525|NCT05312359|Device|Transcranial alternating current stimulation-true stimulus|The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. Before the intervention, the individual alpha frequency (IAF) of the subjects was measured according to the average peak value of α waves at dorsolateral prefrontal cortex in the closed state. Then an alternating current at θ frequency (θ = IAF - 5Hz) was applied to each subject based on its IAF value. The amplitude of stimulation was increased with a step of 20μA starting from 0. When the subjects had a slight prickling sensation or optical illusion, the stimulation current was decreased with a step of 20μA until the sensation disappeared. The current value at this time was used as the stimulation current of the subjects.
45761526|NCT05312359|Device|Transcranial alternating current stimulation-sham stimulus|The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. The actual stimulation waveform was just implemented in the first 60 s (or more longer) and then faded out.
45761527|NCT05312281|Device|Device : Lombastab immo. wear for 6 weeks post-surgery the Lombastab Immo|Wear for 6 weeks post-surgery
45445906|NCT05460897|Behavioral|Health behaviour change|weekly sessions addressing strategies to tackle behavioural risk factors for chronic disease
45445907|NCT03753321|Dietary Supplement|Whey protein|Whey protein isolate supplementation, individually adjusted to reach a total protein intake of 1.5 g/kg body weight/day for 10 days (7 days pre-loading and 3 days during trials 1 and 2)
45445908|NCT03753321|Dietary Supplement|Soy protein|Soy protein isolate supplementation, individually adjusted to reach a total protein intake of 1.5 g/kg body weight/day for 10 days (7 days pre-loading and 3 days during trials 1 and 2)
45445909|NCT03753321|Dietary Supplement|Placebo (maltodextrin)|Isoenergetic placebo (maltodextrin) for 10 days (7 days pre-loading and 3 days during trials 1 and 2
45445910|NCT05200455|Device|Microelectrodes|Microelectrode implantation
45445911|NCT04646109|Drug|Ivermectin|"Ivermectin 5mg/5ml solution was manufactured by NEUTEC™ Pharmaceutical Company-Turkey, under Good Manufacturing Practices (GMP) certification conditions."
45761528|NCT05444218|Procedure|Open flap debridement|After local anesthesia (2% lidocaine with1:100,000 epinephrine), intrasulcular incisions will be performed to create a horizontal flap extending beyond the adjacent teeth and/or implants. Buccal and lingual full-thickness flaps will be dissected, and granulation tissue will be removed to expose the implant threads and bone defect. The flap will be repositioned in its original position and stabilized with interrupted sutures, which will be removed after 10 days.
45761529|NCT05444218|Other|Er: YAG irradiation|An Er:YAG laser (Lite Touch, Light Instruments, Israel) will be used, with an irradiation energy of 20 mJ, frequency of 20 Hz, output power of 0.4 W, and an energy density of 2.76 J/cm2. An 8 mm long sapphire tip will be used in the respective handpiece and not in contact with the titanium surface, with concomitant water spray irrigation, under air 6 and water spray 6, the irradiation angle will be 90 degrees, at a focal distance of 2 mm, with spot size diameter of 1.3 mm
45761530|NCT05444218|Drug|Metronidazole|Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning after open flap debridement).
45445912|NCT05342337|Other|Telerehabilitation Group|"The Telerehabilitation program includes a Biopsychosocial Exercise Therapy (BETY) approach.~BETY approach includes patient education on pain, functional body stabilization exercises (mind-body information management), dance therapy authentic movement (emotion-state information management), and sexual information management.~Telerehabilitation group participate in the sessions that last for one and a half hours, 3 days a week for 12 weeks, video conference over the Zoom program. The investigator, who provides supervision during the sessions, also participates in the exercises simultaneously."
45619743|NCT03333707|Behavioral|Pacifica App|The app contains several activities which are digital implementations of standard psychotherapy practices. Users may select which app elements they would like to use, and when. These app elements include relaxation and meditation activities, tools to examine your thoughts or self-talk, goal setting lists, and mood and health ratings. The app also has a peer support community where users can communicate with others who are having similar experiences. There is no minimum requirement for amount of time spent on any given activity, or in the app in total. The commercially available app has a feature to connect users to their existing healthcare providers, but this feature will not be available to study participants. Study participants may continue to see their existing providers.
45761531|NCT05444218|Drug|Amoxicillin|Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning after open flap debridement).
45761532|NCT05444218|Drug|Placebos|Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (beginning after open flap debridement).
45761533|NCT01830361|Drug|midostaurin (PKC412)|Midostaurin 50 mg (2 capsules) twice daily days 8-21 in induction II + consolidation I-III; maintenance treatment twice daily continuously for 12 months
45761534|NCT05444140|Behavioral|Health coaching|The health coaching programme includes four monthly health coaching sessions for three months.
45761535|NCT01830439|Drug|PA-824 200mg|Two single administrations of 200mg PA-824 each administered by four 50mg tablets, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
45761536|NCT01830439|Drug|PA-824 50mg|Two single administrations of 50mg PA-824 each administered by one 50mg tablet, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
45761537|NCT05443828|Other|Breakfast Control Meal|The participants consumed extruded puff with added vitacel (cellulose) as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
45761538|NCT05443828|Other|Breakfast Test Meal|The participants consumed bread with added arabynoxylans (AX) as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
45911831|NCT05472441|Behavioral|Mid-Ohio Food Farmacy + Health Impact Ohio Pathways Hub|The Food Farmacy + Health Impact Ohio Pathways Hub Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and has social needs address through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
45911832|NCT05472441|Behavioral|Mid-Ohio Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub|The Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub Arm receives all 3 interventions. Participants receive weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective, Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention and has social needs addressed through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
45445913|NCT05342337|Other|Control group|The control group participants include those who do not want to receive exercise treatment with telerehabilitation and take their routine medications during the 12 weeks period.
45445914|NCT03753165|Other|High intensity interval exercise|High intensity interval exercise at 80% of the maximal heart rate derived from the maximal graded exercise. Each individual will undergo 12 sessions of HIIE over a period of six weeks
45445915|NCT05320107|Drug|Ketamine|0.5mg/kg bodyweight (or 0.25mg/kg bodyweight) ketamine, will be determined in pilot study
45445916|NCT05320107|Drug|Placebo|0.9% NaCl
45619744|NCT03240757|Dietary Supplement|Breakfast|All subjects received a standard 75-g OGTT to assess eligibility for the study. The 19 subjects matching the inclusion criteria completed 2 experimental trials: resting and exercise. During the resting trial, all subjects underwent an OGTT (50-g: A) and 3 meal tolerance tests [one for each breakfast tested: B1 = milk (125ml) and cereals (30g); B2 = milk (220ml), apple (200g) and chocolate cream-filled sponge cake (30g); B3 = milk (125ml), apple (150g), bread (50g) and hazelnut chocolate cream (15g)]. In the exercise trial, 100 minutes after the glucose/meal ingestion, participants cycled for 20 min at 40% of maximum oxygen uptake.
45619745|NCT03240757|Other|exercise|aerobic exercise at 40% of VO2max, for 20 minutes
45445917|NCT03753009|Procedure|corneal cross-linking|"Epithelium-off CXL was performed according to the Siena (Dresden modified) protocol: 2% pilocarpine was instilled 30 minutes before treatment, the epithelium was removed using a blunt knife. An isotonic solution of riboflavin 0.1% and dextran 20% was instilled for 10 minutes of corneal soaking before starting UV-A irradiation. The solution was administered every 3 minutes for a total of 30 minutes of UV-A exposure at 3mW/cm2.~The iontophoresis device was filled with a hypoosmolar riboflavin 0.1% dextran-free solution enriched with ethylenediaminetetraacetic acid and trometamol. The device was then connected to a constant current generator initially set at 0.5 mA and increased to 1.0 mA to find out the individual tolerance. Iontophoresis was then performed for 5 minutes. The corneal device was then removed before performing UVA irradiation. During the irradiation phase (10 mW/cm2 for 9 minutes), good fluorescence was clearly detectable. The total treatment time was 14 minutes."
45445918|NCT03752931|Drug|Celiprolol|receiving 1 tablet per day of Celiprolol 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
45761539|NCT05443828|Other|Breakfast Test Meal|The participants consumed extruded puff with added wheat bran as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
45761540|NCT01830517|Drug|Amlodipine, Losartan|
45761541|NCT04380415|Diagnostic Test|Single lead ambulatory ECG patch|Single lead ambulatory ECG patch worn on the chest
45761542|NCT05443672|Device|Yizhun BUSMS|During the breast scanning, Yizhun BUSMS uses different color box to identify the breast lesion, and the box color indicates the risk grade of the lesion.
45761543|NCT03837457|Drug|Cobomarsen|At least weekly intravenous infusions of cobomarsen (282 mg) throughout study treatment period
45911833|NCT05466240|Drug|AT-752|AT-752 for 5 days
45911834|NCT05466240|Drug|Placebo|Placebo for 5 days
45445919|NCT03752931|Drug|Diltiazem|receiving 1 tablet per day of Diltiazem 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
45445920|NCT05274633|Drug|Ravulizumab|Participants will be observed for 52 weeks after the start of ravulizumab.
45445921|NCT04502979|Behavioral|Responsive Feeding Training|Families will receive 4 monthly 1-hour sessions: (1) Signing with infants; (2) infant communication and responsive feeding; (3) nutrition, portion sizes, and neophobia; and, (4) infant intentionality.
45445922|NCT03752853|Behavioral|internet-based intervention for mild to moderate depression|The six-weeks, therapist-guided, internet-based intervention for depression includes expressive writing tasks and further consists of key elements of cognitive behavioral therapy (CBT) for depression. In seven consecutive modules, patients receive psychoeducation and instructions for weekly tasks, and an individualized feedback letter of their therapist after each module. The intervention is effective in reducing depressive symptoms (Zagorscak et al., 2018). In the current study, patients will be randomly assigned to two different conditions with varying orders of modules: 1. patients will receive two modules (module 3 and 4) of behavioral activation, followed by two modules (modules 5 and 6) of cognitive restructuring; 2. patients will receive two modules (module 3 and 4) of cognitive restructuring, followed by two modules (modules 5 and 6) of behavioral activation. All other modules (1, 2 and 7) will be identical across conditions.
45445923|NCT03758391|Other|Flipped Classroom education|Fellows will receive GI/Bilirubin education in a flipped classroom format.
45445924|NCT05460741|Other|integrated exercise approach|Integrated exercise plan will be given for 16 weeks with frequency of 3 times per week, with duration of session to be 50 minutes being 30 minutes of exercise in total and 10 minutes of rest and 10 min of warm up and cool down exercises.
45445925|NCT05460741|Other|educational program|educational program related to menstrual cycle will be given to females.
45619746|NCT03328247|Other|ASICA digital app|Participants in the intervention arm will be trained to use ASICA (in addition to completing routine follow-up) and participants within the control arm will continue to attend their usual structured melanoma follow-up only. The hypothesis is that the ASICA intervention will increase TSSE practice in those affected by melanoma without affecting psychological well-being and lead to earlier detection of recurrent and new primary melanoma.
45619747|NCT05047809|Other|"Jingchuang Ointment(JCO)"|Applied once a day on the wounds
45761544|NCT03212833|Diagnostic Test|fasting serum insulin|fasting serum insulin in chronic hepatitis C patients
45619748|NCT05047809|Other|Regular Treatment|"Do not use the Jingchuang Ointment(JCO), as the regular treatment as usual."
45619749|NCT03240913|Behavioral|Baseline and Follow-up Surveys|(completed online)
45619750|NCT03240913|Other|Patient Reported Outcome Measure informed Decision Aid|(PROM-DA)
45619751|NCT03240913|Other|Pamphlet|(usual care)
45761545|NCT05443360|Dietary Supplement|DENSITY™ (Amorphous calcium carbonate, ACC)|"Dosage form: tablet~Dose(s): 1000 mg /tablet, comprising 500 mg amorphous calcium carbonate per tablet (calcium element 200mg)~Dosing schedule: The usual dose for oral use is 2 ACC tablets (400 mg calcium element) twice daily given after breakfast and dinner."
45761546|NCT05443360|Dietary Supplement|Crystalized calcium carbonate (CCC)|"Dosage form: tablet~Dose(s): 1000 mg /tablet, comprising 500 mg crystalized calcium carbonate per tablet (calcium element 200mg)~Dosing schedule: The usual dose for oral use is 2 CCC tablets (400 mg calcium element) twice daily given after breakfast and dinner."
45761547|NCT01830751|Other|Restrained Sitting Treatment|Training in avoidance of trunk flexion, with the use of a tall backrest with lumbar support to which the participant straps themselves. Participants are taught to strap into the backrest while while seated in a chair, and with hips and knees bent at right angles, for one hour at the appointed time of day.
45761548|NCT05443282|Diagnostic Test|Prolidase Level|Measurement of venous blood serum level of prolidase enzyme level by ELISA method.
45761549|NCT05443282|Diagnostic Test|Follicle Stimulating Hormone Level|Measurement of venous blood serum level of follicle stimulating hormone level.
45761550|NCT05443282|Diagnostic Test|Estradiol Level|Measurement of venous blood serum level of estradiol hormone level.
45911835|NCT05464784|Drug|MN-001|MN-001 is a novel, orally bioavailable small molecule compound
45911836|NCT05464784|Drug|MN-001 placebo|The placebo tablet is identical in appearance to the MN-001 tablet, and contains excipients of MN-001.
45761551|NCT05443282|Diagnostic Test|Proline Level|Measurement of venous blood serum level of proline level.
45761552|NCT05443282|Diagnostic Test|Hydroxyproline Level|Measurement of venous blood serum level of hydroxyproline level.
45761553|NCT05443282|Diagnostic Test|Anti-mullerian Hormone Level|Measurement of venous blood serum level of anti-mullerian hormone level.
45619752|NCT03328169|Behavioral|Mindfulness-Based Therapy|Participants are taught relaxation and mindfulness techniques to practice. They also learn about various alternative medicine modalities to which they can apply mindfulness with the target of reducing insomnia. The group meets weekly for 2 hours for a duration of 9 weeks.
45761554|NCT05443282|Diagnostic Test|Antral Follicle Count|Ultrasonographic evaluation of antral follicle count to determine ovarian reserve.
45761555|NCT05443282|Diagnostic Test|Prolactine Level|Measurement of venous blood serum prolactine hormone level.
45761556|NCT05443282|Diagnostic Test|Thyroid Stimulating Hormone Level|Measurement of venous blood serum thyroid stimulating hormone level.
45761557|NCT05443048|Device|Ivoclar Ivotion Denture System|Fabrication of maxillary and mandibular complete removable dental prosthesis with the Ivoclar Ivotion Denture System
45445926|NCT04591977|Device|HPV Self-Sampling Kit (Evalyn Brush)|The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.
45445927|NCT03758235|Drug|IncobotulinumtoxinA 100 UNT Injection [Xeomin]|Incobot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis
45761558|NCT00904345|Drug|Cetuximab|Patients will receive a single dose of cetuximab 400 mg/m (Day 0). On day 7 (+/- 1 day), a repeat biopsy will be performed. Radiation concurrent with weekly cetuximab 250 mg/m.
45761559|NCT00904345|Radiation|50-60 Gy and 70 Gy|Within approximately 4 days (after single dose of Cetuximab), definitive radiation will begin (70 Gy in 35 fractions to the gross tumor, 50-60 Gy to subclinical target volumes) concurrent with weekly cetuximab 250 mg/m.
45761560|NCT05442892|Procedure|Multicomponent exercise training programme|The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individuals functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 30-60% of 1RM (Matrix, Johnson Health Tech, Ibérica, S.L. Torrejón de Arroz, Madrid, Spain) combined with balance and gait retraining exercises that progressed in difficulty and functional exercises such as rises from a chair.
45761561|NCT05442736|Drug|Ciprofloxacin|studying the effect of nanoparticles in controlling the release of the drug in addition to in situ gel
45445928|NCT03758235|Drug|OnabotulinumtoxinA 100 UNT [Botox]|Onabot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis
45445929|NCT04587453|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 subclass that specifically binds to human interleukin-13 (IL-13) and blocks the interaction with IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration.
45445930|NCT04587453|Drug|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
45619753|NCT03328169|Behavioral|Cognitive Behavioral Therapy for Insomnia|A licensed psychologist is delivering Cognitive Behavioral Therapy for Insomnia to women for 90-120 minutes weekly for nine weeks. The Cognitive Behavioral Therapy for Insomnia protocol is well documented in published literature.
45619754|NCT05026437|Other|Cardiac surgery score and APACHE II scoring|Cardiac surgery score and APACHE II will calculated on the first postoperative day.
45619755|NCT03333629|Behavioral|Enhanced early detection|standardized screening
45619756|NCT01191697|Drug|bevacizumab|Given intravenously on day 1 of each cycle beginning cycle 2
45619757|NCT01191697|Drug|trastuzumab|Given intravenously on day 1 of each treatment cycle
45619758|NCT01191697|Drug|oxaliplatin|Given intravenously on day one of each cycle beginning cycle 2
45619759|NCT01191697|Drug|capecitabine|Taken orally on days 1-14 of each cycle beginning cycle 2
45619760|NCT05026359|Device|Bilateral ankle coordination training|Developed a novel bilateral ankle coordination training program with visual feedback and bilateral ankle control, based on the concept of bilateral movement therapy. The bilateral ankle coordination training includes 3 days a week, 30 minutes each time, lasting 4 weeks, and a total of 12 training sessions.
45619761|NCT05047497|Diagnostic Test|questionaire and ventilatory function test|we assessed the arterial blood gases and the ventilatory functions and quality of life of whole three groups
45619762|NCT03231553|Other|MiQuit text message support programme|MiQuit is an automated, responsive text message support programme lasting 12 weeks which sends texts containing self-help smoking cessation support and advice to participants mobile phones.
45761562|NCT03212911|Biological|Hepatitis B vaccine|Hepatitis B vaccine (20 mcg/ml) 1 ml intramuscular injection in 3 (at 0, 1, 6 months) or 4 doses (0, 1, 2, 6 months)
45761563|NCT05442502|Procedure|The overlap guiding tube(OGT) method|The overlap guiding tube(OGT) is used to assist the anvil fork placed into the esophageal cavity.
45761564|NCT05442502|Procedure|The conventional overlap method|After firing the stapler, two openings were converted into a single entry hole to create an end-to-side esophagojejunostomy, and the entry hole was closed with full-thickness running suture using barbed sutures intracorporeally.
45761565|NCT01830829|Drug|Jalyn|study drug
45761566|NCT01830829|Drug|Placebo|Placebo
45445931|NCT04587453|Other|Topical corticosteroids (TCS)|TCS administered as needed.
45619763|NCT03327935|Dietary Supplement|Nutrition|150 Faroese surgical patients randomized to one of the following three arms 1) oral nutritional supplements and advice, 2) oral nutritional supplements and training exercise and 3) Standard hospital procedure. Primary outcome is loss of lean body mass
45761567|NCT03212755|Diagnostic Test|serum immunoglobulin G level|measurement of the serum level as a marker of diabetic complications
45761568|NCT05440084|Procedure|Chronic total occlusion percutaneous coronary intervention|Chronic total occlusion percutaneous coronary intervention
45761569|NCT01831063|Behavioral|Simulation|The experimental group received a simulation based seizure teaching session in addition to the traditional seizure teaching
45761570|NCT04381507|Device|endovascular repair|Endovascular repair of descending thoracic aneurysms or PAU using a stent graft.
45761571|NCT05437822|Drug|Tranexamic acid|2 g of tranexamic acid in 50 mL of saline
45761572|NCT05437042|Other|Medial calcaneal wedge|Immediate effect of medial calcaneal wedge for static balance and weight distribution
45761573|NCT03212599|Drug|Disulfiram|alcohol addicted patients receive an oral Disulfiram application as recrudescence prevention after successful detoxication
45761574|NCT05448040|Procedure|Socket preservation|Tooth extraction and preservation with a biomaterial
45619764|NCT05025501|Behavioral|Family based Executive Function Training|Training the executive funtions of shcoolage ADHD children through tasks and games repeatly but with fun. Giving the parental training and support for the parenting role parents strategies to help the shcoolage ADHD childred coping the symptoms and develop EF in the reallife and improve parent-child relationship.
45761575|NCT03212443|Procedure|Suprascapular nerve- axillary nerve block combination|In Group B, suprascapular (10 ml of 0.250% bupivacaine ) and axillary block (10 ml of 0.250% bupivacaine) will be performed with ultrasound and nerve stimulator guidance before induction of anesthesia
45761576|NCT03212443|Procedure|Subacromial infiltration|In group A, the surgeon will apply 20 ml of 0.250% bupivacaine to the subacromial region at the end of the procedure
45761577|NCT05447962|Behavioral|Community-to-Clinic Linkage Implementation Program in Barbershops (CLIP)|Multilevel intervention designed to mitigate adverse social determinants of health (SDoH) via linkage to care, health system navigation, and referral to social services.
45761578|NCT05447962|Behavioral|Barbershop-Based Facilitation (BF)|Trained and qualified facilitators assist community health workers (CHWs) to: 1) increase their confidence in delivering CLIP; 2) understand participants' concerns and beliefs about hypertension (HTN); and 3) develop skills in lifestyle counseling to help the men initiate lifestyle modification.
45761579|NCT05311423|Diagnostic Test|QuantiFERON-TB test & endometrial pathology & endometrial tissue GeneXpert Ultra|Endometrial biopsy is required to diagnose LTBI, SGTB and FGTB, which is an invasive operation and increases patients' economic burden. A screening method has been established that uses the interferon gamma release test as the primary screening test, and those who are positive undergo endometrial biopsy. Therefore, this project will use QFT to screen participants with Mtb infection, and further endometrium biopsy will be performed for QFT positive patients to diagnose LTBI, FGTB and SGTB. For participants with negative results for all diagnostic tests but QFT (defined as LTBI), close follow-up is necessary according to WHO guidelines.
45761580|NCT05447884|Other|A zero impedance mode, controlling a wearable bilateral hip exoskeleton|The bilateral hip exoskeleton has two degrees of freedom to enable the hip joint extension and flexion movement on both left and right sides. The zero impedance mode will not provide any assistance or resistance to the hip joints.
45761581|NCT05447884|Other|A personalized optimal assistance mode, controlling a wearable bilateral hip exoskeleton|The personalized optimal assistance mode includes both individualized hip flexion and hip extension assistance, which is determined by using the reinforcement learning-based automatic control parameters tuning during walking tasks. Therefore, the personalized optimal assistance will be able to improve the walking gait performance and reduce the energetic consumption.
45761582|NCT05447884|Other|A free walking mode, without wearing a wearable bilateral hip exoskeleton|The free walking mode will not include the usage of the wearable bilateral hip exoskeleton, and the human walking subjects will conduct pure natural walking tasks.
45761583|NCT03212053|Biological|biological tests of haemostasis at each consultation (Multiplate, ROTEM, VASP)|Patients will have blood samples at each consultation (2 or 3 sampling tubes) in order to carry out systematically three biological tests
45761584|NCT05447260|Drug|Ruxolitinib|Dosage based on platelet count
45761585|NCT05447104|Behavioral|Mastication|Chewing sugar-free gum for 20 min
45761586|NCT05311267|Other|Action observation training|Subject is asked to observe videos with motor contents
45761587|NCT05447026|Device|Control group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, the sites in the control group received only saline irrigation for 1 min.
45761588|NCT05447026|Device|Antimicrobial photodynamic therapy (aPDT) group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, aPDT group received additional application of a diode laser with a wavelength of 810 nm and a power rating of 200 mW (continuous mode). Indocyanine-green (ICG) as a photosensitizer at a concentration of 1 mg/ml was applied at the surgical site on both the buccal and the lingual sides of the flaps. Irradiation was performed in non-contact mode in a constant distance of 1 mm during 30 s per site
45911837|NCT05457985|Behavioral|Prolonged Exposure for Primary Care (PE-PC)|Treatment follows the standardized PE-PC manual and workbook.PE-PC consists of four weekly 30-minute sessions. In vivo and imaginal exposure are introduced at the first session and reviewed at Sessions 2-4. To conduct in vivo exposure, participants repeatedly and systematically approach objectively safe people, places, objects, and situations that they avoid because these stimuli remind them of their trauma. At the 4th session or 9-week assessment point (whichever comes first), early responders will step down to every-other-week sessions for the duration of the second stage.
45619765|NCT03240367|Other|Coutery|Stapler line bleeding control with coutery
45619766|NCT05024799|Drug|Fentanyl, propofol|The patients in this group will be administered with fentanyl and propofol
45619767|NCT05024799|Drug|fentanyl and dexmedetomindine|The patients in this group will be administered with fentanyl and dexmedetomindine
45619768|NCT05024799|Drug|Butorphanol and propofol|The patients in this group will be administered with butorphanol and propofol
45619769|NCT05024799|Drug|Butorphanol and dexmedetomindine|The patients in this group will be administered with butorphanol and dexmedetomindine
45619770|NCT03333473|Behavioral|PPFP Clinical and Counseling Skills|Facilities will receive whole-site orientations on PPFP basics and skills Through training of trainers, followed by classroom and model-based and clinical-based practice, providers will receive training in PPDP counseling and service provision.
45619771|NCT03333473|Behavioral|Facility-Level Leadership Management and Governance Training|The intervention will strengthen leadership management and governance practices required to help managers establish PPFP services at the facility level.
45619772|NCT05018637|Drug|WJ-MSC|"Other: subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.~Other: intramedullary injection of 4 x 107 WJ-MSCs (direct injection into the recently fractured vertebra) at baseline (day 0). subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months."
45619773|NCT05018637|Drug|Teriparatide|subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.
45619774|NCT03333395|Drug|Nebulized heparin and salbutamol|HS Group medications (study group) (30 patients) which was prepared by adding Heparin 25000 IU in 5ml (5 ampoules of Heparin Sodium 5000 I.U/ML, Nile company for Pharmaceuticals and Chemical Industries-A.R.E.) to Salbutamol 5mg/2.5ml Nebulizer Solution (one Ventolin nebule containing a preservative-free solution of Salbutamol Sulphate BP 2.5mg, GlaxoSmithKline Inc.)
45619775|NCT03333395|Drug|Nebulized salbutamol|S Group medications (control group) (30 patients) which was prepared by adding Salbutamol 5mg/2.5ml Nebulizer Solution + Na cl 0.9% 5ml.
45619776|NCT05018949|Procedure|Lower limb angioplasty|Patients who have undergone LL angioplasty are enrolled in study for a medical records review.
45619777|NCT03327701|Drug|Benralizumab|Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
45619778|NCT05018559|Behavioral|BuG lesson|Participants of the intervention group in nursing care received a co-created setting-specific intervention to promote physical activity called BuG lesson. The BuG lesson comprises a weekly 90-minute lesson for apprentices of nursing care during regular school hours, covering physical activity and health in theory and practice. Previously, the nursing teachers voluntarily underwent a qualification process as physical activity instructors, enabling them to conduct the BuG lessons independently.
45619779|NCT05018559|Behavioral|Tutoring system|Participants of the intervention group in automotive mechatronics received a co-created setting-specific intervention to promote physical activity called tutoring system. In the tutoring system, automotive mechatronics apprentices act as physical activity promotors for their fellow apprentices. In the sense of a peer-to-peer approach, apprentices voluntarily participate in a workshop to be qualified as tutors. Subsequently, the tutoring system takes place every two weeks for about ten to fifteen minutes during regular working hours, allowing the tutors to discuss the issues of physical activity and health among their peers.
45619780|NCT03333239|Behavioral|psychodynamic psychotherapy|the intervention follows the published in german manual: Psychoanalytische Behandlung von Kindern und Jugendlichen mit Angststörungen und Depressionen: Behandlungsmanual (Baumeister-Duru, Hofmann, Timmermann & Wulf, 2013)
45619781|NCT03333239|Behavioral|cognitive behavioral psychotherapy|the interventions follow the published in german manuals: Depression (Ihle, Groen, Walter, Esser, & Petermann, 2012) and Soziale Ängste und Leistungsängste (Büch, Döpfner, & Petermann, 2015)
45619782|NCT03333239|Behavioral|psychodynamic family intervention|the intervention follows an adapted version of the manual: Chimp´s - Children of mentally ill parents (Wiegand-Gefe, Halverscheid, & Plass, 2011)
45619783|NCT01991977|Procedure|Diffusion Weighted Imaging|Undergo DTI
45619784|NCT01991977|Drug|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET
45619785|NCT01991977|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45619786|NCT01991977|Procedure|Perfusion Magnetic Resonance Imaging|Undergo pMRI
45619787|NCT01991977|Procedure|Positron Emission Tomography|Undergo 18F-DOPA-PET
45619788|NCT01991977|Other|Quality-of-Life Assessment|Ancillary studies
45619789|NCT01991977|Drug|Temozolomide|Receive temozolomide
45619790|NCT05024643|Procedure|Endonasal endoscopy|"Complete sphenoethmoidectomy; Draf type IIa, IIb, and III according to defect location.~Defect less than 3 mm closed by a plug of fat and facia lata or middle turbinate mucosa.~Defect more than 3 mm closed by underlying facia lata, underlying cartilage, and overlay facia lata."
45619791|NCT05425199|Other|Habituation exercises + vestibular treatment|"Exercises will include Intensity: 10 repetitions of each set Frequency= 3 sessions per week for 6 weeks.~Time= 30 minutes"
45619792|NCT05425199|Other|proprioceptive training + vestibular therapy|Exercise protocol will include Time= total session of 30 minutes . Each exercise will be hold for 30 seconds . Frequency= 3 session per week for 6 weeks Intensity= 10 repetitions and 3 sets
45619793|NCT05425199|Other|conventional vestibular treatment|Epley's Manuever. Frequency= It will be performed once in a week . Time= 10-15 minutes per session
45619794|NCT05047107|Other|No intervention|Non-interventional study
45445932|NCT02793232|Drug|PF-06751979 single dose|PF-06751979 administered as a single dose suspension in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF 06751979). The planned dose levels are 200 mg, 400 mg, 700 mg, 200 mg fed (these doses are subject to change based on emerging data).
45445933|NCT02793232|Drug|Placebo single dose|Matched Placebo suspension administered as single dose
45619795|NCT05047029|Procedure|Transjugular intrahepatic portosystemic shunt implantation|Transjugular intrahepatic portosystemic shunt is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein. It is used to treat portal hypertension (e.g., in liver cirrhosis)
45761589|NCT05447026|Device|LED photobiomodulation group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, irradiation was carried out with a LED device with a wavelength of 626 nm in the near-infrared region at a dose of 20 mw/cm2 for 20 min with a total energy of 222 J
45619796|NCT05047029|Diagnostic Test|Magnetic resonance imaging|Multiparametric cardiac and hepatic magnetic resonance imaging
45761590|NCT05447026|Device|Topical ozone group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, topical ozone group received ozone application with an ozone generator at 80% concentration using probe #3 for 30 s per site
45761591|NCT05311189|Drug|HLX10, Trastuzumab and Chemotherapy|HLX10 4.5mg/kg, IV, q3weeks, Day 1 trastuzumab 6mg/kg (8mg loading dose), IV, q3weeks, Day 1 S1 40mg/m2, PO, BID, Day 1-14 oxaliplatin 100mg/m2, IV, q3weeks, Day 1 docetaxel 40mg/m2, IV, q3weeks, Day 1
45761592|NCT01831297|Device|measurement of blood pressure|measurement of pulse wave velocity
45761593|NCT01831375|Behavioral|Speak Up|Intervention group_treatment group
45761594|NCT01831375|Behavioral|Get connected|Participants will learn to be connected with social resources in the community.
45761595|NCT05446402|Combination Product|Geologie Acne Regimen - one side of face|"Geologie is an over-the-counter cosmetic acne regimen with three products. The regimen also has three levels over the course of three months, in which the nighttime lotion is switched to a stronger formula each month. The Geologie Clear System regimen for acne prone skin includes:~Clarifying Gel Cleanser - SA Formula (2% Salicylic Acid)~Brightening Day Cream - SPF 15 (5% Azelaic Acid, 2% Hyaluronic Acid, 1%Niacinamide)~Repairing Night Cream -~Level 1 (0.05% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)~Level 2 (0.2% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)~Level 3 (0.3% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)"
45761596|NCT05446402|Combination Product|Proactive Acne Regimen - other side of face|"ProActiv is an over-the-counter cosmetic regimen with three products. The~Proactiv Solution 3-Piece System regimen includes:~Renewing Cleanser (Active ingredient: 2.5% Benzoyl Peroxide)~Revitalizing Toner (Glycolic Acid)~Repairing Treatment (Active ingredient: 2.5% Benzoyl Peroxide)"
45761597|NCT01831453|Drug|omega-3|polyunsaturated fatty acids(PUFAs) 1 gram three times per day for 6 months
45761598|NCT01831453|Drug|placebo|soft gelatinous capsules filled with isopropylmyristate oil
45761599|NCT00369772|Drug|darbepoetin alfa|
45761600|NCT03212209|Device|CPAP Fixed Pressure|Continuous positive airway pressure (CPAP) is the gold standard treatment for moderate and severe OSA, and it has been known to apply positive pressure in the upper airways, acting as a pneumatic splint preventing the upper airway collapse during sleep. CPAP C- Flex Plus by Philips - Respironics works just as CPAP Fixed Pressure, but increases the pressure delivered in the begining of inhalation to softens the breathing rhythm of the CPAP user. CPAP with SensAwake by Fisher and Paykel works just as CPAP fixed pressure but when the breathing pattern suggests that patient is awake, a prompt relief in pressure to the lowest most comfortable level is activated, like ramp feature.
45761601|NCT00369850|Other|laboratory biomarker analysis|Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
45761602|NCT00369850|Procedure|Dual energy X-ray absorptiometry (DEXA)|Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
45761603|NCT00369850|Procedure|Spine X-ray|Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
45761604|NCT01831531|Drug|S-1|S-1 40 mg (BSA ≤ 1.6 m2) or 50 mg (BSA >1.6 m2) p.o bid d1-28
45761605|NCT01831531|Radiation|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
45761606|NCT03211897|Drug|Haloperidol Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
45445934|NCT02793232|Drug|PF-06751979 multiple ascending dose|PF-06751979 suspension administered daily for 14 consecutive days to parallel cohorts. The planned dose levels are mg, 100 mg, 200 mg, 340 mg (these are subject to change based on emerging data).
45761607|NCT03211897|Drug|Ziprasidone Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
45445935|NCT02793232|Drug|Placebo multiple ascending dose|Matched placebo suspension administered daily for 14 consecutive days.
45445936|NCT02793232|Drug|PF-06751979 multiple dose|PF-06751979 suspension administered daily for 14 consecutive days. The planned dose level is 340 mg (this is subject to change based on emerging data).
45619797|NCT02492243|Device|PCI|
45619798|NCT02492243|Device|ILR implantation|
45619799|NCT03231319|Procedure|Fascia iliaca compartment block with IV-PCA|1. Fascia iliaca compartment block: The injection was performed under ultrasound guidance. Surface landmark is identified on the line between anterior superior iliac spine and pubic tubercle. The injection site is at the medial one-third of the line. The needle is threaded medial to lateral and standardization of local anesthetic deposit is in the fascia plane between fascia iliaca and iliacus muscle. Anesthetic regimen: 2% xylocaine 15mL + 0.5% bupivacaine 15mL.
45445937|NCT02793232|Drug|Placebo multiple elderly dose|Multiple dose administration to Healthy Elderly Subjects (Placebo)
45445938|NCT04584645|Other|Targeted digital intervention|Messages that provide informational content on the influenza vaccine (sourced from the Centers for Disease Control and Prevention and the American Heart Association), specific information about influenza and cardiovascular disorders, and behavioral prompts (e.g., reminders) surrounding influenza vaccination behaviors.
45445939|NCT03755817|Device|SCENAR application|Active SCENAR application on the painful area
45761608|NCT03211897|Drug|OLANZapine Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
45761609|NCT03211897|Drug|Midazolam injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
45761610|NCT00422500|Behavioral|Questionnaire|Surveys about symptoms, mood, and quality of life.
45761611|NCT00422500|Behavioral|Telephone Interactive System|Automated telephone system call once a week during therapy, rating of severity of symptoms and daily life interference done with numeric key pad. Post therapy is complete, a call every two weeks for up to six months.
45761612|NCT00422500|Other|Blood Samples|For participating patients, 3 additional tablespoons of blood drawn at the beginning of each chemotherapy treatment (before treatment starts) and at the beginning of each cycle of treatment.
45761613|NCT01831687|Drug|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
45761614|NCT01831687|Drug|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
45761615|NCT05444296|Other|Superficial Dry Needling|"1/2 needles will placed into defined innervation fields of the trigeminal nerve and rotated. Total time will be 5-7 minutes."
45761616|NCT05444296|Other|Non-thrust Mobilizations only|Non-thrust mobilizations to be applied to the most symptomatic level of the upper cervical spine as determined by a treating physical therapist. The mobilization technique will be applied for 3 bouts of 30 seconds.
45761617|NCT05441254|Drug|Camrelizumab; Nab-paclitaxel; S-1|"Camrelizumab: 200 mg, intravenous infusion, d1, q3w;~Nab-paclitaxel: 130 mg/m2 intraperitoneal and 130 mg/m2 intravenously, d1, q3w;~S-1: calculated based on body surface area Dosage, twice a day, orally, d1-d14, q3w;~The dosage can be adjusted according to the protocol according to the adverse reactions of subjects. Subjects will continue to take medication until completion of the prescribed course of treatment, disease progression, toxicity intolerance, withdrawal of Informed Consent Form, or termination in the investigator's judgment."
45761618|NCT00904813|Radiation|Short-course RT|Preoperative radiotherapy (RT) given 5 times 5 Gray during five consecutive days, preferably Monday - Friday, with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
45761619|NCT00904813|Radiation|Long-course RT|Preoperative radiotherapy (RT) given 2 Gy in 25 fractions during 5 weeks, total dose 50 Gy with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
45761620|NCT04016428|Behavioral|OPTIMISM|Six-week online program that emphasizes mindfulness and skills for improving sleep during pregnancy.
45761621|NCT04016428|Behavioral|Sleep Education|Six-week online program that provides education on sleep during pregnancy.
45761622|NCT03211585|Device|Perfecta V-Beam laser|This s a single study and a prototype of the FDA-cleared, flashlamp-pumped pulsed-dye laser, that is currently on the market, that has evolved over almost 25 years of continuous development. The broad-spectrum flashlamp pumps energy into a cavity containing liquid dye. The dye is excited resulting in the emission of 595 nm orange light.
45761623|NCT04738864|Diagnostic Test|ultrasound|extracranial and intracranial ultrasound assessment
45911838|NCT05457985|Behavioral|Full Prolonged Exposure|Treatment will follow the standardized PE manual. Participants will have 60 minute sessions once a week for eight weeks During these sessions, participants will practice in vivo, imaginal, and emotional exposure as well as continue these exposure exercises every day at home.
45445940|NCT03755817|Device|SCENAR application with the device off|Placebo SCENAR application on the painful area
45761624|NCT01832077|Device|90 D|rural doctors exam eye fundus by 90 D
45761625|NCT01832077|Device|fundus camera and grader|taking fundus pictures and graded by graders in ZOC
45761626|NCT00369148|Drug|nateglinide(drug) mitiglinide(drug)|
45761627|NCT00369304|Drug|pharmacokinetic (how the body absorbs and eliminates) interaction|
45761628|NCT04380493|Diagnostic Test|hepatic transient elastography using S probe and M probe|
45761629|NCT03816982|Procedure|Single-injection bupivacaine HCl plus liposomal bupivacaine|Patients in the liposomal bupivacaine with added bupivacaine HCl ISB group will be given a single injection LB ISB in the preoperative area only by faculty who are part of the regional anesthesia division. The injectate will include liposomal bupivacaine 10ml (133mg) mixed with bupivacaine HCl 0.5% 10 ml.
45761630|NCT03816982|Procedure|Single-injection bupivacaine HCl plus a subsequent bupivacaine CISB|Patients in the bupivacaine CISB group will undergo catheter placement with ultrasound guidance only by faculty who are part of the regional anesthesia division. A 20 mL single bolus ISB with 0.25% bupivacaine will be administered followed by catheter infusion of 0.125% bupivacaine at a rate of 5mL/hour postoperatively by the ON-Q pump
45761631|NCT03777202|Procedure|High-flow nasal oxygen|High-flow nasal oxygen will be applied to the patients using Optiflow system through nasal openings during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
45761632|NCT03777202|Procedure|Low-flow nasal oxygen|Low-flow nasal oxygen will be applied to the patients through nasal openings using conventional nasal cannula during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
45911839|NCT05457985|Behavioral|Clinician Supported PTSD Coach App|This is a brief psychotherapy that uses the PTSD Coach mobile app developed by the study team. The PTSD Coach app incorporates evidence-based assessment, psychoeducation, and cognitive behavioral therapy and self-management strategies that are customizable to the user.
45911840|NCT05453006|Device|COPAN 552c.80 FLOQSwab|The study will implement HPV self-sampling as an option for cervical cancer screening alongside usual care for Somali women, and evaluate changes pre and post implementation, compared to Fairview intervention clinics.
45445941|NCT02066350|Procedure|Single pancreas transplantation|
45445942|NCT02066428|Biological|AERAS-404|AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.
45761633|NCT01832233|Procedure|Renal Denervation|The Symplicity Renal Denervation System is indicated for the delivery of low-level radiofrequency energy through the wall of the renal artery to denervate the kidney and reduce blood pressure in adult patients with refractory hypertension. The Symplicity Generator delivers controlled relatively low power radiofrequency energy (approximately 8 watts for 2 minutes). The Symplicity System selectively denervates the kidney by delivering radiofrequency from the generator via the electrode of the catheter through the renal artery wall from the intra-luminal side to ablate the renal sympathetic efferent and afferent nerves and reduce overall sympathetic nervous system activity.
45761634|NCT03775330|Radiation|Stereotactic Radiosurgery (SRS)|"SRS or hypofractionated stereotactic radiation delivered via the Leksell Gammknife Perfexion/Icon radiosurgery system. Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions or 24-27 Gy in 3 fractions at the discretion of the radiation oncologist~Maximum diameter of metastasis (doses in single fraction):~≤ 2 cm: 15-20 Gy > 2 cm and ≤ 3 cm: 15-18 Gy > 3 cm and ≤ 4 cm: 15 Gy~Tumour location (doses in single fraction):~Brainstem: 15 Gy~Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions may be used for lesions > 2 cm at the discretion of the radiation oncologist~Note: SRS dosing reduced by 20% (for all prescriptions > 15 Gy) when patient is randomized to SRS + WBRT arm"
45761635|NCT03775330|Radiation|Whole brain radiation (WBRT)|WBRT 20 Gy in 5 fractions or 30 Gy in 10 fractions at the discretion of the radiation oncologist
45761636|NCT03723694|Dietary Supplement|650 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(650mg) twice a day with meals.
45619800|NCT03231319|Procedure|Femoral nerve block and lateral femoral cutaneous nerve with IV-PCA|"Femoral nerve block: The injection was performed under ultrasound guidance. Femoral nerve was identified in the femoral neurovascular bundle below or around inguinal ligament. The needle is threaded with lateral to medial approach. Local anesthetics will be deposited around the femoral nerve, the standardization of protocol is that femoral nerve should be lifted off from iliacus muscle. Anesthetic regimen: 2% xylocaine 10mL + 0.5% bupivacaine 10mL.~Lateral femoral cutaneous nerve block: The injection was performed under ultrasound guidance. Lateral femoral cutaneous nerve was identified in the fascia plane between sartorius muscle and tensor fascia lata muscle. Anesthetic regimen: 2% xylocaine 5mL + 0.5% bupivacaine 5mL"
45761637|NCT03723694|Dietary Supplement|0 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(0mg) twice a day with meals.
45761638|NCT01832467|Drug|cetuximab-containing chemotherapy|
45761639|NCT03211351|Drug|Liposic|one eye of the participant recieved Lipoic
45761640|NCT03211351|Drug|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
45761641|NCT05442658|Other|Microbiota|
45761642|NCT01832623|Other|Exploration of Vitamin D roles|"Visit 1: questioning, physical examination, blood sampling (including plasma collection for future genetic analyses), carotid ultrasound~Visit 2 (same day as visit 1 or maxi 3 months later): HR-pQCT, dual energy x-ray absorptiometry (DXA), iontophoresis of acetylcholine and sodium nitroprusside"
45761643|NCT03708640|Other|Digital Activity Tracker|Group wears physical activity tracker and receives physical activity feedback information informed by the tracker
45761644|NCT03708640|Other|Smart Text Messaging|"Group receives personalized, health coaching via smart text messages"
45761645|NCT03708640|Other|Physical Activity Counseling|Group receives baseline counseling on physical activity
45761646|NCT01832701|Other|Coffee|coffee versus placebo
45761647|NCT01832701|Other|Placebo comparator|maltodextrine with caffeine
45761648|NCT03617926|Device|X92001666|the X92001666 product is a lotion to be applied on dry hair for 15 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
45761649|NCT03617926|Other|RID shampoo|Active Comparator: RID shampoo The RID shampoo is to be applied on dry the hair for 10 minutes and then rinsed out with water. the product is to be applied on Day 0 and repeated again on Day 7.
45761650|NCT03837613|Procedure|tumor resection and neck dissection|Surgical removal of the tumor with adequate safety margins. In addition to neck dissection to dissect the cervical lymph nodes.
45761651|NCT03610984|Other|type 1 diabetes structured education|The structured education is based on a regular outpatients visit.It is an education that integrated several diabetes related subjects,which mainly aimed at T1D self-management.
45761652|NCT03836911|Other|serious game|Effect of serious game on elderly in comparison of the physical activity adapted meeting
45761653|NCT03836911|Other|classic program|Effect of serious game on elderly in comparison of the physical activity adapted meeting
45911841|NCT05437991|Diagnostic Test|Independent morphological quantifications by echo-doppler using ECST method|The physician who is usually in charge of patient follow-up performs a first evaluation of carotid stenosis percentage by echo-doppler using ECST method. Then a second physician immediately performs a second evaluation using the same echo-doppler device without knowing first evaluation conclusions.
45911842|NCT05437978|Other|"Cap Sport Santé 83 program"|"In Var department (France), the  Maison Sport-Santé 83  has set up a program called Cap Sport Santé 83 to support patients who received a prescription to practice APA regularly. This program helps long-term illnesses patients to restart physical activity by considering their pathology. The Cap Sport Santé 83 program is composed of 5 stages which aim to encourage adherence to APA practice by relying on the medical prescription system. Throughout the process, the patient is supervised and supported by the program's coordinator."
45911843|NCT05431166|Behavioral|Virtual Yoga at First 8 weeks|1 hour per week of virtual yoga delivered by an active movement therapist at the VA during the first 8 weeks of the study
45911844|NCT05431166|Behavioral|Virtual Yoga at Second 8 weeks|1 hour per week of virtual yoga delivered by an active movement therapist at the VA during the second 8 weeks of the study
45911845|NCT05423522|Drug|NanoLithium® NP03|One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.
45911846|NCT05423522|Drug|Placebo|One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.
45619801|NCT03231319|Procedure|IV-PCA|IV-PCA was programmed and provided to the patient for optimize pain control
45445943|NCT02066428|Biological|Placebo|Tris buffer saline consisting (10mM Tris and 169mM NaCI at pH7.4)
45761654|NCT05438446|Procedure|Endovascular ultrasound renal denervation (Paradise renal denervation system, ReCor, CA, USA) (RDN)|"The ReCor Medical Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark, but Investigational in the USA.~The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney."
45761655|NCT05310175|Device|Electroacupuncture|Filiform needles (0.30×50mm, Hanyi brand, Beijing Medical Appliance, China) and the SDZ-V electric acupuncture (Suzhou Medical Appliance) apparatus will be used. After acupuncture at the acupoints group, the needle handle will be connected with the electrode of the electric acupuncture apparatus.
45761656|NCT05310175|Device|Sham acupuncture|Shallow needle insertion of 2-3 mm at sham acupoints without manipulation.
45761657|NCT05318209|Other|Exercise|Closed-chain Shoulder Girdle Scapular Depression Exercise
45761658|NCT02470312|Procedure|CRT implantation|It is a novel 3D electromagnetic navigation system (MediGuide™) that is capable of non-fluoroscopic navigation of sensor-enabled tools in the x-ray environment
45761659|NCT02470312|Device|MediGuide|
45761660|NCT02470312|Procedure|EP|
45761661|NCT03211195|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
45761662|NCT02470390|Drug|Fentanyl|Lazanda (nasal spray), Subsys (sub-lingual) and intravenous fentanyl
45761663|NCT00363532|Drug|infusion of calcitonin gene related peptide (CGRP)|
45619802|NCT03093753|Other|Control (study 1)|Control meal will comprise of 50 g glucose dissolved in 200 ml water, to which the response of the test meals will be compared to
45619803|NCT03093753|Other|Test (study 1)|The test meal will comprise 50 g glucose in 200 ml water plus 50 mg oleuropein from olives
45619804|NCT03093753|Other|Control (study 2)|Control meal will comprise 109 g white bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to
45619805|NCT03093753|Dietary Supplement|Test (study 2)|The test meal will comprise 109 g white bread plus 50 mg oleuropein from olives dissolved in 200 ml water
45619806|NCT03093753|Other|Control (study 3)|Control meal will comprise whole-meal bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to
45619807|NCT03093753|Dietary Supplement|Test (study 3)|The test meal will comprise whole-meal bread plus 50 mg oleuropein from olives dissolved in 200 ml water
45619808|NCT03093753|Other|Control (study 4)|Control meal will comprise 50 g sucrose in 200 ml water, to which the response of the test meals will be compared to
45761664|NCT05311501|Other|Non-surgical periodontal treatment|Non-Surgical periodontal Treatment was performed by removing supra and subgingival calculus and using both ultrasonic and manual instruments. Oral Hygiene Instructions (OHI) were provided throughout the experimental period. Local anesthesia was performed only when needed.
45761665|NCT03505996|Biological|CS1001|Monoclonal antibody
45761666|NCT01832857|Drug|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
45761667|NCT00363610|Drug|Oncaspar & Gemzar; advanced and/or solid tumors and lymphoma|
45761668|NCT03837535|Procedure|Surgery|Neuro, Lung/thorax, GI, Gynecologic, Urologic, Orthopedic, Vascular surgery
45761669|NCT05427292|Other|serratus anterior block and PECs II block combination|The pre-surgery block will be applied. Sensorial block will be evaluated at the surgical incision site with the pinpirick test at 30 minutes after the block, and if the block is successful, surgery will begin.
45761670|NCT03837301|Procedure|NESS-EFTR with sentinel lymph node navigation|Non-exposure Simple Suturing Endoscopic Full-Thickness Resection with sentinel lymph node navigation (basin dissection) for early gastric cancer patients
45761671|NCT00363688|Drug|Penicillin test and challenge|
45761672|NCT01832935|Drug|insulin glargine|The starting dose of insulin Glargine was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
45761673|NCT01832935|Drug|Insulin NPH|The starting dose of insulin NPH was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
45761674|NCT02471326|Biological|VRC-HIVMAB060-00-AB (VRC01)|A potent HIV-specific monoclonal antibody
45761675|NCT01833013|Other|live birth date and quality of life assessment|
45761676|NCT05406778|Device|SPARK Test|Twenty (20) minutes of resting state EEG data collection.
45761677|NCT01833091|Other|artificial night|Infants in the intervention group received light cyclic with pattern 12 hours. Light period was from 7 to 19 during which the infants were put in the normal environmental light and dark period was from 19 to 7 during which was the infants' incubator was covered with linen cloth. The vital signsand & arterial oxygen saturation of the infants in the intervention group were controlled before covering the incubator i.e. at 19. Also, the infant's vital signs were again monitored at 7 am.The infant weighed in every day at 7 am during the 10 days of study. Feeding tolerance was daily determined at 8 am, using nasogastric tube or orogastric tube to control residue as well as to review the presence or absence of abdominal distention, vomiting.
45761678|NCT03216733|Device|COMBO|PCI with COMBO stent
45761679|NCT03216733|Device|ORSIRO|PCI with ORSIRO stent
45619809|NCT03093753|Dietary Supplement|Test (study 4)|The test meal will comprise 50 g sucrose in 200 ml water plus 50 mg oleuropein from olives
45619810|NCT03093753|Other|Control (study 5)|Control meal will comprise 25 g sucrose in 200 ml water, to which the response of the test meals will be compared to
45445944|NCT02066506|Other|asymptomatic group|2 visits with MRI
45619811|NCT03093753|Other|Test (study 5)|The test meal will comprise 25 g sucrose in 200 ml water plus 160 mg oleuropein from olives
45619812|NCT03093753|Other|Control (study 6)|Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
45619813|NCT03093753|Other|Test (study 6)|High carbohydrate diet (23% fat, 55% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
45619814|NCT03093753|Other|Control (study 7)|Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
45619815|NCT03093753|Other|Test (study 7)|High fat diet (44% fat, 34% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
45619816|NCT03333161|Diagnostic Test|Cardiorespiratory monitoring|We will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations).
45619817|NCT03229369|Procedure|Isolated anatomic ACL reconstruction|Hamstrings free grafts using a two-incision intra-articular Anterior Cruciate ligament (ACL) reconstruction technique. Both ST and gracilis will be prepared with doubled strands, a standard quadrupled graft. The femoral tunnel will be performed in outside-in manner. The tibial tunnel will be drilled in the center of the ACL tibial footprint, sparing the ACL tibial stump, when possible. ACL graft will be first fixed in the femur and then in the tibia, both with an interference screw at 30 degrees of knee flexion.
45619818|NCT03229369|Procedure|Combined Anterior Cruciate Ligament and Anterolateral Ligament reconstruction|Hamstrings free grafts using a two-incision ACL reconstruction with the addition of a gracilis prolongation for ALL reconstruction. ACL graft will exhibit a quadruple strand (tripled ST + single gracilis) and the ALL graft, a single strand with the gracilis prolongation. ALL tibial tunnel will be performed with a 5mm drill, 1cm distal to the articular level, midway from the fibular head and Gerdy Tubercle, crossing the tibia toward its anteromedial cortex, 1cm distal to the ACL tunnel. Femoral ACL and ALL tunnels are coincident and located posterior and proximal to the lateral epicondyle. Intra-articular surgery will be performed in the same manner as comparative group. Gracilis prolongation is routed through the tibial ALL tunnel and then retrieved in the anteromedial aspect of the tibia, 1cm distal to the ACL tunnel entrance. ALL is fixed in full extension and neutral rotation, tying both graft extremities with 3 knots.
45619819|NCT03327545|Device|Neural mobilization|Neural mobilization on the right side of the craniocervical region for a total of 12 minutes.
45619820|NCT03327545|Device|Soft tissue techniques and Stretching|Soft tissue techniques and Stretching on the right side of the craniocervical region for a total of 12 minutes
45619821|NCT03327545|Device|Control group|Did not receive any treatment.
45619822|NCT03090711|Device|Transcranial Magnetic Stimulation (TMS)|The investigators recently showed that the repeated application of the so-called continuous theta burst protocol (cTBS) over the contralesional hemisphere resulted in a long-standing improvement of visual hemineglect (Cazzoli et al., 2012). The cTBS protocol was developed by Huang et al. (Huang et al., 2005) and modified by the investigators' group (Nyffeler et al., 2006). TBS protocol consists of a burst of 3 pulses at a frequency of 30 Hz, repeated at 6 Hz. One continuous train includes 801 pulses, the duration of one cTBS train is 44 seconds.
45619823|NCT03090711|Device|Transcranial Alternating Current Stimulation (tACS)|TACS stimulation involves two electrodes placed on either side of the desired site of cortical stimulation. The mode of stimulation used in this experiment is identical to previous studies using tACS in sleep ( Marshall et al., 2006; Prehn-Kristensen et al., 2014 ). Stimulation follows a sinusoidal pattern from 0 to 260 μA. This pattern is delivered at 0.75 Hz and is repeated for 225 cycles; a total of 5 minutes of stimulation. This 5 minute pattern is again repeated 5 times, with a minute of no stimulation between each; thus for a total of 30 minutes.
45619824|NCT03090711|Device|sham Transcranial Magnetic Stimulation (TMS)|Sham coil will be used to exclude possible nonspecific effects of the TMS. The sham coil is shielded i.e., the magnetic field output is weakened and therefore insufficiently powerful to stimulate the cortex.
45619825|NCT03090711|Device|sham Transcranial Alternating Current Stimulation (tACS)|Sham stimulation will be used to exclude possible nonspecific effects of the tACS. Sham tACS stimulation will involve actual stimulation for the first 30 seconds of the ramp-up period (stimulation power is gradually increased until its final level), and then immediately gradually decreased until zero (without the intermediate 4 minutes of actual stimulation). This procedure will be repeated 5 times every 6 minutes and shall induce similar cutaneous sensations as real stimulation.
45761680|NCT03411382|Other|Sit muscle strength training|Sit muscle strength training using a sand bag grip ball conducted twice a week. Each exercise session will begin and end with a 5-15 minute warm-up and cool-down routine. The exercise program consists of 20-40 minute chair-based resistance exercises.
45761681|NCT03411382|Other|Game training|Game training (including ball activities, clay courses, massage, puzzles, painting conducted four times a week). Each section 30-60 minutes.
45761682|NCT03411382|Other|Sitting strength + game training|Sitting strength training (using sandbag training conducted twice a week) and game training (such as ball activities and clay courses) conducted twice a week).
45761683|NCT03411382|Other|Health education|Health education (conducted once a month). Each section 50-60 minutes. The topics are oral hygiene, medicine safe, living safe, food safe.
45761684|NCT03216343|Drug|Chiauranib|CS2164
45445945|NCT02066506|Other|symptomatic group|2 visits with MRI
45445946|NCT03752463|Drug|DAOI-A group|DAOI with A dose
45445947|NCT03752463|Drug|DAOI-B group|DAOI with B dose
45445948|NCT03752463|Drug|DAOI-C group|DAOI with C dose
45445949|NCT03752463|Drug|Placebo oral capsule|Placebo
45445950|NCT02064946|Dietary Supplement|vitamin D|50,000IU/week of vitamin D3
45445951|NCT02064946|Dietary Supplement|Placebo|
45761685|NCT03333616|Drug|Ipilimumab|is an immunotherapy medication that stimulates the immune system to fight cancer cells throughout the body.
45761686|NCT03333616|Drug|Nivolumab|Nivolumab binds to and blocks the activation of PD-1. This results in the activation of T-cells and cell-mediated immune responses against tumor cells
45761687|NCT03210805|Dietary Supplement|Omega-3 Polyunsaturated Fatty Acids Supplementation|28 days of a commercially available supplement. 4 capsules per day.
45761688|NCT04380181|Drug|dobu|Use of dobutamine versus milrinone and epinephrine for separation from cardiopulmonary bypass
45761689|NCT02472262|Dietary Supplement|Cow pea complementary food|A legume-based complementary food made from cowpeas will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
45761690|NCT02472262|Dietary Supplement|Corn soy flour|Corn flour with 10% soy will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
45761691|NCT02472262|Dietary Supplement|Common bean|A legume-based complementary food made from common beans will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
45761692|NCT03210727|Behavioral|Ready to CARE program|"The intervention is built upon a model of caregiver well-being that identifies four domains of quality of life: physical, psychological, social, and spiritual well-being. For each domain, there are stressors (i.e., factors that make it hard to be a caregiver) and buffers (i.e., factors that help people be effective caregivers). Our Ready to CARE intervention begins by presenting caregivers with the model in order to generate a profile of personal stressors and buffers. From there, caregivers select from a menu of strategies that can be used to minimize stressors and create buffers in their daily life. The investigators will have six 45-minute sessions with the caregivers that will primarily occur while the patient is admitted for stem cell reinfusion."
45761693|NCT01833559|Dietary Supplement|Dietary control|
45761694|NCT01833559|Drug|Insulin|If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized and insulin will be used. The kind of insulin used depends on the need of patients.
45761695|NCT03253120|Other|Water|Patient/ Healthy volunteer will drink 5dl of Water
45761696|NCT03210649|Drug|CKD-519|Part 1 : CKD-519(100mg x 4 Tablets) for D1 Part 2 : CKD-519(100mg x 4 Tablets) for D1~D14
45761697|NCT03210649|Drug|Placebo|Part 1 : CKD-519 placebo(100mg x 4 Tablets) for D1 Part 2 : CKD-519 placebo(100mg x 4 Tablets) for D1~D14
45761698|NCT03235804|Dietary Supplement|Soy protein, honey and yogurt.|Participants will be asked to maintain their usual dietary intake and consume a powdered meal replacement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
45911847|NCT05423158|Behavioral|d-Coaching|"MOVN mobile app: Each participant will be assigned a secure login account that does not include personal information for research only. Participants will be trained on how to access and use the MOVN private social network group.~Annie text messaging: Participants will be registered in the Annie VA text messaging program to receive tailored, interactive push messages with a combination of 1 and 2-way tailored messages on goals, barriers, self-management, etc. (based on data collected in real-time from the Fitbit and barriers identified at baseline).~Fitbit wearable device & mobile app: The intervention group will be instructed to use the Fitbit for step counts and maximizing the Fitbit mobile app/desktop platform to track all PA, sharing one's Fitbit profile with others (optional leaderboard), and use of all available features."
45911848|NCT05416060|Behavioral|Dulce Digital Text-Based Education|Participants will be enrolled in the digital texting platform, Dulce Digital in which they will receive on-going support via text messages for 6 months, derived from the Project Dulce curriculum. Topics include medication reminders, motivational prompts, nutrition and stress reduction tips and request to submit weekly blood glucose numbers.
45935039|NCT00214669|Behavioral|PACE (Professional Asthma Care Education)|Education for intervention specialist nurse and GPs and practice nurses from intervention practices, using our adaptation of Clarke's self-regulation education programme, designed to improve shared-decision making, goal-setting and patient-clinician partnership.
45445952|NCT05359809|Behavioral|Graspin Palmar Reflex Stimulation|The grasping reflex is an involuntary response involving the hands and fingers. flexion-adduction movement. The reflex resembles the grasping movement of the hand. The reflex can be achieved by moving an object distally across the palm.
45445953|NCT02064556|Drug|Amlodipine 10mg|Amlodipine 10mg 1T, PO, QD for 9days
45445954|NCT02064556|Drug|Amlodipine 10mg/Candesartan 32mg|Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days
45445955|NCT03787810|Diagnostic Test|Echocardiography|Echocardiography for assessment of left ventricular dysfunction
45619826|NCT03231163|Other|No Music|Participants lie supine on a table while no music is played.
45619827|NCT03231163|Other|Relaxing Classical Music|Participants lie supine on a table while classical music is played.
45619828|NCT03231163|Other|Self-Selected Relaxing Music|Participants lie supine on a table while self-selected relaxing music is played.
45619829|NCT03327389|Drug|Dexmedetomidine|dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure.
45619830|NCT03327389|Drug|placebo|0.9% NaCl was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
45619831|NCT03093441|Other|Multimodal High-Intensity Interval Training Intervention|The intervention will occur 3 times per week for 12 weeks and include a warm-up, MM-HIIT or R-HIIT training protocol, and a cool down.
45761699|NCT01833637|Other|APN Intervention|Patients randomized to this group will be asked to fill out a patient symptom assessment using an iPad at the time of registration and then every day until released from the hospital. It should take about 10 minutes to complete this questionnaire each time. Based on the patients' answers and in cooperation with their health care provider, an Advanced Practice Nurse (APN) will provide information about symptom management and options for services that are available after the patient leaves the hospital. The survey responses will be shared with the patients' healthcare team so that they better understand how they are feeling. The APN will work closely with the healthcare team. Patients will be asked to fill out a Patient Satisfaction Questionnaire at the time of discharge.
45619832|NCT03229447|Behavioral|eLearning Modules|All participating courts will view two eLearning modules. Module one discusses opioid addiction and treatment; module two discusses specific concerns of criminal justice with regard to MAT and ways in which those concerns may be addressed.
45619833|NCT03229447|Behavioral|Change Team Intervention|Courts selected for the experimental condition will participate in a hands-on change team intervention to provide instrumental assistance and to reinforce the information contained in the eLearning modules.
45761700|NCT03221374|Behavioral|Mindfulness Based Stress Reduction|8-week mindfulness based stress reduction course intended to develop mind-body awareness through mindfulness practices.
45761701|NCT03215485|Behavioral|Nutrition lessons|Face-to-face interactive group lessons delivered in the classroom.
45761702|NCT03215485|Behavioral|Virtual world learning environment|Every participant has their own unique avatar in the virtual world learning environment named Rippleville. They can choose to complete quests, watch archived nutrition video lessons, explore, and socialize with other avatars. They receive rewards (Rippleville dollar and badges) for their efforts.
45619834|NCT03333083|Drug|Raltegravir|Raltegravir (1200 mg once a day)
45619835|NCT03333083|Drug|Lamivudine|Lamivudine (300 mg once a day)
45619836|NCT03093597|Other|virgin coconut oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin coconut oil application twice daily for 2 weeks.
45619837|NCT03093597|Other|virgin jojoba oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin jojoba oil application twice daily for 2 weeks.
45761703|NCT03215485|Other|Newsletter|All participants in the intervention and comparison groups receive up to 10 professional newsletters on topics related to sports nutrition and performance, healthy eating and active living tips.
45761704|NCT05394142|Drug|Placebo|Comparator arm with placebo
45935040|NCT00214669|Behavioral|Lay Led Expert Patient Programme|Lay-led 'expert-patient' education in small groups for patients, using an adaptation of Stanford University's chronic disease self-management programme.
45445956|NCT03752385|Behavioral|reducing smartphone screen time|"Cutting average smartphone screen time in half. Sleeping without smartphone in bedroom. Establishing a bedtime to stop smartphone screen time."
45619838|NCT03093597|Other|virgin almond oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin almond oil application twice daily for 2 weeks.
45619839|NCT03093597|Other|white petrolatum ointment|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive white petrolatum ointment application twice daily for 2 weeks.
45619840|NCT03231007|Other|Questionnaire|A structured questionnaire will be administered to maternity service users. Another structured questionnaire will be administered to maternity healthcare professionals, and another to Organisational Leads (e.g. Clinical Directors at each site).
45619841|NCT05018247|Procedure|Revascularization by Coronary Artery Bypass Graft or Percutaneous Coronary Intervention|Urgent revascularization via CABG or PCI combined with Optimal Medical Treatment
45619842|NCT03332927|Other|Egg based breakfast foods|Two eggs/day, 6 days per week provided as breakfast foods such as burrito-type roll-up, egg sandwich and omelet.
45619843|NCT03332927|Other|Non-egg based breakfast foods|Non-egg based control foods provided as breakfast foods 6 days per week such as waffles, ready-to-eat cereal, fruits and cheeses.
45761705|NCT05394142|Drug|Pioglitazone|Pioglitazone 7.5 mg/day
45761706|NCT05394142|Drug|Spironolactone|Spironolactone 50 mg/day
45761707|NCT05394142|Drug|Metformin|Metformin 850 mg/day
45761708|NCT00901225|Drug|G-CSF plus Plerixafor|"On Day 5 of G-CSF mobilization,~if the patient's peripheral CD34+ cell count is < 7cells/µl then 240ug/kg Plerixafor will be given in the evening prior to receiving 10µg/kg G-CSF and undergoing apheresis the next morning for up to 3 days of apheresis or until ≥ 5x10(6) cells/kg are collected.~if the patient's peripheral CD34+ cell count is 7 to 19 cells/ul (inclusive), apheresis will be done. If the apheresis yield is < 1.3x10(6) CD34+ cells/kg then 240ug/kg Plerixafor will be given in the evening prior to receiving 10 µg/kg G-CSF and undergoing apheresis the next morning. If the apheresis yield is at least double that on Day 5, Plerixafor followed the next morning by G-CSF and apheresis will be repeated for up to a total of 3 days of apheresis or until 5x10(6) cells/kg are collected."
45761709|NCT02472730|Device|Distal Attachment Cap|Colonoscopies are performed under the supervision of board certified attending gastroenterologists experienced in colonoscopy. Attending physicians will provide assistance at their discretion or at the request of the trainee. All close examinations for polyps will be carried out on withdrawal of the colonoscope.
45761710|NCT01833715|Drug|Morphine|Morphine group,receive morphine 0.08 mg / kg at the start of surgery
45761711|NCT01833715|Drug|Methadone|Methadone group,receive methadone 0.08 mg / kg at the start of surgery
45619844|NCT03229291|Drug|SM04755|SM04755 is a small molecule inhibitor of the Wnt pathway.
45619845|NCT03229291|Drug|Vehicle|Same formulation as topical SM04755 solution, without SM04755 included.
45619846|NCT03079635|Dietary Supplement|Control|Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
45619847|NCT03079635|Dietary Supplement|Omega 3 fatty acids|Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
45445957|NCT05041647|Drug|25:1 CBD/THC|"1 dose (1 mL) of HIGH CBD~50 mg/ml CBD and 2 mg/ ml THC"
45761712|NCT01833715|Drug|TIVA|TIVA: General anesthesia will be based on Remifentanil and Propofol (TIVA-TCI), titrated to achieve bispectral index (BIS) between 40 and 60.
45445958|NCT05041647|Drug|5:1 CBD/THC|"1 dose (1 mL) of LOW CBD~10 mg/ml CBD and 2 mg/ ml THC"
45761713|NCT05393050|Drug|Colquhounia Root Tablet|Colquhounia Root Tablet is a tripterygium preparation
45761714|NCT05393050|Drug|Methotrexate tablets|Methotrexate is a drug used to treat rheumatoid arthritis
45761715|NCT03210415|Other|Observational Study Model|There is no intervention for the study.
45761716|NCT03166228|Drug|Normal Saline 0.9% Infusion Solution Bag|0.9% saline as distension medium as long as diathermy is not in use
45761717|NCT03166228|Drug|1.5% Glycine only|1.5% Glycine alone during hysteroscopy as long as diathermy is in use
45761718|NCT01833793|Drug|Levonorgestrel IUD (Mirena, BAY86-5028)|Women who have been prescribed Mirena in contraception; followed up for 12 months
45761719|NCT03157102|Device|HFNC|"Oxygen therapy will be delivered through high flow nasal cannulas. Aerosol treatments will be administered through a vibrating mesh nebulizer directly connected to the circuit (aerogen®). The airvo® system (Fisher & Peykel Healthcare, Auckland, New Zealand) will be used as the high flow cannula system in the study. Cannula size will be tailored to the child according to the manufacturer's recommendations. The gas flow will be adjusted according to the child's weight in a predefined chart. FiO2 will be adjusted to allow for a SpO2 >92%.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM (Pediatric Respiratory Assessment Measure) score, pain assessment by the FLACC (Face Legs Activity Cry Consolability) score). ."
45761720|NCT03157102|Device|Standard Oxygen Treatment|"Children will receive supplemental oxygen as commonly delivered through a non-rebreather face mask or low flow nasal cannula (standard oxygen treatment) and beta2 agonist aerosol via vibrating mesh nebulizer (aerogen®) according to the procedures usually used in the unit and according to the GINA (Global Initiative for Asthma) protocol. This group is the standard treatment group and is therefore the control group.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM score, pain assessment by the FLACC score). The use of adjuvant therapies (magnesium sulfate, salbutamol IVSE, and ipratropium bromide) will remain at the discretion of the physician in charge of the child and will be evaluated as a secondary criterion."
45761721|NCT01833949|Procedure|Unilateral laparoscopic drilling|Unilateral laparoscopic drilling with diathermy adjusted to ovarian volume
45761722|NCT01833949|Procedure|Bilateral laparoscopic drilling|Bilateral laparoscopic drilling with fixed doses energy
45761723|NCT03154996|Drug|Topotecan|"Topotecan is a chemotherapeutic agent that is a topoisomerase inhibitor. TPT is administered through an externalized catheter and external microinfusion pump.~Dose: 146 micrometers (uM)"
45761724|NCT03154996|Drug|Gadolinium|Gadolinium is a widely available MRI contrast agent that is used routinely in clinical practice via IV administration, especially for imaging of intracranial tumors.
45619848|NCT03327311|Device|Bellafill|Bellafill injected into site of pre-planned surgery (i.e., mini-abdominoplasty or redundant abdominal tissue removal) at two depths (dermis & deep dermis).
45761725|NCT03154996|Device|Synchromed II infusion pumps|Implanted subcutaneously to facilitate chronic infusion.
45761726|NCT03219307|Combination Product|NOVOCART 3D|Matrix associated autologous chondrocyte implant
45761727|NCT05389306|Diagnostic Test|MRI Scanning|MRI scanning will be performed with a 3.0-T magnetic resonance imaging system with a head and neck-combined coil employing spin-echo technique. The range of the MRI scanning will be from the suprasellar cistern to the inferior margin of the sternal end of the clavicle. The section thicknesses for the axial plane, the sagittal plane and the coronal plane will be 5 mm, 3 mm and 2 mm, respectively. The intersection gaps will be 1 mm. Before the intravenous injection of the MRI contrast agents, T1 weighted images, T2 weighted images and diffusion weighted images will be obtained in the axial planes, while only T1 weighted images will be obtained in the sagittal and coronal planes. After the intravenous injection of the MRI contrast agents, T1-weighted axial sequence, T1-weighted sagittal sequences and T1-weighted fat-suppressed coronal sequence will be performed.
45761728|NCT05389306|Diagnostic Test|Contrast-Enhanced Ultrasonography|A sonographer equipped with a 6-15 MHz linear array probe will be adopted for contrast-enhanced ultrasonography examination. Conventional high-frequency ultrasonography will be performed firstly before the intravenous injection of the ultrasound contrast agents. Then the ultrasound contrast agents will be injected intravenously, and contrast-enhanced ultrasonography examination will be performed. The mechanical index of contrast-enhanced ultrasonography examination will be 0.23. The wash-in and wash-out process within the lymph node will be dynamically observed during the arterial phase. During the Kupffer-phase, the degree of enhancement will also be observed.
45619849|NCT03327233|Device|Connecare self managment system|The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
45619850|NCT03332849|Biological|HM12470|HM12470 is a long-acting insulin analogue
45619851|NCT03240445|Drug|ODM-203 (Period 1)|ODM-203 400mg as tablets taken 30 minutes after food
45619852|NCT03240445|Drug|ODM-203 (Period 2)|ODM-203 400mg as tablets taken 1 hour before a light breakfast
45911849|NCT05416060|Behavioral|Project Dulce Telehealth|Project Dulce will consist of a group-based telehealth diabetes self-management education program consisting of a 5 -week curriculum delivered by a peer educator in English or Spanish. The curriculum provides skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complications, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants learn and practice self-management skills, and help one another address family, cultural or health system barriers to managing your diabetes.
45619853|NCT03240445|Drug|ODM-203 (Periods 3-6)|ODM- 203 400mg as tablets for oral administration or 400mg as oral dispersion either before/after food
45445959|NCT05041647|Other|Placebo|"1 dose (1 mL) of PLACEBO~No active ingredients"
45619854|NCT05018169|Behavioral|BA-A|Session 1 focuses on the treatment rationale, structure, and expectations, and includes psychoeducation on depression. Session 2 focuses on working with parent(s) to help them support their teen through treatment. Session 3 focuses on the (situation)/behavior/feeling cycle and how teens individuals can get trapped in a cycle of depression and inactivity. Session 4 focuses on the assessment of values and choosing preferred activities to target. Session 5 focuses on teaching skills for in-person and electronic communication. Session 6 focuses on identifying barriers to treatment success. Session 7 focuses on teaching teens to handle disagreements. Session 8 focuses on the utilization of adaptive coping skills. Sessions 9-11 are meant to be used flexibly and should include review of any challenging concepts. Session 12 is the termination session and focuses on maintaining treatment gains. Between every session, teens will track their activity for homework.
45619855|NCT03230929|Device|BIS-PLE|Anesthesiologist attaches the sensors of BIS and PLEM 100 on the forehead of the patient, and adheres the neuromuscular monitoring device on the medial side of the wrist and the ipsilateral thumb to continuously monitor the state of consciousness and muscle relaxation before, during and after surgery. Reversal of muscle relaxant could be performed by intravenous injection of sugammadex 4 mg/ kg in the case of deep neuromuscular relaxation, and 2 mg / kg in the case of shallow muscle relaxation degree under neuromuscular monitoring. After then, they monitor and record the values of BIS, PLEM 100, and neuromuscular monitoring in 1 minute increments for 5 minutes.
45619856|NCT03327155|Drug|Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)|One tablet, containing 300mg of TDF and 200mg of FTC once daily with food.
45619857|NCT03090555|Procedure|Translational manipulation|After the patient receives an interscalene block on the affected side, a physical therapist performs a series of thrust manipulations on the participant's affected shoulder. The participant's identified limitations of physiological and accessory motion revealed during manual examination guided the physical therapist's choice of technique, which primarily consisted of an accessory superior to inferior accessory gliding motion performed in a physiological position of limited motion. Additional gliding manipulations in combined movement positions such as increased flexion or abduction plus internal or external rotation were utilized until full passive physiologic motion was restored.
45761729|NCT05389306|Diagnostic Test|Ultrasound-guided Lymph Node Aspiration|After the conventional high-frequency ultrasonography and contrast-enhanced ultrasonography examination was finished, ultrasound-guided aspiration of the target lymph node will be performed. The lymph node tissue obtained from ultrasound-guided lymph node aspiration will be subjected to pathologic evaluation. And the diagnostic performance of MRI and contrast-enhanced ultrasonography will be evaluated using the pathologic diagnosis of the lymph node as the gold standard.
45619858|NCT03090555|Procedure|Manual therapy|The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation of the joints and soft tissue. The MT intervention was targeted toward any identifiable upper quarter pain or movement impairments. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
45761730|NCT04380259|Behavioral|Mindfulness-Based Trauma Recovery for Refugees (MBTR-R)|"MBTR-R is a mindfulness-based group intervention of nine 2.5-hour weekly sessions. MBTR-R format and structure parallel MBSR (mindfulness-based stress reduction) and MBCT (mindfulness-based cognitive therapy). MBTR-R includes systematic training in formal and informal mindfulness practices with trauma-sensitive adaptations and home practice. Trauma-sensitive adaptations include a safe place practice, psychoeducation about posttraumatic stress, stress reactivity, as well as self-compassion practices to cope with fear, self-judgement, guilt and shame. Socio-cultural adaptations include real-time linguistic translation of each session by a cultural mediator from the refugee community and use of socio-culturally specific metaphors. MBTR-R groups were conducted for men and women separately and delivered in an accessible, safe space in the local refugee community. Group meetings included a shared meal of traditional Eritrean food and female participants were offered free child care."
45761731|NCT02475070|Drug|Vildagliptin|Vildagliptin added at 50 mg twice daily for two weeks followed by four weeks washout and then dapagliflozin 10mg once daily for two weeks
45619859|NCT03240289|Behavioral|Texting group|Women receive text messages to aid in their diabetes self-care tasks during pregnancy; these included appointment reminders, motivational messages, and nutrition/exercise tips.
45619860|NCT03332693|Other|Exercise|Leg weight raising
45619861|NCT03332693|Other|No exercise|Volunteers will not participate in exercise
45619862|NCT03090867|Other|Relatives or surrogates are encouraged to perform care|"The relative or surrogate will perform at least two cares a week among feeding, mouth care, hair wash, shaving, eye care, hand, foot and face massage.~All care are planned and perform under the supervision or/and in collaboration with a caregiver.~The relative or surrogate will give his opinion by completing the study questionnaires."
45619863|NCT03090867|Other|Conventional ,care|The relative or surrogate will not be encouraged to perform care. The management of the relative or surrogate wi ll not changed from the regular standard of the ICU.
45619864|NCT03229525|Behavioral|Trauma Related Expressive Writing|Participants will write about the traumatic event over the course of six sessions.
45761732|NCT02475070|Drug|Dapagliflozin|Dapagliflozin added at 10 mg once daily for two weeks followed by four weeks washout and then vildagliptin 50 mg twice daily for two weeks
45761733|NCT05384860|Device|Auricular Trauma Protocol (ATP) Acupuncture|Small filiform (needle) like needles use low frequency electrostimulation at eight ear points for 60 minutes while patient is sedated during surgery. All other aspects of the surgical procedure will go as planned according to the hospital's standard of care.
45911850|NCT05416060|Behavioral|Project Dulce Live|Project Dulce will consist of a group-based diabetes self-management education program consisting of a 5 -week curriculum delivered by a peer educator in English or Spanish. The curriculum provides skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complications, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants learn and practice self-management skills, and help one another address family, cultural or health system barriers to managing your diabetes.
45911851|NCT05413317|Other|Color Doppler Ultrasound|Comparison with conventional diagnosis strategy including a clinical probability score, D-dimers and chest imaging.
45619865|NCT03229525|Behavioral|Neutral Expressive Writing|Participants will write about a neutral event over the course of six sessions.
45761734|NCT05384860|Other|No Acupuncture Group|This involves not receiving the acupuncture treatment and surgery going entirely as normal according to the hospital's standard of care.
45761735|NCT05381506|Drug|Orelabrutinib and Gemox|"Drug: Orelabrutinib Orelabrutinib 200mg, po, qd~Drug: Gemox14 Gemcitabine, Oxaliplatin"
45761736|NCT00902161|Drug|MK0893|Single dose of MK0893 1000 mg (ten 100 mg tablets)
45761737|NCT00902161|Drug|MK0893-matched Placebo|Single dose of placebo to MK0893 (ten tablets)
45761738|NCT00902161|Drug|Propranolol Hydrochloride (HCL)|Propranolol tablets titrated up to 80 mg three times daily over a four week period. Total treatment was approximately 7 weeks.
45761739|NCT01834105|Drug|Liuwei Dihuang Pills|
45761740|NCT03095170|Behavioral|Computerized brain fitness training|Will use the commercially available Posit Science product BrainHQ™ (www.brainhq.com) on tablets (e.g. iPads). Participants will complete 45-60 minutes of training daily in the program.
45761741|NCT03095170|Behavioral|Yoga|Will use adapted Hatha Yoga where participants sit on armless chairs placed on sticky mats for some asana (poses) and use the chair for support throughout. This adapted Hatha Yoga style is appropriate for older adults including those who have limited mobility, use walkers or are in wheelchairs. The appropriately sequenced yoga practice meets the American College of Sports Medicine recommendation for older adults for muscle strengthening and flexibility. Instructions are modeled for the participants
45761742|NCT03095170|Behavioral|Wellness Education|The education component will involve daily 60-minute group sessions with topics such as Introduction to the Program, Living with MCI, Changes in Roles, Communication and Relationships, Sleep Hygiene, Steps to Healthy Brain Aging, Preventing Dementia, MCI and Depression, Nutrition, Safety and Assistive Technologies, and Participating in Research, Community Resources, Meaning and Purpose, and Joy.
45761743|NCT03095170|Behavioral|Support Group (patient and partner)|Journal© as a basis for reminiscence-focused group sessions. Partner: The care partner support group meets separately from the patient group for 45-60 minutes daily.
45761744|NCT03095170|Behavioral|Cognitive Rehabilitation|"Will provide each couple with memory compensation training 5 days per week for 2 weeks, with initial and ending adherence sessions. All sessions will involve 45- 60 minutes of training. The curriculum is described briefly here.~Learning phases. three training stages from learning theory: 1) an acquisition phase in which use of the memory compensation system is learned, 2) an application phase in which a participant is taught to apply to his/her daily life, and 3) an adaptation phase in which a participant practices incorporating into his/her daily life so as to make its use habitual."
45761745|NCT01834183|Drug|Tivozanib|
45761746|NCT01834183|Drug|Gemcitabine|
45761747|NCT04379947|Procedure|Fractional Flow reserve|Measurement of fractional flow reserve in the preoperative work-up for oronary artery bypass surgery
45911852|NCT05410158|Drug|Ketamine in PECS block versus topical wound instillation|On arrival to the operating room, an intravenous line will be inserted in the contralateral upper limb to the side of surgery. Anesthesia will be induced for all participating patients with 2 μg/kg fentanyl, 2 - 3 mg/kg propofol and 1.5 mg/kg lidocaine. Endotracheal intubation will be facilitated by 0.15 mg/kg cis-atracurium.The patients will be randomly assigned into 2 groups ( pecs block group , topical instillation group) using a randomization-computer program . Anesthesia will be maintained by 1 - 1.5 MAC isoflurane in 50% oxygen/ air mixture and 0.03 mg/kg cisatrcurium, respectively, in ventilation parameters that maintain normocapnia. At the end of surgery, a reversal of the muscle relaxant will be done using neostigmine (0.04 mg/kg) and atropine (0.01 mg/kg). After extubation, all patients will be transmitted to the post anesthesia care unit (PACU) for follow up .
45911853|NCT05401487|Other|Pre-hospital and hospital care|Pre-hospital care not exceeding 60 min and a whole body CT scan within 45 min for patients categorized as unstable or critical by the pre-hospital doctor and 90 minutes for patients deemed potentially serious.
45911854|NCT05399355|Device|Active Pulsed Shortwave Treatment with BioElectronics Model 088|Application of 7-30 days of nonthermal, pulsed shortwave (radiofrequency) therapy with BioElectronics Model 088
45911855|NCT05399355|Device|Sham Treatment|Application of 7-30 days of a nonfunctional sham device(s)
45619866|NCT02492321|Drug|EBI-005|
45619867|NCT02492321|Drug|Placebo Comparator|
45619868|NCT05024877|Drug|Hetrombopag|Hetrombopag would be given started with 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L, the maximum dosage is 15mg/day)
45619869|NCT05024877|Drug|Stanozolol Tablets|Stanozolol would be given 2mg tid.
45619870|NCT03228979|Other|Structured Semi-Interactive Stroke Prevention Package|The intervention arm will receive a Structured Semi-Interactive Stroke Prevention Package including patient workbook, short messaging services and health education videos for a period of one-year in addition to standard of care as per current guidelines.
45619871|NCT03327077|Other|Live Preferential Music|Trained musicians will play live preferential music to ED patients who consent to participate.
45761748|NCT02478580|Drug|Nuvigil|Patients will receive Nuvigil before the surgery
45761749|NCT02478580|Drug|Placebo|Placebo will be given before surgery
45761750|NCT03838081|Behavioral|Spielberger State Anxiety Inventory (STAI-S),|STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety
45761751|NCT03838081|Behavioral|Dental Fear Scale (DFS)|DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice
45761752|NCT03838081|Behavioral|Modified Dental Anxiety Scale (MDAS)|MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25
45761753|NCT03838081|Behavioral|Visual Analog Scale (VAS)|"VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable"
45619872|NCT03079557|Drug|Intragastric botulinum toxin type A|200 units Botulinum toxin A (Allergan) injected intragastrically in the antrum every six months
45619873|NCT03230851|Drug|aspirin 100mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/d
45619874|NCT03230851|Drug|aspirin 100mg/2d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/2d
45761754|NCT03210181|Other|Superficial cervical plexus block|A nerve stimulator is used to guide the superficial cervical block. The nerve stimulator needle is first passed over the skin after aseptic preparation from the distal to proximal part of the posterior border of the sternocleidomastoid. Upon contraction of the levator scapulae, a mark is placed and the skin is infiltrated with 1 ml lidocaine 1%. A 22-G, 2.5 cm nerve stimulator needle is subsequently advanced through the skin by 0.5-1 cm depending on patient's weight while passing 5-8.5 mA current at 1 Hz. Then, the stimulating current is reduced to 0.5-0.6 mA while maintaining muscle contraction. At this point, 3-5 ml of the anesthetic mixture is injected.
45761755|NCT03210181|Other|Placebo|Patients will receive an equivalent volume of normal saline
45619875|NCT03230851|Drug|aspirin 100mg/3d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/3d
45619876|NCT03230851|Drug|aspirin 50mg bid therapy|100mg aspirin for at least 5 days followed by aspirin 50mg bid
45619877|NCT03230851|Drug|aspirin 75mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 75mg/d
45619878|NCT03230851|Drug|aspirin 50mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 50mg/d
45619879|NCT03230851|Drug|indobufen 100mg bid therapy|100mg aspirin for at least 5 days followed by indobufen 100mg bid
45619880|NCT05464433|Drug|Tislelizumab combined with Liposomal mitoxantrone hydrochloride|"Drug: liposomal mitoxantrone hydrochloride, tislelizumab Drug: Liposomal mitoxantrone hydrochloride (16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: tislelizumab(200 mg) will be taken orally on day 1 of each 28-day cycle."
45619881|NCT05464433|Drug|Maintenance of tislelizumab|Drug: tislelizumab(200 mg) will be taken orally on day 1 of each 21-day cycle
45619882|NCT05024409|Device|Upper Extremity Orthotic|3D printed orthotic which uses elbow motion to facilitate finger extension
45619883|NCT05024409|Other|Occupational Therapy|6 weekly sessions of occupational therapy, without use of an assistive orthotic device
45619884|NCT03229135|Device|other antibacterial agents，breathing machine|If treatment failure for patients in group A，group B，group C and group D，change dose of teicoplanin or other antibacterial agents. Mechanical ventilation was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of teicoplanin therapy.
45619885|NCT05024565|Behavioral|prolonged intravenous infusion of β-lactams Antibiotics|(1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours.
45619886|NCT03230617|Device|Mechanical ventilator|Mechanical ventilation, in the healthcare setting or home, helps patients breathe by assisting the inhalation of oxygen into the lungs and the exhalation of carbon dioxide. Depending on the patient's condition, mechanical ventilation can help support or completely control breathing.
45619887|NCT03090477|Behavioral|Pharmaceutical care and adherence aids|Medication review including drug-interaction check, individual patient counseling to improve understanding of treatment rationale and to elicit and address treatment-related concerns, provision of information booklets and adherence aids (calender blister packaging and smartphone medication reminder application), phone calls and face-to-face visits to follow-up on medication-related issues scheduled over a period of 6 months.
45619888|NCT03332615|Behavioral|Motivational Interviewing|Clinicians in the intervention arm will be taught Motivational Interviewing via a coaching model in which a didactic session is followed by feedback through review of clinicians' audio-recorded encounters.
45619889|NCT03332615|Behavioral|Wait-list control|After consent, clinicians in the wait-list control arm will complete a survey to self-assess their motivational interviewing skills and burnout.
45619890|NCT03228901|Drug|Oxytocin|Administration of the hormone oxytocin
45619891|NCT03228901|Drug|Placebos|
45619892|NCT03332537|Behavioral|Personalized IBS Pain SM|
45761756|NCT05345470|Other|140 calories per 30 gram test meal|Food
45761757|NCT03210493|Drug|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group
45761758|NCT03210025|Drug|BF-Methyldopa 250mg Tablet|BF-Methyldopa 250mg Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
45761759|NCT03210025|Drug|Metopa Tab 250mg|Metopa Tab 250mg is manufactured by APT
45761760|NCT03219853|Dietary Supplement|selenium enriched parsnips|Parsnips which have been grown in a selenium enriched environment
45761761|NCT03219853|Dietary Supplement|Conventional parsnips|Parsnips which have been grown in a conventional environment
45761762|NCT01834417|Device|TexiMat|
45761763|NCT05330884|Biological|BCG vaccine|0.1ml BCg vaccine to be given intradermally
45761764|NCT05330884|Drug|Oral Chemoprophylaxis|Oral chemoprophylaxis will be standard of care - either 6 months of Isoniazid or 3 months of weekly Isoniazid and Rifapentine
45761765|NCT04338412|Device|ProSeal-LMA™|It is a second generation LMA that is commonly used among all other LMAs
45761766|NCT05312710|Drug|APG-157|Treatment
45761767|NCT02480998|Biological|IL-YANG Flu Vaccine QIV 0.5mL|
45761768|NCT02480998|Biological|IL-YANG Flu Vaccine TIV 0.5mL|
45761769|NCT02482870|Device|Macintosh laryngoscope|Using a Macintosh laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
45911856|NCT05399004|Other|Survey Administration|Complete surveys
45619893|NCT03228745|Behavioral|Pre-operative MBSR|A MBSR program typically consists of 8 weekly 2.5 hour sessions, home practice (typically 45 minutes per day, 6 days per week), and one day retreat. During the program, participants engage in a number of mindfulness practices (e.g., body scan, mindful movement, meditation) and discussions of their experiences, with the aim enhancing awareness to moment-to-moment experiences in a non-judging and accepting manner.
45619894|NCT03090321|Behavioral|Stand Prompt|The participant will receive a notification asking them to stand or walk if they have been sitting for longer than 60 minutes
45619895|NCT03090321|Behavioral|Step Prompt|The participant will receive a notification if they are below 5000 steps by 3pm each day asking them to get to 10000 steps.
45619896|NCT03090321|Behavioral|Cluster Prompt|The participant will receive daily information notifications specific to the activity cluster they fall into based on the activity data collected in phase 1 of the study
45619897|NCT03090321|Behavioral|Read AHA website|Daily reminder to read the newsfeed from the American Heart Association (AHA) website, this is a control arm
45619898|NCT03326765|Other|Questionnaires|"Epworth sleepiness scale~Pittsburgh sleep quality Index (PSQI)~EQ-5D Adults~Pediatric Daytime Sleepiness scale (PDSS)~Sleep disturbance Scale for Children (SDSC~EQ-5D Children~Sleaping diary"
45761770|NCT02482870|Device|King Vision video laryngoscope|Using a King Vision video laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
45445960|NCT03755583|Dietary Supplement|Exclusive Enteral Nutrition|a complete liquid diet of formula for 8 weeks were adminstered in Crohn's Diseas patients ,Nutritional intake was based on the child's estimated energy requirements, no regular table food during 8 weeks treament.
45761771|NCT03218995|Drug|Eteplirsen|Infusion for intravenous use.
45761772|NCT01834495|Device|Balloon expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of > 15mmHg, residual stenosis of >30% and flow limiting dissection
46069154|NCT04038021|Behavioral|Phosphatidylethanol-based Contingency Management|In CM, tangible reinforcers are provided after individuals demonstrate biochemically verified abstinence of various substances. CM is associated with increased abstinence from illicit drugs, nicotine, and alcohol and is the most powerful psychosocial treatment for initiating abstinence of these substances. When participants submit a negative result for alcohol (via blood phosphatidylethanol biomarkers), the subject will receive rewards (gift cards). In contrast, they will not receive rewards when their samples test positive for alcohol.
45761773|NCT01834495|Device|Self expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of > 15mmHg, residual stenosis of >30% and flow limiting dissection
45761774|NCT00905125|Biological|Fluzone®|Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluzone® does not contain thimerosal.
45761775|NCT00905125|Biological|Fluarix®|Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluarix® contains less than 1 microgram (trace or a very small amount) thimerosal per shot.
45761776|NCT00905515|Drug|cyclosporine|Maintain on cyclosporine at target trough level of 50-250 ng/mL.
45761777|NCT00905515|Drug|Prograf (Tacrolimus)|Convert to Prograf at target trough levels of 3.0-5.9 ng/mL (Arm 2) or target trough levels of 6.0-8.9 ng/mL (Arm 3).
45445961|NCT03752229|Device|Acti-Lance Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45619899|NCT03326765|Procedure|electroencephalogram (EEG)|is an electrophysiological monitoring method to record electrical activity of the brain
45619900|NCT03326765|Procedure|polysomnography|type of sleep study, is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine
45619901|NCT03326765|Procedure|Actigraphy|type of sleep study based on bracelet around the wrist
45619902|NCT03228823|Procedure|Radiofrequency ablation|RFA to achieve PVC suppression will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study.
45619903|NCT03228823|Drug|Amiodarone (Antiarrhythmic drug)|AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
45619904|NCT03332381|Behavioral|Attention training technique|Attention training involves modifying metacognitive control and enhancing attention flexibility so that people can refrain from responding to intrusions with extended processing.
45761778|NCT00905827|Behavioral|CAMS|Collaborative assessment management in suicidality
45761779|NCT03219541|Behavioral|Interventional Automated mobile phone text|Participants will receive 2 messages per day in the pre-quit phase, 3 messages per day on the quit date and the first week in the post-quit phase, and 2 messages per day in the last 3 weeks of the intervention.
45445962|NCT03752229|Device|Acti-Lance Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45445963|NCT03752229|Device|Acti-Lance Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45761780|NCT03219541|Behavioral|Control Automated mobile phone text|Participants will receive 2 text questions each week asking the number of smoking days in the past week and the average number of cigarette smoked per day.
45761781|NCT03219073|Device|Active tDCS using tDCS device|Active tDCS using tDCS device is a noninvasive brain stimulation technique that utilizes low amplitude direct currents applied via scalp electrodes to apply currents to the brain and modulate the level of cortical excitability. tDCS applied over the dorsolateral prefrontal and motor cortex has been reported to be able to decrease pain sensation and to increase pain threshold in healthy subjects and is effective in reducing central chronic pain in PwMS.
45761782|NCT03219073|Device|SHAM tDCS using tDCS device|SHAM tDCS emulates active tDCS in all but the actual stimulation. Electrodes of the tDCS device are placed in the same place as with active tDCS however no current is activated.
45761783|NCT00894127|Device|CyPath|CyPath diagnostic assay for the early detection of lung cancer using sputum
45761784|NCT03216499|Drug|HIF-2alpha Inhibitor PT2385|Given PO
45619905|NCT03332381|Behavioral|Mindful self-compassion|Self-compassion involves not avoiding painful or distressing feelings. Instead these experiences are held in awareness with kindness, understanding, and a sense of shared humanity.
45619906|NCT03090243|Device|Virtual colonoscopy|Inserting a Foley catheter through the anus, and gas inflating of the bowel.
45619907|NCT03079713|Device|Handheld vibrator triggered during intravitreal injection for wet ARMD|A vibratory device cleaned with alcohol swabs between each use will be attached to the injectors' finger, placed on the lower eyelid of the treatment eye, and triggered during intravitreal injection
45619908|NCT03079713|Device|Normal eye esthesiometry with and without vibration|Healthy patients will undergo corneal and conjunctival esthesiometry with and without triggering of the wearable vibrator placed upon the lower lid of a single eye.
45619909|NCT03079713|Device|Handheld vibrator not triggered during intravitreal injection for wet ARMD|Control group undergoing standard intravitreal injection without triggering of the vibrator.
45619910|NCT03326687|Behavioral|Treatment ABAB|Participants will perform the phases in the ABAB order.
45619911|NCT03326687|Behavioral|Treatment BABA|Participants will perform the phases in the BABA order.
45445964|NCT03752229|Device|Medlance Plus Super Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45445965|NCT03752229|Device|Medlance Plus Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45911857|NCT05392803|Device|Active then Sham Treatment|"Application of 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy; then sham treatment after a 7-day washout period"
45619912|NCT05024175|Diagnostic Test|Disease assessments|CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol
45761785|NCT03216499|Other|Pharmacological Study|Correlative studies
45761786|NCT03216499|Other|Laboratory Biomarker Analysis|Correlative studies
45761787|NCT03216499|Other|Pharmacogenomic Study|Correlative studies
45761788|NCT03215797|Drug|phenylephrine|phenylephrine 100ug/ml IV infusion at a rate of 5ml/h in case of hypotension.
45761789|NCT03215797|Drug|Norepinephrine|Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of hypotension
45761790|NCT03219463|Dietary Supplement|Ginger|3g ginger powder supplement once a day with meals (preferably in the morning) for a duration of 8 weeks. Powder can be mixed with juice or water.
45445966|NCT03752229|Device|Medlance Plus Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45619913|NCT05024175|Procedure|Tumor Biopsy|Tumor Biopsy per protocol
45619914|NCT05024175|Diagnostic Test|Blood test|Blood Test per protocol
45761791|NCT01834573|Behavioral|physical exercise|10 weeks physical exercise; three times a week
45761792|NCT03211507|Other|Computer-assisted telephone interview|Occupational history
45761793|NCT03211507|Genetic|Genetic analysis|To include analysis of known susceptibility markers
45761794|NCT01830049|Other|Take blood|
45761795|NCT02485834|Procedure|FDG-PET|
45619915|NCT03332225|Drug|Anakinra|Treatment with anakinra
45619916|NCT03332225|Drug|Recombinant human interferon-gamma|Treatment with recombinant human interferon-gamma
45619917|NCT03332225|Drug|Placebo|Treatment with Placebo
45619918|NCT05023941|Drug|Acetazolamide|Start orally take acetazolamide 125mg twice daily, 2 days before entering the hypoxic chamber. Subjects will enter the hypoxic room at 9am on the third day. At that time, the subject should have taken the drug 5 times.
45619919|NCT05023941|Device|Doctormate® (twice daily for 6 days)|Start RIPC training twice daily, 6 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the seventh day. At that time, the subject should have finished 13 times of RIPC training.
45761796|NCT02485834|Procedure|surgery|
45761797|NCT02485834|Drug|5-FU|200 mg/m^2/day IV
45935041|NCT00214669|Behavioral|Asthma self management education by a specialist nurse|asthma education and self management, asthma action plans
45445967|NCT03752229|Device|Medlance Plus Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45619920|NCT05023941|Device|Doctormate® (forth daily for 3 days)|Start RIPC training forth daily, 3 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the forth day. At that time, the subject should have finished 13 times of RIPC training.
45761798|NCT02485834|Drug|capecitabine|oral 800 mg/m^2 BID
45761799|NCT02485834|Drug|docetaxel|30 mg/m^2 IV
45761800|NCT02485834|Drug|Irinotecan|50 mg/m^2 IV
45761801|NCT02485834|Radiation|3D-CRT|
45761802|NCT02485834|Radiation|IMRT|
45761803|NCT01830283|Biological|varicella vaccine|The providers would get varicella vaccine
45761804|NCT01834885|Drug|QVA149|QVA149 via inhaler twice a day
45761805|NCT01834885|Drug|fluticasone/salmeterol|fluticasone/slameterol via inhaler twice a day
45911858|NCT05392803|Device|Sham then Active Treatment|"Application of 30 days of sham treatment; then 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy after a 7-day washout period"
45445968|NCT03752229|Device|Medlance Plus Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45445969|NCT03752229|Device|Prolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45619921|NCT03090399|Device|FloTrac|For patients belonging to case group a Pulse Contour Analysis was adopted for optimize fluid administration
45619922|NCT03332147|Device|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
45619923|NCT03332147|Device|reference group-Earlysense system|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
45619924|NCT03093519|Drug|KHK6640|Intravenous administration
45619925|NCT03093519|Drug|Placebo|Intravenous administration
45619926|NCT03332069|Device|Modulated electro-hyperthermia|Modulated electro-hyperthermia device used is the EHY 2000 by Oncotherm GmbH
45619927|NCT03332069|Radiation|External beam radiation|
45619928|NCT03332069|Drug|Cisplatin|
45761806|NCT01834963|Drug|Interferon Alfa、Fluorouracil|"Hepatic Arterial Infusion of 5-fluorouracil combined with systemic administration of Interferon-alpha~Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks~Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks"
45761807|NCT01834963|Drug|Cisplatin、Fluorouracil|"Hepatic Arterial Infusion of 5-fluorouracil and Cisplatin (Low-dose FP)~Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks~Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks"
45761808|NCT03219385|Device|Mirabilis System|The intervention is a transabdominal treatment performed with the Mirabilis System, during which high-intensity focused ultrasound (HIFU) is applied noninvasively through the skin using an applicator placed against the abdomen. One or more appropriately selected uterine fibroids will be treated with HIFU using integrated ultrasound imaging to guide the treatment. HIFU causes localized heating and mechanical effects to develop in the targeted fibroid(s) that result in therapeutic destruction of the fibroid tissue, leading to improvement in related symptoms.
45619929|NCT03332069|Radiation|Brachytherapy|High Dose Rate
45619930|NCT03090087|Biological|Hypoxia|The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo
45761809|NCT03219151|Device|eMAR game|The eMAR simulator videogame affords students a virtual and immersive opportunity to practice medication administration using an eMAR system, in a structured fashion that provides real-time feedback related to best-practices and safety compliance of the medication process
45761810|NCT03219151|Other|Normal pre-work|Participants complete normal education pre-work related to eMAR administration, in advance of simulated return-demonstration
45761811|NCT04380103|Drug|XELOXIRI/Bevacizumab|bevacizumab 5mg/kg on day1, irinotecan 150mg/m2 or 165mg/m2 on day1, oxaliplatin 85mg/m2 on day1 and capecitabine 1000mg/m2 twice a day on day1-7 repeated every 2 week for 12 cycles, after 12 cycles, bevacizumab 5mg/kg on day 1 and capecitabine 1000mg/m2 twice a day on day1-7 as maintenance therapy repeated every 2 week
45761812|NCT01954966|Drug|Progesterone|Participants will consume four pills of Progesterone over a period of four days. Participants will be asked to remain abstinent from smoking while taking Progesterone.
45761813|NCT01954966|Drug|Placebo|Participants will consume four pills of Placebo over a period of four days. Participants will be asked to remain abstinent from smoking while taking Placebo.
45761814|NCT01835119|Drug|gum|gum
45761815|NCT01839019|Drug|ODM-102|Single dose escalation
45761816|NCT01839019|Drug|Placebo for ODM-102|Single dose escalation
45761817|NCT01835275|Behavioral|Enhanced Audio|
45761818|NCT01835275|Behavioral|Audio|
45761819|NCT01835353|Drug|Prasugrel 100mg loading dose|
45761820|NCT01835353|Drug|Prasugrel 60mg loading dose|Prasugrel 60mg loading dose
45911859|NCT05389696|Drug|Single subcutaneous administration and Blood collection|Single subcutaneous administration and Blood collection
45911860|NCT05389696|Drug|Single subcutaneous administration and then IV injection.|Single subcutaneous administration and then single intravenous administration after 2 weeks. In addition Blood collection is conducted as scheduled.
45911861|NCT05389696|Drug|MIT-001 20mg and 40mg_Multiple administration|Multiple subcutaneous administration for 7 days and then blood collection
45911862|NCT05373823|Other|MSS enhancement|Focuses on MSS enhancement using stakeholder collaboration
45935042|NCT00214708|Procedure|Screening for Tuberculosis|
45619931|NCT03090087|Drug|Regadenoson|The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo
45761821|NCT01916122|Drug|Fluorestradiol (FES)|
45761822|NCT01916122|Procedure|PET/CT Imaging|
45761823|NCT03836443|Other|"western diet meal"|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal) after an overnight fast."
45761824|NCT05210608|Behavioral|Working Memory Training (Active Intervention) + Behavioral Intervention|Participants will be randomized to complete 10 sessions of a Working Memory Training. All participants will receive behavioral activation (a behavioral intervention for smoking cessation) and nicotine patches.
45761825|NCT05210608|Behavioral|Control Training (CT) + Behavioral Intervention|Participants will be randomized to complete 10 sessions of a Control Condition Memory Training. All participants will receive behavioral activation (a behavioral intervention for smoking cessation) and nicotine patches.
45761826|NCT03836365|Other|Preoperative counseling office visit|All patients undergo a preoperative counseling session prior to surgery. Participants in this arm will have an in person preoperative counseling office visit.
45761827|NCT03836365|Other|Preoperative counseling phone call|All patients undergo a preoperative counseling session prior to surgery. Participants in this arm will have a preoperative counseling phone call.
45619932|NCT03331991|Biological|influenza vaccine|exposure to influenza vaccine
45619933|NCT03093363|Other|Pharmacist's intervention|"Pharmacist's intervention with asthmatic patients:~Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)~Explanation of asthma and inflammation~Explanation of triggers and how to avoid it~Explanation of asthma treatments~Explanation of the inhalation technique with a physical demonstration~Emphasis on treatment adherence~Assessment of comorbidities and their treatment~Emphasis on influenza vaccination"
45619934|NCT03093363|Other|Questionnaires for control group|- Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)
45761828|NCT03836521|Device|Transcatheter aortic valve replacement|
45761829|NCT01835509|Behavioral|Intervention, Camp plus reunions|
45761830|NCT02485912|Biological|ChAd3-EBO Z|This is a viral vectored vaccine using a chimpanzee adenovirus as a vector encoding a Zaire strain Ebola glycoprotein
45761831|NCT02485912|Biological|MVA-EBO Z|This is a viral vectored vaccine using a modified vaccinia Ankara virus as a vector encoding a Zaire strain Ebola virus glycoprotein
45619935|NCT05009433|Behavioral|High intensity interval training program for pregnant women|"Pregnant women will participate in 8-week HIIT cycles until the day of delivery, 3 times a week, in a volume of each session of 60 minutes. The main part (15-20 min) will be conducted in a form of high intensity intervals, approx. 85-90% of maximum exercise capacity. The intervals will consist of performing exercises for 30-60 seconds, alternating with a 30-60 second rest break, in the ratio of exercise time to rest 1:2, 1:1 or 2:1, according to the individual possibilities of the participant and taking into account the training progression and stage of pregnancy. The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~After birth, women will participate in 3-month HIIT cycles from the moment of achieving postpartum readiness to training until one year postpartum. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
45761832|NCT03836599|Drug|Verinurad|Participants will receive verinurad 24 mg in cohort 1 and 12 mg in cohort 2 once daily.
45761833|NCT03836599|Drug|Allopurinol|Participants will receive allopurinol 300 mg once daily.
45761834|NCT03836599|Drug|Placebo|During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.
45911863|NCT05373823|Other|Educational webpage on SSE|Longitudinal RCT comparing behavioral outcomes and effectiveness of enhanced MSS versus an educational webpage on SSE as well as new recurrences/melanomas
46069155|NCT04038021|Behavioral|Non-Contingent Control|In the non-contingent control intervention, participants will receive rewards (gift cards) regardless of the alcohol biomarker results in their samples. Once the samples have been received, the subjects will receive reinforcers that is consistent with the average from the CM group's earnings.
46069156|NCT04020471|Other|Pain Scale/Medication Log|Daily recording of pain level after surgery and recording of medication taken for pain relief.
46069157|NCT04005534|Drug|Standard group|Ultrasound examination of the brachial plexus 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
45761835|NCT01839097|Drug|Belinostat|"Belinostat will be administered by intravenous infusion once daily for up to 5 days depending on the dose cohort as follows:~Cohort 1: belinostat 1000 mg/m2 IV on Day 1~Cohort 2: belinostat 1000 mg/m2 IV on Day 1-2~Cohort 3: belinostat 1000 mg/m2 IV on Day 1-3~Cohort 4: belinostat 1000 mg/m2 IV on Day 1-4~Cohort 5: belinostat 1000 mg/m2 IV on Day 1-5"
45761836|NCT01839097|Drug|CHOP|"Cyclophosphamide - 750 mg/m2 - IV - Day 1~Vincristine - 1.4 mg/m2 - IV - Day 1~Doxorubicin - 50mg/m2 - IV - Day 1~Prednisone 100mg PO - On Day 1 Prednisone will be administered after chemotherapy part of CHOP, and on Day 2-5 after belinostat."
45761837|NCT02488018|Biological|Provision of experimental honey|"Acacia, Becium grandiflorum, Croton macrostachys, Eucalyptus globules, Hypoestes, Leaucas abyssinica, Schefflera abyssinica, Syzygium guineense and reference glucose were used as test food.~25g available carbohydrate of the test food was provided to ten human subjects after fasted for 11 hours overnight."
45761838|NCT01835665|Drug|Nimodipine|Nimodipine is an FDA-approved drug for subarachnoid hemorrhage indication
45761839|NCT01839175|Biological|Hexavalent vaccine|0.5 mL intramuscular injection at 2, 3 and 4 months of age (primary series) 0.5 mL intramuscular injection at 12 or 13 months of age (booster)
46069158|NCT04005534|Drug|Preemptive group|Ultrasound guided brachial plexus blockade 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
46069159|NCT04004611|Drug|Mirikizumab|Administered IV and SC
46069160|NCT03993678|Drug|IP-001|Dose and route: Immediately (within 15 - 30 min) after thermal ablation, IP-001 will be injected in and around the ablated lesion. The amount of IP-001 injected depends on the dose level.
45761840|NCT01839175|Biological|NeisVac-C|0.5 mL intramuscular injection at 2 and 4 months of age
45761841|NCT01839175|Biological|Prevenar 13|0.5 mL intramuscular injection at 2 and 4 months of age (primary series) 0.5 mL intramuscular injection at 13 months of age (booster)
45761842|NCT01839175|Biological|RotaTeq|2 mL oral administration at 2, 3 and 4 months
45761843|NCT01839175|Biological|Nimenrix|0.5 mL intramuscular injection at 12 months
45761844|NCT01839175|Biological|M-M-RVAXPRO|0.5 mL intramuscular or subcutaneous injection at 13 months of age
45761845|NCT01582048|Drug|immunosuppression|Conditioning with treosulfan 14 g/m2 day -6 to -4, fludarabine 30 mg/m2/24h day-6 to -2, ATG-Fresenius 20 mg/kg day -4 to -2, rituximab 500 mg/m2 day -1. Unmanipulated PBSC day 0. Postgrafting immunosuppression with mycophenolate mofetil (15 mg/kg TID) and sirolimus (2 mg QD).
45761846|NCT01835821|Device|prosthetic crowns|prosthetic crowns
45761847|NCT01839253|Drug|b-blocker(Atenolol)|
45761848|NCT01839253|Drug|ACE inhibitor(Enapril)|
45761849|NCT01839253|Other|control|
45761850|NCT00404170|Drug|B-CIT and SPECT imaging|Optional ongoing B-CIT SPECT imaging scans at follow-up visits
45761851|NCT01839409|Behavioral|vestibular stimulation|Physical activity and vestibular stimulation will be used in order to improve circadian rhythms
45761852|NCT01835977|Device|Irreversible Electroporation (Nanoknife)|
45761853|NCT01839565|Device|Quadrilateral Surface Plate|Patients with acetabular fracture surgically treated using the Quadrilateral Surface Plate
45761854|NCT01836211|Other|Fast strategy|High sensitivity troponin T followed by computed coronary tomography angiography
45761855|NCT01836211|Other|Standard of care strategy|Standard of care strategy: serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
46069161|NCT03993678|Device|Thermal Ablation|"The medical device includes a laser unit. The system continuously measures the temperature of the tissue, guiding the user to perform precise and safe treatments.~Treatment time: 30 min"
45761856|NCT04379869|Drug|NNZ-2591|Single dose of NNZ-2591
45761857|NCT04379869|Drug|Placebo|Comparator for double-blind MAD
45761858|NCT01836289|Drug|High-dose Cyclophosphamide|
45761859|NCT03218839|Device|PrePex male circumcision device|PrePex non-surgical male circumcision device applied to eligible, consenting HIV-infected men in Zimbabwe to determine the rate of adverse events as compared to non HIV-infected men.
45761860|NCT01839643|Drug|Meloxicam 2.4 g|2.4 g in Vaginal Ring
45761861|NCT01839643|Drug|Meloxicam 3.0 g|3.0 g in Vaginal Ring
45761862|NCT01839721|Drug|Bifilact®|placebo, standard dose 1.3 billion twice a day, high dose 10 billion three time a day
45761863|NCT01839721|Other|placebo|
45761864|NCT01836367|Drug|Ingenol Mebutate 0.015%|Picato
45761865|NCT04379557|Procedure|Catheter Ablation|Catheter Ablation is a procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias
45761866|NCT04380025|Dietary Supplement|Experimental: Oral Mirtogenol|The experimental arm is Oral Mirtogenol dietary supplement, one capsule daily in addition to bimatoprost ophthalmic drops with primary open angle glaucoma
45761867|NCT04380025|Dietary Supplement|Placebo of oral Dietary supplement|This is the oral placebo of the supplement (control) un daily capsule in addition to the bimatoprost ophtalmic drops
45761868|NCT00908791|Drug|Conjugated Linoleic Acid (CLA)|Conjugated linoleic acid (CLA, Clarinol™) oral soft gel capsules will be administered in an open-labeled, manner to all subjects enrolled in the study. Subjects will be treated with 7.5 grams of oral CLA daily, taken in divided dose, twice daily between 8 am and 12 noon and between 8 pm and 12 midnight. CLA will be taken for a minimum of ten days prior to surgical resection of their breast malignancy. In the event that the subject's surgical resection date is delayed, subjects may take CLA for up to 28 days. The last dose of CLA prior to the surgical resection will be taken at 12 midnight or as close as possible to that time and the patient will record the time of the last dosing.
45761869|NCT01836601|Behavioral|Family-centered nighttime communication bundle|
45761870|NCT03218371|Procedure|chandelier-assisted peripheral vitrectomy under air|chandelier-assisted peripheral vitrectomy under air for management of peripheral vitreous during RD vitrectomy; whether using indentation or non-indentation
45761871|NCT01836679|Drug|Chidamide|Given orally
45761872|NCT01836679|Drug|Paclitaxel|Given IV
45761873|NCT01836679|Drug|Carboplatin|Given IV
45761874|NCT01836679|Drug|Placebo|Given orally
45761875|NCT03218293|Device|RIPC device (IPC-906X)|Patients in the RIPC group had five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm after thrombolysis.
45761876|NCT02489110|Behavioral|Webnovela|
45761877|NCT02489110|Behavioral|Information|
45761878|NCT05452876|Other|ABCp|Intervention is a care pathway that helps primary care physicians categorize back pain patients with each category having preferred interventions.
45761879|NCT05452876|Other|Usual Care|Standard of care treatment
45761880|NCT05452252|Diagnostic Test|functional mandibular evaluation|Active mandibular movements including depression, protrusion, and left-right deviation, facial anthropometry was measured on facial shape on photograph, and phenotype and asymmetry
45935043|NCT00073281|Procedure|Islet transplantation|
45935044|NCT00214747|Drug|Vehicle gel formulations|
45935045|NCT00397202|Device|Diva Cup TM|See Detailed Description.
45935046|NCT00214825|Drug|eplerenone|50 mg daily for 6 weeks with placebo
45935047|NCT00214825|Drug|Hydrochlorothiazide|HCTZ 12.5 mg with potassium (10 mEq) daily for 6 weeks
45935048|NCT00214864|Drug|docetaxel, capecitabine|cohort 1 = capecitabine 900mg/m2 BID POx14 days and docetaxel 36mg/m2 day1&8 cohort 2 = capecitabine 650mg/m2 BID POx14 days and docetaxel 30mg/m2 day1&8 cohort 3 = capecitabine 850mg/m2 BID POx14 days and docetaxel 30mg/m2 day1&8
45935049|NCT00214942|Drug|ORAVESCENT Fentanyl Citrate|
45935050|NCT00069498|Drug|5-aminosalicylic acid|
45935051|NCT00214981|Drug|Modafinil|
45935052|NCT00397241|Drug|Drug: dorzolamide/timolol|
45935053|NCT00397241|Drug|Drug: latanoprost/timolol|
45935054|NCT00397241|Drug|dorzolamide/timolol and latanoprost|
45935055|NCT00397241|Drug|placebo (artificial tears)|
45935056|NCT00073320|Drug|Paliperidone Palmitate|
45761881|NCT05452096|Behavioral|Education program and ergonomic schedulling|"The duration: six months. The explicit choice for a multimodal intervention to be tested as a whole is in line with the assertion of other experts that workplace interventions using a single approach will not be effective.~Multimodal intervention~Implementing healthy scheduling. This will imply fast forward-rotating shift schedules, being adapted to chronotype, allowing for adequate resting times between shifts and series of shifts, allowing for napping at work, in particular during the first two days of an early shift.~Education program for drivers: psychoeducation on the sleep-wake cycle chronotypes, based on the cognitive-behavioral treatment of insomnia (CBT-i), information on the impact of light on wakefulness and sleep, information on napping and creating awareness on daytime sleepiness, tools for stress reduction, physical exercise, information on healthy eating in the context of shiftwork The education program will consist of a one-day, 8-hour session."
45761882|NCT00369460|Other|physiologic testing|Weight, body mass index, age, ECOG performance status, gait speed, concomitant medications, CA19-9, and total lymphocyte count measured before start of cancer treatment of the patient's choosing. Patients will be re-assessed at approximately 2 months, 4 months, 6 months, and with any change in tumor burden.
45761883|NCT00369538|Drug|losartan, hydrochlorothiazide|Two administrations of losartan per day,up to 100mg per day, during 2 months, followed by a wash-out during 1 month, and then one administration of hydrochlorothiazide, 25 mg per day during 2 months
45761884|NCT00369538|Drug|hydrochlorothiazide, losartan|One administration of hydrochlorothiazide, 25 mg per day during 2 months, followed by a wash-out during 1 month, and then, two administrations of losartan per day,up to 100mg per day, during 2 months
45761885|NCT05137132|Dietary Supplement|CARDIO®|"CARDIO® is manufactured according to Good Manufacturing Practices for food facilities complying with the Hazard Analysis and Critical Control Points (HACCP) principles.~The product is intended for use in manufacturing of human food products and human consumption, including food supplements, and have been Generally Recognized as Safe (self-affirmed GRAS). The fresh unrefined salmon oil is produced by Hofseth Biocare ASA"
45761886|NCT05137132|Dietary Supplement|Placebo|MCT oil
45761887|NCT05129878|Procedure|scaling and root planing|patients with PCOS on combined oral contraceptives (COCs) having stage 1/2 periodontitis will receive scaling and root planing
45619936|NCT05009433|Behavioral|Moderate intensity continuous training program for pregnant women|"Pregnant women will participate in 8-week MICT cycles until the day of delivery, 3 times a week, in a volume of each session of 60 minutes. The main part (20-25 min) will be conducted in a form of moderate intensity continuous exercise, of 70-80% of the maximum exercise capacity, e.g. in the form of high- and low-impact aerobics choreography with music. The sessions will also include resistance, neuromotor, body posture and flexibility exercises (25 min), breathing exercises, relaxation and visualization of pregnancy or childbirth (10 min). The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~After birth, women will participate in 3-month MICT cycles from the moment of achieving postpartum readiness to training until one year postpartum. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
45761888|NCT05129878|Procedure|oral Hygiene instruction|patients with PCOS on combined oral contraceptives (COCs) having stage 1/2 periodontitis will receive oral hygiene instructions only
45761889|NCT05129878|Procedure|Scaling and Root Planing|Systemically Healthy (age and BMI matched) females with stage 1/2 periodontitis will receive with OHI and SRP.
45761890|NCT02489734|Drug|sevoflurane|extubation when end-tidal concentration of sevoflurane < 0.5%
45761891|NCT02489734|Drug|Sevoflurane|extubation when end-tidal concentration of sevoflurane >= 0.5%
45619937|NCT05009433|Behavioral|Standard obstetric care with extended education on healthy lifestyle|Pregnant women will get standard obstetric care according to the national law. They will attend educational sessions on a healthy lifestyle, physical activity in the perinatal period and selected aspects of pregnancy and motherhood. Educational classes will be conducted online in real time, at least once every two weeks, until one year postpartum.
45761892|NCT05124262|Other|Low- FODMAPdiet group intervention|Diet intervention
45761893|NCT02490670|Drug|Cephalexin|Administered orally
45761894|NCT05451784|Drug|PD1+ TILs (NUMARZU-001) product infusion|"The cryopreserved NUMARZU-001 product will be thawed in 37ºC water bath and will be infused by gravity, a 5 mL to 10 mL/ minute. Concomitant medications will be given to the patient starting within 24 hours prior to NUMARZU-001 product infusion*. This therapy will include the following:~Hydration as per institutional standards (Saline solution 0,9% NaCl 500ml every 8 hours) 24 hours prior the NUMARZU-001 product infusion.~Within 30 to 60 minutes prior to infusion of NUMARZU-001, premedicate the patient with acetaminophen (650 mg) and diphenhydramine (25 to 50 mg IV), or another H1- histamine antagonist.~Continuous supervision of the patient by site medical staff is required until completion of infusion of the NUMARZU-001 product, to monitor for potential signs and symptoms (e.g. hypersensitivity reaction)."
45761895|NCT00908947|Device|PTA followed by placement of LifeStent® Vascular Stent|PTA followed by placement of LifeStent® Vascular Stent
45761896|NCT02492854|Device|PICO Single-Use Negative Pressure Dressings|Negative pressure wound therapy (NPWT), over the past several years, has provided a way to post-operatively manage complex wounds. This is a therapy with potential to decrease rates of SSIs post-LE bypass. Unlike standard gauze dressings, negative pressure wound therapy provides a sealed, moist environment and shuttles fluid away from the wound. A suctioning unit applies even, negative pressure (typically -80 to -120 mmHg) and exudate is suctioned and collected in a control unit. The investigators would like to investigate the efficacy of PICO (Smith&Nephew), a single-use one-step wound dressing which is effective for 7 days. It is lightweight and uses a small hand-held vacuum pump, both of which allow for ease of use. PICO has been FDA-approved.
45911864|NCT05373823|Other|Assess implementation outcomes|A mixed-methods study with multi-level stakeholders to assess implementation outcomes and identify contextual factors to facilitate scale-up for future dissemination and implementation.
45911865|NCT05370352|Behavioral|Standard smoking cessation treatment|Standard smoking cessation treatment (behavioural and pharmacotherapy) provided by Tung Wah Group of Hospitals Integrated Centre on Smoking Cessation
45935057|NCT00215176|Drug|modafinil|
45935058|NCT00215215|Device|Vagus Nerve Stimulation Therapy|
45935059|NCT02966145|Other|Observational Study|
45935060|NCT00215254|Drug|quetiapine|
45935061|NCT00215293|Device|Cervical I/F Cage|
45619938|NCT05009433|Behavioral|High intensity interval training program for nonpregnant women|"Nonpregnant women will participate in 8-week HIIT cycles for a period of 8 months, 3 times a week, in a volume of each session of 60 minutes. The main part (15-20 min) will be conducted in a form of high intensity intervals, approx. 85-90% of maximum exercise capacity. The intervals will consist of performing exercises for 30-60 seconds, alternating with a 30-60 second rest break, in the ratio of exercise time to rest 1:2, 1:1 or 2:1, according to the individual possibilities of the participant and taking into account the training progression. The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~For the next 12 months of the project, women will participate in 3-month HIIT cycles. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
45761897|NCT02492854|Other|Sterile Gauze Dressings|Current standard-of-care dressings used to cover surgical wounds post-operatively.
45761898|NCT05451706|Behavioral|Mental help-seeking self-persuasion|Employing a longitudinal design, this study used a self-persuasion framework in a 4-arm intervention to increase college students' help-seeking intentions during the COVID-19 pandemic.
45761899|NCT05451628|Device|Default CI fitting|Programming of cochlear implant speech processor according to standard clinical care
45761900|NCT05451628|Device|Anatomy-based CI fitting|Programming of cochlear implant speech processor with anatomy-based fitting
45761901|NCT01836757|Drug|MethylSulfonylMethane (MSM)|Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
45761902|NCT01836757|Drug|Placebo|
45761903|NCT05451472|Diagnostic Test|thyroid function tests|Thyroid function tests:thyroid stimulating hormone (TSH), total thyroxine (T4), free thyroxine (FT4), total triiodothyronine (T3), and free triiodothyronine (FT3)
45761904|NCT05451472|Diagnostic Test|complete blood count|complete blood count
45761905|NCT05451472|Diagnostic Test|serum creatinine|serum creatinine
45761906|NCT05451472|Diagnostic Test|blood urea|blood urea
45761907|NCT05451472|Diagnostic Test|serum electrolyte|serum electrolyte
45761908|NCT05451472|Diagnostic Test|serum calcium|serum calcium
45761909|NCT05451472|Diagnostic Test|serum phosphorus|serum phosphorus
45761910|NCT05451472|Diagnostic Test|parathyroid hormone level|parathyroid hormone level
45935062|NCT00215293|Device|Autograft or allograft with a plate, or autograft alone.|
45761911|NCT05451472|Diagnostic Test|liver function test|ALT_AST_Total biliruin_total protein _serum albumin
45445970|NCT03752229|Device|Prolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45445971|NCT03752229|Device|Prolance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45445972|NCT03752229|Device|Prolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45761912|NCT05451472|Diagnostic Test|arterial blood gases|PH_PCO2_PO2_HCO3_base deficit
45761913|NCT05451472|Diagnostic Test|complete urine analysis|complete urine analysis
45761914|NCT01836835|Other|Pregnancy Unique Questionnaire of Emesis (PUQE)|For hyperemesis gravidarum patients the Pregnancy Unique Questionnaire of Emesis (PUQE) (3 questions regarding the amount of nausea and vomiting during 24 hours) will be answered both at hospital admittance and discharge. For control patients the questionnaire will be answered at inclusion.
45761915|NCT01836835|Other|24 hours self-reported nutritional intake form|A nutritional intake form where relevant food and liquid items can be checked prospectively after consummation during 24 hours. This form will be filled in starting the morning following inclusion.
45761916|NCT01839877|Drug|HIA DEBIRI + systemic FOLFOX|
45761917|NCT05451394|Other|ROAF|"Use of the method Ressource Optimisation of Armed Forces (ROAF). 6 one-hour workshops"
45761918|NCT05451394|Other|Active Comparator|6 one-hour workshops on cognitive process
45761919|NCT03218059|Procedure|Methotrexate Combined With Transvaginal Surgery|The methods of treatment of CSP
45935063|NCT00215332|Device|CHARITE|Lumbar Total Disc Replacement
45761920|NCT05107492|Drug|450mg|following a single subcutaneous dose of PF-06480605 450 mg
45761921|NCT05107492|Drug|150mg|following a single subcutaneous dose of PF-06480605 150 mg
45445973|NCT03752229|Device|Prolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45445974|NCT03752229|Device|Prolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45761922|NCT05107492|Drug|Placebo|following a single subcutaneous dose of placebo
45761923|NCT01839955|Drug|erlotinib hydrochloride|"Dose Escalation Group:~Begins day 1: given 150mg daily, orally~Extension Group:~Begins Day 1: 150mg daily, orally"
45761924|NCT01839955|Drug|quinacrine dihydrochloride - Escalation dose|Begins Day 8: Loading dose (first cycle only) 50mg three times daily for 7 days followed by 21 days of 50mg maintenance dose. Level -1: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg every other day for three weeks). Level 1 [starting dose]: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg daily for three weeks). Level 2: Loading dose (100mg three times daily for 7 days), maintenance dose (100mg every other day for three weeks). Level 3: Loading dose (150mg three times daily for 7 days), maintenance dose (200mg every other day for three weeks). Level 4: Loading dose (200mg three times daily for 7 days), maintenance dose (400mg every other day for three weeks). Subsequent patient cohort(s) will be enrolled depending on the safety and tolerability of subjects
45761925|NCT01839955|Other|laboratory biomarker analysis|Correlative studies
45761926|NCT01839955|Other|pharmacological study|Correlative studies
45761927|NCT01839955|Drug|quinacrine dihydrochloride - Extension dose|Participants will be treated at recommended dose from expansion group to confirm tolerability and evaluate early response
45761928|NCT02493088|Other|Antisocial personality recording of behavior and contextual elements|aberrant driving behaviors and upstream contextual elements of individuals diagnosed with antisocial personality disorder will be recorded during the study
45761929|NCT01831843|Device|Group C|non-heated, non-humidified conventional breathing circuit was used in group C patient
45761930|NCT01831843|Device|Group E|breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer & Paykel)was used in group E patient
45761931|NCT01831843|Device|Group M|Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient
45761932|NCT02494102|Drug|Modafinil|Atypical Psychomotor stimulant
45761933|NCT02494102|Drug|Placebo|
45761934|NCT01836991|Procedure|surgery|
45445975|NCT03752229|Device|Haemolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45445976|NCT03752229|Device|Haemolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45761935|NCT03219619|Device|Cap-EGD|Undergoing cap-assisted endoscopy
45761936|NCT03219619|Device|Duo|Undergoing side-viewing duodenoscope
45761937|NCT05451160|Device|steep pulse therapy system|The steep pulse therapy system is produced by Zhejiang CuraWay Medical Technology Co., Ltd. for liver tumor ablation
45761938|NCT05451160|Device|RF Ablation System|RF Ablation System
45761939|NCT00894517|Biological|Botulinum Toxin Type A|OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.
45761940|NCT00894517|Drug|Placebo (saline)|Saline injected into the prostate on Day 1.
45761941|NCT05450926|Procedure|Ultrasound-guided selective cervical nerve root block|The volunteer will be placed in the lateral decubitus position with the examined side up and the ultrasonographic examination will be started. Using a high frequency 6-18 MHz linear transducer, scanning in the cephalad and caudal direction until the cervical tubercles are identified in the short axis of the vertebra at the cricoid level, the localization and number of the target nerve root and vascular structures in the foraminal opening between the anterior and posterior tubercles of the transverse process from C4 to C8. will be defined as Unlike healthy volunteers, local anesthetic and steroid injections will be administered to the target nerve.
45761942|NCT01833871|Other|Three dimensional Power Doppler to the myometrial mass|Trans-vaginal 3D power Doppler Ultrasonographic examination will be done for all participants prior to surgery. The ultrasonographic examination will provide data related to lesion size, lesion volume, vascular location (location), vascular index (VI), flow index (FI), and vascular-flow index (VFI). The region of interest will include the entire region of the uterine mass. The virtual organ computer aided analysis (VOCAL) software for the analysis of 3D power Doppler histograms will be used with computer algorithms to form indices of blood flow and vascularization. All data will be collected and compared with the post operative histopathology results.
45761943|NCT01833871|Other|Uterine artery Doppler|uterine artery Doppler indices(RI,PI) are measured for all cases with myometrial mass
45761944|NCT05059210|Behavioral|Coach McLungs Intervention|Practices have received implementation of Coach McLungs
45761945|NCT01838395|Drug|Ara-C|IV
45761946|NCT01838395|Drug|BL-8040|SC
45761947|NCT05051176|Diagnostic Test|2D usg and 3D/4D usg|IRD distance measured by a linear probe 2D usg. Pelvic floor muscle morphometry measured by 3D/4D usg
45761948|NCT01837147|Behavioral|Technology-Based Physical Activity Promotion|Participants assigned to this group will use a web-integrated physical activity monitor, and accompanying website, to improve their physical activity levels.
45761949|NCT01837147|Behavioral|Pedometer Intervention|Participants assigned to this group will receive a pedometer and be trained in its use.
45761950|NCT00422578|Drug|tadalafil|
45445977|NCT03752229|Device|Haemolnace Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45761951|NCT01837303|Procedure|Pap smear|"A pap smear/cervical cytology is performed using a spatula and brush to obtain cells from the ectocervical and endocervical region of the cervix. The specimen will be collected twice to put in the standard clinical pap medium and another to put in the study pap medium.~These slides will be processed so that they may be reviewed by a single board certified pathologist.~There are no other interventions or follow up. All participants will undergo the above described procedures. There is no placebo."
45761952|NCT05048056|Drug|Placebo|Placebo subcutaneous injection every 2 weeks for 16 weeks then Crossover to AK120 Regimen 1
45761953|NCT05048056|Drug|AK120|AK120 Regimen 1- subcutaneous injection every 2 weeks.
45761954|NCT05048056|Drug|AK120|AK120 Regimen 2- subcutaneous injection every 2 weeks
45761955|NCT03217981|Other|Sepsis protocol|Adherence to the sepsis protocol
45911866|NCT05370352|Behavioral|Personalised chat messaging|Personalised chat messaging focusing on smoking relapse prevention for 3 months from randomisation. A trained counsellor will interact with a participant individually and provide relapse prevention advice via WhatsApp. The participant can also access a supportive chatbot in WhatsApp, which will provide on-demand smoking relapse prevention support when the counsellor is not available (e.g., during nighttime).
45445978|NCT03752229|Device|Haemolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45761956|NCT02494180|Drug|fentanyl|arm A receiving iv fentanyl
45761957|NCT02494180|Drug|pethidine|arm B receiving iv pethidine
45761958|NCT02494180|Drug|Diazepam|arm B receiving iv diazepam
45761959|NCT02494180|Drug|Midazolam|arm A receiving iv midazolam
45761960|NCT05450848|Device|StrataXRT|StrataXRT is a flexible wound dressing for the prevention and treatment of radiation dermatitis. It is in the form of a gel which, when applied, creates a protective film that maintains skin integrity. The product is used to relieve low grade inflammatory radiation changes such as dry, itching, flaking, peeling and irritated skin. For more severe inflammatory changes with open wound components, StrataXRT reduces pain, redness and heat and helps soothe the exposed skin areas. StrataXRT can be applied where skin integrity has been compromised and may also be used in conjunction with other adjunctive treatments to improve overall results. StrataXRT contains Polydimethylsiloxanes, Siloxanes and Alkylmethyl Silicones and is transparent and odourless. It does not contain alcohols, parabens or fragrances. StrataXRT can be used with or without a secondary protective dressing. It is suitable for children and people with sensitive skin.
45761961|NCT05450848|Other|Sorbolene|Aqueous cream (moisturizer) that soothes itchiness and dryness of the skin, and aids skin hydration. It is non-greasy, fragrance free, colour free, GMO free, paraben free and pH balanced.
45761962|NCT05032690|Drug|Bosutinib capsule|Bosutinib four 25 mg capsule taken after a high-fat and high calorie breakfast
45761963|NCT05032690|Drug|Bosutinib capsule|Bosutinib 100 mg capsule taken after a high-fat and high calorie breakfast
45761964|NCT05032690|Drug|Bosutinib|Bosutinib 100 mg capsule taken after an overnight fast of at least 10 hours
45761965|NCT05032690|Drug|Bosutinib capsule|Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast
45761966|NCT02494336|Procedure|Trans-incisional rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon. This will be done after closure of the fascial incision but prior to closure of the skin incision.
45761967|NCT02494336|Procedure|Laparoscopic guided rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered intra-abdominally under direct laparoscopic visualization into the rectus sheath bilaterally by the attending surgeon.
45761968|NCT02494336|Drug|Ropivacaine|Ropivacaine is a long-acting local anesthetic. It has been shown to be effective for peripheral nerve, caudal, and lumbar/thoracic epidural blocks and produce less motor blockade than bupivacaine after caudal administration. It will be the local anesthetic used to perform the rectus sheath block for both arms.
45761969|NCT01839331|Biological|4 mL injection of Ampion|4 mL Injection of Ampion
45761970|NCT01839331|Biological|10 mL Injection of Ampion|10 mL Injection of Ampion
45761971|NCT01839331|Drug|4 mL Injection of Placebo|4 mL Injection of Placebo
45761972|NCT01839331|Drug|10 mL Injection of Placebo|10 mL Injection of Placebo
45619939|NCT05009433|Behavioral|Moderate intensity continuous training program for nonpregnant women|"Nonpregnant women will participate in 8-week MICT cycles for a period of 8 months, 3 times a week, in a volume of each session of 60 minutes. The main part (20-25 min) will be conducted in a form of moderate continuous intensity exercise, of 70-80% of the maximum exercise capacity, e.g. in the form of high- and low-impact aerobics choreography with music. The sessions will also include resistance, neuromotor, body posture and flexibility exercises (25 min), breathing exercises and relaxation (10 min). The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~For the next 12 months of the project, women will participate in 3-month MICT cycles. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
45761973|NCT05450770|Biological|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL) for HIV positive and negative subjects
45761974|NCT01837381|Procedure|TEA|Arterial feeders to tumors were identified and catheterized with a microcatheter to a branch supplying a Couinaud segment or subsegmental level for delivery of the therapeutic agent, which was Lipiodol-ethanol mixture at 2:1 ratio by volume for TEA (Lipiodol Ultrafluide, Guerbet, France; Dehydrated alcohol [absolute alcohol], Martindale Pharmaceuticals, United Kingdom). The agents were delivered under fluoroscopic control to completely fill up the vasculature of all tumors. The maximum total volume of Lipiodol-ethanol mixture or cisplatin emulsion to be delivered in one treatment session was 60 mL.
45761975|NCT02495038|Drug|10% reduction of combination of Esmeron® and Nimbex®|Patients were randomly assigned to each group by opening of sealed allocation envelope. After collection of data, allocation number was matched with each group. The participants matched at Group S were administered with NMBAs reduced 10% of each ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. Each drug dosage was determined by allocation number. The syringe containing each study drug was conveyed to the performer of this study as the status of shielding the scale. The syringes of rocuronium and cisatracurium used each other syringe.
45761976|NCT02495038|Drug|20% reduction of combination of Esmeron® and Nimbex®|The participants matched at Group L were administered with NMBAs reduced 20% of each ED95.
45761977|NCT01834339|Biological|AlloDerm|
45761978|NCT01834339|Biological|EVPOME|
45445979|NCT03752229|Device|Haemolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45445980|NCT03752229|Device|Haemolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45761979|NCT01830985|Drug|VX-509|VX-509 dose may be increased every 8 weeks in a stepwise fashion from 100 to 150 mg and from 150 to 200 mg, as needed (determined by ongoing disease activity by CDAI)
45761980|NCT05450614|Other|Thrive app|The application has already been developed using the Flutter framework and provides users with the main CBT-based strategies to reduce depressive symptoms. In order to engage users, gamification strategies were also implemented. Some examples are 1) development and achievement: quiz on psychoeducation with rewards; 2) epic sense: like the messages in the psychoeducation session; 3) unpredictability: surprise quiz. An avatar will also be available for the participant, who will gain experience as he interacts with some of the application's functions. Finally, participants will receive weekly videos of less than 5 minutes with tips on how to use the app. There will be a total of 12 videos with psychoeducation tips and how to use the application.
45761981|NCT05450614|Behavioral|TCCG|In the literature, there is no single protocol for the treatment of depression through CBCT, therefore, a systematized protocol was developed for this study, aiming to structure and unify this intervention. Participants selected for the TCCG group will be randomly divided into 10 groups of 10 members each. The TCCG will be held through weekly meetings, exclusively online. Twelve sessions lasting 90 minutes each will be applied. The structuring of the sessions is based on the cognitive-behavioral model, starting with psychoeducation about the disorder and self-knowledge, starting with cognitive restructuring and relapse prevention. Homework will be part of the protocol. The sessions will be held on a digital platform (Google Meet) and access instructions will be provided to the participants of this group in the evaluation interview.
45761982|NCT00370006|Biological|Towne CMV vaccine|
45761983|NCT00422110|Drug|Seletracetam|
45761984|NCT01837615|Device|Photopill treatment|
45761985|NCT01837693|Procedure|Experimental: immediate colposcopy|A immediate colposcopy in this arm may detect potentially spontaneous regressive cervical lesions, so may determine an over diagnosis and over treatment, which the study want to estimate
45619940|NCT05009433|Behavioral|Standard health care with extended education on healthy lifestyle|Nonpregnant women will get standard health care according to the national law. They will attend educational sessions on a healthy lifestyle, physical activity and selected aspects of preparation to pregnancy and motherhood. Classes will be conducted online in real time, at least once every two weeks, for a period of 20 months.
45619941|NCT03326609|Drug|Ropivacaine|Perineural injection using a peripheral nerve block catheter and a constant infusion rate (10mL/h)
45619942|NCT03331913|Drug|Botulinum Toxin type A (intradermal / submucosal injection at pain area)|Comparison of two different treatment methods of Botulinum Toxin type A for the treatment of trigeminal neuralgia
45761986|NCT04993144|Device|continuous theta burst stimulation|stimulatory protocol
45445981|NCT03752229|Device|MediSafe Solo 29 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45619943|NCT03331913|Drug|Botulinum Toxin type A (intra-masseter injection on the ipsilateral of pain involved)|Comparison of two different treatment methods of Botulinum Toxin type A for the treatment of trigeminal neuralgia
45619944|NCT02490995|Other|Movie|Besides the anesthesist explanations the children will have a movie explanation.
45619945|NCT03090009|Drug|Flurbiprofen|100 mg twice a day for 14 days
45619946|NCT03090009|Drug|Placebo Oral Tablet|placebo group
45761987|NCT03837769|Device|Aktiia OBPM PulseWatch wrist device|The optical signals at the wrist are recorded non-invasively. The BP measurements are further determined from these optical signals and are compared to the reference BP readings.
45761988|NCT04956484|Biological|Belimumab|Belimumab 10 mg/kg
45761989|NCT04956484|Drug|Standard of care|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
45761990|NCT03217435|Procedure|Corneal epithelial allograft|A living-related donor's epithelial flap, equal in area to the recipient's diseased cornea bed, will be created using femtosecond laser technology. This corneal epithelial allograft is then ready for transplantation on the recipient's disease eye, following removal of the recipient's scarred and diseased epithelium.
45761991|NCT03217435|Procedure|Limbal conjunctival allograft|A 3- to 5- clock hour limbal-conjunctival allograft will be obtained from the living-related eye. This is then ready for transplantation on the recipient's disease eye following removal of the recipient's scarred and diseased epithelium.
45761992|NCT03217435|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
45761993|NCT03217435|Device|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
45761994|NCT05450458|Drug|KNEE JOINT INFILTRATION WITH HYALURONIC ACID WITH SORBITOL SYNOLIS VA|KNEE INFILTRATION WITH HYALURONIC ACID WITH SORBITOL IN SPORTSMEN
45445982|NCT03752229|Device|MediSafe Solo 23 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45761995|NCT01837771|Device|Diaphragmatic stimulation|
45761996|NCT05449990|Other|Participation in PFCC-IR|PFCC-IR with the critical care team is standard practice in ICU but it doesn't usually include family members. The intervention for this study is multidisciplinary patient care rounds that include one family member of the patient.
45761997|NCT05449912|Other|Collection of environmental exposure data|noise pollution air pollution proximity and accessibility to green spaces, blue spaces
45761998|NCT01720615|Drug|Propofol / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
45761999|NCT01720615|Drug|Sevoflurane / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
45762000|NCT01837927|Drug|NVA237|Once daily for 52 weeks
45911867|NCT05370352|Behavioral|SMS text messaging|SMS text messaging on generic information about the harms of smoking and the benefits of quitting for 3 months from randomisation.
45445983|NCT03752229|Device|ergoLance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45619947|NCT02492087|Drug|Topical tranexamic acid|Topical tranexamic acid 2g diluted with normal saline 0.9% to a volume of 120mls solution (Concentration 16.7mg/ml)
45619948|NCT02492087|Drug|Normal saline 0.9%|Sterile Normal saline 0.9% 120mls solution
45619949|NCT03093129|Drug|artesunate|"Artesunate (Trade name : Arinate®)~Artemisinins are a family of sesquiterpene trioxane anti-malarial agents derived from Sweet wormwood (Artemisia annua L) that have been used in traditional Chinese medicine for centuries to treat fevers. Artesunate, artemether and arteether are derivatives of artemisinin that are converted into their active metabolite dihydroartemisinin (DHA). Artesunate is approved for the treatment of uncomplicated and multidrug-resistant malaria and is on the WHO list of Essential Medicines (WHO., 2015)."
45619950|NCT03093129|Other|placebo|The matching placebo tablets contain lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica and a magnesium stearate blend.
45619951|NCT03326531|Other|Not applicable for this study|Not applicable for this study
45619952|NCT02491697|Biological|DC-CIK Immunotherapy|DC-CIK cells are used to treat advanced breast cancer with capecitabine.
45619953|NCT02491697|Drug|Capecitabine Monotherapy|All patients receive capecitabine monotherapy (2500 mg/m2 twice daily) for 2 weeks followed by a 1-week rest period.And the treatment is repeated every 3 weeks.
45762001|NCT01837927|Drug|Tiotropium Respimat®|Once daily for 52 weeks
45762002|NCT02503852|Device|Puregraft System|The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
45762003|NCT02503852|Device|Celution System|The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
45762004|NCT02503852|Procedure|Kerastem Therapy|The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
45762005|NCT02503852|Procedure|Liposuction|Tissue collection involving the micro-harvest of subcutaneous adipose tissue.
45619954|NCT03093675|Device|TELELAP ALF-X Robotic Surgical System|The surgical procedures will be performed using the innovative TELELAP ALF-X robotic system, equipped with multiple independent arms. Initial entry will be through a classic open in which the arm with the video camera will be inserted. The device has four independent arms (one for the video camera and three for surgical instruments). Patients will be in the lithotomy position, supported by Allen stirrups and under general anesthesia. The uterus will be manipulated with a multi-use uterine manipulator. After having induced a pneumoperitoneum, high-definition 3D-technology optics will be inserted. Three laparoscopic instruments will be used to complete the procedure. Standard techniques will be used.
45619955|NCT03326453|Device|Mini dental implant|titanium mini dental implant which diameter less than 3 mm
45619956|NCT03092973|Diagnostic Test|Ultrasound|
45619957|NCT03331757|Other|Glucose as reference food|Eleven subjects (male: 2, female: 9) consumed 50g glucose diluted in 300ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
45762006|NCT01838005|Behavioral|Conditional cash transfer|Eligible women randomized to the intervention group will receive the standard of care plus small and increasing cash payments, on the condition that they attend scheduled clinic visits on time (+/-5days), accept HIV services, deliver in a health facility, and at six weeks postpartum adhere to prescribed infant prophylactic drugs (cotrimoxazole, extended NVP) and provide blood sample for DNA PCR infant early HIV diagnosis.
45619958|NCT03331757|Other|Fir honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of fir honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
45762007|NCT01838083|Drug|Insulin glargine new formulation HOE901|Pharmaceutical form: solution Route of administration: subcutaneous
45762008|NCT05441644|Device|Bispectral index|A new placemewnt to monitor intraoperative BIS
45762009|NCT01838161|Behavioral|Part II|Parents will be exposed to an educational video intervention if they are enrolled in this intervention condition.
45762010|NCT01838161|Behavioral|Part III|•video educational
45762011|NCT01838161|Behavioral|Part I|Parental Interviews
45762012|NCT04943926|Other|Energy restricted diet|Nutritional complete formula diet followed by an energy restricted diet
45762013|NCT04943926|Other|Low carbohydrate high fat diet|Very low-carbohydrate high-fat ketogenic diet (VLCHF) diet followed by a low-carbohydrate high-fat diet (LCHF)
45762014|NCT01838239|Dietary Supplement|Fish Oil|Ocean Nutrition Fish Oil Capsules containing 1.9 g eicosapentaenoic acid (EPA) and 1.5 g docosahexaenoic acid (DHA)
45762015|NCT01720693|Procedure|Hypoperfusion of renal artery|The renal artery is occluded to 30% of it's baseline, prior to kidney tumour removal
45762016|NCT02504554|Drug|oral Vancomycin|an antibiotic
45762017|NCT02504554|Drug|MoviPrep|a bowel cleanse
45762018|NCT02504554|Drug|Prilosec|a stomach acid suppressan
45762019|NCT02504554|Biological|human fecal material; processed, frozen administered orally|human fecal material; processed, frozen, administered orally
45762020|NCT02504554|Biological|human fecal material; processed, frozen; administered orally and rectally|human fecal material; processed, frozen; administered orally and rectally
45762021|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
45911868|NCT05366413|Other|Early Referral|Directing a patient for a pain specialist consult earlier than standardly occurs.
45619959|NCT03331757|Other|Heather honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of heather honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
45619960|NCT03331757|Other|Citrus honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of citrus honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
45619961|NCT03331757|Other|Pine honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of pine honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
45762022|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
45762023|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
45762024|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
45762025|NCT03217123|Device|Deep Brain stimulation|Electrical stimulation at subcortical level
45762026|NCT04937452|Drug|Rotigotine 4Mg/24Hrs Patch|Rotigotine 4 mg/24Hrs administration for 24 weeks
45762027|NCT04937452|Drug|Rotigotine 6Mg/24Hrs Patch|Rotigotine 6 mg/24Hrs administration for 24 weeks
45911869|NCT05366413|Other|Pain Management Strategies|Specialized plan with procedures to ease pain
45762028|NCT04937452|Drug|Placebo|Placebo administration for 24 weeks
45762029|NCT03216811|Drug|nutraceutical|8-week administration of nutraceutical compound
45762030|NCT01720771|Dietary Supplement|probiotic tablet|Intake of one probiotic lozenge tablet per day
45762031|NCT01720771|Dietary Supplement|sugar pill|one tablet daily
45762032|NCT01838707|Drug|0.125% Bupivacaine HCL @ 4-5 ml/h|
45762033|NCT01838707|Drug|0.125% Bupivacaine HCL , Morphine sulphate @ 3 mg 3-5 ml/h|
45762034|NCT01838707|Drug|0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h|
45762035|NCT01720849|Drug|Fampyra|The will be given as per normal patient treatment plan
45762036|NCT04379479|Drug|Dialyzable Leukocyte Extract|Experimental Intervention. Dialyzable Leukocyte Extract
45762037|NCT04379479|Drug|Placebo oral|Placebo
45911870|NCT05358613|Behavioral|My Choices|"The My Choices program is an harm reduction program to modify substance use habits. It is based on the Miller & Rollnick Motivational interviewing as well as Deci and Ryan's Self-determination theory and Bandura's social learning theory.~It is presented as a guide, divided in 6 phases. In every phase, participants will find, in the guide, some auto-observation exercises about their alcohol use habits and other aspects about their quality of life, reflexions and information about alcohol. The participants are also invited to note the number of standard units of alcohol they use on every occasion."
45911871|NCT05357677|Drug|SR419|SR419 capsule
45762038|NCT00914485|Behavioral|Provider Communication Skills Training|"Consists of 4 separate 1-hour sessions, 1 per best act, in which physicians view 3 video-recorded performances of each act performed by trained actors of varied race/ethnicity."
45762039|NCT02506114|Biological|PROSTVAC V/F|PROSTVAC-V/F is a prostate-specific antigen(PSA)-based immunization strategy. It is intended to generate immune responses to prostate specific antigens and prostate cancer cells. It uses poxviral vectors to introduce modified PSA to the patient in an immunogenic manner to break self-tolerance, and thereby induce immune responses directed against prostate cancer cells.
45762040|NCT02506114|Drug|Ipilimumab|
45619962|NCT03331757|Other|Thyme honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of thyme honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
45619963|NCT03331757|Other|Chestnut honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of chestnut honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
45619964|NCT05017467|Drug|undefinedCentella Asiatica Extract|"All patients were asked about scar hypertrophy, scar tenderness, and pillar pain.~The scar assessment was performed using the Vancouver Scar Scale (VSS) at the one, three and 6 months after surgery.~Patients were asked to complete pre- and postoperative functional evaluations. The VAS score and QuickDASH test was used"
45619965|NCT05017389|Diagnostic Test|Griffiths development scales|Griffiths development scales Chinese Edition (gds-c) was used to evaluate the development levels of children up to 6 years and WISC for children more than 6 years.
45762041|NCT00915031|Device|UroCool|Hypothermia Endorectal Device
45762042|NCT00370084|Drug|Itopride|oral, three times daily
45762043|NCT00370084|Other|Placebo|oral, three times daily
45762044|NCT04923256|Behavioral|AAT-APP: A novel smart-phone approach-avoidance bias modification intervention|Participants allocated to the intervention group will be required to upload photos of drinks they wish to avoid, as well as activities they wish to engage in more, and be trained to avoid and approach by repeatedly 'swiping' images away from and towards themselves, respectively.
45762045|NCT04923256|Behavioral|Sham training control|Complete an AAT on a weekly basis for four weeks
45762046|NCT01725685|Drug|FF 400 mcg|FF will be available as 100 mcg strength administered as 4 inhalations from a DPI
45762047|NCT01725685|Drug|UMEC 500 mcg|UMEC will be available as 125 mcg strength administered as 4 inhalations from a DPI
45762048|NCT01725685|Drug|FF/UMEC 400/500 mcg|FF/UMEC will be available as 100/125 mcg strength administered as 4 inhalations from a DPI
45762049|NCT05449366|Drug|Intraperitoneal Paclitaxel Solution (Ml)|Weekly cycles of intraperitoneal paclitaxel monotherapy
45762050|NCT01721083|Procedure|Procedure: Z-track|Subject received immunization by z-track
45762051|NCT01721083|Procedure|Procedure: Bunch|Subject receives immunization by bunch method.
45911872|NCT05352347|Drug|NuSepin® 0.2 mg/kg|NuSepin® 0.2 mg/kg in 100mL NS bid
45762052|NCT05449054|Procedure|Anterior colporrhaphy|All patients will be operated by the vaginal route. They are prepared under strict aseptic conditions in the dorsal lithotomy position. The bladder is emptied preoperatively with a thin disposable catheter and antibiotic prophylaxis (cefazolin) is administered before incision. A vasoconstricting solution (combination of vasopression and NaCl) is administered and a vertical anterior vaginal incision is made from the apex to two centimeters short of the external urethral meatus using an electric cautery or a scalpel. The vaginal epithelium is grasped on both sides and the fibromuscular layer of the anterior vaginal wall is sharply dissected laterally to the inferior pubic ramus. The bladder is completely dissected from the apex and up to 4 to 6 cm from the pubic ramus. The anterior colporrhaphy is defined as a native tissue repair and rows of absorbable sutures (2/0 vicryl) are used.
45619966|NCT03326375|Radiation|SBRT|Maximum dose : 60Gray (Gy) Fraction : 2 to 5
45619967|NCT03331679|Behavioral|HIIT|2 Weeks of High Intensity Interval Training on a Cycle ergometer
45619968|NCT05024019|Drug|Nimotuzumab|The study group received nimotuzumab (200mg, weekly, for 6 weeks) in combination with radiotherapy.
45619969|NCT03326297|Other|Osteopathy manual therapy|Technique for the treatment of parasympathetic innervation, Techniques for the treatment of sympathetic innervation of the digestive system, Functional visceral techniques.
45619970|NCT03326297|Behavioral|Measures to support and education to the family|Pedagogical intervention in parents and health education
45762053|NCT04920994|Procedure|M-TAPA block|A high-frequency linear ultrasound probe will be used, probe will be placed on the costochondral angle in the sagittal plane and angled deeply to view the lower aspect of the chondrium in the midline, then using in-plane approach, a 22 Gauge Tuohy needle will be introduced into the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side.
45762054|NCT04920994|Procedure|SCTAP block|A high-frequency linear ultrasound probe will be placed obliquely on the upper abdominal wall, along the subcostal margin near the midline. After identifying the rectus abdominis muscle, the ultrasound probe will be gradually moved laterally along the subcostal margin until the transversus abdominis muscle will be identified lying posterior to the rectus muscle, then using in-plane approach, a 22 Gauge Tuohy needle will be introduced medially and directed towards the transversus abdominis plane until its tip reaches the fascia between the rectus abdominis and the transverse abdominis muscles on entering the neurofascial plane. The same procedure will be repeated on the contralateral side.
45762055|NCT04920994|Drug|Bupivacaine Hydrochloride|20 ml 0.25% bupivacaine will be injected after the negative aspiration test.
45762056|NCT03409939|Dietary Supplement|Aromatic Amino Acid Intake|Intakes will be randomly chosen from a list of 8 doses of aromatic amino acids. Each intake will will be repeated approximately 4 times.
45762057|NCT01721395|Dietary Supplement|Agave Syrup|
45762058|NCT02506660|Drug|Bupivacaine|
45762059|NCT02506660|Drug|Perineural dexamethasone|Dexamethasone in nerve block
45911873|NCT05352347|Drug|NuSepin® 0.4 mg/kg|NuSepin® 0.4 mg/kg in 100mL NS bid
45911874|NCT05352347|Drug|Placebo|Normal saline (NS) 100mL bid
45935064|NCT00041483|Drug|Anecortave Acetate 15 mg sterile suspension|
45935065|NCT00041483|Other|Photodynamic Therapy (PDT)|
45935066|NCT00215371|Drug|Formoterol Fumarate|
45935067|NCT00069537|Device|The GlucoWatch® G2™ Biographer (GW2B)|
45619971|NCT05017077|Device|DynaVision System|Telemonitoring for pediatric heart failure
45619972|NCT03089619|Drug|Human-Spongiosa|after tooth extraction, the dental alveolus is filled with the bone substitute material (Human-Spongiosa) and covered with a membrane (mucoderm®)
45619973|NCT03089619|Device|collacone®|after tooth extraction, the dental alveolus is filled with the bone substitute material (collacone®) and covered with a membrane (mucoderm®)
45619974|NCT03326219|Procedure|Clarivein|The Clarivein technique uses mechanical damage to the endothelium of the vein wall through a rotating tip of the catheter. At the same time a sclerosans is injected, causing occlusion of the vein. No heating is used in this technique .
45619975|NCT05008731|Drug|Botulinum toxin|100 units (0.5ml) in 1 injection
45619976|NCT05008731|Other|Placebo|Placebo 0.5 ml in 1 injection
45619977|NCT03331523|Drug|Calcipotriene/Betamethasone Dipropionate|Topical suspension 0.005%/0.064% (Glenmark Pharmaceuticals Ltd)
45619978|NCT03331523|Drug|Taclonex®|Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (LEO Pharma Inc.)
45619979|NCT03331523|Drug|Placebo|Placebo of Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd.)
45619980|NCT05023863|Drug|Alpha Lipoic Acid 600 MG Oral Tablets|Alpha Lipoic Acid (ALA) is a drug which has been used in treatment of diabetic neuropathy . It act through enhancing nitric oxide-mediated endothelium-dependent vasodilation, thus improving microcirculation in patients with diabetic polyneuropathy. It is considered a safe drug, generally with a daily dose of 200 to 2400 mg/day is considered tolerable without significant side effects. Only gastrointestinal tracts side effects like nausea, vomiting, dyspepsia and abdominal pain have been described in some clinical trials. Also FDA experts confirm its safety and efficacy in humans
45619981|NCT05023863|Other|Placebo tablets|placebo tablets of the same generic of active drug which contain all the same ingredients as active tablets except alpha lipoic acid
45619982|NCT05023863|Radiation|radiation or concurrent chemoradiation|radiation or concurrent radiotherapy plus platinum-based chemotherapy
45619983|NCT05463809|Drug|Continuous Gastrocnemius plane block with ropivacaine|After extubation, the patient was routinely monitored for his vital signs.The nerve block operation was performed by the same doctor: let the patient take the lateral decubitus position, use the ultrasonic high-frequency array probe under the popliteal socket to scan the sciatic nerve, move the probe down to find the tibial nerve and the common peroneal nerve, and then a single injection of 0.375% Ropivacaine 15milliliters was given into the common peroneal nerve, medial sural cutaneous nerve, and lateral sural cutaneous nerve. Then avoid common peroneal nerve, use the indwelling needle (16GA 3.25 IN), and put the catheter after saline expansion.
45619984|NCT05463809|Drug|oxycodone|The patient was revived and received intravenous oxycodone titration according to the numerical rating scale (NRS) score, and was treated with no background dose of oxycodone patient-controlled intravenous analgesia (PCIA) pump for analgesia.
45619985|NCT03331445|Drug|Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation|Inhaled Nitric Oxide 160ppm balance air
45619986|NCT05008497|Other|Questionnaire|Questionnaire
45619987|NCT05008029|Procedure|In situ immobilization|Immobilization with an above-elbow cast. A 2, 3, or 4-year orthopedic resident or pediatric orthopedic fellow supervised by a pediatric orthopedic surgeon will perform the procedure without reduction, sedation, or anesthesia. Analgesia will be administered with paracetamol at doses of 10-15 mg/kg/dose or tramadol 0.5-1mg/kg/dose. Supposing immobilization is not satisfactory, or the patient or family member does not authorize the procedure to be carried out by staff in training. In that case, the procedure will be supported or carried out by the pediatric orthopedic surgeon.
45619988|NCT05008029|Procedure|Reduction under general anesthesia|The participants will receive paracetamol at 10-15 mg/kg/dose or tramadol 0.5-1 mg/kg/dose for pain control until the time of surgery. Under general anesthesia, radius closed reduction, and above-elbow casting will be performed. After the reduction maneuvers, the radius reduction is satisfactory if the translation in the coronal and sagittal planes of less than 50% and angulation in the same planes is less than 10 °. If the radius does not remain reduced, it is unstable. Unstable fractures require percutaneous fixation with K-wires, a sugar tong splint immobilization, and a nerve block. The procedures will be carried out by a 2, 3, or 4-year orthopedic resident or pediatric orthopedic fellow under the supervision of a child orthopedist. Suppose reduction is not satisfactory or the patient or parent doesn´t authorize the procedure performed by personnel in training. In that case, the procedure will be supported or carried out by the pediatric orthopedic surgeon.
45619989|NCT03331367|Procedure|Blood draw|Patients in all four study arms will provide a blood sample to evaluate the immune response to prostate cancer treatment.
45619990|NCT03331367|Procedure|Urine sample|Patients in all four study arms will provide a urine sample to evaluate the immune response to prostate cancer treatment.
45619991|NCT05008263|Diagnostic Test|Liver elastography (2D-SWE)|All patients were referred for 2D-SWE liver elastography and liver liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy.
45619992|NCT05008263|Diagnostic Test|Liver scintigraphy with 99mTc-mebrofenin|All patients were referred for 2D-SWE liver elastography and liver liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy.
45619993|NCT03325907|Device|navigational template|The navigational template was created based on computed tomography data using three-dimensional technology.
45619994|NCT02490917|Device|ACT™ device|Implantation of the Adjustable Continence Therapy device ACT®
45619995|NCT02490917|Device|AMS 800 ™ device|Implantation of the artificial urinary sphincter AMS 800 ™
45619996|NCT03325127|Drug|radium Ra 223 dichloride (Xofigo, BAY88-8223)|Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injections
45762060|NCT02506660|Drug|Intravenous dexamethasone|
45762061|NCT02506660|Drug|Intravenous saline|
45762062|NCT02506660|Drug|Perineural saline|Saline in nerve block
45762063|NCT04377529|Behavioral|Local Champion|Local champions (physiotherapists) will co-develop the champion training support based on a comprehensive behavioural analysis, previous implementation work and evidence-based theory. The study team will provide this training and support to the champions, who will then provide additional support to their peers participating in the study.
45762064|NCT04377607|Other|File scanning|RBC, HGB, HCT, MCH, MCV, MCHC, WBC values will be noted in the hemogram test performed at the time of initial admission
45762065|NCT01725997|Procedure|hook plate|Surgery with hook plate followed by physiotherapy
45762066|NCT01725997|Other|Physiotherapy|Patients will be following a program specific for AC joint dislocations
45911875|NCT05337293|Behavioral|COPE-HF Partnership Intervention|Participants were trained to use a 4-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems experienced in the home over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention was to move HF patients toward a positive problem orientation and use of rational problem-solving strategies that support greater HF self-care and reduce depression. The COPE-HF Partnership Intervention consisted of 1 home visit and 7 follow-up telehealth sessions led by a registered nurse interventionist.
45619997|NCT03325127|Drug|Zytiga|Abiraterone 1000 mg per day orally
45619998|NCT03325127|Drug|Xtandi|Enzalutamide 160 mg per day orally
45619999|NCT03325049|Behavioral|The health-promoting conversations|The health-promoting conversations
45620000|NCT03325049|Other|Usual Care|Usual Care
45620001|NCT03088761|Device|cuffed tracheal tube|the changes in cuff pressure will be determined using a cuff manometer
45911876|NCT05337293|Other|Attention|Participants in the attention group received a sham intervention that consisted of scheduled telephone calls consistent with the timing of that received by the intervention group. During these calls, basic information was gathered on key areas of heart failure self-care management and the frequency of healthcare usage. No intervention or education was provided.
45620002|NCT03092583|Other|Blood sample|35 mL, 7 tubes
45620003|NCT05016063|Drug|Fludarabine|recommendation: 30mg/m2 (D-5~D-3),determined by tumor burden at baseline.
45620004|NCT05016063|Drug|Cytoxan|recommendation: 300-500mg/m2 (D-5~D-3),determined by tumor burden at baseline.
45935068|NCT00069537|Device|The Continuous Glucose Monitoring System (CGMS™)|
46069162|NCT03974828|Device|Anesthesia Control Tower Notification|Real-time data will be monitored through the AlertWatch system as well as the electronic health record. Risk forecasts of adverse events (30 day mortality, acute kidney injury, postoperative delirium, respiratory failure), PACU length of stay, and hospital length of stay will be generated by a machine learning algorithm. Additional outputs identifying the most important predictors and their effects will be combined with risk forecasts to form a report card.
45620005|NCT05016063|Biological|Dual CD33-CLL1 CAR-T cells|CD33-CLL1 CAR-T infusion (starting at dose level 1 [DL1]: 0.5 x 106 transduced CAR-T cells/kg) on Day 0.
45620006|NCT03325751|Diagnostic Test|Visual field testing|Standard Automated Perimetry using a perimeter is one of the most commonly used techniques for measuring perceived visual ability of a subject. For a given eye, it provides quantitative measurements of visual function represented as a 2D spatial visual field map. It is of great clinical importance for diagnosing and monitoring glaucoma and detecting neurological conditions.
45620007|NCT03092739|Diagnostic Test|PD-L1 Immunocytochemistry (ICC)|PD-L1 expression in the cytological specimens will be assessed using different antibodies.
45620008|NCT03092739|Diagnostic Test|PD-L1 Immunohistochemistry (IHC)|PD-L1 expression in the histological specimens will be assessed using different antibodies.
45762067|NCT02509624|Drug|Selonsertib|6 mg tablets administered orally in fed state
45620009|NCT03324971|Other|Medications review|"Medications review. Elimination of all unnecessary prescription to cut down the number of medications to the least possible number.~This is in line with the best practice guidelines."
45620010|NCT03079245|Other|Education Plus (E+)|Education Plus was an intervention developed by the study team based on the Center for Disease Control (CDC) 12 Step Campaign to Prevent Antimicrobial Resistance in Healthcare Settings. The study team provided Education Plus quarterly to prescribers at the three sites (NICU A, B, C) randomized to this intervention. Examples of topics presented were an overview of antimicrobial stewardship principles, epidemiology of healthcare-associated infections (HAIs), prevention of surgical site infections, antimicrobial susceptibility testing, and pharmacokinetic principles. Educational formats included didactic lectures, participation via the audience response system, case vignettes, and panel discussions.
45762068|NCT01726075|Drug|COLIRIOBCN070660|One drop per eye twice a day during 24 months
45762069|NCT01726075|Drug|Placebo|One drop per eye twice a day during 24 months
45762070|NCT01726075|Drug|Brimonidine|One drop per eye twice a day during 24 months
45762071|NCT01726153|Behavioral|Condom-HIM|The tailored on-line Condom-HIM intervention is composed of a single session involving activities to increase individuals self-efficacy and intention to use condoms.
45762072|NCT04338334|Other|Manual drainage & arm therapeutic exercise|See arm/group descriptions.
45620011|NCT03079245|Other|Clinical Decision Support|The CDS tool was an intervention developed in consultation with neonatologists and pediatric infectious disease physicians from NICU A and B. Algorithms for empiric and targeted antimicrobial therapy for common pathogens and common clinical scenarios using local antimicrobial susceptibility patterns were developed. The CDS tool also provided additional components to facilitate antimicrobial prescribing, e.g., patient weight, day of life, previous culture results, antimicrobial orders, and selected laboratory results including white blood cell and platelet count, C-reactive protein, creatinine, and therapeutic drug levels. NICUs A and B also received E+
45620012|NCT03079245|Other|Prescriber Audit and Feedback|The prescriber audit and feedback (PAF) intervention was developed by the study team which held focus groups with neonatologists at NICU A (the site randomized to this intervention) to determine the feedback parameters and feedback format as previously described. Neonatologists at NICU A were provided aggregated prescribing data bimonthly that described inappropriate use as described below and prolonged therapy (>7 days) for culture-negative late onset sepsis. NICU A also received CDS and E+.
45620013|NCT03078933|Device|Standard of Care|Standard of Care arm which includes wound care, dressings and debridement.
45762073|NCT04338334|Other|Cohesive bandaging & arm therapeutic exercise|See arm/group descriptions.
45762074|NCT01721629|Procedure|Sudden wean of nasal CPAP|
45762075|NCT01721629|Procedure|Gradual wean of nasal CPAP|
45620014|NCT03078933|Device|Nitric Oxide Therapy 2x week 6 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound twice a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
45620015|NCT03078933|Device|Nitric Oxide Therapy 2x week 12 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound twice a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
45620016|NCT03078933|Device|Nitric Oxide Therapy 4x week 6 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound four times a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
45620017|NCT03078933|Device|Nitric Oxide Therapy 4x week 12 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound four times a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
45620018|NCT03092193|Drug|Naproxen|20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen (500mg) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
45620019|NCT03092193|Drug|Naproxen-esomeprazole|20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen-esomeprazole, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen-esomeprazole (500mg+20mg) (after one month of the first collection) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
45620020|NCT05015907|Drug|Ropivacaine|The nerve involved in the operation of Hickman catheter, chemoport, and Perm cath is the supraclavicular nerve. Therefore, it is judged that if only this nerve is selectively blocked, pain control can be effectively performed with a small amount of local anesthetic, and relatively few side effects occur.
45620021|NCT05015907|Other|Control (without intervention)|No intervention
45620022|NCT03092349|Device|Vector optimisation|Evaluation of hemodynamically best LV Stimulation vector and device programming according to measurements
45620023|NCT05015595|Drug|Memantine Oral Tablet|Thirty-two-week double-blind up-titration treatment period (from T0 to T4): patients will be randomly assigned to one of two arms (Memantine or placebo) in a 1:1 ratio and will receive a daily administration of Memantine/placebo up to 20mg/day. Eight-week double-blind down-titration treatment period (from T4 to T5): At T4, the dose of Memantine/placebo will be reduced at 10mg/day due to safety reasons before the end of treatment (T5).
45620024|NCT05015595|Drug|Placebo|Thirty-two-week double-blind up-titration treatment period (from T0 to T4): patients will be randomly assigned to one of two arms (Memantine or placebo) in a 1:1 ratio and will receive a daily administration of Memantine/placebo up to 20mg/day. Eight-week double-blind down-titration treatment period (from T4 to T5): At T4, the dose of Memantine/placebo will be reduced at 10mg/day due to safety reasons before the end of treatment (T5).
45620025|NCT05023785|Behavioral|Cardio-oncology Rehabilitation (CORE)|Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
45620026|NCT05023785|Behavioral|PAI Group (PAI)|Participants in the PAI group will be asked to download the same PAI Health application as CORE participants and be challenged to meet and maintain a weekly PAI Score ≥100 throughout the 24-month follow-up period.
45620027|NCT05023785|Behavioral|Exercise Guidelines for Cancer Survivors (ExGL)|Participants in the ExGL group will be asked to download and use the Map My Walk (Under Armour, Baltimore) application and will be challenged to meet and maintain the updated weekly physical activity guidelines for cancer survivors (i.e. 90-150 minutes of moderate to vigorous-intensity physical activity).
45620028|NCT05007795|Diagnostic Test|Targeted sequencing using the GenoScreen Deeplex assay|Targeted sequencing to be performed on DNA extracted directly from clinical sputum samples using an on-demand strategy to generate a drug resistant profile. Clinicians treating the patients will have access to this and prescribe 5 or more effective drugs to the patients within 14 days of diagnosis.
45620029|NCT05023239|Other|UG-SZM Group|The patients will be receive Ultrasound-Guided Suprazygomatic Maxillary Nerve Blocks 10 mL of a local anesthetic mixture composed of 0.25% plain bupivacaine .
45620030|NCT05015517|Procedure|Erector spinae plain block|Patients will be placed in the lateral position.Ultrasonography will be performed by an experienced anesthetist.The 4th lumbar vertebral level will be determined using the conventional method (imaginary line between two iliac crests). The low frequency convex probe (2-5MHz) will then be placed at the mid-vertebral line in the sagittal plane. It will be shifted from the midline, 3.5-4 cm lateral to the side of the surgery to visualize the erector spinae muscle and transverse process. Using the out-plane technique a 22G/80-mm block needle will be advanced until it reaches the transverse process. After negative aspiration, 0.5-1 ml of the prepared local anaesthetic solution (20 ml bupivacaine 0.5%, 10 ml lidocaine 2%) and 10 ml normal saline will be administered for hydrodissection to confirm correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurred when injecting local anesthesia
45620031|NCT05015517|Procedure|Fascia Iliaca block|"Patients will be placed in supine position. Ultrasonography will be performed by an experienced anesthetist using ultrasound device equipped with a low frequency (2-5 MHz) convex probe and an echogenic 21 G/ 10 cm needle will be used.~The probe will be placed in the inguinal crease. Scan will be started laterally from the femoral artery and nerve in the inguinal crease to identify the Sartorius muscle. The muscle will then be traced until its origin at the anterior superior iliac spine is identified and the shadow of the bony of iliac crest & iliacus muscle will be seen. Injection will be performed at the plane deep to the fascia iliaca and above the lateral part of the iliacus muscle. After negative aspiration, the prepared local anaesthetic solution (15 ml bupivacaine 0.5%, 15 ml normal saline) will be injected incrementally, aspirating every 5 ml."
45762076|NCT05448898|Drug|Traditional Chinese Medicine CU Xiu Tang|Oral Traditional Chinese Medicine CU Xiu Tang once a day and repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months
45935069|NCT00215410|Drug|Formoterol Fumarate|
45935070|NCT00215449|Drug|Formoterol Fumarate|
45935071|NCT00215527|Drug|laronidase|0.58 mg/ml solution for intravenous injection, dose 1.74 mg intrathecally once per month for four injections.
45935072|NCT00073359|Behavioral|Cognitive Behavioral Therapy|
45762077|NCT05448898|Other|Olfactory Training|repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months
45762078|NCT00369616|Biological|CYT002-NicQb|
45762079|NCT00369694|Drug|Terlipressin|2 mg Terlipressin stat, then 1 mg q6h for total of 72 hours
45762080|NCT00369694|Drug|Terlipressin & then Dummy|2 mg Terlipressin stat then 1 mg q6 hours for 24 hours, then a Dummy of Terlipressin q6 hours for the next 48 hours.
45620032|NCT05015829|Diagnostic Test|Dobutamine Stress Echocardiography|Change in echocardiographic 2D and doppler measurements during infusion with Dobutamine 5 µg/kg/min till max dosage of 20 µg/kg/min.
45762081|NCT01721707|Drug|Latanoprost+Brinzolamide combination|1 drop in each eye, 1x/day, at 9PM
45620033|NCT05015673|Drug|SEP363856|
45620034|NCT05015673|Drug|Placebo|
45620035|NCT05015361|Drug|Remimazolam Tosilate|Treatment group A: Remimazolam Tosilate; high dose Treatment group B: Remimazolam Tosilate; low dose
45620036|NCT05015361|Drug|Propofol Injection.|Treatment group C: Propofol Injection.
45911877|NCT05333211|Drug|Ortho-R/PRP|Ortho-R® is a freeze-dried drug/biologic combination product containing a chitosan component and trehalose, a disaccharide that acts as a lyoprotectant during the lyophilization process and calcium chloride, which acts as a PRP coagulation agent.
45620037|NCT01375075|Drug|LY2484595|Administered orally
46069163|NCT03973580|Behavioral|Attentional Bias Modification (ABM) task|Participants will be presented with a fixation cross (500ms) followed by a pair of identity-matched, angry-neutral faces (1000ms). The pair presentation is replaced by a single arrow-probe (1000ms) in the position of the neural face. Inter-trial intervals (ITI) are 500ms. Participants indicate arrow direction (left or right) by pressing one of two buttons as quickly as possible. By responding to the probe that always replaces the neutral face, participants learn to attend to the non-threat cues and away from threat cues. There are 120 trials of angry-neutral faces in total, and 40 other catch trials with neutral-neutral faces.
46069164|NCT03973580|Behavioral|Control task|The control task is identical with the ABM task, except that in the 120 angry-neutral trials, the arrow-probe replaces the angry face and the neutral face with equal probabilities (60 trials each).
45620038|NCT01375075|Drug|Placebo|Administered orally
45620039|NCT01375075|Drug|Atorvastatin|Administered orally
45620040|NCT05022381|Procedure|Radiofrequency thermal coagulation of articular branches of femoral and obturator nerves|Patients are operated under sedation in the operating room. C-arm fluoroscopy device is used for imaging purposes for radiofrequency thermocoagulation process. In order to prevent vascular injury, the needle is advanced under the guidance of ultrasonography. There are target points determined in fluoroscopy for the femoral nerve and the obturatory nerve. Before the thermocoagulation procedure, local anesthetic and steroid are injected into each of the target points. Patients who do not have any complications after the procedure and who are mobilized are discharged in the 2nd hour.
45762082|NCT01721707|Drug|Latanoprost|1 drop in each eye, 1x/day, at 9PM
45762083|NCT03409783|Device|ENSO Device|An active ENSO device that delivers neuromodulation therapy.
45762084|NCT03409783|Device|Sham Device|Sham Device
45911878|NCT05331222|Drug|JT-1|JT-1 is a physiological salt with recently detected pharmacological properties that warrant testing for its therapeutic potential in chronic rhinitis and chronic sinusitis.
45911879|NCT05317442|Drug|Fespixon Cream|"Name: Fespixon Cream~Dosage form: Topical cream, 15 g ointment per tube~Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~Dose(s): Apply 1 cc per 5 cm^2 ulcer size (not exceeding 2 mm in thickness)~Dosing schedule: Apply once a day~Duration: up to 16 weeks"
45911880|NCT05305391|Other|Dietary intervention|The arising gastrointestinal symptoms and inflammation markers from consumption of milk + lactase capsule / placebo.
46069165|NCT03972306|Drug|Ocrelizumab|Administered by subcutaneous Injection
45620041|NCT00706433|Drug|aminolevulinic acid HCL (ALA)|Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA). Up to 4 treatments will be given at 3 week intervals.
45762085|NCT03409705|Dietary Supplement|Skate Skin group|2,000 mg of low-molecular collagen peptide was orally administered per day for 12 weeks.
45762086|NCT03409705|Dietary Supplement|Control group|2,000 mg of starch was orally administered per day for 12 weeks.
45762087|NCT05448586|Drug|Opioid|Use of balanced anesthesia including opioids during anesthesia for gynecologic cancer surgery
45762088|NCT01726465|Drug|Methylprednisolone|Methylprednisolone is a glucocorticoid, which is an adrenocortical steroid. The chemical name for methylprednisolone is pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6α,11β)-and the molecular weight is 374.48. It is an analog of naturally occurring glucocorticoid (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Methylprednisolone is used for their potent anti-inflammatory effects in disorders of many organ systems, it modify the body's immune responses to diverse stimuli. The usual dosage of medication varies in relation to pathology for which is prescribed: normally varies from about 40-60 mg per day up to very high doses of 30 mg/kg bolus as used in spinal cord injury.
45762089|NCT01726465|Drug|N-acetylcysteine|Acetylcysteine is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. Chemically, it is N-acetyl-L-cysteine. The compound is a white crystalline powder which melts at 104°-110°C and has a very slight odor. Acetylcysteine may form cysteine, disulfides, and conjugates in vivo (N, N'-diacetylcysteine, N-acetylcysteine- cysteine, N-acetylcysteine-glutathione, N-acetylcysteine-protein, etc). No metabolites were identified. Acetylcysteine likely protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive metabolite.
45762090|NCT02509936|Behavioral|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
45935073|NCT00215566|Drug|DDP733|
46069166|NCT03972306|Drug|Ocrelizumab|Administered by Intravenous (IV) Injection
45620042|NCT00706433|Other|Vehicle (VEH)|Levulan Kerastick containing vehicle ingredients only (VEH). Up to 4 treatments will be given at 3 week intervals.
46069167|NCT03972306|Drug|rHuPH20|Administered in a 2-mL glass vial as a sterile, single-use, injectable liquid to be manually mixed with SC ocrelizumab
45762091|NCT02509936|Dietary Supplement|Standard-of-care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder dietary supplement (Chispitas)
45762092|NCT01720303|Drug|repaglinide|2 mg (tablets) before each main meal
45445984|NCT03752229|Device|ergoLance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45620043|NCT05022303|Drug|Larazotide Acetate|AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.
45762093|NCT01720303|Drug|isophane human insulin|Injection s.c. (under the skin) at bedtime
45762094|NCT01720303|Drug|insulin|Injection s.c. (under the skin) twice daily
45620044|NCT05022303|Drug|Placebo|Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
45762095|NCT03216889|Behavioral|Cognitive Behavioral Therapy for Insomnia|Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will be one-on-one or in a group.
45620045|NCT05021445|Combination Product|plates based exercises|12 elderly participants receive intervention protocol of Plates- based exercises program total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
45620046|NCT05021445|Combination Product|conventional exercises|12 elderly participants,intervention protocol of Conventional balance training exercises,total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
45620047|NCT05015205|Other|Muscle Energy Technique|Post isometric relaxation technique MET was applied in two muscle groups; Lumbar Extensors (Erector Spinae) and Hip Flexors (Iliopsoas). The muscle was positioned in position and patient was asked to apply 20% force isometrically and hold the isometric contractions for 7-10 seconds. Then the patient was asked to relax for about seconds. On exhalation, therapist takes muscle to new restriction barrier. Hold this position for 30 seconds at the end barrier as an end-stretch with 3 repetitions.
45620048|NCT05015205|Other|Postural Correction Exercises|: Postural Correction Exercises was applied to one group. Exercises performed included stretching and strengthening exercises. Hip flexors and back extensors were stretched while hip extensors and abdominals were strengthened. Seated hip flexion used to stretch back extensors while lunge position used to stretch hip flexors. The abdominals were strengthened by using curl up exercises while hip extensors were strengthened by resisted contractions in prone lying.
45620049|NCT03087825|Procedure|preoxygenation without inward leak|breathing a 100% inspired oxygen gas flow during 3 to 10 minutes
45620050|NCT03087825|Procedure|preoxygenation with inward leak|breathing a 100% inspired oxygen gas flow during 3 to 10 minutes with an inward air leak made possible through a specific calibrated piece on the inspiratory branch
45762096|NCT03216889|Behavioral|Control|Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will involve stretching and thinking games.
45762097|NCT02733042|Drug|Durvalumab|Administered as an IV infusion (250 mL) over approximately 1 hour in duration
45445985|NCT03752229|Device|ergoLance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45762098|NCT02733042|Drug|Lenalidomide|Administered orally
45762099|NCT02733042|Drug|Rituximab|Administered by intravenous infusion
45762100|NCT02733042|Drug|Ibrutinib|Administered orally
45762101|NCT02733042|Drug|Bendamustine|Administered as a 30-minute intravenous infusion
45762102|NCT00912301|Drug|Sodium chenodeoxycholate (NaCDC)|500 or 1000 milligrams NaCDC per day each for a period of 4 days
45762103|NCT00912301|Other|Placebo|Placebo capsules with identical appearance to the study drug were prepared by the Mayo Clinic research pharmacy.
45762104|NCT04872478|Drug|MRX-2843|MRX-2843 capsules
45762105|NCT04341766|Other|No special intervention|No special intervention : Ultrasound data will be collected
45762106|NCT01726543|Procedure|Canaloplasty and phacoemulsification|As soon as the two scleral flaps (deep and superficial -similar to deep sclerectomy) are dissected, the phacoemulsification is performed and a artificial lense is implanted. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and is advanced 12 clock hours within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. When the catheterisation of the canal is done, the distal tip is exposed and a 10-0 propylene suture is tied to the distal tip. Then the microcatheter is withdrawn and suture is pulled into the canal. As it appears at the other ostium of canal the microcatheter it separated from the suture. A loop is created, encircling the inner wall of Schlemm canal. Then suture loop is tightened to distend the trabecular meshwork inward, placing the tissues in tension, the locking nods are added. The superficial flap is sutured watertight to prevent bleb formation.
45445986|NCT03752229|Device|Medlance (light blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45762107|NCT01726543|Procedure|Non-penetrating deep sclerectomy and phacoemulsification|A fornix-based conjunctival ﬂap is dissected superiorly, and the sclera is exposed. A 5 x 5 mm scleral ﬂap is dissected anteriorly into clear cornea using a No. 69 Beaver blade. Then the phacoemulsification procedure is performed and a artificial lense is implanted. Afterwards second deep scleral ﬂap is dissected and excised leaving only a thin layer of deep sclera over the choroid. Anteriorly, the dissection is made down to remove Schlemm's canal and juxtacanalicular trabeculum. Excision of the corneal stroma is performed more anteriorly down to Descemet's membrane. This allows aqueous humor to percolate through the thin trabecular-Descemet's membrane. The superficial scleral ﬂap is then closed with two 10-0 monofilament nylon sutures.The conjunctiva is sutured down over the limbus with one interrupted 10-0 monofilament nylon suture at each corner.
45620051|NCT03240055|Drug|spinal anesthesia|The spinal puncture was performed with a 25 G Sprotte needle at the L3-4 or L2-3 interspinous space. Hyperbaric bupivacaine 0.5% (3 ml) was administered into the spinal space. Hyperbaric bupivacaine is obtained through the addition of glucose 10% (1ml) to bupivacaine 0.75% (2ml). Cerebrospinal fluid aspiration (0.1 ml) was done to confirm correct needle placement before and after spinal drug administration. Whereafter the patient was turned rapidly to the supine position, sensory anesthesia height was evaluated bilaterally using a pinprick test with the sharp tip of a safety pin every 1 min until 15 min after the initiation of the spinal anesthesia, bed tilting (upwards, horizontal, or downwards) was performed until bilateral sensory anesthesia level was confirmed to remain at the T4-T6 level
45620052|NCT03240055|Other|etomidate|receive etomidate only
45620053|NCT03087201|Drug|nabiximols|"starting dose (1 puff): 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD), maximum dose (12 puffs): 32.4 mg THC/30 mg CBD, no target dose is defined~Duration of treatment: 13 weeks"
45762108|NCT03409627|Biological|INXN-4001|Retrograde coronary sinus infusion of triple effector plasmid (INXN-4001)
45762109|NCT04862416|Biological|R0.6C transmission blocking vaccine|Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168.
45620054|NCT03087201|Drug|placebo|analogous to experimental intervention
45620055|NCT03230539|Drug|Ulipristal Acetate IUS delivering Cu and 5μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
45762110|NCT01721863|Other|Exercise training|Exercise group will undergo progressively aerobic exercise training with 40-85% maximal oxygen consumption for 40 minutes, 3 sessions per week for 12 weeks.
45762111|NCT04850638|Drug|SHR4640 tablets and furosemide tablets|SHR4640 tablets and furosemide tablets
45762112|NCT01721941|Drug|Phase I Dose level -1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
45620056|NCT03230539|Drug|Ulipristal Acetate IUS delivering Cu and 20μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
45620057|NCT03230539|Drug|Ulipristal Acetate IUS delivering Cu and 40μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
45620058|NCT03086811|Behavioral|Mother Infant Feeding Interaction very early training|"weekly training meetings on 4 topics:~What - proper nutrition and supplements for solid feeding phase (dietitian); What - the meaning of feeding to mother and infant (social worker).~Who - feeding skills - knowledge and actual practices~From anxiety to serenity - knowledge concerning growth patterns and common physical and emotional issues troubling parents of infants 4-12 months old.~Prevention of obesity and emotional eating - practical advise and tips."
45762113|NCT01721941|Drug|Phase I dose level 1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
45935074|NCT00215605|Drug|XL184|Flavored liquid suspension or gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing or intermittent schedule (daily dosing followed by dosing holiday in cycles)
45620059|NCT03239977|Behavioral|Online Social Intelligence Training|The SII consists of short 5-10 minute sessions organized into 7 modules designed to raise awareness of human nature and social relationships. The approach is based on evidence that SII is best advanced through interventions that modify key social cognitions regarding social engagement and enhance efficacy expectations regarding performance in social situations.
45620060|NCT03239977|Behavioral|Attention Control (AC)|A placebo condition delivered online to both custodial grandmothers and their adolescent grandchild which presents health-related information only.
45620061|NCT05007327|Other|Exposure to pollen and air pollution|For all subjects of the cohort, we will follow exposure to pollen and air pollution.
45620062|NCT04486729|Other|High PEEP with end inspiratory pause|Applying a PEEP value 10 cmH2O higher than the lower inflection point of the pressure-volume curve of the respiratory system with end inspiratory pause addition in volumen control ventilation
45620063|NCT04486729|Other|Low PEEP - FiO2 high|Applying a PEEP value equal to the lower inflection point of the pressure-volume curve of the respiratory system with a FiO2 necessary to achieve a SpO2 96-98%
45620064|NCT04486729|Other|High PEEP without end inspiratory pause|Applying a PEEP value 10 cmH2O higher than the lower inflection point of the pressure-volume curve of the respiratory system without end inspiratory pause addition in volumen control ventilation
45762114|NCT01721941|Drug|Phase I Dose level 2|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
45762115|NCT01721941|Drug|Phase I Dose level 3|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
45762116|NCT05448508|Device|Automatic lancet|An automatic lancet, which can reach a depth of 2.4 mm-3 mm, was used for safe piercing in babies.
45762117|NCT05448430|Device|Theta burst stimulation|a new paradigm of high frequency repetitive transcranial magnetic stimulation
45762118|NCT03409549|Radiation|Fluciclovine PET/CT|Fluorine-18 Fluciclovine PET/CT scan of the brain
45762119|NCT01726387|Behavioral|Psychosocial Counseling|Depending on their condition, counseling assistants support patients in self-management support, enhancing self-efficacy, reducing psychological symptoms
45762120|NCT01726387|Behavioral|Usual Care|Depending on the conditions, patients get usual care of their general practitioner
45762121|NCT01722175|Procedure|ALPPS surgery|
45762122|NCT01722175|Procedure|PVO surgery|
45762123|NCT02511730|Device|FFDM Plus DBT|FujiFilm Aspire Cristalle System
45762124|NCT02511730|Device|FFDM|FujiFilm Aspire Cristalle System
45935075|NCT00411853|Drug|Fermented Wheat germ extract|Fermented Wheat Germ powder, given orally, per os, 17 gram daily
45935076|NCT00411931|Drug|Multihance|0.5M administered as a single injection
45935077|NCT00411970|Device|20- and 23 gauge vitreoretinal surgery systems|
45762125|NCT05602896|Other|Sepsis education|The education program has been reviewed and approved by BJH Center for Practice Excellence
45620065|NCT04486729|Other|Low PEEP - FiO2 low|Applying a PEEP value equal to the lower inflection point of the pressure-volume curve of the respiratory system with a FiO2 necessary to achieve a SpO2 88-92%
45620066|NCT03078699|Radiation|stereotactic body radiation therapy|A total radiation dose of 35-50 Gy was delivered to the 50% isodose line covering at least 95% of the PTV (3.5-5Gy/fraction), and a total radiation dose of 49-70 Gy was delivered to the 70% isodose line covering at least 95% of GTV (4.9-7 Gy/fraction).
45620067|NCT05007171|Device|Very low calorie diet|During 3 weeks in hospital patients will eat prepared very low calorie diet composed of 50-60% complex carbohydrates with low carbo-glycemic index, 20-25% proteins and 25-30% fat
45620068|NCT03228589|Dietary Supplement|probiotic strain|8 weeks of treatment with probiotic strain
45620069|NCT03228589|Dietary Supplement|Placebo|8 weeks of treatment
45620070|NCT04463043|Device|SelfBACK app|The selfBACK is an evidence-based and data-driven decision support system (DSS) to support self-management of low back and neck pain delivered via a smartphone app. The selfBACK app provides individually tailored self-management plans to participants on a weekly basis by matching the participant's health information with targeted educational messages, physical activity advices and exercise recommendations via the DSS.
45620071|NCT04463043|Other|e-Help webpage|The e-Help is an evidence-based web-based resource to support self-management of low back and neck pain. The e-Help webpage provides evidence-based self-management content equivalent to the selfBACK including educational messages, physical activity and exercise recommendations. Instructions on how to compose exercise programs will be given to participants, however no tailored self-management support will be offered in this solution.
45620072|NCT04463043|Other|Usual care|Usual care refers to seeking care or receiving treatments or help as usual.
45620073|NCT02452489|Device|acupuncture|Patients will be acupuncture with Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
45620074|NCT02452489|Device|acupuncture|Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment, follow-up after 4 weeks.
45762126|NCT04308096|Drug|KRN23|The starting dose of KRN23 will be the dose used for the last administration in the preceding studies. The dose may be modified subsequently in accordance with the criteria for dose and dose adjustment.
45762127|NCT02512276|Behavioral|Telepharmacist intervention|The intervention consists of a brief telephonic consultation with a clinical pharmacist using behavioral interviewing techniques tailored to patient's level of health activation and progress reports of medication-taking and disease control. Based on the barriers identified during the initial telephone consultation, patients will be offered more intensive support including reminder and motivational text-messages, video visits and pillboxes.
45762128|NCT00915499|Device|VPAP Adapt SV|Comparison of ASV and CPAP modes
45620075|NCT02452489|Device|acupuncture|Patients in Control group,will be acupuncture with at the junction of deltoid and biceps,needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
45762129|NCT05326776|Drug|Pitocin|At each session, 4mcg/2ml oxytocin or 2ml isotonic saline (0.9% sodium chloride; placebo control) will be injected into the middle of the dorsal forearm. Sessions will be separated by at least 48 hours to ensure drug clearance.
45762130|NCT01726777|Dietary Supplement|Control|Normal cheddar cheese
45911881|NCT05301439|Procedure|Restoration with Resin|"Prophylaxis with prophylactic paste and rubber cup. Relative isolation (lip retractor, cotton roll and saliva sucker). Selective removal of carious tissue with dentin spoons at the dentin-enamel junction.~Cleaning the cavity with water. Application of the Universal Adhesive System (Shofu). Excess removal. Application of a new layer of adhesive system. Light rubbing and excess removal. Photoactivation - 20s. Insert Bulk Fill Resin (Shofu) in 4mm increments. Photoactivation for 20. Preservation. Clinical and radiographic control at 1, 3, 6 and 12 months."
45762131|NCT01726777|Dietary Supplement|Vitamin D|Vitamin D3 supplemented cheddar cheese
45762132|NCT04833088|Other|Focus group discussions|Focus group discussions will be organized to investigate the needs and requirements of the participants in terms of three pre-defined user scenarios.
45762133|NCT03409471|Device|Flocked Swab|At the colposcopy clinic, vaginal self-sample will be collected with the Flocked Swab (Noble Bioscience, Inc., Korea).
45762134|NCT03409471|Device|Cervical Brush|Physician collected cervical sample will be collected also at the colposcopy center with the Cervical Brush (Noble Bioscience, Inc., Korea).
45762135|NCT03409471|Diagnostic Test|HPV assay|The hrHPV assay used, will be the Roche Cobas® 4800 HPV test, Anyplex™ II HPV HR detection kit and Realtime HPV HR-S Detection kit.
45762136|NCT05532306|Drug|Ribavirin 400 mg film coated tablet (1*400mg)|an immediate release film-coated tablet containing 400 mg Ribavirin
45762137|NCT05532306|Drug|Copegus® 200 mg film coated tablet (2*200mg)|an immediate release film-coated tablet containing 200 mg Ribavirin
45762138|NCT01722253|Procedure|Electroacupuncture|Electrical stimulation device with frequency 2 Hz and 'frequency scanning mode'
45935078|NCT00412009|Procedure|Comprehensive package of activities|
45935079|NCT00215722|Drug|Cetuximab|
45935080|NCT00215800|Drug|Ampligen|
45762139|NCT05320614|Other|Web-Based Education|Web-Based Education Information about the operation that the child will undergo; animation films about the hospital, the operating room and the medical equipment to be used; training with presentation including methods of coping with anxiety, fear and pain, postoperative wound care, possible complications in nutrition and nursing care; educational games Education with Therapeutic Play Method Training with the therapeutic game method for 30-45 minutes in the game room in the service one day before the surgery
45762140|NCT05320614|Other|Routine maintenance Training|Explaining the routine care given to the child and parent in the control group by the pediatric surgery nurse in the service.
45762141|NCT02512900|Drug|MEDI9929, 140 mg|On Day 1, two MEDI9929 subcutaneous injection of 70 mg each were given into the anterior aspect of one thigh immediately followed by the second injection into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants of 12 to 17 years of age.
45762142|NCT01726855|Procedure|vascularized finger dorsal fascial flap|
45762143|NCT05602038|Procedure|Quadratus laborum block|quadratus lumborum block will be performed using ultrasound machine (Sonosite Portable Ultrasound System, SonoSite, Bothell, Washington, USA). A 5-8 MHZ curved probe will be used with the patient positioned on the lateral side
45762144|NCT05602038|Drug|Intrathecal morphine|Intrathecal morphine 100mcg will be added to bupivacaine 0.5% 15mg and fentanyl 20 µg
45911882|NCT05301439|Procedure|Hall Technique|"Prophylaxis with prophylactic paste and rubber cup. Relative isolation (lip retractor, cotton roll and saliva sucker). Clinical evaluation through inspection of the texture of the remaining dentin with a rounded exploratory probe.~Cleaning the cavity with water. Take drying. Proof of the steel crown. Relative isolation. Filling the inner part of the crown with bioactive resin cement or glass ionomer cement for cementation.~Clinical and radiographic control at 1, 3, 6 and 12 months."
45445987|NCT03752229|Device|Medlance (blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45445988|NCT03752229|Device|Medlance (dark blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45445989|NCT03752229|Device|Medlance (yellow)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45620076|NCT04466007|Drug|High dose allogeneic mesenchymal stromal cells|Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly
45445990|NCT03752229|Device|Medlance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45620077|NCT04466007|Drug|Low dose allogeneic mesenchymal stromal cells|Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly
45620078|NCT04466007|Drug|Placebos|0,9% physiological saline
45620079|NCT03230305|Other|Ethnographic interview|"If a patient is invited to participate in the a clinical trial, inclusion's status (included or/not) will be sought.~If included: an ethnographic interview will be held with patient (or his representant) who agreed to participate in the clinical trial, his family caregivers, his physician(s) in charge of him and the trial and, and clinical studies technician responsible for management.~If not included, an ethnographic interview has offered to him, his caregivers, his physician(s) in charge of him and the trial and clinical studies technician responsible for management. In parallel, the reasons for non-inclusion are collected from a pre-established epidemiological questionnaire.~If a patient is not invited to participate,an ethnographic interview will be held with his physician(s) in charge of him and the clinical trial and with clinical studies technician responsible for management.The reasons for non-invitation will be collected from an epidemiological survey multiple choices."
45620080|NCT02452411|Behavioral|Cognitive Behavioral Treatment approach supported by virtual reality and positive psychology strategies.|The CBT program consists of 6 weekly sessions (and 2 additional ones depending on the patient's needs) with the following main therapeutic components: educational component, exposure/processing of the stressful event with VR (EMMA's World) and relapse prevention. EMMA's World is an open and flexible VR system that uses symbols (e.g., 3D-objects, pictures, sounds) to reflect and evoke the negative emotions associated to the stressful event. Also, several strategies from Positive Psychology (e.g., My best virtues or strengths exercise) and others based on Neimeyer's (2000) suggestions for pathological grief (e.g., projection letter to the future) are also included in the protocol.
45653338|NCT05728177|Combination Product|Inhalation Aromatherapy|"Aromatherapy is safe, well prepared mixture used in the study that prepared by professor of pharmacology, faculty of pharmacy by mixing lavender essential oil and lavender hydrolate~Patients' medical charts in the outpatient clinic were reviewed to identify those who meet the inclusion criteria. Patients who meet the predetermined inclusion criteria were recruited in the study using simple randomization technique using computer-generated sequence technique to pick up these patients. After simple sampling and dividing patients into two groups of study and control. Patients from the study and control groups were interviewed individually by the researcher to apply the study tools as a pretest. Aromatherapy intervention was carried out for patients in the study group while those in the control group were left without any intervention to undergo the usual outpatient routine care."
45762145|NCT05602038|Drug|intrathecal bupivacaine|intrathecal bupivacaine 0.5% 15mg and fentanyl
45762146|NCT01722409|Drug|sevoflurane and 0.5 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
45762147|NCT01722409|Drug|sevoflurane and 1 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
45762148|NCT04817488|Other|Prehospital emergency ultrasound with tele-supervision|Prehospital emergency ultrasound with tele-supervision in patients with acute dyspnoea
45762149|NCT04817488|Other|Prehospital emergency ultrasound without tele-supervision|Prehospital emergency ultrasound without tele-supervision in patients with acute dyspnoea
45620081|NCT03086031|Behavioral|Program -based vocational rehabilitation intervention|"The VR intervention lasts for a total of 6-9 months with first six different modules (3-month) that are individually planned, and second a work placement program (approximately 3-6 months). Each of the different modules follows a comprehensive standard operating procedures (SOP's). The six modules will be grouped into (a) individual therapies which includes neuropsychological sessions (10-hours), balance between work and everyday life (20-hours), and job matching (10-hours), (b) grouped-based therapies which includes psycho education (18-hours), mindfulness (15-hours), and physiotherapy training (15-hours), (c) an manualized family intervention program (8 sessions of 90 minutes), and an individual caregiver coaching (12-hours), (d) a work placement program including work practice (3-6 month), supported employment by the rehabilitation team (30-hours), and the development of a post rehabilitation plan (4-hours)."
45620082|NCT03086031|Behavioral|Conventional vocational rehabilitation (controls)|Treatment as usual delivered by the municipalities.
46069168|NCT03967834|Other|Patient with Soft Tissue Sarcoma|"Tumor specimens will be collected for the study at diagnosis.~A blood sample will be collected in all included patients at baseline, after the completion of the treatment (for patients included with a localized disease) or at the time of the first tumoral evaluation (for patients included with a metastatic disease), and at the time of progression.~Patient's data (clinical, biological and disease data) will also be collected at baseline visit and then at each time point planned in the center for clinical benefit assessment (i.e. every 2 or 3 months) until progression or for a maximum duration of 5 years."
45620083|NCT03228511|Device|endoscope|It is a Prospective descriptive hospital based clinical study to determine the value of introduction of endoscope after microscopic excision of cerebello-pontine angle lesions
46069169|NCT03967704|Procedure|Life quality evaluation|As part of this research, 2 additional consultations at 12 months and 24 months will be carried out by one of the rheumatologists in the department. At the consultation 12 months after his inclusion, the patient will have a clinical examination, a quality of life questionnaire to complete and additional images (x-rays). For the 24-month consultation, the patient will have a clinical examination, a quality of life questionnaire to complete and the patient may have an additional X-ray of the spine if there is height loss > 2 cm and/or pain.
46069170|NCT03953677|Drug|Dexmedetomidine 100 Mcg/mL Intravenous Solution|Continuous infusion of dexmedetomidine at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
46069171|NCT03953677|Drug|5% glucose Infusion solution|Continuous infusion of placebo (5% glucose) at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
45620084|NCT03085329|Device|Seattle-PAP|Seattle-PAP is a modified bubble CPAP device that has been given 510(k) clearance by the US FDA (K131502, October 11, 2013) and is thus recognized as substantially equivalent to other approved devices on the market. Results of a recently completed study in infants indicate that Bn-CPAP is associated with lower effort to breathe by spontaneously breathing premature infants.
45620085|NCT03085329|Device|Conventional bubble nasal CPAP|Infants enrolled in the study and randomized to this arm will be given respiratory support by bubble nasal CPAP using the Fisher & Paykel bubbler device, which is the standard of care at Nationwide Children's.
45620086|NCT03239743|Device|Virtual Reality|Child will wear and interact with virtual reality headset while waiting for surgery.
45620087|NCT03239743|Drug|Midazolam|Child will receive Midazolam to help with pre-operative anxiety prior to surgery
45620088|NCT05021523|Other|Hot ambient conditions exposures|Participants rest or exercise for 40min to 1h daily in hot ambient conditions
45620089|NCT05021523|Other|Immobilization|Participants are wearing a walking boot (with crutches) for 2 weeks
46069172|NCT03937713|Drug|eszopiclone|Eszopiclone is a nonbenzodiazepine benzodiazepine receptor agonists, effective for both sleep onset insomnia and sleep maintenance insomnia
45620090|NCT03239821|Device|VIPUN Balloon Catheter 0.1 deflated|deflation balloon
45620091|NCT03239821|Drug|Codeine Phosphate|58.8 mg codeïne phosphate
45620092|NCT03239821|Drug|Placebo|Sirupus Simplex
45762150|NCT04307238|Diagnostic Test|PLR|PLR measurements will be performed within the first 2 postoperative hours.
45762151|NCT04307238|Diagnostic Test|Alertness testing|Preoperative (baseline) and every 30 minutes postoperative computer based alertness testing will be performed.
45620093|NCT03239821|Device|VIPUN Balloon Catheter 0.1 inflated|VIPUN Balloon Catheter 0.1 inflated
45620094|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
45620095|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
45620096|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
45620097|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
45620098|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
45762152|NCT04307238|Procedure|Propofol anesthesia|Maintenance of anesthesia will be performed using propofol.
45762153|NCT04307238|Procedure|Sevoflurane anesthesia|Maintenance of anesthesia will be performed using sevoflurane.
45762154|NCT01726933|Drug|LAS41008|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
45911883|NCT05301439|Procedure|Conventional Steel Crown|"Prophylaxis;~Relative isolation;~The preparation of the tooth will be performed conventionally with reduction of the occlusal, mesial and distal surface of 1 to 1.5 mm and selective removal of the decayed tissue;~Cleaning the cavity with water;~Slight drying;~Trial of steel crown;~Relative isolation;~Filling the inner part of the crown with bioactive resin cement or glass ionomer cement for cementation.~Clinical and radiographic control at 1, 3, 6 and 12 months."
45762155|NCT01726933|Drug|LASW1835|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
45762156|NCT01726933|Drug|Placebo|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
45620099|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
45620100|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
45620101|NCT03230383|Drug|Placebo|Matching Placebo for PF-06865571 for each cohort.
45620102|NCT05021367|Drug|TQB3823 tablets|TQB3823 is a small molecule Poly ADP-ribose Polymerase (PARP) inhibitor that can inhibit the enzyme activity of PARP1/2, making it difficult to repair the DNA in cancer cells, leading to cell death and delaying or blocking tumor development.
45620103|NCT03092115|Device|HIV medication adherence app|A medication adherence mobile application for HIV+ youth. It is a theory-driven, patient-centered, mobile phone-based intervention targeting medication adherence and engagement in care among HIV+ youth with features including, but not limited to: custom avatar, medication reminders, calendar tracking of medication adherence, and anonymous chat function for social support.
45620104|NCT03230461|Behavioral|Compression depth|
45620105|NCT05463653|Device|Experimental|A digital pad developed to help, support and monitor the adherence of patients to rehabilitation excercices post surgery
45620106|NCT03078621|Biological|Stem Cell Therapy|Intravenous and Intrathecal transplantation of purified autologous bone marrow-derived stem cells and mesenchymal stem cells.
45620107|NCT03230227|Drug|Bupivacaine magnesium|bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
45620108|NCT03230227|Drug|Bupivacaine only|bupivacaine 0.125% infusion in the presternum , for 48 hours
45620109|NCT04493879|Other|Bioptron Light Therapy (BLT)|BLT for 30 days 10 minutes every day. The treatment points displayed were: one point in the right jugal mucosa, one point in the left jugal mucosa, one point in the lower lip 's inner mucosa, analgesics, anti-inflammatory treatment, and antimicrobial treatment for any new mouth infections)
45620110|NCT04485169|Procedure|Therapeutic Plasma Exchange|a. 1-1.5 plasma volume exchange, 2/3rd plasma should be replacing with FFP to avoid coagulopathy, adequate dieresis to prevent volume overload, 1-5 sessions in total, 1 session daily
45620111|NCT04493723|Procedure|Surgery|To collect tumour tissue
45620112|NCT04493723|Procedure|Venepuncture|To collect blood samples
45620113|NCT03078465|Drug|Ticagrelor|Daily administration of ticagrelor 180mg for 12 months
45620114|NCT03078465|Drug|Clopidogrel|Daily administration of clopidogrel 150mg for 12 months
45620115|NCT03325595|Drug|AEF0117|0.2, 0.6, 2, or 6mg of AEF0117
45620116|NCT03325595|Drug|Placebo|Matching capsule placebo
45620117|NCT03228199|Other|Intervention group|Will immediately receive a free pair of presbyopic glasses through the Clear Vision Workplace program. These glasses will correct the worker's vision at their usual working distance, and will not correct astigmatism.
45620118|NCT03228199|Other|Control Group|Will be deferred to receive spectacles as above, after the 12 week evaluation period.
45620119|NCT03324815|Drug|Morphine|Pain Treatment
45620120|NCT03324815|Drug|Methadone|Pain Treatment
45620121|NCT05006469|Drug|Bendamustine|Bendamustine 70-90mg/m2, d1, d2 Liposome Adriamycin 15-20mg/m2, d1 or Adriamycin 10mg d1-d4 Dexamethasone 40mg qw po. (20mg, >70 years old) There is a course of treatment every 28 days, and a total of 6 courses are completed.
45620122|NCT04485247|Procedure|Transumbilical Laparoscopic-Assisted Appendectomy|appendectomy performed extracorporeally through umbilical port
45620123|NCT04485247|Procedure|3-port laparoscopic appendectomy|appendectomy performed intracorporeally with 3-port
45620124|NCT03324737|Device|Interactive Smartphone App|"There are six main components to the APP.~Goal Setting: personalizes diet, activity, and weight loss goals for patients based on their starting point.~Food choices and recommendations: App has an automated and immediate recommendation of foods if the choice selected from food database is not optimal. It has a calorie and nutrients tracker to enable patients to track their food intake.~Activity and steps tracker: App has a pedometer to count physical activity and steps to enable patients to track their progress towards goals.~Interactive video lessons: App has video lessons pushed weekly to the patient according to her needs. The videos encompass aspects of diet, lifestyle and behavior management.~Healthcare Professionals Support: App has a chat channel to enable interaction between participants and healthcare professionals."
45620125|NCT03084783|Drug|Dexamethasone|Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
45620126|NCT02452645|Behavioral|Healthy Food and Physical Activity Environments|Tailored written materials, videos, telephone counseling, active toys
45620127|NCT02452645|Behavioral|Comparison Group|Written materials, videos, books, and telephone counseling.
45620128|NCT03228355|Drug|Levcromakalim|To investigate the role of Levcromakalim on cerebral hemodynamic in migraine patients
45620129|NCT03228355|Drug|Saline|To investigate the role of levcromakalim compared with saline cerebral hemodynamic in migraine patients.
45911884|NCT05297695|Drug|Triple therapy for H. pylori infection|Triple therapy for H. pylori infection (Esomeprazole, Amoxicillin, and Clarithromycin) for two weeks
45935081|NCT00215839|Drug|Peginterferon a-2a plus Ribavirin|
45620130|NCT05232617|Other|Rheumatological rehabilitation training|Online rheumatological rehabilitation training is planned. Online rheumatological rehabilitation training will be video-based via the Edpuzzle application and interactively via the zoom application. Online trainings are planned for 15-person intern physiotherapy student groups 4 days a week, 2 hours a day, for 4 weeks on a case-based basis. With the Edpuzzle application, videos will be prepared for 10 different rheumatological diseases. In each video, a case with rheumatic disease will be introduced, evaluations made from a physiotherapy perspective and their results will be included. Before the lesson, students will watch the video defined for them every day from the application called Edpuzzle, answer the questions and plan a disease-specific assessment and treatment program according to the directions in the video. Then, the assessment and treatment programs prepared by a group of 15 people through the zoom platform will be discussed during the lesson.
45620131|NCT05021289|Behavioral|guided imagery|guided imagery
45620132|NCT03228277|Drug|Olmutinib|Patients to be provided with Olmutinib 800mg (2 x 400 mg tablets) once daily (QD)
45935082|NCT00215878|Drug|D-serine (~2g /day)|Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine ~2g /day), in the second arm adjuvant treatment with placebo (~2g /day)
45762157|NCT04707586|Other|Cold Application|Created by the researcher; A bandage with 3 pieces of 13x10 cm cold gel and a cold gel container in which they are placed will be used, which can be adjusted according to the head circumference of the patient between 60-80 cm in length. The ability of the cold gel cups of the bandage to be moved on the bandage will allow comfortable cold application to the patient's bilateral frontotemporal and occipital areas at the same time. After waiting for 20 minutes in the freezer part of the refrigerator, the temperature and temperature of the gels applied and the cold application area before and after each application will be measured and recorded. An Infrared Non-Contact Food Thermometer will be used for temperature measurement of cold gel packs, and an Infrared Non-Contact Thermometer device will be used for temperature measurement of the cold application area.
45762158|NCT01722565|Procedure|laparoscopic abdominoperineal resection with a lightweight mesh (polypropylene and poliglecaprone 25)|
45762159|NCT04735198|Procedure|Primary tumor surgery|Large bowel resection.
45620133|NCT03324659|Behavioral|Exercise and Meditation|The Exercise and Meditation group will listen to recorded meditations (15 minutes) that are based on mindfulness. They will then walk on a treadmill for 30 minutes at a moderate intensity. The intervention is completed five days per week for four weeks.
45620134|NCT03324659|Behavioral|Control|The Control group will listen to a recorded audio book for 15 minutes, They will then sit quietly for 30 minutes. The intervention is completed five days per week for four weeks.
45762160|NCT04735198|Procedure|Primary tumor surgery (bowel resection) combined with prophylactic cholecystectomy|Large bowel resection combined and cholecystectomy.
45762161|NCT04305366|Other|Tissue collection|Blood draw, Fine Needle Aspiration, Saliva Swab, Tumor/tissue sample
45762162|NCT01727401|Drug|Fondaparinux|Fondaparinux once daily sc injections at a dose of 2.5 mg if renal clearance of creatinine above 50 ml/min or Fondaparinux once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
45762163|NCT05532228|Procedure|Adenotonsillectomy|adenotonsillectomy by cold dissection
45762164|NCT02513212|Device|Potassium Oxalate|Professionally applied liquid
45445991|NCT03752229|Device|Medlance (red)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45445992|NCT03752229|Device|Unistik 3 Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45762165|NCT02513212|Drug|Stannous fluoride paste|SnF2 Paste
45762166|NCT02513212|Device|Manual toothbrush|Marketed manual toothbrush
45762167|NCT02513212|Device|Power toothbrush|Marketed power toothbrush
45762168|NCT03409081|Drug|gilteritinib|oral
45762169|NCT05595720|Device|hight intenisty laser|7W(LAZR-207)/15W(LAZR-215&115)HIGH POWER LASER THERAPYUNIT WITH 2 WAVELENGTHMODES,COMBINATION(810+980 NM) AND SINGLE(1064 NM)
45762170|NCT05591508|Dietary Supplement|Ketogenic Diet|Ketogenic diet will be in the form of artificial powder which can be diluted and given through NG tube. It will be started at a ratio of 1:1 followed by daily increment (2:1,3:1 and 4:1) till a urine ketone of 2+ is seen
45762171|NCT05318898|Other|Vegetal protein|Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from vegetal protein sources
45762172|NCT05318898|Other|Animal protein|Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from animal protein sources.
45935083|NCT04722406|Other|This item is not applicable to our observational study.|This item is not applicable to our observational study.
46069173|NCT03937713|Behavioral|Brief behavioral therapy for insomnia|BBTI is based on the core principles that are fundamental to other empirically-supported behavioral treatments of insomnia delivered over four consecutive weeks.
45620135|NCT03228121|Procedure|Treatment Then Placebo|Cohort A will receive stem cells/PRP infusion during round one then placebo of normal saline infusion during round two.
45620136|NCT03228121|Procedure|Placebo Then Treatment|Cohort B will receive placebo of normal saline infusion during round one then stem cells/PRP infusion during round two.
45620137|NCT03325361|Other|Tube drain insertion|A de-Pezzer catheter was placed transanally after the creation of the anastomosis, secured to the buttocks, and connected to a urine bag to allow monitoring the amount and the color of the drainage. The catheter was removed on the 3rd day postoperative if the volume collected was insignificant.
45762173|NCT02513446|Drug|BI 1026706|Single dose of BI 1026706 on Day 1
45762174|NCT02513446|Drug|Itraconazole|7 days of itraconazole treatment combined with a single dose of BI 1026706 on the fourth day
45762175|NCT02527044|Procedure|Fractional Flow Reserve (FFR)|An FFR will be performed pre-operative to the CABG procedure
45762176|NCT00363844|Drug|Sitagliptin phosphate|50 mg QD or 100 mg QD for 12 months
45762177|NCT04703062|Behavioral|Experimental group 1|It is planned to do exercises for 50 minutes a day, 2 days a week during 8 weeks with physiotherapist. It will be planned individually according to the needs of the patients. Exercises will progress in the following weeks by changing the number of repetitions, the amount of resistance and the amount of time. Counseling about physical activity and the suggested sports activity will be provided. In daily living activities ergonomics and joint protection principles will be taught. Informing Family.
45762178|NCT04703062|Behavioral|Experimental group 2|Counseling about physical activity and the suggested sports activity will be provided.Patients make aerobic and strengthening exercises by himself based on physiotherapist's suggestions. Informing Family about; Why are the exercises necessary To what extent the families should be protective The harmful effects of inactivity There will be information about the resting-activity cycle when there is bleeding.
45935084|NCT00215917|Drug|D-serine 2100 mg daily|
45935085|NCT00215956|Drug|topotecan|Preoperative treatment: oral topotecan 5 days per week for up to 5 weeks
45935086|NCT00215956|Procedure|radiation|Preoperative radiation
45935087|NCT00215956|Procedure|surgery|surgery to remove tumor 4 to 8 weeks following completion of preoperative treatment
45935088|NCT00215995|Drug|Cisplatin|As outlined in Detailed Description
45762179|NCT04687800|Drug|Dextenza 0.4mg intracanalicular Insert|intracanalicular insert delivery system
45762180|NCT04687800|Drug|Durezol 0.05% Ophthalmic Emulsion|Standard therapy, topical steroid drop
45620138|NCT05014425|Procedure|pancreaticoduodenectomy|
45762181|NCT00864383|Drug|Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin|"Moxifloxacin 400 mg Rifampicin < 45 kg 450 mg > 45 kg 600 mg Isoniazid 300 mg Pyrazinamide < 40 kg 25 mg/kg rounded to nearest 500 mg* 40-55 kg 1000 mg > 55 kg - 75 kg 1500 mg > 75 kg 2000 mg Ethambutol < 40 kg 15 mg/kg rounded to nearest 100 mg 40-55 kg 800 mg > 55 kg - 75 kg 1200 mg > 75 kg 1600 mg *For pyrazinamide dosing in patients < 40 kg, 1000 mg used instead of 500 mg~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm."
45620139|NCT03223051|Other|Motor assessment|An occupational therapist install the patient sitting in front of the test board and tell him the instructions
45620140|NCT05014269|Procedure|Phacoemulsification in eyes with corneal opacities|senile cataract extraction using lens emulsification under the slit illuimnation of the surgical microscope
45620141|NCT03324503|Drug|Glucocorticoid (prednisone or prednisolone)|≥ 30 mg/day prednisone or prednisolone taken orally as per local clinical practice of sarcoidosis initial induction therapy
45620142|NCT03229993|Diagnostic Test|OCT|OCT is used to assess whether PCI will be of benefit to the treatment of the borderline coronary artery lesions
45935089|NCT00215995|Drug|Irinotecan|As outlined in Detailed Description
45620143|NCT05006547|Other|Electromyograph Biofeedback training of the peroneal muscle|The exercise will be performed with the subject sitting in front of a computer monitor, on an elevated chair, and his feet will be in the air. The examiner will ask the subject to perform a maximum contraction of the paronal muscles, in an open kinematic chain. After reference, the subject will begin a five-minute practice. The practice will be divided into rounds of: eight seconds of muscle work and 15 seconds rest.
45620144|NCT03229681|Behavioral|Baduanjin exercise|"Participants in this groups received routine rehabilitation training and Baduanjin exercise. During the period of rehabilitation, physicians provides a wide range of medical, nutrition and mental health counseling, as well as rational drug-treatment. Baduanjin exercise protocol according to the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Due to the low-activity tolerance of CHF patients, we performed with a refined version of Baduanjin. Each Baduanjin exercise session lasts 45 minutes and continues twice per week for 12 weeks."
45620145|NCT03229681|Behavioral|Routine rehabilitation group|Participants in this qroup only received the routine rehabilitation training. During the period of rehabilitation, physicians provides a wide range of medical, nutrition and mental health counseling, as well as rational drug-treatment. They should also come to rehabilitation center for physical exercise,45 minutes per day，twice per week, lasts 12 weeks.
45620146|NCT05020431|Other|Biological measuring of collagen fragments biomarker during orthodontic tooth movement|Biological measure the levels of type I collagen fragments ICTP and CTX levels in the GCF and saliva during initial leveling and alignment in adolescent patients treated with fixed orthodontic appliances.
45620147|NCT03222739|Device|Ultrasound|An industry standard ultrasound will be fitted with a self-tracking probe to track along the spine. The ultrasound will be performed three (3) times along the spine at initial consultation for scoliosis.
45762182|NCT04701268|Other|Device: Hemiverse|Implantation of the hemiverse shoulder prothesis
45762183|NCT05532072|Drug|Rapamycin|Rapamycin plus Methylprednisolone
45762184|NCT05532072|Drug|Methylprednisolone|Methylprednisolone Alone
45935090|NCT00215995|Drug|ZD 1839|As outlined in Detailed Description
45445993|NCT03752229|Device|Unistik 3 Comfort|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45935091|NCT00216034|Drug|Tegafur-gimeracil-oteracil potassium (TS-1)|From 4-8 weeks after surgery to 27-31 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 21 day cycle. Number of Cycles: 8 From 28-32 weeks after surgery to 53-57 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 28 day cycle. Number of Cycles: 7
45620148|NCT03325283|Device|ProtEmbo Cerebral Protection System|A catheter-based embolic deflection device will be positioned in the arch of the aorta to prevent debris liberated during the TAVR procedure from entering the three major vessels of the aortic arch.
45620149|NCT05006157|Device|ViaOne device|ViaOne device is designed to allow percutaneous subxiphoid pericardial access utilizing a proprietary mechanism of entry into the pericardial sac.
45620150|NCT03222661|Diagnostic Test|Refraction|Refractive error measurement
45620151|NCT03324347|Procedure|Therapydog|Presence of a therapydog during a clinical examination in a dental clinic
45620152|NCT05006001|Drug|Colchicine and NSAID|Colchicine and nonsteroidal anti-inflammatory drug combination therapy
45620153|NCT03227965|Biological|Immune cells population assesment|T lymphocytes population description through blood, urine and faeces samples
45762185|NCT03239626|Radiation|POHIM-RT|postoperative adjuvant IMRT with hypofractionation (2.5 Gy/fraction, 16 fractions, once a day)
45762186|NCT03216772|Device|Olympus PK Morcellator in PneumoLiner|Laparoscopic Supracervical Hysterectomy (LSH) or Total Laparoscopic Hysterectomy (TLH) using Olympus PK Morcellator in PneumoLiner containment device
45762187|NCT02514070|Drug|EPA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
45762188|NCT02514070|Drug|DHA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
45762189|NCT00864539|Dietary Supplement|fortified milk|daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 ml package for 10 weeks
45762190|NCT00864539|Dietary Supplement|plain milk|daily intake of 200 ml plain milk
45762191|NCT00864539|Dietary Supplement|fortified orange juice|daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium/250 ml package
45935092|NCT00216034|Drug|Krestin (PSK)|From 4-8 weeks after surgery to 53-57 weeks after surgery, 3 g/day, PO every day
45935093|NCT00216073|Drug|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
45935094|NCT00216073|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
45935095|NCT00216073|Drug|Trastuzumab|Trastuzumab 6mg/kg IV, day 1. 8 mg/kg loading dose given in cycle 1 for patients without previous trastuzumab therapy only.
45620154|NCT04493489|Drug|Propranolol Hydrochloride|Trial group: BCG + propranolol: after TURBT administered for 2 consecutive years, oral propranolol, starting dose 10mg, tid, then 20mg, tid,lastly increased to 40mg, bid. After the last BCG infusion, propranolol was gradually reduced, in the order of 20 mg, tid to 10 mg, tid.
45620155|NCT04493489|Drug|BCG|Control group: BCG vaccine: After TURBT, the first year: once a week for 6 times, from the 7th week, once every 2 weeks, and 3 times. Administer once a month starting from the 13th week and continue to give 10 times. Second and third years: once a month, 12 times a year.
45620156|NCT05005923|Procedure|Non-surgically performed scaling and root planing|Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.
45620157|NCT03227809|Behavioral|Handbook condition|Parents of first-year university students receive parent handbook summer before start of university. Handbook contains suggestions for activities and conversations parents can conduct with students.
45620158|NCT03227809|Behavioral|Handbook plus condition|Parents of first-year university students receive parent handbook summer before start of university. Handbook contains suggestions for activities and conversations parents can conduct with students. Parent also receive text messages throughout the year.
45620159|NCT02490683|Dietary Supplement|Luna Rich X|
45620160|NCT02490683|Dietary Supplement|Placebo|Starch pill/or powder manufactured to mimic Luna Rich X and Reliv Now
45620161|NCT02490683|Dietary Supplement|Reliv Now|
45620162|NCT05014113|Device|DELTA-ST cup in combination with MINIMA stem|Advance articular destruction generated by primary degenerative or post-traumatic arthrosis or reumatoid arthritis; fracture or avascular necrosis; congenital or acquired deformity.
45620163|NCT03324269|Device|NOL|"After tracheal intubation, a Tetanus test (60 mAmp,100 Hz) is done during 30 sec at remifentanil level Ce of 4 ng/ml (with starting NOL value <10). According to the NOL response: increment of 1 ng/ml of RemiCe if NOL gradient ≥ 20 / decrement of 1 ng/ml of remifentanil Ce NOL gradient < 10. During the testing period propofol Ce is fixed at the concentration associated with BIS levels between 45-60 during the first calibration.~Upon the incision and 2 minutes after skin incision, Propofol TCI (Schnider model) is adjusted to BIS between 45-60 and remifentanil Ce at which the variation of NOL index variation is less than10 units at a NOL starting value <10. MAP (mean arterial pressure), HR (heart rhythm) and NIBP (non-invasive blood pressure) will be measured.~The formula derived from the calibration phase will be tested during a single tetanic stimulation at remifentanil Ce of 4 ng/ml during the validation phase."
45620164|NCT03228043|Drug|Apatinib|Apatinib combine with CAPEOX adjuvant chemotherapy for resectable colorectal
45620165|NCT03228043|Drug|CAPEOX|CAPEOX adjuvant chemotherapy for resectable colorectal
45620166|NCT03119857|Drug|Antiandrogen|
45620167|NCT03119857|Drug|Antiandrogen+docetaxel|"Antiandrogen (bicalutamide 150 mg x 1) + docetaxel (Taxotere®) 75mg/m2 (max 2.0m2) i.v. in 60 minutes on day 1. One cycle is 21 days. Docetaxel will be given for up to 8-10 cycles or until unacceptable toxicity or consent withdrawal whichever comes first.~Antiemetic therapy may be used if necessary."
45620168|NCT04434339|Procedure|erector spinae block|A volume of 20 ml for each side of erector spinae plane with 0.25% plain bupivacaine
45620169|NCT04434339|Procedure|transversus abdominis block|A volume of 20 ml for each side of transversus abdominis plane with 0.25% plain bupivacaine
45620170|NCT03120169|Other|treadmill endurance training|n = 15 patients with COPD. Walking intensity will be initially set at 80 percent of 6-minute Walking test Speed with progressive increase in Duration and intensity.
45620171|NCT03120169|Other|cycling endurance training|n=15 patients with COPD. Cycling intensity will initially be set at 60 percent of Peak work rate with progressive increase in Duration and intensity
45620172|NCT03325205|Other|Anodal tDCS|Anodal Transcranial direct current stimulation (tDCS) is a non- invasive brain stimulation technique. Low intensity current (1-2 mA) is induced to increase excitability, stimulate plasticity and enhance cognitive functions.
45620173|NCT03325205|Other|Sham tDCS|The electrodes are placed over the same areas as in the anodal tDCS condition. Participants will receive sham tDCS instead of anodal tDCS
45620174|NCT05013723|Other|Surveys|Mental health validated psychometric surveys: Depression (PHQ-9), Anxiety (GAD-7), PTSD (PC-PTSD-5) Quality of Life surveys: Post COVID-19 Function Status Scale, Quality of life (SF-12)
45620175|NCT03230071|Drug|TMBCZG|0.1g per pill which contains 14mg TMBCZG
45935096|NCT00216112|Drug|Imatinib Mesylate|Imatinib mesylate 600 mg po qd
45620176|NCT03230071|Other|placebo|0.1g per pill which contains 0mg TMBCZG
45620177|NCT05020041|Behavioral|Physical activity|"The schools in the intervention group will receive the online educational talk aimed at schoolchildren and a talk aimed at Physical Education teachers, given that they are fundamental for the development of habits in the school stage; besides, painted games will be implemented in the school playground.~The implementation of painted games will consist of adapting a space destined for recreation, designing a psychomotor circuit that does not require contact between peers or manipulation of objects in order to maintain COVID-19 sanitary and safety protocols. The psychomotor circuit includes a line circuit, a jumping sequence game, and a letter spiral. All the games will be implemented in a space within the educational establishment to which the students will have access during recess. The game designs involve activities to develop motor patterns such as jumping with different supports, running, and dynamic balance."
45620178|NCT02488577|Procedure|Transanal minimally invasive total mesorectal excision|
45935097|NCT00216112|Drug|Docetaxel|Docetaxel 30 mg/m2 (4 of 6 weeks); 1 cycle = 6 weeks
45935098|NCT00216151|Drug|Zoledronic Acid|Zoledronic Acid 4mg, every three months
45935099|NCT00216190|Drug|Dexmedetomidine HCL Injection|
45935100|NCT00216190|Drug|Midazolam Injection|
45935101|NCT00216229|Biological|Combined vaccine against hepatitis A and B (Twinrix)|
45935102|NCT00216268|Drug|Ribavirin|
46069174|NCT03936478|Radiation|MRIdian Radiation Treatment Unit|partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm planning tumor volume (PTV) margin
46069175|NCT03934216|Drug|BMS-986165|Specified Dose on Specified Days
46069176|NCT03934216|Other|Placebo|Specified Dose on Specified Days
45935103|NCT04722211|Dietary Supplement|PS128|daily ingestion of 2 capsules of Lactobacillus plantarum PS128 (>10 billion CFU/capsule)
45762192|NCT00864539|Dietary Supplement|plain orange juice|daily intake of 250 ml plain orange juice
45762193|NCT00864539|Dietary Supplement|calcium-vitamin D supplement|daily calcium-vitamin D supplement (500 mg calcium + 200 IU vitamin D)
45762194|NCT00864539|Dietary Supplement|Placebo|daily placebo
45620179|NCT02488577|Procedure|transanal minimally invasive locoregional resection|
45620180|NCT05020197|Diagnostic Test|self-questionnaires on attachment and PTSD|The questionnaires (attachement type, PTSD symptoms) are administered face to face at the inclusion visit (at D0-D3). Validated self-questionnaires in French will be sent to the patients, either electronically or by post, according to their choice at D30 and D90. To describe the characteristics of the subjects, socio-demographic data, lifestyle, and medical history will be collected. The questionnaires will be administered three times to study the evolution of the parameters over time.
45445994|NCT03752229|Device|Unistik Touch|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45620181|NCT03227887|Other|Two samples of saliva|"Without stimulation : the 1st will be used to measure the flow of naturally secreted saliva~With stimulation: The 2nd will be used to measure the flow and viscosity of the saliva secreted after stimulation"
45762195|NCT05460312|Diagnostic Test|prostate biopsy|trans rectal ultrasound guided biopsies of prostate . Biopsy smaples will be referred to staining and western blot analysis.
45762196|NCT03143920|Combination Product|Hyperbaric Oxygen Therapy-|Hyperbaric oxygen therapy provides 100% medical grade oxygen at 2.4 atmospheres of absolute pressure with a Class A multiple person chamber or Class B single person chamber. Hyperbaric chambers are classified as a Class II medical device and have been FDA cleared.
45762197|NCT00827255|Drug|Cyclosporine Ophthalmic Emulsion 0.05%|One drop two times a day approximately 12 hours apart
45762198|NCT04639258|Device|Medtronic Evolut™ PRO+ System|TAVR treatment with Medtronic Evolut™ PRO+ System
45762199|NCT02442102|Behavioral|Exercise and sensory stimulation|60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate
45762200|NCT05235503|Drug|Medicinal cannabis in combination with oxycodon|The intervention will be administering the combination of medicinal cannabis in combination with oxycodon
45762201|NCT05235503|Drug|Medicinal cannabis in combination with placebo oxycodon|The intervention will be administering the combination of medicinal cannabis in combination with placebo oxycodon
45762202|NCT04458610|Biological|Rituximab|Given IV
45762203|NCT04458610|Drug|Zanubrutinib|Given PO
45620182|NCT03227887|Other|Chewing behaviour|Measure the time taken by the subjects to chew the food and the number of bites they use before swallowing The test will be done twice.
45620183|NCT03227887|Other|Study of the food bolus|"2 tests:~Evaluate using a compression test the structure of each bolus to determine their degree of destructuration over time Measure the quantity of the saliva incorporated~The bolus will be analysed visually"
45620184|NCT03227887|Other|Mouthfeel|Describe the mouthfeel by answering a paper questionnaire after consumption of the cereal products
45762204|NCT02153489|Drug|Aclidinium bromide|
45762205|NCT02153489|Drug|Placebo|
45762206|NCT04634344|Drug|DZD2269|A single dose of DZD2269 starting at 5 mg will be given on Cycle 0 and then followed by a wash-out period. Multiple doses of DZD2269 at the same dose level will be given once daily after the wash-out period.
45762207|NCT04627012|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
45762208|NCT04627012|Drug|Opdivo|3mg/mg intravenously every 3 weeks
45445995|NCT03752229|Device|ReadyLance (blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45620185|NCT03323957|Diagnostic Test|nutritional screening tool|screening of disease associated malnutrition in sick infants
45620186|NCT05020119|Drug|Neoantigen-expanded cell therapy.|Infusion of personalized neoantigen-expanded T (CIK) cells
45620187|NCT02488499|Behavioral|Coping Power|15 sessions of concurrent parent and child group treatment
45620188|NCT02488499|Behavioral|Individualized Treatment|15 sessions of individualized child and parent treatment
45762209|NCT04627012|Drug|Camrelizumab|200mg intravenously every 3 weeks
46069177|NCT03925480|Drug|Azithromycin 500 mg Oral Tablet x 4|A single prophylactic dose of antibiotic given during labour
45620189|NCT03229603|Other|Cluster of 3000 women|An evaluation of the feasibility, reach, adoption and implementation of a cervical cancer screening program where we diagnose HPV using the GeneXpert point of care testing kit prior to VIA and cryotherapy.
45620190|NCT03083535|Procedure|Tooth Brushing|Tooth Brushing with Dentifrice Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
45620191|NCT03083535|Procedure|aloe vera Massaging|Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with aloe vera gel
45762210|NCT04627012|Drug|Keytruda|200mg intravenously every 3 weeks
45762211|NCT04627012|Drug|Toripalimab|240mg intravenously every 3 weeks
45762212|NCT04627012|Drug|Sintilimab|200mg intravenously every 3 weeks
45762213|NCT04627012|Drug|Tislelizumab|200mg intravenously every 3 weeks
45762214|NCT04600102|Device|Structure Sensor|A 3D representation of each participant's lower limb geometry will be obtained using a Structure Sensor scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
45762215|NCT00866879|Drug|Sirolimus|Sirolimus will initially be given at a dose of 2-4 mg orally (PO) daily. The dose will be modified to achieve 24 hours trough concentrations of 6-10 ng/ml by high-performance liquid chromatography (HPLC) assay. This medication will be given in an open label fashion. The first dose of sirolimus will be given at the time of randomization to those patients assigned to have tacrolimus switched to sirolimus.
46069178|NCT03925480|Drug|Matching Placebo|Matching Placebo
45762216|NCT00866879|Other|Demographic Data, Medical History, and Donor Data|Age at transplant, sex, race, cause of end-stage renal disease, medical history, donor age, cadaveric vs. living kidney transplant, histocompatibility/cross match data, viral serology, history of acute rejection and delayed graft function, use of induction therapy and immunosuppressants, use of Angiotensin Converting Enzyme Inhibitor (ACEI) and/or Angiotensin Receptor Blockers (ARB) level of renal allograft function-estimated GFR (e-GFR(12) using Modification of Diet in Renal Disease (MDRD) formula, proteinuria.
45762217|NCT00866879|Procedure|Blood Draws for Control Group|Subjects maintaining standard of care drug treatment of TAC and MMF will have monthly labs in addition to the baseline pre-randomization labs, at 6, 12, and 24 Months post-randomization. Peripheral blood leukocytes will be obtained.
45620192|NCT03083535|Procedure|SRP with aloe vera massaging|on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with aloe vera ge; shall be carried out by the patients/subjects
45762218|NCT00866879|Procedure|Blood Draws for Experimental Group|This group will have monthly labs taken but will also have weekly labs during the period of conversion to monitor renal function and bone marrow function. In addition to the baseline pre-randomization labs, and labs collected at 6, 12, and 24 Months post-randomization, peripheral blood leukocytes will be obtained.
45762219|NCT00866879|Procedure|Donor Blood Draws|Peripheral blood leukocytes from living donors obtained at the time of randomization. These donor leukocytes will be used as stimulator cells to study the functional activity of the recipient's lymphocytes function.
45762220|NCT00866879|Other|Donor Information|Donor age, cadaveric vs. living donor, and histocompatibility and cross match to recipient
45762221|NCT00866879|Procedure|Kidney Biopsy|Kidney biopsy at 24 Months to compare to the standard of care biopsy taken at 12 Months. This information will help evaluate renal allograft pathology and renal allograft tissue gene expression profiles of the two groups. Renal allograft biopsies will be stored in RNA later (preservative) to further extend knowledge on the effect of calcineurin-inhibitors (CI) free immunosuppression on gene expression profiles.
45620193|NCT03323879|Radiation|LDR/HDR|Focal LDR to dominant lesion with whole gland 19 Gy HDR
45762222|NCT02311920|Biological|Ipilimumab|Given IV
45762223|NCT02311920|Other|Laboratory Biomarker Analysis|Correlative studies
45762224|NCT02311920|Biological|Nivolumab|Given IV
45762225|NCT02311920|Drug|Temozolomide|Given PO
45762226|NCT02153723|Drug|Glatiramer Acetate|
45762227|NCT04388878|Drug|PF-07054894|Participants will receive oral ascending doses
45762228|NCT04388878|Drug|Placebo|Participants will receive matching placebo
45762229|NCT02234388|Other|Observation|There are no interventions associated with this registry as it is purely observational.
45911885|NCT05291403|Other|Medical thoracoscopic cryotherapy combined with standard first-line therapy for advanced non-cell lung cancer|"Medical thoracoscopic cryotherapy: medical thoracoscopy biopsy hole insert bendable freezing probes, place the frozen probe placed in the center of the tumor at the top will be frozen carbon dioxide gas source pressure adjustment to the bar of 50-60 bar, tread down switch, foot pedal to start the probe, after about 30 s at the top of the probe to form a ice hockey, local tissue after frozen white, sometimes a small amount of bleeding; Fix the probe, loosen the pedal, and wait 30 seconds for automatic melting and rewarming (bleeding probability is low after full rewarming). Freeze 5 to 10 at a time.~In addition, all patients were treated with standard first-line regimens according to guidelines of non small cell lung cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG) scores."
45762230|NCT00828191|Drug|Progesterone|25 mg, once a day, SC
45935104|NCT04722211|Dietary Supplement|placebo|daily ingestion of 2 capsules which only contained 425 ± 25 mg microcrystalline cellulose
45762231|NCT00828191|Drug|Progesterone|100 mg, twice a day, vaginally
45762232|NCT04571320|Behavioral|Summer STRIPES|See arm description.
45762233|NCT04571320|Other|Enhanced School Services as Usual|see arm description.
45762234|NCT05531838|Device|Fu Lishan instant sense hospital dynamic glucose monitoring system|Using CGM Technology (dynamic glucose monitoring system used in Fu Lishan instant sense hospital), on the basis of patients' original eating habits, according to the guidelines and the training of MMC center, patients are guided to adjust their eating patterns according to the glucose map monitored by the dynamic glucose monitoring system.
45762235|NCT04375306|Procedure|RFR guided CABG|All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the experimental arm the decision to revascularize will be based on RFR.
45762236|NCT04375306|Procedure|Angio guided CABG|All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the control arm the RFR values will be blinded to the cardiothoracic surgeon.
45762237|NCT00867659|Drug|Cetrotide acetate|cetrotide acetate is a GnRH antagonist. The dose is 3 mg once on the day of oocyte retrieval.
45620194|NCT02452567|Other|Moderate (8-10%) diet-induced weight loss|MAL participants will meet with the study dietitian to lose ~8-10% of their body weight through diet-intervention.
45620195|NCT05013489|Behavioral|Mindfulness and intercare based intervention|"Eight week online program based on mindfulness, compassion and intercare intervention. A two hour synchronic online session every week plus daily homework based on meditation and journaling exercises.~The topics covered in the program are mindfulness meditation, cognitive behavioral therapy exercises, gratitude and acceptance, compassion and self compassion exercises, conservation of resources theory and intercare."
45620196|NCT03320603|Other|Expert eCRF|An expert eCRF will be used to guide physicians during the management of patients treated with Vitamin K Agonist or Direct Oral Anticoagulant admitted in emergency units for severe bleeding.
45762238|NCT00912925|Biological|rhIDU (recombinant human-Alpha-L-Iduronidase)|Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 units/kg (approximately 0.58mg/kg) administered intravenously over approximately 4 hours once weekly for 26 weeks.
45762239|NCT00912925|Biological|Placebo|Patients in the Placebo-control group were administered a solution of 100mM sodium phosphate , 150mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over a time period of approximately 4 hours once weekly for 26 weeks.
45935105|NCT00216346|Drug|Paromomycin sulfate|
45935106|NCT00216346|Drug|Amphotericin B|
45762240|NCT05531058|Behavioral|AI-driven Vaccine Communicator|The intervention will include six modules web-based psychoeducation programme (two module sessions weekly, each module lasts for 15-20 minutes). And the content of the intervention includes six modules sessions, including Module 1- What is COVID-19, Module 2- Basic knowledge of vaccine; Module 3- Risk and benefit; Module 4- Fear & myth; Module 5- Vaccine policy; Module 6- Review the intervention and end the programme. Also with an MI communication skills-based AI, digital assistant.
45620197|NCT03320603|Other|Prothrombin Complex Concentrate|Prothrombin Complex Concentrate given as standard of care
45620198|NCT03227653|Drug|Efavirenz|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
45762241|NCT05531058|Behavioral|Self-learning of COVID-19 vaccine knowledge|Participants in the control group will be given HK government websites in COVID-19 vaccine and invite to join the online examination in relation to Covid-19 vaccine knowledge (using multiple choices questions similar to the intervention group), and this is to ensure that participants from the control group also use time to search relevant information of covid-19 vaccines, also this is to control the time effects.
45762242|NCT04549870|Drug|Roflumilast|Treatment according to national roflumilast guidelines
45620199|NCT03227653|Drug|Nevirapine|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
45620200|NCT03227653|Drug|Lopinavir-Ritonavir Drug Combination|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
45620201|NCT04434183|Device|Exercises of rehabilitation|Compare and evaluate of the effects of the routin physical medicine and rehabilitation programs in impingement patients
45762243|NCT00828347|Drug|1.0 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 1.0 μg/day in patients whose iPTH level was controlled to < 150 pg/mL by initial maxacalcitol therapy.
45762244|NCT00828347|Drug|0.25 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 0.25 μg/day in patients whose iPTH level was controlled to < 150 pg/mL by initial maxacalcitol therapy.
45762245|NCT05531760|Procedure|Descemet Membrane Endothelial Keratoplasty|DMEK-operated eyes
45762246|NCT02939872|Drug|aspirin and clopidogrel|at the discretion of investigator
45762247|NCT02939872|Drug|Clopidogrel only|at the discretion of investigator
45762248|NCT03835663|Diagnostic Test|No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes|Standard upper GI endoscopy with biopsies
45762249|NCT00829049|Drug|Tazarotene Cream 0.1%|1 pea-size amount, QD x 16 weeks
45762250|NCT00829049|Drug|Adapalene|1 pea-size amount, QD x 16 weeks
45762251|NCT02859064|Drug|Lanreotide|Administered every 28 days irrespective of when SIR-Spheres is administered. No waiting or adjusting of schedule is required. Lanreotide treatment may continue monthly until disease progression or unacceptable toxicity occurs.
45762252|NCT02859064|Device|Y-90 microspheres|To be administered by injection through a trans-femoral catheter into the hepatic artery.
45445996|NCT03752229|Device|ReadyLance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45762253|NCT03835429|Device|MyTAP oral appliance plus mouth shield|The midline traction oral appliance (MyTAP, Airway Management Inc.(AMI), Dallas Texas) is currently marketed as a medical device to treat snoring and obstructive sleep apnea and is FDA cleared.
45445997|NCT03752229|Device|AssureLance|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45445998|NCT03752229|Device|AssureLance MicroFlow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45620202|NCT04434261|Diagnostic Test|PT-PCR test for SARS-CoV-2|Screening test for the diagnosis of SARS-CoV-2 in asymptomatic patients
45935107|NCT00216385|Drug|Gatifloxacin combined regimen|
45935108|NCT00216424|Drug|Capecitabine (Xeloda)|
45620203|NCT02452333|Procedure|Oncoplastic Approach Excisional Breast Biopsy|Evidence based quadrant by quadrant oncoplastic algorithm reinforced with videoscopic applications for peripheral lesions.
45620204|NCT02452333|Procedure|Conventional Excisional Breast Biopsy|Conventional Excisional Breast Biopsy
45620205|NCT02452333|Other|Tezel Method of Breast Volume Measurement|Tezel Method is a simple, accurate and non-invasive method of measuring differences in breast volume based on Archimedes' principle
45620206|NCT02452333|Other|Cosmetic Assessment|Cosmetic Assessment with Harris scale graded by patient, surgeon and professional third party. A standardised photograph of front, side and mediolateral oblique views will be taken using a digital camera for professional third party observers.
45620207|NCT03320525|Dietary Supplement|T-ChOS|T-ChOS 600 mg (two capsules, each 300 mg) daily in the morning 30 minutes before food.
45620208|NCT03320447|Drug|lidocaine-prilocaine 5% cream application|The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
45620209|NCT03320447|Device|2940-nm Er:YAG AFL pretreatment|After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
45620210|NCT03320447|Drug|methyl-aminolevulinate application|Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
45935109|NCT00216463|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 200 mg subcutaneous injection - every other week for 11 weeks
45762254|NCT04303702|Drug|Continue Oxytocin|The administration and titration of oxytocin for labor augmentation is per a hospital based protocol. To summarize, oxytocin is initiated intravenously at 2 milliunits/minute and increased by 2 milliunits/minute every 20 minutes until an adequate contraction pattern is attained or a maximum of 40 millunits/minute has been achieved. This protocol for titration and administration will be applied in this study to the oxytocin group. The intravenous pumps on Labor and Delivery have automated functions for intravenous administration of oxytocin that is milliunit-based and the same routine pumps will be used in this study. The study bag will be administered per current oxytocin protocol. Since patients will already be on oxytocin at time of randomization, their current bag of oxytocin will be continued by the primary provider at a rate of their discretion.
45762255|NCT04303702|Other|Discontinue Oxytocin|Patients will have their oxytocin discontinued in the second stage of labor. The patient will receive routine maintenance IV fluids per the discretion of the provider.
45620211|NCT03320447|Device|Illuminating using red light-emitting diode lamps|Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
45620212|NCT04485091|Combination Product|20% TCM and PBM|The chemical peel (20% TCM) will be carried out monthly, totaling 04 sessions. The application of photobiomodulation (PBM) will start shortly after the observation of frosting level I, which characterizes an exfoliation of superficial depth. Although the application sessions take place monthly, medical evaluations will be carried out fortnightly for the other orientations, filling in scales and photographs. For the PBM, a LED device with an irradiance of 10 milliwatts per square centimeter (mW/cm²) in continuous operation mode and a wavelength of 660 nm will be used. It will provide an energy density of 4 J/cm² within 400 seconds of irradiation.
45620213|NCT04485091|Other|20% TCM and PBM placebo|The chemical peel (20% TCM) will be carried out monthly, totaling 04 sessions. The application of photobiomodulation (PBM) will be simulated soon after the observation of frosting level I. The patient will not be aware of the simulation of the procedure. Although the application sessions take place monthly, medical evaluations will be carried out fortnightly for the other orientations, filling in scales and photographs.
45620214|NCT04433715|Diagnostic Test|ICIQ-SF|All participants completed ICIQ-SF,
45620215|NCT04433715|Diagnostic Test|UDI-6|All participants completed UDI-6
45762256|NCT01727479|Other|Ribose|After each of the 3km time trial (3 in total), participants will be asked to drink the experimental product (or placebo) incorporated in a sports drink.
45762257|NCT01727479|Other|Placebo|
45762258|NCT00868751|Biological|tocilizumab|"Initial therapy: Tocilizumab dosed by body weight (8mg/kg based on body weight ≥ 30kg) given by intravenous infusion every two weeks for 12 weeks.~Extension of therapy: Continuation of treatment with tocilizumab at 8mg/kg by body weight given by intravenous infusion every 2 weeks based upon achievement of Primary Objective by week 12, OR continuation of treatment with escalation of tocilizumab dose to 12mg/kg by body weight, given by intravenous infusion every two weeks, for failure to achieve ACR JIA30 at 12 weeks or ACR JIA50 response at any time after week 16."
45620216|NCT04433715|Diagnostic Test|IIQ-7|All participants completed IIQ-7
45762259|NCT02838316|Drug|Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)|Autologous muscle derived stem cells
45762260|NCT01727557|Procedure|regional anesthesia|Regional anesthesia will be compared to local anesthesia
45762261|NCT01727557|Procedure|local anesthesia|Regional anesthesia will be compared to local anesthesia
45762262|NCT04529044|Drug|Lutetium Lu 177 Dotatate|Given IV
45762263|NCT01821144|Behavioral|Salt reduction|Salt reduction
45762264|NCT01821144|Other|Control|No salt awareness education
45762265|NCT00913003|Drug|Lidocaine|Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)
45620217|NCT04434105|Drug|platlet rich plasma (PRP)|Platelet-rich plasma (PRP) promotes angiogenesis, neurogenesis, and nerve regeneration, also it could reduce swelling and inflammation of the flexor tenosynovitis.
45762266|NCT00913003|Drug|Placebo|Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug
45445999|NCT03752229|Device|Surgilance|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45620218|NCT04434105|Drug|Triamcinolone Acetonide|40 mg triamcinolone acetonide
45620219|NCT04434105|Drug|Saline|Saline
45620220|NCT02451631|Other|Traditional care with paper|Healthcare staff-driven care, Diabetes mgmt. guide-book provided. Patient self-monitoring of blood glucose(SMBG) with paper.
45653339|NCT05070429|Other|Clinic-based audiological rehabilitative service delivery|Participants will have scheduled clinic-based visits at 6 and 12 months post-randomization to reinforce self-management strategies and perform hearing aid checks.
45762267|NCT00869141|Drug|glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)|Subjects may receive glaucoma medications after Ahmed valve implantation
45762268|NCT05530902|Other|Multidisciplinary Primary Rehabilitation Care|As described by the Policy Regulation 'Innovation' (NZa). The MPRC is a structured treatment program following the biopsychosocial approach, aiming to optimize functioning and participation in CMP patients. The treatment program is provided by paramedical specialists and, in cases that are more complex, a rehabilitation physician will be involved. The program has a diagnostic phase, a treatment phase (6-12 weeks) and a follow-up (12 months).
45911886|NCT05291403|Other|Sequential intrathoracic injection of cisplatin/erythromycin combined with standard first-line therapy for advanced non-cell lung cancer|"The pleural effusion was fully drained and cisplatin 40mg/m2 was given, dissolved in 100mL 0.9% sodium chloride (NaCl) solution 100 mL, then injected into the pleural cavity and retained for 24 hours. Erythromycin was sequentially injected into the thorax to seal the pleural cavity.~In addition, all patients were treated with standard first-line regimens according to guidelines of NSCLC and ECOG scores."
45935110|NCT00216463|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 100 mg subcutaneous injection - every other week for 11 weeks
45762269|NCT04522648|Other|Prospective surveillance|A participant with an increase from pre-surgery in total arm volume of ≥6% by self-measurement, or symptoms of BCRL ≥2 NRS will receive an assessment by a lymphedema therapist. At this appointment, participants will receive a physical examination of the arm along with a BIS measurement. A participant is considered having subclinical BCRL if an increase in lymphedema index (L-DEX) ≥7 from pre-surgery measured by BIS is identified. A fitted compression garment and gauntlet is then provided, free of charge, for daily wear 10 hours/day for four weeks along with a recommendation to use the arm for daily activities and maintain regular physical activity. Following the four-week compression period, participants will be re-measured using BIS to evaluate response. Participants who do not respond to compression will receive CDT delivered by the lymphedema therapist.
45762270|NCT01722799|Device|Drug elluting Balloon (DEB)|Percutaneous transluminal coronary angioplasty with drug elluting ballon and Bare metal stent for rescue.
45620221|NCT02451631|Device|Health-on G App. + Physician Web|Patients use their smart-phone or receive rental phone, and download Health-On G application. Algorithm-based personalized feedback are provided when patients' data are linked to Health-On G Application. Patient self-monitoring blood glucose data from glucometer are transferred to App. automatically by bluetooth, or input manually, check medication regimen, input food intake and exercise, and step counts are linked by Activity tracker. Personalized feedback are instantly provided based on data. Entered data are also connected to web-based physician portal. Physician web portal is provided, where they're able to review their patient's all data. Health-On G is defined as a U-Healthcare medical device consisting of gateway and decision support system.
45620222|NCT03208075|Other|normal diet|Diet containing 1500mg of phosphorus
45620223|NCT03208075|Other|low-phosphorus diet|Diet containing 500mg of phosphorus
45762271|NCT01722799|Device|Drug elluting coronary stent (DES)|Percutaneous transluminal coronary angioplasty (PTCA) with stent
45762272|NCT04260022|Drug|Ascentage Pharma HQP1351 bioavailable inhibitor|HQP1351 taken by mouth every other day
45762273|NCT04260022|Drug|Blinatumomab|Administered in all patients as a continuous IV infusion at the dosage of 28μg daily (9μg daily for Cycle 1 Day 1 to Day 7).
45762274|NCT01727635|Other|body-mind-spirit group therapy|8-session therapy
45762275|NCT03408925|Other|Exercise program|The orienteerers are asked to perform specific exercises four times a week throughout the entire study period. The exercises are heel rises, runners pose, single leg stance and one-leg jumps with three difficult levels aiming to mainly improve lower extremity strength and neuromuscular function. Each second week the exercises' difficulty level is increased.
45762276|NCT02828254|Drug|PRI-724|
45762277|NCT01722955|Other|Pre-warmed fluids|IV fluid will be stored at 41℃ set hot cabinet for 8hours
45762278|NCT01722955|Other|Room temperature fluids|Room temperature fluid will be stored at ambient temperature
45762279|NCT04216420|Device|MERM-observed self-administered therapy|The MERM device has an electronic module and a medication container that records adherence, stores medication, emits audible and visual on-board alarms to remind patients to take their medications on time and refill, and enables providers to download the data and monitor adherence. It is manufactured by Wisepill Technologies, South Africa.
45762280|NCT00829985|Biological|Glycerinated German Cockroach Allergenic Extract|Concentrated (1:20 w/v) daily doses of glycerinated German cockroach allergenic extract placed under the tongue to dissolve. The extract is also administered during the preliminary dosing visits in up to five escalating doses or until the maximum study dose (420 microliters, 1:20 w/v) is achieved.
45762281|NCT00829985|Biological|Placebo|Daily doses of cockroach allergenic extract placebo placed under the tongue to dissolve
45762282|NCT01606176|Drug|GW-1000-02|Each actuation of GW-1000-02 (100 μl) delivered a dose containing 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose of study medication was eight actuations in any three hour period (20 mg THC/20 mg CBD) and 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).
45762283|NCT01606176|Drug|Placebo|Each actuation of placebo (100 μl) delivered the excipients only. The maximum permitted dose of study medication was eight actuations in any three hour period and 48 actuations in any 24 hour period.
45762284|NCT00913081|Dietary Supplement|Quercetin|Quercetin 500, 1000, or 2000 mg PO one time
45620224|NCT03208075|Other|high-phosphorus diet|Diet containing 2300mg of phosphorus
45620225|NCT03320291|Device|Regjoint|Implant of poly-L / D-lactide (Regjoints®) in the treatment of trapezo-metacarpal osteoarthritis
46069179|NCT03915769|Drug|Ozanimod|Ozanimod is an orally bioavailable, small molecule compound that activates the sphingosine 1-phosphate 1 receptor (S1P1) and the S1P 5 receptor (S1P5), although it is more selective towards S1P1 over S1P5
45620226|NCT03078777|Drug|Fexofenadine|Fexofenadine will be administered to patients.
45620227|NCT03227497|Dietary Supplement|Whole Walnuts|Intervention arm includes whole walnuts taken as dietary replacement meal during the day, and between breakfast and lunch, and/or lunch and dinner. Importantly, none of the main meals, including breakfast, lunch and dinner are to be replaced by study intervention, and the study subjects are instructed to do so. Walnuts are provided with the same producer at the Belgrade market.
45620228|NCT03078309|Drug|cannabis|single dose sublingual cannabis (THC:CBD 1:1, THC:CBD 1:40)
45620229|NCT02488031|Behavioral|Error-reduction|"During this time participants will use a novel, custom designed computer interface to perform goal-directed movements with each leg in a 3D virtual environment designed to emphasize accurate movements. Leg movement will be detected using the LeapMotion sensor and we will quantify time endpoint errors by comparing the timing of the foot trajectory and the required time to target.~The error-reduction intervention will be a 4-week home-based program. Each participant will train 4 days a week for approximately 1 hours per day. Within a week, the task difficulty will increase by changing the presentation of the targets to be more unpredictable and by increasing movement speed."
45620230|NCT02488031|Behavioral|International Cooperative Ataxia Rating Scale|The ICARS is an assessment of the ataxia severity. The ICARS score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
45620231|NCT02488031|Behavioral|Scale for the Assessment and Rating of Ataxia|The SARA is an assessment of the ataxia severity. The SARA score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
45762285|NCT00913081|Dietary Supplement|Placebo|Placebo PO one time
45762286|NCT04198792|Other|No intervention|No intervention, but ECPR patients will be compared to ECMO-patients that have not had cardiac arrest
45762287|NCT03408769|Other|Medical questionnaire|"Brief Index of Sexual Functioning for Women questionnaire~Quality of life questionnaire (EORTC QLQ-BR23)~Partnership questionnaire (partnerschaftsfragebogen; PFB)~Short interview about their sexual intimacy"
45620232|NCT02488031|Behavioral|Beck Depression Inventory, 2nd Ed|This is a 21 question self-report inventory for measuring severity of depression.
45620233|NCT02488031|Behavioral|Stroop|This test measures selective attention and cognitive flexibility through reading aloud of color names or color of the print.
45620234|NCT02488031|Behavioral|Purdue Pegboard|This test consists of a series of timed hand coordination and dexterity tasks.
45762288|NCT04077424|Biological|Fluzone-High Dose Quadrivalent|Seasonal influenza vaccination with FDA approved vaccines for this age group.
45620235|NCT02488031|Behavioral|Brief Test of Attention|A cognitive test assessing focus and attention.
45762289|NCT04077424|Biological|Fluad|Adjuvanted (MF59) inactivated influenza vaccine
45762290|NCT04077424|Biological|Flublock|Recombinant hemagglutinin vaccine
45762291|NCT05597592|Procedure|Feasability of a personalised physical rehabilitation program at home|Monitoring of the realization of a personalised physical rehabilitation program at home by patients with neuromuscular and neurodegenrative disease
45762292|NCT00869375|Device|Endovascular peripheral intervention|Clearway Balloon: percutaneous transluminal angioplasty with simultaneous in situ thrombolysis using the Clearway balloon AngioJet Rheolytic Thrombectomy System: percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy using the Angiojet
45620236|NCT02488031|Behavioral|6-minute Walk|This test consists on a timed 6-minute walk test to evaluate how much distance is covered.
45762293|NCT01727869|Drug|REGN1400|
45620237|NCT02488031|Behavioral|Hand Grip Dynamometer|This tests measures hand grip strength.
45762294|NCT01727869|Drug|Erlotinib|
45620238|NCT02488031|Behavioral|Montreal Cognitive Assessment|This test is used to assess cognitive abilities.
45911887|NCT05291403|Other|Standard first-line therapy for advanced non-cell lung cancer without intrathoracic treatment|"Only intrathoracic tube was used to drain pleural effusion, and local pleural cavity was not treated.~In addition, all patients were treated with standard first-line regimens according to guidelines of NSCLC and ECOG scores."
45911888|NCT05280665|Other|Specialization|"Who had undergone professional training in gastric cancer surgery in specialized gastric cancer centers (in Japan or Korea),~Who identified themselves as primarily gastric surgeons during the study period~Whose annual gastric cancer surgery volume is more than 21"
45762295|NCT01727869|Drug|Cetuximab|
45762296|NCT04425330|Other|physiotherapy exercises|The evidence on the effectiveness of physical therapy in children with myelomeningocele is limited. The International Classification of Functionality, Disability and Health for Children and Youth is a useful tool to assist therapists in analyzing problems about the focus of the intervention. The evidence in physical therapy practice for individuals of all ages with neurological disorders, focuses on 5 Ps: prevention, prediction, participation, personalized and plasticity. Thus, neurological physiotherapists must perform the care with a focus on preventing the patient's disabilities, predicting the ideal response of an intervention, through measures of results of the movement system. In addition, it is of paramount importance that the goal of rehabilitation is that people with neurological disabilities are fully included and participate in life activities that are important to them and that their care is personalized. All of these measures facilitate the process of positive plasticity.
45762297|NCT04425330|Other|PBM|Photobiomodulation occurs from the application of low intensity light such as low intensity laser and light emitting diode (LED). The therapeutic effectiveness of phototherapy is based on the absorption of photons by photoreceptors or chromophores. Studies on the experimental model of spinal cord injury have shown that both wavelengths have the potential to be an effective and non-invasive means of therapy, promoting axonal appearance, increased concentration of glial cells and nerve connections, in addition to functional and sensitive. The findings of a clinical trial involving individuals diagnosed with spinal cord injury demonstrate that PBM exerted positive effects on motor function, especially during isotonic contraction of stimulated muscles assessed by electromyography, and there was a recovery in sensory perception and muscle strength.
45762298|NCT04425330|Other|SHAM PBM|SHAM PBM
45762299|NCT02684266|Drug|SHR6390|SHR6390 either 25, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg given orally, QD
45762300|NCT00869609|Behavioral|GLB Traditional Maintenance (TM)|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. Participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
45911889|NCT05279690|Drug|Colchicine|Patients will receive 14 days of colchicine in the absence of prohibitive toxicity of disease progression
45911890|NCT05275088|Device|Prizvalve® system|Transcatheter atrioventricular valve replacement
45911891|NCT05271682|Drug|FHND6091|FHND6091 capsules
45911892|NCT05255302|Drug|Pembrolizumab before randomization|Pembrolizumab 200 mg every 3 weeks before randomization
45935111|NCT00216463|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injection - every week for 13 weeks
45620239|NCT02488031|Behavioral|Physical Performance Function|This test consists of a series of physical activities used to evaluate speed, coordination, and ease of movement.
45620240|NCT02488031|Behavioral|Biomechanical Assessments of Dysmetria|Dysmetria will be assessed using a custom-made goal-directed movement protocol where participant perform unloaded limb movement tasks and attempt to reach a space-time target. During these task muscle activity is monitored using Electromyography (EMG) recording.
45620241|NCT02488031|Behavioral|Neurophysiological assessment of brain activity|Neurophysiology will be assessed by monitoring brain activity using Task-based fMRI and motor unit pool activity using a specialized EMG system.
45620242|NCT02488031|Behavioral|Biomechanical gait analysis|Participants will wear APDM's wireless sensors on the hands, legs, trunk and forehead and walk overground a distance of 7 m for 2 minutes. APDM quantifies 80 common biomechanical outcomes of gait (e.g. stride length variability).
45762301|NCT00869609|Behavioral|GLB-Carb-focused Maintenance (CF)|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. GLB-CF participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
45762302|NCT00370864|Biological|H5N1 pandemic influenza vaccine|
45762303|NCT04379167|Drug|YY-20394|YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3 kinase (PI3K-δ) which differs structurally from idelalisib, a PI3K-δ inhibitor approved for patients with relapsed chronic lymphocytic leukemia and indolent lymphoma. PI3K-δ signaling pathways are frequently hyperactive in B-cell cancers, making inhibition of PI3K-δ a promising target for B-cell malignancies. YY 20394 has high potency against PI3K-δ, but with markedly improved selectivity in in vitro assays compared to idelalisib. This higher selectivity for PI3K-δ may decrease the risk of serious infection seen with idelalisib and duvelisib (a PI3K-γ/δ dual inhibitor) due to strong immune suppression.
45762304|NCT01603368|Dietary Supplement|Lactobacillus reuteri|Oil drops with Lactobacillus reuteri DSM 17938, 125 million bacteria=0.2 ml per day
45620243|NCT03227419|Drug|Tocilizumab Prefilled Syringe|"Treatment arm: tocilizumab (RoActemra®):~162 mg weekly a schema for therapeutic adaptation with injection intervals determined according to transaminase levels or blood cell counts (neutropenia, thrombopenia) as recommended by Roche-Chugaï (see table below)."
45620244|NCT03227419|Drug|Abatacept Prefilled Syringe|"Treatment arm: abatacept (Orencia®)~125 mg weekly after an initial dose of 500 mg (body weight <60kg), 750 mg (body weight between 60 and 100 kg), or 1000 mg (body weight >100 mg) 24 hours before the first subcutaneous injection."
45762305|NCT01603368|Dietary Supplement|Placebo|Oil drops without Lactobacillus reuteri
45762306|NCT00370942|Drug|GW823093C A|A=45 mg
45762307|NCT00370942|Drug|GW823093C B|B=30 mg
45762308|NCT00370942|Drug|GW823093C C|C=25 mg
45762309|NCT01727947|Other|MSOME|A total of 200 spermatozoa of each sample will be analyzed under high magnification (x6600) and the incidence of SLV (sperm cells presenting at least one vacuole that occupied > 13% of nuclear area) in each sample will be assessed.
45762310|NCT01728103|Device|APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays|In Vitro Diagnostic Assays
45762311|NCT05206409|Diagnostic Test|Ultrasound|Fetal head position determination using ultrasound
45762312|NCT00371020|Drug|low molecular weight heparin, 5-FU|
45762313|NCT04476628|Drug|Budesonide|Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.
45762314|NCT04476628|Device|Mucosal Atomization Device|MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
45762315|NCT04476628|Device|NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation|INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
45620245|NCT03082911|Other|Phone call|"A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group). Each phone call will last approximately 5 minutes.~Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention."
45620246|NCT03082911|Other|Invitation letter|The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample
45762316|NCT01728181|Drug|Tivozanib|The phase I study will test two dose levels of tivozanib (dose level 1: 1.0 mg and dose level 2: 1.5 mg) given daily for 3 consecutive weeks followed by one week break. Based on the phase I results, the dose of tivozanib will be chosen for the phase II study.
45762317|NCT01728181|Drug|Erlotinib|150 mg/day for 28 day cycle. No rest period.
45762318|NCT01728181|Other|Standard of Care treatment|This treatment will be determined by the study doctor and is considered standard of care.
45762319|NCT04378231|Drug|Amoxicillin-Clavulanate 200 Mg-28.5 Mg Oral dry suspension|dry suspension of amoxicillin clavulanate potassium
45762320|NCT04475302|Biological|BCG vaccine (Freeze-dried)|single dose of BCG vaccine (Freeze-dried) manufactured by Serum Institute of India, Pune. The composition of BCG vaccine is Live, attenuated BCG (Bacillus Calmette-Guerin Strain). (Each 1 ml contains between 2 x 106 and 8 x 106 Colony Forming Units (C.F.U.) with Diluent: Sodium Chloride Injection I.P.)
45762321|NCT04378309|Behavioral|ePREP|6-session online psychoeducational program with supporting coach calls
45762322|NCT04463446|Behavioral|Use of the CHD app|Use of the CHD app
45762323|NCT04463446|Behavioral|Nurse-led intervention|Teaching session with clinic nurse
45762324|NCT01728571|Dietary Supplement|Vitamin D3|
45762325|NCT01728571|Dietary Supplement|fish oil|
45762326|NCT01728571|Dietary Supplement|Vitamin D3 placebo|
45762327|NCT01728571|Dietary Supplement|Fish oil placebo|
45935112|NCT00216463|Drug|ISIS 301012 or Placebo|400 mg subcutaneous injection - every week for 13 weeks
45620247|NCT03227341|Other|Exercise|8 week exercise program including breathing exercises consisted of pursed-lip breathing, diaphragmatic breathing and thoracic expansion exercises, relaxation and stretching exercises, upper and lower extremity muscle strength training, and aerobic exercises. In addition, bronchial hygiene techniques and dyspnea-reducing positions
45620248|NCT04410861|Procedure|Micropulse laser photostimulation|In this treatment invisible, non-damaging laser shots are delivered to the affected area which are believed to lead to absorption of accumulated retinal fluid. Contact lens will be used along with topical anesthesia.Following the procedure eye will be washed with balanced salt solution.
45620249|NCT02488265|Other|Balance Training|Balance training with rhythmical (BRT), is a motor program to improve balance associated with rhythmical auditory cues (RACs).
45935113|NCT00216463|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection - every week for 13 weeks
45935114|NCT00216502|Drug|galantamine hydrobromide|
45935115|NCT00216541|Drug|epoetin alfa|
45620250|NCT02488265|Other|Screening to prevent falls|Questionary to Scheduled screening falls and progression in training will be used to indicate the capacity to continue to progress.
45620251|NCT03208309|Drug|Diacerein|
45620252|NCT03208309|Drug|Placebo|
45620253|NCT02488187|Device|ABUS|Automated breast ultrasound
45911893|NCT05255302|Drug|Chemotherapy|Platinum doublet - 4 cycles: either paclitaxel-carboplatin for patient with SCC or pemetrexed-platinum salt followed by 2 cycles of pemetrexed until reaching the 6 months time-point for randomization Carboplatin AUC 5 for non-squamous cell carcinoma and AUC6 for squamous cell carcinoma every 3 weeks or cisplatin 75 mg/m² every 3 weeks Pemetrexed 500 mg/m² every 3 weeks or paclitaxel 175 mg/m² every 3 weeks
45620254|NCT03091803|Device|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo GOCART DCE MRI
45620255|NCT03091803|Drug|Gadobenate Dimeglumine|Given IV
45620256|NCT03091803|Drug|Gadoterate Meglumine|Given IV
45620257|NCT03091803|Device|Magnetic Resonance Imaging|Undergo QSM and T1WI imaging
45620258|NCT03207685|Device|Additional Seizure Monitoring|Embrace could offer an additional layer of seizure monitoring
45620259|NCT03320135|Procedure|Enamel matrix derivative proteins|Open flap debridement to enamel matrix derivative to treat proximal furcation involvements.
45620260|NCT03320135|Procedure|Open Flap debridement|Open flap debridement will be performed to decontaminate the proximal furcation involvements.
45620261|NCT03227575|Behavioral|Exercise Intervention|The use of exercise to improve glycemic responses in young adults who are at risk for Metabolic Syndrome.
45620262|NCT02638623|Drug|Lactated Ringer|2L Lactated Ringer administered prior to primary knee or hip arthroplasty
45620263|NCT02638623|Drug|Placebo|No additional fluids will be administered
45620264|NCT03323567|Drug|MD Muscle GUNA collagen|intramusclular injections of MD Muscle collagen
45620265|NCT03323567|Drug|Lidocaine 2% Injectable Solution|intramuscular Lidocaine 2% injection
45620266|NCT03323567|Drug|Saline Solution, Hypertonic|intramuscular Saline injection
45620267|NCT03227185|Device|real anodal transcranial direct current stimulation (tDCS)|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
45620268|NCT03227185|Device|sham transcranial direct current stimulation (tDCS)|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
45620269|NCT03091647|Behavioral|acupressure intervention|Women in the acupressure intervention group will learn how to press three chief energy acupoints on each side of the body through an 11-minute Chinese-language video and press three acupoints (1 minute per acupoint) on both sides of the body every day for a total of 6 minutes per day for an 8-week intervention period and record their practice on daily logs. Women will be asked to return the logs every week by email or self-addressed envelopes.
45911894|NCT05255302|Drug|Pemetrexed|Maintenance pemetrexed after randomization Pemetrexed 500 mg/m² every 3 weeks
45620270|NCT03091647|Behavioral|usual care|Women in the usual care group will receive primary and oncology care from their doctors as usual, and complete daily logs recording their fatigue and daily functioning levels. They also need to return the logs every week by email or self-addressed envelopes.
45620271|NCT04492709|Drug|Midazolam|The subjects will receive single doses of midazolam solution 2 mg/mL orally on Day 1 alone in Treatment Period 1 and on Day 7 co-administered with oral AZD5718 tablet in Treatment Period 3.
45620272|NCT04492709|Drug|AZD5718|The subjects will receive oral AZD5718 tablet once daily starting on Day 2 to Day 6 in Treatment Period 2 and on Day 7 co-administered with midazolam in Treatment Period 3.
45620273|NCT03222271|Device|Extubation to NIV|Weaning using NIV immediately after extubation with the mentioned parameters
45620274|NCT03081507|Behavioral|SM-LHW|Will not receive additional follow-up from the LHW, but will be encouraged during the session to make an appointment with their provider to schedule a mammogram and Pap test, or to consult the MARHABA webpage for information on low-cost and culturally appropriate referral sources of screening. Individuals assigned to this arm who did not attend an educational seminar will be mailed a packet containing a palm card, brochure, and letter encouraging them to speak with their provider about breast and cervical cancer screening and/or going to the MARHABA webpage. LHWs will complete a follow-up survey with participants by phone or in-person at 4 months after baseline
45620275|NCT03081507|Behavioral|PN-LHW|PNLHW participants will receive three planned contacts with LHWs that focus on navigation for obtaining mammogram and/or Pap testing.The initial contact will be made by phone and will focus on motivating participants to make an appointment with their primary care provider and/or obstetrician/gynecologist (OB/GYN), as well as provide information on low-cost or free care if necessary. The second contact will discuss the process of going to the appointment and the third contact will focus on the process of obtaining and interpreting. The second and third contacts will be either made by phone or in-person, depending on participant needs.
45620276|NCT03207997|Other|unenhanced MR sequences|2 additional unenhanced MR sequences
45620277|NCT05006235|Drug|Epinephrine Inhalation Solution|
45620278|NCT05006235|Drug|Salbutamol|
45620279|NCT05006235|Drug|Saline Inhalants|
45620280|NCT03323411|Behavioral|Advance Care Treatment Plan|subjects in experimental group are taught information on dementia mechanical ventilation tube feeding and cardiopulmonary resuscitation
45620281|NCT05005611|Dietary Supplement|Placebo|"A pack of powder without probiotics.~1 pack / day"
45620282|NCT05005611|Dietary Supplement|Probiotics-1|"A pack of powder with probiotics-1~1 pack / day"
45762328|NCT00832637|Drug|Cisplatin|Cisplatin is administered intravenously at 40 mg/m2 on day 1 and day 15, every 28 days. Cisplatin is administered following Gemcitabine. Cisplatin administration should occur with hydration with normal saline at 250 mL/ hour for at least 4 hours before and during Cisplatin administration. Additionally, Cisplatin administration should be preceded by osmotic diuresis with Mannitol 25%, 12.5 grams.
45762329|NCT00832637|Drug|Erlotinib|100 mg orally daily. For grade 3 or 4 skin rash, erlotinib should be held until resolution of the rash to no more than grade 1 before resumption of erlotinib.
45762330|NCT00832637|Drug|Gemcitabine|Gemcitabine is administered intravenously at 1000 mg/m2 on day 1 and 15, every 28 days. The clinical formulation is supplied in a sterile form for intravenous use only. Vials of gemcitabine contain either 200 mg or 1 g of gemcitabine hydrochloride (HCl )(expressed as free base) formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.
45762331|NCT03408457|Procedure|Blood sampling after antibiotic administration|Sampling of 6 x 8 mL (in sum 48 mL) via the central venous line (established for the surgical procedure) until postoperative day 2
45762332|NCT04338490|Device|Feedback mannequim|The intervention group received rcp training with their performance being evaluated in real time so that they could correct themselves
45762333|NCT05191901|Other|Stress Ball|Reducing pain and fear by squeezing a stress ball during the blood draw procedure.
45762334|NCT03408301|Procedure|Tourniquet deflation|Tourniquet deflation
45762335|NCT04738084|Behavioral|Meru Health Program|Each week of the 12 week program follows a different theme. Patients and therapists interact asynchronously after their initial Zoom-based intake call. Psychiatrists and medical doctors are available for consults if needed.
45762336|NCT05186285|Drug|CM338|CM338 : a humanized monoclonal antibody.
45762337|NCT05186285|Drug|Placebo|Placebo.
45762338|NCT03408223|Radiation|total body irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
45762339|NCT03408223|Radiation|total marrow and lymphoid irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12-20 Gy TMLI (fraction size of 4 Gy given once a day).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
45762340|NCT05174663|Other|Almond-enriched diet - 1.5 oz|Participants will receive 1.5 oz of almonds consumed as a snack daily for 16 weeks.
45762341|NCT05174663|Other|Almond-enriched diet - 2.5 oz|Participants will receive 2.5 oz of almonds consumed as a snack daily for 16 weeks.
45762342|NCT05174663|Other|Control snack|Participants will receive a control snack daily for 16 weeks.
45762343|NCT00370162|Drug|lactoserum|
45762344|NCT00918229|Device|balloon implant|Absorbable perirectal spacer implantation
45762345|NCT00918229|Procedure|Balloon implantation|Implantation of the balloon between the prostate and the anterior rectal wall
45620283|NCT05005611|Dietary Supplement|Probiotics-2|"A pack of powder with probiotics-2~1 pack / day"
45620284|NCT05005611|Dietary Supplement|Probiotics-3|"A pack of powder with probiotics-3~1 pack / day"
45620285|NCT03319823|Drug|Thiazide Treatment Group|"Thiazide Treatment Group: Non-diabetics with sleep systolic blood pressure of 125-139 mm Hg and awake systolic blood pressure <160 mm Hg Participants will be treated with Indapamide 0.625mg once a day After 4 weeks of treatment, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring the investigators will repeat ambulatory blood pressure monitoring at 4, 8, and 12 weeks after treatment initiation.~If sleep systolic blood pressure is < 120 mm Hg, the investigators will continue treatment"
45762346|NCT00370240|Drug|Chlorhydrate de Ropivacaine|The Ropivacaïne group received 3mg/kg of 0.375% ropivacaïne(0.75% ropivacaïne, Astra, mixed with saline)
45762347|NCT00370240|Other|placebo|The PCB group received saline solution in equal volume.
45762348|NCT05116475|Drug|Darolutamide 300 mg|Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
45762349|NCT05116475|Drug|Placebo of Darolutamide|Placebo of Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
45762350|NCT03408145|Device|Hyaluronic Acid|Injection of 3x 2.5ml of Hyaluronic Acid
45762351|NCT03408145|Device|Amniotic Tissue Allograft|Injection of 1x 1ml of Amniotic Tissue Allograft
45762352|NCT03408145|Drug|Saline|Injection of Saline
45762353|NCT02491840|Procedure|Biopsy|Biopsy of Gastric and cardia adenocarcinomas
45762354|NCT01663896|Device|OCT stent guidance|Participants undergoing pre- and post-PCI fractional flow reserve (FFR) and OCT
45911895|NCT05255302|Drug|Pembrolizumab after randomization|Pembrolizumab 200 mg every 3 weeks after randomization
45935116|NCT00216580|Drug|Risperidone, long-acting injectable|
45935117|NCT00041561|Drug|Nitrogen gas|Nitrogen gas will be given at 5ppm until Day 28 or extubation
45620286|NCT03319823|Drug|Intensified Thiazide Treatment Group|At 4 weeks of therapy, individuals initially assigned to the Thiazide treatment group whose ambulatory blood pressure recheck showed a sleep systolic blood pressure >120 mm Hg, the investigators will intensify their blood pressure medications by adding on Telmisartan 40 mg and Amlodipine 5 mg. In two week intervals, labs and ambulatory blood pressure will be measured. If the systolic blood pressure >120, then the doses of Telmisartan and Amlodipine will be up-titrated until the sleep systolic blood pressure is <120.
45620287|NCT03319823|Drug|Combination Medication Treatment Group|"Combination Medication Treatment Group: Diabetics or sleep systolic blood pressure of ≥ 140 mm Hg, or awake systolic blood pressure of ≥ 160 mm Hg~Participants will be treated with starting doses of a long acting blood pressure regimen of Telmisartan 40 mg and Amlodipine 5 mg daily~After 2 weeks, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring~If sleep systolic blood pressure is < 120 mm Hg, the investigators will continue treatment and repeat ambulatory blood pressure again in another 2 weeks to assess reproducibility~If sleep systolic blood pressure is > 120 mm Hg, the investigators will increase Telmisartan dose to 80 mg and the Amlodipine dose to 10 mg. Ambulatory blood pressure monitoring will be checked again after 2 weeks of therapy to verify efficacy."
45620288|NCT03207919|Behavioral|Lullaby Project|Pregnant women will participate in 3 group sessions. They will write and record a lullaby, and then listen to each recorded lullaby and reflect on their experience.
45620289|NCT03323333|Behavioral|psychosocial counseling|A problem-solving and psychosocial skill-building intervention.
45620290|NCT04961151|Other|Multimodal therapeutic warming w/ esophageal d/c|In order to evaluate the ability to reliably raise patient temperature to a target of 39.0°C, patients will be warmed with forced air warming, surface conductive warming, and esophageal core warming. After 4 hours at target temperature, esophageal warming will be discontinued.
45620291|NCT04961151|Other|Multimodal therapeutic warming w/ conductive d/c|In order to evaluate the ability to reliably raise patient temperature to a target of 39.0°C, patients will be warmed with forced air warming, surface conductive warming, and esophageal core warming. After 4 hours at target temperature, conductive warming will be discontinued.
45620292|NCT02487953|Drug|Nicotine patch|21 mg/24 h for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.
45620293|NCT02487953|Other|ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
45620294|NCT02487953|Other|Placebo patch|21 mg size for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg size for 2 weeks, and 7 mg size for 2 weeks.
45620295|NCT02487953|Other|Placebo ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
45620296|NCT03207607|Other|Control snack|Isovolumetric (238.4g) gel snack prepared by real fruits (186.2kcal)
45620297|NCT03207607|Other|Maltodextrin snack|Isovolumetric (238.4g) gel snack with maltodextrin (271.8kcal)
45620298|NCT03207607|Other|Whey protein snack|Isovolumetric (238.4g) gel snack with whey protein (201.8kcal)
45620299|NCT03207607|Other|Oat snack|Isovolumetric (238.4g) gel snack with oats and maltodextrin (275.8kcal)
45620300|NCT03207607|Other|Coconut oil snack|Isovolumetric (238.4g) gel snack with coconut oil (276.4kcal)
45620301|NCT03207607|Other|Snack skipping|no snack
45620302|NCT03091569|Other|Vitamin K Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
45620303|NCT03091569|Other|Placebo Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
45620304|NCT03226951|Device|Subthreshold 532nm laser|Subthershold 532nm laser
45620305|NCT03323255|Device|repeated transcranial magnetic stimulation continuous theta-burst stimulation|cTBS
45620306|NCT03323255|Device|SHAM repeated transcranial magnetic stimulation|SHAM stimulation
45620307|NCT05005767|Procedure|scaling and root planing|will receive scaling and root planing only
45620308|NCT05005767|Procedure|Frankincense extract gel natural herbal product|will receive Scaling and root planing then. Subgingival application of Frankincense extract gel
45762355|NCT02475772|Drug|Cisplatin and doxorubicin|The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.
45620309|NCT03323177|Dietary Supplement|Gender specific nutritional standardized formula|Patients will continue to consume the study formula until final height: gender specific powder added to water containing about 25% of recommended DRI for calories, high protein (25% of calories) and multi vitamin and mineral (255-100%) of DRI for recommended daily allowance (RDA) or adequate intake
45620310|NCT03323177|Other|Follow-up only|Patients who are reluctant to continue to consume the study formula will come to follow-up visits only without any intervention until final height is reached
45620311|NCT03226873|Behavioral|Peer Navigation|Peer education, counseling, and facilitation of PrEP care
45620312|NCT03323099|Behavioral|N-of-1|Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.
45620313|NCT03323099|Behavioral|Data Tracking|Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
45620314|NCT04948749|Device|Drug Eluting Stent implantation|The Maurora ® Sirolimus Eluting Stent System for intracranial PTA treatment comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
45620315|NCT04948749|Drug|Aggressive medical treatment|Aggressive medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 6 months after enrollment).
45620316|NCT04948749|Behavioral|Risk factor management|Management of risk factors (hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise)
45620317|NCT04948749|Drug|Standard medical treatment|Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after enrollment).
45620318|NCT03226717|Drug|Antiviral agents|combination therapy consists of Sofosbuvir,daclatasvir and ribavirin
45911896|NCT05254379|Device|tDCS|"tDCS is a painless brain stimulation treatment that uses direct electrical currents (at a constant, low-intensity level) to stimulate specific parts of the brain and help modulate neuronal activity. Participants will receive a series of tDCS treatments during the Intensive Outpatient Program (IOP) coupled with blood and saliva collections.~Participants will administer a stimulation session via the Soterix 1x1 tDCS mini-CT Stimulator, after being provided a single-use code to unlock the device by the research staff once proper contact quality is achieved. After the participant enters the unlock code, the screen on the device will show a timer that counts down the minutes until the end of the session. After 20 min, the device will turn off automatically and the study staff will instruct the participant to remove the headset and discard the sponges and to store safely all materials for the next session."
45911897|NCT05237050|Other|Sound therapy associated with relaxation|"Each patient will attend a total of 3 sessions of about 15 minutes each, once by week.~Sessions will start with relaxation. Then, sound therapy will be delivered using weighted medical tuning forks which resonate at a specific frequency. At the end of the session, the patient will be invited to take a short rest."
45620319|NCT03319589|Dietary Supplement|Supplement|locally prepared biscuit with low sugar content (less than 10% weight) designed to facilitate growth and cognitive development
45762356|NCT02475772|Procedure|Cisplatin and doxorubicin|intraperitoneal chemotherapy with cisplatin and doxorubicin in a dose-escalation scheme
45620320|NCT03222193|Device|TRP|3 months of TRP tongue retraining
45620321|NCT05019807|Other|WhatsApp group|Patients under intervention group will attend an education sessions by structured videos and images with the help of digital tool-WhatsApp group chat administered by the researcher. The group will have the objective interaction with patients and researchers to convey about their view of opinion on sight threatening diabetic retinopathy and management. The structured programme included definition of diabetes mellitus, symptoms, risk factors, awareness of DM and DR, importance of self-care about the disease (eye care and blood glucose monitoring), dietary management and importance of physical activity (Life style modification). The groups will be tracked frequently by WhatsApp/telephonic call and will be documented. Confidentiality of all participants will be maintained.
45620322|NCT05019807|Other|Control group|Patient under non-intervention group will not attend or take part in the education sessions or interaction with other patients. Will receive only the general instructions or advises from ophthalmologists about management and follow-up visit.
45620323|NCT03323021|Other|Dehydrated human amnion/chorion membrane|dehydrated human amnion/chorion membrane
45762357|NCT04338256|Behavioral|Wellness and Resilience for College and Beyond (Undergraduate College Course)|"The course, Wellness and Resilience for College and Beyond was originally developed by James Mazza, PhD and colleagues at the University of Washington as a 10-week course. The course developers adapted their course materials to fit the needs of a 16-week semester for the purpose of this study. The Wellness Course teaches students evidence-based skills for improving mental health from dialectical behavior therapy, acceptance and commitment therapy, and the field of positive psychology. Classes meet for 2.5 hours weekly with approximately half of class time spent on teaching new content (lecture) and the other half spent with students working in small groups on practice and discussion exercises."
45620324|NCT03323021|Other|Standard of Care|Standard of Care
45620325|NCT05012553|Other|education of self and peer assesment|Stoma care skill achievement is expected to be higher in the group that received self- and peer-assessment training compared to the group that did not receive training.
45620326|NCT03207373|Diagnostic Test|Stress test (ECG)|Every study participant undergoes a standard diagnostic stress ECG
45620327|NCT05012709|Behavioral|multisensory stimulation therapy|The intervention group received six 30-minute MST sessions. During MST session, participants can choose their preferred sensory stimuli such as essential oil diffuses, music and so on.
45620328|NCT03119935|Device|Amflow|Amflow deviced was developed for monitoring ventiation rate and ventilation volume. Participants ventilated the simulated patients by Amflow-device assist ambu bag
45620329|NCT03119935|Device|Ambu bag|Participants ventilated the simulated patients by ambu bag
45620330|NCT03109145|Other|Menopause educational secure messaging|Participants read educational material about menopause and treatment option for menopause symptoms once a week using secure messaging on a electronic patient portal.
45620331|NCT04946253|Behavioral|DOCC: Evidence-based treatment for disruptive behavior and ADHD|Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. The content covers key topics related to the treatment of behavior problems (e.g., self-management, positive parenting) and ADHD (e.g., psychoeducation, medication).
45762358|NCT00915655|Drug|darunavir|Type=exact number, unit=mg, number=400, formulation=tablet, route=oral. 2 tablets of darunavir administered once daily for 48 weeks
45911898|NCT05237050|Other|Relaxation alone|"Each patient will attend a total of 3 sessions of about 15 minutes each, once by week.~The procedure will be exactly the same than the other arm (relaxation, rest time), but the operator will not activate any tuning fork (so there will be no sound delivered during the session)."
45911899|NCT05234125|Behavioral|Better|It is a nonpharmacologic sleep intervention to improve maternal glucose metabolism in African American Pregnant Women (AAPW). Sleep BETTER is composed of sleep hygiene practices and cognitive-behavioral principles.
45762359|NCT00915655|Drug|ritonavir|Type=exact number, unit=mg, number=100, formulation=capsule, route=oral. 1 capsule of ritonavir administered once daily for 48 weeks
45762360|NCT00915655|Drug|zidovudine|NRTI (zidovudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and < 18 years in a particular country
45762361|NCT00915655|Drug|lamivudine|NRTI (lamivudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and < 18 years in a particular country
45762362|NCT00915655|Drug|abacavir|NRTI (abacavir) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and < 18 years in a particular country
45762363|NCT05531682|Drug|HB0017|HB0017 in different dosing regimens
45762364|NCT05531682|Other|Placebo|Subjects will receive several injections of Placebo
45620332|NCT04946253|Behavioral|TEAM: Implementation support strategies at the care team level following standard implementation of DOCC|Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. Coaching and consultation will be provided to the provider care team to support the use of collaborative care for behavior problems and ADHD. The TEAM intervention includes regular virtual meetings or calls with the providers (about once/month, on average) that cover core chronic care model functions, including registry use, case-finding, collaborative care team roles, and workflows outlining how DOCC is delivered in the practice.
45762365|NCT02409316|Drug|[18F]FES|[18F]FES PET/CT scan
45762366|NCT03622138|Other|Impact|Impact is an easy to use, cost- and time-efficient technology platform that is capable of (a) gathering relevant process and outcomes data in a feasible way within real-world service settings; (b) producing real-time analytics (e.g., graphical displays) and meaningful reports at the provider, service setting, and broader levels (e.g., state-wide); and (c) linking data analytics to continuous quality improvement (CQI) feedback to help providers achieve best practices and targeted youth outcomes.
45762367|NCT04379323|Diagnostic Test|YuWell YE900 Electronic Sphygmomanometer|Measurement blood pressure by YuWell YE900 Electronic Sphygmomanometer and Desk Mercury Sphygmomanometer.
45762368|NCT02246140|Other|Cerebral MRI and MRA|
45762369|NCT01728649|Other|Mild Hypothermia|Hypothermia will be achieved using the Zoll Thermoguard XP technology with the Quattro catheter. This catheter has a 9.3 Fr diameter and is 4 3cm long. It will be placed in the patients femoral vein via Seldinger technique, before reperfusion is achieved. Hypothermia will be initiated prior to reperfusion. Once temperature has reached 33.5 degrees centigrade the patient will remain at that temperature for 12 hours after which the patient will undergo active gradual rewarming at 0.2 degrees centigrade per hour.
45762370|NCT04639128|Device|Adductor Canal Catheter|The adductor canal catheter is a medical device that consists of a tunneled catheter connected to an analgesic solution-containing reservoir that slowly infuses the anesthetic over the first 2-3 postoperative days
45762371|NCT03835507|Drug|recombinant human erythropoietin(rhEPO)|Injection of erythropoietin every months (total 12 months)
45762372|NCT04404556|Behavioral|Diabetes Journey|Web-based telehealth intervention focused on adherence barriers and problem-solving
45762373|NCT04404556|Behavioral|Enhanced Standard of Care|General education via the T1DToolkit website, as well as 4 phone calls with certified diabetes educators (CDEs) will be provided.
45762374|NCT03835195|Other|Diabetes Disease Management Program|The attention is carried out in a single physical place, in the city of Medellin. The scheme of intervention in the comprehensive Diabetes Clinic is based on the concept of disease management. The intervention is composed of 5 phases, which apply to all the patients cared for in the institution (access, reception, entry, clinical consultation, management plan, education, pharmaceutical care). The healthcare team consists of 5 endocrinologists, an endocrinologist pediatrician, 7 general practitioners trained in diabetes, 5 pharmacists trained in diabetes and certified in education for patients with diabetes and 3 nutritionists.
45762375|NCT03835195|Other|Usual Care Process|The patients are treated in the cardiovascular risk clinic (general practitioners) of their Primary Healthcare Provider Institution or by specialists in internal medicine, pediatrics or endocrinology in the different Provider Institutions of Health Services of the insurance service network of health or in private doctors' offices assigned to the insurer. In some cases there is assisted consultation (general practitioner - specialist). There is no defined periodicity for follow-up; Appointments are assigned to need, according to the criteria of the treating physicians. In some cases there is remission to educational activities, not necessarily focused on type 1 diabetes.
46069180|NCT03915769|Other|Placebo|The placebo is a capsule that contains no study medication but looks exactly like the study medication capsule.
45620333|NCT04946253|Behavioral|Implementation support strategies at the leadership level following standard implementation of DOCC|Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. Practice facilitation will be provided to practice leaders to help them support the care team's use of collaborative care for behavior problems and ADHD. The LEAD intervention includes regular virtual meetings or calls with practice leaders (about once/month, on average) that cover the assessment of practice capacity/barriers, ways to overcome organizational barriers and support staff use of DOCC, promoting innovation, and leveraging practice resources to support DOCC delivery and maintenance in the practice.
45620334|NCT03207217|Other|Web-based training Product|A series of 4 modules to train providers to more effectively manage patients who screen positive for risk of suicide. The modules are: Risk Assessment, Safety Planning, Access to Lethal Means, and Willingness to accept referral.
45762376|NCT03581656|Device|ChordArt System|The ChordArt System is intended for chordal replacement in mitral valve insufficiency due to leaflet prolapse or flail. One or more ChordArt System may be utilized within the same intervention for optimal mitral valve treatment.
45762377|NCT02195440|Drug|PRI-724|10 - 160 mg/m2, 7 days CIV (in the vein) with 7 days rest per one cycle. Number of Cycles: 6.
45762378|NCT03834805|Other|lung and liver elastography measurement of fetus|Other: lung and liver elastography measurement of fetus
45762379|NCT05525052|Other|Trans-Facet fixation|Trans-facet fixation (TFF) under local anesthesia and double fluoroscopic and CT guidance is a minimally invasive technique involving the placement of screws through the posterior facet joints, improving spinal stability.
45762380|NCT03834259|Procedure|sitting position|keeping the patient in a sitting position after spinal anaesthesia
45762381|NCT03834259|Procedure|supine position|keeping the patient in supine position after spinal anaesthesia
45620335|NCT02487719|Drug|Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia|
45620336|NCT03207295|Drug|Nesiritide|A standard dose of study drug was administered by a continuous infusion for ≥24 hours and ≤7 days after cardiac intensive care unit admission
45620337|NCT03207295|Drug|Normal saline|Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
45620338|NCT04942041|Other|Simulation based quality program|Stroke team simulation. Virtual reality task training simulation.
45620339|NCT03322787|Device|HFO|Training will be done using the HFO device. Air-flow will set at the highest value tolerated by the patients, until a maximum value of 60 l/min permitted and FiO2 set during the run-in. The HFO will be administered using the AIRVO2® (Fisher&Paykel- NewZealand). Afterwards, the oxygen flow provided into the system will be progressively increased until the pre-fixed FiO2 will be reached, as displayed by the AIRVO2 monitor.
45620340|NCT03207061|Diagnostic Test|3D Ultrasound|A 3D ultrasound will be performed for all patients presenting to the clinic for suspected endometrial cancer (in addition to routine standard of care)
45762382|NCT04356040|Device|TactiFlex SE|Radiofrequency ablation with the TactiFlex SE ablation catheter. The procedure should be performed according to the TactiFlex SE investigational Instructions for Use document using the recommended ablation parameters as noted in the document.
45762383|NCT04356040|Device|TactiFlex SE - HSP|Radiofrequency ablation with the TactiFlex SE ablation catheter. Subjects in the HSP Substudy are to undergo the same study procedures as subjects in the main study, except that ablation power settings of 40-50 Watts are to be used in the left atrium, unless there is a medical reason to use a lower power.
45762384|NCT05524974|Drug|Camrelizumab|Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.
45762385|NCT05524974|Drug|Oxaliplatin|Oxaliplatin for Injection 135mg/m2 /per day，ivgtt，in day1. Given once every 3 weeks.
45762386|NCT05524974|Drug|S1|S-1 was calculated according to body surface area , P.O., bid, d1-d14. And the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time
45762387|NCT05524974|Drug|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday.
45762388|NCT05524974|Drug|Nab paclitaxel|nab-paclitaxel One course will last 21 days. Given twice every 3 weeks at a dose of 260 mg/m2 in day 1 and day 8.
45911900|NCT05234125|Behavioral|Birth Prep|The intervention involves training about pregnancy-related issues, and follow up
45620341|NCT04940871|Drug|Favipiravir HU 200 mg hard capsules|Drug substance: Favipiravir Dose: 200 mg Administration: oral Formulation: capsules
45620342|NCT04940871|Drug|Placebo HU|Name: Placebo clinical sample Drug substance: placebo Dose: - Administration: oral Formulation: capsules
45620343|NCT03319511|Other|spinal group|plain bupivacaine 0.5%,1.5 ml plus dexmedetomidine 5 μg. once injection.
45620344|NCT03319511|Other|paravertebral group|plain bupivacaine 0.5%, 0.3 ml (1.5 mg)/kg plus dexmedetomidine 0.5 μg /kg divided between the T2 and T4 levels.
45620345|NCT03226561|Procedure|Phaco / Panoptix|Phacoemulsification with bilateral diffractive trifocal lens implantation
45762389|NCT03321682|Other|Functional Training|Exercises performed in circuit, using weights, elastic bands, suspension tapes, cones and on unstable surfaces.
45762390|NCT03321682|Other|Strength Training|Exercises carried out using weights and involving the main muscle groups.
45762391|NCT00870467|Biological|Double-blind adalimumab|Double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow)
45911901|NCT05233475|Behavioral|Enhanced usual care (EUC)|"Enhanced usual care (EUC):~All participants will by a health professional be shortly informed about the typical recovery process, the given reassurance about the prognosis.as well as advice on adaptive illness behaviours post-concussion."
45911902|NCT05233475|Behavioral|Get Going after concussIoN Lite|"GAIN Lite:~GAIN Lite in an add-on to EUC, and contains two major components: 1) self-administrated e-learning videos and 2) up to four hours video- or phone sessions with an allocated therapist (either an occupational- or a physiotherapist) during a period of 8 weeks. Health professionals provide feedback and guidance, addressing the specific aims and context of the individual."
45911903|NCT05231512|Other|Respiratory Music Therapy Protocol|Participants will engage in eight (8) 45-minute virtual music therapy groups containing up to 6 participants over the course of 8 weeks. Within these groups, participants will be invited to use instruments provided including a Yamaha recorder and a Grover Trophy slide whistle. 45 minute virtual music therapy sessions facilitated by board-certified music therapy will consist of music-assisted relaxation through music visualization, followed by gentle pulmonary exercise via wind instrumental playing, and concluding with group singing.
45911904|NCT05223192|Behavioral|Music Therapy Entrainment with Ocean Disc Intervention|The studied intervention regards live entrainment with the ocean disc. Entrainment involves the use of an external stimulus, in the case of this study, an ocean disc instrument. Motion of the disc creates sounds in synchrony with the breathing of the infant and then in turn can control and influence the infant's regulation of the breath.
45620346|NCT03322709|Procedure|kidney transplant|Transplantation of a kidney either by open surgery or robotic assisted laparoscopic surgery.
45620347|NCT03091335|Other|Music-listening|Patients listen to music on headphones
45620348|NCT03226405|Other|Patient Navigation Program|PN program improve access, timeliness and adherence with cancer treatment
45620349|NCT03226405|Other|Usual Care|the standard of care provided by the institution
45762392|NCT00870467|Drug|Double-blind Placebo|Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow)
45762393|NCT00870467|Biological|Open-label Adalimumab|Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study
45762394|NCT00870467|Biological|Open-labelAdalimumabRescue|Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) as rescue treatment to complete the first 26 weeks in the study- dependent on participant eligibility (increase in disease activity), applies to Weeks 12 to 26
45762395|NCT05209932|Behavioral|Online New Beginnings Program (eNBP)|The eNBP is a five-hour, asynchronous, fully web-based adaptation of the group-based NBP that can be used on a smart phone, tablet or computer. Separate versions for fathers and mothers consist of the same didactic content and interactive exercises, with gender appropriate references, testimonials and video skills demonstrations.
45446000|NCT03752229|Device|Surgilance Lite (grey)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45446001|NCT03752229|Device|Surgilance Lite (purple)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45620350|NCT04433793|Behavioral|Yoga therapy|"One yoga session will last one hour. It consists of physical exercises (asanas), conscious breathing (Pranayama) and deep relaxation (Savasana). The subsequent body exercises are structured from lying to sitting to standing. The following sequence of exercises will be repeated in each yoga unit: 1) Relaxation: conscious breathing, body scan, mindfulness 2) Vein pump 3) Pelvis and back rotation (adapted variation of the nakrasana) 4) Pelvis opening (adapted variation of the supta baddha konasana) 5) Shoulder bridge (setu bandha sarvangasana) 6) Forward folds (Paschimottanasana and variations with Pranayama) 7) Backbend: intense east stretch (Purvottasana) 8) Diagonal static yoga cat (Majariasana 1 and resting pose) 9) Standing exercise 10) Upward Salute(Urdhva Hastasana) 11) Warrior 1 (Virabhadrasana 1) 12) Warrior 3 (Virabhadrasana 3) 13) Tree (Vrkasana variation) 14) Relaxation (Savasana)."
45620351|NCT03207139|Drug|Ga-68 PSMA ligand|"For PET/CT PSMA ligand scan, the subject will have catheter(s) placed for intravenous administration of [68Ga]PSMA ligand . Subjects will receive a single intravenous bolus of 2-5 mCi [68Ga]PSMA ligand and received PET/CT scan 60 minutes later. The data acquisition begin with non-contrast CT at 120kVp, automated mAs, and a pitch of 1.5, followed by PET acquisition from the mid-thigh to skull-base, 3 minutes each bed. After image acquisition, the subject will be observed for half an hour, and will be discharged if no adverse event happens.~The estimated organ doses show that the kidneys and the urinary bladder wall were the organs with the highest dose. As presented, the effective doses for patients were 0.023 mSv/MBq ± 15% (maximum deviation), leading to an effective dose of 3.4 mSv for an injected activity of 150 MBq."
45762396|NCT01728727|Other|UC-MSC transplantation|After enrolled, Participant will receive umbilical cord MSC transplantation of 1*10E6 cells/kg via hepatic artery. Participant will then be followed until 1 years study visit
45762397|NCT01728727|Other|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
45762398|NCT04350268|Device|Wearable sensor|Wireless sensor
45911905|NCT05200247|Drug|spesolimab|spesolimab
45620352|NCT03319433|Device|Perfusion Index|Use of non-invasive pulse oximeter to determine perfusion index
45620353|NCT03080415|Drug|Combined Therapy SOF and DCV|"1 whole or half tablet sofosbuvir and 1 whole or half tablet daclatasvir per day~SOF dosage: 400 mg/day for greater than 45 kg weight patients; 200 mg/day for 17 kg to 45 kg patients~DCV dosage: 60 mg/day for greater than 45 kg weight patients; 30 mg for 17 kg to 45 kg patients"
45620354|NCT03206983|Device|Cana's Ring|The device is used during cataract surgery to help dilate small pupils (under 5mm)
45620355|NCT03091023|Procedure|Endometrial Biopsy and endometrial fluid collection|
45620356|NCT03206827|Other|70% animal, 30% plant proteins in diet|Diet contains 70% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 30% from plant sources (bread and cereals).
45620357|NCT03206827|Other|50% animal, 50% plant proteins in diet|Diet contains 50% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 50% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
45762399|NCT01723267|Other|3D follicles assessment|3D ultrasound evaluation in IVF treatment (vs 2D ultrasound)
45762400|NCT01723267|Other|2D follicles assessment|2D ultrasound in IVF treatment (vs 3D ultrasound)
45911906|NCT05199636|Other|Dragon fruit product|Frozen dragon fruit based beverage
45446002|NCT03752229|Device|SteriLance Lite2|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45911907|NCT05192486|Drug|GNC-038|Administration by intravenous infusion
45620358|NCT03206827|Other|30% animal, 70% plant proteins in diet|Diet contains 30% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 70% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
45762401|NCT00370318|Biological|10 valent pneumococcal conjugate vaccine|
45762402|NCT00370318|Biological|Infanrix Hexa|
45762403|NCT00370318|Biological|Rotarix|
45762404|NCT00370318|Drug|Paracetamol|
45762405|NCT01723345|Drug|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
45762406|NCT04289116|Behavioral|We Test|This design tests the added benefits of adjunct intervention components delivered prior to receipt of CHTC-Assertive Communication Training (ACT) videos viewed by the couple separately and individually delivered Motivational Interviewing-based Communication Skills Training (MI-CST). These target the development of communication skills necessary to participate fully in HIV prevention and sexual safety discussions inherent to CHTC.
45762407|NCT04289116|Behavioral|IHTC|Individual HIV Testing and Counseling
45762408|NCT01728883|Device|Home vision monitoring using myVisionTrack®|Patients will be asked to test their vision at home twice per week using myVisionTrack® during the study period.
45446003|NCT03752229|Device|SensiLance (pink)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45620359|NCT03091101|Device|Scleral lens wearing keratoconics|Cohort of keratoconics fitted with scleral lenses and monitored over 6 months
45620360|NCT03226483|Radiation|Intraoperative Radiotherapy|Intraoperative Radiotherapy is performed with a mobile radiation device emitting soft energy x-rays in a spherical way. Different size applicators are available to cover the resection cavity after the tightest fit rule.
45620361|NCT03119779|Drug|MTA-Anglus|MTA-Anglus freshly mixed according to manufacturer instructions over glass slap and applied to pulp stump and application of wet cotton for 15 min. till initial setting occur.
45620362|NCT03119779|Drug|TheraCal|TheraCal directly applied from the syringe container tip to pulp stump over incremental layers each layer should not exceed 1 mm thickness and each layer will be light cured for 20 sec.
45620363|NCT03319355|Behavioral|cognitive behavioral therapy|exercise therapy
45620364|NCT03319199|Dietary Supplement|"SLIM WATER"|2 grams of L- CARNITINE and 150 mg MAGNESIUM for a duration of 16 weeks
45620365|NCT03319199|Other|Placebo - water|for a duration of 16 weeks
45620366|NCT03221881|Drug|Pegylated Liposomal Doxorubicin and docetaxel|
45620367|NCT03091257|Drug|Dabrafenib|Administered Orally BID
45620368|NCT03091257|Drug|Trametinib|Administered Orally once daily
45620369|NCT04493255|Drug|[14C]E7090|[14C]E7090, oral capsule.
45620370|NCT03206671|Drug|Rituximab window|Rituximab window (375 mg/m²)
45620371|NCT03206671|Drug|Additional doses of Rituximab|2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle, 1 dose of rituximab before the start of the third chemotherapy cycle, 1 dose of Rituximab before the start of the forth chemotherapy cycle
45620372|NCT03206671|Drug|Cyclophosphamide|see detailed protocol description
45620373|NCT03206671|Drug|Cytarabine|see detailed protocol description
45620374|NCT03206671|Drug|Dexamethasone|see detailed protocol description
45911908|NCT05191966|Procedure|Subcostal Anterior Quadratus Lumborum Block|"S-QLB3 block will be performed 30 min. before general anesthesia. For anterior QL block via subcostal approach, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the interfacial plane between the QLM and PMM.~IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose."
45911909|NCT05191966|Procedure|Thoracic Paravertebral Block|"TPVB block will be performed 30 min. before general anesthesia. TPVB will be performed at T10 transverse process level, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the paravertebral space.~IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose."
45446004|NCT03752229|Device|SteriLance Press|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45620375|NCT03206671|Drug|Doxorubicin hydrochloride|see detailed protocol description
45620376|NCT03206671|Drug|Vindesine Sulfate|see detailed protocol description
45620377|NCT03206671|Drug|Etoposide|see detailed protocol description
45620378|NCT03206671|Drug|Ifosfamide|see detailed protocol description
45620379|NCT03206671|Drug|Methotrexate|see detailed protocol description
45762409|NCT04288336|Other|Food Diary|Ancillary studies
45620380|NCT03206671|Drug|Prednisolone|see detailed protocol description
45620381|NCT03206671|Drug|Vincristine|see detailed protocol description
45620382|NCT03078387|Diagnostic Test|imaging|imaging before and after treatment
45620383|NCT03322553|Device|GERD-X|Endoscopic full-thickness plication will be performed using the GERDX® system. All procedures will be performed under general anesthesia. Savary-guidewire will be placed into the stomach using a gastroscope. The GERDX® system will be introduced over the guidewire into the stomach and retroflexed. The GE junction will be visualized using another slim endoscope passed through a channel present in the GERD-X device. According to study protocol, at least 2 pretied transmural pledgeted sutures will be deployed to achieve a tight closure of gastro-esophageal junction around the GERD-X device.
45935118|NCT00041561|Drug|inhaled nitric oxide|inhaled nitric oxide will be given at 5 ppm until day 28 or extubation
45935119|NCT00216619|Drug|Topiramate|topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening.
45620384|NCT05019573|Dietary Supplement|Black tea|Black tea twice a day for 4 weeks
45620385|NCT05019573|Dietary Supplement|Placebo|Placebo tea twice a day for 4 weeks
45620386|NCT03322475|Device|PiQo4 laser system|The PiQo4 laser system
45620387|NCT03078231|Procedure|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
45620388|NCT03078231|Drug|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
45620389|NCT03322397|Behavioral|Self-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for themselves three times per week. These acts should require effort and be outside of an individual's normal routine.
45620390|NCT03322397|Behavioral|Other-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.
45620391|NCT03322397|Behavioral|Daily Reports|Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
45762410|NCT04288336|Other|Preventative Dietary Intervention|Follow intermittent fasting
45762411|NCT04288336|Other|Questionnaire Administration|Ancillary studies
45762412|NCT01728961|Drug|Artemether/Lumefantrine (AL)|
45446005|NCT03752229|Device|SensiLance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45762413|NCT00870545|Behavioral|Telephone support groups|There was one intervention. Participants were enrolled in one of 14 telephone groups (each with a trained Group Leader and 6 participants) will focus on education, training in and practice of coping skills and cognitive restructuring (identifying and re-shaping negative and destructive thoughts), and support through 12 hour-long structured sessions. The content, modeled on Soldier BATTLEMIND, targets readjustment concepts based on the letters of BATTLEMIND, including Bonds, Adding and subtracting family roles, Taking control, Talking it out, Loyalty and commitment, Emotional balance, Mental health and readiness, Independence and interdependence, Navigating the system, Denial of self and a concluding session entitled Moving forward.
45446006|NCT03752229|Device|mylife|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45620392|NCT05005377|Procedure|Socket Preservation with Platelet-Rich Fibrin|10cc of blood was drawn from each patient and centrifuged at 2700 revolutions per minute (rpm) for 12 minutes to obtain PRF. The extraction socket was filled with PRF and covered using a membrane made of PRF.
45620393|NCT05005377|Procedure|Socket Preservation with Freeze-Dried Bone Allograft|The extraction socket was filled with FDBA (CenoBone®; Tissue Regeneration Corp., Kish Island, Iran) without flap elevation. The socket was covered using a free palatal mucosal graft obtained by the pouch technique.
45620394|NCT03077997|Behavioral|Space from Diabetes|Space from Diabetes is an internet-delivered cognitive behaviour therapy-based programme for symptoms of depression, anxiety, & diabetes distress in people with type 2 diabetes mellitus.
45762414|NCT05524896|Device|ElucidVivo|Plaque morphology characterization for predicting non-invasive fractional flow reserve (FFR)
45762415|NCT01723501|Drug|0.25% chlorhexidine|0.44% chlorhexidine di-gluconate body wipes which would release 0.25% free chlorhexidine on application
45762416|NCT01723501|Drug|sterile water|Sterile water wipes (placebo)
45762417|NCT05524818|Diagnostic Test|the Computerized Adaptive Testing System of the Functional Assessment of Stroke (CAT-FAS)|The CAT-FAS comprises 58 items. The items were selected from four well-known physical function measures for patients with stroke: 26 items from the Fugl-Meyer Assessment-Upper Limb, 11 items from the Fugl-Meyer Assessment-Lower Limb, 12 items from the Postural Assessment Scale for Stroke Patients, and 9 items from the Barthel Index. These items evaluate motor control, postural control, and activity of daily living functions in patients with stroke. The CAT-FAS assesses all these functions simultaneously. Results are automatically reported as Rasch scores. A higher score indicates greater physical functions. In the previous study, results indicated that the CAT-FAS had sufficient efficiency (< 10 items on average), reliability (Rasch reliability ≥ 0.88), concurrent validity (Pearson r ≥ 0.91), and responsiveness (SRM ≥ 0.65) in persons with stroke.
45762418|NCT02056132|Other|Exhaled Breath Condensate|Lab results of Exhaled Breath Condensate
45762419|NCT01729117|Other|Meal Replacement|5 Meal Replacements/day will be given for 3 months and then 1/day for 9 months.
45762420|NCT01729117|Other|Standard Care|Standard Care only
45446007|NCT03752229|Device|VeriFine|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45762421|NCT00872027|Drug|Escitalopram|10 mg of escitalopram administered enterally with the option for dose escalation to 20 mg after 3 to 5 weeks if the medical condition is stable and no liver disease presents
45762422|NCT00872027|Drug|Placebo|Placebo pills for 8 weeks
45762423|NCT05620849|Behavioral|Online program|The online program is 4 weeks and focused on topics such as alcohol and sexual health
45762424|NCT01854814|Drug|Mycophenolate mofetil|Mycophenolate mofetil 1.5g/day plus maximum tolerated labeled dose losartan
45762425|NCT01854814|Drug|Losartan|Maximum tolerated labeled dose of Losartan
45762426|NCT01723657|Drug|Ara-C|"Intermediate dose during induction phase to remission.~High dose during consolidation phase in patients with favorable cytogenetics and leukocyte index below 20."
45762427|NCT01723657|Other|Autologous peripheral blood stem cell transplantation.|"In patients with favorable cytogenetics with a Leukocyte index above 20.~Patients with normal karyotype, and one cycle of chemotherapy to achieve complete remission, without adverse molecular and/or minimal residual disease (MRD) characteristics, regardless availability of a matched donor."
45762428|NCT01723657|Other|Allogeneic matched related or unrelated donor transplant.|-Patients without favorable/intermediate characteristics.
45935120|NCT00216619|Drug|Topiramate - Placebo|the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26)
45935121|NCT00216658|Drug|fentanyl|
45935122|NCT00216697|Drug|bortezomib|
45935123|NCT00216775|Drug|interferon-alfa-2b and ribavirin|
45935124|NCT00041639|Drug|hMN14 (labetuzumab)|
45446008|NCT03752229|Device|Microdot|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
45620395|NCT03319121|Drug|Empirical therapy group|Receive extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks.
45620396|NCT03319121|Drug|Guided therapy group|Receive Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
45620397|NCT02487407|Drug|ODM-109|ODM-109 1 mg capsule for oral administration.
45620398|NCT02487407|Drug|Placebo for ODM-109|Placebo capsule for oral administration.
45620399|NCT03221959|Device|Medical Device Vittamed 205|Intracranial pressure measurement
45620400|NCT03078153|Behavioral|Financial Incentive|Participants will receive a $50 gift card at 3- and 6- month follow-up visits.
45762429|NCT01723657|Drug|G-CSF|"Administration at induction phase to remission, days 0 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatmen arises 30x10e9/L.~Administration at consolidation phase, days 4 to 6 (3 doses). G-CSF will be interrupted if the leukocyte count during treatment arises 30x10e9/L."
45762430|NCT01723657|Other|CD34+ selection.|-Patients with adverse prognosis with allogeneic peripheral blood stem cell (PBSC)tranplantation, CD34+ cell selection of the inoculum was performed.
45935125|NCT00216892|Drug|Calcipotriol, (calcipotriol + betamethasone)|
45620401|NCT03078153|Behavioral|Social Media Group|Participants will be invited to a study Facebook group which will have links to PrEP information and provide a forum for participants to ask questions and communicate their experience with PrEP
46069181|NCT03891160|Other|3D model of heart|To assess if a 3D printed cardiac model improves visualization of VAD and cannula placement sites in CHD-HF patients as compared to 2D imaging. The investigators will prospectively enroll CHD-HF patients at multiple centers and randomize to group A (3D printed models will be used for pre-VAD planning) or Group B (controls).
46069182|NCT03889561|Behavioral|Drink Tap|The Drink Tap intervention consists of increased access to safe and appealing drinking water, multicultural water promotion, and soda taxes.
45620402|NCT05012085|Other|Investigation of Global Interest in Global Surgery|"The investigators searched the terms global surgery and global health on Google Trends (Google Inc., CA, USA) from January 2004 to May 2021. The investigators identified time trends and compared the two search terms using SPSS v26 (IBM, WA, USA) to run summary descriptive analyses and Wilcoxon rank-sum tests."
45620403|NCT03221569|Drug|Intravenous ketamine|0.3mg/kg IVPB over 15 minutes
45620404|NCT03221569|Drug|Ketorolac|as active comparator, will be administered together with metoclopramide in one normal saline 50ml bag
45620405|NCT03221569|Drug|Normal saline|"Will be given as 50ml intravenous bag as placebo for double-blinding purposes in patients who will also receive intranasal ketamine.~Will be prepared in intranasal syringe for double blinding purposes for patients who are randomized to receive intranasal ketamine."
45620406|NCT03221569|Drug|Normal saline|1ml intravenous push as placebo for double-blinding purposes
45620407|NCT03322319|Procedure|Tissue biopsies|"It is commonly accepted that the diagnosis of cardiac amyloidosis may be based on presence of characteristic cardiac abnormalities in echography, associated with the detection of bi-refractive appearance deposits in polarized light after congo red staining of a biopsy fragment.~Usually a biopsy of the abdominal fat or salivary glands can suffice. More rarely, in case of persistent doubt (eg negativity of congo red despite a characteristic appearance, which may occur in 20 to 30% of cases), it will be necessary to perform an endomyocardial biopsy (EMB)."
46069183|NCT03884855|Other|Classical Cardiac Rehabilitation|Patients benefit from classical cardiac rehabilitation during 3 months.
46069184|NCT03884855|Other|Karate rehabilitation|Patients benefit from cardiac rehabilitation with traditional karate during 3 months. Patients will have four 60-minute group sessions four times a week, during which they will have 45-minute individual exercises and 15-minute pairs of exercises. The course of the sessions has been protocolised.
45620408|NCT05012319|Drug|to be given as a treatment|"Nitric Oxide Nasal Spray Enovid"
45620409|NCT03221803|Other|OT Vertical attachment|new extra coronal castable attachment
45620410|NCT03221803|Other|OT cap attachment|standard extra coronal attachment
45620411|NCT03322241|Other|overall wellness|Wellness lab testing
45446009|NCT03755505|Diagnostic Test|obtain samples from sputum, feces and urine|Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
45446010|NCT05359731|Drug|Bupivacaine Hydrochloride|Patients will receive a total volume of 30 ml of bupivacaine 0.5% in an axillary block with a double puncture.
45620412|NCT05011773|Device|Deep brain stimulation|Electrical pulses from implanted generator that has already been implanted for therapeutic reasons
45620413|NCT03221725|Procedure|sacrospinous ligament fixation|sacrospinous ligament fixation will be applied to prevent vaginal vault prolapse
45620414|NCT03319043|Drug|Chanqin granules|All patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation. Patients in treatment group are given additional Chanqin granules 10g three times a day; and analogous for the controlled group.
45762431|NCT01723657|Other|Mylotarg purging before autologous PBSC transplantation|Patients without favorable/intermediate characteristics and without matched related donor.
45762432|NCT02576652|Other|Tetracycline|Treatment during cycle 1 consists of a total oral dose of 1000 mg of tetracycline daily for a total of 3 days.
45935126|NCT00216931|Drug|iloprost|
45935127|NCT00216970|Dietary Supplement|Alteration in nutritional support|The subject is randomized into one of two groups - One receives TPN that does not have arginine, proline or glutamate. The other will receive TPN with extra glutamine. The subject takes part in 3 tracer studies while in the hospital. For each tracer study, the subject will receive a different randomly assigned diet. Blood and air are sampled and the patient receives a stable isotope after which the tests are repeated.
45935128|NCT00217009|Procedure|Narrowband Ultraviolet B (TL-01UVB) Therapy|
45935129|NCT00217009|Procedure|Topical Psoralen plus ultraviolet A (PUVA)|
45935130|NCT00217048|Drug|Yohimbine, oral|
45935131|NCT00217204|Drug|Pancrelipase microtablets|
45935132|NCT00412048|Procedure|fMRI to detect MCI patients who will convert to Alzheimer's disease|There is a fMRI to be realized in the 3 arms. No drug is administered
45935133|NCT00412126|Drug|Insulin|
45935134|NCT00069615|Device|GlucoWatch® G2™ Biographer (GW2B)|
45446011|NCT05359731|Drug|Bupivacaine Hydrochloride with Dexamethasone|Patients will receive a total volume of 30 ml of bupivacaine 0.5% with Dexamethasone 4 mg in an axillary block with a double puncture.
45762433|NCT02576652|Other|Demeclocycline|Treatment during cycle 2 consists of a total oral dose of 600 mg of demeclocycline daily for 3 days.
45762434|NCT02576652|Procedure|Total Hip Replacement|Participants entering this study were prescheduled to undergo elective THR due to osteoarthritis. Surgery was to be performed according to local standard of care. During THR a fragment of femoral bone was acquired for histomorphometry evaluation.
45762435|NCT03407911|Other|Harvested|Metagenomic exam of Gingival crevicular fluid harvested by adsorbent paper point around periodontal teeth and implant affected by peri-implantitis
45762436|NCT01850758|Procedure|Regenexx SD|stem cell treatment
45762437|NCT01850758|Other|Exercise Therapy|exercise therapy control
45762438|NCT01812304|Other|hands-on training|the intervention consists of a predefined hands-on training program including 25 technical steps to manage a vaginal breech
45762439|NCT01812304|Other|frontal teaching|one teacher demonstrates all 25 items listed in the OSATS checklist. Probands listen and watch.
45762440|NCT01729273|Other|Diet and Exercise Intervention|Remote Dietary and Exercise Intervention Program
45762441|NCT04645134|Behavioral|Brain Health Assessments|The investigators are enrolling up to 28 healthy, older adults (ages 65-85 y, BMI 20-35 kg/m2) stratified by current physical activity level (equal inactive vs. equal highly active). Each physical activity group (inactive and highly active) will undergo a blood draw, body composition, resting metabolic rate, cognitive testing, and magnetic resonance (MR) imaging.
45762442|NCT01743742|Drug|Vitamin E, Vitamin C|
45762443|NCT01723735|Drug|Alirocumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
45762444|NCT01723735|Drug|Ezetimibe|"Pharmaceutical form: overencapsulated tablet~Route of administration: oral"
45762445|NCT01723735|Drug|Ezetimibe Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
45762446|NCT01723735|Drug|Fenofibrate|"Pharmaceutical form: tablet~Route of administration: oral"
45446012|NCT03695367|Drug|HTX-011|HTX-011 (bupivacaine/meloxicam), 300 mg/ 9 mg via instillation.
45620415|NCT05019183|Other|Physical training|The subjects will perform 6 indoor rower sessions (30 min each, on Day 1, 2, 3, 8, 9 and 10) with a target heart rate zone of 60%.
45620416|NCT05019183|Other|Virtual reality|The subjects will be able to move freely in virtual environments while training on the indoor rower.
45620417|NCT05019183|Device|Single-photon emission computed tomography (SPECT)|SPECT allows the measurement of cerebral perfusion, reflecting the global synaptic activity, via a 3D acquisition of 20 minutes, 15 minutes after injection of 740 MBq of radiotracers (ECD - Neurolite or HMPAo - Cerestab), with iterative reconstruction. The data will be processed at the voxel scale by the SPM12 software, with analysis of brain connectivity.
45620418|NCT05019183|Biological|Metabolomics|This qualitative approach will aim to identify pathways that are not known (or have not been explored) to optimize the chances of detecting metabolites present depending on the group (physical activity coupled or not with VR). This method is favorable for biomarker discovery.
45620419|NCT02451475|Drug|Amitriptyline|Amitriptyline 25 mg/day
45620420|NCT02451475|Drug|Venlafaxine|Venlafaxine 75 mg/day
45762447|NCT00872729|Drug|Cystagon®|"Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.~Duration of Treatment and Dose: Reference Period up to four doses Q6H."
45762448|NCT00872729|Drug|RP103|"Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.~Duration of treatment and Dose: Single dose of Test Product at dose equivalent to Reference Product."
45762449|NCT01729429|Behavioral|HPV brochure, recall, reminders|"HPV-vaccine specific brochure mailed before clinic visit~Telephone recalls after visit for those who complete pre-clinic survey and decline the vaccine~Telephone reminders for those who complete the pre-clinic survey and are late for receiving the 2nd and/or 3 doses"
45762450|NCT01729429|Behavioral|General Adolescent Vaccine Brochure|Participants were mailed a brochure describing the 4 recommended adolescent vaccines (HPV, meningococcal, tetanus diptheria acellular pertussis (TDAP), and influenza) 1-2 weeks before a clinic visit
45762451|NCT04640376|Drug|Paracetamol Uniflash 125mg|Oromucosal solution 1.25 mL for buccal use
45446013|NCT03695367|Device|Luer lock applicator|Applicator for instillation.
45446014|NCT03695367|Device|Vial access device|Device for withdrawal of drug product.
45446015|NCT03695367|Drug|Ibuprofen|Ibuprofen, 600 mg.
45446016|NCT03695367|Drug|Acetaminophen|Acetaminophen, 1 g.
45762452|NCT04640376|Drug|Panadol 500 MG Oral Tablet X1|Tablet masked in capsule
45762453|NCT04640376|Drug|Panadol 500 MG Oral Tablet X2|Tablet masked in capsule
45762454|NCT04640376|Drug|Placebo|Dummy treatment
45762455|NCT03320200|Other|CNS-focused treatment|The CNS-focused treatment will last for 10 weeks, conducted in 60-minute sessions on a weekly basis. In addition, participants in this group will complete a home treatment program for 30 minutes, five times a week.
45762456|NCT03320200|Other|Standard Care Treatment|The standard physiotherapy group will receive a 10-session treatment program that will include one corticosteroid infiltration provided in the early acute stage followed by a multimodal physiotherapy program including analgesic modalities (e.g. TENS, cryotherapy) and exercise and manual therapy techniques addressing the specific mobility deficits of each patient. This program also include a home treatment based on conventional physiotherapy that involves a training load comparable to that in the CNS-focused group.
45762457|NCT03407755|Procedure|Intraocular gas|Participants randomized to either air or SF6 gas in the anterior chamber.
45762458|NCT00832871|Drug|Mifepristone|Mifepristone 200 mg will be administered orally
45935135|NCT00069615|Device|Continuous Glucose Monitoring System™ (CGMS)|
45935136|NCT00412165|Behavioral|Cell Phone|The cell phone arm receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
45446017|NCT03695367|Drug|Ketorolac|Intraoperative IV ketorolac.
45620421|NCT02451475|Drug|Paroxetine|Paroxetine 25 mg/day
45620422|NCT03322163|Other|Exposure is maternal iodine|The exposure is preconception maternal iodine status There is no intervention in this observational study
45762459|NCT01723813|Biological|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2|Each peptide will be given at a dose of 300 µg in 1 ml of sodium chloride 0.9%, every 3 weeks on 6 occasions, and will be administered at one site in arm or thigh, 20% of the dose intradermally and 80% of the dose subcutaneously.
45762460|NCT01723813|Biological|Galectin-3 inhibitor: GM-CT-01 systemic injections|Systemic injection of GM-CT-01: GM-CT-01 will be administered by slow intravenous infusions at a dose of 280 mg/m2, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination.
45762461|NCT01723813|Biological|Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration|GM-CT-01 will be injected peri-tumoral at a dose of 100 µg per tumor injected, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination. If a patient has one or two superficial metastases at day 43 of the treatment, one of these lesions will be treated. If a patient has more than two superficial metastases at day 43, two of these lesions will be treated.
45762462|NCT05081297|Other|Qigong|Qigong as a traditional chinese medicine technique, composed of several types of exercises: Baduanjin, taijiquan, yijinjing, baojiangong.
46069185|NCT03878069|Biological|elapegademase-lvlr|"Patients transitioning from Adagen: For patients currently receiving Adagen at ≤ 30 U/kg/wk or an unknown Adagen dose, the suggested dosage of Revcovi is 0.2 mg/kg/wk IM. For patients currently receiving Adagen at > 30 U/kg/wk the suggested equivalent Revcovi dosage (mg/kg/wk) is the Adagen dosage in U/kg/wk divided by 150.~At the investigator's discretion, the total weekly dose may be divided and administered in multiple IM injections, increased by 0.033 mg/kg/wk if trough ADA activity is < 30 mmol/hr/L, dAXP is > 0.02 mmol/L, and/or the immune reconstitution is inadequate.~Adagen-naïve patients: The suggested starting Revcovi dosage is 0.2 mg/kg twice weekly IM based on ideal body weight, for a minimum of 12 to 24 weeks until immune reconstitution is achieved. At the investigator's discretion, the dosage may be gradually increased to maintain trough ADA activity > 30 mmol/hr/L, dAXP < 0.02 mmol/L, and/or to maintain adequate immune reconstitution."
45762463|NCT03307018|Procedure|Postoperative systematic bronchial aspiration.|Postoperative flexible bronchoscopy and systematic bronchial aspiration.
45762464|NCT01729507|Other|tDCS|Stimulation will be performed with a DC stimulator MC Location of stimulation: Anode over the left dorsolateral cortex, corresponding with F3 (in 10-20 EEG system); cathode over the right temporal cortex Intensity: 2 mA Total duration: Constant stimulation for 20 minutes
45762465|NCT01729507|Behavioral|standardised behavioural therapy|"The standardised behavioural therapy will be performed according to the certified Smoke-free programme' of the of the Institute for Therapy Research ('Institut für Therapieforschung', IFT). The course leaders' manual specifies that the ideal number of participants is 8-12.~1 group session for 90 minutes/week for 7 weeks, 2 telephone calls of 10 minutes each, first after the fourth session 3 days after collective smoking cessation, second on day 3 after the last session."
45762466|NCT05530200|Radiation|Hypofractionated radiotherapy|24Gy/8Gy/3f
45762467|NCT05530200|Drug|PD-L1 inhibitor|q3w
45911910|NCT05186324|Other|Interview|"During each interview, patients will be asked questions to collect demographic and clinical information, and asked a set of open-ended questions with probes to describe their experiences with Fabry disease (symptomology and impacts on patient's lives [i.e., activities of daily living, school/work, ability to take holidays/vacation]), and pegunigalsidase alfa treatment (experience of infusions and schedule) and their experience of change in symptoms and impacts over the BRIGHT-F51 clinical study.~A semi-structured discussion guide will be used to conduct the approximately 60-minute interviews. The use of open-ended questions avoids bias and questions will not be read verbatim to allow for a free-flowing discussion."
45935137|NCT00412165|Behavioral|Weekly access to interactive web site|This group receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
45935138|NCT00412165|Behavioral|Group|The Group arm receives monthly face to face group sessions plus access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
45620423|NCT03226327|Dietary Supplement|formula salt with very low sodium (Brand name: Manlikang)|hypertension patients will use the formula salt with very low (<20%) sodium （Manlikang) for six weeks, and will be followed up at 1, 2, 4 and 6 weeks to assess the 24-hour urine sodium.
45620424|NCT05019417|Drug|Glycerol Phenylbutyrate 1100 MG/ML|Daily adminisitraion of the study drug (three times a day) in escalting dose over 4 months
45620425|NCT03225937|Drug|Trastuzumab, Lapatinib|Patients enrolled in Cohort A will receive lapatinib 1000 mg daily per os + trastuzumab 4 mg/kg iv load, followed by 2 mg/kg iv weekly. Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first.
45620426|NCT03225937|Drug|Pertuzumab, trastuzumab-emtansine|"Patients enrolled in Cohort B will receive pertuzumab 840 mg iv load, followed by 420 mg iv Q3weeks + trastuzumab-emtansine 3.6 mg/kg iv on day 1 of each subsequent 3 week cycle.~Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first."
45620427|NCT03318887|Drug|Sofosbuvir/daclatasvir with or without ribavirin|Direct-acting antiviral treatment for hepatitis C virus infection
45620428|NCT05011695|Other|physiotherapy|The 1st group will be given ESWT therapy, the 2nd group will be given transverse friction massage, and the 3rd group will be given exercises that are used in the treatment of plantar fasciitis and have proven effectiveness
45620429|NCT02487875|Other|rehabilitation|
45620430|NCT03119077|Drug|BAY1161116|Escalating doses of BAY1161116; single dose administration; redosing of BAY1161116 at dose group 1 together with itraconazole; redosing of BAY1161116 at dose group 2 as liquid service formulation, redosing of BAY1161116 at dose group 3 together with food
45620431|NCT03119077|Drug|Placebo|Escalating doses of respective placebos; single dose administration; redosing of placebo at dose group 1 together with itraconazole; redosing of placebo at dose group 2 as liquid service formulation, redosing of placebo at dose group 3 together with food
45762468|NCT05530200|Drug|GM-CSF|200μg, D1-D7
45762469|NCT05530200|Drug|IL-2|at a dose of 2 million IU, D8-D14
45935139|NCT00412204|Drug|tiotropium bromide|Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
45762470|NCT05044949|Other|Probiotic|The study product is a probiotic strain
45762471|NCT05044949|Other|Placebo|The study product is a placebo to the probiotic strain
45762472|NCT01729585|Procedure|Massage Therapy|The Massage Therapy protocol consists of a series of 5 massages administered over 10 (+2) weeks. Length of time for each visit will be approximately 1.5 - 2 hours Typically, a series of treatments over time allows the body time to integrate tissue related changes and potentially maintain a more healthy musculoskeletal state. Based on expert opinion in the field of MT, following a series of massage treatments administered over time, one can anticipate tissue changes. By adding time between treatments, data will describe the ability of subjects to maintain changes over progressively longer periods of time. Treatment protocol will be based on the application of myofascial trigger point therapy (Timberlake, 1999) to musculoskeletal areas of the body often affected by disease progression in CF.
45762473|NCT03301168|Biological|BPX-501 T cells|T cells transduced with CaspaCIDe® safety switch
45762474|NCT03301168|Drug|Rimiducid|administered to inactivate BPX-501 cells in the event of GVHD
45762475|NCT01723891|Drug|Surfolase capsule|
45762476|NCT01723891|Drug|HT-002-01|
45762477|NCT05531136|Other|Exercise program|a 12-weeks exercise program consisting of foot strengthening exercises prescribed for 5 daily sessions a week, of which 1 supervised, 20 minutes per session on top of the regular exercise therapy to prevent falling
45762478|NCT04981301|Drug|Quadratus Lumborum Block|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions using 10% povidone iodine, the convex probe will be covered with a sterile sheath and a 22G, 100 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the abdominal muscles with the anterior approach, the needle will be punctured in the Petit triangle and 5 ml of saline will be injected into the anterolateral border of the quadratus lumborum muscle. After the block location is confirmed, 15 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (30 ml totally).
45762479|NCT01729663|Biological|CSF470 vaccine, BCG, Molgramostim|
45762480|NCT01729663|Drug|interferon alpha 2b|
45911911|NCT05176106|Behavioral|CHW Incentives Intervention|The intervention comprises of an incentives package provided to VHTs who are active in the intervention-randomized parishes. It will comprise of items that will motivate them and support their work as VHTs in the community.
45446018|NCT05668923|Behavioral|Speech sound stimulation|Behavioral-, electrophysiological-, and magnetic resonance imaging-based speech sound testing
45620432|NCT03119077|Drug|Itraconazole|Redosing of BAY1161116/placebo at dose group 1 together with itraconazole
45620433|NCT03090945|Other|This is an obsevational cohort study|no intervention
45620434|NCT03226093|Procedure|Stromal Vascular Fraction|The fat was separated via centrifuge to isolate the SVF and the cells were delivered intraarticularly, intravenously, intrathecally, or intradiscally directly into the same patient
45620435|NCT05011227|Drug|Camrelizumab|2 cycles before endoscopic surgery and one year after
45620436|NCT05011227|Drug|Chemotherapy|2 cycles before endoscopic surgery, with or without after surgery
45620437|NCT05011227|Procedure|endoscopic surgery|standard endoscopic surgery for recurrent nasopharyngeal carcinoma
45620438|NCT02487329|Other|Calcium Hydroxide|Exposed area was sealed with a self-hardening calcium hydroxide paste then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
45620439|NCT02487329|Other|Er,Cr:YSGG laser + calcium hydroxide|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, it was sealed with a self-hardening calcium hydroxide paste.Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
45620440|NCT02487329|Other|TheraCal LC|TheraCal LC was applied directly to the exposed pulp with a needle tip syringe in incremental layers that was not to exceed 1 mm in depth. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
45620441|NCT02487329|Other|Er,Cr:YSGG laser + TheraCal LC|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, TheraCal LC was used to seal the treated area. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
45762481|NCT05530122|Biological|infliximab, adalimumab, golimumab, vedolizumab, ustekinumab|
45762482|NCT03407677|Device|ROTO track®|An electronic injection form and injection log for keeping track of injection sites in the abdominal region. The device attaches directly to the insulin pen and activates whenever the insulin pen is picked up.
45762483|NCT03070600|Other|Universal PrEP Counseling|Counseling at universal sites, will use a standardized counseling script to state that PrEP is available for women at risk for HIV, explain that HIV prevalence in the region is high, and will note that women with HIV positive partners or who don't know their partner's status may be at risk. Counseling will specify that women may have their own reasons to feel at risk or to want PrEP. Following standardized counseling, women will select PrEP at the same visit or will be allowed to deliberate on the decision and come back at the next visit with a decision. Women will be informed that it is advisable to use PrEP if they know their partner is HIV positive or if they do not know their partner's status and will be encouraged to bring untested partners to clinic if status is unknown.
45762484|NCT03070600|Other|Targeted PrEP Counseling|"Following enrollment, the targeted PrEP clinics will provide two inter-related innovations over two ANC visits. In the targeted PrEP clinics, any of the following three criteria can trigger enhanced PrEP counseling. A participant that meets any one of these criteria will receive PrEP counseling during the study visit where the criteria is met:~Risk Score >6 (Risk score includes male partner status known/unknown, syphilis infection, and lifetime number of male partners) or any National AIDS and STI Control Programme (NASCOP) risk factors~participant declines partner self-tests regardless of partner HIV status, and/or~their partner declines self-testing or tests positive."
45446019|NCT02794480|Device|ELLIPTA DPI|It is the inhaler with two blister strips containing white coloured powder, one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate. It is given as oral inhalation (Inhalation powder)
45446020|NCT02794480|Device|GSK MDI|It is the placebo inhaler with clear liquid containing propellant (1,1,1, 2- Tetrafluoroethane). It is given as oral inhalation (Inhalation Aerosol).
45446021|NCT02794480|Device|AZ MDI|It is the placebo inhaler with clear liquid. It is given as oral inhalation (Inhalation Aerosol).
45620442|NCT03226171|Drug|Dose-adjusted SK-1403|SK-1403 is to be administered to patients for the whole treatment periods (52 weeks), with individual dose adjustment
45620443|NCT03322085|Procedure|radiofrequency ablation or cryoballoon|Patients in radiofrequency ablation group receive circumferential pulmonary vein isolation,and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation. And Cryoablation is performed using a single cryoballoon. The diameter of the cryoballoon is determined as 28 mm or 23 mm according to pulmonary venography results.
45620444|NCT05018715|Diagnostic Test|Machine learning model diagnosis|Machine learning model diagnosis
45620445|NCT03206515|Device|18F Peel-Way Sheath|Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath
45620446|NCT03206515|Device|18F access sheath with a suction-evacuation function|Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function
45446022|NCT02065024|Dietary Supplement|b-cryptoxanthin plus phytosterols|
45446023|NCT03755427|Biological|15μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
45446024|NCT03755427|Biological|Aluminum Hydroxide Adjuvant|The seasonal influenza vaccine was a inactivated, split virion preparation of the influenza virus, propagated in embryonated chicken eggs. The aluminum hydroxide adjuvant was 0.5ml aluminum hydroxide adjuvant.
45620447|NCT03318731|Other|Sugar Pill|Taken orally in capsule form
45620448|NCT03318731|Dietary Supplement|Fenugreek Extract, Low Dose|Taken orally in capsule form
45762485|NCT00873821|Drug|MK-0941|Part 1 (in house): MK-0941 twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. The starting dose on Day 1 was 10 mg tablets twice daily and titrated to a maximum dose of 60 mg twice daily through Day 9. The Day 9 dose was maintained throughout Day 13. Part 2 (at home): participants continued treatment for an additional 14 days with MK-0941 60 mg tablets (or maximum dose achieved in Part 1) twice daily, before meals with 240 mL of water.
45762486|NCT00873821|Drug|Comparator: Placebo|Part 1 (in house): placebo twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. Part 2 (at home): participants continued treatment for an additional 14 days with placebo twice daily, before meals with 240 mL of water.
45762487|NCT01724047|Behavioral|Playground Intervention|Intervention is designed for children diagnosed with an autism spectrum disorder (ASD) included in a regular education k through fifth grade classroom for at least 50% of the school day. Schools will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. This study will take place at school. All intervention activities will be conducted during recess or lunch where children with autism may have the most difficulty interacting with peers. A total of 14-16 intervention sessions will be held with the child with autism, school personnel, and the child's classmates. The intervention will last approximately 3 months with a 3-month follow-up.
45762488|NCT01724047|Behavioral|STAT Intervention|This study will track the behavioral progress of children whose teachers receive training in these instructional methods. This study also will examine the ability and willingness of teachers to use these methods as they were designed. The study will last approximately 18 weeks (6 weeks of intervention, and a 3 month follow up visit). This study will take place at school. Classrooms will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. All intervention activities will be conducted with a teacher during the school day but not during instructional time. Study staff will visit the school on a weekly basis to train your child's teacher on evidence-based strategies for teaching children with autism.
45762489|NCT05208840|Drug|Ocrelizumab|Ocrelizumab will be given as slow intravenous infusion. Each treatment cycle has a duration of 6 months (5 cycles are planned in the study). The first cycle will consist of 2 infusions of 300 mg ocrelizumab (second infusion will be performed 14 days after first infusion). Cycles 2 through 5 will consist of one infusion of 600 mg ocrelizumab administered on Day 1 of each cycle.
45762490|NCT03407599|Drug|Faster aspart|An injection of fast-acting insulin aspart 0.2 U/kg body weight under the skin just prior to a standard meal.
45762491|NCT03407599|Drug|Insulin aspart (NovoRapid®)|An injection of insulin aspart (NovoRapid®) 0.2 U/kg body weight under the skin just prior to a standard meal.
45446025|NCT02066584|Other|Sibling oocyte incubation|
45620449|NCT03318731|Dietary Supplement|Fenugreek Extract, High Dose|Taken orally in capsule form
45620450|NCT03080103|Procedure|Laparoscopic or Open appendectomy|Laparoscopic three-port or single-port appendectomy; or conventional McBurney laparotomic appendectomy; or open appendectomy performed through midline incision
45762492|NCT04974359|Drug|Lu AG06466|Lu AG06466 - capsules
45762493|NCT04974359|Drug|Placebo|Placebo - capsules
45446026|NCT03758079|Drug|Doxepin|10 mg Doxepin for 4 weeks
45446027|NCT03758079|Drug|Gabapentin|dose of 100mg after each hemodialysis session (increased as tolerated) for 4 weeks
45446028|NCT02067910|Drug|Abatacept SC|Weekly subcutaneous administration of 125 mg Abatacept
45446029|NCT05460351|Dietary Supplement|BRJ+Nitrate|Participants in this group drank a 70 mL bottle of Beet It Sport drink with nitrate plus 15 grams of whey protein 3 days a week following a resistance exercise training program
45446030|NCT05460351|Dietary Supplement|Control|Participants in this group drank a 70 mL bottle of Beet It Sport drink without nitrate plus 15 grams of whey protein 3 days a week following a resistance exercise training program
45620451|NCT03080103|Drug|Antibiotic-first therapy|Patients treated with antibiotics as first-line approach
45620452|NCT02487173|Device|Respirio Flu Test|The Respirio Flu Test is a rapid test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
45620453|NCT02487173|Device|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse-transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
45446031|NCT02066662|Drug|Rivaroxaban or Marcumar|"Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing;~Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0."
45620454|NCT02487173|Device|Sofia® Influenza A+B Fluorescent Immunoassay (FIA)|Sofia® Influenza A+B Fluorescent Immunoassay (FIA) employs immunofluorescence to detect influenza A and influenza B viral nucleoprotein antigens in nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash samples taken directly from symptomatic patients.
45620455|NCT03221413|Device|transcranial alternating current stimulation (tACS)|
45620456|NCT03221491|Device|Patient-Controlled Analgesia(PCA)|Patients receive analgesic regimens using Patient-Controlled Analgesia(PCA) with different background infusion.
45620457|NCT04493177|Behavioral|Educational intervention|Monthly 45-minute sessions will be held, including dietary, and physical activity modification, early stimulation, exclusive breastfeeding for 6 months and the proper introduction of foods, and other support for the mother. The sessions will be supported by personalized contact by WhatsApp and programmed telephone calls, in addition to conventional treatment.
45762494|NCT00899626|Genetic|protein analysis|
45762495|NCT00899626|Genetic|proteomic profiling|
45762496|NCT00899626|Other|biologic sample preservation procedure|
45762497|NCT00899626|Other|laboratory biomarker analysis|
45762498|NCT00899626|Other|medical chart review|
45762499|NCT00899626|Procedure|diagnostic colonoscopy|
45762500|NCT00899626|Procedure|diagnostic endoscopic procedure|
45762501|NCT00899626|Procedure|diagnostic endoscopic surgery|
45762502|NCT00899626|Procedure|diagnostic surgical procedure|
45762503|NCT00899626|Procedure|endoscopic surgery|
45762504|NCT00899626|Procedure|screening colonoscopy|
45762505|NCT05529888|Drug|Isotretinoin|Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration
45762506|NCT01724125|Other|personal electronic medical record|
45762507|NCT05524272|Other|This study aims to evaluate the effects of colour by number mandala in decreasing the stress of children hospitalized due to their chronic disease.|Colour by number Mandala in different sizes includes pictures and numbers. The child has to find the colour specified in the number and colour it with the specified colour. Colourful pictures emerge as a result of colouring
45762508|NCT02444741|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
45762509|NCT02444741|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45762510|NCT02444741|Other|Laboratory Biomarker Analysis|Correlative studies
45762511|NCT02444741|Biological|Pembrolizumab|Given IV
45762512|NCT02444741|Radiation|Proton Beam Radiation Therapy|Undergo PBRT
45762513|NCT02444741|Radiation|Radiation Therapy|Undergo low dose radiation therapy
45911912|NCT05143866|Behavioral|Cognitive behavioral therapy guided self help (CBTgsh)|Based on evidence based cognitive behavioral treatment for eating disorders. Self-help version described in self-help book. Participant follows self-help program with encouragement and support of a non specialist guide
45911913|NCT05138068|Drug|MDMA|Two 8-hour experimental sessions will occur within the 11-session intervention in which participants will take a dose of MDMA. In the first Experimental Session, the initial dose will be 80 mg MDMA, with a supplemental dose of 40 mg 1.5 to 2 hours later unless contraindicated. In the second Experimental Session, the initial dose may be increased to 120 mg MDMA unless contraindicated with an additional dose of 40 mg 1.5 to 2 hours after the initial dose is given unless contraindicated.
45911914|NCT05138068|Behavioral|Psychotherapy|Adjunctive, manualized psychotherapy will be provided by a team of two therapists during the MDMA-assisted therapy sessions
45620458|NCT04493177|Other|Conventional treatment Guia de Practica Clinica IMSS-029-08|Conventional treatment includes some early stimulation, monthly visits for height/weight measurement of the offspring.
45762514|NCT02444741|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45762515|NCT05524194|Drug|Intravenous Infusion|Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
45762516|NCT03407365|Behavioral|10 Week Exercise Program|Subjects will complete a 10 week exercise program using DVD with instructions provided. Participants will have to do one session of exercise on 5 different days each week for a total of 5 sessions per week, for 10 weeks.
45762517|NCT03407365|Behavioral|DVD Program After 10 Weeks|If the DVD program shows to help participants in Group 1, the program and DVD will be provided to Group 2 participants
45762518|NCT05518578|Drug|SPN-817|oral capsule
45762519|NCT05518500|Biological|Flu Vaccine (Year 1)|Participants will receive Fluzone® Quadrivalent High-Dose in the 2022-2023 flu season.
45762520|NCT05518500|Biological|Flu Vaccine (Year 2)|Participants will receive FLUAD® Quadrivalent in the 2023-2024 flu season.
45762521|NCT05518500|Biological|Flu Vaccine (Year 3)|The flu vaccine to be administered in the 2024-2025 flu season is to be determined. Researchers are hoping that by the 2024-2025 flu season an mRNA-based influenza vaccine will be approved by the FDA and available for use in this study. In the event an mRNA vaccine is not available, researchers will reassess the vaccine to be administered in Year 3.
45762522|NCT04249492|Device|IOL implantation experimental (Isopure 1.2.3.)|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > intermediate > near
45762523|NCT04249492|Device|IOL implantation active comparator (Micropure 1.2.3.)|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > near > intermediate
45762524|NCT04300764|Behavioral|Gamification Intervention|Intervention participants will receive daily text messages to help them set goals, receive feedback and support on their progress towards daily goals, and receive points for daily goals achieved. Each participant will be given a Fitbit watch that will transmit data to the Way to Health study platform. Data will be passively collected during the inpatient stay and for 30 days after hospital discharge.
45620459|NCT03079479|Diagnostic Test|Muscle Strenght assesment|Muscle Strenght assesment of the hip muscles
45762525|NCT05205174|Device|depth electrodes|The study will be conducted at a single center, in TBI patients requiring neurosurgical intervention in the form of EVD placement. During neurosurgical intervention at the bedside in the Intensive Care Unit (ICU), a single depth electrode will be placed in the brain adjacent to the EVD catheter in the same burr hole. After EVD and depth electrode placement, continuous recording of ECoG activity as well as relevant physiological parameters will be performed for the duration of clinically indicated invasive neuromonitoring in accordance with the standard of care for TBI patients. A single recording station is currently available for data collection, therefore, with an anticipated average recording period of 14 days, the study will take greater than 210 days to complete for a total of 15 patients.
45762526|NCT05518344|Device|"Viziatek ISL™ (hereinafter referred to as the ISL) implanted in blind eye."|"Viziatek ISL™ (hereinafter referred to as the ISL) implanted in blind eye."
45762527|NCT05518266|Procedure|US-guided Parasternal block|Bupivacaine 0.25 % will be injected into the fascial plane between the pectoralis major muscle and external intercostal muscle or costal cartilages on each side of sternum after skin closure under ultrasound guidance
45762528|NCT05518266|Procedure|Surgeon-delivered parasternal block|Just before wiring of the sternum, the surgeon will inject bupivacaine 0.25 % in 4 mL aliquots into the anterior (2nd-6th) intercostal spaces on each side about 2 cm lateral to the sternal edge with a total volume of 40 mL under direct vision.
45762529|NCT03058978|Device|Etonogestrel Implant|Ovarian function will be assessed with weekly serum progesterone levels. Participants will undergo weekly venipuncture for a total of four draws over a 30 day period. Participants will also complete a bleeding diary to assess daily bleeding patterns for the 30 day study period.
45762530|NCT05523960|Procedure|No MBP|No mechanical bowel preparation before operation
45620460|NCT03079479|Diagnostic Test|2D Kinematics Analysis|2D Kinematics Analysis of the gait
45762531|NCT05529576|Drug|Omega 3 fatty acid|Omega-3 fatty acids complementation according to the patient's CRP level
45762532|NCT00212134|Device|Contact lens correction of aphakia|optical correction of infant surgical aphakia with Contact lens
45762533|NCT00212134|Device|Intraocular lens implantation|optical correction of surgical aphakia with intraocular lens
45762534|NCT05517876|Device|Vascular abdominal or peripheral surgery|"replacement or bypass of arteries presenting aneurysm or obliterative arterial disease. Their indication is restricted to abdominal and peripheral surgery not crossing the knee flexion crease.~Abdominal vascular surgery includes abdominal aorto-aortic and/or aorto-iliac and/or aorto-femoral vascular repair, i.e. graft implantation with proximal anastomosis to abdominal aorta (supra and/or infra-renal).~Peripheral vascular surgery includes peripheral arteries repair, i.e. graft implantation with no aortic anastomosis, and/or extra-anatomic vascular repair such as axillo-femoral and/or crossover bypass (femoro-femoral and/or ilio-femoral)."
45762535|NCT02575950|Drug|LEO43204|
45762536|NCT02575950|Drug|Placebo|
45762537|NCT02477878|Biological|BPX-501|Biological: T cells transduced with CaspaCIDe suicide gene
45911915|NCT05121168|Drug|Active bupivacaine 0.25% via an erector spinae plane perineural catheter|Administration of bupivacaine 0.25% through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
45911916|NCT05121168|Drug|Placebo normal saline via an erector spinae plane perineural catheter|Administration of normal saline through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
45446032|NCT05280873|Drug|Pirfenidone, methylprednisolone|Methylprednisolone 2 mg / kg / d+ pirfenidone (starting from 200mg tid, increasing to 600mg tid within one week and maintaining) . Methylprednisolone was reduced according to the researcher's evaluation of the patient's condition and the specific course of treatment was determined.
45446033|NCT05280873|Drug|Methylprednisolone|Methylprednisolone 2 mg / kg / d . Methylprednisolone was gradually reduced after the improvement of symptoms and imaging. The treatment course was 6-8 weeks
45620461|NCT04493021|Device|Dermal Cooling System|Controlled localized cooling will be applied to benign pigmented lesions using the Dermal Cooling System
45762538|NCT02477878|Drug|Rimiducid|Rimiducid administered to treat GVHD
45762539|NCT00371098|Biological|Influenza vaccination: Influvac (SolvayPharma)|
45762540|NCT00371098|Biological|placebo influenza vaccine|
45762541|NCT04114708|Diagnostic Test|Anterior cruciate ligament Reconstruction (ACLR)|All patients will undergo an anatomic ACLR via a standardized fashion using BTB autograft.
45762542|NCT04114708|Diagnostic Test|ACLR with lateral extra-articular tenodesis (LET)|All LETs will be performed in a standardized fashion using the modified Lameire technique. All patients will undergo an anatomic ACLR via a standardized fashion using BTB autogaft graft.
45911917|NCT05091905|Drug|Continuous Infusion of ropivacaine 0.2%|Patients will receive a continuous infusion of Ropivacaine 0.2% (6 mL/hr popliteal-sciatic and 8 mL/hr infraclavicular, 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room.
45935140|NCT00412204|Other|Placebo|Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
45935141|NCT00041678|Drug|aripiprazole|
45620462|NCT03077763|Drug|Sodium Nitrite|
45762543|NCT05523804|Procedure|interval cytoreductive surgery|cytoreductive surgery after 3-4 cycles of chemotherapy
45620463|NCT03120091|Device|Real-time continuous blood glucose monitoring system(CGMS)|A total of 20 patients were enrolled for the place of CGMS.CGMS were placed on the right chest wall of each patients and recorded the interstitial glucose. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
45620464|NCT04955223|Drug|Yinhu Qingwen Granules|For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day.
45620465|NCT03206281|Diagnostic Test|Fetal wight estimation|We will estimate the fetal weight by sonographic and clinical estimation
45620466|NCT04493099|Drug|Alvocidib Hydrochloride|Given IV
45620467|NCT04493099|Drug|Decitabine|Given IV
45620468|NCT04493099|Drug|Venetoclax|Given PO
46069186|NCT03876873|Procedure|Head Rotation During Face Mask Ventilation|Participants will receive face mask ventilation in either a neutral head position (practice standard position) or a head rotation position (45 degree angle).
45620469|NCT05004909|Drug|0.05% Tretinoin|Topical 0.05% tretinoin cream applied daily every night by the subjects according to assigned randomization
45620470|NCT03119545|Behavioral|Beardslee family centered intervention|The method entails six meetings. The time for the meeting is 1-2 hours and is usually held once per week. Meetings 1 and 2) include only the parents and focus firstly on the ill parent's history and secondly on the well parent/relative. Meeting 3) includes interviews with each child aged 6-19 years, without the parents being present, concerning the child´s understanding of the disease, potential worries and questions. During the interview the child can formulate his or her own questions for the family meeting. Meeting 4) includes the parents and focuses on the planning of the family meeting. The child's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5) is the family meeting. Meeting 6) is a follow-up with all of the family members.
45620471|NCT03077529|Dietary Supplement|Galacto-oligosacchride|During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
45620472|NCT03077529|Dietary Supplement|Maltodextrin|During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
45620473|NCT03318575|Device|autoRIC|Automated Remote Ischemic Conditioning
45620474|NCT03318575|Device|autoRIC Sham|Automated Remote Ischemic Conditioning Sham
45762544|NCT05523804|Procedure|delayed cytoreductive surgery|surgery after >5 cycles of chemotherapy
45762545|NCT05523804|Other|no surgery|no cytoreductive surgery (>5 cycles of chemotherapy alone)
45762546|NCT00913627|Drug|ibuprofen|
45762547|NCT00913627|Drug|ibuprofen|
45762548|NCT00913627|Drug|naproxen|
45762549|NCT00913627|Drug|Placebo|
45762550|NCT05517798|Procedure|Alveolar ridge preservation|Alveolar ridge preservation is a method of decreasing bone resorption following tooth extraction and facilitating prosthetically-driven implant placement
45762551|NCT05529498|Behavioral|Moderate paced continuous gait training|walking continuously for 20 minutes at a moderate pace
45762552|NCT05529498|Behavioral|High Intensity Interval gait training|20 minutes of interspersing 30 seconds of fast walking with 1 minute of rest
45762553|NCT04297254|Drug|Lenvatinib|Lenvatinib capsules.
45762554|NCT04297176|Drug|Vancomycin-traditional dosing|The dose is calculated based on 2 vancomycin serum levels
45762555|NCT04297176|Drug|Vancomycin- Trough-only based dosing|The dose is calculated based on 1 vancomycin serum level (i.e. trough)
45762556|NCT02425306|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
45762557|NCT02425306|Drug|Montanide ISA-51|Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant
45446034|NCT02066818|Drug|Lidocaine/tetracaine patch|
45620475|NCT03119623|Drug|sacubitril/valsartan|Sacubitril/valsartan 100mg titrated up to sacubitril/valsartan 200mg
45620476|NCT03119623|Drug|Enalapril|enalapril 5mg, titrated up to 10mg po BID
45620477|NCT04463121|Device|Moderato IPG's CNT pacing signals|Assesment of cardiac function and sympatheric activity will be obtained simultaneously
45762558|NCT02425306|Drug|polyICLC|polyICLC, local adjuvant
45620478|NCT04463121|Device|CD Leycom Pressure/Volume Combination Catheters|Simultaneous recording of the Pressure, Volume measurements and ECG signals will be done for constant monitoring of intra-ventricular pressure and volume.
45762559|NCT02425306|Drug|Cyclophosphamide|Cyclophosphamide, systemic adjuvant
45446035|NCT02066818|Drug|1% lidocaine|
45620479|NCT03318419|Drug|Cladribine|5mg/㎡ d1-5
45762560|NCT05529420|Other|measurement of the depth of neuromuscular blockade|time of TOF 1 measurement (= clinical effect, stimulation of the ulnar nerve - adductor pollicis muscle tension) will be documented in the CRF and if there is no need to add further doses of the muscle relaxant, TOF 2, TOF 3, TOF 4, and TOF-R ≥ 0,9 (= time to full recovery from the effect of the non-depolarizing muscle relaxant) will also be registered.
45762561|NCT05454592|Behavioral|Stress and Coping Online Outreach Program|3 videos and a resource library disseminated over the course of 9 weeks.
45762562|NCT04142034|Behavioral|the iAmHealthy Behavioral Intervention|"iAmHealthy Behavioral Intervention Arm~Child/caregiver pairs in the iAmHealthy behavioral intervention arm will receive:~usual care at their clinic for all issues, including overweight and obesity;~a monthly newsletter that focuses on general child health. The child/caregiver pairs will receive six newsletters (one per month) during the six month intervention period (same newsletter provided to the newsletter-only intervention participants);~weekly group sessions for the first three months, followed by monthly group sessions during the next three months, for a total of 15 group sessions. The trial's iAmHealthy behavioral intervention psychologist or social worker (one team per clinic) will deliver these group sessions via an electronic tablet that the trial sponsor will supply;~11 hours of individual homework sessions with the iAmHealthy behavioral intervention dietician"
45762563|NCT04142034|Behavioral|Newsletter only arm|Newsletter arm participants will receive a monthly newsletter on maintaining a healthy weight through diet and exercise
45762564|NCT04142034|Other|Consecutive Recruitment|Recruitment of study participants through identifying potential participants through their medical records
45620480|NCT03318419|Drug|G-CSF|300ug d0-14
45620481|NCT03318419|Drug|Cytarabine|10mg/㎡ q12h SC d1-14
45620482|NCT03318419|Drug|Pegaspargase|2500U/m2 im d1
45762565|NCT04142034|Other|Traditional Recruitment|Recruitment of potential participants through flyers and advertisements
45762566|NCT05454514|Device|HiDO medication adherence platform|The HiDO medication adherence platform will be shipped directly to the home of record of each participant. The Primary Endpoint is medication adherence as assessed by remote observation through the HiDO device at 90 days.
45762567|NCT05454514|Device|Automated Medication Platform with Video Observation|There is no drug intervention. The device elicits increases adherence of medications.
46069187|NCT03876873|Device|Medline Top Valve Anesthesia Mask|Face mask used per standard of care to provide oxygen to subjects before surgical procedures.
45620483|NCT03221647|Other|Intestinal biopsies|Intestinal biopsies obtained from Patients and Controls by EGDS. The patients and controls had the intestinal biopsies as a diagnostic step or routine check independently from the present study. For this study 3 additional biopsies samples were done in patients and controls that signed the informed consent.
45620484|NCT03076827|Procedure|Total hip replacement|Total hip replacement starts in the morning in group A and starts in the afternoon in group P.
45446036|NCT04558125|Drug|TNKase|Tenecteplase (0.25 mg/kg) supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.
45620485|NCT03076827|Procedure|Hemi-arthroplasty|Hemi-arthroplasty starts in the morning in group A and starts in the afternoon in group P.
45620486|NCT03321851|Device|V-sensor device user|Participants use device to detect the 5 vital signs (Blood Pressure, Pulse, Respiration, SpO2, Temperature).
45620487|NCT03221179|Biological|RO7049665|A single ascending dose (starting dose 1.5 micrograms [mcg])of RO7049665 will be administered SC.
45762568|NCT05454514|Other|Time on Task|"Other Endpoints include Time on Task for initial registration, first click testing, facial recognition setup, medication administration, number and type of critical and non-critical errors and error-free rate, System Usability Scale (SUS), and Net Promoter Score."
45762569|NCT02231710|Biological|BPX-501 and Rimiducid|Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by Rimiducid infusion on day 7
45762570|NCT05523648|Drug|Chronic Hepatitis B|92 patients included in the study were randomly divided into 2 groups, 42 patients in the control group and 50 patients in the treatment group. Both groups of patients received conventional basic treatment such as liver protection. Moreover, in both groups, patients were instructed to change their dietary structure to control low-fat and low-sugar, and were instructed to perform appropriate aerobic exercise.
45762571|NCT02115100|Procedure|procedure|Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only
45762572|NCT05523570|Drug|HNC364|A total of 2 dose cohorts are planned for the formal study: 20 mg and 40 mg, and 8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible). The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
45762573|NCT04084366|Drug|OBI-999|For the dose-escalation phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
45762574|NCT04084366|Drug|OBI-999|For the dose-expansion phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
45762575|NCT05529108|Dietary Supplement|control biscuits|Consumption of plain biscuits everyday during intervention period.
45762576|NCT05529108|Dietary Supplement|autoclaved BSG-containing biscuits|Consumption of autoclaved BSG-containing biscuits everyday during intervention period.
45762577|NCT05529108|Dietary Supplement|bio-transformed BSG-containing biscuits|Consumption of bio-transformed BSG-containing biscuits everyday during intervention period.
45762578|NCT04052698|Drug|Wilate|"Produced from the plasma of human donors, Wilate is presented as a powder or solvent for intravenous injection containing normally 500 IU or 1000 IU human VWF and human FVIII per vial. The ratio between VWF ristocetin co-factor activity (VWF:RCo) and FVIII:C is 1:1. The product contains approximately 100 IU/ml human VWF when reconstituted with 5ml/10mL water for injection with 0.1% polysorbate 80.~The specific activity of Wilate is ≥67 IU VWF:RCo/mg protein. The injection or infusion rate should not exceed 2-3mL per minute."
45446037|NCT04558125|Drug|Placebo|Placebo to match supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.
45446038|NCT04558125|Drug|Enoxaparin|All participants must also receive standard of care anticoagulation therapy.
45446039|NCT03787576|Device|Cataract surgery|Evaluation of patient satisfaction after bilateral cataract surgery with multifocal intraocular lens implantation
45620488|NCT03221179|Biological|Placebo|Matching placebo will be administered SC once.
45446040|NCT02067988|Device|Holmium-166 microspheres hepatic radioembolization.|Holmium-166 microspheres hepatic radioembolization.
45620489|NCT05010447|Device|Virtual Coach App|The avatar-guided app aims to deepen the user's understanding of Acceptance and Commitment Therapy (ACT) and promote application of ACT skills in every-day-life. Event-Sampling-Methodology (ESM) is used to capture the user's progress as it unfolds.
45620490|NCT03221101|Device|Home ventilator|
45620491|NCT03321773|Drug|triple therapy plus bismuth therapy|pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
45620492|NCT03321773|Drug|reverse hybrid therapy|(pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
45620493|NCT03225703|Behavioral|Hopping|A unilateral, hopping based exercise programme lasting six months.
45620494|NCT03077217|Drug|Rifaximin|The investigators use low-dose rifaximin for the treatment of patients with covert hepatic encephalopathy
45762579|NCT05523258|Behavioral|Computerized cognition training|The researchers distribute tablet computers for the patients. The patients in this group receive cognitive function training under the guidance of a full-time cognitive function trainer. The training time is about 45-60 minutes every time, and the frequency is twice a day until the operation. After the operation, cognitive function training should be started as soon as possible when the patient meets the following conditions including Glasgow score ≥ 12, no mechanical ventilation and no sedative drugs. The training intensity is the same as that before operation, generally starting from the 2nd to 3rd day after operation and continuing to discharge or the 7th day after operation.
45762580|NCT05523258|Behavioral|Basic training based on tablet computer|The researchers distribute the same tablet computer to the patients. The patients in this group receive basic training under the guidance of a full-time cognitive function trainer. The training duration is the same as that of the test group.
45762581|NCT04047160|Drug|OP-724|Twice a week for 4 hours continuous intravenous administration of OP-724
45762582|NCT05517720|Other|Aria Trio complete Facial System|Renew Serum, Brighten Serum, and Refine Serum.
45762583|NCT01724203|Dietary Supplement|Lactobacillus rhamnosus|
45762584|NCT01724203|Dietary Supplement|Bifidobacterium animalis subsp. lactis|
45762585|NCT01724203|Dietary Supplement|Placebo|
45620495|NCT02487017|Procedure|Transcatheter Arterial Chemoembolization (TACE)|"Transcatheter Arterial Chemoembolization (TACE):~5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml,the perfusion time should not be less than 20 min"
45762586|NCT02738086|Behavioral|Physical Activity Behavior Change (PABC)|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
45762587|NCT02738086|Behavioral|Physical Activity Behavior Change (PABC)|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning
45911918|NCT05091905|Drug|Titratable Automated Intermittent Boluses of ropivacaine 0.2%|"Patients will receive patient-titratable intermittent boluses of Ropivacaine 0.2% (8 mL popliteal-sciatic or 11 mL infraclavicular automated bolus every 120 minutes, 4 mL patient controlled bolus with 30-minute lockout). In addition, the infusion pump will be set in a pause mode that delays initiation of the automated bolus doses by 5 hours (this can be over-ridden by patients if they would like to initiate their perineural infusion earlier than 5 hours). Lastly, subjects will be able to titrate the volume of their automated bolus up or down within the range of 1-16 mL."
46069188|NCT03875885|Behavioral|CONNECT|A novel web-based intervention with input from an advisory panel of cancer caregivers, oncology providers, and psychosocial oncology professionals empowering caregivers with needs to seek services by providing education about the benefits of supportive care resources, systematically identifying their unmet needs, and connecting them with tailored supportive care resources.
46069189|NCT03875885|Behavioral|CONTROL|This group will receive a generic resource list. The generic resource list will be printed for participants and emailed to them, if participants have an email address.
46069190|NCT03867214|Drug|Glutamine|1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision
46069191|NCT03867214|Drug|Normal saline|100 mL of normal saline intravenously approximately 15 minutes before incision
46069192|NCT03845517|Drug|Placebo|Placebo
45446041|NCT05460195|Drug|sintilimab combined with anlotinib|Sintilimab (200mg/time, every 3 weeks) combined with anlotinib (12mg, once daily on day 1 to 14 per cycle) for 2 cycles (42 days). Radical surgery is performed within 4 - 6 weeks treatment. Sintilimab combined with anlotinib therapy repeats every 3 weeks until one year after surgery.
45620496|NCT02487017|Biological|DC-CIK|"Transcatheter Arterial Chemoembolization (TACE):~5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml, the perfusion time should not be less than 20 min~DC-CIK:~8×10^9 DC-CIK cells for each infusion, IV (in the vein) for each infusion at least 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32"
45620497|NCT05001243|Drug|Compound Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac|PBOHB to improve uncorrected near vision in healthy presbyopic patients
45620498|NCT05001243|Drug|Pilocarpine Hydrochloride|Apply in the fellow eye
45620499|NCT05001243|Drug|Brimonidine Tartrate|Apply in the fellow eye
45762588|NCT04054882|Biological|Sabin-IPV and DTaP|simultaneously administration of Sabin-IPV and DTaP
45446042|NCT05460195|Drug|sintilimab monotherapy|Sintilimab (200mg/time, every 3 weeks) combined with anlotinib (12mg, once daily on day 1 to 14 per cycle) for 2 cycles (42 days). Radical surgery is performed within 4 - 6 weeks treatment. Sintilimab monotherapy repeats every 3 weeks until one year after surgery.
45446043|NCT02065180|Dietary Supplement|commercially available nutrition supplement|the food supplement contains red rice yeast and olive extract
45762589|NCT04054882|Biological|Sabin-IPV|administration of Sabin-IPV only
45762590|NCT04054882|Biological|DTaP|administration of DTaP only
45762591|NCT05523102|Drug|Paracetamol|Intravenous paracetamol/acetaminophen
45762592|NCT05523102|Drug|Ketorolac|Intravenous ketorolac/NSAID
45762593|NCT03407287|Procedure|Peripheral Intravenous Analysis (PIVA)|Non-invasive measurement of peripheral venous waveform analysis (PIVA) obtained by connecting a standard transducer (AD Instruments, Colorado Springs, Co) to a universal adaptor or stopcock on a peripheral IV
45762594|NCT03407287|Procedure|Standard of care invasive vascular monitoring|Standard of care invasive monitoring in the intensive care settings with central venous catheters, pulmonary artery catheters, or trans-esophageal echocardiography for determining volume status.
45762595|NCT03407287|Procedure|Standard noninvasive vascular monitoring|Standard noninvasive vascular monitoring of blood pressure, pulse rate, pulse oximetry and respiratory rate.
45762596|NCT05523024|Dietary Supplement|Probiotic|The probiotic group will receive one capsule of the probiotic mixture (dose:1x109 colony forming units (CFU) per day in one dose (before breakfast). The PRO preparation will contain the following bacterial strains: 50% Lactococcus lactis Rosell® - 1058, 25% Lactobacillus casei Rosell® - 215, 12,5% Lactobacillus helveticus Rosell® - 52, 12,5% Bifidobacterium bifidum Rosell® - 71). Probiotics will be administered orally.
45762597|NCT05523024|Dietary Supplement|Berberine|The berberine group will receive 1500 mg of Berberine (Berberine hydrochloride 97% extract of Berberis aristata) per day in 3 doses. Berberine will be administered orally, before breakfast, dinner, and before supper.
45762598|NCT05523024|Dietary Supplement|Placebo|The placebo group will receive a placebo. Placebo will contain only the excipients and will be administered orally for 24 weeks. Placebo in no way: color, taste, smell, form of taking, the dosage will not differ from the preparations tested. However, it will not contain probiotcs or berberine. Placebo will be orally administered three times a day: before breakfast, dinner, and supper (6.00-7.00 p.m.). To meet the GCP conditions, subjects from all groups will receive the same number of capsules (six) per day.
45762599|NCT05523024|Dietary Supplement|Probiotc and Berberine|Probiotics and Berberine groupwill receive both: a probiotics mixture (as in PRO group: 1x109 CFU/day; in one dose) and 1500 mg/day of Berberine (Berberine hydrochloride 97% extract of Berberis aristata; in 3 doses). Probiotcs and berberine will be administered orally before breakfast, before dinner, and before supper.
45762600|NCT00877877|Procedure|Blood sampling|Blood samples were to be collected at Months 60, 72, 84, 96, 108 and 120
45620500|NCT05399537|Drug|Prismocitrate 18|Prismocitrate 18 solution will be used in pre-dilution mode only; the rate of administration depends on the targeted citrate dose and the prescribed flow rate. The pre-filter infusion rate of Prismocitrate 18 solution will be indexed to the blood flow rate (BFR) to achieve a target blood citrate concentration of 3 mmol/L of blood. A BFR between 100 - 180 mL/min will be advised; a lower BFR can minimize patient citrate exposure, particularly in patients with lower body weight.
45762601|NCT05528796|Diagnostic Test|Whole genome sequencing|"The investigators will study the genes in a fetus' or child's DNA using a test called genome sequencing. Genes are the instructions passed from individuals to a child, and genes determine how bodies are built and grow. Some medical conditions are caused by differences in genes, and the genome sequencing test looks for changes in genes and other parts of a person's genetic sequence (the genome).~Genetic material will be extracted from bio-specimens. Genome sequencing for this study will be performed at the UCSF Genomic Medicine Laboratory at UCSF. When the genome sequencing results are available, the investigators will arrange an in person or telehealth meeting to explain the test results and what the results mean for the fetus, pregnancy, and family."
45620501|NCT03225781|Device|Electrochemotherapy with Bleomycin|Application of Reversible Electroporation (Electrochemotherapy) with Bleomycin
45620502|NCT04492631|Dietary Supplement|Streptococcus salivarius DB-B5|Sachets containing Streptococcus salivarius DB-B5 will be dissolved in water and consumed by the participants (n=30) once daily for 4 weeks. The participants will consume 10 billion colony forming units (CFU) per day.
45620503|NCT04492631|Other|Placebo|Sachets containing a placebo (probiotic carrier) will be dissolved in water and consumed by the participants (n=30) once daily for 4 weeks.
45762602|NCT01724281|Other|No intervention, only follow up|
45762603|NCT02739100|Drug|Triferic|
45620504|NCT03225469|Behavioral|reinforced family member education|Based on regular instructions for patent education, at least one family member who lives with the patient together will be given special instruction.
45762604|NCT04378543|Biological|ART352-L|recombinant human Wnt3a protein delivered on liposomes to local autologous bone graft during posterolateral fusion procedures
45762605|NCT03407209|Other|consumption of local anesthetic measurement|consumption of local anesthetic measurement in both groups
45620505|NCT05397899|Other|Abdominal hypopressive Exercises (AHE)|Active and specific Therapeutic exercises will be used to treat postpartum low back pain in this study. AHE consisted of exhaling to their expiratory reserve volume, then holding their breath (apnea), and expanding their rib cage, to draw their abdominal wall inward and cranially without inhalation. Each exercise will have a specific frequency, intensity, and duration.
45620506|NCT05397899|Other|General exercises|General exercises are therapeutic exercises for core muscles for the treatment of postpartum low back pain.
45446044|NCT02065180|Dietary Supplement|placebo|
45620507|NCT05010135|Device|Zebris Gait System assessment for gait weight distribution + EMG evaluation of Quadriceps, Hamstrings, Tib Anterior and Calves + Positional Sense assessment|To measure the above parameters and to compare between the healthy subjects and the vertebral fracture subjects
45762606|NCT05453734|Procedure|Progressive Muscle Relaxation Exercises|Before data collection, one of the researchers received training and certification from a psychotherapist specialist in this field to be able to apply the PMR exercises. The guidelines on the PMR exercises were prepared in line with the literature and training received by the researcher. In the guidelines, the person is asked to be in a comfortable place and position, to reach the face by following the large muscle groups gradually, starting from the feet, to tense the muscles in each step, and then to release them. It is necessary to take a deep breath after each muscle group, to stop for a while, and release it slowly
45620508|NCT03225391|Behavioral|nap from 0:00 to 3:00 hours|A nap from 0:00 to 3:00 hours during a night shift.
45762607|NCT04141020|Procedure|Microsurgical clipping|Standard of care microsurgical clipping of an unruptured cerebral artery aneurysm.
45762608|NCT04141020|Procedure|Endovascular treatment|Standard of care endovascular treatment of an unruptured cerebral artery aneurysm.
45762609|NCT04141020|Drug|Sirolimus|Daily oral Sirolimus 2 mg tablets, adjusted as necessary per treating physician.
45762610|NCT01724515|Other|Lipid infusion and muscle biopsies|Subjects will undergo a baseline muscle biopsy, a lipid infusion for 5 hours (60 ml/hr), and a muscle biopsy after the lipid infusion.
45911919|NCT05085873|Drug|Sodium Oxybate injection|"Induction dosage : 60 mg/kg by direct intravenous injection.~Continuous dosage : 45 mg/kg/h by continuous intravenous injection.~Additional dosage if the Richmond Agitation Sedation Scale (RASS) score exceeds -4 : 1000 mg sodium oxybate by direct intravenous injection bolus every hour at most until RASS score reaches -4.~Sedation maintained until patient death."
46069193|NCT03845517|Drug|PF-06700841 15 mg|PF-06700841 15 mg
45620509|NCT03225391|Behavioral|nap from 3:00 to 6:00 hours|A nap from 3:00 to 6:00 hours during a night shift.
45620510|NCT05009745|Procedure|PGT-A Strategy|PGT-A strategy involves trophectoderm biopsy, comprehensive chromosome screening (CCS) using Next Generation Screening (NGS), freezing of embryos and replacement in a frozen-thawed embryo transfer cycle.
45620511|NCT03205891|Drug|Brentuximab Vedotin|1.8 mg/kg by vein on Day 1 per cycle by vein over about 30 minutes on Day 1 of each cycle.
46069194|NCT03845517|Drug|PF-06700841 30 mg|PF-06700841 30 mg
46069195|NCT03845517|Drug|PF-06700841 45 mg|PF-06700841 45 mg
45620512|NCT03205891|Drug|TAK228|Starting Dose and Schedule of TAK228: 2 mg by mouth, 5 days on and 2 days off per week with repeated weekly cycles. The study doctor will tell participant how often to take the study drug.
45620513|NCT03205891|Device|Glucose Monitor|Participant monitors glucose (sugar) levels at home with a glucose monitor during the first 2 months participant is taking the study drug.
45620514|NCT05010057|Dietary Supplement|New Zealand blackcurrants (NZBC)|NZBC capsules containing anthocyanin-rich blackcurrant extract
45620515|NCT05010057|Dietary Supplement|Placebo (PLA)|Placebo capsules containing microcrystalline cellulose
45620516|NCT03221023|Drug|Vancomycin Hydrochloride|Individuals in the experimental arm will receive intrawound Vancomycin-saline + IV antibiotics
45620517|NCT03221023|Drug|Saline Solution|Individuals in the control arm will receive intrawound saline solution
45620518|NCT02490839|Drug|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
45620519|NCT02490839|Drug|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
45620520|NCT03077373|Behavioral|Counseling letter|"The brief counseling letter intervention aiming to reduce physical inactivity, sedentary time in leisure time as well as smoking is based on behavior change theories (Transtheoretical model of health behavior change and Health Action Process Approach).~The computerized intervention system includes up to six interactions with participants. Recurrent assessments are initiated by the system and provide data for scheduling the proceeding intervention steps and selection of relevant content. Physical activity, sedentary time, smoking, and motivational measures to change or maintain behaviors according to the recommendations will be monitored over time and used to provide feedback in the form of letters."
45620521|NCT03205969|Device|Functional mobile game|Functional mobile game for chemotherapy side effect education
45620522|NCT02486861|Other|optical coherence tomography|
45620523|NCT05001087|Other|Observation|Not applicable-Observational study
45620524|NCT03205735|Diagnostic Test|lymphocyte DPD dosage|lymphocyte DPD dosage in peripheral blood
45620525|NCT04492865|Device|MSCT|"-Laboratory tests: All routine indicators of CBC are evaluated~Nasopharyngeal and oropharyngeal swabs are obtained from each patient to confirm the positivity to Covid-19 by performing RT-PCR to detect the viral RNA.~MSCT Chest images of all patients are evaluated by three radiologists with variable experiences in CT chest interpretation. The readers are blinded of the RT-PCR results and the CBC indices of the patients and they have access only to the epidemiological history, clinical symptoms, and signs. By consensus, the radiologists score the chest CT as positive or negative for COVID-19 viral pneumonia. When the chest CT is classified as positive, the main CT features are recorded as present or absent (ground-glass opacity, crazy paving, consolidation, nodules, air bronchogram, air trapping, halo sign, reversed halo sign, bronchial wall abnormalities, vascular enlargement, pleural effusion, and lymphadenopathy."
45762611|NCT05528640|Other|Mental Health Literacy Program|Six educational sessions will be delivered on a private YouTube channel which consists of information about mental health literacy (knowledge about priority mental illnesses, attitude/ stigma related to mental illnesses, and help-seeking efficacy). There will be six-weeks unrestricted access period. Afterwards, the round-up session which consists of problem-based learning and group sharing will be delivered in person. Two vignettes based on the clinical scenarios will be given for discussion. Furthermore, participants are encouraged to share their opinion on mental health literacy, strategies for dealing with difficulties of caring for patients with mental illnesses in general hospitals, way to promote mental health literacy of healthcare professionals in general hospitals
45762612|NCT03407131|Procedure|Joint replacement surgery|Joint replacement surgery is to replace the original joint function, so that the patient can recover the joint function as soon as possible.
45762613|NCT03407131|Procedure|Intramedullary nail fixation|Internal fixation surgery is the stable fixation of fracture, which provides the condition for the restoration of joint function.
45762614|NCT05517408|Drug|ciprofol|The first patient received Ciprofol 0.3mg/kg (actual body weight) at a rate of 1 mg/s. If the desired depth of sedation/anesthesia reached, then it was judged as negative, and the dose of Ciprofol in next patient would be decreased by one concentration gradient (the difference between two adjacent drugs was 1:1.1); If the desired sedation/anesthesia depth was not achieved, then it was judged as positive. And the dose of Ciprofol in next patient would be increased by one concentration gradient. Patients were enrolled consecutively until the trial was terminated at the eighth crossing point (positive to negative or negative to positive).
45762615|NCT05453656|Behavioral|exercise|physical activity promotion and engagement following kidney transplantation
45762616|NCT01721239|Other|Standardized Followup program|Standardized written information, patient photos and three followup consultations.
45911920|NCT05085873|Drug|Midazolam injection|"Induction dosage : 1 mg every 3 min by direct intravenous injection until RASS score reaches -4 (with a maximum of 30 min).~Continuous dosage : Half of titration dosage every hour by continuous intravenous injection.~Additional dosage if the RASS score exceeds -4 : 1 mg every 3 min by direct intravenous injection (without exceeding 10 mg/h).~Sedation maintained until patient death."
45911921|NCT05078242|Device|EaseVRx|Participants will experience 7 sessions of the EaseVRx device for chronic pain.
45911922|NCT05077605|Other|Functional residual capacity measure by electrical impedance tomography|Patient functional residual capacity will be measured by electrical impedance tomography before extubation and then at 0, 10, 15 and 20 min after extubation.
45935142|NCT00217243|Other|Evoked fields before and after a local block (Xylocaine)|MEG registration after electrical median and ulnar nerve stimulation in subjects and patients. In the patient group another MEG was performed after an anaesthetic block (1-2 ml Lidocaine 1%) at the site of the nerve injury producing a painfree state
45935143|NCT00069654|Procedure|Forearm blood flow study|
45620526|NCT03077295|Other|High Fibre|High fibre/carbohydrate (50% CHO, 35% fat and 15% Protein) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Total dietary fibre will be at least 30g/d for 2000kcal intake and provided as a mixed soluble and insoluble fibre sources to maintain palatability of the diet (e.g. wheat bran, fava bean, lentil, buckwheat).
45620527|NCT03077295|Other|High Protein|• High protein diet (30% protein, 35% fat and 35% CHO) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Protein will be a mixed meat matrix to include poultry, fish, red meat, prawns, eggs, dairy. Total dietary fibre will be no more than 15g/d for 2000kcal intake.
45620528|NCT02490527|Dietary Supplement|Pure epicatechin capsules (50mg)|Epicatechin is a compound found naturally in dark chocolate.
45935144|NCT00069654|Procedure|Brachial artery reactivity study|
45620529|NCT02490527|Drug|Simvastatin (40mg)|A cholesterol-lowering medication that blocks the production of cholesterol.
45620530|NCT02490527|Other|Placebo|A substance that has no therapeutic effect and will act as a control.
45620531|NCT05000775|Dietary Supplement|G-Niib|G-NiiB®, a patent-protected microbiome immunity formula, composed of naturally occurring food-grade bacteria approved by health authorities, has been developed by a group of CUHK gastroenterology experts.
45620532|NCT05000775|Dietary Supplement|Placebo|Placebo
45762617|NCT03999268|Behavioral|I-START|Designed as a supplementary educational tool for patients on insulin therapy, I-START includes an injection plan to reinforce the knowledge and behaviors that users have been taught by their health care provider. This is done through eight modules created for the benefit of new and experienced insulin users, and those using pens or vial/syringes. The modules address a variety of topics pertinent to insulin therapy, including overcoming psychosocial barriers, injection techniques and best practices, managing hypo- and hyperglycemic events, monitoring blood glucose and troubleshooting and problem solving. At the end of each module, users can self-evaluate their confidence in mastering the information presented. This gives them the ability to move forward into the next module, repeat material already presented and/or save features of the modules that they would like to revisit at another time.
45762618|NCT03999268|Behavioral|Standard Insulin Administration Education|Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
45762619|NCT05522712|Device|Acapella user|"The exercise session will include three sets of deep breaths. Each set will include 10 repetitions which were fol¬lowed by 30 to 60 seconds pause in between. Patients will be instructed to perform slow maximal inspiration, while expiration was done through acapella in a prolonged manner to minimize airway closure and alveolar collapse. In the Acapella device, resistance was increased continuously on each successive day. The technique will be applied for 15 minutes.~Components of Acapella® treatment will include :~Breathing control~10 breaths through the Acapella® device~Inhaling up to approximately three - quarter maximum breathing capacity~2-3 second breath hold~Active exhalation to Functional residual capacity but not too forcefully (3-4 second)~The patient did 2-3 huffs at the end of the session, Cough or forced expiration in a set cycle."
45762620|NCT05522712|Device|Incentive spirometer user|"Sit upright in a chair or in bed. Hold the incentive spirometer at eye level, hold a pillow to help splint or brace the incision to decrease pain at incision.~Put the mouthpiece in mouth and close lips tightly around it. Slowly breathe out (exhale) completely.~Breathe in (inhale) slowly through mouth as deeply as possible. As taking the breath, the ball will rise.~Try to get the ball as high as possible.~When getting it, hold breath for 10 seconds, or as long as possible.~Then, breathe out slowly through mouth. Then, Rest for a 30-60 seconds.~Repeat 10 times. Try to get the ball to the same level or higher with each breath.~repeat 10 times for 3 sets."
45762621|NCT05522712|Procedure|Control|This group is a control group will not receive new intervention just traditional chest physiotherapy and mobilization
45762622|NCT05517330|Biological|Tislelizumab|200mg IV Q3W
45762623|NCT05517330|Drug|Afatinib|30mg PO QD
45762624|NCT04378465|Other|Enhanced Recovery Program (ERP)|An evidence-based perioperative care approach, involving a multidisciplinary team work including surgeons, anaesthesiologists, dieticians, and nurses, which aim to reduce the surgical stress and metabolic responses as well as organ dysfunction, thus leading to a faster recovery after surgery
45762625|NCT00370474|Device|Bi-ventricular lead placement|
45762626|NCT05528406|Drug|HLX208|900mg bid po
45762627|NCT05453422|Other|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
45762628|NCT05517174|Biological|High-Dose Quadrivalent Influenza Vaccine|For this arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used as the active comparator.
45620533|NCT02490449|Drug|Dexlansoprazole MR|Administration of drug after or before diet
45620534|NCT03205501|Drug|IV-administation of EMI-137|Intravenous administration of 0.13 mg/kg of the fluorescent tracer EMI-137 approximately 2.5 hours prior to the endoscopy procedure.
45620535|NCT03205501|Device|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working-channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the endoscopic resection, during the same endoscopy procedure.
45762629|NCT05517174|Biological|Standard-Dose Quadrivalent Influenza Vaccine|Any standard-dose quadrivalent influenza vaccine administered in the Danish governmental influenza vaccine program may be used.
45762630|NCT01729897|Drug|Etomidate|
45762631|NCT01729897|Drug|Fentanyl|
45762632|NCT01729897|Drug|Propofol|
45762633|NCT01048177|Drug|Bladder instillation with heparin/ lidocaine|9 bladder instillations in 6 weeks
45762634|NCT05517096|Other|E-Health|In the intervention phase asthma care is provided on an at-needed-basis via online communication and is always available during working hours.
45762635|NCT02740582|Drug|Tolcapone|
45762636|NCT02740582|Drug|Placebo|
45762637|NCT05453266|Procedure|Application of Tranexamic acid in arthroscopic irrigation solution|Application of Tranexamic acid in arthroscopic irrigation solution
45762638|NCT05453266|Procedure|No application of Tranexamic acid in arthroscopic irrigation solution|No application of Tranexamic acid in arthroscopic irrigation solution
45762639|NCT01724827|Device|ceramic (Empress CAD, Ivoclar Vivadent)|Leucite-reinforced glass ceramic (Empress CAD, Ivoclar Vivadent)
45762640|NCT01724827|Device|composite (Lava Ultimate, 3M Espe)|Nanohybrid composite resin (Lava Ultimate, 3M Espe)
45762641|NCT05522556|Drug|Ritlecitinib|capsules
45935145|NCT00069654|Procedure|Treadmill exercise test|
45762642|NCT05452954|Behavioral|Brief behavioral parent training|In the newly developed intervention, both stimulus control and contingency management techniques will be offered in a brief behavioral parent training consisting of two intervention sessions and one booster session.
45620536|NCT03077139|Device|Cardiac Resynchronization Therapy (CRT)|A CRT device sends small electrical impulses to both lower chambers of the heart to help them beat together in a more synchronized pattern.
45762643|NCT03406663|Behavioral|Group 1|"Patients will be instructed to daily adjust their dose of Gla-300 based on fasting SMPG values. Fasting SMPG will be measured daily by the patient before breakfast and any intake of antihyperglycemic agents.~Fasting SMPG in the range of~≥ 5.6 mmol/L, increase 1 unit of Gla-300 dose, > 4.4 and ≤ 5.6 mmol/L, no change, < 4.4 mmol/L, reduce 1 unit of Gla-300 dose"
45762644|NCT03406663|Behavioral|Group 2|"Fasting SMPG (median of the last 3 days including current day) in the range of~7.8 mmol/L, increase 6 units of Gla-300 dose, > 5.6 and < 7.8 mmol/L, increase 3 units of Gla-300 dose, > 4.4 and ≤ 5.6 mmol/L, no change,~3.3 and < 4.4 mmol/L, reduce 3 units of Gla-300 dose, < 3.3 mmol/L or occurrence of ≥ 2 symptomatic or 1 severe hypoglycemic episode in the preceding week, reduce 3 units of Gla-300 dose or at the discretion of the investigator"
45620537|NCT03225235|Radiation|SBRT|hypofractionated stereotactic radiotherapy (SBRT) using CyberKnife for Patients With Low and Intermediate Risk of Progression Prostate Cancer
45762645|NCT05187702|Other|Functional exersize|Participants will be given balance and strengthening exercises covering the balance exercise protocol.
45762646|NCT05187702|Other|Aerobic exersize|60% of the maximum heart rate is given 3 walking eccentricity per week
45762647|NCT05522478|Device|Fall risk|Fall risk, static postural balance and sensorimotor integration were assessed using the Biodex Balance System.
45762648|NCT01049581|Procedure|aquatic therapy|two hours per week, one hour per time, total 12 weeks
45762649|NCT05522400|Behavioral|Virtual Reality (VR) and human computer interaction system|The experimental group used VR technology and human-computer interaction system for exercise, while the control group used traditional exercise program
45762650|NCT05522322|Other|COPD scoring ststems in ICU|SAPS & APACH scoring systems in COPD ICU pts
45762651|NCT01724905|Dietary Supplement|Modified Stop Light Diet (SLDm)|SLDm includes reduced energy pre-packaged meals (PM) for 6 months, encouraged consumption of low energy shakes and 35 fruits and vegetables (F/V) per week
45762652|NCT01724905|Dietary Supplement|Recommended Care Diet|RC diet includes traditional meal plans and 35 fruits and vegetables per week
45762653|NCT05516940|Other||
45762654|NCT02740660|Drug|Caffeine 100mg / Albuterol 4mg|
45762655|NCT02740660|Drug|Placebo|
45762656|NCT02740660|Behavioral|Family weight management counseling|
45446045|NCT02065258|Other|Breathing exercise|"It will be based on Yoga´s breathing technique (Eliade, 1996) and will be focus on to stimulate nasal and diaphragmatic breathings, to increase expiratory time, to slow respiratory flow and to regulate the breathing rhythm. Breathing exercises will be divided into 3 phases (lasting one month each) with progressive intensity every 8 sessions.~All participants will be required to maintain their normal medical regimens during the interventions. Will be part of the routine of breathing exercises the following exercises: I) Kapalabhati, II) Uddhiyana"
45620538|NCT04993521|Procedure|Block type|Regular block type
45620539|NCT03318263|Diagnostic Test|next-generation sequencing (NGS)|ESR1, PI3KCA and AKT extensive exon sequencing will be performed using NGS (Miseq Illumina) at the Biopathology department, Institut de Cancérologie de Lorraine (ISO15189 certified lab). Samples taken at baseline (t0), at progression (tp) and 3 months before progression (tp-3) will be systematically analyzed. The intermediate samples will be stored and kept for additional studies. Follow up assessment will be performed according to prescriber's directions.
45620540|NCT02452177|Drug|Vitamin D|
45620541|NCT05000697|Drug|Oxaliplatin|Patients will receive 5FU + Oxaliplatin during the consolidation chemotherapy after long course chemoradiation
45762657|NCT05516862|Other|Dragons acupuncture|"The treatment we are studying is supposed to help the rational and emotional brain effectively communicate, so that the emotional brain can finally realize the trauma experienced is no longer a threat. We call this re-processing. It does not take away the memory but it allows the rational brain to see the memory as just a memory without the emotional brain initiating your fight, flight or freeze system. This allows the mind to take the file off the messy desk and put it away. The treatment was named by the Chinese and is called External and Internal Dragons. According to the Chinese, the External Dragons represent all the bad (traumatic) things that happen to us. The Internal Dragons live inside us, and fight off the External Dragons.~Subject will lay on your stomach and have 7 needles placed in head, upper back, lower back and ankles."
45935146|NCT00217282|Drug|oxaliplatin, gemcitabine, bevacizumab|"Gemcitabine 1000mg/m2 IV over 30 minutes, on days 1 and 8 followed by Oxaliplatin 130mg/m2 IV over 2 hours on day 1 followed by Bevacizumab 15 mg/kg IV over 90* minutes, on day 1 Cycles q 3 weeks x 4 cycles One cycle equals 3 weeks. Patients will be re-evaluated every 2 cycles. If CR, PR or SD, patients will continue treatment up to four cycles or until progression or unacceptable toxicity.~Patients achieving CR, PR, or SD after 4 cycles will continue Bevacizumab maintenance:~Bevacizumab 15 mg/kg IV q 3 weeks until relapse/progression"
46069196|NCT03842696|Drug|Vorinostat|"HLA-matched BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 10 days prior to transplant (day -10), until day +30 post-transplant.~Haploidentical BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 5 days after transplant (day +5), until day +30 post-transplant"
45620542|NCT05000697|Drug|5FU|Patients will receive 5FU during the consolidation chemotherapy after long course chemoradiation
45620543|NCT03205189|Other|Comparison between pre-operative prescription and post-operative prescription|The first group will have a pre-operative prescription delivered during the preoperative anesthesia clinic and the second group will receive the postoperative prescription.
45620544|NCT02486705|Behavioral|PTSD Family Coach Full|PTSD Family Coach mobile app is an iOS mobile phone application designed to provide information, support resources, tools for coping with caregiver-related stress, and tools for self-monitoring stress symptoms.
45620545|NCT02486705|Behavioral|PTSD Family Coach Basic|PTSD Family Coach mobile app is an iOS mobile phone application designed to provide information and support resources,
45935147|NCT00041795|Drug|leteprinim potassium (Neotrofin)|
45935148|NCT00217360|Behavioral|a customised multifactorial falls prevention program|
45620546|NCT03220633|Drug|ATB-346|
45620547|NCT03220633|Drug|Placebo|
45620548|NCT04992819|Procedure|Chronobiological Approach Nutrition Model|In the intervention group, a label containing the time of expressed breastmilk will be affixed. In the milk preparation room, breast milk will be stored in a separate refrigerator as 08:00-19:59 day milk and 20:00-07:59 night milk.
45762658|NCT05516862|Other|Dragons acupressure|"The treatment we are studying is supposed to help the rational and emotional brain effectively communicate, so that the emotional brain can finally realize the trauma experienced is no longer a threat. We call this re-processing. It does not take away the memory but it allows the rational brain to see the memory as just a memory without the emotional brain initiating your fight, flight or freeze system. This allows the mind to take the file off the messy desk and put it away. The treatment was named by the Chinese and is called External and Internal Dragons. According to the Chinese, the External Dragons represent all the bad (traumatic) things that happen to us. The Internal Dragons live inside us, and fight off the External Dragons.~Subject will lay on your stomach and have 7 small acupressure adhesive bandages placed on head, upper back, lower back and ankles."
45762659|NCT05516862|Other|Dragons placebo|"The treatment we are studying is supposed to help the rational and emotional brain effectively communicate, so that the emotional brain can finally realize the trauma experienced is no longer a threat. We call this re-processing. It does not take away the memory but it allows the rational brain to see the memory as just a memory without the emotional brain initiating your fight, flight or freeze system. This allows the mind to take the file off the messy desk and put it away. The treatment was named by the Chinese and is called External and Internal Dragons. According to the Chinese, the External Dragons represent all the bad (traumatic) things that happen to us. The Internal Dragons live inside us, and fight off the External Dragons.~Subject will lay on your stomach and the doctor will touch 7 points on head, upper back, lower back and ankles."
45762660|NCT03929068|Drug|carbidopa-levodopa|Motivated by the success of dopaminergic drugs in treating rigidity associated with Parkinson's disease, some neurologists have used carbidopa-levodopa to attempt to improve spasticity in ALS and PLS patients.
45762661|NCT03929068|Drug|Placebo Oral Tablet|Placebo will be given to maintain blinding of participants and study team.
45762662|NCT03925636|Dietary Supplement|Specific Carbohydrate Diet|The diet removes all grains such as wheat, barley, corn, rice, and most dairy products (except yogurt fermented for 24 hours and cheese aged for grater than 30 days). The diet mainly consists of meat, fruits, vegetables, nuts, oils, and honey.
45762663|NCT05528094|Dietary Supplement|GeniusDrops|"The active ingredients listed below are safe and the study sponsor has noted there are no known side effects of the supplement. The main ingredients are:~Hibiscus flower- Has been shown to boost oxygenation to the brain and vital organs. Has also demonstrated efficacy for boosting the immune system.~Gingko leaf- Has been shown to stimulate memory by increasing mental sharpness and clarity.~Rhodiola- Helps regulate energy and stress level. Gotu kola- Has been shown to have impacts on reducing anxiety. Licorice Root- Helps boost the key brain neurotransmitter called Brain Derived Neurotrophic factor which can help with cognitive development Peppermint Leaf- Reduces fatigue while helping improve cognitive abilities. Has also been shown to promote immune system function."
45620549|NCT03224923|Drug|Ticagrelor 60mg|twice daily
45762664|NCT03910972|Biological|Sm-TSP-2/Alhydrogel® vaccine|The Sm-TSP-2/Alhydrogel® candidate vaccine contains recombinant Sm-TSP-2 adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10mM imidazole buffer containing 2mM phosphate and 15% sucrose, with pH 7.4 ± 0.1. The final concentrations of Sm-TSP-2 and Alhydrogel® in the drug product are 0.1mg/ml and 0.8mg/ml respectively.
45935149|NCT00217477|Drug|gemcitabine hydrochloride|Given IV
45935150|NCT00217477|Drug|paricalcitol|Given IV
45935151|NCT00217516|Drug|selenium|Given orally
45935152|NCT00217516|Other|placebo|Given orally
45446046|NCT02065258|Other|Aerobic exercise|Exercise will be performed on a treadmill (Imbramed Export Plus, Brazil) with the initial intensity of 60% of the maximum predicted heart rate for patient´s age (Tanaka et al, 2001) reaching a maximal of 80% during the training. The intensity values will be calculated using Karvonen's formule (1957). Exercise intensity will be increased if the patient do not present any increase in asthma symptoms during the exercise for 2 consecutive training days. Before and after every session, patients will perform a peak expiratory flow test and if values were lower than 70% of the patient´s maximum value, they will be advised to use the rescue dose of bronchodilator prescribed the their physician
45620550|NCT03224923|Drug|Clopidogrel 75mg|once daily
45446047|NCT02793622|Drug|Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|
45620551|NCT03224923|Drug|Aspirin 81 mg|once daily
45620552|NCT03321461|Drug|TMTP1|Fluorescent sites will be removed
45620553|NCT03321461|Drug|ICG|Fluorescent sites will be removed
45620554|NCT05004753|Dietary Supplement|Artemisinin|a herbal supplement
45620555|NCT05004753|Drug|Dexamethasone|corticosteroids
45620556|NCT02486471|Procedure|Monsel´s Paste|surgical method to stop bleeding by using the hemostatic Agent monsel´s paste until no more bleeding is visible
45446048|NCT02793622|Drug|Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy|
45446049|NCT02066974|Genetic|hepatoma requiring radiotherapy|hepatoma requiring radiotherapy
45620557|NCT02486471|Other|Wait and see|finishing examination without hemostatic intervention, awaiting spontaneous coagulation
45620558|NCT05004519|Drug|Dexmedetomidine Injection [Precedex]|dexmedetomidine or remifentanil during laparoscopic gastric bypass
45620559|NCT05004519|Drug|Remifentanil|dexmedetomidine or remifentanil during laparoscopic gastric bypass
45620560|NCT03224689|Device|PEEK-Optima Femoral Component|TKA Surgery
45620561|NCT02486549|Procedure|Supraclavicular Block|Under ultrasound guidance an insulated needle is advanced with in- plane technique into the brachial plexus sheath and 20ml 0.25% bupivacaine will be administered
45620562|NCT02486549|Procedure|Interscalene Block|Under ultrasound guidance an insulated needle will be placed through the middle scalene muscle,into the interscalene groove with in-plane technique and 20ml 0.25%bupivacaine will be administered into the brachial plexus
45620563|NCT02486549|Drug|Bupivacaine|20ml 0.25% bupivacaine will be injected for brachial plexus block
45620564|NCT02486549|Device|Ultrasound|The Ultrasound will be used for brachial plexus visualization
45762665|NCT03910972|Biological|Sm-TSP-2/Alhydrogel® vaccine plus AP 10-701|The Sm-TSP-2/Alhydrogel® candidate vaccine co-administered with the immunostimulant, AP 10-701. b) AP 10-701, also known as Gluco-Pyranosylphospho-Lipid A Aqueous Formulation (GLA-AF), is a Toll-like Receptor-4 agonist. Point-of-injection formulations with this immunostimulant will be prepared immediately prior to vaccination by adding an appropriate volume of AP 10-701 to Sm-TSP-2/Alhydrogel® and withdrawing an appropriate volume to administer the desired amount of Sm-TSP-2 plus 5µg GLA-AF.
45762666|NCT03910972|Biological|ENGERIX-B Hepatitis B Vaccine|Recombinant hepatitis B vaccine containing 10 mcg recombinant hepatitis B surface antigen per dose
45762667|NCT05516784|Drug|Clopidogrel|Comparison of platelet reactivity between clopidogrel and ticagrelor
45762668|NCT05516784|Drug|Ticagrelor|Comparison of platelet reactivity between clopidogrel and ticagrelor
45762669|NCT04337788|Other|telehealth applications|telehealth applications during 30 days/patient
45762670|NCT05528016|Procedure|Upper Eyelid Blepharoplasty|Blepharoplasty is a procedure that the skin, orbicularis oculi muscle, and fat pads are excised to treat visual field loss caused by dermatochalasis.
45762671|NCT05516706|Other|Dynamic stretching|Participants in this group performed a 10 minutes warm-up followed by 15 minutes of dynamic stretching exercises which included arm cross-over, scapular scaption, upper body twist walking lunges, cat and cow pose, and rotator cuff movements.
45762672|NCT05516706|Other|Plyometric push up|Participants in this group performed 10 minutes of warm-up followed by 15 minutes of plyometric push training which included one-arm push-ups and depth push up
45620565|NCT04926597|Dietary Supplement|nutritional supplement|daily use of one or more specific oral nutritional supplement with high energy/protein content (i.e., Resource Ultra, Resource 2.0 (Fibre), Resource Ultra Fruit).
45620566|NCT04926597|Other|individualized nutritional guidelines|nutritional plan supervised by an experienced study dietician based on the usual home nutrition with possibility to increase intake by adaptation to patient preferences, between meal snaking and food enrichment/fortification. Every 2-4 weeks phone call by unblinded study dietician to follow nutritional intervention.
45620567|NCT04926597|Other|general nutritional information|general information about health food behavior upon hospital discharge
45620568|NCT03224611|Device|light wand|"The light wand is used as a stylet of the flexible LMA. When the investigator inserts the flexible LMA in light wand group, the correct position of the LMA is confirmed by the light."
45620569|NCT03318185|Procedure|gasless single-port laparoscopic surgery|The single-port laparoscopic surgery is performed when the maneuvering room is provided by external suspension system.
45620570|NCT03318185|Procedure|conventional laparoscopic surgery|The multi-port laparoscopic surgery is performed when the belly is inflated with carbon dioxide to provide maneuvering room.
45762673|NCT05522166|Other|Digital Stories and Face-to-face Basic Life Support Trainings|In this study, digital storytelling and face-to-face applied techniques will be given to teacher candidates via social media (Whatsapp) and the impact of these trainings on the knowledge and skill levels of teacher candidates will be evaluated comparatively.
45762674|NCT05527938|Other|web-based intervention|"Establishing management teams.~Establishment of a nursing intervention team.~Daily uploading of health intervention records~Regularly delivering related health knowledge.~Home visiting~Psychological guidance. The health teachers in the team should closely understand the psychological trends of the patients during the telephone follow-up and home visits and verbally communicate more with the children to stimulate them to develop good living habits and increase their confidence in healing."
45446050|NCT02067130|Procedure|Fibroscan|Transient elastography (Fibroscan®) is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis. Since Fibroscan® measures liver's stiffness, its utility is not limited to fibrosis, and has been extended to other conditions that would increase the liver's stiffness, such as amyloidosis (Loustaud-Ratti et al. Amyloid 2011) and perhaps iron overload.
45446051|NCT02067208|Device|wedged insole|Wedged insoles are designed to reduce frontal plane knee joint mechanical loads during gait. Specifically, they can alter the knee adduction moment during gait - a variable associated with progression of knee osteoarthritis. In the experimental arm of this study, participants will undergo biomechanical gait analysis to identify the wedged insole that reduces the moments the most. The two options are medial wedge, where the medial aspect of the foot is elevated relative to the lateral aspect, and the lateral wedge, where the lateral wedge is elevated relative to the medial aspect.
45446052|NCT02068144|Dietary Supplement|Cranberry Extract|Participants will drink one 15.2 oz bottle of Cranberry Extract beverage daily for 8 weeks.
45446053|NCT02068144|Other|Placebo|Participants will drink one 15.2oz bottle of placebo beverage daily for 8 weeks.
45620571|NCT03224533|Diagnostic Test|Diabetes Outcome|based on self report definition, fasting plasma glucose, and hemoglobin A1c
45620572|NCT03076125|Behavioral|SCORRE|3 components based on the Health Belief Model
45620573|NCT03076125|Behavioral|Attention-Control Activity|sexual health education
45620574|NCT02490605|Procedure|occlusal plate group|occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides
45620575|NCT02490605|Procedure|therapeutic exercises|"The exercise will consist of the movement of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth 3 times per day with each period consists of of 3 sets with 15 repetitions"
45762675|NCT03738670|Procedure|Percutaneous RFA|Single session percutaneous extra-spinal bone metastasis destruction to achieve pain relief
45762676|NCT02571972|Drug|Dorzolamide-timolol|On enrollment, eligible patients will be started on topical dorzolamide-timolol in the study eye twice daily for the study duration
45762677|NCT03700138|Drug|Privigen® 100mg/ml at the dose of 2g/kg of body weight|The treatment (IV Ig, 100mg/ml at the dose of 2g/kg of body weight) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
45762678|NCT03700138|Drug|NaCl 0,9%|The treatment (NaCl 0,9% 20 ml/kg) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
45762679|NCT03694288|Procedure|Implant removal|Surgical Implant removal
46069197|NCT03842696|Procedure|Blood and Marrow Transplant (BMT)|Undergo allogeneic BMT according to local site institutional practice.
45762680|NCT04996134|Drug|Domperidone Oral Product|10-30 mg of oral domperidone administered QID.
45762681|NCT05435872|Device|The Artificial intelligence Cloud Platform|The Artificial intelligence Cloud Platform would be used as the auxiliary device for endoscopists during the whole endoscopic examination to help endoscopists complete the quality control, indicate potential lesions, and aid in diagnosis.
45620576|NCT03073317|Diagnostic Test|FullPIERS and sFlit/PLGF (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)|Once the centre is randomised to receive the intervention, all eligible women will have serum sFlt1/PlGF measurement performed and fullPIERS assessment and both results will be revealed to the care providers. This will include all women with pre-eclampsia or suspected pre-eclampsia cared for at the main hospital centres (and not be limited to women referred to the hospital from the community health centres). sFlt-1/PlGF will be tested by immunoassays (Roche Platform®). The result read out is provided by specific machines provided by Roche in less than one hour, which permits rapid clinical decision-making. Risk stratification using fullPIERS will be performed on tablet computers using a pre-defined risk scoring system integrated within the MedSciNet database.
45620577|NCT03318107|Device|Transvaginal probe using photoacoustic and ultrasound imaging|-Four optical wavelengths of 730nm, 780nm, 800 nm, and 830 nm will be used to acquire data
45762682|NCT04994496|Behavioral|Two-week web-based self-help intervention based on principles of positive psychology|"The web-based self-help intervention consists of 14 exercises based on the following positive psychology domains: personal strengths, pleasure, gratitude, engagement (flow, mindfulness) and positive relationships.~The (partly interactive) exercises are created to be implemented by the participants themselves without support of a therapist.~Before starting the intervention, the participants are told that they will receive a daily email with an instruction for a short exercise over the period of two weeks. The participants are instructed to complete the exercises every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)"
45762683|NCT04994496|Behavioral|Two-week web-based text messages containing fun facts|"The web-based sham intervention consists of 14 text messages containing random interesting facts (fun facts).~Before starting the sham intervention, the participants are told that they will receive a daily email with a text message to read every over the period of two weeks. The participants are instructed to read these text messages every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)"
45762684|NCT05377840|Behavioral|Cognitive Behavioral Therapy|CBT is a combined psycho-social intervention that aims to improve overall mental health focusing on developing coping strategies. standard CBT Participants will have individual weekly sessions lasting 60 minutes each over an 8-week period with 1 follow-up maintenance session at week 12.
45762685|NCT05377840|Behavioral|Sudarshan Kriya Yoga|SKY Breath Meditation is a deep breathing and meditation technique that enables physiological changes leading to improved mental and physical health. Participants will first attend a 3-day online workshop (2.5 hours each day) delivered live by a certified instructor to learn the SKY Breath Meditation practice. Participants will then practice SKY 25 minutes daily for 6 weeks and 3-4 times per week up to 12 weeks.
45620578|NCT04485403|Drug|Ibuprofen|800 mg/day ( 2 x 400mg) for 3 weeks in women with a bodyweight <70 kg, and a dose of 1200 mg/day (3x400mg) in women weighing> 70kg. The effects of treatment will be compared on the basis of changes in the hormonal profile and inflammatory markers, as well as the clinical assessment of the patient.
45620579|NCT02490059|Other|bronchoscopy|Bronchoscopy for diagnosis of pulmonary nodules
45762686|NCT05516550|Drug|Treamid|Participants will receive Treamid 25 mg once a day daily during 4 weeks
45620580|NCT03073239|Genetic|ALS patients genetic characterization|Genetic findings in ALS patients
45762687|NCT05516550|Drug|Treamid twice a day|Participants will receive Treamid 25 mg in the morning and in the evening daily during 4 weeks
45762688|NCT05516550|Drug|Treamid once a day|Participants will receive Treamid 50 mg in the morning daily during 4 weeks
45762689|NCT05516550|Drug|Placebo|Participants will receive Placebo in the morning and in the evening daily during 4 weeks
45762690|NCT04382339|Drug|SOF/RBV/PegINFα-2|SOF: block the hepatitis C NS5B protein. RBV: a nucleoside inhibitor PegINFα-2: chemically modified form of the standard interferon that treats hepatitis C
45762691|NCT00371332|Drug|Minocycline HCL Microspheres|
45762692|NCT05516472|Drug|Microbial Transplant Therapy|Participants will take microbial capsules, 2 capsules daily for 7 days
46069198|NCT03842696|Drug|Tacrolimus (or cyclosporine)|Tacrolimus (or cyclosporine if tacrolimus becomes in shortage during the study period) will begin on day -3. Intravenous or oral dosing is permitted.In the absence of GVHD, it is recommended that tacrolimus or cyclosporine tapering begin on day +100 post-transplant as per local site BMT program clinical practice guidelines. In the presence of GVHD, it is recommended that tacrolimus or cyclosporine be continued at therapeutic dosing.
46069199|NCT03842696|Drug|Methotrexate|HLA-matched BMT recipients: Methotrexate will be used in combination with tacrolimus (or cyclosporine) for standard GVHD prophylaxis. It will be given at a dose of 5 mg/m2/dose once daily intravenously on days +1, +3, +6, and +11. Standard criteria for administration will be followed per local site institutional BMT program clinical practice guidelines.
46069200|NCT03842696|Drug|Mycophenolate Mofetil (MMF)|Haploidentical BMT recipients: MMF will be used in combination with post-transplant cyclophosphamide and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. MMF will start on day +5 and discontinue after the last dose on day +35 or may be continued if active GVHD is present. Given intravenously (preferred) or orally at a dose of 15 mg/kg/dose three times a day (based upon adjusted body weight) with the maximum total daily dose not to exceed 3 grams.
45446054|NCT04493931|Drug|Gepotidacin|Gepotidacin tablets will be available as unit dose strength 750 mg and will be administered orally.
45446055|NCT04493931|Drug|Cimetidine|Cimetidine tablets will be available as unit dose strength 400 mg and will be administered orally.
45446056|NCT04493931|Drug|Rifampicin|Rifampicin Capsules will be available as unit dose strength 300 mg and will be administered orally.
45620581|NCT03073239|Other|ALS patients epidemiological caracterization|Epidemiological characterization in ALS patients
45620582|NCT03220867|Drug|Risperidone: Xian Risperdal (test)|Participants will receive 1*1 mg tablet of Xian Risperdal under fasting or fed condition.
45762693|NCT05516472|Drug|Placebo|Participants will take placebo capsules
45762694|NCT05257564|Device|Determine the accuracy of quantitative measurements of GLU, HbA1c,CHOL and CRE with POC devices compared to a laboratory reference method (Roche)|Fingerstick capillary blood will be collected according to each manufacturer's Instructions for use. The fingerstick capillary blood samples will be used immediately on the point-of-care assays. The venous blood will be collected in specific tubes for plasma (GLU), for whole blood (HbA1c) and for serum (CREP, CHOL). Plasma will be separated by centrifugation at the PHC facility and health post and aliquots will be prepared. Serum will be left to clot prior to centrifugation and serum aliquots will be prepared at the PHC facility and health post. The samples will be stored until transfer to the BPKIHS reference lab.
45620583|NCT03220867|Drug|Risperidone: Gurabo Risperdal (reference)|Participants will receive 1*1 mg tablet of Gurabo Risperdal under fasting or fed condition.
45762695|NCT00842075|Drug|pramlintide|subcutaneous injection (15 mcg initial dose)prior to meals
45762696|NCT04298190|Behavioral|Dialectical Behaviour Therapy for Adolescents (DBT-A)|"16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus & Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
45762697|NCT04298190|Behavioral|Enhanced usual care|16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive family and/or pharmacological treatment as needed.
45762698|NCT04382105|Other|Observation of salivary IL-6 levels|Observation of salivary IL-6 levels and correlation of salivary IL-6 levels with periodontal disease
45762699|NCT05522010|Procedure|Cervical spine surgery|A standard anterior approach was made with discectomy sparing the cartilage, and with foraminal decompression. Complete excision of the posterior longitudinal ligament was routinely performed to complete neural decompression. Trial inserters were used to identify the proper implant size. Device under sizing may lead to poor ﬁxation and implant migration. The largest possible device that can be safely placed should be selected to maximize device- endplate contact and to gain support from the apophyseal rim. The teeth of the implant were optimally ﬁxated to the endplate via Caspar pin compression following device insertion. The device may be replaced or changed using the same insertion instrument if ﬁnal imaging demonstrated suboptimal positioning. Rinsing the implanted disc space removes rests of blood and bone dust, all potentially promoting HO
45911923|NCT05070624|Behavioral|The Virtual Peer Support Program|Training: We have previously developed and beta-tested a virtual peer mentor training program adapted from the St. Jude's Research Hospital's (Memphis, USA) program for FCs of children with cancer for adults using HMV. Content & Design of the Virtual Peer-Support Program: The program will be delivered by the aTouchAway™ App used for the LIVE program. Participants will be requested to access peer mentors ≥1 time/week. Participants can choose to interact with a peer mentor which will be assigned as well as other peer participants. Onboarding: Participants and mentors will create a personal profile of their caregiving situation (e.g., duration of care, family member age and diagnosis), to enable selection of mentors by the research team believed to be well suited to address support needs, questions, and concerns based on similar lived experience.
45446057|NCT04493931|Drug|Midazolam|Midazolam oral syrup 2 milligrams per milliliter (mg/mL) will be available to be administered orally.
45620584|NCT02490137|Behavioral|Race Car Video Game|Repeatedly playing a race car video game
45620585|NCT03073473|Diagnostic Test|NantHealth GPS Cancer Test|Quantitative targeted proteonomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing.
45620586|NCT03205345|Drug|Emricasan (25 mg)|25 mg emricasan
45620587|NCT03205345|Drug|Emricasan (5 mg)|5 mg emricasan
45620588|NCT03205345|Drug|Placebo|Matching Placebo
45620589|NCT03318029|Dietary Supplement|Vitamin D supplementation|Vitamin D supplementation of 600 IU daily for 12 weeks
45620590|NCT03318029|Dietary Supplement|Placebo|rice flour with no vitamin D
45620591|NCT03076281|Drug|Metformin Hydrochloride|Given orally
45620592|NCT03076281|Drug|Doxycycline|Given orally
45620593|NCT03076281|Drug|Metformin +Doxycycline|Given orally
45620594|NCT03317951|Other|Novel integrated care concept (NICC)|Integrated care concept including, e.g., call center, guideline therapy, tablet and medical devices
45620595|NCT03317951|Other|Standard care|Guideline therapy according to the guidelines of the European Society of Cardiology (ESC).
45620596|NCT03317873|Dietary Supplement|Testmeal A|The tesmeal A is is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
45620597|NCT03317873|Dietary Supplement|Testmeal B|The tesmeal B is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
45620598|NCT04992897|Device|Remote Electrical Neuromodulation (REN)|Acute migraine treament
45620599|NCT02452255|Drug|Fenofibrate|Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
45762700|NCT05521932|Other|endometrium collected|endometrium tissue collected following adhesiolysis surgery
45762701|NCT05233150|Behavioral|PriCARE/CARIÑO|PriCARE/CARIÑO is a group caregiver training program designed to improve child behaviors, caregiver-child relationships, parenting capacity, and reduce caregiver stress. Sessions occur in the primary care clinic or virtually. PriCARE/CARIÑO uses the 3 P skills (Praise, Paraphrase and Point-out-Behavior). The training starts with skills on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second part of the training teaches skills for giving effective commands in order to set age-appropriate limits and increase compliance. PriCARE/CARIÑO includes a stress education section that contextualizes the use of these skills with the types of behaviors and problems exhibited by many children living with psychosocial adversity and familial stress. Caregivers are encouraged to practice the skills with their child in between sessions. CARIÑO is the culturally adapted version of PriCARE for Spanish speaking participants.
45762702|NCT00879359|Drug|carboplatin, paclitaxel, and bevacizumab|All patients enrolled will receive carboplatin AUC 5 plus paclitaxel 175 mg/m2 (135 mg/m2 if prior radiation to greater than 25% of bone marrow) plus bevacizumab 15 mg/kg every 3 weeks.
45762703|NCT05527782|Drug|modified TPF|modified docetaxel-cisplatin-fluorouracil followed by concurrent chemoradiotherapy
45762704|NCT05516394|Procedure|Laparoscopic liver resection|Liver tumors are resected with minimally invasive approach, laparoscopically.
45762705|NCT05146726|Other|BARMER anemia treatment|BARMER insured patients are informed about the machine autotransfusion directly by the patient blood management (PBM) service and its intraoperative use is organized. The aim of these measures is to ensure that the intraoperative transfusion trigger does not fall below the intraoperative transfusion trigger by integrating the PBM into standard care and to avoid a perioperative transfusion. In addition, a postoperative treatment recommendation is made for the cause-related anemia treatment, e.g. in order to reduce the risk of a renewed anemia-related perioperative transfusion risk in the event of a possible follow-up operation or other elective operations.
45911924|NCT05057013|Drug|HMBD-001|Intravenous infusion given over a 21 or 28 day cycle dependent on dosing frequency. Number of cycles: 6 or until disease progression or unacceptable toxicity develops.
45911925|NCT05049291|Behavioral|telehealth advance care planning|An education information sheet containing prognosis and outcomes of acute care and intensive treatments
45620600|NCT02452255|Drug|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months
45620601|NCT02452255|Drug|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
45620602|NCT04492787|Drug|Changkang Granule|Take Changkang granule before meals twice a day , one bag for each time
45620603|NCT04492787|Drug|Changkang Placebo Granule|Take Changkang Placebo granule before meals twice a day , one bag for each time
45620604|NCT04992741|Other|education and motivational interview|The control group will remain subject to the routine process without any intervention.
45620605|NCT03205033|Drug|Melatonin 20 MG Oral Capsule|1 capsule/day 1 hour before go to bed
45911926|NCT05048082|Drug|pegsitacianine|An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
45911927|NCT05041114|Device|Motor Neuroprosthesis|Type of implantable brain computer interface
45911928|NCT05028647|Device|Virtual reality training|one hour a day for 5 days of engagement in tasks proposed by a specially crafted software through a VR device (Oculos)
45911929|NCT05028647|Device|Augmented reality training|one hour a day for 5 days of engagement in tasks proposed by a specially crafted software through a AR device (tablet)
45911930|NCT05025943|Other|Diet intervention|The intervention group will receive diet counseling and information to implement a standard lifestyle intervention plus omega-3 fatty acid enriched foods Diet assessment and counseling provided throughout study.
45911931|NCT05025943|Other|Control group|The control group will receive diet counseling and information to implement a standard lifestyle intervention Diet assessment and counseling provided throughout study.
45620606|NCT03205033|Drug|Placebo oral capsule|1 capsule/day 1 hour before go to bed
45620607|NCT03205267|Drug|Bosulif|Patients will start with dose-level 1 (300 mg once daily) Bosutinib. If patients do not experience any toxicity or only G1 toxicity, they will be dose-increased first to dose-level 2 (400 mg once daily ) and then to dose-level 3 (500 mg once daily). Dose will not be escalated above 500 mg which is the dose recommended by the summary of product information. If patients experience G2 toxicity, the study drug will be further continued at the same dose-level. In patients with G3 or G4 toxicities, therapy will be withheld until toxicity resolved to <G2.
45620608|NCT03076905|Drug|F901318|Evaluation of AUC0-t
45620609|NCT02452099|Procedure|Cryopreservation of HSCs using 5% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 5% DMSO concentration.
45762706|NCT05146726|Other|NON-BARMER anemia treatment|Patients not insured with BARMER also receive early anemia detection, selection according to indication intervention (transfusion probability> 10%) and evaluation for machine autotransfusion through the above-mentioned patient blood management (PBM) restructuring of standard care. In the case of preoperative anemia before an indication intervention and / or an intervention with machine autotransfusion application, the operating clinic will be given a recommendation by the PBM service for the diagnosis and treatment of the preoperative anemia and / or the use of the machine autotransfusion (implementation is the responsibility of the operating clinic)
45762707|NCT00880919|Drug|quetiapine extended-release|Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
45762708|NCT00880919|Drug|Placebo|Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
45620610|NCT02452099|Procedure|Cryopreservation of HSCs using 7,5% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 7,5% DMSO concentration.
45762709|NCT02741284|Drug|Room air|
45762710|NCT02741284|Drug|10L Oxygen by nonrebreather mask|
45762711|NCT00880997|Drug|Doxazosin|"Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:~Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)~Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)~Both doxazosin groups will be tapered off doxazosin or placebo over study weeks 14-17."
45762712|NCT00880997|Other|Placebo|Participants will be administered a sugar pill to mimic the doxazosin active medication with administration being the same as the active medication.
45762713|NCT05102370|Drug|Enasidenib|Study participants will receive enasidenib 100 mg daily for 18 months. Participants will continue treatment with enasidenib until confirmed progression to AML or MDS, development of unacceptable toxicity, or suspicion of disease progression, provided the patient is deriving clinical benefit, which will be determined at the discretion of the principal investigator.
45762714|NCT05521620|Behavioral|The father-friendly NICU|"Fathers have skin-to-skin contact with their infants~Fathers participate in important situations~Fathers receive information and guidance directly~Both parents participate in meaningful conversations~The department organize mother and father groups~The families have the opportunity to have a close family member to support them~Older siblings have the opportunity to stay overnight.~The department offer counseling by a social worker"
45762715|NCT00881465|Behavioral|Cognitive-behavioral therapy|Cognitive-Behavioral Therapy. The psychotherapy protocol will include 14 90-minute sessions of videophone administered CBT over 12 weeks.
45762716|NCT00881465|Behavioral|Wait-list control|Waitlist Control. The participant and his/her parents will be instructed to not obtain treatment outside of the protocol or make medication changes/additions. This will be assessed through interview at the Post-Waitlist assessment.
45762717|NCT03611374|Procedure|Bilateral Erector Spinae Plane Block (ESPB)|Bilateral ESPBs will be placed after anesthesia induction in eligible and consented patients who are undergoing a sternotomy for congenital heart repair. Patients will receive a local anesthetic agent through each catheter prior to surgery start. If possible, levels of the local anesthetic will be measured during the case. After surgery, patients will be admitted to the CVICU and extubation will be managed by the CVICU team. The ESPB group will have an automatic, alternating side boluses of the local anesthetic started through their nerve block catheters. Levels of the local anesthetic will be measured at intervals.
45620611|NCT02452099|Procedure|Cryopreservation of HSCs using 10% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 10% DMSO concentration.
45620612|NCT03076671|Behavioral|Palliative Care|Palliative care training for community neurologists and use of telemedicine for team-based support of patients
45620613|NCT03317717|Drug|Meditoxin|injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
45620614|NCT03317717|Drug|Botox|injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
45620615|NCT03076593|Other|Exposure: Fall|Participants will be asked about prior falls
45911932|NCT05010005|Drug|Ruxolitinib|Ruxolitinib 20mg BID
45911933|NCT05010005|Drug|Duvelisib|Duvelisib 25mg, 50mg, or 75mg BID
45935153|NCT00217555|Drug|gemcitabine hydrochloride|
45935154|NCT00217555|Drug|topotecan hydrochloride|
45620616|NCT03220789|Procedure|Drilling at low speed|
45620617|NCT03220789|Procedure|Drilling at conventional or high speed|
45620618|NCT03076749|Other|Creating models for the diagnosis of BL allergy|
45935155|NCT00217633|Procedure|Conventional Surgery|
45935156|NCT00069732|Behavioral|qigong|
45935157|NCT00069732|Behavioral|acupressure-TAT|
45620619|NCT03317639|Behavioral|Behaviour Change Wheel model guided intervention|Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
45620620|NCT03220555|Device|Buzzy® device|Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.
45620621|NCT03220555|Drug|EMLAPATCH (lidocaine, prilocaine)|The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
45762718|NCT05527548|Drug|Alendronate (ALN)|The oral ALN is the first-line therapy for osteoporosis, and it has been proven that once-weekly ALN 70 mg is an effective and well-tolerated dose for the treatment of postmenopausal osteoporosis. In this study, after receiving the approval of CREC and the Department of Health, we will purchase ALN from drug store. Previous clinical studies have shown that oral administration of ALN at 70mg/week for 1 year and at 5mg/day for 2 years reduced bone loss in postmenopausal women and patients who underwent total hip arthroplasty, respectively. Therefore, in the proposed study, ALN at the dose of 70mg/week will be given to patients post-ACLR for a duration of 8 weeks.
45762719|NCT00883103|Drug|2% Lidocaine jelly|2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
45762720|NCT00883103|Drug|Plain aqueous gel|Plain aqueous gel will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
45620622|NCT05004597|Other|three dimensional photography using a 3dMDHead System (3dMD, Atlanta, GA, USA)|A series of 3D craniofacial photos were captured using a 3dMDHead System (3dMD, Atlanta, GA, USA) within 7 days before or after the age of 1, 2, 4, 6, 9, and 12 months.
45762721|NCT02742532|Drug|Oxytocin|Intranasal oxytocin 40 IU
45762722|NCT02742532|Drug|Placebo|Intranasal saline solution
45762723|NCT05521464|Other|Group 1|Application of a short arm cast from just below the elbow to the finger's knuckles. The cast was from a Plaster of Paris bandage over a cotton pad. The participants who received this treatment modality were considered group 1 (control group)
45762724|NCT05521464|Other|Group 2|Modified RJ bandage (firmly applied two layers of bulky cotton layers alternating with three layers of elastic bandage in the following order: bandage - cotton - bandage - cotton - bandage). It was applied from below the elbow to the finger's knuckles. The participants who received this treatment modality were considered group 2 (trial group).
45762725|NCT03573544|Drug|OBI-888|For the dose-escalation phase, OBI-888 will be given weekly at the dose levels of 5, 10, and 20 mg/kg.
45762726|NCT03573544|Drug|OBI-888|For the dose-expansion phase, OBI-888 will be given weekly at 20 mg/kg dose level.
45762727|NCT03573544|Device|Globo H IHC Assay|This assay will be used to identify eligible patients who may clinically benefit from the OBI-888 treatment, defined by Globo H expression.
45620623|NCT02489669|Device|RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA)|Patients in the RenalGuard group will be treated by hydration with normal saline controlled by the RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA). The RenalGuard system includes a) a closed loop fluid management system; b) a high volume fluid pump, c) a high accuracy dual weight measuring system; d) motion detection artifact reduction; e) a single use intravenous set and urine collection system that interfaces with a standard Foley catheter; f) real-time display of urine and replacement fluid volume; g) a timely alerts to drain the urine bag or to replace the hydration fluid bag; f) and safety features such as automatic air and occlusion detection.
45762728|NCT05521386|Drug|Caffeine|Single pill in an acute dose of 5 mg per kg of body mass
45762729|NCT05521386|Drug|Placebo|Single pill in an acute dose of 5 mg per kg of body mass
45762730|NCT00370630|Drug|Avastin (Bevacizumab) and triamcinolone|
45762731|NCT05521230|Drug|Placebo Mouthwash|Application of mouthwashes
45762732|NCT05521230|Drug|Cymenol mouthwash|Application of mouthwashes
45762733|NCT00370708|Procedure|Oral Intake following admittance to the postpartum ward|
45762734|NCT04984980|Drug|Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab|Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab
45762735|NCT00370786|Drug|bevacizumab|
45762736|NCT04981158|Procedure|(Epidural /GA using tolerable endotracheal tube (TET) group, group II|patients will undergo a single shot epidural bupivacaine (15 ml with 0.25% concentration) followed by a standard general anesthetic technique in which the trachea was intubated using TET, through its side port 2mg/kg , lidocaine 2% will be sprayed immediately after intubation when the patient is in flat supine position then the same dose of lidocaine will be repeated 10 minutes before anesthetic discontinuation.
45762737|NCT04981158|Procedure|standard general anesthetic technique, control group, group I|patients will undergo standard general anesthesia with classic endotracheal tube
45911934|NCT04997655|Diagnostic Test|Ultrasound measurement|In the patient group who will undergo elective laparoscopic cholecystectomy, the diaphragmatic thickness values measured and recorded routinely at the pre-operative, post-extubation and post-operative 30th minute, at the end of inspiration and expiration, and the inspiratory amplitude in m-mode in the ultrasound measured from the right anterior axillary line subcostal area were observed as observational data. will be saved in our file.
45911935|NCT04995549|Device|Cutiscan® CS 100|Repeated measures on healthy volunteers skin (forearm) are performed using Cutiscan® CS 100 device
45911936|NCT04987983|Other|Experimental SLP-R|SLP-R will be given to the infant during bottle-feeding.
45762738|NCT03437356|Other|Pulmonary vein isolation using CLOSE protocol|'CLOSE' protocol: Ablation index > 400 at the posterior wall (reduce to 300 if esophagus temperature rise), ablation index > 550 at the anterior wall, and inter-lesion distance < 6.0mm
45911937|NCT04987983|Other|Experimental SLP-L|SLP-L will be given to the infant during bottle-feeding.
45935158|NCT00217711|Drug|Capecitabine|capecitabine
45620624|NCT03204877|Drug|Melatonin|Oral capsules
45620625|NCT03204877|Other|Placebo|Oral capsules
45620626|NCT03220399|Drug|NVP-1603-1 (P)|1capsule, single oral dosing
45620627|NCT03220399|Drug|NVP-1603-2 (T)|1tablet, single oral dosing
45620628|NCT03220399|Drug|NVP-1603-1 and NVP-1603-2 (P+T)|1capsule and 1tablet co-administration, oral single dosing
45620629|NCT02489747|Dietary Supplement|WBE|wheat bran extract (3 g/day)
45620630|NCT02489747|Dietary Supplement|Placebo|Placebo
45620631|NCT03076437|Combination Product|Drugs and Anti-CD19-CAR transduced T cells|"Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 IV will be infused over 30 minutes. Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.~Biological: Anti-CD19-CAR transduced T cells Modified cells will be infused IV over 30 minutes (1-3 days after the last dose of fludarabine)."
45620632|NCT03224845|Behavioral|Cognitive behavioural skills training|The intervention will be delivered in two stages: First, the parent with an anxiety disorder will attend between six and sixteen weekly sessions of cognitive behavioural skills training focusing on their own anxiety. They will work on developing behaviours that will help them become less anxious in the long-run and on learning to evaluate danger in a realistic way. Next, the parent will take part in four to eight weekly sessions of anti-anxiety parenting skills training aiming to help them transfer the skills that they learned into parenting their children. In the parenting intervention, the parents will be guided to gradually expose their children to new situations, build communication skills and confidence, in addition to general parenting skills and principles.
45620633|NCT02486393|Procedure|Parotid surgery|Surgery of the parotid gland tumours
45446058|NCT04493931|Drug|Digoxin|Digoxin tablets will be available as unit dose strength 0.25 mg and will be administered orally.
45620634|NCT05003973|Behavioral|home-based anti-resistance exercise|It is a 12-week, middle-level, home-based, anti-resistance exercise. Exercise was recommended 1-2 times per day for 15-20 mins per session.
45620635|NCT05003973|Behavioral|usually care|The leaflet of the lymphedema self-care, including skin care and manual lymphatic drainage
45620636|NCT03204799|Other|Metformin|newly diagnosed type 2 diabetes patients who start to metformin monotherapy
45620637|NCT03204799|Drug|SGLT2 inhibitor|newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy
45762739|NCT03437356|Drug|Antiarrhythmic drug therapy (ADT)|"During the first 3 months after PVI, patients continue oral anticoagulants and antiarrhythmic drug therapy (ADT). ADT is a continuation (or restart) of previously ineffective Class IC and III ADT. At the time of discharge, dosage is optimized according to the 2016 ESC guidelines on AF management.~Preferred dosages:~Flecainide: Tambocor or Flecainide EG 100mg b.i.d., Apocard R 100 to 200mg overdose (OD) Propafenone: Rytmonorm or Propafenone EG 300 mg b.i.d., except 225 mg b.i.d. if ≥70 years or <70 kg Sotalol: Sotalex or Sotalol EG 80mg b.i.d., Except 80mg t.i.d. if men < 70 years, Cr <1.5mg/dl, >70kg, except 80 mg OD if female >70 years or Cr >1.2mg/dl~In case of amiodarone intake before PVI, amiodarone is switched to sotalol or class IC ADT."
45762740|NCT05516160|Diagnostic Test|diagnostic of optical aberrations|diagnostic of optical aberrations with new device
45911938|NCT04987645|Procedure|Water-only infusion technique|During a routine colonoscopy, a resident in the study will use water only infusion technique for this intervention. This intervention is used to look at the impact that water assisted colonoscopy has on resident learning.
45911939|NCT04987645|Procedure|Water infusion and air insufflation|During a routine colonoscopy, a resident in the study will use water infusion and air insufflation technique for this intervention. This intervention is used to look at the impact that water assisted colonoscopy has on resident learning.
45620638|NCT03204799|Drug|ezetimibe|newly diagnosed dyslipidemia patients who start to ezetimibe therapy
45620639|NCT03317327|Drug|Nivolumab|Nivolumab is a humanized antibody used in cancer immunotherapy.
45620640|NCT03317327|Radiation|Radiotherapy (RT)|Radiotherapy (RT) will be given to a total dose of 60 Gy (1,5 Gy fractions twice daily) for a total period of 4 weeks
45620641|NCT03220243|Drug|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
45911940|NCT04983589|Drug|Pilocarpine HCl|Pilocarpine HCl ophthalmic solution 1.25% ocular drops.
45446059|NCT04493931|Other|Placebo matching to gepotidacin|Placebo matching to gepotidacin tablets will be administered orally.
45446060|NCT03437278|Drug|Ligelizumab|Ligelizumab comes in 120 mg per 1 ml liquid vials. Participants received one injection every 4 weeks at a dose of 120 mg or 24 mg, high and low doses respectively.
45446061|NCT03437278|Drug|Placebo|Placebo 0 mg per 1 ml liquid injection once every 4 weeks.
45620642|NCT03204331|Drug|Relugolix|Relugolix 40-mg tablet administered orally once daily.
45620643|NCT03204331|Drug|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
45620644|NCT03204331|Drug|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
45620645|NCT03204331|Drug|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
45620646|NCT03317249|Diagnostic Test|ECG|12-lead electrocardiogram
45762741|NCT03387670|Drug|Simvastatin|"One (1 = 40mg) simvastatin tablet once daily at night for 1 month~Two (2 = 80mg) simvastatin tablets once daily at night, for the next 35 months"
45762742|NCT03387670|Drug|Placebo|"One (1) placebo tablet once daily at night for 1 month~Two (2) placebo tablets once daily at night, for the next 35 months"
45762743|NCT04979832|Drug|GM-CSF, fosfomycin and metronidazole|GM-CSF 50 micrograms Fosfomycin 400 milligrams Metronidazole 100 milligrams applied as a gel in the pouch
45911941|NCT04983589|Drug|Vehicle|Oxymetazoline HCl and pilocarpine HCl placebo ocular drops.
45911942|NCT04976127|Drug|Talineuren|Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration
45762744|NCT03368092|Drug|Dornase Alfa Inhalant Solution [Pulmozyme]|Dornase alfa (Pulmozyme®, Roche 2500U, 2,5mL) given by aerosol in the respiratory circuit (Aerogen solo®) within 6h at day 1 and 24 hours after on day 2.
45762745|NCT03368092|Drug|Placebos|NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.
45762746|NCT05521152|Drug|Norepinephrine Bitartrate|"anesthesia resident (who will not be involved in patient management to ensure the blinding) will be responsible for preparing norepinephrine infusion or placebo as instructed in the envelope as follow: 1 mg norepinephrine will be diluted in dextrose 5% in a 50 mL syringe using a nomogram based on the infant body weight so that 1mL= 0.05 µg/kg/min norepinephrine infusion.~the attending anesthetist will be instructed to set the 2 syringe pumps on 2 mL/h continuous infusion following skin incision."
45762747|NCT05521152|Drug|Placebo|Placebo
45762748|NCT02740114|Drug|Bupivacaine|150 mg (0.25%) injected on each side of the wound at the end of surgery before wound closure.
45762749|NCT02740114|Drug|Liposomal Bupivacaine|266 mg injected on each side of the wound at the end of surgery before wound closure.
45762750|NCT02740114|Drug|Oxycodone|1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.
45762751|NCT02740114|Behavioral|Pill Diary|Participants complete a pill diary every day for 30 days after hospital discharge.
45762752|NCT02740114|Behavioral|Symptom Questionnaire|Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks.
45762753|NCT05527158|Behavioral|Yi Jin Jing exercise|Yi Jin Jing of The General Administration of Sport of China, which consists of twelve operational processes as the standard intervention
45762754|NCT03356470|Other|F-FDG PET/CT|F-FLT PET uses a thymidine analogue that accumulates in proliferating tissue. Proliferating tissue could include malignant lesions or immune cells. In this study, FLT PET/CT will be utilized as a molecular imaging tool to detect immune activation after administration of immune checkpoint blockade with pembrolizumab or nivolumab.
45762755|NCT04987216|Device|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
45762756|NCT04906096|Drug|PAXALISIB|Each study treatment cycle lasts 28 days, up to 24 months. Oral, daily, dosage per protocol
45762757|NCT05520996|Behavioral|Cyberball|Social exclusion or ostracism can be measured by the Cyberball 5 task. The principle of Cyberball is based on the creation of a situation of exclusion through a computerized task. During this task, the participant passes a ball to 2 other players controlled by Artificial Intelligence (AI). The ball-passing method of AI-controlled players is determined in advance in the computer program code. A series of ball passing is carried out with initially an equal passing between the three participants and then an exclusive passing between the players controlled by an artificial intelligence
45762758|NCT05515926|Procedure|Cranial manipulation group, or cranial osteopathic techniques (OMM)|"Cranial OMT procedure:~Subjects were relaxed and lying on the back for entire time of the research protocol (approximately 30 min). Osteopathic physician performed the osteopathic manipulations using his hands. The physician gently applied a small amount of force to the neck and head to release tissue tension until feeling a softening and warmth of tissues. Subjects experienced a sensation of slight pulling, releasing, or relaxing of the tissue."
45762759|NCT05515926|Procedure|Sham manipulation|The osteopathic physician placed his hands on the skull of the subject but did not influence cranial motion.
45762760|NCT04800016|Device|AcrySof IQ Vivity Extended Vision IOL|UV and blue-light filtering extended depth of focus foldable IOL intended to provide a full range of vision from distance to functional near.
45762761|NCT04800016|Procedure|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ Vivity Extended Vision IOL
45911943|NCT04975334|Drug|kisspeptin, GnRH, naloxone|Six IV doses of kisspeptin 112-121
45911944|NCT04975334|Drug|GnRH|Two IV doses of GnRH
46069201|NCT03842696|Drug|Cyclophosphamide|Haploidentical BMT recipients: Post-transplant cyclophosphamide (PT-Cy) will be used in combination with MMF and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. PT-Cy (50 mg/kg/dose) given for two days, Days +3 and +4 after transplantation.
45620647|NCT03317249|Diagnostic Test|heart rate monitor|24-hour heart rate monitor used to calculate mean heart rate and heart rate variability
45620648|NCT03317249|Diagnostic Test|Autonomic Nervous System (ANS) Activity|"Heart Rate Variability (HRV) and Baroreflex sensitivity (BRS):~Resting and exercise HRV and BRS calculated from ECG, Dundee Step test and blood pressure measurements."
45620649|NCT03317249|Diagnostic Test|Haemodynamic variables|Cardiac output (CO), stroke volume (SV) and systematic vascular resistance (SVR) will be assessed and calculated using a non-invasive, inert gas re-breathing technique whereby expired gases will be sampled and analysed alongside and blood pressure measurements.
45446062|NCT02068378|Device|CMPE Optical Sensor Device|Christie Medical Physics & Enginieering visual feedback with optical sensing device.
45762762|NCT05515848|Other|No intervention|There is no intervention in this retrospective study.
45762763|NCT05527080|Other|physiotherapy|Some infants will receive physiotherapy as a part of their clinically indicated care.
45762764|NCT05527080|Device|brace|Some infants in the hip dysplasia group will receive brace and/or cast as a part of their clinically indicated care
45911945|NCT04975334|Drug|Naloxone|One bolus and one infusion of naloxone
45446063|NCT02067364|Device|Fit & Function test|
45911946|NCT04961580|Drug|Ceftazidime Avitbatan Sodium|For 6-18 years children, 62.5 mg/kg/once，q8h ; 3-6 months of age 50 mg/kg/ once,q8h, intravenous administration for 2 hours, daily dose is not more than 2.5g, children will be administrated at least five times.
45911947|NCT04945759|Device|Isokinetick Exercise, Aussie Current, Russion Current, Plasebo Electirical Stimulasyon|Evaluation and treatment will be done with the Cybex humac device.
45911948|NCT04941560|Other|No intervention|No intervention
45911949|NCT04929951|Biological|Micro Fragmented Adipose Tissue|Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection
45911950|NCT04929951|Biological|Corticosteroid injection|Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
45620650|NCT03317249|Other|Echocardiogram|optional (for non-IST participants only)
45762765|NCT04745104|Drug|SHR-1707|SHR-1707 will be administered through IV infusion
45762766|NCT04745104|Drug|Placebo|Placebo will be administered through IV infusion
45446064|NCT05536492|Procedure|A-PRF|EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF
45762767|NCT00371410|Procedure|vitrectomy|
45762768|NCT00371410|Drug|intravitreal triamcinolone acetonide|
45762769|NCT00371410|Procedure|macular focal laser photocoagulation|
45762770|NCT04296474|Drug|ALK Alutard 5-grasses and birch|Intralymphatic injections
45762771|NCT04296474|Drug|ALK Diluent|intralymphatic injections
45762772|NCT04659616|Drug|Cytarabine|Given IV
45762773|NCT04659616|Drug|Daunorubicin|Given IV
45762774|NCT04659616|Drug|Pemigatinib|Given PO
45762775|NCT04658680|Drug|BCG vaccination at first health facility contact|"Intradermal injection at first health facility contact: 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine in the left deltoid region.~The strain supplied by the national vaccination programme is provided through UNICEF. Different strains are used interchangeably. The additional BCG vaccines provided through this study will be procured by the Bandim Health Project. Vaccines will be from the WHO list of prequalified vaccines and the same strain will be used in intervention and control health centres."
45762776|NCT04295850|Drug|Aspirin 81 mg|Aspirin 81mg daily PO
45446065|NCT05536492|Procedure|ALLOGRAFT|EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF + ALLOGRAFT
45446066|NCT04949373|Device|High-intensity laser therapy (HILT)|"High intensity laser therapy-Patients will receive pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program will be performed on each session.~Other: Tendon and nerve gliding exercises will be performed three times a day with 10 repetitions each time for 3 weeks. Exercises will be performed by a trained physiotherapist.~Other: Rest splint(at night) Participants will be splinted in neutral position with standard cotton-polyester splints.The patients will be encouraged to use the splints during nighttime for 12 weeks."
45762777|NCT05520918|Diagnostic Test|the LIT test|The retained functional capacity of leukocytes (primarily neutrophils) to produce ROS in response to PMA in whole blood samples could provide a rapid 10-minute detection method for objectively determining onset or occurrence of severe COVID-19 and monitoring progression and treatment of COVID-19.
45762778|NCT04738240|Diagnostic Test|Intra-operative endoscopy|Intra-operative endoscopy to assess rectal anastomosis
45762779|NCT05520840|Diagnostic Test|blood sampling for screening of biomarkers|Patient aged 50 years or older referred for screening colonoscopy after a positive fecal immunochemical test or for endoscopic resection of a previously identified suspicious colorectal lesion will have a blood sampling for biomarkers detection
45762780|NCT05527002|Other|Satisfaction of patients after medical and surgical treatment for thoracic endometriosis|"It is a retrospectively evaluation of cases of thoracic endometriosis in our clinic over the last 20 years, based on the review of medical records and on outpatient follow-up visits.~The questionnaire are filled in routinely by patients attending the endometriosis center of this institute every 6 months. We will collect data relating to these questionnaires referring prospectively to the study period.~If the questionnaires have not already been filled in by the patient, she will be contacted to fill them in, after signing the informed consent of the study."
45762781|NCT02166905|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given via intracutaneous injection
45762782|NCT02166905|Drug|Epacadostat|Given PO
45762783|NCT02166905|Other|Laboratory Biomarker Analysis|Correlative studies
45762784|NCT02166905|Other|Pharmacological Study|Correlative studies
45620651|NCT03072849|Procedure|Pulmonary function testing|Each enrolled patient will receive pulmonary function testing every three months. Pulmonary function testing includes spirometry, plethysmography, and diffusion capacity measurements.
45620652|NCT03072849|Drug|FAM Therapy|All patients who have evidence of early airflow obstruction on pulmonary function testing will be started on FAM therapy. Early airflow obstruction is defined by a FEV1 decline of ≥10% predicted in addition to a FVC <0.8.
45620653|NCT05463497|Drug|Treatment A|JW0201: single administration, Tablet, Oral, BID for 5 days
45620654|NCT05463497|Drug|Treatment B|C2103: single administration, Tablet, Oral, BID for 5 days
45620655|NCT05463497|Drug|Treatment C|JW0201 and C2103 : combination administration, Tablet, Oral, BID for 5 days
45620656|NCT05463497|Drug|Treatment D|C2104 : single administration, Tablet, Oral, QD for 5 days
45762785|NCT02166905|Drug|Poly ICLC|Given SC
45762786|NCT02743078|Drug|Bevacizumab|10 mg/kg every 2 weeks intravenously over 30 minutes.
45762787|NCT02743078|Device|TTFields Therapy|Device is worn continuously at least 18 hours a day on average, with 1-3 days off every four weeks.
45762788|NCT04294368|Dietary Supplement|Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid|The control group will receive mother's breast milk when it is available. Mother's breast milk will be fortified with 4 packets of Similac Human Milk Fortifier (HMF) per 100 mL. When mother's breast milk is not available, participants will be fed donor breast milk with 4 packets of HMF.
45762789|NCT04294368|Dietary Supplement|Similac Liquid Protein Fortifier|For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU. The standard dose is 1 ml per 30 ml of breast milk.
45762790|NCT04294368|Dietary Supplement|Nestle Microlipid|For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU. The standard dose is 1 ml per 30 ml of breast milk.
45620657|NCT05463497|Drug|Treatment E|JW0201 and C2104 : combination administration, JW0201 twice a day and C2104 once a day for 5days
45620658|NCT03073083|Procedure|Hamstring tendon autograft|ACL reconstruction surgery with hamstring tendon
45762791|NCT04294368|Dietary Supplement|Medica Nutrition SolCarb|For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU.
45911951|NCT04920799|Dietary Supplement|Nitrate rich beetroot juice|Participants will drink nitrate rich beetroot juice (2.4 floz ; Beet It Sport Nitrate 400 concentrated beetroot shot; James White Drink, ltd) twice daily for two weeks.
45762792|NCT04294368|Dietary Supplement|Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid (Targeted Fortification)|The experimental group will receive mother's breast milk when it is available. Mother's breast milk will be fortified with 4 packets of Similac Human Milk Fortifier (HMF) per 100 mL. When mother's breast milk is not available, participants will be fed donor breast milk with 4 packets of HMF. For participants in the experimental group, the investigators will continue to add fortification. Two packets of HMF per day will be added until goal fortification is reached.
45762793|NCT04294368|Dietary Supplement|Similac Liquid Protein Fortifier (Targeted Fortification)|Participants in the experimental group will receive a dose that will vary depending on the base protein content in the donor breast milk for each particular batch of donor breast milk.
45762794|NCT04294368|Dietary Supplement|Nestle Microlipid (Targeted Fortification)|Participants in the experimental group will receive a dose that will vary depending on the base fat content in the donor breast milk for each particular batch of donor breast milk
45762795|NCT04294368|Dietary Supplement|Medica Nutrition SolCarb (Targeted Fortification)|Participants in the experimental group will receive a dose that will vary depending on the base carbohydrate content in the donor breast milk for each particular batch of donor breast milk
45620659|NCT03073083|Procedure|Pattella tendon autograft|ACL reconstruction surgery with patella tendon
45620660|NCT03073083|Procedure|Quadriceps tendon autograft|ACL reconstruction surgery with quadriceps tendon
45620661|NCT03317171|Dietary Supplement|Flavonoids, DHA, EPA|oral administration
45762796|NCT04294368|Other|Analysis with Miris (AB) Human Milk Analyzer|For participants in both the control and the experimental arms, each batch of donor milk will be analyzed using the Miris Human Milk Analyzer. Manufacturer recommendations for milk analysis will be strictly followed.
45762797|NCT03323398|Biological|mRNA-2416|mRNA encoding human OX40L
45620662|NCT03317171|Dietary Supplement|placebo compound|oral administration
45762798|NCT03323398|Biological|Durvalumab|PD-L1 inhibitor
45762799|NCT05526846|Behavioral|Plant-based diet education|"Participants will attend a virtual kick-off introductory session and will receive weekly emails with information about plant-based diets and a goal/task for each week.~There will be a 'core curriculum' that will be sent to all participants, as well as additional information according to the participant's stage of change and food choice preferences.~All information will be available on a website that will be created for this study. The website will feature curated information about plant-based diets, that is tailored to patients who had recent colorectal operations and may have a colostomy or an ileostomy.~Bi-weekly office hours will be held for patients to have the opportunity to discuss questions or concerns that may arise."
45762800|NCT00890981|Procedure|high-resolution peripheral quantitative computed tomography (HR-pQCT)|Bone densitometry and microarchitecture assessments of the distal radius and the distal tibia by HR-pQCT on Day 1.
45762801|NCT00890981|Procedure|Dual energy X-ray absorptiometry (DXA)|Bone densitometry assessments of the forearm by DXA on day 1.
45762802|NCT00890981|Biological|Denosumab|Denosumab 60 mg subcutaneously every 6 months in the previous study
45762803|NCT00890981|Drug|Placebo|Placebo to denosumab subcutaneously every 6 months in the previous study
45762804|NCT05515770|Drug|Cabotegravir Injection|Long action cabotegravir injection
45762805|NCT04502758|Device|MagVenture TMS Therapy System w/Theta Burst Stimulation|During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field properties on the active site are identical to that of the standard Cool-B70 coil, cleared for iTBS treatment.
45911952|NCT04920799|Dietary Supplement|Nitrate depleted beetroot juice|Participants will drink nitrate depleted beetroot juice (2.4 floz ; Beet It placebo concentrated beetroot shot; James White Drink, ltd) twice daily for two weeks.
45620663|NCT03220321|Other|PICN (VITA Enamic) hybrid abutment crown|Hybrid ceramic
45620664|NCT03220321|Other|Lithium disilicate (IPS e.max) hybrid abutment crown|Glass ceramic
45620665|NCT03075657|Drug|Risperidone|Risperidone will be prescribed at dose of 2 mg per day
45620666|NCT03075657|Drug|Risperidone and Ramelteon|Ramelteon will be prescribed 8mg/day as an add-on therapy to Risperidone 2 mg per day
45620667|NCT03075657|Drug|Haloperidol|Haloperidol will be prescribed at a dose of 4 mg per day
45620668|NCT03075657|Drug|Haloperidol and Ramelteon|Ramelteon will be prescribed 8mg/day as an add-on therapy to Haloperidol 4 mg per day
45911953|NCT04919408|Other|telephone survey|telephone survey with a questionnaire to assess pain at 3 months and then 6 months after their cesarean section
45911954|NCT04914663|Behavioral|Exercise training|Supervised exercise training performed in small groups over 12 weeks while patients undergo chemotherapy for breast cancer.
46069202|NCT03832361|Drug|IMGN853|IMGN853 6 mg/kg intravenously every 3 weeks until disease progression
46069203|NCT03824652|Other|walnuts|2 ounces of walnuts daily for 4-10 weeks
45620669|NCT02451865|Drug|Binimetinib|Given PO
46069204|NCT03824652|Other|usual diet|Subject continues usual diet
45620670|NCT02451865|Drug|Docetaxel|Given IV
45620671|NCT02451865|Other|Laboratory Biomarker Analysis|Correlative studies
45620672|NCT05004207|Diagnostic Test|99mTc Scintigraphy|"After fasting for at least 8 to 12 hours, standardized meal mixed with 99mTc-sulfur colloid radiolabeled test will be administered as quickly as possible, optimally within 10 min. Imaging will be obtained with Siemens SYMBIA E dual head (SPECT) scanner in a format of at least 128 x 128 pixels. Anterior and posterior planar images (or a single left anterior oblique image) with the distal esophagus, stomach, and proximal small bowel in the field of view will be obtained for 1 min immediately after ingestion of the test meal and repeated images will be obtained in the same projections with 2 min static images at hourly intervals up to 6 h and at 24 hours as was used for the initial images.~Next day LHBT will be performed after at least 12 hours of fasting. Following administration of test substrate (Lactulose 10 grams) with one cup of water, breath samples will be analyzed for hydrogen every 15 minutes for 1 hour followed by every half hour for next 2 hour with LACTOFEN 2 device."
45762806|NCT04502758|Device|Sham MagVenture TMS Therapy System w/Theta Burst Stimulation|During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field on the sham site is significantly reduced, and is less than 5% of that of the active site.
45762807|NCT05520684|Diagnostic Test|urine culture and urinalysis|urine culture and urinalysis
45620673|NCT03317093|Drug|Ceftobiprole Medocaril|1 single intravenous dose of 500 mg of Mabelio (Ceftobiprole Medocaril) perfused for 2 hours at D0
45620674|NCT03317093|Other|Blood samples and cerebrospinal fluid|Before and immediately before the end of the perfusion and then at 0.5h, 1h, 3h, 6h, 12h and 24h.
45620675|NCT03224143|Behavioral|Doll Therapy Intervention|"Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the doll in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the doll in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the doll after the second request, the N will not insist and she will leave. If the doll will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P."
45620676|NCT03224143|Behavioral|active control group (SI)|"Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the cube in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the cube in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the cube after the second request, the N will not insist and she will leave. If the cube will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P."
45620677|NCT02486315|Device|AXXESS stent|Axxess stent is a conically-shaped, self-expanding nitinol stent, with a 0.006-inch strut thickness, specifically designed to preserve and to match the anatomy of the bifurcation at the carina level. The stent is coated with Biolimus A9™, a highly lipophilic, semi-synthetic sirolimus analogue, immersed in the biodegradable polylactic acid (PLA) applied primarily to the abluminal surface. PLA completely dissolves after 6 to 9 months.The stent has 3 radiopaque markers at the distal end and one at the proximal end to aid in the visibility and placement. The AxxessTM stent is 7 Fr guiding catheter or Sheathless Guiding Catheter compatible. During the study period, the AxxessTM stent was available in 3 different diameters (3.0, 3.5 and 4.0 mm) and lengths (9, 10 and 14 mm)
45762808|NCT04480138|Drug|Pegylated Interferon-α2b|1 mcg/kg on day 1 and day 8 after safety evaluations.
45762809|NCT04480138|Other|Standard of Care|Standard of care as per local authority
45762810|NCT01610843|Other|Survey|Longitudinal surveys
45762811|NCT04463992|Behavioral|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
45762812|NCT04463992|Other|Usual Care|Usual care as provided by local oncologists
45762813|NCT00371488|Drug|GW572016 oral tablets|Tablets contain 405mg of lapatinib ditosylate monohydrate, equivalent to 250mg lapatinib free base per tablet. Oval, orange, film-coated tablets.
45762814|NCT02743312|Device|Torso Weights|Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss.
45762815|NCT02743312|Device|Sham Weights|Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss. The garment is then taken by another investigator and the actual weights are replaced with sham weights.
45762816|NCT02743312|Device|Fitbit Flex|Potential effect on participants' physical activity to see their own step count using this wrist-worn remote monitoring device.
45762817|NCT01501955|Device|Metaphyseal Hip Prosthesis|Metaphyseal Hip Prosthesis (MHP) hip replacement
45762818|NCT01501955|Device|Stanmore|Stanmore hip prosthesis
45762819|NCT02743702|Other|RESPIRATORY PHYSIOTHERAPY|"The protocol designed was composed of the following exercises:~supine position: inhalation and exhalation with abdominal and thoracic pressures. 5 times~lateral decubitus, with incentive spirometer lung inflation are made on right/left sides. 3 sets on each side~sitting position, with the body leaning slightly forward, head and shoulders bent inwardly directed. It inspire called for 3 times, sent off in air through the mouth, after that the child was coughing~diaphragmatic breathing in a sitting position: after a slow exhalation requested, child should steam a mirror with his mouth slightly open. 3 replications~in a sitting position, with help of an ambu bag, we made inflations. Repeated 3 times~exercises of upper member coupled to respiratory rhythm: shoulder flexion and extension was carried out during the inspiratory phase and the extension and adduction of them during expiration. 3 times"
45762820|NCT02743702|Other|USUAL THERAPIES|
45911955|NCT04903522|Behavioral|Baroque music listening|"Patients will listen to a 30-minute musical path of baroque pieces. Before and after this, anxiety, depression and consciousness fluidity will be evaluated thanks to different questionnaires"
45911956|NCT04886154|Combination Product|MenABCWY-2Gen low dose vaccine|MenABCWY-2Gen low dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY low dose Group in study Phase I, ABCWY low dose_06 Group and ABCWY low dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY low dose_01 Group, ABCWY low doseS_02 Group and ABCWY low doseS_06 Group in study Phase II (Sourcing).
45935159|NCT00217711|Drug|irinotecan hydrochloride|irinotecan hydrochloride
45762821|NCT04335760|Combination Product|Modified Bruce protocol on treadmill|"Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available."
45911957|NCT04886154|Combination Product|MenABCWY-2Gen high dose vaccine|MenABCWY-2Gen high dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY high dose Group in study Phase I, ABCWY high dose_06 Group and ABCWY high dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY high dose_01 Group, ABCWY high doseS_02 Group and ABCWY high doseS_06 Group in study Phase II (Sourcing).
45911958|NCT04886154|Combination Product|Placebo|Placebo is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the Placebo low dose Group, Placebo high dose Group in study Phase I and as 1 dose to participants in the ABCWY low dose_06 Group, ABCWY low dose_02 Group, ABCWY high dose_06 Group, ABCWY high dose_02 Group in study Phase II (Formulation and Schedule-finding).
45911959|NCT04886154|Combination Product|MenB vaccine|MenB vaccine is administered intramuscularly in the deltoid region of the non-dominant arm, whenever it's possible, as 2 doses in a 0,6-months schedule to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
45911960|NCT04886154|Biological|MenACWY vaccine|MenACWY vaccine is administered intramuscularly in the deltoid region of the dominant arm as 1 dose to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
45620678|NCT03224065|Diagnostic Test|Genotype detected through GenSeizer high-throughput gene capture technology|The sputum and/or alveolar lavage fluid of the optimal treatment group was first identified by GenSeizer, which was used to remove the resistant agents and choose the sensitive agents, so as to optimize the initial antimicrobial program. All agents are within the recommended range of 2007 ATS / IDSA Guidelines. All treatment regimens need to be corrected in time according to the final results of culture and in vitro susceptibility testing.
45762822|NCT05520606|Procedure|pancreatoduodenectomy|Pancreatoduodenectomy (Whipple surgery) is a complex surgical procedure and has been accepted as the gold standard treatment for resectable lesions of the pancreatic head and periampullary region
45620679|NCT02489513|Drug|[14C]-AG-120|Labeled investigational drug
45911961|NCT04878263|Other|Conventional hospitalization|Conventional care pathway : patients will be hospitalized as long as necessary and then followed according to High Health Authorities recommendations and usual practices.
45911962|NCT04878263|Other|FIL-EAS ic care pathway|Organized care pathway with a maximum 4 working day long conventional hospitalization followed by hospitalization at home with a follow up combining hospital and private practice competences.
45935160|NCT00217711|Drug|oxaliplatin|oxaliplatin
45935161|NCT00217789|Procedure|Bronchoalveolar Lavage and Venipuncture|
45620680|NCT02451397|Other||This is a cross-sectional study, and we do not assign specific interventions to the subjects of the study.
46069205|NCT03824652|Other|phone counseling with dietitian|Weekly calls with dietitian
46069206|NCT03824132|Behavioral|Improvisational comedy classes|6 consecutive improvisational comedy classes
45620681|NCT03317015|Drug|triamcinolone XRG5029|"Pharmaceutical form: spray solution~Route of administration: nasal"
45620682|NCT03317015|Drug|fluticasone|"Pharmaceutical form: spray solution~Route of administration: nasal"
45620683|NCT03204487|Drug|Tafluprost 15µg/ml|Tafluprost 15µg/ml (Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis, Merck Sharp & Dohme, Wien)
46069207|NCT03824132|Behavioral|Waitlist control|After 10 week waitlist control, subjects will complete 6 consecutive improvisational comedy classes.
46069208|NCT03815266|Diagnostic Test|transcranial Direct Current Stimulation (tDCS)|"transcranial Direct Current Stimulation (tDCS) is device which consist in setting up an electrode on the skull of the patient to deliver the low intensity current.~Patient will have transcranial Direct Current Stimulation (tDCS) at each session and at the same time of Computerized Mirror Therapy (CMT)."
45620684|NCT03316937|Procedure|Types of scalers|Scaling
45620685|NCT03204565|Procedure|coronally advanced flap|coronally advanced flap alone (CAF- control)
45620686|NCT03204565|Device|hyaluronic acid|hyaluronic acid associated to coronally advanced flap (CAF + HA- test)
45620687|NCT03321227|Other|Snack skipping|No snack provided
45620688|NCT03321227|Other|Whole eggs|2 whole large eggs scrambled, provided as a snack
45620689|NCT03321227|Other|Egg whites|2 egg whites scrambled, provided as a snack
45620690|NCT03321227|Other|Egg yolks|2 egg yolks scrambled, provided as a snack
45762823|NCT00883415|Drug|Darbepoetin alfa|Subjects will undergo anemia management with darbepoetin after baseline assessment of MGU and will continue for six months with repeat assessment of MGU at completion of protocol
45762824|NCT05515614|Dietary Supplement|Targeted Fortification|Mother's breast milk will be fortified in modular fashion based on the level of macronutrients (protein, carbohydrate, and fat) found from analysis using the Miris Human Milk Analyser. For protein supplementation, Amino Acid powder will be utilized as a modular component. For carbohydrate supplementation, PolyCal will be utilized. Mother's breast milk will be fortified in modular fashion. For protein supplementation, Amino Acid powder will be utilized as a modular component. For carbohydrate supplementation, PolyCal will be utilized. For lipid supplementation, safflower oil will be utilized. We will set our goal energy level between 110 - 135 kcal/kg/day, protein level between 3.5 - 4.5 g/kg/day, lipid level between 4.8 - 6.6 g/kg/day, and carbohydrate level between 11.6 - 13.2 g/kg/day. We will regard daily fluid volume to be between 150 to 180 mL/kg/day.
45762825|NCT05515614|Dietary Supplement|Enfamil Liquid Human Milk Fortifier|Mother's breast milk will be fortified using Enfamil Liquid Human Milk Fortifier as per standard feeding protocol defined by LLUCH NICU manual.
46069209|NCT03815266|Diagnostic Test|Computerized Mirror Therapy (CMT)|Computerized Mirror Therapy (CMT) will be realizing by the device Intensive Visual Simulation 3 (IVS3). Patient will have Computerized Mirror Therapy (CMT) at each session and at the same time of transcranial Direct Current Stimulation (tDCS).
45620691|NCT03321227|Other|Yogurt|A serving of full fat yogurt that is isocaloric to the 2 whole eggs
45620692|NCT02451319|Procedure|Retrograde Intrarenal Surgery|Endoscopic treatment of Kidney Stones
45620693|NCT02486159|Drug|Herbal plaster (Sanfujiu)|The Acupoint herbal plaster consisted of mustard seed, fumarate, asarum, angelica, cinnamon, and ginger at a ratio of 3:3:2:2:0.5:4, respectively. The treatment was prepared by dissolving the ginger in water and adding the powder to form a plaster. Mixtures were formed into cakes of approximately 1.5 × 1.5 × 0.5 cm3 and were held in position using plastic sheets.
45620694|NCT02486159|Procedure|Acupuncture|Eight (8) acupuncture treatment sessions over 4 weeks were performed for each volunteer. The standard protocol for acupuncture treatment covered the most commonly treated acupoints for allergic rhinitis: LI4, ST36, LI20 in both sides, and EX-HN3. After insertion of needles at each acupoint, manual stimulation of needles on LI20 and EX-HN3 was repeated 3 times at 5-minute intervals. Electrostimulation was applied to the needles inserted in ST36 and LI4 with a frequency of 3-5 Hz, and the intensity was adjusted according to each volunteer's tolerance. All needles were removed 20 minutes later in each treatment session.
45620695|NCT03224377|Diagnostic Test|anti mutated citrullinated vimentin antibodies|Blood sampling using ELisa technique
45620696|NCT02489435|Drug|VM-1500|VM-1500
45762826|NCT02743936|Device|Nasal cannula|Placement of nasal cannula under non-invasive positive pressure ventilation mask
45620697|NCT02489435|Drug|Placebo|Placebo
45620698|NCT02451787|Dietary Supplement|Vitamin D|2400 units per day for 3 months
45620699|NCT03321149|Other|RiseTx|Participants were given access to the RiseTx application, as well as given a Jawbone, a wrist-worn device that can assess activity patterns throughout the day and provide sensory alerts to stand after prolonged sitting (i.e., ≥30 minutes of sedentary time). The intervention consisted of five phases following initial data collection that comprised of self-regulatory strategies to reduce sitting time and self-monitoring of step counts.
45620700|NCT03224221|Drug|Apatinib|Patients will receive Apatinib at 500mg/times,oral one times daily for 28 days
45620701|NCT03224221|Drug|fluorouracil and platinum|the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
45620702|NCT03204253|Drug|rFSH + r-LH in combination|29 women stimulated with rFSH supplemented by rLH in the late follicular phase started at the same time of starting the antagonist administration.
45620703|NCT03204253|Drug|rFSH alone|32 women who were stimulated with recombinant FSH alone
45620704|NCT03204175|Other|FIT Plus|"Group handwashing facilities~Daily group handwashing and toothbrushing activities~Sanitation operation and maintenance manuals for school officials~Toilet cleaning consumable~Toilet and handwashing station maintenance kits~Soap, toothbrushes, and toothpaste"
45620705|NCT03204175|Other|Comparator arm|This is the same intervention as FIT Plus, but will be delivered to schools following endline data collection
45911963|NCT04868851|Behavioral|Here for Health Only|Patients will complete the Here for Health Healthy Lifestyle intervention designed by the Paediatric Diabetes Dietitians at Oxford University Hospitals NHS Foundation Trust.
45620706|NCT02486081|Device|smart soccer ball|smart soccer ball was used to measure participant's performance in total time and distance for completion, and acceleration
46069210|NCT03815266|Diagnostic Test|Tolerance Assessment Questionnaire|The Tolerance Assessment Questionnaire will be completed at the end of each session.
45620707|NCT03204097|Drug|placebo|Oral prophylaxis followed by placement of placebo gel
45620708|NCT03204097|Drug|Alendronate|Oral prophylaxis followed by placement of Alendronate gel
45620709|NCT03204097|Drug|Aloe Vera|Oral prophylaxis followed by placement of Aloe Vera gel
45620710|NCT03321071|Behavioral|Healthy Summer Learners|"Physical Activity Component. The physical activity component of Healthy Summer Learners is designed to engage children in moderate-to-vigorous physical activity (MVPA) for at least 50% of the time. With 3 hours each day dedicated to physical activity, this translates into children accumulating 90 minutes of MVPA daily. This is 30 minutes above the 60 minutes of MVPA each day recommended by the Physical Activity Guidelines for Americans.~Nutrition Component. The nutrition component of Healthy Summer Learners is designed to provide healthy snacks and meals and nutrition education via standardized pre-existing curricula.~Food/Beverage Guidelines. Meals will follow the USDA Nutrition Standards for the National School Lunch and School Breakfast Programs.~Academic Component. The academic component will consist of existing, effective academic programs focused on Math and Reading."
45620711|NCT03321071|Behavioral|21st Century Summer Learning Center|Children in this condition will attend a 21st Century Summer Learning Program.
45620712|NCT03203941|Biological|Autologous Cord Blood Stem Cells|This is an individual patient expanded access protocol.
45762827|NCT02743936|Device|Non-invasive positive pressure ventilation|Non-invasive positive pressure ventilation
45762828|NCT00842231|Other|Visual performance measures|Collection of visual performance measures in subjects with low levels of astigmatism.
45762829|NCT05526690|Drug|Metformin|1000 mg dose of immediate-release metformin
45762830|NCT05526690|Drug|CIN-107|10 mg dose of CIN-107
45762831|NCT00372034|Device|Temporary Collagen Inserts|
45762832|NCT03751709|Drug|Blinatumomab|Blinatumomab per package insert - via continuous infusion days 1-28 of Cycle 1 and Cycle 2, every 42 days.
45762833|NCT03751709|Other|Haplo-Mismatched Cell Therapy (HMCT)|HMCT infusion Cycle 1, Day 15 and Cycle 2, Day 8 & Day 15
45762834|NCT04337632|Drug|Doxorubicin Hydrochloride Liposome Injection+carboplatin|Doxorubicin Hydrochloride Liposome Injection 25mg/m2, carboplatin AUC 5, first day, intravenous drip, repeated every three weeks.
45762835|NCT04337632|Drug|paclitaxel +carboplatin|paclitaxel 175mg/m2, carboplatin AUC 5, day 1, intravenous infusion, repeated every three weeks.
45762836|NCT05526612|Other|Group 1 Motor imagery and Bobath Therapeutic Approach (BTA+MI)|Motor imagery (MI) is the mental rehearsal of motor abilities to improve function. Without revealing any movement in the body, the representation of the movement is created in the mind, the person imagines that he/she is performing the movement. Eating activity will be applied in motor imagery. Individualized therapy sessions in the Bobath Therapeutic Approach will also be received by the Physiotherapist along with Motor imagery. 2 days a week, 30 minutes session will be applied for a total of 8 weeks.
45620713|NCT02486237|Other|None, observational study|None, it is an observational study
45620714|NCT03223831|Other|Partially covered pyloro-duodenal stent|The PCDS (Niti-S COMVITM - Flare, Taewoong, Gyeonggi-do, South Korea) used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions (Figure 1). The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. This is designed to provide anchorage of the stent to surrounding tissue and reduce the risk of migration. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh to prevent the risk of tumour ingrowth into the stent. The stents come in lengths of 6, 8, 10 & 12cm.
45620715|NCT03223831|Other|Uncovered pyloro-duodenal stents|The UCDS (Niti-S pyloric-duodenal D stent, Taewoong, Gyeonggi-do, South Korea) used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm and length of 6,8,10,12cm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.
45620716|NCT03223987|Dietary Supplement|Strath® Kräuterhefe Original (liquid)|"The food supplement is taken 3 x 1 coffee spoon à 5ml = 15ml per day for three weeks.~Stool analysis at 2nd visit and last visit. Before-after study."
45620717|NCT03320993|Other|Mixed meal with different macronutrient composition|A mixed meal with identical amount of carbohydrates but different content of protein, fat and alcohol will be given
45762837|NCT05526612|Other|Group 2 Motor imagery, Bobath Therapeutic Approach and Physical practice (BTA+MI+PP)|Individualized therapy sessions in the Bobath Therapeutic Approach with motor imagery will be performed by the physiotherapist, and in addition to these, 5 repetitions of the eating activity used in motor imagery will be practiced. 2 days a week, 30 minutes session will be applied for a total of 8 weeks.
45762838|NCT05349058|Drug|Immune Checkpoint Inhibitors|Patients receive Immune Checkpoint Inhibitor as per oncology protocol
45762839|NCT05348980|Drug|Phenylephrine Hydrochloride 4 mg|Intramuscular Phenylephrine HCL 04 mg were administered as prophylactic stat dose in Vastus lateralis muscle of thigh 05 minutes before giving spinal anesthesia.
45762840|NCT05348980|Drug|Phenylephrine Hydrochloride 8 mg|Intramuscular Phenylephrine HCL 08 mg were administered as prophylactic stat dose in Vastus lateralis muscle of thigh 05 minutes before giving spinal anesthesia.
45762841|NCT00884585|Drug|Cyclosporine Vehicle|Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months.
45762842|NCT00884585|Drug|Cyclosporine 0.010%|Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
45446067|NCT04949373|Device|Sham High-intensity laser therapy (sham HILT)|"Sham high intensity laser therapy-Participants will receive pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions.~Other: Tendon and nerve gliding exercises will be performed three times a day with 10 repetitions each time for 3 weeks. Exercises will be performed by a trained physiotherapist.~Other: Rest splint(at night) Participants will be splinted in neutral position with standard cotton-polyester splints.The patients will be encouraged to use the splints during nighttime for 12 weeks."
45762843|NCT05520372|Combination Product|Autologous immune enhancement therapy (AIET) for cancer patients|Autologous NK cell and CD8 T cell therapy for cancer patients
45446068|NCT02260336|Dietary Supplement|Panax Notoginseng Powder 1g|
45762844|NCT05079516|Other|Theta burst transcranial magnetic stimulation|Real or sham continuous theta burst TMS (cTBS) will be delivered to a location on the head, determined by randomized group assignment. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.
45762845|NCT05348902|Other|In this study, only cases were collected and reported without any intervention or adverse reactions|In this study, only cases were collected and reported without any intervention or adverse reactions
45762846|NCT05526456|Procedure|Esophagectomy|McKeown, Ivor-Lewis, and Sweet procedure
45762847|NCT00884897|Drug|Oxytocin|Oxytocin given as 20 IU BID
45762848|NCT00884897|Drug|Placebo|Placebo given as 20 IU BID
45762849|NCT02753842|Device|5 Fitted Condoms, 5 Thin Condoms, 5 Standard Condoms|"Fitted condoms are available in 56 sizes based on combinations of length (approximately 10mm increments) and circumference (approximately 2 mm increments). Fitted condom thickness is 70 microns ± 10 microns. Appropriate condom size is user-determined with a paper template fitting tool graduated with non-sequential numbering and lettering for maximum privacy. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant.~Thin condoms have dimensions of 185mm ± 10mm length, 53mm ± 2mm width, and 50 microns ± 5 microns thick. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant.~Standard condoms have dimensions of 185mm ± 10mm length, 53mm ± 2mm width, and 70 microns ± 10 microns thick. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant."
45762850|NCT05515146|Diagnostic Test|near infra red fluorescence lymphatic imaging|ICG (0.2 ml from 25mg of ICG diluted by 5.0 ml of aqua ad injectabilia) was injected intradermally at the basis of the tattooed cutaneous area and at one point chosen so that the tracer had to flow under this area directly towards the root of the limb
45762851|NCT03216473|Drug|Neuronox|Clostridium Botulinum Toxin A 100 U
45620718|NCT02485769|Drug|PF-06650833|Suspension
45620719|NCT02485769|Drug|Placebo|Suspension
45762852|NCT03216473|Drug|Botox|Clostridium Botulinum Toxin A 100 U
45762853|NCT05526378|Behavioral|Sensory Interventions|"Group 1 will be hear mother's voice before, during and after the procedure. Group 2 will be sniffed mother's breast milk before, during and after the procedure.~Group 3 will be skin contact with mother's before, during and after the procedure."
45762854|NCT00886145|Device|Vibration: Right Leg and No Vibration: Left Leg.|"Vibration- right leg: The subjects will undergo a mechanical vibration intervention (Juvent Vibrating plate) in the seated position, with a load of 50lbs will be added to the right leg by using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month.~No Vibration-left leg: At each vibration training session, the left leg will serve as a control with a load of 50lbs added to the left leg using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month."
45762855|NCT02753920|Other|voiding trial|1 of 2 tests to assess bladder function after vaginal apex suspension surgery with or without mid-urethral sling
45762856|NCT02753920|Device|Foley catheter|If subject is unable to void adequately, a Foley catheter will be placed as per protocol and the subject discharged home with catheter. The subject will follow up in the office for removal of catheter.
45762857|NCT00887471|Procedure|PITA or T&A|PITA - Microdebrider-assisted Partial Intracapsular Tonsillectomy and Adenoidectomy T&A - Bove Electrocautery Complete Tonsillectomy and Adenoidectomy
45762858|NCT05520216|Device|Spinal mouse (idiag m360)|A noninvasive Spinal Mouse device will be used to measure the thoracic kyphosis and lumbar lordosis angle of the spinal column in the sagittal plane. It will be displayed on the computer aided software screen where the thoracic and lumbar region angles are calculated by swiping over the spinal processes from top to bottom with the Spinal Mouse (IDIAG m360) device. Measurements will be taken while standing on a flat surface. The volunteer will take off his upper clothes and shoes during the examination. Relax your arms and torso will be positioned next to you. The distance between the feet will be approximately waist width and parallel to each other, the knees will be straight and face motionless. He will stand where he feels comfortable. A Spinal Mouse examination will be performed and data will be recorded.
45762859|NCT05520216|Behavioral|chest circumference measurement|Measurements will be taken from the axillary (4th rib level - two fingers below the axilla), epigastric (xiphoid process level) and subcostal (9th rib level) regions at the time of normal, maximal inspiration, and maximal expiration using a tape measure while the patient is in a sitting position. The tape measure will be placed in the area to be measured. Care will be taken that there is no folding or horizontal level difference in the tape measure and that the fingers are not under the tape measure. Normal respiration will be measured first and recorded in centimeters (cm). The patient will then be asked to take a deep, long breath towards the bottom of the tape measure. The value obtained will be recorded as the deep inspiration value. Immediately after deep inspiration, the patient will be asked to make a deep and long expiration. The obtained value will be recorded as deep expiration.
45762860|NCT05520216|Behavioral|Maximum Breath Hold Test|During the breath-hold measurement, the subject will sit in a chair with a backrest. He will take a deep breath through his nose. We do not want maneuvers (Valsalva and Müller) and diaphragm contractions that will affect the breath-hold time, so volunteers will be observed throughout the test. The test will be terminated as soon as involuntary diaphragm contractions are seen. This test will be applied 3 times by resting the volunteer with breaks for 5 minutes. The average of 3 test results will be taken (Lin, Y. C.: Effect of O2 and CO2 on breath hold breaking point. In The Physiology of Breath Hold Diving. (eds): CEG Lundgren, M Ferringo, Undersea and Hyperbaric Medical Society Inc, Bethesda, Maryland, p: 75-87 1987.).
45762861|NCT05520216|Behavioral|Sit and Reach|While the participant is sitting on the floor with his back to the wall and his legs are fully extended in front of him, his knees should be in full contact with the floor. The box will be placed on the sole of the participant's feet (without shoes) in full contact with the volunteer's feet. The participant will be instructed to lean forward as slowly as possible, keeping their fingertips level with each other and their legs straight on the floor. He will be asked to slowly lie down along the ruler three times, and on the third attempt the volunteer will be instructed to reach out as far as possible and hold for 2 seconds. This value will be saved
45911964|NCT04868851|Behavioral|mHealth technology assisted exercise counselling|Patients will complete the Here for Health intervention before completing a 3 month exercise and physical activity intervention supported by mHealth technology
45446069|NCT02260336|Dietary Supplement|Panax Notoginseng Powder 5g|
45620720|NCT02485769|Drug|PF-06650833|Tablet (Modified Release)
45911965|NCT04861922|Drug|Unfractionated Heparin|10 unit/kgBW/hour continuous infusion for 5 days
45911966|NCT04855630|Device|DREEM 2 Headband|Participants will wear the DREEM 2 headband for 3 months for a minimum of 4 out of 7 nights per week and will participate in its digital therapeutic Cognitive Behavioral Therapy - Insomnia (CBT-I) intervention (entails brain stimulation to improve slow wave sleep and sleep hygiene counseling tips to improve sleep behaviors).
45446070|NCT02260336|Dietary Supplement|Panax Notoginseng Powder 10g|
45446071|NCT02260336|Dietary Supplement|Panax Notoginseng Powder 15g|
45620721|NCT02485769|Drug|Placebo|Tablet (Modified Release)
45620722|NCT03223519|Drug|Comboprofen|Triple combination of Ibuprofen, Magnesium and Vitamin C Powder for oral solution administered TID for 3 days
45620723|NCT03223519|Drug|Placebo|Powder for oral solution administered TID for 3 days
45620724|NCT03223519|Drug|Ibuprofen|Powder for oral solution administered TID for 3 days
45620725|NCT03223519|Drug|Magnesium|Powder for oral solution administered TID for 3 days
45620726|NCT03223519|Drug|Vitamin C|Powder for oral solution administered TID for 3 days
45620727|NCT03320915|Drug|Cholecalciferol|Cholecalciferol 5mg (200,000 IU) up to maximum of three times during 1 year follow-up period according to measured 25(OH)D3 level.
45620728|NCT03220165|Drug|MGL-3196|oral, 100 mg
45620729|NCT02488889|Drug|Varenicline|
45911967|NCT04855630|Other|Exercise Routine|Participants will partake in a guided exercise routine. Each routine consists of 30-minute mild circuit training session twice per week for 3 months.
45911968|NCT04854824|Drug|Recommended treatment schedule|Relatively selective Cox-2 inhibitors, Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
45620730|NCT02488889|Drug|Placebo pill (for varenicline)|
45911969|NCT04854824|Drug|Control treatment schedule|Treatment regimens different from the recommended one according to family physician personal practice
45620731|NCT02488889|Drug|Alcohol|
45620732|NCT02488889|Drug|placebo beverage (for alcohol)|
45620733|NCT03220087|Other|Data collection|The study consists of a single visit in which socio-demographic and clinical variables will be collected from the medical record or directly from the patient. In addition, the physician will provide information on the clinical status of the disease and the patient will fill in the questionnaire.
45620734|NCT02485847|Procedure|Ophthalmology|A registry of ophthalmic ambulatory encounters which captures essential data elements for continuous quality improvement efforts, enhanced patient care outcomes, and pay for performance programs.
45620735|NCT02485535|Other|Laboratory Biomarker Analysis|Correlative studies
45620736|NCT02485535|Drug|Selinexor|Given PO
45620737|NCT03219931|Drug|Bifidobacterium breve BR03 and Bifidobacterium breve B632|This is the active product containing 108 viable cells/strain
45620738|NCT03219931|Drug|Placebos|This is the placebo product containing a similar product without bifidobacterium inside.
45620739|NCT03320759|Behavioral|Occupational therapy rehabilitation|Participants in the experimental arm will receive occupational therapy that is individualized to each participant's needs from week 4 post-decompression surgery until week 12.
45620740|NCT03203863|Diagnostic Test|anthropometric measures of fatness|The aim of this study was to determine the discrimination capacity for cardiovascular risk factors of BMI, fat mass (FM), waist circumference (WC), and waist to height ratio (WHtR) in a population of Chilean children from Puente Alto County. Additionally, new cutoff points were established and compared with those described by other authors
45620741|NCT03320681|Device|Electrical Stimulation|Percutaneous electrical nerve stimulation
45762862|NCT02754310|Other|Variation of scenarios|Three different scenarios of pediatric asthma exacerbations: a mild exacerbation, a moderate exacerbation, and a severe exacerbation.
45762863|NCT02754310|Other|Repeated scenarios|The same scenario of a moderate pediatric asthma exacerbation is repeated three times.
45762864|NCT05526222|Drug|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
45762865|NCT03384563|Drug|Dexmedetomidine|Dexmedetomidine 9 arms
45762866|NCT05065944|Behavioral|Telemedicine|Pre-anesthesia assessment (history and physical examination) via telemedicine. Intervention is a one-time telemedicine clinic visit for approximately 30 minutes to 1 hour. Individual patients will be randomized to telemedicine and that visit will be scheduled via the Zoom video conferencing platform.
45762867|NCT05065944|Behavioral|In Person Visit|Pre-anesthesia assessment (history and physical examination) in person at Moffitt Cancer Center (usual care)
45620742|NCT03320681|Other|Dry Needling Stimulation|Percutaneous nerve stimulation
45620743|NCT03203785|Dietary Supplement|Carbohydrate (maltodextrin)|maltodextrin flavored
45620744|NCT03203785|Other|Placebo|non-caloric drink
46069211|NCT03815266|Diagnostic Test|Ashworth's scale|Ashworth's scale evaluates the resistance to stretching. This test will be completed before the start of the program, at the end of the program and one month after.
45446072|NCT02260336|Drug|Celecoxib Capsule 400 mg daily|
45620745|NCT02485457|Procedure|Volume loading|Volume loading with Ringer Lactate
45620746|NCT02485457|Drug|Ringer solution|
45620747|NCT03220009|Procedure|Conventional Surgery|Undergo surgery
45620748|NCT03220009|Biological|Ipilimumab|Given IV
45620749|NCT03220009|Other|Laboratory Biomarker Analysis|Correlative studies
45620750|NCT03220009|Biological|Nivolumab|Given IV
45620751|NCT03220009|Other|Patient Observation|Undergo active surveillance
45620752|NCT03220009|Radiation|Radiation Therapy|Undergo RT
45620753|NCT03316703|Procedure|Conventional open surgery|"Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.~The vertebral fixation system will be applied through the conventional open approach (group A)."
45620754|NCT03316703|Procedure|Minimally invasive percutaneous surgery|"Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.~The vertebral fixation system will be applied through the minimally invasive percutaneous approach (group B) according to allocation after randomization."
45620755|NCT02488733|Procedure|LSG|In addition to all previously described aspects of conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines
45620756|NCT02488733|Drug|CMT|CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss, administered on the basis of the current guidelines of the American Diabetes Association (ADA)[50] and determined on an individual basis [52].The administration of such pharmacological and non-pharmacological therapies will be adjusted in accordance with the algorithms of the ADA .
45620757|NCT03316625|Diagnostic Test|Bone densitometry measurement|Bone Densitometry and measurement of body composition
45620758|NCT03203707|Behavioral|Interpersonal and Social Rhythm Therapy|The Brief IPSRT intervention for at-risk youth includes : 1) Psychoeducation about risk for BP ; 2) Social rhythm therapy (SRT) aiming to establish and maintain stable routines to protect against onset of mood symptoms in vulnerable individuals ; and 3) Interpersonal Psychotherapy (IPT) centering on the adolescent's feelings about having a parent with BP, and linking stressful family events to mood. The intervention is delivered in 8 in-person sessions over 6 months of treatment. Parents are involved in the psychoeducation sessions, and further involvement is determined as clinically appropriate based on age and developmental status.
45620759|NCT02485613|Drug|bortezominb and dexamethasone|The initial BD regimen included bortezomib (1.3 mg/m2 i.v.) and dexamethasone (40 mg i.v.) twice weekly for 2 weeks (days 1, 4, 8, and 11), which was followed by a 10-day rest period (days 12-21). The dose of bortezomib and dexamethasone can be adjusted according to the patients' condition.
45620760|NCT03223363|Diagnostic Test|2D and 3D ultrasonography|All of the examinations are performed with the same transabdominal ultrasonic transducer (RAB 2-5-D) on the same E8 (GE Medical Systems, Milwaukee, WI, USA) ultrasonic machine experienced operators. 2D ultrasonic measurements includes 5 standard fetal biometry parameters, and after routine 2D ultrasonography, the acquisition of 3D measurements are performed.
45620761|NCT02485379|Procedure|Prostate biopsy|"Systematic biopsies (SB) and targeted biopsies (TB) are performed in the same patients by two independent operators. In patients without abnormalities on mp-MRI, no targeted biopsies will be carried out and the detection of clinically significant cancer will be considered as negative for the TB strategy."
45762868|NCT03375437|Genetic|Blood and tumor samples|"FFPE tumor block (archival or a dedicated freshly collected tumor biopsy) will be collected for all enrolled patients and centralized.~Blood sampling for Translational Research (optional) (2*10mL EDTA)"
45762869|NCT04946526|Dietary Supplement|Broccoli seed extract|2 capsules, one dose
45762870|NCT04946526|Dietary Supplement|Broccoli seed extract with mustard seed powder|2 capsules, one dose
45762871|NCT02748070|Drug|Prednisone|
45762872|NCT02748070|Drug|Flonase|
45762873|NCT03216629|Behavioral|"Saying sorry"|"The objective of this study is to investigate how empathy expressed in form of saying sorry affect the perception of pain during dressing change?"
45762874|NCT05514756|Device|Active t-VNS|Active t-VNS at 8 Hz for up to 60 minutes will be applied to the left cymba conchae
45762875|NCT05514756|Device|Sham t-VNS|Sham t-VNS at 8 Hz for up to 60 minutes will be applied to the left earlobe
45762876|NCT05514756|Other|Baseline assessments|Baselines assessments with no stimulation will serve as control in this three-part crossover design
45762877|NCT05311709|Drug|sotorasib|single group, all patients receive sotorasib
45762878|NCT02748928|Device|UltraShape Power|Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
45762879|NCT05310383|Combination Product|Tislelizumab plus radiotherapy|During the period of radiotherapy, patients receiveTislelizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W). Tislelizumab 200mg q3W was administered for up to 35 cycles (up to approximately 2 years) after radiotherapy until disease progression or toxicity.
45762880|NCT02574312|Device|ATTUNE TKA with ATTUNE RUI|ATTUNE TKA with ATTUNE RUI
45762881|NCT02574312|Device|ATTUNE TKA with ATTUNE SUI|ATTUNE TKA with ATTUNE SUI
45762882|NCT05310305|Combination Product|Radiotherapy for targeted lesions and PD-1 antibody|Radiotherapy for targeted lesions in all enrolled participants, with concurrent PD-1 antibody. Patients may or may not accept subsequent PD-1 as maintenance therapy.
45762883|NCT03216551|Diagnostic Test|Intra-operative frozen section|Tumor histologic subtypes (whether it is lepidic predominant adenocarcinoma), N1 nodes metastasis (lymph nodes adjacent to the tumor will be sent to frozen section) and visceral pleural invasion will be determined by the intra-operative frozen section.
45762884|NCT04424784|Biological|5% O2|5% oxygen will be used during oocyte retrieval, fertilization check and embryo grading
45762885|NCT05149638|Diagnostic Test|Cosyntropin stimulation test|In this test, Cosyntropin is administered as an intramuscular injection into the arm. Cortisol levels are measured before and after injection. Cosyntropin tests are routine medical tests that are done in doctors' offices to diagnose adrenal insufficiency. Cosyntropin is a synthetic version of a hormone, called ACTH, that is secreted by our bodies to help produce cortisol.
45446073|NCT04948203|Drug|Sirolimus|Triangular-shaped tablet
45620762|NCT03223285|Behavioral|Real Treatment Group|"Real Diaphragm manoeuvres The experimental manoeuvres include the Doming The Diaphragm Technique as described by Digiovanna (2004), Chila (2011) and Yao (2014) and the Manual Diaphragm Release Technique as described by Ricard (2009), De Coster (2005) and Roha (2015). Both manoeuvres are performed in two sets of 10 repetitions, within a 1-minute interval.~Multifaced physiotherapy/osteopathic treatment includes: vertebral mobilisations (C0-D1), high-velocity low-amplitude (HVLA) thrusts of the cervical spine, soft tissue techniques"
45762886|NCT05519826|Device|Vascular surgery|"POLYMAILLE® EXTRA THIN vascular prostheses are indicated for replacement or bypass of arteries presenting aneurysm or obliterative arterial disease. Their indication is restricted to abdominal and peripheral surgery not crossing the knee flexion crease.~Abdominal vascular surgery includes aorto-iliac and/or aorto-femoral vascular repair, i.e. graft implantation with proximal anastomosis to abdominal aorta (supra and/or infra-renal).~Peripheral vascular surgery includes peripheral arteries repair, i.e. graft implantation with no aortic anastomosis, and/or extra-anatomic vascular repair such as axillo-femoral and/or crossover bypass (femoro-femoral and/or ilio-femoral) and/or femoro-popliteal bypass above the knee."
45911970|NCT04851249|Procedure|Hallux Valgus - chevron osteotomy, lapidus procedure|The purpose is to compare the preoperative clinical features (previous medical history, age, BMI, occupational status etc), PROMs (Manchester-Oxford Foot and ankle questionnaire, SF-36, VAS activity scale) and radiological parameters (both two and three dimensional) with the postoperative PROMs (+ likert scale) and the postoperative radiological parameters.
45911971|NCT04850794|Behavioral|Decision Support Tool|The decision support tool is an observational checklist with recommendations for specific specialist referrals based on what the provider observed during the feeding evaluation.
45762887|NCT05140902|Device|Point-of-care Portable Perfusion Phantom (P4)|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
45762888|NCT05519670|Drug|Niraparib Oral Product|Niraparib + capecitabine treatment
45762889|NCT05519592|Drug|Ropivacaine injection|Intramuscular ropivacaine injection (gluteus maximus and rectus femoris)
45762890|NCT05519592|Drug|Sodium Chloride Injection|Intramuscular sodium chloride injection (gluteus maximus and rectus femoris)
45762891|NCT05519514|Drug|Cortiment|Budesonide 9 mg prolonged release tablets
45762892|NCT05519514|Drug|Budesonide|Experimental (Budesonide 9 mg prolonged release tablets)
45762893|NCT02756572|Drug|Cladribine|Given IV
45762894|NCT02756572|Drug|Cyclosporine|Given PO
45620763|NCT03223285|Behavioral|Sham Treatment Group|"Sham Diaphragm manoeuvre: the physiotherapist will simply lie hands on the rib cage, and rest along the anterolateral costal margin below rib 7, during normal breathing of the patient for 40 breathes.~Multifaced physiotherapy/osteopathic treatment includes: vertebral mobilisations (C0-D1), high-velocity low-amplitude (HVLA) thrusts of the cervical spine, soft tissue techniques"
45620764|NCT02484833|Drug|Cetuximab|
45620765|NCT02484833|Drug|FOLFIRI|
45762895|NCT02756572|Drug|Cytarabine|Given IV
45911972|NCT04844437|Diagnostic Test|Transperineal ultrasound|The fetal head station is evaluated by transperineal ultrasonography in valsalva.
45911973|NCT04840472|Drug|111I-n panitumumab|Imaging Agent
45446074|NCT02068456|Drug|Roflumilast|
45620766|NCT03204019|Drug|Tegafur and Temozolomide|Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qd(d10-d14)
45620767|NCT03204019|Drug|Tegafur and Temozolomide combined with Thalidomide|Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qe(d10-d14) Thalidomide 100mg po qd(d1-d7) /Thalidomide 200mg po qd(d8-d14)/Thalidomide 300mg po qd(d15-d21)
45620768|NCT02484521|Device|PPI monitoring device protocol|The investigators would use a monitoring device that would assess startle reflex reaction measured by blinking or the eye. Monitoring would be done with electrodes of EMG device that would be located on orbicularis oculi muscle and will monitor response.
45762896|NCT02756572|Biological|Filgrastim|Given SC
45911974|NCT04840472|Procedure|Single photon emission computed tomography/computed tomography (SPECT/CT) scans|Day 1 to 5 (Day of Surgery inclusive)
45762897|NCT02756572|Drug|Fludarabine Phosphate|
45911975|NCT04832477|Behavioral|Stigma counseling for PrEP use|This counseling consists of a single-session (45 minute) delivered by trained peer counselors. The primary aims and relevant content areas for counseling are: (1) Assessing and discussing factors known to be drivers of emotional barriers to accessing health care. This counseling aim has two main sub-components: (a) participants will be asked about their prior experiences with accessing health care and their concerns regarding future access, and (b) the counseling will focus on creating personal agency around needing to prioritize one's health. (2) Evaluating concerns around discussing PrEP with health care providers. The counseling combines motivational interviewing with medical decisional balance, which focuses on points to consider when evaluating PrEP. (3) Promoting resiliency beliefs and positive adaptation. For this objective the counselor works with the participant to establish PrEP use goals and problem-solving strategies.
45911976|NCT04805450|Procedure|ES before fully covered SEMS placement|
45911977|NCT04805450|Procedure|no ES before fully covered SEMS placement|
45911978|NCT04804137|Other|Blood|Blood samples are taken at each visit to the day hospital for a programmed injection of immunotherapy.
45911979|NCT04804137|Other|sputum|induced by saline aerosol sputum during each visit to the day hospital for a programmed injection of immunotherapy.
45762898|NCT02756572|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
45762899|NCT02756572|Other|Laboratory Biomarker Analysis|Correlative studies
45762900|NCT02756572|Drug|Melphalan|Given IV
45762901|NCT02756572|Drug|Mitoxantrone Hydrochloride|Given IV
45762902|NCT02756572|Drug|Mycophenolate Mofetil|Given PO
45762903|NCT02756572|Other|Questionnaire Administration|Ancillary studies
45762904|NCT02756572|Drug|Sirolimus|Given PO
45762905|NCT02756572|Radiation|Total-Body Irradiation|Undergo TBI
45762906|NCT02756572|Drug|Melphalan Hydrochloride|Given IV
45762907|NCT01049035|Biological|Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate|0.5 milliliter (mL), Intramuscular (IM) injection
45762908|NCT01049035|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined)|0.5 mL, IM injection
45762909|NCT01049035|Biological|M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live|0.5 mL, Subcutaneous (SC) injection
45762910|NCT01049035|Biological|Varicella Virus Vaccine Live|0.5 mL, SC injection
45762911|NCT01049035|Biological|Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)|0.5 mL, IM injection
45762912|NCT01049035|Biological|Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)|0.5 mL, IM injection
45620769|NCT02484521|Other|Questionnaires|"Group of patients diagnosed with schizophrenia would be interviewed using well validated questionnaires.~Questionnaires what would be used are:~GAF- Global assessment of functioning~PANSS- Positive and negative syndrome scale~SANS- Scale for the Assessment of Negative Symptoms~The Calgary Depression Scale for schizophrenia~Demographic Questionnaire~Hamilton Anxiety scale"
45762913|NCT01049035|Biological|Rotavirus Vaccine|oral
45762914|NCT01049035|Biological|Hepatitis B Vaccine|0.5 mL, IM injection
45762915|NCT05514288|Procedure|Endobariatric procedure|Endoscopic sleeve gastroplasty or transoral outlet reduction
45620770|NCT03203629|Device|Wearable Cardioverter Defibrillator (WCD)|Observe and compare the heart sound measurements recorded by the WCD
45762916|NCT05134272|Device|Neuromuscular electrical stimulation|Neuromuscular Electrical Stimulation will be applied by the therapist to infant's finger flexors and extensor for 15 min./day, 3x/week.
45911980|NCT04804137|Other|saliva|spontaneous saliva during each visit to the day hospital for a programmed injection of immunotherapy.
45620771|NCT02484599|Behavioral|Computerized attention training (CAT)|Three sessions of active computerized attention training.
45620772|NCT02484599|Behavioral|Sham computerized attention training (control condition)|Three sessions of sham computerized attention training.
45620773|NCT02450461|Other|no intervention|
45620774|NCT03223129|Other|Oral glucose tolerance test|Oral glucose tolerance tests were glucose is administrated orally with an increasing load (25g, 75g, 100 g)
45762917|NCT05134272|Behavioral|Modified constraint induced movement therapy|Modified CIMT will consist of constraint 24 hours/day using a splint in addition to therapy two hours/day, 3x/week for three weeks. Parents will be trained to carry over home program activities one hour/day, 6 days/week.
45762918|NCT05134272|Behavioral|Standard care for infant with asymmetrical hand function|Infants will receive one hour of therapy, one time/week for three weeks. Parents will be trained to carry over home program activities one hour/day, 6 days/week. In addition the infant will wear a sock on their preferred hand during the hour of therapy/home program activity.
45762919|NCT05131698|Combination Product|Tislelizumab and Lenvatinib|"TACE therapy: For transarterial infusion chemotherapy before or after TACE embolization, each drug will generally be diluted with 0.9% sodium chloride solution or 5% dextrose solution 150-250 mL and injected slowly into the target artery for ≥20 min. Subsequent TACE therapy will be administered on an as-needed basis as assessed by the clinician, with each treatment interval exceeding 6 weeks and no more than 6 treatments in total.~Lenvatinib: The starting dose of lenvatinib will depend on the patient's baseline weight: if baseline weight ≥ 60 kg, patients will receive 12 mg of lenvatinib administered once daily; if baseline weight < 60 kg, patients will receive 8 mg of lenvatinib once daily. TACE therapy will be given 3 days apart.~Tirelizumab: Tirelizumab 200 mg , intravenous infusion on the same day as the first dose of lenvatinib, once every three weeks.~Translated with www.DeepL.com/Translator (free version)"
45762920|NCT05455138|Procedure|Arterial bypass grafting|Arterial bypass grafting in patients with critical limb ischemia due to peripheral artery disease
45762921|NCT00371722|Procedure|Appendectomy|
45762922|NCT01724983|Drug|ketamine|
45762923|NCT01724983|Drug|fentanyl|
45762924|NCT02973958|Drug|Bupivacaine|See active comparator description
45911981|NCT04804137|Other|stool|Stool analyses will be carried out on a sample taken by the patient at home and brought back at the time of a day hospital.
45446075|NCT03755193|Drug|"SERM Viviant®Tablet 20mg and ELD Edirol®Tablet 0.75ug"|To examine the effects of SERM and ELD in osteoporosis patients
45620775|NCT03223129|Other|Graded intravenous glucose infusion|Graded intravenous glucose infusion where glucose is infused in order to receive an plasma glucose pattern comparable to those received during the oral glucose tolerance tests.
45620776|NCT03203551|Other|Disinfection Protocol|The participants assigned to this group carried out the disinfection protocol that recommended brushing the palate (3 times a day), brushing the total prosthesis with neutral liquid soap (3 times a day) and immersing in different desinfection solutions (once a day/ 20 minutes)
45620777|NCT02485145|Drug|A/B|This arm uses the test product first, which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm. The B arm is the second arm, and consists of the VersaPro cream alone.
45911982|NCT04794517|Drug|Dapagliflozin 10Mg Tab|Dapagliflozin 10 mg/die will be administered orally for six-weeks.
45620778|NCT02485145|Drug|Placebo|The placebo, which consists of the VersaPro cream, will be utilized in the study.
45762925|NCT02973958|Drug|Sevoflurane|See active comparator description
45762926|NCT02973958|Drug|Acetaminophen|See active comparator description
45762927|NCT02973958|Drug|Ibuprofen|See active comparator description
45762928|NCT02973958|Drug|Ketorolac|See experimental arm description
45762929|NCT05519280|Behavioral|the Biopsychosocial-Spiritual Group Intervention|The Experimental group received 8 sessions of weekly BPS-S group therapy for 80 minutes each.
45762930|NCT01048333|Drug|Formoterol|Formoterol Turbuhaler 9 μg and Placebo Diskus
45762931|NCT01048333|Drug|Salmeterol|Salmeterol Diskus 50 μg and Placebo Turbuhaler
45762932|NCT01048333|Drug|Placebo|Placebo Diskus and Placebo Turbuhaler
45762933|NCT05513976|Drug|SHR4640 tablet|SHR4640 tablet 5mg
45762934|NCT05513976|Drug|SHR4640 tablet|SHR4640 tablet 10mg
45762935|NCT05513976|Drug|febuxostat tablet|febuxostat tablet 40mg or 60mg or 80mg based on prior medication
45762936|NCT05513976|Drug|SHR4640 placebo tablet|SHR4640 placebo tablet 5 or 10mg
45762937|NCT04335526|Drug|Cholestyramine Resin|Change bile acid pool by cholestyramine treatment
45762938|NCT05525832|Other|Normal saline|Nasopharyngeal washes with NaCl 0.9%
45762939|NCT05348746|Other|Advanced Analysis of Polymorphism|Assessment of Plasmodium falciparum drug resistance. Target P. falciparum drug resistance genes: Pfk13 propeller, Pfdhfr and Pfdhps. The polymorphisms analysis of the propeller domain of the Pfk13 gene will be performed by PCR amplifications and subsequent sequencing. Analysis of Pfdhfr gene at codons 51, 59, 108 and Pfdhps gene at codon positions 436, 437, 540, 581, 613 will be done by means of amplifications and subsequent Sanger sequencing. Molecular studies will be performed only for research purposes and will have no impact on the clinical management of study patients.
45620779|NCT02485145|Drug|B/A|This arm uses the placebo product first, which consists of the VersaPro cream alone. This is the B arm. The A arm is the second arm, which consists of the test product which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm.
45762940|NCT04599192|Other|No study intervention|The study does not determine any interventions. Any intervention performed during coronary angiography is considered standard of care.
45762941|NCT04335370|Other|Blood Draw|"Blood samples will be collected from enrolled patients at 5 time points during a single dosing interval:~Prior to start of infusion~End of infusion~One hour after end of infusion~Three hours after end of infusion~Eight hours after start of infusion"
45911983|NCT04794517|Other|Placebo|Placebo one tablet/die will be administered orally for six-weeks.
45911984|NCT04791371|Behavioral|Cardiovascular exercise|15 weeks of cardiovascular exercise 3x/week for 50 minutes/session
46069212|NCT03815266|Diagnostic Test|Frenchay arm test|"Frenchay arm test evaluates your abilities with the affected hand to perform several actions.~This test will be completed before the start of the program, at the end of the program and one month after."
45911985|NCT04783389|Drug|CBP-201|CBP-201 subcutaneous (SC) injection.
46069213|NCT03815266|Diagnostic Test|Abilhand questionnaire|"Abilhand questionnaire evaluates your abilities to perform several activities in the daily life with your arm affected.~This test will be completed before the start of the program, at the end of the program and one month after."
45911986|NCT04783389|Drug|Placebo|Placebo subcutaneous (SC) injection.
45911987|NCT04782830|Device|Accelerometer|A uniaxial accelerometer-based activity monitor (ActivpalTM) will be worn by participants on one of the thighs during the 7 days of the placebo and treatment periods.
45620780|NCT02637141|Biological|AMG 714|AMG 714 administered by subcutaneous injection
45620781|NCT02637141|Biological|Placebo|Matching placebo to AMG 714 administered by subcutaneous injection
45762942|NCT01725295|Other|NST|A form of physical therapy
45762943|NCT01725295|Other|Hydrotherapy|
45911988|NCT04782830|Drug|placebo pill|Placebo pill will be taken for 7 days at the same frequency as their regular treatment with either midodrine or atomoxetine.
45911989|NCT04782830|Drug|Midodrine or atomoxetine pill|Either midodrine or atomoxetine at their regular dose.
45911990|NCT04771000|Drug|Ambrisentan|Endothelin receptor antagonist
45911991|NCT04771000|Drug|Placebo|Placebo
45911992|NCT04766944|Other|No intervention|No intervention
45911993|NCT04763590|Behavioral|Cognitive Behavioral Therapy|"This study focuses on patients who are on a mechanical ventilator and who have been medically cleared to come off of it. The purpose of the study is to learn more about the possible influence of cognitive behavioral therapy in helping patients who are having some trouble getting off of the ventilator. Cognitive behavioral therapy is a highly effective intervention for anxiety and the investigators are evaluating whether cognitive behavioral therapy might be helpful in cases where it is difficult to come off of the ventilator.~Cognitive behavioral therapy is experimental for mechanical ventilation assistance as no research to date has evaluated whether it might be helpful."
45911994|NCT04753307|Diagnostic Test|Laboratory measurements|Inflammatory and cardiac biomarkers will be measured before surgery, and on the first, second, third and fifth postoperative day
46069214|NCT03815266|Diagnostic Test|Fugl-Meyer test|"Fugl-Meyer test evaluates your ability to perform different movements with all the joints of your arm affected.~This test will be completed before the start of the program, at the end of the program and one month after."
46069215|NCT03815266|Diagnostic Test|Goal Attainment Scaling (GAS)|"Goal Attainment Scaling (GAS) sets therapeutic goals with the patient before the start of the program.~These goals will be checked at the end of the program and one month after."
46069216|NCT03789240|Biological|Rituximab|Rituximab is administered at a dose of 375 mg/m2 via IV weekly for the first 4 weeks on Days 1, 8, 15, and 22 during cycle 1. With subsequent cycles (cycles 2-6), rituximab will be dosed only once on Day 1 of the cycle.
45620782|NCT02637141|Other|Placebo Gluten Challenge|Gluten-free cookies (Finnish rusks)
45620783|NCT02637141|Other|Gluten Challenge|Gluten-containing cookies (Finnish rusks), 1-2 g gluten per serving
45620784|NCT02451709|Device|Activated Smartinhaler or Smartturbo|Medication reminder alarms
45620785|NCT02451709|Other|Feedback of adherence data|Review of adherence data with action planning
45620786|NCT02451709|Device|Deactivated Smartinhaler or Smartturbo|Alarms deactivated and no feedback
45620787|NCT02484755|Drug|Gefitinib|See Arm Description
45762944|NCT05525754|Procedure|computed tomography-guided nasotracheal intubation|Before intubation, the lower part of the nasal valve region, aka the narrowest area of the nasal passage, was measured by calculating the distance between the anterior border of the inferior concha and the septal cartilage
45762945|NCT05348434|Procedure|3D printed polyether ether ketone facial implants in repairing maxillofacial deformities|All patients underwent Computed Tomography (CT) scans under the condition of providing a large number of slices (more than 200 slices) per axis, and the thickness of each slice is less than 1 mm with 64-bit resolution, Then the design of the required facial implant was carried out in coordination between the designer and the surgical team. The final form of the facial implant was printed from PolyEther Ether Ketone (PEEK), and then surgical work was performed for patients under general anaesthetic according to the appropriate surgical entrance. The implants were fixed in place using titanium screws
45762946|NCT05348278|Drug|Urea cream|apply 10% urea cream at both hands and feet twice daily
45762947|NCT02323113|Drug|TAK-659|TAK-659 tablets.
45762948|NCT05519202|Drug|S-1,Oxaliplatin, Penpulimab|S-1 ( 40 mg/m2 bid po d1-14) and Penpulimab (200mg ivgtt d1) and Oxaliplatin ( 130 mg/m2 (d1)
45620788|NCT03222817|Behavioral|HPV self-sampling|Participants will be provided with education regarding cervical cancer screening, as well as instructions regarding how to use the HPV self-sampler. Participants will also receive referrals to trans-competent healthcare providers for follow-up screening and care.
45620789|NCT03316469|Drug|Clomiphene Citrate|100 mg daily will be provided to the subjects to be taken for 5 days starting from day 2 of their spontaneous periods
45762949|NCT05519124|Device|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
45762950|NCT04337242|Behavioral|B-DIT|Blended Dynamic Interpersonal Therapy
45762951|NCT04337242|Behavioral|B-CBT|Blended Cognitive Behavioral Therapy
45762952|NCT04337242|Behavioral|DIT|Dynamic Interpersonal Therapy
45762953|NCT04337242|Behavioral|Cognitive Behavioral Therapy|CBT
45762954|NCT05519046|Device|Cardiac Contractility Modulation (CCM)|Cardiac Contractility Modulation (CCM) implantation
45762955|NCT05519046|Device|CRT|Cardiac Resynchronization Therapy
45762956|NCT04934670|Drug|T-Guard|T-Guard will be administered intravenously inpatient over 4 hours every 2 calendar days on Days 0, 2, 4, and 6, at a dose of 4mg/m2 Body Surface Area (BSA).
45762957|NCT04934670|Drug|Ruxolitinib|Ruxolitinib will be administered orally twice a day starting on Day 0 through Day 56, at a dose of 10mg. Ruxolitinib taper can be initiated starting on Day 56 for participants responding to treatment, tapering will be done according to institutional practices.
45762958|NCT02759146|Other|Reflexology|Reflexology is a specialized foot therapy that applies a firm walking motion pressure to the feet. It is based on the premise that the foot has reflexes that mirror the rest of the body. It has been shown to reduce symptoms.
45762959|NCT02759146|Other|Meditative Practices|Meditative Practices include elements of meditation, gentle yoga and breathing exercises. These practices focus purposeful attention to the present moment and have been shown to enhance one's ability to adapt to serious health concerns
45762960|NCT02281383|Biological|Bacillus Calmette-Guérin (BCG)|
45762961|NCT01047553|Drug|Formoterol (OT)|9 μg/dose, Inhaled, twice daily for 52 weeks
45620790|NCT03316469|Diagnostic Test|Follicular growth|Follicular growth assessment by TVU will be performed at day 12 of the menstrual period.
45620791|NCT03217903|Diagnostic Test|Myelogram|Bone marrow aspiration after 3 cycles of Azacytidine treatment
45762962|NCT05525442|Procedure|percutaneous cholecystostomy|Transhepatic gallbladder drainage was performed under ultrasound guidance after local anesthesia was administered by interventional radiology to patients with acute cholecystitis. Subsequently, an 8-10 Fr pigtail catheter was inserted into the gallbladder using a guide wire under fluoroscopy.
45762963|NCT05715333|Biological|CM326|CM326 Injection
45762964|NCT04337398|Behavioral|Exercise training for 12 weeks (wearables)|Activity trackers with adaptive weekly step goals, weekly walking groups and coaching.
45762965|NCT04337398|Behavioral|Exercise training for 12 weeks (wearables and exergames)|Activity trackers with adaptive weekly step goals, weekly walking groups, coaching and exercise programme based on exergames (aerobic, resistance and stretching training three weekly group sessions).
45762966|NCT05041140|Device|29-XeMRI imaging|129-XeMRI scan
46069217|NCT03789240|Drug|Copanlisib|Copanlisib is administered at a fixed dose of 60 mg via IV weekly for the first 3 weeks on Days 1, 8, and 15 followed by a 1-week break (no infusion on Day 22)
45911995|NCT04712565|Device|Astra Tech Implant System Profile EV|dental implant with a sloped neck configuration
45446076|NCT03755193|Drug|"Bisphosphonates and ELD Edirol®Tablet 0.75ug"|To examine the effects of BP and ELD in osteoporosis patients
45762967|NCT00372346|Procedure|Transplantation of autologous endothelial progenitor cells|
45762968|NCT05120232|Behavioral|Unified Protocol|A transdiagnostic, cognitive behavioral therapy.
45762969|NCT05120232|Behavioral|Modified Unified Protocol (UP+)|A transdiagnostic, cognitive behavioral therapy.
45762970|NCT05720793|Combination Product|FMT Capsule + SIMBA Capsule|Participants in this arm will receive FMT capsules in addition to their usual treatment. participants will also be administered SIMBA sample collection capsules.
45762971|NCT03837717|Behavioral|Holding|Mothers will be assisted with holding their infants (and the cooling blanket) for a single 30-minute period, with the use of a thin foam barrier for thermal protection. Mothers and infants will not be skin-to-skin.
45762972|NCT03837717|Other|Saliva collection|Saliva will be collected from infants (via syringe suction) and mothers (via passive drool), and tested for levels of cortisol and oxytocin
45762973|NCT03837717|Behavioral|No Holding|Saliva will be collected from Mothers and infants, and vital sign information will be collected from infants in the same manner as the Holding intervention, with the exception of having mother's hold their infants.
45911996|NCT04712565|Device|Astra Tech Implant System EV|dental implant with a conventional neck configuration
45911997|NCT04711109|Drug|Denosumab|Given SC
45911998|NCT04711109|Drug|Placebo|Given SC
45911999|NCT04711109|Other|Quality-of-Life Assessment|Ancillary studies
46069218|NCT03779191|Drug|Alectinib|Alectinib dosed 600 mg twice a day (BID) with meals until disease progression, unacceptable toxicity, or other reasons specified in the protocol
45762974|NCT02760862|Drug|hydrocortisone 100mg.|Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours
45762975|NCT02760862|Drug|mannitol 20% intravenous fluid|group (II), received mannitol 20% 100ml intravenously which was given over 30 minutes and followed by 100 ml on a 12hour basis. Urinary catheter was inserted for patients in group (II) under complete aseptic conditions by the anesthesia resident before the start of mannitol infusion and removed after its discontinuation, accompanied by the intravenous fluid infusion over 48 hours of 500ml of normal saline or Ringer's solution every 8 hours and the input/output fluid chart for evaluation of fluid balance.
45620792|NCT04992663|Device|PICO glasses and controller with BirthVR|"PICO glasses will be used for VR in the intervention group. BirthVR is a guided meditation VR application designed by qualitative research (VIREL study) performed by this study group.~The BirthVR application contains the following components:~Information/introduction video (including a virtual reality tour through the labour ward of the Zuyderland MC)~Fase 1: Beach environment, guided meditation/breathing exercise (1 session: 25 minutes)~Fase 2: Underwater environment, guided meditation/breathing exercise (1 session: 25minutes)~Fase 3: Mountain environment, breathing technique exercise on demand by using the controller (1 session: 30 minutes)~Counseling video (cesarean section, epidural anesthesia)"
45620793|NCT02485067|Drug|THVD-201|Combination of Tolterodine 2mg and Pilocarpine 9mg
45620794|NCT02485067|Drug|Placebo(For THVD-201)|
45762976|NCT05720637|Drug|SSRI|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for the duration of the trial.
45620795|NCT02485067|Drug|Detrusitol 2mg tablet|Tolterodine 2mg
45762977|NCT05720637|Device|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
45620796|NCT02485067|Drug|Placebo(For Detrusitol 2mg tablet)|
45762978|NCT05720637|Device|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20*1.5mm or φ0.20*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
45762979|NCT03838107|Behavioral|observation and measure of trajectory of recovery in CRPS|Child participants enrolled in this study will undergo three sessions, which will include psychosocial measures, brain imaging, and quantitative sensory testing. Parent participants will also complete three sessions, which only include psychosocial measures.
45762980|NCT05720559|Drug|Oxaliplatin|Oxaliplatin via intravenous drip on d1 at a dose of 130mg/m2 × patient 's body surface area
45762981|NCT05720559|Drug|S1|Orally on d2-d15 at 20 mg three times daily
45762982|NCT05720559|Drug|Cetuximab|Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.
45762983|NCT05720559|Drug|Metronidazole|Metronidazole 0.4g/time, qd
45762984|NCT05720559|Drug|Vitamin A|Vitamin A 25,000 units/time, qd
45762985|NCT05720559|Drug|Folic acid|Folic acid 0.4 mg/time, qd
45620797|NCT03075813|Other|Intervention Cluster|Surgical surveillance date will be analyzed by optimized SPC methods. if signal is generated, study personnel in DICON will be notified to adjudicate the signal and determine if further action is needed.
46069219|NCT03779191|Drug|Bevacizumab|Bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol
45446077|NCT03755193|Drug|"ELD Edirol®Tablet 0.75ug"|To examine the effects of ELD in osteoporosis patients
45620798|NCT03203395|Behavioral|Screening and counselling|Screening for symptoms of depression and anxiety in heart patients, giving advice for prevention and managing of such symptoms and stimulating collaborative care between the hospital and the general practitioner.
45762986|NCT05720559|Drug|Capecitabine|Capecitabine via orally on d2-d15 two times daily at a dose of 1000mg/m2 × patient 's body surface area.
45762987|NCT05720247|Diagnostic Test|Fibroscan|Fibroscan is a safe and effective test using ultrasound to measure liver elasticity and can detect early signs of liver disease even before a patient shows symptoms.
45446078|NCT03755115|Drug|Epirubicin plus SHR1210|First intravenous injection of epirubicin injection, D1,30mg/m^2 Then intravenous administration with SHR-1210,D1, a fixed dose of 200mg, 30min per infusion, Q2W. The total dose of epirubicin is 360 mg/m^2.next SHR-1210 single drug maintenance .Until to secdonary disease progression or intolerance side effects.Evaluate efficacy every 3 cycles.
45620799|NCT03075579|Drug|Medication Other|medication of atomoxetine
45620800|NCT03075579|Device|motor measurement and saliva collection|motor measurement by actometer and saliva collection for measurement of saliva cortisol and saliva alpha amylase
45620801|NCT03203317|Drug|Insulin|2 h insulin clamp
45620802|NCT03203317|Other|Exercise|Cycling exercise
45620803|NCT03316313|Diagnostic Test|Hepatitis C Antibody|Patients who received a blood test to screen for the Hepatitis C virus.
45620804|NCT02484131|Behavioral|Educational materials/mail|Participants in this group will receive any educational materials by mail during hte follow-up period.
45620805|NCT02484131|Behavioral|Educational materials/participant choice|Participants in this group will not receive any educational materials by participant choice during hte follow-up period.
45620806|NCT04992351|Procedure|WALANT|WALANT as anesthesia method for upper and lower limb palstic surgery operations
45762988|NCT05720247|Behavioral|Brief Intervention|Short counselling session to discuss drinking behavior, risks to health and available sources of treatment and support.
46069220|NCT03762850|Drug|sparsentan|Target dose of 400 mg daily
45620807|NCT03201601|Drug|D-chiro-inositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
45620808|NCT03201601|Drug|Myoinositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
45620809|NCT03316157|Dietary Supplement|ProSure|Patients will take 2x 220mL nutritional supplements per day for 8 weeks and be given dietary advice to optimise their nutrition
45620810|NCT03316157|Behavioral|Physical Exercise|Patients will receive an individualised exercise regimen consisting of 60 minutes aerobic and 3x resistance elements per week
45620811|NCT04992585|Device|Percutaneous transhepatic implantation of self-expandable metal stent|A self-expandable metal stent is inserted into the extrahepatic bile duct which is obstructed by malignant disease
45620812|NCT02450227|Dietary Supplement|Spinach - Whole leaf (10 mg lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
45620813|NCT02450227|Dietary Supplement|Spinach - Minced (10 mg/lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
45620814|NCT02484989|Other|Surviellance card|
45620815|NCT03216577|Other|Phone interview measuring health-related quality of life variables|A phone interview will be conducted by a dedicated nurse who will be blinded to the exposed/non-exposed status of the patient.
45620816|NCT03316079|Other|Chest physiotherapy techniques|Respiratory manual CPT
45620817|NCT03316079|Device|Mechanical insufflation-exsufflation|CPT + MI-E (4 series of 5 inspiratory-expiratory cycles at +/- 40 cmH2O, 3 seconds of inspiratory time, 2 seconds of expiratory time and 1 second pause between cycles).
45620818|NCT02637063|Behavioral|BlipHub mobile-web app|Mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
45620819|NCT02637063|Behavioral|BlipHub mobile-web app + health coaching|Telephonic coach-supported mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
45620820|NCT02637063|Other|Usual care|No intervention beyond participants' own medical care.
45620821|NCT02480387|Drug|Ledipasvir/Sofosbuvir FDC|
45762989|NCT02761252|Drug|Bilastine 20mg|
45762990|NCT02761252|Drug|Montelukast 10mg|
45762991|NCT02761252|Drug|Placebo Bilastine 20mg|
45762992|NCT02761252|Drug|Placebo Montelukast 10mg|
45762993|NCT05714475|Procedure|Pancreas surgery|"Criteria~Inclusion Criteria:~Isolated pancreatic metastases from Colorectal cancer~Previous surgery for colorectal cancer~Surgically manageable lesions: duodenal-pancreatectomy surgical removal of metastatic repetitions in pancreas~pancreaticoduodenectomy total-pancreatectomy distal-pancreatectomy other metastases resection"
45762994|NCT01047007|Drug|MK-1775 20 mg|MK-1775 20 mg capsule administered orally on days 1-5 of a 21 day cycle.
45762995|NCT01047007|Drug|5-FU 1000 mg/m^2/day|5-FU 1000 mg/m^2/day administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle
45762996|NCT01047007|Drug|CDDP|CDDP 60 mg/m^2 to 100 mg/m^2 administered as an IV infusion on Day 1.
45762997|NCT01047007|Drug|MK-1775 65 mg|MK-1775 65 mg capsule administered orally on days 1-5 of a 21 day cycle.
45762998|NCT00357357|Drug|HF0220|comparison of different dosages of drug
45762999|NCT05448742|Device|Biplanar PSI slope-reducing MOWHTO.|High tibial osteotomy (HTO) is a widely performed procedure in case of varus knee with medial compartment osteoarthritis (OA), with medial-opening wedge version performed more often than lateral-closing wedge one. While in most cases the goal of medial-opening wedge HTO (MOWHTO) is isolated correction of coronal limb alignment, intentional or unintentional increase of posterior tibial slope (PTS) after MOWHTO can occur, however its extent is usually limited and depends on accurate hinge axis placement. One of the ideas developed to improve accuracy of hinge axis placement and accuracy of biplanar correction are Patient-Specific Instruments (PSI). Our intervention is novel, biplanar, medial-opening wedge, posterior tibial slope-reducing high tibial osteotomy aided by PSI, with tibial tuberosity serving as hinge axis.
45763000|NCT01046695|Device|TENS Unit|TENS is a method of pain relief that uses a battery operated electronic device with cutaneously applied electrodes that deliver electrical signals to peripheral nerves through the intact skin. The TENS Unit is a low voltage system that will only be used to a level to create alternative to pain sensation and will not create muscle response.
45763001|NCT05443984|Drug|JP-1366 20mg|1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals)
45763002|NCT05443984|Drug|Esomeprazole 40mg|1 capsule of JP-1366 placebo, 1 tablet of esomeprazole 40 mg placebo (irrespective of meals)
45620822|NCT03203161|Procedure|bariatric surgery|Roux-and-Y Gastric Bypass or Sleeve gastrectomy
45620823|NCT04999293|Drug|Ticagrelor|Patients were survivors and treated with DAPT (aspirin [100 mg once daily], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist [clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.
45620824|NCT03316001|Other|Review of multidetector row computed tomography scans|multidetector row computed tomography scans
45620825|NCT02451241|Other|acupuncture|electroacupuncture
45620826|NCT03315923|Drug|Rituximab|Patients will receive 1 g of rituximab (two vials of Zytux 500 mg/50 ml) in 500 cc normal saline serum through intravenous infusion as one treatment cycle. This cycle will be repeated every 6 months. Along with rituximab, patients will receive 100 mg of methylprednisolone, 10 mg of chlorpheniramine, and 500 mg of acetaminophen. Before each cycle, patients will be evaluated regarding complete blood count (CBC)-diff, blood urea nitrogen (BUN), Cr, and liver function tests.
45620827|NCT03315923|Drug|Glatiramer Acetate|Patients will receive 40 mg of glatiramer acetate three times per week through subcutaneous injection. Patients will undergo electrocardiography before starting the treatment to find any abnormal finding. Also, lab tests will be checked for them prior to the treatment, including CBC-diff, BUN, Cr, and liver function tests.
45620828|NCT05003739|Procedure|Hip arthroplasty with Logica Mirror femoral stem|Total or partial hip arthroplasty with implant of Logica Mirror femoral stem
45620829|NCT02451085|Behavioral|training with video therapy|training with video therapy
45620830|NCT02451085|Behavioral|conventional exercise|training in conventional way
46069221|NCT03762850|Drug|irbesartan|Target dose of 300 mg daily
46069222|NCT03762850|Drug|Dapagliflozin|Target dose of 10 mg daily
45620831|NCT03315845|Other|Palpation of bony landmarks for neuraxial anaesthesia.|"Manual palpation of anterior and posterior iliac crests; lumbar spinous processes; scapulae; and sacral cornua.~Ultrasound of neuraxial anatomy to assess depth to epidural space."
45620832|NCT03201133|Diagnostic Test|Neuromuscular evaluation|(1) Muscle trunk endurance test; (2) Hip isometric strength (abductor, lateral rotation, extension); (3) Knee extensor isometric strength; (4) unilateral squat; (5) navicular drop test; (6) muscle architecture at rest of gluteus medius, gluteus maximus,vastus lateralis, vastus medialis and rectus femoris; (7) muscle activation during unilateral squat (gluteus and quadriceps muscles); (8) pennation angle of obliques vastus medialis; (9) medial patellofemoral ligament length; (10) knee pain.
45763003|NCT01725607|Drug|general anesthesia combined with dexmedetomidine infusion|general anesthesia combined with 1 μg/kg dexmedetomidine infusion after induction (Group D)
45763004|NCT01725607|Procedure|general anesthesia combined with TEA|general anesthesia combined with TEA (Group E)
45763005|NCT02763124|Procedure|Verion-LenSx|The Verion-LenSx femtosecond laser system will be used to create one or two partial-depth corneal arcuate incisions
45620833|NCT02480075|Other|Observational|Observational Study only
45763006|NCT03304379|Drug|Fasinumab|Solution for injection in pre-filled syringe
45763007|NCT03304379|Other|Diclofenac|NSAID active comparator (capsule)
45763008|NCT03304379|Other|Celecoxib|NSAID active comparator (capsule)
45763009|NCT03304379|Drug|Matching placebo|Fasinumab-matching placebo (solution for injection in pre-filled syringe); NSAID-matching placebo (capsule)
45763010|NCT00915967|Drug|Vancomycin|Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.
45763011|NCT00915967|Drug|Placebo (Saline Solution)|Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.
45620834|NCT03201055|Device|Snore PAP System|The Snore PAP system delivers a set Continuous Positive Airway Pressure (CPAP) and consists of a CPAP flow generator and an approved pillows mask.The system will deliver a fixed positive airflow to the participant via approved tubing and pillows mask.
45620835|NCT03072693|Procedure|Home-based remote heart failure management|For patients randomized to Group 1, the home-based remote heart failure management system will be connected via the internet for active intervention. In Group 2 patients, the system will not be activated although all data will continue to be stored and reviewed at clinic visits. For patients in Group 1, clinically-assigned targets and alert thresholds of individual physiological parameters including blood pressure, pulse rate, and body weight will be decided before discharge and at entry into the three management modes. Site investigators will review individual patient physiological parameters upon clinic visits, and treatment can be initiated through instant communication (electronic communication and/or phone).
45620836|NCT03072693|Procedure|Home-based physiological parameter recording only|For patients randomized to Group 2, the home-based remote heart failure management system will continuously record and store patients information to be reviewed at clinic visits but not connected to internet. Site investigators will review individual patient physiological parameters upon clinic visits, and no treatment will be initiated through instant communication.
45763012|NCT05327842|Device|New training simulator|Participants receive training with new simulator
45763013|NCT05327842|Device|Traditional simulator|Participants receive traditional training
45763014|NCT02763826|Device|transcranial direct current stimulation|brain stimulation using progressively increasing amounts of direct currents and in a variety of electrode montages
45763015|NCT01044745|Drug|rituximab|Given IV
45763016|NCT01044745|Drug|mycophenolate mofetil|Given IV or PO
45763017|NCT01044745|Drug|tacrolimus|Given IV
45763018|NCT01044745|Drug|anti-thymocyte globulin|Given IV
45763019|NCT01044745|Procedure|allogeneic hematopoietic stem cell transplantation|Stem cell transplant
45763020|NCT01044745|Other|laboratory biomarker analysis|Correlative studies
45763021|NCT01044745|Biological|graft versus host disease prophylaxis/therapy|Undergo graft versus host disease prophylaxis/therapy
45763022|NCT01044745|Drug|cyclophosphamide|Given PO or IV
45763023|NCT01044745|Drug|fludarabine phosphate|Given IV
45763024|NCT01044745|Drug|busulfan|Given IV
45763025|NCT01044745|Radiation|total-body irradiation|Undergo TBI
45763026|NCT01044745|Biological|graft-versus-tumor induction therapy|Undergo graft-versus-tumor induction therapy
45763027|NCT01044745|Biological|immunosuppressive therapy|Undergo immunosuppressive therapy
45763028|NCT05032560|Drug|ABX464|Drug: ABX464 ABX464 is a new anti-inflammatory drug
45763029|NCT05032560|Drug|Placebo|Drug: Matching Placebo placebo matching with ABX464
45763030|NCT02766244|Device|ICG/SPY|indocyanine green fluorescence imaging
45763031|NCT02766244|Drug|Antibiotic Ointment|Antibiotic ointment
45763032|NCT05031078|Biological|Gardasil|"Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180 The 9-valent HPV vaccine, or Gardasil-9, is a non-infectious recombinant vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.~Gardasil-9 is supplied as a 0.5-mL single-dose vial or 0.5-mL single-dose prefilled Luer Lock syringe with tip cap."
45763033|NCT05031078|Drug|Lidocaine injections|"1-2% lidocaine injections.~1% lidocaine, an FDA approved local anesthetic, will be injected subcutaneously to numb the area of the lymph node being sampled; whereas 2% lidocaine will be injected into the tissue surrounding the area where the bone marrow will be removed. In adults the recommended dose is 7 mg/kg with a maximum of 500 mg."
45763034|NCT03270059|Drug|Ferumoxytol|Given IV
45763035|NCT03270059|Drug|Gadolinium|Given IV
45763036|NCT03270059|Procedure|Magnetic Resonance Imaging|Undergo MRI
45763037|NCT03406117|Drug|HAT1|All the participants will have the test product applied to the appropriate test sites by trained study staff. The study was conducted on a mixed population comprising of normal subjects, and patients with atopic dermatitis and active plaque psoriasis.
45763038|NCT03406117|Other|Saline Solution|Only for CIT portion of the study. Participant will have product applied topically on site by the trained study staff.
45763039|NCT05513664|Drug|Osimertinib|80 or 160 mg/qd
45620837|NCT02480231|Device|Retropubic Midurethral Sling|
45620838|NCT03201367|Drug|Rivaroxaban|Rivaroxaban 10 mg/12 hour
45763040|NCT03216395|Device|Over-the-scope Clips|Over-the-scope Clips is mounted onto a transparent cap, which is attached to the tip of the endoscope. To deploy the claw device, a cogwheel at the scope head is turned pulling a trip string. This in turn retracts the cap releasing the OTSC onto tissue.
45620839|NCT03201367|Other|symptomatic therapy for ascites, abdominal pain|
46069223|NCT03759288|Drug|Brazikumab low dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
45620840|NCT04998903|Procedure|Fiberoptic Bronchoscopy|Fiberoptic bronchoscopy done under conscious sedation
45620841|NCT02479685|Procedure|PKS BILL-PKS PlasmaSORD Versus Conventional surgical techniques|To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) vs. conventional monopolar hook and conventional mechanic morcellator.
46069224|NCT03759288|Drug|Brazikumab high dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
45620842|NCT03202927|Drug|PEGFILGRASTIM|Pegfilgrastim is a covalent conjugate of recombinant methionyl human granulocyte colony-stimulating factor and monomethoxy polyethylene glycol.
45912000|NCT04696562|Behavioral|Deep Breathing Exercise with Triflo|The investigators will do deep breathing exercises 5-10 times an hour with the triflo device.
46069225|NCT03759288|Drug|Humira®|Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50.
46069226|NCT03759288|Drug|Placebo|Intravenous placebo on Days 1, 29, 57 followed by subcutaneous placebo on Day 85 and every 4 weeks through Week 48
45620843|NCT04992039|Other|WHO HEARTS technical package|"Components of WHO HEARTS technical package are~Universal BP screening via A&D arm-in BP device.~Training of Medical Officers and Nurses on BP measurement using standard techniques.~Training of the nurses on screening, registration data collection via the Simple mobile smart-phone digital clinical hypertension information application.~Use of a drug and dose specific hypertension treatment protocol.~Standardized inventory and procurement practice to ensure a reliable supply of protocol medications.~Training and support for team-based model of hypertension care delivery.~Access to the Simple data dashboard for program monitoring.~Standardized procedure for patient follow-up.~Community-based prescription refilling."
45620844|NCT02484287|Device|The Integra External Drainage Catheter.|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
45620845|NCT02484287|Device|The Ventriclear EVD Antibiotic Catheter|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
45620846|NCT02484287|Device|The Codman Bactiseal EVD Catheter Set|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
46069227|NCT03741127|Drug|Rimiducid may be administered as indicated|Patients who received P-BCMA-101 in a previous trial will be evaluated in this trial for long term safety and efficacy. Rimiducid (safety switch activator) may be administered as indicated.
45620847|NCT03215563|Radiation|18F PET-MRI|18F-fluoride Hybrid PET-MRI
45620848|NCT03215563|Diagnostic Test|Transcranial Doppler|Microembolic Signals detection
45620849|NCT04991961|Diagnostic Test|withdraw antihypertensive drugs|patients need to withdraw of all antihypertensive drugs or change therapy to Doxazosin/Diltiazem for 2-4 weeks prior
45763041|NCT03216395|Device|Hemo-clipping|Hemo-clipping <=20 clips
45763042|NCT03216395|Device|thermo-coagulation|contact thermo-coagulation < = 8 pulses
45912001|NCT04695262|Procedure|EUS-FNB|Endoscopic ultrasound (EUS)-guided fine needle biopsy (FNB)
45912002|NCT04693780|Other|Structured guide|Structured guide
45912003|NCT04693780|Other|List|List
45912004|NCT04690946|Behavioral|Cognitive Behavioral Therapy|14-18 sessions of CBT
45620850|NCT03203005|Drug|IMA970A plus CV8102 and Cyclophosphamide|"Study treatment starts with a single intravenous infusion of 300mg/m2 Cyclophosphamide.~Three days later patients start vaccination therapy with IMA970A plus CV8102 Each vaccination consists of a dose of 6.80 milligrams (mg) IMA970A (containing approx. 400 micrograms [µg] of each individual peptide) followed by a dose of 50 µg CV8102. First IMA970A is injected intradermally (i.d.) and about 10 minutes later CV8102 is injected i.d. at the same vaccination site in close proximity. Patients will receive 4 vaccinations at weekly intervals followed by 5 vaccinations at 3-weekly intervals for a total duration of about 4.5 months."
45620851|NCT02484209|Drug|Metformin|Metformin 1500 mg daily for 16 weeks
45620852|NCT02484209|Drug|Glimepiride|glimepiride 2-4 mg twice daily for 16 weeks
45620853|NCT02484209|Drug|Metformin|metformin 1500 mg daily for 16 weeks
45620854|NCT04991727|Behavioral|recruitment maneuvers|"Immediately after endotracheal intubation is completed~First RM (pulmonary retraction), maintain pressure at 40cmH2O for 30s, and then~Mechanical ventilation was maintained with 7cmH2O PEEP, and the RMS was repeated every 30 minutes until the end of surgery"
45620855|NCT02484365|Other|No treatment|Attach adhesive probe on thumb or index finger
45620856|NCT03119467|Drug|RP4010|Escalating doses starting at 25 mg
45620857|NCT04991883|Other|case series review of clinical and histological data|We will review all the medical records, radiological imaging, and histological data of these cases. The immunohistochemical analysis of the principal alterated genes identified in this tumor will be performed.
45620858|NCT03315767|Diagnostic Test|ARFI-elastography and portal vein flow measurement|Liver and spleen-elastography assessed by ARFI-technique and the portal vein flow value-assessment by ultrasound investigation.
45620859|NCT03315767|Diagnostic Test|HVPG-measurement|Evaluation of Portal Hypertension by HVPG-measurement
45620860|NCT04999137|Drug|Vitamin C|Vitamin C (ascor), infused intravenously in 50 mls sodium chloride (NaCl) over 30 minutes every 6 hours for 16 doses
45620861|NCT04999137|Drug|Vitamin B1|Vitamin B1 (200 mg) administered intravenously every 12 hours for 8 doses
45620862|NCT02451163|Dietary Supplement|wheat polysaccharides|Consumed once daily for 12 weeks.
45620863|NCT02451163|Dietary Supplement|maltodextrin|Consumed once daily for 12 weeks.
45620864|NCT02484053|Drug|Rituximab|Giving rituximab as a rapid infusion over a period of 90 or 120 minutes.
45620865|NCT03200821|Biological|G17DT|250 µg/0.2 mL administered by intramuscular injection at Weeks 0, 2 and 6. 125 µg booster administered at Week 24.
45763043|NCT03216395|Drug|Epinephrine|epinephrine injection (diluted 1:1000) beneath peptic ulcer <20 mls
45912005|NCT04690946|Behavioral|Emotion-Focused Therapy|14-18 sessions of EFT
45912006|NCT04686786|Drug|CVL-865|Participants will receive 25 mg CVL-865 tablets orally BID during the treatment period. The dose may be decreased to 17.5 mg BID for tolerability.
45620866|NCT03200821|Drug|Gemcitabine|1000 µg/m^2 intravenously administered once weekly for seven weeks starting at Week 0 followed by one week of rest. After, treatments will occur in cycles of 3 weeks of treatment followed by one week of rest.
45620867|NCT02635737|Device|Sentimark|Placement of a metallic clip with paramagnetic properties for tumour localisation
45620868|NCT05353361|Drug|SHR-A1811：Pyrotinib|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pyrotinib：Tablet, 160mg / tablet, 80mg / tablet, oral
45620869|NCT05353361|Drug|SHR-A1811；Pertuzumab|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pertuzumab：Injection, 420 Mg (14 ml) / bottle, intravenous drip
45620870|NCT05353361|Drug|SHR-A1811；SHR-1316|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip SHR-1316：Injection, 12ml: 0.6g/bottle, intravenous drip
45912007|NCT04620382|Drug|Midodrine|Midodrine 5-10 mg, single oral dose
45620871|NCT05353361|Drug|SHR-A1811；Albumin paclitaxel|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Albumin paclitaxel：Injection, 100mg / box, intravenous drip
45620872|NCT03072615|Diagnostic Test|Stiffness measurement|Transient Elastopgraphy (TE) or Shear-Wave-Elastography
45620873|NCT02483897|Drug|Tetracaine 0.5% ophthalmic drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
45620874|NCT02483897|Drug|Normal Saline placebo drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
45763044|NCT03401125|Other|Medical file data collection|The information described in the 'outcome measures' section will be collected from the medical files of the patients.
45912008|NCT04620382|Drug|Placebo pill|single oral dose
45912009|NCT04620382|Device|Abdominal compression|abdominal compression up to 40 mmHg during head-up tilt
45912010|NCT04620382|Device|sham compression|Sham abdominal compression during head-up tilt
45912011|NCT04607564|Other|Ntombi Vimbela! intervention|Ntombi Vimbela! constitutes a series of ten workshops running for a total 35 hours. The intervention is designed to raise awareness about sexual rights, violence against women and girls and its drivers; sensitise about gender inequality and build more gender equitable beliefs; sensitise about sexual assault; equip participants with skills to assess and act in situations where there is a high risk of sexual assault; build resilience and skills to withstand social and material pressures in college or university ; enable utilisation of health, psycho-social services and access to justice for survivors; enhance communication skills and building healthy sexual relationships; promote mental health and coping and build empathy towards survivors.
45912012|NCT04575935|Drug|Chemotherapy|Receive standard of care chemotherapy
45912013|NCT04575935|Procedure|Laparotomy|Undergo laparotomy
45912014|NCT04575935|Procedure|Minimally Invasive Surgery|Undergo MIS
45912015|NCT04575935|Other|Quality-of-Life Assessment|Ancillary studies
45912016|NCT04575935|Other|Questionnaire Administration|Ancillary studies
45912017|NCT04575207|Diagnostic Test|caFFR|caFFR is a new index of physiological assessment of coronary artery stenosis severity, based on angiographic images. Through two-dimensional analysis and three-dimensional reconstruction of two coronary angiography image series with an angle-off > 30 degrees, combined with fluid mechanics, TIMI frame counting method, and optimized CFD algorithm, the pressure drop from coronary ostium to every point in the vessel can be obtained, and then the caFFR value of each point in the vessel can be computed. The cutoff value in this trial is caFFR ≤ 0.80 for myocardial ischemia.
45620875|NCT03203083|Other|performance of the single leg squat task|The single-leg squat (SLS) is a clinical functional test commonly used to evaluate clinical abnormal movement patterns of the lower limbs in terms of kinetic chain or co-ordinating muscle activity. This scale accounts for the assessment of five dimensions: overall impression, trunk posture, pelvis in space, hip joint motion and knee join motion. The SLS is potentially promising as a functional test since it involves both daily activity and athletic task.
45620876|NCT03200899|Behavioral|MAPSS-MS|MAPSS-MS is a computer-assisted cognitive rehabilitation intervention. It is a combination of home computer training and 8-weeks of group sessions on lifestyle change and compensatory cognitive strategies.
45620877|NCT03200899|Other|Usual Care plus computer games|"Participants assigned to this arm receive their usual medical care and referral to the My Brain Games website."
45620878|NCT02636907|Drug|BI 695501 Autoinjector|
45620879|NCT02636907|Drug|BI 695501 Prefilled syringe|
45620880|NCT03200665|Diagnostic Test|Ultrasound 35-36 (6 / 7 days weeks)|An obstetric ultrasound will be performed at 35-36 (6 / 7 days weeks) including biometric parameters and functional parameters of the fetus
45620881|NCT05348915|Drug|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
45620882|NCT05714189|Other|Low FODMAP diet|The Low FODMAP diet is an avoidance diet and consist of three phases. In the first phase, all nutrients high in FODMAPs (high-FODMAPS) are eliminated from the daily diet over a period of 2 to 6 weeks to calm down the bowel. The second phase consists of the addition of FODMAP challenges. During this phase the patient continues the Low FODMAP diet, but will reintroduce one high-FODMAP nutrient once every three days to see whether exposure to this high-FODMAP causes IBS symptoms. When this is not the case, the patient can continue eating this high-FODMAP group in their daily diet. In the third and final phase, the diet is fully personalized. This personalization is based on whether the patient tolerated the high-FODMAP nutrient or not during the FODMAP challenges. Only when the high-FODMAP nutrient is not tolerated, it is advised to permanently remove it from the daily diet.
45620883|NCT05714189|Other|Endometriosis diet|The endometriosis diet The endometriosis diet is a patient experience based, avoidance diet developed by women diagnosed with endometriosis. Therefore no specific recommendations exist regarding the application of the endometriosis diet. With the endometriosis diet, women avoid nutrients they noticed provoked or aggravated their endometriosis-related symptoms such as red meat, coffee, sugar, lactose and soy.
45620884|NCT04998513|Drug|Medical Management Alone Arm|"The medical intervention consists of intravenous dexamethasone (10 mg if bodyweight < 70 kilograms, 20 mg if bodyweight > 70 kilograms), intravenous cefazolin 2 grams, intravenous metronidazole 500 mg, oral probenecid 2 grams, and 1 liter of intravenous crystalloid fluid given over 1 hour.~If, during the initial post-enrolment day 1 follow-up, patients report a failure of signs and symptoms to improve since their medical therapy, a second round of intravenous crystalloid fluid, cefazolin, probenecid, metronidazole and dexamethasone will be given at the same dose as the initial medical therapy. Failure to improve patient signs and symptoms over a two-hour observation window will prompt surgical intervention to be performed in the same fashion as the surgical intervention group."
45620885|NCT04998513|Procedure|Surgical Arm|"Surgical intervention consists of attempted incision and drainage of the abscess. Specific procedure steps and details are at the discretion of the treating surgeon. In general, incision and drainage consists of topical and submucosal local anesthetic followed by a mucosal incision along the palatoglossal arch and soft palate junction, and blunt dissection of the abscess cavity to evacuate pus. Some surgeons may first perform a needle aspiration. For purposes of the trial, positive aspiration of pus on needle aspiration must be followed by attempted incision and drainage. Failed needle aspiration or surgical drainage will be considered as a failed attempt at surgical intervention.~Patients randomized to receive surgical intervention will also receive medications as per the medical management arm."
45620886|NCT03202771|Device|Home Biofeedback Therapy|Patients will be taught how to use the home-trainer in a single lab session. Then we will place a reusable, dual sensor, probe into their rectum. The probe is connected to a hand- held pressure monitor displaying the patient's response. Next, the clothed patient will be asked to sit on a commode, and attempt 15 bearing down maneuvers. When the anal sphincter pressure decreases more lights go on. If the patient cannot relax then fewer lights go on. Thus, the number of lighted lights gives instant feedback about their performance. Patients will get a 20-minute tape recording for home use. Patients will be asked to insert the probe at least twice daily and each time practice at least 15 bearing down maneuvers; a daily log will be kept. At 4 and 8 weeks, they will return for follow up. Based on their progress, new targets will be set by adjusting the device's sensitivity.
45912018|NCT04575207|Diagnostic Test|FFR|FFR is a widely used, pressure-based functional assessment index of coronary stenoses obtained with an intracoronary pressure wire fitted with pressure sensors. The pressure wire passes through the stenosis and directly measures the pressure distal to the stenosis. FFR value can be obtained by combining the pressure at the coronary ostium and the distal pressure to the stenosis. The cutoff value in this trial is FFR ≤ 0.80 for myocardial ischemia.
45446079|NCT03751995|Behavioral|Mindfulness meditation|"Participants in the intervention group will have their choice of two commercially available mindfulness programs, HeadspaceTM and eMindful for 6 weeks.~The Headspace program provides progressive guided mindfulness meditation instruction via a website and mobile app to help users learn the skills of mindfulness for use in everyday life. Sessions last 3-20 minutes. Videos encourage the integration of mindfulness into daily life.~eMindful offers an online virtual classroom where participants can participate in synchronous, 1-hour mindfulness classes 1-2 times per week. The program is modeled after the mindfulness-based stress reduction (MBSR) program. eMindful also offers a cancer-specific meditation course that participants may choose to participate in."
45620887|NCT03202771|Other|Office Biofeedback Therapy|A monitor screen will provide visual feedback by showing changes in pressure activity. First patients will be taught abdominal muscle coordination exercise to improve the pushing effort during defecation. Here, patients are taught how to distend the abdomen by inhaling slowly and then holding their breath for at least 15 seconds and to practice this for 20 minutes, twice a day. Thereafter, patients will be asked to attend the motility laboratory, biweekly for up to 6 training sessions. Biofeedback Therapy (BT) will be performed by a 3-sensor manometry probe. The clothed patient will be seated on a commode in front of a monitor. The physician/nurse therapist will give verbal feedback by either complimenting the patient for performing a correct maneuver or rectifying any errors. Each 60 minute treatment session will comprise of the following maneuvers:
45620888|NCT02483741|Biological|Manuka Honey|This material is going to be placed into the sockets of the extracted third molars in the experimental group
45620889|NCT03072303|Other|Web-based Survey|Patients will be sent an email invitation describing the study. If the participant wants to participate and is eligible, she will follow the survey link in the email message, which directs her to an IRB-approved online consent form. A unique survey link will be generated for each participant and included in the survey invitation, which is a customized email message. This link will allow the investigators to determine who completed the survey. The investigators will send repeat email invitations every two months (total of 3 invitations) to those invitees who have not yet participated. The investigators will allow approximately 6 months for enrollment and survey completion and expect that the study will close soon thereafter.
45763045|NCT04337086|Device|T4k Appliance|The pre-fabricated, hard, polyurethane, pink T4K™ (Myo functional research Co., Australia) was used in the study. It consisted of: facial bows, lingual bows / tongue guard, lingual tag / tongue tag, dental channels with a pre-determined bite position and a lip bumper. In the first week, the patients were instructed to gradually increase the wearing time of the appliance during the daytime. By the second week, the patients were instructed to wear the appliance achieving at least 8 hours during sleeping. The Trainer usually needs no adjustments. The patients were asked to place it themselves inside their mouths. The distal ends of the appliance were trimmed 2-3 mm with an acrylic bur on a straight hand piece if they were too long or the patient could not keep his lips together. By the end of the first 4 weeks, the patients were wearing the appliances minimum of 1 hour during the day plus the overnight wear following the manufacturer's instructions.
45763046|NCT04337086|Device|Twin block appliance|The twin block was used, and instructions were given to wear the appliance nearly full-time. Selective sequential inter-occlusal trimming was done monthly after the 2nd month in the occlusal surface of the maxillary bite blocks to clear over the mandibular molars allowing their eruption in a more favourable mesial direction and to increase the vertical dimension. Trimming was done in the fitting surface over the maxillary and mandibular premolars whenever needed to allow their full eruption and to level the occlusal plane
45763047|NCT03405961|Device|Carestream 3600 intra oral scan|"Carestream 3600 is CE marked intra oral scanner manufactured by Carestream Dental. It is already licensed for use in dentistry to produce digital study models. The scanner is 220 x 38 x 58 mm large and operates using video capture technology. It emits no radiation.~Carestream 3600 is connected to a computer via a USB port and a computer software (CS Model +) converts the scan into digital study models using trigonometric calculations. The software is then used to take measurements on the digital models and calculate PAR scores"
45620890|NCT05714111|Other|Radiology evaluations and interventions|Diagnostic and interventional radiology procedures
45763048|NCT04920162|Other|Biospecimen into patients who had skin diseases|Collect of blood samples without DNA into patients who had a vitiligo or a melanoma at day 0 until 1 year after their treatment
45763049|NCT03838835|Behavioral|Augmented equine-facilitated CBT group program|Consists of CBT strategies including 1) providing psychoeducation about anxiety, 2) teaching coping strategies when anxious,and 3) identifying and addressing dysfunctional thoughts that maintain anxiety.
45763050|NCT03838835|Behavioral|TAU is equine-facilitated group therapy|TAU is equine-facilitated group therapy at GallopNYC, which consists of horseback riding and integrates strategies to support the development of cognitive, physical, emotional, and social skills.
45763051|NCT03838835|Other|WLC|WLC consists of youth who are not yet receiving any services at Gallop NYC.
45763052|NCT02767492|Device|BioD Restore|Investigational product, BioD Restore, will be injected into the articular space of the knee.
45763053|NCT02767492|Drug|Kenalog|Active comparator, Kenalog steroid, will be injected into the articular space of the knee.
45763054|NCT05525208|Biological|SARS-CoV-2 subunit protein recombinant vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
45763055|NCT05525208|Biological|Active Comparator|The Pfizer-BioNTech® COVID-19 vaccine or BNT162b2, is an mRNA vaccine encoding a P2 mutant spike protein (PS 2) and formulated as an RNA-lipid nanoparticle of nucleoside-modified mRNA (modRNA).
45763056|NCT05310149|Device|Prosthetic intervention with maxillary obturator prosthesis|Prosthetic intervention with maxillary obturator prosthesis is necessary to restore the contours of the resected palate and to recreate the functional separation of the oral cavity and sinus and nasal cavities. Followings are the objectives of maxillary obturator Restoration of esthetics or cosmetic appearance of the patient, Restoration of function, Protection of tissues, Therapeutic or healing effect and psychological therapy.
45763057|NCT01044433|Drug|lapatinib ditosylate|Given orally
45763058|NCT01044433|Drug|capecitabine|Given orally
45446080|NCT03755037|Drug|Clomid, Respatio and Ethinyl estradiol|Drugs were received during the menstrual cycle.
45620891|NCT01374919|Drug|ferumoxytol|IV administration of 1020 mg of ferumoxytol in 15 minutes
45620892|NCT03072381|Biological|Platelet Rich Plasma - Group 1|Subjects in Group 1 (PRP) will receive a single ultrasound-guided intratendinous (common extensor tendon origin) injection of up to 3 mL autologous PEAK platelet-rich plasma at week 0 (baseline).
45763059|NCT04336774|Device|Caption AI|Software program that guides the investigator or any other non-sonographer to take the best possible pictures of the heart.
45763060|NCT05025384|Other|Acupressure|"Acupressure stickers will be applied to one ear in accordance with the NADA protocol acupuncture technique. Application will occur at designated points including Shen Men, Liver, and Lung: in the room with the mother; and potentially during breast feeding, holding, skin to skin contact or bottle feeds. Stickers will remain in place for 24 hours.~At 24 hours, skin will be assessed, and stickers will then be rotated to the opposite ear every 48 - 72 hours if there are no adverse effects such as skin irritation."
45763061|NCT04336930|Diagnostic Test|Pupillary pain index (PPI)|Measurement of PPI with a pupillometer
45763062|NCT03400969|Device|Glycerol 17%|Glycerol will be applied, using gauze on a lockable tweezer, at the end of the oral care procedure performed by a dentist.
45763063|NCT03400969|Device|Aequasyal (OGT)|Aequasyl (OGT) will be sprayed on the mucosa, at the end of the oral care procedure, preformed by a dentist.
45912019|NCT04573387|Procedure|Operation|All participants are treated with burr-hole craniotomy and a drainage system as follows. Participants undergo surgical procedure under local anesthesia in the hemisphere with a lateral position, but general anesthesia is performed when participant cannot tolerate the operation. A single 1.5 cm burr hole is drilled over the maximum width of the hematoma cavity. After coagulating with bipolar diathermy, dura mater is opened with a cruciate incision. A soft catheter is placed carefully in all directions of the hematoma cavity for irrigating subdural collections with 1,000 mL warm Ringer's lactate saline until clarification. The drainage catheter is inserted ½ length of the maximum diameter of the hematoma cavity toward the frontal region. After the skin is closed, the catheter was connected to a soft collection bag that is placed under the head for passive drainage. During the drainage period, participants stay in bed until the drain is removed.
45912020|NCT04573387|Procedure|Fixed-time drainage|All participants will be treated with a one-burr-hole craniotomy with irrigation and a closed drainage system. The drainage will be removed after 48 hours.
45912021|NCT04573387|Procedure|Exhaustive drainage|All participants will be treated with a one-burr-hole craniotomy with irrigation and a closed drainage system. If the computed tomography (CT) scan on the first day after surgery indicates that the affected brain region shows sufficient re-expansion, the drainage catheter will be removed when drainage ceases. If subdural collections remain in the hematoma cavity, the participant will be treated with 30,000 U urokinase injection into the hematoma cavity through the catheter. The catheter will be closed and reopened in 1.5-2 hours, and a CT scan will be performed when drainage ceases. If the CT scan shows sufficient re-expansion of the brain, the catheter will be removed. However, if the brain does not show good re-expansion and there is still a residual subdural collection, the above steps will be repeated. If the participant is subjected to urokinase injection for 3 times, the catheter will be removed when drainage ceases.
45912022|NCT04573387|Procedure|Postoperative computed tomography|All participants undergo a CT scan before the drain is removed, and the last CT scan will be performed before the patient is discharged from the hospital.
45912023|NCT04567420|Drug|Palbociclib|4 week cycles
45912024|NCT04567420|Drug|Fulvestrant|4 week cycles
45912025|NCT04567420|Drug|Adjuvant Therapy|Standard of Care
45912026|NCT04565483|Drug|Benralizumab Prefilled Syringe|Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.
45912027|NCT04565119|Other|No intervention. This is an observational study.|There are no interventions being tested in the Bio-BOOST study.
45912028|NCT04556591|Behavioral|Just-in-time adaptive intervention (JITAI)|JITAI is an emerging intervention that incorporates passive mobile sensor data feedback (sleep and activity [step] data from a Fitbit ®), and real-time self-reporting of HRQOL via a study specific app called CareQOL to provide personalized feedback via app alert.
45763064|NCT03400969|Device|Salient (new product)|Salient (new Product) will be applied/given on a spoon, at the end of the oral care procedure, preformed by a dentist.
45763065|NCT04381871|Dietary Supplement|Acacia Senegal|Oral Digestion of Gum Arabic to be consumed early morning on daily basis for 4weeks
45763066|NCT04381871|Dietary Supplement|Pectin|Oral Digestion of Pectin to be consumed early morning on daily basis for 12 weeks
45763067|NCT04633278|Drug|CMP-001|Subjects will receive CMP-001 10mg weekly for 2 doses after which CMP-001 will be administered every 3 weeks. The first dose of CMP-001 may be administered subcutaneously (SC) or Intratumorally (IT) at the discretion of Investigator. All subsequent doses will be injected intratumorally every 3 weeks (Q3W).
45446081|NCT04553913|Device|cooling device|device placed on patient in recovery on non surgical side to determine resolution of spinal anesthetics.
45620893|NCT03072381|Drug|Corticosteroid Control - Group 2|Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.
45620894|NCT02483507|Other|Ultrasound-guided approach to peripheral vascular access|the transversal approach is in short axis with an out of plane puncture, the longitudinal approach is in transversal axis with an in plane puncture, the oblique view approach is in obliques axis with an in plane puncture
45620895|NCT05003193|Device|pedometer|2000 steps per day in 20 minutes for 90 days, guided by a pedometer after a kidney transplantation
45620896|NCT03202615|Dietary Supplement|L (lactoferrin)|Dietary Supplement: Pravotin sachets (Hygint, Egypt) containing bLf One sachet of Pravotin contains 100 mg of bLf. Dosage: one sachet twice a day before meals with placebo tablets
45763068|NCT04633278|Drug|Pembrolizumab|Pembrolizumab 200 mg IV is administered Q3W.
45763069|NCT04337008|Other|blood draw|20 mL blood draw will be performed at J1 et J7
45446082|NCT03751917|Drug|Arsenic Trioxide|This is an observational study. Patients who have received or are receiving all trans retinoic acid (ATRA) + Arsenic Trioxide will be followed and analyzed.
45620897|NCT03202615|Drug|F (ferrous sulphate)|Drug: FerroGrad by Abbott Dosage: one capsule three times /day containing150 mg of dried ferrous sulfate capsules (Ferrofol capsules, Eipico, Egypt), with placebo sachets.
45763070|NCT03400813|Behavioral|R-TEP EMDR|Recent Traumatic Episode Protocol Eye-Movement Desensitization and Reprocessing is a early and short adaption protocol of EMDR developed by Shapiro E. EMDR is a psychotherapeutic approach that can rapidly process disturbing experiences adaptively together with the aid of eye movements or other forms of bi-lateral stimulation.
45763071|NCT03262415|Device|LabPatch Continuous Glucose Monitoring (CGM)|"The patch device that will be applied to subjects' arms in this study is about 3 inches in length and one inch in width, with adhesive tape on the sides.~The LabPatch circuit chip lies on the underside of the bandage. The circuit is in the form of a small chip (approximately 15.7 mm [0.618] x 15.7 mm [0.618]) placed in contact with the skin. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact.~A wire that connects the chip to a laptop that continuously captures glucose data."
45620898|NCT05455853|Other|Experimental: bilateral transcutaneous tibial nerve stimulation,exercise and advices|"• First group they will receive morning bilateral transcutaneous tibial nerve stimulation, for 30 minutes, three times per week for 4 weeks, in addition to abdominal muscle training and breathing exercise for 15 minutes three times per week, for 4 weeks and bowel care advices.•They will perform abdominal muscle training and breathing exercise, for 15 minutes three times per week, for 4 weeks in addition to bowel care advices.~Second group•They will perform abdominal muscle training and breathing exercise, for 15 minutes three times per week, for 4 weeks in addition to bowel care advices."
45620899|NCT02479841|Other|Self management program|
45763072|NCT05518890|Other|Diet Only|Participants caloric intake will be reduced by 5000kcal per week over 4 weeks
45620900|NCT03202459|Drug|Group A - gabapentin 600 mg|The patient will receive oral 600 mg gabapentin 2 h before surgery
45763073|NCT05518890|Other|Diet plus Exercise|Participants caloric intake will be reduced by 5000kcal per week over 4 weeks. Participants will also be asked to perform 5x30 minute cycling exercise sessions at home. Each week the intensity of exercise will be increased (week 1 = RPE 12, week 2 = RPE 13, week 3 = RPE 14, week 4 = RPE 15)
45763074|NCT05518812|Drug|Carboprost Tromethamine|During myomectomy, low-dose carboprost will be injected at the base of the fibroid and repeated as necessary. The efficacy of low-dose carboprost is being assessed, and the total dose administered will not exceed single vial for other indications.
45620901|NCT03202459|Drug|Group B - pregabalin|The patient will receive oral pregabalin 150 mg 2 h before surgery
45620902|NCT03202459|Drug|Group C - placebo|The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
45620903|NCT04991181|Drug|400 mg BIA 5-1058|Capsules, oral administered to subjects between 08:00 and 09:00 hours in the morning of Day 1after an overnight fast of at least 10 hours. The study drug was swallowed together with 240 mL tap water (room temperature).
45763075|NCT04336696|Procedure|Total thyroidectomy and central neck dissection|
45763076|NCT02758210|Device|Use of a Tablet|Testing of the electromagnetic field exposure and it's affect on the participant's previously implanted MICRA device is assessed by interrogation of the device before using Tablet and while using the Tablet. The measured position of the Tablets tested will be normal routine position (noting at least 6 inches/15 centimeters from their pacemaker).
45763077|NCT02758210|Device|Use of a Smart Phone|Testing of the electromagnetic field exposure and it's affect on the participant's previously implanted MICRA device is assessed by interrogation of the device before using a Smart phone and while using the Smart phone. The position of the Smart phone tested will be normal position at the ear and while texting (noting at least 6 inches/15 centimeters from their pacemaker).
45620904|NCT03215641|Device|Fitbit|The Fitbit is a consumer-grade personal activity tracker. It is used to track physical activity. Patients will be given devices at the beginning of the study, and they will continue to use it for 7 weeks. Their data will be collected on a weekly basis, and patients will receive feedback on their level of activity based on the Fitbit data.
45620905|NCT04492319|Drug|Control Test|spermatic cord block by 9.5 ml Levobupivacaine 0.5% plus 0.5 ml 0.9 normal saline in each side
45620906|NCT04492319|Drug|Neostigmine|spermatic cord block by 9,5 ml Levobupivacaine 0.5% plus neostigmine 250 μg in each side .
45763078|NCT04334512|Drug|Hydroxychloroquine|Treatment with hydroxychloroquine
45763079|NCT04334512|Drug|Azithromycin|Treatment with azithromycin
45763080|NCT04334512|Dietary Supplement|Vitamin C|Treatment with vitamin C
45763081|NCT04334512|Dietary Supplement|Vitamin D|Treatment with vitamin D
45763082|NCT04334512|Dietary Supplement|Zinc|Treatment with Zinc
45763083|NCT01043185|Drug|AZD3355|30 mg orally in the morning and 30 mg in the evening for 1 day
45446083|NCT05460117|Device|Radiofrecuency|he use of 448kilohertz capacitive resistive monopolar radiofrequency as the focus of the treatment looking for improve the quality of the tissue is still to be explored.
45620907|NCT02483663|Device|Functional Magnetic Resonance Imaging|Measure brain activity.
45620908|NCT02483663|Radiation|Dual Energy X-ray absorptiometry|Body composition measurements.
45763084|NCT01043185|Drug|AZD3355|90 mg orally in the morning and 90 mg in the evening for 1 day
45620909|NCT02483663|Other|Questionnaires|Questionnaires related to: health, weight, sleep, mood, dietary habits, attitudes towards eating, how you describe yourself.
45446084|NCT03751839|Diagnostic Test|Biochemical Tests|The investigators will perform blood tests in every participant.
45620910|NCT02483663|Other|Mood and Appetite Ratings|Answer questions about how you are feeling at the moment.
45620911|NCT02483663|Other|Test Meals|Breakfast, a snack, and lunch provided during study visit.
45620912|NCT02483663|Other|Computer Tests|Perform a series of computer tests to determine reaction time.
45620913|NCT02483663|Procedure|Intravenous Catheter (IV) placement|Blood samples collected throughout regular intervals during the study visit day to measure levels of hormones involved in regulating appetite and body weight. We will also determine if twins are fraternal or identical and will examine DNA to see if participants carry two genes that affect appetite or body weight, the FTO gene and the MC4R gene.
45620914|NCT03118609|Other|Understanding Needs Survey|"2-hour Focus Group~Mailed or E-mailed Survey"
45620915|NCT03118999|Dietary Supplement|OM3-FFA|Comparison of the effects of OM3-FFA versus OM3-MAG and OM3-EE in a crossover design
45620916|NCT03118999|Dietary Supplement|OM3-MAG|Comparison of the effects of OM3-MAG versus OM3-FFA and OM3-EE in a crossover design
45620917|NCT03118999|Dietary Supplement|OM3-EE|Comparison of the effects of OM3-EE versus OM3-FFA and OM3-MAG in a crossover design
45620918|NCT04456959|Drug|Inotuzumab Ozogamicin|Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a recombinant humanised IgG4 kappa CD22-directed monoclonal antibody (produced in Chinese hamster ovary cells by recombinant DNA technology) that is covalently linked to N-acetyl-gamma-calicheamicin dimethylhydrazide.
45620919|NCT03202693|Drug|PA-824|
45620920|NCT05374187|Device|Active eTNS|Participants will receive active trigeminal nerve stimulation (eTNS) administered by the Monarch eTNS system nightly during sleep for 4 weeks. Participants deemed to be positive responders to blinded active treatment will be invited to continue open nightly eTNS in a 12 month extension period.
45620921|NCT05374187|Device|Sham eTNS|Participants will receive sham trigeminal nerve stimulation (eTNS) administered by the Monarch eTNS system nightly during sleep for 4 weeks. At conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open active eTNS treatment. Participants deemed to be positive responders to open active treatment will be invited to continue open nightly eTNS in a 12 month extension period.
45763085|NCT01043185|Drug|AZD3355|120 mg orally in the morning and 120 mg in the evening for 1 day
45446085|NCT03751839|Diagnostic Test|Osteodensitometry|The investigators will perform an osteodensitometry in every participant.
45446086|NCT03751839|Diagnostic Test|Clinical Tests|The investigators perform the following clinical tests: vibration threshold test, monofilament test, chair rise test and timed up and go test in every participant.
45446087|NCT03751839|Diagnostic Test|HR-QCT|The investigators will perform HR-QCT measurements of the proximal femur and tibia in every participant.
45446088|NCT03751839|Diagnostic Test|HR-pQCT|The investigators will perform HR-pQCT measurements of the distal radius and distal tibia in every participant.
45446089|NCT04490499|Biological|HBVAXPRO™|Single 0.5 mL intramuscular dose
45620922|NCT03202381|Drug|Degarelix|"Degarelix (Firmagon®) will be administered as a subcutaneous injection in the abdominal region every 28 days, in according to the following schedule:~Starting dose: 240 mg administered as two consecutive subcutaneous injections of 120 mg each (2 x 3 mL injections).~Maintenance dose: 80 mg administered as one subcutaneous injection of 80 mg (1 x 4 mL injection).~Treatment will be continued till clinically indicated or till disease progression."
45620923|NCT05713721|Device|Transcranial magnetic stimulation (TMS)|TMS over the left primary motor cortex will be performed. To investigate sensorimotor integration, an electrical stimulus on the right index finger will precede the TMS pulse.
45620924|NCT05713721|Other|Video-based clinical examination|A standardized neurological examination will be performed and video taped. The videos will be rated by movement disorder specialists, wo are blinded for the symptom and mutation status of the participants.
45620925|NCT05713721|Other|24 hours drug withdrawal of dopaminergic medication|Examinations will be done under chronic dopaminergic treatment and after a 24 hours dopaminergic drug withdrawal.
45620926|NCT05713721|Other|Evaluation of deep brain stimulation|Examinations will be done before and after implantation of deep brain stimulation (clinically optimal stimulation vs. switched off stimulation)
45620927|NCT05002647|Other|NO intervention|There is no intervention
45446090|NCT04909983|Device|DPLX-PT1|A polymer skin patch for occlusional therapy
45446091|NCT04909983|Other|Control arm|Standard of care
45446092|NCT01332994|Drug|rituximab [MabThera/Rituxan]|1 g intravenously at Week 16 and 18
45446093|NCT01332994|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 12 weeks.
45446094|NCT01332994|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks from Week 16 to Week 28
45446095|NCT03698331|Drug|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
45620928|NCT03200509|Other|Physical Activity Intervention|Participants will receive a group exercise program, health coaching sessions and an activity monitor.
45620929|NCT03200509|Other|Control group|Participants will receive a group exercise program, sham health coaching sessions and a sham activity monitor.
45620930|NCT03315611|Drug|'Eucerin AtopiControl Lotion' (for the body)|Treatment with Eucerin AtopiControl Lotion
45620931|NCT03315611|Other|Allergen challenge chamber|Exposure to Dactylis glomerata pollen in an environmental challenge chamber
45620932|NCT05002725|Drug|Lidocain|300mg (20ml) will be injected
45620933|NCT03200041|Procedure|Blood sample|20 ml blood sample taken from vein in arm
45763086|NCT01043185|Drug|AZD3355|240 mg orally in the morning and 240 mg in the evening for 1 day
45446096|NCT03698331|Drug|Placebo oral capsule|non-active dosage form
45620934|NCT05713643|Procedure|ESPB Technique|The patient will be in sitting position. The probe will be positioned with longitudinal alignment, 3 cm lateral to the spinous procedure of T8 to obtain a parasagittal view. An echogenic needle will be introduced from the caudal end of the probe and advanced in-plane direction until the needle tip hit the tip of the transverse process. Bupivacaine will be afterwards injected into the erector spinae plane block. Linear spread cranially and caudally below the muscle upon injection will be visualized on the US screen indicating successful block.
45620935|NCT05713643|Procedure|TPVB Technique|The patient will be in sitting position. The probe will be positioned with longitudinal alignment, 3 cm lateral and parallel to 8th spinous process till transverse process, superior costotransverse ligament, and pleura will be visualized then lateral tilt of the probe was done for better visualization of the PVS between the superior costotransverse ligament and the pleura. An echogenic needle was introduced at caudal end of transducer using the in-plane technique till piercing the superior costotransverse ligament . Bupivacaine will be injected into the PVS with downward displacement of the pleura indicating a successful block.
45620936|NCT05713643|Procedure|QLB Technique|"The patient will be in lateral position. The probe will be placed above the iliac crest. The Petit's triangle will be identified. The three abdominal muscles (i.e., the external oblique, internal oblique and transversus abdominus muscles) will be detected. Both the external oblique and internal oblique muscles will be followed posteriorly until the layers of the thoracolumbar fascia appear as a bright hyperechogenic line. The quadratus lumborum muscle appears below to the latissimus dorsi muscle. While performing the quadratus lumborum block, Shamrock sign is identified; the transverse process of L4 appears as a stem whereas the three muscles psoas muscle, quadratus lumborum muscle and erector spinae appear as the leaves. A 22G (50mm) needle was inserted using an in-plane technique along the posterior edge of the ultrasound probe in the anteromedial direction. The needle tip was placed between the quadratus lumborum muscle and the Erector spinae muscle."
45620937|NCT03075345|Behavioral|Acceptance and commitment therapy|Four sessions of the ACT protocol will be psychoeducational in nature, with brief experiential exercises in the class and in-between session practice. It's aim is to allow individuals to be able to sit with difficult experiences (rather than fight against them) and in turn this may allow them to live towards what they value in life.
45620938|NCT03075345|Behavioral|Treatment as usual (dietetic intervention)|Six sessions of a dietetic intervention will be psychoeducational in nature around weight and nutrition, delivered by professionals working in the service.
45620939|NCT03215251|Other|Intervention bundle|Assessment of the patient's mouth and lips determined, to check any stickiness or dryness in the mouth or around lips or split skin at the corners of the mouth or cracked lips. Intervention bundle consisted of sterile cold wet oral swab wipes and sterile ice cold water sprays administered for in two sessions of 15 minutes each. First session was given in 15 minutes, patients received cold wet oral swab wipes in oral cavity 2 to 3 times and mouth spray with 5 to 6 sprays. A maximum of 9 wipes and 18 sprays of sterile water. After administration of intervention bundle, Posttest 1 was taken after 15 minutes observation with the same tools. Then researcher waited for 15 minutes after post test1 and session two was administered in 15 minutes with a maximum of 9 wipes and 18 sprays of sterile water. Post test 2 was taken after 15 minutes of session two.
45620940|NCT03315533|Drug|Duloxetine 30 milligrams (MG)|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
45763087|NCT01043185|Drug|placebo|Placebo capsules orally in the morning and placebo capsules in the evening for 1 day
45763088|NCT05207254|Diagnostic Test|Ultrasonic test|Ultrasonic test to the patient's head, neck and jaw area.
45763089|NCT02769442|Device|Terumo SurFlash Plus catheter|
45763090|NCT02769442|Device|BD Insyte Autoguard catheter|
45763091|NCT01042093|Drug|Ropivacaine|Ropivacaine 5mg/ml (49.25 ml)
45763092|NCT01042093|Drug|Toradol|Toradol 30mg/ml (1 ml)
45763093|NCT01042093|Drug|Clonidine|Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
45763094|NCT01042093|Drug|Epinephrine|Epinephrine 1 mg/ml (0.5 ml)
45763095|NCT03400735|Combination Product|Cefdinir/clavulanic acide 300/125 mg film-coated tablets|Cefdinir is already an approved drug. In this study, developed cefdinir/clavulanic acide combination will be compared against to cefdinir alone.
45763096|NCT03400735|Drug|Cefdinir 300Mg Capsule|Cefdinir is used as comparator
45446097|NCT03754959|Drug|BI 1358894|Film-coated tablet
45446098|NCT03754959|Drug|Placebo|Film-coated tablet
45446099|NCT03754959|Drug|Midazolam|Solution for injection
45763097|NCT03400657|Procedure|Multi-disciplinary Treatment|due to suggestion of Multi-disciplinary Treatment ,the patients would be suggested to chemotherapy or surgery.
45763098|NCT02770846|Procedure|Immediate loading|
45763099|NCT02770846|Procedure|Delayed loading|
45446100|NCT05391165|Behavioral|Back school|Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
45446101|NCT04889625|Device|senofilcon A C3|Test Lens
45446102|NCT04889625|Device|Dailies Total 1® Multifocal Contact Lenses|Control Lens
45763100|NCT04737928|Drug|Latanoprost|latanoprost 0.05%(one drop, once daily)
45763101|NCT04737928|Drug|tafluprost|tafluprost 0.015% (one drop, once daily)
45763102|NCT04336540|Other|Menu configuration (presence of energy labelling)|Restaurant menus are altered to accommodate energy labelling intervention
45763103|NCT04336540|Other|Menu configuration (more lower energy options added)|Restaurant menus are altered to include more lower energy options
45763104|NCT05034718|Other|PIBIS clinical decision support|The intervention is the presence of the PIBIS physician alert and powerform, which is clinical decision support for the treating provider if a patient meets inclusion criteria for Pittsburgh Infant Brain Injury Score (PIBIS) calculation.
45446103|NCT04883541|Behavioral|yoga and meditation|The pregnant women in the study group were given yoga and meditation classes, which included a total of twenty 10-week lessons, which were done by the researchers as 6-week birth preparation training, and with the onset of the birth action, birth processes were followed in the course of labour period yoga and meditation.
45620941|NCT03315533|Drug|Duloxetine 60 milligrams (MG)|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
45620942|NCT03315533|Drug|Placebo Oral Tablet|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
45620943|NCT05002491|Other|High protein diet|Normal vs high protein dietary feeding
45620944|NCT03214861|Other|Carbohydrate quality|This is an observational study examining the association between carbohydrate quality and coronary heart disease. The investigators used a variety of carbohydrate quality metrics to evaluate carbohydrate quality including carbohydrate, starch, total fiber, cereal fiber, fruit fiber, and vegetable fiber intakes, and the ratios of carbohydrate to total fiber, carbohydrate to cereal fiber, starch to total fiber, and starch to cereal fiber intakes.
45620945|NCT02483351|Other|Liberal Red Blood Cell Transfusion Strategy|RBC Transfusion strategy with hemoglobin trigger of 100g/L
45620946|NCT02483351|Other|Restrictive Red Blood Cell Transfusion Strategy|Optional RBC Transfusion with hemoglobin trigger of <=80g/L
45620947|NCT03075189|Dietary Supplement|Whey protein supplement|"During hospitalization the intervention group will receive a whey protein enriched snack/meal in the morning and before bedtime. They will be given 15 gr of protein every morning, and the meal before bedtime will vary in protein content according to the individual needs. Diet registration will be carried out every day during hospitalization. At discharge, participants in the intervention will be instructed and advised with focus on consuming more protein at home.~The control group are having the ordinary hospital diet and are following normal guidelines. They are not offered the protein focused counseling at discharge.~Both groups have diet registration and testing at baseline, discharge and follow-up."
45620948|NCT05437835|Drug|Ropivacaine|Ropivacaine 20 ml injection into the subparaneural space of sciatic nerve
45620949|NCT03075033|Device|Shikani optical stylet|Tracheal intubation is performed using Shikani optical stylet. The shikani optical stylet was bent to the same bend as a Mackintosh laryngoscope blade, lubricated and the endotracheal tube was mounted on it. The tube was settled to the stylet by the 'adjustable tube stop' so that the tip of the stylet did not project beyond the end of the tube. After intubation the 'tube stop' was released and the tube was unmounted into the trachea; the stylet was removed.
45620950|NCT03075033|Device|Flexible fiberoptic bronchoscope for|AwakeRracheal intubation using flexible fiberoptic bronchoscope in patients with cervical spine instability
45620951|NCT03107143|Device|Q2 System|
45620952|NCT03200197|Other|Menthol chewing gum|The experimental group received one unit of mentholated chewing gum, chewing and swallowing the saliva in a natural rhythm for 10 minutes. The menthol chewing gum used is called TRÍDENT®and is composed as follows: base gum, hydrogenated vegetable oil, vegetable oil, sweeteners: sorbitol, xylitol, mannitol, maltitol, aspartame, acesulfame potassium, and sucralose, humectants: glycerin and triacetin, flavorings (contains wheat derivatives), anti-humectant talc, emulsifiers: esters of mono- and diglycerides of fatty acids with acetic acid, soy lectin and mono and diglycerides of fatty acids and colorings: tartrazine and brilliant blue FCF, presenting a weight of 1.8g per unit.
45620953|NCT03200197|Other|Usual care (fasting)|The control group received the usual care given at the hospitalization units, that is, when the patient reported thirst, the need to maintain fasting for 10 minutes was reaffirmed.
45620954|NCT05002179|Drug|Echinaforce Chewable tablets|"Preventive treatment: 3X2 EC tablets daily during 2 + 2 months of prevention after run-in of 1 week and intermittent treatment break of 1 week without treatment + 1 month of voluntary follow-up prevention.~Acute treatment: 5 X 2 EC tablets daily for max. 10 days per individual vRTI or until symptom resolution."
45620955|NCT03107299|Other|Communication methods to encourage adherence|Prospective randomized controlled study in intention to treat in open monocentric in 3 arms: all patients benefiting from the current management (medical consultation every 4 to 6 months in the department of rheumatology)
45763105|NCT05034718|Other|Standard of care|Standard of care, absent the PIBIS powerform and alert for providers.
45763106|NCT04336462|Device|oxyhydrogen|Hydrogen-Oxygen Generator with Nebulizer Model: AMS-H-03 Gas production: 2.0 L/min, 2.5 L/min, and 3 L/min, three gears in total (in this study, the gas production of each machine is 3 L/min, two sets are connected and used together by three-way connection, and the total gas production is 6 L/min.) Manufacturer: Shanghai Asclepius Meditech Co., Ltd.
45763107|NCT04336462|Device|Oxygen|oxygen inhaled,3 L/min . 6 hour a day.
45763108|NCT04336306|Other|virtual reality-based therapy (VRBT)|"The warm-up was performed using the Just Dance 2015 game, in a sequence previously defined in a pilot study, aiming to increase HR progressively. A multimedia projector (Epson Power Life, H309A, China) connected to a console (Xbox One KinectTM, Microsoft, Redmond, WA) was used to project the game onto a white wall.The conditioning phase was performed using the Shape Up exercise game, in which patients perform exercises following a virtual therapist."
45763109|NCT04962412|Other|"Standard care bundle"|"The management for AKI patients were performed by implementing a standard care bundle suggested by the Kidney Disease Improving Global Outcome (KDIGO) guideline."
45763110|NCT00372502|Procedure|Modified EGDT|Early goal directed therapy with lactate clearance
45446104|NCT04883541|Behavioral|Birth preparation training|The control group was only given delivery preparation training for 6 weeks, and the birth processes were followed by routine follow-ups.
45446105|NCT02068612|Behavioral|Moderate Intensity Continuous Training+Interval Training|
45620956|NCT04997967|Drug|Ketamine/Propofol|The level of sedation was assessed at 1-3 min intervals, and the infusion rate was adjusted accordingly to achieve a Ramsay Sedation Scale (RSS) score of 5. Any movement of the patient was treated by increasing infusion rate and the infusion was discontinued at the end of the procedure. The total propofol consumed was calculated and the recovery time was recorded and calculated as the time from discontinuation of infusion of the study drug till achievement of RSS score of 3. Then patients were discharged to post-anesthesia care unit (PACU) after attaining an Aldrete Recovery Scale Score of 9- 10 [19]. Time taken to achieve this score was also recorded.
45620957|NCT04997967|Drug|Propofol|Sedation was initially started by bolus dose of 0.5 mg/kg propofol IV over 3 minutes then, infusion was started at the rate of 50 µg /kg/min till RSS score of 5.
45620958|NCT02479607|Device|Smartphone or tablet|
45446106|NCT02068612|Behavioral|Low Intensity Continuous Training|
45446107|NCT02068690|Drug|BI 425809 PfOS|BI 425809 PfOS
45620959|NCT03202225|Device|constrained polyethylene|constrained polyethylene insert
45620960|NCT03315299|Drug|ASP2215|Subject will take ASP2215 by mouth daily for 28 day cycles
45620961|NCT03200275|Diagnostic Test|Immunocatch™ Legionella Urine Antigen Test|A total number of 503 urine specimens from study participants will be tested with LUAT - Immunocatch™. This test utilises the immunochromatographic (ICT) membrane assay to detect antigenuria which has revolutionized the usage of UAT to diagnose Legionella infections. The results can be obtained within minutes and the test does not require any sophisticated laboratory support. A comparison of the ICT with the Enzyme Immuno Assay (EIA) test showed comparable performance characteristics.
45620962|NCT02479295|Device|Tenckhoff catheter|Peritoneal dialysis catheters for long term use
45620963|NCT04991415|Other|Manual Therapy|
45620964|NCT03214471|Behavioral|Lifestyle intervention|Nutritional and behavioural tele-counselling , self-monitoring and a 12-week supervised tailored exercise programme. Participants will receive a regular tele-counselling throughout the 12-month. Each session will take approximately 15 minutes, underpinned by behavioural psychological techniques. After their 3-month post-surgery assessment visit, participants in the BARI-LIFESTYLE Intervention Study will be enrolled in a supervised exercise programme at health facility gyms for 12 weeks.
45620965|NCT04990947|Other|lifestyle / RYGB|No intervention, just 2 different groups will be included
45763111|NCT00372502|Procedure|Standard EGDT|Early goal directed therapy
45763112|NCT00371800|Drug|cinnamon|
45446108|NCT02068690|Drug|Placebo|Placebo
45446109|NCT02068690|Drug|Placebo|Placebo
45446110|NCT02068690|Drug|BI 425809 tablet|BI 425809 tablet
45620966|NCT02483195|Drug|5% Minoxidil|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
45620967|NCT02483195|Drug|200mg Spironolactone|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
45620968|NCT02483195|Drug|5mg Finasteride|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
45763113|NCT01041859|Drug|Tapentadol extended release (ER)|Type= range, unit= mg, number= 100 to 250, form= tablet, route= oral use. Tapentadol ER optimal dose ranging between 100 mg and 250 mg twice daily for 15 weeks.
45763114|NCT01041859|Drug|Placebo|Form= tablet, route= oral use. Matching placebo twice daily.
45912029|NCT04556591|Behavioral|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a three-month (90 day) period
45446111|NCT02068690|Drug|BI 425809 PfOS|BI 425809 PfOS
45446112|NCT04882995|Dietary Supplement|Psyillium fiber|Participants receive 7 days of psyllium fiber dietary supplement prior to scheduled surgery
45446113|NCT02068924|Other|Slow freezing versus vitrification|
45763115|NCT04868032|Behavioral|Positive Psychology-Motivational Interviewing|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
45763116|NCT04868032|Behavioral|Physical Activity Education Control|Participants randomized to this condition will be provided with a Fitbit, and will be mailed educational materials about physical activity at 4 time points throughout the intervention period. They will not receive a manual or phone calls with an interventionist.
45763117|NCT04827550|Other|STUDY|Fibromyalgia Patient
45620969|NCT02483195|Other|Placebo|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
45620970|NCT03071991|Procedure|study group|local anesthetic drug will be used
45763118|NCT03405805|Biological|13-valent pneumococcal conjugate vaccine (PCV13)|Vaccination with PCV13
45763119|NCT00371878|Biological|7-valent pneumococcal conjugate vaccine (Prevnar)|
45763120|NCT03400423|Drug|Caffeine|Oral administration of 1.2mg/kg of powdered caffeine with water.
45763121|NCT03400423|Behavioral|Moderate Intensity Exercise|Moderate intensity exercise conducted on a treadmill. Moderate intensity exercise defined as (220-age)*0.6.
45763122|NCT04336072|Behavioral|RFPP|
45763123|NCT04336072|Behavioral|TFCBT|
45763124|NCT04377139|Procedure|Prophylaxis|The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
45763125|NCT04377139|Procedure|Preemptive|The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
45763126|NCT00372580|Procedure|blood test|
45763127|NCT03405727|Dietary Supplement|Oral dietary supplements|Protein enriched diet
45763128|NCT05349994|Other|Extended physiotherapy|At admission to the surgical ward after ICU care, participants received an individual rehabilitation plan developed in collaboration with the participants and the ward-based physiotherapist. The rehabilitation plan included specified exercises for 1- 2 sessions of approximately 30 minutes a day. For example breathing exercises, practicing transfer in and out of bed and from sitting to standing, stairclimbing, and walking with or without walking aids.
45763129|NCT01040845|Drug|Norethindrone/Ethinyl Estradiol|one tablet daily - 1 mg norethindrone/0.035 mg ethinyl estradiol on Days 1 to 21; inert ingredients on Days 22 to 28
45763130|NCT01040845|Drug|Colchicine|0.6mg tablet every 12 hours on Days 8 to 21
46069228|NCT03736941|Other|Patients with venous leg|The medical device Venotrain® Ulcertec will be prescribed according to the indications supported by the Health Insurance and used according to the recommendations of the manufacturer. It will be dispensed in town pharmacies. After inclusion, follow-up visits are scheduled at 4, and 16 weeks (± 1 week) as well as an end-of-study visit, not later than 20 weeks after enrollment or in case of premature termination. follow-up.
45446114|NCT02067442|Drug|oral acetaminophen|1000 milligrams given orally before surgery
45446115|NCT02067442|Drug|intravenous acetaminophen|1000 milligrams of intravenous acetaminophen given before surgery
45446116|NCT04483011|Dietary Supplement|RiaGev|Dietary supplementation
45620971|NCT03071991|Procedure|control group|no local anesthetic drug will be used
45620972|NCT02479373|Other|Ren-Ex Machine|The exercise is performed once per week with individualized instruction using moderate resistance on Ren-Ex Machines, ultra-low-friction equipment to minimize force on joints.
45620973|NCT02479373|Other|Dual-Emission X-ray Absorptiometry (DEXA) scan|To study body composition
45620974|NCT02479373|Other|Biodex dynamometer|To study muscle strength
45620975|NCT02479373|Other|Sub-maximal test|To study lung capacity, a sub-maximal (limited exercise) test on a stationary bicycle is performed.
45446117|NCT02067520|Drug|intrathecal hydromorphone (IT hydromorphone)|
45446118|NCT02067598|Other|scapular exercise|
46069229|NCT03736668|Diagnostic Test|echocardiography|One year after patient's inclusion, an echocardiography / doppler will be performed to evaluate any changes.Two years after the patient's inclusion, an investigating cardiologist will contact the physician, cardiologist and / or diabetologist treating the patient by telephone to find out if any cardiovascular events have occurred.
45446120|NCT02069002|Behavioral|Cognitive-Behavioral Therapy (CBT)|
45446121|NCT02069002|Behavioral|Applied relaxation group therapy|
45446122|NCT02069002|Behavioral|Information session (psychoeducation)|
45620976|NCT02479373|Other|Quality of life questionnaires|
45763131|NCT01040845|Drug|Placebo (for Colchicine)|placebo tablet every 12 hours on Days 8 to 21
45763132|NCT05349916|Other|Control|300 g rice porridge + 150 ml drinking water
45763133|NCT05349916|Other|Isomaltodextrin Low Dose|300 g rice porridge + (5 g IMD in 150 ml drinking water)
45763134|NCT05349916|Other|Isomaltodextrin High Dose|300 g rice porridge + (10 g IMD in 150 ml drinking water)
45763135|NCT05349916|Other|GPC partially digestible maltodextrin|300 g rice porridge + (15 g GPC fiber in 150 ml drinking water)
45763136|NCT05349916|Other|Resistant Starch Type 4|300 g rice porridge + (15 g RS4 starch in 150 ml drinking water)
45763137|NCT04336150|Other|Hypopressive exercises|See information included in arm/group descriptions.
45763138|NCT04336150|Other|Hypopressive maneuver|See information included in arm/group descriptions.
45763139|NCT04336150|Other|Hypopressive exercises plus pelvic floor muscle contraction|See information included in arm/group descriptions.
45763140|NCT04336150|Other|Hypopressive maneuver plus pelvic floor muscle contraction|See information included in arm/group descriptions.
45763141|NCT00371956|Drug|raloxifene|60mg/day
45763142|NCT00371956|Drug|placebo|tab 1 daily
46069230|NCT03663530|Behavioral|Meal times|Meal times vary based on the arm: aligned or misaligned
45446123|NCT05255757|Behavioral|Script Intervention|This intervention provides language to participants to allow them to discuss kidney transplantation with their social network.
45446124|NCT05255757|Behavioral|Search Intervention|This group will complete the candidate survey, refer members of their family and social network for participation in a web survey, and be given information about the statistical likelihood that each member of their social network will be free of contraindications for living kidney donation.
45763143|NCT04334200|Behavioral|Cultivate yourself: support for caregivers of dementia persons|The Chinese cultural values, including philosophical thoughts, will be included in the intervention. Chinese philosophical thoughts including the concepts of moderation, improving oneself, and harmony with nature will be used in the intervention. Confucianism, Taoism and Buddhism are the foundation for Chinese for concepts of health and illness, health promotion, and health-seeking behavior. Therefore, it is necessary to incorporate such philosophies in the sessions of the program.
45763144|NCT05349604|Dietary Supplement|Garlic extracts|One intake in total
45763145|NCT05349604|Dietary Supplement|Placebo|One intake in total
45763146|NCT04335838|Other|retrospective analysis|The investigators retrospectively analyzed the outcome and possible prognostic factors in polytrauma patients.
45763147|NCT04581460|Other|Questionnaire|Questionnaire intended for patients on the course of pregnancy and postpartum, the neonatal period and contraceptive modalities.
45763148|NCT01040689|Drug|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
45763149|NCT01040689|Drug|Placebo (for olodaterol BI1744)|Placebo (olodaterol low and high dose)delivered by Respimat
45763150|NCT01040689|Drug|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
45763151|NCT01040689|Drug|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
45763152|NCT01040689|Drug|Tiotropium 18 mcg|18mcg inhaled once daily from Handihaler
45763153|NCT04436068|Device|Hyperfine MRI scan|Participants receive a Hyperfine low field strength brain MRI scan in addition to a regularly scheduled standard clinical CT or MRI scan.
45763154|NCT04133584|Biological|EV71 +SIV|Give 2 doses of EV71 +SIV, get 2 blood samples before the first dose and 28-43 days after the last dose.
45763155|NCT04133584|Biological|EV71|Give 2 doses of EV71 , get 2 blood samples before the first dose and 28-43 days after the last
45446125|NCT03559972|Other|on-label facial injection|Assessing if adding SkinMedica's cosmetic topical skincare regimens improves the appearance of the skin and the subject's experience, when used after pre-elected on-label facial injection
45620977|NCT03074955|Device|leg wrapping with tension|"Apply elastic bandages with tension to both legs before injecting propofol.~After 3 minutes, remove elastic bandages."
45620978|NCT03074955|Procedure|Trendelenburg position|"Apply Trendelenburg position positon of 10 degree after injectin propofol~After 3 minutes, change to supine position"
45620979|NCT03074955|Device|leg wrapping without tension|"Apply elastic bandages without tension to both legs before injecting propofol.~After 3 minutes, remove elastic bandages"
45620980|NCT03074955|Procedure|supine position|1.maintain supine position
45620981|NCT03200431|Other|New adhesive strip|This is a newly developed strip.
45620982|NCT02450149|Drug|sorafenib|
45620983|NCT02479217|Drug|Docetaxel|
45763156|NCT04133584|Biological|SIV|Give 2 doses of SIV , get 2 blood samples before the first dose and 28-43 days after the last
45763157|NCT00372658|Drug|1% Lidocaine intracervical injection|
45763158|NCT01048255|Drug|VX-765|300mg Oral Tablet, 900mg TID
45763159|NCT04109638|Device|Endonovo SofPulse|The active device emits PEMF signal whereas the placebo device does not emit a PEMF signal. The active device is on for 15 minutes at a time, every two hours, for 10 days.
45763160|NCT03400189|Drug|Sulthiame|Single dose (50, 100, 200 mg)
45763161|NCT04429048|Device|Acupressure elastic band (Sea-Band)|The PC6 acupressure was done via Sea-Band in persistent compressive state for 3 minutes per time and three times a day , then at least 5 days in one week for 6 weeks continuously except modern routine standard therapy
45763162|NCT04429048|Device|General elastic band (no bud)|general elastic band was put over bilateral PC6 acupoints
45763163|NCT04098874|Drug|Bupropion Extended Release Oral Tablet|12 weeks postpartum of blinded study medication
45763164|NCT04098874|Drug|Placebo oral tablet|12 weeks postpartum of blinded placebo
45763165|NCT01043263|Drug|EN3324 (axomadol)|twice daily dosing
45763166|NCT01043263|Drug|Placebo|twice daily dosing
45763167|NCT04334434|Other|Telerehabilitation|15 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. An online exercise protocol was created for individuals who will participate in the study. Each exercise session was planned as 30 minutes for 3 days a week for 4 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The exercise protocol was additionally determined as a combination of aerobic and strengthening exercises. Individuals were asked to participate in the study via Skype and aimed to do their exercises with a physiotherapist
45763168|NCT04087174|Drug|Capivasertib|Patients will receive multiple oral dose of capivasertib.
45763169|NCT04087174|Drug|Enzalutamide|Patients will receive 160 mg oral dose of enzalutamide.
45763170|NCT04087174|Drug|Abiraterone|Patients will receive 1000 mg oral dose of abiraterone.
45763171|NCT01043029|Drug|aleglitazar|Aleglitazar 150 mcg po daily for 52 weeks
45763172|NCT01043029|Drug|pioglitazone|Pioglitazone 45 mg po daily for 52 weeks
45763173|NCT04065958|Behavioral|Yoga-mindfulness|Body-mind therapy
45620984|NCT02479217|Drug|Xeloda|
45763174|NCT04065958|Behavioral|Patient education and physiotherapy|Lectures and physiotherapy
45763175|NCT04294342|Behavioral|Active Comparator: Participants in 10 week Judo Inspired Exercise program|The intervention included 10 sessions, using a 10-week (45-50 minutes /week) pre-established program called Judo4Balance, a structured exercise program. Each session consisting of warm-up, balance, strength, power and break fall exercises. There is clear a progression within the 10 week program in three main blocks. Block 1: learning the exercises and principle movements, Block 2 more resistance and advance falling techniques, Block 3 Power training and falling strategies from stand up positions.
45763176|NCT04282954|Drug|JP-1366|JP-1366, QD
45763177|NCT04282954|Drug|JP-1366 placebo|JP-1366 placebo, QD
45763178|NCT04282954|Drug|Esomeprazole 40mg|Esomeprazole 40mg, QD
45763179|NCT04282954|Drug|Esomeprazole placebo|Esomeprazole placebo, QD
45763180|NCT04248322|Behavioral|Semi-structured interview|Using iterative, semi-structured interviews or focus groups to explore the lived experience with CC and usual customary care (UCC) of catheter users with NLUTD and their caretakers to generate user-defined themes regarding bladder function and catheter-related barriers and the daily impacts on one's life.
45763181|NCT04221490|Device|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve through a transcatheter approach
45763182|NCT04791358|Diagnostic Test|KidneyIntelX|KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function and kidney failure in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).
45763183|NCT03881800|Other|titration- blood sample|Ceftazidime titration
45763184|NCT05337436|Biological|Lymphatic drainage|Biological determination in plasma:
45763185|NCT05337436|Biological|Total and ionized magnesium|Total and ionized magnesium
45763186|NCT05337436|Biological|Total and ionized calcium|Total and ionized calcium
45763187|NCT04755712|Drug|Rachianesthesia|Administration of different anesthesia drugs in accordance with the courant practice (mixture of bupivacaine and sufentanil)
45763188|NCT04755712|Drug|Sodium Chloride Injection|"Subcutaneous injection of Sodium chloride at the usual quadratum lumburum block 2 (QLB2) injection site under ultrasound (sham-QLB2)."
45763189|NCT04755712|Drug|Morphine|Morphine via pump (patient controlled analgesia)
45763190|NCT04751812|Procedure|High-pain extra|"Paracetamol, Etoricoxib, Oxycodone, Ondansetron po. Betamethasone 4 mg iv.~Anesthesia:~As standard + bolus esketamine 0.25 mg/kg iv + Clonidine 1 µg/kg i.v.~Postoperative pain treatment:~At pain NRS ≥ 4 - 5 mg of oxycodone i.v. Paracetamol will be administered every 6 hours. If above is not sufficient bolus Clonidine 1 µg/kg i.v."
45763191|NCT04751812|Procedure|Low-pain opioid free|"Paracetamol, Etoricoxib, Ondansetron p.o. Betamethasone 4 mg iv.~Anesthesia:~Infusion Dexmedetomidin 0.2 mikrogram/kg/h iv started 5 min before induction Induction: Esketamin 0.1mg/kg + Propofol 1.5-2 mg/kg iv + rocuronium 0.5 mg/kg iv Start of surgery: Esketamin 0.1 mg/kg iv. Maintenance of anesthesia: Sevoflurane Dexmedetomidin inf 0.2 mikrogram/kg/h Esketamin inf 0.1-0.3mg/kg/h and 0.1 mg/kg adjusted after BP and HR 30 min before end of surgery Lidocaine 1 mg/kg iv~Postoperative pain treatment:~• Dexmedetomidin (inf 01-0.2 µg/kg/h) 4 hours postoperative~If pain NRS ≧3 Esketamin 0.1mg/kg iv + Lidocain 0.5 mg/kg iv (max 4 mg/kg /4 h) If pain NRS ≧3 within 30 min after treatment above is given with Esketamin + Lidocain, 2.5 mg Oxycodone iv. is given and may be repeated."
45763192|NCT04751812|Procedure|Standard|"Paracetamol, Etoricoxib, Oxycodone, Ondansetron p.o. Betamethasone 4 mg iv.~Anesthesia:~Target controlled infusion (TCI) with doses of propofol and remifentanil based on age, weight and height. Oxycodone 0.1 mg/kg 30 minutes before cessation of remifentanil.~Postoperative care:~At pain NRS ≥ 4 - 5 mg of oxycodone i.v. Paracetamol will be administered every 6 hours. If above is not sufficient bolus Clonidine 1 µg/kg i.v."
45446126|NCT02076490|Other|Physical/Occupational therapy|At least 10 individual sessions over the clinical intervention period of 4 weeks followed by a 6 weeks self-management phase.
45620985|NCT03200119|Behavioral|Daily health-related lifestyle modification prescription|Daily health-related lifestyle modification prescription
45446127|NCT04545567|Device|RocketAP|Artificial pancreas system which is designed to be able to identify when you have eaten and provide insulin for this meal
45620986|NCT05459909|Dietary Supplement|Synbiotic supplementation|Daily supplementation of synbiotic
45620987|NCT05459909|Behavioral|Dietary intervention|Increased fruits and vegetables consumption
45620988|NCT03199807|Biological|NRT|Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory. NRTs 0.5~1 x 10^10, will be i.v.Q3 weeks for total 4-6 doses.
45912030|NCT04523714|Behavioral|Online CBT-CP based program|Self-completed, online program in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills
46069231|NCT03642808|Other|rehabilitation program|Availibility of patients to complete a rehabilitation program during 8 weeks and to come back 4 times for a careful medical examination
46069232|NCT03642782|Device|Electroretinogram Pattern (Diopsys® NOVA System)|it's an additional examination that extends the duration of the ophthalmological consultation by 30 minutes
45620989|NCT03199807|Radiation|Radiotherapy|Radiotherapy of the major mass by dose of 5Gy/F * 10F
45620990|NCT03074877|Behavioral|Family Check-Up|The Family Check-Up (FCU) is a brief, family-based program to prevent Substance Use/Substance Use Disorder (SU/SUD) with replicated efficacy
45763193|NCT04746274|Behavioral|Online large-group one-session multicomponent positive psychological intervention|The intervention is aimed at enhancing positive mental health by using components from positive psychology or positive psychotherapy. These include for exapmle using character strengths, savoring the moment, goal setting and goal attainment. The intervention is conducted in an online group format via videoconference with a duration of approximately 3 and a half hours.
45763194|NCT04746274|Behavioral|Online large-group one-session cognitive intervention targeting dysfunctional thoughts|The intervention is aimed at reducing dysfunctional thoughts by applying strategies known from the cognitive therapy of depression. These include for example identification of automatic thoughts and cognitive biases as well as evaluating evidence for and against automatic thoughts. The intervention is conducted in an online group format via videoconference with a duration of approximately 3 and a half hours.
45763195|NCT04733638|Device|Viz ICH VOLUME|Viz ICH VOLUME software is a module that identifies and segments Intraparenchymal Hemorrhage (IPH) from NCCT imaging. This software is for investigational use in the study and is not FDA cleared. For subjects who undergo a brain scan, Viz will use deep learning algorithms to analyze computed tomography (CT) or magnetic resonance (MR) images of the brain for ICH in parallel to standard of care image interpretation. If a suspected ICH is detected, Viz will perform an automatic volumetric analysis and will send a notification to a specialist, such as a neurointerventionalist or a neurosurgeon. Notifications prompt the specialist to review the patient's case. Additionally, non-diagnostic previewing of DICOM images, and HIPAA-compliant text messaging and phone calls are available in the software platform. Viz ICH VOLUME is not intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man.
45763196|NCT05330026|Combination Product|Diaphragm´s study during yoga breathing|Study and compare the activation of the diaphragm during different breaths: rest, ujjayi and pursed lips
45763197|NCT05285488|Other|"focused attention group"|"focused attention group: adult subjects practicing focused attention meditation.~contemplation group: adult subjects practicing contemplation meditation."
45763198|NCT03690154|Drug|FN-1501|Eligible patients will receive a single intravenous infusion of study drug on Days 1, 3, 5, 8, 10, and 12 of a 21-day cycle. Dosing will begin at 2.5 mg once per day on the assigned days. Dose escalation will use the traditional 3+3 design and follow a modified Fibonacci sequence until MTD is reached. Increments of 33% in the dose of FN-1501 will be undertaken after reaching 30 mg/day. At least 3 patients will be enrolled in each cohort. Administration of FN-1501 will be continued until disease progression, intolerable toxicity, withdrawal of consent, or termination according to the Principal Investigator's judgment or at the sponsor's request.
45763199|NCT04334044|Drug|Ruxolitinib Oral Tablet|Ruxolitinib 5 mg twice a day
45620991|NCT02479529|Drug|Norepinephrine|Administration and weaning of norepinephrine is based on dynamic arterial elastance
45763200|NCT03576976|Behavioral|Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition to and bridge newly learned cognitive skills to everyday life.
45620992|NCT02479529|Drug|Norepinephrine|The usual procedure of withdrawal norepinephrine is based on hemodynamic parameters (blood pressure, cardiac output), clinical (cutaneous perfusion, mottling, hourly diuresis) and biological (SVO2, arterial lactate).
45763201|NCT00372736|Drug|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
45763202|NCT00372736|Drug|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
45763203|NCT00372736|Genetic|protein expression analysis|Cycle 1: Pre-dose on Days -2, 1, 8 and 15; repeat every 2-4 days if LFTs > 5 x ULN1 Cycle 2: Prior to each infusion; repeat every 2-4 days if LFTs > 5 x ULN1
45763204|NCT00372736|Genetic|reverse transcriptase-polymerase chain reaction|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
45620993|NCT03202147|Drug|Cromolyn|Active capsules for inhalation.
45620994|NCT03202147|Other|Placebo|Non-active capsules for inhalation.
45620995|NCT04997889|Combination Product|Artificial salivary containing cumin and ginger extract|The artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the artificial salivary containing cumin and ginger extract will be stopped for 7-10 days. After that, the artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 3 days.
45620996|NCT04997889|Other|Commercial artificial salivary|The commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the commercial artificial salivary will be stopped for 7-10 days. After that, the commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 3 days.
45763205|NCT00372736|Other|flow cytometry|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
45763206|NCT00372736|Other|immunoenzyme technique|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
45763207|NCT00372736|Other|immunohistochemistry staining method|The plasma concentration/ time data will be analysed using non-compartmental methods. The pharmacokinetic parameters to be determined for AEG35156 include the maximum observed plasma concentration (Cmax), the half-life (T1/2), and mean residence time (MRT).
45912031|NCT04523714|Behavioral|Virtual coach-led CBT-CP based program|Live, coach-led program delivered by telephone or videoconference in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills
45620997|NCT04492085|Other|Questionnaire survey|A customized questionnaire will be delivered by the social software WeChat to explore the prevalence, potential reasons and solutions of workplace violence against physicians of obstetrics and gynecology in China
45620998|NCT03213769|Drug|topical coenzyme Q10 gel|Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
45620999|NCT03213769|Drug|Carpabol gel|placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
45763208|NCT00372736|Other|laboratory biomarker analysis|The plasma concentration/ time data will be analysed using non-compartmental methods. The pharmacokinetic parameters to be determined for AEG35156 include the maximum observed plasma concentration (Cmax), the half-life (T1/2), and mean residence time (MRT).
45763209|NCT04681768|Drug|Abemaciclib|Abemaciclib tablets 150 mg, 100 mg, 50 mg as clinical routine: 150 mg twice daily per os, in-label administration in combination with endocrine therapy (aromatase inhibitor or Fulvestrant)
45621000|NCT05002101|Dietary Supplement|zinc|The zinc syrup was prepared with a concentration of 7 mg zinc in each 5 ml solution. Accordingly, children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
45621001|NCT05002101|Drug|Placebo|Children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
45621002|NCT02483117|Other|Adaptation of the CIA|Adaptation of the CIA into Spanish was performed using the backward-forward translation process, which ensures conceptual. Forward translation into Spanish was carried out by two independent native Spanish speaking translators who were fluent in English. Two other independent translators, totally blind to the original version, whose native language was English and who were fluent in Spanish, back-translated the consensus version into English. After reaching consensus on a final translated version, it was sent to the CIA's original author (Dr. Bohn) who gave her approval. We undertook a cognitive debriefing process with a group of 5 ED patients to identify any problems with language. The pre-final version was administered to two small groups, one made up of patients (a sample of 5 respondents) and the other of clinical experts (2 psychiatrists and 2 psychologists who were experts on ED).
45621003|NCT03201913|Drug|TTC-352|Phase 1 study to determine the maximum tolerated dose (MTD) of TTC-352.
45621004|NCT02483039|Behavioral|AKI Follow-up Clinic|Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. At the AKI Follow-up Clinic, assessment forms that were developed during the pilot study at St. Michael's Hospital may be used, but this decision will be left to individual sites. Routine laboratory investigations will be performed at minimum every three months.
45621005|NCT02482883|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|All patients will undergo placement of a facial transcutaneous electrical nervous stimulation (TENS) device, but device activation will be randomized [active stimulation vs non-active (placebo) stimulation], for an initial period of 10 days.
45763210|NCT04335448|Other|No intervention is planed|No intervention is planed
45763211|NCT05259436|Behavioral|Caregiver-child Intervention|"Intervention Groups:~Resilience Clinic (Benioff Oakland): 6 weekly interactive group-based visits in primary care that draws from the evidence-based Circle of Security Parenting along with the principles of mindfulness;~ABC Intervention (Lifelong): 10 weekly home visiting sessions. ABC is an empirically supported parenting program that focuses on improving maternal sensitivity;~and,~Resiliency Family Program (Santa Barbara Neighborhood Clinic): 4 primary-care-based visits, every 2-3 weeks, that include psycho-education materials drawing from the culturally-responsive, evidence-based program, Madres a Madres."
45763212|NCT05259436|Behavioral|Enhanced Primary Care|Enhanced Primary Care (control group): This includes care coordination services for community resources in addition to usual care. Participants will be asked about any unmet social needs, e.g. food insecurity, financial strain, safe places to play. Those who endorse need will be offered navigational services to link to community resources.
45763213|NCT05250388|Procedure|Arthroscopic Bankart repair|Arthroscopic Bankart repair is a minimally invasive surgical procedure with the aim to reattach and tighten the detached labrum and ligaments within the shoulder joint.
45763214|NCT05220670|Other|HIIT|It will be carried out after a 10-minute warm-up period with joint mobility exercises and dynamic stretching. The intervention will consist of a training in which intense work intervals and active rest periods are combined using a cycle ergometer. The session will be divided into 4 intervals of 4 minutes duration at an intensity of 85-95% of the maximum heart rate [MHR], individually controlled during all sessions (Polar Team pro®), followed by active rest intervals of 3 minutes duration at 50-70% FCM. After training, a 10-minute cool-down of gentle pedaling and joint range exercises will be carried out.
45763215|NCT05220670|Other|MICT|Heating phase identical to the previous one. Subsequently, the participants will perform training on the cycle ergometer with an intensity close to 70% FCM maintained for 40 minutes and will be individually controlled (Polar Team pro®). The session will conclude with a cool-down phase identical to the previous one.
45763216|NCT04334122|Other|Instrument-assisted soft tisue mobilization|"All patients in the experimental group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.~In addition to the traditional physiotherapy program, the patients in the experimental group were subjected to tool-assisted soft tissue mobilization 3 times a week (12 sessions with 1 day interval).~All evaluations were repeated to all patients in the experimental and control groups after four weeks."
45763217|NCT04334122|Other|Traditional physiotherapy|All patients in the control group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.
45763218|NCT00372814|Behavioral|Intensive Home-Based Family Therapy|Multisystemic Therapy (MST): Adolescents receiving MST will receive home-based, family psychotherapy sessions 2-3 times a week, lasting 60 minutes in duration from a pediatric mental health worker for six months. The purpose of the therapy sessions are to improve the youths' ability to complete their dilay diabetes illness management tasks, reduce average blood glucose levels and improve metabolic control.
45446128|NCT04545567|Device|USS Virginia|Artificial pancreas system which responds to glucose fluctuations by modulating insulin delivery but does not specifically detect meal ingestion
45446129|NCT02076568|Behavioral|Education - Diabetes and Partnership|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Partnership was created. The module covers specific and detailed aspects of the topic partnership such as dealing with hypoglycemia, late complications, and talking about diabetes in a relationship. With this module, a more comprehensive education of patients with specific interest in these topics is possible."
45446130|NCT02076724|Device|Biological mesh|
45446131|NCT02076724|Device|Synthetic mesh|
45446132|NCT02076802|Behavioral|physical exercises|
45446133|NCT03754647|Dietary Supplement|Vitamin C|One tablet of Vitamin C (500 mg) twice daily with SSRIs for 8 weeks
45621006|NCT04997421|Device|Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes|Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (intervention arm)or mere CVVHDF using the Oxiris®-AN69 membrane (control arm).
45621007|NCT04997421|Device|Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes|Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (control arm)
45763219|NCT00372814|Behavioral|Supportive Telephone Calls|Telephone Support Calls: Adolescents receiving TS will receive weekly 30 minute phone calls from a pediatric mental health worker for six months. The purpose of the call is to provide emotional support regarding the adolescent's chronic medical condition, assess adherence to the prescribed regimen and to help the adolescent brainstorm solutions to any barriers they identify to completion of diabetes care.
45763220|NCT03299530|Other|patients with corneal astigmatism|The total corneal astigmatism, anterior chamber depth, will be measured by a Scheimpflug tomographer. Pupil size will be measured by itrace device and MONCV3 device. Residual astigmatism will be tested by subjective refraction.
45763221|NCT04544800|Device|Use of Splint for UADT Visualization|The use of a splint to assist the patient and the surgeon with UADT procedures.
45763222|NCT03223714|Drug|Conbercept Ophthalmic Injection|"Subject receive 0.5 mg Conbercept injection into their study eyes every month (Day 0 - Month 5).~If subjects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)."
45763223|NCT03223714|Drug|sham injection|"Subjects receive sham injection into their study eyes every month (Day 0 - Month 5).~Subjects receive a single intravitreal injection of 0.5 mg Conbercept ophthalmic injection in month 6, followed monthly review, if he/she meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)."
45763224|NCT00372268|Device|Aeroneb® Pro (Nektar® Company)|The Aeroneb® Pro (Nektar® Company) permits cold and wet nebulization of either saline solution or ropivacaïne 0.75% (Naropeine) during the surgical procedure.
45763225|NCT00372268|Device|Aeroneb® Pro (Nektar® Company)|The Aeroneb® Pro (Nektar® Company) permits cold and dry nebulization without saline solution neither ropivacaïne (Naropéine) during the surgical procedure.
45621008|NCT03199729|Other|Slip-only training|Subjects in this arm will receive overground, slip specific perturbation training only. The total perturbation training trials received by this group will be 24 but the protocol will consist of a total of 70-75 trials (to match the training length and time of Combined slip and trip training group).
45446134|NCT02076880|Other|Caloric restriction|"Caloric restriction of 1000 kcal per day compared to the usual food intake.~usual breakfast of the patient (possibly limited in quantity)~midday and evening meals from mixed and dehydrated meals, soups with protein and dairy desserts sweetened"
45621009|NCT03199729|Other|Trip-only training|Subjects in this arm consisting of a total of 24 trials of trip specific training delivered in an identical sequence (mixed with non-trip trials) as the Group with slip only training.
45621010|NCT03199729|Other|Combined slip+trip training|Subjects in this arm will receive training consisting of repeated exposure to both slips and trips with a total of 24 slips plus 24 trips to keep the number of trials of each perturbation same as the perturbation specific training groups (slip only and trip only), however, the total dose will be doubled. The total trials walked (perturbed + unperturbed) will be 75.
45621011|NCT02726945|Device|GID SVF-2|The GID SVF-2 device is a sterile single-use disposable canister used for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain associated with joint osteoarthritis.
45763226|NCT05113498|Dietary Supplement|(-)-Epicatechin|Administration of a capsule with 150 mg of pure (-)-epicatechin after 48h low-flavanol diet.
45763227|NCT04518670|Device|Comaneci Embolization Assist Device|assist in the coil embolization of wide-necked intracranial aneurysms with a neck width ≤ 10 mm.
45763228|NCT04501822|Diagnostic Test|Evaluation of clinical, instrumental and laboratory diagnostics tests|During follow-up visits patients undergo clinical, instrumental and laboratory diagnostics tests
45763229|NCT05457088|Other|1.5 protein|dietary plan having dietary protein of 1.5 gr/kg/day
45763230|NCT05457088|Other|0.8 protein|dietary plan having dietary protein of 0.8 gr/kg/day
45763231|NCT02415712|Drug|Fomepizole|The first dose of fomepizole is administered at a dose of 15 mg/kg, followed by the second to fifth doses administered at a dose of 10 mg/kg. The sixth and subsequent doses are administered at a dose of 15 mg/kg. The interval of the intravenous doses is 12 hours with one administration lasting more than 30 minutes.
45763232|NCT04485754|Other|Telemedicine FU|Participant will get telemedicine follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
45763233|NCT04485754|Other|Office FU|Participant will get office follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
45763234|NCT05441098|Other|Neoadjuvant therapy|Preoperative systemic therapy for breast cancer patients
45763235|NCT05456698|Drug|Inotuzumab ozogamicin|"Patients who achieved CR/CRi had their InO dose at 1.5mg/m2 per cycle (28days/cycle), with 0.5mg/m2 administered on days 1, 8, and 15.~Patients received treatment for up to two cycles in the absence of disease progression or unacceptable toxicity."
45446135|NCT02076880|Other|No caloric restriction|No change in eating habits to patients in this arm
45763236|NCT04383340|Behavioral|Mother-Infant Transaction Program|Parent sensitivity training for mothers of premature infants
45763237|NCT04383340|Behavioral|Treatment as usual|Standard hospital care and parental support
45763238|NCT02973724|Drug|Remifentanil|The concentration of remifentanil was determined by biased-coin up and down design, starting from 1.0 ng/ml (0.4 ng/ml as a step size)
45621012|NCT02726945|Other|Placebo|Placebo Control
45763239|NCT02973724|Drug|Propofol anesthesia|Anesthesia was induced with propofol target-controlled infusion at an effect-site concentration of 5.0 μg/ml.
45912032|NCT04502225|Other|Tilt|Tilt of the whole bed so that the head is elevated by 9 and/or 12 inches in an acute trial or overnight.
45446136|NCT03757923|Drug|TAB METFORMIN|INSULIN SENSITIZING AGENTS
45446137|NCT03757923|Drug|TAB PIOGLITAZONE|INSULIN SENSITIZING AGENT
45446138|NCT02077036|Device|Kinetic Oscillation Stimulation Device|
45446139|NCT02077036|Device|Kinetic Oscillation Stimulation Device in placebo mode|
45763240|NCT05456542|Diagnostic Test|Cuff Leak Test|Clinicians perform the cuff leak test (CLT) to help optimize extubation. The test requires deflation of the cuff at the end of the endotracheal tube (ETT) and auscultation for air passing around the ETT. If air movement is not audible on auscultation (a failed CLT) there is a potential presence of laryngeal edema (LE) that may cause post-extubation airway obstruction.
45621013|NCT02449993|Device|MammaTyper™|MammaTyper™ is an in vitro molecular diagnostic test for the quantitative detection of the biomarkers estrogen receptor (ESR1), progesterone receptor ( PgR), Human epidermal growth factor receptor 2 (HER2) and proliferation antigen Ki-67 on the basis of the values of the messenger ribonucleic acid (mRNA).
45763241|NCT05456542|Drug|Dexamethasone 4mg|Dexamethasone, will be administered to those patients who fail the CLT in the intervention arm (4mg intravenous every 6 hours for 12-24 hours). Dexamethasone belongs to a class of drugs known as corticosteroids
45763242|NCT05456464|Other|Reiki|Reiki is applied touching the energy centers of the body (chakras). There are seven main and many small chakras on a body. Chakras are located on the front and back sides of the body in a vertical line that runs along the middle of the body in humans. A complete Reiki therapy includes all the chakras and organs.
45763243|NCT03216005|Device|BlueLeaf System|The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.
45763244|NCT05456308|Procedure|Hydrodistention during cystoscope|Hydrodistention for treatment of interstitial cystitis will be performed. Participants will be randomly selected to one of the arms described. There are three variables that they will be assigned: the pressure of fluid in the bladder that will be filled, the duration of time that the fluid will be held in the bladder, and the number of times the procedure is completed.
45763245|NCT05311007|Other|Evaluation of the incidence and nature of adverse events|Evaluation of the incidence and nature of adverse events during intra-hospital transport of patients undergoing high-flow nasal oxygen therapy provided by intensive care units
45763246|NCT03215693|Drug|X-396 capsule|225mg once daily
45763247|NCT05315687|Device|Y-90 SIR-Spheres|Y-90 SIR-Spheres
45763248|NCT05315687|Procedure|Yttrium-90 Microsphere Radioembolization|Undergo Y90 radioembolization
45763249|NCT05315687|Other|Systemic Therapy|Systemic Therapy
45763250|NCT04369612|Procedure|Standard follow-up|Standard post-transplant follow-up
45763251|NCT04369612|Procedure|Home-based monitoring|Patients take capillary blood sample by finger-prick and send to lab for analyses. Telecom follow-up that day by treating physician
45763252|NCT03215615|Procedure|Periodontal surgery|Coronally advanced flap for root coverage
45763253|NCT03215615|Procedure|Total Etch adhesive|Total-etch adhesive system (two step)
45763254|NCT03215615|Procedure|Universal Adhesive|One-step self-etching adhesive system
45763255|NCT03215615|Procedure|Nanofilled Composite|Partial nanofilled-resin composite restoration
45763256|NCT03215615|Procedure|Micro-Hybrid Composite|Partial micro-hybrid composite restoration
45763257|NCT04264000|Drug|platelet-rich plasma|Ultrasound-guided 3cc PRP injection between medial epicondyle and ulnar nerve
45763258|NCT04264000|Drug|5% dextrose|Ultrasound-guided 3cc 5% dextrose injection between medial epicondyle and ulnar nerve
45763259|NCT05455996|Drug|MDMA|MDMA-assisted therapy
45446140|NCT02077114|Biological|Vaccine consisting of a peptide derived from the protein IDO|All patients will receive seven vaccines containing IDOlong
45446141|NCT05459883|Procedure|splenic artery ligation|We identified portal hyperperfusion as a cause of potential small-for-size liver remnant dysfunction and we applied splenic artery ligation as a technically simple procedure to manage the situation
45763260|NCT05455918|Drug|TIP treatment (paclitaxel/ifosfamide/cisplatin)|Paclitaxel 240mg/m2/day D1 (total 240mg/m2) Ifosfamide 1.5g/m2/day D2~5 (total 6g/m2) Cisplatin 25mg/m2/day D2~5 (total 100mg/m2)
45446142|NCT02077192|Drug|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
45621014|NCT03072225|Drug|Herbal Medicine C-117|Herbal Medicine C-117 formula including 2 herbals and 2 insects
45763261|NCT04334902|Device|mPDia|Clinical decision support system for diagnosing neurodegenerative parkinsonism
45446143|NCT03757767|Other|Fasting for 26-hours|"All research subjects will have to fast for 26 hours in total.~All research subjects start with a standardized meal. Two hours after the standardized meal the samples in the fed state will be taken. Research participants are not allowed to eat anything after the consumption of the standardized meal until the second measurements on day 2, 26-hours later. There are 24 hours between the two measurement points."
45446144|NCT02077270|Procedure|electroacupuncture|Patients allocated to this arm will receive electro-acupuncture bilaterally on the following points which are considered relevant both for sedation and abdominal distention:LI4 (Hegu),ii. St36 (Zusanli), Sp6 (Sanyinjiao), St25 (Tianshuv),. Du20 (Baihui),
45446145|NCT02071888|Drug|CB-839|Glutaminase inhibitor
45446146|NCT02071888|Drug|CB-839 and low dose dexamethasone|CB-839 and low dose dexamethasone
45621015|NCT03072225|Drug|The Placebo of Herbal Medicine C-117|The Placebo of Herbal Medicine C-117 formula including 4 herbals
45621016|NCT03212677|Dietary Supplement|Ferrous sulfate|Standard-of-care therapy for iron deficiency anaemia
45763262|NCT02958748|Other|taking blood sample|
45763263|NCT05455762|Other|Exercise|The intervention consists of 8 week of combined resistance and aerobic exercise. Patients will exercise 6 days a week;3 days aerobic ones and 3 days resistance ones. The aerobic exercise include 20 minutes of walking divided into three parts. In the first five minute the patients walks slowly to warm up, in the next 10 minutes the patient will speedup to reach the intensity described by the physiotherapist. In the last 5 minutes the patient walks like the first five minutes. The middle 10 minutes may be increased or not based on patient's weekly report. The resistance training consists of 5 exercise; hip abduction, shoulder abduction, bridging, elbow flexion and knee extension. each of these exercises is done in 3 set of 10 repetition with one minute break between each set. Based on patients' weekly report a 0.5 kilogram weight might be added.
45763264|NCT00889187|Radiation|Neoadjuvant Short-Course Photon Radiation|
45763265|NCT00889187|Drug|Capecitabine|
45763266|NCT04334824|Drug|Hydrochlorothiazide|Exposure to hydrochlorothiazide will be defined as a prescription for hydrochlorothiazide alone or in combination with non-ACE inhibitor antihypertensive drugs at cohort entry date.
45763267|NCT04334824|Drug|Angiotensin-converting enzyme (ACE) inhibitors|Exposure to ACE inhibitors will be defined as a prescription for an ACE inhibitor alone or in combination with non-hydrochlorothiazide antihypertensive drugs at cohort entry date.
45763268|NCT03215537|Behavioral|comprehensive intervention|preoperative and postoperative exercise program
45763269|NCT05314127|Drug|Tazarotene 0.1% Gel,Top|once daily topical application at night with a cotton tipped applicator on every lesion
45763270|NCT05314127|Drug|Imiquimod|Imiquimod cream 5% applied once daily at night with a cotton tipped applicator applied once daily.
45763271|NCT05314127|Drug|Fluorouracil Cream|5- Fluorouracil Cream 5% is applied once daily at night with a cotton tipped applicator
45763272|NCT05314127|Drug|Petrolatum|applied once daily at night
45763273|NCT04932850|Biological|MAD0004J08|Human mAb 100 mg / 2.5 mL solution for injection
45763274|NCT04932850|Other|Placebo|Placebo matching to MAD0004J08 2.5 mL solution for injection
45763275|NCT03130127|Drug|Terlipressin|According to the current practice guidelines and consensus, terlipressin is the standard treatment option for acute variceal bleeding in liver cirrhosis.
45621017|NCT03212677|Dietary Supplement|IHAT|IHAT is a nanoparticle composed of three General Regarded As Safe (GRAS) substances, iron hydroxide, tartaric acid and adipic acid. The particle itself resembles the normal metabolite ferritin, which is a larger polyatomic particle. Like ferritin, IHAT can be absorbed by endocytosis, but dissociates within the enterocyte and is subsequently metabolized as ferrous iron.
45621018|NCT03212677|Dietary Supplement|Aspiron|Aspiron is a product of the natural fermentation of Koji (Aspergillus oryzae) in the presence of ferrous sulfate. The iron-rich koji biomass is heated, harvested and dried which results in the inactivation of Koji powder that contains 8-10% iron. Koji (A. oryzae) is widely used for making such foods as soy sauce, tempeh, miso, and for producing food-grade α-amylase, and is considered safe by Joint Food and Agriculture Organization of the United Nations (FAO)/WHO Committee on Food Additives and has been accepted as a GRAS constituent of food.
45621019|NCT03212677|Other|Placebo|Cornstarch
45763276|NCT05455528|Diagnostic Test|estimated GFR calculation|The estimated GFR is computed with Modification of Diet in Renal Disease (MDRD) formula
45446147|NCT02071888|Drug|CB-839, pomalidomide, and low dose dexamethasone|CB-839, pomalidomide, and low dose dexamethasone
45446148|NCT02071966|Drug|Ticagrelor|Comparison of Ticagrelor with another anti-platelet drug (Clopidogrel)
45446149|NCT02071966|Drug|Clopidogrel|Comparison of Clopidogrel with another anti-platelet drug (Ticagrelor)
45446150|NCT02072044|Drug|Anlotinib|Anlotinib p.o. qd
45621020|NCT04991259|Procedure|Continuous Renal Replacement Therapy (CRRT)|Continuous renal replacement therapy will be administered as continuous venovenous hemodiafiltration (CVVHDF) using Prisma and Prismaflex (Gambro) devices, with blood flows ranging from 150-180 mL/hr and target effluent rates of 20 - 25 mL/kg/hr. Anticoagulation was not used during dialysis. CRRT would be continued until resolution of cerebral edema and in decrease in ammonia levels below 150 ug/dl or in those who develop adverse effects of therapy.
45763277|NCT03215459|Device|Cardiopulmonary Exercise Test|Cardiopulmonary Exercise Test
45763278|NCT04225078|Drug|Loperamide|Loperamide will be administered as a single oral dose at the expected therapeutic or supratherapeutic doses respectively.
45763279|NCT04225078|Other|Placebo|Matching loperamide placebo capsules will be administered orally.
45446151|NCT02072278|Drug|Vortioxetine 10 mg|
45446152|NCT02072278|Drug|Vortioxetine 20 mg|
45446153|NCT02072278|Drug|Escitalopram 15 mg|
45763280|NCT04225078|Drug|Moxifloxacin|Moxifloxacin tablets will be administered orally.
45763281|NCT04380935|Biological|Convalescent plasma|Convalescent plasma of recovered COVID-19 patients (donor)
45763282|NCT04380935|Drug|Standard of care|"According to national or hospital guidelines COVID-19 Management Protocol"
45763283|NCT00373048|Drug|mefloquine|tablet, once weekly
45763284|NCT00373048|Drug|placebo|tablet, once weekly
45763285|NCT05455372|Drug|PPI quadruple therapy|PPI quadruple therapy refers to ilaprazole 5mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid.
45763286|NCT00372892|Drug|Rituximab|375mg/m2 per week for 4 consecutive weeks
45763287|NCT00372892|Drug|Placebo|Saline IV placebo once per week for 4 consecutive weeks
45763288|NCT04127656|Other|Amino Acid-Based Experimental Study Formula|Amino Acid-Based Formula; fed ad libitum
45763289|NCT00895817|Drug|Swallowed fluticasone|440 µg twice daily for 8 weeks
45763290|NCT00895817|Drug|Esomeprazole|40 mg once daily for 8 weeks
45446154|NCT02072278|Drug|Placebo|
45446155|NCT02072512|Drug|Fulvestrant|Fulvestrant 500mg I.M. Once/28days,until progression or unacceptable toxicity develops
45446156|NCT02072512|Drug|Goserelin|goserelin 3.6mg subcutaneously every 28(± 3) days
45446157|NCT02072512|Drug|Anastrozole|Anastrozole 1mg P.O. once daily, until progression or unacceptable toxicity develops
45446158|NCT02072512|Drug|Goserelin|goserelin 3.6mg subcutaneously every 28(± 3) days
45763291|NCT03020303|Drug|Spironolactone 25Mg Tablet|Randomized participants will receive a study supply of spironolactone 25 mg tablets. They will be instructed to take 1 tablet daily.
45763292|NCT03020303|Drug|Placebo Oral Tablet|Randomized participants will receive a study supply of placebo tablets with no active medical ingredients. They will be instructed to take 1 tablet daily.
45763293|NCT04825522|Drug|Vancomycin|During spinal surgery, participants will receive intrawound vancomycin powder in their wound before closure.
45763294|NCT00373204|Drug|Motexafin Gadolinium|"On Day 1 of each 3 week cycle for up to 12 cycles:~MGd 10 mg/kg infused over approximately 30 to 60 minutes, followed ≥ 30 minutes later by Docetaxel 75 mg/m2 administered IV over approximately 1 hour."
45763295|NCT00373282|Drug|Triamcinolone acetonide|
45763296|NCT01047319|Drug|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
45763297|NCT00373438|Procedure|Fetoscopic tracheal balloon occlusion|Maternal local anesthesia, percutaneous ultrasound-guided fetal analgo-sedation and relaxation, percutaneous ultrasound-guided access into amniotic cavity with trocar, fetoscopic tracheal ballon occlusion, removal of fetoscope and trocar, maternal abdominal closure, skin-to-skin time 30 minutes
45763298|NCT04033354|Drug|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
45621021|NCT04991259|Other|Standard Medical Treatment|In the L- ICU, patients will be managed by a multidisciplinary team. Intubation and ventilation will be undertaken for standard indications in addition to the development of grade 3 encephalopathy or evidence of cerebral edema on CT-scan. Fluid management will be done with crystalloids, with the use of colloids (5% albumin) in patients with severe hypoalbuminemia (serum albumin less than 2.5gm/dl). Norepinephrine will be the primary vasopressor used to target a mean arterial pressure of 65-70 mm of Hg. with adjunctive use of intravenous low dose hydrocortisone and vasopressin in patients not responsive to initial therapy.
45621022|NCT03315065|Drug|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas and Mixture of 30% perfluoropropane and 70% oxygen to measure perfusion single visit, < 1 hour
45763299|NCT04033354|Drug|carboplatin and nab paclitaxel|chemotherapeutics
45763300|NCT04033354|Drug|Placebo|Placebo
45763301|NCT03838679|Diagnostic Test|Best-corrected Visual acuity testing (BCVA)|Best-corrected visual acuity (BCVA) will be measured using Early Treatment of Diabetic Retinopathy Study (ETDRS) charts at 4 meters and 1 meter, respectively.
45763302|NCT03838679|Diagnostic Test|Optical coherence tomography (OCT)|Optical Coherence Tomography (OCT) is a non-invasive diagnostic technique that renders an in vivo cross sectional view of the retina.
45763303|NCT03838679|Diagnostic Test|Color fundus photography (CFP)|Color fundus photography is a non-invasive, fast and reliable imaging method providing a true-to-life depiction of the ocular fundus.
45763304|NCT03838679|Diagnostic Test|Optical coherence tomography angiography (OCTA)|OCTA, an extension of conventional OCT, offers noninvasive imaging of the retinal and choroidal vasculature.
45763305|NCT03838679|Diagnostic Test|Polarization-sensitive optical coherence tomography (PS-OCT)|PS-OCT, a functional exten- sion of conventional OCT technology, enables differentiation of retinal layers based on their distinct interference with the polarization state of the probing light beam, as opposed to mere light intensity.
45763306|NCT03838679|Diagnostic Test|Microperimetry (MP)|Microperimetry allows testing of retinal sensitivity at specific locations in the area of the fovea, parafovea or even more peipheral areas of the macula.
45763307|NCT03838679|Diagnostic Test|Adaptive-optics optical coherence tomography (AO-OCT)|AO-OCT, an extension of conventional OCT, offers non-invasive imaging of the retina with improved lateral resolution of up to 2-3 μm.
45763308|NCT03838679|Diagnostic Test|Fluorescein angiography (FA)|FA imaging is a standard imaging technique used for the diagnosis of vascular pathologies of the retina such as choroidal neovascularization.
45763309|NCT02911805|Behavioral|Aerobic exercise|Stationary bicycle ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes
45763310|NCT02911805|Behavioral|Balance exercise|Instructor-led exercises done in a group setting for strengthening, balance, flexibility
45763311|NCT03215225|Procedure|Root canal orthograde treatment|
45763312|NCT01123018|Behavioral|Memtrax Memory screening test|Memory Screening test
45763313|NCT03405649|Behavioral|Group A|Muscle conditioning exercise for postpartum women and infants less than 20 weeks of age.
45763314|NCT03405649|Behavioral|Group B|Muscle conditioning exercise for postpartum women and infants more than 20 weeks of age.
45912033|NCT04502225|Other|Elevated trunk|Elevation of the trunk through raising just the head of the bed until the head is elevated by 9 and/or 12 inches in an acute trial or overnight.
45446159|NCT04534491|Drug|Oxybutynin (Oxytrol, BAY839380)|Oxybutynin transdermal patch, 3.9 mg daily (Oxytrol Transdermal System)
45446160|NCT02069080|Drug|64-Cu-plerixafor|"Five subjects with CXCR4-positive tumor sample(s) will be administered an initial intravenous (IV) infusion of 64Cu-plerixafor of up to 8+0.8 mCi (0.48+0.048 rem) not to exceed 5 g of 64Cu-plerixafor at Day 0. These subjects will undergo an initial lowdose CT scan followed by 3 consecutive torso PET scans as soon as practical after the infusion, and 2 additional PET/CT scans at 4 hours +/- 1 hour and 24 hours +/- 2 hours post-infusion. Human dosimetry will be calculated based on these results, and a maximum dose will be used, not to exceed the calculated limit of a total effective dose of 5 rem, or the radiation exposure limit for each organ.~The remaining subjects with CXCR4-positive (n=15) and CXCR4-negative (n=5) tumor sample(s) will be administered 64Cu-plerixafor at the same or a newly calculated dose and will undergo 1 PET/CT scan between 1 and 4 hours post-infusion."
45763315|NCT02872805|Other|PEPFAR Enhanced Standard of Care (PESCA)|Standardized materials will be provided to PEPFAR supported clinical sites to assist clinic teams with supporting patients in the transition from pediatric to adult medical care
45763316|NCT02872805|Behavioral|Peer Transition Advocate (PTA)|The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors. They will engage patients in role-plays to simulate appointments in adult practices. The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care. PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients. PTA will support counseling and testing services for adolescents within the facilities. For those perinatally-infected, important care and support services include disclosure and stigma issues.
45763317|NCT02884414|Device|Cutaneous stimulation|A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.
45912034|NCT04502225|Other|Tilt - In home|Tilt of the whole bed so that the head is elevated by 8 inches overnight.
45912035|NCT04502225|Other|Elevated Trunk - In home|Elevation of the trunk through raising the head 8 inches on a wedge pillow overnight.
45912036|NCT04495855|Drug|Dienogest (Visanne,BAY86_5258)|2 mg (once a day), oral, tablet.
45912037|NCT04478747|Procedure|TVM|Transvaginal mesh operation using BSC mesh (A.M.I., Feldkirch, Austria)
45912038|NCT04478747|Procedure|Colposacropexy|Colposacropexy using EndoGYNious mesh (A.M.I., Feldkirch, Austria)
45912039|NCT04461587|Drug|Pirfenidone|see previous entries
45912040|NCT04428034|Behavioral|Learning Skills Together|Information provided in arm/group description.
45912041|NCT04424355|Diagnostic Test|Chest MRI|Patients referred by the primary care physician with suspected pneumonia
45621023|NCT04997343|Other|Neurophysiological assessment|EMG will be recorded from the Abductor pollicis brevis muscle (APB) with surface electrodes. EEG will be recorded with a 32-channel elastic cap via a TMS compatible system. TMS will be performed using a Magstim 200 stimulator with a 90 mm figure-of-eight coil localized on motor and non-motor areas using a neuronavigation system together with an optical tracking system. Coordinates for neuronavigation will be calculated in the MNI space and fit of each participant's anatomical MRI. Three minutes of continuous-EEG will be recorded with subjects at rest. Single-pulse neuronavigated TMS (sp-TMS) will be delivered at rest below the resting motor threshold intensity (RMT) over the APB hotspot on M1 during concurrent EEG recording. In a final block, the subject will maintain a voluntary muscle contraction (50% of the maximal voluntary contraction) of the left APB, and sp-TMS will be delivered at 130% RMT over the ipsilateral APB hotspot in order to record the lpSP.
45446161|NCT03751527|Device|ZENFLEX peripheral stent system|The ZENFLEX Peripheral Stent System is designed to deliver a self-expanding stent to the iliac artery, superficial femoral arteries and / or proximal popliteal arteries to improve luminal diameter. The self-expanding stent is composed of nickel titanium alloy (nitinol); contains a total of 12 tantalum / gold radiopaque markers and imparts an outward radial force on the luminal surface of the vessel to establish patency.
45621024|NCT04997343|Other|clinical assessment|"Clinical evaluation, performed at each time point, will include:~The assessment of clinical disability using EDSS score~The multiple sclerosis functional composite (MSFC), a three-part quantitative objective measure of neurologic function, measuring lower limbs (timed 25-foot walk [T25FW]), upper limbs (nine-hole peg test [9HPT]) and cognitive (three-second paced auditory serial addition test [PASAT3]) function.~In order to reduce inter-rater variability, the same physician/technician with adequate training will administer all three tests. The patient should feel comfortable with the situation. Examiner should explain the instructions in a professional but friendly way and let the patient ask any questions before starting the tests. Examiner should write down the test results, as well as any situation that disturbs the performance of patient. Examiner should not provide direct feedback to the patient about his/her performance"
45621025|NCT03199339|Drug|TBA-7371|The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
45621026|NCT03199339|Drug|Placebo|The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
45621027|NCT02478905|Other|Influenza|
45763318|NCT04382027|Dietary Supplement|Omega-3 + vitamin K2 (monoacylglycerol form)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.~Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments."
45763319|NCT04382027|Dietary Supplement|Omega-3 + vitamin K2 (ethyl ester)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.~Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments."
45621028|NCT03071523|Procedure|coronally advanced lingual flap|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.
45763320|NCT01044901|Procedure|MRI, Transthoracic Echocardiography, tonometry, EKG|Unless contraindicated, subjects will receive Regadenoson and Gadolinium contrast agent during the Cardiac magnetic resonance. The tonometer, EKG, and echo are non-invasive procedures.
45763321|NCT02884492|Drug|18F-THK-5351|18F-THK-5351 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
45763322|NCT02884492|Procedure|Lumbar Puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
45912042|NCT04371107|Other|consultation|Patients are followed up by teleconsultation or remote follow-up until the end of symptoms and for a maximum of 2 months
45912043|NCT04371107|Drug|Azithromycin|azithromycin treatment 500 mg on day 1 then 250 mg the following 4 days from day 2 to day 5, per os.
45912044|NCT04368494|Behavioral|12-week home based exercise|Patients allocated to the exercise arm will be prescribed a home-based walking exercise programme consisting of 30 minutes of walking on 5 days per week at an RPE in the range of 12-14 (somewhat hard). Each patient's heart rate range will be established during the baseline exercise test by recording the heart rate response at the required RPE target range. This will be provided to each patient to use in conjunction with the activity monitor they will be given to wear on their non-dominant wrist. The monitor reports heart rate and records daily steps, distance and activity duration.
45621029|NCT03071523|Procedure|periosteal releasing incision|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
45621030|NCT03201991|Other|Resistance Exercise Program|The resistance exercise program will involve three sets of 10 repetitions of each exercise in levels 1 and 2 every day. Participants will be given instructions to follow.
45912045|NCT04364984|Drug|Angiotensin converting enzyme inhibitor|routine drug intake
45912046|NCT04364984|Drug|Angiotensin Receptor Blockers|routine drug intake
45912047|NCT04364984|Drug|Direct renin inhibitor|routine drug intake
45621031|NCT03071679|Drug|Omiganan|Omignan 1%, 2.5%
45621032|NCT03071679|Drug|Imiquimod|Imiquimod 15mg
45763323|NCT00896441|Drug|Citalopram|"Refer to Detailed Description Section for full description of intervention. Week 1 (baseline): Subject will complete several tests to assess the subject's memory and concentration. Following visit, they will begin treatment with the antidepressant citalopram.~Week 1 MRI: Subject will have their first MRI. Week 2 visit: Physician will meet with they to assess the subject's overall condition.~Week 2 MRI: Subject will have the subject's second MRI. Week 4 visit: The study physician will meet with the subject to assess their overall condition.~Week 6 (Telephone check-in): The study physician will check in with the subject by telephone to assess the subject's overall condition.~Week 8: (End-of-study visit) Subject will take repeated tests of memory and concentration. The study physician will also discuss recommendations for further treatment of the subject's depression.~Week 8 MRI: Around the time of the subject's week 8 visit they will have the subject's third and final MRI."
45763324|NCT02885350|Drug|Spinal analgesia for labour pain|Intrathecal dose of either fentanyl or sufentanil delivered by combined spinal-epidural technique
45763325|NCT02885350|Drug|Epidural analgesia for labour pain|Epidural dose of either fentanyl or sufentanil delivered through an epidural catheter.
45763326|NCT02790515|Drug|Anti-thymocyte globulin (rabbit)|Given intravenous (IV) prior to transplant on Days -14, -13, -12.
45763327|NCT02790515|Drug|Blinatumomab|Given by continuous IV infusion at least 2 weeks post-engraftment. Blinatumomab will be given only to patients with CD19+ malignancies.
45763328|NCT02790515|Drug|Cyclophosphamide|Given by IV infusion prior to transplant on Day -9.
45763329|NCT02790515|Drug|Fludarabine|Given IV prior to transplant on Days -8, -7, -6, -5, and -4.
45763330|NCT02790515|Drug|G-CSF|Given IV or subcutaneous (SQ) following transplant on Days 6 and 7.
45763331|NCT02790515|Drug|Melphalan|Given IV prior to transplant on Days -2 and -1.
45763332|NCT02790515|Drug|Mesna|Given IV prior to cyclophosphamide administration and at approximately 3, 6, and 9 hours after cyclophosphamide infusion.
45763333|NCT02790515|Drug|Rituximab|Given IV prior to transplant on Day -1.
45763334|NCT02790515|Drug|Tacrolimus|Given oral (PO) or IV beginning prior to transplant on Day -2. The dose will begin to taper at approximately day +60 after transplant in the absence of GVHD. Tacrolimus was used for the first 5 participants enrolled on study. Subsequent participants receive sirolimus.
45763335|NCT02790515|Drug|Thiotepa|Given IV prior to transplant on Day -3.
45763336|NCT02790515|Biological|HPC,A Infusion|Hematopoietic Progenitor Cell, Apheresis (HPC,A) infusion of TCRɑβ+ depleted cells on day of transplant (Day 0) and HPC,A infusion of CD45RA+ depleted cells on Day +1 following transplant.
45763337|NCT02790515|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
45763338|NCT02790515|Drug|Sirolimus|Given orally (PO) starting Day 0. The dose will be tapered off over two weeks starting on Day +42 in the absence of GVHD.
45763339|NCT03400111|Radiation|low-level laser therapy|low-level laser therapy will be used to relieve pain and discomfort during orthodontic treatment at specific time points.
45763340|NCT03400111|Drug|Panadol-extra|Tablets of 565-mg Panadol-extra will be used at specific time points to control pain and discomfort
45763341|NCT03407833|Other|Endoscopy biopsy|Tissue samples will be collected from the jejunum, duodenum, and colon during the subject's standard of care procedure.
45763342|NCT03407833|Other|Surgical biopsy|Biopsy of the liver is standard of care for diagnosing NAFLD. Biopsy of omentum, skeletal muscle and subcutaneous adipose (the latter two tissues taken at the site of trocar placement) will be collected intraoperatively at the time of Roux-en-Y gastric bypass (RYGB) or vertical sleeve gastrectomy (VSG).
45763343|NCT03407833|Other|Mixed-meal tolerance test|The mixed meal tolerance test (MMTT) shows how much insulin your body is making after drinking a liquid meal beverage that contains fats, protein and carbohydrates (sugar). Glucose, C-peptide, free fatty acids, triglycerides, incretins, pancreatic polypertide, bile aceis, and fatty acid amides can also be measured. A total of 9 tablespoons of blood is taken over a 255 minute period.
45621033|NCT03071679|Drug|Omiganan 1% and Imiquimod|Omiganan 1% and Imiquimod
45621034|NCT03071679|Drug|Omiganan 2.5% and Imiquimod|Omiganan 2.5% and Imiquimod
45763344|NCT03407833|Other|Excised Liver Tissue Sampling|Tissue will be collected from the excised liver for research after the diseased liver has been removed as part of the standard of care procedure.
45763345|NCT03403465|Other|FDG PET scan|At radiation planning subjects will have a PET-CT. The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
45763346|NCT03404791|Drug|TAR-200|TAR-200 will be placed for 21-day dosing cycles, with up to 7 doses per participant.
45763347|NCT03215381|Drug|[11C]AZD1390|[11C]AZD1390
45621035|NCT03071679|Drug|Placebo|Vehicle
45621036|NCT03199261|Drug|rE-4 Injection|During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Injection 10µg administered 30 minutes prior to the start time of a standard breakfast.
45621037|NCT03199261|Drug|rE-4 Freeze-dried Powder|During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Freeze-dried Powder 10µg administered 30 minutes prior to the start time of a standard breakfast.
45621038|NCT02478827|Behavioral|Cognitive training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. Participants randomized one of the cognitive training arms will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
45621039|NCT05001321|Radiation|The whole abdomen contrast-enhanced CT scan|All the participants were measured by the whole abdomen contrast-enhanced CT scan.
45621040|NCT05001321|Other|H&E stained sections and slides|HE pathological examination was performed on all specimens of enrolled patients.
45621041|NCT03201679|Procedure|Repair of hip fracture|Patients undergoing hip fracture surgery
45621042|NCT02482961|Drug|colistimethate sodium|At least once a week, all patients with carbapenem-resistant Acinetobacter baumannii infection were screened from the database at the clinical microbiology laboratory
45621043|NCT02478749|Procedure|arm retraction|gently pulling through the ipsilateral arm to the knee
45446162|NCT02077348|Drug|Insulin withdrawal|Withdrawal of usual (evening) insulin, replaced by Insuman Rapid (10% of the amount of usual evening insulin) as a continuous IV- administration overnight until 8 o'clock on the study day.
45621044|NCT02449525|Procedure|Perfusion of flaps by a special bypass system|Free flaps are perfused via a special bypass perfused by a new technique supported by a intermittent perfusion support system.
45621045|NCT02478593|Behavioral|Educational booklet|Participants in the intervention group will receive an 8-page booklet that includes a list of generic and brand benzodiazepine names, benzodiazepine medication knowledge test, information about the associated risks of benzodiazepine use, and a list of safe alternative to their potentially inappropriate medication, as well as a stepwise tapering method. Recommendations to discuss decreasing use of benzodiazepines with physicians as well as to consult physicians before stopping any medication are also advised in the booklet. Participants in the control group will receive a booklet, produced by the Centers for Disease Control and Prevention, containing information regarding the important of exercise for seniors.
45763348|NCT03406039|Behavioral|Integrated Online CBT and MI|The treatment condition will have access to 12 treatment modules and have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, young adults will identify goals related to alcohol use and mood, learn strategies to cope with alcohol cravings, triggers, and social pressures, and learn how to prevent relapse. There will also be several modules to target anxiety and depression, focusing on strategies designed to help reduce negative thinking and worry, increase behavioural activation, and increase self-care (e.g., sleep hygiene).Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially.
45763349|NCT03839069|Procedure|minor salivary gland transplantation|The investigators will harvest the autologous labial salivary gland tissue and transplant to the upper and lower conjunctival fornix of the lesion eye.
45763350|NCT03834415|Dietary Supplement|Lactobacillus reuteri DSM17038|Oil drops of L. reuteri containing 1x10>8 CFU
45763351|NCT03834415|Other|Placebo for Probiotics|Oil drops mimicking in consistency and flavor to experimental product
45763352|NCT03834649|Procedure|partially de-epithelized connective tissue graft|graft procedures to obtain simultaneous tissue augmentation in the horizontal and vertical dimensions. The donor site was prepared with a full-thickness coronal dissection and a partial-thickness apical dissection.The objectives were to use a single procedure to achieve simultaneously apico-coronal and buccolingual augmentation,to have a smaller open wound in the donor site and less patient discomfort, and to guarantee better revascularization of the onlay section aided by the submerged connective tissue section of the graft.
45763353|NCT03834649|Procedure|Mucograft|"For preprosthetic defects, a standard mucosal augmentation procedure, which is well reported in the literature, was performed. The surgical site produced by the surgery leaves a denuded area supraperiosteally that is addressed by grafting with a xenogeneic collagen membrane (Mucograft).~purpose of the surgery is to improve the quantity of attached mucosa to facilitate the final dental reconstruction"
45763354|NCT03405571|Other|No intervention|No intervention
45621046|NCT03199417|Drug|Multiprofen|A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel.
45621047|NCT03199417|Other|Placebo|An identically packaged placebo cream
45621048|NCT04990713|Procedure|Serratus Plane Block (Local Anesthetic) and Intercostal Block (Local Anesthetic)|Patients will receive local anesthetic via serratus plane block as opposed to saline placebo
45621049|NCT04990713|Procedure|Serratus Plane Block (Placebo) and Intercostal Block (Local Anesthestic)|Patients will receive saline placebo via serratus plane block
45621050|NCT02482727|Device|occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with dopplar ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
45621051|NCT03212131|Drug|Somapacitan|3 once-weekly subcutaneous administrations (s.c., under the skin) of somapacitan with a dose of 0.08 mg/kg
45763355|NCT04380623|Behavioral|Mobile Phone-Based Web-Page: HPV vaccine|Website to be accessed via mobile phone to deliver tailored educational material
45935162|NCT04722757|Procedure|ta-IPAA|A trans-anal port (gelpoint path, Applied Medical®) will be used for transanal acces and pneumopelvis will be created. The initial purse string is to be placed approximately 3cm above the dentate line, followed by a rectotomy. The perirectal dissection is then continued and should be pursued for at least 5cm. More proximal dissection can be done by transabdominal access. After completion of the proctectomy, a double purse string anastomosis is performed after creation of the J-pouch. A defunctioning loop ileostomy can be placed according to surgeon's preference.
45446163|NCT02077348|Drug|Norditropin|0,4 mg of GH administered at 7.05 A.M. on the study day.
45446164|NCT03694821|Drug|Ketorolac Tromethamine Injection|One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
45763356|NCT05314283|Device|DV3395 C1|Participants will be exposed to and swallow DV3395 C1 once. The participants will stay at the clinic research center for up to 6 days .
45763357|NCT00918931|Drug|Obatoclax Mesylate|30 mg given by vein over 3 hours on Days 1-3 of each 14-day study cycle.
45763358|NCT04381715|Genetic|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
45763359|NCT03405493|Behavioral|Wake and Light Therapy|Participants will be helped to change the pattern sleep by depriving participants of sleep for one night. On Day 1 participants will be supported to stay up all night and the following day at the Hospital. Participants can go to bed by 5pm at home on Day 2. Participants will need to get up by about 1am and return to the hospital to be supported to stay awake. Participants will then go to bed at 7pm on Day 3. Participants will be asked to sleep until 3am and then stay awake at home until bed at 9pm on Day 4. Participants will then get up by 5am on Day 5 and stay awake until 11pm to resume a normal sleep routine waking by 7am on Day 6. Participants will also be given a light box to use each morning. For the light box, participants will be asked to sit about one foot away from a light box. You will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes. Participants may continue to have treatment as usual.
45763360|NCT03405493|Behavioral|Sleep and Light Therapy|Participants will be given information and advice on how to get a good night's sleep. Participants will be also given a light box to use in the morning for 1 week. For the light box, participants will be asked to sit about one foot away from a light box. Participants will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes when you get up. Participants may continue to have any treatment as usual (for example medication or talking therapies).
45763361|NCT02885506|Drug|Oral administration of P218 capsules|Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.
45621052|NCT03314909|Procedure|Hemodialysis|Participants in this group will be catheterize in the internal jugular vein and connect to a hemodialysis machine.
45621053|NCT03314909|Procedure|Hemoperfusion|Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine.
45763362|NCT02885506|Drug|Oral administration of P218 matching placebo|Oral administration of P218 matching placebo. The number of capsules is identical to the corresponding number of P218 capsules administered to the volunteers on the investigational drug.
45763363|NCT03214913|Other|Early Goal Directed Therapy|EGDT therapy ：30ml/kg in the first bolus to have a CVP 8-12 mmHg and MAP 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%；If not, use noradrenine，red blood cell transfusion if necessary.
45763364|NCT03214913|Other|Ruijin Strategy|"Ruijin Strategy：10~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary.~target： fulfillment of two or more of four criteria:1. HR <120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT 25%~35%."
45763365|NCT03215147|Diagnostic Test|Confirmation of Airway Disease combined with IPF|To confirm the airway disease combined with IPF, PFT+BDR+DLCO, MBPT, Induced sputum exam, MAST, Total IgE, serum Eosinophil count, FENO will be done at the time of registration and 6~8 weeks later.
45763366|NCT03404011|Other|Propylene glycol and Glycerol intake|Intake of 1 gram of propylene glycol/Glycerol mix (50:50). Blood sample before, 5 minutes and 20 minutes after intake.
45763367|NCT03404011|Device|Mimicking intake|Mimicking propylene glycol/glycerol intake with the device turns off. Blood sample before, 5 minutes and 20 minutes after intake.
45763368|NCT04381949|Procedure|positive pressure extubation|"Two arms:~the first with classic extubation with disconnection of the ventilator and the second with an extubation without disconnection of the respiratory positive pressure"
45763369|NCT03840382|Behavioral|Tele-PrEP Intervention|Telemedicine conferences with PrEP-specialists
45763370|NCT03214835|Device|Endo CDx Brush biopsy|In patients with laryngeal lesion the brush biopsy will be taken with the standard cup biopsy - either in the clinic or in the OR. In LPR patients brush biopsy will be taken in the clinic.
45763371|NCT05312099|Other|Case control|Case control study
45763372|NCT03214757|Other|treatment of anemia.|drug treatment of anemia.
45763373|NCT05311865|Other|Club event|Participate in a club event without a mask, indoors, with vaccinated people.
45763374|NCT05311787|Procedure|esophagectomy with simultaneous reconstruction|Subtotal resection of esophagus and simultaneous reconstruction by gastric pull-up or colon conduit
45763375|NCT02895100|Drug|PTG-100|Daily dosing of PTG-100 by subject for a 12 week treatment period.
45763376|NCT02895100|Drug|Placebo|Daily dosing of Placebo capsules by subject for a 12 week treatment period.
45763377|NCT01830491|Drug|Clopidogrel|
45763378|NCT01830491|Drug|aspirin 100mg|
45763379|NCT03837275|Procedure|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique (Intralift Technique) and implant placement
45763380|NCT03837275|Procedure|closed maxillary sinus lift|transdcrestal sinus lift and immediate implant placment
46069233|NCT03641300|Device|Magnetic Seizure Therapy (MST)|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
45621054|NCT03314909|Procedure|HP-HD|Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine and then a hemodialysis machine for one course.
45621055|NCT04990791|Drug|Aspirin 75mg|Aspirin 75mg OD for 14 days
45621056|NCT04990791|Drug|Aspirin 20mg|Aspirin 20mg BD for 14 days
45621057|NCT04990791|Drug|Rivaroxaban 2.5 mg|Rivaroxaban 2.5mg BD
45763381|NCT00904007|Other|Interactive Spaced Education (ISE) --- online education|"ISE is a novel educational methodology based on the spacing effect, the psychological finding that repeated presentations of educational material over spaced intervals increase learning efficiency and improve knowledge retention. ISE is delivered using periodic emails that contain clinical case scenarios and multiple-choice questions."
45621058|NCT03211819|Procedure|immediate implant placement|"A prophylactic antibiotic(Flumox 500mg, Egyptian Int. Pharmaceutical Industries Co.,A.R.E.) would be given to the patient 3 days prior to the surgery. Then on the day of surgery, (AK) will extract the remaining root or tooth in an atraumatic procedure using lancet, periotome (Nordent Manufacturing Inc. U.S.A), minimal force and rotational movement.~After extraction the socket will be examined for intact labial and palatal bone using depth probe. If all walls are intact the socket would be eligible for immediate implant placement."
45763382|NCT02777944|Behavioral|Motivate: a web-based intervention|A web-based intervention focuses on managing expectations of assessment, addressing ambivalence and increasing users' motivation and confidence to attend their initial appointment. This is achieved through the use of information, motivational tools, interactive activities and stories from other individuals with EDs spread across four 15-20 minute modules.
45763383|NCT01830569|Behavioral|The EBMeDS system|"The EBMeDS system receives structured patient data from the electronic medical records in HealthOne and returns reminders, therapeutic suggestions and diagnosis-specific links to guidelines. Electronic forms and calculators (e.g. a calculator for glomerular filtration) are integrated in the system.~The original EBMeDS system was developed by Duodecim in Finland and covers a full spectrum of all clinical areas. Relevant reminders in all clinical areas are shown to the physicians in the intervention group."
45763384|NCT01830569|Other|Evidence Linker|The Evidence Linker is already integrated in Belgian routine practice since 2012 and could be considered as part of the usual care process. When entering a diagnosis coded in ICPC, relevant clinical practice guidelines are retrieved by the Evidence Linker and could by consulted on the initiative of the family physician.
45763385|NCT02778880|Drug|Ketamine|
45763386|NCT02778880|Drug|Fentanyl|
45763387|NCT05311319|Drug|HAIC+TQB2450+Anlotinib|HAIC: FOLFOX for 24hour perfusion chemotherapy. Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. TQB2450: 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.
45763388|NCT05311163|Procedure|MitraClip|Transcatheter Mitral Edge-To-Edge Repair
45763389|NCT05310929|Drug|Labetalol and Glyceril trinitrate|for control of blood pressure
45763390|NCT03214133|Other|Epicatechin-rich cocoa dose response|Subjects consume randomized doses of 0, 1, 2, 3 mg epicatechin/kg from epicatechin-rich cocoa. The optimal dose of epicatechin-rich chocolate will be the dose which have the greatest increase PNIP levels.
45763391|NCT03214133|Other|Epicatechin-rich cocoa vs placebo on performance|An optimized dose of epicatechin-rich cocoa or placebo will be given for 3 weeks alongside a prescribed power-based training program. In a randomized parallel design the effect of the optimal dose of epicatechin-rich chocolate, compared to placebo, on maximal isometric squat force, RFD, and jump testing will be quantified.
45763392|NCT00891995|Device|Closed loop|Closed loop therapy for up to 4 to 6 days
45763393|NCT00891995|Device|Home glucose monitoring|Standard diabetes management using a home glucose meter.
45763394|NCT00891995|Device|Insulin pump|Insulin pump use for 2 years
45763395|NCT00891995|Device|Continuous glucose monitor|Continuous glucose monitor use for 2 years
45763396|NCT02781454|Drug|Mexiletine|
45763397|NCT02781454|Drug|Placebo|
45763398|NCT00892697|Drug|Telaprevir|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if < 75 kg).
45763399|NCT00892697|Drug|Peginterferon alfa-2a|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if < 75 kg).
45446165|NCT03694821|Drug|Methylprednisolone Acetate Injection|One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
45446166|NCT03694821|Drug|Hylan G-F 20|One knee injection of Hylan G-F 20 (Synvisc-One)
45763400|NCT00892697|Drug|Ribavirin|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if < 75 kg).
45446167|NCT02077426|Other|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
45446168|NCT02077504|Other|MEG and MRI|CONDUCTOME
45621059|NCT05713487|Other|preventive treatment group|each athlete belonging to the preventive treatment group performed the protocol of preventive treatment 2 times a week, before or after the training session for five months
45621060|NCT04990557|Drug|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
45763401|NCT04381403|Other|Bio-descaling D-Tart toothpaste|Patients received Bio-descaling D-Tart toothpaste, which is a new dentifrice (Visionaturolab Inc., QC) that contains a natural bio-descaler powder of cuttlefish bone
45763402|NCT04381403|Other|Crest® toothpaste|Patients received Crest toothpaste; Anti-tartar toothpaste
45763403|NCT04381793|Dietary Supplement|Recovery Factors|Porcine serum amino acid/peptide
45763404|NCT01830959|Drug|Roflumilast|Roflumilast
45763405|NCT01830959|Drug|Placebo|Placebo one a day
45763406|NCT02155465|Drug|Ruxolitinib|"Ruxolitinib 10mg PO BID~Ruxolitinib 15mg PO BID~Ruxolitinib 20mg PO BID"
45621061|NCT04990557|Drug|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
45621062|NCT04990557|Drug|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
45621063|NCT02478437|Procedure|Conventional radiofrequency ablation (RFA)|A conventional RFA electrode with a 10mm active tip will be used. RFA lesions will be performed for 90 seconds with the maximum electrode temperature raised to 80°C.
45621064|NCT02478437|Procedure|Cooled Radiofrequency Ablation (CRFA)|Following 18G C-RFA electrode positioning, 1cc of 2% lidocaine will be injected through the introducer needle for anesthesia during the ablation. The maximum electrode temperature is 60°C.
45763407|NCT02155465|Drug|Erlotinib|Erlotinib 150mg PO QD
45763408|NCT01831193|Drug|Curcumin|
45763409|NCT01831505|Drug|Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them|
45763410|NCT02781610|Drug|Standard of care IV antibiotic(s)|IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.
45621065|NCT03201835|Drug|PNL-THC:CBD soft gelatin capsule|3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
45621066|NCT03201835|Drug|Sativex|spray X 4 actuations
45621067|NCT03201835|Drug|CBD hard capsule dose 1|1 hard capsule containing 10 mg CBD
45621068|NCT03201835|Drug|P-PNL-THC:CBD soft gelatin capsule|2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
45621069|NCT03201835|Drug|CBD hard capsule dose 2|1 hard capsule containing 100 mg CBD
45621070|NCT03074721|Device|PCI Suite Software|PCI with PCI Suite Software
45621071|NCT03074721|Other|conventional PCI|conventional PCI without PCI Software
45763411|NCT01831583|Device|Measurement of PPG waveforms|The ViSi Vital Signs Monitor will measure PPG waveforms for 4 hours.
45763412|NCT01831583|Device|Measurement of Pulse Arrival Time (PAT)|The ViSi Vital Signs Monitor will measure PAT waveforms for 4 hours.
45763413|NCT02155543|Drug|AGN-223575 Formulation A|One drop of AGN-223575 Formulation A administered in the study eye(s) per protocol.
45763414|NCT02155543|Drug|AGN-223575 Formulation B|One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
45763415|NCT02155543|Drug|AGN-223575 Formulation C|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
45763416|NCT02155543|Drug|AGN-223575 Vehicle|One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.
45763417|NCT03214055|Drug|Mannitol|The mannitol has been administered routinely to prevent renal dysfunction in patients undergoing robot-assisted laparoscopic radical prostatectomy. Participants will receive the mannitol as part of routine medical care, and we will evaluate the change in optic nerve sheath diameters before and after mannitol administration.
45763418|NCT03405337|Drug|FVIII products|Adynovate, Eloctate, Afstyla, Kovaltry
45621072|NCT03199495|Other|electroacupuncture|acupuncture needle with TENS device
45621073|NCT03071367|Other|Clinical Simulation|
45621074|NCT02478515|Drug|Ranibizumab|Intraviteal injection of 0.5mg ranibizumab
45621075|NCT02448199|Drug|Meloxicam and Glucosamine|Experimental
45621076|NCT02448199|Drug|Meloxicam|Active Comparator
45621077|NCT02448199|Drug|Glucosamine|Active Comparator
45763419|NCT03405337|Drug|Conventional FVIII replacement therapies|Advate, Kogenate FS, Helixate, Novoeight, Nuwiq, Recombinate, Xyntha
45763420|NCT01831661|Drug|Metformin Hydrochloride Extended-Release Tablets USP 750 mg|Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
45621078|NCT03071289|Radiation|Radiation Method B|The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and included all the lymphocyst. The CTV is given a dose of 45Gy.
45621079|NCT03071289|Drug|Cisplatin|The regimen of chemotherapy is cisplatin 30mg/m2 every week.
45621080|NCT03071289|Radiation|Radiation Method A|The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and given a dose of 45Gy.
45621081|NCT05713409|Diagnostic Test|Intestinal ultrasound|As part of the routine care, patients will undergo ileocolonoscopy at 6 months, IUS will be performed 3, 6, 12, 18, 24, 30 and 36 months (using B-mode and CDS) and at 3 and 6 months elastography will be performed on the neo-terminal ileum. Biomarkers (CRP and fecal calprotectine) will be measured according to routine care.
45621082|NCT03199183|Radiation|PET-CT|PET-CT will be proceed on the basis of clinical status and aspiration of individual patient. The imaging results will be analysed by professional radiologists.
45763421|NCT01831661|Drug|GLUCOPHAGE®XR|GLUCOPHAGE®XR 750 mg once a day
45763422|NCT03403387|Dietary Supplement|GlutenShield|combination probiotic, prebiotic, and enzyme supplement
45763423|NCT03403387|Other|Placebo|Avicel (cellulose) and bentonite powder
45763424|NCT03213977|Drug|R-DA-EPOCH|R-DA-EPOCH-21 treatment without auto-SCT for DLBCL patients age between 16 to 60 years with intermediate and high risk for IPI.
45763425|NCT03213977|Drug|R-DA-EPOCH + auto-HSCT|R-DA-EPOCH-21 treatment with auto-SCT for DLBCL patients age between 16 to 60 years with intermediate and high risk for IPI.
45763426|NCT03213977|Drug|R-CEOP90|R-CEOP90 treatment without auto-SCT for DLBCL patients age between 16 to 60 years with intermediate and high risk for IPI.
45763427|NCT03213977|Drug|R-CEOP90 + auto-HSCT|R-CEOP90 treatment with auto-SCT for DLBCL patients age between 16 to 60 years with intermediate and high risk for IPI.
45621083|NCT03199183|Other|laboratory biomarker analysis|Screening of potential biomarkers related to Takayasu arteritis and verification tests will be operated.
45621084|NCT03199183|Genetic|genetic sequencing|Genetic sequencing results will be analysed to identify susceptible alleles or single nucleotide polymorphisms of Takayasu arteritis.
45621085|NCT04987827|Other|No intervention|No intervention
45763428|NCT03799432|Other|COAST-IS|COAST-IS has been designed to equip organizations with the knowledge, motivation, and skill needed to thoughtfully match implementation strategies to identified determinants by applying intervention mapping. The COAST-IS intervention will include four different modes of delivery: 1) dissemination of educational materials; 2) five web-based interactive education sessions on the need for tailoring implementation strategies and the application of intervention mapping; 3) site visits to discuss change objectives necessary to successfully implement trauma-focused cognitive behavioral therapy; and 4) organizational coaching related to using an intervention mapping approach.
45763429|NCT03799432|Other|TF-CBT Learning Collaborative|The learning collaborative model was adapted from the Breakthrough Series Collaborative model. Leadership of the collaboratives includes experts in evidence-based practices, implementation, and quality improvement. Main components include: 1) three face-to-face learning sessions (2-days each) that provide clinical training; 2) post-learning session action periods structured to facilitate therapists' application of learned skills; 3) a secure website to facilitate faculty-to-participant and peer-to-peer learning and document use of quality improvement methods; 4) fidelity monitoring and coaching; 5) a senior leader track supporting organizational change; 6) monthly outcomes monitoring; and 7) sustainability planning.
45763430|NCT03405181|Other|Training with additional weight|The infants will be positioned in a reclined position. A bracelet with an additional weight (20% of the total mass of the upper limb) will be placed on both wrists. The training will happen 2x/week, during 4 weeks (8 sessions). An object will be used to stimulate the reaching behavior, which will be displayed by the examiner (positioned in front of the infant), and presented in the midline at shoulder height, considering the distance from the arm's length of the infant to the height of the wrist. The physiotherapist will draw the attention of the infant to the object, moving it momentarily so that the infant perceives it and reaches it. After reaching, the object will be carefully removed and resubmitted in order to elicit a new movement. The interval between each presentation will be of approximately 5 seconds. At least 10 movements will be stimulated. If the infant does not achieve the 10 reaches within the maximum interval of 15 minutes, the session will be terminated.
45763431|NCT03405181|Other|Training without additional weight|The infants will be positioned in a reclined position. A bracelet without the additional weight will be placed on both wrists. The training will happen 2x/week, during 4 weeks (8 sessions). An object will be used to stimulate the reaching behavior, which will be displayed by the examiner (positioned in front of the infant), and presented in the midline at shoulder height, considering the distance from the arm's length of the infant to the height of the wrist. The physiotherapist will draw the attention of the infant to the object, moving it momentarily so that the infant perceives it and reaches the object. After reaching, the object will be carefully removed (or picked up) and resubmitted in order to elicit a new movement. The interval between each presentation of the object will be of approximately 5 seconds. At least 10 movements will be stimulated. If the infant does not achieve the 10 reaches within the maximum interval of 15 minutes, the session will be terminated.
45763432|NCT04375501|Other|Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail|If fit for anaesthesia patients may undergo relevant procedure for fractured neck of femur as per NICE guidelines within limitations of resources as defined by BOAST
45763433|NCT05311085|Drug|Cytisine|"Standard dosing of:~days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~days 13-16: one tablet every three hours (four tablets/day)~days 17-20: one tablet every 4-5 hours (three tablets/day)~days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)"
45763434|NCT05311085|Drug|Nicotine delivered via an e-cigarette|Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco
45763435|NCT05311085|Combination Product|Cytisine plus nicotine delivered via an e-cigarette|"Cytisine: Standard dosing of:~days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~days 13-16: one tablet every three hours (four tablets/day)~days 17-20: one tablet every 4-5 hours (three tablets/day)~days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)~Nicotine e-cigarette: Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco"
45763436|NCT00373516|Drug|Vehicle (Placebo) applied BID|
45763437|NCT00373516|Drug|QRX-101 75 mcg/g ointment applied QD|
45763438|NCT00373516|Drug|QRX-101 75 mcg/g ointment applied BID|
45763439|NCT04375579|Other|Comprehensive geriatric assessment (CGA)|Questionnaires on nutritional status, autonomy and quality of life
45763440|NCT03402217|Behavioral|Patient Centered Postpartum Contraception App|This is a theory-based smart phone-based application designed to provide immediate postpartum contraception information to young women aged 15-25.
45763441|NCT03219827|Other|Human biological samples|Blood samples collection
45763442|NCT03796468|Other|Best Medical Therapy|The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies. The rescue MT may be performed in case of deterioration within the 24 hours
45763443|NCT03796468|Procedure|Mechanical Thrombectomy|MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus medical, the MT is performed immediately after the randomization
45621086|NCT03314675|Device|BIOTRONIK CRT-D|Pre-specified follow-up and measurements
45621087|NCT04987437|Device|Friendly short stem|Total Hip Arthroplasty with Friendly Short stem
45621088|NCT03199105|Other|Preoperative education with image illustrations and/or local tetracaine mucilage|The patients were given preoperative education with image illustrations and/or local tetracaine mucilage to alleviate CRBD during the post-operative period.
45621089|NCT05713331|Behavioral|CLS-R|CLS-R Training includes school provider training in CLS via web platform and videoconferencing for workshops, consultation and coaching.CLS is a 10-12 week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom and home.
45621090|NCT03074799|Other|Symptom -based Screening(Child Contacts)|"Aim 1: Determine the number of child contacts per adult index case of tuberculosis to assess quality of contact tracing.~Aim 2: Determine the percentage of child contacts initiated on IPT or antituberculous therapy (ATT) and compare between intervention (symptom-based, nurse-led initiation of IPT) vs control clinics (TST-based screening with referral to hospital, current standard of care).~Aim 3: Compare outcomes of children initiated on IPT between both groups including: completion of therapy, discontinuation due to side effects, lost to follow up, and adherence while on therapy."
45763444|NCT04375423|Behavioral|Ecological momentary assessment and intervention: Behaviorally-dependent messaging|In response to behavioral data submitted intervention arm participants receive messages on their phones reinforcing healthy behaviors or encouraging alternative behaviors to limit risks
45763445|NCT04375423|Behavioral|Ecological momentary assessment only|Participants will receive twice daily and weekly prompts to submit behavioral report data and self-initiate event-contingent behavioral report data submissions
45763446|NCT03709732|Other|no intervention|observational study
45763447|NCT03211793|Drug|Mesenchymal stromal cells|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
45763448|NCT03211793|Other|Placebo|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
45763449|NCT03405103|Behavioral|Striving|
45763450|NCT03405103|Behavioral|Boning-Up|
45763451|NCT03405103|Behavioral|Personal Choice|
45763452|NCT03679468|Other|Cognitive Rehabilitation|"RehaCom software~Information processing speed and attention modules"
45763453|NCT03679468|Other|Sham Exercise|Sets of balance and stretching exercises
45763454|NCT03679468|Other|Sham Cognitive Rehabilitation|"Kompozer software~24 session module consisting of basic internet searches"
45763455|NCT03679468|Other|Aerobic Exercise|"Recumbent NuStep Bike~Aerobic cycling"
45763456|NCT03400267|Drug|Paracetamol|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
45621091|NCT03074799|Other|Clinical based Decisions|the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT
45763457|NCT03400267|Drug|Fentanyl|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
45763458|NCT04375345|Device|hip arthroplasty|complex primary total hip arthroplasty or revision total hip arthroplasty performed through anterolateral or posterolateral approach
45763459|NCT01831973|Drug|Lipotecan|
45763460|NCT03213821|Other|protein intake|For each participant, weighed food records of 3 consecutive days will be analyzed for estimation of calorie and macronutrient intake and dietary preferences. To make sure good compliance, diets will be developed regarding patient's dietary habits and preferences individually. High calorie (30-35 kcal/kg Ideal body weight) diets including 6-8 small meals will be formulated. Intervention group will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg IBW). Comparison group will receive protein based on GFR to preserve renal function. For older adults (>65 years) protein content of diet will be as recommended by the international study group to review dietary protein needs with aging (PROT-AGE). In subjects with lower intake of protein, carbohydrate will be substituted. Both group will receive low fat diet.
45763461|NCT01832051|Drug|89Zr-trastuzumab injection|
45763462|NCT00898937|Genetic|microarray analysis|tumor specimen will be assessed by microarray analysis
45763463|NCT00898937|Procedure|breast biopsy|A breast biopsy will be done to obtain a tumor specimen
45763464|NCT02785432|Device|Sham low level laser|Sham laser will be administered using the same time and contact exposure as delivered for the active group, but without any energy delivered.
45763465|NCT02785432|Device|Active low level laser|Active treatment will be delivered using the time, contact, and energy exposures described in the arm description.
45763466|NCT01832129|Drug|Oral administration of vitamin B12|Daily high dose oral vitamin B12 (1mg) will be administered over 4 weeks. The patients adherence to this regimen will be monitored with an electronic punch card.
45763467|NCT01832129|Drug|i.m. injection of vitamin B12|Intramuscular injections of 1 mg vitamin B12 will be performed at days 7, 14, and 21.
45763468|NCT03219359|Procedure|Autologous stem cell transplant|Hematopoietic stem cell transplantation
45763469|NCT03219359|Drug|Cyclophosphamide|Days 1 and 2: Cyclophosphamide 2gm/m2/day x 2 days (total dose 4gm/m2) Day 3 until leukapheresis: G-CSF 10μg/kg/day to CD34+ >20x104/ml then leukapheresis daily to collection goal
45763470|NCT03219359|Drug|Cyclophosphamide|Day -6 to -3: Cyclophosphamide 50 mg/kg/day (200 mg/kg total dose)
45763471|NCT03219359|Drug|Thymoglobulin|Day -3 to -1: 2.5 mg/kg/day (7.5 mg/kg total dose)
45763472|NCT03219359|Drug|Methylprednisolone|Day -3 to -1: 1 gram prior to each ATG dose
45763473|NCT03219359|Drug|Vedolizumab|Starting first day after discharge from transplant admission, then 2 weeks after 1st infusion, 4 weeks after 2nd infusion, followed by every 8 weeks for 52 weeks (8 doses)
45763474|NCT02786134|Radiation|PET scan|A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.
45763475|NCT02786134|Radiation|Echocardiogram|An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.
45763476|NCT04380857|Drug|Dexamethasone ophthalmic insert 0.4 mg|intrcanalicular dexamethasone insert
45763477|NCT03217643|Drug|Brentuximab Vedotin|The first part of the treatment (induction) will evaluate BV-CHP. The second part of the treatment (consolidation) will use standard drugs for the treatment of lymphoma. HDT will consist of BEAM conditioning regimen (or BAM if carmustine is not available). Management of HDT/ASCT will be done according to standard practice.
45621092|NCT03199027|Other|Adherence Club|Participants will be referred to an Adherence Club at 4 months post-ART initiation. Adherence club visits occur 2-4 monthly at a community hall near the Community Health Centre (CHC). At routine visits, which last 1-2 hours, community health workers provide health education, weigh patients, ask about symptoms and dispense pre-packed ART. Symptomatic patients are sent back to the ART clinic for clinician assessment. An assigned nurse takes blood tests annually at each club, and then returns on the subsequent visit to perform a clinical assessment and check the results. Patients requiring more follow-up or with high viral loads are referred back to the ART clinic at the CHC by the nurse.
45621093|NCT02482649|Behavioral|EAA/T|bi-weekly for 12weeks
45446169|NCT05342259|Procedure|Caudal nerve block /neuroaxial|"Technique of the caudal block The patient was placed in lateral decubitus position for blind caudal epidural block. A line was drawn to connect the bilateral posterior superior iliac crests and used as one side of an equilateral triangle; then the location of the sacral hiatus was approximated by palpating the sacral cornua as 2 bony prominences, the sacral hiatus was identified as a dimple in between. A needle was inserted at 45 degrees to the sacrum and redirected if the posterior surface of sacral bone was contacted.~A subjective feeling of loss of resistance suggests piercing the sacral ligament.The whoosh test, performed by auscultation at the thoracolumbar region with a stethoscope while injecting 2 mL of air, Palpating for subcutaneous bulging on rapid injection of 5 mL air or saline had a positive predictive value of 83% and a negative predictive value of 44%."
45621094|NCT02482649|Drug|Methylphenidate|dosage adjustment according to clinical effectiveness, QD for 12weeks
45621095|NCT02482649|Drug|Atomoxetine|dosage adjustment according to clinical effectiveness, QD or BID, for 12weeks
45621096|NCT03198637|Drug|Cisatracurium's monitoring by TOF (train-of-four) WATCH device.|Neuromuscular blockade's monitoring by Cisatracurium thanks to TOF (train-of-four) WATCH device.
45621097|NCT03198637|Drug|clinical assessment|
45621098|NCT02635347|Procedure|Remote Ischemic Conditioning (RIC)|Each RIC intervention will comprise three cycles of 5 minutes of inflation followed by 5 minutes of deflation of a pneumatic tourniquet placed in mid-thigh.
45621099|NCT02635347|Device|Pneumatic tourniquet|Portable Tourniquet System(PTSii, Delfi Medical Innovations, Inc.) used to perform RIC interventions.
45621100|NCT03314597|Other|Balance exercise|Patients in the balance exercise group received a personalized exercise program developed by an expert physiotherapist. There was no predefined duration for each item of the set of exercises, but all patients underwent an overall 45 min period training per day according to the same schedule. This schedule was based on the Otago Exercise Program and Practice Guidelines for the treatment of Parkinson's disease. Patients did not wear shoes for balance training. All exercises were performed without upper-limb support and with the supervision of a physiotherapist.
45621101|NCT03314597|Other|Mobile platform exercise|Patients entered the mobile platform and put on a security harness (no weight unloading), which they wore during the entire session on the platform training. The arms were free to move, but they were asked not to reach out for support. Each patient underwent 45 minutes of training (resting periods included), in which from 6 to 8 perturbation patterns were administered, each one lasting about 4 minutes. During training, the platform moved in the antero-posterior, latero-lateral and diagonal (45 deg) direction with respect to the body. The periodic platform displacement was 10 cm, regardless of the frequency, which could range from 0.3 to 0.6 Hz. Patients stood with eyes open and closed and feet together or 20 cm apart depending on the perturbation subtype.
45621102|NCT03211429|Behavioral|Cognitive behavioural therapy|The program aims to teach participants how to deal with their concerns about falls and related avoidance of activity
45621103|NCT03211429|Other|Tai chi|Tai Chi training in the Yang style of 24 movement
45621104|NCT03211429|Other|Postural control exercise|Individually adjusted progressive and specific postural control training,
45621105|NCT02478281|Drug|Methylene Blue|
45621106|NCT02482337|Procedure|POEM|POEM procedure in the OR
45621107|NCT03074565|Device|Ultrasonic alone|Sanative therapy using ultrasonic instrumentation alone
45621108|NCT03074565|Device|Ultrasonic+|Sanative therapy using ultrasonic plus hand instrumentation
45621109|NCT03211039|Genetic|Genomic sequencing and molecular diagnostic results, if any.|Patients and their families will be randomized to either receive whole genome sequencing or whole exome sequencing.
45621110|NCT02482415|Other|Psycho-educational|
45621111|NCT03209947|Diagnostic Test|Ulnar nerve Ultrasound|No drug and no placebo were used in this arm. Patients were followed by Ultrasound approach by measure of ulnar nerve surface
45621112|NCT02478125|Drug|Burixafor Hydrobromide|Investigators will determine the kinetics of PCa cell release into the blood with four daily dosages of Burixafor hydrobromide alone or in combination with G-CSF
45763478|NCT02903446|Drug|Denosumab|Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy
45763479|NCT01832285|Drug|fluvoxamine|100mg/day, PO(in the mouth) each day during 6 weeks
45763480|NCT01832363|Drug|HXe MRI guided treatment sequence for BT|HXe MRI consists in imaging the inhaled xenon gas inside the human lungs during a short breath-hold. High resolution 3D maps of the HXe distribution inside the lungs provide information regarding ventilation of the lungs, as the signal is proportional to the local concentration of HXe. A high MRI signal translates in unobstructed ventilation, while ventilation defects appear as dark regions on the map. HXe MRI will be performed pre and post bronchodilator in order to determine the airways which potentially are the most responsive to BT treatment. All HXe MRI images will be repeated within the same day for consistency check and after three weeks to study temporal variability. The reactivity of the airways will establish the treatment order, with the most problematic airways to be treated in the first BT session (not to exceed six).
46069234|NCT03641300|Device|Electroconvulsive Therapy (ECT)|In the ECT arm treatment, the MECTA spectrum 5000Q machine will be used, which is an FDA approved device used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes
45621113|NCT02478125|Drug|Docetaxel|Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV. The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2
45763481|NCT01832363|Other|Standard treatment sequence for BT (control)|Patients undergoing standard BT procedure will have HXe MRI performed at time intervals similar to HXe MRI guided BT patients. While HXe images will not be used for guiding the sequence for airways to receive the BT treatment, metrics extracted from HXe images will be compared with clinically accepted asthma severity metrics (spirometry and asthma questionnaires) to assess HXe MRI as a biomarker for asthma severity.
45621114|NCT02478125|Drug|G-CSF|G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
45621115|NCT03070197|Other|Exposure of interest: Brain MRI|Brain MRI will be conducted in all participants
45621116|NCT03070197|Other|Exposure of interest: neurodevelopmental assessments|neurodevelopmental testing will be conducted in all participants.
45621117|NCT02448121|Procedure|Autologous bone marrow stem cell graft|All patients will undergo autologous bone marrow stem cell implantation into the necrotic lesion area using a minimally invasive technique.
45621118|NCT02478047|Drug|only antiemetic (Ramosetron, Tropisetron and dexamethasone)|The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.And plus antiemetic drug as the comparator group.
45621119|NCT02478047|Other|Matching points ST36+CV12 plus antiemetic drug|"Choose both Zusanli(ST36) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
45621120|NCT02478047|Other|Matching points PC6+CV12 plus antiemetic drug|"Choose both Neiguan(PC6) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
45621121|NCT02478047|Other|Matching points CV13+CV12 plus antiemetic drug|"Choose both Shangwan(CV13) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
45621122|NCT04996485|Drug|Secukinumab Injection|Pathogenetic therapy with biologic drugs
45621123|NCT04996485|Drug|Ustekinumab Injection|Pathogenetic therapy with biologic drugs
45621124|NCT04996485|Drug|Dupilumab Injection|Pathogenetic therapy with biologic drugs
45621125|NCT04996485|Other|Symptomatic therapy|Active external agents, Emollients, systemic retinoids if needed
45621126|NCT02447965|Drug|Bupivacaine|Using ultrasound guidance bupivacaine will be injected into the active group's rectus abdominis sheath.
45621127|NCT02447965|Drug|Normal Saline|Using ultrasound guidance normal saline will be injected into the placebo group's rectus abdominis sheath.
45621128|NCT05713175|Device|EVA plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 45º shore A hardness Ethyl Vinyl Acetate (EVA), which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.
45621129|NCT05713175|Device|Polypropylene plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 4mm polypropylene, which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.Orthosis fabricated following the inverted orthotic technique.
46069235|NCT03623139|Behavioral|Standard nutritional education|Routine dietary care consists of three individual consultations with a trained dietitian. The individual guidance will be in accordance with the dietary guidelines in type 2 diabetes.
46069236|NCT03623139|Behavioral|Basic carbohydrate counting|The BCC concept is a group-based program consisting of three group sessions delivered by trained dietitians.
45763482|NCT02903836|Drug|Nafithromycin 800 mg 3 days|
45763483|NCT02903836|Drug|Nafithromycin 800 mg 5 days|
45763484|NCT02903836|Drug|Moxifloxacin 400 mg|
45763485|NCT01832441|Other|Intra thecal transplantation of autologous MNC|Intra thecal inj.of 100 millions MNC in 3 doses at 7 days interval
45763486|NCT00014911|Procedure|Islet Transplantation|Participants will receive portal vein islet infusions (up to 3), e.g., islet transplantations, with a targeted total of exceeding 10,000 islet equivalents per kilogram of body weight (IE/kg) per infusion. Up to three transplants are possible depending on individual results.
45763487|NCT00014911|Drug|Sirolimus|Administered at a dose of 0.2 mg/kg by mouth once pre-transplantation then 0.1 mg/kg daily post-transplantation. Dosing will be adjusted to achieve a trough peripheral blood level of 12-15 ng/mL x3 months after transplantation and 7-12 ng/mL for the remainder of the study.
46069237|NCT03617562|Procedure|Superior Capsular Reconstruction|Residual rotator cuff defect is reconstructed with a dermal allograft secured to the glenoid and humeral head.
46069238|NCT03617562|Procedure|Partial Repair|Rotator cuff is repaired with residual defect remaining.
45621130|NCT05713175|Device|Fixtoe device|Fixtoe Device, simulating the metatarsophalangeal stabilization tape technique is worn for one month, prior to definitive treatment consisting of a personalized plantar orthosis.
45763488|NCT00014911|Drug|Tacrolimus|Administered at a dose of 1 mg by mouth once pre-transplantation followed by 1 mg twice daily post transplantation. Levels will be adjusted to achieve a peripheral blood trough level of 3-6 ng/mL for maintenance immunosuppression.
45763489|NCT00014911|Drug|Daclizumab|Administered at a dose of 1 mg/kg intravenously immediately pre-transplantation and 2, 4, 6, and 8 weeks post-transplantation, totaling 5 doses(over 8 weeks). Further daclizumab dosing may be necessary based on individual results and islet transplantation needs.
45763490|NCT00014911|Drug|Sulfamethoxazole|An antibacterial used to prevent opportunistic infections
45763491|NCT00014911|Drug|Ganciclovir|An antiviral used to kill viruses and stop viral replication
45621131|NCT03070275|Biological|Biocomplex: aBM-MSCs/fibrin glue/collagen fleece|Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
45621132|NCT03070275|Procedure|Two-stage surgical implant placement|Implants are surgically placed on the alveolar crest following a two-stage protocol and the manufacture's guidelines with no adjunctives.
45621133|NCT02450695|Device|rTMS|
45621134|NCT03070041|Other|Baby-friendly Hospital Initiative|The intervention is Baby-friendly Hospital Initiative as described by WHO and UNICEF. The ten steps to successful breastfeeding will be implemented in the hospital.
45621135|NCT03209557|Other|SmartWatch SmokeBeat Application|The SmokeBeat app is a digital health app that allows for the user to monitor their smoking behavior in real time, set smoking cessation goals, and allows investigators, doctors and others using the app with participants to send messages directly related to smoking behavior. The SmokeBeat app, developed by Somatix Inc., will collects time-stamped on hand movements associated with smoking behavior. Participants will receive notifications on their phone and smartwatch when a smoking bout has been detected. In addition this app will deliver daily text messages aimed at improving quit rates among participants. We will be able to create the types of messaging we want to send and to modify when these messages will be sent to all participants. http://somatixinc.com/smokebeat/
45621136|NCT02482103|Procedure|Renal denervation|Catheter based renal nerve ablation
45763492|NCT00014911|Drug|Trimethoprim|An antibacterial used to prevent opportunistic infections
45446170|NCT05342259|Procedure|Dorsal penile nerve block|"Technique of Dorsal penile nerve block:~Under aseptic technique and under ultrasound guidance. A 'hockey-stick' probe was used, covered by transparent sterile dressing. The probe was placed vertically over the pubic symphysis and the base of the penile shaft. With adjustment of the probe, a sagittal view of the penile shaft was produced. Scarpa's fascia was seen as a hyperechoic line superficial to the penile shaft. Under real-time guidance, the needle was inserted and advanced until its tip laid deep to Scarpa's fascia (i.e., within the subpubic space), where local anesthetic was deposited. The local anesthetic solution injected was 0.5% bupivacaine in a recommended volume. (2 ml up to 3 years and an additional 1 ml for each3 years up to maximum 6 ml)."
45621137|NCT03070977|Other|Interprofessional clinical training unit|"In 2015, Psychiatry in Slagelse established an interprofessional clinical training unit. The aim was to create a new environment for learning, where students could learn from each other and develop competence in interprofessional collaboration. In the training unit there are more students than in the other standard psychiatric wards and several professions are included.~A facilitator team is responsible for the interprofessional training. In autumn 2016 seven professionals participate in course of facilitating interprofessional collaboration and training. The intervention involved the total staff participation in an initial workshop.~The training unit is based on two educational interventions: Student participation in clinical care teams and interprofessional group tuition sessions."
45621138|NCT03209635|Dietary Supplement|Placebo|4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
45621139|NCT03209635|Dietary Supplement|Probiotic|4 capsules (300 mg/capsule) containing each capsule 1.0 x 10^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
45763493|NCT00014911|Drug|Pentamidine|An antiprotozoal used to prevent disease
45763494|NCT01832675|Drug|Xylocain, cutaneous spray, solution|10 mg lidocaine/spray. The patient will be sprayed three times and get a maximal dose of 30 mg lidocaine just before the examination.
45621140|NCT05713097|Diagnostic Test|TSI|TSI was measured several times during the course of treatment when planning to stop medication (at the discretion of the attending physician).
45763495|NCT01832675|Drug|Bupivacaine lozenge|25 mg bupivacaine/lozenge. The patient will get one lozenge 10-15 minutes before the examination.
45621141|NCT03198481|Behavioral|Patient-Centered Counseling Video|Patients will watch a patient-centered education video regarding MUS prior to standard pre-operative counseling.
45763496|NCT03213587|Drug|Apatinib|500 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
45763497|NCT00013897|Drug|Atazanavir|
45763498|NCT00013897|Drug|Lamivudine/Zidovudine|
45763499|NCT00013897|Drug|Efavirenz|
46069239|NCT03601078|Biological|bb2121|bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)
46069240|NCT03601078|Drug|Lenalomide|Specified dose on specified days
46069241|NCT03591510|Drug|Midostaurin|midostaurin 30mg/m2 bid
46069242|NCT03591510|Drug|Fludarabine|30mg/m2/day on D1-D5 of Block 2 FLADx
45621142|NCT03198481|Behavioral|Physician Counseling Video|Patients will watch a physician-centered video regarding MUS prior to standard pre-operative counseling.
45621143|NCT05713019|Device|Adenosine triphosphate (ATP) solution inhalation from nebuliser|ATP and 0.9% saline solution will be inhaled from a nebuliser on separate days, and their effects will be examined.
45621144|NCT05713019|Diagnostic Test|Inhalational challenge with increasing concentrations of capsaicin solutions|Coughs are counted for one minute after single-breath inhalations of 0.9% sodium chloride and capsaicin solutions of increasing concentrations (0.98-500 μm) generated from a dosimeter (P.K. Morgan Ltd, Gillingham, UK) set at a dosing period of 1 s. The concentration that caused more than 2 or 5 coughs was recorded as C2 and C5, and the data is analysed as log10 C2 or C5.
45621145|NCT05713019|Device|Recording of Cough Count and frequency using the Hyfe Cough Monitor|"All enrolled study participants will be provided with a dedicated Android phone or watch loaded with the Hyfe Research application to monitor and record their cough sounds. The participant will be provided with a carrying case to ensure the phone stays within five feet of their mouth. They will be asked to wear the phone for the duration of 3 weeks, and keep the phone within five feet of their mouth over nights - keeping it, i.e., on a bedside table.~Hyfe is a research use only tool which does not provide clinical diagnosis. Cough collection within this study will not lead to specific medical interventions or differential clinical management. Hyfe records only short snippets (<0.5 seconds). As such, the recordings will not be identifiable. Conversations or acoustic environments are not recorded. The informed consent form will explicitly describe exactly what is recorded."
45621146|NCT05713019|Procedure|Collection of exhaled breath condensate|EBC will be collected by asking the subject to breathe normally onto a handheld breath collection apparatus from Respire Diagnostics, Imperial College, that will cool the exhaled breath to allow for condensation of the exhaled air. The subject will breathe for 2 periods of 5 minutes each separated by a 3-4 min rest to allow the collection of up to 500 uL of liquid. The liquid will be stored for later analysis.
45621147|NCT05713019|Diagnostic Test|Continuous laryngoscopic examination|Continuous laryngoscopy testing is performed based on previous methodology. Continuous laryngoscopy testing is performed by placing a fibreoptic nasendoscope in the posterior nasopharynx and securing it using specialist headgear. A small quantity of lubricating jelly is used to ease passage of the scope. Video images of the laryngeal inlet are, thereafter, continuously recorded whilst a subject performs various manoeuvres including respiratory movements and cough. These movements will be observed and recorded before and following the various aspects of the challenge protocol and thus allow us to evaluate laryngeal movement abnormalities and for example position of the vocal folds. The size and change in size of the glottic aperture will be evaluated.
45621148|NCT05713019|Diagnostic Test|Sputum induction|"Sputum is induced by inhalation of an aerosol of sterile 3% saline solution and subsequently increasing to 4% and 5% during 3 periods of 5 minutes each. Particular care is taken to avoid contamination with saliva and post-nasal drip by instructing subjects to rinse orally with water and to blow their nose after each inhalation. Sputum samples are collected into sterile pots. Peak flow measurements are made after each inhalation. If there is a fall in peak flow of 20% or more or if symptoms occurred during the procedure, the induction is stopped.~Sputum plugs are selected and one portion is used to perform differential cell counts. To perform differential cell counts, dithiothreitol is added to the sputum plug and mixed vigorously on a plate shaker to solubilize the sputum. Cytospins are then prepared, and differential cell counts obtained."
45621149|NCT05713019|Diagnostic Test|Spirometric measurements|Spirometry (FEV1 and forced vital capacity, FVC) is measured using a dry wedge spirometer (Vitalograph, Buckinghamshire, UK).
45621150|NCT05713019|Diagnostic Test|Blood sample collection|Venous blood (30 cc) will be taken from a vein in the forearm. This test causes a transient discomfort as a needle is used to obtain the blood sample. The blood sample will be used for measuring various proteins and for getting white blood cells to obtain some types of stem cells.
45621151|NCT04990089|Device|VIVO|VIVO is a per-procedural planning tool designed to non-invasively identify the origin of a ventricular arrhythmia.
45621152|NCT03198403|Drug|Bupivacaine-epinephrine|Popliteal plexus block with 10 mL of bupivacaine-epinephrine 5 mg/mL + 5 microgram/mL.
45621153|NCT03314441|Behavioral|Yoga|4 yoga lessons with and instructors on a 3 months period. Patients are asked to exercise yoga daily for 5 to 30 minutes.
45621154|NCT03198793|Drug|QGC001|Twice daily (BID) administration of oral (PO) QGC001 (250 mg BID, 500 mg BID, and 500 mg BID + hydrochlorothiazide (HCTZ) 25 mg once daily [QD]) over 8 weeks.
45621155|NCT04990245|Diagnostic Test|endoscopic biopsies|patients with planned endoscopy for ulcerative colitis have endosocpic data recorded aswell as biopsy sampling and blood tests
45621156|NCT03198949|Drug|Afinitor (everolimus)|"Everolimus doses will be 4.5mg/m2 po daily given at first time and then during the 4-week titration period everolimus dose may get adjusted to reach trough concentration of 5 - 15 ng/mL.~(In order to keep the blind, placebo doses will be also adjusted during core phase based on a random scheme of dose changes.)"
45621157|NCT04990011|Procedure|BioXclude amnion chorion membrane|The OAC will be closed by the Bioxclude ACM Amnion chorion membrane which is applied over the extraction socket then supported with a buccal advanced flap.
45621158|NCT02447809|Drug|Clopidogrel|(ASA 100mg daily and Clopidogre 75mg daily)* 12 month.
45621159|NCT02447809|Drug|acetylsalicylic acid (ASA)|
45621160|NCT04989933|Procedure|Ultrasound-guided erector spinae plane block|Ultrasound-Guided erector spinae plane block with 0.25% bupivacaine
46069243|NCT03591510|Drug|Cytarabine|"Part 1:~2000mg/m2/day D1 to D5 of Block 2 FLADx 1000mg/m2 every 12 hours D1 to D3 Block 3 HAM 3000mg/m2 every 12 hours D1 to D3 Block 4 HA3E 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC~Part 2:~1000mg/m2 every 12 hours D1 to D3 Block 2 HAM 3000mg/m2 every 12 hours D1 to D3 Block 3 HA3E 1000mg/m2 every 12 hours D1 to D3 Block 4 HAM 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC"
45446171|NCT05342259|Procedure|Combined caudal and dorsal penile nerve block|Combined techniques of caudal and dorsal penile nerve block
45763500|NCT03219983|Drug|Ropivacaine|Patients will have an interscalene block under ultrasound guidance and receive .5% ropivacaine pre-operatively. Upon arrival to the Post-Operative Care Unit a continuous infusion of .5% ropivacaine will be started at 8ml/hr and increased by 2ml/hr every 15 minutes for pain score > 4 with a maximum rate of 14ml/hr. Infusion will be delivered by ON-Q Select-a-Flow pump (volume 750ml)
45763501|NCT03219983|Drug|liposomal bupivacaine|A total injection volume of 100ml will be comprised of 60ml 0.9% normal saline+ 20ml .5% bupivacaine + 20ml liposomal bupivacaine will be administered into the deep tissue of the operative are with an 18 or 20 gauge needle.
45621161|NCT05712863|Device|BreatheSmart|BreatheSmart is a comprehensive asthma monitoring system combining medical devices and a mobile application designed for use with iOS and Android operating systems. Using Bluetooth to connect, the devices sync with the mobile application to facilitate the collection of medication adherence and lung function data.
45763502|NCT03219905|Device|Therapeutic Kinesio-taping|"The experimental group received a therapeutic Kinesio Tape application. Three I strips were applied to the both ankle joints for joint stability with subject's ankle at 90 degrees."
45621162|NCT04989855|Drug|Fruquintinib plus Tislelizumab|2 cycles of Fruquintinib(F) 5mg QD d1-d14 + Tislelizumab(T) 200mg IV d1, Q3W as preoperative therapy, and F +T after TME as postoperative therapy for 6 months
45763503|NCT03219905|Device|Sham Kinesio-taping|"The control group received a sham Kinesio Tape application. Ankle position was hold at minimally plantar flexion during taping. AI strip was placed from the anterior midfoot, not stretched and attached to the midline of anterior leg."
45763504|NCT03219749|Behavioral|exercise training|Eligible participants will undergo 6 weeks of a combined aerobic and resistance exercise intervention. Training will take place 3 times per week for 1 hour. Forty minutes will be dedicated to aerobic training while 15 to 20 minutes will be devoted to resistance training.
45763505|NCT04347577|Drug|duloxetine|open-label study
45763506|NCT02240017|Drug|Carboplatin|Carboplatin AUC (area under curve) 4,5 at day 1 of each cycle until 6 cycles.
45763507|NCT02240017|Drug|Fractionated Cisplatin|Cisplatin 35mg/m² at day 1 and day 8 of each cycle until 6 cycles.
45621163|NCT03198325|Other|Stop of ART|Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values >50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.
45621164|NCT04987125|Behavioral|Dyspnea Neuroscience education|"Patients will follow an online therapeutic education course about dyspnea. Education about the cognitive and emotional aspects of dyspnea processing, with the goal of changing maladaptive cognitions and behaviors.~The course will be group-based (5 participants). The frequency will be of 1 session per week for 4 weeks, each session will have a duration of 1 hour."
45621165|NCT04987125|Behavioral|Usual care|General health advice, physiotherapy treatment. The frequency will be of 1 session per week for 4 weeks, each session will have a duration of 1 hour.
45621166|NCT04492163|Device|TTFields|"TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.~Other Names:~• TTFields"
45763508|NCT02240017|Drug|Gemcitabine|Gemcitabine 1000mg/m² at day 1 and day 8 of each cycle until 6 cycles.
45621167|NCT03209245|Biological|Purethal Mites|perennial allergren specific immunotherapy during 24 months
45763509|NCT00899717|Procedure|Occlusal adjustment|modification of occlusal surfaces
45621168|NCT03209245|Other|placebo injection|perrenial injection wich were administered in same protocol as Purethal
45763510|NCT00899717|Procedure|Placebo occlusal adjustment|Simulated modification of occlusal surfaces
45621169|NCT03209245|Diagnostic Test|monitoring of allergen specific IgE|measurement the serum specific IgE at the start and at the end of trial
45621170|NCT03209245|Diagnostic Test|monitoring of allergen specific IgG4|measurement the serum specific IgG4 at the start and at the end of trial
45621171|NCT04915287|Drug|Avatrombopag maleate|"Mean baseline platelet count 40 to less than 50 × 10^9/L: 40mg Avatrombopag QD × 5 days from 10-13 days pre-procedure~Mean baseline platelet count less than 40 × 10^9/L: 60mg Avatrombopag QD × 5 days from 10-13 days pre-procedure"
45621172|NCT04915287|Biological|Platelet transfusion|Mean baseline platelet count less than 50 × 10^9/L pre-procedure: platelet transfusion if needed
45621173|NCT04915287|Drug|Medicine|Mean baseline platelet count less than 50 × 10^9/L pre-procedure: rhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc.
45763511|NCT04374955|Dietary Supplement|Activia Probiotics Shot|The product contains Actiregularis - at least 2x106 cfu / g.
45763512|NCT04374955|Other|Routine care|Routine care of the hospital will be provided.
45763513|NCT03219593|Drug|Apatinib mesylate tablets|Apatinib is taken 500 mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death. The dose of the study drug may be decreased to 250 mg/d following the occurrence of a clinically significant adverse event (AE). Treatment will be discontinued if the subject is unable to tolerate a daily dose of 250 mg.
45763514|NCT02240095|Behavioral|Intervention A - Online Clinical Questions Recorder|Students allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
45763515|NCT02240095|Behavioral|Intervention B - Online Evidence Retrieval Coach|Students allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
45763516|NCT02240095|Behavioral|Intervention C - Online Audit and Feedback|Students allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
45763517|NCT04375267|Drug|177Lu-DOTA-TATE + olaparib|177Lu-DOTA-TATE in four cycles in combination with escalated doses of olaparib
45763518|NCT03836807|Drug|Ketoprofen|40 mg KLS granules (corresponding to 25 mg ketoprofen)
45763519|NCT03836807|Other|Placebo|0 mg KLS granules
46069244|NCT03591510|Drug|Daunorubicin or idarubicin|daunorubicin 60 mg/m2/day OR idarubicin 12mg/m2/day On D2, D4, D6 of Block 2 FLADx
46069245|NCT03591510|Drug|Mitoxantrone|10mg/m2/day D3 and D4
46069246|NCT03591510|Drug|Etoposide|100mg/m2/day D1 to D5
45621174|NCT05709353|Behavioral|Prolonged exposure therapy|"COPE represents an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence (see manual DOI: 10.1093/med:psych/9780199334513.001.0001). COPE used in the current study will represent an integration of existing evidence-based manualized CBT interventions for PTSD and substance dependence. COPE only begins when the participant in a safe environment and no longer in contact with the traumatic event/exposure.~COPE employs imaginal and in vivo exposures to treat PTSD and consists of 12 individual 90-minute sessions (ie, 19.5 hours) delivered by a clinical psychologist."
45621175|NCT05709353|Drug|MDMA|Administration of 80 to 160 mg MDMA across two 'dosing' sessions. Supplemental doses (additional 40mg during first session, additional 40- 80mg during second session) will be dependent on clinician and patient consensus during preparatory period of 'dosing session'. These supplemental amounts will be dispensed 60 to 90 minutes after initial 80 mg dose.
45621176|NCT05709353|Drug|Placebo|Administration of inactive placebo during two 'dosing' sessions.
45763520|NCT03404713|Behavioral|Pathways to Health|Manualized sessions will follow an acceptance based behavioral weight loss treatment approach, including guided goal-setting and self-monitoring, identifying barriers and solutions, contingency management, stimulus control, dealing with setbacks and relapse prevention. Daily food and physical activity are logged and monitored. Parents learn strategies to support and facilitate their child's weight management via family-based change.
45763521|NCT03404713|Behavioral|Be4U|This intervention is grounded in Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), and Acceptance and Commitment Therapy (ACT). The core elements include regulating eating patterns, self-monitoring, developing openness to an acceptance perspective, fostering a willingness to accept distress, teaching defusion from distressing thoughts and feelings, practicing mindful awareness, fostering self-as-context, and directing patients towards clarifying and focusing on life values. Self-monitoring of eating behaviors and emotions are encouraged using a free app that facilitates electronic self-monitoring of eating patterns and symptoms. For participants who elect not to use this app, paper self-monitoring records are provided.
45763522|NCT03213197|Other|CPR video|Patient watches a short CPR video
45763523|NCT02240173|Dietary Supplement|Jobelyn|Jobelyn is a dietary supplement made from Sorghum bicolor
45621177|NCT03195673|Drug|Terazosin|TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.
45621178|NCT03195673|Procedure|Carotid artery stenting|Carotid artery stenting is an alternative treatment of carotid artery stenosis, which would be performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.
46069247|NCT03582956|Procedure|Euglycemic hyperinsulinemic clamp with tracer enhancement|To characterize the impact of adiposity on metabolism during puberty, adolescents will undergo the euglycemic hyperinsulinemic clamp study with tracer enhancement.
45621179|NCT02481791|Drug|Remifentanil and/or propofol|Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.
45621180|NCT02481791|Drug|Remifentanil and/or propofol|Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.
45621181|NCT02481791|Drug|propofol|Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min
45763524|NCT02240173|Drug|Haloperidol|Conventional drug normally used for psychotic problems
45763525|NCT01832909|Other|Walnut Diet|Controlled diet with 1.5 oz/d of walnuts.
45763526|NCT01832909|Other|Control Diet|Controlled diet without walnuts.
45763527|NCT02240641|Drug|Lacidipine|
45763528|NCT02240641|Drug|Diuretics|
45763529|NCT02240641|Drug|antihypertensive drugs|
45763530|NCT02240641|Drug|alpha blockers|
45935163|NCT04722757|Procedure|tabd-IPAA|Patients in the control group will undergo a rectal dissection by laparotomy, Pfannenstiel incision, (hand-assisted) laparoscopy, single port laparoscopy or robotic surgery, but performed from the abdominal side (tabd-IPAA). Dissection will be performed down to the pelvic floor and include the distal rectum. It is anticipated that most dissection will occur using the TME plane, however, close rectal dissection is also acceptable. Transection of the distal rectum approximately 2 cm above the dentate line will be performed using a linear stapler of the surgeon's choice. After placing the anvil in the J-pouch, a circular stapler will be introduced through the sphincter and a circular anastomosis will be performed. A defunctioning loop ileostomy can be placed according at the surgeon's discretion.
45935164|NCT00217828|Drug|citalopram|
46069248|NCT03582956|Procedure|Euglycemic hyperinsulinemic clamp with tracer enhancement|A comparison control group of 36 lean young adults with T1D will also be enrolled, since they will be unaffected by the adverse metabolic effects of puberty or obesity.
46069249|NCT03564132|Drug|Yigansan|Yigansan granules
46069250|NCT03564132|Drug|Placebo|One-tenth concentration of Yigansan manufactured to mimic Yigansan granules
45621182|NCT02447731|Device|"Induction of sound waves in lungs by sonic oscillator"|A device called sonic oscillator will add sonic waves to the inhaled gases while the subjects are going through 3 tests measuring the variations made in pulmonary functions induced by sound waves.
45763531|NCT02240641|Drug|Angiotensin-Converting Enzyme Inhibitors|
45621183|NCT03314285|Other|Sleep Quality|Sleep quality to be measured by the Pittsburgh Sleep Quality Scale.
45621184|NCT04484467|Dietary Supplement|Food Supplement With Standardized Menthol, Limonene, and Ginger|Components of Standart Zdorovya GASTRO: Peppermint oil (40% menthol, 1.5% limonene) - 240 mg, Ginger oil (14% gingerol) - 50 mg, olive oil - 440 mg, 1 capsule, 730 mg, once a day for 30 days
45621185|NCT04484467|Other|Placebo|Components of placebo Olive oil - 730 mg, 1 capsule, 730 mg, once a day for 30 days
45763532|NCT02240641|Drug|beta blockers|
45763533|NCT03219671|Drug|Nivolumab|nivolumab 240mg every 2 weeks
45763534|NCT03219671|Drug|Ipilimumab|ipilimumab 1 mg/kg every 6 weeks
45763535|NCT03404635|Drug|Apixaban|Apixaban as standard of care for VTE
45763536|NCT03404635|Drug|Rivaroxaban|Rivaroxaban as standard of care for VTE
45763537|NCT03213275|Other|Microbiome Sequencing, Neurophysiologic Assessment, Immunological test|Stool sampling, aEEG, VEP, NIRS, ydTCR, Treg, biomarker
45621186|NCT03209167|Behavioral|Questionnaire|Two study-specific questionnaires
45621187|NCT02478203|Device|Airtraq|videolaryngoscope for difficult airway
45621188|NCT02478203|Device|Glidescope|videolaryngoscope for difficult airway
45621189|NCT02478203|Device|direct laryngoscopy|gold standart for intubation
45621190|NCT03198247|Other|Usual care|"The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises."
45621191|NCT03198247|Other|PNE + CST|The PNE and CST program will be divided in 3 individual sessions.
45621192|NCT03198169|Device|Atteris Antimicrobial Skin and Wound Cleanser|Wounds will be cleansed with either the experimental wound cleanser or a placebo and will then be covered with standard of care wound dressings.
45763538|NCT03404557|Other|Proteomic analysis|Proteomic analysis of Crohn's disease macrophages in response or not to Adherent-Invasive Escherichia coli
45621193|NCT03198169|Device|Atteris Antimicrobial Barrier Film Dressing|Wounds will be covered with either the experimental barrier film dressing or a placebo and will then be covered with standard of care wound dressings.
45621194|NCT03195361|Device|SRS - Self Retaining Support system|
45621195|NCT02726399|Drug|Ramucirumab|Ramucirumab 8mg/kg administered intravenously on days 1 and 8 ever 21 days
45763539|NCT01832987|Drug|co-trimoxazole|On 4, 5 or 6 consecutive days, co-trimoxazole 960 mg will be added to the normal treatment regimen
45763540|NCT03404479|Drug|Diacerein|For 12 weeks, administered twice a day by oral.
46069251|NCT03563339|Behavioral|P-POD|. P-POD will include seven 30-minute online, educational, interactive modules that teach at-risk pregnant women skills derived from the gold standard, empirically supported cognitive-behavioral treatment for anxiety disorders and OCD. Additionally, P-POD will include three modules for fathers, to help them support their partners during the postpartum period. We will modify P-POD from an already existing in-person prevention program for postpartum OCD (developed by Co-Investigator Kiara Timpano). The m-health foundation of P-POD will be an already existing Internet-delivered treatment infrastructure (OurRelationship.com, developed by Co-Investigator Brian Doss).
45621196|NCT02726399|Drug|Trastuzumab|Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
45621197|NCT02726399|Drug|Capecitabine|Capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period
45621198|NCT02726399|Drug|Cisplatin|Cisplatin 80mg/m2 administered as an IV infusion every 21 days
45621199|NCT03198091|Drug|Dun Ye Guan Xin Ning|Dun Ye Guan Xin Ning tablet 320 mg orally every time and 3 times per day for 6 months.
45621200|NCT03209323|Device|electroencephalography (EEG)|Four EEG channels were recorded using electrode positions as defined in the International 10-20 System with Ag/AgCl2 cup electrodes (Spes Medica) attached to the scalp with EC2 Electrode Cream (Grass Technologies). The impedance was set below 1 k, and the electrodes were attached to module S/5 E-EEG of the anaesthetic monitor S/5 (GE Healthcare).
45763541|NCT03404479|Drug|Celecoxib|For 12 weeks, administered twice a day by oral.
45763542|NCT03837665|Biological|Platelet Rich Plasma|Platelet Rich Plasma (PRP) is blood plasma that has been enriched with platelets.
45763543|NCT03219203|Biological|Hepatitis B vaccine|Hepatitis B vaccine (20 µg/ml) 1 ml intramuscular injection in single (at 0 month) or 3-dose series (at 0, 1, 6 months)
45763544|NCT04374643|Other|Slef questionnaires fulfilment|Questionnaires to assess the psychological impact of confinement and its evolution over 6 months
45763545|NCT04374487|Drug|Convalescent Plasma|200 ml of ABO compatible plasma transfusion will be done to the subject randomized for the test arm therapy
45763546|NCT04374487|Other|Standard Care Therapy|Subjects randomized to control group will be on standard care treatment according to Institutional Protocols.
45763547|NCT04380467|Dietary Supplement|Vitamin D (cholecalciferol)|(aviticol) 5x 20,000unit capsules administered monthly over 20 weeks
45763548|NCT03218735|Procedure|Labor induction at 37.0 weeks to 37.6 weeks of gestation|Diagnosis of LGA with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
45763549|NCT03218735|Procedure|Expectant monitoring and delivery|Diagnosis of LGA with expectant monitoring and delivery as indicated by standard obstetric practices
45763550|NCT04374409|Dietary Supplement|High-flavanol cocoa powder|Non-alkalized fat-reduced cocoa powder (Natural Acticoa)
45763551|NCT04374409|Dietary Supplement|Low-flavanol cocoa powder|Alkalized fat-reduced cocoa powder (10/12 DDP Royal Dutch)
45763552|NCT03218579|Dietary Supplement|Probiotic treatment|4 weeks of probiotic treatment after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
45763553|NCT03218579|Biological|Bacteriotherapy|Bacteriotherapy (autologous fecal microbiota transplantation) after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
45763554|NCT04374331|Other|video-assisted training|The patients in the VAT group watch a training video in the patient rooms before RCR. The VAT prepared by the researchers consisted of information about things to pay attention to in the hospital in the early period after RCR (nursing care on post-operative day 1, early mobilization, pain control, shoulder protection, and wearing/removing the shoulder sling), maintaining ADL at home (bathing, nutrition, eating, sleeping position, driving, doing household chores, sexual life, worship, and safety measures to be taken at home) and gradual exercise programs (for the first 90 days after discharge).
45621201|NCT03209323|Device|bispectral index (BIS)|The BIS score was derived from a sensor (Aspect Medical Systems) positioned diagonally on the patients' foreheads according to producer's instructions.
45763555|NCT03218657|Drug|levamisole hydrochloride|levamisole hydrochloride take orally 150mg qod
45763556|NCT03218657|Drug|Androgens|Androgens take orally 80mg qd
45621202|NCT03209323|Device|response and state entropy (RE and SE)|The respone and state entropy (RE and SE) score was derived from a sensor (Aspect Medical Systems) positioned diagonally on the patients' foreheads according to producer's instructions.
45621203|NCT03209323|Device|middle latency auditory evoked potentials (MLAEP)|value of A-line Auto Regressive Index (AAI) derived from middle latency auditory evoked potentials (MLAEP) (A-line Monitor, Danmeter A/S, Odense, Denmark) was observed which measures the central nervous system responsiveness to a specific auditory stimulus
45621204|NCT05356481|Device|segmental muscle vibration|Segmental muscle vibration will delivered over the target muscles by means of vibrator with general physical therapy session
45763557|NCT03218657|Drug|Cyclosporins|Cyclosporines take orally 3-5mg/kg*d qd
45763558|NCT02240719|Drug|everolimus|Given PO
45763559|NCT02240719|Drug|bendamustine hydrochloride|Given IV
45621205|NCT02477969|Drug|PEX168(100µg)|PEX168,100µg,Subcutaneous injection,once a week. continued for 52 weeks
45621206|NCT02477969|Drug|PEX168(200µg)|PEX168,Subcutaneous injection,once a week. continued for 52 weeks
45621207|NCT02477969|Drug|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then followed by PEX168 100µg,qw sc. or 200µg qw sc.for 28 weeks.
45621208|NCT02477969|Drug|Metformin|0.5mg,oral,tid.
45621209|NCT03195205|Diagnostic Test|OraQuick HCV Rapid Antibody Test|HCV Screening
45621210|NCT02481401|Behavioral|Intensive Individual Intervention Program|
45621211|NCT02481401|Behavioral|Peer-To-Peer Program Intervention|
46069252|NCT03562728|Device|MRP and NMES(neuromuscular electric stimulation)|nutrition supplementation includes addition of essential amino acids 3 times a day to feeding
46069253|NCT03562728|Other|Standard of Care|Patients in the control group are going to receive standard of care
45621212|NCT03209011|Drug|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
45621213|NCT02481323|Drug|isosorbide mononitrate|slow release nitric oxide donor that enhances vasodilation and widely used in angina prophyaxis
45621214|NCT02481323|Drug|cilostazol|phosphodiesterase 3-inhibitor that enhances vessel wall function with weak antiplatelet effects
45621215|NCT03197779|Drug|BMS-962212|Intravenous Infusion administration over 2 hours or 5 days
45621216|NCT03197779|Drug|Aspirin|Oral administration
45621217|NCT03197779|Other|Placebo|Oral administration
45763560|NCT01833299|Procedure|TACE-Sorafenib group|"Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.~Oral sorafenib (400 mg BID) will be start the 2-4 weeks after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination."
45763561|NCT01833299|Procedure|TACE|
45763562|NCT02240797|Other|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
45763563|NCT01833377|Dietary Supplement|caraway sample|
45763564|NCT01833377|Dietary Supplement|placebo|
45763565|NCT03213041|Drug|Carboplatin|Given IV
45763566|NCT03213041|Other|Laboratory Biomarker Analysis|Correlative studies
45763567|NCT03213041|Biological|Pembrolizumab|Given IV
45763568|NCT02240875|Biological|cAd3-EBO Z at 1 x 10^10 vp|Low dose cAd3-EBO Z
45621218|NCT05715203|Device|Pulsotonometry|Evaluation of arterial stiffness
45621219|NCT05702567|Device|RF + PFMT|"During each session the patient is lying face up, with knees bent and feet resting on the stretcher.~Then, the vaginal probe is introduced into the cavity using a lubricant suitable for intracavitary use and radiofrequency. The device is started at 15% intensity and adapting to a 10-point Likert scale, at point 3 or 4 of intensity.~At the same time that the radiofrequency is applied, pelvic floor contractions are performed guided by the physiotherapist, and these contractions are three:~10 fast contractions of one second each, with 10 seconds of rest.~5 seconds of sustained contraction and 10 seconds of rest.~10 seconds of contraction maintained with 10 seconds of rest.~The contraction maintenance time will be adapted to what each woman can keep the pelvic floor contracted, with a view to the goal being to complete these exercises cyclically during the entire session."
45763569|NCT02240875|Biological|cAd3-EBO Z at 2.5 x 10^10 vp|Medium dose cAd3-EBO Z
45763570|NCT02240875|Biological|cAd3-EBO Z at 5 x 10^10 vp|High dose cAd3-EBO Z
45763571|NCT02240875|Biological|4.4x10^8 TCID50s MVA-BN® Filo|High dose MVA-BN® Filo
45763572|NCT02240875|Biological|2.2x10^8 TCID50s MVA-BN® Filo|Low dose MVA-BN® Filo
45763573|NCT02240875|Biological|4.4 x 10^7 TCID50s MVA-BN® Filo|Very low dose MVA-BN® Filo
45763574|NCT01833611|Drug|Entecavir|entecavir 0.5mg qd
45763575|NCT01833611|Drug|placebo|placebo qd
45763576|NCT02240953|Drug|Warfarin|Only warfarin is given with a target INR level of 2.5-4 to the patients with prosthetic heart valve thrombosis
45763577|NCT02240953|Drug|Warfarin + ASA 100 mg + PPI|100 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
45935165|NCT04729881|Other|Conventional Rehabiliation Group|Transcutaneous Electrical Nerve Stimulation, Ultrasound and Exercise
45763578|NCT02240953|Drug|Warfarin + ASA 300 mg + PPI|In the third arm 300 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
45621220|NCT05702567|Other|PFMT + Placebo RF|"The intervention is exactly the same as the group RF + PFMT, unlike the non-functioning of the RF in the patients belonging to this group.~The patient is lying face up, with knees bent and feet resting on the stretcher. Then, the vaginal probe is introduced into the cavity using a lubricant suitable for intracavitary use and radiofrequency, the device is started at 15% intensity, but in this case, the program does not work or apply radiofrequency to the patients.~At the same time, that the radiofrequency's probe is applied, pelvic floor contractions are performed guided by the physiotherapist, and these contractions are the three named in the Radiofrequency + PFMT.~The contraction maintenance time will be adapted to what each woman can keep the pelvic floor contracted, with a view to the goal being to complete these exercises cyclically during the entire session."
45621221|NCT03197623|Drug|LLP2A-ALENDRONATE|A small molecule, LLP2A-Ale that directs endogenous mesenchymal stem cells (MSCs), the cells that have the potential to grow bone tissue, to the bone surface to form new bone. Single administration of LLP2A-Ale given intravenously over 120 minutes.
45621222|NCT03197623|Drug|Placebo|Placebo, one time single administration given intravenously over 120 minutes.
45763579|NCT02240953|Drug|Observational Warfarin|This is an observational group of patients who do not have prosthetic heart valve thrombosis. These patients also are followed under only warfarin therapy with INR level of 2.5-4.
45763580|NCT04377217|Other|Video recording|The experimenter will make a standardized video of the patient during the inclusion process, and a second one after 18 months, in order to evaluate the evolution of facial damage. Then algorithms will be developped to be able of differentiating FSHMD patients with facial damage from control subjects using video and audio recordings.
45621223|NCT03195595|Device|mitral valve replacement|early postoperative outcome regarding pain in minimal invasive technique
45763581|NCT03218813|Behavioral|Intervention cohort ('after' group)|"The intervention will take place during hospitalisation. Patients will complete the BMQ-S and their responses will form the basis of what will be discussed in Session 1. Pharmacists will elicit patients' thoughts and opinions about their medicines and highlight the need to take them. Any erroneous treatment beliefs will be discussed and any concerns will be addressed.~After Session 1, patients will be given a planning sheet and will be asked to think about their usual daily routine and how taking medicines may fit into it. Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose')."
45763582|NCT03212729|Radiation|ANTIMICROBIAL PHOTODYNAMIC THERAPY|The aPDT was performed with 0.01% methylene blue and irradiated with low-level laser therapy (InGaAIP, 660 nm; 100 mW; 40 sec) with an optical fiber-coupled. Another irradiation (3 J; 30 sec; spot size of 3 mm2) was performed in the gingiva close to the apical foramen.
45763583|NCT03212729|Procedure|Conventional endodontic treatment|After local anesthesia the supragingival calculus, biofilm and the carious tissues were removed. The access cavity preparation was completed. The crown-down technique was performed using Gates Glidden and Kerr files with an anatomic diameter compatible to the radicular canal, and the irrigation was performed with 5 mL of 2.5% NaOCl solution between each endodontic file. The working length was established 1 mm short of the radiographic apex. Smear layer was removed by rinsing the canal with 17% ethylene diamine tetra-acetic acid solution, which was left in the canal for 5 min, followed by a final irrigation with 15 mL of 2.5% NaOCl solution. Calcium hydroxide paste with paramonoclorophenol, was inserted into the canal, filling the root canal as temporary medication between the sessions. The coronal sealing was performed using Coltosol, followed by glass ionomer Maxxion R. Seven days later the root canal was filled by the hybrid Tagger technique, with a Mc Spadden condenser.
45763584|NCT03218501|Drug|SK-1405 high dose|SK-1405 high dose is to be administered orally once daily for 2 weeks
45763585|NCT03218501|Drug|SK-1405 low dose|SK-1405 low dose is to be administered orally once daily for 2 weeks
45763586|NCT03218501|Drug|Placebo|Placebo is to be administered orally once daily for 2 weeks
45763587|NCT02241031|Biological|MPs|MPs are generated from cord blood using a combination of cytokines.
45621224|NCT03195595|Device|conventional mitral valve replacement|early postoperative outcome regarding pain in conventional median sternotomy
45621225|NCT05679323|Other|KATZ index of independence in activities of daily living|KATZ index measures self-care tasks using a dichotomous rating (dependent-0/independent-1) including; bathing, dressing, toileting, transferring to and from a chair, maintaining continence, and feeding. Six points are considered independent and 0 points are considered fully dependent. Assessment of each patient is made through a phone call at day 1, 3 and 5 after discharge
45763588|NCT02241031|Drug|thrombopoietin (TPO) and interleukin-11|Platelet stimulating factors include thrombopoietin (TPO) and interleukin-11 and so on.
45763589|NCT01833689|Dietary Supplement|food consumption|"Reference food The reference food is 50 g glucose powder dissolved in 250ml water~Test foods The test foods are prepared according to manufacturer's instructions, representing the food as normally consumed. The test foods are consumed once only on separate occasions as a portion providing 50g of available carbohydrate.~Breakfast cereals should be consumed with 150 ml milk which is additional to the 50 g available carbohydrate in the cereal. In testing breakfast cereals, the reference food must also be consumed with an additional 150 ml milk."
45763590|NCT02156167|Device|CP810 and Codacs™ system test|Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)
45763591|NCT03212807|Drug|Durvalumab|Investigational Medicinal Product
46069254|NCT03550066|Behavioral|Values affirmation|A health message with a prompt asking participants to reflect on important personal values
45621226|NCT02449603|Drug|Exenatide|
45621227|NCT02449603|Drug|Biphasic insulin Aspart 30|
45621228|NCT02481479|Drug|Saxagliptin|Eligible patients will undergo baseline CMR, commence treatment and then after 6 months undergo repeat CMR
45763592|NCT03212807|Drug|Lenalidomide|Investigational Medicinal Product
46069255|NCT03550066|Behavioral|No affirmation|A health message alone
45912048|NCT04298905|Other|CHW mHealth patient intervention for trigger escalation|"The CHW dashboard is a tablet-based, per-patient summary of the patient intervention. It is this dashboard that identifies a trigger to escalate the adherence intervention. This dashboard is created by receiving information from the patient's smartphone application as well as the National Health Laboratory Service (NHLS) data feed of laboratory results. The monitoring features included in this dashboard:~NHLS laboratory results: Dashboard receives and flags NHLS results for any positive smear or culture (new positive after prior negative results) or detectable viral load (with prior viral suppression)~Triggered, escalating adherence coaching:~Safety monitoring: reports all abnormal laboratory values to provider~Appointment keeping (RETAIN):~a. Triggered, escalating adherence coaching~vDOT submissions:~a. Triggered, escalating adherence coaching~Symptom reports:~Triggered, escalating adherence coaching"
45912049|NCT04294095|Other|My Baby My Move +|This is a community-based, peer-led 12-week wellness intervention to decrease excessive gestational weight gain.
45446172|NCT02077660|Dietary Supplement|Four green tea bags per day for 12 weeks|Four green tea bags per day for 12 weeks
45446173|NCT02077660|Other|4 daily placebo tea bags for 12 weeks|4 daily placebo tea bags for 12 weeks
45621229|NCT02481479|Drug|Saxagliptin|Eligible patients will undergo baseline echocardiogram, commence treatment and then after 6 months undergo repeat echocardiogram
45621230|NCT02481479|Drug|saxagliptin|Eligible patients will undergo baseline venipuncture, commence treatment and then after 6 months undergo repeat venipuncture
45621231|NCT03208777|Genetic|taking blood samples|taking blood samples and measure telomeric abnormalities
45446174|NCT02069158|Drug|PF-05212384|iv administrartion
45446175|NCT02069158|Drug|Paclitaxel|iv administration
45621232|NCT03195829|Behavioral|Computerized Cognitive Stimulation|The intervention group performed 12-week, 90-minutes per week of cognitive stimulation in group using a tablet with a commercial software with specific exercises to train the cognitive functioning and promote the relation ties in group-session.The program's difficulty level was adjusted to the MMSE score, and was gradually increased.
45621233|NCT03195829|Behavioral|Multimedia-based internet|The active control group had access to different Multimedia contents (travel, photos, music, TV program, cooking recipes) using a tablet, 90-minutes per week each week during 3-months. Each group session was centered in a particular topic, participants were able to select different media free available in Internet.
45621234|NCT03195049|Diagnostic Test|blood group,complete blood count|measure levels of total and direct bilirubin before, during and after the procedure of exchange transfusion
45446176|NCT02069158|Drug|Carboplatin|iv administration
45446177|NCT04531527|Drug|Butenafine HCl 1% (BAY1896425)|Approximately 60 μl of Butenafine HCl 1% applied twice to the treated irradiated site and to the treated non-irradiated site for a total application of 240 μl of Butenafine HCl 1%.
45446178|NCT03334006|Drug|Pentaglobin®|Standard of Care + Pentaglobin®
45621235|NCT05667233|Other|Resistance Training Program|Participants will undergo a high exertion machine-based resistance training protocol.
45621236|NCT03195439|Device|TTP|TTP™ allows to continuously measure body temperature using a new non-invasive method, and was cleared for marketing by US FDA (K150160) for as a temperature monitoring system intended to measure and monitor core body temperature of patients of all ages, by applying a sensor unit on the forehead.
45621237|NCT02481089|Other|validation group|
45621238|NCT03195283|Other|Meal service|The type of meal service in the hospital (usual care)
45621239|NCT05667155|Biological|CB dualCAR-NK19/70|Lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19/CD70 CAR and IL15
45621240|NCT02449759|Behavioral|ACT Intervention Group|A six chapter, 58 page self-help manual based on the principles of Acceptance and Commitment Therapy
45912050|NCT04294095|Other|Control|This is a 12-week basic prenatal education class.
45912051|NCT04281446|Device|Photobiomodulation|Application of light at specific wavelength for interaction with biological tissue
45912052|NCT04278833|Drug|Triamcinolone or Betamethasone|Image guided intra-articular, peri-tendinous, or intra-bursal corticosteroid injection
45912053|NCT04278833|Drug|Dexamethasone|Image guided intra-articular, peri-tendinous, or intra-bursal corticosteroid injection
45446179|NCT02077738|Device|HFCWO (Hill-Rom Vest™ Airway Clearance System)|study subjects in the HFCWO group received HFCWO for 15 min twice a day for 5 days after extubation
45446180|NCT02069236|Other|G6PD Test|All subjects are tested by multiple G6PD tests
45446181|NCT03165994|Drug|APX005M|APX005M intravenous (IV) infusion
45446182|NCT03165994|Radiation|Radiation Therapy|Radiation therapy, total dose 5040cGy in 180cGy fractions
45446183|NCT03165994|Drug|Paclitaxel|Paclitaxel IV infusion
45446184|NCT03165994|Drug|Carboplatin|Carboplatin IV infusion
45446185|NCT03165994|Procedure|Surgical resection of tumor|Surgical removal of the tumor will occur between weeks 10-16
45621241|NCT05666609|Procedure|placement of non-cutting seton (silicone)|Treatment of Fistula in ano is conducted according to the institution's treatment guidelines. Silicon seton placement is conducted under general anesthesia. Identification of the FIA is secured by the insertion of a bulb-headed lacrimal probe, on which a silicon vessel loop is attached and pulled through the entire fistulous tract. In case of a perianal abscess, drainage and sphincter-sparing debridement is performed followed by secondary wound healing. The loop is ligated loosely outside the anus without any additional tension to the skin. Duration of placed seton is depending on group assignment and is set to either 4 or 12 weeks.
45621242|NCT03198013|Drug|Prednisolone|Specified dose on specified days
45621243|NCT03198013|Drug|BMS-791826|Specified dose on specified days
45621244|NCT03198013|Drug|Placebo|Specified dose on specified days
45621245|NCT05651399|Drug|Remimazolam|Patients receive remimazolam at a rate of 1 mg/kg/hr. When a patient's MOAA/S reaches 3 or less, the rate of remomazolam is maintained at a rate between 0.3 mg/kr/hr and 1.0 mg/kg/hr until the end of surgery.
45621246|NCT05651399|Drug|Propofol|Patients are administered propofol with an effect-site concentration of 1.0 mcg/mL to 2.5 mcg/mL by target controlled infusion.
45621247|NCT02477891|Drug|Daratumumab|Participants will receive daratumumab (16 milligram per kilogram [mg/kg]) as intravenous infusion on Day 1, 8, 15, and 22 of Cycles 1 and 2 (weekly dosing), on Day 1 and 15 of Cycles 3 to 6 (every 2 weeks dosing), and on Day 1 of Cycle 7 and subsequent cycles (every 4 weeks dosing) until documented progression, unacceptable toxicity, or study end. Each cycle is of 28 days.
45763593|NCT04373941|Drug|Filgrastim|G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.
45763594|NCT03212417|Other|Educational intervention|Presentation of risk factors, signs and symptoms, and interventions on compassion fatigue
45763595|NCT01833767|Drug|Cyclophosphamide and Interleukin 2|Cytoxan IV day 1, IL2 IV days 1-5
45912054|NCT04270838|Biological|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 1x10^10 and 5x10^10
46069256|NCT03549091|Diagnostic Test|transthoracic echocardiography|This involves the acquisition of 1 additional sequence: a 10-minute sequence for transthoracic echocardiography.
46069257|NCT03549091|Diagnostic Test|Cardiovascular Magnetic Resonance Imaging|This involves the acquisition of 1 additional sequence: a 10-minute sequence for Cardiovascular Magnetic Resonance Imaging 4D Flow.
45621248|NCT02447263|Procedure|interventional therapy|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
45621249|NCT03208543|Device|HECT-CL|To evaluate the effectiveness, safety and feasibility of thermotherapy with the low cost Hand-held Exothermic Crystallization Thermotherapy pad in the treatment of cutaneous leishmaniasis in Quetta, Balochistan, Pakistan.
45763596|NCT01833923|Drug|anlotinib|oral medicine.
45912055|NCT04270838|Biological|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units
45621250|NCT02477813|Drug|Temozolomide|200 mg/m2 die for 5 consecutive days every 28 days. Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
45621251|NCT05715047|Behavioral|CBT for Fatigue|10, individualized counseling sessions with a behavioral health counselor via Zoom platform.
45621252|NCT05715047|Behavioral|Usual Care|Standard transplant care.
45621253|NCT03119311|Diagnostic Test|Video-oculography|Diagnostic Method for Exotropia Using Video-oculography
45621254|NCT03119311|Diagnostic Test|APCT|alternative prism cover test
45446186|NCT02069314|Dietary Supplement|Whey protein supplementation|subjects are asked to consume a smoothie with whey protein added
45446187|NCT02069314|Dietary Supplement|Carbohydrate (polycose) supplementation|Subjects are asked to consume a beverage with polycose added
45621255|NCT02481011|Drug|antithrombotic drugs|
45763597|NCT01834079|Biological|STEM CELL THERAPY|Autologous stem cells(MNCs ) intra thecal .Intra thecal transplantation of single arm autologous MNCs 100 millions per dose in 3 divided doses at interval of 7 days,Intrathecal/Intravenous .Follow up will be taken to three Months or as required
45912056|NCT04266028|Biological|DM-101|DM-101 administered by subcutaneous (SC) injection
45912057|NCT04266028|Biological|Placebo to match DM-101|Placebo to match DM-101 administered by SC injection
45912058|NCT04264442|Drug|Losmapimod|Patients will receive Losmapimod 15 mg by mouth twice daily for a total of 30 mg daily until 90 days after commercial drug is available post regulatory approval or until the study is discontinued by the Sponsor. The study drug should be taken with food and the date and time of each dose taken should be recorded in the subject diary.
45763598|NCT03213353|Drug|Tablet paracetamol, guaifenesin and phenylephrine HCL|Each subject will receive two tablets, each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride
45935166|NCT04729881|Other|Spesific Exercise Group|Cervical stretching exercise, Craniocervical flexion exercise, Neck isometric exercises, Cervical retraction exercise, Scapular retraction exercise, Modified push-up plus exercise
45935167|NCT04729881|Other|Control group|No intervention will be aplied
45935168|NCT00217867|Behavioral|Animated character intervention with telephone follow-up|Animated character will teach the discharge plan before discharge, then this teaching will be reinforced by computerized telephone system.
45935169|NCT00041990|Drug|decitabine (5-aza-2'deoxycytidine)|
45446188|NCT02069470|Behavioral|Continuing Medical Education|3-hour after work meeting. Multifaceted form. Content: Cancer symptoms positive predictive values, pit falls, reflections on barriers and attitudes towards early cancer diagnosis.
45446189|NCT02069626|Procedure|compression time of the laparoscopic linear stapler|
45621256|NCT02480855|Other|Questionnaire and feedback|
45621257|NCT02450617|Behavioral|Conventional individual treatment|Individual psychotherapeutic treatment and case-management delivered by public outpatient clinics or private practicing psychologist/psychiatrist
45621258|NCT02450617|Behavioral|Stabilizing group treatment for PTSD|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training.
45621259|NCT02450617|Behavioral|Stabilizing group treatment for Dissociative disorders|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training
45621260|NCT02480933|Procedure|Bilateral mastectomy|Bilateral mastectomy and imaging study of cadaveric breasts
45621261|NCT02480933|Other|Biopsy|Biopsy of BI-RADS 3 and superior lesions
45621262|NCT03197857|Behavioral|Physical activity program : aquabike|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation.
45935170|NCT00217906|Behavioral|A+ Asthma early intervention program|
45935171|NCT00217945|Behavioral|Shared-Decision Making|
45935172|NCT00217984|Other|Usual Care|Referral to smoking cessation clinic
45935173|NCT00217984|Behavioral|Extended cognitive behavior therapy|16 sessions of cognitive behavior therapy over 6 months
45935174|NCT00073437|Drug|Infliximab|
45446190|NCT02077972|Device|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
45621263|NCT03197857|Behavioral|Physical activity program : bicycle|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation.
45763599|NCT03213353|Drug|Vicks Active SymptoMax Plus powder for oral solution|Each subject will receive one sachet, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride
45446191|NCT02078050|Other|Phrenic nerves magnetic stimulations|
45446192|NCT02070016|Device|Transcranial Magnetic Stimulation|
45763600|NCT04381013|Device|Emergency Ventilator Splitter|Device to enable oxygen delivery to two patients independently from a single ventilator.
45763601|NCT03218267|Other|Static Posturography|The balance platform (Good Balance by Metitur) and one leg standing test (OLS) were used to assess the static balance. OLS test was performed on left and right foot separately. The static posturography was performed with several various positions of feet. Position : normal standing with eyes open and eyes closed - an upright standing with feet placed parallel 20 cm apart for 30 s. Position: tandem - a stance with one foot placed ahead of the other for 10 s. Position: second form of tandem - a stance with one foot placed ahead of the other with feet placed on both sides of the line dividing platform to two parts for 20s. Position: one leg standing: stance on the one leg for 5 s.
45763602|NCT03218267|Other|One-leg standing test (OLS)|During the one-leg standing test (OLS) the time of maintain this position by the patients was measured. The placement of the limbs was the same as in the case of the balance platform test. Subjects performed 3 trials on each lower limb. Time ended when subject either: loosed balance and touched raised foot the floor, moved supporting leg on the ground, a significant loss of balance or a maximum of 60 s had elapsed. Results achieved by the subjects after THR on both operated (OLS-O) and non operated limbs (OLS-N) were compared with the index of the control group (OLS-C: mean result of the tests performed on the left and right legs).
45763603|NCT03218111|Other|MR Imaging|All subjects will undergo six sessions of MR imaging over a 10-12 hour period
45935175|NCT00218101|Drug|Buprenorphine|
45446193|NCT02078128|Dietary Supplement|oral beta-glucans|30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
45446194|NCT02078128|Drug|oral sugar powder|30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
45935176|NCT04722367|Behavioral|Art Pedagogy and Mindfulness|Each participant will take part in four 1-hour sessions. Study activities include guided meditation, close looking, drawing, writing, and storytelling. Each session will begin with a guided meditation that is followed by an exercise inspired by two works of art, and end with an opportunity for students to reflect on the experience.
45446195|NCT02078440|Drug|Bromocriptine mesylate|Cycloset (bromocriptine mesylate quick release) 0.8 mg tablets, weight adjusted 1.6 mg- 4.8 mg
45446196|NCT02070250|Behavioral|From Cancer to Health (C2H-D)|From Cancer to Health gives people with cancer the information and tools they need to manage their stress to improve their health throughout the cancer journey. Each institution involved in this study will implement the core techniques of the C2H-D Intervention but may alter the format somewhat to meet their patient population needs (e.g., shorten hourly 18 week intervention into 2-hour 9 week intervention).
45446197|NCT04474197|Drug|VX-864|Tablets for oral administration.
45446198|NCT04474197|Drug|Placebo|Placebo matched to VX-864 for oral administration.
45446199|NCT02070406|Drug|cyclophosphamide|Given IV
45446200|NCT02070406|Drug|fludarabine phosphate|Given IV
45446201|NCT02070406|Biological|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Given NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells IV
45446202|NCT02070406|Biological|dendritic cell vaccine therapy|NY-ESO-1157-165 peptide pulsed DC vaccine given ID
45446203|NCT02070406|Biological|aldesleukin|Given SC
45446204|NCT02070406|Radiation|fludeoxyglucose F 18|Correlative studies
45446205|NCT02070406|Procedure|positron emission tomography|Correlative studies
45446206|NCT02070406|Other|laboratory biomarker analysis|Correlative studies
45621264|NCT03197857|Behavioral|Physical activity program : with protein supplementation|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation
45621265|NCT03197857|Behavioral|Physical activity program : without protein supplementation|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation
45621266|NCT02480777|Biological|Autologous Human Schwann cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
45763604|NCT03218111|Other|CT-guidance|All subjects will be injected, intrathecally using CT-guidance, with an MRI contrast.
45763605|NCT03212573|Combination Product|ERAS protocol|ERAS protocol includes early oral intake and deambulation and multimodal analgesia
45763606|NCT03212573|Combination Product|Standard care|Oral intake and deambulation 24h after surgery and only intravenous analgesia.
45763607|NCT03218189|Other|Country characteristics|Observational study of country characteristics
45763608|NCT03218033|Behavioral|Social Media|
45621267|NCT03197311|Other|Mobile app|A customized mobile application will be developed and downloaded to subjects; smartphones to monitor postoperative analgesic consumption, and disposal; pain control and patient satisfaction. The mobile app will provide notifications for medications and select education links on the prescribed analgesics. Subjects will receive reminders to take medications as directed. Subjects will be able to monitor and report their pain during the first week after surgery.
45621268|NCT02480543|Drug|Misoprostol (cytotec)|
45621269|NCT03197233|Other|Maternal vitamin A and D intake during pregnancy|Dietary exposures during pregnancy and infant supplement use were assessed from maternal questionnaire report
45621270|NCT02447185|Drug|Ranibizumab|"A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.~All subjects in Ranibizumab group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation."
45621271|NCT02447185|Drug|Triamcinolone Acetonide|"A week before 25-gauge vitrectomy, all subjects in TA group will receive Triamcinolone Acetonide 4mg/0.1ml intravitreal injection.~During operation all subjects in Ranibizumab group and in TA group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in TA group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation."
45621272|NCT05714813|Behavioral|High-Speed Circuit Resistance Training|Performance of 24 weeks of high-speed concentric and low-speed eccentric lift across three circuits on eleven pneumatic machines. Each training session will be in person and will last between 45 minutes and one hour.
45621273|NCT05714813|Behavioral|Lecture on Diet, Exercise and Cognition|Lectures on diet, exercise, and cognition. Lectures will be provided in person or online and will last approximately one hour.
45621274|NCT05714735|Radiation|Cerebral Venography|Cerebral Venography Observation by DSA examinations
45763609|NCT03217955|Behavioral|CBT-SA|Info has been included in arm description
45763610|NCT03217955|Behavioral|Standard Treatment|Info has been included in arm description
45763611|NCT01834235|Drug|Gemcitabine|Gemcitabine IV at a dose of 1000mg/m2 on days 1, 8, and 15 of a 4 week cycle.
45763612|NCT01834235|Drug|nab-paclitaxel|Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on Days 1, 7 and 15 for a 28 day cycle
45763613|NCT01834235|Drug|NPC-1C|NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 28 day cycle. This will be administered 30 minutes after completion of the gemcitabine infusion.
45763614|NCT03212339|Other|Therapeutic intervention|Therapeutic interventions will be delivered in ten 2-hour sessions over 12-15 weeks, which includes 2 research data collection sessions at the beginning of the study (pre-intervention) and at the end of the study (post-intervention). During the pre-intervention data collection session, participants will be asked to provide demographic information and complete interviews about their past experiences and current experiences as a parent, and their child's current functioning. Parents will also be video recorded interacting with their child for 10 minutes. During the post-intervention data collection session, participants will be asked to complete a similar set of interviews and will also be video recorded interacting with their child for 10 minutes.
45763615|NCT03217799|Device|Measurement of coagulability of blood|A small pneumatic cuff is attached to the root of the index finger. The sensor cuff is attached several centimeters distal to the pneumatic cuff. Measurement is taken for a 60-second control period, and then the pneumatic cuff is inflated to above-systolic blood pressure (200 mm Hg) for 180 seconds, and measurement is taken during this period of time. The cuff is then deflated, and another 60-second measurement is taken. Data is collected by the measuring device for later analysis.
45763616|NCT03211871|Drug|Dexmedetomidine|Intraoperative intravenous dexmedetomidine infusion 0,5 mcg/kg/h
45763617|NCT03211871|Drug|Normal Saline Flush, 0.9% Injectable Solution_#1|Intraoperative intravenous normal saline infusion
45763618|NCT01834469|Drug|iv injection of ICG|An iv injection will be performed for the ovarian cancer patient before the operation.
45763619|NCT03217487|Procedure|Corneal epithelial autograft|Epithelial tissue, equal in area to the diseased eye's cornea bed, will be obtained from the fellow eye using femtosecond laser technology. This corneal epithelial autograft is then ready for transplantation on the disease eye, following removal of scarred and diseased epithelium.
45763620|NCT03217487|Procedure|Limbal conjunctival autograft|A 3- to 5- clock hour limbal-conjunctival autograft will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following removal of scarred and diseased epithelium.
45763621|NCT03217487|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
45763622|NCT03217487|Device|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
45912059|NCT04248244|Other|Palliative Care|Early PC Integration - Participants will meet with a member of the outpatient PC team, which consists of board-certified PC physicians, advance practice providers and nurse care coordinators, within three weeks of enrollment. Participants will be scheduled to meet with a PC provider at least once per month. Additional visits may be scheduled at the discretion of participants, oncologists or PC providers. All participants will receive routine oncologic care throughout the study period.
45912060|NCT04248244|Other|FACT-MM questionnaire|FACT-MM questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.
45935177|NCT00218140|Drug|nicotine transdermal system|
45621275|NCT05714657|Radiation|adjuvant radiotherapy|Shortened Course Adjuvant Radiotherapy Following TORS
45621276|NCT03118219|Other|Positive adjustment coping intervention|see arm description
45763623|NCT03838133|Drug|TLC590|TLC590, a sustained-release formulation of the local anesthetics with lipid-based excipients
45763624|NCT03838133|Drug|Naropin®|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. 50 mg (0.5%, 10 mL)
45763625|NCT03838133|Drug|Normal Saline|Normal Saline (0.9% sodium chloride, 10ml)
45621277|NCT03118219|Other|Brainteaser|see arm description
45763626|NCT03838133|Drug|Bupivacaine|Bupivacaine 50 mg (0.5%, 10 mL)
45763627|NCT03217409|Drug|Rosuvastatin+Ezetimibe|Rosuvastatin 5mg+Ezetimibe 10mg
45621278|NCT05714579|Procedure|Transcatheter Aortic Valve Implantation|"The TAVI procedure is performed transfemorally under local anesthesia most often, or more rarely under general anesthesia via the subclavian or transaortic route. Identification is carried out under fluoroscopy in the cardiac catheterization room. The crossing of the aortic valve allows the establishment of a guide at the bottom of the left ventricle. Aortic valve predilation can be performed. The tightness of the device is checked by an aortography. Sometimes, post-dilation of the implanted bioprosthesis proves necessary, particularly in the event of under-deployment or significant para-prosthetic leakage.~The duration of the intervention is approximately 1 hour."
45763628|NCT03217409|Drug|Rosuvastatin|Rosuvastatin 5Mg Tablet
45763629|NCT00895193|Other|Apple pectin|Apple pectin 2000mg
45763630|NCT00895193|Drug|Aspirin 325 mg|Aspirin 325 mg
45763631|NCT00895193|Other|Placebo|Placebo
45763632|NCT01834547|Drug|Drugs use: methylphenidate|40 mg tablets
45763633|NCT01834547|Drug|Drug use: modafinil|40 mg tablets
45763634|NCT01834547|Drug|caffeine|400 mg
45621279|NCT02449447|Behavioral|Cognitive behavioral therapy|CBT based on behavioral activation and cognitive therapy techniques including homework
45763635|NCT01834547|Drug|placebo|placebo
45763636|NCT03211637|Combination Product|Wounds Protocol|Nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
45763637|NCT03217253|Other|Laboratory Biomarker Analysis|Correlative studies
45763638|NCT03217253|Other|Pharmacological Study|Correlative studies
45763639|NCT03217253|Drug|Tazemetostat|Given PO
45763640|NCT03212105|Behavioral|60 Second Video|The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
45763641|NCT03212105|Other|Educational Brochure|The educational pamphlet will contain information about pain and stress, which patients will be able to read within 60 seconds.
45763642|NCT01834703|Procedure|UAE|The patient will be admitted into hospital for UAE. UAE was performed with patients under local anesthesia. Embosphere particles (BioSphere Medical) with a size of 500 - 700µm were used in all procedures. Embospheres were mixed with contrast material and saline and injected into each uterine artery until either parenchyma filling of the fibroids had stopped (target embolization) or the main uterine artery was blocked with stasis of contrast material (selective embolization). After the procedure, women were admitted to the gynecology ward for postprocedural care. All patients were advised to stay in the hospital for at least 1 night.
45763643|NCT01834703|Procedure|HIFU|Treatment will be given to the patient in one or more sessions on an outpatient basis. The uterine fibroid will be identified and located with ultrasonography and ablated with HIFU. For lesion beyond 6 cm distance from skin, HIFU is given at a power of 1200-1500 watt for 1500 - 2000 times at each spot, for 50 milli-second each time, at an interval of 100 milli-second, at a spot distance of 1.5cm, a line distance of 1.5cm, and a plane distance of 1.0 -1.5cm; for lesion within 6 cm distance from skin, HIFU is given at a power of 1300±15% Watt for 40 times at each spot, for120 milli-second each time, at an interval of 100 milli-second, at a spot distance of 0.3cm, a line distance of 0.3cm, and a plane distance of 0.8cm.
45763644|NCT03211559|Other|Exercise|clinical pilates on mat
45763645|NCT01834781|Device|Pulsed electromagnetic fields|
45763646|NCT01834781|Device|w/o pulsed electromagnetic fields|
45621280|NCT02449447|Other|Treatment as usual|Treatment as usual in primary care including antidepressants and counselling
45621281|NCT05456555|Procedure|Flapless with Enamel Matrix Derivatives (EMD)|Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. In the test group, the roots will be conditioned with 24% ethylenediaminetetraacetic acid (EDTA) for 2 minutes. After rinsing with sterile saline, enamel matrix derivatives (EMD) will be applied on the dried root surface.
45763647|NCT03217331|Drug|CRD-102|14 mg CRD-102 capsules administered twice daily orally for 14 days.
45763648|NCT03211715|Other|questionnaire|Rectal cancer patients who received sphincter saving surgery will be asked to fill up questionnaire related to bowel dysfunction
45763649|NCT03216863|Other|Respiratory rehabilitation|It consists of a global care of the patient: therapeutic education, nutritional maintenance, psychological support and re-training to the effort at home after discharge or after follow up visit of targeted therapy
45763650|NCT01834937|Device|ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)|Focused Ultrasound Surgery - FUS delivered by ExAblate for the palliation of pain due to bone metastases.
45763651|NCT03211169|Procedure|Biopsies of bile duct stricture with pediatric biopsy forceps|Biopsies of the stricture will be taken to evaluate diagnostic yield of Pediatric Biopsy Forceps
45763652|NCT03211169|Procedure|Biopsies of bile duct stricture with cholangioscopy-directed biopsies|Biopsies of the stricture will be taken to evaluate diagnostic yield of cholangioscopy-directed biopsies
45763653|NCT04380389|Diagnostic Test|hypoxia|Brief stable arterial oxygen desaturation in healthy volunteers and sampling arterial blood when a stable level of hypoxia has been attained.
45763654|NCT03217019|Procedure|Guidewire-assist|catheter insertion with guidewire-assist(catheter over guidewire)
45763655|NCT03217019|Procedure|Direct|catheter insertion without guidewire assist(catheter over needle)
45763656|NCT03211403|Drug|SHR4640|SHR4640 or placebo once daily for a week
45763657|NCT03211247|Biological|Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, once daily
45935178|NCT00042029|Drug|MK0869, aprepitant|
45446207|NCT03757611|Dietary Supplement|Tabetri capsule|1,000 mg/capsule (Taheebo extract 600 mg/day)
45446208|NCT03757611|Dietary Supplement|Placebo capsule|1,000 mg/capsule
45912061|NCT04248244|Other|HADS questionnaire|HADS questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.
45621282|NCT05456555|Procedure|Flapless without Enamel Matrix Derivatives (EMD)|Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. No adjunct will be administered.
45621283|NCT03196921|Drug|Encochleated Amphotericin B|lipid-crystal nanoparticle formulation of amphotericin B; oral
45621284|NCT02477735|Device|Actigraphy|Actigraphy will be conducted for each participant for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
45621285|NCT02480465|Drug|Lobelitazone 0.5mg|Lobelitazone 0.5mg, placebo of Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
45763658|NCT03211247|Biological|Viaskin Peanut 100 mcg|Viaskin Peanut 100 mcg, once daily
45763659|NCT03211247|Biological|Placebo|Placebo patch, once daily
45763660|NCT03216941|Drug|Ketamine|"study medications were packaged in identical color-coded boxes. first dosage included either 10 mg of olanzapine, or 10 mg of ketamine Dosages were chosen based on previous studies After the initial dose, no additional dosis were allowed if supplemental medication eas needed according to clinician judgment the subject will be immediately removed from the study.~All subjects will be assessed 1 hour, 2 hours, 4 hours, 6 hours and 12 hours after t he first administration of the medication."
45763661|NCT03216707|Device|HD tDCS active motor cortex|the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min
45763662|NCT03216707|Device|HD tDCS active insula cortex|the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min
45763663|NCT03216707|Device|HD tDCS sham motor cortex|the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min
45763664|NCT03216707|Other|Capsaicin cream|Capsaicin cream
45763665|NCT01835093|Drug|Tipepidine Hibenzate|
45763666|NCT01835249|Other|Intensive BP Arm|Participants in the Intensive arm have a goal of SBP <120 mmHg.
45763667|NCT01835249|Other|Standard BP arm|Participants in the Standard BP arm have a goal of SBP <140 mmHg.
45763668|NCT01838993|Drug|Lidocaine inhalation|Lidocaine inhalation before intubation
45763669|NCT01838993|Drug|Placebo|
45763670|NCT03211013|Drug|Oxytocin|single-dose administration of OT nasal spray, complete computer-based tasks post-dose for approximately 1 hour
45912062|NCT04227132|Device|Adaptive computer game training|Patients sit in front of a computer monitor and play the adaptive videogame with a joystick. The game requires to orient and move inside a maze, and it includes phases that engage multitasking abilities. The level and speed of the game is adapted online to patients' performance.
45621286|NCT02480465|Drug|Sitagliptin 100mg|placebo of Lobelitazone 0.5mg, Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
45763671|NCT03211013|Drug|Placebos|single-dose administration of placebo nasal spray, complete computer-based tasks post-dose for approximately 1 hour
45763672|NCT03836495|Dietary Supplement|lysine and phosphorus|addition of lysine and essential amino acid and/or phosphorus an essential mineral
45912063|NCT04227132|Device|Standard computerized training|Patients sit in front of the computer monitor and perform simple computerized exercises using a keyboard to respond. Exercises are organized into modules according to the trained cognitive functions. Patients will perform four different modules that are designed for neglect rehabilitation. The level of exercises adapts periodically based on patient's performance.
45912064|NCT04225065|Drug|Chlorhexidine|Chlorhexidine prep prior to surgery
45763673|NCT03836573|Behavioral|Smoking Cessation iPad Decision Aid Tool|Patients will be provided with the iPad-delivered decision aid. The patient will answer a series of questions and based on their responses be shown information based on the group of which they are a member: 1. Uninterested in quitting cigarettes (Harm-reduction Group); 2. Interested in quitting and using e-cigarettes (E-cigarette Cessation Group); 3. Interested in quitting but does not use e-cigarettes (Standard Smoking Cessation Group). Upon visiting the patient, the physician will address smoking cessation with the patient incorporating the provided decision aid results.
45763674|NCT01835405|Device|LiquiBand Flex|
45763675|NCT01835405|Device|Dermabond Advanced|
45763676|NCT01835405|Device|Sutures (Prolene)|
45446209|NCT02078518|Other|Questionnaires|
45621287|NCT05633771|Other|Hyrimoz|There is no treatment allocation. Patients administered Hyrimoz by prescription that have started as routine medical treatment will be enrolled.
45621288|NCT03208465|Drug|Empagliflozin|In empagliflozin group, patients will be prescribed empagliflozin 10mg/day.
45621289|NCT03208465|Drug|Sitagliptin|In sitagliptin group, patients will be prescribed sitagliptin 100mg/day.
45621290|NCT03196999|Behavioral|Personalized Attention Bias Training|This self-help program will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing a low-cost and highly scalable self-help tool to alleviate symptoms of PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be personalized for each user.
45621291|NCT03196999|Behavioral|Neutral Attention Training Condition|This self-help program is a placebo control program that will be used on an iOS compatible phone. The placebo will contain only neutral words.
45446210|NCT02078596|Drug|Divalproex|Patients were randomly assigned to receive divalproex or placebo first, follow by the converse treatment, for six weeks each
45621292|NCT03196999|Behavioral|Non-Personalized Attention Bias Training|This self-help program administered on an app will aim to reduce neurobiological threat sensitivity with the ultimate goal of a low-cost and highly scalable self-help tool to alleviate symptoms of PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be the same for each user.
45621293|NCT05714423|Procedure|Mini-PCNL|Mini-PCNL will done as follows. A 6 Fr ureteral catheter will be introduced through cystoscopy and dye will be instilled to opacify the pelvicalyceal system. After elaborating the calyceal system through fluoroscopy, selective calyceal will be punctured and tract will be dilated using 16 F sheath. Miniature nephroscope 14 Fr will be then introduced and stones will be fragmented by holmium: YAG laser. Afterwards the collecting system will be examined through nephroscope and fluoroscopic confirmation will be done to ensure complete stone clearance. In all the cases, 6 Fr 24 cm DJ stent will be placed and if remained uneventful, the patient will be discharged on postoperative day 2 with oral antibiotics.
45621294|NCT05714423|Procedure|RIRS|RIRS will be performed as follows. In this procedure a double J stent will be placed to dilate the calyceal system 2 weeks prior the surgery. During the procedure, cystoscopy will be done, and 0.035-inch guide wire will be placed in the pelvi-calyceal system. Ureteric access sheath of 12 Fr will be placed and with the help of digital polyscope the stone will be fragmented using Holmium: YAG laser using 220 μm fiber. DJ stent 6F 24 cm will be placed in all the cases. In uneventful surgery patient will be discharged on postoperative day 1 with oral antibiotics
45621295|NCT03197155|Drug|Direct Acting Antivirals against hepatitis C virus infection|The cohort includes cirrhotic patients infected with HCV and successfully treated for their first history of hepatocellular carcinoma. Some of these patients were treated with direct-acting antivirals for their HCV infection while the others did not receive any direct-acting antivirals treatment during the follow-up period.
45763677|NCT03210857|Other|apnea performing|"The included subjects will make an apnea of two minutes or more, sitting on a chair with cold strips on the face, initially with the head in neutral position. Then, when they feel the end of their apnea, they will have to raise their left hand to signal it to the Doppler manipulator, who will then realize the apnea reference measurement.~As soon as this is done, the subjects will be asked to perform an extension of the neck, so as to look at the ceiling. A final measurement will then be made in apnea, the head always in extension. Subjects then resume their breathing in this same position. A final measurement will then be made."
45621296|NCT02447107|Other|Electronic Diary|The electronic diary asks subjects questions about their compliance with mobile application usage. The questions contained in this diary ask patients how often their personal mobile device has been on their person, if and how long the applications relevant to the study were turned off, and why patients failed to comply with study requirements.
45621297|NCT02447107|Other|Questionnaire|Study patients will be asked to complete a questionnaire at the 1 and 2-week endpoints. This questionnaire is administered in order to measure patient satisfaction with the mobile applications.
45621298|NCT03118687|Other|Biospecimen and survey collection|Blood, microbiota, surveys/questionnaires, electronic medical records.
45621299|NCT05621447|Drug|TAS-303, [14C]TAS-303|oral administration on day 1
45621300|NCT02446873|Other|Egg supplementation|A weekly supply of eggs will be given to the mother in the egg supplementation group with instructions to give the child one egg per day.
45763678|NCT01835561|Drug|Pomalidomide|Single oral dose of 4-mg capsule
45763679|NCT01835561|Drug|Pomalidomide|4-mg capsule
45763680|NCT01835639|Dietary Supplement|Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks|Supplements will be provided as oral capsules.
45763681|NCT01839071|Procedure|biopsy|
45763682|NCT03210623|Device|stent retriever(TonbridgeMT)|mechanical thrombectomy with stent retriever(TonbridgeMT), digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging (MRI), diffusion weighted imaging (DWI)
45763683|NCT03210623|Device|Solitaire™|mechanical thrombectomy with Solitaire™ , digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging(MRI), diffusion weighted imaging(DWI)
45763684|NCT01839149|Drug|TI-001|TI-001 is intranasal oxytocin
45763685|NCT01839149|Drug|Placebo|
45763686|NCT01839383|Other|different dialysate calcium concentration|
45912065|NCT04225065|Drug|Betadine|Betadine prep prior to surgery
45912066|NCT04221087|Drug|Placebos|Sugar water based on same ml dosing of intervention arm drug
45446211|NCT02070718|Drug|Standard Dose Kappa Agonist|
45763687|NCT01835795|Device|Swiss DolorClast® CLASSIC applicator|Radial Extracorporeal Shock Wave applicator use in 6 sessions with 1 week of interval, 1000 impulses per myofascial trigger point, 5 to 7 hertz frequency, 2 to 4 bar pressure
45763688|NCT01835795|Device|Swiss DolorClast® CLASSIC placebo applicator|Placebo applicator, use in 6 sessions with 1 week of interval, 1000 impulses per myofascial trigger point, 5 to 7 hertz frequency, 2 to 4 bar pressure
45763689|NCT00906425|Device|Straumann Bone Level Implant|Straumann Bone Level Implant, SLActive surface, diameter 4.1, length 8, 10, 12, and 14 mm
45446212|NCT02070718|Drug|Half Dose Kappa Agonist|
45446213|NCT02070718|Other|Placebo|
45446214|NCT02078830|Device|3M™ Tegaderm™ CHG I.V. Securement Dressing|Chlorhexidine gluconate (CHG) has been dissolved into a soft gel pad (3x4 cm) to provide a reservoir for consistent and continuous antimicrobial action over time. The gel pad is active on contact without requiring additional moisture. CHG migrates under the catheter to provide continuous circumferential antimicrobial protection at the insertion site. Soft and conformable, the gel pad moulds around the catheter and hub.
45446215|NCT02078830|Device|Placebo Comparator: 3M™ Tegaderm™ I.V. Advanced Dressing|Placebo Dressing with the same shape like the CHG-Dressing without CHG.
45763690|NCT01835873|Other|Lactated Ringer's|
45912067|NCT04221087|Drug|Dexamethasone Oral|0.6mg/kg/dose - single oral dose administration to intervention arm
45912068|NCT04200911|Drug|Rapamune|Sirolimus 1mg capsules
45912069|NCT04181710|Procedure|Kidney transplant|Organ preserved in preservation solution
45621301|NCT02477033|Dietary Supplement|Butyricicoccus pullicaecorum 25-3T|
45621302|NCT02477033|Other|Maltodextrin|
45621303|NCT03118453|Behavioral|Active implementation clinics|Physical therapy treatment as the physical therapist chooses
45621304|NCT03118453|Behavioral|Passive implementation clinics|Physical therapy treatment as the physical therapist chooses
45621305|NCT02477579|Device|NovaCross|The NovaCross™ is a guidewire positioning and support microcatheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment, both at its distal tip.
45621306|NCT02446639|Other|Blood collection|
45621307|NCT02476721|Other|detection of pulmonary embolism|
45621308|NCT04484779|Device|IIM System|IIM System
45621309|NCT04484779|Drug|Insulin Lispro and/or Insulin Glargine|Administered subcutaneously (SC)
45621310|NCT02476643|Other|Integrative Therapy|This group receives an integrative therapy at the Department of Internal and Integrative Medicine, i.e. a combination of conventional diagnostic and therapeutic interventions with specific naturopathic, and complementary medicine approaches, and physical therapy.
45621311|NCT02477501|Drug|Norepinephrine|continuous infusion
45621312|NCT02477501|Drug|Ephedrine|continuous infusion
45621313|NCT02446795|Drug|Sunitinib|Sunitinib: 50mg once daily orally for 4 weeks followed by 2 weeks off treatment (either at 8 a.m. or at 8 p.m.)
45621314|NCT02446795|Drug|Isoquercetin|Isoquercetin: 225mg twice a day(at 08 a.m. and at 4 p.m)/Isoquercetin: 450 mg twice a day(at 08 a.m. and at 4 p.m).
45621315|NCT02446795|Drug|Placebo|Placebo: 225mg twice a day(at 08 a.m. and at 4 p.m)/Placebo: 450 mg twice a day(at 08 a.m. and at 4 p.m).
45621316|NCT02477267|Drug|SL spray|
45621317|NCT02477267|Drug|SL film|
45621318|NCT03196765|Drug|Sobetirome (NV1205)|Once a day oral dose of the study drug
45621319|NCT03196843|Drug|Raltitrexed|Raltitrexed 2.5mg/m2 on day 1,22,43 during radiotherapy
45763691|NCT01835873|Other|HES 130/0.42|Balanced colloid solution
45763692|NCT01835951|Other|Grouped Debriefing|Debriefing consists in an analysis by the investigator of the management of the anaesthesia crisis simulated in the presence of all the subjects included in the Groupe Debriefing group.
45763693|NCT01835951|Other|Individual Debriefing|Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
45621320|NCT03196843|Radiation|Intensity Modulated Radiotherapy|Radical radiotherapy:70Gy/2Gy/7 weeks Preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 week
45621321|NCT03196609|Biological|Collection of stool and serum samples|"During the inclusion visit (for the 5 cancer sites): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) +Blood sample (1 tube SST + 1 tube EDTA)~1 month after treatment (only for non-small cell lung cancer): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) + Blood sample (1 tube SST + 1 tube EDTA)"
45621322|NCT02477345|Drug|Omegaven IV|"Omegaven will be initiated at a dose of 0.5 gram/Kg/day and is infused over 24 hours for 1-2 days, and then advanced to~1 gram/Kg/day. Omegaven will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven will continue until weaned from PN. Monotherapy with Omegaven can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/Kg/day, advancing to 1 gm/kg/day."
45621323|NCT02446561|Drug|MRXXX|
45621324|NCT02446561|Drug|MR1XXX|
45621325|NCT02446561|Drug|MR2XXX|
45621326|NCT02446561|Drug|MR3XXX|
45763694|NCT01839539|Biological|dendritic and cytokine-induced killer cells|
45621327|NCT02477189|Procedure|Silicone Block|
45621328|NCT02476955|Drug|ARQ 092 + carboplatin + paclitaxel (Closed)|Subjects will receive ARQ 092 orally at dose levels specified for their respective dose cohorts plus carboplatin (AUC6, intravenously, Day 1) plus paclitaxel (175 mg/m2, intravenously, Day 1) on a 21-day schedule.
45621329|NCT02476955|Drug|ARQ 092 + paclitaxel (Closed)|ARQ 092 will be administered orally at 200 mg twice a day (BID) weekly (Cohort 1P) of a 28-day cycle in combination with an intravenous (IV) infusion of paclitaxel (80 mg/m2). ARQ 092 will be administered once a week on Day 1, Day 8, Day 15, and Day 22 of each 28-day cycle; paclitaxel will be administered once a week on Day 1, Day 8, and Day 15 for three consecutive weeks followed by one week off of each 28-day cycle.
45621330|NCT02476955|Drug|ARQ 092 + anastrozole|ARQ 092 will be administered orally at 150 mg QD, 5 days on/9 days of a 28 day cycle in combination with anastrozole which will be administered orally at 1 mg QD continuously.
45621331|NCT04484389|Other|Telerehabilitation|Exercise protocol according to Ipaq will be prepared for 30 patients with chronic disease . Exercise protocol; warm-up exercises include, stretching exercises, postural exercises, aerobic exercise and cooling exercises. People will practice the exercises 3 days a week for 6 weeks. People will need to reserve 30 minutes a day for this study.
45621332|NCT04484389|Other|Exercise brochure|General exercise protocol will be prepared and given to the control group as a brochure
45621333|NCT02634801|Drug|Fumaric Acid Esters|Administered orally
45621334|NCT02634801|Drug|Methotrexate|Administered orally
45621335|NCT02634801|Drug|Ixekizumab|Administered SC
45621336|NCT03196453|Dietary Supplement|Probiotic|probiotic and/or placebo intervention in toddlers
45621337|NCT05587595|Other|questionnaires & data collection|questionnaires
45763695|NCT00901199|Drug|Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)|All subjects will be given Deferasirox 20-30 mg/kg for 7 days per week. All subject will be given Deferoxamine 50 mg/kg for 3-7 days per week. The number of days for Deferoxamine will be determined by liver iron concentration at baseline.
45763696|NCT01839617|Dietary Supplement|Early parenteral nutrition|
45763697|NCT01839617|Dietary Supplement|Late parenteral nutrition|
45763698|NCT01836341|Drug|Afatinib|
45763699|NCT01836341|Drug|Cisplatin|
45763700|NCT01836341|Drug|Carboplatin|
45763701|NCT01836341|Drug|Pemetrexed|
45763702|NCT01836341|Radiation|Radiation therapy|
45763703|NCT01836419|Procedure|classic LMA insertion|
45935179|NCT00042029|Drug|Comparator: placebo|
45621338|NCT02449135|Procedure|interventional therapy|Pancreatic cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）.
45621339|NCT02476253|Drug|Sodium Bicarbonate|Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30
45621340|NCT03196531|Drug|Loratadine (Xisimin [Test Treatment])|Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
45621341|NCT03196531|Drug|Loratadine (Clarityne [Reference Treatment])|Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
45621342|NCT04996407|Device|survival thermal blanket|patients were given a thermal blanket
45621343|NCT04996407|Device|draping fabric|Patients were given a draping fabric
45621344|NCT02476799|Procedure|Rectus sheath block|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
45763704|NCT00906503|Drug|dexamethasone|Four 4 mg dexamethasone tablets by mouth after food 40, 28, 16 and 4 hrs before the scan
45446216|NCT02070796|Drug|Rotigotine PR2.2.1|"Treatment A:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm^2) Test drug product PR2.2.1. Single application of 1 patch for 24 hours."
45763705|NCT00906503|Procedure|PET/Computed Tomography (CT)|Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
45763706|NCT00906503|Radiation|fludeoxyglucose (18F)|Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
45763707|NCT01836575|Drug|Pemetrexed|Pemetrexed, 500 mg/m2 + Pretreatment [dexamethasone + vitamin B12 + folic acid, as per pemetrexed label] + Antiemetic therapy at investigator's discretion.
45763708|NCT01836575|Drug|Carboplatin|Carboplatin [Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle].
45763709|NCT01836653|Drug|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
45763710|NCT01836653|Drug|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
45763711|NCT01836653|Drug|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
45763712|NCT01836653|Drug|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
45763713|NCT01836653|Drug|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
45912070|NCT04174092|Other|completing self-questionnaires|completing self-questionnaires on quality of life, anxiety, insomnia, activity of rheumatic disease and catastrophism
45446217|NCT02070796|Drug|Rotigotine PR2.1.1|"Treatment B:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm^2) Reference drug product PR2.1.1. Single application of 1 patch for 24 hours."
45621345|NCT02476799|Drug|Ropivacaine|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
45621346|NCT02476799|Other|Bandage|After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
45621347|NCT02476799|Drug|IV-PCA containing Fentanyl and Ketorolac|All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl and 150 mg of ketorolac for 48 hours postoperatively.
45621348|NCT02449369|Drug|Preop acetaminophen IV|
45621349|NCT02449369|Drug|Preop orphenadrine IV|
45621350|NCT02449369|Drug|Postop oral oxycodone & acetaminophen|
45621351|NCT02449369|Drug|Postop hydromorphone IV|
45621352|NCT02449369|Drug|Postop oral orphenadrine|
45621353|NCT02449369|Drug|Postop oral oxycodone|
45621354|NCT02449369|Drug|Postop acetaminophen IV|
45621355|NCT02449369|Drug|Postop orphenadrine IV|
45621356|NCT04456569|Device|Geniculate Artery Embolization|All patients within the embolization group will undergo unilateral angiography and embolization of the appropriate treatment limb geniculate arteries. For patients with bilateral disease the more clinically symptomatic side will be chosen as the treatment/control knee.
45621357|NCT02476331|Behavioral|Working memory training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
45621358|NCT04989777|Device|IABP (Intra-aortic balloon pump ) implantation|Eligible AMI patients in SCAI-B stage will receive IABP implantation from the femoral artery
45621359|NCT03192943|Drug|BMS-986205|Specified dose on specified days
45621360|NCT03192943|Biological|Nivolumab|Specified dose on specified day
45763714|NCT01836653|Drug|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
45763715|NCT01836731|Behavioral|Classic Intervention|"The standard classic approach will implement a total of 20 community health club sessions delivered through weekly education programs in the target communities as per the training manual. Community health workers (CHW) will receive careful training in the delivery of the CBEHPP instruction. High quality instructional materials (in color) will be used. Club members will each receive a membership card to be used to track attendance and compliance. Finally model home competitions and a graduation ceremony will be held. Monitoring of the clubs will be conducted by community health workers using mobile phones."
45912071|NCT04154683|Device|Cellvizio®|use of the Cellvizio® optical biopsy
45912072|NCT04153357|Device|airtraq|device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords
45912073|NCT04153357|Device|c-mac|device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords
45763716|NCT01836731|Behavioral|Minimum Intervention|"The lite trial arm will only implement 8 sessions covering all the WASH topics. It will be facilitated by CHWs receiving minimal training and using black/white photocopies of instructional materials. Members will not be issued with membership cards and will not have a graduation ceremony or home garden competitions. Minimal monitoring of this arm will be carried out by environmental health officers."
45763717|NCT03836885|Drug|Apremilast|Apremilast tablets. Titration will occur in the initial five days of treatment as per dosing in psoriasis as follows: Day 1: 10 mg; Day 2: 20 mg; Day 3: 30 mg; Day 4: 40 mg; Day 5: 50 mg. Day 6 and thereafter patients will be dosed at 60 mg for a total of 12 weeks.
45763718|NCT03836885|Drug|Placebo|Placebo Oral tablets. Patients randomized to the control arm will receive color, taste, shape and odour matched oral placebo. The number of tablets and the days taken is analogous to the intervention arm had they been randomized to the intervention arm.
45621361|NCT02724839|Behavioral|Group nutrition sessions|The intervention will consist of 6 nutrition group sessions co-led by parent and a professional from the community who will rotate at each session. Group nutrition sessions will consist of a facilitated discussion of benefits and barriers to healthy eating, a short lesson led by the content expert, and a fun game or activity to reinforce the lesson. Three non-concurrent phases of the study will compare the efficacy of the group sessions when offered biweekly (Arm 1), monthly (Arm 2) and weekly (Arm 3).
45763719|NCT03837119|Other|pregnancy outcome|descriptive statistics of variables
45763720|NCT00920647|Other|Control|3 dose cohorts were planned. Within each dose cohort, patients will be randomized to 1 of 2 treatment options: treatment with study drug or no treatment with 4 treated patients per dose group and a total of 4 untreated patients (1-2 untreated patients will be assigned in each dose cohort). They will not undergo surgical placement of an Intrathecal Drug Delivery Device (IDDD), and will not receive Idursulfase-IT.
45621362|NCT02724839|Device|Fitbit|Parent and child dyads will each receive a Fitbit Flex wearable device at the second session. This device will be used by participants and investigators to motivate and track participants' physical activity for up to 9 months.
45621363|NCT04986813|Drug|Tranexamic acid injection|1 g of TXA in 100 ml of normal saline
45621364|NCT04986813|Other|Normal Saline|100 ml
45621365|NCT04996329|Other|early health warning intervention|early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD.
45912074|NCT04153344|Other|Electro-oculogram|Electrophysiological recording of changes in electrical potential across the retinal pigmentary epithelium during successive periods of dark and light adaptation, according to ISCEV standards. Results will comprise dark trough value and light/dark (Arden) ratio.
45912075|NCT04153344|Other|Full-field electroretinogram|Electrophysiological recording of retinal function. Results will comprise amplitudes and latencies of each electroretinography response (dark-adapted 0.01, dark-adapted 3.0, dark-adapted 10.0, dark-adapted 3.0 oscillatory potentials, light-adapted 3.0, light-adapted 3.0 flicker).
46069258|NCT03533855|Diagnostic Test|CS plus FRFSE|"we perform a classic Fast Relaxation Fast Spin Echo (FRFSE) 3D MRI and add compressed sensing sequence"
46069259|NCT03505801|Device|Confirm Rx ICM insertion procedure|Insertion of Confirm Rx ICM device
45912076|NCT04124315|Other|Accelerometry|Patients will be given accelerometers at this visit and informed on how to use them (e.g., wear on the ankle during waking hours, upright, etc).
46069260|NCT03479502|Drug|Methylprednisolone Injectable Product|3 intra-articular injections of Methylprednisolone Injectable Product spaced every two weeks
45912077|NCT04124315|Other|Daynamica app|Participants will be asked to record location/activity on the app in order to characterize activity patterns both inside and outside of the hospital SET setting.
45912078|NCT04112641|Drug|Nicotinamide riboside|Daily oral ingestion of 1 g/day NIAGEN in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
45912079|NCT04112641|Drug|Placebo capsules|Daily oral ingestion of placebo in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
45912080|NCT04102007|Drug|Risankizumab|Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS).
46069261|NCT03479502|Drug|Doxycycline Injection|3 intra-articular injections of Doxycycline Injection spaced every two weeks
46069262|NCT03420859|Diagnostic Test|qPCR for abnormal vaginal microbiota|qPCR for A.vaginae and/or G.vaginalis as developed in the pilot study (Hum Reprod. 2016 Apr;31(4):795-803. doi: 10.1093/humrep/dew026. Epub 2016 Feb 23.)
45621366|NCT04986735|Drug|Empagliflozin|All subjects will have a baseline assessment and be prospectively followed up for 52 weeks to examine their outcome after receiving empagliflozin for neutropenia and neutrophil dysfunction.
45621367|NCT04995783|Diagnostic Test|Coral FRS test|A novel clinical test to predict autoimmune medication response
45621368|NCT03069729|Other|no intervention|This study evaluates s system intended to detect bio-markers of DPN. No interventions are involved in this non-invasive study.
46069263|NCT03341052|Other|Normal Diet|The normal diet will consist of the participants' normal eating habits, and will be tracked by a food log. The participants will be on their normal diet during week 1 and week 3.
45621369|NCT03109301|Drug|Selumetinib (AZD6244 hyd sulfate) 50mg/dose|Selumetinib will be administered at a starting dose of 50 mg/dose orally in patients 18 years or older; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
45763721|NCT00920647|Drug|Idursulfase IT (1 mg)|The original design of the study was to test the dose levels of 10, 30 and 100 mg. This was based on a calculation of a minimally effective dose around 10 mg, with subsequent dose levels being chosen as increasing half-log steps. During the conduct of the study; however, it became clear that the 10 mg dose elicited a strong Pharmacodynamic response, as measured by a dramatic and sustained drop in the CSF GAG levels. This indicated the need to explore a lower level as a minimally effective dose level, leading to the introduction of the 1 mg group. Enrollment of patients in this dose cohort will commence after the last patient has been enrolled in 30 mg dose cohort. 4 patients will be undergo surgical placement of an IDDD and receive 1 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
45763722|NCT00920647|Drug|Idursulfase IT (10 mg)|Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 10 mg idursulfase-IT as an intrathecal (IT) injection via an IDDD once per month (ie, every 28 days) for 6 month.
45763723|NCT00920647|Drug|Idursulfase IT (30 mg)|Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 30 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
45621370|NCT03109301|Drug|Selumetinib (AZD6244 hyd sulfate) 25mg/m2|Selumetinib will be administered at a starting dose of 25 mg/m2/dose in children < 18 years of age; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
45763724|NCT01836887|Dietary Supplement|Very low polyphenol fruit based drink (control)|
45912081|NCT04100161|Dietary Supplement|Protein supplementation|Daily dose of 40 g whey protein for 3 months
45621371|NCT03069651|Other|Virtual Care|The use of Videoconferencing software to enable remote access to monitor patients in the 'Virtual Care' cohort.
45763725|NCT01836887|Dietary Supplement|Polyphenol-enriched fruit-based drink - low|
45763726|NCT01836887|Dietary Supplement|Polyphenol-enriched fruit-based drink - high|
45763727|NCT01836965|Behavioral|Social Skills Intervention|Twelve week manual based social skills curriculum targeting social fluency and responsiveness.
45763728|NCT04373395|Procedure|D-CLAG|Decitabine+Cladribine+Cytarabine+Granulocyte Colony Stimulating Factor
45763729|NCT01837043|Drug|Belatacept|
45763730|NCT01837043|Drug|Calcineurin Inhibitor|
45763731|NCT01839773|Drug|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
46069264|NCT03341052|Other|High Fat Diet|The high fat diet will consist of 2700 kcal, 100g total fat (33%), 300mg cholesterol, 350g carbohydrates (52%), and 100g protein (15%). The participants will be on this diet during week 2.
45621372|NCT03109223|Other|sole source nutrition|Infant formula
45763732|NCT01839773|Drug|Paclitaxel|Premedication, IV infusion on day 1 of 3-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
45763733|NCT04373239|Procedure|Assisted Reproductive Technology|Assisted reproductive technology includes IVF and IVF+ICSI.
45763734|NCT04373161|Device|Home Pulse Oximetry Monitoring|Patients to check their home oxygen saturation three times daily and return to the ED for sustain oxygen <92% or for worsening symptoms.
45763735|NCT00909155|Drug|Venlafaxine ERT|Titrated to a minimum dose of 75mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 37.5 mg; Days 7-14: 75 mg; Days 15-180: 75-300mg based on clinician assessment. Titration rate is a maximum of 75mg/7d.
45763736|NCT00909155|Drug|Fluoxetine|Titrated to a minimum dose of 20mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 20mg; Days 7-14: 20mg; Days 15-180: 20-80mg based on clinician assessment. Titration rate is a maximum of 20mg/7d
45763737|NCT01839851|Drug|Treatment with any inhaled corticosteroid|Use of any inhaled corticosteroid (daily frequency and dose will be registered)
45763738|NCT01839851|Drug|Treatment with any intranasal glucocorticoid|Use of any inhaled intranasal glucocorticoid (daily dose and frequency will be registered)
45763739|NCT01839929|Drug|Prograf|oral
45763740|NCT01839929|Drug|Advagraf|oral
45763741|NCT03403855|Device|Rocket® IPC- Long External Length|Rocket® IPC- Long External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
46069265|NCT03341052|Other|Low Fat Diet|The low fat diet will consist of 1200 kcal, 26g fat (20%), 78mg cholesterol, 150g carbohydrates (50%), and 100g protein (30%). The participants will be on this diet during week 4.
46069266|NCT03295994|Procedure|Operative|Arthroscopic rotator cuff surgery followed by physical therapy.
45763742|NCT03403855|Device|Rocket® IPC- Short External Length|Rocket® IPC- Short External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
45763743|NCT04373083|Drug|Cemiplimab|Administered in 3-week intervals
45763744|NCT04373083|Radiation|Involved-site radiotherapy (IS-RT)|Patients will receive IS-RT with a dose of 20 Gy. Involved-site radiotherapy will be carried out on the basis of 3D imaging as described in the protocol
46069267|NCT03295994|Procedure|Non-Operative|Physical therapy (without surgery).
45912082|NCT04100161|Dietary Supplement|Carbohydrate supplementation|Daily dose of 40 g maltodextrin for 3 months
45912083|NCT04100161|Procedure|Active rehabilitation|Progressive rehabilitation following a muscle strain injury for 3 months
46069268|NCT03294460|Drug|Alcohol (Oral)|Oral Self-administration
45912084|NCT04099862|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
46069269|NCT03294460|Drug|Alcohol (IV)|IV Self-administration
46069270|NCT03294460|Drug|Alcohol (Ethanol)|IV and Oral Self-administration
45763745|NCT03210545|Drug|Betamethasone|A cross-over study where patients with Addison´s disease will undergo two treatment periods where their usual hydrocortisone replacement therapy will be replaced by the glucocorticoid betamethasone in physiological and supra physiological doses. A wash-out period of 2-5 weeks in-between the treatment periods will be carried out where participants intake their usual hydrocortisone replacement therapy.
45763746|NCT04372849|Other|Human nasal insulin|single dose of 160 U of human insulin as nasal spray
45763747|NCT04372849|Other|Placebo|Single dose of placebo solution as nasal spray
45763748|NCT03210389|Drug|Lobaplatin|Patients enrolled will receive lobaplatin 30mg/m2 d1+ 5-FU 0.5g/m2/d d2-5 in every 21days. 4-6 cycles of chemotherapy are recommended.
45763749|NCT03403777|Drug|Avelumab|AVELUMAB will be administered intravenously 10mg/kg every 2 weeks.
45763750|NCT01837121|Other|the SMS reminder message|the SMS reminder message will sent to the SMS group patients 1 week and 3 day before there appointment,to remind them the exact time and address of the revisit appointment.
45763751|NCT02241421|Drug|Amoxicillin|
45763752|NCT02241421|Drug|Vancomycin|
45763753|NCT02241421|Other|Placebo|
45763754|NCT01837199|Drug|Metronidazole plus Amoxicillin|All subjects will receive scaling and root planing combined with systemic metronidazole (400 mg) and amoxicillin (500 mg). Both antibiotics were administered T.I.D. for 14 days.
45763755|NCT03210233|Procedure|Blood test, skin testing and challenge testing.|Skin Prick Testing (SPT) and Intradermal Testing (IDT). We will follow the STARD framework for reporting studies of diagnostic accuracy
45763756|NCT01837355|Dietary Supplement|Lactobacillus rhamnosus|
46069271|NCT03243097|Device|Phase I - Standard Microphone Cros Input|Subject will be fit with the research processor plus CROS microphone and wear for a 4 week period
46069272|NCT03243097|Device|Phase II - Automatic directional microphone Cros Input|Automatic directional microphone technology will be activated in the research processor. Subjects will wear the CI+CROS configuration with directionality activated exclusively for 4-weeks.
45621373|NCT03069885|Device|Prevena|Incisional negative pressure wound therapy (iNPWT), is a new approach for surgical site closure using negative pressure wound therapy (NPWT). Recently, PrevenaTM have been approved as an iNPWT-system applied at the end of surgery, while still in a sterile environment. PrevenaTM consist of a sponge foam with a bactericidal silver lining dressed with an adherent film, connected to a vacuum device, producing a vacuum of 125 mm Hg. The PrevenaTM foam and dressing is placed over the suture line, and is recommended to be kept in place for a continuous period lasting between 2 and 7 days.
45621374|NCT03069885|Other|Standard Postoperative dressing|The standard postoperative dressing, using steri strips placed over the suture line.
45621375|NCT02475941|Other|Non Weight bearing|"The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient."
45621376|NCT02475941|Other|Early Weight Bearing|"The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient."
45621377|NCT02475863|Device|Warfarin Dosing Aid|A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin
45621378|NCT02475863|Other|Standard Practice|Warfarin dose adjustments according to standard unit protocol
46069273|NCT03243097|Device|Phase III - No Cros Input|Subjects will return the research processor and CROS device and wear their own processor for a 2-week period
46069274|NCT03240016|Drug|Pembrolizumab|200mg IV D1
45621379|NCT03071055|Drug|Ranibizumab Injection [Lucentis]|intravitreal injection
45621380|NCT04433559|Drug|Tadalafil 1,5 mg oral tablets|Use of tadalafil in the treatment of FSIAD
45763757|NCT01837355|Dietary Supplement|Placebo|
45912085|NCT04099862|Procedure|EUS-BD|Endoscopic UltraSound Biliary Drainage
45763758|NCT03210311|Device|compression|a compression stocking is worn, a garment compression class 2, flat knitted
45763759|NCT00926185|Drug|Lifitegrast|Ophthalmic Solution
45763760|NCT00926185|Drug|Placebo|Ophthalmic Solution
45763761|NCT01837511|Other|Data acquisition and analysis|Tumor tissue samples submitted with a Patient and Tumor-Sample Characteristics. Form containing previously collected specific clinical data of patients with pathologically proven stage I, II and III NSCLC.
45763762|NCT00921895|Device|RPS Adeno Detector IV|One time test with the RPS Adeno Detector IV
45763763|NCT03210077|Device|Monitoring|Monitoring
45763764|NCT04372771|Other|Curves Circuit|The Curves Circuit consists performing 13 hydraulic resistance exercise machines that utilize bidirectional resistance that work all major muscle groups. These are interspersed with floor-based calisthenic exercises designed to maintain an elevated heart rate.
46069275|NCT03240016|Drug|Abraxane|100mg/m^2 D1 and D8
45763765|NCT04372771|Other|Weight Watchers|The Weight Watchers program encourages one to increase physical activity.
45763766|NCT01837589|Other|QCT|
45763767|NCT01837589|Other|DXA|
45763768|NCT02241499|Radiation|Radiation therapy|Radiotherapy at a dose of 4 Gy will be given to a total dose of 20 Gy, treatment duration 5 days.
45763769|NCT02241499|Drug|Oxaliplatin and fluorouracil.|Oxaliplatin at a dose of 85 mg/m2 and will be given on day 1, infusion (44 hours) of fluorouracil will be given for 4 cycles, cycle length 14 days.
45763770|NCT01837667|Drug|LB-100 for Injection|Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.
45763771|NCT01837667|Drug|Docetaxel|Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.
45763772|NCT02241577|Procedure|Surgical treatment|Flap surgery around dental implant for scaling and disinfection of the titanium surface under local anesthesia
45763773|NCT02241577|Procedure|Non-surgical treatment|Non-surgical subgingival scaling and disinfection of the titanium surface of dental implant under local anesthesia
45621381|NCT04433559|Drug|Placebo oral tablets|Use of placebo in control group
45446220|NCT02070874|Behavioral|telehealth enhanced pain management|
45446221|NCT02078908|Drug|Sodium nitrite, 40 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour
45763774|NCT04379765|Behavioral|Exercise and physical therapy|Decompression operation
45446222|NCT02078908|Drug|Sodium nitrite, 120 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour
45621382|NCT03071211|Device|Plug-unplug catheter management|Transurethral catheter is plugged with a plastic cap and participants are taught to unplug during the day when they feel the urge to void or at least every 4 hours.
45763775|NCT04372303|Behavioral|Compassion Fatigue Resiliency Program (CFRP)|The purpose of Compassion Fatigue Resiliency Program (CFRP) is to provide oncology-hematology nurses with knowledge and skills that will increase their level of resilience by helping them recognize compassion fatigue, cope with its consequences and work effectively.
45763776|NCT03217877|Diagnostic Test|routine stress testing|In the group of routine stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed at 9~15 months after the procedure according to the practice pattern of each participating center.
45621383|NCT03071211|Device|Continuous drainage catheter management|Transurethral catheter is attached to a continuous drainage bag.
45621384|NCT02475785|Device|FFRD and mini plates group|FFRD direct loading over mini plates inserted in the mandibular symphysis
45763777|NCT03217877|Diagnostic Test|No Routine stress testing|In the group of symptom oriented stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed when chest pain or angina symptom is occured after the procedure according to the practice pattern of each participating center.
45763778|NCT04379531|Diagnostic Test|Low-dose Chest CT|Patients referred by the primary care physician with suspected pneumonia.
45763779|NCT03833947|Drug|lignocaine+bicarbonate|ETT cuff was filled with mixture of 2% lignocaine with bicarbonate
45912086|NCT04095663|Procedure|Partial Colectomy|Most partial colectomies are performed using a laparoscopic approach, when possible, and surgeons sometimes use a temporary, protective stoma if the re-connection is considered high risk.
45912087|NCT04095663|Other|Medical Management|"Patients will be offered a varying combination of tools from the best medical management toolbox (diet and exercise, fiber supplementation/probiotics, and rifamycin/mesalazine) depending on what they have already tried. Based on the evidence-based best medical toolbox clinicians will be asked to consider rifamycin (dose/frequency) for those with AUD who are not responding to diet and exercise and mesalazine (dose/frequency) for those with lingering symptoms who are not responding to diet and exercise."
45912088|NCT04062591|Drug|Piroxicam group|patients will receive 0.4 mg/kg piroxicam IM
45912089|NCT04062591|Drug|Placebo|saline IM in the same dose of piroxicam
45912090|NCT04059770|Drug|single dose of L-AmB|(i) single IV dose of 10 mg/kg of L-AmB on day 1;
45912091|NCT04059770|Drug|2 doses of L-AmB|(ii) IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;
45446223|NCT02078908|Drug|Sodium nitrite, 240 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour
45446224|NCT02078908|Drug|Placebo|Continuous 2 hour infusion of sodium chloride, 25 ml/hour
45446225|NCT02078986|Other|Whole Body Electromyostimulation|Supervised WB-EMS, 3 sessions in 2 weeks (1,5 sessions/week) for 14 weeks
45446226|NCT02078986|Other|High Intensity Resistance Exercise Training|Supervised High Intensity Resistance Exercise Training (HIT) 2-3 sessions/week for 14 weeks
45446227|NCT02079064|Drug|Desflurane|Inhalational anesthetic
45446228|NCT02079064|Drug|Propofol|Intravenous anesthetic that can be given by continuous infusion
45446229|NCT02070952|Radiation|CyberKnife Stereotactic Ablative Body Radiation Therapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
45621385|NCT02475785|Device|Conventional FFRD|FFRD inserted between maxillary and mandibular arches with the pushrods placed distal to mandibular canines
45621386|NCT04989153|Diagnostic Test|pepsinogen|serum pepsinogen diagnosed gastric cancer and precanceous lesion
45621387|NCT04911959|Drug|Lenvatinib|Lenvatinib is taken orally.
45763780|NCT03833947|Drug|lignocaine+dexamethasone|ETT cuff was filled with mixture of 2% lignocaine with dexamethasone
45763781|NCT03219437|Drug|risankizumab|subcutaneous (SC) injection
45763782|NCT03219437|Drug|methotrexate|capsule
45763783|NCT00920023|Drug|Superparamagnetic Iron Oxide Magnetic Resonance Imaging|Two MRIs will be performed over a two day period. The second scan will be done 48 hours after intravenous infusion of ferumoxytol
45763784|NCT03212963|Drug|Halobetasol Topical Lotion|Halobetasol Lotion 0.05%, applied twice daily in subjects aged 12 to 16 years 11 months with stable plaque psoriasis.
45763785|NCT03403309|Drug|1) Inosine 5'-monophosphate|1) Subjects are initiated with 1 tablet (500mg of inosine 5'-monophosphate per one tablet) two times per day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL, so that reducing dose of administration may be considered in case of being way over the top of limited level.
45763786|NCT03403309|Drug|Placebo|2) Subjects are initiated with 1 tablet (500mg of placebo tablet with inactive therapeutic effect) two times a day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL.
45763787|NCT04347499|Other|CaCBT based guided self help using Khushi aur Khatoon Manual|CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm
45763788|NCT03218969|Drug|Ecopipam|oral drug in subjection currently experiencing dopamine agonist induced augmentation
45763789|NCT03218969|Drug|Placebo|matching placebo
45763790|NCT02982499|Device|magnetic resonance image (MRI)|Radiographic imaging that takes about 30-45 minutes
45621388|NCT04911959|Procedure|TACE|TACE treatment once.
45763791|NCT02982499|Device|Optical Coherence Tomography (OCT)|Images taken from the back of the eye (retina)
45621389|NCT03070665|Drug|Norepinephrine|Increasing blood pressure up to 150mmHg for 5min using norepinephrine pump as initial dose 0.05μg/Kg.min during ESD operation, meanwhile check out the potential hemorrhage spot which is not obvious and then use the hot biopsy forceps to coagulate the bleeding spot, after that withdraw the norepinephrine and record the potential bleeding spot's location. The other procedures are the same as control groups'.
45621390|NCT04988919|Dietary Supplement|4D|multi-ingredient supplement mixed with 24 ounces of water
45763792|NCT03214523|Behavioral|Sleep Education|The subject will undergo a 30-minute session on sleep education from one of the study coordinators.
45763793|NCT04372537|Behavioral|hypnosis|use of hypnosis.
45763794|NCT04372537|Behavioral|standard care|standard clinical procedure
45763795|NCT04372225|Other|analysis of hypocalcemia|analysis of postoperative calcium and PTH levels
45763796|NCT03214289|Biological|Fecal Microbiota Transplantation|Thirty fecal microbiota capsules produced from a single healthy donor, unrelated to the participant.
45763797|NCT04372459|Behavioral|Online integrated and stepped psychosocial care|"This program features four levels of care, increasing in intensity of psychosocial care as patients move from one level to the next one.~Step 1: Screening and monitoring of several psychosocial variables through the central mobile application of the program (App ICOnnecta't).~Step 2: Online guided and self-help psychoeducation Campus in which patients can consult videos and online resources, co-constructed between health professionals and patients, containing reliable and rigorous information related to the oncological process.~Step 3: Online community of psychosocial support. Participants can choose from 12 cancer-related discussion forums and share with the community any health-related question that worries them fostering, thus, debate and stimulating peer-support.~Step 4: Intensive online group psychotherapy (App ICOnnecta't Videoconsultation), based on the Group Positive Psychotherapy program for cancer survivors (Ochoa, Sumalla, Maté, Castejón, Rodríguez et al., 2010)."
45763798|NCT04372459|Behavioral|Usual psychosocial care|This active control group will receive the standard psychosocial treatment for cancer survivors in the participating centers, led by a clinical psychologist and consisting of 8 individual, 45/60-minute sessions, each of which every 1-2 months, focused on providing emotional support and psychoeducation during the first year of primary cancer treatment.
45763799|NCT01830023|Device|cardiac ultrasound examination|cardiac ultrasound examination to examine the vitality
45763800|NCT01830101|Drug|TMZ plus concurrent re-irradiation|
45763801|NCT01830101|Drug|Temozolomide|low-dose temozolomide daily for one year
45763802|NCT01838603|Other|Qualitative interview|Qualitative interview to sample the patients feelings, experiences and thoughts risen by the treatments in the program
45763803|NCT01830257|Other|sending message|Sending the suggestive short message
45763804|NCT01834625|Diagnostic Test|PET scan|
45763805|NCT01830335|Drug|Indomethacin|
45763806|NCT01830335|Drug|Placebo|
45446230|NCT02079142|Behavioral|High Intensity Strategy: Train-the-trainer|"Trainers in the high intensity condition will attend two separate workshops at Washington University in St. Louis designed to teach participants to conduct IPT and then to train IPT. Following participation in the first, two-day workshop, each trainer will return to their site and be encouraged to treat at least two cases with eating disorders or depression, audio recording each session.~Trainers will then return to Washington University to be trained in how to train their other staff members in IPT."
45621391|NCT04988919|Dietary Supplement|placebo|taste-matched placebo mixed with 24 ounces of water
45763807|NCT00926263|Biological|CP-751,871|single dose, 1-hr IV infusion
45763808|NCT00926263|Biological|CP-751,871|single dose, 1-hr IV infusion
45912092|NCT04059770|Drug|2 weeks of L-AmB|(iii) IV dose of 3 mg/kg of L-AmB for 2 weeks.
45912093|NCT04051892|Device|FixNip™ NRI|The FixNip™ NRI is an implantable hypodermic, silicone implant specially designed for nipple areola definition
45763809|NCT00926263|Biological|CP-751,871, moxifloxacin, saline|Two doses at 20 mg/kg each on two consecutive days, each administered via 1-hr IV infusion
45763810|NCT01838915|Dietary Supplement|Prebiotics+Glutamine|"Prebiotics are nondigestible food ingredients, generally oligosaccharides, that modify intestinal microbiota balance by stimulating the growth of beneficial bacteria.~Glutamine is a non-essential amino acid that can be metabolized by epithelial cells, enhancing barrier function."
45763811|NCT01838915|Dietary Supplement|Placebo|Maltodextrin, 20 g.
45763812|NCT01725659|Other|Motor Learning|training of the hemiplegic upper limb with motor learning
45763813|NCT01725659|Other|Robotics|subjects perform training of hemiplegic arm using an upper extremity robot
45763814|NCT01725659|Other|surface FES|subjects are provided with surface FES to the hemiplegic upper limb
45763815|NCT00926497|Other|Procalcitonin-guided decision making|Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early onset sepsis
45763816|NCT00916643|Device|HELP Secura (apheresis treatment)|Process is described in Arm (above).
45763817|NCT04372147|Procedure|MMA embolization|Patients in the intervention group will undergo a CT angiography scan of the supra aortic trunks, followed by MMA embolization procedure within 7 days of the burr-hole surgery in addition to standard medical care
45763818|NCT03409913|Radiation|FDG PET/CT|Conventional FDG PET/CT including head in order to asses cranial arteries.
45763819|NCT03403075|Behavioral|ETAF|Therapeutic education and Physical activity
45763820|NCT03403075|Behavioral|Usual care|Usual care
45763821|NCT04378361|Device|endovascular repair|Endovascular repair of complicated acute, subacute or chronic type B aortic dissection with double lumen
45935180|NCT00218179|Other|Non-intervention|Measured total NNAL and PheT as biomarkers of exposure
45935181|NCT00218218|Drug|Transdermal Nicotine Patch|42 mg transdermal nicotine
45935182|NCT00218218|Drug|21 mg transdermal nicotine|
45935183|NCT00218218|Drug|placebo patch|
45935184|NCT00218374|Drug|Gabapentin|Gabapentin initiated up to a daily dose of 2400mg PO x 5 weeks
45935185|NCT00218413|Biological|NicVAX|100 μg, Formulation A, on Days 0, 21, 42, 91 & 182
45935186|NCT00218413|Biological|NicVAX|200 μg, Formulation A, on Days 0, 21, 42, 91 & 182
45446231|NCT02079142|Behavioral|Low Intensity Strategy: Expert Consultation|Investigators will provide a two-day workshop on IPT at each site randomized to this condition to train therapists to use IPT for the treatment of Eating Disorders and depression.
45763822|NCT03833869|Procedure|Assisted hatching|Controlled hatching of the zona pellucida in the laboratory prior to embryo transfer
45763823|NCT01725737|Drug|GlyTI-M|
45621392|NCT05382533|Dietary Supplement|Menu plans|The study participants in group A and C receive defined personal nutritional counselling every two weeks and they are provided with daily menu plans (isocaloric) with optimized nutrient profiles and chosen study products (plant oils, nuts mixture etc.) over the study period of 10 weeks.
45912094|NCT04050280|Drug|Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)|"Induction:~G-CSF 300 mcg subcutaneously daily on days 0-5.~Cladribine 5 mg/m2 in normal saline given intravenously over 2 hours daily on days 1-5.~Cytarabine 2000 mg/m2 in normal saline given intravenously over 4 hours daily on days 1-5.~Gemtuzumab ozogamicin 3 mg/m2 intravenously over 2 hours on days 1 and 4, prior to cladribine and cytarabine.~Consolidation:~If CRMRD-, CR or CRi is confirmed by bone marrow biopsy and aspirate after induction chemotherapy, patients may receive one cycle of consolidation chemotherapy (at the discretion of the investigator) with the same CLAG-GO regimen at the same doses given for induction. In addition, the investigator has the option of giving CLAG alone without GO if there is concern for increased risk of sinusoidal obstruction syndrome.~Patients who remain in CRMRD-, CR or CRi after consolidation chemotherapy may receive up to eight infusions of GO 2 mg/m2 approximately every 28 days."
45621393|NCT02475473|Other|Exercise Training|Chronic High-Intensity Resistance Training
45763824|NCT01725737|Drug|Placebo|Placebo Comparator: starch
45763825|NCT04371991|Diagnostic Test|blood test|blood test (serum samples) for biochemical examination
45446232|NCT02071030|Procedure|Third molar removal|Surgically removing the third molar in the lower jaw
45763826|NCT02242279|Drug|BEA 2180 BR|
45763827|NCT02242279|Drug|Tiotropium|
45621394|NCT03070743|Procedure|Posterior Approach Compression Distraction Reduction Surgery|Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
45763828|NCT02242279|Drug|Placebo|
45763829|NCT04371757|Drug|α1-adrenergic block|Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an α-1 adrenoreceptor blocker (Drozazosin; 0.05 mg / kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
45763830|NCT04371757|Other|Placebo|Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an placebo (microcrystalline cellulose; 0.05 mg.kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
45912095|NCT04026308|Other|Safety Net App|The Safety Net app is an electronic version of a safety plan and it is available for download in Apple's App Store. A preview of the app is available at: https://apps.apple.com/us/app/stanley-brown-safety-plan/id695122998. This app is owned by Two Penguins Studios, LLC. It was developed in partnership with the New York State Office of Mental Health. Unlike the paper version, the Safety Net app allows participants to email a copy of their safety plan to whomever they wish. It also allows patients to dial 911 or the National Suicide Prevention Lifeline from the app.
45912096|NCT04018755|Biological|anakinra|anakinra single-use prefilled glass syringes
45446233|NCT02079220|Drug|Arm A|"Capecitabine~Oxaliplatin~Ziv-aflibercept"
45446234|NCT02079220|Drug|Arm B|Capecitabine Oxaliplatin Ziv-aflibercept
45446235|NCT03559894|Diagnostic Test|Trans-thoracic echocardiography|Trans-thoracic echocardiography
45446236|NCT02071186|Device|Virtual Reality training|"Subjects will train with the VR system at the Tel Aviv Sourasky Medical Center 3 times per week for 6 weeks with each session lasting approximately 30 minutes.~To assure participants' safety and maintaining progress, training with the VR will be individual and provided by qualified physiotherapists, who use the system on a daily basis."
45446237|NCT02071186|Other|Computerized Cognitive Remediation|Subjects in this study will train with the AttenGo program at home 3-5 times per week for 6 weeks with each session lasting approximately 30 minutes.
45446238|NCT02071186|Other|Standard of care|
45446239|NCT02079298|Drug|Treatment with fluconazole.|
45446240|NCT02079298|Drug|2. Treatment with both fluconazole and Ibuprofen.|
45446241|NCT02079298|Drug|3. Treatment with ibuprofen.|
45446242|NCT02079298|Other|4. No treatment with either fluconazole nor ibuprofen.|
45621395|NCT02475551|Drug|IdeS|Intravenous infusion
45763831|NCT00917735|Drug|Green tea extract supplement|Two green tea extract capsules twice daily after breakfast and dinner for one year
45763832|NCT00917735|Other|Placebo|Two placebo capsules twice daily after breakfast and dinner for one year
45763833|NCT04371601|Drug|Oseltamivir|Oseltamivir capsules
45763834|NCT04371601|Drug|hormones|a moderate amount of hormone
45763835|NCT04371601|Device|oxygen therapy|oxygen therapy,mechanical ventilation and other supportive therapies
45763836|NCT04371601|Procedure|mesenchymal stem cells|mesenchymal stem cells
45763837|NCT01832207|Device|Transcutaneous electrical nerve stimulation|
45763838|NCT01832207|Device|Placebo transcutaneous electrical nerve stimulation|
45763839|NCT04371523|Drug|Apo-Hydroxychloroquine|Hydroxychloroquine sulfate 400mg PO BID on day one, then 400mg PO weekly, to be taken with meals for two months total.
45763840|NCT04371523|Drug|Matched Placebo|Matching Placebo
45763841|NCT03402997|Diagnostic Test|Resistivity measurement|To measure and compare the tissue impedance values obtained by analysing ex vivo non-neoplastic (healthy and peritumoral) and neoplastic breast tissues
45763842|NCT01837979|Procedure|cell-free fetal DNA|cell-free fetal DNA for DBS and maternal serum screening high risk pregnant women. Comparison of multiple Down's syndrome screening tests.
45763843|NCT02242357|Drug|Micardis®|
45763844|NCT02242357|Drug|Micardis® Plus|
45763845|NCT03409835|Drug|Ramosetron|Ramosetron 0.3 mg is administered after induction of general anesthesia.
45763846|NCT03409835|Drug|Normal saline|Normal saline 2 ml is administered after induction of general anesthesia.
45763847|NCT02242513|Device|Pulsed radiofrequency (PRF)|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury.
45763848|NCT02242513|Drug|Xylocaine|
45763849|NCT03409757|Drug|Velphoro|4 weeks
45446243|NCT02079376|Device|DIAMOND System|DIAMOND Implantable Pulse Generator (IPG)
45763850|NCT03409757|Other|saliva collection|2 samples
45763851|NCT03409757|Other|Supragingival biofilm collection|2 samples
45763852|NCT03409757|Other|stool collection|2 samples
45446244|NCT02071264|Behavioral|HIV/STI intervention|The intervention covers HIV101 information, reproductive health and human rights national policies, goal setting activities as individuals and as a group, results of prior research on ethics of doing research with sex workers.
45763853|NCT03409757|Other|blood collection|2 samples
45763854|NCT03402763|Behavioral|Educational Video|The intervention is an educational video presented to patients in the ED with the intent to promote ACP among older adults.
45912097|NCT04004000|Drug|Losmapimod|"The main study includes a treatment period of approximately one year. Subjects will receive 15 mg of losmapimod twice daily by mouth; for a total of 30 mg daily. The study drug should be taken with food and the date and time of each dose taken recorded in the subject diary.~Only subjects who participated in and completed all procedures for the main study (Week 60) will be eligible to participate in the extension.~For the extension, subjects will receive 15 mg of losmapimod by mouth twice daily for a total of 30 mg by mouth daily. Participation will continue until 90 days after commercial drug is available post regulatory approval or study termination."
45446245|NCT02071342|Procedure|angioplasty|patients with acute coronary syndrome and coronary angioplasty with bioresorbable vascular scaffold.
45621396|NCT04995705|Behavioral|Acceptance and Commitment Therapy (ACT)|"ACT is a psychological intervention. ACT encourages individuals to remain open to internal experiences (positive, negative and neutral), rather than attempting to control or ameliorate them (which may only serve to increase pain and suffering). It also encourages individuals to focus on committing to a life that is congruent with their core values, regardless of the experiences that show up for them. The premise of this model is to learn to modify the relationship one has with their internal experiences (thoughts, feelings, physical sensations etc.), rather than change the experiences per se. This is achieved through different processes including mindfulness, acceptance, defusion and exploration of values. These core tenets of ACT help to cultivate psychological flexibility.~This ACT intervention is delivered as a 5-week group for stroke survivors and adults with brain injury. It comprises of experiential and didactic components."
45621397|NCT04891133|Drug|Baricitinib|4 mg baricitinib (2 tablets of 2 mg) once daily
45621398|NCT04891133|Drug|Placebo|4 mg placebo (2 tablets of 2 mg) once daily
45621399|NCT04891809|Drug|Isatuximab-Irfc 20 MG/ML [Sarclisa]|Induction: 10mg/kg on day 1,8,15,22 in cycle 1, subsequently on day 1, 15; every 28 days (q28 days) Maintenance: 10mg/kg, day1, q28 days until progression or intolerance but for a maximum of 24 cycles from start of maintenance
45763855|NCT03402763|Behavioral|Primary Care Provider Email|For intervention patients, an email will be sent to primary care providers explaining that the patient has seen a video about advance care planning, providing a synopsis of the video, and giving instructions about how to document end-of-life care preferences in the electronic health record.
45763856|NCT03409679|Drug|Murepavadin|Murepavadin IV every 8 hours + 1 anti-pseudomonal antibiotic (Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin)
45763857|NCT03409679|Drug|Two anti-pseudomonal antibiotics|Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin
45763858|NCT00926887|Device|Erchonia(R) EML Laser|Low level laser red light of 635 nm and delivering 1.5 joules/cm2.
45763859|NCT00926887|Device|Placebo Laser|Inactive light
45912098|NCT03994731|Biological|Pegloticase|IV pegloticase 8 mg Q2W
45912099|NCT03994731|Drug|methotrexate|Oral MTX 15 mg weekly
45912100|NCT03994731|Drug|placebo|Oral placebo for MTX
45446246|NCT02071498|Device|Pillbox app named ALICE|Participants in the experimental group were given a BQ tablet or an iPad with the ALICE app installed and personalised according to the medications they had been prescribed as listed in their medical record
45446247|NCT02071498|Other|oral and written information|oral and written information about the most common errors of patients
45763860|NCT04371367|Biological|avdoralimab|intravenous administration of avdoralimab
45763861|NCT04371367|Other|Placebo|intravenous administration of placebo
45763862|NCT02242591|Drug|Ropivacaine 7,5 mg/ml|
45763863|NCT02242591|Drug|Saline|
45763864|NCT03409601|Other|100% Portion Size|Meal portion size at baseline
45912101|NCT03994731|Dietary Supplement|folic acid|Folic acid 1 mg orally every day beginning at Week -6 until prior to the Week 52 Visit.
45935187|NCT00218413|Biological|NicVAX|200 μg, Formulation B, on Days 0, 21, 42m 91 & 182
45763865|NCT03409601|Other|125% Portion Size|Meal portion size 125% of baseline
45763866|NCT03409601|Other|150% Portion Size|Meal portion size 150% of baseline
45763867|NCT03409601|Other|175% Portion Size|Meal portion size 175% of baseline
45763868|NCT01726127|Other|Broccoli and Brussels Sprouts|
45763869|NCT01726127|Dietary Supplement|Cruciferous Complete|
45763870|NCT01726127|Other|Placebo|
45763871|NCT02982577|Drug|Pilocarpine|Spray the basis of 1.54% pilocarpine, 3 times per day (each 8 hours), during 90 days.
45621400|NCT04891809|Drug|Lenalidomide|"Induction: 25mg*, day 1-21, every 28 days (q28 days); Maintenance: 5-10mg, day 1-21, q28 days (according to individual tolerance) until progression or intolerance but for a maximum of 24 cycles from start of maintenance~*) for patients with moderate renal impairment (30≤ GFR (MDRD formula) < 50 mL/min) starting dose is 10 mg"
45763872|NCT02982577|Other|Spray without Pilocarpine|Spray without pilocarpine, 3 times per day (each 8 hours), during 90 days.
45763873|NCT03409445|Other|no intervention|no intervention (observational study)
45763874|NCT02242747|Drug|ingenol mebutate|an application a day for three consecutive days in a pre-determined area
45763875|NCT02242747|Drug|5% 5-FU|two applications a day for four weeks in a pre-determined area
45763876|NCT04371133|Diagnostic Test|Adropin (ng/L)|Thawed samples were measured on a Molecular Devices SpectraMax i3 Multi-Mode, Microplate Reader (batch number: SER 35 370-1448, made in Austria) using enzyme linked immunosorbent assay (ELISA).
45763877|NCT01726205|Drug|Pregabalin and normal saline infusion, PRG|
45763878|NCT01726205|Drug|Pregabalin and ropivacaine 02% infusion|
45621401|NCT04891809|Drug|Dexamethasone Oral|"Induction:~Patients aged <75 years: 40mg, once weekly; Patients aged ≥75 years: 20mg, once weekly"
45763879|NCT01726205|Drug|Placebo drug, normal saline infusion|
45763880|NCT02242825|Drug|Micardis®|
45763881|NCT02242825|Drug|MicardisPlus®|
45763882|NCT04370743|Other|No intervention|
45935188|NCT00218413|Biological|NicVAX|300 μg, Formulation B, on Days 0, 21, 42, 91 & 182
45763883|NCT04370977|Drug|Coartem™ (Artemether-lumefantrine combination)|AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to <15kg, two tablets per dose for those 15 to <25kg, and three tablets per dose for those 25 to <35kg.
45763884|NCT04370977|Drug|Winthrop™ (Amodiaquine-artesunate combination)|AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children <9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children >18-35kg.
45763885|NCT01726283|Device|Corneal Cross-Linking|Corneal cross-linking procedure conducted during vision correction surgery.
45763886|NCT01726283|Drug|Riboflavin|Riboflavin will be instilled prior to corneal cross linking.
45763887|NCT02243683|Drug|AX-024.HCl|
45763888|NCT02243683|Other|Placebo|
45452324|NCT02262208|Device|Continuous glucose monitoring system (Guardian, Medtronic, Northridge, USA)|Subjects will be admitted to the laboratory in the morning at approximately 9:00 a.m., 24 h before the exercise session, when the glucose sensor (Sof-SensorTM, Medtronic Mini-Med, Northridge, USA) will be inserted subcutaneously. The sensor is a glucose oxidase based platinum electrode that is inserted through a needle into the subcutaneous tissue of the anterior abdominal wall, using a spring-loaded device (Senserter, Medtronic, Northridge, USA). Glucose profiles will be collected the day before (day 1), the day of (day 2), and the day following (day 3) and 40 min of exercise. Each sensor will be used continuously for up to 72 h.
45621402|NCT03074253|Diagnostic Test|Echocardiography|Patients are undergoing echocardiography
45621403|NCT03074253|Diagnostic Test|magnetic resonance imaging|Patients are undergoing magnetic resonance imaging
45621404|NCT03074253|Diagnostic Test|computed tomography|Patients are undergoing computed tomography
45621405|NCT03074253|Diagnostic Test|blood withdrawl|Peripheral blood samples are being collected from all patients
45763889|NCT03409211|Dietary Supplement|PEVCO|All subjects will receive PEVCO for 6 more weeks.
45763890|NCT03409211|Dietary Supplement|Dietary Supplement Capsules without Coconut Oil|All subjects will receive placebo (PBO) for 3 weeks
45763891|NCT04370899|Other|lifestyle assessment|"A semi-quantitative assessment of the consumption of different food groups will be carried out using a frequency questionnaire validated by the Spanish population27. This questionnaire consists of 137 food items and will be obtained by the dietitian of our Unit (see annex).~The child population and/or their parents will be instructed on how to fill the data in the food diary for a period of 3 days, in order to be able to analyse the nutritional composition of the intake and the effect on the lipid profile. The first food register, will be obtained at the collection visit before starting any type of treatment. Another food diary will be included after one year.~Physical activity will be collected from the Minnesota Test and we will ask about the consumption of tobacco."
45763892|NCT01720121|Other|Printed, digital video disc|The three groups of patient received: 1)informative material in details about the cardiac catheterization provide by the researchers; 2)informative provide by a digital video disc; 3)the control group received the conventional informative provide by the nursing team.
45763893|NCT04370431|Drug|TTYP01 single ascending doses|TTYP01 (30 mg edaravone tablet) will be orally administrated at single ascending doses of 60 mg, 120 mg, 180 mg and 240 mg (n=6 per dose)
45763894|NCT04370431|Drug|Placebo|Placebo control for Part A of the study
45763895|NCT04370431|Drug|TTYP01, 60 mg|TTYP01 oral tablets (30 mg edaravone per tablet)
45763896|NCT04370431|Drug|TTYP01, 120 mg|TTYP01 oral tablets (30 mg edaravone per tablet)
45935189|NCT00218413|Biological|NicVAX|400 μg, Formulation B, on Days 0, 21, 42, 91 & 182
45935190|NCT00042068|Drug|Meloxicam|
45935191|NCT00218452|Behavioral|Lifestyle counseling|assigned to a 6-week individual behavioral treatment involving: 1) a novel brief office intervention for cigarette smoking that includes a treatment component intended to eliminate binge drinking
45935192|NCT00218530|Drug|Lofexidine|
45763897|NCT04370431|Drug|Radicut® (ampoule), 30 mg|An intravenous dose of edaravone injection, containing 30 mg edaravone in a 20 mL ampoule, will be administered at a dose of 30 mg over 30 minutes
45763898|NCT04370431|Drug|Radicut® (bag) , 60 mg|An intravenous dose of edaravone injection, containing 30 mg edaravone in a 100 mL injection bag, will be administered at a dose of 60 mg over 60 minutes
45763899|NCT04370431|Drug|TTYP01, up to 120 mg|TTYP01 oral tablets (30 mg edaravone per tablet). The fixed oral dose level of TTYP01 will depend on the results obtained in Part B of the study (no more than 120 mg)
45763900|NCT01726361|Behavioral|Multidimensional Treatment Foster Care|Out of home placement in MTFC family for 10-12 months
45763901|NCT01726361|Behavioral|Treatment as usual|Other kinds of out of home placement
45763902|NCT04370353|Dietary Supplement|Cocoa flavanols|Flavonoid-rich cocoa powder, containing 100mg total flavanols per 316mg.
45446248|NCT02079688|Drug|SB011, 2 % (Water/Oil/Water) emulsion of hgd40|"Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site"
45763903|NCT04370353|Dietary Supplement|Placebo supplement|Microcrystalline filler, containing 0mg total flavanols.
45763904|NCT04369963|Procedure|Esophagogastroduodenoscopy and Colonoscopy with Biopsies|Participants will have an esophagogastroduodenoscopy and colonoscopy with biopsies. Biopsies from esophagogastroduodenoscopy will not exceed 16 pinch biopsies, biopsies from colonoscopy will not exceed 16 pinch biopsies. Participants will have anesthesia for both procedures.
45763905|NCT02245165|Biological|L-Nitro-Monomethyl-Arginine (LNMMA) 10 mg/kg IV|
45621406|NCT02472509|Drug|Ursodeoxycholic Acid|"Patients will be commenced on UDCA 15mg/kg/day (maximum dose 900mg/day) in 2-3 divided doses for 12 months.~Patients who are unable to tolerate tablet medication will be started on UDCA syrup at the same dose."
45763906|NCT02245165|Biological|saline|
45763907|NCT03408977|Other|probe meal|The probe meal will be served in 150 Kcal portions (10 g foie, 10 g cheese, 5 g chips, 2 g peanuts, 3 g toast, and 27 mL soft drink) up to the level of maximal satiation.
45763908|NCT03835871|Drug|Placebo|Intervention: Drug: placebo
45763909|NCT03835871|Drug|400 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 400 µg HFA per day
45763910|NCT03835871|Drug|200 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 200 µg HFA per day
45763911|NCT03835871|Drug|100 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 100 µg HFA per day
45763912|NCT03402373|Dietary Supplement|Lycoderm|soft gel contains nutritional supplement
45763913|NCT03402373|Dietary Supplement|Placebo|soft gel without active ingredients
45452325|NCT04474990|Drug|Tradipitant|NK-1 Receptor antagonist
45621407|NCT04985877|Dietary Supplement|Yakult light 300|2 bottles of fermented Milk containing Lactobacillus casei Strain Shirota per day, Intervention for 12 weeks.
45621408|NCT02475161|Drug|JNJ-42847922|JNJ-42847922 will be administered as 20 mg tablet orally.
45763914|NCT03402295|Drug|Bortezomib, cyclophosphamide, thalidomide, dexamethasone|Comparison between two triple combination chemotherapy that include in different new drugs (bortezomibe e talidomida)
45763915|NCT03836183|Diagnostic Test|Pleuropulmonary ultrasound with clinical examination|Pleuropulmonary ultrasound associate with a clinical examination
45763916|NCT02243761|Other|DBT Based Skills Groups for Families|12 weeks of Dialectical Behaviour Therapy skills training group for families (90-minute once-weekly sessions)
45621409|NCT02475161|Drug|Rabeprazole|Rabeprazole will be administered as 20 mg tablet orally.
45621410|NCT03074097|Drug|Bupivacaine 0.25%|Each patient received bilateral single shot ultrasound guided rectus sheath block under complete aseptic condition in a dose of 30 ml of bupivacaine 0.25% in each side immediately after induction of general anaesthesia
45621411|NCT02472587|Other|Questionnaire|
45763917|NCT02243839|Drug|Thrombolytic Therapy|Thrombolytic therapy is performed to the patients with obstructive prosthetic valve thrombosis
45763918|NCT02243839|Procedure|Surgery|Redo valve surgery is performed for obstructive valve thrombosis
45763919|NCT03402061|Dietary Supplement|nutrient enhanced recipes|normal ingredients will be substituted to promote nutrient density of products
45763920|NCT04369495|Other|BAFF serum levels|BAFF levels in serum in visit 0,1,2 during induction therapy
45763921|NCT02243917|Drug|CB-5083|
45763922|NCT03401983|Other|Pelvic Floor Muscle Training and Abdominal Training|Pelvic Floor Muscle Training + Abdominal Training program was used in the study. The follow-up measurements of the PFMT+AT group were obtained in the 0th, 4th, and 8th weeks.
45763923|NCT03401983|Other|Pelvic Floor Muscle Training|Pelvic Floor Muscle Training program was used in the study. The follow-up measurements of the PFMT group were obtained in the 0th, 4th, and 8th weeks.
45763924|NCT02243995|Other|Physical training|
45763925|NCT02243995|Behavioral|Physical training|
45763926|NCT03401905|Procedure|Low frequency|A dry needling on trapezius muscle is performed, until two local twitch responses are obtained. The needle is kept inside the trigger point, as it will be the negative electrode, and an adhesive electrode will be added as the positive one. After that, a low frequency TENS is applied, at 2 Hz frequency and 120 microseconds of pulse width.
45763927|NCT03401905|Procedure|High frequency|A dry needling on trapezius muscle is performed, until two local twitch responses are obtained. The needle is kept inside the trigger point, as it will be the negative electrode, and an adhesive electrode will be added as the positive one. After that, a high frequency TENS is applied, at 12o Hz frequency and 200 microseconds of pulse width.
45935193|NCT00218569|Drug|Naltrexone|Naltrexone
45935194|NCT00218569|Drug|Placebo|Placebo
45763928|NCT02244073|Drug|Human insulin - Insulin administration to control blood glucose level.|On ICU admission, the glycated hemoglobin level (A1c) is measured and insulin IV is possibly administered using a web based nurse driven insulin infusion protocol (https://extranet.chu-lyon.fr/cpg) to maintain blood glucose level below 10 mmol/l. Glycated hemoglobin result triggers patient randomization. Thereafter, during ICU stay, blood glucose level is maintained either below 1.59 × A1c - 1.59 (mmol/l) (Individualized blood glucose target group), or bellow 10 mmol/l (Conventional blood glucose target group).
45763929|NCT02244151|Drug|Decapeptyl® diario|Decapeptyl® daily administration (Triptorelin acetate) and follicular puncture at 24, 30, 36 or 40 after administration.
45763930|NCT02244151|Drug|Decapeptyl® daily|Decapeptyl® daily OPU 36 hrs after GnRH administration
45763931|NCT03401827|Drug|Chemotherapy (Gemcitabine + nab-paclitaxel)|"Nanoparticle albumin-bound paclitaxel (125 mg/m2) miv over 30 min, Day 1,8,15~Gemcitabine (1,000mg/m2) and N/S 150mL miv over 30 min, Day 1,8,15"
45763932|NCT03833791|Behavioral|education and modifying diet|The control group maintains a sedentary lifestyle and is only subjected to follow a hypocaloric diet
45763933|NCT03833791|Behavioral|education, modifying diet and physical activity prescription|"One group, in addition to fulfilling a hypocaloric diet identical to the control group, is subjected to prescribe moderate physical activity.~Other group, in addition to fulfilling a hypocaloric diet identical to the control and moderate group, is subjected to prescribe intense activity."
45763934|NCT03833401|Procedure|Autologous tissue transplantation|Root canal disinfection and revascularization with patient's own minced pulp tissues
45763935|NCT03833401|Procedure|Root canal revascularization|Root canal disinfection and revascularization without tissue transplantation
45935195|NCT00218608|Drug|Disulfiram|Disulfiram at 0, 62.5, 125 and 250 mg/day were administered during weeks 3-14
45763936|NCT03833635|Other|osteopathic manipulative treatment|OMT will be used to treat premature infants after having performed a manual osteopathic assessment. Techniques used are indirect
45763937|NCT03833635|Other|Sham|the sham intervention consists in a stable skin-to-skin contact with the participant
45763938|NCT04376671|Device|Electroencephalography|The patients underwent EEG recordings according to previously published methods (Bonanni et al., 2008). . EEG recordings were analyzed with methods described in our previous work (Bonanni et al., 2008) by 2 experimenters unaware of the clinical conditions of the subjects. Briefly, quantitative EEGs (QEEGs) were recorded from 21 scalp derivations. Ag/AgCl disk scalp electrodes (19) were placed according to the international 10-20 system, EEG was recorded from Fp1, Fp2, Fz, F3, F4, F7, F8, Cz, C3, C4, Pz, P3, P4, T3, T 4, T5, T6, O1, and O2. Two additional electrodes were placed on A1 and A2. EEG activity was analyzed from single or multiple leads grouped to define the following scalp regions: anterior (Fz, Fp2, F7, Fp1, F3, F4, and F8), central (Cz, C3, and C4), posterior (Pz, P3, P4, O1, and O2), and temporal (T3, T4, T5, and T6).
45446249|NCT02079688|Drug|Multiple W/O/W formulation, active ingredient-free vehicle|"Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site"
45446250|NCT02079766|Drug|florbetapir F 18|370 megabecquerel (MBq) IV single-dose
45446251|NCT02079766|Drug|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
45446252|NCT02071576|Device|Proscan|One device (500 Hz Excimer Laser - TENEO) with one intervention (Proscan)
45446253|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
45446254|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
45621412|NCT05368259|Device|AGBS|The AGBS is designed to promote weight loss in individuals with obesity. The AGBS includes the Allurion Balloon, which is a temporary gastric balloon that promotes weight loss in individuals with obesity. The AGBS consists of up to 2 balloons placed during a 1-year period.
45621413|NCT04433481|Drug|Dabigatran|T. Dabigatran 150 mg twice a day
45621414|NCT04433481|Other|Placebo|placebo
45621415|NCT04860635|Drug|F14 (sustained release celecoxib)|Celecoxib in BEPO® drug delivery system
45763939|NCT00909545|Drug|Isradipine CR 5mg|5mg dose: 1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily
45763940|NCT00909545|Drug|Isradipine CR 10mg|10mg dose: 2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily
45763941|NCT00909545|Drug|Isradipine CR 20mg|20mg dose: 4 Dynacirc CR 5mg tablets once daily
45763942|NCT00909545|Drug|Placebo|4 Placebo to Match (PTM) tablets once daily
45763943|NCT02244229|Drug|Tamsulosin|
45763944|NCT02244229|Drug|Finasteride|
45763945|NCT02244229|Drug|Placebo|
45763946|NCT04369027|Diagnostic Test|passive leg raising|"passive leg raising: to raise the legs of the patients by adjusting the angle of the patient's bed during one minute.~Tidal volume challenge: an increas by 2ml/Kg of the tidal volume during one minute"
45763947|NCT04368793|Behavioral|Remote pulmonary rehabilitation|The pulmonary rehabilitation intervention includes respiratory exercise, barehanded aerobic training, exercise prescription of elastic band impedance training, respiratory muscle strength training, etc.
45763948|NCT04369339|Other|Colposcopy|
45763949|NCT02157103|Drug|Bevacizumab 25 mg in 1 ml subcutaneously daily|Bevacizumab delivered by subcutaneous injection instead of intravenous infusion.
45763950|NCT00924001|Drug|DMF5 Melanoma Reactive TIL|given intravenously over 20-30 minutes (between 1 x 10^9 and 1 x 10^11 lymphocytes) after expansion in interleukin-2 and OKT-3
45763951|NCT00924001|Drug|Cyclophosphamide|60 mg/kg/day x 2 days intravenously
45763952|NCT00924001|Drug|Fludarabine|25 mg/m^2/day intravenously x 5 days
45763953|NCT00924001|Drug|Aldesleukin|720,000 IU/kg/dose intravenously every 8 hours for up to 15 doses
45621416|NCT04986111|Procedure|Linear skin closure with wound drain|"An oval incision is made around the ileostomy and the continuity of the intestinal tract is restored after adhesion division.~Methods of anastomosis include either side-to-side or end-to-end, hand-sewing or stapling.~Linear suture of the rectus abdominis fascia layer by layer. A Jackson-Pratt drainage tube is placed in the subcutaneous tissue and vertical mattress suture is performed with a non-absorbable thread."
45763954|NCT02244307|Drug|alpha-adrenergic blocker|
45763955|NCT00910481|Device|Intra-Aortic Balloon Pump|Elective IABP insertion before PCI
45763956|NCT03401593|Drug|midazolam with fentanyl|Radio-frequency catheter ablation is performed in the post-absorptive state after sedation with midazolam and fentanyl. Multipolar catheters were positioned in the coronary sinus, His, and the right atrium. The three-dimensional LA geometry was reconstructed using a CARTO or NavX electroanatomical mapping system. Circumferential pulmonary vein isolation was performed in all patients using a irrigated-tip catheter. A circular mapping catheter was used to confirm the isolation of the pulmonary veins. Successful ablation was defined by the elimination of all the pulmonary vein potentials along the antrum or inside the veins. If the AF was not terminated after elimination of all the pulmonary vein potentials, linear ablation and complex fragmented atrial electrogram ablation were performed.
45912102|NCT03994731|Drug|gout flare prophylaxis regimen|Prior to beginning the Pegloticase + IMM Period, participants must have been taking at least 1 protocol-standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤ 10 mg/day) for ≥ 1 week before the first dose of pegloticase and to continue flare prophylaxis per American College of Rheumatology guidelines [Khanna D et al. 2012] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA < 6 mg/dL) for participants with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA < 5 mg/dL) for participants with one or more tophi detected on initial physical exam that then resolved.
45621417|NCT04986111|Procedure|Purse-string skin closure with negative pressure wound therapy|"Recover the intestinal continuity after adhesion division by making a circular incision along the ileostomy Methods of anastomosis include either side-to-side or end-to-end, hand-sewing or stapling.~Linear suture of the rectus abdominis fascia layer by layer. Negative pressure wound therapy is performed after suturing the subcutaneous tissue using absorbable thread."
45446255|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
45621418|NCT02472431|Other|Intracavernosal administration of autologous ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After isolation autologous ADRC suspension will be injected intracavernosally.
45621419|NCT02472431|Procedure|Liposuction|
45621420|NCT02472431|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
45621421|NCT03070821|Other|rtfMRI neurofeedback training|Information about the state of brain activation was given to subjects. That information was visualised as a thermometer bar. Subjects tried to modulate that activation while performing a mental imagery task.
45621422|NCT03070821|Device|3T MRI|A 3T Siemens MRI scanner was used to implement rtfMRI neurofeedback training.
45621423|NCT02475083|Other|Virtual Reality|Rehabilitation with virtual reality, using Football games, Boxe, Bambolê and Tennis.
45621424|NCT02475083|Other|Conventional|Stretching exercises in limbs, trunk mobilization in the three planes, balance training in standing position, training of balance reactions and gait training.
45621425|NCT03074019|Dietary Supplement|Xylooligosaccacharide|XOS95 powder
45621426|NCT03074019|Dietary Supplement|Maltodextrin|Maltodextrin powder
45621427|NCT02475239|Behavioral|Postural restriction|The patients were instructed to avoid head movements, wear a soft collar during the daytime, wear a supporting pillow and sleep in the semi-upright position at a 45 degree head elevation from the horizontal plane during the nighttime for 48 hours.
45621428|NCT02475239|Behavioral|Normal daily activity|The patients did not follow any postural restrictions and were asked to live as normally as possible.
45621429|NCT04988607|Drug|Osimertinib|osimertinib plus bevacizumab arm is dosed at osimertinib 80 mg orally once every day combined with bevacizumab 15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle
45763957|NCT03408821|Other|Problem Solving Therapy (PST)|Participants will attend 8 weekly session of Case Manager (CM) implemented PST, a form of group talk therapy.
45912103|NCT03994731|Drug|fexofenadine|For IR prophylaxis, fexofenadine (180 mg orally) taken the day before each infusion and on the morning of each infusion.
45912104|NCT03994731|Drug|acetaminophen|For IR prophylaxis, acetaminophen (1000 mg orally) taken the morning of each infusion.
45912105|NCT03994731|Drug|methylprednisolone|For IR prophylaxis, methylprednisolone (125 mg IV) given over an infusion duration between 10 - 30 minutes, immediately prior to each infusion.
45621430|NCT04988607|Drug|Bevacizumab|osimertinib plus bevacizumab arm is dosed at osimertinib 80 mg orally once every day combined with bevacizumab 15mg/kg by intravenous drip infusion on day 1 of a
45621431|NCT04988607|Drug|Osimertinib|Osimertinib is dosed orally at 80 mg once per day
45621432|NCT04995471|Behavioral|In presence RRT - prototype software|Rhythmic Reading Training (RRT) is a prototype software which includes reading exercises presented simultaneously with a rhythmic stimulation with gradually increasing speed.
45621433|NCT04995471|Behavioral|In presence RRT - online platform|"RRT is a web application with a client-server structure developed in javascript/php language using open-source support libraries. The server-side system uses a LAMP stack (Linux, Apache, Mysql, Php) on Server Cloud. The application can also be activated as a desktop application through portable web server installation systems, available for linux, windows and OS operating systems. In this form, the application can also be used in contexts without an Internet connection. The system is also accessible from tablets. RRT consists of a module of progressive reading exercises. The exercises are organized according to different types (syllables, words, non-words, short texts) and accompanied by a rhythmic-melodic stimulation, which is coordinated with a visual cue. Both remote (Rhythmic Reading Tele-Training, RRTT) and in presence administration (RRT) are available."
45446256|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
45621434|NCT04995471|Behavioral|Tele-RRT - prototype software|Rhythmic Reading Training (RRT) is a prototype software which includes reading exercises presented simultaneously with a rhythmic stimulation with gradually increasing speed.
45621435|NCT04995471|Behavioral|Tele-RRT - online platform|"RRT is a web application with a client-server structure developed in javascript/php language using open-source support libraries. The server-side system uses a LAMP stack (Linux, Apache, Mysql, Php) on Server Cloud. The application can also be activated as a desktop application through portable web server installation systems, available for linux, windows and OS operating systems. In this form, the application can also be used in contexts without an Internet connection. The system is also accessible from tablets. RRT consists of a module of progressive reading exercises. The exercises are organized according to different types (syllables, words, non-words, short texts) and accompanied by a rhythmic-melodic stimulation, which is coordinated with a visual cue. Both remote (Rhythmic Reading Tele-Training, RRTT) and in presence administration (RRT) are available."
45621436|NCT02475317|Drug|Placebo|Participants will receive placebo matched to maralixibat/volixibat orally for 7 days.
45621437|NCT02475317|Drug|Maralixibat|Participants will receive maralixibat in 10 mg, 20 mg, 50 mg or 100 mg doses.
45621438|NCT02475317|Drug|Volixibat|Participants will receive volixibat in 10 mg and 20 mg doses.
45621439|NCT04988763|Other|Opinions about tele-rehabilitation for consulting a clients with neurological impairments|Opinions about telerehabilitation for consultation purpose
45621440|NCT02472041|Device|Reanimator group|Resuscitator of Muller Group (intermittent positive pressure): Patients allocated to this group received intermittent positive pressure breathing (resuscitator Muller, Engemed, Brazil), adjusting the positive pressure around 1.5 kgf / cm2, which corresponds to 15 20 cm / H2O, positive pressure was applied through a face mask (Respironics®).
45621441|NCT02472041|Device|Control|Control Group: In position Fowler 45, patients assigned to this group was administered as treatment lung expansion exercises using the incentive inspiratory flow (Respiron, NCS, Mexico) and concomitantly blocking contralateral to the drain maneuvers were performed, compression / decompression associated with the incentive spirometry (Respiron) consisting of 4 sets of 10 active patient breaths with an interval of two minutes between sets. Since the load of the respiratory stimulator will be zero throughout treatment. Guidelines to the active, progressive and early mobilization.
45621442|NCT03070509|Drug|Lisdexamfetamine|lisdexamfetamine 50 mg single dose
45621443|NCT04844489|Other|Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19|"Blood samples at:~D0 (the day of the injection of the SARS-CoV-2 vaccine),~during the 2nd injection as part of the national vaccination campaign (on D28)~during the 3rd injection for patients for whom a third injection is recommended (according to the recommendations in force)~then to M1, M6 and M12 of the last injection"
45621444|NCT04259463|Procedure|Third molars extraction|Third molars extractions with concious sedation or general anesthesia
45621445|NCT04433871|Other|No intervention, observational|No intervention, observational
45621446|NCT04995393|Procedure|Heating with a disposable glove containing water|Heating of the infants heel with a glove before blood sampling.
45621447|NCT04995393|Procedure|Heating with a blanket|Heating of the infants heel with a blanket before blood sampling.
45621448|NCT04995393|Procedure|Heating with a gel pack|Heating of the infants heel with a gel pack before blood sampling.
45621449|NCT02472119|Dietary Supplement|rusks made of wheat flour enzymatically treated|100 g of rusks obtained from commercial wheat flour enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
45621450|NCT02472119|Dietary Supplement|rusks made of wheat flour not enzimatically modified|100 g of rusks obtained from commercial wheat flour NOT enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
45621451|NCT02472119|Dietary Supplement|Gluten-free diet|gluten-free diet
45621452|NCT04988139|Other|individualized educational training|50 min per session, one session per week, 4 sessions per month, of individualized educational training to preschool children with developmental delays under traditional rehabilitation programs
45621453|NCT05322473|Drug|Sonelokimab (M1095)|randomized treatment; parallel-group
45621454|NCT05322473|Drug|Adalimumab|randomized treatment; parallel-group
45763958|NCT04376359|Procedure|hyperbaric oxygen therapy|Hyperbaric oxygen therapy is the patient put in airtight oxygen tank, by increasing the air pressure in the environment (1.5 to 3.0) under atmospheric pressure, to give 100% oxygen, the patient treatment time is approximately 60 minutes to 120 minutes in this way, can achieve the purpose of greatly increase the oxygen partial pressure in the organization, so as to achieve reverse brain edema, reduce lipid peroxidation, inhibiting leukocyte hyperactivity, rebuild the blood brain barrier.
45763959|NCT03408743|Behavioral|Knowledge Alone|Increase knowledge relate d STIs, STI risk, alcohol impairment, condom use skills, alcohol use behavior tracking skills, testing & treatment services.
45446257|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
45446258|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
46069276|NCT03222752|Device|Cranial Electrotherapy Stimulation|Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
45446259|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
45621455|NCT05322473|Other|Placebo|randomized treatment; parallel-group
45621456|NCT04995159|Drug|Single anti-platelet therapy|Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Aspirin will be discontinued one year after surgery and clopidogrel will be continued until 5 years after surgery.
45621457|NCT04995159|Drug|Dual anti-platelet therapy|Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Patients continue to take dual antiplatelet (DAPT) drugs, including aspirin and clopidogrel, for 2 more years; then aspirin will be used alone from the 4th year to the 5th year.
45446260|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
45621458|NCT02472275|Drug|Antiandrogen Therapy|Undergo ADT with leuprolide acetate, goserelin acetate, or degarelix
45621459|NCT02472275|Other|Laboratory Biomarker Analysis|Correlative studies
45621460|NCT02472275|Drug|Multitargeted Tyrosine Kinase Inhibitor PLX3397|Given PO
45621461|NCT02472275|Radiation|Radiation Therapy|Undergo radiation therapy
45621462|NCT03109067|Other|Standardized meal|Blood samples performed at 5 different times : H0 before the meal, H2, H4, H6 and H8 after the meal
45621463|NCT04491773|Drug|Tadalafil 20 MG|To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, for more than 6 months.
45621464|NCT02472197|Procedure|Hysteroscopic morcellation|The endometrial polyp is resected by a transcervical approach. During the procedure, the polyp is placed by suction against the window of the device, then cut by mechanical energy, in chips which are directly aspirated by the device.
45621465|NCT02472197|Procedure|Standard hysteroscopic resection|The endometrial polyp is resected by a transcervical approach in several chips using a mono or bipolar cove after distension of the uterine cavity under endoscopic control.
45621466|NCT04783571|Other|Placebo|Auditory stimulation will not be delivered during the nap
45621467|NCT04783571|Other|Auditory Stimulation|Auditory stimulation will be delivered during the nap
45446261|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
45763960|NCT03408743|Behavioral|Self-efficacy alone|Increase self-efficacy to us e protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45763961|NCT03408743|Behavioral|Perceived benefits alone|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
46069277|NCT03222752|Device|Sham Cranial Electrotherapy Stimulation|The sham treatment will be using a sham Alpha-Stim AID which will look and sound exactly like the active treatment but will deliver no current.
46069278|NCT03200353|Device|system NATROX (device name)|system NATROX (device name) application on the wounds of lower limbs
46069279|NCT03183128|Biological|SER-109|"SER-109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors~Other Names:~Eubacterial Spores, Purified Suspension, Encapsulated"
46069280|NCT03183128|Drug|Placebo|Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline(0.9%).
46069281|NCT03149484|Device|Personal remote microphone (RM) system|Speech perception in noise performance will be evaluated in the unaided, bone conduction device (BAHA) aided, and bone conduction device (BAHA) + RM conditions. All test measures are non-experimental and commercially available.
45446262|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
45621468|NCT03070353|Drug|Dextran 40|Dextran-40 infusion with the dose of 1 g/kg/day (10 ml/kg/day) for 2 days.
45621469|NCT04743245|Device|TherOx DownStream System|SSO2 Therapy with Therox downstream System after Percutaneous Coronary Intervention (PCI)
45621470|NCT04743245|Device|PCI|Standard Care of PCI
45621471|NCT04994847|Drug|Amyloid and Tau PET|NAV4694 and MK6240 PET scans completed every two years
45621472|NCT03073863|Drug|Atorvastatin|Analysis
45621473|NCT04994925|Other|Control ready meal|Supermarket brand lasagne ready meal
45621474|NCT04994925|Other|Test ready meal|The Slimming World lasagne ready meal
45621475|NCT02474849|Other|Use electronic cigarette or smoke conventional cigarette|Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
45621476|NCT03068403|Procedure|Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration|Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration
45621477|NCT02471963|Drug|Empagliflozin|
45621478|NCT02471963|Drug|Placebo|
45763962|NCT03408743|Behavioral|Benefits and self-efficacy|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45763963|NCT03408743|Behavioral|Injunctive norms alone|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
45763964|NCT03408743|Behavioral|Injunctive norms and self-efficacy|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45446263|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
45621479|NCT03074175|Radiation|radiotherapy|The patient in supine position with hands catch the plate column by crossing the head, and body fixed by vacuum mould. An enhanced 4DCT scan is conducted with a layer thickness and a distance each of 5 mm. the imaging information is input into the Eclipse program system,the gross tumor volume of the primary tumor (GTVt) and pathological lymph nodes (GTVn) are delineated,GTV is expanded in all 3D direction to create PGTV by 5mm margin for squamous cell carcinoma, or an 8mm margin for adenocarcinoma.Radiaion therapy is delivered by 5F-IMRT.For conventional fractionated radiotherapy,the prescribed dose covering 95% of PGTV is 60Gy/30F/6W.For hyperfractionated radiotherapy,the prescribed dose covering 95% of PGTV is 50Gy/11F/2W.lung V20 <25%, lung V30 <18%, spinal cord <36 Gy.
45621480|NCT05290181|Other|A support program with pilates exercise and whatsapp text message|Female students in the intervention group will be given online pilates exercises 2 days a week for 8 weeks. Pre Pilates exercises, Pilates Mat Program: Beginner Level, Pilates Mat Program: Intermediate Level, Pilates Mat Program: Advanced level exercises will be provided. The exercises will be performed in the company of a research physiotherapist who has The Australian Physiotherapy & Pilates InstituteMatwork Level 1 (APPI) certificate. 3 days a week, individual short messages will be sent to the smartphones of female students via the Whatsapp application. General information about PMS will be sent in the first week, and motivational messages about lifestyle will be sent in the following weeks. Short message contents will be prepared by researchers in line with the literature and expert opinion will be taken. When the support program ends, PMSS will be applied to female students in the intervention group.
45621481|NCT03068325|Other|TF-EAT|
45621482|NCT03068481|Drug|KDT-3594|Oral administration
45621483|NCT03068481|Drug|Placebo|Oral administration
45621484|NCT01375751|Biological|Evolocumab|Administered by subcutaneous injection
45621485|NCT01375751|Biological|Placebo|d by subcutaneous injection
45621486|NCT04984863|Device|Magnetically controlled capsule endoscopy|Magnetically controlled capsule endoscopy (MCE) is a non-invasive detection method independently developed in China that covers the whole digestive tract (except colon) mucosa.
45621487|NCT04985175|Behavioral|Question prompt list|The specific QPS was a one page leaflet for chronic kidney disease which developed by applied literature and public QPL from the National Health Agency. It contains 3 domains 25 questions related to treatment, dialysis, and Kidney transplant. The QPL group participants were asked to read and mark those questions they concerned or write down additional problems.
45621488|NCT04985019|Procedure|Arm I (Prepectoral)|Participants followed the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for 4 weeks.
45621489|NCT04985019|Other|Arm II (Subpectoral)|Participants followed the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for 4 weeks.
45621490|NCT05249621|Drug|MZE001|Small molecule inhibitor of muscle glycogen synthase
45621491|NCT05249621|Drug|Placebo|Product containing excipients with no active ingredients
45763965|NCT03408743|Behavioral|Injunctive norms and benefits|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
46069282|NCT03149484|Other|Subjective Questionnaire|These subjective questionnaires will be given pre- and post-evaluation to both the subject and their guardian in order to determine the impact of RM on subject and guardian perceptions of listening in noise.
46069283|NCT03127423|Procedure|Hybrid ablation|This intervention includes totally thoracoscopic surgical ablation and percutaneous catheter ablation simultaneously.
45621492|NCT03073707|Behavioral|Sample collection|Stool samples will be collected from household members of children diagnosed with NTS infection. In addition stool samples of animals and rats will be collected as well as samples of the water supply of the household.
45621493|NCT02475005|Behavioral|pain self management app on smartphone|
45653340|NCT05070429|Other|Telehealth audiological rehabilitative service delivery|Participants' scheduled clinic-based visits will be complemented with asynchronous and synchronous telehealth that will allow for routine troubleshooting of communication challenges, hearing aid technical issues, and reinforcement of self-management support strategies. At an initial session, participants will be instructed in the use of a study-provided, internet-enabled tablet device for telehealth sessions, re-introduced to the hearing loss toolkit for self-management and C2Hear Reusable Learning Objects within the context of the telehealth platform, re-evaluated on the Client Oriented Scale of Improvement (COSI) goals. Two remote follow-up sessions will be scheduled 3 and 6 weeks later to confirm participants' comfort with the telehealth platform and then completed every 6 months, in addition to scheduled 6-month clinic-based visits.
46069284|NCT03127423|Procedure|Thoracoscopic surgical ablation|This intervention only includes totally thoracoscopic surgical ablation without percutaneous catheter ablation.
46069285|NCT03118375|Device|super-power BAHA processor|The super-power BAHA processor will be provided for use at the study visit only to run different types of hearing tests, speech understanding tests in quiet, and speech understanding tests in noise. The same tests will be performed with the use of the subject's current BAHA processor for comparison.
46069286|NCT03098576|Other|Matched targeted drug treatment|Matching a specific genetic abnormality (i.e. mutation) with the appropriate targeted drug.
45446264|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
45446265|NCT02080000|Other|Optimisation of V-V timing using R wave on surface ECG|
45446266|NCT02080000|Other|Standard V-V timing settings|
45446267|NCT02071654|Device|Venus P-valve transcatheter implantation|Percutaneous implantation of Venus-P valve to treat RVOT stenosis patients
45763966|NCT03408743|Behavioral|Injunctive norms, benefits, self-efficacy|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45763967|NCT03408743|Behavioral|Descriptive norms alone|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
45446268|NCT02080078|Drug|Theophylline|
45446269|NCT02080078|Drug|Erlotinib|
45763968|NCT03408743|Behavioral|Descriptive norms and self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45763969|NCT03408743|Behavioral|Descriptive norms and perceived benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
45763970|NCT03408743|Behavioral|Descriptive norms, benefits, self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45763971|NCT03408743|Behavioral|Descriptive norms and injunctive norms|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
45763972|NCT03408743|Behavioral|Descriptive and injunctive norms, self-efficacy|orrect misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45763973|NCT03408743|Behavioral|Descriptive and injunctive norms, and benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
45763974|NCT03408743|Behavioral|Descriptive & injunctive norms, benefits, efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45912106|NCT03984357|Drug|PD-1 blocking antibody|"Whole-course concurrent PD-1 blocking antibody: every 3 weeks × 6 cycles; 360 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone.~Adjuvant PD-1 blocking antibody: every 4 weeks × 6 cycles; 480 mg, day 1"
45912107|NCT03984357|Drug|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
45912108|NCT03984357|Drug|Cisplatin|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
45912109|NCT03984357|Radiation|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
45912110|NCT03921489|Procedure|Subchondroplasty|Calcium phosphate mineral compound injected into the bone marrow lesions
45912111|NCT03868943|Drug|Soliramfetol|Solriamfetol will be dosed by flexible dose titration starting at 75 mg daily in all patients and escalating after 7 days (1 week) to 150 mg daily and then after 7 days to 300 mg daily for a total duration of 3 weeks (flexible dose titration period).
45621494|NCT05217563|Behavioral|Memory-reframing intervention (Reframe the Pain)|Parents will be taught to reminisce with their children about the vaccination experience by emphasizing positive aspects of the child's pain memory, using less utterances about pain and fear, correcting negative exaggerations in memory, and enhancing children's self-efficacy regarding their ability to cope with pain (e.g., when children used coping methods such as deep breathing, highlighting that they were brave). Parents will be instructed to reminisce with their children about the vaccine experience using the intervention strategies. Parents in the intervention groups will receive text/email reminders to use needle pain management strategies before each second vaccination appointment. Additionally, parents randomized to the intervention groups will receive text/email reminders approximately once every two weeks to use the memory-reframing principles until the second vaccination appointment.
45446270|NCT02080156|Device|CPAP|
45446271|NCT02071732|Device|real repetitive Transcranial Magnetic Stimulation|
45446272|NCT02071732|Device|sham repetitive Transcranial Magnetic Stimulation|This sham stimulation is not true stimulation.
45446273|NCT02083276|Drug|Pivmecillinamhydrochlorid|PO 400 mg x3 for 7 days
45621495|NCT02471729|Device|EnligHTN™ Renal Denervation System|The renal nerve ablation will be performed according to the EnligHTN™ Renal Denervation System Instructions for Use. This system has the CE mark and is marketed in Europe and manufactured in France. The ablation catheter is indicated for use in renal denervation procedures for the treatment of hypertension.
45763975|NCT03408743|Behavioral|Expectancies alone|Decrease the expectation that alcohol is needed to have good sexual encounter.
45621496|NCT04984707|Drug|KX0826|AR antagonist
45621497|NCT04984707|Other|Placebo|Placebo of KX-826
45621498|NCT02474615|Procedure|ENDODONTIC SURGERY|ENDODONTIC SURGERY
45446274|NCT03559504|Drug|Sevoflurane Inhal Soln|Anesthesia will be induced by sevoflurane inhalation only with a tight-fitting facemask and a 4-l airflow of 100% oxygen. Sevoflurane inhalation will be adjusted in all age groups to maintain 1.0 MAC concentration
45621499|NCT02474537|Drug|INC280|Single 200 mg dose INC280
45621500|NCT04985097|Procedure|Implantation of trifocal diffractive intraocular lenses|Postsurgical monocular and binocular assessment of corrected and uncorrected near, intermediate and distance visual acuity and near and distance mesopic contrast sensitivity before and after the assigned vision training
45621501|NCT05338853|Other|Gongs mobilization|to deal adhesive capsulitis
45446275|NCT03558646|Other|There is no intervention planned (observational)|There is no intervention planned (observational)
45621502|NCT05338853|Other|scapular mobilization|scapular mobilization
45621503|NCT03073551|Other|Wii Group|Participants in the Wii group will be given a Wii console and video game to take home. The console includes a Wii balance board and remote controller. The Wii Fit game allows participants to choose different types of exercise such as yoga, aerobics, balance training, and more. Participant movements are shown on screen as they move with the balance board and remote control.
45621504|NCT04601129|Procedure|enhanced recovery after surgery program|practice of an enhanced recovery after surgery program, according to the international reviews of literature and national recommendation
45621505|NCT04984395|Diagnostic Test|Post-treatment CT-guided bone marrow biopsy|At post-treatment, 12 +/- 3 weeks after initiating treatment, patients will undergo a CT guided bone marrow biopsy of the same lesion as baseline.
45621506|NCT00705575|Drug|Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week.
45621507|NCT00705575|Drug|Aliskiren (300 mg)|During the titration period, patients received aliskiren 150 mg for one week. Subsequently, patients were up-titrated and received aliskiren 300 mg.
45621508|NCT04994379|Device|1 mA tDCS|One session with stimulation intensity of 1 mA.
45621509|NCT04994379|Device|1.5 mA tDCS|One session with stimulation intensity of 1.5 mA.
45763976|NCT03408743|Behavioral|Expectancies and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45763977|NCT03408743|Behavioral|Expectancies and perceived benefits|Decrease the expectation that alcohol is needed to have good sexual encounter and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
45912112|NCT03841448|Drug|Placebo|Normal saline (0.9% NaCl) matching volume of cemdisiran doses will be administered SC.
45912113|NCT03841448|Drug|Cemdisiran|Cemdisiran will be administered by subcutaneous (SC) injection.
45912114|NCT03829683|Drug|Vitamin C|200mg/kg/24hours
45912115|NCT03829683|Drug|Dextrose 5% in water|50mL intravenously every 6 hours
45621510|NCT04994379|Device|Sham tDCS|One session of sham stimulation.
45912116|NCT03824522|Biological|ADYNOVATE|Pegylated recombinant human factor VIII
45912117|NCT03812991|Drug|Miacalcin Calcitonin Salmon Nasal Spray|Miacalcin nasal spray is 1 spray (200 International Units) per day administered intranasally, alternating nostrils daily
45912118|NCT03812653|Device|CPAP|Automatically-adjusting continuous positive airway pressure (CPAP) delivered using a study supplied device.
45621511|NCT04993989|Drug|Iberogast (STW5, BAY98-7411)|Survey without any intervention assigned in the study.
45763978|NCT03408743|Behavioral|Expectancies, benefits, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45763979|NCT03408743|Behavioral|Expectancies and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
45763980|NCT03408743|Behavioral|Expectancies, injunctive norms, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45912119|NCT03801915|Drug|MVT-5873|1 mg/kg or 3 mg/kg for pre-operative dose, 1 mg/kg during post-operative period
45912120|NCT03801915|Procedure|pancreatectomy or hepatectomy|Pancreatectomy or hepatectomy
45653341|NCT04401553|Drug|cephalosporin|First tier antibiotics, cephalosporin, will be given before anesthesia induction in the subjects with a history of allergy-like event to beta-lactam
45912121|NCT03800277|Dietary Supplement|Cranberry|Supplementation of polyphenols from cranberry extract
45912122|NCT03800277|Dietary Supplement|Agaves|Supplementation of inulin from Agaves powder
45912123|NCT03800277|Dietary Supplement|Placebo|Supplementation with placebo
45912124|NCT03787173|Device|Optimized|Inspiratory trigger and Expiratory trigger settings optimized by investigator
45912125|NCT03787173|Device|Automated|Inspiratory trigger and Expiratory trigger settings automatized
46069287|NCT03098576|Other|Unmatched standard of care|"All patients with either no identified mutation or no available matching treatment but undergoing a systemic treatment will be enrolled in the control group."
45621512|NCT05208437|Behavioral|Complete oral feeding intervention|Premature infants will be assessed 12 times a day before feedings using the Feeding Preparation Scale by trained nurses. Assess the premature infants by using the Feeding Preparation Scale. If the premature infant does not meet the oral feeding standard, let the premature infant use the non-nutritive sucking for 3 minutes before the nasal feeding. If the premature infant meets the oral feeding standard, use the non-nutritive sucking for 3 minutes, and refer to the feeding schedule for the premature infant.
45763981|NCT03408743|Behavioral|Expectancies, injunctive norms, and benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
45763982|NCT03408743|Behavioral|Expectancies, injunctive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45763983|NCT03408743|Behavioral|Expectancies and descriptive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
45763984|NCT03408743|Behavioral|Expectancies, descriptive norms, & self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45763985|NCT03408743|Behavioral|Expectancies, descriptive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
45912126|NCT03737968|Drug|Durvalumab|Patients in the durvalumab (MEDI4736) monotherapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months
45912127|NCT03737968|Drug|durvalumab + tremelimumab|Patients in the durvalumab (MEDI4736) + tremelimumab combination therapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months
45621513|NCT05208437|Behavioral|Routine nursing care group|Pre-feeding assessments will be performed from premature infants corrected for gestational age at 34 weeks. If the baby's vital signs are stable, the method of oral feeding and then nasal feeding is used, and feeding 8 to 12 times a day until the baby reaches complete oral feeding.
45621514|NCT03068247|Drug|Duloxetine|10 week treatment
45621515|NCT03068247|Drug|Placebo|10 week treatment
45621516|NCT03108833|Drug|Recombinant Human Prourokinase|The drug is used for intravenous thrombolysis therapy
45621517|NCT03108833|Drug|Alteplase|The drug is used for intravenous thrombolysis therapy
45621518|NCT02636595|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
45621519|NCT03108911|Other|Best Practice|Receive standard diet
45621520|NCT03108911|Procedure|Biospecimen Collection|Provide stool sample
45621521|NCT03108911|Other|Dietary Intervention|Receive GFD
45621522|NCT03108911|Other|Laboratory Biomarker Analysis|Correlative studies
46069288|NCT03097796|Drug|PUL-042|PUL-042 Inhalation Solution
45621523|NCT02636361|Drug|LY900014|Administered subcutaneously (SC)
45621524|NCT02636361|Drug|Insulin lispro (Humalog)|Administered SC
45621525|NCT04585763|Device|Shockwave Medical M5+ Peripheral Intravascular Lithotripsy (IVL)|The Shockwave Medical M5+ Peripheral IVL System is indicated for lithotripsy-enhanced, low-pressure balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. This device is not intended for use in coronary, carotid, or cerebrovascular arteries.
45621526|NCT05199935|Behavioral|Video|Information on violence and safety behaviors. Women are encouraged to share their experience of domestic violence with others.
45621527|NCT05199935|Other|Control|Control video on healthy pregnancy
45621528|NCT02471885|Procedure|Remote Ischaemic Conditioning|each cycle of Remote Ischaemic Conditioning (RIC) consists of inflating a blood pressure cuff on the upper limb (arm) upto 200mm Hg (systolic BP + 20 mm Hg for low platelets, e.g. 50-150 x 10^9/L; skip RIC if platelets < 50 x 10^9/L) for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
45621529|NCT02471885|Other|Placebo|Sham control blood pressure cuff placement at 10 mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
45621530|NCT02636283|Drug|Entresto|Oral pills
45621531|NCT02636283|Drug|Placebo group|The placebo pills
45621532|NCT05317949|Other|Integrated neuromuscular training program group|Integrated neuromuscular training program group will do plyometric training, speed and sensitivity training, resistance training for 3 days in a week and total for eight weeks.
45621533|NCT05317949|Other|General fitness exercises program group|General fitness exercises program group will do general fitness exercise for 3 days in a week and total for eight weeks.
45621534|NCT03668223|Behavioral|Promoting Resilience in Stress Management (PRISM)|Manualized skills training targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
45621535|NCT02471573|Procedure|Freeze-all protocol|Embryos are selected for cryopreservation using vitrification technique. Two vitrified embryos will be warmed and transferred in subsequent cycle.
45621536|NCT02471573|Procedure|Fresh transfer protocol|Two embryos are selected and transferred fresh in the same cycle.
45621537|NCT04451265|Other|MRI|Diffusion sequence (8 minutes long) added to the initial MRI
45621538|NCT02471417|Dietary Supplement|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be on a single occasion by the study subjects.
45621539|NCT02471417|Dietary Supplement|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be on a single occasion by the study subjects.
45621540|NCT04450953|Drug|Eplerenone 50mg/day (cross over design)|Eplerenone 50mg/day for 6 months followed
45621541|NCT04450953|Other|Period without eplerenone (cross over design)|6-month period without eplerenone
45621542|NCT04983849|Drug|metronidazole hydrogel|scaling and root planning in adjunct to the use of metronidazole in the periodontal pocket
45621543|NCT04983849|Procedure|scaling and root planning|scaling and root planning
45621544|NCT02474381|Biological|EPCs plus PTA|Intra-arterial infusion of autologous CD133+ cells on diabetic subjects with PAD,plus angioplasty
45912128|NCT03730701|Behavioral|Prevention program for stroke|The prevention program include individual and group intervention sessions supported by a digital platform. The program will be personally tailored in relation to what the person needs and what to change and the individuals rediness for change. The digital platform will support the person during and in between sessions by prompting goals and goal-fulfilment, logging activities, step counts and provide a forum for sharing and reflection.
45912129|NCT03725202|Drug|Upadacitinib|It will be administered orally.
46069289|NCT03084627|Behavioral|Tailored dietary advice|The nutrient adequacy of the diet of each patient will be evaluated, at baseline, by a diet quality index: the PANDiet. Then, tailored dietary advice aiming at improving the nutrient adequacy of the diet will be generated for each patient in the arm #2. Patients will choose 3 tailored dietary advices among 3 options during three appointments with a research project team member (the first in person and the second and the third by phone). Each appointment will be spaced of 2 weeks. In total, each patient in the arm #2 will choose nine tailored dietary advice. Tailored dietary advices are of two kinds: substitution of a consumed food item by a food item in the same food subgroup or modification of the consumed amount (increase or decrease) of a food item. Tailored dietary advices cannot generate an increase of more than 190 kcal or a decrease as compared to the observed energy intake.
46069290|NCT03067051|Drug|Verteporfin|In the last decade a clinical interest of developing new methods for minimally invasive treatments of organ-confined prostatic malignancies has been pursued. In this study the drug verteporfin for injection (VFI) is to be used with the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software).
46069291|NCT03067051|Device|SpectraCure P18 System|Interstitial Photodynamic therapy is provided with the the SpectraCure P18 system
45621545|NCT02474381|Device|Single PTA|Angioplasty of arteries below tibial plateau level only
45621546|NCT04983537|Drug|Gam-COVID-Vac / Gam-COVID-Vac|A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and the Gam-COVID-Vac / ChAdOx1 nCoV-19 and Gam-COVID-Vac / BBIBP-CorV groups as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.
45621547|NCT02474303|Drug|Truvada|Demonstration Study
45621548|NCT03664713|Behavioral|Eye Movement Desensitization and Reprocessing (EMDR) Therapy|EMDR is an 8-phase psychological treatment composed of protocols and standardized procedures applicable to both adults and children. The eight phases (patient history, patient preparation, evaluation of the main aspects of the memory, desensitization of the traumatic memory, installation of the positive cognition, body scan, close and re-evaluation) and the protocol of the time line of past-present-future, allow a holistic evaluation of the image of the traumatic memory, and allow for the patient to be well-prepared before processing past events which underlie current pathology, current situations which cause perturbation, and challenges and possible future stimuli which might lead to the appearance of symptoms. (Shapiro, 2014)
45621549|NCT02474225|Drug|Intravitreal injection (bevacizumab or ranibizumab)|The intravitreal anti-vascular endothelial growth factor agent of 0.1 ml of bevacizumab (2.5 mg/0.1 ml) or ranibizumab (1 mg/0.1 ml)
45912130|NCT03725202|Drug|Corticosteroid (CS)|It will be administered orally.
45912131|NCT03725202|Other|Placebo|It will be administered orally.
45912132|NCT03696433|Dietary Supplement|Low-salt diet|The low-salt diet (7 days) will consist of meals, snacks and water provided by Vanderbilt's metabolic kitchen.
45446276|NCT02080234|Drug|GELOX|gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days
45446277|NCT02080234|Radiation|IFRT|IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions
45446278|NCT02083432|Behavioral|5 session of CBT performed by specially trained dentists|"A total of 60 participants are randomly assigned to a 5-weeks waiting list Control Group or directly enrolled to the 5-session of CBT treatment Group.~The participants in the waiting list Control Group are enrolled to the treatment Group (5 sessions of CBT) after 5 weeks if they still meet the diagnostic criteria of a specific phobia (according to DSM-IV)."
45621550|NCT04491851|Diagnostic Test|68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 PET/CT|Patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-DOTA-LM3 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
45621551|NCT04491851|Diagnostic Test|68Ga-NODAGA-LM3 and 68Ga-NODAGA-JR11 PET/CT|Patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-NODAGA-JR11 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
45621552|NCT03066453|Drug|Tobi Inhalant Product|inhaled tobramycin 300 mg twice per day
45621553|NCT03066453|Drug|Nebcin|10 to 12 mg/kg/day in 1 injection for adults and 10 to 15 mg/kg in 1 pediatric injection (combined with another IV antibiotic)
45621554|NCT03558711|Diagnostic Test|18F-PSMA|18F-PET imaging
45621555|NCT02471495|Device|Synergo® RITE + MMC|"Synergo® system delivers homogenous microwave hyperthermia to the bladder wall in combination with bladder instillation of cold chemotherapeutic agent - Mitomycin C (MMC).The energy-delivering unit and the intravesical irrigation system are computer-controlled, The irrigation system consists of a disposable tubing line and catheter set. The catheter is a triple-lumen, silicone, transurethral Foley-type catheter.~MMC is constituted as a powder (40 mg) dissolved in 50 ml sterile water for injection."
45621556|NCT04983381|Other|Multimedia education video|The multimedia education video was a 30 minutes information-based patient education program and contained information about pelvic anatomy and how to practice vaginal examination. The same gynecologist (M.S.) (male) who 15 years of experience explained details of vaginal examination, who told about vaginal examination in this video to the study participants, also did the gynecologic examination. The gynecologic examination which contained pelvic ultrasound scan and vaginal examination lasted approximately 20 minutes practice.
45621557|NCT02474459|Device|iPad-Based Clinical Support Care|Subjects in this treatment arm will receive deep brain stimulation (DBS) programming at regular intervals as part of routine clinical care. DBS stimulation programming will be done with the use of a iPad-based decision support system.
45621558|NCT02474459|Other|Standard Clinical Care|Subjects in this treatment arm will receive DBS programming at regular intervals as part of routine clinical care.
45621559|NCT05315063|Other|Eccentric Training|Once achieved, this flexed hip position will be held for 5 seconds. This procedure will be repeated 6 times with no rest between repetitions
45621560|NCT05315063|Other|Muscle Energy Technique (PIR)|"The participant will be asked to resist the movement with no more than 25% of strength. The contraction will be held for 7-10 seconds followed by complete relaxation of the limb.~On exhalation, the knee joint will be straightened (extended) towards its new barrier and through that barrier a stretch was applied and maintained for 30 seconds.3 repetitions of this process will be done"
45621561|NCT02474147|Other|Processed meat hamburger|MacMuffin Fresh 300 ml Cafe Latte + 21 g sugar Energy: 513.6 kcal Carbohydrates 55g (44.8%) Proteins 20.5g (16.7%) Lipids 22 g (38.6%)
45621562|NCT02474147|Other|Vegan sandwich|Burger with tofu + 300 ml green tea Energy 514.9 kcal Carbohydrates 54.2 g (44%) Proteins 19.9 g (16.2%) Lipids 22.8 g (39.8%)
45763986|NCT03408743|Behavioral|Expectancies, descriptive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
46069292|NCT03013998|Biological|Samalizumab (BAML-16-001-S1)|300 mg/m2, IV, on days 1, 3, and 24; followed by 300 mg/m2, IV, every 21 days for 2 years in the absence of toxicity or disease progression. Dose may be de-escalated to 150 mg/m2 or escalated to 600 mg/m2 based on occurrence of dose-limiting toxicity.
45621563|NCT04521413|Drug|CFI-402411|CFI-402411 is administered orally once daily. The starting dose is 80 mg/day for escalation arms and the recommended dose for the expansion arms.
45621564|NCT04521413|Drug|Pembrolizumab|Pembrolizumab will be given at its labeled dose and schedule, 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.
45621565|NCT02473835|Other|Calorie restriction|Participants will reduce calorie intake by 50 % for a period of 3 consecutive days.
45621566|NCT02473835|Other|Activity monitoring|For 1 week, participants will be fitted with an activity monitor (Actiheart) to estimate energy expenditure (during the same week as the diet monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
45621567|NCT02473835|Other|Diet monitoring|For 1 week, participants will be asked to record all food and fluids consumed to estimate energy intake (during the same week as the activity monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
45621568|NCT03108755|Drug|ASP7713|oral
45621569|NCT03108755|Drug|Placebo|oral
45621570|NCT04448873|Drug|Sirolimus|After at least 2 years of remission of KHE, we compare guided discontinuation with maintenance treatment in pediatric patients with KHE.
45763987|NCT03408743|Behavioral|Expectancies, descriptive and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
45763988|NCT03408743|Behavioral|Expectancies, descriptive & injunctive norms, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45763989|NCT03408743|Behavioral|Expectancies, descriptive & injunctive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
45763990|NCT03408743|Behavioral|Expectancies, descriptive & injunctive, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45763991|NCT03401515|Drug|Propranolol Hydrochloride 1 MG/ML|Propranolol 1 mg every 6 hrs in the first 24 hrs after isolated blunt traumatic brain injury
45763992|NCT03401515|Other|Normal saline|Normal Saline 1 ml every 6 hrs
45763993|NCT04368715|Device|Laser-assisted frenectomy with 2780 nm Er:Cr;YSGG and 940 nm diode laser|
45763994|NCT01726829|Device|MD-Logic Artificial Pancreas (MDLAP) system|
45763995|NCT01726829|Procedure|sensor augmented pump therapy|
45763996|NCT02244385|Other|no intervention|
45763997|NCT03408509|Behavioral|Computerized cognitive training|Posit Science Inc. will supply the software for the computerized cognitive training through the platform BrainHQ, which is available on line. The training program consists of a set of computerized exercises designed to improve the speed and accuracy of sensory information processing while engaging neuromodulatory systems involved in attention and reward. The rationale is that, in order to understand and remember information, the brain must first generate precise and reliable neurological responses that represent the sensory stimuli. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations. The goal is to increase the effectiveness with which these stimuli engage and drive plastic changes in brain systems. Engagement is monitored by electronic data upload following each training session.
45763998|NCT02244541|Drug|ANAVEX2-73 Oral|
45763999|NCT02244541|Drug|ANAVEX2-73 Intravenous|
45764000|NCT02244541|Drug|ANAVEX2-73 Oral|30 mg hard gelatin capsule
45446279|NCT02080390|Procedure|Transthoracic echocardiogram (ultrasound)|Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.
45764001|NCT02244541|Drug|ANAVEX2-73 Oral|50 mg hard gelatin capsule
45764002|NCT01720433|Procedure|intervention|The patient was placed in the Trendelenburg position (30°) and two manual lung inflations to a maximum pressure of 60 cm H2O for five seconds, with the valves on the operative ports fully open.
45764003|NCT04368325|Diagnostic Test|Serum creatinine levels|Comparison of treatment length using mechanical ventilaton, length of stay in ICU, survival between two groups
45764004|NCT01720511|Dietary Supplement|Purple Rice|Incorporate one cup of purple rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
45446280|NCT04841577|Biological|RSVPreF3 OA investigational vaccine|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
45446281|NCT04841577|Biological|FLU-QIV|FLU-QIV administered intramuscularly in the deltoid region of the dominant (Co-Ad Group) arm or the non-dominant (Control Group) arm.
45446282|NCT04529109|Device|etafilcon A investigational cosmetic lens 1|TEST
45446283|NCT04529109|Device|etafilcon A investigational cosmetic lens 2|CONTROL
45446284|NCT04528641|Biological|GRAd-COV2|Single intramuscular administration.
45621571|NCT04430855|Drug|Upadacitinib|Tablet; Oral
45621572|NCT04430855|Drug|Placebo|Tablet; Oral
45621573|NCT04378907|Other|ECIG Lab Session, 30 watts|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
45621574|NCT02471105|Drug|Preserved Bimatoprost 0.01%|Eye drops solution Topical use Once in the evening 3 months
45621575|NCT02471105|Drug|Tafluprost Unit Dose Preservative Free 15microgram/ml|Eye drops solution Topical use Once in the evening 3 months
45621576|NCT03108989|Drug|Sugammadex|After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
45621577|NCT03108989|Drug|Neostigmine|After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.
45764005|NCT01720511|Dietary Supplement|Brown Rice|Incorporate one cup of brown rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
45764006|NCT01720589|Dietary Supplement|Melt (test oil)|
45764007|NCT01720589|Dietary Supplement|Corn oil (control)|
45764008|NCT03401359|Genetic|tissue biopsy, blood sample|At baseline, 100 tumor/blood samples will be banked. Only ~60 will be profiled if the paired samples are acquired post-progression or on-treatment. On-treatment blood samples will be serially collected and banked from all consenting patients.
45912133|NCT03696433|Dietary Supplement|High-salt diet|The high-salt diet (7 days) consists of each subject's typical diet, supplemented each day with 2 bullion broth packets, which will be provided to the subject by the study staff.
45912134|NCT03657849|Device|EBUS TBNA|All patients undergo EBUS TBNA with two needle sizes
45912135|NCT03652753|Drug|N-acetylcysteine|4 mL of a 20% solution of NAC will be injected into the ankle of patients with pilon fractures at the time of their external fixator surgery
45621578|NCT02470871|Biological|Eptacog alfa (activated) or pdFVII|"Comparator Drug 1: Recombinant activated FVII (rFVIIa). Subjects with eptacog alfa (activated) as their routine FVII replacement therapy will receive a single dose of eptacog alfa (activated) in the study.~Comparator Drug 2: Plasma-derived FVII (pdFVII). Subjects with pdFVII as their routine FVII replacement therapy will receive a single injection of pdFVII in the study."
45621579|NCT02470871|Biological|CSL689|Experimental Drug: Recombinant fusion protein, linking activated FVII with albumin (rVIIa-FP). Subjects will receive a single dose of CSL689 at either a low dose (Arm 1) or a high dose (Arm 2)
45621580|NCT02471027|Procedure|Neoadjuvant chemotherapy|There is no uniform schemer,commonly used drugs including carboplatin,cisplatin,paclitaxel,vincristine,bleomycin,fluorouracil,ifosfamide,mitomycin,gemcitabine,and so on.Methods including intravenous chemotherapy and artery intervention chemotherapy,also has not been unified.
45621581|NCT05111015|Device|AtriCure Isolator® Synergy™ Surgical Ablation System|The AtriCure Isolator® Synergy™ Surgical Ablation System is used in the Maze IV procedure for the treatment of Atrial Fibrillation.
45621582|NCT05111015|Device|AtriCure AtriClip® LAA Exclusion System|The AtriCure AtriClip® LAA Exclusion System is used to exclude the Left Atrial Appendage.
45446285|NCT04832607|Other|Multivirus (CMV, EBV, AdV)-specific T cells|Cell therapy product which is individually produced for each patient and administered via IV bolus injection.
45446286|NCT05459727|Procedure|Non-surgical periodontal therapy|Non-surgical periodontal therapy includes basic oral hygiene instructions and full-mouth subgingival scaling and root planing under local anesthesia.
45446287|NCT05459727|Procedure|Control periodontal treatment|Control periodontal treatment includes basic oral hygiene instructions and full-mouth supragingival ultrasonic scaling.
45446288|NCT05337189|Diagnostic Test|Urine DNA methylation analysis|Urine specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)
45621583|NCT02470793|Procedure|Descemet Stripping Automated Endothelial Keratoplasty|Descemet Stripping Automated Endothelial Keratoplasty
45621584|NCT02470793|Procedure|Descemet Membrane Endothelial Keratoplasty|Descemet Membrane Endothelial Keratoplasty
45653342|NCT04401553|Drug|Second tier antibiotic (Vancomycin)|Second tier antibiotics, vancomycin, will be given before anesthesia induction for infection prevention in the subjects with a history of allergy-like event to beta-lactam (standard of care)
45653343|NCT01364649|Drug|Vortioxetine|Vortioxetine tablets
45653344|NCT01364649|Drug|Escitalopram|Escitalopram tablets
45653345|NCT01364649|Drug|Placebo|Vortioxetine Placebo-matching capsules
45653346|NCT05336227|Behavioral|Virtual Reality Exergaming|The VR intervention will include home-based exercise using the Oculus Quest, a heart rate monitor (Polar OH1), BP cuff, and mobile application. The games will include rhythmic movements to music and sport/recreation activities that elicit high energy expenditure. Participants will be instructed to reach 150 minutes per week of moderate-exercise in week 1 and maintain this volume across the 12-week intervention. The intervention will include behavioral, physical education coaching through videoconference, which we refer to as Tele-PE. Tele-PE will aim to enhance adherence, provide basic exercise knowledge, and increase mastery playing the games. Calls will last 15 minutes, and be provided weekly in month 1, bi-weekly in month 2, and one call at the end of month 3.
45653347|NCT03065569|Drug|Bupivacaine|16 mL of 0.125% bupivacaine
45653348|NCT05723419|Procedure|axillary block using 5 ml local anesthetics|ultrasoud guided axillary block
45653349|NCT03065491|Dietary Supplement|Combined nutraceutical|Plant sterols 800 mg + Red Yeast Rice containing 5 mg monacolin K + L-Tyrosol 50 mg per daily dose Oral administration: 1 tablet per day
45653350|NCT03065491|Other|Placebo|Oral administration: 1 tablet per day
45653351|NCT04990401|Behavioral|Behavioral Activation Teletherapy|A total of 10 teletherapy sessions to be delivered over 12-14 weeks, designed to increase physical activity among depressed individuals.
45653352|NCT02588261|Drug|naquotinib mesilate|Participants received ASP8273 300 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day.
45653353|NCT02588261|Drug|Erlotinib|Participants received erlotinib 150 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
45764009|NCT01726907|Device|Robotic SMG resection|The surgical procedure and the considerations for surrounding neurovascular structures were similar to that of the endoscope-assisted SMG resection. The da Vinci surgical system (Intuitive Surgical Inc., Sunnyvale, CA) including a 30° dual channel endoscopic arm and two instrument arms was introduced. The SMG was retracted using the 5-mm Maryland forceps on the left and the dissection was conducted using a 5-mm spatula monopolar cautery or a Harmonic curved shears on the right. A Yankauer suction handled by a bed-side assistant could be used for counter traction of the gland which facilitated the dissection procedure.
45764010|NCT01726907|Device|Endoscopic SMG resection|An assistant held a 10-mm 30° rigid endoscope allowing the operating surgeon to use both hands. Surgical resection tools such as dissector and Harmonic scalpel (Harmonic Ace 23E®; Johnson & Johnson Medical, Cincinnati, OH, USA) was held in the right hand and a Yankauer suction or a Debakey forcep was held on the left for traction of the SMG. The dissection plane between the capsule of the SMG was conducted under magnified endoscopic view using the the blade of the Harmonic scalpel and the endoscopic dissector. Routine identification of the marginal mandibular branch of the facial nerve was unnecessary in SMG resection, since the dissection plane was always deep to the middle layer of the deep cervical fascia which includes the fascia of the gland. The Wharton's duct, facial artery and vein were ligated using the Harmonic scalpel or vascular clip.
45764011|NCT03401281|Other|Coconut oil|50g extra virgin coconut oil daily for four weeks
45764012|NCT03401281|Other|Butter|50g butter daily for four weeks
45764013|NCT03401281|Other|Olive oil|50g extra virgin olive oil daily for four weeks
45764014|NCT03408431|Device|Ambu® AuraGain™|Ambu® AuraGain™ laryngeal mask will be placed first, and then, a lubricated endotracheal tube will be gently intubated through the laryngeal mask under each position according to the assigned group.
45764015|NCT03408431|Procedure|neck extension|Patients' neck will be maximally extended (~60°) during blind intubation.
45764016|NCT04368169|Dietary Supplement|Teramune Botanical Extract|Combination blend of aromatic plant extracts in an emulsifier carrier.
45446289|NCT05337189|Procedure|medical imaging and/or cystoscopy and/or pathological examination|Subjects will undergo medical imaging and/or cystoscopy and/or pathological examination
45446290|NCT04527471|Drug|Ensifentrine Dose 1|Study drug delivered twice daily via pMDI
45764017|NCT04368169|Other|Placebo|Emulsifier carrier without active supplement ingredients.
45446291|NCT04527471|Drug|Placebo pMDI|Placebo delivered twice daily via pMDI
45446292|NCT05070039|Genetic|Expression of Cortactin anti body|assessment of Cortactin immunohistochemical expression in invasive and non-invasive urothelial carcinoma.
45446293|NCT03754569|Procedure|Peritoneal biopsies after complete macroscopic cytoreduction|We will perform at the end of complete macroscopic cytoreductive surgery (CC-0) for epithelial ovarian cancer random peritoneal biopsies in apparently healthy peritoneum in order to assess the presence of microscopic peritoneal metastases
45452326|NCT05547958|Other|Focus group and online survey|"Focus group with parents of children with disabilities or chronic condition will be organized to identify hypotheses regarding their needs in terms of informations exchange with pediatric rehabilitation professionals about the rehabilitation care of their children.~Then, an online survey will be proposed to parents of children with disabilities or chronic condition in France to identify their needs regarding the development of apps that offer the feature to share informations with rehabilitation professionals."
45452327|NCT01154374|Drug|MEBO Wound Ointment|Topical application twice daily
45764018|NCT03408275|Other|None - observational|None - observational
45452328|NCT01154374|Procedure|Standard of Care (sterile saline moistened gauze)|
45764019|NCT04368247|Diagnostic Test|Skin Fluorescent Imaging|Application of reagents, then imaging and scoring
45764020|NCT02244775|Device|SR™MCP|
45764021|NCT00911495|Drug|GMI-1070|Intravenous GMI-1070 given as two doses over the course of one day
45912136|NCT03652753|Drug|Saline|4 mL of a 20% solution of saline will be injected into the ankle of patients with pilon fractures at the time of their external fixator surgery
45764022|NCT03834103|Behavioral|Self-rehabilitation program and protein supplement|"Participants follow a home-based self-rehabilitation program consisting of the realisation of a set of physical exercises using an elastic band. The exercises have to be performed 3 times a week, and are associated with a protein supplementation.~The rehabilitation follow-up by the physician is planned once a week, by phone, and with face-to-face appointments at inclusion, 6 weeks and 3 months follow-up."
45764023|NCT03408197|Device|EasyWarm|Perioperative warming with EasyWarm to prevent inadvertent hypothermia during anaesthesia
45764024|NCT03408197|Device|BairHugger|Perioperative warming with BairHugger to prevent inadvertent hypothermia during anaesthesia
45764025|NCT01726985|Other|Parameter Based Clinical Disposition|"Parameter Based Clinical Disposition'~Physicians will initiate / titrate medications and obtain consults as usual but are highly encourage to keep patients in the hospital until at least 2 of the following 3 criteria are met:~NT-ProBNP reduction of > 23% from peak value during admission~Fluid Reduction of > 1.3L (orders for I/O q8h required)~Serum Sodium of > 135 mmol/L the day of planned discharge"
45764026|NCT04367701|Diagnostic Test|Hemolysis|Authors measured free plasma hemoglobin concentration in gram
45764027|NCT01727063|Procedure|Cell Therapy|Intramyocardial injection of autologous bone marrow-derived cells
45764028|NCT02244931|Device|Servomatic™ assisting device|Servomatic™ is an hand controlled motorized device assisting to propel the wheelchair .
45764029|NCT02244931|Device|E.Motion© assisting device|E.Motion© is an hand controlled motorized device assisting to propel the wheelchair .
45764030|NCT02244931|Device|Standard manual Wheelchair|Standard manual Wheelchair
45764031|NCT00918671|Other|No new specific intervention|No new specific intervention
45764032|NCT04366297|Device|Intravenous access|obtaining intravascular access using a standard intravenous cannula
45764033|NCT04366297|Device|Intraosseous access|obtaining intravascular access using a ready intravenous NIO needle set
45764034|NCT03408041|Other|Medical file data extraction|Medical file data extraction
45764035|NCT04366375|Diagnostic Test|PTX-3|Pentraxin-3 ng/mL PTX-3 levels were measured using human PTX3 ELISA Kit 96 Tests/Box (Cat. No: CK-E90303) (Hangzhou Eastbiopharm Co.,Ltd., PRC) read by a ELISA device matching with the kit. For the purpose of measurement, microplate washer RT 2600 device and Rayto microplate reader RT 2100C device were used.
45764036|NCT01720823|Device|home polysomnography (GETEMED)|
45764037|NCT01720823|Device|standard polysomnography (BRAINNET II)|
45764038|NCT02245009|Procedure|Cardioversion|
45764039|NCT04379453|Procedure|Robot Assisted Percutaneous Cardiovascular Intervention|Robot Assisted Percutaneous Cardiovascular Intervention
45912137|NCT03642249|Behavioral|OSCEs|Scenario-based education intervention, including objective structured clinical examinations (OSCEs)
45912138|NCT03642249|Behavioral|Lecture|Face-to-face Education using Delirium Care Flip Chart
45452329|NCT05533216|Other|Performance of different upper limb functional tests|The participants will have to perform 3 to 5 different upper libm functional tests, depends on the sport they practice.
45764040|NCT04376047|Other|Reverse Trendelenburg position|The Reverse Trendelenburg position is a position in which patients' hip and knee are not flexed but the head and chest are elevated at 30° than the abdomen and legs.
45764041|NCT04376047|Other|Semi-recumbent position|The semi-recumbent position is an upright positioning of the head and torso at an angle of 45° while legs are lying on the bed.
45764042|NCT04379609|Other|Masticatory efficiency|"Two-color chewing gum mixing ability test was used to measure masticatory efficiency in the control group, before and after treatment in the experimental group.21 Commercial two-color chewing gum was used.The gum was left on the patient's tongue and he/she was asked to chew 20 times naturally.~After chewing, the gum was put in a transparent plastic bag and squeezed to 1 mm. Both sides of the sample were scanned at 300 dpi resolution on a desktop scanner (HP Deskjet, California, USA) in the same day to prevent the colors from deteriorating due to saliva. For each patient, two sides of scanned images were processed in ViewGum software (version 1.4, Dhal Software, Kifissia, Greece, www.dhal.com) using the method of Halozenitis et al. (2013).22 The value of VOH (variance of hue) was taken as the value of chewing activity. The highness of this value indicates low masticatory efficiency."
45764043|NCT04366141|Device|COVID-19 barrier box|Attending anesthesiologists will use a plastic proprietary barrier enclosure for intubating patients in the intervention group to protect spreading aerosolized droplets from patient to health care provider.
45764044|NCT04366453|Procedure|echocardiography|Four measurements in echocardiography performed in addition to standard care
45764045|NCT04379375|Behavioral|Nudge|Application of behavior-change strategies based on principles of behavioral economics, decision-making heuristics, psychological/environmental variables.
45764046|NCT03834233|Drug|Nivolumab|Nivolumab 3mg/kg IV every 14 days until disease progression, unacceptable toxicity or up to 12 months.
45764047|NCT04367389|Behavioral|Physical activity promotion|Physical activity promotion activities consist of two phone or video calls with a therapists, two group video calls with a therapist, a complementary e-learning course and a fitness tracker that was provided.
45764048|NCT04367389|Behavioral|Exercise|Participants will agree with their therapist on an exercise plan (endurance and resistance training) that will be made available through the studies mobile app. Frequency and duration of endurance and strength training shall be prescribed in accordance with exercise guidelines for persons with MS. However, they can be adjusted according to participants prior physical activity level and their time for exercise during the week.
45764049|NCT01727375|Other|Circadian light|"Artificial ceiling lighting throughout the day will be provided by the Philips HealWell system, CE marked, which is able to deliver varying light levels and warmer or cooler light according to the time of the day (circadian light). Emergency or examination lighting can be set on demand as circumstances require.~Lighting conditions at the patients bedside will be characterized by transformations on the time-series of light levels as measured by a luxmeter. The following metrics will be used for lighting characterization in a period of 24h: mean levels of bright and dark periods, contrast between bright and dark periods, clustering of bright and dark periods, and circadian variation."
45764050|NCT04367545|Diagnostic Test|Saliva collection|Saliva collection will be done in addition to standard diagnosis collection (nasopharyngeal collection using swab)
45912139|NCT03642249|Behavioral|E-learning|delirium care video
45912140|NCT03636230|Device|Remote Monitoring|Remote Monitoring only
45764051|NCT03407963|Procedure|Embolization|Embolization by microparticles (300-500 microns)
45764052|NCT04367155|Drug|Tranexamic acid injection|hemostatics use
45764053|NCT01727453|Drug|warfarin|Warfarin in anticoagulant dose
45764054|NCT01727453|Drug|Bemiparina|"Group 2 (VKA oral anticoagulation: warfarin), which is the control group will receive VKA anticoagulation as before they had the bleeding episode, with regular monitoring by measurement of prothrombin time (INR). Patients taking acenocoumarol before bleeding episode will be treated with warfarin and the once who were receiving warfarin will continue with the same treatment. Treatment control is performed by measuring the INR periodically.~Randomization will be performed using sealed opaque envelopes that contain the treatment option that will be obtained through a list of random numbers generated by computer."
45764055|NCT04376125|Other|Suboccipital inhibition in tension headache|Deep maneuver of myofascial induction in the suboccipital muscles
45764056|NCT04377347|Other|Time|Exposure is the time from patients call the Emergency Medical Coordination Center to they are admitted to a neurosurgiocal department.
45764057|NCT04375969|Other|whole body cryostimulation treatment|The WBC is apporved by National Ministry of Health. It uses cryochamber with low temperature -110 oC. The patient, minimally dressed (e.g., bathing suit, socks, clogs, headband, and surgical mask), remains 30sec at -60°C (vestibule) for body adaptation and, then, passes to the cryochamber, at -110°C and stay there 3 minutes.
45764058|NCT04375969|Other|Connection WBC treatment and HIIT training|WBC combination with Exercise HIIT according to Litlle protocol from 2011. This exercise protocol will be applied together with cryo-sessions
45446294|NCT05459649|Drug|Cyclosporine Oral Product|A combination of cyclosporin with standard steroid in newly diagnosed ITP patients: cyclosporin was started orally 1 mg/kg/d in two divided doses for 1 week, increased to 1.5 mg/kg/d for 1week, further increased to 2.5 mg/kg/d and then continued for 24 weeks. The therapeutic serum level of cyclosporin was 75 to 150 ug/L. After 26 weeks of cyclosporin treatment, the dose for patients who achieved complete response was reduced by 25 mg/d every 2 weeks to ensure continuing the lowest dose that achieved the targeted serum level of cyclosporin and a safe platelet count; standard steroid regimen included orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
45446295|NCT05459649|Drug|Prednisone|Standard steroid in newly diagnosed ITP patients: orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
45764059|NCT04375969|Other|Control Group|This group willnot to change their daily habits . The measurements will be taken at baseline and at the end of the study
45912141|NCT03636230|Other|Standard of care|In-Clinic visits only
45446296|NCT04471935|Device|At home Speech Hero therapy app|Participants will be instructed to use the Speech Hero therapy app for three hours per week over a 4-week period.
45446297|NCT04468347|Drug|Flortaucipir F18|IV injection, 240 megabecquerel (MBq) (6.5 mCi)
45446298|NCT04468347|Procedure|Brain PET scan|positron emission tomography (PET) scan of the brain
45446299|NCT03754491|Behavioral|One stage treatment for mild and moderate cholangitis with choledocholithiasis|one stage of stone removal in mild or moderate cholangitis.
45446300|NCT04822701|Drug|BI 767551 intravenous|BI 767551 intravenous
45446301|NCT04822701|Drug|BI 767551 inhaled|BI 767551 inhaled
45446302|NCT04822701|Drug|Placebo intravenous|Placebo intravenous
45446303|NCT04822701|Drug|Placebo inhaled|Placebo inhaled
45446304|NCT03754413|Device|experimental|Neuramis® Deep Lidocaine
45764060|NCT04375969|Other|HIIT training group|This group will do the training program without cold exposure
45764061|NCT04377425|Diagnostic Test|COVID-19 swap test PCR|COVID-19 swap test PCR performed according to hospital standard operating procedures
45764062|NCT04376203|Procedure|Thyroidectomy|Typical Thyroidectomy
45764063|NCT01720901|Drug|Icotinib|Icotinib will be administered 250 mg one time by month, 3 times per day.
45764064|NCT04357561|Behavioral|Exercise group (Schroth best practice)|Exercise program will be structured with scoliosis specific exercises (schroth best practice). Schroth best pratice is a pattern spesific scoliosis rehabilitation concept which aimes active self correction during curve pattern specific curve activities of daily life. Exercises for rotational breathing, everyday activities, spinal mobilization and corrective exercises will be specified based on the curve type and applied under the supervision of a physiotherapist.
45764065|NCT01727531|Drug|Chloroquine diphosphate|250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks
45764066|NCT02982343|Behavioral|Falls management plus exercise training|Participants will undergo a session of falls management and education followed by 12 weeks of strength and balance training. Strength training will be performed 4 times per week. Resistance training of the proximal muscles will be prescribed progressing to loads of 60% of 1 repetition maximum, 8-12 repetitions. Weaker muscles will be trained using 2 sets of 8-12 repetitions against gravity. They will also give a selection of exercises targeting balance to challenge stability and sensory feedback using equipment such as foam cushions, though will be individual based on participants' limitations and abilities. Participants will be asked to perform balance exercises daily.
45912142|NCT03621774|Behavioral|Mobile-assisted CBT-informed Skills Training|mCBTn combines the CBT-informed components that target defeatist attitudes from Cognitive Behavioral Social Skills Training (CBSST) group skills training and mobile smartphone interventions from our prior clinical trials research.
45621585|NCT02473601|Drug|Mivacurium Chloride|"Anesthesia induction:~Intravenous injection of midazolam 0.05 mg/kg,Etomidate 0.3 mg/kg,Sufentanil 0.5 g/kg,TOF detection and adjustment of the first twitch height (T1)100%, Mivacurium Chloramine 0.07 mg/kg intraveous injecting in 5 minutes.~Anesthesia maintenance:~Two groups of sevoflurance 1%~8% inhalation anesthesia plus intravenous infusion of remifentanil 0.05～0.2 µg/kg/min,Mivacurium Chloramine 6mg/kg/h, Appropriate supplementary analgesia dose of sufentanil before skin incision and the abdomen was closed. The two groups were maintained until the Bis value was 40 ~ 60. PetCO2 was 30 ~ 35mmHg. Hemodynamic fluctuations did not exceed 20% of the baseline value.At least 20 minutes before the operation stopping Mivacurium infusion,Before the end of operation 5-10 minutes stopping infusion of remifentanil and sevoflurane."
45653354|NCT02588261|Drug|Gefitinib|Participants received gefitinib 250 mg was taken orally once daily with water, with or without food, at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
45653355|NCT03065257|Procedure|Endoscopic Resection|Any Endoscopic resection for Gastrointestinal disorders including neoplasms.
45764067|NCT02982343|Behavioral|Falls management only|Participants will undergo a session of falls management and education.
45446305|NCT03754413|Drug|comparator|No-treatment
45446306|NCT05050305|Drug|Marizomib|Intravenous Infusion
45446307|NCT05050305|Drug|Pomalidomide|Taken orally
45446308|NCT05050305|Drug|Dexamethasone|Taken orally
45446309|NCT04461795|Drug|Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]|225 MG/1.5 ML Subcutaneous Solution
45446310|NCT04461015|Drug|0.4mU Insulin followed by withdrawal period followed by 0.8mU study|Clamp study with insulin infused at 0.4 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.8 mU/Kg/min
45446311|NCT04461015|Drug|0.8mU Insulin followed by withdrawal period followed by 0.4mU study|Clamp study with insulin infused at 0.8 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.4 mU/Kg/min
45446312|NCT04810221|Other|Controlled desaturation study|Measure of SpO2 and Heart Rate by BrOxy M device and reference device in a controlled desaturation study.
45446313|NCT03754179|Drug|Dabrafenib|"Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease"
45446314|NCT03754179|Drug|Trametinib|"Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease"
45446315|NCT03754179|Drug|Hydroxychloroquine|Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2. Add-on at progression of disease in Arm B phase 2
45446316|NCT03694353|Drug|Pegvaliase|40-60mg/day
45446317|NCT04521777|Behavioral|Exercise Intervention|Participate in an 8-week home-based strengthening and walking program
45446318|NCT04521777|Other|Physical Performance Testing|Complete a physical function test
45446319|NCT04521777|Other|Questionnaire Administration|Ancillary studies
45764068|NCT01721135|Drug|GSK2190915 100mg|Film coated oral tablet
45764069|NCT01721135|Drug|GSK2190915 200mg|Film coated oral tablet
45764070|NCT01721135|Drug|moxifloxacin 400mg|Film coated oral tablet
45764071|NCT01721135|Drug|moxifloxacin placebo|Film coated oral tablet
45764072|NCT01721135|Drug|GSK2190915 placebo|Film coated oral tablet
45764073|NCT02982421|Behavioral|Group art therapy|Participants will engage in an art therapy group tailored at emotion expression related to the experience of breast cancer survivorship.
45764074|NCT02982421|Behavioral|Control|Participants will receive Psychoeducational material in the form of a lecture and will engage in the coloring of mandalas.
45621586|NCT04359017|Drug|Lidocaine 1% Injectable Solution|The lidocaine will be injected into the fracture hematoma using buffered 1% lidocaine solution at a dose of 2.5 mg/kg (0.25 mL/kg), maximum dose 100 mg (10 mL). Using a 30-gauge needle to minimize pain, a small skin wheal of lidocaine will be injected over the fracture site. A 21-gauge needle will then be attached to the lidocaine filled syringe and passed through the skin wheal used to inject the lidocaine into the fracture hematoma. To confirm the needle is in the fracture hematoma, a small amount of blood from the hematoma will be aspirated into the syringe filled with lidocaine before injecting the lidocaine, as in standard practice.
45621587|NCT04315961|Drug|Blinded drug dose conditions|Capsules will contain commonly prescribed or over-the-counter drugs or placebo. Capsules in this study may contain sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, or antihistamines which must remain blinded for the purposes of this study.
45621588|NCT02470559|Biological|Aldesleukin|Given SC
45621589|NCT02470559|Biological|HER2Bi-Armed Activated T Cells|Given IV and IP
45621590|NCT02470559|Other|Laboratory Biomarker Analysis|Correlative studies
45621591|NCT02470559|Biological|Sargramostim|Given SC
45621592|NCT05081531|Radiation|Adaptive Radiotherapy|All the patients will be treated with VMAT technique in its RapidArc form. A simultaneous integrated boost (SIB) technique will be used. The GTV will encompass the tumor delineated on CT scan, adjusted for MRI and PET scans. Patients will be treated with a total dose of 66 Gy, 60 Gy and 54 Gy on PTV1, PTV2 and PTV3, respectively, delivered in 30 fractions, 5 fractions per week.
45621593|NCT02473211|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered once daily
45621594|NCT02473211|Drug|Daclatasvir|Daclatasvir 60mg tablet administered once daily
45621595|NCT02473055|Other|Kangaroo Care|skin-to-skin, chest-to-chest placement of diaper clad preterm infant up against his mother's chest and covered by a receiving blanket folded into fourths for 2-3 hours from one feeding to the next.
45621596|NCT02470637|Drug|SAR439065|"Pharmaceutical form:dry powder insulin~Route of administration: inhalation"
45621597|NCT02470637|Drug|Insulin lispro|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
45621598|NCT02473133|Radiation|Personalized dose redistribution|Patients will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy. An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week.
45764075|NCT03407885|Other|Bundled payments for knee and hip replacement|"The bundled payment model holds acute care hospitals (ACHs) financially responsible for the spending and quality of an entire episode of care for two types of hospital admissions: MS-DRG 469 and 470. An episode begins with an ACH stay that results in a discharge in one of the two DRGs, and ends 90 days after discharge. Before each performance year begins, hospitals receive target prices from CMS, determined by historical hospital and regional episode expenditures. Hospitals are eligible for reconciliation payment from CMS if they spend less than the target prices for an episode, provided that they met an acceptable quality standard. Conversely, they are responsible for paying the difference if they spend more than the target prices."
45912143|NCT03621774|Behavioral|Supportive Contact|The SC intervention will provide the same amount of group and mobile device contact as the mCBTn condition. Participants will be carrying a phone but will not have access to the CBT-informed app. Group contact sessions will be semi-structured and consist of trouble-shooting device use and check-in about symptoms and potential crisis management, followed by a flexible discussion involving psychoeducation, instructions for accessing community crisis lines and related community resources, empathy, and non-directive reinforcement of health, coping, and symptom management behaviors that grow out of group discussions, with only minimal group leader guidance.
45912144|NCT03617458|Drug|Metformin|Metformin is a drug has been on the market for several decades and is considered first line therapy for diabetes mellitus type 2.
45621599|NCT02473133|Radiation|No personalized dose redistribution|Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET2 result).
45621600|NCT05065541|Drug|CC-97489|Specified dose on specified days
45621601|NCT05065541|Drug|[18F]T-401|Specified dose on specified days
45621602|NCT05065541|Drug|[11C]MK-3168|Specified dose on specified days
45621603|NCT04177121|Other|qualitative analysis|Qualitative analysis of physiotherapy prescriptions
45621604|NCT01375673|Other|Exercise|Walking Strength Training Bicycling
45621605|NCT05064761|Device|Sculptra new dilution|Treatment to improve appearance of cellulite.
45621606|NCT02470715|Genetic|Molecular profile|Patients and their treating physician will obtain the patient's genetic risk assessment
45621607|NCT03108599|Other|Enhanced Cab|The cab engineering intervention includes the introduction of an active suspension seat and a therapeutic mattress system. After a baseline phase, the intervention arm will receive the enhanced cab intervention alone, and then the enhanced cab plus a behavioral sleep intervention.
45764076|NCT00929071|Device|Evolence|Injectable collagen
45621608|NCT03108599|Behavioral|Fit4Sleep|The behavioral sleep intervention includes a friendly dyad-based physical activity competition; self-monitoring and logging of physical activity, sleep hygiene behaviors, and sleep; and individual coaching. The intervention arm will receive the behavioral sleep intervention in combination with the enhanced cab intervention.
45621609|NCT02470481|Other|No Intervention|This is an obervational study
45764077|NCT00929071|Device|Lidocaine|admix anesthetic
45764078|NCT00929071|Drug|topical anesthetic|
45764079|NCT04378205|Procedure|0.014-inch NiTi on one side /0.018-inch NiTi on the other side|Where each patient received 2 archwire sizes (0.014-inch and 0.018-inch) at one time joined in the midline by crimpable hook and applied in the lower arch.
45764080|NCT04378205|Procedure|0.016-inch NiTi on one side /0.018-inch NiTi on the other side|Where each patient received 2 archwire sizes (0.016-inch and 0.018-inch) at one time joined in the midline by crimpable hook and applied in the lower arch.
45764081|NCT00929305|Device|Erchonia PL2000|The Erchonia PL2000 Laser emits 1 mW of red (635nm wavelength) light via an electric diode energy source. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
45764082|NCT00929305|Device|Placebo laser|Inactive laser light
45764083|NCT01727687|Behavioral|behavioral training for crossing road|behavioral training programs for crossing road, such as verbal oral cues and simulated traffic scenes
45764084|NCT04347265|Other|NMP|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
45764085|NCT01721525|Drug|Afatinib, Ribavirin, and weekly carboplatin/paclitaxel|Patients will receive oral daily afatinib (days 1 - 21, per dose escalation scheme) plus daily oral ribavirin (days 1- 21) and paclitaxel (80 mg/m2 intravenously, days 1 and 8) + carboplatin (AUC 1.5 intravenously, days 1 and 8) of a 21-day cycle. Ribavirin will be administered according to standard weight-based dosing for this drug (1). Subjects ≤75 kg receive Ribavirin 400 mg PO qAM and 600 mg PO qPM (= 1000 mg/day). Subjects > 75 kg receive Ribavirin 600 mg PO BID (=1200 mg/day). During the Dose Escalation portion of the study (Part 1), research bloodwork for pharmacokinetics is performed on days 1 and 8 of Cycle 1 only.
45764086|NCT04366063|Biological|Cell therapy protocol 1|Cell therapy protocol 1(n=20). Patients will receive two doses of MSCs 100×10e6 (±10%) at Day 0 and Day 2 plus Conventional treatment.
45764087|NCT04366063|Biological|Cell therapy protocol 2|Patients will receive two doses of MSCs 100×10e6 (±10%)at Day 0 and Day 2, intravenously plus two doses of EVs at Day 4 and Day 6 plus conventional treatment.
45764088|NCT01727843|Drug|Tranexamic Acid|drug and placebo applied topically at end of surgery at hip site.
45764089|NCT01727843|Other|placebo|applied topically to surgical site in OR.
45764090|NCT04365751|Procedure|Percutaneous microwave ablation, Laparoscopic hepatectomy|For patients with hepatocellular carcinoma who meet the enrollment requirements, under the guidance of ultrasound, microwave ablation electrodes were implanted into the tumor tissues by percutaneous puncture, and the high-temperature heat energy was generated to cause coagulation necrosis of the tumor, so as to achieve the goal of local tumor treatment with minimally invasive technology.
45764091|NCT01727921|Device|22 gauge ProCore needle biopsy|22 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
45764092|NCT01727921|Device|25 gauge ProCore needle biopsy|25 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
45764093|NCT04365907|Drug|Zafatek tablets|Once weekly new anti-diabetic drug approved only in Japan
45764094|NCT01728155|Drug|chemotherapy|
45764095|NCT04357639|Other|No intervention|No intervention: Usual care for nasopharyngeal sampling and blood sampling for COVID-19 detection
45764096|NCT00937105|Device|lotrafilcon A contact lenses|FDA approved soft contact lenses
45764097|NCT00937105|Device|Renu Multiplus|
45764098|NCT00937105|Device|Clear Care|
45764099|NCT04367077|Biological|MultiStem|intravenous infusion
45764100|NCT04367077|Biological|Placebo|intravenous infusion
45764101|NCT01721915|Drug|Vitamin D supplementation|The treatment group will receive an oral dose of 20,000 IU vitD weekly (equivalent to 2857 IU/day) as oily drops (Oleovit D3-drops; producer: Fresenius Kabi Austria GmbH, Linz)
45764102|NCT01721915|Drug|Placebo|
45764103|NCT04357483|Drug|flowable thrombin containing collagen hemostat matrix|A 5 ml flowable hemostat matrix (CollaStat®) was applied to the stump or anastomosis site after pancreatectomy.
45764104|NCT04357483|Drug|thrombin coated L-dopa contained collagen patch|A 5x2.5cm sized thrombin coated L-dopa contained collagen patch (CollaSeal®) was applied to the stump or anastomosis site after pancreatectomy.
45446320|NCT03751293|Biological|C-CAR088|Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10^6 anti-BCMA CAR+ T cells/kg
45764105|NCT01721993|Drug|T121|
45764106|NCT01721993|Drug|Zoledronic acid|
45764107|NCT04366609|Drug|Methylphenidate|Treatment with methylphenidate through dose escalation
45764108|NCT03407339|Other|Shared Oral Care intervention|"One hour of teaching in oral hygiene and oral diseases to health care professionals at the intervention nursing homes.~The dentists will make an assessment of the elderly's oral hygiene at baseline, after three and six months using a mucosal and plaque score. During the six months, a dentist will be doing ward rounds at each nursing home in a specific time interval. In dialog with the resident and the healthcare professional, the dentist will present individual advice on how to perform oral care based on the resident's oral care routines, oral hygiene status, and the resident's physical and cognitive function level."
45912145|NCT03617458|Drug|Placebo|A treatment with no active ingredients or therapeutic effect.
45621610|NCT02472821|Behavioral|Interactive youth educational program|Participation in a community-based face-to-face interactive youth educational program focusing on hearing health (i.e., noise hazards, risk of noise-induced hearing loss, mechanism of injury to the internal ear, and preventive measures)
45764109|NCT04366843|Other|chair massage|Chair massage was performed useing only traditional methods of Swedish massage were used, consisting of stroking (smooth, continuous movements to relax and calm the sympathetic nervous system), kneading (consisting of wringing, squeezing muscles, compressing pressure points for the relaxation of soft tissues, i.e. muscles, tendons, fascia), stretching combined with swaying and passive movements of the upper limbs (to mobilize the joints of the upper limbs) and final stroking combined with slapping and shaking percussion, vibration.
45764110|NCT04366843|Other|the exercise program|The original set of exercises was developed based on the knowledge and clinical experience of the authors of the study and based on EBP (Evidence Based Practice). The program consisted of 14 strengthening and stretching exercises involving the muscles of the trunk and limbs whose main goal was to mobilize the joints and strengthen the weakened muscles and relax overloaded muscle groups.
45764111|NCT03407261|Procedure|micro-osteoperforations|Three vertical micro-osteoperforations, using Excellerator, in the buccal extracted site were executed following the aseptic procedure and local anesthesia
45764112|NCT04366687|Behavioral|Smart Parents - Safe and Healthy Kids|Smart Parents - Safe and Healthy Kids (SPHSK) is a module designed to be added to existing evidence-based parent education programs. Because the module builds off of the core parenting skills developed in existing parent education programs, the module can be delivered in one session. SPSHK is comprised of three key CSA-prevention components: healthy child sexual development, parent-child communication about sex and sexual behaviors, and CSA-specific safety strategies such as vetting a babysitter and monitoring one-on-one time with adults. Behaviorally based, the module presents developmentally comprehensive information to parents of children 0-13 and utilizes role-playing scenarios and activities to maximize parents' use of learned skills.
45764113|NCT04366687|Behavioral|Parents as Teachers|Parents as Teachers (PAT) is a parent-support program delivered to parents of children under five and focuses on improving parenting skills through parent-child interactions, development centered parenting, and general well-being. PAT has demonstrated positive effects on child and parent outcomes related to school readiness.
45764114|NCT03407183|Procedure|intradetrusor injection of botulinumtoxinA (Botox)|intradetrusor injection of botulinumtoxinA (Botox®, Allergan, Irvine, USA) to assess the efficacy of Botox in treatment of neurogenic bladder.
45764115|NCT03407105|Biological|MDX-010|Specified dose on specified days
45764116|NCT01728233|Drug|Dacomitinib|PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
45764117|NCT01722149|Genetic|Adoptive Transfer of re-directed T cells|Adoptive Transfer of 10e6 re-directed T cells in the pleural effusion
45764118|NCT01722227|Drug|Liraglutide|
45764119|NCT01722227|Drug|Placebo|
45764120|NCT01722305|Drug|Dexamethasone|Given PO
45764121|NCT01722305|Other|Laboratory Biomarker Analysis|Optional correlative studies
45764122|NCT01722305|Other|Pharmacological Study|Optional correlative studies
45764123|NCT01722305|Drug|Pomalidomide|Given PO
45764124|NCT04365595|Other|Questionnaires, spirometry|Questionnaires targeting health-related quality-of-life, symptoms, anxiety and depression
45764125|NCT04365517|Drug|Sitagliptin|We propose a randomized controlled open label intervention study. Patients with type 2 diabetes admitted to COVID-19 and randomized to the study group will be treated with sitagliptin at an adjusted dosage for estimated glomerular filtrate: 100 mg once daily (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2 ) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2) in combination or not with insulin. Patients with stage IV and V renal failure (estimated glomerular filtration rate less than or equal to 30 mL / min / 1.73 m2) will be excluded
45764126|NCT03406871|Drug|Regorafenib|One course will last 28 days. Oral administration at a dose of 80 mg/day, 120mg/day or 160 mg/day for 21 consecutive days, with a 1-week washout period.
45764127|NCT03406871|Drug|Nivolumab|One course will last 28 days. Given once every 2 weeks at a dose of 3.0 mg/kg.
45446321|NCT03700671|Other|High intensity interval training|Participants performed HIIT twice a week for eight weeks. Findings were compared to moderate intensity continuous training which followed the same exercise frequency and duration
45446322|NCT03700671|Other|Circuit training|The CT group completed a practical seven-station mixed modality exercise circuit (cycle ergometer, rower, treadmill, sit to stand, knee to elbow and leg kickback with bicep curl) at an intensity of 60-80% HRmax twice per week for eight weeks. Participants initially performed 20 minutes of CT with duration gradually increased to the desired 40 minutes as tolerated
45621611|NCT02472821|Behavioral|Internet-based educational booster|Visit to an educational Web site focused on hearing health
45621612|NCT02472743|Device|Custom-built phototherapy lamp|Described in the arm description
45621613|NCT02472899|Other|Blood sample|Non-interventional study based on blood samples taken at a single study visit
45621614|NCT02470325|Drug|Avidekel oil|Avidekel cannabis oil 6:1 CBD:THC
45446323|NCT05377125|Behavioral|Computerized cognitive training|This intervention offers 45-minute computerized training sessions to each participant. This intervention aims to improve the individual's RI capabilities. All participants will receive 8 to 16 sessions after being randomized to this condition.
45764128|NCT04365439|Biological|Blood plasma|Convalescent plasma after COVID-19
45764129|NCT04365283|Procedure|New Bioactive Restorative Material (ACTIVA Presto)|New Bioactive Restorative Material
45764130|NCT04365283|Other|High Viscosity Glass Hybrid Reinforced Glass Ionomer (EQUIA Forte)|High Viscosity Glass Hybrid Reinforced Glass Ionomer
45764131|NCT01728311|Drug|BAY1082439|BAY1082439 will be given orally once daily with a 21 days cycle. Dose will be started from 15mg.
45764132|NCT04357093|Other|Grape seed extract mouthwash|Mouthwash 15% grape seed extract
45764133|NCT04357093|Other|Sodium fluoride mouthwash|Sodium fluoride mouthwash
45764134|NCT03406793|Dietary Supplement|Standard MNP|Standard MNP, 15 micronutrients (Vitamin A 400 µg, vitamin D 5 µg, vitamin E 5 mg, vitamin C 30 mg, thiamine 0.5 mg, riboflavin 0.5 mg, niacin 6 mg, pyridoxine 0.5 mg, vitamin B12 0.9 mg, folate 150 µg, iron 10 mg, zinc 4.1 mg, copper 0.56 mg, selenium 17.0 µg and iodine 90 µg). Daily supplementation for 24 weeks.
45764135|NCT03406793|Dietary Supplement|High zinc, low iron MNP|Same as group 1, except with 10 mg zinc instead of 4.1 mg and 6 mg iron instead of 10 mg. Daily supplementation for 24 weeks.
45764136|NCT03406793|Dietary Supplement|High zinc, low/no iron on alternating days|Same as study group 1, except with 10 mg zinc instead of 4.1 mg, and 6 mg iron and no iron on alternating days instead of 10 mg. Daily supplementation for 24 weeks.
45764137|NCT03406793|Dietary Supplement|Dispersible zinc supplement|10 mg zinc in a dispersible tablet. Daily supplementation for 24 weeks.
45764138|NCT03406793|Dietary Supplement|Intermittent zinc supplement|10 mg zinc in a dispersible tablet. Daily supplementation for 14 days at baseline and 3 months, placebo tablet on all other days.
45764139|NCT03406793|Dietary Supplement|Placebo powder|Daily provision of a placebo powder for 24 weeks.
45764140|NCT04365127|Drug|Progesterone 100 MG|Subcutaneous administration twice daily
45764141|NCT01728467|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
45446324|NCT05377125|Behavioral|Computerized placebo training|This intervention offers 45-minute computerized placebo cognitive training sessions to each participant. This intervention aims to exert no focused training on RI capabilities. All participants will receive 8 to 16 sessions after being randomized to this condition.
45446325|NCT04764669|Drug|E2027|Oral hypromellose capsules.
45621615|NCT02470325|Drug|Enriched Avidekel oil|Enriched Avidekel cannabis oil 20:1 CBD:THC
45621616|NCT03652961|Drug|Abatacept|Abatacept for reconstitution and dilution prior to intravenous (IV) administration. Each single-use vial of Abatacept for injection provides 250-mg Abatacept, maltose (500 mg), monobasic sodium phosphate (17.2 mg), and sodium chloride (14.6 mg) for administration.
45621617|NCT03652961|Drug|DMARDs|Patients will receive methotrexate or remain on pre-existing conventional synthetic disease-modifying anti-rheumatic drug (DMARD) if already prescribed.
45621618|NCT03581981|Behavioral|Prolonged Exposure for Primary Care (PE-PC)|Brief version of PE provided in 30 minute sessions in PC
45621619|NCT03581981|Behavioral|Treatment as Usual|Veterans assigned to PCMHI-TAU will receive standard PCMHI care for PTSD in PC that does not include any PTSD-specific therapy in PCMHI but may include referral for specialty care (including specialty MH), medication management or general supportive contact while awaiting referral. All PTSD care received during the study will be collected and monitored as TAU.
45621620|NCT03948347|Drug|Liraglutide|The treatment arm will receive the starting dose of liraglutide of 0.6 mg/d subcutaneously once daily, and the dose will be increased to 1.8 mg/d in two weeks, and then continue to administrate this dose for 90 days.
45621621|NCT03512249|Biological|H56:IC31|5ug H56/500 nmol IC31
45621622|NCT03512249|Biological|Placebo|Sterile saline for injection
45764142|NCT01728467|Drug|Placebo, RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
45764143|NCT03406637|Device|BPK-S Integration|primary total knee endoprosthesis
45764144|NCT00929383|Device|Wingspan Stent System with Gateway PTA Balloon Catheter|"The Wingspan Stent System is used in conjunction with Gateway PTA Balloon Catheter to improve cerebral artery lumen diameter in patients with intracranial atherosclerotic disease.~The Gateway Balloon Catheter is indicated for balloon dilation of the stenotic portion of intracranial arteries prior to stenting the artery for the purpose of improving intracranial perfusion."
45764145|NCT03406559|Other|orthodontic treatment|fixed orthodontic treatment in adolescent males initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion,
45764146|NCT01722461|Device|Ulthera System|Focused ultrasound energy delivered below the surface of the skin
45764147|NCT01722461|Device|Sham treatment|Ulthera System delivering no ultrasound energy
45764148|NCT00929773|Device|Erchonia PL2000 Laser|Low level laser light therapy device that emits 1 mW of red (635 nm wavelength) light. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
45764149|NCT00929773|Device|Placebo laser|Inactive laser light.
45764150|NCT01722539|Drug|Sulfadoxine-pyrimethamine|Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more
45764151|NCT01722539|Drug|Piperaquine|Piperaquine tablet 320 mg manufactured by Sigma Tau will be used at two treatment doses of 16-24 mg/kg at 24 hours intervals as follows: 1 tablets for weigh 15-19 kg, 1.5 tablets for 20-29 kg, and 2 tablets for 30-39 kg, and 2.5 tablets for 40 kg or more.
45446326|NCT05007717|Behavioral|Data-informed Stepped Care (DiSC)|"The DiSC intervention is comprised of a data-driven system to assign adolescents to care based on their health needs and the different levels of care for each assignment group.~The trajectory of services moves from a relative position of ALHIV autonomy to more intensive service provision. Intervention steps start with 1) multi-month refills or community treatment delivery (differentiated care); 2) a standard of care level for those with medical needs such as pregnancy or opportunistic infections or patient choice; 3) patient reminders/tracking and counseling and referral services for mental health needs; 4) case management of unsuppressed individuals, including enhanced counseling and case conference problem-solving"
45446327|NCT03753867|Drug|Acitretin|Acitretin will be provided to participants in the formulation Soriatane. Soriatane doses are oral tablets taken daily by the participant. Participants will then receive 35mg of oral acitretin (Soriatane) daily for 8 weeks during the intervention phase. Participants will be asked to return two months after completion of the acitretin course for clinical follow-up and additional phlebotomy for laboratory testing.
45764152|NCT01722539|Drug|Albendazole|One oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.
45764153|NCT01722539|Drug|Praziquantel|Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up.
45621623|NCT02723591|Drug|Tacrolimus|Oral Capsule
45764154|NCT01722617|Other|Questionnaire|Patients in groups 2 and 3 will be asked to fill in questionnaires FLARE.
45764155|NCT03406403|Device|Laryngeal mask airway|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
45764156|NCT03406403|Drug|Magensium sulphate|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
45764157|NCT03406403|Other|Control group (closure of anesthetics)|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
45764158|NCT04378517|Other|psychosocial education in parents groups|psychosocial education
45764159|NCT04378517|Other|psychosocial parents support, interviews with APN|Family strength-oriented therapy conversation
45764160|NCT04357171|Procedure|Low anterior resection with protective loop ileostomy|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta or right below left colic artery. Nerve-sparing total mesorectal excision is performed. Side-to-end sigmoido-rectal anastomosis is created. A loop defunctioning ileostomy is performed.
45764161|NCT04357171|Procedure|Low anterior resection with protective loop transverse colostomy|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta or right below left colic artery. Nerve-sparing total mesorectal excision is performed. Side-to-end sigmoido-rectal anastomosis is created. A loop defunctioning transverse colostomy is performed.
45912146|NCT03617458|Device|mHealth Intervention|Our Health Insurance Portability and Accountability Act (HIPPA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.Subjects assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
45912147|NCT03617458|Device|Usual Care|Our HIPPA compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.
45912148|NCT03615053|Other|Implementation of WAPPS-Hemo personalized dosing regimen|Twelve months after enrollment in the study, WAPPS-Hemo will be used to calculate each patients individual pharmacokinetic estimate. Once completed, the WAPPS-Hemo clinical calculator will be used to calculate the optimal regimen based on individual needs.
45446328|NCT05459415|Procedure|Reducing Excision Margins|Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy
45446329|NCT03751215|Procedure|Cataract surgery|During cataract surgery the patient is implanted with the monofocal IOL Clareon in one eye and the monofocal IOL AcrySof in the contralateral eye
45452330|NCT02262442|Device|Enk Fiberoptic Atomizer|Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the flexible bronchoscopy
45621624|NCT02723591|Drug|Tacrolimus immediate release|Oral Capsule
45621625|NCT00705341|Drug|fluticasone|Inhaled corticosteroid approved for treatment of asthma
45621626|NCT02470013|Dietary Supplement|Balanced, energy dense, moderate protein sip feed|2x 125 ml bottles (equiv. 600 kcal) of Fortimel Compact daily for 3 months in addition to normal eating habits
45621627|NCT02723201|Drug|TAK-020 Captisol Oral Solution|TAK-020 solution.
45621628|NCT02723201|Drug|TAK-020 CCT|TAK-020 co-crystal tablet
45621629|NCT02723201|Drug|TAK-020 SDT|TAK-020 Solid dispersion tablet.
45764162|NCT03406169|Drug|Sildenafil 25 MG Oral Tablet|twice a day dosing
45764163|NCT03406169|Drug|Pentoxifylline|400mg twice a day
45764164|NCT03406169|Other|Placebo|placebo twice a day
45764165|NCT04346875|Procedure|Regularly changing of dressing|Conventional dressing
45764166|NCT04346875|Procedure|No application|No dressing change
45764167|NCT01722695|Other|Dialyzer comparison|"Each patient is treated by hemodialysis for one week (3 sessions) with each dialyzer type (Revaclear or FX).~The order of dialyzers used will be randomly assigned to the patient at randomization."
45764168|NCT04357327|Diagnostic Test|rapid salivary test|a rapid salivary test to detect SARS-CoV-2 spike protein in saliva with a lateral flow immunoassay
45764169|NCT03835793|Diagnostic Test|CAC-score|Testing for possible unfavourable health effects of early surgical menopause
45764170|NCT04357015|Drug|intravenous tranexamic acid|The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision
45764171|NCT04357015|Drug|intravenous carbetocin|The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision
45621630|NCT02723201|Drug|TAK-020 IRT|TAK-020 immediate release tablet.
45621631|NCT02723201|Drug|TAK-020 CCT|TAK-020 co-crystal tablet.
45764172|NCT04357015|Drug|placebo|the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
45764173|NCT03835637|Drug|ORIC-101|Capsule or oral suspension
45764174|NCT04364893|Other|Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors|Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
45764175|NCT01722773|Device|Bipap (Respironics, Inc)|Bipap every night pressure at 15/5 with heated humidifier
45764176|NCT04356703|Other|Neuropsicomotor developmental test|Children will be evaluated trough Bayley III and PEDI scale. They also will be examined by pediatrician, neurosurgeon, orthopedics and phisiatry
45764177|NCT03406091|Drug|Plerixafor|Plerixafor (AMD3100) is a selective, reversible inhibitor of the receptor chemokine (C-X-C motif) receptor 4 (CXCR4) and prevents binding of its cognate ligand stromal cell derived factor-1α (SDF-1α), also known as chemokine (C-X-C motif) ligand 12 (CXCL12) [3]. CXCR4 is a co-receptor, along with CD4, for the binding of human immunodeficiency virus, type 1 (HIV-1) to its receptor cells.
45764178|NCT04364815|Drug|Hydroxychloroquine plus standard preventive measures|Hydroxychloroquine and standard preventive measures
45912149|NCT03607942|Dietary Supplement|HMO supplement|HMO supplement will be given three times a day, not mixed with any feeding.
45621632|NCT02723201|Drug|TAK-020 Solid Formulation|TAK-020 solid formulation
45912150|NCT03607942|Dietary Supplement|Placebo comparator|Control product without any HMOs. The Placebo Comparator will be matched to the experimental product in energy content.
45912151|NCT03581877|Drug|Alteplase|As stated before, low dose r-tpa will be administered through a peripheral vein for PLST.
45912152|NCT03581877|Device|EKOS|As stated before, the EKos device will be used for ultrasound assisted catheter directed thrombolysis or ACDT, same dose t-tpa will administered through the pulmonary catheter. It will be given at a fixed dose over 24 hours.
45764179|NCT04364815|Drug|Placebo plus standard preventive measures|Placebo tablet plus standard preventive measures as defined by PGH-HICU
45446330|NCT05412381|Procedure|platelet rich plasma (PRP) injection|We aim to evaluate early catabolic and inflammatory changes in knee joints in patients receiving PRP injections following ACL injury, as these patients are at higher risk of developing PTOA. We also aim to establish correlations between markers of biologic activity of PRP and clinical outcomes (including both patient-reported outcomes and clinical functional outcomes), with emphasis on cellular and molecular inflammatory parameters modulated by PRP.
45764180|NCT03406013|Behavioral|Written Information|Receive written information on diet and exercise relevant to older men with prostate cancer
45764181|NCT03406013|Behavioral|Prescription|Participants receive tailored exercise prescription and tailored diet recommendations
45446331|NCT05412381|Procedure|placebo saline injection|Patients randomized into the control arm will receive the placebo or saline injection
45446332|NCT04439253|Drug|Crizotinib|Given PO
45621633|NCT03193931|Drug|Pembrolizumab Injection|Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
45621634|NCT03193931|Drug|Methotrexate Injectable Solution|Methotrexate 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
45764182|NCT03406013|Behavioral|Technology|Participants receive motivational text messages and can electronically log and track their exercise and diet habits
45764183|NCT03406013|Behavioral|Coaching|Participants receive access to an exercise and diet coach to provide advice by phone and/or email
45621635|NCT03846479|Drug|Itacitinib|for up to 56 days
45621636|NCT03067259|Other|Exposure Group|Surgeries of high or low impact. They could be local , regional o general anesthesia; sedation or a combination of both.
45621637|NCT03750227|Procedure|Conventional Surgery|Undergo surgery
45621638|NCT03750227|Other|Quality-of-Life Assessment|Ancillary studies
45621639|NCT03750227|Other|Questionnaire Administration|Ancillary studies
45621640|NCT03750227|Radiation|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
45621641|NCT00705263|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
45621642|NCT00705263|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
45764184|NCT04673383|Drug|SPL026|Intravenous solution
45764185|NCT04673383|Drug|Placebo|SPL026-matched placebo
45764186|NCT01728701|Biological|PfSPZ Challenge|PfSPZ Challenge is a suspension of aseptic, purified, cryopreserved PfSPZ that are thawed and formulated in diluent on the day of administration.
45764187|NCT01728701|Biological|Normal Saline (NS)|Normal saline
45764188|NCT03405857|Other|Cognitive rehabilitation program|Cognitive rehabilitation programs have been developed to improve the cognitive functions of the elderly or patients with cognitive impairments. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
45912153|NCT03581305|Drug|18F-FDOPA|High resolution positron emission tomography (PET) of the brain and radioligands targeted against the dopaminergic (18F-FDOPA) system.
45912154|NCT03581305|Drug|11C-DASB|High resolution positron emission tomography (PET) of the brain and radioligands targeted against the serotonergic (11C-DASB) system.
45912155|NCT03575364|Device|ClotTriever|Thrombectomy
45912156|NCT03556202|Drug|Mirikizumab|Administered SC
45621643|NCT02470169|Drug|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
45764189|NCT04356625|Diagnostic Test|MEPic|"patient in the supine position sitting 45° to 60°,~closed suction catheter was removed~a 90° elbow was placed and a bacterial filter in series with endotracheal tube~adapter was also coupled to the aneroid pressure gauge~in series an inspiratory unidirectional valve was placed that did not allow expiration~2 ml of physiological solution was slowly instilled through the port in the 90º elbow to cause induced cough"
45764190|NCT04377269|Other|Taping and Bandaging|Ankle taping: a hard preventive Zinc oxide tape was used. The taping procedures consisted of three separate steps. 1) included the application of the anchor tape. 2) application of the stirrup tape. The stirrup tape was performed two times by holding the foot in a neutral position and the tape is placed as it passed through the medial side of the ankle (under the foot), just over the heel area (posterior one-third of the foot) and up along the lateral side of the ankle. Bandaging: standard 10cm width elastic bandage used. The bandage wrapped around the ankle joint in the form of an 8-figure. Bandage started from the forefoot, moving diagonally upwards and steeply enough to go well above the heel to end around the lower calf area to form an anchor. Then, it moved diagonally down across the mid-foot. Placebo: 10cm long tape was applied on the lateral side of the leg, just above the lateral malleolus and aligned with peroneus longus tendon
45446333|NCT04438785|Device|The intervention consists of myofunctional therapy (MT) using the AirwayGym app.|Intervention. Patient newly diagnosed with severe OSAHS should perform muscle upper airway exercises using the App AirwayGym 20 minutes a day during 90 days.
45446334|NCT05280951|Other|Focused-PPC Care|Individual clinical assessments and counseling for each group member will last about 15 minutes. Then, there will be 1 hour of group time dedicated to education and support. Each group session will be led by two trained and registered midwives who will provide both clinical care, education, and support as needed. In addition, each group session will be supported by a project assistant. Focused-PPC will be implemented in addition to newborn care.
45764191|NCT04652713|Other|Protein-rich breakfast|"High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) yoghurt with 40 g oats for breakfast.~1 glas of water (150 ml)"
45764192|NCT04652713|Other|Carbohydrate-rich breakfast|"Low protein breakfast containing approx. 2 g protein per 100 g. Participants will be asked to consume ~60 g bread, 20 g jam and 250 ml juice for breakfast.~1 glas of water (150 ml)"
45446335|NCT05280951|Other|Usual Care|Women in the control group will receive standard postnatal care (PNC) currently practiced in the health centers. This involves attending PNC visits at the health center within 14 days after birth, at 6 weeks, and monthly thereafter up to one year.
45621644|NCT02470169|Procedure|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
45764193|NCT04652713|Other|No breakfast|1 glas of water (150 ml)
45764194|NCT04377191|Other|exergame|Microsoft Xbox 360 Kinect The exercises were advanced from simple to complex. The program started with exercises in a sitting position. In the next stage, the games requiring weight transfer and use of upper limbs in standing position were continued. The program ended with games that require more complex movements such as lunge and mini squats.
45764195|NCT04377191|Other|exergame|ALDA In the training, games that could be controlled by balance swing, trunk movements and weight transfer in sitting or standing position were used.
45764196|NCT04377191|Other|exercise|Standard Exercise Program The program included warm-up, main exercise and cooling. Warm-up and cooling included neck, trunk, upper-lower extremity range of movement (ROM) exercises and stretching exercises. Main exercise included postural alignment, strengthening for trunk and lower extremity, balance and walking exercises.
45764197|NCT01728857|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
45446336|NCT04741503|Other|Breast Cancer Screening Decision Support Tool|-Provides a description of screening mammography, current screening recommendations, benefits and downsides, narratives, and questions for the participant's physician.
45446337|NCT04741503|Other|National Cancer Institute Breast Cancer Screening PDQ|-Provides current information about breast cancer screening and is meant to inform and help patients
45446338|NCT04734873|Drug|CPI-006 2 mg/kg + SOC|IV CPI-006 2 mg/kg up to a maximum dose of 200 mg plus standard of care
45446339|NCT04734873|Drug|CPI-006 1 mg/kg + SOC|IV CPI-006 1 mg/kg up to a maximum dose of 100 mg plus standard of care
45446340|NCT04734873|Drug|Placebo + SOC|IV placebo plus standard of care
45446341|NCT03750669|Drug|AG regimen|Combination of Nab-paclitaxel 125 mg/m^2 and Gemcitabine 1000 mg/m^2
45621645|NCT02470169|Drug|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
45621646|NCT02470169|Device|shepherd catheter|
45653356|NCT04989699|Drug|OTX-TKI/Sham|OTX-TKI is one dose so subsequent visits will be sham to maintain the mask
45653357|NCT04989699|Drug|Aflibercept/Sham|Aflibercept administered every 8 weeks
45764198|NCT02245243|Drug|Delafloxacin|Plasma pharmacokinetic parameters: AUC0-t, AUC0 inf, Cmax, Tmax, λz, t1/2, MRTinf, CL, CLnr, Vss, Vz
45764199|NCT03405701|Procedure|IVM|Patients in IVM group will receive FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and the ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
45764200|NCT03405701|Procedure|IVF|Patients in IVF arm will undergo controlled ovarian hyperstimulation with recombinant FSH (Menopur, Ferring) in GnRH antagonist protocol, treatment monitoring using ultrasound scans and blood tests. GnRH agonist will be used for final oocytes maturation. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
45764201|NCT04364971|Procedure|singleradius and multiradius total knee arthroplasty|singleradius and multiradius total knee arthroplasty
45764202|NCT01728935|Drug|Tenofovir disoproxil|Tenofovir disoproxil 300mg daily
45764203|NCT03834311|Device|isokinetic strengthening|isokinetic upper extremity (forearm) strengthening for 4 weeks 3d/w
45621647|NCT02470169|Procedure|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
45621648|NCT02469935|Procedure|ultrasound|surgeon-performed ultrasound
45621649|NCT02469779|Behavioral|Surveys|At baseline participants complete survey about their mental and physical health and their opinions concerning health information and the internet. The survey will take about 15-20 minutes to complete.
45621650|NCT02469779|Behavioral|ASPIRE Website|Participants view the ASPIRE website containing videos, activities, and health information facts about the effects of smoking, the benefits of meditation, and healthy living. This viewing will be videotaped
45764204|NCT03834311|Other|exercise band strengthening|upper extremity (forearm) strengthening with exercise band 4 weeks 3d/w
45764205|NCT04356547|Device|Fiberoptic intubation with laryngeal mask AuraGain|Participants should perform an fiberoptic tracheal intubation through the AuraGain laryngeal mask, in a pediatric simulator.
45764206|NCT04356547|Device|Fiberoptic intubation without laryngeal mask|Participants should perform an fiberoptic tracheal intubation without laryngeal mask, in a pediatric simulator.
45764207|NCT02904226|Drug|JTX-2011|Specified dose on specified days
45764208|NCT02904226|Drug|Nivolumab|Specified dose on specified days
45764209|NCT02904226|Drug|Ipilimumab|Specified dose on specified days
45764210|NCT02904226|Drug|Pembrolizumab|Specified dose on specified days
45764211|NCT03833999|Drug|Ondansetron 8mg|ondansetron, a 5HT3 receptor antagonist used clinically in nausea and vomiting
45764212|NCT03833999|Diagnostic Test|abdominal MRI|serial MRIs on day 1 and day 3 of the study, at baseline and 2 hours apart 0-6 hours after meal ingestion on day 1 and 0-4 hours after the meal on day 3
45764213|NCT03833999|Drug|Lactulose|Participants will receive 20mls lactulose twice daily for 48 hours prior to the third study day
45764214|NCT03833999|Drug|Placebo oral capsule|overcoated placebo tablet, identical to the ondansetron
45764215|NCT04356313|Device|GORE® EXCLUDER® Iliac Branch Endoprosthesis|Compare between patients where Gore Excluder Iliac Branch Endoprosthesis and the Hipogastric component can be used with the group where the Hipogastric component can't be used for anatomical issues and a Gore Viabahn VBX is used instead of the Hipogastric component
45764216|NCT04379219|Drug|Methotrexate|giving methotrexate at least 1 w week before surgery
45446342|NCT03750669|Drug|mFolfirinox|Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2
45452331|NCT02262442|Device|bronchoscope|Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the flexible bronchoscopy
45764217|NCT04364659|Behavioral|Food-Specific Inhibitory Control Training (FoodT App)|FoodTrainer (FoodT) is a simple game that aims to train individuals to 'stop' to certain unhealthy foods. Repeatedly playing this game is hypothesised to help build associations between certain foods (such as chocolate) and stopping, putting the brakes on unhelpful eating behaviour.
45452332|NCT02271724|Procedure|Lumbar puncture|Lumbar puncture for spinal fluid
45452333|NCT02271724|Procedure|Blood sample|Blood sample
45621651|NCT02469779|Behavioral|ASPIRE Text-Based Website|Participants view the ASPIRE text-based website containing health information facts about smoking, the benefits of meditation, and healthy living.
45621652|NCT02469779|Behavioral|Follow Up Survey|Participants complete a follow-up survey about their opinions concerning health information and the internet immediately after they have completed their last session on the website.
45621653|NCT02842463|Other|2 times : 6-minute stepper test with a rest of 20min between each test.|
45764218|NCT04356079|Diagnostic Test|International Headache Society Test|Thorough History of Patients and families
45764219|NCT03658096|Device|pressure monitor ultrasound system|Patients and healthy volunteers will be tested sitting with the elbow flexed and the forearm pronated. The forearm of the examinee will be secured to the table. The hand will be positioned on an adjustable block such that the forearm will be in a horizontal position. At the distal radioulnar joint level, the transducer will be maintained perpendicular to the longitudinal axis of the ulna. The dorsal surface of the distal radius and the center of the ulnar head will be displayed on a monitor.To determine the same measurement level in each volunteer, the highest aspect of the ulnar head will be taken. The DRUJ motion during cyclic loading toward the palmar direction at the distal ulna will be recorded. The compression-release cycles will be applied with the pressure-monitor ultrasound system. The cycle will be set to 1.5Hz. The pressure in the palmar direction will be applied with different levels of transducer displacements, i.e. 1 mm, 2 mm, and 3 mm.
45764220|NCT04347031|Drug|Mefloquine|"1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."
45764221|NCT04347031|Drug|Hydroxychloroquine|"st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."
45764222|NCT04347031|Combination Product|Mefloquine + azithromycin + / - tocilizumab|"1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."
45764223|NCT04347031|Combination Product|Hydroxychloroquine + azithromycin + / - tocilizumab|"st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."
45764224|NCT04586569|Other|Pediatric Interactive Relational Agent (PIRA)|The PIRA is an interactive, online tool used to educate children and families about their child's upcoming surgical and anesthesia experience.
45764225|NCT02906566|Drug|Retinol|Retinol in the form of vitamin A lotion
45764226|NCT02906566|Drug|Placebo|Placebo of Retinol
45764227|NCT00913133|Drug|Desirudin|Desirudin SC 15mg q12h
45764228|NCT00373126|Drug|transdermal nicotine patch|
45912157|NCT03554616|Other|Chlorfenapyr LLIN|Dual active ingredient Long Lasting Insecticidal Net
45764229|NCT04356235|Procedure|A: expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction|expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction
45764230|NCT04356235|Procedure|B: expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling|expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling
45621654|NCT02767427|Device|Chlorhexidine Wipes|(Standard of Care) Chlorhexidine wipes are a commonly used pre-operative skin cleansing measure, designed to reduce bacterial load on the skin of the surgical site.
45764231|NCT04356235|Procedure|C: expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation|expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation
45764232|NCT04356235|Procedure|D: expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation|expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation
45764233|NCT04356235|Procedure|E: unilateral simple mastectomy|unilateral simple mastectomy
45764234|NCT04356235|Procedure|F: after bilateral SSM, ASM, NSM, expander-implant exchange|after bilateral SSM, ASM, NSM, expander-implant exchange
45764235|NCT02787694|Other|Factor Targeted Walking Training|Individuals walk on a treadmill for 30 minutes while exposed to either endurance, balance, challenge, strength, or speed focused approaches
45764236|NCT02787694|Device|treadmill|
45764237|NCT04378283|Drug|LET gel (lidocaine 4%, epinephrine 0.1%, and tetracaine 0.5%)|The study is designed to evaluate topical anesthetics
45764238|NCT04378283|Drug|EMLA plus infiltration as anesthetic for wound repair.|EMLA plus infiltration as anesthetic for wound repair.
45764239|NCT03534076|Other|Cohort Observational study|Cohort Observational study - there is no intervention
45764240|NCT04356157|Behavioral|Behavioural change interventions|"The study evaluates three different interventions aimed at improving adherence and retention to Anti Retroviral therapy among HIV positive women through engagement with their life partner. The interventions are 1) opening the facility once a month, only for men, special day; 2) testing peer-to-peer counselling among men, male champions; 3) providing incentive to all women accompanied by their partners at the facility, nudge or incentive."
45764241|NCT04355845|Drug|Sumatriptan|25 milligrams (mg) single dose tablet
45764242|NCT04355845|Drug|PF-06651600|PF-06651600 400 mg single dose
45764243|NCT02789410|Drug|Morphine|Morphine is administered as part of spinal anesthesia for post-operative pain relief.
45764244|NCT02789410|Drug|Hydromorphone|Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.
45621655|NCT02767427|Other|No intervention|Chlorhexidine wipes will not be used though it is a commonly used pre-operative skin cleansing measure.
45764245|NCT01723241|Drug|XAF5, concentration A|
45764246|NCT01723241|Drug|XAF5, concentration B|
45912158|NCT03554616|Other|pyriproxyfen LLIN|Dual active ingredient Long Lasting Insecticidal Net
45912159|NCT03554616|Other|Piperonyl butoxide LLIN|Combination insecticide and synergist Long Lasting Insecticidal Net
45621656|NCT02702687|Behavioral|PEF Feedback|Intervention group will receive PEF feedback and verbal feedback sessions across 3 feedback visits and asthma education.
45764247|NCT01723241|Drug|XAF5, concentration C|
45912160|NCT03554616|Other|Standard LLIN|Standard Long Lasting Insecticidal Net with one insecticide
45912161|NCT03551496|Combination Product|Drug Eluting Stent - Below the Knee|Treatment arm with DES-BTK, starting with one size of the device - 3.5 mm X 80 mm
45452334|NCT01146574|Biological|Sotatercept|Part 1: Sotatercept single dose 0.1mg/kg subcutaneous Part 2: Sotatercept starting dose groups of 0.3mg/kg, 0.5mg/kg or 0.7 mg/kg in a sequential design, dosed subcutaneously every 28 days for up to 8 doses
45452335|NCT01146574|Biological|Placebo|Placebo
45621657|NCT02702687|Behavioral|Control Feedback|Control feedback group will receive feedback consisting of standardized messages and have 3 control feedback visits and asthma education.
45621658|NCT02523443|Other|IV PCA|Patients undergoing IV PCA for pain control will have intravenous (IV) analgesia provided through a demand pump started in the recovery room.
45621659|NCT02523443|Other|PCEA|Patients in this group will have the epidural catheter placed by the anesthesia pain service team in the pre-surgical center (PSC) as performed routinely at MSKCC. The epidural will be used intra-operatively at the end of liver resection phase of the surgical procedure, once the specimen has been extracted, and continued subsequently in the post-operative phase for pain management.
45621660|NCT03311009|Drug|GLPG1972 cohort 1|GLPG1972 dose 1 provided as oral tablets q.d.
45621661|NCT03311009|Drug|GLPG1972 cohort 2|GLPG1972 dose 2 provided as oral tablets q.d.
45764248|NCT01723241|Drug|Placebo|
45764249|NCT04356001|Procedure|Socket preservation|'One-Piece' autologous tuberosity graft combining hard and soft tissue, harvested from the maxillary tuberosity, placed in extraction sockets.
45912162|NCT03551496|Device|Standard PTA Control Arm|The PTA device used must be market-released in the investigational center's geography and the size (ie, diameter, balloon length and catheter length) will be determined by the investigator.
45912163|NCT03541174|Drug|Aprocitentan 12.5 mg|Tablet, oral use
45912164|NCT03541174|Drug|Aprocitentan 25 mg|Tablet, oral use
45912165|NCT03541174|Drug|Placebo|Matching placebo tablet
45621662|NCT03311009|Drug|GLPG1972 cohort 3|GLPG1972 dose 3 provided as oral tablets q.d.
45621663|NCT03311009|Drug|Placebo|Matching placebo provided as oral tablets q.d.
45621664|NCT03310463|Drug|ETX2514SUL|Single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hr IV infusion
45621665|NCT05333315|Dietary Supplement|IP1|"IP1: 2 softchews 3 times a day before meals with 1-2 glasses of water for eight weeks.~OTHER: Placebo"
45621666|NCT05333315|Dietary Supplement|IP2|"IP2: One bag per day mixed in 200 mL of cold water or tea and consumed immediately, on an empty stomach, half an hour before breakfast for eight weeks.~OTHER: Placebo"
46069293|NCT03013998|Biological|BI 836858 (BAML-16-001-S2)|20 mg/m2, IV, on days 9, 16, and 23 of a 28-day cycle; followed 20 by mg/m2, IV, on days 1, 8, 15 and 22 of each 28-day cycle for 2 years in the absence of toxicity or disease progression (reduced to monthly administration in event of complete response or complete response with incomplete blood count recovery). Dose may be escalated to a maximum dose of 320 mg/m2 or de-escalated to 10 mg/m2 based on occurrence of dose-limiting toxicity.
45446343|NCT03757221|Combination Product|Ixazomib and Daratumumab|"Daratumumab will be administrated every week for the first 2 cycles. For cycle 3 to 6, it will be administrated every two weeks at day 1 and day 15. From cycle 7 until progression Daratumumab will be administrated every 4 weeks.~Ixazomib will be administrated every week three weeks on one week off at D1, D8 and D15 on a 28-d cycle basis.~Dexamethasone will not be given except one series of 4 days of dexamethasone, 20 mg/day or a maximum of 80 mg, for emergencies and complications at initiation of treatment."
45621667|NCT05333315|Dietary Supplement|IP3|"IP3: One bag per day in the morning, dissolved in a glass of warm water and three capsules per day with a glass of water or tea (one capsule at breakfast, one at lunch and one at dinner) for eight weeks.~OTHER:Placebo"
45621668|NCT05333315|Dietary Supplement|IP4|"IP4: Twice a day 20 mL half an hour before breakfast and half an hour before dinner for eight weeks.~OTHER:Placebo"
45621669|NCT05333315|Dietary Supplement|IP5|"IP5: Formula 1: One capsule per day at breakfast with a glass of water for eight weeks and Formula 2: Two capsules a day at breakfast and at dinner with a glass of water for eight weeks.~OTHER:Placebo"
45621670|NCT05309993|Device|PTNS|See arm description
45621671|NCT05309993|Device|TENS|See arm description
45621672|NCT02215265|Drug|Cisplatin|Chemotherapy
45621673|NCT02215265|Radiation|Postoperative radiotherapy|Postoperative radiotherapy (PORT)
45621674|NCT03310385|Drug|GHX02|Herbal medicine originating from gualouhengryunhwan
45621675|NCT03310385|Drug|Placebo|Placebo tablets
45621676|NCT03310307|Drug|Vit D|50,000 IU
45621677|NCT03310307|Other|Placebo|
45621678|NCT03310229|Radiation|plain chest x-ray|the participants will be subjected to plain chest x-ray with other tools to help diagnose pulmonary hypertension in haemodialysis patients
45621679|NCT00704405|Drug|Vaniprevir|Participants took capsules containing 100 mg Vaniprevir twice daily (b.i.d.), three in the morning (300 mg and 600 mg regimens) and three in the evening (600 mg regimen only), orally, for 24 or 48 weeks.
45621680|NCT00704405|Drug|Pegylated Interferon (Peg-IFN)|Participants used prefilled syringe containing 180 µg/0.5 mL Peg-IFN, for weekly subcutaneous injection, for 24 or 48 weeks
45621681|NCT00704405|Drug|Ribavirin (RBV)|Participants took tablets containing 200 mg RBV, 5 or 6 tablet dosage based on the participant's weight, with food, for 24 or 48 weeks. The dose was 1000 mg for participants weighing <=75 kg and 1200 mg for participants weighing >75 kg.
45621682|NCT00704405|Drug|Placebo (PBO)|Participants took PBO capsules matching Vaniprevir capsules, three in the morning and three in the evening, for 24 or 48 weeks.
45621683|NCT01534481|Biological|Donor Milk|Donor milk provided by the Human Milk Banking Association of North America
45621684|NCT01534481|Dietary Supplement|Preterm Formula|Preterm Formula determined by center practice.
45621685|NCT03310151|Procedure|Imagined movements|Imagined wrist movements, 10-15 minutes, 4 times a day.
46069294|NCT03013998|Other|Laboratory Biomarker Analysis|Molecular genomic assessment to assign patients to targeted therapy (sub-study) based on their specific subtype of acute myeloid leukemia
46069295|NCT03013998|Drug|Daunorubicin (BAML-16-001-S1)|60 mg/m2, IV, on days 4, 5, and 6 of the induction cycle
46069296|NCT03013998|Drug|Cytarabine (BAML-16-001-S1)|100 mg/m2, IV, on days 4 through 10 of the 24-day induction cycle; 1000 mg/m2, IV, on days 2, 4, and 6 of the consolidation cycle 1 and days 1, 3, and 5 of consolidation cycles 2 through 4
45621686|NCT01470755|Drug|salbutamol|Metered dose inhaler, 100µg+300µg per puff, administered one day
45621687|NCT01470755|Drug|Salbutamol - dose2|Metered dose inhaler, 100µg+500µg per puff, administered one day
45621688|NCT01470755|Drug|Salbutamol -dose3|Metered dose inhaler, 200µg+600µg per puff, administered one day
45621689|NCT01470755|Drug|salbutamol -dose4|Metered dose inhaler, 200µg+200µg per puff, administered one day
45621690|NCT03310073|Biological|bOPV|Batch Number: 2042015
45621691|NCT03310073|Biological|Pentabio|Batch number: 5050115 The vaccine shall be given intramuscularly.
45621692|NCT03310073|Biological|IPV|The vaccine shall be given intramuscularly.
45621693|NCT03309995|Device|Lozenges|The participants will be instructed to take 6 lozenges daily over the time awake, evenly distributed, allowing the lozenge to dissolve in the mouth as slowly as possible.
45621694|NCT03309995|Device|Placebo lozenges|Placebo lozenges
45621695|NCT03309917|Other|MAP set at 80-85 mmHg for 5 min|MAP is set at 80-85 mmHg for 5 min by infusion of noradrenaline.
45621696|NCT03309917|Other|MAP set at 70-75 mmHg for 5 min|MAP is set at 70-75 mmHg for 5 min by infusion of noradrenaline.
45621697|NCT03309917|Other|MAP set at 60-65 mmHg for 5 min|MAP is set at 60-65 mmHg for 5 min by infusion of noradrenaline.
45621698|NCT03309839|Other|Blood collection|A sample of an additional blood tube will be taken in parallel with the blood test carried out for the treatment.
45621699|NCT03309761|Other|Blood test|6ml blood sample taken
45621700|NCT00704171|Procedure|Standard Tissue Closure Techniques|Standard Tissue Closure Techniques (sutures and staples only)
45621701|NCT00704171|Device|PleuraSeal Lung Sealant System|
45621702|NCT03313973|Procedure|with self stretching same muscle|with self stretching
45621703|NCT03313973|Procedure|with self stretching of forearm muscles|without self stretching
45621704|NCT05160077|Diagnostic Test|Multispectral optoacoustic tomography (MSOT)|MSOT Acuity Echo, iThera medical, Munich
45621705|NCT03313739|Other|An Educational Program|An educational program was designed for self-care during menopause using teach back method.
45764250|NCT01729325|Behavioral|Preventive Narrative Exposure Therapy|During Pre-NET the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. During two sessions a chronological overview of the whole life with a focus on traumatic events is developed and the most important traumatic experiences are processed.
45621706|NCT03309527|Behavioral|e-aid Cognitive Behavior Therapy|e-aid Cognitive Behavior Therapy
45621707|NCT03309527|Behavioral|e-aid Sleep Hygiene Education|e-aid Sleep Hygiene Education
45621708|NCT03313661|Drug|Cabergoline|cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
45621709|NCT03313661|Drug|Gliclazide|gliclazide (60-120 mg)
45912166|NCT03493633|Device|EzyGain|"Each patient performs a minimum of 3 sessions per week with the investigator / APA investigator, for 4 weeks, each walk for a few minutes (<60 min).~Evaluation of the spontaneous physical activity of the patient by actimetry for seven days QAPPA (questionnaire of physical activity for elderly person) a week and a month after the training phase of four weeks"
45912167|NCT03489980|Other|coloring-type artistic task of a complex form|coloring-type artistic task of a complex form
45912168|NCT03486730|Drug|BT1718|Dose escalation will consist of Stage 1 and 2. Stage 1 patients will receive BT1718 intravenously twice a week (D: 1,4,8,11,15,18) for 3 out of 4 weeks. Starting dose will be 0.6mg/m2. Single patient cohorts will be explored, but it will change to 3 to 6 patients cohorts. Stage 2 patients will receive BT1718 intravenously once a week (D: 1,8,15) for 3 out of 4 weeks. This stage will have 3 to 6 patient cohorts until the recommended dose is established. The expansion phase will consist of two or more expansion cohorts to include tumour types known to commonly over-express MT1-MMP and where MT1-MMP overexpression is confirmed during prospective and retrospective (in appropriate patients) selection at enrolment. A squamous NSCLC and basket cohort will include approximately 16 patients each with high MT1-MMP levels. In the expansion cohorts BT1718 will be administered intravenously at the once weekly RP2D established in Phase I, Stage 2.
45912169|NCT03480438|Drug|Blinatumomab|Patients will receive standard of care chemotherapy before blinatumomab, between blinatumomab cycles and after blinatumomab.
45912170|NCT03467919|Biological|Micro Fragmented Adipose Tissue|Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection
45912171|NCT03467919|Biological|Corticosteroid injection|Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
45912172|NCT03463876|Drug|SHR 1210+apatinib|SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks;Apatinib,250 mg/day.
45912173|NCT03461120|Drug|Experimental continuous peripheral nerve blocks|Bupivacaine 0.3% [or ropivacaine 0.5%] infusions for 7 days via femoral and sciatic perineural catheters
45912174|NCT03461120|Drug|Control continuous peripheral nerve blocks|Bupivacaine 0.1% [or ropivacaine 0.2%] infusions for 1 day followed by normal saline for a total of 7 days via femoral and sciatic perineural catheters
46069297|NCT03013998|Drug|Azacitidine (BAML-16-001-S2)|75 mg/m2, IV, on days 1 through 7 of each 28-day cycle for 2 years in the absence of toxicity or disease progression
46069298|NCT03013998|Drug|AG-221 (BAML-16-001-S3)|100 mg, oral, daily until time of intolerance or disease progression. Dose may be de-escalated to 50 mg based on occurrence of dose-limiting toxicity.
46069299|NCT03013998|Drug|Azacitidine (BAML-16-001-S3)|75 mg/m2, IV or SC, on days 1 through 7 of each 28-day cycle starting with cycle 6 and ending after 12 cycles for patients not attaining complete remission or complete remission with incomplete blood count recovery after 5 cycles of monotherapy with AG-221
45446344|NCT03757143|Drug|Povidone-Iodine-Alcohol|Povidone-Iodine-Alcohol will be used to disinfect the skin
45764251|NCT01729481|Drug|Gemcitabine|1000 mg/m² iv weekly
45764252|NCT01729481|Drug|Erlotinib|100mg, once per day
45764253|NCT01729481|Drug|Oxaliplatin|85mg/m², q2weeks
45446345|NCT03757143|Drug|Chlorhexidine-Alcohol|Chlorhexidine-Alcohol will be used to disinfect the skin
45621710|NCT00703781|Drug|bromfenac ophthalmic solution|sterile ophthalmic solution
45621711|NCT00703781|Drug|placebo|sterile ophthalmic solution
45621712|NCT03313583|Procedure|Transfusion of blood products|
45621713|NCT02468609|Radiation|Ultralow-Dose-CT|Patients undergoing thoracic normal dose-CT with undergo an additional Ultralow-Dose-CT
45621714|NCT03313505|Biological|S100B protein dosage|S100B protein dosage will be carried out, by a blood sample, on the earliest after admission and before 3th hour following brain injury S100B protein dosage will be left to the assessment of the emergency physician in charge of the patient
45621715|NCT03313505|Other|Brain CT scan|No injected brain CT-scan, regardless of the time between the brain injury and the arrival in the emergency unit. Realization of CT-scan will be left to the assessment of the emergency physician in charge of the patient
45621716|NCT03313427|Other|Physical Therapy Early Intervention|"At the UCIN:~Parental education to empower them on motor development and parent-infant relationship. Consisted on 6 sessions during the first weeks at the NICU.~Tactile and kinaesthetic stimulation managed by parents. 2 times a day, 15 minutes each, during 10 days.~At home:~Psychomotor Development Program for the baby; comprised of different exercises, in different phases, depending on child maturation stage. Started after hospital discharge until 2 months corrected age."
45446346|NCT03757143|Device|Insyte Autoguard BC Winged|Pose of Insyte Autoguard BC Winged
45621717|NCT03313427|Other|Usual Care|NICU usual care
45621718|NCT03309293|Biological|blood samples|blood samples
45621719|NCT03313349|Behavioral|Psychotherapy: 1. cognitive therapy 2.family intervention|Psychotherapy delivered by trained psychologist for the student and the student´s parents
45621720|NCT00703157|Procedure|Catheter Ablation|Patients undergoing left atrial circumferential pulmonary vein ostia ablation.
45621721|NCT00703157|Procedure|Surgical Ablation|patients undergoing left atrial circumferential pulmonary vein ostia ablation via minimal invasive surgery.
45764254|NCT01729481|Drug|Folinic Acid|400 mg/m², q2weeks
45764255|NCT01729481|Drug|Irinotecan|180 mg/m², q2weeks
45764256|NCT01729481|Drug|5-FU|400 mg/m² Day 1; 2400 mg/m² 46 hour invusion, q2weeks
45621722|NCT03309215|Other|Experimental stimulation with nickel discs|"All participants will be exposed to 8 metal discs, 3 cm in diameter, 4 on each arm, placed on the volar side of the forearms (figure 1). Three of the metallic discs consists of >99 wt.% nickel one consist of >99wt.% Aluminium.The latter is used as a negative control. The discs will be applied under occlusion and with initial pressure and friction.~One metallic disc with nickel, and one with aluminium, will be randomized for the earlobes on the patients with nickel allergy"
45621723|NCT03309059|Device|water and soap|Use of soap and water in the area and subsequent diaper placement disposable.
45621724|NCT03309059|Device|zinc oxide|Use of soap and water sanitation and application of zinc oxide.
45621725|NCT03309059|Device|Non-Irritant Barrier Film|Use of soap and water hygiene and application of Non Irritant Barrier Film.
45621726|NCT03308981|Device|REThink therapeutic online game|The REThink therapeutic online game has seven levels. Each level has various degrees of complexity, which increase as the player progresses in the game. The scenario of the game was developed based on the REBT model, such that it focuses on: a. identifying the emotional and behavioral reactions; b. identifying cognitive processes; c. identifying the relation between cognitive processes and emotions and behavioral reactions; d. changing irrational cognitions into rational cognitions; e. building problem solving skills; f. building relaxation skills and g. building happiness skills.
45621727|NCT03308981|Other|REBE group|In the Rational-Emotive-Behavioral Education (REBE) group participants will follow 7 modules, structured based on the strategies practiced in each of the REThink level.
45621728|NCT02469545|Drug|Lactobacillus Plantarum 299v|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and probiotic - 2x1 caps. per day of Lactobacillus Plantarum 299V (10mld colony forming units in 1 caps.) for 8 weeks.
45621729|NCT02469545|Drug|Crystalline cellulose powder|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and placebo of probiotic - 2x1 placebo caps. filled with micro-crystalline cellulose powder for 8 weeks.
45621730|NCT02469545|Drug|Escitalopram|5-20mg daily
45621731|NCT02469545|Drug|Sertraline|50-100mg daily
45621732|NCT03308903|Diagnostic Test|DEXA scan|The participant will undergo a whole-body DEXA (DEXA; GE Medical Systems, Chalfont St Giles, UK) scan, lasting approximately 5 minutes. This scan will produce body composition data, including estimates of lean body mass (LBM), appendicular lean mass (aLM) and body fat percentage (BF%).
45621733|NCT03308747|Dietary Supplement|Instantized Whey Protein Isolate|0,4 g of whey protein isolate/kg body weight will be ingested as a bolus of 250 ml immediately after the resistance exercise bout.
45621734|NCT02469467|Dietary Supplement|VS-505|VS-505 is orally administered with meal for 8 weeks
45621735|NCT03313193|Other|Acupressure for Children in Treatment for a Childhood Cancer|This study will describe the benefits and risks of an acupressure intervention to decrease nausea/vomiting and other treatment-related symptoms compared to a control group receiving usual care. Children in Arm A will receive usual symptom management care + acupressure 5 days/week for ~20 treatments. Parents will be taught how to provide acupressure as well. Children in Arm B will receive usual care alone.
45621736|NCT03308591|Drug|NACT|Platin based chemotherapy
45621737|NCT03308591|Procedure|RT+PLND|radical hysterectomy+pelvic lymphadenectomy
45621738|NCT03308591|Drug|Adjuvant chemotherapy|Platin based chemotherapy
45621739|NCT03312959|Drug|hyperbaric bupvacaine in Peribulbar block|hyperbaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
46069300|NCT03013998|Drug|Entospletinib (BAML-16-001-S4)|200 mg, oral, twice daily for 5 years until time of intolerance or disease progression. Dose may be escalated to 400 mg.
45621740|NCT03312959|Drug|isobaric bupvacaine in Peribulbar block|isobaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
45621741|NCT03308357|Diagnostic Test|Drug assays to measure infliximab|See protocol
45621742|NCT03312725|Device|WEB aneurysm embolization system|The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/iridium radiopaque markers.
45621743|NCT03308279|Diagnostic Test|Ultrasound|Ultrasound and Anthropometric meassures
45621744|NCT02469311|Other|chlorhexidine impregnated cloths|Pre-operative use of Chlorhexidine cloths night before and morning of surgery
45621745|NCT02469311|Other|Standard of care bathing with antibacterial soap and water|Patients had standard pre-operative bathing with antibacterial soap and water the night before surgery.
45621746|NCT02469233|Behavioral|Transdiagnostic Intervention for Sleep and Circadian Dysfunction|The intervention is a modular treatment composed of core modules that are given to all participants and modules that are delivered based on the need/s of the participants. The interventions are all cognitive behavioral.
46069301|NCT03013998|Drug|Azacitidine (BAML-16-001-S4)|75 mg/m2, IV or SC, on days 1 through 7 of each 28-day cycle and continuing for 12 cycles. Treatment starts after 1 cycle of monotherapy with entospletinib for patients not attaining complete remission or complete remission with incomplete blood count recovery or after later cycles of monotherapy with entospletinib for patients with disease progression.
46069302|NCT03013998|Drug|Entospletinib (BAML-16-001-S5)|400 mg, oral, twice daily for 2 years on study until time of intolerance or disease progression. Dose may be de-escalated to 200 mg twice daily or 200 mg once daily based on occurrence of dose-limiting toxicity.
45621747|NCT03308201|Drug|Hemay022+exemestane|"Part one: Hemay022 tablets will be taken orally once daily in doses of 200mg, 300mg,400mg or 500mg for 28 days in combination with exemestane.~Part two: Hemay022 tablets combination with exemestane."
45621748|NCT03308201|Drug|Hemay022+letrozole|Part two: Hemay022 combination with letrozole.
45764257|NCT03405077|Behavioral|IPT Online Training|"First, college mental health clinicians will complete baseline online questionnaires and deliver their usual treatment to 1 or 2 clients with symptoms of eating disorders. Then, they will complete the guided online training program and post-training assessments. Next, they will treat 1 or 2 different clients with eating disorders and complete post-training assessments. As part of the baseline and post-training assessments, clinicians will complete a telephone-based simulation assessment with staff raters, in which the investigators will recreate a client session and rate how well the clinicians adhere to IPT in treating the simulated client. The guided on-line training program will ultimately be compared to the gold standard training."
45764258|NCT00939211|Drug|AZD9164|Solution for inhalation through nebulization, single dose
45764259|NCT00939211|Drug|Tiotropium|Dry powder for inhalation, single dose
45764260|NCT00939211|Drug|Placebo|Placebo
45446347|NCT03757143|Device|Nexiva single port catheter, MaxZero needless connector, PureHub Deinfecting Caps and Posiflush prefilled saline syringes|Pose of Nexiva single port catheter
45621749|NCT03308201|Drug|Hemay022+ fulvestrant|Part two: Hemay022 combination with fulvestrant.
45764261|NCT03404999|Other|clinical decision support|Decision support system (see description of hypertension decision support system alerts and order sets for details)
45764262|NCT02791906|Drug|ISMN|
45764263|NCT02791906|Dietary Supplement|Vitamin C|
45764264|NCT03404921|Procedure|ESTD|During the ESTD procedure,after marking and submucosal injection, incisions were made at both the anal and oral sides of the lesion, and the submucosa under the lesion was then dissected to create a tunnel between the distal and proximal incisions. When the endscope reached the lower incision, the distal end of the esophageal lumen could be visualized , then two lateral mucosal incisions were made, thus completing the ESD procedure.
45764265|NCT03404921|Procedure|ESD|The ESD procedure involved marking,injection,circumferential cutting, submucosal dissection.
45764266|NCT01729715|Behavioral|Internet|
45764267|NCT01729715|Behavioral|DVD|
45446348|NCT01562067|Device|ultrasound examination|ultrasound and doppler studies to evaluate size and vascularity of tumor during radiotherapy
45764268|NCT04466293|Behavioral|Choice Architecture|"Providers will receive general training on TPT benefits, indications, and contra-indications.~Providers will be provided with updated ART and TPT prescribing approach. This will be adapted to the country context and may include a pre-printed prescription pad (Mozambique), adaptations in clinical stationary (Zimbabwe), or adaptations to an electronic prescribing system (Malawi).~The pharmacy or clinician (if the clinician dispenses) will dispense ART, cotrimoxazole, and TPT as prescribed"
45446349|NCT04435665|Drug|NFX-179 Gel|gel for topical administration
45621750|NCT03308123|Other|Observational study, not interventional|Not an intervention study
45621751|NCT03307967|Behavioral|SBIRT-PM|SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.
45621752|NCT03312413|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride 0.2 μg·kg-1·h-will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
45764269|NCT03404765|Behavioral|Tai Chi|
45764270|NCT01723319|Device|HBLPADD coil deep TMS|20 daily deep TMS treatment
45621753|NCT03312413|Drug|Normal Saline|Normal saline 0.5 mL·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
45621754|NCT03312413|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride 0.5 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
45621755|NCT03312413|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride 0.7 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
45621756|NCT02722967|Drug|Aripiprazole + IEM (Ingestible Event Marker)|Oral aripiprazole (2, 5, 10, 15, 20, or 30 mg) with an ingestible event marker in a single daily dose for duration of the trial.
45621757|NCT04442633|Drug|Glutamine Cap/Tab|Glutamine Capsules: One capsule three times daily on an empty stomach for one month
45621758|NCT04442633|Drug|Miconazole Oral gel|Miconazole oral gel: applied three to four times daily for three weeks
45621759|NCT04442633|Drug|Kenacort in orabase|Kenacort in orabase: applied two to three times a day for 3 weeks followed by tapering the following 9 weeks until a maintenance dose of two to three times a week is reached
45621760|NCT03307811|Other|22 gauge needle liver biopsy|EUS will be performed. Specimens obtained from each pass will be placed in a separate biopsy jar. If the third pass does not result in sufficient diagnostic material, a 19 G will be used. A maximum of 3 passes will be made using the alternate needle. The total number of passes with the 22 G needle and the 19 G needle is 6. Data will be collected about the procedure and the performance of the needles for each procedure.
45621761|NCT03312335|Drug|Low-dose Aldesleukin (Proleukin®)|Subcutaneous injection of 1.5 million international units (MIU) of Aldesleukin (Proleukin®, Interleukin-2) once daily in 5-day courses every three weeks for a total of 4 cycles.
45621762|NCT03312179|Device|PCI and DES stenting|Percutaneous coronary intervention (PCI) and direct stenting (DES) of culprit lesion vessel.
45621763|NCT03312179|Drug|Incretins|Patients treated before study enrollment by incretin drugs (6 months drugs exposure)
45621764|NCT02468531|Other|oxygen|50% oxygen inhalation
45621765|NCT02468531|Drug|Xenon|50% Xenon inhalation
45446350|NCT04435665|Drug|Vehicle Gel|vehicle gel for topical administration
45764271|NCT01723319|Device|Sham|inactive treatment
45764272|NCT01729793|Dietary Supplement|Digestive Enzyme #2|Contains dietary supplement proteases, lipases and carbohydrases
45764273|NCT01729793|Other|Placebo|Capsule containing microcrystalline cellulose
45764274|NCT02793154|Drug|Exenatide|Supplied as SC injection containing 250 mcg/mL of exenatide, provided in the following dose regimens: Part A: 10 mcg taken twice daily for 5 days; Part B: 5 mcg twice daily taken for 4 weeks followed by uptitration to 10 mcg for 4 weeks In both parts, it will be administered within 60-minute period before morning and evening meals (or before 2 meals with approximate >=6 hours apart)
45446351|NCT04428411|Drug|Enbrel|As provided in real world practice
45621766|NCT03312101|Other|exercise program|functional exercises consisting of a therapeutic exercise program based on concentric strengthening the gluteal muscles (maximus, medius and minimus) , the tensor fasciae latae muscle and the pyramidal muscle; ischiotibial muscle stretching ; and empowerment in eccentric and stretching of the gastrocnemius muscle, soleus muscle, tibialis posterior muscle and flexor of the big toe muscle,
45621767|NCT03307733|Behavioral|walking and behavour change techniques|a Fitbit pedometer with individualised step targets and partaking in a closed Facebook group
45621768|NCT05280431|Device|AGREE exoskeleton|"Upper limb exoskeleton with four actuated degrees of freedom (shoulder horizontal adduction/abduction, shoulder flexion/extension, humeral rotation, elbow flexion/extension), and one passive degree of freedom (wrist pronation/supination), implementing different rehabilitative strategies.~The intervention consists of the execution of different exercises with the affected arm supported by the AGREE device. The subject is actively involved in the exercises and the system provides different kinds of assistance that can be tailored according to the patient's status.~The following exercises can be performed:~anterior reaching (in a plane or in the space)~lateral elevation of the arm~hand to mouth movements with or without an object in the hand~moving objects (on a plane or in the space)~exergames.~A subset of exercises is defined based on the patient's capability."
45653358|NCT05333185|Behavioral|DİABOT (mobile application robot )|"DİABOT (mobile application robot ) Thanks to the trainings given through the mobile application robot developed for pediatric diabetes management, it is aimed to have an effect on the quality of life, diabetes self-management and physiological parameter levels of children with Type~1 diabetes, and to easily obtain the information they need even when they cannot come to the outpatient clinic. In addition, thanks to the application robot, he will be able to create his own exercise program and determine his diet."
45764275|NCT02793154|Drug|Albiglutide|Part B: Albiglutide will be supplied as follows:30 mg SC injection pen containing 40.3 mg lyophilized albiglutide and 0.65 mL; 50 mg SC injection pen contains 67 mg lyophilized albiglutide and 0.65 mL water; Starting dose will be 30 mg weekly for 4 weeks and then uptitrated to 50 mg weekly for 4 weeks; Administered as a single SC injection once a week in the morning
45764276|NCT03404687|Radiation|ultrasound|for assessment of adnexal masses size and pattern
45621769|NCT05280431|Device|FEXO exoskeleton|After patient's preparation (tDCS and FES) the FEXO assessment is conducted. The subject performs FEXO assessment games. This stage is also used to calibrate the reach and grasp movement intention EEG patterns. The movement is recorded using internal kinematic sensors; therefore, these measures can be extracted for both reaching and lifting movements. Trunk forward bending is measured to avoid compensatory movements when doing reaching assessment. The clinician then reviews the plan for today's session: game selection, number of repetitions and assistance levels. The patient gets ready to play the games and the clinician starts the first activity of the active stage of FEXO therapy. The patient plays the game and sees his own results. The clinician monitors patient activity, assistance levels, effort and signs of discomfort. The patient plays the next game and sees his own results, and the clinician checks the patient's progress with the results overview.
45621770|NCT05280431|Other|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the patient's specific needs:~Upper limb passive motion~Occupational therapy exercises~Constraint-induced movement therapy~Upper limb active movement (reaching, grasping, elevation, spatial orientation)~Repetitive task training"
45621771|NCT03311945|Drug|Raltegravir|Raltegravir (1200 mg QD)
45621772|NCT03311945|Drug|Lamivudine|Lamivudine (300 mg QD)
45621773|NCT03307655|Other|Control (fertile semen donors)|"The sperm will be capacitated in the presence and absence of follicular fluid (FF). In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.~Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined."
45621774|NCT03307655|Other|Patients (subfertile men)|"The sperm will be capacitated in the presence and absence of follicular fluid (FF). In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.~Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined."
45621775|NCT03311867|Other|Ethibond Suture|Cerclage placement with ethibond
45621776|NCT03311867|Other|Prolene Suture|Cerclage placement with prolene
45764277|NCT03404687|Diagnostic Test|cancer antigen 125 level|for prediction of malignancy
45764278|NCT03404687|Radiation|Doppler|for detection of blood flow
46069303|NCT03013998|Drug|Decitabine (BAML-16-001-S5)|20 mg/m2, IV, on days 1 through 5 or 10 of each 28-day cycle and continuing for up to 11 cycles. During the first induction cycle, and the 2nd and 3rd induction cycles if they are needed, administration occurs on days 1 through 10 of each 28-day cycle. During subsequent consolidation, decitabine is administered on days 1 through 5 of each 28-day cycle and continuing for up to 11 cycles. Duration may be reduced by 1 day based on occurrence of dose-limiting toxicity, and patients may switch to entospletinib monotherapy maintenance at any time if they develop toxicity or are unwilling to continue decitabine during consolidation therapy.
45621777|NCT03311789|Drug|PD-1 inhibitor + Gemcitabine + Cisplatin|Gemcitabine: 1000mg/m2 on day 1 and 5 every 3 weeks. Cisplatin: 75mg/m2 on day 1 every 3 weeks. PD-1 inhibitor: Nivolumab 3mg/kg, or SHR-1210 200mg.
45653359|NCT05040633|Device|BTL 4110 Smart Laser Therapy Equipment (BTL Industries Ltd, United Kingdom (UK))|Participants will receive 12 LLLT sessions during the course of the trial, thrice weekly for 4 consecutive weeks. Doses will be as per the recommendations of the Wold Association of Laser Therapy.
45764279|NCT01729949|Dietary Supplement|Active Treatment Beverage|Strawberry and Blackcurrent extract
45764280|NCT01729949|Dietary Supplement|Placebo Treatment Beverage|without active components
45764281|NCT03404531|Behavioral|Social Media Messages Intervention Group|The Social Media Messages Intervention Group will receive theoretically-grounded messages through social media in order to encourage participants to regularly access the newly developed, culturally-tailored website that includes information about treatment as prevention and pre-exposure prophylaxis.
45764282|NCT03404531|Behavioral|Website Only Group|The Website Only group will have access to the newly developed, culturally-tailored website but will not receive social media messages.
45764283|NCT01723553|Drug|C-11 PiB|One time intravenous administration of ~740 megabecquerel (MBq) of [N-methyl-C-11]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
46069304|NCT03013998|Drug|Entospletinib (BAML-16-001-S6)|400 mg, oral, twice daily for 2 years until time of intolerance or disease progression.
46069305|NCT03013998|Drug|Daunorubicin (BAML-16-001-S6)|60 mg/m2, IV, on days 1-3 or 1-2 of each 28-day cycle for the first and second induction cycle, respectively
45446352|NCT03751059|Drug|Bromfenac 0.07% Oph Susp|Bromfenac 0.07% Oph Susp to be used post-operatively (week 1 to month 3) by one treatment group.
45452336|NCT01143064|Drug|Progesterone|Intravenous administration of 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
45621778|NCT02722499|Behavioral|High Frequency Financial Incentive|"Diabetes Education/Skills Component. Subjects will receive weekly telephone-delivered diabetes/skills training for 12 weeks with home telemonitoring.~High Frequency Financial Incentive: the high frequency incentive structure will receive a reward for uploading glucose measurements, attending educational sessions, and absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300. Each week participants can receive up to $10 for uploading glucose measurements and having good glucose control throughout the week. If they upload measurements every day of the week and their average glucose measurements at the end of the week are 150 or below they will receive an additional $3. Participants can also earn $5 each week if they attend the educational session. After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $130, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $65."
45621779|NCT02722499|Behavioral|Moderate Frequency Financial Incentive|"Diabetes Education/Skills Component. Subjects will receive weekly telephone-delivered diabetes/skills training for 12 weeks with home telemonitoring.~Moderate Frequency Financial: the moderate frequency incentive structure will receive a reward for uploading glucose measurements, and absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300. Each week participants can receive up to $10 for uploading glucose measurements and having good glucose control throughout the week. For each day they upload at least one glucose measurement, they will receive $1 (up to $7 at the end of the week). If they upload measurements every day of the week and their average glucose measurements at the end of the week are 150 or below they will receive an additional $3. After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $170, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $85"
45621780|NCT02722499|Behavioral|Low Frequency Financial Incentive|"Diabetes Education/Skills Component. Subjects will receive weekly telephone-delivered diabetes/skills training for 12 weeks with home telemonitoring.~Low Frequency Financial Incentive: the low frequency incentive structure will receive a reward for absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300. After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $300, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $150."
45621781|NCT03307499|Other|NeoPatch|NeoPatch as an adjunct to foot and ankle tendon revision/repair surgery
45621782|NCT02468999|Drug|human insulin|
45621783|NCT03311477|Drug|ABBV-399|Intravenous infusion
45621784|NCT03307421|Other|debriefing without instructor|"The randomization will focus on the allocation of the debriefing method: group without instructor versus group with instructor (AI). It will be stratified by center and performed before the first simulation session. The randomization will be carried out by the clinical methodology center of the Besançon University Hospital.~The sequence of scenarios for each binomial will also be determined by randomization."
45621785|NCT03307421|Other|debriefing with instructor|The randomization will focus on the allocation of the debriefing method: group without instructor versus group with instructor (AI). It will be stratified by center and performed before the first simulation session. The randomization will be carried out by the clinical methodology center of the Besançon University Hospital.
45621786|NCT03311399|Other|SSI Screening Tool used in home visits by CHWs|Individuals in Arm 1 will be visited at home by the sCHW who will administer the optimized SSI protocol via the mHealth device. Following the screening, the sCHWs will use the cell phone to photograph the surgical wound and record the GPS location of the visit.
45621787|NCT03311399|Other|SSI Screening Tool used via phone call follow-up|Individuals in Arm 2 will be phoned by the sCHW who will administer the SSI protocol over the phone.
45621788|NCT03307265|Device|Personalized weighted jacket|Patients in this group will wear a jacket with weights (1,5 to 2% of the total body mass) strategically placed in order to correct their imbalance.
45621789|NCT03307265|Device|Control jacket|Patients in this group will wear a jacket with weights (200 grams maximum) evenly distributed.
45621790|NCT03311321|Dietary Supplement|Vitamin K2 (menaquinone-7; 360-mcg/d)|four 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
45621791|NCT03311321|Dietary Supplement|Placebo-Control|four placebo softgel capsules per day for 8 weeks containing no vitamin K2 (menaquinone-7)
45452337|NCT01143064|Drug|Lipid emulsion without progesterone|Intravenous administration equal to 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
45621792|NCT03311243|Procedure|Non surgical periodontal therapy|
45621793|NCT03311243|Drug|Chemical plaque control|
45621794|NCT03307187|Behavioral|GLB Adapted for Individuals with Impaired Mobility|The 12-month Group Lifestyle Balance program, Adapted for individuals with Impaired Mobility (GLB-AIM) promotes 5% - 7% weight loss by reducing calories and increasing energy expenditure to 150 minutes of weekly activity. The 23 GLB-AIM sessions were delivered through monthly in-person and teleconference calls. Participants were encouraged to self-monitor daily caloric/fat intake and physical activity using materials to accurately measure daily calories and exercise, which included a food scale, measuring cups and spoons and a loaned Garmin vívofit® activity tracker and heart rate monitor. Participants shared their logs with lifestyle coaches over the 13 core sessions and lifestyle coaches provided positive reinforcement, feedback, and problem solving techniques as needed.
45621795|NCT03307031|Other|High Volume Group|Performed four weekly session, during 10 weeks with 45 to 55 minutes per session.
45621796|NCT03307031|Other|Low Volume Group|Performed only twice a week, during 10 weeks with 45 to 55 minutes per session.
45621797|NCT03307031|Other|Control Group|Did not exercise, during 10 weeks.
45621798|NCT03311165|Other|no intervention|no intervention was given
45621799|NCT03306953|Procedure|Rectus muscle approximation|The surgeon will take sutures to approximate rectus muscles at the end of cesarean delivery.
45621800|NCT03306875|Behavioral|Cognitive Training|Individuals will take part in a computer-based cognitive training program. The program is aimed at building attention, processing speed, memory, and executive function.
45764284|NCT03404453|Diagnostic Test|Difficult airway incidence and prediction|Paediatric patients scheduled for surgery under general anaesthesia will be examined and a set up of airway prediction tests will be performed to predict the possibility of difficult airway
45764285|NCT02907268|Drug|onabotulinumtoxinA|OnabotulinumtoxinA (Botox; Allergan) was approved by the FDA in 2002. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
45912175|NCT03433781|Drug|50 gm CIVI/24 hours x 5 days every 4 week|Each one ml solution will contain 500 mg ascorbic acid in the addition of disodium edetate 0.25mg, sodium hydroxide 110 mg in water with a pH in the range of 5.5 to 7.0 adjusted with sodium bicarbonate and sodium hydroxide. Vitamin C will be dispensed continuously by a computerized ambulatory drug deliver (CADD) pump, which will bereplaced every 24 hours.
45912176|NCT03420066|Other|Retrospective data collection|Retrospective collection of data recorded as standard of care for patients that were implanted with the Nexus device as part of Compassionate Use duly authorized according to country specific regulations.
45912177|NCT03405740|Device|Remote Patient Management|"Transmissions will occur at six monthly intervals, with no in-clinic visits. If there is an actionable event on the remote transmission, patients will be seen at their closest community clinic.~All patients will be required to follow up with their family physician at least annually, and their cardiologist at least every 2 years.~Patients will be contacted by phone at 6 months and 12 months to document their current health status (change in cardiovascular medications, any cardiovascular hospitalizations, in-clinic device checks, or any new cardiovascular testing completed since the last visit)~VIRTUES access"
45912178|NCT03405740|Device|Standard of Care|No intervention
45912179|NCT03396588|Drug|Clonidine|1mcg/kg/dose (with a dosing interval of 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
45621801|NCT02468765|Other|Neuropsychological and emotional evaluation with monitoring|Recognition tasks of emotional facial expressions with electroencephalogram, electrodermal activity measure and heart rate measure, questionnaires and neuropsychological tests
45621802|NCT02468921|Procedure|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
45621803|NCT02468843|Device|Biphasic DBS stimulation|"The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~Current best/optimized DBS setting (considered baseline)~DBS off for 30 minutes~Biphasic pulse stimulation mode (immediate assessment)~Biphasic pulse stimulation mode (assessment at 1h)~Biphasic pulse stimulation mode (assessment at 2h)"
45621804|NCT02468843|Other|Unified Dystonia Rating Scale|Neurologist use the UDRS to determine the severity and duration of dystonia on 14 body areas.
45621805|NCT02468843|Other|Burke-Fahn- Marsden scale|Neurologist use the BFMDRS to rate the severity of dystonia in 9 regions of the body.
45621806|NCT03306797|Other|STANDARD REHAB|"The rehabilitative standard intervention (Occupational Therapy) consists of 15 minutes of warm-up exercises plus a 20 minutes training with at least 6 exercises selected from:~wrist~ulnarization radialization~prono-supination~horizontal flexion-extension~vertical flexion-extension hand~grasping~pinching~extensors~interosseous shoulder-elbow~vertical flexion-extension~push forward"
45621807|NCT03306797|Device|SONICHAND|"The intervention is similar to the standard protocol (15 minutes of warm-up plus 20 minute of training) but involves the sonification of the exercises selected from the list. The Leap Motion Controller is managed with an ad-hoc developed application that is able to associate the movements with a 4 notes arpeggio or with a modulated texture.~With the first mode the movement produces and modulates an harmonic progression built on the consecutive grades of the major scale played as ascending and descending arpeggio with also a volume crescendo and decrescendo.~With the second mode, the movement modulates the volume and the low-pass cutoff frequency of a synthetic texture."
45621808|NCT03306719|Biological|Blood sampling|Serial blood sampling
45621809|NCT04442321|Other|PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~TENS Frequency 2 Hz~TENS Pulse width - 250 microseconds~Duration - 30 minutes.~TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week."
45621810|NCT04442321|Other|Sham PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The electrical current will not be working, and the needles will be placed during 30 minutes:~- Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week."
45621811|NCT03306563|Diagnostic Test|Sample collection|Samples of blood, urine and saliva will be collected at up to five successive time points.
45764286|NCT02907268|Drug|abobotulinumtoxinA|AbobotulinumtoxinA (Dysport; Galderma) was approved by the FDA in 2009. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
45912180|NCT03396588|Drug|Morphine|Starting dose is 0.06 mg/kg/dose (every 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
45912181|NCT03361852|Drug|Rituximab|Rituximab is classified as a monoclonal antibody. It works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
45912182|NCT03361852|Biological|Neo Vax|"Neo Vax is an experimental viral mimic and an activator of immunity."
45912183|NCT03361852|Drug|Pembrolizumab|Pembrolizumab is a monoclonal antibody that targets PD-1. It is a type of immunotherapy
45621812|NCT02468297|Device|Electronic Acupunture Shoes|"Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoes three times a week. 6 weeks of treatment was given.~Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy."
45621813|NCT02468297|Drug|Ibuprofen|Experiment group took placebo only in the first week. Control group took ibuprofen(400mg, TID) only in the first week. No more placebo or medicine was prescribed to either two groups since the second week.
45764287|NCT04376957|Behavioral|Multinational Association of Supportive Care in Cancer Oral agent Teaching Tool|"This tool was developed by an expert panel of oncology nurses and was further revised following external review of health care providers world-wide. This tools involves four key modules 1) patient's baseline knowledge, 2) patient education of oral cancer drugs 4) patient education tailored to a specific cancer drug 4) evaluation of the educational material.~It was originally studied in 30 patients with lung cancer and was shown to be feasible with acceptable knowledge retention. Similarly, in a single center cohort study of general oncology patients, medication adherence self-efficacy appeared to improve with MOATT. The MOATT interventional tool incorporates key components of patient education and also has the advantage of being a potentially feasible tool that can be incorporated into future routine clinical practise."
45764288|NCT04376957|Behavioral|Standard of care consisting of standard counselling|Consists of instructions and information on the regimen, common side effects, symptom management, medication safety and how to contact a clinician for any problems encountered.
45764289|NCT02907814|Device|Optical Coherence Tomography (OCT)|The OCT scan is a brief, non-contact scan of the back of the eye using infrared light. Subjects will see a light and be asked to look forwards while the scan is completed.
45764290|NCT02907814|Other|Eye Exam|This is a brief, non-contact ocular exam.
45764291|NCT03404297|Other|Locally sourced compression therapy|The dressing is made up of a zinc oxide impregnated compression wrapping
45764292|NCT02909140|Drug|Topical phenylephrine 2.5%|
45764293|NCT02909140|Drug|Topical cyclopentolate 1%|
45764294|NCT02909140|Drug|Intracameral Lidocaine 1%|
45912184|NCT03350516|Dietary Supplement|Daily 500 mg elemental calcium as calcium carbonate|Pregnant women in this arm will be provided and counselled to take three tablets, one containing 500 mg elemental calcium as calcium carbonate and 2 placebo supplements daily (total of 500 mg daily). The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.
45621814|NCT03304925|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
45764295|NCT02909140|Drug|Intracameral 0.2- 0.3ml of epinephrine 1:10,000|
45764296|NCT01723631|Device|Trap Myelin Test|
45764297|NCT02909764|Other|Low Sodium Group|Breakfast Cereal
45764298|NCT01724879|Drug|Dasatinib|Dasatinib p.o. + Chemotherapy (Dexamethasone, Cyclophosphamide, Vincristine, Methotroxate, 6-Mercapto-Purine, Cytarabine, Vindesine, VP16 (Etoposide))
45764299|NCT04348435|Biological|HB-adMSCs|Hope Biosciences allogeneic adipose-derived mesenchymal stem cells
45764300|NCT04348435|Other|Placebos|Saline
45764301|NCT03404141|Other|Parent craft|Midwife-guided classes for pregnant women about pregnancy and childbirth
45764302|NCT03404141|Behavioral|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy to reduce stress levels among pregnant women
45764303|NCT04377893|Device|Eye gaze AT intervention|"The eye-gaze AT intervention includes eye-gaze AT and service delivery to support the participants using this technology in daily life. The Tobii PCEye Mini (Tobii, Danderyd, Sweden) and specialized software are applied with adaptation to meet each child's individual needs.~To ensure the consistency of service delivery, two-day courses are conducted before the intervention. The participant's teachers or parents are invited as the main interventionist to facilitate the child's usage of eye-gaze AT in daily life under team support. The service delivery involves parents in joint goal-setting, planning, and jointly review the progress of the usage of eye-gaze AT as a family-centered practice. Individual meetings and individual supports are provided during intervention periods. The collaborative team will perform biweekly follow-up contacts during intervention periods.~The researcher will conduct the fidelity checklist every month to determine the extent of treatment integrity."
45764304|NCT01722929|Device|Skin sensor|
45764305|NCT02982031|Procedure|shamrock|This scanning technique is performed in the lateral decubitus position with the side of interest facing upwards. The transducer is placed in the transverse plane on the flank of the patient cranially to the iliac crest. The quadratus lumborum muscle is identified medial to the aponeurosis of the transversus abdominis muscle. With the psoas muscle anterior to the transverse process, the erector spinae muscle posterior to the transverse process, and the quadratus lumborum muscle attached to the apex of the transverse process of L4.
45764306|NCT02982031|Procedure|paramedian transverse scan|The ultrasound transducer is positioned 4 cm lateral to the midline along the intercristal line and just above the iliac crest. The transducer is also directed slightly medially.
46069306|NCT03013998|Drug|Cytarabine (BAML-16-001-S6)|100 mg/m2, IV, on days 1 through 7 or 1 through 5 of each 28-day cycle for the first and second induction cycle, respectively; then 1000 mg/m2 (patients ≥60 years) or 3000 mg/m2 (younger patients with creatinine clearance >30 mL/min and <50 mL/min), IV, every 12 hours on days 1, 3, and 5 of each 28-day cycle for up to 4 consolidation cycles
45621815|NCT03306407|Other|Improved hand hygiene|The intervention group receives pre-travel advice with a special focus on improved hand hygiene including the use of hand gel sanitizer (Hartmann Sterillium) (bundle intervention)
45621816|NCT03304847|Other|ablation|radio-frequency applications on arrhythmogenic substrate
45764307|NCT03404063|Drug|Cardiac Drug|"Patients in the AMI trial will receive one dose of IMP during the index procedure. The IMP administration will be performed by dedicated catheter into infarct related artery.~Active IMP consist of 30 000 000 of Wharton's jelly mesenchymal stem cells (WJMSCs) in each IMP dose prepared for patients randomized into active treatment group."
45764308|NCT03404063|Drug|Placebos|"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
45764309|NCT04347109|Diagnostic Test|Non invasive epicardial mapping|Non invasive mapping using Cardio Insight system is performed in all included patients.
45764310|NCT02793856|Drug|Cyclophosphamide|To deplete Tregs before collecting peripheral blood
45764311|NCT02793856|Other|PD-1 Knockout T Cells|Autologous lymphocytes are collected and PDCD1 gene is knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
45621817|NCT03304769|Device|Virtual Reality|Virtual Reality Headset applied to the patient during placement of IV. Control is patient group without headset applied.
45764312|NCT03403985|Drug|Calcium Hydroxide (Ca(OH)2)|Ca(OH)2 will be used in this group
45446353|NCT03751059|Drug|Dexamethasone|Topical dexamethasone to be used by all study participants for one week pre-trabeculectomy and by all study participants for one week post-trabeculectomy. At one week post-op, one of the treatment groups will continue to dose with dexamethasone.
45446354|NCT04422561|Drug|Ivermectin Tablets|two doses 72 hours apart
45764313|NCT03403985|Drug|Mineral Trioxide Aggregate|MTA will be used in this group
45446355|NCT03750591|Drug|Herbal medicine|Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
46069307|NCT03013998|Drug|Pevonedistat (BAML-16-001-S9)|20 mg/m2, IV, on days 1, 3, and 5 of each 28-day cycle and continuing for 24 cycles in the absence of toxicity or disease progression
45764314|NCT04364425|Drug|Triamcinolone Acetonide|ultrasound guided steroid injection using 1ml of 10mg or 4ml of 40mg triamcinolone acetonide
45764315|NCT04364425|Drug|lidocaine hydrochloride|Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)
45764316|NCT04364425|Drug|Normal saline|Ultrasound guided injection using 15ml or 12 ml of normal saline
46069308|NCT03013998|Drug|Azacitidine (BAML-16-001-S9)|75 mg/m2, IV or SC, on days 1 through 7 or days 1 through 5 and then 8 through 9 (based on institutional guidelines) of each 28-day cycle and continuing for 12 cycles in the absence of toxicity or disease progression
45764317|NCT01723943|Other|educational intervention|"Receive the What's Happening to the Woman I Love? booklet"
45764318|NCT01723943|Other|counseling intervention|Undergo Helping Her Heal educational counseling program
45764319|NCT01723943|Other|educational intervention|Undergo Helping Her Heal educational counseling program
45764320|NCT01723943|Other|psychosocial support for caregiver|Undergo Helping Her Heal educational counseling program
45764321|NCT04355377|Other|Non intervention|Non intervention
46069309|NCT03013998|Drug|AG-120 (BAML-16-001-S16)|500 mg, oral, daily until time of intolerance or disease progression. Dose may be de-escalated to 250 mg based on occurrence of dose-limiting toxicity.
45621818|NCT02468375|Drug|mirabegron 50mg|434 OAB patient intake mirabegron 50mg/day for 12 weeks.
45621819|NCT02468453|Device|velos|VELOS combines 595nm pulsed dye laser energy with bipolar RF energy. The study device can deliver 0.45 to 40 ms laser pulses at a maximum of 25 J/cm2
45653360|NCT05040633|Other|Standard Exercise Therapy|Exercise therapy will consist of strengthening and stretching exercises. At each visit, participants will perform each of the exercises under the supervision of a licensed physiotherapist.
45653361|NCT05711407|Genetic|Gene Polymorphisms of MMP-8|Saliva Samples
45653362|NCT05068479|Device|Bilateral Laser Scleral Microporation procedure|Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.
45653363|NCT05306665|Behavioral|ACT intervention|One day in person workshop + telephone booster
45764322|NCT04364503|Device|Multiple interventions depending on diagnostic test being run.|Remnant samples and corresponding data from multiple diagnostic tests will be stored for future research and development.
45764323|NCT04378829|Diagnostic Test|Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19|Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19
45764324|NCT02911324|Drug|Nabilone|"Nabilone is a synthetic cannabinoid that is thought to be a Cannabinoid receptor type 1 (CB 1) agonist. It acts on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."
45764325|NCT02911324|Behavioral|Exposure and Response Prevention Therapy|Exposure and Response Prevention Therapy (EX/RP) is a type of Cognitive-Behavioral Therapy for OCD that involves intentionally confronting situations that trigger obsessional distress while refraining from doing compulsions.
45764326|NCT04355299|Behavioral|balance training|The training to improve balance is to work on the core muscle groups that help to maintain your posture.,and increase muscular strength.
45764327|NCT04355299|Behavioral|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity, bands, weighted bars or dumbbells.
45621820|NCT02467985|Procedure|FIGARO|flow of insufflation set to 2-3L / min. Once the intervention is complete, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed with or without fascial closure according to the standard display. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. A suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who apply 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 seconds. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures. The patient will be given to neutral at the end of the procedure.
45764328|NCT04355299|Behavioral|aerobic exercise|Aerobic exercise is any activity that gets your blood pumping and large muscle groups working. It's also known as cardiovascular activity.
45621821|NCT03306329|Drug|DNS-7801 (low-dose)|DNS-7801 (low-dose) tablets administered once daily.
45621822|NCT03306329|Drug|DNS-7801 (high dose)|DNS-7801 (high dose) tablets administered once daily.
45764329|NCT04355299|Behavioral|usual care|received usual care
45764330|NCT01729403|Drug|aleglitazar|150 mcg orally daily, 16 weeks
45764331|NCT01729403|Drug|metformin|patients will continue on their existing dose and regimen of metformin (but not more than the maximum dose specified in the label)
45764332|NCT01729403|Drug|placebo|orally daily, 16 weeks
45621823|NCT03306329|Drug|Placebo|Placebo tablets administered once daily
45621824|NCT03304457|Drug|Olanzapine|Olanzapine 10mg once daily orally for 6 weeks
45621825|NCT03304457|Drug|Lurasidone|Lurasidone 80mg once daily orally for 6 weeks
45621826|NCT03306095|Other|Early refeeding group|Food Intake by patient with in 4 hours i.e <4 hours after the EVL procedure
45621827|NCT03306095|Other|Delayed refeeding group|Food Intake by patient after 4 hours i.e > 4 hours after the EVL procedure
45621828|NCT03304301|Behavioral|sunlight exposure|Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and receiving sunlight exposure (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months
45621829|NCT04490759|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
45621830|NCT03306017|Other|Blood sampling|Three venous blood sampling before the left ventricular assist device implantation and 1 and 2 months after implantation in ambulatory patients.
45764333|NCT04355611|Other|Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2)|Epidemiological characteristics of coronavirus infection (SARS-CoV-2) in patients with MS or NMO
45764334|NCT03254758|Biological|Mesenchymal stem cell|"Phase1 The dose of AD-MSCs are escalated from low to mid and high step by step. Each administration is one time via intravenous infusion for one hour.~Phase2 The recommended dose of ADR-001 is administrated once a week 4 times. The administration route and time is same method with Phase 1."
45764335|NCT01724645|Dietary Supplement|Korean traditional diets|"The consumption of Korean traditional diets reflecting the characteristics of Korean traditional diets without the limitation of calories has an effect on control of cardiovascular risk factor, so this study instructed all subjects of the intervention group to consume about 2,100kcal of served meals freely.~The Korean Traditional diets, which encourages the intake of cooked rice, vegetables,soup,Kimchi and soy fermented foods."
45764336|NCT01724645|Dietary Supplement|Control group|"Told to  eat as usal diets."
45764337|NCT02914132|Device|Seraph 100 Filter|Treatment of renal replacement therapy patients with bacteremia.
45764338|NCT01724099|Drug|Euiiyin-tang|Korean medicinal herbal drug
45764339|NCT01724099|Drug|Placebo|Placebo drug, same odor and formula as Euiiyin-tang
45912185|NCT03350516|Dietary Supplement|Daily1500 mg elemental calcium as calcium carbonate|Pregnant women in this arm will be provided and counselled to take three tablets each containing 500 mg elemental calcium as calcium carbonate daily (total of 1500 mg daily) as currently recommended by the World Health Organization. The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.
45621831|NCT03304145|Other|The Carevive CPS|The Carevive Care Planning System (CPS) was developed to overcome challenges by providing an efficient, clinically integrated solution for both psychosocial and physical symptom distress screening and management through the delivery of personalized and evidence-based care plans at the point of care. The Carevive CPS simultaneously collects and aggregates discrete data for quality reporting and improvement.
45621832|NCT03304067|Behavioral|Tueo Program|The asthma management solution utilizes devices (2 to attach on the child's bed and 1 for data transmission), which collect various metrics for a tailored smartphone application experience. The smartphone application provides access to view metrics from the devices, educational and clinical context content, and an asthma coach.
45653364|NCT05286229|Drug|ABBV-383|Intravenous (IV) Infusion
45764340|NCT04281667|Drug|Oral Antibiotics|Oral antibiotics (neomycin 1g and metronidazole 1g at 3pm and 11pm the day before surgery)
45764341|NCT04281667|Drug|Placebo|Oral placebos (placebo 1 and placebo 2 at 3pm and 11pm the day before surgery)
45764342|NCT04281667|Drug|Mechanical Bowel Preparation|Mechanical Bowel Preparation using 2L polyethylene glycol (Moviprep)
45764343|NCT04378985|Device|Wearing a Wearable device (Fitbit inspire HR)|"'Wearing a wearable device (the smart watch) for 8 weeks~The smart watch to be used in this study is Fitbit Inspire HR. This is a device that has a high worldwide use rate and has active research on its accuracy. It is worn like a normal watch, and it can check heart rate, exercise level, energy consumed, and sleep quality. The values can be checked in real-time on a smartphone application.'"
45764344|NCT02914210|Device|Virtual physical therapy rehabilitation program|Virtual Exercise Rehabilitation Assistant (VERA), a virtual physical therapy delivery system installed in patient's home
45764345|NCT02914210|Other|No intervention|Traditional physical therapy delivered in clinic or via home-health visits
45764346|NCT04355455|Drug|Citalopram|40 mg citalopram intravenously
45764347|NCT04355455|Drug|Placebo|Saline solution
45764348|NCT04182373|Drug|Antithrombin gamma|Intravenous infusion, once a day, 7 days
45621833|NCT03305939|Behavioral|Life style Intervention|"The intervention will include 4 face-to-face group sessions in the first 6 months, followed by remote support strategies and intensification counseling sessions when needed. Ongoing support and contact shown to be important in supporting behavior change will consist of reminders, and motivational messages for small actionable behaviors, delivered using mobile text or voice messages. Program intensification will be offered to women who fail to meet their weight goals by the 6 month time point. All phases of the program focus on self- management across 3 themes~simple healthy eating and moderate physical activity messages;~behavioral skills such as problem solving/goal setting/self-monitoring; and~enhancing internal motivation, self-efficacy and self-management. The program is deliberately not prescriptive, and has a focus on sustainable behaviors and local context."
45621834|NCT03305861|Procedure|ThuLEP|Thulium laser enucleation of prostate
45621835|NCT03305861|Procedure|Green LEP|Greenlight laser enucleation of prostate
45912186|NCT03350451|Drug|Lumasiran|Multiple doses of lumasiran by subcutaneous (sc) injection
45912187|NCT03329508|Drug|P2B001 0.6/0.75 mg|Fixed low dose extended release combination capsule of pramipexole and rasagiline
45912188|NCT03329508|Drug|Rasagiline 0.75 mg|Rasagiline 0.75 mg oral extended release capsule, component
45446356|NCT03750591|Procedure|Chuna manual therapy|"Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving highvelocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.~Chuna manipulation will be administered at the physician's discretion."
45621836|NCT03305705|Drug|Iron Carboxymaltose|Single intravenous infusion within 20 min
45621837|NCT03305705|Drug|Sodium chloride 0.9%|Single intravenous infusion of 250 ml within 20 min
45621838|NCT04490837|Diagnostic Test|ELISA and Rapid test to detect antibodies against COVID-19|Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices
45621839|NCT04491149|Device|virtual reality glasses|In the intervention arm, women undergoing amniocentesis/foeticide will use virtual reality glasses during the procedure.
45621840|NCT02468219|Behavioral|cardiovascular rehabilitation program|"Phase I: 2-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at hospital).~Phase II: 6-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at home).~Phase III: 8-weeks of supervised, structured, combined aerobic and resistance training."
45621841|NCT03303833|Other|No intervention, observational study.|
45621842|NCT02468141|Drug|SJDBT|Sipjeondaebo-tang
45621843|NCT02468141|Drug|Placebo|Placebo
45653365|NCT05279131|Drug|Tirbanibulin ointment 1%|Participants will apply Tirbanibulin ointment 1% topically for 5 days over a field of approximately 100 cm^2 on the face or balding scalp with Actinic Keratosis (AK).
45653366|NCT04426487|Drug|Progesterone|Intramusculer progesterone
45653367|NCT03797937|Other|Magnetic resonance imaging (MRI)|MRI scanner
45764349|NCT04182373|Drug|physiological saline|Intravenous infusion, once a day, 7 days
45912189|NCT03329508|Drug|Pramipexole 0.6 mg|Pramipexole 0.6 mg oral extended release capsule, component
45912190|NCT03329508|Drug|Marketed Pramipexole ER|Marketed Pramipexole ER titrated to optimal dose of 1.5, 3 or 4.5 mg tablet
45764350|NCT00913913|Biological|DC vaccine|DC Vaccine therapy 10E7 intranodally every cycle
45764351|NCT00913913|Drug|Bevacizumab|Bevacizumab 10mg/kg iv every 2 weeks
45764352|NCT00913913|Biological|IL-2|IL-2 18 MiU/m2 CI 5 days
45764353|NCT00913913|Biological|IFN|IFN 6 MiU subc TIW
45764354|NCT00373594|Drug|Rituximab|
45764355|NCT00373594|Drug|Fludarabine|
45764356|NCT03403829|Drug|Gemcitabine|Gemcitabine maintenance chemotherapy
45764357|NCT03403829|Radiation|standard chemoradiotherapy|standard chemoradiotherapy
45912191|NCT03312556|Device|continuous positive airway pressure (CPAP)|Continuous positive airway pressure(CPAP) will be applied during the night starting from 20:00. CPAP level will be determined during an acute CPAP trial.
45621844|NCT03305549|Other|Conservative dialysis strategy|"Participants will receive RRT only when meeting 1 of the following indications (patterned after the AKIKI trial's delayed RRT initiation arm):~Blood urea nitrogen >112 mg/dL (40 mmol/L)~Serum potassium concentration >6 mmol/L~Serum potassium concentration >5.5 mmol/L despite medical treatment (e.g., bicarbonate, glucose-insulin infusion, albuterol, diuretics, sodium polystyrene sulfonate)~Arterial blood gas pH <7.15 in a context of pure metabolic acidosis (PaCO2 <35 mmHg) or in a context of mixed acidosis with PaCO2 50 mmHg despite medical treatment to reverse respiratory acidosis (e.g., naloxone), or in the absence of an available arterial blood gas, serum bicarbonate <12 mmol/L~Acute pulmonary edema due to fluid overload, responsible for hypoxemia requiring oxygen flow rate >5 L/min to maintain SpO2 >95% or requiring FiO2 >50% in patients already on invasive or non-invasive mechanical ventilation and despite diuretic therapy"
45621845|NCT03305549|Other|TIW dialysis strategy|Thrice-weekly acute intermittent hemodialysis schedule.
45621846|NCT03305471|Drug|DS-2330b PIB|DS-2330b as powder in bottle with stock solution (PIB)
45621847|NCT03305471|Drug|Placebo|Placebo matching stock solution in bottle
45621848|NCT03305471|Drug|Sevelamer|Sevelamer is a phosphate binder. It is used to decrease serum phosphate (Pi) level in people with chronic kidney disease who are on dialysis.
45621849|NCT03305471|Drug|DS-2330b Tablet|DS-2330b as tablet formulation
45621850|NCT03303677|Drug|Saline Nasal|topical nasal saline rinses
45621851|NCT03303677|Drug|Budesonide Nasal|saline + budesonide nasal saline irrigation
45621852|NCT03303677|Drug|Topical Antibacterial (Product)|The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole
45621853|NCT02468063|Drug|Low dose terlipressin|Terlipressin-2mg (low dose )
45621854|NCT02468063|Drug|Noradrenaline|Noradrenaline at 7.5 mcg/min, maximum of 60mcg/min. stepped up every 15 min
45621855|NCT02468063|Drug|Noradrenaline|Noradrenaline- 3.75 mcg/min to 30 mcg/min. stepped up every 15 min
45621856|NCT03305393|Device|Adaptiv CRT|Adaptiv CRT algorithm to be programmed to ON in CRT devices of study patients at 6 month follow-up visit
45621857|NCT03305315|Other|Measurements of jaw movement|Jaw mobility will be measured during simple movements of the mouth (opening the mouth, side-to-side and backwards-and-forwards movement of the jaw). These movements will be measured using a specific apparatus, part of which will be placed on the head like a helmet with the other part placed in the mouth and stuck to the teeth using a dental adhesive. The part in the mouth is specifically designed for this purpose. Measurements using this apparatus will take around 30 minutes.
46069310|NCT03013998|Drug|Azacitidine (BAML-16-001-S16)|75 mg/m2, IV or SC, on days 1 through 7 or days 1 through 5 and then 8 through 9 (based on institutional guidelines) of each 28-day cycle and continuing for 12 cycles in the absence of toxicity or disease progression
46069311|NCT03013998|Drug|Gilteritinib (BAML-16-001-S8 Group 1)|"120 mg, oral, daily, with treatment continuing based on bone marrow results at 28 and 56 days. Patients with partial response at 28 days continue treatment for an additional 28 days. Patients with complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) at 28 or 56 days continue treatment for 5 years until time of intolerance or disease progression. Patients with less than partial response at 28 days or partial response at 28 days followed by less than CR or CRi at 56 days proceed to combination treatment with decitabine or non-study alternative.~The combination dose is 80 mg, oral, daily, for 5 years until time of intolerance or disease progression (patients who do not achieve CR or CRi after 3 cycles will discontinue study treatment). The combination dose may be escalated to 120 mg daily or de-escalated to 80 mg daily given after decitabine rather than in combination with decitabine based on absence or occurrence of dose-limiting toxicity."
45621858|NCT03305315|Other|Measurement of natural electrical activity of facial muscles|Natural electrical activity of the facial muscles will be measured using electrodes placed on the skin.
45653368|NCT04989465|Biological|Investigational 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0·5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection
45653369|NCT04989465|Biological|Control 23-valent PPV|The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd. 25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0·5 mL of light disodium phenol phosphate, sodium hydrogen phosphate and sodium chloride per injection
45764358|NCT03233542|Behavioral|Cognitive Behaviour Therapy|Cognitive Behaviour Therapy (CBT) for diagnosed anxiety disorder (i.e. CBT for Panic Disorder in the Panic Disorder group, or other diagnosed anxiety disorders in the Anxious Control group.
45764359|NCT04355221|Procedure|pulsed radiofrequency|Pulsed radiofrequency of the trigeminal nerve using NeuroTherm NT 1100 RF generator device
45912192|NCT03312556|Drug|Placebo|Placebo pill or patch. Single dose
45912193|NCT03289039|Drug|Neratinib|Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2)
45764360|NCT03403673|Other|Frailty assessment tools|There is evidence to suggest that patients who are frail have a higher risk of developing complications after major surgery. Our aim is to ask you simple questions about your physical ability to perform daily life activities, assess your general health condition and ask you to do simple tasks such as drawing a clock or walking for a short distance to assess your speed of walking. Our main aim is to identify a tool that will assist us to identify patients who are at risk of frailty
45764361|NCT04364113|Other|Usual Protein Diet|The usual protein diet contains 1.30 g/kg/day protein and 16-20 mg/kg/day of Phosphorus
45764362|NCT04364113|Other|Low Protein Diet|The low protein diet contains 0.575 g/kg/day protein and 5-10 mg/kg/day of Phosphorus
45912194|NCT03289039|Drug|Fulvestrant|Fulvestrant, works in treating breast cancer that has spread to other parts of the body
46069312|NCT03013998|Drug|Decitabine (BAML-16-001-S8 Group 1)|20 mg/m2, IV, on days 1 through 10 of each 28-day cycle and continuing for up to 3 cycles. Treatment starts after 1-2 cycles of monotherapy with gilteritinib if patients do not attain complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) with monotherapy. Patients who do not achieve CR/CRi after 3 cycles of combination therapy will discontinue study treatment. If CR or CRi is obtained with combination therapy after 3 cycles, decitabine will be administered on days 1-5 of each subsequent 28-day cycle until progression, intolerance, or patient desire to discontinue therapy.
45446357|NCT03750591|Procedure|Bee venom pharmacopuncture|"Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test.~Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26gauze(G) x 1.5 syringe, Shinchang medical co., Korea)."
45446358|NCT03750591|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26gauze(G) x 1.5 syringe, Shinchang medical co., Korea).
45446359|NCT03750591|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
45446360|NCT03750591|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
45446361|NCT03750591|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
45446362|NCT03750591|Other|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
45446363|NCT03747861|Device|SenceBand|Wristband for registration of ECG RR intervals for one hand, SenceBand will collect data from 5-minutes intervals each 30 minute within 24 hours
45446364|NCT01369498|Drug|Simtuzumab|Simtuzumab administered intravenously over approximately 30 minutes every 2 weeks
45621859|NCT03303365|Radiation|stereotactic radiosurgery (SRS)|"All patients will receive a pre-treatment cranial MRI for diagnostic and treatment planning purposes.~In Arm A, the contrast-based T1-weighted SPACE sequence is utilized for GTV definition. In Arm B, the contrast-based T1-weighted three-dimensional MPRAGE sequence is utilized for GTV definition. In both cases the GTV consists of all contrasted tissue associated with the target lesion and all additional tissue judged by an experienced physician to be part of the suspect target lesion. To the GTV a PTV margin of 1 mm is added by isotropic expansion that can be slightly modified if deemed necessary by the treating physician (e.g. intersection with adjoining OAR).~Dose prescription to the PTV for target lesions will be as follows:~20 Gy to the 70%-isodose (lesions < 2 cm max. diameter)~18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)~6 x 5 Gy to the conformally surrounding isodose (lesions > 3 cm max. diameter)"
45621860|NCT04490681|Drug|Ertugliflozin|Fixed dose Ertugliflozin (5mg)
45621861|NCT04490681|Drug|Placebo|Placebo group
45621862|NCT04491305|Procedure|Surgically treated women with endometriosis and confirmed diagnosis|Women with indication for surgery or diagnostic laparoscopy will be enrolled in study.
45764363|NCT04364113|Other|Very Low Protein Diet|The very low protein diet contains 0.28 g/kg/day or protein, mg/kg/day of Phosphorus and a keto acid mixture.
45912195|NCT03281304|Drug|CP-690,500 5 mg|CP-690,550 5 mg tablet BID
45912196|NCT03281304|Drug|CP-690,550 10 mg|CP-690,550 10 mg tablet BID
45912197|NCT03204305|Drug|11C-OMAR|11C-OMAR is a PET radiotracer that binds to cannabinoid type 1 receptors (CB1R). It is an analog of the CB1R antagonist/inverse agonist rimonabant. 11C-OMAR was developed, synthesized and validated for inhuman use at the Johns Hopkins University PET center.
45446365|NCT01369498|Drug|Ruxolitinib|In Stage 2, participants will be on a stable dose of ruxolitinib
45446366|NCT03756987|Drug|Ropivacaine Injection|Ropivacaine will be injected in the erector spinae plane
45446367|NCT03756987|Drug|Normal saline|Normal saline will be injected in the erector spinae plane.
45446368|NCT02072746|Dietary Supplement|Zinc|
45446369|NCT02072746|Dietary Supplement|Placebo|
45446370|NCT04940338|Drug|Bromfenac Ophthalmic 0.09% Ophthalmic Solution|topical bromfenac (0.9 mg/mL) 2x daily 7 days before the surgery
45446371|NCT04940338|Drug|Dexamethasone Ophthalmic|topical dexamethasone (1 mg/mL) 2x daily 7 days before the surgery
45764364|NCT04364113|Drug|Medications needed to maintain usual blood pressure|The MAP goal for the usual blood pressure group is <=107 mm Hg for ages 18-60 and <=113 for ages 61+. Pharmacological and non-pharmacological therapies will be used to achieve the desired blood pressure values. The recommended anti-hypertensive regimen is a angiotensin-converting-enzyme inhibitor with or without a diuretic agent; a calcium-channel blocker or other medications can be added as needed.
45764365|NCT04364113|Drug|Medications needed to maintain low blood pressure|The MAP goal for the low blood pressure group is <=92 mm Hg for ages 18-60 and <=98 for ages 61+. Pharmacological and non-pharmacological therapies will be used to achieve the desired blood pressure values. The recommended anti-hypertensive regimen is a angiotensin-converting-enzyme inhibitor with or without a diuretic agent; a calcium-channel blocker or other medications can be added as needed.
45621863|NCT03303287|Behavioral|School health education|School health education program in Pakistan(SHEPP): The health education program will be directed towards children, parents and teachers
45621864|NCT03305237|Other|Big Breakfast|Weight loss diet (Calories fed to measured RMR) with calories distributed predominantly at breakfast (percent daily calories split between breakfast, lunch and dinner as 45-35-20%). The diet will be high protein (30% protein, 35% fat and 35% CHO) with all meals provided.
45621865|NCT03305237|Other|Big Dinner|Weight loss diet (Calories fed to measured RMR) with calories distributed predominantly at dinner (percent daily calories split between breakfast, lunch and dinner as 20-35-45%). The diet will be high protein (30% protein, 35% fat and 35% CHO) with all meals provided.
45764366|NCT03403595|Drug|177Lu-EB-PSMA-617|accepted intravenous injection of 177Lu-EB-PSMA-617 and monitored at 2, 24, 72, 120 and 168 hours post-injection.
45764367|NCT04354987|Drug|CKD-391 10/10mg|Drug T: CKD-391 10/10mg(Other Name: Test Drug)
45764368|NCT04354987|Drug|D090, D337|D090 and D337 co-administration(Other Name: Reference drug)
45764369|NCT03835091|Other|BRASS score|Brainstem response on neurologic examination
45621866|NCT03305003|Other|Spiral notebook|
45621867|NCT03305003|Other|Mobile application|
45621868|NCT03303209|Other|Patient-centered opioid tapering protocol|All patients who entered the study agreed to partner with their pain physician on a patient-centered opioid tapering program. The research component of the study was to observe patient response (in terms of change in MEDD and pain intensity) at month 4.
45621869|NCT03303131|Other|Discharge from community-based management|Comparison of patient characteristics and treatment outcomes between two groups
45764370|NCT03197194|Drug|Alteplase|alteplase administered as an intravenous infusion (0.9 mg/kg; maximum dose 90 mg): 10% given as an IV bolus, followed immediately by the remaining given as an IV infusion over 1 hour.
45764371|NCT03197194|Drug|acetylsalicylic acid|one tablet of aspirin 300 mg
45621870|NCT03303053|Drug|Cholestyramine Powder 4g|Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
45621871|NCT03303053|Drug|Prednisolone|Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
45621872|NCT03303053|Drug|Standard treatment|Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
45621873|NCT05728073|Procedure|ERCP|Patients separated to two groups according to having a ERCP history before the operation
45621874|NCT03302897|Biological|LEP-F1 + GLA-SE|Investigational vaccine
45621875|NCT05727995|Device|PICO7|"The use of PICO is contraindicated in the presence of:~Patients with malignancy in the wound bed or margins of the wound~Previously confirmed and untreated osteomyelitis~Nonenteric and unexplored fistulas~Necrotic tissue with eschar present~Exposed arteries, veins, nerves or organs~Exposed anastomotic sites~Emergency airway aspiration~Pleural, mediastinal or chest tube drainage~Surgical suction."
45621876|NCT05727995|Other|usual care dressing|usual care dressing
45621877|NCT02467907|Drug|Bevacizumab|Intravenous (i.v.) administration of 15 mg/kg bevacizumab once every 3 weeks
45621878|NCT02467907|Drug|Carboplatin|Administration of carboplatin at 5 milligrams per milliliter*minute (mg/mL*min) on Day 1 every 3 weeks for at least 6 cycles
45621879|NCT02467907|Drug|Paclitaxel|Administration of paclitaxel at a dose of 175 milligrams per square meter (mg/m^2) on Day 1 every 3 weeks for at least 6 cycles
45621880|NCT02467283|Genetic|Genom-based whole-genome transcriptomic|Gene expression profiling is a powerful means of generating comprehensive genome-level data sets.
45621881|NCT02467127|Dietary Supplement|vitamin D supplementation|In patients with headache and with low vitamin D plasma levels, will be administered a vitamin D supplementation.
45764372|NCT03197194|Drug|Placebo Oral Tablet|One placebo oral tablet which doesn't contain the active ingredient acetyl salicylic acid
45764373|NCT03197194|Drug|placebo IV|IV saline solution (0.9 %):10 mL in a syringe administered over 1 minute, followed by 50 mL as an infusion over 1 hour
45764374|NCT03834935|Drug|Elidel (pimecrolimus 1%)|topical application of product on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
45764375|NCT03834935|Drug|Cold Cream|Topical application on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
45764376|NCT01724255|Other|questionnaire|
45764377|NCT02796352|Drug|High dose bolus interleukin-2 (HD IL2)|"Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second cycle).~The planned treatment consists of 3 courses (6 cycles) of HD IL-2."
45764378|NCT00939367|Drug|Zolpidem Tartrate Tablets 10 mg|
45764379|NCT00939367|Drug|'Sanofi-Synthelabo Inc's Ambien® Tablets 10 mg|
45764380|NCT03168880|Drug|Paclitaxel + Carboplatin|Platinum based chemotherapy against the standard taxane based chemotherapy in the neo- adjuvant setting
45764381|NCT03168880|Drug|Paclitaxel only|
45621882|NCT03302819|Diagnostic Test|MARIA scan|The patient will have an additional MARIA scan along with conventional imaging, pathology and surgical procedures.
45764382|NCT04347187|Drug|Anticoagulants|oral anticoagulants, dual or triple antithrombotic theraphy
45621883|NCT02466893|Other|Adapt/Standard Stent Retriever (SR) Group|If the patient is randomized to mechanical thrombectomy, the groin puncture to initiate the procedure should occur within 1 hour of the clinical imaging used to determine trial candidacy. An introducer sheath will be placed in the femoral artery. Diagnostic angiography is initially performed via the transfemoral approach with catheterization of the carotid artery appropriate to the patient's presenting symptoms. Once thrombus in the appropriate vessel is identified, the thrombectomy procedure will be initiated.
45764383|NCT01724411|Other|Resistant Starch type 3|Resistant Starch 3: 26g/day males for 11 days, 22 g/day females for 11 days
45764384|NCT02797054|Behavioral|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
45912198|NCT03204305|Drug|Cannabis|Cannabis will be administered to cannabis users. Doses include 0 and 25 mg THC.
45621884|NCT05727917|Drug|Hetrombopag|After hematopoietic stem cell reinfusion, the patients begin to take hetrombopag orally 7.5mg/d, until the patients reach complete platelet response.The treatment will stop when patients accept 21 consecutive days of treatment or reach the discontinuation criteria.
45621885|NCT05727917|Other|placebo|After hematopoietic stem cell transfusion, the patients will be only observed, and the observation during the treatment period will be ended after 30 days
45446372|NCT04940338|Drug|Placebo|topical placebo (artificial tears substitute) 2x daily before the surgery
45621886|NCT03302663|Diagnostic Test|MRI scan|Addition of advanced imaging sequences for fetal MRI
45621887|NCT03302585|Drug|Vitamin D3|50,000 IU/d of oral vitamin D3 x 5 days followed by 10,000 IU/d of oral vitamin D3 x 85 days
45621888|NCT03302585|Drug|Placebo/Standard of Care Vitamin D3|50,000 IU/d of oral vitamin D3 x 5 days followed by 40,000 IU/d of oral vitamin D3 x 85 days
45446373|NCT04940338|Procedure|Phacoemulsification surgery (PHACO)|About 0.1-0.2 mL of aqueous humor will be collected at the beginning of the cataract surgery (PHACO) through paracentesis, aqueous will then be transported in dry ice with a dedicated box to the laboratory and stored at -80C until the analysis. IL6 concentration will be analyzed with Human IL6 Quantikine Elisa kit (R&D System).
45621889|NCT02898233|Other|Deprexis|Deprexis is an experimental internet-based treatment program for depression created by Gaia (Hamburg, Germany).
45764385|NCT02797054|Behavioral|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
45764386|NCT02797054|Behavioral|Usual care|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
45764387|NCT00920075|Drug|Alendronate (Fosamax)|Pill, 35mg or 70mg depending upon the body weight for 12 months. This was given for participants during the open label or double blind study. Current study is a post study evaluation of the current status of bone density after the participants completed the study. In this post study, no treatment is involved.
45764388|NCT04364035|Biological|ChAdOx1.HTI|ChAdOx1.HTI at week 0 and week 12; Vaccine delivered as one 0. 5 mL IM injection
45764389|NCT04364035|Biological|MVA.HTI|MVA.HTI at week 24 and week 36; Vaccine delivered as one 0. 5 mL IM injection
45764390|NCT04364035|Drug|GS-9620|GS-9620 at week 26,28,30,32,34,38,40,42,44 and 46 Unit-dose tablet, delivered as two 3-mg tablets
45764391|NCT04364035|Biological|Placebo|Saline placebo delivered as one 0. 5 mL IM injection
45912199|NCT03200717|Drug|Pazopanib|Participants received 800mg of pazopanib once daily orally. Pazopanib was supplied as aqueous film-coated tablets containing 200 mg or 400 mg.
45446374|NCT04709835|Drug|AT-527|Results from Arm AT-527 500 mg determined the dose and regimen to be used for AT-527 1100 mg.
45621890|NCT02898233|Device|Active low-level light therapy|Administration of LLLT consists of applying light of a specific wavelength (1064 nanometers) that intersects with the absorption spectrum of cytochrome oxidase, using a laser diode, the high density laser (HD laser; Cell Gen Therapeutics, LLC). Active LLLT includes 4 days, once per week for 4 weeks, during which LLLT is applied to two alternating positions on the participant's right forehead for 8 minutes total.
45621891|NCT02898233|Device|Sham low-level light therapy|Administration of LLLT consists of applying light of a specific wavelength (1064 nanometers) that intersects with the absorption spectrum of cytochrome oxidase, using a laser diode, the high density laser (HD laser; Cell Gen Therapeutics, LLC). Sham LLLT includes 4 days, once per week for 4 weeks, during which sham LLLT (5 seconds active, 55 seconds sham) is applied to two alternating positions on the participant's right forehead for 8 minutes total.
45621892|NCT03302507|Procedure|BESS|Biportal endoscopic surgery
45621893|NCT03302507|Procedure|ULBD|Unilateral laminotomy bilateral decompression
45621894|NCT03302429|Other|PRF/ BCP|Platelet rich fibrin combined with biphasic calcium phosphate(experimental group)
45621895|NCT03302429|Other|Autogenous bone graft|Bone obtained from the same individual who receiving the graft
45621896|NCT05727761|Drug|pioglitazone-metformin|Treatment with pioglitazone-metformin (15mg/500mg) twice a day for 12 weeks
45621897|NCT04871477|Other|Communication Intervention|Audio record part of clinic visit
45621898|NCT04871477|Other|Questionnaire Administration|Ancillary studies
46069313|NCT03013998|Drug|AZD5153 (BAML-16-001-S10)|20 mg, oral, once daily during 7-day lead-in and then on days 1 through 21 of each 28-day cycle for up to 2 years or until allogeneic stem cell transplantation, time of intolerance, or disease progression [if the continuous administration AZD5153 on Days 1-21 of a 28-day cycle is not tolerated, an alternative schedule of 2 weeks on and 2 weeks off (i.e. AZD5153 will be administered on Days 1-14 of a 28-day cycle) will be explored]. Dose may be de-escalated to 10 mg or escalated to 30 mg based on occurrence of dose-limiting toxicity during phase 1 dose escalation. Starting with Cycle 2, patients may receive concomitant fluconazole, isavuconazole, or posaconazole and doses adjusted to 2, 5, or 8 mg daily. The Phase 1b expansion pharmacokinetics cohort will allow for posaconazole starting at Cycle 1 with AZD5153 dose adjusted from 10, 20, or 30 mg daily to 2, 5, or 8 mg daily. Phase 2 dose will be based on Phase 1 results.
46069314|NCT03013998|Drug|Venetoclax (BAML-16-001-S10)|400 mg, oral, on days 1 through 21 of each 28-day cycle and continuing for up to 12 cycles (for Cycle 1, day 1 dose will be 100 mg, day 2 dose 200 mg, and days 3 onward 400 mg). Starting with Cycle 2, patients may receive concomitant fluconazole or isavuconazole and daily doses adjusted to 200 mg, or posaconazole and daily doses adjusted to 70 mg. The Phase 1b expansion pharmacokinetics cohort will allow for posaconazole starting at Cycle 1 with Venetoclax dose adjusted to 10 mg on day 1, 20 mg on day 2, 50 mg on day 3, and 70 mg on day 4 onward).
45621899|NCT03302351|Drug|Dexmedetomidine|30 patients will receive intravenous dexmedetomidine 1 mcg/kg.
45912200|NCT03191578|Drug|RUTI®|Administration of RUTI®
45621900|NCT03302351|Drug|ketamine|31 patients will receive intravenous ketamine 0.4 mg/kg.
45621901|NCT03302351|Drug|Dexmetedomidine+Ketamine|33 patients will receive combination between intravenous dexmedetomidine 0.5mcg/kg + low dose ketamine 0.25mg/kg.
45621902|NCT04866563|Drug|AX-8|orally disintegrating tablets, BID
45621903|NCT04866563|Drug|Placebo|orally disintegrating tablets, BID
45621904|NCT04862351|Behavioral|exercise training for TechCR|3 times of supervised exercise training at the centre-based, outpatient cardiac rehabilitation clinic
45621905|NCT04862351|Behavioral|audio/video conference|weekly audio/video conference
45764392|NCT04364035|Drug|Placebo Oral Tablet|Unit-dose placebo tablet delivered as two 3-mg placebo tablets
45621906|NCT04862351|Behavioral|educational video|weekly for 6 weeks, duration of video about 10-15 minutes
45621907|NCT04862351|Behavioral|Daily log|daily dietary and exercise log
45621908|NCT04862351|Behavioral|exercise training for centre-based|6 times of supervised exercise training
45621909|NCT05727683|Biological|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|Subjects will receive Lymphodepleting chemotherapy with intravenous (IV) fludarabine (25 mg/m2/day for 3 days) plus cyclophosphamide IV (250 mg/m2/day for 3 days) (flu/cy) concurrently, followed by JWCAR029 cells infusion. Phase 1 will evaluate up to 4 JWCAR029 cells dose levels.
45621910|NCT03302117|Other|Wood smoke exposure|Healthy volunteers will exposed to filtered air alternate with wood smoke generated from incomplete wood smoke combustion to assess the local and systemic effect of theses exposures
45621911|NCT02881307|Dietary Supplement|Whey Protein&Prebiotic Supplement|Dietary supplement (protein drink) commercially available protein shakes
45621912|NCT02881307|Behavioral|Dietary Counseling|Dietary Counseling
45621913|NCT02881307|Behavioral|Dietary recommendations|recommendations for one meal per day including lean protein and vegetables
45621914|NCT03302039|Drug|Single shot phenylephrine|A single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously.
45621915|NCT03302039|Drug|Fixed infusion phenylephrine.|Fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min
45764393|NCT00920231|Device|initial system|The computer vision system is used to assist blind subject to navigate an extended path with multiple turns within a hospital setting.The initial prototype system would have been successfully tested for outdoor navigation and basic object recognition tasks.
45764394|NCT00920231|Device|modified system|The problems associated with the initial system were identified and modified. This modified system was tested with a second separate group of subjects. The redesigned system is used to assist blind subject to navigate the same extended path with multiple turns within a hospital setting.
45764395|NCT04737538|Other|Experimental Dentrifrice|Toothpaste containing sodium bicarbonate, sodium hyaluronate and sodium fluoride
45912201|NCT03191578|Drug|Placebo|Administration of placebo
45764396|NCT04737538|Other|Positive control dentifrice|Dentifrice containing 67% w/w sodium bicarbonate and 0.221% w/w sodium fluoride
45764397|NCT04737538|Other|Negative control dentifrice|Dentifrice containing 1100ppm fluoride as sodium fluoride (Crest Cavity Protection)
45621916|NCT03302039|Drug|Variable infusion phenylephrine.|Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.
45764398|NCT03403439|Drug|BI 1015550|Reference and Test Treatment
45446375|NCT04709835|Drug|Placebo|The dose and regimen of the placebo will match that of the respective AT-527 comparator arm.
45446376|NCT02083510|Drug|Colchicine|
45621917|NCT03302039|Drug|Bupivacaine|Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia.
45764399|NCT03403439|Drug|itraconazole|Test treatment
45764400|NCT04346797|Drug|Eculizumab|"Intravenous administration as follows:~Induction dosage regimen at 1200 mg on Days 1, 4, 8 then 1200 mg or 900 mg on Day 12 depending on the monitoring of Eculizumab Plasma Level and CH5O and sC5B9 and maintenance doses of 900 mg on Days 15, 18 and 22"
45764401|NCT02798380|Drug|HTS-519 Insert|Maximum feasible dose of HTS-519 Insert per diseased nail
45764402|NCT04377815|Other|General Public cohort|No intervention is being tested
45764403|NCT04355065|Behavioral|Cognitive Traning with The Secret Trail of Moon|Patients are pharmacologically stable and receive a cognitive intervention with our videogame once a week in the hospital.
45764404|NCT04355065|Behavioral|Cognitive Traning with Therapeutic Chess|This group is pharmacologically stable. This group performs cognitive training through a therapeutic chess protocol designed by a chess psychologist. The training is done from home and we contact them weekly to correct the exercises done and to follow up.
45912202|NCT03183713|Behavioral|Cognitive Behavioral Therapy|Psychologically symptomatic patients will then be randomized to 4-8 weeks of placebo phone calls (Group PS-PL-Sx) or 4-8 weeks of cognitive behavior therapy treatment (PS-CBT-Sx) based on a 1:1 randomization ratio. Subjects randomized to receive CBT before surgery will proceed to 6 sessions given within 4-8 weeks by a licensed psychologist specializing in pain. CBT sessions will be 30 minutes in length, and focus on empirically supported behavior management, problem solving, cognitive restructuring, and relaxation training. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone.
45912203|NCT03183713|Behavioral|Sham Therapy|Study nurse will conduct six sessions (30 minutes/ session) over a 4-8 week time period. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone. Sham sessions will entail how to prepare for surgery and expectations for recovery, and will go over content that the treatment and control groups will receive in handout form.
46069315|NCT03013998|Drug|TP-0903 (BAML-16-001-S14)|37 mg, oral, once daily on days 1 through 21 of each 28-day cycle for up to 2 years to time of intolerance or disease progression. Dose may be de-escalated to as low as 12 mg or escalated to 50 mg based on occurrence of dose-limiting toxicity during Phase 1 dose escalation. Phase 2 dose will be based on Phase 1 results.
45446377|NCT02083588|Device|dTMS|All subjects will receive prefrontal deep rTMS of H1 Coil (75 trains of 2 seconds, 20 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold, a total of 3000 pulses per session), for 4 weeks, 5 days a week, overall 20 sessions.
45446378|NCT02073058|Device|No treatment|
45446379|NCT02083666|Drug|SOBI002|Test Product
45446380|NCT02083666|Drug|Placebo|Reference product
45446381|NCT02083744|Behavioral|PsychoEducational Support|
45446382|NCT02083744|Behavioral|Usual Care|Standard Heart Failure Care
45446383|NCT04407507|Drug|Ivermectin|ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days
45446384|NCT04407507|Drug|Placebo|Placebo of ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days
45446385|NCT02073136|Other|Diet with phosphate containing additives|
45446386|NCT02073136|Other|Diet without phosphate containing additives|
45446387|NCT02073214|Other|Probiotic|Standard treatment plus probiotic
45621918|NCT02467205|Other|pedometer supported walking and education|"A Physical activity; pedometer will be given to each person in the intervention group at the first education session. Participants will be encouraged to use the pedometer for a 6 month period.~The strength exercises will be performed at home. Education will incorporate the behavioural change techniques (BCTs) known to be effective in increasing physical activity (Goal setting,Self-monitoring of behaviour,Feedback on outcomes of behaviour,Problem solving,Relapse Prevention (RP) and social support)."
45621919|NCT03301727|Other|Cognitive-Behavioural Therapy for Insomnia (CBT-I)|Cognitive-Behavioural Therapy for Insomnia (CBT-I) is an evidence-based psycho-therapeutic intervention, combining cognitive and behavioural principles to provide psycho-education concerning contributing thoughts to sleep problem maintenance, and behavioural technique instruction to reduce sleep onset latency and promote effective sleep maintenance.
45764405|NCT04355065|Drug|Control Group|"These patients continue their stable pharmacological treatment and do not receive any additional cognitive intervention.~They are contacted weekly by phone to follow up on the group."
45764406|NCT03403127|Diagnostic Test|PET/CT Scans|PET Imaging requires the use of an investigational drug, a radioactively-labelled sugar called 18F-Fluorodeoxyglucose (FDG). FDG is glucose labelled with a radioactive fluorine atom. It is given by intravenous injection and is particularly absorbed by cancer cells. The radioactive signal given off by the FDG can then be detected by the PET scanner providing an image of the cancer (or tumour).
45621920|NCT02721875|Drug|Volasertib|
45764407|NCT02917642|Device|Ultrasonic Irrigation|Passive Ultrasonic Irrigation is based on the transmission of acoustic energy through the irrigant by a stainless steel wire or endodontic file
45621921|NCT02721875|Drug|Volasertib|
45764408|NCT02917642|Device|Non-Ultrasonic Irrigation|Syringe and needle irrigation with no-ultrasonic activation
45621922|NCT02721875|Drug|Azacitidine|
45764409|NCT04364581|Drug|Letrozole|Women will be treated with letrozole (5 mg daily) for 10 days before hysteroscopic intervention
45912204|NCT03153319|Drug|Adalimumab Injection [Humira]|Investigational Drug
45912205|NCT03153319|Drug|Saline Solution for Injection|Placebo Comparator
45446388|NCT02073214|Other|Placebo|Standard treatment plus placebo
45446389|NCT04698993|Diagnostic Test|Dräger Antigen Test SARS-CoV-2|Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test
45621923|NCT03301571|Other|Change in preload and afterload|Afterload: Three levels of positive end-expiratory pressure (PEEP) will be examined post-operatively: 0 cm H20, 5 cm H2O, 10 cm H2O Preload: Trendelenburg position for 5 minutes will be investigated
45764410|NCT04364581|Drug|Placebo|Women will be treated with placebo for 10 days before hysteroscopic intervention
45764411|NCT04363723|Other|Pulmonary Rehabilitation|Patients performed a comprehensive pre-lung transplant inpatient pulmonary rehabilitation program for 4 to 5 weeks duration.
45764412|NCT01049009|Drug|Nebivolol|"Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug."
45764413|NCT01049009|Drug|Metoprolol XL|"Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug."
45764414|NCT04363645|Other|Multicontext (MC) approach|The Multicontext approach is a metacognitive intervention designed to improve awareness, strategy use, and executive functioning.
45764415|NCT02918656|Other|Infographic presentation of health information|"The students in this group will read Cochrane systematic review summary in infographics format.~Infographics format is a form of visual presentation of results of systematic review, supported by pictures and graphs."
45764416|NCT02918656|Other|PLS presentation of health information|The students randomized in PLS group will read text format with simple explanation of the survey topic main findings which is intended for lay audience.
45912206|NCT03145272|Drug|Oxycodone|A single weight-adjusted oxycodone dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines
45452338|NCT05247502|Biological|Data observation|At the time of participant inclusion in the study, demographic data and a baseline serum creatinine measurement will be collected. During the patient's ICU stay, the occurrence and duration of any AKI episode will be recorded. Data related to diagnostic examinations of these AKI episodes will also be collected in accordance with practices guidelines. Data related to AKI monitoring will also be collected, including serum creatinine and urea daily follow-up measurements, diuresis, and nephrotoxic use. The patient's need for extrarenal epuration or use of catecholamines will also be recorded. In the 3-month and 12-month.
45621924|NCT03301571|Other|Inspired oxygen|Following fractions of inspired O2 will be investigated: 0.5 and 1.0 for 10 minutes respectively
45621925|NCT03301571|Other|Pacemaker mode|Following pacemaker settings will be investigated: Atrioventricular pacing 10 bpm over the patients' intrinsic rhythm, atrial pacing 10 bpm over the patients' intrinsic rhythm, ventricular pacing 10 bpm over the patients' intrinsic rhythm
45621926|NCT02466503|Drug|Fluticasone propionate|Inhaled corticosteroid, pMDI
45621927|NCT02466503|Drug|Salmeterol (as xinafoate)|Beta-agonist, LABA, pMDI
45621928|NCT03301259|Other|One-shape rotationary system|OneShape (MICRO-MEGA) rotary nickel-titanium use roation movement and available in two sizes N°30 - .06 rotary files. , N°25 - .06
45621929|NCT04839029|Procedure|Bipolar En bloc TURBT|patients subjected to Bipolar resection of bladder tumor by Collins loop
45621930|NCT04839029|Procedure|Monopolar En bloc TURBT|patients subjected to Monopolar resection of bladder tumor by Collins loop (hot Knife)
45621931|NCT03301181|Drug|BGB-3111 (Arm A)|320 mg BGB-3111 single oral dose
45912207|NCT03127007|Drug|Atezolizumab|Atezolizumab is given on day 1 of week 3, 6, 9 and 12 at 1200 mg IV.
45912208|NCT03127007|Drug|5-FU based radio-chemotherapy|IV protracted 5-FU given at 225mg/m2 over 24h 5 days/week for 5 weeks associated to radiotherapy.
45912209|NCT03119233|Device|PQ Bypass System|Intended use from CLN114 Rev F (CLN114 is the DETOUR2 protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm (TASC D) that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis (complex TASC C).
45912210|NCT03116139|Diagnostic Test|V/Q imaging|Standard of care
45912211|NCT03116139|Diagnostic Test|Computed tomography scan|Standard of care
45621932|NCT03301181|Drug|Rifampin|600 mg rifampin once daily
45621933|NCT03301181|Drug|BGB-3111 (Arm B)|Up to 80 mg BGB-3111 single oral dose
45764417|NCT02918656|Other|Scientific abstract presentation of health information|The students in scientific abstract group will read the the text written for the academic population and practitioners.
45621934|NCT03301181|Drug|Itraconazole|200 mg itraconazole once daily
45621935|NCT02721251|Behavioral|Exercise|16 weeks. 4 days per week of aerobic exercise; 45 min for 2 days and for 30 min for two days. 2 days per week of resistance exercise for 15 min (coinciding with the days involving 30 min of aerobic exercise)
45621936|NCT02721251|Behavioral|Weight Loss|16 week. the goal is 10% weight loss.
45621937|NCT02721251|Behavioral|Exercise + Weight Loss|Combined exercise and weight loss components of the other arms
45621938|NCT03301103|Biological|E. coli strain E1392-75-2A|After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14).
45621939|NCT03301103|Device|PTM202|PTM202 is a dietary formula containing a proprietary mixture of dried bovine colostrum and dried whole egg.
45764418|NCT02850874|Procedure|Hyperthermic intraperitoneal chemotherapy|HIPEC in this study involves the washing of the peritoneal cavity with a heated (40-48°C), (1000 mg/m sq) solution of gemcitabine in 1.5% dextrose for 90 min. Compared with systemic delivery of chemotherapy, intraperitoneal delivery can increase site-specific concentration of chemotherapeutic agents and decrease duration of perfusion, vascular complications, and systemic toxicity. The use of heated chemotherapeutic agents, compared to conventional protocols, has been shown to increase direct cytotoxicity to malignant cells and augment penetration into tumors.
45764419|NCT02850874|Procedure|Open pancreaticoduodenectomy|"Tumors of the pancreatic head will be surgically removed by open PD (standard and pylorus-preserving approaches) with the aim of achieving en bloc R0 tumor resection (no macroscopic residual cancer remaining). In all patients, a lymphadenectomy will be performed along the hepatoduodenal ligament, common hepatic artery, vena cava, and the interaortocaval and right side of the superior mesenteric artery. In cases with portal vein involvement, a venous resection will be performed to achieve R0 resection. Patients with arterial infiltration by the tumor will be deemed locally nonresectable and will be excluded from analysis.~Established, routine surgical and ERAS protocols will be followed for pre-, intra-, and postoperative care of patients. Patients will be discharged after postoperative day 5 if tolerating oral intake and showing no signs or symptoms of complications."
45764420|NCT02850874|Drug|Gemcitabine|Neoadjuvant and adjuvant systemic chemotherapy will be administered to all PDAC patients with the aim of diminishing the tumor burden and maximizing the chance of complete surgical resection. Gemcitabine (GEMZAR®) will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional guidelines for dosing, frequency, duration, administration route, and setting.
45764421|NCT01047683|Drug|AMR101 (ethyl icosapentate) - 4 g/day|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks (Weeks 1-12)
45446390|NCT02080624|Drug|Drug: Topical Rapamycin|"After signing this consent form, you will be asked to undergo some screening tests or procedures to find out if you can be in the research study.~A medical history, which involves questions about your health history, any medications you are taking or plan to take, any allergies and the treatments you received for your CM.~A physical exam, during which you will be asked about any problems that you might be having. Additionally, your clinician will check your vital signs (blood pressure, heart rate, weight and height). The doctor will also evaluate your performance status, which indicates how much your illness affects your activity level.~Blood tests, which will be done to make sure your hemogram, triglyceride and cholesterol levels are normal.~A pregnancy test for females will be done to check that you are not pregnant. If theses tests show that you are eligible to participate in the research study, you will begin the study treatment."
45446391|NCT02080702|Device|Monosyn|Monosyn will be used to perform the gastrointestinal anastomoses
45446392|NCT01562457|Drug|activated recombinant human factor VII|Administered as a single dose. Injected as a slow intravenous injection over 2 minutes (from start to completion of injection)
45452339|NCT00033371|Drug|Celecoxib|Given 400 mg PO twice a day
45452340|NCT00033371|Other|Placebo|Given PO to match DFMO
45621940|NCT00702221|Biological|Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant|Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant given as 3 separate intramuscular injections into the arm, 21 days apart
45621941|NCT00702221|Biological|CoVaccine HT™ adjuvant|Given as three separate intramuscular injections into the arm, 21 days apart
45621942|NCT05726981|Procedure|Fine needle aspiration biopsy (FNAB)|"Thyroid FNAB is a minimally invasive procedure performed routinely by an experienced sonographer.~It is a safe and brief procedure, performed with a 27G or 25G (very fine) needle (3 needles, i.e. 1 needle per pass)"
45621943|NCT03301025|Drug|Pregabalin|Pregabalin 150 mg capsule, one h preinduction of general anesthesia
45621944|NCT03301025|Drug|placebo|given a placebo identical capsule once one hour before anesthesia
45621945|NCT05726903|Drug|Depo-subQ Provera Injectable Product|SC Injection at Home
45621946|NCT05726825|Device|Therapeutic Plasma Exchange (TPE)|"The TPE treatment will be initiated within 6 hrs after randomization. Duration of TPE treatment is approximately 120-180 minutes. An additional second TPE can be performed if the patient remains vasopressor dependent ≥ 0.4 ug/kg/min after 24 hours following the first TPE procedure.~Both unfractionated heparin (UFH) and citrate may be used as anticoagulant medication.~To ensure treatment comparability between different patients, we will replace plasma in a fixed ratio of 1.2 x the individual patient's total plasma fluid."
45621947|NCT03300791|Other|Admitted|Readmitted patients in the next months after an episode of aute heart failure will be recruited. Controls will be selected between those who were admitted in the baseline but not readmitted in this month.
45621948|NCT05726747|Diagnostic Test|Quality of Life surveys|QoL and sarcopenia assessments
45621949|NCT03300635|Other|Mental distress and relaxation test|
45621950|NCT03300635|Other|Glucose tolerance test|
45621951|NCT03300635|Other|Exercise test|
45621952|NCT05726513|Diagnostic Test|Weaning trial - Low support, high Positive end-expiratory pressure|The researcher will evaluate the readiness to be weaned of the patient using a weaning trial with low pressure support ventilation and a positive end expiratory pressure of 5 cmH2O
45764422|NCT01047683|Drug|AMR101 (ethyl icosapentate) - 2 g/day|AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks (Weeks 1-12)
45764423|NCT01047683|Drug|Placebo|Placebo 4 capsules/day for 12 weeks (Weeks 1-12)
45764424|NCT02919826|Behavioral|Adapted Dialectical Behaviour Therapy|12 weekly sessions of DBT group therapy
45764425|NCT02920918|Drug|Canagliflozin|
45621953|NCT05726513|Diagnostic Test|Weaning trial - Low support, zero positive end-expiratory pressure|The researcher will evaluate the readiness to be weaned of the patient using a weaning trial with low pressure support ventilation and a positive end expiratory pressure of 0 cmH2O
45764426|NCT02920918|Drug|Sitagliptin|
45912212|NCT03113201|Behavioral|Collaborative care|Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation and medication according to a stepped care model
45912213|NCT03113201|Behavioral|Consultations-Liaison|Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
45912214|NCT03113175|Behavioral|Collaborative care|Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation, medication according to a stepped care model
45912215|NCT03113175|Behavioral|Consultations-Liaison|Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
45446393|NCT03747783|Procedure|Radical Operation|The surgery treatment selection was based on the American Joint Committee on Cancer stage both of the primary and of the recurrence, as well as on patterns of local spread that were not included in the T classification and on the general condition and preferences of each patient.
45446394|NCT02083822|Procedure|term MRI, executive EF functions testing|An MRI will be realized at term born between 25 and 32 weeks GA
45621954|NCT05726513|Diagnostic Test|Weaning trial - Zero support, zero positive end-expiratory pressure|The researcher will evaluate the readiness to be weaned of the patient using a weaning trial with 0 pressure support ventilation and a positive end expiratory pressure of 0 cmH2O
45621955|NCT02467595|Drug|Rocuronium bromide 0.15 mg kg-1|Rocuronium bromide 0.15 mg kg-1 was injected at I.V. line to patients (R 0.15 group), as muscle relaxants during anesthesia for adenotonsillectomy.
45621956|NCT02467595|Drug|Rocuronium bromide 0.3 mg kg-1|Rocuronium 0.3 mg kg-1 was injected at I.V. line to patients (R 0.3 group), as muscle relaxants during anesthesia for adenotonsillectomy.
45621957|NCT02467595|Drug|Fentanyl|Fentanyl 2 mcg kg-1 was injected at I.V. line to patients
45912216|NCT03110224|Device|Subchondroplasty Procedure with AccuFill|Injection of the commercially available flowable calcium phosphate (CaP) synthetic bone-void filler, AccuFill®, into subchondral bone defects in the knee(Subchondroplasty (SCP) Procedure).
45912217|NCT03109093|Drug|Blinatumomab|"Patients will receive blinatumomab at a dose of 28 µg/day as continuous intravenous infusion at constant flow rate for four weeks, followed by a two-week infusion free interval, defined as one treatment cycle. Up to of four cycles will be performed.~In case of defined toxicities, the dose of blinatumomab may be reduced to 9µg/day.~Patients with an MRD relapse may qualify to receive additional treatment with blinatumomab."
45912218|NCT03105700|Device|Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (TMS) is a focal, nonpharmacological, noninvasive method for stimulating the brain and modulating neural network activity. To administer TMS, an electromagnetic coil is placed on the scalp, and uses electrical current to create magnetic fields that depolarize or hyperpolarize neurons in the brain.
45621958|NCT02467595|Drug|Propofol|Propofol 2.5 mg kg-1 was injected at I.V. line to patients
45621959|NCT02467595|Drug|Sevoflurane|After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
45621960|NCT03300401|Drug|Perflutren Lipid Microspheres|Receive intravenous injection just prior to ultrasound
45621961|NCT03300401|Drug|Sulfur Hexafluoride Lipid Microspheres|Receive intravenous injection just prior to ultrasound
45621962|NCT03300401|Device|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo Contrast-Enhanced Ultrasound Imaging
45621963|NCT03300401|Device|Positron Emission Tomography|Undergo PET/CT
45764427|NCT03403049|Radiation|Carbon Ion|Study subjects will receive carbon ion radiotherapy (CIRT), with daily fraction sizes of 3 GyE. The total CIRT dose will increase with each dose level. Subjects in dose level 1 and 2 will receive photon radiotherapy as well.
45764428|NCT03403049|Drug|Gemcitabine + Cisplatin|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
45764429|NCT03403049|Drug|Gemcitabine + Capecitabine|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
45621964|NCT03300401|Device|Computed Tomography|Undergo CT scan
45621965|NCT03300401|Biological|Yttrium-90 (90Y)|Given IV
45764430|NCT03403049|Drug|Gemcitabine + Erlotinib|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
45621966|NCT02467517|Drug|Ketamine|
45621967|NCT02467517|Drug|Magnesium Sulfate|
45621968|NCT02467517|Drug|placebo : sodium chloride|
45621969|NCT03300323|Diagnostic Test|IV fluid challenge administration|Administration of an intravenous fluid challenge to assess for fluid responsiveness
45621970|NCT02467673|Drug|Micronized estradiol + progesterone|Administration of micronized estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
45621971|NCT02467673|Drug|Nanoparticulate estradiol + progesterone|Administration of nanoparticulate estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
45621972|NCT02467439|Other|Notification cards|detection of AHI, contract partner notification, and social contact referral to find persons unaware of their HIV infection.
45621973|NCT02467829|Device|Increase in handle height|Elbow flexion is measured with the child standing in their walker using an electronic goniometer. Approximately 10° of elbow flexion is current recommended practice. 30° and 50° are increased handle heights.
45621974|NCT02953145|Drug|Tisseel|Tisseel will be applied to open areas lateral to the cleft palate repair
45621975|NCT02467049|Device|ECG-guided insertion of PICC|Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
45621976|NCT02467049|Device|ULTRASOUND-guided insertion of PICC|Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
45621977|NCT03300245|Radiation|Maxillofacial CT|clinical and maxillofacial CT data will be tabulated and analysed using by computer software e.g. Statistical Package for the Social Sciences (SPSS)
45912219|NCT03063398|Diagnostic Test|No intervention, this is an observational study|Assessment for exocrine pancreatic insufficiency
45912220|NCT03048201|Device|Physica Kinematic Retaining Knee System|Modular total knee prosthesis with a Kinematic Retaining mechanism and posterior cruciate ligament (PCL) preservation
45621978|NCT03300167|Device|The Liquid Biopsy System|The Liquid Biopsy System is a single use percutaneously-delivered coronary blood sampling device designed to collect blood samples from within a target coronary artery so that the blood can be analysed.
45621979|NCT05726435|Dietary Supplement|Soluble dietary fiber with prebiotic properties|14 adult professional baskeyball players will be divided randomly in two groups, each containing 7 players. One group shall receive Nutriose fiber, two times per day 10 grams per dose in total duration of 4 weeks. Second group shall receive same amount of Placebo in form of Maltodextrin. Each group will undergo a series of sports performance tests and questionnaires and shall donate their feces several times during the study in order to monitor gut microbiota changes. The Nutriose group in this particular intervention contains 7 randomy selected players.
45621980|NCT05726435|Dietary Supplement|Placebo|"14 adult professional baskeyball players will be divided randomly in two groups, each containing 7 players. One group shall receive Nutriose fiber, two times per day 10 grams per dose in total duration of 4 weeks. Second group shall receive same amount of Placebo in form of Maltodextrin. Each group will undergo a series of sports performance tests and questionnaires and shall donate their feces several times during the study in order to monitor gut microbiota changes. This second (Placebo) group also consists of the 7 players and receives Maltodextrin supplementation. Since the study type is double-blind, neither the participants (players) nor the person handing out the supplementation know the exact nature of fiber substance being handed during the entire duration of the trial. Independent statistician is handling the randomization of both interventions."
45621981|NCT03300089|Procedure|General anaesthesia|General anaesthesia
45621982|NCT03300089|Procedure|Regional anaesthesia|Regional anaesthesia
45621983|NCT03300011|Device|stent|PTCA or PCI
45621984|NCT00702143|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
45912221|NCT03048201|Device|Physica Cruciate Retaining Knee System|Total knee prosthesis with posterior cruciate ligament (PCL) preservation
45621985|NCT05725031|Drug|Ephedrine|70 μg/kg as pretreatment
45621986|NCT05725031|Drug|Rocuronium 0.6|0.6 mg/kg
45621987|NCT05725031|Drug|Rocuronium 0.8|0.8 mg/kg
45621988|NCT05725031|Drug|Rocuronium 1.2|1.2 mg/kg
45912222|NCT03048201|Device|Physica Posterior Stabilized Knee System|Total knee prosthesis that sacrifices the posterior cruciate ligament (PCL) and replaces the functionality of the PCL with a post-cam mechanism.
45912223|NCT03048201|Device|Physica Cruciate Retaining Knee System with LMC Liner|Total knee prosthesis with posterior cruciate ligament (PCL) preservation
45621989|NCT02902601|Drug|JNJ-54175446, 600 mg|Participants will receive JNJ-54175446, 600 mg as an oral suspension.
45446395|NCT02083900|Device|Banana Leaf Dressing|Banana leaf dressing will be prepared by cutting the mid rib of the leaf cutting the leaf into standard size of 12 x 12 inches to facilitate packing. The leaves are rolled and packed in polypropelene bags and subject to gamma irradiation or packed in paper bags for autoclaving. The Banana Leaf Dressing site will receive a single layer of banana leaf without any topical antibiotic applied to the wound followed by a layer of dry gauze for absorption of exudates. The dressing is secured with cling wrap to maintain an occlusive environment. This is then covered by rolled gauze and elastic bandage.
45446396|NCT02083900|Drug|Hydrocolloid Dressing (DuoDERM CGF)|The donor under HCD was covered with hydrocolloid (DuoDERM CGF). The hydrocolloid dressing was cut to the size of the donor site with an overlap of at least 2 centimeter around the wound edge. After pulling off the adhesive backing, care was taken to ensure that the adhesive was in direct contact with the raw surface. This was likewise covered with a top dressing of gauze for absorption of exudates and an elastic bandage to secure dressing.
45621990|NCT02902601|Drug|JNJ-54175446, 150 mg|Participants will receive JNJ-54175446, 150 mg as an oral suspension.
45621991|NCT02902601|Other|Placebo|Matching placebo to JNJ-54175446
45764431|NCT03403049|Drug|Gemcitabine|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
45446397|NCT03649971|Drug|Guselkumab|Guselkumab SC will be administered every 4 weeks.
45446398|NCT03649971|Drug|Placebo|Placebo SC will be administered every 4 weeks.
45446399|NCT02080858|Drug|Ticagrelor + Apixaban + ASA|
45446400|NCT02080858|Drug|Ticagrelor + Apixaban|
45621992|NCT04983615|Drug|fentanyl-based sedation|fentanyl-based sedation instead of midazolam-based sedation in ventilated patients
45621993|NCT04983615|Drug|midazolam-based sedation|midazolam-based sedation
45621994|NCT05307315|Other|listening to music|The experimental group will listen to Turkish instrumental music with headphones for 30 minutes.
45621995|NCT00702923|Drug|Bicalutamide and CP-675,206 (Tremelimumab)|"Dose level -1 :~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 3 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
45912224|NCT03042988|Other|Heating pad|Heat stress applied on the trunk for up to 8 hours
45446401|NCT05320809|Biological|3D189|"3D189 (200 mcg per peptide x 4 WT1 peptides within the drug product; total weight: 800 mcg) is mixed (1:1 v/v) and emulsified with the adjuvant Montanide, which is then injected subcutaneously to the patient.~A maximum of 15 total injections of 3D189 will be administered as follows:~Initial immunization induction phase（the first series of 6 injections of 3D189): every 2 weeks (Weeks 0 - 10) followed by a 4-week period of no treatment.~Early immune booster phase（the second series of 6 injections of 3D189): every 4 weeks (between Weeks 14 and 34) followed by a 6-week period of no treatment.~Late immune booster phase（the third series of 3 injections of 3D189): every 6 weeks (between Weeks 40 and 52)."
45446402|NCT02083978|Other|MRI scanning|
45446403|NCT03750435|Procedure|AF ablation or left-sided AT ablation|According to the type of AF/AT, single or double transseptal and subsequent catheter ablation in the left atrium using radiofrequency will be performed.
45446404|NCT04923243|Procedure|hip/knee replacement|hip/knee replacement
45446405|NCT02073526|Drug|Infliximab, adalimumab, certolizumab pegol|Patients are treated with the above mentioned drugs decided by clinicians
45621996|NCT00702923|Drug|Bicalutamide, CP-675,206 (tremelimumab)|"Dose level 1:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 6 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
45621997|NCT00702923|Drug|Bicalutamide, CP-675,206 (Tremelimumab)|"Dose level 2:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 10 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
45621998|NCT00702923|Drug|Bicalutamide, CP-675,206 (Tremelimumab)|"Dose level 3:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 15 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
45621999|NCT00702923|Drug|Bicalutamide, CP-675,206|"Final Dose Level:~Bicalutamide 150 mg p.o. q.d. day 1-28, day 85-112~At month 9, if evidence of PSA progression:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 (MTD dose) I.V. over 1 hour, day 29"
45622000|NCT05294055|Drug|Etoposide|Etoposide 1.5-1.8g/m2, single dose
45622001|NCT05294055|Drug|Cyclophosphamide|Cyclophosphamide 50mg/kg or 2g/m2, for 2 days
45622002|NCT05294055|Drug|Mecapegfilgrastim, day 2|Mecapegfilgrastim 12mg SC, on day 2 after chemotherapy
45912225|NCT03042988|Other|Sham control|heating pad turned off applied on the trunk for up to 8 hours
45912226|NCT02953431|Device|CPAP|CPAP will be administered with a CPAP machine
45764432|NCT03403049|Radiation|Photon|During this study, the prescribed dose shall be administered according to the dose escalation shown in the table, starting with dose level 1. The carbon ion dose shall be gradually escalated while gradually reducing the dose of photons until eventually administering a full dose of 56 GyE/14 Fx carbon ions (fractional dose of 4 GyE). Dose escalation will be performed in parallel for two patient groups: patients whose pancreatic tumors are greater than 5 mm from the duodenum (Group A) and those whose tumors are within 5 mm of the duodenum (Group B). Enrolled patients will be monitored for 90 days after radiotherapy starts for any acute toxic reaction and to explore the maximum tolerated dose, in addition to being observed for any related long-term toxic reactions in accordance with the protocol.
45764433|NCT00944047|Drug|nab-paclitaxel|100 MG/M2 IV over 30 minutes once a week for 12 weeks
45764434|NCT00944047|Drug|trastuzumab|4 MG loading dose followed by 2 MG/KG every week for a total of 12 weeks
45764435|NCT00944047|Drug|Doxorubicin|60 MG/M2 every two weeks for a total of 4 cycles
45764436|NCT00944047|Drug|cyclophosphamide|600 MG/M2 every 2 weeks for 4 cycles (administered with Doxorubicin above)
45764437|NCT00944047|Biological|Growth Factor Support|"All patients will receive pegfilgrastim 6.0 mg sc on Day #2 of each doxorubicin/cyclophosphamide neoadjuvant treatment cycle.~Erythropoetic growth factor support for fatigue/anemia will be allowed at the discretion of the treating physician."
45764438|NCT00944047|Procedure|Surgery|"After completion of neoadjuvant therapy, patients will proceed with either modified radical mastectomy or lumpectomy.~All patients with pretreatment lymph node positive disease and positive sentinel lymph node will undergo complete axillary lymph node dissection."
45764439|NCT03402971|Diagnostic Test|echocardiography|echocardiography focused on right heart: Parameters include RV enddiastolic diameter basal, mid-cavity and longitudinal, RVOT distal, pulmonal outflow AT and AT/ET, endsystolic RA area. RV wall thickness, TAPSE, S', tricuspidal E/A, E/e', RIMP. V. Cava to estimate CVP and sPAP.
45764440|NCT02921386|Drug|Oral Testosterone Undecanoate|All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
45622003|NCT05294055|Drug|Mecapegfilgrastim, day 5|Mecapegfilgrastim 12mg SC, on day 5 after chemotherapy
45446406|NCT03558568|Device|Deep Brain Stimulation|Deep Brain Stimulation is an established surgical method for Parkinson's Disease.
45622004|NCT03378219|Drug|Sarilumab SAR153191 (REGN88)|Pharmaceutical form:injection Route of administration: subcutaneous
45622005|NCT04983147|Other|Obesity Training Based on Health Belief Model|Trainig was given with initiatives for cognitive and affective learning areas within the framework of health belief model.7 weeks.This application will only be made in the experimental group.
45622006|NCT04983147|Other|Post-training follow-up|"After 7 weeks of training to women were completed, women were included in the follow-up program.For 6 mounts. This application will only be made in the experimental group.It will be made by phone call.~This follow-up will increase motivation and answer questions regarding obesity management.~It was made by calling every 15 days."
45622007|NCT05723939|Dietary Supplement|Carnosine supplementation|Intake of carnosine supplement in form of capsules or functionally enriched chicken meet for three weeks
45764441|NCT03402815|Drug|Maraviroc 300 mg|Patients were randomly allocated with an AB/BA cross over design to either maraviroc 300 mg/day to current ART for 24 weeks (A) or no additional treatment (B). At the end of the first 24-week period patients were switched to the alternative arm.
45764442|NCT02245555|Drug|Tamsulosin|
45764443|NCT03402737|Radiation|Stereotactic body radiotherapy|"The range of dose-painting will be escalated in following levels:~2x 6-8Gy (day 1-4)~3x 6-8Gy (day 1-4-7)~3x 6-10Gy (day 1-4-7)~3x 6-12Gy (day 1-4-7)~Patients will take cyclophosphamide orally 50 mg tablets, 1 tablet a day from the first day of irradiation for 8 consecutive weeks.~Nivolumab will be considered as standard therapy in patients with cisplatin refractory locoregional disease recurrence. Nivolumab will be administered as per current standard of care. In case patients that are treated with nivolumab will be included in the trial, they will not be treated with cyclophosphamide."
45764444|NCT04378673|Other|not interventional|This randomized controlled trial included data from 120 cases in the pediatric health and diseases department.
45764445|NCT03904771|Behavioral|Nutrition counselling + peer support|Behavioral nutrition counselling and peer support, delivered in small groups. Includes six sessions extending over 8 weeks, with participatory activities facilitated by a nutrition therapist.
45764446|NCT03904771|Behavioral|Social activation + peer support|Social activation and peer support, delivered in small groups. Includes six sessions extending over 8 weeks, with participatory activities facilitated by group leader.
45764447|NCT01724801|Radiation|whole brain radiation(WBI)|WBI (30Gy/3Gy/10 fractions) plus concurrent or sequential chemotherapy for 4-6 cycles
45764448|NCT01724801|Drug|Icotinib|administered orally at a dose of 125 mg 3 times daily
45764449|NCT04354441|Drug|hydroxychloroquine sulfate 200 MG|Hydroxychloroquine sulfate (Plaquenil) 2MG will be taken twice a day for 10 days. Participants will be couriered the medication upon giving consent and will start taking the medication immediately.
45764450|NCT04354441|Drug|Placebo oral tablet|Placebo that is identical in appearance to the study medication will be taken twice a day for 10 days. It will be couriered to participants upon giving consent. They will start taking the medication immediately.
45764451|NCT04378595|Other|During COVID-19 Pandemic|Assessing status of food insecurity during the COVID-19 pandemic
45764452|NCT04378595|Other|After COVID-19 Pandemic|Assessing status of food insecurity after the COVID-19 pandemic
45446407|NCT02073604|Other|Healthy volunteers|Morphological and functional brain MRI; transcranial magnetic stimulation
45622008|NCT05723939|Dietary Supplement|Controls|Intake of placebo capsules or regular chicken meet for three weeks
45622009|NCT05263869|Drug|MRG002|Administrated intravenously
45622010|NCT04455789|Procedure|routine lung protective, conventional mechanical ventilation|routine lung protective, conventional mechanical ventilation with stabil PEEP
45622011|NCT04490525|Device|Telerehabilitation|Blood pressure (iHealth Neo/BP5s), weight (iHealth Lina), step counters(Fitbit Inspire & Charge 3), sleep sensor (Emfit QS), and tablet (iPad Air 2).
45622012|NCT03299621|Device|PLE (Phase Lag Entropy)|Monitoring of PLE value using the monitoring of PLEM™ device during propofol anesthesia.
45764453|NCT02802514|Drug|Albiglutide 50mg|It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. A 50 mg pen contains 67 mg lyophilized albiglutide and 0.65 mL diluents. It will be injected subcutaneously (SC) in the upper arm.
45764454|NCT02802514|Drug|Albiglutide matching placebo|It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. It will be injected subcutaneously (SC) in the upper arm
45764455|NCT02802514|Drug|Exenatide 10microgram|It is provided as a sterile solution containing 250 microgram/mL exenatide. One dose of 10 microgram is equivalent to 0.04 ml. It will be injected subcutaneously (SC) in the upper arm
45764456|NCT02802514|Drug|Exenatide placebo (saline)|It is provided as a sterile saline. It will be injected subcutaneously (SC) in the upper arm
45764457|NCT00944671|Drug|famotidine (+) calcium carbonate (+) magnesium hydroxide tablet|A single dose of famotidine/antacid tablet with 120 mL of water in one of three treatment periods
45764458|NCT00944671|Drug|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water|A single dose of famotidine/antacid combination EZ Chew tablet without water in one of three treatment periods
45764459|NCT00944671|Drug|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water|A single dose of famotidine/antacid combination EZ Chew tablet with 120 mL of water in one of three treatment periods
45764460|NCT03875131|Other|Biomarkers of Dementia and Cognitive Decline|"Biomarkers will be obtained at baseline, 6, 12, 18, and 24 months.~The six questionnaires listed below will be administered at the baseline visit, and repeated at the 24-month visit to evaluate cognitive decline.~Mini-Mental Status Evaluation~Hachinski Ischemic Scale~Cognitive Subscale of Alzheimer's Disease Assessment Scale~Disability Assessment for dementia~Quality of life improvement as assessed by:~Minnesota Living with Heart Failure Scale~Anti-Clot Treatment Scale (ACTS) Quality of Life Survey"
45764461|NCT02922868|Device|EndoSheath CST-5000 Scope|Cystoscopic procedures will be performed using the EndoSheath CST-5000 Scope.
45764462|NCT02922868|Device|Olympus Visera Elite OTV-S190 Scope|Cystoscopic procedures will be performed using the Olympus Visera Elite OTV-S190 Scope
45764463|NCT00944749|Drug|h-ATG (ATGAM )|
45764464|NCT00944749|Drug|Cyclosporine (Gengraf )|
45764465|NCT02763202|Other|CHS Transition Services|"The CHS Transition Services (CHS-TS) pathway includes the following seven components:~(i) Introduction to CHS-TS process prior to discharge (ii) Hospital follow-up evaluation within 72 hours either in home with paramedicine or in the CHS-TS clinic (iii) Medication reconciliation by a pharmacist within 72 hours (iv) Weekly contact with care management team (v) Entry into the Heart Success Program if appropriate (vi) Access to 24/7 phone support, 24/7 paramedicine visits, and same day clinic scheduling (vii) Coordinated transition to the next appropriate care location after 30 days from time of discharge"
45446408|NCT02073604|Other|Congenital mirror movements|Morphological and functional brain MRI; transcranial magnetic stimulation
45446409|NCT04359771|Device|Yellow micro-pulse laser|applying 577-nm yellow laser in a micro-pulse mode over the macular area including the fovea
45446410|NCT04359771|Device|Diode micro-pulse laser|applying 810-nm infra-red diode laser in a micro-pulse mode over the macular area including the fovea
45446411|NCT02084212|Other|Microperimetry|
45446412|NCT03756831|Diagnostic Test|Core Stability Assessment|Core Stability Assessment will be consisted of bilateral static balance with open and close eye, right foot balance test, and dynamic balance test.
45622013|NCT03299621|Drug|Muscle Relaxant|Monitoring of PLE value using the monitoring of PLEM™ device before and after the injection of muscle relaxant that used for tracheal intubation.
45622014|NCT03299543|Device|LEVL (Medamonitor)|Subjects will provide duplicate breath samples to the LEVL device for analysis of breath acetone
45622015|NCT05718167|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting the programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, making T cells recover their activity, thereby enhancing the immune response.
45622016|NCT05718167|Drug|Anlotinib hydrochloride capsule|Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor, which can target angiogenesis related kinases, such as VEGFR 1/2/3, FGFR 1/2/3 and other tumor cell proliferation related kinases like Platelet-derived growth factor receptor (PDGFR) α/β、 C-kit, RET.
45622017|NCT05718167|Drug|Tislelizumab injection|Tislelizumab injection can bind to human programmed cell death 1 (PD-1), a cell membrane protein that is mainly expressed on activated T cells and inhibits T cell activation.
45622018|NCT03053193|Diagnostic Test|MammaPrint, BluePrint, and Full-Genome Testing|Agendia will run MammaPrint and BluePrint tests using the full genome testing array.
45622019|NCT03299465|Behavioral|Yoga|This is a single arm study and all participants will be assigned to a six-week restorative yoga intervention. Restorative yoga sessions will consist of gentle physical poses (asanas), breathing control (pranayama), and relaxation (savasana).
45764466|NCT01047293|Drug|RAD001|"RAD001 (everolimus) is a novel oral derivative of rapamycin.~RAD001 is being investigated as an anticancer agent based on its potential to act:~Directly on the tumor cells by inhibiting tumor cell growth and proliferation~Indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell HIF-1 activity, VEGF production and VEGF-induced proliferation of endothelial cells). The role of angiogenesis in the maintenance of solid tumor growth is well established, and the mTOR pathway has been implicated in the regulation of tumor production of proangiogenic factors as well as modulation of VEGFR signaling in endothelial cells."
45764467|NCT01047293|Drug|FOLFOX|FOLFOX regimens combine oxaliplatin and leucovorin with bolus and infusional 5-fluorouracil (5-FU). 1 Oxaliplatin is a DNA cross-linking agent consisting of a platinum ion chelated with1, 2-diaminocyclohexane (DACH) and an oxalate ligand. It undergoes spontaneous activation in aqueous solutions via displacement of the labile oxalate ligand by water. The activated compounds bind with DNA, resulting in inter- and intra-strand platinum-DNA crosslinks. 5-FU is an anti-metabolite that blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, causing thymidine-less cell death in rapidly growing cells. Leucovorin is reduced folic acid that modulates the activity of 5-FU by stabilizing the ternary 5-FdUMP/ thymidylate synthetase complex. Side effects associated with FOLFOX include neuropathy including pharyngo-laryngodysesthesia, diarrhea, nausea, vomiting, and mild myelosuppression.
45764468|NCT01047293|Drug|Bevacizumab|Bevacizumab, a monoclonal antibody directed against VEGF (vascular endothelial growth factor) has been studied in a multitude of Phase I, II, and III clinical trials in more than 5000 patients in multiple tumor types. Phase III data in metastatic cancers
45764469|NCT01045967|Drug|Lansoprazole|30 mg delayed-release Capsule
45764470|NCT01045967|Drug|Prevacid®|30 mg delayed-release Capsule
45764471|NCT02808052|Drug|Minocin (minocycline) for Injection|200mg IV Minocin given over 1 hour
45764472|NCT01724957|Procedure|Intracoronary ECG|Recording of icECG from the tip of PCI guidewire. The wire end is connected through alligator clips to V-lead from surface ECG
45764473|NCT03402581|Device|c-mac laryngoscope|type of laryngoscopes
45764474|NCT02808130|Other|hyperlipidemia, periodontitis, gingivitis|GCF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva
45764475|NCT02677870|Drug|saproterin dihydrochloride|The drug will be given as described in the arm/group descriptions.
45764476|NCT02677870|Other|Diet treatment|Patients will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week.
45764477|NCT02809846|Device|Quell|
45764478|NCT02809846|Device|Sham Quell|
45764479|NCT00945061|Radiation|intracavitary balloon brachytherapy|Patients undergo brachytherapy
45764480|NCT00945061|Radiation|intraoperative radiation therapy|Patients undergo radiotherapy
45764481|NCT02924350|Other|Stannous fluoride|"Supervised direct application (Day 0): Participants applied a pea-sized dose of test dentifrice to each of the 2 qualifying test teeth using their washed and clean finger to gently rub the dentifrice into the tooth's cervical margin for 60 sec. No rinsing was permitted after treatment.~Supervised brushing (Day 0, before leaving the site) and Home use (3 days): after dosing a dry toothbrush with a full strip of dentifrice, participants brushed each of the 2 qualifying test teeth first, followed by their whole mouth for at least 60 sec. Participants were permitted to rinse with 5 mL tap water (room temperature) for 5 sec. maximum after brushing on supervised brushing (Day 0) and were also permitted to rinse with tap water after brushing on home use (3 days)."
45622020|NCT03299387|Drug|Nitrofurantoin|Participants will receive oral Nitrofurantoin 100 mg twice daily for 7 days
45622021|NCT03299387|Drug|Gentamicin|Participants will receive intravesical via catheter Gentamicin solution 25 mg in 50cc for 3 days
45622022|NCT04954313|Drug|Subgingival chlorhexidine irrigation|The dose information for the Chlorhexidine gluconate will be 0.12% with 1 mL in each dental pocket at a frequency of every 3 months for the duration of the study (18 months).
45622023|NCT04954313|Other|Dental Supplies|Subjects in the Treatment Group will receive a commercial electric toothbrush (Colgate hum), toothpaste (Colgate Renewal), mouthwash (Colgate Zero), proxabrush (Colgate), and floss (Colgate Palmolive brand) to be used at home along with instructions on their use. Brush heads for the electric toothbrush will be replaced every 3 months and products (toothpaste, mouthwash, proxabrush, and floss) will be replenished at every site visit.
45622024|NCT04954313|Other|Periodonal Treatment|Initial periodontal treatment consisting of a pre-procedural rinse and scaling & root planing (SRP).
45622025|NCT03299231|Device|OPEP Aerobika|Previous studies of OPEP device shows preliminary benefit in subjects with COPD. No serious adverse events were recorded in previous studies. The device is FDA registered.
45764482|NCT02924350|Other|Sodium monofluorophosphate|"Supervised direct application (Day 0): participants applied a pea-sized dose of control dentifrice to each of the 2 qualifying test teeth using their washed and clean finger to gently rub the dentifrice into the tooth's cervical margin for 60 sec. No rinsing was permitted after treatment.~Supervised brushing (Day 0, before leaving the site) and home use (3 days): after dosing a dry toothbrush with a full strip of dentifrice, participants brushed their whole mouth thoroughly for at least 60 sec. Participants were permitted to rinse with 5mL tap water (room temperature) for 5 sec. maximum after brushing in supervised brushing on Day 0 and were also permitted to rinse with tap water after brushing on home use (3 days)."
45622026|NCT03299231|Device|OPEP Aerobika Sham device|The same OPEP device which is devoid of the nebulizer port valve to render it inactive. Used for control sham arm.
45764483|NCT00374062|Behavioral|relaxation therapy 1|relaxation therapy 1
45764484|NCT00374062|Behavioral|relaxation therapy 2|relaxation therapy 2
45764485|NCT00374062|Behavioral|relaxation therapy 3|relaxation therapy 3
45446413|NCT02081170|Procedure|Autologous platelet concentrate|"pars plana vitrectomy~internal limiting membrane removal~Fluid-air exchange~Intravitreal autologous platelet concentrate injection~Intravitreal gas (14% C3F8) injection~Keep prone position for 7-14 days after surgery"
45446414|NCT03750357|Device|Primary Relief v 2.0|To prove the effectiveness of Post Operative Pain Solution using Primary relief v 2.0 by Percutaneous Electrical Nerve Stimulation in the auricle.
45764486|NCT02469220|Dietary Supplement|Low FODMAP|Blinded food supplements containing only items with a low content of FODMAPs
45622027|NCT03299153|Other|barberry juice|
45622028|NCT03068013|Behavioral|CALM|CALM intervention covers four domains, namely: 1) Symptom management and communication with health care providers; 2) Changes in self and relations with close others, 3) Spiritual well-being, sense of meaning and purpose, 4) Preparing for the future, sustaining hope and facing mortality
45764487|NCT02469220|Dietary Supplement|Standardized FODMAP|Blinded food supplements containing FODMAPs
45622029|NCT03068013|Behavioral|SPI|Active Comparator: Supportive psycho-oncology intervention Supportive psycho-oncology intervention (SPI) includes counseling, psychoeducation and crisis intervention, which is the usual care intervention provided in our centres.
45764488|NCT00374218|Drug|High Fructose Corn Syrup|
45622030|NCT05673005|Device|MED3000 topical gel|Topical gel that has been shown to improve erectile dysfunction when used as needed.
45622031|NCT05178381|Device|Continuous theta burst transcranial magnetic stimulation|Participants will receive cTBS (50Hz stimulation at 80% AMT for 40 seconds). Stimulation will be applied to either the target area (frontal pole or IFG) or control area (vertex). Targeting of each region will be achieved using a frameless neuronavigation system with a Polaris Spectra infrared camera that enables stimulation to be centered on specific coordinates in Montreal Neurological Institute space. We will use coordinates [x,y,z] = [35,50,15] for frontal pole and [x,y,z] = [56,16,22] for right IFG based on the location of our activations in the young pilot group (Figure 4). The vertex control site is defined as the Cz position of a 10-20 EEG system. After receiving TMS, participants will stare at a white wall for 1 minute before performing the Horizon Task for 45 minutes.
45622032|NCT02658981|Biological|Anti-LAG-3 Monoclonal Antibody BMS 986016|Given IV
45622033|NCT02658981|Biological|Anti-PD-1|Given IV
45622034|NCT02658981|Other|Pharmacological Study|Correlative Studies
45622035|NCT02658981|Other|Laboratory Biomarker Analysis|Correlative Studies
45764489|NCT00374218|Drug|Sucromalt|
45764490|NCT02344498|Drug|Tenofovir disoproxil|
45912227|NCT02885337|Other|Multi-Modal Frailty Intervention|"Exercise: A physiotherapist will develop an individualized exercise program and schedule appointments with the patient at a physiotherapist clinic. Participants will be offered free YMCA membership.~Cognitive-behavioural Change Strategy(CBCS) and education: Throughout the intervention, CBCS and education about exercise, hip or knee arthroplasty and osteoarthritis will be administered.~Protein Supplement: Participants will be provided with 1-2 daily supplements (containing 20-40 gram protein, 1.5 g β-Hydroxy β-Methylbutyrate /serving) to be taken with a meal or on activity days within 3-hours of exercise.~Vitamin D: All participants in the intervention arm will be provided with a supply of Vitamin D3 (1000 IU/day tablets) for the duration of the intervention period.~Medication Review: A geriatrician will review the medications for patients in the intervention arm."
45622036|NCT02658981|Biological|Anti-CD137|Given IV
45622037|NCT05145855|Other|Patient-tailored multimodal neglect rehabilitation|Patient-tailored neglect rehabilitation program which comprises 30-45 minutes of sessions, five times per week includes a combination of reading, copying, and representational drawing tasks with visual or verbal cueing, visual scanning, mirror therapy, and allocation of attention to the neglected side using multimodal stimulus in daily activities.
45622038|NCT04983303|Other|TICK-B group|These interventions will distract the child during venipuncture
45622039|NCT05730465|Behavioral|Use of Omron Home Blood Pressure Cuff|Use of an Omron Home Blood Pressure Cuff to monitor blood pressure after discharge
45622040|NCT05636007|Device|Huawei Watch|pulse rate variability measured by a smartwatch
45622041|NCT02633787|Biological|Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be administered in this trial
45622042|NCT05016531|Device|Low Intensity Focused Ultrasonic Stimulation|Brain stimulation using ultrasonic stimulation in a sequence of increasing intensity (sham, 1 W/CM2, 2 W/CM2, 4 W/CM2, 6 W/CM2, 8 W/CM2)
45764491|NCT00945139|Drug|Doxil|Open label study of Doxil given as 30 mg/m2 every three weeks by itself in cycle 1
45764492|NCT00945139|Drug|Avastin|First agent (Doxil) will be following by Avastin 15 mg/kg on cycle 2 and every cycle thereafter until disease progression
45622043|NCT05016531|Device|Low Intensity Focused Ultrasonic Stimulation Frequency|Brain stimulation using ultrasonic stimulation of intensity level determined from intervention 1 at progressively increasing frequency levels (0.35 MHz; 0.5 MHz; 0.75 MHz, 1.0 MHz and 1.5 MHz)
45622044|NCT05635773|Device|Use of Alexa Visual Cognitive aid|The intervention is the use of of a cognitive aid to determine the efficacy of the aid in completing the steps correctly.
45622045|NCT05635695|Other|Free Museum visit|People are tested when they arrive at the museum. Then, they freely visit the different rooms for 45 to 75 minutes. No instructions are given.
45622046|NCT05635695|Other|Cultural pathways App|Cultural pathways in the park of the museum will be proposed to people with a smartphone application that will give directions, cultural and sustainable health contents, points of interest with games and specific information about the pathways (distance, noise level, walkability, practical information). There will be two possible levels: contemplative or active.
45622047|NCT04895553|Other|Observation of ICH and VTE|The treating physician will initiate and prescribe the apixaban, the protocol will only observe and record intracranial pressure (ICP) and VTE incidences.
45622048|NCT02719691|Drug|Alisertib|Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.
45622049|NCT02719691|Drug|MLN0128|Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.
45622050|NCT04490135|Behavioral|Group psychotherapy|As described above
45622051|NCT04794699|Drug|IDE397|IDE397 dosed orally
45622052|NCT04794699|Drug|Docetaxel|Intravenous infusion
45446415|NCT04893681|Other|Fluoridated bottled drinking water|Study participants are asked to consume study water, as frequently and in amounts as necessary or desired, whenever they drink water (e.g., as plain water or mixed with other ingredients) or use water in food preparation.
45446416|NCT04893681|Other|Non-fluoridated drinking water|Study participants are asked to consume study water, as frequently and in amounts as necessary or desired, whenever they drink water (e.g., as plain water or mixed with other ingredients) or use water in food preparation.
45446417|NCT02073760|Other|There is no intervention. The investigators are interviewing cardiac surgery staff with knowledge of infection prevention.|The investigators will conduct tape recorded interviews with hospital staff about infection prevention.
45622053|NCT04794699|Drug|Paclitaxel|Intravenous infusion
45764493|NCT02812342|Drug|Tofacitinib ointment|Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
45764494|NCT02254642|Procedure|Ischemic preconditioning during aortic clamping|Ischemic preconditioning during aortic clamping
45622054|NCT04794699|Drug|Gemcitabine|Intravenous infusion
45622055|NCT04794699|Drug|Nab paclitaxel|Intravenous infusion
45622056|NCT04794699|Drug|Pemetrexed|Intravenous infusion
45622057|NCT05456243|Biological|Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)|Single intra-arterial infusion of 1 x 10^5 cells/kg
45622058|NCT05456243|Biological|High dose adipose tissue derived mesenchymal stromal cells (A-MSC)|Single intra-arterial infusion of 5 x 10^5 cells/kg infused over 5 minutes
45622059|NCT05671211|Other|Task-Oriented Training|Participants in this group will receive 30 minutes of task-oriented training and 1 hour of conventional therapy for 6 weeks 5 times a week.
45622060|NCT05671211|Other|Conventional Therapy|Conventional therapy will be consisted of balance,upper and lower extremity strengthening exercises.
45622061|NCT05635617|Procedure|Lower Extremity Surgery|Patients 18 years of age or older with high energy lower extremity fractures. Provision of informed consent.
45622062|NCT05635539|Dietary Supplement|"Analimentary detoxication (ANADETO) weight loss based on very-low-calorie-diet"|calorie restriction to 50-100 kcal/day with fat-free vegetables (tomatoes and cucumbers) with mandatory salt intake to 5-6 gr/day, hot water drinking 1000-1500 ml/day, walking at least 2,000 steps/day after normalized body temperature, and sexual self-restraint. The walking provided to promote of blood circulation and decrease in metabolic intoxication. The weight loss method lasted 14 days. Then the patients followed for 4-week a diet where they ate one meal a day without any food restriction.
45622063|NCT04782687|Drug|Selinexor|oral drug that comes in 20 mg tablets
45764495|NCT02254642|Procedure|Procedure/Surgery: usual surgery|Procedure/Surgery: usual surgery
45446418|NCT02084290|Behavioral|Shared Decision Making Program|This study is cluster randomized by study-site, Subjects enrolled at intervention sites will access an educational program and risk prediction tool. Their decisions about treatments will be compared to subjects that did not view the educational program or risk prediction tool.
45622064|NCT04782687|Drug|Dexamethasone Oral|Dexamethasone 40 mg on Days 1, 8, 15, 22 of each cycle. However, those >75 years old may be administered a weekly dose of 20 mg dexamethasone.
45622065|NCT04782687|Drug|Daratumumab|"Patients will receive daratumumab subcutaneously (SC, or under the skin) as an injection. The recommended dosage of the SC formulation is 1,800 mg daratumumab and 30,000 units hyaluronidase administered SC into the abdomen over approximately 3 to 5 minutes according to recommended schedule.~Daratumumab 1800 mg subcutaneously once weekly in Cycles 1 and 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter."
45622066|NCT04782687|Drug|Lenalidomide|Patients will receive a 21-day supply of lenalidomide (15 mg) as oral capsules, as appropriate, for each 28-day treatment cycle
45622067|NCT05442359|Drug|Nano-bio fusion gingival gel|Thin coat applied to cover the palate after free gingival graft harvest. A stent will be placed to retain its effect. Patients will receive the gel to be used at home twice daily till 3rd week and once in the 4th week
45622068|NCT05442359|Device|stent|Applied as a palatal stent for palatal wound
45622069|NCT05655689|Drug|Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution|In the observational study, patients treated with topical antibiotic moxifloxacin 0.5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
45622070|NCT05655689|Drug|Ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with topical fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
45622071|NCT05655689|Drug|Gentamicin 1.4% + vancomycin 5%|In the observational study, patients treated with the topical fortified antibiotics gentamicin 1.4% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
45622072|NCT05655689|Drug|Natamycin 5% Oph Susp|In the observational study, patients treated with the topical natamycin 5% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
45622073|NCT05655689|Drug|Voriconazole 1%|In the observational study, patients treated with voriconazole 1% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
45622074|NCT05655689|Drug|Natamycin 5% + voriconazole 1%|In the observational study, patients treated with the topical natamycin 5% and voriconazole 1% antifungals eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
45622075|NCT05655689|Drug|Natamycin 5%+ ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with the topical natamycin 5% and antifungal and the fortified antibiotic ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
45622076|NCT05655689|Drug|Voriconazole 1% + ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with the topical voriconazole 1% antifungal and the fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
45622077|NCT04779177|Drug|Lumateperone 42 mg|Lumateperone 42 mg, oral administration
45622078|NCT04779177|Drug|Lumateperone 28 mg|Lumateperone 28 mg, oral administration
45622079|NCT04745013|Behavioral|PRIORITY|PeRsonalIzed remOtely guided preventive exeRcIse therapy for a healThY heart
45622080|NCT04745013|Behavioral|Usual care|Only a written personalized exercise prescription will be provided.
45622081|NCT05428865|Other|correlation study|investigate the correlations between body mass index, spasticity, functional ability and isolated motor control in children with spastic diplegia.
45446419|NCT04356573|Dietary Supplement|Green Hayward Kiwifruit first, then Gold Kiwifruit|Subjects ate 2 peeled green kiwifruit with their midday meal for 2 weeks prior to testing.
45622082|NCT05639933|Drug|HT-001 2% Topical Gel|Topical gel, 2% active
45622083|NCT05639933|Drug|HT-001 1% Topical Gel|Topical gel, 1% active
45622084|NCT05639933|Drug|HT-001 0.5% Topical Gel|Topical gel, 0.5% active
45622085|NCT05639933|Drug|HT-001 Placebo|Topical gel, vehicle gel
45622086|NCT05635461|Drug|CVN424|150 mg of either tablet or suspension formulation
45622087|NCT05729841|Other|Ocean row|the Talisker Whisky Atlantic Challenge annual ocean rowing race.
45622088|NCT05405231|Behavioral|Crisis Line Facilitation (CLF)|Crisis Line Facilitation (CLF) is a promising translational strategy designed to increase MVCL use among NG members during periods of elevated suicidal risk by addressing individual-level barriers.
45622089|NCT05405231|Behavioral|Passive Implementation|The PI condition includes an educational resource brochure describing the MVCL, including the phone number for the crisis line, as well as other mental health services available to National Guard members.
45622090|NCT04739943|Device|Mobile Monitoring Device|App for self monitoring device for respiratory symptoms
45622091|NCT02466347|Drug|Fluticasone propionate|Inhaled corticosteroid, pMDI
45622092|NCT02466347|Drug|Salmeterol (as xinafoate)|Long Acting Beta-agonist (LABA), pMDI
45622093|NCT05729763|Other|3D-PADUA nephrometric score|Evaluation of the PADUA nephrometric score with 3D images
45764496|NCT03871465|Drug|Triamcinolone SASD injection|2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.
45764497|NCT03871465|Procedure|Physiotherapy|The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.
45764498|NCT03871465|Drug|Triamcinolone injections & Physiotherapy|"2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.~The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles."
45764499|NCT02125864|Procedure|intravitreal injection|collecting blood samples
45764500|NCT04363489|Device|Wearable Medical Device (Empatica E4)|A wearable medical device (Empatica E4) which is a smart wristband that detects skin temperature, heart rate and sleep. It is CE and FDA approved.
45764501|NCT04363489|Diagnostic Test|COVID-19 PCR Swab|COVID-19 PCR Swab will be self-taken by doctors every day. Fischer nasopharyngeal PCR Swabs
45764502|NCT04363489|Diagnostic Test|Pulse Oximeter|Participants will measure their oxygen saturations every day, and report them on the survey. Pulmolink A310 pulse oximeters
45622094|NCT05729763|Other|2D-PADUA nephrometric score|Evaluation of the PADUA nephrometric score with 2D images
45912228|NCT02885337|Other|Usual Care|"Patients in the control arm will receive usual care which may include the recommendation to attend fitness classes before surgery, however these patients will not receive the more intensive assessment/intervention of the physiotherapist and other intervention components. Control participants will be asked pre-operatively and post-operatively to indicate whether or not they exercise, take protein or vitamin supplements.~For participants in intervention and control groups will, 1) we will monitor the YMCA attendance and 2) participants will be instructed on the completion a dietary intake log (including days of the week and weekend days) that indicate the type of food and amount over a four-day period in order to calculate energy and micronutrient consumption."
45764503|NCT02814448|Device|CryoPen|Provides a means of freezing tissue without the use of gases or liquids
45764504|NCT02814448|Device|CO2 standard cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
45764505|NCT02814448|Device|Thermocoagulator|The use of heat produced by high-frequency electric current to bring about local destruction of tissues
45622095|NCT03067935|Drug|glembatumumab vedotin|
45764506|NCT00931489|Drug|ranibizumab (Lucentis(R))|0.5 mg intravitreal injection once a month for 4 months, then as needed for 2 months
45764507|NCT04363333|Diagnostic Test|Home Sleep Apnea Testing or In-hospital Polysomnography|Home Sleep Apnea Testing or In-hospital Polysomnography will be conducted 4 to 6 months after the Covid-19 diagnosis
45764508|NCT02816710|Drug|Conbercept|Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.
45764509|NCT04363411|Other|finger prick screening for BBV infections and questionnaires by outreaching methodology|Screening by fingerprick for HCV Ab, HBsAg and HIV Ab and a questionnaire will be performed at sites outside of the regular treatment facilities.
45622096|NCT05635383|Other|PERIPHERAL NERVE BLOCK|Observation of rebound pain after peripheral nerve block application
45764510|NCT04363255|Drug|Etoposide Injection|Etoposide(100mg/m2, d1-3, q3w) combined with platinum was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
45912229|NCT02807506|Device|Mobile Service Robot|The goal is to build a low-cost mobile service robot with an arm that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact).
45622097|NCT03066375|Device|Echocardiography-Doppler|Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
45622098|NCT02466269|Procedure|The supratemporalis approach|The supratemporalis approach was applied in treatment of diacapitular condylar fractures
45622099|NCT05635149|Radiation|radiotherapy|In radiotherapy group, the modality of radiotherapy was conventional radiotherapy (CRT) or stereotactic body radiotherapy (SBRT) for cancer.
45622100|NCT03067857|Biological|Stem Cells|Autologous bone marrow-derived stem cell populations injected via the intravenous and intrathecal routes.
45622101|NCT02466191|Drug|Memantine|
45622102|NCT02466191|Drug|Gabapentin|
45653370|NCT05557565|Drug|QL1706|The dosage of QL1706 is 5.0 mg/kg, and QL1706 is administered every 3 weeks (Q3W) by intravenous infusion
45653371|NCT03066895|Device|BabyGentleStick|Experimental device.
45653372|NCT03066895|Device|Standard Lancing Device|HMC standard of care.
45764511|NCT04363255|Drug|Carboplatin Injection|Carboplatin(AUC 5, d1, q3w) or Cisplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
45764512|NCT04363255|Drug|Cisplatin injection|Cisplatin(75mg/m2, d1, q3w) or carboplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
45764513|NCT04363255|Drug|Toripalimab|After 4-6 cycles of chemotherapy, JS001(240mg, d1, q3w) combined with anlotinib were followed and continued until disease progression.
45764514|NCT04363255|Drug|Anlotinib hydrochloride|After 4-6 cycles of chemotherapy, anlotinib(12mg qd, d1-14, q3w) combined with JS001 were followed and continued until disease progression.
45764515|NCT02818114|Behavioral|Peer Enhanced Prolonged Exposure|Peer support interventions as adjunct to prolonged exposure
45622103|NCT05729685|Other|Interval training|"The interval training group trained using the interval method. During the exercise sessions the participants ran each bout at an intensity corresponding to 90% of PTV. PTV was used to prescribe the exercise intensity at the INT group. The duration of the running-bouts was equal to ¼ of the individual time to exhaustion at 90% of PTV (determined during the CV testing) followed by passive rest equal to 2/3 of exercise duration. The duration of the exercise-bouts was individualized based on the time to exhaustion at 90% of PTV to reduce the between subject's variability. The participants terminated each exercise session when an RPE value of 17 was reached. Running bout duration and intensity were adjusted after 7 training sessions (during the 3rd week) following a reassessment of the time to exhaustion at 90% of the new PTV achieved during mid-testing as a result of training."
45622104|NCT05729685|Other|Continuous training|The continuous group trained using the continuous method. During the training sessions the participants ran with an intensity corresponding to -2,5% of CV until they reported a rating of 17 at the 6-20 Borg's scale. Running velocity was adjusted after 7 training sessions (during the 3rd week) after reassessment of CV. CV was used to determine the exercise intensity in the CONT group to ensure that all individuals would ran at the heavy intensity domain and be able to complete at least 15 min of continuous running, and to minimize the high inter-individual variations in endurance time at intensities near the upper limit of the heavy intensity domain. Using PTV to determine the intensity in the CONT group, would increase the possibility for trainees to exercise at different exercise intensity domains.
45622105|NCT02466113|Other|A 6 microRNA stratified tool|Investigators randomly assign patients to be assessed by a 6 microRNA stratified tool. MicroRNA(miRNA) tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miRNA-21-5p)+(0.086×status of miRNA-20a-5p)+(0.240×status of miRNA-103a-3p)+(0.095×status of miRNA-106b-5p)-(0.238×status of miRNA-143-5p)-(0.237×status of miRNA-215),low expression status equals 0 and high expression status equals 1). Investigators defined high risk patient if their score larger than 1, the others as low risk patient.The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
45764516|NCT02930824|Genetic|CYP2C19 genotyping|All proton pump inhibitors are metabolized in part by the CYP2C19 enzyme, which is encoded by the highly polymorphic CYP2C19 gene. Based on variations within this gene the effectiveness of the drug may be reduced.
45764517|NCT00931879|Drug|omega-3-ethyl esters|Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (>500 mg/dL) triglyceride (TG) levels in adult patients.
45764518|NCT00931879|Drug|Placebo|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
45764519|NCT02930980|Device|Investigational Software loaded on Micra device|Subject will receive an investigational software loaded on subject's Micra device
45912230|NCT02807506|Other|Survey|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot.
45912231|NCT02787499|Procedure|HIV-1 RNA Resistance Testing|Perform drug resistance on enrollment to guide management of virologic failure
45912232|NCT02747836|Other|Ultrasound of the wrist|using sound waves to create images capturing the movement of the SSCT and flexor tendon and transformation of the median nerve in the wrist
45622106|NCT02466113|Other|A classic stratified tool|Investigators randomly assign patients to be assessed by by classical pathological features. Pathological features include poorly differentiated histology(exclusive of those cancers that are MSI-H),lymphatic/vascular invasion,bowel obstruction and <12 lymph nodes examined. Investigators defined high risk patient if they had any pathological features, the others as low risk patient. The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
45622107|NCT04667481|Other|Aerobic Exercise Intervention|Participate in aerobic exercise intervention
45622108|NCT04667481|Other|Resistance Exercise Intervention|Participate in resistance exercise intervention
45622109|NCT04667481|Other|Exercise Intervention: Digital copies and outline of sessions|Receive digital copy of AE and RE sessions and an outline of sessions
45622110|NCT04667481|Other|Questionnaire Administration|Ancillary studies
45622111|NCT04667481|Other|Quality-of-Life Assessment|Ancillary studies
45622112|NCT05573321|Other|BFR-RE|In the BFR-RE intervention, the exercise will be done as a set of 30 repetitions with a loading of 30% of 1 RM and an additional 3 sets x 15 repetitions, with 30 seconds rest between sets. In both groups, bilateral leg extension exercise will be performed by using the leg extension machine for resistance exercise. In the blood flow restriction group (BFR-RE), the cuff will be placed in the proximal region of the thigh bilaterally, inflated to a pressure equivalent to 50% of the estimated arterial occlusion pressure (AOP), and leg extension exercise will be performed under this condition. In the BFR-RE group, the blood flow restriction time will be between 5-10 minutes. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken.
45622113|NCT05573321|Other|HL-RE|In the HL-RE intervention, the exercise will be performed with a loading of 80% of 1 RM, with 4 sets x 7 repetitions, with 60 seconds of rest between sets. In both groups, bilateral leg extension exercise will be performed by using the leg extension machine for resistance exercise. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken.
45622114|NCT03067623|Drug|PRP|PRP intrauterine infusion
45622115|NCT03067623|Device|Tomcat catheter|PRP intrauterine infusion by means Tomcat catheter
45622116|NCT05729529|Other|Lipoid acid gel|Topic lipoid acid gel used with topic oral gel used on tongue
45622117|NCT05729529|Drug|Placebo|Placebo oral gel used on tongue
45622118|NCT02466815|Drug|JNJ-42756493 Current Clinical Formulation (G-018)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as current clinical formulation (G-018) in treatment A in either period 1, 2 or 3 as per treatment sequence.
45622119|NCT02466815|Drug|JNJ-42756493 Prototype Formulation I (G-025)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation I (G-025) in treatment B in either period 1, 2 or 3 as per treatment sequence.
45912233|NCT02738853|Device|Medtronic Transcatheter Aortic Valve 2.0 Replacement System|Treatment of severe symptomatic aortic stenosis in subjects who are considered at high through extreme risk for surgical aortic valve replacement.
45622120|NCT02466815|Drug|JNJ-42756493 Prototype Formulation II (G-025)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation II (G-025) in treatment C in either period 1, 2 or 3 as per treatment sequence.
45622121|NCT03067779|Other|mHealth Tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing common patient safety themes in CKD and includes a pre- and post-test knowledge assessment. Topics of emphasis included NSAID risk awareness, hypoglycemia awareness, avoidance of volume depletion when ill (Sick Day Protocol) and avoidance of contrast-induced nephropathy."
45912234|NCT02730858|Behavioral|Palliative and Oncology Care|Patients randomized to the intervention will receive collaborative care from palliative care and oncology for the remainder of their illness. The initial five visits with palliative care will be conducted in accordance with the study specific clinical practice guidelines and occur at least monthly.
45912235|NCT02730858|Behavioral|Standard Oncology Care|Patients randomized to oncology care alone will continue to receive routine care identical to what they would have received if they had not participated in the trial. Either patients or their oncologists can request palliative care consultation at any point in time.
45912236|NCT02726711|Drug|Trimethaphan|Trimethaphan will be infused (0.5 - 4.0 mg IV)
45912237|NCT02726711|Drug|Placebo|0.5 - 4.0 mg IV to be infused
45446420|NCT04356573|Dietary Supplement|Gold Kiwifruit First, then Green Hayward Kiwifruit|Subjects ate 2 peeled gold kiwifruit with their midday meal for 2 weeks prior to testing.
45622122|NCT05555069|Other|Menthol-flavored electronic cigarette|Participants will receive 12 weeks of menthol -flavored electronic cigarettes to aid in switching from combustible cigarettes. Participants will be instructed on proper use of the electronic cigarettes, educated about electronic cigarettes and participate in motivation enhancement and substituting electronic cigarettes for cigarettes.
45622123|NCT05555069|Other|Tobacco-flavored electronic cigarette|Participants will receive 12 weeks of tobacco-flavored electronic cigarettes to aid in switching from combustible cigarettes. Participants will be instructed on proper use of the electronic cigarettes, educated about electronic cigarettes and participate in motivation enhancement and substituting electronic cigarettes for cigarettes.
45764520|NCT03001258|Other|Presbyopia screening training|The training module and the protocol were designed in a way that a layman with limited education could be trained for screening and could sell reading glasses without any hassle, accurately and responsibly. Training module included the general anatomy of eye, common vision problems, aetiologies, determination of proper acuity of vision, sales techniques of the reading glass, marketing of products and services, and management of inventory and referrals. All the providers who participated in the current study, had no prior experience/training of screening presbyopia before the intervention. Each of the intervention arm used letter acuity chart i.e. Snellen chart as it commonly used for as a test of visual acuity
45764521|NCT00945295|Drug|Botulinum toxin type A, BoNT-A|Participants will receive IM injections of BoNT-A between 200 and 400 Units with the total dose not to exceed 6 U / kg. The primary targets for BoNT-A injection are the wrist and finger flexor muscles (flexor carpi radialis, flexor carpi ulnaris, flexor digitorum profundus, flexor digitorum superficialis).
45764522|NCT00945295|Other|Rehabilitation Therapy|Rehabilitation therapy
45764523|NCT03772873|Procedure|minimally invasive pilonidal excision|MIPE procedure with trephine excision of pits and sinuses
45764524|NCT03706027|Device|radiation therapy-3 fractions|Radiation therapy given in a 3 fraction schedule (over 3 days). Total dose is 54 Grays.
45764525|NCT03706027|Device|Radiation therapy-5 fractions|Radiation therapy given in 5 fractions (over 5 days). Total dose is 60 Grays.
45764526|NCT03634813|Device|High Blood Pressure Monitor|High Blood Pressure Monitoring device (Omron MX3 model BP742, Omron, Shaumberg, IL)
45764527|NCT03634813|Procedure|Usual Care|Usual Care
45764528|NCT04354363|Other|Platelet rich plasma|Giving women PRP before ICSI
45764529|NCT03490825|Dietary Supplement|Melatonin 1 mg|Melatonin (1mg) will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
45764530|NCT03490825|Dietary Supplement|Placebos|Placebo will be administered daily during the intervention. The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the pills so the placebo (lactose/starch) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
45764531|NCT03490825|Other|Meal timing|Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.
46069316|NCT03013998|Drug|Decitabine (BAML-16-001-S14)|20 mg/m2, IV, on days 1 through 5 or 10 of each 28-day cycle and continuing for up to 2 years to time of intolerance or disease progression. During the first induction cycle, and the 2nd and 3rd induction cycles if they are needed, administration occurs on days 1 through 10 of each 28-day cycle. During maintenance, decitabine is administered on days 1 through 5 of each 28-day cycle. Patients may switch to TP-0903 monotherapy maintenance if they develop toxicity or are unwilling to continue decitabine during maintenance therapy.
45764532|NCT03490825|Other|Non-Meal timing|Subjects are instructed to maintain their habitual meal timing.
45622124|NCT03067701|Drug|Carbon Monoxide|In healthy young adults 18-39 years of age, The investigator will determine if intermittent inhalation of 0.1% CO, from a 1-Liter bag once every minute for 30-40 min at a level that approaches the CO boost with hookah smoking, augments endothelial function.
45764533|NCT04363099|Other|observational|observational management of outpatients COVID 19
45764534|NCT04354207|Diagnostic Test|Peripheral vein punction|Vitamin D level, vitamin D receptor genetic polymorphisms, allergen specific IgE and total IgE will be measured in peripheral blood
45764535|NCT04354207|Diagnostic Test|Stool collection|Gut microbiome will be investigated in stool samples.
45764536|NCT04362787|Device|High pressure non invasive ventilation in acute hypercapnic respiratory failure|Usage of High pressure non invasive ventilation in acute hypercapnic respiratory failure
45622125|NCT05548439|Biological|VBI-2901a|Intramuscular injection of VBI-2901a, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate adjuvant.
45622126|NCT03069339|Drug|Carvedilol|Carvedilol will start at starting dose of 3.125 mg BD followed by 6.25 mg BD followed by 12.5 mg BD if BP 90/60 mmHg and HR 55/min
45622127|NCT03069339|Procedure|Endoscopic Variceal Ligation|EVL will be done every 3 weeks till eradication
45622128|NCT05546411|Drug|mFOLFIRINOX|Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
45764537|NCT04354051|Drug|Sodium Nitrite|Intravenous nitrite sodium infusion, dose 70μmol, of 5 minute duration (14μmol /min-1).
45912238|NCT02691065|Drug|Integrase Inhibitor|Raltegravir
45912239|NCT02684201|Device|Boston Scientific Stimulator Lead|A Boston Scientific PMA P030017 spinal cord stimulator lead will be placed in the cervical epidural space of ten upper-limb amputees and steered laterally towards the dorsal spinal roots under fluoroscopic guidance.
45912240|NCT02649998|Drug|Furosemide|Furosemide is the most commonly used medication for treatment of heart failure. It causes a direct vasodilator effect shortly after administration, followed by diuresis induction. However, furosemide also activates both the sympathetic and the renin angiotensin systems, causing a rise in peripheral resistance.
45622129|NCT05546411|Drug|5-Fluorouracil (5-FU)|Part of the FOLFIRINOX drug combination, given by intravenous infusion
45622130|NCT05546411|Drug|Oxaliplatin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
45622131|NCT05546411|Drug|Irinotecan|Part of the FOLFIRINOX drug combination, given by intravenous infusion
45622132|NCT05546411|Drug|Leucovorin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
45446421|NCT02073916|Drug|T-DM1|antibody-drug conjugate of trastuzumab and emtansine
45912241|NCT02649998|Drug|Isosorbide Dinitrate|Isosorbide dinitrate is a vasodilator which is also well-known for treating acute decompensated heart failure. It induces acute venodilatation at low dose and arteries dilation when gradually increasing the dose. The effect peaks 5 min after administration.
45912242|NCT02503358|Other|Laboratory Biomarker Analysis|Correlative studies
45912243|NCT02503358|Drug|Paclitaxel|Given IV
45912244|NCT02503358|Other|Pharmacological Study|Correlative studies
45912245|NCT02503358|Drug|Selumetinib|Given PO
45912246|NCT02482493|Device|Sigma PFC|patients will receive either an all polyethylene tibial component or a metal- backed component
45912247|NCT02432963|Other|Laboratory Biomarker Analysis|Correlative studies
45622133|NCT05546411|Drug|NIS793|Given by intravenous infusion
45912248|NCT02432963|Biological|Modified Vaccinia Virus Ankara Vaccine Expressing p53|Given SC
45622134|NCT05546411|Radiation|Chemoradiation|Combination of Chemo (Capecitabine) and Radiation Therapy
45622135|NCT05546411|Procedure|Surgery|Surgical removal of tumor
45622136|NCT03069105|Other|Questionnaire|Participants will complete paper and pencil or electronic questionnaires at the cancer center or in the privacy of their own homes.
45622137|NCT05542589|Other|Phenytoin phonophoresis|Phenytoin phonophoresis for 5-10 minute sessions, three times per week and six weeks as a total period treatment.
45622138|NCT05542589|Other|Sham phenytoin phonophoresis|Sham phenytoin phonophoresis for 5-10 minute sessions, three times per week and six weeks as a total period treatment.
45622139|NCT03069027|Procedure|External nasal nerve block|Three single (midline injection) and 4 paired (bilateral injection) sites to block the external nasal sensation.
45622140|NCT03069027|Drug|saline adrenaline|
45622141|NCT03069027|Drug|Xylocaine, adrenaline|
45764538|NCT04362943|Drug|Baricitinib or Anakinra|Treatment with either Baricitinib or Anakinra during hospitalization, in real world, and under usual clinical care.
45764539|NCT03317899|Procedure|Hematopoietic Cell Transplantation|Undergo auto HSCT
45764540|NCT03317899|Drug|Tbo-filgrastim|Given subcutaneously
45764541|NCT03317899|Other|Laboratory Biomarker Analysis|Correlative Studies
45764542|NCT04353505|Drug|Ketorolac|Intra-arterial delivery of Ketorolac in the internal maxillary artery, once
45764543|NCT04353505|Drug|Dexamethasone|Intra-arterial delivery of Dexamethasone in the internal maxillary artery, once.
45912249|NCT02432963|Biological|Pembrolizumab|Given IV
45912250|NCT02432950|Dietary Supplement|Dietary Intervention|Participate in the PNP
45622142|NCT05263973|Other|Music|The infants in the music group (Acem Aşiran Maqam music prepared by TÜMATA group) will be applied music for a about total of 12 minutes, starting 3 minutes before the ROP examination and continuing during the ROP examination, 3 minutes after ROP examination
45622143|NCT05635071|Drug|Nintedanib 100 MG [Ofev]|Nintedanib 100mg bid *15 days orally after hysteroscopic surgery
45622144|NCT05635071|Drug|Nintedanib 150 MG [Ofev]|Nintedanib 150mg bid *15 days orally after hysteroscopic surgery
45622145|NCT04489979|Other|Antibiotics|Children with epididymitis / orchitis who were treated by antibiotics in addition to analgetics.
45622146|NCT05634993|Other|Assessment|Assessment of disability level and trunk control
45622147|NCT04568967|Diagnostic Test|Concentrated urine with Xpert Ultra|Molecular TB diagnostic test on urine
45622148|NCT04568967|Diagnostic Test|Stool with Xpert Ultra|Molecular TB diagnostic test on stool
45622149|NCT02720081|Drug|MK-1029 150 mg|150 mg tablet administered orally, once a day (QD), at bedtime
45764544|NCT03005899|Drug|SyB P-1501|"After extubation and adequate titration by Fentanyl intravenous injection, the investigational product is applied to outer upper arm or chest on patient who confirmed treatment eligibility. Fentanyl 40 μg per dose is delivered over a 10-minute period by pressing the dosing button by the subject as needed. The 10-minute dosing period is a system lock-out time, allowing for a maximum of 6 doses per hour. One system is operable for 24 hours or until 80 doses are delivered, whichever occurs first.~Duration of application of the investigational product is 24 hours. Duration of application may be extended for up to 72 hours or until the third system is used, whichever occurs first, if the patient requests it and the specified tests can be performed"
45622150|NCT02720081|Drug|MK-1029 Matching-image Placebo|Matching-image placebo tablet administered orally, QD, at bedtime
45622151|NCT02720081|Drug|Montelukast 10 mg|10 mg tablet administered orally, QD, at bedtime
45622152|NCT02720081|Drug|Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation|1 or 2 inhalations 4 times a day (QID) as needed (PRN) as a Rescue Medication
45622153|NCT04552197|Drug|JNJ-64251330|JNJ-64251330 tablet will be administered orally.
45622154|NCT04552197|Drug|Tofacitinib|Tofacitinib tablets will be administered orally.
45446422|NCT02073916|Drug|Lapatinib|Dual tyrosine kinase inhibitor (HER2 and EGFR)
45622155|NCT05729295|Procedure|Endovascular embolization or surgery|Endovascular embolization with embolizing agents (including glue, non-adhesive agents) or neurosurgical excision of the lesion.
45764545|NCT03005899|Drug|SyB P-1501 placebo|Identical to SyB P-1501 containing hydrogel that contains the active ingredient fentanyl HCI in its structure and appearance but production of an electric current and subsequent drug administration by iontophoresis are prevented because of its modified circuit.
45764546|NCT02929927|Procedure|Rubber dam isolation|tooth was isolated using a rubber dam in order to avoid the outside microbe
45764547|NCT02929927|Device|aPDT|Inject the photosensitizer (PS)to the parallel orifice of the canal,use the small file to stir the PS for 60 s,then irradiation 120 s.
45764548|NCT02929927|Drug|1% iodine tincture|use 1% iodine tincture to disinfect the crown of the teeth.in order to avoid the outside microbe
45764549|NCT02929927|Drug|2.5%NaClO|use 2.5% NaClO as irrigants
45764550|NCT02929927|Procedure|root canal preparation|mechanical preparation with NITIMTWO to 25#06, and cleaned with 5 ml of 2.5% NaClO between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2.5% NaClO, 17% EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer
45764551|NCT02929927|Procedure|root canal obturation|filled the canals with AH-Plus sealer and Gutta-percha by vertical condensation
45764552|NCT02693665|Behavioral|FAmily CEntered Advance Care Planning for Teens with Cancer|3 session weekly intervention: 1) survey completed by adolescent and family (surrogate decision maker) separately with facilitator; 2) Respecting Choices structured interview about patient's representation of illness, goals of care, hopes, treatment preferences; 3) completion of an advance directive.
45446423|NCT02073916|Drug|Abraxane|albumin-bound paclitaxel. Chemotherapy - microtubule inhibitor
45446424|NCT02084368|Procedure|Nerve block|Patients in this group were assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacaine 30ml guided by PNS
45622156|NCT03067545|Other|Step rate increase|increase the step rate during running by 10% steps per minute
45622157|NCT05244473|Drug|brentuximab vedotin|Given into the vein (IV; intravenously)
45622158|NCT05244473|Drug|Placebo|Given by IV
45622159|NCT05244473|Drug|ART|Daily use of a combination of HIV medicines
45622160|NCT03067389|Diagnostic Test|Diagnostic test|Genetic diagnostic test
45622161|NCT05239403|Procedure|Biospecimen Collection|Undergo collection of blood and stool samples
45622162|NCT05239403|Other|Questionnaire Administration|Complete questionnaires
45653373|NCT05040243|Other|Yanqing Zhitong Ointment Acupoint application|Yanqing Zhitong Ointment is a traditional external preparation of experiential prescription, which is an extract made by water extraction and concentration of Qingfengteng, Corydalis yanhusuo, Interleukin, Kansui, Asarum, etc. Clinical studies in the past ten years have preliminarily shown that it has the effects of warming meridians, promoting blood circulation, dredging collaterals and relieving pain, and has a definite effect.
45764553|NCT02427451|Drug|Bcl-2 Inhibitor GDC-0199|Given PO
45764554|NCT02427451|Biological|Obinutuzumab|Given IV
45764555|NCT02427451|Drug|Ibrutinib|Given PO
45622163|NCT05634759|Drug|Azithromycin for Routine Community-wide MDA|"Oral azithromycin, also known as the brand name Zithromax®, is a macrolide antibiotic and is used in the treatment of active trachoma. The recommended dosage for the treatment of trachoma is a single dose of 20mg/kg of body weight and is implemented by a Age-height based dosing strategy for the trachoma MDA campaigns. Oral azithromycin can be administrated in either tablet form or powder for oral suspension (POS). Zithromax® is donated by Pfizer Inc through the International Trachoma Initiative (ITI) to the South Sudan Federal Ministry of Health to use in community-wide MDA throughout South Sudan."
45764556|NCT02427451|Other|Pharmacological Study|Correlative studies
45764557|NCT02427451|Other|Laboratory Biomarker Analysis|Correlative studies
45764558|NCT02427451|Other|Quality-of-Life Assessment|Ancillary studies
45764559|NCT00932035|Procedure|axillary lymph node dissection|Undergo reverse mapping-guided axillary lymph node dissection
45764560|NCT00932035|Drug|isosulfan blue based lymphatic mapping|
45764561|NCT00932035|Procedure|axillary lymph node dissection|Undergo standard axillary lymph node dissection
45764562|NCT00932035|Procedure|quality-of-life assessment|Ancillary studies
45764563|NCT00932035|Other|Questionnaire administration|Ancillary studies
45764564|NCT04362397|Behavioral|FoCo|This is an attention, care and self-care training.
45764565|NCT04362397|Behavioral|No intervention|This is a waiting list
45764566|NCT04362241|Drug|Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]|Prednisolone Acetate 1% ophthalmic drops
45764567|NCT05620069|Other|Music listening|Participants are asked to select one of four music playlists and listen to it for appr. 30 minutes at bedtime during the intervention period.
45764568|NCT05619757|Behavioral|Compliance with medical treatment for endometriosis|"During their scheduled consultation at the Hôpital Femme Mère Enfant (HFME), women who meet the eligibility criteria will be presented with the study and given the written information note. If they agree to participate, the investigator will give them a QR code redirecting them to the online self-questionnaire.~Patients will be included once they log in and complete the questionnaire."
45764569|NCT04362319|Diagnostic Test|Questionnaire forms|Assessment of demographics, burnout, depression and self-perceived medical errors
45764570|NCT01384513|Drug|Fludarabine|Given IV
45764571|NCT01384513|Drug|Busulfan|Given IV
45764572|NCT01384513|Radiation|Total Body Irradiation (TBI)|2 Gy administered as part of the conditioning regimen
45764573|NCT01384513|Biological|Donor Lymphocyte Infusion (DLI)|Undergo DLI
45764574|NCT01384513|Drug|Cyclophosphamide (CY)|Given IV
45764575|NCT01384513|Drug|Tacrolimus|Given IV or PO
45764576|NCT01384513|Drug|Mycophenolate mofetil|Given IV
45764577|NCT01384513|Device|Allogeneic hematopoietic stem cell transplantation|Undergo CD34+ allogeneic PBSCT
45764578|NCT01384513|Procedure|Peripheral blood stem cell transplantation (PBSCT)|Undergo CD34+ allogeneic PBSCT
45764579|NCT05613907|Other|CLTI Clinic|This is a specialist clinic designed to assess and manage patients with CLTI.
45764580|NCT03035617|Drug|Bupivacaine|Bupivacaine is long acting local anesthetic drug. Though minimum toxic dose of bupivacaine for intra-peritoneal use is not defined, analgesic effect of its intra-peritoneal use especially after laparoscopic cholecystectomy has been assessed in several interventional studies. Intra-peritoneal use of up to 50ml of .25% , , or up to 20ml of .5% solution has not shown any drug related adverse reactions .
45764581|NCT03035617|Other|Saline|In control arm mesh will be soaked in normal saline solution as is routinely done.
45764582|NCT02933320|Biological|BI-1206 single agent dose escalation phase|BI-1206 single agent dose escalation phase to determine the MTD or maximum administered dose (MAD) and recommended Phase II dose (RP2D) for evaluation of BI-1206.
45764583|NCT02933320|Biological|Combination of BI-1206 with rituximab escalation phase|An investigation of combination treatment of BI-1206 with rituximab.
45764584|NCT02933320|Biological|BI-1206 single agent expansion phase|BI-1206 single agent expansion phase at the RP2D.
45764585|NCT02933320|Biological|Combination of BI-1206 with rituximab expansion phase|BI-1206 in combination with rituximab at the RP2D.
45764586|NCT05613829|Other|Burn surgery|Patients underwent burn surgery
45764587|NCT04361773|Radiation|Photobiomodulation|Treatment with a device with 144 light emitting diodes (LEDs) at wavelengths of 420, 660 and 850nm, 3J per point for 10 minutes.
45764588|NCT04361773|Other|Sham Photobiomodulation|Simulation of the LED application, with a device with external characteristics identical to that of the PBM group, for the same period of time.
45912251|NCT02432950|Other|Educational Intervention|Participate in the PNP
45912252|NCT02432950|Other|Laboratory Biomarker Analysis|Correlative studies
45622164|NCT05634759|Drug|Two Additional Rounds of Azithromycin for Children|An additional round of treatment will be given one week after the routine community-wide MDA, and a second additional round will be given two weeks later (3 weeks after the routine community-wide MDA).
45622165|NCT05634759|Drug|Azithromycin for Second Community-wide MDA|A second community-wide MDA will be given 6 to 8 months after the routine community-wide MDA. The timing of the second MDA will depend on local conditions and logistical concerns.
45622166|NCT05501795|Device|WaveLight® FS200 femtosecond laser|Flap creation with the WaveLight® FS200 femtosecond laser
45622167|NCT05634681|Radiation|Plan of the day|Several treatment plans are prepared and the appropriate plan is used at each treatment session.
45622168|NCT05634681|Radiation|Standard plan|One treatment plan
45622169|NCT05728983|Other|Sleep levels|Sleep levels are what the experimenter prescribes to participants in the study.
45622170|NCT05233319|Other|There is no intervention|There is no intervention
45622171|NCT05634603|Dietary Supplement|Lactose-free milk formula (Frisolac LF ®)|Following the initial rehydration phase, children were alternately assigned to receive 100 ml/kg/day of either lactose-free or lactose-containing formula
45622172|NCT04809233|Drug|Tipifarnib|
45622173|NCT03067233|Other|Polysomnography|Complete polysomnography with : Electroencephalogry, electro-oculography, surface electromyography (chin muscle, anterior tibial muscles), nasal pressure, respiratory movements (plethysmography of thoracic and abdominal inductance), pulse oximetry and electrocardiography.
45622174|NCT05728905|Other|Therapeutic exercise|Intervention with therapeutic exercise: coordination, relaxation and disc recapture exercises.
45764589|NCT02933476|Device|Vibrotactile Stimulation|The tactile stimulator is being tested for an off-label use as treatment for Parkinson's disease. There are nodes embedded into the fingertips of gloves that gently vibrate in an alternating pattern. The sensation is similar to the feeling of a phone vibrating. This is a non-significant risk device.
45912253|NCT02432950|Other|Quality-of-Life Assessment|Ancillary studies
45446425|NCT02084368|Procedure|Combined spinal and epidural anesthesia|Combined spinal and epidural anesthesia were performed in patients of this group with 0.5% hyperbaric bupivacaine 8~10mg at L2-3 or L3-4.
45912254|NCT02414477|Drug|Deuterated NNN|Smokeless tobacco study product
45622175|NCT05728905|Other|Orthopedic manual therapy|Intervention with orthopedic manual therapy: traction, ventral sliding and massage.
45622176|NCT02310269|Drug|SOM230|
45622177|NCT03069183|Drug|0.5% Ropivacaine|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.
45622178|NCT03069183|Drug|Normal saline|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
45622179|NCT05728827|Other|Blood flow restriction training + Anti-gravity treadmill|Blood flow restriction training is administered via straps applied to the proximal limb with the possibility to adjust the applied occlusion pressure in order to prevent venous return leaving the arterial flow partially free. The consequent blood pooling causes a reduction in tissue saturation with oxidative stress and an increased growth factors secretion. The intervention will be applied while walking/running on the anti-gravity treadmill.
45622180|NCT05728827|Other|Anti-gravity treadmill|The intervention will be applied walking/running on the anti-gravity treadmill.
45622181|NCT05728749|Other|Non-interventional|As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
45622182|NCT04489745|Radiation|SBRT|
45622183|NCT04489745|Drug|Androgen deprivation therapy (ADT)|
45622184|NCT05634447|Drug|Drug: CKD-391, QD, PO|Drug: CKD-331, D337 QD, PO
45622185|NCT05728671|Drug|IP2015|Test drug
45622186|NCT05183165|Other|Patients with Wilson's disease declaring pregnancy,|Blood and urine biological assessment Dietary assessment
45764590|NCT04361695|Procedure|Hemorrhoidectomy|The patient receives spinal anaesthesia and is placed in lithotomy position. A complex of external and internal haemorrhoid or internal haemorrhoid only is excised with monopolar electrocautery or bipolar electrosurgery device. Haemorrhoid pedicle is tied with absorbable polyfilament suture. One, two or three nodes can be removed per a procedure.
45764591|NCT04361695|Drug|Ketoprophenum|Ketoprophenum
45912255|NCT02396134|Biological|CMVpp65-A*0201 peptide vaccine|Given SC
45622187|NCT03065907|Other|Vision rehabilitation|A service menu containing the minimum vision rehabilitation visits will be provided and assessed according to the participant's vision needs. Minimum vision rehabilitation visits include refraction, best-corrected visual acuity assessment, near vision, contrast sensitivity, central visual field test, education and consultation; rehabilitation visit will then be individualized.
45446426|NCT02084368|Drug|Ropivacaine|Patients will be assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacain 30ml guided by PNS.
45622188|NCT04392765|Device|eXciteOSA|eXciteOSA transoral neurostimulation device
45764592|NCT04361695|Drug|Placebo|Placebo
45764593|NCT03035773|Behavioral|Care Plan Only|Patient participants randomized to Arm A will be sent a copy of the SCP within 3 months of completion of treatment and a copy will be added to their medical record. A copy of the SCP will also be sent to the PCP on record. The SCP will be completed by a nurse, nurse practitioner, or physician assistant. The SCP will be accompanied by a cover letter that will be signed by a member of the clinical team.
45912256|NCT02396134|Other|Placebo|Given SC
45622189|NCT05180123|Procedure|Anterior cruciate ligament reconstruction|Adolescent patients with confirmed full thickness ACL injury were operated arthroscopically with semitendinosus and gracilis autograft anatomical reconstruction.
45622190|NCT05179811|Procedure|Hypnosis sessions|"Physical examination~Psychiatric Assessment~VHI, SF-36, IPQ-R questionnaires~Standardized voice recording~3 Standardized Hypnotherapy sessions~CGI-I-Patient Questionnaire"
45622191|NCT02464865|Drug|Thiamine 1|"If severe symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~Intervention 1 : severe symptom (heart failure, convulsion, or coma) : 50 mg thiamin administered very slowly intravenously, followed by a daily intramuscular dose of 10 mg for a week, and finally followed by 3-5 mg of thiamine per day orally for at least 6 weeks"
45764594|NCT03035773|Behavioral|Care Plan During a Visit|Patient participants randomized to Arm B will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider on record. The visit will be scheduled after consent is signed and will occur between 1 and 3 months after completion of treatment. The visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues.
45764595|NCT03035773|Behavioral|Care Plan During a Visit with an Additional Visit|Participants randomized to Arm C will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider. The visit will be scheduled after consent is signed and will occur between 1-3 months after completion of treatment. The initial visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues. Patients will also receive a follow up survivorship visit 7-10 months after the end of treatment that will focus on a review of the SCP and offer the opportunity to ask about any persistent or emerging issues.
45764596|NCT03035149|Other|Weight Management Program|Obese subjects partake in a medically supervised weight management program. This lifestyle modification program involves weekly three hour sessions for six months and monthly sessions for six months. The first twelve weeks comprise an initial weight loss phase when patients are placed on a 900 Kcal/day meal replacement. This is followed by a four week transition to a 1200-1800 Kcal diet followed by a ten week maintenance phase of 10 weekly sessions.The majority of weight loss occurs during the first 26 weeks followed by a 26 week period of stabilization of weight loss. Hence subjects are evaluated after the first 26 weeks.
45764597|NCT03035383|Procedure|Purse string technique|Thyroidectomy closure is performed using purse string suturing technique.
45764598|NCT03035383|Procedure|Conventional technique|Thyroidectomy closure is performed using conventional suturing technique.
45764599|NCT05563675|Drug|Long acting muscarinic antagonists (LAMAs) at bedtime|LAMAs administered at bedtime (approx 8-10pm)
45764600|NCT02933866|Drug|DSXS topical|topical treatment
45764601|NCT02933866|Drug|Vehicle topical|topical treatment
45764602|NCT05555251|Drug|BI-1607|administered at different doses in Phase I by intravenous infusions every 3 weeks.
45764603|NCT05555251|Drug|BI-1607|administered at the recommended dose in Phase 2a by intravenous infusions every 3 weeks.
45764604|NCT05555251|Drug|Trastuzumab|administered at 8mg/kg for the first infusion and at 6mg/kg in subsequent infusions by intravenous infusions every 3 weeks.
45912257|NCT02396134|Other|Laboratory Biomarker Analysis|Correlative studies
45912258|NCT02380079|Drug|SCD-101|Administered as gelatin capsules
45912259|NCT02358538|Drug|Ganaxolone|oral suspension or capsules
45912260|NCT02349906|Drug|Treosulfan|
45446427|NCT02084368|Drug|Bupivacaine|Combined spinal and epidural anesthesia will be performed in patients with 0.5% hyperbaric bupivacaine 8~10mg.
45446428|NCT02084446|Drug|Everolimus|Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.
45622192|NCT02464865|Other|Non-thiamine|no symptoms and signs of thiamine deficiency
45622193|NCT02464865|Drug|Thiamine 2|"If symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~If mild symptom : a daily oral dose of 10 mg thiamin during the first week, followed by 3-5 mg of thiamin per day orally for at least 6 weeks"
45622194|NCT02466035|Dietary Supplement|Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG|Extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG
45912261|NCT02349906|Drug|Busilvex|
45912262|NCT02338037|Procedure|Therapeutic Conventional Surgery|Undergo tumor resection
45912263|NCT02338037|Procedure|Biopsy|Undergo biopsy
45912264|NCT02338037|Drug|Eribulin Mesylate|Given IV
45912265|NCT02338037|Procedure|Microdialysis|Undergo intracerebral microdialysis
45912266|NCT02338037|Other|Pharmacological Study|Correlative studies
45912267|NCT02336087|Drug|Gemcitabine Hydrochloride|Given IV
45622195|NCT05728593|Other|parent-based occupational therapy|Parent-based occupational therapy intervention While the therapist, parent and child were in the therapy area in the first session, the child received the same standard occupational intervention as the control group, and during this process, the parents recorded the therapy with a video recorder. In the second 20 minutes, three activities (such as eating, dressing or mobility activities), which had been decided and planned by the parent and the therapist before the session, were performed by the child and helped by the parent and video-recorded by the occupational therapist.
45446429|NCT02084446|Drug|Very Low Tacrolimus|Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.
45622196|NCT05728593|Other|Standard occupational therapy intervention|"The sessions in this intervention included the creation of a client-based programme to increase each child's individual skills, functions and social participation. Each session lasted 45 minutes and took place twice a week until 10 sessions had been completed.~Various materials such as toys, blocks, paper and pencils were used to increase the child's participation in daily living, leisure and play activities."
45446430|NCT02084446|Drug|Low Tacrolimus|Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.
45622197|NCT05173337|Drug|Nefopam|"Nefopam 20 mg is mixed to 100 mL of normal saline, and is infused intravenously over 15 minutes.~20 mg of nefopam is administered intravenously for two times, after induction and at the end of surgery."
45622198|NCT03066921|Dietary Supplement|Probiotic packet|Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
45622199|NCT03066921|Dietary Supplement|Placebo|Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
45622200|NCT02464787|Dietary Supplement|LifePak Nano|Two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period.
45622201|NCT05728515|Drug|68Ga-NY104|Patients will undergo PET/CT scans after receiving an intravenous injection of 68Ga-NY104
45622202|NCT02464631|Drug|Sofosbuvir + Ribavirin 1|
45622203|NCT02464631|Drug|Sofosbuvir + Ribavirin 2|
45622204|NCT02464631|Drug|Sofosbuvir + Ribavirin 3|
45622205|NCT03066687|Drug|Erdafitinib|Erdafitinib 9 mg (provided as one 4-mg tablet [G-024] and one 5-mg tablet [G-025]) will be administered orally on Day 1 in each Treatment Period of assigned sequence.
45622206|NCT04880577|Drug|TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]|The study is designed to add on TAF to anti-CD20 therapies
45622207|NCT04880577|Drug|Placebo|Placebo arm
45622208|NCT04353921|Other|No intervention will be administered as part of this study.|No intervention will be administered as part of this study.
45622209|NCT04290897|Drug|Anhydrous Enol-oxaloacetate|Given PO
45446431|NCT02084446|Drug|Steroids|Corticoids: endovenous Methylprednisolone will be administered 30-60 minutes before the first 3 doses of r-ATG: 250 mg (D0) and 125 mg (D2 and D4); Prednisone, 10 mg per oral, will be administered before the last dose of r-ATG (D6). Maintenance with Prednisone at post-transplant period will be performed in accordance with center local practice, i.e., only in patients with chronic previous use of corticosteroids, as well as in patients with autoimmune disease (systemic lupus erythematous, rheumatoid arthritis, etc).
45446432|NCT02084446|Drug|Thymoglobulin|All patients will receive induction with rabbit Thymoglobulin (r-ATG) in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg), administered according to center local practice (before graft revascularization and at days 2, 4, and 6 post-transplant).
45446433|NCT02084446|Drug|Sodium Mycophenolate|Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1.
45446434|NCT02877316|Other|MYPLAN-safety plan as an application for smart phones|MYPLAN app as a integral part of the standard treatment
45622210|NCT04290897|Other|Questionnaire Administration|Ancillary studies
45622211|NCT04280211|Other|Respiratory Assessment|Spirometric measurement
45622212|NCT04280211|Other|Vestibular Assessment|Assessment of peripheral vestibular dysfunction, angular vestibule ocular reflex, vestibular dysfunction
45622213|NCT04280211|Other|Balance Assessment|Postural stability
45622214|NCT02465957|Biological|aNK (NK-92)|A natural killer cell line recovered from a patient with large granular lymphoma
45653374|NCT05040243|Other|placebo acupoint application|"The control group was combined with placebo acupoint application on the basis of conventional acupuncture treatment.~Placebo patch: colored and drug-free patch (composition: petrolatum, food coloring) Acupuncture, application of acupuncture points and treatment course were the same as those in the treatment group."
45622215|NCT04248933|Behavioral|Peer-Delivered Behavioral Activation (Peer Activate)|The Peer Activate intervention consisted of weekly one-hour BA sessions led by a peer recovery specialist (PRS) for up to 12 weekly sessions, with the first five being the core treatment sessions and content, and the subsequent seven designed to reinforce core content. In these sessions, participants received individualized support in learning skills to assist in their retention and persistence in methadone treatment and were guided through exercises aimed at incorporating substance-free, rewarding activities into their daily life.
45622216|NCT04680689|Diagnostic Test|128 Multislice CT coronary angiography|128 Multislice CT coronary angiography with the evaluation of coronary stenosis, the plaque vulnerability markers ( necrotic core, low attenuation plaque, spotty calcifications, napkin ring sign, positive remodeling), asses polar maps of the myocardium
45622217|NCT04680689|Diagnostic Test|2D Cardiac Transthoracic Echocardiography|2D Cardiac Transthoracic Echocardiography with the evaluation of the cardiac cavity dimensions
45622218|NCT04680689|Diagnostic Test|Laboratory Blood tests|Laboratory tests for evaluations the level of inflammatory biomarkers ( hs-CRP, MMP, IL6 and NT-pro-BNP), complete blood count, biochemestry
45622219|NCT04489901|Other|Olive oil|To apply 10 cc (4 tablespoons) of extra virgin olive oil to the entire abdomen by hand without massaging twice a day in the morning and evening.
45622220|NCT04656587|Device|Philips Respironics V60 Non-invasive ventilator, BPAP|Continuous albuterol will be administered through the BPAP circuit.
45622221|NCT04656587|Other|Standard Therapy|Standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
45622222|NCT02718131|Device|INFUSE Bone Graft (BMP-2)|The INFUSE bone graft, containing BMP-2 on a collagen sponge, will be wrapped around the tibia during the surgical process.
45622223|NCT02718131|Procedure|Control Group|The control group will receive the standard surgical protocol, without addition of the INFUSE device.
45622224|NCT02465879|Other|Therapist Triage|An extended role occupational or physical therapist will triage each subject in the study to determine the urgency of their case and how soon they need to see the rheumatologist.
45622225|NCT03066765|Device|Linguaflex Tongue Retractor|Tongue implant
45764605|NCT03035305|Dietary Supplement|Lipid-based Nutrient Supplement (LNS)|"For each round of SMC distribution (total of 4 rounds):~For children aged 6-11 months: 15 sachets/month or 50g every two days for 4 weeks~For children aged 12-59 months: 21 sachets/month or 50g per day for 3 weeks"
45764606|NCT03035305|Drug|Seasonal malaria chemoprevention|"For each round of SMC distribution (total of 4 rounds):~For children aged 6-11 months: sulfadoxine 250mg/pyrimethamine 12.5mg and amodiaquine 75mg~For children aged 12-59 months: sulfadoxine 500mg/pyrimethamine 25mg and amodiaquine 150mg~D1 : 1 tablet sulfadoxine-pyrimethamine + 1 tablet amodiaquine D2 : 1 tablet amodiaquine D3 : 1 tablet amodiaquine"
45912268|NCT02336087|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
45912269|NCT02336087|Drug|Metformin Hydrochloride|Given PO
45622226|NCT02465723|Device|MRI with IVIM DW-MRI|
45622227|NCT02465723|Other|Blood draw|For each patient enrolled, 8-10 mL of whole blood will be collected into glass, anti-coagulant-free tubes and allowed to clot 20-30 minutes.
45764607|NCT02935036|Drug|ADPS topical product|topical product
45764608|NCT02935036|Drug|Placebo Control|topical product
45622228|NCT03069261|Device|Indocyanine green angiography|
45764609|NCT05518045|Drug|LM-108|Administered intravenously
45764610|NCT05518045|Drug|Toripalimab|Administered intravenously
45764611|NCT03035071|Procedure|minimally invasive esophagectomy|In the MIE group the laparoscopic procedure was performed for gastric tube formation. The patient was placed in supine position with legs apart. The surgeon stands between the legs using a five-trocar technique. Laparoscopy will be followed by an anterolateral thoracotomy in the fourth intercostal space.
45764612|NCT03035071|Procedure|open esophagectomy|in the open group the gastric mobilization and gastric tube formation will be perfumed with an open surgical approach. Laparotomy will be performed, followed by an anterolateral thoracotomy in the fourth intercostal space.
45764613|NCT03034837|Drug|resin sealant|Sealing the occlusal surface of the included molars using the market product of SDI conseal f once.
45764614|NCT03034837|Drug|ART sealant|"Sealing the occlusal surface of the included molars using the market product of 3M ESPE KetacTM Molar Easymix glass ionomer cement once."
45912270|NCT02336087|Dietary Supplement|Therapeutic Dietary Intervention|Given PO
45912271|NCT02336087|Other|Laboratory Biomarker Analysis|Correlative studies
45912272|NCT02336087|Other|Quality-of-Life Assessment|Ancillary studies
45912273|NCT02332980|Drug|Ibrutinib|Given PO
45912274|NCT02332980|Drug|Idelalisib|Given PO
45912275|NCT02332980|Other|Laboratory Biomarker Analysis|Correlative studies
45912276|NCT02332980|Biological|Pembrolizumab|Given IV
45912277|NCT02268253|Drug|SL-401|
45912278|NCT02235051|Behavioral|exercise intervention|Undergo Curves exercise program
45912279|NCT02235051|Other|laboratory biomarker analysis|Correlative studies
45912280|NCT02235051|Other|questionnaire administration|Ancillary studies
45912281|NCT02235051|Other|quality-of-life assessment|Ancillary studies
45912282|NCT02197234|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
45622229|NCT04490213|Other|Allevyn, Aquacel and Tegaderm, Mediskin|Wound dressing tested earlier on donor sites, in this study scar outcome between the 3 dressing groups are compared.
45764615|NCT03034759|Other|individualized insulin sensitivity index (ISind)|"The new insulin sensitivity index, named SISP is calculated from data derived from insulin pump and glucose monitoring (CGM) uploads."
45764616|NCT02158273|Drug|Sugar Pill|145 mg/day, oral pill, 9 days
45764617|NCT02158273|Drug|TRICOR (fenofibrate)|145 mg/day, oral pill, 9 days
45912283|NCT02197234|Drug|Simvastatin|Simvastatin (CYP substrate) 40mg taken once daily on Days 1 and 31 (Part A)
45446435|NCT02877316|Other|safety plan on paper|Standard treatment with safety plan on paper
45622230|NCT05728437|Procedure|Resistance exercise|The program will consist of seven exercises: triceps press, biceps curl, lat pull down, calf raise, leg press, leg extension and sit-ups using dumbbells and sand bags. Each session will last approximately 45 minutes and consist of a 5-minute warm-up with stretching following by resistance exercise that will be done as a cir¬cuit, ending with 5-minute cool down. The 1 repetition maximum (1RM) is measured at baseline and follow¬ing the intervention. Initially, participants will do two circuits using 50% of their 1RM and repeat them 10 times for the first and second weeks, progressing to two circuits, using 60% of their 1RM and repeat 10 times for the third and fourth weeks. In fifth and sixth weeks, participants will do three circuits using 60% of their 1RM and repeat 10 times. In the last two weeks, patients will do three circuits using 70% of their 1RM and repeat 10 times. A 90-second rest will be allowed between sets of exercises.
46069317|NCT03013998|Drug|Decitabine (BAML-16-001-S8 Group 2)|20 mg/m2, IV, on days 8 through 12 of the first 35-day induction cycle, then on days 1 through 5 of subsequent 28-day cycles and continuing for up to 60 cycles, disease progression, intolerance, or patient desire to discontinue therapy.
45446436|NCT02801656|Biological|Fecal Microbiota Transplantation|Oral, encapsulated FMT
45446437|NCT02801656|Drug|Vancomycin|Vancomycin po 125 mg qid x 10 days
45446438|NCT02801656|Biological|Fecal Microbiota Transplantation Placebo|Matching placebo to FMT
45446439|NCT02801656|Drug|Vancomycin Placebo|Matching placebo to Vancomycin
45446440|NCT02074072|Device|15 degree left-lateral tilt wedges|The wedges are made of aluminium
45446441|NCT02074072|Device|30 degree left-lateral tilt wedges|The wedges are made of aluminium
45446442|NCT02084524|Procedure|Malnutrition screening and perioperative nutritional support|"Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines~Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)~Implementation of an adapted nutritional support based on ESPEN Guidelines"
45446443|NCT02081482|Radiation|18F-FDG PET|
45446444|NCT02084602|Drug|Artesunate|Orally administration of artesunate 4mg/Kg by three days
45764618|NCT02819284|Drug|KPI-121 0.25% Ophthalmic Suspension|
45764619|NCT02819284|Drug|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
45764620|NCT04361461|Drug|Hydroxychloroquine Sulfate|400 mg orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once daily, orally, for 10 days.
45764621|NCT04361461|Drug|Hydroxychloroquine Sulfate + Azythromycin|400 mg, orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once a day, orally, for 10 days associated with azithromycin, intravenously or orally, 500 mg / day, for 1 day and then 250mg / day for another 4 days.
45764622|NCT03002506|Drug|Ceftolozane/tazobactam|Single dose of 2 grams/1 gram intravenously administered over 60 minutes.
45764623|NCT03034993|Behavioral|Text Messaging|"Subjects will receive text messages with reminders of their upcoming outpatient health care appointments at the Boston Health Care for the Homeless Program (BHCHP) clinic. The text message will indicate the time of the appointment and the location (e.g. Remember appointment Friday March 15 at 10am in the Yawkey building). Appointment reminder text messages will be sent 3 days ahead and again 1 day ahead of the appointment date. Medication related texts will be sent every other day and will be educational and motivational (e.g. Keep taking medications that way the doctor prescribed them, even if feeling fine). Mood related texts will also be sent every other day and ask about mood on a 1 to 5 scale. The participant will text back a response."
45764624|NCT02822950|Drug|Ceftazidime/avibactam|Ceftazadime/avibactam dosing in ICU patients
45764625|NCT03034681|Other|Physiotherapy technique: TENS|
45912284|NCT02197234|Drug|AZD9291 tablet dosing|AZD9291 80mg tablet taken from Days 3 to 32. (Part B) AZD9291 80mg tablet taken daily for 12 months.
45912285|NCT02197234|Procedure|Pharmacokinetic sampling - simvastatin|Blood sampling to measure simvastatin levels
45764626|NCT03034681|Other|Physiotherapy technique: Vojta Therapy|
45764627|NCT02935738|Drug|Prednisolone treatment|Infertile men were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles.
45764628|NCT00932659|Device|continuous cardiac monitoring device (REVEAL, Medtronic)|hemodialysis patients without a prior history of cardiac arrhythmias will undergo implantation of a continuous cardiac monitoring device, and will undergo 6 months of follow-up
45622231|NCT05728359|Other|Observational study|Blood sampling and clinical data collection
45764629|NCT03034447|Other|Questionnaire|Children and parents are going to inform data regarding socioeconomical status, asthma and rhinitis diagnosis, asthma and rhinitis control, medications, sleep complaints, and sleep habits
45764630|NCT03034447|Other|Lung Function Test|Children are going to blow in a machine that measures how the lung is working
45622232|NCT04562597|Drug|Dose Response Curve Placebo|5 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.
45764631|NCT03034447|Other|Home Sleep Study|Children are going to sleep at home with a device that tells if they stop breathing during sleep
45764632|NCT05435677|Drug|IcoSema|One single dose of IcoSema administered subcutaneously, S.c. into the left thigh
45764633|NCT05435677|Drug|insulin icodec|One single dose of insulin icodec administered subcutaneously, S.c. into the left thigh
45764634|NCT05435677|Drug|semaglutide|One single dose of semaglutide administered subcutaneously, S.c. into the left thigh
45764635|NCT00939991|Drug|Vorinostst/Bevacizumab/Temozolomide|Bevacizumab will be administered intravenously at the dose 10 mg/kg every other week. Temozolomide will be administered on a continuous daily dosing schedule at 50 mg/m2/day. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen. Bevacizumab doses may be given by the local oncologists under the direction of the Duke investigators.
45764636|NCT03034369|Other|Access to Care|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with access to care.
45764637|NCT03034369|Other|Depression Screening|Analysis of health care claims data for depression screenings at baseline and 12 months.
45764638|NCT03034369|Other|Patient-Provider Relationship|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-provider relationship.
45764639|NCT03034369|Other|Patient-Clinic Interactions|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-clinic interactions.
45764640|NCT03034369|Other|Stigma|Patient reported outcome survey administered at baseline and 12 months to measure perceived stigma.
45764641|NCT03034369|Other|Provider Continuity|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with provider continuity.
45764642|NCT03034369|Other|Symptom Severity|Patient reported outcome survey administered at baseline and 12 months to measure symptom severity.
45622233|NCT04562597|Drug|Dose Response Curve N-acetylcysteine 50 mg/kg|5 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.
45764643|NCT03034369|Other|Diagnoses|Patient reported outcome survey administered at baseline and 12 months to measure diagnoses.
45764644|NCT03034369|Other|Social support|Patient reported outcome survey administered at baseline and 12 months to assess social support and outlets.
45764645|NCT03034369|Other|Preventive Screening|Analysis of health care claims data for preventive screenings at baseline and 12 months.
45764646|NCT03034369|Other|Inpatient Hospitalization Utilization|Analysis of health care claims data for Inpatient Hospitalization Utilization at baseline and 12 months.
45764647|NCT03034369|Other|Inpatient Readmissions|Analysis of health care claims data for Inpatient Hospitalization Readmissions at baseline and 12 months.
45764648|NCT03034369|Other|Post-Admission follow-up|Analysis of health care claims data for Post-Admission follow-up at baseline and 12 months.
45912286|NCT02197234|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
45622234|NCT04562597|Drug|Dose Response Curve N-acetylcysteine 100 mg/kg|5 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.
45622235|NCT04562597|Drug|Dose Response Curve N-acetylcysteine 150 mg/kg|5 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.
45622236|NCT04562597|Drug|Opioid Reduction with Optimal N-acetylcysteine Dose|Once the optimal N-acetylcysteinedose is identified, 15 participants will be randomized to the optimal dose (50,100, or 150 mg/kg) to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
45622237|NCT04562597|Drug|Placebo|15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
45622238|NCT04433637|Dietary Supplement|Cake + fruit juice|Cake+fruit juice experiment group, pregnant were allowed to consume fruit juice and cake, and it was expected that half an hour would pass after feeding to get NST.
45912287|NCT02087826|Other|Mixed Meal Tolerance Test|The meal will provide a standard amount of total calories, protein, fat, and carbohydrate to each participant at both study visits. Pre-packaged and prepared food, weighed to the nearest gram, will be used.
45912288|NCT02087826|Drug|Metformin|Metformin will be administered during this study. This medication is safely prescribed at a maximum dose of 1000 mg twice daily for the treatment or prevention of type 2 diabetes, as well as for other metabolic conditions. To minimize potential side effects of metformin (e.g., GI upset), participants will take ½ the maximum dose of this medication (500 mg twice daily) and for only 5 days. Participants will be informed of the potential side effects of metformin. They will be asked to contact study staff and discontinue the medication if symptoms are very uncomfortable.
46069318|NCT03013998|Drug|Venetoclax (BAML-16-001-S8 Group 2)|Oral dosing based on concurrent antifungal use. Dose without use of concomitant antifungal is 400mg, dose if on posaconazole is 70mg, dose if on voriconazole is 100mg, and dose if on moderate CYP3A inhibitors (ie fluconazole, isavuconazole) is 200mg continuing for up to 12 total cycles. For the 35-day induction cycle 1, dosing is days 2 through 28. For the 28-day induction cycle 2, if needed, dosing is days 1 through 21. For the 28-day consolidation cycles, dosing is days 1-15.
45622239|NCT04433637|Other|Video group|Music with motivational video experimental group, pregnant women were provided with fruit juice and cake, and it was expected that half an hour would pass after feeding to get NST. During this waiting period, the researchers were informed about the development and changes in the body and the fetus specific to the gestational week and NST. Later, NST was applied, and during the procedure, the pregnant women were watched with music that provides relaxation with the video regarding the fetal development appropriate for the gestational week and changes in the mother.
45622240|NCT05728281|Other|Recommended time after hysterectomy|Currently there is no consensus on the optimal time to resume sexual activity. Using a randomization, we will therefore compare two groups: one, whose postoperative instructions will indicate a resumption of sexual activity from 4 weeks after the operation and the other from 8 weeks postoperatively. The primary endpoint is the FSFI® score. The patients will answer the FSFI® questionnaire preoperatively and then at 3 months after surgery.
45622241|NCT04562129|Drug|Interleukin-2|High dose interleukin-2 (HD IL2) administered week 1 and 4 of each course (approximately 12 weeks)
45622242|NCT04562129|Drug|Ipilimumab|Low dose Ipilimumab given at time of HD IL2 administration on day 1 of the first 2 cycles of each course.
45622243|NCT04562129|Drug|Nivolumab|Nivolumab will be given at a dose of 480 mg IV week 7 of each course.
45622244|NCT04130685|Diagnostic Test|Allosure Test|Venous Blood Draw
45622245|NCT04554719|Drug|68Ga-DOTA-FAPI|Intravenous access is established in advance, intravenous bolus injection, 68Ga-DOTA-FAPI dose is about 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
45622246|NCT04554719|Device|PET/MR|Each subject undergoes PET/MR imaging within 40-60 minutes after injection.
45446445|NCT02084602|Drug|Mefloquine|Orally administration of mefloquine 15mg/Kg in the fourth day Orally administration of mefloquine 10mg/Kg in the fifth day
45446446|NCT03542877|Drug|Oral Tablet: Cabozantinib|Patients will take 60mg cabozantinib, by mouth, once daily, every day for 12 weeks. This medication should be taken on an empty stomach. Patients should not eat 2 hours before or 1 hour after taking cabozantinib. Only water is permitted during this 3 hour time frame.
45446447|NCT02081560|Drug|Colistin|Colistin i.v. three times daily as long a necessary for infection treatment
45446448|NCT02074150|Drug|Gadolinium|"Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients.~Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs."
45446449|NCT02074150|Drug|Gadolinium|"Gadolinium .1cc/ diluted with .9ccNS subdermally with ASIS Device for 30 patients.~Total cumulative Persistent % of Gadolinium subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs."
45622247|NCT04554719|Device|PET/CT|Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
45622248|NCT04452981|Device|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
45622249|NCT04539041|Drug|antisense oligonucleotide|solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels
45622250|NCT04539041|Drug|placebo|placebo for each dose level
45622251|NCT03068793|Diagnostic Test|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|We will use these techniques combined with tests of reward anticipation and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, gambling disorder, or post traumatic stress disorder and healthy controls.
45622252|NCT04504175|Drug|Ketamine|ketamine will be infused using an IV infusion pump at a rate of 0.5 mg/kg of body weight over 40 minutes
45622253|NCT03068871|Other|ACT|Psycho-educational group
45622254|NCT03068871|Other|CET|Psycho-educational group
45622255|NCT05723367|Procedure|lumbar ESPB group where ESPB is performed at L4 with local anesthetics 20ml|ultrasound guided fascial plane injection
45622256|NCT03853395|Diagnostic Test|Tests for drug levels and anti-drug antibodies|Measurement of drug levels and anti-drug antibodies will be undertaken using commercially available enzyme-linked immunosorbent assays (ELISAs) and/or radioimmunoassays
45622257|NCT05720403|Other|pilates group|Pilates, which lasts for eight weeks, three days a week for 1 hour, will be carried out by Australian Pilates and Physiotherapy Institute certified and experienced Ph.D. Physiotherapist Halil Ibrahim Bulguroglu. Microsoft Teams program will be used to implement the online practice method. The individuals in both pilates exercise groups will be divided into six small groups of 3 or 4 people to make the exercises more effective. In this study, the program will be 15 minutes of warm-up, 30 minutes of pilates, and 15 minutes of cool-down and stretching exercises. The exercises will be performed in ten repetitions. The same exercises will be applied in online pilates and face-to-face pilates training.
45622258|NCT04433169|Drug|All-trans Retinoic Acid|ATRA 20 mg, three times a day, for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles
45622259|NCT04433169|Drug|VEGFR inhibitor|VEGFR inhibitor
45764649|NCT05375695|Other|Time-restricted eating|"The intervention consists of an 8-week strict time-restricted eating period, where participants follow the same 10-hour eating window (self-selected timing from 6 am to 8 pm) each day with minimal support to obtain lived experiences with challenges associated with time-restricted eating. Followed by an individually adjusted 4-week time-restricted eating period, including supporting components.~Staff will help participants select a time-interval that fits into their daily life. Diet is ad libitum and with no further dietary restrictions. The time-restricted eating intervention is an addition to standard care."
45622260|NCT04433169|Drug|Chemotherapy|chemotherapy
45764650|NCT03034213|Device|Gentrix™ Surgical Matrix (Treatment)|Gentrix™ Surgical Matrix will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
45764651|NCT03034213|Device|Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend (Control)|A biological or prosthetic mesh (Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend) will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
45764652|NCT03034291|Dietary Supplement|Cacao 70%|Consumption for 8 weeks of 50 grams of chocolate per day with 70% cocoa solids.
45764653|NCT03034291|Dietary Supplement|White chocolate|
45764654|NCT04361305|Drug|Dapoxetine|30 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 8 weeks Tadalafil 5 mg tablets every day for 8 weeks
45764655|NCT04361305|Drug|Tadalafil|5 mg tablets every day for 8 weeks
45764656|NCT04361305|Drug|Tadalafil|5 mg tablets every day for 8 weeks
45764657|NCT04361383|Other|control group|the patient will receive general anesthesia
45764658|NCT04361383|Procedure|quadratus lumborum block type 3|patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
45764659|NCT04361383|Procedure|erector spinae plane block|patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
45764660|NCT04361071|Device|stent|stent
45764661|NCT04361071|Device|plaque excision system|plaque excision system
45764662|NCT02245321|Dietary Supplement|Ferrous gluconate- 19 mg|Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).
45764663|NCT02245321|Dietary Supplement|Ferrous gluconate- 38 mg|Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
46069319|NCT03013998|Drug|AZD5991 (BAML-16-001-S18)|150 mg, IV, on days 1, 4, 8, 11, 15, and 18 of three 28-day cycles; followed by 150 mg/m2, IV, on days 1, 4, 8, and 11 of twenty-one 28-day cycles; followed by 150 mg/m2 on days 1 and 4 of each 28-day cycle until time of progression, unacceptable toxicity, death, or 57 total cycles of treatment. Dose may be escalated to a maximum dose of 400 mg or de-escalated to 100 mg based on occurrence of dose-limiting toxicity.
45622261|NCT05716581|Device|Catheter ablation|Catheter ablation for atrial fibrillation will be done according to the current medical praxis. Pulmonary vein isolation using either radiofrequency or pulsed-field ablation will be done in all patients. In patients with non-paroxysmal AF, additional ablation lesions (posterior wall ablation, roof or mitral isthmus line, ablation of complex fractionated atrial electrograms) could be done based on the operator´s discretion
45764664|NCT02245321|Other|Letter Group- Information Provided|Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.
46069320|NCT03013998|Drug|Azacitidine (BAML-16-001-S18)|75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 28-day cycle until time of progression, unacceptable toxicity, death, or 57 total cycles of treatment
45622262|NCT05711121|Procedure|Transforaminal epidural steroid injection|Fluoroscopy-guided transforaminal epidural injection for radicular pain resulting from a disc herniation.
45622263|NCT05711121|Procedure|Caudal epidural steroid injection|Fluoroscopy-guided caudal epidural injection for radicular pain resulting from a disc herniation.
45622264|NCT02717195|Drug|Risperidone|4-6 mg/day, encapsulated tablets, orally
45622265|NCT02717195|Drug|Olanzapine|15-20 mg/day, encapsulated tablets, orally
45622266|NCT02717195|Drug|Lu AF35700|10 mg/day, encapsulated tablets, orally
45764665|NCT02245321|Other|Letter - No Information Provided|Receive a letter thanking the participant for their participation.
45764666|NCT02245321|Dietary Supplement|Placebo|Receive pills to take daily that contain 0 mg iron.
45764667|NCT05351437|Drug|MTx-COVAB36|MTx-COVAB36 is a fully human monoclonal IgG1 antibody derived from the memory B cells of convalescent COVID-19 donors and directed against SARS-CoV-2 spike protein with potent virus neutralising activity.
45764668|NCT05351437|Drug|Placebo|0.9% saline
45764669|NCT04361149|Drug|Capsaicin Topical Cream (0.075%)|Capsaicin cream will be administered as a topical skin cream
45764670|NCT04361149|Device|Delsys Trigno Galileo System|A wireless surface EMG device. The sensors will be placed on the trapezius and the infraspinatus muscle, and a recording will be performed.
45764671|NCT04361149|Device|Excaliber, Natus Medical|Intramuscular EMG machine. The intramuscular electrode will be inserted into the trapezius and a recording will be performed.
45764672|NCT04361149|Other|Placebo Cream|Placebo cream will be administered as a topical skin cream
45764673|NCT05332483|Drug|Megestrol Acetate|Megestrol acetate, 160 mg daily (two 40mg tablets twice a day), for a minimum of 18 days.
45446450|NCT02074150|Drug|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
45764674|NCT03033589|Drug|Marcaine 0.25 % Injectable Solution|For the adductor canal block, 20 mL of 0.25% marcaine will be injected with the use of ultrasound guidance into the adductor canal by the attending anesthesiologist on the case in the pre-op holding area.
45764675|NCT03033589|Drug|Marcaine 0.25 % Injectable Solution|For the femoral nerve block, 30 mL of 0.25% marcaine will be injected with the use of ultrasound guidance around the femoral nerve sheath by the attending anesthesiologist on the case in the pre-op holding area.
45764676|NCT04360915|Drug|ASK120067|Take ASK120067 tablets orally in first day at 160 mg in fast condition.
45764677|NCT04360915|Dietary Supplement|ASK120067 in fed condition|Take ASK120067 tablets orally in first day at 160 mg in fed condition.
45764678|NCT05329675|Dietary Supplement|Sinphar Lipucan Capsule|oral Sinphar Lipucan Capsule 1# (Arm A), 2# (Arm B), or 3# (Arm C)/day for 90 days
45764679|NCT05290987|Device|nasal spray|2 sprays in each nostril, 6 times a day
46069321|NCT03013998|Drug|SNDX-5613 (BAML-16-001-S17)|113 mg, oral, every 12 hours on Day 1-28 of each 28-day cycle, until time of progression, unacceptable toxicity, or death. Dose may be escalated to a maximum dose of 163 mg on days 1-28 or de-escalated to 113 mg on days 1-21 based on occurrence of dose-limiting toxicity. Other possible dose escalation and de-escalation would be 163 mg on days 1-21, 75 mg on days 1-21 and 75 mg on days 1-28. Following completion of induction, patients who do not require strong CYP3A4 inhibitor antifungals will have daily doses increased for doses in range of 113-226 mg (days 1-21 or days 1-28).
45622267|NCT02717195|Drug|Lu AF35700|20 mg/day, encapsulated tablets, orally
45622268|NCT03681483|Drug|RO5126766|RO5126766 (CH5126766) is given 4mg twice weekly (Day 1 and Day 4 of each week) and should be taken by mouth on an empty stomach, either one hour before or two hours after a meal.
45622269|NCT04490915|Drug|Crinecerfont|CRF1-receptor antagonist
45446451|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox intramuscularly at Week 6, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
45446452|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 12,|Efficacy of Botox intramuscularly at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
45764680|NCT05147389|Diagnostic Test|AI model classification|AIWorks is an artificial intelligence model for real-time cholangioscopic detection of neoplastic and non-neoplastic bile duct lesions. It allows you to choose using a video file or a USB camera input as the detection source. Once the input source has been selected, the software performs real-time detection by surrounding the area of interest (i.e., the area with malignancy features) inside a bounding box. All detections made are displayed on the right side of the screen and can also be reviewed afterwards.
45912289|NCT02056119|Device|Vibrating Mesh Nebulizer Arm|"Physician order received for subject, randomization to vibrating mesh nebulizer occurred.~Aeroneb® Solo (Aerogen, Galway, Ireland) vibrating mesh nebulizer to be placed before the heater on the dry side of the heater water chamber on the inspiratory ventilator circuit.~Aerosol treatment delivered per physician order.~Mesh nebulizer to be replaced every 30 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
45446453|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox intramuscularly at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
45446454|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 24|Efficacy of Botox intramuscularly at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
45446455|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox intramuscularly at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
45446456|NCT02074150|Drug|Efficacy of Botox subdermally at Week 6|Efficacy of Botox subdermally at Week 6, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
45622270|NCT04490915|Drug|Placebo|Non-active dosage form
45622271|NCT03066219|Drug|BRM421|A topical solution of BRIM421 ophthalmic drops
45622272|NCT03066219|Drug|Placebo|vehicle ophthalmic drops
45622273|NCT03066531|Behavioral|ACT-based intervention|
45622274|NCT03066531|Behavioral|CBT-based intervention|
45764681|NCT05147389|Diagnostic Test|DSOC endoscopist experts' classification|"Six endoscopists with high DSOC expertise will observe and classify a set of videos among neoplastic or non-neoplastic bile duct lesions following a Bernoulli distribution; blinded to clinical records and should have never attended said patients.~Gastroenterologists from each center, with non-DSOC responsibility, will select DSOC videos and corresponding baseline data. DSOC videos and data will be gathered in one set. Each video represents a full DSOC for a single patient. The patient will be the unit of this study.~The neoplastic bile duct criteria are in accordance with the Robles-Medranda et al and the Mendoza classifications (ie. Irregular mucosa surface, Tortuous and dilated vascularity, Irregular nodulations, Polyps, Ulceration, Honeycomb pattern, etc.). The experts will assess neoplastic bile duct by presence or absence of disaggregated criteria. Likewise, by Boolean logical operators, the statistical software will compute disaggregated answers."
45764682|NCT03033667|Dietary Supplement|G group|patients received 500 cc of glucose 10% containing 50 g of glucose proving patients with 200 Kcal with 556 mosmoles/L
45764683|NCT03033667|Dietary Supplement|group L|patients received 100 cc of lipid solution (soybean 30%, medium chain triglycerides 30%,olive oil 25%,fish oil 15% and 20 mg vitamine E) containing 20 g lipid which provided patients with 200 Kcal with osmolarity of 380 mosmoles /L. with a flow rate of infusion of 12.5 cc per hour
45764684|NCT03033667|Dietary Supplement|Group C|Over night fasting with no supplementation
46069322|NCT03013998|Drug|Azacitidine (BAML-16-001-S17)|75 mg/m2, IV or SC, on days 1-7 (during induction cycle/cycles) or can use alternative scheduled on days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) during continued therapy cycles of each 28-day cycle until time of progression, unacceptable toxicity, or death.
46069323|NCT03013998|Drug|Venetoclax (BAML-16-001-S17)|For Cycle 1 induction, day 1 dose is 10 mg, day 2 dose 20 mg, day 3 dose is 50 mg, and day 4 onward dose is 100 mg or 70 mg depending on concomitant antifungal treatment. For Cycles 2 and 3 inductions, daily doses are 100 or 70 mg depending on concomitant antifungal treatment. During continued therapy cycles, if not on concomitant strong CYP3A4 inhibitor antifungals, 400 mg, oral, on days 1 through 28 of each 28-day cycle until time of progression, unacceptable toxicity, or death (patients on moderate CYP3A4 inhibitor antifungals should receive 200 mg/day).
45446457|NCT02074150|Drug|Efficacy of Botox subdermally at Week 12|Efficacy of Botox subdermally at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
45446458|NCT02074150|Drug|Efficacy of Botox subdermally at Week 18|Efficacy of Botox subdermally at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
46069324|NCT03013998|Drug|Gilteritinib (BAML-16-001-S8 Group 2)|Phase 1b induction: 80-120 mg, oral, daily for day 1 up to day 28 of the 35-day induction cycle 1; then 80-120 mg, oral, daily for day 1 up to day 28 of the 28-day induction cycle 2 (induction cycle 2 administered if needed after cycle 1 based on results bone marrow evaluation). Phase 1b consolidation: 80-120 mg, oral, daily for day 1 up to day 21 of the 28-day cycles, for a total of 12 total induction and consolidation cycles. Phase 1b induction and consolidation dose and duration may be escalated or de-escalated based on occurrence of dose-limiting toxicity. Phase 2 induction and consolidation dosage to be based on results of Phase 1b. Phase 1b and 2 maintenance: 120 mg, oral, daily for 28 days of the 28-day cycles until patient is minimal residual disease negative for FLT3 based on scheduled bone marrow biopsy, progression of disease, unacceptable toxicities, or desire to discontinue therapy.
46069325|NCT03013998|Drug|Venetoclax (BAML-16-001-S12 Arm A)|400 mg, oral, on days 1 through 28 of each 28-day cycle for up to 2 cycles or until unacceptable toxicity or death. For Cycle 1, day 1 dose is 100 mg, day 2 dose 200 mg, and day 3 onward dose is 400 mg. (Dose adjusted by anti-fungal agent use per the package insert.)
46069326|NCT03013998|Drug|Azacitidine (BAML-16-001-S12 Arm A)|75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 28-day cycle for up to 2 cycles or until unacceptable toxicity or death.
45446459|NCT02074150|Drug|Efficacy of Botox subdermally at Week 24|Efficacy of Botox subdermally at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
45446460|NCT02074150|Drug|Efficacy of Botox subdermally at Week 30|Efficacy of Botox subdermally at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
45446461|NCT02074150|Drug|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
45446462|NCT02074150|Drug|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
45446463|NCT03747549|Other|Acupuncture and Home Exercise|Acupuncture (needles will be placed at BL 60, BL 61, KI 3, KI 4 with needles directed into the Achilles tendon. Needles inserted until a firm catch of the needle entering the tendon was appreciated. Energy (a small electrical current) is placed from KI 3(-) KI 4(+) and BL 61 (-) BL 60(+) at 30 Hz for 15min) plus the prescribed home exercise program
45446464|NCT03747549|Other|Home Exercise Alone|The prescribed home exercise program alone.
45446465|NCT04797741|Other|IDEA3 Intervention|Delivery of IDEA3 intervention, a 12-hour online sexual assault resistance intervention for college women.
45446466|NCT04352127|Device|TetraGraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
45622275|NCT05664087|Drug|Periowave®|The tooth extraction sockets were filled with photosensitizer methylene blue. The guide head of the laser periodontal therapy instrument (Piperway Laser periodontal therapy instrument) was placed in the tooth extraction sockets to probe and move around the tooth extraction sockets for 1 minute. At the end of irradiation, a cotton ball dipped in saline was used to wipe the guide head and rinse the photosensitizer out of the socket
45764685|NCT03033433|Drug|DCB-DM101|determination of optimal dose for Stage 2
45764686|NCT00947167|Drug|pertuzumab|840 mg, 420 mg, iv
45764687|NCT00947167|Drug|erlotinib|150 mg, PO
45622276|NCT04969991|Drug|Varespladib|250 mg immediate-release oblong, white, film-coated tablet for oral administration
45446467|NCT02074228|Drug|Methylphenidate (Concerta)|
45446468|NCT02084680|Behavioral|community health workers|community health workers offering individual prenatal education to pregnant women
45446469|NCT03750045|Diagnostic Test|Jamar|The grip strength was evaluated through a dynamometer JAMAR 5030-J, formed by two parallel steel bars, one stationary and a mobile one, which can be adjusted in five different positions. The volunteer was sitting with a neutrally rotated abducted shoulder, elbow flexed at 90°, the forearm in neutral position, and the wrist between 0° and 30° of extension, 0° to 15° of ulnar variance and it was requested that he or she made the grip movement. This test was performed three times with a one-minute-break between each one.
45622277|NCT04969991|Drug|Placebo|Oral formulation matched to the oral varespladib tablet
45622278|NCT05594355|Drug|TEBOFORTAN|TEBOFORTAN 240 mg is administrated 1 tablet per day
46069327|NCT03013998|Drug|Venetoclax (BAML-16-001-S12 Arm B)|400 mg, oral, on days 1 through 14 of each 14-day cycle for up to 2 cycles or until unacceptable toxicity or death. For Cycle 1, day 1 dose is 100 mg, day 2 dose 200 mg, and day 3 onward dose is 400 mg. (Dose adjusted by anti-fungal agent use per the package insert.)
46069328|NCT03013998|Drug|Azacitidine (BAML-16-001-S12 Arm B)|75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 14-day cycle for up to 2 cycles or until unacceptable toxicity or death.
46069329|NCT03006328|Behavioral|GEM|Online program designed to support health coach and primary care team counseling. It assesses current behaviors, barriers, and facilitators to weight loss via a 16-item questionnaire, provides tailored advice, and guides patients to set weight loss (5-10%), diet, and physical activity (PA) goals. After completing the tool, participants will meet with a Health Coach. Participants will receive 12 telephone coaching calls by a health coach over 12 months.
46069330|NCT03006328|Behavioral|Enhanced Usual Care|Patients in the EUC arm will receive non-tailored weight management handouts. Patients will follow-up with their primary care teams as needed.
46069331|NCT02996487|Drug|Vancomycin|
46069332|NCT02996487|Other|Placebo|
45452341|NCT00033371|Drug|eflornithine|Given PO at 0.5 gm/m^2/day rounded down to the nearest 250 mg dose (BSA of < 1.4 = 500 mg/day; BSA of 1.5 - 2.0 = 750 mg/day; BSA of 2.1 - 2.5 = 1000 mg/day; BSA of > 2.6 = 1,250 mg/day).
45622279|NCT05646927|Procedure|Selection of parent(mother or father) according to children preference|The parent who will accompany the child during the perioperative period will be determined by children preference
45622280|NCT05646927|Procedure|Selection of parent(mother or father) according to randomization|The parent who will accompany the child during the perioperative period will be determined by randomization.
45622281|NCT04939571|Other|Registry of preterm born infants with treatment-requiring ROP|All prematurely born infants who develop treatment requiring ROP and are treated (independent of the kind of treatment modality) at a center that participates in the registry are eligible for database entry.
45622282|NCT04702919|Other|Registration|Synchronized recording of BTP in ultrasound, brain activity by EEG, heart rate and blood pressure.
45764688|NCT04360759|Drug|Chloroquine or hydroxychloroquine|Chloroquine has in vitro antiviral activity against many viruses, including SARS-CoV-1 and SARS-CoV-2. Chloroquine inhibits coronavirus replication at in vitro concentrations that are not cytotoxic and within a range of blood concentrations achievable during standard antimalarial treatment. Chloroquine inhibits viral replication through interference with glycosylation of coronavirus ACE2 receptors, required for viral entry, and downstream phagolysosome alkalisation, interfering with the low-pH-dependent steps of viral fusion and uncoating. Chloroquine also has anti-inflammatory properties and could provide benefit through this mechanism in Covid-19, where a cytokine storm has been described in critically ill patients. Hydroxychloroquine is a less toxic metabolite of chloroquine, has similar anti-inflammatory properties, and is more potent against SARS-CoV-2 in vitro.
46069333|NCT02911142|Drug|Lenalidomide|Lenalidomide taken orally, daily at assigned dose level on days 1 to 10, up to 25mg.
45764689|NCT04360993|Radiation|Radiotherapy|Patients have received radiotherapy as a treatment modality for Head and neck cancer
45764690|NCT00940771|Drug|Boosted Atazanavir|Boosted Atazanavir, once a day dose adjusted for child's weight for 6 months.
45446470|NCT03750045|Diagnostic Test|Wooden box|The motor coordination evaluation was made through the measurement of the time spent to perform the task of fitting. To do so, a wooden box was built. In its upper part, there is a circular orifice with 6 cm of diameter.
45446471|NCT03750045|Other|Virtual environment|The system proposed is composed by a virtual environment and an access device. The Leap Motion was used as the access device, making it possible to capture the movements performed by the hands.
45622283|NCT04702919|Other|Auditive oddball task|Presentation of an auditory sequence, comprising 'Standard' (probability of occurrence: p = 0.90) and 'Deviants' (p = 0.10, targets) sounds via loudspeakers.
45622284|NCT05634915|Drug|Individual ATG|Individual dose of ATG: Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on population pharmacokinetic modeling). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A, mycophenolate mofetil, and low-dose methotrexate.
45622285|NCT05634915|Drug|ATG|ATG 10mg/kg: The total ATG dose was 10mg/kg. ATG was intravenously infused every day from day -5 to day -2. Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A, mycophenolate mofetil, and low-dose methotrexate.
45622286|NCT05582811|Drug|Dose Riociguat 2,5 or 5mg|A selective stimulator of soluble guanylate cyclase (sGC)
45622287|NCT05582811|Drug|Riociguat|A selective stimulator of soluble guanylate cyclase (sGC)
45622288|NCT05582811|Drug|Placebo|Placebo
45764691|NCT04360603|Device|27G|using 27G vitrectomy system to perform standard transconjunctival sutureless vitrectomy
45764692|NCT04360603|Device|25G|using 25G vitrectomy system to perform standard transconjunctival sutureless vitrectomy
45764693|NCT03033277|Biological|Placebo transplantation|Intraovarian injection of placebo through vagina under the guidance of ultrasonic.
45764694|NCT03033277|Biological|HUC-MSCs transplantation|Intraovarian injection of HUC-MSCs through vagina under the guidance of ultrasonic.
45764695|NCT05119621|Device|TENS application|Assigned Interventions: In addition to the standard pain management applied in the clinic, TENS will be applied to children who have had surgery.
45764696|NCT03033355|Drug|Intradetrusor injection of Botulinum Toxin-A|Using cystoscopy, Botulinum Toxin-A is injected into the bladder.
45764697|NCT03033121|Drug|Growth Hormone|
45764698|NCT03033199|Drug|Probiotic Agent|probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.
45912290|NCT02056119|Device|Jet Nebulizer Arm|"Physician order received for subject, randomization to jet nebulizer occurred.~Jet nebulizer, Misty Max 10™ (Carefusion, CA), placed into spring loaded t-piece between the humidifier and the ventilator (approximately 15 cm from the gas outlet).~Aerosol treatment delivered per physician order at flow rates of 8-10 L/min.~Jet nebulizer to be replaced every 3 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
45912291|NCT02048813|Drug|Cyclophosphamide|Given IV
45912292|NCT02048813|Drug|Fludarabine Phosphate|Given IV
45912293|NCT02048813|Drug|Ibrutinib|Given PO
45446472|NCT02084758|Dietary Supplement|Nitrate supplementation|7 days of supplementation with sodium nitrate solution
45446473|NCT02084758|Dietary Supplement|Placebo supplementation|7 days of supplementation with sodium chloride solution
45452342|NCT00033371|Other|Laboratory biomarker analysis|Correlative studies
45622289|NCT05582031|Combination Product|Regorafenib in combination with Tislelizumab|Regorafenib 30 mg/tablet + Tislelizumab 100 mg/10 ml vial
45622290|NCT04424225|Drug|Psilocybin|25 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)
45622291|NCT04424225|Drug|Niacin|100 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)
45764699|NCT03033199|Drug|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
45764700|NCT02245711|Biological|Stem Cell|
45764701|NCT04360525|Other|Reasons|Causes of sigmoid volvulus
45764702|NCT04360291|Other|Eye tracker|In visual search tasks, participants will sit in front of a screen and observe during each visual scene for a maximum of 45 seconds. Their eye movements will be recorded
45764703|NCT00934141|Other|Learning Session|Learning Sessions occur bi-annually as change teams convene to learn and gather support from each other and outside experts who offer advice on how best to adopt the innovations and learn about new directions for the collaborative (e.g., the need to create business cases for improvements). Learning Sessions and Interest Circles (see below) have similar objectives-to help agencies learn and gather support from each other and from outside experts.
45764704|NCT00934141|Other|Interest Circle Calls|Interest Circles are monthly teleconferences where agency change leaders discuss change-related issues and progress. Circles address how to improve timeliness, continuation, admissions, dropouts and transitions. They also address specialty topics (e.g., programs for women, adolescents). Participants discuss successes, failures, and challenges, and get advice and assignments for their improvement plans. Meeting summaries appear on the Web site. Interest Circles are inexpensive, but are they are sufficient? Should Interest Circles prove effective, they would provide a low-cost, convenient diffusion approach
45764705|NCT00934141|Other|Coaching|Coaching assigns an expert in process improvement to work with an agency to make, sustain, and spread process improvement efforts. Consultations focus on executive directors, change leaders and improvement teams. Coaches help agencies address key issues, but also broker relationships with other agencies, offer process improvement training, and promote the innovations to make and how to make them. Coaching takes place during site visits, monthly phone conferences, and via email.
45764706|NCT00934141|Other|Website|The NIATx Web site features resources central to improvement. The site includes: 1) a catalog of change ideas and case studies; 2) a toolbox providing just-in-time training on topics such as conducting a walk-through and key innovations; 3) on-line tools to assess organizational (or project) readiness for and ability to sustain change; 4) electronic communication services to ask questions of experts, and participate in peer discussion groups; 5) links to relevant process improvement Web sites; and 6) a secure portion for treatment agencies to report and track progress. Hence, our control group will have access to the entire website.
45622292|NCT05581719|Drug|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
45622293|NCT05581719|Drug|Nivolumab|Immune checkpoint inhibitor (anti-PD-1 antibody)
45622294|NCT05581719|Drug|Tislelizumab|Immune checkpoint inhibitor (anti-PD-1 antibody)
45764707|NCT00940927|Drug|albuterol|Albuterol administered sequentially 180mcg (MDI), 90mcg (MDI), 90mcg(MDI), 90mcg (MDI), 90mcg (MDI), 2.5mg (nebulized)
45764708|NCT00941005|Device|Electroacustimulation|Electroacustimulation (EAS) is a derivative form of acupuncture therapy where a small current of electricity instead of a needle is used to stimulate an acupoint on the human body in an effort to create therapeutic effects.
45764709|NCT00934375|Drug|Aricept (donepezil hydrochloride)|5 mg or 10 mg of donepezil hydrochloride (Aricept) taken orally once a day.
45764710|NCT00934375|Drug|placebo|
46069334|NCT02911142|Drug|Rituximab|During cycle 1, rituximab will be administered on day 4 prior to the start of EPOCH. During cycles 2 to 6, rituximab will be administered on day 1 of each cycle.
46069335|NCT02911142|Drug|Prednisone|During cycle 1, Prednisone 60 mg/m2 /day PO days 6 to 10. During cycles 2-6, Prednisone 60 mg/m2 /day PO days 1-5.
46069336|NCT02911142|Drug|Etopside|During cycle 1, Etoposide 50 mg/m2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Etoposide 50 mg/m2/day continuous intravenous infusion days 1 to 4.
46069337|NCT02911142|Drug|Doxorubicin|During cycle 1, Doxorubicin 10 mg /m2/day continuous intravenous infusion days 6 to 9. During cycles 2-6, Doxorubicin continuous intravenous infusion days 1 to 4.
46069338|NCT02911142|Drug|Vincristine|During cycle 1, Vincristine 0.4 mg/m2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Vincristine continuous intravenous infusion days 1 to 4.
46069339|NCT02911142|Drug|Cyclophosphamide|During cycle 1, Cyclophosphamide 750 mg/m2 day 10. During cycles 2-6, Cyclophosphamide 750 mg/m2 day 5.
46069340|NCT02901067|Drug|Aspirin and Rosuvastatin|Patients assigned to the intervention arm will receive the standard of care anti-coagulation plus the combination experimental drugs (20mg of rosuvastatin daily and 325mg of aspirin) daily either orally or via feeding tube.
46069341|NCT02901067|Drug|Placebo (for Aspirin and Rosuvastatin)|Patients assigned to the control group will receive the standard of care anti-coagulation plus identical-looking placebos either orally or via feeding tube.
45622295|NCT04420169|Other|Questionnaire|A digital questionnaire to evaluate the communication by midwives will be send out to IVF patients
45622296|NCT05626101|Drug|BCG|Intravsical induction and maintenance BCG injections.
45622297|NCT05626101|Drug|Gemcitabine|Intravsical induction and maintenance gemcitabin injections.
45622298|NCT05537883|Drug|Liposomal bupivacaine|Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with liposomal bupivacaine
45622299|NCT05537883|Drug|Bupivacaine Injection|Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with plain bupivacaine
45622300|NCT02465801|Drug|HSA-GCSF 1.2 mg|Human Serum Albumin GCSF 1.2mg at day 3 and Day 7
45622301|NCT02465801|Drug|HSA-GCSF 1.5 mg|Human Serum Albumin GCSF 1.5 mg at day 3 and Day 7
45622302|NCT02465801|Drug|GCSF|GCSF 5 mcg/kg/day
45622303|NCT04908839|Other|spot-25 questionnaire|spot-25 questionnaire
45622304|NCT05572437|Device|Music Therapy|Patients randomized to the treatment with music group (classical music), after assessment of anxiety using the APAIS scale, will be given headphones and classical music will be played from their stay in the pre-anesthesia room, during surgery and in the PACU.
45622305|NCT04339439|Device|Vessel loop (FDA product code FZZ)|The intervention will be a vessel loop placed below sutures to raise the sutures from the skin of the palm.
45622306|NCT02465645|Drug|Carvedilol|
45622307|NCT02465645|Drug|Carvedilol + Simvastatin|
45622308|NCT04157205|Diagnostic Test|Non-invasive ECG imaging - CardioInsight test|"Consent session~Fitting of ECGi vest and CT scan of the chest~Supervised exercise test and Valsalva maneuvre~Programmed stimulation via ICD (selected participants)~Blood tests - genetics"
45622309|NCT02465411|Device|Dexcom G4 or later generation|Continuous glucose monitoring with DexCom G4 platina or later generations
45622310|NCT05565495|Drug|Hydromorphone|Hydromorphone was administered intravenously at a rate of 0.03 mg/kg/h for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the contents of hydromorphone and hydromorphone-3-glucuronide (main metabolite) were detected by quantitative liquid chromatography tandem mass spectrometry, and then A population pharmacokinetic model of hydromorphone in patients under ECMO was established.
45622311|NCT04294277|Drug|Pemigatinib|At Day 1, prior to the start of treatment, results from screening visit evaluations are reviewed to determine eligibility requirements. Subsequent visits during treatment phase will take place at Day 8, Day 15 and Day 21 and subsequently at 3 week intervals. Timing of subsequent visits can be prolonged to max. 9 week intervals if no problems exist during the first 12 weeks of therapy. Subjects will self-administer study drug using an oral QD regimen in a continuous dosing schedule. Each dose of Pemigatinib should be taken first thing in the morning upon waking or after a 2-hour fast; subjects should then fast for an additional 1 hour after taking study drug. The starting dose is 13.5 mg Pemigatinib. Study treatment will continue until 12 months, or until the evidence of disease relapse or onset of unacceptable toxicity.
45622312|NCT03065829|Behavioral|ASSIST|Wearable sensor technology delivering mindfulness meditation training (MMT) and health promotion (sleep hygiene and physical activity) .
45622313|NCT03065829|Behavioral|Attention-Control|Wearable sensor technology only viewing biophysical sensor data.
45764711|NCT05105425|Dietary Supplement|NUTRIOSE®|"After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of active formula (NUTRIOSE®) during 4 weeks.~They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot)."
45764712|NCT05105425|Dietary Supplement|GLUCIDEX® IT21 (Placebo)|"After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of placebo during 4 weeks.~They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot)."
45446474|NCT02074306|Device|UROSHIELD®|An active UROSHIELD® device (low energy acustic wave generator) will be connected to an intratracheal tube externally. The device will transform low energy ultrasound waves on to the tube. These waves will by assumption lower the formation of bacterial growth and resistance to antibiotics.
45764713|NCT03002974|Drug|Anakinra 100 mg|100 mg/0.67 mL solution in single-use prefilled syringes for subcutaneous injection
45446475|NCT02074306|Device|SHAM UROSHIELD®|SHAM UROSHIELD® will be connected to endotracheal tubes unable to transform any waves.
45446476|NCT04351269|Device|CanGaroo Envelope|CanGaroo Envelope with Cardiac Implantable Electronic Device (CIED) implantation
45764714|NCT03002974|Drug|Triamcinolone Acetonide 40 mg|1 mL intramuscular injection of a 40 mg/mL injectable suspension
45764715|NCT03002974|Drug|Placebo to Anakinra 100 mg|sterile solution for injection (0.67 mL) in a single-use prefilled syringe identical to the anakinra syringe
45622314|NCT02465021|Other|Dietary intervention|All arms are given to all participants, in a randomized order
45764716|NCT03002974|Drug|Placebo to Triamcinolone Acetonide 40 mg|1 mL intramuscular injectable suspension with identical appearance as the Triamcinolone Acetonide suspension
45622315|NCT03068637|Behavioral|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
45622316|NCT02464241|Other|only examination|
45446477|NCT04351269|Device|TYRX Envelope|TYRX Envelope with Cardiac Implantable Electronic Device (CIED) implantation
45653375|NCT05697133|Other|SEMSTOP|This program has been developed based on Story Theory and will be implemented individually online. The session content, units and topics in the program are arranged according to the conceptual content and flow of the theory. The program has been created in a certain flow, based on the concepts of purposeful dialogue, connecting with itself and facilitating the theory.
45764717|NCT02245477|Device|obstetric Ultrasound|Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.
45446478|NCT02084836|Other|Functional Magnetic Resonance Imaging|
45446479|NCT02081794|Other|Tailored education intervention|Receive 2 minute video-assisted intervention on the risk and prevention of falls with tailored hand-outs depending on participant answers about fall risks
45446480|NCT02081794|Other|Standard fall care|Patient are given a generic handout on falling and receive standard care by nurses comprising of a fall risk assessment and verbal education
45452343|NCT00033371|Other|Questionnaire administration|Ancillary studies
45653376|NCT05697133|Other|control|control grup
45912294|NCT02048813|Other|Laboratory Biomarker Analysis|Correlative studies
45912295|NCT02048813|Other|Pharmacogenomic Study|Correlative studies
45912296|NCT02048813|Other|Quality-of-Life Assessment|Ancillary studies
45446481|NCT04348851|Behavioral|Caregiver problem-solving|Registered nurses will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue
45446482|NCT04348851|Behavioral|Attention Control|The RNs will only provide active listening and paraphrasing. The RNs will ask caregivers to talk about their caregiver experiences. The nurses will not provide advice, but rather direct caregivers to access information on the Caregiver Family Alliance website (www.caregiver.org) for managing problems or to contact their healthcare
45446483|NCT02084914|Procedure|Endometrial scratching|Group A: pipelle Group B: sound
45446484|NCT05508568|Diagnostic Test|ADXBLADDER|ADXBLADDER is a non-invasive, qualitative ELISA utilising a combination of two monoclonal antibodies for the detection of MCM5 in urine sediment. It is intended to aid in the monitoring of bladder cancer recurrence in non-muscle-invasive bladder cancer patients. Participants will be asked to provide a full void urine specimen, which will be centrifuged before the urine sediment is lysed. The lysed sample will then be tested with ADXBLADDER.
45446485|NCT02074540|Other|Questionnaire|Questionnaire that is based on socio-demographic characteristics, Morisky's Four-Item Self-Reported Adherence Measure, Becker's Theory of Health Beliefs and Mishel's Theory of Uncertainty
45622317|NCT05530317|Behavioral|Cardiac Rehabilitation|Exercise prescriptions will be based on the heart rate performance during the baseline CPET. The intensity of the exercise prescription and level of monitoring will be tailored to the individual participant's performance on their baseline CPET according to guidelines. Exercise will be prescribed by a Cardiac Exercise Physiologist in accordance with standard cardiac rehabilitation protocols. Resistance exercise activities will also be incorporated. Recumbent exercise will be utilized based on assessment by exercise physiologist and patient. Dietary counseling, smoking cessation counseling for smokers, and medication counseling will be incorporated according to standard cardiac rehabilitation protocols. Participants are asked to commit to attending at least 24 sessions, of which 12 (one per week for 12 weeks) must be in person. Participants will be allowed to select a fully in-person approach (36 sessions) or hybrid approach (12-24 in person, 12-24 virtual for up to 36 total sessions).
45622318|NCT04872257|Drug|Oral Vitamin D|Vitamin D 5,000 UI for 6 months (oral capsule, daily, single-dose)
45764718|NCT02245477|Other|serum Vascular Endothelial Growth Factor|Maternal blood samples (10 cc) were taken from an antecubital vein. Plastic clean sterile tubes were used for collection of blood. Two cc of the blood sample were put in other clean sterile tubes containing ethylene diamine tetra-acetic acid (EDTA) to be used in measuring maternal hemoglobin concentrations and evaluating the complete blood count. The rest of maternal blood samples were centrifuged within 3 hours and sera collected equally in 2 suitable containers and stored at -80 degrees until assayed (first container for routine laboratory investigations and the second for VEGF assay).VEGF sample was allowed to clot for 30 minutes before centrifugation for 15 minutes. Serum is removed and assay immediately or sample was stored at -80 degrees
45764719|NCT03833557|Procedure|Nanohydroxyapatite Pulpotomy|Biphasic calcium phosphate 500-1000 Um Straumann BoneCeramic
45764720|NCT03833557|Procedure|MTA pulpotomy|Angleus grey MTA
46069342|NCT02889926|Biological|a swab according to the method of Levine|A swab according to the method of Levine: choose the pathological area by pressing the swab over the area, with a rotation supported on at least 1 cm² for 5 seconds, to well up from the liquid.
46069343|NCT02889926|Biological|Bacteriological referred to biopsy|Bacteriological referred to biopsy: (This is the hole protocol) Choose the pathological area, debridement of the wound to the pad and a scalpel, cleaning with betadine followed by rinsing with saline, local anesthesia with xylocaine, 6 mm punch for drawing a carrot, put into a sterile container
46069344|NCT02859896|Drug|Doxercalciferol (GZ427397)|"Pharmaceutical form: capsule~Route of administration: oral"
46069345|NCT02859896|Drug|Calcitriol|"Pharmaceutical form: capsule~Route of administration: oral"
46069346|NCT02846298|Biological|Drug Monitoring|Evaluation of Pharmacokinetic / Pharmacodynamic Data and Interest Individualized Therapeutic Drug Monitoring Glycopeptides and β-lactam-aminoglycoside ICU
45764721|NCT03833557|Procedure|Formocresol Pulpotomy|Buckley's Fromocresol. diluted full strength foromocresol
46069347|NCT02845479|Other|Integrative Care|Standardized supplemental/natural health product, physical, nutritional and mental/emotional recommendations based on the phases of standard care (neo-adjuvant, perioperative, adjuvant and long-term maintenance).
46069348|NCT02830958|Device|Kinesiotaping|The Kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting. Latex-free and wearable for days at a time, Kinesio® Tex Tape is safe for populations ranging from pediatric to geriatric, and successfully treats a variety of orthopedic, neuromuscular, neurological and other medical conditions.
46069349|NCT02830958|Other|No intervention|No intervention. Uses of an ordinary tape
46069350|NCT02828488|Other|No intervention|It is a descriptive study. No intervention
46069351|NCT02775630|Procedure|hypnosis|It will be proposed to the patient to participate in a study to assess the tolerance of Examination under hypnosis The examination is then conducted in endoscopy room. The patient will benefit from an induction technique of hypnosis by a doctor trained in hypnosis and local anesthesia performed by the endoscopist. In the control group, only local anesthesia is practiced by the endoscopist. The waning, it will ask the patient and endoscopist to complete an evaluation form tolerance of the review
45912297|NCT02048813|Biological|Rituximab|Given IV
45912298|NCT02048150|Biological|anti-PSMA monoclonal antibody MDX1201-A488|Given IV
45912299|NCT02048150|Procedure|robot-assisted laparoscopic surgery|Undergo RALP
45912300|NCT02048150|Other|diffuse optical imaging|Undergo IOOI
46069352|NCT02750358|Drug|Enzalutamide|
46069353|NCT02750358|Behavioral|assessment|
45452344|NCT01001338|Drug|RDEA594|Uricosuric agent for the treatment of gout.
45452345|NCT01001338|Drug|Placebo|Matching Placebo
45452346|NCT01001338|Drug|Allopurinol|Allopurinol
45764722|NCT04360447|Device|Reformer Pilates|Reformer pilates was planned, suitable for the disabled, with an instructor for the patients in the study group for 8 weeks.
45764723|NCT04360447|Other|Home Exercise|A home exercise program with telephone monitoring was planned for the patients in the control group for 8 weeks.
45764724|NCT04360057|Other|PMD|A script used to train the physician to engage with the patient in the topic of hand hygiene compliance used on the initial visit.
45764725|NCT04360057|Other|PMDPlus|A script used to train the physician to engage with the patient in the topic of hand hygiene compliance on follow up visits
45764726|NCT03032887|Behavioral|voice prompts|voice prompts on disinfectant dispenser
45764727|NCT03032887|Behavioral|agitation|Education, reminders and optimising materials
45764728|NCT02825212|Drug|Harvoni|12 weeks for naïve subjects or non-cirrhotic treatment experienced subjects; or 24 weeks for treatment experienced subjects with cirrhosis
45764729|NCT02825212|Drug|Epclusa|once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced or treatment experienced subjects with compensated cirrhosis) for genotype 1-6 subjects.
45764730|NCT03032809|Other|Vessel Wall MR imaging|Magnetic resonance images of the intracranial arteries will be acquired using the 3 Tesla MR scanners. Intracranial vessels will be imaged by high resolution vessel wall MR imaging to characterize vessel wall enhancement characteristics and wall thickness.
45764731|NCT02825680|Other|Enhanced NCP Support|NCP is a central policy office that provides support to MOVE! program teams through monthly phone calls and technical assistance. Facilities will also have access to the audit and feedback process and barrier buster tool
45764732|NCT02825680|Other|LEAP|The Learn. Engage. Act. Process (LEAP) intervention relies on virtual (phone and online) coaching based on the IHI Model for Improvement, an online learning platform for clinician teams to share ideas and progress, an audit and feedback process, and a barrier buster tool.
45764733|NCT04983043|Drug|Low dose Qishenyiqi Dripping Pills 3 bags|Low dose Qishenyiqi Dripping Pills contain Qishenyiqi dripping pills 2 bags(0.52g dripping pills per bag) and Qishenyiqi dripping pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
45912301|NCT02048150|Other|pharmacological study|Correlative studies
45912302|NCT02048150|Other|Laboratory Biomarker|Correlative studies
45912303|NCT02048150|Other|Questionnaire|Ancillary studies
46069354|NCT02718170|Procedure|Buried Intramedullary K-wire Fixation|
45446486|NCT02074618|Other|Physical exercise.|Physical exercises were held three times a week on alternate days to hemodialysis sessions, with duration of 45 to 90 minute, supervised by a physiotherapist. In all the sessions the following measurements were performed: body weight and blood pressure, heart rate and peripheral oxygen saturation in the pre, during and post session. The exercises were: heating and stretching during 5 minutes, followed by aerobic physical exercise on treadmill and/or bike (about 30 minutes), muscle strengthening exercises (15 to 20 minutes), cooling and stretching (5 minutes). The time for aerobic and strengthening varied according to the tolerance of the patient. The resistance exercises have been conducted for the major muscle groups of the lower limbs.
45912304|NCT02038452|Drug|Depo-Medrone|Steroid Injection
45452347|NCT01093313|Behavioral|Cognitive therapy|
46069355|NCT02718170|Procedure|Plate and Screw Fixation|
46069356|NCT02711670|Drug|chlorthalidone|
46069357|NCT02711670|Drug|Hydrochlorothiazide|
45452348|NCT01093313|Behavioral|attention training|
45764734|NCT04983043|Drug|High dose Qishenyiqi Dripping Pills 3 bags|High dose Qishenyiqi Dripping Pills contain Qishenyiqi dripping pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks
45764735|NCT04983043|Drug|Qishenyiqi Dripping Pills placebo 3 bags|Qishenyiqi Dripping Pills placebo contain Qishenyiqi dripping pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
45764736|NCT00373672|Drug|armodafinil (Nuvigil)|armodafinil (Nuvigil)150 mg qd
46069358|NCT02658097|Drug|Pembrolizumab|200mg Pembrolizumab by IV infusion
46069359|NCT02658097|Radiation|Single Fraction Radiation Therapy|8Gy radiation therapy will be given in a single fraction on the first day of treatment
45764737|NCT00373672|Drug|placebo|identical in appearance to active comparator
45764738|NCT03032731|Behavioral|Website and pedometer intervention|Self-directed, website-based intervention delivered with a pedometer to promote understanding of health and health behaviour change.
45764739|NCT03032731|Other|Control|Standard, publicly available NHS resources for healthy lifestyles.
45912305|NCT02038452|Device|Wrist Splint|Simple wrist splint
45912306|NCT02019693|Drug|INC280|Supplied by Novartis as film-coated tablet for oral use.
45912307|NCT01933932|Drug|Selumetinib|Three 25 mg selumetinib capsules (Hyd-Sulfate) be administered orally, twice daily, (total dose 75 mg dose bd) on an uninterrupted schedule.
45912308|NCT01933932|Drug|Docetaxel|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
45912309|NCT01933932|Drug|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
45912310|NCT01933932|Drug|Pegylated G-CSF|All patients will receive pegylated Granulocyte Colony Stimulating Factor (G-CSF) at least 24 hours after administration of every docetaxel dose and not within 14 days prior to the next docetaxel administration.
45912311|NCT01748448|Drug|Vitamin D|"prospective interventional randomized double blind placebo controlled trail~clinical setting (tertiary university hospital)~investigator driven, no pharmaceutical sponsor~cutaneous malignant melanoma patients~add- on study (placebo or vitamin D) on top of optimal standard care~1:1 inclusion ratio (placebo:Vitamin D)~randomisation after informed consent and screening"
46069360|NCT02649270|Biological|T1h|Given T1h for different groups by vein to evaluate safety and tolerability;Collecting blood samples for pharmacokinetics and pharmacodynamics after administration.
46069361|NCT02581527|Drug|Rifampicin|Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)
46069362|NCT02581527|Drug|Isoniazid|Isoniazid 75mg - all arms
46069363|NCT02581527|Drug|Ethambutol|Ethambutol 275mg - all arms
46069364|NCT02581527|Drug|Pyrazinamide|Pyrazinamide 400mg - all arms
46069365|NCT02558010|Drug|Methadone|Perioperative IV methadone to be given
46069366|NCT02558010|Other|Normal Saline|control arm
45764740|NCT03032653|Other|Late Rehabilitation|"Post-0p: Non weight-bearing and no range of motion for 2 weeks post treatment. 2 weeks: Splint removed, removable pre-fabricated walking boot applied. WB as tolerated with boot, range of motion out of boot.~6 weeks: Boot discontinued and full unrestricted and unprotected WB and ROM permitted 6 weeks:"
45622319|NCT04872257|Procedure|NB-UVB Phototherapy|NB-UVB Phototherapy twice per week for 6 months until completing 48 sessions. Initial dose of 200 mJ/cm² with a 10-20% increase to the previous session. Maximum dose for face and neck is 1500 mJ/cm² and 3000 mJ/cm² for the rest of the body.
45764741|NCT03032653|Other|Early Rehabilitation|Weightbearing and range of motion as tolerated within the limitations of participant's own comfort. Use of ambulatory aides of any kind is permitted as needed without restriction. No brace or splint of any kind is permitted
45764742|NCT03004534|Drug|darolutamide|Oral 300 mg tablets; 600 mg (2 x 300 mg tablets) taken twice per day, to a daily dose of 1200 mg.
45764743|NCT04941703|Drug|Magnesium Citrate plus probiotic|296 ml magnesium citrate
45764744|NCT02826694|Genetic|Well infant, whole exome sequencing|Whole exome sequencing will be performed in children with diagnosed conditions. Investigators will analyze results that are associated with their condition.
45764745|NCT02826694|Genetic|Diagnosed, whole exome sequencing|In addition to returning results of conditions associated with a child's phenotype, investigators will also analyze genes that are associated with conditions that have childhood onset and are medically actionable.
45764746|NCT04359823|Drug|Lovastatin 2%, 2% Cholesterol Cream|Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
45764747|NCT04359823|Drug|Lovastatin 2%|Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
46069367|NCT02558010|Drug|Morphine|Both groups will receive morphine via Patient-Controlled Analgesia (PCA) pump.
46069368|NCT02496663|Procedure|Biospecimen Collection|Undergo blood sample collection
46069369|NCT02496663|Procedure|Computed Tomography|Undergo CT scan
45446487|NCT05506384|Behavioral|Relaps Preventions Therapy|The treatment consists of three parts: 1) setting goals, 2) understanding and identifying high-risk situations and problem behaviors, and 3) consolidating the new activity schedule and identifying future high-risk behaviors. The first part is focused on examining the patient's undesirable behavior, his/her motivation for change, and establishing goals with the. The second part, drawing more from traditional Cognitive Behavioral Therapy (CBT) techniques, consists of exploring problematic situations, identifying high-risk situations and events, emotions and cognitions that induce the problematic gaming behavior or result in a relapse; managing game time with activity scheduling and practicing problem-solving skills. The final part consists of recognizing early warning signals that may indicate that the primary problem behavior is more likely to occur and consolidating the parts of the treatment that have been most helpful in maintaining the new activity schedule.
45446488|NCT05506384|Behavioral|Treatment as usual|This group will receive treatment as usual at their Child and Adolescent Psychiatry Clinic.
45446489|NCT04346199|Drug|Acalabrutinib|Acalabrutinib- administered orally
45622320|NCT04872257|Drug|Placebo|Administered orally daily for 6 months
45622321|NCT04157127|Biological|Autologous DC vaccine|Autologous DC vaccine given as 3 doses every 14 days. Dosage is cohort-dependent.
45622322|NCT02464319|Drug|hrIL-2 active|1 million U doses of human recombinant interleukin-2 s.c. injection active group: placebo group =1:1
45764748|NCT02939170|Device|Delefilcon A Multifocal Contact Lenses with Molded Mark|
45764749|NCT02939170|Device|Delefilcon A Multifocal Contact Lenses|
45912312|NCT01748448|Drug|arachides oleum raffinatum|
45912313|NCT01476839|Biological|basiliximab|Given IV
45912314|NCT01476839|Drug|carmustine|Given IV
45912315|NCT01476839|Drug|etoposide|Given IV
45912316|NCT01476839|Drug|cytarabine|Given IV
45912317|NCT01476839|Drug|melphalan|Given IV
45912318|NCT01476839|Other|pharmacological study|Correlative studies
45912319|NCT01476839|Other|laboratory biomarker analysis|Correlative studies
46069370|NCT02496663|Procedure|Magnetic Resonance Elastography|Undergo MRI
46069371|NCT02496663|Biological|Necitumumab|Given IV
46069372|NCT02496663|Drug|Osimertinib|Given PO
46069373|NCT02473497|Drug|Crizotinib|For adult patients, crizotinib 250 mg BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing. For pediatric patients, crizotinib 280 mg/m2 BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing.
46069374|NCT02471040|Drug|Beta-hydroxybutyrate|Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
45622323|NCT02464319|Drug|hrIL-2 placebo|1 million U doses of placebo s.c. injection active group: placebo group =1:1
45622324|NCT05603637|Procedure|Catheter ablation using SmartTouch radiofrequency ablation catheter|Patients will undergo catheter ablation for atrial fibrillation, i.e. pulmonary vein isolation, using radiofrequency energy with SmatTouch ablation catheter (Biosense Webster, USA)
45622325|NCT05603637|Procedure|Catheter ablation using Farawave pulsed-field ablation catheter|Patients will undergo catheter ablation for atrial fibrillation, i.e. pulmonary vein isolation, using pulsed-field energy with Farawave ablation catheter (Boston Scientific, USA)
45622326|NCT03065751|Device|Plasmaexchange|TPE against fresh frozen plasma
45622327|NCT02464397|Device|Stent|In the study, either OPTIMAX or SYNERGY stent will be implanted in coronary artery lesion
45622328|NCT02464475|Other|osteopathic manipulative treatment|
45622329|NCT02464475|Other|sham osteopathic treatment|
45622330|NCT04970121|Drug|Duloxetine|"Duloxetine, tablets, 20mg as starting dose and up to 60mg as maximum dose, once daily.~Taxanes is used according to manual instruction and patient condition."
45622331|NCT04856657|Device|Transcranial alternating current stimulation|The tACS will be applied with a current of 1-2 mA (milliamperes) via two saline soaked electrode sponges (25 cm²) applied to the back of the head. The anode will be located at Oz and the cathode will be located at Cz.
45622332|NCT03065595|Dietary Supplement|Ophiochepalus striatus extract|each sachet of ophiochepalus striatus extract is poured into 50 mL normal water and drink two times/day
45622333|NCT03065595|Other|Placebo|each sachet of placebo drug is poured into 50 mL normal water and drink two times/day
45622334|NCT05540613|Behavioral|Health Education|A 26 weeks brain health and general health education program with two 1.5-hour sessions weekly.
45622335|NCT05540613|Behavioral|Conventional Exercise|A 26 weeks Conventional Exercise training with two 1.5-hour sessions weekly.
45622336|NCT05540613|Behavioral|Tai Chi|A 26 weeks Tai Chi training with two 1.5-hour sessions weekly.
45622337|NCT02463929|Drug|Diphenhydramine|Intravenous Injection
45622338|NCT02463929|Drug|normal saline|Intravenous Injection
45622339|NCT02463929|Drug|Ketamine|Ketamine 0,1 mg/kg intravenously used as rescue tranquilizer if the subject becomes agitated, repeated dose of 0,05 mg/kg every minute can be given if the agitation does not resolve, maximum ketamine dose for tranquilizer 0,25 mg/kg to prevent deep sedation
45622340|NCT02463929|Drug|Sevoflurane|Sevoflurane as single sedation agent for general anesthesia in both arm. 8% Sevoflurane in 100% oxygen used as induction agent, and 2% sevoflurane in 50% oxygen used as maintenance agent
45622341|NCT02463929|Drug|Bupivacaine|Bilateral extraoral infraorbital nerve block with 0,125% Bupivacaine as analgetic for operation and post operation.
45622342|NCT02465255|Drug|Ketorolac|
45622343|NCT02465255|Drug|Tramadol|
45622344|NCT02465255|Drug|Acetaminophen|
45622345|NCT05537337|Behavioral|Multicomponent Intervention|"The multicomponent intervention consists of the following components (already described in the detailed description section):~Food labels (with the summary of healthiness of shopping baskets & targets)~Ordering~Within Group Healthier Substitution"
45622346|NCT02463851|Device|PVAC GOLD multielectrode catheter|Cardiac ablation for Atrial Fibrillation
45622347|NCT02463851|Device|Contact Force single-tip ablation catheter|
45764750|NCT04346953|Behavioral|Video based exercise|Individuals (n = 64) to be included in the study group will be grouped according to the levels of physical activity (low, medium, high level) determined by the International Physical Activity Questionnaire. An exercise program will be created for each group based on physical activity levels and videos of these exercise programs will be prepared. The videos will be scheduled for 20 minutes. Individuals will be asked to apply for these programs with video for 20 minutes every day for 6 weeks. Exercise programs will start with pulmonary exercises and warm-up exercises to prepare for exercise. The exercise program will end with cool down exercises. The exercise protocol will be determined as a combination of aerobic and strengthening exercises.
45764751|NCT03004846|Drug|GSK2981278 ointment|"GSK2981278 ointment will be applied topically twice daily for 8 weeks to all subjects in Part A and to randomized subjects in Part B. GSK2981278 will be a white to off-white ointment and a thin layer will be applied to all affected areas for given timeframe.~GSK2981278 is available as white to off-white ointment in unit strength 4% (w/w), 2% (w/w) and 0.8% (w/w), for topical application for application as thin layer to all affected areas ."
45622348|NCT02464943|Device|Endovascular Treatment (Zenith)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
45622349|NCT04156893|Biological|Red cell units that are genotype matched at the RHD and RHCE loci|Patients will be provided with red cell units that are C, E, and K antigen matched (standard of care for patients with SCD) and genotype matched at the RHD and RHCE loci.
45622350|NCT05459337|Behavioral|MuST AKT|A behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation.
45622351|NCT02464709|Drug|Aminolevulinic Acid|A 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid, Ameluz®) light sensitizer gel is applied on one randomized treatment side of face.
45622352|NCT02464709|Drug|Methyl 5-aminolevulinate|A 0,25mm-thick layer of MAL (methyl 5-aminolevulinate, Metvix®) light sensitizer cream is applied on one randomized treatment side of face.
45622353|NCT04442061|Device|Transcranial magnetic stimulation|"Before the stimulation, identification of a motor hotspot and active motor threshold (AMT) will be performed. The TMS will be applied on the intermittent theta-burst modality (iTBS), i. e., 2 s of TBS trains (30 pulses) repeated every 10 s for 190 s, with a total number of 600 pulses (Huang et al, 2005). The whole TMS session, including preparation, will last up to 1h.~The sham TMS follows the same procedure of the active TMS without stimulating cortical tissue"
45622354|NCT04442061|Device|MRI|Anatomical and functional images will be acquired and review by an experienced neuro-radiologist.
45622355|NCT04442061|Device|Neuronavigation|The neuronavigation system will allow to guide the stimulation using the individual anatomical MRI acquired with MRI, and to record the position and orientation of the coil during successive stimulations
45764752|NCT03004846|Drug|Vehicle ointment|It will be supplied as white to off-white vehicle ointment for topical application.
45764753|NCT03032497|Device|EEG-based BCI analysis of fear avoidance|Scalp EEG signals that are acquired and recorded from experiment 1 and 2 are analysed for healthy controls, participants with low back pain and participants with lower limb pain. Comparisons of signal patterns are made between groups. Assuming unique signal patterns are obtained for each groups, these signals are further analysed and used to develop a feedback brain training system to better manage pain and ideally reduce fear-avoidant behaviors towards pain.
45622356|NCT04442061|Device|Eye-tracking|Eye movements and follow a person's gaze will be recorded during visualization of stimuli presented in the screen by analyzing images of the eye captured by an infrared camera
45622357|NCT04442061|Genetic|Salivary samples|The DNA will be extracted from the salivary sample to genotyping analyses on the BDNF (Val66Met) and COMT (Val158Met) polymorphism
45622358|NCT04442061|Other|Clinical scales|CGI, E-CAR and ABC will be used for behavior and clinical evaluation
45622359|NCT04213547|Behavioral|Loss frame sleep extension intervention|Aim 2 will be an interventional study design utilizing Fitbit and text messaging to perform a loss-framed incentive intervention designed to motivate participants to increase their sleep duration. Glycemic control will be measured via laboratory testing of hemoglobin A1c and Libre continuous glucose monitoring (CGM) for 2 weeks pre- and post-intervention.
45622360|NCT05513859|Procedure|Craniotomy|Undergo craniotomy
45622361|NCT05513859|Device|Quantitative Oblique Back-Illumination Microscopy|Undergo intraoperative microscopy utilizing qOBM
45622362|NCT02464085|Other|Longitudinal evaluation of recovery|Stroke survivors will be assessed at four time frames post stroke to evaluate neuroplastic and clinical changes in arm recovery over the first 12-months post stroke.
45764754|NCT04359667|Drug|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]|1 - 8 mg per kg of body weight once, maximal 800 mg per dose (can be repeated once more after 12 hours, per clinician's assessment)
45764755|NCT00373750|Procedure|Family Spirit Intervention|The Family Spirit Intervention was developed over a decade through community-based participatory research.The intervention content included 43 structured lessons and followed a culturally congruent format.
45764756|NCT03008590|Drug|Naltrexone|One 4.5 mg capsule each evening
45764757|NCT03008590|Drug|Placebo|One capsule each evening
45764758|NCT04359511|Drug|Prednisone|prednisone 0.7 mg/kg/d (PO)
45764759|NCT04359511|Drug|Hydrocortisone|hémisuccinate d'hydrocortisone 3,5 mg/kg/jour (IV)
46069375|NCT02471040|Other|Normal Saline|Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
46069376|NCT02466074|Drug|Acetazolamide|see arm description
46069377|NCT02466074|Drug|Placebo|Placebo arm
45764760|NCT03032419|Biological|IPV-Al SSI|3 primary injections of IPV-Al SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
45764761|NCT03032419|Biological|IPV SSI|3 primary injections of IPV SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
45764762|NCT00373906|Drug|Bortezomib (Velcade)|
45912320|NCT01476839|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic progenitor cell infusion
45912321|NCT01476839|Biological|yttrium Y 90-labeled basiliximab|Given IV
45912322|NCT01441687|Other|laboratory biomarker analysis|Correlative studies
45912323|NCT01441687|Procedure|transrectal prostate biopsy|Undergo prostate biopsy
45912324|NCT01332097|Drug|BCT197|
45912325|NCT01332097|Drug|Prednisone placebo|capsules
46069378|NCT02393794|Drug|Romidepsin|Histone deacetylase inhibitor
45622363|NCT05510973|Other|Enhanced package for AHD care|The enhanced package of AHD care includes CD4 and tuberculosis lipoarabinomannan (TB-LAM) tests and the initiation of patients on TB prophylaxis [TPT and CPT], offered through a hub-and-spoke facility system, with continuous quality improvement (QI)
45622364|NCT02462915|Device|i-gel|"a supraglottic airway devices without cuff and the material was Styrene Ethylene Butadiene Styrene.~gastric channel to the The gastric suction channel can facilitate venting and reduce the aspiration."
45622365|NCT02462915|Device|endotracheal tube|traditional and regularly use in many surgeries for maintaining the airway.
45622366|NCT02462915|Drug|lidocaine, propofol, fentanyl and cisatracurium|
45622367|NCT03064893|Device|Alloderm|Reconstruction material
45622368|NCT03064893|Device|Dermacell|Reconstruction material
45622369|NCT02463617|Other|magnetic resonance imaging|
45622370|NCT05505123|Drug|Sevoflurane|induction and maintenance with sevoflurane for deep sedation
45622371|NCT05505123|Drug|Propofol|induction and maintenance with propofol for deep sedation
45622372|NCT03064815|Device|Videocapsule endoscopy|"Capsule endoscopy is a procedure that uses a tiny wireless camera to take pictures of your digestive tract. A capsule endoscopy camera sits inside a vitamin-size capsule you swallow. As the capsule travels through your digestive tract, the camera takes thousands of pictures that are transmitted to a recorder you wear on a belt around your waist.~Capsule endoscopy helps doctors see inside your small intestine - an area that isn't easily reached with more-traditional endoscopy procedures."
45622373|NCT03064815|Procedure|colonoscopy|Colonoscopy is a test that allows your doctor to look at the inner lining of your large intestine (rectum and colon). He or she uses a thin, flexible tube called a colonoscope to look at the colon.
45912326|NCT01332097|Drug|BCT197 placebo|capsules
45912327|NCT01332097|Drug|Prednisone|capsules
46069379|NCT02393794|Drug|Cisplatin|Platinum compound
46069380|NCT02393794|Drug|Nivolumab|Monoclonal antibody, checkpoint inhibitor
46069381|NCT02319837|Drug|Enzalutamide|
46069382|NCT02319837|Drug|Placebo|Sugar pill to mimic enzalutamide
46069383|NCT02319837|Drug|Leuprolide|
45622374|NCT03064815|Diagnostic Test|PROMETHEUS® IBD sgi Diagnostic™|This test combines serologic, genetic, and inflammation markers in a proprietary Smart Diagnostic Algorithm to provide added IBD diagnostic clarity. This test helps physicians differentiate IBD vs. non-IBD and CD vs. UC in one comprehensive blood test.
45622375|NCT03064815|Diagnostic Test|Fecal calprotectin|A stool test to measure inflammation in the gut.
45622376|NCT03065439|Diagnostic Test|Static balance testing|Postural sway will be measured using a force plate (Metitur Good Balance System®).
45622377|NCT04125459|Procedure|Joint Biopsy|a synovial biopsy of a joint that has been affected by a gout attack
45622378|NCT04914897|Drug|THOR-707|Intravenous infusion: solution for infusion
45622379|NCT04914897|Drug|Pembrolizumab|Intravenous infusion: solution for infusion
45622380|NCT02463695|Procedure|cortical vestibular evoked potentials (CVEPs)|CVEPs utilise an existing method used to interrogate cortical projections from the auditory system in which sound waves stimulate the inner ear and the resulting electrical responses from the brain are recorded (known as Cortical Auditory Evoked Potentials CAEPs)
45622381|NCT02462525|Drug|ABBV-838|Varying doses of ABBV-838
45622382|NCT02462525|Drug|Pomalidomide|Administered orally per the label.
45622383|NCT02462525|Drug|Dexamethasone|Administered orally per the label.
45622384|NCT04111419|Drug|Amlodipine/Atorvastatin 5 Mg-20 Mg ORAL TABLET|amlodipine/atorvastatin (5/20mg tablet) once a day
45622385|NCT04111419|Drug|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET|amlodipine/atorvastatin (5/10mg tablet) once a day
45622386|NCT04111419|Drug|Allisartan Isoproxil|allisartan (240mg/tablet) once a day
45622387|NCT02462447|Drug|11C-sarcosine|Radiotracer injection for PET/CT scan
45446490|NCT02084992|Other|Expanded technology disease management|Tablet computers loaded with a web-based disease management program will be given to patients for the duration of the study.
45446491|NCT02084992|Other|Telephonic disease management|
45622388|NCT02462447|Drug|11C-choline|Radiotracer injection for PET/CT scan
45622389|NCT05473923|Drug|Receiving chemotherapeutic or targeted drugs recommended by molecular tumor board.|Patients will be treated with FDA-approved chemotherapeutic or targeted drugs which were recommended by the molecular tumor board (MTB), based on their expertise, patients willingness as well as evidences from PTCs-drug screening and bioinformatic prediction for drug response.
45912328|NCT01238172|Other|dietary education and counseling|
45912329|NCT01238172|Other|prostate cancer foundation booklet|
45912330|NCT01163357|Drug|bortezomib|Given IV
45622390|NCT02462681|Drug|paravertebral block|Thoracic paravertebral blocks will be performed as described by Moore and Katz. Intradermal lidocaine will be used at the site of the needle insertion. The superior aspect of the spinous processes of T1- T6 will be marked. The skin entry points will 3 cm laterals to the marks. A 22- gauge quincke spinal needle attach to extension tubing to a syringe containing study drugs will be used. The needle will be inserted perpendicular to the skin for a distance of 2 to 4 cm until the transverse process will contact. The needle will be withdrawn and walk cephalad off the transverse process and advance for a further 1.5 to 2 cm.
45622391|NCT03064581|Behavioral|Intervention|The educational session consisted of a one-hour small group discussion (5-10 people). Gender-specific community health educators facilitated sessions for Pacific Islander women and for their spouses/significant others that included an educational video and other materials (brochure, calendar, and resource list). The video emphasized the importance of Pap testing for Pacific Islander women, and showed men supporting their women to get tested. Women's sessions provided basic information on cervical cancer and pap testing, and ended with verbal commitments and target screening dates by women to get screened. The men's education sessions contained similar information, with supplemental information on how to provide support for their wives to get tested and exercises on showing their support.
45622392|NCT04129151|Drug|Palbociclib|Oral, per protocol pre determined dosage, once a day for 21 days
45622393|NCT04129151|Drug|Ganitumab|-Intravenous, per protocol predetermined dosage, twice per cycle
45622394|NCT03064425|Biological|Vaginal and blood sample collection|The researchers will obtain approximately 20 mL of blood from participants. Participants will also undergo a pelvic exam where a sample of cells will be collected from the cervix using two small cytobrushes. In addition, a cervicovaginal lavage will be collected using saline.
45622395|NCT02462369|Drug|Saxagliptin|
45622396|NCT02462369|Drug|glimepiride|
45622397|NCT04114175|Other|Exercise BE|Basic exercises related to amputation will be applied
45622398|NCT04114175|Other|Exercise BE+SS|Basic exercises related to amputation + Spinal stabilization exercises will be applied
45622399|NCT04072835|Drug|Etripamil NS|Patients will be provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS will be self-applied by the patient, when PSVT symptoms begin. Patients will self-administer etripamil NS if vagal maneuver is ineffective. After an episode of PSVT where drug is administered, the patient will return to the investigative site for a study visit and will be given the option to continue in NODE-303 and manage subsequent episodes of PSVT with etripamil NS.
45912331|NCT01163357|Drug|fludarabine phosphate|Given IV
45912332|NCT01163357|Other|melphalan|Given IV
45912333|NCT01163357|Radiation|total marrow irradiation|Undergo TMI
45764763|NCT02981797|Other|Blood Collection During Standard of Care Treatment|Blood collection for baseline CTC numeration and H2AX assay. Circulating prostate cancer cell analysis requires blood draw of 7.5 ml (about 1 ½ teaspoons) of blood, to be performed at the screening, 1-2 hours before the third and sixth dose of radium 223 and 24 hours after the first, third, sixth dose of Radium 223. Standard of care Radium 223 treatment is given every 4 weeks for a total of 6 treatments and post Radium 223 follow up at week 24 is also considered standard of care. Other than these standard clinic visits and treatments, the study only requires 3 extra trips to the cancer center for blood draw at 24 hours after the first, third, sixth dose of Radium 223. Blood draws other than circulating tumor cell analysis is considered standard of care and doesn't require extra visits.
45622400|NCT04446273|Device|Bi-Manu-Track|The PRI and DRI protocol provide robotic training for 45 minutes and impairment-oriented training for 45 minutes. The PRI group will start from the Bi-Manu-Track proximal mode (i.e., forearm) and then the Bi-Manu-Track distal mode (i.e., wrist). The DRI group will start from the Bi-Manu-Track distal mode (i.e., wrist) and then the Bi-Manu-Track proximal mode (i.e., forearm).In every session of robotic training, the patient will practice bilateral passive range of motion exercise, in which affected upper extremity is assisted by the unaffected side, and bilateral active range of motion exercise. Robotic training will be followed by impairment-oriented training.
45622401|NCT04445883|Behavioral|Feeding Assistance|Patients will be receiving assistance during mealtimes. This includes assistance by opening packages, listing/explaining the food products on the tray, providing encouragement and companionship during mealtimes and directly feed patients.
45622402|NCT04445649|Diagnostic Test|Coma-Recovery-Scale-Revised (CRS-R)|CRS-R assessments (15 minutes) are repeated weekly after study entry
45764764|NCT00955513|Drug|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% twice a day
45764765|NCT00955513|Drug|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% three times a day
45764766|NCT00955513|Drug|Placebo|Placebo
45764767|NCT02939326|Drug|EB-001 injection|
45764768|NCT02939326|Drug|Placebo injection|
45446492|NCT03558490|Device|ZEMY software|"The ZEMY software medical device integrates specific algorithms based on international and validated guidelines. It provides individually customized information and defines for the patient an adapted action to follow for each of the following reported symptoms or anti-cancer treatment-related toxicities: diarrhea, fatigue, nausea, vomiting, cutaneous and mucosal toxicities, pain, fever/febrile neutropenia, high blood pressure, anxiety and depression.~During the 3-month study period, participants will be asked to enter their symptoms among the 10 symptoms listed in ZEMY on their smartphone dedicated to the study. Consequently, ZEMY software will provide to the participants adapted real-time information to advise them on the management of the experienced symptom and recommend hygienic-dietetic advice and symptomatic treatments."
45764769|NCT03032185|Device|Transcutaneous Elevtrical Nerve Stimulation|
45764770|NCT02943226|Device|Becton Dickinson Nexiva Diffusics System|Becton Dickinson Nexiva Diffusics System will be used to inject IV contrast and will be compared to a single hole catheter to see if it improves image quality in the main vessels in the abdomen and pelvis because of its novel design.
46069384|NCT02308488|Radiation|Intensity-modulated radiation therapy (IMRT)|Patients will receive 15 daily radiation fractions of 2.7 Gy, Monday to Friday for three weeks, to the entire breast/chest wall and axillary level III and supraclavicular nodes with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7 Gy + 0.5 Gy). The overall dose will be 40.5 Gy to the breast/chest wall, axillary level III and supraclavicular nodes, and 48.0 Gy to the tumor bed.
45446493|NCT03558490|Drug|Investigator's choice of anti-cancer treatment (except immunotherapy)|All anti-cancer treatments (except immunotherapy) will be left to the free choice of investigators. Participants shall be prescribed by the healthcare team both of the following symptomatic treatments: loperamide or any other anti-diarrheic treatment in case of diarrhea; and a prescription for any medication indicated in case of nausea/vomiting. A written prescription will be made by the investigator at screening for loperamide or any other anti-diarrheic treatment and symptomatic treatment for nausea/vomiting with documented dosage and duration.
45446494|NCT04345653|Drug|Hydroxychloroquine Sulfate (HCQ)|Open-label, consecutive at-risk subjects allocation with chemoprophylaxis with HCQ.
45764771|NCT02943226|Device|Standard intravenous catheter|Standard catheter with one hole at the tip will be compared to a novel 3 hole catheter to see which catheter provides the best image quality.
45764772|NCT00935311|Drug|ABT-712 Extended-release|ABT-712 extended-release tablet
45764773|NCT00935311|Drug|Hydrocodone/Acetaminophen Immediate-release|Hydrocodone/acetaminophen immediate-release tablet
45764774|NCT00935311|Drug|Placebo|Placebo tablet
45764775|NCT03019744|Device|MeCFES-assisted task-oriented upper limb rehabilitation|
45764776|NCT03019744|Other|Usual Care task-oriented upper limb rehabilitation|
45804248|NCT05413525|Procedure|ultrasound-guided manual vacuum aspiration (USG- MVA)|USG-MVA was carried out as an outpatient day procedure. Women was given a 400μg oral misoprostol tablet 2-3 hours before the procedure. All patients will be given 500mg naproxen orally an hour before the procedure. During the USG-MVA, all the women were placed in the lithotomy position and aseptically dressed. Speculum was performed to visualize the cervix with PCB performed. USG-MVA was performed using a 60ml charged syringe with a flexible curetteattached to it. Transabdominal USG during MVA was performed. During the procedure, local lidocaine gelwas applied to the cervical canal and over the end of the MVA catheter tip during the insertion.The USG-MVA was stopped as soon as USG confirmed that the uterine cavity was empty, defined as a thin endometrial lining with no evidence of retained products of conception.
45912334|NCT01163357|Drug|tacrolimus|Given IV and orally
45446495|NCT02074774|Device|IntellO2|Automated FiO2 regulator that responds to pulse oximetry measures
45764777|NCT03031951|Behavioral|Lifestyle Intervention Group|The intervention group will start the lifestyle intervention with a 60-minute nutrition appointment given by a certified dietitian. This meeting is intended to provide a well-balanced personalized diet plan, calculated to create a moderate reduction from ~300 to 500kcal/day according to each participant's energy requirements and preferences. Two additional follow-up appointments are also planned to adjust the individual energy requirements throughout the intervention. Subjects will attend 12 educational sessions for a healthy lifestyle in groups of 10-15 participants, for approximately 4 months. Sessions will last 60-90 minutes and will include educational content and practical application classroom exercises in the areas of physical activity and exercise, diet and eating behavior, and behavior modification. The inclusion of self-regulation skills, such as pedometer use, recording food regularly and monitoring weight, is also part of the curriculum. Weight will be monitored weekly.
45764778|NCT02946034|Drug|Viekira Pak ± ribavirin|12 weeks treatment with AbbVie Viekira Pak ± ribavirin
45622403|NCT03587831|Procedure|Vertical Sleeve Gastrectomy|Surgical Procedure: Vertical Sleeve Gastrectomy
45622404|NCT03587831|Behavioral|Lifestyle Modification Counseling|Behavioral Intervention: Lifestyle Modification Counseling
45622405|NCT04083963|Drug|Carboplatin|Low dose weekly carboplatin (AUC 2) will be combined with weekly paclitaxel for 12 weeks.
45622406|NCT04083963|Drug|Paclitaxel|Paclitaxel will be given weekly along with carboplatin for 12 weeks.
45622407|NCT04083963|Drug|Doxorubicin|Dose dense doxorubicin will be administered in combination with cyclophosphamide for 4 cycles after weekly carboplatin/paclitaxel.
45764779|NCT02946034|Drug|Mavyret|8 or 12 weeks treatment with AbbVie Mavyret
46069385|NCT02159950|Other|Laboratory Biomarker Analysis|Correlative studies
45622408|NCT04083963|Drug|Cyclophosphamide|Does dense cyclophosphamide will be in combination with doxorubicin for 4 cycles after weekly carboplatin/paclitaxel.
45446496|NCT02074774|Other|Manual control|Standard practice of manually titrating FiO2 as needed.
45622409|NCT03576365|Behavioral|VOICE Intervention Arm|"Introductory and background information about voice problems and psychosocial distress~Examples of concerns raised by patients with voice problems (e.g., I feel left out of conversations because of my voice problem)~Information about perceived control and how improving perceived control can lead to decreased distress~Examples of strategies that have helped patients identify controllable and uncontrollable aspects of their voice problems (e.g., I learned to plan to take breaks to rest my voice between teaching classes)~Self-guided exercises designed to help improve perceived control and develop better management skills for voice problem symptoms"
45622410|NCT03576365|Behavioral|Information-Only Arm|"General introduction of the program and background on voice related information in an interactive manner~Examples of what patients want to learn more about the voice (e.g., I would like to learn more about how the voice works when it is healthy)~Information on the anatomy of the voice and how the voice works~Educational materials to help understand voice physiology and function~Self-guided learning exercises (e.g., what are some things about vocal function that you would like to learn more about?)"
45446497|NCT02074852|Other|Foley urethral catheter|
45446498|NCT04342689|Drug|Dietary Supplement containing resistant starch|Two tablespoons (~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
45446499|NCT04342689|Dietary Supplement|Placebo Starch|Two tablespoons (~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
45622411|NCT03548285|Radiation|Radiation therapy|Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy (SBRT)
45622412|NCT04888767|Other|Interval Training Hight Intensity Program|"Rehabilitation stay in hospitalization with 18 days of training sessions~Training on an ergometer~Sessions supervised by an Adapted Physical Activities (APA) teacher or a physiotherapist~Control group: 5 times / week; continuous work 20 to 30 min; around the 1st aerobic ventilation threshold~Intervention group: 2 times / week: maintenance sessions + 3 times / week: IHTI sessions - alternating 30s work / 30s rest repeated 6 times; at 60% of the maximum heart rate at the 1st session then increase as fast and large as possible"
45622413|NCT02463383|Drug|Ibuprofen Tab 400 MG|400mg ibuprofen is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
45622414|NCT02463383|Drug|Placebo tab|A placebo tablet is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
45622415|NCT05462457|Procedure|Targeted axilllary dissection (TAD) followed by axillary lymph node dissection (ALND)|Intraoperative excision of TAD lymph nodes followed by ALND in the same surgical session or secondary surgical intervention
45622416|NCT03433469|Drug|Osimertinib|Given PO (orally)
45622417|NCT03433469|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45764780|NCT00955747|Drug|Tagatose|powder; 15 grams three times daily; one year
45764781|NCT00955747|Drug|Sugar Substitute Splenda|1.5 g powder tid
45764782|NCT02946892|Drug|Carvedilol|Carvedilol will be given for 12 weeks and then an exercise test will be performed
46069386|NCT02159950|Biological|Sipuleucel-T|Given IV
45446500|NCT02082028|Device|BGStar|
45446501|NCT02082028|Device|glucose meter|
45446502|NCT02082106|Other|Alpine skiing|
45446503|NCT02082106|Other|cross country skiing|
45446504|NCT02082106|Other|Indoor training (cycling)|
45452349|NCT03952949|Behavioral|Default Option While Online Grocery Shopping|"The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up). Participants in the default condition were presented with a prefilled online shopping cart containing groceries that met nutritional requirements based on participants' gender and age."
45622418|NCT03278873|Biological|either AAV - CNGB3 or AAV - CNGA3|Comparison of different dosages of either AAV - CNGB3 or AAV - CNGA3
45622419|NCT02463461|Device|ActiSleep Activity Monitor|Subjects in this group will wear a ActiSleep Activity Monitor.
45912335|NCT01163357|Drug|sirolimus|Given orally
46069387|NCT02159950|Drug|Tasquinimod|Given PO
46069388|NCT02152137|Drug|efatutazone|Given PO
46069389|NCT02152137|Drug|paclitaxel|Given IV
45622420|NCT02463461|Device|Jawbone Activity Monitor|Subjects in this group will wear a Jawbone Activity Monitor.
45622421|NCT02463461|Device|Actiwatch 2 Activity Monitor|Subjects in this group will wear a Actiwatch 2 Activity Monitor.
45912336|NCT01163357|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
45764783|NCT02946892|Drug|Placebo|Placebo will be given for 12 weeks and then an exercise test will be performed
45764784|NCT03017521|Drug|TAS-117|TAS-117 16mg, daily
45764785|NCT00935857|Device|Single Balloon Colonoscopy|Use of the single balloon enteroscopy system (enteroscope and balloon-overtube) to complete colonoscopy.
45764786|NCT00935857|Device|Standard Colonoscopy|Use of the standard adult colonoscope to complete colonoscopy.
45764787|NCT03017599|Device|20-gauge ProCore FNB needle|"The investigators will prospectively collect data base including patients who underwent EUS-guided biopsy with the 20-gauge ProCore histology needle for the evaluation of Pancreatic solid mass.~EUS procedures will be performed under sedation with linear echoendoscopes. Once the lesion will be penetrated, the stylet will be removed, and suction will be applied for 10 to 20 seconds by using a 10-ml syringe while moving the needle to and fro. All samples will processed at the pathology departments for histological analysis with documentation."
45764788|NCT01045421|Drug|MLN8237 (Alisertib)|"Phase 1:~MLN8237 will be administered orally twice a day on a 7-day dosing schedule~Phase 2:~MLN8237 will be administered orally at the maximum tolerated dose determined in Phase 1 for 7-days followed by a minimum 14-day rest period."
45764789|NCT02947984|Radiation|Standard Treatment|55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
45764790|NCT02947984|Radiation|Higher Dose|55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
45764791|NCT03031717|Procedure|Transjugular intrahepatic portosystemic shunt|
45764792|NCT03031639|Procedure|Endoscopic approach thyroidectomy|Thyroid surgery using endoscopy.
45764793|NCT03402425|Diagnostic Test|18F-FET PET|Patient are investigated with an 18F-FET PET
45622422|NCT02463461|Device|FitBit Activity Monitor|Subjects in this group will wear a FitBit Activity Monitor.
45764794|NCT02981641|Radiation|Intraoperative radiotherapy (IORT)|Total dose: 18~22 Gy; Single dose: 18~22 Gy; Frequency: 1
45764795|NCT02981641|Drug|Sequential chemotherapy|Sequential chemotherapy
45764796|NCT02981641|Radiation|Three dimensional conformal radiation therapy (3D-CRT)|Total dose: 60 Gy; Single dose: 2 Gy; Frequency: 30
45764797|NCT02981641|Drug|Concurrent chemotherapy|Gemcitabine (GEM), 800 mg/m2 weekly on Day 1-21, Q28d; or S-1 orally, 400 mg/d, bid on Day 1-21, Q28d
45912337|NCT01163357|Other|laboratory biomarker analysis|Correlative studies
45912338|NCT00977457|Genetic|DNA analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
45764798|NCT04377737|Diagnostic Test|RT-PCR Covid-19|estimation of the prevalence of positive rt-PCR in school children during the pandemic period
45764799|NCT02981563|Other|Time Together|For a fixed time during the day, staff dedicates their time to exclusively engage with the patients. Different activities will be offered to both patients and staff, such as playing board games, taking a walk, or having individual conversations. Other duties of more administrative nature, visits and meetings will be performed at other times during the day. Through this, opportunities for interaction are both created and protected.
45764800|NCT03402347|Radiation|Non-ionising radiation|Laser regimes will be applied to ex vivo skin samples.
45764801|NCT03017365|Other|Stable Resistance Training|traditional machine-based resistance training
45764802|NCT03017365|Other|Unstable Resistance Training|free weight resistance training using unstable devices
45912339|NCT00977457|Genetic|DNA methylation analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
45622423|NCT02463461|Device|Actigraph by Ambulatory Monitoring Activity Monitor|Subjects in this group will wear a Actigraph by Ambulatory Monitoring Activity Monitor.
45622424|NCT04828629|Diagnostic Test|Diagnostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, co-morbidities, results of selected laboratory tests, lung imaging (X-ray or computed tomography) selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, body mass analysis.
45764803|NCT03017365|Other|Adductor/Abductor Resistance Training|machine-based adductor/abductor resistance training
45764804|NCT03402191|Drug|L-arginine|l-arginine for thalassemia with pulmonary hypertension
45764805|NCT03402191|Drug|Sildenafil|Sildenafil for thalassemia with pulmonary hypertension
45764806|NCT03031561|Device|Ultrasound|Undergo standard ultrasound
45764807|NCT03031561|Device|MicoPure ultrasound|Undergo MicoPure ultrasound
45764808|NCT03031561|Procedure|Biopsy of Breast|Undergo breast biopsy or surgical resection
45912340|NCT00977457|Genetic|RNA analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
45912341|NCT00977457|Genetic|gene expression analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
45912342|NCT00977457|Genetic|polymerase chain reaction|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
45912343|NCT00977457|Other|diagnostic laboratory biomarker analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
45622425|NCT05445141|Behavioral|Little ACF [in Swedish: Lilla ABC]|Little ACF is a modified version of the program called All Children in Focus [in Swedish: Alla Barn i Centrum (ABC)] that originally is developed for parents with children 3-12 years of age. The content is based on positive developmental psychology and involves role plays, discussions and exercises to try at home with the child. Printed material will be provided to the parents at each meeting/session. Little ACF is offered once a week during four weeks. Each session is 60 minutes, thereafter the parents can stay in the facility for 30 minutes to continue discussing with each other.
45622426|NCT05445141|Behavioral|Lectures|The lectures are pre-recorded and available during four weeks. Each lecture is 10 minutes and the content is similar to, but more superficial than, the content in Little ACF.
45622427|NCT05437809|Other|Intake of nutritionally diverse ultra-processed foods|All participants will attend four food consumption assessment visits where, at each visit, they will be asked to consume a standardized snack portion of: 1) ultra-processed foods (UPFs) high in both fat and refined carbohydrates (UPF+FRC), 2) UPF high in fat (UPF+F), 3) UPF high in refined carbohydrates (white flour, sugar) (UPF+RC), or 4) minimally processed foods. The order of the four food consumption assessment visits will be randomized and counterbalanced across participants, who will each consume all the test snacks across the four appointments.
45446505|NCT02085226|Other|Creative Engagement Intervention|"The CEI has 5 component stages which map the participant's journey with the Artist~Meeting with Artist, discuss interests, stroke and explore initial creative goals.~Introduction to materials and mark making to create interpretations of established images.~From mark making and interpretations to developing personal project ideas.~Turning personal project ideas into creative finished pieces.~Review of completed work, mounting and display of work, future plans.~It is recognised that participants will progress differently. Components may be repeated or retuned to or may be addressed simultaneously. Participants may progress rapidly and so move from stage 5 back to stages 2, 3 or 4 to progress new work or experience new materials or processes."
45622428|NCT03268109|Other|assessment of cognitive impairment|Measure of Global Deficit Score
45622429|NCT05419557|Behavioral|Virtual Family-Based Healthy Plate Club|IHPC provides produce boxes, nutrition and meal-preparation, education, and supportive counseling to address barriers related to obtaining produce and food. The intervention provides participants with a bi-weekly produce box for 12 weeks and helps families identify sustainable ways to obtain vegetables once the produce boxes end. The CHW will support families by coaching them on how to prepare these unfamiliar vegetables, give tips on finding sales at grocery stores, as well as by navigation to food assistance sites including food pantries. Parents will learn strategies to increase vegetable consumption by addressing perceived barriers - such as the child doesn't like vegetables. Curriculum will also include topics such as how to increase physical activity and reduce screen time.
45622430|NCT03065673|Procedure|Potassium oxalate 5% gel|"Teeth will be cleaned using rubber cups associated to pumice and water~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
45622431|NCT03065673|Procedure|Placebo gel|"Teeth will be cleaned using rubber cups associated to pumice and water~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the placebo gel~Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
45622432|NCT05383209|Drug|EYP-1901|Intravitreal Injection
45622433|NCT05383209|Other|Sham IVT|Sham IVT
45764809|NCT03402113|Drug|Dexmedetomidine|consistent infusion at a loading dose of 0.15ug/kg/h, increased by 0.15ug/kg/h, with a maximum dose of 1.5ug/kg/h.
45764810|NCT03402113|Drug|Midazolam|consistent infusion at a loading dose of 1mg/h, increased by 1mg/h, with a maximum dose of 10mg/h.
45764811|NCT04359355|Device|Artificial Intelligence System for Detection of colorectal polyps|In this group, an artificial Intelligence System will be used for computer-aided diagnosis of colorectal polyps. Diagnostic Performance of the artificial intelligence System for detection of polyps will be compared against Operator-based detection in the same group
45764812|NCT01725113|Drug|Calcitriol|3 times weekly
45912344|NCT00977457|Procedure|therapeutic conventional surgery|
45912345|NCT00967005|Drug|N Acetyl Cysteine|N-Acetyl Cysteine, 1200mg-3000mg each day for 24-weeks
45452350|NCT03952949|Behavioral|Nutrition Education|"The nutrition education materials were adapted from materials currently utilized by the New York State Office of Temporary and Disability Assistance (Eat Smart New York)."
45452351|NCT01097759|Procedure|Surgery|Hemorrhoidectomy using the LigaSure sealing device or hemorrhoidopexy using the stapler
45764813|NCT01725113|Drug|Paricalcitol|3 times weekly
45764814|NCT03017209|Dietary Supplement|Locally-prepared bar|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
45912346|NCT00967005|Other|Sugar Pill|placebo control
45912347|NCT00873288|Other|Usual care mailing intervention|routine colposcopy reminder letter
45452352|NCT03952715|Drug|Ibuprofen 400 mg|Each subject will receive Ibuprofen once, in between two psycho-physical assessments. Between the drug intake and the second assessment the subject will have to wait for 40 minutes.
45622434|NCT04006223|Diagnostic Test|11C-PIB or 18F-florbetapir PET/MR before biopsy and treatment|10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
45912348|NCT00873288|Other|CIS support mailing intervention|Mailed reminder plus provider recommendation to call CIS and sample questions to ask
45622435|NCT04006223|Diagnostic Test|11C-PIB or 18F-florbetapir PET/MR after treatment|10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
45622436|NCT03108365|Device|Axiostat|"Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.~Axiostat® stops moderate to severe bleeding due to cuts, abrasions, lacerations, venous/arterial punctures and more. Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area."
45622437|NCT03108365|Device|Cotton Gauze|Size: 1 x 1 cm
45622438|NCT02628873|Device|HyCoSy|Saline infused sonogram in which air bubbles are delivered via the FemVue saline air device in order to evaluate the patency (openness) of the fallopian tubes
45622439|NCT02463149|Behavioral|Youth Chef Academy|Nutrition and culinary curriculum delivered in the classroom
45912349|NCT00863369|Biological|rituximab|Given IV
45446506|NCT02085226|Other|Portfolio Group|The Portfolio group will receive conventional rehabilitation activity at each site. In addition, to control for effects of art related attention received by the intervention group, after baseline assessment and randomisation, this group will receive from the research assistant, a portfolio of work produced by previous participants of the Tayside CEI, with details of community programmes that people with stroke can attend after hospital discharge. Participants will be invited to view the portfolio during their stay. Prior to outcome assessment, the research assistant will visit participants again to answer questions and to discuss options for community programmes, if the person is interested.
45446507|NCT02085304|Procedure|Gross total resection and Gliadel(R) wafers implanted|Complete removal of tumor and implant of Gliadel(R) wafers that are small, dime-sized wafers designed to deliver the chemo drug, carmustine, directly into the cavity made when the brain tumor was removed.
45622440|NCT02462993|Drug|Aloe Vera|Local drug delivery of aloe vera gel
45622441|NCT03063333|Other|Coping-oriented hypnosis|Hypnosis using coping-oriented suggestions based on reversal of statements from the pain catastrophizing scale plus current treatment.
45622442|NCT03063333|Other|Neutral hypnosis|Hypnosis using neutral suggestions plus current treatment
45912350|NCT00863369|Drug|bortezomib|Given IV
45912351|NCT00863369|Drug|gemcitabine hydrochloride|Given IV
45912352|NCT00863369|Other|questionnaire administration|Ancillary studies
45912353|NCT00600496|Drug|AZD6244|twice daily oral dose
45912354|NCT00600496|Drug|Dacarbazine|intravenous infusion
45912355|NCT00600496|Drug|Erlotinib|daily oral dose
45912356|NCT00600496|Drug|Docetaxel|intravenous infusion
45446508|NCT02085304|Radiation|GammaKnife(R) stereotactic Radiosurgery|GammaKnife® (GK) radiosurgery dose of 15 Gy in one fraction to the resection cavity margin
45446509|NCT02085304|Radiation|Standard fractionated radiation therapy|standard fractionated RT of 60 Gy in 30 fractions (over approximately six weeks)
45446510|NCT02085304|Drug|Temozolomide|temozolomide 75 mg/m2 daily for 42 days, will be administered to all patients beginning within 24 hours of GK/RT initiation as is routine clinical care. There will be a one month drug holiday following the 42 days before adjuvant chemotherapy begins. Adjuvant temozolomide administered 5 days monthly at 150-200 mg/m2/day will be administered for 12 months as is routine clinical care.
45622443|NCT02935283|Procedure|MRI|MRI, fMRI, 1H MRS, DTI
45622444|NCT02935283|Behavioral|Behavioral|Battery of executive function tasks
45622445|NCT02871167|Procedure|Controlled ovarian hyperstimulation (COH)|"After information and consent, patients are addressed to a reproductive medicine center.~The COH will be performed according to a standardized protocol between surgery and the start of adjuvant chemotherapy. Follicular growth will be achieved with an antagonist protocol and by using high dose recombinant FSH (r-FSH). The triggering of the final follicular and oocyte maturation will be obtained by a GnRH (Gonadotropin Releasing Hormone) agonist injection in order to minimize the risk of ovarian hyper-stimulation."
45764815|NCT03017209|Dietary Supplement|USAID Corn Soy Blend Plus|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
45764816|NCT03017209|Other|Placebo|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
45912357|NCT00600496|Drug|Temsirolimus|intravenous infusion
45912358|NCT00538031|Drug|cyclophosphamide|Given orally
45912359|NCT00538031|Drug|celecoxib|Given orally
45912360|NCT00477958|Other|questionnaire administration|Questionnaire administered prior to chemotherapy and within 30 days of completion of chemotherapy.
45912361|NCT00477958|Procedure|cognitive assessment|Cognitive assessment to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
45912362|NCT00477958|Procedure|psychosocial assessment and care|Psychosocial assessment and care to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
45912363|NCT00203996|Device|continuous positive airway pressure (CPAP)|CPAP is the most effective treatment available for sleep disordered breathing. CPAP provides a constant, controllable pressure to keep your upper airway open during sleep so that you can breathe normally. The pressure acts much in the same way as a splint and holds the airway open.
45622446|NCT02871167|Procedure|Oocyte/embryo freezing|Egg or embryo freezing will be performed according to a standardized protocol: slow-freezing process for embryo; vitrification technique for oocytes. Cryopreserved oocytes and embryos will be stored in the biological bank of each reproductive medicine center (min. 10 years).
45622447|NCT03981549|Biological|Autologous Bone Marrow CD34+ Stem Cells|Single intravitreal injection of autologous bone marrow CD34+ stem cells. The number of cells to be injected per eye will range from 800,000 to 10 million, depending on the yield of the bone marrow aspiration and the isolation procedure.
45622448|NCT03981549|Biological|Sham Therapy|Sham bone marrow aspiration procedure that penetrates the skin, but does penetrate the bone followed by sham intravitreal injection without penetration of the eye
45764817|NCT01725191|Other|Laboratory Biomarker Analysis|Correlative studies
45764818|NCT01725191|Other|Pharmacological Study|Correlative studies
45764819|NCT01725191|Drug|Tivantinib|Given PO
45446511|NCT02085382|Procedure|Kangaroo Mother Care|"The infants were placed on continuous skin to skin contact between the mother and the baby as soon as possible. The mother kept her newborn infant between the breast, in close contact with her body and covered with the kangaroo tube. Infants wore diaper and a cap during the procedure. Breastfeeding was the standard feeding method.~When the baby was not in KMC, the baby was placed in the bassinet under warm lamp, if needed, adequately clothed and covered."
45622449|NCT04657133|Device|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.
45622450|NCT04657133|Device|Sham remote ischemic conditioning|Sham RIC will be performed by the same electric autocontrol device with cuff placed on arm. Sham RIC procedures consist of five cycles of 5-min inflation (30 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.
45622451|NCT04657133|Drug|Standard medication therapy|Standard medication therapy will be performed according to the national and international guidelines.
45764820|NCT03017443|Behavioral|Nutrisystem Turbo 10|Turbo10 plan provided approx. 1000 kcal/d for all subjects and included portion controlled foods/shakes for the first week (week 0). All food, except non-starchy vegetables and no-calorie beverages, was provided for the first week (week 0). Starting week 1, subjects followed the My Way plan intervention through week 16.
45764821|NCT03017443|Behavioral|Nutrisystem My Way|The Nutrisystem My Way plan provided 7 breakfasts, 6 lunches, 6 dinners, and 7 (women) or 14 (men) snacks/desserts as pre-packaged portion controlled foods every week. Subjects were instructed to prepare one lunch and one dinner on their own each week. General guidelines and recommendations were provided by Nutrisystem in order to allow subjects to self-select appropriate foods for these eating occasions that fit within the My Way plan guidelines (~50% kcal from carbohydrate, ~25% from protein, ~25% from fat). Women were assigned to 1200 calories per day and men were assigned to 1500 calories per day. Nutrisystem packaged foods accounted for approximately 60% of daily calorie target; recommended grocery food additions (which subjects purchased on their own) accounted for the balance.
45764822|NCT03017443|Behavioral|Nutrisystem DASH|The Nutrisystem DASH plan was a modification of the My Way plan designed to meet the nutrition profile of the DASH Diet, as described in NIH materials. Key nutritional targets included < 30% fat (< 7% saturated fat), < 150 mg/d of cholesterol, and < 2300 mg/d of sodium. Key dietary targets were consumption of 7-10 servings of fruit/vegetables/day, 2-3 servings of low-fat dairy/day, and 3 servings nuts/seeds/week. The Nutrisystem DASH plan included a subset of the Nutrisystem menu [7 breakfasts, 6 lunches, 6 dinners, plus snacks as portion-controlled foods every week], as well as modified guidelines for grocery additions, to achieve the nutrition targets of the DASH diet. Women consumed 1200 kcal/day and men consumed 1500 kcal/day.
45764823|NCT03017443|Behavioral|Dieting on Your Own (DIY) - DASH|The self-directed diet included publicly available information consistent with the Dietary Approaches to Stop Hypertension (DASH) diet instructing individuals to consume a reduced calorie diet to support self-directed weight loss efforts. Women were assigned to a 1200 calorie diet and men were assigned to a 1500 calorie diet. Information on the self-directed diet was provided at the beginning of the intervention (visit 2, week 0). Subjects randomized to this group did not receive additional dietary counseling throughout the study period.
45764824|NCT04359043|Behavioral|Mediational Intervention for Sensitizing Caregivers (MISC)|MISC is an intervention that focuses on increasing the caregiving capacity of the caregiver by enhancing a set of emotional and cognitive components that collectively, sensitizes the caregiver to the emotional and cognitive needs of the child.
45764825|NCT04359043|Behavioral|Treatment as Usual|Treatment as Usual was delivered by community-based organization caseworkers. It consists of a nutritional curriculum of the same dosage and time commitment as the experimental condition, but with no caregiving component.
45764826|NCT00914069|Device|RIVS vascular access|Access to peripheral vasculature
45622452|NCT02829593|Other|hypoglycemia (low blood sugar) and MRI|hypoglycemia (low blood sugar) and MRI
45622453|NCT02814383|Other|Brain Monitoring Platform|This study is being done to evaluate the changes in brain perfusion measured by the DCM using a comprehensive and innovative brain monitoring platform that encompasses direct and continuous measures of cerebral blood flow (CBF), cerebral oximetry, cerebral autoregulation, partial pressure of carbon dioxide (PCO2), and arterial blood pressure (ABP).
45622454|NCT05345457|Drug|Azithromycin Pill|Azithromycin will be dosed as single 500 mg dose (2-250mg oral tablets) administered immediately following randomization, yet prior to discharge to home, followed with 1-250mg oral tablet daily for 4 additional days (for a total of 5 days).
45622455|NCT05345457|Drug|Amoxicillin Pill|Amoxicillin will be dosed as a single-500mg oral tablet three times daily for 7 days with first dose also being given prior to discharge home.
45622456|NCT03922139|Drug|OnabotulinumtoxinA Injection|"Ultrasound guided 1 mg/1 mL injection.~25 units of Botox will be injected 2 cm proximal and 2 cm distal to the midpoint of the tibialis anterior muscle."
45622457|NCT04729179|Drug|Cannabidiol|Participants will start with 10 mg of cannabidiol daily and the dose will be escalated every third day until the maximum dosage of 50 mg is reached (after two weeks). The participants be on the 50 mg dosage of cannabidiol for 24 weeks.
45764827|NCT00914069|Device|Conventional vascular access|Vascular access using conventional venous access device
45764828|NCT03031405|Drug|Oxytocin nasal spray|
45764829|NCT03031405|Drug|Placebos|Placebo nasal spray
45764830|NCT03031249|Drug|Cytarabine|Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
45764831|NCT03031249|Drug|all-trans retinoic acid|ATRA at a dose of 30mg/㎡/d on day 1-14.
45764832|NCT03031249|Drug|Arsenic Trioxide|ATO at a dose of 10mg/d on day 1-14
45764833|NCT02980315|Other|CAR-T cells|the patients treat with CAR-T cells
45764834|NCT02980393|Behavioral|Lifestyle intervention|The structured lifestyle intervention involves alternating weekly phone calls with two health coaches: a registered dietitian and a fitness specialist. A total of 50 phone calls (25 nutrition-related and 25 physical activity-related) are delivered over the one-year study. After six months in the program, participants are introduced to supporting program-specific software that they can access online, as an additional way to interact with the program, set goals, and record their progress. Client and family-centred nutrition and physical activity counselling includes an initial and regular behavioural assessment, and subsequent conversations (i.e., phone calls) using motivational interviewing techniques intended to increase knowledge or skills, and improve behaviours.
45764835|NCT03016663|Procedure|Technique of Breast Lipofilling|"Identification of the donor site Procedure carried out in single sessions under GA. Abdominal site identified and outlined with a skin marker.~Fat Harvesting Berlin autologous lipotransplantation technique used according to the BEAULI protocol described by Ueberreiter et al.~Infiltration solution -Klein'solution contains 1 cc of epinephrine (1:500,000) diluted in 500 cc of 0.001% lactate ringer solution (LRS).~Fat Processing After aspiration of nonviable components of the aspirate, fat graft washed using Lactate Ringer Solution for three times. The fat processing and washing were performed by the same assistant for all patients.~Fat Transfer (Injection) Fat is injected in small amounts as the needle is gradually withdrawn. Periglandular planes and intrapectoral planes are used. Intraparenchymal injection avoided."
45764836|NCT01042535|Biological|adenovirus-p53 transduced dendritic cell (DC) vaccine|Given intradermally (ID)
46069390|NCT02098538|Drug|Regorafenib|All eligible patients will receive a starting regorafenib dose of 120 mg daily taken orally for 3 weeks in a 4-week cycle. Patients for whom regorafenib dose reduction was not performed or required may have their treatment dose increased to the FDA-approved dose of 160 mg daily orally for 3 weeks in a 4-week cycle in cycle #2 or beyond (this is not mandatory). RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity
46069391|NCT02007512|Drug|Enzalutamide|160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food.
45622458|NCT04729179|Drug|Placebo|Placebo is administered as tablets of 10 mg that are identical in appearance, taste, and smell to the Cannabidiol tablets.The participants will be on the 50 mg dosage of placebo for 24 weeks.
45764837|NCT01042535|Drug|1-methyl-d-tryptophan|Given orally (PO)
45764838|NCT01042535|Other|Laboratory biomarker analysis|Correlative studies
45764839|NCT03031327|Device|Lubricin 20µg/ml eye drops|Lubricin 20µg/ml eye drops 3 times per day
45764840|NCT03031327|Device|Lubricin 50µg/ml eye drops|Lubricin 50µg/ml eye drops 3 times per day
45764841|NCT03031327|Device|Sodium hyaluronate (HA) 0.18% eye drops|Sodium hyaluronate (HA) 0.18% eye drops 3 times per day
45764842|NCT01725503|Dietary Supplement|Creatine and Amino Acid supplement|
45622459|NCT04728243|Other|WHO QualityRights e-training|The WHO QualityRights online training aims to increase knowledge about the rights of people with psychosocial disabilities and change negative attitudes towards these persons and their role as rights holders. Furthermore, the training provides mental health professionals with the skills necessary to support people with psychosocial disabilities to advocate for their rights. The WHO QualityRights online training includes five core modules: 1) Human rights; 2) Mental health, disability, and human rights; 3) The right to health and recovery; 4) Legal capacity and the right to decide; 5) Free from coercion, violence, and abuse. Each module is composed of presentations, videos, interactive exercises, and forum discussions involving all participants. In the online training forum discussions, particular attention will be given to issues relevant to the Ghanaian context.
45622460|NCT04728243|Other|WHO COVID-19 online training|The WHO novel coronavirus 2019 online training series provides a general introduction to COVID-19 and similar respiratory infections and information on what facilities and professionals should be doing to prevent and respond to COVID-19 cases. The training is similar in length to the WHO QualityRights training (13 h 15 min vs. 19 hours) and is intended for health professionals and other stakeholders.
45622461|NCT04706715|Other|89Zr-DFO-REGN3767|Anti-LAG-3 PET imaging tracer
45622462|NCT04706715|Drug|Cemiplimab|Cemiplimab 350 mg every 3 weeks with or without platinum-based chemotherapy.
45622463|NCT04702581|Drug|PCV chemotherapy|"cycle of PCV chemotherapy is given as:~Day 1: CCNU 110 mg/m2 orally;~Days 8 and 29: Vincristine 1.4 mg/m2 IV;~Days 8 to 21: Procarbazine 60 mg/m2 orally~6 cycles are given."
45622464|NCT04702581|Drug|Radiotherapy and PCV chemotherapy|"Radiotherapy will deliver 50.4 Gy in 28 fractions of 1.8 Gy using IMRT technique.~Followed by 6 cycles of PCV chemotherapy~1 cycle of PCV is given as:~Day 1: CCNU 110 mg/m2 orally;~Days 8 and 29: Vincristine 1.4 mg/m2 IV;~Days 8 to 21: Procarbazine 60 mg/m2 orally"
45452353|NCT03952715|Drug|Placebo oral tablet|Each subject will receive Placebo (sugar pill) once, in between two psycho-physical assessments. Between the placebo pill intake and the second assessment the subject will have to wait for 40 minutes.
45622465|NCT03063177|Procedure|Spinal manipulative therapy|A SMT will be delivered by contacting the transverse processes of T7 through our apparatus. Each participant will receive one SMT per session for 3 sessions.
45622466|NCT02462213|Other|Amyloidosis|Patients with amyloidosis without cardiac involvement will undergo cardiac MRI and possible biochemical analysis during the course of the study.
45622467|NCT02462213|Other|Cardiac Amyloidosis|Patients with confirmed cardiac amyloidosis will undergo cardiac MRI and possible biochemical analysis during the course of the study.
45622468|NCT03064347|Dietary Supplement|Sucrose plus Whole Milk Powder in Enteric Coating|Single dose enteric coated sucrose plus whole milk powder will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
45622469|NCT03064347|Dietary Supplement|Non coated Sucrose plus Whole Milk|Single dose sucrose plus whole milk powder with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
45622470|NCT03064347|Dietary Supplement|Sucrose in Enteric Coating|Single dose enteric coated sucrose will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
45622471|NCT03064347|Dietary Supplement|Sucrose with Separate Enteric Coating Materials|Single dose sucrose with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
45622472|NCT03064347|Dietary Supplement|Whey Protein in Enteric Coating|Single dose enteric coated whey protein will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
45622473|NCT03064347|Dietary Supplement|Whey Protein with Separate Enteric Coating Materials|Single dose whey protein with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
45622474|NCT03064347|Dietary Supplement|Pea Protein in Enteric Coating|Single dose enteric coated pea protein will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
45622475|NCT03064347|Dietary Supplement|Pea Protein with Separate Enteric Coating Materials|Single dose pea protein with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
45653377|NCT05039151|Biological|interstitial fluid sampling|The sample will be taken via three small catheters (thinner than the catheters used for conventional infusions) under the skin in the abdomen. 1 to 10 ml of interstitial liquid will be collected. A sample will be taken on D1 and D2.
45653378|NCT05039151|Biological|blood sampling|A blood sample (3 x 5 ml EDTA tubes) will be taken simultaneously. A sample will be taken on D1 and D2
45452354|NCT01137526|Drug|ABT-384|Subjects will take study drug once daily for 12 weeks
45452355|NCT01137526|Drug|donepezil|Subjects will take study drug once daily for 12 weeks.
45622476|NCT02708303|Other|Mayo Clinic Foregut Surgery Report Card Questionnaire|"Patients will be asked to complete the Mayo Clinic Foregut Surgery Report Card Questionnaire at approximately 8-10 weeks following surgery and then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.~Data collected from the questionnaire will be entered into a database that will be maintained for future research."
45622477|NCT03062865|Other|No intervention|
45622478|NCT04586699|Device|Medi1TMS|rTMS theta-burst protocol paired with a consistent attention-to-breath task
45622479|NCT04586699|Device|Medi2TMS|rTMS theta-burst protocol paired with an intermittent deep breathing task
45622480|NCT03063099|Other|ReNu™ Injection|Injection into the hip for the treatment of Osteoarthritis.
45446512|NCT02085382|Procedure|Conventional Mother Care|"This is generally included: an artificial warming system (heated room overhead lamp warmers). Breastfeeding was also the standard feeding method but if indicated, babies can also be fed through tube or cup feeding. The mothers were allowed to visit their babies anytime but skin to skin contact was not allowed.~Babies in both groups were monitored hourly. Their heart rate, respiratory rate and temperature were monitored and recorded. Any untoward events like hypothermia, hypoglycemia, apnea, signs of sepsis, and feeding problems were also noted."
45622481|NCT04545047|Biological|COVID-19 convalescent plasma|Convalescent plasma collected from individuals who have recovered from COVID-19
45622482|NCT04656873|Procedure|Biospecimen Collection|Undergo collection of cheek swab, blood, urine, stool, and tissue samples for research
45622483|NCT04656873|Other|Medical Chart Review|Periodic review of medical records for clinical parameters (labs, ICI dosing and frequency, occurrence, timing and type of irAE, irAE management, etc.) along with relevant demographic information (age, sex/gender, race/ethnicity, insurance type, etc.).
45622484|NCT04656873|Other|Questionnaires/Surveys|Periodic self-report questionnaires/surveys for symptom tracking, quality of life, perinatal outcomes, etc.
45622485|NCT03064191|Combination Product|calcium hydroxide chlorhexidine combination|Endodontic intra-canal medicament used for decreasing postoperative signs ans symptoms
45764843|NCT03031171|Behavioral|Screening patient navigation|The program offered assistance with scheduling, paperwork, arranging transportation, answering questions and providing education about screening and colorectal cancer.
45446513|NCT02260414|Drug|Tinzaparin|single subcutaneous injection of 4500 IU tinzaparin
45446514|NCT02260414|Other|Blood sample|blood sample taken at hours 0, 3, 8, 18 and 24 after subcutaneous injection of 4500 IU tinzaparin
45446515|NCT02085538|Drug|palbociclib|palbociclib 125 mg oral capsule with food once
45622486|NCT03064191|Other|calcium hydroxide intra-canal medicament|Endodontic intra-canal medicament used for decreasing postoperative signs and symptoms.
45622487|NCT03957915|Drug|INA03 administration|INA03 will be administered IV on Day 1, Day 14 of 28-day cycles. The administration of INA03 will begin at 0.02 mg/kg. Study Part I is a titration study to determine the dose for the first INA03 infusion. Patients will be enrolled in sequential cohorts of 2 patients to receive ascending starting doses of INA03, starting from the lowest starting dose (0.02 mg/kg), and followed by subsequent administrations of INA03 (D14 and beyond) at a fixed dose of 0.1 mg/kg. The starting dose will be increased every cohort of 2 patients until evidence of absence of marrow residual erythroblasts by D14 myelogram. This dose is referred to as the MEID and will be selected as the D1 dose for the study Part 2. Patient accumulation in Part I of the study will continue until no evidence of non-hematological DLT within 28 days post dosing
46069392|NCT02007512|Drug|exemestane|25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet after unblinding) by mouth once daily after food.
45446516|NCT02085538|Drug|palbociclib|palbociclib 125 mg oral capsule with food once
45446517|NCT02085538|Drug|palbociclib|palbociclib 125 mg oral capsule with food once
45446518|NCT02085538|Drug|palbociclib|palbociclib 125 mg oral capsule with food once
45446519|NCT02074930|Device|Microporation by P.L.E.A.S.E. Professional / Prick needle|
45446520|NCT02085616|Behavioral|Proactive service|In the proactive service the callers to the quitline are offered a number of callbacks.
45446521|NCT02085616|Behavioral|Reactive service|In the reactive service the callers to the quitline are informed that they can themselves call back whenever they like.
45446522|NCT04169061|Drug|Acthar|Acthar gel for subcutaneous injection
45622488|NCT05291871|Biological|HPV vaccine|One-fifth dose bivalent HPV Vaccine or One-fifth dose nonavalent HPV Vaccine
45622489|NCT02629965|Drug|tiotropium|fixed dose combination
45622490|NCT02629965|Drug|olodaterol|fixed dose combination
45764844|NCT03031171|Behavioral|Non-Navigated|Randomly matched sample of non-navigated clinic patients
46069393|NCT02007512|Drug|Placebo (for enzalutamide)|Sugar pill manufactured to mimic enzalutamide administered as four soft gelatin capsules by mouth once daily with or without food.
45446523|NCT01562691|Procedure|Nasopore|Bilateral nasal packing using Nasopore without airway integrated
45446524|NCT01562691|Procedure|airway integrated Nasopore|post nasoseptoplasty with nasal packing using airway integrated Nasopore
45446525|NCT01562691|Procedure|airway-integrated Vaseline gauze|post nasal septoplasty with packing using airway-integrated Vaseline gauze
46069394|NCT02007512|Drug|exemestane|50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) by mouth once daily after food.
45622491|NCT02629965|Drug|tiotropium|
45764845|NCT01725581|Procedure|Observed Structured Assessment Tool in Pelvic Examination|Participants will be asked to perform a pelvic examination including a speculum and bimanual examination on a pelvic model. They will be asked to approach the pelvic model as if it were a real patient.
45622492|NCT03062787|Device|Cingal® (Hyaluronic Acid plus Triamcinolone Hexacetonide)|Intra-articular injection
45622493|NCT03062787|Device|Monovisc® (Sodium hyaluronate)|Intra-articular injection
45622494|NCT05275881|Device|Virtual Reality|In each arm, patients will benefit from an EMLA-type local anesthetic cream, pain and anxiety assessment. During the act, the physiological constants will be recorded (Fr, O2 and pulse). In the the RV group, The session will be started before the gesture and the patient will wear the helmet throughout the act. In case of pain and / or restlessness, the child will receive analgesics.
45764846|NCT03031015|Device|Cemented K-wire Fixation|Fractures were reduced and then fixed with cemented K-wires.
45622495|NCT05275881|Drug|Usual Practices|In each arm, patients will benefit from an EMLA-type local anesthetic cream, pain and anxiety assessment. During the act, the physiological constants will be recorded (Fr, O2 and pulse). In the control group, the child will receive the usual care: nitrous oxide, anxiolytics, opioid analgesics, psychotropic and benzodiazepine
45622496|NCT04438551|Behavioral|Standard dietary counseling|Subjects will be given a low sodium diet handout with counseling, complete a validated questionnaire on low sodium foods, and complete a 24-hr urine collection.
45622497|NCT04438551|Behavioral|Mobile app|Subjects will be given a low sodium diet handout with counseling, complete a validated questionnaire on low sodium foods, and complete a 24-hr urine collection. Subjects will be given a mobile app to build grocery lists where the sodium level will be recorded and tracked in the app.
45764847|NCT03031015|Device|Plating|Fractures were reduced and then fixed with Plate.
45446526|NCT03749889|Other|100 g carbs|Participants will be assigned a diet of 100g carbs max for the day
45764848|NCT03401957|Drug|Cetuximab|Cetuximab-based infusional 5-FU regimen as the 1st line treatment.
45446527|NCT03749889|Other|MyPlate|40-65% of daily intake is from carbohydrates
45446528|NCT04681677|Radiation|Radiation: Intra-operative Radiation Therapy - IORT|Single fraction, Intra-operative Radiation Therapy at the time of surgical resection of recurrent GBM followed by Bevacizumab 28-56 days after surgery.
45446529|NCT04681677|Drug|Bevacizumab|Bevacizumab
45622498|NCT04624659|Drug|Etavopivat Tablets Low dose|200 mg once daily
45622499|NCT04624659|Drug|Etavopivat Tablets High dose|400 mg once daily
45622500|NCT04624659|Drug|Placebo Tablets|Placebo once daily
45622501|NCT04624659|Drug|Etavopivat Tablets|Selected dose once daily
45622502|NCT05249517|Other|Pain Neuroscience Education|Pain Neuroscience Education (PNE) is a patient education approach that explains in detail the neurobiology, neurophysiology of pain, and the processing of pain by the nervous system in the management of chronic pain.
45622503|NCT05249517|Other|Progressive submaximal exercise program|It has been shown that the long-term results of the use of PNE in addition to physiotherapy are more effective in reducing pain and disability. It has been reported that progressive submaximal exercise program including cervicothoracic strengthening, endurance, flexibility, and coordination exercises has positive effects on chronic neck pain, related disability, quality of life and mood.
45764849|NCT03401957|Diagnostic Test|liquid biopsy|The blood samples taken from subjects will be evaluated for RAS genotype using MassARRAY technique.
45764850|NCT04358965|Drug|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
45764851|NCT04358965|Drug|vaginal misoprostol|patients will be given one vaginal misoprostol tablet (200 mcg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
45764852|NCT04358965|Drug|placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
46069395|NCT01984346|Device|AtriCure EPi-Sense-AF Guided Coagulation System with VisiTrax|Convergent Epicardial Endocardial Ablation Procedure
45622504|NCT04618809|Behavioral|Didactic Session|This session will include an overview of the approach to and management of older mGC patients patients through a case-based presentation.
45622505|NCT04618809|Behavioral|Comprehensive Geriatric Assessment, including an exploratory analysis to evaluate the use of fitness trackers for evaluation of functional status.|"The Comprehensive Geriatric Assessment (CGA) is a composite of assessment scales evaluating physical, psychological, and social well-being, and is the recommended tool for evaluating an older cancer patient and determining appropriateness of therapy.~The patient will receive a FitBit TM to wear for 4 days. Number of steps/day will be recorded."
45764853|NCT04358653|Other|fall prevention exercise program|The intervention protocol was starting with a 10 minute warm up (5 minutes circular walking combined with neck rotation in clockwise and counterclockwise fashion and 5 minutes upper and lower limp stretching exercises) and was followed by 30 minutes of exercises that were aiming to muscle strengthening, balance improvement and functionability enhancement. The muscle strengthening routine consisted of exercises both from standing and sitting position using an elastic band, heel and toe standing, upper limb strengthening using dumbbells. Balance training consisted of standing on one leg, shifting weight laterally from one foot to the other, staggered stance, side stepping. Functionalibility improvement was promoted through walking upstairs and downstairs, standing up from sitting to upright position. At the end a 5 minute cool down procedure was following consisting of circular walking, mild head movements and upper and lower body stretching.
45764854|NCT01041287|Drug|Nebivolol|Nebivolol 5 mg PO qday for 2 weeks, titrated up to Nebivolol 10 mg PO qday if BP is >125/80 for the 2 more weeks, and then titrated up to Nebivolol 20 mg PO qday if BP is >125/80 for the remaining 8 weeks
45764855|NCT01041287|Drug|Metoprolol succinate|Metoprolol 50 mg PO qday for 2 weeks, titrated up to Metoprolol 100 mg PO qday if BP is >125/80 for the 2 more weeks, and then titrated up to Metoprolol 200 mg PO qday if BP is >125/80 for the remaining 8 weeks
46069396|NCT01984346|Device|Endocardial RF Catheter ablation using Open Irrigated-tip RF Abaltion Catheter with unidirectional or bidirectional steering|Endocardial Catheter Ablation Procedure
45446530|NCT04681677|Drug|Avastin|Avastin
45622506|NCT04601883|Drug|Colchicine 0.5 MG|"The intervention tablets are commercially available Colchicine Tiofarma"
45622507|NCT04601883|Drug|Placebo|Encapsulated placebo tablets. Placebo is identical to the active intervention.
45622508|NCT04591587|Procedure|Lenticule Implantation in Keratoconus Disease with RELEX Smile Surgery|Lenticule Implantation in Keratoconus Disease with RELEX Smile Surgery using VisuMax Femtosecond laser- Smile module surgery with primary objective to increase central corneal thickness and secondary objective to improve visual acuity and reduces K-values
45622509|NCT05223075|Drug|articaine local anethesia with vasoconstrictor|buccal infiltration only of articaine local anethesia during extraction of lower anterior teeth
45622510|NCT05223075|Drug|lidocaine local anethesia with vasoconstrictor|buccal infiltration only of lidocaine local anethesia during extraction of lower anterior teeth
45622511|NCT04433247|Behavioral|Peer Led Group Intervention|Four week dissonance-based program wherein women with body image concerns complete verbal, written, and behavioral activities. The program consist of four 60-minute sessions.
45764856|NCT04358731|Biological|NmCV-5|"The NmCV-5 is a fixed-combination available as the lyophilized powder containing meningococcal groups A and X polysaccharides conjugated to tetanus toxoid and meningococcal groups C, W and Y polysaccharides conjugated to CRM197 protein. The vaccine will be reconstituted with normal saline just prior to administration.~The NmCV-5 lyophilized powder component contains sucrose, sodium citrate and trometamol as excipients. This component is presented as a freeze-dried powder in a single dose vial. No preservative or adjuvant is present in the vaccine.~The normal saline diluent is a sterile clear colorless liquid in a single dose glass ampoule."
45622512|NCT01671111|Drug|SSP-004184AQ|"Long term extension study of 8-75 mg/kg/d of SSP-004184AQ (equivalent to 7-68 mg/kg/d free acid or active form)"
45764857|NCT04358731|Biological|Menactra|The control vaccine is the licensed meningococcal serogroups ACYW conjugate vaccine (Menactra), manufactured by Sanofi Pasteur Incorporated. Menactra is supplied as a single 0.5 mL dose formulated in sodium phosphate buffered isotonic sodium chloride solution to contain 4 mcg each of meningococcal A, C, Y, and W polysaccharides conjugated to approximately 48 mcg of diphtheria toxoid protein carrier. No preservative or adjuvant is added during manufacture.
45764858|NCT03401801|Procedure|Stellate ganglion block|Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 4 ml, 6 ml, and 8 ml of 1% lidocaine is injected for the each group, respectively.
46069397|NCT01971489|Drug|Buparlisib|Given PO
46069398|NCT01971489|Drug|Cisplatin|Given IV
46069399|NCT01971489|Drug|Gemcitabine Hydrochloride|Given IV
46069400|NCT01971489|Other|Laboratory Biomarker Analysis|Correlative studies
45622513|NCT05211219|Dietary Supplement|Probiotics|According to the groups, they were involved simultaneously with the treatment, kefir group was advised to consume kefir as a liquid once a day in 14 days; the probiotics group was advised to consume as a chewable tablet once a day in 14 days; the control group was advised without additional food supplements.
46069401|NCT01971489|Other|Pharmacological Study|Correlative studies
46069402|NCT01971489|Other|Questionnaire Administration|Ancillary studies
46069403|NCT01942135|Drug|Palbociclib|Palbociclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
46069404|NCT01942135|Drug|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
46069405|NCT01942135|Drug|Placebo|Placebo orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
45764859|NCT03401723|Other|3D-Colonoscopy Progression Score|3D-Colonoscopy Progression Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.
45764860|NCT03401723|Other|Endoscopy Training System|"The Endoscopy Training System is based on the Colonoscopy Training Model platform and includes four different performance metrics and a scoring system.~Scope Manipulation - The use of torque and tip deflection to move a shape in the colon~Tool Targeting - 10 targets located around the colon must be found. With a biopsy forceps, each target has to been touched.~Loop Management - The management of a standard alfa-loop.~Mucosal Inspection - Randomly placed polyps inside the rubber colon have to be found during withdrawal."
46069406|NCT01942135|Drug|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
45622514|NCT05211219|Dietary Supplement|AOÇ Kefir|AOÇ Kefir
46069407|NCT01889238|Drug|Enzalutamide|160 mg administered as four soft gelatin capsules orally once daily
45622515|NCT05211219|Other|Food without additional food supplements|Food without additional food supplements
45764861|NCT03401723|Other|3D-Colonoscopy Retraction Score|3D-Colonoscopy Retraction Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.
45764862|NCT00955903|Behavioral|Exercise|Participants will participate in supervised exercise sessions
45764863|NCT00955903|Behavioral|Reduced Calorie Diet|Participants will follow a reduced calorie diet
45764864|NCT00955903|Behavioral|Weight Maintenance Diet|Participants will follow a weight maintenance diet
45764865|NCT04376879|Other|Data monitoring for 48h within the first 24 hours of admission for COVID-19|The admission variables and those constituting the predictive score (blood pressure, temperature, oxygenotherapy, biological analysis...) will be collected for 48 hours after enrolment (i.e within the first 24 hours of admission )
45764866|NCT03016585|Other|Tai Chi Training|Participants practiced, under supervised instruction, 10 forms from the classic Yang style of Tai Chi 3 times per wk for 12 weeks.The Tai Chi sessions lasted approximately 55 minutes and included a 10-minute warm up, 40 minutes of practice and exercise finalizing with a 5-minute cooldown period.
45764867|NCT03401021|Other|Questionnaires set|Participants will be asked to respond to the demographic information sheet, Smoking characteristics sheet, the Fagerstrom Test of Nicotine Dependence, the Transtheoretical Model (TTM) variables, Smoking Self-efficacy Questionnaire (SEQ-12), Family Adaptation, Partnership, Growth, Affection, and Resolve (Family APGAR), and a smoking hazard questionnaire.
45764868|NCT04358887|Procedure|piezoelectric surgery|after flap reflection bone and root end cutting are done with piezoelectric surgical insert
45764869|NCT04358887|Procedure|conventional bur|after flap reflection bone and root end cutting are done with surgical bur
45764870|NCT03400865|Drug|HCQ/CQ and CAB combined treatment|Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.After therapy of 3 months the medication will be stopped if does not reduce prl level more than 20% or failure to decrease prolactinoma size.
46069408|NCT01838174|Drug|ACTHAR Gel (ACTH)|15 days of daily injections
46069409|NCT01838174|Drug|IV methylprednisolone (steroids)|3 days of intravenous methylprednisolone followed by 11 days of oral taper
46069410|NCT01753414|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT given every other day 11 Gy in 5 fractions to a total dose of 55 Gy in 10-15 days with an inter-fraction interval of 2-3 days
45446531|NCT03749811|Device|Pupillometry|After induction of anesthesia and determination of the loss of consciousness of the participant, baseline diameter of pupil is measured by electronic pupillometry device. During anesthesia, participant's pupil diameter is repeatedly measured with 5-minute interval. Pupil dilation of 30% or more compared to baseline is indicative of insufficient analgesia.
45452356|NCT01137526|Drug|placebo|Subjects will take study drug once daily for 12 weeks
45622516|NCT01671345|Behavioral|Intervention Video|A video intervention delivered prior to patients' visits with primary care physicians designed to increase use of active participatory communication (patient participation) behaviors, improved communication ratings, and improved medication adherence
45622517|NCT01671345|Behavioral|Control|Attention control
45764871|NCT03031093|Radiation|inhalation protocol|technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution
46069411|NCT01753414|Procedure|Surgery|Complete resection, i.e., removal of the primary tumor with at least a 2 cm margin together with nodal dissection/sampling
46069412|NCT01743131|Drug|Abatacept|Arm B-investigational prophylaxis with abatacept, a calcineurin inhibitor and methotrexate
46069413|NCT01743131|Drug|placebo|
45622518|NCT03064971|Behavioral|Standard Care|Standard of care provided by QuitlineNC includes Quit Coaches, counseling calls, nicotine replacement therapy, and written materials
45622519|NCT03064971|Behavioral|smoking cessation DVD|"The evidence-based How to Quit DVD contains 60 minutes of smoking cessation information and strategies"
45622520|NCT03064971|Behavioral|PTF DVD|Culturally specific smoking cessation DVD. This DVD contains 60 minutes of material.
45653379|NCT04221295|Behavioral|Exercise Group|Previously described in the arm/group descriptions.
46069414|NCT01696968|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
46069415|NCT01696968|Procedure|X-Ray Imaging|Undergo a chest x-ray
46069416|NCT01685814|Drug|Lenalidomide, Bortezomib|Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy
46069417|NCT01685814|Biological|autologous stem cell transplant|
46069418|NCT01685814|Biological|allogeneic stem cell transplant|
46069419|NCT01627093|Other|Medical Chart Review|Review of medical records
45622521|NCT04566237|Procedure|Objective Scatter Index (OSI)|On Optical Quality Analysis System (OQAS) device. At Inclusion, 3 months, 12 months and 24 months after vitrectomy
45764872|NCT03031093|Device|High Flow Nasal Cannula|aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula will deliver the aerosol at a 30L/min flow of oxigen.
45622522|NCT04566237|Procedure|Average Lens Density (ALD)|on IOLMaster® 700 device. At Inclusion, 3 months, 12 months and 24 months after vitrectomy
45622523|NCT05176899|Device|Use of Eko CORE electronic stethoscope|Recording of heart sounds using electronic stethoscope
45764873|NCT01040351|Procedure|ultrasound guided aspiration of hydrosalpingeal fluid|Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
45764874|NCT03016741|Biological|GnRH agonist/antagonist|Given GnRH agonist/antagonist therapy
45622524|NCT04544241|Behavioral|Cancer Survivorship Leadership Training for Clergy Wives and Widows|We will meet with Clergy Wives and Widows monthly for 2-3 hours over 10 months. These sessions will be delivered using innovative online format through Zoom over the ten months. During each meeting session, experienced community and academic leaders will present their expertise with relationship to cancer survivorship and caregiving. These individuals will have extensive experience in the particular area they are presenting in. In addition, allotted time will be given for discussion and group activities that can be performed virtually. To receive credit for completion of the training program, each participant must complete the training and deliver a group workshop. All clergy wives and widows will complete a demographic questionnaire, in addition to pre- and post- intervention questionnaires
45622525|NCT05172843|Procedure|Surgical knee arthroplasty|"Surgery will be performed 3 months from inclusion in the trial (at week 13). The procedure and type of prosthesis and postoperative program will be at the discretion of the involved surgeon and the participating department.~Post-surgical care and rehabilitation will follow current clinical standards."
45622526|NCT05172843|Behavioral|Supervised weight loss|"The supervised intensive dietary weight loss program will be initiated 3 months from inclusion in the trial (at week 13) and lasts for 12 weeks.~The program includes full meal replacement by a standard liquid energy intake in a supervised dietary program. Participants will attend the nutrition department weekly. They will be weighed on a decimal scale, given nutritional and dietetic instructions by an experienced dietitian and formula diet products are handed in sessions of 1-2 h. The participants will be taught to make diet plans.~Following the 12 weeks intensive dietary weight loss program participants will be scheduled for two booster follow-up sessions with a dietician at weeks 39 and 51."
45764875|NCT03016741|Drug|Prednisone|Given by mouth
45764876|NCT03016741|Drug|Abiraterone Acetate|Given by mouth
45764877|NCT03016741|Drug|Enzalutamide|Given by mouth
45764878|NCT03401645|Other|Wrist Alarm|Wrist device with alarm timer
45764879|NCT03401645|Behavioral|Home-based Arm and Hand Exercise|Repeated visuomotor tasks, unilateral arm and hand movements, bilateral arm and hand movements
45764880|NCT04358809|Drug|Suspension of heat killed (autoclaved) Mycobacterium w|Suspension of heat killed (autoclaved) Mw along with Standard of care (SOC) treatment for COVID-19
45764881|NCT04358809|Other|Placebo|Placebo along with Standard of care (SOC) treatment for COVID-19
45764882|NCT01042925|Drug|XL147 (SAR245408)|administered orally once daily as tablet(s)
45764883|NCT01042925|Biological|trastuzumab|administered by IV once every 3 weeks
45764884|NCT01042925|Drug|paclitaxel|administered by IV once every week
45764885|NCT03017053|Radiation|Radiotherapy|Radiotherapy after primary surgery in the treatment of early oral cancer based on adverse pathological factor
45764886|NCT03017053|Procedure|Elective neck dissection|Elective neck dissection after primary surgery in the treatment of early oral cancer based on adverse pathological factor
45764887|NCT03401567|Other|Exercise group|Elbow bending exercises with blood flow restriction will be performed to the exercise group during 6 weeks for 3 times a week. The first set of exercises will be 30 repetitions then 3 sets of 15 repetitions. Totally 75 repetitions will be performed. 30 seconds rest interval between sets will be given.
46069420|NCT01627093|Other|Questionnaire Administration|Complete questionnaires
45764888|NCT03400709|Drug|N Acetylcysteine|Oral administration of drug, before, during and after Chemoradiotherapy including Cisplatin.
45764889|NCT03400709|Drug|Placebo Oral Tablet|Placebo treatment
45764890|NCT00956761|Biological|Seasonal Influenza Vaccine (MF59C.1)|1 dose of a surface antigen, inactivated, adjuvanted with MF59C.1, seasonal influenza vaccine, formulation 2009-2010
45764891|NCT01042769|Drug|Aleglitazar|aleglitazar 150 micrograms po daily
45764892|NCT01042769|Drug|Placebo|placebo control po daily
45764893|NCT02049957|Drug|Sapanisertib|Sapnisertib capsules
45764894|NCT02049957|Drug|Fulvestrant|Fulvestrant IM injection.
45764895|NCT02049957|Drug|Exemestane|Exemestane tablets.
45764896|NCT03030937|Drug|Apatinib|Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
45764897|NCT03030937|Drug|Irinotecan|Irinotecan was used as second line treatment with AGC.
45764898|NCT00950365|Drug|Erlotinib Hydrochloride|Given PO
45764899|NCT00950365|Other|Laboratory Biomarker Analysis|Correlative studies
45764900|NCT00950365|Drug|Pemetrexed Disodium|Given IV
45804249|NCT02959346|Procedure|Sham Acupuncture|"Procedure:~Sham Acupuncture(ipisilateral side, 0.3cun, No needle sensation (de qi) was elicited) Sham acupuncture will be applied by inserting acupuncture needle into acupoints(1cm away from the true acupoint):upper limb: Waiguan TE5; lower limb: Zusanli ST36.~All procedures were carried out to a depth of 0.5 cm with disposable needles measuring 0.16 mm in diameter (40-gauge) and 12.7 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery."
45622527|NCT04541667|Other|Air|Air will be used for luminal inflation.
45622528|NCT04541667|Other|Carbon Dioxide|Carbon dioxide will be used for luminal inflation.
45912364|NCT00203996|Drug|depot leuprolide plus estrogen/progestin replacement|Depot leuprolide is a long-acting, modified version of the natural brain hormone, gonadotropin releasing hormone (GnRH). This study drug will temporarily reduce the pituitary hormones that stimulate the ovaries to make both female (estrogen) and male (testosterone) hormones. The effect of this study drug will last approximately 12 weeks. During this time, your female hormone levels will be brought to normal by the use of a patch that contains estrogen and progesterone. This patch is placed on the skin and is changed twice a week. The subject will continue to wear this patch for 4 weeks after the end of the study, until the effects of the Lupron injection wear off.
46069421|NCT01603849|Radiation|Prophylactic Cranial Irradiation|Patients allocated to this arm will received treatment with whole brain radiotherapy 25 Gy in 10 fractions.
46069422|NCT01495533|Device|uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
46069423|NCT01495533|Combination Product|Drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
45446532|NCT02792218|Drug|Ofatumumab subcutaneous injection|Ofatumumab 20 mg pre-filled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter
45446533|NCT02792218|Drug|Teriflunomide-matching placebo capsules|Placebo capsule, matching in appearance to teriflunomide, taken orally once daily
45622529|NCT03745521|Other|no intervention|no intervention
45622530|NCT05159739|Genetic|Blood Draw or Saliva/Cheek Cell Sample:|Collected samples will immediately undergo genetic analysis to determine the presence or absence of potential candidate genes responsible for the increased incidence of PJI.
45622531|NCT05156151|Other|Relex-Smile|
45653380|NCT04988217|Drug|Interferon-Alpha2B|Nebulized interferon alpha 2B
45653381|NCT04988217|Drug|Placebo|Nebulized placebo
45653382|NCT05038839|Drug|Cabozantinib|Given PO
45653383|NCT05038839|Drug|Pamiparib|Given PO
45653384|NCT01359449|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
45764901|NCT01980147|Behavioral|maCBT|Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT) is an individual manualized psychological intervention. It follows an integrated model focussed on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
45764902|NCT01908465|Drug|Ebastine|
45764903|NCT01908465|Drug|Placebo|
45764904|NCT05720169|Diagnostic Test|Doppler ultrasound|Doppler ultrasound at 13, 16, 20 and 26 weeks for assessment of uterine arteries according to ISUOG criteria.
45446534|NCT02792218|Drug|Teriflunomide capsule|Teriflunomide 14 mg oral capsule taken once daily
45912365|NCT00203996|Drug|pioglitazone|Pioglitazone (Actos). Pioglitazone is an oral medication approved in the Unites States for the treatment of patients with type 2 diabetes (however it is not approved for studies in this protocol). This is one of a class of drugs known as thiazolidinediones. This class of drugs has been associated with potential beneficial changes in the metabolism (use of glucose by the body) as well as lipids (fats) in the blood.
45622532|NCT03064035|Drug|4-factor prothrombin complex concentrate (4FPCC)|4-factor prothrombin complex concentrate (4FPCC) contains all of the vitamin K-dependent clotting factors inhibited by warfarin, making it desirable for use in warfarin reversal for emergent bleeds. Multiple guidelines currently recommend 4FPCC for warfarin reversal in vitamin K-dependent major bleeding or intracranial hemorrhage. 4FPCC has a fast onset of action and has demonstrated significant reversal of INR within 10 minutes. Its duration of action is up to 8 hours, and for this reason it should be given concurrently with vitamin K. Vitamin K has a delayed onset of action due to its need to stimulate the synthesis of clotting factors so its effects begin as the effects of 4FPCC diminish. 4FPCC is the standard of care treatment for this clinical population in the Regions Hospital Emergency Department.
45622533|NCT03065127|Behavioral|Cognitive Training|Training the cognitive domain may be accomplished by training various cognitive and executive functions with guided practice focusing on specific skills (e.g. visuospatial processing, executive function, memory, language, and attention). Cognitive training has been demonstrated to be efficacious in several studies in individuals with PD. Given the potential cognitive contribution to FOG episodes, this type of therapy may alleviate FOG by potentially improving upon planning, set-shifting, and/or response inhibition.
45622534|NCT03065127|Behavioral|Cognitive Behavioural Therapy|CBT has been demonstrated to be effective in the remediation of anxiety in individuals with PD. This may be beneficial to individuals experiencing FOG, given the evidence that anxiety may provoke FOG. During periods of elevated anxiety (e.g. walking in a threatening environment), freezers will be able to more efficiently process this limbic load resulting in greater resources available for movement control.
45653385|NCT01359449|Biological|Meningococcal Group C Conjugate vaccine: MenC|0.5 mL, Intramuscular
45653386|NCT01672723|Drug|Naltrexone|
45912366|NCT00203996|Procedure|REM frag|Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.
45912367|NCT00203996|Procedure|SWS supp|SWS: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.
45653387|NCT04443673|Dietary Supplement|Glycine|Along with habitual treatment for their severe condition, participants will receive 0.5 g/kg/day glycine by nasogastric tube, divided in four equal doses in a day, since their enrollment and until they are weaned from mechanical ventilator or die.
45912368|NCT00099437|Drug|Fulvestrant|intramuscular injection
45912369|NCT00085930|Biological|EBV specific CTLs|CTLs: 2x10e7 cells/m2
45446535|NCT02792218|Drug|Matching placebo of ofatumumab subcutaneous injections|Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter
45446536|NCT02075086|Drug|Xelox or Xeliri Bevacizumab|Chemotherapy treatment
45912370|NCT02009280|Drug|Administration of anesthesia: Propofol|Maintenance of anesthesia with the propofol
45912371|NCT02009280|Drug|Administration of anesthesia: Sevoflurane|Maintenance of anesthesia with the sevoflurane
45446537|NCT02075164|Dietary Supplement|Fructose|High oral Fructose challenge (150g per day for 56 days)
45446538|NCT02075164|Dietary Supplement|Glucose|Dietary Supplement: High oral Fructose challenge (167g per day for 56 days)
45446539|NCT02082418|Dietary Supplement|Alpha-lactalbumin|Subjects will ingest the liquid meal containing alpha-lactalbumin and carbohydrates (0.6 g/kg FFM protein + 0.3 g/kg FFM carbohydrates).
45446540|NCT02082418|Dietary Supplement|Whey|commercially available whey protein
45446541|NCT02082418|Dietary Supplement|Casein|commercially available casein protein
45446542|NCT02082496|Drug|Liraglutide|S.c. liraglutide 3.0mg once daily
45446543|NCT02085694|Drug|Lactobacillus brevis CD2|
45912372|NCT02009293|Other|Cough monitor|questionnaires about cough and quality of life
45446544|NCT02075242|Drug|Mycophenolate Mofetil|experimental group receive Tacrolimus as a main immunosuppressants and assistant is My-rept capsule®(Mycophenolate Mofetil),
45446545|NCT02075242|Drug|Tacrolimus|control group receive same immunosuppressants except for My-rept capsule®(Mycophenolate Mofetil- investigational product
45452357|NCT00993382|Drug|Celivarone|"Pharmaceutical form: capsule~Route of administration: oral"
45912373|NCT02009306|Drug|PecFent and Epistatus|"PecFent will be supplied by Archimedes Pharma as two strengths of nasal spray solution at 1000 or 4000 mcg/mL fentanyl (as citrate). One spray contains 100 mcg or 400 mcg fentanyl (as citrate). Each bottle contains 1.55 ml ensuring delivery of 8 sprays of 100 or 400 mcg fentanyl (as citrate). PecFent is a commercially available product and packaging will be in accordance with the manufacturing authorisations (EU/1/10/644/001, EU/1/10/644/002, EU/1/10/644/005, EU/1/10/644/003, EU/1/10/644/004, EU/1/10/644/006).~Epistatus will be supplied by Special Products Ltd. as buccal solution, packed in bottles containing solution for up to 4 x 1 ml doses, as per Specials licence. A pack also includes 4 x oral syringes used to administer the solution to the buccal cavity on either side of the mouth."
45912374|NCT02009306|Drug|Standard subcutaneous medication|"Subcutaneous as needed medication will include:~Opioids for pain or dyspnoea~Diamorphine~Oxycodone~Fentanyl~Benzodiazepine and / or anti-psychotic for agitation~Midazolam~Levomepromazine~Haloperidol Anti-emetic for nausea~Cyclizine~Metoclopramide~Haloperidol~Levomepromazine~Anti-secretory drug for respiratory secretions~Glycopyrronium~Hyoscine butylbromide~Hyoscine hydrobromide"
45764905|NCT05720169|Diagnostic Test|Blood sample|Blood sampling at 13, 16, 20, 26 weeks of gestation to determine the sFlt-1/PlGF ratio
45912375|NCT02009306|Drug|Epistatus Alone|"Epistatus will be supplied by Special Products Ltd. as buccal solution, packed in bottles containing solution for up to 4 x 1 ml doses, as per Specials licence. A pack also includes 4 x oral syringes used to administer the solution to the buccal cavity on either side of the mouth."
45764906|NCT05720169|Diagnostic Test|Blood sample|Blood sampling at week 13 for DNA extraction for genomic studies
45764907|NCT05720169|Diagnostic Test|Doppler ultrasound|Fetal morphological ultrasound at 13, 16 and 20 weeks.
45764908|NCT00950833|Biological|Pneumococcal vaccine GSK1024850A|1 or 2 intramuscular injections
45622535|NCT03065127|Behavioral|Proprioceptive Training|Currently, studies investigating proprioceptive training as a treatment in PD are limited. However, this type of training has potential by improving proprioceptive processing. It would be expected that due to this training, when sensorimotor processing is challenged during locomotion (e.g. by removing visual feedback and preventing compensation of proprioception deficits), freezers would experience less decrements to gait due to an enhanced ability to process sensorimotor demands.
45622536|NCT03719313|Drug|Lonafarnib|Lonafarnib (LNF) 50 mg BID
45622537|NCT03719313|Drug|Ritonavir|Ritonavir (RTV) 100 mg BID
45622538|NCT03719313|Drug|PEG IFN-alfa-2a|PEG IFN alfa-2a 180 mcg QW
45764909|NCT01766739|Biological|GL-ONC1|Patients will be enrolled in groups of three and individually assessed for safety and dose limiting toxicity (DLT).
45764910|NCT05711901|Device|Efferon LPS|Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 12h immediately following admission to the intensive care unit
45912376|NCT02009358|Other|mental health promotion|
45912377|NCT02009371|Device|Bright Light therapy|In this group, participants will be exposed to the LED treatment device (lightbox) which delivers bright light and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
45622539|NCT03719313|Drug|Placebo Lonafarnib|Placebo
45622540|NCT03719313|Drug|Placebo Ritonavir|Placebo
45622541|NCT03063801|Other|Data extraction in medical files|Data extraction from medical files, countraverified by the bloodbank database for accuracy.
45622542|NCT03063645|Drug|AC-1202|60 g AC-1202 mixed in 240 mL of water at Hour 0 Day 1
45764911|NCT05711745|Procedure|Calf myofascial technique|A 3-pass superficial leg glide technique was applied first and then 5 minutes of the deep calf myofascial induction technique as described by Pilat.
45764912|NCT02246023|Device|Flexible bronchoscopy in moderate sedation|Flexible bronchoscopy for diagnosis of lung cancer, sarcoidosis or interstitial pneumonia in moderate sedation with propofol;
45764913|NCT02246023|Device|Oxygen saturation|Continuous measurement of oxygen saturation;
45764914|NCT02246023|Device|Blood pressure|Measurement of non-invasive blood pressure every 3 minutes
45764915|NCT02246023|Device|Propofol dosage|Report of dose adjustments und cumulative propofol dosage;
45764916|NCT02246023|Device|Recovery time after bronchoscopy|Recovery time after bronchoscopy from removal of bronchoscope to eye opening/answer to verbal stimuli (whatever comes first)
45764917|NCT05720091|Drug|ZX-7101A 80mg|a drug to treatment influenza in Chinese adults
45764918|NCT05711277|Dietary Supplement|Standard milkshake ONS (Fortisip Compact Protein)|Two 125ml bottles of standard ONS administered a day for two days
45764919|NCT05711277|Dietary Supplement|High protein, fortified, ice cream|Two 80g servings of N-ICE CREAM administered a day for two days
45764920|NCT04358263|Device|Continuous Glucose Monitoring Guardian Connect Mobile system (real-time continuous glucose monitoring)|rtCGM and isCGM are used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
45446546|NCT02082652|Drug|Etonogestrel|Etonogestrel single-rod subdermal implant (68mg/rod) is placed upon enrollment (day 0) and remains in place until participant requests removal or for the duration of active drug (currently approved for 3 years of use).
45622543|NCT03063645|Drug|AC-SD-01 (50 g)|50 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1
45622544|NCT03063645|Drug|AC-SD-01 (75 g)|75 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1
45764921|NCT04358263|Device|Continuous Glucose Monitoring FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring)|rtCGM and isCGM are used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
45764922|NCT05720013|Dietary Supplement|Beetroot Juice supplement|The experimental arm includes orally ingesting 140 mL Beet-It Sport Nitrate 400.
45764923|NCT05720013|Dietary Supplement|Placebo supplement|he placebo arm involves orally ingesting a 140 mL placebo solution with the dietary nitrate removed.
45764924|NCT01041677|Drug|R256918|10 mg capsule twice daily
45446547|NCT02082730|Device|ASARM|The ASARM system combines objective and subjective measurements of sleep, rest and activity patterns by using a combination of low-cost devices and technologies. The patient wears a wrist-mounted Actigraphy device to measure their energy expenditure, and carries an electronic diary (a Smartphone app) for recording their activities and their subjective measures of mood and energy level. These synchronise daily with a remote server, accessible by the clinician through a web interface, to allow monitoring, data analysis and feedback to the patient.
45446548|NCT00153101|Drug|Telmisartan|
45764925|NCT01041677|Drug|placebo|placebo capsule twice daily
45764926|NCT01041677|Drug|R256918|15 mg capsule twice daily
45764927|NCT03401411|Behavioral|Survey|Survey of 15 fictional patient case scenarios to be assessed by participant using the standard prioritization or modified SCCMP to prioritize each patient scenario into one of a 5-point likert-scale categories for ICU admission. SCCMP scale categorized as 1-Critically ill to 4-Less likely to require ICU.
45446549|NCT00153101|Drug|Combination of Telmisartan and Ramipril|
45764928|NCT03401411|Behavioral|Algorithm-based Triage Tool|Newly designed flowchart-based triage guide to prioritize each patient case scenario into one of the 5-point likert-scale categories, used in conjunction with SCCMP for ICU admission.
45764929|NCT00358137|Behavioral|Aerobic Conditioning Program|
45764930|NCT00358137|Behavioral|Strength Training Program|
45764931|NCT05719935|Device|KinematX total wrist arthroplasty system|The KinematX total wrist implant is a joint metal/polymer semi-constrained cemented prosthesis that utilizes an articulation that mimics the midcarpal joint instead of the radiocarpal joint.
45764932|NCT03401333|Behavioral|Text Messaging and Brief Negotiation Interview|An in-person brief motivational intervention coupled with 4 weeks of motivational text messages
45446550|NCT00153101|Drug|Ramipril|
45446551|NCT02082808|Drug|DTG|DTG is provided as 9 millimetre white, film-coated, round tablets debossed with SV 572 on one side and 50 on the other side
45622545|NCT03680001|Behavioral|Training in Rating Emotional Connection|Didactic education (video-supported educational module) on emotional connectivity will be offered to the subjects. Subjects will conference with PI to review ratings on modules.
45764933|NCT04375475|Dietary Supplement|Bright Changyou probiotic flavored yogurt|Oral consumption of Bright Changyou probiotic flavored yogurt 100 g at a time and twice per day for 28 days. The experimental product has similar package and taste as the comparators.
45764934|NCT04375475|Dietary Supplement|Bright Changyou lactobacillus flavored yogurt|Oral consumption of Bright Changyou lactobacillus flavored yogurt 100 g at a time and twice per day for 28 days.
45764935|NCT04375475|Dietary Supplement|Bright flavored yogurt|Oral consumption of Bright flavored yogurt 100 g at a time and twice per day for 28 days.
45764936|NCT05719857|Procedure|Hepatic vein pressure gradient measurement|HVPG will be performed after light conscious sedation and with noninvasive vital sign monitoring. The right jugular vein will be catheterized with ultrasound assistance and after local anesthesia. Then a venous introducer will be placed and a balloon-tipped catheter will be advanced under fluoroscopic control into the right hepatic vein. Free hepatic pressure will be obtained with the balloon deflated, keeping the catheter tip in the right hepatic vein. Then, wedged venous pressure will be measured by inflating the balloon with 2 ml of air. At this moment, complete occlusion of the catheterized hepatic vein can be confirmed by injecting iodinated contrast and observing its retention. The presence of veno-venous communications can be detected during the test. To calculate the gradient, we perform the simple difference between the two measurements. Measurements will be performed in triplicate and the average used as the final value.
45912378|NCT02009371|Device|dim Red Light therapy|In this group, participants will be exposed to the same LED treatment device (light box) which delivers dim red light,which is considered to be biologically inactive, and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
45622546|NCT05136651|Behavioral|OurRelationship|The OurRelationship Program is an online adaptation of Integrative Behavioral Couple Therapy (IBCT). It consists of 3 modules that couples complete over the course of 6-8 weeks. Couples also receive a 30-minute coaching appointment following completion of each module.
45622547|NCT03063879|Drug|Sofosbuvir 400 mg and daclatasvir 60 mg|Daily fixed dose combination pill (Sovodak) containing 400 mg sofosbuvir and 60 mg daclatasvir for 12 weeks if not cirrhotic (liver stiffness < 12 KPa) or 24 weeks if cirrhotic
45622548|NCT03063567|Device|CPAP interfaces|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces (nasal mask, oronasal mask, nasal pillows) in randomized order. Trial was 1 month duration for each interface.
45622549|NCT05117463|Other|Optic Flow Stimulation|The optic flow will be displayed at different speeds. The subject will need to look at the center of the optic flow.
45622550|NCT05117463|Other|Auditory Reaction Time|Two different pitches of tones will be played. The participants will need to press a button on the right or left hand based on the pitch of the tone.
45912379|NCT02009410|Drug|Creon|Creon 25000 (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
45912380|NCT02009410|Drug|Creon 25000 matching Placebo|Creon 25000 placebo matching capsules (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
45446552|NCT02082808|Drug|DCV|DCV is provided as a plain, green, biconvex, pentagonal film-coated tablet
46069424|NCT01363596|Other|Creighton Model System in conjunction with Natural Procreative Technology (NPT)|Patients will learn the Creighton Model System to chart their fertility biomarkers, and this information will then be used by their physician in conjunction with Natural Procreative Technology (NPT) to evaluated and treat infertility or history of spontaneous abortion.
45622551|NCT03063723|Drug|Ledipasvir-Sofosbuvir|8 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
45622552|NCT03063723|Drug|Daclatasvir-Sofosbuvir|7 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
45912381|NCT02009436|Drug|Azacitidine|Given via nebulizer
45912382|NCT02009436|Other|Laboratory Biomarker Analysis|Correlative studies
45912383|NCT02009436|Other|Pharmacological Study|Correlative studies
45912384|NCT02009462|Drug|Artefill dermal filler|Four treatment visits will be scheduled at baseline and at weeks 4, 12, and 24. Each treatment session will utilize no more than 8 mL of Artefill and no more than 30 syringes of Artefill.
45912385|NCT02009475|Other|Interval exercise training|
45912386|NCT02009475|Other|Continues aerobic training|
45452358|NCT00993382|Drug|Amiodarone|"Pharmaceutical form: capsule~Route of administration: oral"
45452359|NCT00993382|Drug|Matching placebo|"Pharmaceutical form: capsule~Route of administration: oral~Matching placebo added to active drug if any for a total of 3 capsules per intake"
45622553|NCT04350567|Other|Sleep Deprivation|On the first night, the participant sleeps normally as we assess their melatonin through blood work. On the second night, the participant has 3 PET/MRI scans. On the third night, the participant undergoes sleep deprivation. On the fourth night, the participant sleeps normally and we assess their melatonin again through blood work. Depression scores are taken before and after the intervention.
45622554|NCT04338321|Drug|Esketamine 28 mg|Esketamine will be self-administered at a dose of 28 mg as nasal spray.
45622555|NCT04338321|Drug|Esketamine 56 mg|Esketamine will be self-administered at a dose of 56 mg as nasal spray.
45622556|NCT04338321|Drug|Esketamine 84 mg|Esketamine will be self-administered at a dose of 84 mg (maximum uptitrated dose) as nasal spray.
45622557|NCT04338321|Drug|Quetiapine XR 50 mg|Quetiapine XR will be administered at an initial dose of 50 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
45912387|NCT02009488|Drug|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily
45912388|NCT02009488|Drug|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily
45912389|NCT02009488|Drug|Placebo|One placebo capsule (inactive medication) once daily.
45912390|NCT02009514|Other|Glucose-containing compared to glucose-free hemodialysate|Comparison of effects on glucose variation
45912391|NCT02009527|Drug|N-hydroxy-nor-arginine|
45912392|NCT02009527|Drug|NaCl|
45912393|NCT02009540|Drug|Botulinum toxin injected to bladder body|arm will receive 100u of onaBoNT-A in 20x1ml aliquots (5u/ml). 20 injections will be given into the bladder wall, sparing the trigone. Injections will be given through all layers of the bladder eg suburothelially and intradetrusor. The intervention will be performed under local anaesthetic using a flexible cystoscope.
45622558|NCT04338321|Drug|Quetiapine XR 100 mg|Quetiapine XR will be administered at a dose of 100 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
45622559|NCT04338321|Drug|Quetiapine XR 150 mg|Quetiapine XR will be administered at a dose of 150 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
45912394|NCT02009540|Drug|Botulinum toxin injected into trigone|Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml). The procedure will be performed under local anaesthetic by flexible cystoscopy.
45912395|NCT02009553|Other|Information sheet|
45912396|NCT02009553|Other|No information sheet|
45622560|NCT04338321|Drug|SSRI/SNRI|Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the SmPC (or local equivalent, if applicable).
45622561|NCT04438005|Drug|ICP-022|ICP-022 is a white, round, uncoated tablet, 50 mg. It is administered orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.
45653388|NCT05037903|Behavioral|Cognitive-behavioral therapy|Cognitive and behavioral interventions aimed at increasing behavioral activation, and reducing procrastination and inattentive symptoms.
45764937|NCT05719857|Procedure|Ultrasound-guided percutaneous liver biopsy|Percutaneous liver biopsy will be performed with the aid of US to choose the best site for the procedure, minimizing the incidence of complications. With the patient in dorsal decubitus, venous analgesia with fentanyl 25-50 mcg will be performed. After marking the appropriate site, skin asepsis and antisepsis will be performed with Chlorhexidine® and topical anesthesia with 1% lidocaine. Then, the liver will be punctured using a 14G semi-automatic tru-cut single-use liver biopsy needle. The recovered material will be stored in a 50 ml flask with 10% formaldehyde. Patients will remain at rest supervised for 4 hours, with hourly measurement of blood pressure (BP), heart rate (HR) and assessment of symptoms (abdominal pain, nausea, etc.). In the absence of any complications, patients will be discharged from the hospital.
45912397|NCT02009566|Radiation|Abdominal radiographs with microfabricated tags|Subjects will have 2 x-rays of their lower thorax/ abdomen taken. For each x-ray, a microfabricated tag or no tag will be placed in a different position. The x-rays will take approximately 15 minutes to complete.
45452360|NCT00081731|Drug|Atacand/HCT, Caduet|Atacand/HCT and caduet or optimal medical therapy for hypertension
45452361|NCT00081731|Procedure|GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)|Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device
45912398|NCT02009592|Drug|Rifaximin|Both arms receive Rifaximin
45912399|NCT02009605|Drug|Icotinib|125mg, oral administration, three times per day.
45912400|NCT02009618|Drug|Rifaximin|Rifaximin tablet is given as 200 mg 3x2/daily, for 10 days.
45912401|NCT02009618|Drug|placebo|
45912402|NCT02009631|Drug|Veliparib (ABT-888)|
45912403|NCT02009631|Drug|Placebo|
45912404|NCT02009644|Device|Subjects who receive the Treovance stent-graft|Eligible subjects will be implanted with the Treovance Stent-Graft
45912405|NCT02009670|Dietary Supplement|13C inulin|Oral 13C inulin
45653389|NCT04986969|Behavioral|Online cognitive behavioral therapy|online cognitive behavioral therapy delivered using one of two active methods
45912406|NCT02009670|Other|Placebo|Oral maltodextrin
45912407|NCT02009709|Drug|Riboflavin 0.1% ophthalmic solution|Instillation of 0.1% riboflavin ophthalmic solution, one drop every 3 minutes for 30 minutes before the procedure and one drop every 3 minutes during the procedure.
45912408|NCT02009709|Device|CCL-VARIO UV lamp|Application of ultraviolet light on the eye to be treated at an irradiance of 9 mW/cm2 for 10 minutes
45912409|NCT02009709|Device|CCL-VARIO at 18 mW/cm2|Application of ultraviolet light on the eye to be treated at an irradiance of 18 mW/cm2 for 5 minutes.
45912410|NCT02009735|Device|virosensor|"virosensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-influenza-virus (or anti-EV71-virus) and its influenza virus antigen (or EV71 antigen) present in patients and normal samples.~The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens."
45912411|NCT02009748|Dietary Supplement|Vitamin D supplementation|oral administration of colecalciferol 2.800 IU once daily
45622562|NCT04267107|Other|Individual Managing Fatigue Program|The Individual Managing Fatigue Program includes six weekly sessions that focus on sleep, communication and body mechanics, activity stations, priorities and standards, and balancing daily schedule. Each session includes three parts: 1) a pre-session activity 2) in-session activities/information and 3) homework. Prior to coming to each session, participants will be asked to complete activities that will help them prepare for the in-session discussions. During each session participants will discuss and practice the topics most important to them. Based on their discussions, participants and therapists will decide on activities to complete during each session and as homework. The therapist will help the participant begin the homework at the end of each session, and the participant will finish it outside of the session at home. At the beginning of the following session, the therapist and participant will review the homework.
45622563|NCT00695253|Device|Talent Endoluminal Spring Graft System|Endovascular repair for patients with AAA who meet the inclusion criteria for the study
45622564|NCT00379041|Biological|bleomycin sulfate|
45622565|NCT00379041|Drug|doxorubicin hydrochloride|
45622566|NCT00379041|Drug|mechlorethamine hydrochloride|
45446553|NCT02085928|Other|Intratissue percutaneous electrolysis, associated with eccentric exercise and stretching|"The EPI technique was performed under ultrasound-guidance on the clinically relevant area (or areas of maximum tenderness to palpation and with ultrasonographic degenerative tendon changes) using an intensity of 4-6 mA during 3 seconds, approximately 3 times. We used the EPI machine (Cesmar Electromedicina S.L., Barcelona, Spain) and a GE Logiq E Portable Ultrasound Machine with GE Linear probe 12L-RS (5-13 mhz) (GE Healthcare, Wisconsin, EEUU).~The eccentric exercise program consisted of three series of up to 10 repetitions of eccentric work, repeated twice daily (morning and afternoon), under maximum load (initially with one kilogram) in an optimal and functional pain-free range.~The stretching program consisted of a stretching exercise for the epicondylar muscles consisting in three series of 7 repetitions twice a day (morning and afternoon."
45446554|NCT02075788|Other|Commercial white bread|
45622567|NCT00379041|Drug|prednisone|
45764938|NCT05719857|Diagnostic Test|Multiparametric Abdominal Magnetic Resonance with Elastography|The evaluation of the abdomen by MRI, with special interest to the liver and spleen, will be performed in a Siemens 3.0T Magnetom Prisma MR system. In addition to the routine protocol without contrast administration, MR elastography will be performed to assess liver stiffness and spleen stiffness. Data processing will be carried out at a Syngovia workstation.
45622568|NCT00379041|Drug|procarbazine hydrochloride|
45622569|NCT00379041|Drug|vinblastine sulfate|
45622570|NCT00379041|Drug|vincristine sulfate|
45912412|NCT02009748|Dietary Supplement|Placebo|oral administration of placebo (vehicle) once daily
45622571|NCT00379041|Radiation|radiation therapy|
45622572|NCT04225923|Drug|NPC-21 Low dose|NPC-21 will be administered via an approximately 60-minute intravenous infusion
45622573|NCT04225923|Drug|NPC-21 High dose|NPC-21 will be administered via an approximately 60-minute intravenous infusion
45912413|NCT02009761|Drug|BI 655064|subcutaneous injection
45622574|NCT04225923|Drug|NPC-21 Placebo|Placebo will be administered via an approximately 60-minute intravenous infusion
45764939|NCT00924053|Drug|EGT0001474|Cohort 1: single dose of 25 mg EGT0001474 given as an oral capsule; Cohort 2: single dose of 75 mg EGT0001474 given as 3 oral capsules; Cohort 3: single dose of 150 mg EGT0001474 given as 6 oral capsules.
45764940|NCT00924053|Drug|Placebo|Placebo capsules to match EGT0001474
45764941|NCT05707845|Drug|Medical treatment.|Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs).
45764942|NCT05707845|Behavioral|weight reduction|weight reduction in the form low caloric diet program for 12 weeks.
45764943|NCT05707845|Other|exercise|aerobic exercise in the form of walking on treadmill for 30 minutes 3 times a week for 12 weeks.
45764944|NCT04375319|Device|OCT|OCT can provide clear in vivo imaging and evaluate the vascular repair after stent implantation by measuring the optical echo of near-infrared light reflection
45446555|NCT02075788|Other|Corn based products (porridge etc.)|
45446556|NCT02075788|Other|Millet based products (porridge etc.)|
45446557|NCT03558412|Combination Product|CODOX-M/IVAC|Given ivgtt
45446558|NCT03558412|Drug|Decitabine|Given ivgtt
45622575|NCT04431219|Biological|LIS1|LIS1 is an induction treatment on top of maintenance immunosuppressive regimen. All patients from AD and TD cohort will receive the conventional immunosuppressive regimen: tacrolimus (0.2 mg/kg) / mycophenolic acid (MMF, 2x1000 mg) / prednisone (20 mg from day 2). This conventional treatment should be started and monitored for all patients independently of their participation in the clinical trial. Methylprednisolone 500 mg / 100 mL saline / 30 minutes will be administered before reperfusion during the surgery and on post operation day 1 just before LIS1 administration.
45622576|NCT04432545|Biological|Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly|Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly
45622577|NCT03063489|Drug|Loteprednol Etabonate Ophthalmic Gel|Formulated LE into a gel (loteprednol etabonate ophthalmic gel, [Lotemax® gel])
45622578|NCT04430127|Other|No supplementary intervention is performed|No supplementary intervention will be applied
45622579|NCT04433091|Drug|2-Hydroxybenzylamine|2-HOBA (2-Hydroxybenzlamine) 750mg will be given TID seven days prior to ablation and 28 days post ablation.
45764945|NCT00833313|Procedure|Atrial biopsy|Biopsy of left atrial free wall and possibly left atrial appendage
45764946|NCT03400397|Other|Cool Kids programme|A manualised cognitive behavioural treatment programme that consists of 10 session within 12-16 weeks each lasting 2 hours.
45912414|NCT02009774|Procedure|NBI Function|
45912415|NCT02009787|Drug|vitamin D3 tablets|2000 IU vitamin D3 tablets were taken daily for 6 months
45912416|NCT02009787|Drug|placebo tablets|2000 IU placebo tablets were taken daily for 6 months
45446559|NCT03559036|Procedure|Locomotor Training|Body-weight supported stepping on a treadmill.
45622580|NCT04433091|Other|Placebo|Placebo will be given TID for seven days prior to ablation and 28 days post ablation.
45622581|NCT03368001|Behavioral|SENSE Theatre|SENSE Theatre is a peer-mediated, theatre-based intervention targeting social competence in youth with autism spectrum disorder. The 40 hour intervention is comprised of 10 sessions in which trained typically peers are paired with children with autism spectrum disorder (ASD).
45622582|NCT03368001|Behavioral|Tackling Teenage Together|The Tackling Teenage Together is a psychosocial and sexual education program developed for youth with ASD. It is comprised of 10 sessions.
45622583|NCT03318939|Drug|Poziotinib|"The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.~Cohorts 1-3: 16 mg QD~Cohort 4: 8 mg BID~Cohort 5: randomized to 8 mg BID or 6 mg BID or 10 mg QD~Cohorts 6 and 7: 8 mg BID"
45622584|NCT03305445|Drug|Ipilimumab|Ipilimumab (1mg/kg)
46069425|NCT01260090|Device|Vagus nerve stimulation;|"Name of the Device:~We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).~FDA Facility Registration Number: 1644487"
45446560|NCT02086006|Device|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold|
45622585|NCT03305445|Drug|Nivolumab|Nivolumab (3mg/kg)
45622586|NCT01504893|Procedure|Protective one lung ventilation|Low tidal volume, PEEP and alveolar recruitment maneuver
45622587|NCT01470105|Other|blood sampling, the SF-36 questionnaire|"The patient be asked to fill out a questionnaire. The questionnaire asks about their quality of life and will take approximately 15 minutes to complete. It will be completed at a regularly scheduled clinic visit.~At the scheduled pre-operative testing, an extra sample of your blood (equal to about 4 teaspoons) will be collected for research tests. The research tests will measure levels of inflammation in your body. These tests are not part of routine care. A physical examination of the operative site will be done by the Orthopaedic Surgeon. The patient will complete the same questionnaire at the regularly scheduled three and six month follow-up visit"
45622588|NCT04982523|Behavioral|Online Mental Health Program|The proposed program consisted of eight sessions conducted twice per week, consisting of 5 minutes of introductory material, 12-15 minutes of main content, and 5 minutes of concluding content. The main content intended to improve the control processes and each of the four adaptive modes of the RAM. The eight sessions were uploaded on the web. Links and passwords for each session were provided to the participants through SNS. The program was accessible from any electronic device with Internet access
45446561|NCT04401579|Other|Placebo|The matching Baricitinib placebo contains lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The coating for the placebo tablet is identical to that of the corresponding active tablet.
45446562|NCT04401579|Drug|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
45764947|NCT03834389|Behavioral|Case- based Learning|critical thinking, self efficacy, focus group interview
45446563|NCT04401579|Drug|Baricitinib|Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name [1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
45446564|NCT02082964|Other|SCIM|after lecture students had rotation in 6 groups through 6 stations, trained and practiced under supervision of 6 instructors about Initial Steps, Positive Pressure Ventilation(PPV), Intubation, Chest Compressions, Medications and management of advanced resuscitation
45446565|NCT02082964|Other|video|video about neonatal resuscitation presented then students repeated the video. Workshops was based on NRP and lasted 6 hours for each group the contentof the video was based on the educational content of the course
45446566|NCT03558880|Procedure|Erector Spinae Plane Block|Erector Spinae Plane Block was performed
45446567|NCT03558880|Procedure|Tumescent Anesthesia|Tumescent Anesthesia was applied
45452362|NCT00911248|Drug|PTC299|PTC299 will be administered orally at 100 mg/dose twice per day for up to 1 year or until tumor progression
45622589|NCT04982601|Other|Yoga Exercises|Yoga-based exercises are Hatha yoga-based sessions consisting of breathing exercises, warm-up exercises, relaxation, asanas exercises.
45622590|NCT04436913|Other|Himalaya complete care toothpaste|Herbal toothpaste as a part of a caries preventive regimen
45622591|NCT04436913|Other|Signal toothpaste|fluoride based toothpaste as a part of a caries preventive regimen
45622592|NCT04436913|Other|Signal toothpaste and fluoride varnish|application of fluoride varnish and using fluoride based toothpaste
45764948|NCT00357825|Drug|[S,S]-Reboxetine|
45764949|NCT03400241|Drug|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product A
45764950|NCT03400241|Drug|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product B
45764951|NCT03400241|Drug|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product C
45764952|NCT03400241|Drug|Tiotropium Bromide Monohydrate|Spiriva 18 Mcg/capsule inhaled via HandiHaler
45764953|NCT05706987|Drug|Lidocaine|continuous lidocaine infusion perioperatively
45764954|NCT05706987|Drug|Normal saline|normal saline
45764955|NCT03400007|Device|Dynamic floor magnetic resonance imaging|Dynamic floor magnetic resonance imaging (MRI)
46069426|NCT01260090|Device|No stimulation|Vagus nerve stimulation
46069427|NCT01147016|Biological|HER2Bi-armed activated T cells|Total of 4 of the T cell infusions intravenously over a period of 1 month.
46069428|NCT01147016|Drug|cyclophosphamide|As prescribed by physician, standard of care.
46069429|NCT01147016|Drug|doxorubicin hydrochloride|As prescribed by physician, standard of care.
45622593|NCT04436757|Behavioral|IPS program : Self-image and body representation|"The IPS program consists in 13 sessions of 2 hours over a 13-weeks period.~Sessions content is as follows :~: Introduction~: Sensory approach workshop~: Self presentation and personal hygiene~: Organisation of well-being, planning and pictograms~: Becoming aware of my body, my envelope~: Presentation and self-esteem (photolanguage)~: Self-presentation in social interactions: Social codes~: My ideas and desires for change~: Places of well-being and clothing hygiene~: Vocational insertion devices~: Daring change : presence of a Socio-hairdresser~: The awakening of color : presence of a Socio-aesthetician~: Development of practice sheets and the network"
45622594|NCT04436757|Behavioral|TAU|The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by the health service. No additional session will be proposed.
45912417|NCT02009813|Procedure|Hyperbaric Oxygen Therapy|Participants will undergo 2 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere. During this time, patients will be treated with 100% oxygen delivered via a hood system.
45912418|NCT02009826|Radiation|[18F]-PBR111 Positron Emission Tomography (PET)|[18F]-PBR111 radioligand to assess binding to TSPO
45912419|NCT02009826|Behavioral|Cognitive and psychomotor tasks|Cognitive and psychomotor tasks on digitizing tablet
45622595|NCT02487095|Drug|Topotecan|Topotecan (in combination with VX-970 (M6620) administered by intravenous (IV) Days 1-5 in a 21 day cycle, until disease progression or development of intolerable side effects.
45622596|NCT02487095|Drug|VX-970 (M6620)|VX-970 (M6620 (in combination with Topotecan) administered by intravenous (IV) Day 5 or Days 2 and 5 in a 21 day cycle, until disease progression or development of intolerable side effects.
45622597|NCT02401685|Other|Adjuvant therapy|Adjuvant therapy will include chemotherapy and/or endocrine therapy for all women, and radiotherapy to breast or chest wall if indicated. Human epidermal growth factor receptor 2 (HER2) targeted treatment may also be administered when indicated.
45764956|NCT03400007|Device|Colpocystodefecography|Colpocystodefecography (CCD)
45912420|NCT02009826|Biological|Blood sampling|Blood sampling for peripheral inflammatory and neurotoxicity markers
45912421|NCT02009839|Behavioral|Meeky Mouse program|
45764957|NCT00729573|Drug|Emtricitabine/tenofovir disoproxil fumarate|200 mg/300 mg tabletas a part of MTN-003
45912422|NCT02009839|Other|Computer Games|
45452363|NCT00909766|Drug|BMS-830216|Capsules, Oral, 30 mg, once daily, 28 days
45622598|NCT02401685|Procedure|Axillary treatment|Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.
45764958|NCT00729573|Drug|Emtricitabine/tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
45764959|NCT00729573|Drug|Tenofovir disoproxil fumarate|300 mg tablet as a part of MTN-003
45912423|NCT02009943|Drug|Ferric carboxymaltose|One time dosing
45452364|NCT00909766|Drug|BMS-830216|Capsules, Oral, 100 mg, once daily, 28 days
45452365|NCT00909766|Drug|BMS-830216|Capsules, oral, 300 mg, once daily, 28 days
45622599|NCT03894917|Other|Comprehensive Geriatric Assessment (CGA)|Assessments will be done for participants that are 65 years or older.
45622600|NCT03855137|Drug|Atogepant 30 mg|Tablets containing 30 mg atogepant
45622601|NCT03855137|Drug|Atogepant 60 mg|Tablets containing 60 mg atogepant
45622602|NCT03855137|Drug|Placebo|30 mg/60 mg tablets containing atogepant-matching placebo
45622603|NCT03837899|Drug|Durvalumab / Tremelimumab Combination Therapy|"Starting dose:~durvalumab: 20mg/kg tremelimumab: 1mg/kg at cycles 2 to 5 only co-administered with durvalumab. The Recommended Phase 2 dose will be used for the dose expansion phase."
45764960|NCT00729573|Drug|Tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
45764961|NCT03405389|Procedure|MatrixWAVE MMF System|Standard of care treatment of the injury and use of the MatrixWAVE MMF system to establish occlusion
45764962|NCT05719623|Other|CUEVAS MEDEK EXERCISES|stretchings/strengthening
45764963|NCT05719623|Other|BALANCE AND POSTURAL|BALANCE AND POSTURAL
45764964|NCT02951182|Drug|TEZ|
45764965|NCT02951182|Drug|IVA|
45764966|NCT02951182|Drug|VX-440|
45764967|NCT02951182|Drug|Matched Placebo|
45764968|NCT03403205|Drug|ALXN1840|ALXN1840 administered orally in 15 mg tablets
45912424|NCT02009943|Drug|Iron sucrose|Goal-directed dosing
45912425|NCT02009956|Device|Subjects receiving DESyne Novolimus Eluting CSS|
46069430|NCT01147016|Drug|paclitaxel|As prescribed by physician, standard of care.
45622604|NCT02214719|Behavioral|EASI-IDM use|EASI-IDM use is the intervention involving the use of the Edmonton Automated Sugar Intelligence system linked to the Intelligent Diabetes Website by people with type 1 diabetes to facilitate glucose record keeping, clinical monitoring and we will assess if this app helps lead to improved glucose control and more patient involvement with their diabetes management.
45622605|NCT03756077|Diagnostic Test|68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT|0.05-0.06 mCi per kilogram bodyweight of 68Ga-PSMA, 0.1-0.15 mCi per kilogram bodyweight of 18F-FDG will be injected intravenously prior to imaging
45622606|NCT04535063|Biological|COVID19 convalescent plasma infusion|intravenous infusion of 300-600 mL of convalescent plasma with an antibody title more than 3 according to chemiluminescent microparticle immunoassay (Architect Plus Abbott)
45622607|NCT03742193|Drug|Apatinib|Apatinib 250mg tablet by mouth, bid. 48 hrs break before and 96 hrs after the surgical resection of the pulmonary metastases.
45622608|NCT03742193|Drug|GD regimen|"One cycle: gemcitabine 900 mg/m^2 over 90 min on Day 1, and gemcitabine 900 mg/m^2 and docetaxel 75 mg/m^2 on Day 8. Every 21 days were eligible.~1~2 -week break before and 2-week break after the surgical resection of the pulmonary metastases is taken."
45622609|NCT02462135|Behavioral|Virtual interactive memory training|Training sessions of the VIMT group are divided into initial training and booster training. Each training session is 45 minutes/day, 3 sessions/week, for 12 weeks for both initial training and booster training (36 sessions each). The training content of the four memory training include: (1) spatial encoding memory training task, (2) updating-spatial memory training task, (3) updating-visual memory training task, and (4) rehearsal-visuospatial memory training task.
45622610|NCT02462135|Behavioral|Passive information activities|The active control group (Passive information activities) only accepts the initial training phase, which training content of the two types to include: (1) listening to audio books, and (2) reading online newspaper.
45622611|NCT03108287|Drug|RAK therapy|rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg twice-daily
45622612|NCT03108287|Drug|RBAK therapy|rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg, bismuth subcitrate 360mg twice-daily
45622613|NCT03108209|Other|Photoderm Max lait SPF50+|Subjects apply Photoderm Max lait SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
45622614|NCT03108209|Other|Photoderm Max Stick SPF50+|Subjects apply Photoderm Max Stick SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
45622615|NCT03297203|Behavioral|Blood sample|The investigators will take two kits of blood samples for the group 1, one during the early stage of the septic shock (48 first hours of care) and one during the late stage of the disease (between the fourth and the sixth day). We'll take only one kit of blood samples for the group 2. One kit includes one EDTA tube (5 mL) and five Lithium Heparin tubes (25 mL). The immune mapping will be made by Julien Carvelli, a gold medalist resident, in the framework of a Master 2. The analyses will be made in the laboratory of immunology in the Conception Hospital (Pr Vivier's team).
45622616|NCT02461823|Device|Zirconia crown|patients will receive a Zirconia crown, the Zirconia crown will cover the natural crown.
45622617|NCT02461823|Device|Porcelain metal crown|patients will receive a porcelain fused to metal crown, the Porcelain metal crown will cover the natural crown.
45622618|NCT02461979|Other|The VDR genotype|The VDR genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
45622619|NCT02461121|Genetic|HLA mismatched stem cell|HLA mismatched donor G-CSF mobilized peripheral stem cell infused 24 hours (day 0) after the completion of chemotherapy
45622620|NCT02461121|Genetic|HLA matched stem cell|HLA matched donor G-CSF mobilized peripheral stem cell infused after the conditioning reginmen
45622621|NCT02461121|Drug|cyclosporine A|The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
45622622|NCT02461121|Drug|Mycophenolate mofetil|The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
45622623|NCT02461121|Drug|Ara-C|2.0 to 3.0g/m2 per 12 hours intravenously for 6 dose
45622624|NCT02461121|Drug|fludarabine|30 mg/m2/d for 5days
46069431|NCT01147016|Other|laboratory biomarker analysis|Immune studies will be done pre-immunotherapy, prior to the third infusion of activated T-cells, at the time of surgery, and 1 month after immunotherapy. If there are positive findings, additional optional studies will be done at 3, 6, and 12 months, if the immune studies show changes worthy of follow-up studies.
45622625|NCT02461121|Drug|anti-lymphocyte globulin|1.5-2 mg/kg/d for 4 days
45452366|NCT00909766|Drug|BMS-830216|Capsules, oral, 600 mg, once daily 28 days
45622626|NCT02461121|Drug|cyclophosphamide|40 mg/kg/d for 2 days
45622627|NCT03297047|Device|combi cast|upper arm or forearm combi cast
46069432|NCT01147016|Procedure|neoadjuvant therapy|As prescribed by physician, standard of care.
46069433|NCT01147016|Procedure|therapeutic conventional surgery|As recommended by physician, post immunotherapy.
46069434|NCT01140204|Device|Implantation of a bare metal stent|Bare Metal Stent
46069435|NCT01124890|Device|early percutaneous coronary intervention|
45622628|NCT01846091|Other|Laboratory Biomarker Analysis|Correlative studies
45622629|NCT01846091|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IT
45622630|NCT03296969|Procedure|cesarean section|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
45622631|NCT03296969|Procedure|Rectus muscle approximation|aprroximation of the lower parts of rectus abdomius muscles during cesarean section
45622632|NCT01530659|Drug|NT-501|Study participants will undergo surgery to have an NT-501 Encapsulated Cell Therapy implant placed into the study eye.
45446568|NCT02083120|Device|NHF therapy|AIRVO 2 device therapy is either a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patients through a variety of patient interfaces. Flow rates up to 60 L/min are available to the user, depending on the patient interface and mode of operation.In this study, flow rates of 20 L/min and 35 L/min will be compared.
45446569|NCT02083120|Other|Long term Oxygen Therapy (LOT)|Oxygen will individually be added to NHF in order to achieve stable oxygen saturation by pulse oximetry (SpO2) values of 88% to 92%.
45446570|NCT02075944|Behavioral|High intensity aerobic exercise|
45446571|NCT02075944|Behavioral|Low intensity aerobic exercise|
45912426|NCT02009995|Behavioral|Aerobic Training (AT)|All subjects will participate in a 10-week ramp-in period with the goal of achieving 150 minutes of moderate-to-vigorous physical activity per week. Walking and jogging will be the primary modes of achieving the prescribed aerobic activity as these are the modes of aerobic exercise that are most accurately recorded by an accelerometer. Subjects will use the Rate of Perceived Exertion (RPE) to guide aerobic exercise intensity. Aerobic activity will be objectively monitored by the Technogym MyWellness Key (MWK) accelerometer, which is a lightweight device worn on the waistband.
45912427|NCT02009995|Behavioral|AT plus Primarily Home-Based Resistance Band Training|"The bands + AT group will engage in RBT 3 times per week, progressing to 3 sets of 10-15 repetitions of 12 exercises. The exercises will be: chair squat, sitting chest press, seated rear fly, seated row, overhead press, lateral raise, biceps curl, triceps extension, leg extension, hamstring curl, gluteal extension, and abdominals. The resistance band exercise sessions will be between 25-60 minutes.~Participants in this group will attend supervised group sessions weekly in weeks 1-4, every 2 weeks in weeks 5-8, and every 4 weeks thereafter to ensure proper form and appropriate progression. Participants in this group will be responsible to complete all remaining sessions (a total of 3 per week, including supervised sessions) at home on their own time."
45622633|NCT01530659|Procedure|Sham|Non-penetrating sham procedure to mimic implant procedure in the other eye.
45622634|NCT00701363|Drug|Lanreotide Autogel 120 mg|120mg, injections every 6 weeks, then depending on IGF-1 results at Week 24
45622635|NCT03296891|Other|PoCUS Guided Resuscitation of Shock|Point-of-care ultrasound (PoCUS) will be used to guide resuscitation of the participant with shock. A PoCUS study will consist of limited echocardiography (LE) and thoracic ultrasound (TUS).
45622636|NCT02461043|Drug|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
45446572|NCT02086084|Device|NIV|Standard care
45622637|NCT02461043|Radiation|radiation|radiation
45622638|NCT03296735|Procedure|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally.
45622639|NCT03296735|Procedure|Contralateral tilt|The operation table will be tilted 20 degrees left laterally.
46069436|NCT01124890|Device|late percutaneous coronary intervention|
45446573|NCT02086084|Device|ECCO2R|Application of ECCO2R in addition to NIV
45446574|NCT04161807|Device|Nerivio|The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
45446575|NCT02086240|Drug|XBD173|XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity.
45446576|NCT04401423|Drug|TXA127|0.5 mg/kg per day
45622640|NCT03298997|Procedure|Ligation and Hemorrhoidopexy|"Identification through palpation and ligation of the hemorrhoidal nodules (3rd, 7th, 11th hour), using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Prior to operation, the patients will be submitted to pudendal nerve block."
45622641|NCT03298997|Procedure|Ultrasound Guided Ligation of Hemorrhoidal Arteries|"Ultrasound guided identification and ligation of the hemorrhoidal arteries, using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Prior to operation, the patients will be submitted to spinal anesthesia."
45622642|NCT03296657|Drug|stannous fluoride|subjects will brush with paste twice daily for 2 weeks
45622643|NCT03298919|Behavioral|Exercise Video Games|12 weeks laboratory based exercise videogames
45622644|NCT03298919|Behavioral|Aerobic Exercise|Stationary bike and/or treadmill walking for 12 weeks
45622645|NCT03298919|Behavioral|Home exercise videogames|videogame console and active videogames
45622646|NCT03298919|Behavioral|Home Standard Exercise|Personalized physical activity promotion materials
45622647|NCT03296579|Device|BiPAP|The patient's breathing is assisted by cycling between high and low pressures at a pre-set rate.
45622648|NCT03296579|Device|CPAP|The patient breathes against a constant pressure delivered by face mask.
45446577|NCT04401423|Drug|Placebo|0.5 mg/kg per day
45446578|NCT03749733|Drug|Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Reference Product)|Marketed Drug
45912428|NCT02010008|Behavioral|Motivational Interviewing Intervention|An individual-level intervention that implements a motivational interviewing intervention led by a promotora
45912429|NCT02010034|Drug|Omegaven|Omegaven will be used in place of soy oil Intralipid
45912430|NCT02010047|Device|ALK qPCR assay|72 IHC ALK-negative and 72 IHC ALK-positive FFPE samples will tested with FISH and qPCR to determine the sensitivity and specificity of the ALK qPCR assay.
45446579|NCT03749733|Drug|Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Test Product)|Investigational Medicinal Product
45446580|NCT04399161|Drug|Chlorhexidine mouthwash|A commercially available Chlorhexidine mouth rinse (Hexidine- 0.2 percentage Chlorhexidine gluconate) containing 0.2 percentage chlorhexidine gluconate per 10 ml will be used. 7.5 ml of the concentrate diluted with equal amounts of water to make 15ml will be used for rinsing.
45622649|NCT03296579|Drug|Ipratropium|Nebulized q6h
45446581|NCT04399161|Drug|Xylitol|Xylitol mouth rinse at 10 percentage concentration will be used. The mouth rinse will be prepared by dissolving 1.5 gm of xylitol powder in 15 ml of water.
45622650|NCT03296579|Drug|Magnesium Sulfate|50mg/kg IV, 4 doses q6h
45622651|NCT03296579|Drug|Aminophylline|6mg/kg IV (if no progress)
45446582|NCT04399161|Drug|Probiotic|Probiotic mouth rinse will be prepared by using a commercially available probiotic product (Sporolac Plus powder- 1gm sachet containing not less than 1.5 billion cells of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum, Bacillus coagulans, Saccharomyces boulardii). Each sachet will be dissolved in 15 ml of water in a measuring cup and used as a mouth rinse.
45622652|NCT03296579|Drug|Standard steroid dose, hourly salbutamol, oxygen as needed|Standard common therapies for all three arms.
45446583|NCT02076178|Drug|744 Tablet|White to almost white oval shaped film coated 30 mg tablets for oral administration
45446584|NCT02076178|Drug|744 LA Injection|Sterile white to slightly coloured suspension containing 200 mg/mL of 744 as free acid for administration by intramuscular (IM) injection
45622653|NCT02461901|Other|Environmental sampling|Sampling of five sites in the patient's immediate environment for C. difficile spores
45622654|NCT02461901|Other|Skin swab sampling|Collection of swabs from three sites on the skin for C. difficile spores
45622655|NCT02461901|Other|Fecal sampling|Collection of fecal samples for C. difficile spores
45622656|NCT02461199|Biological|Fecal microbiota transplantation|Transplantation of 100 ml of fecal microbiota suspension obtained from healthy unrelated donor in two consecutive days via the nasoduodenal tube
45912431|NCT02010060|Behavioral|Aerobic Exercise Training|Individuals randomized to the aerobic exercise training group will participate in 6 months of supervised exercise training. Exercise dose (expressed in kilocalories per kg per week [KKW]) during aerobic training will be 8KKW in week 1, 10KKW in week 2 and 12 KKW in week 3. the exercise dose of 12KKW will be maintained throughout the intervention. Pedometers will be worn by participant in blind-mode throughout the intervention, and removed during exercise training sessions. Participants will enter information about whether they wore their pedometer on the study website. Aerobic exercise group participants will be told to make no conscious alterations to their physical activity or dietary habits
46069437|NCT01073475|Other|There is no intervention associated with the parent MNHR study. For the MNHR COVID sub-study, participants will be asked to provide a blood specimen at or near delivery.|"There is no intervention associated with the parent MNHR study~For the MNHR COVID sub-study, each woman will be asked to provide a blood specimen of approximately 3-5 cc at or near delivery (at delivery or 14 days after) to be tested for COVID-19 antibodies. The person collecting the specimen will be a trained member of the registry staff. The ZEUS ELISA SARS-CoV-2 IgG Test System will be used and run at each site. RTI International will provide central quality support of the analyses."
45446585|NCT02076178|Drug|Placebo Tablet|Microcrystalline cellulose, Opadry film-coating, white OY-S-28876
45622657|NCT02461667|Drug|SRP plus Placebo Gel|After SRP, placebo gel was delivered subgingivally into the pocket
45622658|NCT02461667|Drug|SRP plus Alendronate gel|Alendronate (ALN) After SRP, ALN gel was delivered subgingivally into the pocket
45622659|NCT02461667|Drug|SRP plus Metformin gel|Metformin (MF) After SRP, MF gel was delivered subgingivally into the pocket
45446586|NCT02076178|Drug|Placebo Injection|Sterile saline 0.9% Sodium Chloride Injection
45446587|NCT04160091|Drug|FX006|Single intra-articular injection
45446588|NCT04160091|Drug|Normal Saline|Single intra-articular injection
45446589|NCT02076256|Behavioral|The helping relationships intervention program|
45446590|NCT03969251|Device|Transcranial Magnetic Stimulation (rTMS)|active high frequency repetitive TMS of left Dorsolateral Prefrontal Cortex
45446591|NCT03969251|Device|Sham (SS)|repetitive sham rTMS
45446592|NCT03558334|Drug|Transplantation of mesenchymal stem cell|"Human umbilical cord-derived mesenchymal stem cell will be given to preterm infants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg"
45446593|NCT03558334|Drug|No transplantation of mesenchymal stem cell|Human umbilical cord-derived mesenchymal stem cell will be not given to preterm infants through intravenous infusion.
45446594|NCT01582607|Drug|Bupivacaine plain|2.0 mL (10mg) plain bupivacaine hydrochloride 0.5% intrathecally
45446595|NCT01582607|Drug|Ropivacaine plain|2.0 ml (15mg) plain ropivacaine 0.75% intrathecally
45446596|NCT01582607|Drug|Levobupivacaine plain|2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5% intrathecally
45446597|NCT01582607|Drug|bupivacaine plain +fentanyl|2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
45446598|NCT01582607|Drug|ropivacaine plain +. fentanyl|2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl intrathecally
45622660|NCT03296501|Biological|Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients|3 injections of ADRC: 1 intraspinal and 2 intrathecal
45622661|NCT03296423|Biological|Vaccination|Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine
45622662|NCT03296423|Biological|Placebo|Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
45622663|NCT04489511|Drug|STG-001|Dose 1 or Dose 2 of STG-001 will be administered daily for 28 days to compare safety, pharmacokinetics and pharmacodynamics in Stargardt disease subjects.
45622664|NCT03296267|Procedure|Gastroduodenoscopy|Gastroduodenoscopy with duodenal biospies: A tube is placed via the mouth into the second part of the duodenum. Biopsy forceps is used to take duodenal biopsies.
46069438|NCT00967785|Drug|Mozobil (TM)|
45622665|NCT01670877|Drug|Neratinib|
45622666|NCT01670877|Drug|Fulvestrant|
45622667|NCT01670877|Drug|Trastuzumab|
45622668|NCT01670877|Procedure|Tumor biopsy|-Optional at baseline and disease progression
45622669|NCT01670877|Procedure|Research blood sample|-Baseline, cycle 1 day 15, cycle 2 day 1, cycle 3 day 1, day 1 of each odd cycle, end of treatment (progression)
45622670|NCT00701129|Biological|Alglucosidase Alfa|Administered as IV infusion.
45622671|NCT00701129|Drug|Methotrexate|Administered subcutaneously.
45622672|NCT00701129|Drug|Rituximab|Administered as IV infusion.
45622673|NCT03298763|Genetic|MSCTRAIL|"3 doses of MSCTRAIL, administered as an intravenous 60 minutes infusion over 3 cycles, in combination with standard chemotherapy (Cisplatin/Pemetrexed).~After 3 cycles patients will have 1-3 further treatment of pemetrexed and cisplatin without MSCTRAIL."
45622674|NCT03298763|Drug|Placebo|Placebo will be made up of the same material used to cryopreserve the ATIMP (MSCTRAIL) but will not include the active product
45622675|NCT03298685|Other|semi structured interviews for all adolescents and their parent|Before and after transition, individual semi structured interviews will be recorded by one person in the same way in all CF center. And every interview will be transcribed by an other person
45622676|NCT03296189|Drug|Levobupivacaine|intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls
45622677|NCT03296189|Drug|Dexamethasone Sodium Phosphate|intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls levobupivicaine and 2mls dexamethasone
45622678|NCT03296189|Drug|Placebos|10 mls normal saline
45622679|NCT03298607|Dietary Supplement|Placebo|2 months treatment
45622680|NCT03298607|Dietary Supplement|Serelys PMS|2 months treatment
45622681|NCT03298529|Other|glucose solution|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume standard food, a glucose solution at 50%
45764969|NCT03403205|Drug|SoC Therapy|Depending on the site/region, participants randomized to receive SoC treatment will receive trientine, penicillamine, Zinc, or a combination of these medicines, administered according to standard regimens.
45764970|NCT02959359|Drug|Ledipasvir 90mg/Sofosbuvir 400 mg|A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
46069439|NCT00773019|Device|Refills (SynchroMed® II Programmable Drug Infusion Pump)|Refill information at 1, 6, and 12 months post-implant, as well as any additional refills required from implant through end of study. Amount removed from the pump (taken from syringe), Amount placed in the pump (from syringe),Pump predicted amount remaining in the pump.
46069440|NCT00756509|Drug|Nilotinib|800 mg/d orally
46069441|NCT00687115|Behavioral|Weight Loss|liquid diet at 50% of weight maintaining intake
45622682|NCT03298529|Other|Traditional egg pasta|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume traditional pasta, with 8 eggs/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
45622683|NCT03298529|Other|Pasta with eight egg whites/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta, with eight egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
45764971|NCT02959359|Drug|Ribavirin|A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
45622684|NCT03298529|Other|Pasta with four eggs/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta, with four egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
45622685|NCT03298529|Other|Hyperproteic pasta (with added gluten and albumin)|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta with added gluten and albumin.The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
45622686|NCT03298529|Other|Pasta with only four egg whites/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta with four egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
45622687|NCT03296111|Other|Questionnaires on pain and quality of life|"Patients will be asked to complete several questionnaires about their pain and the impact on their quality of life.~They will complete the questionnaires in the ophthalmology consultation room or at home and return it by mail (or present it at the next consultation).~Patients will be asked to complete several questionnaires :~Questionnaire about the characteristics of ocular neuropathic pain (7 items)~DEQ-5 (Dry Eye Questionnaire)~ODI (Ocular Surface Disease Index)~BPI (Brief Pain Inventory)~HADS (Hospital Anxiety and Depression Scale)"
45764972|NCT04375163|Other|Isokinetic intense exercise protocol|The isokinetic protocol included 6 sets of 10 maximum efforts at 60 °/s of one leg with a 2-minute break between the sets.
45764973|NCT04375163|Other|Massage treatment|"Massage consisted of stroking (30) and petrissage (50) for muscle relaxation, then friction (10), pincement and clapping (30) to prepare muscles for the next set."
45622688|NCT03295955|Drug|Amoxicillin Clavulanate|"Per-oral Amoxicillin Clavulanate Given or Non-given, after surgery"
45622689|NCT03298373|Drug|Placebo|Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.
45622690|NCT03298373|Drug|11β-methyl-nortestosterone-dodecylcarbonate|11β-MNTDC doses in castor oil/benzyl benzoate capsules (100 mg each) administered in 200 mg or 400 mg doses orally.
45622691|NCT01670721|Drug|AFLIBERCEPT|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
45764974|NCT04347551|Other|High velocity/low amplitude cervical spine manipulation|The participants will receive a single cervical spine rotary manipulation to the previously identified palpable cervical segmental fixation. During the performance of the manipulation, the supine participant will rest their arms at the sides of their body. Next, the index finger of the chiropractor's contact hand will be placed on the lamina of the restricted cervical segment. The chiropractor will then rotate the participant's head contralaterally until the barrier of the cervical segments volitional end range is reached. The chiropractor's other hand will be placed behind the participant's head to induce gentle neck rotation contralateral to the chiropractor's thrusting hand. The chiropractor will deliver a manual thrust, with the thrust vector directed towards the participant's opposite eye.
45764975|NCT05705661|Device|HIGH FREQUENCY CHEST WALL OSCILLATION|The HFCWO device used a triangular wave form which increases the airflow velocity more than other devices. Therefore, clearing sticky airway mucus and alveolar exudates and maintaining airway patency has become currently the most urgent issue in the ventilatory management of patients with severe COVID-19.
45764976|NCT05705115|Drug|Ringer acetate|Ringer acetate 5 ml/kg.
45764977|NCT05705115|Other|Lower body negative pressure|Lower body negative pressure, 40 mmHg. Experimental hypovolemia.
45912432|NCT02010060|Behavioral|Aerobic Exercise+ Physical Activity|The Aerobic Exercise+ Physical Activity Group will participate in the same supervised exercise training intervention as the Aerobic Exercise Group, but will also increase the amount of non-exercise physical activity in their daily lives. After week 6 of intervention, participants will incrementally increase Non-Ex PA until they reach an average of 3,000 steps/day above baseline. Non-Ex PA will be increased with moderate physical activity consistent with daily living (i.e. leisurely walking in the evening, walking the dog etc.). Participants will also periodically have life-style counseling sessions with instructors with expertise in behavioral change support to their dietary habits
45446599|NCT01582607|Drug|Levobupivacaine plain +fentanyl|2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
45764978|NCT02829034|Drug|Ranolazine|Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.
45622692|NCT01670721|Drug|Irinotecan|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
45622693|NCT01670721|Drug|Fluorouracil|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
45622694|NCT01670721|Drug|Leucovorin|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
45764979|NCT02829034|Drug|Placebo|Placebo by mouth twice per day for a total of 26 weeks
45764980|NCT00924209|Drug|Gemcitabine|1250 mg/m^2 dose for two doses on days 1 and 8
45764981|NCT00924209|Drug|Cisplatin|80 mg/m^2 on day 1
45764982|NCT00924209|Drug|Bevacizumab|7.5 mg/m^2 on day 1 every 21 days for first two cycles only
45764983|NCT00924209|Procedure|Surgery|thoracotomy with lobectomy/pneumonectomy and mediastinal lymph node dissection 4-6 weeks post completion of last cycle of cisplatin
45764984|NCT00924209|Drug|Etoposide|100 mg/m^2 intravenous per day for consecutive 3 days on days 1 to 3 every 3 weeks for 4 cycles.
45764985|NCT05719467|Drug|Buscopan 20 MG/ML Injectable Solution|1 mL intravenously
45764986|NCT05719467|Drug|Sodium bicarbonate|4 g orally
45764987|NCT05719467|Drug|Placebo|4g orally
45764988|NCT05719467|Drug|Nacl 0.9%|1 mL intravenously
45764989|NCT02830438|Device|Shear wave elastography|Ultrasound technique of the kidneys to assess wave elastography.
45764990|NCT03408119|Dietary Supplement|Dried Plum|Dried plum fruit, 100g or 50g depending on treatment group randomized to
45764991|NCT03408119|Dietary Supplement|800 IU vitamin D and 450mg elemental calcium|Supplemental vitamin D and calcium to protect against further bone loss
45764992|NCT03837405|Behavioral|Carbohydrate-restricted diet|Education for carbohydrate-restricted diet
45764993|NCT03837405|Behavioral|Mindfuless|Mindful eating app use plus group sessions to learn mindfulness
45622695|NCT03295877|Drug|RO7171009|Patients will receive RO7171009 via ITV injection.
45452367|NCT00909766|Drug|BMS-830216|Capsules, oral, 1200 mg, once daily, 28 days
45452368|NCT00909766|Drug|BMS-830216|Capsules, Oral, to be determined, once daily, 28 days
45452369|NCT00909766|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
45764994|NCT02832154|Other|Internet-Based Intervention|Complete online PA program
45764995|NCT02832154|Procedure|Quality-of-Life Assessment|Ancillary studies
45764996|NCT02832154|Other|Questionnaire Administration|Ancillary studies
45764997|NCT03405155|Biological|Nivolumab|Given IV
45912433|NCT02010086|Behavioral|Individual Cognitive Behavioral Therapy|Therapists will work with families for 32 weekly sessions, each lasting 90 minutes, implementing the CBT manual for children with ASD (Wood et al., 2007).
45912434|NCT02010086|Behavioral|Standard Community Treatment|In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to provide a standard community therapy treatment.
45912435|NCT02010099|Drug|PP110 Gel|
45912436|NCT02010099|Drug|PP110 Medicated wipes|
45912437|NCT02010099|Drug|Preparation-H Cream|
45912438|NCT02010138|Procedure|small-extent peeling|The internal limiting membrane was peeled in round shape with the radius of 0.75-disc diameter radius (1.5-disc diameter in total) centering at the center of the macular hole.
45912439|NCT02010138|Procedure|large-extent peeling|The internal limiting membrane was peeled in round shape with the radius of 1.5-disc diameter radius (3.0-disc diameter in total) centering at the center of the macular hole.
45912440|NCT02010164|Dietary Supplement|Co-enzyme Q10|600mg for 3 months
45912441|NCT02010242|Drug|GKT137831|1 capsule of 100 mg twice a day for the first 6 weeks of treatment, and 2 capsules of 100 mg twice a day for next 6 weeks of treatment
45912442|NCT02010242|Drug|Placebo|1 capsule of Placebo, twice a day, oral treatment self-administered by the patient for the 12 weeks of treatment.
45912443|NCT02010268|Other|Collection of stool samples|A stool sample will be collected once a week from birth until discharge from the hospital, and every day during digestive episodes, that is to say during an interruption of enteral nutrition for more than 48 hours.
45912444|NCT02010281|Device|rTMS of prefrontal or motor cortex|description:rTMS of the motor or prefrontal cortex (repetitive magnetic stimulation targeting the motor or prefrontal cortex) assisted with neuronavigation
45912445|NCT02010294|Genetic|DNA samples, GAS strains|DNA samples,GAS strains
45912446|NCT02010307|Other|blood extraction|6 ml blood extraction from each patients in all 3 arms of the study
45912447|NCT02010320|Other|Computer dosing|Pharmacokinetic population model for individual dose estimations of tacrolimus based on concentrations measurements and inclusion of relevant covariates
45912448|NCT02010320|Other|Standard dose determination|Tacrolimus dose determination according to trough concentrations and standard TDM at the clinic
45912449|NCT02010346|Procedure|Early headgear treatment|The treatment with headgear is done as early treatment, beginning at ages 7-8 (Arm 1), or later, durning the maximal growth (arm 2)
45912450|NCT02010372|Other|Reminder Recall Report|Practices (administrators) that are randomized to this intervention will receive training in how to run reminder recall reports for patients due to receive any dose of HPV vaccine. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
45446600|NCT02086318|Other|OvAge assessment|Basal serum anti-Mullerian hormone (AMH), Follicle-stimulating hormone (FSH) and Estradiol (E2), antral follicle count (AFC), ovarian volume, Vascularization Index (VI), Flow Index (FI) and Vascularization Flow Index (VFI) will be measured in all women between day 1 and day 4 of menstrual cycle. Evaluation can be repeated after every kind of intervention regarding ovaries, both medical or surgical. Evaluation can be repeated also at interval of 3-6-12 months in order to study the modification of ovarian age when time passes.
45912451|NCT02010372|Other|Audit-Feedback/Immunization Forecasting Reports|Practices (administrators) that are randomized to this intervention will receive training in how to run audit-feedback/immunization forecasting reports for patients due to receive any dose of HPV vaccine and to determine the % of patients in their practice who have received at least one dose of HPV vaccine within the study period. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
45622696|NCT04489043|Other|Exercise and healthy lifestyle recommendations|In the present study, renal transplant patients with proven prediabetes will do a planned exercise programme to test the impact of this treatment on the reversibility of prediabetes. Thus, the persistance of recurrency of prediabetes assessed by an Oral Glucose Tolerant Test (OGTT) at intermediate time points (3, 6 and 9 months) will be checked in order to increase the frequency and duration of aerobic exercise and eventually to add anaerobic/resistance training.
45622697|NCT03063411|Other|Executive Function Intervention|In the executive function training group, children will complete computerised tasks requiring working memory and inhibitory control over four weekly sessions lasting 15-20 minutes. The aim is to improve their executive function skills. In the active control group, children will complete computerised tasks requiring simple decision making and visual search skills over four weekly sessions lasting 15-20 minutes.
45622698|NCT03063411|Other|Active Control Group|This is the active control condition. Children will complete computerised tasks requiring simple decision making and visual search skills over four weekly sessions lasting 15-20 minutes.
45622699|NCT03287427|Drug|TetMYB Vaccine|Weekly intra-dermal injections of either 0.1mg, 0.5mg or 1.0mg on day 1 for week 1 to week 6.
45622700|NCT03287427|Drug|BGB-A317|3 weekly IV injections of 200mg commencing from Week 4.
45622701|NCT04491695|Drug|Tirofiban Hydrochloride|Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion for 71.5 hours.
45622702|NCT04491695|Drug|Oral antiplatelet|Aspirin, clopidogrel or other antiplatelet drugs. Loading dose will be considered if the patients is not on antiplatelet therapy.
45764998|NCT05719389|Drug|CT-P13|CT-P13 is a biosimilar of infliximab approved by EMA since 2015, and it is administered intravenously (i.v.) at a standard dose of 5 mg/kg at week 0, 2, 6 and then every 8 weeks, although the scheduled maintenance regimen can be optimized by administering the drug every 4-6 weeks or increasing the dose up to 10 mg/kg2.The safety profile of CT-P13 SC was comparable to that of CT-P13 i.v.; There were also fewer patients with positive anti-drug antibodies with CT-P13 SC than with CT-P13 i.v.3 At the moment, no data are available on the effectiveness, safety and immunogenicity in a real-world population of patients who have been switched from i.v. to s.c. infliximab.
45764999|NCT04737382|Diagnostic Test|biopsy|The formalin fixed material will be processed for molecular analysis in a clinically validated diagnostic pipeline according to ISO 15189 or other acceptable standard
45765000|NCT04737382|Diagnostic Test|ctDAN analysis|ctDNA analysis will be performed using the AVENIO ctDNA targeted kit according to the guidelines from the manufacturer with respect to isolation, library preparation and bioinformatics analysis.
45912452|NCT02010398|Other|Cross-Training healthy subjects|The phase of intervention will consist of a 6-week cross-training of the stronger limb employing an isokinetic contraction regimen at maximal intensity.
46069442|NCT00687115|Behavioral|Overfeeding|Overfeeding at 150% of weight maintaining intake
46069443|NCT00687115|Behavioral|Overfeeding Low Pro|Overfeeding 150% of normal intake at <5% protein
46069444|NCT00634998|Dietary Supplement|Vitamin C|1000mg Vitamin C capsules orally twice daily
46069445|NCT00634998|Dietary Supplement|Placebo|1000mg Placebo capsules orally twice daily for 90 days
45446601|NCT00149825|Drug|Escitalopram|5 to 20 mg for 12 weeks
45446602|NCT00149825|Behavioral|CBTI|Cognitive Behavioral Treatment for Insomnia
45446603|NCT00149825|Behavioral|CTRL|Control Therapy consists of Pseudo-desensitization Therapy for Insomnia
45622703|NCT04974021|Drug|Ferric carboxymaltose|Intravenous ferric carboxymaltose for the treatment of iron deficiency in HFrEF as per 2016 European Society of Cardiology Heart Failure guidelines.
45622704|NCT05155371|Other|Titration of Optimal Positive End-expiratory Pressure|Titration of Optimal Positive End-expiratory Pressure with two different methods
45765001|NCT04366193|Diagnostic Test|Oximetry|Validation of a high-resolution wireless oximeter for OSA diagnosis comparing with a well established and validated method (home sleep test).
45765002|NCT04374929|Device|StealthTrac Temporary Pacing Lead Plus Negative Pressure Wound Therapy|Following fixation of the StealthTrac Lead, Negative Pressure Wound Therapy is applied over the incision site.
45912453|NCT02010398|Other|Cross-Training multiple sclerosis|The phase of intervention will consist of a 6-week cross-training of the less-impaired limb employing an isokinetic contraction regimen at maximal intensity.
45912454|NCT02010398|Other|Standard-training multiple sclerosis|The phase of intervention will consist of a 6-week standard strength training of the more-impaired limb employing an isokinetic contraction regimen performed at maximal intensity.
45912455|NCT02010411|Drug|Prolastin (drug)|Outcomes compared to saline or no intervention in each subject.
46069446|NCT00628745|Other|None. Observational Study.|
46069447|NCT00539591|Drug|Peginterferon alfa-2b|Given either IV or SQ. Therapeutic drug class: interferon.
46069448|NCT00539591|Drug|Temozolomide|Given PO. Therapeutic drug class: antineoplastic agent.
46069449|NCT00539591|Drug|Recombinant interferon alfa-2b|Given IV. Therapeutic drug classes: antineoplastic agent, immunomodulatory agent, interferon
45622705|NCT04489277|Device|Endovascular Arch Procedures|Endovascular Arch Procedures (TEVAR, Branch endografts, Fenestrated endografts)
45622706|NCT03062397|Drug|JPI-289 Low-dose|JPI-289 Low dose will be intravenously administered during 24 hours
45622707|NCT03062397|Drug|JPI-289 High-dose|JPI-289 High dose will be intravenously administered during 24 hours
45622708|NCT03062397|Drug|Placebo|Same dosage of JPI-289 Low and Hogh dose will be intravenously administered during 24 hours
45622709|NCT03298139|Other|3 levels of gravity (1G, 1.8G, 0G).|healthy volunteers will experience 3 levels of gravity (1G, 1.8G, 0G).
45622710|NCT04982055|Drug|Nadroparin (intravenous Infusion)|Intravenous route of administration over a 4-hours infusion of nadroparin 3800 IU
45446604|NCT04397757|Biological|COVID-19 Convalescent Plasma|2 units of COVID-19 convalescent plasma compatible with their blood type
45622711|NCT04982055|Drug|Nadroparin (subcutaneous group)|Subcutaneous route of administration of nadroparin 3800 IU
45622712|NCT02461277|Other|Fast-track protocol|Preoperatory management, epidural anesthetic management, avoiding the need opioid in postoperatory analgesia and use of an standardized postoperatory management protocol to an early oral intake and early mobilization. At the postoperative recovery room, after extubation and fully awake, patients started physiotherapy exercises, as physical exercises of moving up upper and lower extremities accompanied by deep breathing exercises. After than, the patients standed up beside the bed and if there was no complications, patients performed ambulation. The physiotherapist aided the patients during all period.
45765003|NCT04374929|Device|StealthTrac Temporary Pacing Lead Plus Anti-Inflammatory Glucocorticoid|"• Methylprednisolone 125 mg administered over 30 minutes beginning at least 30 minutes prior to the incision and StealthTrac Lead insertion procedure. This intravenous dose can be repeated every 8 hours on day one of the insertion from 1-3 doses depending on the patient's ability to take oral medications. It can be administered daily thereafter until the patient is able to take oral dosing. In normal circumstances, post op day 2, commence oral glucocorticoid (see below for recommended oral dosing).~Oral (PO) glucocorticoid preparations and dosing:~Prednisone 40-60 mg orally daily based on BMI category. BMI categories: Low (<18); Medium (18-30); High (>30). Low and medium are assigned 40 mg daily. High BMI is assigned 60 mg daily dose. This while the StealthTrac lead remains in place.~Methylprednisolone 16-32 mg daily based on BMI (low, medium and high) while the StealthTrac Lead remains in place."
46069450|NCT00200200|Drug|Bevacizumab HAI plus systemic chemotherapy|Oxaliplatin (mg/m2) IV, over 2 hours, 5 FU (mg/m2) continuous infusion, over two days, leucovorin (mg/m2) IV, over 2 hours
45446605|NCT02792062|Drug|TAK-385 40 mg|TAK-385 40 mg tablet
45446606|NCT02090842|Dietary Supplement|Ca-caseinate|
45446607|NCT02090842|Dietary Supplement|Maltodextrin|
45622713|NCT04982133|Dietary Supplement|Protein supplementation based on plasma urea concentration every other week or human milk analysis on experiment|"At the time that the doctor decides to start fortification, it will be done according to urea levels in active comparator arm or human milk analysis on experimental group.~In Group A, fortification at 4% is started, and according to plasma urea control every 15 days the fortification is modified.~In Group B, fortification is adjusted based on the macronutrient analysis of breast or donated milk."
45622714|NCT03297983|Drug|M7583|Subject will receive either M7583 PiC or M7583 tablet formulation orally under fasted conditions in part 1 followed by M7583 tablet formulation under fed condition in part 2 of the study.
46069451|NCT00200200|Drug|HAI plus systemic chemotherapy|Irinotecan (mg/m2) IV, over 30 minutes, 5 FU (mg/m2) continuous infusion over two days, leucovorin (mg/m2) IV, over 30 minutes
46069452|NCT00106587|Device|PTCA|
46069453|NCT00106587|Combination Product|paclitaxel coated balloon catheter (device with drug)|
46069454|NCT00097474|Drug|Hydrocortisone|Hydrocortisone will be given alone or in combination with Melatonin to see if symptoms of jet lag are alleviated
46069455|NCT00097474|Drug|Melatonin|Melatonin will be given alone or in combination with Hydrocortisone to see if symptoms of jet lag are alleviated
46069456|NCT00097474|Drug|Placebo|Placebo
45622715|NCT04981743|Dietary Supplement|Nigella Sativa capsule twice daily|investigate the safety and efficacy of Nigella Sativa versus Vitamin D3 versus Nigella Sativa / vitamin D3 combination as supplement for management of COVID-19 .
45622716|NCT04441853|Other|YouTube video|Tutoral session on using YouTube personal stories on older people
45622717|NCT04441853|Other|Control|Tutorial session with same content without Youtube video
46069457|NCT02866331|Drug|G-CSF (Leucostim)|
46069458|NCT02866331|Biological|CB (autologous cord blood)|
46069459|NCT02866331|Drug|Placebo (Normal saline)|
45622718|NCT04974255|Other|Measuring of fibrosis in thyroid specimen and measuring of Anti-tTG in serum samples|Examination of pathology specimen and laboratory measuring
45912456|NCT02010437|Drug|Sodium Tetradecyl Sulphate (STS)|
45912457|NCT02010450|Other|Wearable Blanket (Sleep Sack)|
45912458|NCT02010450|Other|Incentive Item|
45912459|NCT02010463|Other|Exercise|
46069460|NCT00694863|Drug|tetracosactide hexacetaat|Intramuscular injections with tetracosactide hexacetaat (Synacthen Depot) 1ml a 1mg/ml. Treatment for 9 months with an increasing dosage from once per 2 weeks to twice a week.
46069461|NCT02868047|Procedure|Endoscopic Ultrasound|Patients will undergo elective upper endoscopic ultrasound to evaluate the pancreas in patients both with and without chronic pancreatitis
46069462|NCT04136301|Other|Informative Video group|Informative Video group before labor in nulliparous women
46069463|NCT04290143|Other|Colored healing water|Patients will be treated with colored healing water for 20 minutes.
46069464|NCT04290143|Other|Placebo treatment (colored tap water)|Patients will be treated with colored tap water for 20 minutes.
46069465|NCT00694941|Drug|ONO-2506PO|1200mg QD / 5 years
46069466|NCT04099823|Other|MRI screening form|Participants will be asked to complete a MRI screening form to check for the presence of metallic implants and materials. People with pacemakers, aneurysm clips, and cochlear implants, or metal/foreign objects in their eyes cannot have an MRI and will not be able to participate in the study.
46069467|NCT04099823|Diagnostic Test|Urine pregnancy test|Pre-menopausal females will be asked if they think they may be pregnant. If yes, a urine pregnancy test will be performed.
45446608|NCT02090842|Dietary Supplement|Whey protein isolate|
45446609|NCT05027295|Drug|riboflavin ophthalmic solution|Administration of riboflavin one drop every 2 minutes during administration of continuous UVA light for 7.5 minutes.
45446610|NCT05027295|Drug|riboflavin ophthalmic solution|Administration of riboflavin one drop every 2 minutes during administration of pulsed UVA light for 15 minutes
45446611|NCT02090920|Drug|Nifedipine|Nifedipine 10 mg immediate release tablet by mouth loading dose Nifedipine administered orally every 15-20 minutes for the first hour to a maximum loading dose of 30 mg, followed by a maintenance dose of 10-20 mg immediate release nifedipine administered orally every 6 hours
45452370|NCT05239234|Other|Inferior vena cava-Aorta diameter index|Before the induction of general anesthesia, inferior vena cava-Aorta diameter index and inferior vena cava collapsibility index will be measured.
45622719|NCT04488809|Other|Exercise|Exercise sessions will include 10 minutes of warming up, 30 minutes of loading, and 10 minutes of cooling down. The exercises will be performed two times in a week for eight weeks.
45622720|NCT03062709|Behavioral|Breathe Easy Coalition written materials|written materials about secondhand and thirdhand environmental smoke exposure in children
45622721|NCT03062709|Behavioral|Maine Tobacco Helpline|referral to tobacco cessation counselor, helpline calls adult referred to provide counseling over the phone.
45622722|NCT03062709|Diagnostic Test|Urine cotinine testing|the child's urine is tested for cotinine, which is produced when the body absorbs nicotine. These results are communicated to the child's parent/guardian.
45622723|NCT03297749|Other|Observational study (no intervention)|No interventions
45622724|NCT04874493|Other|Electronic Health Record Review|Review of medical records
45622725|NCT04874493|Other|Questionnaire Administration|Complete questionnaire
45622726|NCT03297671|Drug|RhIg prophylaxis|Two RhIg prophylaxis injections for Rh negative women
45622727|NCT03297671|Device|ELDONCARD|ELDONCARD point-of-care test.
45452371|NCT05628610|Drug|Tislelizumab|200mg d1, Q3W
45452372|NCT05628610|Radiation|Radiation|Radiotherapy dose: 5,000 c G y / 30f
45622728|NCT03297671|Diagnostic Test|ELDONCARD Test|LHVs will perform ELDONCARD test.
45622729|NCT03295409|Behavioral|Self-affirmation|Participants are asked to complete a standard questionnaire and on the last page they are asked to form a self-affirming implementation intention by copying out a sentence.
45622730|NCT04863027|Radiation|Thoracic radiotherapy|Patients will have pre-treatment and post-treatment perfusion DECT for baseline and post-treatment lung function
45622731|NCT04860843|Drug|Thoracic paravertebral block|Participants will receive a thoracic paravertebral with local anesthetic infiltrate (30ml of 0.35% ropivacaine with 1:400K epinephrine).
45622732|NCT04860843|Drug|Pecs II block|Participants will receive a and a pecs II block with local anesthetic infiltrate (30ml of 0.25% ropivacaine with 1:400K epinephrine).
45622733|NCT04860843|Drug|Sham Pecs II block|Participants will receive a and a pecs II block with saline infiltrate (30ml normal saline; 0.9% NaCl).
45622734|NCT04489121|Drug|Omalizumab|For patients in the Omalizumab group, subcutaneous injections of Omalizumab based on the specific participant's weight and serum total IgE was performed 2 weeks prior the anticipated pollen season.
45622735|NCT04858113|Other|Blephaclean|Blephaclean wipes are used to help treat symptoms of blepharitis (eyelid inflammation) which is commonly associated with dry eye disease and meibomian gland dysfunction.
45622736|NCT04858113|Other|Baby Shampoo|Conventional baby shampoo
45622737|NCT03295253|Procedure|Autologous adipose tissue harvesting/grafting using Lipogems|Adipose tissue harvesting and grafting in the urethra using fat micro-fragmentation and processing device Lipogems
45622738|NCT04981353|Procedure|bilateral erector spinae plane block at T11|A real-time high-frequency linear ultrasound will be used to do the thoracic (ESP) at the level of T11 by visualizing the transverse process of T11 thoracic vertebrae and erector spinae muscle and injecting a 20 ml of bupivacaine 0.25% bilaterally using an in-plane technique, a 20-gauge, 70-mm needle (Tuoren, Henan, China) will be advanced into the plane below (ESM) after injecting lidocaine 1% 2ml at the site of injection, Needle will be advanced with a cranial to caudal directio
45622739|NCT03295175|Diagnostic Test|Hematoxylin-eosin and smooth muscle actin markers|"The foreskin arrives oriented in a single piece in formol to the unit of pathology, and in the pathology unit, they must:~Measure the length, width and thickness of the specimen. The specimen should include skin and mucosa with the underlying areolar tissue.~Examine the surfaces of the sample searching lesions, and describe them in size, appearance (warty, papillary, ulcerated), depth of invasion, and distance from the nearest cutting edge, if they are present."
45622740|NCT04973787|Biological|biological disease-modifying antirheumatic drugs (bDMARDs)|bDMARD therapy (TNF inhibitors), according to the Portuguese recommendations for the use of biological therapies in patients with axSpA and RA
45765004|NCT04374929|Device|Two StealthTrac Temporary Pacing Leads (Increased Electrode Spacing)|"Once the first StealthTrac Lead is placed using the procedure described in the AtaCor Temporary Pacing System Instructions for Use (DOC-10085), load a second StealthTrac Lead into the same MACH I Delivery Tool, unless it was damaged during insertion of the first StealthTrac Lead, in which case a new MACH I Delivery Tool should be used.~Insert the second StealthTrac Lead through (1) a different intercostal muscle path within the same intercostal space or (2) within an adjacent intercostal space. Increased electrode spacing is achieved by pacing between the leads."
45765005|NCT04374929|Device|StealthTrac Lead Only (Control)|A single StealthTrac Lead is placed with no additional treatment.
45765006|NCT05717361|Drug|ketamine-lidocaine|"In the KL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine at predefined concentrations.~As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution"
45622741|NCT03297515|Dietary Supplement|Madeos|Arm 1: Omega 3
45622742|NCT03297515|Dietary Supplement|Placebo|Arm 2 : Placebo
45622743|NCT04973865|Other|Validation & reliability|Translated version of IPAQ(SF) validation & Reliability
45622744|NCT03295097|Other|Clinical Decision Support System|The system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions. This clinical decision support system should improve the clinician's ability to identify the optimal pain medication and dosage, and reduce risks associated with multi-drug treatment.
45622745|NCT04973943|Diagnostic Test|Donor-derived cell Free DNA|Measurement of dd-cfDNA and comparison against grade of rejection as determined by endomyocardial biopsy, taken simultaneously
45622746|NCT03297437|Other|Neurofeedback training|In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.
45622747|NCT04982211|Drug|Propranolol|Oral propranolol hydrochloride capsules, dosed per participant weight
45622748|NCT04982211|Drug|Placebo|Oral placebo capsules, dosed per participant weight
45622749|NCT03295019|Device|Test Oral Spray|HA formulation of FDA listed ingredients
45622750|NCT03295019|Device|Placebo Oral Spray|Placebo formulation without the active ingredients
45622751|NCT03242889|Drug|DARA SC|Participants will receive 1800 mg daratumumab with 30,000 U (2000 U/mL) rHuPH20 SC injection once weekly for the first 8 weeks in Cycles 1 and 2 and every 2 weeks in Cycles 3 to 6 for 16 weeks and then every 4 weeks in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation.
45622752|NCT04488731|Behavioral|Normal BMI and moderate coffee consumption|Normal BMI and moderate coffee consumption
45622753|NCT04488731|Behavioral|Normal BMI and heavy coffee consumption|Normal BMI and heavy coffee consumption
45622754|NCT04488731|Behavioral|overweight and moderate coffee consumption|overweight and moderate coffee consumption
45622755|NCT04488731|Behavioral|overweight and heavy coffee consumption|overweight and heavy coffee consumption
45622756|NCT03290963|Drug|Lithium|Lithium will be dosed in units (LI level > or = 0.4 milliequivalents (mEq)/L)
45622757|NCT03290963|Drug|Placebo|Placebo tablets, dosed in units
45622758|NCT03290963|Drug|Ketamine|All subjects will receive 3 IV ketamine infusions of 0.5mg/kg, over 100 min. over 7 days.
45622759|NCT03062553|Behavioral|Metacognitive Training (MCT)|MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions.
45622760|NCT03062553|Behavioral|Sham/MCT|"The Sham/MCT group will include application of random patterns of low-grade currents to the same brain region as the neuromodulation condition.~MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions."
45765007|NCT05717361|Drug|Remifentanil|In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
45622761|NCT03062553|Device|transcranial alternating current stimulation (tACS)|tACS is a non-invasive brain stimulation technique in which a weak electrical current is applied to the head. The current passing through the brain produces small changes in the excitability of the brain regions falling within the current flow. The current occur in an alternating manner (University of California-Berkeley, 2015).
45765008|NCT02951884|Procedure|Aspiration|A needle is placed into the knee joint and all of the blood that is in the joint is removed.
45765009|NCT02951884|Drug|Bupivacaine|An injection of 20cc bupivacaine 0.5% with 1:200,00 epinephrine
45765010|NCT05701683|Drug|Lactobacillus Reuteri Probiotic|Experimental group receiving Lactobacillus Reuteri Probiotic with sequential therapy
45765011|NCT05700591|Drug|rhPro-UK|35 mg, administered intravenously with a bolus of 15 mg within 3 minutes and the remainder by continuous infusion within 30 minutes
45765012|NCT05700591|Drug|rt-PA|0.9 mg/kg (maximum 90 mg), with 10% administered intravenously as a bolus, followed by 90% infusion within 1 hour
45765013|NCT03021538|Device|Extracorporeal Membrane Oxygenation|ECMO is used during lung transplant procedure
45765014|NCT03021538|Device|Cardiopulmonary Bypass|CPB is used during lung transplant procedure
45765015|NCT05699967|Other|data collection|Participants wear a wristband with a Photoplethysmography (PPG), heart rate and respiratory rate sensor continuously for 3 days. Once gateway and device are linked, all data will be transmitted continuously via Bluetooth to an in-house database. The Device Hub allows to control data availability and signal quality of the wearables, but no scores will be calculated and visualized. The data obtained for calculating the NEWS2 is solely observational and for the study staff. It has no clinical consequence on the treatment of the patient. It is analyzed whether the score with values form the wearables and Electronic Health Record (EHR) corresponds to the conventionally calculated NEWS2 score with values coming only from the EHR.
45446612|NCT01562535|Other|Pronation|"In this technique the arm is flexed 90 degrees and a gentle pronation is applied to the arm; then the arm is further flexed to 45 degrees until the clinician feels a click in the elbow meaning the re-accommodation of the radial head has been accomplished."
45765016|NCT00374374|Behavioral|Administration of probiotic|
45765017|NCT02834806|Device|BioNIR Ridaforolimus Eluting Coronary Stent System|BioNIR Ridaforolimus eluting coronary stent system with modified delivery system
45765018|NCT02835274|Device|BSC Deep Brain Stimulation System with Directional Lead|
45765019|NCT05577663|Other|Routine treatment of the extraction socket|Suturing of the extraction socket with resorbable suture PGA 5/0 in order to protect the blood clot
45765020|NCT05577663|Procedure|Socket seal technique by a free gingival graft|Placement of a free gingival graft in the socket opening in order to protect and stabilize the blood clot followed by suturing
45765021|NCT05577663|Procedure|Socket seal technique using a synthetic resorbable membrane|Placement of a synthetic barrier in the socket opening in order to protect and stabilize the blood clot followed by suturing
45765022|NCT02836990|Device|Prevena Incision Management System|A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections
45765023|NCT02836990|Device|Dermabond|A surgical skin adhesive used to prevent surgical wound infections
45765024|NCT05697393|Device|Shaker Pressure Band|
45446613|NCT01562535|Other|Supination|"The affected arm is in a 90 degrees flexion. The clinician will hold the arm by the elbow and then makes a gentle supination of the affected arm and flexion of the elbow until feeling the click and the child is able to move the arm without pain."
45446614|NCT02091076|Device|Silk fibroin with bioactive coating layer dressing|
45446615|NCT02091076|Device|Bactigras wound dressing|
45452373|NCT05628610|Drug|Paclitaxel|Paclitaxel: 150mg / m2 ,d1, q3w
45452374|NCT05628610|Drug|Platinum: cisplatin, carboplatin, naidaplatin and other platinum drugs|cisplatin, carboplatin, naidaplatin and other platinum drugs
45446616|NCT03747471|Behavioral|Diabetic Conversation Map|"Diabetic Conversation Map education tools are a series of tools for facilitated group education 5-8that were developed by Healthy Interactions in collaboration with the International Diabetes Federation (IDF) and are sponsored by Lilly Diabetes.~CM-based education guides people with diabetes through a process with the aim of helping them understand and internalize information about their disease and generate insightful conclusions, which may then result in improved self-management decisions and actions."
45446617|NCT02086396|Dietary Supplement|pumpkin seed flour|The pumpkin seed flour group received 20g/day of pumpkin seed flour during 12 weeks
45446618|NCT02086396|Dietary Supplement|Placebo (cassava flavored flour)|The group placebo (cassava flour flavored) received 20g/day of cassava flour flavored during 12 weeks.
45446619|NCT03558100|Behavioral|Obstacle crossing intervention for adults with obesity|The obstacle crossing intervention will be done for reducing falls risks in obesity. The intervention will provide gait practice to individuals with obesity who are eligible for and prior to weight loss surgery.
45446620|NCT02086474|Drug|Hyaluronan|Intra-articular injection
45622762|NCT03294785|Procedure|Chuna manual therapy|Chuna is a Korean manual therapy that has absorbed and incorporated aspects of osteopathic manipulative medicine. Chuna manual therapy utilizes spinal manipulation techniques for joint mobilization including high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement, muscle energy, and fascial techniques.
45622763|NCT03294785|Drug|Conventional medication|Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of cervical sprain/strain group, cervical disc disorder with radiculopathy group, or cervicalgia according to Korean Health Insurance Review and Assessment (HIRA) 2014 statistics.
45622764|NCT03294785|Procedure|Physical therapy|Physical therapy will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of cervical sprain/strain group, cervical disc disorder with radiculopathy group, or cervicalgia according to Korean Health Insurance Review and Assessment (HIRA) 2014 statistics.
45622765|NCT03290885|Combination Product|Combined contact aspiration/Stent Retriever Technique|Combined contact aspiration/SR is performed using a balloon-guide catheter (BGC). A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch micro-wire inside is introduced into a large-bore aspiration catheter and this construct is introduced into BGC. The BGC is placed into the origin of the cervical internal carotid artery (ICA). The catheter is advanced past the thrombus over the micro-wire to allow the SR deployment. The SR is deployed across the occlusion. Then the large bore distal access catheter is advanced to contact the proximal edge of the SR. The aspiration pump is connected to the large bore distal access catheter. After at least 90 sec, the SR and the large bore distal access catheter are pulled out as an unit from the BGC and the patient. Manual aspiration is also be applied to the BGC during the pull-out manoeuver which is performed after the temporary inflation of the balloon at the tip of the BGC to ensure flow arrest into the carotid
45622766|NCT03290885|Device|Stent retriever technique|"The technique used should be in accordance with the device instruction for use. A large bore balloon guide catheter has to be placed into the cervical ICA.~A suitable delivery microcatheter is navigated over a micro-wire into the occluded major coronary artery MCA and across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent retriever device is then deployed across the occlusion.~After at least 90 seconds, removal should occur with proximal occlusion by inflation of the balloon guide catheter."
45622767|NCT03062475|Behavioral|lifestyle intervention with dietary and exercise recommendation|"With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake.For example we suggested exchanging carbohydrate-rich foods with a medium-to-high glycaemic index for those with a lower glycaemic index to reduce the glycaemic load, and restricting dietary intake of saturated fat.~With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed, or encourage them to do moderate cycling during pregnancy."
45622768|NCT03290807|Device|SPECT/CT|Combined single photon emission computerized tomography and conventional computerized tomography (SPECT/CT) is a hybrid imaging modality, which combines a 3D bone scintigraphy (SPECT) and a conventional CT into one imaging procedure. The use of SPECT/CT offers the benefit of combined anatomical, mechanical (CT) and functional imaging (SPECT)
45765025|NCT02841046|Device|cardiac index|group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group cardiac index with CI as the primary judgment.
46069468|NCT04099823|Diagnostic Test|MR brain|"You will be asked to lie down on the bed of the MRI scanner. Then a MRI coil/antenna will be placed over your head. This will allow us to get clearer pictures of the tissue of interest. The MRI machine makes loud knocking sounds. Because of this you will be asked to wear earplugs. You will receive a squeeze ball alarm in case you need urgent help. We will be able to talk with you and hear you during the MRI exam. The entire MRI scan will last about 45-60 minutes. The MR exam will include standard clinical images as well as the CSF flow imaging."
46069469|NCT00629213|Drug|acarbose|
46069470|NCT00629213|Drug|placebo|
46069471|NCT00978341|Drug|Pregabalin|Pregabalin 150mg capsules BID for 7.5 days
45446621|NCT02086474|Drug|Bupivacaine|Extra-capsular injection
45446622|NCT05280483|Drug|ABSK021 with fed state|25 mg ABSK021 (1x25 mg ABSK021 capsule) with food
45446623|NCT05280483|Drug|ABSK021 with fasted state|25 mg ABSK021 (1x25 mg ABSK021 capsule) without food
45446624|NCT03749577|Dietary Supplement|L-citrulline|L-citrulline 9g per day (capsule, per os) during 14 days;
45446625|NCT03749577|Dietary Supplement|Beetroot juice|Concentrated 70 ml beetroot juice bottles containing 6.45 mmol of nitrates
45446626|NCT03749577|Dietary Supplement|L-citrulline placebo|L-citrulline placebo (maltodextrin) 9g per day (capsule, per os) during 14 days
45446627|NCT03749577|Dietary Supplement|Denitrated beetroot juice|Concentrated 70 ml nitrate-depleted beetroot juice
45446628|NCT02088268|Other|wound healing|wound healing
45446629|NCT02091310|Drug|Placebo|
45446630|NCT02091310|Drug|GFT505|
45446631|NCT02091310|Drug|Moxifloxacin 400 mg|
45446632|NCT02621398|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT or IMRT
45446633|NCT02621398|Drug|Carboplatin|Given IV
45622769|NCT04980963|Behavioral|Cognitive Support Technology (CST)|Cognitive Support Technology (CST) products and strategies are used to help people with disabilities compensate for or accommodate cognitive limitations (including those related to interpersonal communication and social cognition) that present difficulties for them in the performance of desired social roles, especially education and employment. CSTs may be mainstream everyday technologies such as tablet computers or they may be specialized devices designed for specific goals such as step-by-step instruction in the performance of a particular task (Scherer, 2012).
45622770|NCT03290729|Procedure|wedge shape implants insertion|Narrow dental implants inserted in narrow ridges
45622771|NCT04980729|Device|Acetabular reconstruction after tumor resection.|In the template-guided group (n = 10), a navigation template was designed and applied to assist acetabular reconstruction. In the traditional operation group (n = 14), the patients underwent the same surgery but without the navigation template. To compare the displacement of the hip rotation center before and after surgery between the two groups, an innovative method based on pelvic CT was developed and a validation group of cases was used to assess the effectiveness of this measurement approach. In the validation group (n = 12), patients undergoing periacetabular puncture or curettage without hip joint reconstruction were included. The displacements for the validation group were calculated and compared with 0 cm, the theoretical value. Subsequently, the displacements between the template-guided group and the traditional operation group were compared.
45622772|NCT03294707|Drug|AG10 oral tablet|Active single ascending dose
45622773|NCT03294707|Drug|Placebo Oral Tablet|Placebo single dose
45622774|NCT04973475|Drug|Indocyanine Green|Laparoscopic distal gastrectomy with lymph node dissection for early gastric cancer using Indocyanine Green Tracer
45622775|NCT04371809|Other|DNA methylome|Epigenomics tools combined with bioinformatic analysis to find and correlate putative useful clinical biomarkers with clinical features
45622776|NCT03062319|Drug|Oral Anticoagulant|warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban
46069472|NCT00978341|Drug|Placebo for pregabalin|Placebo capsules BID for 7.5 days
45622777|NCT03062319|Drug|Antiplatelet Drug|aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol
45622778|NCT04488965|Other|Autologous transplant|Autologous transplant obtained from cortical biopsy
45622779|NCT04980261|Procedure|ORIF + autograft|Patients will undergo a standard open reduction internal fixation (ORIF) procedure with autograft implantation (from the iliac crest).
45622780|NCT04980261|Procedure|ORIF + FD BHA/Secretome|Patients will undergo an ORIF procedure and subsequently receive freeze-dried bovine hydroxyapatite/secretome composite implantation.
45622781|NCT03290573|Device|short peripheral venous catheter|short peripheral venous catheter for infusion therapy in adult patients
45622782|NCT03061383|Other|8% Arginine based toothpaste|toothpaste
45622783|NCT03061383|Other|8% strontium acetate based toothpaste|toothpaste
45622784|NCT03061383|Other|placebo|toothpaste
46069473|NCT00695331|Drug|Misoprostol|Titrated Misoprostol Solution
46069474|NCT00695331|Drug|Oxytocin|Titrated Intravenous Oxytocin
46069475|NCT00695487|Drug|THC 9-d-tetra hydro cannabinol|0.125mg/kg iv one time
45446634|NCT02621398|Radiation|Intensity-Modulated Radiation Therapy|Undergo 3D-CRT or IMRT
46069476|NCT00695643|Drug|Mesalazine|3 g per day
46069477|NCT00695643|Drug|Placebo|0 g per day
45622785|NCT03290495|Drug|ketamine|ketamine hydrochloride 250microgram/ ml for iv injection after 30 minutes of stable isoflurane anesthesia
45622786|NCT03290495|Drug|saline|a similar volume of normal saline 0.9% for intravenous injection instead of ketamine will be given to the control group. this because the attending anesthesiologist will be blinded to the study drugs and aim according to the study proposal.
45622787|NCT04429893|Drug|magnesium sulphate|assess the pain intensity of magnesium sulphate as an adjuvant to bupivacaine in serratus anterior plane block for modified radical mastectomy
45622788|NCT04429893|Drug|bupivicaine|assess the pain intensity of magnesium sulphate as an adjuvant to bupivacaine in serratus anterior plane block for modified radical mastectomy
45622789|NCT03290417|Dietary Supplement|Vitamin D|5000 IU/cap; One cap by mouth daily
45622790|NCT03290417|Dietary Supplement|Omega-3|720 mg/cap; one capsule by mouth 3 times per day
45622791|NCT03290417|Dietary Supplement|Turmeric|250mg/cap; two capsules by mouth 4 times per day
46069478|NCT02624349|Drug|Quadravalent human papillomavirus vaccine|Vaccine will be administered to all transplant recipients. Controls will be recruited based on previous documented receipt of vaccine
46069479|NCT02624271|Other|blood samples analysis|Analyze blood samples with GastroPanel test to detect gastric precancerous lesions.
46069480|NCT00695877|Biological|Ad5.ENVA.48 HIV-1 vaccine|Recombinant adenovirus serotype 5 HIV-1 vaccine
46069481|NCT00978029|Drug|Placebo|Placebo sublingual tablet, once daily
46069482|NCT00978029|Biological|SCH 39641|Allergy immunotherapy tablet (sublingual)
46069483|NCT00978029|Biological|SCH 39641|Allergy immunotherapy tablet (sublingual)
45446635|NCT02621398|Other|Laboratory Biomarker Analysis|Correlative studies
45622792|NCT04429347|Drug|Gabapentin|Friday night: 1 capsule of 300 mg, Saturday night: 2 capsule of 300 mg (total 600 mg), Sunday night: choice of 1 or 2 capsule of 300 mg (total of 300 or 600 mg)
45622793|NCT04429347|Drug|Placebo|Friday night: 1 capsule, Saturday night: 2 capsule, Sunday night: choice of 1 or 2 capsules
45622794|NCT04429347|Drug|Tizanidine|Friday night: 1 capsule of 2 mg, Saturday night: 2 capsule of 2 mg (total 4 mg), Sunday night: choice of 1 or 2 capsules of 2 mg (total of 2 or 4 mg)
45622795|NCT03294551|Behavioral|HPV Vaccine Reminder Recall - Autodialer|Investigators will send out HPV vaccine reminder recall notices via autodialer message to the parents of adolescents 11-14 years of age who are eligible to receive a dose of the HPV vaccine per the records in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of the various modalities or reminders as compared to the standard of care control (no reminders)
45622796|NCT03294551|Behavioral|HPV Vaccine Reminder Recall - Texting|Investigators will send out HPV vaccine reminder recall notices via text message to the parents of adolescents 11-14 years of age who are eligible to receive a dose of the HPV vaccine per the records in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of the various modalities or reminders as compared to the standard of care control (no reminders)
45622797|NCT04156581|Drug|Bupivacaine|Bupivacaine is administered typically to reduce sensation in an area. It acts as a nerve block for surgical procedures.
45622798|NCT04156581|Drug|Dexamethasone|Dexamethasone is a corticosteroid that reduces inflammation.
45622799|NCT04156581|Other|Saline|Saline is a mixture of NaCl and water that can be used as a placebo.
45622800|NCT03294473|Behavioral|R/R - Autodialers|Investigators will send out flu vaccine reminder recall notices via autodialer message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
45622801|NCT03294473|Behavioral|R/R - Texting|Investigators will send out flu vaccine reminder recall notices via text message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
45622802|NCT03294473|Behavioral|R/R - mailed postcard|Investigators will send out flu vaccine reminder recall notices via mailed postcards to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
45622803|NCT02983071|Drug|G1T38|
45622804|NCT02983071|Drug|Fulvestrant|
46069484|NCT02624193|Behavioral|MBSR Program|Mindfulness-based stress reduction, as described previously.
45622805|NCT03294395|Drug|Ertapenem 1000 MG|single dose 1000mg intramuscular injection
46069485|NCT02624193|Behavioral|HT Program|Health education curriculum, as described previously
46069486|NCT02624037|Other|Individualized Dosage Precision IFX Dashboard|Pharmacokinetic Dashboard Recommended Dosage and Dosing Frequency of Infliximab
45622806|NCT03294395|Drug|Fosfomycin Oral Suspension|single dose 6g oral suspension
45622807|NCT03294395|Drug|Gentamicin Sulfate, Injectable|single dose 5mg/kg (maximum 400mg) intramuscular injection
45622808|NCT03294395|Drug|Ceftriaxone|single dose 500mg intramuscular injection
46069487|NCT02623881|Device|Cervical pessary|Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
46069488|NCT02623881|Drug|Vaginal progesterone|Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
46069489|NCT04135833|Drug|BPI-7711|BPI-7711 60 mg
46069490|NCT04135833|Drug|BPI-7711|BPI-7711 180 mg
46069491|NCT04135833|Drug|Itraconazole|Itraconazole 200 mg
45446636|NCT02621398|Drug|Paclitaxel|Given IV
45446637|NCT02621398|Biological|Pembrolizumab|Given IV
45446638|NCT00196937|Biological|Cervarix|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
45446639|NCT04397445|Drug|Ranitidine|Ranitidine 300 mg
45446640|NCT04397445|Drug|Placebo|Oral placebo tablet
46069492|NCT04135833|Drug|Rifampicin|Rifampicin 600 mg
46069493|NCT00696033|Drug|Diazepam|Diazépam drug (0,3 mg/kg) on a single oral intake
46069494|NCT00696033|Drug|Lorazepam|Lorazépam drug (0,038 mg/kg) on a single oral intake
46069495|NCT00696033|Drug|placebo|lorazépam placebo or Diazépam placebo
45622809|NCT03061461|Device|rESWT|"All patients will receive standard care as follows:~Wounds will be cleaned with distilled water and applied with collagen gel or collagen sheet on the wound and then closed with foam/gauze or gamgee.~The clean wounds will be assessed using the TIME concept.~Treatment with rESWT.~Subsequently the wounds will be cleansed with distilled water, and collagen and glycerine gel will be applied and covered with adhesive dressings (Melolin, Smith & Nephew, Inc. Advanced Wound Management; Fort Worth, TX, USA).~In addition, patients in arm rESWT will receive rESWT between Steps 2 and 3 of standard care as outlined in arm description rESWT."
45622810|NCT03061461|Device|Sham rESWT|"All patients will receive standard care as follows:~Wounds will be cleaned with distilled water and applied with collagen gel or collagen sheet on the wound and then closed with foam/gauze or gamgee.~The clean wounds will be assessed using the TIME concept.~Treatment with sham rESWT.~Subsequently the wounds will be cleansed with distilled water, and collagen and glycerine gel will be applied and covered with adhesive dressings (Melolin).~In addition, patients in arm Sham rESWT will receive sham rESWT between Steps 2 and 3 of standard care as outlined in arm description Sham rESWT."
45622811|NCT03290339|Procedure|hysterectomy|laparoscopic hysterectomy and vaginal hysterectomy
45622812|NCT03061617|Other|VCV mode|set fixed 6ml/kg tide volume
45622813|NCT03061617|Other|PCV mode|adjust pressure to achieve tide volume of 6ml/kg
45622814|NCT04488887|Diagnostic Test|Optical coherence tomography angiography|patients in all groups will be examined with optical coherence tomography angiography, for every eye 3 macular and 3 papillary scans will be performed by two different OCTA machines, analysis will be carried out to evaluate the repeatability and reproducibility of the test
45622815|NCT04980183|Device|Arthroscopic surgical robot|The surgeon performs cruciate ligament bone canal positioning and ligament reconstruction with the assistance of an arthroscopic surgical robot
45622816|NCT04980183|Device|Conventional arthroscopic cruciate ligament reconstruction|The surgeon performs conventional arthroscopic cruciate ligament reconstruction surgery without other auxiliary equipment
45622817|NCT03294239|Procedure|Transurethral extraction of bladder stone(s)|Patients will have transurethral approach for management of their bladder stones. Either pneumatic or Holmium:YAG laser will be used for stone distentegration. Stone basket and/or Elics current evacuation will be used to retrieve stone fragments. Urethral catheter will be applied for 48 hours.
45622818|NCT03294239|Procedure|percutaneous extraction of bladder stone(s)|Patients will have percutaneous approach for management of their bladder stones. After initial cystoscopy a Foley's urethral catheter will be fixed for continuous irrigation. Then, the bladder will be filled to capacity with normal saline. Access to the distended bladder will be obtained by 10-gauge needle in the midline 1-2 cm above the pubic bone. Once suitable placement is confirmed with return of fluid, a guide wire will be passed through the needle into the bladder. Dilatation will be done using 8-10 Fr coaxial dilators then single fascial dilator with placement of 16 Fr Amplatz sheath as a working tract. No ultrasonic or fluoroscopic guidance will be used. Stone basket will be used to extract the stone. If the stones were larger than the used sheath, disintegration will be performed with a pneumatic lithotrite. Primary skin closure of the suprapubic stab wound by one stitch will be done and the urethral catheter will remain for 48 hours.
45765026|NCT02841046|Device|Stroke Volume Variation|group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group Stroke Volume Variation with the combination of SVV and CI as the primary judgment.
45765027|NCT05717127|Behavioral|Time restricted feeding|Restricted feeding with 20 hours of fasting and a 4 hour window of feeding (between 4 and 8 PM or between 5 to 9 PM).
45765028|NCT05717127|Behavioral|Standard lifestyle|Standard lifestyle recommendations
46069496|NCT02623647|Radiation|stereotactic body radiotherapy SBRT|40 Gy in 3 fractions to the prostate gland delivered with stereotactic body radiotherapy
46069497|NCT00871377|Drug|Placebo|corn oil (n-6 fatty acids)
46069498|NCT00871377|Drug|High Dose Fish Oil|n-3 fatty acids, 1060 mg EPA + DHA
45446641|NCT04397445|Other|Low nitrite/NDMA meals|Meals containing low levels of nitrites and NDMA
46069499|NCT00871377|Drug|Low Dose Fish Oil|n-3 fatty acids, 2160 mg EPA + DHA
46069500|NCT02623569|Drug|Ivabradine|Not Provided
45446642|NCT04397445|Other|High nitrite/NDMA meals|Meals containing higher levels of nitrites and NDMA
45446643|NCT02091388|Drug|LY03004|
45446644|NCT02091388|Drug|Risperdal® Consta®|
45622819|NCT04973007|Drug|Gadoxetate disodium|Gadoxetate disodium is now mainly used for the purpose of HBP liver MR imaging to save MR scanner time and total examination time.
45622820|NCT04973007|Drug|Gadobenate dimeglumine|The most commonly used MR contrast agent in abdominal imaging is gadobenate dimeglumine, which has mainly the characteristics of an extracellular agent used for most indications of MR examinations.
45622821|NCT03290183|Device|Confocal laser endomicroscopy|Real-time microscopic imaging technique
45446645|NCT02088346|Other|Telemedicine consultation system|Telemedicine consultation system based on portable hardwares
45446646|NCT02086942|Drug|Bortezomib|Induction therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,4 cycle Intensive therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,5 cycles.
45446647|NCT02086942|Drug|cyclophosphamide|Induction therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,4 cycles. Intensive therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,5 cycles. Maintenance treatment with CP: 200mg PO Days 1-14 of each 28 day cycles,12 cycles.
45622822|NCT04980105|Biological|Platelet-rich plasma|Two intra-articular injections of autologous platelets-rich plasma (PRP) in two weeks intervals between the first and the second injection.
45622823|NCT04980105|Drug|Hyaluronic acid|Two intraarticular injections of hyaluronic acid (60 mg) in two weeks intervals between the first and the second injection
45622824|NCT04980105|Drug|Methylprednisolone acetate injectable suspension (DEPO-MEDROL®)|Single methylprednisolone acetate intraarticular injection (DEPO-MEDROL® pfizer 80 mg) mixed with 3cc of (xylocaine 2% concentration)
45622825|NCT04973319|Drug|Pyrotinib|Each subject in the test group will receive the test drug (pyrotinib) for 52 weeks, and will be followed up for at least 3 years from the start of randomization, until disease recurrence, intolerable toxicity, withdrawal of informed consent, or termination of the medication as per the investigator's judgment.
45622826|NCT04973319|Drug|Trastuzumab|Each enrolled subject will complete at least ≥ 24 weeks (8 drug delivery cycles) of trastuzumab combined with pertuzumab in the neoadjuvant and/or adjuvant treatment phase.
45622827|NCT03294161|Drug|Immucillin DI4G|Immucillin DI4G was administered by topical use at 2% concentration once a day for 20 days associated with Meglumine antimoniate administered by intravenous route at a dosage of 20mg/kg/day, during 20 days.
45622828|NCT03294161|Drug|Meglumine antimoniate|Placebo for topical use once a day at the ulcer for 20 days associated with Meglumine antimoniate administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
45622829|NCT04973241|Radiation|OPG & CBCT|panoramic images , cone beam computed tomography
45622830|NCT03294005|Diagnostic Test|Thyroid ultrasonography|Each subject had been transverse and longitudinal views of thyroid ultrasonography with high-resolution ultrasound (7-14 MHz) (HP Image Point-HS, Toshiba SSA250, GE ,Aloka SSD-1200 and Siemens S2000) that was performed by our partners - endocrinologist in all patients.
45622831|NCT03289871|Device|Excilor|
45622832|NCT03289871|Drug|Loceryl 5%|
45622833|NCT04979715|Procedure|physitherapy follow-up|preoperative patient informaiton, information leaflet and Physiotherapy meeting will be held every 2 weeks for 3 months
45765029|NCT05694273|Procedure|Radiofrequency catheter ablation|Catheter ablation has traditionally been used primarily in isolated Supraventricular tachycardias (SVT), atrioventricular nodal reentry tachycardias (AVNRT) are the most common paroxysmal SVTS. In recent years, the pathophysiological understanding of SVTS and catheter ablation have steadily advanced. Radiofrequency catheter ablation currently dominates AVNRT due to the high recurrence rate after cryoablation.
45765030|NCT05716971|Procedure|Densiron-68 (heavy silicone oil) tamponade for retinal detachment|pars plana vitrectomy using Densiron-68 at thee end of surgery
45446648|NCT02086942|Drug|Dexamethasone|Induction therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,4 cycles Intensive therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,5 cycles.
45622834|NCT04979715|Other|control|no intervention; preoperative patient informaiton and information leaflet
45622835|NCT03289793|Other|Neurofeedback training|"Children in group A will receive BCI-based training implemented through original P300-based controlled games.~They will attend 30 1-hour long training sessions at a pace of 2 sessions per week.~Each session includes: installation of the child, the EEG system and an eye-tracking system, a 5-minutes relaxation phase, a short EEG recording at rest, a brief reminder of the instructions, 30 minutes of training by playing video games and finally a time for the child to wash her/his hair.~Moreover, 4 neuropsychological sessions will complement the 30 training sessions. During these sessions neuropsychological tests and quality of life questionnaires will be answered."
45765031|NCT03022396|Biological|High Dose Fluzone® (intramuscular)|Licensed seasonal High dose trivalent inactivated influenza
46069501|NCT02623569|Drug|Atenolol|Not Provided
45765032|NCT03022396|Biological|Fluzone® (intramuscular)|Licensed seasonal trivalent inactivated influenza
46069502|NCT02623491|Drug|JNJ-55375515|Participants will receive JNJ-55375515 at a starting dose of 0.75 milligrams (mg) and maximum escalated dose will be 200 mg.
46069503|NCT02623491|Drug|Placebo|Participants will receive matching placebo.
46069504|NCT00977561|Drug|figitumumab|Figitumumab (20 mg/kg)
46069505|NCT00977561|Drug|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
46069506|NCT00977561|Drug|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
46069507|NCT00977561|Drug|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
46069508|NCT00977561|Drug|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
46069509|NCT04291313|Dietary Supplement|Vitamin D3 (90µg)|The intervention is a higher dose of vitamin D than what is currently recommended to Danish pregnant women
46069510|NCT04291313|Dietary Supplement|Vitamin D3 (10µg)|This intervention serves as a control as they get the current recommended vitamin D dose
45446649|NCT02088424|Other|insulin resistance(fasting glucose/fasting insulin)|insulin resistance(fasting glucose/fasting insulin )
45446650|NCT02091544|Other|Lifestyle intervention|
45446651|NCT00191945|Drug|Atomoxetine Hydrochloride|
45446652|NCT00191945|Drug|placebo|
45446653|NCT02091622|Other|Educative intervention|Two municipalities (in charge of nursing homes) and two hospitals were randomized to receive an interactive half-day course about ITEOL for physicians and nurses.
45446654|NCT02091700|Other|Indocyanine Green ICG|
45622836|NCT03289793|Other|Active Sham control|"Children in group B will receive a training that is not based on brain activity, but in a blind fashion. They will attend 30 1-hour long training sessions at a pace of 2 sessions per week.~Each session includes: installation of the child, setting up the EEG and eye-tracking systems, a 5-minutes relaxation phase, short EEG recording at rest, a brief reminder of the instructions, 30 minutes of video game based training and finally a time for the child to wash her/his hair.~Besides, 4 neuropsychological sessions will complement the 30 training sessions. During these sessions neuropsychological tests and quality of life questionnaires will be performed."
45622837|NCT03289793|Other|Baseline control group|The children included in this group will not receive any training. They only take part to the 4 neuropsychological sessions. Like others, they will attend 1 neuropsychological session every two months over six months.
45622838|NCT04972851|Behavioral|Self-Determined Learning Model of Instruction (SDLMI)|"SDLMI is a teaching model that enables providers to teach students to:~make choices and decisions about setting a goal~develop action plans for academic or other goals~self-monitor and self-evaluate progress toward goal attainment~adjust the goal or plan"
46069511|NCT02866253|Drug|DHEA|Interventional patients should take DHEA 25mg tid 12weeks before enter the IVF cycle.
46069512|NCT04080479|Diagnostic Test|Quadriceps Muscle Layer Fitness|The QMLF examination will be performed in all study subjects, with both bolus and continuous enteral feeding.
46069513|NCT04080479|Diagnostic Test|Muscle Strength|All study subjects, with both bolus and continuous enteral feeding, will undergo measurement of the muscle strength using dynamometer.
46069514|NCT04080479|Diagnostic Test|Acute Physiology and Chronic Health Evaluation|All study subjects, with both bolus and continuous enteral feeding, will undergo the APACHE evaluation.
46069515|NCT04080479|Diagnostic Test|Sequential Organ Failure Assessment|All study subjects, with both bolus and continuous enteral feeding, will undergo the SOFA assessment.
45622839|NCT02460809|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) uses two surface electrodes placed on the scalp. These electrodes pass a low voltage current and modulate membrane potentials of underlying neurons.
46069516|NCT04080479|Diagnostic Test|Nutritional Risk Screening|All study subjects, with both bolus and continuous enteral feeding, will undergo the NSR screening.
46069517|NCT04080479|Diagnostic Test|Energy and Protein Intake|The amount of energy and protein supplied to the study subjects will be observed daily in all study subjects, with both bolus and continuous enteral feeding, the percentage of the planned daily intake will be analyzed.
46069518|NCT04074629|Diagnostic Test|Diagnosis, skin volatile organic compounds (VOCs)|"The skin related VOCs will be collected by off-line method using Polydimethylsiloxane (PDMS) patches from different body locations for sensor system and\or GC-MS analysis"
46069519|NCT02867423|Device|CK Boost radiation|single dose of 8 Grays is issued by the CK to the 6th week after conventional radiation
46069520|NCT04289987|Biological|CVI-HBV-002, Normal Saline|Investigational Product
46069521|NCT04290767|Diagnostic Test|Sulphur hexafluoride microbubbles SONOVUE (BRACCO, Milan, Italy)|Enhanced-contrast brain ultrasound with intravenously sulphur hexafluoride microbubbles SONOVUE (BRACCO, Milan, Italy) injection and using the time-intensity curve profile to evaluate brain microcirculation.
45622840|NCT04972539|Drug|AJU-A51 Tab.|Single oral dose AJU-A51(Dapagliflozin/Linagliptin) 10 mg / 5 mg FDC tablet
45622841|NCT04972539|Drug|A51R1 Tab. and A51R2 Tab.|Single oral dose A51R1(Dapagliflozin) 10 mg tablet and A51R2(Linagliptin) 5 mg tablet taken together
45622842|NCT03289715|Device|On Demand Humidification system Mark 2|The on demand humidification humidifier is set up to alternate between periods of humidification and no humidification totaling 6 periods of 30 minutes duration each. Thus, the test will consist of 3 cycles of disabled humidification and enabled humidification. Each cycle will be with a different humidification setting to assess which setting is most comfortable. In the second phase, the patient will be treated with the dose they had the best experience with in the first test.
45622843|NCT04979793|Drug|L-citrulline|3 gram sachet, L-citrulline
45622844|NCT04979793|Drug|Placebo|Milk powder placebo
45622845|NCT03289637|Dietary Supplement|Vitamin D|Vitamin D intervention tested against placebo in a population with heart failure and a 25-OH-vitamin D level<50nmol/L at screening
46069522|NCT02865941|Dietary Supplement|Fortification with modular protein|Modular product supplementation is based on most recent breast analysis done for the participant.
46069523|NCT02865941|Dietary Supplement|Fortification with modular carbohydrate|Modular product supplementation is based on most recent breast analysis done for the participant.
46069524|NCT02865941|Dietary Supplement|Fortification with modular fat|Modular product supplementation is based on most recent breast analysis done for the participant.
46069525|NCT02865785|Drug|Intralipid 20%|intralipid D4-9 of induction ovulation to be repeated within 7 days of positive pregnancy test.
46069526|NCT02865785|Drug|Placebo|saline infusion D4-9 of induction of ovulation to be repeated within 7 days of positive pregnancy test.
46069527|NCT04022213|Drug|131 I-omburtamab|Single dose of IP RIT administered through an IP catheter with 131 I-omburtamab at 80mCi/m2
45622846|NCT04854837|Drug|Remdesivir|Remdesivir treatment
45622847|NCT02460497|Drug|Treatment: Minoxidil 2% / Botanical Hair Solution for Women|
45622848|NCT03289559|Drug|GnRH antagonist|
45622849|NCT03289559|Drug|Aromatase Inhibitors|
45622850|NCT03289559|Drug|Testosterone gel|
45622851|NCT03293927|Drug|Fentanyl|The patient will receive IV fentanyl
45622852|NCT03293927|Drug|Dexmedetomidine|The patient will receive IV dexemedetomidine
45622853|NCT02730429|Drug|Palbociclib/placebo|Palbociclib or a placebo is administered together with standard of care letrozole
45622854|NCT02730429|Drug|Letrozole|Letrozole is standard of care in both arms
45622855|NCT02460731|Biological|Fresh Frozen Plasma|Fresh Frozen Plasma [young (<30 years of age) healthy male donors] Solution for intravenous infusion
45622856|NCT04979559|Device|Mobile health apps|Mobile health application intervention including screening and early intervention such as diet and physical activity suggestion
45765033|NCT05694117|Behavioral|self-determine sequence exercise program|The Taichi exercise utilized the simplified eight styles of Taichi. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
46069528|NCT04022213|Radiation|WAP-IMRT|Group A participants will receive WAP-IMRT approximately 2-4 weeks after completing IP RIT. A dose of 30 Gy will be delivered in 20 fractions of 1.5 Gy given once daily, 5 days per week over the course of approximately 4 weeks
46069529|NCT04049669|Drug|Indoximod|Indoximod will be taken by mouth twice daily during radiation and throughout each chemo-immunotherapy treatment cycle.
45446655|NCT02087020|Procedure|Debridement, antibiotics and implant retention|DAIR treatment protocol embodies an extensive surgical debridement and a radical excision of infected tissue. This is followed by exchange of modular components (articulating surfaces of the implant such as the femoral head, acetabular liner in total hip arthroplasty and the tibial insert, the polyethylene meniscus, in total knee arthroplasty). The wound is then copiously irrigated (> 9 litre) with 0.9 % sodium chloride and then closed.
45446656|NCT02088502|Drug|N-acetylcysteine|
45622857|NCT04979559|Other|Standard care|Regular practice for screening and early intervention for prediabetes patient in primary health cares setting
45622858|NCT04979481|Behavioral|BRAVE|The BRAVE campaign included 3-5 text messages per week for 8 weeks, including 1 role model video per week and a related image. The role model videos (1-3 minutes each) featured relatable characters experiencing and addressing violent behavior, alcohol misuse, and suicidality (through the eyes of a perpetrator, an intimate partner violence survivor, and a peer bystander), intended to demonstrated important coping and help-seeking skills.
45622859|NCT04979481|Behavioral|STEM|The STEM campaign included 3-5 text messages per week for 8 weeks, including 1 role model video per week and a related image. The series promoted STEM career pathways and highlighted Native professionals in Science, Technology, Engineering, Math, and Medical careers.
45622860|NCT04441463|Biological|Blood sampling for tryptase analysis|"3 bloods test~One blood sample taking from the mother's vein punction, during the delivery.~One blood sample tanking from umbilical cord.~One blood sample taking from the baby in day 3 of life, during the Guthrie test."
45622861|NCT03060993|Drug|Cannabis|Patients will be administered cannabis (THC/CBD) in vaporized form.
45622862|NCT03060993|Drug|Placebo|Patients will be administered placebo (cannabis stripped of cannabinoids) in vaporized form.
45622863|NCT03293849|Other|Patient Navigation|The patient navigator will discuss the results and supportive care recommended interventions of the multidisciplinary team with the patient. Those interventions which are accepted by patient are initiated when possible, and referrals are made as planned. The study patient navigator will review advance directive planning with those patients who are candidates to complete an advanced directive under Mexican law, and will facilitate the resources to complete the advance directive.
45622864|NCT03062241|Procedure|Cryoablation|After left atrial appendage (LAA) thrombus exclusion, the transseptal puncture will be performed and intravenous heparin will be administered to achieve Activated Clotting Time (ACT) ≥300 seconds.The pulmonary vein (PV) isolation will be performed. Optimal cryoballoon positioning will be confirmed by PVs angiography. Pulmonary veins isolation will be confirmed by entrance/exit block using appropriate catheter. During cryoablation of the right PVs, high-output right phrenic nerve stimulation will be performed using a diagnostic catheter placed in the superior vena cava. Whenever decrease/loss of pacing capture will be observed, cryoablation will be immediately terminated.
45622865|NCT03289403|Drug|Immunomodulatory|"Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Moreover, patients will receive a treatment course of immunomodulatory drugs for 3 -6 months before ICSI cycle:~Prednisnlone 40mg for 2 weeks to be lowered gradually till become 5mg after 6 weeks and to be continued~Hydroxychloroquine according to body weight, patients who develop hypersensitivity will be shifted to Azathioprin.~Immunoglobulins will be used in cases not responding to treatment."
45622866|NCT03289403|Drug|Thyroxine|"Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Patients will not receive immunomodulatory drugs"
45622867|NCT03289247|Device|tissue adhesive (Leukosan®)|Tissue ahaesive
45622868|NCT03293771|Other|Focus group interviews|Focus group participants will be asked about their postoperative urogynecologic experience. Confidentiality will be enforced and participants will be made aware that they may opt out of answering any questions.
46069530|NCT04049669|Radiation|Partial Radiation|Palliative low-dose or partial-field radiation plan (low-dose radiation or not all disease sites included).
45446657|NCT02088502|Drug|Theophylline|
45446658|NCT02088502|Drug|0.9% sodium chloride|All patients are hydrated with 0.9% sodium chloride (1 mL/kg/hour) for 24 hours, 12 hours before operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg per hour.
45622869|NCT03293771|Diagnostic Test|Questionnaire packet|Participants will be asked to complete a questionnaire packet comprised of three previously validated questionnaires and one newly created focused questionnaire. They will be asked to complete the new questionnaire again 2 weeks later. We estimate about 10 minutes will be required to complete the packet.
45622870|NCT04971759|Drug|Levobupivacaine|Levobupivacaine 5%
45446659|NCT02087098|Drug|Solifenacin|Patients with residual OAB symptoms (urge urinary incontinence, urgency, and frequency) after treatment with other antimuscarinics
45446660|NCT01369342|Drug|Group 1: Placebo|Form=solution for injection, route=intravenous use, in a single dose.
45622871|NCT04971759|Drug|Dexmedetomidine Hydrochloride|Levobupivacaine 5% + 1 µg/kg dexmedetomidine.
45622872|NCT04971759|Drug|Fentanyl|Levobupivacaine 5% + 1µg/kg fentanyl
46069531|NCT04049669|Radiation|Full-dose Radiation|Palliative full-dose radiation plan to all known sites of disease (>50 Gy to brain, >45 Gy to spine).
46069532|NCT04049669|Drug|Temozolomide|Temozolomide will be taken by mouth once daily, on days 1-5 of each chemo-immunotherapy treatment cycle.
45622873|NCT03289169|Drug|MEDITOXIN®|20U of Meditoxin® is injected to two places on the corrugators muscle for each eye and one place on the procerus muscle, total of 5 sites.
45622874|NCT03289091|Behavioral|water-based continuous aerobic training|Participants who will be randomized for the continuous aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle. In the first mesocycle (weeks 1-4), participants will carry out three 4-minute series of each exercise whose intensity corresponds to the Rating of Perceived Exertion (RPE) 13. In the second mesocycle (weeks 5-8), participants will perform four 3-minute series of each exercise corresponding to RPE 14. In the third mesocycle, participants will perform six 2-minute series of each exercise at intensity corresponding to RPE 15 from weeks 9-10, whereas intensity corresponding to RPE 16 will be experienced from weeks 11-12.
45622875|NCT03289091|Behavioral|water-based interval aerobic training|Participants who will be randomized for interval aerobic training group will carry out exercises which associate effort phases, at higher intensity and recovery phases, at lower intensity, with no interval for exercise change. Intensity will be increased every mesocycle. The first mesocycle (weeks 1-4) comprises three 4-minute series of each exercise whose intensity corresponds to the RPE 16 for 2 minutes and RPE 11 for 2 minutes. The second mesocycle (weeks 5-8) includes four 3-minute series of each exercise whose intensity corresponds to the RPE 17 for 1.5 minutes and RPE 11 for 2 minutes. The third mesocycle (weeks 9-12) comprises six 2-minute series of each exercise whose intensity corresponds to the RPE 18 for 1 minute and RPE 11 for 1 minute.
45622876|NCT03061851|Behavioral|conventional treatment|the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.
45622877|NCT03061851|Other|Maltose app|"Weekly diabetes-related science articles.~Patients reported hypoglycemia or other adverse reactions, the competent physician to deal with.~Questionnaires published out the hospital (2 weeks 1), the feedback for the problem.~monitoring of abnormal blood glucose data or the presence of related discomfort, can communicate with the competent physician online.~Personalize the development of diet, exercise program.~different insulin and oral hypoglycemic drug medication time to remind.~hypoglycemic drug side effects query."
45622878|NCT03289013|Other|Standard adhesive 1|This strip consists of a standard hydrocolloid adhesive found in ostomy devices
46069533|NCT04049669|Drug|Cyclophosphamide|Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.
46069534|NCT04049669|Drug|Etoposide|Etoposide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.
45622879|NCT03289013|Other|Standard adhesive 2|This strip consists of a standard hydrocolloid adhesive found in ostomy devices
45622880|NCT03289013|Other|LT-2|Newly developed adhesive
45622881|NCT03289013|Other|LT-21|Newly developed adhesive
46069535|NCT04049669|Drug|Lomustine|Lomustine will be taken by mouth once daily, on day 1 of each chemo-immunotherapy treatment cycle.
45446661|NCT01369342|Drug|Group 2 ustekinumab 130 mg|Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
45912460|NCT02010489|Other|12 week Exercise Program|Patients will be provided with a tour of the Reh-Fit Centre, exercise prescription, and supervised exercise session. The exercise prescription consists of 3 weekly 60-minute sessions, each with 10 minutes warm-up, 30 minutes endurance, 20 minutes strength training and 5 minutes cool-down. The program is overseen by an accredited Exercise Physiologist. Initial exercise intensity is determined by the kinesiologist and based on the patient's baseline fitness level. Goal intensity of endurance activity is based on the heart rate reserve (HRR) method. This is captured with a heart rate monitor at initial assessment and recorded on exercise logs. There are check-ins at each exercise session to determine progress (time, reps, weight, sets, etc). Endurance activities include treadmill, elliptical, walking, and aerobics. Strength training includes upper body, lower body, and trunk circuits. Patients will be asked to attend three weekly sessions at the Reh-Fit Centre.
45446662|NCT01369342|Drug|Group 3: ustekinumab approximately 6 mg/kg|Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg), 390 mg (weight > 55 kg and <= 85 kg), and 520 mg (weight > 85 kg).
45912461|NCT02010502|Dietary Supplement|Beetroot juice|
45446663|NCT00191477|Drug|Gemcitabine|2000 mg, intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
45446664|NCT00191477|Drug|Placebo|intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
45446665|NCT03741413|Other|Gain-frame SMS|Emergency recruitment cell phone short messages that emphasizing donating blood can save patients' lives were sent to donors in this group.
45446666|NCT03741413|Other|Loss-frame SMS|Emergency recruitment cell phone short messages emphasizing that donating blood can prevent patients from death were sent to donors in this group.
46069536|NCT00594165|Drug|Rotigotine|"Rotigotine trans-dermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year:~The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours."
45446667|NCT03741413|Other|Control SMS|Emergency recruitment cell phone short messages that only mentioning the low Rh-negative blood stockpile were sent to donors in this group.
45446668|NCT03969173|Procedure|applying PEEP3|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (3 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
45622882|NCT03289013|Other|LT-25|Newly developed adhesive
45622883|NCT03289013|Other|33-20|Newly developed adhesive
45912462|NCT02010502|Dietary Supplement|Beetroot powder|
45912463|NCT02010502|Dietary Supplement|Placebo|
45912464|NCT02010554|Behavioral|Brief Education|Give patients a pamphlet discussing pros and cons of disease modifying therapies
45622884|NCT04971603|Other|Acupuncture|"All acupuncture operations were done by registered Chinese medicine practitioner. Sterile, disposable acupuncture needles (0.25mmin diameter and 40mmin length) were used, which were purchased from HuaTuo acupuncture instrument.~Principal points: Neiguan (PC 6) *, Sanyinjia (SP 6) *, Weizhong (BL 40) *, Baihui (GV 20), Shuigou (GV 26) *, Zusanli (ST 36) *, Quchi (LI 11) *, Waiguan (TE 5) *, Hegu (LI 4) *, Huantiao (GB 30) *, Yanglingquan (GB 34)* (Grading of recommendation: C, level of evidence: IV).~Supplementary points: If upper limbs hemiplegia occurs, add Jianliao (TE 14) and Shousanli (LI 10); if lower limbs hemiplegia occurs, add Xuanzhong (GB 39) and Taichong (LR 3); if a deviation of the mouth or tongue occurs, add Dicang (ST 4) and Jiache (ST 6)."
45765034|NCT05694117|Behavioral|resistance training|The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions). Participants in the RTG completed four sets of each movement, with two to three minutes of rest between each set.
45912465|NCT02010554|Behavioral|Motivational Interviewing-Cognitive Behavioral Therapy|A telephone based talk therapy discussing pros and cons of medication use in MS.
45912466|NCT02010619|Behavioral|Cognitive behavior therapy|
45622885|NCT03293693|Other|0.5 g beta-glucan|Dietary cross-over study with beta-glucan fiber
45622886|NCT03293693|Other|3.5 g beta-glucan|Dietary cross-over study with beta-glucan fiber
45446669|NCT03969173|Procedure|applying PEEP6|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (6 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
45622887|NCT03293693|Other|8 g beta-glucan|Dietary cross-over study with beta-glucan fiber
45622888|NCT04979325|Other||
45622889|NCT03288935|Behavioral|TICM|The TICM will be designed to include the seven domains of trauma-informed care articulated by SAMHSA (2014): 1) early screening and comprehensive assessment; 2) consumer driven care and services; 3) trauma-informed, responsive and educated workforce; 4) emerging and evidence-informed best practices; 5) safe and secure environments; 6) trauma-informed community partnerships; and 7) a performance monitoring system. The trained agency case managers and staff will provide the TICM to 50 newly resettled refugees during their regular R&P service period (i.e., 60 days).
45622890|NCT03288935|Behavioral|TICO|The community-based TICO will be based on the Im's CHW that comprises 8 sessions (2 hour per session), co-facilitated by trained refugee peer mentors and community service providers. The TICO sessions will include interactive sessions on healthy eating, healthy body and healthy mind, acculturation & resettlement stress, understanding trauma and stress, healthy coping, helping others, and community building.
45622891|NCT04971369|Diagnostic Test|89Zr-NY001|89Zr-NY001 injection followed by 89Zr-NY001 PET scan
45622892|NCT03293537|Diagnostic Test|Skin conductance and Heart rate measurement|while observing selected photos the Skin conductance and heart rate will be measured.
45622893|NCT04979091|Diagnostic Test|Sex Hormones|A panel of 13 hormones was measured in plasma samples of COVID-19 patients (total testosterone, free testosterone, dihydrotestosterone, androstenedione, 17-β-estradiol, estrone, sex hormone-binding globulin, thyroid-stimulating hormone, free triiodothyronine (T3), free thyroxine (T4), luteinizing hormone, follicle-stimulating hormone and cortisol).
45622894|NCT03288857|Device|NeilMed Naspira|NeilMed Naspira is a nasal-oral aspirator
45912467|NCT02010619|Behavioral|Supportive therapy|
45622895|NCT04979013|Other|Smoking Abstinence|Smokers will be switched to smoking abstinence for 14 days
45622896|NCT03293459|Procedure|Shunt Occlusion|Catheterization of the Porto-systemic shunt (via the left renal vein for gastro-lienorenal shunt) will be accomplished using a catheter and occlusion will be performed with balloon catheter/vascular plug. Occlusion venography is then performed to define the type of varix/varices and the anatomy of the venous drainage followed by infusion of sclerosant. The occluded balloon were inflated and remained in place for a maximum of 24 hours deflated under fluoroscopy the next day/plug is deployed and sclerosant is injected to obliterate the shunt and follow up CT is done to look for completion on the next day. Follow up CT abdomen is done periodically to look for effect on shunt and organ.
45912468|NCT02010658|Other|Cognitive Aid|
45912469|NCT02010671|Other|Survey|Survey
45622897|NCT03293459|Dietary Supplement|Standard Medical Treatment (SMT)|These will include diet rich in BCAA (branch chain amino acids), laxatives and rifaximin
45622898|NCT04971291|Drug|AXS-05|AXS-05 taken twice daily for 6 weeks
45622899|NCT04971291|Drug|Bupropion SR|Bupropion taken twice daily for 6 weeks
45912470|NCT02010710|Device|INFANT software|The decision-support software to be evaluated in INFANT has been designed to run on the K2 data collection system (Guardian®). The data collection system (Guardian®) is a system for managing information from labour monitoring. It displays the CTG on a computer screen alongside other clinical data which are collected as part of routine clinical care. As such, it replaces conventional paper labour notes, the CTG machine and other recording systems for documenting care during labour.
45912471|NCT02010723|Procedure|surgery|crossectomy and avulsion of the varicose anterior accessory great saphenous vein (AAGSV) under local anesthesia
45912472|NCT02010723|Drug|sclerotherapy with aethoxysclerol foam|foam sclerotherapy with aethoxysclerol foam
46069537|NCT00975923|Behavioral|Collaborative Group|"In addition to the Tool Kit materials and web site support, facility leaders and managers in this group agreed to participate in a Collaborative to improve critical care. The Collaborative differed from the IHI BTS model in that teams did not come together for face-to-face educational and planning sessions but instead attended web seminars and teleconferences. Between these virtual learning sessions, teams implemented some of the suggested change ideas, measured the results of those changes, and reported back to the larger group. Teams were supported through monthly educational and troubleshooting conference calls, individual coaching by faculty members, and an e-mail listserver designed to stimulate interaction among teams."
45446670|NCT03969173|Procedure|applying PEEP9|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (9 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
45765035|NCT05694117|Behavioral|Taichi exercise and resistance training|The training of the Taichi exercise and resistance training group consisted of two cycles, the first cycle was aimed at learning and consolidating Taichi exercise, and the second cycle was aimed at improving and consolidating. The Taichi exercise and resistance training group was scheduled for 30 min of Taichi exercise per training. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
45765036|NCT05694117|Behavioral|Randomly selected exercise program|Participants in the randomly selected exercise program group who chose Yijinjing exercise were required to complete one hour of Yijinjing exercise training, and those who chose Yijinjing exercise hybrid strength training had to complete half an hour of Yijinjing training. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
45622900|NCT03288701|Device|Seca medical Body Composition Analyser 515|Comparison of reduction of whole body water and body weight in patients with decompensated heart failure under forced diuretic treatment
45622901|NCT04971057|Other|multimedia information program of renal biopsy|Multimedia information program is based on self-efficacy theory. The multimedia videos contain the information associated with renal biopsy, which including the purpose, indications, preparations for the examination, process, patient experience sharing, complications, precautions, home care and stress adjustment strategies.
45622902|NCT04360811|Diagnostic Test|COVID 19 diagnostic test by PCR|"Inclusion of patients with clinical data (in a eCRF) and various samples collection according to the outcome of pregnancy~Storage and freezing samples for subsequent analysis by RT-PCR COVID-19 (maternal saliva, cord blood, fetal stools, placenta, fetal tissue, amniotic fluid according to pregnancy outcomes) and by maternal and newborn and / or fetal serologies testing~Pathological study of placentas and fetal autopsies~Histology of positive COVID-19 placentas~Brain and visceral histology of positive COVID-19 fetuses autopsied~Analysis of patient comorbidities and comparison in the different groups~Final statistical analysis"
45622903|NCT04971135|Drug|SAN711|SAN711 liquid formulation
45446671|NCT04320615|Drug|Tocilizumab (TCZ)|Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.
45622904|NCT04971135|Other|Placebo|Matching placebo
45622905|NCT04299659|Diagnostic Test|Landolt C entry method|Four different methods for entering the Landolt C gap position are compared
45765037|NCT05574387|Drug|Metformin|Metformin is an antidiabetic biguanide drug that acts by promoting glucose uptake and utilization in the liver.Recent studies proved that metformin could reduce colonic inflammation by AMPK-mediated inhibition of p38 mitogen-activated protein kinase (MAPK)
45622906|NCT04978623|Other|high frequency ultrasound|high frequency ultrasound in subgroups of patients with CIDP, anti-MAG, NMMBC and L-S syndrome
45622907|NCT03107507|Drug|Levetiracetam|Given in a bolus dose first 50mg/kg as levetiracetam reaches a therapeutic serum level rapidly in 1.3 hours. Titration will not be attempted in our study to reach drug level rapidly and consequent rapid effective control of seizures. Maintenance dose is then given at a dose of 10 - 40mg/kg/day divided every 12 hours.
45622908|NCT03107507|Drug|Phenobarbital|Phenobarbital is given intravenously in the form of a loading dose of 15mg/kg that can be repeated after a 20 minute interval not to exceed 30mg/kg then a maintenance dose 2-4 mg/kg/day divided every 12 hours.
45765038|NCT03023176|Biological|Fluzone® standard IIV3|Influenza Virus Vaccine Suspension (0.5ml) for Intramuscular Injection
45765039|NCT03023176|Biological|Fluzone® standard IIV3 Pediatric Dose|Influenza Virus Vaccine Suspension (0.25ml) for Intramuscular Injection
45765040|NCT03839745|Other|Electronic Cigarette|E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W, which is inclusive of the three power levels we intend to study.
45912473|NCT02010736|Other|Single treadmill gait training with additional loading|
45912474|NCT02010762|Drug|Vitamin D|25.000 IU oral drops
46069538|NCT00975923|Behavioral|Tool Kit|Hospitals received a tool kit:evidence-based guidelines, CLABSI/VAP fact sheets, change ideas,quality improvement and teamwork methods, standardized data collection and charting tools. Periodic reminders of their commitment to the Safe Critical Care Initiative and access to web site containing all of the educational seminars, clinical tools, and quality improvement tools. ICUs in this group were on their own to initiate and implement a local hospital quality improvement initiative preventing CLABSI and VAP.
46069539|NCT00928070|Drug|Fesoterodine|Fesoterodine 4 mg and 8 mg
46069540|NCT00928070|Drug|Placebo|Placebo sham 4 mg and 8 mg
46069541|NCT02623257|Other|mutation detection|
46069542|NCT02623257|Other|ARMS|
46069543|NCT02623257|Genetic|ctDNA analysis|
45446672|NCT04320615|Drug|Placebo|Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
45446673|NCT02087332|Drug|Prolonged release Torasemide (Britomar)|
45446674|NCT02087332|Drug|Torasemide (Diuver)|
45446675|NCT02092012|Drug|dexketoprofen trometamol|ıv 50 mg dexketoprofen trometamol after anaesthesia induction
45765041|NCT04366505|Behavioral|Treatment as usual (TAU) and neurofeedback (NFB)|This group will receive Treatment as usual (TAU) and neurofeedback (NFB). During NFB, participants will be asked to regulate the signal from a target brain region during the presentation of alcohol cues. The ventral striatum was chosen as target region.
45622909|NCT04978935|Other|Care protocol|"Before starting the application, the investigator (DS) will fill out the Introductory Characteristics Form of all patients, the Pre-thoracotomy Pulmonary Function Test (PFT) section of the Patient Results Form. The PFT section will be re-evaluated on the 1st, 5th day and on the day of discharge after thoracotomy.~Nursing interventions will be applied to the study group (n=40), starting from the 0th day (the first day spent in the intensive care unit) after the thoracotomy in line with the prepared care protocol application steps until discharge. Care protocol consists of patient's position, mobilization, use of spirometer and shoulder exercises."
45622910|NCT03293303|Behavioral|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
45765042|NCT04366505|Behavioral|mindfulness-based relapse prevention (MBRP) and NFB|This group will receive MBRP and neurofeedback (NFB). MBRP consists of 5 extensive sessions of a specific manualized mindfulness-based intervention for alcohol dependent patients which will be carried out by trained psychologists and psychotherapists. During NFB, participants will be asked to regulate the signal from a target brain region during the presentation of alcohol cues. The ventral striatum was chosen as a target region.
45765043|NCT04366505|Behavioral|TAU and sham NFB|This group will receive TAU and sham NFB. Sham NFB means that the signal displayed to the participant is based on activity in a control region, the auditory cortex, which is not involved in cue reactivity.
45622911|NCT02711137|Drug|INCB057643|Initial cohort dose of INCB057643 at the protocol-specified starting dose (Part 1), with subsequent dose escalations based on protocol-specific criteria. The recommended treatment group-specific dose(s) will be taken forward into expansion cohorts (Part 2).
45622912|NCT02711137|Drug|Gemcitabine|Standard of Care (SOC) agents
45622913|NCT02711137|Drug|Paclitaxel|Standard of Care (SOC) agents
45622914|NCT02711137|Drug|Rucaparib|Standard of Care (SOC) agents
45765044|NCT04366505|Behavioral|MBT and sham NFB|This group will receive MBRP and sham NFB. MBRP consists of 5 extensive sessions of a specific manualized mindfulness-based intervention for alcohol dependent patients which will be carried out by trained psychologists and psychotherapists. Sham NFB means that the signal displayed to the participant is based on activity in a control region, the auditory cortex, which is not involved in cue reactivity.
46069544|NCT04012073|Device|Invasive Mechanical ventilation|"Volume-control ventilation with tidal volume will be set at 6 mL/Kg of predicted body weight, respiratory rate to maintain pH>7.30 and PaCO2<50 mmHg and FiO2 will be set to achieve a SpO2>88-95%.~In case of hypercapnia with Ph<7.30 despite a respiratory rate=30-35, an increase in tidal volume up to 8 ml/kg will be allowed.~In both groups, the assigned ventilation protocol will be followed for a minimum of 72 hours from randomization and any time fully controlled ventilation is deemed necessary by the attending physician up to 14 days from randomization. After 14 days from randomization, PEEP will be set according to the clinical practice of each institution.~After 72 hours from the study protocol, the PEEP setting protocol according to the assigned treatment will be resumed at any time within 14 days from enrolment if fully controlled ventilation is established, according to the decision of the attending physician in charge."
45446676|NCT02092012|Drug|Dexmedetomidine|ıv 1 mcg/kg dexmedetomidine after anaesthesia induction
45446677|NCT00149747|Behavioral|Moderate-Intensity Aerobic Physical Activity|Moderate-Intensity Aerobic Physical Activity. 4+ days per week, 60+ minutes per day, moderate or greater intensity physical activity
45446678|NCT00149747|Behavioral|Health Education Class|2 classes a week, 90+minutes per class, general health education, excluding information on physical activity
45446679|NCT02092090|Behavioral|Dietary sodium reduction|Ongoing dietary advice and a supply of a reduced-sodium added-potassium salt substitute
45622915|NCT02711137|Drug|Abiraterone|Standard of Care (SOC) agents
45622916|NCT02711137|Drug|Ruxolitinib|Standard of Care (SOC) agents
45622917|NCT02711137|Drug|Azacitidine|Standard of Care (SOC) agents
45622918|NCT03288623|Dietary Supplement|Dark Chocolate (85% cocoa)|Dark chocolate (85% cocoa) in tablet
45622919|NCT03288623|Dietary Supplement|White/Milk chocolate (<35% cocoa)|white or milk chocolate (<35% cocoa) in tablet
45622920|NCT04970979|Other|survey|questionnaire about the influencing factors of home-based cardiac rehabilitation
45622921|NCT04970823|Device|The somatosensory interactive game for preschool children|The somatosensory interactive game, an independent nursing intervention, promotes pain relief for preschool children.
45622922|NCT04970823|Device|A VR (virtual reality) game for school-age children|A VR (virtual reality) game environment promotes pain relief for school-age children.
45622923|NCT04488653|Dietary Supplement|Oligopin®|French Maritime Pine Bark Extract - 100mg/day
45765045|NCT03023488|Procedure|flexible ureteroscopy|Flexible ureteroscopy is an endourological procedure performed for kidney stones. The flexible ureteroscope is a device used to reach the renal cavities through the natural urinary tract in a retrograde fashion. During the operation, irrigation fluid is used to expand the cavities to provide space for movement of the device and also to provide clear vision.
45912475|NCT02010762|Drug|Placebo|placebo oral drops
45622924|NCT04488653|Dietary Supplement|Placebo|Maltodextrin
45765046|NCT03023488|Device|Doppler Ultrasound examination|peak systolic velocities (PSV) and end diastolic velocities (EDV) of the arteries will be measured and then resistive index (RI) and pulsatility index (PI) will be calculated.
45446680|NCT00187889|Drug|Eplerenone|Eplerenone 25 mg (1 pill) daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
45765047|NCT03023488|Device|laser lithotripsy|The laser fiber extending into the cavities through the working channel of the ureteroscope is used to fragment the stones. Laser energy is generated by the laser machine and transmitted to the stones via the laser fiber.
45446681|NCT00187889|Drug|Placebo or sugar pill|Placebo blinded as 25 mg tablet(1 pill) once daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
45765048|NCT05716815|Diagnostic Test|CT scans 2D Reconstruction|Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
45622925|NCT04970745|Other|Transcranial parenchymal color Doppler ultrasound (TCS)|tracing the nigrostriatal echogenic area
46069545|NCT04012073|Drug|Neuromuscular Blocking Agents|All patients will receive NMBA for 48 hours after the enrolment. The decision to stop NMBA administration after 48 hours will be left to the attending physician, but muscle paralysis will be strongly encouraged if PaO2/FiO2 ratio remains lower than 80-100 mmHg. NMBA administration will be resumed anytime deemed necessary by the attending physician.
46069546|NCT04012073|Procedure|Prone positioning|Prone positioning will be used in all enrolled patients as a standard of care: the decision about the timing and the duration of prone position sessions will be left to the attending physician and the time spent by the patient in the prone and in the supine position will be recorded: PEEP will be re-set according to the protocol of the allocated treatment anytime patient's position is changed.
46069547|NCT04012073|Procedure|Resume of spontaneous breathing|"Assist/control and assist ventilation will be allowed after 72 hours from the enrolment if deemed appropriate by the attending physician.~During spontaneous breathing, PEEP will be set according to the decision of the attending physician and the practice of each institution: however, in order to standardize the treatments, moderate PEEP (10-15 cmH2O) will be encouraged in case of moderate hypoxemia (PaO2/FiO2<150 mmHg) in control group, while PEEP close to the value set during controlled ventilation according to the treatment protocol but <15 cmH2O will be suggested in the intervention group.~During assist/control and assisted ventilation, PEEP will never be higher than the last PEEP set according to the assigned protocol during controlled ventilation.~Fully controlled mechanical ventilation will be resumed any time during the study period if the patient meets the criteria described above or any time deemed necessary by the physicians in charge"
46069548|NCT04012073|Procedure|Rescue treatments|Recruitment maneuvers, extracorporeal membrane oxygenation (ECMO), extracorporeal CO2 removal (ECCO2-R) after randomization will be allowed in both groups as rescue therapies and according to the decision of attending physicians: any of these procedures will be accurately recorded on the case report form.
45622926|NCT04970745|Other|Electromyography (EMG) tremor analysis|observed 1, frequency 2, amplitude (amplitude) 3, correlation between the two sides 4, load and post-drug test differences
45622927|NCT03292835|Device|LeiProtect®|Filmogenic dressing gel
45622928|NCT04970589|Other|Mango|400g of mango/day
45622929|NCT04970589|Dietary Supplement|Probiotics|1 probiotics capsule/day
45622930|NCT04970589|Other|Placebo|1 Placebo capsule/day
45622931|NCT03193099|Other|Brain imaging|Volume, DWS and DTI
45622932|NCT03193099|Other|Neurological assessments|UHDRS
45622933|NCT03193099|Behavioral|Psychological assessments|STAI (Spielberger state and Trait Anxiety Inventory) A and B, BDI-II (Beck Depression Inventory), MINI (Mini-International Neuropsychiatric Interview) and MINI-SEA (mini Social cognitive and Emotional Assessment)
45622934|NCT03193099|Behavioral|Behavioural assessments|Computerized game
45622935|NCT02460653|Device|HFNC Flow Rate|We only change the flow rates between low, medium and high settings.
45622936|NCT04155411|Drug|Dasatinib|70 mg of Dasatinib orally daily for 12 months
45622937|NCT03292757|Drug|Indocyanine Green|Fluorescent dye - indocyanine green
45622938|NCT04427163|Genetic|Blood sample analysis|Nucleic acids sequencing, presence of proteins and metabolites.
45622939|NCT04427163|Other|Health status|Health status will be examined by a physician and subject will complete a health status questionnaire.
45622940|NCT04427163|Other|Race and ethnicity|Subject will complete race and ethnicity questionnaire to make sure subjects are from the Czech population.
45622941|NCT03192865|Procedure|diaphragmatic assessment using ultrasounds.|A diaphragmatic assessment will be performed using ultrasound. This is a pain free assessment. This assessment is commun in our unit after arthroscopic shoulder surgery.
45622942|NCT04970667|Drug|Flupentixol melitracen tablets|Patients were treated with Flupentixol and melitracen tablets for 12 weeks
45622943|NCT05233813|Behavioral|Active Body and Mind|The intervention group attended three 45-min group exercise lessons per week and wore a Fitbit activity tracker during the weekdays for 12 weeks combined with weekly feedback and personalized activity goals.
45622944|NCT03288467|Procedure|Root canal treatment with 5% NaOCl|
45622945|NCT03288467|Procedure|Root canal treatment with 1% NaOCl|
45765049|NCT05716815|Diagnostic Test|CT scans 2D plus 3D Reconstruction|Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions plus a 3D reconstruction are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
45765050|NCT04376645|Procedure|Mandibular Setback with maxillary impaction|Occlusal bite force will be measured after surgery to correct vertical disproportions
45765051|NCT04376645|Procedure|Mandibular setback only|Occlusal bite force will be measured after surgery without changing vertical disproportions.
45912476|NCT02010788|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
45912477|NCT02010801|Procedure|irreversible electroporation|
45912478|NCT02010801|Device|nanoknife AngioDynamics US Ltd|
45912479|NCT02010827|Biological|isoglycemic intravenous glucose infusion and Glucagon infusion, day C|Infusion of 0.8ng/kg/min glucagon from time 0-25min
45622946|NCT02446327|Other|Blood sampling for biomarker assessment|
46069549|NCT04012073|Procedure|Weaning from PEEP|"In order not to delay weaning from mechanical ventilation, when a patient is managed with assist/control or assist ventilation with PEEP higher than 8 cmH2O, a daily PEEP weaning trial will be performed whether PaO2/FIO2 ratio>150 mm Hg and FIO2<0.5: PEEP will be decreased to 8-5 cm H2O and arterial blood gas will be sampled after 20 -0 minutes. Previous ventilatory settings will be resumed if during the procedure transcutaneous oxyhemoglobin saturation decreases below 88%, PaO2/FIO2 falls below 150 mm Hg or if the patient experiences abnormal changes in respiratory rate or other clinical signs suggestive of respiratory distress.~When PaO2/FIO2 is no lower than 200 mm Hg at PEEP≤8 cmH2O, the patient will be considered to have acceptable gas exchange on 8-5 cmH2O of PEEP and will be deemed capable to tolerate this setting"
45622947|NCT04978233|Other|sociodemographic and health, daily self-assessment, and feasibility of using the Opal app for COVID|The intervention consists of having confirmed COVID-19 infected participants register for the Opal app and complete a daily questionnaire on symptoms related to their physical and mental health as well as on certain key vital signs (e.g., oxygen saturation, heart rate, temperature). A nurse will check the questionnaire results each day and determine the need for a teleconsultation with an infectious disease physician. Participants will be followed up for a minimum of 14 days, depending on their symptoms.
45622948|NCT03288389|Dietary Supplement|NTFactor Lipids®|Membrane Lipid Replacement with NTFactor Lipids wafers
45622949|NCT03288389|Dietary Supplement|Placebo|Placebo wafers
45622950|NCT03192631|Other|Financial incentive|Incentive of $15 Canadian
45622951|NCT03118141|Procedure|blastocyst morphologic score|Blastocysts will be scored by Gardner morphologic criteria.
45622952|NCT03118141|Procedure|blastocyst biopsy and sequencing|Three blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.
45622953|NCT03118141|Procedure|freeze-all and single thawed blastocyst transfer|All blastocysts will be vitrified in fresh cycle. Single blastocyst will be thawed and transferred.
45622954|NCT03292445|Procedure|Immune tolerance after kidney transplant|Induction of immune tolerance after kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and anti-thymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no kidney rejection.
45622955|NCT03292445|Drug|Donor blood stem cells and T cells|"Immune tolerance after kidney transplantation resulting from mixed blood cells chimerism will be induced by donor blood stem cells and T cells given to the kidney recipient. Donor cells will be collected by apheresis after mobilization of blood stem cells from bone marrow 6-8 weeks before kidney transplant. Collected cells will undergo CD34 selection to recover >10 million donor blood stem cells/kg of patient weight to be combined with up to 150 million donor T cells/kg for transfusion soon after kidney transplant. The IND for this study covers the infusion of donor blood stem cells."
45622956|NCT02449057|Other|JUST|Swift, certain, and proportionate sanctions for violations of terms of community supervision.
45622957|NCT03288311|Other|Protocolized post-extubation respiratory support|Qualifying patients undergoing extubation in an ICU bed randomized to post-extubation respiratory support will receive either non-invasive ventilation or high flow nasal cannula (as determined by a prespecified protocol and applied by a respiratory therapist) from the time of extubation until 5AM the following morning
45622958|NCT03288311|Other|Usual Care|Qualifying patients undergoing extubation in an ICU bed randomized to usual care will receive standard-of-care treatment, which may include post-extubation respiratory support at the discretion of their clinical team.
45622959|NCT03196141|Diagnostic Test|StO2 and EndoPAT|"StO2 probe is a lightweight plastic probe that will be applied over the brachioradilalis muscle (anterolatereal aspect of the forearm) where there is less subcutaneous fat and taped in place.~The EndoPAT probe will be place on a finger on the same arm.~Pulse oximeter probes will be connected to a finger on each hand."
45622960|NCT03292367|Procedure|ldTRA|After puncture of left distal radial artery, coronary angiography and percutaneous coronary intervention, if needed, will be performed.
45622961|NCT03196375|Drug|FLX-787-ODT (orally disintegrating tablet)|FLX-787-ODT taken three times daily for 28 days
45622962|NCT03196375|Drug|Placebo ODT|Placebo ODT taken three times daily for 28 days
45622963|NCT03292211|Behavioral|early mobilization|early out-of-bed activities including supine to sit training, sit on the edge of bed without supporting, standing with hand supporting, stepping while standing etc.within three days after stroke while being monitored by medical equipment.
45622964|NCT03292211|Behavioral|early standard intervention|Conventional early in-bed activities within three days after stroke
45622965|NCT03288233|Diagnostic Test|Breath carbon monoxide measurement|Participants will be asked to breath in designed breathing circuits or hold their breath for short period of time and then their breath samples will be collected in special bags and the carbon monoxide and carbon dioxide will be measured with electrochemical techniques.
45622966|NCT03117829|Behavioral|Diet and Exercise|Diet and Exercise Study to Improve Brain Blood Flow
45622967|NCT03288155|Dietary Supplement|Cocoa|Participants will receive either a high flavonoid cocoa or a low flavonoid placebo cocoa.
45622968|NCT04484233|Device|iAnemia Decision Support System|iAnemia permits to display the appropriate guideline using several inputs about a patient: age, type and delay of the surgery, gender, hemoglobin level, and iron deficiency status.
45622969|NCT03288077|Other|Tryptophan|Beverage including tryptophan
45622970|NCT03107065|Device|Thermi Radiofrequency|Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation
45912480|NCT02010827|Biological|Oral glucose tolerance test, day A|
45622971|NCT00777127|Drug|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
45765052|NCT02977923|Device|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the site of the injury, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, were adapted for children and tailored to minimize cyber sickness.
45622972|NCT00777127|Drug|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
45622973|NCT00761371|Drug|Imiquimod 5% cream|Subjects were treated with imiquimod (one sachet/20 cm2), three applications per week, for up to 16 weeks, or fewer in the case of total clearance of initial warts. At the visit at the end of treatment, a second scraping of the lesion area was carried out to determine the sub-type of HPV.
45622974|NCT03287999|Diagnostic Test|Thrombophilia screen|Thrombophilia screen (including antithrombin activity (AT:Ac), protein S antigen (PS:free), protein C activity (PC:Ac) , genetic analysis for FV Leiden and Prothrombin 3'UTR mutations and screening for lupus anticoagulant.
45622975|NCT03287999|Diagnostic Test|Initiation pathway analysis|Evaluation of inter-individual variability in regulation of TF.VIIa.Xa.TFPI complex (tissue factor, activated Factor VII, activated factor X, tissue factor pathway inhibitor)
45765053|NCT02977923|Other|Standard pharmacological treatment|according to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
45765054|NCT04374851|Device|Polaris miniRITE BTE|The Polaris device is programmed with computer software to match the Hearing loss of the participant.
45765055|NCT04374851|Device|Viron miniRiTE BTE|The Viron Hearing device is programmed with computer software to match the Hearing loss of the participant.
45622976|NCT03287921|Drug|mono bronchodilatation|within indication according to current GOLD recommendation
45622977|NCT03287921|Drug|dual bronchodilatation|within indication according to current GOLD recommendation
45622978|NCT03196063|Other|Eccentric|Exercises based on eccentric contractions of the quadriceps femoris muscle, using a 15º inclined plane. A serie of 15 repetitions of the squat will be performed, with the frequency of three times a week for eight weeks. The load of the exercises will be increased weekly.
45765056|NCT03024112|Device|Heated humified high-flow nasal cannula Oxygen|
45765057|NCT03024112|Other|Standard oxygen therapy|
45765058|NCT04374383|Drug|Phthalocyanine Dye|following LASER assisted SRP, a novel photosensitizer phthalocyanine dye will be placed
45765059|NCT04374383|Drug|LASER assisted SRP|LASER assisted SRP will be carried
45765060|NCT02978001|Other|Stabile Isotope tracers|Non-radioactive tracers used in hyperinsulinaemic euglycaemic clamp
45765061|NCT02978079|Device|Automated pupillometry|Automated pupillometry will be performed in patients with acute stroke with the intention of diagnosing Horner's syndrome
45765062|NCT04366427|Combination Product|L-HBO|as previously described.
45765063|NCT04366427|Combination Product|HBO|as previously described.
46069550|NCT04012073|Procedure|Weaning from mechanical ventilation|"A 30-120-minute spontaneous breathing trial will be initiated as the following criteria are met and whether the patient tolerates fully assist ventilation with PEEP≤8 cmH2O for at least 4 hours without experiencing hypoxemia (SpO2<88% or PaO2/FiO2<150mmHg):~improvement or resolution of the underlying cause of acute respiratory failure~normal sensorium~correction of arterial hypoxemia (PaO2 ≥ 60 mmHg at a FiO2 ≤ 0.4 with PEEP ≤ 8 cmH2O);~absence of fever (≥ 38 °C) or sepsis;~blood hemoglobin concentration of 7 g/dL or more;~hemodynamic stability~For the purpose of the study, success of the spontaneous breathing trial will be defined as presence of the following criteria:~respiratory rate < 35/min,~arterial oxygen saturation ≥ 90%,~heart rate < 120/min,~systolic blood pressure > 90 and < 160 mmHg~adequate cough. If the spontaneous breathing trial is successful, the patient will be extubated."
45765064|NCT04366427|Combination Product|30% O2|as previously described
45765065|NCT04366427|Combination Product|50% O2|as previously described
45765066|NCT02842060|Behavioral|myDEx|myDEx will consist of a 6-session online program. Cognizant of challenges maintaining users' attention in a web application and to facilitate delivery through a smartphone, the investigators will design each session to be no more than 20 minutes in length. In the course of these 6 sessions, participants will have a total of 120 minutes of intervention exposure. Across sessions, the investigators will emphasize the importance of sexual decision-making across different partner types, help men consider what type of relationship(s) they want, and align these relationship desires with safer sex practices.
45765067|NCT02842060|Behavioral|NTHP|The investigators will create a 6-session attention-control comparison to match the intervention in time and attention yet have non-tailored and non-interactive content (NTHP). NTHP will include HIV/STI information currently available on sex education websites. The attention-control condition allows the investigators to avoid confounding due to content and ensures that all participants receive some HIV prevention content given their high vulnerability to HIV. Further, this comparison will help critically examine the extent to which tailoring increases the acceptability to the program, above and beyond having a non-tailored, non-interactive intervention.
45912481|NCT02010827|Biological|intravenous iv glucose infusion, day B|
45912482|NCT02010840|Behavioral|Psychoeducation program|
45912483|NCT02010853|Other|IRMf|"evaluation in resting state fMRI during three successive visits:~During the acute phase within 24 hours~In 72 hours~In 3 months"
45622979|NCT03196063|Other|Modified Protocol|Protocol based on the Heavy Slow resistance program, with the addition of an isometric phase at the beginning of the protocol, and with exercises using body weight without the use of mechanotherapy.
45622980|NCT03291977|Drug|Fluorescéine Sodique Faure|Fluorescéine Sodique Faure given intravenously during the induction of the anesthesia, at the dose of 3mg/kg, diluted in 50mL of physiological serum, in 10 minutes.
45622981|NCT03291977|Procedure|White-light surgery|The surgery will be performed under classical conditions
45622982|NCT02448979|Procedure|Left thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
45622983|NCT02448979|Procedure|Right thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
45622984|NCT03287609|Drug|Evolocumab 140 mg/mL|Three injections with pre-filled auto-injector pen at day 1 and at week 4.
45622985|NCT03287609|Drug|Placebo|Three injections with pre-filled auto-injector pen at day 1 and at week 4.
45622986|NCT02448745|Device|Insecticide treated wall lining|Polypropylene non-woven fabric.
45622987|NCT03291899|Combination Product|FOLFIRINOX|combination chemotherapy using Oxaliplatin, Irinotecan, Leucovorin and Fluorouracil, given every 15 days for a total of 12 cycles
45622988|NCT03194815|Drug|Intravenous immunoglobulin|This is a blood product containing antibodies from thousands of healthy donors.
45622989|NCT03194815|Drug|Placebo|This is the control, or sham, treatment
45622990|NCT03194815|Drug|Rituximab|Rituximab is a type of biological therapy. It removes B-cells and helps to reduce the inflammation
45622991|NCT03287531|Other|conventional therapy|Exercise therapeutic Ultrasound
45622992|NCT03287531|Other|low level laser therapy|LLLT with the appropriate parameters (904 nm, 8 j/cm2, 250mw) for duration of 20 min with repletion of three treatment sessions per week.
45622993|NCT03195907|Other|Pulmonary physiotherapy|
45622994|NCT03291821|Drug|human menopausal gonadotropin|human menopausal gonadotropin subcutaneously
45622995|NCT03291821|Drug|GnRH antagonist|GnRH antagonist subcutaneously
45622996|NCT03291821|Drug|GnRH analog|GnRH analog subcutaneously
45622997|NCT03291821|Procedure|Trophectoderm biopsy|Trophectoderm biopsy is the process of removing few cells from an in vitro fertilization embryo.
45622998|NCT03291821|Diagnostic Test|MitoScore|The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be used to assess the mitochondrial DNA content as a viability indicator in the euploid embryos.
45622999|NCT03291821|Procedure|Intracytoplasmic sperm injection|ICSI is an in vitro fertilization procedure in which a single sperm is injected directly into an oocyte.
45623000|NCT03291821|Procedure|Ovarian puncture|Egg retrieval is a simple procedure. It is performed in an operating room for safety reasons. It is performed vaginally and involves aspirating the follicular fluid through a thin needle. Embryologists then retrieve from this fluid the eggs that have matured during stimulation. It lasts for 5 to 15 minutes, and a mild sedative is administered to prevent any kind of pain during the procedure.
45623001|NCT03291821|Diagnostic Test|Preimplantation genetic test|The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be tested for chromosomal normalcy before transferring the embryo to the uterus.
45623002|NCT03291821|Procedure|Embryo transfer|Embryo transfer refers to a step in the process of assisted reproduction in which embryos are placed into the uterus
45623003|NCT03291821|Diagnostic Test|Pregnancy test|A pregnancy test is used to determine whether a woman is pregnant.
45623004|NCT03291821|Procedure|Embryo freezing|Embryo freezing is a method for cryopreserving embryos.
45623005|NCT03291821|Procedure|Embryo thawing|Embryo thawing is the procedure to recover previously frozen embryos prior to an embryo transfer.
45623006|NCT02445937|Behavioral|PARTNER II|"The PARTNER intervention is a multifaceted intervention delivered by a trained PARTNER Champion who has undergone 16 hours of intense communication training, with audit and feedback, quarterly booster training, and expert implementation support. Additionally, there is academic detailing of ICU physicians and ICU bedside nurses to augment the intervention. The PARTNER Intervention deploys three strategies to improve: 1) the timeliness and frequency of clinician-family communication, 2) the emotional and decision support provided to families and 3) the appropriate involvement of palliative care specialists."
45623007|NCT03287297|Diagnostic Test|OGTT & HBA1c|oral glucose tolerance test & HBA1c: by measuring glycated hemoglobin
45623008|NCT02448901|Drug|Edoxaban|In vitro study. Various concentrations of Edoxoban added to blood sample and tested
45623009|NCT02448667|Dietary Supplement|FAXE Kondi|Sucrose and glucose containing softdrink
45912484|NCT02010866|Behavioral|counseling|in-person counseling through RFWP offered to distressed respondents on the ISP and others who seek counseling (due to other reasons for referral)
45912485|NCT02010892|Procedure|Stent Grafting (ESR)|
45912486|NCT02010892|Procedure|Open Surgery (OSR)|
45912487|NCT02010905|Drug|Losartan|
45623010|NCT02448667|Dietary Supplement|Faxe Kondi Free|Diet softdrink with artificial sweeteners aspartame and acesulfame potassium. Both sweeteners are approved for use as food additives in the European Union and by the FDA. Aspartame metabolism is well understood and normal doses does not affect plasma concentrations of lipids, amino acids, glucose levels, key regulatory hormones or skeletal muscle metabolism. Acesulfame Potassium is not metabolized in humans and is excreted as the parent compound in urine. Since the two artificial sweeteners does not affect skeletal muscle metabolism or blood glucose levels, and both compounds have a well documented safety profiles, FAXE Kondi Free is considered to be an ideal placebo soft drink in this study.
45623011|NCT03287141|Diagnostic Test|Shuttle walk test|A shuttle walk test was performed without any previous intervention.
45765068|NCT05569551|Device|Adhesive pouch|Is a barrier dressing categorized under class C medical device. It is used to seal up the umbilical stump to prevent contamination until its cord detachment. It has an adhesive film that sticks to skin with a centrally located non-adhesive pouch ensuring that zero pressure is applied on the umbilicus. It is made of polyurethane, the same material as transparent intravenous cannula dressings making it hypoallergenic waterproof and breathable.
45623012|NCT03287141|Device|Noninvasive ventilation (Bi-pap)|After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
45765069|NCT02978313|Drug|Cetuximab|anti-EGFR monoclonal antibody
45765070|NCT02978313|Drug|mFOLFOX6|Oxaliplatin+LV5FU2
45765071|NCT02978313|Drug|FOLFIRI|Irinotecan+LV5FU2
45765072|NCT00958477|Biological|EMD 525797|Subjects will be administered with 250 milligram (mg), 500 mg, 1000 mg or 1500 mg of EMD 525797 intravenously over 1 hour every 2 weeks for 6 weeks. Subjects who will be clinically benefitted at the end of week 6 were continued at the same dose-level until disease progression, intolerance to treatment, withdrawal of consent or if the subject is no longer benefitted from the treatment as per Investigator's discretion.
45765073|NCT02958826|Other|Questionnaire|Anonymous questionnaire asking patients about their experiences with surgical lights, surgical smoke, and surgical sounds during their outpatient procedure.
45765074|NCT05716737|Radiation|Irradiation|3 Gy in 6 fractions to the TMJ, every other day, LINAC based
45765075|NCT05620459|Procedure|Ridge augmentation using chin bone ring with simultaneous implant placement|surgical guides are to be used to harvest chin bone ring, the rings are to be used for bone augmentation in extraction sockets (salama and salama classsification type II),simultaneously implant placement.
45765076|NCT00014495|Biological|filgrastim|
45765077|NCT00014495|Drug|cytarabine|
45765078|NCT00014495|Radiation|bismuth Bi213 monoclonal antibody M195|
45765079|NCT02978469|Other|Life style changing: reducing sedentary behavior|"The program includes 23 meetings held once per week (with holiday breaks). Each meeting lasts 90 minutes, consisting of exercise training.~the group will meet for information providing and discussion. Participants are guided in the process of creating a focussed individualized activity plan.~In the group setting they will experience a variety of activities enabling them to explore activities they prefer: each participant receive three personal consultation meetings. The group will experience sport and recreational activities with persons with physical impairments. Also activities in sport in community facilities."
45765080|NCT03017287|Device|GlucoMe App|Assessment of the the GlucoMe App
45623013|NCT03287141|Device|Noninvasive ventilation (CPAP)|After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
45623014|NCT03291353|Drug|pembrolizumab|200 mg IV given every three weeks
45765081|NCT04366271|Biological|Mesenchymal cells|1 infusion of undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue
45765082|NCT04366271|Drug|Standard of care|Best treatment option for COVID-19 according to investigator criteria
45765083|NCT05566041|Drug|RRx-001 + eLOOP Device|"RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device~Drug: Cisplatin/carboplatin plus etoposide Standard of care platinum doublet chemotherapy"
45765084|NCT05566041|Drug|Cisplatin/carboplatin plus etoposide|Standard of care platinum doublet chemotherapy
45765085|NCT03030547|Device|SenseWear activity monitor|Individuals will wear SenseWear activity monitors on right triceps muscle for 5 days. The data stored on the device will be recorded in computer using the software. Individuals will be given information of the resulting data (total number of steps, total energy expenditure, the number of daily steps and energy expenditure, physical activity duration in different intensity).
45765086|NCT02245997|Radiation|External beam radiotherapy|
45765087|NCT02245997|Radiation|proton beam RT|
45765088|NCT04374617|Diagnostic Test|Duplex ultrasound and Computed Tomography Angiography|All venous thromboembolisms suspected will diagnosed with ultrasound and CT-angiography
45765089|NCT04366037|Other|Routine training|Training will be defined by each club coach
45912488|NCT02010905|Drug|Placebo|
45912489|NCT02010918|Drug|glucosamine sulfate /chondroitin sulfate - capsules|500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
46069551|NCT04012073|Procedure|Extubation|"Each extubated patient will undergo oxygen therapy via high flow nasal cannula (maximum flows tolerated and FiO2 titrated to obtain 96%>SpO2>92%). Pre-emptive noninvasive ventilation (NIV) after extubation will be allowed in prolonged to wean patients (i.e. more than 3 SBT failure or more than 7 days from the first spontaneous breathing trial to being extubated) if deemed necessary by the physician in charge.~In case of respiratory failure during oxygen therapy via high flow nasal cannula after extubation and, a rescue NIV trial will be allowed before intubation in both groups at the discretion of the attending physician."
45765090|NCT04366037|Other|Routine training + proprioceptive exercise in warm-up|"Training will be defined by each club coach, adding four proprioceptive exercises in warm-up:~Exercise Description Duration Antero-posterior bipodal horizontal jump Players will jump forward and backward with both feet together, keeping their hands on their waists 30 seconds Unipodal lateral jump Players will perform single-leg lateral jump on both sides of a previously drawn line on the ground, and keeping their hands on their waists. 30 seconds per limb.~Antero-posterior unipodal horizontal jump Players will jump forward and backward with one foot, keeping their hands on their waists 30 seconds per limb.~Bipodal vertical jump with or whitout ball. Players will perform vertical jumps with both feet carrying a ball in their hands (this added difficulty will be optional). 30 seconds"
45765091|NCT04366037|Other|Routine training + proprioceptive exercise in cool-down|"Training will be defined by each club coach, adding four proprioceptive exercises in cool-down:~Exercise Description Duration Antero-posterior bipodal horizontal jump Players will jump forward and backward with both feet together, keeping their hands on their waists 30 seconds Unipodal lateral jump Players will perform single-leg lateral jump on both sides of a previously drawn line on the ground, and keeping their hands on their waists. 30 seconds per limb.~Antero-posterior unipodal horizontal jump Players will jump forward and backward with one foot, keeping their hands on their waists 30 seconds per limb.~Bipodal vertical jump with or whitout ball. Players will perform vertical jumps with both feet carrying a ball in their hands (this added difficulty will be optional). 30 seconds"
45623015|NCT03195751|Device|Software development kit measurements|This proprietary SDK (FocusMotion) processes user motions recorded by the hardware (accelerometer, gyroscope, magnometer). As data is collected, the software development kit (SDK) classifies the motion as repetitive or non-repetitive, and repetitive motions are further analyzed. As the user completes a movement, the SDK tracks the number of repetitions performed, technique, and rest time. The SDK can provide real-time feedback to the user regarding their form by comparing the movement to a template of an ideal motion for that particular action. The SDK is compatible with any operating system, phone, or wearable device, providing seamless integration with pre-existing technologies.
45765092|NCT03030391|Other|PET|
45765093|NCT03030391|Other|MRI|
45765094|NCT04374227|Procedure|Osteopathic Manipulative Treatment|Body regions that were treated included head, cervical, thoracic, ribs, lumbar, pelvis, sacrum, lower extremity, and upper extremity.
45623016|NCT03195751|Device|Manual Goniometer Measurements|A manual goniometer was used to measure the range of motion of the shoulder.
45623017|NCT03286907|Behavioral|Online videos|Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise and receive reminders at month 1, 2, 4, 6 & 8.
45623018|NCT03286907|Behavioral|Online videos and MI|Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise, receive 15 minutes motivational interviewing through telephone and reminders at month 1, 2, 4, 6, & 8.
45623019|NCT03286907|Behavioral|Control group|Receive online health communication messages about prevalence of some common mental health problems among MSM and introduction of stress reduction exercises
45623020|NCT03195985|Other|Mindfulness-based intervention|A shortened, 4 week mindfulness intervention course based on the original 8 week mindfulness-based stress reduction course by Jon Kabat-Zinn
45623021|NCT03195985|Other|Age Well psycho-education|4-week active control condition aimed at psycho-education regarding healthy ageing
45623022|NCT02460185|Behavioral|Study group: Maternal Physical Exercise|Exercise: 30 minutes of walking, 3 times a week at 4 Km/h.
45765095|NCT00960505|Other|Alternate day fasting|
45765096|NCT00960505|Other|Calorie restriction|
45765097|NCT00960505|Other|Control diet|
45765098|NCT04374071|Drug|Methylprednisolone|IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 days
45765099|NCT02958982|Drug|RP3128|Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
45765100|NCT02958982|Drug|Placebo|Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
45765101|NCT02244749|Other|skin specimen|skin specimen
46069552|NCT04135755|Other|no drug intervention|no drug or treatment intervention
45765102|NCT00357981|Drug|ORTHO EVRA, the contraceptive patch|
45623023|NCT02448433|Device|Phototherapy light-emitting glasses|"The intervention consists of four weeks of bright light exposure with light-emitting glasses (blue-green 500 nm dominant wavelength; 506 Lux lm/m^2) upon awakening and progressive shift to earlier wake-up times.~Participants are encouraged to complete the light exposure sessions for 60 min each day. Participants are also instructed to progressively shift their schedule 15 min earlier every day. This shift continues until the end of the four weeks of the intervention, or stops if the target wake-up time of 7:30am is reached (in which case, participants keep a stable wake-up and light session schedule at 7.30am for the remainder of the intervention). If participants already wake-up before 7.30am at study entry, they do the light exposure sessions upon awakening across the four weeks of the intervention.~During the intervention, participants are asked to note down the time of each light exposure session in a diary. Adherence is also monitored and promoted through weekly phone calls."
45765103|NCT03030703|Dietary Supplement|phytic acid|350 mg phytic acid (inositol hexaphosphate) three times daily for four weeks
45623024|NCT02460341|Drug|ondansetron|Ondansetron 8mg, 16mg, 24mg
45765104|NCT02157623|Drug|Levulan|Levulan application followed by Red or Blue light PDT
45623025|NCT02460341|Drug|placebo|placebo pill
45623026|NCT00189319|Drug|Flecainide controlled release|
45623027|NCT00189241|Drug|imiquimod|
45623028|NCT02460107|Biological|Botulinum toxin type A|
45623029|NCT02460107|Other|Normal saline|Placebo
45765105|NCT02157623|Other|Red Light PDT|Aktilite™ (red lamp) after Levulan application on lesions
45765106|NCT02157623|Other|Blue Light PDT|Blu-U® (blue lamp) after Levulan application on lesions
45765107|NCT03030469|Other|Change in electronic health record default for new opioid analgesic prescriptions|
45765108|NCT03028324|Device|Transcranial Magnetic Stimulation (TMS)|Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
45765109|NCT00358059|Behavioral|Behavioral Family Systems Therapy for Diabetes|
45765110|NCT00952081|Drug|Clevidipine|Clevidipine (0.5 mg/ml in 20 % lipid solution) will be administered via peripheral vein using syringe pump; drug infusion will be initiated at 5 mg/hr (10ml/h) and titrated to effect up to a maximum rate of 32 mg/hr when SBP exceeds 130 mm Hg. The anesthesiologist will be allowed to administer the alternative antihypertensive treatment (e.g. labetalol, hydralazine) after achieving a maximum clevidipine infusion rate.
46069553|NCT04289909|Other|Adaptive Optics Ophthalmoscopy (AOO)|AOO will permit to detect and quantify retinal perivascular inflammation in patients with MS in comparison to Healthy volunteers (control group)
45446682|NCT03747315|Other|In vitro functional test|Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on an additional blood sample (4 ml for children under 12 and 10 ml for children 12 years and older and adults) during a sample for patient care.
45623030|NCT03192553|Behavioral|Double Gloving Procedure|Participants will doff PPE using a double gloving procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
45623031|NCT03192553|Behavioral|Intensified Hand Hygiene Procedure|Participants will doff PPE using an intensified hand hygiene procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
45623032|NCT03192553|Behavioral|One Step Procedure|Participants will doff PPE using a one-step procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
45623033|NCT03192553|Behavioral|CDC Procedure|Participants will doff PPE using a CDC recommended procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
45623034|NCT03291275|Other|Follow-up for death and recurrence|All patients are followed up to determine definite date of diagnosis, recurrence and death.
45623035|NCT02448511|Other|Ozone|ozone gas generated by a generator applied to the affected part for a period of one hour each day under sub atmospheric pressure condition.
45765111|NCT04365881|Other|Cross-sectional observational study|Survey
45765112|NCT05716347|Biological|the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine|one booster dose intramuscularly in the deltoid muscle of the upper arm.
45765113|NCT02959840|Device|Acupressure Point P6 stimulator|This device stimulates the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device is placed on patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device is removed from the patient in the operating room, before the patient is transported to the recovery room. Patients receive continuous stimulation at a level that is comfortable for the patient prior to administration of the standardized regional anesthesia.
45765114|NCT02959840|Drug|Metoclopramide|10 mg Reglan IV immediately prior to administration of the standardized regional anesthesia.
45765115|NCT02959840|Drug|Ondansetron|8 mg of Zofran IV immediately prior to administration of the standardized regional anesthesia.
45765116|NCT04358341|Drug|Irinotecan|150 mg/m2 ivdrip every 14 days
45765117|NCT04358341|Drug|DOXOrubicin Liposome Injection|25 mg/m2 ivdrip every 14 days
45765118|NCT04358341|Drug|5fluorouracil|400mg/m2 iv bolus and 2400 mg/m2 civ 46h every 14 days
45765119|NCT02978547|Drug|Metformin Hydrochloride 500Mg Tablet|In the event of any grade 2 toxicities (with the exception of hyperglycemia), metformin will be withheld until improvement to ≤ grade 1, then restarted at a dose of 500 mg daily. In the event of grade ≥ 3 toxicities related to metformin, treatment will be discontinued. Metformin therapy will also be discontinued if serum lactate levels are above normal values.
45765120|NCT00929357|Drug|DMARDs or Biologics|
45765121|NCT00961051|Device|Investigational MPS|Multi-purpose solution
45765122|NCT00961051|Device|Opti-Free|Multi-purpose solution
45765123|NCT02240303|Procedure|Quantitative Sensory Testing (QST)|Participants in both groups will have a sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin.
45446683|NCT03747315|Other|In vitro functional test|Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on samples from healthy subjects who donated their blood to the French Blood Establishment.
45446684|NCT02087488|Other|auricular acupuncture(AA)|"Auricular acupoints: Shenmen (TF4), Heart (CO15), Subcortex (AT4), modifying points according to different patterns.~Auricular attachment material: disposable Seirin Pyonex Needle Seirin Pyonex Needle manufacturer: Seirin Corporation, a Japanese company. Medical Device Certification number: No. 15500BZZ00806000.~Treatment frequency: every 3 days.~Duration: 4 weeks."
45623036|NCT02448511|Device|Placebo|a similar looking device was applied to the affected part for a period of one hour each day under sub atmospheric condition. the device did not produce any gas.
45623037|NCT02448511|Other|Conventional treatment|Conventional treatment for ulcers in the form of daily dressings, debridement and antibiotics was administered to both groups
45765124|NCT02240303|Procedure|Physical Performance|Participants in both groups will have a Physical Performance test.
45765125|NCT02240303|Procedure|Magnetic Resonance Imaging (MRI)|Participants in both groups will have an magnetic resonance imaging (MRI).
45623038|NCT03286673|Dietary Supplement|calcium phosphate|
45623039|NCT03286673|Dietary Supplement|Tricalcium Phosphate|
45623040|NCT03286673|Dietary Supplement|Calcium carbonate|
45623041|NCT03286673|Dietary Supplement|Placebo|
45623042|NCT04483843|Other|No intervention|No intervention will be performed while it is retrospective observational study.
45623043|NCT04233593|Biological|Lipopolysaccharide|Endotoxin E Coli
45623044|NCT02448589|Drug|TAS-119|
45765126|NCT02240303|Procedure|Blood Sample|Participants in both groups will have blood samples taken.
45446685|NCT02087488|Other|placebo AA|"Auricular acupoints: Wrist (SF1), Clavicle (SF6), Shoulder (SF4、5), Tooth (LO1), Tonsil (LO7, 8, 9).~Auricular attachment material: the disposable Pyonex Zero Needle Pyonex Zero Needle manufacturer: Seirin Corporation, a Japanese company.~Treatment frequency: every 3 days.~Duration: 4 weeks."
45623045|NCT03286595|Other|Mobi mHealth app|"Mobile application (i.e. the app) that patients interact with via their smartphone to collect daily and weekly survey information. Data is visualized on a clinician-facing Dashboard, which can be used to inform treatment."
45623046|NCT03194425|Diagnostic Test|Pelvic floor EMG|Define pelvic floor EMG template measured by probe
45623047|NCT03283163|Behavioral|Exercise Testing and Training|Each study group will perform a baseline maximum load exercise test which will inform the individualized exercise prescription for the participant. Based on a progressive methodology, the participant will engage in 12 weeks of exercise of their choice (walking, running, cycling or swimming) with the goal of working towards a maximum heart rate range of 80% between weeks 6 and 12 of the study.
45765127|NCT05716191|Other|Naturally different iodine levels exposure|A cross-sectional survey of thyroid disease in elderly people in areas with different iodine nutrition backgrounds
45765128|NCT05556291|Drug|Combinations of Oral Blood Glucose Lowering Drugs|Combination of Ertugliflozin and Sitagliptin
45765129|NCT02959996|Drug|Liposomal bupivacaine|liposomal bupivacaine injection in the Pfannenstiel incision
45765130|NCT02959996|Drug|Placebo|placebo injection in the Pfannenstiel incision
45765131|NCT00929981|Drug|Tablet Methylprednisolone (4 or 16 mg)|Oral Methylprednisolone tablets (4mg, 16mg) will be given as per locally approved prescribing information
45446686|NCT02087488|Drug|Eszopiclone|"Dosage form: tablet.~Dosage: 1 piece (3mg).~Drug manufacturer: Kanghong pharmaceutical limited liability company, Chengdu.~Production license: NO. H20100074 approved by the state.~Treatment frequency: 15 mins before going to bed everyday.~Duration: 4 weeks."
45446687|NCT02092246|Device|Ultrasound machine|Use of ultrasound machine guidance for accurate needle placement into the knee joint
45446688|NCT02092246|Device|Unguided injection|Needle placement will take place without ultrasound machine guidance
45446689|NCT00148343|Device|Odstock Dropped-Foot Stimulator (ODFS)|Device implementation & use for ~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The ODFS then will be returned to the investigators.
45623048|NCT03286517|Biological|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)|A neurohormone
45623049|NCT02445703|Biological|Inactivated Hepatitis A vaccine (HAV)|Dosage of HAV is 250u hepatitis A antigen/0.5ml/dose.
45623050|NCT02445703|Biological|Combined hepatitis A and hepatitis B vaccine (HABV)|Dosage of HABV is 250u hepatitis A antigen and 5µg hepatitis B antigen/0.5ml/dose
45623051|NCT03286439|Other|there will be offered a follow up visit|The investigators will offer the patients a follow up visit 3 and 12 months after discharge from the hospital.
45765132|NCT00961441|Drug|Keppra XR|"Keppra XR 500 mg tablets and Keppra XR 750 mg tablets~Dosage: Keppra XR 1000-3000 mg/day taken once daily. Duration: 4-7 days"
45623052|NCT02448355|Device|OCT swept source DRI-Atlantis, Topcon|3-dimensional scanning protocol with 3 μm axial resolution and a speed of 100,000 A-scans per second. 256 B-scans to be taken on an area of 12 × 9 μm.
45623053|NCT04484545|Diagnostic Test|Prognostic score|Validation of scores of systemic inflammatory response
45623054|NCT03286205|Drug|IV iron|IV iron infusion based on weekly or every 3 week dosage.
45623055|NCT02448277|Device|Macintosh Laryngoscope|the device is to assist nasotracheal intubation
45623056|NCT02448277|Device|Pentax Airway scope|the device is to assist the nasotracheal tube into trachea
45623057|NCT02448277|Device|Glidescope|the device is to assist the nasotracheal tube into trachea
45765133|NCT05555355|Device|Prevena Plus 125 Therapy Unit|"The investigators will utilize the KCI USA, Inc Prevena Plus 125 vacuum-assisted closure device in patients undergoing spine surgery as a method to prevent surgical site infections and wound dehiscence after surgery. The device has been approved by the FDA under the name Prevena 125 and Prevena Plus 125 Therapy Units and regulation number 21CFR 878.4783."
45765134|NCT05555355|Procedure|Spine surgery|Patients will receive spine surgery
45765135|NCT02240381|Procedure|assessment of therapy complications|During OGTT 75gm of glucose will be given followed by phlebotomy
45765136|NCT02240381|Procedure|assessment of therapy complications|During clamp procedure tritiated glucose, D20, regular insulin will be given, followed by phlebotomy.
45765137|NCT02240381|Other|laboratory biomarker analysis|Correlative studies
45765138|NCT05716113|Drug|RD13-02 cell infusion|CAR-T cells
45623058|NCT02444299|Device|Shoulder hemi-arthroplasty|
45623059|NCT03286127|Other|specialized palliative care|specialized palliative care provided in different settings
45623060|NCT02444377|Behavioral|Interval training|
45765139|NCT02961946|Drug|Nitroglycerin|Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.
45765140|NCT02240459|Drug|fesoterodine 4mg|7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning
45765141|NCT02240459|Drug|Oxybutynin|5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo
45446690|NCT00148343|Other|Conventional Standard of Care|Conventional standard of care (which may include implementation & use of a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) for ~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The AFO, if implemented, may continue to be used afterwards since it is an element of the standard of care for this patient population.
46069554|NCT04135599|Device|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive, safe and easy-to-operate neuro-electrophysiological technique, which becoming an emerging therapeutic option for many mental disorders.It can modulate cortical excitability of target brain region, neuron plasticity and brain connections. Previous studies suggest that tDCS could reduce cue-induced craving and improve cognition in drug addiction.
46069555|NCT00629369|Device|Extra 3 mouth guard, Shock doctor mouth guard v3.0|Dental mouthguard, molded for each individual patient when in labor. The device is put in the water then in microwave for one minute to soften the device. The device is then applied to the patient's mouth for over 10 seconds to mold it.
45623061|NCT03194659|Dietary Supplement|Choline|Choline chloride is a water soluble choline salt that will be provided in a juice solution to participants to be consumed daily. The intervention will increase dietary choline intake by 500mg/day.
45623062|NCT03282929|Device|Part 1|A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order
45623063|NCT03282929|Device|Part 2 Group 1|300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
45623064|NCT03282929|Drug|Part 2 group 2|500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
45765142|NCT02240459|Drug|placebo|placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes
45765143|NCT02240459|Drug|fesoterodine 8mg|2, 4mg fesoterodine capsules taken together in the morning
45765144|NCT02978235|Drug|TAS4464|Intravenous (IV) Infusion
45765145|NCT02846740|Device|Alpha-Stim®.|cranial electrical stimulation
45765146|NCT02846740|Behavioral|Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale, The Pittsburgh Sleep Quality Index and agitated behavior Scale|A summed global score from rating scales measuring the Modifiable suicide risk factors (MSRF's).
45765147|NCT02240537|Drug|Sargramostim|Drug: Sargramostim (GM-CSF) Other Names: Leukine Sargramostim (250 ug vial) is reconstituted with 0.5 ml of Sterile Water for Injection. Subjects will receive 0.5 ml intradermally (250 µg) near the arm pit or inside of thigh.
45765148|NCT02240537|Drug|BB-MPI-03|Other Names: Multi-peptide immunotherapy (MPI) is comprised of 3 cytotoxic T-cell epitopes derived from oncofetal antigen. There are 3 dose levels of study vaccine planned to be tested, starting at 0.25 mg each peptide (0.75 mg total peptide dose), then 0.5 mg of each peptide (1.5 mg total) and finally 1 mg each peptide (3 mg total). At the starting dose of 0.75 mg, the BB MPI 03-15 mg vial is used and 100 ul is administered; at the 1.5 mg dose, 200 ul of the BB MPI 03-15 mg vial is used; at the 3 mg dose, 200 ul of the BB MPI 03-30 mg is used.
45765149|NCT02240537|Drug|Montanide|"Drug: Montanide Other Names: mineral oil, USP BB-MPI-03 is emulsified with Montanide and administered intradermally (ID) within 1-2 cm of the 2 sargramostim injection sites 1-3 minutes after sargramostim administration.~Subjects and the injection sites are to be monitored for 1 hour after sargramostim and BB-MPI-03 emulsion administration."
45765150|NCT05716035|Drug|Tocilizumab Injection|Participants will receive IV tocilizumab
45765151|NCT02240615|Device|Sinopsys Lacrimal Stent|Procedural insertion of the Sinopsys Lacrimal Stent in patients with epiphora
45765152|NCT05676333|Drug|Secukinumab|
45765153|NCT02240771|Procedure|Transarterial chemotherapy|"Femoral artery would be punctured at the upper thigh using 18 gauge needle under local anesthesia. Catheterization of the hepatic artery feeding the tumor would be done and placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~Mixture would be prepared by using Doxorubicin 50mg and Cisplatin 100mg. Hydrocortisone 100mg and augmenting dose of analgesic and sedative would be injected prior to the administration of the drug.~The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-leur lock syringes."
45446691|NCT00148343|Procedure|Traditional Physical Therapy Treatment|Traditional physical therapy treatment for 12 weeks.
45446692|NCT02087566|Drug|600 mg linezolid|
45446693|NCT02092402|Other|Fecal transplantation|
45446694|NCT03557866|Diagnostic Test|running|individuals will be asked to run for 5 km in self selected speed
45623065|NCT03282929|Device|Part 2 group 3|300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)
45623066|NCT03282929|Device|Part 2 Group 4|300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)
45623067|NCT02445547|Other|UC-MSCs by peripheral intravenous infusion|
45623068|NCT02445547|Drug|received hormone maintenance therapy|
45623069|NCT03285815|Device|Proton Therapy|
45623070|NCT03194191|Device|Acupuncture needles|The patient will be in a semi recumbent position during needle penetration. Duration of needle insertion: 30 minutes
45623071|NCT03282851|Drug|MSB11456|Subjects will receive a single injection of MSB11456 on Day 1.
45623072|NCT03282851|Drug|US-licensed Actemra|Subjects will receive a single injection of US-licensed actemra on Day 1.
45623073|NCT03282851|Drug|EU-approved RoActemra|Subjects will receive a single injection of EU-approved RoActemra on Day 1.
45623074|NCT02444065|Behavioral|Cognitive Behavior Therapy (CBT)|The CBT intervention is a 4 session (1 hour each) individual psychotherapy intervention that uses a manualized treatment protocol developed by the investigators. It uses standard CBT for eating disorders interventions, including orientation to the CBT model, psychoeducation, commitment and goal setting, behavioral strategies for normalizing eating and reducing bulimic symptoms, planning, and homework. 1-2 sessions are delivered before starting day hospital treatment, and the remaining sessions are delivered in the first weeks of day hospital.
45623075|NCT02444065|Behavioral|Motivational Interviewing (MI)|The MI intervention is a 4 session (1 hour each) individual psychotherapy intervention that uses a manualized treatment protocol (Carter & Bewell-Weiss, 2012). It uses standard MI for eating disorders interventions, including decisional balance, exploring values, readiness and confidence rules, and MI communication strategies. 1-2 sessions are delivered before starting day hospital treatment, and the remaining sessions are delivered in the first weeks of day hospital.
45623076|NCT03285737|Dietary Supplement|Whey|Supplement provided twice daily in 30g doses
45623077|NCT03285737|Dietary Supplement|Collagen|Supplement provided twice daily in 30g doses
45623078|NCT04483531|Drug|Odevixibat|A4250 is a small molecule and selective inhibitor of IBAT
45623079|NCT03285659|Other|Intervention: INDI Implementation|Implementation of a collaborative care model in the context of primary care to manage depression
45623080|NCT03190603|Drug|Celecoxib|Continue celecoxib 400mg/day for 3months in axial spondyloarthritis patients.
45623081|NCT02459639|Other|Anthroposophic integrative care rehabilitation program|"The programme for chronic pain at AIC consists of two phases:~A three-week in-patient period. During the first three-week in-patient stay, patients meet regularly with a multi-professional team. Usually, each patient receives two of the following therapies 2-4 times per week: art therapy, massage, physiotherapy, eurhythmy and baths. Nursing care is provided twice daily. Moreover, patients are offered to participate in group activities.~Two-three day inpatient follow-up and treatment period closure. The second phase of the treatment programme consists of a 2-3 day inpatient stay, 6 months after closure. During this time, physician, nurse and therapist appointments are made according to individual needs. The patients who have been engaged in group activities are gathered in groups."
45623082|NCT02459639|Other|Conventional multi-modal care rehabilitation|The standard approach at Linköping University Hospital admits patients for bio-psycho-social assessment, pharmacological treatment and multimodal rehabilitation (main components: education, intense physical exercise, cognitive behavioural therapy and workplace interventions) for a 6 week intensive phase period (75%) followed by 4 weeks (25%). Here a number of professional disciplines collaborate and form a team of professionals focused on individual patient needs The multimodal rehabilitation outpatient program delivered by this team has the following aims: 1) reduce pain and psychological burden, 2) improve work capacity and decrease sick-leave and 3) increase perceived health and quality of life. These general aims are combined with the aims of the patient in a plan of rehabilitation.
45623083|NCT05233579|Dietary Supplement|Sulforaphane|Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning. The supplement should be taken around the same time each day.
45623084|NCT03285581|Device|arm-1|Subject(s) will receive 2 RF treatments
45623085|NCT03194347|Diagnostic Test|molecular genetic analyses|molecular genetic analyses
45623086|NCT03282773|Device|Deferred stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted 4-10 days after restoration of blood flow in left main coronary artery in a secondary PCI.
45623087|NCT03282773|Device|Immediate stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted immediately after restoration of blood flow in left main coronary artery in a secondary PCI.
45623088|NCT02445469|Other|MRI exam of the brain|MRI exam of the brain
45623089|NCT03285503|Drug|Aripiprazole IM Depot|administration of Aripiprazole IM Depot formulation at doses of 400 mg for 5 times in patients with schizophrenia.
45623090|NCT02440087|Dietary Supplement|Refill Bypass|Dietary supplement
45623091|NCT03282617|Biological|CD137L-DC-EBV-VAX|Patients will receive CD137L-DC-EBV-VAX at a dose of approximately 5-50 millioncells every 2 weeks, for a total of 5-7 times.
45623092|NCT02439931|Behavioral|Remote psychosocial intervention|
45623093|NCT03285347|Device|Computer-based cognitive training|Computer-based cognitive programmes are computer programmes designed as games with the aim of training patients in certain cognitive domains.
45623094|NCT03282539|Device|LAMS|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents
45623095|NCT03282539|Device|LAMS + pigtail|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents and a coaxial double pigtail stent
45623096|NCT02443909|Procedure|Retrograde Intrarenal Surgery|endoscopic stone treatment with flexible ureteroscopy and 20w holmium laser device
45623097|NCT02443909|Procedure|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working over 20w power)
45623098|NCT02443909|Procedure|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working under 20w power)
45623099|NCT02443909|Device|Holmium laser device|
45623100|NCT03285191|Other|Numerical rating scale|Following the concept elicitation interview, participants will be presented with a list of typical RA symptoms and asked to rank how bothersome each symptom is and how important it would be to improve with treatment on a 1-5 numerical rating scale (NRS).
45912490|NCT02010918|Drug|glucosamine sulfate /chondroitin sulfate - sachet|1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
45912491|NCT02010918|Drug|Cosamin DS®|500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
45623101|NCT03285191|Other|Real-time data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms using a study-specific application on their own smart device. Up to ten of the thirty interview participants can participate in the app sub study, which is voluntary.
45623102|NCT02445235|Other|Patient Reported Outcome Survey Tool|Patient Reported Outcome Survey Tool
45623103|NCT04136951|Other|PREVENT clinical decision support|PREVENT clinical decision support tool consideres five patient risk factors as significant predictors of patient's priority for the first homecare nursing visit: (a) Presence of wounds (either surgical or pressure ulcers); (b) a documented comorbid condition of depression; (c) need for assistive equipment, assistive person, or both for toileting; (d) number of medications; and (e) number of comorbid conditions. Each risk factor was assigned a specific score based on the logistic regression weights. For instance, for a wound (e.g., pressure ulcer, vascular ulcer), the patient received a score of 15 points. For each additional co-morbid condition, one point was added to the final score. Summing the scores for the factors generated a cumulative score. The optimal cut-off point was established based on the regression model performance statistics, indicating that patients with a score greater than 26 points are a high priority for the first nursing visit.
45765154|NCT02240771|Drug|Oral chemotherapy|"Drugs used would be Thalidomide and Capecitabine in the following dosage schedule- Thalidomide---50mg once a day (OD) for 7 days, increased to 100mg OD for 7 days, 200mgOD for 7 days further increased to 300 mg OD.~Capecitabine---- 500mg OD for 7 days, then 1000mg OD for next 7 days, increased to a maximum dose of 1500mg OD~Maintenance dose - Capecitabine 1500 mg - every alternate week Thalidomide - 300 mg OD. Total leucocyte count & Platelet count would be monitored every 15 days"
45765155|NCT02848222|Device|Bruder Moist Heat Compress|
45765156|NCT02848222|Other|Washcloth|
45765157|NCT05715957|Other|No intervention|No intervention
45623104|NCT02439697|Other|Darbepoetin alfa|Conversion from Aranesp® to NESP®
45623105|NCT03285035|Device|Administration of questionaires to patients receiving an upper endoscopy with cryotherapy in addition to chemotherapy for esophageal cancer palliation.|Upper endoscopy with cryotherapy using liquid nitrogen.
45623106|NCT02445313|Device|Nidek MP-3|Nidek MP-3 device to be used to take images which will allow measurement of GA in patients with AMD
45765158|NCT02240849|Device|Functional pillow|streamlined shape for cervical lordosis memory foam pillow functional design considered several sleep position
45765159|NCT02240849|Device|Placebo general pillow|
45765160|NCT00962065|Drug|LX4211 Low Dose|A low dose of LX4211; daily oral intake for 28 days
45765161|NCT00962065|Drug|LX4211 High Dose|A high dose of LX4211; daily oral intake for 28 days
45765162|NCT00962065|Drug|Placebo|Matching placebo dosing with daily oral intake for 28 days
45765163|NCT02240927|Drug|Low Molecular Weight Heparine : Enoxaparine|During first trimester, warfarin is stopped and enoxaparine is started in 1mg/kg dose twice a day. Dose is adjusted according to Anti Factor Xa levels (between 0.7-1.2). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
46069556|NCT04290221|Other|Ultrasound-guided percutaneous electrolysis in the lumbar nerve root|This group will be treated with intratissue percutaneous electrolysis using a needle G32 with galvanic current as a cathodic flow electrode in the posterior nerve root of L3 (one times per week / 3 weeks). The intervention will be guided by ultrasound equipment medically certified (Directive 93/42 / EEC) device (EPI Advanced Medicine, Barcelona, Spain).
45446695|NCT04150341|Drug|TD-8236|The study drug will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
45765164|NCT02240927|Drug|Enoxaparine and 2.5 mg Warfarin|If the patient's therapeutic warfarin dose is more than 5 mg before pregnancy, warfarin dose is decreased to 2.5 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4)
45765165|NCT02240927|Drug|Enoxaparine and 4mg Warfarin|If the patient's warfarin consumption dose is more than 5 mg before pregnancy, warfarin dose is decreased to 4 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
45765166|NCT02240927|Drug|Warfarin|If the patient's therapeutic warfarin dose is less than 5 mg before pregnancy, warfarin is continued in the same dose during all the pregnancy and the dose is adjusted according to INR level (between 2.5-4).
45765167|NCT03038308|Drug|Ropinirole|0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole
45765168|NCT04358497|Device|Medtronic® Concerto® detachable coil system|coil embolization of the reflux pathways
45765169|NCT04358497|Procedure|sclerosis|Pelvic varices sclerosis with polidocanol foam
45765170|NCT04358497|Drug|Diosmin / Hesperidin|Best chronic medial treatment
45765171|NCT04358497|Drug|Ibuprofen 400 mg|NSAID treatment
45765172|NCT05545683|Biological|VLA 2001|VLA2001 is a highly purified whole virus, inactivated, adjuvanted vaccine, using the manufacturing platform of Valneva's encephalitis (JE) vaccine
45912492|NCT02010944|Drug|solifenacin succinate|oral
45912493|NCT02010944|Drug|mirabegron|oral
45623107|NCT03284801|Other|management of acute disseminating encephalomyelitis|clinical audit on management of acute disseminating encephalomyelitis
45765173|NCT04373291|Biological|BCG-Denmark|Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.
45765174|NCT04373291|Biological|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
45765175|NCT02849938|Device|TytoCare Device|Tyto is a handheld, mobile device designed for capture and transmission of ear/throat/skin images and lung/heart auscultations. It may be used to perform non-invasive, medical examinations, either on a patient (by another person, most commonly a family member, or by a medical professional) or self-performed by the patient, for remote review by a medical practitioner. It is suitable for use on patients in both clinical and home environment.
45765176|NCT04373447|Procedure|lap fundus-calot cholecystectomy|use laparoscopic fundus-calot approach
45765177|NCT04373447|Procedure|open cholecystectomy|use open approach
45765178|NCT05715801|Procedure|hyperbaric oxygen therapy|The hyperbaric oxygen group was given 60 minutes of pure oxygen under 2ATA (Atmosphere Absolute, ATA) and 5 minutes of rest in between.
45765179|NCT05715801|Procedure|conventional oxygen therapy|Conventional oxygen therapy group breathed 27% oxygen at 1.03 ATA for 60 minutes. (The chamber pressure was increased to 1.2ATA with circulating air noise for the first 5 minutes of the experiment, then reduced to 1.03 ATA for the next 5 minutes.)
45765180|NCT04373213|Diagnostic Test|Pleth variability index|The usefulness of Pleth variability index in predicting fluid response in patients with COVID 19
45765181|NCT04373135|Behavioral|Brief educational video|A brief educational video will be displayed explaining the mechanics of how SRA policies operate, how they are decided, and what patients' and healthcare workers' rights are surrounding them.
45765182|NCT05671107|Diagnostic Test|NET|Online survey measuring a variety of developmental domains including anxiety, motor, daily living skills, challenging behaviors, social communication, restrictive and repetitive behaviors, ADHD, executive functioning, mood, quality of life, and sleep
45765183|NCT02851108|Drug|Methylene Blue|50 patients will receive methylene blue
45765184|NCT02851108|Drug|Primaquine|50 patients will receive primaquine
45623108|NCT05179603|Drug|THOR-707|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
45765185|NCT04372667|Behavioral|Community score card approach|"The CSC intervention is a participatory community approach. Health care workers (HCWs), PMTCT clients identified the issues that most impacted PMTCT service quality and uptake, and came together to implement actions for improvement. The core implementation strategy is using dialogue in a participatory forum that engages both service users and service providers. The CSC consists of five core phases, repeated on a regular basis (called rounds), for the life of the project. The five core phases include:~Phase I: Planning and preparation~Phase II: Conducting the Score Card with the community~Phase III: Conducting the Score Card with service providers~Phase IV: Interface meeting and action planning~Phase V: Action plan implementation and follow-up"
45765186|NCT00358995|Behavioral|Cognitive Behavioral Therapy|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
45623109|NCT05179603|Drug|Pembrolizumab|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
45623110|NCT03284645|Drug|Tenofovir Disoproxil Fumarate (TDF) 300 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg|Fixed-dose combination of 300 mg TDF, 300 mg 3TC and 600 mg EFV taken once daily.
45765187|NCT00358995|Behavioral|Stress Management Therapy (SMT)|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
45912494|NCT02010944|Drug|mirabegron/solifenacin succinate|oral
45623111|NCT03284645|Drug|Abacavir (ABC) 600 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg|Fixed-dose combination of 600 mg ABC, 300 mg 3TC and 600 mg EFV taken once daily.
45623112|NCT03284645|Drug|Zidovudine (AZT) 300 mg + Lamivudine (3TC) 150 mg twice daily + Efavirenz (EFV) 600 mg once daily|Fixed-dose combination of 300 mg AZT and 150 mg 3TC taken twice daily, plus 600 mg EFV taken once daily.
45623113|NCT02445157|Other|4MGS|Measurement of usual gait speed over 4 metres (metres/second)
45623114|NCT03284567|Behavioral|Football fitness|"The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games.~Training will take place on a natural grass pitch. In adverse weather conditions (i.e., < 5°C or heavy rain) training will be performed indoors"
45765188|NCT04347395|Procedure|Respiratory Bundle & Prevention|The respiratory care bundle intervention comprised of: bed tilt, swallow screen, mouth wash and vaccinations. The bed tilt was a 30-degree whole bed-up positioning both day and night throughout the hospital stay and is shown in Figure 1. Swallow screen was undertaken within 48 hours of admission. Chlorhexidine mouth wash was prescribed initially four times daily. The protocol was amended to twice daily chlorhexidine mouth wash in August 2017 due to poor compliance with four times daily administration. Mouthwash administration was monitored in the intervention group only and deemed non-compliant if missed more than 3 times during the admission. Pneumococcal and influenza vaccination was offered at discharge or within 2-4 weeks post discharge, at no charge to the patient. Post discharge advice was to use pillows in bed to minimize the time the patient laid flat and to avoid lying down for an hour after meals.
45765189|NCT02854540|Device|Hydrogel electrode-based iontophoresis|Hydrogel was administered through iontophoresis, a process of transdermal drug delivery by use of a voltage gradient on the skin.
45765190|NCT05670405|Other|The Trauma PORTAL|"Participants will have 9 weeks to complete the 8 modules which each take on average 45 minutes to complete. Each module consists of psychoeducational handouts, videos, interactive exercises, and discussion topics that has been adapted from the R&R curriculum. The participants will also receive a pdf of the handouts from the modules, which can be used to take notes or refer back to in the future.~There will be an optional 60-minute weekly virtual group session for participants to engage with other participants in their group and for group facilitator providers to discuss the materials covered and answer any questions. Participants will join a Zoom video group visit to access the group. Each weekly group will be facilitated by 2 clinicians specializing in trauma-focused therapy within the WCH TTP who have extensive experience with in-person and virtual synchronous R&R."
45765191|NCT00930293|Behavioral|Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)|16 weekly IPT-PS sessions, each lasting approximately 45 minutes
45765192|NCT00930293|Behavioral|Brief Supportive Psychotherapy (BSP)|16 weekly BPS sessions, each lasting approximately 45 minutes
45765193|NCT00930293|Drug|Citalopram hydrobromide|A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day
45765194|NCT02977767|Procedure|Conversational hypnosis|Conversational hypnosis starts since the enter of the nurse in patient's room and last since the nurse leaves the room. Change of canula is performed under conversational hypnosis.
45765195|NCT02855086|Biological|Cetuximab|Administered intravenously (IV)
45765196|NCT02855086|Drug|Cetuximab-IRDye 800CW|Administered intravenously (IV)
45765197|NCT02855086|Procedure|Tumor resection|Standard of care treatment
45912495|NCT02010957|Other|FDG positron emission tomography|2 consecutive imaging studies (diagnostic study) within 1-2 weeks: FDG-PET and 123I-Iodometomidate imaging in patients with an indeterminate adrenal neoplasm
45912496|NCT02010957|Other|Iodometomidate imaging|2 consecutive imaging studies (diagnostic study) within 1-2 weeks: FDG-PET and 123I-Iodometomidate imaging in patients with an indeterminate adrenal neoplasm
45912497|NCT02010970|Drug|Group 1 AZD3293|AZD3293 oral solution
45623115|NCT03190447|Device|Aquacel Surgical®|Measuring the skin integrity with each dressing and the patient satisfaction
45623116|NCT03190447|Device|Mepilex Border post-op®|Measuring the skin integrity with each dressing and the patient satisfaction
45765198|NCT05368857|Drug|Afamelanotide|Up to 10 adult healthy volunteers will be enrolled in this study in which small areas of their skin will be exposed to UVR and skin samples taken. UV-induced DNA damage and repair will be analysed.
45765199|NCT02241005|Other|Theraworx™ bath wipes|Theraworx™ bath wipes will be supplied in packaging similar to the standard bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
45912498|NCT02010970|Drug|Group 2 AZD3293|AZD3293 oral solution
45912499|NCT02010970|Drug|Group 3 AZD3293|AZD3293 oral solution
45912500|NCT02010970|Drug|Group 1 Itraconazole|itraconazole capsule
45912501|NCT02010970|Drug|Group 2 Diltiazem|Diltiazem ER tablet
45912502|NCT02010970|Drug|Group 3 Midazolam|midazolam syrup
45446696|NCT04150341|Drug|Placebo|The placebo will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
45623117|NCT03190447|Device|Opsite post-op visible®|Measuring the skin integrity with each dressing and the patient satisfaction
45912503|NCT02011009|Other|HIV seropositive patients|During a routine visit, a self-administered anal swab will be proposed as well as an anonymous questionnaire about sexual practices. In addition to usual outpatient treatment an examination and an evaluation of a possible sexually transmitted infection (STI) will be realized. Some questions about risk factors traditionally associated with carriage of resistant bacteria will also be investigated with the aid of the questionnaire such as: use of antibiotics during the year, travel in areas at risk.
45912504|NCT02011022|Drug|3g MTX|The group of patients which are treated with 3g/m2 MTX, low risk ALL or NHL
45912505|NCT02011022|Drug|5g MTX|The group of patients which are treated with 5g/m2 MTX, they are high or middle risk ALL patients
45912506|NCT02011048|Procedure|Endoscopic components separation|Endoscopic components separation hernia repair
45623118|NCT03190447|Device|Urgotul ABSORB border silicona®|Measuring the skin integrity with each dressing and the patient satisfaction
45765200|NCT02241005|Other|Standard bath wipes|Standard bath wipes will be supplied in packaging similar to the Theraworx™ bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
45912507|NCT02011087|Procedure|bioelectric impedance analysis|Undergo bioelectric impedance analysis
45623119|NCT03190447|Device|Conventional dressing|Measuring the skin integrity with each dressing and the patient satisfaction
45623120|NCT03284489|Other|Collection of medical datas from ICU patients|Collection of medical datas from ICU patients with pancreatitis on a secured electronic database
45623121|NCT03189979|Behavioral|Physical activity and healthy eating intervention|Using a community-based participatory approach, BGC staff and academic researchers developed intervention components informed by formative studies and based on a social ecological theory framework. Components included healthy eating and physical activity policy implementation, staff training, a challenge/self-monitoring program for healthy behaviors, a peer-coaching program for healthy behaviors, and a social marketing campaign.
45623122|NCT03284333|Device|other|no arm
45623123|NCT02445001|Procedure|ICG loaded erythrocytes|For each subject, on the morning of the day angiography was scheduled, or no longer than 4 days prior to angiography, 9 ml of blood will be withdrawn from an antecubital vein. Using sterile procedures, erythrocyte ghosts produced from the blood will be loaded with ICG dye (for the diagnostic part of the study) or with ICG and one of several drugs (for the therapeutic part of the study) by the following procedure, which requires about 2 hours and yields approximately 1 ml of packed cells (80% Ht) that, after microscopic examination, are ready for autologous re-injection
45623124|NCT03284255|Device|study group|study group in which patient will accept the treatment of Bioresorbable Coronary Stent
45446697|NCT00148109|Drug|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes.
45446698|NCT00148109|Drug|Cetuximab|Cetuximab 400 mg/m2 over 120 min IV initial does followed by weekly Cetuximab 250 mg/m2 over 60 min
45623125|NCT03284255|Device|control group|control group in which patient will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
45623126|NCT03194113|Behavioral|Trauma-focused treatment|Weekly sessions
45623127|NCT03194113|Behavioral|Emotion regulation training|Managing and tolerating negative emotions, e.g. anger, sadness. Weekly sessions; preparatory to Prolonged exposure treatment
45623128|NCT03194113|Behavioral|Intensive Trauma-focused treatment|Intensive version (3 sessions per week) of Trauma-focused treatment
45623129|NCT03284177|Drug|Calcium (13C)Carbonate|C13-CAC breath test containing Calcium (13C) Carbonate was performed twice under fasting conditions.
45623130|NCT03284177|Drug|Gastric acid inhibitors|Gastric acid inhibitor was orally administrated once daily for 4weeks after first C13-CAC breath test.
45623131|NCT03284177|Other|Gastric pH monitoring|Gastric pH monitoring was performed once under fasting condition.
45765201|NCT05541081|Diagnostic Test|Point-of-care STI testing|"Testing for:~Chlamydia and gonorrhoea using the GeneXpert platform (Cepheid)~Trichomoniasis using the OSOM Trichomonas Rapid Test (Sekisui Diagnostics)~HIV and syphilis using the SD BIOLINE HIV/Syphilis Duo (Abbott Diagnostics Medical Co. Ltd)~Hepatitis B using the HBsAg2 rapid test (Abbott Diagnostics Medical Co. Ltd)"
45765202|NCT04347005|Drug|Cohort 1: AR882|Single dose of AR882 or matching placebo
45912508|NCT02011100|Dietary Supplement|Carnosine|
45912509|NCT02011126|Drug|Imetelstat Sodium|Given IV
45912510|NCT02011126|Other|Laboratory Biomarker Analysis|Optional correlative studies
45912511|NCT02011139|Behavioral|Cognitive-behavioral group therapy|
45765203|NCT04347005|Drug|Cohort 2: AR882|Single dose of AR882 or matching placebo
45765204|NCT04347005|Drug|Cohort 3: AR882|Single dose of AR882 or matching placebo
45765205|NCT04347005|Drug|Cohort 4: AR882|Single dose of AR882 or matching placebo
45765206|NCT04347005|Drug|Cohort 5: AR882|Single dose of AR882 or matching placebo
45765207|NCT04347005|Drug|Cohort 6: AR882 Food Effect|Single dose of AR882 or matching placebo in a fed state
45765208|NCT04347005|Drug|Cohort 7: AR882 Solid Oral Formulation|Single dose of AR882 or matching placebo
45765209|NCT04347005|Drug|Cohort 8: AR882 in combination with allopurinol|Single dose of allopurinol alone and a single dose of AR882 in combination with a single dose of allopurinol
45765210|NCT04347005|Drug|Cohort 9: AR882 in combination with febuxostat|Single dose of febuxostat alone and a single dose of AR882 in combination with a single dose of febuxostat
45765211|NCT02856490|Device|vSculpt|A genital vibration device that operates in two modes, vibration only or vibration and light, to help tone and tighten pelvic floor muscles.
45765212|NCT02856490|Device|InTone|A genital device using electric muscle stimulation to treat incontinence.
45446699|NCT03558256|Behavioral|Mindfulness-based Cognitive Therapy|Patients participating in the experimental group will receive the MBCT intervention besides the usual medication treatment. The intervention is implemented by the manual adapted from the MBCT for Depression (Segal et al. 2013). The modified version of the program has the same structure with the original manual combined the mindfulness training and the cognitive elements from CBT, but the content is more suitable for the Chinese. The instructors in this study are trained and certificated psychiatrists and psychotherapists with rich experience of working with MDD, and they will receive a weekly supervision conducted by a senior supervisor.
45623132|NCT02439619|Other|TechCare|The TechCare software is being developed specifically for use on a touch screen mobile phone. The mobile application will alert participants through notifications and ask a number of questions. Based on participant responses the app will provide a CBT based response to individuals or the service users preferred multimedia such as music, images and videos.
45446700|NCT03558256|Drug|Medication|Both of the MBCT group and the medication group will receive the medication treatment. The initial dose conforms the drug instructions, the dosage can be adjusted once a week, and the maximum dosage should not exceed the maximum amount by the instructions. MDD patients with sleep disorders can use drugs combined with benzodiazepine drugs, but not continuing for more than two weeks; while other psychotropic drugs are not allowed. All of the drugs used in this study are usual clinical drugs with good security, the common adverse reactions include nausea, dry mouth, constipation, diarrhea, indigestion, dizziness, drowsiness, fatigue, sweating, heart palpitations, delayed ejaculation in male, increasing blood aminotransferase without symptoms occasionally and so on.
45446701|NCT02088580|Procedure|Triple Chronotherapy|
46069557|NCT04290221|Other|Ultrasound- guided Percutaneous electrolysis in trigger points|It consists in apply the ultrasound-guided percutaneous electrolysis on active and/or latent TPs in the gluteus medius, quadratus lumborum, and erector spinae muscles of the subjects L3 (one times per week / 3 weeks).
46069558|NCT04135287|Drug|GLP-1 receptor agonist|The main objective of the study is to determine the relationship between the increase in glucose-stimulated insulin secretion and decrease in HbA1c caused by GLP-1 RA therapy in poorly controlled T2DM patients. We also will identify a cut point of an increase in beta cell function which produces a clinically meaningful decrease in HbA1c.
46069559|NCT04135521|Drug|Intraperitoneal chemotherapy|Intraperitoneal or intravenous dose-dense platinum/taxane chemotherapy
45623133|NCT03192709|Drug|Sildenafil vaginal suppositories|Sildenafil vaginal suppositories (100 mg/day) from the start of HMG administration day until the day of oocyte retrieval.
45623134|NCT03192709|Other|vaginal placebo|Daily vaginal placebo from the start of HMG administration day until 2 days before the hCG injection day, then will be switched to vaginal sildenafil suppositories (100 mg/day) until the day of oocyte retrieval.
45623135|NCT03192709|Other|vaginal placebo|Daily vaginal placebo from the start of HMG administration day until the day of oocyte retrieval.
45623136|NCT02460029|Other|Ventral hernia|Visualization of the mesh surface and the confirmation with MRI scan at 1 month and 13 months after standardized retromusculare incisional hernia repair with the visible CICAT mesh (Dynamesh®).
45446702|NCT04623801|Procedure|Percutaneous Laser Ablation (PLA)|Percutaneous Laser Ablation / PLA will be carried out in a single session by advancing one 21-gauge spinal needle into the target lesions under real time US guidance.
45765213|NCT00358293|Drug|Tizanidine (sublingual or oral)|
45765214|NCT02241083|Drug|Dopamine|
45765215|NCT02241083|Drug|Norepinephrine|
45765216|NCT02241083|Other|no medication|
46069560|NCT04001621|Drug|Pyrotinib combined with capecitabine|pyrotinib 400 mg once daily; Capecitabine 1000 mg/m2 per day on day 1 through 14, every 21 days.
46069561|NCT02623179|Other|culture versus Molecular diagnostics|Treatment based on the results of the FH C & S testing - Odd Numbers on randomization table
46069562|NCT02623101|Device|Reflectance confocal microscopy|Non-invasive imaging of the lesion
46069563|NCT02623101|Procedure|Punch biopsy|Obtaining a skin sample of the suspicious lesion under local anesthetics
45765217|NCT05367531|Device|Autoinjector|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
45912512|NCT02011165|Procedure|Positioning measuring device|A tennis ball in the night shirt will prevent supine position during sleep.
45912513|NCT02011178|Procedure|Optimal medical treatment and surgery|
45912514|NCT02011178|Procedure|Optimal medical treatment|
45912515|NCT02011191|Dietary Supplement|Biotin Supplementation|10,000 micrograms biotin supplement daily for 8 weeks
46069564|NCT02623101|Procedure|Surgical excision|Excision of the basal cell carcinoma lesion under local anesthetics
45623137|NCT02443753|Device|EndoBarrier SANS|Eligible subjects will be implanted with the EndoBarrier® SANS™ Device for a period of 3 months. The GI Dynamics' EndoBarrier® SANS™ is an endoscopically positioned device that represents an alternative to the use of gastric bypass operative techniques as a means of re-routing food and altering the gut-hormone axis. The EndoBarrier® SANS™ provides an alternate passage of chime through the duodenum and proximal sixty centimeters of jejunum replicating in part the bypass of bariatric surgery.
45623138|NCT02443987|Other|Intravenous fluid|500ml infusion of 0.9% Sodium Chloride intravenously.
46069565|NCT00924404|Drug|Xylitol|5% solution for sinus rinse
45623139|NCT02459873|Behavioral|Computer games to assess change in executive function skills|Children get access to computer games for 10 weeks for an hour each week.
46069566|NCT00924404|Drug|Saline|saline for sinus rinse
45446703|NCT00186485|Device|MagStim|The MagStim delivers low frequency 1Hz stimulation to the right frontal area of the brain
46069567|NCT00976937|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
45623140|NCT02444923|Device|Scleral rigid gas permeable contact lenses (SRGPcl) (Zenlens™)|Custom manufactured scleral rigid gas permeable contact lenses. These lenses are designed to fit the eye with high level of precision. The aim is to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with the corneal rigid gas permeable lenses.
45623141|NCT02444923|Device|Corneal Rigid gas Permeable contact lenses (CRGPcl) (Rose K2)|The Rose K2 lens is a widely used corneal gas permeable lens designed for keratoconus and other irregular cornea disorders
45623142|NCT03283943|Radiation|Focal radiotherapy|Focal sensitizing radiotherapy will be given at a starting dose level of 24 Gray (6 Gy X 4 fractions), and may be escalated to 32 Gy (8Gy X4 fractions).
45765218|NCT05367531|Device|Standard Injector|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
45912516|NCT02011191|Dietary Supplement|Sugar Pill|Identical sugar pill, identical bottle as the biotin supplementation group
45912517|NCT02011204|Device|Electrical impedance myography (EIM)|"In EIM, high-frequency alternating electrical current is applied to localized areas of muscle via surface electrodes and the consequent surface voltage patterns analyzed.~EIM is very sensitive to the compositional and structural elements of muscle. Data from both human subjects and animal disease models, including ALS, spinal muscular atrophy (SMA), and Duchenne muscular dystrophy (DMD), show that EIM may be sensitive to a variety of pathological states. It is anticipated that EIM will thus likely be able to assist in quantifying the severity of the disease affecting various muscle groups as well as in measuring changes in the disease over time."
46069568|NCT00976937|Drug|Lixisenatide Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
46069569|NCT00976937|Device|Pen auto-injector|
46069570|NCT00976937|Drug|Sitagliptin|Administered orally once a day in the morning with or without food at approximately the same time each day.
45623143|NCT03283943|Drug|Durvalumab|Durvalumab 1500 mg IV every 28 days
45623144|NCT02443597|Other|ultrasound|trans abdominal or trans vaginal ultrasound to detect some of the soft markers of trisomy screening
45765219|NCT05367531|Device|Prefilled|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
46069571|NCT00976937|Drug|Sitagliptin Placebo|Administered orally once a day in the morning with or without food at approximately the same time each day.
45912518|NCT02011217|Other|Rye crisp bread A|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
45912519|NCT02011217|Other|Rye crisp bread B|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
46069572|NCT00976937|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
46069573|NCT02623023|Drug|Combigan|brimonidine/timolol fixed combination (Combigan®, Allergan; Dublin, IRL)
45765220|NCT04376723|Other|Mental Health Mobile Application|Mobile phones will not be provided to participants, but app subscriptions will be provided.
45765221|NCT05360667|Other|Standard care plus plus Exergame-based multicomponent training program|"The program contains PRT and functional movement of the four extremities but mainly upper limbs. We will use the commercialized exergame Ringfit Adventure (RFA) to deliver the program.~RFA is a ﬁtness action role-playing game. The player advances the story while exercising as the movement of the player is linked to the main character on the screen. The movements of the player and battle actions are based on performing certain physical activities using the Ring-Con and Leg Strap. RFA itself could estimate the optimal exercise intensity for each player and performs ﬁne-tuned up-and downregulation based on these physiological feedbacks. Therefore, it has become possible to provide an appropriate amount of exercise for all generations from children to the elderly.~The standard care is applied as usual in our LTCF. (descriped as the below in the control group)"
45765222|NCT05360667|Other|Standard care|The standard care in the control group is applied as usual in our LTCF, in the way of group activity, including calisthenics (that could be done in sitting position), horticultural therapy, and group activity of peace (like tabletop games). The programs are performed twice per week, about 30 to 60 minutes (depends on different activity), leading by a therapist.
45765223|NCT04372901|Procedure|Digitally constructed frameworks before implant placement|Intervention group in which the edentulous area will be restored with 3-implant screwmented CAD/CAM frameworks constructed based on planned implant positions.
45765224|NCT04372901|Procedure|Digitally constructed frameworks after implant placement|Control group: edentulous area will be restored with 3-implant conventional screw retained CAD/CAM frameworks constructed after implant placement.
45765225|NCT02963974|Device|Cochlear implant|Implantation
46069574|NCT02623023|Other|Refresh tears|This is a placebo group. Refresh tears®, Allergan; Dublin, IRL, is a lubricant eye drop that keeps they eye hydrated
45446704|NCT02092480|Behavioral|If I Were Jack|The If I Were Jack intervention is a classroom-based RSE resource designed to be delivered by teachers over four weeks. It is composed of: (i) An interactive video drama which asks pupils to put themselves in Jack's shoes and consider how they would feel and what they would do if they were Jack; (ii) Classroom materials for teachers containing detailed lesson plans with specific classroom-based and homework activities; (iii) 60-minute training session for teachers wishing to implement the intervention; (iv) 60-minute information and discussion session for parents/guardians delivered by RSE teachers; (v) Brochures and factsheets about the intervention and unintended teenage pregnancy for schools, teachers, teacher trainers, young people and parents.
45446705|NCT03746223|Drug|Methotrexate|400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses as maintenance
45623145|NCT03283865|Diagnostic Test|Ultrasound guidance for caudal block|The attending anesthesiologist will perform or instruct the placement of a caudal block according to their standard of practice. At the time of administration of local anesthetic into the caudal space, the study collaborator (SC) will ultrasound the caudal space keeping the provider placing the block blinded to the imaging. The provider placing the block will inject 0.5mL of preservative free saline. The provider will then be asked to state if they are correctly in the caudal space or not. If the provider feels they are not in the caudal space, they will re-do the procedure. If the provider fails to identify incorrect location and this is noted by ultrasound, the SC will inform the provider to re-do the procedure
45623146|NCT03108053|Procedure|Semirigid Ureteroscopy (URS) With Guide Wire|Semirigid URS is the operations used for ureteral stone disease. In routine practice it is most commonly done with the use of a guide wire. It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
45623147|NCT03108053|Device|Semirigid Ureteroscopy (URS) Without Guide Wire|Semirigid URS is the operations used for ureteral stone disease . It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
45623148|NCT02710045|Biological|Measles Vaccine at 9 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 9 months of age
45623149|NCT02710045|Biological|DTP Vaccine at 9 months of age|Single intramuscular (i.m.) dose of diphtheria-tetanus-whole cell pertussis vaccine (Serum Institute of India Ltd.) into the thigh at 9 months of age
45623150|NCT02710045|Biological|Measles Vaccine at 18 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 18 months of age
45623151|NCT03283631|Biological|EGFRvIII-CARs|Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells
45623152|NCT04483375|Biological|SCTA01|recombinant humanized anti-SARS-CoV-2 monoclonal antibody
45765226|NCT04372589|Drug|Heparin|"Low molecular weight heparin (LMWH) Preferred therapeutic anticoagulant is enoxaparin. Generally regimens: 1.5 mg/kg subcutaneous once daily or 1 mg/kg subcutaneous twice daily. Alternatively, other subcutaneous LMWH used, including tinzaparin (175 anti-Xa IU/kg subcutaneous once daily) or dalteparin (200 IU/kg subcutaneous once daily or 100 IU/kg subcutaneous twice a day).~Unfractionated heparin (UFH) Commenced, administered, and monitored according to local hospital policy, and guidelines that are used for the treatment of venous thromboembolism (i.e. not for acute coronary syndrome). Intravenous infusion of UFH is according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value. If UFH is used, the availability of a local hospital policy that has specifies an aPTT target in this range or an anti-Xa value is a requirement."
45765227|NCT05537493|Other|Telerehabilitation|It will be followed by exercising on whatsapp
45623153|NCT04483375|Other|Placebo|Placebo
45623154|NCT03283475|Procedure|thigh lift|liposuction-assisted medial avulsion thighplasty enables technically refined contouring of the thigh and the possible preservation of the local microvasculature, which results in reduced complication rates
45623155|NCT02444767|Drug|13mg Bimatoprost Ocular Insert|13mg Bimatoprost Ocular Insert in each eye.
45623156|NCT02459717|Other|Probiotics and prebiotic|Patients will receive daily (at breakfast) a fermented milk (125 grams), containing multiple probiotics strains and prebiotic fiber
45623157|NCT02459717|Other|Placebo|Patients will receive daily (at breakfast) a placebo (pasteurized fermented milk without prebiotics)
45912520|NCT02011217|Other|Wheat crisp bread C|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
45912521|NCT02011230|Other|Hoist Group|Hoist is a commercially available drink that is sold locally. This solution is isotonic meaning that it contains similar concentrations of salt and sugar that are found in the human body
46069575|NCT02622945|Device|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain not affected by the lesion(perilesional areas, right hemisphere or cerebellum). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
45446706|NCT03746223|Drug|Rituximab|Rituximab：375mg/m2 intravenous infusion d1, every 28 days for 1 cycle. 6 cycles will be prescribed as protocol
45446707|NCT03746223|Drug|Lenalidomide|25mg Qd, oral , d1-21 in 28-day cycle in the induction phase and maintenance phase.
45446708|NCT03969017|Drug|pegylated interferon (Peg IFN)α-2b|Participants in NAs+Peg IFN Group will be treated by Peg IFNα-2b （180ug per week, the dose will be changed to 135ug or 90ug per week during the treatment if patients could not tolerate the side effects of Peg IFNα-2b). Peg IFNα-2b treatment will be performed until HBsAg <0.05IU/ml, with a maximum duration of 48 weeks.
45446709|NCT03969017|Drug|Nucleoside （acid）analogue (NAs)|Both of NAs Group and NAs+Peg IFN Group will be treated with NAs as before enrollment.
45623158|NCT02439541|Biological|UCMSC group|Human umbilical cord MSCs are transplanted by intracoronary infusion(1×10^7)
45623159|NCT03282149|Biological|XT-150|IL-10 transgene DNA plasmid injected into the knee synovial capsule
45623160|NCT02444689|Behavioral|Electronic Media Application|Children in the intervention group will receive motivation, education and coaching regarding therapeutic lifestyle changes via a smart phone electronic media application.
45623161|NCT02444689|Behavioral|Standard of care education|
45623162|NCT03281993|Other|CPAP AT|If the investigators observe rapid desaturation defined as a decline in O2 saturation below 85%; the CPAP apnea test (CPAP-AT) test was aborted.
45623163|NCT03281915|Procedure|High inguinal Varicocelectomy|Semen parameters after high inguinal varicocelectomy will be collected
45623164|NCT03281915|Procedure|Subinguinal varicocelectomy|Semen parameters after subinguinal Varicocelectomy will be collected
45623165|NCT02443285|Drug|Cefotaxime|Cefotaxime 2 gram every12 hours for 5 days
45623166|NCT02443285|Drug|ceftriaxone|Ceftriaxone 2 gm every 24 hours for 5 days
45623167|NCT02445079|Other|This is an observational study only|Observational study only
45623168|NCT03284099|Drug|ACEi, ARB|To take the ACEis or ARBs before bedtime instead of in the morning
45623169|NCT03281837|Device|HYMOVIS plus Physical Exercise Program (PEP)|1 injection of intra-articular (IA) hyaluronan (HA), Hymovis 24mg/3ml, injection per week for 2 weeks combined with at least 8 weeks of Physical Exercise Program (PEP)
45623170|NCT03281837|Other|Physical Exercise Program (PEP) alone|Physical Exercise Program (PEP) alone for at least 8 weeks
45623171|NCT02439463|Procedure|Below-knee amputation|Patients with traumatic below-knee amputation.
45623172|NCT02459405|Procedure|NIR anastomotic perfusion assessment|Patient will have their anastomosis assessed by near infrared technology after indocyanine green has been injected i.v. The procedure will be repeated twice, once before the anastomosis and the second time after the anastomosis has been performed.
45623173|NCT02459405|Device|Near infrared camera|Use of the Pinpoint laparoscopic scope (Novadaq, Vancouver, Canada) after injection of indocyanine green
45765228|NCT05537493|Other|Face to face|It will be followed by face to face
45765229|NCT04364399|Biological|Mumps vaccine|One dose of mumps vaccine: 0.5 ml per dose, mumps live virus not less than 3.7 lg CCID50
45912522|NCT02011256|Device|Implantable loop-recorder|All patients not diagnosed with atrial fibrillation with regular ECG or 72-hour Holter-monitoring will receive an ILR for 3 years.
45912523|NCT02011269|Biological|Trichuris Suis Ova|
45912524|NCT02011282|Other|Patients will receive daily sessions of electro-neuro-stimulation in the quadriceps muscle for 10 days|
45912525|NCT02011295|Procedure|ankle arthroscopy with debridement and microfracture of the OLT|ankle arthroscopy with debridement and microfracture of the OLT
45912526|NCT02011295|Other|Bone Marrow Aspirate injection|
45912527|NCT02011308|Device|Green light Laser|Laser vs TURP
45912528|NCT02011308|Device|Transurethral Resection of the Prostate (TURP)|Laser vs TURP
45623174|NCT02439073|Behavioral|Rehabilitation|The postoperative intervention are the same in both intervention groups and consists of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.The postoperative physical exercise consists of an individually prepared supervised strength exercise - and a group-based cardiovascular exercise twice a week (60 minutes/session) on non-consecutive days for 12 weeks, a total of 24 sessions.
45623175|NCT03190135|Behavioral|BOKS: 2 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 2 times per week.
45765230|NCT04364399|Biological|measles, mumps and rubella combined vaccine, live|One dose of measles, mumps and rubella combined vaccine, live: 0.5 ml per dose, mumps live virus not less than 4.3 lg CCID50
45446710|NCT04596033|Biological|GEN-011|Personalized neoantigen adoptive cell therapy (ACT)
45765231|NCT05537025|Drug|ARO-MMP7 Inhalation Solution|ARO-MMP7 by inhalation of nebulized solution
45765232|NCT05537025|Drug|Placebo|Calculated volume of normal saline (0.9% NaCl) to match active treatment by inhalation of nebulized solution
45765233|NCT02982551|Drug|Insulin|Insulin will be administered peripherally to observe the effects of circulating insulin on brain activity
45765234|NCT02982551|Other|Taste Task|Participants will taste milkshakes and a tasteless solution to observe the brain responses to palatable taste.
45765235|NCT02982551|Other|Magnetic Resonance Imaging|Participants will complete two MRI scans approximately 60 minutes apart - one under baseline fasting conditions and the second during isoglycemic-hyperinsulinemia. Each functional scan will include a resting-state BOLD sequence followed by a taste-reward task. Functional MRI sequences will last approximately 30 minutes. MRI scanning will also include approximately 30 minutes of structural MRI scans.
45765236|NCT02982551|Drug|Dextrose|During hyperinsulinemic clamp, participants will be infused with a variable rate dextrose infusion will be used to keep the blood sugar level within 5mg/dl of the baseline glucose value.
45912529|NCT02011334|Drug|tocilizumab [RoActemra/Actemra]|162 mg will be administered once weekly by subcutaneous injection.
45912530|NCT02011347|Drug|Ketamine|
45912531|NCT02011347|Drug|Placebo|
45912532|NCT02011360|Other|Low Carbohydrate diet|Low carbohydrate diet: 15%carb; 65%fat; 20% protein
45912533|NCT02011360|Other|Low Fat diet|Low Fat diet: 65%carb; 15%fat; 20% protein
45623176|NCT03190135|Behavioral|BOKS: 3 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 3 times per week.
45623177|NCT03281759|Device|Transcranial LED Therapy (Active coil helmet)|The patients will undergo 18 sessions of repetitive transcranial LED stimulation.
45765237|NCT04745481|Device|Trunk stabilization training device|"Conventional rehabilitation 30min daily, 20times 4weeks~+Trunk stabilization training device 30min daily, 20time 4weeks"
45765238|NCT04745481|Device|Conventional rehabilitation|"Conventional rehabilitation 30min daily, 20times 4weeks~+Conventional rehabilitation 30min daily, 20times 4weeks"
45765239|NCT02964910|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
45912534|NCT02011373|Procedure|fixation technique using a sterile synthetic liquid tissue glue: IFABOND™|
45912535|NCT02011399|Procedure|Brain Computer Interface for Mu Rhythm|"Device: Brain Computer Interface Subjects will wear an EEG (electrode) cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate a computer. Subjects will be asked to participate in 4-20 sessions.~Arms: Brain Computer Interface Keyboard"
45912536|NCT02011425|Device|mandibular advancement appliance|mandibular advancement appliance
45912537|NCT02011438|Behavioral|UTalk|Prevention intervention delivered in group format adapted from IPT-AST, for adolescents who experience peer victimization and who are at risk for developing social anxiety and depression.
45912538|NCT02011451|Drug|95% Pure ECGC capsules 200mg|Theaphenon 95% 95% Pure EGCG
45912539|NCT02011451|Drug|Placebo Comparator:|
45912540|NCT02011477|Other|Neural Glide|This technique involves two movements, throughout several joints to glide the nerves. The subject sit on a couch with the right lower limb extended and the left lower limb flexed. The therapist will take the subject's head by putting his hands on the suboccipital and front region. In the initial movement, performe craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject performed dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as performing plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject
45446711|NCT04596033|Drug|IL-2|Cytokine
45446712|NCT04596033|Drug|Fludarabine|Lymphodepletion drug
45446713|NCT04596033|Drug|Cyclophosphamide|Lymphodepletion drug
45446714|NCT02087644|Biological|CYT003|Injections
45446715|NCT02087644|Biological|Placebo|Injections
45446716|NCT03968783|Other|Monofilament suture|1.0 monofilament synthetic absorbable suture for closure of the low transverse uterine incision
45446717|NCT03968783|Other|Multifilament suture|1.0 multifilament synthetic absorbable suture for closure of the low transverse uterine incision
45623178|NCT03281759|Device|Transcranial LED Therapy (Inactive coil helmet)|The patients assigned to this group will undergo 18 sessions of transcranial LED but with an inactive coil, which will not generate LED emissions, only a similar red light color.
45623179|NCT03193957|Drug|Etanercept|Etanercept PFS and Autoinjector
45623180|NCT03193957|Device|Autoinjector|Autoinjector
45765240|NCT02156687|Device|Y mesh|Y mesh
45765241|NCT02156687|Device|Dual flat mesh|Dual flat mesh
45765242|NCT05658393|Behavioral|ReLiver-N App|Web-based mobile health application for patients with liver cirrhosis
45765243|NCT02965144|Other|no treatment|no treatment
45765244|NCT04376411|Diagnostic Test|Flow-cytometric assay|100 µl of blood sample was incubated for 20 minutes at 4 C in the dark. Following incubation, red blood cells lysis, washing and analysis a specific software.Forward and side scatter histogram was used to define the lymphocytes population.
45623181|NCT03281681|Drug|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.
45623182|NCT03281603|Device|CAD/CAM complete denture|complete denture will be designed by computer aided designing (CAD) and manufactured by computer aided manufacturing(CAM) utilizing Milling and 3D printing techniques
45623183|NCT02439151|Device|New lung ventilation strategy|New ventilation strateg: pressure assist control mode; inspiratory pressure was lowered to keep Ppeak less than 25cmH2O; set the PEEP at such a level that expiratory transpulmonary pressure stays between 0 and 5 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.
45623184|NCT02439151|Device|Conventional ventilation strategy|Conventional ventilation strategy: pressure assist control mode; keep the Ppeak between 20 and 25 cmH2O; set PEEP between 10 and 15 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.
45623185|NCT02443363|Other|Estimating of formula MDRD, CKD-EPI, Cockroft-Gault,|
45623186|NCT02443363|Device|Tanita BC 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
45623187|NCT03281447|Other|Nurse navigation|
45623188|NCT03281447|Other|Current care coordination|
45623189|NCT02444611|Drug|BCG Vaccine|intradermal vaccination
45623190|NCT02444611|Drug|Hepatitis B Vaccine|intramuscular vaccination
45446718|NCT02092558|Drug|Second-generation cephalosporin, nitrofurantoin, 1% aminoglycoside solution|
45446719|NCT02092558|Drug|cephalosporin with chemotherapeutics|Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months
45623191|NCT03545477|Other|Novel locomotion treatment: curved-walking training|"Each training session is comprehensive of a 30-minute walking training on curved trajectory (S trajectory composed by two semicircle with a radius of 1.2 m)"
45765245|NCT04376411|Diagnostic Test|2D Echocardiographic analysis|Trans thoracic echocardiographic examination was performed through (PHILIPS -33) echocardiography device with broadband S5-1 transducer
45446720|NCT03747237|Other|Edema measurement methods|A correlation between the results of the first and second methods will be examined.
45623192|NCT03545477|Other|Standard locomotion treatment: straight-walking training|It consists of 30 minutes of locomotion training on straight trajectories, as typically proposed during traditional gait rehabilitation
45623193|NCT03545477|Other|Standard physical therapy|It consists of 60 minutes of stretching, muscular conditioning and coordination,postural exercises for trunk control, standing, functional exercies and upper limb rehabilitation, customized on patient's need.
45623194|NCT03281213|Other|Thoracotomy|
45623195|NCT02438761|Drug|PF-05212384|"PF-05212384 will be delivered by intra-venous route at a fixed dose of 150 mg per week. Each treatment cycle includes four weekly injections~The treatment is administered in cycles of 28 days for a period of 4 cycles. Patients will be treated on a weekly basis continuously during 112 days or until progression."
45765246|NCT04376411|Diagnostic Test|Two-Dimensional speckle tracking echocardiography|Two-Dimensional speckle tracking echocardiography was performed on grey scale images of the left ventricle. For offline analysis digital storage software (Qlab 10.4) was used. The frame rate was adjusted to be 60-90 frame/second.
45623196|NCT03536429|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
45765247|NCT05655351|Biological|anti-SARS-Cov-2 vaccination|For the purposes of the study, 10 mL of venous blood will be collected from each patient.
45765248|NCT04364243|Other|Digitally supported home exercises|The training will comprise of 9 sessions (3 weekly) Each of the training sessions will last 20 minutes. This will result in a cumulative total intervention exercise time of 180 minutes.
45765249|NCT02965534|Device|Spectacle/Glasses|
45765250|NCT04372511|Device|Binaural Beats|Device: Sound with Binaural Beats at acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz with a white background noise
45765251|NCT02965924|Drug|Phenylephrine 2.5%|Instilling phenylephrine 2.5% eye drop
45765252|NCT04364477|Procedure|transversus abdominis plane (TAP) block|The transversus abdominis plane (TAP) block is a regional anesthesia technique described in recent years that provides analgesia for the anterior portion of the abdominal wall after abdominal surgery.
45765253|NCT02241395|Biological|Intrathecal autologous bone marrow mononuclear cell transplantation|
45765254|NCT02967016|Behavioral|Actigraph|following delivery a ActiGraph will be offered to patients to track their steps
45765255|NCT04372277|Drug|Enstilar|topical Enstilar foam
45765256|NCT05654805|Dietary Supplement|Drinking powder supplement|Drinking powder supplement, to be taken twice daily over 12 weeks
45623197|NCT03536429|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
45765257|NCT04372355|Drug|WF10|WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five subsequent weeks.
45623198|NCT02438683|Drug|BI 409306|medium dose, single dose, oral administration
45623199|NCT02438683|Drug|BI 409306|low dose, single dose, oral administration
45623200|NCT02438683|Drug|Placebo|single dose, oral administration
45623201|NCT03411239|Device|Adult esophageal balloon catheter (obc)|Using OBC to determine airway pressure changes in patients undergoing general anaesthesia for laparoscopic surgery
45623202|NCT02444455|Biological|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous infusion(5×10^5/kg) once a day,a total of three times.
45765258|NCT05529693|Dietary Supplement|Experimental: Bif-038 arm, high dose|Active trial product with minimum 10 billion CFU daily dose
45623203|NCT03281135|Other|HPV testing|Clusters randomly allocated to this arm of the study will be sensitized to be showed up in nearby health posts for self sampling with Evalyn brush for HPV testing.
45623204|NCT03193645|Drug|Degarelix|Injection
45623205|NCT03280979|Drug|rescue regimen|In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of TX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.
45623206|NCT03280979|Drug|high dose methotrxate|In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid
45623207|NCT02714153|Device|Bridge Balloon|The Bridge Balloon will be used in a non-emergent setting to allow for evaluation of how best to integrate this new technology into the investigators clinical practice. The study will focus on the effect of the Bridge balloon on the patient preparation clinical workflow, ease of insertion/positioning/deployment, and the ability to recognize proper inflation and vein sealing under fluoroscopy.
45623208|NCT02438527|Behavioral|Chart for CPR guidance|
45765259|NCT05529693|Dietary Supplement|Experimental: Bif-038 arm, low dose|Active trial product with minimum 1 billion CFU daily dose
45623209|NCT03192085|Diagnostic Test|SITA FAST VISUAL FIELD TEST|Diagnostic test for glaucoma
45623210|NCT03192085|Diagnostic Test|SITA STANDARD VISUAL FIELD TEST|Diagnostic test for glaucoma
45765260|NCT05529693|Dietary Supplement|Placebo Comparator: Placebo arm|Similar product to trial product but without Bif-038
45765261|NCT05620667|Dietary Supplement|immature ponkan (Citrus reticulate) extract|Drink 25mL for once, and once a day.
45765262|NCT05620667|Dietary Supplement|placebo|Drink 25mL for once, and once a day.
45765263|NCT05620667|Behavioral|time restricted feeding|Controlling a shortened period of time for eating within 8 hour each day.
45765264|NCT02968420|Biological|Human Papillomavirus 9-valent Vaccine, Recombinant|All groups will receive a single dose of the Gardasil9 vaccine at Visit 1/Day 0 of the study.
45765265|NCT04364321|Drug|Clonazepam 0.5 MG|Clonazepam 0.02 mg/kg only one dose
45765266|NCT04364321|Drug|Diazepam Tablets|Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr)
45765267|NCT03039088|Other|Follow-up after 12 weeks after TNF alpha blockers initiation|
45765268|NCT05528913|Drug|Fasenra Prefilled Syringe|Fasenra 60mg s.c. administration at weeks 0,4 and 8
45765269|NCT05528913|Other|Matching Placebo Solution|Placebo s.c. administration at weeks 0,4 and 8
45765270|NCT02241473|Other|Training|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in normoxic (continuous normoxic training; CNT) or hypoxic (continuous hypoxic training, CHT; simulated altitude of 3000 m) condition in a single-blind fashion. Both CNT and CHT sessions will be performed in an hypoxic chamber (ATS Altitude, Sydney, Australia) built in our laboratory at an altitude of 380 m (Lausanne, Switzerland). In order to blind subjects to altitude, the system will also run for normoxic training groups with a normoxic airflow into the chamber.
45765271|NCT05337345|Drug|Cendakimab|Specified Dose on Specified Days
45765272|NCT04364009|Drug|Anakinra plus oSOC|"Anakinra plus Optimized Standard of Care (oSOC) on the condition of patients with COVID-19 infection and worsening respiratory symptoms.~The patients will receive intraveinous injection of Anakinra 400mg from Day 1 to Day 3 (two injections of 100 mg each 12 hours) and 200mg the remaining 7 days. The total duration of Anakinra is 10 Days. Efficient dosage of Anakinra as previously described will be continued until Day 10"
45765273|NCT04364009|Drug|oSOC|Optimized Standard of Care (oSOC) on the condition of patients with COVID-19 infection and worsening respiratory symptoms.
45765274|NCT04344015|Other|Plasma Donation|Previously infected COVID-19 patients will be recruited to donate convalescent plasma.
45765275|NCT03040414|Device|MedtronicMinimed 670G 3.0 hybrid closed loop system|The components of the intervention are the insulin pump with insulin delivery algorithm (PID).
45765276|NCT03040414|Device|Medtronic Minimed 670G 4.0 AHCL with Guardian Sensor (3) continuous glucose monitoring sensor.|The components of the intervention are the insulin pump with insulin delivery algorithm (PID + Fuzzy Logic) and Guardian Sensor (3).
45623211|NCT03280901|Other|HD, Magnetic Resonance Imaging (MRI) scans|HD, Magnetic Resonance Imaging (MRI) scans using a specifically designed unit able to perform MRI scanning during HD sessions
45623212|NCT03189823|Device|Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA|In MCS, an electrode is placed perpendicular to the central sulcus in the epidural space (Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA) in order to obtain pain relief.
45623213|NCT03270839|Drug|Bonine 25Mg Chewable Tablet|Motion sickness drug
45623214|NCT03270839|Drug|Kwells|Motion sickness drug
45623215|NCT03270839|Drug|Placebo Oral Tablet|No active substance in the tablet
45623216|NCT02458547|Drug|Desflurane|Inhalation anesthesia with desflurane at age-adjusted MAC of 0.8~1.0
45623217|NCT02458547|Drug|Propofol|Total intravenous anesthesia with propofol target controlled infusion
45623218|NCT02458547|Drug|Bupivacaine|Spinal anesthesia with 0.5% bupivacaine
45623219|NCT02459561|Device|EndoBarrier TM Gastrointestinal Liner|If subjects are randomised into the EndoBarrier Group of the trial they will receive the device for 12 months followed a 12 months follow-up period.
45623220|NCT02459561|Other|Best Medical Care|If subjects are randomised into the Control Group of the trial they will receive best medical care and dietitian advice for 12 months followed a 12 months follow-up period.
45623221|NCT02458625|Dietary Supplement|Iron sucrose 500 mg|
45623222|NCT02458625|Dietary Supplement|Iron bisglycinate 60 mg|
45623223|NCT04978155|Diagnostic Test|Duplex ultrasound performed by the surgeon after locoregional anesthesia|Just after locoregional anesthesia, the surgeon perform a duplex ultrasound to determinate if the target vessel chosen to create the arterio-venous fistulae match with the pre-operative duplex performed during the consultation. So the plan can be changed such as more distal, more proximal creation, changing vein or artery target.
45623224|NCT03270449|Other|Multidisciplinary intervention|10 week multidisciplinary education and exercise
45623225|NCT04970043|Drug|Camrelizumab+ pemetrexed + platinum|"Induction period: (4-6 cycles) Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle.~Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Carboplatin: AUC = 4-5, given on the first day, every 3 weeks as a cycle; After 4-6 cycles of treatment, the patients entered the maintenance treatment period of carrizumab combined with pemetrexed.~Maintenance treatment period:~Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle.~Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Every 3 weeks is a treatment cycle, and the drug is maintained until the following conditions occur: disease progression, intolerable toxicity, or receiving immunotherapy for no more than 35 cycles (2 years)."
45623226|NCT03280745|Drug|Hypertonic saline|At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl by infusion pump over 60 minutes.
45623227|NCT03280745|Drug|0.9% saline|At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
45623228|NCT04977921|Other|lab session|assign students to clinical modules for study the clinical lab scope of practice
45623229|NCT03270371|Device|Medium cut off dialysis|Hemodialysis
45623230|NCT03270371|Device|Standard High Flux Dialyzer|Hemodialysis
45623231|NCT04977999|Other|Exercise|Both arms/conditions use varying forms of exercise as the intervention.
45623232|NCT03107741|Other|Conventional Exercise|Subjects in this group will receive three 1-hour conventional exercise training sections per week for 12 weeks
45623233|NCT03107741|Other|Tai Chi|Subjects in this group will receive three 1-hour tai chi training sections per week for 12 weeks
45623234|NCT04977843|Procedure|EARLY BRONCHOALVEOLAR LAVAGE|E-BAL done with instillation of 100cc normal saline and sucked out
45623235|NCT03107975|Biological|human amniotic epithelial cells|intrathecal injection of human amniotic epithelial cells
45623236|NCT04977219|Behavioral|Prism Adaptation Training|Therapists administering PAT followed the protocol developed by the Kessler Foundation (2014).PAT sessions lasted approximately 30 minutes during which patients with left sided neglect don 20 diopter prism goggles deviating their visual field to the right while aiming their finger at a series of visual targets.
45623237|NCT03107819|Diagnostic Test|Plasma and urine metabolomics|Through the use of high-pressure liquid chromatography and mass spectrometry, quantitative measurements of targeted metabolites associated with amino acids, methylation, acetylation and the tricarboxylic acid (TCA) cycle will be analyzed on the blood and urine specimens.
45623238|NCT04969809|Diagnostic Test|Ultrasound of the jugular veins|Ultrasound of the jugular veins to assess the thickness of the carotid intima media
45623239|NCT04969809|Dietary Supplement|addition of phenylalanine-free protein substitutes|addition of phenylalanine-free protein substitutes for sufficient daily intake of essential amino acids and other vitamins and minerals and nutritional plan
45623240|NCT04432233|Drug|Esomeprazole|Proton pump inhibitor
45623241|NCT04432233|Drug|Metronidazole|antibiotic for H. pylori eradication
45623242|NCT04432233|Drug|Levofloxacin|antibiotic for H. pylori eradication
45623243|NCT03269903|Device|HILZO esophageal stent|A fully covered esophageal self-expandable metal stent for malignant dysphagia
45623244|NCT04977609|Behavioral|VR+MUSIC|A novel VR intervention designed for upper limb motor rehabilitation in post-stroke hemiparetic patients consisting in 10 daily sessions of 30 minutes, over 2 weeks, supervised by a physical therapist.
45765277|NCT02241629|Drug|placebo|placebo of levo phencynonate hydrochloride
45765278|NCT02241629|Drug|levo phencynonate hydrochloride|levo phencynonate hydrochloride
45765279|NCT04372043|Other|Questionnaire|"Sleep Hygiene Index and demographic questions."
45765280|NCT02863198|Device|endometrial injury|Endometrial injury was done only for patient of the study group. It was done on day 5, under complete aseptic conditions, no anesthesia, was given in most of cases. Endometrial local injury was performed on the posterior wall, midline, and 10-15 mm from the fundus using pipelle endometrial sampling (Pipelle).
45765281|NCT02959281|Other|Providing caring physicians with hemodynamic variables|NICAS electrodes are applied to the skin of the forearm bilaterally (similar to EKG electrodes). Conductors, attached to the electrodes, connect the patient with the measuring system.
45765282|NCT04371965|Drug|Povidone-Iodine|Patients in the experimental group will be asked to gargle with a 1% povidone-iodine solution, spray their nose with the same antiseptic solution, and finally applied 10% povidone-iodine cream in each nostril, all four times a day for five days.
45623245|NCT04977609|Behavioral|VR|A novel VR intervention designed for upper limb motor rehabilitation in post-stroke hemiparetic patients consisting in 10 daily sessions of 30 minutes, over 2 weeks, supervised by a physical therapist.
45623246|NCT04977609|Behavioral|TAU|Traditional post-stroke upper limb motor rehabilitation under the supervision of a physical therapist, for 0 daily sessions of 30 minutes, over 2 weeks.
45623247|NCT03269747|Drug|Prednisone|2 tablets of Prednisone 20 Mg in the morning
45623248|NCT03269747|Drug|Placebo|2 Placebo tablets in the morning
45765283|NCT02959125|Other|NutFish Based Food Supplementation|Cookies contain 500 Calories and 15 gram protein make from nut and ocean fish
45765284|NCT02959125|Dietary Supplement|Multiple micronutrients|Vitamin A 5000 iu, vitamin D 400 iu, vitamin C 100 mg, vitamin B1 7.5 mg, vitamin B2 3 mg, vitamin B6 10 mg, vitamin B12 10 mcg, fluoride 1 mg, Fe fumarate 91 mg, niacinamide 20 mg, Ca pantothenate 7.5 mg, folic acid 400 mcg, Zn 5 mg, Ca lactate 250 mg, copper 0.1 mg, iodine 0.1 mg
45765285|NCT02959125|Behavioral|Health Education in Pregnancy Class|Health education on pregnancy, complication, and breastfeeding by research team members
45765286|NCT02959125|Other|Government Food Supplementation|Cookies contain 500 Calories and 5 gram protein make from flour and egg
45765287|NCT02959125|Dietary Supplement|Fe Supplementation|Ferrous Fumarate 60mg and folic acid 0.400 mg
45446721|NCT02092636|Other|NIR/US Diagnostic Group|Patients receiving an ultrasound-guided biopsy will participate in one study visit on the day of the biopsy. The NIR/US scan will be completed immediately prior to the biopsy procedure and takes about 5-10 minutes to perform.
45623249|NCT04976985|Procedure|Osteopathic Manipulative Therapy (OMT)|"Osteopathic Manipulative Therapy (OMT) is a non-pharmacological, noninvasive form of manual medicine. Osteopathic physicians receive special training in the musculoskeletal system to detect somatic dysfunction. Osteopathic physicians then move a patient's muscles and joints using techniques that include stretching, gentle pressure and resistance to improve muscle tonicity, treat structural abnormalities, relieve joint restriction, and decrease activation of the pain proprioception pathway.~OMT Standardized Protocol A:~Occipital- Alanto release~Muscle energy and soft tissue to mid trapezius muscle~Muscle energy to cervical spine in all three planes of flexion/extension, rotation and side bending~Screening for tender points of C2-C6 at transverse and spinous processes and treatment with counterstain if tender point identified~Soft tissue to cervical paraspinal muscles~Myo-fascial release of frontal forehead~CV4 cranial technique"
45623250|NCT04976985|Other|Standard of care|Receiving standard of care for migraine headaches with pharmacological medications, with no more than two prophylactic medications during the study period. Participants may also take abortive migraine medications.
45765288|NCT04347473|Drug|Ilumya Injectable Product|IL-23 injection
45623251|NCT02459483|Behavioral|Nurse phone call|
45623252|NCT03280433|Other|Aortic valve replacement|
45623253|NCT03269513|Behavioral|Physical Exercise|The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
45623254|NCT04369469|Biological|Ravulizumab|Weight-based doses of ravulizumab were administered intravenously on Days 1, 5, 10, and 15.
45623255|NCT04369469|Other|BSC|Participants received medications, therapies, and interventions per standard hospital treatment protocols.
45765289|NCT03040804|Radiation|Low dose Radiotherapy|Subjects in this protocol will only receive radiotherapy directed at one region, typically the region that is most bothersome to the patient. Patients will receive a total radiotherapy dose 7.5 Gy in five daily fractions of 1.5 Gy.
45765290|NCT02958891|Other|Data collection|Collection epidemiological dental measures
45765291|NCT04364165|Behavioral|Standard invitation to free HIV testing at mobile clinic|Participants receive standard invitation to same day HIV testing at mobile clinic.
45765292|NCT04364165|Behavioral|U=U messaging and invitation to free HIV testing at mobile clinic|Participants receive messaging about being undetectable equals untransmittable (U=U) and invitation to same day HIV testing at mobile clinic.
45765293|NCT00963157|Drug|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg inactivated H1N1 vaccine.
45765294|NCT00963157|Biological|Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of the vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
45765295|NCT02972554|Drug|Propanolol hydrochloride|One-time dose of 40mg of propranolol
45765296|NCT02972554|Other|Placebo|Outside casing matching that of active drug
45765297|NCT04371731|Other|Care4todayheart failure platform|Platform allowing patients to enter information about their health at home, namely weight and BP and medications
45623256|NCT03269591|Device|Pulsed electromagnetic field|EASY Qs portable (by ASA, Italy)
45623257|NCT03269591|Drug|diclofenac tablets|drugs
45623258|NCT03269591|Diagnostic Test|Visual analogue scale|a graphic rating scale
45765298|NCT05643807|Device|Flexible cystoscopy|Urinary cytology will be collected through the flexible cystoscope itself at the end the cystoscopy. Before starting the urinary collection, the cystoscope will either be placed in front of a suspected intravesical lesion (if present) or at the bladder neck (if no lesion present).
45765299|NCT05643807|Device|Urinary catheter|Urinary cytology will be collected through a Ch14 urinary catheter after the cystoscopy
45765300|NCT00921947|Biological|VAX102|Universal M2e influenza vaccine
45765301|NCT02241941|Drug|Daptomycin|
45765302|NCT03041896|Device|coflex® Interlaminar Technology|Interlaminer Technology
45765303|NCT03834051|Drug|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation Enema Open Label
45765304|NCT04363541|Device|Electric pad for human external pain therapy|An electric pad for local heat production will be put on the back of the patient for two hours
45765305|NCT05316129|Drug|Follicle Stimulating Hormone Receptor T Cells|Participants will receive an infusion of autologous t cells genetically modified ex vivo to express the FSHR-specific 4-1BB/CD3ζ CER.
45765306|NCT03043534|Other|shave gel|"Non marketed pre-shave gel with the following INCI list of ingredients:~WATER, GLYCERIN, DIMETHICONE, LAURETH-23, PETROLATUM, ACRYLAMIDE/SODIUM ACRYLOYLDIMETHYLTAURATE COPOLYMER, ISOPROPYL PALMITATE, HYDROXYETHYLCELLULOSE, FRAGRANCE, PEG-23M, C13-14 ISOPARAFFIN, DMDM HYDANTOIN, DISODIUM EDTA, LAURETH-7, IODOPROPYNYL BUTYLCARBAMATE"
45765307|NCT03043534|Other|Brush|All subjects randomized to brush will use the brush with each shave
45765308|NCT04363775|Device|The standard Macintosh laryngoscope|intubation with the standard Macintosh laryngoscope and endotracheal tube 7.0 internal diameter with standard tube stylet
46069576|NCT02622945|Device|Sham plus Speech-Language Therapy|Speech-Language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
46069577|NCT02622867|Other|Lactobacillus plantarum 3547|During one period of parallel study (12 weeks) volunteers consumed 1 capsule/daily with Lactobacillus plantarum 3547 immediately after finishing their meal.
45446722|NCT02092636|Other|NIR/US Neoadjuvant Chemotherapy Group|Patients may have the NIR/US scan performed at the time of their initial ultrasound-guided biopsy. In addition, patients in this group may also have NIR/US performed according the schedule in Table 1. The number of NIR/US study visits for these subjects will vary from 1-11 depending on the subject's treatment regimen. The expected duration of study participation for these patients is approximately 6 months.
46069578|NCT02622867|Dietary Supplement|Maltodextrin|During one period of parallel study (12 weeks), volunteers will consume 1 daily capsule of maltodextrin immediately after finishing their meal.
45446723|NCT02092636|Other|NIR/US Process Validation Group|Patients who present with visible lumps at initial ultrasound but do not have ultrasound visible lumps on the day of the biopsy procedure will not require a biopsy. NIR/US scan will be performed. Data from the NIR/US scan will be used to validate instrument measurements.
45623259|NCT03269591|Diagnostic Test|Progesterone blood level|blood test
45623260|NCT03269591|Diagnostic Test|Menstrual symptom questionnaire|questionnaire
45623261|NCT03989609|Drug|Dexmedetomidine Injection [Precedex]|Dexmedetomidine infusion will be started at 0.1 µg.kg-1.hr-1 and will be adjusted by 0.1 µg.kg-1.h-1 to a maximum of 0.5 µg/kg/h,
45623262|NCT03989609|Drug|Midazolam|midazolam will be started at 1 mg.h-1 (3 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (15 mL.h-1).
45623263|NCT03988205|Behavioral|Outpatient Care Model|Outpatient care model includes a nurse teacher educational program, scheduled outpatient visit protocol, and quality of life surveys for both subjects and caregivers.
45623264|NCT03988205|Drug|CPX-351|CPX-351 is administered, according to FDA approval, to subjects who meet medical and logistical criteria for study enrollment.
45623265|NCT03280355|Behavioral|Singing training|"Each session will contain technical instruction in order to achieve better respiratory control and primary muscular strength, and with focus on techniques for efficient expiration. Sessions will also focus on musical content and interpretation as well as interaction, the social aspects and joy of singing together.~Prior to the trial all singing teachers will participate in a 2 days' workshop, where they will be instructed in sufficient methodology and didactics, and will obtain profound knowledge about the disease pathology and related physiology."
45623266|NCT03280355|Behavioral|Physical Training|"Physical Training (golden standard training activity in pulmonary rehabilitation) - usual care - is the active comparator in the trial.~The programme is based on the national guidelines for pulmonary rehabilitation, and consists of supervised warm-ups, aerobic exercises, workout (strength), and breathing exercises.~Physical Training is conducted by the local physiotherapists in the local health centres."
45623267|NCT03280277|Procedure|Contrast-enhanced Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
45623268|NCT03280277|Drug|Ferumoxytol|Given IV
45623269|NCT03269357|Other|LARC forward structured contraceptive counselling|Training of health care providers (HCPs), use of information material and counselling tools
45623270|NCT03280199|Other|simulation types|Different types of simulation interfaces and image acquisitions
45623271|NCT03269123|Device|Pressop 1|A pressure device attached to the spectacles which mimics a sensory trick (geste Antagoniste)
45623272|NCT03280043|Procedure|Hematoma|Hematoma requiring return to operating room.
45623273|NCT03278795|Procedure|pressure support ventilation mode|PSV is the sole mode of mechanical ventilation and will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In PSV weaning group , PS(pressure support) will be adjusted at 8 cmH2O until 2-h successful spontaneous breathing trial parameters according to ERS(European Respiratory Society) guidelines will be achieved and then patient will ex-tubated.
45623274|NCT03278795|Procedure|volume support ventilation mode|"VSV mode could be viewed as PRVC for spontaneous breathing as it delivers a variable pressure to meet a target VT. VSV will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In VSV weaning group ,VT(tidal volume ) will be adjusted at 6 ml/ Kg until 2-h successful spontaneous breathing trial parameters according to ERS guidelines will be achieved and then patient will ex-tubated."
45623275|NCT03269045|Drug|ORL-1B|Oral ORL-1B
45623276|NCT03269279|Drug|Mifepristone|Medication used in conjunction with misoprostol for abortion
45623277|NCT03269279|Drug|Misoprostol|Medication used in conjunction with mifepristone for abortion
45623278|NCT03278483|Drug|Isoniazid 300 mg Oral Tablet|Isoniazid tablets 300mg daily plus pyridoxine 50mg daily
45623279|NCT03278483|Drug|Rifampin 600 mg Oral Tablet|Rifampin capsules 600mg daily
45623280|NCT03277937|Procedure|angiography in EUS-injection of coils + CYA|Doppler imaging will be used to allow direct visualization of the varices flow. The gastric vessels will be followed from the cardia to the proximal part of the esophagus, to detect the feeding vessel (FV). Once the FV has been found, a 19-gauge EUS-FNA will be used to access the vessel. An angiography will be performed using 5-10 ml of water-soluble contrast under fluoroscopy, to ensure intravascular location and study varix flow direction. Finally, patients will be treated by EUS-deployment of coils followed by CYA injection. The coils will be delivered into the vessel through the FNA needle, using the stylet as a pusher. The 2-Octyl-CYA will be used. It will be injected always after the coils deployment and then 1 mL of saline solution will be used to flush the glue completely.
45623281|NCT03268733|Drug|Folic Acid|Tablet 5 mg
45623282|NCT03268889|Drug|Chidamide|Chidamide is given to the patients in this study along with CHOP regimen, to access the efficacy and safety in this cohort of PTCL patients. The dosage of the above regimen is as follows: Chidamide, 30mg,po,biw; Cyclophosphamide 750mg/m2, ivgtt, d1; Epirubicin 70mg/ m2, ivgtt, d1; Vincristine 3mg/ m2, ivgtt, d1; Prednisone 100mg/ m2, po, d1-5.
46069579|NCT04256252|Drug|Rituximab|A scheduled therapeutic regimen with low-dose rituximab was performed.
46069580|NCT04256096|Device|Thrombectomy|Endovascular treatment of large vessel occlusion (mechanical thrombectomy) with stent-retriever and/or thromboaspiration (neurointerventionalist choice)
46069581|NCT02622633|Device|Epidural Electrode|Epidural electrode of high frequency (50Hz) stimulation in the dorsolateral prefrontal cortex.
46069582|NCT02865239|Procedure|Position for the 3.0 Tesla in Magnetic Resonance Imaging|"Eligible patients will have a standard MRI in prone position. At the end of this examination, all patients will have an other standard MRI in supine position.~This examination is then extended by 10 minutes without additional injection of contrast medium"
46069583|NCT02622555|Drug|Mirabegron|Patients with overactive bladder eligible for drug treatment who fulfill the EMA prescription guidelines receive mirabegron 50 mg extended release once daily according to clinical routine
45446724|NCT00147251|Drug|FDA approved drugs to treat blood pressure and cholesterol|
45446725|NCT04390191|Device|Continuous Positive Airway Pressure|CPAP at fixed pressure (8-10cm H20) for 72 hours continuously (except for daily activities such as eating, personal activities and breaks for ambulation etc).
45765309|NCT04363775|Device|The Vie Scope laryngoscope|intubation with the Vie Scope laryngoscope with bougie stylet and endotracheal tube 7.0 internal diameter
45623283|NCT03268967|Behavioral|Structured admission procedure|A structured ICU admission was inspired by principles of Crisis Resource Management and simulation training of ICU staff members. The Principles of Crisis Resource Management consisted of a treatment manual, a learning video, clear precise communication tool based on Identification-Situation-Background-Analysis-Recommendations (ISBAR) and Closed loop, actions cards, and ABCDE-evaluation of the patient including debriefing, and training in the simulation environment.
45623284|NCT03277391|Procedure|Serratus anterior plane block|SPB realized under ultrasound guidance. Infiltration of local anesthetic (bolus then infusion through a multi-holed catheter) is realized under the serratus anterior muscle at a level situated around the 5th to 6th intercostal space on the anterior axillary lign, in order to anesthetize the cutaneous lateral branches of the intercostal nerves, with a first ropivacaine 0,375% bolus (0,4ml/kg), followed by an infusion of ropivacaine 0,2% at a 10ml/hr rate, through a multi-holed catheter, for a duration of 24 hours.
45623285|NCT03277391|Device|patient-controlled analgesia|Each patient controls his analgesia with an IV bolus of 2mg of morphine every 10 minutes if needed, with a maximum of 20mg every 4 hours.
45765310|NCT00359151|Drug|Celecoxib|7 days pre-surgery (excluding day of surgery): 1 celecoxib 200 mg capsule or matching placebo QD; Day of surgery: 2 celecoxib 200 mg capsules or matching placebo within 2 hours prior to surgery, and 1 celecoxib 200 mg capsule or matching placebo following surgery; Post-surgery: starting the day after surgery, 1 celecoxib 200 mg capsule or matching placebo BID for the duration of the study.
45765311|NCT00359151|Drug|Placebo|Placebo once daily (QD) for 7 days pre-surgery (excluding the day of surgery); Placebo within 2 hours prior to surgery; and post surgery on the same day of the surgery; Placebo twice daily (BID) following the day of surgery and for the duration of the study.
45765312|NCT02242097|Drug|ibrutinib|Given PO
45765313|NCT02242097|Other|laboratory biomarker analysis|Correlative studies
45765314|NCT00374686|Drug|Valganciclovir|
45765315|NCT04371575|Drug|Carbamazepine|There is no actual intervention as the study is observational. First choice tratment is Carbamzepine and Oxcarbazepine. In medically refractory patients, first choice surgery is microvascular decompression
45765316|NCT00359229|Drug|Zolpidem|Administration of Zolpidem 5mg
45623286|NCT02458391|Other|Standard of care complete decongestive therapy|Participants will receive standard of care complete decongestive therapy consisting of meticulous skin and nail care, manual lymphatic drainage, compression bandaging, remedial exercises and self-care training.
45623287|NCT03277001|Drug|Rivaroxaban|Rivaroxaban, po. 10mg/day（CrCl≥ 50 ml/min）or 5 mg /day (CrCl ≥ 30 and < 50 ml/min) po.
45623288|NCT03277001|Drug|Enoxaparin|Enoxaparin 40mg IH
45623289|NCT03268577|Other|Internet-Based Intervention|Complete ASA24
45623290|NCT03268577|Other|Internet-Based Intervention|Complete ACT24 reporting
45623291|NCT03268577|Device|Monitoring Device|Wear accelerometer and inclinometer physical activity monitors
45623292|NCT03268577|Other|Questionnaire Administration|Ancillary studies
45765317|NCT04363853|Drug|Tocilizumab|We study the impact of the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome (ARDS) in patients with severe or critical SARS-CoV-2 infection.
45765318|NCT02979262|Behavioral|Fathers for Change|
46069584|NCT02866019|Device|CLS2702C/CLS2702D|CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month [4 weeks]; cell sheet culture period, 0.5 month [16 days]; transplantation period, assessment/follow-up period, 6 months [24 weeks])
46069585|NCT05329454|Drug|Ibuprofen Tablets|"Treatment A:~One tablet of IBUMR will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBUMR every 12 hours for a total of 7 doses.~Treatment B:~One tablet of IBURed will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBURed every 8 hours for a total of 10 doses.~Treatment C:~Single dose of IBUMR will be given to the subjects under fed condition (a standard high-fat, high calorie breakfast should be consumed within 30 minutes prior to dosing)."
45765319|NCT02979262|Behavioral|Parent Education|
45765320|NCT04363931|Procedure|Manual Therapy|Participants in this group received 4 weeks of manual therapy and massage of the masticatory muscles intra and extra orally together with massage of the cervical muscles. Massage and Manual Therapy brings about benefits by increasing local circulation and decreasing muscle tonus . Additionally, stretching exercises aiming to decrease pain and elongate shortened masticatory muscle fibers by autogenic inhibition of the masseter muscle were performed.
45765321|NCT04363931|Procedure|Kinesio Taping|Participants in this group had an application of Kinesio Taping on the masseter muscles. The material used for bruxism Kinesio Taping application was Kinesio Tex Gold Finger Prints (Kinesio Holding Corporation, Albuquerque, USA), a 100% cotton, latex-free, 5-cm wide, elastic tape. Kinesio Taping placement was chosen according to principles described by Kase et al. Tapes were cut 2.5 cm in width (cut in half vertically from 5 cm width). Two strips of Kinesio Tape were crossed over the masseter muscle area with 0-5% tension in maximum stretched epidermis position. Web-cut strips epidermis-dermis-fascia technique were used. Tape was applied bilaterally after every session of manual therapy.
45765322|NCT02980978|Behavioral|Coaching|Focus on nutrition, activity and appropriate medication use and adherence
46069586|NCT02622789|Other|Pilates Exercises|Pilates method based stability exercise intervention
45623293|NCT03276611|Other|echocardiograghy|transthoracic echocardiograghy
45623294|NCT03268655|Dietary Supplement|Ginger extract|2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout
45623295|NCT03268655|Other|Placebo|2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout
45765323|NCT04363229|Other|maslach burnout inventory questionnair|The Maslach Burnout Inventory (MBI) is an introspective psychological inventory consisting of 22 items pertaining to occupational burnout
45765324|NCT05639517|Other|Augmented Reality Based Telerehabilitation Application|Spinal stabilization training with augmented reality-based telerehabilitation will be applied twice a week for 8 weeks.
45765325|NCT05639517|Other|Training face-to-face|Spinal stabilization training will be applied face-to-face twice a week for 8 weeks.
45765326|NCT04371341|Procedure|erector spinae block by 0.25% bupivacaine|A mark will be applied on the required level (T8), the midline (spinous processes) and the injection points 3 cm from midline.While the patient is in a sitting position with support from a member of staff, Preparation of the field with iodine will be made. Using ultrasound guidance with a 6-10 MHz linear probe anatomical landmarks will be identified including the transverse process at T8 level and the three layers of muscles from posterior to anterior: trapezius-rhomboid-erector spinae. After subcutaneous lidocaine 2% injection a 22-G spinal needle will be inserted under ultrasound guidance in plane, aiming towards the transverse process. After a Gentle contact with the transverse process, 0.25% bupivacaine is injected in increments with careful repetitive aspiration to avoid intravascular injection.
45623296|NCT02459249|Other|Healthy Lifestyle|A physician and a nutritionist will be give recommendations for diet and exercise emphasizing the importance of a healthy lifestyle (suggesting moderate-intensity activity at least 150 minutes/week and to eat less sodium, fat, sugar, portions and calories). Verbal and written individualized recommendations from trained professionals (nutritionists, and physician) will be provided. Monthly sessions of at least 30 minutes covering diet, exercise, and behavior modifications were held. The first was a one-to-one meeting and was followed by group sessions based on behavioral counseling
45623297|NCT02459249|Other|Placebo Comparator (Treatment of Mexican Health Minister)|General and unspecific recommendations of diet and physical activity for the metabolic syndrome treatment, given for a physician
45912541|NCT02011477|Other|Neural stretching|In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. The therapist was on the subject´s side, with his knee below the subject's head, bringing stability. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject
45912542|NCT02011503|Procedure|Multi-layer compression therapy|Application of multi-layer compression therapy.
45912543|NCT02011503|Other|Application of dHACM|Application of dHACM to ulcer.
45912544|NCT02011529|Other|TEAMcare treatment of diabetes|TEAMcare is an evidence-based collaborative care approach to the treatment of diabetes and psychiatric illness. It involves structured visits with a study nurse to monitor psychiatric symptoms, control of medical disease, and self-care activities. The nurses use motivational coaching to help patients solve problems and set goals for improved self-care and medication adherence. Medications for diabetes, hypertension, and hyperlipidemia are monitored and therapy intensified based on treat-to-target guidelines. All of these process and outcome measures are tracked in a registry designed for the study, and the nurses receive weekly supervision with a psychiatrist, an endocrinologist and a psychologist in order to review new cases and to track progress. Once a patient achieves targeted levels for relevant measures, the patient and the nurse develop a maintenance plan.
45912545|NCT02011568|Other|Therapeutic Hypothermia|
45623298|NCT02458859|Device|PICO (single use portable negative pressure wound therapy)|Single use portable negative pressure wound therapy
45623299|NCT02458001|Behavioral|SAFFRON stepped care|"Behavioral: SAFFRON stepped care Stepped care (Improving Access to Psychological Therapies, 2012; Richards et al., 2012) adapted for the gynaecological cancer setting to produce a 3-step model including a clinical assessment and treatment algorithm.~Assessment Algorithm FSFI Interventions~Level 1:~Best available self-help literature on psychosexual difficulties after cancer as judged by the project team and two patient advocates.~Level 2:~A 3-5 session manualised psycho-educational intervention delivered fortnightly by study trained CNSs with taping and supervision for adherence to protocol and manual.~Level 3:~16 weekly session manualised brief psychotherapy adaptation of InterPersonal Therapy, IPT (Interpersonal Psychotherapy for Sexual Adjustment post Gynaecological Cancer, IPT-APGyC)"
45623300|NCT03268187|Device|Biofeedback|The skin conductance of the patient is measured and fed back to the patient via screen.
45623301|NCT03268187|Behavioral|Self-Alert Training|Self-Alert Training
45765327|NCT00374764|Drug|Risperidone|
45765328|NCT00374764|Behavioral|ABA|
45765329|NCT05297643|Device|Ekstracorporeal Shock Wave Therapy (ESWT)|Extracorporeal Shock Wave Therapy (ESWT); It is a treatment method in which high-intensity pressure waves are applied to the desired point in the body. It has been used in the treatment of kidney stones in previous years, and changes in bone tissue have been observed (12). Today, it is used in musculoskeletal system diseases such as plantar fasciitis, epicondylitis, achiltendinitis, osteoarthritis
45623302|NCT03268187|Behavioral|Relaxation Training|Relaxation Training
45765330|NCT05297643|Other|complex decongestive therapy|Complex decongestive therapy consists of manual lymphatic degeneration, compression therapy, skin care and remedal exercise.
45765331|NCT04371185|Drug|BAT2206|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
45765332|NCT04371185|Drug|Stelara(US-licensed)|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
45765333|NCT04371185|Drug|Stelara(EU-licensed)|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
45765334|NCT03834077|Other|Tissue flossing|Electrotherapy (transcutaneous electrical nerve stimulation) and Ultrasound in addition to tissue flossing.
45765335|NCT03834077|Other|Placebo comparator|Conventional physiotherapy in addition to flossing without tension
45912546|NCT02011594|Drug|Nimotuzumab|400mg Q2W intravenously
45912547|NCT02011594|Drug|Placebo|Normal saline
45912548|NCT02011620|Other|Isosorbide-5-mononitrate|Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
45912549|NCT02011633|Drug|HCP1201 500/10mg|500mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
45912550|NCT02011633|Drug|Metformin SR 500mg|Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
45912551|NCT02011633|Drug|Rosuvastatin 10mg|Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
46069587|NCT02865863|Dietary Supplement|Eurycomalongifoliawater extract (Physta®)|
46069588|NCT02865863|Dietary Supplement|Placebo|
46069589|NCT02865863|Dietary Supplement|Multivitamin|
46069590|NCT05331560|Device|Transcranial Pulse Stimulation (TPS)|"A global brain stimulation approach, which homogenously distributes the total energy of 6000 TPS pulses per session over all accessible brain areas.~Prefrontal, Temporal and Occipital brain areas were stimulated by ultrashort (3μs) ultrasound pulses with typical energy levels of 0.2-0.25 mJ/mm2 and pulse frequencies of 4-5 Hz (pulses per second)."
45623303|NCT03273881|Drug|glucose solution and Insulin|"Women in group 1, will receive intravenous saline solution boosted with 5% glucose combined with 8 units of insulin at a rate of 125mL/h. The desirable intrapartum glucose level will be 70 to 100 mg/dL. Glucose levels will be checked hourly.~Glucose level between 100-140 mg/dL will be treated with additional intravenous insulin, 1 units/hour.~Glucose level between 141-160 mg/dL will be treated with intravenous insulin, 2 units/hour. Additionally, the 5% glucose solution will be substitute with lactated Ringer's solution.~Glucose level between 161-200 mg/dL will be treated with intravenous insulin, 4 units/hour.~Glucose level above 200 mg/dL will be treated with intravenous insulin, 6 units/hour."
45623304|NCT03273881|Drug|glucose solution only|Women in group 2, will receive intravenous saline solution boosted with 5% glucose only, at a rate of 125mL/h. Women in this group will be treated similar to group 1 if glucose levels crossed over 100 mg/dL.
45623305|NCT03272711|Drug|Vortioxetine 10 mg|
45623306|NCT03272711|Behavioral|Cognitive training program|Online training program, 30 minutes a day, 5 times a week
45623307|NCT03267719|Device|laser therapy|Transvaginal erbium-laser treatment
45623308|NCT03267797|Other|Peripheral Blood Monouclear Cell|Blood samples (20 mL) were taken from individual patients at the time of ovulation induction. Then PBMC were isolated and cultured (20-30 million cells) 48 hour at the presence of hCG (10IU/ml daily). Afterward,15-20 million PBMCs in 500 microlitres PBS were injected into the uterine cavity two days before embryo transfer (ET) using ET catheter.
45623309|NCT03267797|Other|Phosphate Baffer Saline|Only 500 microlitres PBS will be injected into the uterine cavity, instead of PBMCs, two days before embryo transfer (ET) using ET catheter.
45623310|NCT03267953|Behavioral|My Health CheckUp Online Stress Management Program|Self-contained, web-based, stress management program developed by team of health care professionals, designed to encourage patients to learn evidence-based cognitive and behavioural strategies to effectively manage stress. Health risk appraisals include evidence-based recommendations to address risks. Stress management modules include education about the impact of stress, self-monitoring through a stress diary, and using four key strategies: physical activity, deep breathing and relaxation, problem-solving/addressing negative thoughts, and sleep hygiene. Through the modules, patients will learn new stress management strategies and have an opportunity to practice these, track their progress, and obtain feedback via the website. To facilitate self-monitoring of stress levels and tracking of strategies such as physical activity, tracking tools can be used on mobile devices.
45623311|NCT03267953|Behavioral|Lay telephone coaching|The goal of telephone coaching will be to provide brief encouragement on how to use the modules; however, no formal therapy will be provided. Sessions will range between 10-15 minutes. Each coach session will follow the process outlined by the GROW model, which stands for Goal, Reality, Options/Obstacles, and Will/Way forward. The sessions will start with the coach and participant agreeing on the topics for discussion and desired outcomes (goal). Then, coaches will explore the use of the intervention over the previous week, guide participants through the modules, identify barriers to using these modules, offer advice to overcome these barriers, and provide positive reinforcement. The development of an action plan for the following week will conclude each session. The short Perceived Stress Scale will be used at the end of each session to monitor progress. A script will guide the lay coach through each call.
45623312|NCT03267953|Behavioral|Motivational interviewing (telephone)|Sessions will range from 30 to 45 minutes. The goal of MI is to strengthen patients' motivation and confidence for adopting the stress management strategies suggested. The MI practitioner's interventions are based on the four processes of MI: Engaging, Focusing, Evoking, and Planning.
45623313|NCT03268031|Diagnostic Test|Visual field and OCT tests|Visual field test and OCT are commonly used essential tests to make accurate diagnosis of glaucoma. Algorithms to classify Visual field and OCT tests would both be developed and verified.
45623314|NCT03267875|Procedure|Blood Test|draw out 2 blood tubes from a patient
45623315|NCT05075447|Behavioral|Emotion Control Treatment Program|Intervention programs include Child Training and Training in real scenes
45623316|NCT05075525|Other|High Intensity Laser Therapy Group|High Intensity Laser Therapy (HILT) and exercises will be used.
45623317|NCT05075525|Other|Ultrasound and Transcutaneous Electrical Nerve Stimulation Group|Transcutaneous electrical nerve stimulation(TENS), ultrasound (US) will be applied.
45623318|NCT05075525|Other|Ultrasound and Interferential Current Stimulation Group|Ultrasound (US) ,interferential current stimulation and exercise will be used.
45623319|NCT05075369|Diagnostic Test|water drinking test|Water drinking test-glaucoma diagnostic test - marker for outflow facility reserve to detect IOP instability when the body ingests 800 ml of water within a 5 minute period of time
45623320|NCT05074901|Behavioral|digital behavioral intervention|interaction with a conversational agent to implement physical and cognitive programs
45623321|NCT03961919|Drug|Fludarabine|Fludarabine i.v. 30 mg/m²/d day -6 to -2
45623322|NCT03961919|Drug|ARA-C|Cytarabine i.v. 2 g/m²/d day -6 to -2
45623323|NCT03961919|Drug|Treosulfan|Treosulfan i.v. 10 g/m²/d day -6 to -4
45623324|NCT03961919|Procedure|Peripheral Blood Stem Cell Transplant|"Autologous stem-cell transplantation i.v.: day 0 (source: peripheral blood)~Pegylated-Filgrastim s.c. 6 mg day +3"
45623325|NCT03267485|Device|real time PCR|Real Time PCR is based on the detection of the fluorescence produced by a reporter molecule which increases, as the reaction proceeds. These fluorescent reporter molecules include dyes that bind to the double-stranded DNA or sequence specific probes . Moreover, there is no need for the post PCR processing which saves the resources and the time. .
45623326|NCT02459015|Device|Implantation|A peripheral nerve defect up to 26 mm in the finger will be repaired by implantation of either a Reaxon® Nerve Guide or an autologous nerve graft (depending on the randomization group) on day 0.
45765336|NCT03834155|Other|Hospital-based CR + Movn Application|Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application.
45765337|NCT03834155|Other|Choice of Hospital or home-based CR + Movn Application|Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application.
45765338|NCT03834155|Other|Hospital-based CR + Movn Application + Nudge|Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application, plus encouraging nudge messages.
45446726|NCT02092714|Other|laboratory biomarker analysis|Correlative studies
45446727|NCT03967691|Drug|Tocilizumab infusion|Tocilizumab (8mg/kg body weight diluted to 100 ml NaCl 0.9%) will be infused over 1 hour
45446728|NCT03967691|Drug|Saline 0.9%|100 ml NaCl 0.9% will be infused over 1 hour
45623327|NCT03267407|Other|Preemptive high-dose Fluconazole|Patients with advanced HIV diseases are screened for Cryptococcal Antigen using LFA CrAg tests. Then patients with CrAg positivity and without meningitis are given preemptive high-dose fluconazole to prevent the development of cryptococcal meningitis, which is one of the leading cause of death among immunocompromized patients.
45623328|NCT03267329|Drug|Duowell®|telmisartan 80mg/rosuvastatin 10mg for ASCVD risk=5%~7.5% or telmisartan 80mg/rosuvastatin 20mg for ASCVD risk≥7.5%
45446729|NCT02088736|Device|Intraosseous|
45446730|NCT02088736|Device|Intravenous|
45623329|NCT03267329|Drug|Telmisartan|telmisartan 80mg
45623330|NCT05074589|Drug|Irinotecan liposome、5-Fluorouracil、Leucovorin|Irinotecan liposome、5-Fluorouracil、Leucovorin
45623331|NCT05074589|Drug|Placebo、5-Fluorouracil、Leucovorin|Placebo、5-Fluorouracil、Leucovorin
45623332|NCT03267173|Drug|Chimeric antigen receptor T cell|Evaluate the efficacy and safety of targeted Mesothelin/PSCA/CEA/HER2/MUC1/, EGFRvIII and other chimeric antigen receptor engineered T cell immunotherapy in the treatment of pancreatic cancer.
45623333|NCT03267251|Other|Vacteens Web app for mobile devices|The Web app provides parents of young adolescent girls (ages 11-14) accurate information about HPV Vaccination, and a number of tools to aid informed decision making.
45623334|NCT03267251|Other|Standard Usual and Customary HPV Information - CDC pamphlet|The usual communication about HPV Vaccination in clinics is for parents to be issued the CDC pamphlet on HPV Vaccination.
45623335|NCT03266939|Drug|Lorcaserin|10 mg acute administration of lorcasein
45623336|NCT03266939|Drug|Placebo Oral Tablet|Placebo
45623337|NCT02458937|Other|Functional Mobility Assessment|Functional Mobility Assessment (FMA) is a tool that was developed to measure functional mobility in children and adolescents with lower-extremity sarcoma. It is comprised of well-established outcome measures that examine various domains of function. The six categories tested by the FMA include pain, functional mobility, use of assistive devices, satisfaction with quality of gait, participation in the community, and endurance.
45623338|NCT02458937|Other|GAITRite® System|Subjects will be required to walk at a self-selected comfortable pace and again at fast speed. Software will then calculate and report the temporo-spatial gait parameters for collection and evaluation by the primary investigator.
45623339|NCT02458937|Other|Range of Motion|Measurements will include hip flexion, hip abduction and adduction, and hip internal and external rotation. Range of motion (ROM) will be attempted on bilateral lower extremities, however if post-operative ROM precautions are implemented, the involved extremity will not be measured. Goniometry is a reliable and valid measure for active and passive ROM when following standardized procedures.
45623340|NCT05074199|Procedure|W-plasty/Linear closure|"The patient's wound will be labeled A if it is on the left or superior side of the investigator and B if it is on the right or inferior side. A predetermined, concealed randomization number will be obtained from the RedCap randomization module, which will specify how side A is to be treated. Side B will be treated the opposite way as A. Side A will always be closed first. The side assigned to be closed in a traditional straight line (SL) will have the standing cutaneous deformity (dog ear) excised in the standard manner using Burrow's triangles, resulting in an elliptical defect amenable to linear closure. The side assigned to be closed with W-plasty will have the dog ear excised in a zig-zag fashion consistent with the W plasty flap design. Both sides of the wound will receive subcuticular closure with interrupted subdermal sutures as is the standard of care, followed by a standard running cuticular closure with absorbable suture material."
45623341|NCT03267095|Behavioral|music therapy sessions .|In this intervention songs compose by the therapist will be use for the study. The songs included the target word .The target words will be selecte from functional vocabularies that typically developing 3years old children can use effectively in everyday interactions.The general criteria for vocabulary words included: names of familiar objects and persons, functional action words such as words for social control , and emotional words . Inherent musical structures structures and organized musical patterns in the songs will be provide .The patients will reflect on the music therapy activity as singing the song together.
45623342|NCT03267017|Other|posture changes|Following induction of general anesthesia and initiation of positive pressure ventilation, patients will be tilted 15 degrees head up for 5 minutes with positive end expiratory pressure of 8 cm H2O, and then 15 degrees head down for 5 minutes with positive end expiratory pressure of 3 cm H2O
45765339|NCT03834155|Other|Choice of Hospital or home-based CR + Movn Application + Nudge|Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application, plus encouraging nudge messages.
45446731|NCT02092792|Drug|DLYE5953A|Escalating doses of DLYE5953A
45446732|NCT02092792|Drug|DLYE5953A|Administration of DLYE5953A at the recommended phase II dose (RP2D)
45446733|NCT03968549|Dietary Supplement|Probiotic|Those patients in group Probiotic will receive the capsules containing Lactobacillus acidophilus and will need to take one of it everyday during the study.
45446734|NCT03968549|Other|Placebo|Those patients in group Placebo will receive the capsules containing vegetable oil and corn starch and will need to take one of it everyday during the study.
45446735|NCT03558178|Procedure|Doin with acupuncture|Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise as indicated. Doin sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).
45446736|NCT03558178|Device|Acupuncture|Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).
45446737|NCT04333563|Device|CPAP|Continuous positive airway pressure
45446738|NCT04333563|Device|NIV NAVA|Non-invasive neurally adjusted ventilatory assist
45446739|NCT04405076|Biological|Biological: mRNA-1273|Sterile liquid for injection
45446740|NCT04405076|Biological|Placebo|0.9% sodium chloride (normal saline) injection
45765340|NCT01005355|Biological|IMC-1121B|Cycle 1: Upon completion of enrollment criteria confirmed at screening, the first dose of study medication should be administered within 7 days. The infusion will be planned every 2 weeks or every 3 weeks on the same day of the week of the first infusion. Dose escalation to Cohort 2 may occur in the absence of a dose-limiting toxicity (DLT) in the first three participants treated in Cohort 1 during the initial 6-week dosing period (Cycle 1). The same procedure will be followed for dose escalation from Cohort 2 to Cohort 3. If 1 of 3 participants in any cohort experiences a DLT in the first 6 weeks (Cycle 1), 3 additional participants will be enrolled in that cohort. Dose escalation to the next cohort may occur if less that 2 of 6 participants experience a DLT during Cycle 1.
45765341|NCT02242175|Device|Glucose breath test (hydrogen breath test)|Glucose breath test (hydrogen breath test) is the current gold standard for diagnosis of irritable bowel syndrome. Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen or methane gas as a by-product. The breath sample will be analyzed for hydrogen or methane content to determine if you are able to properly break down the lactose, fructose or sucrose, or if you have bacterial overgrowth.
45765342|NCT05498649|Device|DT1fA|DT1fA contact lenses
45765343|NCT05290389|Other|SMART AMI APPLICATION|"SMART AMI allows real-time sharing and review of patient history and ECG between Emergency Department physicians and Interventional Cardiologists to allow for immediate decision-making regarding the need for percutaneous coronary intervention.~Participant physicians will use a smartphone application to communicate, transmit the ECG, and activate the STEMI team. This application enables calling and transmission of up to three images of ECGs, which can be reviewed immediately by the Interventional Cardiologist when communicating with the referring physician."
45765344|NCT04363151|Other|No intervention.|
45623343|NCT05074043|Combination Product|antiviral, surgical|surgical debridment
45623344|NCT05073809|Diagnostic Test|Photoacoustic Imaging Scan|A relatively novel modality that combines exquisite spatial resolution with the ability to image multiple biological tissues, including blood, water and lipid.
45623345|NCT03266705|Drug|tafamidis|bioequivalence study
45623346|NCT05073965|Dietary Supplement|Vitamin D|Subjects were assigned to receive a 1000IU vitamin D supplement dose
45623347|NCT05073965|Other|Placebo|Subject were assigned to receive a placebo
45623348|NCT03266549|Procedure|botulinum toxin augmented surgery|unilateral recess-resect procedure, or bilateral rectus muscle recession plus intraoperative injection of 2.5 to 5 units of botulinum toxin A into the recessed muscle.
45623349|NCT03266549|Procedure|conventional surgery|unilateral recess-resect procedure, bilateral rectus muscle recession, or 3 horizontal rectus muscle surgery according to the type of strabismus and the presence or absence of deep amblyopia. The standard correction tables will be used as a guide for the amount of muscle recession and, or resection.
45623350|NCT03266861|Diagnostic Test|Exercise oximetry|Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
45765345|NCT03030313|Device|Reassure Non-Contact Respiration Monitor|Reassure Respiration Monitor uses very low power radio waves to detect respiratory movements of a person while asleep in bed - without physical contact with the individual. Algorithms analyze the respiratory movement signals and extract information about respiration rate and variability. This data is uploaded to a secure cloud infrastructure for storage.
45765346|NCT02981368|Drug|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
45765347|NCT02981368|Diagnostic Test|PET/CT imaging|PET/CT imaging will be acquired 1-2 hours post-PyL injection
45765348|NCT02242253|Drug|Tiotropium|administered via HandiHaler®
45765349|NCT02242253|Drug|Salmeterol|administered via metered dose inhaler (MDI)
46069591|NCT02622711|Behavioral|DI|Participants will be offered an individualized dietary counselling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
45623351|NCT05065775|Device|Dexmedetomidine|Single intranasal dexmedetomidine dose of 100 µg. Intranasal dexmedetomidine will be administered shortly after induction of anesthesia using a mucosal atomization devise (LMA MAD Nasal™)
45623352|NCT05016323|Drug|HR19042 Capsules|HR19042 Capsules
45623353|NCT05016323|Drug|Placebo|Placebo
45623354|NCT02458703|Other|Cardiopulmonary exercise test|"Subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down, they will fill in a short questionnaire describing how they feel. 20-30mls of blood will be taken for analysis."
45623355|NCT04955951|Device|polarized light|A Bioptron light therapy phototherapeutic device (Bioptron AG, Wollerau, Switzerland) with 5 cm treatment diameter (BIOPTRON MedAll®, 480-3400 nm, polarization level of 95%, power density 40 mW/cm2, energy density 2,4 J/cm2 per minute
45765350|NCT02242253|Drug|Placebo-MDI|
45765351|NCT02242253|Drug|Placebo HandiHaler®|
45765352|NCT05285943|Drug|Olive oil cream|Olive oil prepared in a base cream to be applied to irradiated areas.
45765353|NCT05285943|Drug|Betamethasone Valerate Cream|Betamethasone valerate prepared in a base cream to be applied to irradiated areas.
45765354|NCT05285943|Other|Base Cream|The base cream used for preparation of both the betamethasone valerate cream and olive cream will be used as a placebo control to be applied to irradiated areas.
45765355|NCT03030001|Biological|PD-1 antibody expressing mesothelin specific CAR-T cells|Patients will receive an IV infusion of PD-1 antibody expressing mesothelin specific CAR engineered peripheral blood leukocyte. On day 21, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
45765356|NCT02242331|Drug|Micardis®|
45765357|NCT05495061|Drug|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 3 months
45765358|NCT05495061|Drug|Latanoprost ophthalmic solution 0.005%|1 drop Latanoprost ophthalmic solution 0.005% once daily for 3 months
45446741|NCT04405076|Biological|mRNA-1273.351|Sterile liquid for injection
45623356|NCT04955951|Drug|Topical corticosteroid ointment|corticosteroid 1 %.
45623357|NCT03266159|Drug|GSK525762 Besylate tablets|GSK525762 Besylate film coated tablets will be available as a 20 mg tablet strength, yellowish pink in color, round and biconvex with no markings. It will be administered with 240mL of liquid.
45623358|NCT03266159|Drug|Trametinib tablets|"Trametinib film coated tablets will be available as 0.5 mg and 2 mg dose strengths. Trametinib 0.5 mg will be yellow colored, modified oval, biconvex, tablets with 'GS' debossed on one face and 'TFC' on the opposing face.~Trametinib 2 mg will be pink colored, round, biconvex tablets with 'GS' debossed on one face and 'HMJ' on the opposing face. Doses will be taken at least 1 hour before or at least 2 hours after a meal."
45446742|NCT01074359|Drug|A0001 (alpha-tocopherolquinone)|28 days (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
45446743|NCT01074359|Drug|Placebo|28 days of placebo oral capsules. Treatment taken twice daily with meals.
45446744|NCT02088814|Behavioral|'EPICAP'|standardized, secondary preventive psychological intervention with parents of children ages 1-4 with acute burn injuries, consisting of psychoeducation, trauma narrative, storybook, provision of coping skills
45623359|NCT04800887|Device|TECNIS Eyhance intraocular lens|Cataract surgery and implantation with extended depth of focus intraocular lens
45623360|NCT04800887|Device|Monofocal intraocular lens Tecnis ZCB00|Cataract surgery and implantation with monofocal intraocular lens
45623361|NCT03266237|Drug|Vaxigrip®|To describe the humoral immune response to Vaxigrip (IM) vaccination at Day 0 (baseline) and Day 28 according to the age and frailty status at baseline (i.e. in each study group) for each Influenza strain.
45623362|NCT02457923|Other|Mobile phone counselling|i) Data collection and counselling by ASHA using the cell application (App) developed by CommCare Dimagi ii) Mobile phone counselling iii) Routine counselling schedules
45623363|NCT04742933|Other|There is no intervention in this observational trial|There is no intervention in this observational trial
45623364|NCT03265769|Other|radial access site|radial route
45623365|NCT03265769|Other|femoral access site|femoral route
45623366|NCT02458781|Drug|Metronidazole|Metronidazole 500mg given twice daily for 14 days
45623367|NCT02458781|Drug|Ciprofloxacin|Ciprofloxacin 500mg given twice daily for 14 days
45623368|NCT02458781|Drug|Placebo|Placebo given twice daily for 14 days
45623369|NCT04647383|Drug|Placebo|OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
45623370|NCT04647383|Drug|Lemborexant 10 mg|OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
45623371|NCT04647383|Drug|Placebo|COPD: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
45623372|NCT04647383|Drug|Lemborexant 10 mg|COPD: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
45623373|NCT03266003|Other|Electronic DOT|"Electronic DOT is the use of electronic communication methods to observe patients swallow anti-TB drugs and monitor for medication side effects. This study will use two variations of electronic communication methods, referred to as electronic directly observed therapy or eDOT. This includes: (1) eDOT conducted live in which TB program staff interact with patients via a computer or phone application as they ingest their medication (eDOT-live), and (2) eDOT conducted using time stamped, recorded videos in which TB program staff log into an electronic system and review videos recorded by patients in order to verify that patients ingested their medication doses as scheduled (eDOT-recorded)."
45623374|NCT03266003|Other|In-person DOT|A trained person is in the physical presence of patients as anti-TB drugs are ingested.
45623375|NCT02457689|Biological|GTU®-MultiHIV B Clade Vaccine|The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein) built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of an HAN2 HIV-1 B clade isolate.
45623376|NCT02457689|Other|Sodium chloride BP|For use in prophylactic and replacement therapy, requiring the use of isotonic saline solution.
45623377|NCT03265691|Other|Early detection and treatment of hyponatremia|In the experimental group, hyponatremia will be diagnosed and treated early. Therefore, the researchers will review the patients' sodium levels at admission and throughout their stay.
45623378|NCT03265691|Other|No Intervention (SOC)|Usual pattern of work will be performed in all patients who enter in Hospital.
45623379|NCT03265847|Behavioral|Culturally-tailored Safety Planning|The intervention will provide safety planning/referrals tailored to the DA
45623380|NCT02458157|Drug|Furosemide (Furix)|"Loading dose: 40 mg I.V.~Infusion rate 40 mg/h~Continued until neutral cumulative fluid balance is achieved (the overall treatment goal) or average negative fluid balance is below 1 ml/kg/h for 8 hours."
45765359|NCT00963859|Procedure|Robotic-assisted laparoscopic surgery|During radical cystectomy, robotic-assisted technique used to perform cystectomy and pelvic lymph node dissections. Each patient will undergo a second-look open lymph node dissection once the incision is made at the end for the urinary diversion.
45446745|NCT02087722|Drug|KI1001|
45446746|NCT02087722|Drug|Placebo|
45446747|NCT01326221|Drug|tenofovir + emtricitabine|tenofovir 300mg + emtricitabine 200mg x one dose
45446748|NCT04311177|Drug|Losartan|Losartan; 25 mg daily; oral administration
45446749|NCT04311177|Other|Placebo|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
45765360|NCT04370717|Other|telehealth consultation|"A telehealth consultation will be scheduled and conducted without modifications from the routine clinic protocol. The case report will include ICD-10 code and plan of care.~After one week, patients will receive an electronic satisfaction survey. An in-person follow-up and/or procedural visit will be subsequently scheduled. During this visit, the same physician will complete physical examination, document the diagnosis and proceed with either the same or modified plan of care. The research coordinator will enter diagnostic and procedural codes in the case report form."
45623381|NCT02458157|Other|Continuous renal replacement therapy (CRRT)|"Initiated in case of contraindications or inadequate effect of furosemide.~Fluid removal is started at 2 ml/kg/h~The efficacy is evaluated 3 times daily and removal rate increased by 0.5 ml/kg/h if the therapeutic goal is not achieved"
45765361|NCT04370951|Procedure|Erector Spinae Plane Block - Ultrasound guided|20mls 0.25% Levobupivicaine ultrasound guided bilaterally
45765362|NCT03030157|Drug|pirarubicin(THP)|
45623382|NCT02458157|Other|Resuscitation|"The physiologic response to fluid removal is monitored with three variables indicating inadequate circulation. These are:~Mottling beyond the edge of kneecaps~Hypotension (MAP < 50) resistant to inotropes and vasopressors~Plasma lactate ≥ 4 mmol/l~Mottling and MAP are monitored continuously and lactate is measured routinely 4-6 times each day and on clinical indication. If one or more variable is present:~Fluid removal is paused~A crystalloid fluid bolus of 250-500 ml is given~Circulatory status is reevaluated within 30 minutes~Step 1-3 is repeated until signs of inadequate circulation have been resolved for minimum 1 hour~Fluid removal is restarted in 25% reduced dose for minimum 4 hours before evaluation of effect."
45765363|NCT00359385|Drug|Alendronate 70mg weekly|70mg weekly
45765364|NCT04371029|Other|PSG|Polysomnography at 3 times, actimetry measure and Pittsburgh questionnaire
45623383|NCT02458157|Other|Usual Care|"All interventions are performed at the discretion of the treating physician apart from initiation of renal replacement therapy which is discouraged unless one or more of the following criteria are met:~Hyperkalaemia (p-K+ > 6 mmol/l)~Severe metabolic acidosis attributable to AKI (pH < 7.25 and standard base excess < -10 mmol/l) resistant to IV bicarbonate infusion~Severe respiratory failure with PaO2/FiO2 < 13 kPa and bilateral infiltrates/oedema on the chest x-ray.~Progressive azotaemia and a blood urea nitrogen (BUN) > 25 mmol/l."
45623384|NCT02457533|Behavioral|Lifestyle behavioral. Health plan, telephone support|'Lifestyle behavioral. Health plan, telephone support'
45765365|NCT00966433|Procedure|Spontaneous ventilation|The patient will breathe spontaneously (on their own)while under general anesthesia throughout the duration of the surgery.
46069592|NCT02622711|Behavioral|PAI|Participants will be offered an individualized physical activity counseling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
46069593|NCT02622711|Behavioral|PADI|Participants will be offered an individualized dietary and physical activity counseling to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
45765366|NCT00966433|Device|Pressure support Ventilation|The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
46069594|NCT02622711|Behavioral|LII|Participants will be considered as control group. They will receive a general healthy counselling providing materials and guidelines available for the general public.
45446750|NCT01582685|Behavioral|Exercise|The participant will exercise for 16 weeks under supervision. The exercise regimen is increased slowly over 16 weeks.
45623385|NCT03264677|Combination Product|Group 1|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel
45623386|NCT03264677|Combination Product|Group 2|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel
45623387|NCT03264677|Combination Product|Group 3|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion
45623388|NCT03265457|Other|Specular microscopy|Comparison between corneal Endothelial count in patients with pseudoexfoliation syndrome and age matched group
45765367|NCT00966433|Device|Pressure control ventilation|The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
45765368|NCT05279547|Other|Constant-load bed-cycling exercise|Patients will actively cycle for a minimum duration of 10 minutes and a maximum duration of 20 minutes without breaks.
45765369|NCT05279547|Other|Interval bed-cycling exercise|Patients will cycle for the same duration as during constant-load exercise. Interval bed-cycling session will consist of 30 seconds of high intensity exercise alternated by 30 seconds of passive cycling designed so that volume of training will be equal.
45765370|NCT05628129|Other|smartphone application service and phone reminder|smartphone application service and phone reminder for appointments of parents of congenital ectopia lentis patients
45765371|NCT03029455|Drug|VX-659|
45765372|NCT03029455|Drug|Tezacaftor|
45765373|NCT03029455|Drug|Ivacaftor|
45765374|NCT03029455|Drug|VX-659 Matching Placebo|
45765375|NCT03029455|Drug|Triple Combination (TC) Matching Placebos|
45765376|NCT02983552|Other|iPad®|Binocular therapy using a Dig Rush application on an iPad®
46069595|NCT00629447|Drug|Innohep|The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
45765377|NCT02983552|Other|Spectacle correction|Spectacle correction for all waking hours, 7 days per week
45765378|NCT04370405|Drug|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
45765379|NCT04370561|Procedure|ORIF non-locking|Open reduction and internal fixation using 1/3 tubular plate
45765380|NCT04370561|Procedure|ORIF locking|Open reduction and internal fixation using active ankle polyaxial locking plate
45623389|NCT03265613|Biological|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 0.5 million cells/kg.
45623390|NCT03264599|Device|transabdominal ultrasound|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle) will be performed to quantify the degree of fetal head flexion in respect to the trunk
45623391|NCT03265067|Device|autoRIC|Application of the autoRIC device
45765381|NCT02245789|Procedure|Tracheal intubation|Tracheal intubation will be performed using a Macintosh laryngoscope or a McGrath Mac videolaryngoscope
45623392|NCT02458079|Drug|Pentoxiphylline|
45623393|NCT02458079|Drug|Stool microbiota transplantation|
45623394|NCT03264833|Other|TempTraq|no intervention
45765382|NCT02245789|Drug|Propofol and remifentanil anesthesia|The standardized anesthetic procedure used a closed-loop anesthesia system with bispectral index as control variable and with two proportional-differential control algorithms, one for propofol target-controlled infusion system and one for remifentanil target-controlled infusion system.
45623395|NCT03264911|Drug|Amoxicillin or Placebo|Children will be randomized to either 6 days of amoxicilline or 6 days of placebo treatment
45623396|NCT03264755|Device|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation for cortical excitability in smokers and non smokers
45623397|NCT03264521|Other|Surveys|Web surveys about experiences with chronic low back pain, demographics, coding qualitative text.
45623398|NCT03265223|Drug|0.2% ropivacaine|Intraperitoneal instillation versus intraincisional infiltration
45623399|NCT03264365|Behavioral|Intervention|"Intervention (plus standard care)~Patients photographs during the ICU-stay,~Written information about life after ICU~First consultation face-to-face in hospital setting at three months after ICU~Visit ICU and photographs given~Consultations as needed"
45623400|NCT02457377|Procedure|laparoscopic cerclage|The vesico-uterine peritoneum is opened & the urinary bladder is dissected downwards . Both needles are passed through the lower uterine tissue medial to uterine vessels on the right & left sides . Then, both needles are passed through the remaining cervical tissue medial to uterosacral ligaments towards the posterior vaginal fornix (on the right & left sides) guided by laparoscopic illumination . When the needles' blunt ends pierce the vaginal vault, the assistant pull them through the posterior vaginal fornix . After trimming of both needles, the Mersilene tape is tied tightly behind the intravaginal segment of the cervix with five knots &
45623401|NCT02457299|Procedure|Two Stage Esophagectomy|Patients will undergo laparoscopic staging and ischemic gastric conditioning and pyloric Botox injection 7-10 days prior to an esophagectomy with gastric pull-up reconstruction
45446751|NCT02088892|Drug|BCG SSI|Intradermal injection
45446752|NCT02088892|Drug|BCG Tice|Intradermal injection
45446753|NCT03968627|Other|Rehabilitative intervention|intensive multidisciplinar rehabilitation
45623402|NCT02457299|Procedure|One Stage Esophagectomy|Patients will undergo an esophagectomy with gastric pull-up reconstruction without any preconditioning.
45623403|NCT03938129|Other|Blood sample|1st trimester blood sample for bio-bank
45623404|NCT03938129|Other|Urine sample|1st trimester urine sample for bio-bank
45623405|NCT03938129|Other|Pregnancy, maternal health, and fetal health data|Pregnancy, maternal health, and fetal health data
45446754|NCT02092870|Drug|Adipose derived stem cells|ASCs harvested from autologous lipoaspirate
45446755|NCT04304781|Drug|KSP/QRH dimer|Peptide 919288G, Lot No. 17081402, Molecular Weight 3577.0, ≥95% purity. Stored at <20°C. Dark green, lyophilized powder in single-use amber vials.
45446756|NCT02092948|Radiation|[124I] PSCA-Minibody PET/CT imaging of the whole body|Whole body Imaging
45446757|NCT03267212|Device|Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
45623406|NCT03264287|Procedure|3 times per week therapeutic frequency|Participants will receive acupuncture, moving cupping and ear-tapping procedure 3 times per week over the 6 weeks period.
45623407|NCT03264287|Procedure|1 time per week therapeutic frequency|Participants will receive acupuncture, moving cupping and ear-tapping procedure 1 time per week over the 6 weeks period.
45623408|NCT03259451|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
45765383|NCT04370639|Device|AccuFlow sensor|AccuFlow sensor will be worn and survey completed
45765384|NCT04370639|Other|Survey|Patients will be asked to complete a survey regarding device tolerability after completing their cesarean section.
45765385|NCT05484141|Other|Rehabilitation with blood blow restriction|The rehabilitation program will be applied 2 days a week, for total of 8 weeks.
45765386|NCT05484141|Other|Rehabilitation without blood flow restriction|The rehabilitation program will be applied 2 days a week, for total of 8 weeks.
45765387|NCT05482971|Drug|Ropeginterferon alfa-2b-njft (P1101)|Ropeginterferon alfa-2b-njft (P1101)
45765388|NCT04370171|Other|care modalities|For these patients the consultation has been postponed for 6 months. No specific intervention for this group of patient.
45765389|NCT04370171|Other|Teleconsultation either by phone or by computer consultation|Management of diabetic patients by telemedicine with a teleconsultation either by phone or by computer consultation
45765390|NCT04370015|Drug|Hydroxychloroquine|Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with oral hydroxychloroquine 400 mg twice a day (four 200 mg tablets) on day 1 followed by 400mg (two 200 mg tablets) once a week for 11 weeks.
45765391|NCT04370015|Drug|Placebo oral tablet|• Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with placebo twice a day (four tablets) on day 1 followed by 2 tablets once a week for 11weeks.
45446758|NCT03267212|Device|Sham Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
45623409|NCT03264209|Behavioral|Smart After-Care (Mobile health)|Patients in intervention group will be provided with Smart After-Care Service including intervention for physical activity (aerobic exercise at least 90 or 150 minutes every week for 12 weeks depending on patients' aerobic fitness by monitoring with smartband and strengthening exercise at least 2 times a week for 12 weeks), information for prostate cancer and adequate life style, and smartband that can connect to the smartphone. Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
45623410|NCT02456363|Biological|TNF alpha|Depending on patient need to use different TNF alpha
45765392|NCT05482581|Other|Questionnaires set|Participants will be asked to respond to the demographic information sheet,e-cigarette using characteristics sheet,awareness of e-cigarettes sheet;,willingness to use e-cigarettes sheet, knowledge, attitudes and cognitions related to e-cigarettes sheet, awareness of new regulations on e-cigarette control sheet.
45765393|NCT04369781|Diagnostic Test|transcutaneous oxygen pressure recording at rest|Recording of limb and chest transcutaneous oxygen pressure
45446759|NCT03267212|Other|Functional Electrical Stimulation Row Training (FESRT)|FESRT couples volitional arm and electrically controlled leg exercise to allow whole body exercise training
45765394|NCT02982629|Behavioral|Reminder letter Intervention|Patients in this group receive letters and phone calls to reschedule missed follow-up appointments.
45765395|NCT01006369|Drug|hydroxychloroquine|hydroxychloroquine 200 mg po BID daily
45765396|NCT03046966|Procedure|Intervention: Receives Training|"• Complete a Hands-on Intubation in the Simulation Lab with PI instructing:~Using state of the art technology, a Storz C-MAC video laryngoscope~Identifying anatomical landmarks~Practice on the manikin until intubation occurs within 15 seconds"
45765397|NCT03046966|Other|Intervention: Control No Training|• Does not receive simulation training with PI. Only standard training.
45446760|NCT01074593|Biological|Interferon beta-1a|12.000UI - single dose
45446761|NCT01074593|Biological|Interferon beta-1a|12.000UI - Single dose
45623411|NCT02456363|Drug|NSAIDs and sulfasalazine|randomized case, combine with use of NSAIDs(-/+) and sulfasalazine(-/+)
45623412|NCT03264443|Behavioral|Health education|Weekly group lectures (1h each) giving information on patient's best practices to manage hypertension.
45623413|NCT03264443|Behavioral|Combined training|Combined training (aerobic and strength exercises), in moderate intensities (perceived exertion controlled) performed 3x/week (1h) duration with a education component (10') based on the contents of the health intervention.
45623414|NCT03259607|Drug|Nicorette Extra Mint 2 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
45765398|NCT05260515|Behavioral|Staying Sharp intervention|"In the Staying Sharp online program, participants have the opportunity to select which health pillars they are most interested in improving (Be social, Engage your brain, Manage stress, Ongoing exercise, Restorative sleep, and Eat right). After selecting the health pillars, participants can set plans and goals. There are designated activities in each health pillar for participants to complete, including watch videos, read articles, or play games. Participants will follow a step-by-step guide to achieve these goals. The website tracks the status of these goals.~Participants will use Staying Sharp program for 4 months. Research staff will call participants to encourage participants to use the program. Right after the completion of the 4-month program, we will send out a survey to understand user experiences. We will follow participants for another 4 months. After 4 months follow-up, an exit study survey will be conducted either via videoconferences or in-person visits."
45446762|NCT02088970|Device|Crosslinking|"The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.~Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation."
45623415|NCT03259607|Drug|Nicorette Mint 2 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
45623416|NCT03259607|Drug|Nicorette Extra Mint 4mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
45623417|NCT03259607|Drug|Nicorette Mint 4 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
45623418|NCT02457143|Behavioral|Letter|
45765399|NCT05476419|Other|Direct intra-oral scanning technique for the post space.|scanning of prepared dental post space directly inside the patient mouth by using an intra-oral scanner
45765400|NCT00374530|Drug|PGE2|
45446763|NCT02088970|Drug|antibiotic treatment|"If not the contact lens wearer -> Cocci Gram positive cocci~Vancomycin + Fortum~If contact lens wearer -> Gram negative bacillus~Fortum + Amiklin~If corticosteroids, immunosuppression, latent evolution -> Fungus.~= Fortum + vancomycin + Fungizone"
45446764|NCT01326299|Other|Carbohydrate placebo|dissolve in water and consume with meal
45446765|NCT01326299|Other|Nutritional ingredient|Dissolve in water and consume with meals
45446766|NCT01326299|Other|#1 Nutritional ingredient +Fiber|Dissolve in water and consume with meal
45446767|NCT01326299|Other|#2 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
45446768|NCT01326299|Other|#3 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
45446769|NCT04160468|Drug|Exebacase|Participants will receive a single IV infusion of exebacase in addition to SoCA selected by the investigator. Participants with normal renal function or mild renal impairment will be administered a dose of 18 mg; participants with moderate or severe renal impairment will be administered a dose of 12 mg of exebacase; participants with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg of exebacase.
45446770|NCT04160468|Drug|Placebo|Participants will receive a single IV infusion of placebo in addition to SoCA selected by the investigator.
45765401|NCT02242877|Drug|Telmisartan|
45765402|NCT02242877|Drug|Telmisartan combined with hydrochlorothiazide|
45623419|NCT02457143|Behavioral|Phone call|
45623420|NCT02456987|Device|Samsung Gear|Intervention arm will be exposed to a series of virtual reality experiences using the Samsung Gear hardware one time during their inpatient stay at Cedars-Sinai.
45623421|NCT03259061|Device|Flexible fiberoptic nasopharyngoscopy|"Flexible fiberoptic nasopharyngoscopy (FFN) allows direct transnasal observation of the anatomy and dynamic activity of the velopharyngeal sphincter. Such observations can be recorded for permanent documentation by coupling FFN to a video camera with simultaneous audio recording. Numerous published reports discuss the advantages of FFN as a clinical method for evaluating velopharyngeal function during speech (10).~Cephalometric analysis, is the clinical application of cephalometry. It is analysis of the dental and skeletal relationships of a human skull and is frequently used by dentists, orthodontists, and oral and maxillofacial surgeons as a treatment planning tool.~Cephalometric analysis can also be applied for assessing the velopharyngeal structure and function. More specifically, velopharyngeal function in terms of its shape and mobility was analyzed quantitatively on the basis of cephalometric principle"
45623422|NCT03259217|Drug|Stem Cell Product|Adipose tissue derived mesenchymal stem cell seeded in Curcumin loaded chitosan nanoparticles into collagen-alginate
45623423|NCT03264053|Device|Socket shield|Socket shield is the Removal of the lingual portion of the anterior root thus retaining the lingual portion
45623424|NCT03264053|Procedure|Conventional immediate implantation|Conventional immediate implantation
45623425|NCT03263819|Diagnostic Test|Oral glucose tolerance test|75 grams of glucose
45623426|NCT03258983|Other|Alpha-linolenic acid|Exposure to dietary intake of alpha-linolenic acid (ALA) will be assessed using a detailed food frequency questionaire filled in by participants included in the Diet, Cancer and Health cohort at baseline. Exposure to adipose tissue content of ALA will be determined by gas chromatography in all incident cases and in subcohort of 3500 participants randomly drawn from the total cohort.
45623427|NCT03263975|Other|Gatorade or Enterade|Commercially available oral rehydration therapies
45623428|NCT03258827|Procedure|Exercise with a towel|Exercise program composes with warm-up, strengthening exercise, cold-down, 60 minutes/time, 3 times/week. A towel is an important tool for exercise. Total duration of the program is 3 months.
45765403|NCT01007071|Drug|Human Growth Hormone (1-134)|Subjects randomized to human growth hormone (1-134) for 16 weeks. In this arm, growth hormone is dosed sc on a daily basis and increased over first 6 weeks (Men: start at 0.2 mg sc/d, increase to 0.6 mg sc/d after 4 weeks. Women, postmenopausal: start at 0.3 mg sc/d, increase to 0.9 mg sc/d after 4 weeks. Women premenopausal or on estrogen: start at 0.6 mg sc/d, increase to 1.3 mg sc/d after 4 weeks.) Dose adjustments based on serum IGF-1 levels at 6 and 12 weeks, with final IGF-1 measurement for efficacy performed at 16 weeks, with goal in range of -0.5 SD to +2SD. An elevated serum IGF-1 value will result in a 20% dose reduction in GH in an active and random placebo patient. Similarly, a low serum IGF-1 will result in a 20% dose increase in an active and random placebo subject.
45765404|NCT01007071|Drug|Placebo|Subjects randomized to placebo
45765405|NCT05475639|Other|Axillary Diclofenac phonophoresis|axillary diclophenac phonophoresis (voltaren gel) will be received three times per week for four weeks
45765406|NCT05475639|Other|Post isometric facilitation|Post isometric facilitation exercise will be received three times per week for four weeks
45765407|NCT05475639|Other|Traditional physiotherapy|Traditional physiotherapy will be received three times per week for four weeks
45765408|NCT02242955|Drug|Diazepam|40 mg per day.
45765409|NCT02984644|Drug|Dapagliflozin|Three 5-hour measurements (after dapagliflozin 10mg administration) of endogenous glucose production (EGP) will be performed on separate days.
45765410|NCT02984644|Drug|Placebo|Three 5-hour measurements (after placebo administration) of endogenous glucose production (EGP) will be performed on separate days.
45765411|NCT00358605|Device|The Klearway™ oral appliance|See Detailed Description.
45765412|NCT03026959|Behavioral|Mindfulness|The mindfulness intervention follows the structure described by Short, Mazmanian, Ozen, & Bédard, (2015).
45446771|NCT02087800|Behavioral|F phase lab session|F phase sessions will occur three to seven days post the onset of menses. It will include blood draws, an acute stressor and completion of questionnaires.
45446772|NCT02087800|Behavioral|L phase lab session|L phase sessions will occur six to ten days prior to the onset of the next expected menses. It will include blood draws, an acute stressor and completion of questionnaires.
45446773|NCT03968861|Drug|Xenon|Inhaled xenon gas given via purposely designed ventilator
45446774|NCT04292535|Drug|Placebo into the intranasal mucosa|6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer
45446775|NCT04292535|Drug|20 IU NovoLog Insulin aspart into the intranasal mucosa|5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
45446776|NCT04292535|Drug|40 IU NovoLog Insulin aspart into the intranasal mucosa|4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
45623429|NCT03258827|Procedure|Home-based exercise|Home-based program focuses on walking activity at fast speed, 3 times/week, 60 minutes/times. The total duration is 3 months.
45765413|NCT02243111|Radiation|Doppler ultrasound|Detecting Doppler signals from the lungs on the right chest wall
45765414|NCT05621577|Device|MANDIBULAR ADVANCEMENT DEVICE|orthodontically treating obstructive sleep apnea
45765415|NCT02243189|Drug|JNJ-43260295|A single nasal dose of JNJ-43260295, 6400 microgram, will be given.
45765416|NCT02243189|Drug|Placebo|A single nasal dose of placebo matching to JNJ-43260295 will be given.
45623430|NCT02456129|Drug|Vilaprisan (BAY1002670)|single oral doses of 4 mg tablet Vilaprisan, administered once without the comedication of ITZ (period 1) and once with the comedication of ITZ (period 2)
45623431|NCT02456129|Drug|[14C] Vilaprisan|an intravenous microtracer dose of [14C]Vilaprisan administered together with the 1st single oral dose of Vilaprisan
45765417|NCT02243189|Drug|Nasal Allergen Challenge|Participants will be challenged by the nasal route with an appropriate allergen based on skin test reactivity.
45765418|NCT00966823|Device|Fetal tracheal obstruction with detachable balloon (device)|"Fetal tracheal obstruction with detachable balloon (device): Endoscopic placement of a detachable balloon in the fetal trachea at 28-30 weeks gestation.~- Ultrasound-guided puncture of balloon or, if not feasible, repeat endoscopic tracheoscopy with puncture and retrieval of the balloon at 34 weeks gestation."
45623432|NCT02456129|Other|Itraconazole(ITZ)|Itraconazole(ITZ) 200 mg as solution, once daily for 14 days
45623433|NCT03263741|Drug|Paclitaxel + S-1 + Oxaliplatin|"Paclitaxel: 135 mg/m2, iv, 3h, at D1. S-1: S-1: 40mg twice daily for patients with a body surface area (BSA) < 1.25 m2, 50mg twice daily for patients with a BSA of 1.25 m2 to < 1.5 m2, 60mg twice daily for patients with a BSA of ≥ 1.5 m2 for two weeks, and then suspend for one week.~Oxaliplatin: 85 mg/m2, iv, 2h, at D1."
45623434|NCT02456207|Drug|SCT400|
45623435|NCT02456207|Drug|Rituximab|
45623436|NCT03258749|Drug|Tiotropium|inhaled Tiotropium(18μg, qd)
45623437|NCT03258749|Drug|Formoterol|inhaled formoterol(4.5μg, bid)
45765419|NCT02977845|Behavioral|Qigong|"Qigong has long been regarded as a form of mind-body intervention in Traditional Chinese Medicine (TCM), which simultaneously exercises the mind and the body for treating many chronic diseases and promoting wellness. About a hundred million people are currently practicing Qigong in China. Qigong is now regarded as a form of self-practise mind-body exercise and recently relevant to sports activity, which is officially known as Health Qigong. It is different from Medical Qigong which involves a TCM practitioner to emit Qi to heal the patients."
45765420|NCT02984878|Device|Revanesse Ultra|Nasolabial Fold correction
45623438|NCT03258671|Drug|EGFR-TK Inhibitor|·EGFR-TKI：gefitinib will be administered 250mg/d ivgtt qd; icotinib will be administered 150mg/d ivgtt tid;
45623439|NCT03258671|Radiation|Intensity Modulated Radiation Therapy|"High dose group：DTGTV=70Gy；~first course radiotherapy：40Gy/20f/4w（DTPTV：36Gy/20f/4w）,2Gy/f/d；~late course radiotherapy：1.5Gy/f、2f/d、interval≥6 hs、DTGTV=30Gy（DTPTV=27Gy）。~Low dose group：DTGTV=50Gy;~first course radiotherapy：32Gy/16f/3w（DTPTV为28.8Gy/16f/3w），2Gy/f/d；~late course radiotherapy：1.5Gy/f、2f/d、interval≥6小时、DTGTV为18Gy（DTPTV为16.2Gy）。"
45765421|NCT05469867|Device|CorNeat EverPatch|The CorNeat EverPatch will be implanted subconjunctivally over an ocular implant (e.g. glaucoma shunt, exposed suture tags) and fixed to the eye wall. The overlying conjunctiva will be closed over the patch.
45765422|NCT04370249|Other|pulmonary ultrasound|pulmonary ultrasound on admission
45446777|NCT04292535|Drug|60 IU NovoLog Insulin aspart into the intranasal mucosa|3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
45765423|NCT05260437|Biological|CV2CoV (2 µg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
45765424|NCT05260437|Biological|CV2CoV (4 µg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
45765425|NCT05260437|Biological|CV2CoV (8 µg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
45765426|NCT05260437|Biological|CV2CoV (12 µg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
45765427|NCT05260437|Biological|CV2CoV (16 µg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
45623440|NCT03263663|Drug|targeted substance according to the avatar model|individualized second line treatment
45623441|NCT03258515|Drug|AZD6094 200 mg|A potent and selective small molecule mesenchymal epithelial transition (MET) kinase inhibitor with significant antitumor activity.
46069596|NCT04289831|Procedure|Preoperative Biliary Drainage (PBD)|Endoscopic retrograde biliary drainage (ERBD) and stent placement was the first choice for PBD while ultrasound-guided percutaneous transhepatic biliary drainage (PTBD) was done if ERBD was not feasible. Biliary drainage was considered successful if the serum bilirubin level decreased by 50% or more within 2 weeks after the procedure. Patients with failed PBD were referred directly to surgery, while those with successful PBD were referred to surgery 4 to 6 weeks after first drainage procedure according to the latest guidelines
46069597|NCT04289831|Procedure|Surgery|The standard surgical procedure for operable tumors Whipple procedure with triple reconstruction, namely pancreatogastrostomy or pancreatojejunostomy,hepaticojejunostomy and gastrojejunostomy
45623442|NCT03258515|Other|Placebo|AZD6094 matching placebo without any pharmacological activity.
45623443|NCT03258515|Drug|Moxifloxacin|A fluoroquinolone broad-spectrum antibiotic, produces a mild, but reproducible increase in QT interval corrected (QTc) in healthy normal participants at time to reach maximum concentration (tmax - approximately 2 hours (0.5 to 4 hours)). This effect is close to the ECG interval measured from the onset of the QRS complex (onset of the QRS complex to the J point) to the offset of the T wave (QT)/QTc effect that represents the threshold of regulatory concern, around 5 ms mean QTc interval prolongation.
45623444|NCT03258359|Biological|PACTN|To treat patients with MDS who have failed treatment with hypomethylating agents or have relapsed after treatment with hypomethylating agents or have declined hypomethylating therapy.
45623445|NCT03263585|Device|Spinal orthosis Spinomed|
45623446|NCT03263585|Other|Equipment training|
45765428|NCT05260437|Biological|CV2CoV (20 µg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
45765429|NCT02986282|Device|ABI measurement using both doppler and oscillometric method|
45623447|NCT04427007|Device|Moisture Management Liner|A prototype liner designed to reduce and/or remove moisture and heat that builds up on the limb.
45623448|NCT04427007|Device|ICE Socket Cooling System|The ICE Socket Cooling System is a battery-powered cooling device for lower-limb amputees.
45623449|NCT03788525|Behavioral|Reduced recreational screen time|Participants must remove all recreational screen-based media use beyond 3 hours/week. This includes all recreational screen-based media use inside and outside the household. As a tool to comply with the intervention the families will hand-over all portable screen-based media devices. In return, each participant who own a smartphone will receive a regular cell-phone which can only make phone calls and send text messages. For a maximum of ½ an hour a day, adult participants may use this device for necessary contact. The families are allowed a maximum of 3 hours/week of recreational screen time. If participants can not hand over their smartphones due to daily use for work purposes we will install an app tracking screen use on these devices.
45623450|NCT03788525|Behavioral|Timed recreational screen time|Participants must remove all recreational screen-based media use after 6 PM. There are no restrictions on the amount of screen-based media use before 6 PM. Thus, before 6 PM, the participants must continue their habitual screen-based media use completely. However, after 6 PM, both work-related and recreational screen-based media use must be removed completely.
45623451|NCT04977141|Other|Decisional Conflict Scale|Decisional Conflict Scale
45623452|NCT03258437|Dietary Supplement|DA-9401|
45623453|NCT03258437|Dietary Supplement|Placebo|Placebo for 12 weeks.
45623454|NCT04976673|Drug|Triamcinolone Acetonide|The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
45623455|NCT04976673|Procedure|Photodynamic Therapy|the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power density
45765430|NCT04362605|Procedure|Endoscopic Negative Pressure Therapy|"In patients with suspected insufficiency of the esophagojejunostomy first an index endoscopy under general anesthesia with endotracheal intubation was indicated. Standard gastroscopes with outer diameter of 9.8mm were used with carbon dioxide insufflation.~Definition of a anastomotic leak were endoscopic or radiological dehiscences at the esophagojejunostomy with extravasation of fluids and gas. In cases of insufficiencies start of endoluminal ENPT were indicated.~Decision criteria for placement of OPD or OFD were the defect size, radiological findings and clinical situation of the patient. A CT scan in patients with suspected EJAL was done in all cases.~For endoluminal ENPT, the open-pore drainage system is placed within the lumen of the digestive tract at the entrance to the cavity."
46069598|NCT02622477|Drug|Pirfenidone|This is an observational study. Pirfenidone is available as an 267 mg capsule for oral administration.
46069599|NCT04290065|Other|Manual therapy|The patient will be lying supine, relaxed. The physiotherapist, located at the patient's head, will cover the occipital bone with one hand while the palm of the hand will rest on the lambdoid suture, and the fingers will be introduced into the suboccipital space. The other hand, with a glove, will be inserted into the patient's oral cavity, resting respectively the index and middle fingers, each in an upper dental hemiarchy, on the chewing face of the tooth. An axial traction will be carried out until the three tension barriers of equal size between them are overcome, in an estimated time between 1.50 and 3 minutes. All manual therapy sessions will be performed by the same physiotherapist, following the same protocol and under the same conditions.
46069600|NCT02622243|Drug|Tiotropium|long acting muscarinic antagonist
46069601|NCT02622243|Drug|glycopyrronium|long acting muscarinic antagonist
46069602|NCT02622243|Device|Respimat|inhaler device used to deliver active tiotropium or placebo
45446778|NCT04292535|Drug|80 IU NovoLog Insulin aspart into the intranasal mucosa|2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
45446779|NCT04292535|Drug|100 IU NovoLog Insulin aspart into the intranasal mucosa|1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
45446780|NCT04292535|Drug|120 IU NovoLog Insulin aspart into the intranasal mucosa|6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
45446781|NCT04325204|Behavioral|Faith-based Home Activity Toolbox (Faith-HAT)|"They will select activities from Faith-HAT at least 3 times a week. Possible examples of these activities include devotional readings, prayer, music, religious images, and video and audio recorded sermons.~Faith-HAT will be placed on online, which requires little technical know-how by users. The PI will provide training to participants on how to use the Faith-HAT and online diary on the tablet computer provided by the project."
45446782|NCT03967457|Diagnostic Test|questionnaires survey|Including four kinds of questionnaires: European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (V3); EORTC QLQ-CX24; Eligibility Criteria (FSFI); and Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFIQ-7)
45446783|NCT03967457|Diagnostic Test|Urodynamic testing|"Urodynamic testing consists of important urodynamic parameters including:~Bladder capacity at the first void sense Bladder capacity at normal desire to void Bladder capacity at strong desire to void Qmax Qave Pves at Qmax Pdet at Qmax Cves at SDV Cdet at SDV Residual urine volume"
45446784|NCT03967457|Diagnostic Test|Rectum dynamics testing|Rectum dynamics testing consists of important parameters of rectum activities
45446785|NCT03967457|Diagnostic Test|ovarian reserve function|"Testing for ovarian reserve function consists of:~Follicle-stimulating hormone Estradiol Anti-mullerian hormone Inhibin B"
45623456|NCT04969497|Drug|"Treatment A: M207 3.8 mg MiniMac"|"Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MiniMac coater and packaged in foil cups"
45623457|NCT04969497|Drug|"Treatment B: M207 3.8 mg MACAP"|"Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MACAP coater and packaged in foil cups"
45623458|NCT04969497|Drug|Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0|Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
45623459|NCT03258047|Combination Product|CAR-T|CAR-T is a novel technique for cancer treatent, it includes procedures of modifying patients' T cells outside the body and re-transfuse these cells back into the human body to fight against the cancer cells.
45623460|NCT03258125|Genetic|real time PCR (rPCR)|A villus tissue (2.5 cm * 2.5 cm * 2.5 cm) will be cut off immediately from the center of placenta, avoiding the area of infarction, bleeding or calcification. After being washed with normal saline, the tissue will be preserved in liquid nitro¬gen at once for subsequent detection of miR-452 and MMP-9 expression by real time PCR (r-PCR). During this procedure total RNA will be extracted including miR-452 and mRNA of MMP-9. Then by reverse transcriptase RNA will be converted into DNA which will be amplification during the PCR, i.e. in real-time, and not at its end, as in conventional PCR. Expression of miR-452 and MMP-9 will be estimated and correlated with each other.
45623461|NCT04976751|Drug|Percutaneous electrical nerve stimulation treatment|Using the percutaneous electrical nerve stimulation instrument to different points of the body
45623462|NCT03258203|Other|Preventing Overweight Using Novel Dietary Strategies|The study tests the effectiveness for weight loss and weight maintenance of four diets differing in macronutrient composition: moderate in fat (40% energy) with two different protein levels (15% and 25%), and low in fat (20% energy), also with 15% and 25% protein levels.
45623463|NCT04976829|Device|Antibiotic stewardship and healthcare-associated infections surveillance assisted by computer|Implementation - in our tertiary care university hospital - of a computerized-decision support system (CDSS) facilitating antibiotic stewardship and of an electronic surveillance software (ESS) facilitating infection prevention and control activities
45623464|NCT02456831|Other|Experimental Infant Formula 1|method A phytate reduction and 5% protein hydrolysis
45623465|NCT02456831|Other|Experimental Infant Formula 2|method A phytate reduction and 10% protein hydrolysis
45623466|NCT02456831|Other|Experimental Infant Formula 3|method B phytate reduction and 5% protein hydrolysis
45623467|NCT02456831|Other|Active Comparator: Control Infant Formula|Ready-to-Feed (RTF) Soy Infant Formula
45765431|NCT01008319|Drug|clomiphene citrate|Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, another ultrasound and blood draw (to test progesterone level) will be done one week later to confirm no response to the medication dose. Medroxyprogesterone acetate (Provera) 10 mg per day for 10 days. Increased dose of clomiphene citrate for 5 days starting on cycle day 5. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
45912552|NCT02011646|Behavioral|Healthy Weight|The PI will train 4 group leaders to deliver the intervention. Groups will be offered four times per week and consist of approximately 10 participants. Each group will be led by 2 group leaders and each group leader will lead two sessions per week during the 2.5 mo intervention period. Group leaders will digitally video-record all sessions of the first two groups they deliver so the PI can provide supervision and rate fidelity and competence for a random selection of 6 of these 12 sessions. Group leaders will transmit the video recordings via an encrypted, secure internet connection to Dr. Ochner (who was trained by Dr. Eric Stice, the creator of the intervention) within 3 d for supervision, and competence and fidelity assessments.
45623468|NCT04969029|Drug|Tirelizumab|In the immunotherapy group, the treatment regimen was Tirelizumab 200mg, intravenously infused once every 3 weeks until the end of 12 months of treatment, with a total of 17 infused times.
45623469|NCT02456285|Procedure|Primary/Bowel-first Surgery|Patients undergoing primary/bowel-first surgery as part of a staged curative procedure. The liver metastases will be resected in a second planned operation.
45623470|NCT02456285|Procedure|Liver-first surgery|Patients undergoing liver-first surgery as part of a staged curative procedure. The colorectal primary will be resected in a second planned operation.
45623471|NCT02456285|Procedure|Synchronous resection surgery|Patients undergoing a synchronous colorectal primary resection and liver resection in a single operation.
45623472|NCT02456285|Procedure|No surgery|Patients who have no surgery.
45623473|NCT04968795|Other|Heartfulness Meditation|A four-week Heartfulness Wellness seminar, where people are exposed to Heartfulness Meditation and its meditation tools. Participants experience: Heartfulness Guided Relaxation, Heartfulness Meditation and Heartfulness Unwinding/Rejuvenation Technique.
45912553|NCT02011646|Behavioral|Controlled Intervention|"The Weight of the World is a 51 min documentary focusing on the topics of obesity and healthy living. Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Participants will be given a copy of the DVD. They will also be given the choice to stream it free on the web."
45912554|NCT02011659|Drug|Ramosetron|
45912555|NCT02011672|Other|nutrient-enriched milk|
45912556|NCT02011672|Other|regular milk|
45623474|NCT03263039|Drug|Pembrolizumab|Pembrolizumab 200 mg Q3W
45623475|NCT03919097|Other|Medical Data extraction|Data extraction from the patient's Medical Files
45623476|NCT04976907|Device|Contactless vital sign information collection|Collection of facial blood flow and temperature information via conventional and infrared/thermal video of the face for the purpose of estimating vital signs using machine learning-based computational models.
45623477|NCT03257735|Diagnostic Test|next-generation sequencing|"Patients' cerebrospinal fluid, blood and tumor tissue were collected within 3 days before treatment at diagnosis.~Patients' cerebrospinal fluid and blood were extracted at the time of first evaluation of efficacy after treatment (TKI began after 1 month or chemotherapy after 2 cycles).~Patients' cerebrospinal fluid and blood were extracted at first time of tumor progression，and re-biopsy of tumor tissue was done as much as possible.~All the samples were tested by next-generation sequencing."
45623478|NCT04432389|Biological|ALLOB|After thawing, ALLOB® is a ready-to-use product for local administration at fracture site.
45912557|NCT02011698|Procedure|Lichtenstein technique groin hernia repair with mesh. Use of absorbale sutures for mesh fixation|
45912558|NCT02011698|Procedure|Lichtenstein technique groin hernia repair with mesh. Use of non absorbable sutures for mesh fixation|
45446786|NCT04301180|Device|Education food|The intervention consisted of the presentation of food education content while conducting an orchard with seasonal vegetables
45446787|NCT03967535|Device|MRI Brain Imaging|Up to two Magnetic Resonance Imaging (MRI) scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.
45765432|NCT01008319|Drug|clomiphene citrate|Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, a blood draw (to test progesterone level) will be done. Increased dose of clomiphene citrate for 5 days starting that day. A repeat transvaginal ultrasound in one week to determine if there is a dominant follicle. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
45765433|NCT05252949|Dietary Supplement|Oleoylethanolamide (OEA)|Oleoylethanolamide (OEA) is a naturally occurring ethanolamide that acts as a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, thereby modulating lipid profiles.
45765434|NCT05252949|Dietary Supplement|Placebo|Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured OEA capsules, with the exception of any OEA compound.
45623479|NCT04432389|Other|placebo|Placebo injected is a saline solution injectable grade (4 mL of 0.9% NaCl) filled in single-dose vial
45623480|NCT03262805|Dietary Supplement|Lanconone|. Lanconone® is a joint pain supplement containing natural herbs such as Shyonak, Ashwagandha, Shunthi, Guggul, Chopchini, Rasna and Shallaki in therapeutic quantities and documented in the ancient scriptures as pain relievers.
45623481|NCT03262805|Other|Placebo|Microcrystalline cellulose
45623482|NCT03262961|Drug|Sildenafil 20 MG|
45623483|NCT03262961|Drug|Placebo Oral Tablet|
45623484|NCT04968873|Procedure|Cholecystectomy and common bile duct exploration|During elective open cholecystectomy, a basal commcn dile duct (CBD) manometry was obtained immediately after cholecystectomy, with a 10 Fr. silicone T tube introduced into the cystic duct and connected to a glass manometer.
45623485|NCT03257891|Drug|Cabazitaxel|Cabazitaxel will be administered every 21 days
45765435|NCT04369391|Drug|SEP363856 150 mg|SEP363856 tablet 150 mg
45765436|NCT04369391|Drug|Placebo|Placebo tablet
45765437|NCT04369391|Drug|moxifloxacin 400 mg|moxifloxacin tablet 400 mg
45446788|NCT03967535|Behavioral|Mental Health Assessment and Computerized Cognitive Test|Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.
45446789|NCT03967301|Dietary Supplement|Probiotic|Intervention: defined as probiotic consumption
45446790|NCT03967301|Dietary Supplement|Placebo|Placebo consumption. The placebo will be provided by the company that produces the probiotic.
45765438|NCT02873104|Device|truSculpt rf device|radiofrequency device
45765439|NCT05469321|Other|None, pure observationnal study|None, pure observational study following the usual management of the patients
45765440|NCT04369313|Procedure|delayed cord clamping|umbilical cord clamping more than 30 seconds after birth
45765441|NCT04369313|Procedure|early cord clamping|umbilical cord clamping within 15 seconds after birth
45765442|NCT00358683|Drug|Certolizumab pegol|
45446791|NCT04158986|Behavioral|Nurse-driven post-discharge intervention|"Home visits based on the concepts of Family Nursing:~The participants will receive three home visits by a nurse who is trained in the Family Nursing principles during the first 12 weeks after discharge.~The home visits will comprise of:~Filling in the Chronic Liver Disease Questionnaire.~Therapeutic conversations including drawing and review of genogram and eco-map.~Information about- and help to initiate contact to relevant municipal offers.~Evidence-based information based on the patient's current problems or symptoms, base-line knowledge and receptiveness.~Follow-up telephone calls:~• After the first 12 weeks participants will be followed-up by telephone monthly during the following 12 weeks.~Pamphlet:~• All participants will receive a pamphlet with brief information regarding preventive measures and early signs of decompensation as well as relevant contact details. The pamphlet will be handed out before discharge"
45623486|NCT03262493|Device|Interventional Group|Use of the feeding tube attachment device (FTAD).
45623487|NCT01670097|Drug|Dexamethasone|"Group 1 Blinded Phase: 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days.~Open Label Phase Groups 1 and 2: 4 mg by mouth twice a day for 7 days."
45623488|NCT01670097|Drug|Placebo|Group 2 Blinded Phase: Two capsules by mouth twice a day for 4 days, followed by one capsule twice a day for 3 days.
45623489|NCT01670097|Behavioral|Questionnaires|Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.
45623490|NCT01670097|Device|Spirometer|Patient to blow into spirometry machine 1 time a day to test lung function.
45765443|NCT00967369|Drug|Bortezomib|Given IV
45765444|NCT00967369|Drug|Carboplatin|Given IV
45765445|NCT00967369|Drug|Etoposide|Given IV
45765446|NCT00967369|Drug|Ifosfamide|Given IV
45765447|NCT04361981|Other|Deep Venous Disease Diagnostic|Clinical and/or echographic diagnosis of Deep Venous Disease in a patient with COVID-19 infection
45765448|NCT02876926|Behavioral|"Smart home-based test for HIV"|A standard home-based HIV test kit, fit with a Bluetooth low energy beacon to allow remote monitoring.
45765449|NCT02876926|Behavioral|Home-based testing only|A standard home-based HIV test kit.
45765450|NCT02876926|Behavioral|Reminder letters for clinic-based testing|Letters reminding patients to get tested at a free clinic location
45765451|NCT04369235|Device|tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. tCES will be applied for 20 minutes at an intensity of 1.0 -1.5 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 6 weeks.
45765452|NCT04369235|Device|Sham tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. Sham tCES will consist of a 5-second ramp up to 1.0-1.5 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
45623491|NCT01670097|Other|Phone Calls|Patient called by phone 1 time each day to ask about level of shortness of breath and to remind patient to take capsules. These calls should last about 5 minutes.
45623492|NCT03257423|Drug|Ertapenem followed by levofloxacin and metronidazole|Ertapenem 1 g i.v. daily for either 2 days (MAPPAC + APPAC II patients) or 3 days (MAPPAC + APPAC III) followed by p.o. levofloxacin 500 mg x 1 + metronidazole 500 mg x 3 for either 5 days (APPAC II + MAPPAC) or 4 days (APPAC III + MAPPAC)
45765453|NCT04369001|Behavioral|Community-Based Exercise|Participants will complete 150 minutes of exercise per week for 12 weeks. Exercise per week will be documented using exercise logs. The exercise protocol will be a culturally-tailored community-based exercise intervention based on the aerobic exercise goals used in the Program ACTIVE study and psychoeducational materials adapted from Program ACTIVE based on feedback from Black men with T2D. Exercise in Program ACTIVE will be obtained through individualized community-based activities that participants in the focus groups indicate as feasible rather than the highly controlled laboratory environment. Exercise goals will be adapted to accommodate the physical and medical restrictions of an older-adult diabetes population.
45765454|NCT04369001|Behavioral|Cognitive Behavioral Therapy|Participants will receive 10 sessions of CBT using a manualized approach based on Beck's model of cognitive therapy. Sessions are to be completed once weekly in conjunction with weekly exercise. The Program ACTIVE CBT intervention includes: presentation of CBT model; thought records, cognitive distortions, counterarguments, cognitive reframing, automatic thoughts, core beliefs, and relapse prevention. Session goals will be tailored to the needs of men so that the order of topics may vary. Each session will begin with the designation of session goals, review of previously assigned homework, and introduction of new concepts and skills. Individually-tailored homework assignments designed to provide practice with the concepts/skills of the session will be assigned.
45912559|NCT02011698|Procedure|Lichtenstein technique groin hernia repair with mesh. Use of fibrin biological glue for mesh fixation|
45912560|NCT02011724|Device|Apligraf|
45912561|NCT02011737|Drug|naftopidil 75mg|
45912562|NCT02011750|Drug|Sodium Valproate treatment|Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment group, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
45912563|NCT02011750|Drug|Placebo|Placebo: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
46069603|NCT02622243|Device|Breezehaler|inhaler device used to deliver active glycopyrronium or placebo
45446792|NCT03747081|Drug|Rivaroxaban|Rivaroxaban will administrate to patient with CVT. In first day, enoxaparin is injected to patients and the next day, patients will receive Rivaroxaban and enoxaparin discontinue. Then, patients receive Rivaroxaban for 3 months daily.
45446793|NCT03747081|Drug|Warfarin|Warfarin as a antocoagolant drug will administrate to patient with CVT. In first day, Warfarin plus enoxaparin until adjusting INR index to 2-3. Then, patients receive warfarin for 3 months daily.
45623493|NCT03257423|Drug|Moxifloxacin|Moxifloxacin 400 mg once a day for seven days (APPAC II + MAPPAC)
45623494|NCT03257423|Procedure|Appendectomy|Primarily laparoscopic appendectomy for either complicated acute appendicitis or uncomplicated acute appendicitis (refusing to participate in APPAC II or III trials or recurrent acute appendicitis).
45623495|NCT03257423|Other|Placebo|Placebo i.v. once a day for three days (APPAC III + MAPPAC) followed by placebo capsules three times a day for four days.
45623496|NCT03257501|Device|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
45623497|NCT01670019|Drug|Asenapine 5-20 mg daily|5 mg QHS, or 5 mg BID, or 5 mg QAM and 10 mg QHS, or 10 mg BID
45623498|NCT01670019|Drug|Placebo 1-4 tablets daily|One placebo tablet QHS, or one placebo tablet BID, or one placebo tablet QAM and two placebo tablets QHS, or two placebo tablets BID
45623499|NCT04488341|Other|aerobic exercises in addition to diet recommendations|aerobic exercises time of session 40-50 min initial 10 min warm up exercises on treadmill in low intensity and active phase 20- 30 min intensity will increase until patient reach to target heart rate then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercises 3 times per week for 12 weeks
45623500|NCT04488341|Other|diet recommendations|control group will receive diet recommendations for 12 weeks
45623501|NCT03262571|Diagnostic Test|Lung ultrasound|Duretic therapy is then optimized according to the presence and severity of B-lines in group A.
45623502|NCT04976439|Other|co-occuring mutation|APC, TP53, PIK3CA, KRAS APC, TP53, PIK3CA, MLH1 APC, TP53, PIK3CA, KRAS, and MLH1 APC, TP53, PIK3CA
45765455|NCT03050320|Other|Exercise|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
45623503|NCT01669629|Device|delefilcon A|Daily wear soft contact lens for bilateral distance vision correction use.
45623504|NCT01669629|Device|etafilcon A|Daily wear soft contact lens for bilateral distance vision correction use.
45765456|NCT03050320|Other|No Exercise|A no exercise (control) group will be asked to maintain their existing activity level for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
45623505|NCT03262727|Drug|BMS-986165|Oral administration of specified dose on specified days
45623506|NCT03262727|Drug|Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)|Oral Contraceptive
45623507|NCT03262025|Procedure|Operated|Patients were either managed conservatively or underwent emergency laparotomy
45765457|NCT05467605|Dietary Supplement|probiotics( Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),|therapeutic intervention, Children will be randomized into two groups using sealed envelopes on admission after meeting inclusion criteria, group ONE will receive multi strain probiotic product which contains(Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),
45765458|NCT05467605|Other|maltose dissolved in distilled water|the other group placebo (GROUP TWO ) will receive maltose dissolved in 10 ml distilled water .
45765459|NCT00967993|Drug|ferric citrate|KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate
45765460|NCT04369157|Procedure|Elective surgery|Patients will be scheduled to undergo elective orthopaedic (knee/hip replacement) or colorectal surgery.
45765461|NCT04362215|Diagnostic Test|Subjective accomodation amplitude measurement|ECG:Electrocardıography Echocardiography, Holter implementation(for Lf/Hf ratio))
45765462|NCT02878486|Device|Jawbone Up|Jawbone Up is a wrist wore water resistant activity monitor.
45765463|NCT02878486|Behavioral|Physical Activity Education|A study team member will discuss benefits of changing sitting habits and ways to make changes to personal habits.
45765464|NCT02878486|Device|ActivPAL|Devices measures postural changes over time. Participants will wear device for 7 days. The device measures time sitting, standing, and posture changes (i.e. sit-to-stand).
45765465|NCT02245295|Procedure|Moderate Sedation for EBUS/TBNA|EBUS-TBNA was performed by one of the pulmonologists in moderate sedation (D.F., M.K.).
45765466|NCT02245295|Procedure|General anesthesia for EBUS/TBNA|EBUS-TBNA was performedin general anaesthesia by one of the thoracic surgeons (D.S., P.K.)
45912564|NCT02011763|Biological|Avaxim 80U Pediatric: Inactivated Hepatitis A Virus|0.5 mL, Intramuscular (2 injection 6 months apart)
46069604|NCT04289675|Drug|Interferon-Beta|Theses drugs have been administered as part of routine care. Biological samples that will be analyzed (blood and cerebrospinal fluid) have been taken as part of routine care.
45446794|NCT03967613|Device|Functional eletrical stimulation|Aplication of functional eletrical stimulation on contralesional upper limb during functional tasks
45623508|NCT03062007|Drug|BI-CON-02|BI-CON-02 prescribed as intravenous infusion once per 3 weeks. Investigational product therapy during 1 year (up to 18 cycles, duration of 21 days each).
45623509|NCT03257111|Other|activity monitors|activity monitors are worn on the wrist, much like a watch. Data from the activity monitors will be downloaded once a week and at discharge. Normal hospital and therapy activities will not be altered.
45623510|NCT03262181|Other|Isometric Exercise|5 sets of 45-seconds quadriceps contraction, each followed by 2-minutes of rest.
45623511|NCT03262181|Other|Sham Transcutaneous Electrical Nerve Stimulation|5 sets of 45-seconds intervals without quadriceps contraction, each followed by 2-minutes of rest.
45623512|NCT04976361|Other|PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)|PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)
45623513|NCT03262337|Other|none, this is an observational study|none, this is an observational study
45765467|NCT01009333|Device|InterStim Therapy at rate 5.2 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
45765468|NCT01009333|Device|InterStim Therapy at rate 14 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
45765469|NCT01009333|Device|InterStim Therapy|All subjects enrolled in this study were programmed to each rate setting (low, medium, high) for a 1-week period.
45765470|NCT04344093|Device|Patch validation|Use of connected patch to collect blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature
45912565|NCT02011789|Dietary Supplement|Citrus Limonoid Beverage|The limonoid containing beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C, 11 mg riboflavin and 250 mg limonin glucoside.
45912566|NCT02011789|Dietary Supplement|Placebo beverage|The placebo beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C and 11 mg riboflavin.
45912567|NCT02011802|Device|Algosteril TM|
45912568|NCT02011802|Device|Sorbact TM|
45912569|NCT02011828|Drug|Ergocalciferol|50,000 IU/week
45623514|NCT04968327|Other|Micro-osteoperforations (MOPs)|MOPs included shallow perforations of the buccal cortical plate surrounding the tooth that requires orthodontic tooth movement, with no flap reflection was performed using a surgical bur using the special calibrated device called PROPEL
45623515|NCT04968327|Other|Conventional canine retraction|using nickel-titanium (NiTi) closed coil-springs delivering a force of 150 grams per side
45623516|NCT05234645|Other|Kefir consumption|Following confirmation of eligibility and the provision of informed consent, recruited participants were provided with a 4-week supply of kefir (Live Kefir Company, Pontefract, UK) being instructed to consume 150ml of Kefir per day for the whole 4-week period. No break periods of kefir consumption were offered to any of the participants. In addition, they were instructed to not change their usual dietary habits and exercise routine for the study duration.
45446795|NCT05031819|Other|Nurse-led Task-Shifting Strategy for Hypertension Control (TASSH) plus Practice Facilitation.|"TASSH includes CVD risk assessment; medication initiation and titration; lifestyle counseling and patient referral to physician care for complex cases.~Practice Facilitation includes the training of external experts to support the HIV nurses implementing TASSH"
45446796|NCT04548830|Procedure|Transbronchial cryobiopsy|After enrollment, and pre-treatment procedures are complete, patients will undergo flexible bronchoscopy with a therapeutic bronchoscope under general anesthesia via an advanced airway at Memorial Hospital in an inpatient or outpatient setting.
45623517|NCT02456519|Other|PaedQoR-15 questionnaire|Children/ young people and one parent/ guardian will complete the questionnaire before and after general anaesthesia for surgery or diagnostic imaging.
45623518|NCT04975971|Drug|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
45623519|NCT03256955|Device|Tof cuff|The Tof Cuff will be installed on one arm. After anesthesia induction the Tof Cuff will be calibrated and continuos monitoring of the neuromuscular block started until complete recovery of neuromuscular block.
45623520|NCT03256955|Device|Tof Watch SX|The Tof Watch SX will be installed on the opposite arm to the Tof Cuff. After anesthesia induction the Tof Watch SX will be calibrated and continuos monitoring of the neuromuscular block started until complete recovery of neuromuscular block.
45623521|NCT04968483|Other|Data collection|The general data, data of postoperative complications, data of nutritional assessment and nutritional support will be collected.
45623522|NCT02456441|Other|Intervention group|"The device current generator TENS used was  Neurodyn Portable Tens / Fes  of IBRAMED brand. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used. Through a chain of 1Hz, the aim is to correctly identify the tibial nerve. This position is confirmed with the rhythmic movement of the finger flexion. The frequency is then changed to 10Hz, the pulse width set at 200 microseconds and adjusted according to the intensity threshold for each patient, below motor threshold. This current generator also has a device, the VIF (variation in intensity and frequency) that aims to ease the accommodation of sensory receptors and enhance its effects. The application time is 30 minutes"
45623523|NCT02456441|Other|Placebo group|The placebo group received an active current for 15 seconds by means of an apparatus also IBRAMED brand externally similar to that used in GI. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used.The application time for GP also was 30 minutes .
45623524|NCT03062163|Other|Resveratrol lipoic Acid|Transdermal patch loaded with resveratrol and lipoic acid
45623525|NCT03062163|Other|Placebo|Transdermal patch loaded with normal saline
45623526|NCT02456597|Drug|lidocainhydrochlorid|Lidocaine injected through the novel Catheter
45623527|NCT02456597|Drug|Isotonic Saline|Isotonic saline injected through the novel Catheter
45765471|NCT04362371|Device|Ainara|1 g at each administration
45765472|NCT05238207|Drug|BBI-001|Part A: 1 dose BBI-001 administered in a crossover fashion Part B: 2 doses BBI-001 administered in a crossover fashion
45623528|NCT03061773|Other|Exercise|Physical training: The combined training program consisted of 12-week aerobic, resistive and flexibility exercises, with 3 sessions per week of aerobic and resistive training in the same session (supervised by physical exercise coaches) and 2 sessions per week of Flexibility training (unsupervised). As stretching sessions were interspersed with sessions of aerobic and weathered training in the daytime period.
45623529|NCT03061773|Behavioral|Conventional hospital treatment|Conventional hospital treatment: The patients did not perform physical training
45446797|NCT01075841|Drug|Cetuximab|Subjects who are eligible for Erbitux treatment according to the indication in the national label of Erbitux (i.e. where Erbitux is used in combination with platinum-based therapy for the treatment of subjects with recurrent and/or metastatic SCCHN) according to the approved national label as in routine clinical practice under the supervision of an investigator experienced in the use of antineoplastic medicinal products.
45446798|NCT01313390|Drug|docetaxel|
45446799|NCT01313390|Drug|everolimus|
45446800|NCT01313390|Other|laboratory biomarker analysis|
45765473|NCT05238207|Dietary Supplement|Original Fibre Metamucil|Part A: 1 dose placebo administered in a crossover fashion Part B: 2 doses placebo administered in a crossover fashion
45765474|NCT02981875|Other|oculomotor training|a sequence of vision training exercises which focused mainly in oculomotor skill
45765475|NCT02981875|Other|placebo|placebo vision training exercises involving minimal accommodation and vergence eye movement.
45912570|NCT02011828|Drug|Placebo|Placebo tablet
45912571|NCT02011841|Drug|Rifaximin|rifaximin 1200 mg/day orally for 6 months
45623530|NCT03261635|Drug|Ranibizumab Injection|patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata
45623531|NCT03261635|Drug|Indomethacin|patients self-administered one drop of indomethacin 0.5% eye drops three times a day for 12 months
45623532|NCT03059979|Drug|Methylprednisolone|methylprednisolone 1000 mg dissolved in 100 cc of NaCl 0.9%, by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
45623533|NCT03059979|Other|sodium chloride|100 cc of NaCl 0,9% , administered by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
45623534|NCT03256721|Drug|Apatinib/docetaxel/pemetrexed|Participants are randomly assigned to treatment group or control group
45623535|NCT03256721|Drug|docetaxel/pemetrexed|Participants are randomly assigned to treatment group or control group
45623536|NCT03256565|Diagnostic Test|Q-tip test|A Q-Tip lubricated with anesthetic gel is inserted into the urethra, woman is then asked to cough and strain, and the angle of the Q-tip rotates is recorded.
45623537|NCT03061149|Other|Low-level laser therapy|
45623538|NCT03061149|Other|Ultrasound treatment|
45623539|NCT03256643|Behavioral|Exercise|Exercise intervention will consist of 8 exercise classes and exercises at home. A booklet will be given to each person that has a description and photograph of each exercise that designed to work on core strength and balance.
45623540|NCT03256643|Behavioral|Delayed Exercise|People will be tested up to 40 weeks after beginning the intervention.
45623541|NCT03256643|Behavioral|Exercise and enrichment|Exercise and enrichment will consist of the same exercise program described for the exercise intervention. The enrichment protocol consisting of cultural educational program will take place during the exercises and breaks for this group.
45623542|NCT03061071|Device|NightBalance Sleep Position Trainer (SPT)|Subject to sleep with the SPT for a 6 week home use period followed by in-lab PSG.
45623543|NCT03061071|Device|Automated Adjusting Positive Airway Pressure (APAP)|Subject to sleep with the APAP for a 6 week home use period followed by in-lab PSG.
45623544|NCT03904589|Diagnostic Test|Quality of Life assessment|Quality of life will be assessed by means of the Seattle Angina Questionnaire and the Patient Health Questionnaire.
45623545|NCT04967859|Drug|0.1% gentamicin|Patient using 0.1% gentamicin ointment at the exit site of the hemodialysis catheter
45623546|NCT04967859|Drug|Placebo|Patients using placebo ointment at the exit site of the hemodialysis catheter
45446801|NCT01313390|Other|pharmacological study|
45623547|NCT03261869|Other|Cold application|
45623548|NCT03256487|Drug|Buprenorphine|buprenorphine 0.3mg IV
45623549|NCT03256487|Drug|Morphine Sulfate|morphine 0.1 mg/kg IV (max 8mg per dose)
45623550|NCT04968093|Behavioral|Mindfulness-based therapy.|"Educational. Patients are given recommendations on the approach to the use of drugs for acute treatment of migraine headache and on lifestyle issues. Patients will be encouraged to restrict use of acute medications to headaches and to engage in regular physical activity, avoiding skipping meals, remain well hydrated, maintain a regular sleep.~Mindfulness therapy. The intervention is delivered in small groups and consisted of 7 weekly group sessions. It was aimed to teach and make direct practice with skills intended to enhance sustained, non-judgmental present moment awareness. Each session was conducted by a neurologist and a psychologist. To patients were asked to close their eyes and focus their attention on the breathing so that they can concentrate on the present moment and on all the sensations. Intervention's main topics: posture education; breath use and control; guided body scan; work with sounds; tension release; guided imagery; decentralization of thoughts."
45623551|NCT03256331|Drug|BEL-X-HG|"This study will be carried out in 2 parts:~A sequential Dose Escalation Part of four doses following a 3 + 3 design where dose escalation will be made based on DLT, for a single cycle (28 days) of BEL-X-HG treatment~A Dose Extension Part of up to 5 cycles (28 days each) at the same dose level (starting dose) of BEL-X-HG treatment~Escalating dose levels of BEL-X-HG in 5 study cohorts and one modified dose will be as follows:~Cohort 1: Dose level 1 - 0.5 g/day (0.25 g, bid)~Cohort 2: Dose level 2 - 1.0 g/day (0.5 g, bid)~Cohort 3: Dose level 3 - 2.0 g/day (1.0 g, bid)~Cohort 4: Dose level 4 - 4.0 g/day (2.0 g, bid) Modified dose level Cohort 5: Dose level 5 - 1.5 g/day (0.75g bid) This re-escalation is allowed only when dose de-escalates from Dose level 3 to Dose level 2, and 1 DLT in 6 evaluable subjects of Dose level 2."
45623552|NCT04975425|Diagnostic Test|Fractional Flow Reserve|Comparison between FFR and NHPR before and after guiding catheter disengagement
45623553|NCT03256409|Other|Adherence mold and yeast and mesophyll aerobe|Adherence mold and yeast and mesophyll aerobe to BOD and BJOD Microbial populations have been controlled in the saliva at initial time and adherence at 30 - 180 days after the overdentures in the mouth. The saliva sample was obtained from the patient in a sterile sputum collection bottle through a sterile solution. The overdenture samples were extracted and processed for analysis. Each sample was submerged in ¼ sterile Ringer and subjected to vigorous ultrasound shaking. From each of the microbial suspensions, successive dilutions were made to determine the total number of viable microorganisms present. Total count of mold and yeast and total count of mesophyll aerobe were performed.
45446802|NCT04385199|Biological|Convalescent plasma|One 200mL transfusion of ABO compatible convalescent plasma over 3 hours
45912572|NCT02011841|Drug|Ciprofloxacin|ciprofloxacin 500 mg/day orally for 6 months
45765476|NCT04369079|Other|manual myofascial techniques|Fascial techniques were used together with the following techniques: deep massage of neck and shoulder girdle muscles; trigger point therapy; tissue scar treatment in the vicinity of the scar and directly on the scar, by stretching, breaking, pulling, as well as static and dynamic rolling; post-isometric relaxation (stretching) of shoulder and neck muscles; active release technique of the chest and shoulder; selected fascial distortion model techniques; and fascial manipulation techniques consisting of developing specific CC-center of coordination and CF-center of fusion points in the operated area and the shoulder on the same side.
45765477|NCT04369079|Other|conventional therapy consisting of exercise and massage.|Underwent kinesiotherapeutic procedures that included various floor gymnastic exercises with gymnastic stick, balls, and/or elastic tapes, conventional massage of neck and shoulder girdle muscles and therapeutic exercises to increase ROM in the upper limb and in the chest area.
45765478|NCT00359463|Drug|eltrombopag|Subjects will be administered a single oral dose of 50 mg eltrombopag.
45452375|NCT00079937|Drug|Omalizumab|The omalizumab dose administered, based on the patient's body weight and total serum IgE level at Screening, and the number of injections and injection volume was determined from the dosing tables in the protocol. Omalizumab 75 to 375 mg was administered subcutaneous (SC) every 2 or 4 weeks depending on the dose.
45623554|NCT03256409|Other|Surface Roughness (Ra)|The surface roughness of BOD and BJOD was determined with the rugosimeter the Mitutoyo Surfest SJ-301® (Mitutoyo Corporation Inc., Kanagawa, Japan), through a displacement force of 4mN and of the tray to 0.5 mm/s and back to 1 mm/s (Murtra and Arcís,1999). The roughness profile Ra was evaluated and determined in microns (ųm) through five readings for each of the samples in the study respectively.
45623555|NCT03061227|Drug|Intravenous glucagon|Randomized application of glucagon or saline during oral glucose tolerance test
45623556|NCT03061227|Drug|Intravenous saline|Randomized application of glucagon or saline during oral glucose tolerance test
45623557|NCT03261713|Device|Virtual reality|Virtual reality training is provided using Jintronix Rehabilitation software. A Kinect camera captures the movements of the participant using infrared technology and allows them to control an avatar, which interacts with an activity. Several games and activities are available to train standing balance (ex. slalom skiing), reaching (ex. planting seeds/harvesting tomatoes), stepping (ex. whack-a-mole), gentle strengthening (ex. knee extensions) and aerobic exercises (ex. marching on the spot). Game and activity difficulty can be increased by requiring more repetitions, or greater speed, distance and/or accuracy. Specific games and activities, and their parameters are customized for each participant. The exercise plan is performed 5 times a week for 6 weeks for 30 minutes at each session.
45623558|NCT03261713|Device|Control|Participants in the control group are provided with an iPad which contains a selection of apps suited for memory (ex. memory card game), cognition (Sudoku, cross-word), visual tracking (word search) and fine motor skills (ex. writing, whack-a-mole). Participants are instructed to perform their exercise plan 5 times a week for 6 weeks for 30 minutes at each session.
45623559|NCT04975659|Behavioral|Placebo and Nocebo effect|Positive suggestion and words is used on Placebo group Negative suggestion and words is used on Nocebo group
45623560|NCT04964349|Drug|Corticosteroids Acting Locally|topical application of jessener solution
45623561|NCT03256175|Procedure|Percutaneous Coronary Intervention|PCI technique (e.g. pre-dilatation vs. direct stenting and stent choice) was left to operator discretion. Stent post dilatation was permitted as per individual operator practice
45623562|NCT03060915|Device|Polysomnography|Patient's undergo a polysomnography
45623563|NCT03060915|Device|Actigraphy|Patient's wear an actigraphy while doing the polysomnography
45765479|NCT02880514|Device|PROPEL Mini Sinus Implant|Sinus implant with 370 mcg of mometasone furoate released over 30 days
45623564|NCT03261791|Drug|Apatinib|Apatinib mesylate tablets 500 mg po qd.
45452376|NCT00079937|Drug|Placebo|Placebo was administered subcutaneous (SC) every 2 or 4 weeks depending on the dosing schedule in the protocol.
45623565|NCT04975113|Other|progressive neuromuscular exercise program|The exercises to be performed in the following week at the beginning of each week were explained by the researcher physiotherapist on the brochure and given as a home program and continued for a total of 12 weeks. The researcher physiotherapist saw the patients every week and carried out exercise compliance and control.
45765480|NCT02880514|Procedure|Balloon Sinus Dilation Alone|
45765481|NCT04361747|Behavioral|nursing counseling|The counseling intervention was designed to facilitate self-awareness, reduce self-blame, clarify doubts, listen to patient concerns, promote forward thinking, and encourage life planning.
45765482|NCT05605431|Diagnostic Test|Polysomnography|over nightSleep study
45765483|NCT00968071|Drug|Decitabine|20 mg/m^2 IV over an hour and half daily for 5 days.
45765484|NCT00968071|Drug|Gemtuzumab Ozogamicin|3 mg/m^2 IV on day 5.
45765485|NCT04368923|Device|Oxygen Therapy|Patients receive oxygen therapy
45765486|NCT04368923|Procedure|Physical Therapy|Patients receive physical therapy
45912573|NCT02011854|Device|rehabilitation|rehabilitation,To treat five times a week,Total course is eight weeks
45912574|NCT02011854|Device|Acupuncture|
45912575|NCT02011867|Device|Cork Electrode|
45765487|NCT02987374|Biological|2011-2012 Fluzone IIV3 (IM)|2011-2012 Fluzone IIV3 vaccine delivered intramuscularly (IM)
45623566|NCT04975113|Other|Exercise and Taping|"I taping for accurate positioning of the tissue was applied to the patients to neutralize the patellofemoral joint. During the knee flexion in the supine position, the tape was adhered to the skin with a moderate-to-extreme stretch (50%-75%) . Clinical therapeutic applications of the Kinesio taping methods (Tokyo, Japan: Ken Ikai Co Ltd.). In addition to the patellar taping, correction taping to neutralize the subtalar joint by elevating the midtarsal joint and medial arch was applied. The patients were positioned in prone lying and knee flexion position, the taping was started at the 5th metatarsal level on the dorsal side of the finger and finished extending towards the medial of the tibia . Tapings were renewed at the beginning of each week for 6 weeks."
45623567|NCT03256019|Procedure|Endotracheal Intubation|Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation
45623568|NCT04967625|Drug|Sintilimab|A humanized anti-PD-1 monoclonal antibody
45765488|NCT04368611|Procedure|start with fundus|fundus first dissection then complete cholecystectomy as usual
45623569|NCT04967625|Drug|Anlotinib hydrochloride|A tyrosine kinase inhibitor selectively targeting VEGFR-2
45765489|NCT04368611|Procedure|calot first dissection|start dissection by calot approach
45623570|NCT03261557|Behavioral|CBT + SST|"It will consist of 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: cognitive skills module, which includes the basic principles of CBT for psychosis; Social skills module, which includes the usual strategies in HHSS training; and problem solving module.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual."
45623571|NCT03261557|Behavioral|Psychoeducation, habits and healthy lifestyle|"Patients randomized to the control treatment will receive the same number of Individual and group sessions, with the same periodicity and format: 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: psychoeducation, habits and healthy lifestyle.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual."
45623572|NCT04975035|Drug|Zolodine|Collect 200 patients who meet the criteria into the group. After enrollment, according to the principle of cross dressing change, the attending physician can decide the dressing change method according to the patient's condition, individual condition and other factors; within 2-4 weeks, the original antipsychotics should be gradually stopped, and Zoladine capsules will be gradually added to the target The dose is 120-160mg/d, orally 1-2 times a day, with meals.
45623573|NCT03255395|Device|Magnetic resonance-guided focused ultrasound|Ten amputees wil recieve a magnetic resonance-guided focused ultrasound treatment aimed at ablating neuromas, which are believe to contribute to their phantom / residual limb pain
45623574|NCT04967937|Other|Strengthening, resistance exercise, plyometric and dynamic movement training|(1) balance training and hip/pelvis/trunk strengthening, (2) plyometrics and dynamic movement training, and (3) resistance training.
45623575|NCT03643367|Drug|Sevoflurane|Included patients, randomized in experimental group, intravenous sedation will be interrupted and followed by a 4 hour sedation with the volatile anesthetic sevoflurane.
45623576|NCT03643367|Drug|Control Group|Included patients randomized in control group, intravenouse sedation is continued with propofol
45623577|NCT04967781|Behavioral|autoimmunity|autoimmunity is characterized as self attacking from self immune system, which may involve in the severe progression of COVID-19.
45765490|NCT00968227|Biological|Red blood cell transfusion|Transfusion of 1 unit of packed red blood cells over 1 hour.
45765491|NCT04368767|Behavioral|Skin-to-skin|Skin-to-skin contact will be performed for two hours daily for three consecutive days in the first week of life, usually in the afternoon. This time interval will allow all pre-intervention sample collection to begin 1 hour after the infant's feeding schedule in the afternoon. After pre-intervention measures of axillary temperature, heart rate, respiratory rate, and oxygen saturation by pulse oximetry (SPO2) are obtained; cotton balls placed in the diaper for urine collection will be removed and stored in an appropriate container. Salivary oxytocin and cortisol will be collected per protocol below. Mothers will be requested to sit in reclining chairs with a front opened blouse or hospital gown. Infants will be removed from the incubator and placed naked except for a diaper and hat directly onto the skin between the mother's breasts and covered with a blanket. All infants will be monitored. After the two hours of SSC is completed, the infant will be returned to the incubator.
45765492|NCT02988856|Device|Magnetic lid system|Small externally mounted magnetic lid arrays are attached to the eye lid (s). Glasses with a second magnet system may be combined with the arrays depending on the lid condition. The device intends to facilitate eye opening and closing.
45446803|NCT01341626|Behavioral|Treatment Foster Care (TFCO)|Youth placed individually in well-trained and supervised foster homes. Basic components: (a) daily telephone contact with TFCO parents; (b) weekly foster parent group meetings focused on supervision, training in parenting practices, and support; (c) an individualized behavior management program implemented daily in the home by foster parent; (d) individualized skills training for the youth; (e) family therapy for aftercare family focused on parent management strategies; (f) close monitoring of school attendance, performance, and homework completion; (g) case management to coordinate TFCO, family, peer, and school settings; (h) 24-hour on-call staff availability to TFCO and biological parents; and (i) psychiatric consultation. Services typically last approximately 6 months.
45623578|NCT03060603|Drug|Erythropoietin|Recombinant Human Erythropoietin, three times in a week, until the correction of anemia, approximately two months.
46069605|NCT02622165|Behavioral|The REWARD serious game intervention|The REWARD intervention is based on the dual process model incorporating strategies to influence both the automatic pathway (i.e., operant learning theory) and the conscious pathway (i.e., a focus on certain determinants). The central idea of the intervention will be that participants will earn credits in the game when scanning healthy (rather than unhealthy) snacks which will influence the advancement of the players in the game. This credit system will be related to the dietary quality index of the consumed snacks.
45765493|NCT04361903|Drug|Ruxolitinib Oral Tablet|Ruxolitinib Oral Tablet dosage of at least 20 mg x 2 / day in the first 48 hours
45765494|NCT05231265|Other|Walking task|Treadmill walking task with study of fractal variability (complexity) for 10 minutes.
45765495|NCT02989246|Other|Ventilator protocol|Open loop ventilator management by a computer based protocol
45765496|NCT02989246|Device|Esophageal Catheter|Esophageal manometry measurements of patient effort of breathing will be used to guide the protocol recommendations
45623579|NCT03255317|Behavioral|Reinforcers|Memes/Gifs: Immediately after completing their daily ecological momentary assessment using the app, each participant is randomized to receive an inspirational or funny meme or gif that is displayed within the app. Life Insights: Immediately after completing both daily active tasks using the app, each participant is randomized to unlock a life insight. Life insights track data provided by the participant, are stored in a virtual library within the app, and are regularly updated with recent data points.
45623580|NCT03255317|Behavioral|Notifications|Reminder Push Notifications: All participants receive a push notification reminder from the app at 6pm (the time at which data collection opens) to complete their daily data collection activities. Each day, each participant will be randomized to receive either a generic reminder or a reminder that contains more detailed information (e.g., about upcoming incentives). Inspirational Push Notifications: Each day, each participant will be randomized to receive a push notification at 4pm that contains inspirational song lyrics or celebrity quotes.
45623581|NCT04431921|Diagnostic Test|Functional capacity|Six minute walk test used assessment of functional capacity. For respiratory function mouth pressures, for cognitive functions MoCA scale and for pain assessment pain threshold and tolerance test assessed.
45623582|NCT04833153|Behavioral|Person-First - Please (PFP)|PFP takes 10 weeks and consist of four modules: Information, Person, Autonomy and Dignity. Information module takes 1 hour contact on first week. The other modules will follow every third weeks, starting from week 2. So that on week 2, 5 and 8 researcher meet nurses in 4 hours education session. Between the modules, nurses can take contact online to the researcher.
45452377|NCT00079937|Drug|Fluticasone|Patients entered the study using their current formulation of any inhaled steroid (proprietary drug and device) ≥ 200 μg/day equivalent of fluticasone administered with a dry-powder inhaler.
45623583|NCT04488107|Drug|FCN-437c|- FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
45623584|NCT04488107|Drug|Letrozole 2.5mg|"Letrozole is the latest generation of aromatase inhibitor. Letrozole lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body.~Letrozole is used to treat breast cancer in postmenopausal women. It is often given to women who have been taking tamoxifen (Nolvadex, Soltamox) for 5 years."
45623585|NCT04974957|Drug|SHR-1701；BP102|"Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion"
45623586|NCT04974723|Drug|Abaloparatide|Abaloparatide subcutaneous (abaloparatide SC [ABL]; Tymlos®)
45452378|NCT00909610|Drug|Ursodiol|Ursodiol Tablets, 500 mg
45452379|NCT00909610|Drug|Urso Forte™|Urso Forte™ Tablets, 500 mg
45452380|NCT00909298|Drug|TTP889|300 mg
45452381|NCT00909298|Drug|Placebo|Placebo
45623587|NCT04974723|Drug|Teriparatide|Teriparatide subcutaneous (TPTD; Forteo®)
45765497|NCT00971737|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|Given intradermally
45765498|NCT00971737|Biological|trastuzumab|Given IV
45765499|NCT00971737|Drug|cyclophosphamide|Given IV
45765500|NCT04368377|Drug|Tirofiban Injection|Patients will receive 25 microgram per kilogram of body weight tirofiban as bolus IV injection (3 minutes) followed by continuous infusion at a rate of 0,15 microgram/kg//minute for 48 hours.
45765501|NCT04368377|Drug|Clopidogrel|Patients will receive a loading dose of clopidogrel 300 mg PO, followed by 75mg daily for 30 days
45765502|NCT04368377|Drug|Acetylsalicylic acid|Patients will receive acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at a dose of 75mg daily for 30 days.
45765503|NCT04368377|Drug|Fondaparinux|Patients will receive concurrent fondaparinux 2.5mg s/c per day for the duration of the in hospital stay
45765504|NCT02243267|Other|sample collection|
45765505|NCT05223699|Biological|MGTA-117|MGTA-117 will be administered as an IV infusion
45765506|NCT04361513|Drug|Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)|3 point genicular nerve block
45765507|NCT04361513|Drug|triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)|intra-articular injection of triamcinilone
45452382|NCT03961607|Procedure|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
45623588|NCT04488029|Other|PCT|PCT is designed to deliver similar therapy as is conventionally provided in-clinic by a Speech Language Pathologist (SLP), which the patient can access from any location using the application installed on a supported tablet. The device functions by allowing clinicians to create a personalized therapy program for each patient from 75 categories of clinical therapies, which patients may access from their tablet device remotely. The PCT software is comprised primarily of authentication and an algorithm that suggests advancement of the therapy program based on observed patient deficits and progress.
45623589|NCT04488029|Other|Workbooks|Subjects in this group will be provided with a standard regime of paper workbooks (e.g. Workbook for Aphasia: Exercises for Expressive and Receptive Language Functioning; Brubaker, 2006) that are typically used by clinicians to practice therapy tasks with individuals. Notably, the control procedure employed here is similar to that employed on a large-scale study examining technology as a treatment option and involved usual care control group by Palmer and colleagues (2015).
45623590|NCT03060681|Drug|Bupivacaine 0.5% injected in the thoraco-lumber inetrfacial plane block|After attaching basic monitors (ECG, SpO2, NIBP), the patient will take the prone position. Using the superficial probe of the ultrasound machine, the probe will be placed in transversally in midline position at selected level. The spinous process and interspinalis muscles will be identified. The probe was then moved laterally to identify the mulifidus muscle (MF) and the longissimus muscles (LG) where the local anesthetic will be injected. The needle will be advanced under real-time in-plane ultrasound guidance till it reaches the interface between the two muscles then a 1-2 ml of saline will be inserted to confirm needle site. 15 ml of bupivacaine 0.25 will be injected each side.
45623591|NCT02456753|Device|trans-perineal ultrasonography|Assesment of the fetal head-perineum distance via a trans-perineal ultrasonography
45623592|NCT04974411|Other|infection|this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared
45623593|NCT04974411|Other|sepsis|this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared
45623594|NCT03261479|Diagnostic Test|Thermal image|We will take a non-invasive thermal image with the FLIR ONE thermal imaging camera that attaches to a study-designated iPhone.
45623595|NCT03261401|Drug|M5717|Subjects will receive single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
45623596|NCT03261401|Drug|M5717|Subjects will receive multiple ascending oral doses of M5717 after an overnight fast of at least 8 hours once daily for 3 days, followed by a 4-hour post-dose fast
45623597|NCT03261401|Drug|Placebo|Subjects will receive placebo matched to M5717
45623598|NCT03261401|Drug|M5717|Subjects will receive single ascending oral dose of M5717 from Part A or as applicable multiple ascending oral doses of M5717 from Part B after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
45623599|NCT04831203|Dietary Supplement|An egg-protein hydrolysate (NWT-03)|As described in the experimental arm
45623600|NCT04831203|Dietary Supplement|Placebo|As described in the Control arm
45623601|NCT03260777|Device|Trichoscopy|Trichoscopy (hair and scalp dermoscopy) is a noninvasive diagnostic tool that allows the recognition of morphologic structures not visible by the naked eye Structures which may be visualized by trichoscopy include hair shafts of different types, the number of hairs in one pilosebaceous unit, hair follicle openings (dots), the peri and interfollicular areas and the vasculature.
45623602|NCT03060837|Diagnostic Test|Preoperative Parameters|Preoperative Hmg and serum creatinine levels
45623603|NCT03060837|Other|Peroperative Parameters|Scope duration, perforation, hemorrhage, etc. complications
45623604|NCT03060837|Other|Postoperative Parameters|Stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc
45765508|NCT05595993|Drug|Cilostazol|Study participants will be allocated to receive oral administration of 200 mg cilostazol.
45765509|NCT05595993|Drug|Placebo|Study participants will be allocated to receive oral administration of placebo.
45765510|NCT02243501|Behavioral|Intervention Group|The BNBD intervention for caregivers of children 1 to 10 years with insomnia is a self-guided program delivered online. The intervention is conceptually consistent across age groups. Interactive and personalized content and evidence-based strategies are incorporated: sleep education, positive routines, faded bedtime with response cost, sleep restriction, extinction/graduated extinction, stimulus fading, and scheduled awakenings. BNBD includes five sessions available sequentially: Sleep Information; Healthy Sleep Practices; Settling to Sleep; Going Back to Sleep; Looking Back and Ahead. The completion time of the intervention will range from 5-10 weeks.
45623605|NCT03060837|Other|Movement of kidney|Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
45765511|NCT05593341|Other|Opioid education in person|"The presentation and handouts contain information regarding the following topics:~Reviewing opioids and strategies for analgesia~Defining and identifying opioids~Goals for postoperative pain management and utilizing opioids to treat pain~Alternative modes of treating pain~Regional anesthesia/analgesia defined~Side effects and risks of opioids~Common side effects of opioids~Risks of addiction, tolerance, dependence, opioid-induced hyperalgesia with long-term use~Proper use and handling of opioids~Safe practices when taking opioids~Weaning off opioids~Safe storage and disposal of opioids"
46069606|NCT04940780|Other|Acupuncture|Acupuncture points will be selected on an individualized and symptom-directed basis, with the incorporation of points shown in clinical research to be effective for specific symptoms
45452383|NCT00908752|Drug|Brivanib|Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
45452384|NCT00908752|Other|Brivanib Placebo|Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
45623606|NCT03060837|Procedure|single lung ventilation|Patients in this group will intubated with an endotracheal tube and then a bronchial blocker will be placed with the help of a fiberoptic bronchoscope or will be intubated with a double lumen endobronchial tube. One lung ventilation will be applied
45623607|NCT03060837|Procedure|standard ventilation|Patients in this group will be intubated with standart single lumen endotracheal tubes and standart two lung ventilation will be applied.
45623608|NCT03260933|Other|No intervention given. This is a qualitative interview study|This is a qualitative interview study
45912576|NCT02011880|Dietary Supplement|Chinese Herbs|"Dietary Supplement:Experiment group:~Fructus Cnidii,Psoralea Corylifolin L.，monkshood~-Granules,Oral(add into the breast cancer postoperative prescription solution),A Pack(Fructus Cnidii 9g，Psoralea Corylifolin L. 15g，monkshood 9g),Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity~Breast Cancer Postoperative Prescription~-Water Decoction,Oral,200ml,Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity~Dietary Supplement:Contrast Group:~Breast Cancer Postoperative Prescription~-Water Decoction,Oral,200ml,Bid Days,3 Periods( a month is a period),Until progression/unacceptable toxicity"
45623609|NCT04967547|Other|Self-care PD ability assessment form|Subjects will be evaluated using the self-care PD feasibility assessment tool within 7 days after randomization. The evaluation results will be provided to the patient on the same day
45623610|NCT04967547|Other|Education|Education on renal replacement therapy and dialysis
45623611|NCT03522701|Behavioral|CBTI|Refer to the arm description
45623612|NCT04964037|Other|No intervention|No intervention
45623613|NCT03255551|Drug|Amosartan|amosartan is a combination of amlodipine, which is a calcium channel blocker (CCB), and rozatan, an angiotensin II receptor antagonist (ARB), and is an antihypertensive agent
45623614|NCT04853433|Other|Radiation therapy of unresected keloids|radiation therapy (RT) for the treatment of unresected keloids. The primary endpoint will be toxicity within 10 weeks of follow-up. Secondary endpoints will include cessation of growth or shrinkage of keloids, symptomatic response, and impact on quality of life.
45623615|NCT03255239|Procedure|Ventral hernia repair|Hernia repair is a surgical procedure to return an organ that protrudes through a weak area of muscle to its original position.
45623616|NCT04842591|Diagnostic Test|exercise echocardiography|All patients will undergo exercise echocardiography during a symptom-limited cardiopulmonary exercise test.
45623617|NCT03255161|Behavioral|community health worker-audiologist communication education and support group|A 5-week educational program on hearing loss, communication strategies, and peer support facilitated by community health workers supervised by an audiologist.
45623618|NCT04967469|Drug|Calcitriol|end-stage renal failure patients who is hyperparathyroid with ESRD take calcidol preoperative Parathyroidectomy
45623619|NCT04967469|Drug|Alfacalcidol 0.5 MCG Oral Capsule|end-stage renal failure patients who is hyperparathyroid with ESRD take alfacalcidol preoperative Parathyroidectomy
45912577|NCT02011906|Dietary Supplement|omega 3|
45765512|NCT05593341|Other|Opioid education via video|"The video and handouts contain information regarding the following topics:~Reviewing opioids and strategies for analgesia~Defining and identifying opioids~Goals for postoperative pain management and utilizing opioids to treat pain~Alternative modes of treating pain~Regional anesthesia/analgesia defined~Side effects and risks of opioids~Common side effects of opioids~Risks of addiction, tolerance, dependence, opioid-induced hyperalgesia with long-term use~Proper use and handling of opioids~Safe practices when taking opioids~Weaning off opioids~Safe storage and disposal of opioids"
45765513|NCT00972205|Drug|paclitaxel|Paclitaxel 135 mg/m^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days.
45765514|NCT00972205|Drug|CBT-1(Registered Trademark)|CBT-1 500 mg/m^2 oral dose daily for 7 days in divided doses 3 times a day. Cycle days 1-7, repeated every 21 days. no antacids, H2 blocker, or gastric acid inhibiting agents will be administered within 4 hours before or after each daily dose.
45765515|NCT00972205|Radiation|Tc 99m sestamibi|20 mCI baseline scan day 0; 20 mCI scan on 6th day of CBT-1 administered.
45765516|NCT00928421|Drug|Polidocanol Endovenous Microfoam 0.125%|Polidocanol Endovenous Microfoam 0.125%, single dose
45765517|NCT00952315|Device|Cyberwand|Dual probe lithotrite Cyberwand will be used to remove kidney stone. Duration will be timed and documented.
45765518|NCT00952315|Device|Stonebreaker|Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
45623620|NCT03261011|Biological|AK-104|Subjects will receive AK104 by intravenous administration.
45623621|NCT03260465|Device|seleXys PC|Total hip arthroplasty using the seleXys PC cup
45623622|NCT03260465|Device|RM|Total hip arthroplasty using the RM cup
45623623|NCT04954521|Drug|Anlotinib|This is an observational study
45623624|NCT03254849|Drug|Empagliflozin|1 tablet
45623625|NCT03254849|Drug|Hydrochlorothiazide 25 mg|1 tablet
45623626|NCT04954209|Other|Physical activities in hospital|3 month in a resumption program of physical activity in hospital
45623627|NCT04954209|Other|Physical activity outside hospital|3 month in a resumption program of physical activity outside hospital with discovery sessions
45623628|NCT02455895|Device|iLid Cleanser|Application of iLid Cleanser to reduce bacterial load on the lid and lash margins
45623629|NCT04963647|Diagnostic Test|Adult subjects diagnosed with IS or TIA|From the moment the person decides to participate, the patient will undergo the first 24-hour cycle of monitoring with a high-resolution 12-lead Holter. The following day, the Holter report generated will be analyzed by an expert electrocardiographic. After the removal of the first Holter, the study subject will undergo a second monitoring with a 3-lead Holter device for a duration of 6 days, followed by decontamination of the device and archiving of data The electronic data relating to the monitoring periods with Holter will be analyzed with various high-sensitivity AF detection algorithms in order to identify the outcome of the study.
45623630|NCT00701051|Behavioral|Aerobic exercise training|24 weeks of aerobic exercise training: 3 times per week, 60 minutes per session, at 70% of maximal aerobic capacity
45452385|NCT00908752|Procedure|TACE Therapy|Trans-Arterial Chemo-Embolization Therapy
45623631|NCT00701051|Behavioral|Detraining (cessation of exercise)|Cessation of exercise for 2 weeks
45623632|NCT04963881|Diagnostic Test|Antibody testing|Blood samples were taken and analyzed for APS antibodies
45623633|NCT04963335|Behavioral|Exergame Training|The individualized exergames were designed for a pressure sensitive plate connected to a personal computer and a frontal screen. The pressure-sensitive plate allows a precise analysis of the user's movements. This concurrent motor-cognitive training aims to improve motor and cognitive functions in an ecological valid setting. The cognitive functions are triggered by specific stimuli in the game scenarios. The video games are controlled via specific (whole body) movements as steps, weight shifting, jumps, and arm movements. The training focus is mainly on multi-tasking, balance and coordination as well as executive functions and attention. Furthermore, the meaningful games (colorful and appealing visuals) were designed to motivate the players to move. As the exergame will automatically adapt (individual progression) during play time, participants are challenged at their individual motor and cognitive level.
45623634|NCT03260543|Dietary Supplement|fermented ginseng powder|tablets (2 tablets/day, 125 mg & 500 mg/day) for 12 weeks.
45623635|NCT03260543|Dietary Supplement|Placebo|Placebo for 12 weeks.
45623636|NCT04432155|Drug|Xenon|30% xenon, 30% oxygen, and 40% nitrogen
45623637|NCT04432155|Drug|Placebo|30% oxygen, and 70% nitrogen
45623638|NCT04487951|Other|Pro BNP , Vitamin D|This study is designed to assess the difference between level of NT-pro-BNP, and Vitamin D in moderate cases who progressed to severe or critically ill category compared to those who did not.
45623639|NCT04966611|Drug|Anlotinib|This is an observational study
45623640|NCT03260621|Diagnostic Test|stress CMR|additional stress CMR to the established clinical diagnostics
45623641|NCT04487639|Diagnostic Test|SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics|a nasopharyngeal swab for SARS-CoV-2 research by RT- qPCR will be performed on the day of semen collection. On the same day, serological tests will be carried out, and 30 to 50 days after, according to HAS specifications with methods validated by the National Reference Center
45623642|NCT04963257|Drug|sertraline fluvoxamine|the initial dose of sertraline was given 50mg/d and the initial dose of fluvoxamine was 50mg/d, and the target dose of sertraline was gradually increased to 200mg/ d and the target dose of fluvoxamine was 200-300mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions
45623643|NCT04963257|Drug|sertraline|The initial dose of sertraline was 50mg/d and the initial dose of aripiprazole was 5mg/d. The target dose of sertraline was 200mg/ d and the target dose of aripiprazole was 5-20mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions
45623644|NCT04953819|Other|Revascularization|Percutaneous coronary intervention and/or coronary bypass grafting for coronary artery disease
45623645|NCT04953819|Other|Medical therapy|Optimal medical therapy for coronary artery disease
45623646|NCT03260309|Procedure|Semi-closed loop infusion system tactic.|"Semi -closed loop infusion system tactic.Use volume loading test twice (before surgery and 12hrs postoperatively). Computer provides advisory hypotension treatment algorithm. Computer provides advisory anemia treatment algorithm. Programmed iv fluid and blood infusions system ,,Belmont Rapid Infuser and programmable syringe pump for adrenaline infusion."
45623647|NCT03260309|Procedure|Routine infusion therapy tactic|Routine re-hydration bolus before surgery. Routine treatment of hypotension. Routine treatment of anemia.
45623648|NCT03260153|Drug|Deproteinised Calf Blood Serum Injection|
45623649|NCT03260153|Drug|Placebo (Sodium Chloride)|
45623650|NCT04966845|Diagnostic Test|measurement of concentration on exhaled Carbon Monoxide|Εxhaled carbon monoxide (eCO) concentration [parts per million (ppm) was measured by a specific device [Bedfont Scientific, Maidstone, Kent UK]
45765519|NCT00952315|Device|Lithoclast Select|Lithoclast Select will be used to break up and remove the kidney stone. Duration will be timed and documented
45912578|NCT02011906|Dietary Supplement|vitamin E|
45452386|NCT03126110|Drug|INCAGN01876|In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().
45452387|NCT03126110|Drug|Nivolumab|Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
45623651|NCT04953741|Drug|Fluticasone propionate inhaled aerosol|The study consists of two stages and include three groups. Three groups include: Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped Fluticasone propionate Inhaled Aerosol and continuation of montelukast once a day; Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug once a day; Stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug twice daily, and then Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day. The scheme of every group is divided into two stages. Only those whose asthma are well controlled at the end of the first phase will be allowed to proceed to the next phase.
45623652|NCT03254771|Other|Decision aid|Decision aids are tools that enables to promote and facilitate patients' involvement in medical decisions concerning their health
45623653|NCT02455739|Other|chewing gum|postoperative gum chewing to improve gastrointestinal function
45623654|NCT04966143|Biological|LY011|Targeting CLDN 18.2 Car-T injection
45623655|NCT03260231|Dietary Supplement|Milled seed mix|Dietary intervention with or without seed mix
45623656|NCT04953663|Biological|it-hMSC|Different doses of it-hMSC
45765520|NCT03051256|Drug|REL-1017|REL-1017 will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
45623657|NCT03255005|Device|Endomina|Endoscopic sleeve reduction
45623658|NCT03255005|Behavioral|Diet|Multidisciplinary follow-up
45623659|NCT04953585|Procedure|radical gastrectomy|According to the size and location of the tumor, the appropriate surgical method was selected for radical gastrectomy
45623660|NCT03440801|Device|Synergy|Biodegradable-polymer everolimus-eluting stent Synergy
45623661|NCT03440801|Device|Xience|Durable-polymer everolimus-eluting stent Xience
45623662|NCT04953429|Behavioral|workload|Mental needs, physical needs, time needs, self performance, effort, frustration, technical autonomy, decision-making autonomy and work needs of nursing work
45623663|NCT03254537|Dietary Supplement|Mediterranean Organic|Traditional Mediterranean diet comprised of organic ingredients
45623664|NCT03254537|Dietary Supplement|Mediterranean conventional|Traditional Mediterranean diet comprised of conventional ingredients
45623665|NCT04953351|Procedure|Cognitive registration targeted biopsy and TRUS-system biopsy|Cognitive registration is a visual guidance technique in which the surgeon samples a visually estimated location on ultrasound that corresponds to the MRI suspicious regions location. TRUS-system biopsy includes 12 biopsy cores.
45623666|NCT04953351|Procedure|MRI-ultrasound fusion targeted biopsy and TRUS-system biopsy|MRI-ultrasound fusion targeted biopsy is conducted with an mpMRI-TRUS biopsy system that provides realtime fusion of TRUS images and MRI images to guide the biopsy needles. TRUS-system biopsy includes 12 biopsy cores.
45623667|NCT03423017|Other|Recording of data|"Recording during one hospitalization of 48 hours between birth and 2 months of life and one hospitalization of 24 hours between 6 and 10 months of life~General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs : first and second visit~Respiratory rate, respiratory signs, stridor : first and second visit~24h holter-ECG : first and second visit~24h impedance pH-metry : first visit~Nocturne polysomnography : 50% prone position, 50% supine : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram) : first and second visit~24 h gaz exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index : first and second visit~succimetry procedure : at first visit only between birth and 2 months"
45623668|NCT03423017|Other|Recording of data|"Recording during one hospitalization of 48 hours between birth and 2 months of life~General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs~Respiratory rate, respiratory signs, stridor~24h holter-ECG~24h impedance pH-metry~Nocturne polysomnography : 100% supine position : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram)~24 h gas exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index~Succimetry procedure : at first visit only between birth and 2 months"
45623669|NCT04963491|Device|Personalized TKA prosthesis|TKA prosthesis that is designed and manufactured according to the patient's knee joint anatomy
45623670|NCT04963491|Device|Zimmer NexGen prostheses|Commercial products used on a large scale
45765521|NCT03051256|Drug|Placebo|Placebo will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
45765522|NCT00932321|Drug|Norethindrone Acetate/Ethinyl Estradiol 24 Days|One tablet per day for 24 days of each 28 day cycle followed by 4 placebo tablets
45765523|NCT00932321|Drug|Norethindrone Acetate /Ethinyl Estradiol 21 Days|One tablet per day for 21 days of each 28 day cycle followed by 7 placebo tablets
45765524|NCT00952393|Drug|Pharmacokinetic|Subject receives 150 mg of compound formulated with hypomellose and Pharmcokinetics is determined
45765525|NCT05445609|Drug|VLP-encapsulated TLR9 Agonist CMP-001,|Given SC or IT
45765526|NCT05445609|Biological|Nivolumab|Given IV
45765527|NCT05591859|Device|Restoration Anatomic Acetabular Shell|Multi-hole acetabular shell intended for cementless fixation into a prepared acetabulum and is a modular component design that is assembled intra-operatively.
45452388|NCT03126110|Drug|Ipilimumab|Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
45912579|NCT02011906|Dietary Supplement|placebo of omega 3|
45912580|NCT02011906|Dietary Supplement|placebo of vitamin E|
45912581|NCT02011919|Device|Echopulse|HIFU Under ultrasound guidance
45623671|NCT03259919|Drug|Metformin|Metformin 850 mg x 1 per day for the first week, and 850 mg x 2 per day for the rest of the study period.. Orally. From inclusion (before gestational week 8) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
45446804|NCT01341626|Behavioral|Group Care|Group Care is the usual service for youth placed in out-of-home care for chronic delinquency in Oregon. These programs represented typical services for girls being referred to out-of-home care by the juvenile justice system and had 2-51 youth in residence (M = 21) and 1-50 staff members (Mdn = 2); most also had onsite schooling. Although the programs differed somewhat in theoretical orientations, 86% reported that they endorsed a specific treatment model, of which the primary philosophy was a behavioral (70%), eclectic (26%), or family-style therapeutic approach (4%). Services typically last approximately 6 months.
45623672|NCT03259919|Drug|Placebo|Placebo, 2 tablets x 1 daily for the first week, and 2 tablets x 2 for the rest of the study period.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
45623673|NCT04965987|Drug|Oxaloacetate|Oxaloacetate (OAA) is a four-carbon molecule involved in many metabolic pathways, including gluconeogenesis, citric acid cycle, glyoxylate cycle, urea cycle, and amino acid metabolism. In the glyoxylate and citric acid cycles, oxaloacetate is formed as the result of the catalysis by malate dehydrogenase. In this reaction, the hydrogen atoms from malate are transferred to NAD+, forming NADH, H+ and oxaloacetate. Oxaloacetate can be converted to citrate with the addition of acetyl-CoA by the enzyme citrate synthase. Oxaloacetate is a critical component in the production of ATP and must be constantly regenerated in order for the citric acid cycle and the electron transport chain to continue
45446805|NCT04131062|Behavioral|Electronic Consent (iPad)|Participants who receive the intervention will be consented using an electronic app presented via iPad and developed according to the Sage eConsent framework.
45446806|NCT04284813|Behavioral|CRAFT-FT|CRAFT-FT will be delivered via telemedicine. Topics include building motivation, self-care, communication, understanding patterns of behavior, positive reinforcement, and negative consequences. The intervention will be tailored to families of individuals experiencing psychosis and substance use who are enrolled in first episode psychosis outpatient services. Participants will be asked to completed assessments at pre-treatment, mid-treatment (approximately week 3), post-treatment, and a follow-up assessment approximately 3 month post-treatment.
45623674|NCT04965987|Drug|Placebo|Placebo
45623675|NCT02455973|Behavioral|Lifestyle modification and cardiovascular risk|Group meetings will be performed in the presence of a member of the nursing staff, physiotherapy, nutrition and psychology. The meetings are weekly, lasting 1 hour and 45 minutes. In the first 1 hour and 15 minutes will be addressed health issues related to lifestyle modification (self-care, healthy eating and physical activity) using the fundamentals of motivational interviewing technique. All topics will be focused on the major cardiovascular risk factors considered modifiable.Likewise, it is envisaged to include a time of physical activity (30 minutes) oriented in conjunction with the research team. Run in: There will be a meeting with the parents in order to inform them about the participation of children in the program and guide them about the procedures of the research protocol.
45623676|NCT02455973|Behavioral|Health Education|The meetings will be weekly with 45 minutes duration on a schedule of lectures about cardiovascular risk
45623677|NCT04962945|Procedure|Oblique-axis approach group|The first two attempts via the oblique-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the long-axis approach.
45765528|NCT01011829|Drug|Varenicline|Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
45765529|NCT01011829|Drug|Placebo|Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
45446807|NCT04151966|Diagnostic Test|Blood sample collection|Blood sample collection for markers of myocardial injury
45446808|NCT04133012|Other|Samplings|"blood samples~rectal biopsies~nodes biopsies~cutaneous fat tissues biopsies~semen sample"
45446809|NCT05571332|Drug|Avatrombopag 20 MG Oral Tablet|p-ATG and CsA in combination with Avatrombopag to treat
45446810|NCT03263780|Drug|18F-Fluciclovine|Imaging (comparing standard and experimental high resolution diffusion-weighted imaging [DWI] MRI with 18F-Fluciclovine)
45446811|NCT02791438|Drug|Azilsartan|Azilsartan granules and tablets
45623678|NCT04962945|Procedure|Long-axis approach group|The first two attempts via the long-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the oblique-axis approach.
45623679|NCT03254615|Behavioral|"I Prefer Plain Water"|The students will receive four educational sessions of approximately 1 hour. These sessions will be given every 2 weeks, and some will be supervised by a nutritionist.
45446812|NCT02791438|Drug|Placebo|Placebo-matching azilsartan granules and tablets
45446813|NCT02089048|Drug|Auranofin|Auranofin is a gold-containing chemical salt available as 3mg capsules. Cohort 1 receives 6mg oral dose of auranofin once every 24 hours for 7 days
45446814|NCT02089126|Drug|Gemigliptin/Glimepiride combination|
45446815|NCT05571176|Drug|S-ketamine|S-ketamine infusion 0.29 mg/kg/h for 4 hours
45446816|NCT03920462|Device|Programme of intelligent electric bike for health|It is a programme of 6 excursions with an intelligent electric bike for health and connected vests during 1 month (two excursions per week according the weather)
45452389|NCT01088087|Dietary Supplement|colostrum|colostrum, 2g, 2 times a day, for 3 weeks
45452390|NCT00908128|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg Tablet
45452391|NCT00908128|Drug|CellCept®|CellCept® Tablets, 500 mg
45765530|NCT05591157|Device|CSF-3 watch, designed to monitor a user's heart rate based on ECG (electrocardiogram) and PPG (Photoplethysmograph) readings|The subjects will be connected to an ECG Holter, and an investigational Device will be placed simultaneously on the subject's wrist. All subjects in this phase will be asked to participate in a single continuous data recording measurement for seven (7) minutes
45623680|NCT04965831|Drug|Furmonertinib|Furmonertinib 80mg/d as neoadjuvant therapy for 8 weeks before surgery, then as adjuvant therapy for 3 years after surgery.
45623681|NCT03254693|Combination Product|1-step self-etch approach (SE)|Application mode - Do not use etchan. According to the manufacturer's instructions.
45623682|NCT03254693|Combination Product|selective enamel etching (SEE)|Application mode - Etch only on enamel for 15 s. Rinse for 15s. Air dry to remove excess water.According to the manufacturer's instructions.
45623683|NCT03254693|Other|1-step self-etch for double time (SE2X)|Application mode - Do not use etchan. According to the manufacturer's instructions, but for the double time (20 s) in the each application.
45623684|NCT03254693|Other|1-step self-etch additional layer (SE1+)|Application mode - Do not use etchan. According to the manufacturer's instructions, but apply tree times.
45623685|NCT04966065|Device|Parietex Parastomal mesh|Laparoscopic Modified Sugarbaker technique for repair of parastomal hernias in end-colostomies
45623686|NCT03259997|Dietary Supplement|Probiotic supplement|Probiotic supplement
45623687|NCT03259997|Dietary Supplement|Placebo|Placebo
45623688|NCT04953117|Device|DCB of Lepu Medical(dimeter≥2.00 mm)|subjects receiving DCB of Lepu Medical(dimeter≥2.00 mm)
45623689|NCT04953117|Device|Restore DEB|subjects receiving Restore DEB
45623690|NCT04953117|Device|DCB of Lepu Medical(dimeter<2.00 mm)|subjects receiving DCB of Lepu Medical(dimeter<2.00 mm)
45623691|NCT02455661|Device|TR Band (TM)|
45623692|NCT02455661|Device|AngioSeal|
45623693|NCT02455661|Device|StarClose|
45623694|NCT03259841|Other|Ultrasound assessment of gastric contet|Ultrasound assessment of gastric content is performed in fasted patient undergoing cholecystectomy.
45623695|NCT04965441|Procedure|Computer-assisted surgery|Preoperative head and neck computed tomography (CT) and lower extremity CT angiography were acquired for all patients. In the CAS group, CT images (slice thickness<1 mm) were imported into a 3D surgical planning software (Proplan, Version 2.0/3.0 Materialise, Leuven, Belgium). Virtual surgical planning was performed to determine the mandibular and fibular resection and cut margins with localization of the optimal angles for performing osteotomies. After that, surgical guides were designed utilizing a 3D designing software (3-Matic, Version 9.0-13.0, Materialise, Leuven, Belgium). The generated virtual templates were exported in Standard Tessellation Language (STL) format and printed with a professional 3D printer (Connex 350, Stratasys, Eden Prairie, MN, USA). The reconstructive plates were pre-bent on a 3D printed planned mandibular model.
45446817|NCT03556930|Device|AlignRT system (VisionRT LTD, UK)|Pediatric patient will watch age-proper movie during radiation treatment. The motion of pediatric patient will continually be monitored by an AlignRT system (VisionRT LTD, UK). Both movie and radiation beam will be paused if the motion of pediatric patient is beyond positioning accuracy threshold. Movie and beam will be resumed if pediatric patient is positioning with in tolerance.
45446818|NCT03772652|Other|Observation|Soft tissue implant measurements
45446819|NCT02095756|Other|755nm Alexandrite Laser and Lytera Skin Brightening System (Non-Hydroquinone Topical Therapy)|
45446820|NCT02095756|Other|Lytera Skin Brightening System (Non-hydroquinone topical therapy)|
45623696|NCT03260075|Other|cat|Cat living at the ward
45623697|NCT03060525|Behavioral|Deaf Weight Wise 2.0|"Deaf Weight Wise 2.0 is a group or individual intervention lead by trained, American Sign Language fluent Deaf counselors, who utilize an existing evidence-based curriculum that emphasizes healthy eating, exercise, and lifestyle components. It is a behavior change intervention that uses motivational interviewing techniques to help participants identify/recognize their own unhealthy behaviors, help individuals build skills that will promote behavior change, and help group members to support each other to make behavior changes. The Curriculum includes group exercise activities (Do It!), experiential learning activities (Try It! such as learning how to read a nutrition label or modify a recipe to make it healthier), and group activities related to food preparation or sampling healthy foods (Taste It!). Self-monitoring using daily food diaries and weekly weigh-ins is also a key component. The intervention also includes a 6-month follow up and maintenance phase."
45623698|NCT03058965|Drug|[18F]MNI-958|Subjects will undergo PET imaging using [18F]MNI-958, a PET radioligand for imaging tau.
45623699|NCT03058965|Drug|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a [18F]florbetapir scan to compare distribution of tau in the brain compared to that of [18F]MNI-958.
45623700|NCT03058965|Drug|DaTscan|DaTscan SPECT imaging will be completed in those PSP subjects who have not previously had DATScan imaging as part of the screening procedures.
45446821|NCT02250430|Drug|SB204|Applied topically twice a day on days 1, 2 and 3 to left and right cheeks
45446822|NCT03712124|Drug|CNSA-001|CNSA-001 Powder for Suspension
45446823|NCT03712124|Drug|Placebo|Placebo Suspension
45446824|NCT02093260|Biological|Vaccine|"Flubio (Influenza HA) Vaccine~The vaccine will be given intramuscularly."
45446825|NCT03556540|Other|physical exercise|Each participant will perform 30 minutes of aerobic physical activity, using cycle ergometer. The exercise will begin 30 minutes after the start of hemodialysis.
45765531|NCT00932477|Drug|Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
46069607|NCT04940780|Other|Touch Therapies|Touch therapies are to include Reflexology, Shiatsu and Therapeutic Touch
45623701|NCT03254303|Other|Difficulty of catheterization in group 60 s|
45623702|NCT03254303|Other|Difficulty of catheterization in group 90 s|
45623703|NCT03254303|Other|Difficulty of catheterization in group 120 s|
45623704|NCT03254381|Behavioral|Resistance Training|Six months of thrice-weekly resistance training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down). Classes will be group classes, with up to five participants in each.
45446826|NCT03689582|Drug|68Ga-PSMA|"Positron Emission Tomography/Computed Tomography (PET/CT) imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi)."
45623705|NCT03254381|Behavioral|Balance and Tone Training|Six months of thrice-weekly stretching and relaxation exercises. Each session will be 60 minutes. Classes will be group classes, with up to five participants in each.
45623706|NCT03058887|Other|Exercise intervention - Cycling|The patients that will be randomly allocated to the exercise group - cycling will be requested to perform an exercise session on a cycle ergometer. Each training will be consisted of high intensity interval training for 30 minutes (30s 100% PPO/ 30s passive recovery) twice per week for 3 months. Patients will perform two visits for the baseline measurements prior the exercise intervention by repeating them at the end of the exercise intervention (follow up measurements).
45623707|NCT03058887|Other|Exercise intervention - arm cranking|The patients that will be randomly allocated to the exercise group - arm cranking will be requested to perform an exercise session on an arm crank ergometer. Each training will be consisted of high intensity interval training for 30 minutes (30s 100% PPO/ 30s passive recovery) twice per week for 3 months. Patients will perform two visits for the baseline measurements prior the exercise intervention by repeating them at the end of the exercise intervention (follow up measurements).
45623708|NCT03606161|Other|Questionnaire Administration|Ancillary studies
45623709|NCT03606161|Procedure|Transcranial Magnetic Stimulation|Undergo nrTMS
45623710|NCT03259529|Drug|Bendamustine hydrochloride|70 mg/m2 by intravenous (IV) infusion for up to 2 cycles
45623711|NCT03259529|Drug|Gemcitabine 500 mg|500 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
45623712|NCT03259529|Drug|Gemcitabine 700 mg|700 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
45623713|NCT03259529|Drug|Gemcitabine 1000 mg|1000 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
45623714|NCT03259529|Drug|Nivolumab|1 mg/kg by intravenous (IV) infusion on day 1,15 for up to 2 cycles
45623715|NCT03259529|Drug|Rituximab|375 mg/m2 by intravenous (IV) infusion on day 0 for up to 2 cycles
45765532|NCT00932477|Drug|Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
45765533|NCT00932477|Drug|Glycerin and Polysorbate 80 based artificial tear|1 to 2 drops into each eye three times per day
45446827|NCT02093338|Dietary Supplement|Lactobacillus fermentum CECT5716|
45446828|NCT02093338|Other|Placebo Comparator: maltodextrin|Placebo
45446829|NCT04089956|Other|No interventation|A retrospective cohort Observational study with no intervention
45446830|NCT02095834|Drug|Bendamustine Hydrochloride|Given IV
45623716|NCT04962555|Procedure|Meniscus Suture|Patients with knee joint meniscus injury undergoing meniscus suture
45623717|NCT04962555|Procedure|Partial meniscus resection|Patients with knee joint meniscus injury undergoing partial meniscus resection
45623718|NCT04962555|Procedure|Subtotal meniscus resection|Patients with knee joint meniscus injury undergoing subtotal meniscus resection
45623719|NCT04962555|Procedure|Complete meniscectomy|Patients with knee joint meniscus injury undergoing complete meniscectomy
45623720|NCT03252821|Behavioral|High-intensity interval training|High-intensity interval training sessions will be conducted on cycle ergometers or treadmill with heart rate measured throughout each session.
45623721|NCT03252821|Behavioral|Resistance training|Resistance exercise will be performed on eight exercises targeting major muscle groups at 60% to 85% of their estimated one-repetition maximum (1RM).
45623722|NCT03254069|Device|Stainless Steel Crowns|SSCs were placed on children's primary molars, and bite force was registered prior to the study, and periodically after the study.
45623723|NCT03060369|Device|CareGuide™ device|CareGuide™ is a minimal risk, non-invasive device that uses near-infrared spectroscopy to measure skeletal muscle oxygen saturation.
45623724|NCT03252743|Behavioral|Exposure-based internet-delivered CBT|"The main target in treatment is exposure for abdominal symptoms by reducing avoidance and provoking symptoms. Participants are encouraged to gradually increase the difficulty by combining multiple challenges.~The parents are taught how to reduce the risk for reinforcement of children's symptom behavior, and to support their child to complete the treatment.~All treatment content is delivered over the internet, containing texts, videos, audio-files and examples. The modules are unlocked sequentially as participants worked their way through the treatment.~Therapist support consists primarily of encouragement of any progress made in the treatment and support to find individual exercises."
45623725|NCT03252665|Drug|Alprostadil|alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
45623726|NCT03252665|Drug|Nicorandil|Nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
45765534|NCT00972439|Drug|Oral Contraceptive: Ortho-Novum® 1/35|
45765535|NCT00972439|Drug|Oral Contraceptive: Ovcon Fe®|
45765536|NCT00358371|Drug|flucloxacillin 250 mg|Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose
45765537|NCT00358371|Drug|flucloxacillin 500 mg|Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose
45446831|NCT02095834|Drug|Carfilzomib|Given IV
45446832|NCT02095834|Drug|Dexamethasone|Given PO or IV
45446833|NCT02095834|Other|Laboratory Biomarker Analysis|Correlative studies
45446834|NCT03126266|Radiation|re-irradiation|if DIPG has progressed or recurred at 180 days or later from completion of primary radiation therapy, a second course of radiation therapy will be given
45446835|NCT02791516|Drug|Romosozumab|Administered by subcutaneous injection once a month (QM)
45446836|NCT02791516|Drug|Placebo|Administered by subcutaneous injections once a month
45446837|NCT02093494|Device|Initial Specimen Diversion Device (ISDD)|
45446838|NCT02093494|Procedure|Lab standard practice (LSP)|
45623727|NCT03252665|Drug|Nitroglycerin|Nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
45765538|NCT02989714|Drug|Interleukin-2|600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apart
45623728|NCT03059745|Procedure|Cholecystectomy|Single Port and Multi-Port approaches trans-laparoscopic approaches with or without the use of the daVinci Surgical Robotic System.
45446839|NCT02093494|Device|Peripheral Intravenous Catheters (PIVC)|
45623729|NCT02455583|Behavioral|Project AIM (Adult Identity Mentoring)|Project AIM consists of 14 sessions that are delivered twice a week. Each session is 40 minutes long.
45623730|NCT03059667|Drug|Atezolizumab|Atezolizumab at 1200 mg IV every 3 weeks
45623731|NCT03059667|Drug|Topotecan|oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended
45623732|NCT03059667|Drug|Carboplatin|In accordance with the summary of product characteristics.
45623733|NCT03059667|Drug|Etoposide|In accordance with the summary of product characteristics.
45623734|NCT03058419|Drug|JNJ-54175446 150 mg|Subjects will receive JNJ-54175446 150 mg capsules orally (1*100 mg + 1*50 mg) under fasted conditions on Day 7, 9, 10 and 11.
45623735|NCT03058419|Drug|JNJ-54175446 600 mg|Subjects will receive JNJ-54175446 600 mg (6*100 mg capsules) orally on Day 8.
45623736|NCT03058419|Drug|Midazolam 2 mg|Subjects will receive midazolam 2 mg oral emulsion [2 (milligram per milliliter (mg/mL)] as a drug cocktail on Day 1, 7 and 11.
45623737|NCT03058419|Drug|Warfarin 10 mg|Subjects will receive warfarin 10 mg tablets (2*5 mg) orally as a drug cocktail on Day 1, 7 and 11.
45623738|NCT03058419|Drug|Caffeine 50 mg|Subjects will receive caffeine 50 mg tablet (1*50 mg) orally as a drug cocktail on Day 1, 7 and 11.
45623739|NCT03058419|Drug|Dextromethorphan 30 mg|Subjects will receive dextromethorphan 30 mg capsule (1*30 mg) orally as a drug cocktail on Day 1, 7 and 11.
45623740|NCT03058419|Drug|Bupropion 150 mg|Subjects will receive Bupropion 150 mg tablet (1*150 mg) orally as a drug cocktail on Day 1, 7 and 11.
45623741|NCT03058419|Drug|Omeprazole 20 mg|Subjects will receive omeprazole 20 mg capsule (1*20 mg) orally as a drug cocktail on Day 1, 7 and 11.
45623742|NCT03253757|Other|This study is non-interventional.|This study is non-interventional.
45623743|NCT03252509|Procedure|Percutaneous radiologic gastrostomy|Percutaneous radiologic gastrostomy: Under conscious sedation and local analgesia, the ultrasound is performed to determine abdominal structures. The stomach is distended using room air through a nasogastric catheter or a 5 French (Fr) catheter. Gastropexy is performed under fluoroscopic guidance. The stomach is accessed using a 18 gauge (G) needle. Guidewire is advanced to the stomach. Progressive tract dilatations until the size of the gastrostomy tube is achieved. The catheter is advanced through the peel-away sheath. The catheter's balloon is inflated with 10ml of distilled water. Iodine contrast is injected to confirm position. After the procedure, the patient is observed for 3 hours. If there are no complications, the patient is discharged.
45623744|NCT04965051|Drug|insulin degludec/insulin aspart (IDegAsp)|To evaluate the efficacy and safety of the IDegAsp in T1DM
45623745|NCT04965051|Drug|basal insulin plus pre-prandial insulin|To evaluate the efficacy and safety of basal insulin plus pre-prandial insulin in T1DM
45623746|NCT02455427|Device|Active tDCS|Active tDCS will be applied with the anode positioned over the ipsilesional primary motor cortex and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
45452392|NCT05628454|Procedure|Endobronchial ultrasound-guided transbronchial needle Slow-pull capillary sampling|The slow-pull capillary technique was performed as follows: after identification and measurement of the target lymph node, a needle was used to puncture the lymph node with the stylet in place.At the same time, the stylet was slowly and continuously pulled to create weak negative pressure.
45623747|NCT02455427|Other|Physical Therapy|Physical therapy will be administered for 60 minutes
45623748|NCT02455427|Device|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
45623749|NCT03060291|Behavioral|FCU-Online, web/ mobile only|Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior.
45623750|NCT03060291|Behavioral|FCU-Online, web/ mobile + coach|"Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior. Participants will also have access to a family coach who will motivate parents to enhance parenting skills and provide support while they are learning to use these skills."
45623751|NCT03253601|Behavioral|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
45623752|NCT04953195|Drug|Levothyroxine Sodium Tablets|Levothyroxine Sodium(50ug/Tablets,dosage form 25ug,once a day) was administered to patients with autoimmune thyroiditis with mild subclinical hypothyroidism,
45623753|NCT03253523|Procedure|Occipital neurolysis|Surgical occipital nerve decompression
45623754|NCT04952571|Drug|Camrelizumab and Bevacizumab|"Stage 1: Targeted therapy induction phase: bevacizumab 5mg/kg, intravenous infusion, once every two weeks, 2 cycles in total.~Phase 2: Targeted combined immunotherapy: once every three weeks with the following drugs: (1) bevacizumab 7.5mg/kg intravenously;(2) Carrelizumab: 200mg/ time, intravenous infusion."
45623755|NCT03252119|Device|High flow humidified oxygen therapy|application of high flow humidified oxygen therapy at 2l/kg/min
45623756|NCT03253445|Behavioral|Acceptance and commitment therapy|All participants are given a brief educational talk on encouraging quitting smoking (about 5 mins) and a self-help leaflet on smoking cessation. Ten sessions of face-to-face ACT individually will additionally be provided by trained therapists on a weekly basis. Each session will last about 20-30 minutes. The therapy is guided by ACT smoking cessation protocols based on relevant literature (Gifford et al 2004, 2011; Bricker, 2010).
45623757|NCT03253445|Other|Control|All participants are given a brief educational talk on encouraging quitting smoking (about 5 mins) and a self-help leaflet on smoking cessation. Ten sessions of face-to-face Social Support will additionally be provided on a weekly basis. Each session will last about 5 minutes.
45623758|NCT04952259|Drug|Shexiang Tongxin Dropping Pills + routine treatment|oral+percutaneous coronary intervention
45623759|NCT04952259|Procedure|routine treatment|percutaneous coronary intervention
45623760|NCT03252197|Device|UGIJVC with needle guide device|Study subjects assigned to each group were trained in ultrasound guided internal jugular venous cannulation (UGIJVC) in separate spaces. On each session, subjects were educated about UGIJVC for 30 minutes, and the instructor who was in charge of session, consisted of experienced physicians who had 50 or more UGIJVC success experiences without a supervisor in clinical field. The instructors explained the anatomical structure and the principles of UGIJVC and then demonstrated the procedures directly to the subjects using phantom. After that, all subjects were instructed to perform hands on practice for 30 minutes. In case group, the instructor trained subjects using device. On the other hand in control group, UGIVJC was demonstrated as a conventional method of approaching the target vessel while confirming the needle tip on the ultrasound screen in real time without a device.
45623761|NCT03252197|Device|UGIJVC without needle guide device|participants who are tested performance for ultrasound guided cannulation using conventional method.
45623762|NCT04962399|Diagnostic Test|Enzyme linked immunosorbent assay|Serum N / OFQ and IL-6 levels were detected，and the genotype and allele frequencies of rs1800796 in IL-6 gene were determined.
45623763|NCT03252275|Other|Peer learning|Peer learning plus HBB and ECEB
45623764|NCT04962243|Procedure|Repair surgery for Achilles tendon rupture|Repair surgery for Achilles tendon rupture
45623765|NCT04487483|Behavioral|Sleep App|A sleep app offering 6 evidence based techniques to improve sleep (such as Cognitive Behavioural Therapy for Insomnia, Progressive Muscle Relaxation and Mindfulness Meditation), allowing for a personally tailored journey of sleep aids within the app.
45623766|NCT03253367|Other|Blood is obtained, mostly during routine venipuncture|
45765539|NCT02989714|Drug|Nivolumab|Nivolumab will be administered intravenously at 240 mg/dose over 60 minutes every 14 days, starting 1 week to 3 weeks after the start date of the first cycle of IL2 and continued for up to 48 weeks total in the absence of disease progression
45765540|NCT02243657|Drug|ASP3652|oral
45765541|NCT02243657|Drug|Placebo|oral
45765542|NCT05213013|Other|inhaler treatment with the toy-type nebulizer and training on on the use of a nebulizer/mask|"The children (experimental group), will receive training and inhaler treatment with the toy-type nebulizer. The training topics is as follows:~For effective nebulization, it should be ensured that the parts of the mask are assembled completely and correctly.~The child should be in an upright sitting position during nebulization.~During the procedure, normal breathing should be given into the mask.~As the medicine is finished, a sizzling sound is heard from the device.~After the nebula is over, the face should be washed and the mouth should be rinsed to remove the drug residues accumulated on the face and mouth."
45765543|NCT04361279|Drug|SIBP-02|Injection，100mg/10ml
45765544|NCT04361279|Drug|Rituximab|Injection，100mg/10ml
45765545|NCT02991820|Device|Miller|Direct laryngoscopy and endotracheal intubation attempted by each provider using direct laryngoscopy (DL) with a Miller laryngoscope
45446840|NCT03263702|Device|Computational Mapping Algorithm|This software enables high resolution temporospatial mapping of atria for the identification of drivers of AF. CMA receives data from standard of care, commercially available 3D Mapping Systems (St. Jude Ensite System) and catheters and processes the data in a unique way. Electrogram and anatomy data are fed from the commercially available 3D Mapping System to an adjacent laptop computer, via an Ethernet connection, that is running CMA. CMA then processes the electrogram data and generates a map of where the potential AF driver domains are located and superimposes those potential AF driver domain targets onto the 3D geometry of the anatomy (provided by the 3D mapping system).
45446841|NCT03556852|Drug|Carbetocin|1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby
45446842|NCT03556852|Drug|Misoprostol|2 rectal misoprostol tablets (800 μg) after the delivery of the baby.
45623767|NCT03060135|Behavioral|Check Your Drinking|A anonymous brief survey designed to provide normative feedback of individual's drinking with the intent of motivating reductions in drinking
45623768|NCT03060135|Behavioral|Hello Sunday Morning|Brief online intervention that allows Individual's reflect on their drinking reductions progress and goals.
45623769|NCT03252977|Other|Tailored regimen of IV PCA according to pain sensitivity|In tailored group, fentanyl dosage in IV PCA will be determined according to preoperative pain sensitivity. In control, group, fentanyl dosage in IV PCA will be determined without consideration of patient's pain sensitivity.
45623770|NCT03252977|Other|Regimen of IV PCA without considering pain sensitivity|In control group, regimen of IV PCA will be determined without consideration about patient's pain sensitivity.
45623771|NCT04952103|Other|no intervention|The patient's treatment is determined by the physician in charge according to the patient's clinical situation and relevant guidelines, without additional intervention.
45765546|NCT02991820|Device|Macintosh|Direct laryngoscopy and endotracheal intubation attempted by each provider using DL with a Macintosh laryngoscope
45623772|NCT03252041|Device|MRI|Magnetic Resonance imaging modalities and sequences in pelvic congestion syndrome
45623773|NCT04961775|Drug|Perflubutane Microspheres for Injection|16 µL as perflubutane microbubbles (1 vial) is reconstituted with 2 mL of attached water for injection; usually, once for an adult, 0.015 mL/kg as dispersion is administered intravenously.
45623774|NCT03251807|Device|Twin-block|Functional treatment will be achieved using the Twinblock appliance
45765547|NCT02991820|Device|C-MAC|Indirect laryngoscopy and endotracheal intubation attempted by each provider using the C-MAC video laryngoscope
45765548|NCT02991820|Device|GlideScope|Indirect laryngoscopy and endotracheal intubation attempted by each provider using the GlideScope video laryngoscope
45623775|NCT03251807|Other|LIPUS (Low-intensity pulsed ultrasound)|Functional treatment will be combined with LIPUS (Low-intensity pulsed ultrasound )
45623776|NCT03251885|Other|swabs|Two swabs will be taken at each screen: one from the vagina and the other from the rectum for vaginal and rectal assessment of maternal colonization
45623777|NCT04951869|Drug|Protescal gel|Protescal gel (0.5 mL) was again applied over the subcutaneous tissue prior to skin closure in Protescal group
45765549|NCT05585229|Drug|Psilocybin-assisted Psychotherapy|Participants will complete a 6-week structured psychotherapeutic intervention involving administration of 25mg PEX010 on two separate occasions.
45765550|NCT02991898|Biological|Infusion of Treg|"Allopurinol on day -7 to day 0 Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 Fludarabine 30mg/m2 IV over 1 hour on day -6, -5, -4, -3, and -2 Total Body Irradiation 200 cGy as a single dose~Sirolimus 8mg-12mg oral loading dose followed by single dose 4mg/day. Levels are to be monitored 3 times/week in the first week, weekly until day +60, and as clinically indicated until day +100 post-transplantation.~Mycophenolate Mofetil (MMF) 3 gram/day IV/PO divided in 2 or 3 doses. Stop MMF at day +30 or 7 days after neutrophil recovery, whichever day is later, if no acute GVHD.~DUCBT followed Tregs - double umbilical cord blood transplant (FIRST) followed by the Treg cell infusion (SECOND) no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion."
45765551|NCT05195541|Drug|CU-20401|Subcutaneous injection in the subcutaneous fat area，0.2ml
45765552|NCT04361435|Procedure|Chest physiotherapy using a non-invasive oscillating device|NIOD will be implemented on four different parts of the chest walls, 3 minutes for each part and 12 minutes in total per each session. Left and right front and posterior chest walls will be stimulated, particularly, on the anterior chest, intercostal spaces 1-2 above nipple line and lateral side of the mid-clavicular line 1-2 below intercostal spaces. The intensity of the NIOD can be selected between 80-100%, which is pre-specified on the machine.
45446843|NCT05571098|Behavioral|individualized colorectal cancer education|"Subjects taught within the scope of individualized colorectal cancer education:~Common symptoms and management related to disease and treatment,~Importance of nutrition in the treatment process."
45446844|NCT05571098|Behavioral|psycho-oncological counseling|"Topics discussed within the scope of psycho-oncological counseling:~Psychological state (anxiety, depression, etc.),~Coping strategies about the process,~Presence of fear about the disease and/or treatment,~Lifestyle changes/problems,~Changes in body image,~Family/friendship/work-related concerns,~Additional issues, comments he wishes to convey"
45623778|NCT03251261|Device|illumigene CMV assay, illumipro-10|CMV assay for detection of CMV
45623779|NCT02455271|Drug|Eszopiclone|The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
45623780|NCT04964661|Other|Medical Imaging|MRI imaging
45623781|NCT03251339|Drug|MSB11455|Participants received a single subcutaneous injection of MSB11455 6 milligram (mg) per (/) 0.6 milliliter (mL) on Day 1 in morning of treatment period 1 (28 Days) and 2 (28 Days). Period 1 and Period 2 are separated by a washout period of 35 Days.
45623782|NCT03251339|Drug|US-Neulasta|Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a washout period of 35 Days.
45623783|NCT04961853|Radiation|Ultrasound and MRI|Ultrasound examination and magnetic resonance imaging on the hand
45765553|NCT05584995|Procedure|Control group|Women will undergo normal cesarean section without Postpartum Hemorrhage or Idiopathic pulmonary hemosiderosis (IPH)
45765554|NCT05584995|Procedure|BUAL group|"Bilateral Uterine Artery Ligation Technique:~All uterine surgeries will be conducted by externalizing the uterus as much as possible and holding it by the fundus. The BUAL will be done using absorbable suture no. 1 Vicryl (Vicryl 1, Ethicon, France, Neuvilly-sur-Seine, France) will be placed through an avascular space in the broad ligament and tied from the anterior to posterior aspects of the myometrium 2-3 cm medial to the descending portion of the uterine vessels. In all patients, the suture will be carried from the anterior to the posterior at 1 cm to the myometrium medial to the Uterine artery and will be knotted after passing it through the avascular region at 1 cm to the wide ligament section adjacent to the uterus in both sides. All patients will be examined for uterotonics during and after the surgery. The ovarian arteries will be assessed at the level of the ovarian hilum."
45623784|NCT04964583|Drug|Hydroxychloroquine with Azithromycin|Fixed combination of Hydroxychloroquine with Azithromycin 200 mg / 250 mg one tablet every 12 hours for five days and continue with Hydroxychloroquine 200 mg one tablet every 12 hours for 5 more days.
45623785|NCT03251417|Drug|Irinotecan|Irinotecan 150mg/m2, repeated very 2 weeks for 3 to 6 cycles.
45623786|NCT03251417|Drug|Apatinib|Apatinib 500 mg oral take, daily
45765555|NCT02881840|Drug|14C-APD421|
45765556|NCT05583201|Biological|KD-496|Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells
45623787|NCT04426773|Device|High-Definition transcranial direct current stimulation|The tDCS device will deliver a direct current of 1.5mA for 20 minutes. Cathode electrode will be localized in front of the OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8).
45623788|NCT03251573|Other|cognitive impairment|one are of patients were exposed to cognitive impairment
45623789|NCT04961931|Drug|Empagliflozin 10 MG|After qualifying for the study all subjects received oral empagliflozin 10 mg once daily for 7 days.
45623790|NCT03251105|Device|supraglottic airway intubation|
45623791|NCT04952181|Device|optical biometry|optical biometry is a fast, noncontact method it uses the method of partial coherence interferometry (PCI) to measure the axial length (AXL), based on reflection of the interference signal of the retinal pigment epithelium.
45623792|NCT04952181|Device|ultrasonic biometry|ultrasonic biometry is contact method depends on ultrasonic transducer producing thin sound beam travelling through different media of the eye when it faces interface of substance dissimilar from that it is travelling through part is reflecting and the other travel through the different substance
45623793|NCT02454881|Drug|Dexmedetomidine|
45623794|NCT02454881|Drug|Oxycodone|
45623795|NCT04431687|Drug|CKD 501|QD, PO
45623796|NCT04431687|Drug|D759, D150|QD, PO
45623797|NCT04431687|Drug|CKD-501, D759, D150|QD, PO
45446845|NCT05571098|Behavioral|telephone support hotline service|Within the scope of the NNP, a telephone support hotline service was provided to the participants, where they could consult at any time about the subject they wanted.
45623798|NCT02455037|Other|Neck Strengthening|Targeted neck strengthening exercises
45623799|NCT03058341|Drug|propofol|Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.
45623800|NCT03058341|Drug|Sevoflurane|Propofol 1.5-3mg/kg, remifentanil 0.5-1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously (IV) for induction of general anaesthesia. Otrivin can be applied nasally at the discretion of the anaesthetist. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to keep a BIS value of 40-60. Intravenous remifentanil infusion between 0.1-0.25mcg/kg/min will be given and this will be titrated to optimal haemodynamic parameters. Muscle relaxants can be given during the operation as required.
45765557|NCT04367597|Device|Home-based Neuromuscular Electrical Stimulation (NMES) therapy|A home-based NMES treatment applied by the subjects daily
45765558|NCT05582499|Drug|Dalpiciclib|an oral cyclin-dependent kinases (CDK) 4/6 inhibitor
45765559|NCT05582499|Drug|Pyrotinib|an irreversible dual pan-erbb receptor tyrosine kinase receptor tyrosine kinase (ERBB) inhibitor
45765560|NCT05582499|Drug|SHR-A1811|an anti-HER2 antibody-drug conjugate (ADC)
45765561|NCT05582499|Drug|SHR-1316|an anti-programmed death ligand 1 (PD-L1) antibody
45765562|NCT05582499|Drug|Camrelizumab|an anti-programmed death-1 (PD1) antibody
45446846|NCT02093572|Other|3 standard meals/day|
45623801|NCT03250949|Procedure|implant site over drilling protocol|"Osteotomy preparations for the loose fit group will be identical to those of the tight fit group until final drill, which will be 0.2mm wider than the diameter of the implant.~osteotomy site of the implant is wider by 0.2mm than the implant diameter"
45446847|NCT02093572|Other|2 meals/day (omit breakfast)|
45446848|NCT02093650|Drug|black cohosh extract|Black cohosh extract 80 mg
45765563|NCT05582499|Drug|Trophoblast cell-surface antigen 2 (TROP2) ADC|anti-TROP2 ADC
45765564|NCT05582499|Drug|Pertuzumab|Pertuzumab
45765565|NCT05582499|Drug|Trastuzumab|Trastuzumab
45765566|NCT05582499|Drug|Goserelin|goserelin
45765567|NCT05582499|Drug|Letrozole|letrozole
45765568|NCT05582499|Drug|Nab paclitaxel|Albumin paclitaxel
45765569|NCT05582499|Drug|Carboplatin|Carboplatin
45765570|NCT05582499|Drug|Epirubicin|Epirubicin
45765571|NCT05582499|Drug|Cyclophosphamide|Cyclophosphamide
45765572|NCT05582499|Drug|Fluzoparib|an original poly adenosine diphosphate-ribose polymerase (PARP) inhibitor
45765573|NCT05582499|Drug|HER2 ADC|anti-HER2 ADC
45765574|NCT02881996|Drug|IV tylenol|IV tylenol given scheduled in addition to standard PCA
45765575|NCT02881996|Drug|No IV tylenol|No additional IV Tylenol given
45623802|NCT03058575|Dietary Supplement|Dietary MACs|"All subjects will have a dose-escalation period when randomized to the active arm that will occur as follows:~Day 1: 1 scoop of product (morning, in the clinic)~Day 2: 1 scoop of product (morning)~Day 3: 2 scoops of product (morning and evening)~Day 4: 2 scoops of product (morning and evening)~Days 5-60: 3 scoops of product (morning, afternoon, evening)~Other Names:~Dietary fiber supplement"
45623803|NCT03058575|Other|Control|No Intervention for 8 weeks
45623804|NCT03250871|Other|Hypnosis|Hypnosis will be supervised by a nurse trained by the French Institute of Hypnosis.
45623805|NCT03250871|Other|Placebo|Placebo consists in non-hypnotic relaxation suggestions and in hearing white noise through headphones
45623806|NCT03058497|Device|Temperature-Controlled Laminar Airflow Device (Airsonett®)|
45623807|NCT03250793|Device|Physiologic study measuring work of breathing which can be estimated by the esophageal and trans-diaphragmatic pressure-time product obtained by an esophageal transducer|While the patient is under respiratory assistance on the SERVO-I respirator, he will be included in the study and one esophageal transducer of 2,3 mm of diameter will be inserted through the mouth / nose in addition to NAVA's naso / Oro-Gastric tube( Edi Catheter, 6Fr, 49 cm, PHT free 5 pcs / pkg or Catheter Edi, 6Fr, 50 cm, PHT free 5 pcs / pkg). Measurements will be performed using the esophageal transducer under two conditions: 2 hours in conventional ventilation (pressure controlled), 2 hours in NAVA ventilation and then again 2 hours in conventional ventilation (PC) for a total duration of 6 hours.The parameters of conventional ventilation will be left free at the choice of the neonatologist and will be identical between the two periods of conventional ventilation. The initial NAVA level will be defined by the neonatologist using pre-visualization curves. All signals will be recorded via an amplification and acquisition system. Values will be averaged over 100 cycles.
45623808|NCT04961463|Behavioral|psychoeducation|
45623809|NCT03250559|Procedure|Percutaneous nephrolithotomy|Endoscopic kidney stone extraction technique.
45623810|NCT04961385|Biological|Immunogenicity after first dose of participants who received first dose of ChAdox-1 n COV-19 vaccine|Blood samples were taken from the vaccinated participants for antibody testing against SARS-CoV-2
45623811|NCT04944459|Device|Muse-S headband; InteraXon Inc., RRID:SCR_014418|"Muse-S is used as a technology-supported Mindfulness Training (tsMT) device as a way to introduce meditation as a method for managing chronic pain in individuals as it facilitates the learning process, requires minimal training to use and provides mechanisms to enhance compliance and track progress. The availability of direct feedback data from Muse-S may encourage the participant to perform meditation sessions and may increase time spent in the calm brain state."
45623812|NCT04952025|Diagnostic Test|Diagnostic criteria|Diagnostic criteria of ALS
45623813|NCT04951791|Drug|SMOFlipid|will receive intravenous infusion of 2ml\kg of smoflipid 20%, in the internal jugular vein 10 minutes before removal of aortic cross clamp in a constant speed
45765576|NCT02881996|Drug|Ketorolac|both groups receive as part of our standard postop pain protocol after all operations
45446849|NCT02093650|Drug|Placebo|Soy bean oil
45446850|NCT02808572|Biological|Plasma osteoprotegerin level|dosage of plasma osteoprotegerin
45446851|NCT02808572|Biological|Plasma fibroblast growth factor 23 level|dosage of plasma fibroblast growth factor 23
45623814|NCT04951791|Other|Normal saline 0.9%|will receive intravenous infusion of 2ml\kg of normal saline 0.9%, in the internal jugular vein 10 minutes before removal of aortic cross clamp in a constant speed.
45623815|NCT04951713|Drug|XZP-3287 combined with clarithromycin|Drug: XZP-3287, oral, 120 mg once daily for day 1 and day 12 Drug: clarithromycin, oral, 500 mg twice daily for day 8 to day 21
45623816|NCT04951713|Drug|XZP-3287 combined with rifampicin|Drug: XZP-3287, oral, 360 mg once daily for day 1 and day 14 Drug: rifampicin, oral, 600 mg once daily for day 8 to day 19
45765577|NCT04367831|Drug|Enoxaparin Prophylactic Dose|"Prophylactic dose anticoagulation (per Columbia University Irving Medical Center (CUIMC) Guidelines):~If eGFR ≥30 mL/min (stable kidney function):~BMI < 40 kg/m2: Enoxaparin 40 mg SC daily~BMI 40 - 50 kg/m2: Enoxaparin 40 mg SC q12h~BMI > 50 kg/m2: Enoxaparin 60 mg SC q12h"
45765578|NCT04367831|Drug|Heparin Infusion|Unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1 -0.3U/mL.
45446852|NCT02808572|Procedure|Vascular calcification score|measurement of vascular calcification score by multidetection computerized tomography
45765579|NCT04367831|Drug|Heparin SC|Unfractionated heparin at 5000-7500 units subcutaneous (SC) every 8 hours.
45765580|NCT04367831|Drug|Enoxaparin/Lovenox Intermediate Dose|If estimated glomerular filtration rate (eGFR) ≥ 30 mL/min: enoxaparin 1mg/kg subcutaneous (SC) daily.
45765581|NCT02243891|Procedure|Atrial fibrillation ablation|Percutaneous catheter ablation for Atrial fibrillation.
45446853|NCT02093728|Drug|selumetinib|Volunteers will recieve single oral dose of 25mg selumetinib in sequence 1, treatment A
45446854|NCT02093728|Drug|itraconazole|Volunteers will receive oral doses of itraconazole 200 mg twice daily on Day 1 to Day 7 in sequence 1 treatment B:
45446855|NCT02093728|Drug|itraconazole|Volunteers will recieve a single morning dose of 200mg itraconazole on Day 8 and twice daily doses of 200mg itraconazole on Day 8 to Day 11; sequence 1 treatment C.
45446856|NCT02093728|Drug|selumetinib|Volunteers willl recieve a single oral dose of 25 mg selumetinib (4 hours fasted state) on Day 8; sequence 1 treatment C.
45446857|NCT02093728|Drug|selumetinib|Volunteers will recieve single oral dose of 25mg selumetinib in sequence 2, treatment A.
45446858|NCT02093728|Drug|fluconazole|Volunteers will recieve a single dose of 400 mg fluconazole on Day 1 and daily doses of 200 mg fluconazole on Day 2 to Day 7; sequence 2 treatment D.
45446859|NCT02093728|Drug|fluconazole|Volunteers will receive a morning dose of 200mg fluconazole on Day 8 and daily doses of 200mg fluconazole on Day 8 to Day 11; sequence 2 treatment E
45446860|NCT02093728|Drug|selumetinib|Volunteers will receive a single dose of 25mg selumetinib (4 hours fasted state) on Day 8; sequence 2 treatment E
45446861|NCT03692871|Biological|V114|V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
45765582|NCT02243891|Procedure|ROX Coupler insertion|The ROX Coupler is a CE-marked device designed to maintain an iliac arteriovenous fistula
45623817|NCT04944225|Other|Opiod Reduction Strategy|The intervention will involve a multi-faceted 3 component approach involving 1) opioid prescription caps (default maximum number of tablets for discharge prescriptions, as defined by evidence-based guidelines) 2) patient education tools (e.g. What is a normal pain trajectory? How to manage the pain? Benefits and potential harms of pharmacologic analgesia. Non-pharmacologic analgesia management? What to do if pain is excessive?), 3) provider education tools (e.g. including procedure-specific evidence-based recommendations for multi-modal analgesia; comparison of local baseline prescribing patterns with exemplary prescribing patterns; defining targeted reduction if baseline prescribing is at odds with best evidence; review of best evidence about optimal analgesia perioperatively), and 4) bi-weekly cumulative prescriber feedback on opioid prescribing patterns post-intervention and until end-of-study.
45623818|NCT04951557|Procedure|Transsphenoidal resection|Transsphenoidal resection of pituitary adenoma
45623819|NCT04944303|Drug|Sugammadex|Sugammadex is a modified γ-cyclodextrin designed selectively to reverse the effects of the neuromuscular blocking agents (NMBAs) rocuronium and vecuronium
45623820|NCT04944303|Drug|Normal saline|Equal doseage of normal saline was injected to reverse the NMB.
45623821|NCT04944069|Drug|Almonertinib|110 mg oral once daily
45623822|NCT04944069|Drug|Bevacizumab|15 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks)
45623823|NCT04951167|Drug|Norepinephrine|in the form of infusion
45623824|NCT04951167|Drug|Norepinephrine|in the form of bolus
45623825|NCT04950933|Drug|Huolingshengji Granules|1 bag of Huolingshengji Granules each time + 1 tablet of Riluzole tablet simulation agent each time, twice a day, orally;
45623826|NCT04950933|Drug|Riluzole tablet|Huolingshengji granules simulation agent 1 bag each time + Riluzole tablet 1 tablet each time, 2 times a day, orally.
45623827|NCT04951011|Diagnostic Test|Serum beta HCG|Raising numbers of S BHCG or decreasing with different management of tubal Ectopic Pregnancy
45623828|NCT04961307|Drug|Trastuzumab|30 female breast cancer patients using trastuzumab, collected demographic and clinical information of all patients before chemotherapy, performed echocardiography (conventional echocardiography, three-dimensional spot tracking technology), and collected blood samples to detect plasma biology Markers (TnT, BNP, GDF-15, topoisomerase
45623829|NCT04961229|Biological|The Pfizer mRNA-based BNT162b2 vaccine|"participants who gave informed consent to participate in either the prospective non-randomised study or RCT will receive a single vaccine dose.~In addition, participants in the RCT will be randomised into two groups:~Third booster dose of BNT162b2 (one standard dose) with no change in immunosuppression protocol~Third booster dose of BNT162b2 (one standard dose) with immunosuppression reduction according to protocol (mycophenolic temporary cessation 4 days before (5 half-lives) and one week (expected antibody response) after vaccination (to allow for antibody response)."
45623830|NCT04943835|Other|Observational - No intervention|
45623831|NCT04943991|Diagnostic Test|blood sampling (alpha-Galactosidase & LysoGb3)|"A blood sample will be taken. Alpha-Galactosidase level and LysoGb3 will be measured.~Amendment: Offering of genetic testing for fabry specific GLA-gene"
45623832|NCT04942977|Device|telemonitoring|"The system consists of the following elements:~Professional website at the hospital, which allows:~To set up an individualised care plan~To establish the patient's risk profile and targets for improvement.~Long-term monitoring of the evolution of cardiovascular risk factors and events that occurred~Advise the patient on self-management strategies.~Mobile application software with the following functions:~Scheduled exercise sessions~Medication reminder~Measurement reminder (weight, blood pressure, heart rate, waist circumference, etc.)~Messages: Inbox folder for system messages and messages generated by professionals for a specific patient or video conference.~Training monitor: guides the patient in the performance of their exercise.~Access to certified health information for patients"
45623833|NCT04942977|Other|Centre-based cardiac rehabilitation|The physical activity consisted of a workout routine and aerobic cycling training. Patients are instructed to perform 150 minutes per week of moderate physical activity when the hospital phase finishes.
45765583|NCT03051646|Drug|Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit|650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise; Placebo oral capsule is administered one hour prior to exercise
45623834|NCT04960839|Radiation|Prophylactic contralateral breast irradiation|The whole contralateral breast will be irradiated once daily, 5 days a week, for 5-6 weeks, using 1.8-2 Gy/fx to a total dose of 45-50 Gy.
45623835|NCT04950699|Genetic|Single-nucleotide Polymorphism of genes related with Dyslipidemia|This study is an observational study to study the effect of different genotypes on the incidence of myocardial infarction
45623836|NCT04950387|Other|Breathing exercises|Based in yoga, common load
45623837|NCT04943055|Procedure|Low temperature plasma lacrimal duct obstruction ablation combined with lacrimal duct catheterization|The operation used a tear point dilator to expand the patient's upper and lower tear points, YAG laser/low-temperature plasma knife was used to clear the obstructed site of the patient, and normal saline was used to rinse to ensure the patency of the lacrimal passage. The silicone lacrimal duct drainage tube was selected to put the lacrimal duct drainage tube in the upper and lower lacrimal dots of the patient, and the metal probe was removed after using a crochet, and the drainage tube was moderately pulled upward from the center of the upper and lower lacrimal dots to facilitate the smooth passage of the drainage tube through the whole lacrimal duct and achieve the purpose of dredging the blocked site again. Adjust the length of the drainage tube in the nasal vestibule and leave it in the nasal cavity.
45765584|NCT03051646|Drug|Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit|Placebo oral capsule is administered one hour prior to exercise; 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise
45765585|NCT03831477|Device|Venus Viva|The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
45765586|NCT02243969|Dietary Supplement|Flaxseed oil|The flaxseed oil will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
45623838|NCT04943055|Procedure|YAG lacrimal duct laser combined with lacrimal duct catheter|The operation used a tear point dilator to expand the patient's upper and lower tear points, YAG laser/low-temperature plasma knife was used to clear the obstructed site of the patient, and normal saline was used to rinse to ensure the patency of the lacrimal passage. The silicone lacrimal duct drainage tube was selected to put the lacrimal duct drainage tube in the upper and lower lacrimal dots of the patient, and the metal probe was removed after using a crochet, and the drainage tube was moderately pulled upward from the center of the upper and lower lacrimal dots to facilitate the smooth passage of the drainage tube through the whole lacrimal duct and achieve the purpose of dredging the blocked site again. Adjust the length of the drainage tube in the nasal vestibule and leave it in the nasal cavity.
45623839|NCT04943133|Device|Blood pressure measurement and collection of the oscillometric curve for later SFATI analysis|Brachial systolic arterial blood pressure will be systematically taken with acquisition of the oscillometric curve for analysis and measurement with the SFATI system and simultaneous electronic recording of the Korotkoff sound (auscultatory method) and a search for SFATI arterial stiffness markers for all patients. Brachial systolic arterial blood pressure will be measured with the help of a cuff equipped with a Biopac SS30L electronic stethoscope and a MA-300 phonocardiographic microphone, placed side-by-side immediately downstream from the brachial occlusion cuff. The various signals (pneumatic cuff, oscillometric signal and Korotkoff sounds) will be digitalized by an MP35 system.
45623840|NCT04943133|Device|Blood pressure measurement with the usual equipment used in the department|Brachial systolic blood pressure will be taken via the conventional oscillometric method, only for hospitalized women. Blood pressure will be measured on the same arm with the help of a conventional Dinamap-type automat (GE), with at least 2 minutes between the end of the first measurement and the start of the second inflation.
45623841|NCT04943133|Device|systematic measurement of pulse wave velocity (aortic and brachial)|"Carotid to femoral and carotid to radial pulse wave velocity (Complior) will be systematically determined for hospitalized women and offered to all women seen for consultation.~Pulse wave velocity will be measured with the help of a Complior tonometric system (Alam Medical, Vincennes, France), with which the aorta and the arterial axes of the upper limb used to measure blood pressure can also be measured."
45623842|NCT03058263|Drug|Dose of Neostigmine|Subjects were given partial dose of neostigmine as rocuronium reversal after the surgery had finished; subjects were given TOF ratio-based dose of neostigmine after the surgery had finished
45623843|NCT04942821|Procedure|Platelet rich fibrin and coronally advanced flap|CAF were used in treatment arms. Root planning was performed on the exposed part of roots to provide more biocompatible surface for re-attachment. Two 10 cc tubes with clot activator were used to collect blood from the patient; blood was centrifuged at 2700 rpm for 12 min. PRF box was used to form fibrin clots into membranes. PRF was positioned at the level of the cemento-enamel junction (CEJ), and sutured on the periosteum bed with 6/0 absorbable sutures. Gingival margins on the flap were placed at least 1 mm coronally of the CEJ and sutured with 5/0 absorbable sutures. Sutures were removed at 2nd week.
45623844|NCT04942821|Procedure|Connective tissue graft and coronally advanced flap|Control sites were treated by coronally advanced flap (CAF) combined with connective tissue graft (CTG). CAF were used in both treatment arms. Root planning was performed on the exposed part of roots to provide more biocompatible surface for re-attachment. CTG was obtained with single incision method. CTG was positioned at the level of the cemento-enamel junction (CEJ), and sutured on the periosteum bed with 6/0 absorbable sutures. Gingival margins on the flap were placed at least 1 mm coronally of the CEJ and sutured with 5/0 absorbable sutures. Sutures were removed at 2nd week.
45623845|NCT04416321|Device|Surgery with the Keos Lumbar Interbody Fusion Device|All subjects will received the Keos Lumbar Interbody Fusion Device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease, spondylolisthesis and retrolisthesis
45623846|NCT04415853|Drug|Lerotinib|Specification: 50 mg/capsule and 150 mg/capsule
45623847|NCT04415853|Drug|Irinotecan/Tegafur|Irinotecan:Specification: 2mL: 40mg;5mL:0.1g Tegafur:20mg/capsule
45623848|NCT04415151|Drug|Tofacitinib 10 mg|Tofacitinib will be administered in a dose of 10 mg twice daily by mouth (PO BID) until return to their clinical baseline (as defined by supplementary oxygen requirement), and then will continue to be administered at 5 mg PO BID for a total treatment duration of 14 days.
45623849|NCT04415151|Drug|Placebo|Matching placebo tablets will be administered.
45623850|NCT04942743|Diagnostic Test|MRI|MRI OF TMJ
45623851|NCT04949997|Other|diagnose|HF was divided into HF with preserved ejection fraction, HF with median ejection fraction and HF with reduced ejection fraction.
45623852|NCT04950231|Other|The questionnaire survey|Questionnaires were issued and collected by 6 competent nurses with strict training, data entry by 2 researchers, statistical analysis by 1 researcher, and quality control by the other 2 researchers throughout the process.
45623853|NCT04960761|Other|İntervention Group|"In the experimental group, pre-operative anxiety and quality of life scales will be applied to the child and their parents before and after the operation with audio and picture books, the preoperative quality of life scale will be made, the postoperative anxiety and quality of life scale will be repeated and the early mobilization scale will be made.~The control group will be routinely informed before the operation, an anxiety scale will be given to the child and their parents before the operation, a quality of life scale will be given to the child, the postoperative anxiety and quality of life scale will be repeated, and early mobilization form will be applied."
45623854|NCT04960605|Procedure|Dental implants|Treatment of the toothless regions with dental implants
45623855|NCT03059277|Drug|Intravitreal Aflibercept|Intravitreal Aflibercept 2mg
45623856|NCT04942509|Behavioral|Coloring as a brief mindfulness-based intervention|Participants watched an instructional video on mindful coloring at the beginning of the intervention and colored mindfully for at least 5 days or 100 minutes in total during a 10-day period. The intervention included a coloring booklet that contained mandala patterns for coloring.
45446862|NCT03692871|Biological|Prevnar 13™|Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 ml dose
45446863|NCT02089204|Radiation|FMISO-PET/CT|Fluorine-18-labeled fluoromisonidazole PET/CT-guided dose escalation chemoradiotherapy (group C). Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.
45765587|NCT02243969|Dietary Supplement|high oleic sunflower oil (HOSF)|The HOSF will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
45765588|NCT03110458|Drug|SENS-111 100mg|SENS-111 100mg is presented as 1 Oral Dispersible Tablet of SENS-111 100mg + 1 Oral Dispersible Tablet of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 500 mg for the entire study.
45623857|NCT04949763|Other|rehabilitation|Patients underwent ususal rehabilitation treatment
45765589|NCT03110458|Drug|SENS-111 200mg|SENS-111 200mg is presented as 2 Oral Dispersible Tablet of SENS-111 100mg given twice on Day 1,second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 1000 mg for the entire study.
45623858|NCT04942587|Behavioral|LISTENING TO THE RECORDINGS SAYING BY PARENTS|The baby was made listen to the lullaby recorded in the voice of parents starting with, during and after the care for 10 minutes.
45765590|NCT03110458|Drug|Placebo Oral Tablet|Placebo is presented as 2 Oral Dispersible Tablets of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 0 mg for the entire study.
45623859|NCT04942431|Behavioral|Rebirth active SCHOOL 2.0 movement program|60 Minutes of physical activity per day integrated in every school-day.
45623860|NCT04942119|Other|Multifactorial intervention|"Correction of magnesium and/or potassium deficit and the underlying disease.~Education reinforcing optimal diet and exercise, in addition to, post-nutrition assessment , diabetes self-care activities and adherence will be given at each follow up visit by a specialized dietitian.~Comprehensive medication therapy management by clinical pharmacist, and medication adherence will be measured by adherence questionnaire as well as fixed medication possession ratio (FMPR)."
45623861|NCT04949451|Dietary Supplement|Whey protein supplement|Participants consume whey protein at the beginning of the eating period.
45623862|NCT04949451|Dietary Supplement|Ketogenic aid|Participants consume ketogenic aid upon waking.
45623863|NCT04949451|Other|Control group - time restricted feeding only|Time restricted feeding.
45623864|NCT04942197|Other|use pregnancy management application|Pregnant women who used pregnancy management application, which tells patients what she need to know during pregnancy, when to perform tests, and what precautions to take for your baby.
45623865|NCT04949217|Procedure|Inlay Bristow|A modified Bristow procedure
45623866|NCT04949217|Procedure|Bristow|Traditional Bristow procedure
45623867|NCT04960449|Procedure|shoulder arthroscopy|Patients underwent ubacromial bursectomy and acromioplasty , cuff debridement and cuff repair, side to side suture of rotator cuff combined with suture anchor.
45623868|NCT04410393|Procedure|vaginal cuff prolapse surgery|Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes
45765591|NCT04361357|Other|whey protein|whey protein powder was added on the basis of standardized enteral nutrition preparation.
45765592|NCT04344405|Drug|Vitamin D|vitamin D supplementation
45765593|NCT04344405|Drug|Steroid Drug|control
45765594|NCT05187429|Drug|Nivolumab 10 MG/ML [Opdivo]|Cohort A: Dose escalation phase: Nivolumab will be administered intravenously as a single dose in the dose escalation phase.
45765595|NCT05187429|Drug|Nivolumab 10 MG/ML [Opdivo]|Cohort B: Randomisation phase: Nivolumab will be administered intravenously as a fixed single dose in the randomisation phase.
45765596|NCT05187429|Drug|Saline|Cohort B: Randomisation phase: Saline will be administered intravenously as a single dose in the randomisation arm.
45765597|NCT02993302|Drug|1α-D3|patients were given PTU and 1α-D3
45623869|NCT04960527|Dietary Supplement|Tart cherry juice|250 mL tart cherry juice (30 mL tart cherry concentrate [CherryActive, UK] diluted with 220 mL water) is consumed on a single occasion by each participant. This will be consumed immediately following the baseline measurements one laboratory visit.
45765598|NCT02993302|Drug|Placebos|patients were given PTU and placebos
45765599|NCT05419869|Drug|ALTO-100 PO Tablet|Two tablets daily
45452393|NCT05628454|Procedure|Endobronchial ultrasound-guided transbronchial needle aspiration|The operation steps are the same as above, but the negative pressure device of 10ml syringe is connected behind the puncture needle.
45623870|NCT04960527|Other|Water|250 mL water is consumed on a single occasion by each participant. This will be consumed immediately following the baseline measurements one laboratory visit.
45623871|NCT04948593|Procedure|Native kidney biopsy|
45623872|NCT00700817|Drug|liraglutide|1.2 mg once daily, subcutaneous (under the skin) injection
45623873|NCT00700817|Drug|sitagliptin|Tablets, 100 mg daily
45623874|NCT00700817|Drug|metformin|Tablets, minimum 1500 mg daily
45765600|NCT03052972|Drug|Flortaucipir F18|370 megabecquerel (MBq)(10 millicurie [mCi]) single dose
45765601|NCT03052972|Procedure|Brain PET scan|positron emission tomography (PET) scan of the brain
45623875|NCT00700817|Drug|liraglutide|1.8 mg once daily, subcutaneous (under the skin) injection
45623876|NCT04960293|Procedure|uterine artery embolization using spherical gelfoam|Uterine artery embolization is performed using spherical gelfoam. All other processes are same.
45623877|NCT04960293|Procedure|uterine artery embolization using tri-acryl gelatin microsphere|Uterine artery embolization is performed using tris-acryl gelatin microsphere. All other processes are same.
45765602|NCT00359853|Drug|Oral norfloxacin|
45765603|NCT02994238|Device|Remote Health Management Sensor Platform|The Propeller sensor monitors the use of inhaled medications, capturing the date, time, and number of uses. The sensor then transmits this information using Bluetooth to a paired smart phone or hub. Data can be uploaded to the caregiver's smart phone and to the patient's web portal, which their healthcare team will have access to help overall management.
45765604|NCT05181189|Drug|DAOIB+Omega-3|The omega-3 fatty acids dose will be adjusted every 8 weeks according to clinical evaluation.
45765605|NCT05181189|Drug|DAOIB+Placebo|Placebo
45765606|NCT02244203|Drug|BI 60732|
45765607|NCT02244203|Drug|Placebo|
45623878|NCT04941495|Other|conventional physiotherapy|"TENS for 15 minutes on Constant Mode according to patient comfort.~Infrared for 15 minutes.~Isometric exercises: Isometric neck flexion, extension, side bending exercises were given. 3 sets of 10 repetitions each were given. And resistance was given for 6-8 seconds for each movement.~Stretching exercises: Passive stretching for Sternocleidomastoid, short sub occipital muscles, Trapezius & Scalene, Pectoralis Major was given. 3 sets of 10 reps were given and each stretch was maintained for 10 seconds.~Home Plan: self stretches and isometrics.~Postural Education: posture correction in daily life activities in sitting, walking, lying."
45765608|NCT05168709|Biological|Tozinameran|Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
45623879|NCT04941495|Other|Cervical proprioceptive training|"TENS for 15 minutes on Constant Mode according to patient comfort.~Infrared for 15 minutes.~Isometric exercises: Isometric neck flexion, extension, side bending exercises were given. 3 sets of 10 repetitions each were given. And resistance was given for 6-8 seconds for each movement.~Stretching exercises: Passive stretching for Sternocleidomastoid, short sub occipital muscles, Trapezius & Scalene, Pectoralis Major was given. 3 sets of 10 reps were given and each stretch was maintained for 10 seconds.~Home Plan: self stretches and isometrics.~Postural Education: posture correction in daily life activities in sitting, walking, lying.~The patients wearing a cap with a laser pointer attached to it were seated three feet away from the target A, B and C. Start Chart A with a 3 cm, chart B 2cm and chart C 1cm narrow pathway were presented to the patients. The time taken by the patient to complete the pathway without any error was noted."
45765609|NCT03110692|Behavioral|Default initiation|A default prescription template will be introduced in the palliative setting in order to reduce unnecessary daily image guided radiation.
45765610|NCT04367441|Drug|608|recombinant humanized anti-IL17A monoclonal antibody injection
45623880|NCT04941417|Drug|PD-1 inhibitor|Two to three cycles of neoadjuvant chemotherapy in combination with PD-(L)1 inhibitor will be administered before surgery, followed by another one to two cycles of neoadjuvant chemotherapy in combination with PD-(L)1 inhibitor and PD-(L)1 inhibitor monotherapy for up to 1 year.
45623881|NCT03058029|Device|Gelesis200|Subject would take Gelesis200 capsules 2 times per day.
45623882|NCT03058029|Device|Placebo|Subject would take placebo capsules 2 times per day.
45623883|NCT04948125|Drug|camrelizumab|200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.
45623884|NCT04948125|Drug|Apatinib Mesylate|250 mg qd
45623885|NCT04960137|Device|button plates fixation system|The button plates fixation system consists of fixing plate, prefabricated mix, button and fuse. In the process of use, the fuse plays the role of guiding the fixed plate through, pulling the button and shortening the distance between the button and the fixed plate. The prefabricated mix is pre-worn between the button and the fixed plate, and the lead pulls the distance between the fixed plate and the button after tightening and fixing. Prefabricated mix, make mix tight and knot. Finish the preliminary work of fixing.
45452394|NCT05628454|Procedure|Endobronchial ultrasound-guided transbronchial needle capillary sampling|The operation steps are the same as above, but there is no negative pressure device behind the puncture needle
45623886|NCT04960137|Device|Non-absorbable Suture Anchor|A conventional device used in surgery for shoulder dislocation.
45623887|NCT04410315|Other|Serum-lactate < 2,2 mmol/L|Bloodgas analysis every hour from start surgery until recovery ward discharge
45623888|NCT04410315|Other|Serum-lactate >/= 2,2 mmol/L|Bloodgas analysis every hour from start surgery until recovery ward discharge
45623889|NCT04960371|Diagnostic Test|coronary flow reserve (CFR)|Coronary flow velocity profiles in the left anterior descending artery were obtained using colour-guided pulse wave Doppler. We measured peak diastolic coronary flow velocity of the diastolic coronary waveform at rest and after ATP infusion (140 µg/kg. min) for 2 min. The CFR was calculated as the ratio of hyperaemic peak diastolic velocity to resting baseline diastolic velocity. All patients abstained from caffeine-containing drinks for at least 24h before testing.
45623890|NCT02455115|Other|Alternating mean arterial pressure|In normovolemic patients directly after liver transplantation, target mean arterial pressure is altered using norepinephrine according to study protocol.
45765611|NCT04367441|Drug|Placebo|auxiliary material of 608 include histidine, histidine hydrochloride, sucrose and polysorbate 80
45765612|NCT04367051|Drug|Withdrawal of Spironolactone|Other recommended medications for heart failure than spironolactone will be continued for withdrawal group.
45765613|NCT04367051|Drug|Continuation of spironolactone|Specific dose of spironolactone for continuation group is on each physician's discretion with acceptable range of 12.5 mg - 50 mg once or twice daily.
45765614|NCT04367363|Behavioral|Social media & news consumption|Daily reports of social media use and consumption, including reports on receiving and disseminating news articles related to the COVID-19 situation (e.g., how many messaging groups shared news on the outbreak, how many items related to the outbreak they forwarded to others, etc).
45765615|NCT03111316|Drug|Cervidil 10 MG Vaginal Insert|Dinoprostone vaginal insert is a thin, flat, polymeric slab which is rectangular in shape with rounded corners contained within the pouch of an off-white knitted polyester retrieval system, an integral part of which is a long tape. Each slab is buff colored, semitransparent and contains 10 mg of dinoprostone in a hydrogel insert. An integral part of the knitted polyester retrieval system is a long tape designed to aid retrieval at the end of the dosing interval or earlier if clinically indicated. The finished product is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
45623891|NCT02455115|Drug|Norepinephrine|Infusion rate of norepinephrine is raised and lowered, respectively, in order to reach MAP 60, 75 and 90 mmHg in patients already requiring vasopressor for adequate blood pressure control.
45765616|NCT03111316|Device|Foley Catheter|The balloon on the end of the Foley catheter will be inflated with 30 mL of sterile water, pulled back against the internal os of the cervix, and taped to the maternal thigh under minimal tension.
45765617|NCT04360733|Other|Blood draw|serial blood draw and subsequent deep immune phenotyping analysis, (ii.) immune activation assays, (iii.) transcriptome and (iv.) epigenome analysis in an overarching (v.) bioinformatics data analysis
45623892|NCT02455115|Drug|Chromium ethylenediaminetetraacetic acid|Extraction of 51Cr-EDTA measured for FF and GFR
45623893|NCT04948281|Other|no intervention|no intervention
45623894|NCT04940793|Device|POD FT|Cataract surgery
45623895|NCT03094247|Drug|Amoxicillin|All patients with severe acute malnutrition will receive a course of amoxicillin.
45623896|NCT03094247|Dietary Supplement|HO-RUTF|HO-RUTF: Milk, perilla oil, palm oil, white sugar, high oleic peanuts
45623897|NCT03094247|Dietary Supplement|D-HO-RUTF|D-HO-RUTF: DHA, milk, perilla oil, palm oil, white sugar, high oleic peanuts
45765618|NCT03833687|Device|Profhilo®|Profhilo® (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2.25 ml non-pyrogenic pre-filled syringe, containing 2 ml of 3.2% hyaluronic acid for intradermal use (32 mg H-HA + 32 mg L-HA dissolved in 2 ml of saline buffered sodium chloride.
45446864|NCT02089204|Radiation|FDG-PET/CT|18F-FDG PET/CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.
45623898|NCT03094247|Dietary Supplement|S-RUTF|S-RUTF: Milk, canola oil, palm oil, white sugar, standard peanuts
45623899|NCT04947891|Procedure|Intensive recovery management|Intensive recovery management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
45623900|NCT02904629|Behavioral|Respecting the Circle of Life (RCL)|"Intervention activities will consist of the delivery of RCL: an holistic sexual, reproductive health and teen pregnancy prevention curriculum. RCL was adapted in 2011 from an evidence-based intervention (EBI) for the prevention of HIV/AIDS called Focus on Youth (FOY) + Informed Parents and Children Together (ImPACT)."
45623901|NCT02904629|Other|Control Program|Control activities will consist of the delivery of educational lessons on nutrition, fitness, outdoor recreation, safety, environmental protection and nature.
45623902|NCT04947969|Device|laser acupuncture|This study will use German-made low-level laser pen (Al-Ga-As diode laser, 810nm, NIR, Physiolaser Olympic Basic, RJ laser). The parameters are power of 100mW, frequency of Bahr, apply on acupoint. Well will irradiate each point for 2 J. Each patient will receive this treatment six times for one week.
45446865|NCT02089204|Radiation|contrast-enhanced CT|contrast-enhanced CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy
45623903|NCT03250403|Drug|PRP injection|peri-neural injection of platelet rich plasma
45623904|NCT03250403|Other|traditional medical treatment|traditional medical treatment
45623905|NCT04947423|Drug|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel or Placebo
45765619|NCT03054844|Drug|Lidocaine|Lidocaine will be administered before administration of midazolam.
45765620|NCT03054844|Drug|Lidocaine and midazolam (PREMIX)|Lidocaine will be administered as a mixture with midazolam.
45765621|NCT03054844|Drug|Midazolam|Midazolam will be administered either after lidocaine, or as a mixture with lidocaine.
45765622|NCT04360967|Other|Standard Formula|Standard Formula
45623906|NCT04947423|Drug|Placebo|Subjects will self-administer DPI-386 Nasal Gel or Placebo
45623907|NCT03250481|Drug|Propofol|Sedation targeted to RASS -3-0 or RI 20-40
45623908|NCT03250715|Other|Low Level Laser Therapy|For application of the LLLT in the quadriceps muscle the patient will be in dorsal decubitus, with the legs extended and will be defined by the palpation of the muscle belts six points of application: two points in the distal region of the vastus medialis muscle, two points of the distal region of the vastus lateral muscle and two points of the central region of the rectus femoris muscle. For the application of LLLT in the gastrocnemius muscle the patient will remain in the supine position, but will be oriented to keep the hips and knees flexed at 90º and 45º respectively. Two application points will be defined, one in the lateral ventricle and the other in the medial ventricle, but both in the distal region of the muscle.
45446866|NCT03985592|Behavioral|Education|Intervention description provided in elaboration on arms of the study.
45446867|NCT02089282|Device|Ultrasound|
45446868|NCT02095990|Drug|Hydroquinone|
45623909|NCT04947267|Drug|3% Mepivacaine Hydrochloride|1.8 ml of 3% mepivacaine (3% Scandonest, Septodont) was administered to Group B patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
45623910|NCT04947267|Drug|2% Mepivacaine with 1:100,000 epinephrine|1.8 ml of 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special, Septodont) was administered to Group A patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
45623911|NCT03250637|Other|Observational|Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews
45446869|NCT02095990|Drug|Placebo|
45446870|NCT03557632|Behavioral|Virtual Reality Cue Exposure Therapy|As above.
45446871|NCT03557632|Behavioral|Relapse Prevention Drug Education|As above.
45446872|NCT02096068|Drug|Dexmedetomidine (Dexdor®)|Dexmedetomidine (Dexdor 100 micrograms/ml concentrate for solution for infusion)
45452395|NCT00906334|Drug|ON 01910.Na|The original dosing regimen was 800 mg/m^2 ON 01910.Na.
45765623|NCT04360967|Other|Nutrient-enriched Formula|Nutrient-enriched Formula
45765624|NCT05405595|Drug|ADG126|ADG126 and Pembrolizumab combination treatment both will be dosed until progressive disease (PD), intolerable toxicities, withdrawals of consent, or up to 35 cycles.
45623912|NCT04941885|Drug|Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI|Each participant receives Inetetamab plus cyclophosphamide metronomic chemotherapy plus AI.
45765625|NCT00359697|Drug|Hypertonic Saline, Mannitol|
45623913|NCT04423731|Drug|Folfirinox|Neoadjuvant chemotherapy is given according to different regimens, preferably FOLFIRINOX according to the recommendations in the national Norwegian guidelines. The choice of chemotherapy regimen is decided by the treating oncologist.
45623914|NCT03250091|Procedure|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for histopathological examination, including H.pylori detection
45623915|NCT03250091|Procedure|Plasma/serum sampling|Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination, serum biomarkers
45765626|NCT03111550|Device|Investigational Intraocular Lens Device #1: TECNIS Model ZHR00|Intraocular lens replaces the natural lens removed during cataract surgery.
45765627|NCT03111550|Device|Investigational Intraocular Lens Device #2: TECNIS Model ZQR00|Intraocular lens replaces the natural lens removed during cataract surgery.
45623916|NCT03250091|Procedure|Biopsies for gastric microbiota|During upper endoscopy biopsies for gastric microbiota analysis will be obtained
45765628|NCT03111550|Device|TECNIS Symfony® Extended Range of Vision Intraocular Lens: Model ZXR00|Intraocular lens replaces the natural lens removed during cataract surgery.
45765629|NCT05447013|Biological|Coronavirus-2-specific T cells|Coronavirus-2-specific T cells ex vivo expanded from selected COVID-19 recovered donors
45765630|NCT05447013|Other|standard of care (SOC)|standard of care (SOC)
45765631|NCT03111628|Drug|Omalizumab|omalizumab 300 mg every 4 weeks by subcutaneous injection
45765632|NCT00359775|Behavioral|Coping Skills Training|6 session behavioral program
45623917|NCT03250091|Procedure|Faecal sample acquisition|Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
45623918|NCT04959747|Other|acupuncture|"Body acupuncture will choose eight acupoints as Yingxiang (LI20),Shangxing (GV23), BiTong, Yintang, Hegu. Disposable acupuncture needle (0.25 mm in diameter and 25-30mm in length) are inserted at a depth of 10-25 mm obliquely into scalp acupuncture points (ShangXing, YinTang) and straightly into face/body acupuncture points (Yingxiang, BiTong, Hegu).~We will also deliver electro-acupuncture will be applied to the face points at fast and dispersed waves through electric needle stimulator which is provided by Chinese Medicine Clinic (ES-160 6-Channel Programmable electro-acupuncture) for 30 minutes."
45623919|NCT03249857|Behavioral|cognitive tasks + IQ + MINI|"Patients will perform different tasks:~cognitive tasks : reaction time (Alert TEA, Zimmermann and Fimm, 2005) + Edinburgh laterality questionnaire (Oldfield,1971) + hamilton and young's scale (Tohen et al., 2009) + Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) + experimental task (approach/ avoidance and affordance task).~Intelligence Quotient (IQ) test (PM38, Raven, 1960)~Mini International Neuropsychiatric Interview (MINI, Van Vliet et al., 2006)"
45623920|NCT03249857|Behavioral|cognitive tasks|Healthy volunteers will perform only the cognitive tasks = reaction time alert TEA, Zimmermann and Fimm, 2005 + Edinburgh laterality questionnaire (Oldfield, 1971) + experimental task (approach/ avoidance and affordance task).
45765633|NCT03111940|Procedure|Optimisation of the result of intracoronary stenting according to specific algorithm|
45765634|NCT05120505|Drug|Metformin|The patients in this group will be obtain Metformin starting from 50mg everyday at night, and gradually increase to maximum tolerable dose of 1-2g per day according to weights of patients for 6 months.
45765635|NCT05120505|Drug|Placebo|The patients in this group will be obtain starch tablets (which had same appearance and size comparing to Metformin) starting from 50mg everyday to 1-2g per day according to weights of patients for 6 months.
45765636|NCT05161065|Device|Cardiologs|Apple Watch recordings interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
45765637|NCT03113656|Other|Weighted Blanket|Weighted blanket placed on infant for 30 minutes
45765638|NCT03113656|Other|Non-Weighted Blanket|Non-Weighted blanket placed on infant for 30 minutes
45623921|NCT04959669|Other|DeSSBack|The DeSSBack (Decision Support System for Low Back Pain) is a decision support tool developed in the University of Malaya Medical Centre's (UMMC) electronic medical record system by adopting and re-packaging the STaRT system to suit the local context. It stratifies patients with low back pain to low, medium or high risk, which are then managed differently. The DeSSBack has also been incorporated the local clinical practice guidelines and feedback from local experts.
45765639|NCT05118711|Diagnostic Test|Cardiorespiratory fitness|Cardiopulmonary exercise testing
45765640|NCT05118711|Diagnostic Test|Lung function|Body plethysmography
45765641|NCT05118711|Diagnostic Test|Muscular strength and balance tests|Handgrip strength test, mid-thigh pull test and standing balance test in static tandem stance
45765642|NCT05118711|Diagnostic Test|Micro- and macrovascular endothelial function and cardiac function|Measurement of flow-mediated dilation, static and dynamic retinal vessel analysis, echocardiography
45765643|NCT05118711|Diagnostic Test|Blood sampling and analysis|Blood sampling by venepuncture
45765644|NCT05118711|Diagnostic Test|Physical activity|Physical activity surveillance using accelerometers
45765645|NCT05118711|Diagnostic Test|Questionnaires|Global physical activity questionnaire (GPAQ), short-form 8 health survey (SF-8), barriers to physical activity, fatigue assessment scale (FAS), modified medical research council dyspnea scale (mMRC), depression, anxiety, and stress scale (DASS21), post-COVID-19 syndrome symptoms
45765646|NCT05118711|Diagnostic Test|Body composition|Dual-energy x-ray absorptiometry (DXA)
45765647|NCT03114124|Device|MIFI Catheter|Multielectrode Catheter: standard ablation catheter that has the ability to record low and high frequency signals with high fidelity
45765648|NCT03114124|Device|Standard Ablation Catheter|Standard of care for patients with certain cardiac arrhythmias.
45765649|NCT02977533|Drug|GZ402668|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45765650|NCT02977533|Drug|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45765651|NCT02977533|Drug|Acyclovir|"Pharmaceutical form: tablet~Route of administration: oral"
45446873|NCT02096068|Drug|0.9% Sodium Chloride|Solution for infusion: Sodium Chloride : 9.0 g/l; Each ml contains 9 mg sodium chloride mmol/l : Na+ : 154. Cl-: 154.
45446874|NCT02093806|Other|measurment|
45623922|NCT03249701|Device|Transcutaneous Electrical Acupoint Stimulation|The intervention will be administered by electrical acupoint machine, the brand is Great Wall.
45623923|NCT03249701|Device|Electroacupuncture|The intervention will be administered by electrical acupoint machine, the brand is Great Wall.
45623924|NCT03249701|Device|sham Transcutaneous Electrical Acupoint Stimulation|The intervention will be administered by transcutaneous electrical acupoint machine, even no truly actualized.
45623925|NCT04940715|Other|Passive joint mobilization|Dosage: 5 sets of 2 minutes with 30 seconds of rest were applied, with a strong force (>50% of maximum therapist strength), according to patient's irritability and severity.
45765652|NCT02997904|Device|Apply Liquid Then Comb Out|Apply liquid to dry hair, wait for 5 minutes, then comb out lice and eggs for up to one hour
45623926|NCT04940715|Other|Mobilization with movement|Dosage: 3 sets of 10 repetitions were performed, with 1-2 minutes of rest between sets.
45623927|NCT04947111|Diagnostic Test|Estimate the distribution of antibodies by serotype by Dengue virus in areas of low and high incidence of dengue|"Indirect IgG ELISA to estimate seroprevalence: The seropositivity will be evaluated with the Indirect IgG ELISA following the instructions of the Panbio E-DEN 01 G manufacturer, which has a specificity of 98% and a sensitivity of 100%. In brief, 10 microliters of participant serum will be used for each assay. Each kit provides a positive and negative control, as well as three calibrators, with the respective values for quality control. Samples will be classified as positive, negative or indeterminate according to the cut-off point for each ELISA kit.~Neutralizing antibody titers serotype-specific: To establish the type of humoral immunity that the selected city presents, the measurement of the neutralizing antibody titers will be carried out by means of the neutralization test by reducing the number of lytic plaques to 50% (PRNT50%) , using Vero cells and the following reference strains for each serotype: DENV-1 (HAWAI), DENV-2 (NEW GUINEA), DENV-3 (H-887) and DENV-4 (H-24)"
45623928|NCT03249623|Device|Beacon Caresystem|The core of the system is a set of physiological models including pulmonary gas exchange, acid-base chemistry, lung mechanics, and respiratory drive. The Beacon Caresystem tunes these models to the individual patient such that they describe accurately current measurements. Once tuned, the models are used by the system to simulate the effects of changing ventilator settings. The results of these simulations are then used calculate the clinical benefit of changing ventilator settings by balancing the competing goals of mechanical ventilation.
45623929|NCT04947345|Drug|Remimazolam Besylate|Remimazolam Besylate are used as sedatives for subjects in this arm.
45623930|NCT04947345|Drug|Propofol|Propofol are used as sedatives for subjects in this arm.
45623931|NCT04947189|Drug|Seviteronel-D (Seivteronel in combination with dexamethasone)|Use of Seviteronel-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.
45623932|NCT04947189|Drug|Docetaxel|Use of docetaxel chemotherapy for solid tumours
45623933|NCT03249311|Drug|Levomilnacipran|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
45623934|NCT03249311|Drug|Duloxetine|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
45623935|NCT03249311|Drug|Placebos|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
45623936|NCT04413123|Drug|Cabozantinib|Cabozantinib predetermined protocol dosage po daily
45765653|NCT05160753|Procedure|Laparoscopic gastric function preserving surgery combined with resection of the anterior lymphatic drainage area|A 4mL volume of double tracer is injected into the submucosa of the four quadrants of the primary tumor by intraoperative gastroscopic method., and 15 minutes after gastroscopic tracer injection, the green anterior lymph nodes were carefully dissected and removed from the surgical area and evaluated for lymph node metastasis by parallel intraoperative freezing.If all collected anterior lymph nodes are negative, laparoscopic gastric function preserving surgery will be performed.
45765654|NCT04343625|Behavioral|Modified yoga class|Modified yoga was used to see if it would improve pain, fatigue, depression and anxiety, as well as improve sleep quality.
45446875|NCT02089438|Drug|Saxagliptin|Saxagliptin (5 mg) is given before breakfast
45446876|NCT02089438|Drug|Vildagliptin|Vildagliptin (50mg) is given before breakfast and dinner
45446877|NCT02089438|Drug|Sitagliptin|Sitagliptin (100 mg) is given before breakfast
45446878|NCT02096146|Procedure|TMT Fusion plate|Patients are treated with TMT Fusion Plate a post-market device to encourage bony fusion of the 1st TMT joint.
45446879|NCT02096146|Procedure|Two crossed screws|Patients are treated with two crossed screws.This procedure is a standard treatment for 1st TMT joint fusion.
45446880|NCT05471674|Drug|Nivolumab|3 mg/kg on Day 1 of each 2-weekly cycle for 3 doses
45446881|NCT05471674|Procedure|Hepatectomy|Hepatectomy will be performed approximately 2 weeks after the 3rd dose of nivolumab
45446882|NCT02093884|Other|Text Messaging Intervention|
45446883|NCT02093884|Other|Standard Referral|
45446884|NCT02250040|Other|Conventional physiotherapy|Physiotherapy techniques that included muscle training, stretching and endurance.
45446885|NCT02250040|Other|Techniques based on patients' functional level were added.|The added techniques aimed to improve balance and movement dissociation.
45446886|NCT02096224|Drug|Sevoflurane|Sevoflurane will be used.
45623937|NCT04413123|Drug|Nivolumab|Nivolumab predetermined protocol dosage via IV every 3 weeks
45623938|NCT04413123|Drug|Ipilimumab|Ipilimumab predetermined protocol dosage via IV every 3 weeks
45623939|NCT04940559|Drug|Danicopan - Tablet|Oral tablet.
45623940|NCT04940559|Drug|Danicopan - Softgel|Oral softgel capsule.
45623941|NCT04940559|Drug|Danicopan - LFC|Oral LFC.
45623942|NCT03249389|Biological|Blood sample|patients will have a blood sample of 20 ml (4 x 5ml) for inclusion, the J1 of each course and at the end of treatment
45623943|NCT03248921|Procedure|cardiac surgery|cardiac surgery including non-emergency, elective coronary artery bypass grafting surgery with or without valve surgery, aortic or mitral valve surgery
45623944|NCT04940325|Drug|DS-1062a|First infusion for 90 minutes and then infusion duration can be decreased to 30 minutes if participant didn't experience infusion related reactions (IRR)
45623945|NCT02454725|Behavioral|Social Network|Leaders of social networks will undergo small group training to develop skills to convey information effectively and deliver messages endorsing regular HIV testing to members of their social networks.
45623946|NCT02454725|Behavioral|Comparison|All participants will receive HIV counseling and rapid testing following the Wisconsin Department of Health guidelines. Sexually active men who receive a negative test result will be told that they should be HIV-tested every three to six months, unless they have a monogamous HIV negative partner
45765655|NCT01012297|Biological|Bevacizumab|Given IV
45623947|NCT03059199|Behavioral|Single-Arm Feasibility Study|Participants are provided with the HAT TRICK Playbook, a resource manual including weekly healthy eating and physical activity challenges and tracking logs. Each face-to-face session is facilitated by trained research staff, community partners, and health care professionals. Weekly sessions include information on physical activity, healthy eating, and behaviour change techniques (e.g., social support, goal setting, self-monitoring) and include an opportunity to be active/exercise.
45623948|NCT02454491|Drug|Heparin|intraradial administration of heparin 5000 ui
45623949|NCT02454491|Drug|Verapamil|intraradial administration of verapamil 5 mg
45623950|NCT04940091|Drug|Epidural analgesia|Epidural analgesia is performed with a mixture of local anesthetics (ropivacaine) and opioids (sufentanil).
45623951|NCT03249155|Behavioral|AO - plus sonification|patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture. Each video-clip is composed by images and sounds of the gestures. The sound of gestures is obtained with the sonification technique, by transforming kinematic data (velocity) recorded during the execution of gesture, into pitch variations (for an example see: bit.ly/sonif_example)
45623952|NCT03249155|Behavioral|CUE - visual and auditory|patients re-learned 8 motor gestures practicing a traditional protocol combining visual and auditory cues
45623953|NCT03058809|Device|Oncopheresis|Oncopheresis is a type of apheresis incorporating an extracorporeal blood circuit and a filter to separate circulating tumor cells from normal blood components.
45765656|NCT01012297|Drug|Docetaxel|Given IV
45765657|NCT01012297|Biological|Filgrastim|Given SC
45765658|NCT01012297|Drug|Gemcitabine Hydrochloride|Given IV
45765659|NCT01012297|Biological|Pegfilgrastim|Given SC
45765660|NCT01012297|Other|Placebo|Given IV
45765661|NCT02998684|Device|Active Transcranial Direct Current Stimulation|
45765662|NCT02998684|Device|Sham Transcranial Direct Current Stimulation|
45446887|NCT02096224|Drug|Desflurane|Desflurane will be used
45446888|NCT02096302|Dietary Supplement|Infant Formula with a novel probiotic CECT7210|Bottle-feeding with a new infant formula enriched with probiotic CECT7210 during the first 3 months of life.
45446889|NCT02096302|Dietary Supplement|Standard formula|Standard formula without probiotics
45446890|NCT02096380|Drug|One cycle TPF induction chemotherapy for NPC|"One cycle TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2."
45446891|NCT02096380|Drug|Three cycles TPF induction chemotherapy for NPC|"Three cycles TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for three cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2."
45446892|NCT03557554|Other|Massage|A 20 minute massage protocol will be administered in a chair by a licensed massage therapist no more than 24 hours prior to each paclitaxel infusion.
45623954|NCT03248765|Other|post-surgical opioid use measured at 1 day and 1 week.|"Evaluation of intra-hospital perioperative opioid administration (including intraoperative opioids and Patient Controlled Analgesia (PCA) use). This endpoint is calculated as the total amount of morphine equivalents administered intraoperatively and in the first 24 hours after the end surgery (measured on postoperative day 1).~2) Opioid utilization after discharge from hospital (prescription refills and pills count at subsequent hospital visits). This endpoint is calculated as the total amount of morphine equivalents consumed in the first week after the surgery (measured at 1 week after surgery by electronic questionnaire and verified by direct pill count performed on occasion of the patient's postsurgical visit )."
45623955|NCT04939857|Drug|Trimetazidine|The experimental group will be treated with trimetazidine, and the control group will not be intervened
45765663|NCT02998684|Behavioral|PEERS Social Skills Training|14 weekly social skills training sessions for all participants
45765664|NCT03000010|Device|Incisional Wound Vac|
45765665|NCT03000010|Other|Standard Bandage|
45765666|NCT00358839|Drug|CGRP|
45765667|NCT03000088|Device|intubate with 60° angled stylet|
45765668|NCT03000088|Device|intubate with 60° angled stylet|
45765669|NCT03000166|Behavioral|Step-Up Intervention|Intervention group participants will meet with a study facilitator during 5 regularly scheduled visits for chemotherapy. The facilitator will provide education about the benefits of physical activity and strategies to overcome barriers to physical activity, help the participants to set physical activity goals based on ability and preferences, and educate the participant on using a physical activity tracker.
45765670|NCT00923117|Drug|Sutent (sunitinib)|Oral dose 37.5 mg daily on a continuous 4 week cycle
45765671|NCT04737070|Biological|Prenatal test for Trisomy 21 screening|prenatal routine test for Trisomy 21 screening (blood test + nuchal translucency test)
45765672|NCT00953173|Device|LAP-BAND AP® Adjustable Gastric Banding System|The LAP-BAND AP® is a device surgically implanted via a laparoscopic procedure. It is designed to induce weight loss in severely obese patients by limiting food consumption.
45912582|NCT02011958|Drug|Liposomal Amphotericin B|"40 mg/kg total dose: IV infusion of 5mg/kg per day on day 1 to 5, 10,17,24 (when administered as a monotherapy)~30 mg/kg total dose: IV infusion 5 mg/kg per day on day 1, 3, 5, 7, 9, 11 (when administered in combination with Miltefosine)"
45623956|NCT03248609|Other|Milano grapes|Milano grapes to test post-prandial glycemic response
45623957|NCT03248609|Other|Table grapes|Table grapes to test post-prandial glycemic response
45623958|NCT03248609|Other|Grape juice|Grape juice to test post-prandial glycemic response
45623959|NCT03248609|Other|Glucose beverage|Standardized glucose beverage to test post-prandial glycemic response
45623960|NCT04959513|Procedure|LPRF bone block|Guided bone regeneration using an L-PRF bone block (composite graft composed of a xenograft, a membrane from the patient's blood and a collagenous membrane) after a short healing period of 6 to 8 weeks after tooth extraction
45623961|NCT03248687|Other|Follow up|The intervention will be method of follow up.
45623962|NCT04959357|Diagnostic Test|Two dimensional speckle tracking imaging|lobal longitudinal strain and strain rate, subendocardial LS and subepicardial LS were quantified by two dimensional speckle tracking imaging
45623963|NCT04487015|Behavioral|MP|The app-based menu planner (MP) given to the participants has an automated carbohydrate periodisation menu planning tool, an educational and motivational nutrition content (infographics, video and text articles), and recipes. Participants using the app will input their training schedule into the app to produce their own menu plans. The behaviour change techniques (BCT) underlying the intervention are goal & planning, feedback & monitoring, shaping knowledge, natural consequences, comparison of behaviour, comparison of outcome, associations, repetitions, reward & threat, regulation and antecedents.
45623964|NCT04487015|Behavioral|Call|A 30-45 minutes coaching consultation telephone/Skype call from the nutrition coaching to give social support. The BCT underlying the intervention is goal & planning, social support, natural consequences.
45765673|NCT05107401|Behavioral|Digital Crowdsourced Intervention to Reduce HIV Stigma among Adolescents and Young Adults|Adolescents and young adults will participate in a crowdsourcing contest to create digital materials to reduce HIV stigma in order to increase HIV testing. Entries will be judged by a community judging panel and expert judging panel. Winning entries will be selected for the digital intervention and presented to participants in the intervention arm.
45623965|NCT04487015|Behavioral|MesC|Nutrition coach-led messaging (MesC) is where the mobile app (MP) has the text messaging feature activated, and the nutrition coach proactively initiates a conversation via text messaging up to three times a week to offer nutrition support to the participant. The BCT underlying the intervention is goal & planning, social support, natural consequences.
45623966|NCT04939779|Drug|LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)|Oral administration
45623967|NCT04939779|Drug|LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)|Oral administration
45623968|NCT04940169|Procedure|anterior cruciate ligament recontruction|Firstly graft is harvested with help of arthroscopy femoral and tibial tunnels created then graft placed into tunnels
45623969|NCT03249233|Device|ZenLens™|The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
45623970|NCT03249233|Device|Zen™ RC|The Zen™ RC semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
45623971|NCT04946565|Diagnostic Test|Semen analysis|Semen analysis according to WHO laboratory manual for the examination and processing of human semen, Fifth edition
45765674|NCT03054922|Drug|Normal Saline|IV infusion of 0.9% NaCl throughout surgery.
45765675|NCT03054922|Drug|Lactated Ringer|IV infusion of lactated ringer throughout surgery.
45623972|NCT04939155|Biological|SARS-CoV-2 mRNA vaccine|mRNA vaccine for COVID
45446893|NCT04384107|Biological|V114|15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in PCV13 plus 2 additional serotypes (22F, 33F) in each subcutaneous 0.5 mL single dose.
45765676|NCT03054922|Drug|Normosol-R Inj|IV infusion of Normosol throughout surgery.
45765677|NCT02977611|Drug|Iron sucrose|Iron sucrose will be infused at dose of 500 mg over a one hour period
45765678|NCT05405764|Dietary Supplement|Porcine protein supplement|Porcine protein supplementation
45446894|NCT04384107|Biological|PCV13|13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each subcutaneous 0.5 mL single dose.
45446895|NCT03557398|Device|Hydeal-D vaginal pessaries|One vaginal application of Hydeal-D vaginal pessaries every 3 days to a total of 12 consecutive weeks.
45623973|NCT03248999|Diagnostic Test|rectal swab|stool samples by rectal swab
45623974|NCT04939077|Biological|Allogeneic Human Umbilical Cord Mesenchymal Stem Cells|In CABG with hUC-MSC treatment group, 1×10^7 Human Umbilical Cord Mesenchymal Stem Cells were injected at the edge of the myocardial infarction area at 20 points at the same time in CABG
45623975|NCT03248453|Other|CoPS|The COPS is an automated and objective computer-based program which generate a score/number after the colonoscope has reached the cecum. The participants are able to compare the score with experts.
45623976|NCT04946487|Procedure|total laminectomy|Total laminectomy removes the posterior ligamentous complex (PLC) at the fusion and superior levels.
45623977|NCT04946331|Device|Electrical impedance tomography system|Which can use the applied current and measurement voltage through the body surface electrode group, and use the reconstruction algorithm to construct an image imaging system that exceeds the cross-sectional, which can provide images of the internal physiological changes of the chest contour, in order to quantify the changes in lung function caused by rib fractures.
45623978|NCT03247907|Device|Condition A: CPAP with No Humidification|CPAP with No Humidification with no mouth leak
45623979|NCT03247907|Device|Condition B: CPAP with No Humidification|CPAP with No Humidification with mouth leak
45623980|NCT03247907|Device|Condition C: CPAP with Cold Passover|CPAP with Cold Passover with mouth leak
45623981|NCT03247907|Device|Condition D: CPAP with Modified humidifier|CPAP with Modified humidifier with mouth leak
45623982|NCT03247907|Device|Condition E: CPAP with Ambient Tracking|CPAP with Ambient Tracking with mouth leak
45623983|NCT03247907|Device|Condition F: CPAP with Heated Humidification|CPAP with Heated Humidification at default setting with mouth leak
45765679|NCT05405764|Dietary Supplement|Control product maltodextrin supplement|Maltodextrin supplementation
45765680|NCT04360655|Procedure|bronchoscopic microwave intervention|bronchoscopic microwave intervention
45765681|NCT04360655|Drug|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
45765682|NCT03116230|Device|Cutaneous Stimulation|A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.
45765683|NCT03116230|Device|Knee Sleeve|Commercially-available knee sleeve.
45623984|NCT03247907|Device|Condition G: CPAP with Heated Humidification|CPAP with Heated Humidification at max setting with mouth leak
45765684|NCT05102565|Behavioral|sleep education program|A multicomponent behavioral sleep program, consisting of sleep hygiene, stimulus control, sleep compression, pleasurable activity, daily walking, and light exposure.
45912583|NCT02011958|Drug|Miltefosine|"Orally taken every day during 28 days~1 x 50 mg capsule per day if the patient weights less or equal to 25 kg~2 x 50 mg capsules per day if the patient weights more than 25 kg (1 capsule in the morning / 1 capsule in the evening)"
45623985|NCT03247907|Device|Condition H: CPAP with New level humidification|CPAP with New level humidification with mouth leak
45623986|NCT04938531|Other|Exercise|Participants will perform an entry passive exercise test within 48 hours of onset of severe sepsis. Patients then will perform 30-60 min supine passive cycle ergometry exercise 5 days/week.
45623987|NCT02454647|Drug|Induction chemotherapy|
45623988|NCT02454647|Radiation|Radiotherapy with concurrent chemotherapy|
45623989|NCT02454647|Procedure|Salvage surgery|
45623990|NCT03247595|Dietary Supplement|Magnesium Citrate Capsules|36 magnesium citrate gelatin capsules
45623991|NCT03247595|Other|Polyethylene Glycol 3350|4 liters of Polyethylene Glycol for colonoscopy preparation
45765685|NCT04367129|Diagnostic Test|ECG|12 lead electrocardiogram
45765686|NCT00375232|Drug|Administration of montelukast or placebo|
45765687|NCT04347317|Procedure|Low Intensity IMT|"The control group will get a supervised IMT with Threshold IMT device, once a day, 5 days a week for a maximum of 28 days or until the participant is weaned successfully. In each session the participant will do 5 sets of 6 repetitions with 2 minutes of rest between sets. The initial training load will be adjusted to 30% of the MIP and will be increased by 10% of the initial MIP weekly.~The patient will be placed in a semi-incorporated position (head of the bed elevated 45º). The ICU physiotherapist will check before training that the cuff of the tracheal tube is correctly swollen to avoid air leaks during the training. The ICU physiotherapist will disconnect the mechanical ventilation during the IMT and will provide supplemental oxygen when required. However, between series the participant will be returned to ventilator support. Patients will be instructed to do a whole expiration and immediately inspire as forceful as possible until reaching the total lung capacity."
45912584|NCT02011997|Procedure|patients undergo cVATS segmentectomy|
45912585|NCT02011997|Procedure|Patients undergo cVATS lobectomy|
45912586|NCT02012010|Procedure|Manual syringe infusion method|Infuse the distension medium of hysteroscopy by manual syringe infusion method
45912587|NCT02012010|Procedure|Pump infusion method|Infuse the distension medium of hysteroscopy by pump infusion method
45912588|NCT02012023|Device|Low anterior resection|
45912589|NCT02012023|Device|tube ileostomy|
45912590|NCT02012023|Device|loop ileostomy|
45623992|NCT03247595|Other|Dulcolax Tablets|4 Dulcolox Tablets
45623993|NCT04938843|Dietary Supplement|F. prausnitzii and D. piger|Dietary supplementation with capsules containing F. prausnitzii and D. piger once daily for 12 consecutive weeks
45623994|NCT04938843|Dietary Supplement|Placebo|Dietary supplementation with placebo capsules identical to those containing F. prausnitzii and D. piger once daily for 12 consecutive weeks
45623995|NCT03247751|Device|intraocular lens|Implant NIDEK intraocular lens after cataract surgery
45623996|NCT04938453|Drug|nintedanib (formulation A, test treatment)|nintedanib (formulation A, test treatment)
45623997|NCT04938453|Drug|nintedanib (formulation B, reference treatment)|nintedanib (formulation B, reference treatment)
45623998|NCT03247829|Device|Hemodynamic management using CardioMEMS|Using the CardioMEMS HF system, clinicians will treat to target PA pressure ranges
45623999|NCT04946097|Other|gross Myofascial Release|Gross Myofascial Release : is amanual technique in form of Stretch of the Posterior Cervical Musculature and Gross stretch of gross Myofascial Release upper quarter: Arm Pull for duration of 10-15 min per session each stretch position was healed for 90sec
45624000|NCT04946097|Other|conventional selected exercise program|stretching exercises for cervical muscles and pectoralis major and source of heat in form of hot packs for 15 minutes
45624001|NCT04946097|Device|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is a method of pain relief involving the use of electrical current, the electrode placement on the course of pain for 15 minutes
45624002|NCT03247439|Device|Cartiva|Synthetic Cartilage Implant
45624003|NCT03247361|Other|High-intensity IMT + Aerobic/resistance exercise|High-intensity IMT
45624004|NCT03247361|Other|Low-intensity IMT + Aerobic/resistance exercise|Low-intensity IMT
45624005|NCT03247361|Other|Sham IMT + Aerobic/resistance exercise|Aerobic and resistance exercise
45912591|NCT02012023|Device|accept reversal operation|
45912592|NCT02012023|Device|remove the tube ileostomy|
45624006|NCT04959045|Other|intervention group (Flipped Teaching Method Group)|"Students will be given skill training with the Flipped Teaching method, which consists of outside and in-class applications.~Out-of-Class Practice: A Learning Management System-Web-Based Distance Education System will be created for the Flipped Teaching method. Theoretical course topics and skill training videos will be uploaded to the system 7 days before the course day. Students will be able to watch the video tutorials in the number and frequency they want until the day of the lesson. At the end of the lesson, the mini-exam will be uploaded to the system.~In-class practice: The researcher will come to the lesson prepared for classroom activities such as question and answer. Theoretical lectures and skill demonstrations will not be made by the researcher. The researcher will only guide the students. Then, the students will be provided to perform the skill under the guidance of the researcher in the clinical skills laboratory."
45624007|NCT03247283|Drug|BMS-986205|Carbon 14 tagged BMS-986205
45624008|NCT04945785|Other|No intervention|no intervention
45624009|NCT03247127|Radiation|Hippocampal avoidance whole brain radiotherapy|Planning target volume(PTV) for whole brain is Whole brain parenchyma plus2mm margin excluding metastases and HA region, 30Gy in 10 fractions will be delivered to PTVwhole brain. Bilateral Hippocampus will be contoured according to Radiation Therapy Oncology Group 0933 and hippocampal avoidance region is Hippocampi + 5mm margin. According to Radiation Therapy Oncology Group 0933 trial, dose to 100% of the hippocampus could not exceed 9 Gy, and maximal hippocampal dose could not exceed 16 Gy; dose to 100% of the hippocampus exceeding 10 Gy
45624010|NCT04938297|Drug|Rituximab, Lenalidomide, Zanubrutinib|Induction therapy: Rituximab 375 mg / m2, day 1, Zanubrutinib 160 mg bid, orally, Lenalidomide 25mg QD, orally on day 1-21, 28 days as a course of treatment, 8 courses of treatment.
45624011|NCT04938297|Drug|Lenalidomide, Zanubrutinib|Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) or Zanubrutinib 160 mg bid. Continuously use for 2 years or until disease progression
45765688|NCT04347317|Procedure|High Intensity IMT|"The experimental group will get a supervised IMT with Threshold IMT device, once a day, 5 days a week for a maximum of 28 days or until the participant is weaned successfully. In each session the participant will do 5 sets of 6 repetitions with 2 minutes of rest between sets. The initial training load will be adjusted to 60% of the MIP and will be increased by 10% of the initial MIP weekly.~The patient will be placed in a semi-incorporated position (head of the bed elevated 45º). The ICU physiotherapist will check before training that the cuff of the tracheal tube is correctly swollen to avoid air leaks during the training. The ICU physiotherapist will disconnect the mechanical ventilation during the IMT and will provide supplemental oxygen when required. However, between series the participant will be returned to ventilator support. Patients will be instructed to do a whole expiration and immediately inspire as forceful as possible until reaching the total lung capacity."
45765689|NCT00975637|Drug|70 mg SC|70 mg SC
45765690|NCT00975637|Drug|210 mg SC|210 mg SC
45765691|NCT00975637|Drug|140 mg SC|140 mg SC
45765692|NCT00975637|Drug|280 mg SC|280 mg SC
45765693|NCT00975637|Drug|Placebo|Placebo SC
45446896|NCT02089594|Drug|Hyperbaric Oxygen|HBOT Group: Pressurization will proceed with 100% oxygen at 1.0 pounds per square inch (psi) per minute, the minimal pressurization rate, to 1.5 ATA (atmospheres absolute) or 7.35 psi and will take approximately 7 minutes. Pressurization will then resume until the final depth of 1.5 ATA is achieved. The patient will remain at depth for approximately 45 minutes and the subject will be informed of the onset of depressurization, which will occur at the same rate as pressurization. Total dive time will be 60 minutes.
45624012|NCT04938297|Drug|Lenalidomide|Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) . Continuously use for 2 years or until disease progression
45624013|NCT02454413|Other|denture brushing with water and soap|denture brushing with water and soap
45624014|NCT02454413|Other|ultrasonic denture cleaning|ultrasonic denture cleaning
45624015|NCT02454413|Other|cleansing tablet|addition of a cleansing tablet to the water in which the dentures are stored overnight
45624016|NCT03057873|Dietary Supplement|High protein, high fiber dietary supplement|Dry powder to be mixed with 10 ounces of cold water
45624017|NCT03057873|Dietary Supplement|Placebo|Dry powder to be mixed with 10 ounces of cold water
45624018|NCT04945551|Behavioral|Aerobic exercise training|12 weeks intervention period consisting of aerobic exercise training 3 sessions/week, 45 min/session. All training sessions are supervised. Aerobic training is conducted as ergometer bicycle training at an intensity of 70% of maximal oxygen uptake (x2/wk.) and rowing ergometer exercise at 70% of maximal heart rate (x1/wk.). In week 3, 6 and 9 VO2 max is measured to ensure sufficient adjustment of the workload during the training sessions.
45765694|NCT04376567|Other|randomization|subjects scheduled to have a BBAVF will be randomized to either the One-stage or the Two stage BBAVF
45765695|NCT04360343|Drug|Film-coated tablet|uncoated tablet
45765696|NCT04343703|Behavioral|Telephone-based management|The intervention consists of a series of phone calls aimed at providing follow up care of individuals at risk. At each phone call the case manager collects information regarding the current treatment, adherence to mental health services, and current life stressors.
45912593|NCT02012036|Drug|Hexvix|"As this is a non-interventional study, detection of NMIBC with Hexvix is in a pre-defined group, chosen prior to and independently from the decision to enrol the subject in this study.~The detection with Hexvix should be in accordance with local Summary of Product Characteristics [SmPC].~Subjects will be treated in accordance with usual medical practice during their participation in this study, no additional assessment or tests will be required."
45446897|NCT02089594|Drug|No Hyperbaric Oxygen|Subjects will receive their usual care during the equivalent eight-week HBOT treatment period. There will be no hyperbaric chamber experience. At the conclusion of the eight-week control period both control and experimental subjects will be retested and the control group will be crossed over to receive the identical 40 HBOTs of the HBOT group.
45624019|NCT03057717|Other|2D ultrasound assessment|2D ultrasound assessment of fetal thymus size with measurements of the maximum transverse diameter and thymus perimeter
45765697|NCT04343703|Behavioral|iFightDepression for Suicide|The iFD-Survive is a cognitive-behavioral, internet-based self-management tool, developed by the European Alliance Against Depression (EAAD). The iFD is intended to address mild-to-moderate depressive symptoms. The iDF tool is structured in seven core modules focused on: behavioral activation, cognitive restructuring, sleep regulation, mood monitoring, and healthy lifestyle habits. The content of each module is intended to be followed over 1 week and consists of written information, tasks to do over the week and worksheets. All of these aims to consolidate learning and promote self-monitoring. For this study, an additional module (iFD-S) will be developed. The iFD-S also provides telephone guidance (2h per participant).
45624020|NCT03246893|Device|Noninvasive positive pressure ventilation|"Noninvasive positive pressure ventilation will apply via a face mask with initial setting as the following:~Inspiratory pressure 6-8 cmH2O Expiratory pressure 3-5 cmH2O FiO2 30-60% Respiratory rate 12-16 per min"
45624021|NCT03246893|Device|High flow oxygen nasal cannula|"High flow oxygen nasal cannula will apply to patient via a nasal cannula with initial setting as the following:~Temperature 37 degree celsius Flow 30 liter per min FiO2 40-60%"
45624022|NCT04421937|Behavioral|Procedure: Traditional Dysphagia Therapy (TDT)|"Traditional dysphagia therapy includes diet modification training, teaching postural compensatory methods, training of oral motor control exercises and tongue root exercises, training of swallowing maneuvers, and practice of chin-resistance exercise, which is the exercise of opening the upper esophageal sphincter.~Traditional Dysphagia Therapy will be applied for 45 minutes a day, 5 days a week for 3 weeks."
45624023|NCT04421937|Device|Procedure: Neuromuscular Electrical Stimulation with TDT|The skin to be treated will be cleaned and dried. NMES will be implemented with signals received from two channels. In the first channel, the upper electrodes will be placed horizontally just above the hyoid bone. This is the place where the cupping is felt when the finger is pressed right under the chin. In the second channel, the lower electrodes will be placed horizontally, just above the thyrohyoid muscle. This is the place where you can feel a cupping when pressed with your finger, on both sides of the apple in the larynx. The device will be set to start at the lowest power, with very short pulses of approximately 700 microseconds, at intervals of 1 second. The power will be gradually increased according to the device and the power that the patient feels vibration will be stopped. The power to be applied will not exceed 25 milliamps. NMES application and Traditional Dysphagia Therapy will be applied for 45 minutes a day, 5 days a week for 3 weeks.
45765698|NCT04343703|Behavioral|Treatment as Usual|Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy. For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual.
45624024|NCT03246737|Other|monitoring|
45624025|NCT04937907|Drug|Hydroxychloroquine Sulfate 100 milligram (mg) Tab|Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day at least 6 months.
45912594|NCT02012049|Drug|Risperdal OD Tab. 2mg|1 tablet Risperdal OD 2 mg administered orally.
45624026|NCT04937907|Drug|Benazepril hydrochloride 10 milligram (mg) Tab|Patients administered Benazepril by oral at a dose of 5mg or 10mg once a day at least 6 months.
45624027|NCT03246971|Drug|Wafermine™ 50 mg|Administered as needed for 12 hours
45624028|NCT03246971|Drug|Wafermine™ 75 mg|Administered as needed for 12 hours
45624029|NCT03246971|Drug|Placebos|Administered as needed for 12 hours
45624030|NCT03246971|Drug|Wafermine™ 25 mg|Administered as needed for 12 hours
45624031|NCT02625909|Drug|SOF/VEL for 6 weeks|Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm A (6 weeks short treatment duration).
45624032|NCT02625909|Drug|SOF/VEL for 12 weeks|Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm B (12 weeks standard treatment duration).
45624033|NCT03246659|Drug|111In-CP04|Radiopharmaceutical preparation
45624034|NCT03246659|Drug|111In-CP04 with co-administration of gelofusine/gelaspan|Radiopharmaceutical preparation with co-administration of gelofusine/gelaspan
45624035|NCT04945005|Procedure|Transesophageal guidance of lead implantation|In patients undergoing lead implantation including transesophageal echocardiography for clinical reasons (e.g. intraprocedural cardioversion), echocardiography was also used for guidance of lead implantation to reduce lead-leaflet interactions
45624036|NCT03246581|Drug|Tiotropium|inhalation
45624037|NCT04944693|Other|Different ATS values.|"Observational, different ATS values were measured on MRI images and were regarded as interventions for different cohorts."
45624038|NCT03246269|Diagnostic Test|MoCA|
45624039|NCT04937985|Other|Performance Tests|Performance tests consist of Six Minute Pegboard Ring Test, 30-Second Push-Up Test and Arm, Shoulder and Hand Injury Questionnaire (DASH), Neck Disability Index, New York Posture Rating Chart and Short Form-36 Health Survey.
45624040|NCT03246191|Other|blood sample collection|blood sample collection
45624041|NCT04938063|Other|Assessing the correlation between Functional Impairment and Parenting Stress|Association Between Functional Impairment and Parenting Stress Among Children Diagnosed With Diplegic Cerebral Palsy
45624042|NCT03246113|Drug|Cannabis|Cannabis cigarettes provided by NIDA that contain high levels of CBD (4.8%) and low levels of THC (3.23%). Patients will smoke one-half (1/2) to two (2) cannabis cigarettes prior to receiving chemoradiation.
45624043|NCT03246113|Drug|Temozolomide|Oral alkylating agent with demonstrated antitumor activity.
45624044|NCT03246113|Radiation|Radiation Therapy|standard fractionation radiotherapy of 60 Gy in 30 treatments with temozolomide.
45624045|NCT04937673|Drug|Camrelizumab+Albumin bound paclitaxel+Cisplatin|"Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.~Albumin bound paclitaxel: 130 mg / m2, intravenous drip for 30 minutes, D1, D8, repeated every 3 weeks.~Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks."
45624046|NCT04937673|Drug|Camrelizumab+ Paclitaxel+ Cisplatin|"Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.~Paclitaxel: 80 mg / m2, intravenous drip for 180 minutes, D1, D8, repeated every 3 weeks.~Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks."
45624047|NCT03245957|Other|Ischemic stroke|Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
45624048|NCT03245957|Other|Haemorrhagic stroke|Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
45624049|NCT03245879|Behavioral|Program 1|Program 1 hospitals received a basic curriculum and tools for implementation of basic antibiotic stewardship interventions. Hospitals required an indication for every antibiotic order. A daily email was sent to a designated email account when a patient had been on an antibiotic for >48 hours. Curriculum included implementing antibiotic time-outs, IV to PO conversion, indications, evaluating for bug-drug mismatches, and recommendations on when to call the Infectious Diseases (ID) hotline. A daily antibiotic stewardship check list was created. All materials were provided to all pharmacists and remained on-site. Clinicians had access to an ID telephone hotline to answer clinical questions. Pharmacy directors and hospital leadership were provided a monthly, hospital-specific, antibiotic use dashboard. All pharmacy directors and staff received a monthly newsletter.
45765699|NCT04343703|Behavioral|Self Awareness of Mental Health|The SAM consist of five, face-to-face, individual sessions designed to raise awareness about depression, anxiety and suicidal behaviors as well as to enhancing skills to effectively cope with stressful life events and mood.
45624050|NCT03245879|Behavioral|Program 2|Program 2 hospitals received all the interventions of Program 1. In addition, Program 2 hospitals received more intense antibiotic stewardship education. Educational topics included audit and feedback, antibiotic de-escalation, the need for antibiotics targeting anaerobic bacteria, antibiotic allergy verification, and antibiotic restrictions. Pharmacists in Program 2 hospitals reviewed patients on vancomycin, piperacillin/tazobactam, imipenem, meropenem, and cefepime. For patients receiving one of these antibiotics, pharmacists reviewed the patients' microbiology data to identify opportunities for antibiotic de-escalation, IV to PO conversion, bug-drug mismatches, and/or indications for calling the ID hotline. Program 2 hospitals also restricted daptomycin, linezolid, imipenem, meropenem, ceftaroline, tigecycline, and all mold active antifungals. In Program 2 hospitals, the local pharmacy staff pre-authorized restricted antibiotics based on defined criteria.
45653390|NCT05065593|Other|resistance and aerobic exercise|Resistive exercises allow loading the muscle under suitable conditions with various weights or resistances. In order to increase the level of physical fitness with the increase of muscle strength and bone mass in individuals, resistance exercises were preferred. Aerobic exercises, on the other hand, are a special type of exercise that develops both the musculoskeletal system and the cardiovascular system, which includes large muscle groups and should be performed for at least 20 minutes when the heart rate accelerates at certain rates. Aerobic exercise was preferred in order to increase cardiovascular endurance, accelerate fat burning and reduce fatigue.
45765700|NCT03024229|Device|LifePort® perfusion machine|Renal perfusion on LifePort® machine
45765701|NCT02244437|Drug|Ibuprofen|
45765702|NCT02244437|Drug|Acetaminophen|
45912595|NCT02012049|Drug|Risperdal Quicklet Tab. 2mg|1 tablet Risperdal Quicklet Tab. 2mg administered orally.
45624051|NCT03245879|Behavioral|Program 3|Program 3 hospitals received all the interventions of Program 1 and Program 2. In addition, pharmacists in program 3 hospitals reviewed an expanded list of antibiotics for audit and feedback. These antibiotics included: Vancomycin, piperacillin/tazobactam, imipenem, meropenem, cefepime, ertapenem, aminoglycosides, ceftriaxone, and fluoroquinolones. Program 3 hospitals implemented the same antibiotic restrictions as Program 2 but ID pharmacists controlled pre-authorization of restricted antibiotics. In addition, an ID physician reviewed pre-specified positive cultures (e.g. all positive blood cultures, cultures with highly resistant Enterobacteraciae) and contacted providers with recommendations as needed. ID physician review occurred Monday through Friday and alerts were batched daily at 6am.
45624052|NCT04958343|Procedure|pelvic reconstruction|After radical cystectomy, the pelvic reconstruction including the ligation of dorsal vascular complex and posterior reconstruction will be performed on patients.
45624053|NCT02454335|Procedure|Peroral Endoscopic Myotomy|The intervention is the POEM procedure performed by either anterior approach or posterior approach orientation of the incision for mucosal entry.
45624054|NCT04937439|Other|Traditional Physical Therapy program|"Facilitation of head control will be conducted.~Facilitation of trunk control will be applied~Facilitation of rolling~Facilitation of righting, protective and equilibrium reactions from supine, prone and sitting on a ball~Stretching exercises for the muscles liable to be tight~Facilitation of sitting"
45624055|NCT04937439|Other|Segmental trunk training A|Group (A) will wear an external segmental trunk support extended from the level of pelvis to a level just below the rib cage.
45624056|NCT04937439|Other|Segmental trunk training B|Group (B) will receive the same program given to (group A) while wearing an external segmental trunk support extended from the level of pelvis to a level just below the inferior angle of scapula.
45624057|NCT04937439|Other|Segmental trunk training C|Group (C) will receive the same program given to (group A and B) while wearing an external segmental trunk support extended from the level of last rib to the level of the inferior angle of scapula.
45624058|NCT03245567|Other|PLM|Participants will take the PLM on the visual estimation of LVEF. They will also take a pretest, a post-test and a delayed test at 6 months.
45624059|NCT03245567|Other|Pre, post, delayed test|Participants will perform a pretest, a posttest and a delayed test at 6 months.
45624060|NCT04944381|Biological|SARS-Cov-2 mRNA vaccine immunization|The 98 participants will be inoculated with one dose SARS-Cov-2 mRNA vaccine from Stemirna Therapeutics Co., Ltd and .
45624061|NCT04944381|Biological|Inactivated SARS-Cov-2 vaccine immunization|The 14 participants will be inoculated with one dose inactivated SARS-Cov-2 vaccine from institute of medical biology, Chinese academy of medical sciences(IMBCAMS).
45624062|NCT03245177|Biological|Pembrolizumab|Anti-PD-1 antibody
45624063|NCT03245177|Radiation|Radiotherapy|60-66 Gy in 30-33 fractions, 2 Gy per fraction
45624064|NCT03245333|Drug|Recombinant Human Growth Hormone Injection|Stage 1：JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）for 52 weeks.
45624065|NCT03245333|Drug|Recombinant Human Growth Hormone Injection|Stage 2: After completing phase 1, patients are administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd weeks to the final height.
45624066|NCT04944537|Other|No Intervention|No Intervention
45624067|NCT04937283|Procedure|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
45624068|NCT04937283|Procedure|Lobectomy with hilar and mediastinal lymph node dissection|Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
45624069|NCT03245255|Drug|Sonazoid|Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Sonazoid infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure, SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
45765703|NCT05448495|Other|Posterior TAP block|Using high-frequency linear ultrasound probe, a total volume of 24 ml (20 ml isobaric bupivacaine 0.5% + 2 ml dexmedetomidine [0.5 mcg\kg] + 2ml dexamethasone [0.1mg\kg)] will be injected at the plane between internal oblique and transversus abdominis near the aponeurosis at the posterior axillary line.
45624070|NCT03245099|Other|cross sectional|Electroencephalograph will be done to all patients who fulfill the inclusion criteria to detect presence of electrical discharge with in the brain.Complete blood count ,liver function test ,kidney function test ,blood glucose level and serum electrolytes will be done to selected cases according to the clinical presentation
45624071|NCT04933305|Procedure|Roux-en-Y Gastric Bypass|Laparoscopic surgical procedure
45624072|NCT03244787|Behavioral|patient navigation|Current standard of care is for PNs to work with patients from health centers who are referred by providers. Intervention patients will appear on a PN list without any referral by providers. Control high risk patients will proceed normally and will be eligible to transfer to a PN list after the 6-month study period.
45624073|NCT04937049|Other|EMAeHealth digital tool|eHealth intervention to support Maternal Education
45765704|NCT05448495|Other|ESPB|Using high-frequency linear ultrasound probe, a total volume of 24 ml (20 ml isobaric bupivacaine 0.5% + 2 ml dexmedetomidine [0.5 mcg\kg] + 2ml dexamethasone [0.1mg\kg)] will be injected at T9 erector spinae plane
45765705|NCT04346927|Other|Telerehabilitation|15 volunteers diagnosed with coronavirus will be included in experimental group. An online exercise program has been created for individuals who will participate in the study. This program is planned to continue 3-4 days a week, in a 30-minute session and for 6 weeks. Treatment sessions will include breathing exercises, posture exercises, peripheral muscle exercises and light aerobic exercises. Individuals were asked to participate in the research via telerehabilitation connection system and were told that they would do their exercises with a physiotherapist.
45765706|NCT04346927|Other|exercise brochure|15 volunteers diagnosed with coronavirus will be included in control group.The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.
45624074|NCT03244631|Procedure|Lumbar Plexus BLock|Peripheral nerve block
45624075|NCT03244631|Procedure|Pericapsular injection|Injection around the area undergoing surgery
45624076|NCT04932993|Behavioral|Writing down goals|Patient will write their health goals down before the visit.
45624077|NCT03244709|Drug|Tocilizumab|Intravenous Tocilizumab followed by subcutaneousTocilizumab
45624078|NCT04409145|Drug|VT30|VT30 gel is intended as a topical treatment of cutaneous VMs, LMs, or VLMs that driven by inappropriate PI3K activation. In the skin, VT30 is rapidly metabolized to VT10, an active drug form, and is intended to sufficiently permeate the stratum corneum and achieve target engagement. It is expected that VT30 will lead to amelioration of the signs and symptoms of cutaneous VMs, LMs and/or VLMs.
45765707|NCT03023527|Drug|Nivolumab|
45765708|NCT03023527|Drug|Pomalidomide|
45912596|NCT02012062|Drug|TPF neoadjuvant chemotherapy|
45624079|NCT03244943|Procedure|Non surgical periodontal Treatment|The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under local anesthesia. On average, the treatment of the entire oral cavity was completed within four sessions (sessions of 50 minutes). The SRP was performed by one experienced periodontist (KRVV) using Gracey curettes (Hu-Friedy MFG. Co. Inc., Chicago, IL, USA), ultra-sonic devices (Bob-Cat, Dentsply/Cavitron, Long Island City, NY, USA) and, if necessary, with multilaminated drills.
45624080|NCT04958187|Drug|ANG-3777|Arm assigned to this intervention will receive 2 mg/kg, IV
45624081|NCT03244319|Drug|Edoxaban|Patients who are randomly assigned to edoxaban group will be received 60mg qd or 30mg qd (creatinine clearance 30-49ml/min, body weight <60kg or concomitant use of certain P-glycoprotein inhibitors).
45624082|NCT03244319|Drug|Warfarin|All patients who are assigned to VKA group, bridging with warfarin and UFH is mandatory until INR reach therapeutic target range (INR 2-3). Warfarin dose will be adjusted for maintain therapeutic range (INR 2-3) during follow up period.
45624083|NCT03244319|Drug|parenteral anti-coagulant (UFH)|parenteral anti-coagulant (UFH)
45624084|NCT03244553|Drug|Prucalopride|5 day treatment
45624085|NCT03057327|Behavioral|Improve awareness of checking moles|"Intervention:~Improve awareness Each of the eight changing rooms will have a large mirror that can be used to see the face and chest. Each room will be equipped with a poster, brochures and the SSE kit consisting of the laminated card with a ruler on one edge and the magnifying lens will be fastened to the wall on a cord.~Provide education The subject may chose to read the poster and a brochure. c) A woman research assistant will perform in-person exit interviews with participants to ascertain if women noticed the poster, and found the information relevant."
45624086|NCT03057327|Other|Comparator|Prior to placing the intervention materials into the changing rooms, 100 eligible subjects will be asked if they regularly check their moles for concerning features. If the response is yes, then they will be asked if they have found concerning moles and what they did next.
45624087|NCT03244397|Other|Physical therapy + educational strategy|See arm/group descriptions
45624088|NCT03244397|Behavioral|Educational strategy|See arm/group descriptions
45765709|NCT03023527|Drug|Dexamethasone|
45912597|NCT02012062|Drug|Concurrent chemotherapy with cisplatin during radiotherapy|
45624089|NCT03244241|Drug|Insulin Degludec 100 UNT/ML [Tresiba]|Basal-bolus insulin regime
45624090|NCT04932837|Biological|Blood and Saliva collection|Serological, viral RNA and antigenic test
45624091|NCT04937205|Behavioral|MOVE|The MOVE physical activity support program is based on the Self-Determination Theory and targets autonomous motivation for physical activity by encouraging 1) choice in physical activity type (e.g. walking, household chores, yoga), 2) a meaningful, value-based rationale for engaging in physical activity, and 3) physical activity that is intrinsically enjoyable. MOVE was delivered during two, 60-75 minute group-based classes and one, 45 minute individualized 1:1 support session to enhance adherence to physical activity recommendations within a lifestyle weight loss program. The group-based classes included a combination of PowerPoint slides, participant handouts, and group-based discussions. All MOVE content was delivered by trained study staff.
45624092|NCT03244085|Drug|QL-007 tablet|Patients will be enrolled in 1 of 3 cohorts (6 patients per cohort): QL 007 200 mg/day (100 mg BID), or QL 007 400 mg/day (200 mg/BID), or QL 007 600 mg QD. QL 007 will be administered orally daily over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
45624093|NCT04937361|Other|rectal swab|collection of rectal swabs
45653391|NCT05065593|Other|physical activity recommendation|Patients will be informed about the importance of lifestyle change in disease management, walking training will be given to increase their physical activity level, and participants will be asked to follow a 45-minute walking program every day within their own means.
45765710|NCT03023527|Drug|Elotuzumab|
45912598|NCT02012062|Drug|Concurrent nimotuzumab during radiotherapy|
45912599|NCT02012062|Radiation|Radical radiotherapy|
45912600|NCT02012075|Drug|Extended-Release Carvedilol Sulfate|
45912601|NCT02012075|Drug|Sustained-release Metoprolol Succinate|
45912602|NCT02012088|Drug|RCOMP|Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
45912603|NCT02012088|Drug|RCHOP|Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
45765711|NCT04359875|Behavioral|Phone-call screening and management by a medical student/general practitioner tandem|"Systematic phone contact of the patient by a medical student, under the indirect supervision of the general practitioner. This phone contact will be standardized with 3 questions to ask to the patient:~How are you doing? (with a Likert scale from 1=very bad to 10=very well)~Would you have made an appointment with your general practitioner if there had not been COVID19 epidemic and containment?~Would you like an appointment with your doctor and / or has your doctor ever contacted you? In view of the answers to these 3 questions, the general practitioner will decide whether it is necessary to propose a consultation or a teleconsultation to the patient, taking into account his/her medical background."
45624094|NCT03243929|Behavioral|Translation of District Sun Safe Policies to Schools|Translation of District Sun Safe Policies to Schools intervention was guided by Diffusion of Innovation Theory. Principals and other staff in intervention schools received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices. These components promoted implementation of the 10 policy components recommended by CDC.
45765712|NCT04367285|Other|Sensor-based Training|Sensor-based Training consists of twelve sessions of upper limb training with PABLO®-Tyromotion. For each session the training consists in interactive-games based on virtual reality which allowed a task-oriented approach and a neurocognitive feedback. The exercises require precision tasks and one-dimensional and bidimensional reaction, allowing to train the attention, the strength control and movement control, the coordination and the movement precision. The interactive-games were chosen from those proposed by the Tyromotion PABLO® System.
45624095|NCT03243929|Behavioral|Attention Control|Schools in the control condition received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
45624096|NCT03243851|Drug|Temozolomide+Metformin|Low dose temozolomide+metformin for 24 weeks
45624097|NCT03243851|Drug|Temozolomide+Placebo|Low dose temozolomide+placebo for 24 weeks
45624098|NCT02623959|Behavioral|Questionnaires|Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline or Doxycycline.
45765713|NCT04367285|Other|Upper limb motor training|Upper limb motor training, without robotic support. Subjects performed specific exercises aimed to recovery global upper limb functions, to control hand grasp and to improve hand's fine movements.
45624099|NCT02623959|Drug|Fentanyl Patch|Participant given a Fentanyl patch, 12 mcg/hour, which should be worn at follow up visit 5 days after IPC placement.
45624100|NCT02623959|Drug|Fentanyl (IV)|Fentanyl 50 mcg given by vein prior to catheter draining.
45624101|NCT02623959|Other|Saline|Catheter is drained then Saline placed in the catheter. Catheter is capped for 1 hour and then drained again.
45624102|NCT02623959|Drug|Doxycycline|Catheter is drained then Doxycycline 500 mg placed in the catheter. Catheter is capped for 1 hour and then drained again.
45624103|NCT02623959|Behavioral|Phone Calls|After the IPC is removed, participant is called one time each month by study staff to check on their status.
45624104|NCT02454023|Device|Portable sleep monitor (ApneaLink Air)|Use of a portable sleep monitor that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
45765714|NCT02977689|Drug|IDH305|study drug used to inhibit IDH1 mutation in these tumors, resulting in anti-tumor activity.
45624105|NCT02454023|Device|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
45624106|NCT04936503|Diagnostic Test|Resting electrocardiogram|An ECG at rest is performed for all participants at Day 0. A centralized reading is performed by one of the 6 expert cardiologists participating in the research.
45624107|NCT04936503|Diagnostic Test|Stress test|In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a stress test is performed.
45624108|NCT04936503|Diagnostic Test|Cardiac echocardiography|In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac echocardiography is performed.
45624109|NCT04936503|Diagnostic Test|Cardiac rhythm monitoring|In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac rhythm monitoring is performed.
45624110|NCT04936503|Other|Questionnaire|To determine the rhythmic risk of athletes
45765715|NCT04366661|Diagnostic Test|low dose CT|Invited participants from institutes exposed to a high level of smoke pollution such as employees of Transport and Oil Ministries are inquired for their personal history of cigarette smoking then subjected to low dose CT
45624111|NCT04936503|Device|Injected Cardiac MRI|"High resolution MRIs is performed on 200 athletes :~100 athletes without rhythmic abnormalities (50 individuals with positive COVID-19 status and 50 individuals with negative COVID-19 status)~100 athletes with rhythmic abnormalities (50 individuals with positive COVID-19 status and 50 individuals with negative COVID-19 status)"
45765716|NCT04878627|Drug|Cannabidiol|patients receive cannabidiol at various doses for 3 weeks
45624112|NCT04936503|Biological|Blood sampling for biobank|"For all athletes included at the D0 inclusion visit, a centralized COVID-19 serology is performed to search for biomarkers associated with the occurrence of myocardial fibrosis: analysis of genetic determinants in relation to cardiac damage.~For athletes who have performed MRI: Search for biomarkers associated with the occurrence of myocardial fibrosis: analyses of low-grade inflammation markers (cytokine assay and fibrosis markers)."
45765717|NCT04878627|Drug|Placebo|patients receive placebo for 3 weeks
45765718|NCT02244515|Drug|dexmedetomidine|dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
45765719|NCT03833375|Other|Decision Aid|Shared-decision making tool
45624113|NCT03244007|Procedure|Vitrectomy|
45765720|NCT05095935|Other|N/A observational registry|N/A observational registry
45765721|NCT04360031|Drug|Tacrolimus|Tacrolimus and Mycophenolate Mofetil are given in accordance with patient's current regimen
45765722|NCT00953719|Device|36 mm ceramic head on a ceramic acetabular liner|Total hip replacement with a 36 mm ceramic head on a ceramic liner
45765723|NCT00953719|Device|28 mm ceramic head on a polyethylene acetabular liner|Total hip replacement with a 28 mm ceramic head on a polyethylene liner.
45765724|NCT04366739|Drug|CHLORPROMAZINE (CPZ)|"Drug List 1, AMM obtained in 1952, AMM 3400930571187 1952/90, RCP revised 22/08/2019 Administration: oral route, if the clinical condition requires it, intravenous administration.~Initial dosage: 75 mg per day orally (or 37.5 mg per day orally in subjects 75 years of age or older).~Then: titration up to the maximum tolerated dose, with a minimum of 12.5 mg and a maximum of 300 mg per day by the oral administration (or 600 mg per day by the oral in certain exceptional cases which also correspond to the CPM CPM marketing authorization indications); or from 6.25 to 150 mg per day intravenously.~Duration of treatment: until healing criteria are obtained (≥ 8 days from the onset of COVID-19 symptoms AND ≥ 48 hours of apyrexia and absence of dyspnea) or 21 days maximum"
45765725|NCT04366739|Combination Product|Standard of Care (SOC)|"In the absence of a reference treatment in COVID-19, the standard of care (SOC) is the comparison arm"
45765726|NCT04876599|Behavioral|IN FOCUS|Adapted Resiliency Group Intervention
45624114|NCT03243617|Other|Placebo|"Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~Subjects may not wash their body with soap and water AFTER the applications"
45765727|NCT04876599|Behavioral|Usual Care|Referral to Virtual Group Support
45765728|NCT03023059|Drug|Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet|See Arm description
45765729|NCT04873869|Drug|NBI-921352|Administered orally
45765730|NCT04873869|Drug|Placebo|Administered orally
45765731|NCT03022513|Other|Gluten free diet|The investigators will evaluate the prevalence of fibromyalgia-like joint/muscle pain and the possible ultrasonographical alterations (i.e. synovitis) of hands and feet joints in NCWS patient at baseline (i.e. at the moment of diagnosis) and after a gluten free diet period of almost 6 months.
45765732|NCT02244827|Drug|WCK 2349|levonadifloxacin (active drug) and the sulfate metabolite
45765733|NCT00360789|Behavioral|Conventional UK physical therapy|
45765734|NCT00360789|Behavioral|Increased intensity of UK conventional physical therapy (PT)|
45765735|NCT00360789|Behavioral|UK conventional PT plus functional strength training|
45765736|NCT02244905|Behavioral|Positive Deviance|The recipients of the Positive Deviance intervention are the staff members of the three wards in the intervention arm, while the outcomes are measured among the patients receiving care in the three wards in the intervention arm. Key components of the intervention were invitation to participate voluntarily, open-ended dialogues with staff members to discover barriers and seek solutions to prevent HAI, discussion of outcomes, and encouragement to prioritize and implement the solutions generated.
45624115|NCT03243617|Other|AO+Mist|"Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~Subjects may not wash their body with soap and water AFTER the applications"
45765737|NCT02244905|Other|Standard-of-Care Infection Control approach|Standard-of-Care Infection Control approach
45765738|NCT01012921|Device|barrier membrane|The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
45446898|NCT02094040|Behavioral|Receive municipality-based follow-up visit|Systematic electronic referral from hospital to municipality of high risk people at discharge from a medical ward. Contact from municipality service to primary physician and citizen, to arrange first home visit within 7 days with focus on: medication, rehabilitation plan and health care appointments, functional level and need for further health care initiatives. The visit is concluded by planning of further visits (up till tree) and division of responsibilities between primary physician and the municipality service.
45765739|NCT01012921|Device|MembraGel|Device application at surgery
45765740|NCT01012921|Other|Bio-Gide® membrane|Device application at surgery
45765741|NCT04360499|Other|Low- weight-high-repetitions training|LWHR refers to a specific form of resistance exercise which utilizes low weights and very high repetitions
45765742|NCT04360499|Other|Pilates training|Pilates style exercise training
45765743|NCT04359485|Procedure|Glycolic acids peel 70%|Glycolic acid peel 70% applied in 3 coats medium depth
45765744|NCT04359485|Other|Saline|Sodium chloride
45765745|NCT03055000|Biological|AGS-v|AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
45446899|NCT02250118|Drug|Bevacizumab|Intrapleural Bevacizumab
45452396|NCT00906334|Drug|ON 01910.Na|Per Amendment 3 to the Protocol, the dosing regimen was changed to 1800 mg ON 01910.Na. Patients enrolled at the original dosing regimen could choose to remain in the original regimen or switch to the new regimen.
45452397|NCT00905164|Drug|Topiramate Capsules, 25 mg|Topiramate Capsules, 2 x 25 mg
45624116|NCT03243773|Other|Lung ultrasound|Point-of-care ultrasound exam of both lungs in 4 predefined zones.
45624117|NCT04936659|Other|neuromodulation|Palpatory neuromodulation of the V1 and V2 branches of the trigeminal nerve where they exit onto the face.
45624118|NCT03243695|Other|Angled Abutment|virtual implants will be placed on a planning software allowing abutments to be placed at an angle to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The angled abutment will be placed and a temporary crown material will be fabricated.
45624119|NCT03243695|Other|straight abutment|virtual implants will be placed on a planning software allowing abutments to be placed at straight to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The straight abutment will be placed and a temporary crown material will be fabricated.
45624120|NCT04957797|Procedure|round tunnel|reamed with round tunnel
45624121|NCT04957797|Procedure|flat tunnel|reamed with flat tunnel
45624122|NCT03243539|Procedure|Lung Protective Ventilation|Neuro lung protective ventilation for patients with acute brain injury is designed to target a normal partial pressure of arterial carbon dioxide and decrease initial tidal volumes toward a target 6 ml/kg predicted body weight PBW (range 6 to 8 ml/kg PBW)
45624123|NCT04936347|Procedure|cold knife|Transcervical resection of adhesions is performed with scissors to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
45624124|NCT04936347|Procedure|hot knife|Transcervical resection of adhesions is performed with bipolar electric cutting to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
45624125|NCT03243227|Other|Neurodynamic techniques|4 sessions of Neurodynamics treatment will be provided by and experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.
45624126|NCT03243227|Other|Exercise therapy|AROM exercise stretching exercise strengthening exercise 4 sessions
45624127|NCT03243383|Other|DiaTOHC Program|"Patient-centered education 1a) Standardized diabetes discharge instructions and education 1b) Comprehensive discharge plan review~Peri-discharge coordination of care~A1c-based adjustment of diabetes therapy~Post-discharge support"
45765746|NCT03055000|Biological|AGS-v + adjuvant|ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL) on Day 0 and on Day 21
45624128|NCT04957563|Behavioral|olfactory rehabilitation|treatment for improve olfactory function
45624129|NCT03242993|Drug|[18F]-AzaFol|[18F]-AzaFol is a radiotracer produced at ETH Hönggerberg in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 6 mL of formulated product, the maximal applicable dose being 600 MBq.
45765747|NCT03055000|Other|Placebo|WFI (0.5mL) on Day 0 and Day 21
45624130|NCT03242993|Drug|folarell|"For the purpose of this study only 1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to [18F]-AzaFol. Due to this low dose of a single injection of folic acid it is unlikely that adverse events would occur.~Folarell® is a folic acid preparation for intravenous or intramuscular injection"
45765748|NCT02245061|Other|paired pulses cortical electrical stimulation|
45765749|NCT04376099|Diagnostic Test|Transcutaneous oxygen pressure measurement during the treadmill test|"Calculation of the decrease from rest of oxygen pressure (DROP) throughout the period of rest exercise and recovery.~The DROP is calculated as chanegs on each limb probe minus changes on a chest reference probe from rest.~Analysis of the recovery period of the recordings will be done to seach for recovery 50% and 90% from the minimal DROP observed Evaluation of calf and non calf pain during the tests. Evaluation of calf and non calf (buttock or thigh) ischemia during the tests. Ischemia being defined as a monimal DROP lower than minus 15 mmHg."
45765750|NCT04376021|Behavioral|Babywearing|Increase mother-infant physical contact through babywearing
45765751|NCT00922883|Drug|Eltrombopag|
45912604|NCT02012101|Device|niv plus oxygen therapy|NIV given on Philips Respironics BiPAP Vision apparatus.
45912605|NCT02012101|Device|oxygen therapy|
45912606|NCT02012140|Drug|ticagrelor|
45452398|NCT00905164|Drug|Topamax® Capsules, 25 mg|Topamax® Capsules, 2 x 25 mg
45624131|NCT03057249|Other|Dynamic infrared thermography (DIRT)|Evaluating abdominal skin perfusion with DIRT
45624132|NCT02559323|Other|Survey|
45624133|NCT04957407|Other|pepsinogen|diagnostic value of pepsinogen for severe atrophy and gastric cancer
45765752|NCT03055156|Device|Low rebound mattress toppers|Patients will sleep on this mattress topper during their diagnostic sleep study.
45765753|NCT03055156|Device|High rebound mattress toppers|Patients will sleep on this mattress topper during their diagnostic sleep study.
45765754|NCT04357613|Drug|Experimental drug|Imatinib 800mg/d during 14days
45765755|NCT02976987|Drug|Cidofovir|
45765756|NCT02244281|Drug|tamsulosin hydrochloride|
45912607|NCT02012166|Drug|MK-0893 10 mg|MK-0893 10 mg administered orally in 240 mL of water
45912608|NCT02012166|Drug|MK-0893 40 mg|MK-0893 40 mg administered orally in 240 mL of water
45452399|NCT05344118|Other|Survey|REDCap survey
45452400|NCT05628298|Device|Soovu Pain Relief System|The Soovu Pain Relief system uses pulses of heat to block the TRPV-1 calcium channel on peripheral pain nerves. The study will determine if the FDA cleared device significantly reduces the subject's pregnancy related pain.
45765757|NCT02244281|Drug|Placebo|
45912609|NCT02012166|Drug|MK-0893 200 mg|MK-0893 200 mg administered orally in 240 mL of water
45912610|NCT02012166|Drug|MK-0893 1000 mg|MK-0893 1000 mg administered orally in 240 mL of water
45912611|NCT02012166|Drug|Placebo|Placebo administered orally in 240 mL of water
45624134|NCT04487093|Drug|neoantigen vaccine + EGFR-TKI|"Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 5 weeks.~The targeted drugs are used continuously according to the instructions and dosage until disease progression or intolerance."
45624135|NCT04487093|Drug|neoantigen vaccine + anti-angioge|neoantigen vaccine + anti-angioge
45624136|NCT03242837|Behavioral|Army Resilience Training|The Army Resilience Training consists four training sessions of 90 minutes each. Participants learn to reflect their stress management (including thinking, emotions, behavioral consequences; coping strategies) and build resilience using specific strategies.
45624137|NCT03242837|Other|Diversity Management Training|Diversity Management Training consists four training sessions of 90 minutes each. Participants learn about diversity and social awareness reflecting different situations and settings.
45624138|NCT04936971|Drug|Switch from Mycophenolate Mofetil to Everolimus manteinance treatment in Active Comparator Arm|Switch from Mycophenolate Mofetil in Active comparator Arm if assymptomatic Cytomegalovirus viremia >1000-<5000 copies/mL observed
45765758|NCT04376177|Diagnostic Test|Ultrasound|Echodoppler imaging of upper limbs performed by trained operators at rest and during provocative maneuvers for TOS diagnosis.
45765759|NCT04376177|Diagnostic Test|angiography|Angiography (arterial and/or venous) of upper limbs performed by trained operators at rest and during provocative maneuvers such for TOS diagnosis.
45624139|NCT04936971|Other|no intervention|Manteinance of assigned Arm treatment even if assymptomatic Cytomegalovirus viremia >1000-<5000 copies/mL observed
45624140|NCT03242681|Procedure|Endoscopy Assisted Probing procedure|The patency of the system will be tested by irrigation with 1 ml normal saline. A cannula was introduced via the upper or lower canaliculus as far as the lacrimal sac and fluid injected through the system from a 5 ml syringe. Nasal endoscopy and irrigation will be performed simultaneously and free flow of fluid from the lacrimal sac to the nose will confirm anatomical patency of the system
45624141|NCT03242525|Diagnostic Test|POCT and central laboratory blood analysis|In every participant blood analysis will be performed by POCT and central laboratory investigating the time advantage.
45765760|NCT04376177|Diagnostic Test|questionnaires|Use of standard questionnaires (MASC, DASH, SF36) for the evaluation of upper limb symptoms self-completed by the patients at admission.
45765761|NCT04376177|Diagnostic Test|Transcutaneous oximetry|Mesurement of transcutaneuos oxygen pressure on both forearms performed at rest and during provocative maneuversfor TOS diagnosis.
45765762|NCT04376177|Diagnostic Test|plethysmography|Photoplethysmography of the forearms or fingers performed at rest and during provocative maneuvers for TOS diagnosis
45765763|NCT04376177|Diagnostic Test|Electromyogram|Electromyography of the upper limbs with encoding of the physician for the presence or abnsence of signs of plexis compression (impairment of the response on C8 T1 erea
45765764|NCT04376177|Diagnostic Test|Standard X-Ray|Standard X-Ray performed for the research of apophysomegaly or additionnal cervical rib.
45765765|NCT04499781|Behavioral|ACCESS II mHealth Intervention|Participants in the intervention condition will use videoconferencing to connect synchronously with trained HIV+ peer health coaches who will deliver eight weekly, 60-minute cognitive behavioral, motivational sessions for improved ART adherence.
45624142|NCT03242603|Biological|Anti-GD2 in combination with NK cells|Haploidentical donor NK cells will be expanded over 10 days and infused in combination with anti-GD2. Anti-GD2 will be given as daily infusion for 5 days ; D-1, 0,+1, +2 and +3. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day -3 and day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
45624143|NCT04931433|Drug|Lignocaine|Group A will receive 1.5mg/kg IV lignocaine bolus prior to induction followed by 2mg/kg/hour of lignocaine infusion throughout surgery until wound closure in which the infusion will be halved to 1mg/kg/hour until the end of surgery. The same rate will be infused in the recovery room for another half an hour before participant is discharge.
45624144|NCT04931433|Drug|Normal saline|Group B will receive saline of similar volume and rate as Group A
45624145|NCT03242369|Procedure|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose (2+2l) PEG. 2 liters will be drunk during 2 hours in the evening the day before colonoscopy, the second 2l during 2 hours in the day of colonoscopy finishing the dose 4- 6 hours before colonoscopy.
45765766|NCT04499781|Behavioral|ACCESS II control condition|Web-based HIV adherence education. Participants in the control group will connect asynchronously to a web-based HIV ART adherence education condition.
45765767|NCT00361413|Drug|Alefacept (AMEVIVE®)|Alefacept
45765768|NCT00361413|Drug|control group|these patients will receive the same treatment as group A, without alefacept
45765769|NCT03062488|Drug|IV acetaminophen|multi-modal analgesia with IV acetaminophen
45765770|NCT03062488|Drug|Fentanyl|single modal analgesia
45765771|NCT03062488|Drug|PO acetaminophen|multi-modal analgesia with PO acetaminophen
45765772|NCT00936299|Drug|Bupropion|Bupropion (target dose 300 mg/day) + cognitive behavioral therapy; matched placebo + cognitive behavioral therapy
45765773|NCT00936299|Other|Placebo|
45624146|NCT03242369|Procedure|colonoscopy|100 patients undergoing colonoscopy will by prepared with split dose of SS. The first bottle of SS with water (total volume 0,5l) will be drunk in the evening the day before colonoscopy during 1 hour, than another 1liter of clear fluid will be drunk. The same procedure will be repeated with the second bottle of SS finishing at least 3 hours before colonoscop
45624147|NCT03242369|Procedure|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose of PEG (1+1L) with ascorbic acid. The first 1l of solution will be drunk in the evening the day before colonoscopy, the second 1l of solution in the day of colonoscopy finishing 4-6 hours before the examination. Another 1l of clear fluid should be drunk during the cleansing process.
45624148|NCT03242369|Procedure|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose (150ml +150ml) of solution of magnesium acid and sodium picosulfate. The first dose will be drunk in the evening the day before colonoscopy, then at least 1l of another clear fluid will be drunk within a few hours, the second dose will be drunk in the day of examination finishing 4-6hours before colonoscopy and then another at least 750ml clear fluid.
45624149|NCT03242291|Other|Conventional resin-based flowable composite|assessment of marginal integrity of Conventional resin-based flowable composite
45624150|NCT03242291|Other|Hydroxyapatite Nanofiber reinforced flowable composite|assessment of marginal integrity of Hydroxyapatite Nanofiber reinforced flowable composite
45624151|NCT04486937|Drug|S410914 tablet|S410914 tablet
45624152|NCT03242213|Behavioral|Mobile App|The intervention in this study is a mobile health app, which provides patients with a way to track emotional wellbeing and depression symptoms, set up medication reminders, track adherence to medications, record side effects experienced, and take surveys/tests to assess cognitive symptoms and depression.
45624153|NCT04931121|Drug|Viscosupplements|Synovial fluid is collected as part of a conventional injection of viscosupplement
45624154|NCT04931277|Procedure|cataract surgery|stepped surgery in the form of primary phacoemulsification and secondary posterior chamber intraocular lens (PCIOL) implantation in patients with uveitis.
45624155|NCT03241823|Diagnostic Test|Abdominal ultrasound .|Abdominal ultrasound for each patient before and after treatment.
45765774|NCT04835493|Other|Intervention|In the proposed study, we will conduct a randomized clinical trial of low-income, adult Latino(a)s with type 2 diabetes randomized at the individual level to TIME (Telehealth-supported, Integrated CHWs, Medication-access, group visit Education) (intervention) versus usual care enhanced with education (EUC). Our research team will provide telementoring to local clinic teams (providers and CHWs) to initiate the 12-month TIME program into their clinics.
45624156|NCT03241823|Diagnostic Test|Model for End-Stage Liver Disease|Model for End-Stage Liver Disease before and after treatment.
45765775|NCT04375943|Drug|Antidiabetic|Verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy
45624157|NCT03241823|Diagnostic Test|Fibro Scan.|Liver stiffness by Fibro scan before and after treatment.
45624158|NCT03241823|Diagnostic Test|Child-Turcotte-Pugh score.|Child-Turcotte-Pugh score before and after treatment
45624159|NCT03241901|Drug|Artemether-Lumefantrine Tab 20-120mg|Artemether-Lumefantrine Tablet 20-120mg
45624160|NCT03241901|Drug|Primaquine Phosphate 0.25 mg/kg|Primaquine Phosphate 0.25 mg/kg
45446900|NCT03556306|Procedure|Bariatric surgery|"The gastric bypass (simplified technique) was performed in an antecolic fashion, with a calibrated 2 cm gastro-jejunal anastomosis (linear stapler); biliary and alimentary limbs measured 70 and 150 cm respectively [17] . Mesenteric defects were closed and the omentum divided. The sleeve gastrectomy was performed at 5-6 cm from the pylorus over a 36 Fr. bougie, with oversuture of the staple line (2-0 polypropylene). Methylene blue test and the use of drains were done routinely."
45624161|NCT03241901|Other|Placebo|Aqueous solution prepared to mimic the taste of the intervention drug.
45624162|NCT04930575|Other|Muscle Energy Technique|A biomechanical correction approach can lead to the normalization of spinal curvatures and a decrease in the compressional and tensional stress on joints and soft tissues of the body.
45765776|NCT04375865|Drug|AD-2111|celecoxib 200mg
45765777|NCT04375865|Drug|AD-2112|Tramadol 150mg
45765778|NCT01014091|Biological|GSK pandemic vaccine GSK2340272A|2 intramuscular injections
45765779|NCT03117634|Drug|Treat and Extend with Aflibercept 2mg|Drug treatment regime which allows extension of treatment interval based on disease activity
45765780|NCT03117634|Drug|Fixed Dosing with Aflibercept 2mg|Fixed 8 weekly dosing regime throughout the study duration
45765781|NCT04375709|Other|Physical exercise|The intervention consists out of combined aerobic and strength exercise supervised and guided by specialized physical therapists; additional methods like functional electrical stimulation or oxygen supplementation are added during the main training if indicated.
45624163|NCT04930575|Other|Mulligan Technique|"The patient will be in a supportive low back chair, thus cervical region will be in a vertical position (Weight-bearing position) with the therapist position will be behind the patient.~Then the therapist will move the spinous process up in the direction that must follow the apophyseal joint plane under treatment, that is, toward the eye ball. While sustaining this pain-free accessory glide, the patient will be instructed to actively perform the physiological movement gradually until the end ROM with over pressure at the end of the range."
45624164|NCT03242057|Other|NAVA|Infant will be extubated to NAVA, settings based per protocol
45624165|NCT03242057|Other|NIPPV|Infant will be extubated to NIPPV, settings detailed in protocol
45624166|NCT04957251|Procedure|anterior approach to the hip|anterior hip hemiarthroplasty
45624167|NCT04957251|Procedure|posterior approach to the hip|posterior hip hemiarthroplasty
45624168|NCT04957017|Behavioral|Training|"After the data was collected, the women in the intervention group were trained on Hand-Washing and Nutrition during the COVID-19 period. The training on hand-washing and nutrition was given using the Hand-Washing and Nutrition Training Guide prepared by the researchers, and the Hand-Washing and Nutrition Training Manual covering the content of the training, was distributed to the women at the end of the training"
45624169|NCT03241433|Other|High intensity interval training|exercise by use of stationary cycles
45624170|NCT03241433|Other|Moderate intensity continuous training|exercise by use of stationary cycles
45624171|NCT03241433|Other|No Exercise|no exercise training will be given and no exercise will be added to subjects routine
45624172|NCT03058731|Device|Matristem|Paraesophageal hernia repair with MatriStem Surgical Matrix
45624173|NCT03058731|Device|Control|Paraesophageal hernia repair with other biologic mesh
45624174|NCT03241511|Other|Test|Briefly, treatment sessions will include oral hygiene behavioral modification and scaling and root planning (removing the bacterial biofilm and calculus below the gum line) in order to eliminate etiologic factors and control periodontal inflammation. Once the treatment sessions are completed, the patients will enter the maintenance phase and will be followed for 6 months. In this phase, the patients will receive systematic supportive periodontal treatment (tooth cleanings above the gum line with re-enforcement of oral hygiene).
45624175|NCT04936737|Dietary Supplement|Beta-alanine supplementation|The supplementation will be administrated in the dosage of 20mg.kg-1. On the first and the sixth (last one), one dose of beta-alanine will be taken. On the other four days of supplementation, the volunteers will take 2 doses (20mg.kg-1) of Beta-alanine.
45624176|NCT04936737|Other|High intensity interval exercise|The HIIE sessions will consist of 10 series of 1 min of effort, divided into two blocks of 5 series each. There will be an interval of 5 min of passive recovery; within each block, the interval between sets will be 1 min of active recovery. The exercise will be conducted in a mechanical brake cycle ergometer, with load applied by placing washers on a load plate (Biotec 2100, Cefise, Brazil).
45624177|NCT03241745|Drug|Nivolumab|Nivolumab 480 mg IV once every 4 weeks
45765782|NCT04375709|Behavioral|Education sessions|Sessions include information on physical activity (behaviour), coping with stress and anxiety, dyspnoe, or fatigue; Professional support is given in case of risk for nutritional deficits or post-traumatic stress; sessions are conducted by medical specialists or specialized physiotherapists. All sessions are individually-tailored. In case of nutrition or psychological issues individual sessions are guided by specific health-professionals.
45765783|NCT05071365|Other|Early access to virtual resources|Single arm study. Participants are given access to self help videos for the management of plantar fasciitis while they are on the waiting list
45765784|NCT01014169|Behavioral|Note taking|The mothers in the intervention group will be given a pen and encouraged to take written notes in the notes section of a discharge envelope using their language of preference when receiving standard newborn discharge information.
45912612|NCT02012166|Biological|Sandostatine®|Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min.
45912613|NCT02012166|Biological|Insulin|At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.
45624178|NCT04956861|Behavioral|Individualized Targeted Sleep|The investigators will employ an 8-week individualized targeted sleep intervention. Individualized targeted interventions have the advantage of improving adherence, reducing attrition, and making the strategy personally meaningful.
45624179|NCT03241667|Device|HemoCartridge|Our goal is to apply MEMS (microelectromechanical systems) and nanotechnology to miniaturize the bioartificial kidney (BAK) into an implantable, self-monitoring, and self-regulating renal surrogate. The implantable BAK (iBAK) is a biocompatible cartridge containing stacks of hemofilter membranes (HemoCartridge) and renal tubule cell bioreactors (BioCartridge) combined to mimic nephron function. Here, we plan to test ONLY the material being used to construct the HemoCartridge, to be sure in humans when substituted for a standard hemodialysis filter, subjects don't develop any clinical problems or side effects during several hours of blood exposure to the material. The AK material will be engineered by the study team to allow the system to be substituted in place of a standard HD filter.
45624180|NCT00700739|Device|DISCOVER™ Artificial Cervical Disc|DISCOVER™ Artificial Cervical Disc
45624181|NCT00700739|Device|ACDF|Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
45624182|NCT04486703|Other|Exercise with music|physical therapy program combined with music therapy 15 min, 3 times weekly for 12 weeks.
45624183|NCT04930497|Procedure|vestibular socket technique with bone grafting|a vestibular horizontal incision was made then a subperiosteal tunnel was created and a facial bone membrane was placed. The facial gap was filled with a mixture of autogenous bone and deproteinized bovine bone mineral
45624184|NCT04930497|Procedure|vestibular socket technique without bone grafting|the vestibular incision was done horizontally about 3 to 4 mm apical to the mucogingival junction and extending 5 to 10 mm horizontally. A submucoperiosteal tunnel was created labially from the socket orifice till the vestibular access incision
45624185|NCT03241277|Procedure|Non surgical periodontal treatment|Scaling and root planning that will be performed with manual curettes or ultrasonic instruments
45765785|NCT00937235|Drug|Varenicline|1 mg tablets, orally, twice daily x 12 weeks
45765786|NCT00937235|Behavioral|Medication Management Counseling|15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
45765787|NCT00937235|Behavioral|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
45765788|NCT01014403|Drug|enoxaparin|Enoxaparin 30 mg sq q 12 hours
45765789|NCT01014403|Drug|placebo|vehicle
45765790|NCT03120832|Biological|PAN-301-1|
45765791|NCT00937859|Drug|SER120|SER120
45912614|NCT02012166|Biological|Glucagon|At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min.
45446901|NCT02250196|Drug|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
45765792|NCT00937859|Drug|Placebo|Placebo
45765793|NCT05405608|Drug|Ondansetron|hemodynamic stability in orthopedic surgeries
45765794|NCT01014871|Drug|Botulinum Toxin Type A - Azzalure|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
45624186|NCT02623335|Other|QPL (question prompt list) brochure|The QPL intervention includes the QPL intervention brochure, plus a letter from the surgeon encouraging its use during the upcoming office visit. Intervention materials will be mailed in advance of the patient's appointment with an enrolled surgeon.
45624187|NCT03241199|Drug|Imatinib Mesylate|a first-generation tyrosine kinase inhibitors
45624188|NCT03241355|Dietary Supplement|prebiotic inulin-type fructan|
45624189|NCT03241355|Dietary Supplement|Placebo maltodextrin|
45624190|NCT04930419|Device|Videolaryngoscopy group|Tracheal intubation will be performed using Videolaryngoscope in first intention and will be performed using standard pre-hospital intubation procedures : preoxygenation before intubation, maintenance of oxygenation throughout procedure, standard sedation technique (using rapid sequence intubation (RSI)), correct position confirmation using a capnogram and conditioning (hemodynamic monitoring, respirator settings, securing). If the first attempt at intubation is unsuccessful, further management will be left to the discretion of the clinician according to the procedures and algorithm of usual standard care
45624191|NCT04930419|Device|Direct laryngoscopy group|Tracheal intubation will be performed using Direct laryngoscopy with Macintosh blades in first intention. and will be performed using standard pre-hospital intubation procedures : preoxygenation before intubation, maintenance of oxygenation throughout procedure, standard sedation technique (using rapid sequence intubation (RSI)), correct position confirmation using a capnogram and conditioning (hemodynamic monitoring, respirator settings, securing). If the first attempt at intubation is unsuccessful, further management will be left to the discretion of the clinician according to the procedures and algorithm of usual standard care
45624192|NCT02349893|Device|RFA treatment|RFA treatment using CelonProSleep plus system
45624193|NCT04935333|Procedure|Collection of Leiomyoma samples|"Peripheral blood will be collected from the candidate patient with suspected myometrial tumours, prior to the surgery already planned form medical indication in accordance with routine clinical practice.~A sample of tumour tissue will be collected during surgery and sent to pathologists for diagnosis in accordance with the usual clinical practice. The tumour paraffin block/sections will be requested for the study only after the diagnosis."
45624194|NCT04935333|Procedure|Collection of Leiomyosarcoma samples|"Peripheral blood will be collected from the candidate patient with suspected myometrial tumours, prior to the surgery already planned form medical indication in accordance with routine clinical practice.~A sample of tumour tissue will be collected during surgery and sent to pathologists for diagnosis in accordance with the usual clinical practice. The tumour paraffin block/sections will be requested for the study only after the diagnosis."
45624195|NCT04935333|Procedure|Collection of control samples|Peripheral blood will be collected during an analysis or gynaecological consultation already planned by routine clinical practice. The sample will be sent to Igenomix for molecular analysis.
45624196|NCT03241043|Drug|Treatment 2 weeks Envarsus followed by 2 weeks Advagraf|
45624197|NCT03241043|Drug|Treatment 2 weeks Advagraf followed by 2 weeks Envarsus|
45765795|NCT01014871|Drug|Botulinum Toxin Type A - Vistabel|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
45765796|NCT04357769|Other|PSS (Perceived Stress Scale)|Self-administered scale for the evaluation of the stress perceived by the subject in the last weeks
45912615|NCT02012205|Procedure|wet cupping|Participants assigned to the treatment group will receive wet-cupping therapy 3 times per week for 2 weeks
45446902|NCT02250196|Drug|SPMC 2|received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
45624198|NCT03240497|Behavioral|Cold Exposure|"The start of the training is scheduled 7 to 12 days before the endotoxemia experiment day. Subjects in this group will participate in a 4 day intensive cold exposure course (see section 5.1). On day 1, venous blood will be sampled directly after ice water immersion. On day 4, venous blood will be sampled before the training procedures on that day and after the last ice water immersion.~After the 4 day course, subjects will continue to practice cold exposure at home using cold showers. The timing and length of this training is analogous to the time spend on training in the cold in our previous study protocol [7]."
45765797|NCT04357769|Other|GAD-7 (7-item Generalized Anxiety Disorder)|Self-administered scale for the evaluation of anxiety symptoms in the last weeks
45624199|NCT03240497|Behavioral|Strength Ventilation|The training is scheduled 2 to 6 days before the endotoxemia experiment day. Subjects in this group will receive a detailed, written instruction about the strength ventilation technique (see section 5.1). In addition, they will receive a 2 hour instruction session during which the research team will supervise the practices and clarify the instructions of needed. Subjects are instructed not to practice the learned techniques at home.
45624200|NCT02453945|Device|Adjustable Support Bra|A ClearPoint Medical support bra
45765798|NCT04357769|Other|PHQ-9 (9-item Patient Health Questionnaire)|Self-administered scale for the evaluation of depressive symptoms in the last weeks
45912616|NCT02012231|Drug|PLX8394|PLX8394 is a next-generation, orally available, small-molecule, selective inhibitor of BRAF.
45912617|NCT02012244|Drug|fentanyl-based analgesia|fentanyl based patient-controlled analgesia + additional pethidine for postoperative 48 hour
45912618|NCT02012244|Drug|local anesthetic wound infiltration-based anlagesia|continuous wound inflitration with ropivacaine + tramadol patient-controlled analgesia + additional ketorolac or propacetamol for postoperative 48 hour
45912619|NCT02012257|Procedure|AMSA nerve block injectio|Sites of injection
45446903|NCT02089672|Device|Catheter ablation|This is observational trial studying the effects of a standard intervention of a catheter ablation procedure.
45624201|NCT04956315|Diagnostic Test|Side-to-side difference (reproducibility)|The experienced examiner performed tests on 20 healthy subjects
45624202|NCT04956315|Diagnostic Test|Side-to-side difference (availability)|Two examiners performed the test on one healthy subject with both devices for ten consecutive days.
45624203|NCT04956315|Diagnostic Test|Side-to-side difference (Accuracy)|200 ACL rupture and 200 healthy subjects were recruited as contrast to compare the accuracy of the devices in diagnosing ACL rupture.
45624204|NCT02453867|Other|Reduced immunosuppression|Stop steroids at month 3 Stop mycophenolate at month 6 continue tacrolimus once daily (Advagraf, trough levels > 5ng/ml) Stop mycophenolate at month 6
45765799|NCT04357769|Other|SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales|Self-administered scale for the evaluation of sub-threshold psychotic symptoms in the last weeks
45765800|NCT04357769|Other|Zaritt Burden Interview|Self-administered scale for the evaluation of severe mental disorder patients' caregiver burden
45624205|NCT02453867|Drug|Tacrolimus|Tacrolimus is used in both the acitve comparator arm and the interventional arm
45624206|NCT02453867|Drug|mycophenolate|Mycophenolate is used in the acitve comparator arm for the whole study period; Mycophenolate is stopped at month 6 after Transplantation (month 3 of the study) in the experimental arm
45624207|NCT02453867|Drug|Steroids|Steroids are used continually in the active comparator arm and are stopped at the beginning of the study (month 3 after Transplantation) as an Intervention in the experimental arm
45624208|NCT04956471|Other|interview|A sample method: convenience sampling, selecting A 3 armour hospital between September 2019 and January 2020 neurology hospital patients with swallowing disorder after stroke, about 15 cases.
45624209|NCT04935645|Behavioral|Progressive Muscle Relaxation|PMR is a technique that provides relaxation in the whole body by voluntary and regular relaxation of large muscle groups in the human body, which is included in mind-body applications.
45624210|NCT04956393|Behavioral|Immediate 8-Week SOAR Program|"This is an 8-week, virtually delivered, exercise-based, knee health program delivered to knee injury participants by trained physiotherapists. The program has 3 components:~Knee Camp: This includes an interactive education session about knee health, 1:1 knee exam, and 1:1 counseling session to identify Specific, Measurable, Attainable, Relevant, and Time-bound (SMART) weekly home-based exercise-therapy and physical activity goals, Participants are asked to wear Fitbit's® 24-hours/day.~Weekly Home-based Exercise-Therapy and Physical Activity, with Tracking: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises are tracked with an online bespoke form and activity, with a Fitbit.~Weekly PT-guided Exercise-Therapy and Physical Activity Counseling Sessions: Each week participants will attend a 1:1 virtual physiotherapist counseling session to modify SMART goals and have the option to attend a group exercise class."
45624211|NCT04956393|Behavioral|Delayed 8-Week SOAR Program|"This is an 8-week, virtually delivered, exercise-based, knee health program delivered to knee injury participants by trained physiotherapists. The program has 3 components:~Knee Camp: This includes an interactive education session about knee health, 1:1 knee exam, and 1:1 counseling session to identify Specific, Measurable, Attainable, Relevant, and Time-bound (SMART) weekly home-based exercise-therapy and physical activity goals, Participants are asked to wear Fitbit's® 24-hours/day.~Weekly Home-based Exercise-Therapy and Physical Activity, with Tracking: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises are tracked with an online bespoke form and activity, with a Fitbit.~Weekly PT-guided Exercise-Therapy and Physical Activity Counseling Sessions: Each week participants will attend a 1:1 virtual physiotherapist counseling session to modify SMART goals and have the option to attend a group exercise class."
45624212|NCT02453789|Drug|Alginate oligosaccharide|Inhalation of dry powder for inhalation (DPI)
45624213|NCT02453789|Drug|Placebo|
45624214|NCT03240185|Behavioral|deep breathing exercises|Patients receive education on deep breathing exercises for pain control as part of their pre-operative appointment
45624215|NCT03240107|Procedure|levator resection|"The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~The aponeurosis was measured for the desired amount of resection and fixed to the exposed tarsal border with three point mattress sutures with 6-0 prolene then amount measured resect.~The skin incision closed by continuous suture with 6-0 prolene."
45765801|NCT00375466|Drug|Tranexamic acid|Tranexamic acid 10 mg/kg as a bolus dose followed by an infusion of 1 mg/kg/hour. Bolus given before start of surgery, infusion continued during surgery.
45765802|NCT00375466|Drug|placebo|0.9% sodium chloride 10 mg/kg, as a bolus injection before surgery followed by 1 mg/kg/h as an infusion during surgery
45624216|NCT03240107|Procedure|levator tucking|"The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~. The aponeurosis was measured for desired amount of tucking The skin incision closed by continuous suture with 7-0 prolene."
45765803|NCT04357691|Behavioral|Conventional training|Participants will perform a conventional training for 4 weeks, using low-moderate-high-low intensity progression training model
45624217|NCT03057561|Drug|Cardiac MRI taken using contrast agent, Dotarem® (Gd-DOTA)|Gadolinium based contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
45765804|NCT04357691|Behavioral|AI-led training|Participants will perform an AI-led training for 4 weeks
45765805|NCT00976183|Drug|Vorinostat|Vorinostat will start at 200 mg QD on weeks 1 and 3, and escalating to 300 mg QD after safety has been evaluated following 2 cycles of treatment. If safety is acceptable, then the following patients could be treated at 400 mg QD on weeks 1 and 3.
45765806|NCT00976183|Drug|Vorinostat|Vorinostat will be given as a lead-in dose escalation starting at 200 mg QD.
45765807|NCT00375544|Device|Low level light therapy|
45624218|NCT03057561|Drug|Cardiac MRI with contrast agent, Gadovist|Brand of Gd-DO3A-butrol; contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
45624219|NCT03240029|Other|Questionnaires|SPP questionnaire (Self Perception Profile for Children), Systemic inventory of life quality for children (ISQV-E), Anxiety questionnaire (STAI-C), Depression questionnaire (CDI)
45624220|NCT04935567|Other|Statistical model for the prediction of VNS efficacy|statistical model for the prediction of VNS efficacy based on a mathematical and statistical analysis of scalp EEG data
45624221|NCT03239795|Other|Advertisement|Advertisement by means of a poster and pamphlets in FP waiting rooms, removing all the other posters and pamphlets (except mandatory information, like opening hours, fees, etc.)
45624222|NCT03057093|Other|Non interventional study|retrospective noninterventional study
45765808|NCT04357535|Drug|Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)|ACE-I and ARB are a class of blood pressure lowering medications used to manage hypertension.
45624223|NCT03239951|Device|iTind|temporary implant
45765809|NCT03121144|Device|Masimo Centroid System|Noninvasive positional monitoring device
45912620|NCT02012270|Procedure|PRINCIPLES technique|"Principles technique for closure of midline laparotomy incisions~closure with a running suture of a slowly absorbable monofilament suture- Monomax 2/0 of 150 cm length with a taper needle point ((1/2 circle, size: 30mm) (B.Braun, reference 0041453)~the suture is started and ended with a self-locking knot, if more than one suture is used sutures are knotted separately, only the fascia will be sutured with small stitches close to each other~the SL/WL ratio should be at least 4/1~SL/WL = (150cm x number of sutures used) - (the suture remnants)~the mean stitch length should be less than 4 cm (suture length / number of stitches placed)"
45765810|NCT04789577|Biological|FLU-Q-PAN H7N9 Formulation 1|Participants will receive two doses of the FLU-Q-PAN H7N9 Formulation 1 vaccine by intramuscular injection in the non-dominant arm.
45765811|NCT04789577|Biological|FLU-Q-PAN H7N9 Formulation 2|Participants will receive two doses of the FLU-Q-PAN H7N9 Formulation 2 vaccine by intramuscular injection in the non-dominant arm.
45765812|NCT04789577|Biological|FLU-Q-PAN H7N9 Formulation 3|Participants will receive two doses of the FLU-Q-PAN H7N9 Formulation 3 vaccine by intramuscular injection in the non-dominant arm.
45624224|NCT04935099|Dietary Supplement|Wild blueberry powder|22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder, mixed with 250 ml water, and served in an opaque container.
45624225|NCT04935099|Dietary Supplement|Placebo powder|22 g placebo powder matched for macronutrients and flavor, mixed with 250 ml water, and served in an opaque container.
45624226|NCT03239717|Other|Whey protein powder|Participants in the Control Arm will replace two-thirds of participants dietary protein intake with a commercially available whey protein powder.
45624227|NCT03239717|Other|BCAD2|Participants in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
45765813|NCT04789577|Biological|AS03B|Participants will receive two doses of the AS03B adjuvant by intramuscular injection in the non-dominant arm.
45912621|NCT02012270|Procedure|Conventional group|the fascia will be closed with the current method by the surgeons. There will be a great variation in sutures and techniques used. Study group: the fascia will be closed according
45624228|NCT03056781|Behavioral|social interaction|Participants will engage in a social interaction with another person
45624229|NCT03056781|Behavioral|food consumption|Participants will be offered food stuffs to eat/drink
45624230|NCT03239327|Drug|Misoprostol|
45624231|NCT04930185|Behavioral|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the pamphlet about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
45624232|NCT04930185|Behavioral|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the webinar last for half an hour about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
45765814|NCT04789577|Biological|AS03A|Participants will receive two doses of the AS03A adjuvant by intramuscular injection in the non-dominant arm.
45765815|NCT04789577|Drug|Placebo|Participants will receive two doses of Placebo by intramuscular injection in the non-dominant arm.
45765816|NCT01015807|Drug|Bupivacaine Placebo|2 x 20mL 0.9% NaCl
45765817|NCT01015807|Drug|Clonidine Placebo|2 x 1mL 0.9% NaCl
45765818|NCT01015807|Drug|Bupivacaine|2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine
45765819|NCT01015807|Drug|Clonidine|2 x 1ml Clonidine = 150 µg Clonidine
45765820|NCT03067948|Behavioral|Patient Designated Positive Screen Shared with Provider|Patient Designated Positive Screen Shared with Provider -- In the intervention, participants will be given the opportunity to determine which positive screen, if any, that the participant would like to discuss with the participant's provider at the next HIV primary care appointment. The participant will be notified that all positive screens will be shared with the provider prior to their next HIV primary care visit, and that any positive screen the patient has chosen to discuss with the provider will be specified. The provider will receive the PROs result (score, interpretation, and recommendation) prior to their next HIV primary care visit
45765821|NCT04784429|Device|Kenevo or C-Leg 4|Kenevo fitted to subjects walking slower than 0.8 m/s as measured by the 2-minute Walk Test. C-Leg 4 fitted to subjects walking faster than 0.8 m/s.
45765822|NCT04784429|Device|Non microprocessor controlled knee (NMPK)|NMPK consistent with current standards of care
45624233|NCT04930185|Behavioral|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the SMS about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
45765823|NCT04827225|Behavioral|questionnaires|Questionnaires (EPDS, HADS, PPQ, MIBS, etc.) will have to be completed by the parents at different stages of their child's development (38 weeks of amenorrhea, 3 months and 24 months).
45765824|NCT04825743|Drug|zalunfiban|zalunfiban is a novel small molecule inhibitor of the platelet αIIbβ3 receptor specifically designed for first medical contact therapy of ST-elevation myocardial infarction (STEMI).
45765825|NCT04825743|Drug|Placebo|A placebo will be prepared to those subjects assigned to placebo. Less than 1 mL (depending on subject's weight) will be administered by subcutaneous injection.
45765826|NCT01575925|Drug|4 mg Oral POM + 40 mg Oral DEX|
45765827|NCT01575925|Drug|2 mg Oral POM + 40 mg Oral DEX|
45765828|NCT03121612|Device|CPAP|CPAP therapy
45765829|NCT00978445|Other|vMetrics protocol|use vmetrics protocol and device or use standard in clinic monitoring
46069608|NCT02622399|Behavioral|Project NOW|This intervention aims to reduce social isolation and promote engagement in health promoting enrichment and activities, by embedding a community health worker-assisted forum in a community-driven mobile communications through a private, secure, and confidential platform supported by txtwire. The principal innovation is harnessing both the behavioral change utility of a mobile health application and the social support potential of an online social network the investigators can deliver more timely and dynamic reinforcement to caregivers and social support more in rhythm with the pace of community events and stressors.
45624234|NCT03239639|Behavioral|Advance care planning education session|Administration of values clarification tool, elicitation of preference for treatment options, if preference for resuscitation, shown an educational video about cardiopulmonary resuscitation, summary document of values and preferences created by a facilitator to share with doctor
45624235|NCT03239639|Other|Wait list control|No intervention
45765830|NCT04818645|Device|Confirm Rx Insertable Cardiac Monitor|Subjects will be subcutaneously implanted with an Abbott Confirm Rx ICM with the device implant procedure per standard of care and current labelling. Data related to subjects' arrhythmias, via the Merlin.net Patient CareNetwork will be transmitted on a monthly basis to the treating physician and subsequently to the study coordination and database center (CCRC) at the University of Rochester. Data on the frequency/types of symptomatic (patient triggered) versus ICM detected (asymptomatic) arrhythmic events will be collected and adjudicated. Clinical data on medication, device interventions, cardiovascular events will be collected at follow-up visits.
45765831|NCT04818645|Other|Conventional Management and monitoring|Subjects randomized to the conventional management arm of the trial will undergo arrhythmia monitoring based on clinical indications and per standard available modalities including periodic electrocardiograms (ECG), Holter and/or event monitoring.
45765832|NCT00936377|Drug|Dexmedetomidine|Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days
45765833|NCT00936377|Other|Placebo|Normal saline for five days.
46069609|NCT00976703|Other|weighted bag|For the weighted bag, a 500cc saline bag will be taped to an empty Foley bag which will be attached to the cervical Foley catheter. This bag will then be placed to gravity over the end of the bed. The bed will be raised so that the bag does not touch the floor. The foley and the bag will be re-assessed every 30min by the nursing staff.
45765834|NCT03022357|Other|Patient assessment|Clinical examination, Examination, Questionnaires
45765835|NCT03022357|Radiation|DATScan|In small subgroup
45765836|NCT03022357|Radiation|Orbital X-Ray|If foreign body in eye needs exclusion
45765837|NCT03022357|Other|Magnetic Resonance Imaging (MRI)|MRI scanning of all subjects
45765838|NCT03123874|Device|Sterile pump set-up|Medela symphony breast pump (model number 0240108) and disposable, sterile collection kits (model number 67399S).
45765839|NCT03123874|Device|Mother's Own pump set-up|Mother's own electric breast pump and own collection kit (previously used and cleaned at home using her usual practices).
45765840|NCT03124342|Other|VANDERBILT ICU RECOVERY PROGRAM|"10-component ICU Recovery Program intervention, including:~Nurse Practitioner In-Person Visit at the time of transfer from the ICU~Provision of an ICU Recovery Program Pamphlet describing post-intensive care syndrome and providing online resources~Performance of formal medication reconciliation at the time of transfer from the ICU~Access to a dedicated 24-hour a day, 7-day a week contact line~ICU Recovery Clinic Visit Medical Examination.~ICU Recovery Clinic Medication Reconciliation and Counseling~ICU Recovery Clinic Cognitive/Mental Health Assessment and Psychoeducation. A brief session of psychotherapy conducted by a clinical psychologist~ICU Recovery Clinic Case Management. A brief case management consultation~ICU Recovery Clinic Patient Centered Consultation. A final consultation with patients and families by a PCCM physician~Directed Subspecialty Referrals"
45765841|NCT04471233|Other|Multimodal analgesia including pregabalin|Standardized protocol for our institution with multiple medications used for pain (NSAIDs, opioids, dexamethasone) and non-narcotic spinal. Patient will be provided with an preoperative pregabalin dose and will continue medication two weeks postoperatively.
45765842|NCT04471233|Other|Multimodal analgesia not including pregabalin|Standardized protocol for our institution with multiple medications used for pain (NSAIDs, opioids, dexamethasone) and non-narcotic spinal.
45912622|NCT02012309|Biological|PCV-13|
45912623|NCT02012309|Biological|PPSV-23|
45912624|NCT02012322|Dietary Supplement|Coenzyme Q10|100mg/day for three months
45765843|NCT04359095|Drug|Emtricitabine/tenofovir|Generic drug distributed by the Colombian Health System for Human Immunodeficiency Virus (HIV) positive patients It is classified as an anti infectious drug and its current indications include HIV infections.
45765844|NCT04359095|Drug|Colchicine Pill|Generic drug distributed by the Colombian Health System as an insurance treatment for Gout. It has been suggested that colchicine would be useful in SARS Covid 19 becouse its antiinflammatory effects through reduction of cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome
45624236|NCT04930341|Other|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
45624237|NCT03239171|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
45765845|NCT04359095|Drug|Rosuvastatin|Generic drug distribute by the Colombian Health System. It is used in people with High levels of cholesterol. An action against the main protease (Mpro) of COVID 19 virus has been described, There is evidence suggesting that statins could exert anti Covid 19 action and the infectivity of enveloped viruses
45765846|NCT04359095|Other|Standard treatment|Standard treatment n, multiple organ failure related to the acute infection including respiratory support (oxygen, positive end-expiration pressure with external devices or invasive ventilatory support), cardiovascular, renal, haematological or coagulation, or co-infection with bacterial or mycotic organisms, standard care to prevent pressure ulcers or other care required by the patient. No viral therapies are included.
45765847|NCT05402956|Behavioral|Aerobic exercise|Moderate aerobic exercise training
45912625|NCT02012322|Dietary Supplement|Coenzyme Q10|300mg/day for three months
45912626|NCT02012322|Dietary Supplement|Placebo|Three month period
45912627|NCT02012335|Drug|ECT + Ketamine|Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session
45912628|NCT02012361|Procedure|Control Group|This group will be treated as any other patient would. Their anesthesia will be conducted as per routine with a target FiO2 of 0.25, (25%oxygen / 75%nitrogen) the only exception being that they will not be treated with inspired heliox.
45912629|NCT02012361|Procedure|Single-Dose Heliox Group|This group will be treated with a single dose of inspired 75/25 heliox (75% helium 25% oxygen) breathed continuously for 15 minutes over any convenient window prior to the inflation of the surgical tourniquet. This will be the only change in their clinical care. Their anesthesia will be conducted as per routine and as the anesthesia team sees fit with a target FiO2 of 0.25, the only exception being that they will receive 75/25 heliox prior to the inflation of the tourniquet.
45912630|NCT02012361|Procedure|Muscle Biopsy|During the course of the operation a small muscle biopsy will be collected.
45912631|NCT02012387|Biological|Active|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
46069610|NCT00976703|Other|leg taping|For the leg taping, the cervical foley catheter will be pulled to gentle traction and attached to the patient's inner thigh using a reclosable foley catheter fastener. The foley catheter and the traction will be assessed every 30min by the nursing staff. The tension will be renewed and the Foley re-adjusted if necessary at each check.
45624238|NCT03239171|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
45624239|NCT02314559|Drug|Manual titration of propofol|One group will be sedated with a manual titration technique: here the titration of propofol is done manually by the anesthetist. Dosages may range between 50 and 400mg, given by boluses of 20-50mg.
45624240|NCT02314559|Drug|Target controlled infusion of propofol|The other group will be sedated with a target controlled infusion technique (pump, marsh or Schneider). The anesthetist can titrate indirectly by adjusting the target controlled infusion to achieve adequate sedation. The concentrations of propofol may vary between 2 and 6 µg/ml, achieved by increments of 0.5-1.5 µg/ml.
45624241|NCT04934709|Device|Active PBMT-sMF|PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter. Six different sites of the knee extensor muscles (two medial, two lateral and two central points) were irradiated at the same time.
45624242|NCT04934709|Device|Placebo PBMT-sMF|Placebo PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter, but without any emission of therapeutic dose. Placebo PBMT-sMF was applied at six different sites of the knee extensor muscles (two medial, two lateral and two central points).
45624243|NCT04955535|Procedure|Arthroscopic synovectomy|Arthroscopic synovectomy
45624244|NCT03239093|Other|No intervention|Observational study using official data from the Federal Office of Statistics
45624245|NCT04934631|Other|Recording of CBT-ED session.|Therapists will deliver treatment as usual (CBT-ED) to eating disorder patients. Therapy session will be audio recorded.
45624246|NCT04934631|Other|Assessment of CBT-ED clinician competence.|Independent raters will assess CBT-ED competence using the Cognitive-Behavioural Therapy Scale for Eating Disorders (CBTS-ED).
45624247|NCT03238937|Device|Phrenic nerve stimulator|Implantation of phrenic nerve stimulator
45765848|NCT05345080|Behavioral|Exposure-Reduction Intervention|The customized exposure-reduction intervention includes a phone-based telehealth visit, collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies (optional), and a customized asthma self-management and exposure-reduction plan developed using motivational interviewing techniques, support, and exposure-reduction supplies.
45765849|NCT04359251|Other|Gas exchanges at different PEEP|Gas exchanges measurement at different PEEP
45765850|NCT04359251|Other|lung mechanics at different PEEP|lung mechanics measurement at different PEEP
45765851|NCT04359251|Other|Hemodynamics changes at different PEEP|Hemodynamics changes measurement at different PEEP
45765852|NCT02163421|Drug|Vedolizumab SC|Vedolizumab injection, for subcutaneous use (vedolizumab SC)
45765853|NCT02163421|Drug|Vedolizumab IV|Vedolizumab injection, for intravenous use (vedolizumab IV)
45912632|NCT02012387|Biological|Placebo|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
45912633|NCT02012387|Biological|Open labeled|Two injections will be administered every four weeks for 8 months, we will administer 4 doses within 32 weeks
45624248|NCT03056859|Device|Extravascular blood pressure transducer|Listed device is included in central venous catheter placement apparatus for consenting patients, according to manufacturer directions
45624249|NCT03238859|Device|Real cTBS|This will be delivered with the Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
45624250|NCT03238859|Device|Sham cTBS|This will be delivered with the sham Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
45624251|NCT04929873|Behavioral|Closed transdyser|When the average arterial pressure ≥ 50mmHg, it is indicated that the basic blood supply of the lower extremities is satisfied without special treatment, and when the average arterial pressure < 50mmHg, it indicates insufficient perfusion, by adjusting the pipe position, changing the ECMO flow rate, and properly clamping the artery end to divert part of the blood flow to the side branch circulation, so that the average arterial pressure is maintained above 50mmHg.
45765854|NCT05320510|Dietary Supplement|Se-yeast|The participants will be asked to take Se-yeast tablet. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
45912634|NCT02012400|Other|Exercise|The exercise group is given a 24-week individualized training program, including aerobic exercise, muscular training, relaxation exercises and stretching. Patients are asked to observe their asthma control daily and to mark in their diary asthma symptoms and activity limitations as well as duration, intensity and form of exercising on daily basis. They are also asked to perform PEF-measurements twice a day for one-week period every 4 weeks. The control group receives ordinary instructions.
45765855|NCT05320510|Dietary Supplement|Placebo|The participants will be asked to take placebo-yeast tablet. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
45765856|NCT02982317|Procedure|Manual palpation identification lumbar spine|
45765857|NCT02982317|Procedure|Automated ultrasound technology identification|This technology involves a standard ultrasound machine and curvilinear probe- what is novel is the software which will be connected to the ultrasound machine
45624252|NCT04929873|Behavioral|Routine monitor|Obtain oxygen saturation, skin color, temperature, etc
45624253|NCT04486547|Behavioral|Information-Motivation-Behavioral Skills model-based intervention|Home visits were made to the study group and nursing interventions were administered in accordance with the components of the Information-Motivation-Behavioral Skills model
45624254|NCT03239405|Device|Suction callibrated system|One-step suction callibrated SG system
45765858|NCT02982317|Procedure|Lumbar level identification gold standard ultrasound|
45765859|NCT04737148|Other|Mortality scores|Revised Baux, BOBI and FLAMES scores
45765860|NCT05240716|Other|FES program|8 weeks intervention. 3 sessions per week. Previous to the intervention, volunteers will familiarize with the electrical stimulation by receiving three trials of the stimuli. Electrical current intensity will be set for each volunteers, with the capacity of generating a muscle contraction without inducing discomfort in the volunteer. During the FES program, patient in standing position will perform a step, while electrical current stimulation will be applied to the skin over the tibial nerve on the contralateral of the stimulation side. The FES will be delivered during the paretic plantarflexor activation according to the gait cycle. The FES session will consist of 5-minutes stimulation blocks with breaks between blocks (total session time: 30 minutes). For safety reasons, a physical therapist will supervise all the FES intervention sessions.
45765861|NCT02982395|Drug|Nanoxel®M|Intravesical
45765862|NCT02982395|Drug|Mitomycin-C|Intravesical
45765863|NCT00979069|Behavioral|Aerobic group|12 weeks of aerobic exercise 3 times a week
45765864|NCT03124966|Device|Pulse Oximeter sensor|
45765865|NCT02982005|Drug|KHK4827|Administered KHK4827 by subcutaneous (SC) injection until week 62.
45765866|NCT02982005|Drug|Placebo|Administered placebo by subcutaneous (SC) injection until week 12. Administered KHK4827 by SC injection from week 13 until week 62.
45446904|NCT03060772|Drug|Pioglitazone|Participants will take 30 mg of pioglitazone once daily for a total of two to four weeks for those randomized to therapy, until the next bronchoscopy is performed. Participants will receive 14 to 28 tablets of active pioglitazone, which is enough to complete the minimum 14-day course of therapy.
45446905|NCT02096536|Drug|Vancomycin|vancomycin administration based on decision of treating physician
45446906|NCT02089750|Other|Orthotics|
45446907|NCT02089750|Other|Orthotics Plus Chiropractic Care|The six week Chiropractic Care portion of this intervention may include the use of ice packs, hot packs, massage, and chiropractic manipulations to the spine or lower extremities (utilizing High Velocity Low Amplitude and/or Flexion Distraction manipulations).
45624255|NCT03238703|Drug|Anastrozole|Given PO
45624256|NCT03238703|Drug|Exemestane|Given PO
45624257|NCT03238703|Other|Laboratory Biomarker Analysis|Correlative studies
45765867|NCT00979303|Device|Intracardiac echocardiography and 3D navigational system|Patients assigned to the intervention group will receive both intracardiac echocardiography as well as a 3D navigational system in addition to fluoroscopy during their ablation procedure.
45912635|NCT02012413|Device|PST - Pulsed Signal Therapy|PST application is a painless over-the-skin eletromagnetic field application. 9 sessions of application of electromagnetic therapy - PST - during 60 minutes
45446908|NCT02089750|Other|Wait List|
45446909|NCT02096614|Drug|TBI-1201|TBI-1201(5*10^8 or 5*10^9) is administered.
45446910|NCT02096614|Drug|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1201
45446911|NCT02096614|Drug|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1201 in combination with cyclophosphamide.
45624258|NCT03238703|Drug|Letrozole|Given PO
45446912|NCT02089828|Other|autologous purified CD34+ cells|
45446913|NCT02089828|Other|autologous peripheral blood mononuclear cells|
45446914|NCT02094196|Other|Alcohol detoxification|Detoxified alcohol- dependent patients in an inpatient setting
45624259|NCT03238703|Other|Quality-of-Life Assessment|Ancillary studies
45624260|NCT03238703|Other|Questionnaire Administration|Ancillary studies
45624261|NCT03238703|Drug|Tamoxifen Citrate|Given PO
45624262|NCT03238703|Drug|Toremifene Citrate|Given PO
45624263|NCT03238547|Diagnostic Test|semi-quantitative urine albumin-to-creatinine ratio test|measurement of urine albumin-to-creatinine ratio using URiSCAN 2ACR, a semi-quantitative urine albumin-to-creatinine ratio test
45446915|NCT03556774|Behavioral|'WeChat WeQuit' smoking cessation training program|Providing 'WeChat WeQuit' smoking cessation training program for healthcare service providers (HSPs) and assessing their utilization of behavioral and pharmacotherapy interventions for cigarette smoking cessation.
45624264|NCT03238547|Diagnostic Test|standard quantitative spot urine albumin-to-creatinine ratio|measurement of urine albumin-to-creatinine ratio using a standard turbidimetric immunoassay
45624265|NCT03238625|Drug|Lidocaine and sodium bicarbonate|Lidocaine and sodium bicarbonate ratio 3:1
45624266|NCT03238625|Drug|Lidocaine and sodium bicarbonate|Lidocaine and sodium bicarbonate ratio 9:1
45765868|NCT04333264|Procedure|suction drainage|After primary total hip arthroplasty closed suction drainage will be used.
45765869|NCT04333264|Procedure|no suction drainage|After primary total hip arthroplasty closed suction drainage won't be used.
45765870|NCT04736836|Drug|Rifaximin|locally absorbed antibiotic
45765871|NCT03021109|Device|Measurement of inferior vena cava diameters with ultrasound|The patient is placed in the supine position. Curvilinear probe is used. Subxiphoid view is obtained. The IVC is visualized in the longitudinal plane as it enters the right atrium. The diameter of the IVC for calculation of the caval index is measured 2 cm from where it enters the right atrium
45765872|NCT03126370|Drug|TDF with a boosted protease inhibitor|"Participants who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.~Other: Blood draws for tenofovir PK, renal function assessment"
45765873|NCT03126370|Drug|TAF with a boosted protease inhibitor|"Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide 25 mg/emtricitabine 200 mg with a boosted protease inhibitor.~Other: Blood draws for tenofovir PK, renal function assessment"
45765874|NCT03126370|Drug|TAF with a boosted protease inhibitor and LDV/SOF|"After taking tenofovir alafenamide/emtricitabine for 12 weeks, participants will then start taking ledipasvir 90 mg/sofosbuvir 400 mg (Harvoni) in combination with the tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for 4 weeks. Subjects will then return to taking tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for the final 12 weeks.~Other: Blood draws for tenofovir PK, renal function assessment"
45765875|NCT05059899|Behavioral|Exercise group|The exercise group will receive a 12-week home-based exercise programme, with a wearable activity watch to regulate physical activity behaviour. This group will also receive biweekly telephone calls from the investigator.
45765876|NCT00979459|Drug|MK-1006 DFC|Each dry filled capsule contains 20 mg MK-1006
45765877|NCT00979459|Drug|MK-1006 FCT|Each film coated tablet contains 40 mg of MK-1006
45765878|NCT04467801|Drug|Ipatasertib|Ipatasertib is a novel ATP-competitive inhibitor. It is taken by mouth once daily.
45765879|NCT03126448|Diagnostic Test|Highly Sensitive Assays|Tissue will be collected at the time of surgery from patients in each arm of the study. In addition to tissue stored in RNAlater and sent to a research laboratory, cultures will also be sent to Quest Diagnostics for independent culture results.
45765880|NCT01019707|Drug|Atomoxetine, then Placebo|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
45912636|NCT02012413|Device|Placebo - Sham PST|"Placebo PST will be performed by applying the same device over the patient knee. The machine is not applying the PST but it appears to be on. In this way, patients are blinded to the intervation.~9 sessions of application of Sham PST - during 60 minutes"
45912637|NCT02012426|Behavioral|Weight management program|
45446916|NCT02094274|Drug|LAS40468|
45446917|NCT02094274|Drug|Salmeterol/fluticasone propionate|
45624267|NCT03238625|Drug|Lidocaine|Lidocaine injection
45624268|NCT03238625|Drug|Sodium cloride 0.9%|Placebo
45624269|NCT03238391|Procedure|Ischemic preconditioning|It is mentioned before in arm/group descriptions
45624270|NCT03238469|Device|Microwave ablation|A one-sided (either right or left axillary area) single MWA treatment using a miraDry system. The miraDry device has a microwave output frequency of 5.8 GHz and microwave energy level settings ranging from 1 to 5, corresponding with a delivery time in seconds between 2.40 sec and 3.00 sec. For this study standard 5 (i.e. 3.00 sec) is set as treatment setting.
45624271|NCT04486469|Other|Physical Therapy Group|"Performing direct physical treatment on the diaphragm, using stretching, followed by teaching exercises for re-education of the abdomen and diaphragm.~Transcutaneous retrograde electrostimulation: L1-L4 (2hz-10hz) rectangular asymmetric biphasic at the level of the dermatome. From the anterior inferior iliac spine to a pubic symphysis. Second canal from the greater trochanter to the saphenous veins. (30 min). Parameters of this program: 2 Hz and 180ms.~Connective Tissue Massage or Dicke~Massage with direct maneuvers on the abdomen: The direction of the maneuvers will be clockwise. We will perform 6 very slow strokes adding small pressures on the ascending, transverse and descending colon respectively and repeating this maneuver 3 times. (10 minutes)"
45765881|NCT01019707|Drug|Placebo, then Atomoxetine|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
45446918|NCT02094274|Drug|Placebo|
45446919|NCT02094430|Drug|biological: human fibrinogen concentrate|
45624272|NCT04486079|Dietary Supplement|Nutricia PreOp|A clear, non-carbonated lemon-flavored, iso-osmolar carbohydrate drink for preoperative surgical patients. Used in studies supporting the Enhanced Recovery After Surgery (ERAS) Society Consensus Guidelines.
45446920|NCT03556150|Other|Manual Therapy protocol|"This protocol consists of:~Six minutes of joint's mobilisation (two minutes of each technique).~Nine minutes of ischemic pressure . Three minutes per muscle in this order: temporal muscle, masseter muscle and lateral pterygoid. Choosing the two most painful trigger points.~Three minutes of trigemino's nerve stretching."
45624273|NCT03238313|Behavioral|Plan A|
45624274|NCT03238313|Behavioral|Toxic Life Cycle of a Cigarette|Video
45765882|NCT04457271|Behavioral|Goal Management Training (GMT)|GMT is a structured, short-term cognitive remediation program with an emphasis on mindfulness and practice in planning and completion of goal-oriented behaviours. The main objective of GMT is to help participants regain executive control in order to better define goals and monitor performance in achieving them. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments. Mindfulness meditation is also incorporated for the purpose of developing the skill of bringing one's mind to the present to monitor ongoing behaviour, goal states, and the relationship between them, and for the development of attentional control. The program incorporates real-life examples to illustrate goal attainment failures and successes, as well as in-session practice of complex tasks that mimic real-life tasks - typically a challenge for individuals with executive function deficits (e.g., planning and set-shifting tasks).
45624275|NCT03238079|Biological|10% IGIV|300-900 mg/kg
45624276|NCT05387681|Drug|Envafolimab|short course radiotherapy ：5*5Gy (25Gy/5F) ； Envafolimab：300 mg, subcutaneously, D1, Q3W; Endostatin ：210mg (14 doses), CIV continuously pumped for 72h, Q3W; chemotherapy：SOX regimen
45624277|NCT03238157|Drug|Fluocinolone Acetonide (FA) implant|Fluocinolone Acetonide (FA) implant is designed to release FA at an initial rate of approximately 0.6 g/d, decreasing over the first month to a steady rate of 0.3 to 0.4 g/d with a duration of approximately 30 months.
45624278|NCT03237923|Device|EasySense device|Implementation of EasySense device during hospitalization and daily post-discharge for thirty days.
45624279|NCT04485845|Drug|Vildagliptin|to compare the effect of both metformin and vildagliptin on the progression of diabetes and metabolic complications and risk factors
45624280|NCT04485845|Drug|Captopril Tablets|used to treat hypertension in metabolic syndrome patients and as a renal protector
45624281|NCT04485845|Drug|MetFORMIN 500 Mg Oral Tablet|antihyperglycemic drug for elevated plasma glucose level and help in weight loss for patients suffering from diabetes or metabolic syndrome
45624282|NCT03237767|Other|MIE|"The moderate intensity exercise (MIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The MIE bout will be in coherence with the physical activity guidelines for people with CF (150 min/week of moderate to vigorous physical activity). For the MIE, participants will cycle for approximately 30 minutes at 90% of their gas exchange threshold."
45765883|NCT00979615|Drug|Olopatadine HCL (Patanase) Nasal Spray, 0.6%|2 sprays/ nostril BID
45765884|NCT00979615|Drug|Azelastine HCl (Astelin) Nasal Spray, 137 mcg|2 sprays/ nostril BID
45765885|NCT03126682|Drug|Wellbutrin SR 300Mg Extended-Release Tablet|Wellbutrin SR 300Mg Extended-Release Tablet
45624283|NCT03237767|Other|HIIE|"The high-intensity interval exercise (HIIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The HIIE will be matched for the projected work done during the MIE. The HIIE protocol has been extrapolated from recent reports which have shown improvements in glycaemic control and vascular endothelial function. Specifically, participants will cycle at 90% of their peak power output for 60 seconds, followed by 60 seconds of active recovery."
45624284|NCT00700427|Drug|atomoxetine hydrochloride|Oral 40-100 mg/day
45624285|NCT00700427|Drug|Placebo|Oral delivery of matching placebo
45624286|NCT03237533|Drug|Dexamethasone|Dexamethasone will be applied locally on the lesion
45624287|NCT03107663|Drug|⁸⁹Zr-Df-IAB22M2C Infusion|A single dose of 3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes.
45624288|NCT03237221|Drug|Treat patient according to Global Initiative for Asthma (GINA) guideline|Treat patient according to Global Initiative for Asthma (GINA) guideline
45765886|NCT04456413|Biological|Convalescent Plasma|Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection
45765887|NCT04456413|Other|Best Supportive Care|Patients will receive best supportive care. Patients randomized to this arm may receive plasma should they require hospitalization for progression of COVID-19 disease.
45446921|NCT03556150|Other|Effleurage|"The protocol consists of:~Five minutes in temporal muscle.~Ten minutes superficial massage in the neck and cheek of the most painful joint.~Five minutes of effleurage in the cheek, with the index finger inside the mouth and the thumb outside."
45446922|NCT03556072|Other|Routine ERCP|
45446923|NCT02094742|Procedure|biopsy|
45765888|NCT05236738|Drug|Atazanavir|Specified dose on specified days
45765889|NCT05236738|Drug|Cobicistat|Specified dose on specified days
45765890|NCT05236738|Drug|Atazanavir/Cobicistat Mini-tablet|Specified dose on specified days
45765891|NCT00980395|Drug|rituximab|375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
45765892|NCT00980395|Drug|bortezomib|1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
45765893|NCT00980395|Drug|cladribine|4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.
45624289|NCT02453633|Other|Emotional SMS text|"SMS appointment reminder with the following text (translated from Norwegian):~Reminder about your appointment. There are many who are waiting for treatment. Please notify us if you can not make your appointment on: Tuesday 31 March at 10:00.~tel. 23225501 or send email to kirpolonh@lds.no later than one weekday prior to your appointment.~No-show fee: Kr. 640.~Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat. Do not reply to this message per SMS."
45765894|NCT03072550|Device|RenewalNail™ Plasma Treatment System|application of cold atmospheric plasma to a fungal infected toenail
45765895|NCT01021111|Device|Activity Training with Feedback|The feedback system consisted of three small inertial measurement units affixed on the chest, thigh, and shank segment respectively. These units were connected to a computer that recorded the signal from the inertial sensors at 240 Hz during the jump task. Using custom software, the knee flexion angle, trunk lean, and coronal thigh angular velocity were calculated immediately after the subject completed the jump trial. A projector was used to display the results of the jump analysis. It took less than 10 minutes to place this system on a subject and less than five seconds to analyze a jump.
45446924|NCT02089984|Behavioral|Internet Based CBT Training|
45446925|NCT03038074|Device|Pulse Oximeter with respiration rate sensor|
45624290|NCT02453633|Other|Standard SMS text|"SMS appointment reminder with the following text (translated from Norwegian):~Reminder of appointment at Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat: Wednesday 11.feb 2015 at 10:00. For a change, call tel. 23225501 or send email to kirpolonh@lds.no. Do not reply to this message per SMS."
45624291|NCT02453399|Device|Randomized treatment/placebo delivery of transcutaneous electro stimulation via a dedicated device Avital.|Transcutaneous electro stimulation
45765896|NCT02976597|Drug|Bupivacaine 0.25% 20ml on each side Sonar guided TAB|Bupivacaine 0.25% 20ml on each side Sonar guided TAP block. After careful aspiration injection of 20ml of 0.25% bupivacaine will be performed and hypoechoic layer will be detected on ultrasound then the maneuver will be repeated on the other side
45765897|NCT02976597|Drug|Morphine 10mg|Morphine 10mg will be added to bupivacaine in sonar guided- TAP block divided into 5mg on each side.
45765898|NCT02976597|Drug|Morphine 15mg|Morphine 15mg will be added to bupivacaine in sonar guided- TAP block divided into 7.5mg on each side.
45765899|NCT03020329|Drug|Paclitaxel liposome|"Patients receive paclitaxel liposome(135mg/m2 on day 1),cisplatin (75mg/m2 Separate injection on day 1 to 3) and 5-fluorouracil (3750mg/m2 CIV 120h ) every three weeks for three cycl es before the radiotherapy.~Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.~Radical radiotherapy:Intensive modulate radiotherapy (IMRT),total dose for nasopharynx and nodule of neck:60Gy/30F,2.0Gy/daily."
45765900|NCT03020329|Drug|Cisplatin|Cisplatin (75mg/m2 Separate injection on day 1 to 3) with Paclitaxel liposome and 5-fu every three weeks for three cycles before the radiotherapy.Cisplatin(100mg/m2) every three weeks for three cycles during radiotherapy.
45765901|NCT03020329|Drug|5-fu|Fluorouracil (3750mg/m2 CIV 120h)with Paclitaxel liposomeand cisplatin every three weeks for three cycles before the radiotherapy.
45765902|NCT03020329|Radiation|Radical radiotherapy|Intensive modulate radiotherapy (IMRT) will be implement,total dose for nasopharynx and nodule of neck:60Gy(Gray)/30F(Fraction),2.0Gy/daily,5 days/week.
45912638|NCT02012439|Behavioral|Mindfulness Based Cognitive Therapy|
45446926|NCT04130919|Drug|Tilpisertib|Tablets administered orally once daily
45446927|NCT04130919|Drug|Placebo|Tablets administered orally once daily
45446928|NCT03749031|Other|Orange juice + Orange Pomace|16 oz. orange juice + orange Pomace per day for 4 weeks
45446929|NCT03749031|Other|Orange Juice|16 oz. orange juice per day for 4 weeks
45446930|NCT03749031|Other|Apple Juice and Apple Pomace|16 oz. apple juice and apple Pomace per day for 4 weeks
45446931|NCT03749031|Other|Apple Juice|16 oz. apple juice per day for 4 weeks
45446932|NCT02096926|Drug|Placebo|
45446933|NCT02096926|Drug|Ibuprofen|400 mg PO
45446934|NCT04128267|Device|IPC-1000|Delivers pressure to thumbnail for five seconds at a time
45446935|NCT04128267|Device|Magnetic resonance imaging|Scan of brain using Magnetic resonance imaging
45624292|NCT03236831|Other|Clinical Recommendations|"The investigators will provide clinical recommendations to the subject's primary care provider. These will be in regards to the following:~Avoidance of potentially nephrotoxic medications.~Optimizing volume status (avoidance of volume overload or depletion)~Optimizing electrolytes and acid-base status~Minimizing IV contrast exposure when appropriate~Treating severe anemia~Optimization of hemodynamics (Mean arterial BP>65mmHg)"
45765903|NCT04791579|Drug|Ciprofloxacin|Fluoroquinolone antibiotic
45765904|NCT04791579|Drug|Placebo|Placebo pill
45912639|NCT02012439|Behavioral|Cognitive Therapy|
45935196|NCT00218725|Behavioral|Cognitive Therapy|The cognitive therapy intervention for suicide attempters has been designed to provide a brief, timely, flexible intervention that can be incorporated into general and psychiatric inpatient and outpatient services and applied to the population of patients who attempt suicide. A central feature of the intervention is the adaptation of cognitive therapy to the population of patients who attempt suicide. The focus of the intervention is the identification of core beliefs and key automatic thoughts that were elicited prior to and during the most recent suicide attempt. Once these beliefs and thoughts have been articulated, the counselor and patient develop more adaptive responses during an acute suicidal crisis.
45624293|NCT03236753|Procedure|Thread-embedding Acupuncture (TEA)|"The acupoints and size of TEA are as follows:~Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints): perpendicular insertion, 4cm~Both BL24: transverse insertion toward L1 level along the erector muscle of spine, 6cm~Both BL25: transverse insertion toward iliac crest, 4cm~Both BL26: transverse insertion toward L1 level along the erector muscle of spine, 6cm~Both BL26: oblique insertion toward iliolumbar ligament, 6cm~Both EX-B7: oblique insertion toward gluteus medius muscle, 6cm~Both BL28: oblique insertion toward sacroiliac ligament, 6cm~Both GB30: perpendicular insertion, 6cm~Symptomatic side GB34, BL57 and ST36: oblique insertion toward foot, 4cm"
45624294|NCT03236753|Procedure|Sham Thread-embedding Acupuncture (STEA)|All procedure of STEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
45624295|NCT02453477|Genetic|Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene|Autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the human beta-globin gene resuspended in their final formulation medium. The target dose in the transduced product is 5x10^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10^6/Kg and a maximum dose of 20 x 10^6/Kg, depending on the yield of cells. The product will be injected intraosseously.
45765905|NCT05042895|Procedure|Group A|"Office diagnostic hysteroscopy for assessment of the following:~cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.~Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.~Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.~Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.~Physical and laboratory examinations follicle-stimulating hormone [FSH], LH, thyroid-stimulating hormone [TSH], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle."
45935197|NCT00218725|Other|Enriched Care|The Enriched Care condition will be used as the treatment comparison condition for this study. The Enriched Care condition consists of the usual care that patients may obtain in the community as well as the assessment and referral services provided by the case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health and substance abuse treatment in the community.
45624296|NCT03236597|Other|Treadmill desk|A standing height desk with a treadmill attached.
45765906|NCT05042895|Procedure|Group B|"Office diagnostic hysteroscopy for assessment of the following:~cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.~Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.~Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.~Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.~Physical and laboratory examinations follicle-stimulating hormone [FSH], LH, thyroid-stimulating hormone [TSH], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle."
45765907|NCT05395975|Device|Oxygen Reserve Index|It is a new non-invasive and continuous measurement parameter that aims to provide information about the oxygen status of patients in the moderately hyperoxic range (100 mmHg< PaO2 ≤ 200 mmHg).
45624297|NCT02453165|Procedure|TRANSVAGINAL SUTURE|The closure of the vaginal cuff will be performed transvaginally using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with vaginal valves and needleholders
45624298|NCT02453165|Procedure|LAPAROSCOPIC SUTURE|The closure of the vaginal cuff will be performed laparoscopically using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with laparoscopic needleholders
45624299|NCT02453243|Behavioral|Safety Planning|Suicide screen-positive patients who are to be discharged from the ED will receive personalized safety planning by a mental health clinician or nurse
45624300|NCT02453243|Behavioral|A Lean Implementation Strategy|"The Safety Planning Intervention will be implemented using Lean performance improvement strategies.~Sites will be trained on the Safety Planning Intervention and Lean."
45624301|NCT03236363|Behavioral|MOVI-da10! active breaks|MOVI-da10! active breaks, is a physical activity intervention that consists on two daily physical activity breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
45624302|NCT03236363|Behavioral|MOVI-da10! integrated physical activity|MOVI-da10! integrated lessons, is a physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate <150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
45765908|NCT00980785|Drug|Ramipril|Ramipril 5 mg/day
45765909|NCT00980785|Drug|Placebo|Matching Placebo
45765910|NCT04772547|Drug|Vigabatrin Only Product|enteral medication administration, serial blood draws, and outcome assessment
45765911|NCT04772469|Behavioral|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for men in their social networks.
45765912|NCT04772469|Other|Small monetary incentives|Use of small incentive voucher (~$5) to encourage linkage to confirmatory testing.
45935198|NCT00218803|Behavioral|Nurse asthma education intervention|Asthma Education
45446936|NCT04128267|Other|Correlative Studies|Administration of questionnaires via computer
45446937|NCT02097004|Biological|Peginterferon alfa-2a|once weekly 180 μg subcutaneous injection for 48 weeks
45935199|NCT00218803|Behavioral|Control Group|Asthma Education
45624303|NCT03236285|Behavioral|High-intensity interval exercise training in the fed state|High-intensity interval exercise training in the fed state
45624304|NCT03236285|Behavioral|Continous exercise training in the fed state|Continous exercise training in the fed state
45624305|NCT03236285|Behavioral|High-intensity interval exercise training in the fasting state|High-intensity interval exercise training in the fasting state
45624306|NCT03236285|Behavioral|Continous exercise training in the fasting state|Continous exercise training in the fasting state
45624307|NCT03235895|Other|Educational material|Educational material given as a part of CME activity as through enhanced internet method
45624308|NCT03236051|Procedure|Multimodal analgesia|Multimodal analgesia is the name of a procedure or program. Multimodal analgesia doesn't mean different interventions are used. Patients in this group need receive this analgesia program (procedure) instead of one analgesic drug or technology. The program consists of incision infiltration with ropivacaine, intravenous injection of parecoxib, and oral administration of oxycodone/paracetamol mixture.
45624309|NCT03236051|Procedure|PCIA analgesia|PCIA analgesia:patient-controlled intravenous analgesia with tramadol.
45765913|NCT04772469|Behavioral|Use of SMS/text reminders to motivate adherence to ART or PrEP|"Messages will be motivational, will not include any identifying information and will include generic texts such as maintain your good health, to cater for status-neutral language that can work for both HIV positive individuals taking ARVs, as well as HIV-negative individuals on PrEP who may need adherence support."
45624310|NCT03236129|Procedure|T-reg depleted DLI|The patients in the experimental arm benefit of a DLI depleted from regulatory T lymphocytes
45765914|NCT03019861|Behavioral|Ayurvedic nutritional counseling|
45624311|NCT03236129|Procedure|Standard DLI|The patients in this arm benefit of a standard DLI.
45624312|NCT03236207|Other|Test extensively hydrolyzed formula|extensively hydrolyzed formula with HMOs
45624313|NCT03236207|Other|Control extensively hydrolyzed formula|extensively hydrolyzed formula without HMOs
45765915|NCT03019861|Behavioral|Conventional nutritional counseling|
45624314|NCT03235973|Drug|Fludarabine-Cladribine-Busulfan conditioning regimen|"Conditioning regimen will be performed from day -6 to day -2 and contains:~Fludarabine 10 mg/m²/d during 5 days (day-6 to day-2).~Cladribine during 5 days (day-6 to day-2) at one the following define dose level:~Dose 1: 10 mg/m²/d~Dose 2: 15 mg/m²/d~Dose 3: 20 mg/m²/d~Dose 4: 25 mg/m²/d~IV busulfan will be given on day-6 using fixed dose as following:~If age ≤ 60 years: starting dose of 130 mg/m²~If age > 60 years: starting dose of 100 mg/m² No busulfan will be administered at day-5, allowing the pharmacokinetic (PK) analyses . Subsequent infusion of IV busulfan will be performed from day-4 to day-2 at the dose recommended by PK analyses"
45624315|NCT03235661|Device|BiPAP|BiPAP is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
45624316|NCT03235661|Device|nCPAP|nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
45624317|NCT02453087|Drug|DCDS0780A|Participants will receive escalating doses of DCDS0780A as intravenous infusion.
45765916|NCT00981253|Behavioral|SMT-enhanced Cardiac Rehabilitation|Standard exercise-based cardiac rehabilitation, three times per week, enhanced with weekly stress management training for 12 weeks.
45935200|NCT00218842|Behavioral|Individualized exercise|individualized exercise, physical activity and training in daily life situations given by trained physical therapists and occupational therapists
45935201|NCT00218881|Procedure|HIV educational video|
45446938|NCT02097004|Biological|HBV vaccination|1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks
45446939|NCT02097004|Drug|Entecavir|Continue Entecavir(0.5mg) for 100 weeks
45624318|NCT02453087|Drug|Rituximab|Participants will receive rituximab at a dose of 375 mg/m^2 of body surface area as intravenous infusion.
45624319|NCT02453087|Drug|Obinutuzumab|Participants will receive obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion.
45624320|NCT03235583|Device|MOTIONPODTM device validation|MOTIONPODTM validation in free-living conditions using gold standards, including the DLW method
45624321|NCT03235193|Other|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
45624322|NCT03235193|Other|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the CHH electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
45624323|NCT02128763|Drug|Omega-3 supplements|2000 mg EPA and 1000 mg DHA per day
45624324|NCT02128763|Drug|Placebo|Olive oil gelcaps manufactured to mimic Omega-3 gelcaps
45624325|NCT02124772|Drug|Trametinib|Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).
45624326|NCT02124772|Drug|Dabrafenib|Dabrafenib was administered orally, twice daily. The daily dose was divided into two equal doses. It was available in capsules (50 mg and 75 mg), dispersible tablets (10 mg) and powder for oral suspension (10 mg/mL dose).
45624327|NCT02159482|Drug|Interferon Alfa-2a|
45624328|NCT05269030|Drug|Ivermectin Topical|Ivermectin 1% in a dose of two drops per nostril twice daily.
45624329|NCT05269030|Drug|Budesonide Nasal|64 µg per puff in a dose of 1 puff for each nostril twice daily.
45624330|NCT02622321|Drug|Emicizumab|Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.
45765917|NCT00981253|Behavioral|Standard Cardiac Rehabilitation|Supervised exercise, three times per week, for 12 weeks.
45765918|NCT03019705|Other|Observation|
45765919|NCT05028153|Drug|Azithromycin Oral Liquid Product|10 mg/kg for 3 consecutive days
45765920|NCT05028153|Other|Placebo mixture|Placebo mixture containing no active substance
45624331|NCT02622321|Drug|rFVIIa|Participants will continue to receive rFVIIa.
45765921|NCT03126760|Drug|Acthar Gel|Acthar Gel 1 mL (80U) for subcutaneous injection
45624332|NCT02622321|Drug|aPCC|Participants will continue to receive aPCC.
45624333|NCT02187172|Drug|Ustekinumab|
45624334|NCT02187172|Drug|Placebo|
45624335|NCT03056937|Other|Bariatric surgery|evaluations pre and post bariatric surgery.
45765922|NCT03126760|Drug|Placebo|Placebo for subcutaneous injection
45624336|NCT03056937|Other|Control|without intervention, it will be performed only evaluations
45765923|NCT00982033|Drug|aliskiren|aliskiren 300mg qd versus placebo for 24 weeks.
45765924|NCT00982033|Drug|placebo|placebo qd for 24 weeks
45765925|NCT03127228|Other|Standard mechanical debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with dental scalers prior to bone grafting regenerative therapy
45765926|NCT03127228|Device|Er:YAG laser-assisted debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with the aid of the laser prior to bone grafting regenerative therapy
45624337|NCT03057015|Drug|Clonidine|50 mcg Clonidine added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the treatment group.
45765927|NCT05026905|Drug|Gemcitabine 1000 mg|Gemcitabine 800mg/m2 in N/S 250ml over 30 minutes (or fixed dose rate 10 mg/m2/min) IV infusion on day 1 repeated every 14 days.
45912640|NCT02012465|Biological|Insulin protocol|"Within 24 hours of admission for diabetic participants, the inpatient oncology team will consult the endocrine team to apply the following part of the protocol, confirm NPH insulin dosing, and ensure that oral hypoglycemics are held.~The following basal-bolus protocol is standard of care for inpatient diabetics requiring insulin at Barnes Jewish Hospital. The alternative practice has been to use 60-80% of the home insulin regimen while patients are hospitalized. For patients using home insulin, the admitting oncology team will enact one of these methods while awaiting the endocrine service's formal recommendations.~Determine basal-bolus insulin requirement for the patient based on body weight: Patient weight (kg) x 0.5-0.7 Units/kg = Units of total insulin per 24 hours~The TDD can be divided into 50% basal (glargine) and 50% meal time (lispro) insulin, plus sliding scale insulin (lispro)."
45912641|NCT02012478|Behavioral|MI- informed SMS program|
45446940|NCT02090218|Device|I-Gel|I-Gel supraglottic airway device
45624338|NCT03057015|Drug|Placebo|Normal saline added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the placebo group.
45624339|NCT03057015|Drug|Ropivacaine|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
45624340|NCT03057015|Drug|Dexamethasone|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
45624341|NCT03057015|Drug|Epinephrine|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
45624342|NCT04929717|Other|Breastfeeding education and counseling|Breastfeeding education was applied for four weeks.
45624343|NCT04929717|Other|Routine postpartum breastfeeding training included in the hospital procedure|The routine breastfeeding postpartum educational training given to all women by healthcare personnel as part of the hospital procedures.
45624344|NCT04955613|Device|MyMove/VR system|"The treatment system consists of two lightweight MyMove bands and Virtual-Reality (VR) gear. Proprietary software and content allow tracking of performance in real-time, with feedback to both the patient and treating - personnel.~MyMove is a wearable device that allows patients with loss of upper limb function to operate computers, cellular phones, and similar devices. The technology is non-invasive and does not involve risk to the patient.~Virtual-Reality (VR) gear is a wearable computer running within goggles that project content and allow for interaction using controllers."
45624345|NCT04955613|Device|Mirror therapy|Mirror therapy or mirror visual feedback is a therapy for pain or disability that affects one side of the patient more than the other side
45624346|NCT04934475|Drug|Isatuximab|treatment with Isa-KRD during induction and consolidation , with revlimid or Iberdomide +isatuximab during maintenance phase
45624347|NCT04934475|Procedure|ASCT|ASCT for ams B, C and D during consolidation
45624348|NCT04929639|Other|measurment of intraabdominal surgery|Immediately after intubation, while the patient is lying in the supine position, an intra-abdominal measurement will be made from the bladder catheter and recorded. Then, after the surgical site antisepsis, when the trocar required for the operation is placed by the general surgeon, another measurement will be made from the trocar port. Measurements will be recorded.
45765928|NCT05026905|Drug|Nab paclitaxel|Nab-paclitaxel 125mg/m2 over 30 minutes IV infusion on day 1 repeated every 14 days, followed by Gemcitabine
45765929|NCT05026905|Drug|S1|"S-1 orally 60-100 mg/day day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~BSA < 1.25 m2: 60 mg/day~1.25 m2 ≤ BSA < 1.5 m2: 80 mg/day~BSA ≥ 1.5 m2: 100 mg/day"
45765930|NCT05026905|Drug|leucovorin|leucovorin 30mg BID day 1 to 7 on in a 2-week cycle
45765931|NCT05026905|Drug|Oxaliplatin|Oxaliplatin 75mg/m2 in 250 mL of D5W over 120 minutes IV infusion on day 1 repeated every 14 days
45765932|NCT00982189|Drug|Pravastatin|Participants randomized to take pravastatin (active) or matching placebo pill once daily
45765933|NCT00982189|Drug|Lisinopril|Participants randomized to take lisinopril (active) or matching placebo pill once daily
45765934|NCT04752735|Other|endovascular treatment|all enrolled patients must receive endovascular treatment.
45765935|NCT03019471|Genetic|Isolation of tumor DNA|
45624349|NCT04431531|Other|10 Sessions of yogatherapy associate with EMDR|The first group will have Yogatherapy plus EMDR treatment
45624350|NCT04431531|Other|The second group will have EMDR without yogatherapy|the second one will have EMDR treatment
45624351|NCT04929561|Behavioral|Video-conferencing group|No intervention
45624352|NCT04934241|Other|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body
45765936|NCT05017545|Biological|carfilzomib|"Administered: Intravenously (IV). Carfilzomib is administered intravenously, on two consecutive days, each week for three weeks per cycle. In this study, subjects will receive 2 cycles of carfilzomib. Dosing for each cycle is based on the recommended dosing for carfilzomib monotherapy in the package insert.~Carfilzomib is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma. In this study, carfilzomib will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant."
45765937|NCT05017545|Biological|belatacept|Administered: Intravenously (IV). Belatacept is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in highly sensitized subjects who are awaiting a kidney transplant.
45765938|NCT05017545|Procedure|Bone marrow aspiration|Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 16 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been >4 weeks since the previous bone marrow aspiration.
45765939|NCT03128008|Drug|Carboplatin|Single arm non randomized open label study. Subjects will receive standard of care Carboplatin IV once a week. Chemotherapy is given concurrently with daily hyperfractioned radiation therapy.
45624353|NCT04929093|Biological|Novel dose adjustment of Alutard SQ|novel dose adjustment schedule means directly reaching dose of Vial 4, 10,000 SQ
45624354|NCT04929093|Biological|conventional dose adjustment of Alutard SQ|conventional dose adjustment schedule means restarting from dose of Vial 1, 10 SQ
45624355|NCT04929093|Biological|Routine continuous cluster of Alutard SQ|Patient receiving continuous cluster SCIT for DM during the same period
45624356|NCT04408209|Procedure|Convalescent Plasma|"Convalescent Plasma - early treatment of patients with severe COVID-19. Clinical and laboratory data of patients will be collected before initiation of the procedure, 30 minutes after the first dose, 30 minutes after the second dose and 30 minutes after the third plasma dose and then on days 1-7, 14, 21, 28, 35 from the start of treatment. In case of adverse reactions during transfusion such as acute shortness of breath, haemodynamic instability or high pre-existing and non-disease-related fever, the transfusion will be interrupted and detailed recording of the event as well as updating the Adverse Events Management Committee will be performed.~In addition to the standard assessments, the titer of neutralizing anti-SARS-CoV-2 antibodies will be measured in a sample drawn prior to plasmapheresis.~All donors will be tested for:~the titer of IgG anti-SARS-CoV-2 antibodies (Pasteur Institute)~the titer of neutralizing anti-SARS-CoV-2 antibodies (Pasteur Institute)"
45765940|NCT03128008|Drug|Paclitaxel|Single arm non randomized open label study. Subjects will receive standard of care Paclitaxel IV once a week. Chemotherapy is given concurrently with daily hyperfractioned radiation therapy.
45765941|NCT03128008|Radiation|Daily hyperfractionated radiation therapy|All subjects will receive 6 fractions(2Gy per fraction) of radiation therapy weekly. All subjects will complete an interim PET-CT after 48Gy-54Gy of RT . Subjects with a complete response on PET will complete RT at 60 Gy; subjects who have residual disease on interim PET and meet strict planning constraints eligibility will proceed to boost RT for a total RT dose of 72Gy. Interim PET-CT response will be measured using PERCIST criteria.
45765942|NCT04744935|Device|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser, with surface temperature monitored by infrared camera.
45624357|NCT03057483|Biological|Seasonal Influenza vaccine|Seasonal Influenza vaccine
45765943|NCT05017311|Drug|Escitalopram|All patients will receive open-label escitalopram (10-20 mg/d) for the entire study duration (12 weeks).
45765944|NCT05017311|Drug|Brexpiprazole|Depending on the initial randomization process, patients will either receive blinded brexpiprazole (0.5-2 mg/d) for the entire study duration (12 weeks) or for the last 4 weeks of the study if they received the placebo during the first 8 weeks of the study and were non-responders.
45624358|NCT04929327|Procedure|Self etch Pit and fissure sealant application (prevent seal)|Sealing deep pits and fissures
45624359|NCT04929327|Procedure|Self etch Pit and fissure sealant application (prevent seal) with prior sandblasting|Sandblasting before Sealing deep pits and fissures
45624360|NCT04929327|Procedure|Total etch resin based sealant ultraseal xt|Sealing deep pits and fissures
45624361|NCT04955145|Drug|RUTA C 60|Rutin known as vitamin p or rotoside and C-retard is Ascorbic acid
45624362|NCT04933461|Device|Safety lancet|There are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.
45765945|NCT03128086|Procedure|Protocol-directed weaning|A protocol-directed weaning in neurological patients undergoing mechanical ventilation will reduce the rate of extubation failure and associated complications comparing with a conventional weaning (control group)
45765946|NCT05395273|Device|Game Ready cryocompression|Cryotherapy on the coldest tolerable level and intermittend compression on the knee
45765947|NCT00360087|Drug|Bosentan|
45912642|NCT02012517|Drug|Prolonged antibiotic treatment|
45912643|NCT02012517|Drug|Short antibiotic course (standard of care)|
45446941|NCT02090218|Device|LTS, ETI or current airway management practice|Laryngeal tube, endotracheal tube, bag-mask-ventilation
45624363|NCT04955067|Diagnostic Test|Diagnositic test|The results of hip arthroscopy were taken as the gold standard, and MRI examination was taken as the research object
45624364|NCT04929171|Other|Physical Therapy|Physical therapy for chronic upper quarter myofascial pain syndrome, as prescribed by the patients' physicians
45446942|NCT02090296|Drug|Hydroxyurea|
45624365|NCT04928937|Procedure|Roux-en-Y gastric bypass, sleeve gastrectomy|bariatric surgery with the goal loosing weight
45765948|NCT00982423|Drug|Furosemide|Subjects received their clinically prescribed dose of furosemide for a 3 week stabilization period, then were assessed for cardiorenal and humoral function. Subjects then had a 50% reduction of the furosemide dose for a 3 week stabilization period, and were assessed for cardiorenal and humoral function again.
45765949|NCT03073486|Drug|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
45765950|NCT03073486|Other|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
45765951|NCT04742439|Device|Sham transcranial direct current stimulation|Participants will receive 30 seconds of ramp up and down stimulation at the start and end of the 20 minute stimulation period.
45765952|NCT04742439|Device|Individualized transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at the individualized dose (maximum of 4mA).
45624366|NCT04928469|Other|No intervention performed|Collection of clinical and laboratory data
45624367|NCT04922151|Drug|601|intravitreal recombinant humanized anti-VEGF monoclonal antibody
45624368|NCT04922151|Drug|Ranibizumab|intravitreal recombinant humanized anti-VEGF monoclonal antibody
45624369|NCT04928313|Drug|Glatiramer Acetate|Cinnomer® was injected subcutaneously 3 times per week at least 48 hours apart.
45765953|NCT04742439|Device|2mA transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at a 2mA dose.
45624370|NCT04928859|Drug|Albumin|"At least one dose of human albumin was used for the patients during hospitalization in the burn ward consisted the albumin group.~The patients who have no albumin use during their hospitalization in the burn ward consisted the control group."
45624371|NCT04928079|Procedure|deep brain stimulation|performing deep brain stimulation if needed
45765954|NCT04742439|Device|4mA transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at a 4mA dose.
45765955|NCT00983281|Drug|Hextend|IV fluid resuscitation to restore euvolemia after traumatic injury and surgery.
45765956|NCT05448573|Diagnostic Test|Fatigue Screening and assessment|(Newly) diagnosed cancer-patients from any cancer entity. No intervention.
45765957|NCT05394961|Procedure|Treatment in an intensive care unit with a diagnosis of sepsis and/or ARDS and/or covid-19|As above
45765958|NCT03129178|Dietary Supplement|Concentrated beetroot juice|Acute and chronic supplementation of beetroot juice.
45446943|NCT02090296|Other|Placebo|
45624372|NCT04928079|Drug|Anti-Parkinsonian Drugs|Using anti-parkinsonian drugs if needed
45624373|NCT04928001|Other|internet based iCBT program, Youth Thrive|iCBT program is a skills program which teaches assertive communication, constructive thinking and rewarding activities
45624374|NCT04928547|Diagnostic Test|Test|Different test
45624375|NCT04955457|Other|Healthy women active teachers|The neuropsychological testing data, psychometric measure, demographic, clinical and lifestyle information and blood samples were collected at similar time points. This group not received any intervention.
45624376|NCT04928625|Drug|SHR-A1904|SHR-A1904
45624377|NCT04920747|Drug|Taxane|docetaxel or paclitaxel
45624378|NCT04927767|Device|denture adhesive|Denture adhesive is a commercially available denture care product used to adhere a denture to the oral mucosa, in order to improve the retention and stability.
45624379|NCT04927611|Procedure|Biopsy, open or laparoscopic surgery|Collect NEN and PDAC biopsy or surgical fresh tissue to conduct single cell sequencing or model construction.
45624380|NCT04927299|Drug|Losartan/Chlorthalidone in fixed dose|1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg
45765959|NCT04742361|Drug|[18F]PSMA-1007|diagnostic radiopharmaceutical for PET scan
45765960|NCT03019393|Other|Beef|200 g beef topside which is fully cooked will be provided to participant after overnight fast. The intervention is one time only.
45765961|NCT04741425|Other|REST intervention|"The breastfeeding talk will be conducted by Zoom at the third trimester about breastfeeding benefits and other practical advices. There is also a sharing session by a successful breastfeeding mother and a group discussion with different breastfeeding scenarios.~Once the mothers return home after delivery, individualized breastfeeding coaching will be provided by PI through a daily Zoom videoconference within 24 hours upon hospital discharge till Day 7 after delivery.~During the last breastfeeding videoconference, mothers will be reminded to have weekly telephone follow-ups by PI from week 2 to 2 months postpartum.~Women who are randomised into the intervention group will receive REST in addition to the standard antenatal and postnatal care (described at below) by the Obstetrics Department of their delivery hospitals."
45765962|NCT03129568|Biological|CDC infusion|Injection of CDCs (0.3 million per kg of body weight).
45765963|NCT04737759|Behavioral|Taking Care of Us|A social-behavioral intervention that is targeted at the couple living with heart failure and delivered via Zoom.
45765964|NCT04737759|Other|SUPPORT|SUPPORT is an educational counseling intervention that is targeted at the couple living with heart failure and delivered by Zoom.
45765965|NCT00983359|Radiation|Radiation Therapy|Patients undergo conformal stereotatic radiation therapy QD (every day) over 5 days.
45765966|NCT04719819|Procedure|Spinal anaesthesia for caesarean section|Descriptive questionnaire with open and closed questions, to be completed during the procedure
45765967|NCT02981719|Procedure|simultaneous gemcitabine and irreversible electroporation|gemcitabine intravenous infusion prior to irreversible electroporation treatment
45765968|NCT02981719|Procedure|irreversible electroporation|percutaneous irreversible electroporation was performmed for locally advaanced pancreatic cancer.
45765969|NCT03073876|Drug|Donepezil Hydrochloride|5mg of Donepezil Hydrochloride by mouth
45765970|NCT03073876|Drug|Placebo|prepared placebo looking exactly the same as drug. Participants took placebo by mouth for approximately 6 weeks, and after unblinding, they took donepezil hydrochloride for 6 months.
45912644|NCT02012530|Procedure|HA|HA is widely applied in clinical practice with good results in many studies. HA forms part of the inflammatory process that can lead to the regeneration of cartilage in defective areas of the knee.
45624381|NCT04927299|Drug|Losartan + hydrochlorothiazide in fixed dose|1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg
45765971|NCT05011305|Drug|Saroglitazar Magnesium 2 mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment (76 weeks).
45765972|NCT05011305|Drug|Saroglitazar Magnesium 4 mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment (76 weeks).
45765973|NCT05011305|Drug|Placebo|Patients randomly assigned to this group will receive Placebo tablet orally once daily in the morning before breakfast without food, for the duration of treatment (76 weeks).
45765974|NCT00954109|Behavioral|Exercise|daily exercise: supervised treadmill walking or cycle ergometry use
45765975|NCT05006625|Other|Collaborative Care Model|Use of the collaborative care model to screen and deliver care for depression in adolescents and young adults aged 15-24 years seeking HIV prevention and treatment services
45765976|NCT02980237|Other|eHealth_additional support|An e-learning education program whose audiovisual content will be implemented. Nine audiovisual e-Health program will be composed of nine video classes addressing the following topics: 1) musculoskeletal health, 2) healthy diet and 3) mental health were identified through focus group. A communication tool will be adopted is the Moodle environment. All the participants will be able to whipping the web platform and questions regarding access and navigation are answered by e-mail. All participants will be monitored, as viewing the videos, and whenever it is identified that the participants not accessed and lack of interest of reasons. A team of tutors will be responsible for online support providing reinforcing stimuli and clarifying any questions (intervention group) on the content.
45912645|NCT02012530|Procedure|PRP|PRP uses reparative growth factors taken from the patient's own blood to create an environment in the knee conducive to wound healing that can fill cartilage defects. It's autologous origin, easy preparation and safety profile makes it a potentially ground breaking treatment option for knee cartilage defects and osteoarthritis.
45624382|NCT03056625|Other|Vitamin A fortified rice|Lactating women will receive fortified rice one meal per day on weekdays for a period of 14 weeks.
45624383|NCT03056625|Other|Normal rice|Lactating women will receive normal rice one meal per day on weekdays for a period of 14 weeks.
45624384|NCT03056547|Other|Induced dyspnea|"Biological samples will be assessed during and after breathing discomfort induced by laboratory models of dyspnea (work/effort, air hunger)."
45624385|NCT04913181|Diagnostic Test|Artificial intelligence sepsis prediction model|The main purpose of this paper is to evaluate the accuracy of the sepsis prediction model established in the early stage. The occurrence of sepsis is determined by the daily clinical judgment of doctors, and the results of sepsis prediction model are matched and corrected.
45624386|NCT04913103|Drug|Polatuzumab vedotin|treatment by a study drug polatuzumab-vedotin, i.v.
45912646|NCT02012543|Dietary Supplement|Agar jelly|
45624387|NCT04913103|Drug|Bendamustine Hydrochloride|treatment by a study drug bendamustin i.v.
45624388|NCT04913103|Drug|Rituximab|treatment by a study drug rituximab, i.v.
45624389|NCT04913259|Other|Remote monitoring|Online remote monitoring tool during the care of patients over the age of 65 who are receiving medical treatment for cancer
45912647|NCT02012556|Drug|Tesamorelin|
45624390|NCT04912635|Other|Neo App|Neo is a smartphone-based dashboard application that utilizes concepts from behavioral science and health psychology to support patients to improve their adherence to therapy. This is done through behavior change techniques and intervention functions (Michie, Atkins & West, 2014). This app is designed to prompt participants' self-regulation of lifestyle and health behaviors, to support adherence to therapy. Such self-regulation of lifestyle behaviors is informed by presenting health metric data (through wearables, myAir (biofeedback) and self-report), in an easy to understand dashboard platform on the app. Participants will be asked to use their PAP device (as normal), use a Withings blood pressure cuff and activity monitor. This data is brought into the Neo app through an API Exchange gateway. This data will be presented to the participant and communicated in an easy to understand way.
45624391|NCT04920669|Procedure|erector spinae block with bupivacaine|Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%
45624392|NCT04920669|Procedure|erector spinae block with bupivacaine + dexmedetomidine|Patients will receive a sonar-guided erector spinae plane block with 19 ml of bupivacaine 0.5%+ 1 ml dexmedetomidine
45624393|NCT04912947|Dietary Supplement|Immusystem|Dietary supplement containing: Piceid, Glycine, Glutamine, Acetylcysteine, Zinc and Vitamin B6
45624394|NCT04912947|Other|Placebo|Maltodextrin placebo capsule
45912648|NCT02012569|Drug|TT-173|Bleeding of the lesion will be evaluated after each product application and will be recorded as bleeding vs. not bleeding. The product will be applied at 4 times for about 1 minute apart each application after skin graft obtention.
45912649|NCT02012569|Drug|Placebo|
45624395|NCT04926987|Other|brain tissue single-cell sequencing|Using single-cell sequencing to study the brain tissue single-cell transcriptome difference in aging, epilepsy, and mental disorders
45912650|NCT02012595|Other|[11C]donepezil PET|Positon Emission Tomography (PET) imaging of acetylcholinesterase using the ligand [11C]donepezil
45912651|NCT02012660|Other|Seasonality|The impact of high temperature during summer months on the prevalence of hyponatremia will be explores.
45912652|NCT02012673|Device|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system. The RePneu LVRC is an implantable device, delivered through a fiber-optic bronchoscope, designed specifically to treat patients suffering from emphysema. The Coil is intended to compress the most damaged parenchyma and tension the surrounding tissue, which increases elastic recoil, reduces hyperinflation and redirects air to healthier portions of the lung for more effective ventilation.
45935202|NCT00218920|Behavioral|Strength training|a strength training regime of 4 series with 5 repetitions each, at approximately 90% of 1 repetition maximum (RM), in a leg press apparatus to develop maximal strength mainly from neural adaptation with minimal weight gain due to muscular hypertrophy.
45935203|NCT00218920|Behavioral|continuous moderate-intensity aerobic training|The moderate-intensity group walked continuously for 47 min at 60-70% of maximum heart rate (HRmax) to ensure that the training protocols were isocaloric.
45624396|NCT04926753|Drug|5-Fluorouracil, Cisplatin, Toripalimab|Drug: FP combined with Toripalimab Combination drugs: 5-Fluorouracil(F), Cisplatin/Carboplatin(P) and Toripalimab every 21 days for 2 cycles This is a single-arm study with all patients receiving these three drugs.
45624397|NCT04920357|Drug|Vaccination|Persons that are vaccinated within the national and regional vaccine program are invited to participate in the follow-up study.
45624398|NCT04402437|Procedure|LP Block|Subjects randomized to the lumbar plexus block group will receive a subcutaneous lidocaine skin wheal 3-4 cm lateral to midline on the operative side along the intercristal line. A nerve stimulator will be sent to 1-1.5mA and a stimulating needle inserted perpendicular to the skin. The needle will be advanced slowly until the quadriceps muscle is stimulated and maintained at less than 0.6mAs. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement.
45765977|NCT02980237|Other|eHealth_program|The comparative group will receive the same eHealth education program that intervention group. But the comparative group will receive only audiovisuals without additional support. .
45624399|NCT04402437|Procedure|QL Block|Subjects randomized to the quadratus plexus block group will receive a subcutaneous lidocaine skin wheal that will be placed after ultrasound identification of external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A needle will then be advanced under ultrasound guidance below the internal oblique aponeurosis and lateral to the quadratus lumborum muscle. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement. Local anesthetic injection will also be observed with real time ultrasound guidance.
45765978|NCT04718961|Drug|Volixibat|Oral capsules, administered twice daily. Volixibat is an ileal bile acid transporter (IBAT) inhibitor.
45765979|NCT04718961|Drug|Placebo|Capsules matched to study drug minus active substance.
45624400|NCT04920591|Other|doll treatment|"The doll used in the study is the empathy doll; these dolls are designed to obtain an optimal interaction with patients and to arouse empathy."
45624401|NCT02621931|Drug|Fremanezumab|Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration. The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site.
45624402|NCT02621931|Drug|Placebo|Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
45765980|NCT03130738|Drug|7-Day Miconazole Oil (Miconazole 2%)|7 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
45624403|NCT04926441|Diagnostic Test|Stress Levels and Mental Well-Being assessment|At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.
45624404|NCT02621073|Drug|VeraFlo with Prontosan|VeraFlo device with Prontosan instillation (n=10).
45624405|NCT02621073|Device|V.A.C Ulta System|V.A.C. Ulta Negative Pressure Wound Therapy System without instillation (n=10).
45624406|NCT04925973|Drug|Tofacitinib 10 MG [Xeljanz]|Tofacitinib 10mg PO BID
45765981|NCT03130738|Drug|14-Day Miconazole Oil (Miconazole 2%)|14 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
45765982|NCT03130738|Drug|14-Day Placebo - Oil Vehicle|14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
45765983|NCT00374920|Drug|MEM 1003|
45912653|NCT02012712|Behavioral|Personal Health Record (PHR)|"Iowa PHR is a Web-based application that features a tabbed interface design. Users can enter, view, and print their current and past medicines, allergies, health conditions, and health event tracking over time. An embedded tutorial video provides assistance with the system. The PHR was developed and refined using participatory design and focus group sessions as well as evaluation in a usability laboratory. The resulting design emphasizes the reduction of physical and cognitive demands on users, focusing on simplicity, readability, and quick navigation.~Iowa PHR displayed a message when a user entered a medication with an associated Assessing Care of Vulnerable Elders project (ACOVE-3) safety concern. This included 16 safety issues for 12 drugs or drug classes with safety concerns. We also adapted four general medication use patient safety indicators from the ACOVE project and displayed them to all users on a rotating basis upon login."
45912654|NCT02012725|Drug|Arm 1 MRI with gadolinium|Healthy volunteers will not receive gadolinium
45765984|NCT02977377|Other|Exercise therapy|Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
45765985|NCT02977377|Other|Whole body vibration|4 sets, 1 min application and 1min rest whole body vibration and after that exercises. Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
45765986|NCT02976675|Biological|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks
45912655|NCT02012738|Behavioral|FORNET|"8 individual sessions:~1 lifeline~6 exposure sessions~1 outlook"
45912656|NCT02012738|Behavioral|CBT|"7 individual sessions, according to the Integrated cognitive behavior change program manual, Bush et al., 1997, National Institute of Corrections, US Dept. of Justice."
45624407|NCT04400175|Device|Valved ergonomic teat|Administration of milk with a feeding system with a valved ergonomic teat in late preterm newborns.
45624408|NCT04400175|Device|Standard silicon teat|Administration of milk with a feeding system with a standard silicon teat
45624409|NCT04431297|Other|Mindfulness Rounds|Virtually delivered mindfulness education sessions of 15-30 minutes, two times/week, for four weeks
45765987|NCT02976675|Biological|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per two weeks:0.20 mg /kg/2w，once per two weeks for 26 weeks
45765988|NCT04996251|Drug|Bupivacaine Injection|0.25% Bupivacaine being used as local anesthetic to inject into incision sites of tracer sites during a laparoscopic/robotic-assisted sacrocolpopexy
45765989|NCT04994613|Other|Sensory adaptive environment|A dedicated, private room that is set up in accordance with the patient's coping plan and individual needs regarding sound, light, activity level, and other stimuli.
45765990|NCT04988373|Device|Modified aligner appliance|Patients will be treated using a single aligner appliance with NiTi Springs in order to align their crowding teeth.
45624410|NCT04926519|Other|Type of periodontal treatment|Identify factors that contribute to disease recurrence due to periodontal classification and periodontal treatment. One group have got the diagnosis aggressive periodontitis at baseline and the other group chronic periodontitis. Since 2018 we have the classification system with stage and grade.
45624411|NCT03056235|Device|ELAPR002f|30mg/ml Tropoelastin cross-linked with derivatised hyaluronic acid
45765991|NCT04988373|Device|Traditional fixed appliance|Patients will undergo typical orthodontic treatment using an MBT-prescription of metallic brackets.
45765992|NCT00983983|Dietary Supplement|Oxepa|Oxepa: Tube feed containing 1.5 calories/ml of which 55% calories are from fat, including eicosapentaenoic acid and gamma-linolenic acid. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
45624412|NCT03056235|Device|Saline|Saline control
45624413|NCT04926207|Behavioral|Physical Activity Breaks Intervention|Participants will be asked to walk on a treadmill for 3 min at a moderate intensity (55% of heart rate reserve) at an increasing speed and incline to reach and maintain their target heart rate.
45624414|NCT04926207|Behavioral|Talking Breaks Control|Every 30 min a researcher will start a brief conversation with a participant based on a pre-selected topic, which will change with each break. Topics are standardized across participants and include, for example, pollution, smart clothes, and hydration. A presentation will be followed by questions and answers. The break will last 3 min.
45624415|NCT04912167|Drug|Sacubitril-Valsartan|After initiation of the treatment of sacubitril/valsartan, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (24/26 mg, 49/51 mg and 97/103 mg, twice daily)
45624416|NCT04912167|Drug|Enalapril|After initiation of the treatment of enalapril, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (2.5 mg, 5 mg, and 10 mg,twice daily)
45624417|NCT04912167|Drug|Valsartan|For patients who were previously treated with ACEI and receiving the last dose of that agent during the last 36 hours prior to randomization, Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day was used.
45624418|NCT04925661|Drug|HEC53856|Either dose of HEC53856 will be administered after fasting .
45624419|NCT04925661|Drug|Roxadustat|Roxadustat will be administered after fasting .
45765993|NCT00983983|Dietary Supplement|Jevity 1.5|Jevity 1.5: Tube feed containing 1.5 calories/ml of which 29.4% are from fat. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
45765994|NCT00983983|Dietary Supplement|Jevity 1.0|Jevity 1.0: Control tube feed. Subjects will receive 1.0 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
45765995|NCT04985565|Other|Dietary Intervention|Participate in Mediterranean diet
45765996|NCT04985565|Procedure|Radical Prostatectomy|Undergo standard of care radical prostatectomy
45765997|NCT00984139|Biological|Engerix™-B Kinder|Intramuscular, one dose.
45765998|NCT04672395|Biological|CpG 1018/Alum-adjuvanted SCB-2019 vaccine|Group 1: Participants will receive 1 intramuscular (IM) injection of 30 microgram (ug) SCB-2019 with CpG1018/Alum adjuvant on Day 1 and on Day 22
45765999|NCT04672395|Biological|Placebo; 0.9% saline|Group 2: Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 1 and on Day 22
45766000|NCT04672395|Biological|SCB-2019 vaccine|Participants will receive 1 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant
45766001|NCT04672395|Biological|SCB-2019 vaccine for Placebo|Participants will receive 2 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant, 21 days apart
45766002|NCT03131206|Drug|Alectinib|"Oral, BID~Phase I: A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days.~Phase II: Participants will be treated at the RP2D identified during Phase I. Each treatment cycle will be defined as 28 consecutive days."
45766003|NCT03132298|Other|Implicit Theories of Personality Program|This 30-minute, self-administered computer program teaches youths that personality is malleable, as opposed to fixed, due to the human brain's constant potential for change and growth (i.e., neuroplasticity).
45912657|NCT02012738|Other|Waiting List Control Group (camp)|Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
45624420|NCT04925661|Drug|Placebo|Either dose of placebo will be administered after fasting .
45624421|NCT04919889|Other|Exercise prescription|All individuals referred to the community-based Exercise on Prescription program
45766004|NCT03132298|Other|Control Program|This 30-minute, self-administered computer program was designed to control for nonspecific aspects of completing a series of computer-based activities in the context of the present study. It was also designed to mimic 'supportive therapy' that youths might receive in usual care settings, stressing the importance of sharing one's feelings with close others.
45624422|NCT04925115|Other|Brisk walking|"Warm up and cool down (10 minutes before physical activity)~Brisk walking ( 30 minutes each session for 5 days in a week)"
45624423|NCT04925037|Behavioral|self-questionnaire to patients undergoing SpAax follow-up|On the occasion of a single visit in consultation or hospitalization, an anonymous self-questionnaire will be distributed to patients undergoing SpAax follow-up
45766005|NCT00985543|Drug|lopinavir/ritonavir|Each participant received three sequential doses of lopinavir/ritonavir: 400/100 mg twice daily (2 heat-stable 200/50 mg tablets BID), 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID), and 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.
45766006|NCT04978467|Device|Exoskeleton|Participants will receive assistance to move finger joints away from the compensatory coordination (compensation avoidance), toward the desired trajectories (task assistance), both, and none in different days.
45912658|NCT02012738|Other|Waiting List Control Group (no camp)|Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
45912659|NCT02012751|Device|Nevus doctor program|The Nevus doctor program supplies a diagnostic category of pigmented skin lesions based on dermatoscopy images.
46069611|NCT02622087|Behavioral|One-Session-Treatment|There are a total of five steps, each to be repeated until the participant experiences a reduction of at least 50% in their anxiety. Step 1 is catching a spider with a glass and postcard. Step 2 is touching a spider from behind with the dominant index finger. Step 3 is letting a spider walk on the participant's hands. Step 4 is allowing a spider to walk on the participant's legs and body. Steps 1-4 are repeated with larger spiders, and then the two biggest spiders will walk on the participants' hands simultaneously. Step 5 is using a chopstick to guide a huntsman spider over their gloved hand. Treatment ends when all steps are completed, or if the maximum 3 hour time limit has been reached, or if the participant indicates that they do not want to continue.
45624424|NCT03056703|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|One Fast Release Tablet containing 1000 mg acetylsalicylic acid
45624425|NCT03056703|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|Two Fast Release Tablets containing 500 mg acetylsalicylic acid each
45624426|NCT02158936|Drug|Eltrombopag|Eltrombopag will be round film-coated tablets containing eltrombopag equivalent to 50 mg (white to off-white), 200 mg and 300 mg (green) of eltrombopag free acid
45624427|NCT02158936|Drug|Azacitidine|Subcutaneous Injection (IV if local standard)
45624428|NCT02158936|Drug|Placebo|Eltrombopag matching placebo tablets
45624429|NCT02158936|Drug|Placebo|Eltrombopag matching placebo tablets will be supplied
45624430|NCT03054441|Other|Actigraph|Actigraphs worn on wrists
45624431|NCT04924647|Drug|lenalidomide and dexamethasone|lenalidomide 25mg d1-21 and dexamethasone 20-40mg d1，8，15，22
45624432|NCT04919577|Diagnostic Test|X-ray|We defined RSS as (1) the presence of symptoms such as nausea, vomiting, or abdominal fullness, (2) refasting after liquid or semi-liquid diets, (3) imaging methods (X-ray, CT, upper gastroenterography) confirmed without mechanical obstruction. All three conditions must be met at the same time and should occur within 30 days after operation.
45766007|NCT05440305|Procedure|surgery type/exstirpation/debulking|Evaluation of benefit according to surgery
45446944|NCT02094976|Device|Jackson surgical table|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a Jackson table with two padded supports on each side. The supports were positioned under the lateral chest and at the iliac crest.
45624433|NCT04919421|Drug|Dental injection and topical gel application|Topical anesthesia gel will be applied followed by dental injection with 1.8 ml Xylocaine 20mg/ml (DENSPLY Pharmaceutical); adrenaline: 1 : 100.000, delivered in cartridges using a 27 -gauge short needle (0.4 x 25 mm,C-K jet) and sterile non-aspirating syringe.
45624434|NCT04919421|Device|Dental injection and virtual reality device|Dental injection will be made while the participants are wearing virtual reality device.
45766008|NCT05394415|Drug|Tislelizumab|The 1st and 2nd doses were administered concurrently with TP regimen chemotherapy, 200 mg each, on D1 and D22 by intravenous infusion. In patients with successful conversion therapy, one dose of 200 mg on D60, was administered sequentially at the time before surgery after radiation therapy, and two doses of immunotherapy, on D150 and 171, were administered 8 weeks after surgery in concurrent with the 3rd and 4th cycles of chemotherapy as adjuvant therapy; in patients with failed conversion, two doses of chemotherapy combined with tislelizumab, on D60 and D81, were administered 2 weeks after the completion of radiation therapy.
45766009|NCT05394415|Drug|Paclitaxel|A TP regimen with paclitaxel 135 mg/m^2 + carboplatin AUC=5 was used, on D1 and D22 infused intravenously. Two cycles of adjuvant chemotherapy, on D150, 171, were started 8 weeks after surgery in patients with a successful conversion, and 2 cycles of consolidation chemotherapy, on D60, 81, were started 2 weeks after the end of radiotherapy in patients with unsuccessful conversion therapy.
45766010|NCT05394415|Drug|Carboplatin|A TP regimen with paclitaxel 135 mg/m^2 + carboplatin AUC=5 was used, on D1, 22 infused intravenously. Two cycles of adjuvant chemotherapy, on D150,171, were started 8 weeks after surgery in patients with a successful conversion, and 2 cycles of consolidation chemotherapy, D60,81, were started 2 weeks after the end of radiotherapy in patients with unsuccessful conversion therapy.
45446945|NCT02094976|Device|Wilson frame|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a Wilson frame. The supports were positioned vertically from shoulder to iliac crest.
45446946|NCT02094976|Device|Chest roll|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a chest roll. The supports were positioned vertically from shoulder to iliac crest.
45446947|NCT03691779|Drug|ELX/TEZ/IVA|Fixed-dose combination tablet orally once daily in the morning.
45624435|NCT04924959|Other|Logistic Regression Analysis|Using logistic regression analysis to analyze the independent risk factors of PICC catheter displacement
45624436|NCT04924725|Procedure|Endoscopic ultrasound-guided fine needle biopsy|Endoscopic ultrasound-guided fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions
45912660|NCT02012777|Drug|propranolol|Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent. This will be administered in an open-label single administration to 3 cohorts (10mg, 20mg, and 40mg) of children with sickle cell disease. Patient blood will be evaluated for red cell adhesion and patient data evaluated for safety monitoring.
45766011|NCT05394415|Radiation|Radiotherapy|Radiotherapy was scheduled to be given on D1 of the 2nd cycle of chemotherapy. The primary lesions and/or lymph nodes in the operation area would be radiated in 2 stages. A dose of 30Gy/12F would be given in the first stage. When 12 Fractions were given, our MDT team would evaluate the regression of the lesions according to CT and MR results. If surgery is feasible, radiotherapy would be stopped for the primary lesions and lymph nodes in the operation area; if not resectable, the 2nd stage of radiotherapy would be given with a dose of 15Gy/6F, totaling to 45Gy/18F to the ESCC lesions. Radiotherapy for all lymph nodes outside the operation area was with DT of 45Gy/18F. All radiotherapy in this study was scheduled to be 2.5Gy/F, 1F/d, 5F/w. The preoperative radiotherapy target area was outlined by the consensus of the thoracic surgeon and radiotherapist.
45766012|NCT03134092|Other|Probabilistic Risk Communication Tool (PRT)|The probabilistic risk communication tool (PRT) is a visual tool that communicates risk using the previously validated Opioid Risk Tool (ORT). The ORT is designed to assess risk of opioid dependency for patients for whom an opioid pain relief prescription is being considered in outpatient settings. Patients in this arm will be given an iPad which will prompt them to take a short survey that automatically communicates their risk score. After which the iPad will show them a color coded visual thermometer that informs them of their risk of having issues related to opioids.
45766013|NCT03134092|Other|Narrative Enhanced Risk Tool (NERT)|Participants assigned to this arm will receive the PRT described above but will also be instructed to watch one or more narrative videos. This video intervention will include a brief narrative video of an individuals' cautionary tale around prolonged opioid uses. Narrative videos are developed from actual patients sharing their stories - put into a in a structured format of ~ 2-minute length and recorded.
45624437|NCT04911933|Behavioral|Family Therapy|There will be systemic family psychotherapy sessions every two weeks. Families and individuals who require a more intensive service will be referred to a higher level of care.
45766014|NCT04352959|Device|mouthrinse with bêta-cyclodextrin and citrox|3 daily mouthrinses for 7 days
45766015|NCT04352959|Device|mouthrinse without bêta-cyclodextrin and citrox|3 daily mouthrinses for 7 days
45766016|NCT00360945|Drug|cisplatin|
45766017|NCT00360945|Drug|temozolomide|
45766018|NCT00360945|Genetic|fluorescence in situ hybridization|
45766019|NCT00360945|Genetic|loss of heterozygosity analysis|
45766020|NCT00360945|Other|immunohistochemistry staining method|
45446948|NCT03691779|Drug|IVA|IVA tablet orally once daily in the evening.
45624438|NCT04912011|Drug|Canrenoate Potassium|Intervention: 200 mg of Canrenoate potassium in 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
45766021|NCT00360945|Other|laboratory biomarker analysis|
45446949|NCT02095054|Drug|Regorafenib|"Dose Escalation Group Starting Dose of Regorafenib: 80 mg by mouth once a day for 21 days (5 days on and 2 days off) in a 28 days cycle.~Dose Expansion Group Starting Dose of Regorafenib : MTD from Dose Escalation Group."
45766022|NCT00360945|Radiation|radiation therapy|
45766023|NCT05394181|Other|Notification|Notification of patient and primary care clinician of presence of at least moderate coronary artery calcium on a prior non-gated chest CT
45766024|NCT03019237|Drug|anti-IgE|intranasal anti-IgE
45766025|NCT03019237|Other|intranasal allergen|intranasal allergen
45766026|NCT03019237|Other|intranasal saline|intranasal placebo
45766027|NCT03134248|Device|Dailies Aquacomfort Plus Toric|daily disposable contact lens
45766028|NCT03134248|Device|1-Day Acuvue Moist for Astigmatism|daily disposable contact lens
45766029|NCT03134248|Device|MyDay Toric|daily disposable contact lens
45766030|NCT00361023|Drug|losartan|
45766031|NCT03019159|Device|Teleconsulting|
45766032|NCT00361101|Drug|AMD11070|200 mg PO BID (by mouth two times per day) for 10 days.
45766033|NCT03134326|Device|R1-25 and R2-25 Pulse Oximeter Sensor|
45766034|NCT03019081|Drug|Isoproterenol|The goal of this experiment is to use isoproterenol in the context of inhibitory fear learning to reduce eating-related anxiety in AN, and to explore whether these changes are related to interoceptive awareness and autonomic reactivity.
45766035|NCT03019081|Other|placebo|placebo
45446950|NCT02095054|Drug|Cetuximab|"Dose Escalation Group Starting Dose of Cetuximab: 200 mg/m2 initial dose, then 150 mg/m2 by vein over about 1-2 hours on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose Expansion Group Starting Dose of Cetuximab: MTD from Dose Escalation Group."
45446951|NCT02095054|Behavioral|Questionnaire|Symptom questionnaire completed at each study visit.
45446952|NCT02095210|Other|Radiolabeled [68Ga]ABY-025|Single dose of 100 μg ABY-025 labeled with 500 MBq gallium-68, administrated as a slow intravenous injection. All patients will receive the same dose.
45446953|NCT03555994|Drug|MEDI0382|MEDI0382 administered subcutaneously
45446954|NCT03555994|Drug|Placebo|Placebo administered subcutaneously
45446955|NCT03555994|Drug|Liraglutide|Liraglutide administered subcutaneously
45624439|NCT04912011|Drug|Normal Saline|Placebo: 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
45766036|NCT00374998|Biological|FP9-PP (FP9 polyprotein)|
45766037|NCT00374998|Biological|MVA-PP (Modified Virus Ankara polyprotein)|
45766038|NCT02976831|Drug|AZD0284|Oral solution, concentration: 2 mg/mL and 15 mg/mL
45766039|NCT02976831|Drug|Placebo|Placebo matching AZD0284 in the form of an oral solution with water.
45766040|NCT04959838|Behavioral|Impact of prolonged work|Evaluate the impact of prolonged work (up to 60 consecutive hours) on the surgical capacities evaluated on a simulator, as well as on stress markers (questionnaires, saliva assays, skin conductance, quality of sleep) compared to a standard day.
45766041|NCT04965129|Drug|Placebo|Drug: Placebo olive oil pill manufactured to mimic fish oil. Other Names: • Placebo
45766042|NCT04965129|Drug|Fish oil|All subjects will be given fish oil with a dose of of 2.100 mg of EPA and 924 mg of DHA, in four tablet twice daily for four mounths.
45766043|NCT00986401|Drug|Trospium Chloride (Sanctura XR®)|extended release, 60 mg, oral daily
45766044|NCT00986401|Drug|Metformin hydrochloride (Glucophage®)|immediate release, 500mg
45766045|NCT04957498|Behavioral|Guided Self-Help for Family Based Treatment|A online website provided to parents containing information learned in Family Based Treatment and up to 12 coaching sessions with a therapist.
45766046|NCT04957498|Behavioral|Family Based Treatment|Standard Family Based Treatment provided for up to 15 sessions.
45766047|NCT05443191|Drug|Semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
45766048|NCT03018847|Device|COPD Co-Pilot|The COPD Co-Pilot is a system that guides a patient through a software application (web or mobile app) to collect, track, and trend daily symptoms related to Chronic Obstructive Pulmonary Disease (COPD). The system is intended to be used by patients as a support tool to track COPD symptoms as part of their personal disease management plan. The COPD Co-Pilot allows health care providers to view and triage subject symptoms via the provider web-based application. Health care providers also have the ability to send responses to subjects, like medication recommendations, through preset forms in the system.
45766049|NCT04963023|Other|Physical examinations|BPCO physical examinations
45766050|NCT04963023|Diagnostic Test|blood test|blood test in order to study immunologic markers
45624440|NCT04918719|Drug|Acetylcysteine|The dosing of Acetylcysteine will be similar to the standard intravenous acetaminophen toxicity dosing: 150mg/kg in 200 milliliters of 5% Dextrose (D5W) infused over 1 hour, immediately followed by 50mg/kg in 500mL D5W infused over 4 hours, then 100mg/kg in 1000 milliliters D5W infused over 16 hours. (Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion. )
45624441|NCT04918719|Drug|Dextrose in Water|The placebo will consist of a 5% Dextrose in Water instead of NAC (dosage and timigs are the same as the NAC arm). (Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion. )
45624442|NCT04911699|Behavioral|breast adenocarcinoma receiving chemotherapy|for chemotherapy
45624443|NCT04911699|Behavioral|Control-for|hormonal drug treatment
45624444|NCT04924335|Procedure|Erector spinae plane block|Preoperative ultrasound-guided bilateral erector spinae plane block with 20 ml 0.025% bupivacaine.
45624445|NCT03056391|Drug|Paracetamol|">50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.~<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine."
45624446|NCT04404153|Device|tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS.|At-home remotely supervised tDCS delivered over the dorsolateral prefrontal cortex with the anode on the left, cathode on the right, at an intensity of 2 mA, delivered for 30 minutes five times per week (Monday-Friday) for 26 weeks (6 months).
45624447|NCT04404153|Device|tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver sham tDCS.|Sham treatment will consist of the current ramped up to 2mA over 30 seconds, ramped down over 30 seconds and stay at 0 current for the remaining time of the 30-minute application period five times per week (Monday-Friday) for 26 weeks (6 months).
45624448|NCT04924413|Drug|Tislelizumab|PD-1 positive lymphocytes are isolated from peripheral blood and amplified for transfusion
45624449|NCT02158546|Drug|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
45624450|NCT02158546|Drug|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
45624451|NCT04923711|Behavioral|Moderate intensity exercise prescription|"Exercise Intensity： Low-risk patients: the lower of 60-69% reserve heart rate or the heart rate at the anaerobic threshold.~Moderate-risk or high-risk patients: the lower of 50-59% reserve heart rate or the heart rate at the anaerobic threshold."
45766051|NCT00375076|Drug|enoxaparin|
45766052|NCT04638933|Other|No intervention|No intervention
45766053|NCT04897594|Drug|TERN-201|Investigational drug
45766054|NCT04897594|Other|Placebo|Matching placebo
45766055|NCT02977143|Procedure|Fluid loading of volulyte 300 ml|Administration of volulyte 300 ml and measurement of increase in cardiac index
45766056|NCT00987415|Drug|allopurinol|Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
45766057|NCT00987415|Drug|sugar pill|Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
45766058|NCT04807504|Drug|Ropivacaine|All patients receive erector spinae plane blocks with ropivacaine.
45766059|NCT04784884|Device|HSI|diagnostic hyperspectral imaging
45766060|NCT04586751|Other|Pecs block|Pecs block under real-time ultrasound guidance after anesthesia induction will be performed.
45766061|NCT04586751|Other|no Pecs block|no regional block will be performed in this arm
45912661|NCT02012790|Other|Diet|The dietary intervention provides dietary counseling, whole foods (enough for 2 meals and 2 snacks per day) including study oils
45912662|NCT02012803|Procedure|End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture|Operative treatment of achilles tendon rupture; End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture and after operation identical protocol as conservative treatment.
45452401|NCT00978016|Drug|arbaclofen placarbil-Cohort 1|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg QD) for 7 weeks including titration and taper periods
45766062|NCT04771156|Drug|Ketorolac|Ketorolac 0.5mg/kg will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of Ketorolac
45766063|NCT04771156|Drug|Placebo|0.9% Normal Saline will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of normal saline.
45912663|NCT02012803|Other|Conservative treatment of achilles tendon rupture|Conservative treatment of achilles tendon rupture; 1 week equinus-cast without bearing, and then 6 week Vacoped orthosis with different equinus degrees and full weight bearing.
45624452|NCT04923711|Behavioral|High intensity exercise prescription|"Exercise Intensity： Low-risk patients: the lower of 70-85% reserve heart rate or the heart rate at the anaerobic threshold.~Moderate-risk or high-risk patients: the lower of 60-70% reserve heart rate or the heart rate at the anaerobic threshold."
45624453|NCT04923945|Drug|Savolitinib|Patients meeting the study inclusion criteria will receive Savolitinib [Savolitinib 600 mg, po, once per day (QD) continuously in patients with baseline weight ≥50 kg, and Savolitinib 400 mg, po, QD in patients with baseline weight <50 kg] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest.
45766064|NCT04945395|Device|FES and Conventional training|The experimental group will be fitted with the Functional electrical stimulation system L300 Go to be used during 4 weeks of inpatient rehabilitation in the subacute phase after hemiplegic stroke. Settings will be adjusted continuously to enhance dorsiflexion of the affected foot during walking and mobility training.
45766065|NCT04945395|Device|AFO and Conventional training|The control group will be fitted with an ankle-foot-orthosis (AFO) according to clinical practice to enhance dorsiflexion of the foot while taking part in conventional rehabilitation interventions during 4 weeks of inpatient rehabilitation including walking and mobility training in the subacute phase after hemiplegic stroke
45766066|NCT03138382|Device|Vestibular Nerve Stimulator|Electrical stimulation of the vestibular nerve with vestibular nerve stimulator (GVS device) for for 45 minutes using binaural mastoid placement.
45766067|NCT03138382|Device|Sham stimulator|Looks identical to vestibular nerve stimulator but discharges current into an internal resistor rather than activating the vestibular nerves.
45766068|NCT00955201|Behavioral|Exercise|Structured aerobic exercise (treadmill).
45766069|NCT00955201|Behavioral|Exercise|Structured isokinetic strength exercise (dynameter).
45446956|NCT02095366|Drug|Morphine|"Intravenous administration Patient receives simultaneously IV morphine administration and IN placebo spray.~Pain is controlled by:~at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg~at 10 minutes and if NPRS>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg~at 20 minutes and if NPRS>3: Pacebo (1 spray) + morphine IV 0,05mg/kg"
45766070|NCT04926129|Other|Other: Assessments|Administered as specified in the treatment arm.
45766071|NCT04707040|Other|Neurocognitive Exercise Program|Neurocognitive Exercise Program (NEP) is defined as a multimodal exercise program including different motor coordination exercises and cognitive tasks. Exercise progression is performed from easy to difficult, and consist of simple and complex tasks. Different sports equipment (such as different sizes of balls, racket, tulle, pilates ball, eye band, rope, etc.) is used in motor coordination exercises where multiple extremities can be used in NEP. These materials are used during different exercises including cross-limb movements, throwing, jumping, walking, involving different cognitive tasks. The cognitive task used and the degree of difficulty of the task are provided by different visual (colored cards, numbered cards, gestures, etc.) or auditory (keywords, ring signal, etc.) signs. For example, showing a red card might indicate throwing a ball with the left hand, while showing a blue card indicates throwing a ball with the right hand and walking forward
45766072|NCT04707274|Other|Survey study|Victorian Institute of Sports Assessment for Gluteal Tendinopathy (VISA-G) Questionnaire will be applied.
45624454|NCT03056469|Other|Completion of patient-reported outcome (PRO) questionnaires|Patient-reported outcome (PRO) questionnaires are completed at home within one week before a patient-physician consultation at the outpatient clinic. The questionnaires are submitted online or on paper depending on the participants choice.
45624455|NCT04747054|Drug|Pembrolizumab|Pembrolizumab 200 mg every 3 weeks until disease progression (as confirmed according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)) or unacceptable toxicity. The treatment of pembrolizumab should not be delayed because of radiotherapy planning.
45624456|NCT04747054|Radiation|Loco-regional radiotherapy|The loco-regional radiotherapy will start at D8 after the first administration of pembrolizumab (D1) (if delayed, RT should be started no later than three weeks after the first administration of pembrolizumab, i.e. before the second administration of pembrolizumab if possible), with 54 Gy/18 fractions in the head and neck region. The volume of RT will include only involved loco-regional tumor region and no prophylactic neck volume will be necessary.
45624457|NCT04747054|Drug|Chemotherapy|If the investigator decides before randomization to add chemotherapy with pembrolizumab, the chemotherapy will be composed of carboplatin AUC 5 mg/mL/min or cisplatin 100 mg/m² every 3 weeks with 5-FU 1000 mg/m²/day during 4 days every 3 weeks for a maximum of 6 cycles
45624458|NCT04918563|Drug|Nitroglycerin|Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
45624459|NCT04918563|Drug|Acetylcholine|Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
45624460|NCT04918641|Other|assessment|Physical, developmental, neurological, behavioral, and neurocognitive assessments
45624461|NCT02123446|Drug|Cephalexin|Administered orally.
45624462|NCT04918953|Drug|methylprednisolone|The patients were treated with three protocols: (1) oral methylprednisolone, 40 mg for 3 days, 20 mg for 3 days, and 8 mg for 6 days; (2) oral methylprednisolone, 20 mg for 3 days, 10 mg for 3 days, and 4 mg for 6 days. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
45766073|NCT04343547|Drug|DWP16001|Tablets, Oral, once daily single dose
45766074|NCT04343547|Drug|DWC202001+DWC202002|Tablets, Oral, multiple doses of DWC202001 and DWC202002 in combination
45446957|NCT02095366|Drug|Sufentanil|"Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV placebo administration and IN sufentanil spray.~Pain is controlled by:~at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV~at 10 minutes and if NPRS>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV~at 20 minutes and if NPRS>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV"
45766075|NCT04343547|Drug|DWP16001+DWC202001+DWC202002|Tablets, Oral, DWP16001 , DWC202001 and DWC202002 in combination
45766076|NCT04707118|Drug|cisplatin+Nab-paclitaxel+GEM|Laparoscopic exploration + thermal perfusion cisplatin 40 mg/m2, Postoperative exploration D1, 8 Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 after the second thermal perfusion 4 weeks plan, 6 cycles
45766077|NCT04707118|Drug|Nab-paclitaxel+GEM|Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 4 weeks plan, 6 cycles
45766078|NCT02977221|Procedure|Piezosurgery|The device tip will be used to to create small vertical incisions into the cortex of the dento-alveolar process of the lower anterior teeth.
45766079|NCT03086356|Drug|Dabigatran etexilate|Days 1-4 and Day 8-11
45624463|NCT04918953|Drug|budesonide atomization suspension|(3) budesonide atomization suspension (AstraZeneca Trading Co., Ltd, AU.) inhaled through the nose atomized with an air compression atomizer for 4 weeks, 2 mg for the first 2 weeks and reduced to 1 mg for the last 2 weeks. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
45624464|NCT04918485|Other|preoperative psychological intervention|including closing the relationship between nurse and patient , knowledge education,
45624465|NCT04922931|Procedure|scheduled surgery|Patients undergoing scheduled surgery with lung ultrasound before surgery and determination of lung compliance during general anesthesia
45766080|NCT03086356|Drug|Idarucizumab|Day 11
45766081|NCT03140254|Drug|Chlorhexidine gluconate|
45766082|NCT03140254|Drug|N,N'-(1,10-decanediyldi-1(4H)-Pyridinyl-4-ylidene)-Bis-(1-octanamine) Dihydrochloride|
45766083|NCT03140254|Drug|Placebo|
45766084|NCT04343391|Behavioral|Brief transdiagnostic cognitive-behavioral therapy|Time-limited transdiagnostic evidence-based psychological treatment
45766085|NCT04343391|Drug|Pharmacological treatment|Treatment as usual in PC
45766086|NCT03140722|Drug|vadadustat|vadadustat
45766087|NCT03140722|Drug|epoetin alfa|epoetin alfa
45766088|NCT03142438|Device|F&P Seal Improvement Project|Participants will be placed on this arm for a total 14 ± 4 days from Visit 1. Participants will be using the trial full face or nasal mask during this treatment arm.
45766089|NCT00982345|Drug|quetiapine (Seroquel XR)|Seroquel XR (starting dose 100mg and increased up to 400 mg as tolerated) treatment.
45766090|NCT00375622|Drug|Tamoxifen|
45766091|NCT03087604|Procedure|Thoracic epidural block|Thoracic epidural block with epidural placed with a loss of resistance technique alone.
45766092|NCT03087604|Procedure|Electrical Nerve stimulation|In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall.stimulating peripheral nerve catheters(19 Ga. x 90 cm StimuCath® Continuous Nerve Block Catheter with SnapLock™ Adapter (Arrow by Teleflex Medical, Morrisville, NC), and stimulation will be achieved using a B Braun Stimuplex HNS12 Nerve Stimulator product id 4892098.
45766093|NCT03087604|Drug|Solution For Thoracic epidural block|Dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine
45766094|NCT03090256|Device|AcrySof® IQ PanOptix™ IOL|Multifocal intraocular lens (IOL) (near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
45766095|NCT00987727|Drug|carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)|One drop in each eye three to six times daily, as needed
45766096|NCT00987727|Drug|sodium hyaluronate 0.18% (VISMED® Multi)|One drop in each eye three to six times daily, as needed
45766097|NCT02160535|Drug|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA administered intramuscularly. Injections are divided across seven injection specific head/neck muscle areas every 12 weeks to prevent chronic migraine post traumatic headache
45766098|NCT05386693|Procedure|Ilioinguinal nerve block|Local anesthetic injection of the ilioinguinal nerve. This is performed in the outpatient clinic.
45766099|NCT04913337|Drug|NGM707|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."
45766100|NCT04913337|Drug|NGM707 plus pembrolizumab|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab~Pembrolizumab will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
45766101|NCT04913337|Drug|NGM707|"Drug: NGM707~Preliminary recommended phase 2 dose (RP2D) of NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle."
45624466|NCT02123134|Drug|ATX-101|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
45624467|NCT02123134|Drug|Placebo|Phosphate buffered saline placebo for injection
45624468|NCT03054207|Drug|Clopidogrel 300Mg Tablet|
45624469|NCT03054207|Drug|Prasugrel 60Mg|
45624470|NCT03055689|Behavioral|Educational telephone intervention|Subjects will receive a nurse-led educational telephone intervention for bowel preparation 24-48 hours before the colonoscopy
45766102|NCT04913337|Drug|NGM707|"Drug: NGM707~Preliminary recommended phase 2 dose (RP2D) of NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle."
45766103|NCT04913337|Drug|NGM707|"Drug: NGM707~Preliminary recommended phase 2 dose (RP2D) of NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle."
45766104|NCT04913337|Drug|NGM707 plus pembrolizumab|"Drug: NGM707~Preliminary recommended phase 2 dose (RP2D) of NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle.~Drug: pembrolizumab~Pembrolizumab will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
45766105|NCT04913337|Drug|NGM707 plus pembrolizumab|"Drug: NGM707~Preliminary recommended phase 2 dose (RP2D) of NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle.~Drug: pembrolizumab~Pembrolizumab will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
45766106|NCT05386459|Drug|Interferon Gamma|injection form
46069612|NCT00696579|Drug|BCG|6 weekly instillations of Tice-strain BCG (Organon Teknika Corp.) as induction chemotherapy, with a dose of 5 x 108 CFU diluted in 50 mL of saline held in the bladder for 2 hours.
45624471|NCT03055689|Behavioral|Standard education for colonoscopy|Standard education for bowel preparation at the time of colonoscopy scheduling
45624472|NCT04911387|Device|Intraocular pressure measurments|Intraocular pressure measurements with iCare Home by participants (patients, volunteers) and healthcare staff as well as intraocular pressure measurements with GAT by participants different healthcare staff.
45624473|NCT02185534|Drug|Clopidogrel|European clopidogrel tablets, 75 mg (test) versus Japanese clopidogrel tablets, 75 mg (reference); European clopidogrel tablets, 75 mg (test) versus US clopidogrel tablets, 75 mg (reference)
45766107|NCT02245945|Drug|TFV 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
45766108|NCT02245945|Drug|HEC Placebo Gel|Placebo gel contains hydroxyethylcellulose (HEC) as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4. Each pre-filled applicator will contain approximately 4 mL of placebo gel for delivery.
45766109|NCT04531761|Behavioral|Parent Support Program|The parent support program includes three modules aimed at increasing knowledge, positive attitudes, and supportive behaviors towards trans youth. Each online module includes several activities including writing prompts, videos, interactive quizzes, and other educational activities.
45766110|NCT03018613|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation and the traditional treatments for chronic functional constipation in part 1.
45766111|NCT03018613|Other|Normal Saline|Normal saline and the traditional treatments for chronic functional constipation in part 2
45624474|NCT03056079|Drug|Intravitreal aflibercept|Patients will receive intravitreal aflibercept on a variable dosing regimen and have aqueous humor sample obtained for cytokine analysis at every visit when an intravitreal injection is done.
45624475|NCT03055767|Drug|OnabotulinumtoxinA|The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
45624476|NCT03055767|Other|Placebo (Saline)|The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
45624477|NCT04923009|Procedure|ICE visualization and map construction|Radio-frequency ablation of atrial fibrillation
45452402|NCT00978016|Drug|Placebo-Cohort 5|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (placebo) for 7 weeks including titration and taper periods
45624478|NCT02121808|Procedure|NIPPV|"Ventilation: non-invasive positive pressure ventilation (NIPPV)~Positive end-expiratory pressure: 10 cmH20 Pressure support: 5 - 20 cm H2O for tidal volume of 10 mL / kg (ideal body weight)"
45624479|NCT02121808|Procedure|Tidal volume|Tidal volume spontaneous ventilation, no assistance.
45624480|NCT04923087|Device|Compare the noise and pleasure of crunching between two hyperprotein nutritional supplements|"Validate the evaluation criteria Do you hear the biscuit crunch? and Is it a pleasure?"
45624481|NCT03055845|Drug|STA363|STA363, containing 3 different doses of active ingredient, in a volume of 1.5 mL. Administered as intradiscal injection.
45624482|NCT03055845|Drug|Placebo|Matching placebo solution with identical appearance to the test product, used as reference treatment. Administered as intradiscal injection.
45624483|NCT04922775|Procedure|conventional taping|Participants will accept conventional taping before muscle fatigue exercise.
45624484|NCT04922775|Procedure|Chinese medicine technique taping|Participants will accept Chinese medicine technique taping before muscle fatigue exercise.
45624485|NCT02157376|Drug|Esomeprazole|iv esomeprazole 30 min intermittent infusions given for maximum 14 days
45624486|NCT02157376|Drug|Cimetidine|iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
45624487|NCT04918251|Procedure|128 electrode electroencephalography (EEG)|128 electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting or performing tasks designed to engage specific cortical motor networks of interest (cognitive, behavioural, motor and sensory)
45624488|NCT04918251|Procedure|Transcranial magnetic stimulation (TMS)|Single and paired pulse TMS protocol will be delivered while surface bipolar EMG is recorded over hand muscles to interrogate corticospinal tract function and cortical motor network component functions
45766112|NCT04342845|Behavioral|Experimental: Motivational interviewing Placebo Comparator: Traditional lectures|Patients in the intervention group (n=117) received a four-session patient empowerment program in small groups over one month by trained nurses and doctors. he control group received traditional lectures that consisted solely of conveying healthcare information to patients.
45766113|NCT03018535|Drug|Rituximab|Rituximab,1 g IV, day 1 and day 15
45766114|NCT03018535|Drug|Methylprednisolone|Methylprednisolone 1 g IV daily for 3 doses, then oral methylprednisolone (0.4 mg/kg/day) or oral prednisone (0.5mg/kg/day) for 27 days during Month 1, 3, 5.
45766115|NCT03018535|Drug|Cyclophosphamide|Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days
45766116|NCT04890873|Drug|ERX1000|ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension and 8 mg/10 mL oral suspension
45766117|NCT04890873|Drug|Placebo|A suspension containing magnesium hydroxide carbonate in polysorbate
45766118|NCT04889547|Drug|Dexamethasone|Intraoperative intravenous dexamethasone
45624489|NCT03055455|Diagnostic Test|MR imaging|Conventional structural imaging will be combined with advanced neuroimaging modalities to evaluate integrity of white matter tracts, regional brain perfusion, and the 3-dimensional volume of specific brain structures.
45766119|NCT04889547|Other|No dexamethasone|No intraoperative intravenous dexamethasone
45766120|NCT02160847|Behavioral|DRIVE Program|The DRIVE program (Developing Relationships that Include Values of Eating and Exercise) is a home-based parent training program, which involves 15 sessions focusing on parent-child interactions, health and nutrition, and physical activity
45624490|NCT04922541|Drug|PD-1 inhibitor|dosage form: intravenous injection; frequency: 2-3 weeks; duration: at least 3 months
45766121|NCT00360477|Procedure|Floseal|Bioglue that seals the kidney
45624491|NCT02157298|Drug|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
45624492|NCT02157298|Drug|Placebo tablet|Placebo tablet. Oral dose
45624493|NCT04904055|Other|Value-based Formulary|Prescription drug formulary tiers informed by estimated value
45624494|NCT04430907|Biological|HPV 9-valent Vaccine, Recombinant|"After consent, participants will complete an intake survey confirming eligibility. Participants will also complete a survey asking about knowledge, attitudes, and beliefs around vaccination, including HPV vaccination, as well as breastfeeding intentions.~After survey completion, the participant will be asked if they would like to be administered the HPV vaccine, Gardasil 9. If participants do not agree, they will be contacted 1-week later for the follow-up survey. If participants do agree, the project coordinator will notify the study physician, who will place an order for the vaccine. The vaccine will be administered to the patient prior to discharge from the hospital. Participants will be contacted 1-week later for the follow-up survey."
45624495|NCT03054285|Drug|Levetiracetam|Participants assigned to the experimental arm will receive a seven day course of levetiracetam for post-traumatic brain injury
45624496|NCT04917627|Drug|Vancomycin|one vial of vancomycin (1000 mg ) powder form.
45766122|NCT00360477|Procedure|Cope Loop|Nephrostomy tube for fluid drainage from the kidney
45766123|NCT00360477|Procedure|Fascial Stitch|Stitch that closes the kidney
45766124|NCT02975739|Device|Holmium-166 (poly L lactic acid) microspheres|Intratumoral injections of Holmium-166 (poly L lactic acid) microspheres
45766125|NCT05386069|Drug|NOMO Protocol|Standard weight-based ketamine bolus (0.5 mg/kg) at procedure start, no Opioid rescue medications
45766126|NCT00989911|Drug|Bosentan|Bosentan 62.5 mg tablet taken orally twice daily for one month, followed by Bosentan 125 mg tablet taken orally twice daily for three months.
45766127|NCT05343091|Device|cardiac ultrasound|Cardiac ultrasound with Pocket ultrasound by expert and non expert physician
45766128|NCT05311891|Diagnostic Test|RT PCR|Characterize the different molecular variants of SARS-CoV-2, determine the escape potential of the new variants from neutralization by monoclonal antibodies and currently available vaccines and characterization of the mRNAs expressed in infected persons
45446958|NCT02095366|Drug|Placebo|"Intravenous administration Patient receives simultaneously IV placebo administration and IN sufentanil spray.~Pain is controlled by:~at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV~at 10 minutes and if NPRS>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV~at 20 minutes and if NPRS>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV"
45624497|NCT04910451|Other|No Intervention|
45624498|NCT04904133|Other|Low/No Calorie Sweeteners|LNCS powdered and then dissolved in water.
45452403|NCT00978016|Drug|arbaclofen placarbil-Cohort 2|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 40 mg QD) with for 7 weeks including titration and taper periods
45624499|NCT04904133|Other|Placebo Group|Water
45624500|NCT04904211|Other|Home-based chemotherapy|To investigate the feasibility and safety of home-based intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Furthermore, we examined the quality of life (QOL) and psychological wellbeing while receiving induction and consolidation chemotherapy at home.
45624501|NCT04903743|Drug|bupivacaine|group B received 28ml of 0.25% bupivacaine and 2ml normal saline
45624502|NCT04903743|Drug|magnesium sulfate|group BM received 28 ml of 0.25% bupivacaine and 2 ml magnesium sulfate 10%.
45624503|NCT02184988|Biological|Botulinum purified neurotoxin, Type A|The subject is to be injected intra-muscularly into a total of five sites: the mid-line of the procures muscle, the inferomedial aspect of each corrugator muscle and the superior middle aspect of each corrugator, at least 1 cm above the bony orbital rim. Each site is injected with 0.1 ml (4U), for a total of 20 U and 0.5 ml.
45766129|NCT04038957|Drug|SEP-363856|SEP-363856 50mg, 75mg flexable dosing, dosed once daily capsule
45766130|NCT05189119|Diagnostic Test|non invasive ventilation|invasive mechanical ventilation session in the BIPAP Mode with a pressure support (PS) level of 5cmH2O, a positive end expiratory pressure (PEEP) level of 5 cmH2O and an inspiratory fraction of oxygen (FiO2) allowing a pulse saturation (SpO2) of at least 92% for a one minute and followed by an increase of the PS level to 30cmH2O.The plethysmographic PAR (PAR) was calculated based on the following formula: PARpleth= PP30 / PP5
45766131|NCT02977065|Drug|Atorvastatin 20mg|PO daily for 4weeks
45766132|NCT02977065|Drug|Atorvastatin 20 mg + CKD-519 50 mg|PO daily for 4weeks
45766133|NCT02977065|Drug|Atorvastatin 20 mg + CKD-519 100 mg|PO daily for 4weeks
45766134|NCT02977065|Drug|Atorvastatin 20 mg + CKD-519 200 mg|PO daily for 4weeks
45766135|NCT02977065|Drug|Rosuvastatin 10 mg|PO daily for 4weeks
45766136|NCT02977065|Drug|Rosuvastatin 10 mg + CKD-519 100 mg|PO daily for 4weeks
45766137|NCT03018769|Drug|Chinese Herb|
45624504|NCT04917939|Other|RNA sequencing|Samples in both groups will be sequenced by single-cell sequencing and spatial transcription sequencing.
45624505|NCT03055143|Drug|SPARC-08-038|2 mg/ml intravenous infusion
45624506|NCT03055143|Drug|Ref-08-038|2 mg/ml intravenous infusion
45624507|NCT04753840|Other|Antihypertensive drugs|One of ACEI / ARB, beta blocker, calcium channel blocker, diuretic
45624508|NCT04753840|Other|remote ischemic preconditioning（RIPC）|40 minutes per day, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle)， a total of 4 cycles.
45624509|NCT04753840|Behavioral|lifestyle intervention|Such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.
45624510|NCT04903275|Procedure|Topical fluoride application and Laser irradiation|Topical fluoride varnish application (Clinpro™ White Varnish 5% Sodium Fluoride, 3M ESPE, USA) of the vestibular surfaces of the left maxillary anterior teeth followed by laser irradiation with CO2-laser (Ultra Dream Pulse, DS_40U, Daeshin Enterprise, Seoul, South Korea), emission wavelength 10,600 nm, time on-100 μs, time off-40 ms; average power-0.73 W; peak power-292.73 W; speed of movement-2 mm/s; energy density with movements-5 J/cm2; tip-to-tissue distance-20 mm; tip diameter 700 μm; irradiation time-30 s.
45624511|NCT04903275|Procedure|Topical fluoride application|Topical fluoride varnish application (Clinpro™ White Varnish 5% Sodium Fluoride, 3M ESPE, USA) of the vestibular surfaces of the left maxillary anterior teeth
45624512|NCT03054129|Other|Rehabilitation and balance training|"Stretching will be applied as hold-relax technique in PNF for shoulder flexion, abduction, internal and external rotations. Isotonic exercises will be done with elastic bands for strengthening.~Home exercises will include postural, stretching and strengthening exercises. Balance exercises will receive as non-supervised program."
45624513|NCT03054129|Other|Rehabilitation program|Rehabilitation program will be same in this group except balance exercises.
45624514|NCT03055299|Other|COMEX intervention|Comprehensive Exercise
45624515|NCT04917003|Other|RIC plus EDAS|Patients who are allocated into RIC group will undergo EDAS surgery combined 3-month RIC treatment. The opposite operation will be performed at 3 months after the first operation.
45624516|NCT04917003|Other|EDAS|Patients who are allocated into the control group will accept EDAS surgery twice. The second operation will be performed at 3 months after the first operation.
45624517|NCT04902963|Device|PE tube|Gelatin mixed with antibiotic and steroid ear drop to create a rigid device that maintains a lumen, acting as an intermediate-duration bioabsorbable ear tube.
45624518|NCT04902807|Biological|Collection of samples|Blood, Urine and Stool samples will be collected from the participants.
45624519|NCT02121262|Drug|Dexamethasone|Dexamethasone 700 μg intravitreal injection in the study eye on Day 1, Months 5, and 10.
45624520|NCT02121262|Procedure|Laser Photocoagulation|Laser photocoagulation on Day 1, and on Months 3, 6, and 9, if retreatment indicated.
45624521|NCT03053739|Drug|Sildenafil 20mg and Bosentan 62.5mg|Sildenafil 20 mg three times a day and bosentan 62.5mg two times a day
45624522|NCT03053739|Drug|Sildenafil 20mg and Placebo|Sildenafil 20 mg three times a day and placebo (matched for bosentan)two times a day
45624523|NCT04916925|Drug|Vitamin D|Adding vitamin D to PCOS patients who are resistant to clomiphene regime for induction will or not improve the Clinical pregnancy rate and will or not increase chances of ovulation and pregnancy.
45624524|NCT04916925|Drug|Clomid|CLOMID is adrug used for ovulation induction
45624525|NCT04909827|Procedure|3D-printed endocrown|pulpotomy and restoration with 3D-printed microfilled hybrid composite endocrown
45624526|NCT04909827|Procedure|Zirconia crown|pulpotomy and restoration with prefabricated zirconia crown
45624527|NCT04917081|Behavioral|Mindful Self-Compassion|Mindful Self-Compassion has been developed by Neff and Germer as a specific kind of Mindfulness-Based Interventions to promote self-compassion. It combines the skills of mindfulness and self-compassion, providing a powerful tool for emotional resilience and enhancing the capacity for emotional wellbeing. In this study, a shortened version of the MSC program is used which is applied once a week for 75 minutes throughout the patients' stay in the rehabilitation clinic.
45624528|NCT04917081|Behavioral|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a deep relaxation technique that helps relieve muscle tension and is based on the premise that mental calmness is a natural result of physical relaxation. In this study, Progressive Muscle Relaxation is applied once a week for 75 minutes throughout the patients' stay in the rehabilitation clinic.
45766138|NCT04031547|Device|Transcranial Electrical Stimulation (tES)|In tES, a mild electrical current is passed between two or more electrodes placed on the scalp.
45766139|NCT04886895|Other|Let's Move|Motor intervention
45766140|NCT04343937|Procedure|retrolaminar block|local anesthetic injection on the between the lamina of the vertebra and the paraspinous muscle
45766141|NCT04886427|Other|No intervention|Measure the experiences of the current care
45766142|NCT04009161|Procedure|Tooth extraction|Tooth extraction before the beginning of radiotherapy in patients irradiated for Head and Neck cancer
46069613|NCT00696579|Drug|gemcitabine|14 days after II look-TURB the patients received 6 weekly instillations of Gemcitabine (Gemzar, Eli Lilly SpA), using a dose of 2000 mg diluted in 50 mL of saline held in the bladder for 2 hours
45766143|NCT03146806|Drug|Intranasal ketamine|"10mg of intranasal ketamine will be given to make sure that the study patients are able to tolerate a small dose of NAS ketamine.~On the second visit, 10 mg of IV ketamine will be given to help establish bioavailability of NAS ketamine, with patients serving as their own controls.~On the third and fourth visit, higher doses of ketamine, 30 mg and 50 mg respectively, will be given.~All doses of ketamine will be administered by an anesthesia research nurse."
45766144|NCT03090958|Behavioral|AllyQuest|AllyQuest is a novel, high impact secondary prevention intervention delivered via mobile phones to improve linkage and engagement in care among newly diagnosed HIV+ YMSM. The development of this intervention is both timely and vital given the urgency of the ongoing HIV epidemic among YMSM. The features of the intervention aim to target previously identified barriers to care among newly diagnosed youth, namely, low HIV health literacy, lack of social support, and internalized stigma related to their diagnosis.
45624529|NCT04909749|Genetic|Oneome RightMEd Pharmacogenomic testing Kit|The RightMed test is an end-to-end solution which includes sample collection, pharmacogenomic (PGx) testing services, data analysis, and clinical interpretation that helps physicians select treatments based on evidence-driven predictions of patient drug response and tolerance. Genetic components of an individual's drug response are well established and often included on Food and Drug Administration (FDA) medication labels. The OneOme RightMed test has incorporated existing evidence to classify the risk and likelihood of an antidepressant working for different patients. Patient results for each medication can fall into one of three categories: 1.) Green - use as directed; 2.) Yellow - use with caution; and 3.) Red - adjust dose or choose alternative mediation and can be used proactively or reactively
45766145|NCT04468516|Device|KKT|Vibroacoustic sound waves applied focally.
45766146|NCT04468516|Device|sham KKT|sham KKT
45624530|NCT04902261|Drug|Tislelizumab|Tislelizumab 200 mg every three weeks
45624531|NCT04902261|Drug|Nab paclitaxel|Nab-paclitaxel 125mg/m2 on d1 and d8 every three weeks
45766147|NCT04706806|Dietary Supplement|apple cider vinegar|2 tablespoons diluted in water taken twice daily with meals
45766148|NCT04706806|Dietary Supplement|vinegar pill|one pill taken daily
45624532|NCT04902261|Drug|Gemcitabine|Gemcitabine 1000mg/m2 on d1 and d8 every three weeks
45624533|NCT04430751|Behavioral|Medical QiGong training|"The study intervention consisted of a 12-week training program that introduced students to a progressive series of 10 QiGong forms that are designed to build upon each other to restore balance and function and to enhance well-being. These forms involve both physical movement and visualization."
45766149|NCT00362349|Drug|IgNextGen 10%|"Ig NextGen 10% is a liquid formulation and is to be administered intravenously. At the discretion of the Investigator, patients could be administered Ig NextGen 10% in accordance with either of two dosage regimens:~Regimen One: 1 g/kg body weight of Ig NextGen 10% administered daily for two days.~Regimen Two: 0.4 g/kg body weight of Ig NextGen 10% administered daily for five days"
45624534|NCT04916301|Behavioral|Early Mother-Infant Attachment|Early Mother-Infant Attachment Indicators will be observed.
45624535|NCT04902183|Drug|CovenD24|The drug will be administrated once daily for 5 days
45624536|NCT03052413|Dietary Supplement|Nutrafol|Eligible subjects will receive Nutrafol® to take daily for 180 days
45624537|NCT03052413|Dietary Supplement|placebo|Eligible subjects will receive Placebo to take daily for 180 days
45766150|NCT03997929|Diagnostic Test|1.3 BETA D GLUCAN|dosage of 1.3 BETA D GLUCAN in the peritoneal fluid obtained during surgery with the β-glucan test (Fujifilm Wako Chemicals, Osaka, Japan)
45766151|NCT03438357|Other|Analysis of cerebral MRI with automatic segmentation software|Pixyl.Neuro software versus manual analysis of lesions
45766152|NCT02975427|Other|Diet group|All participants were prescribed an appropriate diet with caloric restriction and an exercise program and underwent a follow-up examination 3±1 months later.
45446959|NCT02095366|Drug|Placebo|"Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV morphine administration and IN placebo spray.~Pain is controlled by:~at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg~at 10 minutes and if NPRS>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg~at 20 minutes and if NPRS>3: Pacebo (1 spray) + morphine IV 0,05mg/kg"
45624538|NCT03052335|Device|Pillcam® COLON 2 Capsule|The second generation of PillCam colon capsule endoscopy (CCE-2) is 11.6 mm × 31.5 mm in size and has two imagers, that each have a 172° angle of view, allowing for almost 360° visual coverage of the colon. CCE-2 has an adaptive frame rate from 4 to 35 images per second. This means that the camera is able to capture up to 35 pictures while in motion whereas 4 images per second are captured when it is virtually stationary. During the examination the patient wears a sensor array which is attached to the abdomen and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the workstation and a video is generated.
45766153|NCT03422679|Drug|CB-103|Hard gelatine capsules taken orally during treatment period. Treatment cycle is 28 days.
45766154|NCT02975583|Drug|Vorapaxar|2.08 mg oral tablet daily
45766155|NCT02975583|Drug|Placebos|Placebo oral tablet daily
45766156|NCT03983421|Other|Screening|Screening for Early Psychosis and Clinical High Risk of Psychosis
46069614|NCT02866097|Other|mHealth inventory management|Improved stock management of iCCM commodities using the DHIS2 mHealth platform
45624539|NCT03052335|Procedure|Colonoscopy|Optical colonoscopy is the standard method for evaluating the colon
45446960|NCT04258995|Biological|Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)|2 formulations at 1 dose level
45446961|NCT02097082|Device|STANZA Drug-eluting resorbable Scaffold|
45446962|NCT02097160|Other|Vitamin D fortified yogurt and cheese products|
45624540|NCT03052179|Dietary Supplement|Poly-biotic|Before-after treatment
45624541|NCT04902339|Behavioral|Mindfulness-Oriented Recovery Enhancement|8 weeks of therapy integrating mindfulness, reappraisal, and savoring skills.
45624542|NCT04902339|Other|Neurofeedback|Near-infrared spectroscopy neurofeedback during savoring practice.
45624543|NCT04902339|Behavioral|Supportive Psychotherapy|8 weeks of supportive, process-oriented psychotherapy.
45624544|NCT04902027|Drug|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
45624545|NCT04902105|Drug|ecopipam HCL|oral tablets
45624546|NCT04902105|Drug|Mefenamic acid|oral capsules
45624547|NCT04902105|Drug|Divalproex Sodium ER|oral tablets
45624548|NCT04399941|Diagnostic Test|Venography|The venography will be performed as part of the patient's standard of care. The dialysis access will be punctured upstream of the arteriovenous anastomosis in AVF or AVG using a 4-F coaxial access set (Micro- puncture; Cook, Inc, Bloomington, Indiana). The contrast will be injected intravenously by a pump with 200 psi and a bolus of 2m/sec for total of 5 ml during upper extremity vein filming and 10 ml of contrast bolus by 3 ml/s during central vein filming while holding the breath in inspiration in anterioposterior plane.
45624549|NCT04399941|Diagnostic Test|Intravascular ultrasound (IVUS)|IVUS will be performed through the same sheath of the coaxial access set using an Eagle Eye Platinum RX digital catheter 7F over a compatible guidewire under fluoroscopic guidance. The lesion will be estimated fluoroscopically from the marker IVUS catheter in the vein and the cranial and caudal margins of stenotic lesion will be directly visualized during pullback of the IVUS catheter.
45624550|NCT04399941|Other|Image processing|Image processing will be performed by two radiologists in a blinded manner on the images devoid of personal identifier. An adjudication committee will oversee the process and confirm their findings in case of a discrepancy.
45624551|NCT04916379|Dietary Supplement|Momordica charantia|Momordica Charantia: 2000 mg per day for 12 weeks
45624552|NCT04916379|Other|Placebo|Placebo: 2000 mg per day for 12 weeks
45624553|NCT04901871|Drug|0.02 mg/kg, age<65|Remimazolam of 0.02 mg/kg will be infused in patients aged<65.
45624554|NCT04901871|Drug|0.07 mg/kg, age<65|Remimazolam of 0.07 mg/kg will be infused in patients aged<65.
45766157|NCT03983421|Other|Warm Hand-Off|Among those determined eligible, transfer of care between the student health and counseling center and the coordinated specialty care program outreach coordinator occurring over the phone while the student is in the counselor's office immediately following the results of the screening.
45766158|NCT03953235|Biological|GRT-C903|a shared neoantigen cancer vaccine prime
45766159|NCT03953235|Biological|GRT-R904|a shared neoantigen cancer vaccine boost
45766160|NCT03953235|Biological|nivolumab|anti-PD-1 monoclonal antibody
45766161|NCT03953235|Biological|ipilimumab|anti-CTLA-4 monoclonal antibody
45446963|NCT02097160|Other|Control Group 1|
45624555|NCT04901871|Drug|0.12 mg/kg, age<65|Remimazolam of 0.12 mg/kg will be infused in patients aged<65.
45624556|NCT04901871|Drug|0.17 mg/kg, age<65|Remimazolam of 0.17 mg/kg will be infused in patients aged<65.
45624557|NCT04901871|Drug|0.22 mg/kg, age<65|Remimazolam of 0.22 mg/kg will be infused in patients aged<65.
45766162|NCT03402945|Device|Prevena|Negative-Pressure Wound Management System
45766163|NCT03402945|Drug|Cefazolin|antibiotic
45446964|NCT04247061|Other|Educational video|One of two different 10 minute educational videos on smoking cessation will be viewed by participants during a dental cleaning visit. The video that is watched will depend on participants' level of motivation to quit and project needs
45624558|NCT04901871|Drug|0.27 mg/kg, age<65|Remimazolam of 0.27 mg/kg will be infused in patients aged<65.
45624559|NCT04901871|Drug|0.02 mg/kg, age≥65|Remimazolam of 0.02 mg/kg will be infused in patients aged≥65.
45624560|NCT04901871|Drug|0.07 mg/kg, age≥65|Remimazolam of 0.07 mg/kg will be infused in patients aged≥65.
45624561|NCT04901871|Drug|0.12 mg/kg, age≥65|Remimazolam of 0.12 mg/kg will be infused in patients aged≥65
45624562|NCT04901871|Drug|0.17 mg/kg, age≥65|Remimazolam of 0.17 mg/kg will be infused in patients aged≥65.
45624563|NCT04901871|Drug|0.22 mg/kg, age≥65|Remimazolam of 0.22 mg/kg will be infused in patients aged≥65.
45624564|NCT04901871|Drug|0.27 mg/kg, age≥65|Remimazolam of 0.27 mg/kg will be infused in patients aged≥65.
45624565|NCT04901793|Behavioral|Virtual Reality Headset and handheld remote control.|Brand name: Oculus Quest
45766164|NCT03402945|Drug|Vancomycin|antibiotic
45766165|NCT03402945|Other|standard wound dressing|Any non-negative pressure wound dressing that is routinely used at study sites will be considered standard of care in the control arms.
45766166|NCT02974959|Device|gammaCore active device|The nVNS therapy will be performed using the gammaCore-R (electroCore LLC, NJ), which is an external hand-held vagal nerve stimulator. The gammaCore-R produces a low voltage electric signal consisting of five 5000 Hz pulses that are repeated at a rate of 25 Hz. It allows for a 120 second stimulation session. The stimulation will occur twice daily, one time in the morning and one time in the evening. This should be done as close to 12 hours apart as possible and should occur twice daily for the entire 12 week study period.
46069615|NCT02866097|Other|Supportive supervision|Strengthening of supportive supervision using DHIS2
45766167|NCT02974959|Device|gammaCore sham device|The sham device appears identical to the gammaCore but does not provide a frequency of stimulation powerful enough to stimulate either efferent or afferent fibers of the vagus nerve. However, it does supply a low frequency current which will cause a tingling of this skin to improve blinding of the patients.
45624566|NCT02120950|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea is administered as an intravitreal injection
45624567|NCT02120950|Other|Visudyne|Photodynamic therapy is a combined therapy of drug (Visudyne) applied to reinforce the action of a device (laser)
45766168|NCT03095638|Drug|Conventional dolutegravir 10 mg tablet|Single dose of five 10 mg DTG tablets will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
45766169|NCT03095638|Drug|Conventional dolutegravir 50 mg tablet|Single dose of one 50 mg tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
45766170|NCT03095638|Drug|Dispersible dolutegravir 5 mg tablet|Single dose of five 5 mg DTG tablets will be administered as dispersed in water or direct to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
45624568|NCT04916145|Device|SAT-008|SAT-008 is a digital device containing several types of activities related to the immune function of adults.
45624569|NCT03053817|Other|Exercise group|Interval training will be performed for 21 minutes including a 3 minute warm-up and cool-down period. The interval program will be 15 minutes at 65-75% of maximal heart rate with 30 sec. bursts of exercise to 80-85%; intervals. Resistance training will be done as a circuit and will make use of weight machines and functional exercises. Resistance will be done in 2 sets of 15 repetitions and will last 24 minutes. The work load of the program is calibrated and is conducted at a specified rhythm. All exercise sessions will be supervised.
45624570|NCT03053895|Procedure|CSDH - Bedside twist drill technique|For patients randomized to bedside drainage of CSDH, the twist-drill procedure will be conducted at the patient's bedside using local anesthetic
45624571|NCT03053895|Procedure|CSDH - Operating Room Burr-hole technique|For patients randomized to burr-hole drainage, the procedure will be performed in the operating room under local or general anesthesia based on the surgeon's and anesthesiologist's judgement of the clinical stability of the patient.
45624572|NCT04915989|Drug|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
45624573|NCT04901481|Device|Empower Neuromodulation System|Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
45624574|NCT04901559|Procedure|Graft type at ACLR|The choice of graft at primary ACL Reconstruction
45766171|NCT03095638|Drug|Conventional dolutegravir 25 mg tablet|Single dose of one 25 mg DTG tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
45766172|NCT03942783|Other|WORKWELL|Individualised, tailored work advice and work/vocational rehabilitation, including self-management and job modifications.
45446965|NCT04247061|Other|Text-message program|A one-month text message program to motivate and facilitate contact with smoking cessation resources.
45766173|NCT03942783|Other|Control|Published arthritis work booklets;written guidance on work problem identification; potential actions
45766174|NCT03385707|Device|Dexcom continuous glucose monitor and activity monitor|Participants will wear the Dexcom continuous glucose monitor and activity monitor for two weeks. They will not be able to see sensor glucose values. A stool sample will be collected to determine if there is a relationship between postprandial glycemia patterns and microbiome composition.
46069616|NCT02866097|Other|ICCM current standard of care|ICCM implementation as per current practice without mHealth interventions
45446966|NCT02095444|Drug|Menstrual blood stem cells|10*7 cells/kg, intravenous injection for 4 times during two weeks
45446967|NCT01562223|Other|motexafin gadolinium|
45446968|NCT02090452|Device|Real time transmission of patient related data. Device used: MobiMed 3.1, manufactured by Ortivus AB Sweden|
45446969|NCT02097316|Device|JewelPump|
45446970|NCT02097316|Device|usual insulin pump|
45624575|NCT02120794|Device|530G Insulin pump|Subjects will use 530G insulin pump with Threshold Suspend (TS) feature for one year.
45624576|NCT04915911|Other|cross-sectional study|cross-sectional study
45624577|NCT04915521|Other|erector spina plane block (ESPB) group|"An experienced anesthesiologist performed ESPB in all patients in sitting position bilaterally.~A linear ultrasound probe (6-13 MHz) was used for ultrasound guidance. Injection was done using in-plane technique. A 22G block needle (100mm, B-Braun, Germany) was inserted 3- cm lateral to the T9 spinous process and advanced in cranio-caudal direction. To separate erector spina muscle from the transverse process, initially 1-2 ml saline was injected; then 20 ml 0.5% bupivacaine and 5 ml 0.2% lidocaine were injected following separation. Diffusion of the drugs in erector spina plane at cranio-caudal line was ensured. No analgesic or sedative was used during the procedure."
45624578|NCT04901013|Other|Affinity|Affinity is an aseptically processed, hypothermically stored fresh allograft with viable cells, growth factors/cytokines, and extracellular matrix (ECM).
45624579|NCT04900857|Other|Dry needle|Local twitch responses (LTRs) were obtained by multiple rapid insertions of the needle in and out of the point, similar to Hong's rapid-entry and rapid exit technique. Hong 1994). The needle was not removed from that site for the maximum stimulation time of 1 minute to 3 minutes after a local twitch response was obtained.
45624580|NCT04900857|Device|Localize vibration|the vibration was applied with 110 Hz and 5.57 mm amplitude.
45624581|NCT03053583|Device|Laryngoscope blade|The POGO score assesses the percent of the glottic opening that can be seen with each blade
45624582|NCT04915443|Device|Periotome|"Dental instrument used to perform atraumatic dental extraction.~After the initial de attachment, the periotome was inserted between the root and the bone parallel to the long axis of the root and pushed apically to the maximum depth that the tissue allowes severing the PDL and leaving it for 10-15 seconds allowing the biomechanical creep to occur.~This proses is repeated at different points of entries at all the different surfaces of the tooth."
45766175|NCT03385629|Behavioral|CSM theory-based didactic education and skills training|Common-Sense Model of Self-Regulation (CSM) theory-based education and skills training for the provider to teach him/her to communicate core oral health facts to parents, provide a prescription to take their child to the dentist together with a list of Medicaid-accepting dentists in the area, and document the oral health encounter in EMR.
45766176|NCT03385629|Other|AAP-based didactic education|American Academy of Pediatrics (AAP) based oral health education and follow the usual care for oral health assessment recommended by AAP guidelines.
45766177|NCT03385629|Other|Practice EMR changes|Enhancements to the EMR system to include oral health documentation (four questions) which will be implemented prior to enrolling any parent/caregiver and child participants into the study.
45766178|NCT03913923|Biological|BCD-217|Combination of anti-CTLA-4 and anti-PD-1 monoclonal antibodies, 1mg/kg and 3 mg/mg, respectively, given Q3W as IV infusion for first 4 blinded infusions
45766179|NCT03913923|Biological|BCD-100|Anti-PD-1 monoclonal antibody, 3 mg/kg, given Q3W as IV infusion for first 4 blinded infusions, after - 1 mg/kg, given Q2W as IV infusion
45766180|NCT03913923|Other|Placebo|Placebo
45766181|NCT04458688|Other|Observation of Ocrelizumab as Treatment in RRMS Patients|It is decided by the patient and their physician to begin taking ocrelizumab PRIOR to study enrollment. The study is only observing the effects of ocrelizumab as a pre-decided treatment option for a patient's MS.
45624583|NCT04915443|Device|Piezotome|"Dental device used for many purposes one of which is performing atraumatic dental extraction.~An LC2 tip was used for all the procedures and it was inserted between the tooth root and the bone parallel to the long axis of the root and moved in a sweeping motion 3-4mm toward the apex severing the PDL."
45766182|NCT04450108|Diagnostic Test|Vivatmo pro FeNO Test|Breath gas analysis
45624584|NCT04900467|Biological|Pfizer|BNT162b2 (Comirnaty®), Pfizer/BioNTech, mARN vaccine,
45624585|NCT04900467|Biological|Moderna|mRNA-1273, COVID-19 Vaccine Moderna, mARN vaccine, administrated by intramuscular
45766183|NCT03899883|Drug|Pegloticase 8 MG/ML [Krystexxa]|One time dosing of pegloticase will be administered. Participants will receive an infusion of pegloticase over two hours in the outpatient clinical and translational research center (CTRC) at Children's Hospital Colorado, and will be monitored after infusion.
45624586|NCT02184442|Device|TAVR Implantation with SAPIEN XT|Inoperable operable patients requiring the transcatheter aortic heart valve replacement
45624587|NCT02184442|Device|TAVR Implantation with SAPIEN|Inoperable operable patients requiring the transcatheter aortic heart valve replacement
45624588|NCT04915209|Other|Narrative interviews|During the workshop, the participants will collectively create a common representation of the patient journey and co-design the envisioning care delivery model that support both social care and medical care.
45766184|NCT03891849|Drug|Octreotide Injection|Patients admitted in intensive care unit after variceal hemorrhage treated with norepinephrine perfusion will received an additional octreotide perfusion during one hour.
45624589|NCT04915053|Dietary Supplement|ABG+ Black Garlin|Daily tablet intake during three months
45624590|NCT04915053|Dietary Supplement|Crystalline Cellulose|Daily tablet intake during three months
45624591|NCT04900311|Drug|pyrotinib + trastuzumab + nab-paclitaxel|patients will be treated every 3 weeks for four cycles prior to surgery at following doses: pyrotinib: 400 mg/day, orally, qd trastuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 8 mg/kg in Cycle 1, and 6 mg/kg in Cycles 2-4 nab-paclitaxel: 260 mg/m2 IV infusion on Day 1 every 3 weeks, or 125 mg/m2 IV infusion on Days 1, 8 and 15 every 3 weeks (the nab-paclitaxel administration cycle was determined by investigator at each site)
45452404|NCT00978016|Drug|arbaclofen placarbil-Cohort 3|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg BID) for 7 weeks including titration and taper periods
45624592|NCT04900311|Drug|pertuzumab + trastuzumab + nab-paclitaxel|patients will be treated every 3 weeks for four cycles prior to surgery at following doses: pertuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 840 mg for Cycle 1, followed by 420 mg for Cycles 2-4 trastuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 8 mg/kg in Cycle 1, and 6 mg/kg in Cycles 2-4 nab-paclitaxel: 260 mg/m2 IV infusion on Day 1 every 3 weeks, or 125 mg/m2 IV infusion on Days 1, 8 and 15 every 3 weeks (the nab-paclitaxel administration cycle was determined by investigator at each site)
45766185|NCT04414930|Drug|AMPH|"Suppressing active psychosis with antipsychotics benefits cognitive interventions for schizophrenia, but it is possible that drugs with pro-cognitive effects will specifically, and perhaps synergistically, augment the clinical benefits of cognitive therapies. A proof of concept for this approach is found in the use of the pro-extinction drugs to selectively enhance the impact of cognitive therapy for anxiety disorders. In this proof of concept, a learning-based therapy is paired with a medication that enhances a brain mechanism (extinction) that is both 1) critical to that form of learning, and 2) known to be deficient in some anxiety disorders."
45766186|NCT04414930|Drug|SHAM|"Suppressing active psychosis with antipsychotics benefits cognitive interventions for schizophrenia, but it is possible that drugs with pro-cognitive effects will specifically, and perhaps synergistically, augment the clinical benefits of cognitive therapies. A proof of concept for this approach is found in the use of the pro-extinction drugs to selectively enhance the impact of cognitive therapy for anxiety disorders. In this proof of concept, a learning-based therapy is paired with a medication that enhances a brain mechanism (extinction) that is both 1) critical to that form of learning, and 2) known to be deficient in some anxiety disorders."
45804250|NCT02959346|Procedure|Acupuncture|"Procedure:~Acupuncture(ipisilateral side, the needling depth decided by whether patients feel De qi, neutral supplementation and draining) Acupuncture will be applied by inserting acupuncture needle into acupoints: Zhigou TE6, Shousanli LI10, Hegu LI4, Neiguan PC6, Houxi SI3; lower limb: Biguan ST31, Fushe SP13, Zulinqi GB41; axillary area(Remove Needles right away after De qi): Yuanye GB22, Jiquan HT1; local area(Remove Needles right away after De qi): ashi point close to the pain area.~The other needles will be left for 20 minutes and then removed. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery."
45452405|NCT00978016|Drug|arbaclofen placarbil-Cohort 4|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 30 mg BID) for 7 weeks including titration and taper periods
45624593|NCT04900155|Drug|Atorvastatin 80mg|Initially, hypolipidemic treatment with atorvastatin at a dose of 80 mg / day is prescribed from the first 24-96 hours of myocardial infarction in addition to standard therapy for the disease.
45766187|NCT03884985|Other|Visual stimulation|In the experiments, participants will sit in front of a computer monitor located a less than a meter of distance and will analyze the content of images extracted from collections of natural and computer-generated scenes. Subjects will be asked to report verbally or by pressing keys on a keyboard on image characteristics such as the locations of the objects present in the scenes, their number and/or their identities. Some experiments will involve a search paradigm in which subjects will have to report on the location and/or fine characteristics of a target element among a field of distracting similar elements, and/or visual discrimination tasks. The duration of the interval of time in which the image is maintained on the screen may be varied between few tens of milliseconds to several seconds. In a set of experiments, the eye movements performed by the subjects during the execution of the visual tasks will be recorded as explained below.
45766188|NCT03880383|Behavioral|Coaching|Parents will interact and communicate regularly with a coach in person or by telephone. Coaches will be responsible for: identifying developmental concerns, proactive health promotion, guidance and training for developmental stimulation, parent support and education about child development, navigation of the health care system and self-management techniques. The frequency of coaching will be: once a month (minimum), for 18 months, at an average of 2.5 hours per month.
45766189|NCT03880383|Behavioral|Online parent education|Parents will be provided access to an online platform which will provide educational resources and access to parent-parent support. Online resources on child development are curated by researchers and representative of parent groups, and linked to this online platform. The themes covered in the online tool include resources on child development, accessing health care services and managing emotions and family dynamics. These topics range from: practical tips for managing day-to-day challenges, strategies to cope and support the child's transitions from one stage to another, practical tips when looking for developmental services for the child: knowing where and how to access services.
45624594|NCT04900155|Drug|Atorvastatin-Ezetimibe|In the absence of reaching the target level of LDL-C ≤1.4 mmol / L and ≥50% of the initial level after 4-6 weeks from the onset of myocardial infarction, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.
45766190|NCT03880383|Behavioral|Online peer support|Parents will have access to a secure online social media tool to connect to other parents going through a similar experience. Through this tool, parents can help support each other, and share their experiences and knowledge. This will put each family at the centre of each network (family, friends, health providers), allowing family networks to link with one another. Families will be able to find resources, create connections with the coach, health providers and other families, thus creating a network to support one another.
45804251|NCT00003165|Drug|doxorubicin-HPMA conjugate|
45624595|NCT02155738|Drug|IV Acetaminophen|
45624596|NCT02155738|Drug|IV normal saline|IV normal saline
45624597|NCT03053505|Biological|faecal human microbiota transplant (FMT)|"Non-randomized group R: Patients with recurrent CD infection are treated with FMT in this group.~Randomized group FFMT: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with FMT."
45624598|NCT03053505|Drug|Vancomycin or Fidaxomicin|"Randomized group FAB: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with antibiotics (vancomycin per os 125mg four times a day for 10 days) in this group. In case of treatment failure changes in antibiotic regime (e.g. fidaxomicin per os 200mg per two times a day for 10 days) will be allowed in the line with the recommendations of current CDI treatment guidelines(13)."
45624599|NCT04914039|Combination Product|Combination Product|Cases of brain death confirmed by the classic brain death confirmation test
45624600|NCT04914039|Other|NO CTA examination|NO CTA examination
45804252|NCT05723510|Drug|Tegoprazan 50mg|Oral administration of one tablet of tegoprazan 50 mg once daily
45624601|NCT02181790|Device|Excimer laser|twice weekly treatments with the excimer laser for a total of 8 weeks.
45624602|NCT02181790|Drug|Acitretin|17.5mg/d
45624603|NCT04909281|Diagnostic Test|Self-sampling HPV|In this cohort study nested in the organized cervical screening program, all women who had not participated in the organized screening program for at least 10 years in one Swedish county were eligible.
45624604|NCT03052023|Procedure|dual approach laparoscopic inguinal hernioplasty|after pneumoperitoneum is done preperitoneal pneumo-dissection is done and then peritoneal incision done . dissection preperitoneally and sac dissection will be easy approached
45804253|NCT05723510|Drug|Edoxaban 60mg|Oral administration of one tablet of edoxaban 60 mg once daily
45804254|NCT05723510|Drug|Apixaban 5mg|Oral administration of one tablet of apixaban 5 mg twice daily
45624605|NCT03052023|Procedure|TAPP|pneumoperitoneum is done and then through abdominal approach peritoneal dissection in done and sac reduction and then mesh fixation
45624606|NCT03052023|Procedure|(lichtenstein) repair|inguinal incision is done and inguinal canal approach anteriorly and then sac dissection and excision then mesh fixation to posterior wall and closure the incision in layers
45624607|NCT03051945|Drug|Ketamine Hydrochloride|Study drug will be infused while the participant sits or lies in a comfortable position. The dose of ketamine used does not cause unconsciousness but may cause perceptual disturbances.
45624608|NCT03051945|Other|Normal saline|Placebo
45624609|NCT04899765|Biological|BCG vaccine|It is an attenuated live bacterial vaccine. This vaccine is a freeze-dried product that must be reconstituted.
45624610|NCT04899765|Biological|Measles vaccine|It is an attenuated live virus vaccine. This vaccine is a freeze-dried product that must be reconstituted.
45624611|NCT04899765|Other|Placebo|Saline
45624612|NCT04900233|Other|surgery|emergency surgery
45624613|NCT04899453|Drug|Methotrexate|400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses
45624614|NCT04899453|Drug|Rituximab|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
45624615|NCT04899453|Drug|Zanubrutinib|160mg Bid, oral. 21-day cycle for 6 cycles in the induction phase and for 2 years in the maintenance phase
45766191|NCT02974569|Device|Computer Symptom Capture Tool|"C-SCAT is an investigator developed app that is delivered via an iPad. The original CSCAT included the 30 symptoms from the Memorial Symptom Assessment Scale. The recently updated version includes two additional symptoms feeling bloated and sexual dysfunction that are included in the adult version of the MSAS.21 These symptoms were added based on feedback from the initial AYA sample of 13-29 year olds and in consideration of the developmental perspectives of the AYA population.The CSCAT allows the user to create an image of his or her symptom experience."
45766192|NCT04341831|Drug|Teicoplanin|We will be used 200mg Teicoplanin powder for each level of instrument.Hemovac drains will be used in either group. The drains will remain closed for 6 hours post-operatively for teicoplanin powder penetration in a surgical site.
45624616|NCT04899531|Other|Longitudinal observation|No specific intervention, longitudinal (pre-post measurements) only
45624617|NCT04914273|Drug|Inhalation Spray|400 mcg salbutamol administered per metered dose inhaler
45624618|NCT04914273|Drug|Tablet|8 mg salbutamol administered per tablet for ingestion
45624619|NCT04908891|Other|Clinical Scapular protocol (ClinScaP)|the psychometric properties of two tests: Clinical Scapular protocol (ClinScaP) in PwMS and healthy controls.
45624620|NCT04908891|Other|the prevalence of trunk, scapula and upper limb impairments.|To investigate the prevalence of trunk, scapula and upper limb impairments in PwMS and stroke patients.
45624621|NCT04908891|Other|the interaction between trunk, scapula and upper limb impairments.|To investigate the interaction between trunk, scapula and upper limb impairments in PwMS and stroke patients.
45766193|NCT03158038|Biological|Monovalent Influenza Vaccine|A single dose of monovalent influenza vaccine [10^7.0 +/- 0.5 FFU of each of 1 ca, att, ts 6:2 reassortant influenza strain] will be administered as intranasal spray on Day 1.
45624622|NCT03054987|Procedure|EUS-BD|EUS-BD is a minimally invasive technique where the common bile duct (choledochoduodenostomy) is punctured under EUS-guidance and after transmural dilation, a stent is deployed for biliary drainage.
45624623|NCT03054987|Procedure|ERCP|During the ERCP, a small catheter and guidewire is inserted into the bile duct and the stent can be deployed into the duct.
45452406|NCT00978016|Drug|PPI|Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD
45624624|NCT03054753|Behavioral|Abduction brace wearing time analysis|To evaluate the patient´s abduction brace wearing time a sensor = Orthotimer® (Rollerwerk, 72336 Balingen, Germany, www.orthotimer.com) is implanted in the abduction brace. The sensor measures the body temperature of the patient. Through that the wearing time can be evaluated.
45624625|NCT03054675|Diagnostic Test|Spirometry|Absolute FEV1 is measured in every patient using a handheld spirometer
45624626|NCT02618967|Biological|AMG 570|7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.
45624627|NCT02618967|Biological|AMG 570 Matching Placebo|Placebo administered as single dose subcutaneous in healthy volunteers.
45624628|NCT04899375|Device|Floss band|Tissue-flossing, is the use of an elastic band to provide compression on soft-tissue and joints whilst performing active and, or passive range of motion.
45624629|NCT04899375|Device|ACE bandage|An ACE bandage is a cloth wrap used to provide compression
45766194|NCT03158038|Other|Placebo|A single dose of placebo matching with monovalent influenza vaccine will be administered as intranasal spray on Day 1.
45766195|NCT00361959|Drug|Tiotropium bromide 18mcg|
45766196|NCT00361959|Drug|Fluticasone propionate/ salmeterol combination 50/500mcg|
45766197|NCT03158116|Drug|Inhaled Aztreonam|Inhaled antibiotic with anti-pseudomonal properties
45766198|NCT03096730|Drug|Normal saline|Normal saline is intravenously administrated before anesthesia induction
45766199|NCT03096730|Drug|Remifentanil|Remifentanil is intravenously administrated
45766200|NCT03096730|Drug|Sufentanil|Sufentanil is intravenously administrated
45766201|NCT03096730|Drug|Dexmedetomidine injection|Dexmedetomidine is intravenously administrated before anesthesia induction
45766202|NCT03096730|Drug|Nalmefene|Nalmefene is intravenously administrated before anesthesia induction
45624630|NCT03051555|Device|18F-FDG PET/ CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
45766203|NCT00362037|Drug|Irbesartan (Aprovel)|Aprovel (150 & 300mg) & CoAprovel (300/12.5mg hydrochlorothiazide one per day per os.
45804255|NCT05723510|Drug|Rivaroxaban 20mg|Oral administration of one tablet of rivaroxaban 20 mg once daily
45766204|NCT03353415|Device|Dexcom continuous glucose monitor|The CGM will monitor sensor glucose levels in all participants. During the first two weeks of the study, participants will be masked to the sensor glucose levels and will need to use other methods, such as a blood sample from a finger stick, to check their blood sugar. During the second two weeks, participants will be able to see the sensor glucose levels displayed from the CGM. Participants will be instructed to use this information to treat low glucose levels before symptoms or severely low glucose levels develop.
45766205|NCT04342923|Other|No intervention|Blood analysis
45624631|NCT04898751|Drug|Immune checkpoint inhibitor (ICI)|Immune checkpoint inhibitors included were targeting either PD-1, PD-L1 or CTLA-4, and had received FDA approval at the time of study (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32), and Cemiplimab (L01XC33).
45766206|NCT03872271|Procedure|ileal pouch-anal anastomosis with diverting loop ileastomy|Defunctioning ileostomy has demonstrated its benefits (rate and seriousness of anastomotic leakage) in cancer for low colorectal and coloanal anastomoses, whereas there are no such good quality evidences in case of ileal pouch-anal anastomosis (IPAA) performed for inflammatory bowel disease (IBD). However, most surgical teams do protect systematically IPAA by an ileostomy.
45624632|NCT04898907|Drug|ANG-3777 (Therapeutic Dose)|Arms assigned to this intervention will receive 2 mg/kg, IV, Fasted
45624633|NCT04898907|Drug|ANG-3777 (Supra-therapeutic Dose)|Arms assigned to this intervention will receive 6 mg/kg, IV, Fasted
45766207|NCT03872271|Procedure|ileal pouch-anal anastomosis with diverting loop ileastomy|Defunctioning ileostomy has demonstrated its benefits (rate and seriousness of anastomotic leakage) in cancer for low colorectal and coloanal anastomoses, whereas there are no such good quality evidences in case of ileal pouch-anal anastomosis (IPAA) performed for inflammatory bowel disease (IBD). However, most surgical teams do protect systematically IPAA by an ileostomy.
45624634|NCT04898907|Drug|Placebo|Arms assigned to this intervention will receive normal saline, IV, Fasted
45624635|NCT04898907|Drug|Moxifloxacin Hydrochloride|Arms assigned to this intervention will receive 400 mg, Oral, Fasted
45624636|NCT03052647|Device|Dermaclip|Dermaclip is an adhesive latch device used for skin closure
45624637|NCT03052647|Device|Subcuticular suture|subcuticular suture will be used as the device to close the skin in this arm
45624638|NCT04149249|Other|Computer-Assisted Intervention Video Doctor|Complete CONNECT: participants will undergo in-person assessment questions and follow-up assessment questions. They will view and participate in the interactive Video Doctor about Smoking Cessation.
45624639|NCT04149249|Other|Computer-Assisted Intervention no Video Doctor|Individuals who are randomized to the control group will undergo the same assessment questions and all follow up assessments like the intervention group. Instead of viewing and participating in the interactive Video Doctor about Smoking Cessation, they receive a handout containing smoking cessation resources.
45766208|NCT03344835|Other|No intervention|
45766209|NCT03866031|Other|implant-supported mandibular overdenture|The implant-supported overdentures will be placed in immediate functional loading on the same day of implants placement. A direct restorative protocol will be applied to modify the existing prosthesis to implant-supported overdentures.
45766210|NCT03834441|Other|Oral HRSN screening|Verbal screening delivered by an RA
45766211|NCT03834441|Other|Written HRSN screening|Patient completes written screen on iPad.
45766212|NCT03161158|Device|CHIARA-System|Treatment with veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm. 1-7 Ultrafiltration sessions (6-10h/session, number of sessions depending on clinical assessment) for at least 1-2 consecutive days and a maximum of 7 days.
45766213|NCT03161158|Other|Usual care IV diuretics|Guideline-directed therapy including IV loop diuretics (according to treatment algorithm)
45766214|NCT03161938|Drug|Dexamethasone|intravenous
45624640|NCT04908813|Drug|HLX22|IV Q3W D1
45624641|NCT04908813|Drug|Placebo|IV Q3W D1
45624642|NCT04908813|Drug|Trastuzumab|IV Q3W D1
45766215|NCT02975115|Other|RQ-PCR RNA Analysis|Conventional Q-RT-PCR every 3 months
45766216|NCT03321045|Drug|[89Zr]-Df-Trastuzumab|[89Zr]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 mCi at the time of injection. The amount of injected drug is 5 mg of Trastuzumab.
45624643|NCT04908813|Drug|Oxaliplatin|IV Q3W D1
45624644|NCT04908813|Drug|Capecitabine|PO Q3W D1-D14
45766217|NCT03321045|Diagnostic Test|PET/MRI Imaging|5-6 days post injection the patients will undergo PET/MRI imaging.
45624645|NCT04913571|Drug|Eribulin|Eribulin
45452407|NCT03181958|Device|NHFOV|Nasal high frequency oscillation ventilation (NHFOV) is used as the noninvasive supporting mode after extubation.
45452408|NCT03181958|Device|NCPAP|Nasal continuous positive airway pressure(NCPAP) is used as the noninvasive supporting mode after extubation.
45624646|NCT04913571|Drug|Tislelizumab|Tislelizumab
45624647|NCT03051789|Device|Menstrual Cup|Menstrual cups are reusable bell-shaped receptacles made of high grade medical silicone which collect ~30 ml of menstrual blood when inserted into the vaginal canal
45624648|NCT03051789|Other|Cash transfer|A small stipend of Ksh 1500 (US$15, Dec15 exch) per term will be provided to girls, through a safe and secure mobile money transfer system provider, like M-Pesa, Equity, or Postbank. Monies will be transferred at the beginning of a term, based on school registry statistics confirming participants attended for at least 80% of the previous term.
45624649|NCT03051789|Other|Cups and Cash|Combination of both interventions, using the same interventions and implementation methods.
45766218|NCT00989989|Drug|Ranibizumab|Ranibizumab 0.5 mg intravitreal injection at day 1, month 1 and month 2. If stable vision not reached at month 3, one injection per month continued until stable vision was reached. Intravitreal injections re-initiated if needed.
45766219|NCT00989989|Procedure|Laser photocoagulation|Active laser treatment administered at day 1. Subsequent laser treatments administered if needed at intervals no shorter than 3 months from previous laser treatment.
45766220|NCT00989989|Drug|Sham ranibizumab|Sham intravitreal injections to ranibizumab at day 1, month 1 and month 2. Intravitreal injections re-initiated if needed.
45624650|NCT04894461|Device|Moxibustion|The moxibustion treatment sessions are three times per week for eight weeks. Indirect moxa stick will be used.
45624651|NCT04898361|Procedure|PFO closure|Interventional closure of a patent foramen oval preceded by an electrophysiological study
45624652|NCT04898517|Procedure|Pancreaticoduodenectomy with the CONDUCTJE-ST technique|"The termed technique connexion pancreatic duct to the jejunum stented (CONDUCTJE-ST) in pancreaticoduodenectomy is a novel technique, modification of the pre-existing ones, whose effectiveness lies in the fact that it is not an anastomosis in the strict sense but rather a simple connection for restoring pancreatic juice flow from the pancreatic remnant towards the intestine."
45624653|NCT04894149|Other|Physiotherapy|Supervised physiotherapy one hour twice weekly and 20 minutes three times weekly during 14- 17 weeks before surgery during neoadjuvant chemotherapy or chemoradiotherapy and during eight weeks after surgery (sometimes during adjuvant chemotherapy)
45624654|NCT04894227|Biological|Inactivated SARS-CoV-2 Vaccine (Vero cell）|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
45766221|NCT00989989|Procedure|Sham laser photocoagulation|Sham laser treatment administered at day 1.
45766222|NCT04331080|Drug|Granexin® gel 100 μM|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
45766223|NCT04331080|Drug|Granexin® gel 200 μM|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
45766224|NCT04331080|Drug|Vehicle gel|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
45766225|NCT00362193|Behavioral|Telephonic diabetes care|
45766226|NCT03802773|Procedure|CB transplantation|Myeloablative conditioning with post-transplant cyclophosphamide in patients receiving a matched CB transplant for hematological malignancies.
45766227|NCT04282564|Other|Co-OP treatment|"The Cognitive Orientation to daily Occupational Performance (CO-OP) approach is described as a patient-centred, performance-oriented approach to activities and problem solving that allows skills to be acquired through a process of strategy use and guided discovery. The CO-OP protocol is composed of seven key characteristics: i) the goals chosen by the patient, ii) dynamic performance analysis, iii) the use of cognitive strategies, iv) guided discovery, v) the principles of empowerment, vi) the involvement of a relative, vii) the structure of the intervention (Polatajko and Mandich, 2004/2017). CO-OP is an evidence-based approach to intervention, including evidence of its effectiveness on a physical, cognitive and emotional dimension in adults with stroke"
45766228|NCT03018301|Drug|Ketamine|will receive 0.25 mg/kg intravenous ketamine diluted with normal saline to 20 ml delivered over 10 minutes.
45766229|NCT03018301|Other|Normal saline|will receive intravenous 20 ml of normal saline, delivered over 10 minutes.
45766230|NCT03100864|Drug|Spesolimab|12 weeks treatment
45766231|NCT00990769|Other|Depth of anesthesia|The intervention in this study is the titration of the depth of anesthesia according to the BIS monitor, as maintained by a combination of routine anesthetic agents (nitrous oxide, sevoflurane, and fentanyl).
45766232|NCT03785145|Drug|MT10109L|MT10109L will be injected into the LCL.
45766233|NCT03785145|Drug|Placebo|Placebo will be injected into the LCL.
45766234|NCT04242550|Behavioral|Executive Function- Enhanced CBT for BED (EF-BED+CBT)|EF-BED+CBT will combine CBT (see description below) with executive function training. EF-BED will focus on teaching compensatory strategies to enhance adherence to the strategies recommended in CBT.
45766235|NCT04242550|Behavioral|Cognitive Behavioral Therapy (CBT)|"CBT will be based on the Overcoming Binge Eating book. All participants will be provided a copy of the book. CBT addresses disturbed eating patterns and problematic thoughts/beliefs related to eating, shape and weight that contribute to binge eating. CBT is the current gold standard treatment for BED."
45766236|NCT03018457|Device|ISQ|Measured by Osstell.
45766237|NCT00421941|Procedure|Tube feeding|
45766238|NCT03018067|Drug|RDX227675|
45766239|NCT03018067|Drug|Placebo|
45766240|NCT03292497|Procedure|Treatment Algorithm|Patients will have their procedure dictated by a treatment algorithm. They will have their mitral valve replaced if the posterior leaflet tethering angle >=25 degrees, or repaired if the posterior leaflet tethering angle <25 degrees.
45766241|NCT03292497|Procedure|No Treatment Algorithm|Patients will have their valve repaired or replaced at the discretion of their surgeon.
45766242|NCT04744857|Combination Product|The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.|Using the grip-loading system, the artificial aortic valve was squeezed and loaded into the sheath of the transporter through the vascular approach.The artificial aortic valve is delivered and positioned at the correct anatomical position for release. For example, the artificial main valve is displayed after partial release If the aortic valve is not in the correct anatomical position, the artificial aortic valve can be recovered and placed into the sheath tube of the transporter for re-positioning and release.
45766243|NCT00991081|Behavioral|Counseling|"Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling~One week prior to the target quit date (TQD)~Two weeks post-TQD~Four weeks post-TQD"
45624655|NCT03051711|Drug|GBT440|Capsules which contain GBT440 drug substance in Swedish Orange
45624656|NCT04908345|Drug|Methadone|Used at induction and during surgery
45624657|NCT04908345|Drug|Fentanyl|Used at induction and during surgery
45624658|NCT04893993|Drug|Thiamine|Tablets. 300mg/tablet. Dosage depends on gender and weight
45624659|NCT04893993|Drug|Placebo|Tablets. Same number of tablets as Thiamine
45624660|NCT04907955|Procedure|phacoemulsification with implantation of presbyopia correcting IOL|cataract extraction with phacoemulsification and insertion of presbyopia correcting IOL
45766244|NCT00991081|Behavioral|Self-help guide|A printed self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail
45766245|NCT00991081|Drug|Pharmacotherapy|"8-week course of genetically-tailored pharmacotherapy~Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)~Participants with the A2 allele (CC) were assigned to receive bupropion"
45766246|NCT00991081|Behavioral|Genetic feedback, verbal|During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment
45766247|NCT00991081|Behavioral|Genetic feedback, printed|After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype.
45624661|NCT04403919|Device|Conventional Closure: Knee|Traditional closure will consist of arthrotomy (deep layer) closed with figure of eight number 1 vicryl plus followed by closure of the intermediate layer with 0 Vicryl plus. The intermediate layer will be performed at surgeon's discretion especially in thin patients. Subdermal layer with 2-0 vicryl suture followed by subcuticular 3-0 monofilament suture (monocryl PLUS, Ethicon; Johnson & Johnson) and Dermabond advanced.
45766248|NCT03163342|Biological|Licensed seasonal influenza vaccine|20 healthy subjects will be enrolled and receive a single dose of licensed seasonal influenza vaccine
45766249|NCT03165058|Diagnostic Test|mucosal impedance (MI) testing|During routine colonoscopy, consented study participants will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The physician will take measurements in each segment of the colon, including segments that appear inflamed and normal adjacent areas (up to 10 locations). To obtain a stable reading, the sensor must remain in contact with the mucosa for five seconds. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant. Basic demographic information, prior IBD treatments, and prior colonoscopic data will be collected from the medical record following the procedure for those patients who consent to research.
45766250|NCT03018145|Device|Wagon|
45766251|NCT03018145|Device|Standard stretcher car|
45766252|NCT01351623|Drug|Carfilzomib|Following enrollment patients will be treated with single agent infusional carfilzomib at 56mg/m2. Carfilzomib will be administered intravenously over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses during the first cycle.
45766253|NCT03017911|Procedure|Piccline|
45766254|NCT03168022|Drug|Treatment A|1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.
45766255|NCT03168022|Drug|Treatment B|1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
45446971|NCT04241133|Behavioral|The UnProcessed Pantry Project (UP3)|UP3 uses the Social-Ecological Model to target multiple levels, including the food supply in the rural study location (community level), the food environment at the food pantry (environmental level), and participant dietary intake (individual level). It is hypothesized that UP3 will improve access to minimally processed foods and decrease access to ultra-processed foods at the food pantry, which will improve overall dietary quality of individuals as measured by the Healthy Eating Index-2015 compared to baseline and to the control group. Demographic and food security data will characterize the population. Psychosocial factors will be collected to understand changes in knowledge, attitudes, and perceptions about processed foods. Biomarkers of health data (i.e., weight, systolic blood pressure, HbA1c, fasting lipid panel) will be collected to determine the feasibility of measuring potential short-term health effects alongside UP3.
45446972|NCT02095522|Drug|Colchicine|Colchicine 1mg per day for one month
45446973|NCT02095522|Drug|Placebo|Placebo
45446974|NCT03748875|Behavioral|mindfulness-based relapse prevention|mindfulness-based relapse prevention, 8 weeks
45624662|NCT04403919|Device|Barbed suture closure: Knee|The barbed suture closure will consist of number 2 Stratafix symmetric PDS PLUS for the arthrotomy, intermediate layer will be performed at surgeon's discretion in thin patients, if performed will entail stratafix spiral, subdermal 2-0 stratafix spiral monocryl plus. Followed by subcuticular 3-0 stratafix spiral monocryl plus suture and Dermabond advance.
45766256|NCT03272529|Other|Patient-specific simulated rehearsals|Using 3-D printing and polymer technology, the investigators' team will construct patient-specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology, and pathology specific to each patient. These models will be constructed at the Simulation Innovation laboratory within the Department of Urology, University of Rochester. The process involves importing DICOM files of patient participants C.T. scans into 3D processing software, creating virtual models of kidney parenchyma incorporating the kidney, urinary system, stone and abdominal wall. Surgical phantoms are then created using 3D printing and polymer hydrogels, to recreate the entire procedure.
45804256|NCT04329273|Other|Sliding leg curl|The exercise protocol consists of the following sets and repetitions Week 1- 2 sessions with 2 sets of 6 repetitions Week 2- 2 sessions with 3 sets of 6 repetitions Week 3- 2 sessions with 4 sets of 6 repetitions Week 4- 2 sessions with 4 sets of 8 repetitions Week 5- 2 sessions with 4 sets of 10 repetitions Week 6- 2 sessions with 4 sets of 10 repetitions Week 7- 2 sessions with 4 sets of 8 repetitions Week 8- 2 sessions with 4 sets of 8 repetitions
45624663|NCT04403919|Device|Conventional Closure: Hip|"The capsule will be closed with Vicryl Plus number 1~Deep fascia with figure of eight interrupted number 1 braided absorbable suture (Vicryl plus, Ethicon; Johnson &Johnson, Somerville, NJ)~Subdermal fat layer simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl plus)~Subcuticular 3-0 monofilament suture (monocryl plus , Ethicon; Johnson & Johnson)~followed by the use of skin adhesive (Dermabond Advanced, Ethicon; Johnson &Johnson)."
45624664|NCT04403919|Device|Barbed suture closure: Hip|"The capsule will be closed with stratafix symmetric PDS Plus~Deep fascia will be closed with Stratafix Symmetric PDS Plus (Stratafix symmetric PDS plus, Ethicon; Johnson &Johnson, Somerville, NJ)~Subdermal layer with running number 2-0 barbed suture (stratafix spiral monocryl plus, Ethicon; Johnson & Johnson, Somerville, NJ)~Subcuticular suture with stratafix spiral monocryl plus, Ethicon~followed by the use of skin adhesive (Dermabond advanced, Ethicon; Johnson &Johnson)."
45624665|NCT04403763|Drug|AGN-241622|Topical eye drop
45624666|NCT04403763|Drug|AGN-190584|Topical eye drop
45624667|NCT04403763|Drug|Vehicle|Topical eye drop
45624668|NCT04893369|Other|The Low Back Pain and Disability Drivers Management model|"PTs assigned to the intervention arm will undergo a one-day training specific to the PDDM model. The objectives of the workshop are 1) to acquire knowledge on the functioning of the PDDM model by identifying the different domains of the model, and the specific elements that are deemed problematic for a given patient to appropriately establish the clinical profile and 2) to adopt a structured approach to manage and select appropriate interventions to address problematic areas. The model is composed of five domains upon which the clinician can base his assessment and orientate treatment allocation and includes: 1) nociceptive pain drivers, 2) nervous system dysfunction (NSD) drivers, 3) comorbidity drivers, 4) cognitive-emotional drivers and 5) contextual drivers. This profiling will inform and lead the clinician's treatment approach based on the combined contribution of each domain driving the experience of pain and disability."
45624669|NCT04893369|Other|Low back pain clinical practice guidelines|For the PTs allocated to the control arm, they will participate in a three-hour training on the most recent CPGs on the management of LBP. The content of the training is based on the results of a thorough review of the literature summarizing the different recommendations from CPGs with a focus on the rehabilitation management of LBP. The objectives of the workshop are 1) to acquire knowledge about the recommendations from the most recent and high-quality CPGs for the management of LBP and 2) to foster their integration into clinical practice. An interactive workshop will be conducted to present the results of the review of the literature with the help of case-studies to facilitate implementation and promote active participation.
45766257|NCT03272529|Other|Idealized simulated rehearsals|Using 3D printing and polymer technology, the investigators' team will construct a validated generic simulated hydrogel model with a complex kidney stone, incorporating the necessary anatomy, physiology and pathology. These models will be constructed at the Simulation Innovation laboratory within the department of urology at the University of Rochester. Generic models incorporating the kidney, PCS, staghorn stone, abdominal wall, and other relevant anatomical elements (bowel, perinephric fat, solid organs and bony structures) will be constructed. Participants in his group will complete the simulation replicating all steps of the procedure of this ideal training case that is not specific to a particular patient.
45766258|NCT03272529|Other|Standard simulation|Participants recruited to this cohort will only have completed the standard prerequisite simulation training similar to the two other groups (didactic lecture, hands-on simulation training to proficiency and live case observation), that represents the current standard of care. No further simulation would be conducted in participants of this group in addition to the standard.
45624670|NCT04898205|Other|Treadmill Exercise|The cardiopulmonary rehabilitation protocol utilizes progressive treadmill exercise with alternating increases in intensity and incline with no more than 0.5 Met increase per session.
45766259|NCT03017989|Device|NIRF imaging|By using a fluorescence imaging device (with an adapted light source and camera), a fluorescent dye can be made visible. By injecting the fluorescent dye intravenously, the vascularization will be visible. Thereby, structures with altered vascularization are expected to 'light up' differently than the surrounding.
45624671|NCT04898205|Other|Concentrated Oxygen|Supplemental oxygen from a concentrator (6 liters per minute) will be provided via nasal cannula regardless of oxygen saturation.
45624672|NCT04898205|Other|Concentrated Air|Room air will be delivered through an concentrator provided via nasal cannula.
45624673|NCT04893603|Device|Transcatheter Aortic Valve System|Procedure: Transcatheter aortic valve replacement
45624674|NCT04892979|Other|Cardiopulmonary exercise (centre-based)|Depending on the preference of participants, they can either choose to join three 60-minute centre-based sessions plus two sessions of 30-minute home exercise per week, or two 60-minute centre-based sessions plus four sessions of 30-minute home exercise per week. Each session will include warm-up and cool-down exercises, aerobic exercises, and progressive strengthening exercises prescribed based on individual ability (Table 1). Aerobic exercises will be performed at 60-75% (up to 85% for fit individuals) of the predicted maximum heart rate. The respective rate of perceived exertion during exercise will be maintained between 4 and 6 out of 10 on the Borg CR scale [10], indicating moderate to strenuous exercise levels. Additionally, physiotherapists will provide education related to COVID-19, energy conservation, and stress management during the program.
45766260|NCT04342533|Procedure|Thulium fiber laser enucleation of the prostate|enucleation of the BPH according to standard procedure protocol
45766261|NCT04342533|Procedure|Holmium laser enucleation of the prostate|enucleation of the BPH according to standard procedure protocol
45766262|NCT03102190|Drug|Verapamil Hydrochloride Intranasal|Verapamil solution for injection, supplied in vials, will be utilized in a Neil Med Sinus Rinse of 240mL buffered normal saline.
45766263|NCT04353427|Behavioral|The Seven Pathways to Healing, Health and Wellness curriculum|"The curriculum seeks to increase civic engagement by fostering a sense of community and a sense of social and personal responsibility in community. There will be 7 monthly session that will be approximately 1 hour in duration. Session topics include:~Education and Information (including mental health awareness, and a one-day certificate program in Mental Health First Aid)~Connection with Others~The Body as Temple~Emotional Healing~The Nature of Mind~Life Assessment~The Nature of Spirit"
45766264|NCT03263949|Other|Diagnostic|For the analysis of myocardial function, conventional 2D echocardiography and tissue doppler will be used. For the evaluation of myocardial mechanics, 2D speckle tracking, strain, strain rate and mechanical dispersion will be obtained.
45766265|NCT04342455|Other|double-low scanning|a CT angiography protocol with low radiation and contrast agent exposure
45766266|NCT02163811|Behavioral|VETPALS|"VETPALS is an adaption of an empirically supported self-management program, PALS (Promoting Amputee Life Skills). The PALS program demonstrated improved physical and psychosocial functioning when delivered in community-based support groups for amputees, but this program has not been adapted for the needs of Veterans and implemented in the VA healthcare system.~VETPALS is a five session course for people with life changes after amputation. The five sessions are held weekly, and are facilitated by a VA clinician in conjunction with a peer facilitator (Veteran with limb loss). Veterans receive all usual care."
45766267|NCT02163811|Behavioral|Individual Education Support Program|VETPALS facilitator provide post-amputation education materials from the Amputee Coalition, including First Step - A Guide for Adapting to Limb Loss and Side Step - A Guide to Preventing and Managing Diabetes and Its Complications. Veterans receive all usual care.
45766268|NCT03168334|Drug|IDP-123 Lotion|Tazarotene 0.045% Lotion
45766269|NCT03168334|Drug|IDP-123 Vehicle Lotion|Vehicle Lotion
45624675|NCT04892979|Other|Cardiopulmonary exercise (online-based)|Participants in the OBR group will attend one face-to-face session to learn how to use a mobile application (app) followed by 6 weeks of home exercises. The online treatments will be delivered via the Caspar Health e-system, a German-designed Internet-based system, is available for desktop PCs and as a mobile app for both iOS and Android smartphones. This system will enable patients to follow their therapists' treatment plans in an asynchronous manner. The OBR programme will last for 6 weeks. Participants will be instructed to perform 40 minutes of structured exercises 6 times per week. In the first week, six 40-minute online exercise sessions will be delivered through push notifications on the mobile app.
45624676|NCT03051243|Drug|Linagliptin and Basal Insulin|Linagliptin and bed time insulin glargine linagliptin (trajenta) once daily combined with bed time basal insulin (glargine Lantus; sanofi) before meals
45624677|NCT03051243|Drug|Basal Insulin and Bolus Insulin|Basal bolus insulin regimen and insulin based therapy with glargine once daily before bedtime and glulisine (Apidra; sanofi) before meals
45766270|NCT03254667|Biological|Brodalumab|Brodalumab
45766271|NCT03254667|Drug|Comparator Drug (non-biologic IL-17 inhibitors)|Comparator subjects treated with non-biologic IL-17 inhibitors
45766272|NCT03754803|Other|HIV Symptom Distress Module Questionnaire|The Symptom Distress Module is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment.
45766273|NCT03754803|Other|HIV treatment satisfaction questionnaire|The HIV TSQ is a 10-item-self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience and flexibility.
45766274|NCT05108467|Diagnostic Test|Point of care Lactate|"StatStrip Lactate is a handheld, point-of-care (POC) meter that brings lactate testing directly to the bedside. Lactate measured with blood gas analyzers is problematic for bedside care. Blood gas analyzers require arterial samples, large sample volumes (100-200 μL), and long analysis times (up to 2.5 minutes). In addition, blood gas analyzers are complex to use, stationary, and expensive to purchase and run.~StatStrip Lactate testing is as easy as bedside glucose testing. Single-use, pre-calibrated biosensors provide the fastest turnaround time (13 seconds) from the smallest whole blood sample (0.6 μL) with excellent correlation to central laboratory reference methods."
45766275|NCT03102736|Drug|Placebos|Placebo saline
45766276|NCT03102736|Drug|Ketamine|0.5 mg/kg ketamine
45766277|NCT03102736|Drug|Nitroprusside|0.5 mcg/kg nitroprusside
45766278|NCT03743103|Drug|Brevibloc, 10 Mg/mL Intravenous Solution|10 mL/h every 5 minutes until reaching the pressure target
45766279|NCT03743103|Drug|Nitroprusside, Sodium|0.5 ug/kg/min every 3 minutes until reaching the pressure target
45766280|NCT04049266|Drug|KSI-301|Intravitreal Injection
45766281|NCT04049266|Drug|Aflibercept|Intravitreal Injection
45766282|NCT04049266|Other|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
45766283|NCT03217071|Drug|Pembrolizumab|All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
45446975|NCT02097394|Drug|Combizym|Combizym( 1 tablet, po, tid)
45766284|NCT03217071|Radiation|stereotactic radiation therapy (SRT)|Patients in Cohort 2 of the Safety run-in and patients in the expansion cohort who are randomized to the 'pembrolizumab +radiation arm' will receive one dose of SRT within 1 week (+/- 3 days) following the second administration of pembrolizumab.
45766285|NCT00992719|Biological|Inactivated H1N1 Vaccine|H1N1 vaccine [Influenza A (H1N1) 2009 Monovalent Vaccine] is a licensed, inactivated influenza virus vaccine. It will be provided as prefilled single dose syringes containing 0.5 mL. The 0.5 mL prefilled syringe is formulated without preservative. The 15 microgram (mcg) dose will be administered as a single 0.5 mL intramuscular (IM) injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as two 0.5 mL injections in the deltoid muscle of each arm.
45766286|NCT03715335|Other|Targeted STI Screening|GC/CT screening will be offered to those who screen at risk or at high risk for STIs.
45766287|NCT03715335|Other|Universally Offered STI Screening|GC/CT screening will be offered to all patients who meet the age eligibility criteria.
45766288|NCT03169816|Drug|Lorcaserin|Lorcaserin 10mg, twice daily
45766289|NCT03169816|Drug|Placebo|Matched placebo for lorcaserin condition dosed twice daily
45446976|NCT02097394|Drug|Bifidobacteri|Bifidobacteri (2 tablet, po, tid)
45446977|NCT02097394|Drug|Combizym + Bifidobacteri|Combizym( 1 tablet, po, tid) + Bifidobacteri (2 tablet, po, tid)
45446978|NCT03747003|Other|No intervention is provided|No intervention is provided
45446979|NCT02095600|Radiation|Radiosurgical thalamotomy|
45766290|NCT03672201|Behavioral|Non-Pharmacological Intervention|The behavioural intervention will be a structured implementation of individualized activities to be followed and customized as per the needs of the participant.
45766291|NCT03672201|Other|Pharmacological Intervention|The medication algorithm provides recommendations to the treatment team about algorithmic treatment and assessments as per the ICP but ultimately the decision to prescribe any particular intervention will be the treatment team's decision and the recommendations of the research team for ICP arm will not be binding for the treatment team.
45766292|NCT03103282|Device|PuraStat®|Synthetic haemostatic material
45766293|NCT00362427|Biological|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 mL, 4 doses, IM
45766294|NCT00362427|Biological|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 Ml, 4 doses, IM
45766295|NCT00362427|Biological|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 mL, 4 doses, IM with concommitant vaccines
45766296|NCT01502917|Drug|Radioactive iodine-labeled monoclonal antibody omburtamab|Prior to treatment children will be pre-medicated with super-saturated potassium iodide & liothyronine to prevent thyroid uptake of the therapeutic radioisotopes. The proposed intervention is a surgical procedure using interstitial infusion of the radiolabeled monoclonal antibody 124I-omburtamab into the brain stem tumor. This will be performed by stereotactic placement of a small caliber infusion cannula into the tumor followed by a slow infusion (CED) of 124I-omburtamab. Following treatment, these children will be monitored during inpatient hospitalization with clinical evaluations & PET/CT or PET/MRI scans of the brain & other organs. Clinical observations, intensive care unit monitoring, routine blood & interval imaging studies (MRI & PET/CT or PET/MRI scans) will be performed at predetermined time points. If the PET/CT scan happens to fall on a weekend or holiday, the scan may be done before or after at the discretion of the Study PI. This will not affect dosimetry interpretation.
45766297|NCT01502917|Radiation|External Beam Radiotherapy|Standard radiation therapy is given 4-6 weeks prior to study entry.
45766298|NCT00362505|Drug|Clevudine|
45766299|NCT03103438|Biological|BCD-089|
45766300|NCT00993187|Drug|Sitagliptin/Metformin FDC|Sitagliptin phosphate plus metformin hydrochloride combination tablet (MK-0431A) orally up to 50/1000 mg BID for 30 weeks
45766301|NCT00993187|Drug|Comparator: Glimepiride|Glimepiride tablet orally up to 6 mg daily for 30 Weeks
45766302|NCT00993187|Drug|Matching placebo to Sitagliptin/Metformin FDC|Matching placebo to Sitagliptin/Metformin FDC 50/1000 mg orally BID for 30 weeks
45766303|NCT00993187|Drug|Matching placebo to glimepiride|Matching placebo to glimepiride tablet orally daily for 30 weeks
45766304|NCT03106636|Behavioral|KEEP-P|The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P is a basic version that employs a curriculum of 12 weekly psychoeducational caregiver support groups Across four waves of data collection (baseline, post-intervention, and 12 and 18 months post-baseline), we will examine the extent to which this intervention condition shows improved parenting, reduced rates of disrupted placements, and improved child outcomes.
45766305|NCT03106636|Behavioral|KEEP-P+|The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P+ is an augmented version that consists of the caregiver support groups with extended curriculum including information about recent findings in early brain development and the elements of the Filming Interactions to Nurture Development video coaching program. Across four waves of data collection (baseline, post-intervention, and 12 and 18 months post-baseline), we will examine the extent to which this intervention condition show improved parenting, reduced rates of disrupted placements, and improved child outcomes.
45766306|NCT03173170|Drug|TAK-954|TAK-954 Infusion
45766307|NCT03173170|Drug|Itraconazole|Itraconazole Capsule
45446980|NCT03555682|Dietary Supplement|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
45624678|NCT04897737|Behavioral|HIVST and enhanced adherence biofeedback|"The intervention includes the provision of an OraQuick HIV self-test (HIVST) for the woman and one test for each of her reported sex partners, along with instructions on how to use and interpret the results. Women were asked to report back within one month if their partner was able to test via a SMS, WhatsApp or by bringing in the test to confirm that he had tested.~Women then received adherence based feedback following the urine lateral flow assay (that measures recent tenofovir use in past 48 hours). Study counsellors requested that women provide a urine sample that was tested using the UrSure/Orasure test that provides feedback on the result in 2-3 minutes. Counselors provided counseling based on the results including how to improve daily adherence (for women without tenofovir present in their urine) and importance of condom use."
45624679|NCT04897737|Diagnostic Test|Orasure/UrSure test|See above
45624680|NCT03054597|Device|Circular light motion|Exercise with circular light motion
45766308|NCT03106870|Drug|Insulin Mixtard|"Insulin dose:~0.7 IU/Kg (at the second trimester of pregnancy).~0.8 IU/Kg (at the third trimester of pregnancy). Insulin dose was raised at a rate of 1 IU for every 10 mg/dl higher than the target blood glucose concentration."
45766309|NCT03106870|Drug|Metformin|"Oral metformin at a dose of 1500 mg divided into three doses, were taken with meals, in addition to insulin.~If the target blood glucose concentrations were not attained, the dose of metformin was raised to 2000 mg per day."
45766310|NCT00375154|Device|Noninvasive Positive-Pressure Ventilation (NPPV)|
45766311|NCT00375310|Drug|Gemcitabine, Sorafenib|"Gemcitabine is given IV~Sorafenib is given orally of varying doses:~Sorafenib 200 mg po qd ( during combination therapy)~Sorafenib 400 mg po qd ( during combination therapy)~Sorafenib 400 mg po bid ( during combination therapy)"
45766312|NCT00375310|Procedure|Radiotherapy|1.8 Gy CTV daily for 5 weeks
45766313|NCT03687892|Device|continuous Theta Burst Stimulation|Continuous Theta Burst Simulation will be applied in a continuous manner resulting in cortical excitability.
45766314|NCT03687892|Device|intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation will be applied in an intermittent manner resulting in cortical inhibition.
45766315|NCT03670953|Drug|IR CD-LD|Active comparator - IR CD-LD
45766316|NCT03670953|Drug|IPX203 ER CD-LD|Investigational formulation - ER CD-LD
45446981|NCT03555682|Dietary Supplement|Placebo|Placebo Comparator
45452409|NCT03181958|Device|NIPPV|Nasal intermittent positive pressure ventilation(NIPPV) is used as the noninvasive supporting mode after extubation.
45624681|NCT03054597|Device|Diagonal light motion|Exercise with diagonal light motion
45766317|NCT03670953|Other|Placebo Matching IPX203|Double dummy placebo capsules
45766318|NCT03670953|Other|Placebo Matching IR CD-LD|Double dummy placebo tablets
46069617|NCT04929938|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|This is a combination of cognitive-behavioural techniques oriented to improve the emotional regulation. The Unified Protocol is comprised of 8 modules and it is applied following The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders Manual (Barlow, 2017).
45766319|NCT04736914|Drug|R-CHOP/R-DHAOx； Zanubrutib（induction）； ASCT conditioning ； Zanubrutinib（Maintenance）|"Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:~R-CHOP (cycle 1,3,5):~Rituximab 375 mg/m2 D1, I.V. Cyclophosphamide 750 mg/m2 D1, I.V. Doxorubicine 50 mg/m2 D1, I.V. Vincristine 1.4mg/m2(max 2mg)D1, I.V. Prednisone 100mg D1-5, oral Zanubrutinib 160mg BID D1-21, oral~R-DHAOx (cycle 2,4,6):~Dexamethasone 40mg D1-4 oral/I.V. Rituximab 375mg/m2 D1, I.V. Ara-C 2×2g/m2 q12h D2, I.V. Cisplatin 100mg/m2 D1, I.V.~Maintenance:~Zanubrutinib, 160mg PO BID, continuously for 2 year or until progressive disease。~Zanubrutinib maintenance will start after regeneration of peripheral blood count after the end of the last cycle of induction therapy or ASCT"
45766320|NCT00993655|Drug|carboplatin|Carboplatin AUC 5 if measured GFR or AUC6 if calculated GFR intravenous or intraperitoneal.
45766321|NCT00993655|Drug|cisplatin|Cisplatin 75 mg/m2 intraperitoneal day 1
45766322|NCT00993655|Drug|paclitaxel|Paclitaxel 135 mg/m2 intravenous day 1 plus Paclitaxel 60 mg/m2 intraperitoneal or intravenously day 8. Cycles given Q 21 days x 3 cycles
45766323|NCT00362583|Drug|Fentanyl|
45624682|NCT03054597|Device|Peripheral light motion|Exercise with peripheral light motion
45766324|NCT00657241|Drug|Carvedilol CR|
45766325|NCT00657241|Drug|Valsartan|
45766326|NCT04342065|Drug|Celecoxib capsules|received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.
45766327|NCT04342065|Drug|Pregabalin 150mg|received Pregabalin 150mg 2 hours preoperative and the same dose 6 hours postoperative.
45766328|NCT03179410|Drug|Avelumab|10 mg/kg intravenously every 2 weeks
45446982|NCT04123665|Drug|Stannous fluoride|In this arm, participants will apply a full ribbon of dentifrice ( 0.454% w/w stannous fluoride) to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
45766329|NCT00478465|Drug|valganciclovir|
45766330|NCT05364892|Other|Blood samples (80 mL)|Blood samples (80 mL) at inclusion, once a year for 5 years, and if relapse or change of treatment
45766331|NCT05364892|Other|Fecal samples|Fecal samples at inclusion
45766332|NCT05364892|Other|Urinary sample (20-40 mL)|Urinary samples at inclusion, once a year for 5 years, and if relapse or change of treatment
45766333|NCT05364892|Other|Questionnaires|Questionnaires at inclusion, once a year for 5 years, and if relapse or change of treatment
45452410|NCT05628220|Other|physiotherapy|rehabilitation through using session of virtual reality desensitization
45624683|NCT03054597|Procedure|Exercise|
45624684|NCT04892589|Other|Proprioceptive thumb exercises.|Exercises for recognition of thumb position and thumb force sense.
45624685|NCT04897191|Other|Age|Determination of age-dependence
45624686|NCT04897113|Procedure|plasma exchange with albumin|plasma exchange with albumin, two per week, 110% of the circulating plasma volume
45624687|NCT04897113|Procedure|plasma exchange without albumin|plasma exchange without albumin, two per week, 110% of the circulating plasma volume
45624688|NCT04148781|Drug|Fampridine SR|Fampridine-SR 10 mg twice daily for 8 weeks
45766334|NCT03655587|Device|Solid ankle foot orthotic|
45766335|NCT03655587|Device|Resting night splint|
45935204|NCT00218920|Behavioral|high-intensity interval aerobic training|High-intensity training consisted of a 10 min warm-up period at 50-60% of HRmax [maximal HR (heart rate)], followed by 4×4-min intervals at 85-95% of HRmax with 3 min active breaks in between the intervals, consisting of walking or jogging at 50-60% of HRmax. The exercise session was terminated by a 5 min cool-down period.
45935205|NCT00042146|Behavioral|Cognitive-behavior therapy|
45935206|NCT00042146|Drug|zolpidem|
45766336|NCT04982887|Other|Exercise|The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
45766337|NCT05364736|Dietary Supplement|Highland barley β-glucan dietary supplement|100 mL oral liquid mainly containing highland barley β-glucan once daily for 12 weeks
45766338|NCT05364736|Other|Placebo controls|Placebo with a similar appearance and taste to highland barley β-glucan supplement
45766339|NCT00421785|Drug|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks.|
45766340|NCT02519348|Biological|Tremelimumab|Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
45766341|NCT02519348|Biological|Durvalumab|Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
45766342|NCT02519348|Biological|Bevacizumab|Bevacizumab 15 mg/kg will be administered by IV infusion every 3 weeks until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurred first.
45766343|NCT03155295|Other|Physical reality simulation|Using 3-D printing and polymer technology, the investigators will construct patient specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology and pathology specific to each patient. These models are constructed at the Laboratory for Simulation-based Translational Research at the Department of Urology. Group 1 urologists will rehearse the minimally-invasive partial nephrectomy (MIPN) surgery using these patient-specific models.
45766344|NCT03155295|Other|Virtual reality simulation|The DaVinci surgical skills simulator system uses a virtual reality surgical simulation platform that encompasses a variety of basic exercises specifically designed to give users the opportunity to improve their proficiency with the da Vinci surgeon console controls and basic robotic surgical skills. All urologists have already completed a basic robotic skills curriculum. Group 2 urologists will complete a refresher module on the virtual reality simulator.
45766345|NCT04333030|Other|questionnaire|Tobacco Use and Risk Questionnaire
45766346|NCT03324724|Behavioral|Integrative cognitive-affective therapy for adolescents (ICAT-A)|Participants will receive a 21-session individual psychotherapy approach with 4 phases. In addition, there will be 7-13 additional conjoint parent sessions.
45766347|NCT03653338|Biological|CD3/CD19 depleted leukocytes|Negative selection for CD3+/CD19+ cells will be performed on the CliniMACS® depletion device.
45766348|NCT03653338|Biological|CD45RA depleted leukocytes|Negative selection for CD45RA will be performed on the CliniMACS® depletion device.
45766349|NCT03653338|Drug|Hydroxyurea|Sickle Cell Disease Conditioning
45624689|NCT04891887|Behavioral|Health education program|"Seven face to face sessions and group discussion health education sessions. Two prepared booklets were distributed to all attendants titled Diabetes mellitus and how to control its complications and Mild cognitive impairment and how to prevent it.~Lab results were discussed individually with each participant to discuss his adherence to the lifestyle modification program.~Clinical follow-up and management with endocrinology and neurology specialists. Individualized Medical Nutrition. Participants were then counselled on healthy eating habits.~Individualized biweekly follow-up scheme through mobile phone. A WhatsApp group was created for all participants to contact the research team whenever they have any inquiry concerning life style modifications. Through this group, 12 HE audio electronic messages were shared with participants.~Final reassessment of clinical status and laboratory profile was carried out with participants who continued till the end of the study."
45766350|NCT03653338|Drug|Rituximab|Sickle Cell Disease Conditioning
45766351|NCT03653338|Drug|Alemtuzumab|Sickle Cell Disease Conditioning
45766352|NCT03653338|Drug|Fludarabine|Sickle Cell Disease Conditioning
45766353|NCT03653338|Drug|Thiotepa|Sickle Cell Disease Conditioning
45766354|NCT03157336|Other|Non Inferiority WTM Interventional Trial|The intervention will implement the WTM cassava processing technique in participating households. Twenty women (in leading roles) will be our principal candidates to serve as peer trainers. Together with a 20 community health worker specialists, these women will be trained in the WTM technique by the Kinshasa team of community health workers who are experts in the WTM method. Those who master the technique will then be certified as trainers to train and support other small groups of other mothers throughout a two-year period in the implementation of the WTM for the safer processing of food for their families. Both the community health worker specialists and trained women (prospective trainers) would have to be able to bring the cassava cyanogenic content to the lowest achievable level, which must be < 10 ppm as per the recommendations of the World Health Organization.
45766355|NCT03147885|Drug|Selinexor|Given PO
45624690|NCT04907331|Biological|Vaxzevria|The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria followed by Comirnaty
45624691|NCT04907331|Biological|Comirnaty|The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria
45624692|NCT04906863|Genetic|Blood draw|Blood draw for identification of genetic variants associated with the development of memory problems
45624693|NCT04906863|Other|Neurocognitive testing|Brief memory test
45624694|NCT04906863|Other|Medical questionnaire|Collection of medical history
45624695|NCT04897269|Procedure|Progesterone supplementation|This procedure is to add more progesterone on those who have low progesterone levels on the day of embryo transfer
45766356|NCT03179540|Procedure|Non-operative management|Patients who are eligible and provide informed consent to participate in the trial will undergo non-operative management (i.e., active surveillance for 24 months) according to the schedule outlined in the study protocol.
45766357|NCT05241392|Biological|B7-H3-targeting CAR-T cells|Patients will be treated with anti-B7-H3 autologous CAR-T cells that are delivered into the intracranial tumor resection cavity or ventricular system using an Ommaya device.
45766358|NCT00421863|Drug|Triatec 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
45766359|NCT00421863|Drug|Triatec HCT 5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
45766360|NCT00421863|Drug|Lasix 25|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
45766361|NCT00421863|Drug|Micardis 80 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
45766362|NCT00421863|Drug|Micardis plus 80/12.5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
45766363|NCT00421863|Drug|Catapresan TTS 2|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
45766364|NCT00421863|Drug|Norvasc 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
45766365|NCT00421863|Drug|Triatec 5 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
45766366|NCT00421863|Drug|Pluscor|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
45766367|NCT02853292|Biological|urine collection|
45766368|NCT05241080|Other|Survey|It is a survey based on questionnaire
45766369|NCT03136185|Drug|IMG-7289|Differentiation therapy
45766370|NCT05363956|Drug|salvadora|The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.
45766371|NCT05363956|Drug|Eucalyptus Oil|The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.
45766372|NCT00636818|Drug|Atomoxetine|Study drug is administered once daily in the morning. This study is designed with 4-step titration. At Day 1, study drug is started from 40 mg/day, and is increased to 80 mg/day on Day 7, 105 mg/day on Day 14, and 120 mg/day on Day 28. Total administration period is 8 weeks. The dosage is adjusted according to investigator's decision based on safety and tolerability.
45766373|NCT05363722|Drug|IBI310（0.5mg/kg）|IBI310 0.5mg/kg IV d1 Q6W
45766374|NCT05363722|Drug|IBI310（0.3mg/kg）|IBI310 0.3mg/kg IV d1 Q6W
45766375|NCT05363722|Drug|sintilimab|sintilimab 200 mg IV d1 Q3W
45446983|NCT04123665|Drug|Sodium monofluorophosphate|In this arm, participants will apply a full ribbon of negative control dentifrice (1000 ppm fluoride as SMFP to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
45446984|NCT02090608|Drug|Paricalcitol|Paricalcitol was administered at the dose of 1 mcg/die
45624696|NCT04896723|Diagnostic Test|Sexual function questionnaire|Sexual function questionnaire and cognitive screening assessments
45624697|NCT04896879|Behavioral|interviews|semi-structured interviews will be conducted in patients with major LARS and their informal caregiver to explore their experiences and needs. Focus groups will be perfomed with healthcare professionals of several professions.
45624698|NCT04891653|Drug|BR790|Subjects will receive oral administration of BR790.
45624699|NCT04891731|Drug|AI or TAM|This is an observational study, the researcher will describe the ratio of E2 control between leuprorelin plus TAM or leuprorelin plus AIs patients based on the actual clinical use.
45624700|NCT04891497|Drug|Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
45624701|NCT04891497|Drug|Placebo|Placebo 240mg orally twice daily for 3 consecutive days
45624702|NCT04896177|Device|Sirolimus drug-eluting coronary balloon catheter|Patients in experimental group will undergo PCI, using sirolimus drug-eluting coronary balloon catheter.Subjects without stent implantation were regularly treated with dual antiplatelet for 9 months after surgery. Subjects with stents were regularly treated with dual antiplatelet for 12 months after the surgery, in accordance with the applicable guidelines for percutaneous coronary intervention.
45624703|NCT04896177|Device|Paclitaxel drug-eluting coronary balloon catheter|Patients in control group will undergo PCI, using paclitaxel drug-eluting coronary balloon catheter.Subjects without stent implantation were regularly treated with dual antiplatelet for 9 months after surgery. Subjects with stents were regularly treated with dual antiplatelet for 12 months after the surgery, in accordance with the applicable guidelines for percutaneous coronary intervention.
45624704|NCT03050853|Behavioral|E-cigarette|The e-cigarette arm will be provided with 8 weeks of free e-cigarettes based on self-report of regular tobacco use. Participants assigned in this arm will be asked to switch combustible tobacco with e-cigarettes. The appeal of e-cigarettes and health impacts will be measured, but we are not targeting quitting combustible tobacco or reducing craving.
45766376|NCT05363722|Drug|bevacizumab|bevacizumab 15 mg/kg IV d1，Q3W
45766377|NCT05363566|Device|airway divice|inserted airway device
45766378|NCT03127995|Radiation|HYPOFRACTIONATED|40 Gy/ 15 fractions / 3 weeks
45766379|NCT03127995|Radiation|NORMOFRACTIONATED|50 Gy/ 25 fractions / 5 weeks
45766380|NCT01922492|Procedure|Autologous islet transplantation|"Islet was isolated from the normal part of resected pancreas with modified Ricordi method.~After purification, the islets were infused into the liver through percutaneous transhepatic portal vein catheterization."
45766381|NCT01922492|Drug|Oral anti-diabetic drugs|"Metformin on the diagnosis of postoperative diabetes mellitus. Starting dose of 500mg per day and dose adjustment as needed to control blood glucose.~Vildagliptin added on the insufficient glycemic control with monotherapy. Starting dose of 50mg per day and dose adjustment as needed to control blood glucose."
45766382|NCT03127137|Drug|Experimental Group 1 triamcinolone and lidocaine|Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)
45766383|NCT03127137|Drug|Experimental Group 2 triamcinolone and saline|Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)
45766384|NCT05356780|Device|Aligner|A method of straightening teeth without fixed braces
45766385|NCT03122847|Drug|Methylprednisolone|Intravenous methylprednisolone
45766386|NCT05355142|Behavioral|PM+|"1 Brief introduction to PM+ & NDA (5 min) Assessment-based review with PSYCHOLOPS (psychopomps psychology ) assessment (10 min) What is PM+ (20 minutes) Understanding Adversity (30 minutes) Stress Management (20 minutes) Closing the meeting (5 minutes)~2 General Review (5 min) Issue management (70 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~3 General Review (5 minutes) Problem Management (35 minutes) Take action and be consistent (35 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~4 General Review (5 minutes) Issue Management (20 minutes) Take action and be persistent (20 minutes) Strengthening Social Support (30 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~5 General Review (20 minutes) Staying Healthy (30 minutes) Imagining how to help someone (20 minutes) Looking ahead (15 minutes) Closing the de-briefing (5 minutes)"
45766387|NCT00636506|Device|AMS 700 IPP with MS Pump|AMS 700 Series Inflatable Penile Prosthesis with MS Pump
45766388|NCT04745091|Procedure|total mesorectal excision|excision of the rectum with complete excision of the mesorectum
45766389|NCT03632356|Behavioral|Stepped Care Intervention (STEP)|A stepwise progression of intervention according to the participant's response to the increasing levels of therapy. There will be 1 session of psychoeducation, followed by 5 sessions of Cognitive Behavioral Therapy (CBT) if panic symptoms do not improve at 1-month follow-up.
45766390|NCT03632356|Diagnostic Test|Screening only|Screening for probable panic attacks or panic disorder using the Structured Clinical Interview for DSM-5
45766391|NCT04342221|Drug|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.
45766392|NCT04342221|Drug|Placebo|Placebo capsules
45766393|NCT03632889|Behavioral|GoToSleep Program|For the control group only the sleep hygiene handout will be given in this arm. For the computerized group a sleep hygiene handout along with assess to the GoToSleep online program.
45766394|NCT03525028|Drug|Metformin|The investigators assumed that the combination therapy of metformin and glucocorticoids can decrease glucocorticoids side effects and synergia the anti-inflammatory and immune inhibitory effect of glucocorticoids. So the investigators use metformin in the experimental group.
45766395|NCT03525028|Drug|Placebo|The investigators use placebo in the control group.
45766396|NCT00636194|Device|Bausch & Lomb Multipurpose Solution|daily care of contact lenses
45766397|NCT00636194|Device|Alcon OptiFree Replenish Multipurpose Solution|daily care for contact lenses
45446985|NCT02090686|Device|Pulsatile Cupping|"8 cupping sessions (each 8 minutes) in 4 weeks (-150 to -350 mbar), interval 2 seconds.~Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day)"
45446986|NCT02090686|Device|Minimal Cupping|8 cupping sessions (each 8 minutes) in 4 weeks witth (-60 to -70 mbar). Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day).
45446987|NCT03746145|Dietary Supplement|Bifidobacterium longum 1714|This is a double-blind randomized placebo-controlled pilot study. Participants under extreme conditions of hypoxia, confinement and isolation receive Bifidobacterium longum 1714 on a daily basis over one year in order to test improvements on stress resilience and immune functions.
45446988|NCT03746145|Dietary Supplement|placebo sachet containing maltodextrin and magnesium stearate.|placebo sachet containing maltodextrin and magnesium stearate.
45446989|NCT02097628|Procedure|tidal volume|In the volume controlled ventilation group using laryngeal mask airway Guardian,a tidal volume of 8-12ml/kg,respiratory rate12-16bpm.
45446990|NCT02097628|Procedure|peak airway pressure|In the pressure controlled ventilation group using laryngeal mask airway Guardian,a peak airway pressure that provides a tidal volume of 8-12ml/kg with an upper limit of 35 centimeter water column,respiratory rate12-16bpm.
45446991|NCT02097784|Procedure|Echocardiography|
45446992|NCT02098720|Drug|Conbercept|
45446993|NCT02250508|Biological|Optivate® (Human Coagulation Factor VIII)|
45624705|NCT04896255|Drug|peginterferon alpha based regimen|peginterferon alpha based regimen or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
45624706|NCT04896255|Drug|nucleos(t)ide|peginterferon alpha based regimen or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
45624707|NCT04895865|Behavioral|RPE-based load and repetition number selection|Providing trainees with choices regarding the load and the number of repetitions to be performed per set and exercise
45624708|NCT04895865|Behavioral|Predetermined load and number of repetitions|Trainees predetermine the load and perform ten repetitions per set and exercise
45624709|NCT04906785|Drug|CKD-385|Test Drug
45624710|NCT04906785|Drug|D744|Reference Drug
45624711|NCT04906551|Device|laser Doppler|A direct measure of blood flow
45766398|NCT03631797|Procedure|Microvascular reactivity evaluation|Microcirculation will be evaluated for each patient before surgery with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of endothelium reactivity: Iontophoresis.
45766399|NCT00754312|Drug|SNDX-275|
45766400|NCT04736368|Other|EDIP Diet Suggestions|CD participants will receive EDIP diet suggestions after random allocation.
45766401|NCT04736368|Other|diet guidance|Control group will be given diet guidance according to routine experience under the participant's request.
45766402|NCT03623373|Drug|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m^2 IV over 30 minutes on Days 1 and 2 of Cycles 1-3
45766403|NCT03623373|Drug|Rituximab|In Cycle 1, rituximab will be administered at a dose of 375 mg/m^2 IV on Day 1 or 2 at the investigator's discretion in order to reduce the risk of a first infusion reaction. Rituximab will be given on Day 1 of Cycles 1 through 6.
45766404|NCT03623373|Drug|Acalabrutinib|The capsules should be swallowed intact with water and with or without food.
45446994|NCT02250508|Biological|Haemate P® (Human Coagulation Factor VIII)|
45624712|NCT04906473|Drug|KY100001|KY100001; Tablet; Oral route; Dose escalation and dose extension
45624713|NCT03052569|Drug|RXDX-105|Oral Capsules
45624714|NCT03050931|Device|Electrical Impedance Tomography|EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt. For intracranial electrode studies, the EIT systems will be linked to the existing EEG video recording systems and EIT will be recorded at the same time using some or all of the available intracranial electrodes.
45653392|NCT05036577|Drug|Orelabrutinib|"Orelabrutinib will be given as 150 mg/d or 200 mg/d orally 72h after MTX infusion or MTX clearance, every 21 days for 6-8 cycles during combination induction treatment.~Daily Orelabrutinb with dose in last cycle of induction will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first)."
45653393|NCT05036577|Drug|Rituximab|Rituximab 375 mg/m2 intravenous infusion d1, every 21 days for 6-8 cycles during combination induction treatment.
45766405|NCT03623373|Drug|Cytarabine|On Days 1 and 2 of Cycles 4-6, following rituximab dosing, cytarabine will be administered IV every 12 hours for a total of 4 doses.
45766406|NCT03623373|Procedure|Leukapheresis|Until collection of ≥ 2 x 106 CD34+ stem cells / kg
45766407|NCT03623373|Procedure|Peripheral blood|-Baseline, end of Cycle 3, 4-6 weeks after Cycle 6 Day 1, and if the patient discontinues protocol therapy prior to completion of Cycle 6
45766408|NCT03623373|Procedure|Oral rinse|-Baseline
45766409|NCT03623373|Procedure|Bone marrow collection|-Bone marrow will be collected at baseline if the patient requires a marrow for staging purposes and at end of treatment if the patient requires a marrow for restaging.
45766410|NCT03505762|Drug|Cyclophosphamide|Given IV
45766411|NCT03505762|Drug|Doxorubicin Hydrochloride|Given IV
45766412|NCT03505762|Other|Laboratory Biomarker Analysis|Correlative studies
45766413|NCT03505762|Drug|Prednisone|Given PO
45766414|NCT03505762|Other|Quality-of-Life Assessment|Ancillary correlative
45653394|NCT05036577|Drug|Methotrexate (MTX)|high-dose Methotrexate 3.5 g/m2 or 5g/m2 intravenous infusion (3h) d2, every 21 days for 6-8 cycels during combination induction treatment.
45766415|NCT03505762|Other|Questionnaire Administration|Ancillary studies
45766416|NCT03505762|Biological|Rituximab|Given IV
45766417|NCT03505762|Drug|Vincristine Sulfate|Given IV
45766418|NCT04744779|Behavioral|Office-based accommodative/vergence therapy and home reinforcement|Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)
45446995|NCT03555604|Diagnostic Test|Gastric ultrasound|Gastric ultrasound to measure antrum cross sectional area
45446996|NCT02097862|Procedure|Adipose Stem Cells|Injection of adipose derived stem cells intra-discally
45446997|NCT03555526|Drug|Esomeprazole 40mg|Nexium (esomeprazole), 40mg, bid, for 14 days
45446998|NCT03555526|Drug|Amoxicillin|amoxicillin, 1000mg, bid, for 7 days (day 1-day 7)
45766419|NCT03622359|Diagnostic Test|SPECT/CT perfusion imaging|Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
45766420|NCT03622359|Diagnostic Test|PET/CT perfusion imaging|Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
45766421|NCT04736524|Other|Rapid antibody test|Serial serology tests on day 21, 90, 180 and 365 following the first dose of the COVID-19 vaccine to detect the temporal trend of the IgM and IgG production in response to the vaccination.
45446999|NCT03555526|Drug|metronidazole|metronidazole, 500mg, bid, for 7 days (day 8-14)
45447000|NCT03555526|Drug|Levofloxacin 500mg|levofloxacin 250mg, bid, for 7 days (day 8-14)
45447001|NCT03555526|Drug|Clarithromycin ER|clarithromycin 500mg, bid, for 7 days (day 8-14)
45447002|NCT03555526|Drug|Esomeprazole 40mg|Nexium (esomeprazole), 40mg, bid, for 10 days
45766422|NCT03097107|Drug|Saroglitazar Magnesium 1 mg|Randomly assigned patients will receive saroglitazar magnesium 1 mg orally once each morning before breakfast for 12 weeks
45766423|NCT03097107|Drug|Saroglitazar Magnesium 2 mg|Randomly assigned patients will receive saroglitazar magnesium 2 mg orally once each morning before breakfast for 12 weeks
45447003|NCT03555526|Drug|Dibismuth trioxide|Dibismuth trioxide，KCB F.C. TABLETS，300mg，qid, for 10 days
45447004|NCT03555526|Drug|metronidazole|metronidazole, 500mg, tid, for 10 days (day 1-10)
45447005|NCT03555526|Drug|tetracycline|tetracycline 500mg, qid, for 10 days
45766424|NCT03097107|Drug|Saroglitazar Magnesium 4 mg|Randomly assigned patients will receive saroglitazar magnesium 4 mg orally once each morning before breakfast for 12 weeks
45766425|NCT03097107|Drug|Placebo|Randomly assigned patients will receive placebo orally once each morning before breakfast for 12 weeks
45766426|NCT00362661|Drug|Cortisol|Cortisol 10 mg/d for 3 months
45766427|NCT04767646|Procedure|Intensive rehabilitation program with CPNB|"The patient will have an intensive rehabilitation program (two 30-minute kinesitherapy sessions every day and 30-minute occupational therapy sessions 5 days a week) with the CPNB.~The patient will have follow-up consultation at 1 month, 3 month, 6 month and 1 year after the beggining of the intensive rehabilitation program"
45766428|NCT03621345|Procedure|Erector spinae plane block|Ultrasound guided bilateral erector spinae plane block will be administered. An intravenous patient control analgesia device with morphine will be given to patients.
45766429|NCT03621345|Other|sham block|A sham block will be applied. Skin will be infiltrated with local anesthetics, and 2 mL subcutaneous saline injection will be applied.An intravenous patient control analgesia device with morphine will be given to patients.
45766430|NCT05232136|Biological|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
45624715|NCT04895397|Device|ultrasound guided Nerve Block procedure|"In group A patients, an ultrasound guided modified pectoral nerve block will be performed Under sterile conditions, US-guided PECSII block will be on the same side of surgery . The 6-13 MHz linear probe will be put transversely in the ipsilateral clavipectoral triangle - between the clavicle medially and above and the shoulder joint laterally.~the needle will be advanced in an in-plane technique targeting the space in which the artery is located. Afterward, 10 mL of bupivacaine, 0.25%, will be injected.~the needle will be advanced in-plane targeting the plane between the pectoralis minor muscle and serratus. Two mL of saline 0.9% will be injected; then, 10 mL of bupivacaine 0.25% will be injected.~Group B: In SAPB Group, a US-guided serratus block will be done The ribs will be then counted, and when the 4th rib will be identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane."
45624716|NCT04430595|Biological|4SCAR T cells|Infusion of 4SCAR-GD2, -Her2 and -CD44v6 CAR-T cells
45624717|NCT04890951|Procedure|Hysteropexy|Uterine preservation through suspension
45624718|NCT04890951|Procedure|Hysterectomy and vaginal vault suspension|Uterine removal and sewing the vagina upwards
45624719|NCT03051399|Dietary Supplement|Placebo|The participants will be asked to orally ingest one capsule per day (500 mg maltodextrin, single serving), in combination with 200mL water.
45624720|NCT03051399|Dietary Supplement|EpiCor|The participants will be asked to orally ingest one capsule per day (500 mg EpiCor, single serving), in combination with 200mL water.
45624721|NCT03052803|Device|Fractional flow reserve measure|Comparison of different devices measuring fractional flow reserve
45766431|NCT03618537|Drug|Ixazomib|Ixazomib at a fixed dose of 4mg on days 1, 8, and 15 of a 28-day cycle. Ixazomib will be given orally on days 1, 8, and 15 of a 28 day cycle.
45766432|NCT03618537|Drug|Dexamethasone|Dexamethasone 4mg-12mg will be allowed on days 1, 8, 15 if patients previously tolerated dexamethasone without issue.
45766433|NCT03410446|Drug|Ketamine Hydrochloride|Ketamine is a N-methyl-D-aspartate (NMDA) antagonist.
45766434|NCT03617445|Drug|FMT oral capsule|FMT oral capsules, single dose of 5 capsules
45766435|NCT03617445|Drug|Oral Vancomycin|Oral Vancomycin 125 mg capsules every 6 hours for 14 days, followed by 125 mg oral placebo every 12 hours for 7 days, followed by 125 mg oral placebo once daily for 7 days, followed by 125 mg oral placebo every 3 days for 14 days
45766436|NCT03617445|Drug|FMT oral placebo|Placebo oral capsules, single dose of 5 capsules
45766437|NCT03617445|Drug|Oral Vancomycin placebo|Placebo oral vancomycin capsules every 6 hours for 14 days, followed by 125 mg oral vancomycin every 12 hours for 7 days, followed by 125 mg oral vancomycin once daily for 7 days, followed by 125 mg oral vancomycin every 3 days for 14 days.
45766438|NCT00375388|Drug|Metformin on top of intensive insulin therapy|
45766439|NCT00375778|Drug|memantine (drug)|
45766440|NCT04663594|Other|WofB|Online experience designed to reduce anxiety and depression and support mental health and wellbeing
45766441|NCT04663594|Other|Ashmolean Website|A generic museum website owned by the Ashmolean Museum of Art and Archaeology at the University of Oxford.
45766442|NCT05222386|Other|Parkinson Disease Standard Care|Under usual care, community providers will deliver their usual care and center coordinators will collect data on our outcomes every 3 months. After one year of baseline data collection, eight practices will be randomized to the intervention, which will include clinician training and coaching as well as access to online services for their patients. Per the stepped-wedge design an additional eight practices will be randomized 18 months into the data collection period, and the final eight will enter the intervention 24 months into the data collection period to allow for 12 months intervention recruitment for all practices.
45447006|NCT02098798|Procedure|HD Colonoscopy|High definition colonoscopy procedure in surveillance colonoscopy
45624722|NCT04906317|Drug|midazolam and dezocine|Midazolam (0.05 mg/kg) and dezocine(5mg) sedation during colonoscopy, targeted to a painless level
45624723|NCT04906317|Drug|Propofol|standard propofol (1.5mg/kg) induction during colonoscopy, targeted to a moderate sedation level
45624724|NCT03051321|Device|Wellness toilet system|Water-based toileting with capacity to apply zinc oxide barrier spray to treat incontinence associated dermatitis
45624725|NCT04890795|Drug|AL8326 tablets|10mg/tablet;Oral administration, once daily.
45766443|NCT05222386|Other|Online Community-Supported Palliative Care|"Neurologist Teleconferences: Training and coaching in palliative care will be provided using the Extension for Community Healthcare Outcomes (ECHO) model augmented by a Community of Inquiry Framework to address a desire for greater peer connection, enhance self-efficacy, and to address potential weaknesses in the ECHO model for more complex interventions such as palliative care.~Additional support services provided to carepartners and patients will be through the Family Caregiver Alliance's CareNav platform, including tailored educational materials, support groups and social support."
45766444|NCT05195788|Behavioral|Cardiac rehabilitation|The cardiac rehabilitation program is based on 3/week exercise training's sessions including aerobic and muscle building exercises. All exercises are individualized, supervised by a certified kinesiologist at the research center, and in line with the latest recommendations for physical activity in individuals with congenital heart disease. Participants are encouraged to do a minimum of 1 supervised session per week at the research center and may, with the agreement of the cardiologist and the kinesiologist, do the other training sessions at home (hybrid program). The characteristics of the activities are recorded with a heart rate sensor. Each session lasts a maximum of 60 minutes in total and includes approximately 30 minutes of aerobic exercise, and approximately 20 minutes of muscle strengthening exercises, with 5 to 10 minutes of warm-up and cool-down.
45766445|NCT00994123|Drug|MM-121|MM-121 (SAR256212) = intravenous solution
45624726|NCT04895319|Device|Computer-assisted surgery|The reconstruction was performed with the help of virtual surgical plan and 3D printed models.
45624727|NCT03051087|Drug|Ganirelix acetate|
45766446|NCT00994123|Drug|Erlotinib|erlotinib = daily oral tablet
45766447|NCT03001726|Procedure|Gastrectomy|In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.
45766448|NCT03001726|Drug|oxaliplatin|oxaliplatin 100 mg/m2
45624728|NCT04430361|Drug|Megestrol|160 mg of megestrol acetate dispersible tablets were taken orally every morning on the day of the beginning of chemotherapy for 10 days.
45766449|NCT03001726|Drug|S1|S1 40mg/m2
45766450|NCT03001726|Drug|Docetaxel|docetaxel 40 mg/m2
45766451|NCT03595527|Diagnostic Test|HIV and HCV screening|HIV test: ARCHITECT HIV Ag/Ab Combo, Abbott HCV test: ARCHITECT Anti-HCV, Abbott
45624729|NCT04430361|Drug|5-HT3 receptor antagonist|5-HT3 receptor antagonist 2.5mg/iv
45624730|NCT04430361|Drug|dexamethasone|dexamethasone 12mg on the first day, 8mg on the 2nd-4th day,
45624731|NCT04412343|Behavioral|Virtual Group Intervention|Participants will receive weekly exercise courses delivered virtually to a group of older adults. This intervention will last for 12 weeks. Participants in addition to participating in exercise will have designated time after each exercise class to socially connect. Participants in this condition will also receive a t-shirt.
45766452|NCT04697329|Drug|Preincisional infiltration with levobupivacaine|Local, preincisional infiltration of port sites with levobupivacaine 5 mg/ml 20 ml
45766453|NCT02974413|Behavioral|self-care supported|The intervention to be performed will be based on the principles and steps of supported self-care, guided by Behavior Change Protocol (Behavior Change Protocol - BCP) and consists of an educational program with quarterly meetings, and individual at home, through home visits, and group in the Basic Health Unit (BHU), in addition to telephone monitoring in the interval between two meetings. This intervention will be applied together adult men with type 2 diabetes who are randomized in the intervention group (IG) for six months. Thus, these men will take part in three meetings, individual or group, and will receive four telephone calls in between the face meetings. Our objective is to draw with this intervention by the participant, an individual plan of self-care, based on concretras goals and supports you in the implementation of this plan, in order to improve their self-efficacy in self-care and therefore glycemic control.The study will also include a Control Group (CG).
46069618|NCT02622009|Procedure|BRONCHOSCOPIC PROCEDURE|After the routine bronchoscopic inspection of the tracheobronchial tree, the investigators performed BAL from subsegmental bronchi and bronchial biopsies (3-4 per patient) from non infiltrated carina
45447007|NCT02098798|Procedure|HD Colonoscopy + iSCAN|
45447008|NCT02098798|Procedure|HD Colonoscopy + dye spray|
45624732|NCT04412343|Behavioral|Personal Exercise Intervention|Participants will receive weekly exercise courses delivered virtually. These classes will be pre-recorded so the individual can complete sessions at any time that is convenient for them.
45624733|NCT04895163|Procedure|Laparoscopic appendectomy|Laparoscopic appendectomy performed for acute appendicitis
45624734|NCT03052881|Device|Robot assisted surgery|The PRECEYES Surgical System is a robotically assistive device developed by PRECEYES Medical Robotics, a Dutch-based research group at the Technische Universiteit Eindhoven. It has been designed to enhance surgical precision, specifically for vitreoretinal eye surgery. The device provides accuracy beyond human capabilities of <10μm in all directions (x, y, z planes). The surgeon is always in control of the instrument by manipulating the motion controller.
45624735|NCT04906083|Drug|Avatrombopag|"Avatrombopag:~PLT：30~50×10^9/L patients, 40 mg/d; PLT：<30×10^9/L patients, 60 mg/d."
45624736|NCT04906083|Drug|Standard medical treatment|Standard medical treatment included transmetil, compound glycyrrhizinate, reduced glutathione and hepatocyte growth factor, et. al.
45624737|NCT02616783|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
45624738|NCT02616783|Drug|TDF|300 mg tablet administered orally once daily
45624739|NCT02616783|Drug|FTC|200 mg capsule administered orally once daily
45624740|NCT02616783|Drug|FTC/TDF|200/300 mg tablet administered orally once daily
45624741|NCT02616783|Drug|3TC|Tablet administered orally
45653395|NCT05036577|Drug|Dexamethasone|Dexamethasone 10-15 mg, iv, d1-4, every 21 days for 6-8 cycles during combination induction treatment.
45653396|NCT04985799|Device|Gynecare TVT Exact Continence System|Participants will have placement of Gynecare TVT Exact sling.
45653397|NCT04985799|Device|Neomedic KIM (Knotless Incontinence Mesh)|Participants will have placement of retropubic Neomedic KIM (Knotless Incontinence Mesh) sling
45766454|NCT00995215|Procedure|Spinal Cord Stimulation|The participant will have wire electrodes temporarily placed - by a routine surgical procedure - over the surface of the spinal cord on the lower back. These electrodes will be activated in the operating room and the degree of muscle activation assessed. The wire electrodes will then be removed. Small, disc electrodes will then be permanently implanted to stimulate expiratory muscles and restore cough. These electrodes are activated using an external control unit.
45766455|NCT00995215|Device|Expiratory Muscle Stimulator|The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
45912664|NCT02012816|Other|Peer-referral incentive program to increase VMMC uptake|The proposed intervention will allow men coming for male circumcision in randomly selected intervention clinics to refer up to 5 uncircumcised men in their social network and receive a monetary reward for each referred man who undergoes male circumcision. Men who come for circumcision will each be given 5 referral vouchers that they can then provide to uncircumcised men in their social network who may be interested in undergoing VMMC. If these uncircumcised men come to the CIDRZ VMMC clinics and undergo the circumcision procedure, they can present the referral voucher to clinic staff who will then retain the voucher until the man who made the referral comes to collect his incentive payment.
45912665|NCT02012829|Behavioral|GPs communication skills and CRC screening|GPs of the intervention group received a four hours educational training focused on patients' centered care to improve GPs communication skills and enhance patients'participation in CRC mass screening . Triangulation of all qualitative data was performed in order to develop educational material and training based on the six components of the Patient-Centered Clinical Method . Two different scenarios were developed: one for a compliant patient, another for a non-compliant patient. Two videos were made with doctor and simulated patient. Interactive methods were used to elaborate educational training including role playing, the presentation of the video followed by an interactive discussion.
45912666|NCT02012842|Other|Non surgical periodontal treatment|Treatment of gingivitis: excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth, supragingival calculus removal. Oral hygiene instruction, training and motivation will be given at each appointment. Treatment of periodontitis: subgingival scaling and root planing under local anesthesia.
45912667|NCT02012855|Behavioral|Exercise|
45912668|NCT02012855|Other|Diet (meal type)|
45912669|NCT02012868|Procedure|bariatric surgery|
45912670|NCT02012881|Behavioral|Physical activity intervention|Physical activity during recess, in academic subjects, active transportation and PA home work
45912671|NCT02012881|Behavioral|Usual practice|Normal curriculum
45447009|NCT03555760|Behavioral|Observation of informed consent form readings of all patients who are scheduled for surgery|All patients who are scheduled for surgery will be observed for their initial reflex of inform consent form readings.
45447010|NCT02102620|Drug|Intra-articular injection with corticosteroid|After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
45447011|NCT02102620|Drug|Intra-articular injection with lidocaine|After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
45624742|NCT02616783|Drug|Third agent|"Third agent may include one of the following regimens: lopinavir+ritonavir (LPV/r; Kaletra®), atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®), ATV + cobicistat (COBI;Tybost®) (or ATV/COBI FDC), DRV + RTV, darunavir (DRV; Prezista®) + COBI (or DRV/COBI FDC), fosamprenavir (FPV; Lexiva®) + RTV , saquinavir (SQV; Invirase®; Fortovase®) + RTV, efavirenz (EFV;Sustiva®), rilpivirine (RPV;Edurant®), nevirapine (NVP;Viramune®), etravirine (ETR;Intelence®), raltegravir (RAL; Isentress®), elvitegravir (EVG) + COBI, or dolutegravir (DTG;Tivicay®)~Drug classes:~Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV, and SQV~Pharmacokinetic enhancer: COBI~Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~Integrase inhibitors: RAL and DTG"
45653398|NCT04982367|Device|Sirolimus-eluting balloon catheter|Sirolimus-eluting balloon catheter designed and produced by Acotec
45912672|NCT02012920|Drug|Seviteronel: given orally once daily in 28 day cycles|
45912673|NCT02012933|Drug|3,4-diaminopyridine|10mg tablets for up to 100mg per day
45912674|NCT02012946|Drug|Levosimendan|patient receiving levosimendan
45912675|NCT02012946|Drug|Dobutamine|patient receiving dobutamine
45912676|NCT02012972|Behavioral|Referral for NCD care|Subjects in the NCD Risks group not already receiving care for the condition will be referred to a primary health clinic for care.
45912677|NCT02012985|Biological|Oxabact OC5 capsules|The dose will be not less than (NLT) 1E+09 colony forming units (CFU) twice daily for 8 to 10 weeks. The dose (an enteric-coated size 4 capsule) will be administered orally with breakfast and dinner.
45912678|NCT02012985|Drug|Placebo capsules|An enteric-coated placebo capsule manufactured to mimic the OC5 capsule. The capsule will be administered orally with breakfast and dinner twice daily for 8 to 10 weeks.
45912679|NCT02012998|Biological|HBVAXPRO 5µg|0.5mL intramuscular injection
45912680|NCT02013011|Procedure|recruitment maneuver(RM) and positive end expiratory pressure(PEEP) or PEEP only|application of recruitment maneuver(RM) and positive end expiratory pressure(PEEP) in RM and PEEP group and application of only PEEP in PEEP group
45912681|NCT02013024|Other|cryopreservation technique|
45912682|NCT02013102|Drug|Decitabine Injection|Decitabine Injection 20mg/m2/d*5d, IV> 1h, one cycles per 4 weeks; Decitabine Injection 12mg/m2/d*8d, IV> 1h, one cycles per 4 weeks.
45912683|NCT02013115|Drug|Budesonide|Experimental: Cursurf and Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation
45624743|NCT04906005|Drug|gadopiclenol|administration by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a saline flush of at least 5 mL at the same rate to ensure complete injection of the contrast agent.The gadopiclenol administration is performed by power injecto
45624744|NCT04906005|Drug|Placebo|intravenous (IV) bolus injection at 2 mL/s, followed by a saline flush of at least 5 mL to be in the same conditions as for gadopiclenol administration.The gadopiclenol administration is performed by power injector
45624745|NCT04895007|Biological|Covid-19 Inactive Vaccine, recombinant human adenovirus serotype number 26, mRNA VAccine|Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody will be evaluated 2, 6, 12 Months after second dose.
45624746|NCT04890561|Drug|Lemborexant|Lemborexant oral tablets.
45624747|NCT04890405|Procedure|Standardized FMT|The group includes 35 patients. They will receive standardized FMT. Fecal bacteria capsules are used for fecal bacteria transplantation, 16 capsules are used each time, each capsule contains 200mg of fecal bacteria, and it is used orally. It was given only once.
45624748|NCT04890405|Combination Product|Precision Flora Transplantation|The group includes 35 patients. They will receive Precision Flora Transplantation. They were used self-developed precision transplant capsules for precision flora transplantation. 4 capsules are used each time. Each capsule contains 400mg of various probiotics effective against diarrhea. It is used orally, once a day,for 28 days.
45624749|NCT04894851|Behavioral|Contingency Management|Participants in the current study will receive contingencies for improvement in clutter, as measured by a trained, independent in-home rater. Ratings will be completed by after study consent, and once every month thereafter, being conducted at weeks 0, 4, 8, 12, and 16 of treatment. Participants will be reimbursed for each new 1-point reduction in CIR score, a set dollar amount per month for each CIR point reduction they maintain from baseline. Therefore, a perfectly performing patient would earn reimbursement (A CIR reduction of 8 points made in the first month and maintained throughout treatment. If a CIR score is higher than the prior month, the reinforcement schedule will reset to zero.
45624750|NCT04894539|Device|DS5 electrical stimulator|TENS
45624751|NCT04894617|Drug|Amantadine|200 mg Amantadine daily for a total of 5 days.
45624752|NCT04894617|Drug|Lactose monohydrate|Lactose monohydrate two tablet daily for a total of 5 days.
45624753|NCT04894695|Diagnostic Test|biomarkers detection in different groups|Biomarkers of urine exosomes in different groups were identified by sequencing technology，then biomarkers were validated using urine samples of different groups
45624754|NCT04398537|Device|5mm retraction of clip deployment apparatus.|Advancing the clip to the biopsy site and retracting 5 mm and then deploying. This is one method of standard of care and involves depositing the clip after retraction of the deployment apparatus 5 mm.
45624755|NCT04398537|Device|No retraction of clip deployment apparatus.|This is one method of standard of care and the clip will be deployed at the biopsy site.
45624756|NCT04397991|Other|Furosemide|Patients will receive nebulised furosemide solution 1 mg/kg
45624757|NCT04397991|Other|Placebo|Patients will receive nebulised 0.9% saline
45624758|NCT04890171|Procedure|Endoscopic submucosal dissection|Endoscopic submucosal dissection by a endoscopist using endoscopic devices
45624759|NCT04890171|Procedure|Surgery|Gastrectomy with lymph node dissection by a surgeon
45624760|NCT04906161|Diagnostic Test|Vitamin D and calcium levels|Mini VIDAS® compact multiparametric immunoanalyzer for vitamin D analysis (BIOMERIEUX- France)
45624761|NCT04885023|Other|Hippotherapy|The hippotherapy program for 10 weeks
45624762|NCT04884633|Procedure|Pancreatic islet transplantation|New method of pancreatic islet transplantation into the omentum using a biodegradable scaffold
45912684|NCT02013154|Drug|DKN-01|Administered by IV infusion
45624763|NCT04890015|Procedure|Intraoperative transanal decompression tube placement|Intraoperatively under direct vision in the lower rectum, the balloon of the catheter will be inflated with 5-10cc of distilled water and it will be secured with a dressing / tape to the buttock connected to a collection bag.
45624764|NCT04393623|Behavioral|Cognitive Reappraisal|This cognitive reappraisal microintervention lasts 45-60 minutes.
45624765|NCT04393623|Behavioral|Psychoeducation|This psychoeducational microintervention lasts 45-60 minutes.
45624766|NCT03051009|Drug|Desmopressin ODT 25 μg|
45624767|NCT03051009|Drug|Desmopressin ODT 50 μg|
45766456|NCT03577431|Biological|arTreg-CSB|"Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 125 x 10^6 total cells. If a minimum arTreg-CSB dose of 1 to < 2.5 x 10^6 cells, the product will be infused. If the dose obtained after product manufacture is < 1 x 10^6 cells, the product will not be infused. When the dose obtained after product manufacture is > 125 x 10^6 cells, a dose aliquot will be prepared so that the administered dose will be ≤ 125 x 10^6 cells, and ≥ 2.5 to 125 x 10^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 15 to 30 minutes."
45912685|NCT02013154|Drug|Paclitaxel|Administered by IV infusion
45912686|NCT02013154|Drug|Pembrolizumab|Administered by IV infusion
45624768|NCT04884711|Other|No Interventions. Participants will be using their everyday digital health technologies.|The investigators will be involving older people to understand the barriers & facilitators of digital health technology adoption for homebound older people. In this process no interventions will be given by us.
45624769|NCT04884711|Other|In depth Interviews|In-depth interviews will be conducted to gather lived experiences of homebound older people.
45624770|NCT04884711|Other|Focus Group Discussions|Focus Group Discussions will be used to create avenues to enhance dignity and human perspectives in digital designs for older people.
45624771|NCT04889781|Drug|Dexamethasone injection|Compare the effect of dexamethasone injection on reducing post-op pain after impacted third molar Surgery
45624772|NCT04889781|Procedure|Piezosurgery|Compare the effect of Piezosurgery device use on reducing post-op pain after impacted third molar Surgery
45624773|NCT04889781|Procedure|Conventional Rotatory instruments|Surgical extraction using conventional rotatory instruments to perform osteotomy
45624774|NCT04884555|Other|Standard neurorehabilitation|Routine post-stroke rehabilitation
45624775|NCT04884555|Diagnostic Test|Thiol-Disulphide Homeostasis|Monitoring the levels of thiol and disulphide in serum
45766457|NCT03577431|Procedure|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure 72 to 120 hours prior to Treg product (arTreg-CSB) IV infusion."
45766458|NCT03577431|Drug|cyclophosphamide|40 mg/kg administered intravenously (IV) within 24 to 72 hours prior to Treg product (arTreg-CSB) infusion.
45766459|NCT03577431|Drug|mesna|Mesna is administered intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide. Administration of mesna is per institutional practice with cyclophosphamide.
45766460|NCT03577431|Drug|everolimus|"EVR, an immunosuppressant (IS), is approved by the FDA for the prophylaxis of allograft rejection in adults receiving a liver transplant. Between day 30 and wk. 48 post-transplant, participant evaluation for eligibility to be converted to an EVR-based IS regimen will occur.~At the start of conversion from tacrolimus (TAC) to EVR IS:EVR will be started at 1.5 mg taken by mouth BID, with dose adjusted to achieve a trough blood level of 5-8 ng/mL. Once an EVR trough level of ≥ 5 ng/mL is achieved, baseline TAC dose will be reduced to achieve a trough level of 3-5 ng/mL.~When target EVR and TAC levels are achieved/ maintained over two consecutive measurements, and liver function tests, ALT and GGT, are ≤50 U/L, participants will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered, monitored and adjusted over time, per protocol."
45766461|NCT04647136|Diagnostic Test|Fertility Health Screening|Basic fertility health screening comprising an anti-Mullerian hormone (AMH) test and semen analysis, a doctor's consultation to explain the results, and standardised reproductive counselling by a trained nurse comprising a discussion of reproductive plans (including addressing barriers the couple face), education on age-related fertility decline and limitations of artificial reproductive technologies, advice on the optimal reproductive timing and when to seek further help. An educational brochure will be handed to the couple during the counselling session.
45766462|NCT04647136|Behavioral|Fertility Awareness Tools|Online intervention consisting of 1) video targeting fertility education and specific attitudes, social norms and perceived control for having children, 2) a fertility awareness tool (FERTISTAT) and 3) an educational brochure on fertility. This intervention can be self-administered and is therefore easily scalable.
45766463|NCT04581031|Device|Continuous vital sign monitoring - Isansys Patient Status Engine|CE marked wearable continuous vital signs monitors
45766464|NCT04581031|Other|Machine Learning/AI Algorithm|Patient data will be subjected to machine learning/AI algorithms to determine whether algorithms may be beneficial as an early indication of patient's condition worsening.
45766465|NCT03078543|Device|ANTHEM™ PS Total Knee System implant|"The ANTHEM™ PS Total Knee System is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties. The ANTHEM™ PS Total Knee System consists of the following components:~Cobalt-Chrome (Co-Cr) femoral components - Posterior stabilised~Titanium primary tibial components~Posterior-stabilised ultra-high molecular weight polyethylene (UHMWPE)~Polyethylene patella components The resulting product is sufficient to accommodate a wide range of clinical applications."
45766466|NCT04646746|Dietary Supplement|100% wheat|100 g of bread backed with 100% wheat
45766467|NCT04646746|Dietary Supplement|50% nude barley and 50% wheat|100 g of bread backed with 50% nude barley and 50% wheat
45766468|NCT04646746|Dietary Supplement|75% nude barley and 25% wheat|100 g of bread backed with 75% of nude barley and 25% wheat
45766469|NCT04646746|Dietary Supplement|50% gene-modified high-amylose barley and 50% wheat|100 g of bread backed with 50% gene-modified high-amylose barley and 50% wheat
45766470|NCT04444843|Drug|Mycophenolate Mofetil Capsules|Patients who received MMF+TAC+ Corticosteroids immunosuppressive regimen as first choice post transplantation
45766471|NCT04341987|Behavioral|brief Imagery Rehearsal Therapy|Two-sessions of behaviorally-based imagery rehearsal therapy.
45766472|NCT04341987|Other|Treatment As Usual|may include medication treatment or behavioral treatment for nightmares other than imagery rehearsal therapy
45766473|NCT04395937|Other|exercises|One hour twice a week to practice respiratory exercises, postural exercises, muscular exercises
45766474|NCT01022359|Device|TesioCath|Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access
45766475|NCT01022359|Device|LifeCath Twin|Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access
45766476|NCT00635804|Drug|MK-3281|MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)
45766477|NCT00635804|Drug|Placebo to MK-3281|Dose-matched placebo to MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose of MK-3281 in serial panel. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
45766478|NCT04353193|Drug|Terlipressin|Terlipressin 1mg IV bolus
45766479|NCT04353193|Drug|Terlipressin|Terlipressin by IV continuous infusion at a rate of 2mg/day (max 4mg/day) during 2 hours
45766480|NCT04353193|Drug|Octreotide|Octreotide 50mcg IV bolus plus continuous infusion at a rate of 50mcg/h during 2 hours
45766481|NCT04583644|Device|Fetoscopic Endoluminal Tracheal Occlusion Surgery|"Fetoscopic Endoluminal Tracheal Occlusion (FETO) surgery will be completed at 27 weeks 0 days - 29 weeks 6 days gestation.~Fetoscopic removal of the balloon occlusion will be performed at 34 weeks 0 days to 34 weeks 6 days gestation."
45766482|NCT01023841|Drug|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
45766483|NCT01023841|Drug|Vehicle Sterile Solution|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
45912687|NCT02013193|Device|Ranger DCB|After successful pre-dilatation the index lesion is treated with one or two Ranger DCB devices that completely cover the lesion. If two devices are deployed, overlap shall be minimal.
45912688|NCT02013193|Device|uncoated PTA balloon|The index lesion is treated with one or more uncoated standard PTA balloons that completely cover the lesion.
45912689|NCT02013219|Drug|Alectinib|Participants will receive 600 mg PO alectinib BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter (21-day cycles from Cycle 2 onwards) in Stage 1 and RP2D PO BID in Stage 2.
45766484|NCT00635648|Drug|caspofungin acetate|Intravenous (IV) caspofungin acetate 50 mg/day. Participants with esophageal candidiasis will be treated for at least 7 days and for at least 72 hours after symptoms resolve for a maximum of 28 days; participants with invasive candidiasis will have a 70 mg loading dose on study day 1 and will be treated for at least 14 days after the last positive culture of Candida from the blood or other normally sterile body site for a maximum of 60 days; these participants should also have improvement in clinical and radiographic signs of disease for at least 48 hours before completion of the study therapy.
45766485|NCT04346563|Other|Kinesio tape, functional correction technique|According to Kinesio Taping, functional correction technique could use for correcting shoulder, scapular alignment and decrease pain.
45447012|NCT02099032|Other|3g milk polar lipid fortified cheese consumption|Women will have to consume daily 100g of a 3g milk polar lipid fortified cheese product instead of usual cheese products during four weeks.
45624776|NCT04884555|Diagnostic Test|Oxidized-reduced Glutathione Homeostasis|Monitoring the levels of intracellular oxidized glutathione and reduced glutathione in whole blood samples
45766486|NCT04346563|Other|Elastic band strengthening shoulder exercise|"The exercise in which both groups will receive Introduction of exercise with rubber bands (Elastic band) It is a home exercise (Home base exercise program) for patients to do with appropriate resistance. Which can be done at least 10 times and not more than 20 times continuously,will be asked to do all 3 positions.~1) Shoulder external rotation in shoulder abduction 90 degrees 2) Shoulder horizontal abduction in shoulder abduction 90 degrees 3) Seated bend row, which will be done 15 times, each hold for 10 seconds, do 3 sets, each set rest 2 minutes, 2 times a day ( Morning-evening) consecutively for 1 week"
45766487|NCT05052580|Other|COVID-19 Testing|Participants who consent to participate in this study will be tested at days 1, 3, 5, and 7 following a known COVID-19 exposure on day 0. If the COVID-19 tests are negative, the participant will remain in the school environment. A positive COVID-19 test or the development of symptoms on any day after exposure would require isolation according to school, local and state guidelines.
45624777|NCT04884321|Other|Complementary And Alternative Medicine|No intervention was done in the cross-sectional study
45624778|NCT03052491|Dietary Supplement|Stem Cell 100+|Open-Label 10-Component Dietary Supplement
45624779|NCT04889391|Drug|[14C]-Danicopan|Liquid-filled capsules.
45624780|NCT04884009|Drug|SHR-1701； Famitinib|SHR-1701+ Famitinib
45624781|NCT04884009|Drug|SHR-1701|SHR-1701
45766488|NCT05240768|Diagnostic Test|Fractional flow reserve, instantaneous wave-free Ratio|Clinical outcomes observed for patients with moderate coronary lesions in whom coronary revascularization was deferred due to a negative physiologic study.
45766489|NCT02619838|Device|Aptus CCS 5.0 or/and 7.0 screws|Fusion of the talonavicular joint, the subtalar joint, and the calcaneal-cuboid joint with a Aptus CCS screws. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
45766490|NCT05240690|Biological|Umbilical Cord Blood Derived MAK Immune Cells|Intravenous drip
45766491|NCT05020990|Device|Lens A (Test)|Test toric lens
45766492|NCT05020990|Device|Lens B (control)|Control toric lens
45447013|NCT02099032|Other|5g milk polar lipid fortified cheese consumption|Women will have to consume daily 100g of a 5 g milk polar lipid fortified cheese product instead of usual cheese products during four weeks.
45447014|NCT02099032|Other|Unfortified cheese product consumption|Women will have to consume daily 100g of a unfortified cheese product instead of usual cheese products during four weeks
45447015|NCT02097940|Other|proprioceptive exercises|Exercises with movements, jumping and imbalance.
45624782|NCT04883853|Procedure|Mild _moderate Ptosis tucking|A modified levator muscle tucking procedure.The level of sutures was determined according to the levator muscle function and the desired eyelid height. The middle (main) suture was taken first at the level of the medial part of the pupil and was tightened to keep the lid height at the superior limbus and the other two sutures (medial and lateral) were then adjusted. A spindle-shaped, horizontal part of the levator aponeurosis (2.5-3 mm wide and 0.5 mm deep) was excised at the site of insertion into the tarsus before tightening the central suture to induce strong fibrosis and adhesion between the tucked levator aponeurosis and the tarsus
45624783|NCT04883697|Other|vitrectomy with ILM peeling and ILM flap technique|outcomes after vitrectomy with ILM peeling and ILM flap technique for macukar hole repair are assessed
45624784|NCT04889235|Procedure|Major liver resection|All patients undergo Major hepatic resection, differences between sarcopenia and no-sarcopenia groups will be observed
45624785|NCT02616393|Drug|Tesevatinib|
45624786|NCT04905147|Drug|Mosapride|Mosapride citrate is prokinetic drug that selectively activates 5-HT4receptors. Mosapride stimulates serotonin receptor in the digestive tract and increases acetylcholine release to promote upper digestive tract (stomach and duodenum) and lower digestive tract (colon) motility and gastric emptying without cardiac side effects
45624787|NCT04905147|Drug|Placebo|Placebo drug 15 mg
45624788|NCT04888689|Device|Actimyo°|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
45624789|NCT04888689|Device|IMU|"IMU is a portable system of miniaturized inertial sensors for objective, instrumental, ambulatory, and validated analysis of normal and pathological human gait. Each miniaturized inertial sensor (2 cm × 0.7 cm × 0.5 cm) includes a triaxial accelerometer and a triaxial gyroscope.~These four inertial sensors are connected to a box by wires and are numbered 1 to 4. They must be attached - using adhesive tapes - on the participant's shoes."
45653399|NCT04982367|Device|Paclitaxel-eluting balloon catheter|Paclitaxel-eluting balloon catheter (trade name:DHALIA)
45653400|NCT05034627|Procedure|Biopsy|Undergo biopsy
45653401|NCT05034627|Drug|Calaspargase Pegol-mknl|Given IV
45766493|NCT00995449|Biological|KB003|KB003 IV x5 doses
45766494|NCT00995449|Other|Placebo Comparator|Placebo IV x5 doses
45766495|NCT05240456|Drug|Beta3-Agonists, Adrenergic|The beta 3 agonist ,Mirabegron, has been shown to be effective for the treatment of OAB in adults through relaxation of bladder wall, with few side effects. This intervention aims to evaluate its efficacy and safety for children with non-neurogenic voiding dysfunction.
45653402|NCT05034627|Drug|Cobimetinib|Given PO
45766496|NCT05240456|Drug|Anticholinergic drug, Solifenacin|Anticholinergic drugs are widely used to treat overactive bladder by relaxation of bladder wall smooth muscles.
45766497|NCT03574779|Drug|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
45766498|NCT03574779|Biological|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to Programmed cell death protein 1 (PD-1) resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
45766499|NCT03574779|Biological|Bevacizumab|Bevacizumab is an Food Drug and Administration (FDA) approved antiangiogenic recombinant humanized monoclonal Immunoglobulin (Ig) G1 antibody against the vascular endothelial growth factor protein, which has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma.
45766500|NCT03574779|Drug|Carboplatin|Carboplatin will be infused intravenously over 60 minutes at the prescribed dose of area under the concentration versus time curve of 5 to 6 mg/milliliters (mL) per minute on Day 1 of every 21-day cycle
45766501|NCT03574779|Drug|Paclitaxel|Paclitaxel will be administered intravenously over 180 minutes at the prescribed dose of 175 mg/meter square (m^2) on Day 1 of every 21-day cycle
45766502|NCT05001568|Device|Immediate in-brace correction: Conventional Brace|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic (supine position) and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
45766503|NCT05001568|Device|Immediate in-brace correction: Optimized Brace|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic (supine position) and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
45766504|NCT05001568|Device|Long-term bracing: Conventional Brace|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
45766505|NCT05001568|Device|Long-term bracing: Optimized Brace|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
45766506|NCT01922570|Dietary Supplement|nutrition|comparion of enteral versus enteral and supplemental parenteral nutrition
45766507|NCT04341883|Drug|anti-PD-1+Albumin-Bound Paclitaxel|"anti-PD-1: 200mg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and anti-PD-1 for up to 2 years.~Other Name: Programmed cell death 1 antibody"
45766508|NCT05240300|Biological|BX005-A|phage gel
45766509|NCT05240300|Other|Placebo|vehicle gel
45766510|NCT00995761|Drug|Docetaxel and Cisplatin|splitted administration of docetaxel and cisplatin.
45766511|NCT00375700|Dietary Supplement|Nutritional Supplement|
45766512|NCT00362271|Drug|Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.|Tablets, Oral, Venlafaxine: 75 mg; Aripiprazole: 10, 15, 20 mg once daily, 14 days.
45766513|NCT00635102|Drug|D-Cycloserine PO and Glycine IV|Test days will involve administration of D-Cycloserine in the morning in pill form then 4 hours later a 30 minute infusion of Glycine.
45766514|NCT00635102|Drug|Placebo D-Cycloserine PO and placebo Glycine IV|Placebo
45766515|NCT00635102|Drug|Placebo D-Cycloserine PO and Glycine IV|
45766516|NCT00635102|Drug|D-Cycloserine PO and placebo Glycine IV|
45766517|NCT04736212|Device|Bed sensor monitoring system|Respiratory patterns in the post-anesthesia care unit will be assessed using a validated, modified under bed weighing scale placed under the patient's bed in the PACU.
45766518|NCT00996775|Behavioral|brief alcohol intervention|this intervention consists of brief assessment and feedback
45912690|NCT02013219|Drug|Atezolizumab|Participants will receive 1200 mg atezolizumab IV infusion q3w on Day 8 of Cycle 1 and on Day 1 of each cycle thereafter in Stage 1 and in Stage 2.
45912691|NCT02013219|Drug|Erlotinib|Participants will receive 150 mg erlotinib PO QD for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter in Stage 1 (21-day cycles from Cycle 2 onwards) and RP2D PO QD in Stage 2.
45912692|NCT02013232|Drug|Aripiprazole|
45452411|NCT05258240|Other|Virtual Reality|Virtual reality workout enhances balance control, self-reported balance and mental stability in healthy and stable adults. Sensory-based exercise and the response to visual acuity can increase the patient's ability to maintain their body in a stable position.
45653403|NCT05033145|Drug|AZVUDINE|AZVUDINE 5 tablets QD + standard treatment, for up to 14 days
45653404|NCT05033145|Drug|AZVUDINE placebo|5 tablets QD + standard treatment, for up to 14 days
45653405|NCT05031975|Drug|Irinotecan|Irinotecan 100 mg/smq intravenous infusion every 14 days
45653406|NCT05031975|Drug|Temozolomide|Oral temozolomide 150 mg/sqm over days 1-5 every 28 days.
45766519|NCT00996775|Behavioral|standard care|education about harmful effects of alcohol use and NIAAA recommended drinking limits
45766520|NCT03041883|Procedure|Crosslinking with riboflavin of the corneal graft-support|Corneal graft support for the KPro will be crosslinked and used with the standard surgical technique
45766521|NCT03041883|Procedure|De-epithelisation of the corneal graft support with instillation of riboflavin|Corneal graft-support will be de-epithelialized and soaked with riboflavin and then used with the standard surgical technique
45766522|NCT04332718|Device|Smartphone ECG|Patients who are randomised to the 30-day smartphone ECG monitoring will be contacted within one month from randomisation. Patients will be taught on how to use the smartphone ECG monitoring. Patients are required to monitor their ECG 3 times a day for 30 days. Patients will be contacted during the monitoring period to assess for compliance and to ensure that the recording is done correctly.
45766523|NCT03554265|Drug|Somatropin|Genotropin given by injection
45766524|NCT03034005|Drug|Budesonide|1600 ug inhaled daily for 6 weeks
45766525|NCT04296916|Drug|IOP lowering eye drops|"Latanoprost 0.005% eye drops will be the first choice. If an IOP reduction of 20% is not achieved within three months, timolol 0.5% will be added as second medication. If an IOP reduction of 20% is then not achieved, alphagan 0.2% or alphagan-P 0.15% will be added. If an IOP reduction of 20% is then not achieved, the individual will be excluded from the study.~If necessary, latanoprost will be switched to other prostaglandin eye drops, alphagan (or alphagan-P) will be switched to brinzolamide 1% eye drops.~If necessary, latanoprost and timolol will be switched to Xalacom eye drops, timolol and alphagan will be switched to Combigan eye drops, timolol and brinzolamide will be switched to Azarga eye drops.~Once daily in the evening for prostaglandin eye drops, and twice daily for other eye drops."
45766526|NCT00635024|Biological|anti-thymocyte globulin|2.5 mg/kg
45624790|NCT04904991|Procedure|Chan-Chuang qigong|"This study applied the Chan-Chuang qigong program, which was a modified form of the manual of Chan-Chuang qigong (Yeh et al., 2006), to tailor to patients with cognitive impairment. The Chan-Chuang qigong program included warmup prior to qigong practice, preparation for qigong practice, core qigong of four moves, and cool down after qigong practice.~The movements should be repeated and maintained for 10 minutes per time, 3 time a day (Yeh et al., 2006), totally 90 minutes per week, for 3 months. The guideline booklet of Chan-Chuang qigong (Chen et al., 2019; Chuang, Yeh, & Chung, 2017) was modified and provided to the participants, which had major sections of introduction to qigong, preparation and precautions, practical procedures with description and photos, normal physical reactions from practicing core Chan-Chuang qigong, precautions of daily life, a confirmation sheet, and a checklist of qigong performance."
45766527|NCT00635024|Drug|melphalan|16 mg/m^2
45766528|NCT03544359|Device|Transcranial electrical stimulation (tES)|"In tES, a mild electrical current is passed between two or more electrodes placed on the volunteer's head (scalp). In this study, a mild unvarying (constant) electrical 2mA current is passed between two rubber electrodes placed on the head over auditory cortex for 20 minutes per session for 5 consecutive days. Because the electrical current direction (positive/negative) and current amplitude (2mA) does not vary or change during stimulation, this type of tES is also called transcranial direct current stimulation, or tDCS."
45766529|NCT01922648|Procedure|Blood sample|An extra volume of blood is obtained, with prior consent, when phlebotomy is required for another unrelated clinical reason.
45912693|NCT02013258|Drug|Intranasal oxytocin|This is a double-blind placebo controlled 2x2 study. Subjects will receive OT for 5 consecutive days during their 7 day stay. This will be followed by a wash out period of 4-6 weeks.
45912694|NCT02013258|Other|Placebo|This is a double-blind placebo controlled 2x2 study. Placebo will be given via intranasal spray, one spray in each nostril daily x 5 days. One month interval between arms of treatment.
45912695|NCT02013271|Device|Lutonix Paclitaxel Drug Coated Balloon (DCB)|Patients exposed to the DCB as part of their routine care.
45766530|NCT04243798|Device|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro x100 TMS system (MagVenture, Denmark)."
45766531|NCT04243798|Device|Sham TBS-DLPFC|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
45766532|NCT02975193|Behavioral|Computer task assessing cognition|Participants will complete a short computer game to assess cognition.
45766533|NCT02975193|Behavioral|Impulsive-Compulsive Disorders in Parkinson's Disease|Standard clinical questionnaire
45766534|NCT02975193|Procedure|Deep Brain Stimulation Surgery|DBS surgery for the implantation of electrodes for the treatment of motor disorders.
45766535|NCT04865458|Drug|HEC89736|HEC89736 tablets QD every 28 days for each cycle
45766536|NCT03005379|Drug|Fecal Microbiota Therapy (FMT)|Oral capsule-delivered FMT
45766537|NCT03005379|Drug|Placebo|Oral capsule-delivered placebo
45766538|NCT03182920|Drug|Lasmiditan|Oral administration
45766539|NCT03182920|Drug|Placebo|Oral administration
45766540|NCT05406388|Procedure|Erector Spinae Plane Block|Intravenous fentanyl patient control device 48-hour fentanyl consumption will be recorded.
45766541|NCT05406388|Procedure|Intravenous fentanyl patient control device|Intravenous fentanyl patient control device 48-hour fentanyl consumption will be recorded.
45766542|NCT03514173|Device|Remote Patient Monitoring|Use of remote patient monitoring
45766543|NCT03485547|Drug|Venetoclax|VENCLEXTA targets BCL-2 in order to help restore the process of apoptosis. Through apoptosis, your body allows cancer cells and normal cells to self-destruct
45766544|NCT03185182|Drug|Ioflupane I123|"185 MBq ioflupane I123 will be administered at one single occasion to the study subjects A one time dose of DaTSCAN is given via intravenous injection of 185 MBq Ioflupane (I123) .~The patient takes potassium iodine tablets prior to the DatSCAN injection to protect the thyroid gland. At the time of the DaTSCAN examination, the patient is injected intravenously at slow rate with 185MBq DaTSCAN solution."
45766545|NCT02992275|Other|Neuromuscular electrical stimulation (NMES)|Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 24 weeks
45766546|NCT02992275|Other|Multi-Modality Balance Intervention (MMBI)|Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 24 weeks
45766547|NCT04089280|Dietary Supplement|Sanprobi Barrier-multispecies probiotic|"Multi-strain probiotic Sanprobi Barrier (Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus lactis W19, Lactobacillus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidum W23, Lactobacillus salivarius W24) or placebo. Patients will be randomized to one of the two products (A or B) each containing probiotic/placebo and administered for 12 weeks. After 12 weeks of supplementation, the probiotic/placebo product A or B will be discontinued and reintroduced again after next 4 weeks - patients will be switched to the other A or B group of probiotic/placebo arm. Patients will be administered with 4 capsules per day for 24 weeks (12 weeks for group A probiotic/placebo and 12 weeks for group B probiotic/placebo allowing 4 weeks washout between the group assignment)."
45766548|NCT04089280|Other|Placebo Comparator|Carrier material of Sanprobi Barrier-multispecies probiotic product, not containing bacterial strains,similar appearance as the probiotic
45766549|NCT04744701|Diagnostic Test|Hemochron Signature Elite Whole Blood Microcoagulation System|Bedside test of Activated Partial Thromboplastin Time
45766550|NCT03187678|Drug|i.v. selexipag|Selexipag for intravenous administration, twice daily as an infusion over 87 min. The dose is individualized for each subject to correspond to his/her current oral dose of Uptravi®.
45766551|NCT03187678|Drug|oral selexipag (Uptravi)|Uptravi is used as an auxiliary medicinal product, as part of the PAH standard treatment and administered according to the local prescribing information
45766552|NCT02942355|Drug|anastrozole|Anastrozole by mouth daily
45766553|NCT02942355|Drug|Palbociclib|Palbociclib by mouth daily days 1-21 every 28 days
45766554|NCT03192826|Drug|Brinzolamide/Brimonidine FC|1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy
45766555|NCT03192826|Drug|Brimonidine 0.2%|1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy
45766556|NCT03192826|Drug|Artificial tears|1 drop of artificial tears 1 hour before Nd-YAG capsulotomy
45766557|NCT02940171|Procedure|Early Excision of full thickness burn|first excision surgery of full -thickness burn performed within 48 hours from burn injury
45766558|NCT02940171|Procedure|Late Excision of full thickness burn|first excision surgery of full -thickness burn performed after 48 hours from burn injury
45766559|NCT03285724|Device|Harpoon Artificial ePTFE Chords|The Harpoon Medical Transapical device is intended to be used to reduce the degree of degenerative mitral regurgitation by delivering and anchoring one or more ePTFE cords to the affected mitral valve leaflet(s) via a small left thoracotomy on the beating heart in patients with anterior, bi-leaflet or posterior prolapse.
45912696|NCT02013323|Drug|Scaling and root planing, and Septilin for 7 days|Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing and checked for clinical and micrbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months.
45447018|NCT03555214|Other|Manual Therapy based on soft tissues|"Manual Therapy:~Technique of suboccipital inhibition.~Cranial frontal technique.~Cranial sphenoid technique.~Cranial fourth ventricle technique.~Antero-posterior abdominal-sacral technique."
45624791|NCT04883151|Behavioral|SOFUS pilot program|"The SOFUS pilot program consists of six pre-loss sessions (Program 1) and a further six post-loss sessions (Program 2), which are delivered over a 3-month period. Each session ranges from 1-1.5 hours. Sessions 1 and 6 includes the whole family, sessions 2 and 3 focus on the parents, while sessions 4 and 5 target the children (with parents if the child is <10 years old).~SOFUS consists of three primary components: i) strengthening COMMUNICATION between parents and children, ii) NORMALIZATION of grief processes (pre and post-lost), and iii) EMOTION REGULATION strategies targeting motivational awareness and regulatory skills in grief management (pre and post-lost).~Families in Program 1 may be offered Program 2 if the child dies before the entire program has been delivered."
45624792|NCT04883307|Behavioral|Coaching|Professional development coaching based on a curriculum of positive psychology principles and coaching principles.
45766560|NCT03287674|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
45766561|NCT03287674|Drug|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
45766562|NCT03287674|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
45766563|NCT03287674|Drug|Interleukin-2|Interleukin-2 is administered as a daily low-dose subcutaneous injection of 2 MIU for a total of 14 days.
45766564|NCT03287674|Drug|Ipilimumab|One dose of Ipilimumab 3 mg/kg is administered 14 days prior to surgical removal of tumor tissue for TIL expansion.
45766565|NCT03287674|Drug|Nivolumab|Nivolumab 3 mg/kg is administered on day -2 before TIL infusion and every 2 weeks for a total of 4 doses.
45766566|NCT00634244|Drug|alvocidib|Given IV
45766567|NCT00634244|Drug|mitoxantrone hydrochloride|Given IV
45766568|NCT00634244|Drug|carboplatin|Given IV
45766569|NCT00634244|Drug|cytarabine|Given IV
45766570|NCT00634244|Drug|sirolimus|Given PO
45766571|NCT00634244|Drug|etoposide|Given IV
45766572|NCT00634244|Drug|topotecan hydrochloride|Given IV
45766573|NCT03929614|Other|MOBI validation|Final version will be distributed to 176 French speaking subjects, 30 of whom are randomly selected and will fill it a second time, at after 72 hrs. To consider of its kind, Moreover, the Bem Inventory for Children will be completed by everyone as well as the SF-12 and SRS-22.
45766574|NCT03194698|Device|Intense Pulsed Light Treatment (IPL)|IPL is a high-intensity light source consisting of visible light in the wavelength range of 515-1200 nm, that is aimed at the eyes. Treatments are spaced four to six weeks apart for a total of 4 treatments.
45766575|NCT03194698|Procedure|Meibomian Gland Expression|Manual expression of the meibomian glands by placing the thumb against the lid margin and press firmly against the eyeball to determine the percentage of meibomian pores that are blocked. This assessment is performed on both the upper and lower lid of each eye.
45766576|NCT01922804|Dietary Supplement|K2 vitamin|K2 vitamin tablet
45766577|NCT01922804|Dietary Supplement|Placebo|Placebo tablets
45766578|NCT03289858|Drug|Exparel|Subcutaneous injection at conclusion of surgical fixation of hip fracture
45766579|NCT03289858|Drug|Sodium Chloride|Saline Injection
45766580|NCT04396418|Behavioral|Education|Randomization between two groups at site level. One cluster with education and one without.
45766581|NCT03160274|Genetic|Genetic screening|Germline and/or tumor samples will be screened for mutations
45766582|NCT00375856|Device|DePuy P.F.C.® Sigma Rotating Platform Knee|no details
45766583|NCT03418714|Drug|Salvinorin A|Salvinorin A, blinded doses
45766584|NCT03155906|Other|Health care delivery|Integrated HCV treatment within the OST clinics will compared to standard treatment. Those who are eligible to receiving treatment in line with national guidelines, have no exclusion criteria and consent to study participation, will be randomised to either standard or integrated treatment. For the integrated treatment, treatment initiation, follow-up and delivery of medication will be given at a MAR outpatient clinic where they already receive care including OST. Those randomised to standard treatment will be referred to a medical ward clinic for assessment of treatment initiation and follow-up. Assessment of outcomes will be done 12 weeks after completed treatment and adherence will be assessed at 4, 8 and 12 weeks after initiation of treatment.
45766585|NCT01922960|Other|micro-imaging|micro-imaging
45766586|NCT03153488|Radiation|MRI|All participants will perform one MRI session before initiation of treatment. The imaging session will last about an hour including the structural and functional MRI portions. The subjects lie on a padded scanner couch in a dimly illuminated room, and wear foam earplugs to attenuate scanner sounds.
45766587|NCT03194776|Drug|LLG783|LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
45912697|NCT02013323|Drug|Scaling and root planing, and Placebo drug for 7 days|Subjects in placebo group received placebo tablets taken thrice daily for 7 days and checked for clinical and microbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months
45912698|NCT02013349|Device|coronary intervention|
45912699|NCT02013362|Drug|Pralatrexate injection|
45912700|NCT02013362|Dietary Supplement|Vitamin B12|
45912701|NCT02013362|Dietary Supplement|Folic Acid|
45912702|NCT02013453|Drug|Omeprazole|40mg of Omeprazole will be administered daily by mouth.
45447019|NCT03555214|Other|Control group|"Placebo treatment:~The patient remains supine and the therapist sits on a stool at the bedside with the forearms resting on the couch. Both hands are placed on the posterolateral part of the patient's head and the position is maintained for 10 minutes without exerting any force or movement."
45447020|NCT03555214|Other|Manual Therapy based on structural techniques|"Manual Therapy:~Technique of manipulation of the occipito-atlanto-axoidea joint (OAA).~Articulation technique of the high cervical spine (C0-C1).~Postero-anterior articular technique of C2-C7 in supine position.~Postero-anterior articular technique of C2-C7 in prone position.~Manipulative technique of the flapper C7-T1.~Dorsal spinal manipulative technique (T1-T8).~Lumbosacral global manipulative technique."
45452412|NCT05258240|Other|Conventional Physical Therapy|Postural training, standing, walking, and walking activities are included in the conventional physical therapy in domain of balance exercise training programs. These activities are usually boring and tedious because these exercises are repeated many times.
45624793|NCT04883307|Behavioral|Wellness resources|Residents in the control group received three emails across the 9 month study period that contained materials related to physician well-being such as personal development and resilience, mindfulness, and work life-integration. Materials included recommended readings, videos, and exercises and were curated by members of the Association of Women Surgeons who were not involved in the coaching program.
45624794|NCT04889001|Other|Simulation enhanced HBB training|Simulation enhanced HBB is a one-day course delivered using a format of Explain, Demonstrate and Facilitate practice. Compared to the standard HBB training, the simulation enhanced HBB course is designed with increased peer-to-peer feedback and scripted expert facilitator feedback at HBB practice exercises.
45624795|NCT03050229|Drug|Empagliflozin|Empagliflozin 10mg/day once daily before or after breakfast
45624796|NCT03050229|Drug|Placebo|Placebo once daily before or after breakfast
45766588|NCT03194776|Drug|Placebo|Placebo to LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
45766589|NCT03421210|Drug|Nicotine patch|Participants will wear nicotine patches for 10 weeks after their quit date. 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment.
45766590|NCT01025791|Drug|MK-8266 0.1 mg|Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.
45766591|NCT01025791|Drug|MK-8266 1.0 mg|MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
45766592|NCT01025791|Drug|Placebo|Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
45766593|NCT03195010|Biological|Platelet Transfusion|Undergo lower dose platelet transfusion
45766594|NCT03195010|Biological|Platelet Transfusion|Undergo higher dose platelet transfusion
45766595|NCT03423082|Drug|18F fluciclovine|Each subject will receive one IV dose of 18F fluciclovine for PET scanning
45766596|NCT03423082|Device|18F fluciclovine PET|Each subject will undergo one 18F fluciclovine PET scan on a hybrid PET/MRI scanner
45912703|NCT02013453|Drug|Carboplatin|Carboplatin will be administered over 30 minutes by continuous infusion.
45912704|NCT02013453|Drug|5FU|Administered by infusion.
45766597|NCT04736290|Other|NLR|Calculation of NLR
45766598|NCT04736290|Other|PLR|Calculation of PLR
45766599|NCT03294850|Procedure|Bariatric surgery|Subjects enrolling in the study who are undergoing bariatric surgery as part of their medical care will be studied
45766600|NCT03294850|Device|HepQuant SHUNT Dual Cholate Liver Diagnostic Kit|For the experimental group, the device will be used to monitor the effect of bariatric surgery on liver function. For the active comparator group, the device will be used for the assessment of baseline liver function.
45624797|NCT04888299|Device|Raman spectroscopy (SPECTRA IMDx)|The SPECTRA IMDx comprises a laser system, a spectrometer, a computer with an analysis algorithm installed, and other ancillary parts. The SPECTRA IMDx probe is connected with the main system. The SPECTRA IMDx probe is an assembly of optical fibres and optical components arranged for maximal transmission of light energy. When in use, the laser system will emit a 785nm near infra-red laser that will be transmitted through the SPECTRA IMDx probe to the distal end. When the laser is interrogated upon a tissue surface, the light energy is absorbed and reflected. The reflected energy is then collected from the distal end of the SPECTRA IMDx probe, transmitted back to the main system, and passed through the spectrometer. The collected signal is then processed to obtain the clean Raman signal for diagnostic classification.
45766601|NCT00996931|Drug|lenalidomide|2.5 mgs per day orally for 12 weeks
45766602|NCT03295630|Device|Accelerometer|Participants will perform a semi-structured movement protocol to investigate the ability of the Actigraph GT3X accelerometer to identify body position (lying, sitting or standing) and quantify step count.
45766603|NCT01026805|Device|Interlace Medical 1st Generation Hysteroscopic Morcellator|The Interlace Medical hysteroscopic morcellator system has been cleared by the FDA(K073690)and consists of a motor drive unit connected to a 3mm morcellator. The morcellator is approximately 12 cm long and is equipped with an open channel that houses a reciprocating blade. When the motor is activated, the reciprocating blade will cut the tissue within the channel. The tissue travels down the 3mm morcellator shaft cannula via suction coupled to the proximal end of the morcellator and is captured in a tissue trap in a suction canister for pathological diagnosis following the procedure.
45766604|NCT00997555|Procedure|bronchoscopy|Scheduled bronchoscopy.
45766605|NCT03197038|Behavioral|Partially supervised home-based walking exercise|Participants will be asked to exercise at home by walking at a moderate intensity. Each participant will receive an exercise prescription. Participants will receive a heart rate monitor. The heart rate monitors will be used to achieve a desired exercise intensity and to monitor adherence levels. The participants will receive biweekly to weekly phone calls, and monthly in person meetings will be used to address any barriers, provide encouragement, and progress the exercise.
45766606|NCT03197038|Behavioral|Control|Participants will be asked to exercise at home by walking at a moderate intensity. The participants will receive biweekly phone calls, but will not receive a heart rate monitor, individual exercise prescription, or meet with the investigators monthly.
45766607|NCT00634088|Drug|Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg|Lapatinib, 1000 mg, administered orally, once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone (Day 1). Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m^2, administered as a 3-hour IV infusion. Lapatinib, 1000 mg, administered orally, once a day, every day, for a 21-day cycle.
45766608|NCT00634088|Drug|Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m^2 + lapatinib, 1000 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m^2, administered as a 3-hour IV infusion. Lapatinib administered, 1250 mg, orally, once a day, every day, for a 21-day cycle.
45766609|NCT00634088|Drug|Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m^2 + lapatinib, 1250 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 40 mg/m^2, administered as a 3-hour IV infusion. Lapatinib, 1250 mg, administered orally, once a day, every day, for a 21-day cycle.
45766610|NCT00634088|Drug|Ixabepilone + Lapatinib + Capecitabine|Planned escalating doses of the triplet combination of ixabepilone, lapatinib, and capecitabine. No participants were enrolled in this arm due to premature termination of the study.
45766611|NCT01027195|Device|Bipolar Radiofrequency (Aquamantys 6.0)|
45766612|NCT01027195|Device|Standard Bovie Electrocautery|
45766613|NCT00998023|Device|Mynx Vascular Closure Device|Comparison of two different vascular closure devices.
45766614|NCT00998023|Device|AngioSeal Vascular Closure Device|Comparison of two different vascular closure devices.
45912705|NCT02013453|Drug|Paclitaxel|Administered by infusion.
45912706|NCT02013453|Drug|Pemetrexed|Administered by infusion.
45912707|NCT02013466|Dietary Supplement|Bolus ONS A|High-whey protein, leucine-rich, low-caloric ONS in powder format
45447021|NCT03555214|Other|Manual Therapy based on soft tissues and structural techniques|"Manual Therapy:~Technique of suboccipital inhibition.~Cranial frontal technique.~Cranial sphenoid technique.~Cranial fourth ventricle technique.~Antero-posterior abdominal-sacral technique.~Technique of manipulation of the occipito-atlanto-axoidea joint (OAA).~Articulation technique of the high cervical spine (C0-C1).~Postero-anterior articular technique of C2-C7 in supine position.~Postero-anterior articular technique of C2-C7 in prone position.~Manipulative technique of the flapper C7-T1.~Dorsal spinal manipulative technique (T1-T8).~Lumbosacral global manipulative technique."
45447022|NCT02098018|Behavioral|Program 2|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
45624798|NCT03050151|Drug|Dupilumab|Administration of dose of Dupilumab as per protocol by auto-injector or prefilled syringe
45624799|NCT03050151|Device|Auto-injector Device|Delivery of Dupilumab by auto-injector device
45624800|NCT03050151|Device|Prefilled syringe|Delivery of Dupilumab by prefilled syringe
45624801|NCT04882761|Device|Dental implant|Comparative
45624802|NCT04888533|Other|EHSSA- An Efficient and Holistic/Heuristic Semi-structured Suicide Assessment Tool|EHSSA will be used to evaluate every patient for suicide risk.
45766615|NCT03428230|Drug|30 mg Paracetamol 3% (1 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injection will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
45766616|NCT03428230|Drug|60 mg Paracetamol 3% (2 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
45766617|NCT03428230|Drug|90 mg Paracetamol 3% (3 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
45624803|NCT03049527|Behavioral|Education, Incentives and Feedback|The study participants will receive additional educational activities, including low-literacy fact sheets on liquid intake guidelines, cards with instructions on how to self-monitor urine color and volume, and flyers and posters placed throughout the worksite. All consenting study participants will be offered incentives to start the work day hydrated and then to maintain or improve their hydration status over the work shift. Participants who do not meet hydration goals will receive additional coaching and feedback on ways to improve hydration.Feedback will also be provided to all groups about their productivity level to help participants recognize the connection between improved health and function.
45766618|NCT03428230|Drug|Placebo, 0.9% saline solution|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Placebo followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Placebo will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
45766619|NCT03428230|Drug|NIMP: Chloroprocaine HCl 1% (10 mg/mL), solution for injection|Immediately after intrathecal administration of the Paracetamol dose or Placebo, all patients will receive a single intrathecal dose of Chloroprocaine HCl 1% according to the Summary of Product Characteristics indications. Time interval between the 2 administrations should not exceed 2 min.
45766620|NCT01027819|Device|Mobile bearing|Mobile bearing in total knee arthroplasty
45766621|NCT01027819|Device|Fixed bearing|Fixed bearing in total knee arthroplasty
45447023|NCT02098018|Behavioral|Program 1|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
45447024|NCT02102698|Drug|Ecopipam|Ecopipam is a selective antagonist of the dopamine D1 receptor family.
45447025|NCT02098096|Other|Negative Work|"Exercise will be performed twice per week for 12 weeks and exercise intensity will be progressed in three phases. These phases are:~Familiarization~Acclimatization~Progression~Exercise volume will be 3 sets of 10 repetitions (progressing to 4 sets at Week 6) for the knee flexors and extensors.~All exercise will be supervised by a physical therapist and performed on a Biodex isokinetic dynamometer."
45447026|NCT02098096|Other|Stretching|Home exercise program will be performed by the Placebo Comparator group and feature stretching over the 12 week intervention period.
45447027|NCT02102776|Procedure|MMC|Standardized cotton soaked in mitomycin C (0.02%) will be applied underneath conjunctiva for 5 minutes after pterygium excision.
45447028|NCT02102776|Procedure|AMT|Amniotic membrane transplantation will be applied to cover the conjunctival defect after pterygium excision.
45447029|NCT02102776|Procedure|CAG|A conjunctival autograft, harvested from the superior bulbar conjunctiva of the operating eye, will be applied to cover the conjunctival defect after pterygium excision.
45447030|NCT02102776|Procedure|Pterygium excision|Pterygium head, minimal conjunctiva and anterior tenon's capsule underneath will be removed in the excision of pterygium tissue.
45447031|NCT05570942|Dietary Supplement|Oral Lactobacillus rhamnosus TCELL-1|A kind of probiotics which was isolated from the intestinal mucosa of health Taiwanese people
45447032|NCT02102854|Drug|rATG|Infusion of horse or rabbit-derived antibodies against human T cells, used to prevent & treat acute rejection in organ transplantation
45447033|NCT03637244|Behavioral|Decision Support Aid and PrEP for Black Canadians|Ottawa Decision Support Framework Adaptation.Investigators will use the inputs from the qualitative findings, CDC public health guidance and the tenofovir + emtricitabine product monograph to tailor the ODSF for use in the C5TM PrEP decision support web-app.
45447034|NCT02099500|Procedure|Liposuction|Liposuction using aspiration syringe and tumescent local anesthesia
45447035|NCT02099500|Other|Stem Cell Injection|Stem cell implantation will be performed using intramuscular injection into the affected ischemic site of interest
45447036|NCT02661620|Device|REDAPT Revision Femoral System modular stem|Medical record review for retrospective information and observational prospective data collection of standard of care items at 5 years and 10 years post operatively plus a 7.5 year post op telephone call to assess stem status and adverse events.
45766622|NCT02163967|Device|Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)|low voltage alternating current transcranial electrical stimulation
45766623|NCT03296800|Drug|Bexagliflozin|Bexagliflozin 20 mg, tablet; qd
46069619|NCT02865629|Drug|N-acetyl cysteine|N-acetylcysteine will be initiated at 600 mg PO daily for Week 1, then increased to 600 mg PO twice a day for Week 2, then increased to 600 mg PO morning and 1200 mg PO evening for Week 3, and then increased to 1200 mg PO twice a day for Week 4-8. Doses might be decreased anytime if clinically indicated. Following the study, all patients will be referred to treatment as usual. Adherence will be assessed in weekly visits in the first month and then bi-weekly in the second month. Adherence will be assessed by subject interview, pill counts during each study visit, and by legal guardian interview (if minor).
45624804|NCT03049605|Device|Magnetic therapy|low intensity pulsed magnetic therapy with a frequency of 200 Hertz and intensity of 50 Gauss . Magnetic device will be applied on each patient from a comfortable supine lying position. After the connection of appliance to electrical supply, the actions of PEMF will be directed and adjusted over lumbar spine, hip regions and calf muscles of both lower limbs.
45624805|NCT03049605|Device|laser therapy|laser therapy of Helium neon infrared laser (850 nano-meter) was used in continuous wave mode from a comfortable prone lying position on the whole plantar surface of the foot and the lumbo-sacral area by four points, and two points laterally to the spine.
45624806|NCT03049605|Drug|Only medical treatment|Fifteen patients with diabetic peripheral neuropathy were treated with antidiabtic drugs and lyrica 150 milligram daily
45624807|NCT04904367|Procedure|Deep tissue massage|The amount of pressure during the massage was adjusted by the physiotherapist with reference to muscle tissue palpation in the patients. During the massage, olecranon, pisiform bone protrusion, metacarpophalangeal and proximal interphalangeal joint faces forearm, wrist and fingers were used during the massage to reach deep tissue. As a massage technique, compression and stretching techniques are used in combination.
45624808|NCT04904367|Procedure|Conventional physiotherapy|For 4 weeks 20 session, this group were applied hot pack with 20 minutes of conventional TENS to back and neck region, followed by 4 minutes of ultrasound at a frequency of 3 MHz and at a dosage of 1 w / cm2.
45624809|NCT04904523|Diagnostic Test|Diagnostic Test:Blood test|Drop of blood for RNA and metabolic analysis
45766624|NCT03296800|Drug|Probenecid|Probenecid tablets, 500 mg; bid
45766625|NCT03296800|Drug|Rifampin|Rifampin, 600 mg (2 x 300 mg capsules); qd
45766626|NCT03296800|Drug|Verapamil|Verapamil hydrochloride tablet, 120 mg; qd
45766627|NCT00634010|Drug|Morphine|15 mg oral every 12 Hours; additional capsules taken every 2 hours as needed.
45766628|NCT00634010|Drug|Methadone|5 mg orally every 12 hours; additional capsules every 2 hours as needed.
45447037|NCT05426746|Drug|ALT-100|intravenous infusion of drug substance diluted in 0.9% normal sterile saline
45447038|NCT05426746|Other|Normal Saline|intravenous infusion of placebo (0.9% normal sterile saline)
45447039|NCT02098174|Drug|MP-3180|MP-3180 (1 µmol/kg or 0.372 mg/kg) (fluorescent tracer agent) was administered by IV injection (2.5 mL to 3.5 mL for participant weights of 70 kg to 91 kg) over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
45766629|NCT04053751|Procedure|closed suctioning system|a randomized allocated patient will be monitored for two days. Closed suctioning system will evaluate as experimental group. open suctioning system will evaluate as control group.
45766630|NCT03202264|Other|TAPER|"The intervention is medication reduction. This arm is comprised of:~Medication reconciliation~Identification of patient priorities for care~Identification of medications that are potentially appropriate for discontinuation/dose reduction~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~Identification of medications for trial of discontinuation/dose reduction (shared decision making)~Pause of medication and clinical monitoring"
45766631|NCT00633932|Drug|Esomeprazole|20mg once daily
45447040|NCT02098174|Other|Iohexol comparator|Iohexol (Omnipaque 300, 5 mL) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
45447041|NCT02099578|Dietary Supplement|25 g of Freeze-dried Strawberry Powder|Participants will be given one packet of 25 g of freeze-dried strawberry powder and one packet of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
45447042|NCT02099578|Dietary Supplement|50 g of Freeze-dried Strawberry Powder|Participants will be given two packets of 25 g of freeze-dried strawberry powder and asked to consume one packet in the morning and one at night.
45447043|NCT02099578|Dietary Supplement|Placebo Powder|Participants will be given two packets of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
45447044|NCT02670044|Drug|Cobimetinib|Cobimetinib will be administered orally as per schedule in Arm description.
45766632|NCT00633932|Drug|Esomeprazole|40 mg once daily
45766633|NCT00633932|Drug|Omeprazole|20mg once daily
45766634|NCT01028131|Behavioral|Computer-delivered brief intervention (5As)|After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model and Motivational Interviewing.
45912708|NCT02013466|Dietary Supplement|Bolus ONS B|High casein-protein, low-caloric control product (isocaloric to product A)
45912709|NCT02013466|Dietary Supplement|Bolus ONS C|High casein-protein, high-caloric control product.
46069620|NCT04253210|Other|psychological|Participants will either view body positive images that are sexualized (vs. nonsexualized) and a great deal of evidence of photo modification (vs. low photo modification).
45766635|NCT01028131|Behavioral|Contingency Management|Participants randomized by the computer into this condition will view a 20-minute music and tv videos after completing the brief assessment. The research assistant will then briefly describe the CM process, with a period for questions to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
45766636|NCT03297112|Drug|Perflutren Lipid Microspheres|Given IV
45766637|NCT03297112|Procedure|Contrast-Enhanced Subharmonic Ultrasound Imaging|Undergo contrast-enhanced subharmonic ultrasound imaging
45766638|NCT03831542|Behavioral|direct follicular aspiration|direct follicular aspiration
45766639|NCT03831542|Behavioral|follicular flushing|follicular flushing
45766640|NCT01028677|Drug|intranasal spray with oxytocin|6 insufflations (24 IU of oxytocin total) given twice daily for 6 weeks
45766641|NCT01028677|Other|nasal spray without oxytocin|6 insufflations of nasal spray without oxytocin (0.1 metered dose/insufflation) twice daily for 6 weeks
45766642|NCT03298048|Biological|Low fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 50g stool for 2 consecutive days
45766643|NCT03298048|Biological|Mid fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool on the 1st day of treatment and from 50g stool on the 2nd day of the treatment
45766644|NCT03298048|Biological|High fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool for 2 consecutive days
45766645|NCT01923038|Procedure|First arm: patients ventilated with zero end expiratory pressure|
45766646|NCT01923038|Procedure|Patients ventilated with Positive End Expiratory Pressure|
45766647|NCT01923038|Procedure|Patients ventilated with Positive End Expiratory Pressure plus Recruitment maneuver|
45766648|NCT01923116|Drug|HPV-16 vaccine|Vaccination with SLP-HPV-01® with or without interferon-a injections.
45624810|NCT04888221|Drug|Tocilizumab|"Tocilizumab will be administered subcutaneously at a dose of 162mg/0.9mL weekly (each week, on the same day) from week 0 to week 24.~At the first injection (Baseline D0), a therapeutic education is provided for patients/caregivers who can carry out the injections themselves as part of their usual care."
45766649|NCT04735276|Device|HFNO for 5 min|1st basic MRI then HFNO for 5 min with mouth closed breathing and 2nd MRI. Analysis of the surface of the gastric antrum.
45766650|NCT04706728|Other|Listening to playlists with music prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first four weeks of their ECT treatment.
45766651|NCT04706728|Other|Listening to playlists with music prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first two weeks of their ECT treatment.
45447045|NCT02670044|Drug|Idasanutlin|Idasanutlin will be administered orally as per schedule in Arm description.
45766652|NCT04706728|Other|Listening to playlists with sound from nature (rain, waves) prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with sounds from nature one day prior to ECT procedures for the first two weeks of their ECT treatment
45624811|NCT04888221|Drug|Placebo|Placebo administered subcutaneously (SC) weekly during 24 weeks
45766653|NCT01028911|Drug|PF-03654746|PF-03654746 capsule of 0.25 mg, 0.5 mg, and 1.0 mg strength. Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator.
45447046|NCT02670044|Drug|Venetoclax|Venetoclax will be administered orally as per schedule in Arm description.
45766654|NCT01028911|Drug|Placebo|"Matching placebo capsules to PF-03654746 with strengths of 0.25 mg, 0.5 mg, and 1.0 mg.~Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator."
45766655|NCT04706884|Device|Near infrared spectroscopy|The rSO2 (cerebral oxygen satutation) was continuously monitored by NIRS (Near infrared spectroscopy) with a sensor positioned on the forehead of the patient
45766656|NCT03204526|Device|deep brain stimulation|
45766657|NCT03302416|Drug|Hydrocortisone|
45766658|NCT03302416|Radiation|[C-11]NOP-1A|
45447047|NCT02103088|Behavioral|Sexual and urological intervention|Sexual and urological intervention consisting of: i) DVD instruction in pelvic floor muscle training ii) group instructions in pelvic floor muscle training by physiotherapist including three individually follow-up and ii) up to six couple sessions performed by a sexual nurse counselor.
45447048|NCT02307656|Drug|Atazanavir|
45447049|NCT02307656|Drug|Cobicistat|
45447050|NCT02307656|Drug|Active Pharmaceutical Ingredient|
45624812|NCT04887987|Radiation|strengthening training and LED PBMT|Participants will be submitted to a supervised 16-wk training program (3 d/week) involving a specific lumbar extension exercise on the Roman bench and four complementary exercises to improve core strength and spine stabilization. Participants will receive LED PBMT 30 minutes before each training session, through a device containing 264 LEDs, which will be placed on the lumbar region (between L1 and L5).
45766659|NCT03435562|Other|JUUL electronic cigarette|Effects of JUUL electronic cigarette use.
45766660|NCT03435562|Other|IQOS electronic cigarette|Effects of IQOS electronic cigarette use.
45766661|NCT03435562|Other|Own Brand cigarette|Effects of own brand cigarette use.
45766662|NCT01000285|Drug|Bortezomib|
45766663|NCT01000285|Drug|Etoposide|
45766664|NCT01000285|Drug|Vincristine|
45766665|NCT01000285|Drug|Doxorubicin|
45766666|NCT01000285|Drug|Prednisone|
45766667|NCT01000285|Drug|Cyclophosphamide|
45766668|NCT01000285|Drug|Raltegravir|
45766669|NCT03207022|Procedure|axillary brachial plexus block|ultrasound guided axillary brachial plexus block with 20 ml local anaesthetic lidocaine with epinephrine and clonidine
45766670|NCT03208192|Procedure|liver transection during laparoscopic liver resection|liver transection during laparoscopic liver resection
45766671|NCT01000987|Drug|varenicline|1mg/day or 2 mg/day Subjects are at steady state medication levels. They are participating during the 4-week medication period of our ongoing study, NCT00580645.
45766672|NCT01000987|Drug|placebo|placebo
45766673|NCT00633464|Drug|ixabepilone|"injection, intravenous (IV), until unacceptable toxicity or progression or 15 months after the Last Subject First Visit (LSFV), whichever comes first.~Ixabepilone 40 mg/m^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant met the re-treatment criteria."
45624813|NCT04887987|Radiation|strengthening training and placebo PBMT|Participants will be submitted to a supervised 16-wk training program (3 d/week) involving a specific lumbar extension exercise on the Roman bench and four complementary exercises to improve core strength and spine stabilization. Participants will receive placebo PBMT 30 minutes before each training session, through a off-line device (turned off) containing 264 LEDs, which will be placed on the lumbar region (between L1 and L5).
45766674|NCT00633464|Drug|ixabepilone + cetuximab|"Ixabepilone: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.~Ixabepilone 40 mg/m^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant meets the re-treatment criteria.~Cetuximab: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.~Cetuximab 400 mg/m^2 was administered as a 2-hour IV loading dose via in-line filtration with an infusion pump, gravity drip, or a syringe pump on Day 1 of first cycle then 250 mg/m^2 1-hour IV once a week, i.e. on Days 1, 8, and 15 of each cycle provided the participant meets the re-treatment criteria."
45766675|NCT03436810|Procedure|Motor imagery|Motor imagery (MI) will be trained for the individuals by imagination of the movement. Program of MI includes 1) body relaxation and awareness 2) visual imagery 3) kinesthetic imagery and 4) refocusing of body and environment.
45766676|NCT03436810|Procedure|Health education|Topic of Health education (HE) consists of 1) Changes caused by stroke 2) Complications after stroke 3) Emotional changes after stroke 4) Living at home after stroke 5) High blood pressure and stroke and 6) Preventing recurrent stroke.
45766677|NCT03436810|Procedure|Task-Oriented Circuit Class Training|Program of Task-Oriented Circuit Class Training (TOCCT) consists of warm up and perform tasks 1) Stepping forward-backward onto block 2) Stepping sideway onto block 3) Heel lifts in standing to strengthen affected planter-flexor muscles 4) Standing with a decreased base and reach for object 5) Standing up from chair, walking a short distance, and returning to chair 6) Symmetrical walking and 7) Walking at fast speed.
45766678|NCT03129776|Drug|Hyperpolarized 13C-Pyruvate|The new imaging method being tested is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast agent, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The participants will be injected with the study drug at a dose of 0.43 ml/kg and then receive a MRI scan.
45624814|NCT03049839|Behavioral|Intervention_ S|One year Structured intervention program for members of high-risk group (Subjects with FINDRISC score ≥12 points and impaired glucose tolerance (IGT))
45624815|NCT03049839|Behavioral|Intervention_ I|One year Informative intervention program for members of moderate risk group (People with normotolerant or impaired fasting glucose in the OGTT and a FINDRISC score ≥12 points)
45766679|NCT03129776|Drug|18F-FDG|18F-FDG is a radiopharmaceutical used in medical imaging. The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which is correlated with certain types of tissue metabolism, particularly in cancer cells. The participant will be injected with the study drug at a dose of 5 MBq/kg to a maximum of 500 MBq and then receive a PET scan.
45766680|NCT03437044|Drug|Ticagrelor|After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
45766681|NCT03437044|Drug|Clopidogrel|After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
45766682|NCT03148106|Device|Somatosensory Electrical Stimulation|We will put adhesive electrodes on the affected arm and connect it to a device that will deliver a gentle electrical stimulation to the hand and arm. The stimulation will last for different amounts of time, depending on the stimulation condition. This can be 30 minutes twice a day (1 hour apart), 1 hour continuously, 2 hours continuously, or 3 hours continuously. The stimulation conditions will also vary in stimulation strength. It is normal that some people may feel a tingling sensation, while others may feel nothing.
45766683|NCT01923194|Drug|Highly Purified Urofollitropin|for Injection
45766684|NCT01923194|Drug|Recombinant Human Follitropin Alfa|for Injection
45766685|NCT03303196|Device|Bihormonal Bionic Pancreas|A 4-day inpatient admission in which subjects will wear the bihormonal pancreas. The bihormonal pancreas will be placed upon admission and there will be 1 day of run-in. This will be followed by 3 days of data collection for comparison with the data obtained from the standard of care during the control admission.
45624816|NCT03049839|Behavioral|Intervention_ C|One year, Intervention program at Community level. People with a FINDRISC less than 12 points
45624817|NCT03049683|Other|Vestibular evoked myogenic potentials (VEMPs)|The c- and oVEMPs will be assessed in three different sessions including conventional sequential recordings and two different simultaneous recording methods, i.e., unilateral simultaneous recording of cVEMPs and oVEMPs during monaural stimulation (Figure 1A) and bilateral simultaneous recording of each VEMP during binaural stimulation (Figure 1B).
45766686|NCT04759508|Dietary Supplement|Flax Oil Capsule|Flaxseed with brand name Flax Oil Capsule will be administered to subjects receiving antihypertensives.
45766687|NCT04759508|Dietary Supplement|Placebo Soya Oil Capsule|Placebo capsule filled with soya oil and inert(inactive) substances will be administered to subjects remaining anti hypertensives.
45766688|NCT01923272|Device|AlphaCore Device|Active stimulation to the vagal nerve
45766689|NCT01923272|Device|AlphaCore|Active AlphaCore treatment
45766690|NCT03082664|Device|PICO Single Use Negative Pressure Wound Therapy|The PICO device will be placed over the closed cesarean section incision.
45766691|NCT00633152|Drug|ceftaroline|600 mg injected every 12 hours for at least 5 but not more than 14 days
45624818|NCT03049761|Device|Water Flosser|Power interdental cleaner
45624819|NCT03049761|Device|String Floss|Mechanical interdental cleaner
45624820|NCT03049761|Device|Manual Toothbrush|ADA standard soft bristle toothbrush
45624821|NCT04392999|Drug|Intraarticular platelet rich plasma cervical facet injection|Injection of PRP into the cervical facet joints.
45624822|NCT04392999|Drug|Corticosteroid injection|Injection of corticosteroid into the cervical facet joints.
45624823|NCT03048981|Drug|Fish oil|Blood samples before and after 10 day intake of maximum dose fish oil
45624824|NCT03050385|Device|transcranial direct current stimulation|
45624825|NCT04882605|Genetic|MHC typing|Allelic genotyping resolution of MHC genes (HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, -DPA1, -DPB1 and -DRB3/4/5) using Illumina technology.
45624826|NCT04882605|Genetic|KIR typing|Allelic genotyping resolution of all 13 KIR genes (KIR2DL1, KIR2DL2/2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS3/2DS5, KIR2DS4, KIR3DL1/3DS1, KIR3DL2, KIR3DL3), 2 KIR pseudogenes (KIR2DP1 and -3DP1) using Illumina technology.
45624827|NCT04882605|Genetic|Assessment of KIR-based prediction scores|Compiling donor/recipient MHC and KIR typings into 28 major KIR-based prediction scores
45624828|NCT04882371|Drug|Chemotherapy|Neoadjuvant Chemotherapy for Breast Cancer
45624829|NCT04882371|Diagnostic Test|Magnetic Resonance Imaging (MRI)|Performed contrasted MRI for evaluate response of neoadjuvant chemotherapy
45624830|NCT04882371|Diagnostic Test|Positron emission tomography - Copmputer Tomography (PET-CT)|Performed contrasted PET-CT for evaluate response of neoadjuvant chemotherapy
45624831|NCT04887753|Other|Synchronisation abilities|The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations.
45624832|NCT04882683|Drug|Prednisone|0.75 mg per kilogram per day for three months
45624833|NCT04882683|Drug|Azathioprine|1 mg per kilogram per day for three months
45624834|NCT04882683|Drug|Adalimumab|40mg every two weeks for three months
45624835|NCT04882683|Biological|umbilical cord blood mononuclear cells|Peripheral intravenous infusion method, infusion of umbilical cord blood mononuclear cell suspension 50ml (cell number 2×10^8).
45624836|NCT02155660|Drug|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
45624837|NCT02155660|Drug|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
45624838|NCT02155660|Drug|Benralizumab Arm C|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
45624839|NCT02155660|Drug|Placebo|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
45624840|NCT04882215|Behavioral|GMT combined with WMU Training|"GMT teaches the use of mental strategies to support sustained attention during complex (multi-step) task performance following an interactive programme. GMT is structured into nine modules, with interactive discussions and homework assignments. It will be conducted on a group basis.~WMU training consists of computerised working memory updating tasks in which trial accuracy and response time are recorded. Two tasks will be trained: 1. a visuo-spatial Matrix Updating (MU) and 2. a verbal Keep Track (KT). For both training tasks, level of difficulty can be modulated by increasing or decreasing the update level, i.e., the number of updates on each trial."
45624841|NCT04881981|Radiation|SCART radiation therapy|We will deliver high dose radiation therapy using SCART method. Beam energies of 6Mv will be used. The high dose SCART therapy will be delivered using LINAC systems, as available and appropriate for each patient. The treatment plan used for each patient will be based on an analysis of the volumetric dose including DVH analyses of the PTV and critical normal structures.
45624842|NCT04881513|Diagnostic Test|Narrow Band Imaging|Testing the taste buds structure (blood vessels morphology- classified to 5 types) and the number of taste buds per 20mm2, by Narrow Band Imaging technique before and after the operation (one and six months)
45624843|NCT04881513|Diagnostic Test|Tongue sensitivity testing|testing the tongue sensitivity change prior to surgery and after (1 and 6 months) the surgery with two point discrimination test in mm.
45624844|NCT04881513|Other|Qualitiy of life|Testing the patients quality of life before and after (one and six months) the stapes surgery by SF 36 questionnaire
45624845|NCT04881513|Diagnostic Test|Threshold change|Measuring the intraoperative chorda tympani stimulation threshold change at the beginning and at the end of the procedure- surgery
45624846|NCT04881513|Diagnostic Test|Taste|Taste is measured by applying taste strips (sweet, sour, salty, bitter) in 4 concentrations prior to, 1 and 6 months after surgery.
45624847|NCT04881591|Device|Treatment as usual + APP|Participants at this condition will receive the usual medical treatment for their scoliosis but also they will be monitored daily using the Scoliosis Pain Monitor APP. Alarms will be generated in the face of certain preestablished undesired events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
45624848|NCT04881669|Device|obturator|variable bulbs
45624849|NCT04881435|Device|Hydrogen gas therapy|Hydrogen gas therapy three times one day for 5 days
45624850|NCT04881279|Other|Event|Ransomware attack
45624851|NCT04753372|Drug|Rivaroxaban 2.5 MG [Xarelto]|rivaroxaban 2.5mg bid on top of ASA for CAD and/or PAD
45624852|NCT04881201|Procedure|blood sample|blood sample
45624853|NCT02119936|Behavioral|Heart Rate Variability Biofeedback Tool|The Heart Rate Variability Biofeedback tool (emWave 2) will capture heart rate variability (HRV) before and after deep breathing exercises are used among participants. Participants will be able to visualize changes in their HRV and then fill-out self-reported anxiety measures to determine if the breathing exercises and visualization of HRV affected anxiety.
45624854|NCT03048357|Device|Freedom Bed|Fully Integrated Lateral Rotation Bed System that automatically turns the patient to a specific angle in degrees between from 15-25 with dwell times between 1-120 minutes.
45624855|NCT03048357|Other|Standard hospital bed|Caregiver turning patients to one side then the other every 2 hours for pressure relief over bony prominence's.
45624856|NCT05154123|Drug|Drug: AT-527 + rosuvastatin|"Day 1: A single dose of rosuvastatin will be administered.~Day 8: A single dose of AT-527 and rosuvastatin will be co-administered."
45624857|NCT05154123|Drug|AT-527 + rosuvastatin|"Day 1: A single dose of rosuvastatin will be administered.~Day 8: A single staggered dose of AT-527 and rosuvastatin will be administered (2 hours later)"
45624858|NCT04745572|Behavioral|High Carbohydrate Diet|Participants randomized to this group will participate in a group-based weight behavioral management program and consume a high carbohydrate (HC) diet. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine HC diet with time-restricted eating (TRE) or HC diet with additional exercise counseling and support.
45624859|NCT04745572|Behavioral|Reduced Carbohydrate Diet|Participants randomized to this group will participate in a group-based behavioral weight management program and consume a reduced carbohydrate (RC) diet. Because this is a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine RC diet with time-restricted eating (TRE) or RC diet with additional exercise counseling and support.
45624860|NCT04743999|Other|Quality of life questionnaire|We will evaluate patients' quality of life with a series of questionnaires at baseline, 3, 6, 12, and 24 months after surgical staging. These are prospectively validated questionnaires and include FACT-G (physical and functional well-being sections), FACT-En (additional concerns section), FACT/GOG-NTX-4 (additional concerns section), and FACT-C (items C3 and C5).These sections will be combined into one single form for ease of completion for the patients (a total of 36 items).
45624861|NCT04887675|Diagnostic Test|MRI|Both groups with undergo neuroimaging on 3T magnetic resonance unit (Trio Tim, Siemens, Erlangen, Germany) in the Center for Diagnostic Imaging, Oncology Institute of Vojvodina, Serbia. Multivoxel MRS will be performed in the supratentorial cerebral parenchyma, covering white matter of frontal and parietal lobes, as well as cortical grey matter in frontal and parietal lobes and the whole cingulate gyrus.
45624862|NCT04887363|Behavioral|Core exercise|Participants will receive12-week, 60 minutes, 36-session exercise-based core stability training class. Participants need complete baseline assessments of muscle performance, and balance ability measures 1 week prior and 1 week and 12 weeks following the intervention. All subjects will receive two post-exercise measurements at 13th week and 25th week.
45624863|NCT04887363|Behavioral|Tai Chi exercise|Participants will receive 12-week, 60 minutes, 36-session Tai Chi exercise training class. Participants need complete baseline assessments of muscle performance, and balance ability measures 1 week prior and 1 week and 12 weeks following the intervention. All subjects will receive two post-exercise measurements at 13th week and 25th week.
45624864|NCT03048435|Other|EORTC QLQ CX-24|Disease specific Patient Reported Outcome measurement tool developed by the European Organization for Research and Treatment of Cancer (EORTC). This questionnaire covers symptoms common to women with cervical cancer and captures the impact of disease and/or treatment on domains including: urologic and gastro-intestinal symptoms, sexual functioning and body image.
45624865|NCT03048435|Other|Physician Feedback Form|This Feedback form to be completed by oncologists who have had at least one consenting patient participating in this study.
45624866|NCT04881357|Other|test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).|The experimental group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).
45624867|NCT04881357|Other|control group|The control group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the control mouth rinse (Lacer Oros Acción Integral - new formula, without active ingredients, Barcelona, Spain).
45624868|NCT04880811|Drug|Afatinib|Afatinib is orally administered at 40mg Qd of each 21 day cycle.
45624869|NCT04880811|Drug|Toripalimab|Toripalimab is given by intravenous infusion at 200mg d1 of each 21 day cycle.
45624870|NCT04880343|Dietary Supplement|Group (A)|Group that will take a daily dose of the commercial dietary supplement provided by the sponsor, composed of mannose, cran-max and vitamin D for 6 months
45624871|NCT04880343|Dietary Supplement|Group (B)|Group that will take a daily dose of the commercial dietary supplement provided by the sponsor, composed of mannose, cran-max and vitamin D for 3 months
45624872|NCT04412109|Procedure|thoracic epidural catheterization|thoracic epidural catheterization for postoperative pain control
45624873|NCT04886661|Other|CHRONIC NECK PAIN|Demographic information will be collected. Neck Disability Index will be filled. Physical examination will be performed.
45624874|NCT02181634|Drug|Nab-Paclitaxel and Gemcitabine|Nab-Paclitaxel will be administered first, at a dose of 125 mg/m² IV over a period of 30 minutes; gemcitabine will be administered second, at a dose of 1000 mg/m² over a period of 30 minutes.
45624875|NCT04879953|Drug|PIPAC with systemic chemotherapy|PIPAC procedures were performed every 6 to 8 weeks, alternating with systemic chemotherapy, replacing a cycle of intravenous chemotherapy.
45766692|NCT00633152|Drug|linezolid|600 mg parenteral infused over 60 minutes for a minimum of 5 days and a maximum of 14 days
45624876|NCT04879953|Drug|Systemic chemotherapy alone|Intravenous chemotherapy
45624877|NCT04569045|Device|HA+Lidocaine|20 mg
45624878|NCT04569045|Device|HA|20 mg
45624879|NCT04887051|Other|pulmonory based home exercises|web based telerehablitation
45624880|NCT04886349|Biological|Platelet-rich plasma|Platelet-rich plasma injection for first CMC OA
45766693|NCT00633152|Drug|Aztreonam|1000 mg infused over 60 minutes every 24 hours may be started with linezolid or added later (up to 72 hours after the first dose of linezolid) for subjects with a gram-negative infection indicated.
45766694|NCT01030783|Drug|tivozanib (AV-951)|Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
45766695|NCT01030783|Drug|Sorafenib|Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
45766696|NCT00633074|Biological|Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
45766697|NCT00633074|Biological|Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
45766698|NCT03304054|Drug|Amifampridine Phosphate|tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
45447051|NCT04232943|Biological|Inactivated Poliomyelitis Vaccine (IPV)|"IMOVAX® Polio is a highly purified, inactivated poliovirus vaccine. Each 0.5 mL dose contains:~Type 1 (Mahoney) 40 D-antigen units~Type 2 (MEF1) 8 D-antigen units~Type 3 (Saukett) 32 D-antigen units"
45766699|NCT03304054|Drug|Placebo Oral Tablet|tablets matching amifampridine phosphate, 3 to 4 times a day
45766700|NCT01929278|Drug|CT Gel (clindamycin 1% and tretinoin 0.025%)|Three CT Gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures.
45766701|NCT01929278|Other|Vehicle gel patch|Three vehicle gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 2. Vehicle gel contained the identical ingredients and packaging as CT Gel but without the active ingredients. All vehicle gel used during the study was from batch ZLU C.
45766702|NCT01929278|Other|Blank patch|Three blank patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 3. Occlusive patches consisted of a non-woven cotton pad (Webril [approximately 2 cm x 2 cm]) covered and secured on all sides by an occlusive hypoallergenic tape (approximately 4 cm x 4 cm).
45766703|NCT01929356|Procedure|Chest physiotherapy|20 minutes of chest physiotherapy by physiotherapist
45766704|NCT01923350|Behavioral|Weight Reduction Intervention|"The weight trial intervention components were:~Electronic feedback from the ADAPT interactive obesity treatment approach (iOTA) system, tracking participants' behavior change goals. Participants received feedback either by daily SMS (text messaging) or by weekly IVR (interactive automated calls).~Seven behavior change coaching calls, once a month for 6 months, and then one at 7.5 months halfway through the maintenance period.~Print mailings/emailings~3 Get Ready e-messages in the four weeks before the weight intervention began~Pedometers and program guides. (IVR users received printed activity logs with their program guides.)~Access to the ADAPT iOTA website for reviewing their progress and obtaining information on behavior change goals."
45766705|NCT01923350|Behavioral|Weight Reduction Control Arm|Participants received an initial brochure about managing diabetes risk, a digital scale to use in entering their weights in online questionnaires, and monthly emailed wellness messages unrelated to diabetes.
45766706|NCT01923350|Behavioral|Tested for diabetes|Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a sub-sample of those tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
45766707|NCT01923350|Behavioral|Not tested for diabetes|Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a subsample of those not tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
45766708|NCT03210376|Drug|Deep Neuromuscular Blockade (NMB)|Deep Neuromuscular Blockade (NMB) given during surgery.
45766709|NCT03210376|Drug|Moderate Neuromuscular Blockade (NMB)|Moderate Neuromuscular Blockade (NMB) given during surgery.
45766710|NCT03210376|Drug|Sugammadex|4 mg/Kg, intravenously as a single bolus injection after surgery.
45766711|NCT03210376|Drug|Neostigmine|70 mcg/Kg up to a total of 5 mg, intravenously slowly over a period of at least 1 minute after surgery.
45766712|NCT03210376|Behavioral|Pain Assessment|Pain assessment done at about 15, 45, and 90 minutes after surgery.
45766713|NCT04396028|Other|data collection|retrospective data collection
45766714|NCT01929434|Other|rehabilitation|Patients only receive rehabilitation of physical therapy and occupational therapy.
45766715|NCT01929434|Biological|stem cell injection|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
45766716|NCT01929512|Drug|HCP1201 750/20mg|750mg Metformin/20mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
45766717|NCT01929512|Drug|Metformin SR 750mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
45766718|NCT01929512|Drug|Rosuvastatin 20mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
45766719|NCT03127904|Procedure|Vein Fitness|Vein fitness is a combination of whole-limb exercises, manual lymphatic drainage, and usual care (wound care and compressive therapy).
45766720|NCT03127904|Procedure|Compressive therapy and wound care|"Compressive therapy consists in the application of pressure to the inferior limb. Investigators describe the specifics in the arm section.~As previously described, a trained nurse will be in charge of keeping the wound healthy, verifying the surface is clean, debriding it, and removing biofilm from it."
45766721|NCT04447898|Drug|PPV-06 10 μg|Low dose + Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
45766722|NCT04447898|Drug|PPV-06 50 μg|High dose+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
45766723|NCT04447898|Drug|Placebo|Placebo+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
45912710|NCT02013466|Dietary Supplement|Bolus ONS D|high whey-protein, leucine-rich, high-caloric control product (isocaloric to product C)
45766724|NCT03211234|Drug|2.0 mg DE-122 Injectable Solution + Lucentis|Subjects will receive 6 monthly intravitreal injections of low dose DE-122 in the study eye, in combination with Lucentis.
45766725|NCT03211234|Drug|4.0 mg DE-122 Injectable Solution + Lucentis|Subjects will receive 6 monthly intravitreal injections of high dose DE-122 in the study eye, in combination with Lucentis.
45766726|NCT03211234|Drug|Lucentis|Subjects will receive 6 monthly intravitreal injections of Sham in the study eye, in combination with Lucentis.
45766727|NCT01030861|Drug|Teplizumab|intravenous infusions
45766728|NCT01030861|Drug|Placebo infusion|Placebo for Teplizumab
45766729|NCT03105518|Drug|Fentanyl|0.5, 1 mcg/kg
45766730|NCT03105518|Drug|Acetaminophen|Single + Oxycodone
45766731|NCT03105518|Drug|Oxycodone|With Acetaminophen
45766732|NCT01929668|Drug|polyethylene glycol|
45766733|NCT01929668|Drug|Ascorbic Acid|
45766734|NCT01031095|Other|coronary intervention|elective coronary intervention
45766735|NCT01929746|Biological|BIIB019 subcutaneous injection|participants will be randomized to receive a single subcutaneous injection of BIIB019, 75 mg or 150 mg per dose group
45766736|NCT03212638|Drug|Baricitinib suspension|Administered orally
45766737|NCT03212638|Drug|Baricitinib tablet|Administered orally
45766738|NCT03933397|Other|Patient-Specific Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on the pain medicine(s) they take at home for pain and what was needed during their past hospital and emergency department visits to treat pain. Medicines will include opioids, either morphine or hydromorphone. A member of the outpatient SCD provider team will review the patient's medical record to determine: 1) the patient's maximum home opioid dose, and 2) previous ED analgesic medication(s) and doses that have been effective and safe in the past. The patient's regular hematologist/sickle cell team will write the treatment plans. Medications will be given every 20-30 minutes for up to 6 hours.
45766739|NCT03933397|Other|Weight-based Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on their weight. Medicines will include opioids, either morphine or hydromorphone. Plans will be written by the patients regular hematologist/sickle cell team.
45766740|NCT03933397|Drug|Morphine|4 mg for participants weighing <50 kgs, 6mg for participants weighing 50-69.9 kgs, 8mg for participants weighing 70 - 89.9 kgs and 10mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
45766741|NCT03933397|Drug|Hydromorphone|1 mg for participants weighing <60 kgs, 1.5 mg for participants weighing 60 - 89.9 kgs, and 2 mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
45766742|NCT03506048|Drug|Lenvatinib|Given orally once daily continuously
45766743|NCT02161705|Drug|Ropivacaine|0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg) administered in paravertebral block
45766744|NCT02161705|Drug|Saline|Up to 0.8 mL/kg of normal saline administered
45766745|NCT01929824|Other|Oral Nitric Oxide testing|o Oral nitric oxide is measured by a breathing test where the participant will be seated in a chair and asked to breathe out into a small hand-held instrument for about 6 seconds.
45766746|NCT03216382|Behavioral|Attention Training Technique|The ATT is a 12-minute audio recording that includes sounds and a voice guiding attention to the sounds. The sounds play continuously during the training task.
45766747|NCT03216382|Behavioral|Control Condition|In the control condition, participants listen to an audio recording with the same sounds as the ATT recording, and a voice that delivers placebo instructions.
45766748|NCT03104504|Behavioral|Suicide Risk Screening|Suicide risk screening will be implemented as the standard of care for all patients who present for treatment.
46069621|NCT00696735|Procedure|chemotherapy|injection cyclophosphamide doxorubicin (25 mg/m2), and teniposide (60 mg/m2)(600 mg/m2)on day 1 and prednisone (40 mg/m2), administered orally on days 1 to 5.4,12 Treatment consisted of a 6-course induction phase administered monthly, followed, for responders and patients presenting a stable disease, by a maintenance phase that consisted of 1 cycle every 2 months for 1 year. Concomitant subcutaneous interferon alfa-2b was administered at 5 x 106 3 times a week for 18 months.
45452413|NCT05240222|Behavioral|Pre-implementation enhancement strategies (SC-PIES)|The SC-PIES was delivered to teachers as a one-hour professional development session immediately before receiving specific training about evidence-based student behavioral management practices and follow-up consultation. SC-PIES content was grounded in three social-cognitive principles: (a) growth mindset, (b) saying-is-believing, and (c) commitment and consistency.
45624881|NCT04464993|Behavioral|Device-based feedback, self-monitoring, and education: CORE|"Participants will receive a core intervention which will include a basic version of the StandUPTV app on an android tablet and a Fitbit to use throughout the 16-week intervention.t. SST feedback will be provided within the smartphone application. Self-monitoring will provide passive and objective feedback regarding SST behaviors. StandUPTV will also contain basic education including information on the risks of SST and tips for reducing SST. As part of this education, all participants will be provided a behavioral target of reducing their SST by 50% from their baseline. This target will be customized for the participant within StandUPTV based on a baseline week of observation."
45766749|NCT03104504|Behavioral|Safety Planning|Suicide screen-positive patients who are to be discharged from the hospital will receive personalized safety planning by a mental health clinician or nurse that includes means restriction counseling as a step in the safety plan.
45766750|NCT03104504|Behavioral|Care transition facilitation|Include post-acute telephone phone call follow-up to foster engagement with outpatient care and problem solving within 24 hours of discharge
45766751|NCT03104504|Behavioral|A Lean Implementation Strategy|The Interventions will be implemented using Lean performance improvement strategies
45766752|NCT01031953|Drug|fosaprepitant dimeglumine|A 150 mg dose will be given to study patients as rescue therapy after chemotherapy only in the event of breakthrough nausea or vomiting.
45766753|NCT01031953|Drug|systemic chemotherapy|Patients will receive chemotherapy on Day 1 of their scheduled therapeutic regimen in combination with the pre-defined standard 5-Hydroxytryptamine-3 (5HT3) antagonist, corticosteroid regimen, with or without benzodiazepine based on published guidelines3 or as clinically indicated
45766754|NCT01031953|Other|survey administration|Prior to the first dose of chemotherapy patients will be instructed on how to complete their patient diary
45766755|NCT01031953|Procedure|quality-of-life assessment|Patients will also be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero and then after 24 hours
45766756|NCT03310450|Other|140kms cycling|Main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms, and 240kms (investigator did not give any treatment/intervention, just observed the cycling touring event)
45766757|NCT01923584|Drug|EPI-743 400mg|
45766758|NCT01923584|Drug|EPI-743 200mg|
45766759|NCT04305626|Device|Endovascular treatment of intracranial aneurysms|Endovascular treatment of intracranial aneurysms with flow diversion.
45766760|NCT01032733|Behavioral|Lifestyle Counseling|In the WL+E group, participants attended a group-based weight management session plus three supervised exercise sessions each week.
45766761|NCT01032733|Other|Educational Control|Participants in the educational control group attended monthly health education lectures on topics unrelated to weight loss (e.g., skin protection).
45766762|NCT01928420|Drug|Drug: NIC5-15|A natural product, found in many foods and plants with mild insulin sensitizing effects
45766763|NCT01928420|Drug|Placebo|Subjects with Alzheimer's Disease placebo comparator
45766764|NCT03441178|Device|ENSEAL X1|ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.
45766765|NCT01004107|Device|Radiesse Injectable Dermal Filler|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier
45766766|NCT03218566|Device|Indigo Aspiration System|use of mechanical thrombectomy to treat pulmonary embolism
45766767|NCT00630344|Drug|RAD001|
45766768|NCT00630344|Drug|Bicalutamide|
45766769|NCT02167867|Device|Lay End Users|Lay End Users administer 40 minutes of treatment with the ZERONA Z6 to the waist, hips and thighs (20 minutes to the front side and 20 minutes to the back side) of a Treatment Subject, 6 times evenly spaced across two consecutive weeks.
45766770|NCT02167867|Device|Treatment Subject Group|Treatment subject received 6 40-minute evenly spaced treatments to the hips, waist and thighs (20 minutes to the front side and 20 minutes to the back side) with the ZERONA Z6 over 2 consecutive weeks. The ZERONA Z6 contains 6 17.25 milliWatts (mW) 635 nanometers (nm) light-emitting diodes.
45766771|NCT01923818|Drug|rivaroxaban|orally active direct factor Xa inhibitor
45766772|NCT01923818|Drug|Aspirin|non-steroidal anti-inflammatory drugs
45766773|NCT01923818|Drug|placebo|
45766774|NCT03442036|Device|Suture-Method Technique|Perineural catheters are attached to the back of a hollow suture-shaped needle that pulls the catheter adjacent to the target nerve
45766775|NCT03442036|Device|Through-the-Needle Technique|Perineural catheters are inserted through a straight hollow-bore needle
45766776|NCT02913261|Drug|Ruxolitinib (RUX)|Ruxolitinib was provided as 5 mg tablets for oral use.
45766777|NCT02913261|Drug|Best Available Therapy (BAT)|BAT was based on the investigator's best judgment, taking into account the manufacturer's instructions, labeling, patient's medical condition, and institutional guidelines for any dose adjustment. The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab. No other types or combinations of BAT were permitted.
45624882|NCT04464993|Behavioral|Sedentary Screen Time lockout: LOCKOUT|Sedentary Screen Time lockout: LOCKOUT Sedentary Screen Time lockout: LOCKOUT The investigators will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits feature to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be prompted to plan for their screen time and provided modest allowances for exceeding their screen time in a given week.
45766778|NCT02169115|Drug|Omalizumab|150mg, s.c., every 4 weeks
45624883|NCT04464993|Behavioral|Context-based prompts: TEXT|The TEXT component uses app-based prompts (i.e., prompts generated through StandUPTV, not text message based) that will provide simple adaptive content. Content of the prompts will be educational (i.e., based on risks of sedentary screen time) and motivational (i.e., advice to reduce sedentary screen time).
45766779|NCT02169115|Drug|Omalizumab|300mg, s.c., every 4 weeks
45766780|NCT02169115|Drug|Placebo|Placebo, s.c., every 4 weeks
45766781|NCT03537794|Diagnostic Test|PET scans|PET scans and PHNO scans
45766782|NCT03219892|Device|High-frequency rTMS|It is delivered at a 5-second burst of 10Hz stimuli, repeated 20 times at every minute. Each treatment contains a total of 1000 pulses. Stimulus intensity is 90% of resting motor threshold. The SMA stimulation will be given using a coil centered at points 3-cm anterior to the leg motor area in the sagittal midline.
45766783|NCT03219892|Device|Sham rTMS|The procedure will be same as the high-frequency rTMS except that the coil is 90° angled away.
45766784|NCT03656107|Behavioral|Cognitive Training|Lumosity© is a commercially available software, developed by a group of neuropsychologists, which has been used across several studies of brain training and disciplines. The brain training software targets multiple brain areas, is based online, and is relatively easy to use and administer. It has been designed to adapt to the individual's memory performance to personalise the training program to their needs. Brain exercises will be selected with the support of Lumosity© to target the following brain areas; attention, memory, visuospatial, verbal fluency, and language.
45766785|NCT00376792|Drug|docetaxel|
45766786|NCT00376792|Other|active surveillance|
45766787|NCT00376792|Procedure|adjuvant therapy|
45766788|NCT03015415|Procedure|Elbow Open Arthrolyses|Elbow arthrolysis by posterior access
45766789|NCT03015415|Procedure|Non-surgical intervention|Rehabilitation with splinting protocols
45766790|NCT03220048|Drug|PrEP-001|
45766791|NCT03220048|Other|Placebo Comparator|
45766792|NCT00635882|Drug|mometasone furoate/formoterol 100/10 mcg|mometasone furoate/formoterol 100/10 mcg twice daily (BID) (two inhalations of MF/F 50/5 from a metered-dose inhaler) for 14 days
45766793|NCT00635882|Drug|mometasone furoate/formoterol 200/10 mcg|mometasone furoate/formoterol 200/10 mcg twice daily (BID) (two inhalations of MF/F 100/5 from a metered-dose inhaler) for 14 days
45766794|NCT00635882|Drug|mometasone furoate/formoterol 400/10 mcg|mometasone furoate/formoterol 400/10 mcg twice daily (BID) (two inhalations of MF/F 200/5 mcg from a metered-dose inhaler) for 14 days
45766795|NCT00635882|Drug|MF DPI 200 mcg|MF DPI 200 mcg twice daily (BID) (one inhalation of MF DPI 200 mcg) for 14 days
45766796|NCT00635882|Drug|MF MDI 200 mcg|MF MDI 200 mcg twice daily (BID) (two inhalations of MF MDI 100 mcg) for 14 days
45447052|NCT04232943|Biological|E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant)|"LT (R192G/L211A), or dmLT, is a protein toxoid derived from wild-type enterotoxigenic Escherichia coli (ETEC) labile toxin (LT). The LT toxin has been shown to have inherent mucosal adjuvant properties for co-administered antigens and thus has potential as a mucosal adjuvant for different co-administered vaccines. LT has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites, which are critical for activation of the secreted toxin molecules."
45766797|NCT00635882|Drug|Placebo|MF/F MDI placebo twice daily (BID) (2 inhalations)
45766798|NCT03148015|Other|Biomarkers|Evaluate the intracellular and intraluminal distribution of autophagy and calcium efflux markers in each breast lesion in comparison to the HER2, proliferation (Ki-67, PCNA), p53, inflammatory, and apoptotic (Annexin-1) markers in the same patient. Determine the qualitative amount and localization of PMCA2 and Vitamin D Receptor in each breast lesion with intraductal calcium spicules compared to lesions without microcalcifications.
45766799|NCT03445156|Behavioral|Video game|Participants played either a violent shooting game or nonviolent shooting game in the pilot study, and either either a violent shooting game, nonviolent shooting game, or nonviolent non-shooting game in the experiment proper.
45766800|NCT03445156|Behavioral|Controller|Participants used either a gun-shaped or regular controller to play the violent and nonviolent shooting video games.
45766801|NCT03082495|Behavioral|Exercise|Supervised high-intensity interval training (HIIT) during NACRT followed by unsupervised moderate-to-vigorous intensity continuous exercise training after the completion of NACRT and before surgery
45766802|NCT03001063|Other|Supported Self-Management|This Supported Self-Management intervention consists of bibliotherapy (the Antidepressant Skills Workshop) that is provided to a patient by a health or social worker. The patient is supported in the use of the skills found in the workbook over the course of two months. The skills in the workbook are based on the principles of Cognitive Behavioural Therapy.
45766803|NCT03001063|Other|Enhanced treatment as usual|Participants in the control arm will received enhanced treatment as usual in the form of usual care at primary care centres and a leaflet providing information about depression.
45766804|NCT03316378|Drug|Ropivacaine injection|single dose, subcutaneous injection
45766805|NCT00637130|Drug|Travoprost ophthalmic solution, 0.0008%|
45766806|NCT00637130|Drug|Travoprost ophthalmic solution, 0.001%|
45766807|NCT00637130|Drug|Travoprost ophthalmic solution, 0.0012%|
45766808|NCT00637130|Drug|TRAVATAN|
45766809|NCT00637130|Other|Vehicle|
45766810|NCT02847559|Biological|Bevacizumab|Given IV
45447053|NCT04232943|Biological|Bivalent Oral Polio Vaccine (bOPV)|"Polio Sabin™ One and Three (oral) is a bivalent, live attenuated poliomyelitis virus vaccine of the Sabin strains Type 1 (LSc, 2ab) and Type 3 (Leon 12a, 1b), propagated in MRC5 human diploid cells.~Each dose (0.1 mL) contains not less than 10⁶ 50% cell culture infectious dose (CCID₅₀) of Type 1 and 10⁵·⁸ CCID₅₀ of Type 3."
45447054|NCT02098330|Drug|Ginkgo biloba & Methylprednisolone|Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month. Methylprednisolone 48 mg/day(per oral, once a day for first 9 days. And then methylprednisolone tapering was started every 2 days. The entire duration of methylprednisolone treatment was 14 days.
45624884|NCT04464993|Behavioral|Earn sedentary screen time through moderate-vigorous physical activity: EARN|Earn sedentary screen time through moderate-vigorous physical activity: EARN Participants assigned to the EARN component will earn SST by engaging in a >5 min continuous bout of exercise (as defined by Fitbit minutes >4 metabolic equivalents). They will earn SST on a 3:1 ratio up until they reach their baseline level of MVPA (5 mins of exercise earns 15 mins of SST). They will receive behavioral strategies to reduce screen time within the app (e.g., self-efficacy, barriers, exercising safely) and a planning tool for scheduling MVPA.
45624885|NCT04425291|Biological|4-valent HPV Vaccine|Subjects received 3 doses of 4-valent HPV vaccine according to a 0, 2, 6-month schedule.
45766811|NCT02847559|Procedure|Electric Field Therapy|Undergo electric field therapy using Optune device
45766812|NCT02847559|Device|NovoTTF-200A Device|Undergo electric field therapy using Optune device
45766813|NCT02847559|Procedure|Quality-of-Life Assessment|Ancillary studies
45766814|NCT00637052|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
45766815|NCT01921868|Drug|Acetyl-L-Carnitine|Acetyl-L-Carnitine, 2 g/day, up to 24 months.
45766816|NCT02150785|Drug|Streptokinase|
45766817|NCT03220204|Behavioral|PP-based health behavior intervention|The positive psychology exercises include 3 modules: gratitude-based activities, strength-based activities, and meaning-based activities. The goal-setting portion of the program focuses primarily on physical activity (8 weeks) but also includes 4 weeks focusing on diet and medication adherence.
45766818|NCT03220204|Behavioral|MI-based educational control condition|The MI-based educational program includes information on five topics: (1) information about heart disease and risk factors for worsening heart disease, (2) physical activity, (3) a heart-healthy diet, (4) medication adherence, and (5) stress management.
45766819|NCT01925534|Device|High-flow humidified nasal oxygen delivery system|During breaks from NIV oxygen will be provided through the Optiflow with FiO2 and flow-rate titrated to maintain the oxygen saturation (SpO2) above 90%.
45766820|NCT01925534|Device|Standard oxygen therapy|During breaks from NIV oxygen will be provided by standard nasal cannula or mask to maintain the SpO2 above 90%.
45766821|NCT02165605|Drug|HylaCare|cream
45766822|NCT02165605|Drug|Placebo|placebo
45766823|NCT01926158|Drug|Denosumb|Prefilled syringe of 1 mL denosumab solution
45766824|NCT01926158|Drug|Placebo (for denosumab)|
45624886|NCT04425291|Biological|9-valent HPV Vaccine|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
45624887|NCT04425291|Biological|GARDASIL®|Subjects received 3 doses of GARDASIL® according to a 0, 2, 6-month schedule.
45624888|NCT04879719|Behavioral|Ego-depletion|The surgery video lasts for 9 minutes and participants are asked to suppress their emotions. After the intervention several implicit aggression tests, as well as a task, measuring cognitive performance in general are assessed.
45766825|NCT03445390|Drug|Acetaminophen|Acetaminophen 1 g intravenous given at the beginning and end of surgery.
45766826|NCT03445390|Drug|Placebo|Placebo to match acetaminophen given at the beginning and end of surgery.
45766827|NCT00981890|Drug|Sunitinib|Sunitinib is a tablet that is taken by mouth every day. Patients will be treated with Sunitinib alone for 7 days. On the seventh day of taking the drug they will be given SRS. Sunitinib will continue for seven days per week after SRS, and depending on how far along the study is when patients join, they may continue taking the drug for up to 13 weeks after SRS.
45766828|NCT02165761|Device|GORE® Hybrid Vascular Graft|
45766829|NCT02165761|Device|Non-heparin bonded synthetic graft|
45766830|NCT03080948|Behavioral|survey|Research assessments as part of this protocol will be scheduled during routine clinic visits
45766831|NCT03080948|Other|Saliva samples|Germline DNA analysis
45766832|NCT03221764|Drug|Amiodarone with CoSeal|CoSeal Surgical Sealant (Baxter Healthcare) consist of 2 formulations of synthetic polyethylene glycols, a dilute hydrogen chloride solution along with a sodium phosphate/sodium carbonate solution. These separate solutions are mixed at the time of application to form a hydrogel. Amiodarone hydrochloride powder (1mg/kg) will be mixed with CoSeal at the time of application to form an amiodarone containing hydrogel. The dosing of amiodarone is based on previous study using amiodarone hydrogel in post-operative coronary artery bypass patients [8]. This hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
45766833|NCT03221764|Device|CO2 driver|The amiodarone hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
45447055|NCT02098330|Drug|Ginkgo biloba|Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month.
45766834|NCT03122444|Drug|Imipramine|Imipramine will be given daily for 21-30 days.
45766835|NCT05593783|Procedure|lithotripsy|lithotripsy
45766836|NCT01924130|Other|Classroom feeding|Students are fed breakfast in the classroom at the start of the school, rather than the cafeteria before school.
45766837|NCT01924130|Behavioral|Nutrition education lessons|Students receive breakfast specific nutrition education lessons.
45766838|NCT01924130|Behavioral|Social Marketing|A social marketing campaign designed to promote consumption of one healthy breakfast a day. The marketing includes a healthy breakfast points-based reward program designed by the students and promotional campaigns.
45766839|NCT01924130|Behavioral|Parent outreach|A variety of communication methods that engage families and offer education that meets their needs, including school breakfast menus, parent newsletters, and information tables at parent-teacher meetings.
45624889|NCT04879719|Behavioral|Control|The surgery video lasts for 9 minutes and participants in the control group are asked to watch the surgery video without the need to suppress their emotions. Several implicit aggression tests, as well as a task, measuring cognitive performance in general are assessed after the 9 minute video sequence.
45624890|NCT04879485|Biological|Blood products|Compare two different transfusion strategies against standard transfusion regimen
45766840|NCT05593627|Drug|Lithium Carbonate 250 MG Oral Tablet|Patients undergoing heart valve surgery withcardiopulmonary bypass will take 250mg lithium carbonate
45766841|NCT05593627|Drug|Calcium Carbonate 500 MG Oral Tablet|Patients undergoing heart valve surgery withcardiopulmonary bypass will take 500mg calcium carbonate
45766842|NCT02848989|Other|Qigong Mind-Body Exercise|An exercise program that involves gentle movements combined with breathing/relaxation techniques
45766843|NCT05593159|Other|Dentin Conditioning|After washing and drying -but not desiccating- Dentin Conditioner 20% (GC, Japan) will be applied using a cotton pellet for 20 seconds then rinsed thoroughly and gently dried
45766844|NCT05593159|Other|RM-GIC|RM-GIC (Fuji II LC) will be applied in <2mm incremental layers afterword light-cured for 10 sec (1,000 mW/cm2) per increment to fill the cavity.
45766845|NCT05593159|Other|1-step adhesive|A universal adhesive system (Tetric® N-Bond Universal) will be applied on both enamel and dentin and gently scraped for 20 sec, then dispersed with oil-free gentle air stream, then light-cured for 10 sec (1,000 mW/cm2).
45766846|NCT05593159|Other|Cention N|The cavity will be restored using cention N followed by light curing for 10sec (1,000 mW/cm2)
45447056|NCT02103166|Drug|Hyoscine bromide|20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).
45624891|NCT04879407|Drug|Rivaroxaban|Any rivaroxaban dispensing claim is used as the exposure group
45624892|NCT04879407|Drug|Warfarin|Any warfarin dispensing claim is used as the reference group
45766847|NCT05593159|Other|Dentin roughness|Using a round carbide bur size 14/16, (H1SEM.204.014 VPE5 or H1SEM.204.016 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece. (No bevel preparation will be made)
45766848|NCT05593159|Other|Gingival retentive groove preparation|Using size-010 round carbide bur (H1SEM.205.010 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece.
45766849|NCT02824731|Radiation|Radiation with protons|
45766850|NCT02824731|Radiation|Radiation with photons|
45766851|NCT03317002|Drug|AZD5718|Oral dose of AZD5718 (tablet)
45766852|NCT03317002|Drug|AZD5718|Oral dose of AZD5718 (tablet)
45766853|NCT03317002|Drug|Placebo|Matching placebo (tablet)
45766854|NCT02390505|Drug|Vitamin C|
45766855|NCT02390505|Drug|Placebo|
45766856|NCT05593081|Genetic|HLA|Distinguish based on clinical features
45766857|NCT05592925|Diagnostic Test|coagulation-related factors|We retrospectively evaluated the relationship between lymph node metastasis and coagulation-related factors in 516 patients with T4a stage gastric cancer.
45766858|NCT03223246|Other|Additional teaching|A brief safety intervention, combining a pictorial handout, dosing demonstration with dispensed syringe, and teach-back for confirmation of understanding.
45766859|NCT02169427|Drug|OPC|The drug substance of 100 mg OPC was administered as 1 capsule.
45766860|NCT02795247|Procedure|Anterior Cruciate Ligament Reconstruction|
45624893|NCT04886193|Drug|FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1)|"FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ 24h Q2W~Treprizumab 3mg/kg, intravenously administered on the first day of each cycle, Q2W~Tiggio capsule (S-1) 40-60mg (BSA<1.25 m2: 40mg, 1.25 m2≤BSA≤1.5 m2: 50mg, BSA> 1.5 m2: 60mg) po bid d1-14 Q3W, continuous treatment for 1 year;~Teriprizumab 240mg, intravenously, given on the first day of each cycle, Q3W, continuous treatment for 1 year."
45624894|NCT04878939|Other|Power chain used for anterior segment retraction|Elastomeric chain rendering 160 g/side extending between mini-screw implant and a hook crimped on 0.017- by 0.025-inch stainless steel wire distal to the lateral incisor.
45766861|NCT05592847|Other|Nurse Navigator Program|Identification of specific chronic conditions and suggestion of management care of primary care physicians and referrals to specialists via nurse navigator team members.
45766862|NCT03452176|Device|Scrambler|Scrambler is a non-invasive pain modifying technique that utilizes transcutaneous electrical stimulation of nociceptive fibers with the intent of re-organizing maladaptive signaling pathways which has been investigated for treatment of peripheral neuropathy.
45766863|NCT03452176|Device|Scrambler Sham Control|Sham control should be indistinguishable to the participants from experimental Scrambler therapy.
45766864|NCT05590975|Behavioral|PACT Intervention|PACT Intervention is a group based session delivered by Peer supporters and adult coaches on PACT module. There will be 10 sessions, one per week for 90 to 120 minutes each.
45766865|NCT03454048|Drug|Piperaquine (low dose)|subcurative regimen (480 mg)
45447057|NCT02103166|Drug|Physiological serum|100 ml of physiological serum (0.9% NaCl).
45447058|NCT02103244|Drug|Carboplatin|carboplatin will be dosed according to newly developed dosing algorithm.
45447059|NCT02099656|Drug|Lebrikizumab|Lebrikizumab will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
45766866|NCT03454048|Drug|Piperaquine (high dose)|Curative regimen (960mg)
45766867|NCT03454048|Drug|Sulfadoxine pyrimethamine|Curative regimen (1000mg/50mg)
45766868|NCT03454048|Drug|Atovaquone Proguanil|Curative regimen (1000/400 mg, for 3 days)
45766869|NCT03454048|Other|malaria challenge infection, P. falciparum 3D7|malaria challenge infection by P. falciparum 3D7-infected mosquito bites
45766870|NCT03454048|Other|Blood stage malaria challenge infection, P. falciparum 3D7|P. falciparum 3D7-infected human erythrocytes administered intravenously for the purpose controlled human malaria infection.
45766871|NCT02165839|Behavioral|Brief Behavioral Therapy for Insomnia (BBT-I)|
45766872|NCT02165839|Behavioral|Healthy Eating Education Learning (HEAL)|
45766873|NCT04396184|Procedure|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
45766874|NCT03226366|Other|Immediate evaluation by multidisciplinary team|Simultaneous initial evaluation by the ED physician, nurse, and patient care associate
45447060|NCT02099656|Drug|Placebo|Lebrikizumab matching placebo will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
45447061|NCT02099656|Drug|Inhaled corticposteroids (ICS)|Participants will continue their ICS controller therapy, as they are receiving prior to screening, throughout the study. Protocol does not specify any particular ICS.
45766875|NCT04395872|Behavioral|Psychiatric counseling|Patients who are admitted to the COVID-19 care unit of the Catholic University of Daegu Hospital are subject to consultation with the psychiatrist. By retrospectively reviewing the medical records of the request and the results of the subjects, We collected Socio-demographic information, medical severity (oxygen saturation, chest x-ray readings, medication being administered), clinical psychological scale (PHQ-9, GAD-7, PC-PTSD-5, AIS, P4, SF-36, SCL-90-R) This study evaluates whether there is a difference in psychological scale according to differences in socio-demographic status and medical severity, and compares psychological psychological measures before and after referral to mental health medicine to evaluate the effectiveness of psychiatric counseling.
45766876|NCT03015337|Behavioral|New physical education instructions|
45766877|NCT04395092|Biological|K-NK002|"K-NK002 will be administered intravenous (IV) on Day -2, Day +7 and Day +28.~Part One (Safety run-in):~An initial safety run-in to confirm the starting dose, and safety and tolerability of K-NK002;~Dose cohort 1 will include 3 patients who will receive a dose of K-NK002 at 1 x 10E7 NK cells per kg.~Dose cohort 2 will include 3 patients who will receive K-NK002 at 1 x 10E8 NK cells per kg.~Part Two (Open Enrollment):~Enrollment into the second part of the study (Open Enrollment) can begin following Part One, confirmation of dose and safety."
45766878|NCT04395092|Procedure|Conditioning Regimen|"From Day -7 to Day -3:~Melphalan: 140 mg/m2 (100mg/m2 in patients ≥ 60) on Day -7.~Fludarabine: 40 mg/m2 daily for 4 doses starting on days -7.~TBI: 2 Gy on Day -3."
45766879|NCT04395092|Procedure|HaploBMT|Bone marrow is the only allowed graft source for patients enrolled in this clinical trial
45766880|NCT03015571|Device|Esophagus inspection in Narrow Band imaging.|During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection.
45447062|NCT02099656|Drug|Second Asthma Controller Medication|Participants will continue their asthma controller therapy, as they are receiving prior to screening, throughout the study.
45447063|NCT02098408|Behavioral|Cognitive remediation|"Neurocognition will be trained using the NEAR model (Medalia et al. 2003), whereas the training of social cognitive skills will be by use of the SCIT manual (Social Cognition and Interaction Training) developed by Roberts et al. 2014.~The intervention consists of 24 group sessions taking place once a week (two hours) and additional neurocognitive training at home. Furthermore, there will be a total of 12 individual sessions aiming at bridging the cognitive training to the everyday functioning of the patients."
45624895|NCT04878939|Other|T-loop fabricated to perform anterior segment retraction|In the frictionless group, anterior segment retraction was done using closing T-loops fabricated from 0.017- by 0.025-inch titanium molybdenum alloy (TMA) wire rendering comparable retraction force.
45624896|NCT04879173|Device|RS85 Ultrasound device|RS85 Ultrasound device manufactured by Samsung Medison
45624897|NCT04878861|Behavioral|Training in the blind field|Participants will complete visual training at two locations in the blind field. These two locations of training will be determined at the baseline study visit (0 months) and will be located within the perimetry-defined blind field. The training programme involves discriminating the direction of motion in a small circle of moving dots. The computer software and a chin-rest will be loaned to each participant to complete training at home. Participants will perform 300 trials at each location in their blind field, 5 days a week for at least 24 weeks (40-60 minutes in total). The computer programme will automatically generate a record of participant performance after each home training session.
45766881|NCT03015571|Device|Standard High definition endoscopy.|Whole procedure will be performed in standard High definition endoscopy.
45766882|NCT03015571|Device|Esophagus inspection in Narrow Band imaging and increased care.|During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection and with increased care of cervical inlet patches detection.
45766883|NCT03015571|Device|Standard High definition endoscopy and increased care.|Whole procedure will be performed in standard High definition endoscopy with increased care of cervical inlet patches detection.
45624898|NCT04337073|Drug|Propofol|Before anesthesia induction, M group received intravenous injection of 0.3mg/kg Propofol, while N group received corresponding intravenous normal saline of the same volume. After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg.
45624899|NCT04337073|Drug|normal saline|Before anesthesia induction, M group received intravenous injection of 0.3mg/kg Propofol, while N group received corresponding intravenous normal saline of the same volume. After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg.
45624900|NCT04275141|Other|oral glucose load|oral glucose load (60g) followed by exercise at fixed wattage (60W) for 30 min
45624901|NCT04275141|Other|exercise test|oral glucose load (60g) followed by exercise at fixed wattage (60W) for 30 min
45766884|NCT01924286|Drug|Prednisone|
45766885|NCT01924286|Drug|Placebo|
45766886|NCT04443439|Device|GE Discovery MR750 3.0t superconducting MRI|T2WI, FLAIR, DWI, 3D BRAVO, 3D-ASL, rs-fMRI, DKI sequences to exclude other organic lesions
45912711|NCT02013505|Other|Educational video|An educational video was developed based on the current paper instructions for bowel preparation. The video included a physician explaining the process, using more images and short clip videos of the example. The script of the video was approved by the patient education department of the University Hospital and language adjusted to 6th grade level.
45624902|NCT04885959|Behavioral|Personalized Prevotella sp. and butyrate enriching diet guidelines|specially design dietary guidelines with biomarkers monitoring
45624903|NCT04886037|Other|sestrin|Serum sestrin levels involved in inflammation and energy metabolism are compared between endometriosis and healthy control group.
45624904|NCT03049995|Procedure|Left ventricular contractile reserve SE|Stress protocols (either physical or pharmacological) will be performed according to recent guidelines recommendations (1,2,3). with special focus on Wall Motion Score Index.
45766887|NCT03455218|Drug|Nitric Oxide|20 ppm of Nitric Oxide gas delivered to the oxygenator for the duration of cardiopulmonary bypass
45766888|NCT03455218|Drug|Placebo|INOmax device connected to oxygenator, but no gas is delivered
45766889|NCT03455218|Device|INOmax|All patients will have the INOmax device connected to the oxygenator
45766890|NCT01920230|Behavioral|Mindfulness-ACT-intervention|Half of the participants (n=109) is assigned to intervention group. The intervention is based on Mindfulness-program presented by Williams & Penman (2011) and on principles of acceptance-commitment therapy (ACT). It aims to increase mindfulness skills and psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings as well as support clarifying individual values and value-based actions. The basic principles are presented in weekly small group meetings. Participants are guided to deepen their experiences through exercises and information that is provided via specific web-site.
45766891|NCT01920230|Behavioral|No intervention|Half of the participants (n=109) don't get any special treatment. However the present study explores what kind of support they have had during the program.
45766892|NCT01050907|Drug|Miltefosine|2.5 mg/kg/day for 28 days
45912712|NCT02013518|Behavioral|Cognitive Behavioural Therapy|11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.
45912713|NCT02013557|Behavioral|Text-message reminder|
45766893|NCT03120650|Other|Scalp acupuncture|Acupoint selection: Shenting (DU24; Baihui (DU20; and upper 1/5 and middle 2/5 in the contralateral motor area (upper: 0.5 cm posterior to the midpoint of the front and rear midline; middle 2/5: intersection between the eyebrow line and the leading edge of the temple hairline.
45766894|NCT03120650|Other|Conventional rehabilitation|Rehabilitation plans will be made according to the Guidelines for Stroke Rehabilitation in China (Cerebrovascular Disease Association and the Neurological Rehabilitation Association of Neurology Branch of the Chinese Medical Association, 2012), including physical therapy and occupational therapy.
45766895|NCT01924520|Drug|FK949E|Oral
45766896|NCT04433845|Drug|Psilocybin|Open-label
45766897|NCT01920308|Device|5 mm Bard LifeStent Vascular Stent|The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
45766898|NCT04431973|Device|Medacta Shoulder System|Surgical placement of the Medacta Shoulder System prothesis on patients with pathologies requiring the insertion of a total reverse shoulder prothesis for primary omarthrosis, cuff tear arthropathy, massive cuff rupture or post instability arthropathy
45766899|NCT01920386|Drug|Tramadol hydrochloride/Acetaminophen Tab.|
45766900|NCT01920386|Drug|Tramadol hydrochloride/Acetaminophen SR Tab.|
45766901|NCT04408027|Behavioral|Virtual-Care Cognitive Behavioural Therapy|The feasibility, participation barriers, and acceptability of the intervention, virtual-care cognitive behavioural therapy (VC-CBT), will be evaluated for children with anxiety. The VC-CBT protocol will involve 12 sessions (of one hour in duration) delivered by a CBT therapist using PHIPA (Personal Health Information Protection Act) compliant Zoom. An initial session will review therapy goals and psychoeducation about anxiety. Sessions 2 and 3 will focus on feeling identification and will introduce relaxation strategies. Sessions 4 and 5 will introduce cognitive distortions and restructuring strategies. Sessions 6 and 7 will introduce exposure tasks. Sessions 8 to 11 will involve practicing cognitive restructuring skills and completing exposures. The final session will review relapse prevention. Parents will participate in the first and last sessions, as well as join at the end of each session for a brief review of the skills learned during the session.
45766902|NCT03460990|Drug|VX-659/TEZ/IVA|Participants received VX-659/TEZ/IVA orally once daily in the morning.
45766903|NCT03460990|Drug|TEZ/IVA|Participants received TEZ/IVA orally once daily in the morning.
45766904|NCT03460990|Drug|IVA|Participants received IVA orally once daily in the evening.
45766905|NCT03460990|Drug|Placebo|Participants received placebo matched TEZ/IVA orally once daily in the morning.
45766906|NCT03460990|Drug|Placebo|Participants received placebo matched to VX-659/TEZ/IVA orally once daily in the morning.
45766907|NCT01924598|Device|DBS to nucleus accumbens/anterior limb of internal capsule|deep brain stimulation followed by 12 month post switch on followup
45766908|NCT01052545|Behavioral|Audit-Feedback|Applied as a post-prescription antimicrobial review based on established guidelines.
45766909|NCT01924832|Drug|dimethyl fumarate|tablet
45912714|NCT02013570|Drug|Dexmedetomidine|2µg/kg dexmedetomidine in 2 ml normal saline (1 ml per tonsil),
45624905|NCT03049995|Procedure|B-lines SE|SE will be performed with special focus on lung sonography and B-lines score (3,4).B-lines will be scored with the 28-regions antero-lateral chest assessment as previously described at baseline and immediately after stopping exercise. A simplified 8-region scan is also allowed in order to save time without loss of critical information.
45624906|NCT03049995|Procedure|Left ventricular outflow tract gradient SE|SE will be performed with special focus on left ventricular outflow tract obstruction (3,4).
45624907|NCT03049995|Procedure|Diastolic function SE|SE will be performed with special focus on E/e', pulmonary artery systolic pressure, B-lines and left ventricular end-diastolic volume (3,4).
45624908|NCT03049995|Procedure|Mitral regurgitation SE|SE will be performed with special focus on mitral regurgitation and aortic valve gradients assessment (3,4).
45624909|NCT03049995|Procedure|Pulmonary hemodynamics SE|SE will be performed with special focus on pulmonary artery systolic pressure and pulmonary artery hemodynamics.
45624910|NCT03049995|Procedure|Coronary flow reserve SE|SE will be performed with special focus on regional wall motion + coronary artery flow velocity reserve.
45624911|NCT04138017|Device|ViviGen|A cellular bone matrix which includes viable osteoblasts within a corticocancellous and demineralized bone carrier, represents a unique alternative to autograft or existing products which utilize mesenchymal stem cells.
45624912|NCT04878783|Diagnostic Test|CT scan|Patients undergoing CT scan staging for gastric and EJ junction cancer + perioperative chemotherapy (FLOT regimen) , CT scan re-staging and radical gastrectomy or esophagogastrectomy will be enrolled in the study
45624913|NCT04885725|Device|All group|All the participants performed the isokinetic proprioception and strength tests and the functional tests, on the same visit.
45624914|NCT04878705|Drug|TWP-201|a single subcutaneous injection
45624915|NCT04878705|Drug|placebo|a single subcutaneous injection
45766910|NCT04332562|Other|dietary restriction (salt restriction)|salt restriction for one week after being diagnosed with hypertension
45766911|NCT01920542|Drug|Dexmedetomidine|administration of dexmedetomidine on dexemedetomidine group
45766912|NCT01920542|Drug|no dexmedetomidine|no administration of dexmedetomidine on control group
45766913|NCT03319810|Biological|Octagam 10%|FDA approved human normal immunoglobulin solution ready for intravenous administration
45766914|NCT01052701|Drug|Ribavirin|"Daily Ribavirin alone 400 mg in the morning (AM) and 600 mg in the afternoon (PM) orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV alone 600 mg orally every 12 hours (Body Weight >75 kg)"
45766915|NCT01052701|Drug|Ribavirin plus Abacavir (ABC)|"Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV 600 mg orally every 12 hours (Body Weight >75 kg)~Plus~Daily Abacavir 300 mg orally every 12 hours"
45766916|NCT01920620|Behavioral|Inpatient weight loss counseling|Weight loss counseling utilizing a 13 minute patient education video on weight loss and an 25 minute personalized health education session. Subjects set 3 specific behavior set three specific lifestyle goals prior to discharge including a calculated six month weight loss goal (10% of body weight) and specific dietary and fitness goals. Usual care group participants received no specific instruction regarding weight loss prior to discharge.
45912715|NCT02013596|Other|TEAS pretreatment|Electric stimulation was given through electrode attached to specific acupoints for 30mins before anesthesia induction
45766917|NCT01920620|Behavioral|Motivational interviewing and troubleshooting via phone|All subjects were asked to track their weights over the 6 month duration of the study. Weights were obtained by phone at weeks 1,2,3,4, 8, 12, 16, 20 and 24. Phone calls for the intervention group utilized motivational and troubleshooting techniques whereas calls in the usual care group were used only to obtain weight and assess for changes in medications or health condition.
45447064|NCT02098408|Behavioral|Standard treatment|Patients allocated to the control condition are free to choose whatever standard treatment they are offered by the clinicians managing their treatment. Usually standard treatment consists of regular contact to health professionals in the in- and outpatient facilities in Copenhagen, Denmark, and encompass different kinds of supportive counselling.
45624916|NCT04885803|Dietary Supplement|Softgel Vitamin D3|5000IU vitamin D3 taken as single oral softgel once daily for 30 days
45624917|NCT04885803|Dietary Supplement|Nano Liquid Vitamin D3|5000IU vitamin D3 taken as liquid oral spray once daily for 30 days
45766918|NCT01920776|Other|ultrasound examination|
45766919|NCT01920776|Other|Ultrasound group|Ultrasound group will receive ultrasound examination at least once a day, the results will be noted to the attending who is in charge of the treatment.
45766920|NCT03322930|Diagnostic Test|Rod sensitivity|diagnostic test for rod loss in central retina
45766921|NCT05528809|Other|Blood sampling|A blood sampling will be performed during the inclusion visit (day 0).
45766922|NCT01921010|Drug|Niaspan|See Arm Description
45766923|NCT01921010|Drug|Placebo|See Arm Description
45766924|NCT02246491|Other|A-T iPS cell line|Reprogramming A-T patients iPS cell line
45766925|NCT02246491|Other|Carrier patients iPS cell line|Reprogramming iPS cell line from carrier patients
45766926|NCT03115424|Drug|Saxenda|Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients. Subjects will be recruited and screened prior to undergoing bariatric surgery. Subjects undergoing SG will be randomized 1:1 at month 3 post surgery to Saxenda, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
45447065|NCT02098486|Drug|Moxifloxacin|
45624918|NCT04885803|Diagnostic Test|25(OH)D Blood Serum Test|A sample of blood is drawn off and processed for 25(OH)D levels at baseline, after 15 days of supplementation, and after 30 days of supplementation
45624919|NCT04885803|Other|Placebo Control|Liquid oral spray once daily for 30 days. Solution identical in smell, taste, color, and production process to Nano Liquid D3, but containing no Vitamin D3.
45766927|NCT03115424|Drug|Placebos|Subjects will be recruited and screened prior to undergoing bariatric surgery.Subjects undergoing SG will be randomized 1:1 at months 3 post surgery to Placebo, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
45766928|NCT03115424|Procedure|RYGB|Subjects will be recruited and screened prior to undergoing bariatric surgery. After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
45766929|NCT01921088|Other|real-time functional magnetic resonance imaging neurofeedback (RT-fMRI-NF)|Subjects are provided with RT-fMRI-NF.
45766930|NCT01921088|Behavioral|Ambulatory Training|Subjects are provided with an ambulatory training.
45766931|NCT01921244|Other|Decision Aid|"Parents will receive an intervention modified from the previously published tool called Autism: Should My Child Take Medicine for Challenging Behavior? This packet provides parents with educational information, elicits parent ratings of particular behavioral domains, describes behaviors that are and are not amenable to medication treatment, and elicits parent preferences regarding treatment. Providers will be trained on use of the intervention in practice to promote shared decision making during clinical encounters."
45766932|NCT03325816|Drug|Nivolumab|Nivolumab is administered intravenously
45766933|NCT03325816|Radiation|177Lu-DOTA0-Tyr3-Octreotate|"177Lu-DOTA0-Tyr3-Octreotate will be administered every 8 weeks. The first dose of 177Lu-DOTA0-Tyr3-Octreotate will be given two weeks after the first administration of nivolumab. Each dose is infused over 30 minutes. On the day of 177Lu-DOTA0-Tyr3-Octreotate infusion, an intravenous bolus of anti-emetics will be given (suggested options: ondansetron (8 mg), granisetron (3 mg), or tropisetron (5 mg)). Administration of 177Lu-DOTA0-Tyr3-Octreotate may be given one day earlier or delayed up to 1 week due to holidays, inclement weather, conflicts, or similar reasons.~Concurrent amino acids are given with each dose of 177Lu-DOTA0-Tyr3-Octreotate since co-infusion of amino acids leads to a significant reduction (47%) in the mean radiation dose to the kidneys. The amino acid solution and 177Lu-DOTA0-Tyr3-Octreotate are administered in parallel by peripheral vein infusion"
45766934|NCT00986570|Biological|Botulinum Toxin A|100 U DL50 lyophilized powder for reconstitution in 1 ml Saline Solution 0.9%.
45766935|NCT00986258|Drug|Tapentadol Prolonged Release|"Participants started with 50 mg, 100 mg or 150 mg tapentadol prolonged release (PR) twice daily. Opioid rotation to tapentadol was scheduled as follows:~if less than 100 mg morphine equivalent start with 50 mg tapentadol PR;~if on 101 to 160 mg morphine equivalent daily dose start with 100 mg tapentadol PR;~if above 161 mg morphine equivalent daily dose start with 150 mg tapentadol PR.~Tapentadol doses were adjusted to a level that provided adequate analgesia (upwards or downwards on a weekly basis). After 5 weeks, the doses of tapentadol PR were kept stable (start of Maintenance phase). The tapentadol PR formulation was administered for up to 12 weeks. Tapentadol immediate release 50 mg (no more than twice daily; at least 4 hours apart) was considered as medication for acute pain episodes however, participants were not permitted to dose tapentadol immediate release any more when a daily dose of 500 mg tapentadol PR was reached."
45766936|NCT00986180|Drug|NUCYNTA|50, 75, or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
45447066|NCT02098486|Drug|ceftriaxone|
45447067|NCT02250820|Drug|Dexmedetomidine|Nasal administration
45447068|NCT02250820|Drug|Pentobarbital|Oral administration
45447069|NCT02250820|Other|Oral Placebo|Oral placebo will be cherry syrup
45447070|NCT02250820|Other|Nasal Placebo|Nasal placebo will be nasally atomized saline
45766937|NCT00986180|Drug|Oxycodone IR|5, 10, or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
45766938|NCT01053013|Biological|RENCA macrobeads|
45766939|NCT03015493|Other|Neural mobilization combined with traction|Neural mobilization techniques combined with cervical traction for the cervical nerve roots
45766940|NCT03015493|Other|Traction|Traction techniques for the cervical spine
45766941|NCT01054183|Device|GlideScope Ranger Intubation|Intubation with GlideScope Ranger Video Laryngoscope
45766942|NCT01054183|Device|Direct Laryngoscopy|Intubations will be done with direct laryngoscopy.
45766943|NCT01054339|Drug|rAAV1-CB-hAAT|Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin
45624920|NCT04400409|Other|Intervention A - Vascular Care + site 6MWT administration|Implementation of multiple strategies related to improving lipid management, starting with a referral to the vascular care team. The subject will undergo a visit with a vascular care team, including a Vascular Medicine specialist who will obtain a patient history and prescribe a lipid lowering therapy regimen. The subject will also meet with a pharmacist to answer questions related to access to medications, drug side effects, and potential interactions with the subject's other medications. Additionally, the site staff will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
45624921|NCT04400409|Other|Intervention B - Standard Care + site 6MWT administration|Consists of provision of the treating provider with a copy of the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Subjects will return at 6 and 12 months for lab draws and endpoint event assessments but will not meet with vascular care team. Additionally, the site staff will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
45766944|NCT04247971|Procedure|Blood draw|23 ml of blood collected
45766945|NCT04247971|Procedure|Sputum collection|Induced sputum sample collected
45766946|NCT04247971|Procedure|Pulmonary function test|Pulmonary function testing
45766947|NCT01056601|Drug|Bortezomib|1.3 mg/m^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period
45766948|NCT01056601|Drug|Panobinostat|20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period
45766949|NCT01056913|Device|Compression Anastomosis Device|Restoring intestinal continuity using the NITI CAR27 device
45766950|NCT01056913|Other|follow-up colonoscopy|endoscopic exploration of anastomosis after complete healing
45766951|NCT05429203|Device|Duodenoscope with single-use distal cover|Newer duodenoscope with a single-use distal cover
45766952|NCT05429203|Device|Conventional duodenoscope|Conventional duodenoscope with standard methods of reprocessing
45766953|NCT03014947|Drug|MSB11022|Subjects will receive single dose of 40 milligram (mg) MSB11022 as a subcutaneous injection in the lower abdomen on Day 1.
45766954|NCT03014947|Drug|US-licensed Humira|Subject will receive single dose of 40 mg US-licensed Humira as a subcutaneous injection in the lower abdomen on Day 1.
45766955|NCT03014947|Drug|EU-approved Humira|Subject will receive single dose of 40 mg EU-approved Humira as a subcutaneous injection in the lower abdomen on Day 1.
45766956|NCT01057225|Drug|carfilzomib|Given IV
45766957|NCT01057225|Drug|cyclophosphamide|Given orally
46069622|NCT00696735|Procedure|high dose therapy and autologous stem cell transplantation|VCAP regimen 3 cycles , less than PR: 2-3 DHAP, stem cell collection, in vitro purging autologous stem cell transplantation with TBI and cyclophosphamide
45766958|NCT01057225|Drug|thalidomide|Given orally
45766959|NCT01057225|Drug|dexamethasone|Given orally
45766960|NCT01057381|Drug|Dexmedetomidine 0.75 mcg/kg|Single intra-operative administration of dexmedetomidine 0.75 mcg/kg over 10 minutes for analgesia.
45766961|NCT01057381|Drug|Morphine 50 mcg/kg|Single intra-operative administration of morphine 50 mcg/kg over 10 minutes for analgesia
45766962|NCT01057381|Drug|Morphine 100 mcg/kg|Single intra-operative dose of morphine 100 mcg/kg over 10 minutes for analgesia
45766963|NCT01057381|Drug|Dexmedetomidine 1 mcg/kg|Single intra-operative administration of dexmedetomidine 1 mcg/kg over 10 minutes for analgesia
45766964|NCT00986102|Drug|doripenem|500mg vial by injection every 8 hours for 5 to 14 days
45766965|NCT01058239|Drug|bortezomib|Given intravenously on days 1, 4, 8 and 11 of every cycle
45766966|NCT01058239|Drug|rituximab|given intravenously on days 1, 8 and 15 of Cycle 1 and on Day 1 of subsequent cycles
45766967|NCT01058941|Drug|Lipoic acid and fish oil concentrate|Lipoic acid (600 milligrams per day) and fish oil concentrate (3 grams per day) for 18 months
45766968|NCT01058941|Drug|Placebo|Placebo LA and placebo oil capsules for 18 months
45766969|NCT04150549|Biological|Fecal Microbial Transplants|Healthy donor stool will be processed and placed into capsules.
45766970|NCT04150549|Biological|Fecal Microbial Transplants|Participants stool will be processed and placed into capsules.
45766971|NCT00985946|Drug|panobinostat (LBH589)|Panobinostat will be taken once daily at 20 mg three times a week (every Monday, Wednesday, Friday). It will be taken as long as patients are benefiting from treatment.
45766972|NCT01059877|Device|1072nm infrared Photobiomodulation|1072nm infrared light delivering 2.6 Joules (2.6J)/sq cm over a 6 minute treatment period.
45766973|NCT01059877|Device|Photobiomodulation SIMULATED|Device mounted and procedure followed but with no stimulation.
45766974|NCT05382949|Other|SilverBills Financial and Legal Tech Tool for Caregivers|All subjects will be receiving the Silverbills financial and legal tech tool and a pre-post analysis will be conducted.
45804257|NCT04329273|Other|Balance training|"The exercise protocol consists of 2 sessions/week with 4 sets of 30'' single stance.~Week 1 and 2- 1 set of 30'' single leg stance and 3 sets of 30'' single leg stance and ball kicks with contralateral foot Week 3 and 4- 2 sets of 30'' single leg stance while moving the ball around the leg with the contralateral foot and 2 sets of 30'' single leg stance, moving a ball around the knee with hands and kicking a ball with contralateral foot Week 5 and 6- 2 sets of 30'' single leg stance while giving and receiving hand passes with medicine ball (in couples) and 2 sets of 30'' single leg stance with perturbations (in couples) Week 7 and 8- Same as week 5 and 6 with extra 15 in each repetition"
45912716|NCT02013596|Other|TEAS treatment|Transcutaneous Electrical Acupoint Stimulation was given to the patient at the same time of the start of anesthesia induction for 30mins
45912717|NCT02013661|Procedure|Periodontal resective surgery|surgical periodontal debridement is performed after periodontal phase I
45624922|NCT04400409|Other|Intervention A - Vascular Care + CPC EQuIP 6MWT administration|Implementation of multiple strategies related to improving lipid management, starting with a referral to the vascular care team. The subject will undergo a visit with a vascular care team, including a Vascular Medicine specialist who will obtain a patient history and prescribe a lipid lowering therapy regimen. The subject will also meet with a pharmacist to answer questions related to access to medications, drug side effects, and potential interactions with the subject's other medications. Additionally, the CPC EQuIP team will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
45624923|NCT04400409|Other|Intervention B - Standard Care + CPC EQuIP 6MWT administration|Consists of provision of the treating provider with a copy of the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Subjects will return at 6 and 12 months for lab draws and endpoint event assessments but will not meet with vascular care team. Additionally, the CPC EQuIP team will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
45624924|NCT04878237|Other|Nasal Secretion Sampling|Nasal specimen collection will be performed at all visits. For every visit specimens will be collected using nasosorption FXi/PU (containing a synthetic absorptive matrix (SAM)), or a 10 cm-long plastic curette (nasosorption devices from Hunt Developments, UK) (Curette devices from Arlington Scientific, USA)
45624925|NCT04395339|Drug|Monosialotetrahexosyl ganglioside (GM1)|Ganglioside-Monosialic Acid is added into 250 mL of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 15 days. The first dose is given at 1 day before the start of the radiotherapy.
45624926|NCT04395339|Drug|Control|250 mL of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 15 days. The first dose is given at 1 day before the start of the radiotherapy.
45624927|NCT04878081|Behavioral|hot flush|"Hot Flash Diaries to record the change of daily hot flush symptoms for 30 days. The Hot Flash Related Daily Interference Scale to record how much did hot flush effect daily life.~The Kupperman menopausal index to evaluate the severity of menopausal symptoms. The Pittsburgh Sleep Quality Index to evaluate sleep disorder. Wireless temperature monitor to record hot flush and body temperature during sleeping.~Classify patients' traditional Chinese constitution by using Physical classification and judgment self-test table."
45624928|NCT04391517|Diagnostic Test|SpHb measurement|All included patients will have their Hb measured non-invasively by a trained health care provider. SpHb values will be recorded in the documentation software already in use at the clinic.
45624929|NCT04877769|Drug|AT-527|administered twice daily (BID) for 2.5 days (5 doses in total)
45624930|NCT04885335|Other|PAS (Pediatric Appendicitis Score) survey|Score ≤ 5: appendicitis unlikely. Score ≥ 6: probable appendicitis. core ≥ 7: very probable appendicitis
45624931|NCT03049059|Device|Fractional Picosecond 1,064 nm laser|Fractional Picosecond 1,064 nm laser and daily application with 4% hydroquinone cream
45624932|NCT03049059|Drug|4% hydroquinone cream|
45624933|NCT03049137|Procedure|Computer Guided Stent Augmentation|Defective alveolar ridge is to be replaced by simultaneous implant placement with ring graft augmentation (Trephine Drill to obtain the ring graft autogenous bone) using computer guided stent and covered with Platelet-rich fibrin (PRF), by using venous blood from the patient, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 Revolution Per Minute (RPM) for 10 minutes.
45624934|NCT03049137|Procedure|Free Hand Augmentation|Defective alveolar ridge is to be replaced by Free Hand simultaneous implant placement with ring graft augmentation (Trephine Drill to obtain the ring graft autogenous bone) and covered with Platelet-rich fibrin (PRF), by using venous blood from the patient, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM for 10 minutes.
45624935|NCT03049137|Drug|Platelet-rich fibrin (PRF)|
45624936|NCT03049137|Device|implant|
45624937|NCT03048513|Other|Patient who presented with melioidosis in head and neck|Investigators assess the patients who had the pus culture positive with Burkholderia pseudomallei.
45624938|NCT03048591|Device|electroacupuncture|Acupoint selection: Bilateral Hegu (LI4), Qu-chi (LI1) of upper limbs and bilateral Zusanli (ST36) ,Taichung (LR3)of lower limbs.
45624939|NCT04885413|Drug|Niraparib in Combination With Anti-PD1 Antibody|Sintilimab： 200mg i.v., d1, 21days one cycle Niraparib： 200mg p.o qd，d1-d21, 21days one cycle
45624940|NCT03049293|Drug|Midazolam|The impact of Midazolam levels in follicular fluid.
45624941|NCT04872075|Other|Concert|People attending a concert in a closed area, with a mask
45624942|NCT04872075|Diagnostic Test|Rapid nasopharyngeal antigen test for Sars-Cov-2|A nasopharyngeal swab at inclusion (up to 3 days before concert) to confirm eligibility
45624943|NCT04872075|Diagnostic Test|Saliva Sample|Saliva samples sent by participant at Day0 and Day7
45624944|NCT01595529|Drug|Cefixime|Cefixime 8 mg/kg/day orally, in 1 dose, with a maximum of 400 mg. Subjects originally receiving Cefdinir will receive Cefixime.
45624945|NCT01595529|Drug|Cephalexin|Cephalexin 50mg/kg/day in 3 divided doses
45624946|NCT01595529|Other|Placebo|Placebo to match the other four active treatments
45624947|NCT01595529|Drug|Trimethoprim/Sulfamethoxazole|8 mg/kg/day of Trimethoprim-sulfamethoxazole (TMP-SMX) orally in 2 divided doses, with a maximum dose of 160 mg twice a day.
45624948|NCT04411017|Procedure|Endoscopy|Colonoscopy
45912718|NCT02013700|Biological|Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)|
45912719|NCT02013700|Biological|matched placebo|The placebo will be 25 ml of Plasma-Lyte A with 1% HSA in a Cryostore bag.
46069623|NCT02867345|Biological|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
46069624|NCT02867345|Drug|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
45624949|NCT04410705|Other|Extracorporeal shockwave theraphy for hamstring tendinopathy|For hamstring tendinopathy; a total of 2000 impulses will be done. We will apply twice a week and 5 times in total.
45624950|NCT04410705|Other|Extracorporeal shockwave theraphy for quadriceps tendinopathy|Energy flux density will be 0.58mJ/mm2 (2 bar) with 2000 impulses. We will perform twice a week, 5 times in total.
45766975|NCT05351983|Procedure|Surgical biopsy of tumoral tissue for organoid generation|In surgically-resectable lesions, tumoral samples will be collected from the main surgical specimens, before sending it for final pathological examination. Patients with metastatic disease, will be offered to undergo port-a-cath implantation for chemotherapy delivery and concomitant laparoscopic surgical excisional biopsy of suspicious metastatic lesions. Intraoperative frozen section will confirm the presence of malignant cells in the sample. Part of the specimen will be sent for assessment of contamination by bacterial and/or fungal flora by the Microbiology Laboratory. The remaining tumour sample will be sent for patient-derived organoid (PDO) formation. Two patients' blood samples will be retrieved in ethylenediaminetetraacetic acid (EDTA) tubes and will be sent with the surgical specimen. All patients will then receive the standard of care (SOC) treatment according to the clinical judgement of the oncologist in charge, always within the framework of the international guidelines.
45766976|NCT05592457|Diagnostic Test|MSCT|multislice computed tomography
45624951|NCT04410705|Other|Extracorporeal shockwave theraphy for achilles tendinopathy|Each session consisted of 2400 impulses will be administered with an energy flux density ranged from 0.17 to 0.25 mJ/mm2 (1.7-2.5 bar). We will perform once a week, 3 times in total.
46069625|NCT02867345|Drug|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
46069626|NCT04260230|Device|Lifetemp/Lifetouch sensors|Wearing the devices for six weeks. Data only reviewed retrospectively.
46069627|NCT02621853|Device|Raman spectroscopy of the liver|Liver will be illuminated by the Raman spectroscope optic probe in order to assess fat content
45624952|NCT04368507|Drug|YYB101|"b (Dose level 0 cohort): YYB101 20mg/kg, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity~a Stage 1: YYB101 RP2D, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity"
45766977|NCT00985790|Biological|Influenza vaccine GSK2321138A|Intramuscular injection
45624953|NCT04147533|Drug|Imatinib withdrawal|withdrawal of imatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of imatinib is 50% of the standard dose (200 mg daily), during the second 6 months after study entry, the dose of imatinib is 200 mg every other day; 12 months after study entry, imatinib is discontinued, the patient is followed in line with the aims of the trial
45766978|NCT00985790|Biological|Fluarix™|Intramuscular injection
45766979|NCT05351827|Other|Mild Intermittent Hypoxia|Participants will breathe 8% oxygen through a non-diffusable bag that is connected to a 5-way stopcock. The inspiration side of the system is then connected to a 2-way non-rebreathing valve which is connected to a pneumotachometer that is connected to a tight fitting facemask. 100% oxygen and carbon dioxide are titrated into the system to ensure the appropriate hypoxic and hypercapnic stimulus is delivered. The investigators will lower oxygen to 55-60 mmHg and maintain end-tidal carbon dioxide 1-3 mmHg above individual baseline values. The protocol starts with 10 minutes of baseline breathing (room air) then followed by 10 more minutes of breathing room air with the additional carbon dioxide. Thereafter, individuals undergo 12 2-minute bouts of hypoxia with 2 minutes of normoxia (room air) interspersed between episodes. The intervention protocol concludes with 20 minutes of monitoring all breathing and cardiovascular measurements.
45766980|NCT05351827|Other|Sham|Participants will breathe 21% oxygen through a non-diffusable bag that is connected to a 5-way stopcock. The inspiration side of the system is then connected to a 2-way non-rebreathing valve which is connected to a pneumotachometer that is connected to a tight fitting facemask. No supplemental oxygen or carbon dioxide will be used during the sham protocol. The protocol starts with 10 minutes of baseline breathing (room air) then followed by 10 more minutes of breathing room air with the additional carbon dioxide. Thereafter, individuals undergo 12 2-minute bouts of hypoxia with 2 minutes of normoxia (room air) interspersed between episodes. The intervention protocol concludes with 20 minutes of monitoring all breathing and cardiovascular measurements.
45766981|NCT03016273|Procedure|creation of bladder flap|Creation of the bladder flap, i.e., dissecting the urinary bladder from the lower segment of the uterus is a standard part of cesarean section (CS).
45766982|NCT01060345|Drug|Polyphenon E|three 200mg capsules (600mg total dose of the study drug) with food (within one hour of eating a substantial meal) daily for a minimum of 4 weeks, or until the day before surgery
45766983|NCT02170519|Drug|Inhaled Iloprost|A 20 mcg dose of Iloprost will be given initially.
45766984|NCT05288257|Behavioral|Learning Module|Safe Cholecystectomy Learning Module
46069628|NCT02867189|Other|atlas of micro-instrument|Nurses after training can improve the instrument cleaning quality, reduce the reaction after cataract surgery
46069629|NCT02621775|Behavioral|Computer-based stress management program|The program includes 5 one hour weekly sessions that patient follow from a web site accessible from a computer in our unit. He benefits from a minimal contact with a medical member of staff before and after every session. The duration of each session is about one hour. To avoid internet connexion problem between session it is supplied to the patient, from the first session an USB key (Universal Serial Bus) containing videos, audio files, self help book, portfolio in the form of e-guide, log book with the program of the exercises to be realized between two session of the five sessions program. The patient is encouraged to practice a twenty-minutes daily exercises five or six days per week.
46069630|NCT02621775|Behavioral|Stress management in face-to-face|The program includes 5 forty-five minutes weekly session with a therapist (psychologist graduate of a master of cognitive and emotional therapy with a minimal of one year of practice in CBT and CBSM (Cognitive-Behavioral Stress Management ). Information, exercises and homework assignments are delivered by the therapist without self help support.
45624954|NCT04147533|Drug|Dasatinib|withdrawal of dasatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of dasatinib is 50% of the standard dose (40 mg daily; tablets containing 50 mg are not available on the market), during the second 6 months after study entry, the dose of dasatinib is 40 mg every other day; 12 months after study entry, dasatinib is discontinued, the patient is followed in line with the aims of the trial
46069631|NCT02621775|Other|Waiting list|The patients are followed by their General Practitioners without change in treatment .
45447071|NCT02103400|Other|Experimental group|Exercise Training Group
46069632|NCT04259918|Procedure|Alveolar recruitment maneuver|Applying 30 or 60 cmH2O of alveolar recruitment maneuver 5 times every 5 min at the end of bariatric surgery
46069633|NCT02867111|Device|Sperm Selection Assay|Sperm Selection Assay (SSA) that allow the investigators to select functional spermatozoa, which are capacitated, with intact DNA, reduced oxidative stress and with good viability and motility, on the basis of sperm chemotaxis towards a physiological attractant molecule.
45624955|NCT04147533|Drug|Nilotinib|withdrawal of nilotinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of nilotinib is 50% of the standard dose (200 mg every 12 hours), during the second 6 months after study entry, the dose of nilotinib is 400 mg every other day; 12 months after study entry, nilotinib is discontinued, the patient is followed in line with the aims of the trial
45624956|NCT04871841|Biological|Sputnik V|Participants will receive intramuscular (IM) injection of a single dose of rAd26-S and rAd5-S at day 0 and day 21, respectively.
45624957|NCT04871685|Diagnostic Test|lung ultrasound|the patients underwent to a non invasive diagnostic exam to identify and monitor clinical conditions and onset of respiratory complications due to COVID-19
45624958|NCT05257395|Drug|XZP-3287+ Letrozole/Anastrozole|XZP-3287 360 mg orally after meals Twice daily of every 28-day cycle; Letrozole tablets 2.5mg orally once daily of every 28-day cycle or Anastrozole tablets 1mg orally once daily of every 28-day cycle
45624959|NCT05257395|Drug|Placebo + Letrozole/Anastrozole|Placebo 360 mg orally after meals Twice daily of every 28-day cycle; Letrozole tablets 2.5mg orally once daily of every 28-day cycle or Anastrozole tablets 1mg orally once daily of every 28-day cycle
45624960|NCT05257317|Other|Osteopathic Medicine|"Where compression and traction movements will be carried out on these structures.~Technique called CV4, applied on the occipital, and Technique called asynchronous rolling of the temporal bones."
45624961|NCT05257317|Other|Placebo therapy|Circular movements will be induced in a frontal and parietal bones
45624962|NCT05257239|Other|no intervention|National University Health System,
45624963|NCT05257161|Device|Emboshield NAV6™|Embolic Protection System for Carotid Artery Revascularization ( distal - filter) + stent CGuardTM™
45624964|NCT05257161|Device|Mo.Ma™|Embolic Protection System for Carotid Artery Revascularization ( proximal - occlusion) + stent CGuardTM™
45624965|NCT05256771|Device|EMS|Abdominal muscle stimulation using EMS
45624966|NCT05256771|Device|1064 nm diode laser|Adipose tissue heating using 1064 nm diode laser
45624967|NCT05256771|Device|RF/PEMF|Collagen re-modelling and reduction in subcutaneous fat using RF/PEMF
45624968|NCT05256693|Drug|Vancomycin|Oral vancomycin (powder) 125mg twice a day
45624969|NCT05256693|Drug|Placebo|Vancomycine placebo (powder) twice a day
45624970|NCT04871139|Procedure|Biopsy|Undergo biopsy
45624971|NCT04871139|Procedure|Contrast-Enhanced Mammography|Undergo CEM
45624972|NCT04871139|Other|Questionnaire Administration|Ancillary studies
45624973|NCT04871139|Other|Radioactive Iodine|Given IV
45624974|NCT03046953|Drug|Avelumab|anti-PDL1 antibody
45624975|NCT00964977|Radiation|Radiation therapy|Patients receive radiation within 6 weeks after surgery. At primary tumour site and involved lymph node level a total dose of 59.4 Gy in 33 fractions within 45 days is scheduled according to the rules of ICRU report 50.
45624976|NCT04877925|Device|standard chest tubes|2 standard postoperative chest tube used
45624977|NCT04877925|Device|coaxial chest tube|1 postoperative smart drain coaxial tube
45624978|NCT03048903|Drug|Rheum Palmatum Root|Rhubarb is commercially certified rhubarb(Rheum palmatum , Sichuan origin, provided by the pharmacy of my hospital), ground into a powder, over 80 mesh steel mesh.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
45624979|NCT03048903|Drug|Starch Corn|Starch Corn is harmless to people .The use dosage is same as Rheum Palmaturn Root.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
45624980|NCT03047109|Drug|Phenylephrine|30 patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
45624981|NCT03047109|Drug|Ephedrine|30 patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
45624982|NCT03047265|Drug|Paclitaxel|Paclitaxel 135mg / m2 D1, DDP 20mg / m2 D1-4, D1,D29 of RT, a total of 2 courses.
45624983|NCT03047265|Drug|Cisplatin|Cisplatin 100mg / m2 , D1,D22,D43 of RT, a total of 3 courses.
45624984|NCT03047343|Other|Retrospective data extraction in medical files|Retrospective data extraction in medical files
45624985|NCT04871373|Behavioral|Motivational interviewing|A periodontist was trained and evaluated by two expert psychologists in MI, who also supervised the interviewer to ensure that the intervention was properly applied. The periodontist conducted sessions of motivational interviewing monthly to the participants of the experimental group.
45624986|NCT04871373|Behavioral|Oral Hygiene Instructions|A periodontist delivered OHI to all the participants of both studied groups. Also, every single patient received a G.U.M. kit with special orthodontic hygiene tools.
45624987|NCT05256147|Drug|Ibuprofen|Patient will receive ibuprofen 400 mg before the phototherapy session.
45624988|NCT04877067|Biological|Wharton jelly derived mesenchymal stem cell|WJ-MSC
45624989|NCT04877067|Device|Repetitive electromagnetic stimulation|rEMS
45624990|NCT04877145|Other|drill|single 3.25 mm stainless steel drill
45624991|NCT04870749|Diagnostic Test|IPP,IPSS,VPSS|Prostate volume, IPSS, VPSS and IPP were determined after urological examinations of the patients.
45624992|NCT04877301|Device|Ultrasound guidance|Ultrasound guidance used to facilitate insertion of PIV catheter
45624993|NCT04877301|Procedure|Non-ultrasound guidance|Ultrasound guidance will not be used for insertion of PIV catheter
45624994|NCT05255913|Drug|Nanosilver|preventive material for arresting caries
45624995|NCT05255913|Drug|Silver diamine fluoride|preventive material for arresting caries
45624996|NCT05255835|Device|Semiconductor Knee Sleeves|semiconductor elements germanium and carbon within the cotton fabric
45624997|NCT05255835|Device|Cotton Knee Sleeves (Placebo)|cotton fabric knee sleeves
45766985|NCT05263063|Other|Comparison of Face-to-face, Synchronous and Asynchronous Use of Methods Used for Balance Assessment in Individuals With Chronic Stroke|On the first day, information about the patient and the disease, filling in the patient data form and face-to-face evaluation will be made face to face with the patients. The next day, one of the synchronous and asynchronous tele-evaluation methods will be applied. Face-to-face interview and face-to-face evaluation will be made by the first physiotherapist in a clinical setting. The synchronous tele-assessment will be evaluated online in real time by the second physiotherapist. For asynchronous tele-assessment, a reference evaluation video will be sent to the patients. Relatives of the patients will be asked to watch this video, make the evaluation and take a video recording at the same time. Then, these video recordings will be evaluated separately by the first and second physiotherapists and the results will be compared. Each assessment will take approximately 30 minutes.
45766986|NCT04072705|Drug|General principles of care and judgement of researcher|Because our study will be performed by observational design, there will be no intervention for our study. Because it is a registry-based study, overall decision making for medications will be performed according to the general principles of care and judgement of researcher.
45766987|NCT05239117|Device|Plenhyage|"Plenhyage® is an elastic, sterile, injectable, non-pyrogenic, re-absorbable gel made with polymerised polynucleotides (PDRN) of animal origin (fish). Due to its hydrophilic and polyanionic nature, PDRN binds water molecules, thereby filling intradermal spaces and making tissues firmer and more hydrated.~The polynucleotide chain binds water molecules, has an anti-free radical action, and serves as a scavenger of hydroxyl radicals (OH), which accumulate under stress or due to foreign agents, such as UV radiation. Its hydration and anti-free radical activity help create the optimal environment for fibroblast growth, thereby restoring tissue elasticity.~Plenhyage® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile syringe with a Luer Lok adapter."
45766988|NCT00985712|Drug|Insulin Lispro|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
45766989|NCT00985712|Drug|Huminsulin Regular|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
45624998|NCT03046875|Other|Transcutaneous Spinal Cord Stimulation|Transcutaneous Spinal Cord Stimulation is a non-invasive mechanism to enhance excitation of spinal neural circuitry and represents a promising supplement to existing physical therapy programs. Transcutaneous Spinal Cord Stimulation will be applied (via the Vectra Neo) using a 5cm x10cm oval electrode placed midline on the skin between spinous process T11 -T12 as a cathode and two 7.5cm x 13cm rectangular electrodes placed symmetrically on the skin over the lower abdomen as anodes.7,9 A symmetrical biphasic rectangular waveform, at 50Hz and 1millisecond, will be used to provide 30 continuous minutes of stimulation.
45766990|NCT00985712|Device|HumaPen Memoir|subcutaneously, daily for 24 weeks
45766991|NCT00985712|Device|HumaPen Luxura|subcutaneously, daily for 24 weeks
45766992|NCT04275284|Biological|PCV10|0.5 ml injection
45766993|NCT04275284|Biological|PCV13|0.5 ml injection
45766994|NCT02984150|Dietary Supplement|dodecanoic acid|
45766995|NCT02984150|Dietary Supplement|saline|
45766996|NCT04347746|Behavioral|stretching physiotherapy|"A booklet with images and a description of all movements to be performed during therapy will be offered to patients. The booklet illustrates the movements for stretching the upper limbs divided as follows: three movements for the neck, three movements for the arms and forearms and four movements for the hands.~The therapy will be carried out twice a week at the Unopar research center, under the guidance of a physiotherapist trained in technique and supervision by a senior therapist. At the end of each movement, the individual is instructed to maintain the position for 40 seconds.~Patients will be instructed to appear in comfortable clothes and the environment will have favorable conditions."
45766997|NCT04347746|Behavioral|Myofascial therapy|Myofascial therapy will be performed on the upper limbs, pectoral and dorsal regions with the aid of hooks (instrument assisted soft-tissue mobilization). In the supine position, the pectoral muscles will be manipulated (infracromial, external, axillary-claviculopectoral fossa), biceps brachii (short head, long and forearm insertion), round pronator, anterior forearm musculature (compartment of the radial extensor of the long carpus and brevis, finger extensor and ulnar carpal extensor). In lateral decubitus the deltoid muscle in the anterior, middle and posterior portions. In the prone position, the trapezius muscle (in its cervical, scapular and nuchal insertions), scapular levator muscle, great dorsal muscle (in its lateral insertions) and triceps brachii muscle. The hook manipulation time is two minutes of execution for each muscle mentioned above, making a total time of each section of forty minutes. There will be two weekly sessions with an interval between forty-eight hours.
45766998|NCT01921556|Behavioral|active comparator, QualiCCare education|"Physicians randomized into the intervention group get a QualiCCare training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support."
45766999|NCT01924910|Dietary Supplement|250,000 IU cholecalciferol as single, oral dose|250,000 IU cholecalciferol (vitamin D3) provided as a single oral dose.
45767000|NCT01924910|Dietary Supplement|Placebo|
46069634|NCT02867111|Other|Attractant Substance|Capacitated spermatozoa may be oriented by following an increasing concentration gradient of an attractant molecule, a phenomenon called sperm chemotaxis. This is a guidance mechanism observed in vitro, which may transport and retain spermatozoa at the fertilization site. Though several molecules have been suggested to attract human spermatozoa, in the context of gamete interaction prior to fertilization, progesterone has biological importance for several reasons. After ovulation, this hormone is secreted by the cumulus cells that surround the oocyte, diffusing to form a molecular gradient toward the periphery of the cumulus and beyond. Notably, a gradient of very low concentrations (picomolar) of progesterone is sufficient to chemically attract capacitated human spermatozoa
45624999|NCT03046875|Other|Sham stimulation|Sham procedures, well documented in Transcranial DC Stimulation (tDCS), will be used. Electrodes will be placed as they are in the Transcutaneous Spinal Cord Stimulation condition. Stimulation will be applied at subject's maximum intensity for 30 seconds and then discontinued.
45625000|NCT05214417|Drug|Ketamine Injectable Solution|2 IM ketamine sessions with psychotherapy, spaced 9-15 days apart
45625001|NCT05214417|Other|Naturalistic Control|Continuation of pre-existing conventional treatment
45625002|NCT04870671|Drug|Tenofovir Disoproxil Fumarate|Women will take 1 pill orally according the dosing regimen of the arm to which they are assigned
45625003|NCT04388241|Behavioral|The Balance Program|The Balance Program is a four-week behavioral intervention (each session lasting 60 minutes) developed specifically for the pediatric SCD population based on existing evidence-based treatments to target the unique presentation of pain-related disability in SCD.
45625004|NCT04876911|Behavioral|Simulated Presence Therapy|A video recording of a loved one is played (via an iPad) prior to or during periods where a participant is presenting with stressed/distressed behaviours.
45625005|NCT03046485|Behavioral|Self management program 'Living with Vision Loss'|group met for 6 weeks, 2 hours per week, to discuss strategies for living with low vision
45767001|NCT04395638|Dietary Supplement|3200IU Vitamin D3 per day for 8 weeks|3200IU Vitamin D3 per day for 8 weeks
45767002|NCT04395638|Dietary Supplement|20,000IU Vitamin D3 per week for 8 weeks|20,000IU Vitamin D3 per week for 8 weeks
45767003|NCT01921712|Drug|PUR0200|Randomized single doses of 3 selected doses of PUR0200, compared to a placebo and active comparator
45912720|NCT02013726|Device|MBI Scan: The LumaGEM®|The LumaGEM Scanner is a dual-head, MBI scanner that has previously been cleared for medical marketing (510(k) number K111791), and has been used to image more than 5,000 patients to date. The LumaGEM MBI scanner is used as a diagnostic adjunct to mammography screening for problem cases The efficacy of MBI has been well documented in clinical trials. The LumaGEM MBI scanner is a dual-head, small field-of-view (FOV) device for developing an MBI image of Tc99m-Sestamibi uptake within the breast. The device consists of solid-state detectors, a data acquisition system, and a computer. The detectors are also used to immobilize the breast during image acquisition by mild compression. The detectors are housed in two heads that are positioned on both sides of a compressed breast.
46069635|NCT02867111|Procedure|ICSI|An in vitro fertilization procedure in which a single sperm is injected directly into an egg
45625006|NCT04387461|Biological|CG0070|Engineered Oncolytic Adenovirus
45625007|NCT04387461|Biological|Pembrolizumab Injection|Immune checkpoint inhibitor, Monoclonal antibody
45625008|NCT04387461|Other|n-dodecyl-B-D-maltoside|Transduction-enhancing agent.
45625009|NCT03046563|Other|Acupressure and Abdominal Massage|Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes
45625010|NCT03046563|Other|Pressing the Sham points|Pressing the sham points for eight minutes
45625011|NCT04865757|Device|Space Flap|A space flap is formed out of Palacos®, adjusted to the skull surface with temporal augmentation
45625012|NCT03046719|Drug|Bupivacaine 0,5%|Bupivacaine 0,5% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches
45767004|NCT01921712|Drug|PUR0200 Placebo|Randomized, single dose of inhaled placebo matched to PUR0200
45767005|NCT01921712|Drug|Active comparator|Randomized single dose of inhaled active comparator product
45767006|NCT04395404|Diagnostic Test|MRI|Patients with unilateral ASS, with and without the prosthesis in situ, are analysed by 3D- magnetic resonance imaging (MRI) with 64 channel head coil using T1 and T2 weighted, DIXON/ IDEAL, and T2 inversion recovery sequences.
45767007|NCT04395716|Biological|ResCure™|Patients will be treated with nebulized ResCure™
45767008|NCT04347980|Drug|Dexamethasone and Hydroxychloroquine|"Patients included in the Hydroxychloroquine / Dexamethasone group will benefit from standardized ventilatory management and administration of Hydroxychloroquine in the same manner as the Hydroxychloroquine group. They will receive in addition to Dexamethasone at a rate of 20 mg intravenously for 15 min once a day for 5 days (D1 to D5) then at a rate of 10 mg per day from D6 to D10. If the patient is extubated before the 10th day, he will receive his last dose of Dexamethasone before."
45767009|NCT04347980|Drug|Hydroxychloroquine|Patients included in the Hydroxychloroquine group will benefit from standardized ventilatory management. Patients included in the Hydroxychloroquine group will receive 200 mg x 3 / day enterally from J1 of the HCQ for 10 days. If the patient is extubated before the 10th day, he will receive his last dose of HCQ before.
45767010|NCT01925300|Drug|Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab|
45625013|NCT03046719|Drug|NaCl 0,9%|NaCl 0,9% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches
45625014|NCT03046797|Device|Fibroptic intubation through Boussignac valve opening|After patients being put in HELP position to facilitate both ventilation and intubation, mask ventilation will be continued and FOB intubation will be performed from Boussignac valve opening.
45625015|NCT03046797|Device|Classic Fibroptic intubation|After patients being put in HELP position to facilitate both ventilation and incubation, mask ventilation will be terminated then FOB intubation will be done by an experienced anesthetist.
45625016|NCT03046641|Other|Continuous training|Study group I (42 participants) received the continuous training.
45625017|NCT03046641|Other|The interval training|Study group II (40 participants) received the interval training.
45767011|NCT01925300|Drug|Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab|
45767012|NCT01925300|Drug|Concor 5mg 2T and Crestor 20 mg 1Tab|
45767013|NCT04395794|Diagnostic Test|SARS-CoV-2-test|Nasopharyngeal and oropharyngeal testing for SARS-CoV-2
45767014|NCT04395794|Other|SARS-CoV-2 questionnaire survey|Questionnaire regarding SARS-CoV-2 symptoms and contact with COVID patients
45767015|NCT03326986|Drug|MK-7252|1 mg/mL or 20 mg/mL of powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
45767016|NCT03326986|Drug|Placebo|Placebo powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
45767017|NCT04275596|Drug|2QR complex|Application of topical gel containing 2QR complex on the anal wound until complete wound healing
45767018|NCT04275596|Drug|Placebo|Application of topical placebo on the anal wound until complete wound healing
45767019|NCT01921946|Drug|Fimasartan|
45625018|NCT04876755|Drug|MBM-02|MBM-02 is an HIF-1 and HIF-2 inhibitor.
45625019|NCT04876287|Drug|Radioiodine|cancer therapy
45625020|NCT04876521|Drug|Amisulpride|low dose of Amisulpride at 100-300 mg/day
45767020|NCT01921946|Drug|Rosuvastatin|
45767021|NCT01925378|Drug|Nelfinavir|"All medications which a patient is taking will be reviewed at each visit, including the screening, day 1, weeks 4,12, 24.~All patients enrolled in the study will receive 1,250 mg twice PO daily for a 24 week duration."
45767022|NCT03328624|Device|Deep Vein Thrombosis (DVT) Cuff|Recovery Force's DVT II Cuff
46069636|NCT04253366|Device|Clinical investigation device class IIa not marked CE|Patients should perform MammoWave exam. A short visit should be performed and during this visit a qualitative differentiation would be performed between patients with high density breast, and patients with low density breast. After the patients will be ready for the MammoWave exam. The exam will be composed of two phases: the data acquisition and the data processing. During the acquisition that should takes about 10 minutes the patients would be lying in a prone position, on a bed which is part of the MammoWave. The upper part of MammoWave has a container cup shape, which contains the breast, which also has the function of separate it from the internal parts of the device. After patient is on the bed and MammoWave would start to perform the acquisition. Once the acquisition is completed, the data will be processed through an imaging algorithm, which is integrated in the device. The final output will be composed by one or more images, plus one or more parameters describing the images.
46069637|NCT04134975|Procedure|Spine surgery|surgery with pedicle screw placement between L1 and S1
45625021|NCT04876521|Drug|Olanzapine-Fluoxetine Combination|Olanzapine (5 mg/day) and Fluoxetine (10-20 mg/day)
45625022|NCT03044847|Other|COPD group|The treatments will be determined by their treating physicians and no additional investigational drugs will be applied to the patients included in this study.
45625023|NCT02119156|Drug|Belimumab|Monthly intravenous infusions dosed as 10 mg/kg body weight
45625024|NCT04753138|Device|TotalFill Bioceramic Sealer|It will be used in conjunction with TotalFill® bioceramic impregnated gutta percha points for the obturation of root canals. It is dispensed through a fine disposable syringe into the root canals during obturation.
45767023|NCT03095300|Procedure|Prone position|Patients are rotated from the supine to the prone position for a period of 2 hours.
45767024|NCT01925456|Drug|Toviaz|Means of effectiveness, adherence, and utility instruments over time will be examined to evaluate whether changes are linear from baseline to 8 weeks and 3 months. We will demonstrate the validity and responsiveness of pragmatic instruments against existing established measures (Table 3).
45767025|NCT04395950|Drug|PF-05221304|PF-05221304 10 mg daily (two 5mg tablets daily in the morning for 6 weeks)
45767026|NCT04395950|Drug|Placebo|Placebo two tablets daily in the morning for 6 weeks
45767027|NCT01925690|Behavioral|Motivational Interviewing-Cognitive Behavioral Therapy|A telephone based talk therapy discussing pros and cons of medication use in MS.
45767028|NCT01925690|Behavioral|Brief Education|Give patients a pamphlet discussing pros and cons of disease modifying therapies
45767029|NCT03229252|Drug|Placebo Inhalation Solution|Normal Saline Inhalation Solution
45767030|NCT03229252|Drug|SPX-101|SPX-101 Inhalation Solution
45767031|NCT01922180|Radiation|Chest CT scans|CT examinations were performed with a commercially available 64-detector row scanner. Images were acquired in supine position after full inspiration and full expiration, using the following parameters: slice thickness, 0.6 mm; pitch, 1.4; rotation time, 330 msec; tube voltage, 120 kiloVolts; and tube current-time product, 100 milliAmperes, with automatic exposure control (CareDose 4D, Siemens Healthcare) switched on. From raw data, 1-mm-thick section images were reconstructed at 0.7-mm intervals by using a high spatial algorithm and a soft-tissue algorithm. The inspiratory CT scan at the time of exacerbation was performed with intravenous iodinated contrast material, whereas the control scan was unenhanced.
45625025|NCT04753138|Device|AH+ Sealer|It consists of 2 pastes that are mixed together in equal amounts before it is used in conjunction with gutta percha points for obturation during root canal treatment.
45625026|NCT02181556|Drug|FOLFIRI Protocol|injection of FOLFIRI and Aflibercept every 14 days until progression of disease
45625027|NCT02181556|Drug|Aflibercept Injection|injection of FOLFIRI and Aflibercept every 14 days until progression of disease
45625028|NCT02614131|Drug|LY2599666|Administered SC
45625029|NCT02614131|Drug|Solanezumab|Administered IV
45625030|NCT02614131|Drug|Placebo SC|Administered SC
45625031|NCT02614131|Drug|Placebo IV|Administered IV
45625032|NCT04429815|Diagnostic Test|Serological test for COVID-19.|Serological test for COVID-19 performed as part of standard of care.
45625033|NCT03044769|Procedure|Malformations resection|Resection of the malformation lung sections with a healthy adjacent part
45767032|NCT03076658|Radiation|EOS imaging|The EOS imaging system will be utilized to obtain full-body radiographs in frontal and sagittal projections obtained in the upright standing position. Measurements will include a coronal plumb-line, sagittal vertebral axis (SVA), external auditory meatus plumb-line, cervical lordosis, thoracic kyphosis, lumbar lordosis, hip flexion/extension, knee flexion/extension, ankle flexion/extension, T1 tilt, T1 spino-pelvic instance, acetabular index, pelvic tilt (PT), pelvic incidence (PI), and sacral slope (SS).
45625034|NCT04876443|Diagnostic Test|Study questionnaire|Study questionnaire related to drinking behaviour
45625035|NCT04870437|Other|Extracorporeal phototherapy|The principle of ECP is to collect mononucleated cells from the blood by centrifugation. After purification, the mononucleated cells are incubated ex-vivo with a photo-activatable DNA intercalating agent (8-methoxypsoralen, UVADEX®), then re-injected to the patient.
45625036|NCT04865991|Procedure|TCI Propofol|Peripheral venous catheters were placed in all subjects. Subjects in the TCI propofol group had one specific intravenous catheter for propofol infusion apart from medication or intravenous fluid line. Subjects in the TCI Propofol group received TCI propofol (Schneider) with targeted Ce 4 -5 mcg/ml for anesthesia induction and maintenance. Subjects in the TCI propofol group received TCI propofol for anesthesia maintenance, Ce value was titrated until a targeted BIS score of 40-60 achieved.
45767033|NCT03330262|Device|BALCAP prosthesis|The noninvasive BALCAP prosthesis offers uses six degrees-of-freedom (6-DOF) sensing to detect postural imbalance and actuate low-amplitude vibrotactile cues directly to the head to provide the wearer with feedback concerning head tilt in the pitch and roll plane.
45767034|NCT03235180|Drug|Sulfur Hexafluoride|Subjects will receive ultrasound (US) imaging of the terminal ileum without and with sulfur hexafluoride contrast at baseline, 4 week and 6 months. Subjects will receive one to two milliliters of the contrast agent.
45767035|NCT03235180|Device|Ultrasound Elastography|Subjects will receive US Imaging with the GE Logiq E9 Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
45625037|NCT04865991|Procedure|Sevoflurane|subjects in the sevoflurane group were cannulated only with one venous catheter. Midazolam 0.05 mg/kg BW and fentanyl 1 mcg/kg BW were given as premedication. Subjects in the sevoflurane group received intravenous propofol 1 - 2 mg/kg BW.
45625038|NCT04870203|Drug|baricitinib treatment|4 mg daily during 12 months
45625039|NCT04870203|Drug|adalimumab|40 mg every 2 weeks during 6 monts
45625040|NCT04870203|Drug|Placebo|40 mg every 2 weeks during 6 months
45625041|NCT04865523|Other|Manual Lymphatic Drainage|Manual lymphatic drainage is a technique that through gentle passes facilitates the flow of lymph through manual therapy techniques based on Vodder therapy. This technique is being studied to know its effectiveness in pain and for this reason we want to carry out this research.
45625042|NCT04875897|Device|keepMED PAP device|The keepMED PAP device is an automatic, wearable positive airway pressure device indicated for treatment of obstructive sleep apnea. A therapeutic pressure is delivered to the patient upper airway through a nasal interface. It is similar to other marketed positive airway pressure devices with respect to its fundamental use of positive airway pressure for the treatment of sleep apnea as well as with regard to its functional components and accessories (e.g., a PAP unit, a mask/nasal interface, an air filter, tubing, etc.).
45767036|NCT03235180|Device|Ultrasound Vascularity|Subjects will receive US Imaging with the Verasonics Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
45767037|NCT03235180|Device|Magnetic Resonance Enterography (MRE)|Subjects will receive MRE imaging at baseline and 6 months as part of regular clinical care.
45767038|NCT03470740|Behavioral|rheumatoid arthritis self-management program|The intervention group received the rheumatoid arthritis self-management program which was based on Bandura's theory of self-efficacy and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
45767039|NCT03471832|Device|stenfilcon A lens|contact lens
45767040|NCT03471832|Device|narafilcon A lens|contact lens
45767041|NCT00985166|Biological|ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)|A Single 0.5 mL subcutaneous injection at Day 1
45625043|NCT04865211|Drug|Liposomal bupivacaine|Use of liposomal bupivicaine as intraoperative local anesthesia
45767042|NCT00985166|Biological|Comparator: M-M-R II|A Single 0.5 mL subcutaneous injection at Day 1
45767043|NCT00985166|Biological|Comparator: Varivax|A Single 0.5 mL subcutaneous injection at Day 1
45767044|NCT00985166|Biological|Comparator: Placebo|A Single 0.5 mL subcutaneous placebo injection at Day 1
45767045|NCT04735120|Device|iLASE DIODE LASERS|940nm diode laser with 1.5 watts activated in a continuous mode and applied on to the canal orifices during root canal treatment to reduce intraoperative pain and further its effect on post operative pain is assessed
45767046|NCT03235414|Device|MRI|Will receive a one time research MRI (MR elastography)
45767047|NCT03235414|Diagnostic Test|Blood draw|Will receive a one time blood draw to confirm healthy liver status
45767048|NCT04735900|Procedure|Liquid biopsy sampling|Biweekly liquid biopsy sampling to measure circulating tumor DNA (ctDNA) level up to and including 9 months after start first-line therapy.
45767049|NCT03474172|Device|Cloak Shape Device for Sham Tuina|The Cloak Shape Device for Sham Tuina is exactly the same as the real one, which is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a sham Tuina will be manipulated
45767050|NCT03474172|Device|Cloak Shape Device for Genuine Tuina|The Cloak Shape Device for Genuine Tuina is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a genuine Tuina will be manipulated.
45767051|NCT03474406|Other|follow up system and multimodality approach|To provide a new service system for cancer pain in pain clinic by early detecting red flag sign to consult other departments, early alleviating severe pain, following patients intensively by telephone call and giving pain education
45767052|NCT03474874|Device|NeoMatriX Collagen Dressing|Collagen wound dressing
45767053|NCT03476278|Other|Questionnaire|Postoperative questionnaire, and records of complications in the peri-operative period
45447072|NCT02103400|Other|Control group|Exercise control group
45625044|NCT04865211|Drug|Bupivacaine Injection|Use of bupivicaine as intraoperative local anesthesia
45625045|NCT04865211|Drug|Placebo|Use of saline as placebo for local anesthesia
45625046|NCT04865445|Drug|AT-527 550 mg + midazolam|"Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening.~Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening.~Other Names: AT-527 is also know as R07496998"
45625047|NCT04865445|Drug|AT-527 550 mg + midazolam|"Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening.~Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening.~Other Names: AT-527 is also know as R07496998"
45625048|NCT04875819|Drug|Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine|One dose (0.5 ml) of conjugate vaccine against meningococcal serogroups ACWY (Menveo®) and one dose of a recombinant protein-based vaccine against meningococcal serogroup B (Bexsero®) at day 0 followed by another dose (0.5 ml) of each vaccine at day 60.
45625049|NCT04875819|Drug|13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine|One dose (0.5 ml) of pneumococcal conjugate vaccine (Prevenar13®) at day 0 and one dose (0.5 ml) of pneumococcal polysaccharide vaccine (Pneumovax23®) at day 60.
45625050|NCT04875663|Behavioral|Lifestyle Medicine|Lifestyle intervention including diet, sleep, exercise, relaxation and mindfulness
45625051|NCT04869423|Behavioral|Dog-Assisted Therapy|During seven weeks patients will assist one time per week (1 hour). The therapy will be conducted by an expert psychologist. The intervention will consist of 7 weeks conducted once a week (50 minutes each session). It will include three parts: 1) a welcome part aimed to get in touch with the dog, 2) a main part, where participants will be taught basic notions about dog training and then try to train the dogs. In this part, the patients will perform different activities and exercises with the dog. 3) A closing part to say goodbye to the dogs.
45625052|NCT04875741|Other|Neural mobilization|Mobilization of the structures within and around the nervous system is broadly known as Neural Mobilization.
45625053|NCT04875741|Other|Muscle energy technique|Manual therapy technique initially developed and used by the osteopaths is known as Muscle energy techniques(MET).This technique is effective for the pain reduction, lengthening of the shortened muscle and fascia, improvement in blood circulation and promoting lymph drainage.
45625054|NCT04864977|Drug|Basal Insulin|Participants administered basal insulin
45625055|NCT04869735|Other|Data collection: DTPolio vaccine delivery|"with information about booster vaccination group: Sending of information concerning booster vaccination against DTPolio at 25 years using letters, emails and SMS without information about booster vaccination group: no intervention"
45625056|NCT03046407|Biological|retinal pigment epithelium transplantation|Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
45625057|NCT04864821|Drug|Targeting CD276 CAR T cells|Targeting CD276 autologous chimeric antigen receptor T cells
45625058|NCT04865055|Other|cyclic merocyanine|long-UVA absorber
45625059|NCT04865055|Other|placebo|placebo
45625060|NCT03048123|Procedure|Hepatic arterial infusion|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially
45625061|NCT03048123|Procedure|Transarterial chemoembolization|Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.
45625062|NCT03048123|Drug|Folfox Protocol|oxaliplatin,leucovorin and 5-FU
45767054|NCT05443737|Behavioral|Multi-component oncofertility care intervention|The multi-component oncofertility care intervention includes: (1) an adaptive and smart default electronic health record-based oncofertility needs screen and referral pathway, (2) telehealth oncofertility counseling as indicated, and (3) telehealth oncofertility financial navigation as indicated.
45625063|NCT03048123|Drug|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
45625064|NCT03046173|Other|concentrated growth factors|These patients were randomly assigned to receive concentrated growth factors, hydroxyapatite and autogenous bone at bone defect sites in the experimental group.
45625065|NCT03046173|Other|hydroxyapatite and autogenous bone|These patients were randomly assigned to receive hydroxyapatite and autogenous bone at bone defect sites in the control group.
45625066|NCT04869579|Drug|Selenium (as Selenious Acid)|Interventional arm participants will receive Selenium as Selenious Acid infusion plus the standard of care therapy.
45625067|NCT04869579|Other|Placebo|Active comparator arm participants will receive the standard of care therapy plus a Saline-based placebo.
45625068|NCT04864587|Diagnostic Test|Artificial intelligence used for image recognition in pouchoscopy|The aim of this study is to develop an image recognition algorithm that reliably detects the different graduations of pouch inflammation and neoplasms in the pouch
45625069|NCT04864899|Diagnostic Test|Cardiac Magnetic Resonance Imaging (CMR)|Imaging
45625070|NCT04864899|Diagnostic Test|Blood test|Blood investigation
45625071|NCT04864899|Diagnostic Test|6-minute walk test|Correlating the cardiac MRI parameters with functional capacity
45625072|NCT01903733|Drug|bosutinib|The starting bosutinib dose is 500 mg once daily, however the dose can vary from 300 mg to 600 mg.
45625073|NCT03253055|Radiation|DEXA|Dual energy X-ray absorptiometry (DEXA): a total of two scans will be performed, one for the assessment of whole body bone mineral density and body composition, and the other scan is performed to specifically assess fracture risk by scanning the hip and femoral head. Effective exposure doses for these scans are ~8uSv and ~4uSv respectively.
45625074|NCT03253055|Radiation|pQCT|A total of one scan will be performed on the non-dominant Tibia, the effective exposure dose will be between 1.5-1.8uSV.
45625075|NCT03253055|Other|Lifestyle Questionnaire|Participants are required to record their lifestyle, diet (5-day self reported), physical activity (IPAQ questionnaire), injury and illness incidence.
45767055|NCT02264379|Radiation|normal fractionated irradiation|25*2 Gy (once a day, 5 days a week)
45767056|NCT02264379|Radiation|hypo fractionated irradiation|3*10 Gy (once a day, 2-3 days a week)
45767057|NCT02755623|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Participants are sequentially randomly assigned to either 20 active rTMS sessions or 20 sham rTMS sessions that were applied over the left temporoparietal junction. Treatments are administered daily, over a period of two weeks.
45767058|NCT02755623|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|
45625076|NCT03253055|Other|Aerobic Fitness|Aerobic fitness will be tested using a VO2 max exercise protocol using a stationary cycle ergometer, the participants will be expected to perform this to maximal effort or exhaustion.
45625077|NCT03253055|Other|Muscular Strength|Muscular strength of the knee extensor and handgrip muscles will be determined using an Isokinetic Dynamometer and a handgrip dynamometer respectively.
45625078|NCT03253055|Biological|Blood draw and finger prick test|15ml of whole blood will be collected for the measurement of fasting serum 25(OH)D levels, parathyroid hormone, C-terminal telopeptide (CTX) and full blood count
45767059|NCT02255799|Drug|Donepezil|Donepezil 5 mg capsule daily for 14 days. Donepezil 10 mg capsule daily for 56 days.
45767060|NCT02255799|Drug|Placebo|Placebo capsule once daily for 70 days.
45625079|NCT03253055|Other|Muscular Power|Muscular power will be determined using an optical measurement system consisting of a transmitting and receiving bar to determine jump height through the interpretation of jump flight of the participant (reported in cm). The equipment used is an Optojump.
45625080|NCT03252899|Other|Survey therapists|A survey was conducted among therapists on upper limb treatment after stroke.
45625081|NCT03252899|Other|Survey patients|A survey was conducted among stroke survivors on upper limb treatment after stroke.
45767061|NCT03335254|Drug|TSX-011|TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.
45767062|NCT02226159|Drug|Lidocaine|
45767063|NCT02226159|Drug|Lidocaine with Dexamethasone|
45625082|NCT03229421|Other|Survey|18 question symptom assessment tool including non-identifying demographic information questions.
45625083|NCT01375205|Other|Cetaphil Restoraderm|Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
45625084|NCT01375205|Other|Standard of Care|Subjects will apply Johnson&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&Johnson cleanser.
45625085|NCT03234959|Device|CareToy intervention|Infants will perform goal directed activities inside the CareToy System
45625086|NCT03234959|Other|Infant Massage|Infants will received IM by their parents
45625087|NCT03229577|Behavioral|Sudarshan Kriya Yoga|Yoga-based breathing program.
45625088|NCT03229577|Behavioral|Mindfulness-Based Stress Reduction|Mindfulness program.
45625089|NCT03229577|Behavioral|Emotional Intelligence|Emotional Intelligence program.
45625090|NCT03235037|Drug|Levodopa|The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
45625091|NCT03229343|Other|Supportive care|supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
45625092|NCT03229265|Drug|Patiromer|Patiromer (8.4 grams) will be taken daily at 3 hours after oral tacrolimus and MMF dosing by subjects commencing 3 days (± 1 day) prior to visit 1.
45625093|NCT03234803|Other|poly-amide|new denture base material
45767064|NCT03335800|Device|Apple Heart Study App|The Apple Heart Study app is a mobile medical app that analyzes pulse rate data. The app identifies episodes of irregular heart rhythms consistent with atrial fibrillation and other arrhythmias.
45767065|NCT02202369|Other|Multimodal Analgesia Treatment|Subjects are given medications preop (Pregabalin, Oxycodone, Acetaminophen, Transdermal Scopolamine, Cyclobenzaprine), intraop (Propofol induction, Sevoflorane maintenance, Dexamethasone, Fentanyl, Ketamine, Marcaine, Zofran) and postop(Acetaminophen, Pregabalin, Tramadol, Cyclobenzaprine) that implement a multi-modal approach to managing pain.
45767066|NCT02202369|Other|Standard of Care Pain Management Protocol|Subjects will be treated with patient controlled (standard of care) narcotic analgesia for pain management. (Marcaine, Dexamethasone, Zofran, Morphine, Acetaminophen, Cyclobenzaprine)
45767067|NCT03338686|Procedure|Free Gingival Graft (FGG)|Free Gingival Graft (FGG) was performed on all study sites in this arm.
45767068|NCT03338686|Procedure|Connective Tissue Graft followed by Laser Gingivoplasty|Connective Tissue Graft followed by Laser Gingivoplasty one month later on all study sites in this arm.
45767069|NCT03241030|Drug|Sucralfate|Will receive 20mg/kg/dose up to 1 gram.
45767070|NCT03241030|Other|Placebo|Will received placebo solution of similar quantity to that of the weight based dose of sucralfate.
45767071|NCT03241030|Drug|Acetaminophen|All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
45767072|NCT03241030|Drug|Ibuprofen|All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
45767073|NCT03479944|Procedure|FLACS|Femtosecond laser assisted cataract surgery consisting of LenSx® and Centurion® combination
45625094|NCT03234803|Other|poly-methyl methacrylate|gold standard for denture base materials
45767074|NCT03479944|Procedure|Manual conventional surgery|Removal of cataractous lens by phacoemulsification
45625095|NCT02452853|Procedure|HR|"HR:~HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus"
45625096|NCT02452853|Drug|FOLFOX4|"FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin):~4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion. Repeated every 2 weeks"
45767075|NCT03479944|Device|CENTURION® Vision System|Phacoemulsification aspiration platform for use during cataract surgery
45767076|NCT03479944|Device|LenSx®|Femtosecond laser system used for continuous curvilinear capsulorhexis (CCC) and lens fragmentation during cataract surgery
45625097|NCT00700271|Drug|Amlodipine|5 mg or 10 mg tablets.
45767077|NCT02184195|Drug|Olaparib|Tablet -100mg
45767078|NCT02184195|Drug|Olaparib|Tablet-150mg
45767079|NCT02184195|Drug|Placebo|Match Olaparib 100mg placebo
45767080|NCT02184195|Drug|Placebo|Match Olaparib 150mg placebo
45767081|NCT02741037|Behavioral|Dyadic lifestyle intervention|Dyadic lifestyle intervention: The dyadic behavioral lifestyle intervention was modeled after the Diabetes Prevention Program (DPP), and was adapted to make it more easily accessible to low-income Latinas. In addition, this intervention arm has a dyadic component to examine the effectiveness of mothers and daughters engaging in the lifestyle intervention together as partners. Participants also will receive usual care.
45767082|NCT02741037|Behavioral|Individual lifestyle intervention|Individual lifestyle intervention: The individual behavioral lifestyle intervention was modeled after the Diabetes Prevention Program, and was adapted to make it more easily accessible to low-income Latinas. Mothers participate in the Unidas intervention alone, without their related daughters. Unrelated daughters participate in the Unidas intervention alone without their related mothers. Participants also will receive usual care.
45767083|NCT02741037|Other|Usual Care|Usual Care: Mother and daughter participants will receive Usual Care.
45767084|NCT03241810|Drug|Seribantumab|Seribantumab is a human monoclonal antibody that inhibits ErbB3 signalling
45625098|NCT00700271|Drug|Valsartan|160 mg capsules.
45767085|NCT03241810|Drug|Fulvestrant|Fulvestrant is an estrogen receptor antagonist with no agonist effects
45767086|NCT03241810|Drug|Placebo|Placebo
45625099|NCT02613507|Drug|Nivolumab|
45625100|NCT02613507|Drug|Docetaxel|
45625101|NCT03228797|Procedure|an ultrasound guided rectus sheath block|
45625102|NCT03228797|Procedure|multiholed catheter|gauge multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer at 3 to 5 cm away from the lower end of the surgical incision
45625103|NCT03228797|Procedure|an ultrasound guided rectus sheath block &multiholed catheter|a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
45625104|NCT03234647|Device|Doraya catheter|Temporary deployment of the Doraya catheter in AHF patients.
45447073|NCT03694275|Drug|Soticlestat|TAK-935 tablets
45625105|NCT02452541|Other|Prognostic tests|"Brain CT-Scan on day 1, 3 and 7~Brain MRI on day 7~SomatoSensory Evoked Potentials on day 7~Electroencephalogram on day 7~Serum biomarkers on day 1, 3 and 7~Daily clinical exams"
45625106|NCT03046095|Other|Unilateral Resistance Exercise|Unilateral Resistance exercise will include training three days per week and each session will include 3 sets of leg extension and 3 sets of leg press. In each set, the participant will complete a maximum of 12 repetitions.
45625107|NCT03046095|Procedure|Immobilization|During the last two weeks of the study (week 8-10), a Don Joy adjustable knee brace will be applied to the participant's leg randomized to immobilization. The brace will be applied at a 40 degree angle relative to complete extension.
45625108|NCT03228641|Device|micro-excisional skin removal with coring needle|
45767087|NCT02129751|Drug|bupropion hydrobromide|study drug
45767088|NCT02129751|Drug|Placebo|placebo arm
45767089|NCT03242590|Drug|LPCN 1021|Oral testosterone undecanoate
45767090|NCT03481270|Behavioral|Concordant|We will be randomizing across providers - we are particularly interested in racial concordance.
45767091|NCT02699697|Radiation|External Beam Radiation Therapy|Undergo EBRT
45767092|NCT02699697|Radiation|Palliative Radiation Therapy|Undergo EBRT
45767093|NCT02699697|Other|Quality-of-Life Assessment|Ancillary studies
45767094|NCT02699697|Other|Questionnaire Administration|Ancillary studies
45767095|NCT03247738|Drug|Cangrelor|Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
45767096|NCT03247738|Other|Placebo|Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
45767097|NCT02660385|Behavioral|Cognitive Behavioral Therapy for Insomnia|This behavioral intervention includes strategies for modifying thoughts, cognitions and behaviors regarding sleep provided by a therapist in a group format.
45767098|NCT02660385|Behavioral|Self-Management Education for Heart Failure|This is an educational education designed to teach patients about self-management their heart failure. It includes information on medications, lifestyle, cardiac devices, diet, and when to seek assistance from a health care provider.
45767099|NCT03341728|Behavioral|Optical flow perturbations|Continuous mediolateral (i.e., side-to-side) 20-minute perturbations of optical flow that elicit the visual perception of lateral imbalance via virtual reality during treadmill walking.
45767100|NCT03341728|Behavioral|Normal walking|Usual treadmill walking without optical flow perturbations
45625109|NCT03045939|Device|cervical ripening device|insertion of the double balloon device for 12 hours (standard care) vs 6 hours, following oxytocin IV infusion according local protocol guidelines as mentioned above
45625110|NCT03228485|Device|MyBPH Care mobile app|The application that will give daily medication reminders and via which the questionnaires can be filled out.
45625111|NCT04864197|Biological|platelet rich fibrin|prf membrane placement over implant site for gingival thickening
45767101|NCT03345160|Drug|Peanut Flour|open label oral immunotherapy
45625112|NCT02452619|Other|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
45767102|NCT01874067|Device|Arthritis glove|Isotoner three-quarter finger arthritis glove
45767103|NCT03345394|Behavioral|Contingency Management|Participants will receive vouchers with monetary value for submitting crack cocaine negative urine samples
45767104|NCT03345394|Behavioral|Standard treatment|Participants will receive the standard treatment offered at Unidade Recomeço Helvétia treatment program
45625113|NCT03228251|Other|Stroke team simulation training|"The participating centers identify 3-4 senior staff of different professional backgrounds (e.g. senior neurologist, neurointerventionalist, head nurse) who will design a stroke team algorithm tailored to the local circumstances of the stroke center. The centers will be invited to a joint train-the-trainer seminar at the sponsor's institution where they present their algorithm to the participants of all seven stroke centers for discussion to invite suggestions for streamlining and improvement. The teams will be introduced to the concept of simulation-based stroke team training. After the seminar, the principal investigator and the stroke team trainer will visit all centers for one on-site stroke team training and provide teaching materials. Afterwards, each center will be invited to schedule two additional stroke team trainings with the stroke team trainer that will be led by e.g. the senior neurologist from the stroke unit with use of a simulation manikin."
45625114|NCT03044379|Drug|Dapivirine gel (0.05%)|MTN-026/IPM 038 will use the HTI pre-filled applicator, the same applicator that has been utilized in other rectal studies.
45625115|NCT03044379|Other|Universal HEC placebo gel|
45767105|NCT01567605|Drug|Lidocaine lubricant|Subjects using this intervention will receive 30 mL of Lidocaine hydrochloride jelly (2%)
45767106|NCT01567605|Other|Placebo lubricant|Subjects using this intervention will receive 30 mL of placebo lubricant (no topical anesthetic)
45767107|NCT01545999|Other|Brain Stimulation via Transcranial Magnetic Stimulation|"PAS-25 will consist of 180 PNS delivered to right median nerve, each paired with a single TMS pulse delivered over left DLPFC with an interstimulus interval of 25 ms. This ISI was designed to generate approximately synchronous arrival of both inputs in M1 and was reported to markedly enhance TMS-induced MEP following PAS-25.~Patients with schizophrenia will be asked to continue with a 2-week course (5 days/week) of daily PAS-25 or PAS-100 to assess potential of a repetitive course of PAS-25 on enhancing working memory in patients with Schizophrenia. One and seven days after the 2-week course PAS-25 or PAS-100, patients with schizophrenia will be assessed with the N-back task."
45767108|NCT02604537|Drug|betamethasone|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml betamethasone
45767109|NCT02604537|Drug|Ketorolac|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac
45767110|NCT02603133|Behavioral|Three Good Things|"In this tool participants reflect on good things that happened that day during evenings across 10 days. Participants are also able to voluntarily share their good things and read other participants' good things through the nightly anonymous log. By savoring good moments from earlier that day, participants are thought to shift from the natural focus on what went poorly due to negativity bias1 to an appreciation for what went well. This shift in focus is thought to reduce rumination and depression symptoms. In prior research, 3GTs was found to increase happiness and decrease depression in internet participants.2 In prior cohorts of 3GTs, we saw improvements in burnout, depression symptoms, work-life balance, and happiness. Participants also report benefiting from viewing nightly Three Good Things logs of others."
45767111|NCT02603133|Behavioral|Gratitude|In this tool participants are offered the opportunity to cultivate gratitude toward others through a guided gratitude letter writing exercise.2 Through expressing gratitude, we learn more about our vital connections to others, often in surprising and meaningful ways. Previous research has found that gratitude interventions increase well-being in a number of ways, particularly in boosting positive affect.
45767112|NCT02603133|Behavioral|Random Acts of Kindess|In this tool, participants report kind acts that they have committed, received, and/or witnessed, each day. By committing random acts of kindness participants experience a boost of positive emotions, and report lower negative affect. Recipients of acts of kindness benefit as well.
45767113|NCT02603133|Behavioral|Awe|This tool provides participants the opportunity to recount in detail one of their own experiences of awe, and encourages them to be on the lookout for new ones (even minor examples) over a few days. When we experience awe, our sense of time expands, we are kinder to others, we experience higher life satisfaction, and we prefer experiences over material things.
45767114|NCT02603133|Behavioral|1 Good Chat|This tool uses the latest research on cultivating relationships and increasing social connection. Feeling socially connected is linked to health and well-being outcomes, including longevity.6 The 1 Good Chat tool asks participants to reflect on good conversations and to note the prosocial behaviors that he/she and the other person engaged in
45625116|NCT04864509|Drug|Melatonin 10 MG|Nightly dose
45625117|NCT04864509|Drug|Placebo|Nightly dose
45625118|NCT04864353|Behavioral|RestDep: Internet-delivered intervention targeting residual cognitive symptoms|The intervention is fully digital with weekly telephone guidance. Key intervention elements are 1) psychoeducation, 2) attention training, 3) strategy training. Cognitive domains as attention, memory and executive functions are covered and rumination.
45625119|NCT03228407|Procedure|Confocal endomicroscopy|Confocal laser endomicroscopy (CLE) permits real-time in-vivo histologic analysis of esophageal mucosa at the time of upper endoscopy. The technology is based on the principle of illuminating a tissue with a low-power laser and then detecting fluorescent light reflected from the tissue. Because CLE relies upon tissue fluorescence, intravenous fluorescein is generally used to highlight the vasculature and intercellular spaces of the tissue being examined.
45625120|NCT03228407|Diagnostic Test|Endoscopic biopsies|Additional biopsies will be obtained of the esophageal mucosa.These will be obtained with a standard biopsy forceps inserted through the channel in gastroscope.
45625121|NCT03228407|Diagnostic Test|Mucosal impedance (MI)|MI balloon measures epithelial impedance along a 10 cm length of esophagus. The gastroscope will be withdrawn and the MI balloon will be advanced into the esophagus through the mouth. The balloon will be inflated so that the sensors contact the esophageal mucosa. After MI measurements are obtained, the balloon will be deflated and withdrawn.
45447074|NCT02098564|Other|Joint mobility exercises hand therapy|Joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program
45625122|NCT04863963|Procedure|Milligan Morgan|Surgical intervention used in case of Goligher's grade III hemorrhoidal disease
45625123|NCT03228329|Other|fluid boluses|fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations
45625124|NCT04864041|Other|Evaluation of global longitudinal strain using routinely recorded echocardiography images|There are no particular intervention performed in patients in this study, because echocardiography is part of the standard of care of patients hospitalised in the ICU for vaso occlusive crisis.
45625125|NCT03228095|Diagnostic Test|VOC detection in breath and in skin headspace|VOC will be detected in breath with off-line and on-line testing and in skin headspace with off-line testing
45625126|NCT03228095|Diagnostic Test|Breath sampling|Breath sampling for VOCs detections will be carried out using nano-sensor based devices (electronic nose)
45625127|NCT03228095|Procedure|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
45767115|NCT01384773|Other|Riboflavin Solution|This solution is used to saturate the corneal stroma prior to its photochemical activation by the IROC UV-X illuminator.
45767116|NCT01384773|Device|UV-X Illumination System|IROC UV-X irradiation system creates a uniform 11 mm circle of UVA light that is focused onto the corneal surface. This system is designed to irradiate the riboflavin saturated cornea with a uniform field of UVA light centered at 365 nm.
45767117|NCT02539329|Other|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS), Rankin score) and 2 blood collection tubes for antibody screening
45767118|NCT01352403|Procedure|Roux-en-Y gastric bypass|
45767119|NCT01352403|Behavioral|Psychotherapy-enhanced lifestyle intervention|
45767120|NCT01063075|Drug|Cetuximab|Administered Intravenously
45767121|NCT01063075|Drug|Carboplatin|Administered Intravenously
45767122|NCT01063075|Drug|5 - FU|Administered Intravenously
45767123|NCT01341405|Drug|CG100649|once daily for 28 days
45767124|NCT01341405|Drug|Celecoxib|capsule, celecoxib 200 mg, once daily for 28 days
45767125|NCT02981485|Device|Fat Grafting|Treatment of breast cancer related lymphedema by fat grafting
45767126|NCT01153035|Device|Radiofrequency Ablation|Breast conservation surgery followed by Radiofrequency Ablation of the cavity
45767127|NCT03015103|Device|Intimate Lubrificant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
45767128|NCT01113567|Dietary Supplement|Lactose-free milk|3.5 g of lactose
45767129|NCT01113567|Dietary Supplement|Whole milk|Whole milk with 24 g lactose
45767130|NCT01064323|Device|Intermittent pneumatic compression of the lower extremities|IPC will be done for 3 divided hours daily for 4 weeks
45447075|NCT02098564|Other|activity-based hand therapy|intervention involve joint mobility exercises which are appropriate for their injury and training with specific meaningful activities which they performed prior to the hand-related injury. Activity-based hand therapy will be performed both in the therapy setting and as a home exercise program.
45447076|NCT02099968|Behavioral|Comprehensive Lifestyle Modification|"Fasting (1st week), followed by:~Vegetarian and modified DASH diet (plant-based, low-salt)~Aerobic exercise~Stress reduction techniques: progressive muscle relaxation, meditation, yoga"
45625128|NCT03228095|Procedure|Colonoscopy with biopsies|Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
45625129|NCT03228095|Procedure|Whole blood/ Plasma / serum sampling|Whole blood/Plasma/serum sampling will be used to obtain information for group stratification
45625130|NCT03228095|Diagnostic Test|Faecal sampling|Facal samples will be obtained for faecal occult blood testing as well as microbiota analysis
45767131|NCT01064713|Drug|Tesetaxel|"Cohort A: 40 mg by mouth every 21 days.~Cohort B. 50 mg by mouth every 21 days."
45767132|NCT04039789|Behavioral|Project active legs|Home program of exercises of lower extremities includes the performance of 4 exercises of lower extremities of progressive difficulty that must be carried out at home 5 days a week, twice a day and walking progressively until reaching the marked goal (150 min / week (30 minutes for 5 days a week)).
45767133|NCT04039789|Procedure|Usual care|Evaluation, cleaning, debridement, topical treatment (moist healing) and compressive therapy according to the recommendations for the treatment of chronic cutaneous ulcers of the Community of Madrid.
45767134|NCT01065571|Dietary Supplement|carrageenan|The intervention is the carrageenan-free diet. Supplementary carrageenan capsules will be given to mimic the carrageenan in the normal diet.
45767135|NCT01065571|Other|dietary intervention with no-carrageenan diet|The intervention will consist of the no-carrageenan diet.
45767136|NCT05136157|Drug|Rapid-Acting Insulin|50 IU of rapid acting insulin taken by a 100 units (1ml) insulin syringe will be added to a 50 ml syringe containing normal saline (NS) to have a total volume of 50 ml with a concentration of 1 IU of insulin per 1 ml of NS
45767137|NCT05136001|Device|polysomnography|Duration of sleep was collected with polysomnography on second postoperative night. (from 20:00pm to 06:00am).
45625131|NCT03228095|Procedure|Histological examination of surgical specimen|Routine histological exam for patients undergoing curative or palliative surgery. Indication for surgery are set based on underlying condition. Study does not interfere with decision making for surgical treatment
45625132|NCT03228095|Diagnostic Test|Headspace analysis for biological material|VOC analysis from headspace of surgical specimen, biopsy materials, blood/plasma, microbiota etc.
45767138|NCT03965299|Device|VERUM TTNS|"Daily 30-minute TTNS intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase"
45767139|NCT03965299|Device|SHAM TTNS|"Daily 30-minute SHAM intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase"
45625133|NCT03044067|Other|Pain neuroscience education + Exercise|A session of Pain neuroscience education + Exercise covers the activity, strength and endurance of lower and upper muscles of the extremities. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
45767140|NCT03936127|Procedure|Ultrasound (US) Targeted Fusion Biopsy|Ultrasound (US) Targeted Fusion Biopsy
45767141|NCT01921790|Biological|Avastin|Avastin 7.5mg/Kg, intravenous drip D1
45767142|NCT01921790|Drug|Gemcitabine|Gemcitabine 1g/m2 intravenous drip D1,D8
45767143|NCT01921790|Drug|Oxaliplatin|Oxaliplatin 130mg/m2 intravenous drip D1
45767144|NCT01921790|Drug|Pegaspargase|Pegaspargase 2500U/m2 intramuscular injection (IM) D1
45625134|NCT03044067|Other|Exercise|A session of exercise covers the activity, strength and endurance of lower and upper muscles of the extremities.
45767145|NCT01921790|Drug|Dexamethasone|Dexamethasone 20mg/d intravenous drip D1, po D2-3
45767146|NCT02153541|Drug|Antipyrine-benzocaine otic solution|Participants receiving antipyrine-benzocaine otic solution are expected to decrease usage of rescue inhalers.
45625135|NCT03044301|Combination Product|Intramuscular ZENEO® injection|Sodium Chloride (0.9 %)
45767147|NCT02153541|Other|Glycerin with Oxyquinoline Sulfate|50% of participants will receive the glycerin with oxyquinoline sulfate. These participants will be randomly selected and unaware that they are receiving the placebo and are expected to have no change in usage of rescue inhalers.
45625136|NCT03044301|Combination Product|Subcutaneous high ZENEO® injection|Sodium Chloride (0.9 %)
45767148|NCT03248440|Drug|SUN-131 1.5% TDS|SUN-131 1.5% TDS will be worn for 14 days
45625137|NCT03044301|Combination Product|Subcutaneous low ZENEO® injection|Sodium Chloride (0.9 %)
45625138|NCT04875117|Device|Hearing aid|One or two behind the ear hearing aids provided by the UK National Health Service.
45625139|NCT03227783|Device|transcranial direct current stimulation (tDCS)|tDCS is one of non-invasive brain stimulation. Constant, low current is delivered to the specific brain areas to change brain plasticity.
45625140|NCT04875039|Drug|Dexamethasone|dexamethasone 2 mg will be added to the local anesthetic used to block the cords of the brachial plexus with an infraclavicular approach.
45625141|NCT04875039|Drug|Dexmedetomidine-Dexamethasone|A mixture of dexamethasone 2mg with dexmedetomidine 50mcg will be added to the local anesthetic used to block the cords of the brachial plexus with an infraclavicular approach.
45625142|NCT03227939|Procedure|Laparoscopic sleeve gastrectomy（LSG）|LSG：All these operations were performed by the same surgeon team. Dissect the greater omentum alongside the greater gastric curvature, make sure that the greater gastric curvature and fundus of stomach were completely made free from pancreas and spleen.Fully Exposed left and right diaphragm angle and taking care not to injure the esophagus. Resection was started 2 to 4 cm from pylorus and alongside a 40Fr tube up to the esophagogastric junction and created a 60 to 80ml gastric lumen, removed the fundus of stomach thoroughly and take care of the esophagus and preventriculus. Repaired the hiatal hernia if it was exsit.
45767149|NCT03248440|Drug|Placebo TDS|No active substance; Placebo TDS will be worn each day for 14 days
45625143|NCT03227939|Procedure|Uvulopalatopharyngoplasty(UPPP) and Adenoidectomy/Tonsillectomy|UPPP：PPP is typically administered to patients with obstructive sleep apnea in isolation. It is administered as a stand-alone procedure in the hope that the tissue which obstructs the patient's airway is localized in the back of the throat. The rationale is that, by removing the tissue, the patient's airway will be wider and breathing will become easier.
45625144|NCT04874883|Dietary Supplement|Simbyotic|6 grams of the symbiotic will be administered twice a day
45625145|NCT04874883|Device|Control Group|6 grams of the maltodextrin will be administered twice a day
45767150|NCT05074849|Behavioral|A 90-minute self-care education + bi-weekly 30-minute one-on-one follow-up phone discussion|A 90-minute group session to educate patients on foot self-care strategies (daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch). Follow-up Care: A biweekly 30-minute one-on-one follow-up phone discussion (i.e., daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch, addressing feedback and questions regarding the intervention and prevention of foot-related complications).
45767151|NCT03487276|Drug|IFX-1|Single IV infusions of IFX-1 diluted in sodium chloride.
45767152|NCT03487276|Drug|Placebo|Placebo
45767153|NCT04352803|Biological|Autologous Adipose MSC's|Autologous Adipose Derived Mesenchymal Cells 500,000/kg IV
45767154|NCT03487588|Drug|A-101 Topical Solution|A-101 Topical Solution applied Day 1, Day 15 and Day 29
45767155|NCT03250234|Other|Adequate Carbohydrate|During the 3-hr recovery period after glycogen depletion participants will consume a carbohydrate (1 g/kg/hr) beverage For the day participants will consume a diet of 6.0 g/kg/d carbohydrate following glycogen depletion
45767156|NCT03250234|Other|Low Carbohydrate|"During the 3-hr recovery period after glycogen depletion participants will consume a nutrient free beverage.~For the day participants will consume a diet of 1.2 g/kg/d carbohydrate following glycogen depletion"
45767157|NCT03489850|Drug|Ibudilast|Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.
45767158|NCT03489850|Other|Placebo|Placebo is matched to ibudilast active medication.
45767159|NCT03490942|Drug|Glucagon|CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.
45767160|NCT03490942|Drug|Placebo|The placebo solution is a non-active formulation containing excipients only.
45767161|NCT01069003|Drug|Placebo Arm|Placebo and ASA (75 mg - 325 mg)
45767162|NCT01069003|Drug|Thienopyridine Therapy|Prasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg)
45767163|NCT01069003|Device|Surveillance Arm|Non randomized arm to understand clinical outcomes in a commercial setting
45767164|NCT00376870|Drug|Pioglitazone|pioglitazone 30 mg/d
45767165|NCT00376870|Drug|Placebo|Placebo 30 mg/d
45625146|NCT04874727|Procedure|Mandible slacked and captured with Correct Plus™ Impression Material Superfast|In order to simulate the supine position, patients are placed in a supine position (180 degrees) in a dental exam chair, and asked to relax their lower jaw, allowing it to drop back, simulating their jaw falling back while sleeping. That bite is then captured with a Correct Plus™ Impression Material Superfast. Once the bite material hardens, it locks the bite in place. The patient then stands upright, and CBCT is taken standing while the jaw placement is still pseudo sleep-supine, supported by the bite material.
45625147|NCT02452385|Drug|CM082 tablet|CM082 tablets taken orally
45625148|NCT04874649|Other|Balloon-blowing breathing|Participant sit on a chair. Inhale fully through their nose and hold for a full 3 second inhalation, then exhale through their mouth into the balloon fully. By having the balloon inflate until their touch the balloon size control device and hold the exhalation period for 1 second, cover the balloon immediately with your fingers count as 1 breath cycle, then replace the balloon immediately. Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks
45625149|NCT04874649|Other|Sustained maximal inspiration breathing|Participant sit on a chair. Inhale through their nose fully and hold for 3 seconds for a full breath, Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks
45767166|NCT03015025|Genetic|Acenocoumarol|A blood sample was collected for CYP2C9, VKORC1, CYP4F2, APOE and 2 variants of POR genotypes.
45767167|NCT01069315|Procedure|Type of fluid lavage solution|Comparison of castile soap solution vs. normal saline solution.
45767168|NCT01069315|Procedure|Type of fluid lavage pressure|Comparison of low pressure vs. high pressure.
45912721|NCT02013726|Device|3D Mammogram/Breast Tomosynthesis Scan: Selenia® Dimensions®|The breast tomosynthesis procedure involves x-ray imaging of the breast using a moving x-ray source and digital detectors composed of cesium iodide crystals on an amorphous silicon layer or of solely selenium in order to produce an image of the breast. This procedure is considered to basically be a modification of mammography and also is used as a diagnostic adjunct to mammography screening for problem cases.
45767169|NCT03350542|Device|SYNERGY 48 mm|A drug eluting coronary stent system
45767170|NCT03014869|Device|High flow nasal cannula|High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
45767171|NCT03252964|Device|Continuous Glucose Monitor (CGM)|Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
45767172|NCT03252964|Device|Activity Tracker|Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
45767173|NCT03252964|Behavioral|Coaching|Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
45767174|NCT01070095|Other|Electronic Asthma Action Plan System|The electronic asthma action plan system consists of a tablet device in the physician waiting room which participants use to complete a simple questionnaire, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and finally, a printable asthma action plan that is given to patients, along with the URL for an asthma education website.
45767175|NCT03491800|Behavioral|Question/Topic Prompt List|A written document containing suggested questions that the family member and/or patient may want to ask the health care provider during the visit. A section is included for the patient to check which behaviors they would like for their family member to engage in during the visit and space is provided for the family member to check which behaviors they are willing to perform during the visit.
45767176|NCT02246725|Other|Contact with palliative care unit.|
45767177|NCT05017207|Procedure|Pancreaticoduodenectomy|Pancreaticoduodenectomy with one of 2 types of pancreaticojejunal anastomosis: Blumgart and conventional duct-to-mucosa
45767178|NCT03256162|Drug|Ketamine|A sub-anaesthetic dose of ketamine will be administered in four infusions, each one week apart.
45767179|NCT03256162|Drug|Midazolam|A sub-anaesthetic dose of midazolam will be administered in four infusions, each one week apart.
45912722|NCT02013752|Device|Perineal protection device.|A device used to reduce perineal tears during delivery of the baby.
45912723|NCT02013804|Drug|MEDI0680 (AMP-514)|Study has planned dose escalation cohorts
45912724|NCT02013843|Behavioral|Community-based treatment of overweight and obesity|"Community based treatment of overweight and obese children using the Holbaek-method."
45912725|NCT02013856|Dietary Supplement|Low Epicatechin and procyanidin|70 mg epicatechin and 65 mg procyanidins once daily for 28 days
45912726|NCT02013856|Dietary Supplement|High Epicatechin and procyanidin|140 mg epicatechin and 130 mg procyanidins once daily for 28 days
45912727|NCT02013856|Dietary Supplement|High procyanidin|No epicatechin and 130 mg procyanidins once daily for 28 days
45625150|NCT03227627|Device|VitalStim|One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®.
45625151|NCT03227627|Other|Traditional Therapy|The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy.
45625152|NCT03046329|Behavioral|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
45625153|NCT04874337|Other|Disaster nursing and management training will be given to students using Jenning's Disaster Nursing and Management Model.|The subjects for the training program were prepared by the researchers by scanning the relevant literature. In particular, the ICN Framework of Disaster Nursing Competencies developed by the International Nurses Association (ICN) and the World Health Organization (WHO), the second is the universal standards that should be fundamental in nursing and midwifery education (Global Standards for the Initial Education of Professional Nurses and Midwives). The training program was conducted both theoretically and practically. The theoretical section is based on Jenning's disaster nursing management model. Investigator is a First and Emergency Aid instructor. In addition, support was received from an experienced psychologist and AFAD trainers who provided support to the victims of the Izmir earthquake during the training process. In this context, an 8-module training program was created.
45625154|NCT03227393|Behavioral|Yoga training|Subjects will complete in class yoga training weekly for 8 weeks with additional practice at home
45625155|NCT03045783|Drug|Cefotiam|Prophylactic use of antibiotics group：Prophylactic use of antibiotics during endoscopic treatment, cefotiam 2.0g intravenous
45625156|NCT03227549|Procedure|Direct Superior Approach|Total hip arthroplasty using direct superior approach
45625157|NCT03227549|Device|Total Hip Arthroplasty|Total Hip Arthroplasty using direct superior or posterior approach
45625158|NCT03227549|Procedure|Posterior Approach|Total Hip Arthroplasty using posterior approach
45625159|NCT04869033|Other|Farinelli's Breathing Exercise|after 1 minute of normal breathing, follow this instruction; inhale 2 seconds, suspend 2 seconds, exhale 2 seconds. inhale 3 seconds, suspend 3 seconds, exhale 3 seconds. inhale 4 seconds, suspend 4 seconds, exhale 4 seconds. inhale 5 seconds, suspend 5 seconds, exhale 5 seconds. inhale 6 seconds, suspend 6 seconds, exhale 6 seconds. This cycle lasted 1 minute (60 seconds), called Farinelli's breathing (FB). When participants finished these cycle, repeated it again 4 times. 1 minute of NB + 4 minutes of FB called 1 set. The participants were asked to practice 6 sets/day, 5 days/week (Monday-Friday) for week 1-4, and increased duration to 8 sets/day, 5 days/week for week 5-8.
45625160|NCT04869033|Other|Diaphragmatic Breathing Exercise|after 1 minute of normal breathing, inhale 2 seconds and exhale 2 seconds with nasal airway. Continued breathing this pattern until 4 minutes, then back to normal breathing 1 minute . 1 minute of NB + 4 minute of DB called 1 set. The participants were asked to practice 6 sets/day, 5 days/week (Monday-Friday) for week 1-4, and increased duration to 8 sets/day, 5 days/week for week 5-8.
45625161|NCT01375049|Drug|Aztreonam for Inhalation Solution (AZLI)|AZLI 75 mg administered 3 times daily via the investigational eFlow® nebulizer
45625162|NCT04874571|Other|Muscle Energy Technique group|In addition to the home exercise program of 12 sessions for 4 weeks, 3 days a week, muscle energy technique will be applied to the individuals in the MET(Musculer Energy Technique) group.
45625163|NCT04146207|Drug|SHR0302|SHR0302 po QD
45625164|NCT04146207|Drug|Prednisone|Prednisone 1mg/kg/d po
45625165|NCT04863807|Procedure|Regional Anaesthesia|Thoracic epidural/Erector Spinae block/Serratus Anterior block
45625166|NCT03120065|Other|Electronic Dose Monitoring (MEMS)|The MEMS cap is an electronic bottle cap that records the time and date of a bottle being opened. The research personnel will extract the timing of the MEMS bottle opening events for adherence analysis.
45625167|NCT03120143|Other|Small-sided ball game training with high protein intake|In the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation high in protein consists of 18 g protein consumed immediately after and 3 h post exercise
45625168|NCT03120143|Other|Small-sided ball game training with low protein intake|n the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation low in protein consists of 3 g protein consumed immediately after and 3 h post exercise.
45625169|NCT03226925|Diagnostic Test|Non-invasive mechanically-assisted ventilation|Mechanically ventilation will be done through facial masks connected to a respirator. Volunteers/patients are fully conscious during the ventilation.
45625170|NCT03226925|Diagnostic Test|Dynamic MRI acquisition|Dynamic MRI acquisition are specific dynamic sequences intended to visualise the motion of internal structures (anatomical structures or tumour) under non-invasive mechanically-assisted ventilation
45625171|NCT03226925|Diagnostic Test|Planning 4D-CT|In order to perform in-silico planning, 4D-CT will be acquired on patients under non-invasive mechanically-assisted ventilation
45625172|NCT03226613|Procedure|Transcervical Oropharyngeal Ultrasound|One time approximately 15 minute ultrasound will be conducted at the time of clinic visit, focusing on the base of tongue and palatine tonsil via transcervical approach.
45767180|NCT04992169|Behavioral|Smartphone-App Parent Training in Pivotal Response Treatment|Parents are trained in Pivotal Response Treatment, Pivotal Response Treatment is a well-known, scientifically supported treatment that focuses on using child motivation, play-based lessons, and parent involvement to target the language skills and social engagement of children with autism. The core smartphone app will offer eight interactive lessons in PRT, consisting of video examples, slides, and brief quizzes.
45767181|NCT04988503|Device|Coil embolization|coil embolization for ruptured intracranial aneurysm with bare platinum coils or second-generation hydrogel coils
45912728|NCT02013856|Dietary Supplement|Placebo|Placebo control once daily for 28 days
45767182|NCT03493828|Procedure|TAP block using Bupivacaine 0.5%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.5% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
45767183|NCT03493828|Procedure|TAP block using Bupivacaine 0.25%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.25% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
45767184|NCT03493828|Procedure|TAP block using Normal Saline|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of normal saline was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
45767185|NCT03014557|Device|left atrial appendage closure device implantation|to permanently implant a WATCHMAN left atrial appendage closure device through trans-catheter approach
45767186|NCT04936633|Other|Intervention by medical staff based on a cloud system|"Remote intervention by medical staff (between Visit 1 and Visit 2; Week 2, 4, 6, 8, 10) : analyzing continuous glucose monitoring data for last two weeks in the cloud system~- Intervention contents~Diet, exercise pattern~Causes of hypoglycemia~Causes of hyperglycemia~Causes of glycemic variability~Counseling for improvement plans for the cause~Counseling to strengthen lifestyle modification~Counseling for insulin administration~Counseling for Insulin dose adjustment (adjusted dose)~Counseling for how to use a FSGM"
45767187|NCT03495856|Behavioral|Mindfulness Training For Chronic Pain|4-week group Mindfulness training program for adults with chronic pain
45767188|NCT03496324|Drug|Nurofen for Children®|Nurofen for Children® 400 mg/10 ml
45625173|NCT03226613|Procedure|Oral Rinse Collection|Patients will provide a one time oral rinse specimen using a non-alcoholic mouthwash at the time of clinic visit. The participant will be instructed to swish vigorously for 5 seconds and then gargle 5 seconds. The participant will be asked to repeated the swish and gargle (5 seconds each) three times for a total of 30 seconds and then expel the wash in a 10mL conical tube.
45625174|NCT03226613|Procedure|Blood Draw|A certified phlebotomist will perform a one time blood draw of 10mL at the time of clinic visit from each participant for purposes of HPV serologic testing.
45625175|NCT02452307|Biological|Peptide vaccine|subcutaneous
45625176|NCT02452307|Drug|Montanide ISA-51|subcutaneous
45625177|NCT02452307|Drug|Granulocyte macrophage colony stimulating factor (GM-CSF)|intradermal
45625178|NCT02452307|Drug|Imiquimod|epicutaneous
45625179|NCT02452307|Drug|mRNA|subcutaneous
45625180|NCT02452307|Drug|Protamin|subcutaneous
45625181|NCT02452307|Procedure|local hyperthermia|
45625182|NCT02452151|Drug|Infliximab-Biosimilar|
45625183|NCT02452151|Drug|Infliximab-Innovator|
45625184|NCT04485299|Drug|Bifluorid 10 ,VOCO|NaF and CaF 10 %
45625185|NCT04485299|Drug|Sodium Fluoride 5% Dental Varnish|5% NaF
45625186|NCT01594749|Drug|Fosaprepitant dimeglumine|
45625187|NCT01594749|Drug|Fosaprepitant Placebo|
45625188|NCT01594749|Drug|Dexamethasone|
45625189|NCT01594749|Drug|Ondansetron|
45625190|NCT01594749|Drug|Dexamethasone Placebo|
45767189|NCT03496324|Drug|Algifor® Junior|Algifor® Junior 400 mg/20 ml
45625191|NCT01594749|Drug|Ondansetron Placebo|
45625192|NCT01594749|Drug|Rescue Therapy|
45625193|NCT03226535|Device|Ultrasound-CT Fusion|The Clear Guide SCENERGY is an Ultrasound-CT fusion device which supplements existing ultrasound and CT capabilities. The participants randomly selected (out of 20 patients) for use of the Clear Guide SCENERGY (test group) will receive ultrasound-CT fusion guidance from the MDs performing the procedure.
45625194|NCT03225911|Device|Lateral wedge insole (insole)|The lateral wedge insole is an orthotic device that is placed inside the shoe. It has different thicknesses, with the lateral side being thicker than the medial side. This difference in thickness leads to the lateral side being higher than the medial side, with a different angulation.
45625195|NCT03225911|Device|simple knee sleeve (sleeve)|The simple knee sleeve is support which is worn around the knee with no hinge or provide external valgus moment.
45767190|NCT03354598|Drug|Sulopenem-Etzadroxil/Probenecid|Treatment of uncomplicated urinary tract infection
45767191|NCT03354598|Drug|Ciprofloxacin|Treatment of uncomplicated urinary tract infection
45767192|NCT02169895|Drug|BIA 9-1067|
45767193|NCT02169895|Drug|Placebo|
45625196|NCT03225911|Device|simple knee sleeve + lateral wedge insole|The lateral wedge insole is an orthotic device that is placed inside the shoe. It has different thicknesses, with the lateral side being thicker than the medial side. This difference in thickness leads to the lateral side being higher than the medial side, with a different angulation. The simple knee sleeve is support which is worn around the knee with no hinge or provide external valgus moment.
45625197|NCT03226145|Procedure|MRI Motility|MRI sequence to assess colonic motility
45625198|NCT03226145|Procedure|High Resolution Manometry|HRM of colon to assess motility
45625199|NCT03226145|Drug|Bisacodyl|Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
45625200|NCT03226145|Drug|Hyoscine butylbromide|Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
45625201|NCT04863183|Biological|CELLISTEM-OA|The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice.
45625202|NCT04863183|Drug|Triamcinolone acetonide|The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice.
45625203|NCT03119909|Other|First session of fMRI: localization of the premotor areas of the medial frontal cortex|Subjects should perform simple tasks to map the premotor areas of the medial frontal cortex. In this context, they will have to perform hand, tongue, ocular movements for about 20s. Additionally, as part of a control condition, they will need to perform eye fixation on a cross shown at the center of the screen for about 20s.
45625204|NCT03119909|Other|Second fMRI session|The subjects will position their left and right thumbs on response buttons. Each trial will begin with the appearance of one of 2 possible indexes. It will be an unknown abstract visual stimulus). After a variable delay of 0.5 to 6s (average = 2s), a blue or yellow circle will appear on the left or right of the screen.
45625205|NCT03119909|Other|Third fMRI Session|This session is identical to the second session but the subject will have to respond by performing saccadic ocular responses.
45625206|NCT03119909|Other|Training fMRI session|The training session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
45625207|NCT03119909|Other|Pilot behavioral study|In a pilot study, 30 subjects will participate in a behavioral study (2 sessions of 2 hours each) aimed at establishing the learning characteristics of the different types of rare events unrelated to actions (visual and sensorimotors on the hand).
45625208|NCT03119909|Other|fMRI Study|Each subject will participate in 2 fMRI sessions of about 2 hours each: a first session in which a first version of the task will be presented and a second session in which the second version of the task will be presented.
45625209|NCT03234257|Device|UF-ultrasound|the carotid plaque stability by UF in order to improve the stroke prediction in case of asymptomatic stenosis. A UF-ultrasound approach is a non-irradiating, easily accessible, and low cost technique
45625210|NCT04874181|Device|Silverfit 3D|Virtual reality game used for rehabilitation of stroke patients
45625211|NCT03234413|Drug|Botulinum toxin type A|Botulinum toxin type A
45625212|NCT04868955|Other|Oral screen training|Oral screen training (IQoro®) during 13 weeks.
45625213|NCT03119987|Diagnostic Test|Red cell distribution widths|Measured value of Red cell distribution widths in initial laboratory result of blood cell counts at emergency department
45625214|NCT04873947|Device|Pulse Oximeter|The investigational device will be placed on the finger of the left or right hand per the instructions for use. Simultaneous data collection will be set up for the system under test and control oximeter.
45625215|NCT04873791|Diagnostic Test|Assessment of geriatric individuals living in home environment and nursing home.|Assessments explained in the arm section were made as described in one session in both group
45625216|NCT03225521|Behavioral|HeartSteps: A just-in-time adaptive intervention for increasing physical activity amongst sedentary adults.|HeartSteps is an Android-based mHealth intervention that contains two main intervention components: contextually-tailored suggestions for activity and planning of the next day's activity. Activity suggestions provide individuals with actionable suggestions for how they can be active in their current context. Delivered suggestions are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. HeartSteps can deliver a user activity suggestions up to five times a day. Evening planning asks users to create or choose a plan of how they will be active on the following day. Planning can be delivered once a day, in the evening.
45625217|NCT04868487|Other|Health Literacy Education|Health literacy education, consisting of four sessions, was given to the intervention group.
45625218|NCT04380753|Drug|AMG 510|Subjects will be enrolled and will receive AMG 510 PO QD.
45625219|NCT04379973|Drug|Lipiodol Ultra Fluide®|Tubal flush with 5-10mL oil-soluble contrast medium (OSCM) (Lipiodol Ultra Fluide®, Guerbet, France) immediately after Hyfosy. The use will be off-label.
45625220|NCT02453009|Drug|Docetaxel|Pharmaceutical form:solution Route of administration: intravenous
45625221|NCT02453009|Drug|Prednisone|Pharmaceutical form:tablet Route of administration: oral
45625222|NCT02453009|Drug|Enzalutamide|Pharmaceutical form : soft gelatin capsules Route of administration: oral
45767194|NCT02169895|Drug|Prolopa®|levodopa/benserazide 100/25 mg
45912729|NCT02013869|Device|Flow-I|Desflurane Dialed setting 18 %
45912730|NCT02013869|Device|Asys|Desflurane dialed 18%
45912731|NCT02013882|Procedure|1-1-12 wash-in|wash-in phase during start of low flow anesthesia
45625223|NCT03044457|Procedure|TKA|"femoral and tibial positioning using the reversed gap technique"
45625224|NCT03225053|Device|MEP® technique|G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
45625225|NCT04868331|Behavioral|Exercise|Two trials of 7-min High Intensity Interval Training (HIIT) with 12 different exercises. Each exercise lasts for 30 seconds continuously with 10 seconds rest interval.
45625226|NCT03234101|Behavioral|Low-risk lifestyle behaviours|"Low-risk lifestyle behaviours defined as:~1) Healthy body weight (Minimum: BMI <30kg/m2 or WC of <88 in females or <92 in males); 2) Healthy diet (healthy diet, diet score with higher fruits & vegetables to Mediterranean dietary pattern); 3) Regular physical activity (20 minutes ≥ 1 time/week ); 4) Smoking cessation (never smoked to smoking cessation >12 months); 5) Moderate alcohol intake (up to 30g/day); 6) Adequate sleep (>6 hours)"
45625227|NCT04863417|Drug|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 2000 cm2 Body Surface Area
45912732|NCT02013895|Device|99mTc-GSA|
45912733|NCT02013908|Procedure|Acupuncture plus standard ED management|
45912734|NCT02013908|Procedure|Standard ED management alone|
45912735|NCT02013921|Other|Physical activity|
45912736|NCT02013934|Dietary Supplement|Probiotic|
45912737|NCT02013934|Dietary Supplement|Placebo|
45625228|NCT04863417|Drug|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 4000 cm2 Body Surface Area
45625229|NCT03047811|Other|TCR - T cell therapy|Low dose group: 1 x 10 ^8 /kg T cell total reinfusion. High dose groups: 10 x 10 ^ 8 / kgT cell total reinfusion.
45625230|NCT03233789|Behavioral|neurologic rehabilitation|in-patient rehabilitation of neurologic disorders
45625231|NCT04868175|Drug|Timolol|Topical eye drops for lowering intraocular pressure Beta blocker to reduce aqueous production
45625232|NCT04868175|Drug|Travatan|Topical eye drops for lowering intraocular pressure Prostaglandin analogue to increase aqueous outflow
45625233|NCT04868175|Drug|Hypromellose|Placebo eye drop, lubricant
45912738|NCT02013947|Other|2 weeks of exercise in low and moderate altitude|"Group A will spend 2 weeks at an altitude of 1900m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate).~Group B will spend spend 2 weeks at an altitude of 400m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate)."
45912739|NCT02013960|Drug|Cytotec|Cytotec medication compared with cytotec and laminaria
45912740|NCT02013973|Other|AMH-analysis|At the first visit to the IVF-clinic a blood sample for serum-AMH is taken and frozen for later analysis in the AMH-group. The AMH assay used is the Beckman Coulter AMH Gene II assay. The analysis result will be added to the algorthm deciding what starting gonadotropin dose the patient is having.
45912741|NCT02013986|Drug|etomidate|0.3mg/kg IV only once during induction of general anesthesia
45625234|NCT03225209|Other|OPTIFAST|OPTIFAST meal replacement includes shakes, bars and soups. These meal replacements will completely replace the subject's diet for the first 12 weeks of the study (baseline-week 12) followed by a gradual transition back to prepared meals over 6 weeks (week 13-18). Attempt will be made to reduce or eliminate Lantus and Metformin as long as glycemic control is maintained.
45625235|NCT03047889|Drug|standard therapy|standard therapy for advanced/metastatic breast cancer
45625236|NCT02452775|Biological|OC-L|
45625237|NCT02452775|Other|Montanide|
45625238|NCT02452775|Other|poly-ICLC (Hiltonol),|
45625239|NCT03224975|Other|fMRI|During fMRI, patients and control group will have to thought to seven painful memories, seven emotional memories not painful, seven neutral memories. At every memory there is control test. It is to count backwards.
45767195|NCT01072669|Drug|ambrisentan|Subjects will receive ambrisentan 5 mg orally once daily or identical placebo pills for the first 4 weeks and then increased to ambrisentan 10mg once daily[if the lower dose is tolerated] or identical placebo pills for the rest of the study. They will be instructed to take the 5mg/pink pills for 4 weeks and then switch to 10mg /red pills unless they are having any drug related side effects or concerns. There will be no routine visit planned at 4 weeks to assess drug tolerance unless a complication arises. Adherence to treatment will be assessed by pill counting at each follow up visit. Follow up digital blood flow measurements will be obtained with LDPI at 1 week and at 3 months, where the same protocol (as that in the initial visit) will be followed.
45767196|NCT03014713|Drug|Dezocine|Dezocine 0.01mg/kg/h intravenous administration during the first two days after surgery.
45767197|NCT03014713|Drug|Flubiprofen|Flubiprofen 0.5mg/kg/h intravenous administration during the first two days after surgery.
45767198|NCT03014713|Drug|Dexmedetomidine|Dexmedetomidine 0.1μg/kg/h intravenous administration during the first two days after surgery.
45767199|NCT03354754|Drug|LYS228|LYS228 IV infusion every 6 hours
45767200|NCT03354754|Drug|Standard of care therapy|IV infusion of standard of care antibiotics
45767201|NCT01073449|Procedure|In-hospital follow-up of cardiac device|Electrical measures taken during normal follow-up and clinical status of the patient
45912742|NCT02013986|Drug|midazolam|midazolam 0.1mg/kg IV only once before using of etomidate/propofol during induction of general anesthesia
45912743|NCT02013986|Drug|propofol|2mg/kg IV only once during induction of general anesthesia
45912744|NCT02013999|Other|Virtual reality program for upper extremity rehabilitation|
45625240|NCT03045705|Behavioral|Routine pain management|Women that will be asked according to the routine management regarding pain management during labor, meaning frequent inquiries regarding the woman's wishes to receive analgesia by the medical team.
45625241|NCT03045705|Behavioral|No inquiry regarding analgesia|women will not be asked about analgesia during labor by the medical team, but will be able to receive the modality of choice at the time of choice.
45625242|NCT03224897|Device|Cathodal tDCS|"Volunteers will be submitted to 1,0 mA cathodal stimulation during experiment. The stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system."
45625243|NCT03224897|Device|Anodal tDCS|"1,0mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system."
45625244|NCT03224897|Device|Sham tDCS|"1,0 mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 30 seconds, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system. The participant will not know when the stimulator is turned off and will continue to perform the experimental task as in the other groups."
45625245|NCT03045627|Drug|AraC|ARA-C subcutaneously in a 12-hour infusion on days 1 through 14
45625246|NCT03045627|Drug|Aclarubicin|Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8
45912745|NCT02013999|Other|standard occupational therapy|
45912746|NCT02014025|Procedure|Open hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery A and D district is Group A ,they will accept Open Hepatectomy: tumors are totally resected by conventional laparotomy.
45625247|NCT03045627|Drug|Peg-G-CSF|PEG-G-CSF 6mg subcutaneously on days 0.
45912747|NCT02014025|Procedure|Laparoscope hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery E district is Group B ,they will accept Laparoscopic Hepatectomy: tumors are totally resected through laparoscopic.
45447077|NCT02099968|Behavioral|Standard Lifestyle Modification / modified DASH|"Modified DASH (vegetarian focused, plant-based, low-salt)~Aerobic exercise~Stress reduction techniques: progressive muscle relaxation"
45447078|NCT04292457|Drug|Propofol|Anesthesia is maintained with a continuous infusion of Propofol. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
45767202|NCT03270436|Behavioral|Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program|Faith based diabetes curriculum that teaches participants to connect faith and health.
45767203|NCT03270436|Behavioral|Partnership for Improving Lifestyle Intervention Diabetes Prevention Program|Family and community based diabetes prevention curriculum that teaches participants to engage their social support to have a healthy weight.
45767204|NCT01074463|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
46073651|NCT02823288|Other|Sonke CHANGE intervention|"The Sonke CHANGE intervention is a multi-level model aimed at individual, group, community, and societal levels. Sonke's programming is comprised of three core components:~Workshops based on the premise that deeply held gender and sexuality beliefs can be critically examined and transformed in a reflective group setting. Workshops aim to challenge inequitable and harmful ideas about manhood and encourage men to take action to promote equality.~Community Action Teams (CATs) are comprised of interested men and women, who mobilize on a voluntary basis around issues in their neighborhoods. Methods include ambush theatre, murals painting, door to door campaigns, street soccer festivals, rallies, and community dialogues.~Local Advocacy is undertaken by CAT members, who aim to hold government and other duty bearers to account for VAWG prevention. CAT members join local community structures to advance community education and local government accountability."
45447079|NCT04292457|Drug|Sevoflurane|Anesthesia is maintained with a continuous inhalation of Sevoflurane. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
45447080|NCT02100046|Drug|Zarontin® (ethosuximide) and Stodal®|
45447081|NCT02250586|Behavioral|CBT-CSO|Internet-delivered cognitive-behavioral therapy for CSO's of treatment refusing problem gamblers
45447082|NCT02100202|Other|Placebo|
45447083|NCT02100202|Dietary Supplement|BioTurmin (Curcuma longa rhizomes extract)|
45447084|NCT02100202|Dietary Supplement|BioTurmin-WD (Water dispersible curcuminoids)|
45447085|NCT02100202|Dietary Supplement|MaQxan (Tagetes erecta flower extract)|
45625248|NCT03045627|Drug|G-CSF|G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14.
45767205|NCT01074463|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
45625249|NCT03224663|Other|Module based learning|self-reading method using learner's guide module on FBNC provided by Department of Pediatrics.administered 45 minutes
45767206|NCT01075087|Drug|Placebo|Bilateral TAP block using sterile normal saline.
45767207|NCT01075087|Drug|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
45767208|NCT01075399|Drug|[F 18]HX4|Approximately forty (40) patients who have diagnosis confirmed by histopathological examination of tumor tissue from head/neck, lung, liver, rectal or cervical cancers and will receive chemotherapy, radiation therapy or chemoradiotherapy, will be imaged under PET/CT with [F 18]HX4
45447086|NCT05423392|Procedure|Tooth extraction of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Tooth extraction will be following up with the methodological procedures in order to define the effectiveness of anesthetics during indicated dental procedure.
45447087|NCT05423392|Procedure|Endodontic dental treatment of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Endodontic dental treatment will be following up with the methodological procedures in order to define the effectiveness of anesthetics during dental treatment.
45625250|NCT03224663|Other|Mobile application based learning|"learning method using android based mobile application on Facility Based Newborn Care provided by Division of Department of Pediatrics WHO-CC AIIMS FBNC deals with posters , videos , Modules.administered 45 minutes"
45767209|NCT03835819|Drug|Pembrolizumab|Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells
45767210|NCT03835819|Drug|IMGN853|Mirvetuximab soravtansine is an antibody-drug conjugate.
45767211|NCT03358576|Drug|Ertapenem|Antibiotic for complicated intra-abdominal infection
45767212|NCT03358576|Drug|Sulopenem-Etzadroxil/Probenecid|Antibiotic for complicated intra-abdominal infection
45767213|NCT03358576|Drug|Ciprofloxacin|Antibiotic for complicated intra-abdominal infection
45767214|NCT03358576|Drug|Metronidazole|Antibiotic for complicated intra-abdominal infection
45447088|NCT05423392|Procedure|Conservative tooth restoration of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Conservative tooth restoration will be following up with the methodological procedures in order to define the effectiveness of anesthetics during conservative tooth restoration.
45447089|NCT02103556|Other|Mineral oil|4 ml daily (adjusted as needed), for 4 weeks
45447090|NCT02103556|Dietary Supplement|Olive oil|4 ml daily (adjusted as needed), for 4 weeks
45447091|NCT02103556|Dietary Supplement|Flaxseed oil|4 ml daily (adjusted as needed), for 4 weeks
45447092|NCT02099890|Dietary Supplement|Omega-3|
45447093|NCT02099890|Dietary Supplement|Vegetation Protein Powder|
45447094|NCT02099890|Dietary Supplement|InflanNox|
45767215|NCT03358576|Drug|Amoxicillin-Clavulanate|Antibiotic for complicated intra-abdominal infection
45767216|NCT03358576|Drug|Sulopenem|Antibiotic for complicated intra-abdominal infection
45912748|NCT02014064|Drug|Atomoxetine|"MA Group: Dispense 1 cap @ 8 AM on Treatment day 9 and 10 (total daily dose 40mg or 0); 1 cap SID @ 8 AM and 4 PM on day 11,12, and 13 (total daily dose 80mg or 0); 1 cap @ 8 AM on day 14 (total daily dose, 40mg or 0).~Control Group Schedule:~Day 1: 40mg @ 8:00am~Day 2: 40mg @ 8:00am~Day 3: 40mg @ 8:00am, 40mg @ 8:00pm~Day 4: 40mg @ 8:00am, 40mg @ 8:00pm~Day 5: 40mg @ 8:00am, 40mg @ 8:00pm~Day 6: 40mg @ 8:00am = Testing day (fMRI scan & cognitive testing session)"
45625251|NCT04868019|Drug|Fenofibrate Capsules|Solutions will be prepared in the required strengths and labeled accordingly. Group A will receive Solution A i.e. Fenofibrate suspension is prepared by dissolving 200 mg capsule in 10 ml distilled water and given as a single dose of 10mg/kg (0.5 ml/kg) and Group B will receive solution B i.e. 0.5ml/ kg normal saline as a placebo. Both groups will receive LED phototherapy under standard conditions. The serum bilirubin level will be noted at the time of admission and then at 12hr, 24hr, and 48 hours of treatment
45625252|NCT03047967|Diagnostic Test|lung function tests|baby-body plethysmography
45625253|NCT03047967|Diagnostic Test|Nasal brushing|Epithelial sample collecting for in vitro study
45625254|NCT03224741|Behavioral|Monetary Incentive|Subjects in this condition will be read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information.Iin addition, they will be told that if they will get tested for HIV/AIDS within the next two weeks, they will receive $10 (the US dollar became Ecuador's official currency in 2001).
45625255|NCT03224741|Behavioral|Information|Subjects assigned to this condition are read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information. Then, they are invited to get tested in the next two weeks.
45625256|NCT03224741|Behavioral|Active Choice|"Subjects in this condition will receive the same information and flyer as in T1; in addition, they are told that they have the opportunity to express their intention to get tested for HIV/AIDS. To this aim, they will be given a sheet of paper and asked to tick one of two boxes. The first box will say I intend to get tested within the next two weeks, and the second will say I will consider getting tested within the next two weeks but I am not ready to commit at this time. They will also be asked to write their initials at the bottom of the sheet, and will be told to keep it. This is a form of soft commitment which has proven effective in other contexts (Bryan et al. 2010)."
45625257|NCT04863105|Drug|Abiraterone acetate tablets(Zecke ®250 mg);Abiraterone acetate tablets(250 mg)|"Subjects were allocated to one of three groups randomly and equally with a 7-day washout interval between the two periods.Abiraterone acetate tablets(Zecke ® 250 mg,Batch number:VYCB manufactured by Patheon Inc.)and Abiraterone acetate tablets(250 mg,Batch number:17F0023DD9 manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study."
45625258|NCT02179918|Drug|PF-05082566|Starting dose of 0.45 mg/kg q3wks IV, dose escalation
45625259|NCT02179918|Drug|MK-3475|2 mg/kg q3wks, IV
45625260|NCT03233321|Other|Dry cold application|Dry cold application using ice bag (Crushed ice was filled in ice bag with ½ table spoon of salt and then covered by clean linen to prevent moisture) was placed over the injection site for about 20 minutes.
45625261|NCT03233321|Other|sub cutaneous injection (low molecular weight heparin)|sub cutaneous injection (low molecular weight heparin) has been administered on injection site
45625262|NCT04868253|Drug|EMB-01|EMB-001 is a proprietary combination of metyrapone (a cortisol synthesis inhibitor) and oxazepam (a short to medium acting benzodiazepine).
45625263|NCT04486157|Drug|IN-A012|The subjects will be given IN-A012 by Intravenous infusion over 30 minutes.
45625264|NCT04486157|Drug|Akynzeo 300Mg-0.5Mg Capsule|The subjects will be administrated Akynzeo by Orally with water.
45625265|NCT02452073|Other|Thyroid function tests|
45625266|NCT02452229|Other|Review of the Literature for Human Herpes Virus infections|"Review of the Medline database (PubMed and Ovid interface) for human herpes virus infections in burns as well as Web of Science interface.~PRIMSA (preferred reporting items for systematic reviews and meta-analyses) guidelines and checklist were used."
45625267|NCT04862637|Procedure|pull through group|pull through method
45625268|NCT04862637|Procedure|mandibular-lip split group|traditional mandibular-lip split method
45625269|NCT03224273|Other|proximal box inlay retained bridge|inlay retained bridge is the less invasive type to restore single missing teeth in the posterior area
45625270|NCT04868097|Procedure|cervix biopsy|large loop electrosurgical cervix biopsy
45625271|NCT02153788|Drug|Temazepam|Temazepam 15 mg orally at bedtime
45625272|NCT02153788|Drug|Placebo|
45625273|NCT03224117|Drug|DWJ211|inject the Drug into submental fat via subcutaneous
45625274|NCT03224117|Drug|Normal saline|inject the Drug into submental fat via subcutaneous
45625275|NCT04862793|Device|Colonoscopy Progression Score (CoPS)|The Colonoscopy Progression Score consists of five different aspects: Travel length, Tip progression, chase efficiency, shaft movement without tip progression and looping.
45625276|NCT04862793|Device|Colonoscopy Retraction Score (CoRS)|The Colonoscopy Retraction Score consists of three different aspects: Tip Retraction, Retraction Efficiency, and Retraction Distance.
45625277|NCT04862559|Device|NovaCross|A device that is intended to asisst interventional cardiologists during catheterization to cross and open coronary chronic total occlusions
45625278|NCT02451761|Biological|Blood sampling|
45625279|NCT04867629|Dietary Supplement|Rapeseed oil|20mL of rapeseed oil to be consumed daily in replacement to habitual oil
45625280|NCT04867629|Dietary Supplement|Sunflower oil|20mL of sunflower oil to be consumed daily in replacement to habitual oil
45625281|NCT03224429|Other|Qualitative Interviews Decisional Needs Assessment|Subjects will participate in an open-ended interview regarding type of sickle cell disease, complications, current treatment, and experiences with decision making and sickle cell treatment. Participants will be asked to describe what is important when making health care decisions. Treatment options (hydroxyurea, chronic or monthly blood transfusions, and bone marrow transplantation) will be discussed as well as how a web-based decision aid tool should be developed. The interview will be audio recorded and will take 45 to 60 minutes to complete.
45625282|NCT03224429|Other|Sickle Cell Decision Aid|Participants will be asked to navigate the Sickle Cell Decision Aid site that provides information about risks and benefits of therapies. As the participant navigates the site, the interviewer will ask the participants to describe thoughts about the site, including but not limited to ease of navigation, content and construction. Testing may be performed in-person or via telephone. Interviews will be audio recorded and take up to 60 to 90 minutes to complete.
45625283|NCT04862403|Procedure|Umbilical cord clamping distance|Intervention group I: Umbilical cord clamped at a distance of 2cm Intervention group II: Umbilical cord clamped at a distance of 3cm Control group: Usual care (clamped without measurement).
45625284|NCT03224039|Drug|Sufentanil|Intranasal for one dose (experimental)
45625285|NCT03224039|Drug|Normal saline|Intravenous for one dose as placebo (to be administered with sufentanil or morphine arm as part of double-blinding). If patients are randomized to receive IN sufentanil, they will also receive IV normal saline. If patients are randomized to receive IV morphine, they will also receive IN normal saline.
46069638|NCT04290533|Device|Active High Definition transcranial Direct Current Stimulation (HD-tDCS)|TDCS is a non-invasive neuromodulation technique that modulates membrane potentials by means of small electrical currents. Electrical currents induced by tDCS electrodes produce an electrical field that modulates the excitability of brain areas. In the present HD-tDCS montage, one anodal electrode and four return electrodes are applied. Hereby, the anodal electrode modulates the excitability of the targeted area, whereas the other 4 electrodes return electrical currents that flow away from that area. Direct currents will be transmitted through 5 circular PiStim electrodes of 3.14cm2 (Neuroelectrics, Barcelona, Spain; current density=0.32 mA/cm2) with a current intensity of 1.5 mA. The HD-tDCS session will last for 20 minutes in total, with a 60 sec ramp at the beginning and end of the session. The electrodes will be filled with conductive gel and plugged into an EEG cap, with the anode placed over Fz and the four return electrodes over Fp1, Fp2, F7, and F8 (10-20 system).
46073652|NCT04240860|Biological|platlet rich plasma|"Drug: PRP PRP subendometrial infusion~Device: ovum oickup needle PRP subendometrial infusion by hysteroscopic guided ovum pickup needle day 9 of the cycle"
45625286|NCT03224039|Drug|Morphine|intravenous push for one dose (active comparator)
46073653|NCT04240860|Procedure|endometrial scratch|Three Snip Hysteroscopic Endometrial Scratching in luteal phase of preceeding cycle
45447095|NCT02099890|Dietary Supplement|Anti-oxidant Network|
45447096|NCT02099890|Dietary Supplement|Chlorella|
45625287|NCT04862091|Drug|Abiraterone Acetate Tablets (I)|Abiraterone Acetate Tablets (I)
45625288|NCT04862091|Drug|ZYTIGA®|ZYTIGA®
45625289|NCT03119675|Device|GoCheck Kids (iOS)|Photorefraction method is used to screen amblyopia risk factors.
45625290|NCT03119675|Device|GoCheck Kids (Windows)|Photorefraction method is used to screen amblyopia risk factors.
45625291|NCT04873635|Other|Implant support prostheses|Implant support prostheses was provided to restore the missing teeth and tissues removed due to pathological jaw lesions
45625292|NCT04485143|Device|Wisdom bracelet|routine medical
45625293|NCT03119441|Device|Dental Water Jet|Dental Water Jet will be used by subjects to clean their teeth in the interproximal areas.
45625294|NCT03119441|Device|Dental Floss|Dental Floss will be used by subjects to clean their teeth in the interproximal areas.
45625295|NCT03043833|Behavioral|The Wellbeing Course|"The Wellbeing Course (Titov et al., 2011) includes five online lessons:~Lesson 1 presents information on the prevalence of anxiety disorders and depression as well as on how they may interfere with life goals. This lesson also discusses how cognitive, behavioral and physical symptoms can contribute to poor emotional health.~Lesson 2 presents different strategies to generate realistic cognitions.~Lesson 3 describes strategies for physical de-arousal and for re-engaging in reinforcing activities.~Lesson 4 describes avoidance and safety behaviors in relation with anxiety and depression along with graded exposure.~Lesson 5 is about problem solving, relapse prevention and staying well.~For each lesson, a Do It Yourself guide is included as well vignettes and additional material."
45625296|NCT03223961|Drug|EPREX|60 000 U/week for at least 12 weeks
45625297|NCT03045471|Drug|R-EPOCH|Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Etoposide: a topoisomerase inhibitor from the group of epipodofyllotoxins; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
45625298|NCT03045471|Drug|R-CHOP|Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
45767217|NCT03016117|Procedure|Pecs II block and parasternal block|The Pecs II block will be performed under ultrasound guidance, at fourth rib level, on the axillary line, into the fascial plane between pectoralis minor muscle and serratus muscle. The parasternal block will be performed under ultrasound guidance, at the second and fourth intercostal space, between the pectoralis major muscle and the intercostal muscles, near to the external intercostal membrane.
45767218|NCT03822013|Drug|Miglustat|Treatment with Zavesca regimen based on body surface area as follows: SQRT [Height (cm) × Weight (kg)] / 3600 <1.25 : 200mg TDS 0.88- 1.25: 200mg BID 0.73- 0.88: 100 mg TDS 0.47- 0.73: 100 mg BID <0.47: 100 mg Daily
45767219|NCT00376324|Drug|Tigecycline|Each subject will receive 3 IV doses of tigecycline, as 30-minute infusions: Dose 1 = 100 mgDose 2 = 50 mgDose 3 = 50 mg The doses of tigecycline will be administered to the subjects at approximately 12-hour intervals.
45767220|NCT03800563|Device|LipoLife system|Abdominal/ Outer thighs Laser Assisted Liposuction. Five to twenty subjects out of the study group will also undergo facial fat grafting.
45767221|NCT00376402|Biological|H5N1 Pandemic Influenza Vaccine|
45767222|NCT00376480|Biological|anti-thymocyte globulin|
45447097|NCT02103634|Device|NaF PET/MRI|
45447098|NCT02103634|Device|NaF PET/CT|NaF PET/CT images will be obtained through fusion software. Researchers will fuse the Non AC and AC NaF images with the low dose CT obtained in the FDG PET/CT study.
45447099|NCT02103634|Device|FDG PET/CT|
45625299|NCT04873713|Device|Magnetic Tape® aplicación|Magnetic tape® is applied without creating any tension over low back
45625300|NCT04873713|Device|Kinesiology Tape|Kinesiology Tape is applied without creating any tension over low back
45625301|NCT03045315|Other|IVF Procedure|
45625302|NCT03223571|Other|Motor rehabilitation training|Post-stroke participants receive 6 week of rehabilitation training of the paretic upper-limb.
46069639|NCT04290533|Device|Sham High Definition transcranial Direct Current Stimulation (HD-tDCS)|For the sham-condition, the placement of the electrodes was identical to active HD-tDCS stimulation with the anode placed over Fz and the four return electrodes over Fp1, Fp2, F7, and F8 (10-20 system). The direct current, also transmitted through 5 circular PiStim electrodes of 3.14cm2 (Neuroelectrics, Barcelona, Spain; current density=0.32 mA/cm2), was increased in a ramp-like fashion over 60 seconds until it reached 1.5 mA. Directly after ramp-up, the current intensity was gradually switched off over 60 seconds, followed by 20 minutes without active stimulation. Sham procedures for tDCS mimic the transient skin sensation at the beginning of active HD-tDCS, without producing any conditioning effects on the brain. Consequently, participants are reliably blinded for sham tDCS.
46069640|NCT04914260|Other|Questionnaire|The participants will have to fill in an on-line questionnaire regarding quality of life, their level of knowledge of the rehabilitation through sport program and their level of satisfaction toward this program.
46069641|NCT04135053|Biological|Lyophilised Neisseria lactamica|Previously lyophilised Neisseria lactamica will be reconstituted and intranasally given to participants
46069642|NCT04252976|Behavioral|Ethical Living|Ethical principles based on Yoga philosophy, including contents of Yamas and Niyamas.
46069643|NCT04252976|Behavioral|Yoga Exercises|Ujjaii breathing and simple yoga asanas
46069644|NCT04252976|Behavioral|Mantra Meditation|Meditation with mantras
45767223|NCT00376480|Biological|peripheral blood lymphocyte therapy|
45767224|NCT00376480|Drug|fludarabine phosphate|
45767225|NCT00376480|Drug|methylprednisolone|
45767226|NCT00376480|Drug|thiotepa|
45625303|NCT04862169|Other|educational intervention (SPARK)|"There are 3 modules with 11 chapters. These topics were considered as the most relevant topics for implementation of palliative care for PHC nurses. Also, topics were selected based on our previous literature review of the previous study on the content of PHC nurses training program.~The first module is the introduction. This consists of three chapters: introduction, support system and effective communication. Total reading time is estimated to be one hour. The second module is about the nursing approach in palliative care. It is estimated to be completed in around 2 hours and 15 minutes. The last module is about end of life care.~The participants are expected to access this module before the scheduled synchronous mode. Modules will be provided in the electronic version, so that participants are able to download and read them on their own devices. We are also providing video as trigger for case study discussion"
45767227|NCT00376480|Procedure|allogeneic hematopoietic stem cell transplantation|
45767228|NCT00376480|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45767229|NCT00376480|Radiation|total-body irradiation|
45767230|NCT03016039|Dietary Supplement|Curcumin supplementation|use of curcumin supplementation as an additive treatment to the conventional treatment
45767231|NCT03753919|Drug|Durvalumab|Subjects will be allocated in each primary tumor cohort to receive durvalumab 1500 mg every 4 weeks (Q4W) plus tremelimumab 75 mg Q4W for up to 4 doses during the first 4 cycles of combined therapy. After the first 4 cycles (or before is tremelimumab is stopped due to toxicity), patients will continue to receive durvalumab 1500 mg Q4W until disease progression or unacceptable toxicity. Cycles are defined by 4 weeks or 28 days.
45767232|NCT03753919|Drug|Tremelimumab|Subjects will be allocated in each primary tumor cohort to receive durvalumab 1500 mg every 4 weeks (Q4W) plus tremelimumab 75 mg Q4W for up to 4 doses during the first 4 cycles of combined therapy. After the first 4 cycles (or before is tremelimumab is stopped due to toxicity), patients will continue to receive durvalumab 1500 mg Q4W until disease progression or unacceptable toxicity. Cycles are defined by 4 weeks or 28 days.
45767233|NCT03362944|Behavioral|Active Music Therapy|The intervention consists of a standardized series of Music Therapy tasks, all based at a constant rhythmic pulse.
46069645|NCT02621697|Other|Cognitive motor training|Initially an intervention consisting of double duty activities (motor-cognitive) and the control group will be subjected to a conventional treatment based on stretching and strengthening will be held.
46069646|NCT02621697|Other|kinesiotherapeutic conventional treatment|Standardized global stretching and strengthening with squat exercise, plantar flexion in foot and elbow flexion supporting body weight in the hands arranged on the wall
45625304|NCT04862169|Other|electronic version of the modules|electronic version of the modules
45625305|NCT03045549|Device|Digital biofeedback system|"The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:~STAGE 1 (Weeks 0-6) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and abductors (mainly) Ice pack application STAGE 2 (weeks 7-8) Open kinetic chain exercises with added resistance: lying, sitting (high chair) and standing (with progression to standing without support) Strengthening of hip flexors and abductors (mainly) Ice pack application after each session"
45767234|NCT03362944|Behavioral|Passive Music Therapy|The intervention consists of a series of recorded listening tracks, matched in style to the active intervention, all based at a constant rhythmic pulse.
45767235|NCT03497026|Device|Robotic Bronchoscopy Platform|Eligible patients will undergo the robotic bronchoscopy for evaluation of suspected lung nodules.
45767236|NCT02175979|Dietary Supplement|enriched enteral nutrition|enriched enteral tube feeding perioperative
45767237|NCT02175979|Dietary Supplement|standard|standard of care
45447100|NCT03555136|Drug|Vortioxetine|Treatment with vortioxetine as per local SmPC
45447101|NCT03555058|Other|Treatment escalation|Treatment escalation per TDM and physician's decision.
45767238|NCT03498196|Drug|Avelumab|avelumab 10 mg/kg intravenously every 2 weeks for 3 cycles or 42 days.
45804258|NCT04329273|Other|Core stability|"The exercise protocol consists of the following sets and repetitions Week 1 and 2- 3 sets of 30'' front plank, 3 sets of 20'' side plank, 2 sets of 30'' superman, 2 sets of 30'' supine bridge and 2 sets of 10 repetitions leg lowering exercise Week 3 and 4- increasing difficulty in 2 of the sets Week 5 and 6- adding 1 more set at each exercise Week 7 and 8- adding 15 in each repetition"
45804259|NCT02979145|Other|No intervention involved|
45804260|NCT03424187|Dietary Supplement|chickpea|"all three meals are isocaloric but different in the chickpea structure( physical form):~• Whole chickpea, flour chickpea, intact cell flour chickpea"
45804261|NCT00003171|Drug|bryostatin 1|
45625306|NCT03045549|Other|Conventional home-based rehabilitation|"Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:~STAGE 1 (Weeks 0-6) Soft tissue massage Active assisted mobilization of the hip joint to increase range of motion (avoiding internal rotation and adduction) Gait training with bilateral assistive devices Isometric exercises progressing to open chain, low-impact, concentric exercises with strengthening of hip abductors and flexors Ice pack application STAGE 2 (weeks 7-8) Soft tissue massage Gait training with progressive withdrawal of assistive devices Balance exercises with progression to one-leg support Open-chain strengthening exercises against resistance with progression to closed-chain exercises Ice pack application"
45625307|NCT03223415|Other|Detection and isolation of C. difficile carriers|"Screening for C. difficile carriage will be conducted by performing a polymerase chain reaction (PCR) assay detecting the toxin B gene (tcdB) on a rectal swab. Screening will occur within 24 h of admission to the ward. To ensure compliance with the policy, automatic orders will be developed. The patient care nurse will perform the screenings. The results will be reported according to the standard institutional policy.~Isolation precautions for C. difficile carriers: healthcare workers will also follow a set of isolation precaution rules during the care of C. difficile carriers. C. difficile carriers will remain under isolation precaution as long as they remain carriers and on the intervention ward. Precautions would be discontinued upon discharge from the ward."
45625308|NCT04861857|Dietary Supplement|Parmigiano Reggiano|subjects will receive 50 g/die of the dietary supplement
45625309|NCT04861857|Dietary Supplement|Whey Protein|subjects will receive 20 g/die of the dietary supplement
45625310|NCT03223259|Behavioral|Injury Prevention Workshops|Each workshop will last 90 minutes and consist of approximately 20-30 minutes of lecture, 30 minutes of movement, no more than 20 minutes for a pre-test (workshop 1) or post-test (workshop 2), and remaining time for Q&A.
45625311|NCT04861701|Behavioral|Static stretching exercise|The intervention of this study is home-based stretching exercise. The experimental group will receive 6 stretching exercises which stretch 60 seconds for each side (left or right) of each movement, and relax for 10-20 seconds between the movements. It will take 10-15 minutes every day for continuous 4 weeks. The 6 stretching exercises include : (1) pectoral muscles + calf muscles ; (2) quadriceps ; (3) levator scapulae ; (4) gluteal muscles ; (5) hamstrings ; (6) trunk side-flexors.
45625312|NCT03223493|Other|No treatment given|Completion of a questionnaire
45625313|NCT02153398|Drug|D961H sachet 10 mg|
45625314|NCT02153398|Drug|D961H capsule 10mg|
45625315|NCT02153398|Drug|D961H capsule 20 mg|
45625316|NCT03045159|Behavioral|Strong Families Strong Forces|Parenting program
46069647|NCT02621541|Device|PET/CT|
45625317|NCT03045159|Behavioral|Strong Parents|self-care program
45625318|NCT03222947|Genetic|Deoxyribonucleic acid analysis|This study consists in the high throughput exome sequencing and subsequent genetic bio-analysis of 19 deoxyribonucleic acid samples from 6 families, already collected and consented, including patients diagnosed with a Taybi-Linder syndrome and their relatives (parents and/or siblings).
45625319|NCT03047499|Drug|Botulinum toxin type A|Botulinum toxin type-A injection
45625320|NCT03223025|Drug|CinnaTropin®|0.03 mg/kg daily subcutaneous injections
45625321|NCT03223025|Drug|Nordilet®|0.03 mg/kg daily subcutaneous injections
45625322|NCT04867941|Drug|ACP-196|All study participants will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
45625323|NCT03222869|Diagnostic Test|Measure Airway Resistance Across Stenosis|Measure pressure and air flow Across Stenosis
45625324|NCT04873479|Drug|S-ketamine|Participants in the test group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, S-ketamine 0.125mg/kg (low dose) for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and S-Ketamine 0.125mg/kg/h (low dose) and continuous inhalation of sevoflurane at 2-3%.
45625325|NCT04873479|Other|saline|Participants in the control group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, saline 0.125ml/kg for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and saline 0.125ml/kg/h and continuous inhalation of sevoflurane at 2-3%.
45625326|NCT02451683|Other|Electrophysiology Assessment of Time Domain|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability.
45625327|NCT02451683|Other|Electrophysiology Assessment of Location|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability
45625328|NCT02451683|Other|Training with some stimulation|motor task combined with real or sham stimulation
45625329|NCT03222557|Procedure|Electroacupuncture|Refer to arm description
45625330|NCT03222557|Procedure|Sham Acupuncture|Refer to arm description
45625331|NCT03222557|Device|Electroacupuncture|Refer to arm description
45625332|NCT03222557|Device|Sham Acupuncture|Refer to arm description
45625333|NCT04861467|Drug|Camrelizumab|IV
45625334|NCT03222713|Other|Program Self-regulation in health|The intervention program with children will be run by teachers and health professionals (Condition Group II) in 50-minute biweekly sessions which will take place in class in school year. During these sessions, the children will complete the following tasks: the reading of the chapters of Yellow Trials and Tribulations (one chapter per week) and the discussions and activities related to the topics of healthy eating and oral health.
45625335|NCT04861545|Other|Soy|"Isolated soy protein food sources are foods that include isolated soy protein in different forms and matrix (e.g. soy beverage and meat analogue).~Non-isolated soy protein food sources of soy protein are foods made with soy (e.g. Tofu, tempeh, edamame)."
45625336|NCT03222791|Other|Algorithm-based diet|Personalized nutrition plan based on an algorithm for predicting the personalized glucose response to food. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria.
45625337|NCT03222791|Other|Mediterranean-style low-fat diet|The Israeli standard of care dietary guidelines for prediabetes.
45625338|NCT03222635|Procedure|Endoscopic follow-up|Endoscopic follow-up by means of regular upper endoscopies and endoscopic ultrasounds
46073654|NCT00841867|Procedure|All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.|All subjects will ingest a 75 g glucose solution (Glucola brand) and have blood drawn at 7 timepoints over 120 minutes.
45447102|NCT02103712|Other|Qualitative|
45625339|NCT04873167|Behavioral|low fat|subjects subjected to a low-fat dietary regime
45625340|NCT04873167|Behavioral|mediterranean diet|subjects subjected to a mediterranean dietary regime
45447103|NCT03554980|Drug|Silver Diamine Fluoride|SDF will be applied with a brush.
45625341|NCT03222479|Behavioral|Stress guide|smartphone-based application that can evaluate stress level and teach how to manage their stress
45767239|NCT03613519|Behavioral|SHUTi|A woman assigned to SHUTi receives access to an online program that includes 6 interactive sessions that are designed to be reviewed over a period of about 8 weeks. The online sessions include videos and written material that give information about factors that affect sleep, changes that might help sleep patterns, and how to make those changes. Each session takes about 45 to 60 minutes to complete. During and between sessions, the participant fills out sleep diaries to gather information about daily sleep patterns. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health as well as sleep diaries. Time 1 is just before starting the first session of the SHUTi program. Time 2 is about 9 weeks later and Time 3 is about six months after that. The questionnaires will be used to assess the effect of the online program on the participant's sleep and health.
46069648|NCT04862624|Behavioral|Catalina Story-Based Web-App|"Latinas in the experimental group will view a story-based web-app featuring a character named Catalina and psycho-therapeutic modules to motivate them to take action and get help for their symptoms of depression and/or anxiety."
45625342|NCT03045237|Other|physical exercises classes|3 physical exercises classes, one of them in the pool.
45625343|NCT02451527|Drug|Digoxin|Digoxin 0.5mg tablet by mouth on Day 1 and Day 38
45625344|NCT02451527|Drug|PEX168|PEX168 in subcutaneous injection on Day8，15，22，29 and Day 36
45447104|NCT03554980|Drug|Sodium Fluoride varnish|NaF will be applied with a brush
45625345|NCT04872933|Other|Kidney Beam Online Platform|Kidney Beam is a wellbeing digital health intervention platform that offers patients living with kidney disease a way to improve their physical activity and boost their mental health through live and on demand movement classes and expert educational videos, while remaining in their own home. Kidney Beam is led by specialist kidney professionals, including renal physiotherapists and renal counsellors, from a number of different NHS Trusts and backgrounds, as well as people living with kidney disease.
45625346|NCT04867239|Other|A two-day education progra|During the camp, the multidisciplinary team provided disease information, lifestyle modification, nutrition, and exercise.
45625347|NCT03222401|Drug|1 mg/kg single infusion of F598|1 mg/kg single infusion of F598
45625348|NCT03222401|Drug|3 mg/kg single infusion of F598|3 mg/kg single infusion of F598
45625349|NCT03222401|Drug|10 mg/kg single infusion of F598|10 mg/kg single infusion of F598
45625350|NCT04873011|Drug|Quinine Hydrochloride|After a stabilization period of 20 minutes and 10 minutes after the first blood collection, 10 mL of the quinine hydrochloride solution will be infused into the stomach in a randomized, double-blinded fashion
45804262|NCT05392777|Diagnostic Test|Residual syntax score|residual syntax score will be calculated as the conventional syntax score from the web based tool, but subtract the score of the culprit lesion(s) that are fixed (stented) in the index procedure.
46069649|NCT04862624|Behavioral|Attention Control Web-App|Latinas in the attention control group will view non-story based media that is informational.
46069650|NCT00975689|Drug|N-Acetyl Cysteine|900mg effervescent tablet; Dosed as 15 mg/kg/day (maximum dose 900 mg per day) for one week, advanced to 30 mg/kg/day (maximum dose 1800 mg per day) for the second week, and then advanced to 60 mg/kg/day (maximum dose 2700 mg) for the remainder of the trial (6 additional weeks).
45625351|NCT04873011|Drug|Placebo|After a stabilization period of 20 minutes and 10 minutes after the first blood collection, 10 mL of water will be infused into the stomach in a randomized, double-blinded fashion
45447105|NCT02103790|Device|Home NIV installation|
45447106|NCT02103868|Behavioral|Tobacco Cessation Counseling|Doing group and personal counseling for tobacco cessation
45447107|NCT04230213|Drug|PF-06410293|SC injection
45447108|NCT04230213|Drug|adalimumab|SC injection
45625352|NCT02451605|Drug|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade (Ropivacaine) for total knee replacement surgery.
45625353|NCT02451605|Procedure|Total knee replacement surgery.|Total knee replacement surgery.
45625354|NCT04873089|Other|Cosmetic product|"It is a comparative study with two parallel groups of subjects:~Tested group: twice daily application of the cream RV3278A cosmetic product on the whole face~Comparative group: no application of study product or reference product"
45625355|NCT03222323|Drug|Dexmedetomidine perineurally|Dexmedetomidine is added perineurally on one side and will influence the nerve block perineurally on this side. Dexmedetomidine is also absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
45625356|NCT03222323|Drug|Ropivacaine 5mg/ml|Ropivacaine is used in 5mg/ml in the perineural, systemic and placebo nerve blocks.
45625357|NCT03222323|Drug|Ropivacaine 7.5mg/ml|In the high dose ropivacaine group a ropivacaine concentration of 7.5mg/ml is used.
45625358|NCT03222323|Drug|Dexmedetomidine systemically|Dexmedetomidine administered perineurally on one side is absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
45804263|NCT05641610|Genetic|ZS801|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant. The dose levels are as follows: 2.0×10^12vg/kg, 5.0×10^12vg/kg, 1.0×10^13vg/kg.
45804264|NCT00003183|Biological|filgrastim|
45804265|NCT00003183|Drug|mitoxantrone hydrochloride|
45625359|NCT03222323|Drug|Isotonic saline|placebo (saline) is administered perineurally in all but the perineural group.
45625360|NCT04872699|Diagnostic Test|Serology testing, RT PCR|Periodic testings and testings with characteristic symptoms occur
45625361|NCT03043677|Biological|Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab|"Ex-vivo conditioning of lamina propria and peripheral blood mononuclear cells.~Here, we will address whether the current available biological therapies for IBD patients (infliximab, golimumab, adalimumab, vedolizumab and ustekinumab) elicit a differential effect on the mucosal capacity to recruit circulating leukocytes on an ex-vivo approach using transwell culture systems."
45625362|NCT03222089|Drug|Irinotecan|Irinotecan 165 mg/m² 1-hour IV day 1
45767240|NCT03613519|Behavioral|modified SHUTi (i.e., SHUTi-BWHS)|A woman assigned to modified SHUTi (i.e., to SHUTi-BWHS) receives access to an online program that includes 6 interactive sessions that are designed to be reviewed over a period of about 8 weeks. The online sessions include videos and written material that give information about factors that affect sleep, changes that might help sleep patterns, and how to make those changes. Each session takes about 45 to 60 minutes to complete. During and between sessions, the participant fills out sleep diaries to gather information about daily sleep patterns. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health as well as sleep diaries. Time 1 is just before starting the first session of the modified SHUTi program. Time 2 is about 9 weeks later and Time 3 is about six months after that. The questionnaires will be used to assess the effect of the online program on the participant's sleep and health.
45912749|NCT02014064|Other|Placebo|Control Group: Day 1: 40mg @ 8am Day 2: 40mg @ 8am Day 3: 40mg @ 8am, 40mg @ 8pm Day 4: 40 mg @ 8am, 40mg @ 8pm Day 5: 40mg @ 8am, 40 mg @ 8pm Day 6: 40 mg @ 8am = Testing day (fMRI scan & cognitive testing session)
45767241|NCT03613519|Behavioral|Patient education|A woman assigned to patient education receives access to a website that provides detailed information on habits and environments that may help or hinder sleep. The site can be visited as often as desired. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health, as well as sleep diaries to gather information about her daily sleep pattern. Time 1 is just before first logging into the sleep information website. Time 2 is about 9 weeks later and Time 3 is six months after that. The questionnaires will be used to assess the effect of the sleep information program on the participant's sleep and health.
45767242|NCT03500302|Drug|Evolocumab|Evolocumab sq once a month for a total of two doses
45625363|NCT03222089|Drug|Oxaliplatin|oxaliplatin 85 mg/m² 2-hours IV day 1
45767243|NCT02176837|Drug|Sodium Nitrite|Subjects will receive continuous intravenous infusion of study drug for 7 days at a dose of 64 nmol/min/kg. The infusion will begin shortly after angiographic demonstration of cerebral vasospasm and will be for 7 days unless side effects of the drug dictate stopping the infusion.
46069651|NCT05329298|Drug|BPI-361175|Subjects will receive BPI-361175 until disease progression
45767244|NCT03501550|Drug|CDI-31244|investigational drug
45625364|NCT03222089|Drug|Levoleucovorin|Levoleucovorin 200 mg/m² 2-hours IV day 1
45625365|NCT03222089|Drug|5-FU|5-FU 2800 mg/m² 46-hours flat continuous infusion IV
45625366|NCT03222089|Drug|GM-CSF|GM-CSF 150ug s.c. d3-7 , Repeated every 4 weeks.
45625367|NCT03222089|Drug|IL-2|Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.
45625368|NCT03043989|Drug|Docetaxel|6 infusions of Docetaxel with 18 doses clarithromycin
45767245|NCT03501550|Drug|SOF/VEL|sofosbuvir and velpatasvir fixed dose combination
45767246|NCT03503578|Drug|Sevoflurane|Subjects will received sevoflurane for approximately 60 minutes.
45912750|NCT02014077|Procedure|VATS ( Video-Assisted Thoracoscopy )|the patients were randomized to a Video-Assisted thoracoscopy( VATS )for retained haemothorax
46069652|NCT02621385|Drug|tradipitant|test agent
46069653|NCT02621385|Drug|Midazolam|substrate for drug-drug interaction assessment
45625369|NCT03043989|Drug|Cabazitaxel|6 infusions of Cabazitaxel with 18 doses clarithromycin
45625370|NCT03043989|Drug|Clarithromycin|18 doses of clarithromycin with either Docetaxel or Cabazitaxel
45625371|NCT02451371|Device|tDCS|2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
45767247|NCT03503578|Drug|Ketamine|Subjects will received sevoflurane and ketamine for approximately 60 minutes.
45767248|NCT03506386|Other|No Intervention|As it was an observational study, no intervention was administered.
45912751|NCT02014077|Procedure|Thoracostomy Tube reinsertion|the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax
45912752|NCT02014090|Other|Hemodynamic and biological measurements|by MCE, PWA, Doppler, Multiplex, FACS
46073655|NCT00829413|Drug|SonoVue®|SonoVue (2.4 mL)
46073656|NCT00841945|Drug|rituximab|RITUXIMAB 375 MG/M² IV DAY 1 or each course
46073657|NCT00841945|Drug|doxorubicin|doxorubicin 50 mg / m² iv day 1 of each course
46073658|NCT00841945|Drug|vincristine|VINCRISTINE 1?4 MG/M² IV ON DAY 1
46073659|NCT00841945|Drug|prednisone|Prednisone 40 mg/m² DAy 1 to day 5
46073660|NCT00841945|Procedure|radiotherapy|radiotherapy : total dose = 40 GY (5 fractions by week)
45625372|NCT03044145|Behavioral|The Cultural Formulation Interview-Engagement Aid|Culture affects how all people communicate and understand the world. Culture is important because patients and clinicians from different cultural backgrounds may have different preferences for communication. Mismatch in the clinician's approach and the patient's expectations of care can lead to patient dissatisfaction and discontinuation with treatment. Patients and clinicians may also have different views about what caused an illness, how it functions, what makes it better or worse, and the types of treatment needed. The CFI-EA is a series of questions over three sessions that clinicians can use to clarify patient views about treatment and communication so that patients stay in treatment longer. Clinicians can use the CFI-EA to customize their current treatment plans.
45912753|NCT02012647|Procedure|Transcranial Magnetic Stimulation (TMS)|Participants sit in a chair that looks like one in a dentist's office. A magnetic coil will be placed on the scalp on one side of the head, overlying the brain's motor cortex to stimulate the brain's output to the muscles in the opposite hand. A second magnetic coil will be placed on the scalp of the opposite side. Recordings from both hands will be made using the magnetic coils placed on scalp. Results will be compared for participants with and without Parkinson's Disease.
45767249|NCT03270514|Drug|Exparel Injectable Product|Liposomal bupivacaine 20 cc (226 mg) + Bupivacaine Hydrochloride 0.25% 40 cc (100 mg) + made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
45625373|NCT03044145|Behavioral|The Cultural Formulation Interview-Engagement Aid (Revised)|The study team will revise the CFI-EA based on patient and clinician feedback. The study team expects that the revisions will consist of changes to the questions such as adding or subtracting specific items or revising the wording of the content. The study team do not anticipate other changes, though we will let our empirical data analyses guide revisions in consultation with the K23 mentor team.
45625374|NCT03044145|Behavioral|Treatment as usual|Standard mental health treatment at FHMC
45767250|NCT03270514|Drug|Bupivacaine Hydrochloride|Bupivacaine 0.25% 2 mg/kg not to exceed 150 mg - made up to made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
45767251|NCT03277378|Device|lead placement followed by BurstDR stimulation|lead placement followed by BurstDR stimulation
45767252|NCT02178241|Drug|Eribulin Mesylate|Given IV
45767253|NCT02178241|Drug|Gemcitabine Hydrochloride|Given IV
45767254|NCT03509974|Device|Osseointegrated Steady State Implant|Bone anchored, bone conduction hearing system
45625375|NCT04484831|Behavioral|ABT Weight Loss Intervention|This includes 15 sessions that are each 90 minutes in length. Intervention sessions will be weekly for the first 2 months, bi-weekly for the next 2 months, and monthly for the last 2 months.
45625376|NCT04484831|Other|Enhanced Care|This includes 15 handouts on elements of a healthy lifestyle and a midpoint one-on-one nutrition consultation with a registered dietitian.
45625377|NCT03222167|Drug|Elbasvir/ Grazoprevir 50/100 mg fixed dose combination|Enrolled patients will be treated by Elbasvir/ Grazoprevir 50/100 mg fixed dose combination during 12 week. Followed-up on week 24. SVR12 will be evaluated.
45767255|NCT03015727|Drug|Docetaxel|3 cycles of DOC neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2.
45767256|NCT03015727|Drug|Cisplatin|3 cycles of DDP neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 75mg/m2.
45767257|NCT03015727|Radiation|IMRT/TOMO|intensity modulated radiation therapy or tomotherapy
45767258|NCT03015727|Drug|Chemotherapy|2 cycles of cisplatin concurrent chemotherapy at day 64 and 85 with cisplatin 100mg/m2.
45767259|NCT03584659|Device|Electronic patient-reported outcomes|Weekly reporting of patient-reported outcomes for closer contact between patient and clinic between treatment cycles.
45767260|NCT03539731|Drug|Fluorine F 18 DASA-23|Given IV
45767261|NCT03539731|Procedure|Positron Emission Tomography|Undergo PET scan
45767262|NCT03015883|Radiation|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
45767263|NCT01077973|Drug|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen) plus placebo
45767264|NCT01077973|Drug|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg) plus placebo
45767265|NCT01077973|Drug|Placebo|Single-dose of placebo
45767266|NCT03514420|Drug|AKCEA-ANGPTL3-LRx|AKCEA-ANGPTL3-LRx solution for SC injection.
45767267|NCT02973646|Drug|Entecavir or Tenofovir|Patients in nucleos(t)ide analogues treatment for 12 weeks group will receive nucleos(t)ide analogs therapy (Entecavir tablet 0.5mg/d or Tenofovir tablet 300mg/d) from Week 25th to 36th.
45767268|NCT02973646|Drug|Peginterferon Alfa-2B|
45767269|NCT03296059|Other|conventional treatment with RBC transfusion|Besides conventional treatment, neonates is given RBC transfusion.
45767270|NCT03296059|Other|conventional treatment|neonates is treated with conventional treatment.
45767271|NCT03369340|Other|P3P 1|2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
45767272|NCT03369340|Other|P3P 2|2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
45767273|NCT03369340|Other|P3P 3|1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
45767274|NCT03369340|Other|P3P 4|2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
45767275|NCT01078363|Drug|ramipril|Use of a ACE ( angiotension converting enzyme) inhibitors post heart Transplant for Blood pressure control.
45767276|NCT01078363|Drug|Placebo|Use of a placebo post heart Transplant for Blood pressure control.
45767277|NCT03370042|Procedure|semilunar coronally positioned flap with free gingival graft|
45767278|NCT03370042|Procedure|semilunar coronally positioned flap alone|
45767279|NCT03371836|Drug|Clobazam|Clobazam is used as an adjunct medicine for all participants.
45767280|NCT01078753|Drug|Desmopressin|Desmopressin oral lyophilisate tablet, 120 μg or 240 μg, administered sublingually once a day 1½ hours before bedtime.
45767281|NCT01078753|Drug|Placebo|Placebo oral lyophilisate tablet was administered sublingually once a day 1½ hours before bedtime.
45767282|NCT03372382|Drug|Ibuprofen|NSAID
45767283|NCT03372382|Drug|Acetaminophen|analgesic
45767284|NCT03372382|Drug|Norco|acetaminophen plus opioid
45767285|NCT01078909|Biological|Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)|Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
45767286|NCT03372928|Dietary Supplement|Standard EAA|EAA provided relative to body mass at a standard dose (0.10 g/kg) during energy deprivation
45767287|NCT03372928|Dietary Supplement|High EAA|EAA provided relative to body mass at a high dose (0.30 g/kg) during energy deprivation
45767288|NCT03373162|Drug|onabotulinumtoxinA|This study is a pre- and post-design. One scan will be collected prior to BOTOX injection and the second will be collected 14-21 days post-injection. BOTOX injections will be limited to 20 units in the glabellar area, as approved by the FDA .
45767289|NCT03373240|Behavioral|TAU plus Cognitive Remediation Program|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS computerized games that focus on cognitive-affective self-regulatory processes.
45767290|NCT03373240|Behavioral|TAU plus Control Tasks|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS a series of computerized word games.
45625378|NCT04860999|Procedure|Osteopathic Manipulative Treatment|The osteopathic manipulations focused on treating the asymmetric postural dysfunction that was identified by the initial functional structural evaluation. The manipulation consisted of typical time-honored osteopathic treatments directed at the identified somatic dysfunction(s). These techniques were clinically directed and include: soft tissue, muscle energy, high velocity low amplitude, low velocity high amplitude as well as facilitated positional release as indicated.
45767291|NCT03374176|Drug|Amoxicillin 500 mg / Metronidazole 250 mg|Subjects were instructed to take a capsule three times a day for 7 days
45767292|NCT03374176|Drug|Clindamycin 300 mg|Subjects were instructed to take a capsule three times a day for 7 days
45625379|NCT04867005|Behavioral|Impact of a training program|Measurement of the effectiveness of a training program based on the skills and knowledge learning on advance care planning. A 10 hours online course was administered to both arms through an online platform; the 6 hours face-to-face course was administered to each primary care team (5) included in this arm. The 6 hours course was split into 2 sessions of 3 hours each.
45625380|NCT03221855|Drug|Domperidone|Capsules 10mg orally each 8 hours for 7 days.
45625381|NCT03221855|Drug|Placebo|Capsules 10mg orally each 8 hours for 7 days.
45625382|NCT03043521|Drug|Dexlansoprazole 60 MG|
45625383|NCT03043521|Drug|CJ-12420 50mg|
45625384|NCT03043521|Drug|CJ-12420 100mg|
45625385|NCT03043521|Drug|CJ-12420 200mg|
45625386|NCT03221933|Biological|Somatropin Injection low dose group|0.23mg/kg /wk，inject for seven divided doses
45625387|NCT03221933|Biological|Somatropin Injection high dose group|0.46mg/kg /wk，inject for seven divided dose
45767293|NCT03281200|Drug|L - Antineoplastic and immunomodulating agents|L - Antineoplastic and immunomodulating agents
45625388|NCT03047733|Device|The XTRAC Excimer Laser System|Initial irradiation dose was 50 mJ/cm2 on face and 100 mJ/cm2 on trunk and extremities. If there had not been minimal asymptomatic erythema, energy level was escalated by 50 mJ/cm2.
45625389|NCT03047733|Drug|Topical tacrolimus 0.1% ointment|Application of topical tacrolimus 0.1% ointment on the both lesions once daily.
45625390|NCT03222011|Procedure|Standard (single) endoscopic stricture dilatation|single endoscopic stricture dilatation
45625391|NCT03222011|Procedure|Intensive endoscopic stricture dilatation|3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
45625392|NCT03119519|Radiation|Local Definitive Radiotherapy|three-dimensional conformal therapy or intensity modulated radiation therapy
45625393|NCT03119519|Drug|No Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
45767294|NCT03281200|Drug|L01 - Antineoplastic agents|L01 - Antineoplastic agents
45767295|NCT03281200|Drug|L01X - Other antineoplastic agents|L01X - Other antineoplastic agents
45767296|NCT03281200|Drug|L01XE - Protein kinase inhibitors|L01XE - Protein kinase inhibitors
45912754|NCT02012647|Procedure|Motor Physiology Testing|Participants will be asked to move their upper and lower limbs while seated in a chair. Wireless EMG sensors placed on arm and leg muscles will record measurements during this procedure. Upper and lower limb testing will be performed separately.
45912755|NCT02013089|Drug|Erlotinib or Gefitinib|Erlotinib 150mg talbet or Gefitinib 250 mg tablet per day for patients with EGFR gene alternation
45625394|NCT03221699|Other|Formula with ZnO|Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on with ZnO
45625395|NCT03221699|Other|Formula without ZnO|Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on without ZnO
45625396|NCT03221465|Behavioral|Self-monitoring of physical activity with incentives|Participants are given a pedometer (e.g. Misfit brand wrist pedometer) to allow self-monitoring of physical activity and receive financial incentives. Participants also answer two health questions a week for 12 weeks.
45625397|NCT03221465|Behavioral|Usual care and self-monitoring of physical activity|Participants simply given a pedometer (e.g. Misfit brand wrist pedometer) with no other intervention to allow self-monitoring of physical activity.
45625398|NCT02118766|Drug|AN2728 Topical Ointment, 2%|
45625399|NCT02118766|Drug|Matching vehicle control|
45625400|NCT03221543|Device|ReeVue Indirect Calorimeter|The ReeVue Indirect Calorimeter will be used in this study to measure the resting metabolic rate. The test takes approximately ten minutes to complete. The subject should prepare for the test by avoiding stimulants and exercise on the day of the test, as well as eating meals four hours before the test. The subject will be seated during the test. They will be given a nose clip that looks like a clothes pin to be placed on their nose. A plastic mouth piece that allows all of the air they breathe to come in through the top of the mouth piece and the air they breathe out to go into the ReeVue Calorimeter will also be provided. The subject will remain in this position for ten minutes until the testing is complete.
45767297|NCT03281200|Drug|L01XE31 - Nintedanib|L01XE31 - Nintedanib
45767298|NCT03378076|Drug|FX006 32 mg|Drug: Extended-release 32 mg FX006 IA injection into each knee (total 64 mg dose)
45767299|NCT03378076|Drug|TAcs 40 mg|Drug: Immediate-release 40mg TAcs IA injection into each knee (total 80 mg dose)
45912756|NCT02013089|Drug|Everolimus|Everolimus 10 mg orally once daily every day for patients with mTOR gene alternation
45912757|NCT02013089|Drug|Imatinib|Imatinib 400 mg tablet orally per day for patietns with KIT, PDGFR, ABL gene alternation
45912758|NCT02013089|Drug|Sorafenib or Sunitinib|Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day with or without food for patients with VEGFR, KIT, RAF gene alternation
45625401|NCT04484753|Other|Home Exercise Sheet|Received a sheet with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
45625402|NCT04484753|Other|Ipelvis mobile application|Received the iPelvis® Application with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
45625403|NCT04484753|Behavioral|Home exercise sheet + Pelvic Physiotherapy|Performed 12 Pelvic Physiotherapy sessions, in group, once a week and received a sheet with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
45625404|NCT04484753|Behavioral|Ipelvis mobile application + Pelvic Physiotherapy|Performed 12 pelvic physiotherapy sessions, in group, once a week and received the iPelvis® Application with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
45625405|NCT03221231|Drug|N-acetylcysteine|1200 mg/day, twice daily, N-acetylcysteine
45625406|NCT03221231|Drug|Placebo Oral Tablet|twice daily, placebo
45625407|NCT03221231|Other|Magnetic Resonance Imaging|
45625408|NCT03221231|Other|Neurocognitive measures|
45625409|NCT03221231|Other|Neuro-inflammatory measures|
45625410|NCT03221621|Procedure|Wide Excision|Wide excision is performed under general anaesthesia or procedural sedation and analgesia (PSA). All lesional tissue, including fibrosis, is electrosurgically removed until the area is clear. The subcutaneous fat and epithelised sinus floors are left intact where possible. The wounds are left open to heal by secondary intention.
45625411|NCT03221621|Drug|Adalimumab Injection|Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2 until end of study or last surgery.
45625412|NCT03221153|Procedure|Simulation techique|The intervention group will be in a simulated case with mock scenarios and interaction by 'acting out' the clinical situation where knowledge and attitudes about safety in hospitalized patients will be assessed.
45625413|NCT03220997|Dietary Supplement|Vitaflow Preload|Carbohydrate loading drink
45625414|NCT02614287|Drug|Galcanezumab|Administered SC
45625415|NCT03220919|Other|Weight-based|Glargine titration: 0.1U/kg per day when FBG is over 8.0 mmol/L. Aspart titration: total dose 0.1U/kg per day when next pre-meal BG is over 8.0 mmol/L, which is divided into three equal parts adding to three pre-meal boluses
45625416|NCT03220919|Other|Glucose level-based|"Glargine titration: 4, 6, or 8 U when FBG is, respectively, within the following ranges: 8.0-8.9, 9.0-9.9, >10.0 mmol/L.~Aspart titration: 1, 3, 5, 7 or 8 U when next pre-meal BG is, respectively, within the following ranges: 8.0-10.9, 11.0-13.9, 14.0-16.9, 17.0-19.9, > 20 mmol/L."
45625417|NCT03220763|Other|This is an observational study--there is no intervention.|This is an observational study, there is no intervention.
45625418|NCT03220841|Drug|Adalimumab Injection|Standard dose adalimumab induction and maintenance
45625419|NCT03220841|Drug|Thiopurine|Dose optimized thiopurine
45625420|NCT03220841|Procedure|Endoscopic balloon dilatation|Prior to randomization, suitable patients may undergo endoscopic balloon dilatation. Patients undergoing dilatation will be stratified to ensure equal numbers in each study arm.
45625421|NCT03047655|Behavioral|Lifestyle intervention (physical activity)|Dietary treatment with or without additional motivation on more physical activity
45625422|NCT03047655|Dietary Supplement|Lifestyle intervention (PUFA/isomaltulose-enriched muffin)|
45625423|NCT03220607|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
45625424|NCT04866927|Dietary Supplement|Use of stable isotopic dilution to assess protein digestibility from Faba bean and to evaluate amino acid bioavailability|Each participant will receive a test meal containing 13C labelled spirulina, 2H labelled Fava bean and 13C phenylalanine. The test meal will be divided on 11 subdoses: 3 sub-doses will be administrated at T0 and 1 subdose will be administrated at 1, 2, 3, 4, 5, 6 and 7h. The remaining sub-dose will be kept for measurement of IAA in the test meal. After eating the test meal, blood, urine and breath samples will be collected from each participant at the baseline (T0) and after 5-6, 7h and 8h.
45625425|NCT03045393|Drug|Mirvetuximab Soravtansine (IMGN853)|Mirvetuximab Soravtansine is a targeted drug for tumors that express high levels of folate receptor alpha.
45625426|NCT01374971|Drug|Certolizumab Pegol (CZP)|CZP is an anti-TNF, humanized antibody Fab' fragment/polyethylene glycol(PEG)conjugate. CZP liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks.
45625427|NCT01374971|Procedure|Arthroscopic synovial tissue biopsy|Subjects will undergo arthroscopy Pre and Post Treatment. The arthroscopy will be performed on a clinically inflamed joint. A single arthroscopy procedure using a small bore arthroscope will be conducted to obtain synovial tissue in each joint in all subjects. Local anesthesia will be used only. Two small incisions will be made to accommodate the arthroscope and other instruments. Synovial biopsies will be obtained using a motorized shaver.
45625428|NCT03220295|Drug|Single Dose of VU319|Single dose of VU319
45625429|NCT03220295|Drug|Single Dose Placebo|Single dose of placebo
45452414|NCT05240222|Other|Sham comparator|Participants in the active control condition will meet with school administrators to talk about their work irrelevant to SC-PIES or student behaviors. The meeting lasted for the same duration as the SC-PIES at the same time as those in the treatment condition.
45625430|NCT03220295|Other|Fed State|drug is given 30 minutes after a high fat breakfast
45625431|NCT03220295|Other|Fasted State|drug is given after an overnight fast
45625432|NCT03220295|Drug|Dose Escalation of VU319|dose levels of the cohorts will be increased step wise
45625433|NCT03220295|Drug|Placebo Dose Escalation|dose levels of the cohorts will be increased step wise
45625434|NCT03220451|Procedure|Adhesive elastic taping|Adhesive elastic taping placed around a pressure ulcer, according to a planned placement technique
45625435|NCT02506205|Behavioral|Lee Silverman Voice Treatment (SVLT) LOUD|
45625436|NCT02506049|Device|S-LPC:Selective Laser Photocoagulation|Under anesthesia (epidural, general anesthesia with intubation, or intravenous sedation with infiltration of a local anesthetic), one treatment with the use of fetoscopy instrument sets for Selective Laser Photocoagulation (S-PLC) to seal the connecting blood vessels, help to normalize blood flow between twins.
45625437|NCT02505815|Procedure|Surgery|
45625438|NCT02505815|Procedure|Cortisol Level Measurement|
45625439|NCT02505815|Procedure|Neurocognitive Testing|
45452415|NCT05225506|Behavioral|Exercise|Exercise sessions will be one hour in duration and be a combination of resistance, aerobic, and balance exercise, with emphasis on movements specifically targeting common deficits seen in Parkinson's.
45625440|NCT04497545|Device|Luna EMG|The duration of the overall therapeutic intervention in both groups will be the same.
45625441|NCT04497545|Device|lower limb rotor|The duration of the overall therapeutic intervention in both groups will be the same.
45625442|NCT02505737|Behavioral|TH-CBT|Telephone-Based Cognitive Behavioral Therapy (TH-CBT). A 10-session treatment protocol that incorporates behavioral activation, thought monitoring and restructuring, relaxation training, worry control, sleep hygiene, and caregiver psychoeducation and support
45625443|NCT02505737|Other|Enhanced Usual Care|Community-based treatment as usual and supplemental reading material
45625444|NCT02505659|Behavioral|Preoperative re-education|Preoperative re-education (behavior): 8 re-education sessions of 30 to 40 minutes, 2 times a week, for 4 weeks
45625445|NCT02505971|Drug|Nadolol|"Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day. In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be escalated (by 0.5 mg/kg/day at any following study visit) up to 3 mg/kg/day based on the clinical response to maintain the dose that led to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52."
45625446|NCT02505971|Drug|Propranolol|"Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day.~In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be increased by investigator, based on clinical response by 0.5 mg/kg/day at any study visit (up to 3 mg/kg/day divided twice a day) to maintain the dose that lead to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52."
45625447|NCT04497389|Biological|Human Amniotic Fluid|Patients will receive 10ml intravenous hAF each day for 5 consecutive days.
45625448|NCT02505503|Device|Unloading shoes|The unloading shoe will be a trainer-type shoe with a rocker sole incorporated. The sole is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.
45625449|NCT02505503|Device|Unadapted control shoe|During the control condition assessments, participants wear a pair of appropriately-sized shoes, which are similar in appearance to the unloading shoes, but do not contain the altered sole.
45625450|NCT04497311|Diagnostic Test|Thoraxic computed tomography|Diagnostic lung CT.
45625451|NCT02505581|Drug|Extra dosage - cefuroxime (750mg) I.V|In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc
45625452|NCT02505581|Procedure|Colorectal Surgery|Both groups undergo colorectal surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)
45625453|NCT02505581|Drug|Ciprofloxacin 750 mg oral|An oral antibiotic pattern of ciprofloxacin (750 mg / 12h, 2 doses) the day before surgery.
45625454|NCT02505581|Drug|Metronidazole 250 mg oral|An oral antibiotic pattern of metronidazole (250 / 8h, 3 doses) the day before surgery.
45625455|NCT02505581|Drug|Cefuroxime 1.5 g Intravenous|An intravenous antibiotic pattern of cefuroxime 1.5 g during anesthetic induction.
45625456|NCT02505581|Drug|Metronidazole 1 g Intravenous|An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.
45625457|NCT03343847|Biological|Romiplostim|This trial is designed to study romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of lymphoma.
45625458|NCT03343847|Other|Placebo|Placebo Comparator
45625459|NCT02451293|Drug|Melatonin (N-acetyl-5-methoxytryptamine)|
45625460|NCT02451293|Drug|Placebo|
45625461|NCT03343769|Other|BERG scale|Complete the BERG balance scale
45625462|NCT03343769|Other|Functional tests|timed up and go, Mini motor test, retropulsion test
45625463|NCT03343769|Other|Measurement of balance on a force platform|4 trials of 30 seconds x 2 conditions (eyes open; eyes closed)
45625464|NCT03343769|Other|Measurement of maximal moment of the plantar flexor and dorsiflexor muscles|5-second repetitions
45625465|NCT03343769|Other|Measurement of the moment of the plantar flexors and dorsiflexors corresponding to RMS activity during balance measurements|3 10-second repetitions
45625466|NCT03220139|Other|fat intake|Observational study on fat intake and mortality
45625467|NCT02505191|Drug|St. John's wort prolonged-release tablet 500 mg|
45625468|NCT02505191|Drug|St. John's wort film coated tablets 250 mg|
45625469|NCT04497077|Dietary Supplement|tart cherry|Either tart cherry juice or freeze dried powdered tart cherry in capsule was given
45625470|NCT04497077|Dietary Supplement|placebo|either cornstarch capsule or kool-aid
45625471|NCT02505035|Behavioral|Default ordering of palliative consult|
45804266|NCT02979223|Drug|sodium picosulfate and magnesium citrate, polyethylene glycol with ascorbic acid|"sodium picosulfate and magnesium citrate and 2L polyethylene glycol with ascorbic acid are used as combination method.~There is a difference in the order of intake between two group"
45804267|NCT03687723|Device|OCS Heart System|The OCS™ Heart System is a portable organ perfusion and monitoring medical device intended to preserve donor hearts in a near physiologic and beating state prior to transplantation.
45452416|NCT05180864|Procedure|Gastrectomy|Open or minimally invasive (sub)total gastrectomy
45625472|NCT03119753|Device|Rapid Prototyping method of fabrication of complete denture|For Rapid Prototyping Method of fabrication of complete denture : the master casts will be scanned using DENTAL WINGS eco-scan 3, using laser technology for scanning, after spraying the stainless steel pins with scanning spray to be recorded into the denture base. Virtual model will be obtained for fabrication of denture bases. Denture base will be designed and modified on the virtual model, then it will be printed using ZENITH-3D Printer using Urethane acrylate oligomer based photo-polymerized resin.
45767300|NCT03514966|Behavioral|Position change group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the position change group will be instructed to repeatedly change the body position according to a pre-specified protocol for a period of 15 min: in the order of supine to the left lateral position to prone, left lateral, supine, right lateral, and repeat last four positions twice, each for 1 min; finally supine for 1 min. Thirty and 40 min after dimethicone administration, subjects in both groups will additionally take 200 ml and 800 ml water, respectively before undergoing MCE examination.
46069654|NCT04135131|Other|pilates mat exercises and home exercises|Patients with low back pain were randomized into pilates (group 1) or home exercise group (group 2) 3 times/week for 8 weeks. Pilates mat exercise program comprised three sessions a week for 8 weeks (Monday, Wednesday, and Friday), with each session being scheduled for 1 h (5-min warm-up, 50-min exercise, and 5-min cooling) and each set comprising 10 repetitions. The home exercise program included the pelvic tilt in the supine position, hamstring stretch, hip flexors and lumbar extensor stretch, bridge, strengthening the abdominal muscles, cat/camel exercises in the crawl position, leaning on the forearms in the prone position, strengthening the back extensors, and crossed-arms/legs lift exercises.
45625473|NCT03119753|Device|Conventional method of fabrication of complete denture|For Conventional Method of fabrication of complete denture: Self-cured acrylic resin trial denture bases will be constructed on the obtained master casts, then processing of the final denture bases by conventional clamping method cured by long curing cycle (74º C for 8 hours) using heat-cured poly-methyl methacrylate (PMMA) resin material. The position of the pins will be recorded into the denture bases so that the linear changes could be measured.
45625474|NCT03220061|Behavioral|music therapy|
45625475|NCT02505113|Drug|Montelukast|Montelukast (10mg, q.d., p.o.)
45625476|NCT02504957|Procedure|Photodynamic therapy using polyhematoporphyrin|
45625477|NCT03343691|Diagnostic Test|Screening Population|Blood samples taken from screening population
45625478|NCT03343691|Diagnostic Test|Breast Cancer Population|Blood samples taken from Breast Cancer population
45625479|NCT03219515|Drug|Gongjin-Dan|Gongjin-dan (Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea) is composed of Cervi Parvum, Angelica Gigas Root, Cornus Fruit, Ginseng, Steamed Rehmannia Root, and Musk.
45625480|NCT03219515|Drug|Placebo|Placebo drugs (similar in appearance, taste, and odor to the Gongjin-dan) contains excipients, coloring agents, binders, flavoring agents, and preservative, and gilt-paper covering. Placebo pills of Gongjin-dan will be also made by Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea.
45625481|NCT03216317|Behavioral|Intervention Group|Isometric handgrip training consisting of four series
45625482|NCT02504801|Drug|Budesonide|To test the hypothesis that nebulizer Pulmicort Respules could reduce post operation pulmonary complication incidence in primary lung cancer patients with COPD. Compare post-operation pulmonary complication incidence in two arms among primary lung cancer patients with COPD required single lobectomy from 3 days before operation to 7 days after operation.
45625483|NCT02504567|Device|Laser ablation|Pulmonary vein isolation using the laser ablation catheter
46069655|NCT00922766|Drug|Dalteparin|Patients prescribed dalteparin for non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without corornary intervention [PCI] or coronary artery bypass graft [CABG] within 48 hours).
45625484|NCT02504567|Device|RF ablation|Pulmonary vein isolation using the RF ablation catheter
45625485|NCT02504411|Device|Device Assisted Colonoscopy|This will be similar to the standard colonoscopy except the endocuff device will be used.
45625486|NCT02504411|Device|Standard Colonoscopy|No endocuff device will be used on the study participants undergoing standard colonoscopy.
45625487|NCT02451059|Behavioral|WE CARE survey|The WE CARE survey, consists of 14 questions used to identify seven unmet material needs (education, employment, food security, housing, childcare, household heat, language). The survey will be administered with patient's developmental screening forms at all health supervision visits from birth to two years of age. The office staff will instruct parents to give the WE CARE survey, along with the developmental screening tool, to their child's provider at the visit.
45625488|NCT02451059|Behavioral|WE CARE Community Resource Handout|Providers will be trained to review the WE CARE survey at health supervision visits and generate referrals thru the EMR. Specifically, they will receive a one-hour teaching session one week prior to the study implementation. The goals for the session will include providing an overview of pediatric practice guidelines, introducing the WE CARE survey, reviewing the referral process, and discussing the role of peer patient navigators. Study staff will conduct periodic booster sessions; study staff will also train new providers should there be staff turnover
45804268|NCT01805271|Drug|Everolimus|(5 or 10 mg/day, i.e. 1 or 2 tablets/day)
45625489|NCT02451059|Behavioral|Patient Navigator|The peer patient navigator will offer guidance to families with accessing community resources. They will be available at least .5 days per week at intervention health centers to meet with families and offer guidance as well as be available via a hotline number. The navigator will speak with families and offer guidance on community resources and offer assistance with completing applications. In addition, they will offer to schedule and, if desired, accompany parents to the agencies. Interpreter services will be utilized at the health centers in case the navigator does not speak the parent's language. The navigator will also place an update note in the EMR within 1-month post-visit and one week after any contact with families.
46069656|NCT04134897|Drug|Capecitabine|2000 mg/m2, bid, per os, days 1-14, 4 cycles
45625490|NCT02504255|Biological|Biological samplings|Blood, urine and faecal sampling every 3 months
46069657|NCT04134897|Drug|Oxaliplatin|130 mg/m2 iv day 1, 4 cycles
46069658|NCT04134897|Drug|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
46069659|NCT04134897|Radiation|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor
46069660|NCT04134897|Procedure|Rectal cancer surgery|Laparoscopic or open total mesorectal excision
45625491|NCT02504255|Other|Questionnaires|patients fill several questionnaires every month to assess stress and adaptation parameters
45625492|NCT02504333|Drug|nab-paclitaxel|Day 1-8-15: Intravenous, 125 mg/m2 over 30 minutes
45625493|NCT02504333|Drug|gemcitabine|Day 1-8-15: Intravenous, 1.000 mg/m2 over 30 minutes
45625494|NCT02504333|Drug|m-FOLFOX|Day 28 according to the dose levels stablished in Phase I
45625495|NCT02504333|Drug|nab-paclitaxel|Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I
45625496|NCT02504333|Drug|gemcitabine|Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I
45625497|NCT02504177|Drug|novel oral anticoagulant for 30 days|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
45625498|NCT02504177|Drug|novel oral anticoagulant for 24 hour|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
45625499|NCT02450981|Drug|Bevacizumab (BCD-021)|Bevacizumab is a monoclonal antibody against vascular endothelial growth factor A (VEGF-A)
45625500|NCT02504021|Behavioral|Family Consultation|This intervention is based on psychoeducation, social support mobilization, and motivational interviewing techniques.
45625501|NCT02451215|Device|Laser Interstitial Thermotherapy (LITT)|Magnetic resonance imaging (MRI)-guided laser interstitial thermal therapy (LITT) is a minimally invasive surgical option to treat CNS tumors. LITT uses laser energy delivered to a target (i.e. CNS tumor) through a fiberoptic catheter, which results in damage to intracellular proteins and DNA, and subsequent cell death. LITT provides a sharp demarcation between ablated and unharmed tissue, which, when combined with the ability to monitor and control the ablation via MR thermal imaging, results in a high level of precision and control.
45625502|NCT03215303|Device|Continuous Positive Airway Pressure (CPAP)|In the first moment, CPAP will be installed, and the researcher will hold a mask in the position in which it is coherent, explaining the method to the patient and allowing their gradual adaptation. Patients will adapt for a few minutes to make sure the mask is consistent with the specifications, so that the patient is comfortable. Participants in the intervention group will start with a PEEP of 1cmH2O that will increase by 2 cmH2O until a PEEP of 10 cmH2O is reached. Therefore, participants in the intervention group will remain with CPAP, PEEP of 10cmH2O, FiO2 0.21, for a period of 40 minutes.
45625503|NCT02503943|Drug|"Liraglutide and Mitiglinide"|"Liraglutide(1.2mg/d) and Mitiglinide (50mg, 3/d)"
45767301|NCT03520348|Drug|PRO-167|"Dexpanthenol 5%. Ophthalmic gel produced by Laboratorios Sophia, S.A. of C.V., Zapopan, Jalisco, Mexico.~Route of administration: ophthalmic"
45767302|NCT03520348|Drug|Corneregel|Dexpanthenol 5%. Ophthalmic gel developed by Bausch and Lomb, Berlin, Germany. Route of administration: ophthalmic
45767303|NCT03282682|Procedure|Strength training|The participants perform strength training sessions two times per week for 12 weeks. Each training session include 5-minute general dynamic warm-up followed by progressive strength training with exercises for the entire body. The strength exercises are performed with free weights and on machines. The training program consist of 6 exercises for upper and lower body at an intensity of 60-80% (8 - 12RM: the load that induces technique failure in eight or twelve repetitions) of one-repetition maximum and takes approximately 60 minutes. The exercises performed are: leg press, split squats, bench press, knee extension, knee flexion, seated cable rows, seated cable pull downs, dumbbell bench press, incline dumbbell bench press.
46069661|NCT04134897|Radiation|Radiotherapy|Pelvic radiotherapy dose: 25 Gy in 5 Gy fractions
46069662|NCT02621307|Dietary Supplement|Salba|
46069663|NCT02621307|Dietary Supplement|Flax|
46069664|NCT02621307|Dietary Supplement|Control|
45452417|NCT01129648|Drug|Placebo|Administered daily for 21 days
45452418|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
45452419|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
45452420|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
45452421|NCT01129648|Drug|BCX4208|Administered daily for 21 days.
45452422|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
45625504|NCT02503943|Drug|"Metformin and Mitiglinide"|"Metformin(500mg, 3/d) and Mitiglinide(50mg, 3/d)"
45625505|NCT02503943|Drug|"Mitiglinide"|"Mitiglinide (50mg, 3/d)"
45625506|NCT02450825|Procedure|Lung ultrasound examination on Day 1 and Day 2 to 4|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 and repeated on Day 2 to 4. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
45625507|NCT02450825|Procedure|Lung ultrasound examination on Day 1|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 only. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
45625508|NCT02450825|Device|GE Vivid Ultrasound system|The GE Vivid ultrasound system will be used for all lung ultrasound examinations performed in this study.
45625509|NCT02503631|Device|Stool Sample Collection Kit|Stool sample collection kit
45625510|NCT02178592|Drug|DTG 50 mg|DTG is available as 50 mg film-coated tablet. DTG may be administered with or without food
45625511|NCT02178592|Drug|EFV 600 mg|EFV is supplied as film-coated capsule-shaped oral tablet containing 600 mg of EFV and must be administered without food
45625512|NCT03214445|Procedure|Sealing margins with flow composite|Seal the margin of restoration with Composite flow with nanofiller
45452423|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
45625513|NCT03214445|Procedure|Sealing margins with seal|Seal the margin of restoration with sealant without filler
45625514|NCT02503397|Device|Auditory brainstem evoked response (ABR)|Bilateral monaural auditory brainstem response (ABR) test would be recorded in each subject with a Bio-logic Navigator Evoked Response System (Bio-logic Systems, USA) between 24 and 48 hours after birth by an audiologist skilled in administering ABR to newborn infants. ABRs shall be performed using 80 dB nHL broadband click stimuli with insert earphones and with the subject lying supine in a quiet room and normal skin temperature. The clicks would be presented at a repetition rate of 29.9/second, and three runs of 2000 repetitions to be recorded for each ear. The 2 most replicable runs for each ear shall be averaged and used for analysis. Absolute latencies of waves I, III, V and IPL (I-III, III-V, and I-V) shall be measured and considered outcomes
45625515|NCT03213743|Drug|Dexmedetomidine Injection|Investigators gave the patients loading dose of dexmedetomidine for 10 minutes and maintaining dose of dexmedetomidine for 20 minutes. Investigators took blood samples before and after the administration of dexmedetomidine.
45625516|NCT03212495|Drug|dexamedetomidine|intraarticular injection of 1µg/kg dexametomidine +18ml 0.25%bubivacaine in a total volume of 20 ml.
45625517|NCT03212495|Drug|neostigmine|intraarticular injection of 0.5mg/dose neostigmine +18ml 0.25%bubivacaine in a total volume of 20 ml.
45447109|NCT02103946|Procedure|Serratus Anterior Muscle Plane block (SAM block)|The US probe is placed in the mid-axillary line at level of the 6th intercostal space. From caudal to cranial, an in-plane approach, the block needle is inserted until the tip is placed between SAM and intercostal muscles and the LA injection will be visualized in real-time. The injection usually consists of 0.4ml/kg of bupivacaine 0.25% plus adrenaline (5ug/ml). Intraoperatively, all subjects will receive a general anesthetic using inhaled anesthetic and oxygen. Intravenous fentanyl will be administered for cardiovascular stability to noxious stimuli.For postoperative analgesia, all subjects will receive oral acetaminophen. Patients will receive a ketorolac IV injection then morphine as a rescue analgesic for breakthrough pain.
45452424|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
45452425|NCT01129648|Drug|BCX4208|Administered daily for 21 days.
45625518|NCT02503553|Behavioral|Option grid for cerebral aneurysm treatment|Patients will receive an option grid during the preoperative visit. They will be given the chance to read it and ask questions. The option grid will include head to head comparative answers for the two interventions available for cerebral aneurysms (surgical clipping and endovascular coiling). The interaction with the aneurysm surgeon will be voice recorded.
45452426|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
45452427|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
45625519|NCT02503553|Behavioral|Control|Patients will receive the standard information booklet for cerebral aneurysms during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded.
45625520|NCT02503319|Drug|Tranexamic Acid|"2 vials ( =1 gram) of Tranexamic Acid oral administered within 5 minutes from the delivery (third stage after labor)~2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery (third stage after labor)"
45625521|NCT02503319|Drug|Tranexamic Acid|2 vials ( =1 gram) of Tranexamic Acid slow intravenous infusion administered within 5 minutes from the delivery (third stage after labor)
45625522|NCT02503319|Drug|Oxytocin|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
45625523|NCT03212183|Behavioral|EPI-TAVIE|ÉPI-TAVIE is a web-based intervention focusing on epilepsy self-management. This interactive session (25 minutes) is facilitated by a virtual nurse.
45625524|NCT03212183|Other|Websites|The conventional websites offers reliable information about epilepsy. Their content were validated by experts.
45625525|NCT04496843|Diagnostic Test|HWA09 Measurement|Simultaneous recording of Withings HWA09 Device and PSG devices for the reference.
45625526|NCT04496765|Procedure|Total mesorectal excision|Radical resection of rectal cancer and draining lymph nodes
45625527|NCT03211325|Procedure|Biopsy|
45625528|NCT02610777|Drug|Azacitidine|Azacitidine intravenous or subcutaneous formulation.
45625529|NCT02610777|Drug|Pevonedistat|Pevonedistat intravenous infusion.
45625530|NCT03210779|Dietary Supplement|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 16 days and topical application of active oil once daily for 8 days
45625531|NCT03210779|Dietary Supplement|Placebo|Ingestion of inactive lozenge twice daily for 16 days application of inactive oil once daily for 8 days
45625532|NCT01628692|Drug|Daclatasvir|Tablets, oral, 30 mg, once daily
45625533|NCT01628692|Drug|Simeprevir|Capsule, oral, 150 mg, once daily
45625534|NCT01628692|Drug|Ribavirin|Tablets, oral, 500-600 mg, twice daily
45625535|NCT02503007|Dietary Supplement|Placebo|
45625536|NCT02503007|Dietary Supplement|HMB-FA|
45625537|NCT02503163|Drug|KCT-0809 ophthalmic solution|
45625538|NCT04496921|Dietary Supplement|Vitamin K supplementation, dose #1|Vitamin K supplement : 2mg, once a day, for 6 months. Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.). Food frequency questionnaire.
45625539|NCT04496921|Dietary Supplement|Vitamin K supplementation, dose #2|Vitamin K supplement : 7mg, twice a week, for 6 months. Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.). Food frequency questionnaire.
45625540|NCT04860609|Other|Conventional Physiotherapy|"The treatment will be given in the following way.~Tens~Infrared/Moist Heat heat for 10 minutes at low back region.~Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~Postural Education~Home Plan~Bed Rest with lumbar Sacral Support~Home plan:~Exercises Posture Correction Precautions Contra indication"
45452428|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
45452429|NCT01129648|Drug|BCX4208|Administered daily for 21 days.
45452430|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
45767304|NCT03380026|Drug|Triamcinolone|Apply up to three times daily on select lesions.
45767305|NCT03380026|Drug|Valchlor 0.016 % Topical Gel|Apply valchlor nightly on select lesions.
45625541|NCT04860609|Other|Lumber Spinal Decompression|"The treatment will be given in the following way.~Tens~Infrared/Moist Heat heat for 10 minutes at low back region.~Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~Postural Education~Home Plan~Decompression therapy session lumbar spinal decompression therapy for 30 minutes.~Home plan:~Exercises Posture Correction Precautions Contra indication"
45625542|NCT03343613|Drug|LY3381916|IDO-1 inhibitor administered orally
45452431|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
45625543|NCT03343613|Drug|LY3300054|PD-L1 inhibitor administered IV
45625544|NCT03043287|Biological|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX®)100 to 200 U
45625545|NCT02503241|Procedure|PEEP INCREMENTAL|PEEP was progressively increased by steps of 2 cmH2O every 60 second until the end-expiratory transpulmonary pressure became positive between 0-2 cmH2O.
45625546|NCT02503241|Procedure|PEEP DECREMENTAL|Lung recruitment maneuver (LRM) is a transitory and controlled increase in airway pressure to open collapsed alveoli. LRM is the first step of the PEEP DECREMENTAL method. After LRM, PEEP is systematically decreased, in small decrements, until the best respiratory system mechanics is identified.
45625547|NCT03043443|Drug|Melatonin|Natural health product for sleep problems treatment
45625548|NCT03043443|Drug|Placebo|Lactose containing pills
45625549|NCT02502929|Behavioral|Social Services|
45625550|NCT02502929|Behavioral|Lifestyle|
45625551|NCT02502929|Behavioral|Lifestyle Plus Medication Therapy Management|
45625552|NCT04383795|Drug|Antithyroid Drug|Administration of antithyroid Drug for 6 months
45625553|NCT04429737|Dietary Supplement|clam protein capsules|The prediabetes patients in this arm will receive Clam protein capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
45625554|NCT04429737|Dietary Supplement|Clam peptide plus Chlorella capsules|The prediabetes patients in this arm will receive Clam peptide plus Chlorella capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
45625555|NCT04429737|Dietary Supplement|Placebo|The prediabetes patients in this arm will receive Placebo with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
45625556|NCT03209843|Procedure|Percutaneous recanalization of chronic total occlusion|Percutaneous recanalization of chronic total occlusion followed by immediate systematic coronary optical frequency domain imaging (OFDI) at inclusion. Intra-individual post stenting assessment of reendothelialization with a second coronary angiography with OFDI analysis at 3 months.
45625557|NCT03043131|Drug|Plasmalyte A|Plasma Lyte -A is administered intra operatively to maintain the hemodynamic status of patients
45625558|NCT03043131|Drug|Ringer Lactate|Ringer's lactate is administered intra operatively to maintain the hemodynamic status of patients
45625559|NCT02502851|Device|Rotational Atherectomy|Calcified lesion preparation using rotational atherectomy before implantation of the Orsiro drug eluting stent
45625560|NCT02502851|Device|Cutting/Scoring Balloon|Calcified lesion preparation using cutting/scoring balloons before implantation of the Orsiro drug eluting stent
45767306|NCT05064943|Diagnostic Test|2-minute step test|"The participant stands and counts for 2 minutes. The minimum height to raise the knee is determined for each participant by calculating the midpoint between the patella and the anterior superior iliac spine. They are instructed to complete as many steps as possible during the 2-minute period. A verbal command is given every 30 seconds to encourage performance: You're doing great, keep it up. If the claudication symptom becomes unbearable, the patient can stop during the test, but the time is not stopped. Patients who discontinue testing due to symptoms of claudication are encouraged to return to testing as soon as possible. An evaluator records the number of steps in the right leg."
45452432|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
45452433|NCT01129648|Drug|BCX4208|Adminstered daily for 21 days
45452434|NCT05235698|Procedure|Ophthalmological examinations|Visual acuity, slit lamp examination, eye pressure, retinophotography, indocyanine green retinal angiography, OCT-A( Optical Coherence Tomography- Angiography), adaptive optics, automated visual field
45625561|NCT03209765|Other|WhatsApp reminder|An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
45625562|NCT03209453|Other|family work shop|Children with developmental delays, under regular rehabilitation programs, participate 6 sessions of family work shop The family work shop had 6 families in one course, 2 hours per week, for a total of 6 weeks.
45625563|NCT03047421|Diagnostic Test|Comparison of accuracy of DES-OSA and P-SAP scores|Comparison of accuracy of DES-OSA and P-SAP scores with the result of the PSG (polysomnography)
45625564|NCT04866615|Diagnostic Test|Optvue OCT|Optical coherence tomography
45625565|NCT02502773|Drug|Hydroxethyl starch|
45625566|NCT04866225|Drug|Oral [14C]PF-06865571|Oral radiolabeled PF-06865571
45625567|NCT04866225|Drug|Oral PF-06865571|Oral PF-06865571
45625568|NCT04866225|Drug|IV [14C]PF-06865571|IV radiolabeled PF-06865571
45447110|NCT02103946|Procedure|Paravertebral Block|After skin preparation and sterile draping applied. Target paravertebral space will be located using US guidance. The paravertebral space between the third and fourth thoracic vertebrae will be identified in a parasagittal view approximately 3 cm lateral to midline on the side of surgery. A local anesthetic skin wheal will be raised caudal to the ultrasound transducer. A 17-gauge, Tuohy-tip needle will be inserted through the skin wheal in-plane beneath the ultrasound transducer and directed to the paravertebral space. Normal saline (5 mL) will be injected via the needle to help identify the paravertebral space and observe the pleura being displaced anteriorly. 0.4 ml\kg of 0.25% Bupivacaine with epinephrine, 5 μg/mL, will be slowly injected with gentle aspiration every 3 mL.
45447111|NCT02250742|Other|dry needling|Dry needling uses traditional acupuncture needles without injecting any liquid. Dry needling is based on traditional Western medicine whereby the needle insertion sites are located in known anatomical landmarks such as skeletal muscles, fascia and occasionally joints, tendons and bone/tendon junctions.
45625569|NCT03047187|Diagnostic Test|ACLR|"quadriceps and hamstring isometric muscles test~single hop for distance~IKDC, KOOS, Tampa and ACL-RSI Questionnaires"
45625570|NCT03209297|Other|TMD treatment: physiotherapy and/or occlusal splints|The patient will receive the most appropriate TMD treatment, based on current literature.
45625571|NCT03042897|Dietary Supplement|Dietary Intervention|Undergo DASH diet
45625572|NCT03042897|Behavioral|Exercise Intervention|Undergo in aerobic exercise
45625573|NCT03042897|Other|Laboratory Biomarker Analysis|Correlative studies
45625574|NCT03042897|Other|Quality-of-Life Assessment|Ancillary studies
45625575|NCT02502695|Other|VATS-associated best practices|
45625576|NCT02502539|Procedure|Controlled physical activity|
45625577|NCT02612727|Device|Filtered-sunlight phototherapy|Infants will receive >= four hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using Air Blue 80 window tinting film.
45625578|NCT02612727|Device|Intensive phototherapy|Infants will receive >= four hours per day of intensive phototherapy for 1 to 10 days.
45625579|NCT03209219|Drug|Interferon Alfa-2A|3×10^6 IU， subcutaneous or intramuscular injection, qd for × 4 weeks, and qod thereafter
45625580|NCT03209219|Drug|Cyclosporine Pill|100mg， oral, bid
45625581|NCT04866381|Drug|SHR-6390|SHR-6390
45625582|NCT04866381|Drug|SHR-6390 + Camrelizumab (SHR-1210)|SHR-6390 combined with Camrelizumab (SHR-1210)
45625583|NCT04866381|Drug|Camrelizumab (SHR-1210) + SHR-1020|Camrelizumab (SHR-1210) combined with SHR-1020
45625584|NCT03209141|Diagnostic Test|Diastolic function evaluation|Diastolic function assessed by impedance cardiography (test to be validated) is compared with the assessment by echocardiography (clinical standard)
45625585|NCT04872231|Drug|Voriconazole Inhalation Powder|"PART A (SAD): Voriconazole Inhalation Powder (VIP) will be supplied as one to eight 10 mg capsules. Each capsule contains 10 mg of VIP and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 10-minute period.~SAD subjects will receive a single dose of study medication. Subjects in Cohort 1 will receive 10 mg, Cohort 2: 20 mg, Cohort 3: 40 mg, Cohort 4: 80 mg.~PART B (MAD): Voriconazole Inhalation Powder (VIP) and will be administered with a will be supplied as one to eight 10 mg capsules. Each capsule contains 10 mg of VIP and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 10-minute period.~MAD subjects will receive VIP BID for a total of 13 doses. Subjects in Cohort 1 will receive 10 mg BID, Cohort 2: 20 mg BID, Cohort 3: 40 mg BID, Cohort 4: 80 mg BID."
45625586|NCT04872231|Drug|Placebo|"PART A (SAD): Placebo capsules will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART A will receive a single dose of placebo.~PART B (MAD): Placebo will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART B will receive Placebo BID for a total of 13 doses."
45625587|NCT03044925|Procedure|Remote magnetic navigation|Pulmonary vein isolation and other areas ablation guided by remote magnetic navigation
45625588|NCT03044925|Procedure|Cryoablation|Pulmonary vein isolation and other areas ablation used by cryoballoon
45625589|NCT04861389|Procedure|Arterial access|Arterial access for primary percutaneous coronary intervention in STEMI patients
45625590|NCT04860531|Drug|Lumbar Facet Joints intra-articular injection with Platelet Rich Plasma|Floroscopy guided by C-arm Intraarticular injection in Lumbar facet Joints
45625591|NCT04860531|Drug|Lumbar Facet Joints intra-articular injection with a mixture of 0.5% lidocaine and 5mg/ml of betamethasone|Lumbar Facet Joints intra-articular injection
45625592|NCT04384575|Diagnostic Test|blind spots|missed part during map the entire stomach through endoscopy
45767307|NCT03380572|Device|Senhance Assisted Cholecystectomy|Cholecystectomy performed using Senhance surgical robotic system
45767308|NCT03380572|Procedure|Laparoscopic Cholecystectomy|Standard laparoscopic cholecystectomy
45804269|NCT01805271|Drug|Placebo|(5 or 10 mg/day, i.e. 1 or 2 tablets/day)
45767309|NCT01079143|Drug|Certican®|Certican® was supplied to the participating centers by Novartis for the whole duration of the study in the form of tablets containing 0.75, 0.5 and 0.25 mg and packaged in blister packs.
45767310|NCT01079143|Drug|Neoral|Neoral® was also supplied to participating centers for the entire duration of the study in the form of soft capsules of 10 mg, 25 mg, 50 mg and 100 mg, and packaged in blister packs.
45767311|NCT01079143|Drug|Myfortic|"Myfortic ® was supplied to the participating centers for the duration of the study in the form of 180 and 360 mg gastro-resistant, film-coated tablets. Myfortic® treatment was provided to patients preoperatively or within 24 hours post-transplantation according to the practices of the center. The starting dose was generally 1,440 mg/day, in 2 daily oral fractions, administered at 12 hour intervals up to randomization. Depending on the practices of the center and for the first 6 weeks post-transplantation, a maximum daily dose of 2160 mg of Myfortic® could be administered. In the Neoral® group, the daily dose of 1440 mg was maintained throughout the study.~In the Certican® group, the dose was halved (i.e. 720 mg/day) on introducing Certican® and maintained at 720 mg/day until the end of the study.~An increase in the daily dose of Myfortic® (in the Certican® group) was not authorized unless this was a temporary increase that did not exceed a period of 14 consecutive days."
45767312|NCT01079143|Drug|Simulect®|The administration of Simulect® was part of the standard immunosuppressant therapy. This induction therapy was provided to patients in the form of commercial ampoules each containing 20 mg. Simulect® was administered to each patient at the dose of 20 mg on D0 and D4 post-transplantation.
45767313|NCT01079143|Drug|Corticosteroids|An intravenous steroid treatment could be administered peri or intraoperatively according to local practice at each center. Oral steroid treatment was quickly introduced (in the week following transplantation) at a daily dose of 20 mg and was then reduced and continued throughout the study at a minimum dose of 5 mg/day.
45767314|NCT03381742|Drug|Ticagrelor|ticagrelor 45 mg twice daily for 5 consecutive days at least.
45625593|NCT01594827|Drug|Inhaled Vancomycin|On Days 1-28, subjects will receive nebulized Vancomycin. This will be supplied as a 250 mg solution to be nebulized two times a day for 28 days in 5cc sterile water. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
45625594|NCT01594827|Drug|Placebo (Sterile Water)|On Days 1-28, subjects will receive 5cc of a nebulized Placebo (Sterile water) twice a day. This is a taste (quinine 0.1mg/mL) matched nebulized placebo (sterile water). Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
45625595|NCT01594827|Drug|Rifampin|"Oral Rifampin by mouth for 28 days~>45 kg: 600 mg by mouth daily~35-45 kg : 450 mg by mouth daily~25-34.9 kg: 300 mg by mouth daily"
45625596|NCT01594827|Drug|Trimethoprim/Sulfamethoxazole (TMP/SMX)|"Oral trimethoprim/sulfamethoxazole (DS-160/800)~>45 kg: two DS tablets twice a day by mouth (320/1600)~25-45 kg: one DS tablet twice a day by mouth (160/800)"
45625597|NCT01594827|Drug|Doxycycline|"If sulfa intolerant or TMP/SMX Resistant, use instead oral doxycycline~>45 kg: 100 mg by mouth twice a day~35-45 kg : 75 mg by mouth twice a day iii. 25-34.9 kg: 50 mg by mouth twice a day"
45625598|NCT01594827|Drug|Mupirocin Intranasal Creme|Mupirocin 2% intranasal creme: half of single use tube applied into each nostril twice a day for 5 days.
45625599|NCT01594827|Drug|4% chlorhexidine gluconate liquid skin cleanser|Hibiclens 15cc liquid skin cleanser packets (4% chlorhexidine gluconate): use three packets once weekly for four weeks in the shower from the neck to toes, with attention on the axilla, groin, and buttocks.
45767315|NCT03381742|Drug|ticagrelor|ticagrelor 90 mg once daily for 5 consecutive days at least.
45767316|NCT03381742|Drug|ticagrelor|ticagrelor 90 mg twice daily for 5 consecutive days at least.
45767317|NCT03381742|Drug|clopidogrel|clopidogrel 75 mg once daily for 5 consecutive days at least.
45767318|NCT01079299|Device|Intermittent, gradient, pneumatic compression device|lymphedema pump provides external compression in a segmental,gradient fashion
45767319|NCT04735042|Drug|Empagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill|association between SGLT2-inhibitor and DPP4-inhibitor
45452435|NCT05235698|Procedure|GlycoCheck|"Evaluation of the glycocalyx of sublingual capillaries with the GlycoCheck :~A sidestream dark field camera, coupled with GlycoCheck™ software is used to visualize the patient's sublingual microvascularization"
45452436|NCT05239988|Other|no experimental intervention|There will not be any experimental intervention. The study will be conducted according with normal clinical practice
45625600|NCT04858893|Diagnostic Test|CoMDA associated with Neural Net 91 classificator|
45625601|NCT03045003|Behavioral|RESIL Intervention|Interventions tested in this study are the following: i) educational sessions with oncologists and nurses, ii) direct, electronic feed-back of resilience and needs screening in a monitoring sheet including intervention propositions and iii) consultation provided by a clinical nurse specialist to patients (in intervention B only) Interventions have been developed based on previous studies on the efficacy of screening of patient reported outcomes and direct feed-back to health care professionals and on previous studies on interventions to enhance resilience in nursing or psycho-oncology with proven efficacy. Interventions provided in the monitoring sheet have been validated by experienced Swiss oncology nurses, oncologists and psycho-oncologists.
45767320|NCT04735042|Drug|Empagliflozin or Dapagliflozin Pill|SGLT2-inhibitor: diabetic oral drug with diuretic properties.
45767321|NCT04681339|Other|Antibiotic treatment|Antibiotic treatment
45767322|NCT04681339|Other|No antibiotic treatment|No antibiotic treatment
45767323|NCT04734964|Behavioral|exercise training|Exercise training session for 45 minutes.
45767324|NCT04636801|Drug|Experimental: CHF6001 1600µg|CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg).
45767325|NCT04636801|Drug|Experimental: CHF6001 3200µg|CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg).
45767326|NCT04636801|Drug|Placebo|CHF6001 matching placebo, 2 inhalations bid.
45767327|NCT00376012|Drug|Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 4 months.
45804270|NCT03427931|Other|Continuous Glucose Monitor (CGM)|Study subjects will collect Continuous Glucose Monitor data for a minimum of 28 days but may continue for up to 3 months.
45767328|NCT00376012|Drug|Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 7 months.
45625602|NCT04849845|Combination Product|Afrezza Dose 1|The first dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue (RAA) insulin that the subject would normally take for the standardized meal, converted according to the guidelines provided in the current Afrezza U.S. prescribing information.
45767329|NCT04564807|Behavioral|Web-Based Insomnia Education Program|"Participants will be given access to a web-based program on sleep education to read at their own pace during the 9-week intervention period. The program content overlaps with SHUTi on the following topics: insomnia symptoms, impacts, and causes, basic sleep improvement strategies, and when to see a doctor. The information is akin to that found on WebMD or National Sleep Foundation website. Unlike the SHUTi program, the information is fixed, accessible immediately (no week-to-week information unlocking) and there are no customized bedtime or wake-time suggestions based on sleep diary data."
45767330|NCT04564807|Behavioral|SHUTi Intervention|"Sleep Healthy Using the Internet (SHUTi) is a well-validated version of e-CBT-I comprised of 6 weekly educational modules and daily sleep diaries. Participants will have 9 weeks to complete 6 once-weekly educational cores. Cores consist of: insomnia overview, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention, and last approximately 45 minutes each. Participants will receive weekly objectives, as well as review and feedback on the previous core's assignments and sleep diary data, new material, assignments, and a summary. These features are supplemented with interactive features (i.e., personalized goal-setting, video vignettes). Participants receive daily emails prompting them to complete the 11-item sleep and alcohol use diary daily during the intervention."
45767331|NCT00376090|Biological|MVA-CMDR|10^7 PFU IM, 1.0 mL
45767332|NCT00376090|Biological|Placebo|1.0 mL IM
45767333|NCT00376090|Biological|MVA-CMDR|10^6 PFU ID, 0.1 mL
45767334|NCT00376090|Biological|Placebo|0.1 mL ID
45625603|NCT04849845|Combination Product|Afrezza Dose 2|The second dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue that the subject would normally take for the standardized meal, converted by multiplying their RAA dose by 2 and rounding down to the nearest Afrezza cartridge size.
45625604|NCT03042585|Radiation|Total body irradiation|When radiation is given in a way to cover the whole body, it is called total body irradiation.
45767335|NCT00376090|Biological|MVA-CMDR|10^8 PFU IM, 1.0 mL
45767336|NCT00376090|Biological|MVA-CMDR|10^7 PFD ID, 0.1 mL
45625605|NCT04429191|Biological|Humanized anti-CD117 Monoclonal Antibody (JSP191)|Procedure: single intravenous infusion of JSP191 antibody
45625606|NCT02610231|Drug|Istradefylline 20 mg or 40 mg|Istradefylline 20 or 40 mg
45625607|NCT03042741|Biological|atherosclerosis vaccine|Atherosclerosis vaccine, V6, formulated as an oral pill made from from pooled antigens derived from adipose tissue
45625608|NCT03042741|Biological|Placebo pills|Half of the patients will be randomly assigned to receive placebo pill
45625609|NCT04850157|Drug|Tislelizumab|200mg, Q3W
45625610|NCT04850157|Radiation|IMRT|4 Gy* 5 Fx,5Fx/Week
45625611|NCT04849533|Drug|Belatacept|belatacept with everolimus is experimental regimen and it is compared to the labeled regimen of belatacept with mycophenolate with steroids for prevention of rejection in renal transplant recipients
45625612|NCT04849533|Drug|Everolimus|belatacept with everolimus is experimental regimen and it is compared to the labeled regimen of belatacept with mycophenolate with steroids for prevention of rejection in renal transplant recipients
45767337|NCT04521439|Diagnostic Test|18F-florbetapir PET+MRSI|PET and MRS quantitative parameters in MS lesions are simultaneously analyzed using hybrid PET/MR for obtaining demyelination and neuronal damage information.
46069665|NCT04255472|Behavioral|WHO Caregiver skills training (CST) program|Caregivers are provided with tangible strategies to appropriately respond to their children's emotional regulation, engagement, and communication. Further, the program focuses on helping caregivers to develop their children's communication and adaptive skills while reducing challenging behavior by focusing on identifying the function of the behavior and learning to teach developmentally appropriate replacement skills. The WHO CST program includes nine group sessions delivered at a community venue (e.g., BHU, school, home) and three home visits: the first at entry prior to session 1, the second after session 4, and the third after the final group session. Training for program facilitators will be included prior to the delivery of the intervention.
45625613|NCT04849533|Drug|mycophenolate mofetil|belatacept with mycophenolate is approved regimen for prevention of rejection
45767338|NCT04515667|Behavioral|Mindfulness|Participants will view a brief mindfulness video
45767339|NCT04515667|Behavioral|Video|Participants will view a control video
45767340|NCT03530098|Device|BoneAgeModel|BoneAgeModel is an Artificial Intelligence tool that takes in a hand radiograph and gender, and outputs the skeletal (bone) age. The intervention involves using this tool as a factor in the clinical decision making process of the participating radiologists. The radiologist's decision will be considered final.
45912759|NCT02013089|Drug|Vandetanib|Vandetanib 300 mg orally once daily for patients with RET gene fusion.
45912760|NCT02014103|Drug|Tacrolimus|Administration of each formulation will be determined by sequence.
45452437|NCT04438720|Drug|Extended Release Nifedipine Tablets 30 mg|The subjects randomly received single oral administration of extended release nifedipine tablets 30 mg.
45625614|NCT04849533|Drug|corticosteroids|belatacept with chronic steroids is approved regimen for prevention of rejection
45625615|NCT04849533|Drug|rabbit antithymocyte globulin|rabbit antithymocyte globulin induction for prevention of rejection
45625616|NCT03042663|Procedure|USG stellate ganglion block|After verification of proper needle position and aspiration to exclude vascular spread, 1mL of the injectate will be injected to see proper tissue spread as well as patient response. After one minute the remaining volume will be injected under real time ultrasound imaging.
45625617|NCT03040635|Drug|Risdiplam|Single oral doses of Risdiplam will be administered on Day 1.
45625618|NCT03040635|Drug|Placebo|Single oral doses of Risdiplam matching placebo will be administered on Day 1.
45625619|NCT02178358|Drug|LY2157299|Administered orally
45625620|NCT02178358|Drug|Sorafenib|Administered orally
45625621|NCT02178358|Drug|Placebo|Administered orally
45767341|NCT03264235|Device|Keeogo|"Keeogo is a computer-controlled lower extremity motorized orthosis worn over the user's hips and legs. The controller box contains sensors that supply information about the kinematics and the kinetics of the user's lower extremities and includes software that recognizes the user's mobility intentions. The system is powered by a lithium-polymer battery. The leg brace assembly is mainly comprised of the actuator, the electronic boards, hip joint, and soft goods (cuffs, belts) for affixing the assembly to the user's legs. The waist belt comes in various sizes adapted to each wearer, and adds additional support of the device on the user.~Keeogo does not initiate any movement but waits for the user's lead. Once the user makes the first move, Keeogo assists according to the activity. The individual must be able to initiate and terminate steps."
45625622|NCT03042507|Behavioral|Comprehensive Behavioral Intervention for Tics (CBIT)|The existing CBIT protocol includes a functional assessment procedure designed to identify relevant contextual variables (both antecedent and consequent) impacting tic expression and guide the development of an individualized behavioral program to neutralize these contextual influences in the service of tic reduction and psychoeducational component. Given the central role that negative social reactions typically play in tic exacerbation and maintenance, psychoeducation about tics is systematically provided to parents, siblings, and other caretakers and prominent individuals in the child's life. The other primary CBIT component, Habit Reversal Training (HRT), is used to weaken or eliminate the negative reinforcement cycle created by tic-contingent reduction in premonitory urge.
46069666|NCT04255472|Behavioral|Treatment as usual|WHO CST will be compared with TAU. TAU in primary healthcare centers for childhood developmental disorders and delays usually consists of no treatment, or a range of alternate treatment regimes, such as multi-vitamin syrups and tablets. Evidence-based mental health care is currently not available in primary healthcare centers. A complete record of services availed by the trial participants at tertiary mental healthcare center will be maintained by using an adapted Client Services Receipt Inventory (CSRI) for children with developmental disorders and delays at baseline and end point.
45625623|NCT04849689|Behavioral|Whole-food, plant-based lifestyle|"The WFPB lifestyle program included:~Nutrition/plant-based food (energy intake: at least 90% of whole-food, plant-based diet and ≤ 10% of energy intake from plant-based meal replacements (PBMR) and dietary supplements (e.g., vitamin B12, D, and EPA and DHA omega-3 fatty acids).~Physical activity (habitual; organized and other).~Support system (lectures, workshops and individual nutrition counselling, grocery shopping assistance, cooking classes, regular measurements body composition, food logging, regular medical monitoring)."
45625624|NCT04849767|Other|Questionnaire|Questionnaire about socio-behavioral items and conditions of vulnerability. interview with female to male transgender person will be about life conditions, trajectory of the medical transition from female to male and actual medical following of the transition, migration trajectory and condition of HIV acquisition.
46069667|NCT02620995|Drug|sildenafil citrate|the hypertensive patients with erectile dysfunction will be treated with sildenafil citrate (100 mg daily) or placebo (crossover design)
45625625|NCT01598896|Drug|Dronabinol|Dronabinol titrated to 5 mg three times daily
45625626|NCT01598896|Drug|Clonidine|Clonidine 0.1 mg twice daily
45625627|NCT01598896|Drug|Placebo|One placebo capsule by mouth twice daily
45625628|NCT03042195|Other|Parenteral Nutrition|Supplementary parenteral nutrition to achieve 100% coverage of estimated needs
45625629|NCT03042351|Device|Magic Kegel app|Pelvic floor muscles recover exercises with a specific device and Magic Kegel App
46069668|NCT02620995|Other|comparator group|Normotensive individuals age-matched to the hypertensive patients will receive only a single dose of sildenafil citrate (100 mg) - acute protocol. Penile and systemic microvascular function will be evaluated before and one hour after sildenafil administration.
46069669|NCT05313074|Biological|CoronaVac vaccine|An inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.
46069670|NCT04135209|Diagnostic Test|Optical coherence tomography angiography OCTA|Macular scanning using regular structural OCT as well as microvasculature analysis using OCTA
45625630|NCT01598662|Device|Mirena (levonorgestrel-releasing intrauterine system)|The Mirena IUD is a levonorgestrel-releasing IUD which contains 52 mg levonorgestrel total and releases 20 mcg of hormone daily.
45452438|NCT04438720|Drug|Extended Release Nifedipine Tablets 30 mg (Adalat® GITS)|The subjects randomly received single oral administration of extended release nifedipine tablets 30 mg.
45625631|NCT04849065|Drug|MNC (Mononuclear cells)|"Intramuscular infusion of autologous BM CMN into the TA muscle of one of the lower limbs (experimental side)~Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)"
45625632|NCT04849065|Drug|Placebo / Saline|- Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)
45625633|NCT01629706|Device|Balafilcon A contact lens|Commercially marketed silicone hydrogel contact lens
45625634|NCT01629706|Device|Habitual contact lenses|Commercially marketed silicone hydrogel contact lenses as prescribed by eye care practitioner, brand and power
45625635|NCT01629706|Device|Renu multi-purpose solution|Commercially marketed solution for use in removing protein, cleaning, conditioning, and disinfecting contact lenses.
45625636|NCT01629706|Device|ClearCare|Commercially marketed hydrogen peroxide system for cleaning and disinfecting contact lenses
45625637|NCT01629706|Device|Habitual lens care|Lens care per habitual use
45625638|NCT03042429|Drug|Cycles N8, N5 and N6|two chemotherapy cycles N8 followed by standard arm therapy
45625639|NCT03042429|Drug|Cycles N5 and N6|Standard arm six chemotherapy cycles (3xN5 and 3x N6) followed by myeloablative therapy with stem cell support and isotretinoin
46069671|NCT04252898|Behavioral|Front-of-pack nutrition label Nutri-Score|The intervention consists of displaying the Nutri-Score on dishes and pre-packed foods.
45625640|NCT03040557|Device|Flexible footwear|- Arm Flexible footwear: The intervention will be with flexible shoes in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
45625641|NCT03040557|Device|Orthopedic insole|- Arm Orthopedic insole: The intervention will be with orthopedic insole in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
45625642|NCT02153086|Drug|Ramelteon|Ramelteon tablets 8 mg
45625643|NCT04849299|Drug|AT-527 550 mg + cyclosporine|550 mg AT-527 alone on Day 1 and 550 mg AT-527 plus 600 mg cyclosporine administered simultaneously on Day 7 Other Names: AT-527 is also known as R07496998
45625644|NCT04849299|Drug|AT-527 550 mg + cyclosporine|550 mg AT-527 alone on Day 1 and 550 mg AT-527 plus 600 mg cyclosporine administered on Day 7 (with dosing offset by 2 hrs) Other Names: AT-527 is also known as R07496998
45625645|NCT02117050|Drug|Rebif®|Rebif® will be administered subcutaneously three times a week at a dose of 8.8 to 44 microgram (mcg) in initial titration schedule (5 weeks), followed by Rebif® 44 mcg subcutaneously three times a week by using Rebif® Rebidose® auto-injector device till Week 24.
45625646|NCT03042273|Dietary Supplement|High Strength Cranberry|Softgel capsule
45625647|NCT03042273|Dietary Supplement|Placebo|Soy oil to match High Strength Cranberry Softgel Capsule
45625648|NCT04858659|Drug|PK101|1 tablet at each time, 2 times a day
45625649|NCT04858659|Drug|PK101-002|1 tablet at each time, 2 times a day
45625650|NCT04858659|Drug|PK101 placebo|1 tablet at each time, 2 times a day
45625651|NCT04858659|Drug|PK101-002 placebo|1 tablet at each time, 2 times a day
45625652|NCT04848987|Procedure|Etching|Etching enamel surface using phosphoric acid
45625653|NCT04848441|Other|The COVID-19 vaccines BNT162b2, mRNA-1273 and ChAdOx1|The purpose of the study is to compare the effects of BNT162b2, mRNA-1273 and ChAdOx1 with respect to incident COVID-19 infection of different severities.
45625654|NCT04858581|Diagnostic Test|Virological and serological tests|Survey, RT-PCR test and blood test
45625655|NCT04859751|Drug|VB4-845 Injection|Intravesical administration of VB4-845 Injection.
45625656|NCT04860063|Drug|Berberine|Participants randomly assigned to the intervention group will be provided with Berberine 500 mg administrated per os three times a day for six months
45625657|NCT04860063|Drug|Placebo|Participants randomly assigned to the Placebo group will be provided with placebo administrated per os three times a day for six months
45625658|NCT04860219|Dietary Supplement|Lactoferrin|7 successive days treatment of Lactoferrin started within day 0 of COVID-19 diagnosis by RT-PCR
45625659|NCT04848207|Device|Digital impression technique|3D printed generic Scan bodies with unified shape and length replacing the traditional transfer copings will be press fitted on the trans-mucosal abutments and pickup cylinders that are screwed on the implants to capture their position and intra-oral scanning will be done.
45625660|NCT04848207|Other|Open tray impression technique|"Transfer copings will be screwed to the multiunit abutments on the existing implants, and splinted together using pre-cured printed resin splinting framework that will be fixed to the copings using flowable composite .~A one step impression technique using putty and light addition silicon will be made, where light impression material will be injected all around transfer copings and putty silicon will be loaded in tray and then will be seated intra-orally making sure to fully expose the screws of transfer copings through the impression material."
45625661|NCT02728895|Drug|Vedolizumab|Vedolizumab Injection.
45625662|NCT04848363|Procedure|Quadratus lumborum block|QL block will be used for perioperative anesthesia. The blockade will be performed bilaterally by levobupivacaine (20ml) at concentration 0.25%.
45625663|NCT04847895|Drug|Lucentis|There is no treatment allocation. Patients administered Lucentis by prescription that have started before inclusion of the patient into the study will be enrolled.
45625664|NCT02502227|Behavioral|Mindfulness|Mindfulness training practices aim to foster attention and acceptance toward one's present moment experience. Mindfulness consists of two components-- (1) deploying attention to monitor one's moment-to-moment experience, and (2) fostering an attitude of acceptance toward one's moment-to-moment experience
45625665|NCT04496531|Device|Portable Neuromodulation Stimulator|
45625666|NCT02502383|Behavioral|ACTION PAC|Adolescents enrolled in ACTION PAC will meet with SBHC providers. SBHC providers will use Motivational Interviewing to motivate students to adopt strategies for improving nutrition and increasing physical activity. All participants will receive annual BMI results discussion with providers. Overweight/Obese adolescents will meet with providers for 16 sessions over 2 years.
45625667|NCT02502383|Behavioral|Comparison|Annual BMI results will not be discussed with participants in comparison schools; however, a letter containing BMI results and obesity prevention recommendations will be sent to parent/guardians.
45625668|NCT03208829|Other|Rehabilitation exercises|Patients in group 1 will participate in a physical exercise protocol supervised by a physiotherapist. The sessions will focus on the rehabilitation of muscle strength and the exercises will be performed with increased external load.
45625669|NCT03208829|Other|Postoperative guidance|Group 2 will receive only guidelines regarding postoperative care.
45625670|NCT04857957|Drug|Oral dose CNTX-6016 or oral dose Placebo|CNTX-6016 or Placebo
45625671|NCT03208595|Diagnostic Test|Endometrial sampling of a Typical Embryo transfer catheter|no intervention no additional change from unit protocol
45625672|NCT02502305|Behavioral|liveonline course|physical activity and healthy diet are targeted and should be enhanced, health literacy (HL) in older people should be improved
46069672|NCT02620839|Drug|Alpelisib|Given PO
46069673|NCT02620839|Drug|Cisplatin|Given IV
46069674|NCT02620605|Drug|Late Cabergoline 0.5mg|Cabergoline 0.5mg will be administrated once daily at day of HCG trigger and continued for 8days
46069675|NCT02620605|Drug|Early Cabergoline 0.5mg|Cabergoline 0.5mg will be administrated once daily when E2 is more than 4000pg/ml and /or more than 18 follicles of 11mm diameter or more are encountered at any day of the controlled ovarian hyper-stimulation and before HCG trigger to be continued for 8days after HCG trigger.
45625673|NCT04429269|Diagnostic Test|mammography and ultrasound screening|Patients screened by both mammography and ultrasound.
45625674|NCT02450513|Drug|Adalimumab|160 mg at week 0, 80 mg at week 2 and 40 mg every two weeks onwards
45625675|NCT04859283|Drug|Dexmedetomidine|Intranasal dexmedetomidine 1µg/kg will be administered 30min before the induction of anesthesia using a LMA MAD Nasal-device
45625676|NCT04859283|Drug|Placebo|Intranasal saline (10 µL/kg) will be administered 30 min before the induction of anesthesia using a LMA MAD NasalTM -device. The dose is euvolemic to 1 µg/mL dexmedetomidine.
45625677|NCT03208751|Behavioral|Exercise training|"Exercise intervention was divided into 3 phases:~Phase 1: 6 weeks of moderate continuous training (MCT) 20 to 40 minutes at intensity of 60% of VO2peak, 3 times/week Phase 2: 6 weeks of moderate intensity interval training (MIIT) 30-40 min, intensity 60 to 80% of VO2peak, twice weekly plus at least once weekly MCT home based training Phase 3 (after performing new exercise testing to adapt training intensities): 12 weeks of MIIT 40 min once/week, intensity 60-80/85% of VO2peak, plus at least twice weekly home based MCT. From phase 2, supervised sessions included resistance training of at least 3 muscle groups, 3x15 repetitions at moderate intensity (Borg 12-14).~Nutritional counseling is offered up to 4 times in 6 months on an individual basis."
45625678|NCT03208517|Other|Improving Wellbeing and Health for People with Dementia (WHELD) e-learning training programme|The e-learning WHELD intervention The optimised e-learning programme will consist of five 25-minute interactive online modules based on a recently completed RCT of an in person training programme (WHELD), combining the most effective elements of existing approaches to create a comprehensive but practical staff training intervention. Based on a factorial study and qualitative evaluation, WHELD combines: person-centred care, person-centred activities and interactions, and updated knowledge regarding optimal use of psychotropic medications.
45625679|NCT04857801|Drug|Teduglutide|effect of teduglutide on intestinal rehabilitation
45912761|NCT02014155|Other|Inspiratory Muscle Training|Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects.
45625680|NCT03343535|Device|OCS Lung Preservation|OCS Lung Preservation
45625681|NCT03343457|Behavioral|Cognitive therapy|
45625682|NCT03208439|Device|lower-limb cycling system|patients will receive 30-minute cycling exercise
45625683|NCT04857879|Other|GLA:D program (Good Life with osteoArthritis in Denmark)|GLA:D includes disease-specific education combined with neuromuscular exercises. Control interventions include disease-specific education combined with exercises to optimize movement and strength of the affected knee.
45625684|NCT03208361|Drug|Penicillin V|
45912762|NCT02014155|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard deflation (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
45625685|NCT03208361|Drug|Amoxicillin|
45625686|NCT04847115|Procedure|Operative|Intramedullary screw fixation
45625687|NCT04847115|Other|Walking boot orthosis|Non-operative treatment with walking boot orthosis for six weeks. The non-operative study arm will use walking boot orthosis only. The operative study arm will use walking boot orthosis as adjuvant treatment.
45625688|NCT02501915|Device|Kinesio Taping|Group A received the application of KT from muscle Origin to Insertion and group B Insertion to Origin, with both groups taped the nondominant limb and the dominant limb was used as control group. Diferent tensions will be applied with the tape to see its possible different affect in the outcomes.
45625689|NCT03041961|Dietary Supplement|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
45625690|NCT03041961|Dietary Supplement|Aronia full spectrum|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
45625691|NCT03041961|Dietary Supplement|Aronia extract|Powdered extract obtained from aronia berries (Aronia melanocarpa)
45625692|NCT03343379|Other|Core stability tests|A test battery comprised of field tests to evaluate core stability
45625693|NCT04857567|Behavioral|TSC program (Three Self-Commitment program)|"Self-Competence program~- A program for residents who experience exhaustion due to the spirit of volunteerism and high expectations of therapeutic competency in the case of experiencing a decrease in personal achievement.~Self-Care program~- A program to help individuals who experience dehumanization due to emotional suppression and develop exhaustion in the process of suppressing emotions to protect themselves from excessive feelings of compassion experienced in the medical scene~Self-Compassion program - A program for residents who experience emotional burnout and exhaustion due to pressure of failure because medical professionals should be competent and excellent"
45625694|NCT02501837|Drug|Syntocinon-Spray|Intranasal administration of 24 IU Oxytocin
46069676|NCT00696891|Biological|HBV-MPL vaccine|3-dose intramuscular injection
46069677|NCT00696891|Biological|Engerix™-B|3-dose intramuscular injection
46069678|NCT00917852|Device|Gore Conformable TAG Thoracic Endoprosthesis|Endovascular stent graft
46069679|NCT02620449|Other|Diet|Participants will be fed a low-additive diet as the primary intervention
45625695|NCT04859361|Drug|Aldara 5% Topical Cream|5% Imiquimod cream (1 sachet) will be administered via menstrual cup, before going to sleep, 3 times per week for 16 weeks. Menstrual cup will be inserted in the vagina for a duration of 6-8 hours. In case of severe side effects applications can be reduced to twice per week and if side effects are persistent, to once per week. For maximum control of cervical disease, control colposcopy with a PAP smear and a punch biopsy will be scheduled at 10 weeks to rule out progression, and at 20 weeks after treatment initiation to evaluate treatment success. At 20 weeks, biopsies will be performed at the locations where lesions were previously present, and if there are any new lesions present, additional biopsies will be performed. In case of disease progression or persistence, treatment with LLETZ will be offered.
45625696|NCT04859361|Procedure|LLETZ|LLETZ will be performed in an outpatient setting with local anesthesia, using KLS Martin Maxium with loop devices ranging from 10 mm to 20 mm in size. The excision will be performed using monopolar current with a cut frequency set to 100-150 W. Treatment success will be evaluated in accordance with our national guidelines 24 weeks after the procedure using a PAP smear with or without a punch biopsy.
46069680|NCT00976391|Biological|albiglutide + insulin glargine|albiglutide in combination with insulin glargine
45625697|NCT03208205|Procedure|vitrectomy|Complete 23G PPV with scleral indentation was performed using Constellation system. Posterior vitreous detachment was induced very carefully by the cutter probe using aspiration. The peripheral vitreous was removed in all eyes with 360° of the vitreous base shaved under scleral indentation. After complete retinal attachment was achieved, endolaser photocoagulation was applied around the retinal break(s) as three to four rows of burns or/and cryopexy under HPFCL. Then a HPFCL/air/5000cst silicone oil exchange was performed. In one eye only HPFCL/air exchange was performed. Sclerotomies were sutured when needed with Vicryl 8.0 sutures.
45767342|NCT03264235|Other|Traditional Stair Training|Individuals will participate in traditional stair training physical therapy for the same duration of time as Group 1.
45767343|NCT03386110|Behavioral|Couples Health Project (CHP)|The CHP intervention focuses on addresses drug use and HIV transmission risk by enhancing dyadic communication skills and motivation to work towards shared health goals. The last session of the CHP intervention consists of a Couples HIV Testing and Counseling (CHTC) session.
45625698|NCT04840485|Drug|SHR-1314|SHR-1314 high dose
45767344|NCT03386110|Behavioral|Education|The Education intervention consists of a 3-session health education intervention that addresses sexual risk and substance use through a lecture and question and answer format with a male couple. Additionally, the last session of the education intervention consists of a Couples HIV Testing and Counseling (CHTC) session.
45767345|NCT03205657|Procedure|auto transplant followed by allo transplant|patients who got MAC conditioning with auto SCT followed by RIC followed by alloSCT for mature B-NHL
45767346|NCT01082575|Device|Oxygen Monitoring|No intervention
45767347|NCT03578926|Device|fanfilcon A toric lens|contact lens
45625699|NCT04840485|Drug|SHR-1314|SHR-1314 low-dose
45625700|NCT04840485|Drug|Placebo|Placebo
45767348|NCT03578926|Device|senofilcon A toric lens|contact lens
45767349|NCT03172273|Procedure|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
45767350|NCT03172273|Procedure|paracentesis|paracentasis plus albumine invision
45767351|NCT01083199|Device|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
45767352|NCT03388294|Behavioral|Parents and Infants Engaged|A novel in-home parent coaching intervention addressing transactions between pre-linguistic communication and sensory reactivity in infants at-risk for autism and other NDs on the one hand, and parent responses to infant cues on the other hand, using live coaching and video feedback methods.
45767353|NCT02171611|Drug|Dabigatran etexilate pellets|
45912763|NCT02014168|Biological|Viroflu® and MVA-NP+M1|"2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.~MVA-NP+M1 manufactured by by IDT Biologika GmbH, Germany. Each vial of MVA-NP+M1 contains 700 microlitres volume at a concentration of 1.3 x108 pfu/ml in 10mM Tris buffer. The dose of MVA-NP+M1 to be used in this study will be 1.5 x108 pfu."
45625701|NCT03207659|Procedure|Basketing in RIRS|Treament of renal stones by fragmentation of stone under direct vision through a flexible ureteroscope and then actively extracting them using a basket
45625702|NCT03207659|Procedure|Dusting in RIRS|Treament of renal stones by dusting the stone under direct vision through a scope and then leaving them to pass spontaneously
45767354|NCT02171611|Drug|Dabigatran etexilate powder|
45767355|NCT02171611|Drug|Dabigatran etexilate capsule|
45767356|NCT03389854|Device|RestoreX PTT - randomized and open label|Penile traction therapy in the straight and bent positions
45767357|NCT03389854|Device|RestoreX PTT - open label phase only|Penile traction therapy in the straight and bent positions
45767358|NCT01083667|Drug|Pyrimethamine|Open Label, dose escalating,
45767359|NCT01083901|Behavioral|Resistance training|high intensity progressive resistance exercise training
45767360|NCT03533374|Diagnostic Test|Electroencephalogram (EEG) and visual evaluation|Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians).
45767361|NCT01083979|Drug|Liposomes|Intravesical instillation
45767362|NCT03585790|Device|Contact lens with Multifocal Optics|This contact lens has optics to aid the accommodative and convergence systems
45767363|NCT03585790|Device|Contact lens with Single Vision Optics|This contact lens has standard single vision optics
45767364|NCT00942305|Drug|Brincidofovir|Subjects received their first dose of study drug of brincidofovir (BCV) within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.
45767365|NCT00942305|Drug|Placebo|"Subjects received their first dose of study drug within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.~Matching placebo administered for each cohort."
45767366|NCT01084759|Drug|Testosterone injection|Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy). This route and dose of testosterone was selected based on data demonstrating that it produces an initial supraphysiologic serum level of testosterone (i.e. > 3-5 times normal level) with eugonadal levels achieved at the end of two weeks.
45767367|NCT01084759|Drug|Etoposide|On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days. This dose was selected based on Phase II studies of the combination of oral estramustine and oral etoposide. In these trials, myelosuppression was observed when etoposide was given for 21 days out of a 28 day cycle. Therefore, to minimize toxicity, in this study etoposide will be administered for 14 days of a 28 day cycle.
45767368|NCT03012997|Other|Fraction of inspired oxygen 40%|
45767369|NCT03012997|Other|Fraction of inspired oxygen 100%|
45767370|NCT01110187|Drug|lacosamide|200 mg IV over 60 minutes; these patients will then be started on a maintenance dose 100 mg, IV BID as prophylaxis administered as per pharmacy protocol consistent with acceptable standards of care for 7 days. The Lacosamide dose can be adjusted as needed if seizures occur for therapeutic effect up to 200 mg bid (400 mg/d) as a maximum dose.
45912764|NCT02014168|Biological|Viroflu® and saline placebo|"2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.~0.9% saline placebo."
45625703|NCT04846725|Other|Data collection|"Collect in medical records :~Filter's retrieval rate~Complications of vena cava filters~Predictive factors of attempted inferior vena cava filters retrieval: age, the distance between the patient's home and the hospital, the indication or not given by the therapeutic medicine department, patients referred by external structures, patients whose filter was installed during the medical on-call period, the absence of a written request for filter placement, the presence of active neoplasia at the time of filter placement, a peri-surgical context."
45625704|NCT03207971|Procedure|Root coverage treatment with subepithelial connective tissue graft|Periodontal plastic surgery aiming root coverage by palatal tissue graft removed from an area with predominance of lamina propria and predominance of submucosa.
45625705|NCT03038841|Device|Mobile Health|Patients discharged from hospital will be equipped with a tracking bracelet and a smart phone
45625706|NCT04496141|Diagnostic Test|SARS-CoV-2 antibody immunoassays|Different commercial SARS-CoV-2 antibody immunoassays
45625707|NCT03039075|Drug|Metformin SR Tablet|Metformin SR Tablet made in Conquer pharmaceutical co., LTD
45625708|NCT03207893|Behavioral|GEM lifestyle modification & continuous glucose monitoring|Four treatment sessions of GEM lifestyle modification in 3 months and continuous glucose monitoring during the first 14 days of each of the 3 months.
45767371|NCT01110187|Drug|Fosphenytoin|20 mgPE/kg IV over 60 minutes and then will be started on a maintenance dose (5 mgPE/kg/day, rounded to nearest dose of 150 mgPE IV, BID administered as per pharmacy protocol consistent with acceptable standards of care for 7 days
45767372|NCT04357223|Drug|extract from Angelica archangelica leaf|A standardized extract from Angelica archangelica leaf. Capsule, Twice Daily
45912765|NCT02014181|Dietary Supplement|finely ground flaxseed powder|40 grams finely ground flaxseed powder daily for one month to patients with cystic fibrosis
45625709|NCT03207893|Other|Routine Care|Subject's current t2d treatment
45625710|NCT03042039|Other|New Care|New organisational care model delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform).
45625711|NCT04857177|Drug|CKD-701|CKD-701 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.
45625712|NCT04857177|Drug|Lucentis®|Lucentis® (ranibizumab) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.
45625713|NCT02501681|Other|priming solution during cardiovascular surgery|
45625714|NCT03207737|Behavioral|MENTOR + Telehealth|Participants will live on campus for one week and complete the MENTOR program, which is a course about resilience and how nutrition, exercise and mindfulness help with resilience for individuals with a spinal cord injury. Different experts will cover the three main topics with lectures and application of knowledge through related activities. Participants will then begin a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
45625715|NCT03207737|Behavioral|Telehealth Only|Participants will complete a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
45625716|NCT04496375|Other|Survey|Self-completed questionnaires
45625717|NCT03207581|Behavioral|Professional Coaching|Professional, individualized coaching
45625718|NCT03207269|Other|Dietary|Diet will be manipulated by providing different bedtime snacks within an otherwise isocaloric diet.
45912766|NCT02014194|Behavioral|attentional bias modification treatment|The attentional bias modification treatment is a behavioral computerized program (software e-prime)
45625719|NCT04846257|Other|Dynamic contrast-enhanced MRI|Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is the acquisition of sequential images during the passage of a contrast agent within a tissue of interest.
45625720|NCT02501447|Behavioral|Guided audio-visual relaxation|
45625721|NCT03207425|Drug|EDP 305|Each subject will receive a single dose of EDP 305 on Day 1.
45625722|NCT03207113|Behavioral|Ned|Prostate cancer survivorship application.
45912767|NCT02014207|Other|dietary treatment|
45912768|NCT02014220|Other|dietary treatment|
45912769|NCT02014233|Dietary Supplement|Omega-3|
46069681|NCT00976391|Drug|insulin glargine + preprandial lispro insulin|insulin glargine in combination with preprandial lispro insulin
45767373|NCT04357223|Drug|Placebo|Placebo
45767374|NCT04357301|Device|Closed-loop vasopressor|The system will adjust the norepineprhine infusion rate based on a target SAP of 130 mmHg in 20 patients
45912770|NCT02014233|Dietary Supplement|Olive oil|
45912771|NCT02014259|Drug|semaglutide|Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
45912772|NCT02014285|Procedure|Muscle Ultrasound and Muscle Sample|The muscles to undergo ultrasound will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior. A muscle sample will be taken from the rectus femoris.
45912773|NCT02014298|Radiation|non-ablative fractional laser|3 treatments with 4-6 weeks interval
45912774|NCT02014298|Other|control|observation, comparison to laser-treated area
46073661|NCT02823054|Device|EZ-Blocker|the Blocker group, the EZ-Blocker will be set up after anesthesia induction and standard orotracheal intubation to allow lung exclusion during homolateral internal thoracic artery sampling, and thus a one-lung ventilation. This material will be removed at the end of surgical surgery.
46073662|NCT04239612|Behavioral|Physical exercise|Regular physical exercise in groups. Circular training: both strength and fitness
45767375|NCT03013231|Behavioral|Brief Resilience Scale|6 months post-op, patients will complete the BRS survey as a method of evaluating resilience.
45912775|NCT02014324|Procedure|Endosonography|"Complete endosonographic mediastinal staging is performed in 2 steps:~Systematic EBUS (airways)~Systematic EUS-B (esophagus)"
45625723|NCT02606877|Drug|nintedanib|
45625724|NCT02606877|Drug|pirfenidone|
45767376|NCT04358939|Other|Prone decubitus|According to the tolerance, the objective is to spend as much time as possible, up to 16 hours and beyond in prone position every 24 hours. At least two sessions of at least 30 minutes each must be performed daily.
45767377|NCT04357145|Other|High Dosage Home Exercise Training|"By giving more exercise to the experimental group, exercise adherence, pain and functionality will be compared with the standard exercise group.~3 times more reputation than control~Exercise Program to be Applied (0-3 Weeks):~Isometric knee extensor and adductor exercise~Hamstring stretching exercise~Terminal knee extension exercise~Straight leg lifting exercise~Exercise Program to be Applied (3-12 Weeks):~Stepping exercise~Sit up and stand up without support~Active knee flexion exercise~Moving forward exercise"
45625725|NCT03206957|Diagnostic Test|Funduscopic examination and retinal photography|A standardized funduscopic examination and retinal photography will be performed by an ophthalmologist focusing on optic nerve.
45767378|NCT04357145|Other|Standard Dosage Home Exercise Training|"5-6 standard reputations for all exercises~Exercise Program to be Applied (0-3 Weeks):~Isometric knee extensor and adductor exercise~Hamstring stretching exercise~Terminal knee extension exercise~Straight leg lifting exercise~Exercise Program to be Applied (3-12 Weeks):~Stepping exercise~Sit up and stand up without support~Active knee flexion exercise~Moving forward exercise"
45625726|NCT03206957|Diagnostic Test|Serum levels of endostatin and angiogenesis factors|Serum levels of endostatin, angiopoietin and vaso endothelial growth factor will be analyzed
45625727|NCT03206957|Diagnostic Test|Renal and low urinary tract Doppler ultrasound|"Measurements of each kidney will include maximum renal bipolar length in a sagittal plane, renal width and thickness in an axial plane perpendicular to each other at the level of renal hilum and cortical thickness. Intensity of corticomedullary differentiation will estimated.~Doppler ultrasound examination will assess renal arterial resistivity indexes"
45625728|NCT03206957|Diagnostic Test|Urinalysis|Urinalysis assessments will include assessments of microalbuminuria and microalbuminuria to creatinuria ratio. A spot urine sample will be collected from first morning void.
45625729|NCT03206957|Diagnostic Test|Anthropometric measures and vitals signs|weight, height and blood pressure will be assessed
45625730|NCT03206723|Device|Bandage contact lens|"Bandage contact lenses (BCL) have the advantage of pain reduction, facilitating epithelial healing, and improved surface healing. They have been used in the ophthalmology community to treat post-operative eye pain due to the large corneal abrasion created during Excimer photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK), and radial keratotomy (RK) with good success.~Bandage contact lenses have also been used in studies in Europe through ophthalmology clinics to treat traumatic corneal abrasions with excellent results. A British study from 1987, found that large diameter contact lenses can be fitted satisfactorily without the use of special equipment such as keratometry. Studies in rabbits have also been performed showing improved rates of healing when using bandage contact lenses. BCLs have been used to treat epithelial defects from various causes for up to 7 months at a time."
45625731|NCT03206723|Drug|Eyedrop|Fluoroquinolone eyedrops 4x/day
45625732|NCT03206723|Drug|Hydrocodone|Hydrocone 1-2 tabs 4x/day if needed
45625733|NCT04840407|Behavioral|SHARP coach intervention|The Coach provides guidance and support through four 45-60 minute in-home visits: Visit 1: to facilitate effective team communication, this visit is conducted, when possible, with the rehabilitation therapist, the patient/family, the direct care aide and the Coach, who jointly reviews the rehabilitation plan of care. Visits 2-4 include: discussion/observation of HHA/patient exercise repetition sessions, along with: 1) discussing falls prevention, signs of a recurrent stroke and when to call 911; 2) modeling motivation techniques, assessing adherence barriers and revising strategies for addressing them; and 3) identifying/ reporting signs of anxiety/depression. Additional coaching visits and calls may be scheduled as needed depending on the aide's progress in addressing barriers and the patient's progress toward rehabilitation goals.
45625734|NCT03201185|Drug|Ramipril|Initial dose: 2,5 mg. Up-titrated at one month to 5 mg and 10 mg at three months (following clinical practice recommendations for up-titration). Target dose: 10 mg (or maximum tolerated dose).
45767379|NCT01110421|Drug|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
45625735|NCT04840563|Device|Kalifon A|Commercially available kalifilcon A lenses
45625736|NCT04840563|Device|Dailies Total1|Dailies Total1
45625737|NCT04840563|Device|Precision1|Precision1
45625738|NCT04840251|Other|Well-being review and rehabiliation|"For their well-being review, patients will meet with a physiotherapist specialist in PH and discuss:~how they are~what they can do for themselves~what it is challenging for them to do~how active they are~if they have ever exercised before The physiotherapist will then make a referral to the most suitable rehabilitation service local to the patient e.g. rehabilitation classes, physiotherapy at home, weight-loss programmes."
45625739|NCT04840251|Other|Qualitative Interviews|Patients who have previously undergone rehabilitation will take part in a semi-structured interview to explore their experience and the impact it has had
45625740|NCT03201263|Procedure|Sigh|Application of cyclic pressure control breath delivered at 30 cmH2O for 3 seconds once per minute in patients undergoing pressure support ventilation
45625741|NCT03201263|Procedure|Standard of care|Standard of care
45625742|NCT04856709|Procedure|Abdominal Pectopexy|Pectopexy is a new technique for apical repair in which lateral parts of the iliopectineal ligament are used for cuff or cervix suspension.
45625743|NCT04856709|Procedure|Abdominal Sacral Hysteropexy|Abdominal sacrocolpopexy is a procedure that uses a mesh material to support the top of the vagina to treat pelvic prolapse.
45625744|NCT04857021|Dietary Supplement|GABA|oral administration of GABA capsule once daily before sleep
45625745|NCT04857021|Dietary Supplement|Placebo|oral administration of placebo capsule once daily before sleep
45625746|NCT03206567|Dietary Supplement|Nutrafol Supplement capsules|NUTRAFOL's Synergen Complex® is a patent-pending formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some patented ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, USPlus Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, Bioperine (piperine), Cynatine HNS (solubilized keratin), and Capsimax (capsaicin), all of which are standardized and clinically tested. the Nutrafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
45625747|NCT03206567|Other|Placebo capsules|The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
45625748|NCT04846023|Device|aEEG via vEEGix|Amplitude-Integrated EEG can be achieved with a limited number of frontal electrodes. There is a new aEEG technology available: VEEGix, developed by NeuroServo Inc. It is a miniaturized aEEG, non-intrusive, portable and resistant to patient's movements. Its main advantage is its simplicity of use as a single adhesive strip including all electrodes is fixed to the patient's forehead and is connected to the VEEGix device
45625749|NCT03038763|Other|Eligibility Screening|Investigators will call eligible mothers to screen for the possibility that eligible mothers may have passed HCV on to adult children. Investigators will consent these mothers to contact the adult child(ren), as the child(ren) must be informed of the mother's HCV status, if not already known.
45452439|NCT00973024|Drug|JNJ-42160443 3 mg|JNJ-42160443: type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 3 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
45625750|NCT03038763|Diagnostic Test|HCV test|Adult children will be invited to Penn or a Penn affiliate to have labwork, testing HCV antibody and HCV quant. If the quant comes back positive, investigators will also test genotype and fibrosure.
45625751|NCT03201341|Other|Electrooculogram (EOG)|The acquisition of the surface EOG activity will be carried out by means of 3 surface electrodes, one of which, referred to as a reference, is placed on a bone zone (the glabella, above the nasion) and two others placed on The temples, coupled to an EOG amplifier.
45625752|NCT03201341|Other|Surface Electromyography (EMG)|In behavioral or transcranial stimulation protocols, surface EMG activity may be recorded for further analysis. No protocol included in this project will involve the recording of intramuscular electromyographic activity, which is invasive and involves the implantation of needle electrodes into the muscles.
45625753|NCT03201341|Other|Electrodermal response|The electrodermal response is a useful, simple and reproducible method for recording sweat gland activity that reflects autonomic nervous activity. Recordings will be made using traditional devices, including an amplifier (Delsys or BrainAMP or equivalent) as well as disposable electrodes.
45625754|NCT03201341|Other|Changes in skin temperature|The skin temperature will therefore be recorded during behavioral protocols using techniques for manipulating the representation of the body (perceptual illusion, prismatic deviation, etc.) using a specific measuring device.
45625755|NCT03201341|Other|MRI|Whatever the protocol, a diffusion tensor MRI (DTI) acquisition sequence as well as an image of the entire brain and high spatial resolution (T1 weight, 1x1x1 mm, nasion markers and pre-atrial points) will be acquired (Total duration: 20 minutes).
45625756|NCT03201341|Other|MEG|During the examination, the subject will have to perform tasks comparable to those described for the fMRI procedure, but with the additional possibility, offered by the MEG environment, of performing pointing or seizing of objects, provided that the Trunk and the subject's head be held in place by a suitable restraint system.
45625757|NCT03201341|Other|Transcranial magnetic stimulation (TMS)|TMS is a non-invasive technique that uses very short (~ 100μs) magnetic pulses applied to the scalp to transiently and focally disrupt or improve the functioning of neuronal populations in the underlying superficial cortical regions.
45625758|NCT03201341|Other|Transcranial electrical stimulation in direct current (tDCS)|The tDCS consists in passing a current of low intensity (generally ≤ 1mA to stimulate the cerebral cortex) between an anode and a cathode placed on the scalp, a part of this current crossing the tissues, and in particular the cortical regions situated between these two Electrodes. Generally, if the cathode is placed on the region of interest, it will be inhibited, while it will be energized if the anode is positioned thereon.
45625759|NCT04856787|Drug|SHR-1701、 BP102 、XELOX|"Phase 2：Single Group~Drug:SHR-1701 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days"
45625760|NCT04856787|Drug|SHR-1701、 BP102 、XELOX|"Phase 3：Randomized~Drug:SHR-1701 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days"
45625761|NCT04856787|Drug|placebo、 BP102、 XELOX|"Phase 3：Randomized~Drug:Placebo 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days"
45625762|NCT03206177|Drug|Galunisertib|Galunisertib 150mg po BID day 4-17.)
45625763|NCT03206177|Drug|Paclitaxel|Paclitaxel 175 mg/m2 over 3 hours
45625764|NCT03206177|Drug|Carboplatin|IV day 1 Carboplatin AUC 6* over 1 hour (or 5* if no prior radiation therapy)
45625765|NCT04846179|Dietary Supplement|Ginkgo biloba extract|Patients recruited to Ginkgo Biloba Extract (GBE) group will be advised to take Webber Natural Ginkgo Biloba 120 mg soft gel, 1 tablet twice a day for 4 months.
45625766|NCT04856553|Other|Acute effects of handgrip exercise|The participants will be randomized into three sessions, handgrip exercise in the morning, handgrip exercise in the afternoon, and control performed in the morning to analyze the acute effects of handgrip exercise on blood pressure and vascular function at different times of the day. After the morning sessions, ambulatory blood pressure will also be measured for 24 hours.
45625767|NCT04845789|Other|Non-interventional|Non-interventional. Interview would be conducted for data collection.
45767380|NCT01110421|Drug|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
45767381|NCT01110421|Drug|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
46069682|NCT02620371|Procedure|modified pectoral block|"Modified Pecs block was performed under general anesthesia, and 15 min. before skin incision. We performed the modified Pecs block or the  Pecs II block by using a two needle approach instead of one. The first puncture is a Pecs I block with 10 ml of local anesthetic injected between the two pectoralis muscles, and the second puncture injects 20 ml of local anesthetic between the Pectoralis minor muscle and the serratus muscle. This breaks through the 'axillary door' and will reach the long thoracic nerve and reliably at least two intercostal nerves.~We used A high frequency linear US probe is used for this block. a broadband linear array probe, with an imaging depth of 3-4cm. starting from the lateral third of the clavicle and moving distally and laterally to the mid axillary line."
45447112|NCT02098642|Other|MIRT|A 4-week cycle of physiotherapy that entailed three daily sessions, 5 days a week. The first session comprised cardiovascular warm-up activities, relaxation exercises, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, and exercises to improve the functionality of abdominal muscles and postural changes in the supine position. The second session included exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill training associated with auditory and visual cues (treadmill plus). The last was an occupational therapy session with the aim of improving autonomy in daily living activities.
45447113|NCT02098642|Other|Mobilization of the metatarsophalangeal joint of the hallux|MIRT and mobilization of the metatarsophalangeal joint of the hallux
45625768|NCT02606643|Procedure|Slight traction|Slight traction will be applied to the balloon catheter
45625769|NCT02606643|Procedure|Foley Catheter to no traction|Foley Catheter to no traction
45625770|NCT04846101|Other|OMNISHADE|Anterior dental cavities (Class III, Class IV) will be restored with an omnishade composite material
45625771|NCT04846101|Other|MULTISHADE|Anterior dental cavities (Class III, Class IV) will be restored with conventional multishade composite material.
45625772|NCT04846101|Diagnostic Test|Instrumental Shade Analysis|Assessment will be performed by single operator using spectrophotometer (EASYSHADE) to detect color difference between tooth and restoration
45625773|NCT04846101|Other|Visual Shade Analysis|Visual assessment will be performed by two calibrated specialists to evaluate shade matching between the tooth and restoration
45625774|NCT04846101|Other|Patient satisfaction|Patient satisfaction of the final shade match will be assessed on a visual analogue scale
45625775|NCT04845867|Device|ISAR-M THYRO|A diagnostic device for early detection of haemorrhage following thyroid surgery
45767382|NCT01110421|Drug|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
45767383|NCT01110421|Drug|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
45912776|NCT02014337|Drug|Mifepristone and Eribulin in combination|Single Arm, Two Parts Part 1: Dose Escalation Phase to determine MTD and RP2D in up to 20 patients Part 2: Dose Expansion Phase at RP2D in 20 patients
45912777|NCT02014350|Device|DePuy Delta Xtend Reverse TSA|
45912778|NCT02014428|Dietary Supplement|Hyaluronic acid|
45912779|NCT02014428|Drug|Placebo|
45625776|NCT04839939|Other|Conventional physical therapy|Stretching for tight muscles, weak muscles Strengthening, Postural reactions training, Proprioceptive training, and Walking training
45625777|NCT04839939|Other|Ankle Foot Orthosis|Solid prescribed AFO with a wearing schedule of 6-12 hours per day
45625778|NCT04839939|Other|Combination Taping|Combination between elastic and inelastic taping
45767384|NCT04356911|Other|PLACEBO (Negative Control)|"The group received in-office bleaching. A 45-minute application of 35% hydrogen peroxide gel (Whiteness HP, FGM, Joinville, SC) was carried. After whitening therapy, a water-soluble placebo gel (KY®, Johnson & Johnson, SP, Brazil) was applied to the buccal surfaces of incisors, canines and premolars with the help of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the placebo gel for 20 seconds in each tooth surface. After washing the placebo gel, the laser tip was positioned at two points, apical and cervical, without emitting light (placebo), simulating the application of low-level laser therapy (LLLT).~This protocol was performed in 3 sessions, with an interval of seven days between them."
45767385|NCT04356911|Other|FBM|This group received photobimodulation with low level laser therapy (LLLT) of infrared spectrum with a wavelength of 808 nm in its active environment AsGaAl (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil), at two points: cervical and apical region of the incisors, canines and premolars. 60 J / cm² was applied at each point for 16 seconds. The laser was applied in 3 sessions with a time interval of seven days between them.
45767386|NCT04356911|Other|ESTRÔNCIO|After whitening therapy, a toothpaste with 10% strontium chloride (Sensodyne Original, GSK, London, United Kingdom) was applied to the buccal surfaces of incisors, canines and premolars with the help of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the desensitizer for 20 seconds on each tooth , according to the manufacturer's specifications. The desensitizer therapy was realized in 3 sessions with a time interval of seven days between them.
45625779|NCT04845711|Other|Control group|patients will receive general anesthesia only.
45912780|NCT02014454|Drug|Propranolol eye drops|"All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularisation, but no more than 60 days.~The propranolol treatment will be always associated to the conventional approach adopted by the ETROP Cooperative Group."
45912781|NCT02014493|Procedure|High Flow Nasal Cannulae (HFNC)|HFNC 6 l/pr.min
45625780|NCT04845711|Procedure|Erector spinae plane block group|patients will receive general anesthesia and bilateral ultrasound guided erector spinae plane block (20ml Bupivacaine 0.25%)
45625781|NCT04845711|Procedure|Quadratus lumborum block group|patients will receive general anesthesia and bilateral ultrasound guided quadratus lumborum block (20 ml Bupivacaine 0.25%)
45912782|NCT02014493|Procedure|Continuous Positive Airway Pressure (CPAP)|CPAP 6 l/pr.min
45625782|NCT04839627|Other|serum progesterone measurement|progesterone levels measurement on the day of the embryo transfer on all AMP cycles
45625783|NCT03042117|Other|periodontal probing|A periodontal probe will be inserted between the tooth and the gum in the gingival sulcus and a measurement of the pocket depth will be measured by a trained dentist in all subjects
45912783|NCT02014506|Drug|Fludarabine|40mg/M2 once daily IV on days -7 to -2
45912784|NCT02014506|Drug|Cyclophosphamide|50 mg/kg IV on day -3 and -2
45912785|NCT02014506|Biological|anti-thymocyte globulin|
45625784|NCT04845633|Other|Evaluation of the Effectiveness of Conventional Toothbrush in Dental Plaque Control in Healthy Children|Healthy children will be given conventional toothbrush.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 weeks by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
45625785|NCT04845633|Other|Evaluation of the Effectiveness of Customized Handle Toothbrush in Dental Plaque Control in Healthy Children|Healthy children will be given toothbrush with Customized Handle.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 weeks by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
45625786|NCT04845633|Other|Evaluation of the Effectiveness of Conventional Toothbrush in Dental Plaque Control in Children with Down Syndrome|Children with Down syndrome will be given conventional toothbrush.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 week by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
45625787|NCT04845633|Other|Evaluation of the Effectiveness of Customized Handle Toothbrush in Dental Plaque Control in Children with Down Syndrome|Children with Down syndrome will be given toothbrush with Customized Handle.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 weeks by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
45912786|NCT02014506|Biological|filgrastim|Beginning on day 4 and continuing until blood counts recover
45912787|NCT02014506|Radiation|Total body irradiation|200 cGy per day on D-6 to -4 (eligible disease except aplastic anemia) 200 cGy per day on D-5 & -4 (severe aplastic anemia)
46069683|NCT04252664|Drug|Remdesivir|RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
45625788|NCT04845243|Behavioral|Emotionen Verstehen und Ausdrücken (E.V.A.)|The online training is focused on the strengthening of socioemotional competences and consists of different training tasks (up to 3 million) presented to the participant as mini games. These training tasks are specifically designed according to empirical findings to match the socio-emotional recognition needs of people with ASD. During these games, an adapted Elo-Algorithm allows to automatically evaluate the participants' performance and adapts the difficulty levels throughout the users' progress in the training.
45625789|NCT04845399|Drug|Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection|Participants received prophylaxis treatment at 50 IU/ kg every three days.30-50 IU/kg is recommended to administration while bleeding occurs during the experiment.
45625790|NCT04804995|Other|There is no intervention.|No intervention.
45625791|NCT04845009|Behavioral|progressive muscle relaxation|progressive muscle relaxation
45625792|NCT04845009|Behavioral|Usual care|Usual care
45625793|NCT04856397|Drug|Intravitreal Implant in Applicator|Dexamethasone intravitreal implant
45625794|NCT04856397|Drug|Eylea|anti-VEGF medication
45625795|NCT04839471|Drug|BI-754091 plus afatinib|Eligible patients will receive BI-754091 240 mg on D1, afatinib 30 mg/day on day 1 to 21 in a 3-week cycle.
45625796|NCT04839237|Drug|Liraglutide|The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards,1.8mg per day, subcutaneous injection.
45625797|NCT04839237|Drug|Liraglutide;metformin|The treatment of Liraglutide combined with metformin lasted three months.For Liraglutide,during the first week: 0.6mg per day, subcutaneous injection;during the second week: 1.2mg per day, subcutaneous injection; from third week onwards,1.8mg per day, subcutaneous injection.For metformin,during three months:0.5g each time, 3 times per day,oral.
45625798|NCT04839081|Other|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
45625799|NCT04839159|Other|Blood sampling|Blood sampling at the age of 6 and 12 months, 2-3-4 years
45625800|NCT04839159|Other|Blood sampling|Blood sampling before any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
45625801|NCT04845087|Other|Ozonized water|Irrigation of dental implants with ozonized water
45625802|NCT04845087|Other|Placebo|Irrigation of dental implants with water
45625803|NCT03038685|Behavioral|Strokecoach.be - digital coaching program for stroke patients|The stroke coach gives patients two education sessions during hospitalization (risk factor management, review of medications and clinical evolution). During these sessions, study participation will be proposed. Eligibility will partially depend on their historical use of the internet and e-mail. The aim is to have the digital platform personalized for his/her individual needs, risk factors and remaining neurologic signs/symptoms. Tips and tricks to deal with lifestyle modification will be delivered on regular basis. Meanwhile, patients will be asked to complete on a pre-specified frequency their data regarding their cardiovascular risk profile. Additionally, participants will be contacted at 0.5-1-2 and 6 months by phone calls or videoconsultancy. To standardize, an adapted, digital version of the standardized WSO Post-Stroke Checklist shall be used as a decision-support flowchart. A report of the consultation will be derived after the videoconsultancy.
45625804|NCT04844775|Biological|Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L|"Drep-HIV-PT1 The DREP-HIV-PT1 is a vaccine designed to elicit an immune response against human immunodeficiency virus-1 (HIV-1) and prevent infection by HIV-1 and/or disease caused by HIV-1. It is an alphavirus-based DNA replicon in which the sequences coding for the viral capsid and envelope have been replaced by the sequences encoding HIV-1 gp140 (96ZM651) antigen.~CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity."
45625805|NCT04844775|Biological|DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above)|"Drep-HIV-PT1 1mg (see above)~Drep-HIV-PT1 1mg (see above)"
45625806|NCT04844775|Biological|DNA-HIV-PT123 4mg and CN54gp140/MPLA-L|"DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef~CN54gp140/MPLA-L Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity."
45625807|NCT03040245|Behavioral|Whiplash book|
45625808|NCT03038607|Drug|Aspirin|This group were subjected to aspirin 75 mg once daily for 6 weeks.
45912788|NCT02014506|Procedure|TCRαβ-depleted hematopoietic cell transplantation|
45625809|NCT03038529|Procedure|Classic postrolateral extraarticular percutaneous approach for O3 injection|Receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through the classic postrolateral extraarticular percutaneous approach
45625810|NCT03038529|Procedure|Postrolateral transforaminal approach (Yess approach ) for O3 injection|Group B receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through postrolateral transforaminal approach (Yess approach ).
45625811|NCT03038451|Drug|S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet|
45625812|NCT03040401|Drug|Cohort 1, Ceplene® and Proleukin®|"Patients in Cohort 1 will be administered only Ceplene® during the first treatment cycles and Ceplene® in combination with Proleukin® during treatment cycles 2-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
45625813|NCT03040401|Drug|Cohort 2, Ceplene® and Proleukin®|"Patients in Cohort 2 will be administered Ceplene® in combination with Proleukin® during all treatment cycles 1-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
45912789|NCT02014506|Device|CliniMACS|Immunogenetic depletion of TCRαβ cells
45625814|NCT03040401|Drug|Cohort 3, Ceplene® and Proleukin®|"Cohort 3 will receive either only Ceplene® during treatment cycles 1-4 or Ceplene® in combination with Proleukin® during treatment cycles 1-4. Treatment will be decided by the study committee based on the safety profile of treatment administered to cohort 1 and 2.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
45912790|NCT02014532|Drug|Montelukast|Patients in Montelukast Group were treated with scaling and root planing (SRP) along with Montelukast (Montair 10mg), 1 tablet twice daily for 3 weeks.
45912791|NCT02014532|Drug|Placebo|Patients in Placebo Group were treated with scaling and root planing (SRP) along with Placebo therapy, 1 tablet twice daily for 3 weeks.
46069684|NCT04252664|Drug|Remdesivir placebo|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
46069685|NCT00696969|Drug|Amphotericin B Deoxycholate|1 mg/kg e.o.d for 30 days
46069686|NCT00696969|Drug|Ambisome + Miltefosine|Ambisome (i.v. single dose 5 mg/kg)+ Miltefosine 7 days
45625815|NCT03038295|Drug|Propranolol|Oral propranolol:0.25mg/kg daily(every 24 hours)；Eye drop propranolol(0.2%):3 microdrops,in each eye, four times daily (every 6 hours) .Both administration routes will be discontinued until retinal vascularization will be completed, but no more than 90 days.The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:Atropine.Isoproterenol hydrochloride (isoprenaline).Terlipressin.Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular).
45625816|NCT03038295|Drug|placebo|Oral/eye drop placebo will be taken in enrolled newborns. Other treatment will follow the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group.
45625817|NCT03038217|Drug|Capecitabine +/- Oxaliplatin|Patients in ACT group will undergo postoperative adjuvant chemotherapy with single agent Capecitabine regimen or combined Capecitabine +Oxaliplatin regimen.
45625818|NCT03038217|Procedure|local resection|Patients in the LR group will undergo local resection of the T1-2N0 rectal carcinoma
45625819|NCT03038217|Procedure|radical resection|Patients in the RR group will undergo radical resection of the T1-2N0 rectal carcinoma
45625820|NCT03038217|Other|No adjuvant chemotherapy|Patients in Non-ACT group will not undergo postoperative adjuvant chemotherapy.
45625821|NCT03038139|Other|Cervical exercises|Cervical correction program consist of 3 strengthening and 2 stretching exercises for neck and scapula Lumbosacral correction program consist of strengthening and stretching exercises for lumbar and sacral regions
45625822|NCT03038139|Other|Lumosacral exercises|Cervical and Lumbosacral correction program Lumbosacral program consist of 2 strengthening and 4 stretching exercises
45625823|NCT02609607|Drug|Bisacodyl|Rectal suppository
45625824|NCT02609607|Other|Placebo|Rectal suppository
45625825|NCT03040167|Procedure|PEC 1 block|Under echoguidance, injection of the substance of interest between the major and minor pectoral muscles.
45625826|NCT03040167|Drug|Bupivacaine with epinephrine|Treatment group
45625827|NCT03040167|Drug|Normal saline|Placebo group
45625828|NCT04838847|Biological|CVnCoV Vaccine|Intramuscular (IM) injection
45625829|NCT03038061|Other|Patients undergoing Laparoscopic Surgery|Data are to be obtained at three phases at supine horizontal position (during spontaneous breathing, at mechanically ventilated patient under general anesthesia with muscle relaxation and at mechanically ventilated patient under general anesthesia with muscle relaxation during insufflation of carbon dioxide into the peritoneal cavity to achieve exposure during laparoscopic surgery).
45625830|NCT04843839|Drug|Nepafenac 0.1% Oph Susp|Nepafenac 0.1% eye drops - Allergan : Dosage- 1 drop QID for 6 months
45625831|NCT04843839|Drug|Refresh Tears 0.5% Lubricant Eye Drops|Refresh Tears 0.5% w/v eye drops - Allergan : Dose- 1 drop QID for 6 months
45447114|NCT03746691|Drug|Citalopram HCl|Citalopram HCl IV 20 mg in 100 ml saline will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
45447115|NCT03746691|Drug|Placebos|Placebo (100 ml saline IV) will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
45625832|NCT04838691|Behavioral|interpersonal counseling|In the intervention group, it will be administered for 40 minutes for 8 weeks to people with symptoms of premenstrual syndrome.
45625833|NCT04838535|Diagnostic Test|Raman spectrum|The wavelength of the follicular fluids were scaned by Raman spectrum
45625834|NCT04369131|Device|Functional electrical stimulation|Randomized placement of FES pads in one of four locations during each session. Locations include: (a) none, (b) calves only, (c) quads and abdominals only, and (d) calves, quads, and abdominals.
45625835|NCT03037827|Procedure|Endovenous laser ablation (EVLA)|Endovenous laser ablation with laser wavelength 1470 nm and radial laser fiber
45625836|NCT03037827|Device|Laser|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
45625837|NCT04838145|Drug|Ribavirin + Pleconaril|Randomized to treatment with study drugs (ribavirin and pleconaril)
45625838|NCT04838145|Drug|Placebos|Randomized to treatment with placebo
45625839|NCT04837911|Device|Spirobank Smart|Patients using the Spirobank Smart
45625840|NCT03037749|Drug|Alcohol beverage|Alcohol beverage
45625841|NCT03037749|Drug|Placebo beverage|Placebo beverage
46069687|NCT00696969|Drug|Ambisome and Paromomycin|Ambisome 5 mg/kg single dose + Paromomycin Sulphate 15mg/kg/day for 10 days
46069688|NCT00696969|Drug|Miltefosine and Paromomycin|Miltefosine (standard dose) and Paromomycin Sulphate 15mg/kg/day for 10 days
46069689|NCT04203680|Drug|HTK cardioplegic solution|30 ml/kg of HTK cardioplegic solution at 4°C through an antegrade fashion at an initial perfusion pressure of 80-100 mmHg
46069690|NCT04203680|Drug|blood cardioplegia|one liter of blood cardioplegia was given with the antegrade route at 30°C, or lower. Blood maintenance cardioplegia was repeated every 30-45mins
45447116|NCT02100592|Other|Early rehabilitation treatment on Erigo Hocoma|5 weekly sessions of erigo for three weeks. Expected tilt angle up to 60 °
45447117|NCT02100592|Other|Early rehabilitation treatment on Erigo Hocoma|Early verticalization treatment with Erigo Hocoma, a tilt table with stepping system
45447118|NCT04222725|Drug|TRS01 eye drops|Dosed 4 times a day (QID)
45625842|NCT04855383|Drug|The effect of intramuscular injection of triple doses of human chorionic gonadotropin in frozen embryo transfer cycles|Patients receive 5,000 IU of human chorionic gonadotropin by intramuscular injection, 72 hours before embryo transfer, on the day of embryo transfer, and 72 hours after embryo transfer.
45625843|NCT04855149|Other|Patient satisfaction|Patient satisfaction evaluated with EVAN LR questionnaire
45912792|NCT02014545|Drug|Lucanthone|The dose of lucanthone to be administered will be calculated based on the patient's body weight. The dose to be given will be 250 bid, 250 tid or 375 tid dependent upon study progression.
45912793|NCT02014545|Other|Placebo|Only standard treatment of whole brain radiation therapy is done.
45625844|NCT04855071|Device|Non-ablative radiofrequency application|Non-ablative radiofrequency application will be applied with MJS intracavitary probe, in monopolar application, reaching a temperature between 42-45ºC in the tissues (according to the patient's tolerance), and with a power of 50% until the desired temperature is reached. It will be applied with a frequency that will be individualized according to the maximum level of energy absorption by the patient's tissues (between 0.8-1.2MHz) and with a dose of approximately between 3-4 KJ depending on the application time (20 minutes / session). In addition, they will be applied 1 session per week. The treatment will last 8 weeks.
45625845|NCT04855071|Other|Usual intervention|The usual intervention will consist of supervised individualized sessions that will include application of exercises to balance the pelvis and their muscles, treatment of trigger points, teaching activation of the transverse abdominis with ultrasound biofeedback and teaching reflex activation exercises of the transverse abdominis and pelvic floor muscles in different body positions. In addition, standards of water, urination, food, defecation, postural hygiene and physical activity will be provided. It is also recommended different life habit advices related to tobacco use, constipation, etc.
45625846|NCT03041493|Behavioral|Electronic cigarette|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
45625847|NCT03041493|Behavioral|traditional cigarette|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
45767387|NCT04356911|Other|FBM+ESTRÔNCIO|After whitening therapy, a 10% strontium chloride toothpaste (Sensodyne Original, GSK, London, United Kingdom) was applied to the buccal surfaces of whitened teeth with the help of a Microbrush applicator applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the desensitizer for 20 seconds on each tooth , according to the manufacturer's specifications. After washing the desensitizer, the photobimodulation was realized with Low Level Laser Therapy (LLLT) of infrared spectrum with wavelength of 808 nm in its active environment AsGaAl (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil), in two points: cervical and apical region of the incisors, canines and premolars. 60 J / cm² was applied at each point for 16 seconds. This protocol was performed in 3 sessions, with an interval of seven days between them.
45625848|NCT03041493|Behavioral|(sham cigarette) - no actual exposure to cigarettes|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will be compared to the second set of laboratory measurements done at the second encounter that will be scheduled 4 hours after the first encounter. At that time an additional blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
45625849|NCT03041571|Behavioral|Patient Provider Orientation Scale|Investigators are interested in the impact that our activity has on the students' patient-centeredness. Investigators will use the Patient-Practitioner Orientation Scale (PPOS), which will be completed by both the student and the patient prior to the encounter. Following the interview, the co-investigators will lead a discussion with the patient and student. Investigators will discuss differences in patient and student PPOS scores, and how each party felt the interview went. Investigators will examine if the patients feel the interview differed from typical interactions with health care providers, and how this made the patient feel. The students will describe what was learned from the patients story as well as try to explore reasons why providers may not always learn the patient's illness story.
45625850|NCT03041571|Behavioral|Interview performed by MHP student|"The MHP students took a course called Medical Humanities in the fall of 2016. MHP students learned patient interviewing skills and the importance of gathering the patients illness story. The students will conduct an interview with a patient with chronic illness, which will be focused on gather information about how the patients illness affects daily life as well as interactions with the health care system."
45625851|NCT03041259|Drug|Rejuveinix Low Dose|A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
45767388|NCT04357067|Device|Lingual brackets|A type of bracket that applied lingual surface of teeth.
45625852|NCT03041259|Drug|Rejuveinix High Dose|A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
45625853|NCT04429035|Dietary Supplement|Vitamin K2|Administration of 300 μg Vitamin K2 (MQ7) daily p.o
45625854|NCT04429035|Dietary Supplement|Placebo|Administration of 300 μg Vitamin K2 (MQ7) Placebo daily p.o
45767389|NCT04357067|Device|Labial brackets|A type of bracket that applied labial surface of teeth.
45767390|NCT04358627|Drug|Dexmedetomidine Injectable Product|continuous intravenous infusion of dexmedetomidine
45447119|NCT04222725|Drug|TRS01 eye drops|Dosed QID
45447120|NCT04222725|Drug|TRS01 eye drops|Dosed QID
45447121|NCT04222725|Drug|Placebo eye drops|Dosed QID
45447122|NCT03554668|Diagnostic Test|Blood draw|We take blood samples at pre-op and subsequent time points, up to three months post op.
45447123|NCT03746613|Device|HEARO|Robotic system for otological procedures
45447124|NCT02104024|Other|Contrast Enhanced Ultrasound Scanning|
45625855|NCT03041337|Diagnostic Test|stress echocardiography|"stress echocardiography will be performed in accordance with the current guidelines on a variable load 45° cycle ergometer with an incremental workload of 25 W every 2 minutes up to the symptom-limited maximal tolerated workload. Echocardiographic measurements will be acquired at baseline, at peak exercise and during recovery of 5 minutes.~The electrocardiogram and blood pressure will be monitored at each workload. Termination criteria and / or positive test criteria for inducible myocardial ischemia will follow the current recommendations"
45625856|NCT04843449|Drug|ASC40|Oral tablets
45767391|NCT04356677|Drug|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
45767392|NCT04356677|Drug|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
45767393|NCT04356833|Drug|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1|Patients in the cohort 1 rt-PA group will receive the first dose as soon as possible after registration. 10mg rt-PA in 5mL diluent will be administered by nebulisation every 6 hours for 14 days, resulting in a total daily dose of 40mg.
45767394|NCT04356833|Drug|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV|Patients on IMV will receive 60mg daily over three doses for 14 days
45767395|NCT04356833|Drug|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 NIV|NIV patients will receive 60mg daily for over 3 doses for two days, followed by 12 days receiving 40mg daily over two doses.
45767396|NCT04664387|Diagnostic Test|coronary angiography|A coronary angiography is a test to find out if there is stenosis in coronary artery.
45767397|NCT04358783|Biological|Plasma|The plasma unit will be fractionated in 200 mL aliquots for storage at -80°C until use. After thawing, it shall be administered in a single 200 mL dose to subjects who are randomized to that arm.
45767398|NCT04358783|Other|Best Available Therapy|It shall include, but not be limited to, oxygen therapy by means of a nasal cannula; high-flow nasal cannula; invasive or non-invasive mechanical ventilation; intravenous hydration; antibiotic therapy; thrombus prophylaxis; pain and fever management.
45767399|NCT04358861|Procedure|Nonsurgical Root canal therapy|After administration of LA and rubber dam isolation, acess cavity was prepared using carbide burs. Working length was determined using root ZX apex locator and was verified radiographically. Canal preparation was done with protaper gold rotary instruments. 5ml of 5.25% NaOCl was used as irrigant. After instrumentation , the canals were irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals were dried with absorbent paper points, filled with calcium hydroxide paste and access cavity was restored with IRM.At the recall appointment ; after one week,paste removal, copious irrigation was done with 5.25% NaOCl and canals were dried with paper points. Canals were obturated with Gutta-Percha and ZOE based sealer.
45767400|NCT04358861|Device|Dental operating microscope|Dental operating microscope; a high magnification and illumination device was used in experimental group for performing nonsurgical root canal therapy.
45767401|NCT04356521|Procedure|Lateral Sagittal Approach|The US probe will be located medial to the coracoid process in the sagittal plane in the infraclavicular region, and then three cords of the brachial plexus will be viewed. Using the in-plane technique, bupivacaine 0.5% will be administered around the posterior cord (7ml), lateral cord (7ml), and medial cord (6ml).
45767402|NCT04356521|Procedure|Costoclavicular Approach|The US probe will be placed parallel to the clavicle in the midclavicular area and tilted toward the cephalad and the axillary artery, and three cords will be viewed. A needle will be forwarded from lateral to medial with the in-plane technique, and 20 ml of bupivacaine 0.5% will be administered at the center of the three cords.
45625857|NCT04843449|Drug|Itraconazole|Oral capsules
45625858|NCT04843449|Drug|rifampicin|Oral capsules
45767403|NCT04356443|Device|AirGo Respiratory Monitor|AirGo™ is composed of a wearable, miniaturized recorder unit and a medical grade Holter worn over the floating ribs of patients both at rest and during normal activity. The recorder measures live circumference changes.
46069691|NCT02620137|Drug|Multicentrum® (Pfizer, Spain) 3 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 3 months
45447125|NCT04213989|Device|Flexitouch Plus and Conservative Care|A segmental, programmable, gradient advanced pneumatic compression device. The system consists of a controller unit and garments, and provides in-home manual lymphatic drainage therapy in the legs for approximately 1 hour daily. Conservative care may include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT.
45625859|NCT03037593|Drug|4000 IU vitamin D3|vitamin D supplementation (4000 IU vitamin D3 +prenatal vitamin
45625860|NCT03037515|Drug|Tranexamic Acid|To identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion in lumbar spine surgery.
45625861|NCT04838067|Device|Cefaly|Transcutaneous trigeminal nerve electrical neuromodulation
45447126|NCT04213989|Other|Conservative Care|May include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT.
45625862|NCT04843293|Behavioral|Olfactory stimulation|Newborns in the experimental group will be given the smell of breast milk during 3 consecutive feedings and for 3 days in the morning. Smell stimulation will be started 1 minute before gavage feeding and the application of breast milk odor will continue until the feeding ends. A hand-cleaning researcher will drip 15 drops of breast milk on sterile gauze to apply the smell of breast milk. Sterile gauze dripped with breast milk will be placed as close to the newborn's nose as possible and not in contact with the newborn's skin. After the feeding of the newborn is completed, the application of the smell of breast milk will be terminated and the gauze will be removed from the incubator. A new sterile gauze will be used for each feeding, and these processes will be repeated with each smell stimulation for three days.
45625863|NCT03041103|Other|Food Product 1|50 grams of fortified nutritious product from legumes
45625864|NCT04843215|Procedure|Type of omentectomy|Experimental group D2 radical gastrectomy with partial omentectomy. Partial omentectomy with preservation of the greater omentum at >3 cm from the gastroepiploic arcade.Control group with total omentectomy.
45625865|NCT04803357|Device|Continuous glucose monitor|We are offering you an opportunity to wear a medical device that monitors your blood sugars (glucose). This device is called a continuous glucose monitor (CGM). The CGM measures glucose levels through a tiny plastic filament that is inserted under the skin in your abdomen by a skin prick. Typically, you cannot feel this device once it is inserted.
45625866|NCT04837443|Behavioral|Rubber hand illusion|Tactile sensory threshold from quantitative sensory tests, two point discrimination from cortical senses, pressure pain threshold measured by algometer will be examined during and after the rubber hand burning, which causes changes in body perception.
45625867|NCT04842825|Drug|Er Zhi Wan combined with Si Wu Tang|"The TCM medicines used will be Radix et Rhizoma Ligustrum 15 g, Radix Morindae Sinensis 12 g, Fructus Lycii 15 g, Semen Cuscutae 20 g, Radix Rehmanniae 20 g, Radix Angelicae Sinensis 10 g, Radix Paeoniae Alba 12 g, Radix Yam 20 g. The hospital will be responsible for the decoction of 200 mL per dose, 1 dose per day, divided into 2 doses in the morning and in the evening, for 10-15 days. According to follicular development and endometrial growth monitored by ultrasound, the herbs will be changed to Curculus 10 g, Xianling spleen 15 g, Morinda officinalis 15 g, Cuscutae 20 g, Amethyst 15 g, Rehmannia 20 g, Angelica 15 g, Chuanxiong 10 g，which will be taken for 10-15days.~After ET, the treatment group will continue to take Chinese herbal medicine, changing to Cuscuta 15 g, Sambucus 15 g, Chuan Guan Gong 10 g, Agaricus 9 g, Shu Di 15 g, Angelica 10 g, Bai Shao 12 g for 14 days"
45625868|NCT04842825|Drug|Recombinant Human Follitropin Alfa 、Fructose 、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder|The control group will be treated with conventional Western medicine（The specific drug dose is determined according to the individual level of patients）
45625869|NCT04837599|Device|Discovery TM of Pentax medical on/off in colonoscopy|on the monitor artificial integlligence Discovery can be switched on or off.
45625870|NCT04854915|Behavioral|LOOP + mHealth technology assisted exercise counselling|Participants will complete a 3 month exercise and physical activity intervention supported by mHealth technology
45625871|NCT04854915|Behavioral|LOOP Only|Participants will complete the LOOP @ Alder Hey programme
45625872|NCT04842903|Other|Therapeutic Touch|Therapeutic touch is an energy transfer process based on the assumption that every living organism in the universe has an energy field and these energy fields that interact with each other can be changed with the practices made by a conscious and certain intent. TT is an independent nursing practice first applied and developed by nurses Dora Kunz and Dolores Krieger in 1972. TT is also an art of concentration therapy in which the therapist focuses on consciousness as a focus to create balance and coordination in the mutual energy fields of the patient and the environment, and uses their hands to transfer energy. The fact that TT is easy to use, has no known side effects, has low costs, is non-invasive, and its importance among nurses and increasing frequency of its practice in recent years show that it is a powerful alternative to other CAT methods.
45625873|NCT04837287|Other|Static Stretching Exercise for 10 Seconds|The participants were asked to do a static stretching exercise for the Hamstring and Gracilis muscles for 10 seconds. The participants were asked to continue for 8 weeks, 3 days a week, 3 times a day - 10 repetitions.
45625874|NCT04837287|Other|Static Stretching Exercise for 30 Seconds|The participants were asked to do a static stretching exercise for the Hamstring and Gracilis muscles for 30 seconds. The participants were asked to continue for 8 weeks, 3 days a week, 3 times a day - 10 repetitions.
45625875|NCT04842669|Other|low level laser therapy|Endo-laser 422 with interchangeable laser probes will be used for the purpose. It is a 2-channel unit and is software operated. For treatment of small surfaces with mono laser there are diodes of 25, 100 and 500 milliWatt.Frequency will be adjusted to 500 Hz, dose 0.1/cm2 with time duration of 1-5 minutes.
45625876|NCT04842669|Other|Conservative treatment|(Topical ibuprofen gel) for muscle soreness will be provided
45625877|NCT02606253|Drug|tolvaptan|Tolvaptan (Samsca) is a vasopressin 2 receptor antagonist that works in the collecting duct of the nephron to cause diuresis.
45625878|NCT02606253|Drug|Chlorothiazide|Chlorothiazide (Diuril) is an intravenous thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
45625879|NCT02606253|Drug|Metolazone|Metolazone (Zaroxolyn) is an oral thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
45625880|NCT03037125|Procedure|Split Crest with PRF|Narrow ridges are split to increase the ridge width and immediate implants are placed with PRF closing the gap
45625881|NCT03037125|Procedure|Split Crest without PRF|Narrow ridges are split to increase the ridge width and immediate implants are placed without grafting
45625882|NCT03040947|Other|Cardiovascular Magnetic Resonance|
45447127|NCT05414734|Drug|HHT120|Capsule, oral administration
45447128|NCT05414734|Drug|Placebo|Capsule, oral administration
45625883|NCT03040869|Other||
45625884|NCT03040089|Device|PICO+4|picosecond, neodymium-doped yttrium aluminum garnet laser
45452440|NCT00973024|Drug|JNJ-42160443 1 mg|JNJ-42160443: type=exact number, unit=mg, number= 1, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 1 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
45625885|NCT03040089|Drug|Neoquine Cream 2%|2% hydroquinone cream
45767404|NCT05620277|Diagnostic Test|Mobile Dental Photography|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography
45767405|NCT05620277|Diagnostic Test|Mobile Dental Photography with cross-polarization filter|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a cross-polarization filter
45767406|NCT05620277|Diagnostic Test|Mobile Dental Photography with gray reference card|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a gray reference card
45625886|NCT04842357|Other|standardised video concerning clinical skill|watching a video concerning clinical skills.
45625887|NCT04779645|Drug|REMD-477|12-Week, once weekly subcutaneous injection with 70mg REMD-477
45625888|NCT04779645|Drug|Placebo|12-Week, once weekly subcutaneous injection with placebo
45625889|NCT04854759|Drug|Amantadine Hydrochloride|100 mg, capsule
45625890|NCT04854759|Drug|Placebo|100 mg, capsule
45767407|NCT05620277|Diagnostic Test|Mobile Dental Photography with cross-polarization filter and gray reference card|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a cross-polarization filter and gray reference card
45767408|NCT05620277|Diagnostic Test|Digital Camera|Tooth color changes of 30 patients will be evaluated using a Digital Camera
45767409|NCT05620277|Diagnostic Test|Digital Camera with cross-polarization filter|Tooth color changes of 30 patients will be evaluated using a Digital Camera with cross-polarization filter
45447129|NCT02100982|Other|Customized Care|Customized Care consists of two components. The first component is a Discussion Prioritization Tool (DPT) which forces patients to make trade-offs between competing concerns to help them determine which are the most important to discuss. The second component is a customized question prompt list (QPL) to help patients communicate their priorities to the PCP. The QPL will be generated after patients use the DPT, and consists of question prompts tailored to the patients' priorities. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
45625891|NCT04428957|Other|Telemonitoring|Daily telemonitoring of heart rate (HR), blood pressure (BP), pulse oximetry (SpO2), spirometry (FVC), activity (accelerometry) and severity of cough and dyspnea
45625892|NCT04842435|Drug|COVID-globulin|"In a Stage 1 study, COVID globulin is administered to clinical study subjects randomized to groups 1, 2, or 3 by intravenous drip in one of three doses of 1 mL/kg, 2 mL/kg, or 4 mL/kg The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, COVID globulin is administered to clinical study subjects randomized to group 1 by intravenous drip at a dose found optimal based on the results of Stage 1 study."
45625893|NCT04842435|Drug|Placebo|"In a Stage 1 study, Placebo is administered to clinical study subjects randomized to groups 4 by intravenous drip at a dose of 1 mL/kg.~The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, placebo is administered to clinical study subjects randomized to group 2 by intravenous drip at a dose equal to the study drug dose."
45625894|NCT04842279|Other|FACE-Q scale|"FACE-Q is a recently developed and validated patient reported outcome measure (PROM) tool that allows clinicians to assess patient perspectives after skin cancer surgery of the face.The PROM is used to assess the perspective and impact of skin cancer as well as its treatment on the patient's quality of life (QoL). Patients with skin cancer may have increased anxiety, social isolation, and cosmetic concerns after surgery. The FACE-Q utilizes five scales to measure the psychometric, QoL, patient experience, and cosmetic outcomes. Raw scores are transformed to a 0-100 scale with a higher score indicating a better outcome.~Any studies using FACE-Q for facial surgery reconstruction at our center may be eligible for inclusion in the database"
45625895|NCT04854681|Drug|TQB2928 Injection|4 weekly IV infusions (Days 1, 8, 15, and 22) of TQB2928 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.
45767410|NCT05620277|Diagnostic Test|Digital Camera with cross-polarization filter and gray reference card|Tooth color changes of 30 patients will be evaluated using a Digital Camera with a cross-polarization filter and gray reference card
45767411|NCT05620277|Diagnostic Test|Digital Camera with gray reference card|Tooth color changes of 30 patients will be evaluated using a Digital Camera with a gray reference card
45767412|NCT05620277|Diagnostic Test|Rayplicker|Tooth color changes of 30 patients will be evaluated using Rayplicker
45767413|NCT05620277|Diagnostic Test|Rayplicker with gray reference card|Tooth color changes of 30 patients will be evaluated using Rayplicker with gray reference card
45767414|NCT05620277|Diagnostic Test|Vita Easyshade|Tooth color changes of 30 patients will be evaluated using Vita Easyshade
45625896|NCT04774419|Radiation|Intensity modulated radiation therapy (IMRT)|To the pelvic nodes and vaginal cuff (total dose of 45-50.4Gy at 1.8 Gy per fraction) for 5-6 weeks.
45625897|NCT04774419|Drug|Dostarlimab|IV Dostarlimab every 3 weeks for 4 cycles followed by 1 dose of 1000mg (C5). Patients will receive a maximum of 5 cycles of Dostarlimab.
45625898|NCT02607735|Drug|SOF/VEL/VOX|400/100/100 mg fixed dose-combination (FDC) tablet administered orally once daily with food
45625899|NCT02607735|Drug|Placebo|Tablet administered orally once daily with food
45625900|NCT04772313|Biological|Pegloticase|Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
45625901|NCT04770285|Device|MIRAI Depression Study Digital Therapetic|Two different versions of the MIRAI Depression Study digital therapeutics will be compared.
45625902|NCT04769895|Drug|MaaT013|MaaT013 is made of allogeneic, full-ecosystem pooled biotherapeutic intestinal microbiota
45625903|NCT04769037|Dietary Supplement|B. infantis|Activated B. infantis EVC001; Bifidobacterium longum subsp. infantis; 8 x 109 colony forming units (CFU) per day
45625904|NCT04769037|Dietary Supplement|Placebo|Lactose identical in appearance and taste to the active supplement
45625905|NCT04836663|Drug|TQ-B3525 tablet|TQ-B3525 tablet administered orally once a day. Each cycle is 28 days.
45767415|NCT05620277|Diagnostic Test|Vita Easyshade with gray reference card|Tooth color changes of 30 patients will be evaluated using Vita Easyshade with a gray reference card
45767416|NCT01110499|Drug|AGN-210961 Formulation 1|AGN-210961 Formulation 1 in one eye once daily for 7 days.
46069692|NCT02620137|Drug|Multicentrum® (Pfizer, Spain) 12 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 12 months
45625906|NCT04836741|Device|Micro Hand S robot|The surgeries are performed with the Micro Hand S robot
45767417|NCT01110499|Drug|AGN-210961 Formulation 2|AGN-210961 Formulation 2 in one eye once daily for 7 days.
45767418|NCT01110499|Drug|AGN-210961 Formulation 3|AGN-210961 Formulation 3 in one eye once daily for 7 days.
45625907|NCT04836741|Device|Laparoscope|The surgeries are performed with the laparoscope
45625908|NCT03040791|Drug|Nivolumab|Nivolumab
45625909|NCT04429113|Device|Maxillary expansion with conventional Quad Helix bonded on molars.|Maxillary expansion with conventional Quad Helix bonded on molars
45625910|NCT04841811|Drug|Almonertinib|ctDNA dynamic monitoring guided the Almonertinib treatment group after surgery or radical radiotherapy
45625911|NCT04854525|Radiation|Pre reconstruction Radiotherapy|Previous PMRT
45625912|NCT03039855|Device|TIARA valve and transapical delivery system|Transcatheter mitral valve replacement
45767419|NCT01110499|Drug|AGN-210961 Formulation 4|AGN-210961 Formulation 4 in one eye once daily for 7 days.
45767420|NCT01110499|Drug|AGN-210961 Formulation 5|AGN-210961 Formulation 5 in one eye once daily for 7 days.
45767421|NCT01110499|Drug|AGN-210961 Formulation 6|AGN-210961 Formulation 6 in one eye once daily for 7 days.
45767422|NCT01110499|Drug|AGN-210961 Formulation 7|AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.
45767423|NCT01110499|Drug|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LUMIGAN®) in both eyes once daily for 4 weeks.
46069693|NCT04255862|Drug|Bimekizumab|Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period.
45452441|NCT00973024|Drug|JNJ-42160443 6 mg/3mg|JNJ-42160443: type= exact number, unit= mg, number= 3 and 6, form=solution for injection, route= Subcutaneous use or Placebo: form= solution for injection, route= Subcutaneous injection. 1 inj of 6 mg of JNJ-42160443 on Day 1 followed by 1 inj of 3 mg or matching placebo every 4 wks for up to 104 wks.
45625913|NCT04854135|Device|CGM4Home|FreeStyle Libre 2 Continuous Glucose Monitoring System manufactured by Abbott
45625914|NCT04428879|Drug|Topotecan Episcleral Plaque|Sustained Release Episcleral Topotecan Plaques (Chemoplaques) are glued to bare, dry sclera of the eye under conjunctiva and Tenon's capsule. A rolling six dose interpatient escalation schema will be employed. Chemoplaques with 0.6 mg and 0.9 mg of topotecan HCl formulation are available. Patients will receive 1 or 2 Chemoplaques per eye, to deliver 5 escalating doses: 0.6, 0.9, 1.2 [2x0.6], 1.5 [0.6+0.9] or 1.8 [2x0.9] mg. The prescribed dose will escalate or de-escalate by 0.3 mg at each level, and no patient will receive more than 1.8 mg of topotecan hydrochloride due to the physical limitations if the devices available. The planned removal is 42 days ± 7, unless dose limiting toxicity is observed, in which case the plaque is removed as soon as possible. The observation period for the purposes of dose-escalation will be 63 days (i.e. 21 days following Chemoplaque removal on day 42).
45625915|NCT04836819|Drug|Lidocain|IV lidocaine infusion (2 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 1 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS>4.
45625916|NCT04836819|Drug|Ketamine|IV ketamine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS>4.
45767424|NCT04358471|Biological|Intravitreal AAVCAGsCD59|AAVCAGsCD59 is administered as an intravitreal injection in the enrolled eye
45767425|NCT04358471|Other|Intravitreal Sham Injection|Sham injection mimics a real injection in the enrolled eye
45767426|NCT04356131|Other|progressive relaxation exercises and massage|Progressive relaxation exercises included 30 minute rhythmic breathing and muscle relaxation exercises were demonstrated in the second part of the CD with river sounds and verbal instructions. Massage techniques were performed on the site between upper symphysis pubis and umbilicus with 15 minute effleurage demonstrated in the third part of the CD with nature sound.
46069694|NCT04825574|Drug|Avapritinib|avapritinib tablet
45767427|NCT04355897|Biological|Convalescent COVID 19 Plasma|Subjects will be transfused intravenously with 500 mls of convalescent COVID 19 plasma
45767428|NCT04347083|Diagnostic Test|Electrodiagnostic test|Muscle spindle- based reflex latency will be measured
45767429|NCT01112293|Drug|GC1008|GC1008 is a human IgG4 kappa monoclonal antibody capable of neutralizing all mammalian isoforms of TGFbeta (i.e., beta1, beta 2 and beta 3). GC1008 is a high affinity antibody with dissociation constants (Kds) of 1.8 nM, 2.8 nM and 1.4 nM for TGF1,2,and 3, respectively.
45767430|NCT02174419|Drug|nalbuphine HCl ER tablets 90 mg BID|nalbuphine HCl ER tablets 90 mg BID administered for 8 weeks
45767431|NCT02174419|Drug|nalbuphine HCl ER tablets 180 mg BID|nalbuphine HCl ER tablets 180 mg BID administered for 8 weeks
45767432|NCT02174419|Drug|Placebo tablets BID|Placebo tablets BID administered for 10 weeks
45767433|NCT00942851|Drug|Acetyl-Hexapeptide Topical Treatment|AH-8 containing topical treatment
45767434|NCT00942851|Drug|placebo|topical treatment NOT containing AH-8
45767435|NCT05620589|Drug|Amoxicillin + Tetracycline + Bismuth + Esomeprazole|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 40mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid
45625917|NCT04836819|Drug|Dexmedetomidine|IV dexmedetomidine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS>4.
45625918|NCT04836507|Biological|CRC01|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg.
45625919|NCT04836507|Drug|Fludarabine|Administered according to package insert
45625920|NCT04836507|Drug|Cyclophosphamide|Administered according to package insert
45625921|NCT03039933|Behavioral|Fear of Hypoglycemia|Participants will receive exposure and response prevention and/or hypoglycemia awareness training.
45625922|NCT03039933|Other|Treatment As Usual|Treatment As Usual
45625923|NCT04853745|Device|AIR-FLOW® Master Piezon|AIR-FLOW® Master Piezon is intended for use in the cleaning and polishing of teeth by the projection of water,air, and dental powders onto the tooth surface. The device removes dental plaque, soft deposits, and surface stains from pits, grooves, interproximal spaces, or smooth surfaces of teeth. This air polishing device was used for all powder instrumentations.
45625924|NCT04836351|Other|Concentrated rehabilitation for patients with persistent symptoms post COVID-19|3+ 1-2 days concentrated rehabilitation for patients with persistent symptoms post COVID-19 with a mobile application follow-up and physical consultations at 3 months post intervention.
45625925|NCT04372329|Behavioral|CPAP4HealthySleep system|Tailored multimedia messages and tailored feedback messages delivered via web-based system to participants' phones to motivate them to use their CPAP therapy
45625926|NCT04841733|Other|Foam Roller (FR)|Foam Roller (FR): participants will follow the Foam Roller protocol using a polyvinylchloride pipe roller (10.3-cm diameter, 0.3-cm thickness surrounded by a 1,5-cm thickness neoprene foam). They will begin with the Foam Roller at the most proximal portion of the muscle and to roll as much body mass as tolerable back and forth along it as smoothly as possible at a cadence of 1 second superior and 1 second inferior as determined with the metronome. Foam Roller will be performed for 45 seconds followed by a 15-second rest for each muscle group (quadriceps, adductors, hamstrings, abductors and calf) in each extremity and repeated once.
45625927|NCT04841733|Other|Stretching (STR)|Stretching (STR): participants will perform 8-min of static stretching, involving 3 bilateral repetitions of 30 seconds held stretches to the quadriceps, adductors, hamstrings, abductors and calf muscles.
45625928|NCT04841733|Other|Cold-Water Immersion (CWI)|Cold-Water Immersion (CWI): will be the last strategy used. Participants will immerse their lower body to the level of the hips for 10 minutes in cold water (10° C).
45625929|NCT04835883|Biological|CS20AT04 (allogenic bone marrow derived mesenchymal stem cell)|Two intravenous infusions of CS20AT04 (2.0×10^6cell/kg), on 0 day and on 12 weeks The target population of this study is subjects in South Korea with a diagnosis of either lupus nephritis or lupus cytopenia.
45625930|NCT04841421|Drug|89Zr-CD147|The 89Zr-CD147 is a promising positron emission tomography probe and it is possible to select suitable tumor patients with CD147 expression to benefit from anti-CD147 treatment.
45625931|NCT04835337|Behavioral|Air Purifiers|Students are divided into two groups: intervention group and control group. The intervention team places an air purifier in the indoor environment to intervene. All the indoor environment of the group use the same qualified air purifier, and all participants and research staffs are blinded to the group assignment.
45625932|NCT04835337|Behavioral|Sham Air Purifiers|The control group is also intervened. The intervention is to place a sham air purifier (remove the filter screen) in the indoor environment, and all the indoor environment use the same air purifier as the intervention group. All participants and research staffs are blinded to the group assignment.
45625933|NCT04835259|Drug|Selenium Amino Acid Chelate (Selenium ACE cream)|application of a topical agent over the whole face for 6 months
45625934|NCT04368117|Behavioral|Physical Therapy|Directed and prescribe physical therapy program for severely burned patients
45625935|NCT04853901|Drug|Remdesivir|Remdesivir loading dose of 200 mg intravenously followed by 100 mg/day intravenously for 5 to 10days
45625936|NCT04853901|Drug|Standard of care_1|Hydroxycoloroquine 400mg twice on day 1 then 200mg tab twice 2-10 days
45625937|NCT04853901|Drug|Standard of care_2|Methylprednisolone 1-2mg/kg for 5-7 days
45625938|NCT04853823|Drug|PDC-APB|PDC-APB Intra-muscular Injection
46069695|NCT02620215|Device|Cervical Ripening Balloon|Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
45625939|NCT04853823|Other|Placebo|Vehicle
45625940|NCT04853277|Behavioral|Education|Each Patient will undergo a 30 minute telephone visit with a trained Medical Provider outlining the timeline of various common emotional challenges experienced after transplant/CAR-T, as well as coping techniques. A pamphlet with information discussed will also be provided to the patient to review on their own time. The patient will have an opportunity to express any psychosocial/emotional concerns at this time.
45625941|NCT01668537|Biological|LF formulation of IMVAMUNE®|
45452442|NCT00973024|Drug|JNJ-42160443 10 mg|JNJ-42160443 10 mg: type=exact number, unit=mg, number= 10, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 10 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
45625942|NCT01668537|Biological|FD formulation of IMVAMUNE®|
45625943|NCT03039387|Device|anodal transcranial direct current stimulation|
45625944|NCT03039387|Device|transcranial direct current stimulation (sham)|for the placebo control condition, the transcranial direct current stimulation will only last for 30 seconds and will then be ramped down.
45767436|NCT05620589|Drug|Amoxicillin + Tetracycline + Bismuth + Vonoprazan|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth +Vonoprazan 20mg bid or Amoxicillin1000mg bid+ Tetracycline 500mg tid+ Bismuth + Vonoprazan 20mg bid
46069696|NCT02620215|Drug|Prostin|Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.
45625945|NCT04836039|Other|A questionnaire and scales.|Participants will be evaluated by applying a questionnaire and scales created by the researcher physiotherapists based on the researches and examples in the literature.
45625946|NCT03039465|Device|Modified Trans-Esophageal Prosthesis|This device is a biomedical grade silicon voice prosthesis with an inner esophageal flange, a stem and an outer tracheal flange. Insertion would be done through a modified 'romovac' inserter set / curved metal inserter (provided with the TEP) and an oesophagoscope in case of secondary insertion would be used. in patients with existing TEP puncture / who require a TEP change, on out-patient basis, the insertion would be done with a novel two-part inserter device (front loading)
45625947|NCT04840953|Device|Vçac|VAC THERAPY vs SURGICAL DREINAGE
45625948|NCT04841031|Behavioral|NET Treatment|Narrative Exposure Therapy (NET) aims to address PTSD symptoms among survivors of mass violence and torture (Onyut et al., 2004; Schauer, et al., 2005). Mainly, different from other psychosocial interventions which require the survivor to process a single traumatic event in his or her life at a given time, NET treatment recognizes that trauma survivors undergo multiple distressing events within their lifetime (Schauer et al., 2005). Focusing on the traumatic events, the patient constructs a chronological narrative of his or her life story and a coherent narrative is then structured with the assistance of the therapist. They received NET one to three months following their screening and randomization. The therapy involves 8 to 12 individual sessions of about 90 minutes each.
45625949|NCT04841031|Other|Alternative Intervention|Individuals in control group received non-NET psychosocial support in the interim that is provided to SGBV survivors as part of the Great Lakes SGBV project and will then receive NET after endline data has been collected.
45625950|NCT04834947|Procedure|prone position|Choice of prone positioning a patient is at the discretion of the anesthesia physician.
45625951|NCT04840719|Device|RECO|
46069697|NCT04252820|Device|WarmTouch total body blanket, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied in the preanesthetic room
45767437|NCT05620589|Drug|Amoxicillin + Tetracycline + Bismuth + Tegoprazan|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Tegopraza 50mg bid
45447130|NCT02100982|Other|Care As Usual|Participants in this condition will interact with the research staff who will help the participant use an iPad in the waiting room to complete baseline health assessments. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
45625952|NCT04834791|Drug|Letrozole 2.5mg|These patients were treated with letrozole (Femara®, Novartis New York, NY, USA) in a dose 2.5 mg (one tablet daily) orally began on the 3rd day to the 7th day of the cycle. If ovulation is not achieved dose is increased by 2.5 mg in next cycle till 3 cycles
45625953|NCT04834791|Drug|Gonadotropin|These patients were given urofollitropin (fostimon ®, IBSA, Lugano, Switzerland) in a dose of 75 IU/mL I.M from day 3rd to day 7th of the cycle beginning by one ampoule per day and the dose had been modulated according to response.
45767438|NCT05620511|Behavioral|Mindfulness based stress reduction|Mindfulness based stress reduction v.s.Relaxation
45767439|NCT01086475|Drug|D-cycloserine|50 mg dose administered 30 minutes prior to each of the ten Social Skill Training Sessions
45447131|NCT03746067|Drug|TS-134|5 mg, 10 mg, or 20 mg oral solution
45447132|NCT03746067|Drug|Placebo|Matched Placebo oral solution
45767440|NCT01086475|Drug|Placebo|Placebo pill administered 30 minutes prior to each of the ten Social Skill Training Sessions
45767441|NCT01112683|Drug|Memantine|The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 & 10 mg/d divided dose week three, 10mg/BID week four).
45767442|NCT01112683|Drug|Placebo|These are identically-looking pills to those in the Memantine Arm.
45767443|NCT02245373|Drug|Antidepressants|
45767444|NCT02245373|Other|Active Monitoring|
45767445|NCT02906839|Other|Intervention group|Just after AF ablation, nocturnal polygraphy will be performed to diagnose SAS. If present and AHI >15/h, the SAS will be treated, based on type and severity of SAS and on patient tolerance to treatment.
45767446|NCT04355741|Other|Exposure|Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
45767447|NCT03032549|Dietary Supplement|RTD|Ready to Drink Supplement
45767448|NCT03032549|Dietary Supplement|Placebo|Placebo
45767449|NCT01113385|Drug|D-Galactose|Oral galactose will be initiated at a dose of 0.2gm/kg/dose twice daily to a maximum of 15 gm BID for a period of 4 months. The prescribed dose of D-galactose powder will be dispensed to subjects in packets, mixed with 4 ounces of water, and consumed orally.
45767450|NCT04355351|Other|blood sampling|blood sampling done on hospital staff without sars-coV-2 symptoms
46069698|NCT02620059|Behavioral|Lifestyle Intervention|The investigators will provide information on healthy eating and physical activity. They will give pedometers to the participants to monitor their daily steps in order to increase it till 10000 steps/day.
45452443|NCT00973024|Drug|Matching Placebo|Form= solution for injection, route= subcutaneous. Matching placebo given as a subcutaneous (SC) (under the skin) injection (inj) once every 4 weeks (wks).
45452444|NCT01314638|Other|Workshop balances|one workshop per week for 20 weeks. Evaluation before and after.
45452445|NCT03165110|Device|Onyx BG Meter / App System|Subjects with diabetes used the Onyx BG Meter / App System at home and assessed the features of the App.
45452446|NCT05464810|Drug|Letrozole|Given PO
45452447|NCT05464810|Drug|Simvastatin|Given PO
45625954|NCT04835181|Behavioral|Electroacupuncture combined with umbilical moxibustion|"①Umbilical moxibustion intervention: point selection: Shenque point Operation: Place the aconite cake on the Shenque point, place the Aizhu in the middle of the aconite cake, ignite the Aizhu and apply moxibustion to make the local warm sensation without burning pain, until the skin is flushed.~②Electro-acupuncture intervention: Acupoint selection: Tianshu, Zusanli, Zhongwan, Moisture, Daheng, Vein, Waterway, Huaroumen, Abdominal Knot.~Operation: supine position, routine skin disinfection. After routine acupuncture at the acupoints, apply the technique of flattening, replenishing, relieving, and relieving qi. Tianshu and Daheng points, respectively, were horizontally connected to the electrodes of the electroacupuncture instrument on the needle handles of the bilateral Tianshu and Daheng points.~Electroacupuncture parameters: density wave, current intensity 1-5mA, electroacupuncture intensity is subject to patient tolerance."
45452448|NCT05239676|Biological|Autologous hematopoietic stem cell transplantation combined with CD19 CAR-T cells|The patient receives ECHOP chemotherapy or other chemotherapy regimens； G-CSF in the low cell stage mobilizes hematopoietic stem cells and freezes them for later use after collection； Autologous hematopoietic stem cells and prepared CD19 CAR-T cells are reinfused into the patient
45625955|NCT04835181|Behavioral|Electroacupuncture|"②Electro-acupuncture intervention: Acupoint selection: Tianshu, Zusanli, Zhongwan, Moisture, Daheng, Vein, Waterway, Huaroumen, Abdominal Knot.~Operation: supine position, routine skin disinfection. After routine acupuncture at the acupoints, apply the technique of flattening, replenishing, relieving, and relieving qi. Tianshu and Daheng points, respectively, were horizontally connected to the electrodes of the electroacupuncture instrument on the needle handles of the bilateral Tianshu and Daheng points.~Electroacupuncture parameters: density wave, current intensity 1-5mA, electroacupuncture intensity is subject to patient tolerance."
45625956|NCT03039231|Device|Freespira Breathing System|Following authorization from a study team member, patient will be assigned an FBS to take home and perform 4 weeks of training exercises twice a day for 17 minutes each time. Efficacy of the FBS system will be evaluate over the 4 week period and at 2 and 6 month follow-up periods.
45625957|NCT04835025|Drug|PD-1/PD-L1 inhibitor|In non-small cell lung cancer, patients with brain metastases received radiotherapy for brain lesions and immunotherapy (including sequential and concurrent model). Those patients would enter the trial group; After patients experiencing PD in this group, follow-up treatment until tumor progression again or death
45625958|NCT03038919|Drug|Testosterone cypionate|Bi-weekly intramuscular injection of testosterone cypionate 200mg.
45625959|NCT03038919|Other|Standard nutrition and physical therapy at ICU|follow-up of the patient without use of testosterone cypionate
45625960|NCT04852263|Other|Group I|Oral fiberoptic intubation was carried out using lingual traction without nasopharyngeal airway.
45625961|NCT04852263|Other|Group II (NPA group)|Oral fiberoptic intubation was carried out using lingual traction plus modified nasopharyngeal airway.
45625962|NCT04794153|Dietary Supplement|whole food sources|Foods selected are naturally high in protein and consumed by the general population as part of a meal.
45625963|NCT04852341|Device|Collect ocular biological parameters including age, corneal diameter, eye axis, intraocular pressure, steep&flat axis of corneal curvature, corneal thickness, lens thickness, anterior chamber depth|observation
45625964|NCT04833543|Other|Robotic Mobility Device (REX)|A self supporting robotic mobility device (REX) will be utilized. It is a Class I device, and it is classified as powered exercise equipment meant for anyone that requires use of a wheelchair for mobility who has difficulty with standing and walking. The participant will be supported securely within the device using a pelvic harness, and thigh and calf cuffs. The device will be operated under the supervision of a device trained physical therapist and therapy technician. The participant will be transferred into the device in a seated position. Once aligned properly and strapped in, the participant will be passively moved by the device into standing and walking positions. To provide constant vestibular input, a variety of mobility functions will be performed including standing, sitting, walking, turning, shuffling (side-stepping), and backwards stepping.
45625965|NCT04833543|Other|Tilt Table|A tilt table is a table with a footplate that can be tilted at different angles. The participant will lie flat on the table and straps will be placed to stabilize the trunk and lower extremities. The inclination of the tilt table will be adjusted from a horizontal to a vertical position to allow the participant to attain and maintain a standing or partial-standing position. Sessions will be supervised by a physical therapist and therapy technician.
45625966|NCT04834713|Other|clinical classification of HFRS|Based upon clinical classification of HFRS , the patients were classified into four types
45625967|NCT04833621|Device|NMES GROUP|The effects of NMES and muscle strengthening and standard physiotherapy exercises on the development of ICU-AW were observed
45625968|NCT04834479|Device|Ankle US and Ankle MRI|Ankle US and Ankle MRI
45625969|NCT03036891|Drug|Naloxegol 25 MG Oral Tablet [Movantik]|Patients will be given the study drug (Movantik 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
45625970|NCT03036891|Drug|Placebo Oral Tablet|Patients will be given Placebo (Placebo 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
45625971|NCT04834323|Procedure|distal mesogastric fixation after sleeve gastrectomy|Investigators performed traditional laparoscopic sleeve gastrectomy then we fixed the greater omentum & mesocolon that were cut during gastrectomy to the remaining gstric pouch along the new greater curvature as high as possible along the stable line then we plicated the remaining staple line till angle of His. (the greater omentum & mesocolon not reach this part of staple line) , so the remaining gastric pouch remained tension free and was returned to original position and this may prevent the axial gastric rotation
45625972|NCT04851951|Procedure|one-shot PRP injection|A single injection of PRP (7% concentrate) ml 4 was made in the Supraspinatus tendon and in the Subacromial space under ultrasound guidance.
45767451|NCT04355351|Other|additional blood tubes|Additionnal blood tube taken during the classical blood sampling in hospital
45767452|NCT04355507|Diagnostic Test|Chest computed tomography (CT)|Chest computed tomography (CT) examination
46069699|NCT04252352|Device|Ablative fractional CO2 laser resurfacing/Radio-frequency microneedling|Intra-person split-face trial
46069700|NCT02620293|Device|Eczema Repair Emollient|An Emollient
46069701|NCT04288973|Diagnostic Test|Microsoft Kinect Detection during mother child interaction|methodology based on RGB-D sensors applied to the setting of free parent-infant interaction
45625973|NCT04851561|Diagnostic Test|Cardiopulmonary stress test (CPET)|Cardiopulmonary stress test will be conducted under the guidance of sports and exercise physicians and nursing staff. Electrocardiogram, spirometry, blood pressure and gas exchange measuring will be assessed at rest. The participants will then undergo CPET according to a modified Astrand treadmill test protocol. The test will be terminated at maximal exercise or upon the appearance of limiting symptoms. Continuous electrocardiogram and repeated blood pressure measuring will be conducted at the recovery phase. Post-exercise spirometry will also be assessed.
46069702|NCT04252508|Other|Animated film|An animated film depicts the child and the caregivers in the form of avatars and retraces his journey from his room to the transfer area, then to the the operating room and finally to the post-intervention ward.
45625974|NCT01668147|Drug|[11C] desmethyl-loperamide|IV administration of 10-14 mCi of [11C] desmethyl-loperamide with PET/CT imaging
45625975|NCT01668147|Other|Control - no pretreatment|Session 1: IV administration of 10-14 mCi [11C] desmethyl-loperamide (dLop) with PET/CT imaging and brain MRI
45625976|NCT01668147|Drug|Oral ritonavir|Session 2: Pretreatment with oral ritonavir for 3 days followed by IV administration of 10-14 mCi [11C]dLop with PET/CT imaging and brain MRI
45625977|NCT01668147|Drug|Oral efavirenz|Session 3: Pretreatment with oral efavirenz for 14 days followed by IV administration of 10-14 mCi [11C]dLop with PET/CT imaging and brain MRI
45625978|NCT04851639|Other|Wolverhampton Assessment Tool|a proxy means for assessing whether clinician intervention is required and to assess patient's lived quality of life
45452449|NCT05459662|Dietary Supplement|oat based porridge|Consume one preparation per day, orally
45452450|NCT05459662|Dietary Supplement|plant based preparation|Consume one preparation per day, orally
45625979|NCT04833777|Drug|Local Anesthetics Lidocaine|10 mL 1% lidocaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate
45625980|NCT04833777|Drug|Local Anesthetics Bupivacaine|5 mL 1% lidocaine with 1:100,000 epinephrine + 5 mL 0.5% bupivacaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate
46069703|NCT02619981|Procedure|Restorative procedure|A restorative dental procedure requiring maxillary buccal infiltration anesthesia, and not exceeding 30 minutes of working time
45625981|NCT03037047|Drug|0.9% Sodium Chloride Injection|Patients will treated with 0.9% Sodium Chloride Injection on the basis of conventional therapy for 14 days.
45625982|NCT03037047|Drug|salvianolate injection|Patients will treated with salvianolate injection on the basis of conventional therapy for 14 days.
45625983|NCT04323735|Drug|Culturelle 10 Billion CFU Capsule|"LGG® (Culturelle Probiotic with Lactobacillus RhamnosusGG, shown to produce the largest amount of antibacterial substances against pathogenic bacteria) will be used. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 2 or 4 LGG capsules (depending on randomization group) and will repeat this process the following day (Low dose) or twice daily for a total of four doses (High dose) according to randomization group."
45625984|NCT03036501|Drug|[^14C]-Risdiplam|[^14C]-Risdiplam 18 mg oral solution with approximately 0.75 megabecquerel MBq (20 microcuries [μCi]) of [14C]-labeled Risdiplam.
45625985|NCT03036345|Device|Dual-monitoring|Monitored using both INVOS and FORE-SIGHT monitors.
45625986|NCT03036189|Behavioral|baa nnilah|7 meetings in the community led by a trained community facilitator
45625987|NCT04832997|Diagnostic Test|Prostate biopsy systematic random prostate biopsy (TRUS-Bx) + eventual MRI-targeted biopsy (MRI-TBx) + eventual microUS-targeted (Micro-US-TBx)|Patients with both positive mpMRI and Micro-US, defined as the presence of one or more lesions with PI-RADS >= 3 and PRI-MUS >= 3 respectively, will receive a 12-core TRUSBx in addiction to MRI-TBx and Micro-US-TBx. Patients with both negative mpMRI and Micro-US will receive a 12-core TRUSBx. Patients with only positive mpMRI will receive MRI-TBx and 12-core TRUSBx. Patients with only positive Micro-US-TBx will receive Micro-US-TBx and 12-core TRUSBx.
45625988|NCT04834011|Procedure|Laparoscopic right colonic resection with Complete Mesocolic Excision (CME)|
45625989|NCT04834011|Radiation|3D CT angiography|
45625990|NCT04834089|Biological|AntiSARS-CoV-2 Serum|Stage A: 30 kidney transplanted participants (very high risk), where 15 will received 1 vial (5 mL) and 15 will received 2 vials (10 mL) of serum; Stage B: 30 immunocompetent participants with at least 2 risk factors for severe disease (high risk) who will receive the dose selected by stage A; Stage C: 558 participants, of very high risk and high risk, compared with placebo in allocation 2:1.
45625991|NCT04834089|Other|Placebo|Saline solution Administration Route: Intravenous
45625992|NCT04834245|Procedure|Hydrogel/nano silver-based dressing|compare the effectiveness of using hydrogel/nano silver-based dressing vs. traditional dressing on diabetic foot wound healing.
45625993|NCT04851093|Drug|TCM granule plus conventional drug|"All patients will receive conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.~Yiqiwenfei granule for qi deficiency and internal cold fluid syndrome.~Fuzhengqinghua granule for qi and yin deficiency and unclean phlegm heat syndrome.~Fuzhengzaohua granule for lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome.~TCM granule (Jiangyin Tian Jiang Pharmaceutical Co.,Ltd, 10g/packet) will be administered twice daily for 8 weeks."
45767453|NCT04355507|Diagnostic Test|Reverse-transcription polymerase chain reaction (RT-PCR)|Identification of viral RNA by reverse-transcription polymerase chain reaction
45767454|NCT01087801|Drug|ChiRhoStim|Human Secretin for Injection
45767455|NCT01087801|Drug|Placebo|Saline for Injection
45767456|NCT04355273|Drug|Heparin|heparin with a concentration of 2 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
46069704|NCT02619981|Drug|Maxillary infiltration anesthesia with 2%Lidocaine|1.8ml of 2% Lidocaine with adrenaline administered using a 27 gauge 21mm needle
45625994|NCT04851093|Drug|TCM placebo granule plus conventional drug|"All patients will receive conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.~Placebo Yiqiwenfei granule for qi deficiency and internal cold fluid syndrome.~Placebo Fuzhengqinghua granule for qi and yin deficiency and unclean phlegm heat syndrome.~Placebo Fuzhengzaohua granule for lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome.~TCM placebo granule (Jiangyin Tian Jiang Pharmaceutical Co.,Ltd, 10g/packet) will be administered twice daily for 8 weeks.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The placebo granule consists of dextrin, bitter and 5% of the TCM granule."
45625995|NCT04851171|Procedure|Flexible Ureteroscopy|Flexible ureteroscopy is the use of flexible ureteroscope for the treatment of stone in the upper ureter with the aid of laser lithotripsy.
45625996|NCT04851171|Procedure|Semi-rigid Ureteroscopy|Semi-rigid ureteroscopy is the use of the semi-rigid ureteroscope for the treatment of stone in the upper ureter with the aid of laser lithotripsy.
45625997|NCT04851015|Drug|trimethoprim-sulfamethoxazole|10mg/kg/day of TMP component
46069705|NCT03872297|Dietary Supplement|Placebo supplement|"Consumption of a non active food complement during 3 months.~Tests performed :~2 blood tests :~2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study."
45625998|NCT04851015|Drug|trimethoprim-sulfamethoxazole|15mg/kg/day of TMP component
45625999|NCT04365933|Drug|EYP001a|Oral tablets
46069706|NCT03872297|Dietary Supplement|Naticol supplement|"Consumption of the active food complement during 3 months containing Naticol.~Tests performed :~2 blood tests :~2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study."
45626000|NCT04365933|Drug|Entecavir|Oral tablets
45626001|NCT04365933|Drug|Pegylated interferon alpha2a|Subcutaneous
45626002|NCT04832451|Behavioral|Interpersonal Relational Role Analysis|"Interpersonal Relational Role Analysis (IRRA) is a psychosocial group intervention that allows individuals to see the problems they experience in interpersonal relationships and interactions in the group environment and to be handled together with group members.~Similar to Yalom's interactional group therapy model, IRRA sessions comprise warm up, the stages of setting the agenda, working, evaluating, and getting feedback from observers, which are based on the 'here and now' principle. IRRA helps to safely examine the roles in which group members are stuck, in a group environment which is a small example of social life, and these roles are addressed in six steps."
45626003|NCT04825119|Drug|Nusinersen|Patients with SMA who will be treated with nusinersen will be included.
45626004|NCT04824573|Device|Inspiratory Muscle Training|Inspiratory Muscle Training (IMT) was performed with Powerbreathe Classic-Light Resistance device. To determine the intensity of the training, MIP values were measured with the help of the respiratory pressure meter-RP Check (MD Diagnostics Ltd. RP Check MIP & MEP) device before each training. The pressure corresponding to 50 percent of the MIP value in the Powerbreathe device was determined as training workload. It was applied two days a week for four weeks, with five-set and five repetitions, for 20 minutes with 30 seconds rest in between. This inspiratory muscle training program has previously been used by several studies to improve respiratory muscle strength.
45626005|NCT04824573|Other|Manual Therapy|"In the manual diaphragm release technique; While the participant was breathing in, the physiotherapist raised his hand slowly to accompany the rising movement of the ribs and deepened the contact during exhalation. The maneuver was performed in two sets of 10 deep breaths.~In thoracic mobilization application; The physiotherapist, standing behind the participant, wrapped the crossed arms from his right upper arm with his left hand and performed stretching, extension, lateral flexion, and thoracic rotation with his right hand.~In HVLA thoracic manipulation; the physiotherapist, with the support hand on the participant's elbows, applied HVLA thrust in the posterior-anterior and inferior-superior directions with the help of his body while the manipulating hand was on the transverse processes.~For cervical joint mobilization; the physiotherapist was applied using the right hand in flexion, extension, right-left rotation, and lateral flexion directions."
45626006|NCT04824339|Behavioral|Immediate Intervention Group|This study is a partial cross over study. The intervention is 8 weeks in duration. Participants will be randomized to immediate exercise or delayed exercise, and the delayed exercise group will cross over to the intervention after 8 weeks.
45626007|NCT04824339|Behavioral|Delayed Intervention Group|This study is a partial cross over study. The intervention is 8 weeks in duration. Participants will be randomized to immediate exercise or delayed exercise, and the delayed exercise group will cross over to the intervention after 8 weeks.
45626008|NCT04824495|Diagnostic Test|Blood sample|Blood samples at different timepoints during SARS-CoV2 infection
45626009|NCT04378569|Drug|ARQ-252 cream 0.3%|ARQ-252 cream 0.3%
45626010|NCT04378569|Drug|ARQ-252 cream 0.1%|ARQ-252 cream 0.1%
45626011|NCT04378569|Drug|ARQ-252 Vehicle Cream|ARQ-252 Vehicle Cream
45626012|NCT04832373|Device|Interaction with humanoid robot|A humanoid robot will be installed for 30 days in children. It has a touchscreen tablet, allowing manual interaction complementing the voice interaction. The robot speaks, hears, and has facial and voice identification.
45626013|NCT04832217|Other|Pyrenees´ Beef diet|24 participants were randomly assigned to a Pyrenees' beef diet, 3 serving per week during of 8 weeks.
45626014|NCT04824261|Drug|Clotrimazol solution 1%|50 otomycosis randomized patients will receive Clotrimazol solution 1% The treatment will be locally applied for at least 2 weeks. All the patients will be followed up after the 1st week, 2nd week and after 1 month.
45626015|NCT04824261|Drug|4%boric acid in distilled water|50 otomycosis randomized patients will receive 4%boric acid in distilled water The treatment will be locally applied for at least 2 weeks. All the patients will be followed up after the 1st week, 2nd week and after 1 month.
45626016|NCT05618457|Drug|Aminoglycoside dose adjustment|Eligible patients may have the aminoglycoside dose adjusted based on pathogen MIC, to attain the PK/PD target of Cam/MIC~10 (8-12)
45626017|NCT04832061|Other|Respiratory supports|The respiratory supports used in this patient population included conventional oxygen therapy (COT) via nasal cannula or face mask, non-invasive ventilation (NIV), and invasive mechanical ventilation (IMV). NIV has three different methods, including high-flow nasal cannula (HFNC), bilevel positive airway pressure (BiPAP), and continuous positive airway pressure (CPAP).
45767457|NCT04355273|Drug|Heparin|heparin with a concentration of 4 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
45767458|NCT04355273|Drug|normal saline|normal saline is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
45626018|NCT04831905|Device|Micro-wave ablation|Micro-wave ablation
45626019|NCT04823793|Diagnostic Test|Stool DNA methylation detection|Stool specimens are collected from participants in the outpatient department or the inpatient department. Both FIT and stool DNA real-time PCR are performed simultaneously. To improve the sensitivity and specificity of the colorectal cancer screening, this study enrolls multiple candidate genes to distinguish whether the participant has a high risk of colorectal cancer.
45767459|NCT04352725|Procedure|End-expiratory lung volume measurement and incremental PEEP titration|"End expiratory lung volume measurement procedure according to the PEEP level set by the clinician, respecting a Vt at 6ml/kg IBW and Pplat<28cmH2o~incremental PEEP titration procedure in 5 steps starting from 5cmH2o up to 20cmH2o"
45767460|NCT04355429|Drug|captopril 25mg|Drug administration
45767461|NCT01114555|Drug|Bevacizumab, Irinotecan and Temozolomide|Patients will initially receive bevacizumab IV at 15mg/kg/dose (this is defined as Day 1 Three days later (starting day 4), they will receive concurrently, IV irinotecan at 50mg/m2/day x 5 days plus PO temozolomide 150mg/m2/day x 5 days. A second dose of bevacizumab will be administered 14 days after the first one(day 15). The treatment schedule may require minor adjustment as clinically indicated (e.g., due to PDH closure for holidays).
45767462|NCT02673931|Drug|Byetta (Lilly, Exenatide)|See description of arms
45767463|NCT02673931|Drug|Conoxia (AGA, oxygen)|See description arms
45767464|NCT02673931|Drug|20% Human Albumin|
45767465|NCT04433117|Biological|Shefabone|Silica-calcium phosphate composite.
45767466|NCT04433117|Biological|Bio-Oss|Xenograft Bone substitute. Bone from animals.
45767467|NCT04359641|Device|CoMET Display|Display and presentation of predictive monitoring score CoMET
45767468|NCT01114945|Device|McGrath|Intubation with the McGrath device
45912794|NCT02014558|Drug|Gilteritinib|Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.
45912795|NCT02014558|Drug|Voriconazole|Participants received 200 mg voriconazole tablets daily every 12 hours starting from day 16 of cycle 1 through day 1 of cycle 2.
46069707|NCT04252430|Drug|MD1003|Single oral dose administration of MD1003 at Day 1
45626020|NCT04850235|Drug|Nab paclitaxel|Nab paclitaxel plus cisplatin and capecitabine as neoadjuvant chemotherapy
45626021|NCT03036033|Device|SaeboGlove|All participants are given a Saebo glove to use during their stroke recovery.
45626022|NCT04850001|Drug|Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|All patients received standard medical management, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
45626023|NCT04823715|Other|TACE + hypofractionated EBRT|One cure of doxorubicin or DC Beads transarterial chemoembolization by a highly experienced interventional radiologist, followed 1 to 4 weeks later by hypofractionated external beam radiation therapy up to a total dose of 45-60 Gy, 3 Gy per fraction, 5 fractions per week, for an overall treatment time of 3 to 4 weeks.
45626024|NCT04823715|Procedure|Surgical resection|Surgical resection by open-laparotomy or laparoscopy of hepatocellular carcinoma by a highly experienced liver surgeon
45767469|NCT01114945|Device|GlideScope|Intubation with the GlideScope device
45912796|NCT02014558|Drug|Midazolam|Participants received a single oral dose of 2 mg of midazolam syrup on day -1 and day 15 of cycle 1.
45912797|NCT02014558|Drug|Cephalexin|Participants received a single oral dose of 500 mg cephalexin tablet or capsule on day -1 and day 15 of cycle 1.
45912798|NCT02014571|Drug|GSK2878175|Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose.
45912799|NCT02014571|Drug|Placebo|Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose visually matching GSK2878175.
45767470|NCT01114945|Device|Direct Macintosh Laryngoscopy|Intubation with Direct Macintosh Laryngoscope
45767471|NCT01114945|Device|Video-Mac|Intubation with the Video-Mac device
45767472|NCT01115101|Drug|Oral Oxycodon|Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean.
45767473|NCT01115101|Drug|Piritramid|"Patients assigned to the PCA group received a single use intravenous PCA device (Vygon, Medical Products, Aachen, Germany) with a 30ml deposit of 9% sodium chloride solution containing 60mg piritramide. Bolus injection of 0.5ml was administered by the patient herself if needed, with a lock out interval of 5 minutes~Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean. The PCA was discontinued after 24 hours or earlier if demanded."
45767474|NCT00943631|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
45912800|NCT02014623|Other|Grass pollen sublingual immunotherapy tablet|
45912801|NCT02014623|Drug|Control|
45912802|NCT02014636|Drug|Pazopanib|Pazopanib is an orally administered 200 mg tablet available in the dose range of 400 to 800 mg
46069708|NCT02864225|Device|Scalp electrode,|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
45626025|NCT04823559|Other|ThinkCancer workshop|The proposed intervention, the ThinkCancer! Workshop, is practice-based and consists of themed sessions for both clinical and non-clinical staff, the co-production of a Cancer Safety Netting Plan (CSNP) and the appointment of a Cancer Safety Netting Champion (CSNC). The workshop aims to raise awareness and increase knowledge around current cancer diagnosis guidance and will be delivered over half a day during GP protected time in the form of face-to-face educational sessions. Sessions will consist of a series of interactive activities exploring existing processes within practices and developing plans for change to implement each component.
45626026|NCT04823637|Diagnostic Test|Ultrasonography vs Osteopathic manipulative medicine structural exam|Structural examination of the thoracic spine using ultrasound and osteopathic palpatory examination on skin.
45626027|NCT03036111|Drug|Trimebutine|Trimebutine suppository will be inserted in the anal canal on completion of hemorrhoidectomy then at six and 12 hours postoperatively.
45626028|NCT03036111|Procedure|Hemorrhoidectomy|Patients will undergo classic Milliagn-Morgan hemorrhoidectomy
45626029|NCT04831359|Device|Doppler ultrasound|Tissue Doppler ultrasound on pediatric patients
45626030|NCT04823325|Procedure|Orthognathic Surgery|The duration for presurgical orthodontic treatment was; 7,7 ± 1,7 months.
45626031|NCT04823169|Other|podobarometry|podobarometric measures on day 7 and day 30
45626032|NCT04823013|Other|high power pain threshold ultrasound which the dose was kept constant|Participants in HPPT-US 1 group received the HPPT-US treatment. The intensity was gradually increased from 0.5 W/cm² to the pain threshold level at which the patient verbally reported the pain. The therapist kept the intensity at that level for 5 s, and then moved the US transducer in a circle without the change of the intensity for 15 s. The procedure was repeated 3 times. The patients were asked whether serious pain or any abnormal sensation was felt during HPPT-US. The intensity was varied from 0.5 to 1.2 W/ cm².
45626033|NCT04823013|Other|high power pain threshold ultrasound which the dose reduced to one half|Participants in HPPT-US 2 group also received the HPPT-US treatment. The intensity was gradually increased from 0.5 W/cm² to the pain threshold level at which the patient verbally reported the pain. The therapist kept the intensity at that level for 5 s, then reduced the dose half and moved the US transducer in a circle for 15 s. The procedure was repeated 3 times. The patients were asked whether serious pain or any abnormal sensation was felt during HPPT-US. The intensity was varied from 0.5 to 1.2 W/ cm².
45767475|NCT02245529|Drug|Tamsulosin|
45767476|NCT04337021|Behavioral|Caregiver SOS|SOS care is brief, telephonic care (6 one-hour sessions over 3-4 months) tailored to the CG's needs, preferences, and priorities. SOS care addresses both work and caregiving stress. The five pillars of behavior change in SOS care are: 1) knowledge of work and CG stress; 2) stress management skills and abilities; 3) supports and resources; 4) confidence and motivation to modify stress; and 5) work and CG-focused problem-solving skills. The pillars are addressed through seven modules. In six sessions, the CM will cover each module at least once. SOS care involves an ongoing process of formulating self-management goals and action plans and preparing CGs to succeed in implementing them. Addressing both work and caregiving contexts, CMs will educate CGs about stress. CMs introduce strategies for self-managing stress and collaboratively design experiments to test these strategies. The CG's progress is monitored to identify strategies that effectively achieve self management goals.
45767477|NCT00947765|Biological|Autologous blood injection|Patients were infiltrated with injection of 2 ml autologous blood drawn from contra lateral upper limb vein mixed with 1 ml 0.5% bupivacaine, at the lateral epicondyle according to the standard technique.
45767478|NCT00947765|Drug|Local corticosteroid injection|Patients were infiltrated with 2 milliliters of local corticosteroid (Methyl prednisolone acetate 80mg) mixed with 1 milliliters 0.5% Bupivacaine, at the lateral epicondyle according to the standard technique
45767479|NCT01089517|Drug|E10030 plus Lucentis|once a month intravitreal injection
45767480|NCT01089517|Drug|Lucentis|10 mg/mL intravitreal injection monthly
45912803|NCT02014636|Drug|MK-3475|MK 3475 is an intravenously administered 100 mg/ 4mL solution available in the potential dose range of 1 to 10 mg/kg.
45447133|NCT03555370|Behavioral|Vestibular Exercise Intervention|The vestibular exercise intervention group will complete behavioral management activities, and prescribed in--office/at home vestibular exercises from four groups: 1) gaze stability training (integrated eye and head movements on fixed target), 2) visual motion training (integrated eye and head movements on moving target), 3) standing balance (standing with eyes closed in different stances), and 4) dynamic gait (walking with head turns and eye movements). Participants will be prescribed to one of four levels of these exercise groups based on presentation of symptoms/impairment as indicated on VOMS. Progression through the levels will be based on symptom tolerance and successful completion of all exercises at the current level.
45626034|NCT04823013|Other|ischemic compression|Participants in IC group received ischemic compression therapy. The technique was applied in the sitting position to participants. Ischemic compression was performed by compressing trigger points identified by palpation with tolerable intensity using thumb. The duration for each trigger points was 1 minute. Then the muscle containing the trigger point was applied intramuscular stretching for 30 seconds by therapist
45626035|NCT04816695|Device|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
45626036|NCT04816539|Device|TetraGraph|Use of two monitoring devices of neuromuscular function during surgery
45767481|NCT04311515|Radiation|Tau Positron emission tomography (PET)|Tau PET imaging enables the longitudinal assessment of the spatial pattern of tau deposition. Tau accumulates with progression of AD dementia and may be sensitive to disease related changes, particularly those due to intervention with a drug thought to work through a tau related mechanism. Quantitative assessments will be utilized to evaluate the target engagement and pharmacological effects of PU-AD after 6 months of treatment
45912804|NCT02014662|Other|Eccentric exercise|Each subject will perform eccentric exercise against a predefined personal maximal strength of their non-dominant leg on day 1. Changes on strength, biomarker concentrations and muscle protein synthesis during damage and recovery will be measured over 22 days.
46073663|NCT04269031|Drug|AZD2373 subcutaneous injection|Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).
46073664|NCT04269031|Drug|Placebo|Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.
45912805|NCT02014701|Procedure|Echocardiogram|"Contrast echocardiography with Optison for assessment of regional wall motion. This will be performed immediately following the resting echocardiogram by a sonographer specifically trained in myocardial contrast echocardiography.~Contrast echocardiogram with Optison for assessment of myocardial perfusion. This will be performed using a continuous infusion of Optison using low mechanical index power-modulation imaging of the myocardium and blood pool. Myocardial perfusion will be assessed offline using video intensity analysis software."
45912806|NCT02014714|Drug|Morphine|Drug: Morphine Depending on the randomization schedule, 0.1mg of morphine or will be added to the intrathecal mixture.
45626037|NCT05617365|Combination Product|Osteopathic Manipulative Therapy and Exercise Therapy|"At the physician's discretion, each subject will receive a minimum of 4 treatments up to a maximum of 8 treatments over the 12-week duration of the study (Haas et. al., 2018). The patients may be treated in the seated, prone and/or supine positions. Duration of treatment will depend on the degree of documented dysfunction but will be limited to one half hour. The techniques utilized by the physician may vary for many reasons including the degree of restriction, acuity, or patient cooperation.~The THE protocol will involve subjects performing cyclic voluntary retraction and protrusion of their head."
45626038|NCT04830579|Drug|Etoricoxib film-coated tablet 120 mg|Etoricoxib is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 120 mg of etoricoxib.
46073665|NCT04239690|Other|Micromethods for blood sample analysis|Micromethods in the intervention arm are applied aiming to achieve a mean reduction of 50 % of sampled blood volume during the first two postnatal weeks as compared to standard clinical blood sampling analyses
45626039|NCT04830579|Drug|Arcoxia® film-coated tablet 120 mg|Arcoxia® is manufactured by Frosst Iberica SA, Spain. Each tablet contains 120 mg of etoricoxib.
45626040|NCT04428021|Drug|Standard Therapy Protocol (STP)|Standard Therapy Protocol according to the best evidence treatment recommended by the Regional Health System emergency committee
45626041|NCT04428021|Other|STP + Standard Plasma (SP)|Transfusion of three Standard Plasma Units (SP) on day 1,3,5 in addition to STP
45626042|NCT04428021|Other|STP + COVID-19 Convalescent Plasma (CP)|Transfusion of three SARS-Cov-2 neutralizing antibodies positive Plasma Units (CP) on day 1,3,5 in addition to STP
45626043|NCT04816461|Drug|Amodiaquine Sulfadoxine-Pyrimethamin administration|SMC treatment
45626044|NCT04816461|Drug|Dihydroartemisinin-Piperaquine|Roommates treatment if they are positive to malaria
45626045|NCT04816461|Diagnostic Test|Standard HRP2-RDT|Roommates screening with standard HRP2-RDT
45626046|NCT04816461|Diagnostic Test|Highly sensitive RDT|Roommates screening with highly sensitive RDT
45626047|NCT04427865|Drug|prophylactic lactoferrin daily|200 mg oral lactoferrin daily
45626048|NCT02600559|Drug|OTO-201 (ciprofloxacin)|
45767482|NCT04311515|Radiation|Fluorodeoxyglucose (FDG) Positron emission tomography (PET)|Measurement of neuronal function with FDG PET can help to understand the relationship between target engagement and potential clinical effects. FDG PET will be acquired using stringent quality control. Since glucose metabolism captures all neuronal activity, in order to isolate effects due to treatment, patients will be maintained in a consistent state during the tracer uptake period. Subject motion during image acquisition will be minimized and monitored. Images will be quality controlled, processed, and measured quantitatively using methods that maximize signal to noise associated with technical and physiologic variability
45767483|NCT04311515|Diagnostic Test|Cerebrospinal fluid (CSF) Biomarkers|A broad set of biomarkers are being assessed in this study to indicate whether this treatment is able to impact multiple pathways associated with AD related to neurodegeneration
45767484|NCT04311515|Diagnostic Test|Blood Biomarkers|Changes in blood biomarkers may be observable if treatment affects cerebral amyloidosis and loss of nerve cells
45767485|NCT04311515|Behavioral|Rating Scales|Alzheimer's Disease composite score (ADCOMS+), CDR sb, Alzheimer's Disease Assessment Scale Cognitive (ADAS cog), Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS ADL), Mini Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale Cognitive (ADAS-COG 12)
45767486|NCT04311515|Drug|PU-AD|PU-AD 30mg daily for 6mos
45767487|NCT04311515|Drug|Placebo|Placebo 30mg daily for 6mos
45767488|NCT01089595|Drug|Nilotinib|Nilotinib 400 mg po bid
45626049|NCT04427943|Procedure|revision surgery|The intervention is the planned revision surgery according to local guidelines.
45626050|NCT04822857|Diagnostic Test|AMH|The group was divided according to the level of Anti-Müllerian Hormone
45767489|NCT01089595|Drug|Nilotinib with Imatinib|Nilotinib 400 mg po BID Imatinib 400 mg po daily
46073666|NCT05515419|Biological|Allogeneic cord blood treatment|Allogeneic cord blood treatment
45626051|NCT04822779|Device|Sonopuls 490u, Enraf-Nonius, Rotterdam, Kingdom of the Netherlands|"Ultrasound therapy will be applied in continuous output, 1 MHz frequency, the intensity of 1.5 W / cm2, and duration 10 min per treatment, on the front of the shoulder, on the surface of 2 ultrasound heads (10 cm2).~The position of the arm will be in adduction and internal rotation in RCT of the supraspinatus, adduction and external rotation of the arm in RCT of the subscapularis, and the position of the arm over the opposite shoulder in RCT of the infraspinatus."
45626052|NCT04822779|Other|Placebo|"Sham ultrasound therapy will be applied using a frequency of 0 Hz, intensity 0 W / cm2, 10 min per treatment.~The position of the arm will be in adduction and internal rotation in RCT of the supraspinatus, adduction and external rotation of the arm in RCT of the subscapularis, and the position of the arm over the opposite shoulder in RCT of the infraspinatus."
45626053|NCT04830657|Other|Distant reiki|In order to determine the sample size of the study, it is planned to study with a total of 62 patients, including at least 31 patients in each group, in the power analysis based on the statistics of the statistician and previous studies. The remote reiki group will be given remote reiki 3 times a week for 4 weeks by the researcher who has a reiki application certificate. Remote reiki sessions will be performed by the reiki practitioner the night before the hemodialysis day of the patient, and the session duration will take approximately 36-40 minutes. After the individuals receive 12 sessions of remote reiki (1 month later), the questionnaire will be filled in for the second measurement. In order to determine whether reiki has an effect in the long term, 4 weeks (1 month) after the second measurement, the questionnaire for the third measurement will be completed and the research will be completed.
45626054|NCT04830189|Device|shoulder sling|Patients were used shoulder slings
45626055|NCT04830189|Device|forearm sling|Patients were used forearm slings
45626056|NCT04427787|Drug|Cabozantinib|Cabozantinib will be administered orally at a dose of 60 mg/day
45626057|NCT04427787|Drug|Lanreotide|Lanreotide will be administrated 120 mg injection every 28 days
45767490|NCT04268693|Other|urine collection|Collect three urine samples either in the clinic or at home. This will occur prior to starting neoadjuvant chemotherapy, and again at the end of the scheduled course of neoadjuvant chemotherapy.
45447134|NCT03555370|Behavioral|Standard of Care|The standard of care consists of standardized in office/at home behavioral management including sleep, hydration, nutrition, and stress management interventions.
45767491|NCT03032159|Behavioral|Text2Breathe Study Group|
45626058|NCT04816383|Other|"Breastfeeding at AU Apple-Based Smartphone Application"|This is a free Apple-Based Smartphone Application the participant can download. In the application, there is information and tips for breastfeeding success and continuation, as well as information on additional resources both online and in the community as a whole.
45767492|NCT04354961|Drug|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
45626059|NCT04815915|Other|Graston technique|Graston tool was used to treat patients 3 times in a week according protocol for 6 weeks' treatment plan with extensions bised exercises protocol following pattern of APTA.
45626060|NCT04816071|Drug|Essential amino acids|Dietary Supplement
45626061|NCT04816071|Dietary Supplement|Maltodextrin|Control
45626062|NCT04822623|Diagnostic Test|MRI|MRI examination
45626063|NCT04830111|Device|heart rate variability biofeedback Application (Eureka iDestressor)|heart rate variability biofeedback protocol duration time is 10 min twice/day for 5days
45767493|NCT04354961|Drug|Paclitaxel and carboplatin|"Paclitaxel 175 mg/m² IV on day 1 of each 21 day cycle，4-6 cycles. Carboplatin AUC=5 IV on day 1 of each 21 day cycle, 4-6 cycles.~A cycle of treatment is defined as 21 days of once daily treatment."
45767494|NCT01089751|Drug|trospium chloride|Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks
45767495|NCT01089751|Drug|placebo|Placebo once daily on an empty stomach for 14 weeks.
45767496|NCT03032315|Drug|TAH Tablet (Telmisartan80/Amlodipine besylate10/Hydrochlorothiazide12.5)|Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 12.5 mg combination-drug would be administered orally once
45767497|NCT03032315|Drug|TWYNSTA(Telmisartan+Amlodipine besylate)|TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
46073667|NCT02822196|Drug|Lidocaine|Local Anesthesia using 1% Lidocaine
46073668|NCT02822196|Drug|Bupivacaine|Local Anesthesia using 0.25% Bupivacaine
45447135|NCT03745911|Combination Product|Paclitaxel and TAK-228|Treatment with TAK-228 oral (D2, 3 and 4 of each week) and paclitaxel (D1 of each week) on Days 1, 8 and 15 for each 28-days cycle until disease progression or unacceptable toxicity. If paclitaxel is stopped, TAK-228 may be continued
45447136|NCT03242252|Drug|Placebo|"Placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily.~Route of administration: Oral"
45447137|NCT03242252|Drug|Sotagliflozin|"Sotagliflozin 200 mg, tablet, orally once daily.~Route of administration: Oral"
45447138|NCT02106208|Other|Cheese diet|
45447139|NCT02106208|Other|Butter diet|
45626064|NCT03987399|Other|Tailored educational intervention|Educational day (lecture and workshop), clinical supervision and reminders
45626065|NCT04829253|Behavioral|Dialectical Behavior Therapy -3-months|Modification of affect regulation, behavioral regulation, interpersonal functioning and identity functioning through the use of skills training, phone check-ins, crisis management and individual initial assessment.
45626066|NCT04829253|Behavioral|Dialectical Behavior Therapy -6-months|Modification of affect regulation, behavioral regulation, interpersonal functioning and identity functioning through the use of skills training, individual psychotherapy, coaching calls and treatment-team consultation.
45626067|NCT04822233|Device|Hall Technique (HT)|Prior to each restoration, a bacterial sample of the lesion will be obtained with a cotton swap and dispensed in a transport medium for microbial analyses.The preformed metal crown (PMC) will placed without local anesthetic and without crimping or trimming. When the contact points are tight, an orthodontic elastic separator will be placed for 2 hours prior to PMC placement. The PMCs will be cemented with glass ionomer Ketac cem.
45626068|NCT04822233|Device|Modified Hall Technique (MHT)|Prior to each restoration, a bacterial sample of the lesion will be obtained with a cotton swab and dispensed in a transport medium for microbial analyses.This group will in addition to all the procedures for the Hall will have the Caries lesions treated with 30% Silver Diamine Fluoride (SDF) before cementation of the stainless-steel crowns.
45626069|NCT04822233|Device|Conventional Technique (CT)|Prior to each restoration, a bacterial sample of the lesion will be obtained with a cotton swab and dispensed in a transport medium for microbial analyses. Conventional occlusal, proximal slicing and when necessary buccal and lingual surfaces will be carried out under local anesthesia and dental dam isolation local anesthesia.The PMC will be trimmed and crimped at the gingival margin to improve the fit, and cemented with Ketac cem.
45767498|NCT03032315|Drug|Hydrochlorothiazide|Dichlozid 1 Tab.(Hydrochlorothiazide 12.5 mg) would be administered orally once
46073669|NCT00706017|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
45447140|NCT02106208|Other|CHO diet|
45447141|NCT02106208|Other|MUFA diet|
45447142|NCT02106208|Other|PUFA diet|
45447143|NCT03554590|Behavioral|carbohydrate counting|patients will attend a 5 meetings-structured training to learn how to manage their insulin therapy depending on the amount of carbohydrates contained in foods
45447144|NCT03554590|Behavioral|insulin therapy according to standard care|patients will not manage their insulin therapy depending on the amount of carbohydrates contained in foods, but will follow a fix basal bolus scheme
45447145|NCT05362864|Procedure|Fracture fixation via Intramedullary Nailing|Fixation of trochanteric, sub-trochanteric, and shaft fractures and osteotomies.
45447146|NCT02106286|Drug|Bisoprolol|
45626070|NCT04822077|Radiation|Proton radiation|"Patients with radical surgery and unfavourable histology (B2, B3, C) and/or Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE).~Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE)~Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)"
45626071|NCT04821843|Drug|Platinum based chemotherapy|q1-3W according to physician's preference
45626072|NCT04821843|Drug|Paclitaxel based chemotherapy|q1-3W according to physician's preference
45626073|NCT04821843|Radiation|Radiotherpay|40-50Gy/1.8-2.2Gy/20-25f
45626074|NCT04821843|Procedure|Surgery|Radical esophagectomy
45626075|NCT04821843|Drug|Immunotherapy|Anti-PD-1/PD-L1 Antibody
45626076|NCT04821843|Drug|5-FU Analog based chemotherpay|W1-5 qW or d1-14, q3W according to physician's preference
45767499|NCT01090921|Drug|Bortezomib|"Bortezomib will be administered at a dose of 1.6 mg/m2 IV push. Treatment will be administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle.~Dexamethasone will also be administered at a dose of 40mg on the day of and day after each dose of bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone."
45626077|NCT04821843|Drug|Nimotuzumab|200-400mg, d1,qW
45626078|NCT04815837|Behavioral|Intervention|"Viewing a video promoting Human Papillomavirus (HPV) vaccination: participants will watch a 5-minute online video promoting MSM's uptake of HPV vaccination. In the video, a peer MSM discussed about the risk of contracting HPV and having anal cancers among MSM, severe consequences of HPV-related diseases, as well as the benefits of HPV vaccination. He also demonstrated the procedures of taking up HPV vaccination in the collaborative private clinics, which portrayed caring, privacy guaranteed, and non-judgmental environment.~Receiving the discount coupons: each participant will be given a discount coupon. By using the coupon, one can enjoy a 10% discount for taking up three doses of HPV vaccines at a collaborating private clinic.~Visiting the project webpage: Participants can assess the project webpage by scanning the QR code on the discount coupon.~Follow-up reminders: participants received five reminders at Month 1, 2, 4, 6, & 8."
45767500|NCT03537274|Biological|PEG-Intron|PEG-Intron is administered QW for 48 weeks by SC injection at 0.5, 1.0, and 1.5 mg/kg body weight. Body weight obtained at the baseline visit is used to calculate dosing.
45767501|NCT03537274|Biological|Interferon Alfa-2B|Interferon alfa-2b is administered TIW for 48 weeks by SC injection at 3 MIU regardless of participant body weight.
45767502|NCT01091155|Device|ColonRing (Colorectal anastomosis)|Creation of a colorectal compression anastomosis
45767503|NCT00939653|Drug|Clofarabine|40 mg/m2/day IV over 2 hours (given at hours 0 to 2) on days 1 through 5.
45767504|NCT00939653|Drug|Etoposide|100 mg/m2/day IV over 2 hours (given at hours 2 to 4) on days 1 through 5.
45767505|NCT00939653|Drug|Cyclophosphamide|440 mg/m2/day IV as a 30-60 minute infusion (given at hours 4 to 5) on days 1 through 5.
45767506|NCT00939653|Drug|Filgrastim|Administered in Courses 1 and 2 only. 5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is > 1000 x 2 days.
45767507|NCT00939653|Drug|Cytarabine|"Given intrathecally on day 1 at the dose defined by age below:~30 mg for patients age 1-1.99 50 mg for patients age 2-2.99 70 mg for patients >3 years of age"
45767508|NCT02527291|Other|Blood test|Blood test for CMV PCR and IL28
45767509|NCT04355039|Drug|Pomalidomide|4 mg Days 1-21
45767510|NCT04355039|Drug|Dexamethasone|40 mg Days 1, 8, 15 and 22
45767511|NCT04355039|Drug|INCB053914 50 mg bis in die (BID)|Dose level 0: 50 mg BID
45767512|NCT04355039|Drug|INCB053914 65 mg BID|Dose level 1: 65 mg BID
45767513|NCT04355039|Drug|INCB053914 80 mg BID|Dose level 2: 80 mg BID
45767514|NCT03537664|Procedure|Root canal preparation|First endodontic treatment session includes the root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation.
45767515|NCT03537664|Procedure|Intracanal medication|The second endodontic treatment includes the intracanal medication with calcium hydroxide paste, followed by an 2nd-visit root canal preparation
45767516|NCT01116037|Device|ATS 3f Aortic Bioprosthesis|Equine Pericardial Bioprosthesis for replacement of diseased valve
45767517|NCT03991481|Biological|Cryopreserved platelets|Platelets that have undergone a process to freeze, store and reconstitute platelets, extending their expiry to 2 years
45912807|NCT02014714|Drug|Fentanyl|Drug: Fentanyl 40mcg Depending on the randomization schedule, 40μg of fentanyl will be added to the intrathecal mixture.
45912808|NCT02014727|Biological|Group A1 : 50µg AMA1-DiCo + Alhydrogel|
45626079|NCT04829487|Drug|Ergocalciferol Capsules|Given to subjects 50,000 IU per week for 8 weeks
45626080|NCT04829487|Drug|Placebo|Placebo capsules
45626081|NCT04815603|Drug|BGE-117|Active Treatment
45626082|NCT04815603|Other|Placebo|Placebo
45767518|NCT03991481|Biological|Liquid-stored platelets|Liquid-stored platelets as per standard practice
45767519|NCT02524405|Other|Pittsburgh Compound B [11C]-PIB|This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Brain amyloid PET scans using the radioligand Pittsburgh Compound B [11C]-PIB, which is not yet approved for clinical use in Canada, will be performed in all subjects.
45767520|NCT03538678|Other|Kwit smartphone app|Kwit smarphone app
45767521|NCT03032081|Other|High intensity exercise|High intensity exercise, defined as an exercise intensity of > 80% of heart rate reserve. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
45912809|NCT02014727|Biological|Group A2 : 50 µg AMA1-DiCo+ GLA-SE|
45912810|NCT02014727|Biological|Group B2 : Placebo|
45767522|NCT03032081|Other|Moderate intensity exercise|Moderate intensity exercise, defined as 50 to 60% of heart rate reserve for 40 to 47 minutes per day, 4 days per week, for 8 weeks. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
45767523|NCT03014323|Drug|Galantamine|Galantamine 4 mg twice a day for 4 weeks
45767524|NCT03014323|Drug|Placebo|Placebo 1 capsule twice a day for 4 weeks
45912811|NCT02014753|Device|cobalt-chromium everolimus-eluting stent (CoCr-EES)|
45912812|NCT02014766|Procedure|Interscalene block|Ultrasound-guided interscalene block is performed.
45767525|NCT04352413|Drug|PLM60|Administration: Intravenous infusion
45767526|NCT02448823|Other|Mass media and Stylish Events|"Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.~Stylish Man/Living Event (SMLEvent) community mobilization/service provision. SMLEvent activities. Messages on how CHP (including behaviors such as sexual risk reduction) can make men and women feel more in control of their lives, less stressed, and more Stylish are interwoven through the mobilization.~The Stylish Man Van (SMV) accompanies the SMLEvent. The Van includes multimedia and health mobilizers who insert HIV prevention messages, testimonials by satisfied CHP customers and where appropriate their spouses."
45767527|NCT02448823|Other|Mass Media|1. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.
45626083|NCT04829565|Drug|Botulinum toxin|echo-guided injection into the trapezo-medial-phalangeal jointof 0.5 ml of botulinum toxin 50 IU
45626084|NCT04829565|Drug|Placebo|echo-guided injection into the trapezo-medial-phalangeal jointof 0.5 ml of placebo
45626085|NCT04821765|Drug|PD-1 antibody|200mg, d1, q3W
45626086|NCT04821765|Radiation|Chemoradiation|50-60Gy (BED) was given (1.8-2 Gy or 3-4Gy once daily , 5 days a week
45626087|NCT04821765|Drug|Albumin-Bound Paclitaxel|150mg/m2, d1, q3W
45626088|NCT04821765|Drug|Cisplatin|75mg/m2, d1, q3W
45626089|NCT04829097|Combination Product|Temozolomide|The patient received neoadjuvant temozolomide combined with simultaneous increase in intensity-modulated radiotherapy. According to data from previous clinical trials, neoadjuvant temozolomide combined with concurrently increased intensity-modulated radiotherapy PFS for 13.7 months.
45626090|NCT05618145|Other|Clinical information|The investigators will recruit PSC patients and collect important clinical information and laboratory investigation, together with biological samples.
45626091|NCT04829019|Radiation|Osimertinib and whole-brain irradiation|Osimertinib at a dose of 80 mg once per day, and WBI
45767528|NCT03393208|Drug|Test GIR|Participants received 500 milligrams (mg) test GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
45626092|NCT04829019|Drug|Osimertinib|Osimertinib at a dose of 80 mg once per day, until unacceptable adverse events or disease progression occurred. WBI could be given to patients in experimental arm at any time base on investigator's decision after treatment initiated.
45626093|NCT04828941|Device|Electronic Headache Diary|The electronic headache diary is an app-based diary that permits the registration of headaches, their acute treatment and their associated work incapacity. It also permits real-time monitoring of these data.
45626094|NCT04828941|Device|Paper Diary|The paper diary permits the registration of the same variables as the electronic diary in paper format.
45767529|NCT03393208|Drug|Reference GIR|Participants received 500 mg reference GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
45626095|NCT04821063|Drug|ITF2357 10 mg/mL|Dose: 100 mg (administered as 10 mL); Dosage form: suspension; Route of administration: oral
45626096|NCT04821063|Drug|ITF2357 10 mg/mL|Dose: 300 mg (administered as 30 mL); Dosage form: suspension; Route of administration: oral
45626097|NCT04821063|Drug|Placebo|Dose: 20 mL; Dosage form: suspension; Route of administration: oral
45626098|NCT04821063|Drug|Moxifloxacin Hydrochloride|Dose: 400 mg; Dosage form: tablet; Route of administration: oral
45626099|NCT04821063|Drug|Placebo|Dose: 30 mL; Dosage form: suspension; Route of administration: oral
45626100|NCT04815759|Other|routine dental restorative procedures|pulp and restorative therapy
45626101|NCT04828551|Device|Ultrasound based shear wave speed and fat quantification methods|Ultrasound based imaging parameters will be collected from all patients in two visits. These will include but may not be limited to SWE results, Quantitative ultrasound parameters,where available,including Attenuation Coefficient, Backscatter Coefficient, Shear Wave Dispersion, Speed of Sound, Ultrasound derived fat fraction Conventional Bmode (gray-scale) and Doppler ultrasound images,including An image of the liver and right kidney on the same image for hepatorenal index calculation Right liver lobe for skin to liver capsule distance calculation Portal vein Doppler for portal vein pulsatility index measurement VCTE and Controlled Attenuation Parameter measurements with the Fibroscan system
45767530|NCT04352491|Other|No intervention|No intervention
45767531|NCT01092559|Drug|Nitric Oxide generated by the GeNO nitrosyl delivery system|single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.
45767532|NCT01093027|Other|15 - 30|The upper limb with tremor will be cooled with 15 degrees Celsius water for 10 minutes at Visit 1 and with 30 degrees Celsius water for 10 minutes at Visit 2.
45767533|NCT01093027|Other|30 - 15|The upper limb with tremor will be cooled with 30 degrees Celsius water for 10 minutes at Visit 1 and with 15 degrees Celsius water for 10 minutes at Visit 2.
45767534|NCT01116661|Drug|5-Aminolevuline Acid (ALA)|Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery
45767535|NCT00944021|Drug|PA-824|50mg
45767536|NCT00944021|Drug|PA-824|100mg
45767537|NCT00944021|Drug|PA-824|150 mg
45912813|NCT02014766|Procedure|Supraclavicular block|Ultrasound-guided supraclavicular block is performed
45767538|NCT00944021|Drug|Rifafour e-275 mg|275 mg
45767539|NCT00944021|Drug|PA-824|200 mg
45767540|NCT04354883|Procedure|External Chest Compressions on Manikin in Underwater Setting|Two different methods of CPR in an analogue model of mircogravity
45767541|NCT03393754|Biological|Hepatitis B Vaccination|Prophylactic Hepatitis B Vaccination
45767542|NCT03394768|Other|No additional intervention|Patients will be treated as per department protocols and no additional intervention will be performed
45767543|NCT03587428|Drug|Zinc-A toothpaste|Participants received 6.0 grams (g) [± 0.3g] of the Zinc-A toothpaste in the form of slurry, one day per treatment (with at least 2 [generally 7] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
45912814|NCT02014779|Behavioral|eChange|A web-based relapse intervention program consisting of 14 modules. The patient will have access to therapist support through a secure messaging system
46073670|NCT04240236|Procedure|Scalp block|Patients will be randomly divided into two groups using a computer generated random number chart. Group S received scalp block with 20 ml of 0.5% bupivacaine, whereas Group C will not receive any intervention and will be considered as control group.
45626102|NCT04828551|Diagnostic Test|Blood collection|"Blood will be collected by trained phlebotomists at each site using routine methods and standard collection tubes.~Total volume is expected to be about 10 mL or less Blood collected at MGH will be analyzed by the MGH clinical laboratory. Blood collected at UCSD will be analyzed by the UCSD clinical laboratory. Blood results obtained within the 3-month interval prior to the screening visit at the MGH or UCSD laboratories will be considered acceptable for study analyses and may be used at PI discretion. For each laboratory, the normal ranges for each blood test will be recorded and filed"
45626103|NCT04828551|Other|Physical measurements|Height will be recorded at Screening. Weight and vital signs will be recorded at each visit. Body mass index will be calculated at each visit. All measurements will be made by trained coordinators using standard and calibrated instruments.
45447147|NCT04109391|Biological|TX05 (trastuzumab)|Subjects will receive up to 13 cycles of adjuvant treatment.
45626104|NCT04828551|Other|Clinical history and medication reviews|"The following questionnaires will be administered at Screening:~Medical history questionnaire Medication use questionnaire Alcohol consumption questionnaire Physical activity questionnaire~The following questionnaires will be administered at Visit 1 and Visit 2:~Interim medical history questionnaire Change in medication use questionnaire Change in alcohol consumption will be recorded using a modified version of the alcohol use followback. Alcohol use for the 7 day period prior to Visit 1 and for all days between Visit 1 and Visit 2 will be recorded. Change in physical activity questionnaire"
45447148|NCT04109391|Biological|Herceptin (trastuzumab)|Subjects will receive up to 13 cycles of adjuvant treatment.
45626105|NCT03976245|Drug|Etanercept|injection
45626106|NCT03976245|Drug|tofacitinib|tablet
45626107|NCT04814979|Device|Low-intensity pulsed ultrasound (LIPUS)|Low-intensity pulsed ultrasound (LIPUS) consists of frequencies usually ranging from 0.75- 1.5 MHz at intensities <100mW/cm² (usually about 30mW/cm²) and usually pulsed at 1:4. The transducer head is strapped or otherwise held in place and remains stationary for treatment periods in the region of 20 minutes. Again, US medium is used for efficient sound transfer to deeper tissues. This modality was approved by the FDA in the United States in 1994 for the accelerated healing of fresh fractures and then approved by the same body in 2000 for the treatment of established non-union fractures. The studies presented to the FDA demonstrated that LIPUS had a positive effect during all three main stages of fracture healing, i.e. inflammatory, reparative and remodelling by enhancing angiogenesis, chondrogenesis and osteogenesis.
45626108|NCT04814979|Other|Routine physical therapy|"Gentle hamstrings stretching for 15 seconds 3 times a day. Flexibility of these muscle reduces stress to the lumbar region thus enhances the spino-pelvic rhythm (lumbar motion/pelvic motion). Strengthening of abdominal muscles (transversus abdominis and internal oblique). Training of these stability muscles in the lumbar spine provides a solid foundation for the individuals to integrate them into their functional movement patterns. Exercises focusing on these muscles have been shown to significantly decrease pain and disability in people with spondylolysis. Each exercise will be performed as 3 sets of 10 repetitions on alternate days."
45626109|NCT04815135|Other|Observational study|Observational study, the study did not involve any interventions
45626110|NCT04815213|Biological|expanded autologous bone marrow derived MSC|Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
45626111|NCT04820751|Drug|Cyproheptadine Hydrochloride 4 MG|Cyproheptadine associated to standard care
45626112|NCT05619393|Device|Mobilie Bi-planar X-ray Imaging system|on the Mobilie Bi-planar X-ray Imaging system, images are acquired for three movements: walking, downhill walking, and squat
45626113|NCT04828317|Other|Pork Challenge|Double blind oral challenges comparing wild-type and alpha-gal free pork.
45626114|NCT05617989|Other|lung ultrasound|non-invasive ventilation and diuretic
45626115|NCT04828395|Biological|Camrelizumab|200mg iv Q3W
45626116|NCT04828395|Drug|Fluzoparib|150mg bid
45626117|NCT04828395|Drug|Cisplatin，Pemetrexed|Cisplatin 75mg/m2 IV and Pemetrexed 500mg/m2 IV Q3W (Day 1 of each cycle of cycles 1-3) (non-squamous cell carcinoma only)
45626118|NCT04828395|Drug|Cisplatin，Etoposide|Cisplatin 50mg/m2 IV (the 1st and 8th days of the 1st cycle and the 2nd cycle; the 8th and 15th days of the 3rd cycle); Etoposide 50mg/m2 IV (the 1st cycle And the 1st to the 5th day of the 2nd cycle; the 8th to the 12th day of the 3rd cycle).
45626119|NCT04828395|Drug|Carboplatin, Albumin Paclitaxel|Carboplatin AUC=6, Albumin Paclitaxel 100mg/m2 IV; Days 1, 8 and 15 of cycles 1, 2, and 3.
45626120|NCT04828395|Radiation|Radiotherapy|60 Gy (total 6 weeks)
45626121|NCT04820907|Drug|HCP1904-1|Take it once daily for 8 weeks orally.
45626122|NCT04820907|Drug|RLD2001-1|Take it once daily for 8 weeks orally.
45626123|NCT04427553|Device|Percutaneous Peripheral Nerve Stimulation|Participants assigned to this group will received two sessions (once per week) of ultrasound guided Percutaneous Peripheral Nerve Stimulation targeting the femoral nerve.
45626124|NCT04427553|Other|Control Group|No intervention
45626125|NCT01440777|Behavioral|Go! to Sleep|"The online program provides various tools for the delivery of the intervention including:~Daily articles~Daily activities to help get the sleep you need~Daily sleep improvement recommendations~Audio recorded relaxation exercises~Daily e-mails from your program coach~Personal progress charts~An online sleep log and daily sleep score"
45626126|NCT04814823|Device|Pulse oximeter|OLV-4202 pulse oximeter (SW version: 01-11)
45626127|NCT04815057|Behavioral|Wellness Education|The wellness education given to fifth grade students and the quality of life, its effect on physical activity status
45767544|NCT03587428|Drug|Zinc-B toothpaste|Participants received 6.0 grams (g) [± 0.3g] of the Zinc-B toothpaste in the form of slurry, one day per treatment (with at least 2 [generally 7] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
45447149|NCT02104102|Other|Mirror Therapy|Mirror Therapy, which is based on the activation of mirror neurons from the illusion generated by viewing the reflection of a member in a mirror, that is, intended to facilitate the movement through the practice of bilateral symmetric activities, since it is able to stimulate cortical plasticity, promoting reversal of the decrease and the reestablishment of motor function.
45626128|NCT04827303|Other|Kinesio taping|A 10-15 cm sized I band was applied to the trapezius muscles of the first group patients with the patient's neck in lateral flexion. Then, while the patient's neck is flexed, a Y-shaped 15-20 cm tape will be affixed between C1-7 with the arms of the Y up, and I tape of 5-10 cm is attached on the arms. In group 2 patients, 1 cc lidocaine diluted with 4 cc saline (SF) was applied to the trigger points palpated manually in the trapezius muscles. After the trigger point was squeezed between the thumb and index finger, a few cc of local anesthetic mixture was applied into the trigger point with the injector and exited. In the 3rd group patients, a few cc local anesthetic mixture will be applied intradermally over the trigger point without entering into the trigger points palpated manually in the trapezius muscles. Patients were checked 72 hours and 1 week after the first applications.
45767545|NCT03587428|Other|Mineral water|Participants received 6.0g (±0.3g) of mineral water (by weighing out), one day per treatment (with at least 2 [generally 7] days between treatments). Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
45767546|NCT03593200|Drug|Pegcetacoplan|Complement (C3) Inhibitor
45447150|NCT02104102|Other|Kinesiotherapy|Hands movements.
45447151|NCT04082936|Drug|IGM-2323|Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.
45626129|NCT04820439|Drug|recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)|A single intravenous infusion of HS627 420mg
45626130|NCT04820439|Drug|Perjeta ®|A single intravenous infusion of Perjeta ®420mg
45626131|NCT05619315|Other|Charcoal -based whitening toothpaste|The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6 hours) for at least 1 minute using charcoal containing toothpaste. Soft bristles toothbrushes will provided to all patients. After 1 month, re-evaluation of the stains will be performed and the data will be recorded.
45626132|NCT05619315|Other|Calcium carbonate /perlite containing whitening toothpaste.|The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6hours) for at least 1 minute using (calcium carbonate /perlite) containing toothpaste. Soft bristles toothbrushes will provided to all patients. After 1 month, re-evaluation of the stains will be performed and the data will be recorded.
45626133|NCT04814511|Drug|InfectoScab 5 % Creme|InfectoScab 5 % Creme is the already approved standard therapeutic agent, containing the active ingredient permethrin in 5 % concentration. In this study, it is used for topical treatment in the first treatment cycle (standard therapy) as well as in the second treatment cycle (escalation therapy).
45626134|NCT04814511|Drug|Permethrin 10 % Creme|Permethrin 10 % Creme also contains permethrin as the active ingredient, but in 10 % concentration. Permethrin 10 % creme is used exclusively for topical treatment in the second therapy cycle (escalation therapy).
45626135|NCT04814511|Drug|Driponin 3 mg Tabletten|Driponin 3 mg Tabletten are approved for the treatment of scabies, containing ivermectin as the active ingredient. Driponin is used as a supplementary, peroral add-on combination treatment in addition to topical permethrin therapy and is used exclusively in the second treatment cycle (escalation therapy).
45447152|NCT03554512|Other|Telehealth virtual appointment|Appointment with NICU clinician via telehealth equipment.
45626136|NCT04814121|Drug|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
45626137|NCT04814121|Drug|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
45626138|NCT05619159|Device|microscopic pathological evaluation|description of moesin expression between endometrial hyperplasia and endometrial carcinoma
45626139|NCT04814043|Drug|PD-1 inhibitor|systemic PD-1 antibody (Sintilimab) and lenvatinib plus transarterial chemobolization and FOLFOX-based chemotherapy infusion
45626140|NCT04826913|Device|Organoids|"Use of an innovative device to improve the management of patients with NSCLC for precision medicine.~The different drugs used can be conventional chemotherapy (cisplatin, carboplatin, pemetrexed), targeted therapies or immunotherapy molecules. It is also planned to use radiotherapy on our drug testing device."
45447153|NCT02106364|Drug|Insulin Peglispro|Administered SQ
45626141|NCT04813965|Other|Written information about potential chemotherapy-related cognitive symptoms without self-affirmation|
45626142|NCT04813965|Other|Written information about potential chemotherapy-related cognitive symptoms with self-affirmation|
45626143|NCT04814589|Drug|ezetimibe tablets|The subjects randomly received single oral administration of ezetimibe tablets 10 mg.
45626144|NCT04814589|Drug|ezetimibe tablets(Ezetrol ®)|The subjects randomly received single oral administration of ezetimibe tablets 10 mg.
45626145|NCT04819581|Drug|SP-103|lidocaine topical system 5.4%
45626146|NCT04819581|Drug|ZTlido|lidocaine topical system 1.8%
45626147|NCT05619081|Behavioral|POWERNAP|POWERNAP of max 30min while participants ly down comfortably
45626148|NCT04819503|Drug|Spinal anaesthesia (sub-study 1)|We will conduct two sub-studies on the same patient group. Sub-study 1 is an observational study where patients with phantom and/or residual limb pain after lower limb amputation will be given spinal anaesthesia with 1% Chloroprocaine in an open label manner to investigate whether the peripheral nervous system is a necessary driver of their pain.
45767547|NCT03398278|Drug|Oxycodone Tamper Resistant|Orally taking Oxycodone Tamper Resistant 40mg in fast state
45767548|NCT03398278|Drug|OXYCONTIN®|Orally taking OXYCONTIN® 40mg in fast state
45767549|NCT03593902|Drug|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
45767550|NCT03593902|Drug|Fludarabine|A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
45767551|NCT03593902|Drug|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
45447154|NCT02106364|Drug|Insulin Glargine|Administered SQ
45447155|NCT04077866|Drug|Temozolomide|Temozolomide is an FDA-approved drug that is given to patients
45447156|NCT04077866|Biological|B7-H3 CAR-T|B7-H3-targeting CAR-T cells derived from patient own peripheral blood mononuclear cells will be given to patients via intracerebral injection though an Ommaya catheter
45447157|NCT04106817|Biological|Live, wild-type A/California/H1N1 2009 influenza virus|Live, wild type influenza A virus that was inoculated and manufactured in allantoic fluid of SPF embryonated hen eggs
45626149|NCT04819503|Device|Repetitive transcranial magnetic stimulation (sub-study 2)|After sub-study 1, the same patients will enter sub-study 2 where they are randomly assigned to receive either first active rTMS (10 days over 2 weeks), and then after a 9 week washout period, sham rTMS (10 days over 2 weeks), or they first receive sham rTMS, and then after 9 weeks of washout, active rTMS. Thus, patients undergo stimulation with deep rTMS in a double blinded randomised controlled trial with a 2 x 2 cross-over design, receiving both active and placebo stimulation
45626150|NCT04819347|Drug|Albuvirtide|Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
45626151|NCT04819347|Drug|3BNC117|Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120.
45447158|NCT02101138|Drug|Dexpramipexole|Dexpramipexole (KNS 760704) is a synthetic amino-benzothiazole developed for use in amyotrophic lateral sclerosis (ALS)
45626152|NCT04813887|Other|questionnaire|Self-questionnaire on skin diseases reported during pregnancy
45626153|NCT04813809|Device|BARRIER EasyWarm|Application of BARRIER EasyWarm for 10 hours. The treatment with the investigational device will be according to the instruction stated on the investigational device.
45626154|NCT04826679|Drug|Camrelizumab, nab-paclitaxel, cisplatin|"Patients receive Camrelizumab IV on day 1, nab-paclitaxel IV on day 1 and cisplatin IV on day 1.~Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity."
45626155|NCT04813341|Other|Pilates training|Bridging, roll up, one leg circle (both ways); single straight leg stretches; double leg stretches; side kick up and down; side kick circles. The participant will be instructed to perform 3-5 repetitions of these movements at the start, and to add two more repetitions for each movement every week until the end of the intervention.
45626156|NCT04813341|Other|Aerobic Training|"WALKING: 10 mint brisk walk excluding warm up and cool down in 5 days/ week STATIONARY CYCLE: for 10 mints, 5 days/ week~SITTING EERCISES:~Chest stretch: ask to hold for 5 seconds and perform 5 repetitions Upper body twist: ask to cross the arms against chest and hold for 5 seconds, perform 5 repetitions Hip marching: Ask the client to sit on chair with arm rest and lift each of her leg 5 times~BALANCE EXERCISES:~Sideways walking: ask to perform 10 steps on each way (side to side), 5 days/week.~Heel to Toe walk: perform at least 5 steps and increase gradually in each repetition, 5days/ week Step up and down: Ask to step up and down on given surface, 5 repetitions on each leg, 5 days/ week."
45626157|NCT02601573|Drug|Grazoprevir|GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken q.d. by mouth in the morning.
45626158|NCT02601573|Drug|Elbasvir|EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.
45626159|NCT02601573|Drug|Ribavirin|RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose ranging from 800 mg to 1400 mg (total daily dose was based on participant body weight).
45626160|NCT02601573|Drug|Sofosbuvir|SOF 400 mg tablet taken q.d. by mouth in the morning with food.
45626161|NCT04818879|Other|Vojta|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg."
45626162|NCT04818879|Other|Control|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The control group will receive an application in an area with low receptor density located on the thigh, with a force of about 2 kg."
45626163|NCT04813419|Device|1927nm thulium laser|The right face of subjects were treated with fractional 2940nm Er:YAG laser(MCL 31 Asclepion Laser Technologies, Germany), N25 mode. Energy was adjusted from 12 to 27J according to the severity of scarring. The left face of subjects were treated with fractional 1927nm thulium laser(Lavieen, korea). Parameters were set as stamp mode, a spot size of 5*5mm, a pulse time of 1000us, an energy intensity of 3645mJ/cm2 and a repetition of 1-3 times. All patients received 3 treatment sessions totally at an average interval of 4 to 6 weeks.
45447159|NCT04064294|Drug|Intravenous Infusion|Intravenous levodopa given 1.0 to 1.5 mg/kg/hr from 0930 - 1130 on a single visit day.
45447160|NCT04104477|Other|Range of Motion Tasks|Participants will perform range of motion (thumb only) to evaluate fine and gross motor function.
45447161|NCT04104477|Other|Strength Tasks|Participants will perform strength (pinch and grip) tests to evaluate fine and gross motor function.
45447162|NCT02106520|Drug|Bevacizumab|
45767552|NCT03593902|Drug|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
45767553|NCT03593902|Drug|rATG|A rabbit polyclonal antibody to lymphocytes
45767554|NCT03593902|Drug|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
45447163|NCT02106520|Drug|placebo|
45447164|NCT05572268|Drug|to evaluate the safety and efficacy of Ansa for the treatment of UTi and control of Ecoli infection|to evaluate the safety and efficacy of Cranmax for the treatment of UTi and control of Ecoli infection
45626164|NCT04813419|Device|2940nm Er:YAG laser|The right face of subjects were treated with fractional 2940nm Er:YAG laser(MCL 31 Asclepion Laser Technologies, Germany), N25 mode. Energy was adjusted from 12 to 27J according to the severity of scarring. All patients received 3 treatment sessions totally at an average interval of 4 to 6 weeks.
45626165|NCT04826601|Other|essential oils|A total of 40 cancer patients receiving chemotherapy will be recruited as participants in this study. Blood orange and rosewood will be chosen as the essential oils for aromatherapy in this study. Essential oils will be applied to all participants by inhalation for 30 minutes.
45626166|NCT04813575|Other|Cryo lung biopsies|Bronchoscopic lung biopsy utilizing the cryo technique
45626167|NCT04818723|Drug|Montelukast|We wanted to know the role of leukotriene receptor antagonist (LTRA) montelukast in preventing relapses in idiopathic childhood nephrotic syndrome (NS)
45626168|NCT04826445|Other|Data collection|Imaging collection
45626169|NCT04826289|Radiation|X rays|Radiological assessment of vertical distance between medial and lateral malleolus in normal opulation
45626170|NCT04818411|Other|Routine physical therapy treatment with the Stabilization exercises|The program was based on specific training of the transversely oriented abdominal muscles with coactivation of the lumbar multifidus at the lumbosacral region, training of the gluteus maximus, the latissimus dorsi, the oblique abdominal muscles, the erector spinae, the quadratus lumborum, and the hip adductors and abductors. Initially, we focused on the specific contraction of the transversely oriented abdominal muscles. After approximately 2 weeks, loading was progressively increased throughout the intervention period. The women were required to exercise for 30 to 60 minutes, 3 days a week, for 3-4 weeks.
45626171|NCT04818411|Other|Routine physical therapy treatment + High-velocity thrust manipulation|: For high-velocity thrust technique, a modified Chicago technique was used. For this procedure, the lumbopelvic region was targeted. The side to be treated was chosen, based on the subject's report of her most symptomatic side. The physical therapist, performed passively side bend the subject toward the painful side, rotate the upper body in the direction opposite to the side bending, and then deliver a quick posterior and inferior thrust at a grade V including a small-amplitude/high-velocity therapeutic movement. A maximum of 2 attempts per side was permitted if no pop was heard following the first attempt. If the subject showed improvement of 50% or less after the first treatment, the intervention was categorized as a failure, the examination and intervention were repeated, and the subjects were asked to return 2 to 4 days later. If the subject showed greater than 50% improvement, the intervention was categorized as a success, and study participation was concluded.
45626172|NCT02601027|Procedure|Transversus Abdominis Plane (TAP) block|
45626173|NCT02601027|Device|Nimbus Infusion Pump IV Administration|
45626174|NCT02601027|Drug|Bupivacaine infusion|
45626175|NCT02601027|Drug|Acetominophen|
45626176|NCT02601027|Drug|Hydromorphone|
45626177|NCT02601027|Drug|Oxycodone|
45626178|NCT02601027|Drug|Ondansetron|
45626179|NCT04411875|Drug|Amlodipine 10 mg|The subjects randomly received single oral administration of amlodipine 10 mg.
45626180|NCT04411875|Drug|Levamlodipine 5 mg|The subjects randomly received single oral administration of levamlodipine 5 mg.
45626181|NCT02600871|Drug|Provodine|
45626182|NCT02600871|Procedure|Incision and Drainage|
45626183|NCT04813029|Procedure|Straight leg raise maneuver|With the patient in supine position, one leg is raised to form an angle of at least 45 degrees with the bed. The patient will be asked to keep that position for at least 5 seconds. The maneuver will be repeated after 20-30 seconds. The first adequate maneuver will be considered for the study. Intra-esophageal and intra-abdominal pressure will be analyzed both during baseline and SLR maneuver. Intra-esophageal pressure is measured as peak and mean over 5 seconds, 1 cm and 5 cm above the proximal margin of the LES. Intra-abdominal pressure will be measured as peak and mean over 5 seconds 1 cm below the distal margin of the diaphragm notch.
45626184|NCT04427631|Device|Bone conduction headphones|Children will be offered hearing support with bone conduction headphones that can either be paired to a microphone or to a tablet/ phone/ computer to help children to hear. The Hear Glue Ear app is available for free to provide speech and language enrichment.
45626185|NCT04817865|Diagnostic Test|Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST)|M-PCR/P-AST is a dual assessment test that detects pathogenic DNA commonly associated with urinary tract infections and identifies their genotypic and phenotypic antibiotic resistance.
45626186|NCT04817865|Diagnostic Test|Urine Culture|A traditional clinical UTI evaluation consisting of non-molecular standard urine culture (SUC) and sensitivity testing methods.
45626187|NCT04428255|Drug|HBM9161 Dose A|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
45626188|NCT04428255|Drug|HBM9161 Dose B|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
45626189|NCT04428255|Drug|Placebo|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
45626190|NCT04818099|Drug|Vortioxetine 10 mg|Vortioxetine will be used with a dosage of 10mg once a day, for 2 months.
45626191|NCT04818099|Other|Placebo|Placebo will be used with a dosage of one tablet once a day for 2 months.
45626192|NCT04817631|Other|tuboovarian abscess|Evaluating the surgical and medical management of tuboovarian abscess
45626193|NCT04357899|Drug|thrombolysis therapy|
45626194|NCT04357899|Procedure|endovascular therapy|
45626195|NCT04357899|Procedure|decompressive surgery|
45626196|NCT04357899|Diagnostic Test|multimodal imaging in acute ischemic stroke|
45626197|NCT04357899|Procedure|transfer of acute stroke patients to tertiary stroke centers|
45626198|NCT04357899|Drug|initiation of antiplatelets, oral anticoagulation and lipid lowering drugs for secondary prevention|
45626199|NCT04817709|Other|Educational Intervention|Review workbook
45626200|NCT04817709|Other|Usual Care|Receive educational materials
45626201|NCT04817709|Other|Media Intervention|Watch video
45626202|NCT04817709|Other|Medical Chart Review|Review of medical records
45626203|NCT04817709|Other|Questionnaire Administration|Complete questionnaires
45626204|NCT05618847|Device|Acapella,ACBTS|Every subject will perform supervised ACBTs with and without acapella for four weeks. Three sessions per week will be given with 20 repetitions in two sets
45767555|NCT03593902|Drug|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
45626205|NCT05618847|Other|ACBTs|Every subject will perform supervised ACBTs with and without acapella for four weeks. Three sessions per week will be given with 20 repetitions in two sets
45626206|NCT05618769|Combination Product|LONG LOVE Framework|In order to identify modifiable influencing factors, clinical data of the infants included in our multidisciplinary framework will be continuously collected by eHealth (Luscii Healthtech BV, Netherlands). Study visits take place at 1-1,5 3, 6, 12 and 18 months of age. Outdoor air quality measurements will be conducted using RIVM Luchtmeetnet. Indoor air quality measurements will be collected during a period of 6 weeks using a commercial available device. Lung function analysis using impedance pneumatography (Ventica Recorder, Revenio Research LTD, Finland) will take place during 2 nights at 3, 6 and 12 months of age. In the event of modifiable influencing factors medical or lifestyle interventions will be undertaken.
45626207|NCT04428099|Behavioral|Lifestyle change promotion program|The intervention consists of 8 group sessions centered on healthy physical activity, healthy diet, social life, Good Sleep Hygiene, healthy sun exposure, nature contact, how to stop ruminating, review and maintenance tips.
45626208|NCT04428099|Behavioral|Mindfullness based cognitive program|The intervention consists of 8 group sessions with a mindfulness-based cognitive program
45626209|NCT04428099|Behavioral|Written Information|Written information about lifestyle change suggestions
45626210|NCT02598297|Drug|Ruxolitinib|5 mg tablet for oral use
45626211|NCT02598297|Drug|Ruxolitinib Placebo|5 mg placebo tablet for oral use
45626212|NCT04812561|Dietary Supplement|Bronch™|2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week
45626213|NCT04812561|Dietary Supplement|placebo|2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week
45626214|NCT04825977|Other|RISK STRATIFICATION USING AIMS65 SCORE AND RDW|Risk Statification of patients presenting with upper gastrointestinal bleeding to the emergency department using AIMS65 score and Red cell Distribution Width.
45626215|NCT04812405|Diagnostic Test|Trios4|Examination of occlusal surfaces with 3D scanner and optical criteria
45626216|NCT04816929|Other|Bobath Method|Neurodevelopmental Treatment
45626217|NCT04816929|Other|Task-Oriented Approach|Task-Oriented Treatment
45626218|NCT04825899|Other||
45626219|NCT04816851|Procedure|OZAKI technique|an alternative way of repairing aortic valve, involving the use of autologous pericardium for the aortic leaflet reconstruction. Diseased leaflets are removed carefully. The distance between each commissure is measured with invented sizing apparatus. The new leaflet of the size corresponding to the measured value is trimmed with an original template from glutaraldehyde-treated autologous pericardium. Finally, the annular margin of the pericardial leaflet was running sutured with each annulus. Commissural coaptation was secured with additional sutures. The coaptation of three new leaflets were always insured with direct vision.
45626220|NCT04807959|Other|20Lighter anti-obesity program|A customized expert supervised 3-phase program including non-invasive proprietary nutritional, behavioral, and physiological components.
45626221|NCT04807569|Other|Peripheral magnetic neuromodulation|"Non-invasive peripheral magnetic neuromodulation using the BTL Emsella magnetic stimulator according to the manufacturer's standard protocol: pelvic floor rehabilitation"
45626222|NCT04807569|Drug|Taking drug Tamsulosin|Tamsulosin at a dose of 0.4 mg x 1 time per day orally for 1 month.
45626223|NCT04807491|Other|Kabat Technique's|"As with all cranial nerves, some specific techniques can also be applied on the facial nerve to enhance responses and improve recovery; the most important are: The rhythmic start: shows and guides the subject into the movements and the scheme; agonist investigation utilizes sequential concentric and eccentric contractions; The inversion of the antagonist: reinforces responses through the induction phenomenon; Repeated contractions: calls for a response with repeated stretching that briefly enables movement; Isometric contractions: for stabilizing and reinforcing the response.~Conventional therapy exercises"
45626224|NCT04807491|Other|Neuromuscular Re-Education|"After the baseline assessment, the participant in the control will receive Neuromuscular Re-Education. The duration of session will be 45 minutes.Neuromuscular Re-Education: For initiation (acute phase): Active-assisted exercise,Massage and stretch for affected side.For Facilitation ,Active-assisted exercise.For Movement control:Massage and stretching for facial retraction,Assisted and active exercises on involved side.~For Relaxation,Thermotherapy,Relaxation exercises,Alternating rhythmic movements.~Conventional therapy exercises"
45626225|NCT04807413|Drug|Nitric Oxide|The balloon will be opened to deliver nitric oxide at 40 ppm through the cardiopulmonary bypass machine
45626226|NCT04807413|Other|standard of care treatment|standard of care treatment
45626227|NCT05617053|Device|DAART|
45626228|NCT05617053|Device|ATP/Supera stenting|
45626229|NCT04356729|Drug|Atezolizumab|Atezolizumab will be administered intravenously at a fixed predetermined dose every three weeks ith 21 consecutive days defined as a treatment cycle.
45626230|NCT04356729|Drug|Bevacizumab|Bevacizumab will be administered intravenously at a fixed predetermined dose every three weeks, with 21 consecutive days defined as a treatment cycle.
45626231|NCT04825665|Other|Continuous force|"A buccally directed continuous tipping force of 150 g is applied to the maxillary first premolar by a cantilever spring made of 0.017 x 0.025 beta-titanium-molybdenum alloy inserted in the tube of the upper first molar, bypassing the second premolar and attaching to the upper first premolar. The buccal tipping force will be checked and reactivated to the original level on the 28th day of the 8 week study period."
45767556|NCT03593902|Biological|IVIg|Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
45767557|NCT03593902|Biological|Autologous Stem Cells|Infusion of patient's own stem cells
45767558|NCT00948935|Drug|Gemcitabine, Irinotecan, Panitumumab|Gemcitabine 1000 mg/m2 over 100 minutes(Days 1, 8), irinotecan 100 mg/m2 IV over 60 minutes(days 1, 8) and panitumumab 9 mg/kg IV (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.
45767559|NCT04354805|Drug|Chlorpromazine|(Oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days)
45912815|NCT02014779|Behavioral|Face-to-face therapy|Face-to-face psychotherapy, consisting of 20 sessions. The content will be different for different therapists, but all have an evidence based approach to therapy
45912816|NCT02014805|Radiation|radiotherapy|postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
45912817|NCT02014818|Device|CoCr-EES|
45447165|NCT03745833|Device|Virtual Reality Mindfulness|Participating patients will be provided with a VR headset (pre-programmed with mindfulness content) after lunch for 15 minutes with supervision while on strict bedrest. The headset will be collected following the intervention. Patients are currently provided with a post-meal survey following all meals as part of the standard of care, and will complete the survey following the lunchtime intervention.
45626232|NCT04825665|Other|Intermittent force|"A buccally directed tipping force of 150 g is applied to the maxillary first premolar by a cantilever spring made of 0.017 x 0.025 beta-titanium-molybdenum alloy inserted in the tube of the upper first molar and attaching to the upper first premolar. The buccal tipping force will be removed every 21 days for a 7-day rest period, where a passive wire of the same gauge and material of the cantilever spring (0.017 x 0.025 beta-titanium-molybdenum alloy) will be placed instead to maintain the position of the upper first premolar during the rest period."
45447166|NCT03748797|Other|Moderate intensity exercise training under supervision|Upper and lower limbs cycling, treadmill walking, multi-gym strengthening, stepper exercise, dumb bell and squatting exercise
45626233|NCT05618535|Device|Transcranial Doppler.|"Spontaneous arterial blood pressure will be simultaneously recorded using a servo-controlled plethysmograph on the left or right middle finger with an appropriate finger cuff size.~Continuous cerebral blood flow velocities of bilateral middle cerebral artery will be assessed noninvasively using transcranial Doppler."
45626234|NCT04807023|Biological|blood sampling|blood sampling
45626235|NCT04825587|Procedure|Patients will be randomized into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone.|By randomizing patients into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone, following statistical analysis, we hope to determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will longitudinally result in a lower rate of graft failure than ACL reconstruction alone.
45626236|NCT04427319|Dietary Supplement|β-alanine|7 days of consumption
45626237|NCT04427319|Dietary Supplement|wheat semolina|7 days of consumption
45626238|NCT05616975|Other|test-retest reliability|Assessing the test-retest reliability of SWAY Balance, Functional, and Cognitive tests.
45626239|NCT05616975|Other|construct validity|Investigating the construct validity of SWAY Balance, Functional, and Cognitive tests.
45626240|NCT05616975|Other|normative data|Collection of normative SWAY Balance, Functional, and Cognitive data.
45626241|NCT04807335|Drug|CT001|nasal spray
45626242|NCT04807335|Drug|Ketamine|iv single dose
45626243|NCT04807335|Drug|sufentanil|iv single dose
45626244|NCT05616507|Dietary Supplement|fucoidan|It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
45626245|NCT04806945|Drug|HLX10|IV infusion.
45626246|NCT04806945|Drug|Paclitaxel|IV infusion
45626247|NCT04806945|Drug|Cisplatin|IV infusion
45767560|NCT04354571|Procedure|Erector spinae plane block|An ultrasound-guided Erector spinae plane block was performed with the patient lying on the his side and the surgical side on the top. After skin disinfection, sterile draping was be placed and the ultrasound probe was sheathed. The level of the block was the transverse process of L2. The block was performed using a 9-12 MHz linear probe (LOGIQe, GE Healthcare, USA), which was placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) was identified, and a 22 G, 50 mm insulated needle (Sonoplex Stim, Pajunk, Germany) was inserted cranio-caudally in plane between the transverse process and the fascia of the ESM. After negative aspiration, 0.3 ml/kg of 0.25% bupivacaine was injected to confirm the correct position by visualizing the solution lifting the ESM off the transverse process.
45447167|NCT04061720|Behavioral|Enhanced Chronic Care|Enhanced Chronic Care involves four chronic care calls per year. Enhanced Chronic Care is designed to help participants explore their goals and concerns with regard to smoking, engage in a nondirective, supportive, motivational interventions, and provide information about evidence-based smoking treatment available to them and ways to initiate treatment (i.e., warm hand-off from a clinical provider).
45447168|NCT04061720|Behavioral|Standard Care|Standard Care involves one call per year. During the Standard Care call, participants will be encouraged to quit smoking, reminded of the cessation treatment available to them, and provided with a number to call should they become interested in treatment.
45447169|NCT02101216|Drug|Prurisol|Experimental Drug
45447170|NCT02101216|Drug|Ziagen|Active comparator
45452451|NCT00079781|Procedure|RNS® System implantation|Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
45626248|NCT04806945|Drug|Carboplatin|IV infusion
45626249|NCT04806945|Drug|Placebo to HLX10|IV infusion
45626250|NCT04806711|Device|Menicon Z Night|Menicon Z Night orthokeratology contact lenses were used to assess their efficacy in reducing myopia progression in children
45626251|NCT04806711|Device|Control|Distance, single-vision glasses were used as a control
45626252|NCT02596893|Drug|GED-0301|
45626253|NCT02596893|Drug|Placebo|
45626254|NCT04806633|Drug|Dapagliflozin 5mg|Patients randomized in this arm will receive dapagliflozin at a dose of 5mg once daily.
45626255|NCT04806633|Drug|Placebo|Patients randomized in this arm will receive placebo.
45626256|NCT04806867|Other|SePaRIC-Covid19 cohort|All patients with Chronic Inflammatory Rheumatism who were contacted by telephone as part of the innovative organizational strategy and who did not object to the use of their data.
45626257|NCT04353687|Device|Robotic-assisted inguinal hernia repair|Each surgeon will perform the robotic-assisted inguinal hernia procedure per their standard practice. Surgeon subjects will consent to prospectively provide selected procedure and case data.
45767561|NCT04354571|Procedure|caudal block|caudal block was performed using anatomical landmarks and ultrasound guided and confirmed with a concentration of bupivacaine of 0.25%.
45767562|NCT03944681|Drug|Droperidol Injectable Solution|An electrocardiogram analysis in: 5,10,15,20 minutes after injection of 1.25 mg of droperidol used as PONV prophylaxis.
45626258|NCT04353297|Other|EEG-based BCI system for (hand) Motor Imagery training|The Promotoer is an all-in-one BCI-supported motor imagery (MI) training station, equipped with a computer, a commercial wireless Electroencephalography (EEG)/ Electromyography (EMG) system, a screen for therapist feedback (EEG and EMG activity monitoring) and screen for the real-time ecological feedback to patient - a custom software program that provides a for (personalized) visual representation of the patient's own hands. As such, this software allows the therapists to create an artificial reproduction of a given patient's hand/forearm by adjusting a digitally created image in shape, size, skin colour and orientation to match as much as possible the real patient hand/forearm. Training consists of the MI tasks only of the affected hand, grasping or finger extension in separate runs. The trial length will include a constant baseline period of 4 sec and a task period of maximally 10 sec for BCI intervention group. Each training session will consist of 4 runs (20 trials each).
45767563|NCT03032003|Other|Cysticlean|2 BID for 15 days
45767564|NCT03032003|Other|Placebo|2 BID for 15 days
45767565|NCT01116895|Drug|LEO 22811|Oral solution
45626259|NCT04353297|Other|Motor Imagery training|Training consists of MI tasks only of the affected hand, grasping or finger extension in separate runs. MI training will be delivered without BCI support (ie., the Promotoer system will not provide real-time feedback of MI performance; hand/forearm visual representation will remain standstill) with a dose/setting regimen equivalent to EXP intervention. The trial length will include a constant baseline period of 4 sec and a task period of maximally 4 sec. Each training session will consist of 4 runs (20 trials each).
45767566|NCT01116895|Drug|Placebo|Placebo
45767567|NCT03935555|Drug|PU-H71|PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome
46069709|NCT02864225|Device|Fetal doppler|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
45626260|NCT05616897|Behavioral|Physiological responses during sustained CPR|
45626261|NCT04427475|Drug|pabolizumab|100 patients with stage IV EGFR / ALK wild-type NSCLC (squamous cell carcinoma patients do not need to be detected) who received anti-PD-1 (pabolizumab) treatment combined with chemotherapy as the first-line treatment were enrolled in the center. Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles. At the same time, plasma samples were collected at key nodes until the patient's progress.
45626262|NCT04427475|Drug|nafulizumab|nafulizumab
45626263|NCT04812249|Other|Clinical assessment|Clinical assessment and follow up of oral feeding ability
45767568|NCT03031691|Drug|brontictuzumab|starting dose of 1.5mg/kg administered intravenously (IV)
45767569|NCT03031691|Drug|trifluridine/tipiracil|
46073671|NCT04240236|Other|Control Group|Patients will be randomly divided into two groups using a computer generated random number chart. Group S received scalp block with 20 ml of 0.5% bupivacaine, whereas Group C will not receive any intervention and will be considered as control group.
46073672|NCT00849277|Drug|Lactobacillus casei Shirota|
46073673|NCT00829179|Drug|RhuMab-E25|three subcutaneous injections spaced 1 month apart; dose based on subject weight and baseline IgE level.
45767570|NCT01093183|Drug|lenalidomide|Given PO
45767571|NCT01093183|Drug|cyclophosphamide|Given PO
45767572|NCT01093183|Other|laboratory biomarker analysis|Correlative studies
45767573|NCT01093183|Other|questionnaire administration|Ancillary studies
45767574|NCT01093183|Other|quality-of-life assessment|Ancillary studies
45767575|NCT03031613|Procedure|PEEP group|Application of 5cmH20 positive end expiratory pressure
45767576|NCT03031613|Procedure|ZEEP group|No application of positive end expiratory pressure
45767577|NCT02430103|Drug|Goserelin 3.6 MG|In goserelin group, goserelin 3.6mg will be administered every 28 days by subcutaneous injection starting at least 7-14 days before the first cycle of chemotherapy and continued throughout chemotherapy duration.
45767578|NCT03031535|Drug|Intranasal octreotide acetate|Intranasal spray of octreotide acetate
45767579|NCT03031535|Drug|Subcutaneous octreotide acetate|Subcutaneous injectable solution of octreotide acetate
45767580|NCT03031535|Diagnostic Test|Growth hormone-releasing hormone|Part of the well established GHRH/Arginine challenge to detect GH deficiency.
45767581|NCT03031535|Diagnostic Test|Arginine hydrochloride|Part of the well established GHRH/Arginine challenge to detect GH deficiency.
45767582|NCT03031925|Other|ANXA2|serum and urinary concentration
45767583|NCT01118221|Behavioral|pulmonary rehabilitation|structured exercise program
45767584|NCT04353947|Diagnostic Test|Mini Cognitive Examination (MCE)|This test provides information on temporal and spatial orientation, fixation, concentration and calculation, memory and language and construction.
45767585|NCT04353947|Diagnostic Test|Beck Depression Inventory-II (BDI-II)|This test evaluates the absence or presence of depressive symptoms.
46069710|NCT02864225|Device|EUM|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
45626264|NCT04797975|Biological|KDS-1000|"Non-randomized part of study:~At the beginning of each dose level (Cohort), 3 patients will receive KDS-1000. These initial patients will be enrolled in a staggered manner to ensure detection of any early safety signals.~Randomized part of the study (Can start when there are no safety concerns in the non-randomized cohorts):~Cohort 1: Low Dose, 2x10E8 cells/dose~Cohort 2: High Dose, 1x10E9 cells/dose"
46069711|NCT00697047|Behavioral|Automated Mailing|Usual Care plus Automated mailing
46069712|NCT00697047|Behavioral|Automated Mailing Plus Assisted|If not screened after automated mailing, MA assists with screening.
46069713|NCT00697047|Behavioral|Auto Plus Assisted Plus Navigation|If not screened after automated mailing and assistance by MA, RN begins navigation.
45626265|NCT04797975|Other|Placebo|0.9% Normal Saline
45626266|NCT04806477|Other|Telemedicine Consultation|Brief telemedicine consultation, blinded to subsequent face-to-face evaluation.
46069714|NCT04252196|Device|usability evaluation of medical device|participants interact with medical device and rate it for usability
45626267|NCT04806477|Other|Face-to-face Consultation|Direct face-to-face evaluation (without telemedicine consultation before).
45626268|NCT05616819|Other|Blue light exposure|Blue light at the wave length of 470nm will be emitted for 30 minutes over a 2 week time frame, from commercially available ayo glasses, as a method to regulated circadian rhythm.
45626269|NCT05616819|Other|Amber light exposure|Amber light at the wave length of 578nm will be emitted for 30 minutes over a 2 week time frame, from commercially available ayo glasses, as a control to investigate the regulation of circadian rhythm.
46069715|NCT04287881|Genetic|Methylenetetrahydrofolate reductase (MTHFR) deficiency|To investigate the incidence of MTHFR deficiency in patients with adult-onset epileptic seizures and diagnosed ischemic stroke
46069716|NCT04255706|Device|biometric measurement IOLMaster 700|Three biometric measurements will be performed with 3 devices for all the patients included
45626270|NCT04797819|Diagnostic Test|Coronary plaque components|Coronary plaque components were detected by CCTA method
45626271|NCT04806009|Behavioral|'Mindful Living With Insomnia (MLWI)' Intervention via WeChat mini-program|The MLWI Intervention involves 12 sessions over 6 weeks course, 2 sessions a week and 0.5 hours per session. Two new sessions of online lessons will be updated weekly in the 6 weeks. Each session is consisted of theoretical lecture, mindfulness practices, sharing common difficulties and coping way during mindfulness practices and homework assignment in the form of video or audio. The Mindfulness practices embedded in the intervention include mindful breathing, mindful body scan, mindful dealing with thoughts and emotions, mindful meditation, mindful movement, and daily life mindfulness. In the intervention, the participants will also receive sleep hygiene education.Participants in the Intervention Group will receive the MLWI Intervention after follow the WeChat mini-program.
45626272|NCT04806009|Behavioral|'Cognitive Behavioral Therapy for insomnia (CBT-I)'via WeChat mini-program|The CBT-I involves 12 sessions over 6 weeks course, 2 sessions a week and 0.5 hours per session. Two new sessions of online lessons will be updated weekly in the 6 weeks. Each session is consisted of theoretical lecture, cognitive or behavioral regulation techniques, sharing common difficulties and coping way during mindfulness practices and homework assignment in the form of video or audio.Participants in the Control Group will receive CBT-I after follow the WeChat mini-program.
45626273|NCT04806243|Drug|Regorafenib Pill&Camrelizumab|Regorafenib，80 mg，QD，Q3w Camrelizumab，200 mg，IV，Q3w
45626274|NCT04805931|Behavioral|Behavioral economics|Tailored behavioral economic text messaging vs. standard text messaging
45626275|NCT04811703|Drug|Combined PIPAC / IV chemotherapy treatment|Addition of cisplatin-doxorubicin PIPAC sessions to carboplatin-paclitaxel systemic Chemotherapy
45626276|NCT04797507|Drug|SHR-1210 plus Anlotinib|SHR-1210: a novel anti-PD-1 antibody Anlotinib: a multi-kinase inhibitor
45626277|NCT04811859|Other|Inspiratory Muscle Training|Inspiratory Muscle Training is a form of resistance (weight) training which strengthens the muscles that you use to breathe. When these muscles are strengthened regularly for a period of a few weeks they adapt, becoming stronger and being able to work for longer.
45626278|NCT04805697|Dietary Supplement|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
46069717|NCT04255706|Device|biometric measurement Lenstar LS 700|Three biometric measurements will be performed with 3 devices for all the patients included
45626279|NCT04805697|Dietary Supplement|fermented grape drinks|subjects drank 50 ml , 1 bottle a day for 8 week
45626280|NCT04805463|Other|Control group|The group that did not undergo any procedure after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied to the wound area.
46069718|NCT04255706|Device|biometric measurement Anterion Heildelberg|Three biometric measurements will be performed with 3 devices for all the patients included
45626281|NCT04805463|Other|PRF group|The group in which PRF is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA)was applied over the PRF.
45626282|NCT04805463|Other|CGF group|The group in which CGF is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied over the CGF.
45626283|NCT04805463|Other|AFG group|The group in which AFG is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied over the AFG.
46069719|NCT05298345|Other|Anthem Strong Families TYRO Champion Program Primary Services|Primary Services: participants receive 12 hours of TYRO Leadership curricula, 6 hours of Core Communication curricula. Support Services (optional): participants choose from a menu of classes (1-3 hours) at the walk-in mini clinic to meet a variety of self-identified needs.
45626284|NCT04797351|Behavioral|Dialectical Behavior Therapy - Skills|Pre-treatment session + 12 sessions DBT Skills Group (only) intervention
45626285|NCT04797663|Device|Nd-YAG laser|laser hair removal device
45626286|NCT04797663|Drug|TCA 20%|chemical peel
45626287|NCT04805229|Other|Retrospective analysis of opioid use after surgery|Retrospective analysis of opioid use after one of the following surgical procedure categories: laparoscopic cholecystectomy, laparoscopic appendectomy, minor hernia repair (including laparoscopic or open inguinal, femoral, umbilical, and epigastric hernia repair), open and laparoscopic ventral/incisional hernia repair, laparoscopic colectomy, open colectomy, vaginal hysterectomy, laparoscopic hysterectomy, and open abdominal hysterectomy.
45626288|NCT04812327|Diagnostic Test|BD Veritor Plus System for Rapid Detection of SARS CoV-2|Nasal Sawb for the conduct of the Veritor Antigen Test
45626289|NCT04812327|Diagnostic Test|rt-PCR|Nasopharyngeal Swab for the conduct of a rt-PCR
45626290|NCT04812327|Diagnostic Test|viral culture|Nasopharyngeal Swab for the conduct of viral culture
45626291|NCT04796805|Other|Topical essential oil application|We applied black pepper essential oil to the participants in experimental group before the catheter insertion procedure
45626292|NCT04426851|Drug|BI 1358894|BI 1358894
45626293|NCT04796571|Behavioral|Proactive Symptom Monitoring and Care Coordination|Patients randomized to the intervention arm were assigned an IBD-focused care coordinator who facilitated a symptom-based monitoring algorithm and supported patient navigation to complement usual care. Symptom monitoring was facilitated through regular push notifications to participants to complete a validated PRO instrument through the Epic EMR patient portal or telephone. These notifications were scheduled on a monthly basis. The IBD-focused care coordinator made two attempts to reach each participant using portal messaging, followed by a phone call to reduce non-response. PRO questionnaires were reviewed by the care coordinator and out of range scores triggered algorithm-based recommendations to the IBD specialist including stricter monitoring of disease activity, behavioral and medication adherence counseling, facilitation of expedited follow-up with treating providers, and referrals to social work, mental health, and gastroenterology-specific behavioral health services.
45626294|NCT04804683|Genetic|Genetic dissection of Fibromuscular Dysplasia|Blood sampling for genetic analysis aiming at unraveling the genetic basis of Fibromuscular Dysplasia
45626295|NCT04804683|Other|Search for diagnostic and prognostic biomarkers of Fibromuscular Dysplasia|Blood/urine and in rare cases tissue sampling aiming at identifying biomarkers of Fibromuscular Dysplasia
45626296|NCT04811157|Dietary Supplement|Test product|200 g/day of unsweetened yogurt supplemented with a dietary fiber blend
45767586|NCT04353947|Diagnostic Test|Global Deterioration Scale (GDS)|This scale measures the level of deterioration of the subject.
45767587|NCT04353947|Diagnostic Test|Memory alteration test (M@T)|In this test different memory subtypes are evaluated.
45626297|NCT04811157|Dietary Supplement|Control product|200 g/day of unsweetened yogurt
45626298|NCT04811391|Biological|COVID-19 vaccine|Observation of individuals who receive the COVID-19 vaccine (2 doses of PfizerBioNtech COVID-19 vaccine).
45626299|NCT04811313|Drug|Tranexamic acid|patients treated with TXA will have reduced blood loss and transfusion requirements compared with those who did not receive TXA
45626300|NCT04811313|Procedure|caudal epidural block|regional anesthesia in orthopedic procedures are known to help reduction of intraoperative blood loss
45626301|NCT04811313|Other|Placebo|participants will receive standard care but neither TXA nor caudal epidural block
45626302|NCT04795947|Behavioral|Behavioral|There is no intervention in this study
45626303|NCT04810845|Device|Application of Class II A device SmartCardia|Application of SmartCardia monitor patch 30 minutes before coronary angiography (2/3 devices per-patients would be applied). Non invasive recording of single-lead ECG, respiratory rate, pulse transit time, heart rate would occur pre, during and post (30 minutes) primary angioplasty procedure
45626304|NCT04810767|Other|Questionnaire|Pain experienced assessed by questionnaire described by Nikolajsen et al, 2004
45626305|NCT04810923|Procedure|i-PRF|intra-articular i-PRF injection after arthrocentesis
45626306|NCT04810923|Procedure|Arthrocentesis|Arthrocentesis procedure with 2 to 3 mL saline solution to lavage the superior compartment of temporomandibular joint.
45626307|NCT04803981|Other|SpoonfulONE|SpoonfulONE is a line of nutritional food products designed to help improve diet diversity starting in early infancy. SpoonfulONE covers a wide range of food proteins. Each product contains 30 mg of peanuts, milk, shellfish (shrimp), tree nuts (almond, cashew, hazelnut, pecan, pistachio, and walnut), egg, fish (cod and salmon), grains (wheat and oat), soy, and sesame.
45626308|NCT04352439|Drug|Aspirin|81 mg aspirin daily
45626309|NCT04351815|Behavioral|Short term prehabilitation (2 weeks)|"Initial assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine) and a geriatrician (for patients over 75 years old)~Patient will be asked to follow a 2 weeks prehabilitation program~2 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)~6 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)"
45767588|NCT04353947|Diagnostic Test|Spanish-Complutense Verbal Learning Test (TAVEC)|This test is used to assess immediate memory, deferred memory and learning ability.
45767589|NCT04353947|Diagnostic Test|Barcelona test (BT)|"This test evaluates categorical evocation and verbal fluency. The categorical recall subtest consists of recalling the maximum number of words linked to a specific category animals in 1 minute. In the case of verbal fluency, the subject is asked to evoke the maximum number of words that begin with the letter p in 3 minutes."
45626310|NCT04351815|Other|No specific intervention|"Standard care: Initial assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine) and a geriatrician (for patients over 75 years old)~Patients will be asked to maintain regular physical activity without support~2 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)~6 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)"
45626311|NCT04796025|Drug|Sintilimab; Bevacizumab Biosimilar|1-4 cycles, intra-arterial infusion: sindilimab 200mg + bevacizumab 7.5mg/kg, q3w; 5-18 cycles: Sintilimab (200mg ivdrip D1 Q3W)+Bevacizumab Biosimilar (15mg/kg ivdrip D1 Q3W）
45626312|NCT02592447|Other|Therapy for Targeted Therapy-related Fatigue (TTF)|Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) group will receive cognitive behavior therapy to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions. The sessions will initially be held weekly, but the therapist may schedule sessions at 1-, 2-, or 3-week intervals during the 18 week study period. The final session will be conducted either in-person at Moffitt or via FaceTime.
45767590|NCT04353947|Diagnostic Test|Rey-Osterrieth Complex Figure Test (ROCFT)|In this test, the person must carefully copy a complex geometric drawing, which must be memorized later. The first part evaluates multiple cognitive processes such as planning, motor skills, working memory, and visual-constructive and spatial skills. In the second part, memory is evaluated.
46069720|NCT03969329|Drug|Etelcalcetide|Etelcalcetide has been shown to be safe and efficacious in treating adult chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT) by simultaneously controlling intact parathyroid hormone (iPTH), calcium (Ca), and phosphorus and has recently been approved for use in adult patients with secondary hyperparathyroidism (SHPT) treated with hemodialysis in both the United States and Europe
45626313|NCT02592447|Other|Wait-List Control Condition (WLC)|Participants randomized to Wait-List Control Condition will continue to receive care under direction of their Moffitt Cancer Center (MCC) physician. Physicians will be informed by email of patients' participation on the basis of elevated fatigue and their randomization to WLC. Chart review and a patient self-report form will be used at baseline and follow-up assessments to determine what, if any, services or interventions participants received in the preceding 18 weeks that might address fatigue.
45626314|NCT05616351|Other|Data collection in patients with diabetic foot syndrome and infections in the area of the foot|Data collection: on (surgical and antibiotic) treatment and implementation of the recommendations published 2019 with regard to the duration of antibiotic therapy.
45767591|NCT04353947|Diagnostic Test|Frontal assessment battery (FAB)|This test is a composite tool for assessing executive functions related to the frontal lobe.
45447171|NCT03979040|Behavioral|Group Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and [positive] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders. Per protocol, the first six sessions of TBT are designed to educate on, prepare for, and practice the four different types of exposure techniques. The next five sessions are focused on practicing and refining exposure practices as participants work through their lists of avoided situations/sensation/thoughts. The final session reviews treatment progress and relapse prevention strategies.
45767592|NCT04353947|Diagnostic Test|Positive and Negative Affect Scale (PANAS)|It is a self-report questionnaire made up of 20 items (10 of positive affect and another 10 of negative affect) that the subject must answer, obtaining in this way a score in positive affectivity (AP subscale) and another in negative affectivity (AN subscale).
45767593|NCT04353947|Diagnostic Test|Auto-Assessment Manikins (SAM)|It is a self-report questionnaire that assesses the emotional response of the subject, in this case, through a mood induction task that plays different films scenes.
45767594|NCT01093417|Drug|Vitamin D|Vitamin D 4000 IU will be administered to enrollees on the active comparator arm
45767595|NCT01093417|Other|Placebo|Placebo pills will be administered to enrollees in this arm
45767596|NCT04354415|Procedure|Carpal tunnel or trigger finger release|Carpal tunnel or trigger finger release with and without the use of tourniquet
45767597|NCT01586455|Drug|Human Placental Derived Stem Cell|Infusions of thawed HPDSC to be given following UCB infusion.
45767598|NCT04354337|Behavioral|Sleep Innovations for Preschoolers with Arthritis (SIPA)|The SIPA intervention is interactive and personalized. Every week, parent will receive an email sent automatically through the system with instructions for this week's activity, designed to take about 30 minutes to complete. The SIPA weekly modules will begin with a learning module, then direct participants through goal setting, anticipated barriers, and problem solving. The intervention site will include fillable responses to queries, instructions, and assignments. Tasks for parents and their young children will use multimedia elements to enhance delivery of information, such as links to videos and pictures targeting self-efficacy, motivation, and patient activation. Submissions and progress will be monitored by the study team, who will send email, call or text with reminders (whichever the family prefers) and answer questions as needed, review progress, and help problem solve any technology issues or barriers to implementing skills.
45767599|NCT04744545|Behavioral|Meru Health Program|12 week evidence-based mental health intervention overseen by a licensed clinical therapist delivered via Smartphone app
46069721|NCT04204889|Drug|Oxaloacetic Acid|The first 3 patients will receive 500 mg twice daily, and subsequent cohorts will increase by 500 mg per dose to a maximum of 2500 mg twice daily.
45626315|NCT04810455|Other|Purrble|"The objective of this study is to evaluate the impact of having access to the Purrble intervention, compared to an active control in the form of a non-interactive plush toy, on child daily emotion regulation (primary outcome) as well as a range of secondary outcomes over a period of one month.~The investigators hypothesise that engagement with an in-situ, 'bottom-up' emotion regulation intervention which enables in-the-moment soothing for children, will lead to measurable changes in child self-regulatory behaviours over time."
45626316|NCT04810455|Other|Active control toy|The selected active control toy is the Wild Republic 8'' Hedgehog animal. The selection process was guided by: the plush toy needed to have analogous size, weight, quality of materials, and at least similar (if not higher) visual appeal. The investigators also made sure to include the design characteristics our prior work suggested were important for the narrative around the toy. These were selecting a similarly stylised animal (to enable emotion projection and feelings of care), as well as no visible mouth on the toy (to prevent setting an expectation about the toy's emotional state as a mouth would imply an emotional expression). Additionally, the investigators have adapted the one-page parent-facing descriptions of the narrative that come with Purrble also for the active control unit: as such, the active control families will receive the same general narrative-without the explicit mentions of the toy interactivity-and the same suggested activities for parents.
45767600|NCT04744545|Dietary Supplement|Curcumin|1500mg/day curcumin plus black pepper to aid absorption
45767601|NCT03031379|Other|shortened fast|fast of 45 minutes prior to surgery as opposed to standard 6 hour fast
45767602|NCT01093651|Drug|Sitagliptin|100 mg sitagliptin daily for 4-6 months
45767603|NCT01093651|Drug|Placebo|Daily placebo for 4-6 months
45767604|NCT03793127|Other|Maximal oxygen consumption (V02 max)|Aerobic fitness will be determined by measuring V02 max during a stationary bicycle exercise test.
45767605|NCT03793127|Other|Brown adipose tissue (BAT) imaging|Brown adipose tissue will be differentiated from white adipose tissue using fat fraction and T2* relaxation time maps generated from a commercially available modified 6-point Dixon (mDixon) water-fat separation method.
45767606|NCT03793127|Other|Muscle function testing|This test will be done on a machine called a Biodex. We will measure the speed at which subjects move resistance at different percentages of their peak strength.
45767607|NCT00362895|Drug|Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension|One drop in the study eye, single dose
45767608|NCT00362895|Drug|Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)|One drop in the study eye, single dose
45767609|NCT03031301|Device|Vibrant capsule|One Vibrant capsule will be ingested 5 times per week for 8 weeks of treatment.
45767610|NCT03031301|Device|Sham capsule|One Sham capsule will be ingested 5 times per week for 8 weeks of treatment.
45767611|NCT03013465|Other|Control Diet|Participants will receive a controlled diet with 0 g/d of broccoli. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
45767612|NCT03013465|Other|Base Diet with Broccoli|Participants will receive a controlled diet with 100 g of broccoli at both breakfast and dinner daily. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
45767613|NCT04744623|Drug|large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP|10 patients suffering from MMP were selected after complete diagnosis based on their clinical diagnosis and immunopathologic findings of IgG, IgA, and/or C3 targeting skin basement membranes with a linear deposition pattern refered from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intrational injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I) then the prednisolone is withdrawn gradually and substituted with using 1 g of MMF plus 50 mg dapsone till the lowest dose of prednisone could be reached (stage II).
45767614|NCT00939731|Drug|PF-02341066|A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Powder-in-Capsule and 2 x 100-mg Powder-in-Capsules
45767615|NCT00939731|Drug|PF-02341066|A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Immediate Release Tablet and 2 x 100-mg Immediate Release Tablets
45767616|NCT02484417|Biological|RSV A2|Intranasal inoculation of healthy volunteers with 10^5 or 10^6.3 plaque forming units (PFU) of RSV A2.
45767617|NCT03031223|Radiation|low-level laser therapy|low-level laser therapy
45626317|NCT04795479|Drug|Relacorilant|Relacorilant 400 mg (therapeutic dose) or 800 mg (supra-therapeutic dose) capsule by mouth once daily
45626318|NCT04795479|Drug|Placebo to relacorilant|Placebo to relacorilant capsule by mouth once daily
45767618|NCT05620199|Procedure|Upfront resection|Resection of the primary tumor
45767619|NCT00633945|Drug|Lenalidomide|
45767620|NCT03729713|Other|Computerized cognitive rehabilitation|6 week course of cognitive rehabilitation focused on attention, learning, and memory
45767621|NCT03729713|Other|Sham placebo|an alternative home-based computer program not designed for cognitive remediation but of the same duration
45767622|NCT03711773|Other|Group Physical Therapy Classes|Three times weekly, these subjects will have one hour group physical therapy sessions with either a physical therapist, physical therapy assistant, or personal trainer. These sessions will be aimed to improve strength and function in a low-impact setting designed specifically for those with joint pain.
45767623|NCT03665051|Procedure|Muscle Tissue Biopsy|A biopsy of the Vastus Lateralis muscle will be performed on the left leg using the Bergstrom technique.The skin will be incised (approximately 0.75 cm) with a #11 scalpel, and the Bergstrom needle will be inserted into the Vastus Lateralis. Approximately 150 mg of muscle tissue will be obtained under suction. After the biopsy, pressure will be applied to stop bleeding and the skin will be closed with Steri strips (suture(s) if allergy to steri strips and removal 7-10 days post biopsy). A sterile dressing will be applied. Ace bandage may also be used along with applied pressure and an ice pack for any swelling and pain relief.
45912818|NCT02014831|Drug|Cetuximab|"Cetuximab treatment will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~CETUXIMAB I.V infusion of 400 mg/m2 on cycle 1 Day 0 for 2 hours, then 250 mg/m2 for subsequent infusions for 1 hour on Day 8, Day 15 and next cycles Day1, Day8, Day15.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol"
45447172|NCT03979040|Behavioral|Group Disorder-Specific Therapy (G-DSTs)|To provide an evidence-based comparison for the G-TBT condition, G-DSTs will be used that are matched to the participant's principal diagnosis. G-DSTs will include groups for the most common principal diagnoses that have VA-approved protocols and training programs, including PTSD (Cognitive Processing Therapy for PTSD) and MDD (CBT-Depression). Each of these G-DSTs have published manuals for administration and have received extensive support in the literature.
45626319|NCT04795479|Drug|Moxifloxacin|Moxifloxacin 400 mg tablet by mouth
45626320|NCT04810533|Drug|[14C] SH-1028|Volunteer will receive a single oral dose of 200 mg/88 uCi [14C]SH-1028 as a solution on Day 1
45626321|NCT04803903|Device|Flotraq Sensor with EV1000 incorporating the HPI algorithm|"The HPI algorithm is only available on the EV1000, Hemosphere and Flotrac monitoring systems and requires the use of a Flotrac sensor connected to an arterial line (Edwards Lifesciences Corp., Irvine, CA, USA). The Flotrac sensor has a splitter which enables the splitting of the arterial blood pressure signal to facilitate a blood pressure signal on both the anesthesia machine monitor (standard care) and the HemoSphere monitor (study).~In the intervention arm we asked the anesthesiologist and anesthesia nurse to use the study treatment flowchart . If the HPI alarm goes off, which entails both a sound and a flickering light, we ask the anesthesiologist to act upon this alarm immedietaly. Use of the study treatment flowchart ensures that the anesthesiologist has to think about the underlying cause. The HemoSphere/EV1000 with HPI software has a second screen with variables that provide information about the underlying cause of the predicted hypotension."
45767624|NCT03665051|Other|Maximal Oxygen Consumption (V02max)|Aerobic fitness will be determined by measuring maximal O2 consumption (VO2max) during a stationary bicycle exercise test. Heart rate, blood pressure and ECG will be recorded throughout this test. Subjects will breathe through a low resistance mouthpiece and wear a nose clip. Expired gases will be measured by indirect calorimetry and heart rate monitored by a portable heart rate monitor. Following a standardized warm up, subjects will begin exercising at a moderate intensity with the workload increased every minute until the subject can no longer continue. A leveling-off (plateau) or decline in oxygen uptake should be demonstrated in order to be reasonably sure that a subject has achieved the maximum capacity for aerobic metabolism.
45767625|NCT02980445|Behavioral|Outdoor activity 1|40-minute outdoor activity
45767626|NCT02980445|Behavioral|Outdoor activity 2|Dose 1 plus an additional 40-minute outdoor activities during recesses
45767627|NCT03031067|Device|Machine perfusion|"The graft preservation will be performed perfusing with a oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion, developed by Medica s.p.a and our research group.~Flow and pressure values will be set up for the kidney and liver perfusion, differently. The oxygenation of solution will be performed by an oxygenator and a filter for decapneization / oxygenation. During the perfusion the oxygen pressure will be required between 600-750 mmHg (pO2 80-100 Kpa), as reported in the scientific literature. The pH, lactate concentration, and oxygen (PO2) and carbon dioxide (PCO2) partial pressure were measured in the preservation solution at T0 and T1 by means of a standard haemogasanalyzer."
45767628|NCT03609047|Drug|Palbociclib|CDK4/6 inhibitor
45767629|NCT03609047|Drug|Docetaxel / cyclophosphamide|Adjuvant Chemotherapy
45767630|NCT03609047|Drug|doxorubicin/cyclophosphamide|Adjuvant Chemotherapy
45767631|NCT03609047|Drug|epirubicin/cyclophosphamide|Adjuvant Chemotherapy
45626322|NCT04803513|Drug|Galcanezumab|Galcanezumab according to clinical indication in real life
45767632|NCT03609047|Drug|paclitaxel|Adjuvant Chemotherapy
45767633|NCT01118845|Drug|SyB L-0501|"The administration of SyB L-0501 at 120 mg/m^2/day by intravenous infusion on day 2 and 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.~SyB L-0501 60 mg/m^2, 90 mg/m^2 or 120 mg/m^2/day on Day 2 and Day 3 will be followed by 18 days of observation."
45767634|NCT01118845|Drug|Rituximab|The administration of rituximab at 375 mg/m^2/day by intravenous infusion on day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
45767635|NCT05619731|Other|Geriatric oncology tele-consultation and pharmaceutical tele-expertise|tele consultation
45767636|NCT03031457|Diagnostic Test|Duplex ultrasound|Duplex ultrasound of lower extremity venous system
45767637|NCT01130077|Biological|HLA-A2 restricted glioma antigen peptides vaccine|Vaccine given every 3 weeks
45767638|NCT01130077|Biological|Poly-ICLC|Vaccine given every 3 weeks
45767639|NCT05617157|Other|Stair stepping|stepping up and down 32 stairs for 1 minute
45767640|NCT03240887|Behavioral|Peer Group Connection|Faculty advisors at each participating high school are trained to run the program and teach a daily leadership course to peer leaders. Eleventh and twelfth-grade peer leaders who participate in the daily leadership development class facilitate outreach sessions with their assigned group of ninth graders. PGC can be offered in either a half-year (semester) or full-year format. In either format, a minimum of 18, 45-minute outreach sessions are expected to be offered to PGC participants during the course of their ninth-grade year. Outreaches are created to facilitate the transition to high school and encourage students to attend school, set goals for themselves, and make healthy decisions.
45767641|NCT03162731|Biological|Nivolumab|Given IV
45767642|NCT03162731|Biological|Ipilimumab|Given IV
45767643|NCT03162731|Radiation|Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy|Undergo simultaneous integrated boost integrated modulated radiation therapy
45767644|NCT03162731|Radiation|Volume Modulated Arc Therapy|Undergo volumetric modulated arc therapy
45767645|NCT03030911|Drug|Dexmedetomidine|The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
45767646|NCT03030911|Drug|Midazolam|The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
45626323|NCT04803279|Device|Collection of Pure tone thresholds from audiogram measured prior to fitting of Ponto 3 SuperPower|Unmasked and if available masked BC thresholds from audiogram obtained prior to Ponto 3 SuperPower were fitted.
45626324|NCT04803279|Device|Collection of BC In-situ thresholds from BC In-situ audiogram measured during fitting of Ponto 3 SuperPower|BC In-situ thresholds will be collected from the BC In-situ audiogram obtained when Ponto 3 SuperPower were fitted
45767647|NCT03030911|Drug|Fentanyl|The drug will be administered in both groups
45767648|NCT03030911|Device|Indirect calorimetry|The device will be used for measurement of basal metabolic rate
45767649|NCT01120405|Drug|Xenon|
45767650|NCT01120405|Drug|Sevoflurane|
45767651|NCT03030833|Device|Pulse Oximeter|Comparison of pulse oximetry to blood gas analyzer.
45767652|NCT03399370|Drug|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
45767653|NCT03399370|Drug|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
45626325|NCT04803279|Device|Collection of Aided sound field thresholds measured with the Ponto 3 SuperPower|Sound field thresholds for frequencies 500Hz, 1kHz, 2 kHz, 3kHz and 4kHz will be collected from sound field audiogram obtained as follow-up after Ponto 3 SuperPower fitting, typically this is collected 3 months post fitting, alternatively from the fitting visit. Thresholds will be obtained aided, and when available unaided
45626326|NCT04803279|Device|Collection of speech intelligibility scores|"Speech intelligibility is measured in a sound treated room using sentence tests. The sentence tests used at Norwich and Norfolk hospital is the BKB (Bamford-Kowal-Bench) and/or the The AB[s] Isophonemic Monosyllabic Word test (7).~The sentence tests are measured in quiet and/or with background speech-weighted noise."
45452452|NCT00079781|Device|RNS® System responsive stimulation|The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
45626327|NCT04803279|Device|Skin reaction|Classification of skin reactions around skin penetrating implants will be made using the Holgers score. The Holgers classification is a scale from 0 to 4 that is used to grade skin reactions
45626328|NCT04803279|Device|Collection of Glasgow Benefit Inventory|The Glasgow Benefit Inventory (GBI) contains 18 health status questions, which ask specific questions about how the health problem, in this study hearing loss, has affected their quality of life at the time the GBI is completed. In this study GBI has been collected on patients before intervention and 3 months after fitting of Ponto 3 SuperPower on abutment.
45626329|NCT04803279|Device|Collection of power-on usage time with Ponto 3 SuperPower|Average power-on usage hours from Ponto 3 SuperPower will be collected.
45626330|NCT04795011|Other|exercise and manual lymphatic drainage|MLD will be launched with simple neck application. Hemodynamics of blood and lower extremity motoring will be increased by combining active bilateral shoulder-twisting with breathing after effleurage. Cervical lymph nodes will be stimulated. Back-up treatment will be applied for the abdominal area. Suction power in the ductus thoracicus will be increased with breathing exercises. Ventral drainage will be applied to the lower extremity in accordance with the surgery of the patient.
45626331|NCT04795011|Other|exercise|range of motion and walking exercise
45626332|NCT02595723|Drug|Phenytoin 200 mg capsule|Phenytoin oral capsule was initiated on Day 1 and administered at 200 mg twice/day for four consecutive days (Days 1 - 4).
45626333|NCT02595723|Drug|Megestrol 800 mg liquid|Liquid megestrol 800 mg/was initiated on Day 2 and administered at 09:00 for three consecutive days (Days 2 - 4).
45626334|NCT02595723|Drug|Phenytoin-matched Placebo capsule|Phenytoin-matched oral Placebo capsule was initiated on Day 1 and administered for four consecutive days (Days 1 - 4).
45626335|NCT02595723|Drug|Megestrol-matched liquid Placebo|Megestrol-matched liquid placebo was initiated on Day 2 and administered at 09:00 for three consecutive days (Days 2 - 4).
45626336|NCT04810065|Other|SingStrong: Strong lungs through Song|"Participants who have been clinically diagnosed with Covid-19 and who continue to suffer residual adverse effects on the lung health will be invited to participate in the study.~The intervention will involve biweekly hour-long breathing and singing classes that are designed to correct dis-ordered breathing, and retrain the principal muscles of respiration.~Pre and post evaluation of participant bio-psychosocial health and wellness will be conducted. Triangulation of data using focus groups and individual interviews will be conducted after conclusion of the intervention,"
45767654|NCT02859779|Behavioral|education programs|Four audio-recorded discussion groups will be organized in each of the 10 clinical settings
45767655|NCT05613803|Drug|Fish oil|6g of EPA and DHA in a 1.3:1 ratio as six Omacor capsules manufactured by Provona Biocare (Olso Norway), or generic equivalent, taken once daily, or in divided doses, with food.
45767656|NCT05613803|Other|Placebo|Six capsules containing palm oil and soybean oil on an 8:2 ratio taken once daily, or in divided doses, with food.
45767657|NCT03013387|Radiation|90Y-DOTA-3-tyr-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used l as a treatment for both children and adults with neuroendocrine and other somatostatin receptor positive tumors.
45452453|NCT05628064|Device|1C70|Investigational energy storage and return prosthetic foot with using novel elastic elements.
45626337|NCT01667679|Drug|100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally|
45767658|NCT03013387|Procedure|Positron Emission Tomography (PET) whole body scan|68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
45767659|NCT03013387|Drug|Amino Acids|This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing radiation dose to the kidneys.
45767660|NCT00950729|Procedure|Driving with running shoes|Participant was asked to do all the experiments with their own running shoes
45767661|NCT00950729|Procedure|Plaster cast|The participant was ask to do all the experiments with a plaster cast molded on his right leg
45767662|NCT00950729|Procedure|Driving with Aircast|The participant was ask to do all the experiments with a aircast on his right leg
45767663|NCT02784353|Behavioral|Perioperative rehabilitation program|"Perioperative rehabilitation program~preoperative rehabilitation : 2 weeks prior to operation~postoperative rehabilitation : 3 months after operation"
45767664|NCT02784353|Behavioral|Conventional|conventional perioperative management without rehabilitation program
46069722|NCT02619903|Procedure|Dental cleaning|Dental scaling and cleaning to remove dental plaque as well as removing the tongue biofilm.
45767665|NCT03597178|Device|senofilcon A|ACUVUE OASYS® 1-DAY with HydraLuxe™ Technology
45767666|NCT01782989|Drug|ORACEA®|ORACEA® (40mg doxycycline) capsule daily for 24 months
45626338|NCT01667679|Drug|OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet|
45626339|NCT04794933|Other|Conventional therapy|
45626340|NCT04794933|Other|CT+ PNF in extremity pattern|
45626341|NCT04794933|Other|CT+ PNF in extremity pattern+PNF in scapula and upper trunk patterns|
45626342|NCT04286451|Behavioral|Sleep Restriction|Women will be undergo 4 nights of sleep restriction.
45626343|NCT04286451|Behavioral|Habitual Sleep|Women will be undergo 4 nights of habitual sleep.
45626344|NCT02597049|Drug|Dulaglutide|Administered SC
45626345|NCT02597049|Drug|Placebo|Administered SC
45452454|NCT05628064|Device|Pro-Flex XC|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transtibial amputee subjects.
45626346|NCT02597049|Drug|SGLT2 inhibitor|Administered orally as standard of care for type 2 diabetes
45626347|NCT02597049|Drug|Metformin|Administered orally as standard of care for type 2 diabetes
45626348|NCT04809675|Device|Hard occlusal splint|Use of a hard occlusal splint at times they considered helpful.
45626349|NCT04809675|Device|Flexible customized mouthguard|Use of a flexible customized mouthguard at times they considered helpful.
45626350|NCT04809441|Other|Diet change|A specific very low-calorie diet (<800kcal/day), and 2 daily sessions of 15 minutes of anaerobic physical exercise depending on the capacity of the participants, were designed
45626351|NCT04427085|Other|Ultrasound assessment of optic nerve sheath diameter|Using ultrasonography, optic nerve sheath diameter is measured during perioperative period.
45626352|NCT04803045|Other|Follow up email|Patients received an email 3 months after an initial consult asking why they had not returned to care. Patients were provided with 4 options and a space to write in comments. The email asked if the patient had any questions and offered support.
45626353|NCT04802967|Drug|Ketoprofen Lysine Salt combined with Gabapentin|KLS-GABA (80 mg-34 mg) in Part A and KLS-GABA (40 mg-17 mg or 80 mg-34 mg or 160 mg-68 mg) in Part B
45626354|NCT04802967|Drug|Ketoprofen Lysine Salt|KLS (80 mg) alone in each treatment period in Part A and KLS alone (40 mg, 80 mg, or 160 mg) in Part B
45767667|NCT01782989|Drug|Placebo|Placebo capsule daily for 24 months
45767668|NCT03544216|Device|Multifocal Contact Lens|The multifocal contact lens (Bausch + Lomb ULTRA® for Presbyopia) will be worn for two weeks
45767669|NCT03544216|Device|Single Vision Contact Lens|The single vision contact lens (Bausch + Lomb ULTRA®) will be worn for two weeks
45767670|NCT02245607|Behavioral|Compensatory Cognitive Training|
45767671|NCT02245607|Behavioral|Recreational Therapy|
45767672|NCT01120639|Drug|Temozolomide|75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
45626355|NCT04802967|Drug|Gabapentin|300 mg
45767673|NCT01120639|Procedure|Stereotactic Radiosurgery (SRS)|Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)
45912819|NCT02014831|Drug|TIP|"The TIP combination of treatments will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~PACLITAXEL I.V infusion of 175 mg/m2, for 3 hours, on Day 1 of the cycle.~IFOSFAMIDE I.V infusion of 1200 mg/m2, for 2 hours, on Day 1, Day 2, Day 3 of the cycle.~CISPLATINE I.V infusion of 25 mg/m2, for 1 hour, on Day 1, Day 2, Day 3.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol"
45912820|NCT02014857|Procedure|Gingival Crevicular Fluid Sampling|
45452455|NCT03176966|Drug|Vitamin E|Patients will take 400 IU vitamin E nightly for 3 months.
45626356|NCT04802967|Other|Placebo|2 capsules to maintain the blind
45626357|NCT04426617|Procedure|Ultrasound Guided Transversus Abdominis Plane Block|The patient will lie in the supine position. The transducer will be placed in the axial plane on the mid-axillary. transversus abdominis muscle will be visualized. A skin wheel using 3 ml of lidocaine 1 % is made 2 to 3 cm medial to the medial aspect of the transducer and the 22 gauge is inserted in-plane pointing laterally. Then Injection of local anaesthetic mixure in the right plane.
45626358|NCT04282785|Diagnostic Test|Concentration monitoring of antibiotics in plasma|Plasma antibiotic concentration will be measured using a bedside method with UV-VIS spectroscopy. These measurements will be validated with golden standard that is HPLC-MS.
45626359|NCT04263441|Behavioral|NICE Intervention|Subjects enrolled in the intervention arm will be offered assistance in enrolling in healthcare coverage and provided assistance on where they can go for care immediately. Subjects will be followed for 1 year and information including lab tests and insurance coverage status will be collected. This information will be collected from medical record review.
45912821|NCT02014870|Other|1:1000 Live wild-type A/California/H1N1 2009|1:1000 dilution of neat virus
45912822|NCT02014870|Other|1:100 Live wild-type A/California/H1N1 2009|1:100 dilution of neat virus
45452456|NCT03176966|Drug|Ropinirole|Patients will take 0.5mg ropinirole nightly for 3 months.
45626360|NCT04802889|Other|scanning electron microscopy|scanning electron microscopy of the сentral retina and preretinal structures
45626361|NCT05616117|Other|Intrauterine 90µg D-vitamin|Children of mothers who received 90 µg vitamin D3 daily during pregnancy:10 µg from a standard prenatal multivitamin + an additional supplement containing 80µg of vitamin D3
45767674|NCT00951821|Behavioral|Concurrent treatment|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase. The techniques used to teach cognitive restructuring and problem solving to parents will be similar to those taught to the adolescents, except emotion regulation skills will be added to the parent treatment.
45767675|NCT00951821|Behavioral|Adolescent treatment only|Individual CBT for adolescents only plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase
45767676|NCT00676351|Procedure|body plethysmography|Same tests were performed at 18 and 24 months. At 30 and 36 months, pulmonary function was evaluated by measuring respiratory resistances using an oscillometry system and an occlusion system
45767677|NCT02422043|Other|Questionnaires and audio-tape interviews|therapeutic patient education programs (TPE) to type 1 diabetic adolescents are designed to make the teenager to self manage their disease and their treatment. Based on Bandura's social cognitive theory, effects of educational activities for TPE should lead to the strengthening of self-efficacy
45626362|NCT05616117|Other|Intrauterine 10µg D-vitamin|Children of mothers who received 10 µg vitamin D3 daily during pregnancy, which is the dose in a standard prenatal multivitamin and the dose currently recommended by the Danish Health Authorities to all pregnant women. They will receive a prenatal vitamin containing 10µg of vitamin D + a placebo supplement.
45626363|NCT04802265|Procedure|Epiretinal membrane surgery|"The surgery consists of a 23 or 25-gauge pars plana vitrectomy (PPV). The surgery was performed peri-bulbar anesthesia and could be combined with phacoemulsification.~An intraocular dye is used to well visualized and facilitate ERM peeling. The ILM is not actively peeled. A search for iatrogenic breaks is performed towards the end of the procedure. Areas suspicious for breaks are treated with cryotherapy or peripheral endolaser."
45912823|NCT02014870|Other|1:10 Live wild-type A/California/H1N1 2009|1:10 dilution of neat virus
45626364|NCT04802499|Procedure|Turkish Reliability and Validity of TESS|Translation and cultural adaptation of the scale will be designed according to the appropriate procedure. Turkish data will be uploaded in the online online method. The scale will be communicated online to those who have received telerehabilitation services, caregivers and healthcare professionals who have applied it. The reliability of the questionnaire will be made by test-retest and internal consistency analysis. Volunteers will be asked to answer the questionnaire online after 5 days. After two weeks, the participants will be asked to answer the questionnaire again with the same method online with 5 days intervals. After all data are collected, validity analysis will be performed
45626365|NCT04802421|Procedure|alveolar recruitment manoeuver|alveolar recruitment manoeuver are recommended during general anesthesia to prevent pulmonary atelectasis
45626366|NCT05615961|Dietary Supplement|Probiotics (Lab4 probiotics, Cultech, Port Talbot, Wales, UK)|The intervention is a unique blend of probiotic cultures from a well-established manufacturer.
45626367|NCT05615961|Dietary Supplement|Placebo|Placebo Tablets
45626368|NCT02594163|Drug|Brentuximab Vedotin|
45626369|NCT02594163|Drug|Rituximab|
45626370|NCT02594163|Drug|Bendamustine|
45626371|NCT04801875|Other|Selected Exercise|The violin and ney groups performed a structured exercise training program 3 times a week for a total of 8 weeks. Adherence to the exercise training program was checked using a follow-up schedule to ensure regular participation of the musicians. The 8-week exercise training program was given with same physiotherapist under the same conditions. The every exercise session consisted of warm-up (3-5 min), main exercise (30-35 min) and cooling periods (3-5 min). The main exercise period was included ROM (10 min), stretching (5-7 min), isometric (5-10 min) and stabilization exercises (5 min).
45626372|NCT04801719|Device|Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK|Randomised patients in selected arm received endoluminal RFA by 8F catheter (Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK) before stenting procedure. Repeated ablations were processed through stenotic areas of bile ducts (10W, 90-120s, Rita 1500, Angiodynamics Ltd), all drained biliary tracts were used for introducing catheter and performance of ablation. Ablation procedure was followed with uncovered self-expandable metal stent insertion.
45626373|NCT04801485|Dietary Supplement|Myo-inositol|Active group receives myo-inositol 1 gram per day as well as health guidance about diet and exercise. From recruitment until OGTT.
45626374|NCT04801485|Dietary Supplement|Placebo|Placebo (similar appearance but not containing myo-inositol) 1 gram per day before meals. Similar health guidance about diet and exercise. From recruitment until OGTT.
45626375|NCT04801407|Procedure|percutaneous radiofrequency trigeminal rhizotomy|percutaneous radiofrequency trigeminal rhizotomy is a perctaneous procedure that ablate the sensory part of the nerve and
45767678|NCT02266745|Drug|PT-112 Injection|
45626376|NCT04801407|Procedure|Microvascular decompression of the trigeminal nerve|Microvascular decompression is a procedure that decompress the nerve from vascular conflict
45767679|NCT01095757|Drug|Plerixafor|240 µg/kg subcutaneous injection on the day that the absolute neutrophil count (ANC) is > 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.
45767680|NCT03549598|Drug|68Ga-DOTATATE PET/CT|5.4 mCi of 68Ga-DOTATATE will be administered by intravenous route.
45767681|NCT03549598|Drug|18FDG PET/CT scan|This scan will be performed as part of the planned clinical care for the patient. Dose of 18FDG will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
45767682|NCT03549598|Drug|13NH3 PET/CT scan|This scan will be performed as part of the planned clinical care for the patient. Dose of 13NH3 will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
45767683|NCT05497817|Behavioral|Algorithm|Current and/or former Care Partners of persons with dementia will be matched using an algorithm to other Care Partners who might provide emotional support.
45767684|NCT05497817|Behavioral|Random Match|Current and/or former Care Partners of persons with dementia will be randomly matched to other Care Partners who might provide emotional support.
45767685|NCT01034527|Other|Neuromuscular Training|Combination of exercises and phases to initiate lateral trunk perturbations that force the athlete to decelerate and control the trunk in order to successfully perform the techniques.
45767686|NCT03031145|Biological|Felis Domesticus|Nasal Administration of Felis Domesticus
45767687|NCT00376636|Drug|SPP635 (drug)|
45767688|NCT03830125|Drug|BBT-877, Single dose|Single dose of BBT-877, 5 dose levels, oral capsule
45767689|NCT03830125|Drug|Placebo group|Placebo matched to BBT-877, oral capsule
45767690|NCT03830125|Drug|BBT-877, Multiple doses|Multiple doses of BBT-877, 14 days, 8 dose levels, oral capsule
45912824|NCT02014883|Drug|GLUT1 DS|
45912825|NCT02014896|Other|Biomarker blood draw|Comparison of gene expression profiles using RNA isolated from whole blood.
45912826|NCT02014909|Biological|KTN3379|Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive disease
46069723|NCT04287725|Device|exercise + photobiomodulation therapy|Treatment sessions will be provided twice a week for 6 weeks (totaling 12 sessions) with participants receiving either placebo or active PBMT + exercise protocol.
45452457|NCT03176966|Other|Muscle cramp survey|Patients will complete a survey of muscle cramp frequency and severity at baseline, 3 months, and 6 months.
45912827|NCT02014922|Drug|TheraTears® Lubricant Eye Drop|
45767691|NCT02245451|Drug|Tipranavir|
45626377|NCT05615883|Other|AEP Group Walking Sessions|The AEP Program consists in a single walking session on a treadmill lasting 80 minutes
45626378|NCT05615883|Other|CEP Group Walking Sessions|The chronic program consists in a walking session on a treadmill lasting 80 minutes (depending on the AEP results), repeated three time a week for three weeks.
45626379|NCT02712983|Drug|TIP|TIP dose regimen
45626380|NCT02712983|Drug|TIP and placebo|TIP and inhaled placebo dose regimen
45626381|NCT02712983|Drug|Placebo|Inhaled placebo dose regimen
45626382|NCT03201107|Other|Pilates|"Training based on a basic level Pilates exercise program will be as follows:~A duration of weeks with a frequency of 2 sessions a week and with a duration of 55 minutes each. The exercises to be performed will be divided into three distinct phases: warm-up, lasting 15 minutes; Main part with a duration of 30 minutes and the return to calm, based mostly on stretching and with a duration of 10 minutes. The repetitions of the exercises will be between 5 and 10 according to the difficulty."
45626383|NCT02449967|Procedure|interventional therapy|pancreatic cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
45626384|NCT03206255|Procedure|3 doses of HPV 16/18 bivalent vaccine|Participants have received 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
45626385|NCT03206255|Procedure|2 doses of HPV 16/18 bivalent vaccine|Participants have received 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
45626386|NCT03206411|Diagnostic Test|Renal and liver function tests , ECG , Sex Hormones Profile|Renal Function tests as creatinine , Uric Acid , Blood urea. Liver Function tests as AST , ALT, ALP ECG (Electrocardiogram recording) SEX hormones as LH , FSH , and Testosterone
45626387|NCT03200873|Device|repetitive transcranial magnetic stimulation|Each session of iTBS will apply3 trains of 600 pulses to the RDLPFC, with 20 2-second trains and an 8-second inter-train interval. Sham iTBS condition will be administered with the same methodology used for active iTBS condition with a sham coil mimicking noises and vibrations without delivery of magnetic pulses.
45626388|NCT03200951|Drug|Bolus group for epidural block|Randomly selected patients of the bolus group are given 0.3 ml/kg bolus of 0.15% ripivacaine for epidural block.
45626389|NCT03200951|Drug|Infusion group for epidural block|Randomly selected patients of the infusion group are given 0.3 ml/kg/hr 0.15% ripivacaine for epidural block.
45626390|NCT03206021|Drug|5 Azacytidine|Dose escalation of carboplatin combined with 5'azacytidine
45626391|NCT03200795|Other|Rebound exercise|"Each participant will undergo 3 sessions a week for 8 weeks with each session lasting 20 minutes. Bouncing frequency will be determined by signals from an metronom and will be set at between 90 and 120 bounces per minute. Heart rate training zone will be maintained, during the exercise, at moderate intensity of 40-60% and will be calculated using the Karvonen formula ([Heart rate reserve x training percentage] + resting heart rate)(Nuhu & Maharaj, 2017).~The exercise will involve bouncing on the center portion of the mini trampoline (Portable 2013 Model Half-Fold Cellerciser with feet slightly apart and knees in full extension. Each foot strike equaled one step or bounce with step height, this will be defined as the distance between the foot at maximum height of jump and the bed of the center of the trampoline ranging between 10 and 15 cm (Nuhu & Maharaj, 2017)."
45767692|NCT02245451|Drug|Ritonavir|
45767693|NCT02245451|Drug|Methadone|
45767694|NCT01096771|Drug|ClinOleic 20%|96 hour continuous infusion.
45767695|NCT01096771|Drug|Intralipid 20%|96 hour continuous infusion.
45626392|NCT03200795|Other|Circuit training exercise|"Participants will be instructed to exhale while lifting a weight and inhale while lowering it, to minimize blood pressure excursions, and to rest for 2 to 3 minutes between sets. Participants will perform 1 set per resistance exercise three time weekly for the first 2 weeks and 4 sets of each resistance exercise three time weekly during weeks 3 and 4. Resistance will be increase by 5 to 10 kg when the participant could perform more than 15 repetitions while maintaining proper form.~All aerobic activities of the circuit training will be performed on a cycle ergometer or treadmill. Participants are free to vary the machine used from one visit to the next. Exercise intensity will be standardized by using heart rate monitors (Polar Electro Oy) that will display the participant's heart rate and emitted a warning signal when the heart rate was outside the prescribed training zone, thus guiding the participant in adjusting the workload up or down to achieve the desired intensity."
45767696|NCT00951899|Drug|Colesevelam|Colesevelam hydrochloride; three 625mg tablets taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
45626393|NCT03205631|Other|Natural Frequency Patch|Participants will receive in randomized order the differing patches to wear during three nights separated by a washout period of 3-4 nights
45767697|NCT00951899|Other|Placebo|Three placebo tablets matching the active drug colesevelam in appearance, taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
45767698|NCT00951899|Behavioral|Diet|Subjects were instructed to follow a weight maintenance diet (~55% carbohydrate, 30% fat and 15% protein) for the 12 week study period.
45767699|NCT00951899|Drug|Metformin|Subjects continued to take their pre-study therapeutic doses of metformin (Metformin 500mg tablets taken by mouth twice daily for a total daily dose of 1000 to 2000 mg) through the 12 week study period.
45767700|NCT01035151|Behavioral|Experimental|Neighborhood level interventions, peer group (counseling, NRT), and individual level (Coach/CHW)
45767701|NCT01035151|Behavioral|Control|Written Cessation Materials
45767702|NCT01097395|Drug|ribavirin|Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12
45912828|NCT02014922|Drug|TheraTears® preservative-free single-use containers|
45912829|NCT02014922|Dietary Supplement|TheraTears® Nutrition|
45912830|NCT02014922|Other|TheraTears® TheraLid® Eyelid Cleanser|
45912831|NCT02014935|Other|Low intensity laser|"The study wants to evaluate the use of low intensity laser on the spastic muscle.~Want to assess whether the Low level laser prove change in muscle performace of the individual but also alters muscle activity and blood lactate."
45912832|NCT02014948|Other|Exercises|The individuals who make up this group performed exercises for 10 consecutive sessions.
45912833|NCT02014961|Procedure|Dermal biopsy|Skin biopsy
45626394|NCT03200639|Other|Combined training|The CT and CTc protocol (total length time ~60 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by 30-min walk at 70% of maximum heart rate or Borg Scale at 5-6 following resistance exercises (RE: 45-degree half squat, bench press, leg curl, rowing machine and unilateral leg extension) at 70% of one repetition maximum (1RM) with three sets of 8-12 repetitions and 1.5 min rest interval between sets and exercises. If the volunteer exceeded or did not reach the walk intensity, the volunteer was stimulated by to decrease or increase the walk speed, respectively. Regarding the resistance exercises, the load was adjusted in the 6th week with the 1RM test to ensure the 70% of 1RM between 8-12 repetitions.
45767703|NCT03030521|Diagnostic Test|the aortic delamination test|The aortic delamination test will be performed in the dissected tissue of all patient. The processes of this test has been descripted in the summary.
45626395|NCT03200639|Other|High intensity interval training with body weight|The HIITBW and HIITBWc protocol (total length time ~28 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by ten sets of 60 s of high (vigorous) intensity exercises at 80-95% of HRmax or Borg Scale at 8-9 (i.e. 30s of stepping up and down on a step and 30s of squatting up and down as fast as possible) interspersed with a recovery of 60 s of light walk (<60% of HRmax or Borg Scale at <5). To ensure vigorous zone of all sets, if the volunteer exceeded or did not reach the vigorous zone the volunteer was stimulated by the fitness professionals to decrease or increase the number of steps and squats, respectively.
45626396|NCT03200561|Drug|Prednisolone|Prednisolone 2mg/Kg/day for 5 days
45626397|NCT03200561|Biological|immunoglobulin|immunoglobulin 2g/Kg for 12 hours
45626398|NCT03200405|Device|DynaMeshVisible|The umbilical hernias will be fixed with a mesh. In this group a MRI-visible mesh will be used.
45626399|NCT03200405|Device|DynaMeshCICAT|The umbilical hernias will be fixed with a mesh. In this group a non-visible mesh will be used.
45626400|NCT03118817|Drug|HM95573|"Dose: 450 mg BID~Regimen: twice daily (BID), continuous dosing~Duration: until progression disease or unacceptable toxicity develops"
45626401|NCT03118583|Dietary Supplement|300 mg/day of dietary supplement containing carrageenan|300 mg/day of dietary supplement containing carrageenan.
45626402|NCT02449811|Drug|Perindopril|
45626403|NCT02449811|Drug|Olmesartan|
45626404|NCT02449811|Drug|Amlodipine|
45626405|NCT02449811|Drug|Hydrochlorothiazide|
45626406|NCT03200093|Drug|Oral Vancomycin|Oral vancomycin solution 125 mg in 2.5 mL combined with 2.5 mL Ora-Sweet. A total of 5 mL combined solution taken by mouth once daily.
45626407|NCT03200093|Drug|Placebo|Ora-Sweet 5mL taken by mouth once daily.
45626408|NCT03200249|Radiation|Preoperative chemo-radiation with IG-IMRT dose escalation|
45626409|NCT04485533|Device|VisuXL® Gel|"VisuXL® ophthalmic gel, available in a multidose 10ml bottle without preservatives based on Coenzyme Q10, Vitamin E TPGS and cross-linked sodium carboxymethylcellulose.~Dose/dosage: 1 drop per eye twice a day."
45626410|NCT04485533|Device|HYLO®|"HYLO® ophthalmic solution, a phosphate- and preservative-free sterile eye drops containing 2 mg/ml of hyaluronic acid sodium salt, a citrate buffer, sorbitol and water.~Dose/dosage: 1 drop per eye twice a day"
45767704|NCT01036009|Other|Withdrawal of immunosuppression and donor lymphocyte infusion|Intervention will involve fast withdrawal of immunosuppression and DLI until full donor chimerism is achieved.
45767705|NCT00467987|Drug|androgel|androgel 1%
45767706|NCT00467987|Drug|placebo|placebo
45767707|NCT00433589|Drug|anthracycline-based|
45626411|NCT03205787|Dietary Supplement|Trifolium pratense|Red Clover extract standardized to isoflavone content.
45626412|NCT02450435|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
45626413|NCT02450435|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
45626414|NCT03205397|Other|Experimental Group|Preparation for anesthesia (explanations, film, booklet), the presence of a parent in the operating room and the awakening of the child
45626415|NCT03205397|Other|usual care|Usual care
45626416|NCT03205319|Device|e-learning|The e-learning for patients is a user friendly, audiovisual based, online-accessible program, designed especially for this study. The e-learning will contain information on dyspepsia and advice on lifestyle interventions
45626417|NCT03205241|Dietary Supplement|n-3 PUFA|n-3 PUFA capsules containing EPA and DHA
45626418|NCT03205241|Dietary Supplement|Placebo|Olive oil capsules
45626419|NCT03205085|Radiation|magnetic resonance imaging|assessment of right heart dimensions and function by cardiac magnetic resonance Imaging.
45626420|NCT03205085|Procedure|2D and 3D trans-thoracic echocardiography|assessment of right heart dimensions and function by 2D and 3D trans-thoracic echocardiography
45626421|NCT03205085|Other|Blood samples|Blood samples for assays of immune inflammatory biomarkers (InterLeukin-18, CXCL9 or interferon
45767708|NCT00433589|Drug|docetaxel and capecitabine|
45767709|NCT00433589|Drug|tamoxifen|
45767710|NCT00433589|Drug|Letrozole|
45626422|NCT03204929|Drug|Cu(II)ATSM|copper-containing synthetic small molecule
45626423|NCT03204851|Device|Wound Healing|Microlyte Ag is a class-II medical device cleared by the FDA for prescription and over the counter use in humans with skin wounds.
45767711|NCT03013075|Procedure|Spinal anesthesia with Bupivacaine heavy and Morphine|Spinal anesthesia with Bupivacaine heavy 40 mg and Morphine 250 micro grams will be given to patient in addition to the routine general anesthesia before the start of surgery
45767712|NCT03013075|Drug|Bupivacaine heavy and Morphine|
45767713|NCT03013075|Drug|General Anesthetics|
45767714|NCT02180893|Other|Paravertebral Block|Paravertebral nerve block injection
45767715|NCT02180893|Other|Placebo Comparator|"No block~Patients who did not receive PVB"
45767716|NCT03014089|Biological|mRNA-1325|Escalating dose levels
45767717|NCT03014089|Other|Placebo|
45767718|NCT03030677|Procedure|Pectoralis II block & catheter without Lidocaine dissection|B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures
45912834|NCT02014961|Behavioral|Gastro-intestinal questionnaire|Pagi-Sym, Bristol Stool Chart, gastrointestinal symptom rating scale (GSRS)
45767719|NCT03030677|Procedure|Pectoralis II block & catheter with Lidocaine dissection|B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. 10 ml of lidocaine 1% will be injected for plan dissection to facilitate the procedure. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures
45626424|NCT02596971|Drug|Atezolizumab|Atezo-G-Benda: Atezolizumab 840 milligrams (mg) intravenously (IV) on Days 1 and 15 of Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1. Atezo-R-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 1200 mg IV on Day 1 of Cycles 9-25.
45626425|NCT02596971|Drug|Bendamustine|Bendamustine will be administered at a dose of 90 milligrams per square meter (mg/m^2) IV on Days 1 and 2 of Cycles 1-6, during induction treatment.
45626426|NCT02596971|Drug|Cyclophosphamide|Cyclophosphamide will be administered at a dose of 750 mg/m^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
45767720|NCT03030677|Other|catheter insertion|catheter insertion after Lidocaine dissection
45767721|NCT03035513|Other|Continuous spikes and waves during slow sleep (CSWS)|
45626427|NCT02596971|Drug|Doxorubicin|Doxorubicin will be administered at a dose of 50 mg/m^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
45626428|NCT02596971|Drug|Obinutuzumab|Atezo-G-Benda: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6, during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6 during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1 during maintenance treatment.
45767722|NCT03030365|Device|"Siemens Biograph mMR PET-MR (3T)"|Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI.
45626429|NCT02596971|Drug|Prednisone|Prednisone will be administered at a dose of 40 mg/m^2 orally on Days 1-5 of Cycle 1-6/8, during induction treatment. Prednisolone may be given if prednisone is unavailable. The 40 mg/m^2 dose of prednisone on Day 1 will be replaced by oral corticosteroids given as premedication on Day 1 of Cycle 1 (and subsequent cycles).
45626430|NCT02596971|Drug|Vincristine|Vincristine will be administered at a dose of 1.4 mg/m^2 (maximum 2 mg) IV on Day 1 of Cycle 1-6/8, during induction treatment.
45626431|NCT02596971|Drug|Rituximab|Atezo-R-CHOP: Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m^2 IV on Day 1 of Cycle 1-8, during induction treatment.
45767723|NCT01122901|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
45767724|NCT01122901|Procedure|therapeutic conventional surgery|Undergo surgery
45767725|NCT01122901|Other|pharmacological study|Correlative studies
45626432|NCT03205007|Behavioral|Health promotion nutrition program|Health promotion nutrition program
45626433|NCT03204773|Diagnostic Test|EuroQol five dimensions questionaire (EQ-5D)|Testing quality of life.
45626434|NCT03204773|Diagnostic Test|Modified Fatigue Impact Scale (MFI)|Screening for fatigue
45626435|NCT03204773|Diagnostic Test|Brief Pain Inventory (BPI)|Testing for pain
45767726|NCT01122901|Other|laboratory biomarker analysis|Correlative studies
45767727|NCT03035435|Other|fast-track rehabilitation|
45767728|NCT03035435|Other|standard care rehabilitation|
45912835|NCT02014961|Genetic|Whole-exome sequencing|Whole-exome sequencing (WES)
45447173|NCT05412862|Behavioral|Positive Psychology + Motivational Interviewing|The 12-week PP-MI intervention focuses on enhancing well-being (through PP) and increasing physical activity (through MI). Each week, participants will complete a PP activity and work towards a physical activity goal, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to improve physical activity levels, resolve ambivalence to behavior change, set realistic physical activity goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) to encourage completion of PP activities and engagement in physical activity.
45626436|NCT03204773|Diagnostic Test|Becks Depression Inventory (BDI)|Screening for depression
45626437|NCT03204773|Diagnostic Test|Restless-leg Questionaire (RLS diagnostic criteria)|Testing for restless-legs
45767729|NCT01097785|Drug|Simvastatin|40 mg, P.O.,daily for 30 days
45626438|NCT03204461|Diagnostic Test|Oral glucose tolerance test (OGTT)|For the assessment of glucose metabolism, including beta-cell function and insulin sensitivity an 75g-OGTT was conducted.
45767730|NCT01097785|Drug|Placebo|1 capsule daily for 30 days
45767731|NCT03030287|Drug|OMP-305B83|intravenous (in the vein) infusion
45767732|NCT03030287|Drug|Paclitaxel|administered intravenously
45767733|NCT01098253|Behavioral|Adherence Intervention|Factors affecting adherence are addressed using a problem solving process.
45767734|NCT03030209|Procedure|Distal pancreatectomy|Distal pancreatectomy with or without splenectomy using minimal invasive or open approach
45767735|NCT03035279|Drug|SC-006|Intravenous
45767736|NCT03035279|Drug|ABBV-181|Intravenous
45767737|NCT03035357|Drug|Daratumumab|16 mg/kg by vein once weekly for a total of 4 doses.
45767738|NCT00940589|Drug|Circadin|Prolonged Release melatonin (Circadin) 2mg tablets
45767739|NCT00940589|Drug|Placebo|Matched placebo tablets, with identical features to the Circadin tablets
45767740|NCT03603106|Drug|P03277|"Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: P03277 was administered intravenously with a flow rate of 2 mL/s."
45767741|NCT03603106|Drug|Placebo|"Part I: Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: Placebo was administered intravenously with a flow rate of 2 mL/s."
45767742|NCT02574078|Drug|Nivolumab|
45626439|NCT03204461|Other|1H-magnetic resonance spectroscopy|The amount of ectopic lipids in the liver, heart and the skeletal muscle was measured using 1H-magnetic resonance spectroscopy.
45626440|NCT04808739|Biological|Adalimumab|Analysis of survival of adalimumab biosimilar in clinical practice
45626441|NCT03204617|Biological|DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM)|Vaccine DNA.HTI 0.5mL at weeks 0, 4 and 8 + Vaccine MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM).
45626442|NCT03204617|Biological|At least 24 weeks since DDDMM, ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24 (CCM)|At least 24 weeks since second MVA.HTI administration (week 20), administration of ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24.
45626443|NCT03204617|Drug|Placebo|0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20. At least 24 weeks since the fifth Placebo administration, 0.9% sterile normal saline solution at weeks 0, 12 and 24
45626444|NCT04808895|Drug|Acetylsalicylic acid|administration of one tablet daily for 15 days. On the first day a loading dose of 300 mg will be administered
45626445|NCT04808895|Drug|Placebo|administration of one tablet daily for 15 days. On the first day 3 tablets will be administered
45767743|NCT02574078|Drug|Bevacizumab|
45767744|NCT02574078|Drug|Pemetrexed|
45767745|NCT02574078|Other|Best Supportive Care|Palliative radiation, palliative surgery and/or other best supportive care treatments
45767746|NCT02574078|Drug|nab-Paclitaxel|
45767747|NCT02574078|Drug|Paclitaxel|
45767748|NCT02574078|Drug|Docetaxel|
45767749|NCT02574078|Drug|Gemcitabine|
45767750|NCT02574078|Drug|Erlotinib|
45767751|NCT02574078|Drug|Crizotinib|
45447174|NCT04097925|Drug|Doravirine|Doravirine 100 mg tablet
45626446|NCT04485689|Drug|Capsaicin Topical - alone|5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours
45626447|NCT04485689|Drug|Placebo - alone|5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours
45626448|NCT04485689|Drug|Capsaicin Topical - ice|5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
45626449|NCT04485689|Drug|Placebo - ice|5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
45626450|NCT04808661|Procedure|Thoracic endovascular aortic repair plus optimal medical therapy|Endovascular treatment (thoracic endovascular aortic repair) plus optimal medical therapy
45626451|NCT04808661|Drug|Optimal medical therapy|Optimal medical therapy (strictly control of their blood pressure and heart rate)
45626452|NCT03204227|Biological|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
45626453|NCT03204227|Biological|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
45626454|NCT04808271|Dietary Supplement|Bifidobacterium breve Bif195|1 capsule daily for 8 weeks
45626455|NCT04808271|Dietary Supplement|Placebo|1 capsule daily for 8 weeks
45767752|NCT02574078|Drug|Carboplatin|
45767753|NCT03029897|Other|My eReport France|"patients are educated to the use of My eReport France application"
45767754|NCT03030053|Dietary Supplement|Cocoa-Flavanol Supplements|3 capsules each containing 300mg cocoa flavanols (total daily dose of 900mg cocoa-flavanols).
45767755|NCT03030053|Dietary Supplement|Control Supplements|3 capsules each containing 0mg cocoa-flavanols
45767756|NCT03605914|Drug|diclofenac|The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
45767757|NCT03605914|Drug|Norco|The opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
45767758|NCT05340023|Biological|blood sample|to realize proteomic analysis.
45767759|NCT00376714|Drug|GSK233705|
45767760|NCT04353479|Drug|Camrelizumab(SHR-1210)|A humanized monoclonal immunoglobulin
45767761|NCT04353479|Drug|Decitabine|A DNA methyltransferase inhibitor
45767762|NCT03027791|Behavioral|Virtual Reality|Participation in Virtual Reality experiences focused on a) education about the effects of high sodium foods on coronary arteries, blood pressure, the kidneys, and the cerebral vasculature, and b) stress management.
45767763|NCT03027791|Behavioral|Group Sessions|12 weekly group sessions that will provide education on topics related to hypertension, dietary sodium, physical activity and stress.
45767764|NCT03554746|Other|GC group|"core stability training: hold 5s/rep, 20 reps/times~supine, pelvic posterior tilt with TrA contraction.~supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~All four position with leg raise~Stretching ex. : hold 15 s/reps, 5 reps/times~Hamstring~Quadriceps~Additional gluteal muscle control training: hold 10 s/reps, 20 reps/times 1st to 2nd:~clam ex. without resistance~single leg bridge with maintain bil. ASIS even level 3rd to 4th: maintain 1st to 2nd ex. with resistance 5th:~maintain 3rd to 4th ex.~single leg standing on rock board to maintain balance 6th:~maintain 5th ex.~lunge ex. without hip internal rotation"
45626456|NCT03204149|Device|MC-8XL low level laser device and Standard wound care|"The MC-8XL, a handheld Low Level Laser Therapy (LLLT) device, comprised of an infrared laser diode that generates wavelength of 808 nm and a green laser diode with a wavelength of 525 nm will be used to treat the experimental group.~Along with the active LLLT, generally accepted standard wound care procedures will be used during the clinical trial by a qualified study nurse or doctor. These procedures will include wound cleaning and drying before irradiation with the laser device (sham or active). Each ulcer will be also assessed and debrided if needed.~After irradiation, each ulcer will be dressed with saline gauze dressing and offloaded."
45626457|NCT03204149|Device|Sham laser device and Standard wound care|"The Sham device is of similar appearance, emitting only green light for indication with a wavelength of 525 nm of a low power, with inactive IR laser which will be used in the Control group.~Along with the sham device, the same generally accepted standard wound care procedures will be used."
45626458|NCT04801563|Other|MDS and AlloHSCT|Allogeneic stem cell transplantation, based on TMLI and followed by infusion of donor regulatory T cells and conventional T cells and purified donor CD34+ hematopoietic stem cells
45626459|NCT03119051|Behavioral|Online cognitive training|A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.
45626460|NCT03119051|Behavioral|Cognitive training plus physical exercise|"Online cognitive training A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.~Physical Exercise Tai Chi Training：a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction."
45626461|NCT04808037|Drug|Belantamab mafodotin|Belantamab mafodotin in combination with Lenalidomide and Dexamethasone in patients with newly diagnosed Multiple Myeloma transplant-ineligible
45626462|NCT03119207|Behavioral|Naptime Protocol|Between midnight and 4:00 every attempt will be made to limit staff entrance into the patient room.
45626463|NCT03204071|Drug|placebo gel|Oral prophylaxis followed by Placebo gel to be delivered in intrabody sites of chronic periodontitis subjects.
45626464|NCT03204071|Drug|Aloevera|Oral prophylaxis followed by placement of aloevera gel
45626465|NCT03204071|Drug|Metformin|Oral prophylaxis followed by placement of metformin gel
45626466|NCT03203915|Dietary Supplement|Chardonnay grape marc marc high polyphenol dose (120mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 120mg of total polyphenols
45626467|NCT03203915|Dietary Supplement|Chardonnay grape marc powder low polyphenol dose (75mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 75mg of total polyphenols
45626468|NCT03203915|Dietary Supplement|Placebo (0mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 0mg of polyphenols
45626469|NCT04807803|Diagnostic Test|Assessment of Minimal hepatic encephalopathy (MHE)|Assessment of MHE at the inclusion and 6 months after treatment if diagnosed with MHE: Serum ammonia analysis, psychometric hepatic encephalopathy score (PHES), animal naming test (ANT) and evaluation of abdominal imaging, liver and splenic transient elastography, gastroscopy
45626470|NCT04801017|Drug|OT-101|TGF β2 specific synthetic 18 mer phosphorothioate antisense oligodeoxynucleotide
45626471|NCT04801017|Drug|Artemisinin|Herbal Supplement/ Purified extract from Artemisia
45626472|NCT04801017|Drug|Placebo|0.9% sodium chloride injection
45626473|NCT03203837|Other|Plasma collection|We will be collecting plasma at 7 different timepoints in hepatocellular carcinoma patients that are treated with radioembolization.
45626474|NCT04801251|Diagnostic Test|Echocardiographic examination|Each patient included will undergo full cardiac physical examination and echocardiographic examination
45767765|NCT03554746|Other|CG group|"core stability training: hold 5s/rep, 20 reps/times~supine, pelvic posterior tilt with TrA contraction.~supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~All four position with leg raise~Stretching ex. : hold 15 s/reps, 5 reps/times~Hamstring~Quadriceps"
45767766|NCT05260307|Other|hearing aid condition|The intervention will be a hearing aid or a modification to the sound stimulus that simulates a hearing aid configuration, style, or processing strategy.
45767767|NCT05252507|Behavioral|Paint Night|There will be 8 Sessions (4 paint nights and 4 educational sessions alternating weeks). For the painting sessions, participants will paint for 45 minutes and then participate in a combined presentation/discussion session (45 minutes). For the educational sessions, they will attend a 30-minute presentation presented by a researcher on heart health and then have the opportunity to discuss with the researcher and other members of the group (60 minutes).
45767768|NCT03608488|Dietary Supplement|Vitamin D|Vitamin D3 50.000 IU/per week, for 8 weeks
45626475|NCT03233165|Procedure|Er:YAG laser|"Ablation of the lesions Device: Er:YAG laser (LightWalker AT, Fotona, Slovenia, 2013) with a non-contact X-Runner digitally controled hand-piece.~Settings for the Er:YAG laser were as follows: pulse mode was Quantum Square Pulse (QSP), pulse energy of 120mJ, frequency of 20Hz and water sprey level was set to10ml per minute."
45767769|NCT03608488|Other|Exercise|Core stability, balance exercises
45767770|NCT03035045|Drug|Paracetamol|
45767771|NCT03035045|Drug|Placebo Oral Tablet|
45767772|NCT03557086|Behavioral|Advance Care Planning Video Decision Support Tool|Advance care planning video intervention as previously described
45767773|NCT03557086|Other|Verbal Narrative|Verbal description of end of life care options
45767774|NCT03034733|Drug|Dexamethasone|intravenous dexamethasone, two groups: 0,15 mg/kg, 0,25 mg/kg
45626476|NCT03233165|Procedure|Er,Cr:YSGG laser|Ablation of the lesions Device: Er,Cr:YSGG laser(WaterLase iPlus, Biolase LTD, USA) using contact mode. Settings were subsequent: power 50W, frequency 50Hz and concentration ratio of air and water was 2:4.
45626477|NCT04800705|Other|ultrasound assessment|Zinc (Zn), copper (Cu), calcium (Ca), iron (Fe), manganese (Mn), selenium (Se), strontium (Sr), aluminum (Al), antimonium (Sb), phosphorus (P), magnesium (Mg), sodium (Na), potassium (K), barium (Ba) and thallium (Tl) measurements (µg/L,mean±SD)
45767775|NCT03034733|Drug|Sodium Chloride, (24)NaCl 0,9%|intravenous placebo
45626478|NCT03203759|Other|Home hospitalization|See above
45767776|NCT05512416|Drug|dalpiciclib plus letrozole|Six 4-week cycles of dalpiciclib orally, 150mg, day 1-21, and letrozole orally, 2.5 mg, day 1-28
45767777|NCT03034499|Procedure|Single-port sacrocolpopexy|Single-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
46069724|NCT02619669|Drug|TAK-228|Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128 or MLN0128) targets 2 distinct multiprotein complexes, mTORC1 and mTORC2. TAK-228 selectively and potently inhibits mTOR kinase (IC50 = 1.1 nM), inhibits mTORC1/2 signaling, and prevents cellular proliferation.
45626479|NCT03203759|Other|Traditional inpatient hospitalization|See above
45447175|NCT04097925|Drug|Descovy|Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
45447176|NCT04645784|Other|Supporting Student-Athletes Mental Wellness|The module addresses: 1) managing your own mental wellness; 2) signs and symptoms of mental health problems; 3) role of student-athletes in creating a positive team environment that is supportive of mental health care seeking; 4) the role of a student-athlete in helping teammates; 5) how to identify emergency and non-emergency mental health situations.
45626480|NCT04794777|Combination Product|Individualised therapy|"Group I - No uptake: treated with conventional SRT against the prostate bed. Group II -Uptake only in the prostate bed: will receive intensity modulated RT (IMRT) including Volumetric Modulated Arc Therapy (VMAT) for prostate bed with simultaneous-integrated boost (SIB) to the PET positive uptake in the prostate bed.~Group III - Uptake in the prostate bed and involvement of regional lymph nodes in the pelvis: will be treated as Group II plus VMAT for the pelvic lymph nodes with SIB to the PET positive lymph nodes or pelvic lymph nodes salvage lymph node dissection (SLND).~Group IV - Uptake in regional lymph nodes only: will be treated with VMAT for the pelvic lymph nodes with SIB to the PET positive lymph nodes or pelvic lymph nodes SLND.~Group V - Uptake in extra-pelvic lymph nodes or bone metastasis: systemic treatment instead of surgery or radiation. Local treatment with surgery or radiation is acceptable if curative intention."
45767778|NCT03034499|Procedure|Multi-port sacrocolpopexy|Multi-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
45767779|NCT03557476|Dietary Supplement|Octacosanol|One capsules (20-mg) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed twice a day
45626481|NCT04794777|Radiation|Standard salvage therapy|Standard salvage radiotherapy
45767780|NCT03557476|Dietary Supplement|Placebo|A placebo pill was taken twice a day in a double-blinded method at the same frequency and time as the octacosanol supplement
45767781|NCT05512338|Other|Treatment|ACT-informed interventions combined with standard physiotherapy methods.
45767782|NCT05512338|Other|Active control group|Standard physiotherapy methods.
45626482|NCT03203213|Procedure|Sampling of a few drops of blood, lock of hair and urine|Sampling of a few additional drops of blood to deposit them on blotting paper (DBS: Dried Blood Spot) ad hoc and to send this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient. An oriented capillary sampling is also performed if possible. Similarly a urine sample is taken if possible.
45626483|NCT04786665|Other|Strawberry|Freeze dried strawberry powder
45626484|NCT04786665|Other|Placebo group|Comparative placebo powder
45767783|NCT03027011|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
45767784|NCT03027011|Procedure|Control|Control group without remote ischemic preconditioning
45767785|NCT04290624|Other|Experimental Dentifrice: Stannous Fluoride|Participants will be instructed to dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion containing 0.454% w/w Stannous fluoride for 2 minutes twice daily (morning and evening) for 12 weeks.
45767786|NCT04290624|Device|COREGA Denture Foaming Cleanser|Participant will clean their denture using 2 pumps of the denture cleansing foam and a denture cleaning brush for 90 timed seconds outside of the mouth twice daily (morning and evening) for 12 weeks.
45767787|NCT04290624|Other|Mouth rinse: Sodium Fluoride|Participants will take 10 ml of the mouth rinse containing 90 ppm sodium fluoride and swished around the mouth for 1 minute twice daily (morning and evening) for 12 weeks.
46069725|NCT02619669|Drug|Letrozole|An aromatase inhibitor that has a greater inhibitory effect on Ki67 (marker of cell proliferation).
46069726|NCT02866799|Other|Multi-PAP|Complex intervention based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient centered clinical interview.
46069727|NCT02866799|Other|Usual care|Patients will receive the usual clinical care based on current clinical practice guidelines.
45767788|NCT04734496|Other|National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)|National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)
45767789|NCT04353635|Device|dolphin 3d|software
45767790|NCT03403504|Drug|Oxycodone Tamper Resistant|Orally administered Oxycodone Tamper Resistant 10mg
45767791|NCT03403504|Drug|OXYCONTIN®|Orally administered OXYCONTIN® Tablet 10 mg
45626485|NCT04786821|Behavioral|Standard Exercise Training|Participants will receive interventions by an exercise specialist for up to 30 minutes based on the participant's tolerance. The exercises used in control group will depend on the individual and their abilities as evaluated in the baseline assessment session. Possible exercises include arm crank, recumbent cycle, and chair exercises. These sessions will be delivered by a member of the research team.
45767792|NCT04598802|Device|covered stent|atherosclerotic aorto-iliac aneurysm
45767793|NCT05512728|Device|VR|"The IVR environment was provided by Shinecon VR (Shinecon, china). Shinecon VR features, have a large field of view and high-quality display; with aspheric lens , lens diameter 40MM, view angle 108 , sharpness 99%, visibility 100%, color .38MM and pupillary distance adjustment 65 MM.~The shinecon VR setup was powered by a HUAWEI Y7 prime phone running the freely available IVR software.~Shinecon VR provides videos for nature, forest, wind, desert and animals. That included noise-cancelling headphones playing background sound from the IVR simulation."
45767794|NCT05512728|Drug|Midazolam|• (titration of 0.05 mg/kg per dose) according to Modified Wilson sedation scale Score to achieve grade 1 (Oriented, eyes may be closed but can respond to 'Can you tell me your name?' 'Can you tell me where you are right now?'
45767795|NCT03609658|Behavioral|Nurse Navigator Pathway|In the Nurse Navigator Pathway, nurse navigators are being used as leverage to: approach qualified patients to initiate advance care planning discussions, schedule advance care planning visit with patients' primary care provider to further discuss advance care planning and to mail advance care planning resources to patients after their initial advance care planning discussion.
45767796|NCT03609658|Behavioral|Usual Care|In the Usual Care arm, there is no approach by nurse navigators to initiate advance care planning discussions and it does not have a structure advance care planning visit. Therefore, no further action is required for the patients who were randomly assigned to the usual care arm.
45767797|NCT02565810|Drug|Adalimumab PFS and Pen|
45767798|NCT00940901|Drug|sildenafil|sildenafil 50 mg tablet daily for first 8 weeks (phase 1), and then sildenafil 50 mg tablet daily for final 8 weeks (phase 2)
45767799|NCT00940901|Other|placebo|placebo 50 mg tablets daily for first 8 weeks (phase 1), and then sildenafil 50mg tablet daily for final 8 weeks (phase 2)
45767800|NCT05512650|Device|Virtual Reality Meditation|Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
45767801|NCT05512650|Device|Non-VR Meditation|Participants will engage and follow along with a 10-20 minute guided meditation on a computer screen placed before them. The meditation program may include simulated movement visuals, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
45767802|NCT04353713|Dietary Supplement|40% Dextrose Gel|Prophylactic administration of 40% dextrose gel via buccal mucosa to prevent newborn hypoglycemia
45767803|NCT04353713|Dietary Supplement|2% carboxymethylcellulose gel|placebo
45767804|NCT03611062|Behavioral|VR Executive Functions Training|"The Windows 10-based VICT program invites children to rescue an animated character named Lubdub from a castle. The program consists of three challenging and child-friendly tasks that correspond to the three core EFs."
45767805|NCT03611062|Behavioral|VR Placebo Game|In this game, children in the control group will use the VR hand controller to cast different types of spells (bees, bouncy balls, sparkler spells) to objects in the virtual world. Objects in the VR world will all react differently to a spell being cast so as to provide children a relaxing and EF-free gaming experience.
46069728|NCT02619825|Device|Echography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and measurement of all echocardiographic parameters estimated in children with a clinical ultrasound Machine
45767806|NCT05507502|Biological|Influenza vaccination administration|There will be approximately 40 participants who consent; they will be randomized in a 1:1 manner to receiving the influenza vaccination during their heart failure hospitalization versus receiving the vaccine during their first follow-up in the heart failure clinic.
45767807|NCT02981771|Behavioral|Balance activity program|Participants will take part in a biweekly, 12 week physical activity program that will include balance and coordination exercises
45767808|NCT02981771|Behavioral|Strength activity program|Participants will take part in a biweekly, 12 week physical activity program that will include traditional strength exercises
45767809|NCT05512572|Device|IPL|intense pulsed light
45767810|NCT05512572|Procedure|Conservative treatment or excision with curettage|conservative treatment or excision with curettage but without IPL-MGX treatment as a control
45767811|NCT03034655|Device|CDP|Vestibular rehabilitation using CDP
46069729|NCT02619825|Device|Elastography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and
45626486|NCT04786821|Device|Phoenix Exoskeleton suit|Participants will aim to walk wearing the Exoskeleton for up to 30 minutes. Based on the participant's tolerance, the duration of walking can be shorter and can be split into shorter intervals to achieve more activity. Over the sessions, based on the participants' tolerance, gradually the duration of walking can be increased with shorter breaks. This will be delivered by a research physiotherapist.
45626487|NCT03232853|Other|Elearning|Elearning
45767812|NCT03034655|Device|Mobile posturography|Vestibular rehabilitation using mobile posturography
45767813|NCT03034655|Other|10 sessions|Vestibular rehabilitation, ten sessions
45767814|NCT03034655|Other|5 sessions|Vestibular rehabilitation, five sessions
45626488|NCT04800549|Other|Oral Mucositis|The data of the study were obtained by conducting six interviews with each child and the family. The first interview was conducted before starting to treatment on the first day of the treatment, the second interview was conducted on the 2nd day after the treatment and the following interviews were conducted on the 4th, 8th, 16th, and 21st days and in-mouth mucosa of the patient was evaluated by taking in-mouth pictures following interviewing with the child and the family. Oral care application was conducted four times a day with sodium bicarbonate solution and a lollipop made with black mulberry syrup (after meals and before going to the bed at night). Oral care was first conducted by the researcher, the oral care was then taught to the patient and patient's relatives and the application was evaluated. Figure 1 shows the study design.
45626489|NCT03203369|Biological|UCART123|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen.
45626490|NCT04794855|Diagnostic Test|laboratory tests|routine laboratory tests and biomarkers tests
45626491|NCT02450357|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
45626492|NCT02450357|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
45626493|NCT04794309|Other|Circuit training exercise|"circuit training exercise start with 5 minutes of warming-up then followed by a 30-minute conditioning protocol formed 20 minutes of aerobic exercise and 10 minutes of resisted exercise. The cool-down period is doing in form of walking on a treadmill in low intensity for 5 minutes.~Aerobic exercise will be performed on an electronically-braked cycle ergometer (Quinton Excalibur, QuintonInstrument Company, Bothell, WA). resistance exercise (RT) in the form of eight different exercises will be performed during each workout: military press, leg extension, bench press, standing leg curl (ankle weights), lateral pull-down, dumbbell triceps push-down, dumbbell seated biceps curl, and sit-ups (abdominal curls).~The participant will do 10 minutes for Aerobic exercise followed by 10 minutes of resistance exercise then 10 minutes for Aerobic exercise. This cycle training will perform five days per week for eight weeks."
45626494|NCT04794309|Dietary Supplement|Healthy high Fiber diet|The diet will be tailor-made for the individual for the body type and obesity in consultation with the nutritionist.
45626495|NCT03107429|Drug|Acetazolamide|Acetazolamide tablets were placed in capsules to make them look similar to placebo.
45626496|NCT03107429|Drug|Placebo|Placebo was a sugar based placebo placed in a capsule.
45626497|NCT03107429|Other|Trendelenburg Position|Placed in Trendelenburg Position
45767815|NCT03560128|Device|Endocuff Vision device|Subjects randomized to undergo a colonoscopy procedure with the Endocuff Vision device will have this device placed on the colonoscope used during their procedure.
45626498|NCT04794231|Other|Standard dressing|a standard breathable, hypoallergenic, transparent dressing (TegadermTM 1635 [8.5 x 10.5cm] or 1633 [7 × 8.5 cm] depending on patient size; 3M, Neuss, Germany)
45626499|NCT04794231|Other|Chlorhexidine gluconate -impregnated dressing group|A chlorhexidine gluconate -gel impregnated transparent dressing (TegadermTM CHG 1660R [7 x 8.5 cm] or [11.5 x 8.5 cm] depending on patient size; 3M, Neuss, Germany).
45626500|NCT02450201|Drug|Pyruvate|
45626501|NCT04800081|Drug|Sacubitril/Valsartan|Patients will be randomized to receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan.
45767816|NCT03560128|Device|AmplifEYE device|Subjects randomized to undergo a colonoscopy procedure with the AmplifEYE device will have this device placed on the colonoscope used during their procedure.
45767817|NCT02981927|Other|Physical inactivity|
45626502|NCT04800081|Drug|Valsartan|Patients will be randomized to receive once-daily treatment with 80-320 mg of Valsartan.
45767818|NCT05512104|Procedure|bone marrow aspirate and biopsy|fiow cytometry of bone marrow aspirate
45767819|NCT05107739|Biological|Drug Product De-TIL-0255|Autologous tumor-infiltrating lymphocytes
45767820|NCT03614416|Device|EOXY device|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
45767821|NCT03614416|Device|Gold standard oximeter|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
45767822|NCT03614416|Procedure|SaO2 sampling|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
45767823|NCT05507268|Other|no intervention|no intervention
45767824|NCT02981693|Procedure|Root canal sealer|Patients who required root canal therapy were enrolled and allotted into either iRoot SP arm or AH Plus arm randomly.For Test Arm: iRoot SP was used as a sealer. Obturation was performed with Gutta-percha cones and root canal sealer by continuous-wave condensation technique. For Control Arm: AH Plus was used as root canal sealer. The same steps were followed for obturation as in Test Arm.
46069730|NCT03965117|Drug|Norepinephrine|norepinephrine will be started at 0,1 mcg/kg/min and titrated according to its haemodynamic effect. After baseline MAP (which is > 60 mmHg), norepinephrine is targeted according baseline MAP. At T2, MAP is between 10 - 20 % above baseline (T1), at T3 MAP is between 20 - 30 % above baseline (T1).
45626503|NCT03202979|Drug|Trazodone 20 mg|"Oral administration of trazodone 20 mg (corresponding to 10 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 60 mg.~After the 8-week treatment period, patients will receive trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution) three times a day for 1-week tapering period in double blind conditions."
45767825|NCT04900038|Drug|GSK3640254|GSK3640254 will be available as 25 mg or 100 mg tablets to be administered orally
45767826|NCT04900038|Drug|Dolutegravir|DTG will be available as 50 mg tablets, to be administered orally
45767827|NCT04900038|Drug|Lamivudine capsules|3TC will be available as 300 mg capsules, to be administered orally as a blinded treatment
45767828|NCT04900038|Drug|Lamivudine tablets|3TC will be available as 300 mg tablets, to be administered orally as an unblinded treatment
45767829|NCT03026465|Device|Polymer-free stent|PCI using a polymer-free dual-drug sirolimus- and probucol-eluting stent (Coroflex ISAR)
45767830|NCT03026465|Device|Biodegradable-polymer stent|PCI using a biodegradable-polymer biolimus-eluting stent (Biomatrix)
45626504|NCT03202979|Drug|Trazodone 10 mg|"Oral administration of trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 30 mg.~In order to maintain the study double-blind conditions,patients randomized in this group will be co-administered with placebo oral solution (5 drops).~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions."
45626505|NCT03202979|Drug|Placebo|"Oral administration of placebo oral solution (10 drops) three times a day, for 8-week treatment.~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions."
45626506|NCT04799925|Drug|Febuxostat|uric acid lowering agent. dose: 80 mg once daily. duration: for 6 months
45626507|NCT03232775|Other|Treatment: Physical Exam with Visual Pedagogy and Structure|Routine physical examination participants receive visual pedagogy and reinforcement (preferred food treat).
46069731|NCT00917462|Drug|Sorafenib, administered orally|Sorafenib 400 mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days. The cycle start date will coincide with the physician visit date. Because of the potential need for physician visit scheduling to vary (due to both physician and patient issues), to avoid violation of, and deviation from, the protocol, these visits may vary by up to one to fourteen (1-14) days. A study diary will be completed by patients to ensure compliance with the study drug.
45767831|NCT03564886|Drug|Hyperosmolar Saline|The hyperosmolar solution will be created by adding 120cc of 23.4% NS solution to a 3L bag of LR.
46069732|NCT00917462|Procedure|CT/MRI|A CT (computerized tomography) or MRI (magnetic resonance imaging) scan of the chest and abdomen will be obtained at baseline, after the first four weeks of therapy, at eight weeks, and then every eight weeks there afterwith a scheduling window of up to one to fourteen (1-14) days. The same imaging modality performed at baseline (CT or MRI) will be repeated at subsequent imaging.
46069733|NCT02619513|Drug|Dexmedetomidine|Group GTD received thoracic continuous paravertebral nerve block with dexmedetomidine (0.5μg/kg) added to ropivacaine before anesthesia induction, and used continuous thoracic paravertebral nerve block patient-controlled analgesia(with dexmedetomidine 100μg）.
45626508|NCT03232775|Other|Control: Physical Exam without Visual Pedagogy and Structure|Participants engage in routine physical examination without visual pedagogy and reinforcement (preferred food treat).
45626509|NCT04786431|Other|Blood collection for lipid profiling by LC-MS|Blood withdrawal
45626510|NCT03232697|Diagnostic Test|Full version of the Montreal Cognitive Assessment|Patients or subjects will be submitted to the full version of the MOCA
45626511|NCT03232697|Diagnostic Test|5 minutes version of the Montreal Cognitive Assessment|The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call
45767832|NCT03564886|Drug|Normal saline|Lactate Ringer's (LR, 273mOsm/L)
45767833|NCT05086133|Device|transcranial magnetic stimulation|transcranial magnetic stimulation with continuous theta burst pattern, 90% RMT, 50Hz within train and 5Hz train for 200 train and 40 second in total.
45767834|NCT05086133|Device|sham stimulation|TMS coil vertical to the brain surface, with same protocol as cTBS
45767835|NCT05512026|Device|Feasibility Assessment|To validate the performance of the Poseidon System™ for fluid management during water-aided endoscopic procedures in the colon.
46069734|NCT02619513|Drug|Ropivacaine|Group GE\GT\GTD respectively received continuous nerve blocks and postoperative analgesia combined with ropivacaine.
46069735|NCT02619513|Device|Mindray M7 series|Ultrasound real-time guidance have been used in continuous thoracic paravertebral blocks in group GT and group GTD.
46069736|NCT03947255|Drug|brentuximab vedotin|1.8 mg/kg given intravenously (IV)
46069737|NCT02619747|Drug|Compound Sodium Alginate Oral Suspension sachet|
46069738|NCT02619747|Drug|Matched placebo|
45626512|NCT04793997|Biological|Microbiome spray|Throat spray containing 3 beneficial lactobacilli strains
45626513|NCT04793997|Biological|Placebo spray|Throat spray
45626514|NCT03107351|Device|Cardiac contractility assessments with Kino-cardiograph|Cardiac contractility will be assessed with Kino-cardiograph device. Echocardiography will also be used for the experimental arm
45626515|NCT03107351|Device|Cardiac assessment repeatability with Kino-cardiograph|Cardiac contractility will be assessed with Kino-cardiograph device only, at different times of the day to assess the repeatability of the measures.
45626516|NCT04786509|Diagnostic Test|Field tests|In this study we used three different standardized running tests, one sub-maximal test - Cooper 2400 m (C), and two maximal (all-out) tests - 100 m sprint (S) and shuttle run (SR).
45767836|NCT03034109|Device|Transcranial Direct Current Stimulation|TDCS involves sending a weak electrical current to the brain to modulate brain functions.
45767837|NCT03565666|Device|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
45767838|NCT03565666|Drug|iLet Bionic Pancreas insulin-only configuration with Fiasp|iLet Bionic Pancreas insulin-only configuration with Fiasp (faster insulin aspart)
45767839|NCT03565666|Other|Usual care|Usual care
45767840|NCT03034343|Behavioral|Mindfulness|
45767841|NCT05502822|Device|High definition transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
45767842|NCT05502822|Device|sham high definition transcranial alternating current stimulation|. In the sham condition, 6-Hz tACS was delivered only during the ramp-up and ramp-down periods (30 s); no current was delivered during the 30-minute intervention.
46069739|NCT02866877|Other|Pharmacokinetic modeling|Timed blood draws and urine collections to model drug clearance
46069740|NCT00697125|Biological|Engerix™-B|Intramuscular injection, 3 doses
46069741|NCT00697125|Biological|HBV-MPL vaccine (208129)|
46069742|NCT00697125|Biological|Hepatitis B vaccine, experimental formulation|Intramuscular injection, 3 doses
45626517|NCT03107273|Other|Dynamic cultures of in vitro hematopoietic stem cells|Improvement of prognostic scores used in myelodysplastic syndromes by identifying by dynamic in vitro culture of hematopoietic stem cells dynamic factors, reflections of ineffective haematopoiesis
45767843|NCT05502744|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is the standard treatment for acute cholecystitis due to the advantages of small wounds, less use of abdominal drains , less need for antibiotics and analgesics and less postoperative hospital stay time.Laparoscopic cholecystectomy in acute cholecystitis may be performed as soon as begging of the symptoms called emergency or urgent and maybe scheduled in advance after controlling acute attack after 6-8weeks called elective.
45767844|NCT03026153|Behavioral|Control Group Oral Survey 1|Oral survey 1 will be administered as control intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-monthly injections
45767845|NCT03026153|Behavioral|Intervention Group Oral Survey 2|Oral Survey 2 will be administered as the intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-daily injections, then surveyor would ask how willing they would be to take an injectable medication which required only once-monthly injections
45767846|NCT05502666|Behavioral|¡Salud! Por la Vida|Lay health worker (LHW) delivered educational intervention for colorectal cancer screening (CRCS). The intervention consisted in having the participant complete a tailored interactive multimedia intervention (TIMI). TIMI consisted of a series of educational videos that addressed common barriers to colorectal cancer screening as well as provided information about colorectal cancer (CRC) and CRCS tests. Participants were able to tailor the TIMI for sex (male/female) and CRC family history. After TIMI completion, the LHW provided participant with a copy of the SPLV newsletter and printed infographics on CRC, CRCS, and an action plan tailored by type of CRCS (FOBT/FIT or colonoscopy). The Intervention Group subject participation took approx. up to 2 hours and Control Group up to 1 hour (half hour for each: baseline and follow-up interview). Follow-up data was collected 6 months post education session (intervention group) or post-baseline survey (control group).
45767847|NCT03620890|Drug|Neutral Protamine Hagedorn (NPH)|NPH will peak between 4-12 hours after injection with a duration of action around 14 hours
45767848|NCT03620890|Drug|Detemir insulin|Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)
45767849|NCT05507112|Drug|PD-1 inhibitor|Tislelizumab (3 cycles): 200mg i.v. q3w on day 1 of each cycle, and starting from the second week after the start of radiotherapy
45626518|NCT04800003|Diagnostic Test|Gonial angle and submandibular fossa depth measurements from CBCT images|CBCT images were obtained from dry human mandibles
45626519|NCT03202823|Procedure|blood samples|3 tubes (5 ml volume) collected during surgery
45626520|NCT03202823|Procedure|recover samples of atheromatous plaque|a carotid sample collected during surgery
45626521|NCT04794465|Diagnostic Test|Colorectal cancer screening|Patients with IBP diagnosed during the colorectal cancer screening
45767850|NCT05507112|Drug|Capecitabine|Capecitabine 1650mg/m2/d orally twice-daily, 5 days a week for a total of 5 weeks.
45767851|NCT05507112|Radiation|Long-course radiation therapy|45-50 Gy/day, 5 days a week for a total of 5 weeks.
45767852|NCT05511948|Drug|DBI-102|Topical application on dorsal hand and upper volar arm
45767853|NCT05511948|Drug|Vehicle gel|Inactive comparator
45767854|NCT05511948|Drug|Hydroquinone Cream|4% Hydroquinone cream, Acella (approved), twice daily for 12 weeks
45767855|NCT03024983|Other|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
45767856|NCT03024983|Other|Semolina soup|Semolina soup (322 g) eaten with 500 mL of water
45767857|NCT03024983|Other|Bread|Bread (122 g) eaten with 500 mL of water
45767858|NCT03024983|Other|Penne (fresh)|Cooked penne (132 g) eaten with 500 mL of water
45767859|NCT03024983|Other|Penne (dry)|Cooked penne (142 g) eaten with 500 mL of water
45767860|NCT03024983|Other|Spaghetti (dry)|Cooked spaghetti (142 g) eaten with 500 mL of water
45767861|NCT03569020|Other|Subsidy for food purchases and dietitian education|$105/wk of DASH-like foods over 4 weeks purchased with the help of a dietitian in a proportion that reflects the DASH diet.
45767862|NCT05507034|Diagnostic Test|Biomarkers|Each intervention is performed at 4 timepoints namely: before surgery, i.e. baseline (T0), 1-3 weeks post-surgery (T1), 3 months post-surgery (T2) and 1 year post-surgery (T4)
45767863|NCT03833609|Behavioral|Online yoga training (Group A)|The yoga training program is a structured low-intensity Vishwas-Raj (18). This yoga program consists of stretching, strengthening, meditation and deep breathing, and has been shown to be effective among adults with RA. Participants will be asked to complete three individual 1-hour sessions per week for 12 consecutive weeks by watching a previously filmed session led by a qualified yoga instructor and posted on Facebook. They will also take part in a 1-hour virtual group session per week using a video-conferencing platform. Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
45626522|NCT03203057|Other|coronary occlusion|percutaneous coronary intervention
45626523|NCT03202745|Other|Patient Consequences Letter|This letter focuses on the consequences of inappropriate prescribing for patients. It also includes a peer comparison.
45626524|NCT03202745|Other|Prescriber Consequences Letter|This letter focuses on the consequences of inappropriate prescribing for prescribers. It also includes a peer comparison.
45626525|NCT04799457|Other|Suture technique|We wil apply additional sutures to classical caesarean procedure.
45626526|NCT03202589|Other|FOCUS Echocardiography|FOCUS Echocardiography
45626527|NCT04799613|Other|walking speed|walking speed (normal speed vs. fast speed). fast speed was 25% faster than normal speed
45626528|NCT04799613|Other|visual loading|visual loading (walking through narrow pathway using VR)
45626529|NCT04799613|Other|dual task|dual task (serial subtraction using VR)
45626530|NCT04799613|Other|best side reduction|best side reduction (split belt mode, the speed of best side was reduced by 25% compared to the other side)
45626531|NCT03202433|Device|Use of virtual reality lenses, with relaxing audio-visual contents|Use of virtual reality lenses (and audio) as a distraction for the blood donor patients.
45626532|NCT04793529|Drug|Cholecalciferol|Cholecalciferol injection
45626533|NCT03232619|Biological|CD19 CART|Patients will get one course of CART treatment with the dose of 0.5-5*10~6/KgBW.
45626534|NCT04261959|Other|myoActivation|myoActivation is a novel, structured assessment and non-pharmacological therapeutic approach to both diagnosis and treatment of chronic myofascial pain. A detailed history of the timeline of lifetime trauma combined with a quick, structured and reproducible set of posture and movement tests help to easily identify myofascial components of chronic pain. The therapeutic component is delivered utilizing a needling technique, or myofascial release, focused to active myofascial trigger points, fascia in tension and tethered scars.
45626535|NCT04261959|Other|Physiotherapy|Physiotherapy aims to reduce a patient's pain experience and increase their physical function through physical examination, diagnosis, prognosis, physical intervention, rehabilitation and education (including pain neurophysiology education).
45767864|NCT03833609|Behavioral|Online aerobic dance training (Group B)|The aerobic dance program is a low to moderate intensity level program and will also use a video. The video, adapted for youth with JIA, was developed with feedback from a JIA patient with experience in aerobic dance and a physiotherapist with experience in pediatric rheumatology. The aerobic dance program will have the same characteristics in terms of frequency, total number of sessions and total duration as the yoga program (i.e., three 1-hour individual sessions and one 1-hour virtual group session per week for 12 weeks). Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
45767865|NCT05511714|Drug|L-(11C) methionine|Injected intravenously with 20 mCi/1.7 sq m body surface area of L-[methyl-11C]methionine (maximum prescribed dose: 20 mCi).
45626536|NCT03232385|Device|MR-US Fusion Arm|Use of Clear Guide SCENERGY for MR-US fusion guidance
45767866|NCT05502510|Behavioral|MyHealthyPregnancy|MyHealthyPregnancy is a mobile application prescribed to expectant mothers in conjunction with normal prenatal care. The application uses behavioral decision science principles to identify risks of preterm birth and alert the mother and care team of these risks.
45626537|NCT03232385|Procedure|Renal Biopsy or Ablation|Standard of Care
45626538|NCT04793763|Other|traditional therapeutic exercises|group A will receive traditional exercises
45626539|NCT04793763|Other|traditional therapeutic exercises and McKenize technique|Group B will receive traditional therapeutic exercises and McKenize technique
45626540|NCT04793763|Other|traditional therapeutic exercises and deep neck flexor exercises|Group C receive traditional therapeutic exercises and deep neck flexor exercises
45626541|NCT03232307|Drug|Dexamethasone|Given PO
45626542|NCT03232307|Drug|Ibrutinib|Given PO
45626543|NCT03232307|Drug|Lenalidomide|Given PO
45626544|NCT03232307|Biological|Rituximab|Given IV
45626545|NCT05615727|Drug|Dexmedetomidine|2 mcg/kg of undiluted dexmedetomidine [= 0.02 ml/kg] and oral placebo tablet
45626546|NCT05615727|Drug|Zolpidem|zolpidem 10 mg and intranasal saline 0.02 ml/kg
45626547|NCT05615727|Other|Placebo|a placebo oral tablet and intranasal saline at 0.02 ml/kg
45626548|NCT03202355|Device|Fixed Appliance Orthodontic Treatment|Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
45626549|NCT03202355|Device|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
45767867|NCT00952133|Drug|Palonosetron only|The placebo arm will be given a dose of IV palonosetron only, and saline solution prior to surgery to see how this compares with the other combination.
45767868|NCT00952133|Drug|Palonosetron with Dexamethasone|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery to see if this reduces PONV.
46069743|NCT04287491|Other|Oculus Go Virtual Reality System|The VR system will provide a 3D environment that provides distracting stimulus. Participant will put on the Oculus Go VR system headset 1-2 minutes prior to out-patient bedside procedure up to the completion of procedure which takes typically 3-5 minutes.
46069744|NCT04134351|Other|Bronchial challenge test|Bronchial challenge test with sphingosine-1-phosphate
45626550|NCT04785729|Drug|Almonertinib combine with Pyrrolitinib|110mg,qd Almonertinib+（240mg/320mg/400mg）,qd Pyrrolitinib
45626551|NCT04785885|Diagnostic Test|iStat Handheld Blood Analyzer|An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.
45626552|NCT04785885|Diagnostic Test|Hemochron|An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.
45626553|NCT02450279|Drug|technetium-99m - Diethylenetriaminepentaacetic acid|
45626554|NCT02450279|Device|Vibrating-mesh nebulizer|
45626555|NCT02450279|Device|Jet Nebulizer|
45626556|NCT02450279|Other|Planar scintigraphy|
45626557|NCT02450279|Other|Preoperative spirometry|
45626558|NCT04793607|Other|Pleural procedures|Any pleural procedure that removes fluid
45626559|NCT03231839|Behavioral|Caloric restriction|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
45626560|NCT03231839|Behavioral|no red meat|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
45626561|NCT03231839|Behavioral|Increased fiber intake|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
45626562|NCT04347135|Drug|F-18 FES|F-18 FES PET/MRI for detection of endometriosis.
45626563|NCT03231761|Other|Service user testimonial videos|Service users describe their personal experiences receiving care for depression or psychosis and the impact of the treatment on their quality of life
45626564|NCT03231761|Other|mhGAP didactic video|Video with a narrated slide presentation describing diagnosis and treatment of depression and psychosis
45626565|NCT04786041|Procedure|laparoscopic appendectomy|laparoscopic appendectomy
45626566|NCT03231683|Drug|Esketamine|intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Marsh model
45767869|NCT04754412|Other|Behavioral, Psychological or Informational Intervention|Write about stress and coping, emotional disclosure, and benefit finding
45767870|NCT04754412|Other|Behavioral, Psychological or Informational Intervention|Write about positive thoughts and feelings regarding their breast cancer experience
45626567|NCT03231683|Drug|Saline|intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
45626568|NCT03231683|Drug|Remifentanil|Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
45626569|NCT03231683|Drug|Propofol|Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
45626570|NCT04346979|Other|Telerehabilitation-Based|25 volunteers postmenopausal women who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. Online yoga and mindfulness protocol was created for individuals who will participate in the study. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. Respiratory exercise was added to the training protocol. Individuals were asked to participate in the study via telerehabilitation system and aimed to do their exercises with a physiotherapist.
45626571|NCT04346979|Other|Video-Based|25 volunteers postmenopausal women who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. Online yoga and mindfulness protocol was created for individuals who will participate in the study. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The respiratory exercise was added to the training protocol. Video recordings containing only yoga and mindfulness training were sent to individuals. The participants were supervised by the researcher.
45626572|NCT03202277|Behavioral|BeWell24 smartphone app|This app delivers an evidence-based suite of lifestyle interventions targeting behavior change in sleep, sedentary behavior, physical activity, and dietary intake. The app connects with a commercially available activity monitor to provide real-time feedback on behaviors over time.
45626573|NCT03202277|Behavioral|Health education app|This app delivers basic health education and hygiene content related to sleep, sedentary behavior, physical activity, and dietary intake.
45626574|NCT03231605|Biological|Hepatitis A Vaccine|Vaccinating two Hepatitis A Vaccines separately in 18-24 months Children based on the grouping result .
45626575|NCT04798599|Other|Telemonitoring and teleorientation|"Teleservice will be performed through a digital platform (Video for Health - V4H). The service will consist of: a) recognition of the condition identified in the pandemic period, including updates on medical history, current oral health condition, search for dental care in other units, need for referral, change of hygiene habits, b) realization of diet guidance, hygiene and other necessary habits, made from a situational recognition of such habits, c) targeting the needs presented, in which individualized counselling will be given seeking to meet the demand presented by that family nucleus. A dental form developed on the digital platform Google Forms will serve as a guide for the performance of the service and where the collected data will be formally recorded. The guidelines, although individualized for the needs of each child, will follow a pre-defined and standardized structure and based on the best evidence available in the subject."
45626576|NCT04798599|Other|Control Group - Waiting list|No intervention (at least, until the time frame for outcome assessment)
45626577|NCT03202199|Device|PET/MRI|2 PET/MRI examinations
45626578|NCT04793451|Behavioral|Endurance training|The women in group A underwent endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA). Exercise sessions consisted of a five-minute warm-up (stretching exercise) at low intensity (50%-60% of maximum heart rate), a 45-minute exercise (at 50%-80% of maximum heart rate), five minutes of cycling without a load, and five minutes of closing stretching and breathing exercise of low intensity.
45767871|NCT04754412|Other|Best Practice|Write about facts regarding their cancer diagnosis and treatment
45767872|NCT04754412|Other|Quality-of-Life Assessment|Ancillary studies
45767873|NCT04754412|Other|Questionnaire Administration|Ancillary studies
45767874|NCT05511636|Other|Oxygen therapy|This study will be conducted on 180 patients who will be undergoing lung resection (wedge resection, segmentectomy, metastasectomy, lobectomy, or pneumonectomy) surgery at the Cardiothoracic department, Ain Shams University Hospitals; patients are to be extubated intraoperative, and at the ICU we will be comparing HFNC to standard oxygen therapy. The endpoints of the study are to investigate whether high-flow nasal cannula oxygen therapy is superior to conventional oxygen therapy for reducing hypoxemia and postoperative pulmonary complications in extubated patients after lung resection.
45767875|NCT03033953|Dietary Supplement|Native whey|
45767876|NCT03033953|Dietary Supplement|Milk|
45767877|NCT03033953|Other|Strength training|
45767878|NCT05506644|Other|HRV-Biofeedback/Mind-Body Therapy|A 7-week protocol using real-time feedback on heart rate variability
45767879|NCT03033797|Device|MoviLetrando|Half of the participants will play two different levels of the Game MoviLetrando, two minutes each.
45767880|NCT03033797|Device|MoveHero|Half of the participants will play 2 minutes of the game MoveHero.
45767881|NCT04293978|Behavioral|CalmPlace|Self-contained VR application allowing the user to build and custom a relaxation session, with options to vary session length (9-20 minutes), music/sound, relaxation exercises, and specific nature environment (three available) including time of day and events (e.g. rain). Delivered using an Oculus Go devices in kiosk-mode.
45767882|NCT03570658|Drug|RO7049389|RO7049389 will be administered orally either as a single dose (SAD) or as multiple doses defined by the SAD portion of the study (MAD).
46069745|NCT04134273|Drug|CLPG Topical Gel 1%|Clindamycin Phosphate Topical Gel 1% (Taro Pharmaceuticals U.S.A, Inc.)
46069746|NCT04134273|Drug|Clindamycin|Clindamycin Phosphate topical gel 1%
46069747|NCT04134273|Drug|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
46069748|NCT05326659|Drug|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
46069749|NCT05326659|Drug|Placebo|Placebo, applied twice daily for 12 weeks after enrolment.
45767883|NCT03570658|Drug|Placebo|Placebo will be administered orally at a dose and frequency matched to RO7049389.
45767884|NCT00941681|Drug|CK-1827452|50 mg MR CK-1827452 BID for 10 days
45767885|NCT00941681|Drug|CK-1827452|37.5 mg IR CK-1827452 TID for 10 days
45626579|NCT04793451|Behavioral|Endurance-strength training|Group B performed endurance-strength exercise consisting of a five-minute warm-up (stretching exercises) of low intensity (50%-60% of maximum heart rate), a strength component, an endurance component, 5 minutes cycling without a load, and a 5 minutes closing stretching and breathing exercise of low intensity. The 20-minute-long strength component was performed using a neck barbell and a gymnastic ball. Directly after the strength exercise, the women took part in a 25-minute endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA) at 50%-80% of maximum heart rate.
45626580|NCT03202121|Other|insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to insomnia group that contained 25 cases.
45626581|NCT03202121|Other|non-insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to non-insomnia group that contained 25 cases.
45626582|NCT03202121|Other|normal control|Persons without stroke or insomnia served as normal controls that contained 25 cases.
45626583|NCT03231449|Other|observation of current care|The study FEVRIER (survey of hospitalizations in cardiology units in sub-Saharan Africa) aims to establish a description of sub-Saharan standard of care, in order to get a cross sectional analysis (globally and per country) and a longitudinal analysis (evolution during 5 years).
45626584|NCT03201887|Behavioral|Sub-optimal effort|Participants will be asked to play a patient who wishes to present himself as having cognitive deficits or exaggerate existing cognitive deficits
45626585|NCT03201887|Behavioral|optimal effort|Participants will be asked to perform tasks to the best of their abilities.
45626586|NCT02593773|Drug|Interferon γ-1b|The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after Week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
45626587|NCT01526681|Other|Processed Human Nerve Graft|Implantation of appropriate length of processed human nerve graft at the time of surgery
45767886|NCT00941681|Drug|CK-1827452|100 mg MR CK-1827452 BID for 10 days
45767887|NCT04889274|Biological|COVID-19 vaccine|COVID-19 vaccine as offered by NHS England
45767888|NCT04889274|Biological|Concentrate beetroot Juice|Beetroot juice containing approximately 5mmol/l nitrate
45767889|NCT04889274|Biological|Nitrate-deplete beetroot juice|Beetroot juice with nitrate removed
45912836|NCT02014987|Behavioral|Training programmes|"Runners with a high body mass index follow two types of training programmes:~a running programme of 3 kilometres per week~a running programme 6 kilometres per week~The amount of running will be increased with 10 % per week."
45767890|NCT05042375|Drug|camrelizumab + famitinib|Camrelizumab for injection, 200 mg; Famitinib malate capsules, 20 mg.
45767891|NCT05042375|Drug|pembrolizumab|pembrolizumab 200 mg.
45767892|NCT05042375|Drug|camrelizumab|Camrelizumab for injection, 200 mg.
45767893|NCT03571672|Drug|DEFINITY|All subjects will receive a single dose of DEFINITY®
45767894|NCT05502120|Device|Laryngoscopy with Vie-Scope laryngoscope|Evaluation of laryngeal view using Vie-Scope laryngoscope, intubation efficacy, complications
45767895|NCT05502120|Device|Laryngoscopy with Macintosh blade laryngoscope|Evaluation of laryngeal view using stnadard Macintosh blade laryngoscope
45767896|NCT04580940|Device|SpyGlass™ Discover Digital System|Observational, prospective, registry study for the clinical utility of the SpyGlass Discover digital catheter during a PTCS procedure.
45767897|NCT04592172|Behavioral|Bedtime Routine Education|The intervention aims to promote healthy sleep and improved developmental outcomes in infants. Individualized bedtime routine education, including such activities as a bath, teeth-brushing, reading stories, singing songs, and cuddling will be implemented by research assistants at the 12-month well-child visit. Reinforcement of the bedtime routine education will be implemented at the 15-month visit. Each individualized bedtime routine will incorporate 3-5 steps and a bedtime routine chart depicting those steps will be created and provided to the families. Families will receive materials for their bedtime routines, including a CuddleBright kit, 1-2 additional bedtime books, toothbrush/toothpaste , and the created bedtime chart. On top of that, families will also receive a children's book provided by Reach Out and Read through the study period.
45767898|NCT00952211|Device|CPAP|CPAP at therapeutic pressure during nighttime
45767899|NCT00952211|Device|CPAP at sub-therapeutic pressure|CPAP delivered at sub-therapeutic pressure at nighttime
45767900|NCT05506566|Drug|68Ga-FAP-CHX|The dose will be 0.05 (mCi / kg) +/- 10% given intravenously at a single time prior to imaging
45767901|NCT05506566|Drug|68Ga-FAP-CHX|68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) +/- 10% given intravenously at a single time prior to imaging； 68Ga-FAPI-04, the dose will be 1.8 (MBq / kg) +/- 10% given intravenously at a single time prior to imaging； 18F-FDG, the dose will be 3.7 (MBq / kg) +/- 10% given intravenously at a single time prior to imaging；
45912837|NCT02015000|Procedure|P.E.R.F.A.M.T|Surgical Result of Primary and Recurrent Pterygium by Using Pterygium Extended Removal followed by Fibrin Glue Assisted Amniotic Membrane Transplantation (P.E.R.F.A.M.T)
46069750|NCT04134117|Biological|Tisagenlecleucel|One time single predetermined dose level CAR-positive T cells will be utilized based on the FDA approved product label.
45626588|NCT01526681|Other|Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.|Historical control from established literature
45626589|NCT01526681|Other|Autogenous Nerve Graft|Nerve gap reconstructions with autogenous nerve graft within the upper extremity
45626590|NCT01526681|Device|Nerve Tube Conduit|Nerve gap reconstructions with nerve tube conduit within the upper extremity
45626591|NCT01526681|Procedure|Autologous Breast Reconstruction with Neurotization|
45626592|NCT01526681|Procedure|Autologous Breast Reconstruction without Neurotization|
45626593|NCT04798443|Procedure|subureteral endoscopic Injection of Dextranomer/Hyaluronic acid (Dexell)|The subureteral endoscopic injection was done under general anesthesia. the investigators used the subureteral injection technique (STING), as described by O'Donnell and Puri. The volume of Dexell was injected until ureteral orifice collapse in all patients. The needle was held for 30 s.
45626594|NCT04798443|Procedure|open ureteral reimplantation (Lich-Gregoir)|The juxtavesical ureter is dissected by open surgery and a submucosal groove is created extending laterally from the ureteral hiatus along the course of the ureter. The ureter is placed in the groove and the detrusor is closed over the ureter with ureteric stent fixation for 21 days. the surgical wound is closed in layers. Urethral catheter for bladder drainage for 3-5 days.
45767902|NCT03023189|Drug|Tranexamic acid|"At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h.~Total dose : 4 g of TA"
45767903|NCT03023189|Drug|Placebo|At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h Total dose : 40 mL of Placebo
46069751|NCT03853187|Radiation|Zr-89 labelled durvalumab PET/CT|Patients will undergo a Zr-89 labelled durvalumab (MEDI4736) PET/CT and dedicated perfusion-CT prior to treatment with durvalumab (MEDI4736) and in- and ex-vivo In-111-oxine or in-vivo [89zr]-Df-crefmirlimab labelled CD8+ T-cells after two courses of treatment, prior to surgery.
46069752|NCT03853187|Drug|Durvalumab (MEDI4736)|Patients will receive two courses of durvalumab (MEDI4736)at a fixed dose of 750mg Q2W intravenously, prior to scheduled resection of NSCLC.
45767904|NCT04590534|Drug|Chromax|Treatment of BPH by Chromax for 3 Months
45767905|NCT04590534|Drug|Sildosin Group|patients will receive one capsule of Sidosin 8 mg once daily for 12 weeks
45767906|NCT04590534|Other|Placebo Group|patients will receive placebo 3 times daily for 12 weeks
45767907|NCT03033719|Procedure|Laparotomy|Open surgery
45767908|NCT03033719|Procedure|Laparoscopy|Minimally invasive surgery
45767909|NCT03033485|Radiation|18F-P3BZA|18F-P3BZA is a type of 18F labeled Picolinamide targeting melanin which is highly secreted in Melanoma. The toxicity of P3BZA was evaluated by SoBran Bioscience. The final report showed that there no signs of toxicity during the conduct of the toxicity study. No treatment-related differences were noted in mean body weight and body weight changes, clinical chemistry, haematology, or coagulation parameter after a single intravenous dose of P3BZA at 0.0589mg/kg.
45767910|NCT03033641|Device|Ablation procedure|All enrolled subjects who have ablation targets identified will undergo CARTOFINDER guided ablation (CFGA) followed by PVI. Subjects will be followed per the protocol schedule. Subjects who have no ablation target identified on the baseline CARTOFINDER map will undergo ablation per the institution's standard of care and be followed for 7 days for safety monitoring, then exit from the study.
45767911|NCT00941993|Device|Iontophoresis System (Acclarent)|Iontophoresis system will deliver iontophoresis simultaneously to both ears. Active elements of this drug delivery system are lidocaine and epinephrine.
45767912|NCT04852055|Behavioral|Advance Care Planning Video|Clinical assistants determine who is the correct person to receive the informational materials. If the patient is the correct recipient, clinicians will send the informational materials to the patient at the assisted living center. If the proxy is the correct recipient, the clinical assistant will determine whether or not the proxy is using the existing online portal. If the proxy is using the portal, the informational materials will be sent electronically. If the proxy does not access the portal, the informational materials will be sent to their residences.
46069753|NCT02619357|Device|SenseWear Armband Gecko|Subjects will wear SenseWear Armband Gecko up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
45626595|NCT04793139|Drug|Camrelizumab|Camrelizumab-treated advanced NSCLC Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.
45626596|NCT04793061|Other|blood sample collection|Blood is samples from peripheral vein during routine care
45626597|NCT05234333|Drug|SARS-CoV-2 vaccine|SARS-CoV-2 vaccination
45626598|NCT02450045|Procedure|Continuous femoral nerve block|
45626599|NCT02450045|Drug|0.5% Ropivacaine/0.125% Bupivacaine local anesthetic mixture|
45767913|NCT02561832|Drug|Olaparib|tablets taken orally twice daily
45767914|NCT02561832|Drug|Carboplatin|intravenous injections on day one of each cycle
45767915|NCT02561832|Drug|Anthracycline|The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
45626600|NCT03201653|Procedure|Stump closure using NU-KNIT SURGICEL|We would use the Oxidized Regenerated Cellulose as NU-KNIT SURGICEL.
45626601|NCT02593539|Drug|Nemiralisib|Participants will be administered nemiralisib
45626602|NCT00919763|Drug|CD2027 Ointment 3 mcg/g, twice daily|Topical Ointment
45767916|NCT02561832|Drug|Cyclophosphamide|The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
45767917|NCT02982161|Drug|MR308|Over-encapsulated tablet, Dosing frequency: two times daily, Mode of administration: oral
45626603|NCT00919763|Drug|Vehicle Ointment, twice daily|Topical Ointment
45626604|NCT05615571|Genetic|Establishment of mitochondrial markers|Establishment of mitochondrial markers from fibroblasts in culture, obtained from a skin biopsy. Establishment of yeast models to show biochemical mitochondrial alterations: introduction of missense variants in the pantothenate kinase yeast gene Cab1 whose deletion is lethal, followed by growth of mutant strains on fermentation and respiratory media.
45626605|NCT05615571|Genetic|Sequencing tests|sequencing tests of a panel of 22 genes (9 already known and 13 new genes) using a dedicated custom capture and a medium throughput sequencing protocol.
45626606|NCT00306917|Device|non-coated femoral hip stem|total hip replacement
45767918|NCT02982161|Drug|Tramadol|Over-encapsulated capsule, Dosing frequency: four times daily, Mode of administration: oral
45626607|NCT00306917|Device|coated femoral hip stem|total hip replacement
45767919|NCT02982161|Drug|Placebo|Capsule, Dosing frequency: four times daily, Mode of administration: oral
45767920|NCT05506488|Drug|Dasatinib 100 MG + Quercetin (1000 MG)|The intervention group will receive intermittent orally administered dasatinib (100 mg/day) plus quercetin (1000 mg/day) on three consecutive days for three consecutive weeks followed by a four-week medication free period. This cycle will be repeated three times.
45767921|NCT05506488|Other|Placebo|The placebo group will receive intermittent orally administered placebo tablets on three consecutive days for three consecutive weeks followed by a four-week medication free period. This cycle will be repeated three times.
45767922|NCT00942149|Drug|Daptomycin|single dose of 6 mg/kg of daptomycin
45767923|NCT03033563|Procedure|Intracytoplasmic sperm injection|Intracytoplasmic sperm injection
45767924|NCT03023111|Drug|Sbv|Standard treatment for CL, parenteral drug used during 20 days.
45767925|NCT03023111|Drug|Miltefosine plus placebo|Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. Placebo gel cream will be used topically.
45767926|NCT03023111|Drug|Miltefosine plus GM-CSF|Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. GM-CSF gel cream will be used topically.
45767927|NCT03022253|Biological|Liberal platelet transfusion|"Liberal platelet transfusion: In Intervention group the investigators will transfuse platelet concentrates to maintain a platelet count above 1,00,000 per microliter until one of the following endpoints is met, whichever is applicable:~PDA closes or~A maximum of 120 hours after the point of randomisation"
45767928|NCT03022253|Biological|Restrictive platelet transfusion|"The investigators will transfuse platelets only if:~(i) Platelet count is < 20,000 per microliter or (ii) Subject has a clinical bleed or (iii) Subject has platelet count < 50000 per microliter and requires a major non-neurosurgical interventional procedure as per the current standard of care, or (iv) Subject has a platelet count < 1, 00,000 per microliter and requires a neurosurgical procedure"
45912838|NCT02015091|Biological|PfSPZ Vaccine|The PfSPZ Vaccine is composed of radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) and is designed to prevent malaria in adults, children, and infants. It is formulated in phosphate buffered saline (PBS) with 1% human serum albumin (HSA). Sanaria Incorporated (Sanaria), Rockville, Maryland, developed and produced the PfSPZ Vaccine.
45912839|NCT02015130|Other|Individual treatment|See detailed description
46069754|NCT02619357|Device|SenseWear Armband MF|Subjects will wear SenseWear Armband MF up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
45626608|NCT05615493|Device|radial extracorporeal shock wave therapy|Radial extracorporeal shock wave therapy (r ESWT) will be applied by Dornier AR2 machine (Dornier MedTech GmbH, Wessling, Germany) under ultrasound guidance, at musculotendinous junction of medial and lateral head of the gastrocnemius for spastic calf (gastrocnemius muscle and the soleus) muscles . 1.500 pulses will be applied by an R20 probe with a focusing depth of 4cm.The intensity will be 0.10 mJ to 0.3mJ/mm2 (2.5 bar), with frequency 4 Hz every week for one month .No anesthetic or analgesic drugs will be administered to patients during the therapy session
45626609|NCT05615493|Device|sham radial extracorporeal shock wave therapy|Dornier AR2 machine (Dornier MedTech GmbH, Wessling, Germany) used under ultrasound guidance, at musculotendinous junction of medial and lateral head of the gastrocnemius for spastic calf (gastrocnemius muscle and the soleus) muscles . 1.500 pulses will be applied by an R20 probe with intensity of 0.10 mJ to 0.3mJ/mm2 (2.5 bar), & frequency 4 Hz every week for one month without operating the machine .
45626610|NCT03119129|Behavioral|Ho'ouna Pono Drug Prevention Curriculum|Ho'ouna Pono is a school-based, culturally grounded drug prevention curriculum tailored to Native Hawaiian and Pacific Islander youth on Hawai'i Island.
45626611|NCT02593305|Dietary Supplement|Super Beets|Nitrate rich beetroot powder (10g/day) for 4 weeks
45626612|NCT02593305|Dietary Supplement|Super Beets Placebo|Nitrate deficient beetroot powder (10g/day) for 4 weeks
45912840|NCT02015156|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
46069755|NCT02619357|Device|Actigraph GT9x wristband and waistband|Subjects will wear Actigraph GT9x wristband and waistband up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
46069756|NCT02619357|Device|Garmin Vivofit 2 wristband|Subjects will wear Garmin Vivofit 2 wristband up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
45626613|NCT03118973|Procedure|Goff trans-pancreatic septotomy vs. Double wire technique|Goff trans-pancreatic septotomy vs. Double wire technique for achieving biliary access when biliary cannulation is challenging.
45626614|NCT02593149|Device|ClearGuard HD End Cap|The ClearGuard HD end cap elutes chlorhexidine acetate into the hemodialysis hub
45626615|NCT02448173|Biological|OncoVAX and Surgery|OncoVAX is comprised of sterile, live but non-dividing tumor cells obtained following standard-of-care surgical tumor resection for Stage II colon cancer
45626616|NCT02448173|Procedure|Surgery|Surgical resection of Stage II colon cancer
45767929|NCT03022253|Drug|Paracetamol|"As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
45626617|NCT04389411|Drug|Montelukast 10mg|10mg oral Montelukast will be taken daily for 60 days
45626618|NCT04785417|Other|touch screen tablet|traditional occupational therapy in addition to games on tablet
45626619|NCT03231527|Procedure|coronary artery bypass grafting (CABG)|myocardial revascularization
45626620|NCT04384965|Device|MagPro X100 Stimulator, B70 Fluid-Cooled Coil|Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single iTBS treatment, delivering 600 pulses of iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / ~3 minutes) at a target of 110% of the subject's resting MT.
45626621|NCT02448251|Drug|AC0010MA|Following Phase I, a protocol amendment will be submitted to the IND to specify the selected dose and dose justification to be used in Phase II.
45767930|NCT03022253|Drug|Ibuprofen|"As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral"
45912841|NCT02015156|Biological|Herceptin®|Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
45912842|NCT02015169|Drug|Lapatinib|lapatinib 1250mg qd daily up to 8 cycles (3 weeks * 8 cycles = 24 weeks)
45912843|NCT02015182|Other|Blood sample for bupivicaine pharmacokinetics|"Bupivacaine levels will be measured with an assay developed on the 4000 QTrap Tandem Mass Spectrometer (Applied Biosystems/ MDS Sciex).~Data will be collected and analyzed using the Agilent ChemStation software (Rev A.10.02). The analytical column is an Agilent Zorbax Eclipse XDB-C8 (4.6 x 150mm, 5µm).Quantification of bupivacaine is based on analyzing a six point calibration curve (0 to 4.0 mg/L). An internal standard (Prilocaine 221.2/86.1) is included with each calibrator, quality control or patient sample. Instrumentation and Chromatographic conditions: The HPLC system consists of a Specta-System P1000 Isocratic Pump and an AS3000 Autosampler (Thermo Electron Corporation, Waltham MA)."
45912844|NCT02015208|Drug|Ruxolitinib|20 mg orally on day 1 to 21 of each 28 day cycle. Number of Cycles: 7 or until progression or unacceptable toxicity develops.
46069757|NCT02619357|Device|SOMNOwatch plus EEG 6 sleep monitor|In a subset of subjects, this device will be worn as a comparator for monitoring sleep quality and duration.
46069758|NCT02619357|Other|Strength exercises|Subjects will perform strength exercises using elastic bands of varying resistance
46069759|NCT02619357|Other|Field-based exercise tests|Subjects will perform an Incremental Shuttle Walk Test (ISWT) and each individual component of a Short Physical Performance Battery (SPPB).
45447177|NCT02104492|Other|a 12-week Respiratory Muscles Training Program (RMTP)|Every session will be lasted 50 minutes and performed under supervision of a physiotherapist. It will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program which will be supplemented by a 12-week Respiratory Muscles Training Program (RMTP) with ORYGEN Dual® device for 20 minutes. Patients will be instructed to maintain adequate inspiration and expiration while using the Origen-Dual® valve at a rate of 15-20 breaths/minute. Participants will be performed five sets of 10 repetitions followed by 1-2 minutes of unloaded recovery breathing off the device, once a day, 2 days per week, for 12 weeks. The respiratory muscles training will be begun at 30% of MIP achieved at baseline and increased by 5% each week to reach 60% of the baseline assessment MIP.
45626622|NCT04792593|Biological|Senl-h19 CAR-T|Biological: Senl-h19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
45767931|NCT03033407|Other|Tailored mobile coaching messages|Intervention was adding tailored mobile coaching to current usual diabetes care. The participants received regular mobile messages via Switch app according to entered data, such as self-monitoring of blood glucose, blood pressure, exercise, dietary record, medication record, and body weight. Contents of messages were alert for the unused, weather, behavioral recommendation, education about diabetes, and individualized advices.
45767932|NCT01037881|Drug|LEO 29102|comparison of different dosages of drug
45767933|NCT01037881|Drug|Elidel®|comparison
45447178|NCT02104492|Other|Active Comparator|Every session will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program and Health Education Program.
45626623|NCT03195569|Drug|QL1101|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
45626624|NCT03195569|Drug|Avastin®|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
45626625|NCT03195569|Drug|Paclitaxel|175 mg/m2, IV following investigational product on day 1 of each 21 day cycle.
45626626|NCT03195569|Drug|Carboplatin|AUC 5 IV, following paclitaxel on day 1 of each 21 day cycle.
45626627|NCT04792671|Behavioral|Sociodemographic variables|age, residence, education of the mother and her husband, occupation of the mother and her husband, parity, gender, and age of the last baby.
45912845|NCT02015247|Procedure|computer-assisted surgery|use of computer-assisted navigation during periacetabular osteotomy
45912846|NCT02015260|Drug|Topical NO|Varying doses of sodium nitrite and citric acid co-applied to warts
45912847|NCT02015260|Drug|Placebo|Placebo
45912848|NCT02015273|Device|easypod™|Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
45912849|NCT02015286|Device|easypod™|Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
45912850|NCT02015299|Drug|Linagliptin|one tablet linagliptin 5 mg/day for 26 weeks
45626628|NCT04792671|Behavioral|Family affluence scale (FAS)|a four-item measure of family wealth, has been developed in the WHO Health Behaviour in School-aged Children Study as an alternative measure.
45626629|NCT04792671|Behavioral|Edinburgh postnatal depression scale (EPDS)|s a questionnaire originally developed to assist in identifying possible symptoms of depression in the postnatal period. It also has adequate sensitivity and specificity to identify depressive symptoms in the antenatal period and is useful in identifying symptoms of anxiety. more than 9 is clinically diagnosed
45626630|NCT04792671|Behavioral|"Symptom Checklist 90 SCL 90:"|is a 90-item questionnaire used to assess psychological problems. It is designed to evaluate a broad range of psychological problems and symptoms of psychopathology. More than 60 is considered clinically diagnosed
45767934|NCT03017651|Dietary Supplement|OM3-supplement 1|1g of OM3-supplement 1 will be given to subjects to look at DHA/EPA blood absorption
45626631|NCT03195881|Other|Ocular ultrasound|Post-cardiopulmonary arrest patients meeting inclusion/exclusion criteria for targeted temperature management will undergo ocular ultrasound at three time points: within 6 hours (h) of initiation of hypothermic protocol, between 10-24 h after hypothermic protocol initiation, and between 24-36 h after hypothermic protocol initiation.
45626632|NCT04785495|Other|Quality-of-life assessment|Patients will be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero (before the application of chemotherapy) and then after 6 day, after application of chemotherapy.
45626633|NCT02448017|Device|The Herbst appliance|Orthodontic functional appliance
45626634|NCT02448017|Device|Twin block appliance|Orthodontic functional appliance
45767935|NCT03017651|Dietary Supplement|OM3-supplement 2|1g of OM3-supplement 2 will be given to subjects to look at DHA/EPA blood absorption
45626635|NCT02447939|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt).
45626636|NCT02447939|Drug|Trametinib|Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
45626637|NCT04785183|Dietary Supplement|Melatonin drops|Melatonin oral administration
45626638|NCT04785183|Other|Placebo|Oral 5% glucose
45626639|NCT03195725|Other|Review of notes|No intervention will occur
45767936|NCT03021863|Behavioral|Group A Reminder|Tone of reminder email (duty 14 days followed by duty 28 days for non-responders)
45767937|NCT03021863|Behavioral|Group B Reminder|Tone of reminder email (encouragement 14 days followed by encouragement 28 days for non-responders)
45767938|NCT03021863|Behavioral|Group C Reminder|Tone of reminder email (encouragement 14 days followed by duty for non-responders 28 days)
45447179|NCT03637166|Other|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
45447180|NCT03637166|Other|Exposure to High Altitude (2500m above sea level)|"Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours"
45447181|NCT02104570|Other|Kinesio taping with tension|
45447182|NCT02104570|Other|Kinesio taping without tension|
45767939|NCT03021863|Behavioral|Group D Reminder|Tone of reminder email (duty 14 days followed by encouragement for non-responders 28 days)
45447183|NCT02104570|Other|Fatigue protocol|
45447184|NCT04195893|Device|somofilcon A|Contact Lens
45447185|NCT04195893|Device|etafilcon A|Contact Lens
45447186|NCT02106754|Behavioral|Brief Intervention|
45447187|NCT02106754|Behavioral|Brief Intervention with Coaching|
45626640|NCT04297917|Biological|ChAdOx1-HBV|chimpanzee adenovirus-vectored hepatitis B virus vaccine
45626641|NCT03195803|Behavioral|Computerized Cognitive Stimulation|All participants performed 12-week, 60-minutes twice a week of a computer-based cognitive stimulation program in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
45626642|NCT03195491|Biological|Nivolumab|Intravenous infusion administered over 30 minutes at 240 mg
45447188|NCT02106754|Behavioral|Treatment as Usual|
45626643|NCT03195413|Procedure|Ultrasound-guided forearm nerve block|An ultrasound machine will be used to identify the median, radial, and ulnar nerves in the forearm, so that a needle may be used to apply lidocaine into the soft tissue space around those nerves.
45626644|NCT03195413|Drug|1:1 volume measured solution of: 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine|This is the anesthetic solution that will be administered during the ultrasound-guided nerve block
45626645|NCT03195413|Device|Bedside ultrasound machine|This is the device that will be used to visualize tissues during the ultrasound-guided nerve block.
45626646|NCT04338399|Drug|Buparlisib & Paclitaxel|Investigation drug plus paclitaxel
45626647|NCT03195335|Other|Assessment via questionnaire|All the children will be assessed via assessment questionnaires.
45767940|NCT03021863|Behavioral|Group E Reminder|Tone of reminder email (generic reminders 14 days followed by 28 days for non-responders)
45767941|NCT03021863|Behavioral|Group F Reminder|Tone of reminder email (generic 14 days followed by duty for non-responders 28 days)
45767942|NCT03021863|Behavioral|Group G Reminder|Tone of reminder email (generic 14 days followed by encouragement for non-responders 28 days)
45767943|NCT03021863|Behavioral|Group H Reminder|Tone of reminder email ( duty14 days followed by generic for non-responders 28 days)
45767944|NCT03021863|Behavioral|Group I Reminder|Tone of reminder email (encouragement 14 days followed by generic non-responders 28 days)
45912851|NCT02015299|Drug|placebo|one tablet matching placebo/day for 26 weeks
45767945|NCT03017807|Biological|Recombinant Anti-EGFr Antibody|Low-dose level patients received cetuximab initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.High-dose level patients received cetuximab initial dose 400 mg/m2 and 4 weeks later loading 400 mg/m2 and 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.
45447189|NCT04640012|Drug|DC371739|Participants received one of 6 dose levels of DC371739 administered as single oral doses.
45626648|NCT03912753|Behavioral|Comunică|Comunică is based on the Information-Motivation-Behavioral Skills (IMB) model of health behavior change, which postulates that individuals must possess the requisite information for enacting sexual health, motivation to change their HIV risk and alcohol use, and behavioral skills necessary for reducing their risk. Therefore, Comunică includes MI to provide accurate information about HIV transmission, alcohol abuse, and local GBM-affirmative health resources and build motivation to improve behavioral skills (via CBST). CBST is a therapeutic approach used in the treatment of various behavioral problems, such as alcohol abuse and depression and more recently HIV risk. CBST can help modify cognitions driving unhealthy behaviors, promote awareness of contextual triggers and unhealthy behavioral patterns, and teach coping skills to improve health. Comunică also draws upon minority stress theory recognizing that stigmatizing societal contexts compromise health behavior.
45626649|NCT03912753|Other|Education Attention Control|The EAC condition consists of eight self-administered modularized topics, content-matched with the Comunică sessions, which we have generated based on our HIV-prevention education with GBM in the US and Romania.
45626650|NCT04792983|Other|No intervention|This is an observational study with no interventions.
45626651|NCT02447783|Dietary Supplement|Control Capsules|Cocoa-based, flavanol-free, control-matched capsules consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
45767946|NCT00947219|Device|HairMax LaserComb|Device application 3 times week (non-consecutive days), for 26 weeks
45767947|NCT00947219|Device|Control device|Device is used 3 times a week on non-consecutive days
45767948|NCT01124305|Device|Customized Patient Instrumentation|Custom cutting guides based on computed tomography (CT) images of the patient's leg are used to make the bone cuts and select the implant size.
45767949|NCT01124305|Device|Traditional Instrumentation|Traditional surgical instruments will be used to make bone cuts and size the components in this control group.
45767950|NCT03408730|Biological|Hepatitis B Vaccination|Hepatitis B Vaccination
45767951|NCT03033251|Device|Non Invasive Ventilation|Patients will receive non invasive ventilation as a standard of care.
45767952|NCT03033251|Device|High Flow Oxygen Cannula 50|Patients will receive High Flow Oxygen Cannula with a flow set at 50 L/min
45767953|NCT03033251|Device|High Flow Oxygen Cannula 30|Patients will receive High Flow Oxygen Cannula with a flow set at 30 L/min
45767954|NCT03017729|Biological|Botulinum toxin type A|This is an observational study designed to reflect real world clinical practice in the use of abobotulinumtoxinA. AbobotulinumtoxinA injected doses, frequency of injections, number of injection sites and volume injected per site are in accordance with the current USPI and physician's clinical practice.
45767955|NCT03408808|Procedure|Platelet rich plasma|Aspiration of ganglion and injection with platelet rich plasma.
45767956|NCT03408808|Procedure|Aspiration alone|Aspiration of the ganglion
45767957|NCT03021941|Drug|Elelyso 60 units/kg|All patients receive Elelyso 60 units/kg.
45767958|NCT03410914|Device|Hemopatch|Application of hemopatch to the divided end of the pancreas during surgery.
45767959|NCT03017495|Drug|Midazolam|2 mg/mL oral solution
45447190|NCT04640012|Drug|Placebo|Placebo orally administered
45626652|NCT02447783|Dietary Supplement|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 500 mg of cocoa flavanols per capsule consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
45626653|NCT04792905|Device|Cardiologs|Two Apple Watch recordings (one recording with the watch on the wrist and one on the left side of the abdomen) interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
45626654|NCT02447705|Drug|telbivudine|telbivudine replace Lamivudine
45767960|NCT03017495|Drug|ACT-541468|Hard gelatin capsules for oral use at a strength of 25 mg
45767961|NCT03021161|Drug|Probiotic Formula|The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019
45767962|NCT03021161|Other|Placebo Oral Capsule|Capsule containing no probiotic
45767963|NCT01039207|Other|Laboratory Biomarker Analysis|Correlative studies
45767964|NCT01039207|Biological|Rilotumumab|Given IV
45767965|NCT03417466|Device|Enlite 1 connected to iPro2 recorder|Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 in subjects age 14 - 75 years.
45767966|NCT02981615|Drug|Levofloxacin|one tablet (500mg) a day, from day 10 to day 28 in every cycle of the 4 first cycles
45767967|NCT02981615|Drug|Placebo Oral Tablet|one tablet a day, from day 10 to day 28 in every cycle of the 4 first cycles
45767968|NCT03830047|Device|nd yag laser|nd yag laser will be applied on the vulval warts
45767969|NCT02981537|Device|two-staged endobronchial blocker insertion|positioning endobronchial blockers in two-staged method
45767970|NCT02981537|Device|single-staged endobronchial blocker insertion|positioning endobronchial blockers in traditional single-staged method
46069760|NCT02619357|Other|Laboratory-based exercise tests|Subjects will perform an incremental, symptom-limited cardiopulmonary exercise test on a cycle ergometer and will walk at various speeds on a treadmill
45767971|NCT03621202|Device|Saranas Early Bird Bleed Monitoring System (EBBMS)|Participants will undergo their planned endovascular procedure with monitoring for internal bleeding using the Saranas EBBMS.
46069761|NCT03849443|Drug|Tranexamic Acid Injectable Product (1000 mg intravenous bolus)|Intravenous methods to decrease blood loss
46069762|NCT03849443|Drug|Vitamin C 250 MG Oral Tablet|Oral method of placebo
46069763|NCT03849443|Drug|Tranexamic Acid 650Mg Tablet|Oral method of treatment group
46069764|NCT00697281|Drug|OC000459|"Tablets twice daily for 8 days~Dose level 1"
46069765|NCT00697281|Drug|OC000459|"Tablets twice daily for 8 days~Dose level 2"
45626655|NCT04792125|Behavioral|External electrical stimulation (EES) added to pelvic floor muscle training (PFMT)|"Patients will be treated with the Innovo device using eight external electrodes with a combined stimulator. Electrodes will be applied to the buttocks, outer hips and anterior and posterior proximal thighs 3 days a week for 30 minutes each session.~While explaining the exercise to the patients, it was stated that 1 set of exercise consisted of 10 fast contractions and 10 slow contractions. For the first 2 weeks, they were asked to exercise 2 sets a day, every day. Thus, in the first 2 weeks, 20 fast contractions and 20 slow contractions were performed. Then, 2 sets were increased every two weeks and the exercise was ended as 8 sets (80 fast and 80 slow contractions) at the end of the 8th week."
45626656|NCT04792125|Behavioral|External electrical stimulation|Patients will be treated with the Innovo device using eight external electrodes with a combined stimulator. Electrodes will be applied to the buttocks, outer hips and anterior and posterior proximal thighs 3 days a week for 30 minutes each session.
45626657|NCT04792125|Behavioral|Pelvic floor muscle training (PFMT)|While explaining the exercise to the patients, it was stated that 1 set of exercise consisted of 10 fast contractions and 10 slow contractions. For the first 2 weeks, they were asked to exercise 2 sets a day, every day. Thus, in the first 2 weeks, 20 fast contractions and 20 slow contractions were performed. Then, 2 sets were increased every two weeks and the exercise was ended as 8 sets (80 fast and 80 slow contractions) at the end of the 8th week.
45626658|NCT03195257|Other|GIP|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
45626659|NCT03195257|Other|GLP-1|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
45626660|NCT03195257|Other|Saline|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
45626661|NCT03195101|Procedure|transconjunctival orbitotomy approach|approach the orbital tumor through an incision in the conjunctiva, This is followed by blunt dissection of the tenons capsule. A traction suture is applied over the corresponding rectus muscle to guide the globe toward the desired direction. The orbital fat is retracted by malleable retractor and blunt dissection through the orbital connective tissue continues until reaching the edge of the tumor. After the mass is exposed, a biopsy or complete resection of the mass is taken place
45626662|NCT02447393|Drug|levocetirizine|levocetirizine
45626663|NCT02447393|Drug|cetirizine|cetiridine
45626664|NCT02447393|Drug|placebo|placebo
45626665|NCT04785105|Other|No intervention|No intervention
45767972|NCT01125163|Dietary Supplement|Iron Supplement|multivitamin that provides 2mg/kg/day of iron given orally to infants when they are tolerating 120 ml/dg/day of preterm formula or fortified breast milk until they reach 36 weeks adjusted postmenstrual age.
45767973|NCT01125163|Dietary Supplement|multivitamin|daily oral multivitamin without iron until 36 weeks adjusted postmenstrual age
45767974|NCT03033329|Drug|Single intravenous doses of MRX-4|Intravenous single escalating doses of MRX-4
45626666|NCT04785027|Drug|PSORI-CM01 formula|PSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
45767975|NCT03033329|Drug|Single intravenous doses of placebo|Intravenous single doses of placebo to match MRX-4
45767976|NCT03033329|Drug|Multiple intravenous doses of MRX-4|Multiple ascending doses of MRX-4 given intravenously twice daily for 10 days
45767977|NCT03033329|Drug|Multiple intravenous doses of placebo|Multiple doses of placebo to match MRX-4 given intravenously twice daily for 10 days
45767978|NCT03033329|Drug|Single dose of intravenous and oral MRX-4|Crossover single dose of intravenous and oral MRX-4 given on Day 1 and Day 4
45767979|NCT03020693|Procedure|Invasive electrostimulation combined with exercises|Procedure for producing analgesia by introducing the TENS current through a needle combined with a exercises program.
45912852|NCT02015312|Drug|Epigallocatechin-3-gallate (EGCG)|"Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
45447191|NCT03554434|Biological|AM0010|AM0010
45447192|NCT02104648|Other|Placebo RO4602522|Daily oral doses
45767980|NCT03020693|Procedure|Placebo electrostimulation and exercises|First: Sham dry needling. After: electrostimulation using surfaces electrodes. Finally a exercises program.
45767981|NCT01099969|Device|Glidescope videolaryngoscope|
45767982|NCT01099969|Device|McGrath videolaryngoscope|
45767983|NCT01099969|Device|Non-styletted Endotrol endotracheal tube (ETT)|
45767984|NCT01099969|Device|Regular endotracheal tube (ETT) with Gliderite stylet|
45767985|NCT03017339|Other|Functional Exercise|
45767986|NCT03017339|Radiation|Low Level Laser Therapy|
45767987|NCT03017339|Radiation|Placebo Low Level Laser Therapy|Low Level Laser Therapy with the device off
45767988|NCT03417778|Drug|Filgotinib|100 mg tablet administered orally
45767989|NCT03013855|Device|FIT-SOC|Study subjects will be given a standard kit for fecal immunochemical test by their primary healthcare provider. As per standard practice, the patient will take the kit home and use the included FIT applicator to collect a stool sample from spontaneously passed stool during a regular bowel movement. The patient will then mail the stool sample to the lab in a pre-paid envelope, which is provided in the kit.
45912853|NCT02015312|Drug|Placebo|"Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
46069766|NCT00697281|Drug|OC000459|"Tablets twice daily for 8 days~Dose level 3"
46069767|NCT00697281|Drug|OC000459|"Tablets twice daily for 8 days~Dose level 4"
46069768|NCT00697281|Drug|Placebo|"Tablets twice daily for 8 days~Dose level 5"
45626667|NCT04785027|Drug|Gu Ben Hua Yu formula|Gu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
45626668|NCT04785027|Biological|adipose-derived multipotent mesenchymal stem cells|AD-MSCs (adipose-derived multipotent mesenchymal stem cells) will be infused intravenously at a dose of 2 million cells/kg
45626669|NCT02447549|Radiation|WBRT|One RT plan with whole bladder treated to standard dose.
45626670|NCT02447549|Radiation|SART|Three plans (small, medium & large) generated with the standard dose of RT focused on the tumour, sparing the normal bladder from full dose radiation. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
45626671|NCT02447549|Radiation|DART|Three plans (small, medium & large) generated with a higher dose than standard focused on the tumour and the remainder of the bladder treated to the same dose as in the SART group. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
45626672|NCT04792359|Device|Equinometer|Measurement of dorsiflexion of the ankle will be reproduced three times on each ankle in two positions, with a force applied
45767990|NCT03013855|Device|FIT-DRE|Study subjects will have a digital rectal exam completed by their primary care providers during the physical exam portion of a routine clinic visit. The stool collected on the examiner's finger will be applied to the FIT applicator in the standard kit, which will then be sent to the lab for processing.
45767991|NCT03032939|Procedure|endotracheal intubation|standard endotracheal intubation of surgical patients after induction of anesthesia
45767992|NCT04734808|Diagnostic Test|Electroencephalography|Electroencephalography is an electrophysiological monitoring method to record electrical activity of the brain.
45767993|NCT04734808|Diagnostic Test|Electromyography|Electromyography is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles. We will use the hdEMG version.
45626673|NCT04792437|Procedure|surgery|surgery
45912854|NCT02015325|Behavioral|Planet Water Foundation's Program|Planet Water Foundation's Program (PWP) provides a school-based program with an aim to improve health outcomes in children using three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. As part of the PWP, access to safe water is provided through the use of an AquaTower, which incorporates an Ultra Filtration (UF) system. WASH messaging is also posted around the AquaTower as derived from PWP's school-based four week Water-Health & Hygiene education program.
46069769|NCT00979901|Drug|Comparator: montelukast|10 mg montelukast tablet given once daily at bedtime for 2 weeks
46069770|NCT00979901|Drug|Comparator: loratadine|10 mg loratadine tablet given once daily at bedtime for 2 weeks
46069771|NCT00979901|Drug|Comparator: placebo|placebo tablet given once daily at bedtime for 2 weeks
45447193|NCT02104648|Drug|RO4602522|Daily oral doses
45447194|NCT02104648|Drug|RO4602522|Single, oral dose
45626674|NCT02447471|Device|Nexfin|Nexfin cuff placed on finger to measure blood pressure
45626675|NCT02447315|Drug|Pilocarpine|oral
45626676|NCT02447315|Drug|Placebo|oral
45626677|NCT04792515|Drug|Camrelizumab combined with SOX/ or apatinib|"Camrelizumab: every 3 weeks (21 days) was given as one administration cycle. 200mg was given intravenously on the first day of each cycle. Dose adjustment is not allowed. Delayed administration is allowed.~Apatinib mesylate: 250mg, qd, stopped 28 days before surgery, and can be used by the investigator according to the patient's recovery 28 days after surgery.~Chemotherapy: The SOX regimen consisted of one cycle every 3 weeks (21 days).Dose adjustment is allowed. Delayed administration is allowed.~Oxaliplatin (OXA) : 130mg/m2, intravenous infusion, d1, infusion more than 2 hours.~Tigio Capsules (S-1) : Take orally after breakfast and dinner, twice daily, d1-14.~The dosing time window is ±3 days, but within 72 hours before each dosing, subjects must complete an examination that includes all clinical requirements to assess tolerance for continued dosing."
45767994|NCT03013153|Procedure|Low ligation with apical lymph node dissection|Low ligation with apical lymph node dissection (LAND). Left colic artery (LCA) is identified according to the CT 3D-reconstruction, tie the sigmoid artery and superior rectal artery, preserved LCA while low ligation of the inferior mesenteric artery is performed. Lymphadenectomy to the apical lymph nodes (No.253)is performed around the IMA until 2 cm from the aorta.
45767995|NCT03013153|Procedure|High ligation|High ligation (HL) Open the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The IMA is ligated and divided at 2 cm from its origin. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
45767996|NCT03032861|Other|Orange juice|Thirty days before the beginning of trial, women (n= 10; BMI 23.8 kg/m2; 28 years) will be advised to not consumed foods containing prebiotic, probiotic and fibers, and citrus fruits and beverages. After 30 days, the participants will consume 300 mL of orange juice daily during 60 days. After 60 days of orange juice intervention, the participants will be submitted to 30 days of washout. Samples of blood, urine and feces will collect in five different occasions (baseline, 30 day, 60 day, 90 day, and 120 day) in order to evaluate the prebiotic effect of orange juice on gut microbiota and the bioavailability of its flavanones in blood, urine and feces.
45912855|NCT02015364|Procedure|Controlled early mobilization|1. The intervention group: Must perform controlled mobilization-exercises from the beginning of week 3 - 8.
46069772|NCT00979901|Drug|Comparator: montelukast/loratadine|montelukast 10-mg/loratadine 10-mg combination tablet taken orally once daily at bedtime for 2 weeks
46069773|NCT02619201|Drug|Ondansetron|An intravenous dose of ondansetron ( 0.15mg /kg / doses ) .
46069774|NCT02619201|Drug|metoclopramide|An intravenous dose of metoclopramide ( 0.15mg /kg / doses ) .
46069775|NCT04134741|Other|Kinetic Control|"The Kinetic Control training included a functional examination of motor disorders and individual training. The KC training included active exercises, active exercises with torso muscle resistance and exercises involving lower limbs.~The duration of one training was 20-30 minutes."
45626678|NCT04792047|Diagnostic Test|HRP frequency, plaque compostion and local immune-inflammatory activation|HRP frequency, plaque compostion were detected by CCTA method. Local T cell subsets and their intracellular cytokines levels were detected by Flow Cytometry.
45626679|NCT02447237|Other|dietary counselling|the participants will receive dietary counselling in fulfilling their need of energy and protein according to the group they are randomized to (either solid or liquid food).
45626680|NCT04791657|Procedure|Appendectomy|Surgical treatment for appendicitis
45626681|NCT03118193|Other|olfactive tests|olfactive tests: odor identification, odor discrimination and olfactory threshold
45626682|NCT03118193|Biological|blood test|one sample of 4mL
45626683|NCT03118193|Biological|Collection of faeces|Collection of faeces by patient at home - optional
45626684|NCT03118193|Device|Tissue Pulsatility imaging|Ultrasound exploration of brain pulsatility - optional
45626685|NCT04784793|Other|App-based group|"Participants received home exercise programs by a postural alignment exercise mobile app we developed.~The postural alignment app included 3 main emerged themes were recorded as self-assessment, neck/shoulder, and upper back-specific exercise content, and motivational notifications.~Participants can evaluate themselves in the application thanks to the self-assessment, receive motivational notifications during the day, and exercise reminders on the days determined by them. They can apply the exercise program with the formed exercise content videos.~The exercise program consists of combined exercises that postural alignment plus exercises of neck spinal stabilization, stretching, and strengthening of neck/shoulders/upper back regions.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks."
45626686|NCT04784793|Other|Control group|"Participants received home exercise programs as a paper handout.~The exercise program was the same for app-based and control groups.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks."
45626687|NCT02447159|Behavioral|Conditional Cash Transfers|Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
45626688|NCT04784949|Procedure|portland cement|pulpotomy with PRF and white Portland cement
45626689|NCT04784949|Procedure|Mineral trioxide aggregate|pulpotomy with PRF and white Mineral trioxide aggregate
45626690|NCT04784949|Procedure|Biodentine|pulpotomy with PRF and Biodentine
45626691|NCT02446535|Other|achievement of the DW by means of the BIA DW (RE.S.T.)|
45767997|NCT03033017|Other|Blood Testing|
45767998|NCT05308147|Dietary Supplement|First Reference product|Dextrose (containing 25 grams of carbohydrates)
45767999|NCT05308147|Dietary Supplement|Second Reference product|Dextrose (containing 25 grams of carbohydrates)
45768000|NCT05308147|Dietary Supplement|Third Reference product|Dextrose (containing 25 grams of carbohydrates)
45768001|NCT05308147|Dietary Supplement|First Concept product|Infant Formula (containing 25 grams of carbohydrates)
45626692|NCT02446379|Drug|The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose|The FDG is injected at least 120 minutes prior to the imaging by the EnLightTM and LightPathTM Imaging Systems
45768002|NCT05308147|Dietary Supplement|Second Concept product|Infant Formula with new carbohydrate mixture 1 (containing 25 grams of carbohydrates)
45768003|NCT05308147|Dietary Supplement|Third Concept product|Infant Formula with new carbohydrate mixture 2 (containing 25 grams of carbohydrates)
45768004|NCT03575962|Drug|GSK3640254 bis-hydrochloride salt capsule|Administered orally (as single dose) on morning of Day 1, as 2 capsules of 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
45768005|NCT03575962|Drug|GSK3640254 Mesylate Salt Capsule|Administered orally (as single dose) on morning of Day 1, as 2 capsules of , 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
46069776|NCT00975611|Drug|Amantadine Hydrochloride, USP|amantadine tablets 100 mg. BID for 4 weeks
46069777|NCT00975611|Drug|Amantadine Hydrochloride, USP|amantadine 200 mg. tablets BID for 4 weeks
46069778|NCT00975611|Drug|Placebo|tablets BID, for 4 weeks
45447195|NCT02104648|Drug|moxifloxacin|400 mg oral dose given on Day 1 or 11
45626693|NCT02446379|Device|EnLightTM|The surgical cavity and the resected lymph nodes (if any) will be imaged by the EnLightTM system to establish whether radioactive tissue remains after surgery.
45626694|NCT02446379|Device|LightPathTM Imaging System|The resected tumour excision specimens and the resected lymph nodes (if any)will be imaged by CLI and by WLI to establish whether they contain radioactive tissue.
45626695|NCT03818139|Other|radiography thorax|The ultrasound of the thorax will be performed while waiting for the X-ray thorax
45626696|NCT03194945|Drug|CSII followed by Lina+MET|short-term intensive CSII followed by Linagliptin 5mg qd and Metformin 0.5g bid for 48 weeks
45626697|NCT03194945|Drug|CSII followed by Lina|short-term intensive CSII followed by Linagliptin 5mg qd for 48 weeks
45626698|NCT03194945|Drug|CSII followed by MET|short-term intensive CSII followed by Metformin 0.5g bid for 48 weeks
45768006|NCT03019991|Drug|Danoprevir|Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
45768007|NCT03019991|Drug|Ritonavir|Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13
45768008|NCT03019991|Drug|Placebo|ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
46069779|NCT02619279|Other|Livelihood intervention|Participants' mothers will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
46069780|NCT05298189|Behavioral|MindBreaks - Audio-visual|"A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain visual and auditory stimuli."
46069781|NCT05298189|Behavioral|MindBreaks - Auditory-only|"A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain only auditory stimuli."
45626699|NCT03194945|Drug|CSII alone|No OHA is given after short-term intensive CSII
45626700|NCT04791501|Device|Mechanical ventilation|Ventilatory support
45912856|NCT02015377|Other|High sugar versus low sugar meals|Participants visit our lab for two 8-hour periods with a minimum of two weeks washout in between. In one visit they receive high sugar low fiber meals, in the other they receive low sugar, high fiber meals. The order of meals is randomized
45626701|NCT03195023|Drug|Lisinopril|
45626702|NCT03195023|Drug|Amlodipine|Patients in this arm will receive antihypertensive treatment different from RAS blockers. If they previously received RAS blockers, they will be substitute for either Amlodipine or Lercanidipine +/- diuretics
45768009|NCT05307991|Drug|PrEP|HIV pre-exposure prophylaxis (or PrEP) will include the Malawi-approved PrEP regimen at time of study enrollment. At time of submission, the only Malawi-approved regimen includes Tenofovir/emtricitabine (TDF/FTC) containing 300 mg of TDF and 200 mg of FTC. If additional PrEP regimens become available in Malawi during the study recruitment or follow-up, participants will be able to choose from any regimen that they are eligible to receive per Malawi PrEP guidelines.
45912857|NCT02015403|Drug|Standard Care + NAC (N -ACETYLCYSTEINE)|
45626703|NCT03194711|Device|BVS implantation|BVS implantation using conventional semicompliant or non-compliant balloon
45626704|NCT02446301|Drug|Bain®|Nalbuphine HCl 20mg, IM injection
45626705|NCT02446301|Drug|SDE|Sebacoyl Dinalbuphine Ester 150mg/2ml, IM injection
45626706|NCT04336293|Device|sTMS|"sTMS will be delivered following NeoSync guidelines using the device user~manual"
45912858|NCT02015403|Drug|Standard Care (in control arm)|
45912859|NCT02015416|Biological|IDC-G305|NY-ESO-1 recombinant protein together with GLA-SE
45912860|NCT02015429|Dietary Supplement|Pasta meal with added fractions or control with no fractions|
45626707|NCT04336293|Device|sham sTMS|sham sTMS will be delivered following NeoSync guidelines using the device user manual
45626708|NCT04791345|Drug|Methylprednisone|12 mg of methylprednisone (3 pills of 4 mg each) administered orally in a single dose.
45626709|NCT04791345|Drug|Methylprednisone|12 mg of methylprednisone (3 pills of 4 mg each) administered orally every 24 hours during 3 days.
45626710|NCT04791345|Drug|Deflazacort|30 mg of deflazacort (1 pill) administered orally in a single dose.
45626711|NCT04791345|Drug|Dexamethasone|4 mg of dexamethasone (1 pill) administered orally in a single dose.
45626712|NCT04791345|Drug|Dexamethasone|2 mg of dexamethasone (1/2 pill) administered orally every 12 hours during 5 days.
45626713|NCT02445989|Drug|NuvaRing|Provide NuvaRing to women seeking contraception
45626714|NCT04483895|Procedure|Endotracheal tube insertion|ETT was inserted and the depth was estimated by either OHL method or 7-8-9 method
45912861|NCT02015455|Other|Epidemiologic benchmarks included in lumbar imaging reports|Epidemiologic benchmarks inserted into lumbar imaging reports
45626715|NCT03231137|Combination Product|PRGF/ATV|Atorvastatin (ATV) loaded on plasma rich in growth factor (PRGF) Derived Fibrin Scaffold
45626716|NCT03231137|Drug|ATV gel|Atorvastatin gel
45447196|NCT02104648|Other|moxifloxacin placebo|Dose given orally on Days 1 and/or 11
45447197|NCT01562301|Drug|Carboplatin|AUC 6 by vein 7 days after Anvirzel administration in a 21 dayc cycle.
45626717|NCT03231137|Biological|PRF|Platelet rich fibrin
45626718|NCT03231137|Biological|PRGF|plasma rich in growth factor
45626719|NCT03674853|Drug|Wuling Capsule|take Wuling Capsule in experiment group for 2 months
45626720|NCT03674853|Drug|Oryzanol|take oryzanol in active comparator group for 2 months
45626721|NCT02446067|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|The motor threshold for the left abductor pollicis brevis was determined using a figure-of-eight-shaped coil at 1 Hz frequency. Ten (over 2 weeks) rTMS sessions were administered over the right dorsolateral prefrontal cortex with an air-cooled figure-of-eight coil, angled tangentially to the head. At right DLPFC, active high-frequency (10 Hz) stimulation was administered for 4.9 seconds per train, with inter-train interval of 30 seconds, and a total of 20 trains per session. Each patient received 1000 pulses per day. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
45626722|NCT03610815|Behavioral|Screening, Brief Intervention, Referral to Treatment|Screening, Brief Intervention, Referral to Treatment
45626723|NCT03231215|Drug|Dexamethasone|dexamethasone + plain Bupivacaine injected epidurally.
45626724|NCT04784481|Drug|Ivermectin|Experimental Group received Ivermectin orally 4 tablets of 6 mg = 24 mg every 7 days for 4 weeks.
45768010|NCT05307991|Device|STI testing|Urine specimens will be tested for Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (GC) using GeneXpert® (Cepheid, Sunnyvale, CA) Xpert® CT/GC platform and cartridge and syphilis RPR titer (BD Macro-VUE™, Becton, Dickinson and Company, Franklin Lakes, NJ [FDA approved]) with confirmatory Treponema pallidum particle agglutination (TP-PA) (Serodia Fujirebio Inc, Malvern, PA [CE mark]) if RPR is positive.
45912862|NCT02015468|Other|Early mobilization|Early weightbearing and physiotherapy
45912863|NCT02015468|Other|Late mobilization|Late mobilization, none-weightbearing and home exercises
45912864|NCT02015494|Biological|VAX2012Q|Recombinant influenza HA vaccine delivered IM
45912865|NCT02015507|Drug|ivacaftor|
45912866|NCT02015507|Drug|VX-661|
45912867|NCT02015507|Drug|ciprofloxacin|
45912868|NCT02015533|Drug|CR8020|CR8020 50 mg/kg solution will be administered as a single 2-hour intravenous infusion.
45912869|NCT02015533|Drug|Placebo|Placebo will be administered as a single 2-hour intravenous infusion.
45912870|NCT02015559|Drug|mucoadhesive oral wound rinse|Given PO
45912871|NCT02015559|Other|laboratory biomarker analysis|Correlative studies
45912872|NCT02015572|Behavioral|Occupational intervention|Early coordinated occupational intervention and supervision in physically activities by a physiotherapist.
45912873|NCT02015572|Other|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist coordinated by the patient's general physician
45912874|NCT02015585|Procedure|interocclusal appliance|Patients will be submitted to the treatment with interocclusal appliances 30 days before the replacement of their complete dentures.
45912875|NCT02015585|Procedure|Relining of the complete dentures|Patients will be submitted to the relining of their old dentures 30 days before the replacement of their complete dentures.
45447198|NCT01562301|Drug|Docetaxel|75 mg/m2 by vein 7 days after Anvirzel administration in a 21 day cycle.
45626725|NCT02446145|Drug|Eltrombopag|"Patients will receive EPAG in addition to their background standard treatment with Decitabine/Azacitidine~- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c."
45626726|NCT02446145|Drug|Placebo|"Patients will receive Placebo in addition to their background standard treatment with Decitabine/Azacitidine~- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c."
45768011|NCT05307991|Behavioral|Assisted partner notification|"Participants will be asked to provide the name and locator information for all sexual partners in the preceding 6 months. Participants will be asked to refer sexual partners to the clinic and will be provided with cards to distribute to partners. Each card will request that the recipient report to the STI clinic with the card and will contain a linking number that links them back to the index participant.~Sexual Partner Tracing: In accordance with the contract referral approach, if the named partners do not present to an STI clinic within 7-14 days, community outreach workers will contact the partners and counsel them to visit the clinic. Contact may be made through telephone, text message, or in person, as needed and will not disclose the name or identify of the index patient."
45626727|NCT04790877|Other|Sub-study 1|Subjects were provided with: a) Glucose beverage; b) Regular alcohol-free beer; c) Alcohol-free beer with modified composition (isomaltulose + maltodextrin); d) Alcohol-free beer with modified composition (++ maltodextrin).
45626728|NCT04790877|Other|Sub-study 2|Subjects were provided with: a) White bread + Water; b) White bread + Regular alcohol-free beer; c) White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin); d) White bread + Alcohol-free beer enriched with ++ maltodextrin; e) Extra-White bread + Water.
45626729|NCT04791111|Other|Questionnaire|validated questionnaire to assess side effects secondary to antimuscarinics treatment in neurogenic bladder
45626730|NCT04790799|Other|Treatment at the skin department at Gentofte Hospital|Treatment in a hospital setting at Gentofte Hospital skin department
45626731|NCT02445833|Behavioral|Lifestyle on-line intervention|The self-applied on-line intervention will comprise a behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating habits and physical activity in participants (Themes: 1.motivation for change; 2. nutrition and physical activity education; 3. barriers to change, healthy eating principles and how to be active; 4. Influence of thoughts; 5. Emotional eating and self-control; 6. Problem solving; 7. Body image and assertiveness; 8. Relapse prevention)..The program will be established as follows: The first day the participant log in the website where can access the processing modules. A web page was developed specially for this study.
45447199|NCT01562301|Drug|Anvirzel|"Starting Cohort Dose: 6 mg/m2 given 3 times a day administered sublingually for a 21 day cycle.~Expansion Cohort Starting Dose: Maximum tolerated dose from"
45626732|NCT03230825|Drug|Oral contraceptive|Daily oral contraceptive agent for 3 weeks (FLAME, containing 0.02 mg Ethinylestradiol and 0.075 mg Gestodene)
45626733|NCT03230825|Other|Expectant management|No intervention and a follow up visit a wewk later
45768012|NCT05307991|Diagnostic Test|Acute HIV testing|Persons initiating or re-initiating PrEP will also be screened for acute HIV infection (AHI) using Abbott RealTime HIV-1 Assay (Abbott Laboratories, Chicago, IL) or Xpert® HIV-1 Viral Load (GeneXpert, Cepheid, Sunnyvale, CA).
45768013|NCT05307835|Biological|iNeo-Vac-P01|iNeo-Vac-P01 (peptides)： 4 x 300 mcg per peptide given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses;
45768014|NCT05307835|Biological|GM-CSF|4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses
45768015|NCT00947297|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (~17.4 mL) delivers equivalent of PBA that 40 tablets of NaPBA do.
45768016|NCT03576118|Drug|Deep neuromuscular block|Deep neuromuscular block using high dose rocuronium and 8 mmHg pneumoperitoneum
45768017|NCT03576118|Drug|Moderate neuromuscular block|Moderate neuromuscular block using moderate dose rocuronium and 12-15 mmHg pneumoperitoneum
45768018|NCT03017417|Other|Exercise Intervention|Various exercise tests
45912876|NCT02015585|Procedure|Complete denture rehabilitation|All patients will be rehabilitated with new complete dentures in the study
46069782|NCT05298189|Behavioral|MindBreaks - Visual-only|"A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain only visual stimuli."
46069783|NCT04287335|Diagnostic Test|Multitarget stool FIT-DNA test - ColoClear|Multitarget stool FIT-DNA test
45447200|NCT01562301|Behavioral|Questionnaires|Questionnaire completion regarding physical and mental at baseline, 7 days before chemotherapy, day 1 of chemotherapy, day 1 of cycles 2, 3, and 4, and at end of dosing visit.
45626734|NCT05473221|Biological|CD33 CAR-T|CD33 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
45626735|NCT05234489|Biological|Signature Cord Prime|"Low dose - Subjects will receive SIG001 (75 mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate.~High dose - Subjects will receive SIG001 (150mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate."
45447201|NCT04639778|Other|Control Group|Clinical visits conducted by a multidisciplinary team every year
45447202|NCT04639778|Other|Intervention Group|Clinical visits are triggered by weight evolution measured by connected balance
45768019|NCT03017417|Other|standard of care|standard treatment
45768020|NCT03623698|Drug|Nebulised hypertonic saline|Nebulised hypertonic saline used for a period of at least 12 months
45768021|NCT03017183|Procedure|EBUS-TBNA|Endobronchial ultrasound guided transbronchial needle aspiration
45768022|NCT03017183|Procedure|Endobronchial forceps biopsy|Conventional endobronchial forceps biopsy
46069784|NCT04287335|Diagnostic Test|FIT|fecal immunochemical test
46069785|NCT04287335|Procedure|Colonoscopy|diagnostic colonoscopy
46069786|NCT04134039|Device|Polyurethane (PU) condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
45912877|NCT02015598|Drug|Carbocysteine|carbocisteine (2×250 mg, three times daily) for 6 weeks. The tablets are provided by Baiyunshan Pharmaceutical, China. patients will interviewed after 3 weeks to check their adherence to the study regimen by collecting and counting the number of remaining tablets, record adverse events, and refill study tablets for the next 3 weeks.
45626736|NCT02445677|Device|Active transcutaneous electrical nerve stimulation (TENS)|TENS is a technique use to relieve pain in an injured or diseased part of the body in which electrodes applied to the skin deliver intermittent stimulation to surface nerves and block the transmission of pain signals. In this research, the frequency will be set at 100 Hz, implusion duration at 60 μsec and intensity will be increase until having strong but confortable stimulations.
45447203|NCT02104726|Other|Fluoroscopy guided steroid injection|We want to compare if there is a difference between the two arms, with the assumption that with fluoroscopy will deliver the steroid more accurately and see better outcomes.
45626737|NCT02445677|Device|Simulated transcutaneous electrical nerve stimulation (TENS)|A modification of the TENS connexion parameters will prevent the current from reaching the electrods (once a first sensation will be perceived).
45626738|NCT03526185|Drug|Tumor Infiltrating Lymphocytes|The regimen consists of treatment with cyclophosphamide and fludarabine,followed by infusion of up to 3x1011 lymphocytes (minimum of 1x109) expanded in vitro from subjects own resected tumor followed by the administration of aldesleukin (IL-2).
45626739|NCT03526185|Drug|Nivolumab and Ipilimumab|• Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment.
45626740|NCT02445599|Drug|Diclofenac|Orally 100 mg Diclofenac, administered 1 hour before surgery
45626741|NCT02445599|Drug|Midazolam|5 mg Dormicum intramuscularly, administered 1 hour before surgery
45626742|NCT02445599|Drug|Atropine|0.5 mg Atropine intramuscularly, administered 1 hour before surgery
45626743|NCT02445599|Drug|bucain + fentanyl|Via the thocacic epidural cannula 1mg/ml bucain + 5microgr/ml fentanyl solution, with 0.1ml/kg body mass/hour speed is administered.
45626744|NCT02445599|Drug|Nalbuphine|1st choice for rescue analgetic 10-20 mg intravenously
45626745|NCT02445599|Drug|Diclofenac|2nd choice for rescue analgetic 250ml intravenously
45626746|NCT02445599|Drug|Metamizole-sodium|Additional rescue analgetic 2g intravenously
45626747|NCT02445599|Drug|Tramadol|Additional rescue analgetic 100mg intravenously
45626748|NCT03515733|Drug|PF-04995274|PF-04995274 tablets
45626749|NCT03515733|Drug|Placebo Oral Tablet|Placebo tablet, identical appearance to experimental tablet
45626750|NCT03194633|Drug|Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)|Nifedipine GITS 60 mg (once per day)
45626751|NCT03476343|Device|GE OPTIMA MR430s with HDx/GE Electronics|MRI scan
45447204|NCT02104726|Other|Blind Steroid Injection|Want to compare it to fluoroscopy guided, with assumption that it will be less effective in reducing pain
45447205|NCT02104882|Radiation|Intraoperative Radiotherapy (Applicator Surface Dose: 20-40 Gy)|
45626752|NCT03230903|Other|Home telerehabilitation|Patients will receive an individualized exercise plan sent to a computer at their home. Patients will have daily access to a physical therapist and exercise physiologist.
45447206|NCT04195581|Device|comfilcon A|Subjects were randomized to wear each lens and solution combination for a month.
45626753|NCT03230903|Other|Usual Care|Patients will receive a written individualized exercise plan during their baseline visit on top of their usual disease care.
45626754|NCT03194399|Behavioral|Personalized health care service|Physical activity coaching, other functional outcome observation
45626755|NCT04791189|Other|questionnaire|questionnaire to survey the needs of adolescents with juvenile idiopathic arthritis and the views of their parents in the area of sexual health.
45626756|NCT03194555|Drug|Low-Dose Naltrexone and Acetaminophen Combination|Twice daily
45626757|NCT03194555|Drug|Placebo|Twice daily
45626758|NCT03230669|Other|cbt4cbt|This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.
45626759|NCT05473065|Device|Multiaxial Prosthetic Foot Emulator|Participants will walk in the laboratory with the multiaxial Prosthetic Foot Emulator (PFE) in three foot modes corresponding to commercial prosthetic study feet. Walking conditions will include self-selected comfortable, slow, and fast speeds, inclines, cross slopes, and uneven terrain.
45626760|NCT05473065|Device|Commercially available prosthetic feet|"Participants will walk in the laboratory with the commercial prosthetic study feet in three foot modes corresponding to commercial prosthetic study feet. Walking conditions will include self-selected comfortable, slow, and fast speeds, inclines, cross slopes, and uneven terrain.~Additionally, participants will be fit with one of the commercial prosthetic study feet and wear it at home and in the community for approximately one week. Participants will return to the laboratory to follow-up testing, and will complete the community trial with each of the three commercial prosthetic study feet."
45626761|NCT04346121|Other|GPs reports of potential patient safety incidents, non-COVID-19 related|GPs reports of potential patient safety incidents, non-COVID-19 related
45626762|NCT04344717|Drug|Apixaban single dose|A single dose of apixaban 2.5 mg and 5 mg (wash out period of at least 7 days) will be administered and PK characteristics will be measured
45626763|NCT04344717|Drug|Apixaban steady-state|Steady-state apixaban PK characteristics will be measured in patients already treated with apixaban
45626764|NCT03230591|Other|Echocardiography|LV vortex flow in Echocardiography
45768023|NCT03019913|Other|Observational cohort|Evaluation of bedside methods to measure muscularity in critically ill patients
45912878|NCT02015598|Device|Continuous Positive Airway Pressure|Patients will interviewed after 3 weeks and the end of trial.We will check their compliance to device memory download , record adverse events and pressure .
45912879|NCT02015650|Drug|Cetuximab|Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.
45626765|NCT04790643|Other|Exercise-based cardiac rehabilitation program (Stage 1)|In Stage 1 the volunteers will perform 24 sessions of exercise-based cardiac rehabilitation. The rehabilitation session is composed of the following activities: I. Initial rest (where the vital signs are evaluated); II. Warming-up (composed of 15 minutes of stretching and global exercises); III. Aerobic exercise (composed of 30 minutes of treadmill or cycle ergometer exercise, the intensity established varies from 40 to 70% of the heart rate reserve for those diagnosed with cardiovascular diseases and from 60 to 80% of the heart rate reserve for those with only cardiac risk factors); IV. Cooldown (composed of 5 minutes of slow walking).
45768024|NCT03019835|Drug|Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery|
45768025|NCT03019835|Other|Spontaneous recovery|just measuring the Train Of Four at 3 6 9 12 and 15 minutes and measure the Train Of Four Ratio
45768026|NCT03628456|Device|International Biophysics AffloVest|High-frequency chest wall oscillation vest
45768027|NCT03628456|Device|Hill-Rom Monarch|High-frequency chest wall oscillation vest
45912880|NCT02015650|Drug|Mitomycin-C/ 5-Fluorouracil|Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
45912881|NCT02015689|Behavioral|Benefits to Child|CDC VIS + message emphasizing benefits to child of MMR vaccine
45626766|NCT04790643|Other|Exercise-based cardiac rehabilitation program (Stage 2)|In Stage 2, the volunteers will perform 24 sessions of exercise-based cardiac rehabilitation. The rehabilitation session is composed of the following activities: I. Initial rest; II. Warming-up; III. Aerobic exercise (these three activities are the same as stage 1); IV. Resistance training (composed of 15 minutes of individualized resistance exercises); V. Cooldown.
45626767|NCT03230513|Other|Self Epley Manoeuvre|The patient has to position himself long sitting on the bed, then turn his head 45 degrees to the problematic side. When in this head position, he will rapidly lie himself supine with a pillow under his shoulders. He then turns his head 90 degrees to the opposite direction followed by turning of his body to the same side before returning to a sitting position at the edge of the bed. Each position should be kept for 30 seconds each, and the patient is required to perform 3 cycles of this manoeuvre just prior to going to bed daily for 2 weeks.
45626768|NCT03230513|Other|Brandt-Daroff Exercise|The patient has to sit at the edge of the bed, turn his head laterally 45 degrees to one side and move rapidly into the side lying position, keeping his head in the same position. He then returns upright and turns his head to the opposite direction and the same movement is repeated on the other side. Each position is held for at least 30 seconds and the patient is required to perform it for 5 repetitions, three times a day, daily for 2 weeks duration.
45626769|NCT02445209|Other|EOX|combined chemotherapy regimen: epirubicin + oxaliplatin + capecitabine
45626770|NCT02445209|Other|mDCF|combined chemotherapy regimen: docetaxel + leucovorin + 5fluorouracil + cisplatin
45626771|NCT05613699|Behavioral|Exercise - Social Media|The supervised online-social media exercise intervention took place once per week at a fixed, pre-scheduled time, via an online video conference platform. The training sessions lasted for 60 minutes and included a holistic workout with different focuses (e.g. resistance training for lower extremities, sensorimotor training, home-based endurance training). Patients were further recommended independent physical activity like walking or cycling, 1-2 times per week or to maintain the current volume of physical activity.
46069787|NCT04134039|Device|Natural Rubber Latex (NRL) condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
45626772|NCT05613699|Behavioral|Exercise - App|Exercise program in the online-app were personalized and focused on a combination of endurance and resistance training, 2-3 times a week, depending on patient's needs. Additional types of exercise (e.g. sensorimotor training) were added if therapy-related side effects were present. If necessary, exercise trainers conducted one introductory training session as video conference to check for exercise techniques and answer any individual questions.
45626773|NCT05613699|Behavioral|Exercise - closed to patients residence|The supervised exercise program close to patient's home was executed in a certified exercise facility of the network OnkoAktiv and supervised by special qualified exercise trainers. The weekly recommendation was to participate in a personalized in-person exercise program 1-2 per week, plus independent physical activity (or to maintain current level of physical activity)
45626774|NCT02445365|Device|AutoRIC device|
45626775|NCT02444975|Dietary Supplement|Mineral water|1.5L/day of water on top of the normal fluid intake for 1 year
45768028|NCT00955877|Drug|Extended-release Epidural morphine (EREM) 80|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (80μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
45768029|NCT00955877|Drug|Extended-release Epidural Morphine (EREM) 120|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (120μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
45768030|NCT00955877|Drug|Control: Saline|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Preservative-free normal saline (2.5 ml) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
45768031|NCT03951610|Device|Test lens|contact lens
45768032|NCT03951610|Device|Control lens|contact lens
45768033|NCT04332328|Dietary Supplement|Diet|Group of diet types
46069788|NCT02865161|Drug|NISELAT|NISELAT 600MG BD
46069789|NCT02619123|Other|Tailored screening according to breast density|Different interval of mammography screening according to breast density
45447207|NCT04195581|Device|fanfilcon A|Subjects were randomized to wear each lens and solution combination for a month.
45912882|NCT02015689|Behavioral|Benefits to Society|CDC VIS + message emphasizing benefits to society of MMR vaccine
45768034|NCT03960658|Drug|ketamine-enhanced prolonged exposure|Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg (ideal body weight) for 40 minutes. The next day, patients will have a standardized prolonged exposure session which lasts approximately 90 minutes. This co-jointed intervention will be repeated for 3 weeks. Then, patients will continue with therapy sessions to complete a total of 10-12 sessions.
45626776|NCT02444975|Other|Coaching program|Coaching program to support increased water intake
45626777|NCT02444975|Other|No intervention|No intervention
45626778|NCT04790487|Drug|CPM|one spray dose (~100 µL of the solution containing 1.25 mg CPM) per nostril twice a day
45768035|NCT00422890|Drug|5-Azacytidin|in case of decreasing CD34 chimerism
45768036|NCT04580290|Device|JewelACL|The JewelACL is a polyester scaffold for anterior cruciate ligament (ACL) reconstruction
45626779|NCT04790487|Drug|Placebo|Saline
45768037|NCT04617574|Device|AEON Endostapler|Surgery with AEON Endostapler
45768038|NCT04617574|Device|Endo GIA Reloads with Tri-Staple Technology|Surgery with Endo GIA Reloads with Tri-Staple Technology
45626780|NCT03230357|Device|PICC guided by EDUG|ECG Doppler ultrasound guidance technology (EDUG) is the combination of MST puncture and ECG technology through the use of ECG Doppler ultrasound machine and valve conduction PICC to conform the localization of EDUG technology by the study of real-world
45626781|NCT04790331|Drug|Verapamil|Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina
45626782|NCT04790331|Drug|Diltiazem|"Diltiazem is a calcium channel blocker. It works by relaxing the muscles of your heart and blood vessels.~Diltiazem is used to treat hypertension and angina."
45626783|NCT04790331|Drug|Placebo|Placebo oral tablet
45626784|NCT03230201|Procedure|Lymph node dissection|Lymph node dissection during radical nephroureterectomy
45626785|NCT05613465|Drug|Codonopsis|Codonopsis pilosula Nnannf is oral liquid, which has been approved for listing
45626786|NCT05613465|Drug|Placebo|Placebo is packaged in the same package as the drug
45626787|NCT03230279|Procedure|Sacroiliac joint fusion|Minimally invasive SIJ fusion will be performed under general anesthesia with fluoroscopy. Using SI-LOK®, Sacroiliac Joint Fixation System, Globus Medical Inc. (Audubon, PA), this procedure involve placement of 2 to 3 implants across the SIJ to achieve stabilization and arthrodesis.
45626788|NCT03230279|Procedure|Sacroiliac joint radiofrequency ablation|Sacroiliac joint radio frequency ablation will be performed using either conventional or cooled radiofrequency ablation techniques aimed at the S1-S3 lateral branches and the L5 dorsal ramus. The choice between conventional or cooled RFN will be determined by the provider expertise.
45768039|NCT01005407|Biological|HEPLISAV and/or Placebo|Intramuscular (IM) injections on Week 0 and Week 4; placebo (saline) injection at Week 24
45768040|NCT01005407|Biological|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4 and Week 24
45447208|NCT02104960|Other|Dermatological clinical examination|Clinical pictures, Dermatoscopy, Elastography, Sebumetry
45626789|NCT03230123|Dietary Supplement|Green banana biomass|Green banana biomass will be suplemented to diet as 4.5 g per day.
45626790|NCT04790097|Radiation|Moderately Hypofractionated Radiotherapy using Simultaneous In-Field Boost|"78Gy in 30 fractions on FET-PET based target volumes;~60Gy in 30 fractions on 2cm margin from MRI based target volumes;~all patients will be treated with concomitant and adjuvant temozolomide"
45768041|NCT03633448|Drug|Children's Mucinex® Grape Flavor|1 x 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
45768042|NCT03633448|Drug|Children's Mucinex® Grape Flavor|1 x 400 mg (20 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
45768043|NCT05313958|Drug|Cladribine|5mg/㎡/day d1-5 in 2 hours, before the use of Cytarabine
45768044|NCT05313958|Drug|G-CSF|5ug/kg/day d0-5,if Peripheral blood leukocytes<20,000/ul
45912883|NCT02015689|Behavioral|Benefits to Child and Society|CDC VIS + message emphasizing benefits both to child and to society of MMR vaccine
45912884|NCT02015689|Behavioral|CDC VIS|CDC Vaccine Information Statement (VIS)
45912885|NCT02015702|Other|One-on-one physician training|Physicians in the experimental arm were visited by a instructing physician at a computer while performing clinical duties who had observed others to identify best practices. Instructors watched subjects' work, looking for a specific tip that could be applied to the current work, then demonstrated the tip, and answered any questions the subject had about using or applying this new technique .
45912886|NCT02015702|Other|Usual training|Usual training included online e-modules, 12 hours of classroom time, practice in the EPIC Playground, user acceptability training classes,non-physician technical support on all of the floors, and a physician-only help line.
45447209|NCT02104960|Other|Biopsy|Skin biopsy for examinations by confocal microscopy ex vivo and histopathology
45447210|NCT02104960|Other|Confocal microscopy in vivo|Examination by confocal microscopy in vivo
45447211|NCT02105038|Other|Spinner knob|
45447212|NCT02105038|Other|No Knob|
45447213|NCT02101372|Behavioral|treatment as usual|case management
45447214|NCT02101372|Behavioral|Psychoeducation group treatment|Psychoeducation therapy problem solving focus
45626791|NCT03230045|Device|acupoint stimulation|Acupoint Zhongfu and Zusanli are stimulated through electrodes attached on the skin
45626792|NCT03230045|Device|no treatment|electrodes are attached, but no stimulation is given
45626793|NCT04789941|Drug|Cis Platinum + Irinotecan|Studying the efficacy and safety of neoadjuvant cisplatin and irinotecan use in treatment of locally advanced cancer cervix.
45768045|NCT05313958|Drug|Cytarabine|2g/㎡/day d1-5 in 4 hours, after the use of Cladribine
45768046|NCT05313958|Drug|Idarubicin|Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
45768047|NCT05313958|Drug|Mitoxantrone|Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
45768048|NCT05313958|Drug|Sorafenib|200mg/m2/day was taken orally until molecular biology remission for 2 years
45768049|NCT01006655|Drug|Beclomethasone dipropionate HFA|100µg twice a day, through inhaler autohaler, using a spacer device, preceded and followed by adenosine challenge test
45768050|NCT01006655|Drug|placebo|inhalation twice a day for one month, preceded and followed by adenosine challenge test
45768051|NCT01006967|Device|ActiveStep Treadmill|The ActiveStep treadmill is a device that trains patients to effectively react to simulated slips and trips while the patient is safely held in a harness.
45626794|NCT04091451|Biological|Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)|2 doses of the HZ/su vaccine in a 0,2 Months schedule, administered intramuscularly
45626795|NCT04091451|Drug|Placebo|2 doses of the placebo in a 0,2 Months schedule, administered intramuscularly
45768052|NCT01006967|Other|Physical Therapy|Standard program of physical therapy for gait and balance
45626796|NCT02445053|Drug|ivacaftor|
45626797|NCT02444819|Drug|HM61713|HM61713 will be administered to evaluate efficacy and safety of subjects.
45768053|NCT03633526|Drug|VX-659/TEZ/IVA|VX-659/TEZ/IVA FDC tablet.
45768054|NCT03633526|Drug|IVA|IVA mono tablet.
45768055|NCT03017027|Behavioral|Therapy dog visitation (TDV)|The TDV intervention consists of a one-time 10 minute TDV with the dog handler and his/her dog interacting with the patient. The therapy dog visitation program is a currently established program and each therapy dog meets obedience, temperament, and health standards required by the organization and are deemed appropriate to therapy dog visitation. For hygienic reasons, dogs are bathed before visitation and the patient is required to wash hands before and after the visit. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. The therapy dog will be leashed and controlled by the dog handler. If the participant wants the dog to be placed on the bed, a clean sheet will be placed on the bed in between the dog and patient. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Tactile and visual contact with the dog will be promoted.
45768056|NCT03017027|Behavioral|non-TDV control|Participants randomized to the control condition will receive a new plush stuffed animal for the same 10-min timeframe without any structured activities. At the end of the session, a stuffed animal will be offered to the participant to keep.
45768057|NCT03016949|Biological|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
45768058|NCT03016949|Biological|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
45768059|NCT04502056|Behavioral|Acknowledgement Racial Injustice AMA|Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.
45768060|NCT04502056|Behavioral|African American Sender Acknowledgement|Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA
45768061|NCT04502056|Behavioral|African American Sender in Informational Videos.|Investigators will vary the sender of the informational covid-19 videos. In this arm, participants receive a African American sender in informational videos.
45768062|NCT04502056|Behavioral|Racial Inequality Highlighted|Investigators will include information on race-specific covid-19 cases and deaths in one variation in the messaging. In this arm, participants receive disproportionate race-specific Covid-19 facts
45768063|NCT04502056|Behavioral|AMA Acknowledgement Drug Pricing|Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing
45768064|NCT04502056|Behavioral|White Sender in Acknowledgement|Investigators will also vary the messenger of the acknowledgement sender. In this arm, participants receive a white sender in the acknowledgement
45768065|NCT04502056|Behavioral|White Sender in Informational Videos|Investigators will vary the messenger of the informational covid-19 videos. In this arm, participants receive white sender in the informational video
45768066|NCT04502056|Behavioral|No Racial Inequality Highlighting|In this arm, the disproportionate burden of Covid-19 on communities of color will not be highlighted
45912887|NCT02015715|Drug|RO6864018|A single oral ascending dose of RO6864018 capsules on Day 1.
45912888|NCT02015715|Drug|Placebo|A single oral dose of placebo matching RO6864018 capsules on Day 1.
45935207|NCT00412321|Drug|CNTO 328|Patients will receive administrations of CNTO 328 with dose ranging from 3 mg/kg to 12 mg/kg weekly, every 2 or 3 weeks till Day 43 in cohorts 1 to 6. After cohort 6, if the clinical response is found to be suboptimal, the patients will receive 9 mg/kg or 12 mg/kg every 3 weeks in cohorts 7a. Participants in Cohort 7a who will experience intolerable toxicity after escalating to or receiving 12 mg/kg every 3 weeks will have the option of reverting to a dose of 9 mg/kg every 3 weeks if the investigator felt it was clinically indicated. In cohort 7b participants will receive 12 mg/kg CNTO 328 every 3 weeks.
45935208|NCT00218959|Behavioral|Narrative Exposure Therapy|Exposure based treatment for PTSD developed especially for refugees. Built upon Prolonged exposure treatment (Edna Foa) and Testimonial Therapy (Cientifuegos & Monelli).
46069790|NCT02619123|Other|Annual invitation to mammography|Annual interval mammography screening according to international guidelines for women younger than 50 years old
45447215|NCT02250976|Drug|Livasupril Cap.160/2mg|Fenofibrate pellet( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
45447216|NCT02250976|Drug|Lipilfen cap. 160mg|Micronized fenofibrate 160mg
45626798|NCT03079089|Drug|Sequential Packaging (SET)|Sequential chemotherapy: - Thiotepa 5 mg/kg/day for 1 day (D-13) -Cyclophosphamide 400 mg/m²/day for 4 days (J-12 to J-9)- Etoposide 100 mg/m²/day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)-Fludarabine 30 mg/m²/day for 5 days (J-5 to D-1)- Busulfan IV 3.2 mg/kg/day for 2 days (J-5 and J-4)- Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)
46069791|NCT04289129|Diagnostic Test|Myotonometric evaluation|Vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.
45626799|NCT03079089|Drug|Transfusion graft|Graft of peripheral stem cells is preferred at DO
45768067|NCT04502056|Behavioral|Placebo videos|Videos not related to covid-19 will be shown
45768068|NCT05502432|Device|Active repetitive transcranial magnetic stimulation|Consecutive 15-day active treatment with 1 Hz of repetitive transcranial magnetic stimulation
45768069|NCT05502432|Device|Sham repetitive transcranial magnetic stimulation|Consecutive 15-day sham treatment with 1 Hz of repetitive transcranial magnetic stimulation
45626800|NCT03079089|Drug|Prevention of GVHD|"Cyclophosphamide 50mg/ kg/day on days D + 3 and D + 5 - Cyclosporine A (CSA; 3 mg / kg / day IV from D+6)~Mycophenolate mofetil (MMF; 30 mg/kg/ day, maximum x2 1g / day from day J+6)"
45626801|NCT03079089|Drug|Care supports|According to the protocols of each center
45626802|NCT03079089|Drug|Lymphocyte injection of prophylactic donor (PDLI)|"According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade> II."
45626803|NCT02444897|Drug|Epidural PCA Ropivacaine|"Epidural catheter insertion at T10 level before surgery, the tip of catheter location at T8-9 level.~Total volume: 500ml, 16.7mcg/kg+0.75% Ropivacaine 80ml+N/S"
45626804|NCT02444897|Drug|IV PCA Fentanyl+nefopam+Ramosetron|Total volume: 84ml, Fentanyl 1000mcg+nefopam 120mg+Ramosetron 0.3mg Basal infusion: 1ml/hr, Bolus: 0.5ml with a lockout time 15min.
45768070|NCT05314894|Behavioral|Education|Giving training to the students in the initiative group to quit smoking in three sessions, sending messages via whatsapp program and telephone counseling
45768071|NCT01007591|Drug|LEO 80190|Applied once daily
45626805|NCT05615415|Drug|PET Tracer|Standard radiopharmaceutical injected via intravenous catheter during PET-MR scanning.
45626806|NCT05615415|Drug|MRI Tracer|Injected via intravenous catheter during PET-MR scanning.
45768072|NCT01007591|Drug|Hydrocortisone|Applied once daily
45626807|NCT05615415|Device|3T PET/MRI|Used to evaluate neuroinflammation and cerebrovascular measures. Some MRI image acquisitions will employ work in progress (WIP) sequences, including ASL (Arterial Spin Labeling), Diffusion and T2-weighted EPI (DT2W), Golden-angle radial sparse parallel (GRASP) DCE-MRI, and Magnetization Transfer (MT) imaging.
45768073|NCT03019601|Behavioral|Group Education|Structured group education on family planning facilitated by Peer Champions
45768074|NCT03019523|Dietary Supplement|Caffeine Blend|Taken orally in capsule form
45768075|NCT03019523|Other|Sugar Pill|Taken orally in capsule form
45768076|NCT01008059|Drug|Alfentanil|No drug treatment before alfentanil
45768077|NCT03634306|Device|Ultravision System|Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation.
45768078|NCT03634306|Procedure|Laparoscopic Hysterectomy|Laparoscopic hysterectomy will be performed according to standard of care without the Ultravision Visual Field Clearing System
46069792|NCT02865005|Drug|Dapsone 5.0% Gel (SEEGPharm)|Topical Gel
46069793|NCT02865005|Other|Placebo|Topical Gel
45768079|NCT01008605|Other|delivery system|syringe
45768080|NCT00377026|Behavioral|lifestyle intervention|Lifestyle modification including individual sessions with an interventionist to discuss dietary intake and exercise. Group sessions with other participants randomized to the lifestyle intervention to discuss lifestyle modification and group exercise.
45768081|NCT01009619|Drug|Azithromycin|Azithromycin 250 mg daily during 5 days followed by 250 mg three times a week on Mon., Wed. and Fri. during study-period.
45768082|NCT01009619|Drug|Placebo|Placebo once daily during 5 days, followed by one placebo three times a week on Mon., Wed. and Fri during rest of study-period.
45768083|NCT02973568|Other|Observational Study|
46069794|NCT02865005|Drug|Dapsone 5.0% Gel (Allergan)|Topical Gel
46069795|NCT02619045|Other|Telephone follow-up nursing device|"Telephone follow-up nursing device involving:~telephone appointments made by a dedicated nurse and set up at key stage of treatment (1 phone call per week during chemotherapy cycles),~specific questionnaire used by the nurse at each phone call (toxicity, general care, quality of life...),~actions taken for the patient following each phone call (consultation with a doctor, patient hospitalization, sending of a prescription, coordination with the city medical caregiver);"
46069796|NCT03835403|Other|Activation of HeartRunners|Activation of volunteer citizen first-responders to respond to nearby cardiac arrests
45626808|NCT03193775|Biological|HBV vaccine|HBV vaccine which contains Purified HBsAg produced by recombinant DNA technology (Euvax-B, LG Life sciences, Korea) intramuscularly in deltoid region at three different time intervals (0, 1, 6 months).
45626809|NCT03016533|Drug|Dolutegravir film-coated tablets|Dolutegravir film-coated tablets will be provided as 50 mg tablets.
45626810|NCT03016533|Drug|Dolutegravir film-coated dispersible tablets|Dolutegravir film-coated dispersible tablets will be provided as 5 mg dispersible tablets. It will be administered at the appropriate dose as determined by results of the parent protocol to participants as per their age and weight band.
45626811|NCT03016533|Drug|ABC/DTG/3TC immediate release tablets|ABC/DTG/3TC immediate release tablets will be provided as biconvex, oval tablets containing 600 mg ABC, 50 mg DTG and 300 mg 3TC.
45626812|NCT03016533|Drug|ABC/DTG/3TC film-coated dispersible tablets|ABC/DTG/3TC dispersible tablets will be provided as biconvex, oval, film-coated tablets containing 60 mg ABC, 5 mg DTG and 30 mg 3TC.
45626813|NCT03229733|Device|Kinect|Receive Kinect games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks
45626814|NCT03229733|Behavioral|Traditional occupational therapy|Patients will receive individually tailored conventional training consisting of the similar movement and dose by using the traditional equipment, such as climbing bar.
45768084|NCT01010009|Dietary Supplement|Trans- resveratrol|All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
45768085|NCT01010009|Other|Placebo (silica)|All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
45626815|NCT05472363|Diagnostic Test|Electroencephalogram|A routine test that involves attaching small wires to the head to read the electrical activity of the brain
45626816|NCT05472363|Procedure|Transcranial Magnetic Stimulation|Noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. An electromagnetic coil is placed against the scalp near the forehead. The electromagnet painlessly delivers repetitive magnetic pulses to simulate nerve cells in the brain.
45626817|NCT05472363|Procedure|Transcranial Direct Current Stimulation|Noninvasive procedure that uses direct electrical currents to stimulate the brain. A constant, low intensity current is passed through two electrodes that are place on the head.
45626818|NCT03229655|Procedure|Protocol for increasing number of stents across the anastomosis|Sequential placement of straight plastic biliary stents across the duct-to-duct anastomosis without dilation or stent exchange. Multiple ERCPs will be performed with addition of a single stent at each ERCP until the final ERCP when all stents will be removed.
45626819|NCT05472285|Dietary Supplement|Verum|After randomization (visit V1), subjects will consume orally 2 capsules per day, during the breakfast, for 8 weeks (from visit V1 to visit V3).
45626820|NCT05472285|Dietary Supplement|Placebo|After randomization (visit V1), subjects will consume orally 2 capsules per day, during the breakfast, for 8 weeks (from visit V1 to visit V3).
45768086|NCT04467424|Drug|ketamine, propofol|anesthesia with ketofol in pediatric surgery
45912889|NCT02015728|Device|Tumor biology testing|"Tumor biology studies will be performed in a CLIA-approved clinical pathology laboratory using standard procedures. Immunohistochemical (IHC) testing will be performed on formalin fixed tumor obtained at the time of diagnosis and/or relapse. Results will be interpreted by a qualified pediatric pathologist and will be scored on a scale of 0 to 4+ commenting on both percentage of positive cells and intensity of staining. Results will further be reported as a binary result (positive/negative). If more than one tumor specimen is available from different surgical procedures (e.g. initial diagnosis and relapse), the results from the relapse specimen will be prioritized. Results will determine kinase inhibitor treatment arm assignment which will be administered in addition to the best available combination of low-dose oral cytotoxic agents, including temozolomide and etoposide."
45912890|NCT02015728|Drug|Temozolomide|"Temozolomide combined with Etoposide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors."
45626821|NCT03229889|Drug|Cialis 5Mg Tablet|Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Patients will be asked to 1 pill for 7 days prior to surgery.
45626822|NCT03229889|Drug|Flomax 0.4Mg Capsule|Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. Patients will be asked to 1 pill for 7 days prior to surgery.
45626823|NCT03229889|Combination Product|Cialis + Flomax|Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. A combination of these two drugs may increase the relaxation effects in the ureter. Patients will be asked to 1 of each pill for 7 days prior to surgery.
45626824|NCT03229889|Drug|Placebo|This is plant cell based pill that contains no active ingredient. Patients will be asked to 1 pill for 7 days prior to surgery.
45626825|NCT04789785|Diagnostic Test|ultrasound|observation with usg
45626826|NCT04789629|Device|low level laser therapy|3 session per week laser with exercises
45626827|NCT02444585|Drug|Denosumab|Intended to prevent periprosthetic loss of bone mineral density
45626828|NCT03120221|Diagnostic Test|Urine sample for iodine measurement|Women will be required to give a urine sample for iodine measurement
45626829|NCT05472129|Other|self-administered questionnaires|The validation process of a linguistic translation must maintain conceptual and technical equivalence between the source and the target language.The questionnaire was submitted to women during a gynecological medical interview and they were asked to evaluate their perceived degree of difficulty in understanding each question item. After that, the final Italian version of the questionnaire was obtained
45626830|NCT03193073|Diagnostic Test|detailed echocardiography|Detailed Echocardiography including ejection fraction, interventricular septum thickness, posterior wall thickness, left ventricular end -diastolic and end- systolic diameter and left ventricular mass index will be correlated with body surface area for both groups serum FGF-23
45626831|NCT03193073|Diagnostic Test|serum fibroblast growth factor-23|serum levels of FGF-23
45626832|NCT03193073|Diagnostic Test|flow mediated dilatation of forearm|superficial sonar assess the diameter of brachial vessel on exposure to stress
45626833|NCT02715609|Drug|Disulfiram|
45626834|NCT02715609|Drug|Copper Gluconate|
45626835|NCT02715609|Procedure|Surgery|
45626836|NCT02715609|Radiation|Radiation|
45626837|NCT02715609|Drug|Temozolomide|
45626838|NCT02444507|Drug|Nexium powder for injection and infusion 40 mg|Reference Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
45768087|NCT04467424|Drug|ketamine, propofol, lidocaine|anesthesia with ketofol plus lidocaine in pediatric surgery
45768088|NCT03016715|Drug|Sirolimus 2%|
45768089|NCT03016715|Drug|Vehicle|
45768090|NCT03637348|Device|TrueTear|Ues of TrueTear neurostimulator
45768091|NCT00377104|Drug|alvocidib|Given IV
45768092|NCT00377104|Other|pharmacological study|Correlative studies
45768093|NCT00377104|Other|laboratory biomarker analysis|Correlative studies
45768094|NCT03016793|Drug|Puerarin|purabone (puerarin) is a bone graft used for surgical repair of bony defects.
45768095|NCT03016793|Drug|β- tricalcium phosphate|β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
45768096|NCT03016793|Drug|β- tricalcium phosphate alone|β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
45626839|NCT02444507|Drug|Esomelone Powder for Solution for Injection / Infusion 40 mg|Test Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
45626840|NCT04789707|Behavioral|auto-questionnaire|Patients answer the auto questionnaire in last minutes of consultation.
45912891|NCT02015728|Drug|Etoposide|"Etoposide combined with Temozolomide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors."
45626841|NCT03118271|Device|lumbar traction|
45626842|NCT03118271|Procedure|spinal manipulation|
45912892|NCT02015728|Drug|Sorafenib|Sorafenib is a broad-spectrum kinase inhibitor.
45626843|NCT03118271|Procedure|surgery|
45626844|NCT02572791|Drug|Chlorhexidine|
45626845|NCT02572791|Drug|Mupirocin|
45626846|NCT02572791|Behavioral|Household cleaning|
45626847|NCT03118427|Procedure|zero-fluoroscopy 3D navigation|Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.
45626848|NCT03118427|Procedure|conventional x-ray navigation|Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
45626849|NCT05472051|Other|Community-based healthcare offer provided by an the ARCAD Santé PLUS NGO and integrated into the activities of the ADDAD NGO|"In the framework of the current activities of the ARCAD Santé PLUS a team formed by a doctor, a nurse and laboratory assistant will provide prevention and medical activities during the community-based activities organized by the housekeepers ADDAD NGO. The medical consultation will propose:~HIV screening, including pre- and post- counseling~Hepatitis B and hepatitis C screening, including pré- and post- counseling. The HBV vaccine will be proposed to housekeepers with negative results to both HBV and HCV testing~Tuberculosis screening will be proposed to housekeepers with symptoms suggesting the possibility of TB~For housekeepers sexually active, the medical team will propose a gynecological test in order to screen for genital infections. Furthermore, a pregnancy test will be proposed.~Medicines for current diseases (headache, diarrhea, etc. will be provided by the medical staff)."
45626850|NCT02444195|Behavioral|Guided Imagery With Audio Media|Subjects assigned to the experimental arm will be asked to participate in meditation daily using the audio media provided for the 7 days prior to surgery, in the preoperative holding area, for the 7 days following surgery, and are encouraged to engage in affirmations module use at least weekly in the 6-8 week postoperative period.
45626851|NCT04789239|Drug|Sodium zirconium cyclosilicate|SZC is an approved drug in Sweden and subsidized for patients with chronic kidney disease in stages 3 to 5, with or without chronic heart failure, for whom treatment with Resonium is not suitable and for patients with chronic heart failure without con-comitant chronic kidney disease
45626852|NCT04789239|Other|Placebo|Treatment with the same dose of placebo medicine as they would have received had they been treated with the interventional drug (SZC).
45626853|NCT02177812|Drug|GSK2879552|GSK2879552 capsules contain 0.25 mg, 0.5 mg, 2 mg or 5 mg of GSK2879552 as parent. The initial dosing regimen will be continuous oral daily dosing.
45626854|NCT02177812|Drug|ATRA|ATRA (Tretinoin) will be supplied as a 10 mg capsule for oral administration. The initial dosing regimen will be continuous oral twice daily dosing
45626855|NCT02203305|Device|Cochlear Implant|cochlear implantation used a treatment for single-sided deafness and/or asymmetric hearing loss
45626856|NCT02203305|Other|Control Group|Subjects in the control group will have had listening experience with a bone-conduction device, which is an approved treatment for SSD.
45626857|NCT01626352|Drug|Bendamustine|Patients will receive as an IV infusion bendamustine 90 mg/m^2 Days 1 and 2 of Cycles 1 through 6.
45626858|NCT01626352|Drug|Ofatumumab|Patients will receive as an IV infusion ofatumumab 1000-mg IV Days 1 and 8 during Cycle 1 only, and on Day 1 of Cycles 2 through 6
45626859|NCT02080767|Drug|Tecovirimat|Oral tablet 600mg daily dose(three capsules, 200 mg/capsule)
45626860|NCT04789473|Genetic|Polygenic Risk Score Generation|PRS will be calculated for gestational diabetes risk using both cohorts, participants wont have results returned to them during the study.
45626861|NCT01626118|Drug|Indomethacin|capsules, 40 mg, TID
45626862|NCT01626118|Drug|Indomethacin|capsules, 40 mg, BID
45626863|NCT01626118|Drug|Indomethacin|capsules, 20 mg, TID
45626864|NCT01626118|Drug|Placebo|capsules
45626865|NCT05471583|Other|Main group|no intervention; observational only
45626866|NCT04789005|Drug|Norepinephrine|Norepinephrine 8mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
45626867|NCT04789005|Drug|Phenylephrine|Phenylephrine 100mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
45768097|NCT03016637|Device|SharkCore (TM) FNB Exchange System|
45768098|NCT03928522|Drug|hand mixed vancomycin|hand mixed vancomycin powder into cement
45768099|NCT03928522|Drug|hand mixed tobramycin|hand mixed tobramycin into cement
45912893|NCT02015728|Drug|Everolimus|Everolimus is an mTOR pathway inhibitor.
45912894|NCT02015728|Drug|Erlotinib|Erlotinib is a tyrosine kinase inhibitor of the ERBB family of proteins.
45912895|NCT02015728|Drug|Dasatinib|Dasatinib is a broad spectrum SRC inhibitor.
45912896|NCT02015741|Device|EEG monitoring with Bispectral Index and NeuroSENSE|
45912897|NCT02015741|Behavioral|Clinical observation|Patients will be observed during awake periods and during natural sleep.
45912898|NCT02015780|Drug|Fasiglifam|Fasiglifam tablets
45912899|NCT02015780|Drug|Placebo|Fasiglifam placebo-matching tablets
45912900|NCT02015780|Drug|Antihyperglycemic therapy|Including any of the following alone or in combination: insulin, sulfonylurea, thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, meglitinides, alpha-glucosidase inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors acceptable by local practice guidelines.
45912901|NCT02015845|Device|Accuvein|
45935209|NCT00218959|Behavioral|treatment as usual|
45935210|NCT00218998|Behavioral|exercise training|
45935211|NCT00219037|Drug|aliskiren|
45626868|NCT04788849|Diagnostic Test|BD Onclarity™ HPV assay|Women will be asked to self-collect first-void urine using Copan's UriSponge™ 8E031S100 and vaginal swabs using Copan's FLOQSwabs® 5E089N. All samples will be tested with BD Onclarity™ HPV assay. HPV test results on self-collected samples will be compared to those obtained when testing clinician-collected cervical sample
45626869|NCT02152384|Drug|Insulin Peglispro|Administered SC
45447217|NCT02250976|Drug|Livaro tab. 2mg|Pitavastatin Ca 2mg
45626870|NCT02152384|Drug|Insulin Lispro|Administered SC
45626871|NCT02152384|Drug|Insulin Glargine|Administered SC
45626872|NCT05469243|Drug|Psychedelic|retrospective survey of previous use
45626873|NCT02177266|Drug|Colchicine|Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
45626874|NCT02177266|Drug|Placebo|The placebo will match the study drug.
45626875|NCT05468229|Drug|Dorzagliatin|single oral dose of dorzagliatin 50 mg
45626876|NCT05468229|Drug|Placebo|Matching placebo
45626877|NCT05475327|Other|Conventional Physical Therapy|"Heating pad~A total of 3 sessions per week were given for 15 to 20 mins"
45626878|NCT05475327|Other|Relaxation exercises|"The experimental group was given Progressive relaxation exercises along with Deep breathing exercises.~A total of 3 sessions per week were given for 15 to 20 mins."
45626879|NCT04788381|Drug|Bevacizumab|Enrolled patients may be eligibled if bevacizumab was discontinued within 6 weeks prior to unexpected operation.
45626880|NCT05475249|Other|Implant placement and prothesis made with different types of abutment|Dental implants (Tapered internal implants; BioHorizons, Birmingham, EEUU) will be placed in healed residual ridges (minimum of 4 months after tooth extraction). After connecting healing abutments, the flaps will be sutured around the abutments for non-submerged healing. An abutment composed of white yttrium oxide stabilized zirconia abutment (PYRCA; BioHorizons, Birmingham, EEUU) previously immersed in fluorescent liquid (Zirkonzahn, South Tirol, Italy) will be placed in the test group, whether in the control group the same abutment will be used but without fluorescent layer. The selected abutment is machined and designed for use with cemented restorations. A single experienced restorative dentist using one dental laboratory carried out all the prosthetic procedures. Single crowns full ceramic will be performed and cemented with RelyX™ Luting Cement.
46069797|NCT02618889|Behavioral|CBT|All participating subjects will start a 12-week CBT treatment program. These consist of weekly 1-hour CBT sessions led by a cognitive therapist. Assessments will be repeated at week 16. All PsyD subjects will undergo a 15-minute, structured diagnostic interview (Mini International Neuropsychiatric Interview (MINI)) developed to screen for axis I DSM-IV and ICD-10 psychiatric disorders. We will also use two clinician-rated instruments to assess comorbid psychopathology in PsyD patients, the 17-item Hamilton Depression Rating Scale (HAM-D), to evaluate for depressed mood, vegetative and cognitive symptoms of depression; and the 14-item Hamilton Anxiety Rating Scale (HAM-A) to evaluate psychic and somatic anxiety. These scales will be administered as part of a structured interview.
45626881|NCT05466591|Diagnostic Test|Pre-hospital rule-out strategy|Point-of-care troponin measurement for pre-hospital rule-out of acute coronary syndrome
45768100|NCT03928522|Device|pre-mixed tobramycin|this cement is already pre-mixed with tobramycin
45768101|NCT01010399|Dietary Supplement|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing 465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA) for 18 weeks
45447218|NCT04096365|Device|Subcostal Temporary Extracardiac Pacing Lead|The StealthTrac Lead is designed to facilitate extracardiac temporary ventricular pacing and sensing. The distal end of the StealthTrac Lead is designed to reside within the connective tissue of the anterior mediastinum outside the pericardium. The StealthTrac Lead is delivered using the MACH I Delivery Tool, which is designed to facilitate insertion of the StealthTrac Lead through a small skin incision parallel to the sternum, without the need for fluoroscopic guidance.
45626882|NCT04342377|Diagnostic Test|Selective Targeted Sampling|Mediastinal lymph nodes are assessed with the CLNS, and only those appearing malignant with the score are biopsied. Triple Normal lymph nodes (normal appearing on PET, CT and EBUS) are not biopsied.
45626883|NCT04342377|Diagnostic Test|Systematic Sampling|All examined mediastinal lymph nodes are biopsied, regardless of whether they appear normal during PET, CT and EBUS.
45626884|NCT04787913|Behavioral|herdimm|In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers. Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.
45626885|NCT04787913|Behavioral|guardianmeasles|A screen capture of an interactive visualization: https://www.theguardian.com/society/ng-interactive/2015/feb/05/-sp-watch-how-measles-outbreak-spreads-when-kids-get-vaccinated
45626886|NCT04787913|Behavioral|theotheredmundmeasles|A gif showing measles spreading through populations with differing levels of vaccine coverage: https://imgur.com/gallery/8M7q8#J7LANQ4
45626887|NCT04787913|Behavioral|sbsnewsgeneric|A video showing how herd immunity works in general: https://www.sbs.com.au/news/two-sydney-babies-too-young-to-be-vaccinated-infected-with-measles
45626888|NCT04787913|Behavioral|publichealthagencycanadaflu|A video showing how herd immunity works in the context of influenza: https://www.canada.ca/fr/sante-publique/services/video/la-grippe-n-en-passez-pas-les-maux.html
45626889|NCT04787913|Behavioral|robertkochgeneric|A web-based application showing how herd immunity works in general: http://rocs.hu-berlin.de/D3/herd/
45626890|NCT05462925|Device|Functional electrical stimulation therapy.|Functional electrical stimulation therapy will be delivered using the MyndMove system (MyndTec, Inc., Mississauga, Canada).
45768102|NCT01010399|Drug|fosamprenavir/ritonavir|Lexiva (fosamprenavir calcium) 1400 mg per day, Norvir (ritonavir) 100 mg per day
45768103|NCT03638908|Drug|Fluoxetine|
45768104|NCT01041781|Drug|carboplatin|Given IV
45768105|NCT01041781|Drug|celecoxib|Given orally
45768106|NCT01041781|Drug|gemcitabine hydrochloride|Given IV
45768107|NCT01041781|Drug|pemetrexed disodium|Given IV
45768108|NCT01041781|Other|placebo|Given orally
45626891|NCT05613231|Behavioral|Aerobic plus muscle-strengthening physical activity intervention|The intervention is a 12-week Spanish language, Internet-based intervention promoting both aerobic and muscle-strengthening physical activity for Latina women.
45626892|NCT05613231|Behavioral|Original physical activity intervention|The intervention is a 12-week Spanish language, Internet-based intervention promoting aerobic physical activity for Latina women.
45447219|NCT02101450|Procedure|Extra-abdominal removal of the placenta|The uterus will be dragged out of the abdominal cavity, prior to removal of the placenta.
45447220|NCT02101450|Procedure|Extra-abdominal removal of the placenta|The placenta will be manually removed extra-abdominally, with uterine massage as soon as possible.
45768109|NCT01010477|Drug|Nicotine Nasal Spray|minimum 8 doses of nasal spray per day; maximum of 5 doses per hour, no more than 40 doses per day
45626893|NCT05474937|Drug|Sevoflurane Inhalation Solution|Patients in inhalational group will receive Sevoflurane at 7% dial concentration in 100% O2 by an appropriately sized face mask until adequate sedation occurs as adequate jaw relaxation for the endoscope insertion and attainment of Modified Ramsay Sedation Score (MRSS) 7 (i.e., Asleep, reflex withdrawal to painful stimuli only).
45626894|NCT05474937|Drug|Midazolam, Ketamine and Propofol|Preoxygenation with 100% O2 for 1 minute, by proper sized face mask. Patients in Ketamine -midazolam -propofol (KMP) group will receive 1-1.5 mg/kg IV ketamine and 0.05mg/kg IV Midazolam and 1mg/kg IV Propofol as induction dose then followed by incremental doses of 0.5 mg/kg IV Propofol alone for maintenance and if procedure is prolonged propofol infusion at 100 μg/kg/min is given for maintenance of sedation. Induction dose will be considered as adequate if adequate jaw relaxation for endoscope insertion and Modified Ramsay Sedation Score (MRSS) ≥7 occurs with maintenance of spontaneous respiration. Induction time will be considered as time from beginning of IV agent to achievement of MRSS ≥7. After endoscope insertion, maintenance of oxygenation by nasal cannula at flow twice the minute ventilation of the patient
45626895|NCT04788225|Other|Balance assessment|"Static balances will be measured with the Biodex-BioSway 950-462 static balance device according to 3 different standard test procedures (Postural Stability Test, Stability Limit Test and Modified Sensori Organization Test) in single foot stance and double foot stance.~Dynamic balances will be evaluated with the Y balance test."
45626896|NCT04788225|Other|Functionality assessment|Functionality will be evaluated with the Lower Extremity Functional Scale and AOFAS (American Orthopedic Foot and Ankle Society Ankle-Hindfoot Scale)
45626897|NCT04788225|Other|Performance assessment|Performance evaluation will be made with a single leg jump test and time up and go test.
45626898|NCT04788225|Other|ROM assessment|Range of motion (ROM) of the ankle will be measured with an electrogonyometer in dorsi-plantar flexion.
45626899|NCT04787601|Other|Exercise|Cognıtıve-based neuromuscular exercıses will be applied.
45626900|NCT04787601|Other|Classic Training|Classic match preparation training
45626901|NCT05460039|Other|Dance mediated by tecnhology|A web system and a dance mat are used to stimulate participants to perform dance activities for 8 weeks.
45626902|NCT04787289|Drug|Bevacizumab|Low standard dose of bevacizumab, combined with single agent chemotherapy (7.5mg/kg IV Q3w or 5mg/kg IV Q2w)
45626903|NCT05474781|Drug|Epclusa|HCV treatment
45626904|NCT05192577|Other|Electrical stimulation|At the beginning of the session, an electrode will be attached to the participant's ankle. Electrical stimulation will be applied to estimate the electrical perception threshold. This threshold will be used as condition stimuli when different thermal thresholds are assessed.
45626905|NCT05474625|Device|High Intensity Laser Therapy|For each 25 cm² of painful area, 1.02 minutes of treatment will give in the analgesic phase, with an energy of 8.0 watt, a dose of 5 Joules/ cm², a frequency of 25 Hertz(Hz) and a total energy of 125 joules. The application time for one session was approximately 15 minutes. Total 15 sessions will be applied to the neck area for a period of 3 weeks, 5 days a week.
45768110|NCT01010477|Behavioral|Behavioral counseling|Both groups will receive behavioral intervention designed for schizophrenia delivered as 15 individual counseling sessions over 26 weeks.
45447221|NCT02101450|Procedure|Extra-abdominal removal of the placenta|The cesarean incision will be sutured with no. 1 Vicryl ®.
45626906|NCT05474625|Device|Ultrasound|This treatment was applied to the cervical paravertebral region with a direct contact with the skin with the aid of an ultrasonic gel, at a dose of 1 megahertz(MHz) and 1.5 Watt/cm² for 4 minutes
45768111|NCT03921190|Procedure|Local anesthesia|Patients scheduled for a dental procedure that requires local anesthesia will be given the injection using two 2 techniques; an open-mouth and closed-mouth techniques
45768112|NCT00953849|Drug|Celecoxib|Celecoxib (400 mg twice daily)
45768113|NCT00953849|Drug|Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol 3 for each of 3 sequential days followed by 4 days of no treatment)
45768114|NCT00953849|Drug|Celecoxib plus Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol for each of 3 sequential days followed by 4 days of no treatment) plus Celecoxib (400 mg twice daily)
45447222|NCT02101450|Procedure|Extra-abdominal removal of the placenta|Uterus will be replaced in the abdominal cavity.
45447223|NCT04194489|Other|FMF Connect|The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.
45447224|NCT02250898|Other|Myofascial Massage Therapy|Myofascial Massage Therapy is a manual massage therapy consisting of the following techniques: fascial stretch, circular friction, deep fascial restriction release, arm pull, side latissimus dorsi stretch, twisting, moist heat application, cold therapy, and lymphatic drainage.
45626907|NCT05474625|Device|Transcutaneous nerve stimulation (TENS)|TENS was performed using 4 adhesive electrodes 5 × 5 cm size in the cervical paravertebral region, 80 Hertz (Hz) frequency and 180 miliseconds current for 20 minutes.
45626908|NCT05474625|Other|Exercise|A specific program consisted of 15 minutes exercise sessions was provided under the supervision of a physiotherapist . All patients will perform isometric strengthening exercises, active range of motion exercises, and cervical region stretching exercises for 15 sessions (during 3 weeks, on weekdays).
45768115|NCT03911752|Other|Semi-structured interviews|Semi-structured interviews were used to obtain the main data in this study.
45626909|NCT05474547|Behavioral|Meditation|Students will meditate for 30 min every day for 10 days
45626910|NCT05421429|Biological|KN057 doseⅠ|KN057 subcutaneous (SC) injection
45626911|NCT05421429|Biological|KN057 dose Ⅱ|KN057 SC injection
45626912|NCT05421429|Biological|KN057 dose Ⅲ|KN057 SC injection
45768116|NCT03911752|Other|Canadian Occupational Performance Measure|The Canadian Occupational Performance Measure was used with the group of people with Acquired Brain Injury to know their occupational priorities.
45912902|NCT02015845|Device|Routine technique|Placement of peripheral intravenous catheters using the routine technique
45626913|NCT05339997|Other|6 minute walk test,|submaximal exercise test used to evaluate the functional capacity of patients
45626914|NCT02177032|Biological|Rabies vaccine|"12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8)."
45626915|NCT02177032|Biological|Rabies vaccines + Rabies immunoglobulins|"12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle."
45626916|NCT02177032|Biological|Rabies vaccine|"8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29)."
45626917|NCT02177032|Biological|Rabies vaccines + Rabies immunoglobulins|"8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle."
45626918|NCT05187273|Behavioral|Elastance Group|Fluids are given based on dynamic elastane value
45626919|NCT05135325|Behavioral|Patient portal message|Portal message encourages patients to donate blood
45626920|NCT05135325|Behavioral|Social responsibility|Message specifies that there is a shortage of the patient's blood type
45912903|NCT02015858|Procedure|Chest drain withdrawal|
45912904|NCT02015858|Device|Pain Monitor|
45626921|NCT04426305|Other|community health worker support|usual care by professional primary care providers + emotional support by trained community health worker
45626922|NCT04426305|Other|care as usual|care as usual is provided by professional primary care provider
45626923|NCT05474157|Other|Standard care treatment for COVID-19 in Intensive Care Unit|Standard care for ARDS patients consisted of respiratory support, intravenous fluid therapy, medical treatment including anticoagulation and sedation, nutrition, change of position every 4 hours and if needed, hemodynamic support.
45626924|NCT05474079|Other|Moderate intensity exercise training|The exercise training program will consist of individually tailored, progressive moderate-intensity aerobic exercise. Exercise training will comprise of a combination of treadmill, cross-trainer and cycle ergometer-based exercise. Exercise will progressively increase in both intensity and duration throughout the course of the intervention. Participants will begin the intervention with 30 minutes of moderate-intensity aerobic exercise at 40% HRR three times per week for the initial 4 weeks. From week 4, exercise intensity will increase to 50% HRR, and at week 6 the duration of each session will increase to 45 minutes. From week 8, participants will exercise at an intensity of 60% HRR for 45 minutes, and from week 10, this will increase to five sessions per week.
45768117|NCT01010555|Device|lotrafilcon B|Commercially marketed, silicone hydrogel, spherical contact lens
45768118|NCT01010555|Device|balafilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
45768119|NCT01010555|Device|senofilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
45447225|NCT02250898|Other|Global Relaxation Massage|Global Relaxation Massage is a manual massage therapy consisting of a full body relaxation massage that includes light kneading and stroking in order to restore a sense of well- being
45626925|NCT02116972|Drug|FX006 32 mg|Single 5 mL IA injection
45626926|NCT02116972|Drug|Placebo|Single 5 mL IA injection
45626927|NCT02116972|Drug|FX006 16 mg|Single 5 mL IA injection
45626928|NCT05316753|Procedure|Cardioversion with a pulsed biphasic waveform|Cardioversion with a pulsed biphasic waveform
45768120|NCT01010555|Device|enfilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
45768121|NCT03019211|Other|Exercise|
45768122|NCT04425850|Combination Product|Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops)|Topical application in the nose and oral cavity
45768123|NCT01011179|Behavioral|Teens Taking Charge|The intervention is a 12-week multi-component treatment protocol that consists of self-management strategies (e.g., how to deal with stress and treatment related symptoms like pain), information (e.g., common problems associated with treatment and disease) and social support (e.g., monitored discussion boards and narratives in the form of written stories and video clips). It will be delivered on a restricted web-site and through regular contact with a trained coach by means of email and/or telephone using standardized scripts.
45768124|NCT01011179|Behavioral|Self-Management|"Adolescents' own best efforts at managing their JIA"
45912905|NCT02015923|Procedure|Colonic resection|Colonic cancer resection, R0 No surgical intervention on metastasis
45912906|NCT02015923|Drug|Chemotherapy- scheme|Chemotherapy, specified in each center with or without biological drugs
45912907|NCT02015949|Drug|Methylphenidate|Cross-over design comparing methylphenidate 0.3 mg/kg (to nearest 5mg) twice daily to placebo
45912908|NCT02015949|Drug|Placebo|Twice daily placebo tablet for two weeks
45912909|NCT02015962|Drug|Intravenous potassium chloride|
45912910|NCT02015962|Drug|Oral potassium chloride|
45626929|NCT05316753|Procedure|Cardioversion with a biphasic truncated exponential waveform|Cardioversion with a biphasic truncated exponential waveform
45626930|NCT05313945|Procedure|Passive indwelling urinary catheter removal|"After washing the patient's perineal area with water and mild soap, the nurse deflates the indwelling urinary catheter balloon and instructs the patient to take a shower (standing).~During this time, the catheter will fall under gravity."
45626931|NCT05313945|Procedure|Active indwelling catheter removal by a nurse|After washing the patient's perineal area with water and mild soap, the nurse deflates the balloon and removes the catheter from the urethra by manual traction.
45626932|NCT02176642|Drug|Oxybutynin extended release|5mg tablet taken by mouth daily for 6 weeks
45626933|NCT02176642|Device|Posterior Tibial Nerve Stimulation|In office therapy administered for 30 minutes once every week for a total of 6 weeks
45626934|NCT02176642|Drug|Placebo|Tablet taken by mouth daily for 6 weeks
45626935|NCT05032755|Other|SPECTRUM NRC 102/103 investigational cigarettes|Very low nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
45626936|NCT05032755|Other|SPECTRUM NRC 600/601 investigational cigarettes|Normal nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
45626937|NCT05612997|Other|Dietary Assessment|Food Frequency Questionnaire and 24h Recalls.
45626938|NCT05473845|Procedure|Acupressure intervention|Acupressure
45626939|NCT05473845|Procedure|Reiki intervention|Reiki
45626940|NCT02116660|Drug|Raltegravir (MK-0518)|Raltegravir (MK-0518) 400 mg tablets
45768125|NCT03639766|Drug|AbobotulinumtoxinA|AbobotulinumtoxinA reconstituted in non-bacteriostatic saline solution
45626941|NCT02116660|Drug|Nevirapine|Nevirapine (NVP) 200 mg tablets
45768126|NCT03639766|Other|Saline solution|Non-bacteriostatic saline solution
45768127|NCT03016559|Other|releasing muscle|At baseline, hip and knee angles were measured. The quadratus lumborum muscle was released. After that, the hip and knee angles were re-measured.
45768128|NCT03641716|Behavioral|Mealtime PREP Intervention|Each session will include didactic elements and skills training along with skills practice and feedback. Parents will learn to build structured mealtime routines, manage child mealtime behavior, and incorporate exploration and play into routines.
45768129|NCT05307445|Device|Photobiomodulation with Bioptron Hyperlight Therapy|The Bioptron® Device provides polarized visible polychromatic noncoherent light with 90 W; light wavelength = 480-3400 nm; degree of polarization = 95%; specific power = 40 mW/cm2; energy density = 2.4 J/cm2. The duration of each treatment session was 10 min. Bioptron light was positioned 10 cm from the oral mucosa and a mouth opener was positioned for the entire duration of the session. Two weekly sessions during the first 4 weeks of treatment were applied.
45447226|NCT03748719|Device|Stereotactic Body Radiation Therapy (SBRT)|SBRT treatment
45447227|NCT03746457|Behavioral|Behavioral intervention|Individual counseling, group intervention, collective advocacy
45626942|NCT02116660|Drug|Lamivudine|Lamivudine (3TC) 150 mg tablets
45626943|NCT02116660|Drug|Tenofovir|Tenofovir disoproxil fumarate (TDF) 300 mg tablets
45626944|NCT02116660|Drug|Emtricitabine|Emtricitabine (FTC) 200 mg tablets
45626945|NCT02116660|Drug|Lopinavir|Lopinavir (LPV) 200 mg tablets
45626946|NCT02116660|Drug|Ritonavir|Ritonavir (r) 100 mg tablets
45626947|NCT02116660|Drug|Atazanavir|Atazanavir (ATV) 300 mg tablets
45768130|NCT01042795|Drug|Sunitinib|Sunitinib 37.5 mg daily X 16 weeks
45768131|NCT03644212|Drug|Vitamin D3|Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
45912911|NCT02015988|Drug|Fenofibrate|
45447228|NCT02251054|Other|Avatar group|We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials with Avatars.
45447229|NCT02251054|Other|No Avatar group|We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials without Avatars.
45626948|NCT02116660|Drug|Darunavir|Darunavir (DAR) 400 mg tablets
45626949|NCT02589405|Drug|Benzoyl Peroxide|
45626950|NCT02589405|Other|Dermotivin® Soft Liquid cleanser|
45626951|NCT02589405|Other|Cetaphil® Dermacontrol Moisturizer SPF30|
45626952|NCT05192343|Device|Virtual Reality Glasses|"After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before and during the HSG shooting, the SGG application group watched a video with a nature view with glasses.~Glasses were introduced before the procedure. Before the procedure started, glasses were put on and training was given to continue watching the video by wearing glasses during the procedure.~The women included in the SGG application group were made to watch a video with a nature view for 15 minutes before and during the HSG procedure.~Each woman was shown the same video."
45626953|NCT05192343|Other|Music|"After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before the procedure started, glasses were put on and training was given to continuAfter the groups were formed, a nature-based sound was played to the women in the music group before and during the HSG shooting.~Listening to nature-based sound was performed for a total of 15 minutes half an hour before the HSG procedure, and for 15 minutes during the procedure, for a total of 30 minutes."
45626954|NCT05022225|Other|None. This is a qualitative interview study.|There is no intervention in this study. This is a qualitative research study where participants will take part in focus group discussions.
45626955|NCT02176018|Drug|Dextromethorphan and quinidine|
45626956|NCT02176018|Drug|Placebo|
45626957|NCT05612919|Other|Red blood cell from umbilical cord blood|"Patients will receive a volume of 15-20 ml/kg of red blood cell from umbilical cord blood (UCB-RBC). The transfusion will be prescribed and administered with all the routine safety measures carried out by the nurses to ensure compatibility between the administered RBC and the patient. The UCB-RBC bags will contain a minimum volume of 20 mL of RBC, with a haematocrit of about 60% and an acceptable residual leucocyte content of <106/mm3.~Product validation is currently under development."
45768132|NCT03906448|Combination Product|TTFields with adjuvant temozolomide|Patients will begin study treatment with temozolomide and TTFields within 2 weeks of the baseline evaluation, and no later than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and a maximum of 12 cycles of adjuvant temozolomide will be given, depending on tolerability and toxicity.
45626958|NCT05612919|Other|Red blood cell from adult donor|"Patients will receive a volume of 15-20 ml/kg of red blood cell from adult donor according to standard guidelines.~The transfusion will be prescribed and administered with all the routine safety measures carried out by the nurses to ensure compatibility between the administered RBC and the patient.~Blood samples are irradiated according to standard practise."
45626959|NCT05612841|Other|data collection|data collection from drug-drug interaction between anti-cancer treatment and and other medications
45626960|NCT05612763|Device|Self fitting hearing device|comparison of outcomes when device is fit by clinician or self fit
45626961|NCT05612061|Behavioral|Indigenous Recovery Planning|"The Indigenous Recovery Planning (IRP) intervention consists of a 6-week group-based intervention. Each of the 6 weekly sessions is delivered by a community member facilitator. Facilitators lead the group through a series of culturally adapted relapse prevention exercises designed to change their substance use.~Focus areas for the 6 sessions are: 1) introduction and goal setting; 2) relapse and recovery; 3) craving, mindfulness, and self-compassion; 4) coping with trauma and stress; 5) enlisting social support for recovery; 6) envisioning and planning for the future."
45768133|NCT03012919|Other|active decision support system|The active decision support system in this study is a goal directed therapy (GDT) protocol where threshold hemodynamic values are defined when to give fluid, vasopressors and inotropes. Hemodynamic values are measured with the LiDCOrapid device, which uses pulse contour analysis to continuously monitor cardiac output and respiratory variations in stroke volume (SVV).
45768134|NCT03897634|Device|Remote Microphone|Experienced hearing aid users will be trained on and use a remote microphone for 30 days. Pre- and Post- measures will be taken to determine benefit. Participant characteristics will also be assessed (such as self-efficacy) to explore personality factors that may contribute to benefit from devices.
45768135|NCT01011413|Drug|Efavirenz 600mg|3 x EFV 200 milligram (mg) tablets once daily
45912912|NCT02015988|Drug|Simvastatin|
45626962|NCT05465967|Procedure|Quadratus lumborum Block|1-Transverse transmuscular Quadratus lumborum block: ultrasound transducer will placed transverse to the abdominal flank to visualise abdominal muscle layers. moving the probe posteriorly, the transverse process of the lumbar vertebra, Quadratus lumborum, Psoas Major and erector spinae muscles identified as a 'Shamrock sign'. the needle will inserted through the back muscles to fascial plane between the Quadratus lumborum and Psoas Major, local anesthetic will injected .2- paraspinous sagittal Quadratus lumborum block: ultrasound transducer will be directed caudally in a sagittal plane lateral to the spinous process of L4. moving laterally until the Quadratus lumborum is evident in its long axis with a characteristic sonographic image of three muscle layers appearing from posterior to anterior as: erector spinae, Quadratus lumborum, and Psoas major muscle the needle will be advanced through the muscles, until it pierces the Quadratus lumborum. local anesthetic will be injected.
45626963|NCT05465889|Drug|Oral sulfate solution (OSS)|OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Take 177ml sodium, potassium and magnesium sulfates oral solution (diluted to 480ml) within 30 minutes 14-16 hours before colonoscopy, followed by two doses of 480ml warm water within 1 hour; Repeat the procedure 3-4 hours before colonoscopy.
45912913|NCT02016001|Other|toothpaste 1 with maximum fluoride concentration|tooth paste 1 will be the tested intervention with maximum fluoride concentration (1500 ppm), which will be provided to the case group. They will brush the teeth twice daily for 2 minutes
45912914|NCT02016001|Other|toothpaste 2 with 1000 ppm of fluoride|tooth paste 2 will be the intervention with 1000ppm of fluoride, will be used by the control group. They will brush the teeth twice daily for 2 minutes
45912915|NCT02015806|Behavioral|RxTimerCap|The RxTimerCap is a pill bottle cap with a digital timer that shows the time elapsed since the medication was last taken. Patients randomized to receive the RxTimerCap will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
45912916|NCT02015806|Behavioral|Take-N-Slide|The Take-N-Slide device is a patented strip with toggles for each day of the week which are meant to be slid after taking a medication. Each Take-N-Slide can be removed and reused for the next prescription bottle. Patients randomized to receive Take-N-Slide will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
45626964|NCT05465889|Drug|Polyethylene Glycol Electrolyte|Take 1000 ml polyethylene glycol electrolyte solution within 1 hour at 8 p.m. the day before colonoscopy; take 2000 ml polyethylene glycol electrolyte solution within 2 hour 4-6 hours before colonoscopy.
45626965|NCT02116582|Drug|Enzalutamide|Participants received 160 mg of enzalutamide (soft capsules) orally once daily.
45626966|NCT05614947|Dietary Supplement|Powdered tart cherry|500 mg freeze-dried tart cherry per capsule
45626967|NCT05614947|Dietary Supplement|Placebo|500 mg colored cornstarch per capsule
45626968|NCT05611827|Dietary Supplement|Quercetin LipoMicel (250 mg)|Quercetin LipoMicel® soft-gels. Total dose of 250 mg of quercetin
45768136|NCT01011413|Drug|Efavirenz 400mg|2 x EFV 200 milligram (mg) tablets plus 1x matched EFV placebo tablet once daily
45447230|NCT02107066|Behavioral|Exercise|Weekly telephone counseling to increase aerobic exercise to 150 min/wk for 6 months.
45447231|NCT04094883|Biological|Meningococcal Group B Vaccine|All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.
45768137|NCT03889444|Drug|Dexamethasone intravitreal implant|Dexamethasone intravitreal implant 0.7 mg injection, as per routine clinical practice.
45626969|NCT05611827|Dietary Supplement|Quercetin LipoMicel (500 mg)|Quercetin LipoMicel® soft-gels. Total dose of 500 mg of quercetin
45447232|NCT02104258|Other|Physiotherapy ASPETAR|Standardized physiotherapy protocol
45447233|NCT02104258|Other|Physiotherapy ASPETAR+|Standardized physiotherapy protocol including early lengthening exercises
45447234|NCT02101606|Drug|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)|TNK will be administered within 30 minutes once MRI and CTP inclusion criteria are determined to have been met.
45626970|NCT05611827|Dietary Supplement|Quercetin LipoMicel (1000 mg)|Quercetin LipoMicel® soft-gels. Total dose of 1000 mg of quercetin
45626971|NCT05611827|Dietary Supplement|Regular/standard Quercetin (500 mg)|Total dose of 500 mg of quercetin
45626972|NCT04936425|Device|OTSC Stentfix|The OTSC stentfix will be placed during upper endoscopy after a self-expanding metal stent has been deployed.
45626973|NCT05187351|Procedure|Percutaneous coronary intervention of the native coronary artery with Synergy|This is a registry study that will enroll patients with a 50-99% de novo SVG lesion SVG lesion and treated with percutaneous coronary intervention of the corresponding native coronary artery using a SYNERGY stent.
45626974|NCT05612607|Drug|Immunoglobulin replacement therapy (IGRT)|IGRT discontinuation will be dependent on participant's SMB levels. If SMB cells are ≥ 2%, IGRT will be discontinued. If SMB cells are < 2%, the patient will remain on IGRT and a maximum of 40 mL of blood will be drawn again in 3-6 months to reassess SMB levels and eligibility for IGRT discontinuation.
45626975|NCT02589639|Drug|Empagliflozin|
45626976|NCT02589639|Drug|Placebo|
45626977|NCT02589639|Drug|Placebo|For blinding purposes
45447235|NCT05572112|Device|Venous access port implantation|Venous access port implantation
45768138|NCT04352647|Behavioral|female athletes|The type of incontinence is assessed, whether there are risk factors and quality of life and psychological performance
45768139|NCT00956657|Behavioral|Psychological Intervention Session|One-off session aimed at changing participants beliefs around illness control and consequences, applied using a motivational interviewing style.
45912917|NCT02015806|Behavioral|Pillbox|The standard pillbox is a plastic organization box with one compartment for every day of the week. Patients randomized to receive a pillbox will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
45768140|NCT00377650|Device|Percutaneous thrombectomy|
45768141|NCT01104025|Drug|ATG, rabbit|ATG, rabbit (Thymoglobulin, Genzyme) will be dosed at 5 mg/kg/dose, given IV on 5 consecutive days (titrated over 4 to 8 hours).
45447236|NCT02101684|Drug|Orteronel 300mg BID|
45447237|NCT03555292|Drug|11C-PiB|11C-PIB with 555MBq were intravenously injected into the patients immediately before the PET/CT scans
45447238|NCT02101840|Drug|Apo-Oxycodone CR®|a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®
45768142|NCT01104025|Drug|Etoposide|Etoposide will be dosed at 150mg/m2, given IV. The first dose will be given 7 days (+/- 2 days) after the first dose of ATG, and be given weekly for a total of 7 doses.
45912918|NCT02016014|Device|Smartphone with APP|Smartphone with APP (EVIDENT) for 3 months
45912919|NCT02016014|Behavioral|Counseling on lifestyles|Counseling on physical activity and mediterranean diet
45912920|NCT02016027|Drug|Carica folia|
46069798|NCT04287257|Device|Fracture Healing Patch (FHP)|The Fracture Healing Patch (FHP) is an external silicone patch that contains inside micro-electronic modulus, which generates a pulsed electromagnetic field (PEMF) to enhance and improve fracture healing. The FHP is placed under the cast at the fracture site. Throughout the treatment period the FHP produces a pulsed electromagnetic field. The FHP houses a battery, a microelectronic module and a coil that produce the PEMF.
45447239|NCT02101840|Drug|OxyNEO®|a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®
45626978|NCT05611749|Drug|Duloxetine 60 MG|Looking at the use of duloxetine's effect with regards to perioperative narcotics consumption and patient outcomes after lumbar fusion.
45626979|NCT05611749|Other|Placebo|Duloxetine versus placebo in reducing postoperative narcotic consumption among patients undergoing lateral lumbar interbody fusions
45626980|NCT00555555|Biological|Alphanate SD/HT|A general guideline based on the product Full Prescribing Information is recommended with a maximum dose of 80 VWF:RCof IU/kg. The number of administrations before, during, and after the surgery procedure depends on the subject's clinical condition and the type of surgery itself. Single administrations or multiple doses may be appropriate. The dose of Alphanate® administered to each subject will be recorded as IU of VWF:RCof and also as IU of FVIII:C. The lot number for each vial of concentrate administered will also be recorded.
45768143|NCT01104025|Drug|Methotrexate|Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, >3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
45768144|NCT01104025|Drug|hydrocortisone|Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, >3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
45768145|NCT01104025|Drug|Dexamethasone|will be started with the ATG. It will be divided BID, given IV for at least 1 week before switching to PO. Dosing: 20mg/m2/day x7days, 10mg/m2/day x7days, 5mg/m2/day x14days, 2.5mg/m2/day x14days, 1.25mg/m2/day x14days.
45768146|NCT03649750|Drug|Mucinex®|Mucinex® 600 mg ER bi-layer tablets
45447240|NCT02101840|Drug|Placebo|a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
45447241|NCT02107222|Device|CO2-Removal (PALP-Device/MaquetCP)|extracorporeal circuit to remove CO2 out of the blood
45768147|NCT01104103|Device|BOA(R)-Constricting IV Band|Device applied in accordance with manufacturer's instructions
45768148|NCT01104103|Device|Standard elastic constricting band|Standard therapy
45768149|NCT04343092|Drug|Ivermectin (IVM)|Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly
45768150|NCT01105117|Drug|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
45768151|NCT01105117|Drug|Flolan®|per Prescribing Information
45768152|NCT03888274|Device|ClearUP Sinus Pain Relief|Microcurrent Device Treatment
45768153|NCT03650842|Device|Near infrared spectroscopy (NIRS)|One monitor will be placed on the forehead to measure cerebral oxygenation and a second over the lower back to measure tissue (muscle or renal) oxygenation.
45768154|NCT01044589|Device|Biodesign Tissue Repair Graft|Biodesign Tissue Repair Graft reinforcement
45768155|NCT01044589|Other|Overlapping Sphincter Repair|Overlapping Sphincter Repair Alone
45768156|NCT03885154|Drug|Valproic Acid (VPA)|IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours
45768157|NCT03885154|Drug|Dihydroergotamine (DHE)|0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg
45626981|NCT04813185|Behavioral|Bridging the Gap|"Bridging the Gap Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.~Firearm Counseling Program The firearm counseling program was developed to be administered in the hospital alongside the 6-step intervention program, as well as in the patient's home after hospital discharge. The firearm safety counseling program includes 3 components aimed at understanding patient risk, reducing firearm-related violence risk-factors, and helping patients increase firearm safety practices."
45626982|NCT05611593|Drug|FOL100|FOL100 lotion
45626983|NCT05611593|Drug|Propecia 1Mg Tablet|Oral Finasteride
45768158|NCT01106833|Drug|Sirolimus + calcineurin inhibitor + prednisone|"The target serum level for sirolimus is 3-12 ng/mL. The target serum level for tacrolimus is 5-10 ng/mL. The target serum level for cyclosporine is 120-200 ng/mL.~Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day."
45768159|NCT01106833|Drug|Sirolimus + prednisone|"The target serum level for sirolimus is 3-12 ng/mL.~Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day."
45768160|NCT00957047|Drug|eslicarbazepine acetate|oral tablets
45768161|NCT00957047|Drug|placebo|once daily placebo comparator
45768162|NCT00957047|Drug|ESL - Part II|Eslicarbazepine acetate was supplied as scored 800-mg tablets for daily oral administration.
45768163|NCT00957359|Drug|Psilocybin|Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
45768164|NCT00957359|Drug|Niacin|Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg
45768165|NCT03013777|Behavioral|8-week CBT Program|
45768166|NCT03013699|Behavioral|Cruciferous and Dark Leafy Green Intervention|Participants receive individual dietary counseling from a Registered Dietitian who will focus on increasing intake of cruciferous and green leafy vegetables while addressing any disease- and treatment-related eating difficulties experienced by the participant.
45768167|NCT03013699|Behavioral|Usual Dietary Care|Participants receive standard educational materials that focus on healthy eating for cancer survivors and the opportunity to briefly discuss nutrition-related concerns with the Registered Dietitian weekly.
45768168|NCT03880474|Biological|MVA-NP+M1|Trial Vaccine
45768169|NCT03880474|Drug|Saline|Sodium Chloride Placebo
45912921|NCT02016040|Procedure|High Intensity Focused Ultrasound|
45626984|NCT05614713|Procedure|Selected physical therapy program|Gait training and balance training
46069799|NCT02862977|Drug|ketoprofen and cyclobenzaprine association with caffeine|The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h
45447242|NCT02101996|Other|high-fat diet|Subjects consume a high-fat diet for three weeks before the in-hospital stay.
45626985|NCT05614713|Procedure|Modified physical therapy program to increase sensory input|Gait training and balance training using sensory stimulating matts
45768170|NCT01045057|Device|Puncture Set and Flexible Protector|The Provox Vega Puncture Set will be used to create the tracheoesophageal puncture and place the voice prosthesis. In secondary punctures the Provox Flexible Protector may be used for pharynx protection.
45768171|NCT00957593|Drug|Oxytocin|Continuation of oxytocin once in active labor
45768172|NCT00957593|Drug|Oxytocin discontinuation|Oxytocin will be stopped once in active labor
45768173|NCT00957671|Drug|Recombinant human growth hormone|200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total)
45768174|NCT04322968|Drug|A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.|Subjects were randomized into 4 treatment groups: chronic pain subjects treated with ketorolac, chronic pain subjects treated with ketamine, chronic pain+PTSD subjects treated with ketorolac, and chronic pain+PTSD subjects treated with ketamine.
45768175|NCT01108003|Drug|broccoli sprout extract|Given orally
45768176|NCT01108003|Other|laboratory biomarker analysis|Correlative studies
45768177|NCT01108003|Other|Mango Juice|given orally
45768178|NCT03018899|Procedure|paravertebral block|Ultrasound guided two-segment paravertebral block
45768179|NCT03018899|Procedure|epidural anesthesia|thoracic epidural anesthesia
45768180|NCT01108081|Behavioral|Physical activity|Moderate-intensity physical activity
45768181|NCT01108081|Behavioral|Diet|Dietary weight loss
45912922|NCT02016066|Drug|CR6261|CR6261 50 mg/kg solution will be administered as a single 2-hour intravenous infusion
45912923|NCT02016066|Drug|Placebo|Placebo will be administered as a single 2-hour intravenous infusion
45912924|NCT02016079|Dietary Supplement|omega-3|200 ml fruit drink containing omega-3
46069800|NCT02862977|Drug|Cyclobenzaprine with caffeine|The patient will take 2 tablets (combination of cyclobenzaprine and caffeine), oral, per day, each 12h
45626986|NCT05611515|Procedure|TORS|"Arm 1: Intensity-Modulated Radiation Therapy (IMRT)~Arm 2: Trans-oral Laser Microsurgery (TLM)~Arm 3: Trans-oral Robotic Surgery (TORS)"
45768182|NCT01108081|Behavioral|Health education|Attention control intervention
45768183|NCT00958919|Drug|naloxone|10 mg naloxone in 25 ml total volume
45626987|NCT05614635|Device|Plastalgin and Plastalgin Fast|Plastalgin and Plastalgin Fast are potassium alginate-based powders designed for dental impression. The powder is mixed with water to obtain an impression material paste, used to imprint the teeth and mouth of the patient. The product is available under two presentations: Plastalgin and Plastalgin Fast. Plastalgin Fast has a shorter mixing time.
45626988|NCT05612451|Procedure|Regenerative Endodontic Procedures|Regenerative Endodontic procedures were performed by one operator following similar protocols according to the clinical considerations for a regenerative procedure advised by the American Association of Endodontists and European Society of Endodontology
45626989|NCT05612451|Other|non-setting calcium hydroxide|non-setting calcium hydroxide
45626990|NCT05612451|Other|modified triple antibiotic paste|modified triple antibiotic paste
45626991|NCT05611359|Procedure|Thermal Ablation|Thermal hepatic ablation Combined with Chemotherapy
45626992|NCT05611359|Drug|Chemotherapy|Chemotherapy
45626993|NCT04334811|Radiation|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy (SAbR) delivers of a potent, ablative or nearly ablative dose of radiation in oligofractions (ie, five or fewer fractions) primarily to create a compact dose delivered accurately to the intended target with steep gradients in all directions (geometric avoidance) and avoid damaging normal tissues.
45626994|NCT02151682|Drug|Tapentadol prolonged release|
45626995|NCT02151682|Drug|Morphine prolonged release|
45626996|NCT04333485|Other|Home-based Active Case Finding (HACF)|Existing healthcare workers at the participating NTEP TB units will visit all patient homes at 6 and 12 months post-treatment completion. They will administer a standardized TB symptom screen questionnaire to treated TB cases and their household contacts (HHC). All those who screen positive will have a spot sputum taken at the home for microbiological testing at the TB unit.
45626997|NCT04333485|Other|Telephonic Active Case Finding (TACF)|Existing healthcare workers at the participating NTEP TB Units will administer a standardized TB symptom screen questionnaire to the index patient via telephone calls at 6 and 12 months post-treatment completion. The index patient will also be asked about any TB symptoms among household contacts (HHCs). If TB is suspected among any HH members, a home visit will be conducted and spot sputum specimens will be collected for microbiological testing at the TB unit.
45768184|NCT00958919|Drug|normal saline|25 ml
45768185|NCT04323592|Drug|Methylprednisolone|Usual standard of care plus Methylprednisolone (MP) 80 mg/kg IV bolus, followed by MP infusion of 80 mg/day in 240 mL normal saline at 10 mL/h. The infusion is continued for at least eight days and until achieving either a PaO2:FiO2 > 350 mmHg or a CRP < 20 mg/L. Treatment is then switched to oral administration of Methylprednisolone 16 mg or 20 mg IV twice daily until CRP returns to < 20% of normal range and/or PaO2:FiO2 > 400 or SatHbO2 ≥ 95%. The decision to apply the protocol to Covid-19 is left to the discretion of the treating team for each individual patient.
45768186|NCT04323592|Other|standard care|"usual standard of care:~oxygen therapy (regular or high-flow) and monitoring~empiric antibiotic therapy~mechanical ventilation (invasive or noninvasive)~ECMO when needed and available~pronation when possible~other treatment which can be used are: antivirals, chloroquine, vitamins"
45768187|NCT04353245|Other|BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM|Organize care follow-up for patients who have had COVID-19 coronavirus infection for scientific purposes. Thus, it is expected to obtain relevant data on cardiac sequelae and pulmonary. These data are important for understanding the long-term prognosis of patients surviving this infection.
45912925|NCT02016118|Device|Ialuril|The treatment is an intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
45447243|NCT02105194|Drug|Hyperbaric oxygen therapy|total body exposure to greater than atmospheric pressure oxygen
45447244|NCT02107378|Biological|DCVAC/OvCa|DCVAC/OvCa is the experimental therapy added on to Paclitaxel or topotecan or doxorubicin
45626998|NCT05350215|Drug|Placebo oral capsule|Placebo pills for a week, 1 pill 4 hr before sleep and 1 pill 30 min before sleep
45626999|NCT05350215|Drug|Atomoxetine Oral Capsule [Strattera]|Atomoxetine for a week: 40 mg for 3 days 30 min before sleep, 80 mg for 4 days 30 min before sleep Simultaneous administration of DAW2020 for a week, 34 mg 4 h before sleep
45627000|NCT05083923|Drug|Diroximel fumarate|Administered as specified in the treatment arm
45627001|NCT04331691|Drug|Spironolactone|After randomization, this group will receive 12.5 mg of spironolactone daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 25 mg of spironolactone. After 12 weeks of treatment, study will be end.
45627002|NCT04331691|Drug|Amiloride|After randomization, this group will receive 5 mg of amiloride daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 10 mg of amiloride. After 12 weeks of treatment, study will be end.
45627003|NCT04330833|Other|Novel Communication Intervention|The intervention is a series of 3 guided discussions (using visual aids) between the child's primary oncology physician/nurse team and the child's parent(s) with the purpose of improving parental comprehension of the options for goals of treatment, along with the benefits and burdens of each option.
45768188|NCT01047241|Drug|Intranasal sufentanil/ketamine|Nasal spray sufentanil+ketamine, 0,5 microg/kg sufentanil+0,5 mg/kg ketamine, single dose
45447245|NCT02107378|Drug|Standard of Care (Paclitaxel or topotecan or doxorubicin)|Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy
45768189|NCT03651856|Drug|ATM FOG in PD|open label pilot study on atomoxetine 40mg BID on patients with Parkinson's disease and Freezing of Gait
45768190|NCT01012661|Device|Radiesse® Injectable Dermal Filler Mixed with Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier mixed with 2% lidocaine hydrochloride (HCl)
45912926|NCT02016157|Drug|Moxifloxacin|TO ASSESS THE EFFICACY OF MOXIFLOXACIN IN SITU GEL IN THE TREATMENT OF PERIODONTAL POCKET.
45447246|NCT02105350|Drug|MEK 162|
45447247|NCT02105350|Drug|Gemcitabine|
45627004|NCT04330833|Other|Enhanced Usual Care Parent Education|The Enhanced Usual Care Parent Education is a series of 3 discussions between the child's primary oncology nurse and the child's parent(s) designed to control for time and attention. These discussions are focused on answering parents' questions and reviewing routine disease and treatment related information. Parents will receive a 1-hour face-to-face session every 3-4 months for a total of 3 sessions. At each session, parents choose 2-3 topics to review with the nurse.
45768191|NCT01012661|Device|Radiesse® Injectable Dermal Filler without Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier without 2% lidocaine hydrochloride (HCl)
45627005|NCT05304273|Drug|Mifepristone|Participants with 1st trimester miscarriage will receive for medical termination
45627006|NCT05304273|Drug|Letrozole|Participants with 1st trimester miscarriage will receive for medical termination
45627007|NCT04756635|Other|Experimental Group|This 3-year project will include two groups of participants: 1) young men accustomed to resistance training (study #1) and 2) young men accustomed to endurance training (study #2). Inclusion will be limited to healthy participants (i.e. nonsmokers, normotensive with systolic and diastolic values <135/85 mmHg, non-obese, non-medicated, and free of any known disease as assessed by medical history) (Pickering, Hall et al. 2005). Month 1-3 will focus on literature review and month 4 to 8 will address experimental settings preparation and selection of participants to include in each study. Testing and data collection will be scheduled for months 9-14 and 13-18 (study # 1 and 2 related testing, respectively). Data processing, analysis and presentation will occur from month 21 to 33. All participants will read and sign an informed consent document with the description of the testing procedures. The Faculty's ethical committee will be asked to approve this document before testing.
45627008|NCT02174848|Drug|Deferiprone oral solution|Deferiprone oral solution at a dosage of up to 15 mg per kilogram of body weight, twice a day
45627009|NCT05612217|Other|to estimate Sensitivity and Specificity AIVARIX app in detecting C1 and C2 classes of CVD|to estimate Sensitivity and Specificity of the AI-based AIVARIX app in detecting C1 and C2 classes of CVD in patients who are seeking for professional advice from a phlebologist regarding symptoms and signs suggestive to CVD.
45768192|NCT05298943|Other|walking in 4 situations|Recording of cerebral hemodynamic with fNIRS during gait in exoskeleton with Four strength levels of aid : total aid (A100%), partial aid (A50%), no aid (A0%) and resistance of 25 % (R25%) to walking from the exoskeleton. Each subject are recorded during 8 trials for each level (32 trials). The order is counterbalanced among the subjects
45912927|NCT02016196|Drug|Rifaximin|"6 rifaximin caps of 200 mg morning and night, 15 days before and 6 months after TIPS~--------------------------------------------------------------------------------"
45912928|NCT02016196|Drug|placebo|6 placebo caps per day morning and night, during 15 days before TIPS and 6 months after TIPS
45627010|NCT02151058|Drug|Colgate® Regular Cavity Protection|Brushing twice daily with an ADA - Accepted fluoride - containing dentifrice (Colgate Cavity Protection)
45627011|NCT02151058|Drug|Experimental Mouth Rinse|Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 10 mL for 60 seconds with the investigational product.
45627012|NCT02151058|Other|Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint|Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 15 mL for 60 seconds with the active comparator.
45627013|NCT04747197|Drug|EYP-1901|Intravitreal injection
45627014|NCT04744389|Device|Hypothermic Machine Perfusion|The perfusion system was primed with 4 L of Belzer machine perfusion solution University of Wisconsin Machine Perfusion Solution (Bridge for Life, Ltd., Columbia, SC). The arterial and portal pressures were set at 25 mm Hg with a flow and at 3-4 mm Hg with a continuous flow, respectively. The oxygen flow was set at 0.25 L/minute. The target liver temperature was between 4°C and 10°C.
45768193|NCT04325542|Diagnostic Test|HBSAg (sure screen test)|Diagnostic test for Hepatitis B
45768194|NCT04353323|Other|Blood sampling|3 blood samples (D0, D15 and D30) will be taken from each participant
45912929|NCT02016209|Drug|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer
45912930|NCT02016222|Procedure|tears sampling|
45912931|NCT02016261|Drug|Fluvoxamine|The subjects will be prescribed Fluvoxamine treatment for 24 weeks with dose 50-300 mg
45912932|NCT02016274|Other|Sequential chemotherapy (paclitaxel 175mg/m2 d1; cisplatin 37.5mg/m2 d1,d2) and radiotherapy|Sequential paclitaxel/cisplatin chemotherapy and radiotherapy
45912933|NCT02016287|Other|Sequential chemotherapy （paclitaxel 80mg/m2 d1,d8) and radiotherapy|Sequential paclitaxel chemotherapy and radiotherapy
45912934|NCT02016313|Other|physiotherapy|
45912935|NCT02016326|Device|HD Colon|High Definition White Light
45768195|NCT05289583|Behavioral|Dialectical Behavior Therapy|DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
45768196|NCT03016481|Behavioral|Active Comparator: the Community Health Worker -Personalized Support for Progress|Subjects will meet with their CHW to prioritize their needs detected by the Promote psychosocial screening and identify their preferences for intervention using a secure, online card sorting tool called Optimal Sort. The subject will explain her/his rationale for each decision to the CHW, allowing them both to begin to identify goals. The prioritization survey results provide subjects a personalized package of services that map onto the four main intervention options: legal help, problem solving therapy, medical consultation, or social services.
45912936|NCT02016326|Device|I-scan 1|I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
45912937|NCT02016326|Device|I-Scan 2|I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE)and Tone Enhancement(TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities. TE provides a uniform color image and is intended for detailed inspection of distinct lesions.
46069801|NCT02618655|Other|diagnostic methods|explore several laboratory diagnostic methods to find out which will be more helpful for making an accurate diagnosis in the early period of TBDs.
45447248|NCT02105350|Drug|Oxaliplatin|
45627015|NCT04744389|Device|Normothermic Machine Perfusion|Grafts were perfused at 37°C in an OR next to the transplant OR and under medical supervision using a blood-based perfusate. Initial perfusate temperature was set at 20°C and raised by 1°C every 2 minutes. Oxygenation was provided by an anesthesia ventilator initially set at 4 L/minute with 30% fraction of inspired oxygen, and later adjusted based on perfusate pH, partial pressure of oxygen, and partial pressure of carbon dioxide. Blood gas analyses were drawn every 20 minutes during the first hour and every 30 minutes thereafter with the aim to maintain a physiological pH and ionogram result, and a partial pressure of oxygen between 200 and 250 mm Hg. Perfusate glucose, transaminases, and lactate were measured during NMP as were bile production and quality (pH, sodium, glycemia, lactate, and HCO3)
45627016|NCT04699695|Other|Biologic therapy versus no biologic therapy|Biologic therapy administered per standard of care
45627017|NCT05614479|Other|GATEKEEPER intervention|"Agents will identify candidates in their areas of work (e.g., associations of elderly people).~Training sessions will be held for healthcare professionals and community agents.~Dissemination of materials, resources, and channels to contact and inform candidates to invite them to participate in the study. Recruitment procedures posters, leaflets, videos, newsletters, or appointments will be used.~Candidates interested and accepted will download the application on their mobile devices and will surf on the app which pretends to promote healthy aging. Users will provide some data and complete questionnaires (available in the application) for the baseline and final assessment.~Professionals will visualize how and how much participants are interacting by using the MAHA dashboard."
45627018|NCT02149810|Behavioral|Automatic Self Transcending Meditation|as above
45627019|NCT04695171|Device|LINX Reflux Management System|"The LINX Reflux Management System consists of a series of titanium beads each with a magnetic core connected with independent titanium wires to form an annular shape when implanted. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak lower esophageal sphincter (LES) closed. During swallowing, the magnetic beads slide away from each other on the independent titanium wire links to allow esophageal distention as the bolus passes by."
45627020|NCT04695171|Procedure|Fundoplication|A surgical procedure where the fundus of the stomach is wrapped around and sutured to the distal esophagus to restore the function of the lower esophageal sphincter in limiting stomach contents from refluxing into the esophagus.
45768197|NCT03016481|Behavioral|Care as Usual- Social Worker|Based on their assessment and the subjects' needs, brief onsite interventions are provided and consist of empowerment focused advocacy, IPV education, community referrals, and safety planning. Participants determine follow-up. This will be a short-term interaction as routinely practiced across hospital settings.
45768198|NCT02246803|Procedure|CABG+Pulmonary vein isolation procedure|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation in CBP prior to occlusion and CABG
45768199|NCT02246803|Procedure|Isolated CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion.
45768200|NCT02245919|Other|Back on Track intervention|A biopsychosocial primary care intervention based on multidisciplinary pain rehabilitation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
45768201|NCT03655444|Drug|Abemaciclib|Abemaciclib is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.
45768202|NCT03655444|Drug|Nivolumab|Nivolumab is commercially available
45768203|NCT03655444|Procedure|Tumor biopsy|"Phase II patients only~If the patient consents, fresh tumor tissue will be collected at baseline and then during Cycle 2 (between days 8-22) of abemaciclib and nivolumab."
45768204|NCT03655444|Procedure|Peripheral blood|"Phase II patients only~Peripheral blood will be collected at baseline, at the end of the Lead In (cycle 1 day 1 prior to treatment), during cycle 2 (between days 8-22), and during cycle 3 (between days 21-28). If patient does not have progression after cycle 3, patient will also have peripheral blood collected at time of progression."
45768205|NCT03655444|Other|EORTC QLQ-30|"Phase II patients only~Screening , Cycle 2 D1, Cycle 4 D1, and End of treatment (EOT)"
45768206|NCT03018977|Other|The sedative weaning protocol group|After physician decide to wean sedative or analgesic drugs. We divided to 2 groups including high risk group and low risk group. The sedative weaning protocol were used in these patients which rely on the high risk or low risk group.
45768207|NCT03018977|Other|The usual group|After physician decide to wean sedative or analgesic drugs. The sedative/analgesic drugs were weaned depend on physician
45768208|NCT03018821|Drug|Standard - Yinchengao Decoction plus Ganlu Detoxification Pill|Yinchengao Decoction plus Ganlu Detoxification Pill is one Chinese Medicine Formula for the TCM syndrome: Damp-heat blocking middle jiao.
45912938|NCT02016339|Behavioral|Standard care|24-h consultation telephone line to the sleep nurses to answer questions regarding CPAP usage. Patients were reviewed at 1 month and at 3 month intervals during the first year and every 6 months thereafter in the CPAP clinic by the nurse. Additional visits or phone calls by sleep specialist if doubts about a patient's compliance or willingness to continue with the therapy.
45912939|NCT02016339|Behavioral|Intensive care|Standard group care plus: Involvement of the patient's partner or family necessary. Extra education on sleep apnea and CPAP by sleep specialists via a 15-min videotape. 10- to 15-min lecture from the sleep clinic's nurses after CPAP titration study. Phone calls by nurses at 2 and 7 days. Early review of patients by sleep specialists at 15 and 30 days. Home visits by sleep nurses, if there doubts about a patients adherence
45768209|NCT03018821|Drug|Entecavir or Tenofovir|Western drug for anti-HBV such as Entecavir and Tenofovir
45768210|NCT03018821|Drug|Standard - Ge Xia Zhu Yu Decoction|Ge Xia Zhu Yu Decoction is one Chinese Medicine Formula for the TCM syndrome: internal blood stasis.
45447249|NCT02105428|Behavioral|Aerobic Exercise Training|A progressive increase in duration, frequency and intensity so the last 8 weeks of exercise are performed for 60 min, 5 days per week and at 80% of aerobic capacity. The duration includes a 5 minute warm up and 5 minute cool down. All exercise will be performed on a stationary bicycle (i.e., cycle ergometer).
45447250|NCT02102152|Drug|Tobramycin|
45447251|NCT02107456|Device|Dry Needling|Dry needling was performed for one week, three times a week.
45447252|NCT02102308|Other|Exercise|Multicomponent exercise
45768211|NCT03018821|Drug|Advanced - Supplemented Taohong Huazhuo Decoction|Supplemented Taohong Huazhuo Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Damp-heat blocking middle jiao.
45627021|NCT04186546|Device|Zephyr Valve Procedure|The Pulmonx Zephyr Endobronchial Valve is an implantable bronchial valve intended to decrease volume in targeted regions of the lung. It is indicated for the treatment of patients with severe emphysema. The Zephyr Valves are placed in the diseased region of the lung using bronchoscopy. As the diseased region of the lung shrinks in size, healthier regions may expand and function more efficiently, resulting in improved breathing.
45447253|NCT02102308|Other|Education classes|
45447254|NCT01368562|Drug|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the arm.
45627022|NCT04644315|Drug|Alectinib|Participants will receive 600 mg oral alectinib BID until disease progression, unacceptable toxicity, withdrawal from treatment, or death.
45627023|NCT05205759|Drug|Bamlanivimab Etesevimab|Single intravenous infusion of bamlanivimab 700 mg and etesevimab 1400 mg, administered together [1 bamlanivimab vial (700 mg/20 mL) and 2 etesevimab vials (700 mg/20 mL)] in a 250-mL prefilled 0.9% Sodium Chloride infusion bag over one hour.
45768212|NCT03018821|Drug|Standard - Chaihu Shugan San|Chaihu Shugan San is one Chinese Medicine Formula for the TCM syndrome: Liver depression and qi stagnation.
45768213|NCT03018821|Drug|Advanced - Soothe the liver and regulate qi Decoction|Soothe the liver and regulate qi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Liver depression and qi stagnation.
45768214|NCT03018821|Drug|Standard - Xiaoyao powder|Xiaoyao powder is one Chinese Medicine Formula for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
45768215|NCT03018821|Drug|Advanced - Supplemented Ganbi Decoction|Supplemented Ganbi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
45768216|NCT03018821|Drug|Standard - Yiguan Decoction|Yiguan Decoction is one Chinese Medicine Formula for the TCM syndrome: Yin deficiency of liver and kidney.
45768217|NCT03018821|Drug|Advanced - Supplemented Zimu Dan|Supplemented Zimu Dan is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yin deficiency of liver and kidney.
45912940|NCT02016352|Biological|patient CSF extraction with hydrocephalus|CSF extraction
45912941|NCT02016352|Biological|witness CSF extraction|CSF extraction from patient not suffering from hydrocephalus
45912942|NCT02016365|Drug|Doxycycline|200 mg/day (100 mg twice daily, orally) for 4 weeks with a pause of 2 weeks in combination with UDCA
45447255|NCT02105506|Drug|Tachosil patch|
45627024|NCT05205759|Drug|Sotrovimab|Single intravenous infusion of sotrovimab 500 mg (500 mg/8 mL), administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour.
45627025|NCT05205759|Drug|Casirivimab-Imdevimab|Single intravenous infusion of casirivimab 600 mg + imdevimab 600 mg, administered together in 250 mL prefilled 0.9% sodium chloride injection infusion solution over one hour. Casirivimab and imdevimab are each supplied in individual single use vials. Casirivimab is available as 300 mg/2.5 mL (120 mg/mL) or 1332 mg/11.1 mL (120 mg/mL). Imdevimab is available as 300 mg/2.5 mL (120 mg/mL) or 1332 mg/11.1 mL (120 mg/mL).
45447256|NCT02105584|Device|Implantation of LAA closure device|
45447257|NCT02107534|Behavioral|parent training (dyslexia)|The intervention program is designed for group sizes of three to ten persons. A cognitive behavioral approach was chosen.
45447258|NCT03242018|Drug|Placebo|Placebo tablet (identical to sotagliflozin 200 mg in appearance) orally, once daily.
45447259|NCT03242018|Drug|Sotagliflozin|Sotagliflozin 200 mg, tablet, orally, once daily.
45447260|NCT02107612|Device|Integrated system to insert two splinted (bar) mini dental implants for mandibular overdenture|
45447261|NCT02107612|Other|Denture|
45447262|NCT02107690|Procedure|Low temperature lidocaine injection|4 °C
45447263|NCT02107690|Procedure|Room temperature lidocaine injection|20 °C
45447264|NCT02107690|Procedure|Body temperature lidocaine injection|37 °C
45627026|NCT05205291|Drug|Lipopolysaccharide|All participants will receive one dose of Lipopolysaccharide (1ng/Kg) after the first PET/MR scan with [11C]PBR28 and four hours before the second PET/MR scan with [11C]PBR28.
45627027|NCT05205291|Radiation|PET/MR with [11C]PBR28|A PET/MR scan using the tracer [11C]PBR28 will be performed to all participants before and four hours after the administration of LPS
45768218|NCT03018821|Drug|Standard - Fuzilizhong Decoction plus Jinkui Shenqi Bolus|Fuzilizhong Decoction plus Jinkui Shenqi Bolus is one Chinese Medicine Formula for the TCM syndrome: Yang deficiency of spleen and kidney.
45768219|NCT03018821|Drug|Advanced - Guifu Erxian Decoction|Guifu Erxian Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yang deficiency of spleen and kidney.
45912943|NCT02016365|Drug|Ursodeoxycholic acid|750 mg/day (500 mg +250mg orally) continuously
45912944|NCT02016391|Drug|Dexmedetomidine|Dexmedetomidine 0.4 µg/kg/hr infusion during RF procedure
45912945|NCT02016404|Other|Low-sodium, high-potassium salt|Iodized low-sodium, high-potassium botcanh (a traditional mixture of salt, MSG, sugar and herbs) plus and iodized low-sodium, high-potassium salt for home food preparation
45912946|NCT02016404|Other|Regular salt|Regular iodized high-sodium botcanh (a traditional mixture of salt, MSG, sugar and herbs) and high-sodium salt
45912947|NCT02016417|Drug|A combination of Gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
46069802|NCT02864927|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular. 2 doses 3 months apart
46069803|NCT02864927|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
45452458|NCT03961451|Device|Podometer|Patients will be equipped with pedometers for 8 weeks, all day and must complete the number of steps each day. They will have to complete online evaluation questionnaires regularly. The main objective is to correlate the level of physical activity with the level of fatigue, quality of life and well-being weekly during an anticancer treatment.
45452459|NCT04474444|Other|attendance by ambulance crew|hear, attendance, convey
45768220|NCT03018821|Drug|Advanced - Supplemented Ganji Decoction|Supplemented Ganji Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: internal blood stasis.
45768221|NCT04322500|Dietary Supplement|probiotics|use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis
45627028|NCT05558163|Procedure|transverse scrotal approach for PPI|penile prothesis implantation through penoscrotal approach outcome
45768222|NCT04322500|Other|conservative treatment|lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
45768223|NCT01014455|Behavioral|Informing surgical patients about CO monitoring|A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery
45768224|NCT01014455|Behavioral|a brief intervention recommending preoperative abstinence from smoking|a brief intervention that recommends fasting but does not mention that CO will be checked
45768225|NCT01047475|Drug|MB-6|6# TID with meal
45912948|NCT02016417|Drug|A combination of Docetaxel, cisplatin and 5-Fluorouracil|The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
45912949|NCT02016443|Drug|Tizanidine|Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
45912950|NCT02016443|Drug|Placebo|Group Placebo (Group P) will receive a placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
45912951|NCT02016456|Device|Theta-Burst Stimulation|At 80% motor threshold determined using single pulse stimuli. Depending on the hemisphere determined by connectivity analysis and neuronavigation in each individual, either continuous (left prefrontal) or intermittent (right prefrontal) train of pulses will be delivered.
45912952|NCT02016456|Device|High frequency stimulation|Left prefrontal stimulation. 120% motor threshold with a pulse sequence of 10 Hz for 4 seconds, followed by a 26 second quiet period. Treatment will last for a total of 37.5 minutes this is a total of 3,000 pulses
45627029|NCT05558163|Procedure|penoscrotal approach for PPI|penile prothesis implantation through penoscrotal approach outcome
45912953|NCT02016469|Other|co-transplantation of FMT and pectin|300ml Bacterial suspension (from 60g fresh stool )for fecal microbiota transplantation the first day and 20g pectin given continuously for total five days
45912954|NCT02016469|Other|single fecal microbiota transplantation|single fecal microbiota transplantation once the first day
45627030|NCT04984473|Device|Inspiratory muscle training|Inspiratory muscle training for 12 weeks at 40% maximal inspiratory pressure
45627031|NCT04582695|Behavioral|Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder|Participants will receive 5 to 6 weeks of an integrated behavioral therapy that address posttraumatic stress disorder and alcohol use disorder. Sessions will be 60 minutes in length. It will include written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes. In addition, they will receive 20 minutes of intervention focused on cognitive behavioral therapy for alcohol use disorder which involves learning skills to cope with alcohol cravings and behavior (e.g., challenging thoughts, problem solving).
45627032|NCT04582695|Behavioral|Written Exposure Therapy|Participants will receive 5 to 6 weeks of written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes.
45627033|NCT04971447|Drug|gender affirming hormonal treatment in transgender men|testosterone enanthate
45627034|NCT04971447|Drug|gender affirming hormonal treatment in transgender women|GnRH agonists + estrogen
45768226|NCT01047475|Drug|Placebo|6# TID with meal
45768227|NCT03877432|Device|Dermatome stimulation|Dermatome (S2-S4) stimulation is aimed at improving the function of bladder storage and bladder capacity. A total of 8 serial cystometrograms will be performed: 2 control fills, followed by 4 fills with stimulation, followed by 2 control fills. The minimum (or threshold) stimulation amplitude (T) necessary to elicit the genito-anal reflex was first determined for each subject. Subsequently, each subject received a randomized sequence of cystometric fill trials with and without continuous dermatome stimulation. The dermatome stimulation was randomly stimulated at stimulation amplitudes of 1, 2, 3, and 4 T.
45768228|NCT03012451|Behavioral|Advancing Adolescents|"The Advancing Adolescents programme is a structured 8-week psychosocial intervention for adolescents in humanitarian crises, based on profound stress attunement processes. It features three elements that are widely viewed as important to support youth adjustment in contexts of complex emergencies: (i) safety: establishment of a 'safe space' within the community as a base for activities and site of protection; (ii) support: facilitation of social support and self-expression; and (iii) structured activities: access to scheduled group activities."
45912955|NCT02016469|Dietary Supplement|pure give pectin 20g/d for five days|pure give pectin 20g/d for five days
45912956|NCT02016495|Dietary Supplement|Magnesium plus alpha-lipoic acid|
45912957|NCT02016495|Drug|Placebo|
45912958|NCT02016508|Drug|autologous bone marrow derived stem cells|intravitreal injection of autologous bone marrow stem cells in 0.1 ml volume
45627035|NCT04394715|Other|Electronic Alert|"Providers will see an automated electronic alert for each eligible hyperlipidemia patient at high risk for future atherosclerotic CVD events. This alert will appear when the provider enters the order entry screen in the patient's medical record during the patient's first eligible outpatient visit. The alert consists of a pop up that notifies the physician that the patient is at very high risk for ASCVD events, displays the most recent cholesterol values and the patient's current lipid lowering therapy. It also includes a link to full treatment guidelines for hyperlipidemia, which includes a continuing medical education (CME) option to obtain CME credits."
45627036|NCT02149420|Drug|VAY736|
45627037|NCT02149420|Drug|Placebo|
45627038|NCT05557773|Other|Home Based Traditional Scoliosis Exercises|Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.
45627039|NCT05557773|Other|Core Stability Training|Patients in this group will receive traditional scoliosis exercises. In addition, the training group will receive core stabilization exercises for multifidus, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, iliopsoas, gluteus maximus, and pelvic floor muscles.
45627040|NCT04337307|Biological|Skin sampling of the hands of the healthcare workers involved in the decontamination of incubators|"Each incubator will be sampled in 5 points before and after decontamination. The healthcare worker that will be involved in the decontamination will also be sampled (skin sample of the hand) before and after decontamination of the incubator.~All the samples will be analyzed for the presence of pathogenic bacteria, using an inoculation on selective agar then an identification of each bacterial colony."
45627041|NCT05557383|Behavioral|use peanut ball|The peanut ball was placed between the legs of a woman in the intervention group immediately after she received her epidural and consented to participate in the study.
45627042|NCT04819191|Behavioral|SHARING Choices|SHARING Choices is a multicomponent communication intervention to proactively engage family members or friends and to support advance care planning in primary care
45768229|NCT01047709|Device|Positional therapy including the use of a special pillow|Avoidance of supine sleep via a special pillow and other measures.
45768230|NCT03866434|Drug|SPD422|Participants will receive 1 mg of SPD422 (2*0.5 mg) capsule orally on Day 1 and 8 in fasted state.
45768231|NCT03866434|Drug|Omeprazole|Participants will receive 40 mg of Omeprazole orally once daily on Days 2 - 8.
45768232|NCT00962039|Drug|Citalopram|Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
45768233|NCT00962039|Drug|Placebo|Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
45768234|NCT03375385|Drug|dexmedetomidine/ propofol|The loading and infusion doses of dexmedetomidine hydrochloride and 1% propofol were calculated according to the patient's body weight and diluted to a 10 ml volume (labeled as loading-1 and loading-2) and a 50 ml volume (labeled as infusion-1 and infusion-2).
45912959|NCT02016521|Other|Cooling Fabric|Garment made of 100% nylon and consisting of long sleeved shirt and full trouser.
45912960|NCT02016521|Other|Placebo Garment|Garment made of 100% polyester consisting of long sleeved shirt and full trouser
45912961|NCT02016547|Procedure|abciximab IV and thrombectomy|
45627043|NCT02149264|Drug|Testosterone gel (FE 999303)|
45627044|NCT05610969|Other|Music|patients in this group will receive self-selected music after the golden moment has been completed between the patient, provider, and nursing staff
45627045|NCT05610969|Drug|Midazolam|patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
45627046|NCT05557149|Device|Virtual Reality Exposure to Neutral Cues|Virtual reality exposure to neutral stimuli (360 degrees visual and audio immersion with Oculus Quest 2 virtual reality headset). Participants stay sitted on chair and can tilt, rotate and move forward and backward upper body members. No interaction with the investigator during the virtual reality immersion.
45627047|NCT05557149|Behavioral|Respiratory Relaxation|Respiratory relaxation practise. No interaction with the investigator during the relaxation practise.
45627048|NCT05557149|Device|Virtual Reality Exposure to Cocaine-Related Cues|Virtual reality exposure to cocaine-related stimuli (360 degrees visual and audio immersion with Oculus Quest 2 virtual reality headset). Participants stay sitted on chair and can tilt, rotate and move forward and backward upper body members. No interaction with the investigator during the virtual reality immersion.
45912962|NCT02016547|Drug|alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)|
45912963|NCT02016573|Device|Renal Denervation|Renal Denervation Catheter
45912964|NCT02016586|Dietary Supplement|Maternal Nutritional Supplement|S348S0
45912965|NCT02016638|Other|Polysomnography and ambulatory blood pressure recording|
46069804|NCT00697359|Device|Implantable loop recorder (ILR)|The ILR will be implanted subcutaneous following standard surgical procedure.
45627049|NCT04417738|Device|unilateral transcranial photobiomodulation, near infrared mode|The investigators are applying a supra luminous LED at 810 nm and 250 mW/cm2 to the forehead of the participant at F3 and F4.
45627050|NCT04417738|Device|Sham treatment|The sham treatment is identical to the active treatment except that the sham treatment has a piece of aluminum foil covering the led so that the participant will experience warmth but receive no photons.
45627051|NCT04275297|Behavioral|Psychosocial Treatment|The psychosocial intervention will consist of 8 weekly 50-minute individual visits with the assigned therapist.
45627052|NCT04275297|Behavioral|Attention Control|The Attention Control will reflect a similar visit pattern and duration as intervention sessions.
45627053|NCT02115256|Drug|Intravenous Terbutaline|0.25 mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25 mL IV of normal saline.
45627054|NCT02115256|Drug|Intravenous Nitroglycerine|The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it's short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
45768235|NCT03012373|Procedure|Ear acupressure alone|The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes then were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.
45627055|NCT05556759|Procedure|control|patient will be operated under general anesthesia
45768236|NCT03012373|Procedure|Electroacupuncture plus ear acupressure|Acupuncture included Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation was conducted. The frequency of electrical stimulation was 5 Hz and wave form was adjustable. The intensities of the stimulation were increased in 1 mA increments to maximal tolerable intensity. At the same time, The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes. After 15 minutes treatment, acupuncture needles were removed and magnet pellets were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.
45768237|NCT03867838|Device|compliant support|Participants will be given compliant arm support and their reachable workspace measured
45912966|NCT02016651|Behavioral|Right side position|Enrolled infants are positioned on their back or right side. Tracheal aspirate is assessed for pepsin concentration as an index of aspiration.
45627056|NCT05556759|Procedure|IPS|patients will receive ultrasound-guided anterior IPS block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
45627057|NCT05556759|Procedure|Supra-iliac QL|patients will receive ultrasound-guided supra-iliac anterior QL block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
45627058|NCT02173054|Other|Adapalene gel with Eucerin|Eucerin: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
45768238|NCT03018665|Drug|Exenatide|subcutaneous injection，5ug twice a day the first month，10ug twice a day the second and third month
45912967|NCT02016664|Drug|Ketamine|The St.Joseph's Heath Care Pharmacy will supply the compounded oral ketamine capsules. Patients who are going to participate in this study are already taking this oral ketamine as a part of their chronic pain medications. No new patient will start oral ketamine for the sake of this study. Two doses of oral ketamine will be used for the same patient, 10 mg and 20 mg every 8 hours. These doses are the standard doses in our clinic. Other clinics using much higher doses.
45627059|NCT02173054|Other|Adapalene gel|Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
45768239|NCT03018665|Drug|BIAsp30|subcutaneous injection，fit dosage twice a day in three months
45912968|NCT02016703|Other|Erythritol drink|
45912969|NCT02016703|Other|Placebo drink|
46069805|NCT02618499|Drug|Timing of administration of post partum Oxytocin|10 IU of oxytocin given IV at different times after birth
46069806|NCT04133961|Drug|Phenylephrine|Phenylephrine infusion 0.3ml/kg/hour (equivalent to 0.5mcg/kg/min, phenylephrine dilution is 100mcg/ml in 20ml syringe)
45627060|NCT02173054|Other|Adapalene gel with placebo moisturizer|Placebo: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
45627061|NCT04741906|Procedure|Dental implant surgery|Dental surgery in patients treated with antiresorptive medication
45627062|NCT04741906|Procedure|Prosthetic treatment|Prosthetic treatment and loading of the dental implants
45627063|NCT04741828|Drug|Vi-DT Typhoid Conjugate Vaccine|Typhoid Conjugate Vaccine
45627064|NCT04225221|Drug|Estradiol|During estradiol administration, 2mg of estradiol is given twice daily via oral capsule.
45627065|NCT04225221|Drug|Micronized progesterone|During progesterone administration, 200mg of progesterone is given twice daily via oral capsule.
45768240|NCT03018665|Drug|Metformin|oral，0.85g，twice a day in three months
45912970|NCT02016729|Drug|AMG 232|Given an an oral tablet in escalating doses.
45912971|NCT02016729|Drug|Trametinib|Trametinib is an oral tablet given in a fixed dose.
45912972|NCT02016742|Drug|RDC5|
46069807|NCT04133961|Drug|Normal saline|Normal saline infusion 0.3ml/kg/hour (normal saline in 20ml syringe)
46069808|NCT02618265|Procedure|Mobile terminal|multiple strategy including mobile terminal based compliance managment, platelet reactivity modified drug adjustment
46069809|NCT02618265|Procedure|traditional management|aspirin or clopidogrel monotherapy or double treatment for
46069810|NCT02618265|Procedure|website platform management|second prevention based on website platform management
46069811|NCT02618733|Drug|Ticagrelor|90mg, twice a day
46069812|NCT02618733|Drug|Clopidogrel|75mg, once a day
46069813|NCT04134195|Device|Transcranial direct current stimulation|2mA stimulation for 20 minutes
46069814|NCT02617953|Device|Active rTMS(A)|"repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
46069815|NCT02617953|Device|Active rTMS(B)|"repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
45768241|NCT03012763|Drug|Paracetamol|Oral administration of 250 mg paracetamol
45768242|NCT03012763|Drug|Sulfasalazine|Oral administration of 50 mg sulfasalazine
46069816|NCT02617953|Device|Sham condition(C)|"The sham stimulation looks and sounds like the active coil, but diverts the magnetic field away from the patient.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
45768243|NCT03012763|Drug|Fexofenadine|Oral administration of 120 mg fexofenadine
45627066|NCT04225221|Drug|Leuprolide Acetate|Initial 3.75 mg intramuscular injection administered approximately Day 6 of menstrual cycle and then monthly thereafter for a total of 3 months.
45627067|NCT04225221|Drug|Placebo Oral Capsule|Placebo is administered during the addback phase when participants are not taking active medication. Placebo is given so that medication administration occurs throughout the entire 8-week addback period in order to blind participants to when and for how long they are on the active medication.
45768244|NCT03012763|Drug|Valsartan|Oral administration of 40 mg valsartan
45768245|NCT03012763|Device|non-caloric water|Oral administration of 240 ml non-caloric water
45768246|NCT03012763|Device|caloric drink|Oral administration of 240 ml caloric drink
45912973|NCT02016768|Procedure|decompressive cervical surgery|To make decompressive cervical surgery, either anterior cervical discectomy and fusion or posterior laminoplasty on the patients suffering from cervical spondylotic myelopathy and hypertension.
45912974|NCT02016807|Device|ProThelial|August 2013, the FDA cleared the use of ProThelial, a polymerized high potency sucralfate paste, as a device for the management of oral mucositis.Standard potency non-polymerized sucralfate is not recommended by MASCC/ISOO for the treatment or prevention of mucositis, oral or alimentary. However high potency polymerized sucralfate has been associated with rapid amelioration and prevention of both oral and alimentary mucositis in a patient with advanced head neck cancer treated simultaneously with high dose chemo-radiation. High potency sucralfate is standard sucralfate polymerized into 'sucralfate sheets' that adhere and orderly layer upon the mucosa achieving and maintaining elevated concentrations of sucralfate long after the initial dose administration. Three hours following administration, high potency sucralfate maintains a 7 fold greater surface concentration of sucralfate on normal lining and a 23 fold greater concentration on inflamed, ulcerated mucosa.
45912975|NCT02016820|Drug|Omeprazole (suspension)|1 mg/kg/day
45912976|NCT02016820|Other|Lifestyle Modification|Standard lifestyle modification: small meals, upright feeding, elevation of the head of the bed
45912977|NCT02016833|Procedure|Blood Sampling|Sampling of 80mL of whole blood
45912978|NCT02016846|Drug|Liraglutide|
46069817|NCT02618109|Biological|Collection of blood samples|Collection of blood samples
45912979|NCT02016846|Drug|Placebo|
45627068|NCT04187625|Biological|endothelial progenitor cell|Kidney-derived endothelial progenitor cells will be delivered percutaneously to the kidney blood supply.
45627069|NCT04024371|Behavioral|Self-rating Questionnaires|"Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995)~Quick Inventory of Depressive Symptomatology (QIDS; 16 items)~Behavioral avoidance/inhibition Scales (BIS/BAS)"
45768247|NCT03012763|Device|grapefruit juice|Oral administration of 240 ml grapefruit juice
45768248|NCT01015781|Procedure|Progressive Tinnitus Management|"The program follows a five-level progressive intervention model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment. The five levels of progressive intervention are: 1) Triage; 2) Audiologic Evaluation; 3) Group Education; 4) Interdisciplinary Evaluation; 5) Individualized Support"
45768249|NCT01015781|Procedure|Wait List Control|VA audiologists typically (a) perform an audiologic evaluation; (b) fit hearing aids if necessary; and (c) provide basic information about tinnitus in the form of one-time, one-on-one informational counseling and/or a tinnitus handout. We therefore will provide these procedures for subjects who are randomized to receive usual care. Usual care subjects also can be referred for other clinical services as deemed appropriate.
45768250|NCT03661762|Device|CAVA|prototype device for monitoring dizziness
45768251|NCT03012607|Drug|Truvada|Participants will be randomized into 1 of 3 groups (10 participants/group) to receive a controlled number of doses of tenofovir disoproxil fumarate (TDF, 300mg) in a combination pill with emtricitabine (FTC, 200mg) (Truvada®)
45627070|NCT04024371|Behavioral|Measures of Reward processing/reinforcement learning|"Grip Strength Effort Task (Reddy et al. 2015; in combination with EEG)~Doors (Gambling) task (Foti and Hajcak 2009; in combination with EEG)~Reinforcement Learning/Working Memory task (Collins et al. 2017; no EEG)"
45627071|NCT04024371|Behavioral|Additional Schizophrenia-specific Questionnaires and Interviews|"Positive and Negative Syndrome Scale (PANSS: Kay et al. 1987)~Brief Negative Symptom Scale (BNSS; Kirkpatrick et al. 2011)"
45627072|NCT04675593|Behavioral|iTAB-CV|Individualized Texting for Adherence Building - Cardiovascular (iTAB-CV): a personalized patient-centered text message-based adherence intervention
45627073|NCT04675593|Behavioral|Self-Monitoring|The Self-Monitoring (control) group will monitor their medication adherence, take their blood pressure weekly with a home blood pressure monitor provided by the study after being trained by the study staff, and rate their mood weekly in response to a text reminder.
45627074|NCT05556213|Procedure|laparoscopic examination|laparoscopic examination for staging of endometriosis
45627075|NCT05556213|Diagnostic Test|Blood sampling|Blood sample to detect endometriosis
45627076|NCT05556135|Diagnostic Test|level of serun adiponectin|estimation of level of serum adiponectin in NAFLD for early detection of renal impairement
45627077|NCT04425993|Drug|Isosorbide Dinitrate 5 MG|All patients without contraindications should receive sublingual isosorbide dinitrate tablet within 5 minutes before ERCP.
45627078|NCT04425993|Drug|Indomethacin 100 MG|All patients without contraindications should receive rectal indomethacin within 30 min before ERCP.
45627079|NCT04425993|Drug|Sublingual Placebo|All patients without contraindications should receive sublingual placebo within 5 minutes before ERCP.
45627080|NCT04425993|Drug|Rectal placebo|All patients without contraindications should receive rectal placebo within 30 min before ERCP.
45627081|NCT03971643|Drug|IFX-1|IV infusions of IFX-1 diluted in sodium chloride.
45768252|NCT03018509|Drug|JTE-451|Active drug tablets containing JTE-451
45627082|NCT04745559|Biological|Pneumococcal conjugate vaccine (PCV13)|Licensed heptavalent pneumococcal conjugate vaccine (PCV13, Pneumococcal 13-valent conjugate vaccine
45627083|NCT04745559|Biological|CD19 targeted CAR T Cell Therapy|This is a personalized therapeutic approach that entails removal of T cells from patient's peripheral blood, genetic modification, activation and expansion in vitro to retarget cells against CD19 protein on the surface of B cells, and infusion of the genetically engineered cells back into the patient. CD19 is a surface protein that is expressed on B cells starting from early pre-B cells to mature fully differentiated B cells. Therefore, CD19-targeted CAR T cell therapy can effectively treat refractory B cell lymphomas.
45627084|NCT03971175|Procedure|Forceps biopsy|Endobronchial biopsy with the forceps
45627085|NCT03971175|Procedure|Cryobiopsy|Endobronchial biopsy with the cryobiopsy probe
45627086|NCT03961113|Other|Assessment by questionnaire|"At diagnosis a gerontological evaluation will be carried out including the following tests: ADL, iADL, MNA, SF 36, SPPB, FRIED criteria and GDS. The set of scales and scores of the procedure is commonly used in geriatrics to assess the fragility of the patient.~A monthly telephone reassessment conducted by an ARC will collect ADL and iADL from the first month to the eleventh month. The end-of-study consultation will be conducted by a geriatrician at the 12th month and will include the following tests: ADL, iADL, MNA, SF 36, the SPPB, the criteria of FRIED and the GDS"
45627087|NCT04744155|Behavioral|Multi-Level Intervention|Behavioral intervention that assesses uptake of contraception and seeks follow-up care.
45627088|NCT04744155|Behavioral|Enhanced Standard of Care|Behavioral intervention that assesses uptake of contraception from follow-up care.
45768253|NCT03018509|Drug|Placebo|Placebo tablets identical in appearance to the active drug tablets
45912980|NCT02016859|Other|Immature Platelet Fraction|
45912981|NCT02016911|Drug|semaglutide|Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
45912982|NCT02016976|Drug|EMLA Analgesic Cream|
45912983|NCT02016976|Drug|Dormicum 2.5 mg and Pethidine 25 mg|Routine anesthesia and analgesia ( Dormicum 2.5 mg and Pethidine 25 mg )normally given to patients before and during pacemaker implantation
45912984|NCT02016989|Device|RGTA OTR4120 (CACICOL20)|
45627089|NCT04739007|Procedure|Veno-arterial extracorporeal membrane oxygenation (VA-ECMO)|VA-ECMO used for resuscitation after cardiac arrest
45627090|NCT04739007|Device|Electrical Impedance Tomography (EIT)|EIT used to demonstrate ventilation and perfusion distribution in intubated patients on VA-ECMO
45627091|NCT04512885|Other|Survey|Survey via questionnaire
45627092|NCT04480749|Diagnostic Test|Access to Facility based Syphilis Testing|List of facilities where syphilis testing can be accessed
45627093|NCT04480749|Diagnostic Test|Syphilis Self-Test|Rapid Treponemal Test kit
45627094|NCT03792633|Biological|huCART19|huCART19 infusion
45627095|NCT05700747|Behavioral|Health Through Activity|Six, weekly, customized sessions with licensed physical and occupational therapists.
45768254|NCT04316260|Behavioral|Smoking cessation e-visit|electronic visits (e-visits) for smoking cessation
45768255|NCT04316260|Behavioral|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking
45768256|NCT01048879|Procedure|pharmacokinetic blood sampling|blood samples collected to assess oseltamivir concentrations
45768257|NCT01048879|Procedure|pharmacokinetic blood and dialysate sampling|blood and dialysate samples collected and assayed for oseltamivir concentrations
45768258|NCT05272657|Other|low-carbohydrate diet|subjects in this arm are given detailed instructions and coaching in following a low-carbohydrate diet.
45912985|NCT02016989|Device|physiological salt solution|
45627096|NCT02149108|Drug|Nintedanib (BIBF 1120)|
45627097|NCT02149108|Drug|Placebo|
45768259|NCT05272657|Other|Mediterranean diet|subjects in this arm are given detailed instructions and coaching in following a Mediterranean diet.
45768260|NCT04296448|Device|Cellscope|Cellphone otoscope (Cellscope) to evaluate pediatric patient ears.
45768261|NCT05230771|Combination Product|Palliative surgery after translational therapy|"A total, distal, or proximal gastrectomy with D1 lymph node dissection was done depending on tumour after translational therapy .~location."
45768262|NCT05230771|Drug|Chemotheraoy along|Patients receive only the prescribed chemotherapy.
45768263|NCT05314738|Combination Product|NXL Energy 1|Riboflavin drops + NXL System to Total Energy Level 1
45627098|NCT02149108|Drug|BSC|
45768264|NCT05314738|Combination Product|NXL Energy 2|Riboflavin drops + NXL System to Total Energy Level 2
45627099|NCT02149108|Drug|BSC|
45627100|NCT04440891|Device|TMS stimulation with X-Torp task|TMS-Stimulation with X-Torp task
45627101|NCT04440891|Device|TMS-Stimulation with MindMotion Go|TMS-Stimulation with MindMotion Go
45627102|NCT04440891|Device|TMS-Sham with X-Torp task|TMS-Sham with X-Torp task
45768265|NCT05314738|Combination Product|NXL Energy 3|Riboflavin drops + NXL System to Total Energy Level 3
45768266|NCT05314738|Combination Product|Sham Treatment|Sham Drops and No exposure to NXL system
45912986|NCT02017002|Procedure|Ivor Lewis|for the patients with lower-to mid third esophageal cancer, some surgeon performed Ivor lewis esophagectomy, which performing the esophago-gastrostomy in the chest after gastric mobilization without cervical incision wound
45447265|NCT02107768|Other|Aerobic exercise|"Other: Aerobic exercise The intervention group will conduct a 12 week training period with two training sessions of 60 minutes per week at a local hospital. The start shall be made within 6 weeks after stroke . The training shall be conducted in a group with a maximum of 10 participants and start running as new participants in the intervention group will be added.The intensity during the exercise program should be individualized and based on the initial tests . Patients should be advised to reach a degree of exertion 13-15/20,Rate of Perceived Exertion (Borg 's RPE scale) .~Two fitness goals was to be achieved during the training session~1. An individual training level corresponded to 50% or more of maximal oxygen uptake for at least 40 min ( Borg 9-11/20 ) . Which corresponds to 70 % of maximum heart rate.~2:nd 80% or more of the estimated maximum oxygen uptake during two periods of 8 minutes( Borg 13-15/20 ) . Which corresponds to 85 % of maximum heart rate."
45447266|NCT02639780|Other|protein expression pattern of packed red blood cells|the proteome of packed red blood cells will be assessed at predefined time points
45627103|NCT04440891|Device|TMS-Sham with MindMotion Go|TMS-Sham with MindMotion Go
45627104|NCT02148952|Behavioral|WHO Safe Childbirth Checklist Program|The IHF group will receive the WHO Safe Childbirth Checklist Program designed to maximize likelihood of effective and sustained uptake of the program by birth attendants in the designated facilities. The program includes three key implementation steps that involve: engagement of leadership and clinicians at the state, district, and local levels, a formal launch to introduce the Checklist, and support through peer coaching and data feedback. The intervention facilities will also receive a standardized maternity register to ensure appropriate data collection.
45627105|NCT03653091|Device|Duodenal Mucosal Resurfacing (DMR)|The Fractyl DMR procedure utilizes the Revita™ Catheter to perform hydrothermal ablation of the duodenum. The catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DRM treatment are followed for 48 weeks while Sham subjects who cross over and undergo the DMR procedure at 24 weeks are followed for further 24 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
45768267|NCT03181477|Device|Radiotherapy|Radiotherapy of 80 GY + Chemotherapy (Temozolomide)
45768268|NCT03010345|Device|Osmed self inflating tissue expanders|Osmed self inflating tissue expanders will be placed 21 days before bone grafting the cleft to gain soft tissue coverage
45768269|NCT03010345|Other|Iliac bone graft|Bone grafting the cleft without the use of osmed self inflating tissue expander
45768270|NCT04290676|Drug|DEXYCU (dexamethasone intraocular suspension) 9%.|DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).
45768271|NCT03112993|Drug|sugammadex|once at the end of the surgery
45768272|NCT03112993|Drug|Neostigmine|once at the end of the surgery
45768273|NCT03670030|Drug|ABI-009|rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)
45768274|NCT02955355|Biological|HYQVIA|Participants will receive subcutaneous (SC) HYQVIA/HyQvia which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).
45768275|NCT04271020|Device|UroLift|"The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).~During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra."
45768276|NCT02924155|Drug|SJP002|"Period 1 (single dose)~Day1: Placebo, Topical administered one drop to each eye (Once a day)~Day2: SJP002, Topical administered one drops to each eye (Once a day)~Day3: SJP002, Topical administered one drops to each eye (Administered 4 times a day [0h, 4h, 8h, 12h])~Period 2 (multiple dose) - Day10~Day23: SJP002, Topical administered one drops to each eye (Administered 4 times a day [0h, 4h, 8h, 12h])"
45912987|NCT02017002|Procedure|Tri-incision|a cervical incision was required for esophagogastrostomy after esophagectomy and gastric mobilization
45627106|NCT03653091|Device|Duodenal Mucosal Resurfacing Sham (Sham)|The Sham procedure consists of placing the Revita™ Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient.
45912988|NCT02017041|Device|Medsignals|MedSignals (www.medsignals.com) is a cellular communicating medication management device designed to improve adherence. It will be used to track when medication is removed from the device at dosing times and deliver audible and visual alerts at dosing times and to relay adherence data securely to patient files. Participants will use this device throughout the 5-week trial. It is a Class I device.
45627107|NCT04421859|Other|EyeCU Mobile Application|Augmented reality glaucoma education mobile phone application
45627108|NCT03569007|Drug|Larazotide|Synthetic 8-amino acid peptide formulated as enteric-coated beads in gelatin capsules
45627109|NCT03569007|Drug|Matching Placebo|enteric-coated beads in gelatin capsules
45627110|NCT02148718|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
45627111|NCT03397953|Drug|Vinorelbine|Vinorelbine will be used 25mg/m2/week, rest for 1 week after 3 weeks of continuous use, 4 weeks will be a course. After 1 week there will be a simple assessment, after 2 weeks will be a comprehensive assessment. If the patient got disease progression or partial response/stable disease, he/she would be removed from this trial.
45627112|NCT05549973|Drug|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
45627113|NCT02148250|Drug|U-500 insulin, 100 syringe units|Subjects are randomized to receive 100 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
45627114|NCT02148250|Drug|U-500 insulin, 200 syringe units|Subjects are randomized to receive 200 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
45627115|NCT03321747|Radiation|Stereotactic Ablative Body Radiation (SABR)|Treatments shall not be delivered more frequently than every other day.
45627116|NCT03285789|Other|Passing tests in dyslexics with reduced eva|"Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it orally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial tests to judge his visuo spatial abilities.~All of these tests will be made during an unique visit of 1h30."
45627117|NCT03285789|Other|Passing tests in controls|"Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it verbally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial test to judge his visuo spatial abilities.~test de l'alouette : reading test during 3 minutes, we note the number of word read and the errors. We obtain lexical age.~All of these tests will be made during an unique visit of 1h30."
45912989|NCT02017041|Device|smartphone app|The smartphone app being evaluated in this study is designed to support effective medication management of opioid substitution patients taking buprenorphine/naloxone.
45912990|NCT02017054|Other|Cath|No intervention - registry
45912991|NCT02017067|Procedure|hydraulic resistance circuit training|12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 7 types of equipments for different part of strength training.
45627118|NCT02147626|Behavioral|Web-based educational and motivational modules|
45627119|NCT02147626|Behavioral|Information and Screening Group|
45627120|NCT04870359|Procedure|Pre-emptive increase of immunosuppressive treatments|"Increase prednisolone to 0.4-0.5 mg/kg/day; taper by 5 mg every 2 weeks to reach 15mg/day; then further reduce by 2.5 mg every 2 week and aim to reach 5-7.5 mg/day after 12 weeks.~Adjustment of the 2nd agent would be as follows:~For patients who receive AZA <75mg/day; increase the dose of AZA to 75 mg/day.~For patients who receive MMF <1g/day, increase the dose of MMF to 1g/day."
45627121|NCT04870359|Drug|Prednisolone and/or AZA/MMF|Prednisolone and/or AZA/MMF
45912992|NCT02017106|Procedure|Endovenous Laser ablation and concomitant phlebectomies|
45912993|NCT02017106|Procedure|Endovenous Laser ablation and sequential phlebectomies|
45912994|NCT02017119|Drug|Comparison between Lactulose and Lactulose-Paraffin|
45912995|NCT02017132|Dietary Supplement|Pomegranate extract|
45912996|NCT02017145|Drug|Chloraprep|
45627122|NCT02705859|Drug|Copanlisib|Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab.
45627123|NCT02705859|Drug|Trastuzumab|Trastuzumab IV weekly (4mg/kg on Cycle 1 Day 1 followed by 2 mg/kg IV weekly from Day 8).
45627124|NCT05549817|Other|Synchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for shoulder tendinopathy patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
45627125|NCT05549817|Other|Asynchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for shoulder tendinopathy patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
45627126|NCT04741282|Other|Pulmonary telerehabilitation|pulmonary telerehabilitation program include breathing exercise,aerobics exercise and upper and lower limbs muscle strengthening exercise
46069818|NCT00970307|Biological|GSK2202083A vaccine|Intramuscular, three doses
45627127|NCT04741282|Other|progressive muscle relaxation training|summarized Jacobson progressive muscle relaxation training method
45627128|NCT05549583|Drug|Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet
45627129|NCT05554809|Other|Strecthing|Comparing the crossover-effect of dynamic versus static stretching
45627130|NCT02172664|Procedure|Self etch enamel etching|The adhesive will be applied according to manufacturer's instructions. If the lesion is greater than 2 mm in any dimension, incremental placement of Tetric EvoCeram composite (Ivoclar Vivadent) will occur with the first increment being placed against enamel.
45627131|NCT02172664|Procedure|selective etch protocol|Total Etch (37% phosphoric acid; Ivoclar) will be placed on the enamel margin with no intentional placement on the dentin within the lesion. The adhesive will then be applied as instructed by the manufacturer. Tetric EvoCeram composite will be placed, light-cured, finished, and polished in the same manner as for the self-etch group.
45627132|NCT02172664|Device|Adhese Universal|the universal adhesive, Adhese Universal , will be applied to the selected tooth following manufacturer instructions
45627133|NCT05554731|Device|a New Balloon Catheter for Intraairway Hemostasis|In the treatment group, the new balloon catheter was inserted in three steps, that is, the tracheoscope was inserted into the airway to remove the blood in the airway and find the target bronchus.The new airway hemostatic balloon catheter was directly inserted through the tracheoscopy biopsy channel, and then directly inflated and fixed after positioning.Then exit the tracheoscope directly to complete.
45627134|NCT05554731|Device|Traditional Therapy|A six-step technique was adopted to place the traditional balloon catheter, that is, the tracheoscope was entered to find the target bronchus, the guide wire was inserted through the biopsy channel, the tracheoscope was exchanged to exit the tracheoscope, the catheter was entered through the guide wire exchange, the tracheoscope was re-entered, the catheter was positioned, inflated and fixed, and the tracheoscope was withdrawn.
45627135|NCT02659449|Device|made to measure compression gloves|Patients achieve tests with compression glove
45627136|NCT02659449|Device|Compression bandaging|Patients achieve tests with compression bandaging
45912997|NCT02017158|Other|Virtual Sprouts|The Virtual Sprouts intervention group will play Virtual Sprouts in a school-based implementation of the game.
45912998|NCT02017184|Biological|Noninvasive core temperature thermistor|
45912999|NCT02017197|Drug|Marevan®|Branded warfarin sodium tablets (manufacturer União Química Farmacêutica Nacional S/A, Brazil) by mouth; dose adjusted according to INR and medical judgement.
46069819|NCT00970307|Biological|10-valent pneumococcal vaccine (GSK 1024850A)|Intramuscular, three doses
46069820|NCT00970307|Biological|Infanrix hexa™|Intramuscular, three doses
46069821|NCT00970307|Biological|Menjugate®|Intramuscular, two doses
45913000|NCT02017197|Drug|generic warfarin #1|Generic warfarin sodium tablets, manufacturer (União Química Farmacêutica Nacional S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
46069822|NCT02617875|Other|conventional EMS physician|A physically present conventional EMS physician on scene, will treat the patients according to the standard operating procedures.
46069823|NCT02617875|Other|tele-EMS physician|The patients will be treated by the paramedics, which are concurrently instructed by the tele-EMS physicians of the tele consultation center according to the software-based guideline conform algorithms for diagnosis and treatment.
45627137|NCT02659449|Other|Free Hands|Patients achieve tests without device
45627138|NCT02172040|Drug|Over-encapsulated 10 mg amlodipine besylate tablet|Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks
45627139|NCT02172040|Drug|Matched placebo capsule for over-encapsulated celecoxib capsule|Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
45627140|NCT02172040|Drug|Over-encapsulated 200 mg celecoxib capsule|Over-encapsulated 200 mg celecoxib capsule once a day for two weeks
45627141|NCT02172040|Drug|Matched placebo capsule for over-encapsulated amlodipine besylate tablet|Matched placebo capsule for over-encapsulated amlodipine besylate tablet once a day for two weeks
45627142|NCT02367105|Drug|Testosterone|Daily testosterone gel applied once daily in the morning to intact skin
45627143|NCT02367105|Other|Lifestyle Therapy|Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week
45627144|NCT02367105|Drug|Placebo|Placebo gel for testosterone
45627145|NCT05554653|Dietary Supplement|Leucine enriched amino acids|Leucine enriched essential amino acids (4g total, of which 1.6g are leucine). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.
46069824|NCT00917384|Biological|ramucirumab|Administered via intravenous infusion every 2 weeks at a dose of 8 mg/kg
46069825|NCT00917384|Drug|Placebo|Placebo comparator for ramucirumab 8 mg/kg as intravenous infusion every 2 weeks
46069826|NCT00917384|Other|Best Supportive Care (BSC)|BSC as determined appropriate by the investigator(s). BSC may include but are not limited to antiemetic agents, opiate and nonopiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
45627146|NCT05554653|Dietary Supplement|Carbohydrate Placebo|iso-caloric placebo (4g maltodextrin). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.
45627147|NCT05554575|Biological|BT-007 CD7 CAR-T cells|T cells purified from the peripheral blood mononuclear cell (PBMC) of subjects or subjects' relatives which depend on their conditions, transduced with 4-1BB/CD3ζ lentiviral vector, expanded in vitro for future administration.
45627148|NCT02153229|Radiation|Photodynamic Therapy|
45627149|NCT02153229|Procedure|Radical Pleurectomy|
45627150|NCT02153229|Radiation|Chemotherapy|
45627151|NCT02153229|Drug|Photofrin 2.0 mg/kg|If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy
45627152|NCT05549349|Procedure|Cholecystectomy|Gallbladder removal
45627153|NCT01318317|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
45627154|NCT01318317|Biological|Filgrastim|Given IV
45627155|NCT01318317|Biological|Genetically Engineered Lymphocyte Therapy|Receive ex vivo expanded autologous TCM-enriched CD8+ T cells expressing CD19-specific CAR
45627156|NCT01318317|Other|Laboratory Biomarker Analysis|Correlative studies
45627157|NCT01318317|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
45627158|NCT01318317|Drug|Plerixafor|Given IV
45627159|NCT01318317|Biological|Rituximab|Given IV
45627160|NCT05549271|Procedure|Laparoscopic Mini-gastric bypass|The laparoscopic Omega Loop Bypass performed 5 years ago consisted of a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His, a narrow gastric tube calibrated to be approximately 1.5 cm wide, an Omega loop of 200 cm, a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler
45627161|NCT05549271|Procedure|Laparoscopic Roux-en-Y Gastric ByPass (RYGBP)|The laparoscopic Roux-en-Y Gastric Bypass performed 5 years ago consisted of : a small gastric pouch (about 30cc), an antecolic alimentary limb, a gastro-jejunal anastomosis using a linear stapler, a 150cm long alimentary limb, a 50cm biliary limb, a latero-lateral jejuno-jejunal anastomosis, closure of the mesenteric defects.
45627162|NCT05549193|Other|Exercises Training|"Pelvic Floor Muscle Training: For slow contractions, it was asked to contract in 5 seconds gradually, wait at a maximum of 5 seconds and gradually relax in 5 seconds. For fast contractions, it was asked to contract at a maximum of 2 seconds and then to relax. 10 fast + 10 slow contractions were accepted as 1 set exercise. (10 sets x Every Day x 6 weeks)~Transversus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically. 15 repetitions were carried out, each consisting of contraction for 10 s and relaxation for 20 s. 2 sets of 15 repetitions were done.~Internal Obliquus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically and then try to touch the furthest point of their legs with their fingertips for 15 repetitions consisting of contraction for 10 s followed by relaxation for 20 s. The sequence was then repeated on the other leg."
45627163|NCT05700201|Behavioral|Lifestyle / Healthy Behavior Intervention|12-session healthy lifestyle program focused on physical activity, nutrition, sleep, and stress management.
45627164|NCT05700201|Other|standard care|Standard care (psychotherapy)
45627165|NCT04426227|Other|Gaze training|A training module in gaze training for peripheral nerve blockade
45627166|NCT04426227|Other|Discovery learning|A phase of discovery learning guided by novice operators themselves
45627167|NCT05554185|Dietary Supplement|aspirin 100mg and probiotics 1 bag|taking aspirin 100mg and probiotics 1 bag per day from 14-16 weeks of pregnancy until 35 + 6 weeks of pregnancy or emergency delivery.
45627168|NCT05554029|Diagnostic Test|Coronaphobia|Coronophobia will be assessed with COVID-19-phobia scale.
45627169|NCT05548959|Diagnostic Test|Pneumatonometry after microshunt implantation|Pneumatonometry was perfomed over 24 hours at 5 point in time (5 AM, 11 AM, 4 PM, 8 PM, and midnight) using a Pneumatonometer. The measurement was conducted in the habitual position.
45627170|NCT05548959|Diagnostic Test|Pneumatonometry after ab interno trabeculectomy|Pneumatonometry was perfomed over 24 hours at 5 point in time (5 AM, 11 AM, 4 PM, 8 PM, and midnight) using a Pneumatonometer. The measurement was conducted in the habitual position.
45627171|NCT02112994|Drug|Sebelipase Alfa|IV infusion of sebelipase alfa
45627172|NCT04325841|Biological|Murine autologous anti-CD19 chimeric antigen receptor T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In CD19 T cell clinical trials, CAR-T cells was given once. All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR-T cell infusion to determine the disease status.
45768277|NCT02924155|Drug|Placebo|"Period 1 (single dose)~Day1: Placebo, Topical administered one drop to each eye (Once a day)~Day2: Placebo, Topical administered one drops to each eye (Once a day)~Day3 Placebo, Topical administered one drops to each eye (Administered 4 times a day [0h, 4h, 8h, 12h])~Period 2 (multiple dose) - Day10~Day23: Placebo, Topical administered one drops to each eye (Administered 4 times a day [0h, 4h, 8h, 12h])"
46069827|NCT04133571|Drug|0.05% Lidocaine|0.05% lidocaine with normal saline as a bladder irrigation solution after transurethral surgery intravenous pethidine to decrease CRBD if needed
46069828|NCT03749837|Device|C- MAC VS|The C-MAC VS is a new device on the airway management aid market. It will be used according to the instructions of the distributor. Before the study starts on humans, each study participants will do at least 5 intubations on an airway manikin or more until he or she feels confident to use the device.
45627173|NCT05558397|Device|Interventional Group (Epidural morphine)|Implantation of an epidural catheter for administration of morphine and ropvacaine
45627174|NCT05558397|Drug|Control Group (Oral morphine)|Oral administration of morphine, pregabalin or duloxetin
45627175|NCT05558319|Drug|Bortezomib|Bortezomib
45768278|NCT03859960|Diagnostic Test|body composition|fat mass % (FM%) and fat-free mass (FFM%)% of arms, legs, trunk, android, gynoid and total body
45627176|NCT05558319|Drug|Isatuximab|Isatuximab
45627177|NCT05558319|Drug|Iberdomide|Iberdomide
45627178|NCT05558319|Drug|Lenalidomide|Lenalidomide
45627179|NCT05558319|Drug|Dexamethasone|Dexamethasone
45627180|NCT05548725|Other|Reguired field|Investigations to know relationship between acute kidney injury and mineral bone disease
45627181|NCT05700825|Behavioral|Expiratory Muscle Strength Training + Cough Skill Training|"Expiratory Muscle Strength Training (EMST). EMST is a widely used and efficacious treatment approach that uses a calibrated device with a one-way, spring-loaded pressure relief valve to mechanically overload the expiratory and submental muscles.~Cough Skill Training (CST) involves a digital peak flow meter device which measures PEFR (peak expiratory flow rate) in liters/second and allows patients to receive immediate biofeedback."
45627182|NCT05700513|Combination Product|Capsules containing the combination products|Capsules containing dog-rose, Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, and Sumac
45627183|NCT05700513|Drug|Placebo capsules|Placebo capsules containing maltodextrin
45627184|NCT05543343|Drug|High dose or normal dose staphylococcus albicans|8 staphylococcus albicans tablets(0.3 mg) 3 times daily or 4 staphylococcus albicans tablets(0.3 mg)+4 placebo tablets 3 times daily
45627185|NCT05543343|Drug|Placebo|8 placebo tablets 3 times daily
45627186|NCT05548647|Behavioral|Behavioral Treatment|All participants, regardless of medication assignment, will receive the same 60-week behavioral weight loss program. Brief (15-minute), individual lifestyle counseling sessions will be delivered by a psychologist, behavioral health counselor, or registered dietitian (or other trained health care provider) at weeks 0 (i.e., baseline/randomization), 2, 4 and every fourth week from week 4 to week 60 (17 sessions) of Study 1. Subjects will be instructed to consume a self-selected diet of 1200-1500 kcal/day (for those who weigh < 250 lb) or 1500-1800 kcal/day (for those who weigh ≥250 lb). They will be instructed to engage in low-to-moderate intensity physical activity (e.g., walking), gradually building to a goal of ≥150 minutes per week (spread across 5 days) by week 40. They will be instructed to use calorie counting and self-monitoring to meet their goals.
45627187|NCT05548647|Drug|Placebo|An inactive saline solution administered via subcutaneous injection
45768279|NCT03859960|Diagnostic Test|glucose, insulin, glycohemoglobin|In the morning after 12 hours overnight fast, all individuals underwent a 75 gram (g) oral glucose tolerance test (OGTT). Blood samples were taken before loading glucose and then 30, 60, 90 and 120 minutes after taking glucose solution in order to measure serum glucose and insulin levels. Glycohemoglobin (HbA1c) was measured in blood samples taken before the OGTT. We calculated the Matsuda index and Homeostasis model assessment index (HOMA-IR) using glucose and insulin levels.
45768280|NCT01163461|Behavioral|speech therapy|individuals will receive 60 hours of behavioral speech therapy
45627188|NCT05548647|Drug|Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]|Semaglutide 2.4 mg is a once weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist that has been FDA approved for weight loss
45627189|NCT05553717|Drug|Carvedilol|Carvedilol 12.5mg\12hr
45627190|NCT05543031|Other|Music-Integrated Phonological Awareness training program|We would like to observe the effect of the music integrated phonological awareness program on preschool cochlear implant users and to compare the phonological awareness skills of the study group with the control group before and after the online training. The program is prepared as 10 lessons. Participants were guided through online training for 5 weeks, with 20-minute sessions conducted weekly. The training was carried out via Zoom, a free virtual interview program. Each family had a computer.
45627191|NCT05543031|Diagnostic Test|Spectral-Temporally Modulated Ripple Test (SMRT)|Spectral-Temporally Modulated Ripple Test (SMRT) was used to assess the spectral discrimination ability of the study group.Speech stimuli were presented at a calibrated presentation level of 60 dB SPL in a quiet room. The child was positioned at 0° azimuth and 1-meter from the loudspeaker.
45768281|NCT03857230|Drug|Follitropin alfa (Primapur)|"During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur."
45913001|NCT02017197|Drug|generic warfarin #2|Generic warfarin sodium tablets, manufacturer (Laboratório Teuto Brasileiro S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
45447267|NCT02110030|Device|Transcutaneous nerve stimulation|"The group with TENS received electrical stimulation (Endomed 182, Enraf-nonius, Germany) at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: supraspinatus fossa and the insertion of the rotator cuff (channel 1) and V deltoid  (channel 2). The current intensity was set 3 times during each session according to each patient's sensitivity. Current was strong but it did not exceed the threshold of pain."
45627192|NCT05543031|Diagnostic Test|The Phonological Awareness Scale of Early Childhood Period (PASECP)|The Phonological Awareness Scale of Early Childhood Period (PASECP) was used to measure the sound awareness and sound discrimination skills of study group pre-post training. The test has 8 sub-dimensions.
45627193|NCT05543031|Diagnostic Test|Mismatch Negativity Test|Mismatch Negativity (MMN) was used to evaluate the central auditory system.The test was used for electrophysiological recordings of the study group.The standard stimulus presented as /ba/ (%80), and the rare stimulus presented as /da/ (%20) frequency. The onset (rise) and offset (fall) times of the stimuli are 10 ms, and the plateau time is 50 ms. The interval between stimuli for both responses was 1.1 ms. A 0.1-30 Hz filter was applied. The speech stimuli intensity was 70 dB SPL. Speech stimuli were presented at a 1-meter distance from the participant, with speakers placed at an angle of 0°.
45913002|NCT02017236|Drug|Volitinib|600mg Volitinib ,single dose,oral
45913003|NCT02017249|Drug|arginine in powder form|
45913004|NCT02017249|Drug|Silica and cellulose placebo powder|
45913005|NCT02017262|Behavioral|Self-management group|8 weekly sessions of group self-management
45627194|NCT05543031|Diagnostic Test|Early Language Development (TELD-3)|Test of Early Language Development (TELD-3) measured children's receptive and expressive language skills both group for inclusion criteria.
45627195|NCT05553483|Other|pranayama plus acupoint stimulation by laser|"This group will receive 2-session per-week laser stimulation (for six weeks) to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for six weeks) composed from (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama )."
45768282|NCT03857230|Drug|Follitropin alfa (Gonal-F)|"During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur."
45768283|NCT02864485|Procedure|live donor liver transplantation|live donor liver transplantation
45627196|NCT05553483|Other|acupoint stimulation by laser|This group will receive 2-session per-week laser stimulation (for six weeks) to some selected acupoints. The stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2,GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
45768284|NCT05313724|Other|Mind-Body Online Therapy|There are 8 different modules (e.g. relaxation, mindfulness, stress management, disease management, nutrition and exercise behavior) with a mind-body focus available for the patients to independently (time, location) work on.
45627197|NCT05542953|Drug|[18F]APN-1607|In this study, all patients will receive one injection of [18F]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 5-7 mCi IV as a bolus injection. [18F]APN-1607 injection will be followed by a 10 ml saline flush.
45627198|NCT05553327|Behavioral|Multimodal prehabilitation|"Physical state: individualised physical status will be evaluated by a physiotherapist. A specific training program and pelvic floor exercises sessions will be led by a physiotherapist.~Nutritional state: individual nutritional status will be evaluated by a nutritionist and intervention will be done if applicable. A nutrition group session will be held.~Mental health: mindfulness group sessions led by psychologists will be held."
45627199|NCT05553249|Behavioral|Written Exposure Therapy|Virtual, group-based Written Exposure Therapy
45627200|NCT05542875|Procedure|Thrust Manipulation|Prone thoracic extension manipulation technique will be applied from T2 - T6 to participants of Group A (Experimental group). Intervention will be applied on alternate days with a total of 4 treatment sessions
45627201|NCT05542875|Procedure|Non-Thrust manipulation|Maitland grade III or IV thoracic 0manipulation will be given to participants of Control group from T1 to T6. Posterior to anterior glide over spinous process will be maintained for 30 seconds. Intervention will be applied on alternate days with a total of 4 treatment sessions
45768285|NCT02181127|Device|Glucagon-only Bionic Pancreas|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
45768286|NCT03670264|Behavioral|Quitline Incentive|The incentive structure emphasizes engaging with the quitline, with an additional smaller payment for tobacco cessation. Each adolescent can receive compensation for enrolling in the quitline, for maintaining involvement in the quitline program (compensation per call for up to 5 calls), and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative cotinine swab).
45768287|NCT03670264|Behavioral|Tobacco Cessation Incentive|The incentive payment structure emphasizes quitting regardless of engagement with the quitline (though the quitline will be presented as a helpful tool). Each adolescent will receive compensation for enrolling in the Quitline and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative cotinine swab).
45768288|NCT03670264|Behavioral|Way to Health (WTH) Platform|The WTH platform is a web-based platform that sends reminder text messages to participants regarding study procedures and has has secure financial tracking and processing systems to manage participant payments, including the ability to track earnings and pay participants via a non-integrated payment system.
45768289|NCT03670264|Behavioral|Quitline Delivered Treatment|The quitline provides tobacco cessation treatment to individuals who enroll in treatment. This treatment includes 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between proactive calls.
45768290|NCT04241146|Device|Enteric Tube|A post pyloric feeding tube used in patients requiring enteral nutrition
45768291|NCT04241146|Device|CORTRAK enteral access system|Electromagnetic guidance system for enteric feeding tube placement
45768292|NCT01166347|Device|HeartWare® VAS|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
45768293|NCT01166347|Device|Control LVAD|Any FDA-approved LVAD for destination therapy.
45768294|NCT04240678|Other|Electronic HBV Alert|Electronic HBV Alert deployed in electronic medical charts of at risk patients
45768295|NCT04332094|Drug|Tocilizumab|162 mg sc x 2 doses + tocilizumab 162mg sc x 2 doses at 12 hours (day 1)
45768296|NCT04332094|Drug|Hydroxychloroquine|400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)
45768297|NCT04332094|Drug|Azithromycin|500 mg / day v.o. for 3 days
45768298|NCT05122585|Procedure|MagSeed and MagTrace in breast cancer patiënts|Combining MagSeed and Magtracer to perform a wide local excision breast conserving surgery and sentinel node biopsy.
45768299|NCT04234672|Drug|TAK-831 Oral Tablet|TAK-831 tablet.
45768300|NCT04234672|Drug|[14C]TAK-831 IV Infusion|[14C]TAK-831 IV infusion.
45768301|NCT04234672|Drug|[14C]TAK-831 Oral Suspension|[14C]TAK-831 oral suspension.
45768302|NCT05070715|Other|Analyzing of microplastic level|Blood samples will be taken from the vein of the umbilical cord. Placental tissues will be taken from the maternal side of the placenta. Placental tissues and serum samples will be stored in the temperature set to -80 °C until analysis. Extraction methods involving chemical reactions will be used to separate and purify microplastics in placenta and cord blood samples. After the extraction process, analysis of microplastic levels in tissues and serum will be done by µ-Raman spectroscopy.
45447268|NCT02110030|Device|Interferential Currents|"The group with IC received a base frequency of 4000 Hz (Endomed 182, Enraf-nonius, Germany) with an amplitude-modulated frequency (AMF) and slope of 1/1 in tetrapolar mode, as previously indicated. For IC, the same number and type of surface electrodes (5x5 cm Prim-Trode, Spain) were placed onto the anterior and posterior deltoid, supraspinatus fossa and V deltoid. Similarly, the intensity of the current was set 3 times per session and the stimulation was strong but comfortable (without exceeding the threshold of pain)."
45627202|NCT05542875|Procedure|Standard Treatment|"Standard treatment protocol includes moist heat, TENS and Post isometric relaxation technique. Standard treatment will be given to both groups on every session. Standard treatment consists of:~Superficial Moist Heat (Device): Superficial moist heat will me applied for 10 minutes on Upper Trapezius TENS (Device): TENS will be applied for 10 minutes at 80-100Hz, the electrodes will be placed at upper trapezius.~Post-isometric Relaxation (procedure/surgery): 5-10 repetions of Post Isometric relaxation technique will be applied on various muscle groups which include Upper trapezius, levator scapulae, sternocleidomastoid and scalenes."
45627203|NCT05700123|Procedure|In-Office Hysteroscopy|In-office hysteroscopic procedures were conducted using a 5mm continuous flow Office Hysteroscope using a vaginoscopic, no-touch, approach
45627204|NCT05542797|Drug|Duphastone|dydrogesterone hormone
45627205|NCT02147158|Drug|Ulipristal acetate (UPA)|Ulipristal acetate (UPA) tablet.
45627206|NCT02147158|Drug|Placebo|Matching placebo tablet.
45627207|NCT05553093|Drug|Tirzepatide|Tirzepatide ih qw
45627208|NCT05553093|Drug|Insulin Glargine|6 IU ih qd
45627209|NCT05542719|Other|application|"Through the application, determine if the patient is out of LDL-C goals for referral and treatment review.~Show the usefulness of the application in achieving dyslipidemia treatment goals in patients with high and extremely high cardiovascular risk"
45627210|NCT04757740|Biological|intra-articular Platelet rich fibrin and lidocaine|intra-articular injection of 3.5 ml of 1% lidocaine and PRF mixture.
45627211|NCT04757740|Drug|methylprednisolone acetate and lidocaine|intra-articular injection of Mixture of 40 mg of methylprednisolone acetate(1 ml) and 1% lidocaine (2.5 ml). intra-articular steroid
45627212|NCT05552937|Drug|Tafasitamab and Lenalidomide|"Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.~Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles."
45627213|NCT02112448|Drug|continuous infusion|Continuous morphine/midazolam and 'as needed' doses. Will receive scheduled acetaminophen and ketorolac.
45768303|NCT02752243|Drug|CIK-Cells|IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.
45768304|NCT03676270|Other|Phase I|Chemotherapy, ITK, Hormotherapy, Immunotherapy
45768305|NCT02980081|Other|abdominal plain x-ray|Abdominal plain x-ray as prescribed by the emergency physician
45768306|NCT05314270|Diagnostic Test|Diagnostic tests|Diaagnostic tests for all pt diagnosed as Non-B Non-C Liver Cirrhosis
45627214|NCT02112448|Drug|as needed dosing|morphine and midazolam as needed. Will receive scheduled acetaminophen and ketorolac..
45627215|NCT02112448|Drug|Acetaminophen|Acetaminophen will be given every 4 hours for a total of 24 hours.
45627216|NCT02112448|Drug|ketorolac|Ketorolac 0.5 mg/kg will be given every six hours to all subjects in the study.
45627217|NCT02171260|Drug|Eribulin Mesylate|Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle.
45768307|NCT03676972|Device|LithoVue Ureteroscope System|The LithoVue System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes.
45627218|NCT02110732|Dietary Supplement|Lactobacillus rhamnosus GG|
45768308|NCT02335957|Radiation|Irradiation|Intentional versus incidental irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
45627219|NCT02109562|Drug|RBP-7000|RBP-7000 90 mg and 120 mg were a mixture of the ATRIGEL Delivery System and 90 mg and 120 mg risperidone, respectively. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner. Subcutaneous RBP-7000 injections on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
45768309|NCT03681808|Device|Control|Contact Lens
45768310|NCT03681808|Device|Test|Soft Contact Lens
45768311|NCT01166971|Device|ReSTOR +3|Bilateral implantation of ReSTOR +3 Intraocular Lenses (IOLs) after cataract extraction
45768312|NCT01166971|Device|Tecnis MF|Bilateral implantation of Tecnis Multifocal (MF) Intraocular Lenses (IOLs) after cataract extraction
46069829|NCT03749837|Device|Video Endoscope|Fiberoptic video endoscopic devices are standard aids to facilitate intubation on all study sites and are used according to the instructions to use. To facilitate fiberoptic intubation a macintosh blade to raise the root of tongue will be used. Also with these devices the study participants need at least 5 trials to intubate a manikin (or more to feel confident) before they are going to use the study device in patients.
45627220|NCT02109562|Drug|Placebo|Subcutaneous injection of placebo using the ATRIGEL Delivery System on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
45627221|NCT02109562|Drug|Risperidone|Oral risperidone 0.25 mg tablets daily for the first two days of the screening period. The two 0.25 mg tablets confirmed whether study participants had any negative reaction to risperidone prior to receiving a long-acting injection of risperidone (RBP-7000).
45627222|NCT02109484|Biological|P2-VP8 Subunit Vaccine 10mcg|10 mcg
45627223|NCT02109484|Biological|P2-VP8 Subunit Vaccine 30 mcg|30 mcg
45627224|NCT02109484|Biological|P2-VP8 Subunit Vaccine 60mcg|60 mcg
45447269|NCT05572034|Procedure|Ganglionated Plexi ablation|"Electrophysiological study: patients in a fasting state and under total intravenous anesthesia Intracardiacelectrogramsare displayed simultaneously on a multichannel recorder. Programmed atrial and ventricular stimulation are performed to rule out sustained arrhythmias, primary conduction system dysfunction, and sick sinus syndrome.~GP Mapping and Cardiac denervation: Specific atrium sites are empirically identified as GP by presumed anatomic location based on previous works17-19 (anatomic mapping):~1. In the LA: 1, the inferior right; 2, the anterior right GP ; 2. In the RA: 5, the posterior aspect of the interatrial septum, between the posterior wall and coronary sinus ostium; and 6, the septal aspect of the superior vena cava junction (opposite to the LA GP tags).~A 3.5-mm irrigated tip catheter will be used to deliver radiofrequency energy (50°C, 20-30 W, for 30-60 seconds) with a 17 mL/min irrigation flow."
45627225|NCT02109484|Other|Placebo|
45627226|NCT05134792|Drug|intravenous immunoglobulin|All pediatric burn patients allocated in group intra venous immunoglobulin admitted will receive 200 mg/kg IVIG once after their initial resuscitation before 48 hours passes of burn incident.
45627227|NCT04738318|Drug|Glucocorticoids|Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone intraoperatively. Following surgery, the participant will be provided with a six-day oral methylprednisolone taper course.
45768313|NCT04208698|Drug|CIN-102 Dose 1|Deuterated domperidone (deudomperidone)
45768314|NCT04208698|Drug|CIN-102 Dose 2|Deuterated domperidone (deudomperidone)
45768315|NCT04208698|Drug|Placebo for CIN-102|Placebo
45627228|NCT04738318|Drug|Saline|Patients will receive a single intraoperative dose of 10 mg of saline. Following surgery, the participant will be provided with a six-day placebo course.
45768316|NCT01167595|Other|PEP uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) will be made available to all nurses, in bedside manuals and/or on the local intranet.
45768317|NCT03835078|Device|methafilcon A contact lenses|Bilateral daily wear of methafilcon A contact lenses
45768318|NCT03835078|Device|fanfilcon A contact lenses|Bilateral daily wear of fanfilcon A contact lenses
45768319|NCT02184169|Device|General Electric Healthcare E-COVX Gas Monitoring Module for VO2 Measurments|Breath to breath VO2 measurements
45768320|NCT02184169|Device|Edwards Continuous SVO2 Catheter and Monitoring System - 4.5 fr|Edwards continuous SVO2 measurement system
45768321|NCT03681886|Device|Harmoni Modular Intraocular Lens|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag.
45768322|NCT03681886|Procedure|Optic Exchange|Removal of one optic and replacement with another for the purpose of improving refractive outcomes
45768323|NCT01167829|Drug|Oral Testosterone|Oral Testosterone: 300 mg, pills, three times daily Day 1 - 10 (total of 27 pills)
45627229|NCT05177692|Device|Vguard|VGuard is a system that has been created to ensure that the patients´ ventricular drainage system and pressure monitor closely follows the patient when the head is adjusted vertically. The system consists of a pressure sensor that is connected to the patients´ head. The pressure sensor is connected to a motorized column that automatically adjusts to keep the zero level at level with the patients´ head at all times.
45627230|NCT04737850|Drug|Hetrombopag|Thrombopoietin receptor agonist
45768324|NCT01167829|Drug|Acyline|300 ug/kg injection on Day 0
45627231|NCT04737850|Drug|Placebo|Placebo with no active pharmaceutical ingredient
45627232|NCT04751656|Behavioral|Steady Intervention|"Participants will be asked to weigh themselves daily via a smart scale that transmits weight data directly to the study team via the cellular network for 12 months. Every-other week, participants will be sent text messages providing brief feedback encouraging continued self-weighing. Moreover, if a small weight gain is observed, participants will be sent text messages aiming to engage them in commercial or community-based evidence-based weight management resources."
45627233|NCT02105974|Drug|Fluticasone Furoate/Vilanterol|100 mcg FF micronized drug blended with lactose per blister in one strip and 25 mcg VI micronized drug blended with lactose and magnesium stearate per blister in another strip, administered together by ELLIPTA™ inhaler
45627234|NCT02105974|Drug|Vilanterol|25 mcg of Vilanterol micronized drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister in one strip and lactose in another strip, administered together by ELLIPTA™ inhaler
45627235|NCT02105662|Drug|Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets|MK-5172A FDC tablet: MK-5172 (100 mg)/MK-8742 (50 mg)
45627236|NCT02143024|Behavioral|Family-based depression intervention|The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.
45768325|NCT03820258|Drug|SOF/VEL/VOX|Administered once daily with food.
45768326|NCT02066623|Device|ABSORB Scaffold|Implantation of a drug-eluting vascular scaffold, which is completely resorbable to improve the blood flow in coronary arteries in the presence of stenosis
45768327|NCT04974151|Drug|Amlodipine besylate tablets|The amlodipine used in this study is a listed product. All drugs used in the Randomized Treatment Period of this study will be packed into bottles with the same outer appearance and corresponding labels of the clinical trial (100 tablets/bottle).
45768328|NCT04974151|Drug|Amlodipine besylate And Folic Acid Tablets|The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020. All drugs used in the Randomized Treatment Period of this study will be packed into bottles with the same outer appearance and corresponding labels of the clinical trial (100 tablets/bottle).
45768329|NCT04974151|Drug|5-methyltetrahydrofolate (5-MTHF)|The 5-MTHF used in this study is a listed product. All drugs used in the Randomized Treatment Period of this study will be packed into bottles with the same outer appearance and corresponding labels of the clinical trial (0.2mg/tablet, 200 tablets/bottle).
45768330|NCT04195594|Other|Nic's Keto Diet|Participants will be instructed to follow Nic's keto diet plan for 140 days. They will be asked to not exceed 20 g of carbohydrates (up to 5% caloric intake) and to consume the remaining 70% of calories from fat sources and 25% from protein sources.
45768331|NCT04918693|Device|Ultrasound scanning|All participants will scan with and without device and trainee on 4 models. The order of the device assistance and models will be randomized between participants, but participant will always have exposure to device first before supervising the trainee.
45768332|NCT01924819|Drug|Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel|"Epirubicin 50 mg/m2 IV day 1, cisplatin 60 mg/m2 IV day 1, 5-fluorouracil 200 mg/m2/d IV 21 day continuous infusion (ECF chemotherapy).~Epirubicin 50 mg/m2 IV day 1, Cisplatin 60 mg/m2 IV day 1, Capecitabine (X = Xeloda) 625mg/m2, bid days 1-21 (ECX chemotherapy)~Epirubicin 50mg/m2 IV day 1, Oxaliplatin (O) 130mg/m2 IV day 1, Capecitabine 625mg/m2, bid days 1-21 (EOX chemotherapy)~5-Fluorouracil 2600 mg/m² IV 24 h infusion day 1, Leucovorin (L) 200 mg/m² IV day 1, Oxaliplatin 85 mg/m² IV day 1, Docetaxel (T) 50 mg/m² IV day 1 (FLOT chemotherapy)"
45627237|NCT02143024|Behavioral|Usual care plus educational materials|Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.
45768333|NCT01924819|Radiation|Preoperative chemoradiotherapy|"Chemotherapy: Continuous infusional 5-fluorouracil 200mg/m2/day, 7 days per week, throughout the entire period of radiotherapy or capecitabine 825 mg/m2, oral tablet twice daily, days 1-5 of each week of radiotherapy (without weekends).~Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks."
45627238|NCT02142712|Drug|Diphenhydramine|Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
45627239|NCT02142712|Drug|Pantoprazole|Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
45627240|NCT02142712|Drug|Famotidine|Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
45768334|NCT01924819|Procedure|Gastric resection|The acceptable resections are a total gastrectomy, a subtotal gastrectomy, and an esophagogastrectomy (Ivor-Lewis esophagogastrectomy for gastroesophageal junction cancers [Siewert Type II and Siewert Type III] invading up to but no more than 2cm of the lower esophagus). The minimum extent of the operation should be a D1+ lymph node dissection but it is recommended that a D2 dissection be performed or a D1+ for gastroesophageal junction cancers requiring an esophagogastrectomy.
45627241|NCT02142712|Drug|Dextromethorphan|Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care. If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration.
45627242|NCT02105272|Drug|OPC-1085EL ophthalmic solution|
45627243|NCT02105272|Drug|Latanoprost ophthalmic solution|
45627244|NCT02141854|Drug|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either fluticasone propionate/salmeterol MDPI 200/12.5 mcg or fluticasone propionate/salmeterol MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
45627245|NCT02141854|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 200 mcg or 100 mcg of Fp one inhalation twice a day for a total daily dose of 400 mcg or 200 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
45627246|NCT02141854|Drug|Placebo MDPI|The placebo multidose dry powder inhaler (MDPI) was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart). Patients were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
45627247|NCT02141854|Drug|Albuterol/salmeterol HFA MDI|Albuterol/salmeterol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
45913006|NCT02017262|Behavioral|Enhanced usual care|Usual care by primary care provider, plus educational pamphlet about depression, list of local mental health resources, and letter for provider advising him/her of depression diagnosis
45627248|NCT02587221|Biological|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)|1 dose approximately 0.5 mL of aQIV
45627249|NCT02587221|Biological|Non-Influenza Comparator (Boostrix)|1 dose approximately 0.5 mL dose of Non-influenza comparator vaccine (Boostrix)
45627250|NCT02141620|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and n-acetylcysteine.
45627251|NCT02141620|Drug|n-Acetylcysteine|
45627252|NCT02141620|Drug|Placebo|
45627253|NCT02106910|Device|Cytosponge|The Cytosponge is a simple, non-endoscopic device developed for endoscopic screening of subjects at risk for Barrett's esophagus (BE) by investigators at the University of Cambridge in the U.K. The Cytosponge is an ingestible gelatin capsule enclosing a compressed spherical polyurethane mesh sponge of 3 cm diameter, the center of which is attached to a string (Astralen, braided synthetic non-absorbable suture) (Figure 1). The capsule and string are swallowed with water. The string is held at the mouth without tension by means of a 7 cm cardboard tab attached to the string, and esophageal peristalsis and gravity move the capsule into the stomach. After 5 to 7 minutes (during which the gelatin capsule dissolves and the sponge is liberated), the sponge is withdrawn by gentle traction on the string and as it does so, collects cells from the lining of the esophagus. The sponge is placed in fixative for 48 hours, then the cells are pelleted, and processed into paraffin blocks
45627254|NCT05698953|Other|Reiki|Reiki is applied to the Reiki group for 20-30 minutes for three consecutive days.
45627255|NCT05698953|Other|Placebo|Placebo group is applied to the sham Reiki group for 20-30 minutes for three consecutive days by an independent nurse during the same application period.
45627256|NCT01664949|Drug|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.
45627257|NCT01664949|Drug|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days.
45627258|NCT05542485|Diagnostic Test|ctDNA liquid biopsy - Roche Avenio Assay|The intervention will involve plasma ctDNA testing for patients with a radiological suspicion for newly diagnosed advanced NSCLC
45627259|NCT05548101|Procedure|ICSI|Using the injecting pipet, one sperm will be isolated. Using the tip of the injecting pipet, the sperm tail will be broken by trapping it between the pipet and bottom of the dish. The sperm will be picked up in the pipet. The oocyte will be positioned so the polar body is at the 12 o'clock or 6 o'clock position. The sperm injecting pipet will be positioned at the 3 o'clock position of the oocyte. The injecting pipet will be advanced into the oocyte cytoplasm and the cytoplasm will be gently aspirated until the oocyte membrane breaks. The sperm will then be injected into the cytoplasm of the oocyte. The pipet will then be withdrawn from the oocyte.
45627260|NCT02587143|Drug|Ethyl chloride|Nurses will administrate ethyl chloride vapocoolant spray on patient's skin a few seconds before arterial puncture (of cubital arteria).
45768335|NCT01168687|Drug|Levetiracetam (Keppra)|"Group A: Twenty moderate to heavy social alcohol users will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.~Group B: Twenty moderate to heavy social alcohol users will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days."
45768336|NCT01168687|Drug|Placebo|
45627261|NCT02587143|Drug|Alcohol|Nurses will use an alcohol-based spray as placebo on patient's skin a few seconds before arterial puncture (of cubital arteria).
45627262|NCT02587065|Drug|peginterferon beta-1a|125 mcg administered subcutaneously (SC) every 2 weeks.
45627263|NCT05552781|Drug|H002 capsule|Small molecule, Capsule
45627264|NCT05548023|Drug|TQJ230|TQJ230 80 mg SC Q4W in pre-filled syringe
45627265|NCT05548023|Drug|Placebo|Corresponding Placebo SC Q4W in pre-filled syringe
45627266|NCT02106832|Drug|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin dry powder for inhalation (DPI) 32.5 mg inhaled twice daily in cycles of 28 days on-treatment and 28 days off-treatment.
45627267|NCT02106832|Drug|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin DPI 32.5 mg inhaled twice daily in cycles of 14 days on-treatment and 14 days off-treatment.
45627268|NCT02106832|Drug|Placebo|Matching placebo inhaled twice daily intermittently for 28 days on / 28 days off
45627269|NCT02106832|Drug|Placebo|Matching placebo inhaled twice daily intermittently for 14 days on / 14 days off
45768337|NCT03685396|Biological|Platelet rich fibrin ( PRF)|"Venous blood was collected with a butterfly needle in two 10 mL tubes without anticoagulants or other chemicals. The tubes were immediately centrifuged at 3000 rpm for 10 minutes.~At the end of centrifugation a fibrin clot (PRF) was obtained in the middle of the tube, just between the red corpuscles at the bottom and acellular plasma at the top. The PRF clot was taken from the tube and the red cells portion at the base of the clot was eliminated with sterile scissors Then the PRF was enveloped in sterile gauzes and positioned between two glass plates: the compression drove out the serum from the clot obtaining PRF membranes that were ready to be used in the surgical site."
45627270|NCT05542329|Device|Monitoring by Tele-Medecine|Monitoring by Tele-Medecine
45627271|NCT05547945|Behavioral|Health Promotion Program|The health promotion program included knowledge guidance on ADHD disease, physical activity, diet nutrition, parental training/stress adjustment, related social welfare resources, mindfulness relaxation, and yoga.
45627272|NCT05547945|Behavioral|Control group|The control group received as usual care.
45768338|NCT03685396|Drug|hemostatic agents with oxidized and regenerated cellulosa|In the Control Group hemostatic agents with oxidized and regenerated cellulosa were sutured to the palatal wound with mattress suture ( silk 5/0).
45913007|NCT02017275|Device|BuMA|This group will contain 1175 subjects.
45913008|NCT02017275|Device|EXCEL|This group will contain 1175 subjects.
45913009|NCT02017301|Other|Nutritional assessment|Daily nutritional assessment with bioelectrical impedance vector analysis, phase angle and mid-arm muscle circumference
45913010|NCT02017314|Drug|Morphine|
45913011|NCT02017340|Drug|Nilvadipine|8mg of Nilvadipine taken once a day at lunch time for 78 weeks
45913012|NCT02017340|Drug|Placebo|8mg Placebo tablet taken once a day at lunch time for 78 weeks
45913013|NCT02017353|Dietary Supplement|Curcuphyt|
45627273|NCT05552703|Procedure|surgical evacuation of extradural hematoma|evacuation of extradural hematoma by craniotomy
45627274|NCT05698797|Other|Hip strengthening exercises|Hip abductor and external rotator strengthening exercises were performed for 4 weeks.
45627275|NCT05698797|Other|Proprioceptive training|Proprioceptive training consisted of eight exercises was performed for 4 weeks.
45627276|NCT05698797|Other|Conventional physical therapy|Conventional physical therapy included interferential therapy and two types of knee-strengthening exercises.
45627277|NCT05552625|Drug|TADIOS|TADIOS is a combination extract which composed of three herbs, and each herbal medicine has been traditionally used as a food or a herbal medicine treating various respiratory diseases in Asia
45627278|NCT05552625|Drug|Placebo|Combination of the following Lactose hydrate, Microcrystalline cellulose, Colloidal silicone dioxide, Povidone, Croscarmellose sodium, Magnesium stearate, Tabshield(79O245)
45627279|NCT05552391|Drug|Bupivacaine|Group bupivacaine(Control) (B) received 0.5 ml/kg bupivacaine 0.25% diluted with isotonic saline (total volume15 ml).
45768339|NCT01653535|Behavioral|Fast Track|First grade intervention included a weekly two-hour curriculum-based day that was attended by high-risk children, parents, program staff, and teachers of the high-risk children. During each session, the staff modeled academic tutoring with target children in the presence of their parents. In 3rd and 4th grades, intervention consisted of monthly parent and child curriculum-based sessions during the academic year, home visiting, and teachers implementing the in-class PATHS prevention program. In 5th and 6th grades, intervention included monthly parent and child groups and home visiting. In grades 8, 9 and 10 staff developed sessions on an as needed basis to cover topics like transition to high school, note-taking, and study skills.
45768340|NCT04214080|Other|Neurodevelopmental treatment (NDT)|NDT is a holistic and interdisciplinary clinical practice model informed by current and evolving research that emphasizes individualized therapeutic handling based on movement analysis for habilitation and rehabilitation of individuals with neurological pathophysiology.
45627280|NCT05552391|Drug|Ketamine Hydrochloride|Group bupivacaine - ketamine (K) received 0.5 ml/kg bupivacaine 0.25% with ketamine 2 mg/kg, diluted with isotonic saline (total volume15 ml).
45627281|NCT05552391|Drug|Dexmedetomidine Hydrochloride|Group bupivacaine - Dexametomedine (D) received 0.5 mL/kg bupivacaine 0.25% with dexmedetomidine 1 µg/kg. diluted with isotonic saline (total volume 15ml).
45627282|NCT02106442|Drug|Sodium risedronate|Sodium risedronate tablets
45627283|NCT05552313|Procedure|kinesio tape|kinesio tape will be applied while patient is in sitting position. Y strip will be applied along C1 till T1.while patient's cervical spine is in contalateral side bending and rotation. same will be performed on the other side. on top of it, an I strip will be applied horizontly along C1 to C4. Both strips will be applied with 15% to 20% stretch.
45768341|NCT04214080|Other|Feeding and oral-motor intervention strategies|Feeding and oral-motor intervention strategies have been developed to address difficulties with sucking, chewing, swallowing, and improve oral-motor skills.
45627284|NCT05552313|Procedure|standard therapy|Thoracic manipulation along with conventional including Tens, stretching and strengthening exercises of entire neck musculature
45627285|NCT04740814|Drug|Certolizumab pegol|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous Subjects will receive certolizumab pegol in a pre-specified sequence during the study."
45627286|NCT05552079|Other|No intervention|Patients will be asked to show their consultation slip to confirm they attend to clinic on the day. The will also be asked to show their HKID card to comfirm they are aged 40 or above. The purpose of the study will be explained. If patient agrees to proceed, he/she will be given a self-administered questionniare. An interviewer-administered questionnaire will be provided for subjects who have poor sightedness or are illiterate. Since only anonymous data and no identifiable information will be collected, participants cannot be identified from the questionnaire. Therefore, inform consent will not be obtained.
45627287|NCT05551923|Other|intestinal flora disturbance|To observe the clinical prognosis of acute cerebral hemorrhage after enterobacterial disorder
45627288|NCT02105116|Drug|fludarabine phosphate|Given IV
45627289|NCT02105116|Drug|cytarabine|Given IV
45627290|NCT02105116|Biological|donor lymphocytes|Undergo infusion of donor lymphocytes
45627291|NCT02105116|Other|laboratory biomarker analysis|Correlative studies
45627292|NCT02105116|Drug|G-CSF|Given IV
45627293|NCT05551767|Drug|Pembrolizumab|3 cycles of induction immunochemotherapy with platinum (cisplatin 75 mg\m2, 5-FU 1000 mg/m2/day 96-hour infusion and pembrolizumab 200 mg)
45627294|NCT05551689|Drug|Psychostimulant|All enrolled patients should be receiving ADHD pharmacological treatment (psychostimulants)
45627295|NCT05551689|Device|FOCUS ADHD App|FOCUS ADHD is a mobile health application to support ADHD treatment adherence, monitoring and psychoeducation. The App was developed by the Attention Deficit Hyperactivity Disorder Program (ProDAH) of the Hospital de Clínicas de Porto Alegre (HCPA) and the Federal University of Rio Grande do Sul (UFRGS)
45627296|NCT05547789|Drug|non steroidal anti inflammatory drugs|effect of non steroidal anti inflammatory drugs on macular changes
45627297|NCT05700357|Procedure|TPVB with 20 ml|The thoracic paravertebral block will be applied to the patients with 20 ml of 0.25% bupivacaine under real-time ultrasound guidance.
45627298|NCT05700357|Procedure|TPVB with 25 ml|The thoracic paravertebral block will be applied to the patients with 25 ml of 0.25% bupivacaine under real-time ultrasound guidance.
45627299|NCT05700357|Procedure|TPVB with 30 ml|The thoracic paravertebral block will be applied to the patients with 30 ml of 0.25% bupivacaine under real-time ultrasound guidance.
46069830|NCT02617641|Behavioral|TAVIEenM@RCHE|The intervention goal is to increase up to 150 minutes per week of moderate-intensity physical activity through walking. The intervention is underpinned by Strengths-Based Nursing Care that specifies nursing values, and by Self-Determination Theory that specifies variables to tailor the intervention. The four intervention strategies are: 1) Providing information and feedback, 2) Exploring reasons to build motivation, 3) Exploring strengths to build confidence (self-efficacy), and 4) Developing an action plan to maintain motivation and confidence (self-efficacy). The TAVIE system platform is designed to provide a fully automated, easy to navigate website, and the main mode of delivery is video clips of a 'virtual nurse' who presents the tailored intervention content.
45627300|NCT05542251|Behavioral|Parent Educational Program|The intervention is a series of 9 educational modules delivered via social media that will teach participants: 1) principles of infant learning, 2) principles of infant motor learning, and 3) principles of positive parenting.
45627301|NCT05551455|Other|Nutritional/dietary intake manipulation ('Normal')|Energy Intake provision (60 kcal/kg FFM/day) to elicit 'normal' energy availability (45 kcal/kg FFM/day), with 60% from carbohydrates.
45627302|NCT05551455|Other|Nutritional/dietary intake manipulation ('Low')|Energy Intake provision (60 kcal/kg FFM/day), with 1.5 g/kg of carbohydrate and 70-80% fat intake, to elicit 'low' carbohydrate availability in energy balance (45 kcal/kg FFM/day).
45627303|NCT05547711|Diagnostic Test|drawing blood|drawing blood annually measurement of heartrate variability annually determine weight with a bioimpedance scale
45627304|NCT05542173|Drug|BALI association|BALI association oral suspension, 25 mg + 25 mg + 15 mg, oral. Three applications per day or more in case of pain, not exceeding six applications per day.
45627305|NCT05542173|Drug|Placebo|Placebo. Three applications per day or more in case of pain, not exceeding six applications per day.
45627306|NCT05547555|Diagnostic Test|embryo selection|The basis of embryo selection for transfer: invasive PGT-A or after non-invasive PGT-A
45627307|NCT04324437|Other|eRAPID online symptom monitoring in lung cancer|The eRAPID in lung cancer intervention is an online symptom monitoring system which provides tailored advice depending on the severity of symptoms reported. The system is integrated into the electronic medical record and results can be viewed by the medical team.
45627308|NCT05542095|Drug|Simvastatin|Compounded simvastatin that is suspended within a nasal saline irrigation will be utilized throughout this study. Participants will suspend the contents of the simvastatin capsules (0.1mg, 0.25 mg, 0.5 mg, and 1 mg) into the sinus rinse bottle containing nasal saline. All participants will receive an 8-ounce sinus rinse bottle and a 4-week supply of USP Grade Sodium Chloride & Sodium Bicarbonate Mixture (pH balanced, Isotonic & Preservative & Iodine Free) commercially prepared packets. Participants will either need to purchase distilled water or boil tap water for five minutes for use with the saline irrigation.
45627309|NCT05542017|Procedure|Surgical Ablation for Atrial Fibrillation|Surgical ablation in combination with other cardiac procedures through a median sternotomy or thoracotomy. Main procedures were valve surgery (i.e. repair, replacement) and/or coronary artery bypass grafting (CABG). Surgical ablation procedures for atrial fibrillation were divided into three different groups according to Heart Rhythm Society (HRS) expert consensus 2017: (1) Pulmonary vein isolation alone; (2) Pulmonary vein isolation combined with left atrial lesion sets; (3) and biatrial procedure.
45627310|NCT05551221|Drug|Silodosin Capsules|Silodosin is a α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieves the dynamic obstruction of bladder outlet, and improves the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule，1 capsule/time, bid, after breakfast and dinner.
45627311|NCT05551221|Drug|Ningmitai capsule|Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
45627312|NCT05551221|Drug|Tamsulosin|Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
45627313|NCT05551143|Other|LiftKit|"The LiftKit contains 7 tools that could assist EMS providers when lifting/moving patients. These tools are:~Simple Strap - A sling to lift a seated patient~Strap and slide stick - A strap system for raising a supine patient to a sitting posture.~Slip Preventer- An envelope that goes over the patients feet with high friction straps for the EMS providers to stand on that prevent the patient from sliding forward when lifted.~Drag Straps - straps with handles that can be clipped on tarps used to drag patients~The Binder Lift - a vest with handles that allow EMS providers to easily get hold of patient they need to lift.~Patient Turning Straps - a way to log-roll a patient that in on the floor while in a standing posture.~The ELK - an inflatable seat cushion that can raise a patient who in the floor to chair level"
45627314|NCT05551065|Device|Point-of-care ultrasound (POCUS)|Point-of-care ultrasound (POCUS) using a hand-held ultrasound (Vscan, GE Healthcare)
45627315|NCT02104804|Drug|Saxagliptin 5mg|Saxagliptin 5mg (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
45768342|NCT04214080|Other|Neck and trunk stabilization exercises|Trunk control affects head control. After gaining head control, it causes jaw stability and oral motor control (tongue control and lip closure). All of these affect communication and quality of life.
45768343|NCT01169311|Device|Hemorrhoidopexy|
45768344|NCT03688282|Device|Wearable vibration belt|The device is worn, a wearable vibration belt, for a specified time. This will provide vibration starting at the hips.
45768345|NCT03688282|Device|Sham, wearing belt|The device is worn, for a specified time. It will not be turned on during this period. It is only sham.
45447270|NCT04688684|Behavioral|Family-based diet and exercise intervention|The participants will meet together weekly as a family unit to receive education and planning to implement diet and lifestyle changes under the supervision of a health coach. This coach will also be available during the week by telephone or messaging for additional individualized support if needed.
45447271|NCT02789176|Other|Surveys|Regarding development, epilepsy, and family impact
45447272|NCT02789176|Other|EEG|
45452460|NCT03175562|Other|Facial micellar cleanser|Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
45627316|NCT02104804|Drug|Placebo for Saxagliptin|Placebo tablets (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
45627317|NCT05541783|Procedure|laparoscopy-assisted distal gastrectomy Group|LADG
45627318|NCT05541783|Procedure|Totally laparoscopic distal gastrectomy|TLDG
45627319|NCT05547009|Other|Blended-learning group|The BL program included paced, asynchronous online learning modules and scheduled online activities with strategic face-to-face lectures. Resources: 1) Moodle platform: it was used as a virtual communication platform. 2) Online syllabus: an online specific syllabus about cardiac physiotherapy was developed. 3) Online glossary: an online glossary performed by the teacher was available for the students. 4) Online videos: several videos of international and national scientific societies were provided. 5) Websites: several links to websites of international and national scientific societies such as the European Society of Cardiology, the American Heart Association or the World Heart Federation were used. 6) Online activities: five four-question online activities were created. 7) Apps, using the app Ariadna to prevent from cardiovascular risk and look for defibrillators around; 8) Online tutorship, through an online communication platform (Blackboard Collaborate).
45768346|NCT01126255|Drug|Clobetasol propionate 0.05%|Topical application, once daily about 2 g, during 12 weeks
45627320|NCT05547009|Other|Face-to-face learning group|The FLG included: 1) Face-to-face classes; 2) Hardcopy syllabus; 3) Hardcopy scien-tific societies information; 4) Face-to-face activities: four questions per each theme; 5) Hardcopy glossary; and 6) Face-to-face tutorships. In all cases, the content of the infor-mation provided was the same as the information provided to the BLG, although in a face-to-face design.
45627321|NCT02075008|Drug|QGE031|QGE031 120 mg/mL solution for subcutaneous injection
45627322|NCT05550675|Other|Questionnaires|Disease specific questionnaires
45627323|NCT05541549|Biological|CE-VST01-JC|CE-VST01-JC at a dose of 1 × 10^8 cells administered as an intravenous (IV) infusion every 28 days for 4 total infusions
45627324|NCT05550441|Drug|Dapagliflozin|The experimental group received dapagliflozin (10 mg qd) for 1 year.
45627325|NCT05550441|Drug|Placebo|The Placebo group received placebo for 1 year.
45627326|NCT05550363|Drug|Dexycu|103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
45627327|NCT05550363|Other|Placebo/Vehicle|Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
45627328|NCT05550285|Device|orbital floor recontriction|Guided Calvarial Graft Harvesting vs 3D Printed Titanium mesh
45627329|NCT05550207|Drug|AXS-07 (meloxicam-rizatriptan)|AXS-07 tablets, taken orally for the acute treatment of migraine
45768347|NCT01126255|Drug|Progesterone 8%|Topical application, once daily about 2 g, during 12 weeks
45768348|NCT04198948|Drug|Omeprazole|Omeprazole (20 mg) will be administered orally once daily for 5 days in one of the two treatment periods.
45627330|NCT04321941|Diagnostic Test|Lumentin|Contrast agent used in combination with CTE
45627331|NCT04321941|Diagnostic Test|Movprep|Contrast agent used in combination with MRE
45768349|NCT04198948|Drug|Placebo oral tablet|Placebo will be administered orally once daily for 5 days in one of the two treatment periods.
45768350|NCT04198948|Drug|Gliclazide|Gliclazide (40 mg) will be administered orally once, concomitantly with omeprazole or placebo on day 5.
45768351|NCT01169467|Drug|Standard-of-Care plus Dexmedetomidine|Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment
45768352|NCT01169467|Other|Standard-of-Care|Subjects who are treated with the standard of care sedation regiment only.
45768353|NCT04186780|Other|Shiitake cereal bar|patients with borderline cholesterol exposed to bars with Shiitake
45768354|NCT04822363|Drug|Aspirin|Low dose aspirin in Arms A and D and High Dose Aspirin in Arm B
45452461|NCT03175562|Other|Saline Solution: Sodium Chloride (NaCl; 0.9%)|Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
45627332|NCT05546931|Behavioral|Coaching application|A digital application for providing education and support for home-based blood pressure monitoring.
45627333|NCT05546931|Other|WebMD|Smartphone-based application for health education and/or monitoring.
45768355|NCT04822363|Drug|Clopidogrel|Arms C and E
45627334|NCT05546931|Behavioral|Home-based blood pressure monitoring|Device for measuring blood pressure at home with blue tooth connectivity for automated collection.
45768356|NCT01170247|Drug|Ketamine|Intranasal Ketamine (100 mg/mL)
45768357|NCT01170247|Drug|Ketamine|Intramuscular Ketamine
45768358|NCT04765423|Device|[F-18] NaF PET/CT|Radiotracer F-18 NaF used on the PET/CT imaging
45768359|NCT04765423|Device|[F-18] fluciclovine PET/CT|F-18 fluciclovine (Axumin ®) used on the PET/CT camera
45768360|NCT03700372|Device|IOWA Approach Cardiac Ablation System|Epicardial ablation using the IOWA Approach Cardiac Ablation System
45768361|NCT04352257|Radiation|pelvic Ultrasound|pelvic and transrectal ultrasound
45768362|NCT04182958|Drug|(14C)-OPC-61815|On the morning of Day 1, all subjects will receive a single IV infusion of (14C) OPC-61815
45768363|NCT01126099|Drug|Prazosin|4 mg capsules twice daily for 12 weeks
45768364|NCT01126099|Drug|Placebo|Placebo capsules twice daily for 12 weeks
45768365|NCT04176406|Device|rTMS|excitatory 5Hz rTMS will be used
45768366|NCT04176406|Device|Sham rTMS|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
45768367|NCT04171102|Device|ProFlor Hernia implant|Inguinal hernia repair
45768368|NCT01126723|Other|Tai Chi|The Tai Chi intervention will consist of a 12 week, instructor-led, group-based Tai Chi training program (two, one-hour sessions per week).
45768369|NCT01126723|Other|Education-Control|The Education-Control intervention consists of a 12 week, instructor-led attention control program consisting of health education and mind-body breathing exercises (two, one-hour sessions per week)
45768370|NCT03807544|Device|TENS|Transcutaneous electrical nerve stimulation
45768371|NCT01170715|Drug|Etanercept|self-administered for 52 weeks
45768372|NCT03809182|Drug|Dexmedetomidine|A bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/h until the end of surgery.
45768373|NCT03809182|Drug|0.9% Sodium-chloride|The same infusion rate used in the dexmedetomidine group.
45627335|NCT05540925|Procedure|Liver resection|"All patients underwent curative-intent resection for early-stage HCC (a solitary tumor nodule≤5 cm, or multiple nodules≤3, each≤3 cm).~We did not take any other intervention. We retrospectively analyzed the prognostic performance of patients with wide (≥1cm) or narrow (<1cm) resection margin in different groups."
45627336|NCT05699733|Device|mechanical traction for knee joint|All participants will receive a single session per condition. This session will consist of continuous mechanical knee traction for 30 minutes while the participant assumes a supine position with the treated limb in semiflexion (30° of flexion). the treated limb will be supported using the traction bed's table that is used for this purpose. The knee position angle will be measured by a standard goniometer. Pelvis and thigh straps will be used to fix the body and prevent slippage during the application of the traction force. A customized leg cuff will be placed around the lower leg (above the ankle joint), and a traction rope will be extending horizontally from the cuff to the traction device. 48 hours of washing out will separate the sessions of different conditions
45627337|NCT05546853|Drug|NP137|NP137 will be administrated at the first day of each cycle (CnD1) of 14 days as an IV infusion at 9 or 14 mg/kg.
45627338|NCT05546853|Drug|Oxaliplatin|Oxaliplatin will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 85 mg/m²
45768374|NCT03809182|Drug|Fentanyl|Intraoperative fentanyl was given in case of 25% increment in the blood pressure and/or heart rate in comparison to baseline (previous anesthesia induction).
45768375|NCT03809182|Drug|Morphine Sulfate|Boluses of 3mg of intravenous morphine were given in the postoperative acute care unit. Once the pain score was equal or less than 3/10 the patient-controlled analgesia pumps were installed and the patients were discharged to their room.
45768376|NCT01170949|Drug|Miltefosine|50 or 100 or 150mg per day
45768377|NCT01170949|Drug|Placebo|Placebo
45768378|NCT03805672|Drug|Low Dose Enoxaparin|
45627339|NCT05546853|Drug|Irinotecan|Irinotecan will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 150 mg/m²
45627340|NCT05546853|Drug|Calcium levofolinate|Calcium levofolinate will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 100 mg/m²
45627341|NCT05546853|Drug|5 FU|5 FU will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 2400 mg/m2 as a continuous intravenous infusion over 46 hours.
45627342|NCT05546775|Diagnostic Test|DHR|"To describe the clinical characteristics and pattern of presentation of patients diagnosed as CGD in Assiut, and to find the most common presenting symptoms.~To mention the immunological profile of patients diagnosed with CGD (Immunogloulins level - B, T, natural killer cells enumeration with flow cytometry- DHR123)~To assess the growth parameters in patients with CGD."
45627343|NCT05535699|Other|exercises|scapular exercise
45627344|NCT05540769|Procedure|catheter guided ASD closure|transcatheter secundum ASD device closure
45627345|NCT05540535|Other|Gait assessment|The average speed of gait and spatiotemporal gait parameters would be calculated by the APDM, inertial motion units. Participants will walk in their normal speed for 1 minute along a corridor, back and forth, with or without performing a cognitive task (single or DT). The DT condition will include serial subtraction (counting backwards out loud) in jumps of 3 from a random three-digit number. Randomization of numbers will be done using the excel function generating random numbers (Excel RAND function). The numbers will be recorded for offline processing and the outcome will be the number of correct numbers. Each condition will be performed once, and all conditions will be randomized.
45627346|NCT05540535|Other|Cognitive assessment|Participants will complete a computerized cognitive battery (CNS vital sign; CNSVS)that will include verbal memory, visual memory, Stroop test, shifting attention and 4-part continuous performance (sustained attention and working memory). Moreover, performance on the single cognitive task (serial subtraction in jumps of 3; measuring working memory and executive function) will also be evaluated while sitting (cognitive single task). The numbers will be recorded for offline processing and the outcome will be the number of correct numbers. These tests do not require the ability to hear in order to pass successfully. Also, there is a need for investigation of cognitive domains such as attention, memory, executive function, and cognitive flexibility in people with HL.
45768379|NCT03805672|Drug|High Dose Enoxaparin|
45447273|NCT04049942|Other|Multimodal prehabilitation group|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization(whey protein supplement), and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence). Patients are advised to record daily exercises and adherence to nutritional, psychological and other recommendations. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
45452462|NCT03957317|Other|Eye mask and ear plugs|Subjects receive one pair of eye mask and ear plugs during their stay in the surgical ICU.
45768380|NCT04555135|Device|EndoVigilant Software|While using this device, colonoscopy will continue to be performed in the standard manner as is done without the use of this device. The video signal from the colonoscope will be fed into a computer running the EndoVigilant software in addition to the standard video output to the procedure monitor. The gastroenterologist performing the procedure will therefore be able to observe a standard colonoscopy video on the primary monitor and the augmented video on the second monitor. The gastroenterologist may rely on the second monitor (with augmented video generated from EndoVigilant software) for polyp detection, but the standard procedure monitor with the original feed will always be operational and available for maneuvers such as fast insertion, polypectomy etc.
45768381|NCT04158466|Device|Kalifilcon A Daily Disposable Contact Lenses|Contact lens
45768382|NCT04158466|Device|Biotrue ONEday Daily Disposable Contact Lenses|Contact lens
45768383|NCT03802864|Drug|Liposomal Bupivacaine|After surgical sperm retrieval, the wound will be injected with liposomal bupivacaine (266 mg) mixed with standard bupivacaine (bupivacaine hydrochloride 50mg) for post-operative pain relief.
45768384|NCT03802864|Drug|Standard Bupivacaine|After surgical sperm retrieval, the wound will be injected only with standard bupivacaine (bupivacaine hydrochloride 100mg) for post-operative pain relief.
45768385|NCT03797872|Drug|Methotrexate|Methotrexate up to 25mg/week as tolerated po or sc
45768386|NCT03797872|Drug|Sulfasalazine|Sulfasalazine up to 3g daily po
45627347|NCT05535543|Procedure|Prone Positioning|Patients will be turned to prone position and they will be left in prone position for a duration of at least 16 hours to a maximum of 24 hours. This duration is recommended by the ARDS guidelines.
45627348|NCT05546619|Drug|HIPEC+tislelizumab + targeted therapy|Patients with open liver lobe/segment resection, tumor excision, lymph node dissection will receive medication.
45627349|NCT05540379|Device|Virtual Reality Training|Training the obstetrics and Gynecologist Residents on Virtual endoscopic simulation and skills acquisition
45627350|NCT05535465|Other|Public health intervention|additional trained mobile health workers are hired to support and supervise the activities of community health workers
45627351|NCT05540301|Other|Modified sleeper stretching|Modified sleeper stretching was performed on shoulder joint to increase internal rotation range of motion.
45627352|NCT05540301|Other|Modified cross-body adduction stretch|Modified cross-body adduction stretching was performed on shoulder joint to increase internal rotation range of motion.
45627353|NCT05540145|Drug|SOX plus Paclitaxel(albumin-bound) followed by PD-1 antibody|"Drug: Paclitaxel(albumin-bound) 130mg/m2, ivgtt, D1, Q2w Drug: Oxaliplatin 70 mg/m2, ivgtt, D1, q2w Drug: S-1 40mg (body surface area < 1.25m2), bid, D1-8, Q2w 50mg (body surface area >1.25m2, <1.5 m2), bid, D1-8, Q2w 60mg (body surface area >1.5m2), bid, D1-8, Q2w~Patients with Her-2 negative, MMR-proficient locally advanced esophagogastric junction or gastric adenocarcinoma will receive 6 cycles of neoadjuvant chemotherapy. After comprehensive evaluations, patients who respond to chemotherapy will further receive 2 cycles of PD-1 antibody as neoadjuvant immunotherapy.~Drug: Pembrolizumab or sintilimab, 100~200mg, ivgtt, D1, Q3w. Patients will make the final decision of PD -1 antibody according to their economic condition."
45627354|NCT05698017|Drug|hOMSC300|Human Oral Mucosa Stem Cells
45768387|NCT03797872|Drug|Leflunomide|Leflunomide 10-20mg daily po
45768388|NCT03797872|Drug|Methylprednisolone|For IA or IM injection 20-120mg
45768389|NCT03797872|Drug|Triamcinolone|For IA or IM injection 20-120mg
45768390|NCT03782272|Dietary Supplement|Enterade|enterade® (an amino acid-based oral rehydration solution [AA-ORS]) is a medical food product that consists of oral rehydration salts, natural flavor, steviol (sweetener), purified water, and a blend of amino acids that drive the uptake of water and electrolytes.
45768391|NCT03782272|Dietary Supplement|Placebo|a placebo solution containing natural flavor, steviol (sweetener), and purified water.
45768392|NCT01127581|Drug|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
45768393|NCT01127581|Drug|Dinoprostone Vaginal Insert (DVI)|Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
45627355|NCT05698017|Other|Sham Procedure|Lumbar Puncture Only
45768394|NCT03794752|Device|Head-Mounted Visual Enhancement Device|Evergaze has designed a head mounted electronic visual enhancement device that is compact and similar to glasses. It is powered by a battery pack connected to the device. The electronic display will be affixed over only one of the participant's eye. The vision through the unobstructed eye will aid with the participant's balance and spatial orientation. The prototype display and camera will be connected to a battery pack/control box that will allow the user to quickly select one of 3 modes. Each mode will represent a combination of parameters (brightness of the display, focus lock, color/black & white, contrast, magnification) designed to optimize the image for different activities (e.g. reading, walking, computer use).
45768395|NCT04124536|Behavioral|HIV self-testing with partner notification.|HIV self-test kits are oral swabs. Partner notification will be offered to all women in the intervention arm, regardless of HIV status.
45768396|NCT02186509|Radiation|Hyperfractionated radiation therapy|Undergo hyperfractionated radiation therapy
45768397|NCT02186509|Radiation|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
45768398|NCT02186509|Drug|Alisertib|Given PO
45768399|NCT02186509|Procedure|Quality-of-life assessment|Ancillary studies
45768400|NCT00377728|Drug|GSK256066|
45768401|NCT01127737|Behavioral|Educational Intervention|Mnemonic and a workbook used by kidney transplant recipients to assist with early early detection of SCCs.
45768402|NCT01127737|Behavioral|Placebo|Completed surveys
45913014|NCT02017366|Other|Enteral feeding|Target of 1000 kCal/day enteral feeding or glucose 20%, perferably given overnight.
45913015|NCT02017392|Drug|Compound Lidocaine Cream|Compound Lidocaine Cream ,1-2 grams per person.
45627356|NCT05697939|Diagnostic Test|NSite 3D Scanning|"Three separate users will enter the exam room and use the NSite application to scan the patient in the bending position. These users may include research coordinators, physicians, or other authorized staff.~The NSite application will have a user tutorial on how to scan patients that users are instructed to watch prior to conducting a scan.~All participants are asked to remove clothing above the waist but may keep a bra or tight-fitting shirt on during the scanning procedures. The patient will be asked to assume a forward bending position. One user will capture a scan of the patient's back in this position. The user will calibrate the device and then walk around the patient while scanning per app directions. Once this user captures the scan, it will be processed by the application. New scans will then be obtained by the two other users. Once all users have captured a scan, the scanning process and patient participation will be completed."
45627357|NCT05546463|Behavioral|Digital games|"A digital game was played via iPad Air 2 32GB 9.7-inch wi-fi model tablet. The researcher created a folder with a range of selected games to appeal to different preferences. Children could choose from the following games: Word Travel, Talking Tom Candy Run, 384 Puzzles for Kids, Masha and The Bear, Subway Surfers, Head Ball 2 and Dream League Soccer."
45627358|NCT05546385|Device|Partial Rebreathing Device|Partial Rebreathing Device
45627359|NCT05546385|Device|Sham breathing device|Sham breathing device
45447274|NCT04049942|Behavioral|Aerobic training group|Aerobic training strategy includes the same guided individualized moderate aerobic exercise as the multimodal prehabilitation group, as well as the conventional guidance. Patients are advised to record daily exercises. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
45447275|NCT05568836|Dietary Supplement|vitamin D supplementation|Intervention group will receive a single IM injection of 300000 IU vitamin D
45627360|NCT05699577|Diagnostic Test|serum sample for ELIZA|ELIZA for Ca15-3 and interferon gamma
45627361|NCT05699421|Other|screening programme|CMV screening during the first trimester of pregnancy and neonatal
45627362|NCT05592327|Procedure|Citric acid abutment|The implant surgery will be performed by 3rd year residents of the Postgraduate Program in Periodontology at UIC, supervised by a board-certified periodontist (J.V). Under local anaesthesia, a mid crestal incision will be performed and a full thickness flap will be raised. Implants will be placed following the manufacturer's recommendations. Implant shoulder (IS) will be placed 1 mm subcrestally, and a distance of ≥ 1.5 mm from adjacent natural tooth and ≥ 3 mm between implants will be always respected. Implant stability will be measured with Ostell ISQ. Straight definitive abutments (2 mm height) will be tightened to 25 N respecting the previous randomization procedure. One of the implants will receive an antibacterial- coated abutment (citric acid), while the other implant will receive a non-coated abutment (C). A protector cap will be screwed manually. Implant sites will be sutured with polypropylene 5/0 (Prolene Ethicon, USA) by simple stitches.
45627363|NCT05539755|Procedure|Non surgical debridement of peri-implantitis|"The procedure was standardized as follows: the implants' prosthesis was checked for its cleansability, and retrieved when possible. Then, the prosthesis was modified following a previously described elsewhere (de Tapia et al., 2019). After local anaesthesia (articaine 4% and adrenaline 1:100,000), the implant surfaces were cleaned with ultrasonic devices (Newtron P5, Satelec Acteon; Olliergues, France) with the steel alloy H3 dental ultrasonic scaler tip (H3, Satelec Acteon; Olliergues, France), curettage (SyG 7/89 Everdge, Hu-Friedy; Chicago, IL, USA) of the bone defect was performed, and glycine air powder applied submucosally (Air-flow® powder subgingival PERIO, EMS; Nyon, France) with an air-flow piezon device (Air-flow master piezon®, EMS, Nyon; France).~Oral hygiene instructions were given and metronidazole 500 mg every 8 h for 7 days was prescribed. Patients were scheduled at 3 months for supragingival plaque control and supragingival debridement, if needed."
45627364|NCT05592171|Procedure|Microwave ablation + Occlusafe + DEB-TACE|"Microwave ablation (MW) is based on the production of heating by friction given by the oscillation of water molecules.~After positioning and inflating the Occlusafe® balloon in the artery that connects to the HCC nodule, the blood flow tends to go preferentially to the HCC nodule compared to the healthy liver. The increase in the water content in the tumor area, after using the Occlusafe® balloon microcatheter, could increase the ability of microwave ablation to cover larger volumes in a shorter time.~The delivery of drug-releasing microspheres (DEB-TACE) at the same time as microwave ablation, could promote the arrest of tumor growth."
45627365|NCT05592171|Procedure|Microwave ablation + Occlusafe|"Microwave ablation (MW) is based on the production of heating by friction given by the oscillation of water molecules.~After positioning and inflating the Occlusafe® balloon in the artery that connects to the HCC nodule, the blood flow tends to go preferentially to the HCC nodule compared to the healthy liver. The increase in the water content in the tumor area, after using the Occlusafe® balloon microcatheter, could increase the ability of microwave ablation to cover larger volumes in a shorter time."
45627366|NCT05592171|Procedure|Microwave ablation + DEB-TACE|"Microwave ablation (MW) is based on the production of heating by friction given by the oscillation of water molecules.~The delivery of drug-releasing microspheres (DEB-TACE) at the same time as microwave ablation, could promote the arrest of tumor growth."
45768403|NCT03709810|Combination Product|Marketed Denture Adhesive (Super Poligrip Max Seal)|The denture adhesive will be applied directly from the tubes. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.1 g for the maxillary and 0.6±0.1g for the mandibular dentures.
45768404|NCT03709810|Other|No Adhesive|No adhesive will be applied.
45768405|NCT01128049|Behavioral|Subjective Questionnaire|The team will use a one page questionnaire to obtain subjective input before the first set of measurements and after instilling the Saline drop.
45768406|NCT01128049|Procedure|Measurement with wavefront sensor (right eye, then left eye)|The wavefront instrument measures the eye's ability to create a sharp image by briefly shining a laser light from the wavefront sensor into the eye and measuring the light that bounces back through the cornea. For these measurements, subjects will sit on a chair and be instructed to place their chin in a chin rest and lean their forehead against a forehead rest. The subject will be instructed to hold his/her head steady, look in a certain direction, blink or not blink. We will obtain the measurements over a short period of up to approximately 45 seconds. We will start recording data asking the subject to either blink naturally or to hold his/her eye open for a few (up to 10) seconds, and repeat the blink and hold sequence usually for up to four times.
45768407|NCT01128049|Drug|Instill Saline Drop|One drop will be instilled in both eyes and patient will wait 5 minutes prior to repeating the questionnaire and wavefront sensor. A single drop is approximately 30 µL and will be placed into the inferior cul-de-sac while the patient looks up.
45768408|NCT04498351|Drug|Control Test|"Spermatic cord block by18ml levobupivacaine 0.5% plus 2 ml normal saline in total volume of 20 ml.~The procedure is repeated on the contralateral side."
45768409|NCT04498351|Drug|Dexmedetomidine|Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine in 2 ml in total volume of 20 ml The procedure is repeated on the contralateral side.
45768410|NCT04498351|Drug|Dexmedetomidine and magnesium sulphate|"Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine and 100 mg magnesium sulphate in 2 ml in total volume of 20 ml .~The procedure is repeated on the contralateral side."
45447276|NCT05568836|Other|control|control group will receive nothing
45627367|NCT05546307|Other|SSEP|Every patient presenting for a SSEP will be offered to participate to the study. If accepted, a randomization will determine whether the examination will be preceded by a relaxation session (Relax Group) or not (control group)
45627368|NCT05546307|Other|relaxation session|The relaxation session will be performed by one of the 5 nurses trained in relaxation
45627369|NCT05539521|Drug|Remimazolam Besylate|sedation drugs
45627370|NCT05539521|Drug|Propofol|Propofol
45627371|NCT05546229|Procedure|Microneedle based interstitial fluid collection|Interstitial fluid will be collected from the skin using microneedles and suction.
45627372|NCT05592015|Drug|Ruxolitinib|Given PO
45627373|NCT05591937|Behavioral|Self-Guided Online Prevention|An online wellness program that contains self-guided online CBT prevention strategies with demonstrated efficacy for depression and anxiety in college samples. Participants can learn skills for coping with common stressful experiences and build resilience at their own pace.
45627374|NCT05591937|Behavioral|Coach-Guided Online Cognitive Behavioral Therapy|An online digital therapy program that consists of online CBT modules supported by coaches through video chats. The modules are evidence-based and formatted into a unified approach for depression, anxiety and worry, panic, social anxiety, trauma and sleep dysregulation (developed as part of the University of California, Los Angeles (UCLA) Depression Grand Challenge). Lessons are designed to respond to participants' specific symptoms. Participants can access the system through any personal device (phone, tablet or computer) and speak to a certified student coach through remote video chat.
45768411|NCT04498351|Drug|magnesium sulphate|Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 100 mg magnesium sulphate in 2 ml in total volume of 20 ml
45768412|NCT03784300|Drug|50 mg PTI-125|PTI-125 50 mg Oral Solution
45768413|NCT03784300|Drug|100 mg PTI-125|PTI-125 100 mg Oral Solution
45627375|NCT05591937|Behavioral|Clinician-Delivered Psychological and Psychiatric Care|Evidence-based clinician-delivered CBT modules. Participants are connected to a team of clinicians who will evaluate participants' specific symptoms and create an individualized and tailored treatment plan. Treatment will include weekly sessions delivered through telehealth, and if deemed appropriate, participants may also have medication appointments.
45627376|NCT05591781|Device|high frequency chest wall oscillation with vest system|Patients were assigned to 2 groups with pre- and post- treatment protocol application. All patients were thoroughly evaluated before and after treatment protocol application.
45627377|NCT05591781|Device|Lung flute (OPEP)|. Thirty patients (Group B) received Lung flute (OPEP) in addition to their prescribed medication, 3 times per week twice a day for three successive weeks
45627378|NCT05538975|Other|Physiotherapy Treatment|Pulmonary Rehabilitation Techniques
45768414|NCT03784300|Drug|200 mg PTI-125|PTI-125 200 mg Oral Solution
45768415|NCT02186665|Drug|calcitriol ointment|
45768416|NCT02186665|Drug|placebo comparator|
45768417|NCT03713398|Behavioral|T4C-SMI|T4C-SMI entails a 25-session, manualized intervention that is delivered in a closed-group format at least twice a week over a three-month period. The intervention curriculum includes three modules: nine sessions on social skills training, five sessions on cognitive restructuring activities, and ten sessions on problem-solving methods. Participants assigned to T4C-SMI receive this intervention in addition to any other prison mental health services that they are otherwise eligible to receive during their incarceration.
45768418|NCT05313646|Biological|batch 1 of Ad5-nCoV|The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101001. It contains 5×10^10 viral particles per 0.5 mL in a vial.
45447277|NCT03554122|Procedure|Shotblocker|Patients spinal injections were performed with Shotblocker placed onto injection site
45447278|NCT03554122|Procedure|Placebo|Patients spinal injections were performed without Shotblocker
45627379|NCT05545995|Other|embryo selection|The basis of embryo seletion for transfer: morphological or genetic after non-invasive PGT-A
45627380|NCT05545917|Other|Experimental: APP care|The experimental arm will receive advanced physiotherapy care (APP) care. Patients will be independently managed (assessment and intervention) by a PT. The PT will make a diagnosis and initiate an intervention plan (e.g. education and exercise). If relevant, the PT will make recommendations for medical imaging tests or medication. PTs will also recommend the proper discharge from the emergency department (ED), such as hospitalization, discharge without medical consultation/follow-up or discharge with a medical follow-up or rehabilitation in an outpatient setting.
45627381|NCT05545917|Other|Control - Usual physician care|The control arm will receive usual ED physician care delivered only by an ED physician. This will include independent assessment, treatment and discharge by an ED physician with no physiotherapy within the ED but physician's referral to outpatient physiotherapy or other professionals/medical specialists will be possible; overall care offered by the ED physician will not be standardized but will be systematically documented.
45627382|NCT04426149|Dietary Supplement|trehalose|patients were instructed to ingest 100g of oral trehalose diluted in 500ml of water or other beverages daily
45627383|NCT05591469|Device|IR Camera|the respiration parameters are measured using an IR camera.
45627384|NCT05591469|Device|Electrical Impedance Tomography|the respiration parameters are measured using an electrical impedance tomograhy.
45627385|NCT05591391|Other|Mallya cap|After Mallya cap is correctly attached to the insulin pen, it will automatically record treatment information (dose, time and date of injection) and send in real time to the Health2Sync's platform by Bluetooth transmission. Suggestions regarding dose titration and glycemic control will be communicated on the Health2Sync's platform.
45627386|NCT05591391|Other|Standard care|Suggestions regarding dose titration and glycemic control will be communicated by weekly telephone calls.
45627387|NCT05538507|Drug|smart soup|Severe AD, mild or moderate AD and MCI will be given smart soup
45627388|NCT05538507|Drug|Donepezil|Severe AD and mild or moderate AD will be given donepezil
45768419|NCT05313646|Biological|batch 2 of Ad5-nCoV|The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101002. It contains 5×10^10 viral particles per 0.5 mL in a vial.
45768420|NCT05313646|Biological|batch 3 of Ad5-nCoV|The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202102003. It contains 5×10^10 viral particles per 0.5 mL in a vial.
45627389|NCT05538507|Drug|Memantine|Severe AD will be given memantine
45627390|NCT05538507|Drug|Placebo|patients with MCI will be given placebo
45627391|NCT05538429|Procedure|erector spinal plane combined with serratus anterior plane block|The experimental group received ultrasound-guided erector spinal block combined with serratus anterior plane block, and erector spinal block was performed at the T5 and T7 levels with 10ml 0.4% ropivacaine for each level, and 20ml 0.4% ropivacaine for serratus anterior plane block. The control group received ultrasound-guided thoracic paravertebral block at T5 and T7 levels, respectively, with 20ml 0.4% ropivacaine at each level.
45627392|NCT05591235|Drug|Metformin|After the screening period, eligible subjects took the hyperinsulinemic euglycemic clamp test and were then admitted to insulin with metformin for 4 weeks. During this timeframe, all patients were instructed to change the insulin pump infusion site and provide one profile of 7-point self-monitored blood glucose every three days. The insulin doses were titrated every day by physicians to achieve the glycemic goal. Participants who failed to attain the glycemic target in three consecutive times or could not afford the side effects of hypoglycemic medications were excluded from this study. On the last day of week 4, a FreeStyle Libre Pro Sensor (FGM system) was inserted to record the glycemic data for up to 14 days. At the end of week 5, all antidiabetic agents were stopped and the hyperinsulinemic euglycemic clamp test was performed again for remaining subjects.
45627393|NCT05591235|Drug|Dapagliflozin|After the screening period, eligible subjects took the hyperinsulinemic euglycemic clamp test and were then admitted to insulin with dapagliflozin (100mg one day) for 4 weeks. During this timeframe, all patients were instructed to change the insulin pump infusion site and provide one profile of 7-point self-monitored blood glucose every three days. The insulin doses were titrated every day by physicians to achieve the glycemic goal. Participants who failed to attain the glycemic target in three consecutive times or could not afford the side effects of hypoglycemic medications were excluded from this study. On the last day of week 4, a FreeStyle Libre Pro Sensor (FGM system) was inserted to record the glycemic data for up to 14 days. At the end of week 5, all antidiabetic agents were stopped and the hyperinsulinemic euglycemic clamp test was performed again for remaining subjects.
45627394|NCT05591235|Drug|Fixed-dose combination of metformin and pioglitazone (500mg metformin plus 15mg pioglitazone)|After the screening period, eligible subjects took the hyperinsulinemic euglycemic clamp test and were then admitted to insulin with fixed-dose combination of metformin and pioglitazone (two tablets of 500mg metformin plus 15mg pioglitazone) for 4 weeks. During this timeframe, all patients were instructed to change the insulin pump infusion site and provide one profile of 7-point self-monitored blood glucose every three days. The insulin doses were titrated every day by physicians to achieve the glycemic goal. Participants who failed to attain the glycemic target in three consecutive times or could not afford the side effects of hypoglycemic medications were excluded from this study. On the last day of week 4, a FreeStyle Libre Pro Sensor (FGM system) was inserted to record the glycemic data for up to 14 days. At the end of week 5, all antidiabetic agents were stopped and the hyperinsulinemic euglycemic clamp test was performed again for remaining subjects.
45627395|NCT04425837|Biological|SARS-CoV-2 convalescent plasma treatment|Plasma transfusion of convalescent patients from COVID-19 with negative RT-PCR, and antibody titers of 1:160 or greater at a dose of 400ml distributed in two doses administered on the same day intravenous administration
45627396|NCT04425837|Other|Standard care|Standard care according to guidelines and national regulations
45627397|NCT05589519|Device|Partial rehabilitation using PEEK|A 3-unit implant-supported fixed prosthesis using PEEK polymer in its composition delivered as definitive prosthesis for partial rehabilitation of edentulous jaws.
45627398|NCT05538351|Device|Body Composition Monitor (BCM)|The hydration status of each participant from the clinical assessment and the patient reported signs and symptoms will be compared with the readings from bioimpedance (BCM machine).
45627399|NCT05545527|Drug|Ferric carboxymaltose|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 1 were given a single dose of ferric carboxymaltose between 14 and 17 weeks of pregnancy.
45627400|NCT05545527|Drug|Iron isomaltoside|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 2 were given a single dose of iron isomaltoside between 14 and 17 weeks of pregnancy.
45627401|NCT05545527|Drug|Ferric Sulfate|As part of the RAPIDIRON Trial, maternal participants randomized to the active comparator arm were given 200 ferrous sulfate tablets immediately after randomization (~12 weeks of pregnancy). Participants were instructed to take two tablets a day, with each tablet containing 60mg elemental iron.
45627402|NCT05538195|Biological|CEA-targeted CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
45627403|NCT05538195|Biological|CEA-targeted CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
45627404|NCT05697081|Other|Medical doctors infected with COVID-19|web-based survey
45627405|NCT05537961|Behavioral|Mindfulness-Oriented Recovery Enhancement|Mindfulness instruction incorporated in classroom-based curriculum
45627406|NCT05523063|Other|Quality of life questionnaire|"The quality of life questionnaire will be performed in routine practice by the CAMI during the initial assessment.~The 3-month visit is part of the routine patient visit to CAMI. During this visit, the quality of life questionnaire will be completed a second time by the patients, through a phone call given by the investigator."
45768421|NCT01172197|Drug|Levobupivacaine|Femoral bolus 150μM followed by femoral infusion 400μM
45768422|NCT01172197|Drug|Ropivacaine|Bolus and infusion
45768423|NCT03771274|Device|Tecnis ZLB00 & Symfony IOL|The Symfony IOL will be implanted in the dominant eye while the Tecnis ZLB00 will be implanted in the non-dominant eye.
45768424|NCT04420663|Diagnostic Test|Pleural Manometry|Recording pleural pressure during therapeutic thoracocentesis using a simple water manometer.
45768425|NCT04141930|Drug|Baloxavir Marboxil|Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset
45768426|NCT04374565|Drug|High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma|Pathogen reduced SARS-CoV-2 convalescent plasma (1-2 units; ~200 mL each for a total of 200-400mls) given preferably in one day, but allowable to be given over 2 days if clinical circumstances delay infusions in 1 day), with titer to be determined after the unit has been infused.
45768427|NCT01128829|Other|Water|60 ml of water were drank 10 min before doing a OGTT
45627407|NCT05537805|Procedure|Ultrasound guided transcervical fallopian tube catheterization during hysterosalpingo-foam sonography in the treatment of proximal tubal obstruction|The intervention included the usage of the modified cornual cannulation set (COOK) which was inserted through cervical canal to uterine cavity, followed by fallopian tube irrigation with contrast foam (Ex-EM) during hysterosalpingo-foam sonography under ultrasonographic imaging.
45768428|NCT01128829|Other|Sucralose|60 ml of 2 millimolar sucralose were drank 10 min before doing a OGTT
45768429|NCT01129141|Procedure|Tele-PTM|Telephone-based Progressive Tinnitus Management (Tele-PTM) is a novel home-based telehealth program that involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education was provided by the Study Psychologist at weeks 1, 3, and 5, and month 6; and by the Study Audiologist at weeks 2 and 4, and month 3.
45627408|NCT05537649|Dietary Supplement|Oatmeal porridge|Investigation of the impact of enzymatic modification of the molecular structure of starch by amylomaltase on the postprandial glycemic responses of an oatmeal porridge.
45627409|NCT01666119|Drug|BEMA Buprenorphine NX films|BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone) will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
45627410|NCT05417217|Procedure|Discontinued ventilation|Ventilation is discontinued after going on CPB and lungs are exposed to atmospheric pressure
45627411|NCT05417217|Procedure|Continued ventilation|Ventilation is continued from going on CPB until clamping of the ascending aorta with tidal volume 3ml/kg ideal body weight, Fraction of inspired oxygen (FiO2) 50%, respiratory rate 5/min and Inspiratory:Expiratory (I/E) ratio 1/2.
45627412|NCT05389839|Device|Wechat program|The experimental group used wechat program to calculate insulin dose to guide insulin treatment .
45627413|NCT05389449|Drug|Danicopan|Oral tablet
45627414|NCT05361993|Drug|Drug Aripiprazole|Considering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded
45627415|NCT05361993|Device|biofeedback|Biofeedback therapy Biofeedback therapy, three times a week, every other day interval, 30 minutes each time, each subject received 20 biofeedback training（using the Infiniti3000A biofeedback system，Thought Technology Ltd.）.Patients in the theta group decreased the theta amplitude at Cz. Patients in the theta group received positive feedback when their theta activity was below the feedback threshold.
45627416|NCT05545215|Device|Dexyane Med|Dexyane MeD® is a non-sterile topical cream, for external use only, available in 30 mL or 100 mL tubes (also available in sample model 5mL tubes).
45627417|NCT04425681|Drug|Osimertinib|Treatment of LM With osimertinb
45627418|NCT04425681|Drug|Bevacizumab|Treatment of LM With Bevacizumab
45768430|NCT01129141|Procedure|Wait List Control|Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.
45768431|NCT04138498|Drug|Dexmethylphenidate 5 Mg Oral Capsule, Extended Release|Reference listed drug (RLD) for comparative BA evaluation
45768432|NCT04138498|Drug|Dexmethylphenidate 6.25 mg Tablet|Experimental drug for comparative BA evaluation
45447279|NCT02106052|Other|Aerobic exercise|The aerobic exercise condition is a graduated program of supervised aerobic exercise up to one hour per day, three days per week, and lasting 6 months. The structured exercise portion of the sessions will initially last for 15-20 minutes at 40-50% heart rate reserve (HRR) and progressively increase up to 35-40 minutes in duration at 65-75% HRR during the last month of the program. The program will focus on large, dynamic movements of the lower extremities (e.g. leg cycling ergometry). There may be some individual variation in adaptations that dictate the exact characteristics of the program.
45627419|NCT05545059|Drug|Sacubitril/valsartan|In sacubitril/valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg, sacubitril/valsartan 200mg to treat. The initial dose of sacubitril/valsartan will be 100mg per day and will be doubled to 200mg per day after 2 weeks then maintain until the end of the 8-week treatment period.
45627420|NCT05545059|Drug|valsartan|In valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg and valsartan 160mg. The initial dose of valsartan will be 80mg per day and will be doubled to 160mg per day 2 weeks later and then maintain until the end of the 8-week treatment period.
45627421|NCT05537259|Other|Observation Group|No intervention; this is an observational study.
45627422|NCT05698173|Biological|blood sample|48 ml whole blood for Peripheral blood mononuclear cell (PBMC) and serum isolation
45627423|NCT05698173|Biological|blood sample|blood for Peripheral blood mononuclear cell (PBMC) and serum isolation
45627424|NCT05536947|Other|Bread product (standard milled)|Bread rolls made from standard milled flour.
45768433|NCT04138498|Drug|Dexmethylphenidate 40 Mg Oral Capsule, Extended Release|Reference listed drug (RLD) for comparative BA evaluation
45768434|NCT04138498|Drug|Dexmethylphenidate 50 mg Tablet|Experimental drug for comparative BA evaluation
45768435|NCT03714256|Device|Device, patient mobility, powered|Pediatric mobility device
45768436|NCT03715426|Behavioral|MKit|MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
45768437|NCT05314192|Diagnostic Test|salivary test|saliva was assessed for MIP-1 alpha
45768438|NCT05314192|Diagnostic Test|salivary test|saliva was assessed for IL-6
45768439|NCT01129531|Drug|AGN-214868|AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment.
45768440|NCT01129531|Drug|Placebo to AGN-214868|Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.
45627425|NCT05536947|Other|Bread Product (micro-milled)|Bread rolls made from micro-milled whole grain flour.
45627426|NCT05536947|Other|Bread Product (standard aleurone)|Bread rolls made from white flour/standard milled aleurone mix
45627427|NCT05536947|Other|Bread product (micro-milled aleurone)|Bread rolls made from white flour/micro-milled aleurone mix.
45627428|NCT05696925|Other|Motor Imagery|Motor imagery (MI) is a cognitive process that involves the ability to perform an action mentally, without the need to perform the movement itself. The perspective that the person uses to imagine can be: internal perspective (first person - imagines himself/herself), which relates to the person's view of the content of the images or to his/her kinesthetic sensation - the person imagines the movement being performed, as if feeling the movement of the action; or external perspective (third person - imagines another person), which relates to the visual imagination of scenes outside the person.
45627429|NCT05696925|Other|Action Observation|Action observation consists of watching another person acting, or doing a motor task, on video or in real-time.
45627430|NCT05696925|Other|Exoskeletons|The term Brain-Machine Interface (BMI) refers to systems that capture brain activity signals, translating them into computer commands to control external devices, with the robotic exoskeletons. The electrodes are positioned on the skull cap.
45627431|NCT05696925|Other|Execution of the Action|In the sitting or standing position, depending on the action to be performed, the participant must execute the same action imagined or observed previously.
45627432|NCT05536869|Procedure|Caesarean|Two different caesarean section techniques : intra or extraperitoneal
45627433|NCT05128773|Drug|Amcenestrant|tablet, oral
45627434|NCT05128773|Drug|Tamoxifen|tablet, oral
45627435|NCT05128773|Drug|Amcenestrant-matching placebo|tablet, oral
45627436|NCT05128773|Drug|Tamoxifen-matching placebo|tablet, oral
45627437|NCT05536635|Behavioral|breathing techniques|Intervention will be daily use of breathing techniques thought by the researcher as explained in detail in arm/group descriptions
45627438|NCT05096949|Other|Home visit delivery strategy|A nurse will deliver and administer Cabenuva injection at patient's home
45627439|NCT05699187|Procedure|Face allotransplantation|Facial allotransplantation
45627440|NCT05536479|Procedure|Autogenous stored mineralized dentin graft (ASMDG)|"Autogenous stored mineralized dentin graft (ASMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze.~The disinfected particles will then be stored at room temperature for 21 days in a sterile container. After 21 days, a second extraction will be performed followed by mixing the stored graft with a few drops of sterile saline to be packed in a socket after extraction"
45627441|NCT05536479|Procedure|Autogenous fresh mineralized dentin graft (AFMDG)|Autogenous fresh mineralized dentin graft (AFMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze.
45627442|NCT05544825|Dietary Supplement|Ice plant group|Ice plant extract 2,000 mg/day for 12 weeks
45447280|NCT02106052|Other|Stretching and toning exercise|The stretching and toning condition is a supervised stretching program with Therabands up to one hour per day, three days per week, and lasting 6 months. The stretching exercises will be based on a manual published by the National Multiple Sclerosis Society (NMSS) that has been standardized, manualized for reproducibility, and the investigators will progressively include more exercises and sets with Therabands for resistance over the course of the 6-month period.
45768441|NCT03746002|Drug|Metolazone 60 minutes prior to furosemide|All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
45768442|NCT03746002|Drug|Metolazone concurrently with furosemide|All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
45768443|NCT01172353|Drug|sodium bicarbonate|hydration with sodium bicarbonate 1ml/Kg/h for 6 hours
45447281|NCT03259490|Drug|Empagliflozin/linagliptin/metformin HCl|Once daily
45447282|NCT03259490|Drug|Empagliflozin|Once daily
45447283|NCT03259490|Drug|Linagliptin|Once daily
45447284|NCT03259490|Drug|Metformin HCl|Once daily
45447285|NCT02107846|Drug|PRX-112|
45447286|NCT02106130|Drug|Rebamipide|oral administration, 3 times/day
45447287|NCT02106130|Drug|Mosapride citrate|oral administration, 3 times/day
45447288|NCT01314092|Biological|Autologous cultured adipose derived stem cells(low dose group)|low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
45627443|NCT05544825|Dietary Supplement|Placebo group|Placebo 2,000 mg/day for 12 weeks
45627444|NCT05536245|Other|Questionnaire|To prevalence of psychological, physical and sexual violence suffered or committed in a population of patients suffering from one or more addictions
45627445|NCT05536011|Drug|Pitolisant|Exposure to at least one dose of pitolisant at any time during pregnancy
45627446|NCT05536011|Drug|Comparator Products|Exposure to at least one dose of a comparator product at any time during pregnancy
45627447|NCT04809051|Other|Stratified Transplant Survival Metric|"Both transplant metric conditions display the number of hearts offered to each center, the number of hearts accepted by each center, and the number of transplants performed at each center (in a year), in addition to the condition-specific metrics below. The stratified condition instead features a pair of values corresponding to each center's offers/acceptances/transplant survival rates for donor hearts of optimal or adequate quality."
45627448|NCT04809051|Other|SRTR Information Format|The information format varies based on how the transplant hospital statistics are organized when presented to participants on the choice screen. The SRTR conditions mimic the information format present on the SRTR public reporting website.
45627449|NCT05544513|Drug|Ferrous sulfate|Ferrous sulfate supplementation
45627450|NCT04015869|Drug|Allopregnanolone|neurosteroid
45627451|NCT04015869|Drug|Placebos|placebo
45768444|NCT01172353|Drug|saline|hydration with saline 1ml/Kg/h for 6 hours
45768445|NCT01129609|Device|Talent Converter Stent Graft and Talent Occluder with Occluder Delivery System|All subject enrolled will be attempted to be treated with or will be treated with the Talent Converter Stent Graft
45768446|NCT04089982|Drug|Varenicline|Chantix
45935212|NCT00042185|Behavioral|Dissonance Eating Disorder Prevention Program|In this intervention, participants voluntarily engaged in verbal, written, and behavioral exercises in which they critiqued the thin-ideal ideal. These exercises were conducted in sessions and in homework activities. For example, they wrote a counter-attitudinal essay about the costs associated with pursuit of the thin-ideal and engaged in a counter-attitudinal role-play in which they attempted to dissuade facilitators from pursuing the thin-ideal.
45627452|NCT05544435|Behavioral|Motivational İnterviewing|Motivational Interviewing (MI), which is one of these methods, is an individual-based counselling approach that can easily be used by nurses who have been trained to help the management of disease in chronic diseases (Berhe et al., 2020; Kızılırmak & Demir, 2018; Maslakpak et al., 2020). The core principles of MI includes expressing empathy by providing acceptance and understanding, realizing inconsistencies, avoiding discussions and supporting self-efficacy (Matinolli et al., 2012). The main purpose of MI is to identify the ambivalent emotions that occur in the patient in health-related activities, to strengthen and encourage insights of patients by supporting healthy lifestyle changes and self-confidence (R.Miller & Rollnick, 2013). Because of its flexibility and ability to be applied in different behavioural aspects, MI can be administered individually and in groups by trained individuals (Maslakpak et al., 2020).
45627453|NCT04744467|Device|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
45627454|NCT04731129|Device|Probe based confocal laser endomicroscopy of the pleura|Every patient referred for medical thoracoscopy will be screened. The pCLE of the pleura will be performed 2 times. First, just before the thoracoscopy, through the Boutin's needle or the thoracentesis catheter and second through the working chanel of the pleuroscope. This last acquisition allows visual control to target the pleural endomicroscopy assessment. These two acquisitions will be compared between each other and with the histological samples of the pleuroscopy.
45627455|NCT04677855|Drug|PCUR-101|50 mg capsules
45627456|NCT04677855|Drug|Dutasteride 0.5 mg|0.5 mg capsules
45627457|NCT04677855|Drug|Abiraterone and Prednisone|500 mg tablets Abiraterone with 5 mg Prednisone Tablets
45768447|NCT04089982|Drug|Placebo oral tablet|Placebo
45627458|NCT05696223|Other|Ultrasound|Doppler mesure
45627460|NCT04626297|Drug|Lebrikizumab|Given SC
45627461|NCT04626297|Drug|Placebo|Given SC
45627462|NCT05544279|Behavioral|Education|Education is given about the focused disease and its nursing care management
45768448|NCT00985088|Biological|GSK2340274A|one or two intramuscular injections
45627463|NCT01665807|Biological|Intanza|Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere
45627464|NCT01665807|Biological|Vaxigrip|Influenza vaccine, trivalent, split-virion, inactivated, approved for the 2012-2013 influenza season in the northern hemisphere
45627465|NCT04585113|Radiation|CT-scanning|All participants will receive dual-energy CT scanning and cone-beam CT scanning prior surgery.
45627466|NCT04425759|Diagnostic Test|Blood sample|Blood sammples for the serological analysis will be collected at 0/90/180/270/360 days.
45627467|NCT04448535|Dietary Supplement|Gingko Biloba|oral intake of Gingko Biloba, 240mg/day for 4 weeks
45627468|NCT05695989|Device|Dual Robotic Arm Accessory (DRAA)|Dual Robotic Arm Accessory (DRAA)
45627469|NCT02584959|Drug|C1 esterase inhibitor [human] liquid|C1 Esterase Inhibitor [Human] Liquid administered Subcutaneously as specified on specified days
45627470|NCT02584959|Drug|Placebo|Placebo
45627471|NCT05544045|Device|Surpass Streamline Flow Diverter System|The Surpass Streamline FDS is indicated for use in the endovascular treatment of adults (age 18 years or older) with unruptured large (≥ 10 mm) saccular, wide-neck (neck width ≥ 4 mm or dome/neck ratio < 2 mm) or fusiform intracranial aneurysms in the internal carotid artery from the petrous segment to the terminus arising from a parent vessel with a diameter ≥ 2.5 mm to ≤ 5.3 mm.
45768449|NCT00985088|Biological|GSK2340273A|one or two intramuscular injections
45768450|NCT00985088|Biological|Saline placebo|One injection
45768451|NCT03783130|Biological|VRC-HIVRGP096-00-VP|Trimer 4571 drug product is an investigational HIV vaccine which mimics the native HIV-1 envelope complex. This soluble HIV-1 envelope product consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505, with stabilizing mutations and engineered disulfide bonds, specifically recognized by broadly neutralizing antibodies and resists gp120 conformational change caused by CD4 binding.
45768452|NCT03783130|Other|Alum Adjuvant|Adjuvant is an aluminum hydroxide suspension (alum) mixed with Trimer 4571 to improve the immune response to the investigational vaccine.
45627472|NCT05543889|Other|Educational package|Online learning package that will discuss the van Herick technique, grading, accuracy and information and discusses the current guidelines for primary angle closure suspect referral.
45627473|NCT05695833|Device|Radiofrequency|Device emitting electric waves generating heat
45627474|NCT02584257|Other|methacholine chloride|
45627475|NCT02584257|Drug|placebo ProAir HFA|
45627476|NCT02584257|Drug|ProAir HFA|
45627477|NCT02584257|Drug|Lupin albuterol HFA MDI|
45627478|NCT02584257|Drug|placebo Lupin albuterol HFA MDI|
45627479|NCT05543655|Other|high fidelity simulation|"Each half-day training session will begin with a reminder of the context and general objectives of the training. Nurses will complete the self-assessment and knowledge tests.~The nurses, each in turn, will start the scenario and will immediately assess the workload felt, by the Nasa-TLX grid. During these high-fidelity simulation sessions, an error cart workshop will allow all the other nurses to summon up their knowledge on safety tools upstream of the administration procedure.~The session begins with a briefing and ends with a debriefing."
45627480|NCT05543421|Device|TMS|rTMS (30sessions) or iTBS (40sessions)
45627481|NCT04272099|Other|Administration of standardized questionnaires|Administration of questionnaires assessing subjective socioeconomic status (SES), health literacy, perceived health, health related quality of life, self-esteem and diabetes self-efficacy
45627482|NCT04272099|Device|Physical activity tracker|PG1 will be asked to wear a physical activity tracker for one week to monitor activity patterns including walking distance, calorie expenditure, sedentary time and sleep.
45913016|NCT02017405|Other|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-derived bovine immunoglobulin protein isolate is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. Serum-derived bovine immunoglobulin protein isolate does not contain any milk products such as lactose, casein, or whey. Serum-derived bovine immunoglobulin protein isolate is gluten-free, dye-free, and soy-free. Serum-derived bovine immunoglobulin protein isolate is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
45913017|NCT02017405|Other|Matching Placebo|
45913018|NCT02017418|Dietary Supplement|zeaxanthin|softgel
45913019|NCT02017418|Dietary Supplement|combinatory supplement|softgel
45627483|NCT04272099|Other|Dietary log|PG1 (or PG2 as proxies when appropriate) will report to a study coordinator via phone a full dietary log of PG1 once per week on rotating days of the week for three weeks.
45627484|NCT04254783|Drug|Risankizumab|Intravenous (IV) infusion
45627485|NCT04254783|Drug|Cytochrome P450 (CYP) Substrates|Tablet: Oral; CYP Substrates: midazolam, caffeine, warfarin, vitamin K, omeprazole and metoprolol
45627486|NCT04090203|Drug|Boiled Peanut Powder|Oral Immunotherapy will be administered utilizing a powder derived from boiled peanuts. Treatment will begin with an initial escalation day in which dosing is begun at 0.1 mg peanut protein and escalated to a final dose of 6 mg peanut protein. Doses are ingested orally. The subjects will continue daily oral ingestion of doses at home and return for updosing every 2 weeks to a final maintenance dose of 300 mg peanut protein. The subjects will continue daily oral ingestion of the peanut product for a minimum duration of 28 days before undergoing exit DBPCFC. At the conclusion of the study, patients will be offered continued maintenance therapy off study in line with current specialty standards.
45627487|NCT04088097|Behavioral|Cognitive-Behavioral Therapy for Adolescent Binge/Loss-of-Control Eating|Cognitive-behavioral therapy (CBT) developed for adolescents with binge eating or loss-of-control eating.
45627488|NCT04088097|Other|Control Condition|Educational and informational materials on adolescent health and nutrition.
45627489|NCT04062201|Drug|Bedaquiline Oral Tablet|Weight Group 16 - 29.9kg: 200mg daily for two weeks; followed by 100mg three times weekly for weeks 3 - 24 Weight Group: 30 - >50kg: 400mg once daily for 14 days followed by 200mg three times weekly for weeks 3 - 24
45627490|NCT04062201|Drug|Linezolid Oral Tablet|Weight Group 16 - 23kg: 180 - 210mg (crush 1 tab and mix in 10ml water, administer 3-3.5ml. Discard rest) Weight Group 23.1 - 29.9kg: 300mg daily Weight Group 30 - 33.9kg: 450mg daily Weight Group 34 - >50kg: 600mg daily
45627491|NCT04062201|Drug|Delamanid in Oral Dosage Form|Weight Group 16 - 23kg: 25mg twice daily for 24 weeks Weight Group 23.1 - 33.9kg: 50mg twice daily for 24 weeks Weight Group 34 - >50kg: 100mg twice daily for 8 weeks followed by 200 mg daily for 16 weeks
45627492|NCT04062201|Drug|Clofazimine Oral Product|Weight Group 16 - 23kg: 100mg three times a week or 50mg daily Weight Group 23.1 - >50kg: 100mg daily
45627493|NCT04062201|Drug|Levofloxacin Oral Tablet|Weight Group 16 - 23kg: 375 - 500mg daily Weight Group 23.1 - 33.9kg: 500mg once daily Weight Group 34 - 50kg: 750mg daily Weight Group >50kg:1000mg daily
45627494|NCT04062201|Drug|Isoniazid Oral Product|Weight Group 16 - 23kg: 300mg daily Weight Group 23.1 - 50kg: 400mg daily Weight Group >50kg: 600mg daily
45627495|NCT04062201|Drug|Ethambutol Oral Product|Weight Group 16 - 23kg: 400mg daily Weight Group 23.1 - 29.9kg: 600mg daily Weight Group 30 - 50kg: 800mg daily Weight Group >50kg: 1200mg daily
45627496|NCT04062201|Drug|Pyrazinamide Oral Product|Weight Group 16 - 23kg: 750mg daily Weight Group 23.1 - 29.9kg: 1000mg daily Weight Group 30 - 33.9kg: 1250mg daily Weight Group 34 - 50kg: 1500mg daily Weight Group >50kg: 2000mg daily
45627497|NCT04062201|Drug|Linezolid Oral Tablet|Weight Group 16 - 23kg: 180 - 210mg (crush 1 tab and mix in 10ml water, administer 3-3.5ml. Discard rest) Weight Group 23.1 - 29.9kg: 300mg daily Weight Group 30 - 33.9kg: 450mg daily Weight Group 34 - >50kg: 600mg daily
45627498|NCT04062201|Drug|Clofazimine Oral Product|Weight Group 16 - 23kg: 100mg three times a week or 50mg daily Weight Group 23.1 - >50kg: 100mg daily
45627499|NCT04062201|Drug|Levofloxacin Oral Tablet|Weight Group 16 - 23kg: 375 - 500mg daily Weight Group 23.1 - 33.9kg: 500mg once daily Weight Group 34 - 50kg: 750mg daily Weight Group >50kg:1000mg daily
45627500|NCT04316715|Behavioral|Lifesteps for PrEP|Four weekly nurse delivered counseling sessions plus two optional booster sessions. Sessions last approximately 40-50 minutes each. Sessions employ cognitive behavioral (CBT) techniques, motivational interviewing (MI), and psychoeducation.
45627501|NCT04316715|Behavioral|Daily text message reminders|Participants get daily text messages on their cell phone reminding them to take their PrEP medication.
45627502|NCT05696457|Behavioral|Passive music therapy|Patients included in the experimental group receive a 25 min passive music therapy session on a daily basis, which changes depending on their emotion.
45768453|NCT00984542|Drug|bendamustine hydrochloride|Bendamustine 120 mg/m2 IV on days 1 and 2 of a 21-day treatment cycle
45768454|NCT03075176|Device|Wavefront optimized LASIK|Wavefront optimized laser vision correction
45768455|NCT03075176|Device|Wavefront optimized Photorefractive Keratectomy|Wavefront optimized laser vision correction
45768456|NCT03075176|Device|Topography-guided LASIK|Topography-guided laser vision correction
45768457|NCT03075176|Device|Topography-guided Photorefractive Keratectomy|Topography-guided laser vision correction
45768458|NCT04395014|Diagnostic Test|2D Echocardiography|In this echocardiographic imaging acquisition protocol, the pregnancy patients, are colocated in the left lateral decubitus position on a clinical bed with the left arm flex and the hand behind the head. All the echocardiographic measurements are taken by the examiner in this position.
45913020|NCT02017431|Other|Allergen|Subject specific allergen is inhaled on day 1 of the triad
45913021|NCT02017431|Other|Saline|Saline is inhaled on day 1 of the triad
45913022|NCT02017431|Other|Particle depleted diesel exhaust|High-efficiency particulate filtration of diesel exhaust
45627503|NCT02583711|Device|Activity sensor (3 axis accelerometer)|Patient cohort will wear the activity sensor from pre-admission clinic until discharge after surgical procedure
45627504|NCT02583477|Drug|MEDI4736 in combination with nab-paclitaxel and gemcitabine|MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
45627505|NCT02583477|Drug|MEDI4736 in combination with AZD5069|MEDI4736 via IV infusion and oral AZD5069
45627506|NCT05696379|Other|Angiography derived index of micro-circulatory resistance (Angio-IMR)|Angiography derived index of micro-circulatory resistance (Angio-IMR) post percutaneous coronary intervention.
45627508|NCT00508443|Radiation|Radiation Therapy|Three radiation treatments guided by the CT-on-Rails or Trilogy procedure over a period of 2 weeks. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
45627509|NCT02583399|Drug|Ibuprofen|Ibuprofen, 10 mg/kg
45627510|NCT05535153|Other|functional movement screen|The volunteer subjects had to perform the FMS test at the request of the investigator, which is made up of seven movements: the squat, the crossing of the hurdle, the line lunge, the active elevation with the straight leg, a movement concerning the mobility of the shoulders, a rotational stability assessment movement and a core stability assessment movement.
45627511|NCT05468463|Behavioral|Living Donor Navigator Program|The investigators have developed a 4-session educational program that simultaneously addresses potential donor concerns with the evaluation/donation process and provides advocacy training to transplant candidates and their advocates.
45627512|NCT05679297|Diagnostic Test|Quantitative sensory testing (QST)|"The QST is a standardized, internationally accepted test battery consisting of several well-established, non-invasive tests, measuring parameters, which reflect nearly all aspects of somatosensation.~Thermal detection threshold for the perception of cold, warm and paradoxical heat sensations~Thermal pain threshold~Mechanical detection thresholds for touch~Mechanical pain threshold for pinprick stimuli~Stimulus-response functions~Wind- up ratio: The wind- up ratio represents the quotient of the pain intensity evoked by 10 pin-prick stimuli and the pain intensity evoked by one single pin-prick stimulus~Vibration detection threshold~Pressure pain threshold"
45627513|NCT05679297|Diagnostic Test|Magnetic resonance imaging (MRI)|"Functional and structural MRI data will be collected using a 3 Tesla Siemens Scanner with a multi-channel head coil.~For the resting state functional MRI the subjects will merely lie in the scanner for about 10 minutes.~A painful heat/cold stimulation will be performed to study the differences in pain processing between the three groups"
45627514|NCT05679297|Other|Clinical interview/exam|The pain characteristics will be assessed through a standardized questionnaire. The german pain questionnaire is a validated questionnaire that assesses various dimensions of pain. Patients will also get a complete neurological examination by an experienced clinician.
45768459|NCT00983918|Drug|Desflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Desflurane
45768460|NCT00983918|Drug|Sevoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Sevoflurane
45768461|NCT00983918|Drug|Isoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Isoflurane
45627515|NCT05679297|Other|Follow-up interview|"Structured telephone interview with 3 Questionnaires~The german pain questionnaire~Questionnaire regarding clinical development since the last visit designed by the investigators~German translation of 12-item-allodynia symptom checklist (ASC-12)"
45627516|NCT05679219|Procedure|Structured Pes Planus Exercises|Structured pes planus exercise group; short foot exercise, towel picking exercise, toe walking, heel walking, tandem walking, eccentric gastrosoleus stretching at the edge of the stairs, picking objects from the ground with the toes, balance exercises on one foot. the purpose of all these exercises; The aim is to increase the medial longitudinal arch by contracting the intrinsic muscles of the foot, and to improve the balance at the same time. Walking exercises will be performed in the form of 10 meters and 10 rounds, other exercises will be performed with 30 repetitions for both feet and the whole session will be 40 minutes in total.
45768462|NCT00983918|Drug|Propofol|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with intravenous Propofol infusion
45768463|NCT03057782|Device|Waveguard (TM) EEG cap|The device is an EEG cap - a non-invasive EEG positioning system used to quickly place a large number of surface electrodes in a quick and consistent manner on the head. The device will measure electrophysiological signals from the scalp at the time points in the study listed in the protocol.
45768464|NCT03057782|Device|Micro Movement Sensor|This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor breathing and movement in children; the device is not used for validation purposes.
45768465|NCT03057782|Device|Pico Movement Sensor|This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor respiration rate and gross body movement in children. The device will not be used for validation purposes.
45768466|NCT03057782|Device|QS Piezostimulator|This device is not FDA approved. This device is used for research purposes by neurologists and physiologists. It is a mechanical tactile stimulator for use in functional imaging experiments like MEG, fMRI or EEG. The stimulation is realized by using several different pin matrices. In this study, the device is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
45768467|NCT03057782|Device|tactileTM sensory evaluator|This device is not FDA approved. This device is used for clinical and research purposes by neurologists and physiologists. It is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
45768468|NCT01925924|Other|Resin-modified glass ionomer cement|This material contains fluoride
45768469|NCT01925924|Other|Composite resin|This material does not include fluoride
45768470|NCT01926002|Drug|Low-Dose MK-8351|Single administration of low-dose MK-8351.
45447289|NCT01314092|Biological|Autologous cultured adipose derived stem cells(high dose group)|high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
45627517|NCT05679219|Procedure|Wii Based Exergame|Wii-based exergame group, Nintendo wii game console balance games; In the literature, frequently used ones in different disease groups will be selected and played. In this context, Penguin Slide, Tightrople Tension, Tilt Table, Soccer Heading and Balance Bubble games will be played in each session under the supervision of an expert physiotherapist (executive), each game will be 8 minutes and the session will be 40 minutes in total. The motion sensor will be placed directly opposite the Balance Board. All games are played in a standing upright position on a double-footed Balance Board.
45627518|NCT05679219|Procedure|Wii Based Serious Game|The lower extremity strengthening and balance exercises within the Becure Balance System, developed in cooperation with the Physiotherapist, Academician and Engineer, will be performed by the Wii-based serious game group through the Wii Balance Board. Three games, Balance Surf, Balance Adventure and Balance Maze, which are among the balance games within the Becure Balance System application, will be played for 40 minutes in each session under the supervision of an expert physiotherapist (executive). The Wii Balance Board will be connected via Bluetooth from the menu in the Becure application. Then the Person will stand on the Balance Board and transfer weight in four directions in line with the instructions of the game on the screen.
45627519|NCT05695755|Diagnostic Test|ECHO, Serum electrolytes|echocardiography, serum electrolytes and cortisol level for all patients
45627520|NCT05454657|Device|Heart rate variability biofeedback + treatment as usual|"Heart rate variability biofeedback is a biobehavioral intervention involving rhythmic breathing at resonance frequency (RF) that stimulates the baroreflex and increases heart rate variability.~Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation."
45627521|NCT05454657|Behavioral|Treatment as usual only|Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation.
45627522|NCT05454189|Device|Reduced IPD Flush Schedule|IPD flush every 12 weeks
45627523|NCT05454189|Device|Standard IPD Flush Schedule|IPD flush every 4 weeks
45627524|NCT05678985|Behavioral|Choose to Move|As described under study arm description.
45627525|NCT02580591|Drug|Empagliflozin|
45627526|NCT02580591|Drug|Placebo|For blinding purposes
45627527|NCT05695677|Procedure|Capacitive-Resistive Radiofrequency therapy of the neck muscles|Capacitive-Resistive Radiofrequency therapy of the neck muscles as a non-invasive technique for treating PDPH.
45627528|NCT05688501|Other|descriptiv group|no intervention
45627529|NCT05561439|Other|Dosimetric monitoring|Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021
45627530|NCT05557461|Device|End-tifdal co2, systolic, diastolic blood pressure, ppv values and vci distensibility|"(0,1,3,5 minutes measurements will be taken) measured before and after the test will be recorded and compared.~Cardiac output and stroke volume variation, vci distensibility will be measured and recorded by a specialist cardiologist using siemens ocuson cv70 (Siemens AG Medical Solutions, Henkestrasse, the Germany) echocardiography before and after the test."
45447290|NCT02110186|Device|Dynamic Stabilization|
45627531|NCT05556057|Other|mindfulness meditation(MM)|Participants will be provided with a unique invitation code that will allow them to download and use the free research version of the Mindfulness Coach app that is designed to deliver mindfulness training developed by the Veteran Affairs' National Center for PTSD.The app is tailored to users who may be skeptical about meditation practices by providing simple instructions and brief meditation exercises. The app offers written information about mindfulness as well as 12 audio-guided meditations each lasting 8-13 minutes, with an average length of 10 minutes
45627532|NCT05556057|Other|Health Education (active control)|Participants will be asked to download and use the free TED Talk app.Each participant's account will include a list of over 80 TED Talks related to the six broad categories of sleep, nutrition, mood, relationships, chronic pain, and health behaviors. These talks range from 4 to 18 minutes and were reviewed/selected by the investigator team. The research coordinator(RC) will instruct them to watch or listen to these videos for ≥ 10 minutes daily for 6 days per week. The RC will ask participants to complete weekly logs of their TED Talk app use
45627533|NCT05555043|Device|Irrisafe ip|This portion of endodontic treatment includes chemical disinfection of the root canal system with these different devices that activate the disinfection solution and distribute it throughout the root canal system with ultrasonic energy.
45627534|NCT05555043|Device|GentleWave System|Prepare, clean and irrigate root canals including activation of the disinfection solution and distribution throughout the root canal system.
45627535|NCT05555043|Device|Waterlase iPlus|Prepare tooth and root canal, including enlargement, to debride, clean and disinfect after endodontic treatment.
45627536|NCT05552001|Drug|Sacituzumab govitecan|Sacituzumab Govitecan (SG) is given by intervenous route, 10 mg/kg on day 1 and day 8 of 21-day treatment cycles. Patient will receive treatment until disease progression, unacceptable toxicity, or decision to withdraw its participation.
45768471|NCT01926002|Drug|High-Dose MK-8351|High-Dose MK-8351 administered as a single inhaled dose.
45768472|NCT01926002|Drug|Placebo to MK-8351|Single-Dose Matching placebo to high-dose or low-dose MK-8351.
45768473|NCT01926080|Other|DVD Intervention Arm|Half of the parents will be prospectively randomized to receive the educational bereavement DVD entitled 'Grieving in the NICU- Mending Broken Hearts When a Baby Dies Too Soon'. A specific aim of the study is to evaluate the additional benefit of the Bereavement DVD over standard bereavement care in reducing parents' grief by comparing level of grief at each time point between the intervention (DVD) and control (no DVD) group.
45768474|NCT01926236|Other|Active Symptom Control|Active Symptom Control: monthly clinical review and active symptom control as needed, including biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy, blood transfusion.
45447291|NCT02110186|Procedure|Discectomy|
45447292|NCT02110186|Device|Instrumentation and fusion|
45447293|NCT02251132|Drug|TPV low 1|
45447294|NCT02251132|Drug|TPV low 2|
45447295|NCT02251132|Drug|TPV medium|
45447296|NCT02251132|Drug|TPV high 1|
45627537|NCT04261725|Genetic|EGFR mutation|Searching the EGFR mutation in pulmonary biopsy
45627538|NCT02580357|Procedure|Low Level Laser Therapy|Low Level Laser Therapy on the palatal donor site of connective tissue graft.
45627539|NCT02580357|Device|GaAlAs laser|Utilization of GaAlAs laser to irradiation on the palatal donor site.
45627542|NCT05680311|Biological|measurement of serum autotaxin serum level|autotaxin expression
45627543|NCT05678751|Diagnostic Test|lower genital tract microorganisms detection using Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS)|Detection of pathogens and microorganisms in the lower genital tract of infertile and spontaneously pregnant women by a new MALDI-TOF MS-based technique
45627544|NCT04097535|Other|PET/MRI|Imaging scan
45627545|NCT05404191|Device|low level laser therapy|"Low level laser therapy will be performed for 30 min 3 times per week for 8 weeks on the wound area.~Wound area was irradiated by a red 655 nm light, 150 mW, 2 J/cm2 at the bed of the wound."
45627546|NCT05390307|Drug|Liraglutide / Semaglutide|Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection for 6 months.
45627547|NCT05390307|Drug|Dapagliflozin|Dapagliflozin 5-10 mg once daily for 6 months.
45627548|NCT05390307|Drug|Liraglutide or Semaglutide / Dapagliflozin|Combined treatment with Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months.
45627549|NCT05390307|Drug|Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition|Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months combined with intensive lifestyle changes.
45627550|NCT05390307|Other|Usual care|Usual standard care
45627551|NCT05678517|Drug|Anti-VEGF|intravitreal ranibizumab or intravitreal aflibercept
45627552|NCT04079439|Behavioral|Physical activity with tailored e-health support|The planned e-health intervention will contain several elements: A motivating smartphone app registers indoor- and outdoor activity as well as activity from the use of an ergometer-bike. For recording of outdoor activity commercial wrist-born accelerometers will be used. The app-solution will be motivating and result in a reward after a predefined level of activity.
45627553|NCT04425369|Procedure|two-sided approaches for iliac crest bone graft|Only one side of the ilium was exposed when surgery.
45627554|NCT05542563|Behavioral|Healthy Minds Program (HMP) App|The full HMP app includes 5 modules with practices designed to cultivate categories of mental and emotional skills linked to both hedonic and eudaimonic well-being. These include the cultivation of mindful attention (Awareness), positive relationships with self and others (Connection), insight into the nature of self and internal experience (Insight), and purpose, values, and meaning in life (Purpose), as well as an initial module which includes abbreviated introductions to the topics and lessons in all four areas (Foundations). For this study, the active intervention will include 4 weeks of training using the Foundations module followed by 4 weeks of training using the Awareness module.
45627555|NCT05695443|Behavioral|Motivational Interviewing|This study investigates the effects of an intervention based on Motivational Interviewing (MI) on oral hygiene, oral cleaning routines, and attitudes towards own oral health. The first step is for the dental staff to ask open questions to the prisoner about their oral health or oral health behavior. The next step is to confirm to the prisoner what he or she is doing. The third step is called reflection. At this stage, dental staff tries to provide reflections on what the prisoner have said, for example by repeating what the prisoner have said or say the same using synonyms (simple reflection), by extracting the underlying opinion or feeling (complex reflection), or by illuminate both negative and positive sides of the situation (double sided reflection). The final step is to summarize the conversation. In addition, the intervention includes a change plan, in which the prisoner and dental staff agrees on specific behavior that the prisoner should follow based on the MI conversation.
45627556|NCT04012749|Behavioral|Advance directive|Patient receives a health system-specific advance directive along with a message crafted with input from a broad group of stakeholders at the clinical sites and external advisors. Messaging introduces advance care planning, the purpose of the advance directive and contains instructions for completing it and turning it in, as well as a prompt to discuss the document with the patient's primary care physician.
45768475|NCT01926236|Drug|L-folinic acid|L-folinic acid 175mg (or folinic acid 350mg) q14d, up to 12 cycles
45447297|NCT02251132|Drug|TPV high 2|
45447298|NCT02251132|Drug|RTV low|
45627557|NCT04012749|Behavioral|Prepare|Patient invited to use the Prepare For Your Care website (www.prepareforyourcare.org) that will introduce and facilitate advance care planning and guide completion of an advance directive.
45627558|NCT04012749|Behavioral|Facilitator|Facilitator engages patient to activate advance care planning and to carry out navigation and facilitation aspects of advance care planning. Facilitator can tee up advance care planning activities with the primary care physician.
45627559|NCT04000035|Other|Health and work environment information and processes|see arm/group description
45627560|NCT03988569|Other|audiovisual decision aid|Will view AVDA and then have opportunity for questions with physician before signing consent forms
45627561|NCT05357313|Device|Bright light therapy|Exposure to 10,000lux bright light for 30minutes a day for six weeks
45627562|NCT05357313|Device|Inactive negative ion generator|Exposure to an inactive negative ion generator for 30 minutes a day for six weeks
45627563|NCT04716777|Behavioral|Brief Transdiagnostic group-based Cognitive-Behavioral Treatment|Weekly group-based transdiagnostic CBT sessions for eight weeks.
45627564|NCT05319249|Biological|NK cells|NK cells will be given as a single intravenous infusion.
45627565|NCT05319249|Drug|Talazoparib 1 MG [Talzenna]|Subjects will receive treatment with Talazoparib capsules 1 mg/day (4 days) with subsequent intravenous NK cell infusion.
45768476|NCT01926236|Drug|5 FU|5 FU 400 mg/m2 (bolus), 2400 mg/m2 (infusion), q 14d, up to 12 cycles
45447299|NCT02251132|Drug|Ritonavir high|
45447300|NCT02251132|Drug|Radiolabelled erythromycin|
45447301|NCT02110342|Drug|[14C] PF-04449913|Single oral dose of 100 mg PF-04449913 + 100µCi of [14C] PF-04449913
45447302|NCT02110420|Drug|CC-90001|CC-90001 10mg will be administered as a single dose
45447303|NCT02110420|Drug|CC-90001|CC-90001 30mg will be administered as a single dose
45768477|NCT01926236|Drug|Oxaliplatin|Oxaliplatin 85mg/m2, q 14d, up to 12 cycles
45627566|NCT05539131|Device|transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) suppresses excitability and regulates excitability of neurons by injecting a small amount of current through electrodes attached to the scalp.
45627567|NCT05678361|Behavioral|Sleep/Nap|Participants sleep after a maximum of three sessions of exposure therapy.
45768478|NCT03049826|Other|Nutritional status|Body composition and nutrient status
45768479|NCT05601986|Other|Physiotherapy and Rehabilitation Program|"The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase: Progressive relaxation. Stretching phase: Stretching exercises for the muscles of the gastrocnemius, hamstrings, hip flexors, hip adductors Strengthening phase: Isometric strengthening exercises for the tibialis anterior, quadriceps, hip extensors, and hip abductors muscles.~Balance training phase: Two legs, one leg, balance with eyes open and eyes closed.~Weight-bearing phase: Weight transfer to the front, back, and sides using the balance board."
45768480|NCT05601986|Other|Additional Motor Imagery Training to Physiotherapy and Rehabilitation Program|The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase, Stretching phase, Strengthening phase,Balance training phase and Weight-bearing phase. Additional to the Physiotherapy and Rehabilitation Program, the Additional Motor Imagery Training program will be carried out for 8 weeks, 2 days a week, in addition to the 40-minute physiotherapy and rehabilitation program, accompanied by 25-30 minutes of supervision. It will be conducted by the researcher on two non-consecutive days of the week, by making appropriate appointments for the participants. During the program, participants will be asked to be in a quiet room. Sessions will consist of 4 consecutive phases: video watching, relaxation, motor imagery, and return to the environment.
45627568|NCT03849885|Drug|Benzoyl peroxide gel|Skin prep with Chlorohexidine wipes and BPO.
45627569|NCT04668885|Drug|CPX-351|"Induction phase: CPX-351 15 mg/m^2 on days 1 and 3 of each 28-day cycle for up to a total of 6 cycles in the absence of unacceptable toxicity~Maintenance phase: CPX-351 7.5 mg/m^2 on days 1 and 3 for two cycles alternating with 15 mg/m^2 for one cycle. Participants may receive up to 12 cycles of maintenance phase in the absence of unacceptable toxicity."
45627570|NCT05271747|Dietary Supplement|Lactoflora colicare|Probiotic multi-strain formulation containing Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8830 for 21 days, 5 drops/day preferably during the first intake of milk
45627571|NCT05271747|Dietary Supplement|Reuteri gotas|Probiotic single-strain formulation containing Lactobacillus reuteri DSM17938 for 21 days, 5 drops/day before or after any daily meal.
45627572|NCT05678283|Drug|[14C]CC-90010|Specified dose on specified days
45627573|NCT05678283|Drug|CC-90010|Specified dose on specified days
45627574|NCT01664091|Radiation|post-mastectomy radiation therapy (PMRT)|
45627575|NCT01664091|Device|tissue expander (TE)|
45627576|NCT01664091|Device|acellular dermal matrix (ADM)|
45627577|NCT02577315|Drug|Empagliflozin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
45627578|NCT02577315|Drug|Metformin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
45768481|NCT00983528|Biological|Alemtuzumab|3mg day 1,10mg day 2, 30mg day 3, 30mg day 5, 30mg day 8, then three times per calendar week thereafter for a total 12- 30mg doses
45768482|NCT00983528|Drug|Clofarabine|"Dose Escalation~Cycle 1 (30 days or until alemtuzumab completed) Clofarabine 10,20,30 or 40 mg/m2 days 5-9~Cycle 2 and subsequent cycles (administered no more frequently than every 28 days) 10,20,30 or 40 mg/m2 days 1-5"
45768483|NCT01926314|Device|PHENIX Neuromuscular Stimulation Therapy System device|
45627579|NCT02577315|Drug|Empagliflozin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
45768484|NCT01926314|Other|usual home care without device|
46069831|NCT02617641|Behavioral|Publicly available websites|"Le Programme de marche (Institut de Cardiologie de Montréal)~L'activité physique (Institut de Cardiologie de Montréal)~L'activité physique (Fondation des maladies du cœur et de l'AVC)~Directives canadiennes en matiére d'activité physique à l'intention des adultes âgés de 65 ans et plus (Société Canadienne de Physiologie de l'exercice)~Directives canadiennes en matière d'activité physique à l'intention des personnes âgées de 65 et plus (ParticipACTION)"
45627580|NCT02577315|Drug|Metformin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
45627581|NCT05535777|Behavioral|Enhanced texts with Callback by a Person|"Enhanced texts - Callback by a person: Patient randomized to this study arm will receive a phone call back by a call center agent if they press 1 in response to a question on the original text message. The call center agent's job is to schedule patients for clinical visits. These call center agents will be trained by our faculty and staff and will have the usual HIPAA and other patient confidentiality training."
45627582|NCT05535777|Behavioral|Enhanced Bidirectional Texts|"Patients randomized to this study arm will receive a text message from a call center agent if they press 1 in response to a question on the original text message. The bidirectional texts will have an agent who can answer questions and schedule an appointment through text message back-and-forth conversations with the patient."
45627583|NCT05529069|Drug|Pirtobrutinib|Given by PO
45627584|NCT05529069|Drug|Venetoclax|Given by PO
45627585|NCT04713345|Other|Virtual Reality Observations|If the patient is included in the Virtual Reality group, they will be asked to observe 1 time per day for 9 days for 5 minutes Virtual Motor Actions (avatar moving in a virtual environment) using a headset. Virtual Reality, followed by 5 minutes of relaxation performed using soothing music played through headphones.
45627586|NCT04713345|Other|Relaxation|If the patient is included in the Relaxation group, they will be offered 10 minutes of relaxation performed using soothing music played through headphones once a day for 9 days.
45627587|NCT05524545|Drug|Evorpacept|Fusion protein that blocks CD47-SIRPalpha pathway
45627588|NCT05524545|Drug|Enfortumab Vedotin|Nectin-4 directed antibody and microtubule inhibitor conjugate
45768485|NCT00983372|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 am on Day 1 after an overnight fast of at least 10 hours.
45768486|NCT00983372|Drug|Diltiazem ER|One 240 mg diltiazem ER capsule administered daily at 7:15 am on Days 15 to 21.
45768487|NCT00983372|Drug|Colchicine|A single dose of 0.6 mg colchicine administered along with diltiazem ER at 7:15 am on Day 21 after an overnight fast of at least 10 hours.
45627589|NCT03827031|Other|Mutlidisciplinary medication Review (MMR)|The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted
45627590|NCT03827031|Other|Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up|"Multidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient.~Community follow-up A summary of the follow-up report stating the therapeutic modifications (called below multidisciplinary correspondence documents) will be sent to the community pharmacist and physician. Within 2 months of discharge, the pharmacist performs a follow-up of medication changes accepted and not accepted by the community physician.~Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted."
45627591|NCT03749421|Other|Prosigna PAM-50 assay|Looks at the gene activity of a person's cancer cells to determine the likely outcome or course of a disease (prognosis) and predict the benefit of chemotherapy or endocrine therapy after breast surgery
45627592|NCT05675631|Other|Suspension training|This group will perform training using suspension devices.
45447304|NCT02110420|Drug|CC-90001|CC-90001 60mg will be administered as a single dose
45627593|NCT05675631|Other|Strength training|This group will perform training using weights and elastic bands.
45627594|NCT05220657|Diagnostic Test|Maximal incremental exercise test|Gas exchanges are measured during all the test on ergocycle until oxygen consumption reach its maximum value
45447305|NCT02110420|Drug|CC-90001|CC-90001 120mg will be administered as a single dose
45447306|NCT02110420|Drug|CC-90001|CC-90001 240mg will be administered as a single dose
45447307|NCT02110420|Drug|CC-90001|CC-90001 10mg will be administered daily for 14 days
45627595|NCT05220657|Diagnostic Test|Submaximal exercise test|A 25-min submaximal exercise test on ergocycle under fasting condition. Gas exchanges are measured during all the test.
45627596|NCT04712877|Diagnostic Test|ctDNA, tumor NGS|Testing for actionable oncogenic drivers
45627597|NCT05215119|Procedure|natural cycle endometrial preparation|Cycles will be monitored from either day-10 or-12, according to patient's menstrual cycle length, with serial analysis of blood serum LH and progesterone levels and assessment of dominant follicle growth. In a spontaneous cycle, ovulation will be determined by a LH surge (>20 IU/L) and a corresponding rise in progesterone (>0.8 ng/ml). In a triggered cycle, ovulation will be determined by the administration of an hCG trigger when the dominate follicle reached >16 mm (and LH was <20 IU/L).
45627598|NCT05210283|Device|MRD|ctDNA MRD test
45627599|NCT01582269|Drug|LY2157299 monohydrate|Orally administered as tablets
45627600|NCT01582269|Drug|Lomustine|Orally administered as capsules
45627601|NCT01582269|Drug|Placebo|Orally administered as tablets
45627602|NCT03658395|Procedure|Laparoscopic Sacrocolopopexy|The LSCP surgery involves pulling up the bladder, vagina, and rectum using a Y-shaped mesh attached to the lower back bone
45627603|NCT03658395|Procedure|Posterior repair|The PR surgery involves tightening the tissue between the rectum and vagina to reduce vaginal bulging during bowel movements.
45627604|NCT05678049|Diagnostic Test|Synovial fluid analysis|"For patients with knee under tension at the joint level, the symptomatology often requires evacuation by puncture under ultrasound guidance. The intervention will be performed only for patients for whom this therapeutic indication exists anyway by their physicians.~After making the evacuation we will want to use this liquid for Microscopic and Spectrophotometric evaluation"
45627605|NCT05187117|Behavioral|CAPABLE Family - Open Label Pilot|"As in CAPABLE (NA_00031539), the delivery characteristics of CAPABLE Family consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (~6 home visits for ≤ 1hour), a registered nurse (RN) (~4 home visits for ≤ 1hour) and a handy worker (HW).~Adaptations for cognitive decline will be made on a per-client basis as part of the open-label pilot. Topics of adaptations include problem areas addresses, care partner involvement, length/frequency of visits, types of assessments and questions asked, and brainstorming/action planning structure."
45627606|NCT05187117|Behavioral|CAPABLE Family - Randomized Control Trial|As in CAPABLE (NA_00031539), the delivery characteristics of CAPABLE Family consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (~6 home visits for ≤ 1hour), a registered nurse (RN) (~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
45768488|NCT01173211|Biological|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
45768489|NCT01173211|Biological|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber..
46069832|NCT02862899|Device|Thermowire|
46069833|NCT04287023|Other|individual physical therapy|cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises - individual
46069834|NCT04287023|Other|group physical therapy|cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises - groups of 10 patients
45627607|NCT05695365|Behavioral|Resistance Exercise Training|Participants will complete a 16-week, twice/week supervised resistance exercise training program to increase strength. Each session will last ~60 minutes and begin and end with a 5-minute aerobic warm-up/cool-down on a cycle ergometer, elliptical, treadmill, or walked laps. Training will begin with a 1-week standard familiarization process to introduce participants to the machines, teach correct lifting techniques, and ensure participant safety and comfort with each exercise machine. Participants will perform 3 sets of 8-12 repetitions on 10 Keiser resistance machines (i.e., leg press, hamstring curl, quadriceps extension, chest press, lat pulldown, shoulder press, biceps curl, triceps extension, abdominal crunch), with a 1-minute rest time between each set. Workload will begin at 50% of the estimated 1-RMs and increase by 5-10% after any session in which a participant completes 12 repetitions in all 3 sets. The workload will be tailored based on progressive increases in strength.
45627608|NCT05509413|Device|DEFLAGYN vaginal gel|DEFLAGYN is a vaginal gel, classified as a medical device, containing silica and citric acid, which binds pathogens, inhibits their spread and exerts an antioxidant effect. It is applied intravaginally (through an applicator) and used for 3 months.
45627609|NCT03580083|Genetic|RGX-111|Recombinant adeno-associated virus serotype 9 capsid containing α-L-iduronidase expression cassette
45768490|NCT01173211|Biological|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone®, Agriflu® and Fluarix® do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
45768491|NCT00983294|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:30 am on Day 1
45768492|NCT00983294|Drug|Azithromycin|Two 250 mg azithromycin tablets administered at 7:30 am on Day 15, then one 250 mg tablet administered daily at 7:30 am on Days 16 to 19.
45768493|NCT00983294|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with azithromycin at 7:30 am on Day 19.
45768494|NCT01926392|Drug|water-soluble therapy|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
45627610|NCT03526887|Drug|Pembrolizumab|200 mg, Q3W
45627611|NCT03526887|Drug|Pembrolizumab|200 mg, Q3W
45627612|NCT03505983|Device|ESR Prosthetic Foot First|Subjects will start with an ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
45627613|NCT03505983|Device|Articulating ESR Prosthetic Foot First|Subjects will start with an articulating ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
45768495|NCT01926392|Drug|silver sulfadiazine|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
45768496|NCT01129765|Device|Use of an automatic nasal irrigator/aspirator|After reading the device's user manual, parents were asked to use it on their congested children to their satisfaction. During this time, a clinical observer recorded predetermined steps that needed to be performed for success as well as presence of any adverse events.
45768497|NCT05601830|Drug|QN-030a|NK cell therapy
45768498|NCT05601830|Drug|Cyclophosphamid|Lympho-conditioning Agent
45768499|NCT05601830|Drug|Fludarabine|Lympho-conditioning Agent
45768500|NCT05601830|Drug|Cytarabine|Lympho-conditioning Agent
45768501|NCT00982280|Drug|Tapentadol PR|"Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg, 100 mg or 150 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period."
45768502|NCT01175317|Procedure|Goal-directed fluid optimization|Fluid administration and optimization based on cardiac output findings during surgery and during the first 8 hours of the postoperative phase.
45768503|NCT01175317|Other|Regimen based on expertise anaesthesist|Fluid regimen based on expertise anaesthesist
45768504|NCT04214587|Diagnostic Test|tissue and blood sampling|only diagnostics will be peformed
45768505|NCT01926470|Procedure|anteroposterior approach group|anteroposterior approach group (n=104): check intravascular injection while performing S1 transforaminal epidural steroid injection in anteroposterior view under fluoroscopy
45768506|NCT01926470|Procedure|oblique approach group|oblique approach group (n=104): same as anteroposterior approach group except using oblique view
45768507|NCT01175395|Drug|IBI-20089/Lucentis|Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.
45768508|NCT03066596|Behavioral|PRAGMATIC|Provider educational seminar, EHR prompt, outreach-worker care coordination
45768509|NCT03011905|Drug|Dexamethasone|4 ml DexaGalen 4 mg/ml
46069835|NCT00629681|Drug|Pregabalin|Pregabalin capsules; initial dose of 75 mg twice daily for 4 days. Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed. Total duration of treatment was 28 days.
46069836|NCT02617485|Drug|Rituximab|375 mg/m2 IV on day 1 of each 21 days chemotherapy cycle. Number of Cycles: 8.
45768510|NCT03011905|Drug|NaCl (Control)|4 ml NaCl 9 mg/ml
45768511|NCT03011905|Drug|Paracetamol|Premedication and as needed after operation
45768512|NCT03011905|Drug|EtoriCoxib|Premedication and first 2 postoperative days.
45768513|NCT03011905|Drug|Oxycodone|Total of 3 doses of OxyContin postoperatively. OxyNorm as needed.
45768514|NCT03011905|Drug|Ropivacaine|In brachial plexus block
45768515|NCT01926548|Drug|CJ Imatinib mesylate tablet|
45768516|NCT01926548|Drug|Gleevec film-coated tablet 2 x 100mg|
45768517|NCT03011983|Device|MEG|MEG is a non-invasive functional imaging technique that can measure slow-wave neural activity.
45768518|NCT03011983|Device|MRI|MRI is a non-invasive imaging modality that provides measures of brain structure.
45768519|NCT03011983|Behavioral|Neuropsychology assessment|A battery of tests will be administered by a neuropsychologist to evaluate the cognitive function of adolescents with concussion compared to healthy controls.
45768520|NCT00981578|Device|ExAblate 2100|Conformal Bone System
45447308|NCT02110420|Drug|CC-90001|CC-90001 30mg will be administered daily for 14 days
45447309|NCT02110420|Drug|CC-90001|CC-90001 60mg will be administered daily for 14 days
45627614|NCT03505983|Device|Powered Prosthetic Foot First|Subjects will start with a powered prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR foot and an ESR foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
45627615|NCT03496779|Drug|Brentuximab Vedotin - induction|Brentuximab vedotin 1.8 mg/kg at D8 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
45627616|NCT03496779|Drug|Gemcitabine|Gemcitabine 1000 mg/m² at D1 and D15 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
46069837|NCT02617485|Drug|Doxorubicin|50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle
45447310|NCT02110420|Drug|CC-90001|CC-90001 120mg will be administered daily for 14 days
45627617|NCT03496779|Drug|Brentuximab Vedotin - maintenance|"Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with brentuximab vedotin every 3 weeks for 12 infusions.~Brentuximab vedotin 1.8 mg/kg at D1 of a 21-day cycle - 12 cycles = 36 weeks for maintenance therapy"
45447311|NCT02110420|Drug|CC-90001|CC-90001 240mg will be administered daily for 14 days
45627618|NCT03496779|Procedure|autologous or allogeneic stem cell transplantation|Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation
45627619|NCT05657379|Other|Other: Product X moisturizer|Product X moisturizer containing Hyaluronic Acid and Rosa Damascena Flower Water
45627620|NCT02711345|Drug|LTT462|ERK Inhibitor
45627621|NCT03398655|Drug|VB-111 + Paclitaxel|VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week
45627622|NCT03398655|Drug|Placebo + Paclitaxel|Placebo will be administered intravenously every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week
45627623|NCT03115983|Device|LimiFlex|LimiFlex implantation at a single level after surgical decompression.
45627624|NCT03115983|Device|Fusion Instrumentation|Titanium alloy top-loading, polyaxial pedicle screws and cylindrical, titanium alloy rod instrumentation using autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only), and/or a synthetic bone graft extender that is on-label for these indications (i.e., decorticated posterolateral gutter only). The TLIF requires a single PEEK or Titanium TLIF cage cleared by FDA for this indication filled with autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only).
45627625|NCT03115983|Procedure|Decompression|Surgical decompression at one or two contiguous levels from L1 to S1.
45627626|NCT03115983|Procedure|Fusion|Transforaminal lumbar interbody fusion (TLIF) with concomitant posterolateral fusion (PLF) at a single level after surgical decompression.
45627627|NCT05695287|Drug|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor
45627628|NCT05695287|Drug|Isoflurane|Isoflurane
45627629|NCT05695287|Drug|Sevoflurane|Sevoflurane
45768521|NCT01176877|Behavioral|"Scripted lecture (educational information talk)"|This scripted lecture will be approximately 5 minutes in length and will include 3 picture examples of keloid and hypertrophic scarring as well as an opportunity to ask questions.
45768522|NCT01176955|Behavioral|Internet survey|A weekly email link will be generated to an internet survey which questions subjects about their acne severity, compliance with the study medication, and attitudes toward acne and the study medication.
46069838|NCT02617485|Drug|Vincristine|1.4 mg of vincristine per square meter, up to a maximal dose of 2 mg, administrated IV on day 1 of each chemotherapy cycle
46069839|NCT02617485|Drug|Cyclophosphamide|750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle
46069840|NCT02617485|Drug|prednisone|100 mg of prednisone administrated PO per day for five days, day 1-5 of each chemotherapy cycle
45447312|NCT02110420|Drug|Placebo|Placebo will be administered once daily for up to 14 days depending on the Part of the study
45447313|NCT02110420|Drug|CC-90001|CC-90001 480mg will be administered as a single oral dose
45447314|NCT02110420|Drug|CC-90001|CC-90001 720mg will be administered as a single oral dose
45447315|NCT02110420|Drug|CC-90001|CC-90001 480mg will be administered daily for 14 days
45447316|NCT03259334|Drug|Ontamalimab|Participants will receive 1 mL of SHP647 sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).
45447317|NCT03259334|Other|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
45447318|NCT02113696|Dietary Supplement|Omega 3 intake, morbid obesity|Individuals of both sexes with ages between 18 and 65 years took 3g of omega 3, and 1.8g eicosapentaenoic acid (EPA) and 1.2g docosahexanoic acid (DHA) for 8 weeks.
45627630|NCT03808025|Behavioral|opioid education|see arm/group descriptions
45627631|NCT03772691|Procedure|lateral suspension|• The vesico-vaginal space was found between the bladder and the anterior vaginal wall in the fascia plane. A polypropylene mesh (25 , 25 cm, Ethicon, Inc., Somerville, NJ) was cut to obtain two long arms (15-20 mm wide) and a rectangular piece (4-7 cm wide).
45627632|NCT03772691|Procedure|sacropexy|• The mesh is fixed on the anterior longitudinal ligament of sacrum with separated number 1 prolene sutures. The other end of the mesh is passed through the peritoneal tunnel and fixed to the cervix using prolene 1 and vicryl o sutures.
45768523|NCT01176955|Drug|Benzoyl peroxide 5% gel|Topical benzoyl peroxide 5% gel, to be used once daily to the face.
45768524|NCT00980798|Drug|OROS hydromorphone HCl|4 to 32 mg taken orally once daily for 16 weeks
45768525|NCT00980798|Drug|Placebo|placebo tablet once daily for 16 weeks
45768526|NCT01177189|Dietary Supplement|Vitamins C, E, and alpha lipoic acid|Oral antioxidant cocktail or placebo to be consumed daily
45768527|NCT05601284|Behavioral|Acceptance and commitment therapy|ACT teaches skills to develop acceptance, mindfulness, and defusion from difficult internal experiences while increasing connections with personal values and encouraging meaningful behavioral changes. ACT for misophonia combines core ACT processes with a traditional audiological behavioral intervention for a integrated, multi-disciplinary approach for the assessment and treatment of misophonia. Treatment begins with a brief focus on the behavioral intervention, followed by the teaching of ACT skills to support the use of the behavioral methods. The intervention consists of 12 total individual sessions of ACT+behavioral management.
45447319|NCT02113696|Dietary Supplement|Placebo Capsules|They received gelatin (colorless) capsules. A nutritional evaluation was performed, a 24-h recordatory was applied to verify macro and micronutrients intake, biochemical evaluation before and after the intervention. Macro and micronutrients were calculated using the Avanutri 2.0 system. Clinical history was verified through a questionnaire previously filled out by a physician.
45447320|NCT03553966|Procedure|Prophylactic|Tooth Brushing HA 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.
45627633|NCT05501067|Other|tai chi exercise|specific tai chi exercise
45627634|NCT05501067|Other|no intervention|no intervention
45627635|NCT03118115|Device|Measurement of the flap bioimpedance|Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.
45627636|NCT05097495|Procedure|Only NNS|"Before the procedure, the Premature Infant Comfort Scale shall be filled out.~Procedure steps for the control group:~Materials shall be prepared (napkins, non-sterile gloves, pacifier)~Hands shall be washed; gloves shall be worn.~The infant shall be given a NNS just before the procedure and continue until the 5th minute after the procedure.~The diapers shall be changed.~Hands shall be washed after the procedure.~The Premature Infant Comfort Scale shall be assessed during, shortly after, and 5 minutes after the procedure."
45627637|NCT05097495|Procedure|NNS Combined with Breast Milk|"Before the procedure, the Premature Infant Comfort Scale shall be filled out.~Materials shall be prepared (napkins, non-sterile gloves, pacifier, breast milk, cup)~Hands shall be washed; gloves shall be worn.~The cylindrical part of a pacifier shall be in touch with breast milk for 5 seconds. The infant shall be given the pacifier, combined with breast milk, just before the procedure and continue until the 5th minute after the procedure.~The diapers shall be changed.~Hands shall be washed after the procedure.~The Premature Infant Comfort Scale shall be assessed during, shortly after, and 5 minutes after the procedure."
45627638|NCT03662009|Other|multilimb dual task|control of arm and foot in two attentional contexts of simulated driving
45627639|NCT05677347|Drug|GSK3923868|GSK3923868 will be administered
45627640|NCT05677347|Drug|Placebo|Placebo will be administered
45627641|NCT05497869|Other|active release group|Patient is in supine lying position with 15-20° shoulder abduction. Then place finger tips under Pectoralis minor tendon and position the arm in 90°/90° shoulder abduction and elbow flexion. Apply the pressure while stroking the tender area and ask the patient to adduct the arm then bring shoulder backward while maintain the pressure 3 sets of 10 repetition/ 4 days per week for 3 weeks.
45627642|NCT05497869|Other|active control group|Conventional treatment- includes gentle shoulder ROMs i.e. flexion, extension, abduction, adduction, internal rotation and external rotation with-in pain free range, 10 repetitions each for 3 times a day
45768528|NCT05601284|Behavioral|Progressive relaxation training|PRT for misophonia consists of basic psychoeducation for misophonia followed by PRT. PRT involves learning to tense and relax muscles. Early sessions focus on tensing and relaxing smaller muscle groups, while later sessions focus on larger muscle groups. Final sessions focus on relaxation as produced by recalling previous relaxation and a review of skills learned. PRT consists of 12 individual total sessions.
45768529|NCT01926860|Biological|Prevenar13|
46069841|NCT05308394|Other|No experimental intervention will take place - the study is cross-sectional. Each participant will provide biological samples.|Each participant will provide a blood and fecal sample.
45627643|NCT03009201|Drug|Doxorubicin Hydrochloride|Given IV
45627644|NCT03009201|Other|Laboratory Biomarker Analysis|Correlative studies
45627645|NCT03009201|Other|Pharmacological Study|Correlative studies
45627646|NCT03009201|Drug|Ribociclib|Given PO
45627647|NCT00591227|Drug|insulin aspart|"insulin aspart: insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER.~If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating."
45627648|NCT00591227|Drug|insulin detemir|"insulin detemir: insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER.~If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating.If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating."
45627649|NCT00408473|Drug|Flecainide|
45627650|NCT00328601|Drug|Thioctic Acid|
45627651|NCT03193697|Device|cemented SPII prosthesis|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-four patients in the control group received a cemented SPII prosthesis (Link, Germany).
45627652|NCT03193697|Device|cementless Wagner prosthesis|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-two patients in the trial group received cementless Wagner prosthesis (Zimmer, USA).
45627653|NCT00189293|Drug|Imiquimod|"Imiquimod 5% cream three times per week for 4 weeks (1 sachet)~1 or 2 sachet(s)"
45627654|NCT00189293|Other|vehicle cream|"vehicle cream three times per week for 4 weeks (1 sachet)~1 or 2 sachet(s)"
45447321|NCT03553966|Procedure|Cleaning teeth|Tooth Brushing F 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.
45627655|NCT03194009|Drug|Metformin|The patient will received metformin 1 tablet of 850mg every 12 hrs besides lifestyle modification recommendations
45627656|NCT03194009|Behavioral|Lifestyle intervention|The patient will received recommendations to modify their diet and increase their physical activity every three months towards prevention of diabetes
45768530|NCT01926860|Biological|Hepatitis A vaccine|
45768531|NCT01177735|Drug|Pomalidomide|Only enough CC-4047 for 1 cycle of therapy may be provided to the patient each cycle. Participants will receive CC-4047 4 mg/day for 21 days, every 28 days. Treatment will continue until disease recurrence or untoward toxicity.
45768532|NCT01135069|Drug|Tretinoin microsphere 0.1%|Treatment of acne vulgaris
45768533|NCT01135069|Drug|Brand Retin-A Micro tretinoin microsphere gel 0.1%|Treatment of acne vulgaris
45768534|NCT01135069|Drug|placebo microsphere gel|treatment of acne vulgaris
45768535|NCT01178281|Drug|Pomalidomide 0.5 mg|Pomalidomide 0.5 mg capsule taken by mouth once daily. Immunomodulatory agent with demonstrated efficacy in the treatment of subjects with RBC-transfusion-dependence associated with MNP-associated myelofibrosis.
45768536|NCT01178281|Drug|Placebo|Placebo Comparator to active drug; Placebo capsule taken by mouth once daily
45627657|NCT03192761|Procedure|ACL reconstruction hamstrings|"HG reconstruction is performed according to the standard procedure of the department:~A double semi-Tendinosus and gracillis graft is used. Placement of the bony tunnels is anatomical, and the femoral tunnel is positioned through the antero-medial portal. Fixation proximally is by CL-endobutton and at the tibia by Intrafix sheet and screw"
45627658|NCT03192761|Procedure|ACL reconstruction patella tendon|"PTBG reconstruction is performed according to the standard procedure of the department:~A bone patella tendon bone graft of 1 cm width from the midportion of the tendon is used. Placement of the bony tunnels is anatomical, the femoral being positioned through the antero-medial portal. Fixation proximally and distally is by interference screws."
45627659|NCT03192761|Procedure|ACL reconstruction iliotibial tract|"TIFLG reconstruction is performed as follows:~The TIFL graft is harvested using two lateral incisions. The graft is left attached to the distal iliotibial tract. Placement of the bony tunnels is anatomical, the femoral being drilled outside-in. The tibial drill tunnel is made by retrograde drilling 20 mm, leaving cortical bone at the distal end of the tunnel. Fixation distally is by CL-endobutton or interference screw and on femur by an interference screw outside-in."
45768537|NCT01178281|Drug|Pomalidomide|Pomalidomide 0.5 mg capsule taken by mouth once daily.
45768538|NCT01135381|Behavioral|IVR-Enhanced Care|Those randomized to e-Coach will receive initial coaching in the hospital and then will be called by the interactive voice response-supported (IVR) system at specified intervals after discharge for monitoring. Any red flags noted through the IVR monitoring system will be transmitted to the care transition coaches, who contact patients and coach them on how to address problems identified.
45768539|NCT03012295|Other||
45768540|NCT03994159|Device|"Use of the PARO emotional robot"|PARO is an advanced interactive therapeutic robot designed to stimulate patients with Dementia, Alzheimer's, and other cognition disorders.
45768541|NCT01178827|Drug|trospium chloride|trospium chloride (60mg) once daily for 10 days
45768542|NCT01178827|Drug|oxybutynin IR|oxybutynin IR (5 mg) three times daily for 2 days
45768543|NCT01178827|Drug|oxybutynin IR placebo|oxybutynin IR placebo three times daily for 2 days
45768544|NCT03012217|Other|Observational Study|
45768545|NCT01135537|Biological|Thymoglobulin (rATG)|"Thymoglobulin 2.5 mg/kg of body weight IV administered daily for 3 days prior to HSCT.~Thymoglobulin infused over a minimum of 6 hours for the first infusion and over at least 4 to 6 hours on subsequent days of therapy."
45768546|NCT03011749|Other|FLT PET/CT|FLT PET/CT before first series of Radium-223 and after 2 series
45768547|NCT02181517|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
45768548|NCT02181517|Drug|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
45768549|NCT02181517|Other|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
45768550|NCT01179217|Drug|L-glutamine|0.3 g/kg of L-glutamine will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration. Mixing L-glutamine with soda or highly acidic juices (such as grapefruit juice or lemonade) is not recommended.
45768551|NCT01179217|Drug|Placebo|0.3 g/kg of placebo (100% maltodextrin) will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration.
45768552|NCT02181829|Radiation|Whole Lung IMRT|External beam radiation therapy will be administered on an outpatient basis, once daily (except weekends and holidays) for approximately two weeks. Patients will undergo a simulation prior to initiation of radiation. Once an IMRT plan is generated which meets all dose constraints specified patients will be treated with 6MV photons for 10 treatments.
45768553|NCT03010267|Drug|DP-R213|Investigational product is prescribed to all of randomized subjects
45768554|NCT03010267|Drug|Raloxifene|Investigational product is prescribed to all of randomized subjects
45768555|NCT03010267|Drug|Cholecaliferol|Investigational product is prescribed to all of randomized subjects
45627660|NCT02581995|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|2 mg aflibercept administered every 8 weeks following 5 initial monthly doses Intravitreal (IVT) injection
45768556|NCT03977311|Device|Sonalleve Magnetic Resonance-guided High Intensity Focused Ultrasound (MR-HIFU)|-To be used in conjunction with radiation therapy in the treatment of locally advanced cervical carcinoma patients
45768557|NCT03977311|Radiation|Radiation therapy|-Standard of Care
45768558|NCT01181323|Other|Placebo|0.2 ml of Intranasal placebo study product (using sucrose phosphate placebo filled sprayers), will be administered to maternal subjects.
45768559|NCT01181323|Biological|Cold-adapted live attenuated influenza virus vaccine, trivalent|Licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose LAIV (Flumist®) 0.1 ml administered to maternal subjects intranasally in each nostril for a total of 0.2 mL.
45768560|NCT01181323|Other|Placebo|0.5 ml of Sterile saline (0.9 percent Sodium Chloride for injection), administered IM to maternal subjects.
45627661|NCT03193385|Procedure|closed reduction|Closed reduction is where the thigh bone is placed into the socket without any surgical incision being made. This is more likely to be performed in a child under the age of four year. The femoral head is gently manipulated into the socket, whilst the child is under anaesthetic. Once the femoral head is in place, a hip Spica is applied and can remain in place for up to three months to maintain the hip in the correct position. This allows time for healing and for the socket and the thigh bone to mould together as a joint.
45768561|NCT01181323|Biological|Trivalent inactivated influenza vaccine|Preservative free, licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose of TIV (Fluzone®) 0.5 ml administered to maternal subjects, IM in the deltoid.
45768562|NCT03872947|Biological|TRK-950|Intravenously over 60 minutes
45768563|NCT03872947|Drug|Irinotecan|Intravenously over 30 - 90 minutes
45768564|NCT03872947|Drug|Leucovorin|Intravenously over 30 - 90 minutes
45768565|NCT03872947|Drug|5-FU|Intravenously bolus and intravenously for two days
45768566|NCT03872947|Drug|Gemcitabine|Intravenously over 30 minutes
45768567|NCT03872947|Drug|Cisplatin|Intravenously over 60 minutes
45768568|NCT03872947|Drug|Carboplatin|Intravenously per package insert
45627662|NCT03192605|Other|Blueberry|Blueberry - 150 grams wild blueberries (whole fruit)
45627663|NCT03192605|Other|Placebo|Placebo - matched for calories and fiber
45768569|NCT03872947|Biological|Ramucirumab|Intravenously over 60 minutes
45768570|NCT03872947|Drug|Paclitaxel|Intravenously
45768571|NCT03872947|Biological|Nivolumab|Intravenously over 30 minutes
45447322|NCT03553966|Device|Restorative dentistry|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
45768572|NCT03872947|Biological|Pembrolizumab|Intravenously over 30 minutes
45768573|NCT03872947|Drug|Imiquimod Cream|Topically
45447323|NCT01331824|Drug|Amrubicin|Patients will receive 35 mg/m2/day of amrubicin intravenously for 3 consecutive days as the initial dose starting on Day 1 of a 21-day cycle for up to 6 cycles
45447324|NCT02113774|Other|antimicrobial treatment according to in-vitro susceptibility|
45447325|NCT05571800|Other|Mango|120g of fresh Mango
45447326|NCT05571800|Other|Placebo|200g isocaloric Granola Bar
45447327|NCT02113930|Biological|Constitution of a biobank of frozen cells, plasma and serum samples|Depending on clinical presentation and based on previous data obtained by our group, we will investigate the immune responses against Human papilloma virus (HPV), Cryptococcus neoformans,implication of chemokines involved in lymphocyte migration (CXCR4 and CCR7 receptors) and signalisation in response to cytokines controlling LT CD4+ homeostasis (IL-7 et IL-2).
45447328|NCT02113930|Genetic|Genetic study|High rate genome wide genetic screening, investigation of mutations associated with identified primary immune deficiencies (adenosine deaminase et class II MHC)
45627664|NCT03192683|Device|Providence Pedi Cast-Sling|Custom made sling with readily available casting materials
45627665|NCT03192683|Device|Regular sling|
45627666|NCT03193307|Drug|Microgynon|Run in period & Treatment Period
45627667|NCT03193307|Drug|BI 409306|Day 18 & 29 (Treatment Period)
45768574|NCT03872947|Biological|Bevacizumab|Intravenously over 90 minutes for the first dose, over 60 for the second dose and over 30 minutes for all subsequent doses
45768575|NCT03872947|Drug|Topotecan|Intravenously over 30 minutes
45768576|NCT03872947|Drug|PLD|Intravenously over 60 minutes
45768577|NCT03855943|Behavioral|Personalized Computer Program|Training with a personalized computerized inhibitory training program
45768578|NCT03855943|Behavioral|CBT|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
45768579|NCT02246881|Biological|Optivate® (Human Coagulation Factor VIII)|
45768580|NCT00980330|Drug|TMC435|One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.
45768581|NCT00980330|Drug|Placebo|One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.
45768582|NCT00980330|Drug|Peg-IFN-alfa-2a (P)|180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.
45768583|NCT00980330|Drug|Ribavirin (R)|1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.
45768584|NCT01138735|Drug|adapalene/benzoyl peroxide|daily topical application for 12 weeks
45768585|NCT01138735|Drug|Topical Gel Vehicle|daily topical application for 12 weeks
45768586|NCT01181479|Drug|AG200-15 (cycles 1-13)|AG200-15 containing ethinyl estradiol and levonorgestrel
45768587|NCT01181479|Drug|Lessina crossover to AG200-15|Low dose oral contraceptive containing 20 mcg ethinyl estradiol and 100 mcg Levonorgestrel in 21 day regimen for 6 cycles followed by AG200-15 for 6 cycles.
45768588|NCT00980174|Drug|60 mg denosumab|60 mg denosumab (SC injection every 6 months)
45768589|NCT00980174|Other|Placebo|Placebo for denosumab (SC injection every 6 months)
45768590|NCT03064568|Drug|Misoprostol 100Mcg Tab|
45768591|NCT03064568|Drug|Placebo|
45768592|NCT01138969|Drug|esomeprazole|esomeprazole 20 mg qd for 6 months
45768593|NCT01139515|Drug|Eletriptan commercial tablet|20 mg tablet, single dose
45768594|NCT01139515|Drug|Eletriptan commercial tablet|40 mg tablet, single dose of 1 X 40 mg
45768595|NCT01139515|Drug|Eletriptan commercial tablet|40 mg tablet, single dose of 2 X 40 mg
45768596|NCT01139515|Drug|Eletriptan commercial tablet|40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first
45768597|NCT00980018|Drug|Nilotinib|Participants received two 150 [a total of 300 mg at each dosing] mg nilotinib capsules twice daily (bid) orally every morning and every evening approximately 12 hours apart and two 200 mg capsules [a total of 400 mg at each dosing] for patients enrolled prior to Protocol Amendment 1).
45768598|NCT01181947|Device|TEVAR|Thoracic endovascular aneurysm repair
45768599|NCT00987272|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
45768600|NCT00987272|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.1%|
45627668|NCT02910843|Drug|Regorafenib|"Regorafenib dosel level 1-3: day 1 to 14 and day 22 to 35 (2 weeks on 1 week off, 2 weeks on, including Saturday and Sunday) at a daily dose according to the escalation table.~Regorafenib dosel level -1: day 1 to 5, day 8 to 12, day 22 to 26 and day 29 to 33 (5 days on and 2 days off during week 1, 2, 4 and 5; week 3 off) at a daily dose according to the escalation table."
45627669|NCT02910843|Drug|Capecitabine|• Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.
45627670|NCT02910843|Radiation|Radiotherapy|Monday through Friday for 5 weeks and 3 days (d1-38) starting on day 1 (daily fraction 1.8 Gy, final dose 50.4 Gy).
45627671|NCT02910843|Procedure|Surgery|6-12 weeks (± 1 week) after radio-chemotherapy (RCT) has been completed (42-84 days after last day of RCT).
45627672|NCT03192527|Drug|KN015|experimental drug
45768601|NCT00987272|Drug|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
45768602|NCT00987272|Drug|Olopatadine 0.1% Vehicle|Inactive ingredients used as placebo comparator
45768603|NCT03709459|Drug|Doxycycline|Participants will be asked to take Doxycycline 100mg/day for 12months duration
45768604|NCT03010033|Other|pulmonary rehabilitation|"pulmonary rehabilitation (preoperative part): lower extremity endurance training (using bike ergometer for 3 days, 2 times/day, 15-20min/time) or stair climbing training (3 days, 2 times/day, 30min/time), keep dyspnea index (Borg) score between 5 to 7 points. And inspiratory muscle training (using threshold inspiratory muscle trainer for 3 days, 5 times/day, 2 sessions/time, every session includes 10-20 cycle respirations).~pulmonary rehabilitation (postoperative part): inspiratory muscle training (using threshold inspiratory muscle trainer until hospital discharge, 3-5 times/day, 1 session/time, every session includes 10-20 cycle respirations)."
45768605|NCT00986882|Drug|SAF312A|
45768606|NCT00986882|Drug|Placebo|
45768607|NCT00986882|Drug|Ibuprofen|
45913023|NCT02017457|Biological|Donor lymphocyte infusion|"On day 1 of cycle 2, 4 and 6 of Azacytidine, patients will be infused with donor lymphocytes (ideally on day 1 but in case of organizational problems, DLI can be administered until day 5) .~Patients with a sibling donor will receive:~5x10exp7 CD3+/kg on day 1 of cycle 2~5x10exp7 CD3+/kg on day 1 of cycle 4~10x10exp7 CD3+/kg on day 1 of cycle 6~Patients with an unrelated donor will receive:~1x10exp7 CD3+/kg on day 1 of cycle 2~5x10exp7 CD3+/kg on day 1 of cycle 4~10x10exp7 CD3+/kg on day 1 of cycle 6"
45913024|NCT02017457|Drug|Azacytidine|"Cycle 1: Subcutaneous administration of 100mg/m2/day for 5 days.~Cycle 2: Subcutaneous administration of 35mg/m2/day for 5 days. Cycles will be administered every 28 days.~All patients will receive at least 6 cycles of Azacytidine except if progression requests additional disease-related treatment such as hydroxyurea or other chemotherapeutic agents. In such cases, the patient will be excluded from the study and only disease status and survival status will be reported during the 3-year follow-up period. In case of complete remission after cycle 5, 2 additional cycles will be administered after achievement of complete remission.~In case of stable disease or partial response, Azacytidine will be continued until progression.~In case of disease progression after cycle 6, Azacytidine will be stopped."
45447329|NCT05571722|Drug|Vancomycin Injection|Patients receive a dose of 30 mg/kg of vancomycin (2 hours infusion) starting 2.5 hours before the scheduled time of surgical incision as defined in the French guidelines.
45627673|NCT03192527|Drug|Placebo|Comparator.
45627674|NCT03192527|Drug|Triptorelin|The drug is used for down-regulation of endogenous FSH.
45627675|NCT05655195|Device|GENUS device (Active Settings)|Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 60 minutes daily for 6 months.
45627676|NCT05655195|Device|GENUS device (sham settings)|Participants in the control group will use the GENUS devices configured to the sham settings for 60 minutes daily for 6 months.
45627677|NCT02444351|Drug|botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle|ultrasound-guided botulinum toxin type A (Nabota®, Daewoong co. Seoul, Korea) injection into the gastrocnemius muscle (maximum 200unit per each calf).
45627678|NCT02444351|Other|no intervention|Patients in the control group will not receive any injection on the gastrocnemius muscle.
45627679|NCT05677269|Procedure|Laparoscopic excision of endometriosis, including colorectal endometriosis|Laparoscopic resection of deep endometriosis, including colorectal endometriosis, in a (candidate) level 2 centre of expertise. Complete resection can exist of either 'shaving' of the nodule from the bowel (leaving the lumen closed), discoid excision or segmental resection, depending on the nodule size and extent of disease.
45627680|NCT05677269|Procedure|In vitro fertilisation|IVF treatment trajectory (maximum of 3 cycles), according to the local protocol. Preferably preceded by 3 months downregulation with either Gonadotrophin-releasing hormone (GnRH) analogue or oral contraceptive pill.One IVF cycle is defined as the transfer of all the embryos created after one follicle puncture until pregnancy confirmation or failure of the last embryo transfer.
45627681|NCT03193463|Drug|Topotecan (<=8cc)|In predominantly enhancing mass with a volume of 8 cc or less of topotecan administered
45627682|NCT03193463|Drug|Topotecan (>8cc)|In predominantly enhancing mass with a volume of > 8 cc of topotecan administered. Initial rate is 0.834ml/hour with an increase to 1.668 ml/hour at the second infusion
45768608|NCT01927094|Dietary Supplement|Probiotic|Comparison of probiotics vs. ORS
45768609|NCT01927094|Dietary Supplement|ORS|ORS ad libitum
45768610|NCT00983060|Drug|NIM811|BID in various doses (between 100 mg - 600 mg bid) + SOC (PEG IFN and RBV)
45768611|NCT00983060|Drug|Placebo BID + SOC|Placebo BID + SOC (PEG IFN and RBV)
45768612|NCT05600816|Device|Pounce Venous Thrombectomy System|The device is indicated for mechanical de-clotting and controlled and selective infusion of physician specified fluids, including thrombolytics, in the peripheral vasculature.
45768613|NCT05607914|Procedure|percussion massage|percussion massage to the dominant leg hamstring muscle for 5 minutes
46069842|NCT04289207|Drug|Romiplostim and danazol|Treatment with romiplostim and danazol
45447330|NCT05571722|Drug|Linezolid Injection|Patients receive a dose of 1200 mg of linezolid (30 minutes infusion) 30 minutes before the scheduled time of surgical incision.
45768614|NCT05607914|Procedure|static stretching|Static stretching to the dominant hamstring muscle for 5 minutes
45627683|NCT03193463|Device|Cleveland Multiport Catheter|an investigational device, will be used to deliver the topotecan
45447331|NCT02114008|Other|Endoscopic examinations|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional fasting (at least 8 hours before the test) and after abbreviated fasting (3 hours with 200ml of water containing 25g of 12.5% maltodextrin). All patients received both oral and written information about the protocol at the outpatient clinic.
45627684|NCT03193463|Diagnostic Test|Magnetic Resonance Imaging (MRI)|to monitor the infusion of topotecan into the tumor
45627685|NCT03193463|Drug|Lower Does Topotecan|Rate for non-enhancing tumors has an initial dose of 0.29ml/hour
45627686|NCT02444273|Procedure|Exercise|Subjects will be given and individualized exercise program.
45768615|NCT04759352|Other|Post-test genetic counseling delivered by telephone|Participants enrolled in the experimental arm will receive genetic counseling for test result communication by telephone.
46069843|NCT04928378|Other|Descriptive retrospective study|characterization of the diagnosis, management and outcome of patients with osteoarticular infection due to MDR M. tuberculosis in France (MDR IOATB).
45768616|NCT01927172|Device|AirSonea|
45447332|NCT02110654|Drug|Montelukast|
45447333|NCT02110654|Drug|mometasone furoate nasal spray|
45768617|NCT04759430|Other|Supervised Group|Individuals will apply ten different stabilization exercises in company with a physiotherapist.
45913025|NCT02017470|Other|Gender-tailored women's heart health outpatient programme|
45913026|NCT02017509|Procedure|Diagnostic Biopsy and Surgical Procedure|A tumor sample from the diagnostic biopsy and surgical procedure will be used for research.
45447334|NCT03258710|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate is a nucleos(t)ide analogue that inhibits HBV growth. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.
45627687|NCT02577003|Drug|Ipragliflozin|50 mg tablet administered orally
45627688|NCT02577003|Drug|Placebo|Placebo to ipragliflozin tablet administered orally
45627689|NCT02577003|Drug|Sitagliptin|Background medication; 50 mg tablet administered orally
45627690|NCT03193229|Behavioral|MapTrek|The objective of the study is to provide an inexpensive and scalable m-health tool to increase both volume and intensity of physical activity and reduce sedentary behavior in patients at risk for or already diagnosed with pre-diabetes.
45627691|NCT03193229|Device|Fitbit|Fitbit
45627692|NCT05487417|Drug|Minocycline|Minocycline is a tetracycline antibiotic. Previous studies have confirmed that its application in stroke patients has good efficacy and safety, suggesting that it could become a synergistic treatment of mechanical thrombectomy.
45627693|NCT03471611|Drug|Autologous CD34+ Cells|The dose will be 1x10^5 cells/kg, injected at the rate of 10 ml/min
45913027|NCT02017509|Procedure|Intravoxel incoherent motion MRI (IVIM)|At the end of a standard MRI, we will perform IVIM, which is a diffusion-weighted imaging sequence that simultaneously characterizes the microscopic diffusivity of water and the macroscopic transport of water via bulk flow. IVIM may more accurately reflect the properties of the tumor microenvironment including vascular permeability, interstitial fluid pressure, and response to neoadjuvant therapy.
45768618|NCT04759430|Other|Telerehabilitation group|Same stabilization exercises will be performed online with the patient by the researcher physiotherapist and supervised through the video conference or phone.
46069844|NCT02617329|Other|Extracorporeal shock wave therapy (ESWT)|The Extracorporeal shock wave therapy (ESWT) was applied on upper trapezius and levator scapulae following parameters 1.5 bar, per intervention 2000 impulse, once a week for three weeks for the experimental group
46069845|NCT02617329|Other|cervical flexion|Education have 8 movement home program for flexion, extension, side bending, rotation in neutral position, and rotation in a position of full cervical flexion.
46069846|NCT04252118|Biological|MSCs|3 times of MSCs(3.0*10E7 MSCs intravenously at Day 0, Day 3, Day 6).
46069847|NCT02863835|Other|EIT|All participants will have continuous monitoring of EIT whilst self venting
46069848|NCT02863835|Other|Salbutamol nebulisation and with CPAP|All participants will have continuous monitoring - salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure during this time.
46069849|NCT00697437|Drug|Docetaxel|70mg q3wx 1 dose
46069850|NCT00697437|Drug|Ketoconazole|6 doses of oral ketoconazole 200mg bid starting 2 days before, and with 1 dose to be completed after, docetaxel infusion
45627694|NCT03471611|Drug|Granulocyte Colony-Stimulating Factor (G-CSF)|5mg/kg twice daily
45768619|NCT00981656|Drug|cisplatin|60-minute intravenous (IV) infusion of 15 mg/m^2 on days 1, 2, 3, 15, 16, 17, 29, 30, and 31 of radiation treatment.
45768620|NCT00981656|Drug|5-fluorouracil|Continuous IV infusion of 500 mg/m^2/24 hrs for 5 consecutive days during weeks 1 and 4 of radiation treatment.
45768621|NCT00981656|Drug|Mitomycin|IV bolus dose of 12 mg/m^2 on day 1 of radiation treatment.
45768622|NCT00981656|Radiation|Three-Dimensional Conformal Radiation Therapy|Total dose to the gross bladder volume of 61.2 Gy as 34 daily fractions 5 days/week, for approximately 7 weeks.
46069851|NCT04252274|Drug|Darunavir and Cobicistat|Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments
46069852|NCT04133727|Behavioral|Use of an ageing suit|The simulation suit consists of a pair glasses which simulates narrowing of visual field; a pair of gloves ; a vest ; elbow and knee wraps and sand bags worn on the wrists and ankles
45627695|NCT03281057|Behavioral|CRAFT|CRAFT is a counseling/therapist to concern significant others to get their loved one, with an alcohol use disorder, into treatment
45627696|NCT05694819|Drug|Darolutamide|Darolutamide at a dose of 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally.
45627697|NCT05694819|Drug|Goserelin|Goserelin at a dose of 3.6 mg will be administered subcutaneously every 4 weeks.
45768623|NCT00988052|Drug|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
45768624|NCT04557800|Drug|DNL151|oral dose(s)
45768625|NCT04557800|Drug|Placebo|oral dose(s)
46069853|NCT04133727|Other|Polypharmacy workshop|Participants will conduct a full medication review for older adults within 1 hour and develop a medication list which can be used for counselling of older adults
45913028|NCT02017509|Procedure|Dynamic Contrast Enhanced MRI (DCE-MRI)|Following a standard MRI scan, Dynamic Contrast Enhanced MRI (DCE-MRI) will be done. DCE-MRI is an indicator-dilution experiment in which the delivery and transcapillary transfer of a contrast agent, typically one of a number of gadolinium-based contrast agents (GBCA), is used to assess a number of parameters characterizing tissue physiology. In locally advanced rectal cancer patients, use of DCE-MRI for determining pathologic response has produced equivocal results but more promising data has been published recently in the cervical cancer literature.
46069854|NCT04133649|Drug|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
45627698|NCT05677113|Drug|QBECO|QBECO is a site specific immunomodulator (SSI) designed to promote innate immune responses in the gastrointestinal tract and related organs, including the liver. QBECO will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
45768626|NCT05607836|Device|IntuBrite intubation|Use of new laryngoscope IntuBrite for intubation in patients with cardiopulmonary arrest and during resuscitation
45627699|NCT05677113|Drug|Placebo|Placebo will be prepared in the same way as the IP. Placebo will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
45627700|NCT03192917|Procedure|Low intensity extracorporeal shock wave treatment (LI-ESWT)|Shock wave treatment with 3000 Hz for 10 min on the penile shaft. This will be done one time a week for five weeks.
45627701|NCT03192917|Procedure|Low intensity extracorporeal shock wave treatment (LI-ESWT) sham|A specialized cap can be applied to the chock wave device, which disallow shock waves to transmit through the unit.
45768627|NCT05607836|Device|Macintosh laryngoscope|Use of standard Macintosh blade laryngoscope for intubation in patients with cardiac arrest and requiring cardiopulmonary resuscitation
45447335|NCT02110810|Drug|Indomethacin|Indomethacin suppository of 100 mg immediately afterwards while still under sedation
45447336|NCT02110810|Drug|2.6-g suppository of glycerin|to receive a 2.4 g of glycerin suppository immediately afterwards while still under sedation
45447337|NCT02107924|Procedure|APPI of TKR-Stimulan|
45447338|NCT02110888|Device|Subcutaneous peripheral nerve stimulation|
45768628|NCT04395170|Biological|COVID-19 convalescent plasma|Plasma from convalescent patients with COVID-19 and at the same time receiving supportive therapy, with inactivation / reduction of pathogens, in the scheme of two doses of 200 - 250 mL administered on days 1 and 3 of the intervention.
45768629|NCT04395170|Biological|Anti-COVID-19 human immunoglobulin|"Anti-COVID-19 human immunoglobulin produced by Lifefactors Zona Franca S.A.S, intravenously at a dose of immunoglobulin 10% IgG solution (10% mL vial) for:~Patient of 50 Kg or more, a dose of 50 mL, administered on days 1 and 3 of treatment.~Patient under 50 Kg, the dose will be 1 mL / Kg, administered on days 1 and 3 of treatment.~The supply of anti-COVID-19 human immunoglobulin produced by Lifefactors Zona Franca S.A.S included once it has been authorized by INVIMA and/or the regulatory requirements in force for the production of drugs are met."
45447339|NCT02110888|Other|SCS Only|
45913029|NCT02017509|Genetic|RNA gene expression analysis|RNA will be collected from biopsy and surgical tissue for gene expression analysis.
45913030|NCT02017548|Behavioral|Life-extension default advance directive|
45768630|NCT04395170|Drug|Standard (specific) therapy for COVID-19|"Standard therapy for COVID-19 according to the recommended pharmacological recommendations of the Colombian Association of Infectious Diseases - ACIN. This therapy is subject to changes that are defined by the Colombian Health Regulatory Authorities.~To date, these therapies may include remdesivir, chloroquine, hydroxychloroquine, azithromycin."
45913031|NCT02017548|Behavioral|Comfort default advance directive|
45913032|NCT02017561|Behavioral|Lifestyle Counseling|Written and individualized information during the interview in all clinic visits, emphasizing the importance of a healthy lifestyle, engaging on regular moderate-intensity physical activity and eating an healthy diet.
46069855|NCT05251844|Other|receiving an email|The email informed that the employee has had been identified as having accessed a patient's electronic medical record without a known work-related purpose and that unauthorized access is a privacy violation.
46069856|NCT02617173|Device|Micro 400 Matrix Therapy Products|Positive electrical current with a low amplitude bellow sensation level situated on the scrotum.
46069857|NCT05296226|Procedure|dry needling and ischemic compression|dry needling is an invasive procedure where a fine Needle or acupuncture needle is inserted into the skin and muscle Ischemic compression is one of the least invasive trigger point therapies. Ischemic compression is a mechanical treatment of myofascial trigger points that consists of application of sustained pressure for a long enough time to inactivate the trigger points.
46069858|NCT04134585|Other|semi-structured interviews|Semi-structured interviews will be performed to determine representations of physical activity, reluctance/motivation to participate in physical activity sessions and facilitators who can help them overcome these barriers.
46069859|NCT04255316|Procedure|Modified method of eversion carotid endarterectomy|Mini approach for CCA bifurcation - Clamping ICA, ECA and CCA - ICA is cut off with a scalpel at the mouth itself - Dissection of the ICA and ECA in the distal direction to the distal border of the atherosclerotic plaque - Endarterectomy - Performing of a new bifurcation of the CCA with prolene 7/0
45447340|NCT02108002|Drug|Vorinostat|
45447341|NCT02108236|Device|acupuncture|Zhong-wan (RN12), Liang-men (ST21), Shui-fen (RN9) and Qi-hai (RN6) and bilateral acupuncture points Dai-mai (GB26), Tian-shu (ST25), Zu-sanli (ST36), Feng-long(ST40) and Liang-qiu(ST34) will be applied through the skin by acupuncture for 30 minutes every time. Electro-acupuncture apparatus will be connected to both Dai-mai, Zu-sanli and Feng-long, Zhong-wan and Qi-hai for 30 minutes with interrupted waves (2/100HZ).
45627702|NCT03200327|Procedure|promontofixation|reconstruction of cystoceles using a subvesical prosthesis
45627703|NCT03200327|Procedure|sacrospinofixation|Utero-vaginal suspension by bilateral anterior sacrospinofixation using the vaginal route
45627704|NCT03192839|Other|Low dose PUFA|Low dose PUFA
45627705|NCT03192839|Other|High dose PUFA|High dose PUFA
45627706|NCT03192839|Other|Placebo|Placebo
45627707|NCT05174741|Other|Conventional Chest Physiotherapy|Diaphragmatic Breathing exercise 15 repetition ACBT *3 sets/session*TD Walk (10-15 minutes) * BD
45627708|NCT05174741|Other|Aerobic training Group|"Supervised Conventional Chest Physiotherapy + Aerobic training~Aerobic training on cycle ergometer:~between 50% and 70% Vo2max, perceived exertion up to 11 on Borg scale 20-30 min/session/day"
45627709|NCT03098693|Behavioral|HIV Self-Testing|Access to home-based HIV self-testing kits for stable couples.
45627710|NCT03098693|Behavioral|Immediate Access to ART for HIV infected couple members|Immediate access to ART for HIV infected couple members (per current Tanzanian standard of care).
45627711|NCT03098693|Behavioral|Access to PrEP for HIV uninfected couple members|Access to PrEP for HIV uninfected couple members.
45627712|NCT02866487|Procedure|Bronchoscopy|A diagnostic bronchoscopy will be conducted for clinical indications in children referred to the University of Virginia Children's Hospital for evaluation of respiratory symptoms
45627713|NCT02600897|Drug|Lenalidomide|All participants will receive lenalidomide oral capsules at doses of 10, 15, or 20 milligrams (mg) on Days 1 to 21 of each 28-day cycle for up to 6 Cycles in dose escalation phase followed by post-induction treatment at a dose of 10 mg once daily on Days 1 to 21 of each subsequent 28-day cycle. Post-induction lenalidomide may continue for up to 12 months until disease progression or unacceptable toxicity for participants with R/R FL and up to 6 months until disease progression or unacceptable toxicity for participants with R/R DLBCL.
45627714|NCT02600897|Drug|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 followed by post-induction treatment at a dose of 1000 mg via IV infusion on Day 1 of every other month for up to 24 months until disease progression or unacceptable toxicity.
45627715|NCT02600897|Drug|Polatuzumab Vedotin|Participants with R/R FL will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) on Day 1 of each 28-day cycle for up to 6 months during induction treatment. Participants wit R/R DLBCL will receive polatuzumab vedotin via IV infusion at dose 1.8 mg/kg on Day 1 of each 28-day cycle for up to 6 months during induction treatment.
45627716|NCT02600897|Drug|Rituximab|Participants will receive a fixed dose of rituximab, 375 mg/m^2 via intravenous (IV) infusion to be given on Days 1 of Cycle 1 to 6 followed by post-induction treatment at a dose of 375 mg/m^2 via IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
45627717|NCT05470335|Procedure|nurse-led sheath insertion|radial sheaths for coronary examination and intervention are performed by experienced nurses
45627718|NCT05674305|Drug|Radiotherapy|IMRT for primary and regional field
45627719|NCT05674305|Drug|Cisplatin|Cisplatin 80mg/m2, 21days/cycle, 2 cycles
45627720|NCT02443649|Behavioral|Sleep hygiene program|Sleep hygiene program
45627721|NCT02443649|Behavioral|Sleep hypnosis|Hypnosis recording with personalized goals and imagery for sleep improvement
45627722|NCT03192449|Drug|Albendazole.|Single dose 400mg orally
45627723|NCT05666973|Procedure|Open Mesh Hernioplasty|"Steps of surgery:~Injection Ceftriaxone 50 mg/kg iv stat dose will be given pre-operatively~Incision:~Incision given over medial 3/5 and 2.5 cms above and parallel to inguinal ligament extending from pubic tubercle upto 1 cm lateral to mid point of inguinal ligament.~bleeding controlled by forcep coagulation.~Cut the subcutaneous tissues,external oblique aponeurosis opened in layers~Nerve Iliohypogastric & ilioinguinal will be preserved (by taking aside from the field)~Intra-operative Injection Tramadol(50 mg) and ondansetron(4 mg) iv stat dose given~Sac ligated with Polygalactin 2-0 suture.~Lichtenstein method of repair~Mesh type: large pore polypropylene mesh~Mesh size: 3 x 6 inches(7.5 x 15 cms)~Mesh Fixation: polypropylene 2-0~External oblique closure~Skin closure: Ethilon 2 - 0 suture"
45627724|NCT04308057|Procedure|Aquatic exercise|Participants belonging to Group D (sedentary group) will be randomised 1-to-1 between remaining sedentary (n=20) and following a self-managed, 8-week, aquatic-based exercise programme (n=20). The latter group will be offered an 8-week access to pool facilities. For Group D participants, all baseline assessments will be repeated at 8 weeks.
45627725|NCT05691933|Procedure|Block group|Patient will be subjected to bilateral external oblique intercostal plane block
46069860|NCT04255316|Procedure|Standard method of eversion carotid endarterectomy|standard eversion technic
45452463|NCT03961373|Procedure|Gastrectomy with D2 lymphadenectomy|Patients who are assigned to the neoadjuvant chemotherapy+ surgical D2 treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2-lymph node dissection is required with specific information about lymph node stations.
46069861|NCT04130607|Other|Conceptual teaching|"The present study is designed to contrast two instructional methods - explicit instruction in likelihood ratios and pretest/posttest probabilities versus implicit instruction based on presentation of multiple cases. These will be compared to a no intervention control group."
46069862|NCT04130373|Procedure|Autologous fat grafting procedure|Surgical intervention based on the injection of autologous fat grafting after radical or conservative breast surgery and breast reconstruction.
45627726|NCT05691933|Procedure|Morphine infusion|Patients will be subjected to morphine infusion at a rate of 0.03mg/kg/h
45627727|NCT02443493|Device|Low-level laser|Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
45627728|NCT02443493|Device|sham laser|Sham Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
45627729|NCT02443493|Radiation|radiotherapy|
45627730|NCT00977483|Drug|Thioctic Acid|600mg tablet once daily 4 years double-blind treatment period
45627731|NCT00977483|Drug|Placebo|1 tablet once daily 4 years double-blind treatment period
45627732|NCT02439905|Drug|Dexmedetomidine|In dexmedetomidine group, dexmedetomidine infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
45627733|NCT02439905|Drug|Placebo control|In normal saline group, normal saline infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
45768631|NCT04394936|Drug|Guselkumab|100 mg guselkumab administered subcutaneously
45768632|NCT04394936|Drug|Placebos|Sodiumchloride 0,9% solution for injection
45627734|NCT03190421|Diagnostic Test|Expanded Urinary Culture|involves the inoculation of 100X (0.1mL) more urine onto diverse types of media (BAP, chocolate agar, colistin and nalidixic acid (CNA) agar, CDC anaerobe 5% BAP) with incubation in more environments and temperatures (5% CO2 at 35°C for 48 h, aerobic conditions at 35°C and 30°C for 48 h, Campy gas mixture (5% O2, 10% CO2, 85% N) or anaerobic conditions at 35°C for 48 h). The level of detection for EQUC is 10 CFU/mL, represented by 1 colony of growth on any of the plates. EQUC is designed to isolate a broad array of Gram-negative and Gram-positive bacteria, including anaerobes and fastidious bacteria that grow slowly.
45627735|NCT03190421|Diagnostic Test|Standard Urine Culture (SUC)|involves inoculation of 0.001 mL of urine onto 5% sheep blood agar plate (BAP) and MacConkey agar plate with the plates being incubated aerobically at 35°C for 24 h. Thus, the level of detection for standard culture is 103 CFU/mL, represented by 1 colony of growth on either plate. Standard culture is designed specifically to grow Gram-negative rods, especially UPEC.
45627736|NCT03192371|Biological|Rabipur|Rabies vaccine administered as an intramuscular injection according to Zagreb or Essen regimen to subjects aged ≥6 to ≤17 years.
45627737|NCT02439983|Dietary Supplement|Proprietary Nutritional Supplement|2 capsules taken by mouth with morning and evening meals.
45627738|NCT02439983|Dietary Supplement|Placebo|2 capsules taken by mouth with morning and evening meals.
45627739|NCT02446899|Biological|Anifrolumab|Intravenous infusion (IV)
45627740|NCT02446899|Drug|Placebo|Intravenous infusion (IV)
45627741|NCT02709785|Drug|SmartMouth Clinical DDS mouthrinse|Subjects use SmartMouth Clinical DDS mouth rinse for six weeks.
45627742|NCT02709785|Drug|0.12% chlorhexidine rinse|Subjects use chlorhexidine mouth rinse for six weeks.
45768633|NCT04394702|Other|One Shape Single-file rotary system|rotational single file system used for mechanical debridement of root canals
45627743|NCT02709785|Drug|Placebo rinse|Subjects use placebo mouth rinse for six weeks. The placebo rinse is the same as SmartMouth Clinical DDS, but without the active ingredients.
45627744|NCT02440061|Drug|Synthetic human AG|Synthetic human AG (0.28 μg/kg) bolus over 1 minute followed by 2 μg/kg/hr continuous infusion for 4.5 hours.
45627745|NCT02440061|Drug|Arginine|Arginine hydrochloride (5 g) intravenously over 45 seconds.
45627746|NCT02440061|Drug|0.9% saline solution|A continuous infusion of 0.9% saline solution (control) for 4.5 hours.
45627747|NCT03190343|Procedure|cholangio-pancreatoscopy|
45627748|NCT05663073|Drug|Irbesartan/Amlodipine FDC|Irbesartan/Amlodipine FDC
45627749|NCT05663073|Drug|Irbesartan|Co-administration of Irbesartan and Amlodipine
46069863|NCT04130373|Procedure|Breast reconstruction|Breast reconstructive procedures after oncological radical or conservative breast surgery
46069864|NCT04130451|Drug|PYODINE AND TALC SLURRY|"pyodine Povidone-iodine is a broad spectrum antiseptic for topical application in the treatment and prevention of wound infection. It may be used in first aid for minor cuts, grazes, burns, abrasions and blisters.~TALC a white, grey, or pale green soft mineral with a greasy feel, occurring as translucent masses or laminae and consisting of hydrated magnesium silicate"
46069865|NCT04130295|Other|Wearable intensive nerve stimulator|The wearable device consists of 2 leads that provide biphasic, with alternating lead phase, asymmetrical rectangular current at a pulse duration of 0.28 msec, a randomly varying pulse frequency between 60-100 Hz, with a maximum intensity of 100mA.
45447342|NCT03769948|Other|risk factors for diabetic retinopathy|Demographic variables: gender, race, marital status, urban rural status. Co-morbidity variable: neuropathy, nephropathy, peripheral circulatory, ketoacidosis, hyperosmolarity Lab tests variables: alanine aminotransferase (ALT), albumin serum, anion gap, aspartate aminotransferase, blood urea nitrogen, calcium serum, chloride serum, creatinine serum, glucose serum plasma, hematocrit, hemoglobin, mean corpuscular hemoglobin concentration (MCHC), mean platelet volume (MPV), potassium serum, protein total serum, red blood cell (RBC) count, sodium serum, white blood cell (WBC) count
45627750|NCT05663073|Drug|Amlodipine|Co-administration of Irbesartan and Amlodipine
45627751|NCT02439827|Behavioral|"Fortaleça sua Saúde program"|The program duration was of one academic semester (approximately four months) in 2014. The intervention strategies focus on teachers' training and activities on health in curriculum (including a specific training to Physical Education teachers), active opportunities in the school environment (availability of spaces and materials for PA) and health education (production and exhibition of health material at school, and distributing pamphlets to students and parents).
45627752|NCT02442947|Other|clothing type, protective garments of Paul Boye Technologies|The experiment aimed at evaluating the physiological stress obtained when dressed in different clothing (NBC protective garment [charcoal base], combat garment and 2 different types of work uniforms- (1)50% cotton and 50% polyester (2)80% cotton and 20% polyester) and during exertion under heat conditions.
45627753|NCT05653323|Drug|VX-993|Suspension for oral administration.
45627754|NCT05653323|Drug|Placebo|Suspension for oral administration.
45627755|NCT02443025|Behavioral|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
45627756|NCT05632341|Dietary Supplement|Lactococcus lactis|1 capsule once a day
46069866|NCT04031079|Device|Wearable tech with feedback|an armwrist device measuring physical activity level. The user will receive information about their physical activity level through their smartphone
45627757|NCT05632341|Other|maltodextrin|1 capsule once a day
45768634|NCT04394702|Other|manual stainless steel K-file|sequential manual filing with stainless steel K-files
45768635|NCT04559516|Behavioral|Exercise Intervention|"The Ethica mobile app will provide a daily alert accompanied by a short educational statement about PAH, disease self-management tips, dietary and nutritional advice, goal setting, and a motivational statement to encourage patients.~Participation with each session will be assessed by a mobile app-embedded survey administered at the end of the day. Patients will be presented with weekly alerts to complete validated patient-reported quality of life questionnaires using the EmPHasis-10 and the Living with Pulmonary Hypertension Questionnaire, as well as the PRAISE self-efficacy score for pulmonary rehabilitation. The app will also ask patients to report their WHO/NYHA functional class every week. Using in-app buttons, participants can log adverse events associated with each exercise session."
45768636|NCT04559516|Behavioral|Standard Care|Participants will be provided usual care administered at the PH clinic at the University of Calgary and no supervised exercise session will be performed.
45768637|NCT01927250|Behavioral|Okada Health and Wellness program|Each participant were encouraged to practice the diet program and art therapy established by the MOA International Corporation, and to receive Okada Purifying Therapy, a domain of biofield therapy, for 3 consecutive months.
45627758|NCT02439671|Behavioral|McGill Transition Support Program|"The McGill Transition Support Program is manual-based, including 15 modules of curriculum, five in each of the following domains of skills:~Social communication (e.g. listening, perspective taking)~Self-determination (e.g. problem-solving, self-advocacy)~Working with others (e.g. knowing your context, teamwork)~Nine out of the 15 modules are selected for each group according to the common needs endorsed by participants on a needs assessment questionnaire. Each group consists of 4 adults and two facilitators who were graduate students in Speech Language Pathology or Educational Psychology.~The intervention follows a Self-Determination Learning Model of Instruction (SDLMI) that considers the individual's strengths and needs in the development of personal goals and plans for one's future. A workbook is used to accompany each module with the aim of having the participants practice and generalize the main content messages."
45627759|NCT04852653|Procedure|Supplementary blood samples collection during the normal follow up of the patients|Supplementary blood samples collection during the normal follow up of the patients
45768638|NCT01927328|Drug|Iron isomaltoside 1000|
45627760|NCT02442791|Drug|Byetta (Lilly, Exenatide)|See description of Arms
45627761|NCT02442791|Other|20% Human Albumin|See description of Arms
45627762|NCT03190655|Device|Aluminaid|Aluminaid wound dressings is a hydrogel based wound dressing that is integrated with aluminium
45627763|NCT03190655|Device|Hydrogel|Hydrogel based wound dressing
45768639|NCT04552808|Drug|Yimitasvir Phosphate|Cohort A: On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects
45768640|NCT04552808|Drug|Yimitasvir Phosphate|Cohort B: were subjects with moderate liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
45447343|NCT03240692|Device|Accelerated theta-burst stimulation treatment|"All participants will receive intermittent theta-burst stimulation (iTBS) to the left dorsal lateral prefrontal cortex (L-DLPFC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered to L-DLPFC using the Magventure Magpro X100 and/or the NextStim TMS system."
45627764|NCT04771221|Diagnostic Test|pH metry|The collection of mucus from the laryngopharynx to determine the acid-base values through pH-metry.
45627765|NCT04771221|Diagnostic Test|Filling out the questionnaire|Completion of the questionnaire index of reflux symptoms. An analysis of the results of the effectiveness of this method in patients with complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching will be carried out. Evaluation results range from 0 to 5, where 0 is an indicator of no problem, and 5 is an indicator of a serious problem
45627766|NCT04771221|Device|Endoscopic laryngoscopy|Video laryngoscopy and assessment of the presence / severity of the symptoms. Evaluation results range from 0 to 4, where 0 is an indicator of no problem, and 4 is an indicator of a serious problem
45627767|NCT04771221|Device|Acoustic voice analysis|acoustic analysis of the voice was performed in singers with voice disorders before and after treatment using program of the Lingwaves
45627768|NCT02442557|Biological|recombinant human alpha B-crystallin|intravenous injection
45627769|NCT02442557|Other|placebo comparator|intravenous injection
45768641|NCT04552808|Drug|Yimitasvir Phosphate|Cohort C: Cohort C are healthy subjects, cohorts C and D, should be matched in terms of sex, age, and body mass index (BMI). On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
45768642|NCT04552808|Drug|Yimitasvir Phosphate|Cohort D: were subjects with severe liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
45768643|NCT04557566|Behavioral|EBT yoga-based eating disorder course|Yoga for Eating Disorder Recovery online course. This course will be led by certified facilitators via Zoom and offered over the course of four weeks, comprising one two-hour session per week. The course will continue to recruit and enroll participants until sufficient power is reached for the study.
45768644|NCT05607602|Other|Comparison of blood samples between the two groups|In this study we will perform global haemostatic assays such as activated partial thromboplastic time (APTT), and prothrombin time (PT). However, these tests provide information about the haemostatic process until the point of initial fibrin formation and ignore the procedure of thrombin generation[18]. In this study we will perform Thrombin Generation studies, Plasma clot Lysis, and RNA sequencing in addition to standard laboratory tests (APTT, PT, FVIII:C, fibrinogen (using Clauss methods), platelet count, liver and renal function tests.
45768645|NCT01927406|Drug|Prostaglandin Analog|The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.
45768646|NCT01927406|Drug|Timolol|Timolol topical eye drop will be administered in Prostaglandin Analog vs Timolol arm only, in patients with elevated intraocular pressure in both eyes.
45768647|NCT05607524|Dietary Supplement|probiotics|Eat a capsule for once, and twice a day
45768648|NCT05607524|Dietary Supplement|placebo|Eat a capsule for once, and twice a day
45627770|NCT04756557|Other|Experimental.|Tooth Brushing HAP 2x daily repeated cleaning of all teeth 3 min. using a standardized electric tooth brush Electric (powered) toothbrushes (Oral-B; P&G, Schwalbach, Germany), brushing head: medium; will be changed every 2 months and a non-fluoridated tooth paste containing microcrystalline hydroxyapatite . HAP-toothpaste (Karex toothpaste with 10 % hydroxyapatite) If a subject shows multiple carious lesions during the course of the study, the study dentist will decide whether the subject must be excluded from the study. In this case the subject will receive additional intensive caries prophylactic measures (e.g. chlorhexi-dine gel application, dietary counselling, etc.). Caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
45627771|NCT04756557|Other|Active comparator|Tooth Brushing F 2x daily repeated cleaning of all teeth 3min.using a standardized electric tooth brush ((Oral-B; P&G, Schwalbach, Germany) and a fluoridated toothpaste (Karex Base with sodium fluoride 1450 F-), brushing head: medium; will be changed every 2 months If a subject shows multiple carious lesions during the course of the study, the study dentist will decide whether the subject must be excluded from the study. In this case the subject will receive additional intensive caries prophylactic measures (e.g. chlorhexidine gel application, dietary counselling, etc.). Caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
45627772|NCT02442635|Behavioral|Yoga|Yoga breathing and postures; After this initial 3 arm experiment, yoga breathing and postures will be studied in combination.
45627773|NCT04742673|Drug|Guanfacine|Patients randomized to the IV Guanfacine arm will receive intravenous guanfacine when they exhibit ICU delirium.
45627774|NCT04742673|Drug|Placebo|Patients randomized to the placebo arm will receive intravenous normal saline when they exhibit ICU delirium.
45627775|NCT02442713|Drug|fluvoxamine|fluvoxamine: 50-300mg/day
45627776|NCT02410473|Other|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the input of the newer technologies that helped for the diagnostic of coagulopathy.
45768649|NCT01182493|Device|Insulin Pump (Medtronic Minimed Paradigm® VEO)|The pump delivers insulin as specified by the patient
45768650|NCT04557488|Other|Music therapy|Each session will follow a similar structure with a hello song, musical activities, and a goodbye song. The musical activities will vary in each session and will be mixed in later sessions to revisit and practice social skills
45768651|NCT04557488|Behavioral|Behavioral-based social skill training|Each intervention session will follow a standard structure of opening greetings, social activities according to the theme of the session, and a closing activity. The activities and games will vary in each session and will be mixed in later session to revisit and practice social skills.
45627777|NCT02410473|Other|Discarded Urine Sample|Will utilized the discarded urine samples from the routinely placed Foley catheter to measure the indices of oxidative stress.
45627778|NCT03190187|Other|Spinal Manipulation|Spinal manipulation based on orthopaedic manual therapy approach
45627779|NCT03190187|Other|Sham manipulation|Patients will receive simulated spinal manipulation without force application
45627780|NCT03189953|Radiation|68Ga-NODAGA-exendin 4 PET/CT|68Ga-NODAGA-exendin 4 PET/CT
45768652|NCT01927484|Drug|25 mg/week oral methotrexate tablets|active oral methotrexate drug
45768653|NCT01927484|Drug|25mg/week oral placebo tablets|placebo comparator oral drug
45627781|NCT02356887|Diagnostic Test|Jugular venous ultrasound|All volunteers will be fully awake throughout the study and be kept comfortable. A cross will be marked where the left and right IJV cross the level of C6. This is where all the measurements will be taken in 3 different conditions at rest, jugular occlusion and valsalva maneuver. At each conditions, the left and right IJV will be scanned with an ultrasound measuring the cross sectional area and Doppler velocity of the IJV. The least amount of pressure will be used to press on the ultrasound probe and the measurements will be obtained at end inspiration. The IJV flow is then calculated.
45768654|NCT01140295|Drug|polyethylene glycol, senna|"Senna dosage: Age 6-12 years: 3 teaspoons or 3 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. Age >12 years: 6 teaspoons or 6 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. A Fleet's rectal enema is administered on the morning of the procedure.~Miralax at a dose of 1.5 grams/kg divided twice a day for two days; maximum of 51 grams per dose. Dissolve each 17 grams (1 capful) PEG-P in 240 mL water or other beverage according to the manufacturer's direction and to give the appropriate amount of PEG solution twice a day for two days."
45768655|NCT04551404|Other|transcranial Random Noise Stimulation (tRNS) with acoustic stimulation (AS)|The study intervention consists of a bilateral tRNS application over temporal regions, parallel to the application of AS with WN 15 dB above the individual MML in one study arm. TRNS will be applied using two electrodes (35 qcm, 0,9% saline -soaked). Stimulus intensity will be below individual sensation threshold, but max. 2 mA. AS will never surpass 85 dB SPL at the ears.
45768656|NCT04551404|Other|transcranial Random Noise Stimulation (tRNS) without acoustic stimulation (AS)|The study intervention consists of a bilateral tRNS application over temporal regions
45768657|NCT01182805|Device|Echocardiography system Ultra DCI Model 5000|Each subject will undergo scanning using the investigational echocardiography system (Ultra DCI Model 5000)to measure Diastolic Circumferential Strain Rate during Isovolumic Relaxation (DCSR-IVR) as novel measure of diastolic function.
45768658|NCT01182805|Device|Echocardiography machine GE Vivid E9|Each subject will undergo echocardiography using a conventional echocardiography machine to evaluate the early diastolic mitral annular velocity (E-prime) using tissue Doppler as a standard measure of diastolic function.
45768659|NCT01182805|Device|Diastolic function assessment|Each subject will undergo standard echocardiographic measure of the mitral inflow pattern and invasive catheter-derived measure of left ventricular end-diastolic pressure to determine their diastolic function. This evaluation will be used as the gold standard for this study.
45768660|NCT04552730|Drug|Cenegermin-Bkbj|Topical Cenegermin-bkbj 6 times per day for 8 weeks.
45768661|NCT04550780|Drug|Mepolizumab|The first administration of mepolizumab.
45768662|NCT01184755|Behavioral|Relaxation|Participants are instructed to use the modified device (which paces the breath at a constant 13 breaths/minute) daily for 15 minutes (timing set automatically by device).
45768663|NCT01184755|Device|RESPeRate|
46069867|NCT04031079|Device|Wearable tech without feedback|an armwrist device measuring physical activity level, no reporting back to the user
45627782|NCT02442479|Behavioral|resistance training|
45768664|NCT04275440|Behavioral|Exercise|Rope-skipping exercise for three times a week (90 minutes each time, and there is a 10 min break after 20 min Rope skipping). Exercise bracelet and smart bracelet would be used to record the energy consumption throughout the study.
45627783|NCT02204085|Drug|GO-203-2c|
45627784|NCT02204085|Drug|GO-203-2c + Decitabine|
45627785|NCT02439593|Other|Chemoradiotherapy (CTRT)|CTRT arm: Locoregional radiotherapy along with concurrent weekly gemcitabine
45627786|NCT02439593|Other|Thermochemoradiotherapy (CTRTHT)|Locoregional hyperthermia with concurrent chemoradiotherapy with weekly gemcitabine
45627787|NCT02067741|Drug|CR1447|400 mg, corresponding to two 4 g stick packs applications twice daily
45627788|NCT02442401|Device|The negative pressure wound therapy|
45768665|NCT04275440|Behavioral|Caloric restriction|"In the first two weeks, participants would reduce their daily energy intake to 100% -110% of his or her basal metabolic energy under instruction, and stick to it till the end of the intervention.~According to the dietary recommendation proposed by Chinese government, participants are required to take in cereals, vegetables, fruits, meat and eggs, while minimize the consumption of sugar-sweeten beverages.~Participants are instructed to arrange their three meals according to the recommended energy distribution (3:4:3)."
45768666|NCT04275050|Drug|TQB3303|TQB3303 tablet is a small molecule oral drug inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6).
45768667|NCT05607446|Drug|TQC3564 tablets|TQC3564 tablets are CRTH2 antagonists.
45627789|NCT02439359|Drug|CF-301|Dose escalation
45627790|NCT02439359|Drug|Placebo|
45627791|NCT02442323|Behavioral|Walking Intervention|12-week walking program
45768668|NCT05607446|Drug|Placebo tablets|The intervention drug is placebo.
45768669|NCT05607446|Drug|TQC3564 tablets, montelukast sodium tablets|The intervention drugs are TQC3564 tablets combined with montelukast sodium tablets. TQC3564 is a CRTH2 antagonist, montelukast sodium is Leukotriene receptor antagonist.
45768670|NCT05607446|Drug|Placebo tablets, montelukast sodium tablets|The intervention drugs are placebo combined with montelukast sodium tablets. Montelukast sodium is Leukotriene receptor antagonist.
46069868|NCT04031079|Behavioral|Rehabilitation program|traditional inpatient rehabilitation program for overweight and obesity (lifestyle change program)
45627792|NCT04314843|Drug|Cyclophosphamide|Administered according to package insert
45627793|NCT04314843|Drug|Fludarabine|Administered according to package insert
45627794|NCT04314843|Biological|Lenzilumab|Administered as an IV infusion
45627795|NCT04314843|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR) transduced autologous T cells administered intravenously.
45627796|NCT02439437|Behavioral|Psychosocial Intervention|Telephone-based psychosocial intervention involving Eight telephone encounters. Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
45452464|NCT03961373|Procedure|Gastrectomy with D2plus lymphadenectomy|Patients who are assigned to the neoadjuvant chemotherapy + surgical D2+ extended lymphadenectomy treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2+ lymph node dissection plus resection of stations 8p, 12p, 13, 14v, 16a2/b1 is required with specific information about lymph node stations.
45627797|NCT03192293|Drug|Metformin/Simvastatin/Fulvestrant|"7 days Lead-in period: Metformin: 850mg (one tablet) twice a day Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle.~Tumour biopsy at 8 weeks. Every 8 weeks for the first 6 months, every 12 weeks thereafter:~Performance status evaluation Medical history and physical examination Clinical tumor measurement Review of treatment-related side-effects Blood taking for research purpose and routine blood tests Routine scans"
45627798|NCT02442089|Behavioral|Health Call|Health Call is an automated interactive voice reminder system that can contact guardians of patients ahead of their child's appointment, asks then confirms a security question about the patient, then, if the call recipient passes the security screen, provides a reminder about upcoming appointment.
46069869|NCT00864513|Drug|pemetrexed|pemetrexed 500 mg/m2 IV day 1 of each 21 day cycle until disease progression or unacceptable toxicity for a maximum of 8 cycles
46069870|NCT04130139|Other|oocyte pick up simulator|oocyte pick up simulation
46069871|NCT02614443|Other|Space from Depression|Delivered through the online SilverCloud platform, the program for the treatment of depression employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
46069872|NCT02614443|Other|Space from Anxiety|Delivered through the online SilverCloud platform, the program for the treatment of anxiety employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
46069873|NCT02614443|Other|Space from Stress|Delivered through the online SilverCloud platform, the program for the treatment of stress employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
45627799|NCT02442245|Dietary Supplement|XSurge|During part one of the study, 28 days of supplementation with XSurge will be provided. During the second part of the study 6 weeks of supplementation with XSurge will accompany a training program.
45627800|NCT02442245|Other|Placebo: Microcrystalline Cellulose|
45627801|NCT02442245|Other|Control: No supplementation|
45627802|NCT01918683|Radiation|TACE transarterial chemoembolization|
45627803|NCT01918683|Radiation|stereotatic body radiotherapy (SBRT)|
45627804|NCT02439515|Device|Cycling|Voluntary cycling augmented by electrical stimulation and biofeedback
45768671|NCT01141075|Drug|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
45627805|NCT02439515|Device|Balance|Balance control exercises with visual biofeedback
46069874|NCT02614521|Other|pulmonary veins ablation's successful outcome|Assessment of predictive factors in patients with successful outcome of pulmonary veins ablations and suffer from paroxysmal atrial fibrillation.
45452465|NCT05186428|Other|carrying out standard care|The adaptation of the diuretic treatment will be made according to the possible diuresis records and the weighing of the patient every 2 days.
45627806|NCT02439515|Other|Standard physical therapy|It consists of stretching, muscular conditioning, exercises for trunk control, standing, and walking training, and upper limb rehabilitation.
45627807|NCT02439203|Drug|JM-010|
45627808|NCT02439203|Drug|Placebo|
45627809|NCT02439125|Drug|Eltoprazine HCl|2.5 mg b.i.d. orally for 3 weeks
45627810|NCT02439125|Drug|Eltoprazine HCl|5.0 mg b.i.d. orally for 3 weeks
45627811|NCT02439125|Drug|Eltoprazine HCl|7.5 mg b.i.d. orally for 3 weeks
45627812|NCT02439125|Drug|Placebo|b.i.d. orally for 3 weeks
45627813|NCT02441933|Drug|taxane plus carboplatin|"Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane plus carboplatin for 4 cycles The taxane plus carboplatin regimen can be selected based on the investigator's discretion from among the following two regimens.~Docetaxel (75 mg/m2) IV plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles~Paclitaxel (80 mg/m2) IV weekly for 12 doses plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles"
45627814|NCT02441933|Drug|Taxane|"Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane for 4 cycles The taxane regimen can be selected at the investigator's discretion from among the following two regimens.~Docetaxel (75 mg/m2) IV every 3 weeks for 4 cycles~Paclitaxel (80 mg/m2) IV weekly for 12 doses"
45627815|NCT01604265|Drug|Placebo|Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
45627816|NCT01604265|Drug|Sativex|Contained delta-9-tetrahydrocannabinol (THC), (25 mg/ml):cannabidiol (CBD), (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
45627817|NCT02439047|Procedure|Biological samples collection|"-Peritoneal samples : will be collected during abdominal surgery~A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum~- Adipose tissue samples : will be collected during surgery for breast reconstruction"
45768672|NCT05607290|Behavioral|Cognitive-Behavioral Treatment|12 sessions of Cognitive-Behavioral Treatment for Alcohol Use Disorder
45768673|NCT01927952|Procedure|Kirschner wire|Surgical fixation utiliziing Kirschner wire
45768674|NCT01927952|Procedure|Integra IPP-On PIP Fusion System|surgical fixation utilizing the Integra IPP-On PIP Fusion System
45768675|NCT01927952|Procedure|Stryker Smart-Toe Implant|surgical fixation utilizing the Stryker Smart-Toe Implant
45768676|NCT02185105|Device|comfilcon A MTO|Randomized to a test lens in one eye and control lens in the other as a matched pair.
45768677|NCT02185105|Device|comfilcon A|Randomized to a test lens in one eye and control lens in the other as a matched pair.
45768678|NCT01928264|Behavioral|Physical activity|
45768679|NCT05606900|Behavioral|addiction-focused eye movements desensitization and reprocessing (AF-EMDR)|AF-EMDR includes desensitization and functional reprocessing of the targeted memory or the moment with lateral eye movements. In each session of the psychotherapy, which will be applied as 3 sessions, a memory or a moment that causes alcohol craving will be practised. The processing will continue until the patient becomes desensitized to the memory or the moment that cause the craving. In the first session, a memory of craving will be discussed, in the second session a current trigger that causes craving, and in the third session, a moment that is thought to cause craving in the future will be focused.
45768680|NCT02185183|Drug|Alequel|Alequel
45768681|NCT05606822|Other|Observational|Collection of data from electronic health record
45768682|NCT02185339|Drug|Rocuronium|Intravenous infusion rate of rocuronium will be titrated to keep post-tetanic count between 1 to 2.
46069875|NCT02614365|Behavioral|Aerobic exercise|Cardiovascular fitness
46069876|NCT02614365|Behavioral|Stretch exercise|Muscle stretch
46069877|NCT04130217|Procedure|addition of positive end expiratory pressure in ventilated patients|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O.
45627818|NCT02441855|Device|echocardiography|echocardiography: Left and right ventricular functions and aortic elastic properties.
45627819|NCT04313751|Behavioral|Education, Physical Activity, and Stress Management Program|Twelve weekly classes for one hour focused on CVD risk factor education using the Su Corazón Su Vida curriculum and coping skills training followed by a 45 minute exercise class and 15 minute stress management session. Then they will return for one hour for continued support, a forty-five minute exercise class, and fifteen minute stress management session.
45768683|NCT02185339|Drug|Rocuronium|Intravenous infusion rate of rocuronium will be titrated to keep train-of-four count between 1 to 2.
45768684|NCT05606744|Device|Eccentric exercise / Eccentric exercise with blood flow restriction|Individuals will be randomized to receive eccentric exercise only, or eccentric exercise with blood flow restriction.
45768685|NCT05606666|Other|reliability of the NPQ|The aim of this study is to study the validity and reliability of the Modified Pain Neurophysiology Questionnaire in patients with neck pain.
45768686|NCT02980159|Other|Triage liaison physician|A triage liaison physician is present from 7:30 am to 10:30 pm, Monday to Friday, with the mission to evaluate quickly patients who cannot be immediately installed in an ED room
46069878|NCT04130217|Procedure|addition of positive end expiratory pressure and recruitment maneuver in ventilated patients|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O and intermittent four times of RM consisting of maintaining airway pressure 40 cmH2O for 40 sec.
46069879|NCT02614209|Device|In Vitro diagnostic tests|Prospective blood collection
46069880|NCT04130061|Biological|Human Amniotic Membrane|Epicardial application of human amniotic membrane during cardiac surgery
46069881|NCT04129671|Genetic|No intervention was applied|No intervention was administered
46069882|NCT04128891|Drug|Sacubitril-Valsartan|Cardiomagnetic Resonance Imaging
45627820|NCT04313751|Other|Wait-list|The wait-list control group will receive 12 weekly one hour education and coping skills training sessions followed by a 45 minute exercise class and a 15 minute stress management session.
45627821|NCT03190031|Other|Endurance respiratory muscle training|Training program of the respiratory muscles in endurance by using sustained isocapnic hyperpnea
45627822|NCT03190031|Other|Resistance inspiratory muscle training|Training program of the inspiratory muscles in resistance by using repeated inspiratory maneuvers against a resistance
45627823|NCT04705233|Other|sputum colour chart|5-point Sputum Colour Chart plus best standard care
45627824|NCT04483427|Combination Product|Nalbuphine, ketorolac, accufuser|multimodal analgesic regimen consisting of nalbuphine combined with ketorolac using IV continuous infusion silicon device (Accufuser)
45627825|NCT02438735|Procedure|laparoscopic endometrioma excision|
45768687|NCT05601206|Behavioral|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
45768688|NCT05601206|Behavioral|Enhanced Usual Care|Usual care from health providers
45768689|NCT01186705|Drug|MK-2206|Patients will receive MK-2206 orally in a once weekly dose of 200mg. There will be no dose escalation. Patients will be treated until disease progression or unacceptable side effects.
45768690|NCT03831464|Drug|Metformin Hydrochloride|"The intervention will consist in IMP treatment during 30 months with half of the patients treated with Metformin Glucophage SR. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.~During the first month of the trial a dose of 1x500mg will be used in order to avoid as much as possible some well-known mainly gastrointestinal side effects of metformin treatment ."
46069883|NCT00698529|Behavioral|Face-to-face training|NGOs will receive the POL intervention through face-to-face training. Staff will receive 2-day training on the POL intervention and individualized telephone follow-up consultations concerning POL implementation.
46069884|NCT00698529|Behavioral|Distance training|NGOs will receive the POL intervention through Web-based training. Staff will receive training delivered entirely by means of a Web-based, distance learning curriculum and through individualized telephone follow-up consultations concerning POL implementation.
46069885|NCT00698529|Behavioral|Popular Opinion Leader (POL)|POL is a community-level HIV intervention that recruits and trains opinion leaders in the community to promote safe sex behaviors through risk-reduction conversations with peers.
46069886|NCT04127955|Other|Theory of Planned Behavior based Physical Activity Intervention|"Health education: The first component of intervention consisted of one session 30 minutes educational lesson relation to physical activity.~Group walking: The format of the 15-minute group walking session included 5 minutes of warm-up, 5 minute moderate intensity walking, 5 minute cool-down.~Counseling (individually tailored): The nurse received training about motivational interview technique for use in their physical activity counseling with participants. Using pedometers and step diary to set goals and monitor progress.~Pedometer: pedometer will be used objective physical activity assessment. Measurement of physical activity levels, wearing a pedometer (Omron HJ321E) on a belt over one hip, all day for 7 days, removing for bathing and sleeping. A diary is also provided to record step count. The pedometer will be used for baseline and outcome measurement of step-counts for the trial."
46069887|NCT02613975|Device|positonal device|positional device detects prone positional and will vibrate to cause patient to lie laterally
45452466|NCT05186428|Other|adult diaper|the diuresis which will be calculated by making the difference between the weight of the soiled protection weighed and the weight of the dry protection
45627826|NCT02438735|Other|Conservative follow up|
45627827|NCT01664247|Drug|insulin degludec|Administered s.c. (under the skin) once daily. Dose individually adjusted.
45627828|NCT01664247|Drug|placebo|Administered s.c. (under the skin) once daily. Dose individually adjusted.
45627829|NCT01664247|Drug|liraglutide|Administered s.c. (under the skin) once daily. Dose: 1.8 mg.
45627830|NCT02441699|Behavioral|Improved water supply and sanitation|Village-level reticulated water supply with distribution to household taps; pour-flush pit latrines.
45627831|NCT02441465|Drug|Vemurafenib|Oral vemurafenib will be administered at a dose of 960 milligrams BID from Day 1 to Day 28.
45627832|NCT02441465|Drug|14C-Labeled Vemurafenib|IV infusion of 18.5 kilobecquerel (kBq) of 14C-labeled vemurafenib (3 milliliters [mL], which corresponds to a dose of 20 micrograms [mcg] of vemurafenib) on Day 21 (immediately after the morning oral dose of vemurafenib).
45627833|NCT02438657|Procedure|median nerve block|
45627834|NCT02441621|Other|passive leg raising|The passive leg raising maneuver (PLR) involves a leg elevation up to 45° with the trunk in a horizontal position and is performed to induce hemodynamic effects by a volume challenge, turning unstressed blood volume to stressed volume proportional to body size.
45627835|NCT02441621|Other|premedication|patients receive premedication with midazolam 7.5 mg p.o.
45627836|NCT02441621|Other|intubation and mechanical ventilation|After induction of anesthesia with sufentanil (0.5 µg/kg) and propofol (1.5 mg/kg), orotracheal intubation is facilitated with rocuronium (0.6 mg/kg). Anesthesia is maintained with sufentanil (1 µg/kg/h) and propofol (3 mg/kg/h) and patients are ventilated with an oxygen/air mixture in volume-controlled mode, using a tidal volume of 8 ml/kg related to the ideal body weight. Positive end-expiratory pressure is set at 5 cmH2O.
45627837|NCT02441621|Other|central venous catheter|a central venous catheter in the right or left internal jugular vein.
45627838|NCT02441621|Other|arterial catheter|Continuous monitoring is performed including electrocardiogram, radial arterial pressure catheter
45627839|NCT02441621|Other|transesophageal echocardiography|Before placement of a transpulmonary thermodilution catheter a transesophageal echocardiography (TOE) is performed. TOE is used to detect diastolic dysfunction of the left ventricle and to exclude right ventricular dysfunction.
45768691|NCT03831464|Drug|Placebo Oral Tablet|The intervention will consist in IMP treatment during 30 months with half of the patients treated with matched placebo. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.
45768692|NCT01928342|Drug|Coenzyme A|Coenzyme A 400mg per day
45768693|NCT01928342|Drug|Placebo|Capsule without coenzyme A.
45768694|NCT03384446|Other|Tooth-borne treatment|Titanium curettes
45768695|NCT03384446|Other|Implant-specific treatment|Implant brush
45627840|NCT02441621|Other|transpulmonary thermodilution catheter|In presence of left ventricular dysfunction a transpulmonary thermodilution catheter is placed in the femoral artery and connected to a PiCCO2 monitor (PiCCO2, Pulsion Medical Systems, Munich, Germany).
45768696|NCT01928498|Device|Paclitaxel Eluting Balloon Angioplasty|
45627841|NCT05441085|Device|programed intermittent epidural bolus interval 90 (EI90)|programed intermittent epidural bolus interval 90 (EI90) of 10 ml, 0.0625% bupivacaine plus 2 μg/mL fentanyl
45627842|NCT05690373|Dietary Supplement|Probiotic effect on influenza vaccine response|Seroconversion rate: the percentage of subjects achieving at least a 4-fold increase or an increase from >10 to 40 in Ab titre for seronegative subjects.
45627843|NCT03189797|Other|tailored preventive program|In the study group they were given a preventive program as homecare program including tooth brushing 2/day with a fluoride toothpaste( 5000 ppm F) following the instructions in addition to fluoride mouth rinse. For the clinical approach motivational engagement was done by discussing with patients how to improve oral health behavior including amount of sugar, fibrous food and junk food. This in addition to pits and fissures sealant, F- varnish 2 times /year. and application of fluoride varnish every 6 months and dietary intake interventions.
45627844|NCT02441387|Drug|Antidepressant|Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year.
46069888|NCT04126785|Other|High Intensity Interval Exercise in Heated Water-Based|High intensity interval exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level of rate perceived exertion (RPE) scale, followed by 21 min of HIIE, alternating 1 min of jogging/running at 15-17 (hard-very hard) level with 2 min of walking at 9-11 (very light-fairly light) level of RPE.
45627845|NCT02441387|Other|Psychoeducation|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score <or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment). The psychoeducation program consists of 10 individual sessions, conducted by a trained psychologist who will explain the main concepts of depression and its symptoms, the importance of adhering to treatment, the main side effects of pharmacological treatment, and how to cope with daily difficulties.
45627846|NCT02441387|Other|Treatment as usual (only pharmacological treatment).|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score <or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment).
45627847|NCT01441947|Drug|Cabozantinib|Part of combination arm
45627848|NCT01441947|Drug|Fulvestrant|part of combination arm
45768697|NCT01928498|Device|Percutaneous Transluminal Angioplasty (PTA)|
45627849|NCT03192059|Drug|Pembrolizumab|Efficacy of the combined treatment
45627850|NCT03192059|Radiation|Radiation|Efficacy of the combined treatment
45768698|NCT04558502|Drug|Minocycline hydrochloride capsule|Antibiotic for H. pylori eradication
45768699|NCT04558502|Drug|Clarithromycin|Antibiotic for H. pylori eradication
45768700|NCT04558502|Drug|Amoxicillin|Antibiotic for H. pylori eradication
45768701|NCT04558502|Drug|colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
46069889|NCT04126785|Other|Continuous Moderate Exercise in Heated Water-Based|Continuous moderate exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level (light) of RPE, followed by 26 min of MICE, walking at 11-13 (fairly light)level of RPE.
46069890|NCT04126785|Other|Control Group|CON session will perform at controlled heated water-base (30 e 32 ºC). Subject will be seated in a chair and submerged at the until xiphoid process level for 30 min.
45768702|NCT04558502|Drug|esomeprazole|Proton pump inhibitor
45768703|NCT01218997|Drug|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for up to 1 year.
45768704|NCT01218997|Drug|Oral naltrexone 50 mg|Tablet taken orally once daily for up to 1 year
45768705|NCT01928654|Device|Micropulse laser treatment|Device for subthreshold treatment of the retina, by decomposing a continuos wave of laser in micropulses, with 5% duty cycle, 200 milliseconds, 100 microns, and power adjusted according to patient's diopter transparency and pigmentation.
45768706|NCT01928654|Device|Laser modified ETDRS|Device for visible treatment of the retina, with direct treatment of microaneurysms or grid pattern covering the area of retinal edema.
45768707|NCT01219777|Drug|carboplatin|Carboplatin AUC 5.0 or 6.0 will be administered on day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
45768708|NCT01219777|Drug|Bevacizumab|Bevacizumab 15 mg/kg administered on Day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
45768709|NCT01219777|Drug|Paclitaxel|60-80 mg/m2 administered on Day 1, 8 & 15 during cycle 1-3. Treatment cycle consists of 21 days duration.
46069891|NCT00917150|Drug|tetomilast (OPC-6535)|oral administration of 12.5mg OPC-6535, once daily for 24months
46069892|NCT00917150|Drug|tetomilast (OPC-6535)|oral administration of 25mg OPC-6535, once daily for 24months
46069893|NCT00917150|Drug|tetomilast (OPC-6535)|oral administration of 50 mg OPC-6535, once daily for 24months
46069894|NCT00917150|Drug|placebo|oral administration of placebo, once daily for 24months
45768710|NCT05603156|Drug|the usage of Olverembatinib combined with Inotuzumab Ozogamicin|patients in this arm will accept a 28 days treatment regimen: Olverembatinib 40mg QOD (d1 to d28 )and Inotuzumab Ozogamicin 1.2mg/m2 (divided into 2 days, d1 and d8, 0.6mg/m2, respectively).
45768711|NCT05603078|Radiation|Preoperative MRI-guided tumor-bed boost and postopreative ultra-hypofractionated radiotherapy (26 Gy/5.2Gy/5)|Preoperative tumor-bed boost was performed under MRI Linac, and a single dose of 10Gy is prescribed. The postoperative radiotherapy of 26Gy/5.2Gy/5 fractions is within 6 weeks following surgery. Adjuvant chemotherapy, targeted therapy and endocrine therapy are initiated no more than 12 weeks after surgery.
45768712|NCT03384134|Other|Pain Buddy|Pain Buddy is a user interface (application) which contains a personalized avatar (Pain Buddy) to guide children and parents through daily diary entries using mobile devices. The Pain Buddy application has been designed to be used with children age 8-18, receiving outpatient chemotherapy, as well as their parents. Pain Buddy will capture real time pain data from patients and that will ultimately allow for remote monitoring of patient symptoms. Remote symptom monitoring in real time will provide an opportunity for implementation of appropriate interventions, thereby introducing the potential to decrease pain and symptoms and improve quality of life in children with cancer. The use of symptom monitoring and skills training will further increase patient engagement in healthcare.
45768713|NCT04759742|Drug|ropivacaine|According to previous clinical experience, 0.5% ropivacaine was given in the subarachnoid cavity, and the initial dose was set at 2.5 mL (12.5mg). Dixon's up-and down method was adopted to adjust or down-adjust the dose of ropivacaine in the next patient according to the experimental results of the previous patient, and the adjusted dose was 0.1 mL (0.5mg).
45627851|NCT03192059|Drug|Vitamin D|Efficacy of the combined treatment
45768714|NCT04556162|Diagnostic Test|fractional sodium excretion|fractional sodium excretion will be compared to urinary sodium/creatinin, sodium/potassium ratio's and sodium concentration.
45768715|NCT04556162|Other|risk subgroups|subgroup analysis will be performed to identify the patient groups at risk for sodium depletion
45627852|NCT03192059|Drug|Aspirin|Efficacy of the combined treatment
45627853|NCT03192059|Drug|Lansoprazole|Efficacy of the combined treatment
45768716|NCT05602922|Combination Product|Liu-Zi-Jue Exercise|Combined with the actual situation of stroke patients, this Liu-Zi-Jue Exercise adopts the sitting position.
45768717|NCT05602922|Other|Basic treatment +Swallowing rehabilitation training|Basic treatment +Swallowing rehabilitation training
45768718|NCT03361826|Device|MagPro MST with Cool TwinCoil|MST treatments will be administered using the MagPro MST with Cool TwinCoil. The investigators will evaluate the effectiveness of MST for reducing suicidality and depressive symptoms in an open-label clinical trial of up to 15 treatment sessions. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
45768719|NCT03361826|Behavioral|DBT|Dialectical behavior therapy (DBT) is a specific type of cognitive-behavioral psychotherapy developed to help better treat borderline personality disorder. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
45913033|NCT02017561|Drug|Metformin|Metformin treatment titrated to a maximum dose of 1000mg twice a day. Metformin treatment will start with 500mg at breakfast during the first week and, if well tolerated, increased to 500mg twice a day (breakfast and dinner) in the second week, 1000mg at breakfast and 500mg at dinner in the third week and finally for the target dose of 1000mg twice a day.
45913034|NCT02017600|Drug|ND-420|ND-420 50 mg/m2 on day1
45913035|NCT02017600|Procedure|Surgery|After induction chemotherapy, participants will be receive right or left thoracotomy for curative resection by total or subtotal thoracic esophagectomy.
46069895|NCT04251962|Drug|Bupivacaine|epidural solution containing bupivacaine 0.1% in normal saline
46069896|NCT04251962|Drug|Fentanyl|Epidural solution containing fentanyl 3 mcg/ml (in addition to bupivacaine) in normal saline
45627854|NCT03192059|Drug|Cyclophosphamide|Efficacy of the combined treatment
45627855|NCT03192059|Dietary Supplement|Curcumin|Efficacy of the combined treatment
45627856|NCT02441075|Other|70% Ethanol|the study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.
45913036|NCT02017600|Drug|Cisplatin|cisplatin 70 mg/m2 on day1
45913037|NCT02017600|Drug|fluorouracil|fluorouracil 700 mg/m2 daily, day1 to day4
45913038|NCT02017613|Drug|RP6530|Escalating doses starting at 25 mg BID
45627857|NCT02441153|Other|Extended Timing|Surgery will be performed at 10-11 weeks after completion of chemoradiotherapy.
45627858|NCT04687683|Other|Post Isometric Relaxation Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform an isometric contraction for 5 seconds in the horizontal abduction direction with 20% of the maximum muscle strength. After the relaxation, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between contractions. This stretching exercise will be applied in 5 repetitions for one session.
45627859|NCT04687683|Other|Isolytic Stretching Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform a contraction in the horizontal abduction direction with 20% of the maximum muscle strength. When the muscle contraction occurs, the arm will be moved quickly in 2-4 seconds towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretches. This stretching exercise will be applied in 5 repetitions for one session.
46069897|NCT04251650|Other|subgingival plaque sample|for subgingival plaque sample, on three affected sites (PD>3mm) and three healthy sites (PD≤3mm), after supra-gingival plaque removal, sterile endodontic paper points were inserted in selects pockets for 30s to collect the subgingival plaque. The material was transferred into eppendorf tube, one for affected samples and one for healthy samples.
45627860|NCT04687683|Other|Static Stretching Group Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier. Then, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretching exercises. This stretching exercise will be applied in 5 repetitions for one session.
45627861|NCT02438579|Other|Nasal Irrigation & Gargling|Participants are advised to perform the intervention as frequently as required (expected frequency around 6 times a day for the first two days, reducing in frequency from day 3 as symptoms improve).
45627862|NCT04664751|Other|Nil-per-Oral|NPO details
45627863|NCT02441231|Drug|Visbiome|Visbiome probiotic
45627864|NCT02441231|Other|Placebo|Placebo
45627865|NCT05562999|Drug|Rocuronium Bromide|Moderate NMB (TOF 1-2)
45627866|NCT05562999|Drug|Rocuronium Bromide|Deep NMB (PTC 1-2)
45768720|NCT01928810|Behavioral|Cognitive Behavioural Therapy|12 sessions of CBT including psychoeducation, interoceptive exposure and in-vivo exposure
45627867|NCT02438501|Radiation|Low-dose involved-field radiotherapy|Low-dose involved-field RT (LD-IFRT) is given in 2 daily fractions (2×2 Gy). Involved-field of radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.
45768721|NCT01928888|Drug|Talcid (Hydrotalcite, BAY4516H)|2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine
45768722|NCT01928888|Drug|Famotidine|2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg
45768723|NCT01928888|Drug|Placebo|2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine
45768724|NCT04557722|Procedure|0-30° Biplanar Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy|after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-30 degree technique of C-Arm.
45768725|NCT04557722|Procedure|New 0-90° Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy|after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-90 degree technique of C-Arm.
45768726|NCT04554914|Biological|Tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
45768727|NCT01928966|Other|Pumpkin Seeds|Participants will be asked to consume 1.5 ounces of raw, unsalted pumpkin seeds per day. The 1.5 ounces will be split in to two servings (each 0.75 ounces).
45768728|NCT04556084|Drug|Blinatumomab|"Blinatumomab will be given as a 28-day continuous infusion with 14-days in between Cycle 1 and Cycle 2 as per the package insert and FDA approved labeling.~Patient weight greater than or equal to 45kg will receive 28 mcg/day~Patient weight less than 45kg will receive 15 mcg/m2/day"
45768729|NCT04394780|Procedure|cooling|First, patients underwent peritoneal dialysis (PD) at 37 C (standard temperature) and then patients underwent PD cooling. After each PD session, the patient had a CT scan for the study team to study myocardial perfusion at rest and after introduction of a pharmacological stressor.
45768730|NCT01929122|Dietary Supplement|Placebo-Control Meals and Snacks|
45768731|NCT01929122|Dietary Supplement|Cooked Navy Bean Powder Meals and Snacks|
45452467|NCT05180162|Drug|68Ga-FAP-2286|A dose of 3 - 8 millicurie (mCi) will be given intravenously (IV)
45627868|NCT02438501|Radiation|Involved-field radiotherapy|Involved-field RT (IFRT) is given in 24 Gy in 12 fractions. Radiotherapy field defined by CALGB is encompassed the prechemotherapy gross tumor.
45627869|NCT05247489|Drug|Ruxolitinib 1.5% cream|Ruxolitinib cream 1.5% applied twice a day (BID).
45768732|NCT01929122|Dietary Supplement|Rice Bran Meals and Snacks|
45768733|NCT04394234|Drug|Direct oral anticoagulant (DOACs)|Data of participants newly exposed to individual DOACs that is rivaroxaban, apixaban, dabigatran from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.
45768734|NCT04394234|Drug|Warfarin|Data of participants newly exposed to warfarin from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.
45627870|NCT05247489|Device|NB-UVB phototherapy|NB-UVB (311-312 nm) phototherapy is an established treatment modality for vitiligo. Starting dose will be 200 mJ/cm2 and dose may be increased by 10% at each visit
45627871|NCT02440997|Other|aromatherapy|
45627872|NCT02440997|Other|foot bath|
45768735|NCT05602844|Procedure|PSI Lapidus|Design of PSI: DICOM files will be imported into the Model Intestinal Microflora in Computer Simulation (MIMICS 21.0) 3D image processing software (Materialize, Belgium) for 3D rendering. The segmented bone images will be used for design of the computer-aided modelling (CAM) surgical jigs. 3D printing of PSI jig. PSI-assisted Lapidus Surgery.
45768736|NCT05602844|Procedure|Conventional Lapidus|exposure of the 1TMTJ via a 3-5cm medial longitudinal skin incision and capsulotomy. Freehand creation of the fusion surface with fluoroscopic assistance. Fixation of the Lapidus arthrodesis will be performed with two 3.5mm headless compression screws
45913039|NCT02017626|Biological|mCyp c 1|2 patient groups with different doses of allergen.
45452468|NCT05180162|Procedure|Positron Emission Tomography (PET)|Imaging will begin 50-100 minutes after injection and last about 45 minutes.
45627873|NCT05641077|Other|Virtual Visit|Patients randomized to this arm will be scheduled for and follow up with the surgeon or an advanced practice provider via a virtual visit using videoconference technology at 6 weeks after the anticipated date of surgery. If the surgery were to be rescheduled to a future date, the postoperative visit will be moved accordingly to ensure follow-up occurs at the 6-week postoperative period.
45913040|NCT02017639|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:Prefilled syringe of sarilumab solution Route of administration: Subcutaneous injection
45913041|NCT02017639|Drug|simvastatin|Pharmaceutical form:Film-coated 20 mg Tablet Route of administration: oral
45627874|NCT05641077|Other|Office Visit|Patients randomized to this arm will be scheduled for and follow up with the surgeon or an advanced practice provider via an in-office visit at 6 weeks after the planned date of surgery. If the surgery were to be rescheduled to a future date, the postoperative visit will be moved accordingly to ensure follow-up occurs at the 6-week postoperative period.
45627875|NCT02438345|Biological|PRO 140|Humanized monoclonal antibody to CCr5
45627876|NCT00030771|Drug|Chemotherapy|Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
45627877|NCT00030771|Radiation|Radiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
45627878|NCT00030771|Procedure|Surgery|3-4 weeks after termination of radiotherapy
45627879|NCT02438189|Device|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
45627880|NCT05245851|Device|Opportunistic screening for low BMD|"Software will analyze x-rays of the chest, thoracic spine, lumbar spine, pelvis, knee or hand/wrist acquired for any reason, and notify the radiologist at time of acquisition if low BMD is detected. The report to the radiologist includes the following statements:~This x-ray was opportunistically analyzed by RhoTM, an investigational device under ITA [investigational testing authorization] from Health Canada, to screen for low bone mineral density (low BMD).~This information should be used by a trained healthcare provider in conjunction with a patient's clinical fracture risk to determine if formal BMD screening with DXA is appropriate.~The radiologist can choose to include this as an incidental finding in their report to the referring physician."
45768737|NCT04552652|Behavioral|High-Intensity Interval Training|Remotely monitored exercises will be performed at home. The high-intensity interval group warms-up for 5 minutes at moderate intensity (65-75% of maximal heart rate). After warm-up exercise, will continue in 4 minutes intervals at high-intensity to reach the target zone (85-95% of maximal heart rate) Each interval will be separated by 3 minutes of active recoveries (at 65-75% of maximal heart rate). The session ends with a 3-minute cool-down phase. Overall training exercise time will be 33 minutes - isocaloric compared to moderate-intensity continous training group. All participants will train using a heart rate monitor during each workout.
45768738|NCT04552652|Behavioral|Moderate-intensity continuous training|Remotely monitored exercises will be performed at home. Patients in the moderate-intensity continuous training group will perform a 41-minute constant workout with an intensity of 65-75% of maximum heart rate, representing the same total training load as the high-intensity aerobic exercise group. All participants will train using a heart rate monitor during each workout.
45768739|NCT02569710|Drug|AL-335|AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).
45768740|NCT02569710|Drug|Odalasvir (ODV)|ODV capsules will be administered in a dose range of 25 to 50 mg.
45768741|NCT02569710|Drug|Simeprevir (SMV)|SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).
45768742|NCT04550624|Drug|Pembrolizumab Injection [Keytruda]|200mg IV on day 1 of each cycle
45768743|NCT04550624|Drug|Lenvatinib Mesylate|20mg PO daily days 1-21 of each cycle
45627881|NCT05245695|Other|Observational study, no intervention|Observational study, no intervention
45627882|NCT03191981|Drug|Cyclophosphamide|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
45627883|NCT03191981|Drug|Lenalidomide|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
45627884|NCT03191981|Drug|Pembrolizumab|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
45627885|NCT05535075|Device|Vancomycin model-informed precision dosing|A dosing calculator is used for a posteriori calculation of vancomycin dose using a target AUC/MIC between 400-600 mg*h/L
45627886|NCT05535075|Drug|Vancomycin|Vancomycin treatment
45627887|NCT05534997|Other|intensive combined rehabilitation therapy|graded exercise therapy and cognitive behavioral therapy
45627888|NCT05534919|Drug|Nefecon|Nefecon is taken orally as capsules once daily for 9 months.
45627889|NCT05640219|Device|laparoscopic trocar 12mm|long laparoscopic trocar 12mm (36 french) with central hole from its tip till its handle with transparent sheath
45627890|NCT04609683|Device|AleriTM sensors|"AleriTM sensors are worn on the bicep or forearm and communicates through BLETM to a mobile App. The data is sent through the mobile App to web-based system processing where PHI is calculated and sent back to the mobile App.~The AleriTM sensor has a form factor similar to a conventional arm band, with a hockey puck shape of approximately 48mm in diameter and 15mm in thickness the AleriTM sensor is a non-significant risk (NSR) device as it does not meet the definition of significant risk device (21 CFR 812.3(m)) because it is: not an implant; is not purported or represented to support or sustain human life; its use is not of substantial importance in the diagnosis, cure, treatment, mitigation, or prevention of impairment of health; and it does not present a serious risk to the health, safety, or welfare of a subject."
45627891|NCT05530941|Behavioral|Online suicide prevention campaign|The online prevention campaign consists of two campaign videos, a website with information about suicide prevention and mental health tailored to men, and testimonials of men who struggled with their mental health.
45627892|NCT05530863|Behavioral|Assisted Therapy|The participant will receive coaching calls and support
45627893|NCT05530863|Behavioral|Sleep Hygiene|Standard Sleep Hygiene instructions.
45627894|NCT05428761|Other|TP1|Participants will receive TP1 during one experimental visit.
45627895|NCT05428761|Other|TP2|Participants will receive TP2 during one experimental visit.
45627896|NCT05428761|Other|Placebo|Participants will receive placebo during one experimental visit.
45768744|NCT03379064|Behavioral|Culturally adapted Cognitive Behavior Therapy for IBS|Culturally adapted Cognitive Behavior Therapy for IBS
45627897|NCT05530785|Combination Product|radiotherapy combined with sintilimab and bevacizumab biosimilar|After signing informed consent, patients received sintilimab 200 mg intravenously on the first day of each cycle, Q3W; Bevacizumab biosimilar 7.5mg/kg was administered intravenously on the first day of each cycle, Q3W; Concurrent radiotherapy (single dose 3-8Gy, times 3-10, total dose 20-50Gy; The duration of radiotherapy was completed between the first administration of sintilimab and the second administration of bevacizumab, but it should be noted that the interval between before and after the administration of sintilimab and bevacizumab was at least 3 days.
45627898|NCT05425173|Other|Conventional treatment|Chest Physical Therapy as required
45768745|NCT04550546|Drug|Nystatin|600,000 U/mL of nystatin in a rinse suspension
45768746|NCT01929200|Drug|1-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 1 year.
45627899|NCT05425173|Other|Limb Range of Motion Exercises + Chest Physical Therapy|"Limb Range of Motion Exercises + Chest Physical Therapy~Frequency: 4 sessions Time: 5 to 10 minutes"
45627900|NCT05530629|Device|resistance training|resistance training lasts for 12 weeks, three times a week, one hour each time, and the program of resistance training in the experimental group was divided into 10 exercises: Chest press, Lat pull down, Shoulder press, Squat, Leg extension, Leg curl, Bicep curl, Triceps extension, abdominal crunches, lower back exercises.
45768747|NCT01929200|Drug|2-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 2 years.
45768748|NCT04394312|Other|Parent PLAYSHOP|"The Parent PLAYSHOP includes:~Educational Training- the 75 min workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities. Parents will be provided with modifications to perform activities 'at home'.~Distribution Education and Activity Resources- At the workshop conclusion parents are given education Resources (e.g. Canada's 24-hour movement guidelines for the early years, activity idea booklet, and a physical literacy handout) and inexpensive activity resources (ball, bean bag, scarves, balloons etc.).~Provide Follow-up Support- Research staff will send parents a follow-up email with key workshop messages (e.g., rationale and importance of physical literacy); support and encouragement for parents to engage in purposeful play with their child; and an opportunity for parents to provide feedback and/or seek further support."
45768749|NCT04394078|Other|Online survey|Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess depression (Zung depression Scale) and quality of life (WHO Qualiy of Life - Bref version).
45768750|NCT01219855|Drug|Cohort 1 CTAP101 Capsules- 60µg|60µg of CTAP101 capsules given once daily for 42 days.
45768751|NCT01219855|Drug|Cohort 1 CTAP101 Capsules - 90µg|90µg of CTAP101 capsules given once daily for 42 days.
45768752|NCT01219855|Drug|Cohort 1 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
45768753|NCT01219855|Drug|Cohort 2 CTAP101 Capsules - 30µg|30µg of CTAP101 capsules given once daily for 42 days.
45768754|NCT01219855|Drug|Cohort 2 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
45768755|NCT04885998|Drug|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
45627901|NCT05530629|Device|Normal P.E. course|Carry out general teaching content according to the college syllabus lasts for 12 weeks , three times a week, one hour each time, and the program of Normal P.E. course in the control group will be Physical recovery exercises, learn and practice queue formation, calisthenics, five step fists, long fist and Basic movements of Gymnastics gradually changed by week.
45768756|NCT04885998|Drug|AMG 404|AMG 404 will be administered as an intravenous (IV) infusion.
45768757|NCT02984072|Drug|Menthol|Topical menthol in aqueous cream
45768758|NCT02984072|Drug|Aqueous Cream|placebo
45768759|NCT04589832|Drug|PAC-1|Pharmacokinetic (PK) and pharmacodynamic (PD) assay for PAC-1 will be performed during Days 1 and 21 of Cycle 1. PAC-1 will be given on Day 1 of Cycle 1, withheld on Day 2 and Day 3 of Cycle 1 then reinitiated on Day 4 of Cycle 1 to continue for 21 days of the 28-day cycle. For each successive cycle, PAC-1 therapy will be initiated on Day 1 and continue for 21 days of the 28-day cycle.
45768760|NCT04589832|Drug|Entrectinib|Pharmacokinetic and pharmacodynamic assay for entrectinib will be performed during Days 3 and 21 of Cycle 1. Entrectinib therapy will be withheld on Day 1 and Day 2 of Cycle 1, initiated on Day 3 of Cycle 1 and continue for the remainder of the 28 day cycle. For each successive cycle, entrectinib will be intiated on Day 1 and continue for 28 days of the 28-day cycle.
45768761|NCT05604326|Behavioral|Pathways Intervention|Pathways-trained research clinicians will conduct 90-minute weekly coaching sessions with caregivers (in English or Spanish) in the family's home or other convenient location. Caregivers will receive a written and audio version of the program manual in English or Spanish, depending on the family's home language. Sessions will review information about autism, interactional strategies, and Applied Behavioral Analysis (ABA) techniques from the program manual, demonstrate intervention strategies, and provide caregivers with practice feedback and self-reflection.
45913042|NCT02017678|Biological|JX-594|5 weekly IV infusions of JX-594 followed by laparoscopy and biopsy on day 10 or 38.
45913043|NCT02017691|Device|Near Infrared Spectroscopy|If crSO2 is <10th centile, CPAP via face mask will be started or oxygen support will be increased depending SpO2, on the infants breathing efforts and the heart rate. If crSO2 remains stable >10th centile, or if crSO2 is > 90th centile CPAP via face mask will be stopped or FiO2 will be reduced depending on SpO2, the infants breathing efforts and the heart rate.
45627902|NCT04655703|Device|DJO X4 brace with Motion Intelligence Platform|The X4 Knee brace with the Motion Intelligence platform uses both a bio-measurement equipment with an interactive application thereby providing the patient with immediate feedback on their exercise regime. The X4 Knee brace is a postoperative brace worn by a patient to monitor compliance to prescribed protocol based on the movement and function of the knee joint. The device also connects wirelessly to a companion mobile application, Motion Intelligence, and streams both real-time and collected data for review and record collection. Prescribed exercises are uploaded into the patient application, with a number of the exercises actively tracked by the Mi360 sensor housed in the X4 brace. Compliance can be tracked by the physician in real-time between postoperative visits and any medical staff on a separate dashboard.
45627903|NCT05637255|Drug|SYL1801|1 drop in the eligible eye
45627904|NCT05633745|Drug|NEU-723|Oral Doses
45627905|NCT05633745|Drug|Placebo|Oral Doses
45627906|NCT04692441|Dietary Supplement|Heavy Cream|100 ml of dairy cream with 40.4g of total fat, to ingest orally
45627907|NCT05530395|Diagnostic Test|Testosterone levels|Blood sample to determine testosterone levels
45768762|NCT05604326|Behavioral|Parent Education Intervention (PEI)|Caregivers will access a 20-30-minute video lesson and associated handouts (in English or Spanish, depending on the parent's home language) every other week for 24 weeks. On the off week, the caregiver will meet with a trained clinician (in English or Spanish) for 30 minutes without the child. Lessons will cover autism, social attention delays, evidence-based interventions, self-regulation, talking with your child, playing with your child, principles of managing behavior, knowing your rights, and self-care. The first and last visit will occur in the family's home or another convenient location. All other visits will take place over Zoom videoconferencing software.
45768763|NCT05506410|Drug|Rituximab|Young patients (< 65 years of age) were treated with R-BAP for 6 cycles (efficacy was assessed every 2 cycles, and adverse events were recorded), together with oral ibrutinib, followed by oral ibrutinib for 1 year after chemotherapy (efficacy was assessed every 3 months). Elderly patients (≥65 years of age) received 4 cycles of R-BAP (efficacy assessed every 2 cycles, and adverse reactions recorded), followed by 4 cycles of rituximab consolidation (efficacy assessed every 2 cycles) and 1 year of oral zanubrutinib (efficacy assessed every 3 months).
45768764|NCT05506332|Drug|Venetoclax|Venetoclax and 6-mercaptopurine
45768765|NCT05506332|Drug|6-mercaptopurine|Venetoclax and 6-mercaptopurine
45913044|NCT02017691|Device|Pulse-oximetry|If SpO2 remains <10th centile, respiratory support via face mask will be started or FiO2 will be increased depending on the infants breathing efforts and the heart rate. If SpO2 remains stable or if SpO2 is >90th centile respiratory support via face mask will be stopped or FiO2 will be reduced depending on the infants breathing efforts and the heart rate.
45913045|NCT02017730|Drug|BMS-986020|
45627908|NCT04545957|Device|MRI Simulator|Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data.
45913046|NCT02017730|Drug|[11C]BMT-136088|
45913047|NCT02017782|Device|Dust|Dust (250-300µg/m3),
45913048|NCT02017782|Device|Ozone|(0,1ppm ozone),
45913049|NCT02017782|Device|Dust and Ozone|Active Dust (250-300 ug/m3)+Ozone(0,1ppm)
45913050|NCT02017782|Device|Placebo (Filtered air)|Placebo treatment (Filtered air <20 ug/m3)
45913051|NCT02017795|Other|electronic asthma action plan (eAAP)|An electronic asthma action plan (eAAP) will be provided to intervention group
45913052|NCT02017795|Other|written asthma action plan (WAAP)|A written asthma action plan will be given to control group arm
45627909|NCT04545957|Radiation|Radiation Therapy|In Phase I, radiation will be institutional standard per disease site. In Phase II, either radiation according to MR-based dose painting or adjusted RT. These adjusted doses and/or RT will vary per disease site and will be pre-specified in the subprotocols.
45627910|NCT05407701|Dietary Supplement|Cranberry Juice|100% cranberry juice
45627911|NCT05407701|Dietary Supplement|Placebo|Placebo juice
45627912|NCT05389995|Drug|Potassium citrate|7 days potassium citrate followed by 24 hour urine collection
45627913|NCT05389995|Drug|Crystal light|7 days crystal light followed by 24 hour urine collection
45627914|NCT05389995|Drug|Potassium citrate + crystal light|7 days potassium citrate + crystal light followed by 24 hour urine collection
45627915|NCT04529265|Drug|Methylene Blue|Intraoperative infusion of 2mg/kg MB after induction of anesthesia and 1mg/kg MB at the end of surgery
45627916|NCT04529265|Drug|Placebo|Equal volume of normal saline after induction of anesthesia and at the end of surgery
45627917|NCT03191903|Combination Product|Cingal|Hyaluronic Acid with Triamcinolone Hexacetonide
45627918|NCT03191903|Device|Monovisc|Hyaluronic acid
45627919|NCT03191903|Drug|Triamcinolone Hexacetonide|Triamcinolone Hexacetonide
45627920|NCT05530239|Other|Blood sample collection|Blood sample collection
45627921|NCT05530161|Other|hypocalcemia|hypocalcemia or normocalcemia
45627922|NCT05534685|Other|intratracheal administration of surfactant/budesonide|328 patients will be included from Group A: 164 patients, from Group B: 164 patients who meet the selection criteria within the first 4 hours of hospital stay, after the authorization of the parents or guardian signing the informed consent. According to the assigned group, the preparation of surfactant or surfactant/budesonide in the syringe will be carried out, prior to performing the tracheal cannulation procedure. Group A will be given surfactant (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) at a dose of 100mg/kg or 4ml/kg and budesonide (budesonide, nebulized suspension 2ml contains 0.500mg) at a dose of 0.250 mg/kg or 1 ml/kg. Group B will receive surfactant alone (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) administered at a dose of 100mg/kg or 4ml/kg.
45913053|NCT02017821|Behavioral|high intensity aerobic training|
45627923|NCT05534685|Other|incidence of bronchopulmonary dysplasia|. Subsequently, follow-up will be carried out at 12 hours to assess the administration of the second dose of surfactant, type of mechanical ventilation, inspired fraction of oxygen (Fi02), arterial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2 ), mean airway pressure (PMVA), oxygen index (IO), oxygen saturation by pulse oximetry, weekly follow-up of the patient will continue for 28 days, evaluating the same parameters to make a diagnosis of bronchopulmonary dysplasia and finally at 36 postmenstrual weeks of gestation in those under 32 SDG or at discharge and at 56 postmenstrual days of life in those over 32 SDG or at discharge, allowing the severity of the disease to be determined
45627924|NCT05530083|Behavioral|group education|Group education is one of strategies and behavioural interventions of smoking cessation. Lectures, group meeting for mutual support, discussion of coping skills and suggestions for prevention relapse can help smokers quit smoking by providing support and encouragement from people in same condition.
45627925|NCT05530083|Behavioral|conventional smoking cessation management|Including regular follow-up of smoking status and giving advice of smoking cessation
46069898|NCT04251650|Other|CGF sample|each site was sampled with a PerioPaper Strip® (Oraflow), and the volumes collected were measured with a Periotron® (Oraflow). Then samples of affected sites were stowed in an eppendorf tube with 120µL of PBS Tween. The same procedure was performed for the healthy sites
45447344|NCT02114320|Device|EUS-BD|EUS-guided hepaticogastrostomy (EUS-HG) will be performed in patients with hilar stricture or altered anatomy such as Roux-en-Y anastomosis, and EUS-guided choledochoduodenostomy (EUS-CD) will be performed in patients with mid to distal extrahepatic bile duct strictures. Because EUS-guided rendezvous technique can be attempted only in patients in whom the papilla is endoscopically accessible. Following bile duct puncture using a 19-gauge fine needle, one-step or graded tract dilatation will be performed. Then, finally we insert a partially or fully covered metallic stent.
45447345|NCT02108314|Behavioral|Video Screening and Counselling|The intervention comprises 1) GP counseling, 2) 3-minute promotional video on mammography and 3) an informational brochure with relevant contact details and information for arranging a mammography screening. Pre- and post-consultation questionnaire were administered to participants to evaluate their health beliefs, with emphasis on breast cancer and mammography.
45627926|NCT03191825|Other|Endre: a digital smoking cessation counsellor|A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen & Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).
45913054|NCT02017834|Procedure|surgical resection|neck dissection and tumour resection will be performed either with or without the harmonic scalpel as an adjunct.
45627927|NCT03191825|Other|Lapse management system triggered from web-page|"The lapse management system is based on a day-to-day logging of the target behavior (smoking). This logging goes on for four weeks after an initial quit attempt. The current version of the system logs by asking the participant about their smoking status every time they log on to Endre (the digital smoking cessation counsellor). Participants that report a lapse is routed to a fully automated counselling session delivered by web."
45768766|NCT01220869|Drug|Degarelix|Degarelix was given as subcutaneous (s.c.) injections with a 240 mg starting dose followed one month later by a 80 mg maintenance dose. The maintenance dosing was repeated for an additional 5 months (total treatment period was 168 days).
45768767|NCT04124666|Biological|Granulocytes|Granulocytes cross-matched for ABO-Rh and CMV; bioactivity of anti-cancer ability meets the criteria.
45768768|NCT05604872|Procedure|Small Incision Lenticule Extraction|A 500 kHzVisumax (Carl Zeiss Meditec AG) femtosecond laser was used with cap thickness ranging from 100 to 130μm, cap diameter from 7.3 to 7.9 mm. The lenticule was dissected with a blunt spatula through a 30 to 60-degree incision at the 10 o'clock position and removed using forceps afterward. Treatment targets of both eyes were set to emmetropia, the refraction corrections were based on manifest refractions
45913055|NCT02017873|Drug|Peroxide Carbamide 10% - Dental bleaching treatment|During 3 hours in 3 weeks of bleaching in both groups in healthy patients and smokers patients
45913056|NCT02017886|Dietary Supplement|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA twice daily for three weeks
45913057|NCT02017886|Dietary Supplement|Placebo|Placebo tablet twice daily for three weeks
45913058|NCT02017925|Behavioral|exercise intervention|Undergo pulmonary rehabilitation
45913059|NCT02017925|Procedure|pulmonary complications management/prevention|Undergo pulmonary rehabilitation
45913060|NCT02017925|Procedure|quality-of-life assessment|Ancillary studies
45913061|NCT02017925|Other|questionnaire administration|Ancillary studies
45913062|NCT02017938|Procedure|Virtual Reality anti-fatigue ergo cycling training (Self-made)|To establish a Virtual Reality systems to reduce fatigue of cycling training for PD subjects.
45913063|NCT02018029|Other|cardiac resynchronisation therapy|
46069899|NCT04251728|Device|Automated mechanical peripheral stimulation|Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles
45447346|NCT05571488|Other|Electronic surveys|Online questionnaires will be used to collect data, at recruitment and follow-up once a year
45447347|NCT05571488|Other|Qualitative Interviews|Remote focus groups or semi-structured interviews will be proposed to a subsample of the participants, first the year after recruitment and then every two years
45447348|NCT02114398|Other|usual treatment|usual treatment
45447349|NCT02114398|Other|usual treatment + sophrology|usual treatment + sophrology
45627928|NCT03191825|Other|Lapse management system triggered by SMS-textmessage|The lapse management system is based on a day-to-day logging of the target behavior (smoking). This logging goes on for four weeks after an initial quit attempt. The current version of the system logs by asking the participant about their smoking status in a textmessage (SMS) sent each evening. Participants that report a lapse, receives a new SMS with a link to a fully automated counselling session delivered by web.
45447350|NCT02114476|Device|progestin implant|two small (2.5 mm × 43 mm) silicone rods each containing 75 mg of levonorgestrel in a polymer matrix
45627929|NCT04524195|Drug|[18F]F-AraG Injection|Single dose of 5 mCi+/- [18F]F-AraG IV injection followed by the PET/CT scan. A baseline [18F]F-AraG PET/CT will be performed at about 0-7 days before patient receives the first dose of PD-1/PD-L1 immunotherapy. A second [18F]F-AraG PET-CT will be performed at less than 14 days after the first dose of PD-1/PD-L1 immunotherapy is administered and before the second dose of PD-1/PD-L1 immunotherapy is given.
45627930|NCT02437955|Other|Ferrous sulfate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
45627931|NCT02437955|Other|ferrous sulfate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
45627932|NCT02437955|Other|Ferrous fumarate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
45627933|NCT02437955|Other|Ferrous fumarate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
45627934|NCT05530005|Other|Manual Therapy|Manual Therapy according to Kaltenborn Evjenth method. Exercises with PT resistance, massage.
45627935|NCT03191435|Device|Inspiratory muscle training.|Patients will perform the inspiratory muscle training using a moderate load of 30% of maximal inspiratory pressure (MIP 30%). The training will be conducted at home in a period of 30 minutes, 7 times a week, during 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed. Furthermore, load in the device (powerbreathe) will be adjusted for the individual to use next week.
45627936|NCT03191435|Device|Placebo inspiratory muscle|Patients will perform the inspiratory muscle training using a very low load of 2% of maximal inspiratory pressure (MIP 2%). The training will be conducted at home in a period of 30 minutes, 7 times a week, in the course of 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed.
45627937|NCT05529927|Drug|Sustained-release Dexamphetamine|"During the first week, patients will be individually titrated to the target dose of 90 mg/day, if tolerated. From the second week onwards, patients are prescribed 3 tablets (30 mg) per day, if tolerated. Titration can be slower but should be finished at the end of week 4. After 4 weeks dosages can no longer be increased, and only be reduced.~Patients will visit the treatment centre 2 times per week to take their study medication under supervision of the treatment staff and to receive take-home medication for the days in between study visits.~After 24 weeks patients will be randomized to either (double-blind) continuation or discontinuation (placebo) of SR-Dexamphetamine treatment to assess the consequences of discontinuation, during a 6 weeks period."
45768769|NCT05511402|Other|Exercise training|People with Parkinson's Disease will be received a supervised physiotherapy and rehabilitation program.
45768770|NCT04124354|Behavioral|Physical Activity|Participants will attend 3 treadmill walking sessions/week for 8 weeks (24 total)-exercising at 60-75% of their heart rate (HR) reserve monitored using Polar FT1 HR monitors. All walking sessions will take place using treadmills within the West Bank Office Building on the UMN-Twin Cities campus. Each walking session will be 30 min long during intervention weeks 1-4 and 45 min each during weeks 5-8. This exercise dose is equivalent to that employed in the only two human studies of exercise and the gut microbiome in addition to the dosage observed necessary to yield meaningful cardiometabolic changes. After the 4th- and 8th-weeks of the intervention, participants in both study groups will again undergo outcome assessments
45768771|NCT05600192|Other|Aerobic or anaerobic exercise|Aerobic or anaerobic exercise in the morning or in the afternoon
45768772|NCT01927874|Procedure|Infiltration|injection of local anesthetic, associated with general anesthesia
45768773|NCT01927874|Procedure|Spinal block|injection of anesthetic
45768774|NCT01927874|Drug|Bupivacaine|10ml 0.5% bupivacaine.
45768775|NCT01927874|Drug|10 mg of hyperbaric 0.5% bupivacaine|Spinal punction and injection of local anesthetic
45768776|NCT05604716|Other|observational study|observational study
45768777|NCT04124276|Dietary Supplement|Lycium barbarum polysaccharide|Experimental groups take Lycium barbarum polysaccharide (LBP) (300mg/day) for 6 weeks
45768778|NCT04124276|Dietary Supplement|Placebo|Placebo control group takes placebo (300mg/day) for 6 weeks.
45768779|NCT04124510|Drug|Brand Name: Flutiform K-haler|Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
45768780|NCT05604638|Drug|Tenecteplase plus Tirofiban|Patients will receive a continuous intravenous infusion of tirofiban at a rate of 0.1 µg/kg per minute for 26.5 h after start of tenecteplase treatment within 90 min
45768781|NCT05604638|Drug|Tenecteplase plus Placebo|Patients will receive a continuous intravenous infusion of Placebo at a rate of 0.1 µg/kg per minute for 26.5 h after start of tenecteplase treatment within 90 min
45768782|NCT04123808|Device|IpsiHand Treatment|The IpsiHand system utilizes a Brain-Computer Interface (BCI) as a control for a robotic hand orthosis donned on the affected upper extremity as participants are guided through a rehabilitation program on a tablet. Participants will complete 16-32 weeks of home therapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 3 months post no-device use, to track progress.
45447351|NCT02114476|Device|Placebo|
45447352|NCT03233048|Device|ORBERA™ Intragastric Balloon|The balloon will be inserted into the stomach and inflated, and will remain in place for 6 months, after which the device will be removed.
45768783|NCT05609630|Drug|Upadacitinib|Oral tablet or Oral solution
45447353|NCT02110966|Drug|Mepivacaine|Drug: Tramadol 1.8 ml of Mepivacaine 2% epinephrine 1:100000.
45447354|NCT02110966|Drug|Mepivacaine plus Tramadol|0.5 ml of Tramadol mixed with 1.3 ml of Mepivacaine.
45627938|NCT05529927|Drug|Placebo|"Dispensed under the same conditions and with similar frequency as the investigational product (see above).~After 24 weeks study medication will be discontinued in the placebo group."
45627939|NCT03191591|Behavioral|First 1,000 Days Program Site|Program components will include 1) Enhancements to and improved use of electronic health records to improve the quality of preventive services and screening for social determinants of health; 2) Staff and provider training; 3) Consistent behavior change messaging; 4) Patient education via print materials, text messaging and short videos; and 5) Strengthening the integration of clinical and public health services to support behavior change and address social determinants of health.
45627940|NCT05534451|Behavioral|video laryngoscope guided nasotracheal intubation|According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be divided into video laryngoscope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
45768784|NCT05609630|Drug|Tocilizumab|Subcutaneous injection or Intravenous infusion
45627941|NCT05534451|Behavioral|video rigid laryngoscope guided nasotracheal intubation|According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be divided into video rigid laryngoscope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
45768785|NCT03033758|Other|Budesonide/Formoterol treated patients|patients who are eligible to start their treatment with budesonide/formoterol therapy
45768786|NCT05604092|Diagnostic Test|VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures)|VolBrain, a fully automated platform that uses anonymized compressed NIFTI files to generate the volumetric data. Volbrain is increasingly recognized and compared to other volumetric tools. LesionBrain is a pipeline to automatically segment WM-L from T1 and FLAIR data. Number of lesions, absolute total lesion volume (in cubic cm), normalized lesion volume (percentage of total lesion volume to whole brain volume), lesion burden (percentage of total WM lesion volume to WM volume), and location (Periventricular, Juxtacortical, and Infratentorial) were obtained.
45913064|NCT02018055|Drug|Aspirin+Ticagrelor|Aspirin+ Ticagrelor after 1month of standard DAPT (Aspirin+Ticagrelor)
45913065|NCT02018055|Drug|Aspirin+Clopidogrel|Aspirin+ Clopidogrel after 1month of standard DAPT (Aspirin+Ticagrelor)
45913066|NCT02018068|Other|Remote control|When pain or sensory and motor block evaluation exceed the thresholds, the patient enters the data in the PCA (patient Control Analgesia) pump. The investigator is alerted by SMS on his smartphone and makes the necessary programming changes by remote control on the Micrel Care TM site. Systematic assessments via the PCA pump are scheduled for 9:00, 13:00 and 19:00 every day during 48 to 72 hours. The patient can alert his physician through his PCA pump of any additional requests (pain, motor blockade, numbness). The anesthesiologist receives an SMS alert and can make any necessary programming changes to the pump via the remote control.
45913067|NCT02018068|Other|At bedside care|When pain or sensory and motor block evaluation exceed the thresholds, the nurse contacts the physician and she will be able to modify the pump settings according to the anesthesiologist prescription. The delay between the call of the patient and the programming changes, the duration of the procedure are reported. Systematic evaluations via the PCA (Patient Control Analgesia) pump are done when the patient arrives in this surgical ward and at 9:00, 13:00 and 19:00 every day for 48 to 72 hours.Throughout the study, if necessary, the nurse or referring physician performs the programming changes directly on the PCA pump and notes the delay in treatment. All the reasons and the duration of any bedside visit are reported.
45913068|NCT02018081|Drug|Levofloxacin|8 blood sampling by patients between the 48th and 60th
45913069|NCT02018094|Drug|Co-amoxiclav|Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days.
45913070|NCT02018094|Drug|Iodine|Intra-operative skin preparation prior to incision to skin.
45913071|NCT02018094|Drug|Metronidazole|500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course
45913072|NCT02018094|Drug|Chlorhexidine|Alcoholic Chlorhexidine skin pre-op preparation
45913073|NCT02018094|Drug|Teicoplanin|Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days
45913074|NCT02018094|Drug|Clindamycin|Clindamycin 300mg 4 times daily orally to be used in case of penicillin allergy
45913075|NCT02018120|Procedure|connective tissue graft|
45627942|NCT05534451|Behavioral|video fiberoptic scope guided nasotracheal intubation|According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be randomly divided into video fiberoptic scope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
45913076|NCT02018120|Procedure|platelet rich fibrin|
45913077|NCT02018133|Drug|Vitamin D 2mg daily for 2 weeks oral paricalcitol|vitamin D 2 capsules daily
45913078|NCT02018133|Drug|Placebo|placebo 2 capsule daily
45768787|NCT05604092|Other|Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)|It includes the Symbol Digit Modalities Test (SDMT) for evaluating the information processing speed, the California Verbal Learning Test (CVLT-II) for evaluating verbal learning and memory, and the Brief Visual Memory Test (BVMT) for evaluating visual learning and memory. Cut off values were calculated as 1.5 SD below mean according to a group of healthy individuals who are matched in age, sex and education as following: 22 for SDMT, 38 for CVLT, and 10 for BVMTR
45768788|NCT03044210|Other|Metabolic evaluation|"diet assessment~biological evaluation~clinical evaluation~metabolic evaluation (calorimetry)"
45627943|NCT02438033|Device|Medtronic Activa PC+S Sensing Deep Brain Stimulator Generator|Patients undergoing deep brain stimulation for Parkinson's disease based on clinically indicated criteria will have the option to enroll in this study, in which the Activa PC+S generator and corresponding extension leads will be implanted rather than the standard Activa PC system. Patients will be assessed every month for 3 months and then every 3 months after, including off and on medication assessments.
45627944|NCT02437799|Other|Dicrotic wave analysis|We will download data from the pulse oximeter that is being used to monitor the patient during their surgery.
45627945|NCT05534217|Biological|corneal debridement of corneal abrasion|Surgical debridement for traumatic corneal epithelial abrasions
45768789|NCT03042962|Other|MRI|Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers
45627946|NCT02437643|Behavioral|Weight Loss|Participants will be prescribed hypo-caloric diet prescription.
45627947|NCT02437643|Dietary Supplement|Dairy Protein|Participants will be provided dairy products: WL-LoEx will be provided 1 dairy serving per day and Pro-WL-LoEx will be provided 8 dairy servings per day.
45627948|NCT02437643|Behavioral|Low intensity exercise|Participants in both groups will participate in chair exercises 3 times a week.
45627949|NCT05534139|Diagnostic Test|7T MRI-scan|MRI-scanning of the brain using a 7T-MRI scanner
45627950|NCT05534139|Diagnostic Test|CSF collection via lumbar puncture|CSF is collected by doing a lumbar puncture
45627951|NCT05534139|Diagnostic Test|Blood withdrawal|Blood is collected by doing a blood withdrawal
45627952|NCT05534139|Diagnostic Test|Clinical measures|UHDRS-Total motor score, UHDRS-short problem behaviour assessment, UHDRS-Cognitive assessments
45627953|NCT02437721|Other|infant formula containing folic acid|
45627954|NCT02437721|Other|infant formula containing MTHF|
45627955|NCT02437565|Other|Stainless steel crown|Placement of stainless steel crowns for teeth that have undergone pulpotomy for the treatment of pulpitis induced by severe early childhood caries under general anesthesia
45627956|NCT02437565|Other|Occlusal Template|Use of an occlusal template for the placement of stainless steel crowns under general anesthesia
45627957|NCT05533983|Other|fecal microbiota transplantation with Nivolumab|This is a single-center, open-label, Phase 2 study to evaluate the efficacy and safety of FMT with nivolumab in patients with advanced, unresectable, or metastatic solid cancer who have progressed during anti-PD-(L)1 therapy.
45627958|NCT02437019|Drug|PCI-32765 (Ibrutinib)|Participants will receive PCI-32765 (ibrutinib) 420 mg (three 140-mg capsules) oral once daily continuously on a 28-day cycle.
45768790|NCT03042962|Procedure|Blood draw|Blood samples will be collected, the DNA will be extracted and banked for genetic studies
45768791|NCT03002870|Other|Questionnaires|Patients will receive questionnaires yearly to follow their QOL
45768792|NCT02999438|Device|Actigraph to check activity levels at home|
45768793|NCT01016483|Drug|Pimasertib|
45768794|NCT01016483|Drug|Gemcitabine|
45768795|NCT01016483|Drug|Placebo|
45768796|NCT02999360|Behavioral|Language therapy|There will be three blocks of treatment, ideally three times a week 100 minutes per day. Treatment will target impairment-directed speech language therapy (SLT) approaches or compensatory-directed SLT in each of the three treatment blocks. Half of the participants will receive the impairment-directed SLT. Half of the participants, will receive treatment that will target compensatory-directed speech language therapy approaches that are focused on functional communication skills in the conversational context. Methods of treatment will include PACE (Promoting Aphasics Communicative Effectiveness (Davis, 2005), conversational coaching (Hopper et al., 2002), and supported conversation (Kagan et al., 2001). The clinician will model and encourage all (verbal and non verbal) modalities of communication.
45768797|NCT02999360|Behavioral|Background Music|30 minutes background music only
45768798|NCT02999360|Behavioral|Aerobic Exercise|There will be three blocks of treatment and the AE will take place for all participants during one or two treatment blocks (randomly assigned), threetimes a week (sessions are three times a week prior to speech therapy but may be one or two times a week if a session is missed or may be up to four or five times a week if one or two sessions are missed and rescheduled due to weather or other circumstances).
45627959|NCT05370183|Procedure|Hyperambulatory tenotomy|Using mini-optics a minimally invasive device, hypermabulatory tenotomy is performed in consultation, with a local anethesia
45627960|NCT05370183|Procedure|Operating room tenotomy|Operating room tenotomy is performed according standard practice, with general anesthesia.
45627961|NCT02436863|Procedure|Surgical performance|Two different surgical performances
45627962|NCT05533905|Diagnostic Test|Lumbar puncture|A thin needle is inserted between the bones in the spine.
45627963|NCT05533905|Diagnostic Test|MRI|A scan of the head.
45627964|NCT05533827|Other|Kaleidoscope|Kaleidoscope
45627965|NCT05533827|Other|Music|Music
45627966|NCT05533827|Other|Virtual reality glasses|Virtual reality glasses
45768799|NCT05603936|Other|Questionnaire|"The original QOLISSY questionnaire was first developed in 2011, it is available as a patient reported and a parent reported instrument. It includes:~QoLISSY questionnaire for children and adolescents (8-12, 13-18 yrs)~QoLISSY questionnaire for parents of children with short stature (4-7, 8-12 and 13-18 yrs) The QoLISSY instrument can be used to assess the health-related quality of life in short stature youth regardless of its cause; however it was specifically developed for patients with GHD and ISS and their parents.The aim of the current study is the adaption, implementation and validation of the instrument for the investigation of the short stature specific quality of life (QoLISSY) for children (age 0-4 years) with achondroplasia (ACH), Small for Gestational Age (SGA) and Growth Hormone Deficiency (GHD) from a parental perspective."
45627967|NCT05533749|Device|GILL eHealth|The aim of the successfully pilot-tested GILL eHealth intervention is to support mental health nurses and clinical nurse specialists in structured somatic screening and lifestyle promotion. The GILL eHealth intervention consists of two parts. Part one is OurGILL which focuses on systematic somatic screening and provides an overview of all somatic abnormalities. It promotes the prevention, early recognition and treatment of somatic problems. The second part is MyGILL. It provides the basis for drawing up a personalized lifestyle plan. The result of MyGILL is an overview of the performance of patients in different lifestyle areas. The eHealth intervention consists of an individual internet environment and is also supported by an app for mobile devices.
45627968|NCT03189407|Dietary Supplement|Moringa oleifera tea|
45627969|NCT02437097|Other|Aerobic exercise|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
45627970|NCT02437097|Other|Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
45627971|NCT02437097|Other|Aerobic exercise and Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
45627972|NCT02437097|Other|Control|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
45627973|NCT02436551|Other|Observation|
45627974|NCT02436629|Dietary Supplement|Nitrate-rich concentrated beetroot juice|James White, Beet It Sport Shot, 70ml (Standard)
45627975|NCT02436629|Dietary Supplement|Nitrate-depleted concentrated red beetroot juice|Beet It Sport Shot, 70ml (Placebo)
45627976|NCT02436785|Other|Music Therapy|In-vivo relaxation where the live music is manipulated in terms of speed and intensity to bring on a state of relaxation for approximately an hour. There will be a brief therapist-led discussion before and after the relaxation portion to increase a sense of group cohesion. Procedures that will be used are based on evidence-based practice for trained Music Therapists.
45627977|NCT02436785|Other|Music Listening|Listening to relaxing music on a CD player for approximately an hour.
45627978|NCT02436473|Drug|Toothpaste containing 1150ppm F|US marketed toothpaste containing 1150ppm of F
45627979|NCT02436473|Other|Toothpaste containing 0ppm F|Experimental toothpaste containing 0ppm F
45627980|NCT02436473|Drug|Toothpaste containing 250ppm F|Experimental toothpaste containing 250ppm F
45627981|NCT02436473|Drug|Toothpaste containing 1150ppm F|Experimental toothpaste containing 1150ppm F
45768800|NCT04123730|Other|Fixed-dose compared to variable oxygen flow supplementation during walking|"At day 1 the patients will perform Walk A and Walk B in a random order:~Walk A: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with the fixed-dose (FOT). O2matic will monitor pulse rate and saturation continuously during the test.~Walk B: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with a variable oxygen flow (AOT) depending on the saturation. O2matic will monitor pulse rate and saturation continuously during the test, and adjust oxygen flow depending on the saturation.~At day 2 the patients will perform two 6 minutes walking (MWT) test in random order:~Walk C: A 6 MWT with FOT Walk D; A 6 MWT with AOT"
45627982|NCT02436161|Behavioral|"Care management program PROMIC"|intensive coaching intervention to optimize care and prevent readmissions, using educational selfcare and worsening symptoms recognition by patients and carers
45768801|NCT05603780|Behavioral|exploratory protocol|physiological and cognitive evaluations
45768802|NCT02569476|Drug|Zanubrutinib|
45627983|NCT05233553|Other|control of liver enzymes|follow-up with clinical and laboratory measurements
45627984|NCT05529849|Drug|TCMCB07|Subcutaneous injection of TCMCB07
45768803|NCT02569476|Drug|Obinutuzumab|
45627985|NCT05529849|Drug|TCMCB07 Matching Placebo|Matching subcutaneous placebo
45768804|NCT04123028|Other|observatory|observation for 1 year period
45627986|NCT02436395|Procedure|Group A (povidone-iodine wash the surgical incision)|Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with povidone-iodine wash the surgical incision
45627987|NCT02436395|Procedure|Group B (normal saline wash the surgical incision)|Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with normal saline wash the surgical incision
45627988|NCT02436317|Device|Point Of Care Ultrasound|Examination with an ultrasound machine
45768805|NCT00963677|Procedure|Nasotracheal Intubation through seeing optical stylet (SOS)|Nasotracheal intubation using seeing optical stylet in the patients with the anticipated difficult intubation. Arm 1:routine anesthesia induction,0.1mg/kg midazolam, 3-8mcg/kg fentanyl, 0.08-0.15mg/kg vecuronium and 0.3mg/kg etomidate, Nasotracheal intubation with seeing optical shikani; Arms 2: Sevoflurane combined with oxyge, 0.3mg/kg Etomidate and 1-2mg/kg succinylcholine for intubation, nasotracheal intubation with seeing optical shikani
45913079|NCT02018146|Other|Mask then nasopharyngeal|Patients will be randomly assigned to Mask ventilation followed by naso-pharyngeal ventilation
46069900|NCT04251728|Other|Physical Exercise|The exercise program will be conducted for 12 weeks lasting 1 hour each session. Sessions will be held in groups and each session will comprise 4 steps: 1) Warm-up (5 min): patients will perform stretching of the main muscle groups of upper limbs, lower limbs and trunk; 2) Aerobic exercise (30 min): patients will perform continuous aerobic exercise consisting of walk on flat ground and ramps; 3) Resistance exercise training (20 min): volunteers will perform resistance exercises (2 sets x 15 repetitions) for upper and lower limbs, and trunk working the following muscle groups: shoulder flexors, extensors and abductors; elbow flexors and extensors; trunk extensors and flexors; knee flexors and extensors; and dorsiflexors and plantar flexors; 4) Cool-down (5 min): Stretching of the main muscle groups worked during the sessions and relaxation.
45627989|NCT02436083|Drug|antibiotic (use of penicilline, unacid, cefuroxime)|prophylactic antibiotics
45627990|NCT02576535|Procedure|Fractionated stereotactic radiosurgery|
45627991|NCT02576535|Device|Leskell gamma unit|FDA approved device
45627992|NCT03189017|Drug|ICP-022|The drug product is a white, round, uncoated tablet.
45627993|NCT03189017|Drug|Placebos|The placebo is a white, round, uncoated tablet.
45627994|NCT05599815|Drug|ADX-629|ADX-629 (250 milligrams) administered twice daily
45768806|NCT05603234|Behavioral|Symptom Monitoring|Reporting symptoms each day via a symptom questionnaire
45768807|NCT04393064|Device|fiberoptic endoscopic evaluation of swallowing|"intreventions name :-Fiberoptic endoscopic evaluation of swallowing(FEES) will be performed on all infants enrolled in this study.~interventions type: flexible nasopharyngeal laryngoscope 3,5 mm in size with portable camera & light source & video recording system will be used. Procedure will be done without anesthesia~."
45768808|NCT00955253|Drug|Guanfacine|2mg oral guanfacine (encapsulated)
45768809|NCT00955253|Drug|Placebo|placebo
45913080|NCT02018146|Other|Nasopharyngeal then mask|Patients will be randomly assigned to naso-pharyngeal ventilation followed by mask ventilation.
45913081|NCT02018159|Drug|menotropin|
45913082|NCT02018172|Drug|somatropin|
45913083|NCT02018185|Device|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
45913084|NCT02018185|Device|Sham Transcranial Magnetic Stimulation|Sham stimulation of the brain.
45452469|NCT05172466|Device|BeCare application|Participants will complete activities on the application 3 times a week for 2 weeks when they first join the study. They will then attend 4 in-person visits where they complete clinical and application based assessments. Activities are clearly marked in the application and participants are assigned specific assessments by the study team. The application analyzes user input during each evaluation to provide an outcome measure for that assessment.
45627995|NCT03189095|Behavioral|WOWii (Workout on Wheels Internet Intervention)|"Participants will self-monitor their exercise on the WOWii website, which has a page to record the type, duration, and intensity of daily exercise bouts.~Two devices will track participants' exercise, a Polar heart rate monitor (RS300X, Polar®), which will provide data on the day, duration, and intensity (average and maximum) of aerobic activity and an ActiGraph accelerometer (model GT3X), which detects movement in three planes to indicate frequency and intensity of movement throughout the day. Experimental participants will be provided a Polar heart rate monitor to wear during each exercise bout for the entire length of the 6-month study, and exercise data will be collected weekly.~Physiological outcomes on fitness will be assessed by measuring weight and aerobic capacity in a Cardiopulmonary Lab by a doctoral-trained physical therapist.~Participants will complete surveys to report on their exercise self-efficacy and perceived barriers."
45913085|NCT02018211|Other|control|passive recovery following exercise test
45627996|NCT03189251|Other|Dietary intakes|Analysis of association between consumption of high excess free fructose (EFF) beverages (high fructose corn syrup sweetened soft drinks, fruit drinks, apple juice)
45627997|NCT05207631|Other|Systematic and standardised assessment of inhalers and implementation of a prescribing guide|Participants included in the intervention cohort receive a systematic and standardised assessment of their inhalers on admission to our department. The assessment is carried out by a physiotherapist and aims to assess inhalation technique, peak inspiratory flow and ability to use the inhaler after targeted teaching. Based on this information and a prescription guide provided, the patient's doctor can select the most appropriate inhaler.
45627998|NCT03117647|Procedure|Mansoura-VV compression suture|two compression suture both are v shaped apex of each suture placed 2 cm below suture line of C.S and 3 cm from the lateral border of the uterus on the right and left side
45913086|NCT02018211|Device|graduated compression socks|graduated compression socks worn after test exercise
45913087|NCT02018211|Device|neuromuscular electrical stimulation device|neuromuscular electrical stimulation device worn after test exercise
45913088|NCT02018224|Procedure|End-to-end suturation without augmentation|End-to-end suturation without augmentation; Irregular tendon ends were cleaned and repaired by the Krackow technique with two separate 0-gauge absorbable sutures.
45913089|NCT02018224|Procedure|End-to-end suturation with augmentation.|End-to-end suturation with augmentation; End-to-end suturation as above with a 10 mm wide central gastrocnemius aponeurosis flap, as proposed by Silfverskjöld.
46069901|NCT04251728|Device|SHAM|Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
45627999|NCT05533593|Drug|Aminoglycoside|Inpatients using aminoglycoside
45628000|NCT03117335|Drug|Placebos|"Drug 1:~Placebo(Sodium Chloride Injection),7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
45628001|NCT03117335|Drug|Sulijia|"Drug 1:~Sulijia(Recombinant Endostatin Injection) Sulijia, 7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
45628002|NCT05533515|Diagnostic Test|CTC Blood Test|We will draw blood to measure the level of Circulating Tumour Cells
45628003|NCT05533437|Device|dry needling|the dry needle inserted to area of pain
45628004|NCT05533437|Other|kinesio taping|kinesio taping
45628005|NCT02435927|Drug|ASLAN001+ CAPOX (Oxaliplatin, capecitabine)|ASLAN001 in combination with oxaliplatin and capecitabine
45628006|NCT02435927|Drug|ASLAN001 + mFolfox6 (5-FU, leucovorin)|ASLAN001 in combination with 5-FU and leucovorin
45768810|NCT05502042|Behavioral|Case Manager and Peer Support Group|Assignment of a Village health team member to provide support to the family through SMS messages (weeks 1-3) and phone call (week 4), as well as home visits as needed if no contacts are reached. These contacts are intended to provide encouragement and education to participants and families to encourage SAP and peer group attendance. Peer groups will have simple play and support activities, led by the village health team member, to improve the experience of SAP for the participating children.
45628007|NCT02435771|Drug|Ergocalciferols|Treatment 1- 400,000 IU
45628008|NCT02435771|Drug|Ergocalciferols|Treatment 2- 800,000 IU
45628009|NCT02435693|Other|PHARMACEUTICAL CARE programe|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
45628010|NCT02435693|Other|Without PHARMACEUTICAL CARE programe|
45628011|NCT02440607|Other|Electronic Cognitive Aid|
45628012|NCT02440607|Other|Static Cognitive Aid|
45628013|NCT02440841|Drug|fedovapagon|
45628014|NCT02440841|Drug|Itraconazole|
45768811|NCT04392986|Other|Sunlight exposure|The weather was sunny and found suitable for outside activity and sunlight exposure program, with a mean temperature of 27.0-28.5 °C, the humidity of 64-80%, and global solar exposure of 1.28 to 2.99 MJ/m2 during treatment.[15] Participants were asked to lie on the beach for 45 minutes per day between 2 to 3 pm to avoid extreme skin irritation and sunburn from direct sunlight exposure.
45913090|NCT02018237|Behavioral|High fructose corn syrup diet|Subjects will consume a high fructose corn syrup diet for 4 weeks. The food will be prepared by the bio-nutrition kitchen, and meals will be picked up every 3-4 days.
46069902|NCT04255238|Drug|Gemigliptin 50mg|The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
46069903|NCT04255238|Drug|Dapagliflozin 10mg|The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
46069904|NCT04251572|Other|Blood sampling|Blood sampling
46069905|NCT04251572|Other|questionaires|Included participants will complete a baseline questionnaire at end of treatment (EOT) and a follow-up questionnaire throughout the follow-up period (Table 1). The questionnaires collect information on socio-demographics (age, gender, ethnicity, employment status, education level, housing status, incarceration, medical history and OST), injecting drug use (drugs injected, injection frequency and sharing of needle/syringe, cookers, cotton/filter or water). Details on the received DAA regime including mode of administration (direct observed therapy, pill box, etc.) and self-reported data on treatment adherence will also be recorded.
45452470|NCT00079391|Device|allogeneic hematopoietic stem cell transplantation|Manipulated Peripheral Blood Stem Cell graft on Day 0. Target CD34+ dose 6 x10e6/kg, (range 3 to 8x10e6/kg) CD3+ dose fixed to 2 x 10e4/kg.
45628015|NCT02440841|Drug|rifampicin|
45628016|NCT02435615|Device|SaniSal Oral Fluid Collector|SaniSal is an oral fluid collector used to collect oral fluid from the mouth with an absorbant sponge.
45628017|NCT02576145|Biological|DT|Diphtheria and Tetanus Toxoid (DT) will be administered intramuscularly as a 1/3 dilution (0.33 flocculation units). The participants will be rechallenged with DT 6 months after Day 29 if failed to show >=1.5 fold increase in lymphocyte proliferative response but have a humoral response.
45628018|NCT02576145|Drug|Daclizumab|The fifth dose (1 milligram per kilogram [mg/kg]) of daclizumab will be administered in this study to participants who already received four doses (one dose at 1 mg/kg within 24 hours post-transplant and then every other week for 3 doses).
45628019|NCT02576145|Biological|KLH|KLH will be administered intradermally with a dose of 250 mcg for participants aged 2 to less than 12 years, and 500 mcg for participants aged 12 to 19 years. The participants will be rechallenged with KLH 6 months after Day 29 if failed to show specified increase in lymphocyte proliferative response or humoral response.
45628020|NCT02435537|Drug|Dexmedetomidine (Precedex)|intrathecal administration
45628021|NCT02435537|Drug|Bupivacaine|intrathecal 10 mg bupivacaine
45628022|NCT02435537|Drug|Morphine|intrathecal 0.5mg morphine
45628023|NCT02440685|Drug|ASN002 Dose Escalation|Multiple ascending doses of ASN002 assigned by cohort
45628024|NCT02440685|Drug|ASN002 RD|Recommended dose of ASN002 from Part A
45628025|NCT05207085|Drug|Valbenazine Oral Capsule|Participants randomized to active treatment will be given a starting dose of 40mg of valbenazine , which may be escalated to 80mg to achieve an optimal dose of the medication for each subject.
45628026|NCT05207085|Other|Placebo Oral capsule|Participants randomized to placebo will be given a capsule that is the same shape and color as the active medication and will subject to the same dose escalation requirements as the other arm but will receive placebo during the treatment period.
45628027|NCT03191513|Dietary Supplement|Interesterified blend of palm kernal and plam stearin|50 g fat provided as interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
45628028|NCT03191513|Dietary Supplement|Un-interesterified blend of palm kernal and plam stearin|50 g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
45628029|NCT03191513|Dietary Supplement|Rapeseed oil|50 g fat provided as rapeseed oil in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
45628030|NCT02576067|Drug|Low dose methotrexate|Study participants will additionally receive 1 mg daily oral folate.
45628031|NCT02576067|Drug|Placebo|
45628032|NCT02435459|Procedure|No lining|No lining material placed under amalgam dental restorations
45628033|NCT02435459|Procedure|Calcium Hydroxide cement|placement of lining material under amalgam dental restorations
45628034|NCT02435459|Procedure|RMGI cement|placement of lining material under amalgam dental restorations
45628035|NCT02435459|Procedure|Resin Bonding Agent|placement of lining material under amalgam dental restorations
45628036|NCT05199909|Drug|zanubrutinib|"The initial dose is 80mg/day. If the treatment is ineffective after 4 weeks, and under the condition of good safety, the researcher will judge that the dosage should be added to 80mg twice/day，or a higher dose for oral maintenance. The maximum dose is 160mg twice a day. The duration of zanubrutinib is 24 weeks.~In case of intolerable adverse reactions, such as severe infection, severe bleeding, hematopenia, arrhythmia, etc., investigator can reduce the dose of zanubrutinib, or withdraw from clinical trials as appropriate."
45628037|NCT02435303|Drug|Sildenafil|
45628038|NCT02435303|Drug|Placebo|
45628039|NCT05529615|Procedure|detection of ctDNA|the ctDNA will be detected during the treatment and served as the andomization basis
45628040|NCT02435225|Behavioral|Mindfulness Based Stress Reduction for Teens Group|A 12-Week weekly group intervention to train adolescents in mindfulness practice
45628041|NCT05533047|Procedure|TURP|Bipolar and monopolar transurethral resection of the benign prostatic hyperplasia
45628042|NCT02434991|Device|Barostat|"During this study, the investigators will ask you to fill out questionnaires about your swallowing, chest pain, and heartburn. The investigators hope the patient will answer all of the questions, but patients can skip any questions they do not want to answer. The questionnaires will take about 15 minutes to complete.~A urine pregnancy test for females of childbearing years.~Patients will be asked to fast overnight (nothing to eat or drink for 8 hours) prior to the barostat test.~At this point healthy controls have completed the study.~Patients with achalasia will then undergo treatment for achalasia at the discretion of the primary clinician managing their case.~Patients will be contacted to complete a phone survey 3 & 6 months and 2 & 4 years after treatment."
45628043|NCT05363787|Other|therapeutic touch|Therapeutic Touch (TT) is an evidence-based holistic treatment method in which universal energy is used intentionally and with compassion for a specific purpose, in order to contribute to one's balance and recovery.In a world dominated by technology, one can lose touch with our inner self. We lose our intuitive abilities for beautiful everyday sensations of nature, the surrounding environment, and various visual and auditory elements. The Therapeutic Touch is an ancient Ayurvedic self-massage technique that connects your body to your soul.It is also used in therapeutic communication. Therapeutic communication is the process of influencing and being influenced by one another. It consists of individual-centered, purposeful, planned, effective and satisfying actions.
45452471|NCT03209570|Other|Care planning using TENA Identifi sensor wear data|All individuals in this arm will receive TENA Identifi sensor wear and will have data available for care planning.
45628044|NCT02434835|Drug|[14C]KWA-0711|
45628045|NCT02434913|Device|SR PIP Implant System|HUD for use in arthroplasty of the PIP joint
45913091|NCT02018237|Behavioral|Standard diet (low in high fructose corn syrup)|Subjects will consume a standard diet (low in high fructose corn syrup) for 4 weeks. The food will be prepared by the bio-nutrition kitchen, and meals will be picked up every 3-4 days.
45913092|NCT02018250|Drug|MMB4 DMS|Subjects will be administered the drug product formulation at the assigned dosage of MMB4 DMS or placebo i.m. to the anterior thigh using a 5 mL syringe.
45913093|NCT02018250|Drug|Placebo|Subjects will be administered the drug product formulation at the assigned dosage of placebo i.m. to the anterior thigh using a 5 mL syringe. The placebo group in each cohort will receive the same injection volume and number of injections as the dose group in that cohort.
45452472|NCT03209570|Other|Care planning without using TENA Identifi sensor wear data|All individuals in this arm will receive TENA Identifi sensor wear but the sensor wear data will not be used for care planning.
45452473|NCT00902200|Drug|AR-12286|See arms
45628046|NCT02575911|Device|Femtosecond Laser System|Used for the creation of a corneal flap in patients undergoing LASIK surgery
45628047|NCT02575911|Procedure|LASIK surgery|
45628048|NCT02434757|Drug|H.P. Acthar Gel|Acthar 40 U given SC daily for 7 days. Depending on the response and the Investigator,Acthar 40 U will continue Acthar 40 U 2x per week or increase to Acthar 80 U daily for 7 days followed by 2x per week
45628049|NCT03189329|Drug|2% lidocaine hydrochloride|Retrobulbar block was performed with 5 ml of 2% lidocaine hydrochloride (AritmalR, Osel, Istanbul, Turkey) in Group L patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
45628050|NCT03189329|Drug|0.5% levobupivacaine|and 5ml of 0.5% levobupivacaine (ChirocaineR, Abbvie, Chicago, USA) in Group LB patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
45628051|NCT03188939|Procedure|single injection supraclavicular brachial pleuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine , In single-injection technique using in plane method and lateral to medial direction, local anesthetic is injected at the point where the subclavian artery meets the first rib.
45452474|NCT00902200|Drug|AR-12286 vehicle|See arms
45628052|NCT03188939|Procedure|intracluster injection supraclavicular brachial pieuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )
45628053|NCT03188939|Procedure|double injection supraclavicular brachial pleuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
45628054|NCT02575833|Drug|Erenumab|A single dose of erenumab 140 mg infused over approximately 60 minutes.
45628055|NCT02575833|Drug|Placebo|A single dose of a matching volume of placebo infused over approximately 60 minutes.
45628056|NCT03188783|Drug|GDC-0853|GDC-0853 tablets orally, either a single dose or twice-daily.
45768812|NCT00963911|Other|Geriatric screening tests|"The G-8 consists of eight items: patient age (>85, 80-85, <80), and seven items from the original 18-item MNA (Mini Nutritional Assessment: appetite changes, weight loss, mobility, neuropsychological problems, body mass index, medication, and self-rated health). The total score ranges from 0 to 17, with lower scores indicating a higher risk of impairments. The cut-off value for an 'impaired' reference test score was <=14 and the time taken to complete the test was recorded.~VES-13 is a self-administered questionnaire that was completed during the first visit after enrollment. For three pre-identified centers, patients also filled in the questionnaire at the following geriatric visit. VES-13 consisted of four groups of questions: age, self-perceived health, difficulties to perform six specific activities, and difficulties to perform daily living tasks due to health concerns. The score ranged from 0 to 10 and a score >=3 was considered to show impairment."
45768813|NCT00963911|Other|Multidimensional geriatric assessment|Patients underwent a geriatric evaluation in the month following the completion of G8 and VES-13 (+/- seven days) before treatment began. The nurse completed six of the seven instruments of the MGA (MNA, Timed Get up and Go (TUG), Activities of Daily Living (ADL), Instrumental ADL (IADL), Mini Mental State Examination (MMSE), and Geriatric Depression Scale (GDS-15)), and the geriatrician rated comorbidity on the Cumulative Illness Rating Scale (CIRS-G), recorded the time required for the consultation, identified patients who needed personalized geriatric interventions, and, if necessary, proposed further geriatric evaluation (outside of the scope of this study).
45628057|NCT03188783|Drug|Placebo|GDC-0853 matching placebo tablets orally, either a single dose or twice-daily.
45628058|NCT05532969|Other|stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
45628059|NCT02709083|Drug|Dasatinib|Given orally
45628060|NCT02709083|Drug|Imatinib Mesylate|Given orally
45628061|NCT02709083|Drug|Nilotinib|Given orally
45768814|NCT04123106|Procedure|ESP block|ESP block bilaterally performed at the level of the surgical site prior to surgery.
45768815|NCT04123106|Procedure|Wound infiltration|Wound infiltration performed at the surgical site at the end of surgery.
45768816|NCT04079504|Procedure|Ligation of indirect hernia sac|Indirect inguinal hernia sac will be separated from the spermatic cord and contents of the sac will be reduced before ligating it at the deep inguinal ring.
45768817|NCT04079504|Procedure|Non-ligation of Indirect Inguinal hernia sac|the indirect inguinal hernia sac will be separated from the spermatic cord and reduced/inverted in to the peritoneal cavity through the deep inguinal ring along with its contents.
45768818|NCT00963989|Device|Penumbra System|The Penumbra System is used to revascularize clotted cerebral blood vessels.
45628062|NCT05357469|Device|Immediate St (Scrambler Therapy)|Participant will receive Scrambler Therapy one (1) time a day, Monday through Friday, for up to 2 weeks (a total of 10 ST treatments).
45628063|NCT05357469|Device|Waitlist ST (Scrambler Therapy)|Participant will receive Scrambler Therapy one (1) time a day, Monday through Friday, for up to 2 weeks (a total of 10 ST treatments).
45628064|NCT04434729|Device|Fetal embolization of vein of Galen malformation using Target XL and XXL Detachable Coils|The study involves a single fetal intervention of maternal transuterine, fetal transcranial torcular puncture and median prosencephalic vein embolization. Detachable platinum coils (Target XL and XXL Detachable Coil, Stryker Neurovascular) will be used to pack the prosencephalic varix.
45628065|NCT02709005|Drug|5% Monolaurin Vaginal Gel|Monolaurin Vaginal Gel is a clear and colorless, non-sterile glycol-based gel for vaginal administration , and commonly referred to as glycerol monolaurate (GML). Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
45628066|NCT02709005|Other|Placebo|The placebo gel is a clear to opaque, colorless to light gray, non-sterile glycol-based gel for vaginal administration. The placebo gel contains the same excipients as the Monolaurin vaginal gel. Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
45628067|NCT05532891|Other|COVID-19 pandemic|Pandemic group underwent surgery during the COVID-19 pandemic. Pre-pandemic group underwent surgery prior to the pandemic.
45628068|NCT05353335|Other|Re-timing of anti-hypertensive drug|The intervention will consist of shifting the anti-hypertensive medication from morning/early dose to an evening/later dose
45628069|NCT05353335|Other|Current regimen|The participants will begin on their current regimen.
45628070|NCT05346627|Procedure|Personalized and mixed training program|Patients perform a personalized and mixed training program (endurance and muscle reinforcement), at home
45628071|NCT03188315|Genetic|HPV oncogenes|PCR and oncogenes detection
45447355|NCT02937740|Drug|NATESTO Testosterone Nasal Gel|"Participants will be instructed to administer 5.5 mg of testosterone (1 actuation) per nostril of NATESTO Testosterone Nasal Gel once in the morning and once in the evening (at least 6 hours apart), preferably at the same time each day for a total daily dose of 22 mg/day of testosterone. Patients should be instructed to completely depress the pump 1 time in each nostril to receive the total dose.~For three times daily (after Visit 4 [Day 90] if symptoms not adequately managed by a BID dose), NATESTO will be administered intranasally once in the morning, once in the afternoon and once in the evening (approximately 6-8 hours apart), preferably at the same time each day for a total daily dose of 33 mg/day of testosterone."
45628072|NCT05528835|Procedure|Frozen embryo transfer|All women in both groups will receive oral estradiol valerate 8 mg/ day from the second day of the menstrual cycle. Endometrial thickness will be assessed by vaginal ultrasonography at the tenth day of treatment. When endometrial thickness reached ≥ 7 mm all subjects, in addition to estrogen, they will receive progesterone vaginal suppositories 400 mg twice daily and 100 mg of progesterone intramuscularly daily. Frozen thawed embryo transfer will be at day 6 of progesterone. Estrogen and progesterone will be continued until 9-10 weeks of gestation
45628073|NCT03188471|Drug|GnRH antagonist|GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days for high risk of ovarian hyper stimulation syndrome patients
45628074|NCT03188471|Drug|aspirin|aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days
45628075|NCT03188549|Other|AniosGel 85 NPC|Hand hygiene formula
45628076|NCT03188549|Other|Softa-Man (Braun)|Hand hygiene formula
45628077|NCT03188549|Other|Septol|alcohol-based hand rub
45447356|NCT02111044|Drug|Octreotide|octreotide 100 mcg sc t.i.d. for 4 weeks
45447357|NCT02111044|Drug|ITF2984 500 mcg|ITF2984 500 mcg sc b.i.d for 4 weeks
45628078|NCT05528679|Drug|610 100mg|100mg administered subcutaneously Q4W
45628079|NCT05528679|Drug|610 300mg|300mg administered subcutaneously Q4W
45628080|NCT05528679|Drug|placebo|administered subcutaneously Q4W
45628081|NCT02434601|Procedure|Treatment of Dentin Surface|"Experimental Group 1: Increase the etching time to 30 seconds, performed with phosphoric acid gel at 37%, prior to application of the resin adhesive.~Experimental Group 2: Prophylaxis cavity probe / blunt tip of ultrasound, applied for 30 seconds on the dentin surface hypermineralized of cervical lesions non-carious.~Both restorative procedures were performed using a conventional adhesive system and composite restorative nanoparticulate."
45628082|NCT02434601|Procedure|Dentin Surface|Treatment of Dentin Surface: Increased etching dentin for 15 seconds to 30 seconds
45628083|NCT02434601|Procedure|Treatment|Treatment of Dentin Surface: Intervention with the cavity prophylaxis probe ultrasound blunt applied for 30 seconds in Surface hypermineralized non-carious dentin cervical lesions. Therefore, the restoration was done following the protocol recommended by the manufacturer of the material.
45628084|NCT04650087|Drug|Apixaban 2.5 MG|Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
45768819|NCT05609006|Dietary Supplement|High-Energy, Low-Volume ONS|2 bottles/day of a High-Energy, Low-Volume ONS
45768820|NCT05609006|Dietary Supplement|High-Energy Standard ONS|2 bottles/day of a High-Energy Standard ONS
45628085|NCT04650087|Drug|Placebo|Participants will take placebo twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
45447358|NCT02111044|Drug|ITF2984 1000 mcg|ITF2984 1000 mcg sc b.i.d for 4 weeks
45447359|NCT02111044|Drug|ITF2984 2000 mcg|ITF2984 2000 mcg sc b.i.d for 4 weeks
45447360|NCT05472818|Drug|[11C]APP311|For each [11C]APP311 (UCB-J) PET scan, up to 20 mCi of [11C]APP311 (UCB-J) will be administered by infusion pump. All participants will receive at least two [11C]APP311 (UCB-J) PET scans approx. 4 weeks days apart. Approximately 8 CUD participants will be asked to return for a third [11C]APP311 (UCB-J) PET scan after an additional 4 weeks following their second scan.
45447361|NCT02108470|Other|Dental consultation using OHIP|The S-OHIP[M] measure assesses the impact of one's oral health condition on QoL, contributing to 7 domains: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability, and handicap. Responses of each item are made on a Likert scale and coded as: 1 = never, 2 =hardly ever, 3= occasionally, 4= fairly often, and 5= very often.
45447362|NCT05444426|Other|Shoulder Rehabilitation|hot pack, conventional TENS (COMPEX Rehab 400), 1 MHz frequency, 1.5 W/cm² intensity ultrasound (Chattanooga Intelect Ultrasound), active assistive and active range of motion exercises, stretching exercises for the shoulder muscles at the pain limit and posture exercises will be applied.
45447363|NCT02114632|Dietary Supplement|Eye Q|3 months of treatment with a polyunsaturated fatty acids or placebo. At 3 months a one-way treatment crossover of the placebo-group to active treatment was made so that both patient groups received active treatment for the remaining 3 month period.
45447364|NCT02114710|Drug|Hydrocortisone|Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
45447365|NCT03927716|Drug|SB206 12%|Topically once daily
45768821|NCT04394390|Dietary Supplement|vitamin d|vitamin D levels
45447366|NCT03927716|Drug|Placebo|Topically once daily
45447367|NCT02108548|Drug|ASP7657|oral
45628086|NCT02434367|Behavioral|Walk With Ease Arm A|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The interention is a self directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes per day, five days per week.
45447368|NCT02108548|Drug|Placebo|oral
45628087|NCT02434289|Dietary Supplement|Dietary protein products|Increased protein intake via dairy products, guided by a dietician.
45768822|NCT05608928|Dietary Supplement|VSL#3|VSL#3 is a commercial probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis. VSL#3 contributes to balancing the gut and vaginal microbiota and is used as a food supplement for management of diseases like irritable bowel syndrome, ulcerative colitis or ileal pouch.
45768823|NCT05608928|Device|Capscan device|"The CapScan device is a short-term single-use class IIa ingestible medical device that collects fluids from the gastrointestinal (GI) tract and is collected in the stool. GI samples are then extracted from the device and analyzed outside the body."
45447369|NCT02108548|Drug|naproxen|oral
45447370|NCT03748563|Diagnostic Test|ds-MCE and EGD|"Procedure of ds-MCE:~The ds-MCE system mainly consists of two parts: the NaviCam magnetic capsule endoscopy guidance system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. The capsule then could be detached from the string system through injecting air into the hollow string with the syringe after completing the examination of esophagus. Then, the examination of stomach under magnetic control and small bowel under the natural action of peristalsis follows.~Procedure of EGD:~The EGD will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session."
45447371|NCT02111122|Drug|Sodium Oxybate|
45447372|NCT02111122|Drug|Placebo|
45447373|NCT03924050|Drug|TORIPALIMAB INJECTION(JS001 )|TORIPALIMAB INJECTION(JS001 ) or Placebo, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
45447374|NCT02108626|Drug|Nicotine|E-Cigarette with nicotine cartridge
45447375|NCT02108626|Drug|Placebo|E-Cigarette with 0mg nicotine cartridge
45447376|NCT04173741|Other|USG measurement|IVC was visualized in the subxiphoid long axis by using convex probe (5-1 MHz). Diameters of IVC was measured 2 cm caudally to the junction of hepatic vein in M-mode. IJV diameter was measured in the short axis by using linear probe (12-5 MHz) and M-mode. IJV visualized in the junction of cricothyroid membrane level and midclavicular line. Maximum and minimum diameter values were measured in the M mode. Distensibility (maximum diameter - minimum diameter / minimum diameter) and collapsibility (maximum diameter - minimum diameter / maximum diameter) indices were calculated after USG measurements were done.
45447377|NCT05431322|Drug|Dexmedetomidine|Initially give loading dose with 0.5 mcg/kg for 10 min and then keep maintenance dose with 0.5 mcg/kg/h until two-lung ventilation then 0.3 mcg/kg/h until the end of suture.
45447378|NCT02108704|Drug|Helicobacter pylori eradication therapy|
45447379|NCT02108704|Drug|Placebo|
45447380|NCT03745599|Drug|Diclofenac|All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
45628088|NCT02434289|Other|Resistance exercise training|Resistance exercise training in small groups for twelve weeks, two times a week, guided by physiotherapists.
45628089|NCT02434211|Other|Questionnaire and focus group|
45628090|NCT03188159|Drug|Vinorelbine|Vinorelbine 25 mg/m2 intravenously on day-1 and day-8 of a 3 week cycle to commence following confirmation of eligibility into the study for a maximum of 12 months, until disease progression, intolerable toxicity or withdrawal of patient consent (whichever event occurs first).
45768824|NCT05608928|Combination Product|Placebo|microcrystalline cellulose
45628091|NCT05528601|Behavioral|use of Endo App®|use of Endo App® smartphone application containing endometriosis relevant exercises and educational material
45628092|NCT05532579|Other|Invasive Physiotherapy Group|The study participants corresponding to the intervention group will receive the treatment proposed by their medical doctor. In addition, and as the main part of the intervention, they will receive an invasive physiotherapy protocol consisting of 3 sessions of ultrasound-guided percutaneous neuromodulation, with a time margin of one week between the first and second session and two weeks between the second and third session. The session will last approximately 15 minutes. Each treatment session will consist of the application of a symmetric biphasic current of 3Hz frequency, 250µsec pulse width, 10 impacts of 10 seconds duration with 10 seconds of rest between them. This application will be performed with acupuncture needles placed in an echoguided manner in the proximity of the dorsal root of the last 3 lumbar levels and in the proximity of the sciatic nerve at its exit from the piriformis muscle.
45628093|NCT05532579|Other|Sham Group|Study participants corresponding to the sham group will receive the treatment proposed by their medical doctor. In addition, they will receive the application of the simulated transcutaneous electrical stimulation technique, placing the patches on the same points where the needles are located, remaining in prone position for the necessary time after the technique is performed until 15 minutes have elapsed. This technique has been studied as a placebo technique for neuromodulation interventions.
45628094|NCT03191669|Other|Auto-questionnaire|Single Auto-questionnaire administered during or after a consultation/hospitalization
45628095|NCT05532501|Drug|Oral Oxytocin|Administer oxytocin (24 IU) orally, 6 individual 0.1 ml puffs (4 IU/0.1ml) on the tongue (lingual), one every 30 seconds
45628096|NCT05532501|Drug|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0.1ml), three puffs per nostril one every 30 seconds
45768825|NCT05608850|Other|Exercise Then Stretch|This arm (sequence) will perform an anti-gravity kinetic chain intervention and then a passive, partner-assisted stretching intervention, separated by a one-week washout period.
45768826|NCT05608850|Other|Stretch Then Exercise|This arm (sequence) will perform a passive, partner-assisted stretching intervention and then an anti-gravity kinetic chain intervention , separated by a one-week washout period.
45913094|NCT02018276|Drug|Lidocaine|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Lidocaine Group, 1% lidocaine 40 mL was prepared in a 50 mL syringe
45768827|NCT05608694|Other|Prostate MRI|Group placement is determined by GRS score, Family history, and germline testing
45768828|NCT01016873|Device|IRay|Low voltage stereotactic radiotherapy system
45913095|NCT02018276|Drug|Magnesium|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Magnesium Group, MgSO4 4g 40 mL was prepared in a 50 mL syringe)
45913096|NCT02018289|Procedure|Triclosan coated suture|Suture of the abdominal wall with triclosan coated suture
45447381|NCT03745599|Drug|Flurbiprofen|All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
45628097|NCT05532501|Drug|Oral placebo|Administer placebo orally, 6 individual 0.1 ml puffs on the tongue (lingual), one every 30 seconds.
45628098|NCT05532501|Drug|Intranasal placebo|Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds
45628099|NCT03188237|Behavioral|AfyaJamii|AfyaJamii is a group antenatal and well-child care program developed in Kenya for use in Kenyan health centers
45768829|NCT04120454|Biological|Pembrolizumab|Given IV
45768830|NCT04120454|Biological|Ramucirumab|Given IV
45447382|NCT03745599|Drug|Benzydamine|All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
45768831|NCT03018431|Other|CT Scan|patients undergoing chest CT scan at admission and repeated lung ultrasonography
45768832|NCT04122404|Diagnostic Test|LF-LAM|Open label multi-center stepped wedge cluster-randomized controlled trial with implementation of LF-LAM. All clusters (i.e. HIV/ART clinic attached wards) start with standard of care and are then randomized to switch to the intervention phase at predefined time points.
45913097|NCT02018289|Procedure|No triclosan|Suture of the abdominal wall with suture without triclosan coat
45913098|NCT02018302|Drug|Triheptanoin|
45913099|NCT02018328|Dietary Supplement|Curcumin|
45913100|NCT02018341|Other|homeopathic remedy in 30C potency|
45913101|NCT02018341|Other|Placebo|
45768833|NCT01017497|Radiation|Stereotactic Radiosurgery|PTV Diameter < 2.0 cm receives 24 Gy; PTV Diameter 2.0-3.0 cm receives 18 Gy; PTV Diameter 3.1-4.0 cm receives 15 Gy;
45628100|NCT05524857|Drug|Fedratinib Oral Capsule 300 mg|300 mg by mouth, once daily
45628101|NCT05524857|Drug|Decitabine 20 mg/m2|20 mg/m2 for injection, for intravenous use
45628102|NCT05524857|Drug|Fedratinib Oral Capsule 400 mg|400 mg by mouth, once daily
45628103|NCT05524779|Device|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
45628104|NCT03191357|Other|n/a observational|Observational study
45628105|NCT05528523|Other|Writing a clinical narrative|The participants had to write a clinical narrative regarding a significant encounter with a patient.
45768834|NCT01017653|Drug|Irinotecan|Irinotecan: for those patients on an enzyme-inducing anti-epileptic drug (EIAED), irinotecan will be dosed at 340 mg/m2 every other week. For those not on an EIAED, irinotecan will be dosed at 125 mg/m2. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
45768835|NCT01017653|Drug|Panitumumab|Panitumumab, 6 mg/kg, as an intravenous infusion every other week. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
45768836|NCT00965237|Device|lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
45768837|NCT00965237|Device|lotrafilcon B single vision contact lens|Commercially marketed, silicone hydrogel, single vision contact lens for daily wear use
45628106|NCT03188003|Other|Exercise Movement Techniques based on mobilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
45628107|NCT03188003|Other|Exercise Movement Techniques based on stabilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
45628108|NCT05528445|Device|Neurosteer EEG recorder|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity.
45628109|NCT02440529|Behavioral|Intervention|Discussion
45628110|NCT02440529|Behavioral|Verbal Group|Detailed Discussion
45628111|NCT05524701|Behavioral|Sleep Restriction and Normal Sleep|The intervention will consist of either sleep restriction (4 hours per night, 3 am to 7 am) or normal sleep (8 hours per night 11 pm to 7 am) for a duration of two nights.
45628112|NCT05192889|Drug|Venetoclax|Given oral (PO).
45628113|NCT05192889|Drug|Navitoclax|Given oral (PO).
45628114|NCT05192889|Drug|Dexamethasone|Given orally (PO) or intravenously (IV).
45628115|NCT05192889|Drug|Vincristine|Given intravenously (IV).
45768838|NCT00965237|Other|Over-reader spectacles|Reading glasses worn over single vision contact lenses for near vision work on an as-needed basis
45768839|NCT00966641|Drug|Naproxen|Single orally administered dose of 500 mg naproxen
45768840|NCT00966641|Drug|PL 3100|Single orally administered dose of PL 3100 (500 mg naproxen)
45768841|NCT02565576|Drug|Placebo|
45452475|NCT01097837|Other|Non-interventional|This is an observational study conducted by anonymous survey. There is no intervention.
45628116|NCT05192889|Drug|Calaspargase Pegol|Given intravenously (IV).
45628117|NCT05192889|Drug|Dasatinib|Given oral (PO).
45628118|NCT05192889|Drug|Cytarabine|Given intravenously (IV) or Intrathecal (IT).
45628119|NCT05192889|Biological|Blinatumomab|Given intravenously (IV).
45628120|NCT05192889|Drug|Methotrexate|Given intravenously (IV), oral (PO), or Intrathecal (IT).
45628121|NCT05192889|Drug|Mercaptopurine|Given oral (PO).
45628122|NCT05192889|Drug|Cyclophosphamide|Given intravenously (IV).
45628123|NCT05192889|Drug|Etoposide|Given intravenously (IV).
45628124|NCT05192889|Drug|Leucovorin|Given oral (PO) or intravenously (IV).
45628125|NCT05192889|Drug|Intrathecal Triples|Given Intrathecal (IT).
45628126|NCT05192889|Drug|Pegaspargase|May be used in place of Calaspargase Pegol where available. Given intravenously (IV) or intramuscularly (IM).
45628127|NCT05192889|Drug|Erwinia asparaginase|To be used in case of hypersensitivity or intolerance to Calaspargase Pegol or Pegaspargase. Given intravenously (IV) or intramuscularly (IM).
45628128|NCT05192889|Radiation|Radiation|See detailed description section.
45628129|NCT02434133|Procedure|Blood Draw/Data Collection|Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.
45768842|NCT02565576|Drug|CFZ533|
45768843|NCT03018743|Drug|Dapoxetine|Patients receive dapoxetine (taken 1-3 hours before sexual intercourse) 30mg as needed. A dose escalation to 60mg will be consented after 1 month in case of low efficacy. Patients will be re-evaluated 1, 3, 6, 12, and 24 months after initiating therapy regarding the treatment status and the reasons for treatment discontinuation in the case of discontinuation. If patients missed any visits, they will be contacted by telephone or mail to collect their treatment data.
45768844|NCT03018119|Other|Survey|
45768845|NCT05511324|Behavioral|Questionnaires|Participants will be asked to complete this assessment on your own time, and it should take about 40 minutes.
45768846|NCT05511324|Behavioral|Caregiver Assessment|These sessions will involve simulation-based, caregiving skill training, and your caregiver will be taught skills to help support you (such as feeding, hygiene, mobility, medication administration, and care coordination).
45768847|NCT05395949|Drug|conservative treatment|Prednisone 30 mg/day, supplemented with calcium and omeprazole, and Prednisone were slowly reduced to 10 mg/day after symptoms were relieved, and combined with 7.5 mg/week MTX therapy.
45768848|NCT03018197|Other|Medication Education|Medication education delivered via the personal health record (MyChart) pertinent to the anticoagulation medication dabigatran. Education newsletters will be sent at 4, 6, and 10 weeks post-enrollment.
45768849|NCT03018275|Biological|Roseomonas mucosa|R mucosa grown in Hank's balanced salt solution. Bacteria is washed, quantitated spectrophotometrically, suspended in 10%-15% sucrose, and lyophilized.
45628130|NCT03191045|Diagnostic Test|MRI and concomitant perfused manometry of bowel motility|We will carry out serial cine MRI of the bowel. At the same time we will record perfused manometry readings of the bowel in healthy adult participants.
45628131|NCT05327439|Other|Nicotine (electronic cigarette)|Participants will be provided with electronic cigarettes and 5% nicotine e-liquid cartridges for 8 weeks and encouraged at in-person and phone assessments to use the electronic cigarette any time they would normally smoke. Participants will be able to choose one of two e-liquid flavors (tobacco, menthol) at baseline.
45913102|NCT02018354|Procedure|Lateral Extra-Articular Tenodesis (LET)|Lateral extra-articular tenodesis: A 1cm wide x 8cm long strip of iliotibial band is fashioned, leaving the Gerdys tubercle attachment intact. The graft is tunneled under the fibular collateral ligament (FCL) and attached to the femur with a Richards' staple (Smith & Nephew), just distal to the intermuscular septum, proximal to the femoral insertion of the FCL. Fixation is performed with the knee at 70 degrees flexion, neutral rotation. Minimal tension is applied to the graft. The free end is then looped back onto itself and sutured using the No. 1 vicryl.
45628132|NCT05327439|Other|Nicotine (nicotine pouch)|Participants will be provided with 4mg nicotine pouches for 8 weeks and encouraged at in-person and phone assessments to use the nicotine pouches any time they would normally smoke. Participants will be able to choose one of two nicotine pouch flavors (tobacco, mint) at baseline.
45628133|NCT03187847|Device|Actigraph GT3X|"The primary outcomes are measured by the Actigraph GT3X (step counts) and FSMC (fatigue scale for motor and cognitive functions questionnaire) at three different points in time (Actigraph is worn for three weeks in total).~The secondary outcomes are emotional status, measured by the hospital anxiety and depression scale (HADS) and quality of life, measured by the Hamburg Quality of Life Questionnaire in MS (HAQUAMS)."
45628134|NCT05528367|Drug|Nab-PTX,S-1,Tirelizumab|"S-1:BSA <=1.25 m2 ,80 mg daily; 1.25 m2 <BSA <1.5 m2,100 mg daily; BSA>=1.5 m2 ,120 mg daily.~Nab-PTX:130mg/m2,d1，8，q3w；100mg qw(during radiation) Tirelizumab：200mg d1 q3w."
45628135|NCT05528367|Radiation|Chemoradiation|45-50Gy/25F
45628136|NCT03191279|Procedure|First aid|Open airway (head tilt, chin lift), recovery position, staunch of bleeding, prevention of hypothermia, cooling of burn, CPR
45628137|NCT05528289|Device|AIRVO 2, with conventional symmetric nasal cannula|"The patients will be asked to breathe with HFNC at flow of 30 L/min with the standard cannula~The size of nasal cannula will be selected to occlude patient's nostril of about 2/3.~Temperature will be set according to the patient's tolerance starting from 31°C, up to 37°C, while FiO2 is adjusted to maintain SpO2 between 91 and 94%."
45913103|NCT02018354|Procedure|ACL Reconstruction|Anatomic ACL reconstruction using a four-strand autologous hamstring graft. If the diameter of the graft is found to be less than 7.5mm, semitendinosus will be tripled (5 strand graft) providing a greater graft diameter. Femoral tunnels will be drilled using an anteromedial portal technique, with femoral fixation provided by an Endobutton or equivalent. Tibial fixation will be provided by interference screw.
45913104|NCT02018367|Drug|Proflavine, high resolution imaging|5-10mL of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the biopsy channel of the endoscope and gently placed against the mucosa. The endoscopist will image each discrete lesion observed during white light endoscopy. For each HRME imaged area, an optical read will be obtained followed by a tissue biopsy.
45628138|NCT05528289|Device|AIRVO 2, the new asymmetric nasal cannula|"The patients will be asked to breathe with HFNC at flow of 30 L/min with the new asymmetric nasal cannula~The size of nasal cannula will be selected to occlude patient's nostril of about 2/3.~Temperature will be set according to the patient's tolerance starting from 31°C, up to 37°C, while FiO2 is adjusted to maintain SpO2 between 91 and 94%."
45628139|NCT02433821|Other|Pilates|
45628140|NCT05322213|Drug|THC|2-Week, once daily, flexible dose, inhaled THC
45628141|NCT05322213|Drug|Placebo|2-Week, once daily, flexible dose, inhaled placebo
45628142|NCT03187691|Drug|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
45628143|NCT02433899|Procedure|MICROSURGERY|Semilunar coronally repositioned flap performed under magnification with a surgical microscope
45628144|NCT02433899|Procedure|MACROSURGERY|Semilunar coronally repositioned flap performed without magnification
45628145|NCT02433899|Drug|Dexamethasone|8mg Dexamethasone, single dose, 1 hour before surgery
45628146|NCT02433899|Drug|Chlorhexidine gluconate|Oral rinses with chlorhexidine gluconate, BID, for 14 days
45628147|NCT02433899|Drug|2.0% Mepivacaine + 1:100.000 epinephrine|Regional block
45628148|NCT03191123|Procedure|hepatic resection|The aim of this intervention is to reach curative resection.
45628149|NCT03191123|Procedure|TACE|The aim of this intervention is one of the palliative treatment.
45628150|NCT05184855|Dietary Supplement|Blueberry|Blueberry powder intake
45628151|NCT05184855|Dietary Supplement|Placebo|Placebo powder intake
45628152|NCT05532267|Drug|Ciprofloxacin 750 mg|an immediate release film-coated tablet containing 750 mg Ciprofloxacin
45628153|NCT05532267|Drug|Ciproxin 750 mg|an immediate release film-coated tablet containing 750 mg Ciprofloxacin
45628154|NCT03191201|Drug|Ferric Carboxymaltose|Ferric Carboxymaltose 1000 mg iron element will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution.
45628155|NCT03191201|Drug|0.9% sodium chloride solution|250 mL of a commercially available sterile 0.9% sodium chloride solution.
45628156|NCT02434055|Device|AVERT PLUS|
45628157|NCT05528055|Drug|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at escalating doses on a continuous basis
45768850|NCT05395403|Device|Blood pressure measurement device|The use of three different devices: traditional office blood pressure measurement cuff (OBPM), automated office blood pressure measurement cuff (AOBPM), and home blood pressure measurement cuff (HBPM).
45628158|NCT05528055|Drug|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
45628159|NCT05528055|Drug|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
45628160|NCT05528055|Drug|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
45628161|NCT03187457|Other|Metronidazole|Women with Bacterial Vaginosis treated with Metronidazole for 5 days
45768851|NCT05395247|Other|Geriatric assessment|Geriatric assessment by a trained nurse and a geriatrician for older kidney transplantation candidates in Caen University Hospital. The geriatric assessment includes a evaluation of cognitive functions, depressive symptoms, risk of fall, nutrition, frailty, and functional status.
45913105|NCT02018380|Other|Shock Absorbing Insole (SofSole Athletes Plus)|The shock absorbing insole used in this study was the SofSole Athletes Plus, (Implus Inc, Durham, NC), recommended by the manufacturer for repetitive activities such as running and walking. It is readily available in most athletic shoe stores, retailing for under $20.00. The insole is full-length with a curved last made of Implus XP that has a shore A durometer reading of 60 (0 = softest to 100 = hardest).
45913106|NCT02018406|Drug|Combination injection of EPO and G-CSF|Subcutaneous EPO(300 U/kg)+G-CSF(10 μg/kg) injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
45913107|NCT02018406|Drug|Injection of normal saline|Subcutaneous normal saline injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
45628162|NCT03187457|Other|Control: no treatment|Healthy women without Bacterial Vaginosis
45628163|NCT05524155|Drug|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
45628164|NCT05524155|Drug|Sintilimab|200mg IV d1,Q3W
45768852|NCT05395169|Other|dietary supplement ,electronic treadmill ,DASH diet.|Control group Will be receive medical treatment for 12 weeks. Study group Will be receive the same medication as in control group in addition to DASH diet and aerobic exercise for 12 weeks.
45913108|NCT02018419|Biological|AlloStim|AlloStim is derived from the blood of normal blood donors and is intentionally mismatched to the recipient.
45913109|NCT02018419|Procedure|Cryoablation|Percutaneous ablation of a single metastatic tumor lesion usually in liver or bone. The procedure is conducted under CT or ultrasound image-guidance.
45913110|NCT02018432|Drug|Roflumilast escalation dosage|"This is a randomized, prospective, open label, comparative study to assess whether the administration of roflumilast by dose escalation varies the incidence of discontinuations due to adverse events when compared with the usual dosage in severe and very severe COPD patients.~Roflumilast 250 μg once daily for 4 weeks and then increased dose of Roflumilast 500 μg once daily for 12 weeks"
45913111|NCT02018432|Drug|Roflumilast conventional dosage|Roflumilast 500 μg once daily for 12 weeks
45913112|NCT02018471|Behavioral|Psychoeducative training|The Psychological education was inspired by the technique, Systematic Desensitization (SD), a therapeutic procedure that seeks to eliminate fear and avoidance behaviour
45913113|NCT02018484|Procedure|Unicompartmental Knee Replacement|
45628165|NCT05524155|Drug|Regorafenib|80mg/day,PO,QD,d1～21,Q4W
45628166|NCT03187223|Drug|Melphalan|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.
45913114|NCT02018510|Biological|1 mg/kg, single dose IV administration of 3BNC117|1 mg/kg, single dose IV administration of 3BNC117
45628167|NCT03187223|Drug|Bendamustine|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive bendamustine at a total dose of 400mg/m2, divided in two doses of 200mg/m2/day on days -4 and -3. Melphalan is given at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day, each on days -2 and -1, with the ASCT at day 0.
45628168|NCT05184075|Procedure|Standard hybrid coronary revascularization|Patients will undergo endoscopic coronary artery bypass grafting (endo-CABG) within four weeks after the diagnostic coronarography. Furthermore, they will receive a percutaneous coronary intervention (PCI) within four weeks after the endo-CABG.
45628169|NCT05184075|Procedure|Reverse hybrid coronary revascularization|Patients will receive a percutaneous coronary intervention (PCI) within four weeks after the diagnostic coronarography. Furthermore, they will undergo the endoscopic coronary artery bypass grafting (endo-CABG) within four weeks after the PCI.
45628170|NCT05532111|Drug|Rituximab combined with tacrolimus induction + rituximab maintenance|RT-R group: Rituximab 1 g/time, once in 15 days, × 2 times, combined with tacrolimus, the initial dose is 0.05-0.1 mg/kg/d, 2 times at an interval of 12 hours, orally. Adjust the dose according to the blood concentration (maintain the blood concentration C0 4-8ng/ml). At the end of 24 weeks, tacrolimus was stopped, and rituximab was given 1 g/time × 1 time.
45768853|NCT05394857|Drug|SHR-1314|SHR-1314 subcutaneously
45768854|NCT00970073|Biological|Thymoglobulin 3mg total|1.5 mg/kg induction on Day 0 and 1.5 mg/kg induction on Day 2 (total of 3 mg/kg)
45913115|NCT02018510|Biological|3 mg/kg, single dose IV administration of 3BNC117|3 mg/kg, single dose IV administration of 3BNC117
45628171|NCT05532111|Drug|Rituximab combined with tacrolimus induction + tacrolimus maintenance|RT-T group: Rituximab 1 g/time, once in 15 days, × 2 times, combined with tacrolimus, the initial dose is 0.05-0.1 mg/kg/d, 2 times at an interval of 12 hours, orally. Adjust the dose according to the blood concentration (maintain the blood concentration C0 4-8ng/ml).
45768855|NCT00970073|Biological|Thymoglobulin 4.5mg total|1.5 mg/kg induction on Days 0, 2 and 4 (total 4.5 mg/kg)
45768856|NCT00970073|Drug|Mycophenolate mofetil|1000 mg PO/IV BID for up to 6 months
45768857|NCT00970073|Drug|tacrolimus 3-8|Trough concentration between 3 ng/mL and 8 ng/mL starting on Day 10 and continuing beyond Day 180
45768858|NCT00970073|Drug|tacrolimus 8-12|Trough concentration between 8 ng/mL and 12 ng/mL on Days 0-10; between 6 ng/mL and 12 ng/mL on Days 10-30; between 6 ng/mL and 10 ng/mL Days 31-60; between 5 ng/mL and 8 ng/mL Days 61-179; and between 3 ng/mL and 8 ng/mL beyond Day 180.
45628172|NCT05532111|Drug|Glucocorticoid combined with cyclophosphamide induction + maintenance|PC-C group: The initial dose of prednisone/prednisolone was 0.5-1 mg/kg/d (the maximum dose was 70 mg/d), and the dose was gradually reduced after 4-8 weeks, and then stopped within 6-9 months. Cyclophosphamide 750mg/m2 (adjusted according to eGFR and other conditions), once a month, intravenous pulse therapy. CTX maintenance therapy.
45628173|NCT03187067|Device|Lung ultrasound|Lung ultrasound will be performed on all children to investigate imaging patterns characteristic of pneumonia.
45628174|NCT05532033|Device|High flow nasal cannula|A device able to delivery high flow oxygen therapy
45628175|NCT05532033|Device|Facial mask|standard oxygen therapy
45628176|NCT03186599|Behavioral|low adherence intervention group|Monthly, the study coordinator will give calls to encourage physical activities and medication adherence using MEMS and WALKON activity data.
45628177|NCT05527899|Drug|Zinc gluconate|30 and 60 mg/d of zinc gluconate
45628178|NCT03117959|Device|Stryker ShapeMatch Technology|Will use this patient-specific guide for alignment with Stryker Triathlon Custom Fit Knee.
45913116|NCT02018510|Biological|10 mg/kg, single dose IV administration of 3BNC117|10 mg/kg, single dose IV administration of 3BNC117
45628179|NCT03117959|Device|Stryker Triathlon Custom Fit Knee|
45628180|NCT05524077|Procedure|Ablation|"Catheter ablation (CA) will be performed in the standard fashion (described in international guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death from the AHA/ACC/HRS and the expert consensus statement on Catheter Ablation of Ventricular Arrhythmias from HRS/EHRA/APHRS/LAHRS). CA will be performed under conscious sedation or GA by an Electrophysiologist trained in cardiac arrhythmia ablation. CA will be guided by a combination of mapping techniques (standard practice), and described in guidelines for CA for VT. Mapping techniques will include pace, entrainment, activation, and electro-anatomic substrate mapping, where haemodynamically tolerated. Expected procedure duration is 3-6hrs.~Post-CA, AAD is stopped if patient was drug naïve pre-randomisation. The baseline type/dose of AAD pre-randomisation is continued if the patient was on an AAD pre-randomisation. Repeat ablations are permitted within 30-days post-randomisation."
45628181|NCT05524077|Drug|Anti-arrhythmic Drugs (AADs)|"Standard care usually encompasses patients who have not previously had AADs, being commenced on sotalol 80mg twice/day. Lower doses may be initiated by treating doctor, as clinically indicated. If there is contraindication to sotalol, another beta-blocker may be initiated using standard doses. Clinicians may consider alternative AADs if there is contraindication to beta-blockers. Doses would be up titrated to the maximal tolerated amount.~For patients already on an AAD, amiodarone would usually be added, as per VANISH trial.~They will receive a loading dose 400mg twice/day for 2 weeks, followed by 400mg/day for 4 weeks and 200mg/day thereafter. Patients who have failed amiodarone dose <300mg/day will receive a repeat loading dose of 400mg twice/day for 2 weeks, followed by 400mg/day for 1 week, and 300mg/day thereafter.~If the treating doctor decides to do a CA for VT, the occurrence and timepoint of cross-over will be recorded. Cross-over is estimated to be <2% (VANISH trial)."
45768859|NCT00970853|Behavioral|MOM Program home visiting|Mixed professional home visiting program.
45768860|NCT00970853|Other|Control|Control group will receive same assessment batteries at follow-up but did not receive the home visiting program.
45768861|NCT02569398|Drug|Atabecestat, 5 mg|One atabecestat, 5 mg tablet orally once daily up to 54 months.
45628182|NCT03186833|Other|no intervention|no intervention
45628183|NCT02433743|Dietary Supplement|Ready-to-use therapeutic food (RUTF)|HIV-infected patients were randomly allocated to receive standard hospital diet (Control: n=33), or this diet combined with 100 g/day of RUTF (RUTF: n=32). All patients was follow-up during hospitalisation and 9 week after discharge at home
45768862|NCT02569398|Drug|Atabecestat, 25 mg|One atabecestat, 25 mg tablet orally once daily up to 54 months.
45768863|NCT02569398|Drug|Placebo|One matching placebo tablet orally once daily up to 54 months.
45768864|NCT00971633|Drug|Comparator: Treatment A (Zofran, ondansetron)|an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)
45768865|NCT00971633|Drug|Comparator: Treatment B (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the U.K., taken PO
45768866|NCT00971633|Drug|Comparator: Treatment C (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO
45913117|NCT02018510|Biological|30 mg/kg, single dose IV administration of 3BNC117|30 mg/kg, single dose IV administration of 3BNC117
45913118|NCT02018510|Biological|10 mg/kg, two doses IV of 3BNC117|10 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
45913119|NCT02018510|Biological|30 mg/kg, two doses IV of 3BNC117|30 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
45913120|NCT02018523|Drug|Lenalidomide|lenalidomide 10mg/day orally until disease progression
45913121|NCT02018536|Drug|GSK2336805 30 mg|A single dose of 1 tablet of 30 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
45913122|NCT02018536|Drug|GSK2336805 60 mg|A single dose of 2 tablets of 30 mg ie, 60 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
45913123|NCT02018536|Drug|GSK2336805 120 mg|A single dose of 4 tablets of 30 mg ie, 120 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
45628184|NCT04299867|Procedure|Bowel Surgery with Metronidazole|"Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately."
45628185|NCT05531877|Diagnostic Test|Penile Prosthesis Implantation|Penile measurement are taken preoperatively to serve as a guide to the surgeon to optimize post-operative penile size.
45628186|NCT05527821|Drug|Surufatinib|Surufatinib 250mg will be taken orally once daily continuously on a 21-day cycle
45628187|NCT05527821|Drug|Sintilimab|Sintilimab 200mg will be intravenously administered on Day 1 of each cycle
45628188|NCT05527821|Radiation|Short course radiotherapy|5Gy*5F short course radiotherapy will be delivered
45447383|NCT02111278|Other|Lumbar Manipulation|The manipulating therapist performs the lumbar manipulation technique. With the patient supine, the therapist stands opposite the side to be manipulated. The patient is passively side-bent away from the therapist. The therapist rotates the thoracic spine and then delivers a quick posterior and inferior thrust through the anterior superior iliac spine. The manipulation is performed on the side the patient reported to be more symptomatic. If the patient is unable to identify a more painful side, the side to be manipulated is left to the manipulating therapist discretion. If a cavitation is experienced, no more manipulations are performed that session. If no cavitation is produced, the patient is repositioned, and the manipulation is attempted again. If no cavitation is experienced again, the therapist attempts to manipulate the opposite side. A maximum of two attempts per side will be attempted.
45628189|NCT05527743|Other|Invasive Physiotherapy|They will receive an invasive physiotherapy protocol of 3 sessions of percutaneous electrolysis and percutaneous neuromodulation guided by ultrasound, with a time margin of one week between the first and the second session and two weeks between the second and the third. Each session will last approximately 30 minutes. Each treatment session will consist of the application of 3 impacts of 3 seconds of 1.5mA intensity (1.5:3:3) (34), in a needle placed in an echoguided manner in the carpal tunnel in relation to the median nerve over the area of fibrosis or entrapment. Subsequently, a second needle will be placed ultrasound-guided at the level of the elbow crease in relation to the median nerve. A symmetric biphasic current with a frequency of 2Hz and a pulse width of 250µs (22,35) will be applied for 17 minutes (36), increasing the intensity of the current until a slight tolerable discomfort is produced in relation to the patient's symptomatology.
45452476|NCT04405102|Drug|Ozanimod|The investigational medical product (IMP) for this study is ozanimod. Ozanimod 0.23 mg be administered once daily for 4 days and then ozanimod 0.46 mg will be administered once daily for ten days.
45628190|NCT05527743|Other|Sham|"The participants of the study corresponding to the sham group will receive the application of the transcutaneous electrical stimulation sham technique (37), placing the patches in the same points where the needles are located in the percutaneous electrolysis and percutaneous neuromodulation technique, remaining in the supine position for the necessary time after the technique is performed, until 30 minutes are completed, thus ensuring that the evaluator does not know to which group each patient has been assigned (37). This technique has been studied as a sham technique for electrolysis and neuromodulation interventions (37).~Once the study is completed and if the results are better in the IF group, the subjects in the sham group will be offered to receive this treatment. The reason for this is to ensure that the entire sample ends up receiving a treatment that, a priori, should improve their functional capacities, thus guaranteeing one of the ethical principles of research."
45628191|NCT05531799|Procedure|OPTIMIZATION PHASE|"The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could~- identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and"
45628192|NCT02433587|Drug|Aspirin|Patients will take Aspirin 81 mg
45628193|NCT02433587|Drug|Clopidogrel|Patients will take Clopidogrel 75 mg
45628194|NCT02440295|Procedure|Lower Extremity Amputation|
45628195|NCT02440295|Device|SPY Elite Imaging System|The SPY Elite Imaging System is an adjunctive tool that can be used to assess tissue perfusion in real-time and provides surgeons with information that may change their operative plan before leaving the operating room. (http://novadaq.com/products/spy-elite) The system is comprised of two components, the first is the Spy Elite Kit, which is a single-use package containing one 25 mg vial of indocyanine green, one 10 ml vial of sterile Water for injection, and one SPY Elite sterile drape. The second component to the system is the SPY Elite Device which contains a near-infrared light source that illuminates the fluorescent agent within the tissues, an HD video camera captures the intensity of fluorescent marker in real-time, and software that allows the user to capture relative and absolute perfusion values within the surgical field.
45628196|NCT02440295|Drug|Indocyaine Green|Indocyaine Green (ICG) is a non-nephrotoxic fluorescent imaging agent with a half-life of 2.5-3 minutes that is administered intravenously.
45628197|NCT04299009|Device|Bright light therapy glasses|Bright light therapy delivered through glasses
45913124|NCT02018536|Drug|TMC435 150 mg (Treatment A)|1 capsule of TMC435 150 mg taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
45913125|NCT02018536|Drug|GSK2336805 60 mg (Treatment B and part of Treatment C and D)|2 tablets of 30 mg GSK2336805 ie, 60 mg of GSK2336805 taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
45913126|NCT02018536|Drug|TMC435 100 mg (part of Treatment C)|1 capsule of TMC435 100 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
45913127|NCT02018536|Drug|TMC435 150 mg (part of treatment D)|1 capsule of TMC435 150 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
45628198|NCT02433431|Behavioral|Mindfulness Training|Mindfulness training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
45628199|NCT02433431|Behavioral|Mindful Attention Only Training|Mindful attention training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
45628200|NCT02433431|Behavioral|Analytic Thinking Training|Comparison analytic thinking intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
45628201|NCT05110599|Drug|Bryophyllum 50% chewable tablets|Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g
45628202|NCT05110599|Other|Placebo|Lactose with adaption in appearance and tast
45768867|NCT05506176|Drug|SIM0417|dose of 750 mg SIM0417 with 100 mg ritonavir.
45628203|NCT03190811|Biological|Anti-PD-1 plus DC-CIK|"Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.~DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible."
46069906|NCT04251494|Diagnostic Test|Carotid intima media thickness measurement (CIMT)|CIMT is a measurement of the thickness of the two inner layers of the common carotid artery wall. Using ultrasound, a linear array transducer is placed on the surface of the skin at the neck. Electrocardiogram(ECG) electrodes are placed on each wrist and one on the ankle. An image of the common carotid artery (CCA) is then produced in anterior, posterior and lateral views, and saved along with the ECG recording. The wall thickness can then be measured at the same point in the cardiac cycle using semi-automated detection software (Philips QLAB), which can reduce observer variability. The CIMT will be averaged across left and right CIMTs, as the control reference values use an average of both sides.
45628204|NCT03190811|Biological|Anti-PD-1 alone|Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
45628205|NCT05527665|Procedure|Midurethral sling surgery|This treatment consists of the placement of a sub-urethral sling, usually made of polypropylene, in order to support the urethra during efforts and thus to avoid leaks linked to its hyper mobility. This is a frequent and rapid surgery, which is performed on an outpatient basis. The sling is placed under the patient's urethra with the help of an awl.
45447384|NCT02111278|Other|Sham Manipulation|The manipulating therapist will perform the sham lumbar manipulation technique with the patient side-lying. The therapist passively flexes both hips until slight lumbar flexion is noted at the patient's most painful vertebral level. The therapist will take time palpating patient's spine taking care to avoid rotating the spine. The therapist will then place both hands on the same lumbar spinous process. An equal and opposite force is then applied to the spinous process with both hands. No physiologic motion is expected with this technique. The patient will then be setup for the same sham technique on the opposite side. The sham manipulation technique will be performed in an attempt to blind the patient to group allocation. This technique is designed to provide similar hands on treatment time as the manipulation intervention.
45628206|NCT02433353|Drug|Venlafaxine XR|Serotonin norepinephrine reuptake inhibitor
45628207|NCT02433353|Behavioral|EMDR|psychotherapy
45628208|NCT02433353|Drug|Placebo|Look-alike venlafaxine XR tablets containing no active drug
45768868|NCT05506176|Drug|Placebo|Placebo (tablet)
45768869|NCT05511246|Drug|Venous ethanol|Cannulation of coronary vein or veins in the VT substrate and balloon injection of ethanol
45768870|NCT05511246|Procedure|Catheter ablation|Endocardial catheter ablation of VT substrate
45768871|NCT05511168|Procedure|Craniostnostosis surgery|Surgery of craniosynostosis
45768872|NCT00971789|Radiation|fludeoxyglucose F 18|Fludeoxyglucose is the radioactive material/compound used as an injection to have a PET scan performed.
45768873|NCT00971789|Drug|sirolimus|sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects
45768874|NCT00971789|Other|Clinical Videography|This examination involves testing of cerebellar function that controls movement, balance, and coordination.
45768875|NCT05510934|Behavioral|Shared-care model|A Shared care follow-up strategy involving patients, PCPs and specialists that uses an automated reminder system (TCARS).
45768876|NCT05510778|Dietary Supplement|Charcocaps|250 mg capsules containing Activated charcoal, Gelatin, Titanium Dioxide, and Carmine
45768877|NCT05510778|Other|Placebo|capsules containing ~250 mg cellulose
45768878|NCT05510622|Other|Vaginal swab and endometrial biopsy|A vaginal swab (DNA/RNA shield collection tube with swab - Zymo Research, CatNo R1107) and endometrial biopsy (Endobrush® - Lab CCD, Paris, France) will be obtained during 18th - 22nd day of the menstrual cycle.
45768879|NCT00972335|Drug|Everolimus|This drug will be dosed at 10 mg orally DAILY for the duration of the study.
45768880|NCT00972335|Drug|Bevacizumab|This drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study.
45768881|NCT02337530|Drug|Selumetinib|
45768882|NCT02337530|Drug|Pemetrexed|
45768883|NCT02337530|Drug|Cisplatin|
45768884|NCT02337530|Drug|Carboplatin|
45768885|NCT03831230|Genetic|collection of blood, urine, tumor and ascite samples|collection of blood, urine, tumor and ascite samples during ovarian surgery
45768886|NCT03038750|Other|Eligibility and lifestyle restrictions check.|Eligibility will be assessed at each study visit and participants will be informed in advance of their visit.
45768887|NCT03038750|Other|Medical history, demographic and lifestyle factors|Medical History, participants demographics and lifestyle factors will be assessed by the participant completion of the medical history and ethnicity questionnaires.
45628209|NCT05527587|Other|Nature Connections Intervention|10 PLWD and their 10 caregivers will be examined for the effects of a park visit program on their behaviour and mood symptoms, cognition, and quality of life over the period of 8-weeks. If participants meet the study criteria, an initial education session on the health benefits of nature will be provided to the them. Participants will then be invited to participate in the park visit program which will have them visiting local parks or outdoors spaces with their caregivers. They will be encouraged to allocate approximately 120 minutes each week to outdoor park activities for 8 weeks. Participants will be provided with a visit passport to record a log of activities completed during the park visits. During the 8 weeks of intervention, participants will also participate in a weekly check-in meeting with other participants to discuss about their experiences with the park visits.
45628210|NCT05307627|Drug|low-dose naltrexone|LDN doses <20 mg/day
45628211|NCT03190733|Drug|ATG|ATG will be intravenously infused via a central venous catheter in 4 or 5 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include fludarabine (Flu), busulfan (Bu),cyclophosphamide (Cy). All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF) for aGVHD prevention.
45768888|NCT03038750|Other|Anthropometric measurements: height, weight, and body fat|Height measured by stadiometer. Weight and body fat measured by Tanita scale bioelectrical impedance analysis.
45768889|NCT03038750|Other|Blood pressure and heart rate|Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.
45628212|NCT04648605|Other|Post traumatic stress disorder questionnaire|Parents of hospitalized children in pediatric resuscitation carry out a validated questionnaire that validates the post-traumatic stress level by a score.
45628213|NCT03190499|Other|Family based assessment|Family of the children will be assessed with questionnaires about their child health condition.
45628214|NCT02433119|Drug|OROSARTAN® 5/160mg|
45628215|NCT02433119|Drug|CODIOVAN® 160/12.5mg|
45628216|NCT05527509|Behavioral|Emotional Resilience Skills Training (ERST)|"The ERST training is designed as a train the trainer model. Sauer-Zavala, a co-developer of the UP, personally trained a group of RCMP trainers during a week-long interactive workshop. The trainers continue to have access to Sauer-Zavala for optional follow-up consultation and support related to delivery of the ERST training for questions or to address any issues that arise during training. Having consultation and support available for the trainers should help to offset concerns raised about ensuring training fidelity subsequent to other mental health programs. Participants have ongoing access to ERST to support skill retention after training is completed, which should help to offset previous indications of problems with skill development for mental health programs."
45628217|NCT05527509|Behavioral|Active Monitoring|Participants in the STC will be assessed for at least 66 months, via full assessments (i.e., self-report surveys, clinical interviews), monthly assessments (i.e., ~20 minute self-report surveys), daily assessments (i.e., ~1 minute self-report surveys), and biometric assessments. The self-monitoring and feedback should be inherently beneficial and should facilitate earlier access to evidence-based care, which is why the STC is considered an active comparator.
45628218|NCT02430467|Behavioral|Caregiver-guided pain management training (CG-PMT)|Patient-caregiver dyads in the CG-PM arm of the study will receive 3 50-minute sessions via Skype with a masters-level therapist over a 3-week period. The intervention integrates educational information about cancer pain and its management with a behavioral training program to teach patients and caregivers pain coping skills including relaxation, imagery, and activity pacing, and to teach caregivers how to guide and coach the patient in the practice and application of these pain control techniques.
45768890|NCT03038750|Other|Forearm blood flow: Visit 1 (EDNRA)|Intra-arterial infusion of Phenylephrine at doses of 0.75, 2.5, and 7.5 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 30 minute washout with saline followed by Endothelin-1 infusion of at a dose of 5 pmol/min for 90 min.
45768891|NCT03038750|Other|Forearm blood flow: Visit 2 (EDNRA)|Intra-arterial infusion of Sodium nitroprusside infusion at doses of 1, 3, and 10 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 20 minute washout with saline followed by infusion of BQ-123 at a dose of 10 nmol/min for 90 min.
45768892|NCT03038750|Other|Blood biochemistry (PNPLA3)|25ml blood will be taken from the participant in a glucose fasting state. Following a high carbohydrate meal, a second 25ml blood sample will be taken. Clinical Biochemistry tests and detailed lipid analysis will be performed.
45768893|NCT03038750|Other|Blood EPCR function (PROCR)|Blood sample taken will be analysed via ELISA and FACS.
45768894|NCT03038750|Other|Blood platelet coagulation and function (PROCR)|Blood sample taken will be analysed using a Platelet coagulation and function assay.
45768895|NCT03038750|Other|Blood endothelial permeability (PROCR)|Blood sample will be analysed in vitro using a permeability assay kit.
45768896|NCT03038750|Other|Blood leukocyte-endothelium adhesion (PROCR)|Blood sample will be analysed in vitro using a leukocyte-endothelium adhesion assay.
45768897|NCT03038750|Other|Baseline Venepuncture (PNPLA3, Visit 1)|Up to 25ml Blood will be taken.
45768898|NCT03038750|Other|Deuterium water - Loading dose 1 (PNPLA3, Visit 1)|Loading dose of 3 g/kg body water.
45768899|NCT03038750|Other|Deuterium water - Loading dose 2 (PNPLA3, Visit 1)|Loading dose of 3 g/kg body water.
45768900|NCT03038750|Other|Energy-balanced dinner (PNPLA3, Visit 1)|Provided following baseline bloods and loading dose 1.
45913128|NCT02018549|Device|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
45768901|NCT03038750|Other|Fasting venepuncture (PNPLA3, Visit 2)|Up to 25ml Blood will be taken.
45768902|NCT03038750|Other|Deuterium water - Maintenance dose (PNPLA3, Visit 2)|every hour, maintenance dose 0.04 g/kg body water
45913129|NCT02018575|Dietary Supplement|Crystalline Lysine Amino Acid Mix|Crystalline Lysine from Amino Acid Mixture in amount of 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
45768903|NCT03038750|Other|Consumption of high carbohydrate meal (PNPLA3, Visit 2)|Provided following fasting blood sample.
45768904|NCT03038750|Other|Postprandial Venepuncture (PNPLA3, Visit 2)|Up to 25ml Blood will be taken.
45913130|NCT02018575|Dietary Supplement|White corn meal porridge|A cornmeal porridge including 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
45628219|NCT02430467|Behavioral|Enhanced treatment-as-usual (TAU)|Patient-caregiver dyads in the Enhanced TAU condition will receive the same educational video and booklet on cancer pain and its management that is used as part of the CG-PMT intervention. They will also receive iPads with icons linked to reputable websites that provide educational information on cancer including cancer pain (e.g., ACS, NCI) and will be encouraged to utilize them for information and support. However, they will not meet with a study interventionist nor receive any training in behavioral pain coping skills.
45628220|NCT05178459|Diagnostic Test|Neuropathy measurement|Patient will step on Withings WBS08 and on the Sudoscan to get their sudomotor dysfunction caused by the neuropathy evaluated.
45628221|NCT04425135|Drug|Camrelizumab|200mg,D1,ivgtt, Q3w.
45628222|NCT04425135|Drug|Apatinib|250mg,Qd,Q3W.
45628223|NCT04425135|Drug|Pemetrixed|500 mg/m2,D1,ivgtt, Q3w.
45628224|NCT04425135|Drug|Carboplatin|AUC=5~6,D1,ivgtt, Q3w.
45913131|NCT02018588|Dietary Supplement|tryptophan|graded levels of tryptophan will be given to each subject
45628225|NCT02433197|Device|Aerobic program|"The intervention will be an 8-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and enduranceas well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression."
45628226|NCT03186911|Behavioral|E-liquid sampling and preference assessment|Participants will sample two different e-liquids that vary in nicotine content, complete questionnaires about each one, and then choose between the two e-liquids in a preference assessment task.
45628227|NCT02429999|Drug|Letrezole plus FSH|letrozole, 10 mg daily from day 3-7 and FSH 75IU/day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till hCG injection.
45628228|NCT02429999|Drug|Standard protocol for induction of ovulation|0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225IU/day) from day 2.
45628229|NCT02430155|Device|Bakri balloon|is a 100% silicone construction, dual channel balloon catheter specifically designed and approved by FDA for intrauterine placement in cases of PPH. The Bakri balloon contains no latex, and therefore can be safely used in patients with latex allergies
45628230|NCT02430155|Device|Condom loaded foley's catheter|Under aseptic precautions a sterile rubber catheter was inserted within the condom and tied near the mouth of the condom by a silk thread.
45628231|NCT02573883|Device|Fractionated Carbon Dioxide Laser|Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center Lafayette Office, 1133 21st St NW, Washington, DC 20036, and include 3 sessions, 4 weeks apart.
45628232|NCT02573883|Drug|Clobetasol Propionate 0.05% ointment|Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment.
45628233|NCT02432885|Drug|Enalapril|up to 20mg bid
45628234|NCT02433041|Drug|Haloperidol|Haloperidol 0.005mg/kg at induction of anesthesia
45628235|NCT02433041|Drug|Ketamine|Ketamine 1mg/kg at induction of anesthesia to test its power to prevent postoperative delirium
45628236|NCT02433041|Drug|Haloperidol + Ketamine|Haloperidol 0.005mg/kg + Ketamine 1mg/kg at induction of anesthesia to test their power to prevent postoperative delirium if given together
45628237|NCT02433041|Drug|Saline solution (NaCl 0.9%)|Placebo being used in one of the four groups
45913132|NCT02018601|Procedure|BRILMA|
45913133|NCT02018601|Procedure|paravertebral block|
45913134|NCT02018601|Drug|dexketoprofen|
45913135|NCT02018601|Drug|paracetamol|
45628238|NCT02429921|Dietary Supplement|high-selenium lentils|lentils grown on naturally selenium-rich soils in the Canadian Prairies
45913136|NCT02018614|Other|algoplus|
45913137|NCT02018666|Device|NAVA endotracheal tube|
45628239|NCT02429921|Dietary Supplement|Low-Se lentils|lentils grown on selenium-deficient soils in Idaho, USA.
45628240|NCT04298697|Drug|TDF/FTC Dose Schedule for Arm A|TDF/FTC is a combination anti-HIV medication that contains the drugs tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg). Participants will take 2 pills on Study Day 1, then one pill per day on Study Days 2 and 3. Participants will have biologic specimens collected at specific time points until 28 days after the last dose.
45628241|NCT04298697|Drug|TDF/FTC Dose Schedule for Arm B|TDF/FTC is a combination anti-HIV medication that contains the drugs tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg). Participants will be on a weekly dosing schedule of 2 pills on the first day, followed by one pill per day for the next two days. They will follow this dosing schedule for four weeks. Participants will have biologic specimens collected at specific time points until 28 days after the last dose.
45628242|NCT02575365|Drug|0,5 mg Fingolimod|0.5 mg p.o fingolimod daily
45768905|NCT03038750|Other|Venepuncture (PROCR)|Up to 50ml Blood will be taken.
45768906|NCT03341156|Drug|Kcentra|Kcentra will be administered in 2 divided doses; Pre-bypass (5-10 units/kg based on body weight and preoperative INR and post-protamine based of the pre-bypass dose and the preoperative INR; daily maximum dose not to exceed 5000 IU (50 IU/kg)
45768907|NCT03341156|Drug|Frozen Plasma Product, Human|If the patient is randomized to receive standard transfusion they will receive 2 U of fresh frozen plasma intravenously before cardiopulmonary bypass and then up to 4-8 U of plasma added to the cardiopulmonary bypass reservoir during rewarming.
45768908|NCT03037346|Other|Questionnaire Administration|Complete questionnaires about MPOAD
45628243|NCT02707991|Behavioral|Nurse Case Management|Participants will receive one baseline nurse case management study visit in addition to appointment reminders one week and one day before the scheduled hepatitis clinic appointment. Those who link to the Viral Hepatitis Clinic and are identified as eligible to start hepatitis C therapy by their health care provider will have one additional study visit with the nurse case manager to coordinate drug-drug interaction prevention.
45628244|NCT05527431|Device|high flow nasal cannula|high flow nasal cannula
45628245|NCT05527431|Device|noninvasive ventilation|noninvasive ventilation
45628246|NCT02432807|Drug|Vancomycin 1.1%|Vancomycin hydrochloride ophthalmic ointment 1.1%
45628247|NCT02432807|Drug|Placebo|Placebo
45628248|NCT02429843|Drug|TRC105|Each patient will be dosed with 6, 8, or 10 mg/kg of TRC105 up to a maximum dose of 850 mg for women and 1,000 mg for men based upon overall body weight.
45628249|NCT05527275|Drug|Mitoxantrone liposome combine with Chidamide|"Mitoxantrone Hydrochloride Liposome Injection： Grade 1: 14mg/ m2, D1; Grade 2: 17mg/ m2, D1; Grade 3: 20mg/ m2, D1; Chidamide：20mg twice a week (D1 and D4 or D2 and D5 or D3 and D6) Every 28 days for a cycle, a maximum of 6 cycles of treatment. Mitoxantrone Hydrochloride Liposome Injection RP2D was determined in the phase I trial, and the combination regimen will be used to in the phase II study, with a cycle of every 28 days and a maximum of 6 cycles of treatment.~Subsequently, maintenance treatment was performed: Chidamide, 20mg twice a week, for 1 year."
45628250|NCT02429765|Drug|ACL/FOR|
45628251|NCT02429765|Drug|Placebo|
45628252|NCT05527197|Device|Lapiplasty|The Lapiplasty® System instruments and implants will be retrospectively evaluated in patients previously surgically treated with the Lapiplasty® Procedure for Triplane MTP and TMT joint arthrodesis.
45628253|NCT03186053|Drug|sodium creatine phosphate|sodium creatine phosphate .Loading dose followed by continuous infusion in operation
45628254|NCT03186053|Drug|saline|.Loading dose followed by continuous infusion in operation
45628255|NCT05531487|Other|Questionnaire Survey|All students received a 'QR code' link to the survey.
45628256|NCT02429219|Drug|Saline Irrigation with Ethanol|Saline Irrigation with Ethanol (alcohol)
45628257|NCT02429219|Procedure|transurethral resection of the prostate|transurethral electro-resection of the prostate (TURP)
45628258|NCT02429219|Procedure|photoselective vaporisation of the prostate|photoselective laser-vaporisation of the prostate (PVP)
45628259|NCT05531409|Behavioral|Responsible Behavior for Younger Children (RBYC)|RBYC is a school-based universal prevention program designed to provide adolescents and their parents (or other guardians) with the knowledge and tools to help adolescents interact appropriately with younger children and avoid engaging younger children in sexual behaviors.
45628260|NCT02429531|Biological|Pneumovax 23 (Sanofi Pasteur MSD)|Intramuscular injection of Pneumovax 23 vaccine (0.5 ml).
45628261|NCT02429531|Biological|Typhim Vi (Sanofi Pasteur MSD)|Intramuscular injection of Typhim Vi vaccine (0.5 ml).
45628262|NCT05287581|Behavioral|MOVES|The experimental intervention is a 16-week progressive home-based exercise program in which participants are supported through seven coaching calls based on social cognitive theory and motivational interviewing principles. The individual sessions will provide tailored support for increasing physical activity behavior towards the recommended guidelines of at least 150 minutes of moderate aerobic activity and two strength-training sessions per week. There are no drugs involved in the intervention.
45628263|NCT04483193|Diagnostic Test|Duplex ultrasound|Point-of-Care compression ultrasound test combined with colour doppler imaging in the range from the groin to the popliteal region of both lower extremities.
45628264|NCT05527041|Device|EyeBOX Lens (EBLens)|"The investigational device, EBLens, consists of eye-tracking scanners and sensors, developed by AdHawk Microsystems, embedded into a rugged pair of eye-glasses. The subject will wear the EBLens form factor while seated about 40 cm from a small handheld computer screen. The subject will be instructed to watch a video on the screen, while trying not to move their head. The operator will then initiate the EBLens test sequence. During this test a video will be displayed on only a portion of the screen (aperture about 1/9 the size of the screen) for 90 seconds. The video aperture will begin in the upper left corner, and, after 10 seconds, moves in a clockwise direction around the screen for 2 cycles, each taking 40 seconds. During the scan, the following data are collected at a frame rate from 100 to 500 Hz:~Gaze coordinates~Pupil sizes~Accelerometer data~Gyroscopic data~Rotation data~Blink data"
45628265|NCT02429141|Procedure|US-guided periarterial techique|The needle will be inserted in the axillary fossa in-plane (cranial to caudal) close to the intersection of the pectoralis and biceps muscles. Two separate injections of local anesthetic will be made deep and superficial to the axillary artery
45768909|NCT03037346|Other|Questionnaire Administration|Ancillary studies
45768910|NCT03037346|Other|Video|Watch educational video
45768911|NCT02983994|Device|TURBUHALER®|
45768912|NCT02983994|Device|SPIROMAX®|
45768913|NCT04122560|Drug|Fluconazole 200mg tab|PO dose of 400mg
45768914|NCT04122560|Drug|Fluconazole 2 MG/ML|IV dose of 400mg
45768915|NCT04122326|Behavioral|Workstation Modification|Participants are asked to work in a sequence of workstation setups for ten minutes each. The sequence include 1. sitting with workstation adjusted by the participant, 2. sitting with workstation adjusted to promote proper posture, 3. sitting with workstation adjusted to promote unnatural posture, 4. standing with workstation adjusted by the participant, 5. standing with workstation adjusted to promote proper posture, and 6. standing with workstation adjusted to promote unnatural posture. After the sequence of setups, the participant allowed to adjust the workstation in either sitting/standing to work in 60 minutes in their own desired position.
45768916|NCT02569242|Drug|Nivolumab|
45768917|NCT02569242|Drug|Docetaxel/Paclitaxel|
45768918|NCT04122014|Other|Progressive balance training|Progressive balance training program
45768919|NCT04122014|Other|Normal daily activities|Usual daily activities
45768920|NCT05608382|Other|sterile Phosphate Buffer Saline|control group
45768921|NCT05608382|Other|SGW13|active comparator
45768922|NCT05501808|Procedure|cerasmart|the patient received a crown made of cerasmart ceramic
45768923|NCT05501808|Procedure|enamic|the patient received a crown made of enamic ceramic
45628266|NCT02429141|Procedure|US-guided multi-injection technique|The median, ulnar and radial nerves will be identified by ultrasound. Local anesthetic will be injected adjacent to each nerve
45628267|NCT05273463|Behavioral|Video-Based Intervention|15-minute video about what to expect before, during, and after your surgery
45628268|NCT05273463|Behavioral|Classroom-Based Intervention|Virtual 30-minute course with an Orthopedic nurse about what to expect before, during, and after your surgery
45628269|NCT02429453|Drug|Four Factor Prothrombin Complex Concentrate|A purified, non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C & S
45628270|NCT02429453|Biological|Fresh Frozen Plasma|A pooled collection of plasma from donors
45628271|NCT02429297|Other|HITCM-only|HITCM-only group: patients receive weekly automated calls with feedback to the clinical team.
45628272|NCT02429297|Other|HITCM+CP|HITCM + CP group: patients receive weekly automated calls with feedback to the clinical team and their CarePartner receives updates via phone or email.
45628273|NCT05526963|Other|Medication plan review|Intervention group patients will receive a revised medication plan by external pharmacologist based on the the STOPP/START criteria. The revised medication plan will be provided to the family physician who then will provide it to the patient. The revision comes along with evidence based information for the physician to prevent possible uncertainties by the physicians.
45628274|NCT05526963|Behavioral|Adherence support|Intervention group patients will receive a study nurse administered adherence support measure based on telephone-based motivational interviewing. The measure includes information on possible consequences of inadherence and signs of adverse drug reactions that is comprehensible for lay persons.
45628275|NCT02428751|Drug|Pegylated liposomal doxorubicin|30 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
45628276|NCT02428751|Drug|Doxorubicin|50 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
45628277|NCT02428751|Drug|Rituximab|375 mg/m2, IV (in the vein) on day 0 of each 21 day cycle
45628278|NCT02428751|Drug|Cyclophophamide|750 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
45628279|NCT02428751|Drug|Vincristine|1.4 mg/m2 (2mg in maxium), IV (in the vein) on day 1 of each 21 day cycle
45628280|NCT02428751|Drug|Prednisone|100mg/d, PO on day 1-5 of each 21 day cycle
45628281|NCT05523375|Behavioral|Intensive Lifestyle Intervention|"Trained health coaches deliver the active intervention - a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines."
45628282|NCT05526807|Drug|Ursodeoxycholic acid|Oral
45628283|NCT02428829|Procedure|Attempt walking from 4 hours post operatively, on the day of their surgery.|Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.
45628284|NCT02428829|Procedure|Control - standard treatment|standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively.
45768924|NCT04122248|Other|standard radiographic imaging|standard radiographic imaging
45628285|NCT05531331|Behavioral|At home education via video conferencing|Educational booklets are given according to the type of stoma. The individual with the stoma was told that the researcher was always reachable by phone and could communicate if he had any problems. The individuals with stoma in the experimental group received the training of the company representative that sells stoma materials, which is routinely given in the hospital. After discharge, training was given by the researcher via video conference in a total of four interviews. The first interview was done on the 5th day after discharge, the second on the 10th day, the third on the 15th day, and the fourth on the 2nd month. A post-test was conducted at the end of the 4th training interview, which was administered via video conferencing.
45628286|NCT03184961|Diagnostic Test|lung recruitment maneuver|Lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s)
45628287|NCT04644783|Diagnostic Test|Blood test assay|Participants will have their blood drawn and be evaluated with a new blood assay that screens a large number of foods (more than 20) in a culture plate. Participants will be asked to eat the identified safe foods by the the blood assay.
45628288|NCT03184883|Procedure|single conventional denture|mandibular conventional denture with soft liner
45628289|NCT03184883|Procedure|single flexible denture|mandibular flexible compete denture
45768925|NCT05501730|Diagnostic Test|Quantra QPlus System|Coagulation monitoring system
45628290|NCT04639947|Device|EyeCheck|EyeCheck is a newly developed device to provide intraocular pressure (IOP) measurements of the eyes.
45628291|NCT04639947|Device|Traditional Tonometer (Goldmann and Tonopen)|Standard of care intraocular pressures will be taken using the Goldmann and Tonopen to compare to the EyeCheck.
45628292|NCT03185195|Drug|AQX-1125 Oral Tablet|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by [14C]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive [14C]-AQX-1125 oral solution.
45628293|NCT03185195|Drug|[14C]-AQX-1125 IV|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by [14C]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive [14C]-AQX-1125 oral solution.
45628294|NCT03185195|Drug|[14C]-AQX-1125 Oral Solution|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by [14C]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive [14C]-AQX-1125 oral solution.
45768926|NCT04124588|Device|Nexpowder (Hemostatic powder)|Nexpowder generates gelation-effects when the powder comes into contact with water, forms a physical barrier to control hemorrhage, preserve ulcer sites and thereby demonstrates its effective hemostatic performance. Hydrogels, which turned into gel-formation through water contacts in the gastrointestinal tract protect the wound sites for over 24 hours, are subsequently detached from the lesion, and completely excreted from the patient body system within 3 days.
45628295|NCT03185039|Procedure|Blood and tumor samples|Blood and tumor samples
45628296|NCT05526651|Other|true electroacupuncture|the investigators use stainless steel acupuncture needle, disposable : Huanqiu® 0.25 x 0.40 mm Electroacupuncture device : Hwato-SDZ V®, continuous wave, 2 Hz, for 30 minutes
45628297|NCT05526651|Other|sham electroacupuncture|"the investigators use the same device like true electroacupuncture group, but the acupuncture needle not puncture on the skin and only attached.~electroacupuncture device, with no electrical stimulation"
45628298|NCT03186365|Drug|Zepatier Oral Product|Grazoprevir, an HCV nonstructural protein 3/4A (NS3/4A) inhibitor 100 mg, plus elbasvir, an HCV NS5A inhibitor 50 mg fixed dose combination,Zepatier Oral Product, will be prescribed for 8-12 weeks
45768927|NCT04124588|Device|Conventional Technique|Argon Plasma Coagulation, Coagulation including Forcep, Hemoclipping, Band Ligation, Epinephrine or Absolute Alcohol Injecction can be used as standard-of-care hemostatic treatment(s).
45768928|NCT05501652|Device|ALV1System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
45768929|NCT05501496|Procedure|intramedullary nailing|Flexible intramedullary nailing using 2 nails
45768930|NCT05501496|Procedure|casting|casting with long leg cast
45768931|NCT05501418|Biological|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be IV infusion with 12 months of follow up after treatment.
45768932|NCT05501418|Biological|Controlled normal saline|Normal saline will be IV infusion with 12 months of follow up after treatment.
45768933|NCT05501340|Drug|Serplulimab|PD-1 inhibitor (HLX10, serplulimab) 100mg intraperitoneal infusion every two weeks after radiotherapy PD-1 inhibitor (HLX10, serplulimab) 3mg/kg intravenous infusion within one week after radiotherapy every two weeks
45768934|NCT05501340|Drug|Molgramostim|200ug qd subcutaneous injection for 7 days
45768935|NCT05501340|Radiation|Hypofractionated radiotherapy/Sterotactic body radiotherapy|8Gy*3f
45768936|NCT00972725|Biological|GSK Biologicals' HIV vaccine (732461)|1 dose intramuscular injection
45768937|NCT00972725|Drug|Chloroquine|One dose of 300 mg
45768938|NCT05501262|Device|Cryoablation|Image (ultrasound and fluoroscopic guided) cryoablation will be performed of the Morton's neuroma after nerve block.
45768939|NCT05501262|Procedure|Nerve block|Ultrasound and fluoroscopic guided nerve block.
45768940|NCT04274660|Behavioral|DWELL (Diabetes and WELLbeing) Programme|12-week psychoeducational programme
45628299|NCT05531175|Other|Reiki apply|The intervention group is the group in which reiki is applied. They receives 3 sessions of hemodialysis per week.
45628300|NCT05531097|Drug|HSK31679|Single or multiple oral doses of HSK31679
45628301|NCT05531097|Drug|Placebo|Matching placebo
45628302|NCT02428907|Behavioral|simulation training|teamtraining of endoscopy staff
45628303|NCT05526573|Device|Ultrathin bronchoscopy (MP190F; Olympus Medical Systems, Tokyo, Japan)|Fluoroscopy + RP-EBUS and consecutive lesion sampling by TBNA and/or TBB
45628304|NCT02432651|Drug|6 mg xanthohumol per day|Participants will consume non-alcoholic beverage with 2 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
45628305|NCT02432651|Drug|12 mg xanthohumol per day|Participants will consume a non-alcoholic beverage with 2 mg xanthohumol at breakfast and lunch and 8 mg at dinner for 3 weeks.
45768941|NCT04394000|Other|thromboprofylaxis protocol|This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
45768942|NCT04394000|Other|standard protocol|This protocol contains a routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH
45768943|NCT05600660|Drug|Orelabrutinib|"Orelabrutinib will be given as 150 mg/d orally 72h after MTX infusion or MTX clearance, every 21 days for 6 cycles during induction treatment.~Daily Orelabrutinb will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first)."
45768944|NCT05600660|Drug|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy.
45768945|NCT05600660|Drug|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
45768946|NCT03830762|Drug|Xanamem|Oral Xanamem capsules 20mg or 30mg, administered PO once daily. Xanamem is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343.
45768947|NCT03830762|Drug|Matching Placebo|Matching placebo which is identical in appearance to the test product (20mg, 30mg Xanamem™ QD) except that it contains no active ingredient.
45768948|NCT03312920|Device|active anodal tDCS|active anodal tDCS with memory task
45768949|NCT03312920|Device|sham tDCS|sham tDCS with memory task
45768950|NCT03312920|Device|active cathodal tDCS|active cathodal tDCS with memory task
45768951|NCT04759118|Behavioral|modified childbirth education program|The participants in the intervention group are pregnant women and their husbands. The instructors employed teaching methods such as a group discussion, watching videos, and brainstorming, as well as questions and answer periods, demonstrations, childbirth simulation, and practice. The primary investigator (PI) will teach particular sessions, including maternal-fetal attachment skills, parenting skills, comfort measures, childbirth positions, as well as knowledge about anatomy and physiology during pregnancy and birth Classes consisted of 120-minute sessions held once a week for four weeks.
45768952|NCT04121702|Procedure|Cardiac Rehabilitation|Implementation of a physical exercise program (PEP) with tele-monitoring
45768953|NCT00972959|Drug|Bortezomib|1.3 mg/m2, iv, bolus, on days 1, 4, 8 and 11 of a 21-day cycle for up to 8 chemotherapy cycles
45768954|NCT00972959|Drug|Zoledronic Acid|4 mg, iv, at a 15 min infusion, Day 1 of every cycle for up to 8 cycles, and then every 28 days for the next 18 months
45768955|NCT00972959|Drug|Dexamethasone|12 mg/m2 p.o. on days 1-2, 4-5, 8-9 and 11-12 of a 21-day cycle for up to 8 chemotherapy cycles
45768956|NCT05609240|Drug|Cefuroxime|See arm/group description
45628306|NCT02432651|Drug|24 mg xanthohumol per day|Participants will consume a non-alcoholic beverage with 8 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
45628307|NCT02432651|Drug|Placebo|Participants will consume a placebo non-alcoholic beverage (0 mg xanthohumol) at breakfast, lunch and dinner for 3 weeks.
45628308|NCT04628091|Other|Sampling on surgery day|"In the morning, the day of the surgery (the patient will be fasting):~Occipital hair sample (without roots)~Venous blood sample (3 tubes of 7mL)~During the surgery:~Sample of 0.5 to 1 cm3 of subcutaneous adipose tissue during laparoscopic umbilical access~Collection of a portion of Ampulla proximal part and Isthmus distal part in order to obtain a piece of approximately 4 cm long (2cm of ampulla and 2 cm of isthmus) for each tube."
45628309|NCT02428517|Procedure|AlloHCT for Young/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Cyclophosphamide 60 mg/kg (D-3 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
45628310|NCT02428517|Procedure|AlloHCT for Young/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
45913138|NCT02018679|Procedure|Er:YAG AFL-PDT|AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
45913139|NCT02018679|Procedure|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
45628311|NCT02428517|Procedure|AlloHCT for Old/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
45628312|NCT02428517|Procedure|AlloHCT for Old/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
45628313|NCT05522985|Drug|Triprilimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
45628314|NCT05526339|Device|High-flow nasal oxygenation combined with nasopharyngeal airway|The patients receive an oxygen flow of 30 L/min for preoxygenation with a high-flow oxygenation device before losing of conscious. At the time of the abolition of the eyelash reflex, the gas flow was increased to 60 L/min with an inspired oxygen fraction 100% and the nasopharyngeal airway was placed.
45628315|NCT05526339|Device|Regular nasal cannula combined with nasopharyngeal airway|The patients receive an oxygen flow of 6 L/min for preoxygenation with a regular nasal cannula until the end of procedure. At the time of abolition of the eyelash reflex, the nasopharyngeal airway was placed.
45628316|NCT02707757|Drug|Iron sucrose|1gram of iron sucrose (5 200mg aliquots) administered if participant's haemoglobin is less than 9.5g/dl
45628317|NCT02707757|Drug|Erythopoietin stimulating agent|Incremental increase in dose of erythropoeitin stimulating agent being administered as per a pre-defined criteria
45628318|NCT02432573|Behavioral|Delayed rounds|
45628319|NCT05522829|Biological|SCTV01E-1 on D0|Day 0; intramuscular injection
45628320|NCT05522829|Biological|SCTV01E-1 on D28|Day 28; intramuscular injection
45913140|NCT02018718|Device|Magnetic Resonance Imaging (MRI)|
45913141|NCT02018731|Drug|Metformin and Metformin & L-Citrulline|
45913142|NCT02018731|Drug|L-Citrulline and Metformin & L-Citrulline|
45628321|NCT05522829|Biological|SCTV01E-1 on D150|Day 150; intramuscular injection
45628322|NCT05522829|Biological|SCTV01E on D0|Day 0; intramuscular injection
45628323|NCT05522829|Biological|SCTV01E on D28|Day 28; intramuscular injection
45913143|NCT02018757|Drug|TACE containing As2O3|transarterial chemoembolization containing a mixture of 20mg of arsenic trioxide, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
45913144|NCT02018757|Drug|TACE containing placebo|transarterial chemoembolization containing a mixture of 20mg of placebo, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
45628324|NCT05522829|Biological|SCTV01E on D150|Day 150; intramuscular injection
45628325|NCT05522829|Biological|SCTV01E-1 on D120|Day 120; intramuscular injection
45628326|NCT05522829|Biological|SCTV01E on D120|Day 120; intramuscular injection
45628327|NCT02432495|Other|ANTERIOR SCREW FIXATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone anterior screw fixation of type II odontoid fractures
45628328|NCT02432495|Other|HALOV VEST IMMOBILIZATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone halo immobilization of type II odontoid fractures
45628329|NCT05518539|Device|The Clareon™ PanOptix™ Trifocal (toric and non-toric models)|Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
45628330|NCT02432339|Drug|mycophenolate mofetil (MMF)|an immunosuppressant - 500 mgs twice a day for 7 1/2 days - in capsule form
45628331|NCT02432339|Drug|Placebo|a sugar pill - 500 mgs twice a day for 7 1/2 days - in the same capsule form as the MMF
45628332|NCT05025345|Device|Tecnis Eyhance|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
45628333|NCT05025345|Device|Tecnis 1 piece IOL|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
45628334|NCT03184805|Drug|Continuing aspirin|Subject assigned to control arm will maintain antiplatelet therapy using aspirin only at least 7 days before surgery. If subject is taking one or more antiplatelet drugs, it should be changed (for subjects taking antiplatelet drug except aspirin at enrollment) or continued (for subject taking aspirin at enrollment) with low-dose, aspirin monotherapy before surgery. Cessation of clopidogrel, ticagrelor, and prasugrel should be started at least 5 days, 3 days and 7 days before surgery, respectively. Administration of aspirin will be started at the day of cessation of previous antiplatelet regimen and maintained until third postoperative day with 100 mg once a day.
45628335|NCT03184805|Drug|Stopping aspirin|Subject assigned to comparison arm will stop antiplatelet therapy before scheduled surgery or procedure. If subject is taking aspirin, clopidogrel, ticagrelor, or prasugrel, it should be discontinued for 7 days, 5 days, 3-5 days, and 7 days before surgery. Antiplatelet therapy may be restarted as previous regimen at fourth postoperative day or sooner unless significant bleeding risk or bleeding event occurs.
45628336|NCT05518383|Drug|Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate|For patients with very limited disease (R1- stage I/II СR), the addition of rituximab might allow the omission of anthracyclines and vincristine without jeopardizing survival rates but reducing acute and long term toxicities. In this treatment arm, it is tested whether the event-free survival is similar to that of the historical control
45628337|NCT05518383|Drug|Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine|R2: Drug: Rituximab 2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle
45768957|NCT00973739|Drug|Lapatinib|"Lapatinib is dosed according to age. Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.~Children/adolescents (<18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO (3 tablets twice daily)~Adults (>=18 years of age): 1,500 mg PO (6 tablets once daily)~Duration: Up to 12 months, depending on treatment response."
45628338|NCT05518383|Drug|Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine|2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second
45768958|NCT05608148|Biological|Biological|Intravenous injection of GAIA-102 alone
45768959|NCT05608148|Biological|Biological|Intravenous injection of GAIA-102 with dinutuximab, filgrastim, teceleukin combination
45768960|NCT00974051|Drug|Terbutaline|Oral (2.5mg) one time administration at 9:00pm
45628339|NCT05518383|Drug|Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin|Rituximab 4 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, Further
45768961|NCT00974051|Other|20% basal insulin reduction|Basal insulin rate is reduced by 20% the normal (home dose) for six hours.
45913145|NCT02018770|Radiation|Phototherapy|Portable Cluster 9 PainAway ® diodes manufactured by Multi Radiance Medical ® (Solon, OH-USA), being 1 905 nm diode (1 mW average power 10 W of peak power, spot of 0.44 cm2), 875 nm diodes 4 (17.5 mW average power for each diode, spot of 1 cm2) and 670 nm diodes 4 (15 mW average power for each diode1 spot, cm2), frequency of 1000 Hz, irradiation time of 300 seconds, energy delivered from 39.3 Joules.
45913146|NCT02018770|Radiation|Placebo phototherapy|The volunteers will be subjected to the same Groups ' intervention and placebo pen Phototherapy.
45628340|NCT02432027|Drug|C-82 Topical Gel, Placebo|placebo
45628341|NCT02432027|Drug|C-82 Topical Gel, 1%|active
45628342|NCT02432027|Drug|Daivonex cream|comparator
45628343|NCT02432027|Drug|Diprosis gel|comparator
45628344|NCT05526261|Procedure|Hemithyroidectoy|Hemithyroidectomy it is a surgical procedure where half of the thyroid gland is operated.
45628345|NCT02428439|Drug|bupropion or lamotrigine|Participants who take the standardized pharmacotherapy (bupropion or lamotrigine) for depression will be observed for 8 weeks. Drugs using in this study are the standard treatment for depression, and are NOT administered as part of this study.
45628346|NCT05526183|Biological|Adeno-viral vector vaccine|The vaccine will be injected intramuscularly, as two doses 28 days apart. Two different dosages will be given to volunteers (low dose: 5x1010 and high dose: 1x1011)
45628347|NCT03186443|Drug|Pregabalin|Pregabalin was taken 300mg,q 12h for 6 month.
45628348|NCT03186443|Drug|Gabapentin|Gabapentin was taken 0.4, tid for 6 month.
45628349|NCT05526027|Diagnostic Test|CFQ-R questionnaire, SNOT-22 questionnaire, fecal elastase measurement|cf supra
45628350|NCT02428361|Drug|Biologically active human fecal material, OpenBiome|Fecal microbiota transplant
45628351|NCT05517993|Drug|Gui-Lu-Er-Xian-Jiao-Wan|Gui-Lu-Er-Xian-Jiao-Wan (GLEXJW) is an ancient CHM formula, mainly originating from processed tortoise shells, antlers, Ginseng, and wolfberry.
45628352|NCT02428673|Other|Assisted Standing Treatment Program|
45628353|NCT03186131|Drug|Ibandronate|To examine the efficacy of oral Ibandronate in osteoporosis
45768962|NCT00974051|Other|Control|No treatment is given for the study. This arm is for comparison with the two intervention arms.
45768963|NCT04129814|Procedure|Non surgical periodontal therapy|single session full-mouth scaling and root planing
45768964|NCT00974363|Procedure|Blood Sampling|A blood sample will be taken yearly at each long-term follow-up visit (i.e. Year 2 through Year 5) after vaccination during the primary study. No vaccines are administered in the long-term follow-up study
45768965|NCT04129892|Behavioral|"In Favor of My Resilient Self Academic course"|Assessing the effect of an academic course on student's emotional resilience.
45768966|NCT05604248|Other|Intervention|Mother : 2.0 μmol 13C2 -retinyl acetate diluted in soybean oil Children : 1.0 μmol 13C2 -retinyl acetate diluted in soybean oil
45628354|NCT03186131|Drug|Oral Ibandronate and Vitamin D|To examine the efficacy of oral Ibandronate and Vitamin D in osteoporosis
45913147|NCT02018783|Procedure|Colgate|Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure
45913148|NCT02018783|Procedure|Sensodyne|Digital application for 60 seconds.
45913149|NCT02018783|Procedure|Nano P|Slow-speed handpiece with a Robson brush for 10 seconds
45913150|NCT02018783|Procedure|Cocorico|Digital application for 60 seconds
45913151|NCT02018848|Behavioral|Attention Training Program|
45628355|NCT02572401|Behavioral|STAND HIV Risk Reduction Intervention|STAND HIV Risk Reduction Intervention, designed to increase consistent condom use and reduce other sexual risk behaviors, is implemented in small groups over 2 weekly 135-minute sessions. It draws on social cognitive theory, the reasoned action approach, and focus groups, a prospective survey, and an intervention pilot test with African American men. It contains culturally appropriate video clips, interactive activities, brainstorming, role-playing, and discussions designed to affect hypothesized mediators of risk-reducing behavior, including outcome expectancies about the effects of condom use on sexual enjoyment; self-efficacy and skill to have condoms available and to stop to use condoms or refuse unsafe sex even when aroused; and self-efficacy and skill to negotiate condom use.
45628356|NCT02572401|Behavioral|Text Messaging Intervention|Text Messaging Intervention participants receive text messages designed to increase the consistent use of condoms and to reduce other sexual risk behaviors. They receive 3 times a week text messages that ask about their sexual behavior and condom use that day and are asked to respond with either a 1 or 2 numeric response to indicate yes or no. Based on their responses, they receive either an affirming, pro safe-sex text message or a cautionary text against unprotected sex.
45628357|NCT03186287|Other|Eccentric training|Eccentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
45628358|NCT03186287|Other|Concentric training|Concentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
45628359|NCT03186287|Other|Standard physiotherapy|The participants will receive standard physiotherapy. The standard physiotherapy exercises will be supervised by the physiotherapist, same as intervention exercises.
45628360|NCT03185975|Behavioral|at-home test kit|Transgender youth in the control arm will receive test kits, but will not receive any testing intervention. Once individual results are reported, participants will be contacted via phone or email by study staff with options for referrals to services. Participants will complete follow-up surveys at 3, 6, 9, and 12 months post-testing.
45628361|NCT03185975|Behavioral|Motivational Interviewing and Certified Testing and Referral|Transgender individuals randomized to the experimental group (MI/CTR) will receive HIV counseling and testing via an online, HIPPA-compliant videoconferencing service. The session will last less than one hour and focus on HIV testing, prevention strategies, and/or linkage to HIV care, depending on the individual's test results. Participants will complete follow up surveys at 3, 6, 9 and 12 months.
45628362|NCT03184649|Drug|Ibuprofen|It is a pre-analgesic will be taken before painful procedures.
45628363|NCT03184649|Drug|paracetamol|it is a pre-analgesic drug will be taken before painful procedure.
45628364|NCT03184649|Dietary Supplement|A fruit-flavored orange color placebo solution|orange juice as a comparative group.
45628365|NCT05517915|Other|Inspiratory muscle training.|Interval inspiratory muscle training was performed using the inspiratory muscle trainer.
45628366|NCT05517915|Other|Sham inspiratory muscle training.|Interval inspiratory muscle training was performed using the unloaded inspiratory muscle trainer.
45628367|NCT05105841|Drug|Venetoclax|Oral Tablet
45628368|NCT05105841|Drug|Ibrutinib|Oral Capsule
45628369|NCT05105841|Drug|Obinutuzumab|Intravenous (IV) Infusion
45628370|NCT02432261|Drug|Nestorone® /testosterone gel|Nestorone® /testosterone combined gel
45768967|NCT03017963|Drug|Sodium Thiosulfate Pentahydrate|Sodium Thiosulfate Pentahydrate is administered intravenously in 250 centiliters infusion fluid in two doses: first dose with an infusion rate of 16.66 milliliter (ml) per minute (min), second dose with 8.33 ml / min
45447385|NCT02111278|Other|Physical Therapy|Patients will receive 4 weeks of physical therapy with 2 visits per week. The treating physical therapist is blinded to group allocation. The treating physical therapist will prescribe exercises based on patient presentation. Therapy visits last approximately 45-60 minutes depending of patient ability to perform exercises. The treating physical therapist will perform no mobilizations or manipulations on the patient.
45447386|NCT02108782|Drug|dovitinib lactate|Given PO
45447387|NCT02108782|Other|pharmacological study|Correlative studies
45628371|NCT02432261|Drug|Testosterone only gel|Testosterone only gel
45628372|NCT03184415|Drug|DWC20155|tablet
45628373|NCT03184415|Drug|DWC20156|tablet
45628374|NCT03184415|Drug|placebo of DWC20155|tablet
45628375|NCT03184415|Drug|placebo of DWC20156|tablet
45628376|NCT05522595|Device|S360|"In the first part of the intervention, after the CISS questionnaire completion by the patient, participant's eyes movements measurement will be performed using the reference procedure (standard of care).~A first diagnosis is established according to the interpretation of the results by a first evaluator.~In the second part of the intervention, the participant's eyes movements will be measured using the medical device S360.~A second diagnosis is established according to the interpretation of the software's displayed data by a second evaluator."
45628377|NCT02431949|Other|Admission to BCPP|There is no intervention associated with this study.
45768968|NCT04121390|Behavioral|Newborn Parenting Class|Newborn Parenting Class designed by Mount Sinai Parenting Center. The class is 1-hour long and taught be pediatric attending and residents to all families who deliver well babies at Mount Sinai.
45447388|NCT02108782|Other|laboratory biomarker analysis|Correlative studies
45447389|NCT03231800|Drug|dasotraline|dasotraline 2mg capsule once daily
45447390|NCT03231800|Drug|Placebo|Placebo capsule once daily
45447391|NCT02111356|Device|Phinhole glasses|Wearing the pinhole glasses (Trayner Pinhole Glasses, Trayner Glasses, U.K.)
45628378|NCT05525871|Dietary Supplement|Nitrates and Citrulline Malate|"Female soccer players should consume the experimental product for 30 days to evaluate the efficacy of a sports supplement high in nitrates combined with citrulline malate in the improvement of performance in high-intensity intermittent exercise.~high intensity"
45628379|NCT05525871|Dietary Supplement|Control product|Fruit puree
45628380|NCT02428283|Drug|Ropivacaine|0.25% ropivacaine 2-3 ml was injected around the scalp nerves that are located on the head.
45768969|NCT03018353|Drug|Patients receiving Sof/Vel (Epclusa) and Navigation services|Implementing HCV treatment in the jails using FDA-approved medications and continuing there treatment in the community if they are released during their treatment regimen.
45768970|NCT04120844|Behavioral|Motivational interviewing (MI)-based patient empowerment program (PEP)|Motivational interviewing (MI) is a collaborative, patient-centered counseling approach that aims to elicit behavior change. Counselors use empathy and other techniques to create an atmosphere to help patients to explore the discrepancies between the goals and their current behavior. The focus of MI is to find and resolve the ambivalence, improve patients' perception of the importance of behavior change, and support them to make the change. MI provides a structural framework with guiding principles that can be easily followed by the primary care doctors. Program content was further informed by the Hospital Authority Patient Empowerment Program in Hong Kong. The education program consisted of four modules, held once a week, that each lasted approximately 1½ to 2 hours. They were grouped under the following four broad headings: Knowing Diabetes, Diabetes Self-Care, Healthy Diet and Physical Exercise.
45913152|NCT02018874|Drug|LY2780301|"LY2780301 will be given orally Q.D. at different dose levels. Because of a favourable safety profile, the different dose levels will be as follow :~Dose level -1: 300 mg Q.D.~Dose level -0.5: 400 mg Q.D.~Dose level 1: 400 mg Q.D.~Dose level 1.5: 500 mg Q.D.~Dose level 2 : 500 mg Q.D."
45913153|NCT02018874|Drug|Gemcitabine|The dose level of Gemcitabine will be fixed (1000 mg/m2). Gemcitabine will be administered over a 30 minutes infusion.
45628381|NCT02428283|Drug|Remifentanil|Remifentanil 1 μg/kg was injected before skin incision.
45628382|NCT02428283|Drug|Sevoflurane|Anesthesia was titrated with sevoflurane, maintaining mean arterial pressure and heart rate within 20% baseline value.
45447392|NCT03553654|Diagnostic Test|low dose CT|CT-based protocol for detection of anthracycline-induced myocardial dysfunction at early stages
45913154|NCT02018900|Dietary Supplement|Ecologic 825/scFOS|
45628383|NCT02428127|Dietary Supplement|Carbohydrate beverage powder|Carbohydrate beverage powder fortified with multiple micronutrients. 20g of study product will be administered orally twice a day
45628384|NCT02428127|Dietary Supplement|Calorie matched beverage powder|Calorie matched beverage powder with 80% protein.20g of study product will be administered orally twice a day
45628385|NCT02428127|Other|Water|lukewarm water
45628386|NCT03185585|Other|Mini Nutrition Assessment (MNA® )|MNA® is a validated nutrition screening and assessment tool that can identify geriatric patients age 65 and above who are malnourished or at risk of malnutrition.
45628387|NCT03185585|Other|Comprehensive Older Adult Screening Tool (COAST)|Develop a comprehensive older adults screening tool for community dwelling older adults who attend congregate meal sites to assist in the evaluation of undernourishment or those at risk that is simple, faster, and less expensive
45628388|NCT02427893|Drug|Cobimetinib|A potent and highly selective inhibitor of MEK1 and MEK2, central components of the RAS/RAF pathway.
45628389|NCT02427893|Drug|Vemurafenib|A low molecular weight, orally available inhibitor of the activated form of the BRAF serine-threonine kinase enzyme, which is commonly found in melanoma
45628390|NCT03184493|Drug|Celebrex plus Metformin|This group patients will receive metformin and celebrex.
45628391|NCT03184493|Drug|Celebrex|This group patients will receive celebrex.
45913155|NCT02018900|Dietary Supplement|Placebo|
45913156|NCT02018939|Other|Pharmacokinetic profiling|Pharmacokinetic samples are taken from each Patient receiving Doripenem in each arm. No other interventions are performed during this trial. Doripenem is not administered due to the trial.
45447393|NCT01314248|Device|each child will receive both the LMA and ILA|each child will receive both the size 2 LMA and size 1.5 ILA
45447394|NCT02114788|Other|Internet-based|
45628392|NCT03184493|Drug|Metformin|This group patients will receive metformin.
45628393|NCT03184337|Behavioral|CDC's PreventT2 Program|The PreventT2 program will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving nutritional intake and increasing physical activity. It will also include individual biweekly phone calls for 6 months.
45628394|NCT03184337|Behavioral|CDC's PreventT2 Program with Added Sleep Content|The CDC's PreventT2 program with added sleep content will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving sleep quality and nutritional intake and increasing sleep duration and physical activity. It will also include individual biweekly phone calls for 6 months.
45628395|NCT02431481|Drug|LEE011|400 mg
45628396|NCT02431403|Drug|ESHAP-Imatinib|After selection of the maximum-tolerated dose of the combination ESHAP with imatinib a phase 2 of the study will be performed in order to evaluate the ORR of ESHAP-imatinib.
45628397|NCT02431325|Drug|Teduglutide|
45628398|NCT02431325|Drug|Placebo|
45628399|NCT03184103|Diagnostic Test|anti streptolysin o titre and serum complement test|diagnostic lab test
45628400|NCT03184025|Other|dentin adhesive|HEMA-containing and HEMA-free Self-Etch dentin adhesives clinical performance with or without surface sealant
45628401|NCT02103478|Drug|ASTX727 Dose Escalation|Oral investigational product and approved IV decitabine
45628402|NCT02103478|Drug|ASTX727 Dose Confirmation|Randomization cross over design for courses 1 and 2
45628403|NCT02103478|Drug|ASTX727 Fixed-Dose Combination|Fixed-dose investigational product
45628404|NCT02431013|Drug|Simvastatin|Simvastatin 40 mg on Day 1 & Day 8.
45628405|NCT02431013|Drug|Pravastatin|Pravastatin 20 mg on Day 1 & Day 8.
45628406|NCT02431013|Drug|Cilostazol|Cilostazol 100 mg twice a day for 6 days & on Day 8 with statin.
45628407|NCT02427503|Procedure|Asthma with NP and require surgery|To evaluate the effect on asthma of functional endoscopic sinus surgery of bilateral sinonasal polyposis in patients diagnosed with persistent asthma and grade II or III sinonasal polyposis.
45628408|NCT02430857|Other|OMT|Manuel osteopathic treatment of the spine
45628409|NCT02427659|Behavioral|Virtual Reality Distraction|The subjects will receive a 20-minute Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
45447395|NCT04577144|Other|Online survey only|There are no interventions planned for this study. This is an observational study only.
45628410|NCT02427659|Behavioral|Audio (sound of nature)|"The subjects will listen to an audio recording called Sounds of Nature during their wound care."
45628411|NCT02427659|Behavioral|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
45628412|NCT02427425|Device|TENS|
45628413|NCT02102464|Device|LipiFlow treatment|The LipiFlow® Thermal Pulsation System is a prescription device intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
45628414|NCT02427347|Other|Acupuncture|Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into gallbladder-meridian(GB)26 about 25-65mm deep by an angle of 15°, following the path of Dai Meridian (towards medial and downside) . The other acupoints are inserted with needles of 0.25-0.3mm in diameter and 25-40mm in length approximately 10-30mm deep, with an angle of 90°. Electro-acupuncture is applied to both sides of GB26 and stomach-meridian(ST)25: cathode is connected to GB26; anode to ST25. Dense-disperse wave pattern and a wave frequency of 2/100 Hertz is chosen. The intensity of the electro-acupuncture is adjusted on average 4-8 milliampere. The needles are subsequently retained for 20min. The results of the study are based on 8 weeks, each week consisting of 3 sessions.
45628415|NCT02427347|Other|Healthy education|Healthy knowledge lectures and issuing brochures are given. Education of patients for conditioning and changing bad habits, diet, quit smoking, limit alcohol consumption, salt restriction, appropriate increase in physical activity.
45628416|NCT03183947|Procedure|fMRI|collection of functional brain data for 1 hour per day
45628417|NCT03183947|Behavioral|Neurofeedback|Task of the participants is to increase the activity in the selected brain region (left or right prefrontal cortex). After regulation they will get a feedback about the regulation success. (Patients: days 3 & 4; controls: Days 2 & 3)
45628418|NCT03183947|Other|PANAS|to assess the mood before and after the fMRI and after 4 weeks during a telephone interview
45628419|NCT03183947|Other|BDI-II|to assess depressive symptomatology before neurofeedback and 4 weeks after the intervention during telephone interview
45628420|NCT03183947|Other|ERQ|To assess emotion regulation strategies before and after neurofeedback training (patients: day 3&4; controls: day 2&3) and after 4 weeks during a telephone interview
45628421|NCT02430935|Behavioral|Cognitive Adaptation Training|Cognitive Adaptation Training (CAT) is a manual-driven standardized approach that uses environmental supports to improve multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia. Interventions for each functional deficit are based on two dimensions 1) level of impairment in executive functions (determined by neurocognitive tests) and 2) whether the overt behavior of the individual is characterized more by apathy (poverty of speech/movement/inability to initiate and follow through on behavioral sequences), disinhibition (distractibility/behavior which is highly cue-driven) or a combination of these styles (based on the Frontal Lobe Personality Scale (FLOPS).
45628422|NCT02430935|Behavioral|Action Based Cognitive Remediation|ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
45628423|NCT02430779|Procedure|rreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Renal Pelvic and Ureteral Neoplasms guide with ultrasound or/and CT.
45628424|NCT02430779|Device|NanoKnife|
45628425|NCT03185429|Biological|Tumor Specific Antigen-loaded Dendritic Cells|Subjects will be given subcutaneous injection of 5.0x10^6-1.0x10^7 TSA-DC on week 1,3,5,11,17,23,35,47.
45628426|NCT03185429|Drug|Cyclophosphamide|300 mg/m2 by vein before the first cell infusion.
45628427|NCT02427191|Other|AmnioFix® Injectable|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
45628428|NCT02427191|Drug|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
45628429|NCT05114291|Other|Explorations are planned as part of the one-day hospitalization|"Clinical parameters : Interrogation, physical examination, morphological data measurements (weight, height, waist circumference, hip circumference) and impedencemetry (body composition).~Biological samples : Blood and urine exam, fasting urine sample (urinary osmolarity)~Standardized blood pressure measurement :~After 5 to 10 minutes of rest, with automated measurements at 1 minute intervals : un-attended, then attended~Hemodynamic parameters :~Sphygmocor® : measure of the central blood pressure and pulse wave velocity~MESI® tool : measure of the Systolic Pressure Index (PSI or IPS)~pOpmetre® : Calculation of the speed of the pulse wave by the pOpmetre® device~Others : if indicated (echocardiography, ABPM)"
45628430|NCT03185507|Device|CryoHelmet|Cryotherapy was administered using the Catalyst CryoHelmet™ (All-Star Sporting Goods®, Shirley, Massachusetts, USA). The CyroHelmet is a flexible helmet equipped with gel ice packs meant to cool the head and neck.
45447396|NCT03553342|Drug|Corticoids|Patients will receive corticosteroids therapy: 1mg/kg of prednisolone daily for seven days.
45447397|NCT03553342|Other|Placebo|Patients will receive placebo for seven days.
45628431|NCT03117413|Other|Positron emission tomography scan|"Binaural hearing assessments: speech recognition in noise and sound source localization~Voice perception assessment: voice/non-voice discrimination task, free categorization task~Positron emission tomography examinations under ecological auditory stimuli (voice/non-voice discrimination task)"
45628432|NCT03184259|Device|Robotic ankle system|Patients will wear the robotic ankle system and undergo 20-minute over-ground walking and 10-minute stair walking.
45447398|NCT04085601|Drug|APL-2|Complement (C3) Inhibitor
45447399|NCT02111434|Drug|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
45447400|NCT03230864|Drug|Lu AF35700|10 mg/day, encapsulated tablets, orally
45447401|NCT03230864|Drug|Risperidone|4-6 mg/day, encapsulated tablets, orally
45447402|NCT03230864|Drug|Olanzapine|15-20 mg/day, encapsulated tablets, orally
45447403|NCT02111512|Drug|Administration of Live attenuated influenza vaccine (LAIV)|
45447404|NCT03636854|Other|Concentric exercises|Resistance concentric straight leg raise and knee extension will be done.
45447405|NCT03636854|Other|Eccentric exercises|Resistance eccentric straight leg raise and knee extension will be done.
45628433|NCT03184259|Device|Robotic knee system|Patients will wear the robotic knee system and undergo 20-minute over-ground walking and 10-minute stair walking.
45628434|NCT03117491|Procedure|GGNB injections|The patients received two GGNB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
45628435|NCT03117491|Procedure|IANB injections|The patients received two IANB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
45628436|NCT03117491|Procedure|GGNB + IANB injections|The patients received one GGNB injection plus one IANB injection of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
45628437|NCT02430701|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Esophageal Neoplasms guide with ultrasound or/and CT.
45628438|NCT02430701|Device|NanoKnife|
45628439|NCT02430545|Drug|Glasdegib|Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin
45628440|NCT02430545|Drug|Rifampin|Subjects receive rifampin 600 mg oral dose daily [Day -6 to day 4]
45628441|NCT03117725|Drug|Melatonin adminstration|The drug, melatonin will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: Melatonin 2mg once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
45628442|NCT03117725|Drug|placebo administration|the drug, placebo pill will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: placebo pill once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
45628443|NCT03185351|Drug|Bupivacaine|20 ml of 0.5% bupivacaine using supraclavicular BPB.
45628444|NCT03185351|Drug|Midazolam|midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB
45628445|NCT03185351|Drug|Midazolam|0.03 mg/kg of midazolam by I.V. route
45628446|NCT02427035|Biological|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
45628447|NCT02427035|Other|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
45628448|NCT02427113|Other|Sound Oasis Vibrating Chair|Sound oasis vibroacoustic chair will be used as treatment for managing TMD related pain
45628449|NCT02427113|Other|Self-Select Music|The self-select music of the participants will be applied for managing the painful symptoms of TMD
45628450|NCT02707601|Drug|E/C/F/TAF|150/150/200/10 mg fixed dose combination (FDC) tablet administered orally once daily
45913157|NCT02018952|Other|Ultrasonography assessment|"All patients will be seen at day 0, day 4, day 15 and at 3 months. These visits are usually programmed. Only monitoring ultrasonography, a non invasive exam, and self-administered questionnaires will be made, additional to standard exams for all patients included (no control group).~Day 0 :~Information of patient and no opposition getting~Clinical exam~Laboratory tests~Radiography of the targeted joint~Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~Day 4 :~Clinical exam~Laboratory tests~Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~Day15 :~Clinical exam~Laboratory tests~Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~M3 :~Clinical exam~Laboratory tests~Radiography of the targeted joint~Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~Functional outcome"
45913158|NCT02018965|Drug|Niacin|"• Group 1: This group will receive an initial dose of ER niacin 500 mg by mouth, the first evening from week 0 to week 4 then increase it to 1000 mg once a day from week 5 to week 8, then increase to 1500 mg from week 9 to week 12 then increase to 2000 mg until weeks 24 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study."
45447406|NCT02111590|Drug|Immunoglobulins|SCIG dosage is individualized for each patient according to previous IVIG dosage
45447407|NCT04085367|Drug|MAL 16.8% cream|Day light photodynamic therapy with MAL 16.8% cream
45447408|NCT04085367|Drug|MAL Vehicle Cream|Day light photodynamic therapy with MAL vehicle cream
45447409|NCT03228836|Drug|Sintilimab|Sintilimab (IBI308) 200mg IV Q3W
45447410|NCT02109250|Drug|Caprelsa|Caprelsa® 100 mg or 300 mg film-coated oral tablets. Each film-coated tablet contains 100 mg or 300 mg of vandetanib.
45447411|NCT02111824|Device|MIMIG System|Minimally Invasive MultiModality Imaging Guidance System (MIMIG)
45447412|NCT02111824|Drug|Indocyanine Green (ICG)|Use of ICG as staining for fiberoptic visualization of lung tissue via introducer needle prior to obtaining tissue samples.
45628451|NCT02707601|Drug|F/R/TAF|200/25/25 mg FDC tablet administered orally once daily
45628452|NCT02707601|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
45628453|NCT02426957|Behavioral|motivational enhancement therapy|The intervention consists of the following components: establishing rapport, assessing motivation for change, enhancing motivation for change, envisioning the future, establishing goals, and completing goals, strategies, and change plan worksheets.
45628454|NCT02430623|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Urinary Bladder Neoplasms guide with ultrasound or/and CT.
45628455|NCT02430623|Device|NanoKnife|
45628456|NCT02707055|Drug|PF-05190457|Ghrelin Receptor Inverse Agonist
45628457|NCT02707055|Other|Placebo|Placebo
45628458|NCT03183635|Procedure|Balance training|Improvement of balance ability in stroke patients
45628459|NCT03183557|Drug|"Zoledronic acid, Reclast®"|To examine the efficacy of zoledronic acid in osteoporosis
45628460|NCT03183557|Drug|"Zoledronic acid, Reclast® and active vitamin D, alfacalcidol®"|To examine the efficacy of zoledronic acid plus alfacalcidol in osteoporosis
45628461|NCT03183479|Drug|Fibrinogen Concentrate Human|After start of surgery when all pedicle screws are placed, the patients in treatment group will receive fibrinogen concentrate 30mg kg-1. For safety concern, functional fibrinogen will be measured and the maximum fibrinogen concentrate administration for each individual shall not exceed 2g. Fibrinogen concentrate will be diluted in 100mL of sterile water and then be administered to patients.
45628462|NCT03183479|Drug|Normal saline|100mL normal saline will be administered to patients in control group as placebo
45628463|NCT02425397|Genetic|Genetic study|study of mutations of metabolic enzymes and membrane transport genes, which will be performed by sequencing.
45628464|NCT02425397|Genetic|Genetic study MT-RN1|study of mutations of the mitochondrial gene MT-RN1, which will be performed by sequencing.
45768971|NCT04120844|Behavioral|Traditional lecture style health education|The control group received traditional lectures that consisted solely of conveying healthcare information to patients. In order to minimize intervention bias, the control group lectures were standardized and adapted into four modules, namely knowing diabetes, healthy diet, physical exercises, and how to use medication correctly, which were similar topic headings, durations and frequencies to those of the intervention group. Each lecture was 1 hour and was provided by one of four health professionals (a pharmacist, dietician, endocrinologist or nurse) who had never received any prior training in MI. We consciously avoided the inclusion of elements of self-reflection and motivation in these lectures.
45628465|NCT02425475|Device|LIMES|All patients will undergo dermoscopic diagnosis and be documented with a video image storing. The diagnosis based on dermoscopy will be immediately documented. Then, as a second diagnostic procedure, fluorescence diagnostics based on the two photon excitation from a dye-laser will be performed. The classification as non-melanoma or malignant melanoma by the medical device LIMES will also be documented immediately. Afterwards, the lesion will be excised and undergo histo-pathologic examination by the respective histopathologist of the participating centers. The histopathologic diagnosis will serve as gold standard for subsequent evaluations of the diagnostic accuracy.
45628466|NCT05526495|Behavioral|Reducing preoperative low-value test ordering|A multi-component approach will be used:1) An administrative change will be implemented whereby medically necessary preoperative tests for patients undergoing non-urgent surgery will be ordered at the discretion of an anesthesiologist based on their clinical assessment. Adoption of the policy change will be facilitated by a local champion using an engagement and education program for anesthesiologists, surgeons, pre-admission clinic nurses and administrative staff; 2) The workshop program will include rationale for the policy, discussion of perceived local barriers to implementation and mitigation strategies. A train-the-trainer model will be used; 3) The departments will commit to supporting the change in policy. Nurses within preoperative clinic will be coached to feel comfortable calling the anesthesiologist about any pre-op tests ordered, and the Pre-Admission Unit will have the authority to cancel tests that deem unnecessary. Check boxes will be removed from medical order forms
45628467|NCT02426723|Drug|Phase 1a: CWP232291|CWP232291 administered alone twice weekly every 4 weeks.
45628468|NCT02426723|Drug|Phase 1b: CWP232291, Lenalidomide, Dexamethasone|CWP232291 administered twice weekly every 4 weeks. Lenalidomide and Dexamethasone administered per standard therapy.
45628469|NCT03182699|Diagnostic Test|cardiac MRI|non contrast heart MRI at baseline and after 1 year of therapy
45768972|NCT00977171|Drug|Droxidopa|Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes up to a 2 week titration period followed by a 12 week treatment period
45768973|NCT04121000|Procedure|VIDEO ASSISTED THOTACOSOPIC SURGERY|VATS
45913159|NCT02018965|Drug|Niacin|"• Group 2: This group will not receive ER niacin for the first 24 weeks. This group will receive an initial dose of ER niacin 500 mg the first evening at week 25 by mouth from week 25 to week 28 then increase it to 1000 mg once a day from week 29 to week 32, then increase to 1500 mg from week 33 to week 36 then increase to 2000 mg until week 48 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study."
46069907|NCT04251494|Diagnostic Test|Pulse Wave Velocity measurement|The PWV measures the speed of a pulse wave travelling between two points in the vascular systems of known distance between them. PWV will be measured by the gold standard carotid-femoral PWV method which is a direct measurement of aortic stiffness. A 3-Lead ECG is connected alongside measurements of the blood velocity trace for the left CCA 2cm proximal to the bifurcation, and for the left common femoral artery origin.
45628470|NCT03182699|Diagnostic Test|echocardiography with strain|echocardiography at baseline and after 1 year of therapy
45628471|NCT03182699|Diagnostic Test|Laboratory tests|drawing blood from dialysis machine
45628472|NCT03182699|Diagnostic Test|Body composition monitoring|Measurement with BCM (Fresenius) machine
45628473|NCT03182699|Diagnostic Test|lung ultrasound|ultrasound
45628474|NCT02426879|Procedure|esophagectomy with three-field lymphnode dissection|robot assisted thoraco-laparoscopic esophagectomy with three-field lymphnode dissection
45628475|NCT02426801|Device|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
45628476|NCT02426801|Behavioral|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
45628477|NCT02426567|Other|Exclusive Enteral Nutrition (EEN)|One week course of an isocaloric exclusive milk-based diet
45628478|NCT02426567|Other|Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)|One week course of an isocaloric, exclusion food-based diet
45628479|NCT03183011|Other|MRI|Cardiac MRI
45628480|NCT03182777|Procedure|Dental restorative procedure|Infiltration of two cartridges (3.6 mL) of local anesthetics with 2% lidocaine with or without epinephrine 1:100,000, in two sessions with an interval of seven days between them, in oral mucosa in patients with cardiac channelopathies.
45628481|NCT02425085|Procedure|multi-endodiathermy retinectomy|patients will receive multi-endodiathermy retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
45628482|NCT02425085|Procedure|relaxing retinectomy|patients will receive relaxing retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
45628483|NCT00709865|Drug|tonapofylline|IV
45628484|NCT00709865|Drug|Placebo|IV
45628485|NCT02425241|Biological|pSG2.HIVconsv DNA vaccine|pSG2.HIVconsv DNA 4 mg at weeks 0, 4 and 8.
45447413|NCT02937350|Drug|D6-25-hydroxyvitamin D3|Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3
45628486|NCT02425241|Biological|ChAdV63.HIVconsv booster vaccine|ChAdV63.HIVconsv 5 x 10^10 vp at week 12.
45628487|NCT02425241|Biological|MVA.HIVconsv booster vaccine|MVA.HIVconsv 2 x 10^8 pfu at week 20
45628488|NCT02425241|Drug|CPHPC|40 mg CPHPC IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
45768974|NCT04129424|Device|Insulin pump (Microtech, Equil®)|Those patients of different types of diabetes mellitus were assigned to different groups, those groups were classified by the time to reach target blood glucose .
45768975|NCT00955487|Drug|Inhaled Nitric Oxide (iNO)|iNO will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
45628489|NCT02425241|Other|Placebo|Placebo IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
45628490|NCT02425007|Device|Incentive spirometry|
45628491|NCT02426411|Drug|EMA401 200 mg|
45628492|NCT02426411|Drug|EMA401 600 mg|
45628493|NCT02426411|Drug|Placebo|
45628494|NCT02425163|Device|Transrectal shear wave elastography of the prostate|Transrectal shear wave elastography of the prostate with SuperSonic Imagine Ultrasound System AIXPLORER and an endocavity sonic head SE12-3 (SuperSonic Imagine, Aix-en-Provence, France)
45628495|NCT02425163|Procedure|Transrectal random biopsy of the prostate|TRUS-SWE-guided random biopsies of the Prostata with 18G-gun
45628496|NCT02426489|Device|MRI + PEM image|Effect of positron emission mammography on diagnostic accuracy
45628497|NCT03182855|Drug|Ticagrelor|ADP-receptor blocker. Oral formulation. Standard Therapy in Acute Myocardial Infarction. Administered in the ambulance in arm 1 and in the hospital (catheterization laboratory) in arm 2.
45628498|NCT03182855|Drug|Cangrelor Tetrasodium|Intravenous ADP-receptor blocker. Administered after hospital arrival in the catheterization laboratory.
45628499|NCT02426333|Other|Abiraterone Acetate|Exclusively determine pharmacokinetics and pharmacodynamics of abiraterone for the indication according to the drug label (CRPC)
45628500|NCT02424929|Procedure|Sedation|Propofol anesthesia administered during entire surgery.
45628501|NCT02424929|Procedure|Original Surgery|No intervention, surgery will be conducted as usual. With sedation only during the drilling of the burr holes.
45628502|NCT02426177|Drug|Labetalol|anti-hypertensive agents
45628503|NCT02426177|Drug|Nifedipine|calcium channel blocker ,for lowering blood pressure
45628504|NCT02426099|Drug|Low dose spironolactone|4-week add-on low dose spironolactone in resistant hypertension
45628505|NCT02426099|Other|Routine intensification of antihypertensive treatment|4-week guidelines oriented intensification of antihypertensive treatment
45628506|NCT03182621|Behavioral|THINK|The THINK curriculum was based on the principles of exercise physiology and health behaviors. Sessions included educational components, concentrating on physiology, nutrition, laboratory experiences, and structured physical fitness activities.
45628507|NCT03182621|Behavioral|SPARK|traditional YMCA program
45768976|NCT00955487|Drug|Nitrogen (placebo)|Nitrogen will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
45768977|NCT04120922|Other|calcium carbonate|See arm description
45913160|NCT02018978|Behavioral|Comprehensive Triaged HIV Prevention (CTHP)|"HIV Voluntary Counseling and Testing at Community Prevention Center-The center will be open to all community members.~Community Mobilization-HIV/AIDS and VCT information will be disseminated with pamphlets, community discussions, and meetings.~Risk Assessment and Triaged Counseling and Recruitment-Clients identified at high-risk for HIV infection and HIV-infected clients we be offered an additional counseling session. Participation will be incentivized. These clients will also be provided with up to 3 referral cards to give to sexual partners. If partners come for VCT, they will receive a small incentive.~Incentives & Support Activities - Modest and ethically appropriate incentives, including those providing nutritional support (food), health and hygiene benefits (bed nets), transport to access interventions, or income generation potential, will be provided for participation in some project interventions, and these will be graduated based on HIV risk potential."
45913161|NCT02018991|Procedure|Everolimus-Eluting Stent (EES)|Patients treated with EES
45913162|NCT02018991|Procedure|Zotarolimus-Eluting-Stent (ZES)|Patients treated with ZES
45913163|NCT02018991|Procedure|Biolimus-Eluting-Stent (BES)|Patients treated with BES
45913164|NCT02019017|Drug|Botulinum Toxin Type A 25 IU|
45452477|NCT04405102|Other|Standard of care|During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).
45452478|NCT03209492|Drug|Leuprorelin acetate|Leuplin PRO for Injection Kit 22.5 mg
45452479|NCT01097993|Other|1-fermented dairy product|Arm 1 - Intervention 1 (probiotics)
45628508|NCT02426021|Drug|MLN1202|Subcutaneous administration of MLN1202
45628509|NCT02426021|Drug|MLN1202 Placebo|Subcutaneous administration of MLN1202 placebo
45628510|NCT03182543|Dietary Supplement|Mango pulp beverage|"The subject consumes mango pulp beverage (200 g mango pulp + 600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
45628511|NCT03182543|Dietary Supplement|Mango pulp and peel beverage|"The subject consumes mango pulp and peel beverage (160 g mango pulp + 40 g mango peel + 600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
45628512|NCT03182543|Dietary Supplement|Control beverage|"The subject consumes control beverage (600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
45628513|NCT03182465|Diagnostic Test|Value of ProCalcitonin|The predictive value of ProCalcitonin in patients with solid tumors presenting a febrile neutropenia due to chemotherapy at emergency unit will be a factor to detect the level of bacteria.
45628514|NCT02425709|Drug|Diclofenac|Women will receive oral diclofenac 50 mg 1 hour before the procedure
45628515|NCT02425709|Drug|Tramadol|Women will receive oral tramadol 50 mg 1 hour before the procedure
45768978|NCT04120922|Other|sevelamer carbonate|See arm description
45768979|NCT01663740|Drug|Valganciclovir|Participants will receive valganciclovir 900 milligrams (mg) orally once daily for up to a maximum of 200 days post-transplant.
45768980|NCT04758884|Other|Telemedicine|Visits by videoconference in months 0, 1, 2, 3, 4 and 6.
45768981|NCT04129190|Biological|Glucose|Oral Intake of Glucose
45768982|NCT02984228|Biological|PRP|
45768983|NCT02984228|Drug|Hyaluronic Acid|
45768984|NCT02984228|Device|Ultrasound|
45628516|NCT02425709|Drug|Placebo|Women will receive an oral placebo 1 hour before the procedure
45628517|NCT03182153|Device|Extended Cardiac Monitoring|Extended External Cardiac Monitoring
45628518|NCT03183089|Drug|Rohto Dry-Aid®|
45628519|NCT03183089|Drug|Systane® Ultra|
45628520|NCT03183167|Other|No intervention|
45628521|NCT02073682|Drug|Edoxaban|After the 5 day treatment with LMWH, patients receive edoxaban 60 mg once daily (QD) as 2 × 30 mg tablets (or 1 x 30 mg tablet QD for patients requiring dose adjustment) for the remainder of the treatment period.
45628522|NCT02073682|Drug|Dalteparin|Dalteparin was administered via subcutaneous injection at a dose of 200 IU/kg (maximum daily dose 18,000 IU) for 30 days, and at a dose of 150 IU/kg from Day 31 to the end of treatment.
45628523|NCT02073682|Drug|Low molecular weight heparin|Therapeutic doses of subcutaneous LMWH were administered for at least 5 days (to patients in the edoxaban group); this 5-day period may have included the pre-randomization LMWH (if applicable). The choice of parenteral LMWH was up to the treating physician.
45628524|NCT03181919|Drug|Letrozole|Letrozole is a third generation inhibitor that is emerging as a new oral agent for induction of ovulation.
45628525|NCT02072980|Device|Delefilcon A contact lenses|Silicone hydrogel contact lenses
45628526|NCT02706899|Drug|vadastuximab talirine|Intravenous (IV) push every 4 weeks
45628527|NCT02706899|Drug|Azacitidine|75 mg/m^2 given intravenously or subcutaneously for 7 days every 4 weeks
45628528|NCT02706899|Drug|Placebo (for 33A)|Placebo supplied in single-use vials matching 33A, IV push every 4 weeks
45628529|NCT03107039|Behavioral|Exercise|A 12 week resistance exercise curriculum
45628530|NCT03107039|Behavioral|Health Education|A 12 week health education curriculum
45628531|NCT03106883|Behavioral|Affective training|3 sessions of active training using affective faces to modify the negative attention bias in depression
45628532|NCT03106883|Behavioral|Sham training|3 sessions of sham attention training using non-affective stimuli
45628533|NCT03181997|Device|Native aortic valve|Native valve, with any transcatheter heart valve type
45628534|NCT03181997|Procedure|Transcatheter aortic valve implantation (TAVI)|Percutaneous aortic valve implantation preformed in one of these methods: transfemoral, transapical,subclavian or other.
45628535|NCT02425553|Other|Diet|High calorie (1200 kcal), high fat (50% energy), 400 ml juice (230 kcal)
45628536|NCT02425553|Other|Diet|High calorie (1200 kcal), low fat (20% energy), 400 ml juice (230 kcal)
45628537|NCT02425553|Other|Diet|Low calorie (600 kcal), low fat (20% energy), 400 ml juice (230 kcal)
45628538|NCT02425553|Other|Diet|High calorie (1200 kcal), high fat (50% energy), 300 ml wine (40 g alcohol, 230 kcal), 100 ml water
45628539|NCT02424773|Device|High Flow Nasal Canula (HFNC)|
45628540|NCT02424773|Device|Venturi mask|
45628541|NCT02424773|Drug|Oxygen|
45628542|NCT02425631|Device|SImmetry Sacroiliac Joint Fusion System|Minimally invasive surgery for implantation of the SImmetry System
45628543|NCT02421575|Drug|Hydroxychloroquine|Given PO
45628544|NCT02421575|Other|Laboratory Biomarker Analysis|Correlative studies
45628545|NCT02424695|Drug|Gabapentin Enacarbil (GEn)|"HORIZANT Extended-Release Tablets containing 600 mg of gabapentin enacarbil are white to off-white, with occasional black/grey spots, oval-shaped tablets debossed with GS LFG, supplied as:~600 mg: NDC 53451-0101-1.The drug will be stored at 25°C (77°F) (excursions permitted 15° to 30°C (59° to 86°F)) Matching placebo will be provided by Xenoport Inc."
45628546|NCT02424695|Drug|Placebo|
45628547|NCT02422277|Device|LI-ESWT group|"The patients in this arm will be subjected to Penile LI-SWT in the following parameters: 6 to 12 sessions with 1500 shocks per session. Each session will comprise the application of 300 shock waves (energy intensity of 0.09 mJ/mm2) to each of five different sites on the penis: three along the penile shaft and two at the crura with Frequency: 4 HZ. Energy level: 8 mJ/mm2. Rate: 120 shocks per minute.~-Intervals: 2 treatment sessions per week for 3 weeks, then 3-weeks no-treatment interval, then 3-weeks treatment period of 2 treatment sessions per week."
45628548|NCT02422277|Drug|PDE-5 inhibitors group|The patient in this arm will receive 50 mg of phosphodiesterase-5 inhibitors, oral intake once daily for 6 monthes.
45628549|NCT02422121|Drug|RNS60|
45628550|NCT02422121|Drug|Placebo|
45452480|NCT01097993|Other|2- milk-based non-fermented dairy product (control product)|Arm 2 - Intervention 2 (control)
45628551|NCT02424305|Drug|LEO 43204 gel 0.018%|
45628552|NCT02424305|Drug|LEO 43204 gel 0.1%|
45628553|NCT02424305|Drug|LEO 43204 gel 0.037%|
45628554|NCT02421107|Other|Glysure CGM|
45628555|NCT02421107|Other|iStat intermittent testing|
45628556|NCT02424461|Drug|Ceftriaxone|1 injection 1 g per day for 2 days
45628557|NCT02424461|Drug|Ofloxacine|400 mg/jour (200 mg/ jour in case of renal failure) for seven days
45628558|NCT02424461|Drug|Ofloxacine|400 mg/jour (200 mg/ jour in case of renal failure) for 14 days
45628559|NCT02424461|Drug|Placebo of ofloxacine|Placebo of ofloxacine for 7 days
45628560|NCT02072824|Drug|Pregabalin Dose Level 1|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 7.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
45628561|NCT02072824|Drug|Pregabalin Dose Level 2|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 14.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
45628562|NCT02072824|Drug|Placebo|Placebo Liquid dosed three times daily beginning at Randomization through Taper Phase
45628563|NCT04440605|Procedure|Preoperative staging--D2 gastrectomy--Postoperative staging|Preoperative TNM staging under CT scan plus endoscopy endoscopic biopsy, and postoperative staging after D2 gastrectomy
45628564|NCT02421185|Drug|JNJ-42756493 (erdafitinib)|"Part 1: Participants will receive 8 mg tablet once daily from Day 1 to 7, and then Day 15 to 21 of 28 days cycle or 8 mg orally once daily of 28 days cycle up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.~Part 2: Recommended Phase 2 JNJ-42756493 (erdafitinib) dose determined in Part 1."
45628565|NCT03117257|Drug|Lobaplatin|Device: Chrono-chemotherapy Drug: induction Chrono-chemotherapy Drug: Lobaplatin chrono-chemotherapy Radiation: intensity-modulated radiation therapy
45913165|NCT02019017|Drug|Botulinum Toxin Type A 50 IU|
45628566|NCT03117257|Drug|Cisplatin|Device: Chrono-chemotherapy Drug: induction Chrono-chemotherapy Drug: cisplatin chrono-chemotherapy Radiation: intensity-modulated radiation therapy
45628567|NCT02072668|Drug|rivaroxaban|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
45628568|NCT02072668|Drug|placebo|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
45628569|NCT03179267|Device|SNAP40|SNAP40 ambulatory monitoring device
45628570|NCT04750876|Other|Conventional support|"Patients in the Conventional support randomisation arm will follow the usual care of amputee patients in the vascular surgery department. They will be cared for by the surgeon, nurses and nursing auxiliaries, who will provide individualised care (nursing care, mobilisation, pain management, technical care, etc.), listening and support."
45628571|NCT04750876|Other|Specific care, including the intervention of a psychologist and a physical therapist.|"In the case where the patient is in the Specific care, including the intervention of a psychologist and a physical therapist. arm, the usual care will be associated with :~consultations with a psychologist~The patient will also be cared for on a daily basis by a physical therapist."
45628572|NCT03181841|Drug|PF-06412562|double-blind oral intake of single doses of the aforementioned drug or placebo
45628573|NCT03181841|Drug|Placebo|double-blind oral intake of single doses of the aforementioned drug or placebo
45628574|NCT03116789|Dietary Supplement|probiotics|Two capsules for daily
45628575|NCT03181685|Drug|Progesterone 25 MG subcutaneous|A single subcutaneous administration per day from the day of oocyte retrieval
45628576|NCT03181685|Drug|Micronized progesterone 200 MG|3 vaginal administrations per day from the day of oocyte retrieval
45628577|NCT03181685|Drug|recombinant FSH|Controlled ovarian stimulation (COS)
45628578|NCT03181685|Drug|Cetrorelix Acetate|Inhibition of Luteinizing Hormone (LH) premature surge during COS
45628579|NCT03116711|Other|Positive CIQ plus High Carbohydrate Diet|Positive Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet
45628580|NCT03116711|Other|Positive CIQ plus High Protein Diet|Positive Carbohydrate Intolerance Questionnaire plus High Protein Diet
45628581|NCT03116711|Other|Negative CIQ plus High Carbohydrate Diet|Negative Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet
45628582|NCT03116711|Other|Negative CIQ plus High Protein Diet|Negative Carbohydrate Intolerance Questionnaire plus High Protein Diet
45628583|NCT03181373|Other|Cognitive rehabilitation program|Rehabilitation
45628584|NCT02140762|Biological|MenABCWY|Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.
45628585|NCT02140762|Other|Placebo|0.5 mL saline solution (IM)
45628586|NCT02140762|Biological|MenACWY|Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.
45628587|NCT03106961|Device|Bioresorbable vascular scaffolds, OCT, non-compliant ballooning|Measure the effect of high-pressure, NC ballooning on scaffold embedding by OCT
45628588|NCT03106727|Behavioral|Household model|The proposed intervention is a 'Household Model' where, instead of being assigned to HIV or TB patients, CHWs will rather be assigned to households and will be trained to provide support for a wider range of conditions including HIV, hypertension, diabetes and pediatric malnutrition. The new model is designed to improve retention in care for clients with chronic, non-communicable diseases, along with increased uptake of women's health services and treatment for pediatric malnutrition, while sustaining the high retention rates for clients in the HIV program.
45628589|NCT02424071|Drug|Melatonin|
45628590|NCT02424071|Drug|placebo|
45628591|NCT02101294|Device|Interossei Lumbricals Neuro Interface|Finger Relief's keyboard home row layout [actual home row placement order: asdeihotlrn], plus substitutions on the upper row [qwfgjyuk;p] and bottom row [zxcvb'm,.] moves or shifts finger and thumb movement from the elbow muscles to the finger muscles. The movement of finger bending toward the palm is shifted to the interosseous and lumbrical muscles of the hand and fingers from the full flexion and extension muscle control to reduce contraction and expansion of tendons and the movement in the carpal canal adjacent to the median nerve and reduces pressure on the median nerve. Pressure on the median nerve compromises the nerve leading to symptoms of the carpal tunnel syndrome of pain, tingling, and numbness.
45628592|NCT02101294|Device|Standard QWERTY keyboard|Report of onset and severity symptoms of carpal tunnel syndrome when typing with QWERTY keyboard and the Finger Relief device.
45628593|NCT03179111|Procedure|Pneumoperitoneum Pressure|There will be two arms in this study. The participants recruited for this study are those who have been screened and planned for elective bariatric surgery.The pneumoperitoneum pressure will be adjusted to either 8-10mmHg or 12-15mmHg until a clear operating field is obtained by the surgeon. Low pneumoperitoneum pressure has been expected to give a clearer and better surgical view than standard pneumoperitoneum pressure. Participants under the low pressure group are expected to have lesser pain score on abdominal pain and shoulder tip pain as compared to participants in the standard pressure group.
45628594|NCT03178955|Drug|Etanercept|Circadian activity rhythm parameters will be evaluated for 7 days prior to Enbrel treatment through 7 days after initiation of Enbrel treatment and again 28-35 days after the second Enbrel treatment.
45628595|NCT01598506|Drug|Hydromorphone|Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
45628596|NCT02423915|Drug|Rituximab|375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.
45628597|NCT02423915|Drug|Fludarabine|40 mg/m2 by vein on Days -8 to -5.
45628598|NCT02423915|Drug|Cyclophosphamide|50 mg/kg by vein on Day -8.
45628599|NCT02423915|Radiation|Total Body Radiation|2 Gy delivered on Day -4.
45768985|NCT03828266|Other|No intervention|Patients will undergo routine clinical practice. There is no additional intervention.
45628600|NCT02423915|Procedure|Fucosylated Regulatory T Cells|"Phase I: Participants treated at cell dose level 1: 1 x 10^6/kg Fucosylated T-reg cells on Day -1.~Phase II: Participants treated at cell dose level 2: 1 x 10^7/kg Fucosylated T-reg cells on Day -1."
45628601|NCT02423915|Procedure|Cord Blood Infusions|Cord blood transplant, MRD, or MUD infused on Day 0.
45447414|NCT02167022|Other|Physical and occupational therapy|The type of physiotherapy to be administered is Perception-Action (P-A). The P-A (motor) intervention is a child-driven approach without the need for special equipment and considers the child and environment as a single unit.Treatment is a coupling of the child with the environment. The environment is changed to enable, enhance or stimulate movement. The action is initiated by the child with the therapist augmenting the child's environment using touch (tactile information) or light support (cushions, bolsters, and gentle touch or pressure) to assist and/or alter the child's active movement. Toys are used and positioned in different places to encourage movement of upper and lower extremities and the trunk; reaching, turning, sitting balance, crawling, walking.
45768986|NCT05501184|Other|Synchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for nonspecific neck pain patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
45628602|NCT02423915|Drug|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.
45628603|NCT02423915|Drug|Sirolimus|12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.
45628604|NCT02423915|Procedure|Bone Marrow Aspiration|Bone marrow aspiration performed at 1, 3, 6, and 12 months after transplant to check status of disease.
45628605|NCT02423915|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on D+0, and continuing until absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
45628606|NCT02423915|Procedure|Non-Fucosylated Regulatory T Cells|"Phase I: Participants treated at cell dose level 1: 1 x 10^7/kg Non-Fucosylated T-reg cells on Day -1.~Phase II: Participants treated at cell dose level 2: 1 x 10^7/kg Non-Fucosylated T-reg cells on Day -1."
45628607|NCT02423837|Drug|Rituximab, bendamustine|
45628608|NCT03178877|Other|No intervention|
45628609|NCT02140060|Drug|Dose Level A / Brinzolamide 1% ophthalmic suspension|Fixed combination
45768987|NCT05501184|Other|Asynchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for nonspecific neck pain patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
45768988|NCT00979121|Drug|Rosuvastatin|Subjects received an initial 40mg loading dose followed by 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.
45768989|NCT00979121|Drug|Placebo|Subjects received placebo by mouth or feeding tube daily for 28 days or until discharged from study hospital.
45628610|NCT02140060|Drug|Dose Level B / Brinzolamide 1% ophthalmic suspension|Fixed combination
45628611|NCT02140060|Drug|Dose Level C / Brinzolamide 1% ophthalmic suspension|Fixed combination
45628612|NCT02140060|Drug|Brinzolamide 1% ophthalmic suspension AZOPT®|
45628613|NCT02140060|Drug|Travoprost 0.004% ophthalmic solution TRAVATAN Z®|
45628614|NCT02140060|Drug|Travoprost solution vehicle|Inactive ingredients used for masking purposes
45628615|NCT02140060|Drug|Brinzolamide suspension vehicle|Inactive ingredients used for masking purposes
45628616|NCT03181295|Behavioral|Personalized exercise Rx and resources|Patients will receive the IPAQ to collect baseline PA levels as well as questions evaluating precursors to behaviour change and identifying medical conditions that may affect PA capability. In the Electronic Medical Record chart, a 'stamp' will be automatically created, accompanied by a link which will open a printable 'toolkit' with individualized PA recommendations, a personalized exercise Rx, as well as educational and community resources, all based on the patient's survey responses. The exercise Rx and resources can be edited by the PCP based on the resulting discussion between patient and PCP, and printed during the PHR for the patient to take home. The exercise Rx and resources will also be emailed to the patient following their appointment.
45628617|NCT03178721|Diagnostic Test|blood sample|study B regulatory in blood and its correlation with atherosclerosis
45628618|NCT02421029|Drug|edetate calcium disodium|All subjects will receive a 250 mL 5% dextrose intravenous infusion over 1 hour that contains 1 gr of edetate calcium disodium
45628619|NCT03181217|Other|water 0|300 ml tap water at 0 ºC
45628620|NCT03181217|Other|water 22|300 ml tap water at 22 ºC
45628621|NCT03181217|Other|Glucose 0|300 ml tap water at 0 ºC with 75 grams of glucose added
45768990|NCT03828032|Procedure|Mannitol injection|Standard mannitol injection to decrease intracranial pressure of patients
45628622|NCT03181217|Other|Glucose 22|300 ml tap water at 22 ºC with 75 grams of glucose added
45628623|NCT02139982|Procedure|specific nerve block|specific nerve blocks of the musculocutaneous, radial, ulnar, or median nerves at axillary region
45628624|NCT02139982|Drug|ropivacaine|Different concentration of ropivacaine
45628625|NCT03181139|Other|ERAS pathway for Total Mastectomy|Enhanced Recovery after Surgery (ERAS) pathway for Total Mastectomy
45628626|NCT03178643|Drug|Proguanil Oral Tablet|Dosing of daily proguanil will be approximately 3mg/kg/day,
45628627|NCT03178643|Drug|Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ)|Age 1-5 on Day 1: One tablet 500/25mg SP and one tablet 153mg AQ Day 2 and Day 3: one tablet 153 mg AQ only each day For ages 6-10: Day 1 - 1.5 tablets 500/25mg SP and 1.5 tablets 153mg AQ Days 2 and 3: 1.5 tablets 153mg AQ only each day
45447415|NCT02109328|Drug|Alisertib|"SINGLE-ARM, SINGLE-DRUG PHASE: Alisertib will be given PO in a dosage of 50 mg BID for 7 Days (Days 1-7) of each 21 day treatment cycle.~In the randomized phase, Experimental arm will consist of the following drugs:~Alisertib will be given PO in a dosage of 40 mg twice daily on days 1-3, 8-10 and 15-17 of a 28 day cycle.~Paclitaxel: 60 mg/m2 over 60 minutes on Days 1, 8, and 15 in a 28-day cycle."
45628628|NCT03178643|Drug|Dihydroartemisinin-Piperaquine (DP)|"3) The weight-based dosing of tablets of 40/320mg of DP is described below:~Weight (kg) No. of 40/320mg tabs DP daily for 3 days~≤ 5 ¼ 6-10 ½ 11-14 ¾ 15-19 1 20-23 1 ¼ 24-25 1 ½"
45628629|NCT03181061|Other|Semi-structured interviews|Providers will participate in a semi-structured interview using an interview guide that addresses 4 domains of interest including: (1) initiation of abortion services, (2) barriers to abortion provision, (3) facilitators of abortion provision and (4) acquired expertise and coaching for success.
45628630|NCT03180983|Behavioral|multimodal intervention|Investigators will propose an online training. In addition, investigators will make phone calls to nursing home interlocutor between two nursing home visits. The tools of this intervention will consist on posters , quiz about bacteriuria and urinary tract infection (UTI) and algorithm to help nurse's reasoning when UTI is suspected.
45447416|NCT02109328|Drug|Paclitaxel|Placebo will be given PO. Paclitaxel will be infused at the dose of 80 mg/m2 IV over a period of 60 minutes on Days 1, 8, and 15 in a 28-day cycle.
45628631|NCT02139826|Drug|IX-01|
45628632|NCT02420561|Behavioral|Motivational Interviewing|"One in-person motivational interviewing session intervention that lasts for 45-minutes~Additional two 15-minute telephone booster sessions post in-person 45 minute sessions"
45628633|NCT02420561|Behavioral|Control (brochure)|Participants received a brochure on alcohol and drug use risks.
45628634|NCT02420483|Other|Cardiopulmonary resuscitation chest compressions|
45628635|NCT02139592|Drug|Brentuximab vedotin (recombinant)|Brentuximab vedotin (recombinant) for IV infusion
45628636|NCT02139280|Drug|Cyclophosphamide|Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.
45628637|NCT02072434|Drug|Edoxaban|Edoxaban 30 mg tablets for oral administration
45628638|NCT02072434|Drug|Warfarin|Warfarin tablet, 1.0 or 2.5 mg, for oral administration
45628639|NCT02072434|Drug|Enoxaparin|Enoxaparin per label, at prescribed dose until PT INR at least 2.0
45628640|NCT04725994|Drug|IDX-1197+XELOX|The dose levels will be escalated following a 3+3 dose escalation scheme.
45628641|NCT04725994|Drug|IDX-1197+Irinotecan|The dose levels will be escalated following a 3+3 dose escalation scheme.
45628642|NCT04725916|Other|Showering|Patients will be instructed to shower after surgery with drains in place
45628643|NCT04725916|Other|Restriction of Showering|Patients will be restricted from showering post operatively if they have drains in place
45628644|NCT02101060|Other|exercise|16-week progressive aerobic and resistance exercise training
45628645|NCT02139124|Drug|Placebo|Oral placebo capsule
45628646|NCT02139124|Drug|PRC-063 25 mg|Oral 25 mg capsule - active
45628647|NCT02139124|Drug|PRC-063 45 mg|Oral 45 mg capsule - active
45628648|NCT02139124|Drug|PRC-063 70 mg|Oral 70 mg capsule - active
45628649|NCT02139124|Drug|PRC-063 100 mg|Oral 100 mg capsule - active
45628650|NCT02139046|Drug|Febuxostat IR|Febuxostat IR over-encapsulated tablets
45628651|NCT02139046|Drug|Febuxostat XR|Febuxostat XR over-encapsulated capsules
45628652|NCT02139046|Drug|Febuxostat placebo|Febuxostat placebo-matching capsules
45628653|NCT02139046|Drug|Colchicine|Colchicine tablets
45628654|NCT02139046|Drug|Naproxen|Naproxen tablets
45628655|NCT02139046|Drug|Lansoprazole|Lansoprazole capsules
45628656|NCT04734262|Drug|Sitravatinib|Sitravatinib QD PO Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
45628657|NCT04734262|Drug|Tislelizumab|Tislelizumab Q3W IV Tislelizumab is a programmed death receptor-1 (PD-1) blocking antibody
45628658|NCT04734262|Drug|Nab-paclitaxel|Nab-paclitaxel D1, D8 Q3W IV Nab-paclitaxel is a chemotherapy drug which combines the chemotherapy drug paclitaxel with albumin
45628659|NCT02138890|Device|APS|Intra-articular Injection
45628660|NCT02138890|Device|Saline|Intra-articular injection
45628661|NCT04725526|Device|Mobile phone compatible with iOS or Android|MHealth (mobile health) intervention is an act whose purpose is to improve, maintain, promote or modify health, functioning or health conditions.
45628662|NCT02100670|Drug|1% diclofenac sodium plus 3% menthol|To be applied four times daily for 10 days.
45628663|NCT02100670|Drug|1% diclofenac sodium plus 0.09% menthol|To be applied four times daily for 10 days.
45628664|NCT02100670|Drug|3% menthol|To be applied four times daily for 10 days.
45628665|NCT02100670|Drug|Placebo with 0.09% menthol gel|To be applied four times daily for 10 days.
45628666|NCT02070484|Biological|NuCel|
45628667|NCT02070484|Biological|Demineralized Bone Matrix|
45628668|NCT02100514|Drug|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection for 52 weeks.
45628669|NCT02100514|Other|Placebo|Subcutaneous injection every 2 weeks for 52 weeks.
45628670|NCT02069392|Behavioral|Cognitive remediation training|
45628671|NCT02069392|Drug|Nicotine polacrilex lozenge|Of interest are the effects of nicotine on cognitive remediation training benefits.
45768991|NCT03828032|Procedure|Hypertonic saline injection|Standard Hypertonic saline injection to decrease intracranial pressure of patients
45768992|NCT04861896|Behavioral|"My Guide (psychoeducation & self-management program)"|12-week long health promotion Smartphone application to support patient's side effects self-management and adherence to endocrine therapy.
45768993|NCT03827876|Drug|Enstilar 0.005%-0.064% Topical Foam|Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
45768994|NCT02960282|Procedure|Biospecimen Collection|Undergo collection of fecal specimens
45768995|NCT02960282|Other|Laboratory Biomarker Analysis|Correlative studies
45768996|NCT01960127|Behavioral|Aerobic Exercise|Aerobic exercise
45768997|NCT01960127|Behavioral|No Intervention|No Intervention
45447417|NCT02109328|Drug|Placebo|Placebo oral tablets
45768998|NCT03898934|Drug|Vitamin D|receive 6000iu daily for 8 weeks
45768999|NCT03898934|Drug|Placebo Oral Tablet|placebo for the same period
45447418|NCT02134574|Biological|hematologic malignancy|hematologic malignancy with a sampling of blood
45769000|NCT00979199|Other|Non invasive cardiac imaging|Non invasive cardiac imaging consists of CTCA combined with one Stress Imaging Test
45447419|NCT02115178|Other|Lithotomy or Prone position|The surgery, haemodynamic measurements will be performed in Lithotomy or Prone position
45447420|NCT02115334|Behavioral|professional therapists delivering the PHPA|PHPA are delivered by professional therapists, which including gross motor, fine motor, cognition verbal, social interactions, activity of daily living(ADL).
45447421|NCT02115334|Behavioral|parents executing the PHPA|PHPA are executed by parents, which including gross motor, fine motor, cognition verbal, social interactions, ADL.
45447422|NCT02115334|Behavioral|health education|health education of the children with DD.
45447423|NCT04085289|Drug|Galcanezumab|Administered SC
45447424|NCT04085289|Drug|Placebo|Administered SC
45628672|NCT02047318|Drug|LUM001 (Maralixibat)|Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 560 micrograms per kilogram (mcg/kg).
45628673|NCT05517759|Other|Educational program|The sessions were delivered in form of face to face, group disscussion, brainstorming and smart cards. The educational package covered all aspect of knowledge regarding VAP such as definitions, risk factors m cause, manifestation, diagnostic criteria, and nursing care to prevent VAP. A PowerPoint and information pamphlet were used to display the material.
45628674|NCT05517681|Other|non-ICG|Laparoscopic radical resection of rectal cancer was performed routinely without ICG injection. The separation should extend from the center to the left, reaching the left paracolic sulcus lateral to the genital vessels. The Superior hypogastric nerve is protected by freeing it at the angle of the common iliac artery on both sides, afterwards, the vessel is free along the surface of the plexus from caudal to cephalic side to reach the root of the IMA. Switching lymph node visualization patterns. Based on the operator's experience and the extent of lymph node visualization, the lymph nodes at the root of the IMA were removed with an ultrasonic knife . The dissection continues caudally along the IMA, preserving the arterial sheath. Expose the left colonic artery, superior rectal artery, and sigmoid artery, maximum preservation of the IMA peripheral plexus while clearing their surrounding lymph nodes.
45628675|NCT05517681|Drug|ICG|Dilute ICG to 2.5 mg/ml with its accompanying sterilized water for injection. Slow injection with a 1ml syringe in 4 parts of the tumor，Inject 0.25ml per site . Procedure started after lymph node visualization.The operation was consistent with the control group.
45628676|NCT05525793|Other|Transitional care model|The patients who were assigned to this group with the transitional care model, 6 weeks of counseling and intervention training provided continuity of care and a safe transition, and patients were encouraged about symptom management and a healthy lifestyle.
45769001|NCT04128800|Drug|Apatinib S-1|apatinib 250 mg PO qd; S-1 40 mg PO in the morning and 60 mg PO in the evening; 14 days in combination, 21 days in a cycle.
45769002|NCT04129112|Drug|We do not modify the normale general anesthesia delivery. We note the concentration of propofol at the effector site of body movementsand awakening|Propofol in our hospital is routinely delivered by Targeted Controlled Infusion (TCI) pumps. We note the concentration of propofol at the effector site of body movements and awakening
45769003|NCT01608893|Drug|Carvedilol|6.25 po bid titrated to 25 mg bid as tolerated over a 1 month period
45769004|NCT01608893|Drug|Metoprolol|titrated to 50 mg po bid as tolerated over a 1 month period
45769005|NCT04128878|Drug|Sotalol|The primary goal of the study will be to evaluate the change in endothelial function seen after initiating anti-arrhythmic medical therapy. Testing will be performed at baseline prior to the 1st dose of anti-arrhythmic therapy and again 1-3 months later at outpatient follow-up visit. We will record the resting flow (RF), biological zero (BZ) and peak flow (PF) as perfusion units (PU). Specifically, we will assess arterial stiffness and vasodilation in response to acetylcholine iontophoresis, nitroprusside iontophoresis, local thermal hyperemia and reactive hyperemia. Laser speckle contrast imaging will be employed to evaluate the microvasculature. SphygmoCor (arterial tonometry) will be used to assess macrovasculature.
45769006|NCT04128878|Drug|Dofetilide|Same as described above with sotalol.
45769007|NCT00979745|Drug|Afamelanotide|One 16mg subcutaneous implant every 2 months for 9 months.
45769008|NCT00979745|Drug|Placebo|One 16mg subcutaneous implant every 2 months for 9 months.
45769009|NCT04120532|Behavioral|Perioperative Rehabilitation|Physical therapist will be consulted one day before and after the operation (OP) day. On the day before the OP day, they focus on education, including how to get up from bed and stand up from a chair. Five rehabilitation exercises are also demonstrated: 1) ankle flexion and extension, 2) knee flexion and extension, 3) hip joint abduction and adduction, 4) hip joint flexion and extension, and 5) drawing-in maneuver. The participants will be required to repeat each component to confirm that they can do it correctly. Each exercise is suggested to be done 10 times per day following MI-TLIF, and the number will be recorded 3 days (pre-OP day, post-OP day, and post-OP day 2).
45628677|NCT05522361|Drug|Risdiplam|administered to participants per product label insert
45628678|NCT05525715|Drug|2mg QY201 tablets or 2mg QY201 placebo,BID|2mg QY201 tablets or 2mg QY201 placebo,BID
45628679|NCT05525715|Drug|5mg QY201 tablets or 5mg QY201 placebo,BID|5mg QY201 tablets or 5mg QY201 placebo,BID
45769010|NCT00042341|Drug|clofarabine (IV formulation)|
45769011|NCT03828110|Device|Robotic Assisted Gait Training (Lokomat)|The RAGT treatment consisted of sessions lasting 45 minutes each performed with the commercially available Lokomat device. The same exercises were offered to the children with preset duration, speed, and difficulty. For all patients, the initial body-weight support was set at 50%, and was then gradually decreased according to the individual functional capacity. The guidance force was initially set to 100% for all children, and then gradually reduced.
45628680|NCT05525715|Drug|10mg QY201 tablets or 10mg QY201 placebo,QD|10mg QY201 tablets or 10mg QY201 placebo,QD
45628681|NCT05525715|Drug|10mg QY201 tablets or 10mg QY201 placebo,BID|10mg QY201 tablets or 10mg QY201 placebo,BID
45628682|NCT05525715|Drug|15mg QY201 tablets or 15mg QY201 placebo,BID|15mg QY201 tablets or 15mg QY201 placebo,BID
45628683|NCT05525715|Drug|20mg QY201 tablets or 20mg QY201 placebo,BID|20mg QY201 tablets or 20mg QY201 placebo,BID
45628684|NCT05525715|Drug|5mg QY201 tablets，BID|5mg QY201 tablets，BID
45628685|NCT05525715|Drug|10mg QY201 tablets，BID|10mg QY201 tablets，BID
45628686|NCT05525715|Drug|20mg QY201 tablets，BID|20mg QY201 tablets，BID
45769012|NCT03828110|Procedure|Physiotherapy|The physiotherapic sessions aimed at strengthening the gluteus and quadriceps muscles, stretching the hip flexor and hamstrings muscles, increasing static balance, increasing dynamic balance, increasing functional abilities, improving ground gait and climbing stairs.
45628687|NCT05525715|Drug|QY201 placebo，BID|QY201placebo，BID
45628688|NCT02100124|Behavioral|Reproductive Life Planning (RLP)|
45628689|NCT02100124|Behavioral|Contraceptive Action Planning|
45628690|NCT02100124|Behavioral|Contraception information|
45628691|NCT05522283|Diagnostic Test|Stool and blood CMV PCR|Quantitative stool CMV-PCR (CMV R-gene® kit, limit of detection 450 copies/ml, Biomerieux, France) and quantitative serum CMV-PCR (Cobas® CMV, limit of detection 150 copies/ml, Roche, USA) were collected within seven days of colonoscopy.
45628692|NCT05522205|Other|Regulated cannabis access in pharmacies|The study does not investigate the health effects of cannabis. The study investigates the effects of regulated cannabis access on cannabis consumption and health in comparison to the unregulated illegal market.
45769013|NCT03827954|Other|HeartMapp+CT|HeartMapp+CT is a mobile system that includes physiological modules that support self-monitoring and exercises that promote heart health, and computerized plasticity-based adaptive cognitive training modules that train participants to enhance cognitive functions and ultimately heart failure outcomes.
45769014|NCT00980681|Drug|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
45769015|NCT00980681|Other|Time of Flight|Each subject will undergo a TOF MRA
45769016|NCT03828188|Dietary Supplement|Red Ginseng Concentrated Powder|Red Ginseng Concentrated Powder(4.9 g/day) for 12 weeks.
45769017|NCT03828188|Dietary Supplement|Placebo|Placebo for 12 weeks.
45769018|NCT04759040|Dietary Supplement|Migraineguard|2 Capsules per day for 7 Months
45769019|NCT04759196|Drug|Topamax|TPM : 50 mg BID, with increased of 50 mg by week until efficacy, to a maximum of 100 mg BID.
45769020|NCT04759196|Drug|Levetiracetam|LEV : 500 mg BID, with increase of 1000 mg die divided in two doses each week until efficacy, to a maximum of 1500 mg BID.
45769021|NCT05506020|Procedure|indocyanine green (ICG) fluorescence cholangiography|indocyanine green (ICG) fluorescence cholangiography during operation
45769022|NCT04128332|Radiation|Pre-operative stereotactic ablative body radiotherapy|Stereotactic ablative body radiotherapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumour, while limiting the dose to the surrounding tissues.
45628693|NCT02068768|Device|Avenue® L Interbody Fusion System (LDR Spine)|PEEK, intervertebral cage for interbody fusion of the lumbar spine
45628694|NCT05016921|Device|TcMS|Transcutaneous magnetic stimulation targeting the stellate ganglion
45628695|NCT02046616|Drug|Tocilizumab|Tocilizumab 162 mg will be administered subcutaneously QW.
45628696|NCT02046616|Drug|Methotrexate|Methotrexate dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
45628697|NCT02046616|Drug|Non-Biologic DMARDs|Participants will receive non-biologic DMARDs (same non-biologic DMARD that participant was receiving at time of study entry). Dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
45628698|NCT05525559|Drug|ET0038|ET0038 for oral administration
45628699|NCT04425057|Other|Interval training|
45628700|NCT05525481|Drug|Tamoxifen|Hormone therapy
45628701|NCT02099344|Device|Artegraft|Surgical placement of graft for hemodialysis access
45628702|NCT02099344|Device|Propaten|Surgical placement of graft for hemodialysis access
45628703|NCT05525091|Other|Feeding Evaluation|Feeding Evaluation with Device
45628704|NCT04706026|Other|Local anesthesia|This is the treatment group. Patients will receive an injection of a 50:50 mix of 1% lidocaine with epinephrine and 0.25% Marcaine at the surgical site (in the skin and subcutaneous layers + beneath the external oblique aponeurosis). Patients in the local arm will also receive intravenous sedation (propofol or Precedex) and pain medication (morphine or fentanyl) at the discretion of the attending anesthesiologist.
45628705|NCT04706026|Other|General anesthesia|This group is the active comparator. General anesthesia will be administered at the discretion of the anesthesiologist and will involve a combination of inhaled and intravenous anesthesia.
45628706|NCT05517447|Other|Observational cohort study|Observational cohort study
45628707|NCT05517447|Drug|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
45628708|NCT05517369|Procedure|Hybrid ESD+|Injection of the Lift Up solution, followed by circumcision of the lesion using a snare tip or ESD knife. Using an additional working channel (AWC), the lesion is resected using a grasper and snare.
45628709|NCT02068222|Drug|ABT-450/ritonavir (r)|Tablet
45628710|NCT02068222|Drug|ABT-530|Tablet
45628711|NCT02068222|Drug|Ribavirin (RBV)|Tablet
45628712|NCT05517213|Drug|Etoposide|Chemotherapy combined with rhG-CSF is widely used in autologous hematopoietic stem cell mobilization programs. For patients who do not meet the criteria of stem cell collection, they can be mobilized again after 1 month of rest. Chemotherapy +rhG-CSF mobilization or rhG-CSF+ ploxafo steady-state mobilization can be used.
45628713|NCT05517213|Drug|Cyclophosphamide|Chemotherapy combined with rhG-CSF is widely used in autologous hematopoietic stem cell mobilization programs. For patients who do not meet the criteria of stem cell collection, they can be mobilized again after 1 month of rest. Chemotherapy +rhG-CSF mobilization or rhG-CSF+ ploxafo steady-state mobilization can be used.
45628714|NCT05517135|Other|Arm 1|Concurrent chemoradiotherapy (CCRT) using cisplatin (100 mg/m2 IV) or carboplatin (AUC 5 IV) with radiotherapy +/- adjuvant chemotherapy (AC) with capecitabine (physician's choice of 650 mg/m2 bid or 1000 mg/m2 bid oral, d1-21, q3w)
45628715|NCT05517135|Other|Arm 2|IC using cisplatin (80 mg/m2 IV) or carboplatin (AUC 3-5 IV) in combination with gemcitabine (1000 mg/m2 d1,8) or 5-fluorouracil (1000 mg/m2 bolus IV d1-4) or docetaxel (75 mg/m2 IV), and CCRT
45628716|NCT05517135|Other|Arm 3|CCRT + metronomic capecitabine (650 mg/m2 bid oral, d1-21, q3w)
45628717|NCT05517135|Other|Group 1|Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil or docetaxel) and consolidative RT to the nasopharynx and neck (if good response to chemotherapy) +/- metastasis-directed therapy (surgery, radiofrequency ablation or RT) +/- immune checkpoint blockade (ICB) or capecitabine
45628718|NCT05517135|Other|Group 2|Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil or docetaxel) with or without ICB +/- maintenance ICB or capecitabine
45628719|NCT05516979|Drug|100 mg AP1189|AP1189 tablets for oral use
45628720|NCT05516979|Drug|Placebo|Matching placebo for oral use
45628721|NCT05516901|Procedure|The erector spinae plane block group|The probe should then slowly be moved laterally until the transverse process is visible. The 100 mm, 25-gauge needle should be inserted using an in-plane approach in the cephalad to caudal direction and advanced under ultrasound guidance towards the transverse process; once the needle tip is below the erector spinae muscle, a small bolus of local anesthetic should be given. The erector spinae muscle should be visualized, separating from the transverse process. After aspiration the local anesthetic (20 ml of 0.25% bupivacaine was injected. Technique was repeated on the other side.
45628722|NCT05516901|Procedure|Control group|Patients in this group will receive general anesthesia alone.
45769023|NCT05501106|Other|Integrated Improvement strategies|"Integrated improvement strategies include postpartum hemorrhage risk screening, hierarchical management and preparedness, postpartum hemorrhage rescue recording, and review of postpartum hemorrhage cases.~A checklist (named as Risk Assessment and Preparedness for Postpartum Hemorrhage (Traffic Light in Delivery Room)) will be used in each virginal delivery to help obstetric staff and teams identify risk factors after admission, before and during labor, and improve the adherence to all known best practices.~The Postpartum Hemorrhage Rescue Format will be asked to be used in each postpartum hemorrhage rescue to record the rescue process.~Each case of postpartum hemorrhage exceeding 1000 ml will be reviewed. We will convene a QI Panel and a Task Force to assist the hospitals in postpartum hemorrhage case review and quality improvement strategy development."
45769024|NCT04274114|Drug|L Glutamine|Powder
45769025|NCT04274114|Drug|Placebos|Powder
45769026|NCT04737642|Procedure|Papillary ballon dilatation|Trans cystic papillary ballon dilatation during cholecystectomy
45769027|NCT03868670|Device|responsive neurostimulation|The RNS® System is a novel, implantable therapeutic device that delivers responsive neurostimulation, an advanced technology designed to continuously monitor brain electrical activity, detect abnormal electrical activity and respond by delivering imperceptible levels of electrical stimulation to normalize that activity before an individual experiences seizures. This is an Early Feasibility Study determining the safety and efficacy of NAc-RNS in the treatment of LOC eating in treatment-refractory obesity.
45769028|NCT04286334|Device|Bone augmentation with cad-cam laser-sintered mesh|Titanium meshes cad cam laser-sintered were applied in sites with alveolar bone deficiency in order to regenerate the bone volume in need of implant-prosthetic restorations.
45769029|NCT04128254|Drug|Apixaban Oral Tablet|Apixaban is a kind of oral anticoagulant drugs used to prevent venous thromboembolism
45628723|NCT05516823|Other|Usage of drugs|Self-reported past usage of drugs belonging to different chemical groups.
45769030|NCT04128020|Drug|Nivolumab|Nivolumab
45628724|NCT05512299|Diagnostic Test|Transcranial Magnetic Stimulation|The CBI is recorded with two different TMS coils. The figure-of-eight coil (2X90 mm) is used for the motor cortex stimulation and the double cone coil (2X126 mm) is used for the cerebellar stimulation. The target recording muscle is first dorsal interosseous (FDI). The TMS intensity used to induce an average MEP amplitude of 0.5 mV is also determined. CBI is measured by a paired TMS with an inter-stimulus interval of 6 ms. That is, the test TMS at M1 is delivered 6 ms following the conditional TMS at contralateral cerebellum.
45769031|NCT04128020|Drug|Azacitidine|Azacitidine
45628725|NCT05521971|Other|multifaceted pharmacist-led intervention|"Educational sessions were provided to the physicians and nursing staff.~Discontinuation regimens were developed. Prescribers were free to choose whether or not to actually use them. The regimens were derived from the regimen used by Petrovic et al. and encouraged a switch from any benzodiazepine to lorazepam 1 mg OD for one week followed by drug stop. Z-drugs were switched to zolpidem 5 mg OD for one week followed by drug stop. If deemed necessary, a pro re nata regimen of lorazepam 1 mg or zolpidem 5 mg for one additional week was prescribed respectively. The discontinuation regimens were incorporated into the hospital's electronic prescribing system. Furthermore, a clinical decision support system provided additional support.~Patient education sessions were provided upon enrolment and at discharge. Specific patient leaflets were used to facilitate patient education.~The patient's primary care physician and, if applicable, the nursing home were informed by phone."
45447425|NCT02112058|Behavioral|A Family-Strengthening Program for Low-Income Families|"The program's central and most intensive component was a series of relationship and marriage education workshops for groups of couples that was offered in the first four to five months of enrollment in the program.~Complementing the workshops was a second component, offered for the year after enrollment, that consisted of supplemental activities: educational and social events that were intended to build on and reinforce lessons from the curricula.~The third component, family support services, paired couples with a specialized staff member who maintained contact with them and facilitated their participation in the other two components throughout the duration of the program."
45628726|NCT05521971|Other|Usual care group|all patients received comprehensive geriatric care without any systematic clinical pharmacist involvement regarding deprescribing of hypnotics. Treating physicians were not actively informed on the patient's participation in this particular study.
45628727|NCT05521893|Other|Telemedicine care|"In the telemedicine group, the appointments are performed online via scheduled videoconferences, on a monthly basis.~All women in the telemedicine group receive a smartphone with the installed application that enable transfer of the measured capillary glucose concentration."
45447426|NCT02251210|Drug|BIIL 284 BS low dose|
45628728|NCT05521893|Other|Standard care|In the standard care group, visits are scheduled at the diabetes clinic on a monthly basis.
45628729|NCT05077761|Device|Active High-intensity laser therapy|"High-intensity laser therapy will be used in the contact method, with the laser beam irradiated over the hamstring muscle. Dosage and parameters for the laser will be calculated.~Parameters-~Wavelength- 980 nm~Intensity/Power density- 3W/cm2~Emission mode- Continuous Emission~Energy (Joules)- 490 J~Irradiation time- 70 Sec on each point~Peak power- 15 Watt~Irradiation points- 09"
45628730|NCT05077761|Device|Sham High-intensity laser therapy|Sham High-intensity laser therapy will be used in the contact method, without the laser beam irradiation over the hamstring muscle.
45628731|NCT05521815|Other|Coma arousal therapy|early coma arousal therapy program in addition to selected physical therapy program (positioning, breathing exercise, passive movement of the four limbs).
45628732|NCT05521815|Other|Selected physiotherapy program|selected physiotherapy program only (positioning, breathing exercise, passive movement of the four limbs).
45628733|NCT05516745|Device|AioCare spirometer|In the first part of the trial, all participants from arms 1 and 2 will receive the AioCare spirometer (Healtup, Poland) to home-based monitoring pulmonary function. Hospital spirometry examinations (Jaeger, Germany) evaluating disease progression will be performed periodically. There are to be follow-up visits after 3 months and after 6 months. The end-point visit is planned for 12 months.
45628734|NCT05516745|Other|telerehabiliation of the respiratory system|A major component of respiratory dysfunction seems to be a decline of respiratory muscle weakness. The proposition is respiratory telerehabilitation to improve the function of respiratory muscles. Telerehabilitation includes breathing exercises for use at home. The participants will be trained in the hospital and will receive video presentations to support the exercises at home.
45628735|NCT04903977|Diagnostic Test|Laboratory tests: blood and faeces tests|To be performed at V2
45628736|NCT04903977|Diagnostic Test|Gynaecological and proctological examinations|To be performed at V1 (Examination with a gynaecological speculum, Bimanual examination, Rectal examination, and Anoscopy)
45628737|NCT04903977|Diagnostic Test|3-D Endoanal Ultrasound|To be performed at V1 (as a reference and for group assignment)
45628738|NCT04903977|Device|ONIRY measurement|To be performed at V2 (the electrical impedance of anal sphincter muscles will be measured)
45628739|NCT04903977|Diagnostic Test|High-resolution anorectal manometry|To be performed at V3
45628740|NCT04903977|Diagnostic Test|ECG|To be performed at V1 and V2 (for safety reasons)
45628741|NCT05516589|Drug|Nab-paclitaxel|260mg/m^2 IV Q3W
45628742|NCT05516589|Drug|Cisplatin|75mg/m^2 IV Q3W
45628743|NCT05516589|Biological|Tislelizumab|200mg IV Q3W
45628744|NCT05516589|Drug|Afatinib|30mg PO QD
45628745|NCT05511987|Device|Madela THOPAZ Digital Device|Digital drainage systems use electronic sensors to measure changes in pressure and thus may allow for quantification of the degree of air leak continuously and provide a graphical representation of the trend over time. Data on intrapleural pressure are also provided by some units. Together, these data may lead to expedited chest tube removal and hospital discharge with obvious financial implications.
45447427|NCT02251210|Drug|BIIL 284 BS medium dose|
45447428|NCT02251210|Drug|BIIL 284 BS high dose|
45447429|NCT02251210|Drug|Placebo|
45447430|NCT02115490|Drug|Bisphosphonates|
45628746|NCT05511987|Device|Atrium Analog Device|Analog drainage systems contain a sequentially numbered series of columns in the water seal chamber. The degree of air leak is assessed by observing the highest numbered column in which bubbling occurs. This provides a qualitative assessment at a specific point in time. This assessment, however, is subject to interobserver variability and does not account for variation over time.
45769032|NCT05510388|Device|High-flow nasal cannula oxygenation|The patients receive oxygen flow of 6L/min for preoxygenation with an high-flow canular oxygenation device before losing of conscious. Then, the oxygen flow is adjusted to 60L/min with the oxygen concentration of 100% and the temperature of 37℃ until the end of procedure.
45769033|NCT05510388|Device|Regular nasal cannula oxygenation|The patients receive an oxygen flow of 6L/min for preoxygenation with a disposal regular nasal cannula until the end of procedure.
45447431|NCT03553264|Device|Virtual Reality Rehabilitation|Track Speed Racing 3D game will run with HMD 'Revelation' 3D VR Headset and each HMD group patient will be instructed to perform the game protocol uninterruptedly for 20min/day, while sitting on a chair or sofa.
45447432|NCT03553264|Other|Vestibular Rehabilitation|The home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises
45447433|NCT02251288|Biological|Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca|MedImmune supplies pLAIV vaccines as a colorless to pale yellow and clear to slightly cloudy suspension in single, unit-dose, Becton-Dickinson Accuspray™ Nasal Spray Systems sprayer devices. Each filled sprayer device contains a 0.5 mL dose of 10^7FFU of H7N9 Anhui 2013/AA ca vaccine. Group I receives the IN dose on Day 29, Group 2 on Day 85, and Group 3 on Day 169.
45447434|NCT02251288|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Sanofi supplies the monovalent influenza A/H7N9 virus vaccine as a sterile, clear, and slightly opalescent suspension in single-dose vials containing 15 mcg HA per 0.5 mL. Group 1 through Group5 will receive the IM vaccine on Day 1
45447435|NCT02251288|Drug|MF59 adjuvant|Novartis supplies the MF59 adjuvant as an oil-in-water milky emulsion in single-use vials containing a fill volume of 0.7 mL. Group 1 through Group 5 will receive MF59 IM on Day 1.
45628747|NCT02099110|Drug|Matching Placebo to Ertugliflozin 5 mg|Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
45628748|NCT02099110|Drug|Matching Placebo to Ertugliflozin 10 mg|Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
45628749|NCT02099110|Drug|Matching Placebo to sitagliptin 100 mg|Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
45628750|NCT02099110|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
45628751|NCT02099110|Drug|Ertugliflozin 10 mg|Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
45628752|NCT02099110|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
45628753|NCT02099110|Drug|Metformin >= 1500 mg/day|Metformin >= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period
45628754|NCT02099110|Biological|Insulin Glargine Rescue Medication|Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion
45628755|NCT02099110|Drug|Glimepiride Rescue Medication|Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion
45628756|NCT02098876|Device|Resolute Integrity Zotarolimus eluting stent|PCI with Resolute stent
45628757|NCT02098876|Device|Xience Xpedition everolimus eluting stent|PCI with Xience stent
45628758|NCT02098876|Device|Optical Coherence Tomography (OCT)|Optical coherence tomography (OCT) will be performed at baseline to assess plaque burden prior to and after stent deployment as well as to evaluate stent expansion and stent apposition. OCT will be repeated at one year follow-up to evaluate neo-intimal tissue coverage within the stent and change in plaque area at the stent edges. Offline, manual detection of lumen area and stent area will be performed for each OCT cross-section from baseline and follow up examinations.
45628759|NCT02098876|Device|Intravascular Ultrasound (IVUS)|Intravascular ultrasound (IVUS) will be performed at baseline to assess plaque burden prior to and after stent deployment as well as to evaluate stent expansion and stent apposition. IVUS will be repeated at one year follow-up to evaluate neo-intimal tissue coverage within the stent and change in plaque area at the stent edges. Offline, manual detection of lumen area, stent area, vessel area (external elastic membrane) and the media-adventitia interface will be performed for each IVUS cross-section from baseline and follow up examinations.
45628760|NCT01624090|Drug|Mithramycin|30 mcg/kg intravenous (IV) over 6 hours once daily for 7 days, to be repeated every 21 days (one cycle) until disease progression or unacceptable toxicity
45628761|NCT02571777|Drug|QVM149 150/50/160|
45628762|NCT02571777|Drug|QVM149 150/50/80|
45628763|NCT02571777|Drug|QMF149 150/320|
45628764|NCT02571777|Drug|QMF149 150/160|
45447436|NCT04080297|Drug|oral capsule of Q-122|
45447437|NCT04371549|Procedure|Glue (Dermabond®; Ethicon, Somerville, NJ).|Arm 1: Skin after cesarean section will be closed by glue
45628765|NCT02571777|Drug|salmeterol/fluticasone|
45628766|NCT05516355|Behavioral|Mindfulness-Based Stress Reduction|"The MBSR is an 8-week standardized program (Kabat-Zinn,1990).~During the retreat, participants will receive intensive training during 3 days (from 4:00pm to 9pm the first day and from 7 am to 10 pm including breaks, the second and third days), including focused attention on the breath, open monitoring of awareness in body-scanning, prosocial meditation (i.e. loving kindness and compassion) and gentle yoga. Training is delivered by certified instructors by the University of Massachusetts Centre for Mindfulness (https://www.umassmed.edu/cfm/)."
45769034|NCT03827642|Drug|Treatment A: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
45769035|NCT03827642|Drug|Treatment B: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
45769036|NCT03827642|Drug|Treatment C: Naloxone HCl Intravenous (IV) Injection|Participants received naloxone HCl IV injection following a 10 hour fast.
45769037|NCT03827642|Drug|Treatment D: Naloxone HCl Intramuscular (IM) Injection|Participants received naloxone HCl IM injection following a 10 hour fast.
45628767|NCT05516355|Behavioral|Compassion Cultivation Training|"The CCT is an 8-week standardized program (Jinpa, 2010; Jazaieri et al. 2013, 2014) consisting of daily formal and informal practices.~Training will be conducted during 3 days of the retreat (same schedule as the MBSR training). The CCT consists of six sequential steps: 1) Settling the mind and learn how to focus it; 2) Loving kindness and compassion for a loved one practice; 3) Loving kindness and compassion for oneself practice; 4) compassion toward others, embracing shared common humanity and developing appreciation of others; 5) compassion toward others including all beings; and 6) active compassion practices (Tonglen) which involve explicit evocation of the altruistic wish to do something about others' suffering. CCT program is delivered by certified instructors by the University of Stanford Centre for Compassion and Altruism Research and Education (http://ccare.stanford.edu/)."
45628768|NCT05521737|Procedure|Electroacupuncture|16 sessions in total for two months.
45628769|NCT05521737|Procedure|Sham Acupuncture|16 sessions in total for two months.
45628770|NCT05521659|Other|Standardized oral care protocol|Standardized oral care protocol (3 times a day at certain hours (06-14-22) with oral care set including chlorhexidine gluconate)
45628771|NCT05521581|Other|Hand massage|Hand massage will be applied to primiparous mothers who gave birth by cesarean section and its effect on pain, comfort and gas release times will be evaluated.
45628772|NCT05516199|Behavioral|Antenatal breastmilk expression|Stimulation of the breast by hand/handexpression of breastmilk during pregnancy from week 34
45628773|NCT05516199|Behavioral|Breastfeeding consultation|60 min standardized breastfeeding consultation with a trained midwife, with focus on practical breastfeeding skills
45628774|NCT05511831|Drug|Ketotifen Fumarate|Ketotifen treatment for 3 months, 1 mg each time, 1-2 times a day according to the patient's tolerance
45628775|NCT05511831|Drug|standard treatment|Standard treatment methods will be determined according to the Guidelines for the Diagnosis and Treatment of Acute ST-segment Elevation Myocardial Infarction (2019) [19], including primary PCI, dual antiplatelet, anticoagulation, ACEI/ARB/ARNI, β-receptor blockade drugs, statins, etc.
45628776|NCT02571075|Other|Auricular acupuncture|The ear will be cleaned with alcohol prior to insertion of the needles. Five sterile, single-use, gold needles will be placed in each ear according to the figure below. The needles penetrate about a millimeter (or 4/100ths of an inch) into the skin.
45628777|NCT02705105|Biological|Mogamulizumab + Nivolumab|i.v. administration
45628778|NCT05521425|Device|"Helping Hands for CAPD bag exchange procedures"|"Training served as Treatment As Usual (TAU) for all participants; The difference between two groups was whether Helping hands were provided to participants for CAPD bag exchange procedures at home."
45628779|NCT05511753|Device|electroacupuncture|Insert stainless steel needles into the above acupoints and twist the needles to get qi. In addition, electroacupuncture stimulation (intensity 1mA, frequency 2Hz) was applied to connect the ipsilateral Yifeng and Wangu, and the ipsilateral Zhongzhu and Quchi.
45628780|NCT05521347|Behavioral|caffeine|we employed a randomized crossover design to divide participants into a caffeine trial (CAF) and a placebo trial (PL). The CAF group took capsules with 3 mg/kg of caffeine, whereas the PL group took a placebo capsule. After a 1-h rest, the Stroop task, visual search ability test, and the shooting ability test were conducted.
45628781|NCT02097472|Biological|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
45628782|NCT02097472|Biological|Synflorix|"1 dose (0.5 mL) contains:~1 μg of each of the following pneumococcal polysaccharide serotypes:~1, 5, 6B, 7F, 9V, 14, and 23 F~And 3 μg of the following pneumococcal polysaccharide serotypes:~4, 18C and 19F.~The serotypes are conjugated to either:~protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein"
45628783|NCT02097472|Biological|Pentavac|"Each PFS contains 0.5 ml (single dose):~Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 % Dose: O.5ml by intramuscular injection."
45628784|NCT02097472|Other|Saline|0.9% Sodium Chloride Injection, USP
45628785|NCT03180671|Device|Deprogramer Sliding Guide|Use of the intraoral device.
45628786|NCT03180671|Device|Deprogrammer Dawson B-Splint|Use of the intraoral device.
45628787|NCT03180671|Device|Deprogrammer Kois|Use of the intraoral device.
45628788|NCT05093517|Drug|REMD-477|A biologic glucagon receptor agonist to which randomized subjects are assigned 2:1
45628789|NCT05093517|Drug|Placebo Subcutaneous injection|Placebo for REMD-477 to which subjects will be randomized 1:2.
45447438|NCT04371549|Procedure|Monocryl|Arm 2: Skin after cesarean section will be closed by running subcuticular sutures using synthetic absorbable monofilament
45447439|NCT02109718|Drug|Open Dressings with Petrolatum Jelly|participants randomized to this arm had their wounds dressed with a thin layer (1mm) of petrolatum gel applied over the burn wound and instructed to reapply the gel as needed in the event of gel coming off.
45447440|NCT02109718|Drug|Silver Sulfadiazine Gauze Dressing Group|Participants randomized to this arm had their wounds dressed using the standard methods at the Burn Center. An initial layer of fine mesh gauze is applied that is laden with a 2mm layer of silver sulfadiazine cream. This is covered with layers of moist gauze and an outer layer of dry gauze, secured by wrapping with rolled gauze. The dressing extends at least 1 inch beyond the wound edge.
45447441|NCT03744897|Behavioral|Hypnotic analgesia|Subjects will receive hypnotic analgesia during 20 minutes
45447442|NCT03744897|Device|a-tDCS|Subjects will receive transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 2mA, 20 minutes
45447443|NCT03744897|Other|Hypnotic analgesia + a-tDCS|Subjects will receive hypnotic analgesia associated to transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 2mA, 20 minutes
45628790|NCT02420249|Behavioral|Qigong training|Participants will learn the 18 Forms of Tai Chi Internal Qigong. Detailed movement and breathing descriptions of the Qigong training protocol can been found in Mak YK. 18 Forms Tai Chi Qigong [in Chinese]. 7th ed. Hong Kong: Wan Li Book Co.; 2012.
45628791|NCT02420171|Other|Adding insulin to In Vitro culture media|We will add insulin for in vitro culture of human embryos
45628792|NCT05516121|Drug|VLT-015|100 mg single dose, 200 mg single dose, 200 mg single dose once a day for two consecutive days
45628793|NCT03180593|Drug|Valsartan 80 mg|Compare office and 24-hour Blood Pressure Control and regression of Left Ventricular Hypertrophy
45628794|NCT05057169|Biological|BNT162b2|BNT162b2 is a nucleoside-modified mRNA encoding the trimerized SARS-CoV-2 spike glycoprotein. The vaccine is formulated in lipid nanoparticles that increase the efficiency of delivery of the mRNA into cells after intramuscular injection. BNT162b2 encodes the SARS- CoV-2 full-length spike, modified by two proline mutations to lock it in the prefusion conformation and more closely recreate the intact virus with which the elicited virus- neutralizing antibodies interact. mRNA vaccines use the pathogen's genetic code as the vaccine; hence they exploit the host cells to translate the code and generate the target spike protein. The protein then acts as an intracellular antigen to stimulate the immune response of the vaccinated individual. The mRNA is then degraded within days.
45628795|NCT05057169|Biological|CoronaVac|CoronaVac is a Vero cell-based, aluminium hydroxide-adjuvanted, β-propiolactone- inactivated vaccine based on the CZ02 strain. This strain of SARS-CoV-2 was isolated from the bronchoalveolar lavage of a hospitalized patient and is closely related to the 2019-nCoV- BetaCoV Wuhan/WIV04/2019 strain. Each 0.5 ml dose is composed of 3 μg of inactivated SARS-CoV-2 virus. The excipients are aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, and water for injection.
45628796|NCT03180437|Procedure|IRE surgery|IRE surgery will be used in local tumor
45628797|NCT03180437|Biological|IRE plus γδ T cells|Combination IRE surgery and γδ T cell will be used in Pancreatic Cancer
45628798|NCT05516043|Procedure|Implantation with POLYTHESE®|thoracic vascular surgery, abdominal vascular surgery and peripheral vascular surgery
45628799|NCT02423759|Drug|ciprofloxacin|500mg ciprofloxacin twice daily starting the day before biopsy and continued for 3 days after
45628800|NCT02423759|Drug|ciprofloxacin and gentamycine|standard chemoprophylaxis plus gentamicin 160mg intramuscular once just before the biopsy
45628801|NCT02423759|Drug|culture based chemoprophylaxis|Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
45628802|NCT02420405|Procedure|Routine gene testing|For those diagnosed with nonsquamous NSCLC, routine gene testing including EGFR, ROS1 and ALK will be performed.
45628803|NCT02420405|Procedure|Next-generation sequencing|For those diagnosed with nonsquamous NSCLC and have done routine gene testing, NGS will be perform on those that have adequate rest tissues.
45628804|NCT02419781|Procedure|Rescue endovascular therapy|endovascular treatment using any devises for acute ischemic stroke patients with large vessel occlusion and not respond to intravenous recombinant tissue plasminogen activator (rt-PA) therapy
45628805|NCT02419781|Procedure|No endovascular therapy|
45628806|NCT01623310|Drug|Fluticasone Propionate|Using Optinose Exhalation Delivery System
45628807|NCT03178565|Other|Mechanical insufflation-exsufflation|The mechanical insufflation-exsufflation device will be connected in the orotracheal tube. Four series of insufflation-exsufflation will be conducted. Each serie will be composed by 10 cycles of alternated insufflation (40 cmH2O) and exsufflation (- 40 cmH2O).
45628808|NCT03178565|Other|Standard Respiratory Physiotherapy|Standard chest physiotherapy will be conducted through bilateral thoracic maneuvers (percussion and vibration) followed by manual hyperinflation using a manual resuscitator bag.
45628809|NCT03180125|Drug|Sodium Hyaluronate|median nerve in CTS hydro-dissection using 1% lidocain followed by injection of Sodium hyaluronate guided by ultrasound
45628810|NCT03180125|Device|ultrasound|ultrasound guided injection
45628811|NCT03180125|Drug|Sodium Hyaluronate and 1% lidocain|injection in the carpal tunnel
45628812|NCT03180125|Drug|Corticosteroid and 1%lidocain|injection in the carpal tunnel
45628813|NCT02046226|Device|Oxygenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
45628814|NCT02423603|Drug|Paclitaxel|Patient receive Once a week for three weeks - with one week off treatment
45628815|NCT02423603|Drug|AZD5363|Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.
45628816|NCT02423603|Drug|Placebo|Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.
45628817|NCT03178409|Procedure|Hepatectomy|Removal of a part of the liver
45628818|NCT03180203|Device|INTELLiVENT-ASV|"After ICU admission:~The first three hours: only ventilation with INTELLiVENT-ASV with Quickwean.~After three hours: Automatic spontaneous breathing trials (SBT) is activated and SBT starts if >10minutes PEEP:<9cmH2O,FiO2:<41%,VT/IBW<5ml/kg and RSB:<106l/l*min.~Settings SBT are MV% 25%,PEEP 5cmH2O.SBT automatically stops if respiratory rate >35b/min or increases >100% since start of SBT, FiO2 >50%, PeTCO2 increases >8mmHg.~Extubation criteria: Leakage <50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT >10min.~If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT."
45447444|NCT03744897|Device|s-tDCS|Subjects will receive sham transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 0mA, 20 minutes
45447445|NCT02115802|Device|Activa PC+S|Subjects will undergo placement of bilateral standard Deep Brain Stimulation (DBS) electrodes (Medtronic model 3387/3389) and implantation of the Activa PC+S, a modified impulse generator (IPG) for DBS with the added technology of neural signal recording.
45628819|NCT03180203|Device|Conventional modes|"After ICU admission:~The first three hours: only ventilation with CMV or PS. If required care providers may change the mode to adaptive support ventilation.~After three hours: manual SBT is required if >10min PS<11cmH2O,PEEP<9cmH2O,FiO2<41%.~Settings SBT are PS 5cmH2O, PEEP 5cmH2O, FiO2 30%. SBT must be stopped if respiratory rate >35b/min or increases >100% since the start of SBT, saturation <92% or the PeTCO2 increases >8mmHg.~Extubation criteria: Leakage <50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT >10min.~If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT."
45628820|NCT03180281|Drug|DPP4|sitagliptin phosphate 100mg qd
45628821|NCT03180281|Drug|Insulin|Insulin Glargine or detemir 0.2U/kg qd
45628822|NCT03180281|Drug|SU|Glimepiride 1-2mg qd
45628823|NCT02419703|Device|STAR™ Tumor Ablation System|Targeted Radiofrequency ablation of painful metastatic tumor in the vertebral body.
45628824|NCT03178175|Procedure|Acupuncture|"In the acupuncture with De Qi group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) until the De Qi phenomenon occurs. The duration is about 30 minutes, and all patients will receive the procedure 16 times within 2 months."
45628825|NCT03178175|Procedure|Needle Insertion|"In the Sham acupuncture group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) but the needle doesn't reach the exact depth and De Qi phenomena doesn't occur. The duration is about 30 minutes, and all patients will receive this procedure 16 times within 2 months."
45628826|NCT03116945|Drug|68Gallium Citrate|Procedure: PET/CT Imaging
45628827|NCT03117023|Drug|dexmedetomidine|sufentanil 0.05ug/kh/h + dexmedetomidine 0.1ug/kg/h for 48h after surgery
45628828|NCT02046148|Biological|GBS trivalent vaccine|Intramuscular injection - Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus and conjugated to the Corynebacterium diphtheriae CRM197 carrier protein
45628829|NCT02046148|Biological|Placebo|Intramuscular injection - Normal saline
45628830|NCT03117101|Drug|Lucitanib|
45628831|NCT03178019|Other|Laser-Doppler methods|This was a cross-sectional study in which participants were subjected to a screening phase before being eligible to participate in the study. All subjects were submitted to Laser-Doppler methods (assessment of microcirculatory blood flow), bioimpedance analysis (assessment of body composition), venous blood collections (laboratory analysis), and Finometer Pro (assessment of heart rate variability and blood pressure variability).
45628832|NCT03107585|Procedure|bilateral cervical plexus block|with a linear probe and after disinfection vascular neck axis are identified at first. At the cricoid cartilage we conducted an apical scan to locate the carotid bifurcation.at this level is carried out a lateral translation to the visibility of the deep cervical space below the sternocleidomastoidien muscle then a needle 50 is introduced in plane. we proceed in inundation of cervical space
45628833|NCT02097238|Drug|Eribulin Mesylate|Given IV
45628834|NCT02097238|Other|Pharmacological Study|Correlative studies
45628835|NCT04703842|Biological|SRD-001|AAV1/SERCA2a
45628836|NCT04703842|Drug|Placebo|SRD-001 matching placebo
45628837|NCT04703764|Drug|HSG4112|Once-daily, 14-day multiple oral administration
45628838|NCT04703764|Drug|Placebo|Once-daily, 14-day multiple oral administration
45628839|NCT02704091|Drug|Smecta|
45628840|NCT02704091|Drug|Smecta placebo|
45628841|NCT03179813|Procedure|Hydrocortisone|During the third molar extraction the hydrocortisone solution will be used in the test group
45628842|NCT03179813|Procedure|Control|During the third molar extraction the saline solution will be used in the control group
45628843|NCT02419625|Behavioral|questionnaires|questionnaires , serum samples will be used
45628844|NCT03179735|Drug|Essential oils|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
45628845|NCT03179735|Drug|Cetylpyridinium Chloride 0.7 mg/ml|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
45628846|NCT03179735|Drug|Placebos|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
45628847|NCT02419859|Device|PaQ® Insulin Delivery Device|PaQ is a 3 day insulin delivery device which delivers U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
45628848|NCT02419859|Drug|Insulin, Asp(B28)-|a fast-acting analog of human insulin
45628849|NCT02419391|Biological|MVA BN RSV|Liquid frozen suspension of MVA-mBN294B
45628850|NCT02419391|Other|Placebo|Tris Buffered Saline, sterile
45628851|NCT03116867|Other|sonosalpingography|transvaginal ultrasound with saline infusion
45628852|NCT03177941|Other|Eviderma Smart Phone Teledermatology Application (Eviderma)|First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle.
45628853|NCT02423681|Device|ThermoSmart|Heated humidification as first intention (HH1st) with ThermoSmart
45628854|NCT02423681|Device|Without ThermoSmart|ThermoSmart is switched off
45628855|NCT02423369|Procedure|Cerebral near infrared spectroscopy|At the start of anesthesia on the patient's forehead two electrodes are attached the for continuous measurement of cerebral near infrared spectroscopy during surgery.
45628856|NCT02423369|Other|S-100B protein in serum|0,5-1 ml of blood from periferal site for determination of serum S-100B concentration.
45447446|NCT02115880|Behavioral|Prevention programme|Based on a group- and family-based cognitive behavioural manual developed by Bruce Compas and colleagues in the USA, and adapted for a German sample. The programme is for parents and children and consists of 8 weekly sessions and 4 monthly booster sessions.
45447447|NCT02112136|Other|Blood Collection|Phenotype and Genotype Analysis, Biological Analysis
45769038|NCT04737252|Behavioral|Sage (formerly known as COMPASS)|Sage is a remote 12 session intervention for couples wherein one individual has Borderline Personality Disorder (BPD) and engages in self-injury thoughts and behaviours. The intervention consists of elements of Cognitive Behavioural Conjoint Therapy (CBCT) and has been adapted for this population. Couples will meet remotely with a clinician (registered psychologists and/or graduate level clinicians) for 8-12 sessions via Zoom Healthcare. The primary outcomes are self-injury thoughts and behaviours (as measured by the Suicide Attempt and Self-Injury Interview-modified, and the Beck Scale for Suicidal Ideation and ecological momentary assessment) and borderline personality disorder symptoms (as measured by the Borderline Symptom List-23).
45628857|NCT02423369|Other|NSE protein in serum|0,5-1 ml of blood from periferal site for determination of serum NSE concentration.
45628858|NCT02419157|Drug|Selective enamel etching with 36% phosphoric acid|Etch: selective 36% phosphoric acid enamel etching
45628859|NCT02419157|Drug|No selective enamel etching with 36% phosphoric acid|Non-etch: without phosphoric acid selective enamel etching
45628860|NCT02419157|Device|Clearfil SE Bond|
45628861|NCT02419157|Device|Xeno V|
45628862|NCT02419235|Other|20% ethanol|Unmedicated 20% ethanol.
45628863|NCT02419235|Other|Homoeopathic complex|20% ethanol medicated with Amylenum nitrosum 6cH, Crataegus oxyacantha 6cH, Natrium muriaticum 6cH and Scutellaria lateriflora 6cH.
45628864|NCT02423135|Biological|Autologous blood transfusion|Volunteers make a blood donation and after 36 days of storage this blood is re-infused in the same volunteers.
45628865|NCT02422901|Drug|vitamin C|According to the character of an observational study no intervention other than the administration of Pascorbin® 7.5g (which is administered routinely in these cases) is provided.
45628866|NCT02418767|Drug|MOD-4023|
45628867|NCT02418767|Drug|Placebo|
45769039|NCT03827720|Device|SENSE Device|Non-invasive radiofrequency (RF) sensor
45769040|NCT05505786|Behavioral|Normal stance width|Normal self-selected stance width when performing squat exercises.
45769041|NCT05505786|Behavioral|Wide stance width|Increased stance with (by 20% over their own self-selected stance width) when performing squat exercises.
45769042|NCT03827486|Other|Standard of care (exercise)|Exercise program according to the standard of care
45769043|NCT03827486|Other|Domicilary exercise program|Domicilary exercise program according to protocol (evidence based medicine)
45447448|NCT02112214|Drug|10-day bismuth-based quadruple therapy|Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days
45447449|NCT02112214|Other|Placebo|Placebo for bismuth-based quadruple therapy
45447450|NCT02112292|Drug|tetrahydrocannabinol|
45447451|NCT02112292|Drug|cannabidiol|
45447452|NCT02112292|Drug|Placebo|
45447453|NCT02109796|Device|transcranial Direct current stimulation|
45628868|NCT02422823|Drug|Articaine|Injection of 1.8mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
45628869|NCT02422823|Drug|Articaine|Injection of 3.6mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
45628870|NCT02422823|Drug|Epinephrine|
45628871|NCT02418923|Other|Procedure: Blood specimen collection|Blood specimen collection
45628872|NCT03179501|Drug|NP001|NP001
45628873|NCT03179501|Drug|Placebo|Normal saline
45628874|NCT03179423|Drug|GNbAC1|Monthly IV repeated dose
45628875|NCT03179423|Drug|Placebo|Monthly IV repeated dose
45628876|NCT03179579|Procedure|HIPEC with neoadjuvant chemotherapy|HIPEC 3 times +NACT 2 cycles +CRS +HIPEC 3 times+ ACT 4-6 cycles
45628877|NCT03179579|Procedure|Systemic chemotherapy|NACT 3 cycles +CRS +ACT 4-6 cycles
45628878|NCT02422589|Drug|ceritinib|
45628879|NCT02422589|Drug|warfarin|
45628880|NCT02422589|Drug|midazolam|
45628881|NCT02422667|Other|Patient Registry|Orthopedic Data Registry
45769044|NCT05510310|Procedure|Breast stimulation|By breast pump
45769045|NCT05510310|Biological|Oxytocin|Oxytocin will be administered intravenously and titrated
45769046|NCT04129034|Device|Neurolyser XR|Non-Invasive Thermal Ablation of the Medial Branch Nerves
45628882|NCT02422199|Drug|pyrotinib|
45628883|NCT02422199|Drug|Lapatinib|
45628884|NCT02422199|Drug|capecitabine|
45628885|NCT02421965|Behavioral|FOCUS (Smartphone Application)|Participants in the FOCUS group will be given a study smartphone device with FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
45628886|NCT02421965|Behavioral|WRAP (Wellness Recovery Action Planning)|Participants allocated to the WRAP group will be provided all other materials (i.e. WRAP binder, handouts) in their first session and will meet weekly in groups with trained facilitators.
45628887|NCT02421653|Dietary Supplement|MNP90|90 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
45628888|NCT02421653|Dietary Supplement|MNP45|45 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
45628889|NCT02421653|Dietary Supplement|IODISED OIL|200 mg iodine oil capsule; oral route; once at study start
45628890|NCT02421653|Dietary Supplement|INERT OIL|Non-iodised evening primrose oil capsule; oral route; once at study start
45628891|NCT02421653|Dietary Supplement|INERT MNP|Un-fortified powder sachet (maltodextrin, no micronutrients); oral route; 1 daily
45628892|NCT02421653|Dietary Supplement|NON-IODISED MNP|Un-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
45628893|NCT02416739|Drug|Nicotinamide|Nicotinamide (1g/day) or placebo treatment is added to the standard drug treatment (gefitinib or erlotinib) to EGFR mutated NSCLC patients
45628894|NCT02416583|Drug|Oxytocin|
45628895|NCT02416583|Drug|Dinoprostone|
45628896|NCT02416583|Procedure|Membrane sweeping|
45628897|NCT02416427|Drug|Atorvastatin|Atorvastatin will be administered at 80 mg/day for 3 weeks in the time window between diagnostic biopsy and curative surgery
45447454|NCT03748407|Other|Dosages of Thyroid parameters|Dosages of the following parameters: TSH, FT4 FT3, TGAb (Tyroglobulin antibody) , TPO Ab (ThyroPeroxydase Antibody)
45628898|NCT02416349|Other|Respiratory Muscles Stretching|"Respiratory Muscles Stretching The stretching will occur throughout the expiratory phase to allow respiratory muscles to reach their maximal length, and two sets with 10 consecutive incursions will be use for each stretching pattern with an interval of 30 seconds between series.~Pattern 1: Neck stretching Pattern 2: Upper chest stretching Pattern 3:Pectoralis major stretching Pattern 4:Lateral chest stretching"
45628899|NCT02416349|Other|Control Group|Control Group - all volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
45628900|NCT03176771|Drug|MT-5199|MT-5199 40 mg capsules
45628901|NCT03176771|Drug|Placebo|MT-5199 placebo capsules
45628902|NCT02416271|Drug|Teriparatide|Administered SC
45628903|NCT02416271|Drug|Alendronate|Administered orally
45628904|NCT02416271|Dietary Supplement|Calcium|Administered orally
45628905|NCT02416271|Dietary Supplement|Vitamin D|Administered orally
45769047|NCT05510232|Device|A treatment group that will watch a non-VR video via an iPad|"The iPad is a tablet computer first offered by Apple in 2010.The device resembles a much larger version of Apple's iPhone or its iPod Touch, and is about the same size as a magazine.The iPad uses the same operating system as the Apple iPhone, and uses very similar hardware. iPad will be used to deliver non VR video to patients.~A standardized age appropriate video will be used for patients between ages 4-9 and a different standardized age appropriate video for patients ages 10-14. The selected videos will be the same for both the cast and suture/pin removal groups."
45769048|NCT05510232|Device|A treatment group that will have headset on and will watch a non-VR video|"Samsung Gear Oculus headset fitted with a Samsung Galaxy S7 phone will deliver non VR video to patients. Headset will be administered before intervention and removed at the completion of the intervention unless patient requests otherwise. Patients visual field will not change with head motion and will remain static throughout cast removal or pin/suture removal.~A standardized age appropriate video will be used for patients between ages 4-9 and a different standardized age appropriate video for patients ages 10-14. The selected videos will be the same for both the cast and suture/pin removal groups."
45447455|NCT02115958|Biological|cancer stem cell vaccine|
45447456|NCT04013529|Behavioral|Regret lottery|Subjects who achieve step goals are entered into a lottery in which they can win a financial incentive of $30 or $100.
45447457|NCT04013529|Behavioral|Way to Health technology enhanced care|Subjects receive text reminders to reach activity goals.
45447458|NCT02109874|Biological|AERAS-404 (mcg H4/nmol IC31)|Dose escalation
45447459|NCT02109874|Biological|Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl|
45447460|NCT02116036|Drug|Rivaroxaban|
45447461|NCT04011735|Drug|Respimat|Soft Mist Inhaler product
45628906|NCT02416271|Drug|Placebo-Oral|Administered orally
45628907|NCT02416271|Drug|Placebo-SC|Administered SC
45628908|NCT02702609|Device|easy-graft CLASSIC|easy-graft will be grafted to a single extraction socket to preserve the ridge dimension for future implant placement.
45628909|NCT02702609|Device|FDBA with collagen plug|FDBA will be grafted to a single extraction socket and covered by collagen plug to preserve the ridge dimension for future implant placement.
45628910|NCT02416505|Behavioral|Verbal+Anatomic Model|
45628911|NCT02416505|Behavioral|Verbal+Video|
45628912|NCT02416115|Drug|Ramosetron|Ramosetron was given iv.
45628913|NCT02416115|Drug|Naloxone|Naloxone added to PCA was given iv.
45628914|NCT02416115|Drug|saline|Saline was given iv.
45628915|NCT02416115|Drug|Morphine|Morphine in the PCA was given iv.
45628916|NCT02416037|Device|level of positive end expiratory pressure (Prone Proseva)|PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
45628917|NCT02416037|Device|level of positive end expiratory pressure (Prone Talmor)|PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
45628918|NCT02415881|Drug|Panitumumab IRDye 800|Patients will receive Panitumumab IRDye 800 prior to their scheduled surgery
45628919|NCT02415881|Device|da Vinci Firefly|Da Vinci surgical robot with build-in fluorescence imaging option (Firefly technology)
45628920|NCT02415881|Device|IMAGE1 + ICG Hopkins telescope and/or VITOM|IMAGE1 + ICG Hopkins telescope and/or VITOM -- Fluorescence camera allowing for imaging of IRDye800. Camera is suitable for open and laparoscopic surgery.
45628921|NCT02415803|Drug|low-dose ticagrelor|90 mg loading dose, then 45 mg twice daily for 5 days
45628922|NCT02415803|Drug|conventional-dose ticagrelor|180 mg loading dose, then 90 mg twice daily for 5 days
45628923|NCT02415803|Drug|Clopidogrel|300 mg loading dose, then 75 mg once daily for 5 days
45628924|NCT02415725|Drug|Indocyanine Green|visualization of the architecture of superficial lymphatic network after Indocyanine Green injection
45628925|NCT04482881|Drug|Isosorbide Mononitrate 40 MG|giving women isosorbide mononitrate 40 MG
45628926|NCT04482881|Drug|Isosorbide Mononitrate 60 MG|giving women isosorbide mononitrate 60MG
45628927|NCT04482881|Drug|Misoprostol|Giving women misoprostol
45769049|NCT05510232|Device|A treatment group that will be immersed in the VR game (Bear Blast) via the headset.|VR using the Samsung Gear Oculus headset fitted with a Samsung Galaxy S7 phone will deliver VR images and sound. Patients will watch a 15-minute VR experience called Bear Blast. Bear Blast is an immersive, 360-degree, game experience that takes place in a fantasy world where the user attempts to shoot balls at a wide range of moving objects by gently maneuvering his or her head toward the targets. Bear Blast is a nonviolent and noncompetitive game that incorporates motivational music and features positively reinforcing sounds, animation, and direct messages to patients. Bear Blast will be used as the standardized game for all patients in the VR group of both study arms. The VR reality Samsung Oculus headset can be controlled entirely via head motion and does not involve the use of patients extremities. iPad will be set up and held for patients in the iPad group.
45769050|NCT04123574|Drug|Talabostat Mesylate|"BXCL701 tablets dosage strengths include 0.2mg and 0.05mg tablets for oral administration.~Patients are to self-administer the prescribed number of BXCL701 tablets for a total daily dose of 0.6 mg. BXCL701 should not be taken on an empty stomach.~Daily blood pressure monitoring will be performed during the dosing period. Administration of at least 1L of intravenous (IV) fluids is required on Day 1.~On days when pharmacokinetic (PK) assessments are being performed, BXCL701 should be administered at the study center and should be administered at (approximately) the same time of day on each treatment day."
45769051|NCT05500950|Other|CDU and CT-DCG or CT examination|patients with space occupying lesions in the lacrimal sac area completed CDU and CT-DCG or CT examination before surgery
45769052|NCT04128098|Other|Evaluation|"Functional tests: 400-meter walking test, 200-meter brisk walking test, Sorensen test, Shirado test, measurement of maximum isometric force of extensors/back flexors.~3D analysis of locomotion and posture~Test of the flexion-relaxation phenomenon of the lumbar erector muscles"
45628928|NCT03176693|Drug|Phenoxybenzamine|Non-selective alpha blocker
45628929|NCT03176693|Drug|Doxazosin|Selective alpha blocker
45628930|NCT02415569|Drug|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
45628931|NCT02415569|Drug|2L PEG-ELP and 10mg bisacodyl|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure.
45628932|NCT02415569|Drug|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 3 to 7, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
45628933|NCT02415491|Other|Correlation Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test|"MRI of the heart, coronary arteries and pulmonary artery at rest and stress induced will be performed. Cine pictures are taken for evaluation of pulmonary perfusion.~Afterwards induced stress MRI will be performed according to standard protocol with elevation of dobutamine levels until the reach of peak HR. If applicable the procedure will be stopped) in case of e.g. arrhythmia.~Cardiopulmonary exercise stress test will be performed; patient will sit at rest on the ergometer, the subject's gas exchange will be recorded; with the pedal speed constant, the resistance will be increased from 0.5 watt/kg to 3 watt/kg over 10 minutes. Electrocardiography and heart rate will be taken continuously during and until 10 minutes afterwards. Blood pressure will be taken before, during and after the stress test. Respiratory gas exchange parameters will be taken continuously, peak oxygen uptake (VO2) determined as well as Ventilatory Efficiency."
45447462|NCT02251366|Procedure|Physician-guided diagnostic|NVAMD participants in the physician-guided diagnostic arm will have receive injections based on diagnostic imaging provided by optical coherence tomography and optional fluorescein angiography, those in this group will only receive retinal examinations at the 4- and 8-month clinic visits.
45628934|NCT02415335|Drug|dexamethasone phosphate|Intravenously administration minimum of 30 minutes preoperatively.
45628935|NCT02415335|Drug|Isotonic NaCl|Intravenously administration minimum of 30 minutes preoperatively
45628936|NCT02415257|Drug|Gentamicin|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
45628937|NCT02415179|Drug|Inhaled Mometasone/formoterol|Inhaled Mometasone/formoterol (100/5 microgram) 2 puffs twice daily via metered dose inhaler for 6 weeks
45628938|NCT02415179|Drug|Inhaled Fluticasone/Salmeterol|Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
45628939|NCT02415101|Procedure|Resective surgery|
45628940|NCT02415023|Drug|fruquintinib+paclitaxel|28-day cycle of fruquintinib qd for 3 weeks followed by 1-week break combined with paclitaxel 80 mg/m2
45628941|NCT02414945|Drug|Cyclophosphamide|
45628942|NCT02414945|Drug|Fludarabine|
45628943|NCT02414945|Biological|Autologous tumor infiltrating lymphocytes (TILs)|
45447463|NCT04009629|Behavioral|Moderate Intensity Aerobic Exercise|Participants will exercise for 15 minutes in a moderate age-predicted heart rate range. The study team will employ an exercise device such as a treadmill, cycle, or recumbent stepper to maintain control over workload.
45628944|NCT02414945|Biological|Interleukin-2|
45628945|NCT02414789|Procedure|Skin biopsies|Skin biopsies of patients with Lyme disease (erythema migrans) infected with Borrelia burgdorferi sensu lato will be analyzed by three diagnostic techniques : molecular technique (PCR), biological technique (culture of the bacteria) and proteomics technique (SRM/ MS-MS)
45628946|NCT02414555|Drug|vasopressor|Patients receive oesophageal doppler-based hemodynamic support either with fluid or with vasopressor
45628947|NCT02414555|Drug|fluid bolus|
45628948|NCT02414555|Device|oesophagus doppler (CardioQ)|
45628949|NCT02414555|Drug|Normal Saline|
45628950|NCT02414555|Device|arterial cannulation|
45628951|NCT02414555|Device|intravenous peripheral line insertion (17 gauge)|for fluid bolus administration
45628952|NCT02414555|Drug|Elo-Mel Isoton (balanced acetat-based infusate)|
45628953|NCT02414711|Other|HSCL25 scale|The patient must answer to 25 questions of the HSCL25 scale. In function of the results, the patients was diagnosed depressed (≥1.75) or not depressed (<1.75)
45628954|NCT02414711|Other|PSE9 questionary|On the 900 patients recruited, 50 patients who was diagnosed depressed or no depressed have to have a psychological interview with the PSE9 questionary to validate the first diagnosis done by the HSCL25 scale
45628955|NCT02414087|Device|ICB Medical insoles|"Study group:~Participants in the study group will be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months.~Control group:~Participants in the control group will not be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months"
45628956|NCT02414399|Drug|Azithromycin|oral administration of Azithromycin
45769053|NCT04128098|Other|Questionnaires|Self-questionnaires: Oswestry, Québec, SF-12, VAS pain, HAD, pain dramatization questionnaire, physical activity questionnaires, VAS and GPE satisfaction, FABQ, GPE functional status and EPICES score.
45628957|NCT02414399|Drug|Placebo|5 days of taste/appearance/bottle-matched inactive substance
45628958|NCT02046070|Drug|Cyclophosphamide|Cyclophosphamide tablets
45628959|NCT02046070|Drug|Ixazomib|Ixazomib capsules
45447464|NCT02116114|Other|Aerobic training|The program of aquatic exercise training was developed involving the following steps : heating : dynamic stretching exercises aerobic exercises , lasting 10 minutes was performed, aquatic fitness : aerobic training and slowdown. The intensity was prescribed based on the Borg scale score 4-6. Aerobic training was performed at intervals. The duration of aerobic fitness was started with eight 20-minute sessions , progressing to eight sessions of 30 minutes and finished with eight 40-minute sessions. Downturn : global stretching exercises , lasting 10 minutes were performed. During all sessions , the patients were instructed to breath with pursed - lip .
45628960|NCT02046070|Drug|Dexamethasone|Dexamethasone tablets
45628961|NCT04483037|Drug|Bowklean|assigned intervention
45628962|NCT01663857|Drug|LY2228820|Administered Orally
45628963|NCT01663857|Drug|Carboplatin|Administered IV
45628964|NCT01663857|Drug|Placebo|Administered Orally
45628965|NCT01663857|Drug|Gemcitabine|Administered IV
45628966|NCT02414165|Biological|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector.
45628967|NCT02414165|Drug|Toca FC|Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
45628968|NCT02414165|Drug|Lomustine|
45628969|NCT02414165|Drug|Temozolomide|
45628970|NCT02414165|Biological|Bevacizumab|
45628971|NCT02094898|Drug|Ketamine|0.3 mg/kg/hr of ketamine infused for 100 minutes
45628972|NCT04887831|Drug|Trilaciclib|Trilaciclib administered IV prior to chemotherapy and avelumab maintenance therapy on each day chemotherapy and avelumab maintenance therapy is administered.
45628973|NCT04887831|Drug|Gemcitabine|Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle
45628974|NCT04887831|Drug|Cisplatin|Cisplatin administered IV on Day 1 of each 21-day cycle
45628975|NCT04887831|Drug|Carboplatin|Carboplatin administered IV on Day 1 of each 21-day cycle
46069908|NCT04251494|Diagnostic Test|Ankle-brachial pressure index (ABPI)|A blood pressure cuff is placed around the ankle and upper arm of the participant. A continuous wave Doppler probe is used over the surface of the skin to locate the artery distal to the cuff (such as the brachial artery in the arm, or the anterior tibial and posterior tibial arteries in the ankle). The cuff is then inflated, and the systolic pressure identified by listening cessation of the sounds produced by the probe corresponding to blood flow in the artery. The ABPI is then the ratio of the highest systolic ankle pressure divided by the highest systolic brachial pressure for the left and right sides of the body.
45628976|NCT04887831|Drug|Avelumab|Avelumab will be dosed on Day 1 of each 14-day maintenance cycle
45628977|NCT02414009|Drug|Capecitabine|Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die refracted in two daily doses from day 1 to day 14 every 28 days
45628978|NCT02414009|Drug|Temozolomide|Patients in Arm A will receive temozolomide 150 mg/mq/die refracted in two daily doses starting on day 10 to 14 every 28 days.
45628979|NCT02414009|Drug|Irinotecan|Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
45628980|NCT02414009|Drug|Fluorouracil|Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
46069909|NCT04251494|Other|Diet questionnaire and diet diary|Dietary information will be collected in two formats. One will be a 14-item questionnaire (Martínez-González et al., 2012), which is a simplified version of a comprehensive food frequency questionnaire. This provides a quick measure of compliance to a Mediterranean dietary pattern and a rough measure of protective and adverse dietary factors that could affect individual CVD risk. The second will be a 3-day diet diary (3DDD). This will consist of participants recording the foods that they consume and the quantities, which will then be analysed for macro- and micronutrient composition once completed.
45628981|NCT02414009|Drug|Leucovorin|Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
45628982|NCT02413697|Device|Two-dimensional ultrasound|Two-dimensional ultrasound guided embryo transfer
45628983|NCT02413697|Device|Three-dimensional ultrasound|Three-dimensional ultrasound guided embryo transfer
45628984|NCT05521113|Behavioral|Home Rehabilitation Monitoring System|The system consists of a small activity monitor worn on the wrist and a pulse oximeter worn on the finger while exercising. Simple exercises will be completed daily and the monitors will send information to a rehabilitation coach during a 12-week period.
45769054|NCT04128098|Other|Rehabilitation care program|"Personalized global exercises (aerobics) on ergometers~Muscle strengthening with resistance~Balneotherapy~Learning health skills related to their condition (therapeutic education)~Personal and group motivational interviews~Nutritional advice~Relaxation session"
45628985|NCT05521113|Behavioral|Health coaching calls|12 telephone-based health coaching calls over a 12-week period
45628986|NCT02413853|Drug|CBP/beta-catenin Antagonist PRI-724|Given IV
45628987|NCT02413853|Biological|Bevacizumab|Given IV
45628988|NCT02413853|Drug|Leucovorin Calcium|Given IV
45628989|NCT02413853|Drug|Oxaliplatin|Given IV
45628990|NCT02413853|Drug|Fluorouracil|Given IV
45628991|NCT02413853|Other|Laboratory Biomarker Analysis|Correlative studies
45628992|NCT04977297|Behavioral|Move to Music Intervention (M2M)|The move to music (M2M) intervention pairs exercise with only music (no video), providing only audio stimulation. The intervention will be provided via an audio playlist that can be played on a phone, tablet, or computer. Each session lasts 10-15 minutes.
45628993|NCT04977297|Behavioral|Move to Music -Video (M2M-V) Intervention|The move to music video (M2M-V) intervention pairs exercise with both music and video, thus providing both audio and visual stimulation. The intervention will be provided via an audio and video playlist that can be played on a phone, tablet, or computer. Each session lasts 10-15 minutes.
45628994|NCT05515965|Other|Kinesiotaping|The mechanical correction method of taping to the Kinesiotape group was used. In rheumatoid hand patients, due to the presence of a deformity called hitchhiker's finger, the thumb is taped with 50-75% tension to create a pulling force in the direction of flexion and abduction. The application was performed with the patient in a sitting position with his arm supported by a pillow from the elbow. Evaluation parameters were evaluated before and 1 hour after the application, and the acute effect was examined. Both the dominant and nondominant hands of the patients were taped and the differences between the two hands were also examined.
45628995|NCT05515965|Other|Sham|Sham application was applied to both dominant and nondominant hands in Control Group patients. Sham taping is the bonding of I tape to the 1st finger without tension and does not contain any features. Evaluation parameters were evaluated before and 1 hour after the application, and the acute effect was examined. Both the dominant and nondominant hands of the patients were taped and the differences between the two hands were also examined.
45628996|NCT02413931|Other|Routine management practices applied|all patients will be treated according to routine procedures, no intervention
45628997|NCT04598295|Drug|DS-01|synbiotic
45628998|NCT02413619|Procedure|Vitrectomy|Vitrectomy
45628999|NCT02413619|Procedure|Cataract surgery|Cataract surgery
45629000|NCT02413619|Procedure|Combined surgery|Combined vitrectomy and cataract surgery at the same time
45629001|NCT00704483|Drug|SBR759|Starting dose of 1g or 1.5g tid, with an increase of 1g tid every 2 weeks until serum phosphate level fall below target.
45629002|NCT00704483|Drug|Sevelamer HCl|0.8 g tid
45629003|NCT00704483|Drug|SBR759|1.5 g tid
45629004|NCT00704483|Drug|Sevelamer HCl|1.6 g tid
45629005|NCT04596189|Drug|Dupilumab 300 MG in 2 ML Prefilled Syringe|"The Dupilumab will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction.~Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas), the upper thighs or the upper arms, so that the same site is not injected twice consecutively. Injection in the upper arms could be done only by a trained person (caregiver trained by Investigator or Delegate) or health care professional but not the patients themselves."
45629006|NCT04596189|Other|Placebo|"The Placebo will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction.~Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas), the upper thighs or the upper arms, so that the same site is not injected twice consecutively. Injection in the upper arms could be done only by a trained person (caregiver trained by Investigator or Delegate) or health care professional but not the patients themselves."
45629007|NCT04596189|Drug|Mometasone Furoate nasal spray|On a daily basis throughout the study, the patient will use a paper diary to record daily use of mometasone furoate nasal spray (MFNS) 50 μg/actuation nasal spray, suspension (refer to the package insert & SmPC for a description, administration details and precautions for use). MFNS is provided in a bottle that contains 18 g (140 actuations) of product formulation. If patient is unable to tolerate 200 micrograms twice a day (total dose 400 micrograms) due to experiencing adverse event, patient may reduce dose to 200 micrograms once per day.
45629008|NCT04590885|Behavioral|Couple Communication Skills Training|Participants attend six 60-minute sessions consisting of education and skills training to enhance cancer-related communication.
45629009|NCT04590885|Behavioral|Healthy Lifestyle Information|Participants attend attend six 60-minute sessions consisting of information and support across a range of cancer-related topics.
45629010|NCT03176537|Drug|Testosterone gel|Androgel (50mg testosterone), gel, daily
45629011|NCT03176537|Drug|Placebos|Placebo, gel, daily
45629012|NCT05511441|Procedure|Surgery Without Aspirin Withdraw|Routine Minimally Invasive Thoracic Surgery Without Aspirin Withdraw
45629013|NCT03176147|Other|Iron deficiency anemia|The prevalence of iron deficiency anemia is determined at T3 (after 34 SA). The predictive factors for this anemia will be sought according to the data collected in T1.
45629014|NCT05515809|Drug|parasternal block|"Echo-guided loco-regional anesthesia by bilateral parasternal block in immediate preoperative.~The drug used is Ropivacaine 2mg/ml, 0.2%. Injection of 20ml per side, under ultrasound control, after general anaesthesia and before skin incision, and therefore before surgery"
45629015|NCT05515809|Drug|Standard pain management|Standard pain management care involves a multimodal strategy that includes the use of intravenous analgesics. Morphine medications are the mainstay of pain management
45629016|NCT02413307|Other|Compassion Focused Therapy (self-practice)|Daily practice of the CFT exercises for a minimum of five minutes per day. This is completed for a period of three weeks.
45629017|NCT05515731|Biological|Autologous platelet-rich plasma (PRP) eye drops|Autologous platelet-rich plasma (PRP) eye drops are used as a sole or adjunctive therapy in many ophthalmological conditions including dry eye, macular holes, retinitis pigmentosa and perforated corneal ulcers. Actions of PRP in these conditions are attributed to the plethora of growth and healing factors concentrated in different PRP preparations.
45629018|NCT02413385|Behavioral|HealtheSteps Program|6-month evidence-based lifestyle Rx program: At set time points over the 6-month period, participants have in-person visits with a HeS coach at the clinic setting. At each in-person session, the participant receives an individualized Rx for exercise, physical activity (step count) and healthy eating. The HeS Coach and participant then engage in a coaching/goal setting conversation to set detailed plans and goals to achieve their prescriptions. Participants independently choose which activities they will take part in to achieve their lifestyle Rx's and goals. In between in-person sessions, the participants have access to a suite of free-of-charge health technology support tools to: a) track their exercise, physical activity, and healthy eating; and b) receive virtual coaching and support.
45629019|NCT05520957|Procedure|Tracheostomy|We collected data from all tracheotomised patients including age, sex, existing comorbidities, duration indicators (length of endotracheal intubation, day of tracheotomy, length of stay in the intensive care unit (ICU), and total length of hospital stay), respirator weaning marked with YES / NO. From the laboratory parameters, we analyzed: lactate, urea, creatinine, potassium and D-dimer. They were collected at two time intervals, before tracheotomy and after tracheotomy.
45629020|NCT02413541|Procedure|Polymyxin-B Hemoperfusion|Endotoxin removal
45629021|NCT02413541|Procedure|Standard treatment|
45629022|NCT04883463|Device|Epidural stimulation|Epidural electrical stimulation implant weekly sessions for 21 months.
45629023|NCT02412995|Other|Meal sequence 1-2-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
45629024|NCT02412995|Other|Meal sequence 1-3-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
45629025|NCT02412995|Other|Meal sequence 2-3-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
45935213|NCT00042185|Behavioral|Healthy Weight Intervention|In this intervention, participants were encouraged to make gradual healthy and lasting changes to their diet and physical activity to balance their energy needs with their energy intake, and thereby achieve a healthier weight and body satisfaction. With support from the facilitator and group members, they initiated an individual lifestyle change plan to reduce intake of fat and sugar and to increase exercise using behavioral modification principles. Food and exercise diaries were used to identify behaviors to target in this lifestyle modification and to monitor change. Motivational enhancement activities were used to promote motivation for behavior change.
45447465|NCT02116192|Behavioral|Experimental: Low-fructose, reduced carbohydrate diet|"Low Carbohydrate (Low Fructose and Sucrose) Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg;40-45% CHO, 20-25% Protein, 30-40% Fat)~● Aim for less than 25g fructose daily."
45447466|NCT02116192|Behavioral|General Healthy Diet|Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat
45447467|NCT04007367|Drug|SAGE-217|SAGE-217 capsule
45447468|NCT04007367|Drug|Placebo|SAGE-217 matching placebo capsule
45447469|NCT02118844|Drug|rocuronium|
45447470|NCT02116270|Biological|Blood sample|3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.
45447471|NCT02116348|Drug|Cerebrolysin (Nerve growth factor)|Cerebrolysin will be given to the intervention group
45447472|NCT02116426|Biological|Blood work in the ambulance|Blood sample for copeptin and troponin HS testing is taken during ambulance care.
45447473|NCT02116426|Biological|Blood work upon arrival in the emergency room|Blood in drawn for copeptin and troponin HS testing upon arrival in the emergency room.
45447474|NCT02116426|Biological|Blood work at 3 hours post-arrival in the emergency room|Blood is drawn for troponin HS testing 3 hours after the patient's arrival in the emergency room.
45629026|NCT02412995|Other|Meal sequence 2-1-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
45629027|NCT02412995|Other|Meal sequence 3-1-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
45629028|NCT02412995|Other|Meal sequence 3-2-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
45629029|NCT03176069|Other|Evaluation and Comparison of women pelvic floor with and without sexual dysfunction|Pelvic floor muscles will also be evaluated by electromyographic biofeedback.
45629030|NCT03176069|Other|The physiotherapeutic treatment|"The available treatment tools are educational, behavioral and rehabilitating. The physiotherapeutic treatment will consist of the following features:~Kinesiotherapy~Manual therapy~Electrotherapy (electric electrostimulation, ultrasound)~Behavioral therapy"
45629031|NCT02045836|Biological|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
45629032|NCT02045836|Biological|Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™|One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
45629033|NCT02413073|Procedure|Whole Body Vibration|We wil use vibration in patients with kidney disease
45629034|NCT02412917|Drug|FV-100|antiviral nucleoside analog
45629035|NCT02412917|Drug|valacyclovir|antiviral nucleoside analog
45629036|NCT02412683|Other|oxaliplatin|
45629037|NCT02412605|Procedure|Trophectoderm embryo biopsy|"Day 5 embryos were incubated in calcium/Magnesium free culture. A laser beam was used to produce a hole in the zona pellucida. Trophectoderm cells were collected by gentle suction using the biopsy pipette.~Florescent in situ hybridization of the trophectoderm nuclei with probes specific to the X- and Y-chromosomes was performed. the embryos were frozen and the cycles deferred.The embryos were thawed in the following cycle and if possible 2 embryos of the desired sex were transferred."
45629038|NCT04588311|Drug|Epoetin Alfa 40000 UNT/ML|Epoetin alfa 40,000IU 1mL pre-filled syringe given as subcutaneous injection.
45629039|NCT04588311|Drug|Sodium Chloride 0.9%|Sodium Chloride 0.9% 1mL in volume given as subcutaneous injection.
45629040|NCT02412527|Other|Patch III heart rate sensor|
45629041|NCT04482101|Other|Root canal obturation|Root canal filling
45629042|NCT02569437|Drug|Doxycycline|Doxycycline (200 mg PO X 1 dose on Day 1, then 100 mg PO daily) for Day 2-20
45629043|NCT02569437|Drug|methylprednisolone|oral methylprednisolone: 32 mg x 5 days, 16 mg x 5 days, 8 mg x 10 days
45629044|NCT02569437|Drug|nasal saline spray|nasal saline sprays: 2 sprays each nostril three times a day
45629045|NCT02569437|Drug|Flonase|daily nasal steroid sprays (Flonase, 2 sprays each nostril daily).
45629046|NCT02569437|Drug|sugar pill|placebo pill to match doxycycline
45447475|NCT02119000|Drug|PEG/electrolytes 2L/2L split dose|Polyethylene glycol 17gm X 4 At 18h00 the day prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes On the day of the procedure, 4-5 hours prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes
45629047|NCT02412449|Drug|AKB-6548 tablet, reference formulation given in the fasted state|
45629048|NCT02412449|Drug|AKB-6548 tablet, test formulation given in the fasted state.|
45629049|NCT02412449|Drug|AKB-6548 tablet, test formulation given in the fed state|
45629050|NCT02412293|Behavioral|Health Education & Promotion|Promotion of antenatal care, adequate nutrition, skilled delivery and healthy newborn care practices at household level.
45629051|NCT02412293|Other|Training of Health Workers|Training of health workers on recognition of danger sign that warrant referral to health care service.
45629052|NCT02412293|Behavioral|Community Mobilization|Community mobilization activities included formation of community health committees and creation of support for the uptake of the interventions.
45629053|NCT05515263|Dietary Supplement|Intervention snack|To be eaten in replacement of usual snacks twice a day for 8 weeks.
45629054|NCT05515263|Dietary Supplement|Control snack|To be eaten in replacement of usual snacks twice a day for 8 weeks.
45629055|NCT02412059|Drug|Prednisolone acetate|
45629056|NCT02045212|Drug|RPh201|SC injection twice a week during 13/26 weeks
45769055|NCT05500872|Other|Cross-education and blood flow restriction training|Cross-education (training of the non-surgical leg) will be given to the participants in addition to the standard rehabilitation program after surgery. This training will be applied with isokinetic system that can be used safely in the rehabilitation field. During this training, a cuff will be worn from the upper part of the thigh muscles, as in the blood pressure devices, which will slow down the blood flow in the leg. The participant will be cross-educated with the cuff inflated to a safe pressure range that will not cause discomfort. Participants will be included in the training for a total of 16 sessions, 2 days a week for 8 weeks. Each session, cross-education will be applied as 3 sets of 12 repetitions. Pain, muscle strength, muscle thickness, knee functions will be evaluated before and after the training.
45769056|NCT05500872|Other|Cross-education|Cross-education (training of the non-surgical leg) will be given to the participants in addition to the standard rehabilitation program after surgery. This training will be applied with isokinetic system that can be used safely in the rehabilitation field. Participants will be included in the training for a total of 16 sessions, 2 days a week for 8 weeks. Each session, cross-education will be applied as 3 sets of 12 repetitions. Pain, muscle strength, muscle thickness, knee functions will be evaluated before and after the training.
45629057|NCT02045212|Drug|Placebo|SC injection twice a week during 13/26 weeks
45629058|NCT02412215|Procedure|Phacoemulsification with toric Nanoflex IOL implantation|A self-sealing incision is made with a 2.2mm knife at 110°. Phacoemulsification is performed. The foldable nanoFlex toric IOL is injected in the capsular bag using the nanoPoint single-use injector system (STAAR) or 1620 sofTip Injector (ASICO). The IOL is rotated to align the cylinder axis with the steep corneal meridian using Z align function by Callisto Eye. Every movement of the IOL axis marks are noted.
45629059|NCT02412215|Device|NanoFlex toric Intraocular Lens|
45629060|NCT05090475|Behavioral|Educational outreach intervention|Educational outreach or academic detailing is a method based on scientific data with the help of educated A-team members in the form of direct (face-to-face) interactions, prescribing practices change and adherence improves according to the application of currently valid therapeutic guidelines
45629061|NCT02412137|Other|Counseled cohort|This group will be counseled after brace temperature/date/time data is logged at each visit.
45629062|NCT03175991|Diagnostic Test|ultrasonography|"A morphologic evaluation will be performed according to International Ovarian Tumor Analysis Group recommendations for the following parameters:~Bilaterality , wall thickness, septations , papillary projections, solid areas, and echogenicity. The presence of ascites also will be recorded. Pattern recognition analysis will be used for ovarian masses highly suggestive of some diseases , then color Doppler will be activated to identify vascular color signals within the lesion."
45629063|NCT05090085|Other|3M Scotchbond Universal Plus|Universal adhesive system
45629064|NCT05090085|Other|Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)|Composite Resin
45629065|NCT05090085|Other|3m ESPE etch|32% phosphoric acid
45629066|NCT05090085|Other|OT Primer|Dimethyl Sulfoxide DMSO [(CH3)2SO] is a polar aprotic solvent that dissolves both polar and non-polar compounds.
45769057|NCT04127552|Procedure|Adrenalectomy|Adrenalectomy accordint to 2016 ESE guidelines
45629067|NCT03175679|Biological|iNKT cells|"Three different dosing schedules will be evaluated. Three patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~Loading Dose 1: 3x10^7/m2 Loading Dose 2: 6x10^7/m2 Loading Dose 3: 9x10^7/m2 The doses are calculated according to the actual number of iNKT cells."
45629068|NCT03175679|Drug|IL-2|IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days.
45629069|NCT03175679|Drug|Tegafur|Tegafur will be given at a dose of 40~60 mg bis in die (BID) 2 weeks.
45629070|NCT05520645|Drug|etomidate|use etomidate for anesthesia induction in hysteroscopic surgery
45629071|NCT05520645|Drug|propofol|use propofol for anesthesia induction in hysteroscopic surgery
45769058|NCT05500794|Other|MBSR (Mindfulness-Based Stress Reduction)|"MBSR (Mindfulness-Based Stress reduction) program : 1 weekly session of 2 hours and a half for 8 weeks, (first and last session: 3 hours) and an optional day of intensive practice of 6 hours, supervised by an MBSR instructor.~In each weekly session, the instructor creates a supportive environment in which:~Guided meditation practices;~Mindfulness stretching and yoga;~Reflection and group discussion periods aimed at promoting mindfulness in daily life;~Practice instructions and opportunity to ask questions;~Instructions for home practice. Audio recordings and a manual are provided to support personal practice.~Audio recordings and a manual are provided to support personal practice"
45629072|NCT03175757|Dietary Supplement|Turmeric and Black Cumin Seed|Turmeric and Black Cumin Seed formulation
45769059|NCT00981227|Drug|Eslicarbazepine acetate|Scored tablets
45629073|NCT03175757|Dietary Supplement|Placebo|Placebo
45629074|NCT04974099|Device|RoadMAB|The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.
45629075|NCT04974099|Drug|Precision dosing with a dashboard|The trial is testing whether precision dosing can more reliably achieve the targeted trough concentrations compared to standard dosing
45629076|NCT03175835|Drug|Rosuvastatin 20 mg|Treatment A: Rosuvastatin 20 mg(20 mg X 1 tablet) for Day1~Day5
45629077|NCT03175835|Drug|CKD-519 200 mg|Treatment B: CKD-519 200 mg(100 mg X 2 tablets) for Day9~Day21
45629078|NCT03175835|Drug|Rosuvastatin 20 mg & CKD-519 200 mg|Treatment C: Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets) for Day22~Day26
45769060|NCT00981227|Drug|Placebo|oral route
45769061|NCT04121858|Other|Brain Safe App|The Brain Safe app includes the medication list, a personalized risk calculator, multimedia educational content, and a conversation starter/doctor's report.
45769062|NCT04121858|Other|Attention Control App|The attention control app, called Med Safe, includes only the medication list feature.
45769063|NCT05505708|Drug|hydroxyethyl starch in sodium chloride injection Brand Name: Voluven|"(6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is a clear to slightly opalescent, colorless to slightly yellow, sterile, non-pyrogenic, isotonic solution for intravenous administration using sterile equipment.~Each 100 mL of the solution contains: 6 g of Hydroxyethyl Starch 130/0.4 and 900 mg of Sodium Chloride USP in Water for Injection USP.~In addition, sodium hydroxide, USP, or Hydrochloric acid, USP, has been added to adjust the final pH so the final solution pH is 4.0 to 5.5."
45769064|NCT05505708|Drug|saline solution|Within each 100 mL of 0.9% sodium chloride Injection USP, there is 15.4 mEq of sodium ions and 15.4 mEq of chloride ions. Additionally, the osmolarity is 308 mOsmol/liter, and it has a pH range of 4.5 to 7
46069910|NCT04251494|Other|Routine blood samples|Blood samples will be taken from participants during their outpatient appointment. Patients routinely have blood samples taken during this clinic. The study will use the results from the routine blood tests, and also extra blood samples to collect data on other biomarkers. The laboratory facilities at Guy's and St Thomas Hospitals will be used to conduct analysis, no other laboratories will be used. Data will be collected on Phenylalanine levels, lipids, vitamin B12 and related biomarkers.
45629079|NCT05515185|Drug|KT095 CAR-T injection|Clearance of lymphocytes
45629080|NCT02044822|Drug|Idelalisib|150 mg tablets administered orally twice daily
45629081|NCT02044822|Drug|Rituximab|375 mg/m^2 administered intravenously once weekly x 8 weeks
45629082|NCT05511051|Drug|Fruquintinib|Fruquintinib
45629083|NCT05511051|Drug|HAIC|HAIC
45629084|NCT03116555|Drug|Apatinib|Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
45629085|NCT03116555|Drug|Irinotecan|Irinotecan was used as second line treatment with AGC
45629086|NCT03175913|Device|vapocoolant spray|As a topical pre caudal epidural block anesthesia, spinal needle insertion site was sprayed using an vapocoolant spray for 10-sec from a distance of 30 cm
45629087|NCT03175913|Drug|local infiltration|As a topical pre caudal epidural block anesthesia, spinal needle insertion site was injected subcutaneously using 3ml of 2% lidocaine
45769065|NCT04525794|Device|BRight DCB|The BRight Drug-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon catheter (BRight DCB) is intended for dilatation of de novo lesions in native superficial femoral or popliteal arteries with a simultaneous release of drug to the vessel wall as a secondary action to reduce occurrence of a restenosis of the treated vessel segment.
45769066|NCT00981305|Drug|Lactate-containing vaginal lubricant|vaginal applying at least 3cc of lactate-containing lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
45769067|NCT00981305|Drug|Placebo vaginal lubricant|vaginal applying at least 3cc of placebo lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
45769068|NCT03827174|Other|Return To Work Coordination|External and internal coordination regarding sick leave. Establishment of a common return to work plan between employer och employee.
46069911|NCT05286164|Drug|Eltrombopag|Eltrombopag 150 mg QD for 8 weeks
45629088|NCT03175445|Other|CBCT scan by planmeca promax|software measurement tool of CBCT
45629089|NCT02044510|Drug|Mirabegron|Mirabegron 25mg PO daily for 2 weeks, with dose increase to Mirabegron 50mg PO daily for the remaining 8 weeks.
45629090|NCT02044510|Drug|Placebo|Matched placebo capsules to the intervention arm
45629091|NCT02411981|Other|Autogenic drainage|
45629092|NCT02411903|Drug|atorvastatin and clopidogrel|Dose: atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months.
45629093|NCT02411903|Drug|rosuvastatin and clopidogrel|Dose: rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months.
45629094|NCT02411669|Other|Operational patient centered care tools|"The FORAP (Fédération des Organismes Régionaux et territoriaux pour l'Amélioration des Pratiques et des organisations) and the la HAS (High Authority of Health) have developed and validated five tools promoting patient centered care at hospital.~They can be implemented one by one or in association according to hospital situation. Hospitals should identify the association of tools fitting the most to their objectives and the actions already done."
45629095|NCT02411825|Drug|SAR425899|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
45629096|NCT02411825|Drug|placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
45629097|NCT02411825|Drug|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
45629098|NCT02411513|Device|CEFALY|
45629099|NCT02411435|Drug|CAB|CAB 30 mg as 1 tablet will be administered orally with 240 mL of water in the fasted state.
45629100|NCT02411435|Drug|RIF|RIF 600 mg as 2 capsules of 300 mg will be administered orally with 240 mL of water in the fasted state.
45629101|NCT05520489|Device|Repetitive Transcranial Magnetic stimulation|"Participants received 15 sessions (15 daily session - Monday to Friday) of active rTMS over the 'hotspot M1 area of the unaffected hemisphere leading to a response in the contralateral thenar muscle using Visor2-navigation system and MagstimRapid -magnetic stimulator. . Hot spot localization was performed by stimulation with 50%:n intensity and found the maximum response area, where the coil was placed using the navigator cursor. The motor threshold was found using Maximum-Likelihood Strategy -algorithm of MTAT system.~Low frequency rTMS was applied at 80-90% resting motor threshold (rMT) intensity, 1 Hz, 600+600 pulses, inbetween 10 minutes break. Intensity was increased after each 2-3 treatment to keep motor threshold 90%."
45769069|NCT03827174|Behavioral|Behaviour Change Ability Program|"Return to work coordination~Education for employers and employees in pain neuroscience, validation and problem-solving.~Patient-specific goal setting for return to work~Exercise and behavioural skills training related to return to work"
45769070|NCT04525404|Diagnostic Test|MRI (heart, brain, lungs, liver)|MRI (heart, brain, lungs, liver)
45769071|NCT04525404|Diagnostic Test|Bloodwork|Serum biomarkers to assess systemic inflammation, renal function, cardiac injury, liver injury and steatosis, ACE-2 related peptides, cytokines, Activin A and autoantibodies to cardiac antigens, humoral cell RNA
45769072|NCT04525404|Other|Cognitive testing|NIH toolbox Cognitive Measures
45769073|NCT04525404|Other|Olfaction testing|Brief Smell Identification Test (BSIT)
45629102|NCT05520489|Device|Robot Assisted Therapy|"This was delivered using the Diego and Pablo (Tyromotion GmBH) robotic gym system. Participants receive robot-assisted training for up to 60 min per day, four days per week for 3 weeks, in addition to usual care. Robotic devices enable 3D interactive exercising, using weight reducing system in Diego and fine motor training in Pablo. Exercises can be one- or two-handed and/or symmetrical. Patient performs 150-400 repetitions in one therapy session. Estimated time is 2-3 minutes per one exercise section. Standard minimum program includes 4 games: swimming, shooting, ship and apple orchard. The therapist instructs the patient and assure the position of trunk and shoulder girdle."
45629103|NCT05520489|Other|Enhanced upper limb therapy programme|Exercises were performed by using different objects for task orientated movements. The therapist provided assistance as needed and encouraged participants to complete the tasks. Training was divided to 3 sessions for fine motor training and complex training and 1 session for shoulder girdle and complex training per week for 3 weeks, in addition to usual care. Each session lasts 1 hour and estimated time is 2-5 min to each exercise section.
45629104|NCT02411279|Other|Equiped group with telemedicine systems|
45629105|NCT02411123|Genetic|IDgenetix Neuropsychiatric Test Panel|The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
45629106|NCT05510817|Other|Multiparametric assessment|neuropsychological assessment, PRO measures, non-conventional MRI metrics
45769074|NCT04525404|Diagnostic Test|Spirometry|Spirometry to evaluate forced expiratory volume in 1 second and forced vital capacity
45769075|NCT04525404|Other|Walk Test|Walk test to record overall distance walked in 6 minutes and time taken to walk the first 25 feet
45769076|NCT04127708|Biological|acupuncture|acupuncture group and control group
45769077|NCT02246231|Device|MR imaging|
45769078|NCT04125368|Behavioral|Health Facility Interventions|"Intensified counselling on dietary diversity and increased meal frequency during pregnancy.~Strengthened government distribution of IFA supplies with counseling about its importance, managing side effects, and reminder about subsequent supplies.~Weight-gain monitoring with messaging to mothers about healthy diet and adequate rest; excess weight gain as a danger sign.~Intensified counseling on importance, benefits, and how-tos of early initiation of breastfeeding and exclusive breastfeeding."
45769079|NCT04125368|Behavioral|Community Interventions|"Home visits to pregnant women by HEWs to discuss maternal nutrition (dietary diversity, adequate food intake, IFA supplementation, and weight gain), early breastfeeding practices, provide ANC and Pregnant Women Conference referrals, and engage husbands.~HEWs use A&T intervention tools (e.g. posters and maternal nutrition follow-up card) at Pregnant Women Conferences/ Mother Support Groups to reinforce maternal nutrition messages, encourage ANC attendance, distribute IFA tablets, measure and track weight gain, promote early breastfeeding practices, and encourage husband participation.~HEWs and community volunteers (Women's Development Army (WDA), imams, etc.) deliver maternal nutrition messages and encourage ANC visits at kebele and community meetings."
45629107|NCT03175289|Other|Best Practice|Undergo therapy session conducted by a speech pathologist
45629108|NCT03175289|Other|Educational Intervention|Receive standard of care patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus
45629109|NCT03175289|Other|Exercise Intervention|Perform prescribed home exercises
45629110|NCT03175289|Other|Expiratory Muscle Strength Training|Participate in EMST
45629111|NCT03175289|Other|Quality-of-Life Assessment|Ancillary studies
45629112|NCT03175289|Other|Questionnaire Administration|Ancillary studies
45769080|NCT04125368|Behavioral|Health System Interventions|"Trainings on the maternal nutrition interventions for health center heads, nurse-midwives, HEWs, community volunteers (WDA, imams, etc.), woreda health officers, and other key actors.~Supportive supervision of maternal nutrition activities conducted by woreda nutrition officers, woreda health officers, TDA or A&T."
45769081|NCT01022567|Procedure|Appendicectomy|Standard appendicectomy
45769082|NCT01022567|Drug|Ertapenem|ertapenem 1g x 1 i.v.for three days + after discharge levofloxacin 500 mg 1 x 1 + metronidazole 500 mg 1x3 for 7 days p.o.
45769083|NCT03831308|Diagnostic Test|clinical and physical assessment|information will be collected on fitness status, lifestyle, cognitive and psychological status, bone's health and quality of life
45769084|NCT05505474|Device|IVF with the Neria™ Guard Subcutaneous Catheter|Use of the Neria™ Guard subcutaneous catheter for administration of subcutaneous medication in an IVF cycle.
45769085|NCT03827096|Drug|Suspension of human autologous MSC 3P in 1.5 ml|During the posterolateral spine fusion operation, 1.5 ml of cell suspension was mixed with 5cc of beta-tricalcium phosphate foam and 3.5 ml of patient's blood, and inserted between the right transverse processes of the lumbar spine.
45769086|NCT04411524|Drug|PD-1 antibody|Before neo-CRT: 2 cycles of PD-1 antibody After neo-CRT: 3 cycles of PD-1 antibody
45769087|NCT04411524|Drug|Capecitabine|During neo-CRT: 625mg/m2 bid Monday-Friday per week
45629113|NCT02411045|Behavioral|Take and send a selfie|Direction to take and send a selfie.
45629114|NCT02411045|Behavioral|Workout gears|Direction to wear workout gears.
45629115|NCT02411045|Behavioral|Exercise|Direction to complete a 30 minute workout.
45629116|NCT02410889|Other|EEG-fMRI scanning|Patients undergo EEG-fMRI scanning
45629117|NCT03175211|Drug|BI 456906|single dose
45629118|NCT03175211|Drug|Placebo|single dose
45629119|NCT03175055|Device|Phoenix|The study to assess safety and efficacy of Phoenix medical exoskeleton.
45629120|NCT03174977|Drug|18F-Raltegravir|A single microdose of 18F-Raltegravir will be given to individuals currently being treated for HIV-1 with antiretroviral therapy.
45629121|NCT03174899|Radiation|Diffusion weighted magnetic resonance imaging|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient.
45629122|NCT05514405|Drug|Remimazolam (Byfavo)|Remimazolam is continuously infused based on bispectral index (within 40-60).
45629123|NCT05514405|Drug|Propofol|Propofol is continuously infused based on bispectral index (within 40-60).
45629124|NCT03175133|Other|Strength exercise|Strengthening exercises performed with physical therapist.
45629125|NCT05514327|Radiation|ultra-fraction radiotherapy|the R/R DLBCL patients would receive ultra-fraction radiotherapy as bridging therapy before the CD19 CART cell infusion
45629126|NCT02410655|Drug|Oxytocin|500 mL bag of oxytocin (30 IU / 500 mL) to be connected to the IV, and controlled at the obstetricians request. Up to two, 50 mL rapid infusion boluses to be given after delivery of anterior shoulder. Upon completing the bolus(es) flow rate should be continued at 100 mL / hour. This should total no more than 4.5 hours.
45629127|NCT02410655|Drug|Oxytocin|A total of two 1000 mL bags of oxytocin (20 IU/ 1000 mL) are to be connected to the IV sequentially, and controlled at the obstetricians request, are each to be administered over 8 hours after delivery of anterior shoulder in vaginal delivery. This will total 16 hours of oxytocin infusion.
45629128|NCT05070351|Drug|PPI deprescribing|Patients currently on a proton pump inhibitor (PPI) undergoing transjugular intrahepatic portosystemic shunt (TIPS) creation as part of routine clinical care will be randomized to receive instructions to stop taking their PPI.
45629129|NCT02410499|Drug|MLN1202 Placebo|MLN1202 placebo-matching solution for SC injection
45629130|NCT02410499|Drug|MLN1202|MLN1202 solution for SC injection
45769088|NCT04411524|Drug|Irinotecan|During neo-CRT: 80mg/m2 qw (UGT1A1*28 6/6) or 65mg/m2 qw (UGT1A1*28 6/7)
45769089|NCT04411524|Radiation|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
45769090|NCT02983916|Procedure|Adhesiolysis|Diagnostic laparoscopy or laparotomy with lysis of adhesions.
45629131|NCT04859127|Other|effects of neck pain|Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology, questioning of the status of the inquiry Neck Disability Survey, stars in the evaluation of balance dynamic balance test, stand on one leg Test in the evaluation of static balance, dynamic balance and physical performance Term rise and walk test, gait speed for the assessment of the 10-meter walk test and dual-task for the evaluation of the motor-the motor and motor-Cognitive dual-task will be used for the evaluation.
45629132|NCT02410421|Procedure|Functional magnetic resonance imaging used to individualize rTMS protocol using robotic coil positioning|
45629133|NCT05514249|Drug|CRD-TMH-001|Participant will receive a single dose of CRD-TMH-001 administered via intravenous injection.
45629134|NCT05510505|Drug|CD20 monoclonal antibody|"4.2 Conditioning Regimen~4.2.1 Matched sibling donor~ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d ~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d ~ -3d）+ ATG 2.5mg/kg/d×5d（-8d ~ -4d）~ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d ~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d ~ -3d）+ ATG 2.5mg/kg/d×5d（-8d ~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor~ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d ~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d ~ -2d）+ ATG 2.5mg/kg/d×4d（-5d ~ -2d）~ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d ~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d ~ -2d）+ ATG 2.5mg/kg/d×4d（-5d ~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d"
45629135|NCT05510505|Drug|ATG|"4.2 Conditioning Regimen~4.2.1 Matched sibling donor~ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d ~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d ~ -3d）+ ATG 2.5mg/kg/d×5d（-8d ~ -4d）~ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d ~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d ~ -3d）+ ATG 2.5mg/kg/d×5d（-8d ~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor~ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d ~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d ~ -2d）+ ATG 2.5mg/kg/d×4d（-5d ~ -2d）~ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d ~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d ~ -2d）+ ATG 2.5mg/kg/d×4d（-5d ~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d"
45629136|NCT05514171|Procedure|Neoadyuvant therapy|Patients of group neoadyuvant therapy will receive any chemotherapy treatment before surgery
45629137|NCT04987775|Drug|N-Acetyl Cysteine|900mg 2x daily
45629138|NCT04987775|Drug|Placebo|Matching placebo bid
45629139|NCT05514093|Device|Beyond Silence app|"The Beyond Silence app is designed to be a mental health coach in your pocket for healthcare workers. It provides opportunities to build mental health literacy and reduce barriers to seeking support, including access to peer support either within or outside the organization."
45629140|NCT04987385|Dietary Supplement|Protein supplementation|Patients will receive a box with 7 sealable of 90-gram protein containers that will be dissolved in maximal 1L liquid (i.e., water or milk) that should be integrated in the usual daily hydration volume documented at baseline and taken daily for the following 7 days, while keeping their usual meal composition and usual fluid intake. A wash-out period of minimum 7 days between Protein supplementation and Oral urea will be performed.
45629141|NCT04987385|Dietary Supplement|Oral urea|Patients will receive a box with 7 30-grams urea sealable containers. The total daily oral urea dosage of 30 grams that will be dissolved in maximal 1L of a liquid of choice (water, milk, juice, …) that should be integrated in the usual daily hydration volume documented at baseline and taken daily for the following 7 days, while keeping their usual meal composition and usual fluid intake.
45629142|NCT05510349|Other|Sonographic measure of placental elasticity and viscosity|Sonographic measure of placental elasticity and viscosity
45629143|NCT05514015|Drug|Rituximab|"Induction therapy:~Rituximab iv infusion 1g, d1, d15, additional glucocorticoid treatment, oral methylprednisolone, initial dose 0.5mg/(KGD), once a day, after 8 weeks of treatment, reduced by 5mg every 2~4 weeks, until 0.25mg/kg, this dose was maintained for 8 weeks, then reduced by 2.5mg every 2~4 weeks, until drug withdrawal, The course of treatment was about 24 weeks; Maintenance therapy after 6 months Patients who achieved CR did not need maintenance therapy; Patients whose 24-hour proteinuria decreased by >25% but did not achieve CR were given an additional course of rituximab 1g, D1, D15 (independent of CD19+ cell count).~Patients whose 24-hour proteinuria decreased less than 25% did not need to continue drug treatment, and were considered as treatment failure and withdrawn from the trial."
45769091|NCT05500638|Behavioral|Virtual Reality|At this stage, trainings were given for epileptic seizures. Parents were asked to wear SG glasses and they were trained on the correct approach to seizures over the Focal to bilateral tonic-clonic seizure scenario integrated into the SG glasses. The clinic and process of focal to bilateral tonic-clonic seizure and the training of what to do and not to do during the seizure were given again through SG glasses. Parents interfered with the patient scenario many times during their free work time and had the chance to interfere with the seizure again and again by restarting the seizure.
45769092|NCT04127396|Drug|Lenvatinib Pill|Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles. Body weight (BW)>60 kilograms(kg)-Lenvatinib 12 mg (taken as three 4-mg capsules); BW<60kg-Lenvatinib 8 mg (taken as two 4-mg capsules)
45769093|NCT04127396|Procedure|Transarterial chemoembolization(TACE)|TACE will be performed one day after oral administration of lenvatinib . TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.
45629144|NCT05514015|Drug|Cyclophosphamide|"Control group (treated with Italian protocol, namely cyclophosphamide-steroid alternating cycle treatment) :~- Treatment regimen: Methylprednisolone 0.5-1.0 g/d was given intravenously for the first 3 days of month 1, 3, and 5, followed by oral prednisone 0.5mg/(kg·d) for 27 days, and cyclophosphamide 2.0mg/(kg·d) for 30 days at month 2, 4, and 6.~-Maintenance therapy after 6 months: Patients who achieved CR or whose 24h urinary protein decreased by >25% but did not achieve CR did not need maintenance treatment, and were followed up.~Patients with 24h proteinuria decreased less than 25% did not need to continue to use drugs, and were considered as treatment failure and withdrawn from the trial."
45629145|NCT03174821|Device|Insulin pump|Blood glucose management device
45629146|NCT05520021|Drug|Nifedipine|A total of 30 pregnancies with preterm labor threats will be treated with Nifedipine.
45629147|NCT05520021|Drug|Magnesium sulfate|A total of 30 pregnancies with preterm labor threats will be treated with Magnesium sulfate.
45629148|NCT02410031|Drug|Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)|Cyproterone acetate 2mg/ethinylestradiol 35 μg
45629149|NCT05510271|Other|White Noise|"Orhan OSMAN's song Don't Let Your Baby Cry-2 from the Kolik album was used."
45629150|NCT05510271|Other|Yakson Touch|In order to transfer the Ki energy to the baby, he took a deep breath and gathered the universal energy in his palms, intending the baby's well-being and healing. The researcher applied the Yakson touch by covering the abdomen and chest of the newborn with his right hand (dominant hand) while the newborn was in the supine position, and supported the baby's back and hips with his left hand.
45629151|NCT02410109|Behavioral|SCRIPT integrated model|Perinatal women will be screened for psychosocial risks at time of home visiting enrollment. Women exhibiting elevated depressive symptoms and/or have a history of clinical depression who are not currently clinically depressed will be referred for depression prevention services. Women experiencing a depressive episode will be referred for group CBT. Women who screen positive for elevated anxiety symptoms, PTSD symptoms, intimate partner violence, or substance abuse will be referred to a mental health or social service agencies. If a client is referred for services, the assessment worker will provide written educational materials about the risk factor that is being addressed through the referral. At the first home visit, the home visitor will discuss these educational materials.
45629152|NCT04939701|Drug|ASP0739|Intravenous (IV)
45769094|NCT04127396|Drug|Sorafenib|Sorafenib capsules will be administered orally, 400 mg twice daily (BID) oral dosing.
45769095|NCT04127396|Procedure|Transarterial chemoembolization(TACE)|TACE will be performed one day after oral administration of Sorafenib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.
45769096|NCT04284540|Radiation|Adjuvant hypofractionation|15 fractions of 2.7 Gy per fraction daily over 3 weeks for a total of 40.5 Gy to the post-operative bed and/or necks.
45769097|NCT04284540|Radiation|Definitive Hypofractionation|15 fractions of 3 Gy per fraction daily over 3 weeks for a total of 45 Gy to regions of gross disease. Elective areas can be treated to 37.5 Gy in 15 fractions.
45769098|NCT04289376|Other|Gaze tracking - no intervention|Monitor gaze as subjects watch a video
45769099|NCT04120064|Drug|Cholecalciferol|Large, one time dose of 300,000 IU oral cholecalciferol or daily 5,000 IU oral cholecalciferol
45769100|NCT04127630|Procedure|mobilization of the larynx|we aim to asses with an magnetic resonance imaging the compressibility of the oesophagus with LPEC
45769101|NCT00982007|Drug|Ferric Carboxymaltose (FCM)|A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
45769102|NCT00982007|Drug|Ferrous Sulfate Tablets|325 mg Ferrous Sulfate tablets taken orally three times a day
45769103|NCT00982007|Drug|IV Iron (standard of care)|IV standard of care (other IV iron) per the Investigator's discretion
45769104|NCT00982007|Drug|Ferric Carboxymaltose (FCM)|A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
45769105|NCT04274582|Dietary Supplement|chokeberry extract|The players received 30 mL of liquid chokeberry extract, in the morning before training, once per day for 12 weeks.
45769106|NCT05500482|Biological|Typhoid conjugate Vaccine|TyphiBEV is a clear colourless monovalent vaccine containing 25 µg of Typhoid Vi polysaccharide manufactured using the Citrobacter freundii sensu lato3056 (Vi) and is conjugated to CRM 197 as a carrier protein. Sodium chloride and Phosphate buffer are used as a buffering agent in the vaccine formulation with 2-Phenoxyethanol as a preservative.
45769107|NCT04274348|Other|Skin biopsies and blood samples|Two skin biopsies and 30 ml of blood will be collected.
45935214|NCT00042185|Behavioral|Expressive Writing Control Condition|In this condition, which is based on the work of Pennebaker (1997), participants wrote about emotionally significant topics in three individual weekly 45-minute sessions. They were told that research indicates that body dissatisfaction is linked to emotional issues and that expressive writing helps resolve these issues. Sample topics included relationships or goals. They were told that their work would not be read and were asked to write continuously for the duration of the session about an emotionally important topic.
45935215|NCT00219076|Drug|aliskiren|
45629153|NCT04939701|Drug|Pembrolizumab|Intravenous (IV)
45629154|NCT02410187|Radiation|SBRT|10 Gy x 3 - 20 Gy x 3 (BED 60Gy-180 Gy) or 8 Gy x 4 - 17 Gy x 4 (BED 58-184 Gy)
45629155|NCT02410187|Drug|systemic therapy (chemotherapy, hormon therapy, target therapy etc)|"Physicians can choose all the options available chemotherapy, hormon therapy, target therapy etc.~Use of chemotherapy schemes containing potent enhancers of radiation damage (e.g. gemcitabine,adriamycin) are discouraged within the first month after SBRT."
45629156|NCT02410187|Radiation|palliative RT|fraction size of RT = < 3 Gy
45629157|NCT02410265|Behavioral|Lantern: Guided self-help program|"Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call."
45769108|NCT04825548|Other|No intervention|Examination of patients with previous DVT
45769109|NCT03826862|Radiation|CT three-dimensional reconstruction|All patients will receive CT three dimensional reconstruction before surgery
45935216|NCT00219115|Drug|aliskiren|
45629158|NCT02410265|Behavioral|Mental Health Online: Self-help program|Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
45629159|NCT05055453|Device|MyPhonak Junior App|The primary objective is to evaluate the effects on speech intelligibility of resulting from the changes that children and adolescents (aged 7 to 17 years) make to the volume control, directionality and noise reduction of the hearing of the hearing aids using the myPhonak app. First, in a controlled laboratory environment under the guidance of the principal investigator is tested. Then, using sound scenarios, the child is allowed to try out two programs with the aid of using the app and the volume control, respectively. After this, the speech comprehension of sentences in noise is tested in the individual programs using the Oldenburg Sentence Test (OLSA).
45629160|NCT02409953|Other|Lying in a bath during 2 hours|
45629161|NCT02409953|Other|Lying in a bed during 2 hours|
45629162|NCT04842981|Drug|Tocilizumab|Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
45629163|NCT04842981|Drug|Sarilumab|Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
45629164|NCT03174587|Biological|allogenic bone marrow derived mesenchymal stem cells|Step -1 dose : 1.0x10^6cells/kg Step 1 dose : 2.0x10^6cells/kg Step 2 dose : 3.0x10^6cells/kg The single injection of CS20AT04 Inj. in the peripheral veins.(IV) The duration of follow up study following the single dose of CS20AT04 is 28 days
45629165|NCT05049837|Other|Group Specific Aim 1|600 cases: two normal and two tumor formalin-fixed tissue samples
45769110|NCT04818294|Device|Pain treatment by electrostatic charge to the whole body|"Study Type is Observational as participants in the study receive therapeutic interventions in the therapy cabin as part of routine medical care and a researcher studies the effect of the intervention.~The study includes all persons who are already receiving therapy in the mentioned facilities, no external, specifically selected persons, but existing patients suffering from chronic pain who meet the specified conditions.~The therapy aims to alleviate chronic pain by applying an electrostatic charge of 50'000 Volt to the whole body in the special, electrically insulated cabin. The treatment is done upon the instructions of a physician. It is done with the patient standing up in the treatment cabin. The person is charged and discharged several times over the course of 2x 4 minutes. The charge can be felt on the skin and it can be seen through bristling of the hairs on the body. This treatment is repeated once a week."
45769111|NCT04346732|Other|Vapocoolant spray|Vapocoolant spray
45769112|NCT04814940|Other|MENOPUR Cohort|"Non-interventional~All directions for medication usage were solely at the discretion of the investigator in accordance with their usual routine clinical practice and are assumed to be consistent with the national prescribing information of the medicinal product in the country in which the study take place."
45769113|NCT03826784|Combination Product|BHA|BHA active ingredients include a blood-derived component and beta-tricalcium phosphate. It is applied directly to the bone fracture and nearby viable bone at the time of wound closure.
45769114|NCT05042934|Procedure|Fine-Needle Aspiration|Undergo fine-needle aspiration
45769115|NCT05042934|Drug|Irinotecan|Given IV
45913166|NCT02019043|Other|Syphilis testing with routine HIV bloodwork|The intervention condition will be implemented as standing orders for syphilis serology whenever patients undergo their standard battery of follow-up bloodwork, i.e., when there is an order for HIV viral load or CD4 cell count. It is standard practice for HIV patients to undergo such tests every 3-6 months. We anticipate that the change in practice will be straightforward, involving minimal training of clinic staff. Team members who are physicians at these clinics will guide the specific approach that will be appropriate and sustainable for their setting. Options are quite simple. They include pre-printing a checkmark for 'syphilis serology' onto existing pre-printed requisitions for routine bloodwork; addition of the serology request form to the routine blood work package; or programming 'syphilis serology' into existing computerized routine order sets.
45913167|NCT02019056|Drug|Placebo /bid P.O|
45629166|NCT05049837|Other|Group Specific Aim 2|600 cases: two normal and two tumor formalin-fixed tissue samples.
45629167|NCT05049837|Other|Group Specific Aim 3|600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples
45629168|NCT05049837|Other|Group Specific Aim 4|600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples
45629169|NCT05049837|Other|Group Specific Aim 5|600 cases; two normal and two tumor formalin-fixed tissue samples
45769116|NCT05042934|Drug|Irinotecan Hydrochloride|Given IV
45769117|NCT05042934|Drug|Lurbinectedin|Given IV
45769118|NCT02983526|Device|Total hip replacement (2 different designs)|Patients will randomly receive either CFP or Corail stem
45769119|NCT05505006|Drug|Ferric Carboxymaltose Injection|Anemic patients with ID will receive i.v. iron. Dosage will be based on Hb level and patient body weight.
45769120|NCT05505006|Drug|Folic acid|Anemic patients with folate deficiency will receive folic acid 5 mg per day for 1 month
45769121|NCT05505006|Drug|B12|Anemic patients with B12 deficiency will receive B vitamin complex 1 tablet per day for 1 month
45769122|NCT03826706|Device|C-MAC Videolaryngoscope D blade|C-MAC videolaryngoscope D blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
45629170|NCT05049837|Other|Group Specific Aim 6|210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.
45769123|NCT03826706|Device|McGrath MAC Videolaryngoscope X3 blade|McGrath MAC videolaryngoscope X blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with McGrath MAC videolaryngoscope.
45769124|NCT05509920|Other|S-PRG barrier coat|S-PRG filler was the best composition of compressive strength and F- and B release acid buffering capacity. It was found to be the most promising for use as a novel cement.
45629171|NCT03174509|Procedure|Positive pressure extubation|Positive pressure ventilation without endotracheal aspiration/suction during extubation procedure.
45629172|NCT03174509|Procedure|Traditional during extubation|Spontaneous ventilation with endotracheal aspiration/suction during extubation procedure.
45629173|NCT05513625|Drug|Pritelivir|oral administration
45629174|NCT05513625|Drug|ESO and pritelivir|oral administration
45769125|NCT04392518|Other|exercise|Breathing, posture, dynamic core stabilization, upper and lower extremity strengthening exercises.
45769126|NCT05509764|Diagnostic Test|lung ultrasound score|determination of atelectasis by lung ultrasound score
45629175|NCT02409641|Drug|Cyclopentolatehydrochloride 0,5% eye drops|1 drop in study eye
45769127|NCT05509686|Device|Intermittent theta burst stimulation (iTBS)|A single-session standard 600-pulse intermittent theta burst stimulation (iTBS) is applied to the ipsilesional primary motor cortex.
45769128|NCT05509686|Device|Sham intermittent theta burst stimulation (iTBS)|The sham stimulation is the same as that of iTBS, but the coil is placed five centimeters away from the scalp. Electrical field simulation shows that the setups for sham stimulation would not induce any valid cortical activation.
45769129|NCT04392752|Other|Dieting intervention|This study includes four laboratory testing sessions over the 50-week period. Testing sessions will be performed over one week. Time points include testing before the diet or the control period start (PRE), one week before the competition (MID), after the competition (COMP) and after a recovery period (POST), during which the participants are advised to continue their normal training regimen, but to stop competition dieting. Participants will spend three hours in the laboratory between 0700-1300. The control group will be advised to maintain their normal physical activity diet throughout the study. The participants will be given identification numbers and the research group is blinded so that they do not know which group participants belong to. All measurements will be conducted at the same time (always within max ±1 hour) due to the importance of standardizing the time of the day of measurements.
45769130|NCT03018392|Device|Stryker Tritanium Spinal System|open transforaminal lumbar interbody fusion (TLIF) utilizing the Stryker Tritanium cages with pedicle screw fixation according to instructions for use and package labeling for on-label indications
45629176|NCT04839705|Device|WEB|"Device: WEB The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.~Other Names:~• WEB Aneurysm Embolization Device"
45629177|NCT02409797|Other|Flexion-Distraction (non-thrust) spinal manipulation|Enrolled participants will receive chiropractic care over a 2-week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach and treatment frequency based upon a participant's clinical presentation. If provided, treatments will include low-velocity (non-thrust) spinal manipulation using the Flexion-Distraction procedure. Recommendations for exercise, lifestyle modifications, or other therapies may also be provided.
45629178|NCT05519943|Behavioral|The Friends program|A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions
45769131|NCT02979548|Drug|Aprepitant|Aprepitant is a non peptide, selective, Neurokinin type 1 (NK 1) receptor antagonist. Group A will receive Aprepitant as an add-on anti-emetic therapy in addition to ondansetron.
45769132|NCT02979548|Drug|Ondansetron|Ondansetron is 5HT3 Receptor antagonist used to treat and prevent chemotherapy induced nausea and vomiting
45629179|NCT05519943|Behavioral|TAU condition|A TAU waitlist condition during which participants received routine care services tailored to each child individually.
45629180|NCT02067676|Biological|Capsule-Conjugate Campylobacter Vaccine (CJCV1)|The capsule of Campylobacter jejuni strain 81-176 (CPS81-176) conjugated to the mutated diphtheria toxin cross-reacting material 197 (CRM197) (lyophilized CPS-CRM197 conjugate) (CJCV1)
45629181|NCT02067676|Drug|Alhydrogel®, aluminum hydroxide adjuvant (alum)|
45629182|NCT03174665|Other|No intervention|
45629183|NCT03174743|Procedure|Convential Ventilation 1|High tidal volume, moderate inspired oygen fraction (FiO2).
45629184|NCT03174743|Procedure|Convential Ventilation 2|High tidal volume, high inspired oygen fraction (FiO2).
45629185|NCT03174743|Procedure|Protective Ventilation 1|Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.
45769133|NCT02979548|Drug|Metoclopramide|Dopamine receptor antagonist , acts at CTZ. Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.
45769134|NCT03016130|Other|Diet|Diet Intervention: Subjects will undergo stratified randomization to account for the heterogeneous population, to receive one of the two diets: liberalized hospital diet (Diet A) or a neutropenic diet (Diet B).
45913168|NCT02019056|Drug|MG-1|
45913169|NCT02019056|Drug|MG-2 : MG1000mg, Placebo /bid P.O|
45913170|NCT02019056|Drug|metadoxine|
45913171|NCT02019082|Device|Electrical Stimulation (BTL-5000 series, United Kingdom)|Direct current ES
45935217|NCT00219154|Drug|aliskiren|
45935218|NCT00219193|Drug|aliskiren|
45935219|NCT00219232|Drug|Rivastigmine Transdermal Patch|
45935220|NCT00219271|Drug|Zoledronic acid|
45935221|NCT00219310|Drug|Famciclovir|
45935222|NCT00219388|Drug|Levosimendan|
45769135|NCT03012776|Device|Total Posterior Spine System (TOPS)|Placement of TOPS System to provide posterior stabilization following decompression to treat lumbar spinal stenosis and spondylolisthesis
45769136|NCT03012776|Procedure|Transforaminal Lumbar Interbody Fusion (TLIF)|Fusion with placement of interbody cage and posterolateral instrumentation
45629186|NCT03174743|Procedure|Protective Ventilation 2|Low tidal volume, PEEP, High inspired oygen fraction (FiO2) and recruitment maneuver.
45629187|NCT05519787|Device|Central Veinous access devices' insertion|"Medical doctor should complete a questionnaire with medical history or any important clinical data that could help for the selection of the location of the port and catheter placement. The insertion will be planned only by a surgeon, interventional radiologist, or anaesthesiologist in the surgery block.~For the patient with a medical history of PICC line, PAC implantation, Central venous access device of any kind, or clinical risk of veinous compression (cervical or subclavian adenopathy, pelerine syndrome, mediastinal involvement…). An echo Doppler exam of the veinous cervical system is required before surgery. This exam should identify potential thrombosis that required a special treatment. It is important that the surgeon who will perform the device's insertion is aware of any history or risks of veinous thrombosis, stenosis, or phlebitis for the patient to avoid procedure's failure."
45769137|NCT05504928|Other|School nurse program|School nurse program providing health care through assessment, intervention and follow-up of group A β-hemolytic streptococcal pharyngitis and facilitation of secondary antibiotic prophylaxis for children with latent rheumatic heart disease.
45629188|NCT05513547|Other|LE protocol 1: exposure to artificial light|Participants stay in the lab with light mimicking usual office lighting. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
45769138|NCT03821246|Drug|Atezolizumab|Given IV
45769139|NCT03821246|Drug|Tocilizumab|Given IV
45769140|NCT03821246|Drug|Etrumadenant|Given Orally
45769141|NCT02568384|Device|Onyx BG Meter / App System|Subjects with diabetes used the Onyx BG Meter / App System at home and assessed software operations, ease of use of the system, and clarity and utility of user instructions.
45769142|NCT03821558|Other|Exercise training|Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions with different intensity levels.
45769143|NCT05509530|Other|anti-BCMA/GPRC5D CAR-T CELL|anti-BCMA/GPRC5D autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy
45769144|NCT03826472|Other|Almond Butter|Natural almond butter
45769145|NCT05499936|Drug|68Ga-FAPI|68Ga-FAPI were injected into the patients before the PET/CT scans
45769146|NCT03826316|Drug|Nalbuphine|Pharmacokinetic study under fasting conditions
45769147|NCT04393610|Drug|Lidocaine|Patients will receive lidocaine 3 mg/kg total of 40 ml (control group).
45769148|NCT04393610|Drug|Magnesium Sulphate|Patients will receive lidocaine 3 mg/kg total of 40 ml plus Magnesium sulphate 30 mg/kg maximum 1.5 gm, mixed with the second 20 ml of block solution.
45769149|NCT04393610|Drug|Fentanyl|Patients will receive lidocaine 3 mg/kg total of 40 ml plus fentanyl 1 mcg/kg, mixed with lidocaine given after the first 20 ml of block solution.
45769150|NCT04502316|Device|Barostim™ System|Implantation of the Barostim™ System
45769151|NCT03826238|Diagnostic Test|Validation Gate task|"The task is to observe several moving unfilled white circles on a dark background. The circles move in straight paths. Every so often, a randomly selected circle will displace to a point inconsistent with its trajectory, which will look like a jump. The subjects' task is to press the space bar every time they detect a displacement (e.g. jump). A session consists of 30 minutes, it starts with 2 training blocks which are followed by 2 no-cognitive load blocks and 6 blocks with increasing cognitive load conditions. During the assessment the eye movement as well as the key presses are registered in order to calculate early and late saccades as well as conscious reporting. Resting-state EEG will also be recorded and compared to the ones of age-matched healthy controls. Task-dependent EEG data will be recorded during the Validation Gate task."
45769152|NCT03820466|Drug|Aspirin|Once daily application of platelet inhibiting medication
45769153|NCT03820466|Drug|Atorvastatin|Once daily application of lipid lowering medication
45769154|NCT03820466|Drug|Placebo Aspirin|Once daily application of placebo
45769155|NCT03820466|Drug|Placebo Atorvastatin|Once daily application of placebo
45769156|NCT03826004|Drug|Clemastine|Clemastine fumarate 2mg/2ml intramuscular injection is administrated into the gluteus maximus muscle
45769157|NCT03826004|Drug|Saline Solution|Saline solution 2ml intramuscular injection is administrated into the gluteus maximus muscle
45769158|NCT04127240|Other|DASH diet containing daily intakes of red meat|Each participant was randomized to consume 3 or 6 ounces of red meat as a part of the DASH dietary pattern for 12-weeks.
45769159|NCT03097094|Diagnostic Test|Male dog|Male dog extract
45769160|NCT03097094|Diagnostic Test|Female dog|Female dog extract
45769161|NCT02338076|Drug|Petrolatum application under occlusion|"Day 0 study patients will have 1 patch applied to either back or thighs ( containing 2 wells)~1 well will be empty and the other well will contain petrolatum~Day 3 patches will be removed and 3 skin biopsies will be performed 1 biopsy from normal skin at a distance from the patch~1 biopsy each from under the 2 wells of the patch ( so 1 biopsy from skin that was occluded with petrolatum and 1 biopsy from skin that was occluded without petrolatum)"
45769162|NCT03829670|Diagnostic Test|Cytochrome P450 test|Blood samples will be drawn for cytochrome P450 testing.
45769163|NCT03829826|Biological|HyQvia|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
45769164|NCT04126694|Behavioral|CBT with smartphone application SenseSupport|SenseSupport intervention system used as an augment to a 12 week in-person CBT treatment for transdiagnostic binge eating pathology
45769165|NCT02978534|Drug|Quetiapine|Quetiapine concentrations will be observed in women who have already (under the guidance of a physician) decided to continue taking Quetiapine for the treatment of Bipolar Disorder (any subtype) or Schizophrenia during pregnancy.
45769166|NCT03829982|Behavioral|Exposure to bright light during the day|Participants will be exposed to bright light (1250 lux) between 8:00 and 18:00 and to dim light (5 lux) between 18:00 and 23:00.
45769167|NCT03829982|Behavioral|Exposure to dim light during the day|Participants will be exposed to dim light (10 lux) between 8:00 and 18:00 and to dim light (1250 lux) between 18:00 and 23:00.
45769168|NCT02983760|Device|Planar V/Q-based strategy|Strategy based on planar pulmonary scintigraphy
45769169|NCT02983760|Device|CTPA-based strategy|Strategy based on pulmonary angiography
45447476|NCT02119000|Drug|Bisacodyl 15 mg and PEG/electrolytes 1L/1L split dose|"Bisacodyl 15 mg x 3~At 14h00 the day prior the endoscopic procedure: take 3 tablets of Bisacodyl ER (15 mg) orally then 5 hr later:~PEG/electrolytes 1L/1L Polyethylene glycol 17gm Dilute one sachet of Polyethylene glycol 17gm in 1 L of water Start drinking at around 19h00 the night prior the colonoscopy Drink 240 ml every 10 minutes The day of the colonoscopy. At (4 hrs prior the procedure). Dilute on sachet of PEG and drink 240 ml every 10 minutes"
45769170|NCT02983760|Device|V/Q SPECT-based strategy|Strategy based on pulmonary tomoscintigraphy
45769171|NCT01222117|Biological|Plasmin|Plasmin prepared in 0.9% saline for injection
45447477|NCT02119078|Other|Acute Care of Elders focused geriatric care|Patients admitted to the ACE Service will receive standard care as well as additional use of geriatric-specific order sets and protocols and oversight of care by a geriatric-trained Advanced Practice Provider (APP).
45769172|NCT01222117|Biological|Plasminogen Activator|Plasminogen activator used according to the Investigator's clinical judgment.
45769173|NCT01222117|Other|Placebo|Normal saline for injection at the same volume as the plasminogen activator.
45447478|NCT02116504|Procedure|Sampling of blood|Sampling of blood for dosage of antibodies
45769174|NCT04392830|Drug|ALZ002 DS|Administered orally
45769175|NCT04392830|Drug|Placebo|Administered orally
45769176|NCT02977442|Behavioral|exercise|
45913172|NCT02019082|Device|placebo|the intervention procedure was the same as that the ES group, but the current intensity was zero
45447479|NCT02119234|Drug|Beclometasone/formoterol/glycopyrrolate|
45447480|NCT02119234|Drug|Placebo|
45447481|NCT02112604|Device|Ventilator|Mechanical ventilator used to replace or assist spontaneous breathing.
45629189|NCT05513547|Other|LE protocol 2: natural daylight|Participants spend the same time outdoors in natural daylight. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
45629190|NCT05513547|Other|LE protocol 3: natural daylight with reduced short-wavelength proportions|Participants spend the same time outdoors in natural daylight wearing tinted glasses that filter out short-wavelength light proportions. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
45629191|NCT01623154|Other|Pranactin citric solution|All patients were required to drink the pranactic citric solution to diagnose H.pylori.
45629192|NCT03174431|Device|Continence Pessary|Continence pessaries are inexpensive, reusable intravaginal devices made of flexible silicon that provide support to the urethra to prevent urinary leakage. Continence pessaries are fitted by trained clinicians in the office and managed by patients or their provider.
45629193|NCT03174431|Device|Poise Impressa (Disposable Intravaginal Device)|In 2014, the FDA approved an over-the-counter disposable intravaginal device as another nonsurgical treatment for SUI. This device is comprised of 4 support poles covered in a non-absorbable nylon mesh that is deployed using an intravaginal applicator.
45629194|NCT04417816|Other|Exercise training intervention with ultrasound induced adipose tissue cavitation|Exercise training intervention with ultrasound induced adipose tissue cavitation
45629195|NCT04417816|Other|Exercise training intervention without ultrasound induced adipose tissue cavitation|Exercise training intervention with ultrasound induced adipose tissue cavitation
45629196|NCT02409407|Drug|Misoprostol , Prostaglandins E1 analogue|
45629197|NCT05510037|Other|no intervention|no intervention was needed
45629198|NCT02409563|Drug|Budesonide nasal spray (100 mcg bid)|
45629199|NCT02409563|Drug|Budesonide nasal spray (50 mcg bid|
45447482|NCT02112604|Device|Alice PDx|Alice PDx is a polysomnography monitor used to study stages of sleep and detect sleep-disordered breathing. The device monitors PO2, airflow, EEG, EOG and abdominal wall movements to detect sleep apnea.
45447483|NCT02112604|Other|Pulmonary function test|The pulmonary function tests are used to study upper airway patency.
45447484|NCT02112604|Other|Muscle strength tests|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
45769177|NCT02976428|Procedure|Sensor Guided Soft Tissue Balancing|Primary TKR with soft tissue balancing with a sensor guided device.
45769178|NCT02976428|Procedure|Standard Soft Tissue Balancing|Primary TKR with soft tissue balancing with a standard of care manual tensiometer device.
45769179|NCT03825380|Drug|Bimatoprost|Eyedrops
45769180|NCT03825380|Drug|Lumigan®|Eyedrops
45769181|NCT01222195|Drug|Lenalidomide|10 mg/day by mouth on days 1-21 of every 28 day cycle.
45769182|NCT01222195|Drug|Darbepoetin alfa|200 mcg subcutaneously every 2 weeks of a 28 cycle.
45769183|NCT04126616|Diagnostic Test|chest Magnetic Resonance Imaging (MRI) using Gadolinium-based contrast agent|chest MRI will be performed at rest and after moderate exercise
45769184|NCT03825458|Other|Blood sampling|Blood sampling at each clinical follow-up visit.
45913173|NCT02019095|Other|Bronchoscopy for the sampling of bronchoalveolar lavage (BAL) fluid|
45913174|NCT02019134|Behavioral|relaxation exercise|relaxation exercise
45913175|NCT02019134|Other|ususal care|
45629200|NCT02409485|Behavioral|Couples Skill-Training (CST)|Patients and partners each receive a workbook and 6 one-hour telephone sessions with a Masters level trained interventionist. Manual content is tailored based on role (patient or partner). Couples participate together via speaker phone for half the sessions and patients and partners receive separate (individual) intervention calls for the other half of the sessions.
45629201|NCT05513313|Biological|JYNNEOS|smallpox vaccine
45629202|NCT02409017|Procedure|Insulin drip|
45629203|NCT05513079|Behavioral|Positive Psychotherapy Based Counseling|The main purpose in Positive Psychotherapy is to develop the individual's main capacities. and to maintain balance in the four areas of life (body, success, relationships and future) in daily life. to help provide. The essence of Positive Psychotherapy is a five-step process: 1. Observation/distance phase, 2. Inventory phase, 3. Situational encouragement phase, 4. Verbalization phase, 5. Expanding the objectives phase. Shaping five-step model therapy It is a helpful guide.
45629204|NCT04824105|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|A repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System will be used to deliver intermittent theta burst to ventromedial prefrontal cortex, and continuous theta burst to pre-supplementary motor area.
45769185|NCT01222273|Dietary Supplement|cholecalciferol (Vitamin D3)|4,000 IU of cholecalciferol (Vitamin D3) orally every day for six months
45769186|NCT04126460|Drug|Toripalimab|Toripalimab is a type of PD-1 antibody
45629205|NCT05519553|Other|Peer support|: 1 hour individual session with a peer support specialist at 1, 3 and 5 months after baseline
45769187|NCT03161912|Drug|Aflibercept (Eylea, BAY86-5321)|As per the treating physicians discretion.
45769188|NCT01222585|Drug|Metronidazole|Metronidazole will be administered intravenously to premature infants as a 15 mg/kg loading dose followed by maintenance doses of 7.5 mg/kg every 12 hours for infants with >=14 postnatal days and every 24 hours for infants <14 postnatal days.
45769189|NCT04126382|Procedure|Intubate-Surfactant-Extubate(INSURE)|Infants are given an endotracheal intubation, with manual lung inflation in order to keep the oxygen supply，and the surfactant(kelisu,China Resources Shuanghe Pharmaceutical) was slowly instilled into the airway through the tracheal tube, and the tracheal tube was removed for non-invasive NCPAP(nasal continuous positive airway pressure)-assisted breathing.
45629206|NCT05512845|Procedure|Double Factor technique|"The double factor computer assisted surgery technique, involves the combination of the static and dynamic computer assisted surgery protocols to place dental implants in the same surgery."
45629207|NCT00702689|Drug|Gleevec, STI571(Imatinib Mesylate)|"Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.~Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)"
45629208|NCT05509881|Device|Continuous glucose monitoring (CGM)|"Patients in the CGM arm will undergo continuous real-time unblinded CGM using Dexcom G6 CGM devices."
45629209|NCT05509881|Device|Usual care (Self-monitored blood glucose)|Patients in the usual care arm will conduct self-monitored blood glucose at least 4 times/day.
45629210|NCT05509725|Drug|Probiotic formulation|Participants will be asked to take 2 doses daily
45629211|NCT05509725|Drug|Placebo|Participants will be asked to take 2 doses daily
45629212|NCT02409251|Behavioral|Education and feedback|
45629213|NCT05512689|Device|Ventilations while using a respiratory function monitor|Healthcare professionals are able to use a feedback device to guide their ventilations.
45629214|NCT02409095|Biological|DTP-HB-Hib vaccine|Diphtheria, Tetanus, Pertussis, Hepatitis-B and Haemophilus influenzae type-B conjugate vaccine (DTP-HB-Hib) has been developed and manufactured by SIIL. The vaccine is pre-qualified by WHO and licensed by the Indian regulatory authority for immunization in children to protect them against above five diseases.
45629215|NCT02409095|Device|Disposable Syringe Jet Injector (DSJI)|Stratis is a needle free injection device manufactured by Pharamjet Inc. and licensed in USA.
45629216|NCT02409095|Other|Needle & Syringe|The conventional needle syringe that is routinely used for vaccination.
45629217|NCT05512533|Device|Linear Ultrasound Bronchoscope BF-UC290F (Olympus)|A thin Olympus EBUS bronchoscope BF-UC290F will be used for all endobronchial ultrasound examinations, and biopsies will be conducted with EBUS needles - the ViziShot 2 22G (Olympus).
45629218|NCT02409173|Device|Noninvasive positive airway pressure flow generator device|Noninvasive positive airway pressure flow generator device.
45629219|NCT02409173|Procedure|Bariatric Surgery|Standard Roux-en-Y gastric bypass
45629220|NCT02065570|Drug|Adalimumab|
45629221|NCT02065570|Drug|Placebo|
45629222|NCT02408705|Drug|Liraglutide|They are receiving liraglutide for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
45769190|NCT04126382|Procedure|less invasive surfactant administration(LISA)|Infants are spontaneously breathing with nasal CPAP(continuous positive airway pressure) support without manual lung inflation and surfactant(kelisu,China Resources Shuanghe Pharmaceutical) is administered through vocal cords via a smaller catheter.
45769191|NCT03829592|Drug|misoprostol in a neutral media|giving misoprostol in a neutral media
45769192|NCT03829592|Drug|misoprostol in an acidic media|giving misoprostol in an acidic media
45769193|NCT03829592|Drug|misoprostol in an alkaline media|giving misoprostol in an alkaline media
45629223|NCT02408705|Drug|Placebo|They are receiving placebo for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
45769194|NCT01142323|Drug|fenofibrate|160 mg po daily
45769195|NCT04126226|Other|Speech-language guidance|Speech-language guidance for speech enhancement and on food management in terms of consistency, volumes, utensils and temperature, beyond the care for safe and efficient swallowing.
45769196|NCT04126226|Other|Speech therapy exercises for swallowing|Use of lip exercises and facial muscles, laryngeal elevation maneuver and airway protection technique, 5 repetitions 3 times a day for a month.
45769197|NCT04126226|Other|Speech therapy exercises for speech|Use of over-articulation technique and glottal firmness exercise, 5 repetitions 3 times a day for a month.
45769198|NCT01142947|Drug|beclomethasone dipropionate|160 mcg twice a day (320 mcg per day total)
45769199|NCT02972294|Drug|Iron Isomaltoside 1000|Iron Isomaltoside 1000 will be use. Blinding procedure will be put in place for the administration of the treatment
45629224|NCT02408705|Drug|Mixed Meal Tolerance Test with paracetamol|At the beginning and end of each period (Visit 2a, 8, 9a, 15) a Mixed Meal Tolerance Test enriched paracetamol will be performed.
45629225|NCT05509569|Drug|Icatibant|Icatibant, 10 to 30 mg, Subcutaneous injection
45769200|NCT02972294|Drug|Tranexamic Acid|Tranexamic acid will be use.
45769201|NCT02972294|Drug|Placebos iron isomaltoside 1000|placebo of Iron Isomaltoside 1000 correspond to a saline solution. Blinding procedure will be put in place for the administration of this treatment
45629226|NCT02408939|Drug|Stress-dose hydrocortisone|Patients with postresuscitation shock received stress-dose (300 mg) of hydrocortisone for 7 days maximum followed by gradual taper and discontinuation over 48 hours after either the resolution of their hemodynamic instability or day 7 of treatment.
45629227|NCT02408627|Device|EEG|
45629228|NCT05507697|Biological|HUC-MSCs|5 × 10^6 cells/mL, 1 mL per injection, each injection point is 2 cm apart ,1.0-1.5 cm deep, total amount of injection is estimated based on the surface area of the patient's lower limb
45447485|NCT02112604|Other|Grip strength measurement|Grip strength has been shown to be an accurate means of assessing muscle function in the critically ill. Muscle weakness may have an impact on upper airway patency.
45447486|NCT02112604|Drug|Sedatives and muscle relaxants given in the ICU|Patients in the ICU are administered sedatives, anesthetics, opiods, anti-pyschotics and neuromuscular blocking agents as part of routine care. We hypothesize that the use of these drugs is associated with sleep-disordered breathing following extubation. We will collect the drug doses from the patient's chart.
45629229|NCT05507697|Biological|Lipoic Acid|Lipoic Acid Injection，600 mg/d for 15 consecutive days
45629230|NCT02408471|Device|Ascension® MCP Finger Implant|Patients who meet inclusion/ exclusion criteria are treated with the Ascension® MCP.
45629231|NCT04292223|Drug|Pimavanserin|Pimavanserin 34 mg (provided as 1×34 mg capsule), administered orally, once daily for 16 weeks
45913176|NCT02019160|Drug|25% AgNO3 solution followed by 5% NaF varnish|Dosage of 4.4μg±1.4μg fluoride per use
45447487|NCT02112682|Procedure|Completion axillary treatment|Completion axillary treatment according to the Dutch breast cancer guideline
45629232|NCT03174119|Device|Light therapy - active|Active light will be used for one week, as compared to placebo light.
45629233|NCT03174119|Device|Placebo light|Placebo light will be used for one week, as compared to real light exposition.
45629234|NCT05509491|Behavioral|A postural awareness program with exercises|A program about postural awareness, bad posture, good posture and their effects on daily life
45629235|NCT03116321|Drug|Eslicarbazepine acetate (ESL)|Oral Tablet of 800 mg and 200 mg of ESL
45629236|NCT03174041|Drug|Midazolam|Single dose midazolam
45629237|NCT03174041|Drug|GDC-0853|Multiple doses GDC-0853 for 6 days
45629238|NCT03174041|Drug|Midazolam and GDC-0853|Multiple doses GDC-0853 and single dose midazolam
45629239|NCT03174041|Drug|Rosuvastatin|Single dose rosuvastatin
45629240|NCT03174041|Drug|Rosuvastatin and GDC-0853|Multiple doses GDC-0853 and single dose rosuvastatin
45629241|NCT03174041|Drug|Simvastatin|Single dose simvastatin
45629242|NCT03174041|Drug|Simvastatin and GDC-0853|Multiple doses GDC-0853 and single dose simvastatin
45629243|NCT03174041|Drug|GDC-0853|Single dose GDC-0853
45629244|NCT03174041|Drug|Itraconazole|Multiple doses itraconazole for 6 days
45629245|NCT03174041|Drug|GDC-0853 and itraconazole|Multiple doses itraconazole and single dose GDC-0853
45629246|NCT02566005|Device|misoprostol|25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist).
45629247|NCT02566005|Device|Foley bulb|a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours.
45629248|NCT02408393|Drug|Saline|
45629249|NCT02408393|Drug|Ropivacaine|
45629250|NCT02408237|Device|Active tDCS Ambulatory|Procedure begins with the placement of an anode electrode placed on the primary motor cortex (cortex contralateral to the dominant) and the cathode is placed on the contralateral supraorbital region. It is used 1mA direct current transcranial stimulation applied for 20 minutes. Will be held a single session of stimulation. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
45769202|NCT02972294|Drug|Placebos tranexamic acid|placebo of tranexamic acid correspond to a saline solution.
45769203|NCT02969798|Drug|Dapagliflozin|10mg/day
45769204|NCT02969798|Drug|Saxagliptin|5mg/day
45913177|NCT02019160|Drug|38% SDF solution followed by placebo varnish|Dosage of 8.8μg±2.8μg fluoride per use
45629251|NCT02408237|Device|Sham tDCS Ambulatory|In sham group, we follow the same procedure and time as the active tDCS ambulatory protocol, but the device will be in the mode sham (inactive). The current is only applied for 30 seconds, so subjects feel a sense of the initial stimulation, but not the remainder receive current. In this group one session will also be held. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
45769205|NCT02969798|Drug|Pioglitazone|the dose will increase from 15 mg/day to 30 mg/day at month two
45769206|NCT02969798|Drug|Metformin|starting at 1000 mg/day and increased to 2000 mg/day at month 2.
45769207|NCT02983214|Drug|Clopidogrel|
45769208|NCT02983214|Drug|Cilostazol|
45769209|NCT03825068|Procedure|ESP Block|20 ml of lacal anaesthetics will be placed below the erector spinae muscle under ultrasound guide
45629252|NCT02408237|Device|Active tDCS Home use|The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. Will be explained to the participant as placement of the cap and the device management. This group will be made 11 sessions of tDCS, the first held in the Hospital, with supervision of the researcher. The remaining 10 will be held in the participant's home. The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
45629253|NCT02408237|Device|Sham tDCS Home use|The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. In sham group, we follow the same procedure and time as the active tDCS protocol, but the device will be in the sham mode (inactive). The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
45629254|NCT05041335|Other|wet heparinzed suction|Needle flushed with 5000 Units in 10mL of heparin
45629255|NCT05041335|Other|Microsieve|A microsieve used for tissue preparation
45629256|NCT05041335|Other|No heparin flush|The needle not prepped
45769210|NCT03825068|Drug|general anesthetic|patient receive general anaesthetic only
45629257|NCT05041335|Other|No microsieve|The tissue is placed into formalin
45629258|NCT03173885|Diagnostic Test|Preimplantation Genetic Screening|"laser assisted hatching~trophectoderm biopsy~next generation sequencing"
45629259|NCT03173807|Behavioral|diet and exercise guidance and modifications|Review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer
45629260|NCT02408159|Drug|Varicella Zoster Vaccine|
45629261|NCT02408159|Drug|Placebo|
45629262|NCT05507619|Other|Acupuncture with Heat Therapy + Standard Care|Biweekly sessions of acupuncture with heat therapy over 6 weeks (total 12 sessions), in addition to standard care (e.g. physiotherapy, dietetics, pain management).
45913178|NCT02019173|Behavioral|Boot Camp Balance Training|Intense physical rehabilitation directed at improving balance and mobility will be provided to individuals in a group setting (6 participants in a group) for 4 weeks, 3 days a week for 6 hours per day.
45913179|NCT02019186|Dietary Supplement|Vitamin C|<30 kg 250 mg 30-60 kg 500 mg >60 kg 750 mg
45913180|NCT02019186|Dietary Supplement|Vitamin E|<30 kg 100 IU, 30-60 kg 200 IU, >60 kg 300 IU
45447488|NCT02119390|Behavioral|Staff-delivered intervention sessions|In addition to standard clinical care, participants in the Pill Trial+ arm will receive staff-delivered intervention sessions individualized for each participant at HAART initiation, 1-month, and 3-month follow-up. Two booster sessions will also be provided at two weeks following intervention session 1 (in clinic) and intervention session 2 (by phone) to assess any difficulties using the created adherence plans.
45447489|NCT02119390|Other|Demographic Questionnaire|Participants will complete a questionnaire developed for the purposes of the current study assessing basic background information.
45447490|NCT02119390|Other|Questionnaires|Self-reported adherence, health-related quality of life and other questionnaire measures will be administered using a password protected laptop the same day as participants' regularly scheduled outpatient clinic appointments.
45913181|NCT02019225|Other|Dialysis session of at least 4.25 hours|Facilities randomized to the Intervention arm will adopt the practice of recommending dialysis session durations of at least 4.25 hours for all patients initiating hemodialysis treatment regardless of body size or dialysis solute clearance measurements.
45447491|NCT03694197|Drug|Praluent|Subcutaneous (SC) administration
45447492|NCT02112760|Other|specific stabilization exercise|The specific stabilization exercise refers to an exercise that targets the deep trunk muscle, including the multifidus and transversus abdominis with ultrasound feedback.
45447493|NCT02119546|Other|Aerobic exercise|Aerobic exercise and dual-task training
45447494|NCT02119546|Other|Stretch exercise|Stretch exercise & sitting balance
45629263|NCT05507619|Other|Standard Care|Treatment as prescribed by orthopaedic surgeon routinely (e.g. physiotherapy, dietetics, pain management)
45629264|NCT02408081|Behavioral|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of one months.
45629265|NCT02407925|Behavioral|Feedback|3-monthly or no 3-monthly feedback on results of optical diagnosis
45629266|NCT05507463|Drug|KBP-7072|KBP-7072
45629267|NCT05507463|Drug|Placebo|Placebo
45629268|NCT03173963|Drug|Empagliflozin|10 mg tablet of empagliflozin daily in addition to best clinical practice for management of diabetes.
45629269|NCT03173963|Other|Placebo|1placebo tablet per day
45629270|NCT05507307|Behavioral|mindfulness-based pregnancy education program.|Pregnant education program based on mindfulness is planned as 2 sessions per week for 4 weeks, in total 8 sessions. Each session is planned to last 40-60 minutes on average. Sessions will continue as individu
45629271|NCT02407847|Other|care provided by Nurse Practitioners|Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
45769211|NCT04393688|Combination Product|Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter|"Procedure:~Percutaneous Transluminal Angiography, Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
45769212|NCT03824678|Drug|CC-220|CC-220
45769213|NCT04393376|Diagnostic Test|PSA Glycomics Assay|PSA Glycomics Assay will be performed on urine and blood samples
45769214|NCT02085356|Behavioral|Protect your family|"Protect Your Family intervention is a manualized, closed, structured behavioral risk reduction program targeting HIV, stigma, disclosure, communication, intimate partner violence (IPV), PMTCT knowledge, safer conception, family planning and dual method sexual barrier use.~Intervention participants will attend 3 prenatal weekly 2 hour gender-specific (male or female, 5-7 participants) group sessions followed by 1 individual counseling session and 2 monthly couples or individual (women-only) counseling sessions (1 prenatal, 2 postpartum) led by study-trained clinic staff (e.g., nurses, HIV counseling and testing (HCT) counselors) plus standard of care (PMTCT)"
45629272|NCT05507229|Biological|Hillchol vaccine|HillChol®(BBV131) (Whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
45629273|NCT05507229|Biological|Shanchol Vaccine|Shanchol™ (Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine)
45769215|NCT03824834|Drug|Exercise training with morphine|Immediate-release oral morphine (syrup, 0.1 mg/kg body mass to a maximum dose of 10 mg) prepared in 250 mL of orange juice 30-min prior to each exercise session. Participants will complete exercise training sessions (three times per week for five weeks) on an electronically braked bike, supervised by a trained exercise specialist. Exercise sessions will be individualized based on participants' peak power output (60% PPO) determined from incremental exercise testing, and progressed to ensure the participant is exercising at a breathlessness intensity rating of between 3-5 Borg CR10 scale units and can complete at least 20-min of continuous cycling. Exercise duration will be increased in 5-min intervals up to 40-min. Thereafter, exercise intensity will be increased by 5-15% of baseline PPO.
45447495|NCT02251444|Procedure|outpatient rehabilitation program|
45629274|NCT03173651|Device|Modified Williams airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group W
45629275|NCT03173651|Device|Modified Guedle's airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group G
45629276|NCT03173651|Device|LMA MADgic airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group M
45629277|NCT03173417|Biological|IM19 CAR-T|T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
45629278|NCT03173417|Drug|fludarabine and cyclophosphamide|Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
45629279|NCT03173573|Drug|FDL176|CFTR modulator
45629280|NCT03173573|Drug|Placebo|Placebo for FDL176
45629281|NCT05507073|Procedure|Manual Total Hip Replacement|Implantation of a hip Device to alleviate pain and recover range of movement
45629282|NCT05507073|Procedure|Robot-Assisted Total Hip Replacement|Robot assisted Implantation of a hip Device to alleviate pain and recover range of movement
45629283|NCT03173495|Dietary Supplement|FRUCTOSE|Fructose-rich beverage with a high fat meal, without exercise.
45769216|NCT03824834|Other|Exercise training with placebo|Diluted simple syrup prepared in 250 mL of orange juice 30-min prior to each exercise session. Participants will complete exercise training sessions as per the experimental group.
45629284|NCT03173495|Dietary Supplement|DEXTROSE|Dextrose-rich beverage with a high fat meal (control), without exercise.
45769217|NCT03829124|Drug|Propofol|Propofol 10mg/ml IV push slowly 0.5-2mg/kg
45629285|NCT03173495|Dietary Supplement|EXERCISE|45 minutes of 60% VO2peak aerobic exercise
45629286|NCT05508945|Device|Dermabond Prineo Skin Closure System|synthetic mesh patch is positioned and lightly pressed over 50% of the surgical incision. 2-octyl cyanoacrylate liquid adhesive is evenly applied over the mesh and allowed to dry
45769218|NCT03829124|Drug|Ketamine|Ketamine 50mg/ml IV push slowly 0.5- 1mg/kg
45769219|NCT03828890|Other|Screening eye exam using Optos technology|Retinal imaging using Optos technology to identify Diabetic Retinopathy
45447496|NCT02251444|Procedure|physical therapy|
45629287|NCT05508945|Device|silk|SERI surgical scaffold with dermaFLEX backing is positioned over the remaining 50% of the surgical incision
45629288|NCT05508945|Device|3M Steri-Strip|non-woven rayon with adhesive backing is applied to 50% of the surgical incision.
45629289|NCT03173339|Procedure|Endotracheal intubation using laryngoscope|Endotracheal intubation was done using laryngoscope for general anesthesia.
45629290|NCT03173339|Drug|High remifentanil|Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
45629291|NCT03173339|Drug|Low remifentanil|Remifentanil was administered as 0.1 mcg/kg/min.
45629292|NCT03173339|Drug|High sevoflurane|Sevoflurane was started as 0.5 MAC. Sevoflurane dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.2 %.
45629293|NCT03173339|Drug|Low sevoflurane|Sevoflurane was administered as 0.5 MAC.
45629294|NCT04759911|Other|Quality-of-Life Assessment|Ancillary studies
45629295|NCT04759911|Other|Questionnaire Administration|Ancillary studies
45629296|NCT04759911|Drug|Selpercatinib|Given PO
45629297|NCT04759911|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
45629298|NCT03173261|Diagnostic Test|Genexpert|diagnosis of tuberculous pleural effusion and genitourinary tuberculosis by Genexpert by urine and pus and pleural fluid aspirate
45629299|NCT03173183|Drug|genuine regional Rhizoma Atractylodis (Maozhu granule)|"Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd."
45629300|NCT04757805|Diagnostic Test|Ultrasound|Ultrasound to locate the appropriate lumbar interspace to perform spinal anesthesia.
45629301|NCT03172871|Drug|Aripiprazole IM Depot|Aripiprazole IM depot 400 mg/300 mg (when not tolerated)
45629302|NCT03172871|Drug|Aripiprazole tablet|Oral aripiprazole tablets 10 to 20 mg daily
45629303|NCT02065336|Drug|ARC-520|
45629304|NCT02065336|Drug|Placebo|
45629305|NCT02065336|Drug|entecavir|
45629306|NCT02065336|Drug|chlorpheniramine|In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.
45769220|NCT03829202|Device|Own mechanical knee|Daily use of own mechanical knee
45629307|NCT02408003|Drug|Levosimendan|"Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
45629308|NCT02408003|Drug|Milrinone|"Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
45629309|NCT05518929|Drug|Ciprofol|The sedation of gastrointestinal endoscopy with Ciprofol
45629310|NCT05518929|Drug|Propofol|The sedation of gastrointestinal endoscopy with Propofol
45629311|NCT02407769|Dietary Supplement|Late evening supplementation with branched chain amino acids|The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during late evening (after 19:00 hours) in comparison with the late evening snack group which will eat a snack based in food with the next nutrimental facts (480 Kcal, 19g of proteins based in casein and vegetables sources, 17g of lipids and 63g of carbohydrates) during the same schedule that intervention group.
45629312|NCT04790409|Drug|sintilimab and anlotinib|This study was a one-arm, open-label, phase II study of PD-1 monoclonal antibody combined with ilotinib in the treatment of advanced EGFR rare-mutant non-small cell lung cancer (NSCLC). 21 patients enrolled in the study who underwent platinum-containing systemic chemotherapy and EGFR-TKI failure were enrolled in the study.
45629313|NCT02407691|Other|Primary care 101 plus mental health|A facility-based stepped care intervention combining depression case detection by non-physician clinicians with group counselling intervention delivered by lay-health workers.
45629314|NCT02407691|Other|Standard Primary Care 101|Standard Primary Care 101 guideline with standard training
45629315|NCT02407535|Device|Intraoperative ultrasound|Diagnostic intraoperative ultrasound in the uterus after hysterectomy for assessing depth of tumor invasion
45913182|NCT02019238|Other|Pulmonary Vein Isolation procedure|comparing the efficacy of PVI ablation vs PVI combined with empiric ablation
45913183|NCT02019251|Drug|perfluorinated gas/oxygen mixture|Subjects are imaged with MRI one time with the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
45629316|NCT05518617|Other|Positron Emission Tomography (PET) scan using DASB tracer|"DASB is a highly selective PET radioligand for serotonin transporter and is a reliable tool to investigate serotonin terminals and neurons.~The included Magnetic Resonance Imaging (MRI) sequences serve to provide additional information plus complement PET data.~To quantify dopaminergic pathology with [123I]FP-CIT SPECT,"
45629317|NCT02407379|Procedure|PAPD+SRP|Photoablation of the gingival epithelium was performed with at 810 nm diode laser (1 W output power, continuous wave mode, 66.7 J/cm2, a 0.6 mm optical fiber). SRP was performed using curettes. The periodontal tissues and the dental root were rinsed with the photosensitizer agent methylene blue (0.3% w/v in water). After 5 min., the treated areas were irradiated with at 635 nm diode laser (100 mW output power, continuous wave mode, 0.6 mm optic fiber). The photodynamic treatment was repeated once weekly until normalization of the cytodiagnostic parameters (range: 4-10 applications).
45629318|NCT02407379|Procedure|Sham-laser +SRP|Sham-treatment was similar to the previously described treatment but with switched off laser, followed by scaling and root planing
45629319|NCT04747431|Drug|PBFT02|PBFT02
45629320|NCT02407301|Other|cough airflow measure|Participants will produce multiple voluntary coughs for cough airflow assessment.
45769221|NCT03829202|Device|RheoKnee microprocessor prosthetic knee|Daily use of RheoKnee microprocessor prosthetic knee
45913184|NCT02019251|Device|MRI|
45913185|NCT02019290|Drug|Midazolam|Single oral doses will be given on Days 1 and 15, after an overnight fast.
45913186|NCT02019290|Drug|bitopertin|An oral dose will be given daily in the morning from Days 2-15. On Days 14 and 15, bitopertin will be given after an overnight fast; on Days 2-13, bitopertin will be given under fed conditions.
45629321|NCT02407301|Other|vocal tasks|The assessment of glottal closure will be performed during phonation tasks.
45629322|NCT02407301|Other|true vocal fold movement|The true vocal fold (TVF) movement in cough will be observed and recorded during cough production.
45769222|NCT03011216|Behavioral|Adaptive emotional cognitive control training|Is supposed to train ability to continuously update emotional material in working memory.
45769223|NCT03011216|Behavioral|Adaptive non-emotional feature match task|Does not train updating of working memory content; may train reaction time speed, visual search, or concentration abilities.
45769224|NCT03828578|Procedure|High flow oxygen therapy|High flow oxygen therapy delivered via Airvo2
45769225|NCT02965976|Biological|Botulinum Toxin Type A|Given IM
45769226|NCT02965976|Procedure|Esophagectomy|Undergo esophagectomy
45769227|NCT02965976|Other|Quality-of-Life Assessment|Ancillary studies
45913187|NCT02019316|Dietary Supplement|BioSteel Sports Drink|Participants will ingest 500ml of BioSteel Sports Drink 3 times during an exercise session.
45913188|NCT02019316|Dietary Supplement|Isoenergetic Control|Participants will ingest 500ml of Gatorade 3 times during an exercise session.
45769228|NCT03824288|Diagnostic Test|Intraoral ultrasound|The ultrasound transducer (either Hockey Stick or Burr-Hole N11C5s transducer from BK Ultrasound) is placed on the palatoglossal arch on the affected side and sweeped from the cranial to caudal end of the tonsil to look for an abscess cavity identified as a hypoechoic area with ill-defined margins.
45629323|NCT02407301|Other|spirometry test|The lung function test will require the participant to perform deep inhalations and forceful exhalations into the flow head of the spirometer during spirometry test.
45629324|NCT02407301|Other|maximum expiratory pressure (MEP)|The assessment of maximum expiratory pressure will require forceful exhalations into a mouthpiece of a manometer during maximum expiratory pressure (MEP) assessment.
45629325|NCT05506917|Procedure|periodontal treatment|Patients will receive an intensive (non surgical) regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrational to treat will be extracted at the oral hygiene visit. After the 2 months re-assessment individuals if presenting with at least one periodontal pocket of 6 mm in depth will undergo additional corrective periodontal therapy consisting of periodontal surgery and re-instrumentation under local analgesia. If surgical periodontal therapy is not indicated, appropriate re-instrumentation of the sites will be performed.
45629326|NCT02407145|Other|24 month follow up of women with validated questionnaire|24 month follow up (clinical and questionnaire based) of women who are already assigned to have a PVDF retropubic midurethral sling (DynaMesh®-SIS soft) as a part of their planned treatment of urodynamic stress incontinence.
45629327|NCT05506839|Other|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
45629328|NCT05506761|Procedure|ultrasound-guided erector spinae plane block|Patients will receive 20 ml plain bupivacaine 0.25 % bolus, then 10 ml per hour plain bupivacaine 0.125 % continuous infusion via ultrasound-guided erector spinae plane block
45769229|NCT03824288|Procedure|The landmark technique|A 14G needle aspiration is inserted blindly in the superior tonsil pol where pus aspiration is attempted.
45769230|NCT03047330|Drug|Leuprolide Acetate|one injection of open-label intramuscular dose of leuprolide (3.75-mg depot), a gonadotropin-releasing hormone agonist that rapidly suppresses estradiol and temporarily achieves ovarian suppression.
45769231|NCT03047330|Other|Fragmented sleep|Fragmented sleep will be experimentally induced.
45769232|NCT03008408|Drug|Everolimus|Given PO
45769233|NCT03008408|Drug|Letrozole|Given PO
45769234|NCT03008408|Drug|Ribociclib|Given PO
45769235|NCT00982397|Device|Protecta VR-ICD|Protecta single-chamber implantable cardioverter defibrillators.
45769236|NCT00982397|Device|Protecta DR-ICD or CRT-D|Protecta dual-chamber implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators.
45769237|NCT03828656|Device|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
45769238|NCT04125680|Behavioral|ESL Health Literacy Classes|The intervention will last 8-weeks, and the first and last classes will be devoted to survey assessments. Participants will be asked to reflect on their health knowledge and behaviors, and how they have changed since starting the program. The curriculum administered during the classes will use pedagogies for health literacy as a practice. It will focus on skills needed to learn about lead exposure in the ESL classroom: (1) vocabulary; (2) grammar; and (3) identifying risk factors, symptoms and preventive strategies. A focus on health literacy as practice will include personal engagement using language in context: (1) role-play interactions about lead exposure prevention; (2) discussing views about risk, and how to talk about it with peers and family members; (3) identifying sources of reliable health information; and (4) learning to ask for support and resources.
45769239|NCT04392596|Device|Bone Mineral Density and Trabecular Bone score|"structural damage in the cervical and lumbar spine was scored according to the modified Stoke AS Spinal Score (mSASSS) which yielded a final summation score ranging from zero to 72.~BMD was measured using DXA (Lunar Prodigy densitometer, GE Healthcare, Madison, WI, USA).~BMD was measured at the lumbar spine (L1-L4) and the left hip (femoral neck and total proximal femur).~TBS was analyzed using DXA images over exactly the same region as the lumbar BMD assessment (L1-L4). Lumbar spine DXA images were reanalyzed using TBS iNight software version 2.1 (Med-I maps, Merignac, France). Patients were divided in 3 TBS groups according to guidelines for fracture risk [22]: any TBS >1.31 was considered as normal; TBS values between 1.23 and 1.31 were consistent as partially degraded structure; and any TBS <1.23 was considered as degraded structure."
45769240|NCT05394389|Other|sensory stimulating therapy|therapy session in the snoozlen room accompanied by social support.
45629329|NCT05506761|Procedure|ultrasound-guided rhomboid intercostal block combined with sub-serratus plane block|Patients will receive 20 ml plain bupivacaine 0.25 % bolus, then 10 ml per hour plain bupivacaine 0.125 % continuous infusion via ultrasound-guided rhomboid intercostal block combined with sub-serratus plane block
45629330|NCT02407067|Device|ChatterVox|A voice amplifier will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.
45629331|NCT02407067|Device|Easy Listener FM system (Phonic Ear Corp.)|"A personal communication (FM) system will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.~Personal Communication System"
45629332|NCT02406989|Drug|MS-553|Study Drug
45629333|NCT02406989|Drug|Placebo|Matching placebo to MS-553
45769241|NCT05394389|Other|social support|ten minutes of conversing.
45913189|NCT02019329|Other|Placebo|Oral daily administration from Days 1-12
45769242|NCT02963948|Behavioral|Meetings with implementation leader(s)|The perceived appropriateness of the intervention to medical staff will affect an intervention's initial adoption as well as sustainability. We will assess this through focus groups with staff, conducted approximately 1-2 months after implementation of the screening and CDS tools.
45769243|NCT02963948|Behavioral|the SAAS survey|Medical staff will be surveyed using the Substance Abuse Attitude Survey (SAAS) to gather information about attitudes from medical staff who do not participate in the focus groups, or may be uncomfortable sharing negative attitudes in a group of their peers. The SAAS is a validated multidimensional instrument that evaluates physician attitudes toward substance-using patients. It includes specific measures of attitudes toward permissiveness, treatment intervention, stereotypes, treatment optimism, and moralism, and has been used in prior studies of primary care physicians. Collecting information on staff attitudes toward substance users and substance use interventions will be helpful to inform about any sources for low adoption of the tools, and any needs for additional provider education and training.
45769244|NCT02963948|Behavioral|Patient surveys|Patient surveys regarding attitudes toward substance use screening and interventions in the primary care clinic will be distributed to patients presenting for care, regardless of whether they completed screening, at regular time periods throughout this study phase. The survey will be conducted for 1 week at the following approximate intervals following successful implementation: 1 month, 4 months, 7 months, and 10 months
45769245|NCT03828812|Behavioral|Breakfast promotion|Recommendation of having breakfast daily
45769246|NCT03828812|Behavioral|Nighttime snack reduction|Recommendation of reducing frequency of nighttime snacking
45629334|NCT05508711|Device|FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device|Concomitant cardiac output measurement with transesophageal echocardiography and with the FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device in 3 different positions (horizontal supine, Trendelenburg and reverse Trendelenburg position).
45629335|NCT02406911|Drug|Ticagrelor|After randomization, each group will be treated as assigned dose of ticagrelor (ticagrelor 90mg once a day or 90mg twice a day) for 14 days. After 1 week wash-out period, cross-over study will be performed
45629336|NCT02406833|Drug|TGF-β2 antisense oligonucleotide|intravitreal injection
45629337|NCT02406833|Procedure|Trabeculectomy|Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control
45629338|NCT03173027|Drug|Fangji Huangqi pill or Fangji Huangqi pill placebo|For the treatment group (Fangji Huangqi pill group), patients will administrate Fangji Huangqi pill (4 g) in 200 milliliter hot water as the instruction and take the solution orally twice a day for 1 month. While patients in the placebo group will take Fangji Huangqi pill placebo as the same way as the Fangji Huangqi pill group. Besides that, both groups will administrate Mobic (7.5 mg once a day) in addition.
45629339|NCT03173105|Device|active tDCS|TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution. For stimulation of the motor motor, somatosensory, and visual cortices with a current of 2mA for 20 minutes. The cathode will be positioned in the medial supraorbital region.
45629340|NCT03173105|Device|sham tDCS|Sham TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution The stimulator will only be switched on for the first 30 seconds, giving the participant the initial sensation of tDCS, but no active stimulation throughout the remainder of the session the proprioceptive exercise session
45629341|NCT03173105|Other|Dynamic proprioceptive exercises|The dynamic proprioceptive exercises will be conducted as follows: 1) walking slowly then more quickly on a trampoline; 2) walking backward with one foot behind the other; 3) walking forward on a beam; 4) going up and down a flight of stairs; and 5) sitting on a Swiss exercise ball (65 cm) and performing laterolateral, anteroposterior, circling movements and bouncing. Activities will be performed in three one-minute sets.
45769247|NCT04393220|Drug|Bevacizumab Injection|15mg/kg (Q3W)
45769248|NCT04393220|Drug|Nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w
45769249|NCT01025453|Drug|Temsirolimus and Sorafenib|Treatment will be with sorafenib 200 mg orally twice a day and temsirolimus 25 mg intravenous weekly. A cycle will be equivalent to 4 weeks of treatment.
45769250|NCT04125602|Other|High fat low carbohydrate diet|Throughout the 6-day intervention, participants are provided with a high fat, low carbohydrate diet (HF-LCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25% respectively while the three macronutrients in the other 3-day diet account for 70%, 15% and 15% respectively. The sequencing of the two diets will be randomized.
45447497|NCT04365699|Drug|AT-001|Investigational novel Aldose Reductase Inhibitor (ARI) Product: AT-001 500mg capsule for oral administration Dosage: 1,500mg (3X500mg capsules) twice daily Mode of Administration: Oral Up to 14 days per discretion of the investigators and treatment team
45447498|NCT04005885|Device|comfilcon A|Contact Lens
45447499|NCT04005885|Device|somofilcon A|daily disposable contact lens
45447500|NCT04005885|Device|stenfilcon A|daily disposable contact lens
45447501|NCT04003623|Drug|Pemigatinib|Pemigatinib administered orally once daily.
45629342|NCT03173105|Other|static proprioceptive exercises|The static exercises will be conducted as follows: 1) standing on toes with feet apart; and 2) with feet together; 3) standing on only right leg without support; and 4) on only left leg without support; and 5) standing with heel of right (or left) foot touching toes of left (or right) foot with feet in a straight line over on an unstable surface (wobble board) performed in six sets of 30 seconds each, with a one-minute rest interval between sets
45629343|NCT03172793|Drug|Telavancin Injection|Receive 3 doses of telavancin as described in arm/groups, followed by collection of blood for pharmacokinetic analyses.
45629344|NCT03116087|Drug|Testosterone patch|300 mcg testosterone patches or placebo applied twice weekly
45629345|NCT03116087|Drug|Placebo|Placebo patch
45629346|NCT03116165|Behavioral|Modified prolonged exposure therapy|Participants will receive three sessions of modified prolonged exposure therapy.
45629347|NCT03116165|Behavioral|Attention control|Participants will receive three sessions of supportive counselling and psychoeducation
45629348|NCT04968821|Behavioral|Physical activity intervention|Participants randomized to the physical activity intervention will receive a Fitbit and be enrolled in Fitabase (Fitbit tracking system). Participants will also participate in 8 tele-health sessions with a physical therapist. Sessions will involve setting weekly physical activity goals and reviewing the participant's physical activity on the Fitbit tracking system.
45629349|NCT04968821|Other|Usual care|Usual postoperative care includes surgeon-directed lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
45629350|NCT03116009|Drug|Screening for diabetes with 1-hour GCT and HbA1|They will receive 50gm oral glucose tolerance test before 20 weeks and if abnormal, they will do the diagnostic test with 100gm OGTT with HbA1C.
45769251|NCT04125602|Other|Low fat high carbohydrate diet|Throughout the 6-day intervention, participants are provided with a low fat, high carbohydrate diet (LF-HCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 20%, 15% and 65% respectively while the three macronutrients in the other 3-day diet account for 10%, 15% and 75% respectively. The sequencing of the two diets will be randomized.
45769252|NCT05394311|Other|sports based mental health promotion program|sports related programs
45629351|NCT03115931|Other|no intervention|no intervention
45769253|NCT03824054|Procedure|colorectal resection|Surgery includes laparoscopic resection of all visible endometriosis, including resection of the affected bowel with primary anastomosis
45769254|NCT05394233|Drug|Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed|Bevacizumab: 7.5 mg/kg administered as an intravenous infusion on Day 1 of each 3-week cycle Cisplatin 75 mg/m2 will be administered as an intravenous infusion over 2 hours, every 3 weeks, Pemetrexed, 500 mg/m2, intravenously every 3 weeks, Tislelizumab, 200 mg IV every 3 weeks
45769255|NCT03824210|Other|App|Mobile phone app
45769256|NCT05394155|Dietary Supplement|Leucine|7 intake levels of leucine, ranging from 10 to 75 mg/kg/d.
45769257|NCT03823976|Other|Types of the dental procedures in general anaesthesia|Analysis of the mean number of preventive, prophylactic, therapeutic and rehabilitation procedures
45769258|NCT00982553|Drug|Ribavirin|800mg once daily
45769259|NCT00982553|Drug|Raltegravir|400mg twice daily
45447502|NCT01562847|Drug|Nilotinib|Patients will be treated with 800 mg nilotinib daily.
45629352|NCT02406755|Other|one-sensory self care (Todo Dia®)|daily use of odorless body moisturizer (Todo Dia® - Natura)
45629353|NCT02406755|Other|multisensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura) + audiovisual stimulus
45629354|NCT02406755|Other|bi-sensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura)
45629355|NCT02406599|Device|Margin Probe|The surgeon will use the MarginProbe System to identify cancerous tissue at the margins (≤ 1mm) of the main ex-vivo lumpectomy specimen following primary excision
45629356|NCT02406599|Other|Control: Additional inspection|The surgeon will perform additional inspection and assessment of the margins of the main ex-vivo lumpectomy specimen following primary excision
45629357|NCT04482023|Behavioral|Training video on anxiety, fear and loneliness in the COVID-19 environment.|Video with the actions identified as essential to address the diagnosis of anxiety, fear and loneliness in the environment COVID-19 identified by a group of experts.
45629358|NCT03172559|Radiation|Stereotactic body radiotherapy|The recommended dose will be 30 Gy in 5 fractions. The treatment will be administered in 5 alternative days and will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues.
45769260|NCT03823898|Behavioral|Supervised exercise|Two supervised exercise sessions per week from months 4 to 16
45769261|NCT03823898|Behavioral|Lifestyle intervention from baseline to 4 months|Lifestyle intervention from baseline to 4 months
45769262|NCT03823898|Behavioral|Monthly behavioral sessions|Monthly behavioral sessions consisted of lifestyle interactive sessions will take place monthly and covered and followed contents that were addressed during the first 4 months of the study
45769263|NCT02943590|Drug|Placebo|A pill taken once a day
45769264|NCT02943590|Drug|Atorvastatin|A pill taken once a day
45769265|NCT02945384|Behavioral|Creating Connections: Strong Families, Strong Brains|Dual-generation intervention
45769266|NCT02939300|Drug|Nivolumab|"Melanoma:~- Combination therapy with Nivolumab 1 mg/kg for 4 doses followed by monotherapy Nivolumab 480 mg per cycle.~Non-small Cell Lung Cancer / Head and Neck Cancer:~- Combination therapy with Nivolumab 3 mg/kg~Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~- Combination therapy with Nivolumab 1 mg/kg for 4 doses followed by monotherapy Nivolumab 240 mg per cycle.~Renal Cell Carcinoma / Other Solid Tumors (not listed above):~Combination therapy with Nivolumab 3 mg/kg for 4 doses followed by monotherapy Nivolumab 480 mg per cycle."
45769267|NCT02939300|Drug|Ipilimumab|"Non-small Cell Lung Cancer / Head and Neck Cancer:~- Combination therapy with Ipilimumab 1 mg/kg~Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~- Combination therapy with Ipilimumab 3 mg/kg for 4 doses~Renal Cell Carcinoma / Other Solid Tumors (not listed above):~Combination therapy with Ipilimumab 3 mg/kg for 4 doses"
45629359|NCT02701985|Drug|Placebo|Matching-placebo capsules will be administered orally, 2 times a day with food.
45629360|NCT02701985|Drug|RO5459072|RO5459072 at a dose of 100 milligrams (as capsules) will be administered orally, 2 times a day with food.
45769268|NCT02918474|Other|Decision Aid|Use decision making tool
45629361|NCT03172169|Other|no Intervention|no Intervention
45629362|NCT02064868|Drug|Serelaxin|30 µg/kg/day IV infusion
45629363|NCT02064868|Drug|Standard of Care|This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
45629364|NCT03171935|Device|High-Flow Nasal Cannula Oxygenation|High-flow nasal cannula oxygenation will be applied immediately after early extubation, with a gas flow rate of 50 liters per minute and a fraction of inspired oxygen of 1.0 at initiation. The fraction of inspired oxygen will be subsequently adjusted to maintain a peripheral oxygen saturation of 92% or more.
45629365|NCT03171935|Device|Noninvasive Positive Pressure Ventilation|Noninvasive positive pressure ventilation will be applied immediately after early extubation, with a noninvasive ventilator (Respironics V60, Philips) using the NIPSV mode at initiation. The fraction of inspired oxygen will be adjusted to achieve SpO2 >92% with an initial expiratory positive airway pressure (EPAP) of 4 cmH2O. EPAP will be increased gradually in increments of 1-2 cmH2O, up to a maximum of 12 cmH2O, to achieve SpO2 >96%. Inspiratory positive airway pressure (IPAP) will be initially set at 8 cmH2O and be increased gradually in increments of 1-2 cmH2O according to patients' tolerance to obtain a tidal volume (VT) of 6-8 mL/kg.
45629366|NCT03171935|Device|Conventional weaning|The patients will undergo conventional weaning protocol. Extubation and subsequent oxygen therapy with venturi mask will be performed after successful spontaneous trial.
45629367|NCT03172013|Diagnostic Test|Platelet indices|MPV, PDW
45769269|NCT02918474|Other|Questionnaire Administration|Ancillary studies
45769270|NCT02918162|Drug|Pembrolizumab|Pembrolizumab dosed IV at 200mg every 21 days per cycle.
45629368|NCT03172091|Device|eNose (electronic nose)|Collection of exhaled breath for an immediate analysis by electronic nose
45629369|NCT03172091|Device|Spectrometry|Collection of exhaled breath for an immediate analysis by mass spectrometry
45629370|NCT02406521|Drug|Pazopanib|
45629371|NCT02406521|Drug|Sorafenib|
45629372|NCT02406521|Drug|Radium-223|
45769271|NCT02918162|Drug|Standard of care chemotherapy regimen|"Standard regimen containing at least a platinum and Fluorouracil (5-FU) agent (per National Comprehensive Cancer Network guidelines) - such as Doublet or Triplet chemotherapy with capecitabine, oxaliplatin, and epirubicin (optional) (21 day cycle). Epirubicin can be excluded at the discretion of the treating physician.~Example:~Oxaliplatin dosed IV at 130 mg/m2 every 21 days per cycle. Capecitabine dosed orally at 625mg/m2 twice a day daily."
45769272|NCT03823664|Diagnostic Test|Cardiorespiratory Fitness|Maximal symptom limited cardiopulmonary exercise test used assessment of cardiorespiratory fitness. For pulmonary function spirometry test and maximal respiratory pressures assessed.
45769273|NCT03823508|Device|anodal tDCS|Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and a high density EEG. The anode will be placed over F3 in order to stimulate the left dorsolateral prefrontal cortex and the cathode over the right supraorbital area.
45629373|NCT02406287|Drug|Netarsudil (AR-13324) Ophthalmic Solution|Topical ophthalmic solution
45629374|NCT02406287|Drug|Netarsudil (AR-13324) Ophthalmic Solution Placebo|Ophthalmic solution once a day
45629375|NCT02406365|Device|Diagnostic imaging aid for one-visit management of cervical lesions|
45769274|NCT03823508|Device|sham tDCS|Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
45769275|NCT02910986|Behavioral|Written educational brochure|Written educational brochure about breast density
45769276|NCT02910986|Behavioral|Promotora interaction|Promotora education about breast density
45769277|NCT03822260|Diagnostic Test|Bezmialem VAkif Unv. Ethical board|If ıs any trials not convenient to Helsinki Agrement about Human research rules
45769278|NCT04392128|Drug|Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Hydroxychloroquine is an anti-malarial drug also used as anti-inflammatory treatment for systemic lupus erythematosus and rheumatic disorders. HCQ also inhibits pH-dependant replication stages of diverse types of viruses including flavivirus, retrovirus and coronaviruses.
45769279|NCT04392128|Drug|Azithromycin 250 MG Oral Capsule|Azithromycin is amacrolide antibiotic.
45769280|NCT04392128|Drug|Placebo oral tablet|Placebo of Hydroxychloroquine Sulfate 200 MG [Plaquenil].
45769281|NCT04392128|Drug|Placebo oral capsule|Placebo of Azithromycin capsules.
45769282|NCT03822026|Other|Hyperventilation test|Increase of the alveolar ventilation by a stepwise increase in tidal volumes and respiratory rate until a reduction of end-tidal CO2 of 0.7 kPa is achieved
45769283|NCT04125056|Drug|Hydronidone Capsule(Specification: 30 mg / grain）|Test group
45769284|NCT04125056|Drug|Hydronidone Capsule(Specification: 15 mg / grain）|Control group
45913190|NCT02019329|Drug|RO5545965|Oral daily administration from Days 1-12
45629376|NCT02406131|Other|Remote Ischemic Preconditioning|standard blood pressure cuffs applied to upper limb . The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles
45629377|NCT02405975|Other|SCRIPT|An online tool designed to train doctors in all areas of prescribing
45913191|NCT02019329|Drug|risperidone|13 day run-in phase until 4 mg daily dose level is reached. 4 mg daily oral dose until Day 17 of study, for a total of 30 days. Dose may be increased up to 6 mg at the investigator's discretion. After study treatment, risperidone dosage may be decreased, increased or omitted at the investigator's discretion during a wash-out phase while patients return to their chronic antipsychotic treatment. Patient response during wash-out will be monitored in-house for 48 hours after the last dose of RO5545965 or placebo is administered. This in-house observation may be extended as needed by the investigator.
45629378|NCT02405897|Device|Cup forceps|In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using cup forceps
45629379|NCT02405897|Device|Alligator forceps|In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using alligator forceps
45629380|NCT02406053|Genetic|oxidative and antioxidant biomarkers|the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.
45629381|NCT02064166|Drug|Intranasal Insulin|"treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks;~placebo arm: normal saline, daily, intranasally, for 4 weeks."
45629382|NCT04482335|Other|No intervention|No intervention
45629383|NCT02405741|Device|Hyperbaric chamber treatment|
45629384|NCT02405819|Other|'My Care Plan'|'My Care Plan' is a patient-initiated survivorship care planning tool.
45629385|NCT02405819|Other|'Survivorship Care Plan Builder'|'Survivorship Care Plan Builder' is a provider-initiated survivorship care planning tool.
45629386|NCT02405663|Procedure|manual removal|one of the standard procedures for placental delivery during caesarean section the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby
45629387|NCT02405663|Procedure|cord traction|one of the standard procedures for placental delivery during caesarean section the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery
45629388|NCT03171467|Procedure|Salpingectomy|
45629389|NCT03171779|Other|Patients approaching the end of their lives|To determine whether the use of simple tools by a primary care team for the early identification of end-of-life patients can improve access to specialized palliative care resources
45629390|NCT03171623|Drug|globalagliatin hydrochloride|orally administration, single dose
45629391|NCT03171623|Drug|placebo|orally administration, single dose
45629392|NCT03171389|Drug|Ponatinib 30 MG|Ponatinib: once-daily oral dose of 30mg. A cycle of treatment is defined as 28 days. Doses may be reduced to manage drug-related adverse events and may be re-escalated once events resolve.
45629393|NCT02405507|Dietary Supplement|wheat bread with wheat germ|
45629394|NCT02405507|Dietary Supplement|wheat bread without wheat germ|
45629395|NCT02405273|Procedure|Pulmonary Rehabilitation|The Intervention Group (IG) will receive an overall rehabilitation treatment based on 10 sessions of pre-operative outpatient PR, early inpatient post-operative PR, and long-term exercise beginning 1 month after surgery and lasting for 15 sessions
45629396|NCT02405273|Procedure|Standard care|Control Group (CG) will receive Standard Care (SC) based upon physiatrist counselling the day before surgery and early inpatient post-operative PR.
45629397|NCT02565615|Other|No intervention|Because this is a non-interventional study, there is no intervention here.
45629398|NCT02405117|Behavioral|LiveWell System|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study
45629399|NCT03170999|Other|Focus group interview|Focus group interviews will take place to discuss the key domains of COPD exacerbation which then will be used in the formation of the draft item set.
45629400|NCT03170999|Other|Draft item set|Items that form the draft item set will be subject to cognitive debriefing. Questions in the draft item set will collect information on whether the subjects with COPD have experienced that item during an exacerbation. Changes in this draft set will result in the formation of candidate item set.
45629401|NCT03170999|Other|Candidate item set|Item reduction will be done using candidate item set and the subjects will be asked to respond to the candidate items on a 4-point scale in terms of how that item changed with the onset of the last episode. Item reduction will take into account frequency and magnitude of items, floor and ceiling items and consistency between regions. The candidate item set will then be used for generation of CERT.
45629402|NCT03171077|Other|Virtual Rehabilitation|It is the use of the NW games for rehabilitation of balance in post-stroke patients.
45629403|NCT03171077|Other|PNF Method|It is the use of the therapeutic exercises based on the PNF diagonals for rehabilitation of balance in post-stroke patients.
45629404|NCT03171077|Other|Virtual Rehabilitation and PNF Method|It is the use of the exercises based on the PNF diagonals and of the NW for rehabilitation of balance in post-stroke patients.
45629405|NCT05508633|Drug|Alverine Citrate|Low-dose group: Alverine (60 mg, 1 capsule) High-dose group: Alverine (120 mg, 2 capsules) The drug is orally given with 200 ml warm water after measurement of the baseline portal pressure.
45629406|NCT04482257|Drug|Irinotecan Liposome Injection combined with 5-FU/LV|Drug: Irinotecan Liposome Injection 70mg/m2 (CSPC) combined with 5-FU/LV; Drug: Irinotecan Liposome Injection 70mg/m2 (Ipsen, ONIVYDETM) combined with 5-FU/LV;
45629407|NCT02701361|Behavioral|mobile mindfulness|Receives audiovisual mindfulness content via internet plus call depending on symptoms or request.
45629408|NCT02701361|Behavioral|standard mindfulness|Receives weekly calls from mindfulness expert for 4 weeks.
45913192|NCT02019342|Other|FACE quality improvement initiative (see below)|Feedback (F): Regular feedback to practitioners; MAP Alerts (A): Change in electronic alert systems for high and low mean arterial pressure with patient specific alerts; Checklist (C): Interactive checklist in relation to the quality improvement initiative; Education campaign (E): Education campaigns about best intraoperative management of blood pressure.
45629409|NCT02701361|Behavioral|education|Receives web-based content about critical illness topics. Also receives two calls from study team to describe materials and answer questions about materials.
45769285|NCT05504850|Other|Multicultural Health Diet|The food-based components will be similar to the anti-inflammatory diet of the ongoing MHD study (NCT03240406), which emphasizes limiting animal and high saturated fat foods with focus on anti-inflammatory foods/food components specific to the cultural context of the participant. The diet will also be tailored to needs of the CKD population including a focus on lowering sodium intake. The intervention (dietary counseling) will be delivered by experienced kidney disease nutritionist.
45629410|NCT05506527|Other|Sensorimotor program and plyometric exercise|"Children in study group A will receive combined plyometric exercises (vertical paradigm) and sensorimotor program~- Children of the study group B will receive sensorimotor program alone."
45629411|NCT04935671|Dietary Supplement|chamomile tea n saffron|20 mg of chamomile and 1 mg saffron in a teabag given twice daily for a month in combination with allopathic treatment for depression.
45769286|NCT02891954|Drug|Canagliflozin|Healthy volunteers will receive canagliflozin (300 mg per day) in the morning for five days.
45769287|NCT02565186|Drug|Lasmiditan|oral tablet
45769288|NCT03823352|Drug|Antroquinonol|Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
45629412|NCT05506371|Drug|Az+SRP|Azithromycin as an adjunct to scaling and root planning in the treatment of periodontitis
45629413|NCT05506371|Drug|SRP|Scaling and root planning (SRP) treatment of periodontitis
45629414|NCT05506371|Drug|No interventions|Diagnostocs to confirm the healthy state of the gingiva
45629415|NCT02404727|Procedure|cup fixation|All patients will preoperatively, 3 months, 1 year, 2 year and 5 year have the hip DXA scanned, answer PROM, X-ray for RSA analysis and wear measurements, and wear accelerometry chip 14 days prior each outward clinic visit for movement analysis.
45629416|NCT02404727|Device|Avantage® Cup|
45629417|NCT05508555|Procedure|hyperthermic intrathoracic chemotherapy|application of chemotherapeutic agent intrathoracic under hyperthermic conditions
45629418|NCT02404883|Other|Online Decision-Aid Tool|
45629419|NCT05502705|Drug|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery
45629420|NCT05502705|Other|Normal saline (NS)|Patients are received equal volumes of saline intravenously until the end of the surgery
45629421|NCT05508477|Biological|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) contains purified S protein of SARS-CoV-2 - Dose: 5 µg, aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005%, Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial (1 ml per vial). One vial will be used for one injection only. The vial should be shaken well before injection.
45769289|NCT03823586|Diagnostic Test|Questionnaire AQUA©, pediatric version|A version of AQUA© recently adapted and pretested in young athletes. It is a self-administered questionnaire composed of 25 items includes items about type, duration and intensity of training sessions, allergic status, habits of children (supplements and drugs intake) and their parents (smoking), presence and burden of infections.
45629422|NCT05508477|Biological|CoronaVac Biofarma COVID-19 Vaccine|Control vaccine in this study is existing CoronaVac-BioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia
45629423|NCT02404961|Other|Vulvodynia|Comparison of reproductive, gynecological and environmental exposures, psychological trauma and psychiatric morbidity, and biological markers of immuno-inflammation and nerve fiber proliferation between cases and controls to determine potential etiology of vulvodynia.
45769290|NCT04124978|Device|mandibular advancement device|use of prefabricated adjustable mandibular advancement device to improve OSA
45769291|NCT04758494|Other|Questionnaire|"In the present study a questionnaire was designed by combining three separate questionnaires, which were weighted for use in Greek population and which are often being used to investigate quality of life of young populations diagnosed with stroke or multiple sclerosis, according to international literature. Those were the following questionnaires: Bathrel (Mahoney et al), Patient Health Questionairre (PHQ-9) (Thomson K et al), Health Survey SF-12 (Kontodinopoulos et al 2007). A draft questionnaire was then created with the addition of questions deemed necessary to provide necessary research information. Overall the questionnaire consisted of 42 questions.~Part A The first part of the questionnaire included demographics of participants. Part B. The second part of the questionnaire included an assessment of the functionality and independence, an evaluation of experienced depression and an assessment of the quality of life of the target population."
45629424|NCT02405039|Drug|EBI-005|EBI-005 is an intervention into one of two (2) study arms; 5 mg/mL topical administered 3 times per day
45629425|NCT02405039|Drug|Placebo|Placebo or Vehicle control comparator is an intervention into one of two (2) study arms; vehicle topical administered 3 times per day
45629426|NCT03171233|Other|Mobilization with movement|Participants Mobilization Group with Movement are positioned knee facing the physiotherapist, are not elastic passages above the participant's malleolus and are from the physiotherapist's pelvis. The therapist applies a posterolateral slip sustained to a tibia through the belt, leaning backward, while the talus and forefoot are secured with the space between the thumb and the second finger of the hand of both hands. The participant will be instructed to perform a slow dorsiflexion movement for their maximum amplitude.
45769292|NCT04274504|Diagnostic Test|Osteopontin|Serum osteopontin (OPN) was measured by ELIZA and osteopontin gene mutation was analyzed by sequencing and correlated with clinicopathological criteria, response, PFS and OS.
45769293|NCT04694586|Drug|rifampicin|rifampicin 35 mg/kg
45769294|NCT04694586|Drug|pyrazinamide|pyrazinamide 40 mg/kg
45769295|NCT04694586|Drug|HRZE|isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg combination tablets
45769296|NCT04694586|Drug|HR|isoniazid 75 mg + rifampicin 150 mg combination tablets
45769297|NCT02872532|Procedure|Testicular tissue cryopreservation|Testicular tissue will be removed
45769298|NCT04274816|Drug|Tremelimumab|Intradermal injection of tremelimumab 7 days prior to sentinel node biopsy, with escalating doses of 2, 5, 10 or 20 mg tremelimumab (3 patients per dose level with an expansion at the optimal dose level with an additional 5 patients).
45629427|NCT03171233|Other|Self mobilization with movement|In the Auto Mobilization with Movement group, participants will self-mobilize the ankle on top of a box (15 centimeters with a 10 ° incline), a non-elastic band will pass below the malleoli and the back of the band will be placed in the middle of the other Lower limb, thus mobilizing the talus in the posteroinferior direction, the participant should maintain the force in that direction while making the dorsiflexion movement in closed kinetic chain until returning to the initial position again. Using the same group protocol as the therapist will help.
45447503|NCT03744195|Other|Group I Experimental Kinesotaping|"For application of kinesotaping following procedure will be adopted:~The skin will be cleaned properly with alcohol~The first strip will be applied in Y-shape (15-20% stretch) surrounding the deltoid muscle to provide inhibition and muscle relaxation~A second strip (I-shape) will be applied for functional correction (50-75% stretch), passing over the supraspinatus, trapezius, glenohumeral joint and middle deltoid Daily Strengthening Exercises (3 sets / 10~30 reps) Joint mobilization (3 sets / 60 seconds hold / 30 seconds interval) Stretching Exercises (3 sets / 30 seconds hold / 30 seconds interval"
45447504|NCT03744195|Other|Group II conventional training group|Joint mobilization (3 sets / 60 seconds hold / 30 seconds interval) Stretching Exercises (3 sets / 30 seconds hold / 30 seconds interval) Strengthening Exercises (3 sets / 10~30 reps)
45769299|NCT03252938|Drug|IMP321|LAG-3Ig fusion protein, highly potent activator of antigen presenting cells
45769300|NCT03252938|Drug|Avelumab|Avelumab i.v.
45769301|NCT05509374|Drug|Carfilzomib 56 MG [Kyprolis]|Carfilzomib 56 mg/m2 (Day1, 8, 15) (Cycle1 Day1, 20 mg/m2)
45769302|NCT05509374|Drug|Pomalidomide|Pomalidomide 4 mg per os (Day1-21)
45769303|NCT05509374|Drug|Dexamethasone|Dexamethasone 40 mg (D1, 8, 15, 22) (20 mg for patients ≥ 75 years old)
45769304|NCT02862938|Drug|NT-501 ECT implant|NT-501 ECT implant will be placed into the vitreous and out of the visual axis of the study eye. The surgical procedure involves making a small incision through the sclera (white part of the eye), inserting the implant and securing it with a suture.
45769305|NCT02862938|Other|Sham|Sham surgery
45769306|NCT04675554|Other|Follow up of physical activity|participants will fill in the non-opposition form via the application and will complete, with their smartphone, a series of psychometric questionnaires. Participants will then use the mobile application for a period of 12 weeks during which time, physical activity data provided from participants smartphone will be gathered After 12 weeks, participants will complete again the same series of psychometric questionnaires.
45447505|NCT04480424|Biological|GAMUNEX-C|Intravenous Immune Globulin (Human), 10% Caprylate/Chromatography Purified.
45769307|NCT04124744|Other|Health Champions intervention|Health Champions are trained volunteers who will support service users with their physical health goals over 9 months, meeting once a week
45769308|NCT04124744|Other|Control group-treatment as usual|Participants will receive treatment as usual from their Community Mental Health Team
45769309|NCT04124822|Drug|Piroxicam 20 mg|Piroxicm is from oxicam family of anti inflammatory drug that inhibits prostaglandin synthesis and effectively lower pain threshold levels
45769310|NCT04124822|Drug|prednisolone 20 mg|prednisolone is from steroid family of anti inflammatory drug that inhibit arachidonic acid and effectively lowers the pain
45769311|NCT01453790|Behavioral|Parent-Specific Depression Education and Motivation|Parent-specific written and verbal depression messages garnered from previous research were consolidated into a pamphlet and script, respectively. These are dispensed after randomization in the pediatric office. At two days, mothers in the experimental group receive a motivational telephone call.
45769312|NCT01453790|Behavioral|General Depression Education-Motivation|General depression education messages were compiled and are delivered verbally (scripted) and written (JAMA Depression Patient Page) after randomization in the pediatric office. At 2 days, mothers in the comparison group receive an attention control telephone call.
45769313|NCT04802226|Other|self exclusion procedure|self exclusion procedure( responsible gambling tool)
45447506|NCT04480424|Drug|Standard Medical Treatment|SMT per local policies or guidelines.
45447507|NCT03745443|Procedure|increase and decrease positive end-expiratory pressure|20 minutes before the end of anesthesia and surgery PEEP was increased by 2 on every 5 breaths to 11. Ventilation with PEEP 11 was maintained for 2 minutes. Then, PEEP was reduced by 2 on every 5 breaths to 5 cmH2O
45447508|NCT03927573|Drug|GEM3PSCA|Infusion of GEM3PSCA, administered intravenously, continuously over 7 days, 2 cycles
45447509|NCT04474886|Dietary Supplement|Fresubin® powder fibre|2 servings per day
45447510|NCT04473716|Drug|Toripalimab|Neoadjuvant therapy with Toripalimab of 240mg, iv, qd, on day 1, 22
45447511|NCT04473716|Drug|Paclitaxcel|Neoadjuvant therapy with Paclitaxcel of 260mg/m2, iv, qd, on day 1, 22
45769314|NCT02938130|Other|Wellness Programs|Wellness Programs delivered in the Community Partners and Community LIFE programs
45769315|NCT05504694|Drug|Ofatumumab|"The enrolled patients will receive ofatumumab (20 mg/0.4 ml) subcutaneously administered at baseline, Day 7, Day 14 and monthly thereafter. Patients will receive ofatumumab therapy for a total of 48 weeks.~The first 4 infusions will be administered at study center site; subsequent infusions will be given in the patient's home with a nurse online interview to administer the infusion."
45447512|NCT04473716|Drug|Cisplatin|Neoadjuvant therapy with Cisplatin of 75mg/m2, iv, qd, on day 1, 22
45769316|NCT02854670|Drug|Capsaicin patch|After a pre-medication with paracetamol, patches are applied and removed after 20 minutes. Patients remain under observation for 2 hours after removal.
45769317|NCT05509296|Device|SINOMED CBC|The Coronary Dilatation Balloon Catheter is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.
45769318|NCT05509296|Device|NSE Coronary Dilatation Catheter|The Coronary Dilatation Balloon Catheter is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.
45769319|NCT02937272|Drug|LY3200882|Administered orally
45769320|NCT02937272|Drug|LY3300054|Administered intravenously
45769321|NCT02937272|Drug|Gemcitabine|Administered intravenously
45769322|NCT02937272|Drug|nab-Paclitaxel|Administered intravenously
45769323|NCT02937272|Drug|Cisplatin|Administered intravenously
45769324|NCT02937272|Radiation|Intensity Modulated Radiotherapy|
45769325|NCT05509218|Behavioral|Mobile-delivered personalized feedback|Following each daily survey on which a participant indicates prior day drinking, personalized feedback will be provided on how their most recent behavior (e.g., drinks last night, drinking days so far this week) compare/contrast with personal goals. Participants will then choose whether to receive additional feedback in any of 7 areas: blood alcohol concentrate on, high risk behaviors, consequences of drinking, caloric intake, spending, how drinking compares to peers, and safe drinking strategies. All participants will receive feedback on drinks consumed, and then be asked to choose at least one additional topic for feedback (following each drinking day). In addition to day-level feedback, an aggregate feedback report on drinking patterns and related behaviors will be delivered twice, once at the end of each 2-week period. Once again, they will have the option to view feedback across the range of topics noted above.
45629428|NCT05506293|Procedure|percutaneous paravalvular leak closure|"the procedure consists of deployment of an occluder or a vascular plug within the cardiac paravalvular leak. The device is inserted percutaneously from a femoral vascular approach or from a trans-apical approach. The device is deployed through a delivery sheath within the leak. Stability and efficacy to occlude the leak are assessed by transoesophageal echocardiography prior to device release.~Type of devices to be inserted varied :~Amplatzer vascular plug 3~occlutech paravalvular leak device~amplatzer vascular plug 2~amplatzer muscular ventricular septal defect~amplatzer vascular plug 4~Devices to be implanted are under the responsability of the local investigator and are not based on the study design."
45629429|NCT05508321|Diagnostic Test|Nasal brushing|Nasal brushing to harvest nasal cells and perform staining experiments
45629430|NCT05508321|Diagnostic Test|Sniffin' Sticks|Assessment of olfactory function
45629431|NCT05502627|Drug|0.25% lemon grass oil mouthwash|0.25% lemon grass oil mouth wash given twice daily for fourteen days to the patients of chronic periodontitis after scaling in experimental group and in control group only scaling was done.
45629432|NCT05506137|Drug|Pilocarpine|study whether topical pilocarpine drops induce a clinically significant improvement in xerostomia
45913193|NCT02019342|Other|Pre-quality improvement initiative|Patients in the pre-quality improvement initiative arm would receive current standard practice.
45913194|NCT02019355|Drug|5-fluorouracil 5% cream|
45447513|NCT04473716|Procedure|Radical surgery|Radical surgery will be performed on the 43th-48th after initiation of inductive therapy.
45629433|NCT05506137|Other|Placebo|study whether topical pilocarpine drops induce a clinically significant improvement in xerostomia
45629434|NCT04742283|Drug|DE-126 Ophthalmic Solution 0.002% QD|DE-126 Ophthalmic Solution QD evening and Vehicle QD Morning
45629435|NCT04742283|Drug|Timolol Maleate Ophthalmic Solution 0.5% BID|Timolol Maleate Ophthalmic Solution BID (morning and evening)
45629436|NCT04289805|Drug|Letrozole|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: letrozole is orally administered (5mg/d) from cycle day 2-3 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist."
45629437|NCT04289805|Other|standard-stimulated cohort|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: Gonadotrophins started from cycle day 2-3 throughout the ovarian stimulation until ovulation triggering.~Random start protocol: Gonadotrophins started at any time of the cycle and throughout the stimulation.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist."
45629438|NCT05502549|Drug|CB03-154|CB03-154 tablet once daily.
45447514|NCT04473716|Radiation|Post-operative radiotherapy/chemoradiotherapy|Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathological diagnosis.
45447515|NCT03891680|Drug|Botox Injectable Product|Intra articular Botox injection
45447516|NCT03891680|Device|Radiofrequancy|Genicular nerves radiofrequancy
45447517|NCT03887234|Procedure|Coracoclavicular ligament reconstruction|Arthroscopically conducted ligament reconstruction for the treatment of an AC dislocation
45447518|NCT03256526|Drug|Placebo|0 mg
45447519|NCT03256526|Drug|PF-06835919 Low Dose|75 mg once daily
45447520|NCT03256526|Drug|PF-06835919 High Dose|300 mg once daily
45447521|NCT03255980|Device|Xonrid® gel|Water based gel for the management of toxicity skin symptoms induced by Radiotherapy
45629439|NCT05502549|Drug|Placebo|Placebo tablet once daily.
45629440|NCT05508165|Device|Stream Dx|home uroflowmetry device
45629441|NCT05508165|Device|DFree|at home wearable bladder scanner
45913195|NCT02019355|Drug|Calcipotriol 0.005% ointment|
45447522|NCT03255980|Other|Standard of Care|Standard of care suggested by MASCC' Skyn Toxicity Study Group guidelines
45447523|NCT03228212|Device|CONTROL|ACUVUE OASYS
45447524|NCT03228212|Device|TEST|senofilcon A with new UV blocker
45447525|NCT04003155|Drug|fezolinetant|Oral Tablet
45913196|NCT02019355|Drug|Vaseline|
45447526|NCT04003155|Drug|placebo|Oral Tablet
45629442|NCT05508165|Device|TestCard|mobile urinalysis reader
45913197|NCT02019368|Dietary Supplement|Placebo|
45629443|NCT05508087|Diagnostic Test|electrocardiography, echocardiography with the determination of global longitudinal strain, cardiopulmonary exercise test, and diagnostic of endothelial function by Angioscan|We use electrocardiography, echocardiography with the determination of global longitudinal strain, cardiopulmonary exercise test, and diagnostic of endothelial function by Angioscan for the prediction of cardiovascular complications after high dose chemotherapy and hematopoietic cell transplantation in patients with haemoblasts.
45629444|NCT05505981|Other|Immediate PT|Patients will start PT immediately
45629445|NCT05505981|Other|Rest until pain resolves|Patients will wait to start PT until their pain resolves
45629446|NCT04286373|Device|active stimulation then placebo stimulation|"The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.~A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation.~VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).~The two stimulation periods will be separated by a 4 weeks wash-out period."
45629447|NCT04286373|Device|placebo stimulation then active stimulation|"VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).~The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.~A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation.~The two stimulation periods will be separated by a 4 weeks wash-out period."
45629448|NCT02566785|Other|Balance Intervention|The multi-component balance intervention will be 1x per week in supervised group sessions and 2x a week sessions at home. Sessions will begin with a 5 minute warm up of major muscle groups using flexibility exercises and end with a cool down. Sessions will focus on improving static balance in the initial stages, then progress to dynamic balance.
45629449|NCT04782921|Device|Xenogenic bone graft material|After access to the periodontal defect via straight incision in vestibulum, at the mucogingival border or short releasing incision on adjacent tooth, Gel 40 (a mixture of collagen gel and xenogenic bone particles) or Gen-Os (pure xenogenic bone particles) will be inserted.
45629450|NCT05502471|Diagnostic Test|Zonulin|Serum zonulin level
45629451|NCT05502471|Diagnostic Test|Occludin|Serum occludin level
45629452|NCT05508009|Drug|Cyclophosphamide 1200 mg/Kg|Cyclophosphamide 1200 mg/Kg will be administered as part of the conditioning regimen A prior to HSCT
45629453|NCT05508009|Drug|Fludarabine|Fludarabine (starting dose 0.5 mg/Kg and then PK guided to reach an AUC of 18-20) will be administered as part of the conditioning regimen prior to HSCT
45769326|NCT01453868|Other|Non Impact Aerobics|a 12 week, twice a week class in non impact aerobics
45769327|NCT01453868|Other|Passive : lecture series|a 12 week, once a week for one hour lecture series with no exercise. Topics will cover symptom management in Multiple Sclerosis
45769328|NCT05509140|Other|observation|investigate the clinical effectivity of intravenous methylprednisolone repeated intermittent pulse combined with mycophenolate mofetil in the treatment of newly diagnosed juvenile dermatomyositis
45629454|NCT05508009|Drug|Cyclophosphamide 100 mg/Kg|Cyclophosphamide 100 mg/Kg will be administered as part of the conditioning regimen B prior to HSCT
45629455|NCT05508009|Radiation|Total Body Irradiation|Total Body Irradiation 200 cGy will be administered as part of the conditioning regimen prior to HSCT
45629456|NCT05508009|Drug|ATG|ATG 7.5 mg/Kg will be administered as part of the conditioning regimen prior to HSCT
45629457|NCT05508009|Drug|Rituximab|Rituximab 200 mg/m2 will be administered within 24 hours of the HSCT
45629458|NCT05508009|Drug|Melphalan|Melphalan 100 mg/m2 will be administered as part of the conditioning regimen prior to HSCT
45769329|NCT03519308|Drug|Nivolumab|Before Surgery Wks 1 &3, After Surgery Wks 1 &3
45769330|NCT03519308|Drug|Nab-Paclitaxel|Wks 1,2,3 before surgery and Wks 1, 2,3 after surgery
45769331|NCT03519308|Drug|Gemcitabine|Wks 1,2,3 before surgery and Wks 1,2,3 after surgery
45769332|NCT03519308|Drug|Paricalcitol|Wks 1,2,3, 4 before surgery and Wks 1,2,3 after surgery
45769333|NCT02843282|Behavioral|Advanced Reasoning Training|This is a strategy-based intervention to enhance frontal lobe function. Strategies equip participants to improve their strategic attention, integrated reasoning, and innovation abilities.
45769334|NCT03821714|Drug|Glucocorticoid combination therapy|Glucocorticoid combination therapy is defined as the combination of hydrocortisone, vitamin C, and vitamin B1.
45769335|NCT03821714|Drug|Glucocorticoid|The glucocorticoid group was defined as the use of hydrocortisone alone.
45769336|NCT01454024|Device|FlexPen®|Prescribed insulin treatment delivered by FlexPen® as part of routine clinical practice
45769337|NCT01454024|Device|NovoPen® 3|Prescribed insulin treatment delivered by NovoPen® 3 as part of routine clinical practice
45913198|NCT02019368|Dietary Supplement|Aged garlic extract|
45629459|NCT05508009|Device|CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System|CliniMACS® TCRαβ-Biotin and CD19 Systems will be used to create the mobilized peripheral blood stem cells (PBSC) from allogeneic donors depleted of TCRαβ+ T cells and CD19+ B cells to be infused into the patient for the HSCT. The target dose for the number of CD34+ HSC infused is > 10 x 10^6 cells/Kg recipient weight. The minimum dose is 2 x 10^6 cells/Kg. There is no upper limit to the dose of CD34+ HSC infused as long as no more than 1 x 10^5 TCRαβ+ T-cells/Kg are infused. The target dose of TCRαβ+ T cells/Kg is < 0.50 x 10^5.
45769338|NCT02565108|Drug|GWP42003-P 20 mg/kg/Day Dose|GWP42003-P was an oral solution containing 25 mg/mL cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
45629460|NCT05508009|Procedure|Kidney Transplant|In the presence of donor myeloid engraftment, at least 3 months post-HSCT, with > 95% donor CD3+ chimerism, in the absence of signs of active aGvHD or cGvHD (moderate or severe), at least 4 weeks off of immunosuppression for any previously occurring acute or chronic GvHD (except single agent treatment of mild cGvHD), and with a BMI >18.5, ambulatory and active in addition to the eligibility for the standard of care KT criteria, patients will undergo a living donor KT using same donor as HSCT
45629461|NCT05505669|Other|One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.|One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.
45629462|NCT05502393|Drug|JS107|JS107, i.v., q3w
45769339|NCT02565108|Drug|Placebo|Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
45769340|NCT02565108|Drug|Clobazam|Participants were already on a stable dose of CLB at Baseline and continued to take a stable dose of CLB for the duration of the blinded phase of the study. CLB was administered either once or twice daily in line with the physician's preferred dosing regimen for the CLB for each participant.
45769341|NCT03821324|Device|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.
45769342|NCT03821168|Drug|injection of bevacizumab and erythropoietin|injection of bevacizumab and erythropoietin
45769343|NCT03821168|Drug|injection of bevacizumab|under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness
45769344|NCT02783690|Radiation|Hypofractionation|40 Gy (RBE) in 15 daily fractions
45629463|NCT05502393|Drug|Toripalimab|Toripalimab i.v., q3w
45913199|NCT02019381|Dietary Supplement|Endocrine Society UL Dosage Vitamin D|Endocrine Upper limit arm will get 10,000IU Vitamin D and 1200mg Calcium
45913200|NCT02019381|Dietary Supplement|Institute of Medicine Dosage Vitamin D|IOM arm will get 600 IU Vitamin D and 1,200 mg Calcium
45913201|NCT02019381|Dietary Supplement|Calcium|1200mg of CaCO3 supplementation will be given to each participant in both groups
45913202|NCT02019394|Drug|Lu AE58054|"Oral dosing: 90 mg Lu AE58054 as a single dose once and after a 3 days washout period, once daily for 7 days.~Intravenous dosing: 90 μg/not more than (NMT) 1000 nCi/37 kBq 14C-Lu AE58054 for intravenous infusion once on Day 10."
45629464|NCT05449431|Other|TLC1_TM6|Following this inclusion, patients are performing 1-minute chair lift test (TLC1) before 6-minute Walk Test (TM6). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
45629465|NCT05449431|Other|TM6_TLC1|Following this inclusion, patients are performing 6-minute Walk Test (TM6) before 1-minute chair lift test (TLC1). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
45629466|NCT05505591|Drug|Cangrelor|Cangrelor administration during percutaneous coronary intervention for both chronic or acute coronary syndromes
45629467|NCT05448807|Drug|OraVerse|Phentolamine mesylate is a vaso-dilator that was used for treating dermal necrosis and severe hypertension cases since 1952. It is alpha-adrenergic antagonist. Oraverse is supplied in a dose equal to the amount of LA taken in adults and children with weights more than 30 kg. While in children less than 30 kg, it is advised to use only half carpule according the manufacturer's instructions.
45629468|NCT05402631|Procedure|Epidural Injection|patient receives an epidural injection due to lower back pain
45629469|NCT05402631|Procedure|Periradicular Injection|patient receives a periradicular injection due to lower back pain
45629470|NCT01662999|Drug|Saxagliptin|
45629471|NCT01662999|Drug|Dapagliflozin|
45629472|NCT05366283|Biological|sargramostim|Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor.
45629473|NCT05319951|Drug|Oral Rehydration Salts power (iii)|Dissolve 2 packs of Oral Rehydration Salts Power (iii) (5.125g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
45629474|NCT05319951|Dietary Supplement|water with white granulated sugar|Dissolve 2 packs of Taikoo white granulated sugar (5g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
45629475|NCT05319951|Dietary Supplement|water|Recommend the subjects to drink up 500ml water in 20 minutes prior to donation.
45769345|NCT01454180|Drug|gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI.|"Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days."
45769346|NCT01454180|Drug|Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI|"Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days."
45769347|NCT03820934|Diagnostic Test|Fibroscan and Fibrosure|Patient's will undergo fibroscan and fibrosure to test their liver for the level of liver fibrosis as measured by these tests. Fibroscan uses vibrations sent through the liver to measure its stiffness and the fibrosure uses laboratory and demographic parameters to create a score associated with a certain level of fibrosis. The scores from these tests will then be compared to the amount of fibrosis noted on a standard of care liver biopsy.
45769348|NCT02564952|Drug|GWP42003-P|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants received up to a maximum of 30 mg/kg/day.
45769349|NCT02564952|Drug|Clobazam|Participants were taking CLB upon entry into the OLE phase of the trial. CLB was not an investigational medicinal product (IMP) for the OLE phase and was not administered by the Sponsor, but was administered at the physician's discretion, as required for each participant. CLB could be stopped, if clinically indicated, without impact on analysis.
45769350|NCT01454336|Biological|Cell injection|MSCs introduced into portal vein
45913203|NCT02019407|Procedure|PVI, CTI block|"PVI (pulmonary isolation)~Catheter ablation of cavo-tricuspid isthmus line for treatment of atrial fibrillation~Catheter is inserted into inferior venacava (IVC) and right atrium (RA) via femoral vein. And the procedure is to block bidirectionally between inferior venacava (IVC) and the annulus of tricuspid valve (TV) by using electrical energy of catheter tip."
45913204|NCT02019407|Procedure|PVI|PVI (pulmonary isolation)
45629476|NCT02565381|Drug|Transdermal nicotine patch|"≥10 cigarettes per day: nicotine 21mg/24hr patch daily x 6 weeks, then nicotine 14mg/24hr patch daily x 2 weeks~<10 cigarettes per day: nicotine 14mg/24hr patch daily x 8 weeks"
45447527|NCT04002843|Other|paraclinical evaluation of single fibre|ENMG 5 channel Digital EMG, NCS and EP System, Neurosoft, Skybox. Amplification of the EMG signal BF 500 Hz, HF 3kHz, mains filter at 50 Hz. Acquisition at 2 ms at 100 µv, parameters can be modified. The single-use needle electrode (Neuroline Concentric, Neurology Needle Electrode; 25x0.30 mm(1''x30G)) of reference inserted into one elbow flexor muscle (biceps brachialis, anterior brachialis) on the parietal side with location of the ground reference. The paroetic arm will be supported by the evaluator in order to generate a minimal tone, necessary for the occurrence of potential actions of two muscle fibres present within the same motor unit.
45629477|NCT02565381|Behavioral|In-person smoking cessation counseling|- One-on-one 15-minute counseling sessions once per week for 8 weeks
45629478|NCT02565381|Behavioral|Contingent financial rewards for smoking abstinence|- Escalating-value financial rewards for smoking abstinence, verified by exhaled carbon monoxide <8ppm
45913205|NCT02019433|Device|Structan®|
45913206|NCT02019446|Device|Laser Treatment YAG laser|YAG Laser / FOX Laser
45913207|NCT02019446|Drug|Standard Treatment (control group) terbinafine hydrochloride tablets|Terbinafine hydrochloride tablets tablets
45913208|NCT02019459|Other|Very low nicotine content cigarettes|
45913209|NCT02019459|Other|standard nicotine content cigarettes|
45913210|NCT02019485|Drug|Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF)|Participants will receive a single dose of tapentadol ER TRF 100 mg tablet orally (by mouth) in treatment sequences AB and BA appropriately.
45913211|NCT02019485|Drug|Tapentadol Prolonged-Release Formulation 2 (PR2)|Participants will receive a single dose of tapentadol PR2 100 mg tablet orally in treatment sequences AB and BA appropriately.
45913212|NCT02019498|Behavioral|Relaxation exercise|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
45913213|NCT02019498|Other|ususal care|Participants allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
45629479|NCT02565381|Behavioral|Text messages to support smoking abstinence|- 1-5 text messages per day starting up to 2 weeks before the quit date and continuing until 6 weeks after the quit date, delivered by SmokefreeTXT
45629480|NCT02063854|Drug|NE-58095 IR|NE-58095 IR tablets
45629481|NCT02063854|Drug|NE-58095 IR Placebo|NE-58095 IR placebo-matching tablets
45629482|NCT02063854|Drug|NE-58095 DR|NE-58095 DR tablets
45629483|NCT02063854|Drug|NE-58095 DR Placebo|NE-58095 DR placebo-matching tablets
45629484|NCT04411719|Device|Electric stimulation device(Neuroconn)|Real electric stimulation
45629485|NCT04458051|Drug|Tolebrutinib|Pharmaceutical form: Film-coated Tablet Route of administration: Oral
45629486|NCT04458051|Drug|Placebo|Pharmaceutical form: Film-coated Tablet Route of administration: Oral
45629487|NCT02063698|Drug|auranofin|Given PO
45629488|NCT02063698|Other|placebo|Given PO
45629489|NCT02063698|Other|questionnaire administration|Ancillary studies
45629490|NCT04701333|Drug|Cabergoline 1 MG|Dopamine agonist
45629491|NCT04701333|Drug|Placebo|Placebo
45629492|NCT02062450|Device|Primary surgery with Dual Mobility Cup|Hip joint replacement with a hip prosthesis including a Dual Mobility cup to replace the acetabular component.
45629493|NCT02062450|Device|Revision surgery with Dual Mobility Cup|Hip joint replacement with a hip prosthesis including a Dual Mobility cup to replace the acetabular component.
45629494|NCT02561247|Device|Prismaflex HF20 CRRT Filter|
45629495|NCT02561247|Device|Prismaflex® System 7.10 and 7.20|
45629496|NCT02061592|Device|etafilcon A|
45629497|NCT02061592|Device|etafilcon A|
45629498|NCT04701112|Device|Temporary His bundle pacing|"Temporary use of a Medtronic 3830 electrode placed in the region of His bundle, in combination with a Medtronic 5392 dual chamber external pacemaker and a temporary Edwards D200F7 Swan Ganz Pacing -catheter with atrial pacing capability.~AV synchronous pacing (DDD 60/minute during rest and 120/minute during exercise, AV delay 150/180ms) will be performed using the atrial port (pacing catheter atrial electrodes) and ventricular port (His bundle electrode), or in the case of atrial fibrillation, only pacing the the His bundle in VVI mode 60/minute during rest and 120/minute during exercise.~The Swan-Ganz will then be used for hemodynamic measurements during pacing. A Cardiotek ECG system will be used for simultaneous 12 lead ECG registration."
45629499|NCT04701034|Drug|Human Intravenous Immunoglobulins, (Privigen (R), CLS Behring)|infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
45629500|NCT04701034|Drug|Prednisolone Tablets|5 mg before ET and 10 mg after ET until gestational week 8+0
45629501|NCT04701034|Drug|Human Albumin Solution|Infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
45629502|NCT04701034|Drug|Placebo tablet|1 tablet before ET and 2 tablets after ET until gestational week 8+0
45629503|NCT04700956|Procedure|primary abdominal closure|The linea alba will be closed to a ratio of 5mm / 5mm. Only the fascia will be sutured ; fat or muscle tissue will be avoided. Subcutaneous tissue will be closed with polyglactin 3/0 suture. The skin will be closed with a stapler.
45629504|NCT04700956|Device|abdominal closure with prophylactic mesh|After the fascia was closed with the same method, 5 cm of subcutaneous tissue will be dissected around the incision. The mesh will be placed in the supra-aponeurotic area (onlay) to a distance of laterally and cranial-caudally 5 cm from the fascia margins. The mesh used will be partially absorbable, light and large porous. After this procedure, the borders of the mesh will be fixed circumferentially on the abdominal wall using polypropylene suture to prevent the intestines from herniating on the mesh. Two subcutaneous drainage catheters will be placed in all patients with mesh.
45629505|NCT01663623|Biological|Placebo|Placebo
45629506|NCT01663623|Biological|Belimumab 10 mg/kg|Belimumab 10 mg/kg
45629507|NCT01663623|Drug|Azathioprine|Azathioprine
45629508|NCT02042950|Drug|Carfilzomib|Starting dose: 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).
45629509|NCT02042404|Device|Sound amplification provided via EarLens System.|The EarLens System has two primary components: 1) an external Behind the Ear (BTE) Sound Processing Unit, and 2) a Tympanic Membrane Transducer (TM Transducer). In this system, light is used to wirelessly transmit both signal and power from the BTE Sound Processor to the TM Transducer. The BTE is designed to be able to be removed, reprogrammed, and have the battery recharged as needed, similar to a BTE for an air conduction hearing aid. The removable TM Transducer is customized for each patient, is placed and removed by a physician in an office visit procedure, and is designed to reside in the ear in a safe and stable manner for long periods of time.
45629510|NCT04582305|Drug|Bleomycin|Intralesional bleomycin treatment administered with an electronic pneumatic jet injector
45629511|NCT04582305|Drug|Normal saline|Intralesional placebo treatment of normal saline administered with an electronic pneumatic jet injector
45629512|NCT04551417|Procedure|Free graft urethroplasty|Free graft urethroplasty will be performed either with ventral or dorsal onlay of the graft.
45629513|NCT02042014|Drug|QTI571|QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day.
45769351|NCT03820856|Procedure|acupuncture plus fire needle therapy|The protocol used in this group was the same as that used in the acupuncture alone group except that fire needle therapy was added. The treatments were administered twice weekly for 6 weeks. Fire needle therapy was performed as follows: an acupuncture needle made of tungsten was heated until red-hot over a lighter and then inserted into the two Ah shi points (the tender points on the common extensor tendon, specifically extensor carpi radialis). The red-hot needle was inserted rapidly into the Ah shi point (approximately 5-8 fen deep, 1 cun = 10 fen) for approximately half a second and then removed. Pressure was then applied to the needle hole using a sterilized dry cotton ball.
45629514|NCT04700410|Device|Pure-Vu System|All patients willing to participate will receive a limited bowel preparation (2-days of dietary restrictions + 2x 150ml picoprep) followed by intra-procedural bowel cleansing with the Pure-Vu System.
45629515|NCT05504967|Drug|Oradexon|With a syringe aspirate 2.5 ml of a 5mg/ml dexamethasone solution, for a total of 12.5mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
45629516|NCT05504967|Drug|Ropivacaine|With a syringe aspirate 2.5 ml of a 7.5mg/ml dexamethasone solution, for a total of 18.75mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
45629517|NCT05504967|Drug|Saline solution|With a syringe, aspirate 2.5 ml of a 0.9% NaCl solution. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
45629518|NCT02041702|Diagnostic Test|Non-Diagnostic Cardiac MRI scan|
45769352|NCT03820856|Procedure|acupuncture|We selected acupoints that have often been recommended for the treatment of lateral epicondylitis. Triple needling was performed at the Ah shi point, i.e., the 1-2-cm area encompassing the most painful spot on the humeral epicondyle. We also manipulated acupuncture needles in the following areas: LI10 (Shousanli), LI11 (Quchi), LI12 (Zhouliao) and LU5 (Chize). The treatments were administered twice weekly for 6 weeks.
45629519|NCT02565147|Procedure|PPCI|PPCI for treatment of participants presenting with large STEMI.
45629520|NCT02565147|Drug|Bivalirudin|Bivalirudin is an anticoagulant that binds thrombin in a bivalent and reversible fashion and directly inhibits it.
45629521|NCT02565147|Drug|Heparin|Heparin is an anticoagulant.
45629522|NCT02061280|Drug|fluticasone/salmeterol 250/50 Dry Powder Inhaler|Participants will receive Advair Diskus 250/50 Dry Powder Inhaler, administered twice daily for 12 weeks after randomization
45629523|NCT02061280|Drug|fluticasone/salmeterol 100/50 Dry Powder Inhaler|Participants will receive Advair Diskus 100/50 Dry Powder Inhaler administered twice daily for 12 weeks after randomization
45629524|NCT02061280|Drug|fluticasone 100mcg Dry Powder Inhaler|Participants will receive Flovent Diskus 100mcg Dry Powder Inhaler administered twice daily for 12 weeks after randomization
46069912|NCT04251104|Other|Images' personal relevance effectiveness in objective and subjective mood recovery|"After completing the PANAS, the negative mood induction phase (viewing a film clip) phase will begin. Before this phase, the participants will be encouraged to experience the feelings generated by the clip as intensely as possible. After viewing the film clip, participants will be asked to complete the PANAS again in order to assess the effectiveness of the negative mood induction procedure.~Following the negative mood induction phase, the emotional recovery phase will be initiated, in which the participants will look at a total of six pictures previously selected according to their experimental condition in order to generate specific positive autobiographical memories. At the end of this phase, participants will once more complete the PANAS in order to assess the effectiveness of the emotional recovery."
45629525|NCT05501847|Radiation|Patient with no ventricular hypertrophy|"Patients without LVH ≥ 12 mm will routinely receive a bone scan as part of the study.~In case of cardiac fixation on bone scan, the patient will be managed as part of routine care according to a standardized care protocol that follows Guillmor's algorithm: monoclonal abnormality testing on biological blood samples +/- genotyping, in order to specify the senile or mutated character of TTR cardiac amyloidosis and to give the genotype."
45629526|NCT05150925|Other|Cast treatment|Dorsal cast placed in OR
45629527|NCT05150925|Other|Immediate mobilization|Immediate mobilization postoperatively without casting
45629528|NCT05150925|Procedure|Volar plating|Volar plating of distal radius fracture
45629529|NCT02061202|Drug|Mometasone Furoate|inhaled cortico-steroid (ICS) with a dosage of 220mcg once daily for 16 weeks
45629530|NCT02061202|Drug|Placebo|placebo training inhaler with the same instructions as the experimental group.
45629531|NCT05112172|Other|Oxygen Therapy|Oxygen Therapy in patients developing an altitude related adverse health effect (ARAHE) during 30h exposure to 2500m of high altitude
45629532|NCT04541433|Drug|AZD9833|AZD9833 taken orally
45629533|NCT04664361|Dietary Supplement|Nicotinamide mononucleotide|Daily supplementation with NMN at 250 and 500 mg for 38 days in total
45629534|NCT04664361|Other|Placebo|Daily supplementation with placebo for 38 days in total
45629535|NCT02059408|Other|Screen-Educate|Education program to improve blood pressure control among hypertensive non-diabetic persons. The Screen and Educate arm will recommend using creatinine, cystatin C and albuminuria for screening and risk stratification, followed by guideline-concordant CKD management appropriate for CKD stage. Recommendations are sent to the primary care provider via an electronic note.
45629536|NCT02059408|Other|Screen-Educate and Intensify Treatment|This arm adds option of a pharmacist. PCPs randomized to this arm will have the additional option to refer their higher-risk patients to a clinical pharmacist-led CKD management program with education. A primary care clinical pharmacist will schedule a series of appointments with patients found to have confirmed higher-risk CKD (defined as eGFRcreat-cys <45, or eGFR 45-59 and ACR ≥ 30 mg/g). The pharmacist will follow treatment algorithms recommended by the 2012 KDIGO international CKD guidelines, and designed by a team of internists and nephrologists.
45769353|NCT05504538|Procedure|arthroscopic fixation of Acute acromioclavicular joint injury using tight rope|arthroscopic fixation of Acute acromioclavicular joint injury using tight rope
45629537|NCT05504811|Device|FitMi AD|Exercise using the motion sensing devices and a tablet computer
45629538|NCT05504811|Other|Conventional exercise program|Exercise following printed sheets or booklet
45629539|NCT05504733|Device|Layperson Audiovisual Assist Tourniquet (LAVA TQ)|The Layperson Audiovisual Assist Tourniquet is a hemorrhage control device designed to occlude blood flow in the event of limb hemorrhage. This device provides audiovisual instructions and feedback.
45769354|NCT05504538|Device|Tight rope|Adjustable button device from Arthrex Naples USA
45629540|NCT05504733|Device|Combat Application Tourniquet|The Combat Application Tourniquet (CAT) is a hemorrhage control device designed to occlude blood blow in the event of a limb hemorrhage. The CAT utilizes a windlass rod design.
45769355|NCT02919956|Other|Magnetic Resonance Imaging|An MRI scan takes pictures of the brain and heart using a magnet and radio waves. During scanning, measurements of oxygen delivery to the brain will be obtained (CMRO2) as well as evaluation of the heart as it relates to the brain. During the scan patients will be monitored for safety by ECG, blood pressure, television camera, pulse oximetry, and carbon dioxide measurements. Cardiac anesthesiologist and cardiologist will be present.
45769356|NCT02919956|Other|Neurodevelopmental Testing|Quantitative ND tests and standardized rating scales will be used in the areas of intellectual, adaptive, visual motor skills, academic achievement in math and reading, attention and executive functioning , motor skills, memory, language, social skills and behavior. Neurodevelopmental Testing will last approximately 3.5-4 hours. Testing will be done through the Neurobehavioral Core at CHOP. Breaks will be taken as needed and a one hour lunch break will be taken, if applicable. ND testing will be performed prior to MRI (if on the same day) or on a different day than the MRI to promote engagement and best performance.
45629541|NCT04698850|Drug|Aflibercept 40 MG/ML [Eylea]|Patients will be receiving intravitreal aflibercept starting with 3 monthly doses and continuing with treat-and-extend regimen with minimal interval of 8 week and maximum interval of 16 week. Interval can be prolonged or shortened by 2 or 4 weeks based on the disease activity and BCVA..
45769357|NCT05564286|Drug|Fosaprepitant|In fosaprepitant group, patients would receive fosaprepitant combined with tropisetron plus dexamethasone to prevent chemoradiotherapy-induced nausea and vomitting while the control group would only be given tropisetron and dexamethasone .
45629542|NCT04698850|Drug|Brolucizumab-Dbll 120 MG/ML [Beovu]|Patients will be receiving intravitreal brolucizumab starting with 3 monthly doses followed by the treatment interval of 8 or 12 weeks based on the disease activity and BCVA.
45629543|NCT04698850|Drug|Ranibizumab 6 MG/ML [Lucentis]|Rescue therapy for patients with study drug related adverse events or with worsening of BCVA and OCT finding even on the shortest treatment interval when resistance to study drug is suspected.
45629544|NCT05113953|Drug|Centanafadine|Sustained-release oral tablets
45629545|NCT05113953|Drug|Placebo|Oral tablets
45629546|NCT04698226|Procedure|25-gauge pars plana vitrectomy with complete internal limiting membrane peeling and SF6 tamponade|Standard 3 port 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling around the macular hole after brilliant blue dye staining and sulfur hexafluoride (SF6) tamponade
45629547|NCT04698226|Procedure|25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade|"Standard 3 port 25-gauge pars plana vitrectomy with inverted flap technique after brilliant blue dye staining and SF6 tamponade. Flower petal type of inverted flap will be performed - multiple small ILM flaps will be created around the macular hole and placed over the macular hole."
45629548|NCT05504577|Drug|Tranexamic acid injection|Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation. .
45629549|NCT05504577|Device|apply the QCG|apply the QCG (Quikclot Z-fold hemostatic gauze, Z-Medica, Wallingford, CT, USA) into the joint space. Compress the knee joint by elastic bandage. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes
45629550|NCT05504577|Device|apply surgical gauze|apply the normal surgical gauze into the joint space. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes
45629551|NCT05504499|Device|Interspinous Fusion|The intended study population are adults 18 years or older with symptomatic lumbar degenerative disc disease resulting in back pain with lower extremity symptoms and neurogenic claudication that improves with spinal flexion who are candidates for use of the Zip™ MIS Interspinous Fusion device when undergoing spinal fixation procedures.
45769358|NCT05564286|Drug|tropisetron|All patients received tropisetron 5mg on day 1.
45769359|NCT05564286|Drug|Dexamethasone|.All patients received dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.
45769360|NCT05508984|Device|Amma Cooling Caps|"Once enrolled, subjects will be provided the Amma device by the clinic on days of chemotherapy treatment, and upon completion of treatment it will be returned to the clinic for safekeeping. Upon completion of chemotherapy, anywhere from 3-6 weeks following treatment, subjects will repeat the questionnaires and their hair will be photographed again.~The overall duration of the study for subjects will be anywhere from 4 months to 8 months, depending on the duration of their chemotherapy regimen."
45769361|NCT03820700|Behavioral|Hypnosis (Hypn)|The hypnosis session will consist of a 20-minute hypnosis recording created by Marie-Elisabeth Faymonville and recorded by Anne-Sophie Nyssen, both professionals in hypnosis from University of Liège. The recording includes suggestions about relaxation, corporal sensations, respiratory techniques and visual imaginative stimuli about a beautiful landscape. With this tool, the hypnosis session is standardized for all patients and there is no need of a psychotherapist to deliver hypnosis.
45629552|NCT05501535|Device|ND:YAG LASER|The standard therapy for PCO is now Nd: YAG laser posterior capsulotomy, which has a success rate of more than 95%. The neodymium: yttrium-aluminum-garnet (Nd:YAG) laser, with a wavelength of 1064 nm, is a solid-state laser that may destroy ocular tissues by achieving optical breakdown with a brief, high-power pulse .Ionization or plasma production occurs in the ocular tissue as a result of optical breakdown. This plasma production subsequently generates acoustic and shock waves, which destroy tissue. Because of its cost-effectiveness, speed, and lack of invasiveness, it is the chosen treatment option in PCO
45629553|NCT05501457|Device|Muscle strengthening with neuromuscular electrical stimulation|The effect of peripheral muscle strengthening training in addition to pulmonary rehabilitation in COPD patients on the patient's performance will be examined.
45629554|NCT05016297|Drug|Baricitinib|baricitinib 4mg per day
45629555|NCT05016297|Drug|Hydroxychloroquine|Hydroxychloroquine 200mg twice a day
45629556|NCT05504343|Device|"Intensity SL Intraocular Lens"|Cataract surgery and intraocular lens implantation
45629557|NCT05504265|Drug|Preemptive flurbiprofen axetil|50mg once，30min before induction anesthesia
45629558|NCT05504265|Drug|Postoperative flurbiprofen axetil|50mg bid
45629559|NCT05504265|Device|Patient-controlled analgesia pump|Sufentanil 2.5 μg/kg+ondansetron 8mg, prepared to 100ml normal saline; background dose: 2 ml/h, single press analgesic pump injection volume: 0.5 ml, locking time: 15 min.
45913214|NCT02019524|Biological|E39 peptide vaccine|500mcg of lyophilized E39 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the E39 peptide vaccine. For patients randomized to the E39 vaccine arm, the primary vaccine series (PVS) consists of E39 vaccine administered intradermally every three to four weeks for six total vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine.
45913215|NCT02019524|Biological|E39 vaccine then J65 vaccine|The E39 vaccine is prepared as noted above. For the J65 vaccine, 500mcg J65 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended E39 peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the J65 vaccine. For patients randomized to this arm, the primary vaccine series (PVS) consists of the E39 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the J65 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
45447528|NCT04000815|Diagnostic Test|C Type Natriüretic Peptide|C Type Natriuretic Peptide will be measured with elisa method
45447529|NCT04000581|Other|Best Practice|Receive standard of care
45629560|NCT01625338|Drug|SOF|SOF 400 mg tablet administered orally once daily
45629561|NCT01625338|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45629562|NCT01625338|Drug|Peg-IFN|Peg-IFN 180 μg administered once weekly by subcutaneous injection
45769362|NCT03820700|Behavioral|Virtual reality (VR)|VR sessions. This session will consist in using a head-mounted 3D graphical display with goggles. With this tool, participants will be able to visualize a 3D immersive landscape for 20 minutes consisting of a shed near a lake at sunrise followed by a relaxing moment in the clouds. The session ends on the lake's edge.
45769363|NCT03820700|Behavioral|Virtual reality hypnosis (VRH)|The combined tool sessions. Participants will be simultaneously subjected to the same hypnosis recording and 3D visual stimuli used in the Hypn and VR conditions.
45629563|NCT05504109|Procedure|mitral valve replacement through full sternotomy approach.|compare between Minimally Invasive Mitral Valve Replacement and Conventional Approach
45629564|NCT05504109|Procedure|mitral valve replacement through right mini thoracotomy approach.|compare between Minimally Invasive Mitral Valve Replacement and Conventional Approach
45629565|NCT05504031|Procedure|Hybrid coronary revascularization|Coronary revascularization is conducted as a combined MIDCAB (LIMA-LAD grafting through a minimally invasive anterior left thoracotomy) and PCI (of all non-LAD stenoses)
45629566|NCT05504031|Procedure|Conventional revascularization|Conventional revascularization with CABG of all significant stenoses through a sternotomy
45629567|NCT05503953|Drug|AGSAVI|Uptitation
45629568|NCT05503953|Drug|AGLS|Uptitration
45629569|NCT05501301|Other|IS weaning off|IS weaning off will be conducted in recipients with chronic virus infection or side effects of IS
45629570|NCT04698148|Other|Biological sample collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
45629571|NCT04698148|Other|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
45629572|NCT04698148|Other|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
45629573|NCT02560623|Procedure|Biopsy|Undergo biopsy
45629574|NCT02560623|Procedure|Biospecimen Collection|Undergo collection of blood sample
45629575|NCT02560623|Procedure|Endoscopic Procedure|Undergo endoscopy
45629576|NCT02560623|Device|Swallowable Sponge Cell Sampling Device|Undergo swallowable sponge cell sampling assessment
45629577|NCT05501223|Other|Medication review|30-60 minutes extra consultation regarding the patients drugs
45629578|NCT05501223|Other|Standard care|Standard care i.e. visit at the Dept. of Endocrinology.
45913216|NCT02019524|Biological|J65 vaccine then E39 vaccine|The E39 and J65 vaccines are prepared as noted above. For patients randomized to this arm, the primary vaccine series (PVS) consists of the J65 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the E39 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
45629579|NCT05501145|Procedure|cesarean section and aortic repair|The timing of aortic repair and delivery have to be determined based on the type of the dissection, the stage of pregnancy (the gestation age), and the status of the fetus, as well as the level of local neonatal service.
45629580|NCT04740099|Other|SOONER Video & Kit|A brief animated video including basic instructions for opioid overdose response accompanied by a Naloxone kit with an info graphic.
45629581|NCT04740099|Other|Standard of Care|A handout including a map and list of locations offering this service.
45629582|NCT05503563|Procedure|terta modal bladder preservation|neoadjuvant chemotherapy, partial cystectomy, radiotherapy
45629583|NCT04537299|Drug|Fisetin|~20 mg/kg/day oral, NG or D tube course for 2 consecutive days twice (Days 0 & 1 and Days 8 & 9)
45629584|NCT04537299|Drug|Placebo|Placebo looks exactly like the treatment drug, but it contains no active ingredient
45629585|NCT04535115|Procedure|Starting LRM (Lung Recruitment Maneuver)|The LRM is performed first for 30 seconds (an insufflation pressure of 30 cmH2O for 30 seconds is applied). After a free interval of 3 minutes, the VtC is done during 1 minute. For VtC, tidal volume is increased from 6 to 8 ml.kg-1 of predicted body weight. Finally, after a new free interval of 3 minutes, the fluid challenge (consisting in fluid administration of 250 ml of Ringer Lactate) is started for 10 minutes (in aim to determine which patients are responders). This sequence is repeated every 30 minutes (maximum four times).
45629586|NCT04535115|Procedure|Starting VtC (Tidal Volume Challenge)|The VtC is performed first for 1 minute. After a free interval of 3 minutes, the LRM is done for 30 seconds. Finally, after another free interval of 3 minutes, the fluid challenge is started for 10 minutes. This sequence is repe-tead every 30 minutes (maximum four times).
45629587|NCT02560389|Drug|Placebo|Sugar pill packaged to resemble levodopa
45629588|NCT02560389|Drug|Levodopa|EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.
45629589|NCT05500989|Other|Venepuncture|The only invasive procedure is a venepuncture where 100 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare).
45629590|NCT05500911|Procedure|sinus lift|when residual bone height is >4 mm sinus lift through crestal approach procedure will be performed and after sinus flor elevation, OSSIX® Bone will be placed in the sinus cavity.
45629591|NCT05500911|Procedure|implant placement|Implant will be placed in edentulous area
45769364|NCT05504460|Device|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|Treatments in the test group will lasts for 12 months, and symptomatic treatment will be provided based on the actual symptoms of the subjects. Subjects in the test group will be required to receive inhalation for at least 4 days every 7 days with at least 3780L inhaled every 7 days (It is recommended to inhale at least 540L per day; If the flow rate is 3L/min, it is recommended that the cumulative inhalation time should be at least 3 hours per day. If the flow rate is 1.5L/min, it is recommended that the cumulative inhalation time should be at least 6 hours per day).
45769365|NCT05504460|Other|basic treatment|supportive treatment determined by the investigator based on the condition of the patients
45769366|NCT01454804|Drug|Pazopanib|Starting dose: 200 mg by mouth every other day starting on day 1 for 28 days.
45769367|NCT01454804|Drug|Lapatinib|Starting dose 500 mg by mouth every day for 28 days.
45769368|NCT01454804|Drug|Trastuzumab (Herceptin®)|"4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1.~Maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.~Dose Expansion Phase: Maximum tolerated dose (MTD) from Dose Escalation Phase"
45769369|NCT01454804|Drug|Pazopanib|Starting dose 200 mg by mouth every day for 28 days.
45769370|NCT03820622|Device|Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)|patients in the study group will be treated by the Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)
45769371|NCT03820622|Device|Paclitaxel-Eluting Balloon (Bingo)|patients in the study group will be treated by the Paclitaxel-Eluting Balloon (Bingo)
45769372|NCT05504382|Device|naproxen phonophoresis|transmission of naproxen molecule by therapeutic ultrasound
45629592|NCT02564211|Drug|Ipragliflozin|one 50 mg tablet QD
45629593|NCT02564211|Drug|Sitagliptin|one 50 mg tablet QD
45629594|NCT04639245|Drug|Atezolizumab|Given IV
45629595|NCT04639245|Drug|Cyclophosphamide|Given IV
45629596|NCT04639245|Drug|Fludarabine|Given IV
45629597|NCT04639245|Biological|MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells|Given IV
45629598|NCT04639245|Biological|PD1 Inhibitor|Given IV
45629599|NCT04596579|Diagnostic Test|SARS-CoV-2 Antibody Analysis|10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.
45629600|NCT04596579|Diagnostic Test|Weck-cel Swab Collection|A Weck-cel swab will be used to collect secretions from the mucosal epithelium
45629601|NCT04596579|Behavioral|Web Based Questionnaire|A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.
45629602|NCT04465461|Procedure|Video-assisted thoracoscopic surgery (VATS) fissure completion|Following Bronchoscopy and Chartis® balloon catheter assessment under general anaesthesia and confirmation of collateral ventilation, a unilateral VATS lobar fissure completion will be undertaken with buttressed staples and Coseal spray intended to eliminate collateral ventilation.
45629603|NCT04465461|Device|Zephyr Valve insertion|Following fissure completion surgery, subjects confirmed to be collateral ventilation negative will undergo bronchoscopic insertion of Zephyr® Valve(s) in the targeted lobe, under sedation or general anaesthesia.
45629604|NCT05503329|Diagnostic Test|arterial lactate level|an arterial lactate level measured from arterial sample from STEMI patients
45629605|NCT04619901|Other|Semi-structured interviews|Exploring the psychological and social impact on parents of a palliative care decision concerning their child in the neonatal period
45629606|NCT04619901|Other|Questionnaire|Assessing the neuro-developmental evolution of children and understanding the determinants of the psychological and social impact of palliative care decisions on parents
45629607|NCT04619901|Other|following Scales|Scales : Hospital Anxiety and Depression, Intolerance to Uncertainty, and Brief COPE.
45629608|NCT04465383|Device|Aqua© 30 on Oncomfort SedakitTM|Digital Sedation session consists in a virtual reality software (Aqua© 30 Version 3.0, Oncomfort SA, Waver, Belgium) including a clinical hypnosis script.Patients in the intervention group will undergo a 30-minute Digital Sedation program through a VR headset and headphones. This medical device called Oncomfort SedakitTM has been created to reduce anxiety and pain during medical/ surgical interventions
45629609|NCT04465383|Drug|Propofol|Standard sedation starting doses of 1 µg/ml to 6 µg/ml depending on patient's reaction and titrated incrementally by 0.5µg/ml. Doses are adapted according to the level of comfort and needs of the patient.
45913217|NCT02019537|Procedure|Steroid injection into the subacromial space|"Group: Steroid~Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)~The number of injections : only once during the study period~Injection site : subacromial space~Material : 25-gauze spinal needle~Subacromial injections were performed using ultrasonographic guidance."
45629610|NCT04388865|Behavioral|Control|Subjects will engage with their providers as is standard of care.
45629611|NCT04388865|Behavioral|Text-based Clinical Hovering|Subjects will receive remote monitoring via text messaging of clinical symptoms and medication adherence reminders with feedback to social support.
45629612|NCT05500755|Device|Implant Treatment|Surgical placement of a DS Prime Taper implant and its posterior prosthesis.
45629613|NCT05500677|Drug|Lidocaine topical|Lidocaine spray, which is a quick and easy-to-use topical local anesthetic, will be applied as a puff to the painful area.
45629614|NCT04361955|Other|EMG|recordings of muscle electrical activity during nerve stimulation using EMG
45629615|NCT04361955|Other|EEG|recordings of brain activity using EEG
45629616|NCT04331535|Diagnostic Test|Polygenic risk score (PRS)|Polygenic risk score report from a Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory for coronary artery disease, atrial fibrillation, type 2 diabetes, colorectal cancer, breast cancer (for women only), and prostate cancer (for men only), delivered along with patient- and provider-level educational material.
45629617|NCT04198779|Device|APPLI|The support with the digital application is including a 10-minutes training about the use of the digital application at the beginning of the study. Patient will have to register information about their Heart failure disease (weight, shortness of breath, fatigue, mood, cardiologist appointments, blood results, ...). During each routine consultation, patients will be encouraged to use the digital app, and the obstacles encountered will be explored and resolved. In addition, participants will receive an email containing relevant information and, every three months, an email reminder of the use of the application.
45447530|NCT04000581|Other|Physical Activity|Walk for minimum 30 minutes per day
45629618|NCT04411563|Other|Taking biological samples|Taking blood samples for biochemical and epigenetic analysis
45629619|NCT02093026|Drug|Rituximab|Participants will receive rituximab 1 gram IV on Days 1 and 15 of each course of retreatment.
45629620|NCT02093026|Drug|Methotrexate|Participants will receive methotrexate 10-25 mg/week orally or parenterally.
45629621|NCT02093026|Drug|Methylprednisolone|Participants will receive methylprednisolone 100 mg IV 30 minutes prior to each rituximab infusion.
45913218|NCT02019537|Procedure|Allogeneic PRP injection into the subacromial space|"Group: Allogeneic PRP~Total volume of injection drugs: 4ml~The number of injections : only once during the study period~Injection site : subacromial space~Material : 25-gauze spinal needle~Subacromial injections were performed using ultrasonographic guidance."
45447531|NCT04000581|Other|Questionnaire Administration|Ancillary studies
45447532|NCT03919617|Drug|REMD-477|4-Week, open-label, once weekly subcutaneous injection with 70mg REMD-477.
45447533|NCT03748251|Other|the patients ate a pizza that fermented for 8 hours|Patients eat pizza prepared with controlled ingredients but fermented 8 hours
45447534|NCT03748251|Other|the patients ate a pizza that fermented for 24 hours|Patients eat pizza prepared with controlled ingredients but fermented 24 hours
45629622|NCT02093026|Drug|Folic Acid|Participants will receive folic acid >= 5 mg/week or equivalent.
45629623|NCT04698070|Dietary Supplement|Nutritional Strategy - OptiMA|"All children randomized to this arm will be treated with a RUTF, with weekly ration determined according to MUAC, weight and presence of nutritional edema. Ration will be adjusted weekly according to the change in MUAC and weight throughout the outpatient follow-up until the child achieves nutritional recovery.~RUTF dosage will 170 kcal/kg/d for the most severely wasted (MUAC < 115 mm or edema) and reduced to 125 kcal/kg/d for children with MUAC 115-119mm and 75 kcal/kg/d for children with MUAC 120-124 mm.~All children will be followed-up for 6 months following randomization. They will have weekly outpatient visit in the health facility until they meet nutritional recovery criteria, and then a monthly community-based follow-up in their villages (vital status, anthropometric measures and clinical condition). Referral to the health facility for appropriate nutritional/medical care if illness or acute malnutrition relapse detected)."
45629624|NCT04698070|Dietary Supplement|Nutritional Strategy - ComPAS|All children randomized to this arm will be treated with RUTF, with weekly ration determined according to MUAC and presence of nutritional edema. Children enrolled with MUAC < 115 mm or edema will receive 1000 kcal/d (2 sachets/day) RUTF until MUAC has surpassed 115 mm and/or edema is resolved for 2 weeks at which time ration will be reduced to 500 kcal/d (1 sachet/day) until MUAC > or = to 125 mm is achieved for 2 consecutive weeks. Children enrolled with MUAC 115-124 mm will receive 1 sachet/day until MUAC > or = 125 mm is achieved for 2 consecutive weeks and clinically well. Following nutritional recovery, a study nurse will conduct monthly community-based follow-up in their villages (vital status, anthropometric measures and clinical condition) with referral to the health facility for appropriate nutritional/medical care if illness or acute malnutrition relapse detected) for the remainder of the 6 month period following inclusion.
45629625|NCT04698070|Other|National nutritional Strategy (Niger)|"Different protocols for SAM and MAM comprise the Niger National Nutrition Protocol:~SAM: Children with MUAC<115 or WHZ<-3 or nutritional edema, will be treated with RUTF, according to a dosage table based on weight at each visit.~MAM: Children aged between 6-24 months with MUAC between 115 -124 mm and WHZ>-3 will be treated with RUSF. Children with the same anthropometry but age 24-59 m will only receive supplementation if they develop criteria for SAM during the 6 month study period. They will be monitored via monthly home visits by a study nurse.~All children will be followed-up for 6 months following randomization. Children eligible for RUTF at randomization will have a weekly outpatient visit in the health facility until they meet discharge criteria, and then a bi-monthly community-based follow-up in their villages (vital & anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated)."
45629626|NCT04697602|Drug|Stepwise dose titration of febuxostat and low-dose colchicine|Febuxostat 10 mg, orally, once daily, in week 1-4 Febuxostat 20 mg, orally, once daily, in week 5-8 Febuxostat 40 mg, orally, once daily, in week 9-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
45629627|NCT04697602|Drug|Fixed dose febuxostat and low-dose colchicine|Febuxostat 40 mg, orally, once daily, in week 1-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
45629628|NCT02040844|Drug|Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762]|
45629629|NCT02040844|Drug|Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]|
45629630|NCT02040844|Drug|Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]|
45629631|NCT02059174|Drug|MK-1293|MK-1293 0.4 units/kg administered subcutaneously
45629632|NCT02059174|Drug|EU-Lantus™|EU-Lantus™ 0.4 units/kg administered subcutaneously
45769373|NCT04391972|Device|SAV|SAV multifocal intraocular lens is a implantable IOL which offers multifocal vision.
45629633|NCT02059174|Drug|Novolog™|Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or EU-Lantus™ dosing in each dosing period to meet basal insulin requirements
45629634|NCT02092324|Other|Laboratory Biomarker Analysis|Correlative studies
45629635|NCT02092324|Other|Quality-of-Life Assessment|Ancillary studies
45629636|NCT02092324|Other|Questionnaire Administration|Ancillary studies
45629637|NCT02092324|Drug|Ruxolitinib Phosphate|Given PO
45629638|NCT04721158|Device|Continuous glucose monitor|Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
45629639|NCT04417582|Procedure|bariatric surgey|patients undergone bariatric surgery or prescribed antiobesity drugs
45629640|NCT02040766|Drug|Beclomethasone dipropionate BAI|Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a breath-actuated inhaler (BAI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.
45629641|NCT02040766|Drug|Placebo BAI|Placebo was delivered by a single inhalation using a breath-actuated inhaler (BAI) twice each day.
45629642|NCT02040766|Drug|albuterol/salbutamol 90 mcg|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
45769374|NCT05047146|Other|Morphological classifications of HCC|Morphological classifications of Hepatocellular carcinoma
45769375|NCT03823040|Drug|Oxiconazole Nitrate Cream 1%|Tinox® group was treated with oxiconazole nitrate cream 1 % . Treatment was performed by rubbing the cream twice daily for two/ four weeks according to different types of tinea.
45769376|NCT03823040|Drug|Oxiconazole nitrate SLNs loaded gel.|Oxiconazole nitrate SLNs loaded gel group was treated with oxiconazole nitrate SLNs loaded gel.Treatment was performed by rubbing the gel twice daily for two/ four weeks according to different types of tinea.
45769377|NCT04282980|Drug|DCC-2618|Oral kinase inhibitor
45769378|NCT03823196|Dietary Supplement|Verum900|Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 900 mg for 16 weeks
45769379|NCT03823196|Dietary Supplement|Verum1800|Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 1800 mg for 16 weeks
45769380|NCT05504226|Drug|Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet|To be orally administered once daily
45769381|NCT05504226|Drug|Teneligliptin Placebo Oral Tablet|To be orally administered once daily
45629643|NCT02040766|Drug|Beclomethasone dipropionate MDI|Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a metered-dose inhaler (MDI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.
45629644|NCT02040766|Drug|Placebo MDI|Placebo was delivered by a single inhalation using a metered-dose inhaler (MDI) twice each day.
45769382|NCT03822728|Diagnostic Test|3D-DESS MRI (3 dimensional double echo steady state MRI)|3D-DESS MRI has been reported useful for the intra-parotid facial nerve imaging. It can provide information about the anatomical relationship between the tumor and the facial nerve in the parotid gland.
45769383|NCT04282044|Biological|CRX100 suspension for infusion|A fixed dose of CIK cells combined with the specified dose of CDSR.
45629645|NCT02040532|Drug|Gabapentin|The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.
45629646|NCT02039908|Drug|Methylphenidate|Children will receive a double-blind assessment to determine their optimal starting dose of Concerta. Doses will be adjusted over the course of the school year and inceased if tolerance to the medication is detected.
45629647|NCT04695730|Other|Active physical therapy (including both pain education and home exercises)|"One session (60 minutes). In this session, a physical therapist will explain and demonstrate the exercises to perform individually at home. Exercises will be performed daily. In addition, an education session will be provided, concerning pain mechanisms and management. To support patients during the treatment, a booklet will be created.~One booster session (30minutes) will be planned after 4 weeks. Patients will follow the active treatment for 8 weeks."
45629648|NCT04695730|Other|Active physical therapy plus manual therapy|"Participants in the Group 2 will receive active intervention plus 8 Pompage technique sessions (1 session/week). In these sessions (30 minutes each), Pompage technique will be performed by a physical therapist."
45629649|NCT04417270|Device|Freestyle Libre 14 day CGM system|The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.
45629650|NCT04417270|Device|Accuchek Inform II platform|The Accu-Chek Inform II system is designed to deliver data with speed and efficiency, helping to provide optimal care. Wireless meter quickly transfers data. The Accu-Chek Inform II system is the first point-of-care blood glucose device to offer truly wireless technology at the meter level.
45629651|NCT04417348|Drug|Retinoic acid|To evaluate the role of Opsin receptors in melasma. The patients were treated with 0.05% Retinoic Acid, a regular therapy to treatment melasma, a ligand of Opsin receptors. Also, Uv-Visible light filter treatment as a posible opsin receptor blocker
45629652|NCT04720300|Other|MaaS app|The MaaS App will be downloaded to students' smartphones and will provide real-time, multimodal trip planning to students on demand when they open the app.
45629653|NCT04720300|Other|No app|students receive no app or housing information
45629654|NCT02058940|Drug|Exenatide|50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours
45629655|NCT02058628|Drug|Clindamycin + BPO|Gel containing 1.2% clindamycin and 3% BPO for once daily application
45769384|NCT03822806|Other|Physical Exercise in addition to Patching|Patch for 2 hours a day, and exercise for the first 30 minutes of those 2 hours using the video game
45769385|NCT05508828|Procedure|Percutaneous Continuous Irrigation assisted Vacuum Drainage Combined With Transgastric Necrosectomy|All patients with SAP were given contrast enhanced CT scan within 48 hours after admission to identify the location and range of the necrosis. If the patient's condition progressively worsened, a multifunctional irrigation-assisted vacuum drainage tube was placed by the CT-guided Seldinger technique in each of the necrosis cavity. Subsequently, transgastric necrosectomy were performed by one or two experienced endoscopist under conscious sedation. The procedure was repeated until all loosely adherent necrotic material were cleared and replaced by granulation tissue. Percutaneous irrigation was stopped and replace with simple drainage if the patient's condition continues to improved and the cavity confirmed by CT was resolution. If the drainage volume was less than 10 mL/day for 3 consecutive days, clamp the drainage tube and remove it finally.
45629656|NCT02058628|Drug|Azelaic acid|Cream containing 20% azelaic acid for twice daily application
45629657|NCT04694638|Other|Body position change|combined use of prone positioning and high-flow nasal cannula (HFNC) and non-invasive positive pressure ventilation (NIPPV) can reduce the rate of intubation in acute hypoxemic and/or hypercapnic respiratory failure secondary to COVID-19 infection.
45769386|NCT01454882|Behavioral|Effects of Clothing|There will be two temperature conditions; warm temperature [WT, 75°F (24°C)] and cool temperature [CT, 60°F (16°C)]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
45769387|NCT01454882|Behavioral|Effects of Temperature|There will be two temperature conditions; warm temperature [WT, 75°F (24°C)] and cool temperature [CT, 60°F (16°C)]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
45769388|NCT01454882|Behavioral|Low Physical Activity|This will be a randomized study with two within subject conditions (high and low physical activity levels)
45769389|NCT01454882|Behavioral|High Physical Activity|This will be a randomized study with two within subject conditions (high and low physical activity levels)
45769390|NCT01454882|Behavioral|Direct calorimetry and doubly labeled water|TDEE will be measured simultaneously for 14 days using direct calorimetry and doubly labeled water. A heterogeneous sample of adult men and women in stable health will be studied.
45769391|NCT02929160|Procedure|Percutaneous nephrostomy|Percutaneous nephrostomy tube insertion under radiological guidance
45769392|NCT02929160|Procedure|Retrograde ureteric JJ stent|Retrograde ureteric JJ stent insertion using cystoscopy
45629658|NCT04731298|Drug|Emapalumab|"Emapalumab (previously referred to as NI-0501, trade name Gamifant®) is a fully human immunoglobulin G1 (IgG1) anti-IFNγ monoclonal antibody that binds to and neutralizes IFNγ. Emapalumab binds to both soluble and receptor (IFNγR1)-bound forms of IFNγ.~Emapalumab is in development for treatment of primary and secondary HLH. The benefit expected from the targeted neutralization of IFNγ by emapalumab has been validated by the recent FDA approval of emapalumab for treatment of patients with pHLH who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. The safety profile has been assessed as acceptable.~Emapalumab will be administered by intravenous infusion over 1 to 2 hours, depending on the volume of the infusion. The first infusion must be performed within 12 hours after CXCL9 levels have been measured above defined threshold. Treatment will last until maximum dose 15 (up to 56 days) or until evidence of engraftment, whichever comes first."
45629659|NCT02058160|Drug|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Insulin glargine/lixisenatide FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using one of 2 SoloStar® pen-injectors: Pen A (ratio of 2 Units (U) of insulin glargine U 100:1 mcg of lixisenatide) or Pen B (ratio of 3 U of insulin glargine U 100:1 mcg of lixisenatide). After run-in, the FRC was initiated at a dose of either 20 U/10 mcg with Pen A or 30 U/10 mcg with Pen B, depending on participant's dose of Insulin glargine on the day prior to randomization.~Dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L). Pen A was used for administration of doses up to 40 U/20 mcg and Pen B for administration of doses from 30 U/10 mcg up to 60 U/20 mcg."
45769393|NCT05504148|Drug|crocin|Take saffron total glucosides tablets for 8 days during each chemotherapy (started on the 1st day before radiotherapy/chemotherapy), 4 tablets/time, 3 times a day.
45629660|NCT02058160|Drug|Insulin glargine (HOE901)|"Insulin glargine was self-administered QD by SC injection at approximately the same time every day.~After screening, eligible participants entered 6 week run-in phase during which they were switched (if necessary) to insulin glargine and dose was stabilized. The first dose after randomization was same as the one administered on the day prior to randomization and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L)."
45629661|NCT02058160|Drug|Metformin (Background Drug)|Pharmaceutical form: Tablet; Route of administration: Oral administration
45629662|NCT02090764|Drug|Ozenoxacin|
45629663|NCT02090764|Drug|Placebo|
45629664|NCT04718896|Drug|bimekizumab|Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.
45629665|NCT04718506|Behavioral|Exercise|Participants from the experimental group will complete 8 weeks of a tailored, educational and supervised multicomponent exercise program adapted from the ACSM guidelines for Chronic Obstructive Pulmonary Disease and Cardiovascular Disease. Participants will complete a 3-days-a-week concurrent training routine: two days of resistance training (50% 1RM (one-repetition maximum), 3 sets, 8 repetitions, 4 exercises [squat, bench press, deadlift and bench pull]) combined with Moderate Intensity Variable Training (MIVT: 4-6 x 3-5 min at 70-80% Heart Rate Reserve (HRR) / 2-3 min at 55-65% HRR), and one day of Light Intensity Continuous Training (LICT: 30-60 min, 65-70% HRR). Progressions will be individualized and consistent with patient tolerance. Sessions will be supervised by certified strength and conditioning coaches, Graduated in Sports Sciences
45447535|NCT03748173|Combination Product|Aerosolized Infasurf|Infants randomized to aerosol treatment will receive Infasurf® aerosol at a rate of 12 ml/hour (the maximal rate using the Solaris CAG). The initial treatment will be for 60 minutes, with reevaluation every 30 minutes thereafter, with a maximum dose of 6 mL/Kg body weight or 2 hours of aerosolization. Treatment will be stopped after 60 minutes (and subsequently at 30-minute intervals) if a 2 point reduction in bronchiolitis score or a score ≤ 4 is achieved. Treatment will also be stopped at any time should there be evidence of other-than-transient deterioration in oxygenation or clinical status or for any serious adverse effect deemed by the infant's clinician to be possibly related to the drug administration.
45447536|NCT03848403|Biological|Ixekizumab|Administered SC
45629666|NCT04718506|Behavioral|Inspiratory muscle training|Participants enrolled in the inspiratory muscle training protocol will used the PowerBreath® Classic Heath Series mechanic threshold devices to perform 1 set of 30 repetitions, twice a day, every day of the week. This assumes a work intensity of approximately 62.5% ± 4.6% of the PIM (maximum inspiratory pressure). Increase in resistance will be made every two weeks by turning the load adjustment clockwise ¼ to 1 full turn, pending on participant tolerance to maintain a 12-15 RPE on modified Borg scale. The training will be preceded by a warm-up at 80% of the 30 RM load, with 2 min of rest between sets
45769394|NCT05504148|Drug|Placebo|Take placebo piece during for 8 days during each chemotherapy (started on the 1st day before radiotherapy/chemotherapy), 4 tablets/time, 3 times a day
45769395|NCT03820232|Device|temperature monitoring|In every patient observed in this prospective observational study, body core temperature will be contemporaneously monitored through the oesophageal probe and the heated controlled servo sensor. Both are routinely used for this purpose in clinical practice
45769396|NCT02566902|Device|T-Piece Nebulizer|Albuterol treatment administered with Hudson RCI® Micro Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ)
45769397|NCT02566902|Device|Breath-Enhanced Nebulizer|Albuterol treatment administered with NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer (Salter Labs®, Arvin, CA)
45447537|NCT03995355|Device|9618X investigational lipid eye drops|Test Eye Drops
45447538|NCT03995355|Device|Blink® Tears|Control Eye Drops
45629667|NCT04718506|Behavioral|Controls|Controls will be advised (non-supervised) to follow the WHO guidelines: Support for Rehabilitation: Self-Management after COVID-19 Related Illness
45629668|NCT04730830|Other|Questionnaire|Patients completing emergence assessment questionnaires at the time of the first dressing placement, as well as at the scheduled weekly placement. As part of a planned repair, the emergence will be assessed at most once a week, preferably at the beginning of the week by the patient. In any other case of dressing change, an emergence assessment will be requested.
45629669|NCT02057692|Drug|LUM001|LUM001 administered orally
45629670|NCT02057692|Drug|Placebo|Placebo administered orally
45769398|NCT02566902|Drug|Albuterol|One time 5mg nebulized albuterol treatment given with one of two devices over 10 minutes.
45769399|NCT02566902|Procedure|Pre-Treatment Spirometry Measurement|Bedside spirometry measurements taken prior to albuterol therapy using ndd® EasyOne Plus® spirometer.
45769400|NCT02566902|Procedure|Post-Treatment Spirometry Measurement|Bedside spirometry measurements taken after albuterol therapy using ndd® EasyOne Plus® spirometer.
45629671|NCT02038036|Drug|Best Available Therapy|Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.
45629672|NCT02038036|Drug|Ruxolitinib|Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
45769401|NCT01454960|Behavioral|Clinical Decision Support: Accountable Justification|Accountable Justification is triggered by discordant prescriptions that populate the EHR note with provider's rationale for guideline exceptions (AJ).
45769402|NCT01454960|Behavioral|Audit and Feedback: Peer Comparison|Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
45629673|NCT02037568|Behavioral|fPER|"Briefly in order, the sessions will include: 1) Overview and introduction to stress management, 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs, and 8) Getting the support they need, modeled after a successful intervention for patient groups. Manualization is crucial for successful wider implementation. Sessions 9 and 10 will provide booster sessions in which the interventionist will assess current challenges for the caregiver, provide review, and emphasize further coping skills training that might assist the caregiver in managing current stressors such as coping with the new normal."
45629674|NCT02088034|Behavioral|Promotora-led Intervention|Behavioral life-style program lead by a team of trained community health workers (called promotoras) with 2 principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
45629675|NCT02088034|Drug|Metformin Therapy|Participants in this group will receive metformin 850 mg bid for one year.
45629676|NCT02088034|Other|Usual Care|Participants in this arm will attend one physician visit to discuss healthy lifestyle behaviors and will receive standard educational materials.
45769403|NCT01454960|Behavioral|CDS Order Sets: Suggested Alternatives|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
45769404|NCT03820154|Diagnostic Test|Skin Prick Test|Skin Prick Testing with inhalant allergens
45769405|NCT03820154|Diagnostic Test|Skin Prick Test TAPE|Skin Prick Testing with a Tape, integrating the allergens and needles
45769406|NCT05508516|Drug|Shugan Dingtong decoction|Patients will accept Shugan Dingtong decoction 150ml (twice, per day) for 12 weeks.
45769407|NCT05508516|Drug|Duloxetine Hydrochloride|Patients will accept duloxetine hydrochloride 20mg (twice, per day) for 12 weeks.
45769408|NCT03820076|Other|AZT-04|Staphylococcus epidermidis
45769409|NCT05563740|Other|Psychosocial|Daily telephone calls with two sessions of Brief Interventions for alcohol
45769410|NCT02902484|Drug|Nintedanib|Nintedanib Monotherapy Followed by Combination Therapy of Nintedanib and Gemcitabine Plus nab-Paclitaxel
45629677|NCT02037256|Drug|bortezomib|Given IV
45629678|NCT02037256|Biological|filgrastim|Given SC
45629679|NCT02037256|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation
45629680|NCT02035696|Biological|Trivalent influenza vaccine (TIVc)|
45629681|NCT02035696|Biological|Trivalent influenza vaccine-licensed|Licensed influenza vaccine
45769411|NCT05563584|Behavioral|Super Rehab|A 12-month healthcare-delivered lifestyle intervention involving exercise and nutritional support
45769412|NCT05503914|Radiation|low-dose radiotherapy|On the first and second days of induction chemotherapy, local tumor were irradiated with 0.5Gy bid for 4 times.
45769413|NCT01455506|Drug|Decitabine plus Fludarabine and Busulfan|"Decitabine will be administered at a dose of 60 mg/m2 IV daily based on adjusted body weight for patient >20% above ideal body weight~Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 5 days starting on transplant day -7.~Busulfan will be administered at a dose of 130 mg/m2 IV daily for 2 days on transplant days -4 and -3.~Patients will also receive rabbit antithymocyte globulin (Thymoglobulin) at a dose of 2 mg/kg IV daily for 3 days on transplant days -4, -3, and -2.~Hematopoietic cells will be infused on day 0."
45769414|NCT05563428|Procedure|Free gingival graft|A free gingival graft will be carried out for recession treatment.
45769415|NCT05563428|Procedure|Connective tissue graft|The pouch technique with a connective tissue graft will be carried out for recession treatment.
45769416|NCT03821012|Other|in-hospital process optimization|
45769417|NCT03821012|Other|PPCI hospital-based regional STEMI transfer network construction|
45769418|NCT03821012|Other|the whole-city STEMI care network construction|
45769419|NCT05508438|Device|Transfemoral mitral-valve repair|Transfemoral mitral-valve repair
45769420|NCT03822104|Dietary Supplement|Bovine Colostrum|Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants start with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5 if the infants only receive DM. The intervention lasts until the infants reach postmenstrual age (PMA) 35+6 weeks or in no-need of fortification due to sufficient growth, whichever comes first.
45629682|NCT02057458|Drug|Sildenafil (Acute-1 hour)|Vascular function will be assessed 1 hour following oral ingestion of sildenafil (50 mg)
45629683|NCT02057458|Drug|Sildenafil (Subchronic-4 weeks)|Vascular function will be assessed 4 weeks following 20 mg three times per day (TID) of sildenafil for four weeks
45629684|NCT02057458|Drug|Placebo|Sugar pill designed to mimic the sildenafil treatment
45769421|NCT03822104|Dietary Supplement|FM85|Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed until discharge.
45629685|NCT04717804|Other|AIP CT|An image taken over a longer time of the lungs (average intensity projection of 4DCT) will be compared with breathing during treatment.
45629686|NCT04717804|Other|FB (Free-Breathing) CT|A snapshot of breathing (free-breathing traditional CT) will be used to compare with breathing during treatment.
45769422|NCT02564796|Drug|Epoetin Alfa and Iron|Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.
45629687|NCT02057068|Behavioral|SLEEP-E Dyads Intervention|Described in arm/group description
45629688|NCT02056834|Device|chronOS Inject|chronOS Inject is used as bone void filler in internal fixation of proximal tibial fractures
45629689|NCT02087176|Drug|AZD1775|AZD 1775 + antimitotic agent+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
45769423|NCT02564796|Drug|Iron|Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
45769424|NCT03829436|Drug|Part 1 TPST-1120|Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression
45769425|NCT03829436|Drug|Part 2 TPST-1120 + nivolumab|Subjects will receive escalating doses of TPST-1120 administered orally twice daily
45769426|NCT03829436|Drug|Part 3 TPST-1120|Selected dose of TPST-1120 administered orally twice daily until disease progression
45769427|NCT03829436|Drug|Part 4 TPST-1120 + nivolumab|Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression
45769428|NCT05563350|Diagnostic Test|Blood samples|p-chlordiazepoxide and metabolites, p-omeprazole and metabolites, p-midazolam and metabolites, CYP3A4 and CYP2C19 genotyping
45769429|NCT05503836|Procedure|abdominal surgeries|abdominal surgeries
45629690|NCT02087176|Drug|AZD1775 Placebo|Placebo (to match dose) + antimitotic+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
45769430|NCT01455584|Drug|HM781-36B tablets|Q1X28D/4W for HM781-36B tablets
45769431|NCT04273100|Combination Product|PD-1 mAb combined with TACE and lenvatinib|the combination of immunotherapy (PD-1 monoclonal antibody), local therapy (TACE) and anti-angiogenic therapy (lenvatinib)
45769432|NCT05508282|Behavioral|Reading Bees app and children's book to enhance parent-infant reading quality (0-2 month visit)|The reading intervention will be provided at the baseline clinic well-visit (0-2 months), and is based on the SHARE/STEP approach.
45769433|NCT05508282|Behavioral|Reading Bees app and children's book to encourage alternatives to digital media (6-month visit)|The digital media (screen time) intervention will be provided at the 6-month clinic well-visit and is based on Baby Unplugged materials (book and app content).
45769434|NCT01457222|Behavioral|Mindfulness intervention|Web-based guided mindfulness meditation 10 minutes daily
45629691|NCT02087176|Drug|Antimitotic Agent|The antimitotic is a drug that stops cells from dividing. This leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by this drug.
45629692|NCT02087176|Drug|pegfiligrastim|Pegfilgrastim is a man-made version of a protein called granulocyte-colony stimulating factor (G-CSF). This protein is made by cells in the body to stimulate the bone marrow to make more infection-fighting white blood cells.Pegfilgrastim is made by attaching filgrastim to a molecule called polyethylene glycol (PEG). This addition helps it stay in the body longer than filgrastim, which means it can be given less often.
45629693|NCT02056288|Drug|Fentanyl|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
45629694|NCT02056288|Drug|Ropivacaine|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction. Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml).
45629695|NCT02086162|Behavioral|Web-based motivational decision support system|
45629696|NCT02086162|Behavioral|NCI Education|
45629697|NCT02404571|Drug|GDP chemotherapy|gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
45629698|NCT03115697|Drug|Lactulose|Lactulose 20 mL
45629699|NCT03115697|Drug|Rifaximin|Rifaximin 550 BD
45629700|NCT03115697|Biological|Plasmapheresis|Plasmapheresis 8 hrly duration
45629701|NCT03115775|Dietary Supplement|Conjugated linoleic acid|Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) daily.
45629702|NCT03115775|Dietary Supplement|Vitamin D|Intervention will last up to 8 weeks. Subjects will receive vitamin D3 (2000 IU) daily.
45629703|NCT03115775|Dietary Supplement|Conjugated linoleic acid and Vitamin D|Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) and vitamin D3 (2000 IU) daily.
45629704|NCT03115775|Other|Corn oil (placebo)|Intervention will last up to 8 weeks. Subjects will receive corn oil (4000 mg) daily.
45629705|NCT02404259|Drug|TDF (Tenofovir)|
45769435|NCT01457222|Behavioral|Music relaxation|Music relaxation 10 minutes daily
45769436|NCT02564718|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venous thromboembolism (VTE) with 20 mg once daily.
45629706|NCT02404259|Drug|Efavirenz|
45629707|NCT02404259|Drug|lopinavir/ritonavir, atazanavir/ritonavir|
45629708|NCT03171155|Device|XPro System|Implantation of the XPro System
45629709|NCT03170921|Other|Angola|The rhythm performance (Angola) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
45629710|NCT03170921|Other|Benguela|The rhythm performance (Benguela) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
45769437|NCT01453946|Drug|Entocort|Entocort capsules, taken orally, 6 mg daily.
45769438|NCT05503758|Device|Myoton PRO device (MyotonPRO; Myoton AS, Tallinn, Estonia)|The MyotoPRO device is a portable objective device for measuring the contractile (tone), and biomechanical (stiffness) properties of lumbar paravertebral muscles (LPVMs).
45769439|NCT05508126|Diagnostic Test|DECT examination|DECT examinations will be performed using a 192-slice CT scanner (SOMATOM, Force, Siemens, Forchheim, Germany).
45769440|NCT05508126|Diagnostic Test|mpMRI examination|The examinations were conducted on a 3-T MR scanner (MAGNETOM Skyra; Siemens Healthcare, Erlangen, Germany).
45769441|NCT01455896|Drug|ITCA 650|ITCA 650
45769442|NCT01455896|Other|ITCA placebo|ITCA placebo
45769443|NCT05503602|Other|Classical Physiotherapy|Only classical physiotherapy application, 5 sessions per week for 4 weeks.
45769444|NCT05503602|Other|IASTM Technique Application|Instrument-assisted soft tissue mobilization application 2 sessions per week together with 3 sessions of classical physiotherapy per week for 4 weeks. IASTM application; A total of 4 minutes will be applied to the sternocleidomastoideus, levator scapula, scalene muscles and upper part of the trapezius for a total of 4 minutes (2 minutes to the right, 2 minutes to the left region).
45769445|NCT05503602|Other|Foam Roller Technique Application|2 sessions of foam roller technique per week along with 3 sessions of classical physiotherapy per week for 4 weeks. Foam roller application; A total of 4 minutes will be applied to the sternocleidomastoideus, levator scapula, scalene muscles and upper part of the trapezius for a total of 4 minutes (2 minutes to the right, 2 minutes to the left region).
45769446|NCT05508048|Behavioral|The existential approach and logotherapy-based psychosocial support program|Existential Approach and Logotherapy Based Support Program, which raises awareness about the meaning and purpose of the individual's life, enables them to produce solutions to the sense of meaninglessness, anxiety, feeling of emptiness, and many other problems, and develops different perspectives.The content of the program is base on existential analysis and logotherapy. The program lasted for eight weeks, with the first and last session of the scale applications. Additional sessions were set for each session where the aims and objectives of the session could not achieve. A session lasting at least 50 minutes were held each week.
45769447|NCT03829280|Behavioral|Cognitive Adaptation Training|Psychosocial treatment using environmental supports to bypass cognitive and motivational problems and improve adaptive behavior
45769448|NCT03829280|Behavioral|Community Treatment|Medication follow-up and case management as provided in usual community care in the setting
45629711|NCT03170921|Other|São Bento|The rhythm performance (São Bento) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
45769449|NCT04460742|Behavioral|CAPABLE Transitions|The CAPABLE Transitions intervention group will receive an occupational therapy-led multidisciplinary in-home intervention in which the study occupational therapist (<6 visits), registered nurse (<5 visits), and handyman (<2 visits) work with participants over 3-4 months. This intervention group also will receive home health agency care as usual services. CAPABLE Transitions in embedded within a home health agency and includes a care transitions emphasis.
45629712|NCT03170765|Biological|Measles vaccine|Live attenuated measles vaccine of brands currently being used in National Immunization Schedule of India.
45629713|NCT03170687|Device|short foot cast|metatarsal foot cast
45629714|NCT03170687|Device|short leg cast|full short leg cast
45629715|NCT03170531|Diagnostic Test|Custom Designed Spine Coil|During the participant's MR scan, the custom spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging.
45629716|NCT03170531|Diagnostic Test|FDA approved spine coil|During the participant's MR scan, the FDA spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging. Volunteers may receive up to 3 scans to allow for comparisons of changes to the calibration files as we continue to test the coil and improve its performance.
45629717|NCT02403947|Drug|Mesenchymal stem cells|After the sampling of bone-marrow and culture of MSCs by the French Blood Establishment (Midi-Pyrénées), patients will receive an IV injection of MSCs.
45629718|NCT02403947|Drug|Suspension media|injection suspension media
45629719|NCT04481633|Diagnostic Test|COVID 19 serology|Diagnosis of Covid-19 past infection will be made by serology
45769450|NCT04460742|Behavioral|Home Health Agency Care|Both the CAPABLE Transitions intervention and care as usual treatment arms will receive home health agency care as usual services, which can include nursing, health aide, medical social work, and occupational, physical, and speech therapy services. Home health agency clinicians will determine the types and duration of CHHA services that the study participants receive; these services will be completely independent from the research study.
45629720|NCT04481633|Other|COVID 19 Self-Questionnaire|COVID 19 Self-Questionnaire
45629721|NCT03170063|Procedure|Procedure/Surgery: Biofluid samplings|Biofluid samplings (blood and cerebrospinal fluid (CSF))
45629722|NCT03169907|Radiation|Mid trimesteric fetal ultrasonography|"Venous and arterial Doppler indices:~Middle cerebral artery (MCA) peak systolic velocity (PSV):~Umbilical Artery Pulsitility Index (PI) and Resistant Index (RI):~Ductus venosus (DV) Doppler:~Cardiac functions:~Global cardiac function evaluated by Modified Myocardial Performance Index (Mod-MPI):~Systolic cardiac function using the four-dimensional (4D) spatiotemporal imaging correlation (STIC) ultrasound technique:~Diastolic cardiac function evaluated by relationship between the maximal velocities of the E and A waveforms of ventricular filling (E/A ratio)"
45769451|NCT01455740|Behavioral|Provider Visit Incentive (PVI)|"All participants received the standard of care (SOC), which included not only medical care but also a wide range of social services. In addition, participants in the PVI arm received financial incentives designed to motivate health-improving behaviors. After the initial study enrollment visit, participants in the PVI arm received a $30 payment each time they showed up as scheduled for one of their next four HIV primary care visits.~Participants in the PVI arm were also asked to return for a sixth, unanticipated study visit approximately three months after the last of the four study visits to which the incentive scheme applied. To reduce attrition, participants were offered $100 for showing up to the fifth and sixth study visits."
45629723|NCT03169751|Device|Brain Sentinel Monitoring and Alerting System|The Brain Sentinel Monitoring and Alerting System is indicated for use as an adjunct to seizure monitoring in adults in the home or healthcare facilities during periods of rest. The device is to be used on the belly of the biceps muscle to analyze surface electromyographs (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures and to provide an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
45629724|NCT03169829|Dietary Supplement|Standard Diet|"Adapted from National Kidney Foundation guidelines for HD1~Animal only Protein~Refined only Grains~Limit Dairy~Low-k only"
45769452|NCT01455740|Behavioral|Incentive Choice (IC)|"All participants received the SOC. In addition, participants in the IC arm received financial incentives designed to motivate health-improving behaviors. At the initial study enrollment visit, participants in the IC arm chose between either the incentive scheme assigned to the PVI arm or an incentive scheme that tied payments to clinic attendance and ART medication adherence. Participants who selected the 2nd option received a $30 payment at each of their next 4 HIV primary care visits if the (i) showed up as scheduled and (ii) presented a dose-recording pill bottle cap indicating that they correctly took at least 90% of doses of a sentinal medication since the previous study visit.~Participants in the IC arm were also asked to return for a 6th, unanticipated study visit approximately three months after the last of the 4 study visits to which the incentive scheme applied. To reduce attrition, participants were offered $100 for showing up to the 5th and 6th study visits."
45769453|NCT04459806|Procedure|intracranial pressure monitoring|Invasive monitoring of intracranial pressure by using CereLink monitor.
45769454|NCT03829748|Procedure|Intermittent aspiration|Endoscopic ultrasound is done for the localization of the lesion and to localize the site of puncture.Prior to the puncture of the lesion the stylet is removed and a vacuum syringe is prepared with 10 cc of vacuum allowing the generation of continous pressure inside and connected to the end of the needle. Once the lesion is punctured 15 movements in and out of the lesions will be made while the syringe is opened and closed on and off for a total of 3 times each pass. A total of 4 passes will be done in each lesion.
45769455|NCT03829358|Drug|Lactobacillus plantarum IS-10506|Fermented milk containing probiotic Lactobacillus plantarum IS-10506 to be consumed once daily for three weeks.
45769456|NCT03829358|Drug|Placebo|Fermented milk containing placebo to be consumed once daily for three weeks.
45769457|NCT01452308|Biological|Simtuzumab|
45913219|NCT02019576|Radiation|Stereotactic radiotherapy|SRT to all areas of oligo-progression as follows: BRAIN: 20-24 Gy in 1 fraction if < 2 cm,18 Gy in 1 fraction if 2-3 cm,15 Gy in 1 fraction for 3-4 cm, alternatively 25-30 Gy in 5 fractions can be used; SPINE: 18-24 Gy in 1-2 fractions,24 Gy in 3 fractions or 30-40 Gy in 5 fractions; NON-SPINE BONE: 30-40 Gy in 5 fractions; LUNG: 48-60 Gy in 4 fractions or 54-60 Gy in 3 fractions for peripheral lung tumours,50 Gy in 5 fractions or 60 Gy in 8 fractions for central lung tumours; LIVER: 30-60 Gy in 3-6 fractions,higher doses for central liver lesions and lower doses for peripheral liver lesions depending on proximity to adjacent organ (stomach, small bowel, large bowel or kidney); ADRENAL OR KIDNEY TUMOURS: 30-40 Gy in 5 fractions; LYMPHADENOPATHY: 30-40 Gy in 5 fractions.
46069913|NCT04255004|Device|Pall Celeris System, point of care device for human cell therapy|Concentration of PB-MNCs autologous cell therapy was produced by a filtration-based point-of-care device. All the procedures were performed in operatory room with anaesthesiologic support (propofol and/or peripheral block). Blood withdrawal (120 ml) was collected through a peripheral venous access. Blood was loaded, and gravity filtration was allowed to proceed until the upstream side of the filter had no remaining blood; filtration last about 10 minutes. During filtration, MNCs were captured in the filter while plasma, platelets (PLTs) and red blood cells (RBCs) were not retained. Immediately concentrate solution is injected in the perilesional area and intramuscular in the foot and the leg (0.2-0.3cc in boluses) below the knee, at intervals of 1-2 cm and to a mean depth of 1.5-2 cm, using a 21G needle. This procedure is repeated on each patient for three times, at intervals of 30-45 days from each other.
46069914|NCT04250948|Drug|JS001|JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.
46069915|NCT04250948|Drug|Oxaliplatin|Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w
46069916|NCT04250948|Drug|S1|S-1: 40~60mg Bid，d1~14, q3w
46069917|NCT04250948|Drug|Capecitabine|Capecitabine: 1000mg/m2 Bid，d1-14, q3w
45629725|NCT03169829|Dietary Supplement|Low-k|"•¼ Animal, ¾ Plant Proteins~•½ Refined, ½ Whole Grain~Limit Dairy, provide Soymilk Dairy~Low-k only Fruit and Vegetables"
45769458|NCT05562882|Drug|Daratumumab Injection|intravenous daratumumab administration
45769459|NCT03825146|Biological|Autologous Multi-lineage Potential Cells (AMPC)|"Multi-lineage potential cells which were induced to de-differentiate from somatic leukocytes from peripheral blood. Cells are autologous with respect to the patient, and are prepared in a suspension and administered via intravenous infusion.~An estimated average of 1 x 10^8 (0.5 to 5.0 x 10^8) cells/per suspension(275 to 450mL) will be infused into the patient via intravenous infusion on day 5. Cell counts depend on yield of initial leukocyte harvest on day 0."
45769460|NCT05562180|Behavioral|Customized meal plan and grocery delivery|Participants will use an app to customize their meal plans
45629726|NCT03169829|Dietary Supplement|Standard|"•¼ Animal, ¾ Plant Proteins~Refined, ½ Whole Grain~•Limit Dairy, provide Soymilk Dairy~Low-k, Fruit and Vegetables~High-k Fruit and Vegetables"
45629727|NCT04481867|Procedure|densah bur|osseodensification densah bur
45629728|NCT02403791|Device|Linear Ultrasonic Sounder|Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
45629729|NCT02403791|Device|Bedside X-ray Machine|Chest Radiography is performed after clinical evaluation without using ultrasound assessment.
45629730|NCT02403713|Drug|Fluticasone/formoterol BAI|Fluticasone/formoterol 125/5 µg breath actuated inhaler (BAI) (250/10 µg total dose)
45769461|NCT05561634|Radiation|Radiotherapy|Irradiation of the tumoral bed.
45769462|NCT05561634|Other|Observation|Patients will be followed up in consultation every 3 months.
45769463|NCT05561634|Drug|Vismodegib|Sonic Hedgehog inhibitors (SHHi) = Vismodegib et Sonidegib,
45769464|NCT02579174|Device|Medacta GMK Sphere|
45769465|NCT05560542|Drug|Atropine and Dexamethasone|Intrathecal dexamethasone, atropine or their combination.
45913220|NCT02019615|Device|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
45913221|NCT02019628|Dietary Supplement|Rice Bran Arabinoxylan Compound (RBAC)|Participants enrolled in the study will receive BRM4 at a dosage level of either 1 gram/day or 3 gram/day for the 60-day period. Subjects will be instructed to not consume any known immune-active pharmaceutical agents, nutritional supplements containing vitamins C and D, and/or any mushroom products for two weeks prior to having the baseline assessments and until the conclusion of the 60-day period. According to the company's literature, RBAC is a water soluble extract of rice bran that has been acted upon by an enzyme complex extracted from Shiitake mushroom. BRM4 contains: microcrystalline cellulose, hypromellose, sucrose fatty acid ester, gellan gum, and potassium acetate.
45913222|NCT02019732|Other|Data collection|Data collection from existing electronic healthcare databases (Marketscan Commercial database, MarketScan Medicare Supplemental database).
46069918|NCT05251766|Drug|Nab paclitaxel|To analyze and compare the efficacy and safety of epirubicin + cyclophosphamide (EC) followed by docetaxel and EC followed by nab-paclitaxel in neoadjuvant chemotherapy of breast cancer; To analyze and compare the efficacy and safety of nab-paclitaxel combined with epirubicin + cyclophosphamide (EC) chemotherapy regimen in neoadjuvant therapy of breast cancer, so as to provide a new treatment option for patients with HER2-negative breast cancer.
45629731|NCT02403713|Drug|Formoterol|Formoterol
45629732|NCT02403713|Drug|Fluticasone/formoterol PMDI without spacer|Fluticasone/Formoteral 125/5µg pMDI without spacer
45629733|NCT02403713|Drug|Fluticasone/formoterol PMDI with spacer|Fluticasone/Formoteral 125/5µg pMDI with spacer
45629734|NCT02403713|Drug|Fluticasone/formoterol PMDI without spacer low dose|Fluticasone/Formoteral 125/5µg pMDI without spacer, low dose
45629735|NCT02700815|Drug|Diclofenac|
45629736|NCT02700815|Drug|Capsaicin|
45629737|NCT02700815|Drug|Placebo|
45769466|NCT01455974|Other|Decreasing dialysate sodium from 138 mmol/L to 136 mmol/L|After 1-month period of dialysis with standard dialysate sodium concentration 138mmol/L, patients were followed up over a 1-year period with dialysate sodium set at 136mmol/L, without changes in instructions to patients about dietary sodium.
45769467|NCT05560308|Drug|Trastuzumab Emtansine for Injection|3.6 mg/kg body weight (IV), administered on day 1, 21 days as a treatment cycle;
45769468|NCT05560308|Drug|Pyrotinib Maleate Tablets|The initial dose is 320 mg (PO), administered orally within 30 minutes after meals, at the same time every day, 21 days as a treatment cycle;
45769469|NCT04782726|Other|Software Solution for Radiation Therapy Treatment|Software has been developed for individualized pre optimization evaluation of the patient anatomy and prescribed dose of radiation therapy.
45769470|NCT04782726|Other|Radiation therapy|Standard of Care planning for Radiation therapy is used to treat the subjects for head and neck cancer
45769471|NCT03822494|Radiation|CyberKnife SBRT|Radiation Therapy
45629738|NCT02403557|Behavioral|Waitlist|Weekly check up.
45629739|NCT02403557|Behavioral|Tailored Internet-delivered CBT|Tailored Internet-delivered CBT during 8 weeks.
45629740|NCT03170297|Other|Research interventions of blood sampling and data collection|Patient-Specific Functional Scale (PSFS) survey will be administered to patients to record symptoms at both the time of evaluation in the emergency department and in follow up by phone at 3, 7, 14, 21 and 28 days after discharge from the emergency department or hospital. The rest of the patients' care will be as usual care, and patients will have had research interventions of blood sampling and data collection as noted in the previously approved SC2i Tissue Data Acquisition Protocol (TDAP) Pro00054947 (ClinicalTrial.gov ID: NCT02182180).
45629741|NCT03169595|Procedure|Surgery|Patients affected by epithelioid hemangioma treated with surgery
45629742|NCT02403401|Drug|Levonorgestrel (BAY98-7196)|Levonorgestrel 40 µg/d intravaginal ring (treatment for 365 days, 28 days wearing period for each ring)
45769472|NCT04779528|Procedure|Fiberoptic intubation in supine position.|"Patients will be placed in supine position after the establishment of full vital signs monitoring and the insertion of an intravenous line.~Under sedation via intravenous infusion of remifentanil plus topical anesthesia with 10 ml of Lidocaine 1% via a 3.7mm bronchoscope. After applying a standard monitoring and preparation of the nose by decongestant and local anesthesia. A loaded flexible scope (by an endotracheal tube ETT) will be introduced through the nostril to reach the carina, then the ETT will be pushed over the scope 3cm above the carina."
45913223|NCT02019745|Biological|LAIV|Standard dose of LAIV administered by a licensed health care providers.
45769473|NCT04779528|Procedure|Fiberoptic intubation in lateral position.|"Patients will be placed in lateral position after the establishment of full vital signs monitoring and the insertion of an intravenous line.~Under sedation via intravenous infusion of remifentanil plus topical anesthesia with 10 ml of Lidocaine 1% via a 3.7mm bronchoscope. After applying a standard monitoring and preparation of the nose by decongestant and local anesthesia. A loaded flexible scope (by an endotracheal tube ETT) will be introduced through the nostril to reach the carina, then the ETT will be pushed over the scope 3cm above the carina."
45769474|NCT04273568|Other|Scapular PNF|Rhythmic initiation and repetitive stretching techniques in scapula anterior elevation-posterior depression and anterior depression-posterior elevation patterns were applied twice a week for 6 weeks.
45629743|NCT02403245|Other|Psychosocial stimulation|"Intervention consists in a session of social stimulation during about 40 minutes through where the speaker introduced himself to the residents and introduces the residents to each others. The date of the day was done to residents. Social stimulation consists here to an exercise about the four seasons. Residents are asked to mention the 4 seasons and to give all the characteristics they can about each season. Two exercises were proposed: 4 pictures of landscapes and residents were asked to tell which season is represent on the pictures and pictures of some fruits and residents tried to tell in which season we find the fruits. Finally, the psychologist speaks about the four season of the compositor Vivaldi and propose to the residents to listen some extracts of each pieces of music."
45629744|NCT02403011|Other|soft tissue mobilization|soft tissue mobilization technique has three phases. First phase 'the passive mobilization phase' is applied by gentle but tight gripping of the SKM muscle two or three fingers below the muscle origo and the muscle is mobilized rhythmically in the antero-posterior direction. Secondly, after gently continue to hold the muscle the baby was encouraged to do active repetitive cervical rotation to the affected side by means of catching the babies attention with colored and sonorous toys. Third phase was mobilization with stretching. Caregiver holds the baby on his/ her affected side while the therapist gently grips and withholds the muscle. Therapist mobilizes the muscle in the antero-posterior direction and stretch the muscle
45629745|NCT02403011|Other|home program controlled once six weeks|Home program which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations
45769475|NCT04273568|Other|Exercise program|An exercise program consisting of exercises used in the conservative treatment of shoulder impingement syndrome for both groups was applied twice a week for 6 weeks.
45629746|NCT02402855|Other|Delivery of a prepaid payment card|Delivery of a prepaid payment card credited according to consultations attended
45629747|NCT02402855|Other|Interview with a sociologist|For a sub-group of 40 womens
45769476|NCT04848740|Device|ReLex-smile|Using VisuMax femtosecond laser we created the stromal pocket with diameter of 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness set to 130 μm from corneal surface and 4 mm superior incision. Hinge position flap was set at 90° angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values We noticed during intervention that implantation of fresh lenticule depends from corneal thickness, for example if c.th.is 300-400 μm we implanted 1/2 stroma, if c.th.is 400 μm or more we implanted 1/3 stroma Example: if corneal thickness is 300 μm we implanted 150 μm (becoming 450 μm) we added more stroma due to more live keratocytes and stromal steam cells, aiming to overcome dead and non-functional keratocytes
45629748|NCT02402855|Other|No intervention|
45629749|NCT02402621|Drug|fentanyl|fentanyl with antiemetic drug
45629750|NCT04481789|Drug|MT-1186|Suspension
45769477|NCT01456208|Drug|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
45769478|NCT01456208|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
45913224|NCT02019784|Drug|Rifaximin-α|Rifaximin-α will be compared to placebo with the various outcome measures assessed at baseline (pre-randomisation), and then at 30 days and 90 days.
45913225|NCT02019784|Drug|Placebo Oral Tablet|Placebo Oral Tablet
45913226|NCT02019797|Drug|Desflurane|Patients are assigned to desflurane group (Des) or propofol group (Prop). Des receives desflurane (1-2 MAC) inhalation between the induction of anesthesia and before cardiopulmonary bypass (CPB). After the induction of CPB, the anesthesia in Des is switched to a total intravenous anesthesia (TIVA) with propofol. Prop receives a propofol during the surgery.
45913227|NCT02019810|Drug|Norepinephrine|
45913228|NCT02019810|Drug|Dobutamine and norepinephrine|
45913229|NCT02019823|Behavioral|Informational SMS-text|
45913230|NCT02019823|Behavioral|Interactive SMS-text|
45913231|NCT02019823|Behavioral|Enhanced usual care|
45913232|NCT02019836|Other|Determining maternal and neonatal vitamin D levels|
45913233|NCT02019862|Device|TRJ® Total Hip Arthroplasty|
45913234|NCT02019901|Other|Nurse-led clinic|
45629751|NCT04481789|Drug|Rosuvastatin|Tablets
45629752|NCT04481789|Drug|Sildenafil|Tablets
45913235|NCT02019953|Other|Yoga|The yoga intervention, which is taught based on Hatha yoga, will be offered to study participants in Study Arms 1, 2, and 3, is a combination of asanas (poses), pranayams (breathing exercises), and meditation. Blood pressure and heart rate measurements are taken before and after each session.
45629753|NCT04481789|Drug|Furosemide|Tablets
45629754|NCT02402387|Procedure|Neutral head position|
45629755|NCT02402387|Procedure|Flexed head position|
45629756|NCT02402387|Procedure|Extended head position|
45629757|NCT02402387|Procedure|Rotated head position|
45629758|NCT02402387|Device|Air-Q SP Airway|
45629759|NCT02402465|Drug|Placebo|Patients will be treated by placebo
45769479|NCT01456208|Drug|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
45769480|NCT05507736|Other|Acupuncture|13 Indwelling, sterile and disposable needles (SEIRIN NEW PYONEX® from 0.9 mm in length and 0.22 mm in diameter) on day 1 and 5 of the second cycle of irinotecan leaving them inserted for 4 days.
45769481|NCT04847726|Diagnostic Test|contrast enhanced ultrasound|contrast enhanced ultrasound with perfluorobutane and sulfur hexafluoride
45913236|NCT02019953|Other|Walking|The walking intervention, which is Study Arm 4 includes, three guided walking sessions per week for 24 weeks. Each class is an hour in length and will include a minimum of 30 minutes of walking at the equivalent of a minimum of three miles per hour. Each session includes a ten-minute warm-up and ten-minute cool-down period of some stretches and walking at a leisurely pace. Blood pressure and heart rate measurements are taken before and after each session.
45913237|NCT02019953|Other|Healthy Lifestyles Education|Participants randomly assigned to the fifth study arm attend one 60-minute healthy lifestyles class per week for 24 weeks. The Healthy Lifestyles curriculum includes 24 independent lesson modules, which allows participants to begin their intervention at any time during the course schedule. Blood pressure and heart rate measurements are taken before and after each session.
45629760|NCT02402465|Drug|Fluticasone propionate|Patients will receive fluticasone nasal spray
45629761|NCT02402465|Drug|Fluticasone/Azelastine nasal spray|Patients will receive Dymista nasal spray
45769482|NCT04847726|Diagnostic Test|Dynamic CT|Participants underwent dynamic CT for hepatic lesion
45769483|NCT04847726|Diagnostic Test|Liver MRI|Participants underwent liver MRI for hepatic lesion
45769484|NCT05475834|Drug|SIM0417|Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.
45769485|NCT04273646|Biological|UC-MSCs|4 times of UC-MSCs(0.5*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7).
45913238|NCT02020005|Other|Non-flavored 2mg nicotine gum|
45913239|NCT02020005|Other|Non-flavored 4mg nicotine gum|
45913240|NCT02020005|Other|Mint-flavored 2mg nicotine gum|
45913241|NCT02020005|Other|Mint-flavored 4mg nicotine gum|
45913242|NCT02020005|Other|Non-flavored nicotine inhaler|
45913243|NCT02020005|Other|Mint-flavored nicotine ihaler|
45913244|NCT02020044|Other|Endothelial Keratoplasty|
45913245|NCT02020057|Procedure|Total knee arthroplasty|Total knee arthroplasty with standard incision and approach, and cement fixation. Zimmer Nexgen posterior stabilized total knee implants are used.
45913246|NCT02020096|Procedure|Ultrasound and nerve stimulator guided lumbar plexus block|An insulated nerve block needle connected to a nerve stimulator that was delivering a current of 1.5 mA at a frequency of 2 Hz was then inserted in the long axis (in- plane) of the ultrasound transducer towards the the hypoechoic psoas compartment. If the quadriceps contraction which produces patella twitching was elicited with an initial current of 1.5mA,then the current should be reduced until contraction is still present between 0.3 to 0.5 mA .Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.3mA, otherwise intraneural needle position should be suspected.
45629762|NCT02402465|Procedure|Nasal Allergen Challenge|All subjects will receive a nasal challenge with allergen to mimick an allergic response and allow the investigation of the different drug effects on that response. Allergen extracts will be used as sprays into the nasal cavity. The extracts are approved by FDA for skin testing or desensitization therapy and an IND was obtained to allow intranasal administration
45629763|NCT04481711|Procedure|Total Knee Arthroplasty|Osteoarthritis (OA) is one of the most common chronic peripheral joint diseases increasing among the aging population.Pathogenesis is not fully known.One of the most common risk factors and causes are loss of pain and function. Knee joint osteoarthritis adversly affects the person's life quality. Total Knee Arthroplasty (TKA) is a surgical approach to restore tibiofemoral joint alignment, especially in the severe level of knee OA.
45629764|NCT02402231|Drug|Omalizumab|Omalizumab is the treatment during oral immunotherapy with peanuts as protection
45629765|NCT02402543|Drug|Gabapentin|
45629766|NCT02402543|Drug|Ketamine|Prior to the incision in the operating room, the anesthesiologist administers 0.15 mg/kg of ketamine IV push in patients randomized to the experimental arm, only.
45769486|NCT04273646|Drug|Placebo|4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).
45769487|NCT05436522|Drug|Remimazolam|Remimazolam is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
45769488|NCT05436522|Drug|Propofol|Propofol is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
45769489|NCT04273334|Drug|68Ga-NEB|68Ga-NEB were injected into the patients before the PET/CT scans
45769490|NCT05503212|Other|Conservative treatment (CT)|Best medical treatment without intravenous thrombolysis nor endovascular thrombectomy
45629767|NCT02402543|Drug|Acetaminophen|
45629768|NCT02402543|Drug|Dexamethasone|Prior to the incision in the operating room, the anesthesiologist administers 8 mg of dexamethasone IV push in patients randomized to the experimental arm, only.
45769491|NCT05503212|Other|Intravenous thrombolysis (IVT)|Best medical treatment with intravenous thrombolysis but without endovascular thrombectomy
45769492|NCT05503212|Other|Endovascular thrombectomy (EVT) ± intravenous thrombolysis (IVT)|Best medical treatment with endovascular thrombectomy with or without intravenous thrombolysis
45769493|NCT01456286|Drug|sapropterin|two weeks of treatment: 5 mg/kg per day during first week 10 mg/kg per day during second week
45769494|NCT05349240|Device|C2 CryoBalloonTM Ablation System.|Cryoablation is used to ablate the tissue under the cryogenic condition. The device is mainly used to destroy the unhealthy tissues.
45769495|NCT03780010|Drug|TRC105|Dose-finding study of TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
45769496|NCT03826550|Drug|Diclofenac Sodium Gel|Twice daily for 60 days. Each patient is expected to receive 120 doses
45629769|NCT02402543|Drug|Placebo|
45769497|NCT03826550|Drug|Solaraze 3% Topical Gel|Twice daily for 60 days. Each patient is expected to receive 120 doses
45769498|NCT03826550|Other|Placebo|Twice daily for 60 days. Each patient is expected to receive 120 doses
45769499|NCT03827018|Combination Product|mavrilimumab|1 mL of 150 mg in a pre-filled syringe
45769500|NCT03827018|Combination Product|placebo|1 mL of placebo in a pre-filled syringe
45769501|NCT03827018|Drug|prednisone|Prednisone tablets for oral administration containing either 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg or 50 mg of prednisone United States Pharmacopeia (USP)
45769502|NCT05325762|Drug|Propofol|At 21:00 on the night of tracheal extubation, propofol was administered intravenously with a microinjection pump for 2min. MOAAS/S was used to evaluate subjects 30 seconds after the end of administration.
45769503|NCT05325762|Drug|Dexmedetomidine|Dexmedetomidine was at 21 PM on the day of tracheal extubation: Dexmedetomidine was injected intravenously beginning at 00. During administration, patients were evaluated with MOAA/S every 2min.
45769504|NCT05325762|Drug|Saline|At 21:00 PM on the day of tracheal extubation, normal saline was injected intravenously. During the administration, patients were evaluated with MOAA/S every 2 minutes.
45769505|NCT04391738|Other|Patients admitted to Intensive Care Unit with SARS-CoV2|Patients admitted to Intensive Care Unit with SARS-CoV2
45913247|NCT02020096|Procedure|Nerve stimulator guided lumbar plexus block|The block was conducted following traditional Winnie approach. The accepted end point for the lumbar plexus is stimulation of the femoral nerve component, observed by contraction of the quadriceps muscle. Quadriceps contraction which produces patella twitching should be sought with an initial current of 1.5mA, and once elicited the current should be reduced until contraction is still present between 0.3 to 0.5 mA. Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.3mA, otherwise intraneural needle position should be suspected.
45913248|NCT02020109|Radiation|splenic irradiation|
45913249|NCT02020122|Drug|Duloxetine|duloxetine 60mg
45629770|NCT02401841|Drug|Two different types of drug for resolution of neuro-muscular blockade|
45629771|NCT02401997|Behavioral|sexual abstinence|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination.
45913250|NCT02020122|Drug|Pregabalin|pregabalin 150mg
45629772|NCT02401919|Behavioral|Tell-us Card|Patients will be invited on a daily basis, during their stay in the hospital, to state what is important for them at that moment or before discharge
45913251|NCT02020122|Drug|Placebo|non active placebo
46069919|NCT05251766|Drug|Docetaxel|To analyze and compare the efficacy and safety of epirubicin + cyclophosphamide (EC) followed by docetaxel and EC followed by nab-paclitaxel in neoadjuvant chemotherapy of breast cancer; To analyze and compare the efficacy and safety of nab-paclitaxel combined with epirubicin + cyclophosphamide (EC) chemotherapy regimen in neoadjuvant therapy of breast cancer, so as to provide a new treatment option for patients with HER2-negative breast cancer.
45629773|NCT04481477|Other|Nursing care to reduce anxiety, fear and loneliness|Decreased anxiety Presence Emotional support Improved security Increasing coping capacity Presence Emotional support Facilitating visits
45629774|NCT02401607|Other|Karasek questionnaire and Saliva prelevement|Karasek questionniare and Saliva collection will be assessed on any health care worker working in any emergency department in France at day 1 and at 5 years
45629775|NCT02401373|Biological|Ad5-EBOV|intramuscular injection
45769506|NCT05313568|Other|static stretching|The stretch will be done by placing both feet on a raised platform, lowering the heel off the platform without touching the ground, and held in this position to perform a static stretch. They will perform 5 repetitions, 15 seconds of rest and 1 minute of stretching.
45769507|NCT05313568|Other|self massage|In addition to the self-stretching application, plantar self-massage will be applied. Plantar self massage will be shown to the participants by the physiotherapist with a 7 cm spiky massage ball. Then, participants will be asked to self-massage the plantar sole of the foot for 5 minutes with a 7 cm spiky massage ball.
45769508|NCT05313568|Other|Manual Stimulation|"In addition to the self-stretching application, manual stimulation will be applied.~Manual protocol:~A) Pressure will be applied in each interdigital space and on the longitudinal arch with shear in the longitudinal direction (5 repetitions of 10 seconds each).~B) Pressure with transverse shear on the metatarsal heads (5 repetitions of 5 seconds each) C) Static pressure will be applied to the first and fifth metatarsal head, center of the midfoot, and heel (5 repetitions per 10-second period each)."
45769509|NCT04391582|Other|Tilapia skin|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, the tilapia skin was applied and covered with gauze and bandage. These dressings were changed only if the tilapia skin did not adhere properly to the wound bed
45769510|NCT04391582|Drug|silver sulfadiazine cream 1%|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of silver sulfadiazine cream 1% was applied and covered with gauze and bandage. In these patients, the dressings were changed daily
45769511|NCT03768856|Radiation|Temporally Feathered Radiation Therapy (TFRT)|Up to 5 different plans are created and delivered on a daily basis Monday-Friday for 7 weeks. The treating physician designates up to 5 organs at risk (OARs) to be feathered based on the proximity to the target. The daily prescription dose delivered to the Planning Target Volumes (PTV) is not changed.
45913252|NCT02020161|Drug|Atra|
45913253|NCT02020161|Drug|Idarubicin|
45913254|NCT02020161|Drug|methotrexate|
45913255|NCT02020187|Other|Exercise on a cycle-ergometer|Home training on an ergometer-cycle 30 minutes every other day or at least three times a week. Subject will exercise in a pulse interval corresponding to 70% of their maximal VO2.
45913256|NCT02020200|Drug|MPH|MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight<40 kg; 30 mg in case weight>90 kg; otherwise 20 mg.
45629776|NCT05232305|Dietary Supplement|Pomegranate Peel|Standard bread and test breads (with added pomegranate peel) to be used in the study will be produced by Asst. Prof. Özlem ÖZPAK AKKUŞ in the Nutrition Principles Laboratory of Toros University. For standard bread, 900 ml of water, 42 fresh yeast, 12 g of salt and 12 g of sunflower oil will be added to 1000 g of sifted whole wheat flour and the prepared bread mixture will be divided into 40 equal parts. To make bread with pomegranate peel added, 1000 g of sifted whole wheat flour, 20 g of pomegranate peel powder, 914 ml of water, 42 g of fresh yeast, 12 g of salt and 12 g of sunflower oil will be added and the prepared bread mixture is divided into 40 equal parts with 500 mg of pomegranate peel powder in each piece).
45629777|NCT02401295|Drug|ATRA|
45769512|NCT05498064|Drug|Ensartinib|Ensartinib 225 mg administered once daily orally
45629778|NCT02401295|Drug|Celecoxib|
45629779|NCT02401295|Drug|Itraconazole|
45629780|NCT02401451|Device|RhythmPadGP|ECG acquisition using a novel device RhythmPadGP
45629781|NCT02400983|Device|Pacemaker, ICD|
45629782|NCT04897763|Drug|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
45629783|NCT03169439|Procedure|Irreversible electroporation|minimal invasive ablative technique for tumors
45629784|NCT03169205|Other|observation registry|observation registry
45629785|NCT02401061|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 1 (3, 6,12, 18, or 24) microgram of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation.
45629786|NCT02401217|Other|Phase 1- Arm 1 Infant Formula|Powder infant formula
45629787|NCT02401217|Other|Phase 2- Arm 2 Infant Formula|Powder infant formula
45769513|NCT04845386|Device|TOF Cuff on arm|The TOF Cuff will be installed on one arm in opposite of TOF Scan. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
45629788|NCT02401217|Other|Phase 2- Arm 3 Infant Formula|Powder infant formula
45629789|NCT03106649|Device|Echocardiography|Before administration of spinal anesthesia, Echocardiography will be performed to determine the LVEDA. If the LVEDA is more than 10 square cms, the patient will be considered as volume replete and spinal anesthesia will be administered. If the LVEDA is less than 10 square cms, a fluid bolus of 250 ml of a balanced salt solution will be given and LVEDA reassessed. This will be repeated till the LVEDA is more than 10 square cms or fluid bolus has been given twice and still the LVEDA is less than 10 square centimeters, in which case phenylephrine 1-2µg/kg will be given before administering spinal anesthesia.
45629790|NCT03106649|Device|Treatment of spinal hypotension|For treatment of spinal hypotension, in the event of hypotension(defined as a mean arterial pressure less than 60 mm Hg or decrease in mean arterial pressure of more than 20% from the baseline value) after spinal anesthesia, the LVEDA will be assessed. If more than 10 square centimeters, the patient will be considered volume replete and a vasopressor in the form of phenylephrine 1-2µg/kg will be given. If the LVEDA is less than 10 square centimeters, a volume bolus of 250ml will be given. On reassessment if the LVEDA is still less than 10 square centimeters the volume bolus can be repeated. In the event of hypotension persisting in spite of volume resuscitation, phenylephrine 1-2µg/kg will be given.
45629791|NCT00708305|Drug|Sodium Fluoride (NaF)|Different fluoride toothpastes containing between 1400ppmF - 1450ppmF of fluoride as NaF
45629792|NCT00708305|Drug|Placebo|Fluoride free toothpaste (0ppmF)
45629793|NCT03169049|Device|High-Frequency Stimulation|high-Frequency electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
45629794|NCT03169049|Device|sham Stimulation|Sham transcutaneous electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
45629795|NCT03169127|Drug|Ibuprofen 600 mg|After lower third molars surgeries, pharmacogenetic and clinical efficacy of Ibuprofen 600mg was study.
45769514|NCT04845386|Device|TOF Cuff on lower leg|The TOF Cuff will be installed on one lower leg. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
45629796|NCT03115307|Drug|Triptorelin|Triptorelin 0,1mg/ml subcutaneously once in a luteal phase in insemination cycles.
45629797|NCT03169283|Other|Cereal with B glucan|A cereal high in viscous dietary fiber B glucan
45629798|NCT03169283|Other|Cereal without B glucan|Cereal without B glucan
45629799|NCT02418533|Drug|menotropin|Menopur is used for controlled ovarian stimulation (COH)
45629800|NCT02418533|Drug|Recominant Follicle Stimulating Hormone (rFSH)|Gonal-f is used for controlled ovarian stimulation (COH)
45913257|NCT02020200|Drug|Placebo|
45629801|NCT03168815|Device|High Flow Nasal Cannula or Low Flow Nasal Cannula|HFNC vs LFNC
45629802|NCT03168893|Device|Deep brain stimulation ON|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is activated
45913258|NCT02020213|Drug|Posaconazole|400 mg po bid for 8 weeks
45629803|NCT03168893|Device|Deep brain stimulation OFF|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is not activated
45629804|NCT02400593|Behavioral|Meditation Workshop|Six weeks of formal instruction in Lovingkindness or Mindfulness meditation.
45913259|NCT02020226|Drug|TH-302|480 mg/m2 30 min IV infusion on Days 1, 8, and 15 of a 28 day cycle
45913260|NCT02020239|Other|Exercise|
45913261|NCT02020265|Device|EEG neurofeedback|
45913262|NCT02020291|Drug|Foxy-5|
45913263|NCT02020317|Behavioral|decision support in potassium-inc. drug-drug-interactions|display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
45629805|NCT02418299|Device|IncontiLase Er:YAG laser treatment|Each patient will receive 2-3 sessions of Er:YAG laser treatment for stress and mixed urinary incontinence (IncontiLase)
45629806|NCT02418221|Dietary Supplement|DAOSiN®/ Placebo & ProvokAmin® Ingestion|Proband is randomly assigned Daosin® or the Placebo before provocation with ProvokAmin®
45629807|NCT02418221|Procedure|Drawing blood, measuring BP & pulse|Taking of a blood sample and recording of blood pressure & pulse
45629808|NCT02418143|Device|CorMatrix CanGaroo ECM Envelope|Subjects who have received CorMatrix CanGaroo ECM Envelope for an implantable electronic device placement following a battery change or upgrade.
45769515|NCT04845386|Device|TOF Scan on toe|The TOF Scan will be installed on hallux . After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
45769516|NCT04845386|Device|TOF Scan on adductor pollicis|The TOF Scan will be installed on Thumb. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
45629809|NCT02400827|Other|malignant cells|
45629810|NCT02417909|Other|questionnaires about quality of life|all teenagers included in the trial and their parents must complete the questionnaires given of them the day of enrollment.
45629811|NCT02418065|Other|training on ergonomic bicycle|
45629812|NCT02418065|Drug|Testosterone|
45629813|NCT02418065|Drug|Oral nutritional supplementation|
45629814|NCT02418065|Drug|n3 polyunsaturated fatty acid|
45629815|NCT02417987|Other|Placebo|The skin was penetrated with a needle and few drops of saline injected in the soft tissue away from the tendon
45629816|NCT02417987|Drug|High Volume injection|Injection with10 mls 0.5% bupivacaine hydrochloride and 20 mg of Depomedrol 40 mls saline (NaCl) around the tendon
45629817|NCT02417987|Biological|Autologous conditioned plasma (ACP)|Injection with 4 mls of ACP around the tendon
45629818|NCT02400515|Other|Exercise|This is a quasi-experimental study and the same group was evaluated before and after the exercise.
45629819|NCT03168581|Drug|CN-105|Patients with supratentorial intracerebral hemorrhage (ICH) will be evaluated for eligibility within 12 hours of symptom onset. Eligible participants will receive CN-105 administered intravenously (IV) for a 30 -minute infusion every 6 hours for up to a maximum of 3 days (13 doses) or until discharge (if earlier than 3 days)
45629820|NCT05058443|Drug|Denosumab 60 mg/ml [Prolia]|denosumab subcutaneously every 6 months (Q6M)
45629821|NCT05058443|Drug|Placebo|placebo subcutaneously every 6 months (Q6M)
45629822|NCT02400281|Drug|Crenolanib besylate|
45629823|NCT02400281|Drug|Idarubicin|
45629824|NCT02400281|Drug|Cytarabine|
45629825|NCT02400281|Drug|Azacytidine|
45629826|NCT02400281|Drug|Mitoxantrone|
45629827|NCT02400281|Drug|Etoposide|
45629828|NCT02400281|Drug|Fludarabine|
45629829|NCT02400281|Drug|G-CSF|
45769517|NCT04845386|Device|TOF Scan on corrugator supercilii|The TOF Scan will be installed on corrugator supercilii. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
45769518|NCT05503134|Biological|Universal Donor Natural Killer Cells|Six doses of UD-NK cells will be given thrice weekly for two weeks for up to 2 cycles of treatment
45769519|NCT03767062|Drug|Topamax|An antiepileptic agent used for migraine prophylaxis.
45769520|NCT03767062|Procedure|Greater Occipital Nerve Block + Supratrochlear Nerve Block|An injection to paralyze the occipital and supratrochlear nerves.
45769521|NCT01456364|Drug|Ticagrelor|A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily
45769522|NCT01456364|Drug|Prasugrel|A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients < 75 years or a 5 mg maintenance dose per day for patients >= 75 years
45769523|NCT05497986|Device|High flow nasal cannula|HFNC with the maximum tolerated flow (up to 60 L/min). Titration of supplemental oxygen to a SpO2 between 88 - 92%.
45769524|NCT05497986|Device|Conventional low flow oxygenation|Conventional oxygenation through nasal prongs or a facemask, with supplemental oxygen titrated to a SpO2 between 88 - 92%.
45769525|NCT02901314|Other|on-demand audio messages of heart failure education themes|
45629830|NCT02417519|Other|DAR|Volunteers ingested 300 mL of coffee with a dark roast containing low levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
45629831|NCT02417519|Other|LIR|Volunteers ingested 300 mL of coffee with a light roast containing high levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
45629832|NCT02417519|Other|CTR|Volunteers ingested 300 mL of water containing no chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
45629833|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week
45629834|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 100 mg Q14D SC for 16 week
45629835|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 150 mg Q14D SC for 16 week
45629836|NCT02055976|Drug|Placebo|Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week
45629837|NCT02055976|Drug|Ezetimibe|Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)
45629838|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|50 mg Q14D SC for 16 week
45629839|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|100 mg Q14D SC for 16 week
45629840|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|150 mg Q14D SC for 16 week
45629841|NCT02055976|Drug|Placebo|Placebo Q14D SC for 16 week
45629842|NCT04717258|Other|Fire and Rescue Service Safe and Well Visit|Safe and Well Visits by the Fire and Rescue Service to prevent falls and improve quality of life in an older population
45629843|NCT04717258|Other|Self-Determination Theory informed trial invitation letter|Invitation letter to take part in the FIREFLI study informed by Self-Determination Theory
45629844|NCT04717258|Other|Pen included with reminder questionaire|A pen will be included with the four-month reminder questionnaire.
45629845|NCT04717024|Device|Observational Study - no intervention|Observational Study - no intervention
45629846|NCT02055898|Drug|Sodium Oxybate|
45629847|NCT02055898|Other|placebo (fresh potable water)|
45629848|NCT02564055|Drug|GSK2894512 1% Cream|1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
45629849|NCT02564055|Drug|GSK2894512 0.5% Cream|0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
45629850|NCT02564055|Drug|Vehicle cream|White to off-white vehicle cream base to be applied topically
45629851|NCT02563899|Drug|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be available at a concentration of 18.5 milligrams (mg) umeclidinium parent per gram. 2 mg of this formulation will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of formulation applied daily to both axillae is expected to range between approximately 204 and 680 mg. Total daily dosage of the active pharmaceutical ingredient (umeclidinium parent) to both axillae will range between approximately 3.8 and 12.6 mg. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects. This lower strength formulation will contain 11.5 mg parent per gram.
45629852|NCT02563899|Drug|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. 2 mg of the vehicle will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of vehicle applied daily to both axillae is expected to range between approximately 204 and 680 mg.
45629853|NCT04406259|Drug|Verapamil|"Patients in groupe A require verapamil initiation as a preventive treatment and patients in group B are patients already undergoing a verapamil treatment for their Cluster Headache.~The doses of verapamil are increased for the patients in group A, after a clinical examination an electrocardiogram, and a blood test."
45629854|NCT05500521|Diagnostic Test|Caloric irrigation|In a healthy ear irrigation with warm and cold water should give rise to an intense sensation of vertigo and involuntary eye movements called nystagmus. This nystagmus can be measured and thereby give an indication of the vestibular function in that ear.
45629855|NCT05500521|Diagnostic Test|vHIT|This test measures the vestibular ocular reflex in all six semicircular canals (three in each ear). By performing a fast head thrust in the direction of the canal the eye response can be detected by a high-velocity video camera. A slower response indicates impaired function in that canal.
45769526|NCT04281420|Drug|ATG-019|ATG-019 30 mg QoD×3 is selected as the staring dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle.
45769527|NCT04281420|Combination Product|ATG-019 + Niacin ER|ATG-019 60 mg is selected as starting dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle. And a starting dose of 500 mg niacin ER (may be titrated up to 1,000 mg of daily dose, per label) co-administered with each dose of ATG-019.
45769528|NCT03765502|Device|Nasal Glucagon Device (NG)|NG devices will be provided empty of drug product
45769529|NCT03765502|Device|GEK|Used to administer glucagon intramuscularly (IM)
45769530|NCT03765502|Drug|IM Glucagon|Administered IM via GEK
45769531|NCT04845230|Behavioral|FreshRx Nourishing Healthy Starts|This is a field experiment study that incorporates referrals to public programs, food supplementation and nutrition education, or integrative care services provided by a Licensed Masters Social Worker.
45769532|NCT04455828|Device|WHOOP strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks heart rate, respiratory rate, sleep, and heart rate variability.
46069920|NCT04254848|Other|oral stereognostic test|Six test pieces were selected from the 20 shapes of test pieces from National Institute of Dental Research. The test pieces comprises of 6 shaped forms which include circle, plus, square, rectangular, triangle and toroid shaped. A 2mm stainless steel wire was bent forming the test piece shape following the standard dimensions (13mm length and 2mm thickness)as described by National Institute of Dental Research to serve as the test pieces mould. Using the six test piece moulds, light cured acrylic resin test samples were fabricated. The test samples were trimmed and polished to meet the standardized measurements. A total of 240 test sample (6 samples for each patient) for 20 completely edentulous patients with maxillary tori and 20 completely edentulous patients without tori were made for the study. The test pieces were attached to dental floss to prevent any accidentally aspiration during the study.
46069921|NCT05253170|Radiation|Hypofractionation|Radiation regimen of 2.5-3.0Gy x 13-17 fractions +/- sequential boost 0-7 fractions
46069922|NCT05253170|Radiation|Conventional Fractionation|Radiation regimen of 1.8-2.0Gy x 23-28 fractions +/- sequential boost 0-5 fractions
45769533|NCT04846322|Diagnostic Test|PD4ED 3-step intervention (ED assessment, outpatient assessment, Brain health plan)|"ED assessment for suspected dementia.~positive ED patients referred for outpatient clinic cognitive impairment assessment.~positive clinic patients referred to primary care with brain health patient plan."
45769534|NCT04587492|Drug|Nusinersen|Treatment with nusinersen
46069923|NCT04809506|Biological|additional blood samples|2 additional blood samples (2 x 7ml) at every visit
46069924|NCT04719338|Diagnostic Test|presence of HCV RNA in peripheral blood mononuclear cells (PBMCs) .|samples of peripheral blood from each patient into EDTA tube will be collected and tested for HCV RNA in peripheral blood mononuclear cells (PBMCs) .
45629856|NCT05500521|Diagnostic Test|VEMP|Utricular and saccular function can be measured by VEMP. Sound is presented in one ear at a time and the evoked myogenic potential in the sternocleidomastoid and the superior oblique muscles can be measured respectively. This gives a measurement of the function of the sacculus (cVEMP) and utriculus (oVEMP).
45629857|NCT05500287|Other|Virtual Care|Children in the virtual care group had distance asthma education, case management and virtual care
45629858|NCT04603911|Drug|Liposomal bupivacaine|The liposomal bupivacaine used in the research study has been approved by the U.S. Food and Drug Administration (FDA) for use in humans for pain management. The specific approved uses are postsurgical single-dose wound infiltration analgesia and brachial plexus nerve block. In this study, we will be using liposomal bupivacaine in an additional way by infiltrating liposomal bupivacaine in a tissue plane to numb the nerves that provide sensation over the chest.
45769535|NCT03761368|Procedure|Remote Ischemic Preconditioning|four cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of left upper - arm cuff
45769536|NCT03761368|Procedure|Sham Remote Ischemic Preconditioning|deflated cuff placed on the left arm for 40 min
45629859|NCT04603911|Drug|Bupivacaine, epinephrine, dexamethasone, and clonidine|The medications that are typically administered as a solution in this block include bupivacaine, epinephrine, dexamethasone, and clonidine.
45629860|NCT05498025|Other|Deterra activated charcoal pouch|drug disposal pouch
45447539|NCT03745365|Procedure|loop bipartition|A loop gastro-ileostomy 250-300 cm from the ileocecal valve or 200-250 cm from duodeno-jejunal junction was created at the dependent part of the antrum with 2 layers of handsewn suture but without division of the 1st part of duodenum. The resultant stomach tube has two outlets, one to the first part of duodenum through the pylorus and one to the terminal ileum through the gastroileostomy.
45629861|NCT03972111|Drug|TPOXX 200Mg Capsule|TPOXX 600 mg (three 200 mg.) capsules twice daily for 14 days
45769537|NCT05503056|Other|art therapy|six sessions of art therapy with licensed therapists
45769538|NCT05503056|Other|nothing|no intervention to this group
45769539|NCT04841642|Other|MANUAL THERAPY|The investigators will apply manual therapy for ten minutes a week, for 8 weeks, based on cervical mobilizations and suboccipital inhibitions.
45629862|NCT05497791|Device|transcranial laser stimulation associated with NMES|"The cluster was applied on the skin covering the head. NMES of the paretic limbs was programmed to generate, alternately, ankle dorsiflexion and wrist extension.~The NMES was started, after 5 minutes the transcranial laser stimulation (active or placebo-treatment) was started. Then, the therapies were combined. After finishing the transcranial laser stimulation (active or placebo-treatment), the NMES was continued until completing 30 minutes."
45769540|NCT04841642|Other|THERAPEUTIC EXERCISE|"The exercises recommendations will be based on a simulation of the exercises in the same session of the manual therapy of each week, helped by the physiotherapist.~The access to telerehabilitation will be through a web page, through which patients could see explanatory videos of the exercises as many times as they need."
45769541|NCT04447716|Drug|Venetoclax|Given PO
45769542|NCT04447716|Drug|Lenalidomide|Given PO
45769543|NCT04447716|Biological|Rituximab|Given IV
45769544|NCT04447716|Biological|Rituximab and Hyaluronidase Human|Given SC
45769545|NCT03774134|Procedure|Complete mesocolic excision|Based on the principles of CME. The inferior mesenteric artery (IMA) was divided at its origin from the aorta to perform central lymph nodes dissection along the IMA between the aorta and the branching of the left colic artery. Sigmoid resection included the complete sigmoid colon and resection of the upper part of the rectum to ensure sufficient perfusion of the colo-rectal anastomosis. To achieve sufficient distance at the proximal bowel resection margin, parts of the descending colon or even left hemicolectomy were performed at the surgeon's discretion.
45769546|NCT03774134|Procedure|Conventional colon resection|The patients underwent what was considered standard colon cancer resections in Denmark during the study period.
45769547|NCT03758716|Drug|FB825, FB825-15D11, Anti-CemX|Pharmaceutical form: 20mg/ml solution Route of administration: IV
45769548|NCT03821402|Biological|DAXI for injection dose LOW DOSE|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline
45769549|NCT03821402|Biological|DAXI for injection dose MEDIUM DOSE|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
45447540|NCT03737409|Other|Ambulatory Oxygen Therapy|Supplemental oxygen delivered during exercise and activities of daily living via a portable oxygen concentrator
45629863|NCT05497791|Other|Placebo|The transcranial laser was applied identically for all groups, but the null dose was used in the placebo group. NMES of the paretic limbs was programmed to generate, alternately, ankle dorsiflexion and wrist extension.
45629864|NCT02699099|Dietary Supplement|Vitamin A|Oral administration of Vitamin A (1 dose)
45769550|NCT03821402|Biological|DAXI for injection Dose HIGH DOSE|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline
45769551|NCT03821402|Other|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
45769552|NCT05285124|Drug|Melatonin|Participants assigned to the melatonin group were given a 3-mg fast-release oral dose of melatonin administered at approximately 21:00
45769553|NCT05285124|Other|Placebo|Participants in this group were treated according to a protocol identical to those receiving active medication at approximately 21:00. For the sham tDCS groups, the same stimulation parameters were employed, except that the stimulator had a built-in placebo mode; when it was activated, two ramp fade-in/fade-out periods in the beginning and the end of sham stimulation mimicked the somatosensory artifact of real tDCS
45769554|NCT05285124|Other|HD-tDCS|Direct current was applied using a battery-driven constant-current stimulator through saline-soaked surface sponge electrodes (7cm×5cm) with the anode placed over the left DLPFC (F3 according to the 10-20 international EEG system) and the reference cathode placed over the right supraorbital region (Fp2). During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes
45913264|NCT02020330|Drug|Artemether-lumefantrine 3 days|One tablet contains 20mg artemether and 120mg lumefantrine. The standard regimen is twice daily for 3 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 3 days arm.
45447541|NCT03737409|Other|Sham Ambulatory Oxygen Therapy|Air delivered during exercise and activities of daily living via a portable oxygen concentrator that has been modified to deliver air
45447542|NCT04054011|Drug|Deoxycholic Acid|Deoxycholic acid (Kybella) 10 mg/ mL subcutaneous
45629865|NCT02699099|Biological|Candidate Plasmodium falciparum malaria vaccine|Intramuscular administration of SB257049 vaccine (4 doses)
45629866|NCT02699099|Biological|MR-Vac|Subcutaneous injection of a combined measles and rubella vaccine (1 dose)
45629867|NCT02699099|Biological|Stamaril|Intramuscular injection of a yellow fever (YF) vaccine (1 dose)
45769555|NCT01450046|Drug|Vitamin E δ-Tocotrienol|Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The first cohort will be dosed with δ-tocotrienol at 100 mg twice daily for 14 consecutive days. A minimum of 3 subjects is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety and available PK data from prior cohorts. At the MTD or MAD, 18 subjects will be enrolled.
45769556|NCT03757312|Diagnostic Test|Ultrasound|Ocular ultrasound to measure optic nerve sheath diameter (ONSD).
45769557|NCT05497596|Other|Vitamin D|Vitamin D (2000IU/day) for 6 months
45769558|NCT05497596|Other|Placebo|Placebo
45629868|NCT04284189|Other|Transition model|Transition of follow-up care of childhood cancer survivors to adult care
45769559|NCT01450124|Drug|Boswellic acids (BOSWELAN)|8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg Boswelan
45769560|NCT05587166|Other|ultrasound guided adductor canal block|ultrasound-guided adductor canal block using oblique short-axis for catheter insertion
45769561|NCT05587088|Drug|Petiveria Alliacea Preparation|Petiveria Alliacea Preparation in pill
45769562|NCT05587088|Drug|Placebo|Placebo in pill
45629869|NCT04399551|Drug|CAB OLI|CAB will be available as 30 milligrams (mg) tablet. It will be administered as one tablet once daily with food from Day 1 to Month 1.
45769563|NCT05243862|Drug|PolyPEPI1018|PolyPEPI1018 vaccine contains 6 synthetic peptides emulsified with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 tumor-specific antigens, which are the most frequently expressed antigens in colorectal cancer.
45769564|NCT05243862|Drug|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.
45769565|NCT01450202|Other|bowel insufflation gas|air insufflation, during colonoscopy and esophagogastroduodenoscopy
45769566|NCT01450202|Other|bowel insufflation gas|CO2 insufflation, during colonoscopy and esophagogastroduodenoscopy
45769567|NCT03748264|Other|Standard of Care|In the standard of care or the control condition, participants will receive the sites therapy initiation standard of care for setting up and educating the participants on their Obstructive Sleep Apnea, mask, and device information. This group will use a wireless modem that is attached to the PAP device and uploads adherence and other therapy information daily to a secured database (Encore Anywhere). With this method, therapy information is not directly available to the participant but will continuously be available to site staff personnel.
45769568|NCT03748264|Device|DreamMapper Application|The DreamMapper application condition will receive the site's therapy initiation standard of care and will also download the DreamMapper application on their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper through the application. Study personnel will have access to adherence and therapy information continuously.
45769569|NCT03748264|Device|DreamMapper Application with Therapist Assist|The DreamMapper with Therapist Assist will review the Therapist Assist automated educational material on Obstructive Sleep Apnea, their Philips Respironics mask and DreamMapper. These participants will download the DreamMapper application onto their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper. Study personnel will have access to adherence and therapy information continuously.
45769570|NCT03751124|Drug|Relugolix|Relugolix 40 mg tablet administered orally once daily
45769571|NCT03751124|Drug|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of estradiol 1.0 mg and norethindrone acetate 0.5 mg administered orally once daily
45769572|NCT03751124|Drug|Placebo for relugolix|Placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor
45769573|NCT03751124|Drug|Placebo for E2/NETA|Placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor
45769574|NCT01456442|Device|anorectal manometry|High-resolution anorectal manometry is done under standard clinical conditions with a 10 cm catheter inserted into the rectum loaded with pressure transducers at a distance of 6 mm in the sphincter area and an attached latex balloon at the catheter tip. It will measure the length of the anal sphincter, the static pressure and the clamping pressure during at least 3 over 40 seconds sustained maneuvers according to a standardized protocol. Mean and maximum pressure increase over the resting pressure during the first 30 seconds of the squeeze and the maximum possible squeeze time will be documented. Moreover, the initial anorectal perception threshold, the perception of urge to defecate and maximum tolerable volume balloon will be documented.
45913265|NCT02020330|Drug|Artemether-lumefantrine 5 days|One tablet contains 20mg artemether and 120mg lumefantrine. The experiment regimen is twice daily for 5 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 5 days arm.
45913266|NCT02020343|Behavioral|taste tests|"Subjects undergo sham feeding in which they take a bit of food, chew it and spit it out. This test should engage sensory mechanisms which may affect intestinal signaling."
45629870|NCT04399551|Drug|CAB LA|CAB LA 600 mg will be administered as intramuscular (IM) injection.
45629871|NCT04399551|Drug|RPV OLI|RPV will be available as 25 mg tablet. It will be administered as one tablet once daily with food from Day 1 to Month 1.
45629872|NCT04399551|Drug|RPV LA|RPV LA 900 mg will be administered as IM injection.
45629873|NCT04399551|Other|Continuous Quality Improvement (CQI) calls|CQI will be attended by the enhanced arm (Arm-E). The CQI calls will be conducted to identify problems/challenges, generate plans to address the challenges, and identify how to measure the change that results from the plan.
45769575|NCT01456442|Device|barostat|For the barostat study a balloon will be attached to the catheter. Instead of a barostat machine a 60ml syringe and a sphygmomanometer will be connected to the catheter and the catheter will be positioned in the rectum. The balloon is then dilated gradually to assess perception, urge and discomfort threshold in relation to rectal volume.
45769576|NCT01450280|Biological|ChAd63 CS|ChAd63 CS 5x10^9 vp intra-muscularly Day 0
45629874|NCT03928587|Dietary Supplement|2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine.|One lozenge once daily for 12 months
45629875|NCT03928587|Dietary Supplement|Placebo|Placebo once daily for 12 months
45769577|NCT01450280|Biological|ChAd63 CS, MVA CS|ChAd63 CS 5x10^9 vp intra-muscularly Day 0; MVA CS 2x10^8 pfu intra-muscularly Day 56
45769578|NCT01450280|Biological|ChAd63 CS|ChAd63 CS 5x10^10 vp intra-muscularly Day 0
45629876|NCT02399969|Other|Battlefield Acupuncture|Patients with low back pain will be randomized to receive Battlefield Acupuncture, ASP indwelling needles in 5 auricular (ear) points plus standard of care, or patients will be randomized to receive standard of care alone.
45769579|NCT01450280|Biological|ChAd63, MVA CS|ChAd63 CS 5x10^10 vp intra-muscularly Day 0; MVA CS 2x10^8 pfu intra-muscularly Day 56
45769580|NCT01456598|Procedure|Laparoscopic gastrectomy|"After laparoscopic observation, the possibility of surgery can be considered by examining inside of abdomen.~The surgeon undergoes laparoscopic subtotal gastrectomy and D2 lymph node dissection~After lymph node dissection, it is possible to undergo gastrectomy on appropriate part and reconstruction under small incision or laparoscopic view.~As the reconstruction, one of the techniques like Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance."
45769581|NCT01456598|Procedure|Open gastrectomy|"After laparotomy, the possibility of surgery can be considered by examining inside of abdomen.~The surgeon undergoes open subtotal gastrectomy and D2 lymph node dissection~After lymph node dissection, one of the techniques likes Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance."
45769582|NCT02859116|Procedure|Collection of digestive tissues|The surgeon will resect a sample (approximately 1-5 cm x 1-5 cm) of healthy tissue from the distal margins of the segment and at least 4 cm from the diseased area. The specimen for research will be obtained from the tissue that would ordinarily be removed during surgery.The tissue collected for our research purposes will be only remnant tissue which is discarded by the surgeon during the surgical intervention and has no diagnostic clinical value.
45769583|NCT02563548|Drug|PEGPH20|PEGPH20 will be administered as an intravenous (IV) infusion as per the dose schedule specified in the arm description.
45769584|NCT02563548|Drug|Pembrolizumab|Pembrolizumab will be administered as an IV infusion as per the dose schedule specified in the arm description.
45769585|NCT01450358|Other|Antibiotic regimen|The medical researcher will change the antibiotic regimen (De-escalation) immediately as a result of Multiplex PCR (6-12 h).
45769586|NCT04081324|Drug|Lasmiditan|Administered orally
45913267|NCT02020356|Behavioral|Music therapy|"U sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase."
46069925|NCT04760522|Genetic|WGS Diagnostic: Blood take for genetic diagnostic|Blood sampling, short clinical characterization, WGS based sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics).
46069926|NCT04254380|Biological|Gan & Lee Insulin Lispro Injection|Route of administration: subcutaneous injection
45447543|NCT04053465|Other|Heat acclimation|14 days of aerobic exercise in a hot environment
45447544|NCT04053465|Other|Exercise in a cool environment|14 days of aerobic exercise in a cool environment
45447545|NCT03743961|Other|geriatric intervention|Geriatric intervention
45629877|NCT05500131|Behavioral|Observation|"Ankle joint dorsiflexion was evaluated with the Weight-bearing lunge test through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain). Subjects were instructed to try to bring the knee to touch the metal rod (initially placed at a distance of 10 cm) without lifting the heel off the ground. The distance achieved was recorded in centimeters.~Single-leg squat test was analyzed through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain). It consists of performing a monopodial squat to test dynamic knee valgus. They were to perform a single-leg squat to 30° knee flexion. The knee was considered to be aligned if the patella was over the second toe."
45629878|NCT02399891|Other|Quality Assurance Implementation|
45629879|NCT02399891|Other|Standard of Care|
45629880|NCT02417597|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would intramuscularly receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) at 0, 1, 6 month.
45629881|NCT05497479|Drug|0.003% AR-15512 to be administered in both eyes|Two rounds of Schirmer tests, performed without anesthetic (per randomization), before and after instillation of 0.003% AR-15512
45629882|NCT05497479|Drug|Vehicle to be administered in both eyes|Two rounds of Schirmer tests, performed without anesthetic, before and after instillation of Vehicle
45629883|NCT05497479|Drug|0.003% AR-15512 to be administered in both eyes|Two rounds of Schirmer tests, performed with anesthetic (per randomization), before and after instillation of 0.003% AR-15512
45629884|NCT05497479|Drug|Vehicle to be administered in both eyes|Two rounds of Schirmer tests, performed with anesthetic (per randomization), before and after instillation of Vehicle
45629885|NCT03177785|Behavioral|EverydayMatters|
45629886|NCT02400047|Drug|Dexamethasone 0.2 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.2 mg / kg after general anesthesia induction and before surgery incision.
45769587|NCT04081324|Drug|Placebo|Administered orally
45769588|NCT01456676|Drug|Nilotinib + LDE225|Nilotinib is an aminopyrimidine ATP-competitive inhibitor of the protein tyrosine kinaseactivity of BCR-ABL.
45769589|NCT05227326|Drug|PCNA Inhibitor AOH1996|Given PO
45769590|NCT01456754|Dietary Supplement|low feeding frequency (3x)|3 meals a day
45769591|NCT01456754|Dietary Supplement|High feeding frequency (14x)|14 meals a day
45769592|NCT04578444|Drug|Zanidatamab|Administered intravenously
45769593|NCT04424706|Diagnostic Test|diagnosed as type 2 diabetes without atherosclerosis|patients diagnosed as type 2 diabetes without atherosclerosis
45447546|NCT03743883|Drug|Acetylsalicylic Acid(BAYE4465, Aspirin )|Administration according to clinical practice
45447547|NCT03737331|Behavioral|Fractal visual cueing|Walking to an external visual fractal (i.e., pink noise) stimulus.
45447548|NCT03737331|Behavioral|Periodic visual cueing|Walking to an external visual periodic (i.e., invariant) stimulus.
45769594|NCT04424706|Diagnostic Test|diagnosed as type 2 diabetes with atherosclerosis|patients diagnosed as type 2 diabetes with atherosclerosis
45629887|NCT02400047|Drug|Dexamethasone 0.4 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.4 mg / kg after general anesthesia induction and before surgery incision.
45629888|NCT02400047|Drug|Ketoprofen 1 mg/kg|Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution) at 1 mg /kg after general anesthesia induction and before surgery incision.
45629889|NCT05497401|Biological|MesenCure|Enhanced mesenchymal cell-based product
45629890|NCT05497401|Other|Placebo|Saline
45629891|NCT02698865|Device|MONOVISC|Two (2) intra-articular injections of 4 ml MONOVISC, separated by 1 month, delivered under image guidance (ultrasound or fluoroscopy)
45629892|NCT02698865|Device|Saline|Two (2) intra-articular injections of 4 ml saline, separated by 1 month, delivered under image guidance (ultrasound or fluoroscopy)
45629893|NCT03842319|Other|Microbiota analysis|From the feces and oral cavity samples, the DNA of the microbiota will be extracted using specific extraction kits and the microbiome will be analyzed through the study of 16S ribosomal RNA amplicons.
45769595|NCT04424706|Diagnostic Test|people without type 2 diabetes or atherosclerosis|normal people without type 2 diabetes or atherosclerosis
45629894|NCT03842319|Other|Immunological analysis|A study of immunological cell populations, inmunogenetics and cytokines will be carried out from fresh blood samples using antibody panels and flow cytometry
45629895|NCT03842319|Other|Proteome analysis|A study of host and microbiota proteome will be carried out from samples using mass spectrometry
45769596|NCT04042324|Drug|Triferic|Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
45629896|NCT03842319|Other|Metabolome analysis|A study of host and microbiota metabolome will be carried out from samples using MS-based as well as NMR-based methods
45769597|NCT04042324|Drug|Heparin|Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.
45769598|NCT04391660|Drug|0.5% sodium hypochlorite solution|Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress. This same antiseptic will be used at each dressing change.
45769599|NCT04391660|Drug|0.5% sodium hypochlorite solution and 70% ethanol|Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress preceded by an application of 70% ethanol with a sterile compress, for its immediate bactericidal action. 0.5% sodium hypochlorite solution will be applied once the alcohol has evaporated and the skin is visually dried. These same antiseptics will be used at each dressing change.
45769600|NCT05497440|Device|All'InCath CBC 035M Balloon Dilatation Catheter|All participants will undergo the same intervention. Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography.
45769601|NCT04842422|Drug|Imiquimod 3.75% Cream|Imiquimod 3.75% Cream
45769602|NCT05497362|Device|Real tDCS|2mA of tDCS was delivered to the orofacial area of the primary motor cortex (SM1) for 15 minutes. Speech therapy was delivered simultaneously.
45769603|NCT05497362|Device|Sham tDCS|2mA of tDCS was delivered to the orofacial area of the primary motor cortex (SM1) for 30 sec. Speech therapy was delivered simultaneously.
45629897|NCT03842319|Other|Clinical evaluation|Clinical evaluation including hemostasis and biochemical studies
45629898|NCT03842319|Other|Diet evaluation|Biochemical analysis and questionaries for diet adherence and exercise registration
45629899|NCT03842319|Other|MedDiet|The high-intensity Mediterranean diet will include the promotion of the following: a) abundant use of olive oil (>40 g/d) for cooking and dressing dishes; b) consumption of >2 daily servings of vegetables; c) >2-3 daily serving of fresh fruits; d) >3 weekly servings of legumes; e) >3 weekly servings of fish or seafood; f) >1 weekly serving of nuts or seeds; g) select white meats instead of red meats or processed meats; and h) cook regularly with tomato, garlic and onion adding or no other aromatic herbs, and dress vegetables, pasta, rice and other dishes with tomato, garlic and onion adding or no other aromatic herbs. Two main meals per day should be eaten (seated at a table, lasting more than 20 minutes). A recommendation to drink a glass of wine per day during meals is given. Limited consumption is advised for cured ham, red meat, chocolate, cured or fatty cheeses
45769604|NCT04066426|Drug|naproxen sodium+codeine phosphate, naproxen sodium+dexamethasone, naproxen sodium, paracetamol|NSAID, steroid, opioid, paracetamol and combinations of this drugs can be used in temporomandibular disorders.
45769605|NCT04232982|Procedure|Transscleral cyclphophotocoagulation using the Micropulse system ( IRIDEX IQ810 Laser systems, Mountain View, CA).|Treatment will be applied over the limbal area to treat the ciliary body. The treatment will be delivered with an energy of 2000mW, a cycle of 31,33% and an on/off time of 0,5ms and 1,1ms. It will be delivered around a 360° surface with avoidance of the 3 and 9 o'clock areas. The treatment will be delivered during 80 secondes in each hemisphere and will be repeated twice, for a total of 320 secondes.
45769606|NCT04232982|Procedure|G-Probe transscleral cyclphophotocoagulation (Iris Medical Instruments, Montain View, CA)|"Treatment will be applied over the limbal area to treat the ciliary body. Sixteen (16) shots in total, which is four (4) shorts per quadrants, will be transmitted with a power from 1750 to 2000mV (titrating according to an audible pop) for a length of 2,0 secondes per shots. Treatment will be delivered around a 360° surface and avoiding the 3 and 9 o'clock areas."
45769607|NCT01450514|Drug|Pipamperone|15 mg PIP once daily per os on top of continued stable treatment with RIS or PAL
45769608|NCT01450514|Drug|Placebo|matching placebo sugar pill once daily per os on top of continued stable treatment with RIS or PAL
45769609|NCT04279314|Drug|Trofinetide|Trofinetide solution of 30-60 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
46069927|NCT04254380|Biological|Humalog|Route of administration: subcutaneous injection
45769610|NCT04059250|Device|Nobio composite|Nobio has developed a bactericidal composite, which does not leak out the bactericidal nano fillers
45769611|NCT04059250|Device|traditional composite|traditional composite which has no bactericidal activities
45629900|NCT02698787|Device|Experimental sound coding strategy (FAST)|Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy
45629901|NCT02698787|Device|Commercially available ACE sound coding strategy|Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy
45769612|NCT01456910|Behavioral|Resistance Training Program|Frequency, volume, repetitions, load, interval
45769613|NCT01450592|Other|No drug|Diabetic Population
45629902|NCT03755349|Device|Placement of burr-hole covers|Placement of a burr-hole cover (Stryker® UN3 BURR HOLE COVER, 20mm, W/TAB, Item code 53-34520) fixed with 2 screws (Stryker® UNIII AXS SCREWS, SELF-DRILLING, 1.5 x 4MM, Item code 56-15934) on each of two burr-holes
45629903|NCT03755349|Other|No placement of burr-hole covers|In the control group, none of the burr-holes is covered, representing our current standard of care. In patients with bilateral cSDH, none of the burr-holes on the control side are covered with burr-hole covers.
45629904|NCT02417051|Behavioral|Disaster Worker Resiliency Training|The Disaster Worker Resilience Training (DWRT) Program is a 4 hour program which consists of a participant training manual, an instructor-training manual, and a digital presentation. It uses adult training techniques that emphasize active participation in individual and group experiential learning activities. The curriculum is organized into a preface and four chapters, each with action oriented learning objectives. Overall program objectives include a demonstrate an ability to: 1) Recognize signs and symptoms of disaster work-related stress, 2) Obtain support through employer and community resources, and 3) Build resilience by using stress reduction and coping strategies.
45629905|NCT05499897|Procedure|ultrasoud guided interscalene block|Open shoulder surgery by ultrasound guided peripherel block. Observation effect of this peripheral block on immunity and wound healing
45629906|NCT05499897|Procedure|general anesthesia|Open shoulder surgery by general anesthesia. Observation effect of this peripheral block on immunity and wound healing
45629907|NCT02417675|Other|Community-based Adherence Clubs|"Women in the AC arm are prescribed 2 months of their current ART medication (compared to 1 month in the SOC) and will be advised to go to the AC office immediately, where they will be scheduled for their first session. Women will attend AC meetings every two months. At these meetings, women will receive a 2 month supply of medication, health education and peer-support. A trained Community Health Worker (CHW) will also collect blood samples, weight, and current signs/symptoms from women.~Each participant has 5 working days after their AC session to come and collect her medication. Those who have defaulted will be followed up by the CHW via phone calls and, possibly, home visits. If reached, women will be told to return immediately to the main ART facility for receipt of ART care."
45629908|NCT02417675|Other|Standard of Care for Mothers|Women will be referred immediately from the maternity ART clinic to their nearest adult ART clinic at their first postpartum clinic visit. At referral, they receive an initial 1-month supply of their current ART medication. At the first appointment after transfer into the general ART service, patients undergo clinical history and examination by a doctor or clinical nurse practitioner. Laboratory investigations are ordered according to standard protocols or based on clinician discretion. For the 1st 4 months in the new service, stable patients are dispensed 1 month of ART; subsequent visits are 2-monthly for medication refill, with clinician review 6-monthly; patients with particular clinical or psychosocial concerns may be reviewed more regularly, or referred to higher levels of care.
45769614|NCT01450592|Other|No drug|Non-Diabetic Population
45769615|NCT04840706|Device|HFNC Airvo|HFNC device (Airvo) long-term use in in stabile hypercapnic COPD patients, who are non-compliant to NIV after an acute exacerbation of COPD
45769616|NCT04840706|Other|Standard care|No HFNC treatment
45769617|NCT04424472|Diagnostic Test|Ultrasonography|Abdominal Ultrasonography
45769618|NCT02899052|Drug|Carfilzomib|"Carfilzomib lyophilized administered intravenously as a 10 to 30 minute infusion in Cycles 1 and beyond within 30 minutes to 4 hours after dexamethasone dosing.~Dose level 1 (K1) Cycle 1: 20 mg/m2 on Days 1 and 2, 27 mg/m2 on Days 8, 9, 15, and 16; Cycles 2 - 12: 27 mg/m2 on Days 1, 2, 8, 9, 15, and 16; Cycles 13 - 18: 27 mg/m2 on Days 1, 2, 15, and 16; Cycles 19 and beyond, for participants that have not previously transitioned to monotherapy: 27 mg/m2 on Days 1, 2, 15, and 16.~Dose Level K2: Cycle 1: 20 mg/m2 on Day 1; 70 mg/m2 on Days 8 and 15 Cycles 2 - onward: 70 mg/m2 on Days 1, 8, and 15. Dose Level K3: Cycle 1: 20 mg/m2 on Days 1 and 2; 56 mg/m2 on Days 8, 9, 15, and 16.~Cycles 2 - onward: 56 mg/m2 on Days 1, 2, 8, 9, 15, and 16."
45769619|NCT02899052|Drug|Venetoclax|Venetoclax tablet administered orally once daily during Cycles 1 - onward. Venetoclax dose level 1 (Ven1) 400 mg once daily, Ven2 800 mg once daily.
45769620|NCT02899052|Drug|Dexamethasone|Dexamethasone tablet administered orally during Cycles 1 - onward. Dexamethasone dose level 1 (Dex1) 40 mg once weekly, Dex2 40 mg once weekly, Dex3 20 mg twice weekly.
45769621|NCT05082870|Behavioral|Supportive-expressive group therapy (SEGT)|The SEGT approach fosters mutual support, promotes openness and emotional expression. SEGT will be delivered and co-facilitated by a psychiatrist and an allied healthcare professional. It is a 6-module program held over a 3-week period (approximately 2 hour sessions X 2 week) that is framed within social cognitive theory, whereby resilience to adversity (limb loss in this instance) relies on personal enablement.
45769622|NCT04065048|Other|Soy based diet|The diet will be based on the detailed descriptions according to the American Heart Association, US Food and Drug Administration (FDA), and the Soyfoods Association of North America Website, which all promote soy products as having beneficial nutrient profiles with a daily consumption of 25 grams or more of soy protein (average serving = 6.25 grams), upper limit of 50g.
45769623|NCT04065048|Other|Non-soy based diet|Diet of identical composition to the soy diet with the exception of soy.
45913268|NCT02020356|Behavioral|Placebo|Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
45913269|NCT02020382|Device|qPCR diagnostic KIT of microRNAS|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
45629909|NCT02417675|Other|Standard of Care for Infants|All infants will receive care at their nearest primary care clinic. Following national protocols, all HIV-infected mothers are issued a 6-week supply of nevirapine syrup after delivery and counselled on daily nevirapine prophylaxis. Infant follow-up takes place within 1 week postpartum with the mother (at the MOU) and then at 6 weeks postpartum (at the nearest primary care clinic) when HIV PCR testing of the infant is carried out. Following national protocols, infants who are breastfed beyond 6 weeks receive HIV PCR testing 2-4 weeks after the cessation of breastfeeding, again conducted at the nearest City of Cape Town primary care clinic.
45629910|NCT02417207|Drug|Entecavir combined long-term low-dose HBIG group intramuscular|HBIG scheme is: the use of intraoperative muscle injection of 800 IU HBIG, postoperative week 1 intramuscular injection HBIG 400 IU 1 times a day, 1 week after intramuscular injection HBIG 400 IU 2 times per week, dosage and time interval according to the HBsAb drops in patients with degree of level adjustment, target drops for 3 months or more after 500 IU/mL, 3 ~ 6 months or 300 IU/mL, after six months of 100 IU/mL or more.
45629911|NCT02417207|Drug|Entecavir combined HBIG group short-term high-dose intravenous|Preoperative HBV DNA level is less than 1000 IU/ml, intraoperative intravenous drip of 2500 IU HBIG static note type, postoperative 1 and 15 days respectively to give 2500 IU HBIG static note type, a total of three times, then no longer apply. Preoperative HBV DNA level greater than 1000 IU/ml, the use of HBIG solution for: intraoperative intravenous drip of 5000 IU HBIG static note type, postoperative day 1, 15 days and 30 days respectively to give 2000-2500 IU HBIG static note type, a total of four times, since then no longer apply. Preoperative HBV DNA level of the unknown, preoperative immediate detection of DNA, intraoperative intravenous drip of 5000 iu HBIG static note type, choose according to test results after dosing frequency.
45629912|NCT02399501|Procedure|hysteroscopy|Hysteroscopy is done under general anesthesia. The hysteroscopy used is rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30º panoramic optic which is 4 mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
45629913|NCT02399501|Device|two dimensional ultrasound|Examination is performed after emptying of the bladder in dorsal lithotomy position .The probe is introduced into the posterior fornix of the vagina, then the following structures are examined, the uterus for site, size and mobility, the myometrium for fibroids and adenomyosis, the endometrium for uniformity, polyps, submucous fibroids and intrauterine adhesions, the cervix for nabothian follicles and polyps, the adenexa and ovaries for site, size, mobility, follicles, cysts and corpus luteum
45629914|NCT02399501|Device|saline sonohysterography|sterile speculum is introduced and the vagina and cervix is cleaned with povidone iodine 10%. Cook ET (embryo transfer) catheter is used. . After introduction of the catheter into the cervix, a twenty milliliter syringe which will be prefilled with the distending media (saline) then fitted to the catheter. The speculum is removed and endovaginal probe is introduced in the posterior vaginal fornix
45629915|NCT02399501|Device|three dimensional ultrasound|The uterus is visualized in the longitudinal plane, the ultrasound probe is kept steady and the patient is asked to lie still on the examination bed. The volume mode is switched on. Three D volume is generated by the automatic rotation of the mechanical transducer through 360º. The acquired volume is in the shape of a transacted cone with a depth of 4.3 - 8.6 cm and a vertical angle α = 90º. Using the medium line density, the typical acquisition time is a round 10 seconds
45629916|NCT02698475|Drug|Ustekinumab 0.75 mg/kg|Participants weighing less than (<) 60 kilograms will receive ustekinumab 0.75 milligram per kilogram (mg/kg) at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 0.75 mg/kg up to Week 248.
45629917|NCT02698475|Drug|Ustekinumab 45 mg|Participants weighing greater than or equal to (>=) 60 kg to less than or equal to (<=) 100 kg will receive ustekinumab 45 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 45 mg up to Week 248.
45629918|NCT02698475|Drug|Ustekinumab 90 mg|Participants weighing >100 kg will receive ustekinumab 90 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 90 mg up to Week 248.
45629919|NCT02399657|Drug|Intravitreal dexamethasone 0.7mg implant|Ozurdex at day 0 (fixed), 5 months (fixed), 10 months pro re nata or 11 months pro re nata
45769624|NCT04758728|Procedure|Great saphenous vein stripping and varicectomies|Removal of the great saphenous vein (partially - from just below the knee up to the saphenofemoral junction) by two 3cm skin and subcutaneous fat incisions and the introduction of a conventional vein stripper device, under general or epidural/regional anesthesia. Removal of varicose veins of the lower limb by 0,5cm skin incisions and the use of a conventional phlebectomy stainless steel hook. Mechanical hemostasis by direct compression of the thigh for 10 minutes.
45769625|NCT04758728|Drug|Epinephrine Topical|Use of epinephrine/adrenaline solution 1:1000 topically
45769626|NCT04758728|Drug|normal saline|Use of normal saline solution NaCl 0,9% topically
45769627|NCT01450670|Dietary Supplement|Kibow Biotics|Month 1, one capsule three times daily (90 Colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3, three capsules three times daily (270 CFU's). Continued on tolerated maintenance dosage for an additional 6 months. Once tolerated dosage is identified the patient will be continued on that maintenance dosage for an additional 6 months. All medical, physical, clinical, QOL and other parameters will be monitored as well.
45769628|NCT01450748|Drug|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
45769629|NCT01450748|Drug|Placebo|matching placebo oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
45447549|NCT03737331|Behavioral|Random visual cueing|Walking to an external visual random (i.e., white noise) stimulus.
45447550|NCT01562925|Dietary Supplement|Red wine|Red wine First dosage: 3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.5 ml per kg bodyweight (60-120 minutes before contrast medium exposure
45629920|NCT03177707|Other|Mindfulness-based Therapy Group for Couples|"Eligible couples will take part in a 4-session mindfulness-based therapy group for couples. The groups will last 2 hours in length, for a total of 8 hours of treatment time, and sessions will be scheduled once per week in successive weeks.~The groups will have one highly experienced female facilitator, who is the Study Coordinator. The facilitator led the design of the treatment manual, and has experience in facilitating similar groups. The facilitator will follow a detailed, empirically-informed mindfulness-based treatment manual that was designed for the purpose of this study. All groups will take place in a private group treatment room at Vancouver General Hospital."
45629921|NCT02399579|Other|Provocation test|The participants will perform 8 provocation tests. Every provocation test consists of petting the cat until the participants become symptomatic. The symptoms of cat allergic participants with the cat owner's cat will be recorded before and after petting the cat.
45629922|NCT03177629|Drug|treatment : H. pylori eradication|"treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole) to treatment group at visit 1 and to control group 2nd stage at visit 4.~Day 1-5: pantoprazole 40mg bid, amoxicillin 1000mg bid, PO Day 6 - 10: pantoprazole 40mg bid, clarithromycin 500mg bid, metronidazole 500mg tid, PO"
45629923|NCT02559687|Biological|pembrolizumab|IV Q3W
45629924|NCT04279119|Drug|ARQ-151- cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 2 weeks
45629925|NCT02399735|Biological|Low Dose NK cells ×4 times|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.
45769630|NCT01457066|Behavioral|Peer Navigator Intervention|Peer navigators will teach HIV retention and linkage skills and knowledge using group-based as well as one-on-one, peer-based learning approaches.
45769631|NCT03808948|Device|VFI|The IV-administered visible fluorescent injectate (VFI)™ agent comprises a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
45769632|NCT02559570|Drug|Placebo|Participants received matching placebo LIN liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
45769633|NCT02559570|Drug|LIN Dose A|Participants received LIN 9 or 18 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
45769634|NCT02559570|Drug|LIN Dose B|Participants received LIN 18 or 36 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
45769635|NCT02559570|Drug|LIN Dose C|Participants received LIN 36 or 72 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
45769636|NCT02559570|Drug|LIN 145 µg|Participants received LIN 145 µg, liquid solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
45769637|NCT01457144|Drug|RiBVD|"Every cycle:~Rituximab intravenous infusion dosage 375 mg/m² day 1 Bendamustine direct intervenous 90 mg/m² day 1 and day 2 Velcade®subcutaneous 1,3 mg/m² day 1,4, 8 and 11 dexamethasone 40 mg IVD on day 2"
45769638|NCT01450904|Procedure|Quadriceps incision < 2 cm|MIS-TKA was performed with less than 2 cm Quadriceps incision length
45769639|NCT01450904|Procedure|Quadriceps incision 2-4 cm|MIS-TKA was performed with 2 to 4 cm Quadriceps incision length
45769640|NCT01450904|Procedure|Quadriceps incision > 4 cm|MIS-TKA was performed with more than 4 cm Quadriceps incision length
45769641|NCT04051684|Procedure|Transverse abdominal plane block|Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
45769642|NCT04051684|Drug|Ropivacaine|Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
45769643|NCT02854124|Procedure|Melanoma and peritumoral skin excision|Surgical retrieval of the primary tumor and safety retrieval of the surrounding normal peritumoral skin and sentinel lymph node
45769644|NCT04057768|Device|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.
45769645|NCT01457300|Other|Rehabilitation|Model 1: Regular Assessment of Rehabilitation Goal, Rehabilitation Plan, Weekly Multi-Disciplinary Evaluation and Adjustment of Plan, Regular use of Measurement Scales, Regular Dialog between Personnel, Patient and Relatives. Model 2: More Occasional use of the Listed Activities. Model 1 and Model 2: Physical Training and Functional ADL Training, in Groups, One by One or Self-Training.
45769646|NCT04846400|Device|ssNPA|The ssNPA is a self-supporting nasopharyngeal airway, a stent that is a non-surgical alternative to treat severe OSA
45769647|NCT04063410|Procedure|Angiography|Undergo standard of care CTA
45769648|NCT04063410|Procedure|MRI-Based Angiogram|Undergo pPCA
45769649|NCT04063410|Other|Quality-of-Life Assessment|Ancillary studies
45769650|NCT04840862|Drug|Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]|Subjects will receive a single dose of trikafta (orange tablet) on day 1 of period 1 and on day 15 of period 2.
45769651|NCT04840862|Drug|Rifabutin 300mg|After washout period greater or equal to 2 days, subjects will receive 300 mg/d of rifabutin on days 1 through 17 of period 2.
45769652|NCT04052542|Behavioral|Traditional online continuing education|30-minute, online, interactive, educational video describing the benefits of preventive post-extubation NIV, the indications and contraindications for preventive post-extubation NIV, and the value of working together as an interprofessional ICU team when implementing preventive post-extubation NIV
45769653|NCT04052542|Behavioral|Interprofessional education|One-time, 90-120-minute, in-person, interprofessional educational workshop consisting of a 30-minute didactic session and a 60-90-minute small group session
45769654|NCT04052542|Behavioral|Just-in-time education|"Just-in-time, point-of-care education provided by trained advanced practice providers who will be on-hand in the study ICU, where they will deliver the education at the bedside during rounds when a patient meets criteria for preventive post-extubation NIV"
45769655|NCT04840238|Drug|Cholecalciferol|30,000IU cholecalciferol
45769656|NCT04840238|Drug|Placebo|Placebo tablets
45769657|NCT01450982|Drug|JNJ-38518168 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose
45629926|NCT02399735|Biological|Normal Dose NK cells ×4 times|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.
45769658|NCT05015010|Drug|Alectinib|600 mg p.o. (four 150 mg capsules) twice daily with food (within 30 minutes after a meal, in the morning and evening).
46069928|NCT00631514|Drug|acetaminophen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
45769659|NCT03829618|Drug|Topical lidocaine|1% lidocaine topically applied in 4 mL aliquots
45629927|NCT02399735|Biological|Normal Dose NK cells ×8 times|Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.
45769660|NCT03829618|Drug|Nebuliser solution|2% lidocaine dose at 2 mg/kg (max 160 mg) applied via jet nebulizer
46069929|NCT00631514|Drug|ibuprofen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
45629928|NCT04278729|Drug|Apixaban 5 MG|1 - 5 mg tablet taken orally twice a day
45629929|NCT02399423|Behavioral|Weight gain|Weight gain of 7% body weight over 4-6 weeks by ingesting an extra 1500-2000 kcal/day
45629930|NCT02399423|Behavioral|Weight loss|Weight loss of 7-15% body weight over 12 weeks by increased exercise and either an alternate day fasting dietary regime or a weight watchers dietary regime
45629931|NCT03177317|Drug|Dexamethasone|"Dexamethasone 8mg IV before chemotherapy on cycle 1 day 1~Once the complete response is achieved, the dose of dexamethasone will be reduced by 2 mg in the next cycle."
45629932|NCT03177239|Drug|Nivolumab|"Dosage Form: Nivolumab BMS-936558-01 Solution for Injection Potency: 100 mg (10 mg/mL) Primary Packaging: 10 mL vial Appearance: Clear to opalescent colourless to pale yellow liquid. May contain particles.~Storage Condition: 2 to 8°C. Protect from light and freezing."
45629933|NCT03177239|Drug|Ipilimumab|Dosage Form: Ipilimumab Solution for Injection Potency: 200 mg (5 mg/mL) Primary Packaging: 40 mL vial Appearance: Clear, colourless to pale yellow liquid. May contain particles. Storage Condition: 2 to 8°C. Protect from light and freezing.
45629934|NCT02399267|Procedure|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
45629935|NCT02399267|Procedure|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
45629936|NCT02399267|Procedure|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS =< 8 cm H2O with PEEP =< 5 cm H2O.
45629937|NCT02399267|Procedure|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece.
45629938|NCT04480775|Drug|Triamcinolone|transversus abdominis plane block with bupivacain and triamicinolone
45629939|NCT04480775|Drug|Methylprednisolone|transversus abdominis plane block with bupivacaine and methylprednisolone
45629940|NCT04480775|Drug|bupivacaine|transversus abdominis plane block with bupivacaine alone
45629941|NCT02399033|Drug|Xihuang Capsules|In two weeks after hepatectomy, Xihuang Capsules group received Xihuang Capsules (2 g, bid), Continuously taking to cancer recurrence or death.
45629942|NCT02416817|Other|Blood Products only|Based solely on massive transfusion triggers Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive blood products by prescription of the patient's anesthesiologist. The patient will be constantly observed and bleeding triggers will be reassessed hourly.
45629943|NCT02416817|Other|Point of Care guided|Based on massive transfusion triggers and thromboelastometry Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive the drugs guided by the results of the thromboelastometry. The dosis of each drug will be based on the analysis of the thromboelastometry curves (established algorithm).
45629944|NCT02399189|Drug|R-MT followed by auto-HSCT|Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous stem cell transplantation: Carmustine 400mg/m2 d1; Thiotepa 5mg/kg q12h, d2-3.
45629945|NCT03106493|Other|None (observational)|None (observational)
45629946|NCT03177161|Other|15 Patient Reported Health Status Questions|The PROMIS-10 Global Health, three single item questions (ambulation, toileting, and dressing) that have been borrowed from the RiksStroke (The National Quality Register for Stroke - Sweden) and two further questions on feeding and communication have been included from the ICHOM Standard Set for Stroke.
45769661|NCT03829618|Drug|Nebuliser Suspension|2% lidocaine dosed at 2 mg/kg (max 160 mg) applied via vibrating mesh nebulizer
45769662|NCT04272788|Drug|Infliximab|The CD patients at initial active stage without treatment of glucocorticoids, immunosuppressants and biological agents are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
45769663|NCT01457690|Drug|Tocofersolan|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
45769664|NCT01457690|Drug|tocopherol alpha|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
45769665|NCT01457690|Drug|Tocofersolan and tocopherol alpha|Administration of a single dose of vitamin E (Vitamin E water-soluble then Vitamin E conventional fat-soluble form)
45629947|NCT03176849|Dietary Supplement|Vitamin D3|The single, oral dose of vitamin D3 is based on patient's age and baseline 25-hydroxy-vitamin D level. Dosing is as follows: (1) For children under 3 years of age. 200000IU for those deficient, 150000IU for those insufficient, and 100000IU for those sufficient; (2) For children 3-12 years of age, 400000IU for those deficient, 350000IU for those insufficient, and 200000IU for those sufficient; (3) For children greater than 12 years of age, 600000IU for those deficient, 500000IU for those insufficient, and 300000IU for those sufficient. This is a single, one time oral dose given prior to the start of transplant.
45629948|NCT03176849|Dietary Supplement|Standard Vitamin D3 Supplementation|"Those who have sufficient vitamin D will be supplemented with 400-600IU/day of Vitamin D3 orally.~Those who have insufficient or are deficient in vitamin D will be supplemented with 50,000IU/week of Vitamin D3 orally."
45629949|NCT03106571|Drug|Pomaglumetad methionil|Tablets twice daily
45769666|NCT05497206|Device|One of the following hip implants may be used within this arm of the study: G7 Acetabular System, Taperloc Complete System, Avenir and Avenir Complete Systems, and Echo Bi-Metric System|Total Hip Arthroplasty
45629950|NCT03106571|Drug|Placebo|1-4 tablets twice daily
45629951|NCT03106571|Drug|Methamphetamine|intravenous methamphetamine
45769667|NCT04390880|Drug|18F-DCFPyL|Study participants will receive intravenous administration of 18F-DCFPyL and undergo a PET/CT imaging study. Patients may be reenrolled in the study, if 18F-DCFPyL PET/CT is performed for subsequent management decision.
45769668|NCT02913092|Behavioral|Electronic sensor and OW education|MDI sensor-generated alerts will be relayed via app platform on participant's phone and responded to (e.g. outreach worker contacts the patient for a missed dose) in real-time to the intervention group. Outreach worker will also assess intervention group participants' need for further asthma education and provide education over the phone
45769669|NCT03741088|Device|VORTX Rx treatment|Cavitation-based cellular destruction using focused ultrasound
45769670|NCT01451060|Drug|Metaraminol|It will be used a dose of 0.5 mg to any fall in blood pressure of the fetus until birth
45769671|NCT01451060|Drug|Ephedrine|It will be used at any one dose de1mg fall in blood pressure of the fetus until birth
45769672|NCT05497128|Device|Ultrahigh-speed cut rate 27-gauge system|The ultrahigh-speed cut rate 27-gauge system (27+®GA HYPERVIT® Vitrectomy Probe (Alcon Laboratories, Fort Worth, TX, USA))
45769673|NCT05497128|Device|Standard cut rate 27-gauge system|The current standard cut rate 27-gauge vitrectomy system (27+®GA Advanced ULTRAVIT® Vitrectomy Probe (Alcon Laboratories, Fort Worth, TX, USA))
45769674|NCT01451138|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
45769675|NCT04904562|Drug|Angiotensin II|Angiotensin II started at 5 ng/kg/min and titrated in 5-10 ng/kg/min increments every 5 minutes up to 80ng/kg/min to achieve target arterial pressure (MAP)
45769676|NCT04904562|Drug|Placebo|Placebo
45769677|NCT01143181|Drug|Brincidofovir|Brincidofovir (BCV) was administered orally either once or twice weekly for up to 3 months. Treatment may have been extended for an additional 3 months depending a satisfactory review of safety parameters. Subjects could not receive more than a total of 6 months of treatment with BCV without prior approval.
45769678|NCT04199676|Diagnostic Test|Glucose tolerance test|Oral administration of a 75g glucose tolerance test during the postpartum hospitalization
45629952|NCT02398955|Device|percutaneous coronary intervention|percutaneous coronary angioplasty with implantation of at least one Biomime stent
45629953|NCT03177005|Biological|CSL830|
45769679|NCT03740152|Device|Transcranial Light Therapy|Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000)
45769680|NCT03739684|Drug|18F-DCFPyL|A single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL
45769681|NCT03739684|Diagnostic Test|PET/CT Imaging|PET/CT imaging will be acquired 1-2 hours post-PyL injection
45769682|NCT04819620|Drug|PN-232|Active Drug
45629954|NCT03177083|Drug|peginterferon beta-1a|SC every 2 weeks
45769683|NCT04819620|Drug|Placebo|Matching Placebo
45629955|NCT03177083|Drug|interferon beta-1a|Per Summary of Product Characteristics (SMPC)
45629956|NCT03177083|Drug|interferon beta-1b|Per SMPC
45769684|NCT01143649|Device|transcranial direct current stimulation (tDCS)|Subjects will be stimulated at 1 mA for 40 minutes.
45769685|NCT01143649|Procedure|constraint induced movement therapy (CIMT)|
45629957|NCT02398721|Other|Fine Needle Aspiration Cytology|
45629958|NCT02398643|Other|Pulmonary Education (PE)|Patients enrolled in PE will undergo focused education sessions following discharge from hospital.
45629959|NCT02398643|Other|Usual Care|Patients enrolled in usual care will receive general education sessions following discharge from hospital.
45769686|NCT01143649|Device|transcranial alternating current stimulation (tACS)|Subjects will be stimulated at 15Hz for 20 minutes.
45769687|NCT04437264|Dietary Supplement|Intermittent feed participant|Patients will be assigned to receive intermittent enteral feeding protocol. They will receive four equal volume feeds at 8:00, 12:00, 16:00, and 20:00 hours.
45769688|NCT04437264|Dietary Supplement|Continuous feeds participant|Patients will be assigned to receive continuous enteral feeding protocol. Typical goal rates are in the range of 60 to 80 mL per hour for 24 hours per day.
45913270|NCT02020395|Dietary Supplement|test meal (500 kcal)|whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
45913271|NCT02020395|Dietary Supplement|test meal (500 kcal)|whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
46069930|NCT00631514|Drug|piroxicam|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
45769689|NCT03937570|Device|echo-optimization|LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.
45629960|NCT02398799|Behavioral|Psychoeducational support|"The intervention was based on a conceptual model from Stuifbergen. The model has sprung from Pender's model of health promotion and Bandura's self-efficacy theory. Cognitive-behavioral strategies were chosen to assist dyads in recognizing and modifying factors that contribute to physical and emotional distress by changing thoughts and behaviors and assisting dyads in solving problems related to implementing strategies for self-care.~Shared care is a dyadic process based on the assumption that each participant affects and is affected by the other. Shared goals and a shared commitment provide the essential building blocks of the dyad relationship. The dyad structure presents an opportunity for healthcare professionals to integrate a collaborative patient-partner centered effort."
45629961|NCT03629925|Drug|Sintilimab|200mg, Q3W, day1, I.V.; consecutive cycles
45629962|NCT03629925|Drug|Gemcitabine|1000mg/m^2, Q3W, day 1and 8, I.V.; first 4 or 6 consecutive cycles.
45629963|NCT03629925|Drug|Cisplatin|75 mg/m^2, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
45629964|NCT03629925|Drug|Placebo|NA, Q3W, day1, I.V.; consecutive cycles
45629965|NCT03629925|Drug|Carboplatin|AUC 5mg/ml/min, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
45629966|NCT04295811|Device|EsoGuard (lab assay)|EsoGuard assay (LDT) will be used on cells collected using the EsoCheck (510K cleared esophageal cell collection device)
45629967|NCT04295811|Diagnostic Test|Esophagogastroduodenoscopy|Planned EGD to diagnose and/or treat disorders of esophagus, stomach, and small intestine. When abnormal tissues are noted, biopsies of the tissue are taken through the scope to diagnose tissue abnormalities.
45629968|NCT04294719|Other|Cognitive Adaptation Training (CAT)|Cognitive Adaptation Training (CAT) is a standardized implementation of environmental supports for improving adaptive functioning including medication adherence, grooming, and daily activities in patients with schizophrenia. Environmental supports (signs, checklists) are manual-driven and grounded upon an assessment of neurocognitive function and behaviour. Assessment results yield one of six CAT classifications (Apathy/Poor Executive Functioning, Disinhibited/Poor EF, Mixed/Poor EF, Apathy/Fair EF, Disinhibited/Fair EF, Mixed/Fair EF).The goal will be to improve organization and self-care, modifying the intervention to be more relevant for an inpatient setting. Once an individual's CAT classification has been determined, strategies for specific functional problems are chosen from a series of tables. CAT interventions are maintained in the client's living space during weekly visits. CAT clinicians will encourage team members to assist with the reinforcement of CAT tools and strategies.
45629969|NCT02703311|Device|Cardioband|Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
45629970|NCT02416895|Other|In vivo immunity model|A measure of in vivo immune function.
45629971|NCT04280133|Behavioral|Educational Video Tool|The video educational tool was written by the investigators in collaboration with a panel of experts on CAR T-cell therapy, medical ethicists, palliative care clinicians, and oncologists.
45629972|NCT02398565|Other|No intervention|
45629973|NCT05499819|Other|Canned black beans, drained and rinsed|Canned black beans, drained and rinsed and consumed in a tortilla wrap
45769690|NCT05496972|Behavioral|Survey Administration|Patients and providers complete survey over 10 minutes about their perspectives on the use of telemedicine
45629974|NCT05499819|Other|Canned red kidney beans, drained and rinsed|Canned red kidney beans, drained and rinsed, drained and rinsed and consumed in a tortilla wrap
45629975|NCT05499819|Other|Extra-lean ground beef|Extra-lean ground beef, pan-fried and consumed in a tortilla wrap
45629976|NCT02398877|Other|stress|
45629977|NCT03595995|Biological|UB-621|Monoclonal antibody by SC injection
45629978|NCT03595995|Other|Placebo|The placebo is a sterile, clear and colorless or slightly yellow liquid, contains the same composition as UB-621 except drug substance. It is given by SC injection.
45769691|NCT01143727|Drug|Santyl|Apply one 24-hr period sufficient to cover the wound.
45769692|NCT01143727|Drug|Tegaderm Hydrogel|Apply once 24-hr period sufficient to cover the wound.
45913272|NCT02020421|Device|rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the center of the right Pars Triangularis for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 90% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
45629979|NCT02398487|Device|cigalike with nicotine|cigalike 24 mg nicotine or 16 mg nicotine
45629980|NCT02398487|Device|Personal Vaporizer with nicotine|Personal Vaporizer 16 mg nicotine or 9 mg nicotine
45629981|NCT02396927|Device|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
45629982|NCT02396927|Device|2D HD laparoscopy|Placebo
45629983|NCT05497245|Other|mobile app-based breastfeeding education|"The main screen of the application used to be six screens. These six screens; Breastfeeding, Expressing, Contingencies, Frequently asked questions and my Breastfeeding Log and Breastfeeding diary. Mothers could record the number and duration of breastfeeding, milking status, the baby's height and weight, if it was a measure, the breastfeeding problem and solutions they encountered, on the Breastfeeding Introduction tab, and they could follow their breastfeeding status in the Breastfeeding Diary tab."
45629984|NCT04480619|Diagnostic Test|Ga-68-PEG-Αvβ3-IAC PET/CT|PET Diagnostic Agent
45629985|NCT03371745|Procedure|Trophectoderm biopsy|Biopsy at blastocyst stage of trophectoderm cells for comprehensive evaluation of the eupolid status of the embryo.
45629986|NCT03371745|Procedure|Cryopreservation|Rapid freezing using vitrification
45629987|NCT03371745|Procedure|Embryo Transfer|Transfer of embryo that has been cultured in vitro into the uterus
45629988|NCT02398253|Behavioral|CBT + Hypo-energetic Diet|This group will have cognitive behavioral therapy classes + follow the hypo-energetic diet after losing at least 10% of their body weight by using a weight loss program. They will also have monthly follow-up to 6 months by fortnightly dietician visit.
45629989|NCT02398253|Behavioral|Hypo-energetic Diet only|This group will receive the hypo-energetic diet only after losing at least 10% of their body weight by using a weight loss program. They will also have monthly follow-up to 6 months by fortnightly dietician visit.
45629990|NCT05497167|Other|Period Kit|This is a single arm interventional study wherein the subjects enrolled will all participate in the study in the same way by being asked to answer pre-study survey questions concerning their attitudes towards menarche, receiving a period kit to explore on their own for two weeks, and then being asked to answer post-study survey questions.
45629991|NCT02398097|Biological|Agripal|2011/2012 influenza season standard dose trivalent subunit inactivated intramuscular vaccine, single dose
45629992|NCT02398097|Biological|IDflu9μg|2011/2012 influenza season reduced-content intradermal split vaccine, single dose
45629993|NCT02398097|Biological|IDflu15μg|2011/2012 influenza season standard-content intradermal split vaccine, single dose
45629994|NCT03348345|Behavioral|Eat Breathe Thrive|Eat Breathe Thrive (EBT) program which was designed to increase positive body image, awareness, self-regulation, and mindful eating habits. This program aims to achieve these things through psychoeducation of cultural influences of beauty standards, the basic neuropsychological systems in the body and how they affect eating habits, creating a community within the group members for support, and finally through the practice of yoga.
45629995|NCT02396615|Dietary Supplement|SATIN pineapple|Active juice with added fibre and ginseng
45629996|NCT02396615|Dietary Supplement|SATIN pineapple control|Control products without active ingredients
45629997|NCT03250299|Drug|Microtubule-Targeted Agent BAL101553|Given PO
45629998|NCT03250299|Radiation|Radiation Therapy|Undergo radiation therapy
45629999|NCT03250299|Other|Laboratory Biomarker Analysis|Correlative studies
45630000|NCT03250299|Other|Pharmacological Study|Correlative studies
45447551|NCT01562925|Dietary Supplement|White wine|White wine First dosage: 3.3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.7 ml per kg bodyweight (60-120 minutes before contrast medium exposure
45630001|NCT02697617|Drug|Pioglitazone|Pioglitazone
45630002|NCT02697617|Drug|Placebo|Placebo
45630003|NCT05499429|Device|Transcranial low intensity focused ultrasound stimulation|Low intensity focused transcranial ultrasound stimulation can safely and effectively regulate neuron excitability through mechanical force.
45630004|NCT02868567|Drug|dalfampridine|Pill open label
45630005|NCT02398331|Other|Standardised information and education on sexuality in women with spinal cord injury|"Program of information and education on the physiology of sexual response in women with spinal cord injury 6 months after their first return to home:~Educational footage~Clinical neurological examination with educational aim~Structured consultation providing information on the physiology of sexual response in women with spinal cord injury"
45630006|NCT02591745|Procedure|Fetal intervention|Type of fetal conditions requiring intervention and medications administered to fetuses undergoing varying types of fetal intervention will be documeted in this database.
45630007|NCT02396771|Procedure|Uterine Massage|The massage will be performed as follows: palpating the uterine fundus, manually stimulating the fundus and the whole body of the uterus using fingers and palms steadily and repetitively.
45630008|NCT02396771|Procedure|Uterine Compression|The sustained uterine compression will be performed as follows: placing one hand in the vagina and pushing against the body of the uterus while the other hand compresses the fundus from above through the abdominal wall.
45630009|NCT05564481|Behavioral|diabetes education and parent coaching support|Intervention sessions will include parent/child discussion about barriers to CGM use, review of CGM data, problem solving, and working as a team.
45913273|NCT02020421|Device|tDCS|2mA cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. tDCS will start immediately before the speech-language therapy session and last throughout the session.
45630010|NCT02396693|Device|NIPPV|Ventilation with nasal intermittent positive pressure - Newborns randomized to this group underwent NIPPV, the respirators in TIME mode, set with the following settings : 5-6 centimeters of water (cmH2O) pressure positive end expiratory (PEEP); Flow rate of 6-8 liters per minute (L / min); PIP(positive inspiratory pressure) < 15 centimeters of water (cm H2O) ; respiratory frequency backup (FR) < 16 bpm; inspiratory time (IT) - 0.30 to 0.33 seconds (adjustable time constant according to the weight and baseline disease)
45630011|NCT02396693|Device|Bubble NCPAP|Bubble NCPAP - Newborns randomized to this group bubble NCPAP, adjusted with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min), provided through oxygen sources and compressed air (15 liters per minute - L / min), which passes through a heated humidifier through a breathing circuit that goes to the newborn, and from him, for a plastic container (250 milliliters (ml) capacity and 14 centimeters) containing sterile distilled water, which is the bubble.
45630012|NCT02396693|Device|Ventilator NCPAP|Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, of respirators in TIME mode set with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min).
45630013|NCT05496699|Behavioral|Mckenzie Exercises|"Cervical Retraction Exercise in Sitting Position The participant sits on the chair, puts the second and third fingers on his chin and pushes his head posteriorly and inferiorly.~Cervical Rotation Exercise in Sitting Position~Cervical Retraction Exercise in Supine Position~Cervical Rotation Exercise in Supine Position The participant turns his head to the right and left, respectively, while taking his head back in the supine position with his head out of the bed.~Cervical Lateral Flexion Exercise~Cervical Flexion Exercise in Sitting Position"
45630014|NCT05496699|Behavioral|Mulligan Exercise|"The exercises to be applied are listed below.~1- C1-C2 Self Mobilization Slip is applied for natural apophyseal cervical right rotation. The belt is put on level C1. At the same time, the participant actively pulls the belt and turns his head to the right. To facilitate the rotation of the belt in C1, pressure is applied to the belt in the same direction as C2 and rotation of the head towards the restricted side is requested. It waits like this for 3 seconds. These movements are done in the painless range."
45630015|NCT02396225|Drug|Voriconazole|
45630016|NCT04272801|Drug|tamoxifen, letrozole, anastrozole, or exemestane|choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist
45630017|NCT04272801|Behavioral|Patient reported outcomes|"Questionnaire inquiries include the following:~how cancer affects daily living~beliefs about medicines and sensitivity to medicine~symptoms~adherence to endocrine therapy~general health and well being~depression and anxiety~preference regarding radiation therapy"
45630018|NCT02398175|Other|reanimation/intubation|
45630019|NCT02396303|Drug|Carbetocin|
45630020|NCT05496621|Other|Questionnaire|1st Stage Keele Start MSk tool translated into Turkish and its cultural adaptation, 2nd Stage Statistical analysis of reliability and validity of Turkish Keele start msk tool
45769693|NCT05496816|Diagnostic Test|CAC in septic patients|"Data collected included demographic parameters, comorbidities, vasopressors requirement, laboratory findings, in-hospital mortality scoring and diagnostic colagulation scores. Demographic parameters were taken on the day of admission, all other variables were taken on the day of admission to the ICU and on the day of initiation of invasive mechanical ventilation or on the day of discharge from the ICU.~Demographic parameters included age and sex of the patient, followed by comorbidities which was marked with Yes or No on the day of admission in the ICU. Mortality was assessed according to the qSOFA score and vasopressor requirements on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge. Laboratory analysis included analysis of platelets, neutrophils, lymphocytes, PCT, CRP, fibrinogen, D-dimer on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge."
45769694|NCT03738826|Behavioral|Behavioral Intervention|Lupus clinic providers will be prompted to assess adherence level using Surescripts refill information and address any adherence barriers that arise during the clinical encounter.
45769695|NCT03011827|Other|Fibrinogen and/or platelets administration|Fibrinogen and/or platelets administration to maintain clot amplitude at 10 minutes of the thromboelastometry between 35-40 mm along liver transplant procedure
45769696|NCT05496660|Other|NHE+KT|the Nodic hamstring exercise plus the kinesio taping with tension during 4-week consisting 12 sessions
45769697|NCT05496660|Other|NHE|the Nodic hamstring exercise plus the kinesio taping without tension during 4-week consisting 12 sessions
45769698|NCT05496582|Diagnostic Test|No intervention|No intervention
45769699|NCT03735862|Biological|Hepatic derived surgical matrix|Hiatal hernia repair with MIROMESH
45913274|NCT02020421|Device|Sham rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the Vertex for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 10% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
45447552|NCT01562925|Dietary Supplement|Beer|Beer First dosage: 7.8 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 3.9 ml per kg bodyweight (60-120 minutes before contrast medium exposure
45769700|NCT01143883|Other|Silverlon|Silverlon dressings are gauze impregnated with silver ions
45769701|NCT01143883|Other|Standard of Care Dressing|Standard dry gauze dressing
45769702|NCT01451294|Drug|Administration of phenylephrine|Phenylephrine: 50-100µg
45769703|NCT01451294|Drug|Administration of ephedrine|Ephedrine: 5- 10 mg
45769704|NCT01187017|Drug|Cyclophosphamide|60 mg/kg
45769705|NCT01187017|Drug|Fludarabine|125 mg/m squared
45769706|NCT00378118|Other|Abbott-rapid HIV antibody test|Abbott will be used to test serum or whole blood
45769707|NCT00378118|Other|OraQuick Rapid HIV-1/2 Antibody test|OraQuick for oral fluid HIV antibody testing
45913275|NCT02020421|Device|Sham tDCS|Sham cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. To elicit the typical skin sensation of real tDCS (tingling sensation on the skin when tDCS is turned on and off), the current will be turned on for 30 seconds and then turned off for the duration of the speech-language therapy session. The same procedure will be done at the end of the session.
45630021|NCT05564247|Behavioral|Wheelchair Skills Training Program (WSTP)|Participants will complete customized MWC skills training based on the evidence-based wheelchair skills program. Lessons plans will be created by the clinicians, children and parents participants based on goals, age, skills and interests, and used to customize the training.
45630022|NCT01918527|Drug|Capecitabine|Orally on days 1-14: 2000 mg/m2/day q3w
45630023|NCT01918527|Drug|Oxaliplatin|Intravenously on day 1: 130 mg/m2 q3w
45630024|NCT02698241|Device|Diagnostic & Medication Management|Single Arm Study. Subjects will be managed using integrated diagnostics.
45630025|NCT01292421|Biological|hepatitis B antigen peptide|Given PO
45769708|NCT02896088|Other|decayed tooth surfaces|The main variable is the number of new decayed tooth surfaces between the end and the beginning of the research. The caries experience will also be evaluated and expressed by the index 'dmfs' (accumulation of decayed tooth surfaces over those missing or filled due to caries). The secondary variable will be the expression of the retention of AS. The comparison of caries incidence between the two groups of teeth (with and without AS) will take into account the membership of the teeth to the same subject by means of the statistical test Chi-McNemar two. Regression models logistics and Poisson regression will be used to test the effect of independent variables on the appearance of new cavities. The Stata statistical software will be used.
45769709|NCT05496504|Other|Holter ECG|
45769710|NCT04553094|Other|Endurance training|Aerobic circuit training
45769711|NCT04553094|Other|Muscle building training|Muscle strengthening circuit training
45769712|NCT01145833|Other|Immediate Treatment Group|The immediate treatment group starts the 5-month treatment right after baseline assessment.
45630026|NCT01292421|Other|placebo|Given orally (PO)
45630027|NCT01292421|Other|immunoenzyme technique|Correlative studies
45769713|NCT01145833|Other|Delayed Treatment Group|The delayed treatment group does not start treatment immediately after the baseline assessment. This group serves as the control group, by not receiving any treatment for 5 months. After the 5 months, the delayed group participants are asked to come in for a second assessment that involves completion of surveys and measurement of height, weight, and physical activity level. After this assessment is completed, the delayed group participants can begin the 5-month treatment.
45769714|NCT04035694|Other|Media Aware Sexual Health - High School|Media Aware is an online media literacy and sexual health education program developed for high school students that addresses the influence of media on sexual behaviors explicitly using established message processing theory. The program consists of 4 self-paced modules each with two to three lessons. Broadly, the modules cover healthy and unhealthy relationships, sexually transmitted infections, consent, substance use, pregnancy, protection and contraception, and communication between adolescents and their partners, parents, or health providers. Users also learn media literacy skills including message deconstruction to help examine the truth behind media messages.
45769715|NCT04391192|Behavioral|Virtual Overdose Response|All participants will be provided the phone number and encouraged to call when they use alone.
45769716|NCT01451450|Drug|QGE031|QGE031 liquid for subcutaneous injection.
45769717|NCT01451450|Drug|Placebo|Placebo liquid for subcutaneous injection.
45913276|NCT02020434|Drug|RPX7009 and RPX2014|The study is designed to enroll approximately 32 subjects. There will be approximately 24 subjects with varying degrees of renal insufficiency and approximately 8 subjects with normal renal function.
45913277|NCT02020460|Device|Subdural trial lead|
45630028|NCT04283019|Drug|CBD|CBD will be orally ingested
45913278|NCT02020460|Device|Epidural trial lead|
45913279|NCT02020486|Drug|Perampanel|2 mg up to 4 mg
45913280|NCT02020486|Drug|Perampanel|2 mg up to 6 mg
46069931|NCT04623944|Biological|NKX101 - CAR NK cell therapy|NKX101 is an investigational allogeneic CAR NK product targeting NKG2D ligands on cancer cells. The starting dose of NKX101 in Part 1/Regimen A is 1 × 10^8 NK cells (2 × 10^6/kg for patients < 50 kg) administered as 3 weekly doses. The starting dose of NKX101 in Part 1/Regimen B is 1.5 × 10^8 NK cells (3 × 10^6/kg for patients < 50 kg) administered as 2 weekly doses. Part 2 will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX101 as determined in Part 1.
46069932|NCT05253014|Procedure|sphenopalatine ganglion block|block of the sphenopalatine ganglion using either lidocaine or bupivacaine to relief postdural puncture headache
45630029|NCT04283019|Drug|THC|THC will be orally ingested
45630030|NCT02396069|Drug|JPI-289|PARP-1 inhibitor
45630031|NCT02396069|Drug|Placebo|Placebo
45630032|NCT05496465|Drug|ARS-1|A single treatment of ARS-1.
45630033|NCT05496465|Drug|Placebo|A single treatment of placebo nasal spray
46069933|NCT05253014|Drug|paracetamol|intravenous paracetamol every 8 hours
45630034|NCT04440215|Other|Telerehabilitation and team meetings and team care plans|A mix of home or rehabilitation center visits and telerehabilitation will be planned by the rehabilitation team for a maximum of 16 weeks. Moreover, for each participant enrolled, a multidisciplinary meeting will be organised. The patient/family will participate in the meeting and the decision making process using the telerehabilitation platform. The team will generate an interprofessional individualized treatment plan, aiming for an interprofessional shared decision making process.
45630035|NCT04440215|Other|Usual care|Rehabilitation teams will be instructed to provide care as they have been doing previously. Currently, this translates into no telerehabilitation, and interdisciplinary meetings not systematically organized and/or not involving a complete team of professionals.
45769718|NCT05491122|Behavioral|Increasing or decreasing daily total fluid intake|1-week intervention where the intake of drinking water will either be increased (if habitually low) or decreased (if habitually high). The total fluid intake (TFI) prescriptions during the intervention are derived from the mean TFI of habitually high and habitually low drinkers from a sex, age and country matched population. Specifically, habitually high drinkers will be permitted a TFI of 1.3 L/day and habitually low drinkers will be permitted a TFI of 3.5 L/day for men and 3.3 L/day for women. Participants will be instructed to maintain their usual intake of other beverages i.e., tea/coffee to achieve their target TFI. The diurnal saliva cortisol response at rest will be examined at the end of both experimental periods and the saliva cortisol response to an acute psychological stress will be examined at the end of the habitual experimental period only.
45769719|NCT04536012|Behavioral|Gamification and Social Incentives|Participants in the intervention arm will receive gamification and social incentives as part of the intervention. See arm descriptions for more detail.
45630036|NCT03168503|Dietary Supplement|LGG+Promitor™|synbiotic
45630037|NCT03168503|Dietary Supplement|Promitor™|Soluble Corn Fiber
45630038|NCT03168503|Dietary Supplement|LGG-PB12+Promitor™|synbiotic
45630039|NCT03168503|Dietary Supplement|Maltodextrin|Control
45769720|NCT01451528|Biological|Allogeneic Umbilical Cord Blood|Allogeneic Umbilical Cord Blood Transplantation via Intravenous or Intraarterial route
45769721|NCT01224145|Drug|5x5cm bupivacaine collagen sponges|
45769722|NCT05496426|Drug|KL130008/Placebo|Drug: KL130008 Drug: Placebo
45769723|NCT01458002|Other|Tailored Internet Communication with Relational Agent|"The Tailored Internet Intervention will include a relational agent component, which is an animated conversational agent that builds a working relationship with subjects over time and uses this alliance to boost intervention effectiveness and retention to the Tailored Internet Communications web site."
45769724|NCT01458002|Other|Tailored Internet Communications|Best practices for TTM tailored communications with two types of feedback: normative - compared to peers and ipsative - self compared to previous assessment.
45447553|NCT03737175|Procedure|Carotid Artery Stenting|Carotid Artery Stenting
45447554|NCT03737175|Procedure|Carotid Endarterectomy|Carotid Endarterectomy
45447555|NCT00143507|Drug|Ivabradine|
45447556|NCT00143507|Drug|Placebo|
45630040|NCT04362111|Drug|Anakinra|The active treatment group will receive anakinra 100 mg subcutaneously every 6-12 hours for a period of 10 days
45630041|NCT04362111|Drug|Normal saline|The control group will receive normal saline placebo subcutaneously every 6-12 hours for period of 10 days
45447557|NCT03988803|Drug|BI 425809|Film coated tablet
45447558|NCT03988803|Drug|Memantine|Film coated tablet
45447559|NCT00181883|Drug|quetiapine|2.5 - 5.0mg/kg PO BID quetiapine
45447560|NCT00180713|Drug|Simvastatin|Simvastatin 40mg od for 1 month, then 80mg od for 11 months
45630042|NCT02397941|Other|Ultrasound|ultrasound measures
45630043|NCT02397863|Drug|Cannabidiol (Epidiolex)|Daily dosage up to 25 mg/kg/day with an optional up titration to a maximal daily dosage up to 50 m/kg/day until End of Treatment.
45630044|NCT04357587|Drug|Pembrolizumab|200 mg intravenously (IV) on days 1, 22, and 43
45447561|NCT00180713|Drug|Placebo|Placebo tablet once daily.
45630045|NCT04357587|Radiation|External beam radiation|Daily fractions of 200 cGy, 5 days a week for the first 5 weeks of the study, excluding weekends
45630046|NCT04357587|Drug|Capecitabine|825 mg/m2 orally twice a day on days where radiation therapy is given
45630047|NCT04058717|Other|Normal Nicotine Content research cigarettes|Research cigarettes with 11.6 mg nicotine/cigarette.
45769725|NCT01187095|Behavioral|Expressive writing|3 consecutive days of writing
45769726|NCT01187095|Behavioral|Active ctrl|Control
45769727|NCT05491044|Drug|orelabrutinib|Orelabrutinib 150mg po qd d1-28, up to 2 years or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first).
45769728|NCT01451840|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
45769729|NCT01451840|Drug|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
45769730|NCT05496270|Procedure|total mesorectal excision|
45630048|NCT04058717|Other|High Nicotine e-cigarette|E-cigarette containing high nicotine e-liquid
45630049|NCT04058717|Other|Very Low Nicotine Content research cigarettes|Research cigarettes with 0.2 mg nicotine/cigarette.
45630050|NCT04058717|Other|Zero Nicotine e-cigarette|E-cigarette containing zero nicotine e-liquid
45630051|NCT05496387|Other|Sciatic nerve neuromobilization techniques|Sciatic nerve neuromobilization techniques (tension and sliding) was applied to the dominant side lower extremities of all participants in the study. While the participant was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to dorsiflexion. After waiting 30 seconds in this tense position, the ankle, head and neck returned to neutral position and relaxed. 3 sets were repeated with 1 minute rest breaks. Sciatic nerve sliding was applied in the same starting position as tension. While the participants was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to plantar flexion.
45769731|NCT01451918|Drug|Resveratrol|500mg bid for one week followed by 1 gram bid for one week prior to lipoprotein study.
45769732|NCT01187329|Other|hyperinsulinemic normoglycemic clamp (HNC)|Prior to anesthetic induction, a baseline blood glucose value will be obtained, followed by an insulin infusion of 5 mU.Kg-1.min-1. When blood glucose is <110 mg/dL, a variable continuous infusion of glucose (dextrose 20%) supplemented with potassium (40 mEq/L) and phosphate (30 mmol/L) is administered to preserve normoglycemia (80-110 mg/dL). The glucose infusion is titrated to target glucose levels by checking blood glucose every 5 - 15 min with Accu-Check (Roche Diagnostics, Switzerland) glucose monitor. At sternal closure, insulin infusion is decreased to 1 mU/Kg/min. On admission to the ICU, insulin treatment follows the ICU protocol. The dextrose infusion is slowly weaned off over 2 - 4 hrs maintaining blood glucose > 80 mg/dL. Arterial blood glucose is measured every 30 - 60 min for 2 hrs, then, as stated in ICU protocol.
45769733|NCT01187329|Other|control group|Baseline arterial blood glucose will be obtained before anesthetic induction. Repeat measurements are performed every 30-90 min. Glucose >150 on CPB will receive insulin according to intraoperative protocol. After surgery, insulin is given according to ICU protocol. Target glucose < 180 mg/dL.
45913281|NCT02020499|Drug|Somatuline Autogel® (lanreotide) 60, 90, 120 mg.|Patients receiving treatment as prescribed by the investigator and according to current treatment recommendations and routine clinical practice, and in line with local regulations.
45769734|NCT04758182|Device|High intensity laser therapy|Device: HIRO 3.0 device high peak power (3kW), a wavelength of 1064 nm
45769735|NCT04758182|Device|Ultrasound therapy|Device: Chattanooga intellect mobile ultrasound device frequency of 1 MHz, an intensity of 2 W/cm2 and a duty cycle of 100%
45769736|NCT01146379|Other|Intensive task-specific upper extremity rehabilitation|The experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
46069934|NCT05278442|Other|LaserArc|LaserArcs.com is an online arcuate incision nomogram calculator initially developed on the basis of 12 months of data tabulation of patients undergoing femtosecond surgery with arcuate incisions
46069935|NCT05252780|Behavioral|My Body, My Rhythm, My Voice|My Body was a behavioral intervention informed by the social cognitive and self-determination theories. Based on the discussions and a systematic review of the literature, we designed the 8-week, 3 times/week rumba physical activity intervention. The goal of the intervention was to gradually increase all participants' physical activity levels to achieve significant health benefits. As part of the physical activity intervention, participants were also taught by their instructor during each class how to utilize behavioral and cognitive self-regulatory skills to increase and maintain their physical activity participation. Examples of such skills were action planning, coping planning, counter conditioning, self-evaluation, among others.
45769737|NCT05490966|Other|isometric trunk extensor muscles fatigue|Participants will perform three sets of intermittent isometric efforts between 50 and 60 percents of their maximal isometric strength. A padded force sensor will be placed approximately at the level of the 7th thoracic vertebrae. The first two sets will last six minutes each, while the third set will last three minutes. Between each set participants will rest for two minutes.
46069936|NCT04254458|Diagnostic Test|Corneal densitometry|Corneal density values were measured by densitometry software of Pentacam HR-Scheimpflug corneal topography
45630052|NCT02395757|Device|MAIA™ (Centervue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)|"An automatic microperimetry exam of the 10° central macular coverage expert test (customized grid) will be performed with the MAIA™ device at each semi-annual follow-up visit."
45630053|NCT02398019|Device|OXIRIS®|"OXIRIS® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication [OXIRIS® (Baxter Gambro)].~PrismafleX eXeed™ II (Hospal) with OXIRIS® set will then be connected to CPB circuit. Blood flow between 150-200 ml/min will be derivatised from the CPB circuit into the PrismafleX eXeed™ so that it all flows through OXIRIS® membrane. Flow, pressure and alarms will be controlled by PrismafleX eXeed™ independently from CPB circuit.~OXIRIS® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."
45769738|NCT00378196|Drug|Ranibizumab|0.3 mg/0.05 ml dose
45769739|NCT00378196|Drug|Ranibizumab|0.5 mg/0.05 ml dose
45769740|NCT00378274|Behavioral|Observation|
45630054|NCT01097733|Other|Randomization of Pre-knowledge of CT coronary venography|
45630055|NCT03168269|Diagnostic Test|Coronary Computed Tomographic Angiography (CCTA)|CCTA of coronary arteries
45630056|NCT04480229|Behavioral|Telenursing and Counseling|After the first face-to-face training, counseling on the phone was conducted every week for four cycles of chemotherapy treatment. In total, six counseling sessions and four face-to-face training sessions were conducted for each patient.
45630057|NCT03168035|Drug|NC-4016|"Dose Escalation Group Starting Dose: 15 mg/m2 by vein on Day 1 of a 21 Day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."
45630058|NCT02397395|Drug|Simeprevir (SMV) 150 mg|Simeprevir (SMV) 150 milligram (mg) capsule orally, once daily for a duration of 12 weeks.
45769741|NCT01188109|Drug|Gemcitabine|"Standard of care chemotherapy and dosage~Dose - 1000 mg/m²~Schedule - Days 1 and 15; Q 28 days"
45769742|NCT01188109|Drug|Cisplatin|"Dose - 50 mg/m²~Schedule - Days 1 and 15; Q 28 days"
45913282|NCT02020525|Procedure|restrictive transfusion strategy|Patients allocated to the restrictive transfusion strategy were transfused only when their hemoglobin concentration decreased below 7.7 g d dL-1 and were then maintained at hemoglobin concentrations between 7.7 and 9.9 g d dL-1.
45913283|NCT02020525|Procedure|liberal transfusion strategy|Patients assigned to the liberal strategy were transfused when their hemoglobin concentration fell below 9.9 g dL-1, aiming at maintaining hemoglobin at or above 10 g dL-1.
45913284|NCT02020538|Other|Low-chloride perioperative intravenous fluid strategy|The low-chloride perioperative IV fluid strategy will include the use of PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice and 20% albumin as the colloid of choice.
45913285|NCT02020538|Other|High-chloride perioperative intravenous fluid strategy|
45913286|NCT02020551|Drug|Lidocaine Spray|
45913287|NCT02020551|Drug|Placebo|
45913288|NCT02020603|Device|epinephrine injection plus soft coagulation using hemostatic forceps|
45447562|NCT02531477|Drug|propofol|intracarotid propofol as an anesthetic agent
45630059|NCT02397395|Drug|Daclatasvir (DCV) 60 mg|Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks.
45630060|NCT02397551|Procedure|IVF/ICSI|
45630061|NCT02397551|Drug|Human Chorionic Gonadotropin|Given in different doses and timing to support the luteal phase
45630062|NCT02395913|Drug|Surfolase capsule (100mg)|Surfolase capsule one capsule twice one days fasting administration
45630063|NCT02395913|Drug|Surfolase CR (200mg, T1)|one tablet once one days fasting administration.
45630064|NCT02395913|Drug|Surfolase CR (200mg, T3)|one tablet once one days fasting administration.
45630065|NCT02395913|Drug|Surfolase CR (200mg, T4)|one tablet once one days fasting administration.
45913289|NCT02020603|Device|epinephrine injection plus argon plasma coagulation|
45913290|NCT02020629|Drug|Lixisenatide|Lixisenatide is given for 6 weeks whereafter a hypoglycemia clamp is undertaken
45913291|NCT02020642|Procedure|Renal transplantation|Renal transplantation from cadaveric or live donor
45447563|NCT03988023|Biological|Ampion|4 mL injection of Ampion
45447564|NCT03988023|Drug|Saline|Saline solution, 4 mL, single intra-articular injection
45769743|NCT01458080|Drug|eltrombopag|eltrombopag
45769744|NCT04180176|Other|Blood Draw|Participants will have blood drawn at enrollment, the first tumor assessment, and at disease progression or end of therapy.
45769745|NCT03980470|Device|TrueFidelity|"TrueFidelity (Deep Learning Image Reconstruction, DLIR) software by GE Healthcare.~The medical device in question is a novel reconstruction algorithm for raw CT data which is based on artificial intelligence approaches, namely deep-learning iterative reconstruction (DLIR). This DLIR algorithm will be installed on the console of the CT Revolution scanning device, which is in routine clinical use for cardiac CT scans at the Department of Nuclear Medicine at the University Hospital Zurich. Purpose of this installation is the assessment of the performance of the DLIR algorithm during a limited time span of six weeks.~The algorithm will be CE-marked at the time of installation and use (statement by GE Healthcare provided separately). Its intended use is the reconstruction of CT datasets.~Of note, the novel DLIR algorithm will not substitute any clinical routine procedures currently in use. That is, diagnosis will still be made using the standard reconstruction algorithms."
45769746|NCT01458236|Drug|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration
45769747|NCT01458236|Drug|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group
45769748|NCT01146457|Drug|Morphine|Active dosage
45769749|NCT01146457|Drug|Saline|Saline Control
45769750|NCT04031430|Device|Telemonitoring|Women who are allocated to the PSM groep, will receive a connected blood pressure monitor. They have to measure their blood pressure twice a day and fill in their weight once a week in the App. These data are automatically transmitted via Bluetooth and Wi-Fi to the hospital, but the caregiver will not see those data, and can not react to it.
45913292|NCT02020655|Other|Shear- force model|Shear- force model
45913293|NCT02020668|Other|Physiotherapy|
45913294|NCT02020668|Other|Wait list control|
45913295|NCT02020681|Device|Curodont Repair|Self-assembling peptide, biomimetic re-mineralisation
45913296|NCT02020681|Other|Placebo|Formulation of Curodont Repair without the peptide P11-4
45913297|NCT02020681|Device|Fluoride|Single application on day D90
45913298|NCT02018796|Drug|Mifepristone, misoprostol|200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol
45630066|NCT02395679|Biological|MesoCancerVac|A leukapheresis is performed of which the monocytes are used for differentiation to DCs using specific cytokines. Pulsed autologous DCs (MesoCancerVac) are re-injected 3 times every two weeks. After the third injection with MesoCancerVac, revaccinations to boost the immune system are given after 3 and 6 months.
45630067|NCT03168191|Drug|Nicotine|Participants will receive low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
45630068|NCT03168191|Other|Experimental Flavor|Experimental fruit flavored e-cigarette for lab session
45630069|NCT03168191|Other|Menthol Flavor|Menthol flavored e-cigarette for lab session
45769751|NCT04031430|Other|Longitudinal CV profiling during pregnancy and before and after the start/switch of antihypertensive medication|Longitudinal CV profiling during pregnancy and before and after the start/switch of antihypertensive medication Registration of medication usage in the Medisafe app Assessment of their beliefs about medicine in general and during pregnancy and their perceptions regarding medication adherence by means of the 'Beliefs about Medicine Questionnaire' and the 'Probabilistic Medication Adherence Scale' at baseline and postpartum.
45769752|NCT04031430|Other|CV profiling before and after the start/switch of antihypertensive medication|CV profiling before and after the start/switch of antihypertensive medication Registration of medication usage in the Medisafe app Assessment of their beliefs about medicine in general and during pregnancy and their perceptions regarding medication adherence by means of the 'Beliefs about Medicine Questionnaire' and the 'Probabilistic Medication Adherence Scale' at baseline and postpartum.
45769753|NCT04018924|Device|Illumination with blue light (400-430nm) for 60 seconds with a power density of 120mW/sqcm (EmoLED device)|Debridement and Dressing or compressive dressing if needed
45769754|NCT05026346|Diagnostic Test|Pathologic Exercise|"In the first phase of the project, a series of 5 active shoulder mobilization exercises characterized by an adequate range of motion will be tested to verify the set up for the video recording.~In the second phase shoulder movements will be recorder by a smartphone.~A questionnaire will be used and adapted on the basis of which to evaluate the correctness of the exercises performed by each healthy subject / patient. This questionnaire will provide a Clinical Score (CS) which assigns a numerical value to the patient's overall performance for each repetition.~The videos of each repetition of exercises performed by the healthy subjects / patients will then be evaluated by two different clinicians, blinded, using the questionnaire.~The Artificial Intelligence learning algorithm will be able to output an evaluation score that will be compared with that produced by clinicians."
45447565|NCT04052139|Drug|Low-dose naltrexone|4.5 mg of low dose naltrexone taken once daily for 8 weeks. In week 1, participants will take 4.5mg of naltrexone once daily. In week 2, participants will take 4.5mg of naltrexone once daily, and a placebo capsule twice daily. In weeks 3 through 7, participants will take 1 placebo capsule with 4.5 mg mg of naltrexone once daily, and 2 placebo capsules twice daily. In week 8, in days 1-4 participants will take 4.5 mg of naltrexone with a placebo capsule once daily and 2 placebo capsules twice daily; in days 5-7, participants will take 4.5 mg of naltrexone once daily, and a placebo capsule twice daily.
45630070|NCT04440293|Other|BBAT|The BBAT was applied by a trained and certified physiotherapist in this area for about an hour, two days a week, as a group therapy. The BBAT program includes movements related to daily activities such as lying, sitting, standing and walking. BBAT focuses on basic movement principles such as postural stability, energy adjustment in movements, comfortable breathing and coordination.
45630071|NCT04440293|Other|CT|The CT program was applied two days a week for about an hour. The CT program includes active range of motion (ROM) exercises, stretching, isometric and resistant strengthening, posture exercises and relaxation training.
45630072|NCT02395445|Device|orotracheal intubation|
45913299|NCT02020733|Device|Balloon catheter|
45630073|NCT02397317|Radiation|Multi-fraction SABR|All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
45630074|NCT02395523|Radiation|Proton Beam Therapy|"Definition of target volume:~Gross tumor volume (GTV) = gross tumor defined using a treatment planning CT scan~Clinical target volume (CTV) = GTV + internal target volume~Planning target volume (PTV) = CTV + 5 - 7 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~Prescription dose to PTV: 70 GyE /10 fx, 7GyE fraction dose, 5 days/week~Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
45630075|NCT05564013|Device|Virtual reality|Up to 25 minutes of virtual reality exposure in supine position
45913300|NCT02020733|Device|metal cannula|
45913301|NCT02020746|Drug|EscharEx|
45913302|NCT02020746|Drug|Gel Vehicle|
45913303|NCT02020759|Device|Transcranial Doppler Ultrasound|Transcranial Doppler Ultrasound is used to monitor cerebral microembolism
45630076|NCT05563935|Device|Repetitive transcranial magnetic stimulation|The OCD group will receive rTMS treatment for 6 weeks. There are 5 rTMS treatments per week (Monday to Friday), and 30 rTMS treatments in total. Treatment is administered by Ma GPro X100 device (Maga Venture) with Cool-DB80 coil. Detailed parameters of rTMS: intensity of stimulus is 120% RMT; the frequency of trains is 1Hz and the number of pulses is 1; no intertrain intervals and the pulses number is 1000.
45913304|NCT02020772|Other|coordinating primary health care|
45913305|NCT02020772|Other|usual primary health care|
45913306|NCT02020798|Other|Dietary Intervention|
45913307|NCT02020811|Device|Sentinel|
45913308|NCT02020824|Behavioral|Exposure to anxiogenous environments|"The anxiogenous environments are defined by several levels of possible anxiety classified progressively and independently by each patient at the beginning of the study. The exposure is applied during the 8 sessions for each of the arms Exposure to anxiogenous environments (with or without control)."
45913309|NCT02020824|Other|Imagery with functional MRI initial|Subjects will be submitted to 1 session of fMRI during their first visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
45913310|NCT02020824|Other|Imagery with PET-scanner initial|Subjects will be submitted to 1 session of PET-scanner during their first visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
45447566|NCT04052139|Drug|Gabapentin|Dose will begin at 300 mg daily (300 mg qd), in week 2 the dose will be titrated up to 900 mg daily (300 mg tid). In week 3, the dose will be titrated to 1800 mg daily ( 2 capsules of 300 mg tid) and participants will remain on that dose until week 8. In week 8, in days 1-4 participants will take 1800 mg daily (300 mg+300 mg tid); in days 5-7, participants will take 900 mg daily (300 mg of gabapentin three times daily).
45630077|NCT05496153|Behavioral|Adaptive posture-balance cardiac rehabilitation exercise|The process of APBCRE consisted of four parts: breathing training and warm-up, aerobic exercise, resistance exercise, and flexibility exercise. The first part lasted for 5-15 minutes, based on balance exercise. The specific steps of balance exercise included stretching of upper limbs, legs, waist, and other parts. And the second part was generally moderate-intensity endurance exercise, thresholding for 60%-75% VO2max/kg metabolic equivalents (METs), 60%-70% maximum heart rate, rating of perceived exertion (RPE) Borg grade 12-13. The exercise duration of this part was usually 30 min. During the self-created APBCRE, the resistance exercise was carried out with the help of the body-building vehicle, and its power was adjusted based on danger assessment level and oxygen uptake at anaerobic threshold. The last part usually lasted for 5-10 min for each-level participants. The total exercise time for one session was generally 50-70 min.
45630078|NCT05499351|Biological|Adult group in immunogenicity and safety study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
45630079|NCT05499351|Biological|Elderly group in immunogenicity and safety study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
45630080|NCT05499351|Biological|Adult group in safety observation study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
45630081|NCT05499351|Biological|Elderly group in safety observation study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
45769755|NCT05496114|Device|Checklist|A checklist is an aid that outlines assessments or actions systematically. In this study, the checklist outlines interventions to consider during management of a patient with tricyclic antidepressant poisoning. Each checklist will include indications, contra-indications and for medication, dose, route and rate of administration.
45769756|NCT01452230|Behavioral|Supervised physical activity|Supervised physical activity
45913311|NCT02020824|Other|Imagery with functional MRI final|Patients will be submitted to 1 session of fMRI during a follow-up visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
45630082|NCT05496075|Drug|Orlistat|Orlistat was administered orally on the basis of lifestyle guidance . Orlistat: Take 0.12g (1 capsule) with or within one hour after meals, 3 times a day. Medication time course: continuous administration for a total of 24 weeks.
45769757|NCT04011436|Other|Strengthening program|"Both protocols lasted eight (8) weeks, the anatomical conditioning phase was carried out in two weeks of intervention, followed by 4 weeks of strengthening or strength increase and two additional weeks as a final or maintenance phase, at the end of which performed the final evaluations to identify if there were differences in the groups after the physiotherapeutic intervention.~Group A: 28 exercises Group B: 24 exercises"
45769758|NCT04272866|Other|Clinpro sealant|Resin based sealant
45769759|NCT04272866|Other|Embrace wetbond sealant|Moisture tolerant hydrophilic resin based sealant
45769760|NCT04272866|Other|Triage sealant|Glass ionomer sealant
45769761|NCT04346498|Other|Chest-to-back|
45769762|NCT02892890|Procedure|Muscle Magnetic Resonance Imaging (RMI) evaluation|
45913312|NCT02020824|Other|Imagery with PET-scanner final|Patients will be submitted to 1 session of PET-scanner during a follow-up visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
45769763|NCT02892890|Device|MRI|
45769764|NCT02886962|Biological|No oral anticoagulation|No oral anticoagulation, and no monitoring of the INR.
45769765|NCT02886962|Drug|Oral anticoagulation with vitamin K antagonists|"Vitamin K antagonist prescription with INR target between 2 and 3 as recommended in the guidelines.~Administration once daily or at the end of each dialysis session, according to the nephrologist choice.~INR monitoring at least once per week"
45769766|NCT05495958|Drug|Topical Vitamin D eye drop|25 Microgram/cc or 1000 IU
45913313|NCT02020876|Other|DECIPHER Questionnaire|Participants are asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant opinion is collected based on a random selection of cases.
45913314|NCT02020902|Other|Cetrizine hydrochloride|As provided on the patient information leaflet
45913315|NCT02020915|Procedure|lateral sphincterotomy|
45913316|NCT02020915|Procedure|ultrasound guided lateral sphincterotomy|
45630083|NCT05496075|Drug|Orlistat placebo|Lifestyle guidance: low-purine diet; orlistat placebo: take 1 capsule with or within one hour after a meal, 3 times a day. Medication time course: continuous administration for a total of 24 weeks.
45630084|NCT05495919|Other|Control|No intervention was perfomed to reduce anxiety in control group
45630085|NCT05495919|Other|video interaction|Before the training, educational materials were given to the students, and they were discussed with the students in the lesson.
45769767|NCT05495958|Drug|Topical placebo eye drop|The same-shape packed drop without vitamin D
45630086|NCT05495919|Other|flipped training|Before the training, the students took videos and during the lesson, the videos were evaluated and feedback was given.
45630087|NCT04280055|Drug|Psilocybin|0.14 mg/kg p.o. in three sessions spaced by one week
45630088|NCT05495607|Device|CARPEDIEN|Continuous renal replacement therapy
45913317|NCT02020928|Device|Low level laser therapy|Low level laser therapy: Laser Therapy XT (DMC) having red light with a wave length of 660 nm (± 10 nm) and infrared light with a wavelength of 808 nm (± 10 nm) is used, both power of 100 mW (± 20%), applied in a timely manner.
45630089|NCT04424823|Procedure|LED photobiomodulation|Patients were submitted to photobiomodulation therapy with wavelengths of both 630-nm and 850-nm for RED and near-infrared LEDs, with power density set to 8.5 mW/cm2 and 12.5 mW/cm2, respectively. The LED device (name of device, Applied BioPhotonics) was designed in Silicon Valley, United States, and was approved by the United States Food and Drug Administration for the treatment of minor muscle and joint pain. LED therapy was applied by placing the device on the skin at a 90° angle. Both groups underwent six times therapy sessions (i.e., three times a week for 2 weeks), and during the therapy, only the researcher in charge of programming the LED device was aware of the treatment employed; the programmer did not participate in the execution of the treatments, evaluations, or data analysis.
45630090|NCT04265781|Drug|BAY1817080|Three different doses over the course of study
45630091|NCT04265781|Drug|Matching Placebo|Matching Placebo to BAY1817080
45630092|NCT05495529|Procedure|Thermal Ablation|Data collection about complications, succes of the procedure, succes of complete treatement, recurrence, biologic pertubations.
45630093|NCT05499117|Device|Light terapy|Carex Day-Light Classic, Light intensity is white Light, 10000UX, and color temperature is 4000K
45630094|NCT05499117|Device|pseudo-light therapy|The pseudo-light stimulation group was red light with intensity less than 100lux
45630095|NCT05495451|Behavioral|Moderate-carbohydrate Mediterranean diet, Personalized exercice prescription and training, Intermittent fasting|Multidisciplinary program will provide the teaching and supervision necessary to integrate the new knowledge and commitment to these lifestyle changes.
45630096|NCT05563311|Other|Exercise on High-intensity interval training|3 times a week, for 8 weeks
45769768|NCT04011592|Drug|Ketamine 0.5 mg/kg|single intravenous infusion of Ketamine (0.5 mg/kg)
45769769|NCT04011592|Drug|Ketamine 0.2 mg/kg|single intravenous infusion of Ketamine (0.2 mg/kg)
45769770|NCT04416828|Device|Portable wireless ultrasonography devices|Patients with suspected ganglion cyst of the wrist or hand receive portable wireless ultrasound imaging
45769771|NCT04416828|Device|Cart-based ultrasonography device|Patients with suspected ganglion cyst of the wrist or hand receive conventional cart-based ultrasound imaging
45769772|NCT05024162|Diagnostic Test|MRT Accuracy|Predicted Grade Group (GG) by the MRI-based Radiomics Tool (MRT) at each Magnetic Resonance Imaging of the Prostate (MRI-P)
45769773|NCT05024162|Diagnostic Test|MRT Stability|MRT's predicted GG at second MRI-P.
45913318|NCT02020954|Procedure|ECG, echocardiography, cardiac MRI, sera biomarkers|
45913319|NCT02021019|Procedure|Renal Denervation|Renal Denervation
45630097|NCT05499039|Device|High flow nasal cannula (HFNC)|"High flow nasal cannula consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers a modified gas flow up to 60 l/ min .~will be set with: -~Temperature at 37°C or 34°C Flow rate 30: 50 L/min. FiO2 will be adjusted to achieve a SpO2 at least 95%"
45630098|NCT05499039|Device|Non-Invasive Mechanical Ventilation (NIV)|"Respiratory assistance is provided by a NIV either Puritan Bennet 840 , Engström Carestation or Hamilton-G5 , will be used for conventional non-invasive ventilation via an oronasal mask. Settings will be adjusted based on the clinical assessment of the respiratory therapist . Initial setting includes: -~Positive End Expiratory Pressure (PEEP): 5 cmH2O. Pressure support (PS): 12-20 cmH2O. FiO2 will be adjusted to achieve a SpO2 at least 95% Intervention: Device: non-invasive ventilation"
45769774|NCT04098172|Device|Pressure Guidewire|Fractional Flow Reserve measurement
45769775|NCT01458470|Drug|Memantine|oral tablet, 1 BID, 24 weeks
45769776|NCT01458470|Other|Placebo|oral tablet, 1 BID, 24 weeks
45769777|NCT04277598|Biological|APO-2|APO-2: dose adjusted gel for topical administration.
45913320|NCT02021032|Device|Prolieve|Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH. This device utilizes a transurethral catheter with microwave antenna to heat the prostate, with simultaneous 46 Fr. prostatic urethral catheter balloon-administered compression.
45913321|NCT02021045|Device|Renal hemodialysis (Fresenius 2008K, Bad Homburg, Germany)|Renal replacement therapy is frequently used in patients with renal failure in order to eliminate substances obligatory excreted by the urine.
45769778|NCT04277598|Other|Placebo|Placebo gel for topical administration.
45913322|NCT02021058|Other|Experimental Formula|Experimental formula
45913323|NCT02021058|Other|Standard control formula|Standard Infant formula
45630099|NCT05495295|Drug|PhOx430|"Dose Escalation Phase: A standard 3 + 3 design will be followed for the escalation phase. PhOx430 will be administered orally twice a day (bid), at a 12-hour interval, continuously in cycles of 21 days. At each dose level (DL), three patients will be included and the first patient will be observed for at least 21 days before enrolling the following two. Three additional patients will be enrolled at each DL if a DLT is observed in the first three patients.~A maximum of 4 increasing Dose Levels are foreseen (10, 20, 40 and 70 mg/kg/day), and PhOx430 will be administered in two doses at a 12-hour interval."
45769779|NCT05025488|Drug|Peptide-based vaccine|ten (10) doses of Mutant-CALR peptides with KLH as helper peptide (in the first vaccine only). Mutant-CALR vaccine will administered every 2 weeks for the first 4 doses and then every 4 weeks for additional 6 doses. Maintenance Treatment The protocol allows for a continued administration of up to four (4) additional Mutant-CALR vaccine and four (4) Poly-ICLC administrations, 12 weeks apart.
45630100|NCT05495217|Device|Conventional Laparoscopy|A procedure in which a laparoscope (LAPAROSCOPES) is inserted through a small incision near the navel to examine the abdominal and pelvic organs in the PERITONEAL CAVITY using Induced pneumoperitoneum.
45630101|NCT05495217|Device|Gasless Laparoscopy|A procedure in which a laparoscope (LAPAROSCOPES) is inserted through a small incision near the navel to examine the abdominal and pelvic organs in the PERITONEAL CAVITY without Induced pneumoperitoneum.It mechanically elevates the abdominal wall and allows laparoscopic visualization through a single incision, providing diagnostic and therapeutic procedures.
45630102|NCT05498961|Other|Gallstone characteristics|stone size, number, the thickness
45769780|NCT05025488|Drug|Poly ICLC|ten (10) doses of Poly-ICLC. Poly-ICLC will be given on weeks 1, 3, 5, 7, 11, 15, 19, 23, 27 and 31. each Poly-ICLC dose must be given the day after the corresponding Mut-CALR vaccination.
45630103|NCT05495139|Device|Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver Disease|This study includes 3 phases; screening period, procedural period, and a follow-up period. Following a 2-week screening period, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 2; Day 0). Following a 6-month treatment period, the device is removed, and subjects are followed for 6 months. In total subject participation will last for approximately 12 months.
45630104|NCT05498883|Other|Score completion|completion of the SRI score
45630105|NCT05494983|Other|Screening visit|The participants will be screened for inclusion and exclusion criteria and will be asked to fill the following questionnaires : Pittsburgh Sleep Quality Index, State and Trait Anxiety Questionnaire, Pain Catastrophizing Scale Fear of Pain Questionnaire, Perceived Stress Scale, Beck Depression Inventory, and questionnaires to assess their health status and the use of medications. A blood sample (to measure pro- and anti-inflammatory cytokines and perform metabolomic analyses) will be obtained. Enrolled participants will be given a wearable actimeter to assess daily total sleep duration during one week before the first experimental session. They will also be requested to complete daily a sleep diary during one week before each experimental session, and a food diary before the first experimental session. A fecal sample (to assess gut microbiota composition and perform metabolomic analyses) will be collected between the screening visit and the first experimental session.
45630106|NCT05494983|Other|Peripheral sensitization session|The extent of neurogenic inflammation induced by topical capsaicin will be used as a measure of the susceptibility to sensitize at peripheral level. A solution of capsaicin will be applied to the skin of the left or right volar forearm for 30 minutes. The capsaicin-induced neurogenic inflammation can be quantified by assessing the intensity, extent and duration of the capsaicin-induced cutaneous flare response using thermal infrared imaging. Using heat stimuli delivered to the treated skin and surrounding skin, the intensity and duration of the capsaicin-induced hyperalgesia will also be assessed. The experimental session will last approximately two hours.
45769781|NCT04019626|Other|Continue-smoking|Ad-libitum use of subjects' usual brand combustible cigarette
45769782|NCT04019626|Other|myblu Tobacco 2.5%|Ad-libitum use of myblu e-cigarette with Tobacco flavor 2.5% nicotine
45769783|NCT04019626|Other|myblu Tobacco 4.0%|Ad-libitum use of myblu e-cigarette with Tobacco flavor 4.0% nicotine
45769784|NCT04019626|Other|myblu Honeymoon 2.5%|Ad-libitum use of myblu e-cigarette with Honeymoon flavor 2.5% nicotine
45769785|NCT04019626|Other|myblu Honeymoon 4.0%|Ad-libitum use of myblu e-cigarette with Honeymoon flavor 4.0% nicotine
45769786|NCT04019626|Other|JUUL 5%|Ad-libitum use of JUUL 5% e-cigarette
45447567|NCT04052139|Drug|Placebo|In week 1, participants will take 1 placebo capsule once daily. In week 2, participants will take 1 placebo capsule three times per day. In weeks 3 through 7, 2 placebo capsules three times per day. In week 8, in days 1-4 participants will take 2 placebo capsules three times per day; in days 5-7, participants will take 1 placebo capsule three times per day. The placebo medications will be composed of lactose and will not contain active ingredients.
45769787|NCT01452464|Biological|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
45769788|NCT05490732|Biological|Blood sampling|"Patient will be subjected to 3 blood sampling over 24hours. At H0, H4 and H12-24.~For each one, one microsampling and one venipuncture"
45769789|NCT01452542|Drug|Eliglustat, common blend proposed commercial formulation|All participants will receive a single oral 150-mg dose of the common blend proposed commercial formulation of eliglustat, administered as one 150-mg strength capsule (Treatment T), on 2 separate dosing occasions.
45769790|NCT01452542|Drug|Eliglustat, Phase 3 capsule formulation|All participants will receive a single oral 150-mg dose of the Phase 3 capsule formulation of eliglustat, administered as three 50-mg strength capsules (Treatment R), on 2 separate dosing occasions.
45769791|NCT04157790|Other|CARE score|CARE score calculation
45769792|NCT01458548|Drug|Rituximab|Rituximab 375 mg/m2 IV on days 1, 8, 15 and 22.
45769793|NCT01458548|Drug|CHOP|Cyclophosphamide 750 mg/m2 IV, adriamycine 50 mg/m2 IV, vincristine 1.4mg/m2 IV, and prednisone 50mg/m2 PO every 3 weeks at days 50, 72, 94 and 116.
45769794|NCT04022668|Radiation|Coronary angiogram|Routine coronary angiogram, if indicated
45769795|NCT05027204|Drug|Docetaxel|Docetaxel for Injection (Albumin-bound), Q3W, i.v. 60 min
45769796|NCT05027204|Drug|Nivolumab|Nivolumab, Q3W, i.v. 30 min
45447568|NCT03745209|Device|Ultrasound|Use of real-time ultrasound in an attempt to establish intravenous peripheral catheter.
45630107|NCT05494983|Other|Central sensitization session|The extent of secondary mechanical hyperalgesia induced by high-frequency electrical stimulation (HFS) of the skin of the left or right volar forearm will be used as a measure of the susceptibility to develop central sensitization. The stimulation will be delivered using a multi-pin electrode designed to preferentially activate epidermal free nerve endings. The strength, spatial extent and duration of the HFS-induced changes in pinprick sensitivity will be characterized by using calibrated mechanical pinprick stimuli. The experimental session will last approximately one hour.
45630108|NCT05498805|Radiation|Radiation|According to the lesion sites, SBRT or hyperfractionated radiotherapy was used.
45630109|NCT05562921|Behavioral|Controls-ususal care|Controls: patients who did not receive remote patient monitoring for blood pressure prescribed during routine care delivery, with multivariable matching to cases
45769797|NCT04115514|Drug|Liothyronine Sodium (T3) (modified formulation)|Liothyronine Sodium (T3), 5-10-25-50µg instilled directly into the airways in a total volume of 10 ml (T3+0.9% sodium chloride). Progressive dosing every 24 hours for total 96 hours.
45769798|NCT01458626|Drug|mirtazapine|mirtazapine 30mg QD
45769799|NCT01458626|Drug|paroxetine 20mg QD|paroxetine 20mg QD
45630110|NCT05562921|Behavioral|Cases-remote patient monitoring prescribed|Cases: patients prescribed remote patient monitoring for blood pressure during routing care delivery
45630111|NCT05494905|Other|VR|In this project, the investigators focus on using our developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the child. It consists of the Microsoft Kinect camera, a laptop, software, and TV screen. The research team will loan the system to the family. While engaged with the game, the child is immersed in a virtual world where virtual objects appear on the screen surrounding the child. Children are asked to move their arms to 'pop' as many virtual objects as possible in a certain amount of time. Playstation 2 EyeToy and EyeToy 2 games will also be used to increase children's motivation by playing a variety of different VR games.
45630112|NCT05494905|Other|FST|FST involves repetitive progressive resistance exercise during goal-directed functional activity with the children focus on the activity being performed. Children will be offered a pamphlet containing suggested functional arm exercises and these exercises are designed to move the more affected arm in overhead, outward, and across midline directions. Each exercise will be embedded in a game-like activity. Children will start with no resistance and gradually add on resistance using elastic bands or weight cuffs.
45630113|NCT05494827|Other|Regular consumption of natural mineral water Borjomi® with high bicarbonate content|"Natural mineral water Borjomi® is a transparent mineral water with specific alkaline taste and smell. The chemical composition includes sodium hydrocarbonate (HCO2-) 3995 mg/l (3500-5000 mg/l), chlorides (Cl-) 360 mg/l (250-500 mg/l), and nitrites (NO2-) <0.005 mg/l (up to 1 mg/l). The Borjomi water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. The day before testing, participants were asked to abstain from their routine training and other physical activities."
45630114|NCT05494827|Other|Regular consumption of processed drinking water Smart Spring®|Processed drinking water Smart Spring® has no colour and smell with delicate specific taste. The chemical composition includes sodium (Na+) 33.6 mg/l, magnesium (Mg2+) 10.03 mg/l, calcium (Ca2+) 34.57 mg/l, chlorides (Cl-) 69.79 mg/l, sulfates (SO42-) 22.00 mg/l, and hydrocarbonates (HCO2-) 96.48 mg/l. The Smart Spring® water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. The day before testing, participants were asked to abstain from their routine training and other physical activities.
45630115|NCT05494827|Other|Regular consumption of still drinking water|Still drinking water Святой Источник®is a standard steal drinking water, that has no colour, taste, and smell. The Святой Источник® water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. Participants were asked to abstain from mineral water consumption for the entire observation period.
45630116|NCT05562843|Biological|Autologous Cellular Therapy with PRP-PC|In this study, cells will be harvested from the patient from the peripheral blood, isolated and concentrated using centrifugation, then returned to the patient same day via the peripheral circulation.
45630117|NCT05562765|Other|Survey|A descriptive characteristics form, the General Comfort Scale and Quality of Life Index Cardiac Version-IV was used to collect data.
45630118|NCT04311723|Procedure|Anesthesia Procedure|Receive anesthesia using laryngeal mask
45630119|NCT04311723|Procedure|Anesthesia Procedure|Receive anesthesia using endotracheal tube
45630120|NCT04311723|Procedure|Bronchoscopy|Undergo standard of care bronchoscopy
45769800|NCT00377806|Drug|Diclofenac gel|
45769801|NCT02886650|Procedure|Thermocoagulation|Thermocoagulation During pre-surgical Invasive EEG Monitoring
45769802|NCT03725098|Device|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
45769803|NCT03725098|Device|FLOSEAL|The FLOSEAL Matrix consists of a bovine-derived Gelatin Matrix component, a human-derived Thrombin component, applicator tips, and several mixing accessories. FLOSEAL is indicated in surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.
45447569|NCT03737097|Other|Online Spaced Education|Investigators created a set of fall prevention strategies for multiple sclerosis patients into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), spaced education has been shown in randomized trials to improve knowledge acquisition, boosts learning retention for up to two years, and durably improves changes in behavior.
45769804|NCT04281030|Behavioral|PMR (Progressive muscle relaxation therapy)|Technique for learning to monitor and control the state of muscular tension. The relaxation therapy should take about 20 minutes a day.
45769805|NCT04281030|Behavioral|Monitored Usual Care (MUC)|General Education Session consisting of basic migraine information of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
45769806|NCT04179708|Other|Pain Neuroscience Education|"Intervention description Patients participate in a back school program including initial and final assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hours of educative initial assessment and ½ hour of educative final assessment.~The content of Pain Neuroscience Education (experimental group) focuses on deconstruction of patho-anatomical and biomechanical believes, and the explanation of pain from the biology. This framework allows the introduction of coping strategies (eg gradual exposure to exercise, activity and physical activity) and regulation strategy (eg fragmentation of activity, stress management, and so on)."
45769807|NCT04179708|Other|Conventional education|"assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hour of educative initial assessment and ½ hour of educative final assessment.~The content of conventional education (control grou) focuses on patho-anatomical and biomechanical notions. This framework allows the introduction of protection strategies (eg education on good posture, good handling techniques, physical activity and therapeutic exercise in stretch and strenghten the spine in order to protect it)."
45769808|NCT04111276|Device|Breg Osteoarthritis Brace gait fluoroscopy|Gait under fluoroscopy surveillance with brace
45769809|NCT04111276|Other|Gait fluoroscopy without brace|Gait under fluoroscopy surveillance without brace
45630121|NCT04424433|Drug|Oxygen|Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
45630122|NCT05494515|Procedure|the early swallowing rehabilitation program|the early swallowing rehabilitation program based on the HRIM evaluation
45630123|NCT05561985|Drug|Itacitinib|
45630124|NCT05494359|Diagnostic Test|The nitrogen isotope|The nitrogen isotope of various mass in oral gas were detected.
45769810|NCT04111276|Diagnostic Test|JointVue ultrasound|JointVue ultrasound procedure to reconstruct 3D femoral and tibial bones
45769811|NCT04111276|Diagnostic Test|Computer Tomography|Computer Tomography scan limited to the study knee and will image 6 inches distal on the tibia and 6 inches proximal on the femur
45630125|NCT05498337|Other|calcium hydroxide|Dental pulp medicament material
45630126|NCT05498337|Other|MTA|Dental pulp medicament material
45630127|NCT05498337|Device|Diode Laser|Device used in pulp therapy
46069937|NCT04254614|Device|Personalised mobile application for IBD patients|"Patients will use a mobile application for ±6months (exact period depends on interval of biologic treatment) with the following functionalities:~Personal interactive timeline to prepare for biologic treatment with reminders for blood tests, a questionnaire to exclude contra-indications for biologic treatment (e.g. current infection) and a message from the gastroenterology nurse when blood tests results and the questionnaire have been checked. Only in case of abnormal results or answers patients will be contacted by telephone by their gastroenterology nurse, which is currently standard care.~Information about the patients' diagnosis and biologic treatment.~General information on e.g. IBD treatment, vaccinations, frequently used medical terms, preparing for outpatient visits, what to do in case of disease symptoms.~Patients will fill in a questionnaire to measure study outcomes at baseline and at the end of the study period."
45630128|NCT04424667|Other|donor milk|pasteurized donor milk
45630129|NCT01663233|Drug|LCZ696|LCZ696 will use tablets available at a strength of 200mg. Patients will be instructed to take the prescribed medication once a day.
45630130|NCT01663233|Drug|Amlodipine|Amlodipine will use tablets available at a strength of 5 mg. Patients will be instructed to take the prescribed medication once a day.
45630131|NCT01663233|Drug|Placebo|Matching placebo to LCZ696
45630132|NCT04064151|Behavioral|My Guide|12-week long health promotion Smartphone application
45630133|NCT04046055|Device|Transcranial direct current stimulation at 2 mA|Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
45630134|NCT04046055|Device|Transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
45630135|NCT04046055|Device|Sham transcranial direct current stimulation|Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
45630136|NCT05494281|Procedure|Serratus Anterior Plane Block with local anesthetic|"A deep analgesic block of the Serratus anterior plane block (SAPB) type by echo-guided lateral approach will be performed by An 8-13 Mhz high frequency linear ultrasound probe witch will be located cranio-caudally, transversely to the 3rd and 4th intercostal space on the mid-axillary line while patients are supine with the ipsilateral upper limb raised to 90°.~Once the landmark anatomical structures have been identified (upper rib, lower rib, pleural line, Serratus muscle, superficial structures), the puncture will begin Under aseptic conditions, an 80 mm 22 gauge needle will be inserted into the in-plane view of the ultrasound probe. When the needle has reached the plane under Serratus between the Serratus muscle and the intercostal muscle opposite the lower edge of the upper rib, 30 ml of 1% Lidocaine will be administered."
45769812|NCT05495724|Drug|Disitamab Vedotin Tislelizumab|Disitamab Vedotin 120mg will be administered on Day 1 of each cycle for 4 treatment cycles;Tislelizumab 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
45630137|NCT05494281|Procedure|Serratus Anterior Plane Block with saline solution|"A deep analgesic block of the Serratus anterior plane block (SAPB) type by echo-guided lateral approach will be performed by An 8-13 Mhz high frequency linear ultrasound probe witch will be located cranio-caudally, transversely to the 3rd and 4th intercostal space on the mid-axillary line while patients are supine with the ipsilateral upper limb raised to 90°.~Once the landmark anatomical structures have been identified (upper rib, lower rib, pleural line, Serratus muscle, superficial structures), the puncture will begin Under aseptic conditions, an 80 mm 22 gauge needle will be inserted into the in-plane view of the ultrasound probe. When the needle has reached the plane under Serratus between the Serratus muscle and the intercostal muscle opposite the lower edge of the upper rib, 30 ml of saline solution"
45630138|NCT05494203|Diagnostic Test|questionnaire survey|All patients received lifestyle questionnaire, medical history, physical signs, auxiliary examination and laboratory examination results before treatment.
45630139|NCT05486091|Behavioral|App-Enhanced Brief Cognitive-Behavioral Therapy|BCBT is a cognitive-behavioral intervention designed to target core skills deficits among suicidal individuals. App-enhanced BCBT incorporates the use of a SmartPhone app during the therapy sessions.
45630140|NCT05494047|Drug|Tetravalent influenza vaccine developed by Sinovac Biotech Co.|15μg Hemagglutinin Antigen (HA) of each of the four strains
45630141|NCT05493969|Drug|Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)|Subjects will discontinue their TDF + 3TC/FTC-based regimen and will switch to DTG+3TC or fixed dose combination DTG/3TC.
45630142|NCT05491629|Other|type of parallel data in a convergent parallel hash pattern (near time)|"The quantitative part of the study is a descriptive study with the Perceived Perioperative Competence Scale-Revised to determine the perceptions of operating room nurses about their competencies.~It is a case study in order to reveal the opinions of the surgical team members about the competencies of the operating room nurses and the affecting factors through individual in-depth interviews and to better explain the current situation at the qualitative stage, which is carried out simultaneously."
45630143|NCT05491473|Device|Closed incisional negative pressure wound therapy (iNPWT) system|The closed incisional negative pressure wound therapy (iNPWT) system (PREVENA Incision Management System, KCI, an Acelity company, San Antonio, Texas, USA)
45630144|NCT05493813|Behavioral|Cognitive function and delirium evaluation|Cognitive functions (including delirium) will be assessed pre-procedure (baseline) and emergency department (before EVT), on day 1 and 7 and 3 months after EVT procedure
45630145|NCT05493813|Behavioral|Neurological functional assessment|National Institute of Health Stroke Scale (NIHSS) and modified Rankin scale (mRS) will be assessed before (baseline but after stroke) and after EVT on days 1 and 7 after procedure up to 3 months follow-up.
45630146|NCT05491395|Radiation|Hypofractionation|Hypofractionation scheme will comprise 40 Gy in 15 fractions
45630147|NCT05493657|Drug|Aspirin single antiplatelet therapy|Patients receive the aspirin (100 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
45630148|NCT05493657|Drug|Clopidogrel single antiplatelet therapy|Patients receive the clopidogrel (75 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
45630149|NCT05485623|Device|PulseNmore FC|"Pulsenmore Ltd. has developed a small portable vaginal ultrasound device for personal use at home. The ultrasound device allows to scan and assess both the uterus and the ovaries. This ultrasound device connects to a smartphone and a user-friendly application simplifies its use. This ultrasound device is based on the company's 'Pulsenmore ES ultrasound system' which is a small abdominal ultrasound device for home and self-use by pregnant women. This (abdominal) ultrasound device allows scanning and detection of fetal pulse, count fetal movements, assess the amount of amniotic fluid and more. The device is an abdominal ultrasound probe that connects to a smartphone using a specially designed socket. The main difference between the devices is the different design of the ultrasound vaginal probe.~The device consists of 2 components: a cradle and an application (software). The cradle contains the electronic components and the ultrasound probe."
45630150|NCT05493579|Other|Implant supported overdenture|Implant supported overdenture compared to complete denture
45630151|NCT05491239|Procedure|Thoracic epidural analgesia|After correct placement of the epidural catheter, a local anaesthetic (ropivacaine, levobupivacaine or bupivacaine) will be started and, according to in house protocols, an opioid will be added to the epidural solution. A provisional stop of the administration of the epidural infusion is planned after 48 hours (on the second postoperative day).
45630152|NCT05491239|Procedure|Continuous regional paravertebral block|"The PVB catheter is placed under general anaesthesia at the beginning of the VATS procedure under direct thoracoscopic vision. The level of the PVB catheter placement is chosen at the intercostal space of the largest incision (mostly thoracic level 4 or 5). Under direct thoracoscopic vision, the surgeon inserts a Touhy needle. The tip of the needle is observed beneath the pleural surface thoracoscopically. Injection of about 2 mL ropivacaine 7.5mg/mL will create subpleural hydrodissection to reach the adequate paravertebral plane for placement of the catheter. The PVB catheter is subsequently placed under direct thoracoscopic vision and left next to the sympathetic chain in the paravertebral space. Next, a bolus of ropivacaine (total amount 20 mL including the given amount for hydrodissection) is given through the catheter.~Postoperatively, a ropivacaine 2 mg/mL pump for continuous infusion is given with an infusion rate of 8-14 ml/hour."
45630153|NCT05491239|Procedure|Single shot intercostal nerve block|At the end of the surgery a single shot ICNB will be placed at 9 levels (thoracic level 2 to 10) with 2-3mL local anaesthetics per intercostal space under direct thoracoscopic vision. The injection site will be chosen just lateral from the sympathetic trunk. This group will have no analgesic catheters for continuous analgesia. No mobility restrictions are instructed in this group.
45769813|NCT05495724|Drug|Disitamab Vedotin|Disitamab Vedotin
45769814|NCT02559414|Drug|Aspirin|
45769815|NCT02559414|Drug|Clopidogrel|
45769816|NCT03527264|Drug|Nivolumab induction|2 doses Nivolumab 240mg IV
45630154|NCT05493423|Device|V Needle AV Fistula Set|Hemotek Medical Inc. has developed the V Needle, a new AV fistula set for hemodialysis designed to reduce patient risk from exsanguination-related injury or death during therapy. In the event of complete dislodgement of the V Needle from the arm during use, the V Needle is designed to activate, creating high line pressure designed to generate an automated dialysis machine blood pump shut down.
45630155|NCT05485545|Other|Electrophysiological exploration of the right ventricle|"CARTO electrophysiological mapping system~3D echocardiography~High Resolution MRI"
45630156|NCT05485467|Diagnostic Test|coronary CT angiography|Coronary CT angiography will be performed on multislice Siemens Somat Force CT scanner
45630157|NCT05491005|Behavioral|Total diet replacement|Total diet replacement (850 kcal/day) for 3 months followed by weight maintenance for 21 months.
45630158|NCT05491005|Behavioral|eHealth|All follow-up through an eHealth application and video meetings.
45630159|NCT05491005|Behavioral|Face-to-face|All follow-up through face-to-face meetings.
45630160|NCT05485389|Other|simulation based learning|An educational methodology that aims to improve participants' attitudes towards the elderly and their perception of individualized care.
45630161|NCT05493345|Behavioral|Bridge-building between municipality-based lifestyle programs and community-based physical activities|Four co-created bridge-building activities has been implemented in the municipality of Odsherred, including (1) A digital portal for information and sharing of knowledge, (2) Visits between municipal rehabilitation programs and community-based physical activities, (3) Co-created teams for the target group, and (4) a 'Bridge builder' coordinator.
45630162|NCT04277091|Other|High-intensity interval training|Arm-cranking exercise
45630163|NCT04277091|Other|Moderate-intensity continuos training|Arm-cranking exercise
45630164|NCT05493267|Drug|Vγ2Vδ2 T lymphocyte-based immunotherapy|Intravenous injection of zoledronic acid, followed by a subcutaneous injection recombinant human interleukin. Zoledronic acid was administered 3 times and recombinant human interleukin was administered 10 times for a total of 6 months.
45630165|NCT05493267|Drug|Treatment regimens for MDR-TB|Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.
45630166|NCT04180449|Other|Screening for dysphagia along clinical routine|Screening for dysphagia using the water swallow test in intermediate care unit patients
45630167|NCT04239261|Dietary Supplement|SBI|Serum-derived Bovine immunoglobulin/protein isolate 10.0 g once daily
45630168|NCT04239261|Dietary Supplement|Placebo|Hydrolyzed gelatin 10.0 g once daily
45630169|NCT05485311|Other|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
45630170|NCT02556255|Device|B-Laser™ Atherectomy Catheter|Laser atherectomy catheter based on 355 nm
45630171|NCT05493033|Procedure|Intracorporeal anastomotic after LRC|Complete laparoscopic dissection of the mesocolon is mandatory. D2 or D3/CME is optional. And the extent of colon resection is based on the location of the tumor while the ileocecal resection is excluded. After fully mobilization of the colon and mesentery, the terminal ileum and transverse colon will be transected by a laparoscopic linear stapler. The side-to-side anastomosis is performed laparoscopically. The enterotomy is closed by a double-layer suture. All the anastomotic procedures are completed laparoscopically. The specimen is then removed through a Pfannenstiel incision within a specimen bag.
45630172|NCT05493033|Procedure|Extracorporeal anastomotic after LRC|The procedures of the mobilization and vessel ligation are similar. After that, the mobilized colon and terminal ileum are brought out through the upper mid-line incision with the wound protector. The colon and terminal ileum are similarly dissected distally to the specimen with a stapling device. The side-to-side anastomosis is completed and the anastomotic site is reinforced. The anastomotic bowel is returned to the abdominal cavity.
45630173|NCT03994029|Dietary Supplement|Effect of polyphenols on hepatic steatosis and vascular elastography and intima media thickness|Measurement of effect of polyphenol supplementation vs placebo on hepatic steatosis and vascular elastography and intima media thickness
45769817|NCT03527264|Drug|Cisplatin|40 mg/m2 of cisplatin: Dosing on Days: 1, 8, 15, 22, 29, 36 beginning on day 1 of radiation therapy.
45769818|NCT03527264|Radiation|Radiation|"Total dose of 45 Gy in 25 fractions at 180 cGy/fx~Whole pelvic or extended field"
45769819|NCT03527264|Drug|Nivolumab with chemoradiation|Nivolumab 240mg IV every 14 days (+/- 3 days) for 3 doses, administered concomitantly during chemoradiation and beginning day 1 of Radiation.
45769820|NCT03527264|Drug|Nivolumab maintenance|Nivolumab 480 mg IV every 4 weeks for 2 years
45769821|NCT04160260|Drug|Omadacycline|Omadacycline: PO Tablets
45769822|NCT05490654|Procedure|Abdominal Massage|Abdominal Massage delivered by manual method or by Mowoot device
46069938|NCT05263154|Other|Goal directed low oxygen|Oxygen is titrated until oxygen saturation is 100% in one-minute steps before the induction of anesthesia, with increasing fraction of inspired oxygen (FiO2) from 0.25 to 0.30 to 0.35 and so on. After intubation, the FiO2 is set to 0.25 to achieve a target saturation of 94-96%. Supplementary oxygen after surgery will be given with the same targets and with as little oxygen as necessary.
45769823|NCT04713904|Drug|Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Test Product Coated Tablets|Investigational Medicinal Product
45769824|NCT04713904|Drug|Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Reference Product Coated Tablets|Evafem 20 (Trademark)
45769825|NCT04081818|Other|Nutritious Mushrooms|The Intervention group will consume antioxidant rich and Vitamin D2-enhanced mushrooms as a snack daily for 3 months.
45769826|NCT01458704|Other|next generation sequencing|next generation sequencing (including targeted gene sequencing, exome sequencing, transcriptome sequenicing)
45769827|NCT03995680|Drug|Mebendazole|Treatment with one of the two formulations of mebendazole. The only difference between both arms is the type of formulation of the drug: chewable versus swallowable tablet.
45769828|NCT01452698|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
45769829|NCT01452698|Drug|Placebo|"Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks."
45630174|NCT05485233|Device|REDSCAR App|"Patients will be discharged after surgery at the time it is considered by the responsible physician. Prior to discharge, patients taking part in the study will follow the same protocol as any other patient treated in our institution. Written consent will be signed after complete explanation of the study protocol by the researcher at this moment. The patient will download the RedScar© application and the researcher will explain how it works and how to answer all the questions about the wound (redness, pain).~At day 3th and 10th after surgery, each patient will upload an image of the surgical wound via RedScar© aplication using their own smartphone device. RedScar© aplication will evaluate the risk of complications of the surgical wound and will assign patients to 2 different groups: potential complications requiring new consultation or satisfactory evolution and discharge."
45769830|NCT01452698|Drug|Lansoprazole|"Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks."
45630175|NCT05490849|Drug|68Ga-HX01|"For pharmacokinetics, healthy volunteer underwent 68Ga-HX01 PET imaging. Blood samples were collected at 25 min, 55 min, and 115 min after imaging agent injection, and urine specimens were collected at 28 min, 58 min, and 118 min after injection to measure radioactivity in blood and urine. PET/MR scans were performed at 30-50 min, 60-80 min, and 120-140 min after injection to understand absorption, distribution, and metabolism.~Cancer patients,~Subjects should have 68Ga-HX01 and 18F-FDG PET scans two days apart.~Blood tests, liver and kidney function, tumor markers (CA125, CA199, CEA, etc.), and other biochemical markers must be performed one week prior to and after imaging.~Tumor biopsies or surgical specimens should be evaluated histopathologically and immunostained for biomarkers associated with angiogenesis."
45630176|NCT05492721|Device|2-Octylcyanoacrylate|Incisions on left will have one glue and on right will have the other glue
45630177|NCT05492721|Device|N-butyl-2-cyanoacrylate|Incisions on left will have one glue and on right will have the other glue
45630178|NCT05492565|Drug|Tenofovir Disoproxil Fumarate 300 MG Oral Tablet|Pre-exposure prophylaxis with coformulated Tenofovir Disoproxil Fumarate 300mg/Emtricitabine 200mg oral QD to prevent HIV infection
45769831|NCT01452698|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
45769832|NCT04033926|Drug|KZR-616|Subcutaneous 30 mg weekly for 2 weeks, then 45 mg weekly for 14 weeks
45769833|NCT04033926|Drug|Placebo|Subcutaneous injection for 16 weeks
45630179|NCT05492487|Drug|Mirena|Mirena Intrauterine System (Mirena-IUS) is a levonorgestrel-releasing intrauterine system. Mirena consists of a T-shaped polyethylene frame (T-body) with a steroid reservoir (hormone elastomer core) around the vertical stem. The reservoir consists of a white or almost white cylinder, made of a mixture of levonorgestrel and silicone (polydimethylsiloxane), containing a total of 52 mg levonorgestrel. Mirena is approved for intrauterine contraception and in 2009 to treat heavy periods for women who choose intrauterine contraception. Mirena is often used off-label for the treatment of endometrial hyperplasia. Levonorgestrel is a progestogen used in a variety of contraceptive products. Low doses of levonorgestrel can be administered into the uterine cavity with the Mirena intrauterine delivery system. Mirena has mainly local progestogenic effects in the uterine cavity.
45769834|NCT05490576|Radiation|[18F] PI-2620 Tau Ligand|Tau binding ligand
45769835|NCT04005586|Device|Light Delivery Device (LDD)|Study eye will undergo Light delivery Device treatments
45769836|NCT04024956|Device|Sealing Device|The Sealing Device is indicated for use in hepato-pancreato-biliary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site.
45769837|NCT01452776|Drug|TAK-438|TAK-438 10 mg, tablets, orally, once daily for up to 52 weeks.
45769838|NCT01452776|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 52 weeks.
45769839|NCT03990298|Diagnostic Test|Awake endoscopy|Awake endoscopic exam will be performed to measure airway size in the retropalatal and retroglossal upper airway regions using different Inspire implant configurations and voltages. The optimal test configuration determined on endoscopy will be tested during a sleep study and compared to the standard-of-care device configuration, with improvements in sleep study outcomes indicating that awake endoscopy is useful during Inspire implant activation.
45769840|NCT03985878|Drug|Eteplirsen|Eteplirsen IV infusion once weekly.
45769841|NCT05029856|Biological|SII B.1.351|"Intramuscular (deltoid) injections of 3 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21."
45769842|NCT05029856|Biological|SII B.1.351|"Intramuscular (deltoid) injections of 5 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21."
45769843|NCT05029856|Biological|SII Bivalent|Intramuscular (deltoid) injections of 6 μg SII Bivalent and 50 μg Matrix-M1 Adjuvant, 2 doses: 1 on Day 0 and 1 on Day 21.
45769844|NCT05029856|Biological|SII Bivalent|Intramuscular (deltoid) injections of 10 μg SII Bivalent and 50 μg Matrix-M1 Adjuvant, 2 doses: 1 on Day 0 and 1 on Day 21.
45769845|NCT05029856|Biological|SII B.1.617.2|"Intramuscular (deltoid) injections of 5 μg SII B.1.617.2 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21."
45769846|NCT05490498|Other|Collection of breast milk|Collection of breast milk through a sterilized breastfeeding device. Once the collection is completed, the milk will be transferred to a sterile jar provided in a dedicated survey package for transport to the laboratory.
45769847|NCT03505372|Device|Contrast enhanced mammography|Contrast enhanced mammography is a new type of mammogram that uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone.
45913324|NCT02021084|Dietary Supplement|probiotic|Probiotics group - patients will received probiotics Bio -25 including 11 types of bacteria total of 25 billion germs in each capsule, patients will received one capsule a day for 3 month.
45913325|NCT02021084|Dietary Supplement|Placebo|Placebo group - patients will received placebo patients will received one capsule a day for 3 month.
45913326|NCT02021097|Drug|Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg|Tablet, orally, opd
45913327|NCT02021097|Drug|Levonorgestrel 150 mcg and Ethinyl Estradiol 30 mcg|Tablet, orally, opd
45769848|NCT02883140|Other|Three-dimensional sialography CBCT and MRI sialography|"MRI sialography: Achieved on a 3 Tesla MRI (INGENA 3T Philips Medical Systems). Patient supine positioned. Sialo-MR sequences (3D T2 DRIVE, TSE, SENSE and SPIR) and conventional sequences (T2 turbo spin echo).~3D CBCT sialography: Achieved same day as the MRI sialography, after acute episode subsided. 0.5ml of high concentration, water-soluble, iodinated contrast product (HEXABRIX 320®, 320g /L, Guerbet, France) is injected in the symptomatic salivary gland and maintained in the gland. Image acquisition performed on a wide-field CBCT device (NewTom VGi, QR, Verona, Italy). Front and profile scout views achieved. mA and exposure time modulated according to scout views. Reconstruction in Maximal Intensity Projection, 3-dimensional and MultiPlanar Reconstructions sections"
45769849|NCT05495412|Other|Rebound therapy|Exercise therapy delivered twice weekly for 6 weeks, during Phase B of an ABA single case study design.
45769850|NCT03429712|Device|Dual-source multi-detector computed tomography (DSSE)|Dose split technique in a cohort of pediatric patients to determine, without increase in patient radiation dose, the optimal patient-specific and task-specific radiation dose levels for pediatric cardiothoracic and abdominal CT applications.
45630180|NCT05492487|Drug|Megace|Megestrol acetate (Megace) is a synthetic derivative of the natural occurring steroid hormone, progesterone. It is licensed for the treatment of anorexia, cachexia or unexplained weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS) and palliative treatment of advanced breast or endometrial cancer. Megace is often used off-label for the treatment of endometrial hyperplasia. While the precise mechanism by which Megace produces its antineoplastic effects against endometrial carcinoma and endometrial hyperplasia is unknown at the present time, inhibition of pituitary gonadotrophin production and resultant decrease in estrogen secretion may be factors. There is evidence to suggest a local effect as a result of the marked changes brought about by the direct instillation of progestational agents into the endometrial cavity.
45630181|NCT02556801|Biological|SUBLIVAC FIX Phleum Prat.|sublingual daily administration
45769851|NCT02881970|Drug|autologous cord blood stem cell|Injection of 5.107 / kg autologous mononuclear cells from umbilical cord blood
45630182|NCT02556177|Procedure|MRI|MRI scanning
45630183|NCT05492019|Drug|Doxycycline|Doxycycline 50 mg capsule twice daily for 8 weeks.
45630184|NCT05492019|Drug|Placebo|Oral placebo identical to Doxycycline
45630185|NCT05484843|Behavioral|telenursing training based on self-care theory|"A training guide based on the self-care theory specific to individuals diagnosed with stroke was prepared.~Identification of the study/control group (randomization)~Patients were informed and consents were obtained.~Sample suitability was evaluated in line with the cognitive levels and inclusion criteria of patients diagnosed with stroke.~All patients included in the sample group were pre-tested before discharge.~Training was offered for the study group patients in line with the guide prepared based on self-care theory.~Tele-nursing training was applied to the study group patients.~Control group patients were followed up~Post-tests were administered at the end of the 12-week period~The training of the control group patients was completed~Your data has been evaluated"
45630186|NCT05484843|Behavioral|just observation|For 3 months, patients were observed without intervention. The standard discharge training of the clinic was given.
45769852|NCT05490420|Other|manual lymphatic drainage (MLD)|MLD is a manual technique that is applied to the lymphatic system with a pressure of approximately 40-50mmHg and increases the working speed of lymphatic nodules/collectors. Its main purpose is to support microcirculation by accelerating lymphatic flow and to prevent/remove interstitial fluid accumulation that may cause fascial adhesions.
45769853|NCT03950310|Device|Excimer laser catheter|The excimer laser catheter is equipped with multiple optical fibers on the periphery of the guide wire lumen corresponding to 0.014 inch, which is used for the purpose of reperfusion of barrier site of coronary artery. The connector on the front side is connected with the CVX-300 laser generator, and the tip at the top contact directly with the lesion. The laser catheter consisting of multiple optical fibers transmits the energy in the ultraviolet region from the CVX300 laser generator to the blockage in the blood vessel. The ultraviolet energy is transmitted from the tip of laser catheter, transpires the fibrous, calcified and arteriosclerotic lesion by light, and enables reperfusion in the lesion. The laser catheter has appropriate hydrophilic coating and easily follows the inside of coronary artery.
45769854|NCT05314348|Device|High-density surface EMG|High-density surface EMG for fasciculation detection
45769855|NCT05314348|Device|Ultrasound|Ultrasound for fasciculation detection
45769856|NCT04424628|Radiation|Low dose radiotherapy A|Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is randomized to 3 or 6 Gy again
45769857|NCT04424628|Radiation|Low dose radiotherapy B|Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is treated with 6 Gy again
45769858|NCT01452932|Other|Physiotherapy|"The physiotherapeutic intervention was based on the Kabat (PNF) technique. Thirty-three sessions were planed. Each session lasted between thirty and fifty minutes.~The experimental group was guided by a physiotherapist or a physiotherapy student and each session took place in a hospital auditorium provided with oxygen cylinders, chairs and water.~Each session consisted of a warm up and stretch period, a period of resistance training of the upper limbs with their rest periods in which diaphragmatic breathing exercises and finally a cooling period.~The instructions and instruments given to each participant such as weights and elastic bands were the same for all of them."
45769859|NCT01452932|Other|Yoga|"The intervention for the other group was the Yoga technique. Thirty-six sessions were planed. Each session was based on breathing, relaxation, and stretching exercises. Each session lasted between thirthy and forty minutes.~The group was led by a Yoga Instructor and each sessions took place in a hospital auditorium provided by oxygen cylinders, chairs and water.~No instruments were needed for this intervention."
45769860|NCT00377416|Genetic|rAAV2-CB-hAAT Gene Vector|Participants will attend a 5-day inpatient visit, during which they will receive a series of injections consisting of one of four different doses of rAAV2-CB-hAAT.
45769861|NCT01458938|Other|treatment plan|Data Collection Study
45769862|NCT05490342|Diagnostic Test|Immunoassay, by ECLIA, for the quantitative in vitro determination of antibodies (including IgG) to the SARS - CoV - 2 spike protein (S) anti-RBD (receptor-binding domain) in serum and plasma samples.|Blood test to value the antibody response to vaccination
45913328|NCT02021110|Drug|Ursodeoxycholic Acid|The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
45769863|NCT03352882|Diagnostic Test|Ultrasound|Hepatic ultrasound using gray scale, color Doppler, and spectral Doppler imaging to evaluate hepatic vein and portal vein patency, direction and velocity of flow respectively. ARFI will be performed in the right hepatic lobe. Three measurements of stiffness (m/s) will be performed and the mean value recorded.
45630187|NCT05491941|Other|Sepsis Bundle|Intervention initiated within 1 hour or 3 hours of presentation depending on the Arm: 1. Measure lactate level. 2. Obtain blood cultures before administering antibiotics. 3. Administer broad-spectrum antibiotics. 4. Begin rapid administration of 30ml/kg crystalloid for hypotension or lactate greater than or equal to 4mmol/L. 5. Apply vasopressor if hypotensive during or after fluid resuscitation to maintain a mean arterial pressure greater than or equal to 65 mm Hg.
45630188|NCT05491863|Other|conservative physiotherapy plan|Physiotherapy plan consist of following exercises, Postural and Proprioceptive facilitation like weight-bearing actions for the upper and lower extremities. Sit to stand, standing , holding on to stand, free arms standing up, holding on standing and asked the patient to lift one leg, one leg standing, standing on balance board,Straight and sideways parallel bar walk, For the effected body side jumping on stable and dynamic surface,Upstairs and down stair activity performed on staircase.This program was given for 40 minutes with a rest period of 2 minutes between each group of exercises, 4 days a week for 8 weeks (32 sessions)
45630189|NCT05491863|Other|trunk stability exercise plan|"trunk stability exercise plan consist of three levels, Proprioception included supine abdominal draw was performed in 1st simple level ,3 sets per 20 repetitions were performed, A double knee to chest abdominal draw was performed with 3 sets per 20 repetition, Supine twist with 3 sets per 20 repetitions was performed.Balance training included pelvic bridging was 2nd complicated level performed with 3 sets per 4-6 repetitions,Twists with a medicine ball were performed with 3 sets per 10-20 repetitions.~for Stability Bridging with head lied on physio ball was performed in 3rd difficult level when holding the position for 4 to 6 seconds, then relaxed slowly for same time with 3 sets per 10 to 20 repetitions, Prone bridging was performed with 3 sets per 4 to 6 repetitions.~There was a 30 seconds to 1 minute break between the sets.This program was given for 1 hour with a rest period of 2 minutes between each group of exercises, 4 days a week for 8 weeks (32 sessions)"
46069939|NCT05263154|Other|High oxygen|FiO2 1.0 before induction until end-tidal oxygen concentrations of 0.80 occur. The FiO2 will be reduced to 0.35 during anesthesia, followed by an increase in FiO2 to 0.80 during 5 minutes before extubating the patient, followed by FiO2 0.40 for at least thirty minutes after anesthesia. Oxgen will then be given at 3 liters a minute with a oxygen saturation goal of 98%
45630190|NCT05491785|Drug|Cebranopadol 600 µg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, 3 cebranopadol 200 µg tablets and 2 cebranopadol placebo tablets
45630191|NCT05491785|Drug|Cebranopadol 800 µg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, 4 cebranopadol 200 µg tablets and 1 cebranopadol placebo tablet
45630192|NCT05491785|Drug|Cebranopadol 1000 µg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, and 5 cebranopadol 200 µg tablets
45630193|NCT05491785|Drug|Oxycodone 30 mg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone 10 mg capsules, and 5 cebranopadol placebo tablets
45630194|NCT05491785|Drug|Oxycodone 60 mg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone 20 mg capsules, and 5 cebranopadol placebo tablets
45630195|NCT05491785|Drug|Placebo|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, and 5 cebranopadol placebo tablets
45769864|NCT01459094|Drug|A (CANA/MET IR FDC tablet - fasting state) / B (CANA/MET IR FDC tablet - fed state)|Treatment A: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally (by mouth) in a fasting state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 2.
45769865|NCT01459094|Drug|B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state)|Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fasting state on Day 1 of Treatment Period 2.
45769866|NCT05495100|Drug|Mitoxantrone liposome、Chidamide、Azacitidine|Mitoxantrone liposome 20mg/m2, d1; Chidamide 20mg, biw; Azacitidine 100mg, d1~7; Every 4 weeks is a cycle, with a maximum of 4 cycles of treatment.
45769867|NCT03325114|Drug|Chlorthalidone|Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks
45630196|NCT05490147|Procedure|conventional tidal volume (tidal volume [ml]= ideal body weight [kg]* 10~12) group|In the conventional tidal volume group, patients are ventilated with a tidal volume [ml]= ideal body weight [kg]* 10~12.
45630197|NCT05490147|Procedure|low tidal (tidal volume [ml]= ideal body weight [kg] * 6~8) volume|In the low tidal volume group, patients are ventilated with a tidal volume [ml]= ideal body weight [kg]* 6~8.
45630198|NCT05484687|Drug|Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation|Administer 1.5 mg/kg lidocaine
45630199|NCT05484609|Other|OUD scenario|The patient actor will make unannounced phone calls to family physicians asking for a new patient appointment. The patient actor will play the role of a patient with opioid use disorder undergoing methadone treatment with an addiction physician.
45630200|NCT05484609|Other|Diabetes scenario|The patient actor will make unannounced phone calls to family physicians asking for a new patient appointment. The patient actor will play the role of patient with diabetes in treatment with an endocrinologist.
45630201|NCT03889197|Drug|Sodium supplementation guided by urine sodium concentration algorithm|4 mEq/kg/d sodium added the first time urine [Na] below threshold; for each subsequent time urine [Na] below threshold, add additional 2 mEq/kg/d.
45630202|NCT04424589|Other|Myofascial release|Myofascial release or induction (IMF) is a widely used manual therapy treatment involving specifically guided, low-load, long-lasting mechanical forces to manipulate the myofascial complex, aimed at restoring optimal length, decreasing pain, and improving function. The experimental group will receive 1 examination session and 6 myofascial induction sessions carried out by a physiotherapist specialized in orthopedic manual therapy, superficial and deep techniques will be applied in the cervical region, for spinal at the level of the lumbar square, sacroiliac region and upper trapezius. 2 sessions per week over the course of 3 weeks.
45630203|NCT04424589|Other|Sham therapy|The control group will receive 1 examination session and 6 simulated myofascial induction sessions, where a physiotherapist will apparently apply the same techniques and maneuvers of myofascial induction, however, they will not follow the basic principles of technique execution, which does a procedure with a placebo effect.
45630204|NCT03873207|Device|PopSole™ offloading device|Offload Device Distribution to remain in use at all times during ambulation and activity instruction to stay off of feet as much as possible for 3 days, then limit ambulation to 10 minutes per hour for 4 weeks and no sports, kicking, running or exercise for 4 weeks. Devices will be provided for both feet to maintain symmetry and gait stability between the two feet.
45630205|NCT03873207|Device|padded insole|the control arm will be provided with standard padded insole to wear inside footwear
45630206|NCT05484531|Device|CLEAR|Reduction or elimination of myopia from -0.50 D to -10.00 D, with astigmatism of 0 D to -5.00 D or without astigmatism, and MRSE of -0.50 D to -12.50 D in the eye to be treated in patients who are 18 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude
45630207|NCT05484453|Diagnostic Test|Complete Eye Examination by Ophthalmologist|complete eye examination (gold standard) including cover test, biomicroscopy and cycloplegic refraction with retinoscopy, performed by an ophthalmologist.
45630208|NCT05489913|Other|cardiac rehabilitation support program|First of all, a preliminary interview was made with the patients in the experimental group, and their information needs were evaluated individually. Which trainings he should receive and his priorities were determined with the patient. After the training requirements were determined, the general introduction of the website was made and they were allowed to register. Experimental group patients received both training on the website and counseling over the phone for 12 weeks after they started working. A total of 3 phone calls were made with the patients in the first week, 4th and 8th weeks. The interviews lasted an average of 20 minutes. In each phone call, patients were informed and reminded. When patients needed, an average of 2-3 more phone calls were made and information was provided on the subjects they needed.
45630209|NCT05484375|Drug|Capecitabine plus toripalimab|Capecitabine tablet: 650mg/m2, orally, twice a day, d1-d21, every 3 weeks Toripalimab: 240mg, intravenous drip, d1, every 3 weeks
45630210|NCT05480007|Drug|sitagliptin and metformin|sitagliptin plus metformin group who received sitagliptin (100mg per day) and metformin (500 mg three times per day) (20 patients)
45630211|NCT05480007|Drug|Sitagliptin|sitagliptin treatment (100mg per day)
45630212|NCT05480007|Drug|Metformin|metformin group who received metformin (500mg three times per day)
45630213|NCT05479929|Other|Canadian Triage Assessment Scale (CTAS)|The CTAS incorporates work of breathing into a subjective measurement in its assessment of patients and triaged.
45630214|NCT05489757|Device|SPY Portable Handheld Imaging (SPY-PHI) System with SPY-QP Software|Perfusion assessment with SPY Q-ICG system
45630215|NCT05484063|Other|Multicomponent, mobility-focused intervention|The intervention group will receive early therapist review (within one working day of admission to HOME unit), to be mobilised at least three times a day. They will also receive additional group exercise therapy sessions, as well as nurse screening for geriatric syndromes. Besides that, they will be screened for 4Ms (Mobility, Mentation, Medication, What Matters) by doctor on admission.
45630216|NCT05489601|Drug|Oxycodone|Oxycodone in 5mg increments up to a maximum of 10mg
45447570|NCT03737097|Other|Brochure Education|The investigators translated and validated the Minimizing Your Risk of Falls A GUIDE FOR PEOPLE WITH MS brochure developed by the National Multiple Sclerosis Society. The control cohort will receive the main education model for patients that has been used in the past few years.
45447571|NCT03737019|Behavioral|Education with Acceptance and Commitment Therapy|Group education with Acceptance and Commitment Therapy of the personnel at each center.
45630217|NCT04016805|Drug|Ublituximab|"recombinant chimeric anti-CD20 monoclonal antibody~administered as an IV infusion"
45630218|NCT04016805|Drug|Umbralisib|"Phosphoinositide-3-kinase (PI3K) delta inhibitor~Tablet form, to taken orally on a daily basis"
45630219|NCT04016805|Drug|Ibrutinib|"Bruton Tyrosine Kinase (BTK) inhibitor~Tablet form, to taken orally on a daily basis"
45630220|NCT04016805|Drug|Venetoclax|"BCL-2 inhibitor~Tablet form, to be taken orally"
45630221|NCT04016805|Drug|Acalabrutinib Oral Capsule|Kinase inhibitor, capsule form, to be taken orally
45630222|NCT05489367|Biological|sars cov 2 biontec vaccine|volunteers will be expected to receive 2 doses of vaccine
45630223|NCT05483985|Device|Hera Score|The device uses patient metadata (patient age, day of image capture) and a software algorithm to analyze features of the blastocyst morphology to provide adjunctive information that may predict further development of the embryo to clinical pregnancy after embryo transfer.
45630224|NCT05483829|Behavioral|Adhera® Fatigue for Long COVID program|"Adhera® for the Long COVID program, which includes an application and a smartwatch, supported by digital health solution based on emotional and behavioral change techniques. Patient Adaptative Self-Management Content (e.g. psycho-educational content, activities for mental wellbeing, personalized motivational messages), and the personalization is based on Adhera® Health Recommender System.~Wearable devices and the mobile app will be used to collect real-time data for 4 weeks to detect biometric and psychometric (patient-reported outcomes) information."
45630225|NCT04424121|Diagnostic Test|CCTA|Coronary Computed Tomography Angiography
45769868|NCT05495022|Behavioral|Mindfulness-based stress reduction (MBSR) program|Mindfulness-based stress reduction (MBSR) program will be applied by the researcher to the midwives in the experimental group. Conscious Awareness-Based Stress Reduction will be applied by the researcher (S.Ö.C.) who has received training (16 hours) and has a certificate in this field. Stress reduction program based on mindfulness is planned as 2 sessions per week for 4 weeks, a total of 8 sessions. Each session is planned to last 40-60 minutes on average. Sessions will continue as individual and group sessions by determining the days when midwives are available online.
45630226|NCT05479695|Device|Spinal Orthoses and Insoles|Evaluation of scoliosis treatment in people using spinal orthoses and insoles
45630227|NCT05479695|Device|Spinal Orthoses|Evaluation of scoliosis treatment in people using spinal orthoses
45630228|NCT05479617|Other|Deep learning model|Use of deep learning model to predict individual patients disease course
45630229|NCT05479539|Behavioral|Action observation therapy|Participants will watch 12-minute video-clips followed by 8 minutes of motor imagery. Video-clips observation and imagination will be focused un shoulder tasks occuring on the three planes of motion.
45630230|NCT04276155|Drug|non-systematic prescription of anticoagulant therapy|the prescription of anticoagulant is managed by an implantable device follow up
45769869|NCT05494944|Procedure|ThuLEP|Minimal invasive prostate intervention
45769870|NCT01453400|Drug|Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo|Single dose, 2 x 500 mg fast release aspirin tablets (1000 mg) + 2 x placebo acetaminophen caplets
45630231|NCT05489289|Biological|AK104|Subjects will receive AK104 until disease progression or for a maximum of 16 cycles
45769871|NCT01453400|Drug|Acetaminophen + placebo|Single dose, 2 x 500 mg Acetaminophen caplets (1000 mg) + 2 x placebo fast release Aspirin tablets
45769872|NCT01453400|Drug|Placebo|Single dose, 2 x placebo Acetaminophen caplets + 2 x placebo fast release Aspirin tablets
45769873|NCT05490186|Procedure|Total Knee Replacement|Surgical technique for Total knee replacement will be standardized with a MicroPort prosthetic knee joint, patella replacement is optional based on the surgeon's assessment. The participants will receive local anesthetic infiltration by the surgeon, and a similar anesthetic technique with spinal anesthesia using epidural morphine and single shot peripheral nerve blocks. They will receive weight based antibiotics and tranexamic acid. Participants will be randomized to one of three groups. 1)Manual adjusted mechanical knee alignment (usual care) involves the surgeon manually. 2) Robot assisted surgery will include using the ROSA© device from Zimmer©. Robot assisted mechanical alignment aims for neutral alignment of the knee joint. 3) Robot assisted restricted kinematic alignment aims to place the knee joint closer to the participant's anatomical positioning.
45769874|NCT05023850|Procedure|TLIPB|Patients will receive TLIPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.
45769875|NCT05023850|Procedure|ESPB|Patients will receive ESPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between erector spinae muscle and transverse process of a vertebra.
45769876|NCT03992014|Drug|Linerixibat tablet|Linerixibat will be available as white to slightly colored film-coated round tablet to be administered as two tablets taken in the fasted state in the morning with 240 milliliter (mL) of room temperature water.
45630232|NCT05489289|Biological|placebo|Subjects will receive placebo until disease progression or for a maximum of 16 cycles
45630233|NCT04139577|Biological|Fecal Microbiota Transplant|FMT- Oral Study Drug, predetermined dosage and timings, up to 2 cycles
45630234|NCT05479227|Procedure|Management of bile duct injury|There are different options for BDI management, we analyzed their utilization and results
45630235|NCT05479071|Diagnostic Test|Blood test|Screening of antibodies against LDL
45630236|NCT02554929|Behavioral|Taming Sneaky Fears|Parents receive coping strategies based on CBT in parent group and children receive coping strategies based on CBT in child group.
45630237|NCT02554929|Behavioral|Parent Psycho-education and Child Socialization|Parents receive psycho-education in parent group and children receive socialization skills in child group.
45630238|NCT05489055|Drug|Iopamidol|A contrast bolus of iopamidol-370 (370 mg I/ml) (iopamidol injection; Consun Pharmaceutical, China) was injected at a ﬂow rate of 4.5-6 mL/s through an 18-20-gauge intravenous antecubital catheter by using a power injector (Ulrich, Germany). The total dose of iopamidol-370 was approximately 0.9 ml /kg body weight.
45630239|NCT04423965|Drug|mFOLFOXIRI|irinotecan 165 mg/m² IV day 1+ oxaliplatin 85 mg/m² IV day 1 + leucovorin 400 mg/m² day 1, fluorouracil 1200mg/m²/day *2 days (total 2400 mg/m² over 48 hours) continuous infusion starting on day 1 of each 2 weeks cycle
45630240|NCT04423965|Combination Product|Chemoradiotherapy|Capecitabine based chemoradiotherapy
45769877|NCT03992014|Drug|[14C]-linerixibat intravenous infusion|[14C]-linerixibat will be available as clear, colorless solution free from visible particulates to be administered 25 mL IV over 3 hours immediately after the oral dose.
45769878|NCT03992014|Drug|Linerixibat oral solution|Linerixibat will be available as clear, colorless solution free from visible particulates to be administered 60 mL solution in the fasted state in the morning.
45769879|NCT05490108|Biological|ZR202-CoV|SARS-CoV-2 adjuvanted recombinant protein vaccine (prototype)
45769880|NCT05490108|Biological|ZR202a-CoV|SARS-CoV-2 adjuvanted recombinant protein vaccine (variant)
45769881|NCT05490108|Biological|Comirnaty®|Comirnaty® (Pfizer-BioNTech)
45769882|NCT05023460|Device|Paresthesia-free (burst) ONS|Stimulation intensity target of 60% of paresthesia threshold.
45630241|NCT05478681|Device|active tDCS|All participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with AD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down.
45630242|NCT03766035|Device|SpyGlass DS I - II|The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
45630243|NCT05483595|Drug|Chinese herbal medicine FYTF-919|Oral liquid 10ml
45630244|NCT03972501|Drug|AZR-MD-001 Vehicle|AZR-MD-001 is an ophthalmic ointment
45630245|NCT03972501|Drug|AZR-MD-001 Active Dose|AZR-MD-001 is an ophthalmic ointment
45630246|NCT05488899|Diagnostic Test|Half iodine Spectral CT|Patients receive half dosage of iodine contrast agent, and Spectral CT acquisition with Virtual Monoenergetic Images at 40 and 50 keV.
45630247|NCT05488899|Diagnostic Test|Standard iodine conventional CT|Patients receive standard dosage of iodine contrast agent, and conventional 120 kv Polychromatic CT acquisition.
45769883|NCT05023460|Device|Placebo|ONS system deactivated
45769884|NCT05025644|Drug|Pre and post-CPB Drug: Dobutamine Hydrochloride|"Pre-CPB provocation test with DBT stress test will be started (starting at 5 mcg/kg/min, increasing every 3 min, to 10, 15 and 20 mcg/kg/min) until a PG ≥ 50mmHg is achieved (DBT peak dose). The DBT peak dose (DBT-pd) will be recorded.~Post-CPB provocation test at the DBT-pd achieved preoperatively."
45769885|NCT05025644|Drug|Post-CPB Drug: Dobutamine Hydrochloride|"Pre-CPB no intervention will be required.~Post-CPB provocation test with DBT stress test will be started (starting at 5 mcg/kg/min, increasing every 3 min, to 10, 15 and 20 mcg/kg/min) or until postoperative provocable PG is >16 mmHg."
45769886|NCT02558790|Drug|L-Threonic Acid Magnesium Salt (L-TAMS)|
45630248|NCT05483517|Device|High energy density pulse electromagnetic field|The treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. A normal energy of high-PEMF with a rate of 2 pulse per second is applied to the patient.
45630249|NCT05483517|Device|sham High energy density pulse electromagnetic field|The sham treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. The setting is the same as the experimental group(normal energy, a rate of 2 pulse per second) with the difference that the energy output doesn't export to the patient.
45769887|NCT01459172|Other|limonene containing massage oil|daily massage application to the breast for 4 weeks
45630250|NCT05483517|Behavioral|physiotherapy|Physiotherapy includes shoulder range of motion (ROM), stretching and muscle strengthening exercises. Under the physiotherapist's guidance, the patient receives the training session about 30 minutes every time.
45769888|NCT05494710|Other|Bleomycin electrosclerotherapy treatment|The combination of Bleomycin and electroporation of the treated area which is called electrochemotherapy (ECT).
45769889|NCT03810066|Drug|Osimertinib|All patients will be treated with osimertinib 80 mg/d for one cycle (28 days).
45769890|NCT03992482|Drug|Intravenous Immune Globulin (IVIG)|Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks
45769891|NCT03992482|Drug|Placebo|Normal Saline Eye Drops (0.9% NaCl) two times a day for eight weeks
45630251|NCT05483439|Drug|cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)|Drug: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
45769892|NCT04390490|Device|Graphene quantum dots combined with Si nanowire photoelectrochemical immunosensor|Graphene quantum dots combined with Si nanowire is a new method of photoelectrochemical immunosensor
45630252|NCT05483439|Drug|anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)|anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
45630253|NCT05483439|Drug|traditional herbal medicine|traditional herbal medicine
45630254|NCT03748095|Drug|pipéracilline/tazobactam|There is not intervention description
45630255|NCT03745989|Drug|MK-8353|Participants will receive MK-8353 orally twice daily (BID), escalated sequentially from 50 mg to 250 mg.
45630256|NCT03745989|Drug|Selumetinib|Participants will receive selumetinib orally BID, escalated sequentially from 25 mg to 75 mg.
45769893|NCT03793920|Other|Facial Emotion Test|All tasks will be delivered using a laptop and E-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh), which will also be used to collect behavioral responses.
45769894|NCT01453478|Drug|GSK1325756|CXCR2 antagonist
45769895|NCT00377494|Biological|MVA-CSO Vaccine|
45769896|NCT00377494|Biological|PfCSP DNA (VCL-2510) Vaccine|
45769897|NCT01459250|Drug|AGO178C|
45769898|NCT03747588|Procedure|Minimally-invasive pancreaticoduodenectomy|Minimally-invasive pancreaticoduodenectomy for resection of pancreatic tumor
45769899|NCT03747588|Other|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy for resection of pancreatic tumor
45769900|NCT03269968|Device|Negative pressure wound therapy (PREVENA Incision Management Therapy System)|After cesarean delivery, women in the intervention group will receive PREVENA Incision Management Therapy System.
45769901|NCT03269968|Device|Standard dressing|After cesarean delivery, women in the intervention group will receive standard dressing.
45769902|NCT01453556|Procedure|Laparoscopic right colectomy|Laparoscopic right colectomy with mechanical ileo-colon anastomosis L-L
45630257|NCT04275375|Other|observation study about the autonomic response after spinal anesthesia|ECG waveforms were continuously recorded using a multichannel polygraphic system (Embla N7000, Natus, Pleasanton, CA). The data were saved at a rate of 1024 Hz directly to a memory card within the device for offline analysis of heart rate variability (HRV) and PPG. All data included in the analysis were obtained from continuous artifact-free ECG recordings for analysis of the immediate effects of spinal anesthesia.
45447572|NCT03737019|Other|Control, no intervention|Control, no interventions.
45630258|NCT04088799|Other|No intervention|No intervention
45630259|NCT04058691|Device|Surgical repair|Open surgery
45630260|NCT03714711|Procedure|total hip arthroplasty|Total hip replacement
45630261|NCT03714711|Procedure|total knee arthroplasty|Total knee replacement
45630262|NCT04058301|Other|Text message information|Geographically proximate resources delivered by text message
45630263|NCT05488821|Drug|QLH11906|QLH11906 only
45630264|NCT05488743|Behavioral|educational intervention|The program consists of five 50-minutes sessions conducted in person as scheduled during weekly class meetings. Educators will conduct workshops with PowerPoint presentations and worksheets dedicated to in-class activities.
45630265|NCT05488665|Device|Crush technique|Treatment for bifurcation with the Crush technique
45630266|NCT05488665|Device|Culotte technique|Treatment for bifurcation with the culotte technique
45630267|NCT05478057|Device|"MAGSTIM Repetitive transcranial magnetic stimulator (rTMS) system"|we plan to recruit 60 patients with Parkinson disease, comprising 30 patients with speech disturbance and 30 age- and sex-match patients without speech disturbance. Each group of patients will be randomly divided into sham stimulation or rTMS. A total of 10 rTMS sessions will be applied in 2 weeks. The effect of rTMS will be evaluated via the changes of speech performance and functional connectivity which was analyzed from resting-state functional magnetic resonance imaging.
45630268|NCT05488587|Diagnostic Test|magnesium and zinc levels|measuring magnesium and zinc levels
45630269|NCT05488353|Drug|Disitamab Vedotin for Injection,Penpulimab Injection|"After completion of all screening activities, patients confirmed to be eligible will enter the study and receive the following treatments.~Neoadjuvant regimen (up to 4 cycles): Disitamab Vedotin for Injection, 2.0 mg/kg, given as an IV infusion on day 1, and Penpulimab Injection, 200 mg, on every 21 days On day 1 of the cycle, it is given as an intravenous infusion. Order of use: Disitamab Vedotin for Injection → Penpulimab Injection."
45630270|NCT05488275|Procedure|Surgery|MPFL reconstruction
45630271|NCT03947619|Device|Impella CP® placement prior to reperfusion with Primary PCI|Subjects randomized to the experimental arm, will undergo Impella CP® placement through a femoral arterial sheath and the Impella device will be activated to unload the left ventricle.
45630272|NCT04543305|Drug|PRT1419|PRT1419 will be administered orally
45630273|NCT05488197|Other|uterine artery doppler at 18-23 weeks of pregnancy|uterine artery doppler at 18-23 weeks of pregnancy
45630274|NCT04543071|Drug|Motixafortide|1.25 mg/kg subcutaneous (SC) monotherapy daily for 5 days during priming, followed by twice weekly
45630275|NCT04543071|Drug|Cemiplimab|350 mg intravenous (IV) once every 21 days
45769903|NCT04390412|Radiation|Low Dose Radiotherapy|0.5 Gy radiation to both lungs in an AP/PA treatment plan
45769904|NCT04166032|Device|Alertgy non-invasive continuous glucose monitoring device (ANICGM)|Alertgy non-invasive continuous glucose monitoring device (ANICGM)
45769905|NCT02556138|Device|ORBERA Intragastric Balloon|The ORBERA Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
45769906|NCT04303156|Drug|Islatravir|Single oral dose of 60 mg Islatravir administered in capsule form
45630276|NCT04543071|Drug|Gemcitabine|1000 mg/m2 IV on days days 1, 8, 14 (every 28 days)
45630277|NCT04543071|Drug|Nab paclitaxel|125 mg/m2 IV on days 1, 8, 14 (every 28 days)
45630278|NCT05483205|Drug|Normaderm Phytosolution Double-Correction Daily Care Moisturizer|Normaderm Phytosolution (NP) was to be applied for up to 90 days once or twice daily, according to the investigator's prescription.
45630279|NCT05488041|Procedure|Performing anorectal manometry|"Anorectal manometry is a safe, low-risk procedure and is unlikely to cause any pain, colorectal perforation is very rare. Seven cases have been published in four reports.~Anorectal Manometry - NY Gastroenterology Associates n.d. https://www.gastroenterologistnewyork.com/preparing-for-procedure/anorectal-manometry/ (accessed July 14, 2021).~Bionda M, Lenglinger J, … AH-J of E, 2020 undefined. Closure of Large Rectal Iatrogenic Perforation by Endoscopic Suture Device: Go for it. BorisUnibeCh 2020;01:13-5. https://doi.org/10.48350/151165."
45630280|NCT05477745|Procedure|total knee arthroplasty|The surgeries were performed under general anesthesia. The medial parepatellar incision was introduced during the TKA. The femoral component size was selected according to the intro-operative measurement. The osteotomy was done according to the intramedullary guide and the cutting guide. After the proximal tibial osteotomy was finished, the cruciate-retaining Total Knee System was used. The lateral rotation of the femoral component was determined by the gap-balancing technique.
45630281|NCT05487963|Drug|Tofacitinib Citrate|Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
45769907|NCT04390334|Drug|Daridorexant|Daridorexant will be administered orally as 1 film-coated tablet of 50 mg strength to be taken in the morning under fasted conditions.
45447573|NCT03743805|Drug|Flumazenil|0.2 mg IV push, which may be repeated every 20 minutes for up to a total of 1 mg
45447574|NCT03743805|Drug|Naloxone|0.4 mg IV push, which may be repeated every 2 minutes for up to a total of 2 mg
45630282|NCT05487963|Other|placebo ointment|Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
45630283|NCT05487885|Device|Continuous theta burst stimulation (cTBS)|a form of transcranial magnetic stimulation, to dorsomedial prefrontal cortex (dmPFC)
45769908|NCT04390334|Drug|Famotidine|Famotidine will be administered orally as 1 film-coated tablet of 40 mg strength to be taken in the morning under fasted conditions.
45769909|NCT04390334|Drug|Efavirenz|Efavirenz will be administered orally as 1 film-coated tablet of 600 mg strength o.d. in the evening.
46069940|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
45769910|NCT02880020|Biological|Ipilimumab|Given IV
45769911|NCT02880020|Other|Laboratory Biomarker Analysis|Correlative studies
45769912|NCT02880020|Biological|Nivolumab|Given IV
45769913|NCT05494554|Device|Changing mechanical ventilation mode|On the 2nd day of intensive care hospitalization, while under deep sedation and in the controlled mode (VCV or PRVC) and in the supine position, the ventilator in the VCV mode was switched to PRVC mode for 60 minutes without changing any of the set ventilator settings (RR, PEEP, TV, I:E ratio). Likewise, if it is in PRVC mode, it is also switched to VCV mode for 60 minutes. MP values were calculated from the minute respiratory parameters of all patients with the MP formulas defined in the software.
45630284|NCT05487885|Behavioral|Positive Affect Training|Psychosocial add-on intervention that could enhance the effects of TBS. PA Therapy (Craske et al., 2016) is an innovative cognitive and experiential technique developed to address anhedonia specifically and, ideally, change altered patterns of frontostriatal function. Standing in contrast to Cognitive Behavioral Therapy, PA training has efficacy for enhancing positive affect and reducing negative affect (Craske et al., 2018). This treatment can be easily applied, and we propose that it will enhance neural circuit-level changes elicited by TBS.
45769914|NCT01453634|Drug|Lunacalcipol 180|4 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
45769915|NCT01453634|Drug|Lunicalcipol 270|8 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
45769916|NCT05494476|Procedure|implant insertion|after flap detachment, implant bed will be prepared with twist-drill, implant will be inserted according to randomization (1 or 2 mm under bone)
45769917|NCT03150160|Drug|brinzolamide 1%/brimonidine 0.2% fixed combination|One drop applied topically to the affected eye(s) in the morning and evening
45769918|NCT03150160|Drug|Placebo|One drop applied topically to the affected eye(s) in the morning and evening
45769919|NCT03150160|Drug|travoprost 0.004% ophthalmic solution|One drop applied topically to the affected eye(s) in the evening
45769920|NCT01459406|Dietary Supplement|Glucose|500 ml water drink containing 40g glucose
46069941|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
46069942|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
45769921|NCT01459406|Dietary Supplement|Fructose|500 ml water drink containing 40g fructose
45769922|NCT01459406|Dietary Supplement|Fructan|500 ml water drink containing 40g fructan
45769923|NCT01459406|Dietary Supplement|Fructose and glucose|500 ml water drink containing 40g fructose and 40g glucose
45769924|NCT01453712|Radiation|Control group|Conventional coronary CT angiography using standard reconstruction technique (filtered back projection).
45769925|NCT01453712|Radiation|Intervention group|Using the new scan protocol with 30 % less tube current and iterative image reconstruction algorithm.
46069943|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
46069944|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
45769926|NCT05494320|Drug|Folfox Protocol|Folfox: It includes the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
45769927|NCT03988426|Biological|Octanorm|Octanorm
45769928|NCT01890356|Device|Transcranial electrical stimulation|
45769929|NCT03549780|Device|Stomal Occlusion Device|Insertion of a novel stomal occlusion device into patients with Brooke Ileostomy and assess feasibility and patient satisfaction
45769930|NCT05026580|Behavioral|Joint Academy exercise and education smart phone application|The Joint Academy® (www.jointacademy.com) program for people with hip or knee OA consists of video instructed and progressively adaptable daily exercises, patient education through text lessons and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period.
45913329|NCT02021123|Drug|Anidulafungin 100mg single dose iv|Anidulafungin 100mg single dose iv pre-surgery (gastric bypass)
46069945|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
45630285|NCT05487885|Drug|Ketamine Injectable Solution|Ketamine is FDA-approved as an anesthetic agent that will be used off-label in this study. It is used routinely in both pediatric and adult patients and is considered extremely safe in substantially higher, anesthetic doses. The dose to be administered here (0.5 mg/kg) is a much lower, subanesthetic dose, and the administration route (intravenous) is the standard when used in anesthesia. Published studies and metaanalyses of this dose of intravenous ketamine as an off label use in depression show clearly that there are no increased risks in this population, including a recent study in adolescents (Dwyer et al, 2021, American Journal of Psychiatry). A single dose of ketamine will be used to determine if it alters the functioning of the anhedonia-related reward functioning and frontostriatal biomarkers assessed in this study.
45630286|NCT05487807|Drug|Nicotine patch|Will be receiving nicotine therapy
45630287|NCT05487807|Behavioral|text messaging|Will be enrolled in an texting app
45630288|NCT05487729|Other|ultrasonography and functional assessment and questionnaire survey|ultrasonography and functional assessment and questionnaire survey
45630289|NCT05477667|Diagnostic Test|real time pcr|Detection of expressin level of MiRNA-124 and let-7a using real time pcr
45630290|NCT05487495|Biological|CD5 CAR T (CT125B)|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m^2/day and cyclophosphamide at 250 mg/m^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.
45630291|NCT05477433|Behavioral|diabetes mellitus type 1|"Pittsburgh Sleep Quality Index PSQI: It is used to detect sleep disturbance or deficits. The PSQI has a scoring key that can be used to calculate a patient's seven subscores, which range from 0 to 3. The subscores are added together to produce a global score that ranges from 0 to 21. A global score of 5 or higher denotes poor sleep quality, The Strengths and Difﬁculties Questionnaire (SDQ) The SDQ is a well-validated screening tool for children and adolescents aged 4-17 years that can identify behavioural and emotional issues,Emotional Avoidance Strategy Inventory for Adolescents (EASI) is used. The EASI-A is a 17-item assessing the use of emotionally avoidant strategies in adolescents and higher scores means significants use avoidant strategies, The Toronto Alexithymia Scale (TAS-20) is a self-administered 20-item questionnaire which assesses difficulties in identifying and describing emotions. TAS scores were significantly higher in alexithymia"
45630292|NCT05477355|Behavioral|Group Problem Management Plus (PM+)|Group PM+ is a low-intensity, trans-diagnostic, brief psychological intervention developed by the WHO. Group PM+ consists of five sessions delivered in five consecutive weeks and includes strategies that are aimed towards decreasing symptoms of depression, anxiety, general distress, and other related conditions. Group PM+ is designed to be delivered by non-specialists, persons without a formal education and licensure in psychology or mental health.
45630293|NCT03602859|Drug|Niraparib|Participants will receive oral capsules of niraparib as a unit dosage strength of 100 milligrams (mg).
45630294|NCT03602859|Drug|Dostarlimab (TSR-042)|Participants will receive 30 minutes intravenous (IV) infusions of 1000 mg dostarlimab on Day 1 every 6 weeks.
45630295|NCT03602859|Drug|Standard of care|Participants will receive SOC that includes paclitaxel 175 milligrams per square meter (mg/m^2) on day 1 every 21 days + carboplatin area under the curve (AUC) of 5 to 6 milligrams per milliliter per minute (mg/mL/min) on day 1 every 21 days +/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days for a total of 15 months.
45630296|NCT03602859|Drug|Dostarlimab-Placebo|Participants will receive 1000 mg of dostarlimab-placebo on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision
45630297|NCT03602859|Drug|Niraparib-Placebo|Participants will receive oral capsules of niraparib-placebo as a unit dosage strength of 100 mg.
45630298|NCT05482815|Device|Provox Vega Voice prosthesis|Voice prosthesis for speech rehabilitation, Provox Vega Voice prosthesis
45630299|NCT05487183|Behavioral|Medoc cutaneous probe|A computer-controlled probe delivers temperatures to the skin to measure pain, OA, and OH
45630300|NCT05487183|Behavioral|Quantitative sensory testing|Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain
45630301|NCT05487183|Behavioral|Computer tasks|QST and computer tasks are used to measure changes in pain intensity
45630302|NCT05482737|Other|no intervention|This is an observational retrospective study (meta-analysis)
45653407|NCT05031273|Behavioral|Residents moving into a congregate-living development with more features that support healthy living|Our team is making evidence-based recommendations to the developer and design team of an upcoming congregate-living development to support the physical activity, healthy eating, and social connections of residents moving into the new building(s). We hope for the developer to integrate into the new building(s) as many as possible of our team's built environment design and amenity recommendations into their site and/or building plans. Additionally, discussions with the municipality are also occuring on built environment design and amenity recommendations to improve the neighbourhood surrounding the site. Although our team has provided these recommendations, it is ulimatily up to the discretion of the developer and the municipality as to whether and what design and amenity changes are made.
45913330|NCT02021136|Device|Rebel Reliever|Rebel Reliever knee brace + usual antalgic treatment + physical exercises recommendations
46069946|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
45913331|NCT02021136|Other|Control|Usual antalgic treatment + physical exercises recommendations
45769931|NCT03536052|Device|Virtual Heart Guided Ablation|If a good quality cardiac MRI is obtained and a virtual heart model with the ablation targets is generated, the operating physician will merge the virtual heart lesion map to the invasive electroanatomical navigation system. After the patient has been catheterized, an attempt should be made to induce VT. The physician should then navigate the catheter to each of the ablation targets specified, and place a lesion as per his or her training and experience, confirming when done that the lesion marker in the mapping system coincides with the target. This will be done for each lesion.
45769932|NCT01459562|Drug|NI-0501|
45769933|NCT01459562|Drug|Placebo|
45630303|NCT05482659|Behavioral|Health education on healthy nutrition and regular physical activity based on the transtheoretic model|An announcement was made by visiting all the faculties at Nuh Naci Yazgan University, stating the content of the research and the duration of the research. Among the volunteer students, students who met the inclusion criteria were included in the study. Afterwards, the students were assigned to the groups by the statistician using a simple randomization method. As a result of the pre-test, it was determined which change stage each student was in according to the Transtheoretic model (TTM). The students were not given information about which group they were in and what stage they were in according to TTM. Health education was given to university students once a week by online education method and it took 4 weeks-30 days to complete the research. The average duration of the health education given to each student is 30-45 minutes. When the training process was over, the post-test questions were sent to the students by the online survey method.
45630304|NCT05477199|Other|Cognitive behavioral principles-based treatment program|The treatment protocol had a total duration of 6 weeks. Two sessions were conducted each week, the first being a group session lasting 1.5 hours and the second an individual session lasting 45 minutes. During the group sessions, emotional disclosure and sharing of the experiences of patients with post COVID-19 syndrome were encouraged. During the individual sessions, a strong relationship was developed between the patient and the healthcare professional, with the healthcare professional helping the patient develop self-efficacy, thought monitoring, helpful self-talk, and reflection on changes in activity levels throughout the program.
45769934|NCT05489952|Drug|iron sucrose and ferrous lactate|The experimental group added to the intravenous iron sucrose during perioperative period according to the degree of iron deficiency. If there is still a iron deficiency or anemia at discharge, oral ferrous lactate is added after discharge.
45769935|NCT03123328|Device|Radical-7 Pulse CO-Oximeter and sensor|Noninvasive device that measures hemoglobin.
45769936|NCT04272398|Other|dynamic elastomeric fabric orthoses|Wore dynamic elastomeric fabric orthoses with a focus on the lower body and pelvis in addition to the physiotherapy and rehabilitation sessions. The frequency of the use of the orthosis was planned to extend through the week and they had the orthosis during their active hours during the day about 8 hours a day.
45630305|NCT05477199|Other|Control intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
45769937|NCT04258566|Device|Optical Molecular Imaging|Tracks and localizes intrahepatic lesions
45630306|NCT04274985|Other|Questionnaire application|Patients will complete the mentioned questionnaires.
45630307|NCT05477043|Diagnostic Test|Transabdominal ultrasound and cistoscopy|Ultrasound detection of the bilateral ureteral jets vs absence of the ureteral jet on one side compared with the presence of bilateral ureteral jet on cystoscopy vs absence on one side.
45630308|NCT04274595|Drug|Generic antiretroviral|200mg emtricitabine plus 245mg tenofovir diisopropyl fumarate for 7 days
45630309|NCT04274127|Diagnostic Test|early detection kit composed of 2 questionnaires (M-CHAT-R + CSBS-ITC)|completion of 2 questionnaires (M-CHAT-R + CSBS-ITC) followed by a confirmation of the detection with a phone call by a neuropsychologist, in children aged 16 to 24 months seen by their usual general practitioner or pediatrician or child care centers or attending nurseries.
45630310|NCT05486871|Procedure|laparoscopic partial nephrectomy|"This is a prospective non- randomized controlled study of patients with RCC Who will be referred to urology department, Sohag university hospital. Our comparative study contained two groups according to tumor stage at preoperative contrast study:~Group [A] : 15 patients with T1 RCC (≤ 7 cm). Group [B] : 15 patients with T2a RCC (≤ 10 cm). the patients will be subjected to laparoscopic partial nephrectomy then will be followed up for two years for oncological and functional outcomes."
45769938|NCT04258566|Radiation|Indocyanine Green|Fluorescent dye used for visualization of cells and tissue
45769939|NCT01459640|Drug|Hyaluronic Acid|Intra-articular injection; 30mg/2ml; three-weekly injection regimen
45769940|NCT01459640|Biological|Autologous bone marrow-derived mesenchymal stem cells|"Single intra-articular implantation of autologous bone marrow-derived mesenchymal stem cells in hyaluronic acid Orthovisc (3rd injection in a three-weekly injection regimen)"
45769941|NCT04257396|Device|Carbon-Fibre Adjustable Reuseable Accessory (CARA)|Breast support device having a carbon-fibre breast cradle for supine patient positioning.
45769942|NCT01500772|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
45769943|NCT01500772|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
45769944|NCT01500772|Drug|Ribavirin|RBV 200 mg tablets (weight-based dose: < 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
45769945|NCT02840630|Other|Tinned mackerel fish|Diabetic fish intervention group will be given two tinned mackerels per week from week 0 until week 16.
45630311|NCT05476965|Combination Product|induction therapy; surgery; radiotherapy|Radiotherapy: de-escalation radiotherapy or standard radiotherapy
45769946|NCT04257162|Other|Tumor and Blood sample collection|"This is a non-interventional protocol and does not provide study drug or specific requirements for how the patients should be treated.~Nevertheless, patients participating in T-DXd trials included in this study are those who were randomized to receive T-DXd.~Tumor sample and blood sample will be collected within the framework of HER2-Predict Study"
45769947|NCT04272476|Other|acupuncture and moxibustion|
45769948|NCT04272476|Drug|Fluoxetine|
45769949|NCT03276390|Behavioral|Hispanic Kidney Transplant Program (HKTP)|The HKTP entails culturally targeted education in Spanish about transplantation, outreach to dialysis patients by bicultural health care providers.
45630312|NCT05482503|Device|12-Lead ECG(I-lead)|All participants will simultaneously record 12-lead ECGs(I-lead)
45630313|NCT04424043|Procedure|neo-TACE-HAIC+Surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
45630314|NCT04424043|Procedure|Surgery alone|hepatic resection remove the liver tumors
45630315|NCT05486715|Drug|Vit D|Vit D
45630316|NCT05482347|Other|Educational video|The intervention is an educational video developed using data from focus groups of families with children diagnosed with neurogenic bladder.
45630317|NCT05482269|Other|no intervention|no intervention
45630318|NCT03560895|Device|cuffed endotracheal tube|Patients will be anesthetized using high-volume low-pressure cuffed endotracheal tube
45630319|NCT03560895|Device|Uncuffed endotracheal tube|Patients will be anesthetized using uncuffed endotracheal tube
45630320|NCT05486637|Behavioral|Perception of acoustic cues to emotion|Using novel methodologies and stimuli comprising both controlled laboratory recordings and materials culled from databases of ecologically valid speech emotions (e.g., from publicly available podcasts), the team aims to collect perceptual data to build a statistical model to test the hypothesis that experience-based changes in emotion identification by pediatric and adult CI recipients is mediated by improvements in cue-optimization.
45630321|NCT05486637|Behavioral|Production of acoustic cues to emotion|The team will acoustically analyze vocal emotion productions by participants, quantify acoustic features of spoken emotions, and obtain behavioral measures of how well normally hearing listeners can identify those emotions.
45653408|NCT05029947|Procedure|Microsurgical Clipping of Unruptured Intracranial Aneurysm|Microsurgical Clipping of Unruptured Intracranial Aneurysm
45653409|NCT02632747|Drug|Empagliflozin|Empagliflozin will be taken once daily
45653410|NCT02632747|Drug|Placebo (matching empagliflozin)|Placebo will be taken once daily
45769950|NCT05029154|Behavioral|High intensity interval exercise|Patients in the exercise group will perform interval training (HIIT) 3 days per week, with each session consisting of four, 4-min intervals at 85-90% peak heart rate (PHR), separated by 3 min at 50% PHR. Each training session will begin with a 10-minute warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Patients will undergo 2 initial training sessions at the exercise physiology core lab. All exercise will consist of stationary cycling to avoid discomfort associated with abdominal surgery as well as stress to the incision and help reduce fall risk. Study investigators will check in weekly with participants and remotely track exercise data and compliance via the Fitbit app.
45769951|NCT05029154|Behavioral|Attention control|Patients in the control group (physical activity education and physical activity monitoring) will receive counseling regarding the benefits of physical activity during chemotherapy treatment. During the intervention, participants will receive a weekly phone call to discuss their physical activity and remind them to engage in physical activity. Patients will be given a goal of working up to 30 minutes of exercise daily. Subjects will be urged to increase daily step counts by 250-500 steps/day. Physical activity will be objectively assessed and made available to the participant using a Fitbit.
45769952|NCT03984838|Drug|JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet|JULUCA tablets will be administered orally once daily with a meal. It will be available as a fixed dose combination of Dolutegravir 50mg and Rilpivirine 25mg.
45769953|NCT03136692|Behavioral|Lose It! commercial weight loss app|Lose It! is a commercial weight loss smart phone app designed for easy caloric tracking. It provides a free mobile and web interface for users to construct an individualized weight loss plan by entering their goal weight and desired weekly weight loss. Using the user's height, current weight, gender and age, the app generates a daily caloric budget designed for the user to reach their goal. Users can then log their caloric intake, exercise, and weight to track progress toward their goal.
45769954|NCT01890668|Other|Osteopathic Manipulative Treatment|"Visit 1 between H60 and discharge :~Interview (pregnancy step, initiation of breastfeeding, baby posture…) Osteopathic Clinical exam (osteopathic specific diagnosis, mobility…) Osteopathic Manipulative Treatment by sweet osteopathic mobilization Time of intervention = 30 to 45 min Visit 2 : 7 days after visit 1 (+/- 24H) with the same procedure~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months"
45913332|NCT02021149|Device|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
45913333|NCT02021149|Behavioral|Psychotherapy|Weekly psychotherapy using cognitive behavioral therapy sessions with a therapist.
45630322|NCT05476731|Diagnostic Test|culture and antifungal sensitivity and molecular detection|"Samples will be cultured on Modified Dixon media for 10 days at temperature between 32-34°C.Molecular detection of malassezia species by Restriction Fragment Length Polymorphism (RFLP) .~Antifungal susceptibility testing of the isolates will be performed using the following antifungals Fluconazole, AmphotericinB and Fluocytosine"
45630323|NCT05482113|Drug|Liposomal bupivacaine|Liposomal Bupivacaine (Exparel) Brachial Plexus Block for Arthroscopic Rotator Cuff Repair
45769955|NCT01890668|Other|No Osteopathic manipulative Treatment|"Visit 1 between H60 and discharge :~Interview (pregnancy steps, initiation of breastfeeding, baby posture…) Osteopathic Clinical exam and Treatment will not be realized. Newborn will be undressed, lying naked (covered with polar sheet) on the exam table, dissimulated to parents by adequate screen. The osteopathic procedure will take place on a dolly to mimic from an indiscernible manner, osteopathic management.~Time of intervention = 30 to 45 min Visit 2: 7 days after visit 1 (+/- 24H) with the same procedure.~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months"
45769956|NCT02994576|Drug|Atezolizumab|Atezolizumab, 1200 mg administered I.V. once
45769957|NCT04272944|Drug|MSB2311 Injection|An intravenous infusion with concentration from 3 mg/kg to 20 mg/kg every 3 weeks (Q3W)or every 2 weeks(Q2W).
45769958|NCT01890902|Drug|Ketoprofen 10% Cream|
45769959|NCT01890902|Drug|Placebo|
45769960|NCT04423926|Drug|Lenalidomide|Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1~d10# 21days a cycle
45769961|NCT04423926|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 d1
46069947|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 32 mcg/kg moxetumomab pasudotox (CAT-8015) of process 3 material every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
45447575|NCT05668533|Diagnostic Test|Interscalene versus PENG Block|"Interscalene group: Patients received ipsilateral ultrasound-guided interscalene nerve after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg).~PENG Block: Patients received ultrasound-guided PENG block after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg)."
45630324|NCT05482113|Drug|Bupivacaine Hcl 0.25% Inj|Standard 0.25% Bupivacaine Brachial Plexus Block for Arthroscopic Rotator Cuff Repair
45630325|NCT05486403|Behavioral|Appetite Toolbox Programme|Preschool educators are trained to deliver a bio-behavioural classroom-based programme focusing on building skills in i) appetite awareness, ii) attention/attention control and iii) sensing body cues. The programme is delivered using a combination of interactive story books, classroom props and activities, and mealtime transitions/routines.
45630326|NCT05482035|Device|wrist blood pressure monitor|Comparing blood pressure measured by wrist blood pressure monitor with mercury sphygmomanometer .
45630327|NCT05476653|Other|MRI procedure|Pulmonary MRI based on a 1.5 T machine (Siemens VIDA) or a 3T machine (Siemens SOLA) without the use of contrast product according to a protocol based on a 3D-UTE sequence acquired in free breathing but with a respiratory synchronization system in association with weightings in T1 and T2.
45630328|NCT05476575|Other|hydrogen inhalation, 4% concentration, given via nasal cannula|4% hydrogen inhalation via nasal cannula perioperatively
45769962|NCT04423926|Drug|Doxorubicin|Doxorubicin 50 mg/m2 d1
45769963|NCT04423926|Drug|Vincristine|Vincristine 1.4mg/m2 (maximum 2mg) d1
45447576|NCT03984825|Drug|GSK3640254|GSK3640254 will be available as a 100 mg capsule. Subjects will be administered 200 mg GSK3640254 once daily via the oral route on Days 11 to 21.
45630329|NCT05486325|Device|Endolumik Gastric Calibration Tube (EGCT)|"Up to twenty participants will undergo laparoscopic or robotic sleeve gastrectomy using the EGCT. This operation will take approximately 60 minutes.~The portions of the sleeve gastrectomy operation where the EGCT will be used include:~To evacuate gastric contents~During construction of the gastric sleeve~To perform the leak test of the gastric sleeve Up to ten participants will undergo laparoscopic gastric bypass using the EGCT. This operation will take approximately 120 minutes.~The portions of the gastric bypass operation where the EGCT will be used include:~To evacuate gastric contents~During construction of the gastric pouch~To calibrate closure of the gastrojejunal anastomosis~To perform a leak test of the gastrojejunal anastomosis In both procedures, The amount of time the EGCT will be inside the patient is approximately 20 minutes. The device is removed prior to the conclusion of the operation, while the patient is under anesthesia."
45653411|NCT02632747|Drug|ramipril|Ramipril will be taken once or twice daily
45769964|NCT04423926|Drug|Prednisolone|Prednisolone 60mg/m2 d1-5
45769965|NCT03979066|Drug|Atezolizumab|840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery.
45769966|NCT03979066|Drug|PEGPH20|PEGPH20 3ug/kg IV twice weekly for 3 weeks prior to surgery and once weekly for 3 weeks (of 28 day cycle) for two cycles after surgery.
45769967|NCT05021432|Other|Virtual reality training group|This group will receive video based games
45769968|NCT05021432|Other|Circuit Training group|They will receive Task-oriented Circuit training exercise program
45769969|NCT03968848|Drug|acalabrutinib|A 50-mg single oral dose of acalabrutinib will be administered.
45769970|NCT05494086|Procedure|DPLDG|Dual-port laparoscopic distal gastrectomy
45769971|NCT05494086|Procedure|LDG|Laparoscopic distal gastrectomy
45769972|NCT02829242|Device|NIRS Monitoring (SenSmart Monitor)|
45769973|NCT05489562|Device|Intraoral Suction|stabilization of the tongue using intraoral suctioning and its effects on sleep parameters in patients with obstructive sleep apnea (OSA).
45769974|NCT01484314|Drug|Eltrombopag|100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy
45769975|NCT05023148|Procedure|Electroacupuncture|Stimulating acupoints using electric stimulator
46069948|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
45769976|NCT05023148|Procedure|Thread embedded acupuncture|Stimulating acupoints using thread embedded
45913334|NCT02021149|Other|Questionnaires|Weekly questionnaires to assess changes in mood, perceptions of self and perceptions of effectiveness of the therapist/patient bond will be administered.
45630330|NCT03477435|Behavioral|Staff training and academic detailing|Both arms will receive training at baseline to help their patients quit smoking. The training will be a mix of content and process education. We will provide brief updates to staff every 6 months throughout the intervention period, which will focus primarily on process education. We will monitor which staff attend and reach out separately to staff who did not. During the month after implementation of the clinical reminders, two study investigators will make a brief outreach visit to each staff member. We will follow a script, using the seven steps recommended by the National Resource Center for Academic Detailing: 1) Introduction; 2) Needs Assessment; 3) Key Messages/Features/Benefits; 4) Understanding Barriers and Enablers; 5) Identifying and Handling Objections; 6) Summary; and 7) Close. The key message (Step 3) will include demonstration of the clinical reminder, review of the evidence for telephone counseling and text messaging and how to refer patients.
45630331|NCT03534141|Device|Esophageal cooling/warming device|The EnsoETM (formerly known as Esophageal Cooling Device) is a non-sterile multilumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while allowing gastric decompression and drainage. It is placed in a manner identical to a standard orogastric tube, which is standard equipment for liver transplant surgery. It is removed at the end of surgery. Control of the patient's temperature is achieved by connecting the EnsoETM to an external heat exchanger (Gaymar Medi-Therm III or similar system). The Medi-Therm III is a standard device used in operating rooms for warming patients with a conductive table warming pad. The Medi-Therm III circulates temperature-controlled water through a closed-loop system via the two outer lumens of the EnsoETM. Water temperature ranges from 4°C - 42°C.
45630332|NCT03534141|Other|Mild hypothermia|Cooling will be initiated after induction of anesthesia and maintained throughout the anhepatic phase of liver transplantation. In all feasible cases the surgeon will cover the peritoneal surface over the right kidney, which is exposed during the operation, with ice-cold sponges to enhance cooling of the renal parenchyma. After blood flow is completely restored to the liver, the esophageal cooling device and other standard measures (forced-air, fluid, and table warmers, plus a heated anesthesia circuit) will be used to actively re-warm the patient (expected warming rate ≥ 1 deg C/hour). The goal is to achieve normothermia by case end.
45630333|NCT03534141|Other|Normothermia|After induction of anesthesia, the esophageal cooling/warming device and standard warming measures will be used to maintain normothermia throughout the operation.
45913335|NCT02021149|Device|Low intensity whole-body infrared heating|Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
45630334|NCT05481957|Drug|Vortioxetine|5-10mg for 16 weeks
45630335|NCT05481957|Drug|valprote|500~1000mg for 16 weeks
45630336|NCT05475561|Procedure|Ultrasound guided Pecto-intercostal- fascial plane block|The probe of the ultrasound will be placed at 2 cm lateral to the lateral sternal border at 5th and 6th rib. On the surface plane subcutaneous tissue is identified, while Pectoralis major muscle, Intercostal muscles and ribs are seen in intermediate plane and lung along with pleura are identified in deep plane. A 22-gauge, 80-mm short bevel echogenic needle is used and advanced in in-plane manner, in a caudal-to-cranial direction, until the tip of the needle is located in the fascial plane between the pectoralis major and internal intercostal muscle, where the local anesthetic will be injected.
45630337|NCT05475561|Procedure|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T6 spinous process corresponding to the T5 transverse process. Three muscles trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process.Local infiltration with 2% of lignocaine at the site of needle insertion will be done. Using in-plane approach a 22 G short bevel needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle, as evidenced by visible hydro dissection below the muscle plane. A 20 ml of 0.25% plain bupivacaine will be injected on each side.
45630338|NCT05475561|Drug|Bupivacain|local anesthetic
45630339|NCT05475405|Other|scapulothoracic mobilization|Patient in prone lying position. The left hand of the physical therapist lifts the scapula to distract from the thoracic wall while the right hand mobilizes and stretches the inferior muscle groups attached to the scapula.
45653412|NCT04218825|Drug|chlormethine gel|Gel to be applied to all skin areas affected by MF-CTCL
45769977|NCT05493930|Other|The hospital where the treatment is performed|
45769978|NCT05600452|Other|Heat acclimation|Repeated heat exposures with light exercise sufficient to elevate deep body temperature to ~ 38.5C
45769979|NCT05489406|Drug|DTG DT (6 x 5 mg)|DTG 5mg dispersible tablet
45769980|NCT05489406|Drug|F/TAF TOS (3 x 60/7.5 mg)|60/7.5 mg TOS emtricitabine/TAF
45769981|NCT03020446|Device|Sorbion Dressing|Sorbion dressing will be placed on venous leg ulcer and changed weekly for 4 weeks
45769982|NCT01459952|Dietary Supplement|Rose hip Liquid|Rose hip Liquid, 20 ml BID
45769983|NCT01479010|Drug|Anakinra 100 mg subcutaneously daily|Anakinra 100 mg subcutaneously daily
45913336|NCT02021175|Behavioral|Tailored CBME Therapy via Technology|6 Sessions of tailored interactive Cognitive-Behavioral Motivational Enhancement Therapy delivered through internet and cell phones
45913337|NCT02021175|Other|Standard of Care|Referral to currently available resources for 6 sessions of a standard smoking cessation approach
45913338|NCT02021201|Drug|risperidone|Patients with schizophrenia will be treated for 10 weeks treatment with risperidone
45913339|NCT02021201|Drug|Sertindole|Patients with schizophrenia will be treated for 10 weeks treatment with serindole
45913340|NCT02021214|Drug|Methylphenidate|
45913341|NCT02021214|Drug|Placebo|
45913342|NCT02021227|Procedure|Early chair sitting exercise|A chair sitting exercise will be done at least once a day and for > 1 hour
45913343|NCT02021240|Drug|Ketamine|
45913344|NCT02021240|Drug|Dexamethasone|
45913345|NCT02021240|Drug|Normal Saline|
45913346|NCT02021253|Dietary Supplement|Probiotic|Lactibiane TOLERANCE vs Placebo
45630340|NCT05475405|Other|IASTM|"Restrictions and myofascial adhesions should be assessed prior to treatment along both sides using IASTM tool and a lubricant.~Once restrictions are assessed, fanning strokes at 45 degree angles to skin should be applied using the tool. This technique should be performed for 20 seconds parallel to the muscle fibers and 20 seconds perpendicular to the muscle fibers for each muscle group in scapulothoracic region. Total time for IASTM application is 10 mints. Upon completing all this patient should be given a home plan consisting of 2 different self-stretches targeting levator scapulae and upper trapezius"
45630341|NCT05476341|Drug|Bevacizumab injection|Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor
45769984|NCT01452074|Other|Exercise Training|During the first 12 weeks of the study, subjects will adhere to an exercise training program while maintaining their original body weight. The exercise training program will entail the following: 40min/session, ~50% of their maximal aerobic capacity (approximately 100-110 beats per min), 5-6 days/week
45769985|NCT01452074|Other|Weight Loss with continued Exercise Training|After the first 12 weeks in the study, subjects will continue with the same exercise program, but then they will be placed on a reduced calorie diet until they lose exactly 10% of their original body weight
45630342|NCT05476341|Drug|Bevacizumab injection（Avastin）|Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor
45630343|NCT03476187|Device|µCor|Monitor with µCor
45630344|NCT05481723|Drug|noradrenaline and vascular filling|In the control group, the haemodynamic management of the patients is done according to usual practice by maintaining blood pressure with noradrenaline and optimising stroke volume with vascular filling.
45769986|NCT01472692|Drug|Febuxostat|80mg PO daily for 8 weeks
45630345|NCT05481723|Procedure|pulmonary ultrasound after vascular filling|In the interventional group, intraoperative haemodynamic management is based on an algorithm that includes measurement of the number of B-lines appearing on pulmonary ultrasound after vascular filling. Monitoring of the stroke volume will also be performed in this group in order to stop the vascular filling if the ESV does not increase by more than 10%.
45630346|NCT05475015|Device|3D-MRE|All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
45769987|NCT05028764|Diagnostic Test|Buccal Swabs, Blood Draws and Skin Punch Biopsy|Buccal Swabs - FXN and specific RNA markers; Blood Draws - Lipid panel, Protein Marker Analysis and Gene RNA Analysis; Skin Punch Biopsy - Protein Markers
45769988|NCT00378820|Behavioral|Whey without milk minerals|
45769989|NCT00378820|Behavioral|Whey with milk minerals|
45769990|NCT00378820|Behavioral|Casein without milk minerals|
45769991|NCT00378820|Behavioral|Casein with milk minerals|
45769992|NCT05600374|Device|Bossdevice|The bossdevice is a real-time digital signal processor consisting of hardware and software algorithms. It is designed to read-in a real-time raw data stream from a bio-signal amplifier (electroencephalography, EEG), to continuously analyze this data and to detect patterns based on oscillations in different frequencies. When such a specific bio-signal pattern is detected, the device indicates this through a standard output port. This enables a connected device to know with millisecond accuracy when a specific biosignal pattern occurs.
45630347|NCT05475015|Device|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures.
45630348|NCT05481645|Drug|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents the binding of PD-L1 to PD-1 and B7.1 receptors on the surface of T cells, thereby reactivating T cells and enhancing the immune response.
45630349|NCT05481645|Drug|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
45769993|NCT01891136|Drug|Peanut protein|Subjects will receive increasing amounts of peanut protein over the modified rush phase and the build-up phase of the protocol. Once the subject reaches the maintenance phase of the study, they will remain on that dose until they reach the oral food challenges at the end of the study.
45769994|NCT02874014|Radiation|Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes|
45769995|NCT01891214|Other|Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ)|
45769996|NCT05020808|Dietary Supplement|NEAA|Food grade mixture of non-essential amino acids in powdered form to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
45769997|NCT05020808|Dietary Supplement|PPI|Food grade plant (legume - Fava) protein isolate to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
45769998|NCT02558400|Drug|PG324 Ophthalmic Solution 0.02%/0.005%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
45769999|NCT02558400|Drug|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
45770000|NCT02558400|Drug|Latanoprost Ophthalmic Solution 0.005%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
45770001|NCT02825264|Device|STARflo Implant|All patients who have been implanted with STARflo implant from 2011 will be offered to participate to this data collection
45770002|NCT05493696|Device|Antigravity treadmill|Alter G training for 30-minute, 3 times/week, 75% body weight
45770003|NCT05493696|Other|Traditional physical therapy program|applied 3 times/week for 12 weeks
45770004|NCT02352818|Other|no study intervention|
45770005|NCT04359732|Other|hybrid PET/MRI|An additional intermediate 18-FDG PET/MRI will be performed during neoadjuvant chemo-radiation therapy. Routine pre-treatment work-up PET/MRI will replace PET alone.
45770006|NCT04758260|Dietary Supplement|Antioxidant|Oral antioxidant oral intake in the 3 months prior to inclusion in the study
45770007|NCT01446250|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
45770008|NCT01446250|Drug|Boceprevir|BOC 800 mg (4 x 200 mg soft gel capsules) administered orally
45770009|NCT01446250|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
45913347|NCT02021253|Dietary Supplement|Placebo|
45770010|NCT01446250|Drug|Ribavirin|RBV 200 mg tablets (weight-based dose: < 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
45913348|NCT02021266|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
45630350|NCT05481645|Drug|Carboplatin Injection|Carboplatin which s similar to alkylating agent, is a second-generation platinum anti-tumor drug, which mainly causes cross-linking of DNA within and between chains, destroys DNA molecules, and disintegrates the helix.
45630351|NCT05481645|Drug|Paclitaxel Injection|Paclitaxel is a diterpene alkaloid with anticancer activity
45630352|NCT05481567|Other|Questionnaire|A series of 14 questions about with the impact of periodontitis on quality of life.
45770011|NCT05489172|Behavioral|Hola Bebe|"Participants will receive the handout It's never too early to prevent diabetes and will meet with the health educator at their CHC and download the Hola Bebe app. The health educator will advise participants to watch one module and complete an action plan for each of the first 12 weeks of study and encourage participants to weigh themselves weekly. The app includes the following features:1) educational/ behavioral audio visual modules, with automatic prompting to complete an action plan at the end of each module; 2) a motivational message library so that participants can chose which motivational texts they wish to receive, how often and time of day; 3) a community forum where participants can interact with each other and ask questions to the health educator; 4) tracking of weights to allow participants to see a graphic of their weight over time by inputting weekly weights; and 5) awards program where participants can earn badges for completing modules."
45770012|NCT04390568|Drug|BI 655130|BI 655130
45770013|NCT05493618|Drug|Pembrolizumab|Pembrolizumab 200 mg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
45770014|NCT05493618|Drug|Belantamab mafodotin|Belantamab 2.5 mg/kg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
45770015|NCT05493618|Drug|Dexamethasone|Dexamethasone 40 mg IV q3 weeks (20 mg if patient >75) until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
45770016|NCT00379600|Drug|rosiglitazone XR|
45630353|NCT05474703|Other|SF-36 Scores|"From the electronic database system of our hospital, patients who applied to the gynecology polyclinics of our hospital due to abnormal uterine bleeding between August 2020 and December 2021 and were administered oral dydrogesterone therapy or an intrauterine device releasing levonorgestrel for at least six months were reached using the phone numbers registered in the system.~The patients were informed about the study conducted by teleconference method, and the patients whose verbal consent was obtained were included in the study. After questioning the patients' sociodemographic characteristics such as age, marital status, educational status, income level, employment status, and obstetric history, the patients received the Short form 36 (P-36), consisting of 36 items; The Quality of Life Scale and the Female Sexual Function Scale (FSFI) composed of 19 items were applied."
45630354|NCT04272021|Drug|Methylphenidate|standard therapy for ADHD
45770017|NCT04139304|Drug|Cyclophosphamide|Given IV
45770018|NCT04139304|Biological|Daratumumab|Given IV
45770019|NCT04139304|Drug|Doxorubicin|Given IV
45770020|NCT04139304|Drug|Doxorubicin Hydrochloride|Given IV
45770021|NCT04139304|Drug|Etoposide|Given IV
45770022|NCT04139304|Drug|Prednisone|Given PO
45770023|NCT04139304|Drug|Vincristine|Given IV
45770024|NCT04139304|Drug|Vincristine Sulfate|Given IV
45770025|NCT05020574|Drug|Cephalexin|Given orally (PO)
45653413|NCT04217811|Other|No intervention|No intervention
45770026|NCT02936206|Drug|Fulvestrant|fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only
45770027|NCT02936206|Drug|Tamoxifen|14 days of treatment with tamoxifen 20mg orally each day
45770028|NCT01891526|Drug|9-cis-retinoic acid|Single dose of 9-cis-retinoic acid (Capsule 30 mg) as oral exposure
45770029|NCT01426516|Device|Genecept Assay|Genetic test which analyzes five pharmacodynamic and two pharmacokinetic genes important in psychiatric disorders
45770030|NCT01891604|Dietary Supplement|breast milk with Bifidobacterium Longum subp. Infantis R0033|
45770031|NCT01891604|Dietary Supplement|breast milk|
45770032|NCT05493462|Drug|Human FGF-1|Intranasal administration of human FGF-1
45770033|NCT02983136|Behavioral|Dialogue and inter-professional learning|"The middle and front-line leaders of the study OR will participate in an intervention based on an iKT model. Components of the intervention will include:~Two workshops, consisting of educational sessions covering the state of the art regarding person-centeredness, prevention of infections, leadership, and implementation. The educational component and results of pre-studies will work as frameworks for the dialogues between the front-line leaders and the research group. In dialogues the participants will be given the opportunity to reflect on barriers to and enablers of change; and~The participants will be supported in creating an action plan aimed at facilitating the anaesthesia providers' change of practice."
45630355|NCT04423887|Other|Lower Extremity Resistance Exercise Training|"Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
45630356|NCT04423887|Other|Home Exercise Plan|"2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension"
45630357|NCT04423887|Device|Electrotherapy + Heating|Interferential Current therapy (2P), in combination with heating pad for 20 minutes
45630358|NCT04423887|Procedure|Joint Mobilization|Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
45770034|NCT04325568|Behavioral|PsyGist and Clinician Manual|This is a pre-post test design aimed at conveying future genetic risk information to those at clinical high risk for psychosis. Participants will be assigned to either complete the Clinician Manual intervention (n= 27 participants) or PsyGist intervention (n=27 participants).
45630359|NCT04423887|Dietary Supplement|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
45630360|NCT05474313|Behavioral|PrEP-3D package|A package of support tools for accessing, adhering to, and monitoring PrEP use, including Alto Pharmacy delivery services, PrEP-3D mobile app, and home laboratory testing.
45770035|NCT02819908|Drug|Imprimis Dropless|Tri-Moxi-Vanc transzonular intravitreal injection
45770036|NCT02819908|Drug|Imprimis Less Drops|Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively
45770037|NCT01453010|Other|Self-directed Upper Limb SaeboFlex Training|"Participants undergo a 12 week self directed upper limb training programme with the SaeboFlex upper limb orthosis. Training consists of a maximum of 3 x 45 minute sessions a day.~Participants are closely monitored at least once a week by a saebo-trained therapist."
45630361|NCT05474313|Behavioral|Standard of Care|Participants are given local standard of care navigation for initiation of PrEP
45630362|NCT03434769|Drug|Cyclophosphamide|Cyclophosphamide 60mg/Kg on day -6
45630363|NCT03434769|Drug|Fludarabine|Fludarabine 25mg/m^2 IV on days -5 to -3
45630364|NCT03434769|Biological|CAR-T Cells|"Chimeric antigen receptor T cells to be implemented in a 3 + 3 design on day 0~Level -1 (1 x 105 cells/kg)~Level 1 [Starting dose] (5 x 105 cells/kg)~Level 2 (1 x 106 cells/kg)~Level 3 (2 x 106 cells/kg)"
45630365|NCT03426891|Drug|Pembrolizumab|200 mg intravenously (IV) every 3 weeks. The dose of pembrolizumab will remain the same throughout study treatment. During the maintenance phase, participants will receive pembrolizumab (for 12 months).
45630366|NCT03426891|Drug|Vorinostat|Dose Escalation Level -1 vorinostat 100 mg/day by mouth on days 1-5 every week during radiotherapy starting on first day of radiotherapy and 300 mg/day 1 week on 1 week off after radiotherapy. Level 1:vorinostat 200 mg/day by mouth on day 1-5 every week during radiotherapy, starting on first day of radiotherapy; and 300 mg/day 1 week on 1 week off after radiotherapy. Dose Escalation Level 2: vorinostat 300 mg/day by mouth on days 1-5 every week during radiotherapy, starting on first day of radiotherapy; and 400 mg/day 1 week on 1 week off after radiotherapy. Dose Expansion:all participants will receive the same dose of vorinostat that was determined to be most tolerated dose. During the maintenance phase, participants will receive vorinostat (for 12 months).
45630367|NCT03426891|Drug|Temozolomide|All participants will receive standard Temozolomide: Temozolomide (chemotherapy) 75 mg/m^2/day by mouth administered during the course of radiotherapy. Temozolomide will be administered continuously from Day 1 of radiotherapy to the last day of radiation. Maintenance Phase: temozolomide will start 4 weeks (+/- 3 days) after last dose of radiotherapy and will continue for 6 cycles post radiotherapy (150-200 mg/m^2/day, days 1-5 every 4 weeks) as per standard of care. During the maintenance phase, participants will receive Temozolomide (for the first 6 months).
45630368|NCT03426891|Radiation|Radiotherapy|All participants will receive standard radiotherapy: a total dose of 60 Gy administered in daily doses of 2 Gy, typically on a 5 days on / 2 days off schedule over 6 - 7 weeks.
45630369|NCT02697773|Other|Placebo|Patient receives one dose of placebo to match tanezumab subcutaneously on Day 1 and one dose of placebo to match tanezumab subcutaneously at Week 8.
45630370|NCT02697773|Biological|Tanezumab 2.5 mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 2.5 mg subcutaneously at Week 8.
45630371|NCT02697773|Biological|Tanezumab 2.5mg/5mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 5 mg subcutaneously at Week 8.
45770038|NCT02678858|Behavioral|Integrated Social Cognitive and Behavioral Skills Therapy|The Integrated Social Cognitive and Behavioral Skills Therapy (ISST) is a newly developed treatment program. It is based on the Training of Affect Recognition (Wölwer et al. 2005) and common social skills trainings, which are combined in an integrated rather than a sequenced manner. ISST uses both repeated practice and strategy-based training, and consists of 12 individual sessions, 5 group sessions and 1 individual final session over a period of 6 months.
46069949|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) continuous every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
46069950|NCT00794989|Dietary Supplement|Ground Flaxseed|Given orally
45630372|NCT02395289|Behavioral|Cognitive-Based Compassion Training (CBCT)|"Cognitive-Based Compassion Training (CBCT) is composed of secular, didactic instruction and meditation practices. CBCT includes the meditative practices of developing one-pointed concentration and mindfulness. CBCT will be one class per week, 2 hours each, for 8 weeks, for a total of 16 hours during the study. Each meditation class will include a didactic and discussion session that will describe the meditative technique introduced during the week and a practice meditation session. The training protocol is highly iterative and techniques introduced early in training are practiced daily. All participants will be asked to meditate approximately 30 minutes a day at home and will be given a meditation diary to record amount of time spent meditating per week."
46069951|NCT00794989|Other|No Intervention|Participants randomized to Arm 2 do not receive any intervention
45770039|NCT02678858|Behavioral|Neurocognitive Remediation Therapy|The Neurocognitive Remediation Program (NCRT) is based on a neurocognitive training already used as active control condition in our earlier studies (Wölwer et al. 2005, Klingberg et al. 2011). The present version of NCRT is matched in dose, mode and scheme of application to the ISST, but differs from the ISST regarding targeted cognitive domains and preferred training strategy (predominantly drill and practice based). The NCRT provides the same amount of group interaction and companionship as well as the same amount of guided community activity as in the ISST, but is structured in such a way that interactional behavior is secondary (e.g. by competition-like tasks rather than cooperative tasks). Thus therapeutic attention and commitment are held constant across study conditions.
45770040|NCT04078230|Procedure|Extend LymphAdenectomy|Expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and stations 12, 1, 3, 7, and 8 for left liver tumors
45630373|NCT02395289|Behavioral|Health discussion|Health discussion therapy is one class per week, 2 hours each, for 8 weeks. Each class will use interactive teaching methods to present the health material in an engaging and relevant manner. Representative weekly topics that will be covered include healthy diet, the role of exercise in emotional health, and the importance of sleep and relaxation. It is important to note that the material presented in the health discussion group, although intended to be beneficial to participants, does not include a contemplative component and is not iterative in nature.
45630374|NCT02395211|Behavioral|Usual Physiotherapy|"Usual physiotherapy consist of active or passive mobilization, extensor digiti and carpi functional electric stimulation, occupational therapy and taping.~The intervention will last 30 minute a day x 4 weeks"
45770041|NCT01891682|Other|Observational|Observational, Translational non-treatment study
45630375|NCT02395211|Device|Gloreha device|Proprioceptive stimulation under visual feedback are provided by the Gloreha device. The intervention will last 30 minute a day x 4 weeks
45770042|NCT01406860|Drug|Droperidol|Droperidol 1.25 mg IV x 1, may repeat 0.625 mg if needed at 60 minutes
45770043|NCT01406860|Drug|Metoclopramide + diphenhydramine|Metoclopramide 20 mg IV infusion q30 minutes as needed with a maximum of 4 doses + Diphenhydramine 25 mg IV injection x 1 given with the first dose of metoclopramide IV infusion and repeated x 1 given with the third metoclopramide IV infusion.
45770044|NCT04138212|Drug|Paclitaxel, Cisplatin|Paclitaxel 175mg/m2 plus Cisplatin 75mg/m2, q21d, 2 cycles
45770045|NCT04138212|Radiation|neoadjuvant chemoradiation therapy|Paclitaxel 50mg/m2 plus Carboplatin AUC=2, q1w, 5 cycles; 41.4Gy, 1.8Gy/d*23
45630376|NCT02394977|Device|Compression with Feedback|"Patients in the intervention group received CPR in accordance to published guidelines using the CFA device per manufacturer instructions. The Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) is a lightweight device that consists of three components . Application of400 ± 30 Newtons of force (41 kg or 90 lb of pressure), which correlates toa sternum compression depth of 50-60 mm, is followed by an audible click sound to alert the rescuer to cease compression. The click sound is also audible upon spring decompression alerting the rescuer to resume compression. The device does not require an electrical power supply."
45630377|NCT02394977|Other|Standard chest compression|CPR in accordance with published international guidelines using standard manual chest compression.
45770046|NCT02813954|Device|Blood Gas Sampling|analyzing amniotic fluid by blood gas device
45770047|NCT05493384|Other|Telerehabilitation Group|The program will include stretching, strengthening, breathing, posture, proprioceptive, relaxation exercises and segmental extremity movements. Each exercise will be performed 10 times in a session for the first 4 weeks and 15 times for the last 4 weeks. Exercises will be performed progressively on the patients.
45770048|NCT02773576|Drug|Risperidone implant|
45770049|NCT01891058|Device|drug-shock vs shock only|procainamide followed by electrocardioversion if necessary vs cardioversion only.
45770050|NCT01891838|Procedure|Volume controlled ventilation|
45447577|NCT03984825|Drug|Portia|Portia will be available in the form of tablets containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel.
45770051|NCT01891838|Procedure|Pressure-controlled ventilation|
45770052|NCT05489094|Combination Product|Nutrition Education and Growing Up Milk for 1 - 3 years old|Nutrition education is a basic information related balanced nutrition for 1 - 3 children including the details of food types and calories. while Intervention product is formulated to deliver macro- and micronutrients as part of the dietary intake for children at 1-3 years old with Iron-C formula
45770053|NCT05489094|Behavioral|Nutrition Education|Nutrition education is a basic information related balanced nutrition for 1 - 3 children including the details of food types and calories.
45653414|NCT04217343|Diagnostic Test|Allosure/Allomap/Cytokines testing|All patients with evidence of Cardiac Transplant rejection will undergo Allosure, Allomap, and cytokine testing. Allosure and Allomap will be performed as part of routine care. Cytokine testing will be performed at time of rejection and resolution.
45770054|NCT05022758|Drug|Rivaroxaban (Xarelto, BAY59-7939)|One of NOAC (Non-vitamin K antagonist oral anticoagulants)
45770055|NCT05022758|Drug|Warfarin|One of OAC (Oral anticoagulation therapy)
45770056|NCT01394926|Drug|Optison|Optison is a sterile non-pyrogenic suspension of perflutren for IV administration.
45770057|NCT05489016|Drug|Yuekang Huoxin Pills (concentrated pills)|Huoxin Pill (concentrated pill) is composed of Radix Ginseng, Radix Aconiti Lateralis Preparata, Ganoderma, Flos Carthami, artificial Moschus, cultured calculus bovis in vitro, Fel Ursi, Margarita, Venenum Bufonis, and Borneolum Syntheticum. It has the effect of invigorating qi and promoting blood circulation. It has been marketed in China for more than 30 years. Clinical studies have shown that Huoxin Pill (concentrated pill) has significant clinical efficacy in improving the symptoms and prognosis of coronary heart disease and angina pectoris. Basic studies have also confirmed that Huoxin Pill (concentrated pill) can play a role in myocardial protection by dilating coronary arteries and promoting angiogenesis. It produced by Guangzhou yuekang biopharmaceuticals co., ltd.
46069952|NCT00805753|Drug|ACTH|comparison of different dosages of drug
45447578|NCT03743727|Drug|Combined therapy LDV and SOF|All patients will receive ledipasvir/sofosbuvir fixed dose combination for 12 weeks. Patients weighing 35 kg or more will receive the adult dose: ledipasvir (90 mg)/sofosbuvir (400 mg). Patients weighing below 35 kg will receive half the adult dose: ledipasvir (45 mg)/sofosbuvir (200 mg).
45447579|NCT03745131|Other|Blood draw|Blood draw to obtain serum to determine anti-orthopox antibody titres.
46069953|NCT00797875|Procedure|PNF stretching|PNF stretching x 5 repetitions and continue 3 days
45770058|NCT05489016|Drug|Yuekang Huoxin Pills (concentrated pills)simulant|Huoxin Pill (concentrated pill) simulant, a placebo-like simulation have no therapeutic effect. The shape, packaging and taste are the same as Huoxin Pill (concentrated pill), produced by Guangzhou yuekang biopharmaceuticals co., ltd.
45770059|NCT05021978|Drug|Part A: 20 and 40 mg PRAX-944|Once daily oral treatment
45770060|NCT05021978|Drug|Part B: 120 mg PRAX-944|Once daily oral treatment with titration
45770061|NCT05021978|Drug|Part B: 120 mg PRAX-944 and Placebo|Once daily oral treatment with titration followed by placebo
45770062|NCT04280406|Drug|Azithromycin|azithromycin 500mg one hour before implant placement
45770063|NCT04280406|Drug|Placebo oral tablet|identical placebo one hour before implant placement
45770064|NCT05599828|Drug|AMG 510|Oral Tablet
45770065|NCT05599828|Drug|Omeprazole|Capsule
45770066|NCT05599828|Drug|Famotidine|Tablet
45770067|NCT05586698|Procedure|Auricular acupressure|We conducted auricular acupressure at zero acupoints on the left ear with Vaccaria ear seed (Group A) or removed seed (Group B) in 20 minutes, with 2 times of auricular acupressure. The stimulation was performed for 30 seconds each time, with two pressure movements per second, resulting in a total of 60 pressure movements per stimulation.
45770068|NCT04275726|Device|Myval THV Series|The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy. Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
45770069|NCT04275726|Device|Contemporary Valves (Sapien THV Series and Evolut THV Series)|The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy. Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
45447580|NCT03736551|Behavioral|5:2 diet|very low energy diet (600 kcal/day) on 2 consecutive days of the week, and 5 days each week on an energy restricted diet to maintain a similar overall energy deficit of 600 kcal/day across the week (5:2 diet)
45630378|NCT02394899|Behavioral|Play therapy|Short films that have been developed to deliver a series of child development messages will be shown at the monthly visits. Nine modules of approximate length 3 minutes each have been developed and cover the topics: Love, Comforting baby, Talking to babies and children, Praise, Using bath time to play and learn, Looking at books, Simple toys mothers can make, Drawing and games, and Puzzles. Nurses at the Sickle cell Unit (SCU) will be trained to discuss the video messages with the mothers/caregivers, demonstrate activities they can do with their children and how to make simple toys from household materials. Mothers/caregivers will practice some of the activities and they will be encouraged to make them part of their daily routine.
45447581|NCT03736551|Behavioral|Renal Weight Management Programme|Dietary intervention includes a standard continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day relative to their estimated total energy expenditure. In addition to the dietary intervention, the programme also includes personal exercise plans, optional pharmacotherapy (orlistat at standard dose), and development of personalised dietary and exercise goals using behavioural therapy techniques and motivational interviewing.
45447582|NCT03981861|Drug|Metformin and Spironolactone|Oral Metformin tablet (500 mg/tablet) twice daily for 6 months. Oral Spironolactone tablet (50 mg/tablet) once daily for 6 months.
45770070|NCT02675270|Behavioral|Phonological|This treatment involves picture viewing and word repetition.
45770071|NCT02675270|Behavioral|Orthographic|This treatment involves picture viewing, reading, and writing.
45770072|NCT02675270|Behavioral|Semantic|This treatment involves learning about the semantic features (meaning) of each trained word.
45770073|NCT02675270|Behavioral|Lexical|This treatment involves learning about the lexical features (letters and sounds) of each trained word.
45770074|NCT02675270|Behavioral|Untrained|These words are not trained during the treatment phase.
45770075|NCT01350232|Drug|Fludarabine|Subjects will receive fludarabine at a dose of 30 mg/m2 daily for 4 days as part of the preparative regimen
45770076|NCT01350232|Drug|Cytarabine|Subjects will receive cytarabine at a dose of 2 g/m2 daily for 4 days, approximately 4 hours after the fludarabine
45770077|NCT01350232|Device|Cellular Infusions|"Subjects will receive the cellular product in 2 steps. The first is a lymphocyte infusion of 2 X 10e8 lymphocytes/kg on the day they receive total body irradiation. The second is a CD34 enriched stem cell product approximately 48 hours after the cyclophosphamide.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
45770078|NCT01350232|Radiation|Total Body Irradiation|All subjects will receive 200cGy TBI in a single fraction on the AM they receive the lymphocyte infusion
45770079|NCT01350232|Drug|Cyclophosphamide|All subjects will receive cyclophosphamide at a dose of 60 mg/kg at approximately 72 and 96 hours after the lymphocyte infusion
45770080|NCT01350232|Drug|Bortezomib|Subjects will receive bortezomib 1.3 mg/kg on Day 1,4,8, and 11 of a 21 day cycle. This will be repeated for 2 cycles.
45770081|NCT01350232|Drug|Rituximab|Subjects will receive rituximab 375 mg/m2 on day 1 and day 8 of a 21 day cycle, on days they will also be receiving rituximab. This will be repeated for 2 cycles.
46069954|NCT00797875|Procedure|passive stretching|passive stretching x 5 repetitions continue 3 days
46069955|NCT00805831|Device|HDH|sutureless vascular anastomosis
46069956|NCT05179915|Other|Therapeutic Touch|In the latent phase of labor, the field energy of the sacral region will be cleared for an average of 15 minutes.
46069957|NCT00656851|Drug|Pioglitazone|30mg/day for 16 weeks
46069958|NCT00656851|Behavioral|Exercise Training|Cardiorespiratory and resistance exercise training 3days/wk for 16 weeks
46069959|NCT00803257|Other|Lumbrical splint and Lumbrical exercises|Subjects receive one of four possible interventions - Dose and Frequency are the same for each
45630379|NCT02394899|Other|Problem solving skills|Problem solving therapy (PST) aims to empower patients or caregivers in attending to daily challenges. It is based on cognitive behavioural therapy and can be used in primary care settings. It encourages persons to use existing resources and skills to function better and find solutions to problems. It will be delivered in 6 sessions over the 6-week period and will last for about 30 minutes per session. The stages of PST are: identification of the problems; generating possible solutions; evaluating and implementing preferred solution; and evaluating to see if the solutions were successful. The parent/caregiver will be taught a process of problem solving with reference to general everyday problems as well as specific problems which may arise while parenting a child with SCD.
45770082|NCT01350232|Procedure|Plasmapheresis|Subjects who continue to have detectable anti-donor antibody will receive plasmapheresis to reduce the antibody further
45630380|NCT02397005|Drug|ZL-2102|A selective and reversible inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).
45630381|NCT02397005|Drug|Placebo matching ZL-2102|
45630382|NCT02394821|Drug|Polihexanide 2%|
45630383|NCT02394821|Drug|Metronidazole 0.8%|
45630384|NCT02394587|Behavioral|Mindfulness-based Stress Reduction|A non-pharmacological approach to pain management.
45630385|NCT02394743|Radiation|18FDG-PET|
45630386|NCT02397161|Other|EEG biofeedback mental attention-neuromuscular training|Mental attention training using EEG biofeedback and neuromuscular training using physio-therapeutic exercises
45630387|NCT02397161|Other|Neuromuscular training|Neuromuscular training using physio-therapeutic exercises
45630388|NCT02397161|Other|EEG biofeedback mental attention training|Mental attention training using EEG biofeedback
45630389|NCT02394509|Behavioral|Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
45770083|NCT01895660|Behavioral|Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation|Types of constraint and dosage amounts will be varied.
45770084|NCT05493228|Drug|Precedex Injectable Product|Precedex activates 2-adrenoceptors, and causes the decrease of sympathetic tone, with attenuation of the neuroendocrine and hemodynamic responses to anesthesia and surgery; it reduces anesthetic and opioid requirements; and causes sedation and analgesia. it is used before and/or during surgical
45770085|NCT05493228|Drug|Saline|mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl
45770086|NCT02758132|Biological|Denosumab|One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
45770087|NCT02758132|Drug|Enzalutamide|160 mg enzalutamide by mouth daily
45770088|NCT02758132|Drug|Abiraterone|1000 mg abiraterone by mouth daily
46069960|NCT00803335|Drug|Vaginal conjugated estrogen cream 0.5gm|Women in this arm will apply 0.5gm vaginal estrogen cream nightly until surgery.
45447583|NCT03743649|Drug|Haloperidol|Given IV
45630390|NCT02394431|Other|Cardiac echography|Ejection fraction measured by Teicholz and planimetry, diastolic function, tissular doppler, myocardiac performance index, global longitudinal strain measured by speckle tracking, arterial pulmonary hypertension, left ventricular hypertrophy.
45630391|NCT02394431|Other|Biological parameters|Hemoglobin levels, red cells, hematocrit, iron, ferritin
45630392|NCT02394431|Other|Clinical parameters|Blood transfusion number, severity of the sickle cell disease damage, evolution duration of the sickness
45630393|NCT05745857|Drug|Avastin|Orally administered
45447584|NCT03743649|Drug|Lorazepam|Given IV
45447585|NCT03743649|Other|Placebo|Given IV
45447586|NCT03743649|Other|Quality-of-Life Assessment|Ancillary studies
45447587|NCT03743649|Other|Questionnaire Administration|Ancillary studies
45447588|NCT03736473|Drug|MEDI9447 (oleclumab)|MEDI9447 administered intravenously
45447589|NCT01332266|Drug|E7050|E7050 given orally at 200, 300, or 400 mg once daily.
45630394|NCT05745857|Drug|Erbitux|Orally administered
45630395|NCT05745857|Device|Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy|Fluorescent endoscope fiber and spectroscopy probe will be inserted through the working channel of the normal clinical therapeutic endoscope
45630396|NCT05476185|Behavioral|READY4Life Programming - classroom instruction|The intervention group receives 16 hours of classroom instruction.
45630397|NCT02394353|Device|Transient hepatic elastography|
45770089|NCT02758132|Drug|Prednisone|5 mg prednisone by mouth twice daily
45770090|NCT04107636|Procedure|Vacuum assisted biopsy|First, the tumor will be removed under local anesthesia using the VAB system with US guidance, through a small skin incision (<0.5 cm). A localization marker will be placed in the biopsy cavity, to help determine the cavity location.
45770091|NCT04107636|Procedure|conventional lumpectomy|After 3 weeks, the breast conserving surgery is performed, excising the VAB excision cavity and a ≥1 cm of surrounding tissue, as deemed appropriate by the attending breast surgeon. A sentinel node biopsy will be performed in the same procedure.
45770092|NCT01891916|Dietary Supplement|Extensively hydrolyzed casein formula + LGG|Extensively hydrolyzed formula containing Lactobacillus GG
45770093|NCT01892072|Procedure|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
45770094|NCT01313416|Biological|CT-011|3mg/kg, intravenous (IV) day 1 of each cycle over 2 hours.
45770095|NCT01313416|Drug|Gemcitabine|1000mg/m^2 intravenous (IV) over 30 minutes on days 8, 15, and 22 of each cycle.
45770096|NCT04236804|Device|Flowly (TMC-CP01)|TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.
45770097|NCT05599360|Drug|Vyxeos|Vyxeos (daunorubicin and cytarabine) liposome for injection
46069961|NCT00803335|Drug|Vaginal conjugated estrogen cream 1.0gm|Women in this arm will apply 1.0gm vaginal estrogen cream nightly until surgery.
45630398|NCT05745779|Diagnostic Test|HbA1c, Vitamin D, Vitamin B12|Serum HbA1c, Vitamin D, Vitamin B12 values of the patients who applied for gingival treatment in the last 3 months from the date of application were found from the hospital archive and serum was not taken from the patients again for the study.
45630399|NCT02394197|Drug|Chloroquine phosphate|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
45630400|NCT02394197|Drug|primaquine|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
45630401|NCT02394119|Drug|Ofatumumab|1500 mg/1.73m2, administered once diluted in 1000 ml of normal saline
45630402|NCT02394119|Drug|Rituximab|375 mg/m2, administered once diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg.
45770098|NCT05599360|Drug|Mylotarg|Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of the CD33-directed monoclonal antibody (hP67.6; recombinant humanized immunoglobulin [Ig] G4, kappa antibody produced by mammalian cell culture in non-secreting 0 (NS0) cells) that is covalently linked to the cytotoxic agent N-acetyl gamma calicheamicin. Gemtuzumab ozogamicin consists of conjugated and unconjugated gemtuzumab. The conjugated molecules differ in the number of activated calicheamicin derivative moieties attached to gemtuzumab. The number of conjugated calicheamicin derivatives per gemtuzumab molecule ranges from predominantly zero to 6, with an average of 2 to 3 moles of calicheamicin derivative per mole of gemtuzumab.
45770099|NCT05499234|Drug|Dolantin|If VAS score is more than 4 even after additional dose, use dolantin 1 mg/kg
45913349|NCT02021344|Behavioral|Mental Health First Aid|Originally developed in 2001, MHFA is a 12-hour course comprised of six modules, covering depression, anxiety, psychosis, substance abuse, eating disorders, and self-harm. Each module includes information about the mental health-related problems (e.g., signs and symptoms), advice on how to respond appropriately, and interactive activities to enhance the learning process. Some modules include videos with perspectives of individuals recovering from mental disorders and examples of how to effectively use the MHFA intervention. Program participants learn how to help individuals in crisis and also how to recognize early warning signs and intervene before mental health problems progress to crises.
45913350|NCT02021383|Behavioral|Bi-weekly in person meetings with a Registered Dietician|"Participants in the Contest Plus group had the opportunity to receive 5 in person meetings with a Registered Dietician. These meetings took place bi-weekly and gave the participants a chance to discuss food consumption, physical activity, meal planning and assessed the participant's weight at each visit.~Participants in the Contest only and Control group were not eligible to receive these meetings."
45447590|NCT01332266|Drug|Cetuximab|Cetuximab is given at an initial dose of 400 mg/m2 given as a 2-hour intravenous (IV) infusion on Day 1 of Cycle 1, followed by a dose of 250 mg/m2 given as a 1-hour IV infusion on Day 8, Day 15, and Day 22 of Cycle 1, and Day 1, Day 8, Day 15, and Day 22 of each subsequent cycle.
45447591|NCT03736317|Device|sham TBS|Stimulate the dorsal lateral prefrontal cortex or medial prefrontal cortex for 2 weeks by sham Theta-burst stimulation (TBS), five times for a week with the sham coil.
45447592|NCT03736317|Device|real mPFC cTBS|Stimulate the medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
45630403|NCT03167333|Drug|platelet rich plasma|The amount of PPR was about 4-5 cc
45630404|NCT03167333|Drug|Hyaluronic acid|HA was 2.5cc
45630405|NCT02394041|Device|Acupuncture|Method of acupuncture: check the condition of skin, disinfect if needed, insert sterile needles with special handling for each point, remove the needles after 15 minutes.
45630406|NCT02394041|Device|Sham acupuncture|Sham acupuncture with sham needles
45630407|NCT02393729|Behavioral|Neuropsychological assessment|"The neuropsychological assessment will include an assessment of:~Intellectual ability~Laterality~Reading Skills~Motor skills~Oral Language~Attention~Child's behaviour"
45630408|NCT02393729|Other|MRI Study|"It will include a first session of about an hour outside MRI for familiarization with the environment of the MRI. The MRI will then be made after a break of 15 minutes~Morphological time: this time include the initial acquisition of a sequence of anatomical 3D T1-weighted high-resolution contiguous axial slices and the imaging of diffusion tensor.~Functional time: The experimental paradigm is a paradigm as a block with alternating phase of motor and rest conditions. The two motor tasks are: a Learning motor sequence or motor sequence task and Automated motor sequence or AT (automated task)."
45630409|NCT03167567|Behavioral|Presence of a medical clown during labor|Presence of a medical clown during labor
45630410|NCT02393963|Drug|Tranexamic Acid|0.5g Tranexamic Acid in 0.9% Sodium Chloride (study group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
45630411|NCT02393963|Other|Placebo|0.9% Sodium Chloride (placebo group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
45630412|NCT03115385|Dietary Supplement|VSL#3|VSL#3 will provide active packets. Subjects will take 2 to 3 packets per day with for 16 weeks. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. VSL#3 probiotic is provided in powder form and needs to be mixed with cold, non-fizzy liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero with stevia).
45770100|NCT05499234|Drug|Paracetamol|If VAS score is more than 4 even after dolantin 1 mg/kg, 10 mg/kg paracetamol IV
45770101|NCT01269034|Drug|Exenatide|1.25 mcg before the boost sub-cutaneously.
45770102|NCT01269034|Drug|Rapid and long acting insulin|Depends on their Carbohydrate ratio and body needs
45770103|NCT01269034|Drug|long acting insulin + rapid acting + 1.25 mcg Exenatide|Depends on their body needs.
45913351|NCT02021383|Behavioral|Financial incentives for weight loss maintenance|Participants in the Contest Plus and Contest Only groups were eligible for a lottery based financial incentive for maintaining their weight lost during phase 1 (Baseline to week 10) of the trial. There were three, month-long follow up assessments (weeks 16, 20 and 24) that participants were eligible for. The lottery prize was contingent upon the length of time they maintained their weight loss.
45913352|NCT02021396|Procedure|Embolization|this arm of the study was interventional (splenic artery embolization)
45913353|NCT02021409|Drug|BAY85-3934|Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets
45913354|NCT02021409|Biological|Darbepoetin alfa|
45630413|NCT03115385|Dietary Supplement|Placebo|A matched placebo to VSL#3 will be provided. The placebo will be identical to the active VSL#3 probiotic in aspects such as packaging, color, taste, texture, shape, and odor. The placebo will not contain active ingredients. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. The placebo is provided in powder form and needs to be mixed with liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero).
45630414|NCT02393807|Drug|PF 06260414 solid dose formulation|Single dose of 30 mg PF-06260414 given under fed/fasted conditions
45630415|NCT02393807|Drug|PF-06260414 nanosuspension|Single dose of 30 mg PF-06260414 given under fasted conditions
45630416|NCT02393651|Device|tDCS|Late LTP-like plasticity tDCS (2 times per week) for 4 weeks.
45630417|NCT03115619|Drug|Pirfenidone|Participants will receive pirfenidone therapy as per clinical practice or summary of product characteristics (SmPC).
45630418|NCT05745623|Drug|ICP-723|ICP-723 tablet administered orally，once a day，for every 28 days as one cycle
45630419|NCT02393495|Device|intrauterine device TCu 380A|
45630420|NCT02393573|Drug|Metformin|Patients will take metformin for two weeks before Surgery and 2 days after the surgery
45630421|NCT02393573|Drug|Placebo|Patients will take Placebo pills for two weeks before Surgery and 2 days after the surgery
45630422|NCT05745467|Drug|Povidone Iodine 5% Soln,Top,Kit|5% povidone iodine will be swabbed in patients nares of the experimental group.
45630423|NCT02393261|Other|2500ml Huaren peritoneal dialysate|use 2-3 bags of 2500ml Huaren dialysate in the daytime and keep 1 bag of 2500ml Huaren dialysate in the night
45630424|NCT02393261|Other|2000ml peritoneal dialysate|use 3-4 bags of normal 2000ml dialysate in the daytime and keep 1 bag of 2000ml dialysate in the night
45770104|NCT05499156|Other|placenal MSC derived exosomes|placenta-MSCs derived exosomes Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of PlacentaMSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial
45630425|NCT02693171|Drug|Dinutuximab|Unituxin was administered along with cytokines according to the prescribing information
45630426|NCT02392949|Behavioral|Passive mobilization|An anterior-posterior manual pressure act on the cervical spine of the subject
45630427|NCT02392949|Other|Placebo|The elbows will be put into a 90 deg elevated position and held for 5 secs, then back to resting position
45630428|NCT03167021|Other|Survey|This observational and transversal study will be conducted as a survey using the REDCap software and the response to this survey will be done online, in real time, with an automatic, secure and centralized data collection (CHU Clermont-Ferrand).
45770105|NCT02670512|Device|Telehome Monitoring|
45447593|NCT03736317|Device|real dlPFC iTBS|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
45447594|NCT03736317|Device|real dlPFC iTBS + real mPFC cTBS|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern, and stimulate medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
45770106|NCT05599126|Drug|Mianserin|Subjects were required to take mianserin regularly during the study period, with the effective dose being taken orally once a night before bedtime.
45913355|NCT02020980|Biological|Botulinum toxin type A|"This is an observational study designed to reflect the clinical practice in real life as closely as possible.~Botulinum Toxin Type A (BoNT-A) injection administered according to the local Summary of Product Characteristics (SmPC) and the locally agreed treatment guidelines."
45630429|NCT05745233|Drug|Nivolumab|Intraperitoneal administration of nivolumab
45630430|NCT05745233|Drug|Pembrolizumab|Intraperitoneal administration of pembrolizumab
45630431|NCT02393027|Drug|[18F] LBT-999 PET|
45630432|NCT04781231|Device|MusicCare® device|The device consists of a headset and a touch pad. The patient can choose the style of music he prefers among 5. The 'U-shaped sequence' offered by MusicCare® is based on the principle of hypnoanalgesia. Musical induction is personalized according to the patient's preference. It will gradually lead to a hypnotic state of consciousness modified by variations in musical components such as rhythm, frequencies, orchestral formation and volume. A listening session lasts about 20 minutes.
45630433|NCT04781231|Device|Device with quiet recorded music|An mp3 device with headphones will be given to the patient. Caregivers will launch a quiet 20-minute music playlist
45630434|NCT04781231|Other|Usual management of anxiety|No specific intervention
45630435|NCT02392793|Drug|Talazoparib|Given orally once or twice on day 1 (depending on the dose level), then daily on days 2-6.
45630436|NCT02392793|Drug|Irinotecan|Given intravenously daily, days 2-6 immediately following the talazoparib dose.
45630437|NCT02392793|Drug|Temozolomide|Given orally daily. Dose to be determined after MTD established with talazoparib plus irinotecan.
45630438|NCT02392793|Drug|Filgrastim|Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is >2,000/μL, unless peg-filgrastim is given.
45630439|NCT02392793|Drug|Peg-filgrastim|Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is >2,000/μL, unless filgrastim is given.
45770107|NCT05599126|Drug|Lorazepam|Subjects were required to take lorazepam regularly during the study period, with the effective dose being taken orally once a night before bedtime.
45770108|NCT02669498|Procedure|Routine fallopian tube removal|Fallopian tubes are removed by dissection of the Mesosalpinx.
45913356|NCT02021422|Drug|anakinra|Dosage Route Administration 100 mg SC Every Other Day
45913357|NCT02021422|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 2-4 hours
45913358|NCT02021422|Drug|Irinotecan|Irinotecan 180 mg/m2 90 minutes
45913359|NCT02021422|Drug|fluorouracil|fluorouracil 2400 mg/m2 48 hours
45630440|NCT05745155|Device|Senti Wear device system with Senti-AI subsystem|"This device is a smart garment, with a similar form to a T-Shirt, jacket or tabard, embedded with ten sensor modules (nine acoustic sensors, one kinetic sensor - all able to detect signals from the chest wall and underlying structures, including the lungs) encased in silicone; the device is charged via a charging port in the garment. The device has two modes of operation: recording mode and charging mode. The device is internally (battery) powered during recording mode and mains-powered during charging mode. The device is accompanied by cloud-based software to listen to both contemporaneous and historically recorded breath sounds, for each Senti patient. To use the device, the user puts the garment on (overhead, like a T-Shirt, before joining the back piece to the front like a tabard).~Additionally, Senti-AI adds an anomaly burden score and an alert flag for review against each acoustic record for each patient."
45630441|NCT05745077|Behavioral|Telemedicine Consultation|Patients will be contacted by their surgeon over the phone to discuss surgical treatment.
45630442|NCT05745077|Behavioral|Traditional Care|Patients will proceed with their surgical consultation as per standard practice.
45630443|NCT03166943|Procedure|Systolic function by echocardiography|"Echocardiography for evaluation of systolic function:~by biplane Simpson's method.~by speckle tracking:"
45770109|NCT05598502|Device|REBOA, Resuscitative Endovascular Occlusion of the Aorta|The balloon catheter is inserted via the common femoral artery in the groin, accessed under ultrasound guidance due to weak femoral pulses, and the puncture is done by the Seldinger technique. The balloon is inserted along a guidewire 25-30 cm, safely below the renal arteries, to be in the right place to stop pelvic hemorrhage including life-threatening post-partum hemorrhage
45630444|NCT03166943|Procedure|Diastolic function by echocardiography|"Echocardiography for evaluation of diastolic function:~Left atrial Volume~Mitral Inflow Patterns~Pulsed wave Doppler~Mitral inflow patterns include normal, impaired left ventricular relaxation, pseudonormal, and restrictive left ventricular filling patterns.~Tissue Doppler Annular Early and Late Diastolic Velocities~Pulsed wave tissue doppler imaging~Primary measurements include the systolic , early diastolic, and late diastolic velocities."
45630445|NCT02392715|Device|Inspiratory muscle training with Threshold by respironics|"Inspiratory muscle training~15 minutes, 3x/weeks, 36 sessions~Intensity: 15% of PiMax during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax."
45630446|NCT02392715|Device|Sham Inspiratory muscle training|"with Threshold by respironics~15 minutes, 3x/weeks, 36 sessions~Intensity: 5 centimeters of water (cmH20)"
45630447|NCT02692703|Drug|glecaprevir/pibrentasvir|Tablet; glecaprevir coformulated with pibrentasvir
45630448|NCT02392325|Biological|rDEN1Δ30|Administered subcutaneously in 0.5 mL containing 10^3.0 plaque-forming units (PFU)
45913360|NCT02021435|Dietary Supplement|salt substitute|Free salt substitute provided
45913361|NCT02021500|Drug|ABI-007|No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
45913362|NCT02021513|Dietary Supplement|Fish Oil|Fish Oil (2.25gm EPA and 2.25gm DHA total)
45913363|NCT02021513|Dietary Supplement|Olive Oil|Placebo group
45913364|NCT02021526|Drug|Triheptanoin|Triheptanoin (C7 oil) is a 7-carbon medium chain triglyceride.
45630449|NCT02392325|Biological|Placebo|Administered subcutaneously in 0.5 mL
45630450|NCT02392325|Biological|rDEN2Δ30-7169|Administered subcutaneously in 0.5 mL containing 10^3.0 PFU
45630451|NCT03106181|Device|iStent inject®|Insertion of iStent inject®
45630452|NCT03106181|Procedure|Phacoemulsification and intraocular lens implant|Conventional phacoemulsification cataract surgery and intraocular lens implant
45630453|NCT03167177|Biological|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
45770110|NCT05598502|Other|National guidelines|Standard management of postpartum hemorrhage according to Uganda national guidelines
45913365|NCT02021539|Procedure|Cervical ultrasound +elastography 1|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
45913366|NCT02021539|Biological|Vaginal fibronectin measurement|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
45447595|NCT03127839|Procedure|Eccentric Strengthening|Use of eccentric strengthening exercises in treatment plan during visits and at home.
45447596|NCT03127839|Procedure|Traditional Strengthening|Use of traditional strengthening exercises in treatment plan during visits and at home.
45447597|NCT03127839|Behavioral|Pain education|Addition of pain neuroscience-focused education in addition to strengthening exercise program
45630454|NCT03167177|Biological|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
45630455|NCT03167177|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
45630456|NCT03167177|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
45630457|NCT03167177|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
45630458|NCT03167177|Drug|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
45630459|NCT03167177|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
45630460|NCT03167177|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
45630461|NCT03167177|Biological|Nivolumab|Recombinant human anti-PD-1 IgG4 monoclonal antibody
45630462|NCT03167177|Drug|omega-3-acid ethyl esters|Omega-3-acid ethyl esters
45630463|NCT03167177|Radiation|Stereotactic Body Radiation Therapy|radiation
45630464|NCT03167177|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
45770111|NCT05313178|Dietary Supplement|Bacillus Coagulans GBI-30, 6086|In a randomized, double-blind, crossover fashion, study participants will supplement on a daily basis for two weeks during one study period with a 25-gram dose of either milk protein concentrate or a 25-gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086. Each dose will be ingested at the same time of day with 8 - 12 fluid ounces of cold tap water. All participants will be required to complete a supplementation log to document when each dose of their assigned protein is consumed. Upon completion of their first assigned study protocol period, participants will observe a three-week washout period by returning to their normal dietary intake and physical activity habits before beginning supplementation for the remaining study period.
45770112|NCT01892150|Other|Sunscreen|Apply sunscreen before and after UVA and UVB irradiation
45770113|NCT02663752|Procedure|Bone marrow aspirate|Patients experiencing a hematological response and patients not experiencing a hematological response while on deferasirox treatment received a new bone marrow aspirate in order to investigate the presence of differential gene expression between those two groups
45630465|NCT03167177|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
45630466|NCT03167177|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
45630467|NCT03167177|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
45630468|NCT03167177|Biological|GI-6207|Heat-killed S. cerevisiae yeast expressing CEA
45630469|NCT03167177|Biological|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
45630470|NCT03167177|Biological|haNK|NK-92 [CD16.158V, ER IL-2] (high-affinity activated Natural Killer cells)
45630471|NCT03166709|Behavioral|Preventing Addiction Related Suicide (PARS)|PARS is a module designed for a single session of an Intensive Outpatient Program (IOP) including a specified combination of didactic presentations and group discussions. PARS topics include: Goals and Objectives; Suicide Overview; The Strong Link Between Addiction and Suicide; Suicide Myths and Facts; Common Triggers of Suicidal Thoughts and Behaviors; Warning Signs of Suicide; Suicide Risk Factors; Suicide Protective Factors; How You Can Prevent Addiction Related Suicide; Action Steps to Take if You or Someone You Know Becomes Suicidal
45630472|NCT03166709|Behavioral|Intensive Outpatient Program standard session|Intensive Outpatient Program (IOP) substance abuse group session focused on depression, grief, or managing emotions. Site-specific session topic is what that IOP usually provides and was chosen by agency leads prior to start of study.
45630473|NCT05744765|Other|breathing exercises|After the initial 5 minutes of relaxed breathing, the participants will perform diaphragmatic and costal breathing for 10 minutes. .5 diaphragmatic breathing will be done in 1 minute.
45913367|NCT02021539|Drug|Tocolytic treatment for 2 hours|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
45447598|NCT03637712|Device|Computer Algorithm|This device is a computer algorithm that runs in the background during routine screening or surveillance colonoscopy that is designed to aid in the detection of polyps
45447599|NCT03255824|Drug|Dexmedetomidine and Midazolam|Administration of Dexmedetomidine and Midazolam for sedation during third molar surgery.
45447600|NCT03255824|Drug|Propofol, Midazolam, and Fentanyl|Administration of Propofol, Midazolam, and Fentanyl for sedation during third molar surgery.
45630474|NCT02392169|Drug|Methylphenidate|Patients used Retina or Concerta twice a day lasting for one year.
45630475|NCT02392013|Other|Home Modification|Removal of home barriers or hazards.
45630476|NCT02391857|Procedure|Gastric decompression|Insertion the Naso(Oro)-gastric tube for early gastric decompression during CPR
45630477|NCT04805177|Procedure|hematoma evacuation|early minimally invasive image guided hematoma evacuation in patients suffering from ICH
45770114|NCT02663752|Drug|Deferasirox|Patients are already on commercial deferasirox before entering the study.
45770115|NCT04389944|Other|convalescent plasma application to SARS-CoV-2 infected patients|In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma as follows: 200ml at enrolment and 200ml at 12-24 hours follow-up.
45913368|NCT02021539|Procedure|Cervical ultrasound +elastography 2|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
45913369|NCT02021552|Other|blood sampling|5 ml blood sampling
45447601|NCT03238352|Device|Potassium oxalate|Oral rinse containing 1.5 percent (%) KOX and 0 ppm fluoride
45447602|NCT03238352|Drug|Sodium fluoride|Oral rinse containing 0.02% weight by weight (w/w) sodium fluoride (NaF)
45447603|NCT03238352|Other|Placebo|Oral rinse containing 0% KOX and 0 ppm fluoride
45630478|NCT03166865|Biological|Umbilical-cord mesenchymal stromal cells (UC-MSCs)|Allogeneic UC-MSCs 1 x 10~7 diluted on 5 mL of Platelet Rich Plasma
45630479|NCT03166865|Other|Hyaluronic acid|intra-articular injection of Hyaluronic Acid
45630480|NCT03166787|Other|Charcoal hookah|The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with either charcoal for 30 min each.
45630481|NCT03166787|Other|E-coal hookah|"The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with electrically (Global First e-coal, ) for 30 min each."
45630482|NCT03166787|Other|Cigarette|The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young cigarette smokers smoke 2 cigarettes down to the stub over 30 min (to simulate real-world use).
45770116|NCT02654782|Drug|Lactated Ringer's|Crystalloid fluid given for hemodynamic resuscitation based off of individual patient needs.
45770117|NCT02654782|Drug|5% Human Albumin|Colloid given for hemodynamic resuscitation based off of individual patient needs.
45630483|NCT03166787|Drug|Carbon Monoxide inhalation|A subset (n=8) of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling 0.3 CO gas from a Douglas bag.
45630484|NCT03166787|Other|Room Air inhalation|A subset 8 of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling room air from a Douglas bag.
45630485|NCT03166787|Drug|vitamin C|in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with either i.v. vitamin C .
45630486|NCT03166787|Drug|tadalafil|in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with one dose of oral tadalafil.
45770118|NCT02821364|Other|Advanced Life Support|IV FLUIDS, INTUBATION
45447604|NCT04284254|Drug|Autologous Plasmablasts|"Autologous Plasmablasts engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty transposon system.~Phase 1:~Dose Level 1: 5 x 10e7 cells/kg on Day 0~Dose Level 2: 1 x 10e8 cells/kg on Day 0~Dose Level 3: 1 x 10e8 cells/kg x 2 doses on Day 0 and Day 30 +/-3 days.~Phase 2:~- Maximum Tolerated Dose (MTD) established in Phase I"
45447605|NCT01222754|Drug|Lenalidomide|"With radiation therapy five days per week, concurrent doses of lenalidomide daily in a standard Phase I dose escalation design.~Maintenance dosing of lenalidomide, post-radiation, for 21 days of a 28 day course."
45770119|NCT02820194|Radiation|Stereotactic Body Radiation Therapy|Stereotactic body radiation is a therapy for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule
45447606|NCT01222754|Radiation|XRT, 54-59.4 Gy|Radiation therapy five days per week to a prescription dose of 54-59.4 Gy, with concurrent administration of lenalidomide
45447607|NCT05331716|Procedure|Cardiac ablation therapy|In a subset of patients with known therapy refractory arrhythmia sole LAVA modification is fashioned
45770120|NCT02820194|Procedure|Microwave Ablation|Microwave ablation (MWA) is a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis
45770121|NCT01253668|Drug|Brivanib alaninate|Brivanib by mouth daily at a dose of 800mg.
45447608|NCT05179694|Diagnostic Test|Prostate biopsy|Prostate biopsy via either the Transrectal route (comparator) or Transperineal route (experimental), each under local anaesthetic.
45770122|NCT01253668|Genetic|Polymerase chain reaction|Undergo 1241-cG250 PET/CT imaging (correlative studies)
45770123|NCT01253668|Other|Iodine I 124 chimeric monoclonal antibody G250|Undergo 124I-cG250 PET/CT imaging (correlative studies)
45770124|NCT01253668|Procedure|Positron emission tomography/computed tomography|Undergo 1241-cG250 PET/CT imaging (correlative studies)
46069962|NCT00797953|Drug|T89|A two-herb botanical drug product in 62.5mg capsule formulation. It is to be used as 125mg or 187.5mg twice daily.
45770125|NCT01253668|Genetic|Protein expression analysis|Correlative studies
45770126|NCT01253668|Other|Immunohistochemistry|correlative studies
45770127|NCT01890200|Drug|Peginterferon alfa-2a|conventional treatment of Hepatitis C
45770128|NCT01890200|Drug|Ribavirin|conventional treatment of Hepatitis C
45447609|NCT03850418|Drug|azacitidine|azacitidine 32mg/m2 x 5 days every 28 days for minimum of 4 cycles if tolerated
45630487|NCT02692235|Dietary Supplement|carnitine|1500 mg/d l-carnitine-l-tartrate
45630488|NCT02692235|Dietary Supplement|placebo|isonitrogenous
45630489|NCT03166241|Diagnostic Test|serum interleukin 21|it is cytokine used as a marker to detect it's level in patients with adverse drug reactions
45630490|NCT03166241|Diagnostic Test|Complete Blood Picture|It is a blood sample will taken from patients to detect any abnormalities in blood component at the start of the study
45630491|NCT03166241|Diagnostic Test|Liver function test|It is a blood sample will taken from patients to detect any associated liver disease at the start of the study
45630492|NCT03166241|Diagnostic Test|Random Blood Sugar|measure blood sugar in patients included in the study at the start of the study
45630493|NCT03166241|Diagnostic Test|Erythrocyte Sedimentation Rate|blood sample will be taken from patients to detect any abnormalities in erythrocyte sedimentation rate at the start of the study
45630494|NCT03166241|Diagnostic Test|Kidney function tests|blood sample will be taken from patients to detect any kidney disease before the start of the study
45630495|NCT03167645|Drug|Human albumin|Substitution according to pre-specified dosage
45630496|NCT03166553|Drug|Elemene|
45630497|NCT03167957|Drug|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
45630498|NCT03167957|Drug|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
45770129|NCT01890200|Drug|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
45770130|NCT01890200|Drug|Placebo|Placebo, without acting ingredient.
46069963|NCT00798031|Device|A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.|A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. The study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prosthesis.
45630499|NCT03166397|Drug|Fludarabine|Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
45770131|NCT01662648|Drug|Paliperidone ER|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion.
45770132|NCT00378586|Procedure|Rectal biopsy|Rectal biopsy.
45630500|NCT03166397|Drug|Cyclophosphamide|Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
45630501|NCT03166397|Biological|TIL|TIL administration
45770133|NCT00378586|Procedure|Measurement of inflammatory markers in the rectal mucosa|IL-6, TNF-alfa.
45770134|NCT00378586|Procedure|Measurement of rectal lactic acid|Equilibrium dialysis.
45447610|NCT05280782|Drug|Ga-68 Galmydar|Single intravenous injection of the PET radiotracer 68Ga-Galmydar.
45630502|NCT03166397|Drug|IL-2|Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.
45630503|NCT03166397|Drug|Nivolumab|Nivolumab 480 mg fixed dose
45630504|NCT03166397|Drug|Ipilimumab|Ipilimumab 1 mg/kg up to 100 mg
45630505|NCT03166397|Drug|FMT Protocol|"FMT given both directly into the colon via colonoscopy and orally using capsules (12 capsules each time).~FMT will be taken from melanoma patients treated with Anti PD-1 who achieved a durable response of more than 12 months."
45630506|NCT05744609|Other|exposures of interest: epidemiological data, clinical characteristics, laboratory data, and chest radiographic reports|epidemiological data (e.g., age, sex, and residential area), clinical characteristics (e.g., fever, cough, and wheeze), laboratory data (e.g., white blood cell, c-reaction protein, and procalcitonin), and chest radiographic reports (e.g., X-ray, CT, and ultrasound)
45770135|NCT05586620|Procedure|3-snip punctoplasty|punctoplasty, more commonly known as watery eye surgery, is an ophthalmic surgical procedure performed to correct punctal stenosis (a condition that causes tears to overflow from the eyes) by widening the punctal opening to allow the tears to drain with ease.
45770136|NCT05586620|Procedure|3-snip punctoplasty and Mitomycin C|"punctoplasty, more commonly known as watery eye surgery, is an ophthalmic surgical procedure performed to correct punctal stenosis (a condition that causes tears to overflow from the eyes) by widening the punctal opening to allow the tears to drain with ease.~Mitomycin C is a chemotherapeutic agent that acts by inhibiting DNA synthesis"
45770137|NCT05596084|Procedure|maxillary sinus augmentation and implant placement|For maxillary sinus augmentation, the area will be prepared by lifting a full-thickness flap. The sinus membrane will be carefully elevated by opening a window through the lateral wall of the sinus on both sides.platelet-rich fibrin prepared with titanium on the other side will be placed in the space prepared in the sinus region by random selection. For Platelet-rich fibrin prepared with titanium (T-PRF), the blood taken from the patient to a 20 cc injektor was put into titanium tubes and prepared by centrifugation at 2700 rpm for 14 minutes according to the standard protocol. Then, 6 months after the surgery, histological sample will be taken with a trephine bur in both groups and the implant will be placed in accordance with the standard protocol. The stability value (ISQ) of the placed implant will be measured with the Ostell device at the time the implant is placed and 3 months after it is placed.
45652948|NCT04790669|Procedure|Daily adjustable progressive resistance exercises (DAPRE)|Daily adjustable progressive resistance exercises (DAPRE) In Group A, 11 participants were received Conventional physiotherapy treatment in addition to DAPRE technique by leg extension machine. In DAPRE technique, four sets of exercises were performed. The first two sets of exercise consisted of ten and then six repetitions, per- formed against one-half and three-fourths of the previously established working weight. Working weight is the amount of weight a patient uses during an individual session. The full working weight was used on the third set, and the patient performed as many repetitions as possible. After performing each of the third and fourth sets, patients rested for 1 min.6 weeks (3 sessions per week)• Hot pack: 10 min• Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale & sphygmomanometer.
45770138|NCT05596084|Procedure|Maxillary sinus augmentation with bovine bone graft|For maxillary sinus augmentation, the area will be prepared by lifting a full-thickness flap. The sinus membrane will be carefully elevated by opening a window through the lateral wall of the sinus on both sides. Bio-oss bovine bone graft on one side will be placed in the space prepared in the sinus region by random selection. For Platelet-rich fibrin prepared, the blood taken from the patient to a 20 cc injektor was put into titanium tubes and prepared by centrifugation at 2700 rpm for 13 minutes according to the standard protocol. Then, 6 months after the surgery, histological sample will be taken with a trephine bur in both groups and the implant will be placed in accordance with the standard protocol. The stability value (ISQ) of the placed implant will be measured with the Ostell device at the time the implant is placed and 3 months after it is placed.
45770139|NCT01893788|Drug|Aliskiren|Aliskiren: 150 to 300 mg daily for 48 weeks
45770140|NCT01893788|Drug|Eplerenone|50 to 100 mg daily for 48 weeks
45935223|NCT04711395|Device|measure the preoperative DLI、 SS-OCT image of the lens,、take photos of the anterior segment and self-scoring of the preoperative visual quality assessment scale.|subjects in the observation group and Healthy used iTrace ocular aberration analyzer（itracey Technologies）and IOL-Master 700 biometer to measure the preoperative DLI(Dysfunctional lens index) and SS-OCT image of the lens, and The researchers used the anterior segment slit lamp to take photos of the anterior segment of the subject's lens in a state of dilated pupils .and self-scoring of the preoperative visual quality assessment scale.
45447611|NCT05274308|Procedure|Blood sampling|Blood sampling from all eligible transplantation patients according to the protocol
45447612|NCT05256914|Other|Ozoral Pro and Ozoral gel administration|Peri-implant mucositis sites will receive in-office Ozoral Pro administration after non-surgical therapy. Patients will use Ozoral Gel for the domiciliary administration once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
45447613|NCT05256914|Other|Curasept chlorhexidine gel 1%|Peri-implant mucositis sites will receive in-office Curasept chlorhexidine gel 1% administration after non-surgical therapy. Patients will use chlorhexidine gel 1% for the domiciliary application once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
45630507|NCT04480073|Procedure|Customized CAD-CAM Titanium Mesh (Y-xoss CBR® by Reoss -Filderstadt - Germany) for Guided Bone Regeneration of atrophic alveolar ridges|"Step one:1) exposure of atrophic areas; 2) bone harvesting from mandible or calvarium; 3) filling the meshes with a mixture of the autogenous bone and particulated xenograft in a 1:1 ratio; 4) stabilization of the mesh with titanium micro-screws.~A post-operative cone-beam computed tomography (CBCT) will be done in all patients to have a reference point for the following controls.~6 months later, patients are re-evaluated with a new CBCT to check bone volumes of the regenerated tissues and to plan implant placement.~Step two: 1) removal of the meshes; 2) preparation of implant sites (one of which will be randomly chosen to obtain a bone biopsy for histomorphometric analysis); 3) implant placement.~3 months later, implants will be uncovered and the prosthetic phases will start.~Patients will be recalled 3, 6, and 12 months later, to assess peri-implant hard and soft tissue conditions, the stability of the reconstructed bone, and the onset of implant-related complications."
45630508|NCT05744531|Other|Internet-based Parenting Education based on the information -Motivation-Behavioral Skills (IMB) Model|Internet-based Parenting Education based on the information -Motivation-Behavioral Skills (IMB) Model
45630509|NCT05746169|Other|Health Questionnaires|A questionnaire with content developed and tested in the investigator's previous reproductive and cancer epidemiology studies as part of the NIH Environmental Influences on Child Health Outcomes (ECHO) consortium will be used to collect information on primary established and hypothesized risk factors for cancer and additional covariates.
45770141|NCT05488938|Other|Rehabilitative Intervention|Each program will require the daily performance of different postures and therapeutic activities at the girls' educational facilities and homes, based on the availability of families, for 10 months. Specific strategies that will be implemented will include maintaining asymmetrical postures that oppose the scoliosis curve during activities and exercises in sitting, standing, and walking positions (according to each participant's functional abilities). These strategies refer to a hypercorrective postural positioning of scoliosis. In addition, activities involving weight bearing on the lower limbs, such as walking and standing for at least two hours a day, will be encouraged, and passive stretching and spinal mobilization exercises will be conducted.
45770142|NCT01231750|Drug|Capsaicin|0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise
45770143|NCT01231750|Other|Placebo cream|cream, 4cm spread over 8cm x 15cm area of skin
45770144|NCT05488860|Drug|Triamcinolone acetonide(scar)/5-ALA(others)|For scar, the drug is triamcinolone acetonide.
45770145|NCT05488860|Procedure|Piezoelectric drived microneedling|Piezoelectric drived microneedling
45913370|NCT02021591|Behavioral|Mobile Diabetes Detective (MoDD)|MoDD is a web-based application that is designed to help individuals with diabetes identify specific problems related to glycemic control, and engage in problem-solving process. MoDD includes a number of messages that explain its users the nature of various problems related to glycemic control, aspects of individuals' behaviors that might have contributed to these problems, and alternative behaviors that could help to improve glycemic control. In addition to these messages displayed on the MoDD website, study participants may receive SMS messages with reminders to test blood glucose, or to follow the selected new behavior.
45447614|NCT03842150|Diagnostic Test|biliary atresia screen score|The investigators aim to develop a scoring system according to clinical, laboratory, imaging features of biliary atresia in the derivation dataset and tested in the validation datasets.
45447615|NCT05175482|Other|Virtual Education|health belief model based virtual education
45447616|NCT00180479|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
45447617|NCT00180479|Device|TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
45630510|NCT05746169|Other|Specimen sample collection|Collection of blood, urine, nails, hair, and saliva samples will be obtained during the participant encounters.
45630511|NCT04480151|Other|standard of care|retrospective study: standard of care
45630512|NCT05744453|Dietary Supplement|Olive Leaf Extract|experimental arm
45630513|NCT05744453|Dietary Supplement|Cellulose|placebo comparator arm
45630514|NCT05746091|Procedure|wrist arthroscopy|Hematoma Distraction Arthroplasty Versus Arthroscopic Partial Trapeziectomy with Hematoma Distraction in Basal Thumb Arthritis
45770146|NCT05488860|Drug|5-ALA (a photosensitizer for photodynamic therapy).|For other diseases, the drug is 5-ALA (a photosensitizer for photodynamic therapy).
45770147|NCT05492838|Procedure|Immediate implantation with the Socket Shield Technique|Immediate implant surgery applied with the Socket Shield Technique
45770148|NCT02549716|Drug|IV acetaminophen|Patients in this group will receive IV acetaminophen and an oral placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
45770149|NCT02549716|Drug|Oral acetaminophen|Patients in this group will receive oral acetaminophen and an IV saline solution placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
45770150|NCT02549716|Drug|Oral placebo|Patients who receive IV acetaminophen will also receive an oral placebo with their IV treatments (every 6 hours for a 14 day period).
45770151|NCT02549716|Drug|IV placebo|Patients who receive oral acetaminophen will also receive a saline solution placebo at the same time that they receive the oral acetaminophen treatment (every 6 hours for 14 days).
45770152|NCT04081350|Drug|LY3471851|Administered SC
45935224|NCT00219466|Other|Zinc Oxide Diaper Rash Ointment|Desitin Original at diaper change
45935225|NCT00219466|Other|Aloe Vera/Tocopherol/Zinc Oxide Cream|Desitin Creamy at diaper change
45630515|NCT03166475|Procedure|Surgical procedures|All the extractions were performed under local anaesthesia, minimally traumatic as possible. After the extraction, each patient was treated according to the group of their allocations.
45630516|NCT05746013|Dietary Supplement|Lipid Emulsion|The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFA) or refined olive oil (MUFA) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA.
45770153|NCT04081350|Drug|Placebo|Administered SC
45630517|NCT05745935|Drug|Oxytocin|This study will include 100 elective cesarean section in parous women who will be randomized into two groups each of 50 patients,
45630518|NCT03115229|Behavioral|Protective Nursing Interventions for Reduction Obesity Risk|"Applications for the experimental group for 11 weeks are grouped under three headings.~These; Nutritional habits, practices for physical activity, and motivational messages sent via social media.~Nutritional practices: Nutritional practices consist of group trainings, individual practices and collective events.~Practices for physical activity: Group trainings, group exercises, individual exercises and collective activities. Physical activity was done for 3 days per week and 45-60 minutes every seans for 8 weeks. In addition, activities such as collective nature walks and cycling have been carried out Practices through social media: For physical activity and healthy eating; Motivational messages were sent twice a week for 11 weeks."
45770154|NCT02540434|Device|ROTEM|ROTEM delta will be used to identify intraoperative coagulation abnormalities. A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
45630519|NCT03106259|Drug|FURESTEM-RA Inj.|Non-interventional observational study
45630520|NCT05744375|Drug|Trastuzumab deruxtecan|"All patients enrolled will be treated with trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks (± 3 days).~The subject's weight at baseline will be used to calculate the initial dose. If during the course of treatment the subject's weight changes by ± 10% of the baseline weight, the subject's dose will be recalculated based on the subject's updated weight.~Patients will receive T-DXd until unacceptable toxicity, progressive disease (PD), informed consent withdrawal, or other discontinuation criterion is met."
45630521|NCT02552121|Drug|Tisotumab vedotin (HuMax-TF-ADC)|
45630522|NCT03488355|Other|Modified laboratory report|"Report from microbiology laboratory: This POSITIVE urine culture collected from an indwelling catheter may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call the microbiology laboratory for identification and susceptibility results."
45630523|NCT03484143|Device|Active Neuro RX Gamma device|Twenty minute treatment session, 6 days a week for 24 weeks
45770155|NCT02540434|Other|Cryoprecipitate|Subjects with hypofibrinogenemia who are randomized to the Cryoprecipitate arm will be transfused with Cryoprecipitate
45447618|NCT05173064|Device|Machine learning-based exercise training system|"The video-based exercise training system will have three key features:~Evidence-based exercise videos instructed by physical therapists~Real-time movement feedback and performance score~Exercise records."
45630524|NCT03484143|Device|Sham Neuro RX Gamma device|Twenty minute treatment session, 6 days a week for 24 weeks
45630525|NCT05473611|Procedure|closed reduction percutaneous fixation with open reduction internal fixation of the posterior pelvic ring|closed reduction percutaneous fixation with open reduction internal fixation of the posterior pelvic ring
45630526|NCT05476107|Drug|AMT-126|Single or daily dosing at doses A, B, C, D, E, F; G, H, and I
45770156|NCT02540434|Drug|RiaSTAP|Subjects with hypofibrinogenemia who are randomized to the RiaSTAP arm will be transfused with concentrated fibrinogen
45770157|NCT05492760|Device|cryoballoon ablation|Patients with AF will accept cryoballoon ablation.
45913371|NCT02021617|Device|Intraosseous access|The EZ-IO Intraosseous Vascular Access System (Vidacare Corporation, Shavano Park, TX, USA) has been cleared by the U.S. Food and Drug Administration, Health Canada, and the European Union for the administration of drugs and fluids anytime vascular access is difficult to obtain in emergent, urgent, or medically necessary cases. It consists of a driver-a small battery-powered drill-and a needle set designed for insertion into the IO space of the proximal tibia, distal tibia, or proximal humerus. Needles are 15 gauge and available in three lengths: 15 mm, 25 mm, and 45 mm. In this study the 45 mm EZ-IO needle set will be used for all humeral placements and the 25 mm needle set will be used for all tibial placements.
45630527|NCT05476107|Drug|Placebo|Single or daily dosing at doses A, B, C, D, E, F; G,H, and I
45630528|NCT05476107|Other|Radioactive Tablet (Part 2 Only)|Single dose in two periods in Part 2 (optional)
45913372|NCT02021630|Other|Outcomes|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
45913373|NCT02021760|Procedure|Primary Percutaneous Coronary Intervention|Primary Percutanous Coronary Intervention is performed in both Groups.
45935226|NCT00219505|Procedure|acupuncture|
45935227|NCT00042302|Procedure|Chemotherapy|
45630529|NCT05472987|Procedure|Ventral Hernia Repair|Patients will undergo retromuscular ventral hernia repair
45630530|NCT03402789|Drug|Docosahexaenoic Acid|Docosahexaenoic acid 1,200mg daily plus 2 hours of eye patching daily
45630531|NCT03402789|Drug|Placebo Oral Tablet|Placebo tablet daily plus 2 hours of eye patching daily
45630532|NCT02552355|Drug|Metformin|Daily administration of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4 during a 12 week exercise training program.
45630533|NCT02552355|Drug|Placebo|Daily administration of matching placebo during a 12 week exercise training program.
45630534|NCT02552355|Dietary Supplement|Carbohydrate Beverage|Supervised aerobic exercise 3 days per week followed by a carbohydrate drink
45630535|NCT02552355|Dietary Supplement|Protein Beverage|Supervised aerobic exercise 3 days per week followed by a protein drink
45935228|NCT00042302|Drug|tariquidar + paclitaxel/carboplatin|
45935229|NCT00042302|Drug|placebo + paclitaxel/carboplatin|
45935230|NCT00219583|Drug|UK-390,957|
45770158|NCT05498922|Procedure|Peak pressure when mechanical ventilation was switched around a reasonable range|The research protocol was approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, and written informed consents were obtained from all patients. After induction of anesthesia, Rb patients were transorally intubated and mechanically ventilated. The inspiratory time, ventilation rate, positive end-expiratory pressure, and oxygen concentration were set consistently among patients. When anesthesiologist switch the peak pressure around a reasonable range, indices including tidal volume, lung compliance, mean airway pressure on ventilator screen changed and were recorded when stable. All the ventilator setting parameters followed the guidance of mechanical ventilation in neonates and children (https://doi.org/10.1007/978-3-030-83738-9_8). All the anesthesia and ventilation performance were conducted by a fully qualified senior anesthesiologist to assure standardized and safe anesthesia, ventilation and operation procedure.
45770159|NCT05488704|Diagnostic Test|Stress Parameters Measurement|"Pre-Test (0-2 minutes before NST starts) - Measurement of vital parameters (Pre-Test)~Glucose measurement~Taking Salivary Cortisol and Saliva ACTH samples~Filling the Spielberger State Anxiety Inventory~• Starting NST by controlling the noise level Interim Test-(NST 10th minute) - Measurement of vital parameters (Intermediate Test)~Taking Salivary Cortisol and Saliva ACTH samples~Filling the Spielberger State Anxiety Inventory~• Termination of NST after 20 minutes Final Test(within 0-2 minutes after NST is over)~Measurement of vital parameters~Glucose measurement~Taking Salivary Cortisol and Saliva ACTH samples~Filling the Spielberger State Anxiety Inventory After Data Collection - Recording of data~Centrifugation and analysis of saliva samples taken"
45770160|NCT01207726|Drug|Azacitidine|Given SC
45630536|NCT02551731|Drug|Cannabidiol Oral Solution|20 or 40 mg/kg/day BID
45935231|NCT00073476|Drug|traxiprodil (CP-101,606)|
45935232|NCT00219622|Drug|tofimilast|
45630537|NCT04479657|Drug|QingFei Granule|QingFei Granule is made from 6 commonly herbal medicine granule, such as Jingjie,Huang Qin,Lianqiao,etc. The children were given one package of QingFei Granule every day, dividing into 3 times to be administrated. It's be given for 5 days.
45935233|NCT00042380|Drug|Novasoy|
45630538|NCT04479657|Drug|Cefuroxime|30mg/kg/d,bid, used until to the normalization of blood routine。
45630539|NCT05476029|Diagnostic Test|Blood samples and alveolar lavage fluid were collected|Blood samples and alveolar lavage fluid were collected for exosome sorting and identification, differential miRNAs, and analysis of serum oxidation and inflammatory indicators.
45630540|NCT05475951|Diagnostic Test|Biomarker measurement of pannexin-1 and gasdermin-D|These biomarkers were measured in the placental and adipose tissues of the participants.
45630541|NCT05475873|Drug|normal saline|A bolus of normal saline (2 ml) by IV was given 5 min before spinal anesthesia.
45630542|NCT05475873|Drug|Ondansetron 4 mg|A bolus of ondansetron (2 ml; 4mg) by IV was given 5 min before spinal anesthesia.
45447619|NCT05173064|Device|Video-based exercise training system|The video-based system will only include the exercise videos as those involved in the machine learning-based system. The features of real-time movement feedback and tracking of exercise progress will not be provided.
45630543|NCT05475873|Drug|Ondansetron 8 mg|A bolus of ondansetron (2 ml; 8mg) by IV was given 5 min before spinal anesthesia.
45630544|NCT05475795|Other|Metapex|obturation of root canals of primary molars with Metapex
45630545|NCT05475795|Other|Endoflas|obturation of root canals of primary molars with Endoflas
45447620|NCT03224234|Device|Insulclock with feedback|Daily information on a smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses.
45447621|NCT03224234|Device|Insulclock without feedback|Not feedback on insulin administration.
45630546|NCT04270305|Other|Orientation|In the first group CP patients undergo a four week training with once daily sessions lasting 30 minutes. The treatment includes exercises to improve navigation competences and orientation. During walk in VR environment with labyrinths of increasing complexity. Exercises include abilities such as orienting in complex environments, perceiving distance and planning routes to distant locations. The presence of landmarks has been included in some exercises to facilitate allocentric orientation strategies.
45630547|NCT04270305|Other|walking|In the second group CP patients undergo a four week training with once daily sessions lasting 30 minutes. The treatment includes exercises to improve walking and balance abilities. Using engaging VR environments (e.g. transfer your load from the left to the right side to avoid obstacles while skiing; shoot balls at targets inside an area; walk in a forest as fast as possible; hit as many elves as possible by squatting, and so on). No exercises for orientation are included in this group.
45630548|NCT05481099|Behavioral|Intervention|Cognitive-behavioural-based intervention combined with mindfulness (attention focus), psychoeducation, and relaxation techniques (short version of Jacobson's progressive relaxation, breathing exercises)
45630549|NCT05480787|Drug|Remimazolam 0.1mg/kg/h|Remimazolam Tosilate for Injection(36mg)
45630550|NCT05480787|Drug|Remimazolam 0.3mg/kg/h|Remimazolam Tosilate for Injection(36mg)
45630551|NCT05480787|Drug|Remimazolam 0.5mg/kg/h|Remimazolam Tosilate for Injection(36mg)
45630552|NCT05471661|Biological|Pentavalent-specific T cells (penta-STs)|Patients will receive penta-STs in a single infusion. If they have a partial response or receive therapy post-infusion which could ablate the infused T cells they are eligible to receive up to 2 additional doses from 28 days after their first dose.
45770161|NCT01207726|Drug|Entinostat|Given PO
45770162|NCT01207726|Other|Laboratory Biomarker Analysis|Correlative studies
45935234|NCT00219661|Procedure|drainage of subglottic secretions (HiLo Evac tube)|
45935235|NCT00219700|Drug|Ibuprofen-PC|
45935236|NCT00219739|Drug|Imatinib mesylate 400 mg|
45935237|NCT00219739|Drug|Imatinib mesylate 600 mg|
45935238|NCT00219739|Drug|Imatinib 400 mg + Peg-Interferon|
45935239|NCT00219739|Drug|Imatinib mesylate 400 mg + Cytarabine|
45770163|NCT05498844|Behavioral|Medical Nutrition Therapy (counselling)|Participants will receive nutrition counseling to enhance adherence to the principles of the Mediterranean diet and support the achievement of adequate levels of lipid control, blood pressure and weight.
45770164|NCT05498688|Dietary Supplement|Low carbohydrate|Participants will have a low carbohydrate meal
45770165|NCT02534038|Drug|AVP-786|d6-DM/Q
45770166|NCT02534038|Drug|Placebo|matching placebo
45770167|NCT01202110|Drug|Propranolol|
45770168|NCT02556918|Drug|Sitagliptin|Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100 mg/day for patients with a glomeruler filtration rate (GFR) greater than or equal to 50. Patients with a GFR between 30-49 will receive 50 mg/day.
45630553|NCT05480709|Behavioral|Psychocardiological Rehabilitation|Psychocardiological Rehabilitation: Regular cardiac rehabilitation with in-depth psychological and psychotherapeutic care, individual and group counseling, relaxation training, and interdisciplinary specialist psychiatric and psychosomatic visits.
45630554|NCT05480631|Procedure|autograft|autologous bone placed in the defect and then be secured with mini-screws to fill the fracture defect gap
45630555|NCT05480631|Procedure|autograft with addition of concenterated growth factor|the bone particulate harvested from the donor site will then be mixed with concentrated growth factor to bridge the fracture defect.
45630556|NCT05480631|Procedure|xenograft with concentrated growth factor|xenogenic bovine bone particulate mixed with platelet-derived concentrated growth factor to be held in place of fracture defect site.
45630557|NCT05480553|Drug|NPC-06|"Initial dose (Day 1) <Dose> An 18 mg/kg of NPC-06 will be injected by intravenous drip infusion once daily. The maximum dose of the test drug should not exceed 1,200 mg as fosphenytoin sodium.~<Administration method> Dilute the study drug 3 to 4-fold using physiological saline for intravenous infusion and then administer the solution over 18 minutes.~Maintenance dose(Day 2～7) Maintenance dose on the next day (Day 2) after the initial dose will be mandatory, and will be dosed up to 6 days. Maintenance dose on Day 3 and thereafter will follow the transition criteria for maintenance dose.~<Dose> A 7.5 mg/kg of NPC-06 will be injected as needed by intravenous drip infusion once daily. The maximum dose of NPC-06 should not exceed 500 mg as fosphenytoin sodium.~<Administration method> Dilute the study drug 3-to 4-fold using physiological saline for intravenous infusion and then administer the solution over 7 minutes and 30 seconds."
45630558|NCT05480553|Drug|Placebo|"Initial dose (Day 1) <Dose> A placebo will be injected by intravenous drip infusion once daily. <Administration method> Dilute the study drug 3 to 4-fold using physiological saline for intravenous infusion and then administer the solution over 18 minutes.~Maintenance dose(Day 2～7) Maintenance dose on the next day (Day 2) after the initial dose will be mandatory, and will be dosed up to 6 days. Maintenance dose on Day 3 and thereafter will follow the transition criteria for maintenance dose.~<Dose> A placebo will be injected as needed by intravenous drip infusion once daily. Dilute the study drug 3-to 4-fold using physiological saline for intravenous infusion and then administer the solution over 7 minutes and 30 seconds."
45630559|NCT05471193|Diagnostic Test|Machine Learning Prediction|Machine Learning Prediction
45770169|NCT02556918|Drug|Placebo|One pill daily starting one day prior to surgery until discharge from the hospital.
45770170|NCT02556918|Drug|Regular Human Insulin|Continuous intravenous insulin given to intensive care unit (ICU) patients with a blood glucose (BG) greater than 180 mg/DL and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol.Intravenous insulin infusion will be continued until the patient is able to eat and/or is transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
45770171|NCT02556918|Drug|Insulin glargine|"Patients that required continuous insulin infusion (CII) at a rate >1U/h will be transitioned to basal insulin (glargine/detemir). Calculate total daily dose (TDD) of insulin from the average CII rate during the last four hours of infusion (example, if the average rate is 2 U/hr., the TDD is 48 U/day) Give 50% of calculated dose as basal (glargine/detemir) insulin every day. Basal insulin will be given approx. 4 hours before discontinuation of CII.~The total daily insulin dose will be adjusted as follow:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change Fasting and pre-meal BG between >180-240 mg/dl: increase basal dose by 10% every day Fasting and pre-meal BG >241 mg/dl: increase basal dose by 20% every day Fasting and pre-meal BG <100 mg/dl: stop basal"
45770172|NCT02556918|Drug|Supplemental insulin (Insulin lispro)|"Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~BG between 181-220 mg/dL; 2-4 units of insulin lispro~BG between 221-260 mg/dL; 3-5 units of insulin lispro~BG between 261-300 mg/dL; 4-6 units of insulin lispro~BG between 301-350 mg/dL; 5-7 units of insulin lispro~BG between 351-400 mg/dL; 6-8 units of insulin lispro~BG greater than 400 mg/dL; 7-9 units of insulin lispro"
45770173|NCT02556918|Drug|Supplemental insulin (Insulin aspart)|"Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~BG between 181-220 mg/dL; 2-4 units of insulin aspart~BG between 221-260 mg/dL; 3-5 units of insulin aspart~BG between 261-300 mg/dL; 4-6 units of insulin aspart~BG between 301-350 mg/dL; 5-7 units of insulin aspart~BG between 351-400 mg/dL; 6-8 units of insulin aspart~BG greater than 400 mg/dL; 7-9 units of insulin aspart"
45770174|NCT00379756|Drug|LEVITRA (vardenafil)|active comparator
45770175|NCT00379756|Drug|placebo|placebo comparator
45935240|NCT00073515|Drug|Alfimeprase|
45447622|NCT04108988|Behavioral|InvestiDate|Participants will be randomly assigned to play either InvestiDate (n=40), or the non-health related attention and time control condition multiplayer videogame (n=40).
45935241|NCT00219778|Drug|mifepristone|
45935242|NCT00219817|Drug|RC-1291 HCl|
45935243|NCT00219856|Drug|Propofol|"Induction : intravenous propofol aiming a concentration of 4 to 8 µg/ml~Maintenance : intravenous propofol aiming a concentration of 3 to 6 µg/ml"
45630560|NCT05480397|Other|TENS, Distractive techniques, cryotherapy|"Group (1): Will receive (TENS , cryotherapy and conventional physical therapy ) Massage with ice was done by the researcher over the AVF puncture site . After that, the TENS electrodes will be applied by the researcher 6 centimeters apart closely up and down the skin area for insertion of the needle.~Group (2): Will receive (Distraction techniques ,cryotherapy and conventional physical therapy ) Initially five minutes before starting hemodialysis, Distraction techniques will be applied. Natural and eye-catching images were broadcasted through a video display device on a laptop monitor in a manner that was easy for the older patient to watch while they were lying on the bed. Massage with ice was done by the researcher over the AVF puncture site~Group (3): Will receive (cryotherapy and conventional physical therapy )"
45630561|NCT05458869|Procedure|HPV Self-Collection|Use HPV self-collection kit
45630562|NCT05458869|Other|Interview|Attend interview
45770176|NCT05492292|Diagnostic Test|Perfusion brain scintigraphy imaging|The cerebral perfusion scintigraphy via a SPECT examination aims to analyze the cerebral blood flow and detect possible lesions or inflammations.
45630563|NCT05458869|Other|Survey Administration|Complete surveys
45630564|NCT02542605|Drug|Erenumab|Administered once on day 1 of Part B of the study by intravenous infusion.
45630565|NCT02542605|Drug|Placebo|Administered once on day 1 of Part B of the study by intravenous infusion.
45447623|NCT04108988|Other|Non-Health Related Video Game|Participants will be randomly assigned to play either InvestiDate (n=40), or the non-health related attention and time control condition multiplayer videogame (n=40).
45630566|NCT02542605|Drug|PACAP-38 Challenge Agent|"Administered by intravenous infusion during Part A of the study for dose selection for Part B.~Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack."
45770177|NCT02518750|Drug|Dexamethasone|Given orally (PO).
45770178|NCT02518750|Drug|Panobinostat|Given PO.
45770179|NCT02518750|Drug|Liposomal vincristine|For intravenous (IV) use only.
45770180|NCT02518750|Drug|Mitoxantrone|Given IV.
45770181|NCT02518750|Drug|Peg-asparaginase|"Given IV or intramuscularly (IM).~In case of allergy or intolerance to Peg-asparaginase, Erwinia L-asparaginase (Erwinase®) will be used. Erwinia L-asparaginase is given by either IV or IM injection."
45770182|NCT02518750|Drug|Bortezomib|Given by IV push over 3 to 5 seconds. For IV use only.
45770183|NCT02518750|Drug|Intrathecal Triples|Given IT as ITMHA.
45630567|NCT02723955|Drug|feladilimab (GSK3359609)|
45630568|NCT02723955|Drug|GSK3174998|
45630569|NCT02723955|Drug|Pembrolizumab|
45630570|NCT02723955|Drug|Docetaxel|
45630571|NCT02723955|Drug|Pemetrexed|
45630572|NCT02723955|Drug|Paclitaxel plus Carboplatin|
45913374|NCT02021786|Behavioral|Mobile phone based intervention|Parents in the intervention group receive a six month mHealth program (the MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet and physical activity behaviors. The program includes information, advice, and strategies to change unhealty behaviours and the possibility to register the child's intake of fruits, vegetables, candy, sweetened beverages, moderate-to-vigorous physical activity, and sedentary time. Feedback is then provided on reported variables. In addition, the parents are able to ask questions through the app to a dietician and a psychologist.
45447624|NCT04004936|Other|EQUIPPED with Active Feedback|Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The active feedback group will receive one-to-one (1:1) in-person academic detailing from a professional colleague that includes in-person audit, feedback, and peer benchmarking and provide on-site expertise.
45630573|NCT02723955|Drug|Gemcitabine plus Carboplatin|
45630574|NCT02723955|Drug|Fluorouracil (5-FU) plus carboplatin or cisplatin|
45630575|NCT02723955|Drug|Dostarlimab|
45630576|NCT02723955|Drug|Cobolimab|
45630577|NCT02723955|Drug|Bintrafusp alfa|
45630578|NCT05471037|Procedure|Long Biliopancreatic Limb LRYGB|LRYGB with an 180 cm biliopancreatic limb (BPL) and an alimentary limb (AL) of 80 cm.
45630579|NCT05471037|Procedure|Short Biliopancreatic Limb LRYGB|Standard LRYGB with a 80 cm BPL and a 180 cm long AL.
45630580|NCT05480241|Drug|Pancreatic Enzyme Replacement Therapy|Pancreatic Enzyme Replacement Therapy (PERT) 50000 Ph.U./meal + 25000 Ph.U./snack + Omeprazole 20mg once daily on fasting
45630581|NCT05480241|Drug|Placebo|Placebo + Omeprazole 20mg once daily on fasting
45630582|NCT02550873|Biological|PRM-151|PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks
45770184|NCT02518750|Drug|High-dose methotrexate|Given intrathecally (IT) or IV.
45770185|NCT02518750|Drug|6-Mercaptopurine|Given PO at consistent time each day.
45770186|NCT02518750|Drug|High-dose cytarabine|Given IT or IV.
45770187|NCT02518750|Drug|Nelarabine|Given IV
45770188|NCT02518750|Drug|Cyclophosphamide|Given IV.
45770189|NCT02518750|Drug|Etoposide|"Given IV.~In case of etoposide reactions, IV etoposide phosphate (Etopophos®) will be used."
45770190|NCT02518750|Drug|Clofarabine|"Given IV.~Clofarabine will be given instead of nelarabine for patients with B-lymphoblastic leukemia and lymphoma in stratum II."
45770191|NCT05492136|Procedure|Additional margin coagulation|After performing the hepatectomy the selected device should be applied onto the surgical margin following the protocol 3-4 s/cm2 of liver transection surface at maximum power output in order to perform an additional margin coagulation
45770192|NCT05592964|Dietary Supplement|Fasting|Standard fasting
45770193|NCT05592964|Dietary Supplement|Water|In Group S, water was given 1 hour before the operation.
45770194|NCT05592964|Dietary Supplement|Carbohydrate fluid|In Group K, carbohydrate fluid was given 1 hour before the operation.
45770195|NCT05492058|Other|tactile stimulation group|The tactile stimulation group will be asked to touch their own abdomen during the NST procedure.
45770196|NCT05492058|Other|listen music|Pregnant women in the music group will listen to a song they want with headphones during the NST procedure.
45770197|NCT05492058|Other|virtual reality group|Pregnant women in the virtual reality group will be shown a nature walk video with nature sounds (stream, bird, etc.) during the NST procedure.
45770198|NCT05498532|Diagnostic Test|Functional MRI|Anatomical MRI : T2 fiesta, SSFE, HASTE ; 3D T2 ; T1 FAT SAT ; LAVA Functional MRI : T1 FAT SAT with gadolinium
45770199|NCT01194856|Drug|Atazanavir/ritonavir|300 mg orally once daily with Ritonavir 100mg orally once daily for 96 weeks
45770200|NCT01194856|Drug|Efavirenz|Maintain dosage - 600 mg orally QHS for 96 weeks
45630583|NCT02550873|Other|placebo|Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks
45630584|NCT05480163|Other|Measurement records|Recordings of spirometry, acoustics, movement (chest volumetry) parameters for FVC and LVC exercises.
45630585|NCT02535741|Device|Triathlon CR Total Knee System|Primary total knee replacement
45630586|NCT02702115|Biological|SB-318|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
45630587|NCT03299049|Drug|Cabotegravir Tablets|CAB tablets are white to almost white oval shaped film coated 30 mg tablets for oral administration. CAB tablets are to be stored up to 30 degree Celsius and protected from moisture.
45630588|NCT03299049|Drug|Rilpivirine Tablets|"RPV tablets are 25 mg tablets that are off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. RPV tablets should be stored at 25 degree Celsius (excursions permitted to 15 degree-30 degree Celsius) and protected from light."
45630589|NCT03299049|Drug|Cabotegravir Injectable Suspension|CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 mg/mL of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.
45630590|NCT03299049|Drug|Rilpivirine Injectable Suspension|RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
45630591|NCT05455905|Diagnostic Test|Patient Health Questionnaire-9|The Patient Health Questionnaire-9 is a nine question self-administered examination in which the patient indicates how often they have experienced different feelings and sensations in the past two weeks. The Patient Health Questionnaire-9 is scored from 0 to 27 where higher scores are associated with more severe depression.
45770201|NCT05488392|Procedure|Hypothermia with intrajugular cooling|Hypothermia with intrajugular cooling will be applied after successful recanalization of the culprit internal carotid artery/middle cerebral artery. The perfusion rate will be set at 30 ml/min. Low temperature saline will be infused into the internal jugular vein for 10 min, 15 min, 20 min, 25 min, and 30 min successively.
45770202|NCT05498376|Device|Conventional pacemaker DDD|Implantation of a conventional cardiac pacemaker
45770203|NCT05498376|Device|Leadless pacemaker Micra AV|Implantation of a leadless cardiac pacemaker
45770204|NCT05488236|Other|Nuclear magnetic resonance analysis of embryo culture medium|Analysis of culture medium from euploid and aneuploid embryos by magnetic nuclear resonance.
45770205|NCT01182610|Drug|Panitumumab|Panitumumab 9mg/kg on Days 1, 22, and 43
45770206|NCT01182610|Drug|Paclitaxel|Paclitaxel 200mg/m2 on Days 1 and 22
45770207|NCT01182610|Drug|Carboplatin|Carboplatin AUC=6 on Days 1 and 22
45630592|NCT05455905|Diagnostic Test|Generalized Anxiety Disorder-7|The Generalized Anxiety Disorder-7 is a seven question self-administered examination in which the patient indicates how often they have experienced different feelings and sensations in the past two weeks. The Generalized Anxiety Disorder-7 is scored from 0 to 21 where higher scores are associated with more severe anxiety.
45770208|NCT01182610|Drug|5FU|5FU 225mg/m2/day on Days 1-15 and 22-36
45770209|NCT05491902|Diagnostic Test|[C11] Leucine PET scan|Each participant will receive an i.v. bolus of the PET radioligand, [11C]-Leucine (<100 μg), for each scan. [11C]-Leucine is a PET radioligand has been used and studied clinically (17-23) at micro-doses (<100 μg) with no adverse effects.
45630593|NCT05455905|Diagnostic Test|Hamilton Depression Rating Scale|The Hamilton Depression Rating Scale is administered by a mental health profession and includes twenty-one questions asking about how the participant has been feeling in the past week. The Hamilton Depression Rating Scale is scored from 0 to 45 where higher scores are associated with more severe depression.
45630594|NCT05455905|Diagnostic Test|Hamilton Anxiety Rating Scale|The Hamilton Anxiety Rating Scale is administered by a mental health profession and includes fourteen questions asking about how the participant has been feeling in the past week. The Hamilton Anxiety Rating Scale is scored from 0 to 56 where higher scores are associated with more severe anxiety.
45630595|NCT02550795|Drug|Dexmedetomidine|administration of dexmedetomidine only
45630596|NCT02550795|Drug|Dexmedetomidine and dexamethasone|administration of dexmedetomidine and dexamethasone
45630597|NCT02550795|Drug|Control|administration of normal saline
45630598|NCT05455281|Device|CHLOE|CHLOE is designed to automatically analyze events related to embryo development from Time Lapse Incubator (TLI) images and provide prediction on the likelihood of embryos developing to the blastocyst. This information can assist embryologists and IVF professionals in the selection of the most viable embryo for transfer or freezing, when there are multiple embryos deemed suitable.
45630599|NCT05469711|Device|PlayPhysio|The gamification will be switched on at day 28 for the participants in arm 1. The trial will run for a further 84 days with the mid-point review half way through this section of the trial.
45630600|NCT02541903|Drug|Gilotrif|Patients will take a single oral dose of Gilotrif each day starting at 40 mg. Dose escalation and reductions can occur.
45770210|NCT05491902|Diagnostic Test|[18F] Flutemetamol PET scan|Each participant will receive an i.v. bolus of the PET radioligand, [18F]-Flutemetamol (< 10 μg), for each scan.
45770211|NCT05491902|Diagnostic Test|MRI scan|Scans will be performed on a 1.5T Philips scanner including a 3D T1-weighted scan for co-registration with PET scans and rating of hippocampal atrophy, as well as standard T1 and T2-weighted sequences for rating of white matter lesions.
45770212|NCT05574946|Procedure|Anterior Cruciate Ligament Reconstruction|Anterior Cruciate Ligament Reconstruction with four strand semitendinosus graft
45770213|NCT05488158|Other|Osteopathic manipulation|Pain and somatic disfunction were treated with osteopathic manipulations as deemed appropriate by a trained DO.
45630601|NCT02541669|Drug|TAK-491|TAK-491 tablets
45770214|NCT01165450|Drug|Nexagon|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
45630602|NCT02541669|Drug|TAK-491 placebo|TAK-491 placebo-matching tablets
45770215|NCT01165450|Drug|Vehicle only|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
45770216|NCT05485896|Drug|Pembrolizumab plus Lenvatinib|Pembrolizumab plus Lenvatinib
45770217|NCT01148056|Radiation|Intensity Modulated Radiation Therapy|Radiation therapy once a day for 5 days
45770218|NCT05488080|Behavioral|Department-level audit and feedback and electronic health record-embedded clinical decision support|This intervention will provide clinicians with Equity Report Cards and clinician decision support on mitigating disparities in quality of care.
45770219|NCT05526430|Drug|Harmine Hydrochloride Capsules|capsules taken orally
45770220|NCT05488002|Behavioral|Pharmaceutical intervention|Pharmacists will provide clinical recommendations to patients allocated to the intervention group. Furthermore, they will monitor patients' parameters and follow-up with them. These interventions include daily medication review, weight, heart monitoring, blood glucose level, follow-up on medication adherence, and even mental status.
45770221|NCT05485818|Drug|Low Dose|12±4 hours after PCI: 0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
45770222|NCT05485818|Drug|Middle Dose|12±4 hours after PCI: 0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
45770223|NCT05485818|Drug|High Dose|12±4 hours after PCI: 2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
45770224|NCT05485818|Other|Placebo|15 subjects will be randomly assigned to the placebo for 7 days
45770225|NCT05507398|Drug|Placebo, metformin and atorvastatin|comparing the anti-tumor effects of metformin and atorvastatin
45770226|NCT05487612|Device|Minimal Invasive Extracorporeal Circulation|Cardiac surgery with Minimal Invasive Extracorporeal Circulation (MiECC).
45770227|NCT05487612|Device|Conventional cardiopulmonary bypass|Cardiac surgery with conventional cardiopulmonary bypass (cCPB).
45770228|NCT02414698|Procedure|Percutaneous Hydrodiscectomy|The HydroD uses a thin supersonic stream of water to cut, ablation, remove disc material percutaneously via a skin puncture.
45770229|NCT02414698|Drug|TESI|Transforaminal epidural steroid injections given in the lumbar spine.
45770230|NCT05485584|Drug|rSIFN-co Nasal Spray|8 million IU (16 μg)/day; Once daily
45770231|NCT05485584|Drug|rSIFN-co Nasal Spray|16 million IU (32 μg)/day; Twice daily
45770232|NCT05485584|Drug|Placebo Nasal Spray|Once daily
45770233|NCT05485584|Drug|Placebo Nasal Spray|Twice daily
45770234|NCT05485506|Other|Multimodal exercise program|"Running technical drills: pogo, askip, dribble, scissor, etc. Exercises for lumbopelvic stabilization: mobility exercises, hip thrust, dead lift, lunge to skip.~Resisted sprints by using a sled: resistance leading to a 60% and 30% of optimal load (previously calculated)"
45770235|NCT02415166|Biological|INFLUENZA VACCINE|THE PURPOSE OF THE STUDY IS TO EVALUATE THE EFFICACY OF THE SEASONAL INFLUENZA VACCINE IN PEOPLE WITH MAJOR DEPRESSIVE DISORDER
45770236|NCT02415166|Other|NaCl-saline placebo|placebo
45770237|NCT02403154|Procedure|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
45630603|NCT05455047|Diagnostic Test|PET-CT at 18F-FDG|PET-CT at 18f6FDG in nuclear medicine departement of Nancy's hospital
45630604|NCT03274479|Drug|PBF-1129|PBF-1129 once a day by oral administration
45770238|NCT02403154|Procedure|External fixator|External fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are outside of the body.
45770239|NCT02381626|Device|HEPA air purifier|air purifiers to remove PM and volatile organic compounds will be placed in drivers cars
45770240|NCT02381626|Behavioral|questionnaires|
45770241|NCT02381626|Other|Log-book|PM and biological measurements
45770242|NCT02381626|Other|Urine sample|PAH (Polycyclic Aromatic Hydrocarbon) will be assessed via urine sample collection of Urinary 1 hydroxy pyrene and particulate matter collected via Polyurethane Foam Filter (PUF) sampler
45913375|NCT02021799|Dietary Supplement|Moringa and Lactobacillus rhamnosus GR-1|
45630605|NCT04423809|Other|clinical assessment|assessment of caregivers suffering when a family member is hospitalized
45630606|NCT02549859|Device|Deep Brain Stimulation (DBS) at 60 Hz|Bilateral subthalamic nucleus deep brain stimulation at 60 Hz
45630607|NCT02549859|Device|Deep Brain Stimulation (DBS) at 130 Hz|Bilateral subthalamic nucleus deep brain stimulation at 130 Hz
45630608|NCT02549859|Device|Deep Brain Stimulation (DBS) Off (Sham)|Deep Brain Stimulation (DBS) Off (Sham)
45630609|NCT05454891|Drug|Extended bolus of insulin then standard bolus of insulin|For a standardized HFHP breakfast, participants will receive an extended meal bolus of insulin on the first morning and a standard meal bolus of insulin on the second morning of the study.
45630610|NCT05454891|Drug|Standard bolus of insulin then extended bolus of insulin|For a standardized HFHP breakfast, participants will receive a standard bolus of insulin on the first morning and an extended bolus of insulin on the second morning of the study.
45770243|NCT05487300|Drug|Autonomic testing on and off levodopa|"Participants with Parkinson's disease with and without orthostatic hypotension will undergo standardized autonomic testing on two separate days on levodopa and off levodopa."
45913376|NCT02021825|Drug|Mitoxantrone|The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 months for 2 years. Dosage was adjusted according to side effects.
45913377|NCT02021838|Other|Lethality Assessment Program|Law enforcement officers conduct risk screen of domestic violence victims, if high risk victims are referred to domestic violence services.
45935244|NCT00219856|Drug|Penthotal|Intravenous penthotal at the dose of 3 to 5 mg/kg
45630611|NCT04470921|Procedure|Opportunistic Salpingectomy|An opportunistic salpingectomy refers to removal of the fallopian tubes without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases.
45630612|NCT02688647|Drug|Belumosudil|
45770244|NCT01147042|Drug|IFN-gamma|Following a washout period subjects have a subcutaneous injection of 50 mcg per meter squared once per week, Monday, for 4 weeks, twice per week, Monday and Thursday, for 4 weeks, then thrice per week, Monday, Wednesday, Friday, for 4 weeks. Total treatment period is 12 weeks.
45630613|NCT02688647|Other|BSC|Treatment/drug as determined by each subject's prescribing physician
45630614|NCT04469127|Drug|Lutetium-177-DOTAGA-PEG-IAC|Study participants be administered therapeutic doses of Lutetium-177-PEG-DOTAGA-PEG-IAC up to three treatments spaced 6-8 weeks apart and a CT scan immediately after. A Ga-68-PEG-αvβ3-IAC PET/CT scan will be performed four weeks before and four weeks after the initial dose of the Lutetium-177-DOTAGA-PEG-IAC.
45770245|NCT03840486|Device|Non-rebreather mask (NRBM)|The non-rebreather mask (NRBM) will be used to assist in the delivery of oxygen. Participants will be placed on NRBM at different flow rates (15 LPM, 35 LPM, or Flush rate at 55 LPM).
45770246|NCT03840486|Device|Non-invasive ventilator mask (NIV)|The NIV is a non-invasive face (nasal) mask for oxygen delivery. Participants will receive oxygen at 50% FiO2 for 3 minutes, 75% FiO2 for 3 minutes or 100% FiO2 for 3 minutes each.
45770247|NCT03840486|Device|Nasal cannula EtO2 sensor|The nasal cannula EtO2 sensor will be placed on the participant's face under the mask to detect the EtO2 levels.
45630615|NCT02687607|Device|WEB Aneurysm Embolization System|
45630616|NCT05743985|Other|Cannabigerol|Hemp-derived full spectrum cannabigerol oil carried in an organic coconut (MCT) oil within hydroxypropyl methylcellulose capsules.
45630617|NCT05433285|Biological|COVID-19 Protein Subunit Recombinant Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
45770248|NCT03840486|Drug|Oxygen (NRBM)|Oxygen will be delivered via the NRBM. Participants will receive oxygen at different flow rates (15 LPM, 35 LPM, or flush rate at 55 LPM).
45770249|NCT03840486|Drug|Oxygen (NIV)|Oxygen will be delivered via the NIV mask. Participants will receive oxygen at 50% FiO2, 75% FiO2 or 100% FiO2 for 3 minutes each.
45770250|NCT05485350|Drug|Anlotinib Hydrochloride|12 mg/d, d1-14, q3w
45770251|NCT05485350|Drug|penpulimab|200mg, ivgtt, d1, q3w
45630618|NCT05433285|Biological|Active Comparator|Covovax® COVID-19 vaccine is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the SARS-CoV-2 betacoronavirus
45630619|NCT03972345|Drug|Norditropin® FlexPro®|Patients will be treated with commercially available Norditropin® FlexPro® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.
45630620|NCT04479839|Diagnostic Test|Ultrasound of the airway|Placing ultrasound on the neck after intubation
45630621|NCT03165851|Other|Risk-stratified therapy|Dose-dense intensive chemotherapy and high dose of Ara-C in the consolidation therapy.
45630622|NCT05453799|Drug|Vudalimab|Given IV
45630623|NCT05453721|Procedure|Indocyanine green fluorescence imaging method|Using indocyanine green fluorescence imaging method to identify intersegmental plane in segmentectomy
45770252|NCT05485350|Radiation|SBRT|55-180Gy
45770253|NCT01136668|Procedure|Transversus Abdominis Plane Block|A high frequency (5-10 mHz) ultrasound probe (Sonosite Micromaxx, Licence No 12407) will be placed on the flank at the midpoint between the iliac crest and lower costal margin. The three muscle layers of external oblique, internal oblique, and transversus abdominis will be visualized. A 22G short-bevel block needle will be advanced in an anterior-to-posterior direction, in-plane with the probe, until the tip is visualized in the transversus abdominis plane. After negative aspiration, 0.4 ml/kg of bupivacaine 0.25% with 1:200,000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
45913378|NCT02021838|Other|Domestic Violence High Risk Team|Law enforcement officers conduct risk screen of domestic violence victims, if high risk victims are referred to domestic violence services and a team who monitors the clinical and criminal justice progress.
45630624|NCT05453721|Procedure|Modified inflation-deflation method|Using modified inflation-deflation method to identify intersegmental plane in segmentectomy
45630625|NCT05453487|Biological|coadministration|the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and rabies vaccine
45913379|NCT02021851|Drug|Dexamethasone and aprepitant|
45630626|NCT05453487|Biological|COVID-19 vaccine|received one dose of inactivated COVID-19 vaccine (BBIBP-CorV)
45630627|NCT05453487|Biological|rabies vaccine|received three dose of rabies vaccine
45630628|NCT05032053|Drug|Antithrombotic drugs|The purpose of our study is to observe the effect of various antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds.
45630629|NCT03968601|Other|Mitral regurgitation surgery such as mitral valve replacement or repair|Mitral regurgitation surgery such as mitral valve replacement or repair. All kind of mitral regurgitation surgery: replacement or repair, by median sternotomy of minimally invasive surgery, with or without tricuspid plasty
45630630|NCT05739617|Other|Comprehensive Respiratory Training Exercise Program|This comprehensive respiratory training exercise program consists of four main components, including oropharyngeal muscle training, respiratory muscle training, aerobic exercise, and sleep hygiene education.
45630631|NCT05739617|Other|Sleep hygiene education|Sleep hygiene education
45630632|NCT05738525|Device|APD-RPM|"APD mode is recommended but not limited to continuous circulating peritoneal dialysis (CCPD); (2) Dialysis dose ranges from 5 to 10 liters per day and depends on previous APD prescription and dialysis adequacy; (3) Glucose concentration starts from low concentration (1.5%) and depends on previous dialysis prescription.~Remote monitoring includes dynamic changes of the overall treatment situation, warning or any abnormal notes, and drainage, retention and duration of APD per day."
45630633|NCT05642507|Drug|AC01|AC01 microtablets
45630634|NCT05630807|Drug|Bepirovirsen|Bepirovirsen will be administered.
45630635|NCT05630807|Other|Placebo|Matching placebo will be administered.
45630636|NCT01662063|Drug|Tocilizumab|TCZ will be given as 162 mg SC QW or Q2W for up to 96 weeks.
45630637|NCT05627999|Procedure|doppler endoanal ultrasound|The primary aim was to assess the reduction in the blood supply by comparing the hemorrhoidal arterial systolic peak (overall and sectorial) before and after Emborrhoid.
45630638|NCT05431725|Biological|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent|The influenza vaccines (Split Virion), inactivated, quadrivalent are developed by Sinovac Biotech Co., Ltd.15 μg hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride,disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region.
45770254|NCT01136668|Procedure|Standard|Circumferential subcutaneous infiltration of the ostomy wound with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg by the surgeon after skin closure.
45770255|NCT05487222|Device|ICON|hemodynamics variability in response to different fluid regiemens
45770256|NCT05485272|Other|Silver Diamine Fluoride combined with Potassium Iodide.|Riva Star, Silver diamine fluoride 38% and potassium iodide, SDI, Bayswater, Australia.
45770257|NCT05485272|Other|Silver Diamine Fluoride.|A clear liquid that combines the antibacterial effects of silver and the remineralizing effects of fluoride.
45770258|NCT05485272|Other|High-Viscosity Glass Ionomer.|A Glass Hybrid material.
45770259|NCT03835416|Dietary Supplement|Foods rich in high quality protein|Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
46069964|NCT00798031|Device|Placement of dental implant|"Device: A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.~A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. the study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prothesis."
45630639|NCT05431725|Biological|Control Quadrivalent influenza virus vaccine|The Control Quadrivalent influenza virus vaccines are manufactured by Sanofi and are purchased by Pontifical Catholic University of Chile.15μg HA of each of the four influenza strains in 0.5 mL of solution per injection.The routine of administration is intramuscular injection into deltoid region.
45630640|NCT05469009|Drug|Aducanumab|Standard aducanumab therapy will be given by intravenous infusion every 4 weeks for 6 cycles with blood brian barrier opening
45630641|NCT05469009|Device|Exablate Model 4000 Type 2|The Exablate Model 4000 will be utilized for the BBBO (blood-brain barrier opening) after each cycle of Aducanumab administered per label.
45630642|NCT05453097|Diagnostic Test|Selvester QRS Score with Preoperative ECG|Selvester QRS score will be calculated with the preoperative ECG of the patients.
45630643|NCT02548455|Device|Quartet 1457Q LV Lead|
45630644|NCT02691455|Device|Baerveldt Glaucoma Implant 350-mm2 / BG101-350|
45630645|NCT02691455|Procedure|Transscleral Diode Laser Cyclophotocoagulation|Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.
45770260|NCT01108666|Drug|Nelfinavir|Two dose levels of Nelfinavir will be evaluated in each concurrent chemotherapy group (carboplatin/paclitaxel and cisplatin/etoposide) at the RPTD does of proton beam radiotherapy: 625 and 1250 mg PO bid.
45630646|NCT02691455|Device|Ahmed Model FP7 Flexible Plate|
45770261|NCT04047030|Other|None- Observational Study|No Intervention
45770262|NCT02317276|Drug|Triamcinolone 0.1%|Topical ointment
45770263|NCT05485194|Other|Reducing dimensional changes following tooth extraction|Use of a titanium bone screw for ridge preservation following tooth extraction
45770264|NCT05413174|Behavioral|Hypnoanalgésia|"Use of Ericksonienne hypnosis in the medical field, aiming to dissociate the patient from the intervention in order to modify his or her perception of pain and limit anxiety.~Ericksonienne hypnosis will use during ultrasound-guided biopsy in radiology ward."
45770265|NCT05374408|Behavioral|BBN for Trauma Informed Care|"Brief explanation of BBN will be provided. Patient will be directed to areas of the app that are congruent with treatment focus identified during their standard of care appointment.~Patient will complete by going online or being contacted by a member of the research team member. The research assistant will contact all the patients in 2-3 days to help the patient navigate the BBN and complete the baseline survey if needed.~The patient will continue to meet with their BHP as determined by the standard of care interactions. BHP will highlight features contained in BBN for patient to use in between appointments.~Follow-up phone calls will be scheduled for 2 week and 6 weeks after the initial visit. During these phone- calls the participant will be contacted by a member of the research team to complete follow-up surveys."
45770266|NCT01662492|Biological|Botulinum toxin type A Dose 1|Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.
45770267|NCT01662492|Biological|Botulinum toxin type A Dose 2|Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.
45630647|NCT02691455|Device|Baerveldt Glaucoma Implant 250-mm2 / BG103-250|
45770268|NCT01662492|Drug|Placebo (Normal Saline)|Placebo (Normal Saline) intramuscular injections into specified muscles.
45770269|NCT00378976|Drug|valacyclovir|500 mg twice-daily oral
45913380|NCT02021851|Drug|Dexamethasone and ondansetron|
45913381|NCT02021864|Drug|vitamin D3 50,000 unit|vitamin D3 50,000 unit/week for 8 weeks
45913382|NCT02021864|Drug|prenatal multivitamin|daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
45630648|NCT04264845|Other|Provider Focus|The provider focus groups will be conducted and data from the focus group sessions will be analyzed and used to evaluate clinicians' interpretation of PROs and acceptability of PRO data in routine clinical care. A formal provider training program will be designed and implemented by a subject matter expert. The focus group session will be repeated at 12 months, with the 12month administration having an increased emphasis on barriers, facilitators, and value of PROs in clinical care.
45770270|NCT00378976|Drug|matching placebo|twice daily as per experimental drug
45935245|NCT00219856|Drug|Desflurane|Inhaled desflurane aiming an alveolar concentration of 4 to 6 per cent.
45935246|NCT00042458|Drug|Pramlintide acetate|Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
45630649|NCT04264845|Other|Patient Interview|A trained professional interviewer will conduct a one-time, one-hour, semi-structured telephone interview of each subject to better understand patient experiences with HF, the treatment process and quality of life determinants. Two semistructured interviews will be conducted with the first 30 patients who have had LVAD therapy (of the 100 patients who agreed to be interviewed), before and 12 months after device implantation. The goal of these interviews will be to describe patient experiences with LVAD therapy, examine factors influencing quality of life, and determine whether currently available PRO tools are likely to capture the intended experiences in HF as they relate to LVAD therapy.
45630650|NCT04264845|Other|PROs/Clinical Data Integration|A plan has been developed that will integrate PRO scores into patient medical records. Information will be obtained from 2 instruments (KCCQ12 and NIH PROMIS) that are routinely administered as part standard of care. PRO and clinical data will be obtained from electronic medical records of patients seen in the heart failure clinic. All required information will be obtained from the subjects' electronic medical records over a period of 3.5 years after enrollment into the study.
45630651|NCT05452005|Drug|[18F]-αvβ6-BP|Subjects will be injected twice with up to 10 millicurie (mCi) of 18F-αvβ6-BP as a rapid intravenous (i.v) bolus.
45913383|NCT02021890|Behavioral|Dance program|two-hour dancing session twice a week, led by instructors in a private hall of a disco. Both solo and partner and group dances were performed during each session: an initial one-hour activity, chaired by two instructors who taught new steps and choreographies to patients (both individually and in group), was followed by a second hour, when patients danced in pairs both Latin and standard ballroom music
45630652|NCT05451615|Drug|Janus Kinase Inhibitor|One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.
45630653|NCT05451615|Drug|Abatacept|One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.
45630654|NCT05451303|Device|OralViome Cancer Testing System|The OralViome Cancer Testing System is intended for the screening of Oral Squamous Cell Carcinoma (OSCC) and Oropharyngeal cancer (OPC). The system consists of the OralViome Saliva Collection and Transport Kit, the Viome laboratory process for metatranscriptomics, and the Viome analytical software that detects an RNA expression signature within a saliva sample.
45630655|NCT05731037|Other|Resistance training for knee extensors|The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).
45630656|NCT05727527|Procedure|Local Anesthesia 1|Local anesthesia injection after applying a candy flavor
45770271|NCT05342974|Drug|Atorvastatin|Oral dose of atorvastatin (80 mg) to swallow at the clinic in the presence of a study provider with additional 6 doses (80 mg each) of atorvastatin to administer at home once daily for the next six days. These 6 pills should be taken orally. Return to the clinic for a follow-up visit approximately 3, 8 and 10 days after enrollment visit. At these visits, trained study clinician will evaluate abortion status using ultrasound and blood draw. At 8-day visit post-enrollment, 800 mcg of misoprostol will be provided to be taken vaginally or allowed to dissolve between cheek and tongue for 30 minutes, within 24 hours of the visit. At the final clinic visit, 10 days post-enrollment, if the termination of pregnancy has failed, standard abortion care at the clinic will be offered. A final phone call to assess any side effects, need for medical care or complications will occur 30 days after enrollment.
45770272|NCT05342974|Drug|Misoprostol|On Study Day 8, participant will be provided will two doses of misoprostol 800 mcg for vaginal or buccal use. Participant will take a single dose of misoprostol on study day 8 (± 1 day), and be instructed to take an additional 800 mcg vaginal or buccal misoprostol if no significant bleeding consistent with passage of tissue (heavier than a menses) has occurred within 24 hours of first misoprostol dose.
45770273|NCT05485116|Other|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
45770274|NCT02297230|Radiation|Radiation Therapy (RT)|Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor. At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
45913384|NCT02021890|Behavioral|Self-selected physical activity|gym sessions (with the support of sports associations), exercising at home (cycling, stepping) or walking, jogging or cycling outside with/without group support
45913385|NCT02021903|Other|V1: HGPO + meal and V2: placebo + meal|"Ambulatory polysomnography for the night preceding each test~Usual antiparkinsonian treatments at their usual dose and timing~Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~continuous digital blood pressure monitoring by Nexfin®~blood pressure monitoring at brachial artery~continuous polysomnographic recording~synchronized continuous digital audiovisual recording~glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP"
45935247|NCT00042458|Drug|Placebo|The placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.
45630657|NCT05727527|Procedure|Local Anesthesia 2|Local anesthesia injection after applying sterile water
45935248|NCT00219895|Drug|Ibuprofen|
45630658|NCT03166007|Behavioral|Abdominal massage|The participant should be supine and in a relaxed atmosphere, though this may depend on level of disability. The massage comprises 4 basic strokes (10minutes); Stroking from the small of the back over the iliac crest and down both sides of the pelvis towards the groin; Effleurage follows the direction of the ascending colon across the transverse colon and down the descending colon. This is repeated several times with increasing pressure; Palmar kneading tracks down the descending colon up the ascending colon and down the descending colon once again. Effleurage is repeated and continued with a relaxing transverse stroke over the abdomen; Vibration over the abdominal wall to relieve flatus concludes the massage session. The participants in this group will receive one telephone call per week for 6 weeks and again at 24 weeks to further discuss their bowel management.
45935249|NCT00077337|Drug|romidepsin|
45935250|NCT02962375|Dietary Supplement|Active|100% orange juice with orange pomace fiber
45770275|NCT02297230|Drug|Capecitabine|Capecitabine (Xeloda®) 750 mg/m2 twice/daily given orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
45770276|NCT02297230|Drug|Trastuzumab|Trastuzumab (Herceptin®) treatment will be administered weekly, together with one of the two weekly doses of Paclitaxel. The first dose will be 4mg/kg given IV over 90 minutes. Subsequent weekly doses will be given at a dose of 2 mg/kg/week IV over 30 minutes. The treatment with Trastuzumab will continue weekly after the completion of the radiation treatment until surgery and thereafter as per standard of care up to 1 year post surgery.
45770277|NCT02297230|Drug|Paclitaxel|Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab. Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose. If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses. Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).
45770278|NCT04038138|Diagnostic Test|Validation of new COA for FSHD patients|Monitoring of commonly used and news COA in patients with facioscapulohumeral muscular dystrophy
45630659|NCT03166007|Behavioral|Optimised bowel care|During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated. The participants in this group will also receive one telephone call per week during the following 6 week period to further discuss their bowel management and again at 24 week time point.
45630660|NCT02534883|Drug|Misoprostol|To be place vaginally
45630661|NCT02534883|Drug|Placebo|To be placed vaginally
45630662|NCT05626439|Drug|Staccato alprazolam|Study participants will receive single dose of Staccato alprazolam by inhalation at pre-specified time points.
45630663|NCT05626439|Drug|Oral alprazolam|Study participants will receive single dose of oral alprazolam at pre-specified time points.
45770279|NCT02282332|Drug|Ticagrelor|
45770280|NCT04016844|Device|transcranial direct current stimulation or SHAM|"A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.~In the sham condition, the participants will receive the initial 30 seconds of stimulation, after which the current will be set to 0. The same tDCS device (Soterix) will be used."
45770281|NCT02287636|Radiation|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
45447625|NCT04004936|Other|EQUIPPED with Passive Feedback|Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The passive feedback group will receive monthly provider feedback via an electronic dashboard with audit, feedback and peer benchmarking.
45630664|NCT02685995|Device|VectorFlow TDC|TDC insertion with VectorFlow will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
45770282|NCT02287636|Procedure|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
45770283|NCT02287636|Procedure|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
45770284|NCT02287636|Procedure|positron emission tomography|Undergo PET/MRI
45770285|NCT02287636|Procedure|magnetic resonance imaging|Undergo PET/MRI
45770286|NCT05479500|Other|Myofascial Chain Release Techniques|Myofascial release is a hands on technique which stretches the fascia and releases, bonds between muscles, integuments and fascia in order to eliminate pain, improve motion and to maintain myofascial balance within the body.
45770287|NCT05479500|Other|Local Release Techniques|Local Release Techniques are a soft tissue method that focuses on relieving tissue tension via the removal of fibrosis/adhesions which can develop in tissues as a result of overload due to repetitive use.
45770288|NCT05486988|Drug|Immunotherapy|PD-1/PD-L1 inhibitors
45770289|NCT05486988|Drug|Chemotherapeutic Agent|2 cycles
45770290|NCT05486988|Drug|Chemotherapy|4~6 cycles
45913386|NCT02021903|Other|V1: placebo 75mg + meal and V2: HGPO 75mg + meal|"Ambulatory polysomnography for the night preceding each test~Usual antiparkinsonian treatments at their usual dose and timing~Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~continuous digital blood pressure monitoring by Nexfin®~blood pressure monitoring at brachial artery~continuous polysomnographic recording~synchronized continuous digital audiovisual recording~glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP"
45447626|NCT03999710|Radiation|Radiation Therapy|Treatment will consist of 60 Gy in 30 fractions to fields encompassing gross tumor and lymph nodes.
45447627|NCT03999710|Drug|Durvalumab|A dose of 1500mg (for patients >30kg in weight) will be administered using an IV bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg/mL, and delivered through an IV administration set with a 0.2- or 0.22- μm filter.
45447628|NCT03224000|Procedure|Modified Barium Swallow (MBS)|Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.
45770291|NCT05484960|Other|cognitive assessment|The clinical diagnosis will be made based on the criteria set by the investigators. Clinical history and bedside objective assessment in the form of Montreal Cognitive Assessment-Philippines (MoCA-P) or Mini Mental Status Examination-Philippines (MMSE-P), supported by a neuroimaging study (if neuroimaging is not done, diagnosis will be supported by the Hachinski Ischemic Score).
45770292|NCT01083472|Device|Strattice(TM) Reconstructive Tissue Matrix|Strattice(TM) TM will be used to support the repair of abdominal wall defect
45770293|NCT01083472|Procedure|Suture/suture with absorbable mesh|Abdominal wall defect will be repaired with suture alone or absorbable mesh with suture
45770294|NCT05486832|Device|Cardiovalve TR valve replacement System|The Cardiovalve system includes a valve and delivery system, designed for replacement of the tricuspid valve through a transcatheter.
45770295|NCT05479266|Other|Muscle Energy Technique|METS-Post isometric relaxation will be applied for piriformis, iliopsoas and hamstrings muscle. There will be three repetitions for each muscle, once per day and thrice a week for three weeks
45770296|NCT05479266|Other|Myofascial release|Myofascial Release will be done for piriformis, iliopsoas and hamstrings muscle. There will be three repetitions for each muscle, once per day and thrice a week for three weeks
45770297|NCT00378664|Procedure|lumbar to sacral ventral nerve re-routing procedure|surgical nerve re-routing procedure
45770298|NCT05486754|Behavioral|Cognitive behavioral stress management|Participants will receive in-person weekly stress management group sessions (3-8 participants) for two hours per week for ten weeks total. Each session will consist of a half hour of relaxation training and one and a half hours of stress management skill training, including coping effectiveness training, anger management, assertiveness training, and stress awareness.
45770299|NCT05486754|Behavioral|Psychoeducational Control|Participants will receive one four-hour seminar in-person groups (3-8 participants) of educational information related to prostate cancer and abbreviated psychological information provided in cognitive behavioral stress management.
45770300|NCT02253394|Drug|Ambrisentan plus Spironolactone|Cardiopulmonary fitness
45770301|NCT02253394|Drug|Ambrisentan plus Placebo|Placebo is a sugar pill manufactured to resemble spironolactone 50 mg Cardiopulmonary fitness
45770302|NCT05479110|Behavioral|Empathy experience courses and case-base clinical reasoning|Four 3-hour training sessions over 2 weeks, which included group instruction on empathy experience, clinical reasoning, and functional therapy case-oriented learning.
45770303|NCT05479110|Other|case studies|active control: case studies(text)
45770304|NCT05312788|Other|Effect of Barley Supplemented Wheat Bread on markers of Cardiovascular and Renal Health|Intervention will involve intake of 50% barley substituted wheat bread.
45770305|NCT05479032|Drug|Amantadine|2x100 mg Amantadine for 3-5 days (dosage can be doubled in case of missing response to treatment after 48 hours)
45770306|NCT02236546|Diagnostic Test|[18F]fluorodeoxyglucose|FDG is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
45770307|NCT02236546|Other|Molecular assays on biopsied tissue|Correlative studies
45770308|NCT02236546|Device|positron emission tomography|Undergo FDG-PET/CT
45770309|NCT02236546|Device|computed tomography|CT that is part of FDG-PET/CT is a low-milliampere, low-resolution scan that is used for anatomic localization and attenuation correction for PET images.
45770310|NCT05484726|Other|perioral sensory motor stimulation|"Step 1 - 6 over 5 minutes~1 With the help of the index finger, on the external surface of the cheek, make a circle starting from the angle of the mouth towards the ear then back 7x each cheek~2 While holding both sides of the cheek with help of the thumb and index finger repeat step 1 7x each cheek~3 Move index finger from one corner to opposite one over both lips separately 7x each lip~4 Gentle massage and compress the gums from center to back of mouth 7x each half of the gum~5 Move the finger from front to back on the hard palate while applying gentle pressure 7x~6 Displace the center of the tongue with gentle pressure 7x~7 Offer pacifier at the end 2 minutes~Note: 7x means 7 times"
45770311|NCT05486676|Behavioral|VR-Moodboost; a Virtual Reality intervention for depression to enhance positive affect and reduce depressive symptoms.|All participants receive the same VR-Moodboost treatment, they only differ in the length of the baseline; 3 or 5 weeks.
45770312|NCT02175628|Device|Acoustic Angiography|"Acoustic angiography imaging involves a research high frequency ultrasound scanner (VisualSonics Vevo 770) and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes. All image data will be de-identified and transferred for off-line analysis based on a study ID. The research images will NOT be interpreted or analyzed for clinical decisions related to the patient."
45913387|NCT02021968|Biological|TetraVax-DV-TV003|TetraVax-DV-TV003 is a live attenuated recombinant tetravalent dengue virus vaccine, which will be administered as a 0.5 mL dose containing 10^3.0 plaque forming units (PFUs) each of DENV-1, DENV-2, DENV-3, and DENV-4. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
45913388|NCT02021968|Biological|rDEN2∆30-7169|The challenge virus, rDEN2∆30-7169, is a live recombinant attenuated DENV-2 candidate vaccine virus and will be administered as a 0.5 mL dose containing 10^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
45913389|NCT02021968|Biological|Placebo|The placebo vaccine is the vaccine diluent 1X L-15, which will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
45913390|NCT02022046|Other|Methylation biosignature|Methylation biosignature, CKD staging, assessment of cardiovascular function, and traditional/uremia-related risk factors will be performed.
45913391|NCT02022072|Device|measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)|measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)
45913392|NCT02022124|Drug|Microcrystalline cellulose (open-label inert substance)|The intervention will be an inert substance, microcrystalline cellulose in a capsule. Participants will take two capsules daily.
45913393|NCT02022137|Dietary Supplement|Red cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
45630665|NCT02685995|Device|Palindrome TDC|TDC insertion with Palindrome will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
45630666|NCT02548143|Biological|Coagulation Factor VIIa (Recombinant)|LR769
45630667|NCT03165149|Drug|group (A)|patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % ) and irrigated onto surgical field after hemostats and before skin closure.
45770313|NCT05484648|Drug|Dexamethasone|"Dexamethasone has been used to generally favorable results in peripheral nerve blocks as adjunct. Several studies have reported prolongation in the duration of ropivacaine, mepivacaine and bupivacaine when used in combination with dexamethasone.~Various mechanisms for the beneficial adjunctive effect of dexamethasone with Local Anesthetics (LA) have been proposed. One theory suggests that the improved analgesia and increased blockade duration is due to its anti-inflammatory properties. It also acts as a local vasoconstrictor and thus may act by reducing LA absorption. Furthermore, it also increases the activity of inhibitory potassium channels on nociceptive C-Fibers."
45630668|NCT03165149|Drug|group (B)|patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
45630669|NCT03165149|Drug|group (c)|patients will receive 3 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
45630670|NCT03165227|Drug|BI 685509|Taken orally
45630671|NCT03165227|Drug|Placebo|Taken orally
45630672|NCT03165305|Other|Sustained Inflation|Administering a pressure of 30 cm H20 by a T-piece resuscitator for 5 seconds immediately after birth.
45630673|NCT02547441|Drug|CLS001 (Omiganan)|Topical gel
45630674|NCT02547441|Drug|Vehicle|Vehicle Gel
45630675|NCT05430009|Radiation|Liver SBRT|24-45 Gy delivered in 3-5 fractions to 1-4 lesions.
45630676|NCT05430009|Drug|Pembrolizumab|200 mg every 3 weeks or 400 mg every 6 weeks
45630677|NCT05429853|Dietary Supplement|Sondalis® HP 2 kcal (with or without fibre)|The participants will take the study product during the two months of the study.
45630678|NCT05429697|Drug|SMT-NK inj.+Pembrolizumab|"SMT-NK inj. will be administered as an intravenous (IV) infusion on Day 1,Day 7 of each 21-day cycle.~Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle."
45630679|NCT05429697|Drug|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
45630680|NCT05450679|Procedure|Cervical Radiofrequency Ablation (RFA)|"During the cervical RFA procedure, all patients will undergo sensory and motor stimulation testing prior to receiving radiofrequency lesioning, which is a standard and recommended practice.~During the motor stimulation testing step, the pain physicians performing the procedure will assess the presence or absence of cervical paraspinal muscle twitching by using a standardized grading scale (per radiofrequency electrode: 0 = no twitches observed or palpated; 1 = twitches palpated but not observed; 2 = twitches observed and palpated at 1-2 levels; 3 = twitches observed at > 2 levels). A total score and a weighted score (total score divided by the number of radiofrequency lesion sites), will be recorded for each patient, and the RFA procedure will be completed per usual practice.~RFAs will be performed in the usual manner and as per standard of care. Providers will not use any new or experimental devices to perform the RFA."
45630681|NCT02540265|Drug|N1539|
45630682|NCT02540265|Drug|Intravenous Placebo|
45630683|NCT05450601|Drug|HCP2102-1|Take once daily for 2 weeks orally
45630684|NCT05450601|Drug|HPP2104-1|Placebo drug. Take once daily for 2 weeks orally
45630685|NCT05450601|Drug|HCP2102-2|Take once daily for 6 weeks orally
45630686|NCT05450601|Drug|HPP2104-2|Placebo drug. Take once daily for 6 weeks orally
45630687|NCT05450601|Drug|RLD2106-1|Take once daily for 2 weeks orally
45630688|NCT05450601|Drug|HPP2103-1|Placebo drug. Take once daily for 2 weeks orally
45770314|NCT05484648|Drug|Dexmedetomidine|Dexmedetomidine is another promising drug being used as a local anaesthetic adjuvant in peripheral nerve blocks. It is an alpha-2 agonist, which has shown to have prolonged duration of postoperative analgesia when given with LA for peripheral nerve blocks with other beneficial effects such as reducing the opioid consumption. Alpha-2-agonists such as dexmedetomidine cause hyperpolarization-activated cation currents which inhibit the transmission of nociceptive fibers.
45630689|NCT05450601|Drug|RLD2106-2|Take once daily for 6 weeks orally
45630690|NCT05450601|Drug|HPP2103-2|Placebo drug. Take once daily for 6 weeks orally
45770315|NCT02184520|Device|TRANSITION|
45630691|NCT02547363|Drug|LEO 43204 gel|
45630692|NCT02547363|Drug|Vehicle gel|
45630693|NCT02539797|Device|tDCS|comparing anodal, cathodal, and sham tDCS
45770316|NCT02184520|Device|REVERE|
45770317|NCT05486598|Drug|AL8326 tablets|"Sequence A group: on the 1st day, take a single dose of AL8326 tablets on an empty stomach. On the 15th day, take a single dose of AL8326 tablets after meals.~Sequence B group: on the 1st day after meal, take a single dose of AL8326 tablets; on the 15th day, take a single dose of AL8326 tablets on an empty stomach."
45630694|NCT03207555|Drug|Ibrutinib|420 mg by mouth once daily.
45630695|NCT02684357|Drug|risankizumab|Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
45630696|NCT02684357|Drug|ustekinumab|Ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection
45630697|NCT02684357|Drug|placebo for risankizumab|Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
45630698|NCT02684357|Drug|placebo for ustekinumab|Placebo for ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection
45913394|NCT02022137|Dietary Supplement|Green cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
45935251|NCT02962375|Dietary Supplement|Control|100% orange juice
45770318|NCT05478954|Drug|Sulfadoxine pyrimethamine|"Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug."
45630699|NCT05586191|Other|Action observation at home|"Exercises included will contain four stages of exercises. Each stage will be followed for 2 weeks i.e. stage 1 for 1st and 2nd week, second stage for 3rd and 4th week, third stage for 5th and 6th week and fourth stage for 7th and 8th week of treatment. Each component of every stage will be played for 1 minute in front of participants, followed by 1 minute rest and then these exercises will be performed for 5 minutes.~All participants will perform AOT 3 times/week for up to 8 weeks along with functional training for the rest of the weeks. Functional training will include stretching and isometric exercises (stretching of hamstring and calf muscle while quads isometric). Assessment will be done by using the tools at baseline and after 8 weeks of intervention. A final reading will be taken after 12 weeks to check the maintenance of training effects."
45630700|NCT05586191|Other|Action Observation therapy at hospital|"Exercises included will contain four stages of exercises. Each stage will be followed for 2 weeks i.e. stage 1 for 1st and 2nd week, second stage for 3rd and 4th week, third stage for 5th and 6th week and fourth stage for 7th and 8th week of treatment. Each component of every stage will be played for 1 minute in front of participants, followed by 1 minute rest and then these exercises will be performed for 5 minutes.~All participants will perform AOT 3 times/week for up to 8 weeks along with functional training for the rest of the weeks. Functional training will include stretching and isometric exercises (stretching of hamstring and calf muscle while quads isometric). Assessment will be done by using the tools at baseline and after 8 weeks of intervention. A final reading will be taken after 12 weeks to check the maintenance of training effects."
45630701|NCT02684279|Drug|Dasotraline|Dasotraline 4, 6, 8 mg flexibly dosed once daily
45630702|NCT05578703|Procedure|Fundic Ablation Sequentially in Combination with Endoscopic Sleeve Gastroplasty|Fundic mucosal ablation followed by endoscopic sleeve gastroplasty in the treatment of adults with obesity
45630703|NCT05578703|Device|Fundic Mucosal Ablation with ERBE HybridAPC|Fundic mucosal ablation utilizing approved ERBE HybridAPC
45630704|NCT05578703|Device|Apollo ESG|Using only Apollo ESG as approved per label
45630705|NCT03115073|Drug|Candiplus|Administration of Candiplus
45630706|NCT03115073|Drug|Clotrimazole|Administration of Clotrimazole
45630707|NCT03166163|Drug|Azadirachta indica|Its a herbal mouthwash that will be given to group of Egyptian Children twice daily for 3 weeks
45630708|NCT03166163|Drug|Chlorhexidine mouthwash|its an antimocrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily (10 ml each) for 3 weeks
45630709|NCT03165929|Drug|Flurbiprofen|oral flurbiprofen spray
45630710|NCT03165929|Drug|placebo|oral placebo spray
45770319|NCT05478954|Drug|Amodiaquine|"Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect. Adverse effect of amodiaquine includes abdominal discomfort and vomiting weakness and when used for prophylaxis it causes agranulocytosis. Amodiaquine is recommended as a partner drug in artemisinin based combination therapy."
46069965|NCT00798031|Device|dental implant|Subjects will have a complete diagnostic work-up performed and assessment for eligibility in the study by both a Prosthodontist and Surgeon. Subjects will then have two and up to three dental implants placed in an out patient basis at the University of Iowa College of Dentistry
45630711|NCT03165773|Other|Oatmeal|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
45770320|NCT01011634|Drug|Intravenous moderate sedation versus oral medication|Intravenous moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and ibuprofen 800 mg)
45770321|NCT02137096|Drug|Etoposide phosphate|Etoposide is one of three drugs used in the high-dose conditioning phase
45447629|NCT03224000|Behavioral|Swallowing Questionnaire|Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
45630712|NCT03165773|Other|Corn grits|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
46069966|NCT00798109|Behavioral|Motivational therapy|One hour of motivational therapy each weak during 4 weeks
46069967|NCT00798109|Behavioral|Usual care|Patients received at least six hour of usual therapy, as in the experimental group
45630713|NCT03165695|Drug|Ramelteon|Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first
45630714|NCT03165695|Drug|Placebo|Placebo, 1 tablet orally at 21:00 or until discharge whichever comes first
45630715|NCT03206073|Drug|Durvalumab|1500 mg of durvalumab via intravenous (IV) infusion on Day 1 of each cycle until patients meet off treatment criteria
45630716|NCT03206073|Drug|Tremelimumab|300 mg of tremelimumab via intravenous (IV) infusion on Day 1 of cycle 1
45630717|NCT03206073|Biological|Pexa-Vec|3 x 10E^8 plaque-forming unit (pfu) (Dose Level (DL) 1) via intravenous (IV) infusion for 4 doses: Day 12, Day 2, Day 16 of Cycle 1 and Day 2 of Cycle 2.
45630718|NCT03206073|Biological|Pexa-Vec|1 x 10E^9 pfu (DL 2) via intravenous (IV) infusion for 4 doses: Day 12, Day 2, Day 16 of Cycle 1 and Day 2 of Cycle 2.
45630719|NCT03190941|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
45630720|NCT03190941|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
46069968|NCT00656617|Drug|Idarubicin|12 mg/m^2 IV over 1 hour daily for 3 days (days 4 to 6)
46069969|NCT00656617|Drug|Cytarabine|1.5 g/m^2 IV as a continuous infusion over 24 hours daily (days 4 to 7)
45630721|NCT03190941|Biological|Anti-KRAS G12V mTCR PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
45630722|NCT03190941|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
45630723|NCT03142893|Drug|Ketoconazole Pill|Ketoconazole pill is taken 4 times per Inpatient Stay
45770322|NCT02137096|Drug|Carboplatin|Carboplatin is one of the drugs used in the high-dose conditioning phase.
45630724|NCT03142893|Drug|Ganirelix|Ganirelix subcutaneous injection is administered twice per Inpatient Stay
45630725|NCT03142893|Drug|Dexamethasone|Dexamethasone Pills is taken twice per Inpatient Stay
45770323|NCT02137096|Drug|Ifosfamide|Ifosfamide is one of the drugs used in the high-dose conditioning phase
45630726|NCT03142893|Drug|Dexamethasone Injection|Dexamethasone IV injection is given twice per Inpatient Stay
45630727|NCT03142893|Drug|Cosyntropin Injectable Product|cosyntropin injection is given twice per Inpatient Stay
45630728|NCT03142893|Drug|Recombinant Human Luteinizing Hormone|Leutinizing-Releasing Hormone is given 6 IV infusion pulses per Inpatient Visit
45630729|NCT03142893|Drug|Hydrocortisone Injection|Hydrocortisone IV push is given twice per Inpatient Visit
45770324|NCT02137096|Procedure|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation follows the high-dose chemotherapy phase of the arm.
45630730|NCT03142893|Drug|Gonadorelin|Gonadorelin IV injection is given twice per Inpatient Stay
45630731|NCT03142893|Drug|Corticorelin|Corticorelin IV injection is given twice per Inpatient Stay
45630732|NCT03142893|Drug|Placebo oral capsule|Placebo for ketoconazole are given 4 times per Inpatient Stay
45630733|NCT03142893|Drug|Saline Solution|Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per Inpatient Stay
45770325|NCT02132884|Other|cytology specimen collection procedure|Undergo collection of tissue and blood samples
45770326|NCT02132884|Procedure|therapeutic procedure|Receive standard of care treatment
45770327|NCT02132884|Drug|targeted therapy|Receive specific targeted therapy
45770328|NCT02132884|Other|laboratory biomarker analysis|Correlative studies
45770329|NCT02130622|Drug|Promethazine|
45630734|NCT03142893|Drug|Saline Solution for Injection|Saline Solution (placebo) for ganirelix subcutaneous injection
45630735|NCT02534493|Device|Carpal Tunnel Tissue Manipulation Device (CTMD)|This piece of rigid, shaped, biocompatible plastic (polypropylene) rated for skin contact and a strong but safe hypoallergenic biocompatible medical adhesive which bonds the skin over the carpal tunnel to the plastic piece for a duration of 2-14 hours.
45630736|NCT05428215|Drug|17beta Estradiol|Subjects will take individualized therapeutic dose of 17-beta-estradiol via sublingual and oral administration
45630737|NCT05428137|Dietary Supplement|Probiotic|Live bacteria strain in a form of a capsule with a daily dose of 1x10^10 CFU per day for 16 weeks
45630738|NCT05428137|Dietary Supplement|Postbiotic|Heat treated bacteria strain in a form of a capsule with a daily dose of 1x10^10 CFU per day for 16 weeks
45630739|NCT05428137|Other|Placebo|Placebo in a form of a capsule given for 16 weeks
45630740|NCT05468151|Other|Cold acclimation|The cold water immersions will last 30-60 minutes per day and the volunteers will undergo 2-3 cold immersions per week.
45630741|NCT05468151|Other|Intervention Control group - volunteers with obesity|Participants with obesity in the control group will undergo PET/CT scans at baseline and 12 weeks after the first scan.
45630742|NCT05468151|Other|Acute cold exposure|All participants (lean and with obesity) will undergo PET/scans after 2 hours of cold exposure to investigate BAT perfusion and BAT glucose uptake.
45630743|NCT02547129|Device|Static Antibiotic Spacer Surgical Implant|Joint spacer for treatment of joint infection
45630744|NCT02547129|Device|Articulating Antibiotic Spacer Surgical Implant|Joint spacer for treatment of joint infection
45630745|NCT05448729|Diagnostic Test|Elastography EUS|Comparison between the values of strain ratio and shear wave in concordance with the final diagnosis
45630746|NCT04423653|Behavioral|Telehealth home exercise program|The intervention will include videos of exercises and also live coaching using telehealth system.
45630747|NCT05467215|Drug|Pure oxygen (99%) from Praxair, Edmonton, DIN# 02014408|Participants will receive oxygen (99%) or room air (placebo) delivered through a face mask at a flow rate of 10 litres/min for 2 minutes. The participants will be exposed twice to both conditions over 4 experiments at a minimum of 2 week intervals between each testing session.
45630748|NCT05447091|Behavioral|LOH game- high dose|Participants will be asked to complete 15 half-hour training sessions, over 3 weeks, ie about 5 training sessions a week, and a total of 7.5 hours of training for 3 weeks.
45770330|NCT02130622|Drug|Sugar pill|
45770331|NCT02134912|Drug|crizotinib|Given PO
45770332|NCT02134912|Drug|pemetrexed disodium|Given IV
45770333|NCT02134912|Other|laboratory biomarker analysis|Correlative studies
45770334|NCT02134912|Other|pharmacological study|Correlative studies
45770335|NCT05484414|Drug|SRP-3D (diethylamide)|SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
45770336|NCT05484414|Drug|Placebo|Matching Placebo for SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
45770337|NCT05486520|Device|Magnetic Resonance Imaging (MRI)|MR images will be acquired using an ultra-low magnetic field 6.5 mT scanner located at the Martinos Center. The study time is estimated to be a maximum of 90 minutes with a maximum of 60 minutes of imaging time
45770338|NCT01226485|Drug|Taladegib|Administered IV
45770339|NCT05486442|Behavioral|ACT for weight-related experiential avoidance|Participants in the experimental group received weight concern-related ACT training in a group setting. Each session focused on different dimensions of ACT and included relevant exercises and homeworks. Dimensions studied included creative hopelessness, control strategies, mindfulness exercises, values and barries to values and commitment to action.
45770340|NCT05484336|Other|Glucose as reference food|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose diluted in 250ml, tested two times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
45935252|NCT00219934|Drug|Antiretroviral therapy|HAART therapy
45630749|NCT05447091|Behavioral|LOH game- low dose|Participants will be asked to complete 6 half-hour training sessions, over 3 weeks, ie about 2 training sessions a week, and a total of 3 hours of training for 3 weeks.
45630750|NCT05447091|Behavioral|LOH sham game|Participants will be asked to complete 15 half-hour training sessions, over three weeks, using sham version of the game. the sham version does not include components of cognitive training.
45630751|NCT05446935|Procedure|HITOC|Doxorubicin(dose: 25mg/m2) + Cisplatin(dose: 50mg/m2).
45630752|NCT05465811|Other|Program of physical exercises and health education by telerehabilitation|"To carry out the telerehabilitation program, the Google Meet platform will be used in order to provide the synchronous service model. This will occur for a period of 16 weeks, three weekly sessions lasting 50 minutes, (total of 48 sessions). The sessions will be given by physiotherapists and students in their final year of graduation in physiotherapy, which will consist of the following phases: initial rest, warm-up, resistance exercises, stretching exercises, relaxation and final rest.~In addition, in exchange for the warm-up phase, every 12 sessions, the telerehabilitation program also will have an approach through health education, using presentations, digital booklets and direct conversation between therapist and participants. The themes exhibited (importance of physical exercise in the pandemic context, reduction of the risk of falls through changes in the home environment and physiological changes resulting from aging) will intend to make them aware of better lifestyle habits."
45630753|NCT02428101|Genetic|polymorphism analysis|
45630754|NCT02420613|Radiation|Radiation Therapy|Undergo radiation therapy
45630755|NCT02420613|Drug|Temsirolimus|Given IV
45630756|NCT02420613|Drug|Vorinostat|Given PO
45630757|NCT02546193|Device|Foley catheter|The Foley catheter is a device used to achieve cervical ripening at the start of labor induction. It is a single balloon catheter placed transcervically by a provider, either digitally or using a speculum for visualization. The balloon is placed above the internal os but below the fetal head, amniotic membranes, and placenta and is inflated. In this study, it will be inflated with 60 cc of normal saline and taped to the patient's thigh for traction. Over several hours, the balloon gradually dilates the cervix. The catheter is typically expulsed when the cervix is 3-4 centimeters.
45630758|NCT02546193|Drug|Misoprostol|Misoprostol is a prostaglandin E1 analogue that is used for cervical ripening during labor induction. A 25 microgram tablet is placed in the vagina by a provider. A new 25 mcg tablet can be used vaginally every 4 hours for up to 6 total doses.
45630759|NCT02538471|Radiation|Radiation therapy|Imaging by PET/CT will be performed at baseline, 5 weeks and 15 weeks. The chosen metastatic sites will receive conformal external beam radiation 7.5 Gy/fraction x 3, to a total of 22.5 Gy over the course of one week.
45630760|NCT02538471|Drug|Study Drug|Patients will receive 300 mg/day of study drug administered via oral drug tablet every day for 14 days on and 14 days off (=28 day cycle) .
45630761|NCT05465421|Other|bone marrow aspiration from maxillary tuberosity and BMMNCs separation to be seeded on PRF and used for socket preservation|"Local anaesthesia will be administered by infiltration or nerve block to achieve the necessary anaesthesia to allow extraction of the indicated tooth Extraction will be done as atraumatically as possible removing any pathosis found that may interfere with bone formation A trapezoidal flap will be created above the extraction socket to allow closure of the surgical site.~BMMNC will be seeded on platelet rich fibrin and inserted in the socket The flap will be closed by interrupted sutures using 5-0 sutures. implant placement 3 months later"
45630762|NCT01661595|Drug|Sildenafil|50 mg/day for 4 weeks
45630763|NCT01661595|Drug|tadalafil|10 mg/day for 4 weeks.
45630764|NCT01661595|Drug|Placebo|Placebo 1 capsule per day for four weeks.
45630765|NCT02213133|Drug|Selinexor (KPT-330)|Oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly in 28-days cycle.
45630766|NCT02146833|Drug|Selinexor|Comparison of different dosages and dosing schedules of drug.
45630767|NCT05446155|Diagnostic Test|Imaging|Diagnostic and prognostic imaging, omics and machine learning methods will be applied
45630768|NCT05445999|Device|High-Definition transcranial electrical stimulation|According to the results of structural phase magnetic resonance and electroencephalogram, four optimal stimulation parameters will be determined.Transcranial electrical stimulation devices (Sorterix)will be used for intervention.In each cycle, the stimulation will be performed every night during weekdays,a total of 10 times.A maximum of four cycles of intervention will be performed for each patient, depending on the efficacy and the their wishes.
45630769|NCT05465109|Other|TBI-AD/ADRD Caregiver Support Intervention (TACSI)|The TBI-AD/ADRD Caregiver Support Intervention (TACSI) incorporates psychosocial and psychoeducational approaches with the objective of: a) identifying stressors associated with caregiving for family members who have the dual diagnosis of traumatic brain injury and dementia; and b) supporting caregivers in developing more effective coping and communication strategies as well as enhanced caregiving self-efficacy. This intervention offers individual and family coaching and knowledge and skills to help manage stress and reduce caregiver burden.
45770341|NCT05484336|Other|Beverage containing 4g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 4g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
45935253|NCT00219973|Drug|Bemiparin|Bemiparin 3.500 IU/day for 28 days compared to 8 days
45935254|NCT00042497|Biological|autologous dexosomes loaded with tumor-specific peptides|
45630770|NCT05426655|Other|Self management|"The program will consist of 3 sessions in which everything related to pain and its management will be explained. In a first workshop, a first educational session on the neurophysiology of pain will be given by means of a Power Point presentation. In a second workshop, a tool will be used to locate those factors that can improve/worse the pain, physical documentation will be delivered with instructions for performing a self-massage and exercises of the temporomandibular region as well as advice and recommendations to manage different situations that may appear on a daily basis and on Lifestyle. A meditation session will also be held. In the third and last workshop, the game the painometer will be played and a meditation session will be held."
45770342|NCT05484336|Other|Beverage containing 6g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 6g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
45770343|NCT05484336|Other|Beverage containing 8g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 8g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
45630771|NCT04262661|Drug|NNC0472-0147|Part 1: A single dose of NNC0472-0147, dose increased in each cohort. Part 2: Daily doses of NNC0472-0147, dose increased in each cohort.
45770344|NCT02094352|Drug|Ketamine Infusion + Epidural Infusion|The ketamine and epidural infusions will be administered over 96 hours with appropriate titration.
45770345|NCT02094352|Drug|Control Group + Epidural infusion|The saline and epidural infusions will be administered over 96 hours with appropriate titration.
45770346|NCT02094352|Drug|Ketamine Booster Infusion|Patients will receive three ketamine booster infusions over the course of three months.
45770347|NCT02094352|Drug|Control Group Booster Infusion|Patients will receive three saline booster infusions over the course of three months.
45913395|NCT02022137|Dietary Supplement|White cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
45770348|NCT05486364|Diagnostic Test|Digital Monitoring|Subjects will perform self-measurements with a PPG based smartphone application (FibriCheck™) to monitor for AF recurrence after the PVI procedure. One-minute measurements will be performed twice daily starting one month before the PVI procedure and continue up to 12 months after the procedure.
45770349|NCT05486364|Diagnostic Test|Standard of care|Subjects will wear a 24-hour holter monitor at 3, 6 and 12 months after the PVI procedure. Additionally, outpatient cardiology clinic visits are organised at 6 weeks, 3 months and 12 months after the PVI procedure (including a 12-lead ECG and cardiologist consultation).
45770350|NCT05478876|Radiation|carbon ion radiation therapy CIRT|"CIRT: The low-dose CTV (clinical target volume) will receive a total dose of 43 GyRBE in 10 fractions, 4 fractions per week. The high-dose CTV will receive a total dose of 68.8 GyRBE in 16 fractions, 4 fractions per week.~The expected duration of treatment is 4 weeks, 4 fractions per week. Treatments lasting longer than 6 weeks, or with less than 6 fractions administered on 14 consecutive days, will not be considered acceptable.~Immunotherapy: Patients will undergo immunotherapy after carbon ion radiation therapy (CIRT) up to maximum response and/or up to tolerance. The concomitant association of immunotherapy is not envisaged in this protocol."
45913396|NCT02022150|Behavioral|Body composition in paracentesis|Takin blood samples and bioelectrical impedance measurmeent, Neuropsychological tests evaluation
45447630|NCT03224000|Behavioral|Symptom Questionnaire|Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
45630772|NCT04262661|Drug|insulin glargine|Part 2: A fixed dose level of 0.5 U/kg insulin glargine will be used in all cohorts.
45770351|NCT05095246|Biological|KB407 (Nebulization)|Nebulized solution of KB407, a replication-incompetent HSV-1 expressing full length human CFTR
45770352|NCT02552238|Drug|Lumason|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
45770353|NCT05088460|Drug|REGN4461|Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
45770354|NCT05088460|Drug|Matching Placebo|Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
45770355|NCT05087446|Behavioral|Early assessment team|Early assessment team (EAT):The patients receive their first assessment by an early clarification team within a few weeks after the team receiving the referral. The team then decides whether further assessment and/or treatment should be given in the general outpatient clinic, and/or whether any other follow-up may be appropriate. In the first meeting the patient preferably meets two therapists, who conduct a semi-structured interview with focus on health and level of functioning. If considered appropriate, the team may offer a short-term intervention.
45913397|NCT02022163|Biological|Low dose of H7 VLP vaccine + Alhydrogel|Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
45913398|NCT02022163|Biological|Med dose of H7 VLP vaccine + Alhydrogel|Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
45913399|NCT02022163|Biological|High dose of H7 VLP vaccine + Alhydrogel|High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
45913400|NCT02022163|Biological|High dose of H7 VLP vaccine|High dose of H7 VLP vaccine, 2 doses given 21 days apart
45913401|NCT02022163|Biological|Placebo|Placebo, 2 doses given 21 days apart
45913402|NCT02022176|Other|Glucose Uptake|Glucose uptake is measured by oral glucose tolerance test and euglycemic clamp
45913403|NCT02022176|Other|Resting metabolic rate|Resting metabolic rate is measured by indirect calorimetry after an over-night fast
45913404|NCT02022176|Other|Nitrite infusion|Sodium nitrite or saline was infused at escalating doses at a rate of 1, 10 or 100 nmol kg-1 min-1 (10 minutes per dose) in a randomized, double blinded cross-over fashion
45913405|NCT02022189|Procedure|Renal Biopsy|
45935255|NCT00220012|Procedure|Folate depletion and supplementation|
45770356|NCT05087446|Behavioral|Admission to General psychiatric outpatient clinic|Ordinary procedures for admission to an outpatient clinic are followed in accordance with the Norwegian Directorate of Health's national prioritization guide. Referrals are assessed on the basis of severity and placed on a regular waiting list (usually a waiting period of 1-3 months). The patients receive their first personal assessment from a therapist in a general outpatient clinic who takes a position on what is to be initiated and, if necessary, offers further assessment / treatment in accordance with procedures in the outpatient clinics. This is not standardized beyond current practice.
45630773|NCT04262661|Drug|Placebo (NNC0472-0147)|Part 1: A single dose of placebo, dose increased in each cohort.
45770357|NCT05478798|Other|ultrasonographic fetal weight estimation|An ultrasonographic estimate will be performed in our ultrasound unit and a calculation by the ultrasound machine is based on Hadlock's formula including measurement of biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC) and femur length (FL).
45770358|NCT05478798|Other|clinical fetal weight estimation|A clinical weight estimate will be performed by using Leopold's maneuvers
45770359|NCT05478798|Other|maternal subjective fetal weight estimation|the pregnant woman will tell her subjective estimation of fetal weight estimation
45770360|NCT01188421|Drug|Buprenorphine/naloxone|up to 8/2 mg Sublingual (SL) per day
45770361|NCT01188421|Drug|Clonidine|up to 0.8 mg per day (oral)
45770362|NCT01188421|Drug|Tramadol ER|up to 600 mg per day
45770363|NCT05066854|Procedure|integron research|"Patients with suspected UTI with fever will be screened at their admission to the pediatric ED.~Urine samples will be sent to the laboratory for culture and integron PCR according to routine practice.~Results of the integron search will be given to the investigator. Patients in the experimental group with a positive or uninterpretable PCR will also receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines.~Patients in the experimental group with a negative PCR will receive a treatment with SXT at the recommended dose."
45770364|NCT05066854|Procedure|usual practice|"Patients with suspected UTI with fever will be screened at their admission to the pediatric ED.~Patients in the control group will receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines."
45770365|NCT03780894|Drug|Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]|Administration of 2 mg of FC together with RBC and TXA
45770366|NCT03780894|Biological|Red blood cells concentrate|Administration of 2 red blood cells concentrates together with FC and TXA
45770367|NCT03780894|Drug|Tranexamic Acid|Administration of 1g of TXA together with FC and RBC
45770368|NCT04424082|Other|Removal of dead space filter|Dead space filters will be removed and Vcap parameters (VCO2 ml/min, PaCO2 kPa, alveolar dead space in ml) recorded before and after removal
45770369|NCT01006018|Drug|Sitagliptin + Pioglitazone PLACEBO|Sitagliptin 100 mg tablet daily + Pioglitazone PLACEBO 15 mg capsule daily
45770370|NCT01006018|Drug|Sitagliptin + Pioglitazone|Sitagliptin 100 mg tablet daily + Pioglitazone 15 mg capsule daily
45770371|NCT01006018|Drug|PLACEBO|Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily
45770372|NCT05478642|Other|The Hospital Anxiety and Depression Scale.|"The study was carried out on the basis of the National Military Medical Clinical Center Main Military Clinical Hospital. All patients participated in Operation Joint Forces and received gunshot wounds during combat operations.~A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.~Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022. Data collection was carried out during the Russian invasion of Ukraine and the offensive on Kyiv."
45770373|NCT05030350|Drug|PH94B|Nasal spray
45447631|NCT03224000|Procedure|Video-Strobe Procedure|Video-strobe procedure to check vocal cords performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
45447632|NCT03224000|Procedure|MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning|IMRT planned with MRI guidance.
45447633|NCT03224000|Procedure|Standard-of-Care Intensity Modulated Radiotherapy (IMRT) Planning|IMRT planned by standard-of-care.
45447634|NCT03224000|Radiation|Intensity Modulated Radiotherapy (IMRT)|Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days.
45447635|NCT03636776|Other|Quality of life in metastatic BC|"1 month after metastatic stage diagnosis, patients complete their 1st therapeutic sequence evaluation visit (T1) within the recommended standard time frames. If the disease remains stable or if a response to treatment is observed then patients continue their follow-up in the same therapeutic sequence (T1).~If progression occurs, treatment is modified and patients move on to the next therapeutic sequence (T2).~And so on as many times as necessary. Before each evaluation visit with investigator, patients complete the questionnaires QLQ-C30, BR23, STAI, BDI II"
45630774|NCT02957097|Drug|Gabapentin|Medication used for management of neuropathic pain conditions
45630775|NCT02957097|Drug|Placebo|Placebo medication. It looks exactly same as the Gabapentin medication in same size, shape, and color.
45630776|NCT05443659|Device|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation(CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
45770374|NCT04424238|Behavioral|m-health management|Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care.
45913406|NCT02022215|Drug|ME1111 Solution, Low strength|ME1111 Solution, Low strength, applied once daily for 48 weeks
45630777|NCT02690207|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
45630778|NCT02689349|Device|Implantation of Esteem|Subjects meeting indications are implanted with the Esteem Totally Implantable Hearing System
45913407|NCT02022215|Drug|ME1111 Solution, High strength|ME1111 Solution, High strength, applied once daily for 48 weeks
45913408|NCT02022215|Drug|Matching Vehicle Solution|Matching Vehicle Solution, applied once daily for 48 weeks
45913409|NCT02022228|Drug|triptorelin|0.2 mg triptorelin, ih
45630779|NCT03165383|Drug|Bupivacaine (Transversus Abdominis Plane Block)|Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly up to 24 hours.
45630780|NCT03165383|Drug|Intravenous Patient Controlled Analgesia (PCA) Morphine|PCA Intravenous Morphine 1 milligram bolus on demand was given as rescue analgesia up to 24 hours.
45630781|NCT03114839|Dietary Supplement|Lactobacillus casei strain Shirota (LcS)|A fermented milk containing LcS, 65 ml for oral administration, 1 bottle per day for 7 days. One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; 0.9 g of protein; and at least 6.5 x 10^9 colony-forming units of LcS.
45630782|NCT03165539|Device|Cerebral oxygen saturation monitoring|Intraoperatively, patients will have baseline cerebral oxygen saturation monitoring while breathing room air. Cerebral oxygen saturation monitoring will continue throughout the entire operation including the time on one-lung ventilation.
45630783|NCT03162575|Behavioral|Mindfulness-Based Cognitive Therapy|Structured MBCT intervention based on the protocol of Williams, Teasdale, and Segal (2002)
45770375|NCT04424160|Biological|PRP injection in the endometrium|Within 5 days after the cessation of menstrual period, endometrial PRP procedure will be planned. Approximately 20 ml of blood sample will be collected under sterile conditions, and PRP will be prepared. The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into the endometrial region of the endometrium in several positions.On the same day after the procedure, the patient will be observed in the outpatient room and will be discharged on the same day.
45770376|NCT00996502|Drug|Docetaxel|"Phase I:~Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle~Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle~Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle"
45770377|NCT00996502|Drug|Bevacizumab|15mg/kg of Bevacizumab every 3 weeks
45770378|NCT00996502|Drug|Erlotinib|200 mg of Erlotinib PO daily days 2-16
45770379|NCT00996502|Drug|Prednisone|5 mg of Prednisone PO bid
45770380|NCT05484258|Behavioral|Shared Medical Visit|Group visit wherein physician and Social Worker, would be discussing topics relevant to the population.
45770381|NCT00984490|Drug|metformin hydrochloride|Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery
45770382|NCT00984490|Other|laboratory biomarker analysis|Blood and tissue collection to determine the in situ biologic effect of metformin
45770383|NCT05484102|Dietary Supplement|milk fermented with lactobacillus paracasei CBA L74|milk fermented with lactobacillus paracasei CBA L74 will be administered daily for 3 months to 100 children. Participants were supplied with the milk product in powder form, by Heinz Italia SpA, Segrate, Italy. The study products were provided in tins containing 400 g of powder, and the packaging was similar and the tins were stored at room temperature in a dry environment. The family pediatricians instructed parents about the daily amount of the assigned study product and the method of preparation. All subjects received 7 g/day of study products diluted in a maximum of 150 mL of cow's milk or water. After dilution, the look and the taste were the same for all of the study products.
45770384|NCT05484102|Dietary Supplement|placebo milk formula|placebo milk formula containing maltodextrins will be administered daily for 3 months to 100 children. The study products were provided in tins containing 400 g of powder, and the packaging was similar and the tins were stored at room temperature in a dry environment. The family pediatricians instructed parents about the daily amount of the assigned study product and the method of preparation. All subjects received 7 g/day of study products diluted in a maximum of 150 mL of cow's milk or water. After dilution, the look and the taste were the same for all of the study products.
45913410|NCT02022228|Drug|hCG|1000 IU hCG, im
45630784|NCT02679287|Device|CLC|The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.
45630785|NCT05357261|Behavioral|Wellness Check and Socialization|In-home delivery with driver observation and interaction
45630786|NCT05357261|Other|Prepared Meals|Prepared meals compliant with Older Americans Act nutrition programs guidelines
45770385|NCT05484024|Drug|Sintilimab|PD-1 inhibitor
45770386|NCT05484024|Radiation|Short-course radiotherapy|Pelvic radiation
45913411|NCT02022228|Drug|hCG|500IU hCG, im
45913412|NCT02022241|Drug|triptorelin|0.2 mg, ih, at night and 0.2 mg, ih, 12 hours later when at least one of the following criteria was reached: (i) serum E2 ≥3500 pg/ml, (ii) ≥18 follicles measuring ≥11 mm.
45447636|NCT03846830|Device|Incremental Velocity Error (IVE)|A lightweight headband has electronics attached that detect head velocity and move a laser target at a fraction of the head velocity.
45447637|NCT03846830|Behavioral|Traditional Vestibular Rehabilitation (VPT)|Standard of care, meta-analysis vetted, eye and head motion exercises to reduced morbidity associated with dizziness and imbalance.
45630787|NCT03162185|Drug|Escitalopram|Experimental group participants (n = 30) will receive 20 mg of Escitalopram for 7 days.
45630788|NCT03162185|Drug|Placebo|Control group participants (n = 30) will receive a placebo for 7 days.
45630789|NCT03162029|Other|CBCT imaging|CBCT imaging of participants, then take measurement by radiomorphometric indices
45630790|NCT02544633|Drug|MGCD265|MGCD265 is a small molecule multi-targeted receptor tyrosine kinase inhibitor
45630791|NCT03162263|Device|EKso training|Patients affected by chronic stroke underwent gait training by using the Ekso device; they performed a total of 20 sessions (5 day/week for 4 weeks) of at leat 40min duration.
45770387|NCT05484024|Combination Product|CAPOX/mFOLFOX|chemotherapy regimen
45770388|NCT02027272|Drug|Dexamethasone|Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart
45447638|NCT05169944|Drug|Magrolimab|Anti-cancer therapeutic agent targeting the CD47-signal receptor protein-alpha (SIRP-alpha) axis
45770389|NCT05475444|Device|Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels|antibacterial nanoparticles were used because of their small size, sustained release and positive charge which interact with the negatively charged surface of bacterial cell causing its destruction.
45770390|NCT05475444|Device|Ciprofloxacin paste and solution|Conventional antibacterial paste and solution were compared to nanoparticles smart gels to treat endodontics bacterial infection
45770391|NCT02012608|Drug|Glutamine|Oral glutamine for subjects undergoing breast conserving therapy
45630792|NCT02678351|Drug|68Ga-PSMA-11|Undergo 68Ga-PSMA-11 PET/MRI
45770392|NCT02012608|Drug|Placebo|For subjects undergoing breast conserving therapy
45630793|NCT02678351|Procedure|Magnetic resonance imaging (MRI)|Undergo 68Ga-PSMA-11 PET/MRI
45630794|NCT02678351|Procedure|Positron Emission Tomography (PET)|Undergo 68Ga-PSMA-11 PET/MRI
45770393|NCT03725592|Other|Standard Treatment|Participant households receive a point of use arsenic removal device and a replacement filter. Households are also provided with an instruction manual on how to use the device.
45770394|NCT03725592|Behavioral|Intensive Education|Participant households receive up to five additional in-person visits and phone calls to provide support regarding the health implications of arsenic and the proper use and maintenance of the arsenic removal device.
45630795|NCT05426265|Device|MEL-T01|A 12 week intervention with MEL-T01.
45630796|NCT05426265|Device|MEL-S01|A 12 week intervention with MEL-S01.
45770395|NCT03472092|Behavioral|Cognitive Behavioral Therapy (CBT)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
45770396|NCT03472092|Drug|Placebo|The placebo pill will be administered once a day at home for 8 weeks, to be taken by mouth with or without food under the supervision of the participant's parent or guardian. To maintain blinding, all participants will receive 1 matching capsule as a daily dose to be taken each evening during the study.
45770397|NCT03472092|Drug|Amitriptyline|Amitriptyline will be administered once a day at home for 8 weeks, to be taken by mouth with or without food under the supervision of the participant's parent or guardian. To maintain blinding, all participants will receive 1 matching capsule as a daily dose to be taken each evening during the study. For this study, a dose of 0.25 mg/kg/day will be provided for the 1st 2 weeks, followed by a dose of 0.5 mg/kg/day for 2 weeks, 0.75 mg/kg/day for 2 weeks and a maximum dose of 1.0 mg/kg/day for 2 weeks based on tolerability. Participants experiencing tolerability issues, may be held a current dose rather than titrated to the next dosage if deemed appropriate by the study doctor.
45770398|NCT03472092|Behavioral|Biofeedback-Assisted Relaxation Training (BART)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
45447639|NCT02955069|Drug|PDR001|PDR001 was administered at a dose of 400 mg via intravenous infusion once every 4 weeks (Q4W). PDR001 was administered on Day 1 of every cycle. Each cycle was 28 days.
45630797|NCT05286437|Drug|Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole|Lenvatinib and letrozole will be given orally (PO) daily from Day -14, while pembrolizumab will be administered intravenously during week 1 of each 6-weekly cycle from Cycle 1 Day 1 (C1D1), with daily lenvatinib and letrozole.
45630798|NCT03161717|Device|Epidural electrical stimulation (EES)|Using loss of resistance technique and electrical stimulation
45630799|NCT03161717|Device|Loss of resistance (LOR)|Using loss of resistance technique only
45630800|NCT04440527|Device|Preserflo / Innfocus Microshunt|The Microshunt features an 8.5-mm tube with an outer diameter of 350 µm and a 70-µm diameter lumen. Implantation creates a subconjunctival bleb and lowers intraocular pressure by increasing aqueous humor outflow.
45630801|NCT04440527|Other|Trabeculectomy|Trabeculectomy is the most commonly performed surgical procedure and is considered the gold standard.
45630802|NCT03161639|Other|Pulpectomies|Primary teeth pulpectomy is an important treatment option for necrotic teeth. The correct working length will determine a better chemical and mechanical disinfection of the root canals, without demanding the surrounding periapical tissues and dental germs. In addition, it decreases the chance of a sub or over-filling, which also may interfere with the achievement of the success.
45630803|NCT05442489|Device|GORE Excluder Thoracoabdominal Branch Endoprosthesis|TEVAR
45630804|NCT05464251|Other|Prospective chart review of subjects diagnosed with spinal epidural abscess|Collection and assessment of available clinical, pathological, radiological, and socioeconomic data on subjects presenting with spinal epidural abscess. Standard of care treatment and outcomes for each group will be analyzed.
45770399|NCT03472092|Behavioral|Cognitive Reappraisal Training (CR)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
45630805|NCT05442099|Behavioral|Iso-principle music playlist|Participants listen to the iso-principle music playlist for 30 minutes.
45630806|NCT05442099|Behavioral|Generic calm music playlist|Participants listen to the calm music playlist for 30 minutes.
45630807|NCT05242367|Device|Modius Spero active device|Battery powered non-invasive neurostimulation device
45630808|NCT05242367|Device|Modius Spero sham device|Placebo comparator sham device (no active stimulation)
45630809|NCT05425641|Behavioral|Goal Setting|"Individuals will receive daily text messages that include the Goal Setting behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Goal Setting BCT is Is your goal to walk an extra 1,000 steps more than your baseline average?."
45770400|NCT04949854|Device|B.Braun 6.35 cm 20 Gauge ultralong intravenous catheter|control Arm 1 (6.35 cm 20 Gauge ultralong intravenous catheter without guidewire
45770401|NCT04949854|Device|B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter|Experimental Arm B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter with guide wire
45630810|NCT05425641|Behavioral|Action Planning|"Individuals will receive daily text messages that include the Action Planning behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Action Planning BCT is Take one minute and plan for today how, where and when you can walk an extra 1,000 steps more than your baseline average. Have you planned for today?"
45630811|NCT05425641|Behavioral|Self-Monitoring of Behavior|"Individuals will receive daily text messages that include the Self-Monitoring behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Self-Monitoring BCT is Check your fitbit for yesterday. Type in the number of steps you did yesterday."
45770402|NCT05478486|Drug|MSP008-22|"It is single group assignment interventional model in this clinical trial, consisting of 5 cohorts of 3 patients in each, to be enrolled such that there exists an overall gender balance for the entire trial and to also ensure including minimum five (5) patients of TNBC and minimum five (5) male patients.~The trial will be initiated with dosing of a cohort of 03 patient with the Safe starting dose for MSP008-22. Dosing of the patients for the next higher dose cohort will initiate only after: (i) All 03 patients have been recruited in the lower dose Cohort and if a repeat Cohort at this dose level is recommended, another 03 patients have been recruited at same dose level (ii) all dosed patients have completed the allocated study cohort duration, (iii) safety and pharmacokinetic results have been reviewed by the Independent Dose Escalation Committee (DEC) and approved for dose escalation to next cohort."
45770403|NCT01996852|Behavioral|Cognitive-behavioral Meetings|"The cognitive-behavioral intervention will consist of six monthly in-person meetings and five telephone follow-ups. In-person meetings include a 90-minute educational group session and five 60-minute therapeutic couple-based meetings which partners are asked to attend. The telephone follow-ups last 15-30 minutes and take place two weeks after each in-person meeting. They will review progress and provide support.~Each monthly meeting has a focused topic: Introduction, Guided imagery, Sensate focus, Communication and relationship issues, and Review.~Homework will be assigned at the end of each meeting. Generally, participants are instructed (a) practice guided imagery daily, (b) engage in sexual activity 1-2 times/ week after sildenafil intake and (c) use the pump every day for 10min."
45770404|NCT01996852|Drug|sildenafil citrate|"100mg of sildenafil citrate will be given twice a week to interested patients. Participants may start Sildenafil at a lower dose when needed.~To increase external validity, participants will be given the choice of using Sildenafil in the study."
45630812|NCT05425641|Behavioral|Feedback on Behavior|"Individuals will receive daily text messages that include the Feedback behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Feedback BCT is Your goal is to walk 1000 steps more than your baseline average. Yesterday you did not meet your goal. If you think this is incorrect you can check your step count from yesterday on your Fitbit app to confirm. "
45770405|NCT01996852|Device|Vacuum Constriction Device|"The medical treatment entails a 10-minute daily use of VCD (pump).~The VCD (pump) is a FDA approved marketing product and has a brochure and DVD that explain its usage. The clinical trials unit (CTU) nurse will dispense the VCD at the drug pick-up time and document it on a Device Accountability Form. The study coordinator has received manufacturer's training and can address questions that a subject may have about VCD on site or through a phone call."
45770406|NCT05478408|Other|Questionnaires set|Participants will be asked to respond to the demographic information，the Depression Anxiety Stress Scale（DASS-21）and the Internet Addiction Test（IAT）.
45630813|NCT03161561|Other|capacity of primary phagocytes|measurement of capacity of primary phagocytes (neutrophils, monocytes and macrophages) isolated from COPD patients' blood or alveolar macrophages isolated from patients' lungs to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
45913413|NCT02022254|Drug|semaglutide|Subjects will initiate treatment with 0.25 mg for the first four weeks followed by dose doubling every four weeks up to a dose of 1.0 mg.
45630814|NCT05554289|Device|Depression Auxiliary Intervention Treatment Software|Depression Auxiliary Intervention Treatment Software
45630815|NCT05464173|Drug|Chidamide|10-30mg biw
45770407|NCT05478330|Drug|Flutamide 1% gel|Group A: Flutamide-treated patients: Consisted of 25 patients with acne vulgaris treated with 1% Flutamide topical gel on the face two times per day for a duration of 8 weeks.
45770408|NCT05478330|Drug|topical gel without flutamide|Group B: Consisted of 25 patients with acne vulgaris treated with topical gel with the same component as the other group, except for flutamide, on the face twice per day for a duration of 8 weeks.
45770409|NCT00978874|Radiation|fludeoxyglucose F 18|
45770410|NCT00978874|Radiation|fluorine F 18 EF5|
45770411|NCT05478096|Behavioral|GetStarted|Guided internet-based intervention for procrastination.
45913414|NCT02022254|Drug|placebo|Semaglutide placebo will be administered s.c.
45913415|NCT02022254|Drug|metformin|For oral administration twice daily, in two periods, each of 3.5 days duration. The first period is initiated before semaglutide treatment and the second period is initiated at the end of semaglutide treatment.
45913416|NCT02022254|Drug|warfarin|For oral administration, given as a single dose. The first dose is given before semaglutide treatment and the second dose is given at the end of semaglutide treatment.
45913417|NCT02022293|Drug|Atorvastatin|Patients in this group will take 20mg per night.
45913418|NCT02022293|Other|Placebo|
45913419|NCT02022306|Drug|TD-6450|
45913420|NCT02022306|Drug|Placebo|
45913421|NCT02022319|Device|Ultrasonographic Shear Wave Elastography|
45913422|NCT02022345|Procedure|Percutaneous Coronary Intervention|
45447640|NCT03254108|Drug|OPC-61815 injection 2mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.
45447641|NCT03254108|Drug|OPC-61815 injection 4mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.
45447642|NCT03254108|Drug|OPC-61815 injection 8mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.
45630816|NCT05464173|Drug|Abemaciclib|150mg or 100mg bid
45630817|NCT05464173|Drug|Fulvestrant|500mg, d1, 15, 29, and then q4w.
45630818|NCT03160937|Other|Manual therapy|The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets.
45630819|NCT05464095|Device|mHealth Intervention|The Health Insurance Portability and Accountability Act (HIPPA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network. Participants assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
45913423|NCT02022358|Drug|Glucarpidase|Glucarpidase rescue (50 units/kg x 1, intravenously)
45630820|NCT05464095|Device|Usual Care|The HIPPA-compliant texting platform is linked to the Fitbit Application Program Interface. Real-time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network.
45770412|NCT04331626|Drug|Gemcitabine Injectable Product|Low dose chemotherapy drug combined with pd-1 antibody, Gemcitabine should be administered at 50% of the recommended dose, i.e. 500mg/m2, for 30 minutes by intravenous drip. Day 1 and day 8 administration.
45630821|NCT02683187|Drug|Active Comparator: Sitagliptin|Subjects will receive sitagliptin prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
45630822|NCT02683187|Drug|Placebo Comparator - No Sitagliptin|Subjects will receive Placebo (instead of sitagliptin) prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
45630823|NCT05515601|Drug|Mirikizumab|Administered SC.
45630824|NCT02683109|Drug|FDC of tiotropium + olodaterol|Fixed Dose Combination of tiotropium + olodaterol
45770413|NCT05478018|Behavioral|High Intensity Interval Training|Supervised high-intensity interval training for 12 weeks three times per week
45630825|NCT02683109|Drug|Placebo|
45630826|NCT02683109|Drug|Tiotropium|
45630827|NCT02683109|Drug|Olodaterol|
45630828|NCT02544321|Drug|Bromocriptine|
45630829|NCT02544321|Other|Placebo|
45630830|NCT05425563|Behavioral|Expectancy Cues|Participants are presented with a social cue that represents how previous participants responded to the upcoming stimulus. In actuality, the cue is a social placebo, constructed by the experimenters and varying in intensity.
45913424|NCT02022358|Drug|Methotrexate|Methotrexate (12 g/m2 x 1, intravenously)
45913425|NCT02022358|Drug|Folinic Acid|Folinic acid rescue 15mg/m2 four times daily adjusted according to methotrexate levels
45913426|NCT02022371|Procedure|Targeted biopsies of the prostate|Multiple biopsies from a MRI lesion for analysis of intratumour heterogeneity
45630831|NCT05195723|Drug|WP1122|Oral solution
45630832|NCT05195723|Drug|Placebo|Oral solution
45630833|NCT02533401|Drug|Cyclophosphamide|Cyclophosphamide will be administered IV at 250 mg/m^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
45630834|NCT02533401|Drug|Fludarabine|Fludarabine will be administered IV at 25 mg/m^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
45630835|NCT02533401|Drug|Rituximab|Rituximab will be administered IV at 375 mg/m^2 on Day 1 of Cycle 1 and then at 500 mg/m^2 on Day 1 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
45913427|NCT02022410|Other|CAS after primary and revision TKA|CAS and RAPT
45913428|NCT02022449|Behavioral|Stress management|Cognitive behavioral stress management Cognitive and emotionally focused coping enhancement strategies Progressive muscle relaxation Social support Strategies for parenting a child with cancer
45770414|NCT03699540|Drug|Marijuana|Experimental, non-therapeutic administration of active and inactive marijuana dose(s)
45770415|NCT03699540|Drug|Alcohol|Experimental, non-therapeutic administration of active and inactive alcohol dose(s)
45770416|NCT00970606|Drug|Rosuvastatin (crestor)|20 mg tablets once daily x max 28 days or for an additional 3 days following ICU discharge
45447643|NCT03254108|Drug|OPC-61815 injection 16mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.
45630836|NCT05497037|Device|PRF stimulation|One time 500 kHZ stimulation for 15 min
45630837|NCT05497037|Device|Sham stimulation|Sham stimulation for 15 min
45630838|NCT05441709|Behavioral|Ci-BPC with Standard of Care (SOC)|"Clinically-integrated breastfeeding peer counseling (ci-BPC) is a practice that, supports the patient and the clinical care team by delivering culturally-appropriate breastfeeding help to motivate breastfeeding initiation, intensity, and duration, inspiring confidence for patients to set breastfeeding goals and meet them. ci-BPC is delivered by community health workers who have breastfed an infant, and have received basic training in breastfeeding support through a qualified BPC training organization. For this project, the Peer Counselor will make initial contact to patients randomized into the treatment arm via phone to schedule the Intake Encounter between 20 and 30 weeks gestation. Subsequently, each patient will receive a minimum of 3 additional encounters which can occur virtually or in-person. Patients randomized to the ci-BPC arm are additionally offered access to a warmline where messages will be returned by the next business day."
45770417|NCT00970606|Drug|Placebo|Placebo tablet identical to active therapy. 1 tablet per day
45913429|NCT02022462|Behavioral|Health Navigation|"Experimental: Immediate peer health navigator intervention vs. waitlist control.~The immediate peer health navigator intervention group will receive assistance for 6 months and then followed up with after an additional 6 months. Participants will receive training in how to self-manage their physical health and healthcare. The intervention is individualized and the number of contacts by the navigator will be determined by their need level. The waitlist control group will complete a baseline assessment and then wait for 6 months before receiving the peer health navigator intervention. They will complete a follow-up assessment after 6 months of the intervention."
45913430|NCT02022475|Drug|Vitamin D|100 000 units oral vitamin D as 2 capsules 50 000 units each
45913431|NCT02022475|Other|placebo|2 placebo capsules will be applied as a single dose
45913432|NCT02022488|Drug|midazolam|Group M
45913433|NCT02022488|Drug|alfentanil|Group MA
45913434|NCT02022488|Drug|ketamine|Group MK
45913435|NCT02022501|Drug|DE-120|
45913436|NCT02022527|Drug|Acetyl Salicylic Acid|
45913437|NCT02022527|Drug|Warfarin|
45913438|NCT02022527|Drug|Placebo (for Aspirin)|Sugar pill manufactured to mimic 75 mg Aspirin
45770418|NCT03664518|Drug|Eltrombopag|subjects will initiate treatment with 25 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts. and maximum dose should not exceed 75 mg daily. Subjects whose platelet count between 50~150×109/L，the eltrombopag dose Maintain. platelet count between 150~250×109/L, need to reduce the dose of eltrombopag to the next lower dose or lower frequency. Subjects whose platelet count exceeds 250×109/L at any point during the treatment period, must have eltrombopag interrupted and increase the frequency of platelet monitoring to twice weekly, until platelet counts fall below 100×109/L.
45630839|NCT03164837|Drug|68Ga-NOTA-RM26|Single-dose 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans.
45770419|NCT01973062|Biological|rituximab|Given IV
45770420|NCT01973062|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
45770421|NCT03661320|Biological|Nivolumab|Specified dose on specified days
45770422|NCT03661320|Drug|Gemcitabine|Specified dose on specified days
45770423|NCT03661320|Drug|Cisplatin|Specified dose on specified days
45770424|NCT00981370|Drug|deferasirox|Treatment starting dose of 20mg/kg/day based on subjects baseline LIC (liver iron concentration) and gradually escalate the dose to a maximum of 35 mg/kg/day based upon toxicity. Duration is up to a max of 12 months.
45770425|NCT00979810|Drug|18F-FLT PET Scan|The patient will undergo MRI and 18F-FLT PET scans of the brain. A IV catheter will be placed in a superficial hand or arm vein for administration of 18F-FLT (approximately 370 MBq), prepared by the MSKCC Radiochemistry Core Facility. A second venous catheter will be placed in the opposite hand or arm for venous blood sampling. If a central venous catheter is present, it will be used for blood sampling or radiopharmaceutical administration, and only a single venous catheter will be placed. Sequential blood samples may be obtained following 18F-FLT infusion for assaying whole blood and plasma radioactivity. All catheters will be removed at the end of the day.
45770426|NCT04549116|Drug|Progesterone-IBSA Injectable Solution|Progesterone-IBSA 25mg, twice daily (BID) SC Injection every 12 hours
45770427|NCT04549116|Drug|Progesterone Vaginal Gel with Applicator|Crinone 8%, 90 mg, QD intravaginally
45770428|NCT04549116|Drug|Placebo Vaginal gel with applicator|Vaginal gel Placebo, once daily (QD) intravaginally
45630840|NCT02370927|Other|Control|Non pulse extruded cereal
45770429|NCT04549116|Drug|Placebo injectable solution|Placebo injectable solution, BID SC Injection every 12 hours
45770430|NCT00947284|Drug|nalbuphine plus naloxone|single dose administered intravenously
45770431|NCT00947284|Drug|nalbuphine plus saline|single dose administered intravenously
45770432|NCT00947284|Drug|naloxone plus saline|single dose administered intravenously
45770433|NCT04547556|Diagnostic Test|BioFire|"A molecular rapid syndromic testing platform, using the following panels:~BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)~BioFire FilmArray Pneumonia Panel plus (PP)"
45770434|NCT04544592|Drug|CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells|The CD19 CAR used in this study consists of three main components: the variable regions of the anti-CD19 monoclonal antibody FMC63 71, linked to the TNFRSF19-derived transmembrane domain, the 4-1BB costimulatory molecule, and the signaling domain of the CD3-zeta molecule. The DNA encoding this receptor was cloned into a lentiviral vector (LV) backbone.
45770435|NCT01946542|Drug|beet juice concentrate|single dose of beet juice concentrate, roughly 70 mL
45913439|NCT02022540|Drug|PAN-90806 Ophthalmic Solution|
45913440|NCT02022540|Drug|Lucentis|
45630841|NCT02370927|Other|Pea protein|Pulse extruded cereal
45630842|NCT02370927|Other|Pea Starch|Pulse extruded cereal
45630843|NCT02370927|Other|Pea fibre + pea starch|Pulse extruded cereal
45630844|NCT02370927|Other|Pea protein + pea starch|Pulse extruded cereal
45770436|NCT01946542|Other|placebo|
45770437|NCT05483790|Behavioral|multidomain intervention|The intervention including： exercise training :The participants chose an activity that they could do for the long term, such as taiji, eight brocade, elastic belt, yoga and so on.which will consist of 5 times a week and lasting half an hour at most once time; cognitive intervention ：which including memory method/strategy and life application, attention training, lifestyle intervention, the development of brain function and will undergo 7 sessions, 90 minutes peer week)； man-machine intervention ：choose developed and mature module tasks, participants will operate on the computer with the help of the project team members, including spatial cognition, brain balance, clock, ATM simulation）programs will be 20-30 minutes peer day, 3 times a week, for a total of 12 training sessions.
45913441|NCT02022553|Procedure|usual rectal cancer surgery|
45913442|NCT02022553|Procedure|RACHEL|
45913443|NCT02022579|Procedure|DCE-MRI and DWI|DCE-MRI defined lesion(s) compared with biopsy results or 1-year follow up
45630845|NCT02370927|Other|Pea fibre + pea starch + pea protein|Pulse extruded cereal
45630846|NCT05441475|Drug|ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w|All subjects will receive continuous oral administration of absk-011 once a day (QD) or twice a day (bid) with an initial dose of 180 mg, and intravenous infusion (IV) of 1200 mg of atilizumab every 21 days (q3w).
45630847|NCT03164915|Biological|LIV-GAMMA SN Inj.|
45770438|NCT01921114|Device|BioFlo™ Peripherally Inserted Central Catheter (PICC)|
45770439|NCT01921114|Device|Bard® Dual-Lumen PowerPICC SOLO2®|
45770440|NCT05483712|Device|Brass Mesh Bolus|During a standard-of-care 15 fraction radiotherapy treatment, a brass mesh bolus will be used for a single fraction. Small in-vivo dosimeters will be used for three treatment fractions to measure and compare skin doses for quantification purposes.
45770441|NCT03995706|Drug|Sacituzumab Govitecan|All 20 subjects will receive study drug Sacituzumab Govitecan preoperatively. Intraoperative tissue collection will follow with contemporaneous CSF (depending on tumor location) and whole blood (serum) sampling. Samples will be tested for total SN-38and free SN-38, as well as SN-38G. Following recovery from surgery, patients will resume treatment
45770442|NCT00932152|Drug|fulvestrant (Faslodex)|Fulvestrant (Faslodex) IM 250 mg monthly after a loading dose of 500 mg on day 1 and 250 mg on day 15 of cycle 1.
45770443|NCT00932152|Drug|anastrozole (Arimidex)|Anastrozole (Arimidex) 1 mg orally QD
45770444|NCT00932152|Drug|Bevacizumab (Avastin)|Bevacizumab (Avastin) 15 mg/kg IV, every 21 days
45935256|NCT00220051|Drug|Oxaliplatin, Capecitabine|
45935257|NCT00220051|Procedure|Pre operative radiotherapy|
45935258|NCT00220051|Procedure|Surgical Resection|
45770445|NCT00932152|Drug|Best supportive care|Subjects will not receive any chemotherapy for NSCLC nor will they received anti-cancer surgery, immunotherapy, radiotherapy or hormonal therapy. Among the therapies they may take are therapies considered acceptable include, but are not limited to, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral
45770446|NCT05483556|Device|Real tDCS|An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the left inferior frontal gyrus during speech therapy.
45447644|NCT03254108|Drug|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
45447645|NCT02585895|Biological|Evolocumab|Administered by subcutaneous injection once every 2 weeks
45447646|NCT02585895|Procedure|Low-density Lipoprotein Cholesterol (LDL-C) Apheresis|Participants received apheresis for LDL-C according the their physician's prescription and local custom.
45770447|NCT05483556|Device|Sham tDCS|An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the left inferior frontal gyrus during speech therapy.
45770448|NCT01916590|Drug|Bupivicaine|After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
45770449|NCT01916590|Drug|placebo|
45770450|NCT05483478|Combination Product|mobile health combined Multi-course Program|mobile health combined Multi-course Program
45770451|NCT01890694|Drug|Tolvaptan|15 mg once daily
45770452|NCT01890694|Drug|Placebo|15 mg once daily
45770453|NCT01890694|Behavioral|Hepatic Encephalopathy Assessment|The Number connection test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge.
45770454|NCT01890694|Behavioral|Quality of Life Assessment|The SF-36 and Liver Disease Questionnaire will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge
45630848|NCT05441241|Device|Leap Motion Controller|The Leap Motion Controller is an infrared device that digitalizes in real-time the movements of the hand above it. This signal will be converted into Musical Instrument Digital Interface (MIDI) and then translated into a sound of a pitch that depends on the distance between the hand and the device. The software is set to produce a pentatonic scale, so every melody created by the patient will sound consonant, and the timbre will be warm, calm and in human vocal range (similar to a cello). The operator will do an example, playing a melody, and will invite the patient to imitate him. When the patient gains confidence with the device, after a limited time lapse (from 30 seconds to 3 minutes), while they are playing it with one hand, the venipuncture is done on the other arm
45770455|NCT01890694|Biological|Vital signs|Vital signs (blood pressure, heart rate, respiration, temperature, weight, height) will be recorded at every visit.
45770456|NCT01890694|Biological|Blood laboratory tests|Blood laboratory tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin) will be recorded at every visit.
45770457|NCT01890694|Procedure|Ascites Evaluation|Ascites will be assessed at every visit.
45770458|NCT01890694|Procedure|Edema|Edema will be assessed at every visit.
45770459|NCT01883908|Device|Acupuncture with Seirin® needles|Participants will be randomized to receive either usual medical care or acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).
45770460|NCT01883908|Other|Usual medical care|usual medical care such as viscous Lidocaine for relief of pain
45770461|NCT03466866|Behavioral|COPDE|Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.
45630849|NCT05441241|Other|Traditional distraction techniques|Common distraction techniques will be used (i.e., visual stimulation, lecture)
45770462|NCT03466866|Behavioral|Intensive Diabetes Education|In-home diabetes education
45770463|NCT05474898|Other|Magnesium Sulphate Iontophoresis +conventional therapy|will receive Mgso4 Iontophoresis in addition to conventional therapy twice a week/4 weeks
45770464|NCT05474898|Other|High- Power Pain Threshold Ultrasound +conventional therapy|will receive HPPT-US on the upper trapezius in addition to conventional therapy twice a week/4 weeks
45770465|NCT05474898|Other|conventional theapy|will receive postural correction exercise-stretching and strengthening twice a week/4weeks
45913444|NCT02022605|Device|Hands-on EMS training|A trainer (SAH) gave a series of demonstrations of the proper techniques of ERCP step by step on the EMS. The demonstration included selective cannulation, sphincterotomy, guidewire exchange, balloon dilation, stone extraction and stent insertion. Then trainees practiced each technique with hands-on coaching from the trainer on the EMS. Each trainee could repeate the practice with the trainer giving only verbal correction of any errors for about 30min.
45447647|NCT03736161|Drug|Group A- Tofacitinib|Group A patients will receive Tofacitinib 5mg BD. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to Tofacitinib 5 mg BD at the end of 3 months will be put on Tofacitinib 10 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.
45770466|NCT04787536|Procedure|Non-cardiac surgery|Non-cardiac surgery excluding cranial neurosurgery
45770467|NCT05483322|Drug|LAM-002A|25mg capsules
45447648|NCT03736161|Drug|Group B- Methotrexate|Group B patients will receive Methotrexate in increasing dose weekly with maximum dose up to 25 mg/week. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to highest dose of MTX at the end of 3 months will be put on Tofacitinib 5 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.
45447649|NCT03773978|Drug|Baricitinib|Administered orally.
45447650|NCT03773978|Drug|Placebo|Administered orally.
45935259|NCT00077415|Drug|gemcitabine hydrochloride|
45935260|NCT00077415|Drug|triapine|
45935261|NCT00220090|Drug|dexloxiglumide|
45935262|NCT00042536|Drug|Naltrexone HCL/ Yohimbine HCL|
45935263|NCT00220129|Drug|Epirubicin, Cisplatin, Capecitabine|
45770468|NCT05483244|Other|discontinuous weaning|"Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. Patients of the discontinuous weaning group were disconnected from the respirator during the spontaneous breathing phases which could then take place via heat moist exchanger, high-flow therapy and/or speaking valve without pressure support by the respirator (spontaneous breathing trial with heat moist exchanger).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient."
45770469|NCT05483244|Other|continuous weaning|"Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. In the case of continuous weaning, spontaneous breathing trial was supported by the respirator, but the positive endexpiratory pressure was lowered to an individual level (between 5 and 10 mbar) resulting in very little pressure support (spontaneous breathing trial trial under continuous positive airway pressure condition).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient."
45770470|NCT05477940|Device|Absorbable zinc alloy drug eluting coronary stent system|"Absorbable zinc alloy drug eluting coronary stent system (hereinafter referred to as stent system) consists of delivery system and drug stent (hereinafter referred to as stent) pressed on the balloon end of the delivery system"
45770471|NCT03428958|Drug|NUC-3373 + leucovorin|NUC-3373 + leucovorin
45770472|NCT03428958|Drug|NUC-3373|NUC-3373
45770473|NCT03428958|Drug|NUFOX|NUC-3373 + oxaliplatin
45770474|NCT03428958|Drug|NUFOX + VEGF pathway inhibitor|NUC-3373 + oxaliplatin + bevacizumab
45913445|NCT02022605|Other|Standard training|The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of CBD or PD. During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within 10min, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
45913446|NCT02022683|Device|ELVR (Endoscopic Lung Volume Reduction) with Zephyr Valves|
45913447|NCT02022696|Genetic|Lentiviral Gene Transfer|
45630850|NCT05181449|Behavioral|Twin Precision Treatment|Combination of Artificial Intelligence algorithms based on daily sensor input and live nutrition, exercise, sleep and breath coaching to help treat type 2 diabetes
45447651|NCT03771716|Behavioral|African Dance|Basic principles and guidelines for exercise programming will be followed including adequate warm-up and cool-down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity (PA) related injury. The African dance group will receive moderate intensity dance 1 hour per day, twice per week, for 6 months. The prescribed intensity will begin at light to moderate and progress to a moderate to high intensity level. Frequent assessment of heart rate and ratings of perceived exertion will ensure appropriate levels of intensity during each dance session. Levels of exertion during the dance will be prescribed and monitored based on baseline assessments of heart rate and cardiorespiratory fitness.
45447652|NCT03771716|Behavioral|African Cultural Immersion|The Culture group will participate in activities, including cooking, art and games, music, traditional crafts, and lectures and discussions about other aspects of Africana culture and customs. Topics will vary from session to session to maintain interest and engagement. The sessions will be held in a small group format and will be lead my personnel with training in each topic. Participants will meet 1 hour per day, 3 times per week, for 6 months.
45630851|NCT05462379|Procedure|Ovarian graft|Before the beginning of pelvic radiotherapy, one of the ovaries will be removed by laparoscopy. Ovary slices of 1-2 mm will be prepared in sterile environment and engrafted in the fatty tissue of inner tight. One representative fragment will undergo histologic evaluation. These procedures will be done in the same surgical time.
45630852|NCT04440137|Behavioral|Bottle-feeding cessation program|Specific brochure and proper oral hygiene education emphasizing on the benefit of stopping bottle-feeding given to subject
45630853|NCT05178173|Other|Placebo Comparator: Sterile Water|Sterile Water Placebo Comparator
45630854|NCT05178173|Other|27% Ethanol plus essential oils|Over-the-counter antiseptic mouth rinse
45630855|NCT05178173|Other|0.075% Cetylpyridinium Chloride|Over-the-counter antiseptic mouth rinse
45630856|NCT05175755|Other|Patients|The procedure involves taking a total of 12 ml of blood.
45630857|NCT04777565|Other|Robotic surgery|Cochlear implant surgery with HEARO procedure
45630858|NCT02536833|Drug|SM04690|
45630859|NCT02536833|Drug|Placebo|
45630860|NCT02680847|Drug|ALO-02|Oral/Capsule, twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 4 week Maintenance Treatment duration.
45770475|NCT03428958|Drug|NUFOX + EGFR inhibitor|NUC-3373 + oxaliplatin + cetuximab/panitumumab
45770476|NCT03428958|Drug|NUFIRI|NUC-3373 + irinotecan
45770477|NCT03428958|Drug|NUFIRI + VEGF pathway inhibitor|NUC-3373 + irinotecan + bevacizumab
45770478|NCT03428958|Drug|NUFIRI + EGFR inhibitor|NUC-3373 + irinotecan + cetuximab/panitumumab
45770479|NCT03428958|Drug|NUC-3373 + bevacizumab|NUC-3373 + bevacizumab
45770480|NCT01869478|Drug|Intravenous Thrombolysis|
45770481|NCT01869478|Device|Endovascular Arterial Reperfusion|
45770482|NCT01844206|Drug|Epidural Morphine|Patients will be given 3mg epidural morphine, 24 hours after the initial dose.
45770483|NCT01844206|Drug|Epidural Saline|Patients will be given epidural saline 6ml, 24 hours after receiving epidural morphine 3 mg.
45770484|NCT03626454|Drug|Norepinephrine Bolus|'Norepinephrine Bitartarte' bolus of 6 µg/mL for 30 seconds immediately after intrathecal injection
45935264|NCT00220129|Procedure|Surgical Resection|
45770485|NCT03626454|Drug|Norepinephrine infusion|an infusion of 6 µg/mL norepinephrine that was started at 6 µg/kg/h immediately after intrathecal injection
45770486|NCT03626454|Drug|Normal Saline Flush, 0.9% Injectable Solution|10 ml normal saline in syringe for bolus for 30 seconds immediately after intrathecal injection
45630861|NCT03164525|Diagnostic Test|Critical care pain observation tool (CPOT)|test validity and reliability of Thai-version CPOT and BPS
45630862|NCT03164603|Drug|NLG802|Indoleamine 2,3-Dioxygenase (IDO) Inhibitor
45630863|NCT05440149|Radiation|No PMRT for mastectomy / No regional RT for BCS|"Regional RT includes high-tangent field, and can include undissected axilla.~The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II.~Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used."
45630864|NCT05440149|Radiation|PMRT for mastectomy / WBI + Regional RT for BCS|"Regional RT includes high-tangent field, and can include undissected axilla.~The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II.~Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used."
45630865|NCT03959241|Procedure|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate|Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
45630866|NCT03959241|Drug|Tacrolimus|Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting on Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-15. If patients are on medications which alter the metabolism of tacrolimus (e.g.concurrent CYP3A4 inhibitors), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices and patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD.
45630867|NCT03959241|Drug|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. Methotrexate should be dose reduced, given with leucovorin rescue, or held for complications such as severe mucositis per institutional guidelines.
45770487|NCT03626454|Drug|Normal Saline 0.9% Infusion Solution|50 ml syringe with normal saline infuse at a rate 1ml/kg/h immediately after intrathecal injection
45630868|NCT03959241|Procedure|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide|Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
45770488|NCT00897910|Other|flow cytometry|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
45770489|NCT00897910|Other|immunoenzyme technique|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
45770490|NCT00897910|Other|laboratory biomarker analysis|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
45913448|NCT02022722|Drug|Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride|The mixture is injected into the levator muscles, with half the volume on each side of the pelvic musculature.
45770491|NCT05477706|Other|Personalized Support for Progress (PSP)|Personalized Support for Progress (PSP) is a Peer Specialist delivered intervention in which a peer supports Veterans in prioritizing their needs and attaining access to the Veterans' preferred services.
45770492|NCT05477706|Other|Tailored Referral (TR)|TR consists of detailed resource information and referral, consistent with standard practice.
45770493|NCT01834144|Other|Exercise Training|
45770494|NCT05477628|Other|Childcare Navigator|"Participants will be contacted by the CN to assist with access to centre-based childcare after enrolment. The CN will: a) educate the family on the benefits of centre based childcare; b) facilitate placement of the child on waiting lists for funding and centre based childcare placement in their neighbourhood with the aim of having full-time centre based childcare start at 1 year of age; and c) work with the family to overcome barriers to childcare placement prior to and during childcare. It is expected that the child will be in full-time centre-based childcare for a minimum of 12 months.~Control: All children randomized to the control condition will receive age-appropriate nutritional recommendations as part of routine healthcare according to the Rourke Baby Record."
45913449|NCT02022722|Procedure|Pelvic Rehabilitation|Pelvic floor massage will be performed on a weekly basis by a licensed physiotherapist specialized in pelvic floor pelvic therapy
45913450|NCT02022761|Drug|Laninamivir octanoate|40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)
45913451|NCT02022774|Drug|Fimasartan|Fimasartan 60 ~ 120 mg/po take one tablet once a day
45913452|NCT02022787|Other|patients with renal cell carcinoma|Chemokines that may be elevated in patients with RCC
45913453|NCT02022800|Other|PET 18FDOPA|contribution of PET 18FDOPAimagery in high level glioma diagnosis
45913454|NCT02022813|Dietary Supplement|Supplemental parenteral nutrition (SPN)|The amount of energy delivered by SPN will depend on the indirect calorimetry measurement and actual enteral feed delivery. SPN will be reduced with progressing EN
45913455|NCT02022852|Drug|Capecitabine|50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy. Rest for 8 weeks and surgery followed.
45913456|NCT02022852|Drug|XELOX|XELOX 2 cycles (oxaliplatin 130mg/m2 ivgtt 2-6h day 1,capecitabine 1000 mg/m2 bid day 1-14 repeat every 3 weeks) → 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy → XELOX 1 cycle. Rest for 2 weeks and surgery followed.
45770495|NCT05477628|Other|Lactation Consultant|"Participants will be contacted by the LC on the same day as their first primary healthcare visit. They will also receive age-appropriate nutrition recommendations according to the Rourke Baby Record. The LC will be an International Board Certified Lactation Consultant (IBCLC) who will provide scheduled and on-call visits, along with phone calls, video conferencing, and text messaging as needed to support exclusive breastfeeding (using virtual care modalities as appropriate during COVID-19). The LC will contact the family once per week for the first 4 weeks to support breastfeeding technique and help with breastfeeding problems such as latching difficulties, painful nursing, and low milk production, monthly thereafter and provide on-call support as required to support exclusive breastfeeding through 6 months of age.~Control: All children randomized to the control condition will receive age-appropriate nutritional recommendations as part of routine healthcare."
45770496|NCT05477628|Other|Lactation Consultant Support and Childcare Navigator Support|This intervention is a combination of the two interventions described above.
45630869|NCT03959241|Drug|Tacrolimus|Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting Day +5. Starting tacrolimus dose can be modified to account for possible drug interactions (e.g. concurrent CYP3A4 inhibitor use) according to institutional guides. Serum levels of tacrolimus will be measured at Day +7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD
45770497|NCT05477628|Other|Control Group|All children randomized to the control condition will receive age-appropriate nutritional recommendations as part of routine healthcare.
45630870|NCT03959241|Drug|Mycophenolate Mofetil|MMF will be given at a dose of 15 mg/kg/dose ter in die (TID) (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day +5 and discontinue after the last dose on Day +35, or may be continued if active GVHD is present.
45770498|NCT01830790|Drug|Sildenafil citrate|Single dose of 100mg Sildenafil citrate
45770499|NCT01662102|Drug|Zevalin|Zevalin administered intravenously.
45770500|NCT01662102|Drug|Rituximab|Rituximab administered intravenously.
45770501|NCT04692766|Biological|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial
45770502|NCT04692766|Drug|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), 5 mL in a polypropylene ampoule, 10 ampoules per labeled package
45770503|NCT03950076|Drug|Edoxaban|Edoxaban 60mg (or 30mg as determined by clinical criteria)
45770504|NCT03950076|Other|Non-anticoagulant medical therapy|Non-anticoagulant medical therapy as determined by the local investigator includes i) No antithrombotic therapy ii) Antiplatelet monotherapy, including de novo indication for antiplatelet monotherapy during course of the study
45770505|NCT05292976|Other|Methacholine Chloride|Serial Methacholine dilutions
45770506|NCT05292976|Drug|Albuterol Sulfate HFA 0.09 mg (Reference)|One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols.
45770507|NCT05292976|Drug|Albuterol Sulfate HFA 0.18 mg (Reference)|One actuation each from two different Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols.
45770508|NCT05292976|Drug|Albuterol Sulfate HFA 0.09 mg (Test)|One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols.
45770509|NCT05292976|Drug|Albuterol Sulfate HFA 0.18 mg (Test)|One actuation each from two different Test inhalation aerosols and one actuation each from two different placebo Reference inhalation aerosols.
45770510|NCT05292976|Drug|Placebo|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols.
45770511|NCT01808950|Drug|0.06% Resiquimod Gel - A|single 60mg dose
45770512|NCT01808950|Drug|0.06% Resiquimod Gel - B|single 100mg dose
45770513|NCT01808950|Drug|0.06% Resiquimod Gel - C|shave biopsy of BCC followed by single 100mg dose
45770514|NCT01808794|Device|Mucograft|Mucograft Collagen Matrix
45770515|NCT01808794|Device|Dynamatrix|Dynamatrix
45770516|NCT00850720|Other|Blood draws|Samples of blood to be drawn before surgery, and nine hours after surgery.
45630871|NCT03959241|Drug|Cyclophosphamide|Cyclophosphamide [50 mg/kg ideal body weight (IBW); if actual body weight (ABW) < IBW, use ABW] will be given on Day +3 (between 60 and 72 hours after the start of the PBSC infusion) and on Day +4 post-transplant (approximately 24 hours after Day +3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
45913457|NCT02022878|Procedure|PCI of CTO|
45913458|NCT02022891|Behavioral|systematic psychological care|Prevention treatment plan that provides systematic medical and psychological care at routine pediatric consultations for SCD. Bio-psychosocial paradigm applied at pediatric consultations.
45770517|NCT05483088|Diagnostic Test|Urine collection for NEPHROCLEAR CCL14 Test|Urine will be collected for analysis with the NEPHROCLEAR CCL14 Test
45770518|NCT04706338|Device|TMS treatment|Using TMS to stimulate (5 Hz, 90%~110% resting motor threshold) patients' primary motor area and SMA.
45770519|NCT05477472|Drug|St John's Wort|daily intake of CERES St John's Wort mother tincture. Dose according to the treating physician.
45770520|NCT04512742|Other|biting by Phlebotomus duboscqi infected with Leishmania major|The first six subjects will be exposed to biting by Phlebotomus duboscqi infected by Leishmania major and assess the 'take rate', that is the number of subjects developing parasitologically confirmed cutaneous leishmaniasis (PCCL) lesions. If 6/6 subjects develop PCCL lesions no further recruitment will take place; if only < 6 subjects develop PCCL lesions, then an adaptive design will be followed.
45770521|NCT03425526|Biological|Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes|Given IV
45770522|NCT00843310|Drug|Lenalidomide (Revlimid)|
45770523|NCT00843310|Drug|Melphalan|
45770524|NCT00843310|Drug|Dexamethasone|
45913459|NCT02022904|Device|Near infrared (NIR) emissive nanotechnology|
45935265|NCT00220168|Drug|Irinotecan, Capecitabine|
45935266|NCT00073554|Drug|Alfimeprase|
45630872|NCT05146973|Biological|177Lu-DOTA-TLX591|TLX591, a monoclonal antibody conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-DOTA-TLX591)
45770525|NCT04706572|Other|Stimulation with external auditory bio-feedback|Administration of an external cue based on a personalized Golden Ratio -rhythm or a metronome-rhythm through an ad-hoc App for Smartphone
45770526|NCT00809458|Drug|Vitamin E|Patients will take one 400 IU tablet of vitamin E or a placebo daily. Patients will continue on this treatment from the time of randomization to the day before surgery or the brachytherapy procedure. This is expected to be between 4 to 6 weeks. The patient will continue with his regular medications. The vitamin E will be supplied by the clinical trial through the UNM CRTC pharmacy.
45770527|NCT05482932|Diagnostic Test|Health-related physical fitness assessment|Participants will complete several questionnaires and perform multiple health-related physical fitness tests
45770528|NCT04706182|Procedure|Platelet-rich fibrin (PRF)|Platelet rich fibrin (PRF) serves as a structural reservoir of cytokines such as platelet-derived growth factor (PDGF), transforming growth factor (TGF-b), insulin-like growth factor (IGF), platelet factor 4 (PF4) and vascular endothelial growth factor (VEGF) which aids in healing and preventing infection. PRF will be prepared as recommended by the manufacturer (Intra-Lock International) by centrifuging 20 mL of the subject's venous blood for 12 minutes at 2700 rpm, followed by compression. The fibrin clot will then be applied to the SSO site prior to fixation. The blood draw for the PRF will be performed approximately 15 minutes prior to fixation of the mandible. 20 mL will be drawn for each PRF side treated. The blood venous draw will be from the subject's arm or from an existing intra-venous line.
45770529|NCT04706182|Procedure|Proximal segment grooving (PSG)|Proximal segment grooving is a mechanical method to create additional space within the inferior alveolar canal to allow the IAN to rest without compression or trauma. The surgeon uses a round or acrylic bur to cautiously remove any bony spicules, and remove cancellous bone in the proximal mandibular segment. PSG will be done by using an acrylic round bur on a surgical handpiece to remove 3 to 4 mm of cancellous bone where the IAN will passively rest into prior to fixation.
45770530|NCT05482854|Other|Analytical Treatment Interruption (ATI)|"Analytical Interruption of Treatment for 24-48 weeks~ART resumption and follow-up for 24 weeks if the participant meets at least one ART resumption criteria"
45630873|NCT03164213|Device|experimental: tDCS|The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of anodal-tDCS (1mA) will be administered at the beginning of the daily treatment session. Following the stimulation will be 45 minutes of naming therapy.
45770531|NCT00422968|Device|Percutaneous coronary intervention|Using silorimus eluting stent
45770532|NCT00422968|Procedure|coronary artery bypass graft|coronary artery bypass graft
45770533|NCT00379054|Behavioral|telephone based skills training intervention|
45630874|NCT03164213|Device|sham tDCS|"The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of sham-tDCS will be administered at the beginning of the daily treatment session.~During sham-tDCS, the current will be ramped up and remained at 1mA only for 30 s before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp. Following the sham stimulation will be 45 minutes of naming therapy."
45630875|NCT05127395|Other|To assess the clinical impact of dosing acyclovir based on IBW or adjBW for HSV encephalitis to definitively guide safe and effective therapy.|The study center utilize Epic ® electronic health record (Verona, Wisconsin; www.epic.com) for which all data will be extracted from. Each study center will obtain individual IRB approval prior to data collection. SSM - St. Clare will serve as the lead center for the study with all other centers sending collected and de-identified data to this central site for analysis.
45770534|NCT04151134|Diagnostic Test|Step serial sectioning histological processing|Step serial sectioning histological processing
45770535|NCT04132492|Other|no intervention|there is no intervention
45770536|NCT00379132|Drug|131-I-TM-601 (chlorotoxin)|"Patients will be administered 1 - 3 (Test Doses A, B, and Dose C) escalating doses of 131I-TM601 by intravenous (IV) administration. Each dose will be administered as a single administration, scheduled at one-week intervals.~Test Dose A - 10 mCi (+/- 20%)/0.2 mg TM601 (131I-TM601) Test Dose B - 20 mCi (+/- 20%)/0.4 mg TM601 (131I-TM601) Dose C - 30 mCi (+/- 10%)/0.6 mg TM601 (131I-TM601)"
45770537|NCT01697332|Drug|Hyperpolarized 129Xe gas|800cc of a gas mixture containing 129Xe and nitrogen will be inhaled by a subject. The subject will hold their breath for no more than 16 seconds while a MRI scan is performed. The gas mixture can contain between 20 and 100% xenon.
45770538|NCT01701622|Drug|febuxostat|"If baseline allopurinol dose < 300 mg daily, will initiate febuxostat 40 mg daily.~If baseline allopurinol dose > 300 mg daily, will initiate febuxostat 80 mg daily.~Febuxostat is to be continued for 4 weeks, with blood pressure assessments by clinic and ambulatory blood pressure measurement at baseline and after 4 weeks."
45770539|NCT00786682|Drug|docetaxel|
45770540|NCT00786682|Drug|hydroxychloroquine|
45913460|NCT02022917|Drug|Bevacizumab|Bevacizumab 15 mg/ Kg (from post-op cycle 2) intravenous infusion for 30 minutes in a 21 days' cycle for at least three cycles (best to 6 cycles) followed by 3-weekly maintenance bevacizumab 15 mg/ Kg intravenous infusion for 17 cycles.
45913461|NCT02022930|Device|Hydros|
45913462|NCT02022930|Device|Hydros-TA|
45630876|NCT05122793|Behavioral|Prevention offer|Improvement of outcomes through lifestyle changes and improved health literacy
45630877|NCT02532855|Drug|Sitagliptin|Sitagliptin 100 mg oral tablet
45913463|NCT02022930|Drug|Triamcinolone Acetonide|
45913464|NCT02022956|Drug|Lorcaserin|
45913465|NCT02023008|Procedure|yoga therapy|Undergo integral yoga intervention with videoconferencing
45913466|NCT02023008|Other|internet-based intervention|Undergo integral yoga intervention with videoconferencing
45913467|NCT02023008|Other|questionnaire administration|Ancillary studies
45770541|NCT01668940|Other|Lillipops Iced Soothies (4 flavours)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger. The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
45770542|NCT01668940|Other|Mr. Freeze Freezies|There are other commercially available freezies, such as Mr. Freeze. Mr. Freeze freezies contain simulated flavours of watermelon, cherry, blue raspberry and cream soda. However, there have been no reports, studies or claims that they are effective as a remedy for the treatment of NVP.
45630878|NCT02532855|Drug|Dapagliflozin|Dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Dapagliflozin 10 mg daily may be down-titrated to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.
45630879|NCT02532855|Drug|Metformin|This medication is a standard-of-care medication and is administered in an open-label fashion. Supply of background metformin oral tablet(s) (at least 1500 mg daily) will be the responsibility of the participant throughout the duration of the study.
45630880|NCT02532855|Drug|Matching placebo to sitagliptin|Matching placebo to sitagliptin 100 mg oral tablet
45630881|NCT02532855|Drug|Matching placebo to dapagliflozin|Matching placebo to dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to matching placebo to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Matching placebo to dapagliflozin 10 mg daily may be down-titrated to matching placebo to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.
45630882|NCT02532855|Drug|Sulfonylurea|This medication is a standard-of-care medication and is administered in an open-label fashion. The dose of the sulfonylurea agent will be required to be at least 50% of maximum labeled dose, consistent with near maximum efficacy of the sulfonylurea agent.
45630883|NCT02061423|Biological|HER-2 pulsed Dendritic Cell Vaccine|Each dose will consist of between 1.0-2.0 x 10^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
45770543|NCT01668940|Other|Lillipop Iced Soothies (Ginger flavour)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger.The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
45770544|NCT01675960|Drug|Gabapentin|The active drug is in a flavored glycerin based solution. The drug will be given orally or through a gastrointestinal tube. Titration up to a stable dose will take 22 days. The total stable dose is 40mg/kg/day. Once 7 days on this dose are finished, children will take 6 days to reduce their dose and begin their 3 day washout period.
45770545|NCT01675960|Drug|placebo|The placebo is a glycerin-based clear solution that is flavored similarly to the commercial product. The placebo will be given orally or through a gastrointestinal tube.
45770546|NCT04092634|Device|Dual mobility implant|Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
45913468|NCT02023021|Drug|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
45770547|NCT04092634|Device|Traditional, Single-bearing hip implant|Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
45770548|NCT04053868|Other|JUUL|Electronic Cigarette
45770549|NCT04053868|Other|Tobacco|Tobacco Cigarette
45913469|NCT02023021|Drug|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
45913470|NCT02023034|Other|Virtual exercises|The exercises will be performed with the Nintendo ® Wii Balance Board ® platform, and consist in: 1) Table Tilt; 2) Obstacle Course; 3) Tilt City; 4) Basic step; 5) Penguin; 6) Heading Soccer; 7) Basic Run. All patients underwent 12 sessions, twice a week for a period of 06 weeks.
45913471|NCT02023047|Drug|Nifedipine 12 mg coated suppositories|
45935267|NCT00220207|Behavioral|Internet co-management module|
45935268|NCT00042575|Drug|Duloxetine|
45935269|NCT00220285|Drug|Zevalin (SH L 749 , BAY86-5128)|0,3mCi/kg
45935270|NCT00220285|Drug|Zevalin (SH L 749 , BAY86-5128)|0,4mCi/kg
45652949|NCT04790669|Procedure|Close kinetic chain exercises (CKC).|Close kinetic chain exercises (CKC). In Group B, 11 participants was received Conventional physiotherapy treatment in addition to close kinetic chain exercises. Close kinetic chain exercises for extensor lag was seated leg press, double or single one third knee bend, step up and down exercise, wall slide with weight. Treatment time was 30 minutes and three session per week was applied on alternate day for up to 6 weeks. Pre interventional readings will be taken at baseline & post interventional readings at 6th week. 6 weeks (3 sessions per week) • Hot pack: 10 min • Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale & sphygmomanometer.
45770550|NCT04026178|Drug|Metreleptin|Subjects will receive prescribed dosage of metreleptin as indicated in the USPI
45770551|NCT03999970|Other|Sand fly bite|Comparison between sand fly bites from two different species (Phlebotomus papatasi and Phlebotomus duboscqi)
45770552|NCT00787618|Drug|50 mg Proellex|Single dose
45770553|NCT00749476|Biological|Factor IX recovery|
45935271|NCT00077454|Drug|erlotinib hydrochloride|Given orally (PO)
45770554|NCT01607320|Drug|Raloxifene|Thirty PCOS patients treated with 3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7 following an initial provera withdrawal
45770555|NCT01607320|Drug|Clomiphene|Thirty PCOS patients treated with 3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7 following an initial provera withdrawal
45630884|NCT05438667|Biological|TCR-T therapy|"1.Preprocessing strategy：~Cyclophosphamide: 500mg/m², dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 60minutes, and 0.4g Mesna injected at 0hour, 4hours and 8 hours after cyclophosphamide,4days and 5 days before TCR-T cell infusion.~Fludarabine: 30mg/m² , dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 30minutes before 3 to 5days before TCR-T cell infusion.~2.Within 3 - 5 days after pretreatment, subjects will receive a single TCR-T reinfusion with an infusion dose of about 1 × 10⁹～1 × 10¹¹.~3.Once every 12 hours within 24 hours after TCR-T cell infusion, recombinant human interleukin-2 (injection unit: 500000 units /m², once every 12 hours, subcutaneous injection) will be injected intravenously for 14 days (24 times in total).~4.6-8 weeks later, if the disease progressed, the second TCR-T treatment will be given(the same as above). This time will combine the DCvaccine injection."
45630885|NCT04262427|Drug|Cyclophosphamide 50mg|cytotoxic chemotherapy
45630886|NCT04262427|Drug|Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]|potent humanized immunoglobulin (Ig) G4 monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor
45630887|NCT04262349|Behavioral|sleep education|As a training program to increase sleep, pregnant women will be given 2 training sessions per week for two weeks and four sessions in total for 60 minutes.
45630888|NCT02530125|Other|Laboratory Biomarker Analysis|Correlative studies
45630889|NCT02530125|Biological|Pidilizumab|Given IV
45630890|NCT05436873|Device|MR-HIFU|MRI guided High Intensity Focused Ultrasound sonication.
45630891|NCT05422521|Other|blood samples and 18FDG PET-CT exams|"18 FDG PET scanner at inclusion and post CART-cells treatment ( 1, 3, 6, 9 and 12 month)~blood collection at inclusion and post CART-cells treatment (7 days, 1 month and 3 month)"
45630892|NCT05422209|Procedure|Mesh-augmented sacrospinal fixation with posterior colporrhaphy and perineoplasty.|Vaginal mesh-augmented sacrospinal fixation with posterior colporrhaphy and perineoplasty.
45630893|NCT05422209|Procedure|Mesh-augmented sacrospinal fixation with posterior colporrhaphy.|Vaginal mesh-augmented sacrospinal fixation with posterior colporrhaphy.
45770556|NCT01606150|Drug|1% lidocaine|0.1 ml/kg of 1% lidocaine injected over lumbar puncture needle insertion site 2 minutes prior to procedure
45770557|NCT01606150|Drug|topical lidocaine|1 gram placed over lumbar puncture needle insertion point 30 minutes prior to procedure
45770558|NCT00747916|Device|CryoSpray Ablation (TM) System|Subjects will be treated with spray cryotherapy using the CryoSpray Ablation (TM) System at Day 0 using up to 3 cycles of 10-40 second sprays as the studied dosimetry and will cover the affected area, including the tumor and the parietal pleural surface. If disease exists bilaterally, only one side will be sprayed. Subjects will be assessed 2-5 days from the initial treatment (Day 0) to check for mucosal sloughing, to reassess tumor burden and for additional CSA therapy as needed.
45770559|NCT04706494|Dietary Supplement|AlphaWave® LTheanine|200 mg of AlphaWave® LTheanine
45770560|NCT04706494|Dietary Supplement|Placebo|microcrystalline cellulose
45770561|NCT03744910|Biological|Clazakizumab|Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
45770562|NCT03744910|Drug|Physiologic saline solution|Normal saline
45770563|NCT03687658|Behavioral|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
45913472|NCT02023086|Procedure|Contrast sensitivity measurement|Contrast sensitivity test is made with targets alternating black and white lines. The larger the lines are, easier it is to see them. Targets are distributed in 5 rows, each oriented at a different angle. Contrast sensitivity level is determined by the smallest target seen by the participant, line by line. This test is done under dim lightning with the habitual visual correction worn.
45447653|NCT03253796|Biological|Golimumab|Injections of 50 mg golimumab. At the investigator's discretion, participants with a body weight of more than 100 kg could receive 100 mg injections with golimumab.
45447654|NCT03253796|Biological|Placebo|Injections of matching placebo for golimumab.
45630894|NCT05421819|Dietary Supplement|Calcium and vitamin D supplement|One hundred fifty postmenopausal women with osteopenia will be randomly and blindly allocated to receive in of the 3 different dietary supplements once per day. Patients of group A will receive orally 600 mg calcium and 2400 IU vitamin D3, group B will receive the same dose of calcium and vitamin D3 plus prebiotics once per day and group C will receive the same dose of calcium, vitamin D3 plus flavonoids once per day.
45630895|NCT05421819|Dietary Supplement|Calcium, vitamin D and prebiotic supplement|One hundred fifty postmenopausal women with osteopenia will be randomly and blindly allocated to receive in of the 3 different dietary supplements once per day. Patients of group A will receive orally 600 mg calcium and 2400 IU vitamin D3, group B will receive the same dose of calcium and vitamin D3 plus prebiotics once per day and group C will receive the same dose of calcium, vitamin D3 and flavonoids once per day.
45770564|NCT00745030|Drug|Rozerem|Subjects take 1 8mg tablet 30 minutes before bedtime everyday for 8 weeks.
45770565|NCT00745030|Drug|Placebo|Placebo 8 mg tablets
45770566|NCT00739024|Drug|Ramelteon|8 mg tablet, oral, once daily
45770567|NCT00739024|Drug|Placebo|Placebo tablet, oral, once daily
45630896|NCT05421819|Dietary Supplement|Calcium, vitamin D and flavonoid supplement|One hundred fifty postmenopausal women with osteopenia will be randomly and blindly allocated to receive in of the 3 different dietary supplements once per day. Patients of group A will receive orally 600 mg calcium and 2400 IU vitamin D3, group B will receive the same dose of calcium and vitamin D3 plus prebiotics once per day and group C will receive the same dose of calcium, vitamin D3 and flavonoids once per day.
45630897|NCT05421585|Other|observational drug study|Postoperative opioid consumption will be evaluated by applying 2 different block methods to patients who have undergone lumbar disc surgery
45630898|NCT05436639|Drug|SPI-62 dose1|SPI-62 is an 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, supplied as oral tablets for dose 1 of drug (0.2mg).
45630899|NCT05436639|Drug|SPI-62 dose 2|SPI-62 is an 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, supplied as oral tablets for dose 2 of drug (0.6mg).
45770568|NCT01602016|Drug|Folinic Acid and placebo|Capsules of folinic acid and placebo will be administered in 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated for 10 weeks.
45630900|NCT05436639|Drug|SPI-62 dose 3|SPI-62 is an 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, supplied as oral tablets for dose 2 of drug (2mg).
45630901|NCT05436639|Drug|SPI-62 dose 4|SPI-62 is an 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, supplied as oral tablets for dose 2 of drug (6mg).
45630902|NCT05436639|Drug|Placebo|Inactive tablets identical to SPI-62 tablets.
45630903|NCT05436327|Behavioral|Geriatric Assessment|Clinical staff receive (a) training in GA and workflow management strategies (<60 minutes) at baseline, (b) monthly facilitation and technical support calls (15-30 minutes) for 12 months, and (c) a group-based quarterly call for 12 months. For 12 months, clinical staff implement GA strategies during visits with older adult (65+) patients planning to receive new chemotherapy regimen and their care partners/caregivers.
45770569|NCT01602016|Drug|Folinic Acid|capsules of folinic acis will be provided. The target dose will be 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated, for 10 weeks.
45630904|NCT01661205|Device|Ablation procedure staged catheter ablation|AtriCure Bipolar System used in conjunction with a catheter ablation procedure performed 1-10 days apart
45630905|NCT05436171|Other|No intervention|No intervention
45630906|NCT02055820|Drug|Venetoclax|Venetoclax 200 to 800 milligrams (mg) tablets will be administered orally once daily (QD) on Days 4-10 of Cycle 1 and Days 1-10 of Cycles 2-8 during Phase I and MTD will be administered according to the same schedule during Phase II.
45630907|NCT02055820|Drug|Cyclophosphamide|Cyclophosphamide 750 milligrams per square meter (mg/m^2) administered intravenously (IV) on Day 1 of each 21-day cycle up to Cycle 6.
45630908|NCT02055820|Drug|Obinutuzumab|Obinutuzumab will be administered by IV infusion as an absolute dose of 1000 mg on Days 1, 8, 15 of Cycle 1 and Day 1 of Cycles 2-8 (cycle length = 21 days).
45770570|NCT01591954|Device|Video Augmentation|Assessment of value of video-based navigation system
45770571|NCT00731770|Drug|Advair 250|1 puff bid inhaled
45770572|NCT00731770|Drug|Placebo- matched|1 puff bid inhaled
45935272|NCT00077454|Drug|temozolomide|Given PO
46069970|NCT00656617|Drug|Vorinostat|Initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).
46069971|NCT00798187|Behavioral|Group Meetings|10 weekly group meetings lasting 2 hours.
45630909|NCT02055820|Drug|Rituximab|Rituximab 375 mg/m^2 dose will be administered IV on Day 1 of every 21-day cycle.
45630910|NCT02055820|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 administered IV on Day 1 of each 21-day cycle up to Cycle 6.
45630911|NCT02055820|Drug|Vincristine|Vincristine 1.4 mg/m^2 (maximum 2 mg) administered IV on Day 1 of each 21-day cycle up to Cycle 6.
45630912|NCT02055820|Drug|Prednisone|Prednisone 100 mg per day orally on Days 1-5 of each 21-day cycle up to Cycle 6.
45630913|NCT05408715|Other|Natural History Study|Longitudinal assessment of symptoms and development of complications in type II collagen disorders
45630914|NCT05408559|Drug|Sulforaphane|Caplets containing SFN-rich broccoli sprout extracts or placebo caplets containing microcrystalline cellulose will be obtained from from Nutramax Labs.
45630915|NCT04258215|Device|Experimental: Routine positive pressure airway management.|The use of the PSA extraglottic airway for routine general anesthesia will be assessed for quality of airway management by measuring the seal pressure when using the device in 20 participants.
45630916|NCT01975233|Device|WEB Aneurysm Embolization System|WEB Aneurysm Embolization System
45630917|NCT05408169|Behavioral|Suggested deadline for return of screening test|"A screening invitation letter modified to state, highlighted in yellow: Please return your kit within [X] weeks (by [DD.MM.YYYY]) or as soon as possible."
45630918|NCT05408169|Behavioral|Planning sheet|A planning tool presented on a separate single sheet of paper inserted into the screening invitation envelope. The colour illustrated tool prompts participants to identify concerns they have with using the bowel screening kit and to link them to a tip to help them overcome this concern.
45770573|NCT00731770|Drug|Placebo|Placebo 1 puff bid inhaled
45770574|NCT00731770|Drug|Advair 250 - matched|i puff bid inhaled
45935273|NCT00077454|Other|pharmacological study|Correlative studies
45935274|NCT00077454|Other|laboratory biomarker analysis|Correlative studies
46069972|NCT00798187|Behavioral|Questionnaire|Surveys
46069973|NCT00805909|Drug|NI-0401|5 daily infusions with escalating doses of NI-0401
46069974|NCT00798343|Biological|Seasonal vaccine|Non-adjuvanted seasonal influenza vaccine (total dose 45ug)
46069975|NCT00798343|Biological|H5 vaccine|MF59-adjuvanted A/Vietnam/1194 H5N1 vaccine 7.5ug dose
46069976|NCT00803491|Other|Problem based learning|Group sessions under supervision from a nurse. Each group including 8 subjects. 10 occasions during a period of one year.
46069977|NCT00803491|Other|Traditional rheumatology care.|Individually base.
45630919|NCT02055352|Drug|Budesonide|Budesonide 400 mcg twice a day via Breezhaler® device
45630920|NCT02055352|Drug|Fluticasone|Fluticasone 250 mcg twice daily via Accuhaler® device
45630921|NCT02055352|Drug|Indacaterol|Indacaterol 150 mcg once daily via Breezhaler® device
45630922|NCT02055352|Drug|Salmeterol|Salmeterol 50 mcg twice daily via Diskus® device
45630923|NCT02034916|Drug|talazoparib|
45630924|NCT01374425|Drug|5-Fluorouracil|5-Fluorouracil 400 milligrams per meter-squared (mg/m^2) by IV bolus and subsequent 2400 mg/m^2 by IV infusion over 46 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
45630925|NCT01374425|Drug|Bevacizumab|Bevacizumab 5 milligrams per kilogram (mg/kg) of body weight via IV infusion will be administered every 2 weeks until disease progression or unacceptable toxicity. If participants are discontinued from oxaliplatin or irinotecan due to unacceptable toxicity, bevacizumab may be given in 3-week cycles with capecitabine.
45630926|NCT01374425|Drug|Irinotecan|Irinotecan 180 mg/m^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
45630927|NCT01374425|Drug|Leucovorin|Leucovorin 400 mg/m^2 or dose deemed appropriate by Investigator via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
45630928|NCT01374425|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
45630929|NCT01374425|Drug|Capecitabine|Capecitabine 850 or 1000 mg/m^2 may be offered in the event of unacceptable toxicity to oxaliplatin or irinotecan, to be given orally twice a day on Days 1 to 14 in 3-week cycles.
45630930|NCT05111249|Drug|Branaplam|messenger ribonucleic acid (RNA) splicing modifier
45630931|NCT05111249|Drug|Placebo|Matching placebo oral solution once weekly
45630932|NCT03161015|Drug|GBT440|Oral
45630933|NCT02085460|Drug|Placebo|
45630934|NCT02085460|Drug|2% Rebamipide liquid|
45630935|NCT02085460|Drug|4% Rebamipide liquid|
45630936|NCT03161171|Other|This is an observational study|This is an observational study
45630937|NCT03164291|Drug|Rifabutin|Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status
45630938|NCT02084134|Drug|hydrocortisone|100mg at the time of surgery
45630939|NCT02084134|Drug|dexamethasone|0.5mg every 6 hours for a total of four doses
45630940|NCT03164135|Genetic|CCR5 gene modification|CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 targeting CCR5 gene.
45630941|NCT03163901|Other|Osteopathic Manipulative Treatment|OMT techniques applied in the thoracic spine soft tissue, cervical spine soft tissue, suboccipital release, occipital condyle condylar decompression, and cranial venous sinus release.
45630942|NCT02034058|Device|Wingspan Stent System|The Wingspan Stent System is used with the Gateway PTA Balloon Catheter. The Wingspan Stent System is a self-expanding, Nitinol stent and delivery system intended for use in the treatment of intracranial atherosclerotic disease. The Gateway PTA Balloon Catheter is an over-the-wire balloon catheter intended for the pre-dilation of the lesion prior to insertion and deployment of the Wingspan Stent System.
45630943|NCT01374269|Other|Exercise program|Standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. 12 sessions, 3 per week.
45630944|NCT01374269|Drug|NSAID (Nonsteroidal anti-inflammatory drugs)|The second group was treated for 10 days with NSAIDs (naproxen 500 mg/d or celecoxib 200 mg/d) according to the indications and contraindications. The patients kept a journal stating whether they had taken the drug and any adverse reactions. If the pain intensity of any participant increased, acetaminophen (1.5 - 2.0 g/d) was proposed as a rescue procedure.
45630945|NCT03163823|Other|Proloquo2Go|Use of communication application Proloquo2Go modified for the ICU setting on an iPad device
45770575|NCT01589926|Device|Bi-level positive airway pressure device|BiPAP initiated for at least 16 hours per day for a minimum of 48hrs.
45770576|NCT01589926|Device|Sham CPAP|Sham CPAP initiated for at least 16 hours per day for a minimum of 48hrs.
45770577|NCT01590394|Device|Large plastic biliary stent|Stent placement for bile duct obstruction.
45770578|NCT00719914|Drug|eptifibatide|Intra-coronary injection, weight based, of eptifibatide.
45935275|NCT00220324|Drug|Minisiston (SH D00342A)|Daily oral administration in 21 days per cycle, followed by a 7-day pill-free interval
46069978|NCT02553187|Drug|Kanglaite Injection|"200 mL, slow IV drip, once daily for 14 consecutive days, subsequent courses repeated after a 7-day interval.~Subjects will be treated for 4 courses (12 weeks)."
46069979|NCT00803725|Drug|Mepivacaine without fentanyl|45 mg 1.5% mepivacaine injection for spinal anesthesia
46069980|NCT00803725|Drug|Mepivacaine with Fentanyl|10 micrograms fentanyl with 30 mg 1.5% mepivacaine injection for spinal anesthesia
46069981|NCT00803803|Drug|Pilocarpine Concentration|Varying concentration 0.5 to 8%
46069982|NCT00803803|Drug|Pilocarpine Frequency|1 to 4 times daily
45630946|NCT03163823|Other|Standard of Care|Standard of Care communication methods
45630947|NCT05036681|Drug|Futibatinib|tablets by mouth 1 time every day
45630948|NCT05036681|Drug|Pembrolizumab|Given by vein over about 30-60 minutes on Day 1 of all cycles
45652950|NCT05092971|Behavioral|Multi-arm bandit tasks|Part 1 to be completed in the clinic. Subject participation is for one part and is pseudo-randomly.
45935276|NCT00412477|Biological|HIV LFn-p24|HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed at 200 µg/ml and 600 µglml. The product will be administered IM in doses ranging from 150µg to 450µg with Alhydrogel.
45935277|NCT00412555|Drug|oseltamivir [Tamiflu]|30-75mg po daily for 6 weeks
45935278|NCT00412633|Behavioral|Diet and physical activity interventions|Weekly web-based intervention that included goal setting, self-monitoring, weekly behavioral skills, nutrition and physical activity tips, and access to a health coach.
45630949|NCT03163979|Biological|18F-FDG PET/CT and Comet assay guide RapidArc|1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
45630950|NCT03163979|Biological|18F-FDG PET/CT and Comet assay guide IMRT|Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
45630951|NCT03163979|Biological|RapidArc|"RapidArc:~A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used."
45630952|NCT03163979|Biological|7f-IMRT|seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
45630953|NCT03114761|Radiation|CT angiography|Patients are subjected to a standard abdominal CT scan and (additional in this study) to abdominal CT angiography (CTA)
45630954|NCT03114605|Behavioral|Mindfulness-based Intervention|
46069983|NCT04797637|Device|ABBy® Adjustable Panniculus Retractor for Wound Care|The ABBy (G-Squared Medical, Brentwood, TN) is an extended-wear panniculus retractor/tissue stabilizer that is intended for use postoperatively after abdominal procedure. It is placed directly onto patient skin, superior to a transverse incision, and is then used to elevate redundant tissues away from an incision or wound (https://www.gsquaredmedical.com/How-it-Works.html). The ABBy can be removed and replaced by patients and can be used for up to 10 days. This study aims to assess the effect of ABBy use on postoperative pain, pain medication requirement, and patient satisfaction, when used as a patient-positioning device in women following cesarean delivery.
45630955|NCT03160781|Biological|Platelet Rich Plasma|Combination of Intraosseous and Intraarticular Infiltration of Platelet Rich Plasma
45630956|NCT03163745|Procedure|paracentesis|paracentesis will be done for all patient for ascitic fluid study and ascitic fluid culture
45630957|NCT03163589|Drug|Erythropoietin|injection
45630958|NCT03163589|Drug|normal saline|injection
45630959|NCT03163277|Drug|emtricitabine, darunavir/cobicistat, maraviroc|Treatment change
45630960|NCT04439903|Other|Web-based Simulation Tool|Glucose, insulin and meal data from the participants' insulin pump will be collected and entered into the WST, which will generate personalized models of the participants' glucose metabolism to enable replay simulations.
45630961|NCT05419817|Drug|pembrolizumab|Pembrolizumab is an immunotherapy (monoclonal antibodies) that will be given at a dosage of 200 mg IV, on Day 1 of each 21 day treatment cycle
45630962|NCT05419817|Drug|Sitravatinib|A small molecule inhibitor of multiple tyrosine kinases that will be taken at a dosage of 100 mg orally, every day
45630963|NCT03160625|Device|Rate Adaptive Pacing|Rate Adaptive Pacing varies the pacing rate in response to the patient's physical motion as detected by an activity sensor.
45630964|NCT03160391|Behavioral|Music Training|Training curriculums were developed using guidelines set by the Ontario Ministry of Education (The Ontario Curriculum, 2009) for teaching music to grades 1 to 3. Music was delineated into duration, pitch, dynamics and other expressive controls, timbre, texture/harmony, and form. training included direct instruction and group activities. All training programs had the same structure: a warm-up period, following by instruction from a teacher, and then group activities to practically demonstrate the concepts learned. Both programs involved working towards a variety of ensembles.
45630965|NCT03160391|Behavioral|Dance Training|As with music training, dance was operationally defined by fundamental concepts for the art form, namely elements for body, space, time, energy, and relationship. The intervention involved both individual and group activities, with a combination of instruction and practical activities, and preparation for a final performance.
45630966|NCT03163355|Other|a gelling agent|Pureed rice containing a gelling agent (Softia U, Nutri Co., Ltd., Yokkaichi, Japan) is compared with the standard purred rice in the condition of swallowing.
45630967|NCT05676905|Device|Neocement|Bone graft substitutes
45630968|NCT03163433|Behavioral|Feedback in the consultation|Patients will complete electronic Patient Reported Outcome Measures (PROM) before the consultation at the hospital. The results are fed back to physicians. In the consultation patients will systematically participate in a dialogue with their physician about issues that are most important for the patients.
45630969|NCT04995419|Drug|Enfortumab vedotin|Intravenous Infusion
46069984|NCT04775329|Drug|Rifaximin|Rifaximin 1000mg OM
46069985|NCT00803881|Other|nasal lavage and sputum collection|non-invasive longitudinal assessment of pathogen colonization in both airway levels
46069986|NCT00798499|Other|Laboratory variables|1 visit
45630970|NCT05676749|Biological|C-TIL051|C-TIL051 given in combination with IL-2 and pembrolizumab
45630971|NCT05392205|Diagnostic Test|18F-FDG|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-2286, and undergo PET/CT imaging within the specified time. A part of participants will also undergo additional 68Ga-FAPI-46 PET/CT for comparison.
45630972|NCT02679755|Drug|Palbociclib|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
45630973|NCT02679755|Drug|Letrozole|2.5 mg/d tablets orally on a continuous regimen
45630974|NCT05676671|Procedure|Applications of self-etching adhesives and dental restorations|
45630975|NCT05231759|Device|L'DISQ|
45630976|NCT02675231|Drug|Abemaciclib|Administered Orally
45630977|NCT02675231|Drug|Trastuzumab|Administered IV
45630978|NCT02675231|Drug|Fulvestrant|Administered IM
45630979|NCT02675231|Drug|Standard of Care Single Agent Chemotherapy|Standard-of-care single-agent chemotherapy of physician's choice administered according to product label
45630980|NCT03163121|Biological|PfSPZ-GA1 Vaccine|Aseptic, purified, cryopreserved, genetically attenuated P. falciparum sporozoites (Pf∆b9∆slarp), strain NF54
45630981|NCT03163121|Biological|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation attenuated P. falciparum sporozoites (PfSPZ Vaccine), strain NF54
45630982|NCT03163121|Other|Normal Saline|0.9% sodium chloride
45630983|NCT03163121|Biological|Mosquito-bite CHMI|Bites of 5 infected mosquitoes of NF54 strain
45630984|NCT03114449|Device|Auricular acupuncture|Auricular acupuncture with indwelling fixed needles at specific AA points
45630985|NCT03114449|Device|Sham auricular acupuncture|Sham auricular acupuncture (AA) with indwelling fixed needles applied at non-AA points
45630986|NCT03114293|Behavioral|Smartphone App|The app includes an EBPI and physical activity feedback
45770579|NCT00719914|Drug|eptifibatide|Intra-coronary injection, based on weight, of eptifibatide
45770580|NCT00719914|Drug|normal saline|Intra-coronary injection, weight based, of normal saline.
45770581|NCT01566370|Drug|Zonisamide|titration of dose to 500mg oral, daily, over 8 weeks, then 6 weeks of treatment at that dose
45770582|NCT01566370|Drug|Placebo|placebo
45770583|NCT03414684|Drug|Carboplatin|Carboplatin interferes with the development of the genetic material in a cell, which will cause the cancer cells to die.
45630987|NCT03114371|Drug|Oxytocin|The study drug is oxytocin in intra-nasal administration, Syntocinon®, reconditioned as a placebo-like spray. The dosage administered will be 8 International Unit, ie 1 spray (4 International Unit per spray) in each nostril per day for the first 12 weeks, in 3 and 6 years old patients. The dosage administered will be 16 International Unit or 2 sprays in each nostril per day for the first 12 weeks, in 3 to 6 years old patients.
45630988|NCT03114371|Drug|Placebo|Placebo should be used as a spray, similar to that of the oxytocin. The dosage administered will be 1 spray in each nostril per day for the first 12 weeks in 3 to 6 years old patients. The dosage administered will be 2 sprays in each nostril per day for the first 12 weeks, in 7 to 12 years old patients.
45630989|NCT03114371|Drug|Oxytocin|Each patient will receive oxytocin in open label (Syntocinon® not reconditioned) from week 13 to week 24 according to the same dosages.
45630990|NCT04905407|Drug|Tamibarotene|Tamibarotene tablets will be administered per dose and schedule specified in the arm.
45770584|NCT03414684|Drug|Nivolumab|Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a different molecule that can turn off the immune system by interacting with PD-L1 on the cancer cells
45770585|NCT01558492|Drug|Carboplatin|AUC = 5 intravenously (IV) on day 1 of a 28 day cycle
45770586|NCT01558492|Drug|Paclitaxel|80 mg/m2 intravenously (IV) weekly on days 1, 8, and 15 of a 28 day cycle
45630991|NCT04905407|Drug|Venetoclax|Venetoclax tablets will be administered per dose and schedule specified in the arm.
45630992|NCT04905407|Drug|Azacitidine|Azacitidine injection will be administered per dose and schedule specified in the arm.
45630993|NCT03162887|Other|Educational Intervention|Receive a research team member-led breast cancer and mammogram educational module
45770587|NCT03579472|Drug|Bintrafusp Alfa|Given IV
45630994|NCT03162887|Other|Counseling|Undergo a web-based decision counseling session
45630995|NCT03162887|Other|Informational Intervention|"Receive a next steps document"
45630996|NCT03162965|Other|Oraquick HIV Self Test|This is an oral swab in home HIV test.
45630997|NCT03162965|Other|Clinic Based HIV Counseling and Testing (HCT)|Receiving Counseling and Testing for HIV at the clinic.
45630998|NCT03163043|Dietary Supplement|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
45630999|NCT04903535|Device|Alonefire SV003 10W 365nm UV Flashlight|Investigator will use a Nitric Oxide Analyzer while attached to a small suction port on the subject's ear lobe to be tested for Nitric Oxide. After getting the baseline assay, the investigator will shine a low-intensity UV Flashlight (Alonefire SV003 10W 365nm UV Flashlight) at the ear lobe for 10 seconds, repeated three times at 20 second intervals, to determine if there is photobleaching. Then the assay will then be performed on the opposite ear lobe. Fifteen minutes after the third UV flashlight exposure, the investigator will collect air from the subject's ear during photolysis into a 20mL glass syringe (once from each ear). Fifteen minutes after the third UV flashlight exposure, the investigator will collect air from the subject's ear during photolysis into a 20mL glass syringe (once from each ear). The subject and the investigator will wear UV goggles during the experiment.
45652951|NCT05092971|Device|Multi-arm bandit tasks|Part 2 to be completed in the scanner. Subject participation is for one part and is pseudo-randomly.
45770588|NCT03579472|Drug|Eribulin Mesylate|Given IV
45770589|NCT03371212|Device|Dual mobility cohort|Patients will receive the Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components > 52mm), polyethylene bearing, and G7 acetabular shell.
45770590|NCT03371212|Device|Conventional cohort|Patients will receive a Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components > 52mm), polyethylene bearing, and G7 acetabular shell
45770591|NCT05482620|Procedure|Nordic walking program|Nordic walking program will consist of three training sessions per week, during eight weeks. Each session will last approximately 60 minutes, including warm-up, the intervention itself and cool-down. Intervention will consist in a 30 minutes Nordic walking, working at 70-85% of maximal heart rate, measured with a Polar pulsometer. Intervention will be delivered in groups (six patients per group as maximum), in designed circuits placed in A Coruña city.
45770592|NCT05482620|Procedure|Educational sessions and usual care|Educational sessions will consist in three classes, about 60 minutes each. In these classes, participants will learn about their pulmonary system, asthma disease, asthma diagnosis, asthma classification, asthma exacerbations and triggers, types of medications, how to take inhalers, how to measure PEF (peak expiratory flow), how to control the environment in order to prevent exacerbations, healthy-lifestyle recommendations and the importance of an active lifestyle, what to do in case of asthma emergency, and how to do required data from patients to note in their Patient's Diary (one of the evaluation tools). Usual care implies following the current therapeutic plan and revisions planned by their specialist/GP.
45770593|NCT05286190|Drug|Bupivacaine 0.25% Injectable Solution|Bupivacaine 0.25% Injectable Solution
45770594|NCT05477316|Radiation|Radiation treatment|Radiation treatment of IMRT to the cerebellum and SRS to the cerebrum
45770595|NCT05473260|Other|Control|In-patient care.
45770596|NCT05473260|Other|Experimental|Early discharge and outpatient follow-up.
45770597|NCT03399552|Drug|Avelumab|10mg/kg delivered by IV infusion
45631000|NCT04837547|Biological|Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)|There will be two immunotherapy products manufactured and administered to subjects enrolled on this trial. The first product will be autologous dendritic cells (DCs) loaded with total tumor messenger ribonucleic acid (mRNA) (TTRNA) derived from malignant tumors. The second product will be autologous T lymphocytes stimulated ex vivo against TTRNA antigens for autologous transfer (TTRNA-xALT). DCs are professional antigen-presenting cells critical for the initiation of B and T-cell responses in vivo.
45770598|NCT03399552|Radiation|Stereotactic Body Radiation Therapy|short course of SBRT after the first two doses of avelumab
45770599|NCT00691444|Dietary Supplement|Melatonin|"Subjects will be given up to 0.5 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
45631001|NCT03162653|Drug|Allopurinol|Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
45631002|NCT03162653|Drug|Mannitol|Placebo (Mannitol, PFI, 20mg/kg in the same volume and at the same time intervals as the intervention group - (2nd dose 10mg/kg only if infant undergoes therapeutic hypothermia)).
45631003|NCT03162419|Drug|Standard Medical Therapy|The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
45631004|NCT03162419|Biological|Plasma Exchange|High volume plasma exchange sessions till a maximum of ten sessions.
45631005|NCT03162419|Biological|GCSF|The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28
45631006|NCT04805489|Other|Mask|"The sequence of mask wearing will be done by drawing lots, in double blind. Only the nurse will be informed of the mask sequence. The doctor will take measurements without seeing the type of mask placed between the athlete's face and the VO2 mask.~The patient will not know which mask will be applied. He will have been informed that he will test three masks (a so-called high-tech mask which will in fact be without a mask, a surgical mask and a general public mask). When the mask is put on, the athlete's eyes will be closed, the sequence without a mask, presented to the subject as a high-tech mask, will be done with a mask that will be put on like a surgical mask or a mask for the general public, except that it will be hollowed out in its center.~The effort tests will be done on a carpet with a filter called COVID on the VO2 masks."
45770600|NCT00691444|Dietary Supplement|Melatonin|"Subjects will be given up to 10 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
45770601|NCT00691444|Biological|Melatonin|"Subjects will be given up to 20 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
45770602|NCT05477004|Drug|Ketamine|A multi-day continuous ketamine infusion delivered intravenously at subanesthetic doses in a monitored setting
45770603|NCT00693628|Device|compression shrinker|Two levels of compression: 20-30 mmHg or 30-40 mmHg shrinker
45935279|NCT00412633|Behavioral|Computer technology to tailor, promote and sustain health behavior change & improve health care delivery.|Weekly web-based intervention that included goal setting, self-monitoring, weekly behavioral skills, nutrition and physical activity tips, and access to a health coach.
45935280|NCT00220363|Drug|SPM 907|
46069987|NCT00659269|Dietary Supplement|Multivitamin (MV)|Multivitamins containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12 will be given to the patients on this arm.
46069988|NCT00659269|Dietary Supplement|Multivitamin + Vitamin B12 + Vitamin B6|Multivitamin (containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12), plus Vitamin B6 tablets and Vitamin B12 injections
45447655|NCT03682107|Biological|Andes virus DNA vaccine|A vaccine targeting the hantavirus pulmonary syndrome (HPS) causative agent Andes Virus (ANDV), with potential pan-hantavirus effect. The plasmid backbone, pWRG7077, is modified to produce the active ingredient of the vaccine, plasmid pWRG/AND-M (opt2), and includes the ANDV M gene responsible for encoding viral GnGc envelope glycoproteins. ANDV DNA vaccine will be administered intramuscularly at 2 mg or 4 mg doses using the PharmaJet Stratis Needle-Free Injection System.
45631007|NCT04708067|Drug|Bintrafusp Alfa|Given IV
45631008|NCT04708067|Procedure|Biopsy|Undergo biopsy
45631009|NCT04708067|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
45631010|NCT04703387|Diagnostic Test|transthoracic echocardiography|Trans-mitral flow velocities (peak early diastolic E and peak late diastolic A) will be recorded with pulsed-wave Doppler, placing the sample volume at the mitral valve tips from the apical 4-chamber view; deceleration time of the E wave (DTE) will be measured. Peak early diastolic velocity will be obtained with tissue Doppler imaging (TDI), in the apical 4-chamber view, positioning the pulsed-wave Doppler sample volume at or 1 cm within the septal insertion sites of the mitral leaflets, so as to cover the longitudinal excursion of the mitral annulus in both systole and diastole. Then, the E/A ratio and the trans-mitral inflow E wave to mitral annular e' (E/e) will be calculated.Diaphragmatic thickness will be assessed in the zone of apposition of the diaphragm to the rib cage between the 8th and 10th intercostal spaces using a 3-12 MHz linear array probe , we will record changes in diaphragm vertical excursion using M-mode ultrasound.
45631011|NCT03114215|Drug|MD1003|capsules 100mg 3 times per day
45631012|NCT03114215|Drug|Placebo oral capsule|capsules 100mg lactose 3 times per day
45631013|NCT04439981|Dietary Supplement|Ice cream|Curcumin extract was added into ice cream
45770604|NCT05482464|Dietary Supplement|Casein glycomacropeptide (CGMP)|Casein glycomacropeptide (CGMP) supplementation for 3 weeks
45447656|NCT03682107|Other|Placebo|Normal saline injections will be administered intramuscularly as matching placebo using the PharmaJet Stratis Needle-Free Injection System
45447657|NCT05179616|Procedure|Transcatheter edge-to-edge tricuspid valve repair|Percutaneous edge to edge repair of tricuspid valve using the TriClip system
45447658|NCT03673046|Device|Smartphone-delivered cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD)|12-week Smartphone-delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
45447659|NCT05103566|Device|gammaCore|Participants will receive two 2-minute non-invasive stimulations to the cervical branch of the vagus nerve (nVNS) three times daily with gammaCore, an FDA cleared device for the acute treatment and prevention of migraine and cluster headache. Intervention will begin within 72 hours post-rupture and end at 10 days post-rupture or discharge, whichever occurs first. The dosing regimen is supported by preclinical models and clinical data.
45447660|NCT02956005|Drug|ENVARSUS®|ENVARSUS XR is a form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant
45447661|NCT02579499|Drug|fixed high potent statin therapy|Patients assigned fixed high-potent statin group will be received high-intensity statin therapy (atorvastatin 40mg or rosuvastatin 20mg) regardless of their baseline LDL-C levels, and maintain high-intensity statin therapy regardless of their follow-up LDL-C level.
45447662|NCT02579499|Drug|targeted LDL-C goal statin|"Statin naïve patients: Patients will be received moderate intensity statin therapy (atorvastatin 20mg or rosuvastatin 10mg)~Patients already received statin therapy~Baseline LDL-C <70mg: same intensity of statin therapy~Baseline LDL-C≥70mg: uptiltrated statin therapy Patients will be tiltrated statin intensity guided by follow-up LDL-C level ( Attained LDL-C < 50mg/dL : down regulated intensity statin therapy, 50mg/dL ≤ Attained LDL-C < 70g/dL: maintain current intensity statin therapy, Attained LDL-C ≥ 70mg/dL: up regulated intensity statin therapy)"
45631014|NCT04683731|Behavioral|Decision aid without personalized message|The decision aid without personalized message consists of a PowerPoint presentation converted to mp4 (video) with text, photos, and an audio track, that is advanced by the viewer and can be viewed online. It begins with a 60 sec video on CRC screening produced by the Centers for Disease Control and Prevention (CDC), followed by slides summarizing the advantages and disadvantages of colonoscopy and stool testing with the fecal immunochemical test (FIT) and DNA+FIT (Cologuard). The presentation is approximately 10 minutes long.
45447663|NCT03253094|Drug|Fluconazole|Oral Antifungal comparator
45631015|NCT04683731|Behavioral|Decision aid with personalized message|The decision aid with personalized message will first present the decision aid without personalized message followed by additional PowerPoint slides converted to mp4 (video) with text, photos, and an audio track briefly explaining the risk tool, the participant's score on the 5 risk factors, total score, ACN risk, and implications for screening and test choice. The presentation is approximately 14 minutes long.
45631016|NCT04683731|Behavioral|Provider notification without personalized message|Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will be sent to them through the EHR within 24 hours of their visit with the enrolled patient.
45631017|NCT04683731|Behavioral|Provider notification with personalized message|Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will also include the patient's ACN risk (very low, low, moderate, high-average) and implications for screening decisions and test choice. Links to a web landing page containing a more detailed explanation of the risk tool and additional references will be included. The notification will be sent to them through the EHR within 24 hours of their visit with the enrolled patient.
45631018|NCT04722887|Biological|Alpha-1 15%|Alpha1-Proteinase Inhibitor (Human), 15%, Subcutaneous infusion
45631019|NCT04722887|Biological|Liquid Alpha1-Proteinase Inhibitor (Human)|Intravenous infusion
45631020|NCT03374267|Other|Routine care as per site standard.|Physician's choice according to patient's needs.
45631021|NCT04665479|Other|Web-based legacy-making intervention through digital storytelling|A child-parent dyad will participate in a nurse-delivered intervention that will guide children to create electronic digital storyboards about themselves during 6 sessions over 6 weeks.
45631022|NCT04614467|Biological|CLBS16|GCSF-mobilized autologous CD34+ cells
45631023|NCT04614467|Biological|Placebo|isotonic solution (no CD34+ cells)
45631024|NCT05675813|Drug|CHOP+selinexor+5-Azacitidine|Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. For the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and selinexor 40mg or 60mg in phase I triaI on days d1,d8 while selinexor RP2D po in phase II trial followed by standard CHOP of every 21-day cycle.
45770605|NCT00689884|Drug|Pegfilgrastim|Pegfilgrastim: Sub Cutaneous, 6 mg on Day 3 of chemotherapy regimen or as otherwise indicated by chemotherapy regimen (ie., 24 hours after completion of chemotherapy).
45935281|NCT00042653|Drug|Placebo|30 mg of placebo taken once daily orally 60 mg of placebo taken once daily orally 90 mg of placebo taken once daily orally 120 mg of placebo taken once daily orally 180 mg of placebo taken once daily orally
45447664|NCT03253094|Drug|SCY-078|Investigational Antifungal
45447665|NCT03654885|Device|XEN-45 Gel Stent|XEN-45 gel stent device implant
45447666|NCT03654885|Procedure|Trabeculectomy|Trabeculectomy surgery
45631025|NCT05675813|Drug|CHOP+duvelisib+5-Azacitidine|Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. For the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and duvelisib 25mg or 50mg in phase I triaI on days d1-21 while duvelisib RP2D po in phase II trial followed by standard CHOP of every 21-day cycle.
45631026|NCT05675813|Drug|CHOP+chidamide+tislelizumab|Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. For the remaining 5 cycles, they will receive tislelizumab 200mg d1 ivgtt and chidamide 20mg or 30mg po in phase I triaI biw while chidamide RP2D po in phase II trial followed by standard CHOP of every 21-day cycle.
45770606|NCT05472870|Device|repetitive Transcranial Magnetic Stimulation|A technique that involves the use of electrical coils on the head to generate a brief magnetic field which reaches the cerebral cortex.
45770607|NCT04266054|Behavioral|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
45770608|NCT01530880|Drug|Intravenous Ibuprofen|Ibuprofen 400 mg/100 mL intravenous (IV) over 30 minutes, followed by a continuous infusion of 2000 mg/500 mL at 85 mg/hour (21 mL/hour) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first
45770609|NCT01530880|Drug|Acetaminophen (Standard of Care)|Acetaminophen 650 mg via oral/nasogastric tube every 6 hours as needed for T>=38.3 C (100.9 F) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first.
45770610|NCT05482230|Other|Changes in intubation position|The change of intubation mode is accomplished in lateral position
45770611|NCT03320122|Other|Telemedicine|Medical direction will be provided to MTUs through a video-based conferencing unit. Each telemedicine unit includes a Rubbermaid medical grade cart with a Polycom RealPresence 500 Series high-resolution video-conferencing unit flat screen to display video. Each cart also comes with an Uninterrupted Power Supply (UPS) to make the unit mobile if needed or to properly shut it down in the event of power failure.
45770612|NCT03320122|Other|In-Person Pediatric Physiatrist|UC Davis pediatric physiatrists will drive out to the school-based MTUs to provide medical direction in person.
45770613|NCT03320122|Other|In-Person Non-Pediatric Physiatrist|A contracted physician (i.e., a non pediatric physiatrist) would provide medical direction in person.
45770614|NCT05482074|Drug|Olaparib|Oral, twice a day, dosage per protocol, per 28 day cycle
45770615|NCT03228472|Device|non invasive brain stimulation|"TDCS stimulation will be administered for 5 consecutive days at 2 mA for 20 minutes.~TMS stimulation parameters will be: 10 Hz frequency; 100% RMT intensity; Train duration 10 sec (100 stimuli); Inter-train interval 1 minute; n. Total of the terrors 12; Duration of a session about 13 minutes."
45770616|NCT03228472|Device|sham stimulation|Placebo treatment
45770617|NCT05476848|Diagnostic Test|ELISA test for Cytokines|ELISA tests specific for cytokines (IL-1, IL-6, IL-10) and immunoglobulins (IgA, IgG, IgM) will be performed by a biochemistry lab, both for blood samples and oral swap samples.
45631027|NCT03186989|Drug|IONIS MAPTRx|"Part 1: IONIS MAPTRx is administered intrathecally at 4 week intervals over the course of a 13 week treatment period for dose levels A, B, C, and D.~Part 2: IONIS MAPTRx is administered intrathecally at quarterly intervals for 48 weeks."
45770618|NCT03195790|Behavioral|Family-based pediatric obesity treatment|Families with at least one overweight/obese child between ages 6 and 11 years will receive 12-months of family-based pediatric obesity treatment that emphasizes healthy changes to the home environment and family routines. The intervention targets dietary intake, physical activity, and consistent sleep.
45770619|NCT03584022|Device|Biopsy + Nerve Repair|During the standard sural nerve biopsy procedure, a single-use, biodegradable implant designed to repair damaged peripheral nerves will be used to repair the nerve. The MCNS1 is a hollow nerve tube made of poly(caprolactone-fumarate) (PCLF), to connect severed nerve ends and promote the growth of regenerating axons.
45770620|NCT03584022|Procedure|Biopsy Only|Standard sural nerve biopsy only, without nerve repair.
45770621|NCT03556488|Diagnostic Test|US air bronchogram score|"On ultrasonographic examination, lung consolidation is defined as a subpleural echo-poor region or one with tissue- like echotexture, depending on the extent of air loss and fluid predominance, which is clearly different from the normal pattern.~The air bronchogram is characterized as: absent, static, dynamic, dynamic with areas of lung recruitment."
45770622|NCT01532362|Drug|Apricoxib|As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
45770623|NCT04541628|Combination Product|SIG-001|Laparoscopic administration of SIG-001 spheres, an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce BDD-hFVIII.
45770624|NCT00678574|Drug|fluoxetine|Fluoxetine 20 mg daily by mouth for 2-3 months.
45770625|NCT05471622|Behavioral|Nudge for PHPC Referral|The case manager and covering providers for inpatients who have been identified according to the study's inclusion criteria as appropriate for Penn Home Palliative Care (PHPC) upon hospital discharge will be asked to refer their patient for these home palliative care services.
45770626|NCT00672178|Radiation|Stereotactic body radiation|Stereotactic body radiotherapy will be given in three cohorts of increasingly higher dose levels: Cohort 1: 6 Gy/fraction x 3 fractions (total=18 Gy) over 5 days; Cohort 2: 8 Gy/fraction x 3 fractions over 5 days; Cohort 3: 10 Gy/fraction x 3 fractions over 5 days.
45631028|NCT03186989|Other|Placebo|A placebo is administered intrathecally at 4 week intervals over the course of 13 weeks in Part 1. No placebo is given in Part 2.
45770627|NCT05476692|Other|AOFAS score and VAS|Clinical outcome by the Visual analogue scale (VAS) and the American Orthopaedic Foot and Ankle (AOFAS) score.
46069989|NCT00659269|Drug|Chemotherapy|"Patients are treated per standard of care according to the choice of the treating physician with heavy metals (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), or vinca alkaloids (vincristine, vinorelbine)~Ranges of cumulative doses (in mg/m2) are:~paclitaxel, 700-960; docetaxel, 240-400; vincristine, 8-16; vinorelbine, 360-480; cisplatin, 240-400; oxaliplatin, 400-800; abraxane, 1200-1800"
45631029|NCT03062657|Device|PRESTIGE LP™ Cervical Disc|The PRESTIGE LP™ Cervical Disc is an artificial cervical disc comprising of two low-profile metal plates that interface through a ball and trough mechanism, permitting segmental spinal motion. The PRESTIGE LP™ Cervical Disc was approved by the Food and Drug Administration (FDA) to be used at a single and two contiguous levels.
45631030|NCT05675891|Other|Supplemental Feeding System Group|The body weight is measured in the morning fasting on the day when oral feeding is decided, 3 feeding between 08-16:00 are carried out with the supplemental feeding system, The amount of food prepared is recorded, Heart rate, oxygen saturation, respiratory rate and early feeding skill score are recorded before, during and after feeding, When the feeding is finished, the total amount of food taken by the baby and the feeding time are recorded, The rate of food intake (%) and the amount of food received per minute are calculated and recorded, Infants who can take 80% of the amount of food given at each meal by being fed orally for 8 meals two days in a row are considered to have switched to full oral feeding.
45631031|NCT05620043|Device|Sculptra|Biostimulator
45770628|NCT01475500|Procedure|Sputum sample|This is a collection of sputum (mucous) you cough up. Three morning samples will be collected at one time. Sputum will be collected at baseline, year 1, year 2 and year 5.
45770629|NCT01475500|Procedure|Pulmonary function tests|A series of different breathing tests designed to measure lung function and to determine the presence or absence of chronic obstructive pulmonary disease will be performed at baseline.
45770630|NCT01475500|Radiation|Computerized tomography (CT) scan of the chest|A CT scan uses x-rays to take detailed pictures of the chest. Performed at baseline, year 2 and year 5. If nodules are present, CT scans will be performed every 3 months for the first year of the study.
45631032|NCT05620043|Device|Radiesse Plus|Semi-permanent filler
45770631|NCT01475500|Other|Buccal epithelium collection|Collect cells from the inside of the cheek. Samples will be collected at baseline and yearly to year 5.
45770632|NCT01475500|Procedure|Nasal brushings|A cytobrush is used to remove cells on the surface of the inside of the nose. Samples will be collected at baseline and yearly to year 5.
45770633|NCT01475500|Procedure|Bronchoscopy|A flexible tube with a light and a camera will be inserted through the nose or mouth, and into the lungs to look at the airway. Bronchial tissue will be obtained.
45770634|NCT01475500|Procedure|Bronchoalveolar lavage|During a bronchoscopy, a flexible tube with a light and a camera is passed through the mouth or nose into the lungs and fluid is squirted into a small part of the lung and collected for examination. Bronchoscopies will be performed at baseline and at year 5.
45770635|NCT01475500|Procedure|Blood sample collection|A venous blood sample will be collected for testing of biomarkers and other relevant tests. Blood will be taken at baseline and yearly to year 5.
45770636|NCT01475500|Procedure|Urine sample|Urine will be collected for routine urine tests at baseline and yearly to year 5.
45770637|NCT01475500|Procedure|Questionnaire-data collection|A questionnaire about the patient's health, medical, and smoking history. Administered at baseline and yearly to year 5. Data will be taken from patient interviews and from the medical record.
45770638|NCT05481918|Procedure|Home-based therapy after ACL reconstruction|Five physiotherapeutic supervisions (individual) take place within the first 12-13 weeks after ACL reconstruction with focus on home exercises
45770639|NCT05481918|Procedure|Standardized ambulant therapy after ACL reconstruction|16 physiotherapeutic supervisions (groups+ individual) take place within the first 12-13 weeks after ACL reconstruction.
45770640|NCT00634582|Drug|paricalcitol|
45770641|NCT00634582|Other|immunoenzyme technique|
45770642|NCT00634582|Other|laboratory biomarker analysis|
45770643|NCT00634582|Procedure|dual x-ray absorptometry|
45770644|NCT00634582|Procedure|quality-of-life assessment|
45935282|NCT00042653|Drug|AMG 073|30 mg of AMG 073 taken once daily orally 60 mg of AMG 073 taken once daily orally 90 mg of AMG 073 taken once daily orally 120 mg of AMG 073 taken once daily orally 180 mg of AMG 073 taken once daily orally
45631033|NCT03113825|Device|Investigational Imaging device|Fluorescence imaging of the of the primary tumor specimen, any secondary breast specimens, and lymph nodes will be performed.
45631034|NCT03113825|Drug|AVB-620|AVB-620 will be administered IV before the surgical procedure.
45631035|NCT03113903|Behavioral|Psychophysical exploration|Psychophysical exploration (multimodal sensitivity, including pain sensitivity) Electronic von Frey applied on forearm; thermal heat applied on forearm; foot immersion in 2°C cold water; exposure to a one-frequency noise up to uncomfortable loudness ; exposure to a halogen-lamp-generated light up to uncomfortable brightness.
45770645|NCT02551692|Drug|Nicotine Patch|Participants will wear 21mg/day patches for days 1-14. After day 14, participants will make a quit attempt continue to wear the 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment. Participants will also take a placebo capsule. During days 8-14, participants will undergo 2 cue-exposure sessions.
45770646|NCT02551692|Drug|Varenicline|Varenicline (VAR) will be administered by titrating to steady state levels over a 7 day induction period (.5 mg once daily in Days 1-3; .5 mg twice daily on Days 4-7 and 1 mg twice daily on Days 8-14). Participants will continue on 1mg twice daily until the end of treatment (days 15-84). Participants will also wear a placebo patch. During days 8-14, participants will undergo 2 cue-exposure sessions.
45770647|NCT02551692|Drug|Placebo Nicotine Patch|"In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.~In the VAR group, participants will wear a placebo patch while taking varenicline."
45770648|NCT02551692|Drug|Placebo Capsule|"In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.~In the NRT group, participants will take a placebo capsule while wearing nicotine patches."
45631036|NCT03113747|Biological|ALLO-ASCs|1). Cryopreserved cell suspension of early passages of cultured allogeneic MSCs isolated from SVF obtained from lipoaspirate, a total of 10 mln. of cultured cells; 2).The TE-construct consisting of collagen- or fibrin-derived hydrogels and cells of early passages (up to P5) suspension of allogeneic cultured MSCs isolated from SVF obtained from lipoaspirate; Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging.
45631037|NCT02742935|Biological|camrelizumab|A fully humanized anti-PD-1 monoclonal immunoglobulin (IgG4 subtype)
45631038|NCT02397083|Drug|Everolimus|Given PO
45631039|NCT02397083|Other|Laboratory Biomarker Analysis|Correlative studies
45631040|NCT02397083|Device|Levonorgestrel-Releasing Intrauterine System|Placed in the uterus
45631041|NCT02673515|Behavioral|Alternate day fasting|Subjects are requested to fast every other day. Calorie free fluids are allowed.
45631042|NCT02667275|Drug|A-101 Solution|
45631043|NCT02667275|Other|Vehicle Solution|Placebo
45631044|NCT04364789|Drug|TT-00920|Tablets
45631045|NCT04364789|Drug|Placebos|Tablets
45631046|NCT02672423|Drug|Abemaciclib Capsules (Reference Formulation)|Administered orally
45631047|NCT02672423|Drug|Abemaciclib Tablet (Test Formulation)|Administered orally
45631048|NCT01907789|Other|Ovarian Cancer Screening|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
45631049|NCT01907789|Procedure|Prophylactic Salpingectomy with Delayed Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
45770649|NCT00247000|Device|Routine Care in a HF clinic vs Home Telehealth Care for HF|
45770650|NCT00547456|Drug|Oxygen|Oxygen 2-3L Nasal cannula
45770651|NCT05481840|Device|Continence material with sensor|"Healthcare organizations are prepared for the use of smart continence care (for the intervention condition) using specially developed implementation guideline. They receive training, including how to apply continence material (only provided to intervention condition).~Each participating location will use the product for 12 weeks. Correct size and absorption level will be determined for each participant. The optimize the result, this can change. Evaluation meetings with the caregivers, supplier and researcher will be held. Resulting in suggestions for alterations in continence care provided or products used, or giving indications that a team needs support in any way to foster the implementation.~After 12 weeks, the implementation guidance from the research group will be phased out.~The waiting list group will continue their continence care as usual during data collection period. Thereafter they will receive support for implementing smart continence care."
45631050|NCT01907789|Procedure|Risk-Reducing Salpingo-Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
45631051|NCT01907789|Behavioral|Questionnaire|"Ovarian Screening Group: Quality of life (QOL) questionnaire completed at baseline, end of year 1, 2, and 3.~Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO): Quality of life (QOL) questionnaire completed at baseline, 1 month 1 year, 2 years, and 3 years after salpingectomy. Also before oophorectomy performed, 1 month and 6 months after oophorectomy.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Quality of life (QOL) questionnaire completed at baseline, then 1 month, 6 months, and 1 year after surgery."
45631052|NCT01907789|Procedure|Transvaginal Ultrasound|"Ovarian Cancer Screening Group: Transvaginal ultrasound performed at baseline and every 6 months for 3 years.~Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) group: Transvaginal ultrasound performed at baseline, every 6 months for 3 years after salpingectomy, then before oophorectomy.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Transvaginal ultrasound performed at baseline."
45631053|NCT01907789|Behavioral|Phone Call|"Ovarian Cancer Screening Group and Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) Group: Phone call made to patient one time a year after third year follow up.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Phone call made to patient 1 day after surgery, 1 week after surgery, then yearly."
45631054|NCT01738139|Drug|Imatinib Mesylate|Given PO
45631055|NCT01738139|Biological|Ipilimumab|Given IV
45631056|NCT01729091|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
45631057|NCT01729091|Biological|Elotuzumab|Given IV
45631058|NCT01729091|Other|Laboratory Biomarker Analysis|Correlative studies
45631059|NCT01729091|Drug|Lenalidomide|Given PO
45631060|NCT01729091|Drug|Melphalan|Given IV
45631061|NCT01729091|Biological|Natural Killer Cell Therapy|Given IV
45631062|NCT01729091|Biological|Umbilical Cord Blood-Derived Lymphocyte Therapy|Given IV
45631063|NCT04205903|Drug|Nilotinib|Given PO
45631064|NCT04205903|Drug|Nilotinib Hydrochloride Monohydrate|Given PO on cycle 1 Days 7, 14, 15 once a day 24 hours prior to the paclitaxel infusion and again 30 minutes prior to the paclitaxel infusion on days 8, 15.
45631065|NCT04205903|Drug|Paclitaxel|Given IV weekly on days 1, 8, 15, of every 21 days, at a starting dose of 80mg/m2
45631066|NCT04205903|Other|Placebo|Given PO
45631067|NCT04205903|Other|Questionnaire Administration|Ancillary studies
45631068|NCT05566691|Other|Positive thinking|Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts.
45631069|NCT05566691|Other|Positive thinking + Mood induction|Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.
45631070|NCT05566691|Other|Thought reevaluation|Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts.
45631071|NCT05566691|Other|Thought reevaluation + Mood induction|Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.
45631072|NCT04144751|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
45631073|NCT01515527|Drug|Cladribine|"Induction cycle: 5 mg/m2 by vein on days 1 - 5 for up to 2, 28 day cycles.~Consolidation cycle: 5 mg/m2 by vein on days 1 - 3 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18."
45631074|NCT01515527|Drug|Cytarabine|"Induction cycle: 20 mg subcutaneously twice daily on days 1-10 for up to 2, 28 day cycles.~Consolidation cycle: 20 mg subcutaneously twice daily on days 1 - 10 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18."
45631075|NCT01515527|Drug|Decitabine|Consolidation cycle: 20 mg/m2 by vein over 1 to 2 hours on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15, and 16.
45631076|NCT02670551|Drug|Cariprazine|
45631077|NCT02670551|Drug|Placebo|
45631078|NCT01478477|Dietary Supplement|omega-3 fatty acid supplement|6 capsules per day (4.3 g)x 6 months
45631079|NCT01478477|Other|Placebo|6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed.
45631080|NCT01478477|Other|Clinical assessments|All three instruments will be administered at baseline, at 3 months, 6 months and at additional time intervals when there is a significant change in therapy (discontinuation/switch, pain medication administration) during routine medical oncology visits.
45631081|NCT01478477|Other|Assessment of therapy complications|Severity/grade of reaction according to the NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE).
45631082|NCT01478477|Procedure|Magnetic Resonance Imaging|Optional bilateral hand and wrist MRI imaging will be obtained at baseline and at 6 months to eligible patients who have no contraindications to MRI imaging.
45631083|NCT01478477|Procedure|Correlative/special studies|Plasma, RBC, and serum samples from the baseline blood draw will also be stored at -70C for fatty acid and biomarker analyses and repeated at 3 month and 6 month intervals. Samples will be analyzed in batches every 6 months.
45631084|NCT01430351|Drug|Mefloquine|Given PO
45631085|NCT01430351|Drug|Memantine Hydrochloride|Given PO
45631086|NCT01430351|Drug|Metformin Hydrochloride|Given PO
45631087|NCT01430351|Drug|Temozolomide|Given PO
45631088|NCT00893399|Drug|Gemtuzumab Ozogamicin (Mylotarg)|"Induction Cycle 1, 2: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after etoposide IVI. No dose reduction is foreseen in elderly (> 60 yrs) patients.~Consolidation 1: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after first dose of high-dose cytarabine. No dose reduction is foreseen in elderly (> 60 yrs) patients.~For all patients experiencing prolonged thrombocytopenia CTC-Grade 3/4 during the first or second induction therapy, which occurs for more than day 35 after start of the cycle, the further cycles of therapy will be administered without Gemtuzumab ozogamicin.~Consolidation 2, 3: no GO"
45631089|NCT00893399|Drug|standard chemotherapy|Idarubicin, Etoposide, Cytarabine, ATRA, Pegfilgrastim
45631090|NCT05675267|Other|data collection|HEART score calculation
45631091|NCT04439591|Other|Computerised cognitive training|A 12-week bi-weekly group-based computerised cognitive training programme conducted in community centres
45631092|NCT05675033|Drug|Serplulimab and Bevacizumab injection|"Serplulimab, 4.5mg/kg, intravenous injection, D1,Q21, until the disease progressed or showed intolerable side effects.~Bevacizumab injection, 7.5mg/kg, intravenous injection, D1, Q21, until the disease progressed or showed intolerable side effects.~Platinum-based chemotherapy: pemetrexed combined with carboplatin, D1-2, Q21, a total of 4 cycles."
45631093|NCT02391935|Drug|RCS-01|Cultured, autologous hair follicle cells suspended in cryomedium
45631094|NCT02391935|Drug|Placebo|Cryomedium
45631095|NCT02391935|Device|Sham injection|skin penetration of the needle without injection of liquid
45631096|NCT04103489|Drug|Eculizumab|Participants will receive eculizumab at diagnosis of HELLP syndrome. Participants will receive a maximum of 4 doses.
45631097|NCT02391779|Dietary Supplement|BeneFlax®|Daily ingestion of 600 mg SDG/day in 1.6 g SDG-enhanced flax lignan (BeneFlax®) with walking training or flexibility training
45631098|NCT02391779|Behavioral|Walking training|30-60 minutes walking training, 5 days/week.
45631099|NCT02391779|Behavioral|Flexibility training|5 days/week; e.g. stretching training at home
45770652|NCT00542542|Procedure|Paravertebral Block|Paravertebral block given as a bolus injection into the paravertebral space.
45770653|NCT00542542|Drug|Propofol|2-2.5 mg/kg IV over 1-4 hours during surgery.
45770654|NCT00542542|Drug|Fentanyl|50-250 mcg IV over 1-4 hours during surgery.
45631100|NCT02391779|Dietary Supplement|Placebo (Whey Protein)|0.6 g/day (an amount equal in volume to BeneFlax®) with walking training or flexibility training
45631101|NCT02391779|Behavioral|Dash Eating Plan|Dietary Approaches to Stop Hypertension (DASH), a balanced eating plan - all participants in all treatment arms will be encouraged to adopt a DASH eating plan.
45631102|NCT05545085|Device|Laser Speckle Contrast Imaging using the PerfusiX-Imaging Device|Patient will undergo the standard of care lobectomy for pulmonary cancer. In addition, peroperative imaging using the Laser Speckle Contrast Imaging device will be performed.
45631103|NCT02391623|Drug|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=8).
45631104|NCT02391623|Drug|Placebo|Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).
45631105|NCT02391623|Drug|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=8).
45631106|NCT02391623|Drug|Placebo|Placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=2).
45770655|NCT00542542|Drug|Ropivacaine|Ropivacaine given by injection into the paravertebral space along the spinal canal.
45631107|NCT02670473|Device|fanfilcon A (test)|contact lens
45631108|NCT02667119|Behavioral|Prolonged Exposure with Contingency Management|"Prolonged Exposure therapy for posttraumatic stress disorder includes psychoeducation, breathing retraining, in vivo exposure, and imaginal exposure.~Contingency Management for substance abuse disorders: participants will have the chance to win prizes for each negative urine drug screen/breathalyzer provided."
45631109|NCT02667119|Behavioral|Standard Care|Standard care will consist of treatment as usual in a community-based substance use treatment center.
45631110|NCT02391389|Procedure|CPAP or PPV during DCC|CPAP or PPV is provided during delayed cord clamping
45631111|NCT04029857|Dietary Supplement|Nutritional Supplement Drink|Given standard of care nutritional supplementation
45631112|NCT04029857|Dietary Supplement|Nutritional Supplementation|Given Impact Advanced Recovery PO or via feeding tube
45770656|NCT00542542|Drug|Midazolam|0.08 mg/kg IV over 1-4 hours during the surgery.
45631113|NCT02391233|Behavioral|E-WORTH|E-WORTH (Empowering African-American Women on the Road to Health) consists of 1 Streamlined HIV Testing session followed by 5 one-and-a-half hour group sessions that will be delivered by a probation provider at the probation site. The main multimedia components used in the E-WORTH: (1) Narrativity; (2) Skill acquisition using simulated video vignettes that provides instruction and demonstration of core skills (e.g., safer sex negotiation and problem-solving skills, technical condom use skills) using culturally congruent role models; (3) Individual interactive exercises and logs that are designed to enhance participant's recall of core knowledge and tracking of their individual progress in reducing risky behaviors and achieving risk reduction goals; and a (4) Facilitator interactive guide.
45631114|NCT02391233|Behavioral|Streamlined HIV Testing|In this intervention Black Women on Probation receive streamlined HIV Testing alone to test primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
45631115|NCT04479527|Drug|Camrelizumab|Camrelizumab for injection is used to treat patients with relapsed or refractory classic Hodgkin lymphoma who have undergone at least second-line chemotherapy. Approved by the Drug Administration (NMPA) on March 4, 2020, for the treatment of patients with advanced hepatocellular carcinoma who have previously received sorafenib therapy and/or oxaliplatin-containing chemotherapy.Apatinib Mesylas is a small-molecule VEGFR tyrosine kinase inhibitor. It mainly treats malignant tumors by inhibiting VEGFR to play an anti-angiogenic effect. It has been approved by the China Food and Drug Administration (CFDA) in November 2014. It is used as a monotherapy for advanced gastric adenocarcinoma or gastric-esophageal junction adenocarcinoma that has progressed or relapsed after receiving two kinds of systemic chemotherapy. Apatinib Mesylas can effectively inhibit VEGFR2 at very low concentrations, and higher concentrations can also inhibit PDGFR, c-Kit and c-Src and other kinases.
45631116|NCT05534945|Drug|Programmed intermittent epidural bolus 5 ml|patients in this group will receive a programmed epidural intermittent bolus of 5 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain > 4/10
45770657|NCT05476614|Other|Yoga (Robot-instructed)|Yoga that is instructed by a social robot
45770658|NCT05476614|Other|Yoga (Human-instructed)|Yoga that is instructed by a human
45770659|NCT05471544|Drug|Sulfadoxine pyrimethamine|"Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug."
45770660|NCT05471544|Drug|Amodiaquine|"Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect."
45770661|NCT00545506|Device|conventional bandage|
45770662|NCT00545506|Device|warming bandage|
45770663|NCT03333486|Drug|Cyclophosphamide|Given IV
45631117|NCT05534945|Drug|Programmed intermittent epidural bolus 6 ml|patients in this group will receive a programmed epidural intermittent bolus of 6 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain > 4/10
45631118|NCT05534945|Drug|Programmed intermittent epidural bolus 7 ml|patients in this group will receive a programmed epidural intermittent bolus of 7 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain > 4/10
45631119|NCT05534945|Drug|Programmed intermittent epidural bolus 8 ml|patients in this group will receive a programmed epidural intermittent bolus of 8 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain > 4/10
45631120|NCT05534945|Drug|Programmed intermittent epidural bolus 9 ml|patients in this group will receive a programmed epidural intermittent bolus of 9 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain > 4/10
45631121|NCT05534945|Drug|Programmed intermittent epidural bolus 10 ml|patients in this group will receive a programmed epidural intermittent bolus of 10 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain > 4/10
45631122|NCT02391077|Other|Povidone-Iodine|Foreskin disinfection with Povidone-Iodine
45631123|NCT02391077|Other|Antibiotic topical cream|Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus
45770664|NCT03333486|Drug|Fludarabine Phosphate|Given IV
45770665|NCT03333486|Other|Laboratory Biomarker Analysis|Correlative studies
45913473|NCT02023086|Procedure|Slit Lamp assessment and intra-ocular pressure measurement|Slit lamp is used to assess the presence of significant lens opacities known as Fabry cataracts. In fact, these opacities can induced a bias on the contrast sensitivity measurement and can increase the symptoms felt by the patient. A grade 2 (CFDI grading chart) of lens opacities is considered clinically significant and this will become an exclusion criteria for the following of the study. Intra-ocular pressure will be measured with a non contact tonometer (air pulsed) (Ocular Response Analyser, Reichert Instrumentation.)
45770666|NCT03333486|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT
45913474|NCT02023086|Procedure|Visual field testing|"Visual field will be assessed with an automated perimeter (Humphrey, Texas) using a threshold strategy. This implies that the subject has to identify not only if he perceives the visual stimulus but the minimal level of this stimulus (in decibels), to be seen, is also recorded. Visual field will be tested up to 30 degrees from the central point of fixation.~In order to measure immediate variability of the visual testing among Fabry subjects, this test will be done at the beginning of the testing session (in the morning) and another time 1h00 later."
45913475|NCT02023086|Procedure|Oxygen flow at the optic nerve head measurement|"Pupils will be dilated with 1 drop of 1% tropicamide. The procedure is similar to the one used for taking a photo of the retina. Each measurement session represents a continuous recording of 20 simultaneous functions of reflectometry from the optic nerve area during 10 seconds.~During all recording sessions, the systemic arterial oxygen saturation will be also monitored at the right index finger using a pulse oximeter (Escort M10, Invivo, Orlando, USA). Arterial blood pressure will be also monitored before and after the testing using a manual sphygmomanometer."
45913476|NCT02023086|Drug|Tropicamide|Used to dilate patient's pupil during testing
45913477|NCT02023086|Device|OSOME|The OSOME system is the only technology able to perform on line and real time capillaries blood oxygenation measurement in the eye. The system operates with 1200 discreet wavelengths between 400 nm to 700 nm with 500 millisecond integration times. It is not invasive, functioning just like a fundus camera.
45913478|NCT02023138|Other|Focus group|Two hours focus group to allow the participants to modify a clinical practice guideline recommendation
45631124|NCT02391077|Other|Chlorhexidine 1%|Daily washes with Chlorhexidine 1% (2-3 times a day), for 6 days
45631125|NCT02391155|Procedure|single lumen needle in oocyte retrieval|single lumen needle use during oocyte retrieval
45631126|NCT02391155|Procedure|double lumen needle in oocyte retrieval|after aspiration of follicles, 3 times flushing will be performed in double lumen needle.
45631127|NCT02390999|Procedure|48 hours of therapeutic hypothermia|
45631128|NCT02390921|Drug|Fisiogen Ferro Forte|The patients will interrupt the endovenous treatment with iron and will receive liposomated iron 28mg/daily during 3 months.
45631129|NCT02390921|Drug|Venofer|The patients will continue their usual endovenous administration of Venofer 300mg every 3 month
45631130|NCT05502029|Behavioral|Extended translation|Translation extended beyond the preoperative area
45631131|NCT05502029|Behavioral|Standard translation|Translation in the preoperative area
45631132|NCT05477069|Device|Innovative medical device for sampling small intestine content|Ingestion of the medical device by the volunteer
45770667|NCT03333486|Radiation|Total-Body Irradiation|Undergo TBI
45770668|NCT02703844|Device|Caloric Vestibular Stimulation|Stimulation of the vestibular nerves
45770669|NCT02703844|Device|Sham Caloric Vestibular Stimulation|Sham stimulation of the vestibular nerves
45770670|NCT03546660|Device|SECM capsule|Subjects will swallow a SECM capsule and the SECM imaging will be performed
45770671|NCT02598778|Drug|Chlorhexidine gluconate (0.12%)|30 second oral rinse of 10mL of solution
45770672|NCT02598778|Drug|Sodium Fluoride (0.05%)|30 second oral rinse of 10mL of solution
45770673|NCT02598778|Other|Paraffin wax chewing gum (sugar-free)|Approximately two minutes of chew time
45770674|NCT02598778|Other|Deionized water|30 second oral rinse of 10mL of solution
45631133|NCT02390609|Drug|Ibrutinib (Treatment A) [Reference]|Participants will receive Ibrutinib 560 milligram (mg) (4*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.
45631134|NCT02390609|Drug|Ibrutinib (Treatment B)|Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.
45631135|NCT02390609|Drug|Ibrutinib (Treatment C)|Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.
45631136|NCT02390609|Drug|Ibrutinib (Treatment D)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment D under fasted conditions in one of the treatment periods.
45631137|NCT02390609|Drug|Ibrutinib (Treatment E)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment E under fed (high-fat) conditions in one of the treatment periods.
45631138|NCT02390609|Drug|Ibrutinib (Treatment F)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules suspended in water as Treatment F under fasted conditions in one of the treatment periods.
45631139|NCT02390687|Drug|Probiotic|Each probiotic lozenge contains not less than 1 billion colony forming unit of Lactobacillus brevis CD2
45631140|NCT02390687|Drug|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
45631141|NCT02390843|Drug|Simvastatin|The starting dose of simvastatin will be 140 mg/m^2/dose BID for 21 days for the first group. Dose escalation for subsequent groups will be 180 mg/m^2/dose BID, 225 mg/m^2/dose BID, and 290 mg/m^2/dose BID. If the maximum tolerated dose (MTD) has been exceeded at the first dose level, then the subsequent cohort of subjects will be treated at a dose of 100 mg/m2/dose BID (dose level 0). Simvastatin will be administered orally twice daily, approximately 12 hours apart. Feeding tube (nasogastric tube or gastrostomy tube, NOT a jejunum localized tube) administration is allowed. If a subject vomits a dose of simvastatin, it will not be repeated.
45631142|NCT02390843|Drug|Cyclophosphamide|The dose of cyclophosphamide will be fixed at 250 mg/m^2/dose. Cyclophosphamide will be administered intravenously over 30 minutes once daily for 5 days every 21 days.
45631143|NCT02390843|Drug|Topotecan|The dose of topotecan will be fixed at 0.75 mg/m^2/dose. Topotecan will be administered, after cyclophosphamide, intravenously over 30 minutes once daily for 5 days every 21 days.
45631144|NCT02390843|Drug|Myeloid growth factor|Myeloid growth factor (G-CSF or pegylated G-CSF) will be initiated 24-48 hours after the completion of topotecan and cyclophosphamide for all subjects, which would be day 6 or 7. Myeloid growth factor should continue until the absolute neutrophil count is greater than 2,000/mm^3
45631145|NCT02390375|Drug|DW-0929|5/10mg
45631146|NCT02390375|Drug|DW-0929|10/10mg
45631147|NCT02390375|Drug|DW-0929|20/10mg
45631148|NCT02390375|Drug|Rosuvastatin|5mg F/U study: DW-0929 5/10mg
45631149|NCT02390375|Drug|Rosuvastatin|10mg F/U study: DW-0929 10/10mg
45631150|NCT02390375|Drug|Rosuvastatin|20mg F/U study: DW-0929 20/10mg
45631151|NCT03926507|Procedure|Computed Tomography|Undergo PET/CT scan
45631152|NCT03926507|Other|Fluciclovine F18|Given IV
45631153|NCT03926507|Procedure|Positron Emission Tomography|Undergo PET/CT scan
45631154|NCT02670083|Drug|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
45631155|NCT02670083|Drug|Placebo|Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
45631156|NCT02669849|Drug|VX-210|
45631157|NCT02669849|Drug|Placebo|
45913479|NCT02023138|Other|Wiki|A specially tailored interactive communication website (Wiki) to allow the participants to modify a clinical practice guideline recommendation
45913480|NCT02023164|Drug|JDP-205 Injection|
45913481|NCT02023164|Drug|Diphenhydramine|
45631158|NCT02390141|Drug|ZP4207|
45631159|NCT02390141|Drug|Placebo|
45631160|NCT03836963|Behavioral|cognitive training|Cognitive training consists of a set of computerize games played on an iPad at home. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.
45631161|NCT03836963|Behavioral|active control cognitive training|The active control consists of a set of computerized games played on an iPad. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.
45631162|NCT03836963|Behavioral|memory strategy training|the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.
45631163|NCT03836963|Behavioral|memory strategy training|the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.
45631164|NCT03806309|Drug|FOLFIRI|Intravenous (IV); folinic acid 400 mg/m^2, irinotecan 180 mg/m^2, 5-FU bolus 400 mg/m^2 and continuous infusion 2,400 mg/m^2
45631165|NCT03806309|Drug|OSE2101|subcutaneous injection on days 1 and 15, every 4 weeks for 6 doses then every 8 weeks until month 12 and then every 12 weeks for a maximum treatment duration of 24 months
45631166|NCT03781583|Device|No HMD used|Participants will use their existing mobility skills and strategies to navigate toward a goal. If the participant cannot perform this task, the participant will not be forced to.
45631167|NCT03781583|Device|HMD worn but not active|Participants will wear the HMD, but the HMD will not be active. This will test whether or not the HMD physical components obscure the participants remaining vision and reduce the participants ability to navigate toward a goal.
45631168|NCT03781583|Device|HMD worn and active|Participants will wear the HMD and the HMD will be active. This will test the HMD function for navigation toward a goal.
45770675|NCT04513002|Dietary Supplement|Triheptanoin|Triheptanoin is a highly purified, synthetic medium odd-chain triglyceride that is catabolized to heptanoate.
45770676|NCT04473690|Biological|Low Dose of KBP-COVID-19|Low Dose of KBP-COVID-19 and adjuvant
45770677|NCT04473690|Biological|High Dose of KBP-COVID-19|High Dose of KBP-COVID-19 and adjuvant
45770678|NCT04473690|Biological|Placebo|Buffered saline solution
45631169|NCT03758105|Other|tDCS associated with usual care|"A tDCS cure will be given to the group tDCS, one week after their randomization.~This will be done in association with usual care: medication and psychotherapy Parameters: Anodal stimulation on dorso-lateral prefrontal cortex left, 2mA current.~Treatment will consist of 15 days with 30 minutes stimulation per day, 5 days a week for 3 weeks."
45631170|NCT03758105|Other|Usual care|Medication and psychotherapy as prescribed in usual care
45631171|NCT03741023|Procedure|Blood draw (venipuncture or fingerstick)|Blood will be drawn from participants by venipuncture and/or by fingerstick. Finger sticks will not be collected in the pediatric population.
45631172|NCT03519659|Diagnostic Test|PET/CT scan with 13 mCi radiation dose|13 mCi 18F-FDG dose
45631173|NCT03519659|Diagnostic Test|PET/CT scan with 5 mCi radiation dose|5 mCi 18F-FDG dose
45631174|NCT03519659|Diagnostic Test|PET/CT scan with 2.5 mCi radiation dose|2.5 mCi 18F-FDG dose
45631175|NCT03519659|Diagnostic Test|PET/CT Scan with 6.5 mCi radiation dose|6.5 mCi 18F-FDG dose
45631176|NCT03519659|Diagnostic Test|PET/CT Scan with not yet determined radiation dose|We plan for the possibility that one of the three-Sub-Studies (A-B) would not demonstrate equivalency, and we would then perform a modified protocol in which the SOC dosing is compared to a lower and higher dose than originally tested.
45631177|NCT03494933|Procedure|CRT-P implantation|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-P device.
45631178|NCT03494933|Procedure|CRT-D implantation|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-D device.
45631179|NCT03489629|Drug|Trimethoprim Sulfamethoxazole (TMP/SMX)|"Dosing if < 40 kg: 8 mg/kg trimethoprim/40 mg/kg trimethoprim sulfamethoxazole given twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing is ≥ 40 kg: 320 mg/1600 mg twice daily for 14 days during Days 1-14 and Days 29-42."
45631180|NCT03489629|Drug|Minocycline|"If a subject has an allergy to or intolerance to TMP/SMX, they may be treated with minocycline provided they are 8 years of age or older.~Dosing if < 50 kg: 2 mg/kg orally twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing if ≥ 50 kg: 100 mg twice daily for 14 days during Days 1-14 and Days 29-42."
45631181|NCT03489629|Drug|Mupirocin|1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 5 days during Days 1-5 and Days 29-33.
45770679|NCT05470296|Behavioral|Move & Eat 2 Live|American Indians suffer disproportionately from several chronic diseases that may be prevented with healthier modifiable factors. Nutrition, physical activity and a healthy weight are key factors that may prevent and reduce risk of disease incidence. The major goals of this project are to develop a culturally adapted intervention that addresses barriers and uses positive cultural values as guiding principles for behavior changes to enhance program retention and improve behaviors. This project will pilot a 12-week standard lifestyle intervention in American Indians.
45770680|NCT00642382|Device|Agilus|Hyaluronic acid (Agilus)given by an intra-articular injection into the ankle for a total of 3 injections for 3 consecutive weeks.
45770681|NCT00642382|Device|Normal saline|Normal Saline given by an intra-operative injection into the ankle for a total of 3 injections for 3 consecutive weeks.
45631182|NCT03489629|Drug|Chlorhexidine Gluconate|For subjects able to swish without swallowing, 0.12% chlorhexidine gluconate oral rinse will be used twice daily for 14 days during Days 1-14 and Days 29-42.
45631183|NCT03489629|Behavioral|Environmental Decontamination|"Subjects will be instructed to wipe down all high touch surfaces and medical equipment with surface disinfection wipes daily during Days 1-21 and Days 29-49.~Subjects will also be instructed to wash all linens and towels in hot water once weekly during weeks 1-3 and weeks 5-7."
45631184|NCT02388503|Dietary Supplement|no added fruit extract|
45631185|NCT02388503|Dietary Supplement|fruit extract|
45631186|NCT02388503|Dietary Supplement|fruit extract|
45631187|NCT02388503|Dietary Supplement|fruit extract|
45631188|NCT02388503|Dietary Supplement|fruit extract|
45631189|NCT04748939|Biological|recombinant subunit herpes zoster vaccine|vaccine administration
45770682|NCT04568382|Other|CI-PVP (context-informed pre-visit planning)|may experience a single additional phone call from clinic staff in addition to the standard clinic staff chart review, email and/or phone call prior to diabetes office visit
45631190|NCT05345015|Device|Radiofrequency Energy Transfer|"Radiofrequency Electrical Currents (TECAR) will be delivered using a winback system (Winback, Villeneuve-Loubet, France) propagating radiofrequency waves of 448 kHz using metallic electrodes via a coupling medium. Radiofrequencies will be used in the capacitive mode , which aims to treat superficial /soft tissues in the area. The active plate will be applied sequentially on the skin in the injured or painful region. The base plate will be located to the other side of the injured body region (for back thigh muscle injuries, for example, the base plate will be located on the frontal thigh area, to close the current circuit. Therapy will be applied for 20 minutes, with a target intensity of 40% and a frequency of 0.5Mhz."
45631191|NCT05345015|Device|Transcutaneous Nerve Stimulation|Transcutaneous nerve stimulation (TENS) will be delivered using a Chattanooga Intellect Advanced Combo system (Chattanooga, Hixson, TN 3 7343, USA). Two electrodes will be placed on the skin at a distance so that they cover the entire painful area. The TENS asymmetric biphasic mode (phase 300 ms, frequency 80Hz, continuous cycle) will be applied. The intensity will be adjusted between 0 and 110A, such that it is tolerable by the participant. The total application time will be 20 minutes or equal to that applied for the TECAR group.
45631192|NCT05231291|Other|hand grip strength|Observational study
45631193|NCT05442827|Drug|SHR7280 tablets|SHR7280 tablets 300mg for 12 weeks
45631194|NCT05442827|Drug|SHR7280 tablets|SHR7280 tablets 400mg for 12 weeks
45631195|NCT05442827|Drug|PlaceboSHR7280 tablets blank preparation|Placebo group: SHR7280 tablets blank preparation for 12 weeks
45770683|NCT04568382|Other|Standard PVP (pre-visit planning)|standard clinic staff chart review, email and/or phone call prior to diabetes office visit
45770684|NCT02203006|Biological|OVIHD|7 ml of blood will be taken during a follow-up consultation and kept in a biological collection. Clinical data will be collected in a database.
45770685|NCT05481372|Other|Imaging|Trans-perineal ultrasound and Magnetic resonance image acquisition
45770686|NCT04508322|Device|HGA|Headgear Activator
45770687|NCT04508322|Device|FA|Fixed Orthodontic Appliance
45631196|NCT04479293|Other|Post COVID-19 Functional Satus Scale|scale from 0-64 assessing functional limitation
45631197|NCT02389751|Drug|Carboplatin|Given IV
45631198|NCT02389751|Drug|Ganetespib|Given IV
45631199|NCT02389751|Drug|Paclitaxel|Given IV
45631200|NCT02389751|Radiation|Radiation Therapy|Undergo radiation therapy
45631201|NCT04740047|Diagnostic Test|Ion Endoluminal System|Robotic bronchoscopy with c-arm imaging.
45631202|NCT02390063|Biological|ChAdOx1.5T4|A recombinant simian adenovirus encoding human tumour-associated antigen 5T4
45631203|NCT02390063|Biological|MVA.5T4|A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
45631204|NCT02390063|Drug|Cyclophosphamide|Metronomic cyclophosphamide (50mg bd)
45631205|NCT02388113|Behavioral|accumulated exercise|
45631206|NCT02388113|Behavioral|traditional exercise|
45770688|NCT05476380|Drug|camrelizumab|Camrelizumab:200 mg, IV., d1, q3w; Paclitaxel:175 mg/m2,continuous IV., d1, 24h q3w; Cisplatin:75 mg/m2, iv., d1,q3w
45770689|NCT00637312|Device|Cervical Artificial Disc (Advent™ Cervical Disc)|Advent™ Cervical Disc
45770690|NCT00637312|Device|Hallmark™ Anterior Cervical Plate System|Hallmark™ Anterior Cervical Plate System with AlloQuent Structural Allograft (corticocancellous allograft bone)
45770691|NCT05476302|Other|Cognitive digital treatment|The remote cognitive-rehabilitation treatment was based on Parkinson's adapted cognitive stimulation therapy (CST). Fourteen twice-weekly sessions were planned, followed by one session per week for a duration of six months for maintenance therapy. The treatment took place in groups of 4 patients in remote mode through the Microsoft-Teams platform. All subjects maintained the prescribed drug therapy and regular physiotherapy activity during the intervention.
45631207|NCT02389673|Device|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
45631208|NCT02388035|Drug|Cefotaxime|
45631209|NCT02387723|Biological|Allogeneic adipose derived stem cells (CSCC_ASC)|Culture expanded allogeneic adipose derive stem cells (CSCC_ASC)
45631210|NCT02389439|Drug|Pyronaridine-artesunate|
45631211|NCT02663687|Drug|Recombinant human C1 esterase inhibitor|Subjects will receive escalating doses I-IV as both IV and SC injections
45631212|NCT02663687|Drug|Placebo|Subjects will receive matching placebo
45631213|NCT02663687|Drug|SHP623|SHP623
45631214|NCT02663687|Drug|Placebo|Placebo
45631215|NCT02389205|Other|kinesio group|"kinesio group, The kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting.~The effect of intervention may affected by the varying durations and frequencies of exercise, different state of arthropathy and joint range of motion limitations of ankle , etc."
45631216|NCT02387645|Procedure|Lavage of the Uterus|The lavage will be performed in the operating theatre under general anesthesia. The ALPINE technique includes the following steps. A three way catheter (catheter for uterine and tubal lavage) is inserted into the cervical canal and a balloon is inflated to seal the cervical canal. The patient is put into anti-Trendellenburg positioning. Normal saline is slowly flushed into the uterine cavity and proximal tubes. After the lavage is finished, the balloon is deflated and the catheter is removed. A cap is put on the collection syringe and the syringe is sent to the laboratory.
45631217|NCT02388971|Drug|MLN1202|MLN1202 solution
45770692|NCT00634972|Drug|ACULAR|infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.
45770693|NCT00634972|Drug|REFRESH TEARS|infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.
45770694|NCT00634972|Drug|placebo|
45770695|NCT02553330|Drug|Placebo Cream|
45770696|NCT02553330|Drug|Ruxolitinib Phosphate Cream|
45631218|NCT02388971|Drug|Placebo|MLN1202 placebo-matching solution
45631219|NCT03113591|Procedure|Minimum invasive total hip arthroplasty|Minimum invasive total hip arthroplasty using the osteo introducer system
45631220|NCT03113591|Procedure|Common total hip arthroplasty|Common total hip arthroplasty using common instruments
45631221|NCT03106025|Device|Ultrasound|Each participant will receive an ocular ultrasound which poses minimal to no harm to the participant and the ultrasound results compared to final diagnosis.
45631222|NCT03106025|Other|Ophthalmology Assessment|Number of subjects with retinal detachment per formal ophthalmology assessment. This assessment is a composite measurement which includes the following chief complain, primary impression, right visual acuity, left visual, acuity, ultrasound diagnosis, diagnosis changed, ophthalmology diagnosis.
45631223|NCT05359991|Other|Exercise|Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables
45631224|NCT02663453|Drug|multicomponent lipid emulsion|Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
45631225|NCT02663453|Drug|pure soybean oil lipid emulsion|Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
45631226|NCT02387489|Behavioral|Brief in-person motivational intervention|Brief in-person motivational intervention tailored to participants' risk behaviors, delivered by a nurse.
45631227|NCT02387489|Behavioral|Computerized Brief Intervention|Computer-delivered motivational intervention tailored to participants' risk behaviors.
45770697|NCT00529282|Drug|Ceftobiprole Medocaril|500 mg every 8 hours
45770698|NCT00529282|Drug|Cefepime with or without vancomycin|120-minute infusion [250 mL]
45770699|NCT00623974|Drug|Teriparatide (Forteo)|Subcutaneous Injection Every 12 Hours for 7 Days
45770700|NCT00623974|Drug|Calcium|1000 milligrams by mouth (PO) Every 12 Hours
45770701|NCT00623974|Drug|Calcitriol|0.25 micrograms PO Every 12 Hours
45770702|NCT02550288|Drug|Ezetimibe 10 mg|
45770703|NCT02550288|Drug|Atorvastatin 10 mg|
45770704|NCT02550288|Drug|Placebo for Ezetimibe 10 mg tablet|
45770705|NCT02550288|Drug|Placebo for Atorvastatin 10 mg capsule|
46069990|NCT00806143|Device|repetitive transcranial stimulation (rTMS)|"Repetitive TMS will be administered using a MAGSTIM rapid magnetic stimulator (Magstim Company, Ltd., Whitland, U.K.) and a 70-mm figure-eight shaped coils.~In monolateral treatment in right DLPFC, three 140-second trains will be applied at 1 Hz and at 110% of RMT. There is a 30 seconds intertrain interval (total of 420 stimuli per session). In sequential treatment, the stimulation will be applied in the first to the right and then to the left dorsolateral prefrontal cortex. In right DLPFC will be applied three 140-second trains at 1 Hz and at 110% of RMT. There will be a 30 seconds intertrain interval (total of 420 stimuli per session). In left DLPFC will be applied twenty 5-second trains were applied at 10 Hz and at 100% of RMT. There will be a 25-second intertrain interval (total of 1000 stimuli per session). Patients will be treated from Monday to Friday, for a total of 15 days."
45631228|NCT05225207|Other|Non-interventional|No intervention will be administered.
45631229|NCT02055118|Biological|idursulfase-IT|10mg
45447667|NCT03736083|Device|Freestyle Libre Blood Glucose Monitor|The intervention arm of this study will begin using the Freestyle Libre glucose monitor within 2 weeks of their diabetes diagnosis
45447668|NCT03236246|Drug|KRX-0502|Oral ferric citrate with meals
45447669|NCT05179070|Drug|Carvedilol|the first is the rapid up-titration group, which will get carvedilol up-titration every day, 3.125mg twice daily on the first day, 6.125mg twice daily on the second day, 12.5mg twice daily on the third day and 25mg twice daily on the fourth day consecutively. And the second group will have carvedilol titration according to established guidelines on Heart Failure, start 3.125mg twice daily, and up titrated every 2 weeks
46069991|NCT00806143|Device|unilateral stimulation|Patients will be treated from Monday to Friday, for a total of 15 days in the same timeframe of the active group right sided low frequency stimulation
46069992|NCT00922129|Drug|Sirolimus (Rapamune)|Started at 5 mg (Target levels 6-10mg/mL), Daily, PO, 24 months
46069993|NCT00922129|Drug|Cyclosporin (Neoral) or Tacrolimus (Prograf)|"Cyclosporin: 3-4 mg/kg, BID, PO, 24 months~Tacrolimus: 0-.038-0.045 mg/kg, BID, PO, 24 months"
46069994|NCT02553655|Procedure|4x 5min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 millimeters of mercury (mmHg) above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 5min and is followed by 5 minutes of reperfusion/rest. This will be repeated 4 times.
46069995|NCT02553655|Procedure|3x 10min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 mmHg above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of reperfusion/rest. This will be repeated 3 times.
46069996|NCT02553655|Procedure|3x 10min Sham Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 40 mmHg, sufficient to apply pressure but not affect blood flow. The presence of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of rest. This will be repeated 3 times.
45447670|NCT05178836|Drug|F520+F007|"Drug: F007~F007 is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC).~Drug: F520~F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)."
45631230|NCT02055118|Other|No IT treatment|Standard of Care
45913482|NCT02023203|Procedure|Totally Extraperitoneal laparoscopic inguinal hernia repair|Laparoscopic hernioplasty
45447671|NCT03477500|Drug|Cyclophosphamide and ATG|Hematopoetic stem cell transplantation
45631231|NCT04439825|Drug|Botulinum Neurotoxin|glabella, forehead lines and/or lateral canthal lines
45631232|NCT04439825|Drug|Placebo|Saline solution (preservative free)
45631233|NCT04439747|Other|Ultrasound, DXA, hormonal tests|Diagnostic tests in selected groups with investigation of revealed hormonal disorders
45631234|NCT02388581|Drug|Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole|Anti-H. pylori Therapy
45631235|NCT02387411|Other|High-intensity interval exercise training|High-intensity interval exercise training [4 reps * (4 min at 80% VO2peak + 3 min at 50% VO2peak)]
45631236|NCT02387411|Other|Combined exercise training|High intensity [2 reps * (4 min at 80% VO2peak + 3 min at 50% VO2peak)] and strength exercise training (2-4 sets, 10-12 reps, 60-65% 1RM, for quadriceps and hamstrings, 14 min in total)
45631237|NCT02387333|Procedure|Polypropylene Mesh Stoma reinforcement technique with ileal conduit urinary diversion|"After standard steps of radical cystectomy and sparing of distal 15 cm of ileum as a conduit for diversion.~A preferred rectal muscle splitting approach is preferred for IC exteriorization.~Dissection of subcutaneous fat off the rectus sheath will be accomplished to create a potential space for mesh placement.~Then, 5 x 5 cm polypropylene mesh will be placed and incised at the center to create an orifice to allow IC exteriorization.~The mesh is then fixed to underlying rectus sheath with 1-0 non-absorbable proline sutures.~The IC is exteriorized through the central orifice and then fixed to the peritoneum and to the cut-edges of the rectus muscle using 3-0 polyglactin sutures.~A 12 CH subcutaneous tube drain will be left and the subcutaneous tissue is closed to collapse the dissected space around the mesh.~The stoma is then everted and fixed to the skin."
45631238|NCT02387333|Procedure|Ileal conduit urinary diversion|In this group, no mesh will be applied with ileal conduit urinary diversion
45631239|NCT02387567|Drug|Lidocaine|Paraspinal block with 3ml lidocaine injection at 1%.
45935283|NCT00073593|Drug|Bivalirudin|250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of surgery with the option to increase or decrease the infusion in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT) >300 seconds (s).
45935284|NCT00073593|Drug|Heparin|: Per institutional practice, at 1.5-3.5 mg/kg (200-400 U/kg) IV bolus to achieve a target ACT of >300 s followed by weight-adjusted boluses as needed during surgery to achieve/maintain the target ACT. Batches from hospital stock.
45935285|NCT00073593|Drug|Protamine|Per institutional practice. Batches from hospital stock.
45935286|NCT00220402|Drug|SPM 907|
45447672|NCT03477500|Drug|Alemtuzumab|Alemtuzumab (Lemtrada)
45935287|NCT00220441|Behavioral|Aerobic exercise|
45447673|NCT03477500|Drug|Cladribine Pill|Cladribine (Mavenclad)
45770706|NCT02550288|Behavioral|Diet control/Daily Exercise|Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)
46069997|NCT00804037|Procedure|Injection Snoreplasty|Injection of 0,5 ml of the sclerosing agent into the soft palate (3 points)
45447674|NCT03477500|Drug|Ocrelizumab|Ocrelizumab (Ocrevus)
45447675|NCT01314170|Device|Susanna Implant|device
45447676|NCT03637088|Device|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
45447677|NCT03637088|Device|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask"
45447678|NCT02937584|Drug|GP MDI (PT001) 14.4 μg|Glycopyrronium
45447679|NCT02937584|Drug|FF MDI (PT005) 9.6 μg|Formoterol Fumarate
45447680|NCT00179621|Drug|Lenalidomide 5 mg|Lenalidomide 5 mg daily 28/28 days
45631240|NCT02387567|Drug|Sham Lidocaine|Sham injection, without lidocaine.
45631241|NCT02387567|Other|Standard treatment|Standard treatment only, without lidocaine or sham injection.
45631242|NCT04715386|Drug|StrataXRT|Patients will be asked to start topical application of their allocated topical preparation on the area of skin that will be irradiated at the onset of radiation therapy, every day until skin symptoms subside (see patient information pamphlet). Apply twice per day and can be reapplied as skin symptoms arise or as needed. The amount of StrataXRT provided to each patient will be recorded throughout treatment.
45631243|NCT02387177|Behavioral|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
45631244|NCT02387177|Behavioral|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
45631245|NCT02389127|Device|Continuous glucose monitor (Dexcom, San Diego, CA)|(Group B) patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor (Dexcom, San Diego, CA) for 2 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks.
45631246|NCT02383121|Drug|Midodrine|Not appliciable
45447681|NCT00179621|Drug|Lenalidomide 10 mg|Lenalidomide 10 mg daily 21/28 days
45631247|NCT02387021|Procedure|Continuous femoral nerve block|
45631248|NCT02387021|Procedure|Continuous adductor canal block|
45631249|NCT02387021|Procedure|infragluteal Sciatic nerve block|
45631250|NCT02387021|Drug|Ropivacaine 0.2%|
45631251|NCT02387021|Drug|Saline|
45631252|NCT02386943|Drug|Sitagliptin|100mg po once.
45631253|NCT02386943|Drug|Saxagliptin|5mg po once.
45631254|NCT02386943|Drug|Blank control|No medication is taken.
45631255|NCT02084056|Drug|Linagliptin|Linagliptin
45631256|NCT02084056|Drug|Metformin|Metformin
45631257|NCT02084056|Drug|Linagliptin/Metformin FDC|Linagliptin/Metformin FDC
45631258|NCT02386787|Device|Ultrasonography|an ultrasonography will be conducted before the anesthesic procedure to provide reliable quantitative information about the volume of gastric content.
45631259|NCT02386631|Device|Custom Made Orthotic|Provides longitudinal arch support
45631260|NCT04714372|Drug|Daratumumab/rHuPH20|Daratumumab 1800 mg co-formulated with 30,000 units of hyaluronidase (rHuPH20) given subcutaneously into subcutaneous tissue of the abdomen approximately 3 inches [7.5 cm] to the right or left of the navel over approximately 3-5 minutes on Day -12 and Day -5 prior to the 1st FT538 infusion, and on Day +3, Day+10, and Day+17 approximately 48 hours after each FT538 infusion.
45631261|NCT04714372|Drug|FT538|FT538 is administered as an IV infusion via gravity using an IV administration set with an in-line filter at the patient's assigned dose levels (DL) on Day 1, Day 8, and Day 15
45631262|NCT04714372|Drug|Fludarabine|Fludarabine 25 mg/m^2 is administered as a 1 hour intravenous (IV) infusion per institutional guidelines once a day on 2 consecutive days (Day -4, and Day -3).
45631263|NCT04714372|Drug|Cyclophosphamide|Cyclophosphamide 300 mg/m^2 is administered as a 2 hour intravenous (IV) infusion per institutional guidelines once a day on the same days that fludarabine is given.
45631264|NCT02386709|Device|FDG PET|FDG PET1 before neoadjuvant chemotherapy FDG PET2 after one cycle of neoadjuvant chemotherapy
45770707|NCT01954576|Device|NovoTTF-100A|
45770708|NCT01954576|Procedure|Quality-of-life assessment|
45631265|NCT04787471|Combination Product|30 minute photoactivation of riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 3mW/cm2 UVA light for 30 minutes
45631266|NCT04787471|Combination Product|10 minute photoactivation of riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 9mW/cm2 UVA light for 10 minutes
45631267|NCT02383277|Other|Stretching|Stretching of the rib cage muscles
45631268|NCT02383277|Other|Control|Rest without stretching (sham)
45631269|NCT02383277|Other|Exercise|Constant load exercise on a bike
45631270|NCT02382887|Procedure|tracheal intubation|tracheal intubation with the Airtraq
45631271|NCT02382887|Device|Airtraq|
45631272|NCT02382887|Device|fiberscope|
45631273|NCT02386397|Drug|Regorafenib|Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment
45631274|NCT02386397|Drug|GEMOX|mGEMOX: infusion on days 1 and 8: Gemcitabine 900 mg/m² IV in 30 minutes Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine
45631275|NCT02386475|Other|placebo|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
45770709|NCT01954576|Genetic|Laboratory biomarker analysis|
45770710|NCT00610558|Device|Arm 1: Juvenile Myoclonic Epilepsy|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
45770711|NCT00610558|Device|Arm 2: Frontal Lobe Epilepsy|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
45770712|NCT00610558|Device|Arm 3: Normal Controls|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
45770713|NCT00380146|Drug|sulfadoxine-pyrimethamine|
45935288|NCT00220480|Drug|escitalopram|10 to 30 mg / day
46069998|NCT00806299|Drug|Loperamide / Red Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without red grapefruit juice
45770714|NCT05476146|Procedure|Rerouting of the track in high anal fitula|Treatment of high anal fistula by rerouting
45770715|NCT00496756|Drug|Sorafenib|initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily.Intrapatient dose escalation will occur providing no dose limiting toxicity (Grade 3 or 4) is observed. Dose level 2 600mg. Dose level 2 800mg
45770716|NCT03985176|Device|ROTEM|ROTEM measurements 24,48, 72, 120, 192 and 288 hours from aneurysmal SAH
45770717|NCT03985176|Procedure|EEG|Continuous EEG-monitoring after aneurysm treatment until patient transferred to ward or up to 14 days after aneurysmal SAH
45770718|NCT03985176|Procedure|bilateral compression ultrasound of the lower extremity veins|to exclude asymptomatic deep venous thrombosis once over days 3 to 7
45770719|NCT00379366|Device|External ionizing radiations|14 Gy in one time
45770720|NCT00500890|Drug|Carboplatin|350 mg/m^2 by vein, Over 2 Hours x 2 Days
45770721|NCT00500890|Drug|Cyclophosphamide|1 g/m^2 by vein, Over 1 Hour x 2 Days
45631276|NCT02386475|Drug|citalopram|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
45631277|NCT02386475|Drug|sinemet plus|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
45631278|NCT02382731|Behavioral|Usual care + letters|A series of five postal educational reminders sent on behalf of each hospital's interventional cardiology team to the patient approximately 4, 8, 20, 32, and 44 weeks post-MI procedure, with an insert for the family physician and pharmacist at approximately 4 and 8 weeks post-MI procedure.
45631279|NCT02382731|Behavioral|Usual care + letters + automated calls|A series of five postal educational reminders as per the usual care + letters arm plus interactive voice response phone calls to the patient delivered approximately 2 weeks after the letters, as well as personalized telephone follow up by trained lay health workers for patients identified by the interactive voice response system as non-adherent. The automated algorithm is designed to identify patients who are non-adherent and who may benefit from personalized educational phone call and/or system navigation support by the lay health worker. Lay health workers will not provide clinical advice.
45770722|NCT00500890|Drug|Etoposide|100 mg/m^2 by vein, Over 1 Hour x 5 Days
45770723|NCT00500890|Drug|Vincristine|1.5 mg/m^2 (by vein)IV Push Over 15 Minutes On Day 5
45770724|NCT00500890|Radiation|Radiation Therapy|Radiation treatment over a period of about 6 weeks.
45770725|NCT05469672|Other|Low-level laser therapy|For LLLT, laser treatment will be applied using gallium-aluminum-arsenide (GaAIAs, infrared laser) diode laser (Chattanooga, Mexico, USA) at a wavelength of 904 nm, output power of 240 Mw and a frequency of 5000 Hz. The spot area is about 0.5 cm2. A total of 9 points will irradiated along the glenohumeral joint, with a power density of 3 j/cm2 at each point. The application time was 50 seconds to each point. The total dose per shoulder was 27 J per treatment. Three sessions of LILT therapy per week will administered over a three-week period.
45770726|NCT05469672|Other|High-intensity laser therapy|HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the shoulder area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first three sessions consisted of a 75-second intermittent phase analgesic effect at 8 W and 10 J/cm2 for a total energy of 100 J. The following six sessions consisted of a continuous 30-second bio stimulating effect with a dosage of 12 W 120 J/cm2. Over the course of three weeks, nine treatment sessions of HILT will be given.
46069999|NCT00806299|Drug|Loperamide/ White Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without white grapefruit juice
45447682|NCT00179621|Drug|Placebo|Placebo, matching to active study drug arms
45447683|NCT02531399|Device|FDOCT|Measurement of retinal blood velocities
45447684|NCT02531399|Device|LDV|Measurement of retinal blood velocities
45631280|NCT05136443|Drug|loteprednol etabonate 0.25% ophthalmic suspension|tapering dose
45631281|NCT05134649|Drug|BOTOX|Intramuscular Injection
45631282|NCT05101031|Device|Starling SV|The Starling SV will monitor the change in hemodynamic variables (i.e. CO, SV, HR, SV) as assessed during the initial fluid resuscitation in individuals with hypotension related to infection.
45631283|NCT02386163|Biological|MSC from synovial membrane and infrapatellar Fat Pad|
45770727|NCT00000736|Drug|Zidovudine|
45770728|NCT05480982|Behavioral|Cognitive functional therapy via tele rehabilitation|Participants in the CFT group will be treated by a physiotherapist with seventeen years of clinical experience and that has attended six CFT workshops with three of the international tutors of the method. She has completed 212 hours of training including workshops, patient examinations and a pilot study under the supervision of a physiotherapist with more than seven years of clinical experience in CFT. Another two physiotherapists, one with more than fifteen years and the other with more than ten years of clinical experience, and both with more than 106 hours of CFT training including CFT via tele physiotherapy, will complete the staff.
45770729|NCT05480982|Other|Pilates via tele rehabilitation|Physiotherapist will have the freedom to judge about the exercises´ progression and the need of adaptation considering both the level of difficulty to perform each exercise according to the original proposal and the individual´s demands. The treating physiotherapists will have at least 2 years of clinical practice in Pilates and clinical experience in Pilates via teleconference.
46070000|NCT00806299|Drug|Loperamide / Pink Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without pink grapefruit juice
45631284|NCT02386241|Other|saliva or blood sample collection|Single saliva or blood sample measuring 10mL for genomic analysis.
45631285|NCT02382653|Drug|oral perixicam|Oral adminstration of buccal perixicam
45631286|NCT02386085|Procedure|Osteopathic manipulative treatment (OMT)|OMT will be provided as part of the patient's health care, prior to enrollment in the study. All participants would have received the same intervention (OMT) if they had not enrolled in the study.
45631287|NCT02382809|Drug|DC071|Mouthwash, twice daily
45631288|NCT02382809|Drug|Placebo|Mouthwash, twice daily
45770730|NCT05480748|Device|monitoring|ORI warning time, SpO2 warning time, added time were recorded.
45770731|NCT00379444|Behavioral|Standard intervention (counseling + self-help written materials)|counseling
45770732|NCT00379444|Behavioral|Enhanced Intervention (same as standard treatment plus 10-15 min of counseling and a culturally tailored video)|counseling
45631289|NCT02382263|Drug|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 days 1 & 15 in a 28 days cycle
45631290|NCT02382263|Drug|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 days 1,8 & 15 in a 28 days cycle
45631291|NCT02382263|Drug|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1 & 15 in a 28 days cycle
45770733|NCT00379522|Drug|Vasopressin|10 minutes after standard shock treatment 10 IU arginine vasopressin will be injected; if shock persists for 5 minutes, another 10 IU arginine vasopressin will be injected; after 5 minutes persisting shock, the last 10 IU arginine vasopressin will be injected; Total duration: approx. 15 minutes; Dose per intravenous injection: 10 IU; max. dose: 30 IU arginine vasopressin
45770734|NCT00379522|Drug|Saline placebo|Placebo for arginine vasopressin
45770735|NCT00437398|Biological|Islet Transplant|Purified pancreatic islets
45770736|NCT03496896|Other|TARGET|The pre-discharge component includes mainly patient information, medication reconciliation, patient education, planning of a first post-discharge primary care physician visit with a timely discharge summary sent to the primary care physician. Two follow-up phone calls are made by a nurse, at D3 and D14, and include the assessment of the general health condition, the verification of the follow-up care plan, a reinforcement of the patient education, and review with the patient of the medication list with assessment of potential adverse drug events.
45770737|NCT03275064|Biological|LNA043|LNA043 intra-articular injection
45770738|NCT03275064|Other|Placebo|Placebo intra-articular injection
45770739|NCT00593320|Radiation|Stereotactic Radiosurgery|
45770740|NCT00421954|Drug|Ziprasidone|subjects will use ziprasidone
45631292|NCT02382263|Drug|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1,8 & 15 in a 28 days cycle
45631293|NCT02386007|Drug|DW-3101_150mg|
45770741|NCT00392860|Device|Natural-Fit|Ergonomic handrim for wheelchairs
45770742|NCT00392860|Device|PalmRim|Ergonomic handrim for wheelchair
45447685|NCT02531399|Device|DVA|Measurement of retinal vessel diameters
45447686|NCT02531399|Device|LSFG|Imaging of retinal blood flow
45447687|NCT04862780|Drug|BLU-945|Oral administration
45447688|NCT04862780|Drug|osimertinib|Osimertinib tablets for oral administration
45631294|NCT02386007|Drug|DW-3101_300mg|
45631295|NCT02386007|Drug|DW-3101_600mg|
45631296|NCT02386007|Drug|Placebo|
45631297|NCT02382419|Drug|carrageenan-containing gel|Applied vaginally
45631298|NCT02382419|Other|Placebo|Applied vaginally
45631299|NCT02382419|Other|Laboratory Biomarker Analysis|Correlative studies
45631300|NCT02382419|Other|Questionnaire Administration|Ancillary studies
45631301|NCT02382341|Device|BIOSURE™ HEALICOIL™ PK Interference Screw|Subjects will receive the appropriate sized BIOSURE™ HEALICOIL™ PK Interference Screw
45631302|NCT02382185|Other|Fluid optimisation|The intervention will consist of optimising stroke volume with 250ml of Hartmanns solution
45631303|NCT02382185|Drug|Optimisation of blood pressure|Phenylephrine infusion will be used to target a mean arterial blood pressure to within 30% of baseline (preoperative) value
45631304|NCT02382185|Device|Application of clearsight monitor|The clear sight monitor will be applied to measure stroke volume.
45631305|NCT02382107|Other|Observational|TB suspects, who present themselves to the pulmonary ambulance at the Marius Nasta Instiute
45631306|NCT02385851|Drug|CHS-1701|
45631307|NCT02385851|Drug|Pegfilgrastim|
45631308|NCT02385773|Dietary Supplement|PTM202|Administration of study nutritional product once per day for 3 days starting immediately after enrollment
45631309|NCT02385773|Dietary Supplement|Enfamil Puramino|Administration of 30 ml of Enfamil Puramino as placebo once per day for 3 days starting immediately after enrollment
45770743|NCT00392860|Device|Handrim Control Group|Participants were given a new standard handrim to test. This intervention group is the control group.
45770744|NCT01662336|Drug|Lopinavir / ritonavir|Prescribed according to the product monograph and physician's discretion.
45770745|NCT01662336|Behavioral|Kaletra Adherence Support Assistance Program|A customized support network for patients treated with lopinavir / ritonavir that offers individual counseling with an HIV experienced nurse who assists patients with various aspects of their therapy including life-style changes, emotional stress, and adverse events, and may provide access to various healthcare professionals or may offer other types of support such as transportation, exercise, etc.
45770746|NCT00387244|Device|Precision for Spinal Cord Stimulation|Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
45770747|NCT00000766|Drug|Foscarnet sodium|
45770748|NCT00000766|Drug|Ganciclovir|
45770749|NCT00000772|Drug|Ribavirin|
45770750|NCT00000772|Drug|Didanosine|
45770751|NCT05480436|Biological|coadministration|the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and IIV4 on Day 0, and the coadministration of BBIBP-CorV and PPV23 on Day 28
45770752|NCT05480436|Biological|COVID-19 vaccine|received two doses of inactivated COVID-19 vaccine (BBIBP-CorV)
45770753|NCT05480436|Biological|IIV4+PPV23|received one dose of IIV4 on Day 0, and one dose of PPV23 on Day 28
45935289|NCT00220519|Drug|Lactobacillus GG|
45770754|NCT00572260|Drug|daptomycin 6 mg/kg IV|daptomycin 6 mg/kg IV given during induction phase as a one-time prophylactic dose for patients undergoing cardiac valve replacement and coronary artery bypass grafting (CABG) who are at increased risk for infection due to methicillin-resistant Staphylococcus aureus (MRSA)
45770755|NCT00000778|Drug|Isoniazid|
45770756|NCT00000778|Drug|Pyridoxine hydrochloride|
45631310|NCT02385929|Behavioral|Swallowing therapy & resistance training|"i) Individual instructions in swallowing and mouth opening exercises 3 days per week by occupational therapist throughout radiotherapy, ii) Progressive resistance training twice weekly by physiotherapist, either individually or group based, throughout radiotherapy, iii) Daily home-based swallowing and mouth opening exercises from beginning of treatment until 2 months after end-of-treatment.~iv) Weekly follow-up phone contacts with occupational therapists from end-of-treatment and 2 months onwards."
45631311|NCT02385695|Procedure|Posterior Dynamic Stabilization|
45770757|NCT00000778|Drug|Levofloxacin|
45631312|NCT02385695|Procedure|Internal Fixation and Fusion|
45770758|NCT02549352|Drug|LEO43204 gel|
45770759|NCT02549352|Drug|Vehicle gel|
45770760|NCT05480358|Dietary Supplement|Fasting-Mimicking Diet ProlonADTM|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides ~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide ~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
45447689|NCT00179309|Drug|Docetaxel|35 mg/m^2 intravenous 30-60 minutes once a week for 3 consecutive weeks with 1 week off drug.
45447690|NCT00179309|Biological|PANVAC-V|2 x 10^8 PFU
45447691|NCT00179309|Biological|PANVAC-F|1 x 10^9 PFU
45447692|NCT00179309|Biological|Sargramostim|Given subcutaneously under the skin, usually in the thigh on the day of vaccination and daily for the next 3 days.
45770761|NCT00000796|Drug|Cycloserine|
45770762|NCT00000796|Drug|Ethionamide|
45770763|NCT00000796|Drug|Capreomycin sulfate|
45770764|NCT00000796|Drug|Aminosalicylic acid|
45770765|NCT00000796|Drug|Streptomycin sulfate|
45770766|NCT00000796|Drug|Ethambutol hydrochloride|
45447693|NCT03594500|Other|PockeTalker|The intervention group will receive PockeTalkers (hearing assistance devices) while they receive care in the ED
45447694|NCT03594500|Other|No PockeTalker|The control group will not receive PockeTalkers while they receive care in the ED
45447695|NCT00178685|Behavioral|Self-determination Intervention for Tobacco Dependence|autonomy supported behavioral intervention for tobacco dependent individuals
45447696|NCT02933528|Drug|DSXS Topical product|once daily for 28 days
45447697|NCT01075919|Dietary Supplement|n-3 PUFAs|1 g DHA-rich fish oil taken daily for 12 weeks
45447698|NCT01075919|Dietary Supplement|Placebo|1 g olive oil taken daily for 12 weeks
45447699|NCT01075919|Dietary Supplement|n-3 PUFAs|1 g EPA-rich fish oil taken daily for 12 weeks
45631313|NCT02382029|Drug|Clonazepam|Active medical treatment for burning mouth syndrome
45631314|NCT02382029|Other|acupuncture|Traditional chinese acupuncture
45631315|NCT02385617|Drug|Octreotide|Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
45631316|NCT02385617|Drug|Placebo|0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
45631317|NCT02385539|Drug|The impact of 10 independent variables on the likelihood of not developing hypotension after intrathecal injection.|The study will be conducted to assess the impact of a 10 independent variables (dose and combination of Levobupivacaine with Fentanyl or Sufentanil, age, basal systolic blood pressure (SBP), basal mean arterial pressure (MAP), time to lowest spinal SBP, upper limit of sensory block (dermatoma level), time intervals of sensory recovery for two consecutive dermatoma level (two-segment regression), time intervals of sensory recovery to the twelfth thoracic dermatoma (T12 regression), time intervals of sensory recovery to the first sacral dermatoma (S1 regression) and Body Mass Index) on the likelihood of not developing hypotension after intrathecal injection.
45770767|NCT00000796|Drug|Amikacin sulfate|
45770768|NCT00000796|Drug|Isoniazid|
45770769|NCT00000796|Drug|Pyrazinamide|
45770770|NCT00000796|Drug|Pyridoxine hydrochloride|
45770771|NCT00000796|Drug|Levofloxacin|
45770772|NCT00000796|Drug|Rifampin|
45770773|NCT00000796|Drug|Clofazimine|
45770774|NCT00000802|Drug|Atovaquone|
45770775|NCT00000802|Drug|Dapsone|
45770776|NCT00271102|Procedure|anterior vaginal repair (colporrhaphy)|vaginal repair
45770777|NCT00271102|Procedure|abdominal paravaginal defect repair|abdominal repair
45770778|NCT02389946|Device|Orsiro DES|Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
45770779|NCT02389946|Device|Xience DES|
45770780|NCT00245128|Drug|imatinib mesylate|Once daily oral administration of Imatinib Mesylate at a dose of 600mg for 12 months.
45770781|NCT00268450|Biological|bevacizumab|"Before surgery: given as a 15mg/kg IV over 90 minutes every 21 days for 4 cycles~After surgery: given as a 15mg/kg IV over 90 minutes every 21 days for 3 cycles"
45770782|NCT00268450|Drug|cisplatin|Before surgery: given as a 70mg/m2 IV over 60 minutes every 21 days for 4 cycles
45770783|NCT00268450|Drug|gemcitabine hydrochloride|Before surgery: given as a 1000mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
45770784|NCT00268450|Drug|paclitaxel|After surgery: given as a 175 mg/m2 dose ver 3 hours every 21 days for 3 cycles
45631318|NCT02385461|Drug|Low Molecular Weight Heparins (LMWHs)|
45631319|NCT02381717|Other|ultra-sound guide|Patients randomized to this arm will have the femoral nerve block with the guidance of a bedside ultrasound
45770785|NCT00268450|Procedure|cysectomy|
45631320|NCT02381717|Drug|bupivacaine|
45631321|NCT02381717|Drug|morphine|
45631322|NCT02381951|Device|spinal cord stimulation (St Jude Medical)|implantation of a spinal cord neurostimulation system : St Jude Medical Octrode 3183 (R) peridural lead connected to a St Jude Medical EonC (R) primary cell IPG
45770786|NCT00000808|Drug|Nevirapine|
45770787|NCT01892384|Drug|Placebo|matching placebo
45770788|NCT01892384|Drug|BI 409306|low dose
45770789|NCT01892384|Drug|BI 409306|medium dose
45770790|NCT01892384|Drug|BI 409306|high dose
45631323|NCT02381639|Behavioral|One interview of 90 minutes with a part of cognitive assessment and a part of self-assessment|The content of the assessment will be the same for all subjects and will consist of a part of cognitive assessment (National Reading Test, Rey Osterreich Complex Figure, Hayling Sentence Completion Task, verbal memory, digit sequencing, token motor task, verbal fluencies, symbol coding, tower of London) and self-assessment (Mini International Neuropsychiatric Interview, Beck Depression Inventory, State Trait Anxiety Inventory, Wender Utah Rating Scale, Adult Self-Report Scale Symptom Checklist, UPPS Impulsive Behavior Scale)
45770791|NCT00000814|Drug|Nevirapine|
45770792|NCT00000814|Drug|Zidovudine|
45770793|NCT00000814|Drug|Didanosine|
45770794|NCT02661932|Drug|Letrozole|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol Standard Protocol: letrozole is orally administered 2 tablets per day (2,5mgx2/d) from cycle day 2 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering. GnRH antagonist is administered as soon as at least one follicle reaches 14 mm.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins and GnRH antagonist, until ovulation triggering.~Oocytes are collected 36h after ovulation triggering. All patients receive GnRH antagonist after oocyte retrieval for 3-7 days or until chemotherapy starts, to induce luteolysis."
45770795|NCT00423124|Genetic|HSV-TK|Infusion of genetically modified lymphocytes (1x10^6-1x10^7 c/kg): first at +21-+49 days after HSCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
45770796|NCT02809586|Behavioral|SMI + I|This 8-week social media based intervention consists of e-coaches delivering positive content to facilitate peer interaction. Participants will earn incentives for interaction during the intervention (8 weeks).
45770797|NCT02809586|Behavioral|SMI|This 8-week social media based intervention consists of e-coaches delivering positive content to facilitate peer interaction. This group will NOT receive incentives for their participation in the secret group.
45770798|NCT02658890|Drug|BMS-986205|
45770799|NCT02658890|Drug|Nivolumab|
45770800|NCT02658890|Drug|Ipilimumab|
45770801|NCT00177970|Drug|intravenous immunoglobulin G (IVIG)|IVIG to be given IV to patients with C-Diff .
45770802|NCT00177970|Drug|Placebo|Placebo to be given IV to patients with C-Diff
45770803|NCT01892618|Drug|Prevenar 13|13-valent pneumococcal conjugated vaccine
45447700|NCT00177671|Drug|Escitalopram|Escitalopram, 10mg to 20mg daily.
45447701|NCT00177671|Drug|Donepezil|Donepezil, 5mg to 10mg daily.
45447702|NCT00177671|Drug|Venlafaxine|Venlafaxine, 150mg to 300mg daily.
45447703|NCT00177671|Drug|Placebo|
45447704|NCT00177671|Drug|Duloxetine|
45447705|NCT02933060|Other|Normal saline (1000 mL)|
45631324|NCT02385383|Drug|Iron-III Isomaltoside 1000|Protocol for optimizing preoperative Hb using IV Iron-III Isomaltoside 1000
45631325|NCT02385383|Other|Standard Care|Standard Care in a historical control cohort
45447706|NCT02933060|Other|Control|
45447707|NCT05178602|Behavioral|Tai Chi Intervention Group|Tai Chi intervention group: routine treatment and tai Chi exercise,5 times a week.
45770804|NCT01892618|Drug|Pneumovax|23-valent pneumococcal polysaccharide vaccine
45770805|NCT02379338|Drug|[18F]Fluortriopride|All subjects will receive a [18F]Fluortriopride PET/CT scan
45770806|NCT00088972|Drug|celecoxib|Given orally
45770807|NCT00088972|Other|placebo|Given orally
45770808|NCT01892696|Device|varying inspiratory flow waveforms|inspiratory flow waveform was changed, in a randomized sequence using a computer ,to one of the following modalities: 1) constant inspiratory flow; 2) decelerating inspiratory flow Each inspiratory flow waveform was maintained for 30 min. During the last 5 min of this period the physiological signals were collected and measures were performed.
45770809|NCT00089128|Drug|gemcitabine hydrochloride|
45770810|NCT00089128|Drug|irinotecan hydrochloride|
45770811|NCT00000832|Biological|MF59|
45770812|NCT00000832|Biological|rgp120/HIV-1 SF-2|
45770813|NCT01892774|Procedure|Radiofrequency catheter ablation|Extended PVAI plus ablation of non-pulmonary vein (non-PV) triggers and complex fractionated electrograms (CAFÉ)
45770814|NCT00000838|Drug|Lamivudine|
45770815|NCT00000838|Drug|Stavudine|
45770816|NCT00000838|Drug|Zidovudine|
45770817|NCT00000838|Drug|Didanosine|
45770818|NCT01892852|Procedure|Acupuncture|Acupuncture treatment will be performed by licensed doctors in Traditional Korean Medicine using 0.20 mm (diameter) X 0.40 mm (length) sized disposable acupuncture 3 times per week for 3 weeks. Acupuncture points are GV20, GB20 (bilateral), LI11 (bilateral), LI10 (bilateral), EX-UE9 (bilateral), ST36 (bilateral), ST40 (bilateral), and EX-LE10 (bilateral). Each session lasts 20-30 minutes.
45770819|NCT02651948|Procedure|Transperineal, MRI-guided, prostate biopsy|
45770820|NCT02651948|Procedure|Transrectal prostate biopsy (TRB):|
45913483|NCT02023216|Device|Pacifier|The effect of NNS on GER features will be evaluated in preterm infants suffering from GER symptoms, for which a 24-hour pH-MII monitoring has been scheduled. During the monitoring period each infant will receive 8 meals: 4 meals will be followed by NNS, applied by pacifier, while the other 4 not. The sequence of NNS application will be consecutively alternated in study participants. At least 2 hours of NNS are required for the validity of each post-prandial evaluation; measures to fix the pacifier will be strictly forbidden. In the subgroup of babies with recurrent desaturations a simultaneous non-invasive 6-hour PSG monitoring comprehensive of 2 meals (one followed by NNS, the other not), will be performed to evaluate the effect of NNS on apneas, bradycardias and hypoxic episodes.
45631326|NCT02385305|Device|Pressure support ventilation by anesthesia machine (Apollo, Dräger)|Pressure support ventilation will be applied by anesthesia machine (Apollo, Dräger) with pressure support (PS) of 3, 8, 13 and 18 cmH2O in this order, with slope of 1.0 second and no PEEP. The fraction of inspired oxygen will be titrated to achieve SpO2 over 98%. Five minutes will be allowed to achieve equilibrium at each PS level after which an additional recording of one minute of data will be obtained. Once the Pressure support ventilation is completed at 18 cmH2O, ventilation will be carried out in reverse order of PS; 13, 8 and 3 cmH2O of PS.
45913484|NCT02023229|Dietary Supplement|Branched-chain aminoacids|
45913485|NCT02023229|Other|High-fiber high protein diet|
45447708|NCT05178368|Procedure|Surgical/ Transcatheter aortic valve replacement|The choice of intervention will be made by the local clinical team. The timing of intervention will be determined by randomisation as part of the main EASY/EVOLVED trials
45631327|NCT02385227|Other|Exclusive blu™ e-cigarette A1|Classic Tobacco rechargeable e cigarette
45631328|NCT02385227|Other|Exclusive blu™ e-cigarette A2|Magnificent Menthol rechargeable e cigarette
45631329|NCT02385227|Other|Exclusive blu™ e-cigarette A3|Cherry Crush rechargeable e cigarette
45631330|NCT02385227|Other|Dual blu™ e-cigarette and usual brand B1|Classic Tobacco rechargeable e cigarette and a usual brand combustible cigarette
45631331|NCT02385227|Other|Dual blu™ e-cigarette and usual brand B2|Magnificent Menthol rechargeable e cigarette and a usual brand combustible cigarette
45631332|NCT02385227|Other|Dual blu™ e-cigarette and usual brand B3|Cherry Crush rechargeable e cigarette and a usual brand combustible cigarette
45631333|NCT02385227|Other|Nicotine product cessation C|Nicotine cessation
45631334|NCT02385149|Other|whole grain wheat|A twelve week intervention of 98g whole grain wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
45631335|NCT02385149|Other|refined wheat|A twelve week control intervention of refined wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
45631336|NCT02381171|Device|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) 10Hz (1600 pulses)
45631337|NCT02381171|Device|Sham rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) with Placebo coil
45631338|NCT02381171|Device|Active Neuroacupuncture|Neurofunctional electrical acupuncture 1Hz, continuous, 10mA current for 20 minutes.
45631339|NCT02381171|Device|Sham Neuroacupuncture|Neurofunctional electrical acupuncture without needles
45913486|NCT02023255|Drug|JNJ-39393406|In Part A of the study, participants will receive single dose of JNJ-39393406 50 mg, 150 mg, 450 mg, 1,350 mg, and 2,700 mg once daily for 7 consecutive days. In Part B of the study, participants will receive single dose of JNJ-39393406 based on the PK data from Part A of the study once daily for 13 consecutive days.
45447709|NCT03235154|Drug|sofosbuvir/velpatasvir|12 week treatment with once daily sofosbuvir/velpatasvir fixed dose combination therapy. Tablets are formulated with 400mg sofosbuvir and 100mg velpatasvir in pink, diamond-shaped, film coated tablets.
45631340|NCT02381249|Drug|Octreotide|Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen
45631341|NCT02381249|Drug|Placebo|Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen
45631342|NCT05003687|Drug|Lu AG06474|solution, orally (Parts A and B)
45770821|NCT02375126|Procedure|Electroencephalography|Electroencephalography (EEG) is a relatively inexpensive measurement of basic brain activity. Traditional EEG techniques rely on the clinician to visually examine the electrical current waveforms to identify abnormal signal patterns and slowing. Abnormalities on EEG have been reported following CO poisoning, though the literature is scarce. While current EEG technologies record EEG signals digitally, rather than writing directly to paper, computer-assisted analysis of the data (quantitative EEG, or qEEG) has not been widely embraced, in part because clinicians are unsure what patterns revealed by computer-assisted analysis represent abnormal activity.
45770822|NCT00001768|Drug|Intravenous immunoglobulin|
45770823|NCT02371460|Dietary Supplement|DHA-rich algal oil|Mothers will receive a DHA-rich algal oil treatment (400 mg DHA per capsule) three times a day before meals from randomization (<72 hours post-delivery) until the infant reaches 36 weeks PMA.
45770824|NCT02371460|Dietary Supplement|Placebo|Mothers will receive a placebo capsule three times a day before meals from randomization (<72 hours post-delivery) until the infant reaches 36 weeks PMA.
45770825|NCT00000844|Drug|Interferon alfa-n3|
45770826|NCT00000844|Drug|Interferon alfa-n1|
45447710|NCT05178290|Behavioral|CHILD back-to-ECE COVID-19 saliva testing|Preschool children and their parent will complete saliva COVID-19 tests at the start of the school year and after winter break as part of a back-to-ECE safely intervention. Tests may be completed during pick up, at drop off, or during school, depending on local on-campus regulations.
45631343|NCT05003687|Drug|Placebo|solution, orally (Part A only)
45631344|NCT02381327|Device|Mandometer|Mandometer is an eating disorder conditioning tool, class 2 device cleared by the FDA for the treatment of eating disorders. Mandometer offers on-line, real-time feedback on how much food to eat and how quickly to eat during a meal.
45631345|NCT03113669|Behavioral|CBT-GSH|
45631346|NCT02381483|Other|Cold exposure|
45631347|NCT02385071|Drug|Treatment A|150 milligram (mg) SMV capsule with water under fed conditions.
45631348|NCT02385071|Drug|Treatment B|Treatment B (3*50 mg capsules of SMV (including 50 mini-tablets of 1 mg each) with water under fed conditions.
45770827|NCT02651480|Dietary Supplement|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
45770828|NCT02651480|Dietary Supplement|Control Group|Unrestricted diet with no instruction.
45631349|NCT02385071|Drug|Treatment C|Treatment C (3*50 mg dispersible SMV tablets dispersed in water under fed conditions).
45770829|NCT00014560|Biological|bispecific antibody 4G7xH22|
45770830|NCT00014560|Biological|sargramostim|
45770831|NCT02367092|Behavioral|Exercise Program|They will perform low-intensity, low-resistance exercise facilitated by a DVD video in their home. This exercise program lasts for 30 minutes at a time. Patients will be instructed to engage in this exercise program 3-4 times per week but not more often than 4 times per week. Pre-transplant patients will be asked to do the exercises from enrollment to transplant. Post-transplant patients will be asked to do the exercises for 6 months.
45770832|NCT00020722|Biological|therapeutic autologous lymphocytes|"Immediately after pheresis, the lymphocytes will be activated with soluble monoclonal anti-CD3 antibody (OKT3) which cross-links the CD3 receptors on T cells and activates T cells.~The time for ATC infusions will vary from patient to patient, but the infusion rate will be based on the rate calculated from the endotoxin level in the cell product. All patients will be observed for at least 1 hr after an infusion."
45770833|NCT00020722|Drug|Ifosfamide, carboplatin, and etoposide (ICE) regimen|"Ifosfamide 2,500 mg/m2 given IV daily on day -8, -7, -6, -5, -4, and -3 prior to PBSCT. Ifosfamide 2,500 mg/m2 infused IV over 1 hour (hour 0-1) on days -8 to -3 for a total dose of 15,000 mg/m2.~Mesna will be administered per BMT Standard of Care Guideline at a dose of 25% of the total Ifosfamide dose 30 minutes prior to and then 3, 6, and 9 hours after ifosfamide daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 2500 mg/m2.~Carboplatin at a dose of 250 mg/m2 will be given daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 1500 mg/m2.~VP-16 (etoposide) at a dose of 200 mg/m2 will be given IV on days -8, -7, -6, -5, -4 and -3. The total dose of VP-16 given prior to PBSCT will be 2,400 mg/m2. VP-16 will be given 200 mg/m2"
45770834|NCT00020722|Drug|Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)|"Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -4, -3, and -2 (total = 6000 mg/m2).~Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -4, -3, -2 (total = 500 mg/m2) as the preparative regimen followed by PBSCT on day 0.~Carboplatin will be given at a dose of 267 mg/m2 in D5W IV over one hour daily on days -4, -3, and -2.~Mesna will be administered per BMT Standard of Care Guidelines at a dose of 25% of the total cyclophosphamide dose 30 minutes prior to and then 3, 6, and 9 hours after cyclophosphamide daily on days -4, -3, and -2 prior to PBSCT for a total of 2000mg/m2."
45770835|NCT00020722|Procedure|Leukapheresis|Peripheral blood mononuclear cells (PBMC) will be collected by leukapheresis (for generation of ATC) prior to or post G-CSF (16 ug/kg/day) priming for collecting stem cells.
45913487|NCT02023255|Other|Placebo|In Part A of the study, participants will receive placebo for 7 consecutive days and in Part B of the study, participants will receive placebo for 13 consecutive days.
45913488|NCT02023281|Behavioral|Exercise|The experimental group will engage in mild-moderate level of exercise. This program will be structured and clinically supervised. Exercise will take place 2-3 days per week for a duration of 30-45 mins. for 12 weeks.
45913489|NCT02023294|Procedure|Convetional laparoscopic Sleeve Gastrectomy|Convetional laparoscopic sleeve gastrectomy using 5 ports (incisions) in the abdominal wall
45913490|NCT02023294|Procedure|SILS Sleeve gastrectomy|Single incision Sleeve gastrectomy using only one port (incision) on the abdominal wall assisted by an special Traction Device for single port surgery (Endograb)
45631350|NCT02385071|Drug|Treatment D|*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3*50 mg dispersible SMV tablets dispersed in water under fed conditions.
45631351|NCT02385071|Drug|Treatment E|3*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3*50 mg dispersible SMV tablets dispersed in water under fasted conditions.
45631352|NCT02385071|Drug|Treatment F|3*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with yoghurt or 3*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions.
45631353|NCT02381405|Dietary Supplement|Enterade beverage|
45631354|NCT02381093|Other|Modified BLS course|BLS using CI
45631355|NCT02381093|Other|Standard BLS Course|Usual BLS teaching
45913491|NCT02023307|Device|V-Loc Suture|
45913492|NCT02023320|Dietary Supplement|Low dose of blueberry dry powder|
45631356|NCT02384681|Other|Exposure to auditory fatigue|12-hour auditory exposure
45631357|NCT02384915|Drug|prilocaine|
45631358|NCT02384915|Drug|mepivacaine|
45631359|NCT02384915|Procedure|Sciatic-femoral Nerve Block|ultrasound-guided 25 ml 2% mepivacaine injection on both femoral and sciatic nerve
45631360|NCT02384915|Procedure|Spinal anesthesia|intrathecal injection of 40 mg hyperbaric prilocaine
45631361|NCT02384915|Device|Sonoplex, Pajunk|
45631362|NCT04895735|Biological|Pembrolizumab|Given IV
45631363|NCT04895735|Drug|Pemetrexed Disodium|Given IV
45631364|NCT04875377|Dietary Supplement|Reformulated pizza|Reformulated food with 400ug of iodine per meal, three times per week (to achieve 122% of weekly recommended intakes - average 140ug/day).
45631365|NCT04875377|Dietary Supplement|Control pizza|Control (placebo) meal to consume thrice weekly (no iodine supplementation).
45631366|NCT04875377|Dietary Supplement|Seaweed capsule|Capsules containing seaweed extract, the iodine-rich ingredient in the reformulated pizza, 400ug iodine per capsule, to be consumed three times per week (122% of weekly recommended intake).
45631367|NCT04875377|Dietary Supplement|Control capsule|Empty capsules (placebo)
45770836|NCT00020722|Procedure|peripheral blood stem cell transplantation (PBSCT)|Will be collected either before or after peripheral blood stem cell collection for stem cell transplant.
45770837|NCT02650700|Radiation|spleen radiotherapy|Radiation: spleen radiation In Experimental arm, combine spleen radiation with chemotherapy. In Chemotherapy alone arm, the subjects should also receive spleen radiation once there is a severe CIT (≧grade III) during chemotherapy after radomization.
45770838|NCT02649764|Drug|Cytarabine|Given IV
45770839|NCT02649764|Drug|Fludarabine Phosphate|Given IV
45770840|NCT02649764|Other|Laboratory Biomarker Analysis|Correlative studies
45913493|NCT02023320|Dietary Supplement|High dose of blueberry dry powder|
45631368|NCT04733495|Other|Counseling|Receive group-based behavioral counseling
45631369|NCT04733495|Behavioral|Dietary Counseling and Surveillance|Receive dietary counseling
45631370|NCT04733495|Other|Quality-of-Life Assessment|Ancillary studies
45631371|NCT04733495|Other|Questionnaire Administration|Ancillary studies
45631372|NCT04733495|Other|Resistance Training|Undergo personalized resistance exercises
45631373|NCT04721327|Other|remote CI programming|provision of CI programming provided remotely via Zoom in a 2 hour session
45631374|NCT04872101|Drug|Delgocitinib cream|Cream for topical application
45631375|NCT04872101|Drug|Cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
45631376|NCT02384837|Device|EXCEL biodegradable polymer-coated sirolimus-eluting stent|
45770841|NCT02649764|Drug|Prexasertib|Given IV
45770842|NCT04051996|Drug|Glasdegib|Glasdegib will be administered at the starting dose of 100 mg orally once daily.
45770843|NCT04051996|Drug|Decitabine|Decitabine will be administered per local label and will be administered by IV infusion at a dose of 20 mg/m2/day for either 5 days or 10 days as determined by randomization. Each cycle will be every 28 days.
45770844|NCT02385292|Device|Oculeve Intranasal Lacrimal Neurostimulator|The Oculeve Intranasal Lacrimal Neurostimulator applies a small electrical current to gently activate the body's natural tear production system.
45913494|NCT02023346|Behavioral|surveys and cognitive tests|
45631377|NCT03113357|Other|Myofascial release technique|myofascial release technique take along about 3 minutes. This phase repeated 3 times in each session. At the end, for more release, sub-occipital traction will commence. The subject lies supine with head supported and therapist places the three middle fingers just caudal to the nuchal line, lifts the finger tips upward resting the hands on the treatment table, and then applies a gentle cranial pull, causing a long axis extension. The procedure is performed for 2 to 3 minutes. Subjects in each group received ten physical therapy treatment sessions. Treatment frequency was six times per week for MFR group and every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist
45631378|NCT03113357|Other|conventional exercise therapy|"All exercises were performed to a count of 7 seconds and subjects were instructed to perform all exercises daily, 15 repetitions each (twice a day). Treatment frequency was every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist. They also could be taught active muscle stretching exercises to address any muscle tightness assessed to be present."
45631379|NCT03105791|Other|Formal education regarding opioid usage|Participannts watched a 2 minute video and were given educational materials
45631380|NCT02384291|Device|Alpha-Bio GRAFT Natural Bovine Bone|Pure Hydroxyapatite ceramic mineral with high similarity to the human bone
45631381|NCT02384291|Device|natural bone substitute|natural bone substitute material derived from the mineral portion of bovine bone
45631382|NCT04729439|Behavioral|Homework Organization and Planning Skills (HOPS) Intervention|A behavioral/organizational skills intervention focused on improving adolescents' homework, organization, and planning skills
45631383|NCT04729439|Device|Digital Health Application (Online Platform) for Encouraging Skills Practice|This online platform can be used on participants' personal devices including laptops, phones, tablets, or other computers and is designed to encourage adolescent's skills practice, monitor and reward treatment progress, and optimize motivation in treatment
45631384|NCT03105947|Other|Coconut oil|50g extravirgin coconut oil daily for four weeks
45631385|NCT03105947|Other|Butter|50g butter daily for four weeks
45631386|NCT03105947|Other|Olive oil|50g extra virgin olive oil daily for four weeks
45631387|NCT03105869|Diagnostic Test|fluorocholine PET/CT|standard diagnostic PET/CT procedure
45631388|NCT02380937|Procedure|ablation for typical atrial flutter|ablation for typical atrial flutter
45631389|NCT02380937|Device|Vision Ablation Catheter|
45631390|NCT02384369|Drug|SNC-102 sustained release tablet|Sustained release oral tablet of SNC-102
45631391|NCT02380547|Other|Sonographic diaphragmatic measurements|
45770845|NCT02640638|Behavioral|CenteringPregnancy|8-12 pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
45770846|NCT01893086|Procedure|LH alone|LH, laparoscopic hysterectomy
45770847|NCT01893086|Procedure|LH with opportunistic salpingectomy|LH, laparoscopic hysterectomy
45770848|NCT02126878|Drug|Kenalog|
45770849|NCT02634008|Drug|Paritaprevir/ritonavir/ombitasvir|
45770850|NCT02634008|Drug|Dasabuvir|
45770851|NCT02634008|Drug|Ribavirin|
45770852|NCT02634008|Drug|Glecaprevir/pibrentasvir|
45770853|NCT00000850|Drug|Indinavir sulfate|
45770854|NCT00000850|Drug|Sargramostim|
45770855|NCT02802254|Behavioral|Patient-targeted individual physical-activity-feedback|At cardiac consultation receive an individual feedback on their personal physical activity level.
45770856|NCT02802254|Device|Pedometer|Patients receive a pedometer two weeks prior to cardiac consultation.
45913495|NCT02023359|Drug|Everolimus and exemestane|
45935290|NCT00220558|Device|Coronary placement of bare metal stent vs. drug eluting stent|
45631392|NCT02384525|Procedure|Fluid management by the value of over hydration in Bioelectrical impedance|In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
45770857|NCT02802176|Device|INVOcell device|intra-vaginal culture of embryos using INVOcell device
45770858|NCT02802176|Other|Traditional IVF|traditional culture of embryos in-vitro
45913496|NCT02023372|Other|NuCel with Autograft|NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Local autograft is bone that comes from the patient's own vertebrae and surrounding bony structures.
45770859|NCT00000856|Drug|Foscarnet sodium|
45770860|NCT00000856|Drug|Ganciclovir|
45770861|NCT04745858|Other|Bowen's Technique|In Bowen's Technique, sequence of short gentle moves are applied over Hamstrings. Skin slack is taken to the lateral side of muscle. The muscle is hooked by the thumbs from its lateral edge. Skin is carried along and thumb is flattened in a medial direction, the muscle plucks under the thumbs. Three alternate sessions per week are given for 4 weeks. The treatment time for each session is 20 minutes.
45770862|NCT04745858|Other|Muscle Energy Technique|Isometric contraction of hamstrings is performed by the patient being employing 20% of the strength. This contraction is resisted by the practitioner for 7-10 s. A three second relaxation period is given. This technique is repeated for three times. Three alternate sessions per week is given for 4 weeks.
45770863|NCT00001810|Drug|Voriconazole|
45913497|NCT02023385|Device|BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with BTL-9000 LLLT for the release of fat and lipids from these cells
45770864|NCT02630498|Procedure|Brachial plexus block|Patients receiving brachial plexus block for hand/arm surgery
45770865|NCT00000862|Drug|Zidovudine|
45770866|NCT02344472|Drug|pertuzumab|HER2 targeted Therapy
45770867|NCT02344472|Drug|Trastuzumab|HER2 targeted Therapy
45913498|NCT02023385|Device|sham BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with sham BTL-9000 LLLT for the release of fat and lipids from these cells
45913499|NCT02023398|Device|BTL-9000 HFT|Deep tissue heating with the BTL-9000 HFT for HFT group
45913500|NCT02023398|Device|sham BTL-9000 HFT|sham deep tissue heating with BTL-9000 HFT in Placebo group
45913501|NCT02023424|Drug|Glatiramer Acetate (Copaxone®)|GA is a potent inducer of Th2-cells and modulates these immune cells to secrete high levels of neurotrophic factors, particularly BDNF. The induced cells cross the blood brain barrier (BBB), accumulate in the CNS and express BDNF and other regulatory substances in situ.
45913502|NCT02023437|Device|Femtosecond laser cataract surgery|The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.
45913503|NCT02023437|Device|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation"
45913504|NCT02023450|Drug|saquinavir and ritonavir|micro and low dose
45913505|NCT02023450|Drug|saquinavir and ritonavir|standard dose
45913506|NCT02023476|Radiation|MRI|MRI- imaging on the upper arm
45913507|NCT02023489|Device|1H/ 13C and 31P Magnetic Resonance Spectroscopy|Study participants will be studied in the fasting state after an overnight fast of at least 10 h. Participants will arrive at the MR-Centre in the morning of the study. Between 6:30 and 10:00 a.m., 1H MRI (3T) will be performed for the assessment abdominal adipose tissue distribution and composition as well as myocardial functional parameters. 1H/13C MRS examinations (7T) will be performed for measurements of myocardial, skeletal muscle and liver lipid content and composition as well as glycogen content. Additionally, ATP synthesis and energy metabolism will be assessed.
45770868|NCT02344472|Drug|Capecitabine|Chemotherapy
45770869|NCT02344472|Drug|Paclitaxel|Chemotherapy
45770870|NCT02344472|Drug|Vinorelbine|Chemotherapy
45770871|NCT02344472|Drug|Docetaxel|Chemotherapy
45770872|NCT02344472|Drug|Exemestane|endocrine therapy
45770873|NCT02344472|Drug|Letrozole|endocrine therapy
45770874|NCT02344472|Drug|Anastrozole|endocrine therapy
45770875|NCT02344472|Drug|Fulvestrant|endocrine therapy
45770876|NCT02344472|Drug|Ribociclib|CDK 4/6 inhibitor
45770877|NCT02344472|Drug|nab-Paclitaxel|chemotherapy
45770878|NCT02344472|Drug|eribulin|chemotherapy
45770879|NCT02344472|Drug|leuprorelin|endocrine therapy
45770880|NCT02344472|Drug|goserelin|endocrine therapy
45770881|NCT02376946|Device|ActiPatch(TM)|Assigned by randomization, this study group will be comprised of subjects that receive the PEMF ActiPatch(TM) treatment for postoperative management of pain and edema.
45770882|NCT02376946|Device|Placebo|Assigned by randomization, this control group will be comprised of the subjects that receive a placebo patch as treatment for postoperative management of pain and edema.
45770883|NCT02338232|Drug|Telmisartan|
45770884|NCT01780636|Drug|botulinum toxin|
45770885|NCT02973490|Device|Transanal Tube Drainage|Using transanal tube drainage after colorectal ESD
45770886|NCT02337452|Other|Questionnaire Administration|Ancillary studies
45631393|NCT02384525|Procedure|Fluid management by clinical-based ultrafiltration|In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
45447711|NCT05178290|Behavioral|ECE personnel back-to-ECE COVID-19 saliva screening|ECE personnel will complete saliva COVID-19 tests biweekly through the school year as part of a back-to-ECE safely intervention. Tests may be completed on the ECE campus or in the parking lot, depending on local on-campus regulations
45631394|NCT02384603|Other|Global postural reeducation|
45631395|NCT02384603|Other|Segmental muscle stretching exercises|
45631396|NCT02384603|Other|Cognitive behavioral therapy|
45631397|NCT02384135|Other|Three-month thromboembolic risk in patient with D-dimer levels between the usual cut-off and the age-adjusted cut-off|
45631398|NCT02380625|Drug|Azithromycin|Adults (>18 yrs): 3 x 500mg tablets daily for 5 days; Children (6 months to <18 yrs): 30mg/kg (oral suspension) daily for 5 days
45631399|NCT02380625|Drug|Sunitinib and Erlotinib|Sunitinib - Adults (>18 yrs): 1 x 50mg tablet daily for 7 days; Children (6 months to <18 yrs): 0.83 mg/kg (oral suspension) daily for 7 days. Erlotinib - Adults (>18 yrs): 1 x 150mg tablet daily for 7 days; Children (8kg to <20kg): 3.5 mg/kg daily for 7 days; Children (>20kg to <30kg): 3.0 mg/kg daily for 7 days; Children (>30kg to < 18 yrs): 25 mg/kg daily for 7 days
45770887|NCT02337452|Behavioral|Web Site|Communicate via family outreach program website
45770888|NCT00000868|Biological|Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203)|
45770889|NCT00000868|Biological|Aluminum hydroxide|
45447712|NCT05178290|Behavioral|SAGE garden programming|The SAGE garden programming includes installation of a garden; teacher training via Zoom and/or short videos, a binder and website support along with other accompanying materials and teacher technical support (email, text, phone); gardening supplies and gear (e.g., hats, watering cans, gloves); and delivers active songs, games, science experiments and other outdoor learning opportunities.
45631400|NCT02380625|Drug|Atorvastatin and Irbesartan|Atorvastatin - Adults (>18 yrs): 1 x 40mg tablet daily until discharge; Children (6 years to <18 yrs): 1 x 40mg tablet daily until discharge; Irbesartan - Adults (>18 yrs): 1 x 150mg tablets daily until discharge; Children (6 years to <18 yrs): 1 x 75mg tablet daily until discharge.
45631401|NCT02380625|Other|IV fluids and laboratory testing|All arms will receive aggressive IV fluid rehydration and frequent laboratory tests to assist with medical management as indicated.
45631402|NCT02383979|Device|Sham (Comparator) Plasma Ball|"will consist of undergoing a sham therapy with a 22 plasma globe involving contralateral limb interaction with the sphere."
45770890|NCT00000868|Biological|MF59|
45770891|NCT00000868|Biological|rgp120/HIV-1MN|
45770892|NCT01893164|Procedure|simple decompression|decompression of the ulnar nerve
45935291|NCT04729842|Procedure|Axillary Brachial plexus block|Brachial plexus block via axillary route was administered using 30 ml of 0.5% Bupivacaine in group B and 30 ml of 0.5% Ropivacaine in Group R
45935292|NCT00220597|Behavioral|Trauma-focused group therapy|
45935293|NCT00220675|Drug|Erythropoietin infusion|
45770893|NCT01893164|Procedure|anterior subcutaneous transposition|transposition of the ulnar nerve into subcutaneous bed
45770894|NCT01893164|Procedure|anterior intramuscular transposition|transposition of the ulnar nerve into muscular tissue
45770895|NCT05586464|Drug|Ban xia xie xin Decoction and bismuth quadruplicate group|Ban xia xie xin Decoction:10g of banxia, 10g of huangqin, 6g of coptis chinensis, 6g of dried ginger, 6g of ginseng, 6g of roasted licorice, 6g of Chinese jujube Bismuth quadruplicate: Esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid).
45770896|NCT05586464|Drug|Bismuth quadruplicate group|Bismuth quadruplicate: Esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid).
45770897|NCT01561378|Drug|Aspart insulin|40 IU of aspart insulin (200 microliters per nostril) will be administered intranasally using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
45770898|NCT01561378|Drug|Normal saline|200 microliters of normal saline will be administered per nostril using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
45770899|NCT01561378|Device|Intranasal mucosal atomizer device|Insulin and placebo will be drawn into identical syringes. Nurses will administer the insulin or placebo by connecting the mucosal atomizer device (MAD) to the syringe, placing the MAD tip in the nostril and compressing the syringe plunger to spray atomized solution into the nasal cavity.
45770900|NCT02628548|Behavioral|Cognitive training program|8 week cognitive training program
45935294|NCT00042731|Dietary Supplement|Lycopene|Daily administration as outlined in treatment arm(s)
45631403|NCT02383979|Device|Mirror|will undergo 14 days of daily mirror therapy sessions preoperatively which will consist of observing the unaffected limb reflected for 30 minutes in a mirror positioned in the midline to block the view of the affected limb
45770901|NCT02627846|Device|EVLA|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. The EVLA fibre is introduced into the vein using the Seldinger technique and its tip will be positioned under duplex ultrasound (DUS). Then tumescent anaesthetic, made of a solution of 100ml of 1% Lidocaine with 1:200,000 epinephrine in 900ml of 0.9% Sodium Chloride and buffered to pH 7.4 with 10ml of 8.4% Sodium Bicarbonate, will be infiltrated around the target axial vein under DUS using a spinal needle and a peristaltic pump. Following deployment of appropriate laser safety precautions, the laser energy will be delivered via the fibre. The wavelength used is 1470nm, with NeverTouch Gold-Tip fibre, at 10W power. This laser light energy is converted into heat inducing a permanent, non-thrombotic occlusion.
45770902|NCT02627846|Device|ClariVein®|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. MOCA is performed by a device called ClariVein® (Vascular Insights, UK) which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip. The sclerosant will be Sodium Tetradecyl Sulphate (STS), marketed as Fibrovein. Concentration of 1.5% Fibrovein will be used, and maximum of 12ml.
45770903|NCT02627846|Drug|Lidocaine with 1:200,000 epinephrine solution|It is used as local anaesthetic given via subcutaneous injection, so that the skin is numb prior to the introduction of either endovenous laser ablation or mechenochemical ablation catheter. Typically 1-2ml is required.
45770904|NCT02627846|Drug|Lidocaine with 1:200,000 epinephrine solution|100ml of 1% lidocaine with 1:200,000 epinephrine is diluted into 900ml of 0.9% Sodium Chloride to make the tumescent anaesthetic solution, which is required when using endovenous laser ablation.
45631404|NCT02380313|Drug|Afuresertib|White of off-white round immediate release tablet for oral administration with unit dose strength of 50 mg and 75 mg to achieve the dosage level of 100 mg, 125 mg, 150 mg or 200 mg once daily.
45770905|NCT02627846|Drug|Sodium Bicarbonate|10ml of 8.4% Sodium Bicarbonate is added into the tumescent anaesthetic solution, to buffer the pH to 7.4. Tumescent anaesthetic solution is required when using endovenous laser ablation.
45770906|NCT02627846|Drug|Sodium Tetradecyl Sulphate|1.5% of Sodium Tetradecyl Sulphate, marketed as Fibrovein, will be used with the mechanochemical ablation device (ClariVein®). This is a sclerosing agent with Manufacturer Authorisation, and it will be used unmodified. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein.
45770907|NCT03236662|Drug|(-)-Epicatechin|
45631405|NCT02380313|Drug|Enzalutamide|Opaque white to off-white capsule for oral administration with unit dose strength of 40mg to achieve dose level of 160 mg once daily.
45631406|NCT02380313|Drug|Abiraterone|White to off-white tablet for oral administration with unit dose strength 250 mg to achieve dose level of 1000 mg once daily.
45631407|NCT02380313|Drug|Prednisone|Continuous twice daily co administration of prednisone 5 mg as per labelled recommendation from United State Prescribing Information.
45631408|NCT02380157|Drug|Kaleorid, 750mg (trade name), Potassium chloride (active substance)|4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
45631409|NCT02380157|Drug|Placebo|4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
45631410|NCT02380235|Biological|PEG-somatropin|0.20mg/kg/w
45631411|NCT02380235|Biological|PEG-somatropin|0.12mg/kg/w
45631412|NCT04835597|Behavioral|Behavioral Assessment|Complete movement assessment
45631413|NCT04835597|Other|Electronic Health Record Review|SAE data is collected
45631414|NCT02380469|Behavioral|Identification and provision of lacking information|The intervention consists of an interview about the caregiver's responses (baseline measurement) to a list about 'lack of information' within 13 areas. For each area, the patient's nurse will enquire about what information is requested by the caregiver and the patient. Subsequently, the nurse provides the requested information. She may involve the doctor and arrange follow-up visits or phone calls until the need is covered
45935295|NCT00042731|Dietary Supplement|Multivitamin|Daily administration as outlined in treatment arm(s)
45770908|NCT02608268|Drug|MBG453|anti human TIM-3 monoclonal antibody
45770909|NCT02608268|Drug|PDR001|anti-human PD-1 monoclonal antibody
45770910|NCT02608268|Drug|Decitabine|commercially available chemotherapy
45770911|NCT02316314|Procedure|Cardiac magnetic resonance imaging (CMR)|"CMR is a non-invasive way to take a high-resolution image of the heart and vessels. CMR uses powerful magnets and radio waves to obtain the image. During the CMR, you will have a substance injected into your vein called contrast to get a better picture of the heart."
45770912|NCT02316314|Procedure|Exercise-stress test|You will be asked to pedal on a bicycle with your arms to see how much work you can do and how far you can go.
45631416|NCT01625182|Drug|Fingolimod|Fingolimod 0.5 mg capsules
45631417|NCT01625182|Drug|Placebo Comparator|Matching placebo capsules
45631418|NCT02383901|Drug|Methotrexate|The study includes osteosarcoma patients who have received MAP treatment, MAP treatment contains 12 courses of Methotrexate
45631419|NCT02383823|Drug|Estrogens|Crossover study of estrogen or placebo in random order in menopausal women
45631420|NCT02383823|Other|Placebo|Crossover study of placebo or estrogen in random order in menopausal women
45631421|NCT02380001|Drug|Dexketoprofen trometamol|White round pill containing 25mg of Dexketoprofen will be administered either prior/after to third molar surgery.
45770913|NCT02316314|Procedure|Echocardiogram (ECHO)|An echocardiogram is an ultrasound of the heart done at rest.
45935296|NCT00042731|Dietary Supplement|Soy isoflavones|Daily administration as outlined in treatment arm(s)
45935297|NCT00220714|Drug|atypical antipsychotics:oral vs. long-acting route|
45770914|NCT02316314|Procedure|Cardiac-related blood studies|The blood test involves drawing blood from a vein in the arm by placing a needle in it. The total amount of blood to be drawn for a single visit will be up to 57 mL (12 teaspoons).
45631422|NCT02380001|Drug|Preoperative control|white round pill containing 25mg of placebo will be administered prior/after to third molar surgery. The placebo pill is identical to active dexketoprofen, in size and color
45631423|NCT02384057|Other|Computerized cognitive training program|1000 minutes of computerized cognitive rehabilitation with C8 sciences program
45631424|NCT02384057|Other|Conventional cognitive rehabilitation|Same amount of conventional cognitive rehabilitation
45631425|NCT02383745|Other|Acute EEG with fast EEG electrode|
45631426|NCT04799717|Behavioral|Gaming session|Participants will be provided the option to play an online game with the clinician for the first half of the session through an online platform.
45770915|NCT02310698|Device|contrast enhanced digital mammography (CEDM)|
45631427|NCT04796597|Device|Subcutaneous implantation of Epios sub-scalp leads|The sub-scalp Epios Leads will be implanted by a trained neurosurgeon and will provide epicranial EEG recording of specific cortical areas identified by the neurologist.
45631428|NCT02379767|Device|Electroconvulsive therapy|
45631429|NCT02379767|Other|Positron emission tomography of the brain using [11C]harmine|
45631430|NCT02379767|Other|Structural magnetic resonance imaging|
45935298|NCT00220714|Behavioral|Family Psychoeducation|
45631431|NCT02383511|Drug|SMT C1100|Period 1, SMT C1100 1250 mg BID; Period 2, Placebo BID; Period 3, SMT C1100 2500 mg BID
45447713|NCT03234608|Behavioral|AASPIRE Healthcare Toolkit|The AASPIRE Healthcare Toolkit includes a variety of resources (information, worksheets, checklists, links) for patients and providers. The centerpiece of the toolkit is the Autism Healthcare Accommodations Tool, which allows a patient or their supporter to create a personalized accommodations report for the patient's provider. Intervention patients will use the toolkit and create an AHAT report. Intervention clinics will receive a copy of each patient's AHAT report, place it in the medical record, and share it with the patient's PCP and other staff.
45447714|NCT03248882|Drug|Placebo|Placebo
45447715|NCT03248882|Drug|PF-05221304|PF-05221304, Experimental Drug
45447716|NCT02116738|Procedure|Flap Transposition Procedures|Modified Limberg Flap Transposition Procedure and Lateral Advancement Flap Transposition with Burrow's Triangle Procedure in The treatment of Pilonidal Sinus Diseases
45447717|NCT03233438|Drug|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
45631432|NCT02383511|Drug|SMT C1100|Period 1, SMT C1100 1250 mg BID; Period 2, SMT C1100 2500 mg BID; Period 3, Placebo BID
45631433|NCT02383511|Drug|SMT C1100|Period 1, Placebo BID; Period 2, SMT C1100 1250 mg BID; Period 3, SMT C1100 2500 mg BID
45631434|NCT02661815|Drug|Paclitaxel|Please see arm/group description.
45631435|NCT02661815|Drug|Ricolinostat|Please see arm/group description.
45631436|NCT02661815|Drug|Bevacizumab|Please see arm/group description.
45631437|NCT02379845|Device|NBTXR3|One intratumor implantation by injection
45631438|NCT02379845|Device|Radiation therapy|5 weeks/50 Gy (5 x 2 Gy by week)
45631439|NCT02379689|Drug|Injectable placental tissue extract called BioDGenesis (Active Product)|
45631440|NCT02379689|Drug|Placebo|
45631441|NCT02377193|Drug|Simulect|"Simulect IV 40 mg/day D0 and D4~and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg"
45631442|NCT02377193|Drug|ATG Fresenius|Simulect IV 40 mg/day D0 and D4 and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg
45631443|NCT02053792|Biological|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
45631444|NCT02379455|Other|Comprehensive drug review|1) Geriatric assessment including medical history, physical examination, supplementary tests. The geriatric work-up will be aimed at evaluating whether current medications are indicated, whether the relevant conditions are satisfactorily compensated, whether the dosages are appropriate, whether the patient has symptoms that may in reality be adverse drug effects, and whether drug-drug interactions or drug-disease interactions are likely to occur. 2) Conference with common drug review. The project physician and the family physician will discuss the patient's drug list systematically. 3) Individualized clinical follow-up depending on the medication changes that have been done.
45631445|NCT02379533|Other|Aerobic exercise|
45631446|NCT02377115|Other|Tablet computer application|Preoperatively, all study participants (entire cohort) will perform in the self-administered tablet computer-based tool to assess the risk of developing POD.
45631447|NCT04356287|Biological|UCMSC|Each infusion will consist of 1 million MSC/kg suspended in 50 mL of PlasmaLyte A.
45631448|NCT04356287|Other|Placebo|Each infusion will consist of 50 mL of PlasmaLyte A.
45631449|NCT04688021|Drug|Cytarabine|4 mg/m2/day administered IV day -10 through -9.
45631450|NCT04688021|Drug|Busulfan|3.2 mg/kg/day administered IV day -8 through -6.
45631451|NCT04688021|Drug|Cyclophosphamide|1.8 g/m2/day administered IV day -5 through -4.
45770916|NCT02310698|Device|whole breast screening ultrasound (WBUS)|
45770917|NCT00000880|Drug|Cyclosporine|
45770918|NCT02308280|Drug|Bortezomib following nonmyeloablative allogeneic transplant|Bortezomib 1,3 mg/m2 subcutaneously every 2 weeks for 1 year (26 injections) starting on day +120 from a non myeloablative sibling or 10/10 unrelated allogeneic transplantation
45770919|NCT04757168|Device|NOGA TM probe|"Each subject will be his own witness since the linear local shortening (LLS) will be measured successively in all patients before, then after stimulation of the scar zone (comparison of LLS measured in sinus rhythm then during stimulation in the scar zone for each patient.~Each subject being his own witness and the two recordings being made a few minutes apart, during the same procedure."
45770920|NCT00000886|Biological|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
46070001|NCT00804115|Drug|Latanoprost with Pilocarpine vs Timolol or Cosopt|Timolol 0.5% bid or Cosopt bid Latanoprost 0.005% qhs Pilocarpine 2%
45631452|NCT04688021|Drug|Me-CCNU|250mg/m2 once administered orally on day -3.
45631453|NCT04688021|Drug|Rabbit antithymocyte globulin|1.5mg/kg/day administered IV day -5 through -2.
45631454|NCT04688021|Drug|Tocilizumab|8mg/kg administered IV on day -1.
45631455|NCT04688021|Procedure|Allogeneic HSCT|Day 0
45770921|NCT01893242|Drug|Aleglitazar|Aleglitazar 150 mcg oral doses, once a day for approximately 3 years
45770922|NCT01893242|Drug|Placebo|Matching placebo to aleglitazar, once a day for approximately 3 years
45770923|NCT05162794|Other|Laparoscopy with excision|Diagnostic laparoscopy will be performed to visually confirm endometriosis in the peritoneum. Then, the relevant tissue will be excised and a histology will be performed.
45770924|NCT05162794|Other|Laparoscopy without excision|Diagnostic laparoscopy will be performed to visually confirm endometriosis in the peritoneum. However, no tissue will be excised and histology will not be performed.
45770925|NCT05162794|Other|Medical treatment-as-usual|Patients continue their hormonal and analgesic treatment-as-usual.
45631456|NCT04688021|Drug|Cyclosporin A|2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.
45631457|NCT04688021|Drug|Mycophenolate Mofetil|500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.
45631458|NCT04688021|Drug|MTX|15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.
45631459|NCT02082340|Behavioral|TB knowledge and socio-psychological counseling session|TB patients and their family members will participate in one-day counseling session provided by a trained psychologist and a TB nurse
45631460|NCT02082340|Other|SMS text messages|TB patients will receive SMS text messages every morning (except Sunday) during the whole ambulatory TB treatment phase as a reminder for taking the TB medication prescribed and provided by the TB physician
45770926|NCT02795156|Drug|afatinib|40 mg orally (p.o.) once daily for each 28-day cycle
45770927|NCT02795156|Drug|regorafenib|160 mg p.o. once daily for the first 21-days of each 28-day
45770928|NCT02795156|Drug|Cabozantinib|60 mg p.o. once daily for each 28-day cycle
45770929|NCT02792582|Radiation|Proton Therapy|The protocol-specific radiation dose will be prescribed to a target defined by the use of computerized tomography (CT) and magnetic resonance imaging (MRI). The target will encompass the residual tumor and/or tumor bed and will include a margin mean to treat subclinical microscopic disease. There is no time limit for the interval from surgery or study enrollment to when proton therapy commences. The time course of administration of proton therapy will be 1 treatment/day, 5 days/week, for a period 6 weeks.
45447718|NCT03233438|Drug|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
45447719|NCT02116816|Dietary Supplement|Polyphenol|Polyphenol
45447720|NCT02251600|Drug|Deflazacort|Oral deflazacort administered once daily at 0.9 mg/kg for eight days
45631461|NCT02082340|Other|phone calls|Family members of the TB patients will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects.
45631462|NCT02082340|Behavioral|Self-administered drug intake strategy|Once a week TB patients will receive the TB medication from their local outpatient TB centers and will use the medication every day (six days a week, except Sunday according to the TB treatment protocol) at home under supervision of a family member in charge.
45631463|NCT02082340|Behavioral|Educational leaflet|Educational leaflet containing information on TB infection; infection control measures; importance of TB treatment adherence and family support will be provided to all TB patients at the end of the counselling session
45631464|NCT04349969|Drug|AK117|All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.
45631465|NCT04349969|Drug|AK117+AK104|All Subjects will receive 3 weekly infusions of AK117 (Days 1, 8, and 15) and 1 infusion of AK104 (on Day 1) as combination therapy in each 21-day treatment cycle until unacceptable toxicity, documentation of confirmed PD, or subject withdrawal.
45770930|NCT02792582|Procedure|Surgery|When possible, tumors will be removed surgically prior to proton therapy. If no tumor remains following surgery, no proton therapy will be given, and participants will be followed for 5 years to collect outcome data for comparison between groups.
45770931|NCT04757792|Other|File inquiry|Data extraction out of file registry
45770932|NCT02599454|Drug|Atezolizumab|Into the vein Day 1 every 3 weeks for 6 cycles
45770933|NCT02599454|Radiation|Stereotactic Body Radiation Therapy|Radiation therapy will be performed to 50 Gy over 4 fractions of 12/5 Gy each for peripherally located tumors and 50 Gy over 5 fractions of 10 Gy each for centrally located tumors
45770934|NCT02791646|Behavioral|Pain Coping Skills Training Full|Pain Coping Skills Training Full(PCST-Full) will consist of a 5-session intervention delivered to participants at the medical center by their therapist.
45770935|NCT02791646|Behavioral|Pain Coping Skills Brief|Pain coping skills training brief (PCST-Brief) will consist of a 60 minute, in-person session followed by 4-weeks of daily text messaging
45770936|NCT02307500|Drug|Regorafenib|oral therapy
45770937|NCT02589938|Other|Standard Oral Hygiene|Oral hygiene care provided per individual institutions standard of care.
46070002|NCT04758247|Device|TheraNova Neuromodulation System|The investigational device is a transcutaneous electrical nerve stimulation (TENS) device that is designed to provide stimulation to the nerves at the site of application via surface electrodes temporarily adhered to the skin.
45770938|NCT02589938|Other|Standard Oral Hygiene + True Acupuncture|Oral hygiene care provided per individual institutions standard of care. 14 true acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
45770939|NCT02589938|Other|Standard Oral Hygiene + Sham Acupuncture|Oral hygiene care provided per individual institutions standard of care. 14 sham acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
45631466|NCT04712968|Behavioral|Regular exposure to morning daylight|"Participants are asked to stay outside in morning daylight for minimum 30 minutes each day before 1 pm for 6 weeks. A specific plan for individual outdoor possibilities for daylight exposure is made (e.g. a walk, a stay in a park or in their garden, a bike trip). Furthermore a detailed instruction to the personal light tracker LYS Button and the matching LYS Insight app is provided. The LYS Insight app gives the user access to real-time insight of light stimulus. Further, the participants receive psycho-education on the connection between exposure to morning daylight and antidepressant effect. All participants in this group receive the intervention as add-on to usual treatment, which may comprise prescribed antidepressants, psychotherapy, including psycho-education and psychiatric care."
45935299|NCT00077493|Drug|BL22 immunotoxin|BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.
45631467|NCT04327505|Drug|Hyperbaric oxygen|1.6- 2.4 ATA, 30-60 min (excluding compression/recompression)
45631468|NCT02053246|Drug|Nebivolol|Nebivolol will be started at 2.5 mg by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
45631469|NCT04678661|Device|Smartphone application and web portal|"My Dose Coach is indicated for single patient use outside the clinic setting by a previously diagnosed Type 2 Diabetic who has been prescribed a once-daily long-acting basal insulin. MDC is intended as an aid to the patient to provide dose suggestions based upon the HCP's independent professional judgment. Before My Dose Coach can be used, the HCP configures the dose instructions for the specific patient and activates the application using the specific patient Instructions. The application uses the dose plan instructions provided by the patient's HCP to provide dose suggestions of once-daily long-acting basal insulin (i.e. basal insulin titration) that are based on the patient's Fasting Blood Glucose (FBG) as well as hypoglycemia occurrence.~MDC includes a Maintenance Module designed to support patients in maintaining proper insulin dosingby enabling logging of administered doses of prescribed diabetes medications and BGM and providing dosing and measurement reminders."
45631470|NCT04678661|Behavioral|Standard Insulin Therapy Education|Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
45631471|NCT04296617|Other|Medical Chart Review|Review of medical chart
45631472|NCT02053168|Device|Resorbable Mesh|Phasix Mesh
45631473|NCT02379299|Device|DiaCon dual-hormone closed-loop glucose control algorithm|Dual-hormone closed-loop glucose control
45631474|NCT02379299|Device|DiaCon single-hormone closed-loop glucose control algorithm|Single-hormone closed-loop glucose control
45631475|NCT03112967|Other|low-volume preparation, oral sulfate solution|Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
45631476|NCT03112967|Other|large-volume preparation, 4L polyethylene glycol|4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
45631477|NCT02379065|Device|The Aerogen Aeroneb Solo©|
45631478|NCT02379065|Device|Phillips Respironic© mask|
45631479|NCT02377037|Other|Metabolic cost and HR associated with distinct postural behaviors|The order of the three conditions will be randomly assigned and all will be undertaken in laboratory settings. Before engaging in the experimental conditions participants will perform anthropometric and body composition assessments and also the resting EE evaluation. All evaluations will be performed at one time only, starting at 7:00 am in the morning after an overnight fast
45631480|NCT02376881|Drug|Erythropoietin|20,000 IU epo IV infusion in 100 ml normal saline in 2 hr for 3 successive days
45631481|NCT02376881|Other|placebo|100 ml normal saline in 2 hr for 3 successive days
45631482|NCT02032888|Drug|Daclatasvir|
45631483|NCT02032888|Drug|Sofosbuvir|
45631484|NCT02376959|Behavioral|"Spiritist passe"|"For a period of 5 min per week, the volunteers will remain in the supine position with their eyes closed, in a quiet environment with controlled light and temperature.~The applied intervention will consist of placing both hands in the classic Spiritist passe position for the stipulated 5-min period. Spiritist passe will be applied by volunteers with training and experience of more than two years with the technique."
45631485|NCT02376803|Drug|Warfarin|Morning vs Evening administration
45631486|NCT02379143|Other|interview method: self report form|the responses about participants perception, behavior pattern and attitude were recorded on the self report form
45631487|NCT02082262|Drug|AGN-229666|One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
45631488|NCT04697069|Biological|Imsidolimab|Humanized monoclonal antibody
45935300|NCT00077493|Procedure|antibody-drug conjugate therapy|CD22 antibody, RFB4 on day 7
45770940|NCT02292368|Behavioral|Questionnaires|At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.
45770941|NCT02292368|Procedure|Acupuncture|Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.
45770942|NCT02292368|Procedure|Electroencephalogram (EEG)|Participants have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes.
45770943|NCT02286674|Other|Tablet (Audio/Visual Device)|Subjects will be given a tablet to use before surgery
45770944|NCT01893398|Other|Multidimensional stimulation group therapy|The MST program involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.
45631489|NCT04697069|Biological|Placebo|Placebo
45631490|NCT04247243|Device|Rapid testing|Abbott ID NOW Strep A testing
45631491|NCT04247243|Diagnostic Test|Reference testing|Culture-based testing
45631492|NCT02082184|Device|Sensor Based Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels. Post completion of the 6 month intervention, subjects participating in this arm of the study will be given a further 6 month period of open access to the device.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation."
45770945|NCT05586854|Procedure|Hydrolink NV membrane|"patient dialysis on a Hydrolink-NV® membrane with an anticoagulant dose decrease protocol.~Period 1 : conventional membrane with his usual anticoagulant for 4 weeks. Period 2 : Hydrolink-NV® membrane with maintenance of the previous doses of Orgaran® Period 3 : Hydrolink-NV® membrane with a decrease in Orgaran® Period 4 : Hydrolink-NV® membrane with the minimum effective dose of Orgaran® or without Orgaran® for a period of 3 months (M4, M5, M6)."
45631493|NCT02082184|Device|Standard Blood Glucose Monitoring|"Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation."
45631494|NCT02378909|Device|Electrical stimulation device.|In the intervention group, all participants will receive Geko device which will produce electrical stimulation to enhance wound healing. This is the non- invasive device, self adhesive, light and does not restrict the patient's movement. Wound will be measured at the beginning of the study (before the device is applied) and after the study is complete. Blood and wound tissue samples will also be taken pre and post electrical stimulation to observe the effect of electrical stimulation on wound healing in people with diabetes.
45631495|NCT04189679|Other|Immune signature in serum associated to the metabolic signature|Immune signature in serum associated to the metabolic signature
45631496|NCT04189679|Genetic|Meta-genomic signature of intestinal flora|Meta-genomic signature of intestinal flora
45631497|NCT04678427|Other|6 Minute Walk Functional Test|Complete 6-minute walk test
45631498|NCT04678427|Behavioral|Behavioral Intervention|Participate in walking and other activities
45631499|NCT04678427|Other|Survey Administration|Complete survey
45913508|NCT02023489|Other|Meal Tolerance Test|"A meal tolerance test meal tolerance test according to Petersen et al. (PNAS, Vol 104, 2007) will be performed. After MRI and MRS examinations subjects will be returned at our outpatients clinic, where small polyethylene catheter will be inserted in an antecubital vein for hourly blood sampling. At 10:30 a.m. and 1:30 p.m. two liquid high carbohydrate meals of equal size containing all the required daily energy (30 kcal/kg of body weight; 55% carbohydrate, 10% protein, and 35% fat) with an additional 25% of the daily energy requirements added in the form of sucrose will be served.~At 5 p.m. subjects will be returned at the MR - Centre for postprandial 1H / 13C MRS (7T) of muscle, liver and myocardial lipid and glycogen contents. Myocardial function parameters and abdominal fat distribution will be assessed again by 1H MRI (3T)."
45913509|NCT02023489|Other|Hyperglycemic-hyperinsulinemic clamp|"All volunteers will be admitted in the morning and basal 13C tracer enrichment will be assessed.~At 8:00a.m. (0 min) a hyperglycemic-hyperinsulinemic-pancreatic clamp test will be initiated by somatostatin (-5-300 min: 0.1 µg·kg-1·min-1, UCB Pharma, Vienna, Austria) and insulin (0 - 8 min: 80 mU·min-1·m-2 body surface area; 8 -300 min: 40 mU·min-1·m-2 body surface area) infusion. Plasma glucose will be raised and maintained at ~180 mg·dL-1 by primed (0.2 g·kg-1)-variable dextrose infusion (20%w/v) enriched with [1-13C]glucose (40%w/w). A second catheter will be placed into an antecubital vein of the other arm and blood samples for the measurement of glucose, insulin and c-peptide. Glucose concentrations will be analysed immediately every 5 minutes, employing a glucose analyser. Myocardial glycogen concentrations will be measured before the clamp (-60 - 0 min) and from 90 min to 180 min during the clamp employing 13C MRS."
45913510|NCT02023502|Other|collection of urine and blood sample|
45913511|NCT02023541|Radiation|Proton beam therapy|
45913512|NCT02023554|Drug|Theophylline with azithromycin|"Drug: Theophylline(100mg,sustained release tablets). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 1 to day 7.~Drug:Azithromycin(250mg, capsules). Multi-dose of azithromycin(500mg,once daily) will administered at 8 pm from day 1 to day 7."
45631500|NCT04678427|Behavioral|Timed Get Up and Go Test|Complete timed get up and go test
45631501|NCT04057157|Device|Biodesign Dural or Duraplasty Repair Grafts|Patients will receive the Biodesign Dural or Duraplasty Repair Grafts according to the Instruction for Use.
45631502|NCT04159415|Drug|Placebo|Intravenous (IV) infusion loading dose or subcutaneous (SC) injection weekly (QW).
45631503|NCT04159415|Drug|Low-Dose REGN4461|IV infusion loading dose or SC injection QW.
45631504|NCT04159415|Drug|High-dose REGN4461|IV infusion loading dose or SC injection QW.
45631505|NCT04132427|Combination Product|vancomycin, magnesium citrate, microbiota|10 days of oral vancomycin, then 1 day of oral magnesium citrate, , then 4 days of high-dose oral microbiota, followed by 12 weeks of low-dose oral microbiota
45631506|NCT04132427|Combination Product|placebo vancomycin, real magnsium citrate, placebo microbiota|10 days of oral placebo vancomycin, then 1 day of oral real magnesium citrate, , then 4 days of high-dose oral placebo microbiota, followed by 12 weeks of low-dose oral placebo microbiota
45770946|NCT05586386|Other|Cherry group|200 mL of DSC juice twice/day supplemented with 3g of DSC powder twice/day for 30 days
45913513|NCT02023554|Drug|Theophylline alone|Drug: Theophylline(100mg,sustained release tablet). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 8 to day 14.
45913514|NCT02023567|Drug|SSRIs|fluoxertine hydrochloride 20-60mg/day, paroxetine hydrochloride 20-60mg/day, sertraline hydrochloride 50-200mg/day, citalopram 20-60mg/day, escitalopram 10-20mg/day, fluvoxamine 50-300mg/day
45631507|NCT02378675|Other|Blood draw|During the routine blood sampling, a 10ml plasma sample as well as a 10ml serum sample will be obtained, spinned and stored at -80°C until the final assessment of adipocytokines.
46070003|NCT00798811|Procedure|high-dose chemotherapy and autologous stem cell rescue|Surgery -> enroll Pre-RT chemotherapy (2 cycles: A1, B1) PBSC collection during first cycle (A1) (2nd look surgery if necessary) RT (Reduced dose CSI) Post-RT chemotherapy (4 cycles: A2, B2, A3, B3) (if relapse or progression prior to HDCT, off study -> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM)
45631508|NCT02376491|Device|Transcranial magnetic stimulation|
45913515|NCT02023580|Behavioral|Video treatments|"The treatment video vignettes to be delivered between Baseline and 3 Months include: 1) Condom use/anal sex without HIV status disclosure (potentially SDCAS); 2) Condom use/anal sex without HIV status disclosure and perceived responsibility; 3) Discussion of nondisclosure of HIV status prior to sex and perceived responsibility, STIs; 4) Stigma associated with disclosing HIV status to sex partners; 5) HIV/STI testing; and 6) Diagnosis of an STI; STI disclosure to sex partners and perceived responsibility.~Video boosters to be delivered weekly for 4 weeks between 6 and 9 Months include: 7) HIV status disclosure, condom use, STIs; 8) STI disclosure to sex partners, disclosure to friends, serodiscordant partnerships; 9 & 10) Support of HIV disclosure and perceived responsibility."
45631509|NCT02378597|Behavioral|Behavioral: Resiliency Intervention|4 hour behavioral session including education in the relaxation response, education about stress and allostatic load, cognitive skills building, review of difficult encounters with patients.
45631510|NCT02031640|Drug|Beclomethasone dipropionate|
45631511|NCT02031640|Drug|Placebo|
45631512|NCT02031640|Drug|Albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
45631513|NCT02376725|Procedure|Phaco/IOL|Phaco/IOL refers to extracapsular cataract extraction (using phacoemulsification) and intraocular lens implantation
45631514|NCT02376725|Procedure|Phaco/IOL + goniosynechialysis|Phaco/IOL refers to extracapsular cataract ectraction (using phacoemulsification) and intraocular lens implantation. Goniosynechialysis refers to mechanical breaking of peripheral anterior synechiae using a spatula and goniolens to view the drainage angle structures.
45631515|NCT03105635|Other|Mixed method feasibility study|"Participating practices will receive the following:~Training on community resources : An orientation regarding the availability of the local community health and social resources, and the existing navigation services that can support individuals identify the appropriate resource.~Facilitation to enhance referrals: help support practices to make the desired adaptations to enhance referrals~Promotional material to engagement patients: Practices will provide an area in the waiting room where promotional material on the benefit and availability of community resources will be displayed.~Navigator: The services of a Navigator"
45631516|NCT02378363|Other|Write, draw and interview|Child should write, draw cancer signifiance and after, they were interview by a school nurse about cancer signifiance.
45631517|NCT02376413|Procedure|Breast surgery|Traditional breast-conserving surgery, oncoplastic breast-conserving surgery or modified radical mastectomy
45631518|NCT02376413|Drug|Chemotherapy or endocrine therapy or Trastuzumab therapy|
45913516|NCT02023606|Drug|SPN-810M|
45935301|NCT00077493|Procedure|immunotoxin therapy|tested for immunogenicity to CAT-8015 before each cycle and at end of study.
45935302|NCT00077493|Procedure|monoclonal antibody therapy|administered intravenously over 30 minutes.
46070004|NCT00798811|Procedure|high-dose chemotherapy and autologous stem cell rescue|Surgery pre-HDCT chemotherapy (6 cycles: A1, B1, A2, B2, A3, B3) PBSC collection during first cycle of chemotherapy (A1) (2nd look surgery if necessary) (if relapse or progression prior to HDCT, off study -> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM) (RT if necessary) Observe
46070005|NCT00798811|Procedure|high-dose chemotherapy and autologous stem cell rescue|(Surgery if possible) Chemotherapy (4 cycles) PBSC collection during first cycle of chemotherapy during 4th cycle of chemotherapy (if BM involvement) (RT, if possible, after PBSC collection) (if less than PR prior to HDCT, off study) HDCT1 (CTE) HDCT2 (CM)
45631519|NCT02376413|Radiation|Radiation therapy|
45631520|NCT04688710|Behavioral|Self-Hypnosis (HYP)|"Self-Hypnosis (HYP) teaches skills people with MS can use to effectively self-manage symptoms related to fatigue. Recordings are designed to help participants learn new strategies for influencing fatigue and its effects on their lives. The Self-Hypnosis recordings will start with a relaxation hypnotic induction (e.g., Notice how with each breath, you are feeling more and more relaxed …) followed by hypnotic suggestions (e.g., for experiencing more energy, improved sleep, more comfort or less pain, etc.). The goal of Self-Hypnosis is to change participant's experiences. To the extent that participants respond to the suggestions, participants would then get more control over their feelings of energy, sleep quality, and comfort levels."
45770947|NCT05586386|Other|Placebo group|200 mL of placebo juice twice/day
45770948|NCT05585840|Device|Biofeedback-based virtual reality game|The application will be a biofeedback-based virtual reality game developed by the researchers in collaboration with engineering in line with the literature review.
46070006|NCT02554123|Drug|Vitamin E ointment application|Vitamin E ointment application. Every 12 hours during 7 days.
45770949|NCT04757870|Other|frequency|Macro-scale risk factors for the frequency of and mortality of infection
45770950|NCT02279654|Drug|Lenalidomide|Lenalidomide as prescribed in routine clinical practice for low to intermediate-1 risk MDS
45770951|NCT02278718|Drug|NexoBrid|NexoBrid is an enzymatic debriding agent for Eschar Removal.
45770952|NCT02278718|Procedure|Standard of Care|Surgical or Non-Surgical methods for Eschar Removal
45631521|NCT04688710|Behavioral|Mindfulness Meditation (MM)|"Mindfulness Meditation (MM) teaches skills people with MS can use to effectively self-manage symptoms related to fatigue. Recordings are designed to help participants learn about a new way to live with chronic fatigue and new ways to relate to how fatigue may influence their thoughts, feelings, and behavior. The mindfulness techniques train the mind to non-judgmentally observe experience (e.g., symptoms of fatigue or pain, etc.) on a moment-to-moment basis, with an attitude of acceptance. The goal of Mindfulness Meditation is not to alter experiences, but rather to change how someone responds to their experiences. With practice, automatic, kneejerk reactions to symptoms are replaced with mindful choices about how best to respond to symptoms. This will lighten the load of living with the symptoms, moving participants in the valued direction of their choosing."
45631522|NCT02376023|Other|mHealth|Text and voice messages sent to study participants reminding them to schedule a PAP smear.
45770953|NCT02780024|Drug|Metformin|Metformin,
45770954|NCT02779478|Procedure|Bronchoscopy|
45631523|NCT02376101|Procedure|Surgery less than 60 minutes|
45631524|NCT02378285|Device|ACP|ACP is prepared using the Autologous Conditioned Plasma (ACP®) device from Arthrex (Naples, Florida, USA), following the supplier instructions. 2 mL of ACP are transferred in a standard 2 mL injection syringe by a nurse. The standard 2 mL injection syringe is then given to the physician.The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
45631525|NCT02378285|Other|Saline solution|2 mL of saline solution are placed in a standard injection syringe by a nurse. The syringe is then given to the physician. The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
45631526|NCT02378441|Drug|Atorvastatin 20mg and Metformin SR 750mg|co-administration of Atorvastatin 20mg and Metformin SR 750mg
45631527|NCT02378441|Drug|CJ-30056 20/750mg|fixed-dosed combination of Atorvastatin 20mg and Metformin SR 750mg
45631528|NCT04072445|Drug|Irinotecan|Given IV
45631529|NCT04072445|Drug|Irinotecan Hydrochloride|Given IV
45631530|NCT04072445|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
45770955|NCT04757948|Procedure|Acupuncture|Acupuncture of acupoints P-6 and St-36
45631531|NCT02378519|Behavioral|Web-prog, followed by CBT + PT|This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.
45631532|NCT02378519|Behavioral|Base, followed by Web + CBT + PT|The intervention consists of a interactive web-based selfadministrated program with cognitive behavioral therapy coaching in combination with tailored physiotherapy according to the person's needs for 16 weeks.
45631533|NCT04600427|Procedure|Epidural anesthesia|T11-12 epidural blockade with 0.25% bupivacaine continuous infusion.
45631534|NCT04595981|Drug|Cisplatin|Subjects will be admitted to the UAB Heart and Vascular Center, pre-medicated with 24 mg Ondansetron IV, 500 mg Prednisolone IV and 1.5 L NaCl with 20 meq KCl IV. The chemo-embolic agent is prepared in the HVC pharmacy by reconstituting 300 mg lyophilized Cisplatin in 60 mL 0.9% NaCl. Subjects are placed under anesthesia in the angiography suite. The access site is prepped and draped in sterile fashion then the femoral artery is catheterized using a 5-French catheter containing a coaxial microcatheter. After superselective visualization of the tumor-feeding vessel, a microcatheter is advanced into the target vessel and infused with 150 mg m2 cisplatin in 45-60 mL NaCl over 30-60 seconds. 10 seconds after the infusion starts, 9 gm sodium thiosulphate is administered IV to neutralize systemic Cisplatin. A post-infusion angiogram is then performed to assess the adequacy of embolization. The catheter is removed and the arteriotomy site closed with a subcutaneous suture.
45631535|NCT03985943|Drug|Placebo|Placebo
45770956|NCT04757948|Device|TENS|TENS of acupoints P-6 and St-36
45770957|NCT04757948|Device|Sham-TENS|Sham-TENS of acupoints P-6 and St-36
45770958|NCT01893476|Other|Implementation educational programme|Implementation educational programme will include: brief anti-smoking counseling, mMRC scale, checklist, training patient on correct use of inhaling. Participating physicians will receive training in brief anti-smoking counselling and will be asked to record information about. Additional form containing the mMRC dyspnoea scale will be inserted into patients' medical records. We will elaborate a checklist for practitioners with information about what should be done while consulting a patient with COPD. Investigators will provide practices with training inhaler and train staff. Practitioners will be asked to teach patients in correct use of each device. Practitioners will be asked to put this information to the patient's medical records.
45770959|NCT02773706|Other|Automated Psychology Services|The automated screening tool determines a positive or negative screen, then informs the clinician, and also automates a psychology visit.
45770960|NCT02773706|Other|Notification of Subspecialist|The automated screening tool determines a positive or negative screen, then informs the clinician.
45913517|NCT02023632|Behavioral|Similar-Age-Same-Gender (SASG)|The core feature of the program is that it is exclusively for those of a similar age and same gender. Such an environment was reported to provide opportunities for social connectedness, as well as personal comfort. Secondly, exercise class instructors are volunteers- both providing 'similar-models' to enhance efficacy as well as reduce costs associated with instructors. Consistent with social identity and self-categorization perspectives, the program also makes use of a series of strategies to foster intra-group attraction and group identity. For many of the participants a major draw of the program is that it provides opportunities for the older adults to connect with one another after the classes have ended.
45631536|NCT03985943|Drug|Nemolizumab|Nemolizumab
45631537|NCT02378129|Drug|Resin-modified glass ionomer cement Clinpro XT|Clinpro XT (3M ESPE, Minnesota, USA)
45770961|NCT02274896|Device|PD Catheter group|PD catheter
45770962|NCT02272556|Other|Brain MRS during hyperglycemic clamp|All patients will undergo brain MRS at baseline and following 2 and 4 hours of hyperglycemia using the clamp technique
45770963|NCT02272556|Other|Analysis of Metabolites in cerebrospinal fluid|All patients will have the option to undergo a lumbar puncture for analysis of metabolites in cerebrospinal fluid
45770964|NCT02582918|Behavioral|Outreach with patient education and patient navigation services|"Outreach invitations include number to call for more information about scheduling an ultrasound and alpha fetoprotein (AFP) blood test.~Patients receive up to three phone calls 2-4 weeks after invitations and a reminder call 5-7 business days before appointments.~If results are normal, the patient is invited to repeat screening in 6 months.~If suspicious mass on ultrasound or abnormal AFP level, the patient is referred for follow-up testing with triple-phase CT scan or MRI.~If CT/MRI is unremarkable, the patient is referred back for routine screening.~If HCC is confirmed, the patient and their primary care provider will be contacted with the results.~All patients diagnosed with HCC will be seen in the multi-disciplinary HCC clinic."
45770965|NCT02268656|Drug|propofol concentration|First subjects start from effect site concentraion of 5ug/ml propofol, after insertion of i-gel, determine the next subjects' effect site concentraion would be increae or decrease 0.5 ug/ml as up and down method
45770966|NCT02772770|Other|Non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions|The non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions.
45770967|NCT02772770|Procedure|Surgical technique: Transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for transphyseal reconstruction with soft tissue graft and metaphyseal fixation.
45631538|NCT02378129|Drug|Glass Ionomer cement Vidrion R|Vidrion R (SS White, Gloucester, UK)
46070007|NCT02554123|Drug|Vaseline ointment application|Vaseline ointment application. Every 12 hours during 7 days.
46070008|NCT00799045|Drug|Clopidogrel|Patients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
45631539|NCT02375945|Device|New non-elastic compression kit|Comparison of new non-elastic bandage kit with the currently accepted method
45631540|NCT02375945|Device|current compression stocking Comprinet®|Comparison of new non-elastic bandage kit with the currently accepted method
45447721|NCT02888288|Behavioral|Mental Health Intervention|Includes a standard format of greetings, review of last session content, homework discussion, new topic, assigning homework and ends with a fun activity, relaxation or game. First session is a joint session with youth and caregivers. Topics include common stresses and worries experienced by HIV+ youth; relaxation and coping techniques; cognitive behavioral triangle; story of finding out HIV status and if willing, to discuss this in an individual session, peer group session, and with caregiver; identify circles of support; discuss stigma and how to disclose HIV status to others; consider values, hopes and dreams for the future, and how to use this information to live positively with HIV. ART adherence is woven into case examples and discussions.
45447722|NCT02888288|Behavioral|Standard of Care|Standard of Care includes enhanced ART adherence based on clinic protocols and monthly HIV teaching sessions prior to adolescent clinic.
45447723|NCT02116894|Biological|PF-03446962|PF-03446962 will be an investigational formulation supplied by Pfizer . PF-03446962 injection, 10 mg/mL is presented as a sterile solution for IV administration in a formulation consisting of precedented excipients. We will be administering PF-03446962 intravenously at a starting dose of 4.5 mg/kg and escalating to up to 7 mg/kg.
45447724|NCT02116894|Drug|Regorafenib|We will be administering regorafenib on-label for the indication of metastatic colorectal cancer. The indicated dose is 160 mg once daily for the first 21 days of a 28 day cycle. We will start at a regorafenib dose of 120 mg in the combination therapy, but may increase to 160 mg during dose escalation.
45631541|NCT02376335|Biological|Rituximab|The Rituximab dosing regimen identified is that used in the proof of concept study, which is also the established treatment regimen for Rituximab use in rheumatoid arthritis. All interventions will be administered with a clinician present throughout the infusion in participants who have been encouraged to have adequate oral hydration in the 24 hours prior to attendance. Resuscitation equipment will be immediately available during the infusion period. Blood pressure, heart rate and temperature will be monitored during the infusion. Participants will continue to be observed in the Clinical Research Facility for at least 1 hour after the infusion.
45631542|NCT02376335|Other|Placebo|Participants will be randomised to Rituximab therapy (1000 mg IV on day 1 and 15) or placebo (0.9% Sodium Chloride 250 mls) control
45631543|NCT02375789|Device|Active RhinoChill|"The device is intended for use for the reduction of temperature via the nasal cavity.~The RhinoChill® System is a British Standards Institution Kite-Marked device that is currently commercially available in Europe. The RhinoChill® device is intended for temperature reduction in patients via the nasal cavity."
45447725|NCT02856620|Other|Observational only|Observational only
45447726|NCT02113072|Drug|Beclomethasone|The wheezing infants will be using the inhaled corticosteroid beclomethasone 50mcg - 02 jets per day (100mcg/dia).
45631544|NCT02375789|Device|Placebo RhinoChill|The placebo RhinoChill device looks and functions in an identical way to the active RhinoChill. All components are used, however through some minor changes in the design of the device it now provides a sufficient placebo treatment to the patient.
45631545|NCT02375867|Drug|prednisolone|Oral administration of 1 mg/Kg/day
45631546|NCT02375867|Drug|methylprednisolone|Intravenous injection of 0.8 mg/kg/day
45631547|NCT02378051|Behavioral|Staying Strong with Schools Intervention|"On-Site Training to Raise Awareness about the Stress of Parental Deployment and Review Resources Helpful in Promoting military-connected children (MCC)'s Resilience. A 60-minute training will be delivered by our Liaison Trainer on-site to school professionals at the beginning of the school year.~Training and supervision of the Resilience Support Liaison (RSL). In each school receiving the Staying Strong with Schools intervention, we will train the guidance counselor to take on the role of a RSL. The RSL will develop for each MCC an individual resilience support plan that will outline the specific intervention components that will be applied for him/her."
45631548|NCT02378051|Other|Waitlist Control|Receipt of an educational pamphlet outlining resources useful to support military-connected children distributed to all educators at the beginning of the school year.
45447727|NCT02113072|Drug|Probiotics|Lyophilized form, each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
45631549|NCT02377739|Other|non-invasive ventilation|patients will undergo a nocturnal non-invasive ventilation
45913518|NCT02023632|Behavioral|Similar-Age-Mixed-Gender (SAMG)|The SAMG physical activity condition will mirror the SASG group condition, but will be open to older adults from both genders. The same strategies to those used within the SASG condition will also be utilized (development of a unique program name, T-shirts, opportunities to socialize after the program), and will be offered three days per week (Mon, Wed, Fri, or Tues, Thurs, Sat). Older adults will also be recruited to be instructors for the group classes (= 65 years), with both males and females invited to occupy these instructional roles. (As with the SASG condition, training will take place between September and December 2013, through the respective YMCA centres. The YMCA will oversee the training of these volunteers through their Fitness Leader Training Program).
45913519|NCT02023632|Behavioral|Mixed-Age-Mixed-Gender (MASG)|The third condition utilized within the RCT is designed to reflect 'standard' group based exercises that one sees in typical physical activity centres. Specifically, these classes are not restricted to participants on the basis of age or gender, and as such older adults will be participating in groups comprised of people younger than themselves as well as those of both gender.
45913520|NCT02023645|Dietary Supplement|active supplement|tablet
45447728|NCT02113072|Drug|Placebo|The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics, 1 g sachet for 60 days, in the juice, milk or yoghurt.
45447729|NCT02113150|Drug|remifentanil|renal function
45447730|NCT02113150|Drug|Ketamine|renal function
45447731|NCT04647500|Drug|Concerta|Evaluation of a treatment of Concerta over a period of 13 days.
45631550|NCT04540133|Drug|dexamethasone 0.5mg/5ml solution|Patient with oral ulcerative conditions will be asked to rinse with dexamethasone 0.5mg/5ml solution three times a day for 4 weeks and expectorate
45631551|NCT04540133|Drug|dexamethasone 0.5mg/5ml solution in Mucolox™|Patient with oral ulcerative conditions will be asked to rinse with dexamethasone 0.5mg/5ml solution in Mucolox™ three times a day for 4 weeks and expectorate
45631552|NCT02375633|Drug|DW-330SR2|
45631553|NCT02375633|Drug|Pelubiprofen|
45631554|NCT02375711|Biological|Blood sample|A blood sample of 35 ml is achieved at 1 month to evaluate the anti-HBV cell response. Two other blood samples of 10 ml are scheduled 3 and 6 months after vaccination to assess humoral response to HBV vaccination.
45631555|NCT04448483|Device|Paretic upper limb functional electric stimulation through RehaStim|"The stimulation will activate upper limb muscles to perform motor rehabilitation exercises for the upper limb with the help of the Gloreha Sinfonia robotic glove that will assist-as-needed hands movements. Motor intention will be detected by a BCI (Brain Computer Interface) from the non-invasive measure of brain activity by using electroencephalography.~The motor rehabilitation exercises include upper limb and hand mobilization and functional tasks, such as hand open/closing, wrist flexion/extension, and reach and grasp a cup, keep and release."
45631556|NCT04448483|Device|Non-invasive transcranial current stimulation through DC-Stimulator|Non-invasive brain stimulation in the form of transcranial direct current stimulation will be provided in addition to the previous intervention.
45631557|NCT02375477|Other|Educational Intervention|Given educational presentation
45631558|NCT02375243|Drug|dexmedetomidine|dexmedetomidine continous infusion 0.5 mcg/kg/h
45770968|NCT02772770|Procedure|Surgical technique: Partial transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include partial transphyseal reconstruction (tibial transphyseal and femoral epiphyseal) with soft tissue graft.
45913521|NCT02023645|Other|placebo|tablet
45913522|NCT02023658|Other|pMTCT systems analysis and improvement|Five-step systems analysis and iterative improvement cycles carried out over a six-month period in intervention facilities.
45913523|NCT02023684|Drug|control saline|Surgical bed irrigation with saline 40ml
45913524|NCT02023684|Drug|Lidocaine|surgical bed Irrigation Lidocaine 0.5%, 40ml
45913525|NCT02023684|Drug|Ropivacaine|surgical bed Irrigation Ropivacaine 0.2%, 40ml
45447732|NCT01368406|Behavioral|wellness program|12-week weight management intervention in patients with severe mental disorders. In the 1-hour weekly group sessions topics like dietary choices, lifestyle, physical activity and self-esteem were discussed with outpatients and their relatives
45447733|NCT02119780|Device|YVOIRE® contour|YVOIRE® contour injection into the anteromedial malar region
45447734|NCT02119780|Device|Restylane SubQ™|Restylane SubQ™ injection into the anteromedial malar region
45770969|NCT02772770|Procedure|Surgical technique: Physeal sparing reconstruction by the Anderson method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for physeal sparing epiphyseal reconstruction with soft tissue graft (Anderson technique).
45770970|NCT02772770|Procedure|Surgical technique: Physeal sparing reconstruction by the Micheli/Kocher method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include physeal-sparing with Iliotibial band combined extra-articular and intra-articular reconstructions (Micheli/Kocher Technique).
45770971|NCT02564978|Drug|Minocycline|Adult participants will be instructed to take their prescribed IP orally two times a day, once in the morning and once in the evening, approximately 12 hours apart. The capsules will be dispensed to the participant in a tight, light-resistant container as defined in the USP in three-month supply aliquots. Starting at Month 9 and continuing at Month 12, a three-month supply will be dispensed to the participant during the study visit or mailed to the participant. Participants will be given an instruction sheet for taking the prescribed IP. Starting at Month 15 participants will receive two bottles for a six-month supply. The IP should be stored between 15-30 degrees C (or 59-86 degrees F).They should be protected from light, moisture, and excessive heat. Participants will be required to bring their bottles of IP to each appropriate visit for capsule counts for compliance monitoring.
45631559|NCT02375321|Behavioral|CPAP and Psychological support|Six sessions of psychological support with cognitive behavioural orientation lasting 1 hour every two weeks for 3 months
45631560|NCT03113045|Other|seated time|Pt will be seated for a predetermined time period. All Patients will receive intrathecal bupivacaine and morphine.
45631561|NCT03105401|Other|Assessment of hallucinations in Parkinson's disease|Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.
45631562|NCT03105557|Device|Urinary collecting device|Urinary collecting device
45631563|NCT02375009|Procedure|Selective laser trabeculoplasty|laser therapy to trabecular outflow pathway of the eye to lower intraocular pressure, delivered to 360 degrees of both eyes in a single session
45631564|NCT02374931|Drug|F-18 16 Alpha-Fluoroestradiol|Undergo 18F-FES PET/CT
45631565|NCT02374931|Procedure|Positron Emission Tomography|Undergo 18F-FES PET/CT
45913526|NCT02023710|Drug|Paclitaxel|175 mg/m^2 by IV infusion on the first day of each 4-week cycle (dose was based on patient's weight and could be adjusted for weight change)
45913527|NCT02023710|Drug|Carboplatin|Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 4-week cycle
45447735|NCT02113306|Device|t-VNS|The device that will be used is approved for systematic use by those with epilepsy and depression in the European Union. It has been used in studies of acute stimulation with healthy participants with no significant changes in heart rate or breathing (Kraus et al., 2007; Busch et al., 2013).
45631566|NCT02374931|Procedure|Computed Tomography|Undergo 18F-FES PET/CT
45631567|NCT02374931|Other|Laboratory Biomarker Analysis|Correlative studies
45447736|NCT02113306|Device|sham stimulation|electrodes will be put upside down
45631568|NCT02374697|Device|During tele-expertise|
45770972|NCT02769416|Other|Data and sample repository|Subjects with spinal cord and/or traumatic brain injury, family members and healthy volunteers will provide data and samples.
45770973|NCT02554890|Drug|sacubitril/valsartan (LCZ696)|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
45770974|NCT02554890|Drug|Enalapril|Enalapril tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
45913528|NCT02023710|Drug|Bevacizumab|5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
45913529|NCT02023723|Dietary Supplement|Energy Drink|16oz energy drinks - 2 consumed within 60 minutes
45913530|NCT02023723|Dietary Supplement|Active Control|16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
45913531|NCT02023736|Other|Systemic Therapy Inventory of Change (STIC)|The STIC is a computerized measurement and feedback system for use in psychotherapy. The measurement system consists of weekly questionnaires, completed on the computer, that target symptoms and functioning in a variety of domains of a clients life (e.g., individual symptoms, couple functioning, family functioning, relationship with children). The feedback system consists of a web-portal where therapists may access their clients' STIC responses, for the purposes of planning treatment, assessing progress, and discussing change with clients.
45631569|NCT02374619|Dietary Supplement|Iron supplement Resoferon Ferrous Sulfate|Oral supplementation with one tablet of iron supplement [Resoferon Ferrous Sulfate 125 (37) mg]
45631570|NCT02374619|Dietary Supplement|Placebo|
45631571|NCT02377661|Drug|Olmesartan medoxomil, amlodipine, hydrochlorothiazide|Up-titration of antihypertensive therapy with single pill combinations (comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide) in 4-week intervals if the target blood pressure of < 140/90 mmHg is not reached at the respective follow-up
45631572|NCT02377505|Device|On-Stimulation|"The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is on"
45631573|NCT02377505|Device|Off-Stimulation|"The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is off"
45631574|NCT02372357|Drug|Posaconazole prophylaxis 120 mg/m² tid|Patients are receiving posaconazole to prevent invasive fungal infections in a dose of 120 mg/m² tid
45631575|NCT02372357|Procedure|Blood sampling|During steady state treatment with posaconazole (at least 7 days), 9 blood samples are taken via a central venous catheter to evaluate the pharmacokinetics of posaconazole.
45770975|NCT02554890|Drug|sacubitril/valsartan (LCZ696) matching placebo|matching placebo of sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
45770976|NCT02554890|Drug|enalapril matching placebo|enalapril matching placebo tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
45770977|NCT02550548|Drug|GIP infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GIP will be infused
45770978|NCT02550548|Drug|GLP-1 infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GLP-1 will be infused
45631576|NCT02374541|Behavioral|Patient Navigation|The Autism Patient Navigator (APN) will interview families to determine system and individual barriers facing the family at each stage of the care process. The APN will help families to overcome any identified barriers through education, coaching, social support, interpretation or translation, linkage to resources (e.g., for obtaining insurance) or logistical support (e.g., scheduling appointments, providing reminders, arranging transportation), in order to ensure timely diagnostic evaluation / eligibility determination; educate the family about autism, tests and treatments; and offer psychosocial support.
45770979|NCT02550548|Drug|Ex-9 infusion|Ex-9 infusion will be initiated at start of hyperglycemic clamp (target: 125 mg/dL)
45631577|NCT02374385|Biological|BPSC-1001 (VSVΔG-ZEBOV)|Ebola vaccine candidate
45770980|NCT02263274|Device|Transcranial Direct Current Stimulation (TDCS)|Conventional tDCS and low-frequency tACS are commonly administered at a current intensity of 2 mA or less
45631578|NCT02374385|Other|Placebo|Normal saline
45631579|NCT02374229|Procedure|Surgical ablation of ganglion plexus pulmonary artery.|Performed ablation zone pulmonary artery bifurcation, at 2mm proximal direction and a distal direction in the left and right branches of the pulmonary artery using the electrophysiological device Atricure.
45631580|NCT02374229|Procedure|mitral valve surgery|The standard procedure for mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement, depending upon the particular morphological condition of the mitral valve.
45631581|NCT02374151|Device|Electrohysterography|The EHG uses a Graphium electrode patch that is applied to the abdomen and records electrical activity non-invasively
45631582|NCT02374073|Other|Functional Massage|The functional massage is a manual therapy technique, indicated in cases of painful muscle tightness that combines a rhythmical and non painful passive joint mobilization in the direction of muscle stretching together with compression/decompression of the muscle to be treated.
45631583|NCT02374073|Other|Protocolized physiotherapy|therapeutic exercises, analgesic electrotherapy and cryotherapy
45770981|NCT02257112|Device|Multistage low-energy stimulation|The parameters of the Multistage waveform will be altered and the response of the atria will be recorded.
45770982|NCT00001864|Drug|Atropine|
45770983|NCT00001864|Device|Patch|
45913532|NCT02023736|Other|Treatment as Usual|Clients receive psychotherapy treatment as planned and implemented by their psychotherapists. Exact type of treatment varies by therapist and according to client need.
45447737|NCT02113384|Other|Observational study.|Biobanking of tissue (tumor biopsy, peritoneal lavage, blood specimen) from patients with locally advanced rectum cancer undergoing surgical resection of the primary tumor at the Norwegian Radium Hospital.
45631584|NCT03672773|Drug|Talazoparib|Given PO
45913533|NCT02023749|Dietary Supplement|Nut group|
45631585|NCT03672773|Drug|Temozolomide|Given PO
45631586|NCT02371967|Drug|Vismodegib|Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.
45631587|NCT02373839|Other|Measurement of PlGF|If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks
45631588|NCT03625349|Drug|NG-Monomethyl-L-Arginine|Inhibitor of nitric oxide synthase.
45631589|NCT02371811|Device|uterine manipulator (v care)|
45631590|NCT02373761|Device|Stryker Triathlon Tritanium primary knee|
45631591|NCT02373995|Biological|LAB4|Additional treatment with the specific LAB4 probiotic preparation
45770984|NCT04491552|Diagnostic Test|Patients monitored with TruGraf and TRAC testing|This is an observational study there are no protocol mandated interventions. TruGraf and TRAC results will be utilized in conjunction with standard of care assessments to determine patient management.
45770985|NCT02232152|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
45770986|NCT02232152|Drug|fluorouracil|Given IV
45913534|NCT02023775|Device|Melody valve implantation|
45913535|NCT02023788|Biological|PNEUMOSTEM|"A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10^7 cells/kg High Dose Group (6 patients): 2.0 x 10^7 cells/kg~* The subjects were administered with Pneumostem in the earlier part of the Phase I study. No drug/biologics will be administered to any subject during this part of the study."
46070009|NCT04713085|Device|Invasive Sacral Neuromodulation|Internal, implanted sacral nerve stimulation (electrodes in contact with neuronal fibers S3/4)
45631592|NCT02371655|Procedure|Diet|A low-fibre diet for three days before the examination
45631593|NCT02371655|Drug|Faecal Tagging|Oral ingestion of iodinated contrast media (Gastrografin 60 ml) 3h before the examination
45631594|NCT02371655|Drug|Bowel cleansing|Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination
45770987|NCT02232152|Other|pharmacological study|Correlative studies
45770988|NCT02232152|Other|laboratory biomarker analysis|Correlative studies
45770989|NCT00000106|Device|Whole body hyperthermia unit|
45631595|NCT02371655|Procedure|CT colonography|CT Examination of the colon aimed to detect polyps and cancer
45447738|NCT03553108|Drug|Olaparib Treatment A|Olaparib Tablet 25 mg
45631596|NCT02371577|Drug|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events Duration of lenalidomide on the clinical trial is for up to 6 cycles, each of 28 day duration.
45631597|NCT02373449|Other|RS-fMRI|Resting State-functional Magnetic Resonance Imaging. Protocols involving BOLD (blood oxygen level-dependent) and non-BOLD techniques will be used.
45631598|NCT02373449|Drug|Ketamine|Part of standard care. To be performed over five consecutive days (Monday to Friday) for six hours per day. A therapeutic range of 0.5 to 2.0 mg/kg/hour is targeted.
45631599|NCT02371733|Other|Upper extremity aerobic exercise training|"Training group will receive upper extremity aerobic exercise training using arm ergometer at 50-80% of maximal heart rate and breathing exercises.~Training will exercise with arm ergometer 3days/week, for 6 weeks with the assistance of a physiotherapist. Training workload will be undercontrol both using target heart rate and Modified Borg dyspnea scale. Training group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks."
45631600|NCT02371733|Other|Alternative upper extremity exercises|"Control group will receive alternative upper extremity exercises and breathing exercises. Control group will perform alternative upper extremity exercises 3days/week, for 6 weeks and also breathing exercises 120 times/day, 7 days/week, for 6 weeks.~Control group will be followed-up by telephone once a week."
45631601|NCT02371499|Dietary Supplement|Lactobacillus casei DG|the patients will receive 1 capsule of Lactobacillus casei DG (Enterolactis plus®) twice daily for 4 weeks
45631602|NCT02371499|Dietary Supplement|Placebo|the patients will receive 1 capsule of product without bacteria (Enterolactis placebo) twice daily for 4 weeks
46070010|NCT04713085|Device|Non-invasive Sacral Neuromodulation|External, non-invasive sacral nerve stimulation via two cutaneously adhesive electrodes (single current).
45631603|NCT02371421|Drug|Allopurinol|
45447739|NCT03553108|Drug|Olaparib Treatment B|Olaparib Tablet 100 mg
45447740|NCT03553108|Drug|Olaparib Treatment C|Olaparib Tablet 150 mg
45631604|NCT02373527|Other|No Fasting prior to catheterization|No restriction for oral intake
45447741|NCT03553108|Drug|Olaparib Treatment D|Olaparib Tablet 250 mg
45447742|NCT02119858|Drug|indocyanine green solution|Given transperineally
45447743|NCT02119858|Other|diffuse optical imaging|Undergo near infrared fluorescence imaging
45447744|NCT02119858|Procedure|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic radical prostatectomy
45447745|NCT02119858|Procedure|therapeutic lymphadenectomy|Undergo lymphadenectomy
45447746|NCT02117128|Drug|Tranexamic acid|
45447747|NCT02117206|Drug|L-arginine (L-arginine Veyron)|
45447748|NCT02117206|Drug|Nacl|
45447749|NCT00175877|Biological|Certolizumab Pegol|"Strength and Form: Lyophilized product reconstituted to 1 ml containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study."
45770990|NCT02229656|Radiation|radiotherapy|Primary tumor and lymph nodes will receive 35 fractions of 2 Gy resulting in a total dose of 70 Gy. Elective fields will receive 35 fractions of 1.55 Gy resulting in a total dose of 54.25 Gy in case a SIB technique is used, or 23 fractions of 2 Gy resulting in a total dose of 46 Gy in case a sequential boost technique is used. The higher total prescribed physical dose to the elective fields in a SIB technique based RT plan compensates for the lower dose per fraction and results in an equal biological effective dose when compared with a sequential boost technique.
45770991|NCT02229656|Drug|Olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, and 300 mg BID
45770992|NCT04482660|Procedure|Positron emission tomography with 18F-RO6958948|tau PET ()
45770993|NCT00001870|Drug|Acetylcholine|
45770994|NCT03252600|Drug|Cyclophosphamide|Given IV
45631605|NCT02373605|Other|Dry Needling,Thrust Manipulation|HVLA thrust manipulation to upper cervical and upper thoracic regions. Dry needling to cervicothoracic and craniofacial regions. Up to 8 treatment sessions over 4 weeks.
45631606|NCT02373605|Other|Exercise,Non-thrust Mobilization|Non-thrust mobilization and exercise to upper cervical and upper thoracic regions. Up to 8 treatment sessions over 4 weeks.
45631607|NCT02371343|Dietary Supplement|Fish oil, Ocean plus|Ocean Plus, 1200 mg, EPA 384 mg DHA 252 mg, total omega-3 782 mg, 50 soft gel, Ocean®, Germany
45631608|NCT02371343|Dietary Supplement|Sunflower Oil|
45631609|NCT02371109|Other|selftaken versus clinically taken swabs|
45631610|NCT02371031|Drug|6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine|
45631611|NCT02371031|Device|PET/MRI|
45631612|NCT02371031|Procedure|Surgical resection (standard of care)|
45631613|NCT03959891|Drug|Ipatasertib|Ipatasertib is a type of inhibitor that is believed to work by inhibiting Akt.
45631614|NCT03959891|Drug|Fulvestrant|Hormone therapies work by stopping the production of a certain hormone, blocking hormone receptors, or substituting chemically similar agents for the active hormone, which cannot be used by the tumor cell.
45631615|NCT03959891|Drug|Aromatase Inhibitor|Letrozole is an aromatase inhibitor. This means it blocks the enzyme aromatase (found in the body's muscle, skin, breast and fat), which is used to convert androgens (hormones produced by the adrenal glands) into estrogen. In the absence of estrogen, tumors dependent on this hormone for growth will shrink.
45631616|NCT03959891|Drug|Palbociclib|Palbociclib (Ibrance®) is a drug that can be used along with an aromatase inhibitor to treat women with advanced hormone receptor-positive breast cancer. Palbociclib is a reversible small molecule cyclin-dependent kinase (CDK) inhibitor. The drug blocks proteins in the cell called cyclin-dependent kinase (CDK) 4 and CDK 6. In hormone positive breast cancer cells, blocking these proteins helps stop the cells from dividing to make new cells. It helps prevent the cells from moving from G1 to S cell cycle phase in the division process. This slows cancer growth.
45770995|NCT03252600|Drug|Dexamethasone|Given IV
45770996|NCT03252600|Biological|Elotuzumab|Given IV
46070011|NCT00658333|Drug|Enteric-coated Mycophenolate Acid (EC-MPA)|
46070012|NCT00658333|Drug|Mycophenolate Mofetil (MMF)|
46070013|NCT00658333|Drug|Placebo MMF|
46070014|NCT00658333|Drug|Placebo EC-MPA|
45770997|NCT03252600|Other|Laboratory Biomarker Analysis|Correlative studies
45770998|NCT03252600|Drug|Lenalidomide|Given PO
45770999|NCT03252600|Other|Pharmacological Study|Correlative studies
45631617|NCT02370953|Device|VERION for toric IOL alignment|The VERION Measurement Module is a diagnostic device which can make high resolution colour reference images of the patient's eye for position reference. The VERION Digital Marker is a medical device that assists the surgeon in planning and performing surgical procedures on the eye. The VERION tools use several reference points on the conjunctiva and limbus, and make an overlay between the preoperative achieved and live-surgery image. During surgery, this device projects the horizontal axis and the estimated placement axis of the toric IOL on the patient's eye, and therefore, the surgeon can accurately place the toric IOL to its preoperatively calculated angle.
45771000|NCT00000118|Device|Sustained-Release Intraocular Drug Delivery System|
45771001|NCT00000124|Procedure|Brachytherapy|
45771002|NCT00000124|Procedure|Eye Removal|
45771003|NCT00001894|Procedure|pacemaker implantation|
45771004|NCT00001894|Procedure|percutaneous transluminal septal ablation (PTSA)|
45771005|NCT02749526|Drug|"Endostar"|30mg civ24h d0-6.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
45771006|NCT02749526|Drug|Liposo|135mg/m2 D1.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
45913536|NCT02023827|Behavioral|RAYS Intervention|The Rise Above Your Situation program (RAYS) is a multimedia computer-tailored intervention that relies on the Transtheoretical Model of Behavior Change (TTM) and expert system technology to deliver assessments, feedback, printed reports, and helpgiver reports with intervention ideas. Helpgivers (probation officers in this case) use the reports to guide 1/2 hour follow-up discussions to reinforce intervention ideas and provide support.
45771007|NCT02749526|Drug|cisplatin|25mg/m2 D1-3.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
45771008|NCT02749526|Drug|Gimeracil and Oteracil Potassium （Tegafur）|40mg bid，D1-14.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
45771009|NCT00000916|Drug|Indinavir sulfate|
45913537|NCT02023840|Drug|metronidazole gel|
45771010|NCT00000916|Drug|Lamivudine/Zidovudine|
45771011|NCT00000916|Drug|Hydroxyurea|
45913538|NCT02023840|Procedure|ultrasonics|
45913539|NCT02023840|Procedure|erythritol|
45913540|NCT02023840|Drug|placebo|
45913541|NCT02023853|Procedure|ultrasonic|
45913542|NCT02023853|Procedure|erythritol|
45913543|NCT02023853|Drug|metronidazole gel|
45447750|NCT02120014|Procedure|blood volume measurement|"Patients will drink a solution 30 minutes prior to the test. They will need to lie still on a flat surface for 15 minutes. During the blood volume analysis portion of the test, a small amount of a radioactive isotope or tracer is injected.Blood samples are taken at 6 time points during the test. The blood volume test is used to measure the amount of blood in the patients body.~A hematocrit measurement is done on the blood samples taken. This blood test calculates the percentage of red blood cells in the bloodstream."
45771012|NCT00000916|Drug|Lamivudine|
45771013|NCT00000916|Drug|Stavudine|
45913544|NCT02023892|Drug|atorvastatin|
45913545|NCT02023892|Drug|placebo|
45913546|NCT02023931|Drug|Broccoli Sprout Extract (BSE)|"The first regimen will involve oral delivery and ingestion of 600 μmole doses of glucoraphanin-rich BSE (GRR-BSE), and will represent systemic delivery of sulforaphane to oral mucosa, due to the necessity to metabolize GRR-BSE in the gut.~The second regimen will involve oral delivery and ingestion of 100 μmole doses of sulforaphane-rich BSE (SFR-BSE), which will represent a combination of systemic and topical delivery to the oral mucosa.~The third regimen will isolate topical exposure of the oral mucosa to sulforaphane. Participants will swish, hold, then spit 100 μmole doses of SFR-BSE. This regimen (SFR-BSE(T)) will theoretically isolate the pharmacodynamic impact of topical exposure of the oral mucosa to sulforaphane."
45913547|NCT02023957|Behavioral|Interactive computer-assisted screening (iCAS)|
45913548|NCT02023970|Device|Patients receiving animal-derived bioprosthetic heart valves.|
45913549|NCT02023970|Other|Echocardiography (1)|
45913550|NCT02023970|Other|Echocardiography (2)|
45913551|NCT02023970|Other|Echocardiography (3)|
45913552|NCT02023970|Biological|Blood sample (1)|
45913553|NCT02023970|Biological|Blood sample (2)|
45913554|NCT02023970|Biological|Blood sample (3)|
45913555|NCT02024009|Drug|nab-paclitaxel|Abraxane is a proprietary solvent-free, protein-stabilized formulation of paclitaxel comprised of paclitaxel and human albumin in a noncrystalline amorphous state
46070015|NCT00804271|Drug|memantine|memantine tablets, OD, 12 weeks
45771014|NCT00000916|Drug|Zidovudine|
45771015|NCT00000916|Drug|Didanosine|
45771016|NCT02744612|Drug|Brentuximab Vedotin|Given IV
45771017|NCT02744612|Drug|Ibrutinib|Given PO
45771018|NCT04423770|Other|No intervention|No intervention; this is a purely observational study
45771019|NCT05475912|Other|Group A, excercises|Each group will receive treatment three times per week for 3 weeks total 7 sessions.
45771020|NCT02548364|Drug|Calcifediol|calcifediol treatment
45771021|NCT02548364|Drug|Placebo|placebo control group
45771022|NCT00000928|Behavioral|Group counseling intervention|Participants will engage in a multi-session group-based condom promotion program for approximately 12 months
45771023|NCT00000130|Drug|Intravitreal Antibiotics|
45771024|NCT00000130|Procedure|Initial Pars Plana Vitrectomy|
45771025|NCT02221310|Drug|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin 7.5 mg/m^2/dose given IV over 2 hours once during conditioning
45771026|NCT00000160|Procedure|Xenon Photocoagulation|
45771027|NCT00000160|Procedure|Argon Photocoagulation|
45771028|NCT00000160|Procedure|Photocoagulation|
45771029|NCT02552316|Device|NB-UVB Phototherapy|
45771030|NCT02215928|Genetic|mutation analysis|Correlative studies
45771031|NCT02215928|Other|cytology specimen collection procedure|Correlative studies
45771032|NCT02215928|Other|laboratory biomarker analysis|Correlative studies
45771033|NCT00000178|Drug|Prednisone|
45771034|NCT04423692|Other|labs|A group of questions to women regarding Corona with laboratory finding suggestive of covid 19 and coagulopathy
45631618|NCT02370953|Procedure|Conventional, manual ink-marking for toric IOL alignment|Several manually performed methods are used to align the toric IOL at the intended axis. Most of them use a 3-step procedure. First, the horizontal axis of the eye is temporarily marked with ink in a seated position to correct for cyclotorsion when changing into supine position. Three spots on the conjunctiva, close to the edge of the cornea, are applied at 0°, 90° and 180°, which may be done by using a bubblemarker or gravity marker with a calibrated horizontal position. Next, the desired alignment axis for the toric IOL is marked intra-operatively. The last step is to rotate the implanted toric IOL until the IOL markings agree with the alignment marks. After surgery is performed, the ink marks will disappear within a few hours.
45631619|NCT02373215|Drug|Nalbuphine HCL ER|Nalbuphine HCL extended release tablet
45631620|NCT02370875|Device|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
45631621|NCT02370875|Device|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
45631622|NCT02370719|Behavioral|Mobile application for diabetes self-management|
45771035|NCT00000190|Procedure|Parotid Gland|
45631623|NCT03808103|Biological|Placebo|Orally, twice a day, for a period of fifteen days
45631624|NCT03808103|Biological|Bacteriophage preparation|Orally, twice a day, for a period of fifteen days
45631625|NCT03785249|Drug|MRTX849|MRTX849 will be administered orally once or twice daily in a continuous regimen
45631626|NCT03785249|Drug|Pembrolizumab|Pembrolizumab is administered as an intravenous infusion once every 3 weeks
45771036|NCT05480280|Drug|Dalpiciclib|Dalpiciclib is orally administered at 125mg qd for 21 days and discontinue for 7 days.
45771037|NCT05480280|Drug|Oxaliplatin injection|85mg/m², ivdrip, D1
45913556|NCT02024009|Radiation|60Gy in 30#|
45913557|NCT02024009|Radiation|50.4Gy in 28#|
46070016|NCT00806533|Drug|HES 130 / 0.42 (Venofundin 6%, Tetraspan 6%)|solution for intravenous infusion applied according to SmPC
45631627|NCT03785249|Drug|Cetuximab|Cetuximab will be administered as an intravenous infusion once per week or once every 2 weeks
45631628|NCT03785249|Drug|Afatinib|Afatinib will be administered orally once a day in a continuous regimen
45631629|NCT02370563|Drug|18F-FSPG|18F-FSPG is a novel F18-labelled, radiopharmaceutical agent for PET imaging. It is administered intravenously at a dose of 300 MBq (8.1mCi ± 10%).
45631630|NCT02373059|Other|Diabetes Issue Cards Decision Aids|
45631631|NCT02373059|Other|Usual Pharmaceutical Care|
45631632|NCT03765983|Drug|Trastuzumab|"Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When targeted therapies attach to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system"
45631633|NCT03765983|Drug|GDC-0084|GDC-0084 has been shown to stop the activity of a protein called PI3-kinase. This action blocks a pathway in the body that cancer cells commonly use to grow and divide
45631634|NCT02372981|Device|mucopexy +/- Doppler-guided haemorrhoidal artery ligation|Mucopexy with or without DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.
45913558|NCT02024009|Drug|Nelfinavir|VIRACEPT® (nelfinavir mesylate) is an inhibitor of the human immunodeficiency virus (HIV) protease.
45913559|NCT02024009|Drug|Capecitabine|Given in combination with gemcitabine, known as GemCap.
45913560|NCT02024009|Drug|Gemcitabine|Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. It is administered as an infusion
45913561|NCT02024022|Drug|Standard approach|bowel cleansing with either 4L PEG or sodium picosulphate/magnesium citrate
45913562|NCT02024022|Drug|Individualized approach|
45913563|NCT02024035|Radiation|Radiotherapy|
45913564|NCT02024048|Other|OCT|Optical coherence tomography in enhanced depth imaging mode
46070017|NCT00804505|Device|SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens|Comparison to control hybrid lens with similar 'dose'minimum 8 hours daily use for up to 90 days.
46070018|NCT00804505|Device|SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens|Comparison to test lens: Daily use for minimum 8 hours up to 90 days.
45631635|NCT02370485|Drug|LY2801653|Administered orally
45631636|NCT02370173|Device|PTSD wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning.
45631637|NCT02370173|Device|PTSD wavelength-2 bright light|6 weeks daily light exposure, 30 minutes per morning.
45631638|NCT02372903|Drug|Administration of micronized Palmitoylethanolamide (PEA)- Transpolydatin|Palmitoylethanolamide 600 mg twice daily for 10 days sublingually and oral palmitoylethanolamide 400 mg and polydatin 40 mg, twice daily for 90 days
45631639|NCT02372825|Procedure|Reconstructive surgery|Reconstructive surgery with the free iliac crest flap
45631640|NCT02372591|Drug|Buprenorphine|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
45631641|NCT02372591|Drug|Hydromorphone|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
45631642|NCT02372591|Drug|Placebo|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
45771038|NCT05480280|Drug|Calcium folinate|400mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
45771039|NCT05480280|Drug|5-fluorouracil|400mg/m², iv, D1; and 2400mg/m², civ, 46-48h
45771040|NCT04757324|Other|breastfeeding education|
45771041|NCT00001906|Biological|Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants|
45913565|NCT02024061|Behavioral|Peer support|
45913566|NCT02024061|Behavioral|Regular treatment|The participants in this arm will receive the regular obesity treatment provided by the hospital and university (interactive sessions and physical activity).
45631643|NCT02372669|Device|Chitosan nerve tube in addition to gold standard therapy|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand with use of an chitosan nerve tube in addition. Clinical Follow-up will be performed after 3,6,12 and 24 months.
45631644|NCT02372669|Procedure|Gold standard Primary microsurgical repair|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand. Clinical Follow-up will be performed after 3,6,12 and 24 months.
45631645|NCT02370017|Biological|ANKL(Ex vivo-expanded NK cell enriched lymphocytes)|add ANKL in 3rd and 4th course in case of stable response after two initial courses
45631646|NCT02372747|Procedure|Delta-shaped anastomosis|The patients in DS group underwent Delta-shaped anastomosis after TLDG.
45631647|NCT02372747|Procedure|Billroth II anastomosis|The patients in B-II group underwent Billroth-II anastomosis after TLDG.
45447751|NCT02120014|Procedure|venous plethysmography|venous plethysmography is a non-invasive test to measure how well your veins and arteries in your forearm and calf work. Cuffs similar to blood pressure cuffs are placed on the upper and lower arm and the thigh and calf. Measurements are taken
45631648|NCT02369861|Drug|ST266|Topical ocular application 4 times per day
45771042|NCT02208830|Other|pulmonary rehabilitation|Pulmonary rehabilitation: 8 week, twice weekly exercise program with aerobic treadmill training and lower limb strength training.
45771043|NCT02208830|Other|conventional program|The conventional program is conducted with duration of 8 week, twice weekly. The techniques used will be: expiration with the glottis open in lateral posture (Eltgol), autogenous drainage (AD) and shaker. Each technique will last for 30 minutes.
45771044|NCT00000196|Drug|Naltrexone|
45771045|NCT05480202|Other|Thoracic block technique|Manual compression of the healthy lung during expiration associated with the use of invasive or non invasive mechanical ventilation
45771046|NCT05480202|Other|Designed chest physical therapy program|Percussion, vibration and postural drainage
45771047|NCT00000946|Biological|HIV p24/MF59 Vaccine|
45771048|NCT00000946|Biological|ALVAC-HIV MN120TMG (vCP205)|
45771049|NCT00000946|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
45771050|NCT00000946|Biological|rgp120/HIV-1 SF-2|
45771051|NCT02525432|Biological|Placebo Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the placebo control group will undergo a sham bone marrow harvest and receive a placebo infusion of saline.
45913567|NCT02024074|Other|Sestamibi (Tc-MBI) scan of the breast|Patients will be given 8mCi of Sestamibi intravenously. following which Sestamibi scan will be performed on the breast. Sestamibi scan will be done prior to any surgical procedure..
45447752|NCT02117362|Biological|1 mg/kg GR-MD-02|1 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
45447753|NCT02117362|Biological|2 mg/kg GR-MD-02|2 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
45771052|NCT02525432|Biological|Autologous BMMNC Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the BMMNC treatment group will undergo a bone marrow harvest and then receive an autologous stem cell infusion.
45771053|NCT02543346|Drug|Cetirizine|Participants will receive either cetirizine (10mg tablet, orally) or a placebo (sugar pill) at one of the two treatment visits.
45771054|NCT02543346|Other|Placebo|Participants will receive either a placebo or cetirizine (10mg tablet, orally) at one of the two treatment visits
45771055|NCT04390100|Drug|hyaluronic acid (Gengiegel 0.2% oral gel )|coverage of the free gingival graft area in the palate
45771056|NCT04390100|Other|Platelet rich fibrin|coverage of the free gingival graft area in the palate
45771057|NCT04390100|Other|Gel foam|coverage of the free gingival graft area in the palate
45447754|NCT02117362|Biological|4 mg/kg GR-MD-02|4 mg/kg GR-MD-02 on Days 1, 22, 43, and 65
45913568|NCT02024113|Other|Venous blood sample|Collection of a venous blood sample to investigate metabolic changes in blood
45913569|NCT02024126|Other|Exercise therapy|Exercise therapy
45913570|NCT02024139|Other|Chewing Sugarless Gum|Chewing sugar free gum three times per day for 5-10 minutes
45447755|NCT02117362|Biological|8 mg/kg GR-MD-02|8 mg/mg GR-MD-02
45447756|NCT02117362|Biological|Ipilimumab|3 mg/kg ipilimumab on Days 1, 22, 43, and 65
45631649|NCT02369861|Drug|Refresh Lubricant Eye Drops|Topical ocular application 4 timer per day
45631650|NCT02369783|Other|Questionnaire and interview|The aim is to detect social fragility.
45631651|NCT02369939|Radiation|Irradiation|Radiotherapy 55,8 Gy - 59,4 Gy
45631652|NCT02369939|Drug|Mitomycin C|MMC w1, w5
45631653|NCT02369939|Drug|5-Fluorouracil|5-FU w1, w5
45631654|NCT02369939|Procedure|Hyperthermia|6x deep regional hyperthermia
45631655|NCT03697577|Diagnostic Test|CT scans|Patients will undergo CT or PETCT as part of their standard of care
45631656|NCT03697577|Diagnostic Test|DEXA scan|Patients will undergo DEXA scan to measure body fat mass. This is part of proposed study.
45771058|NCT00000202|Drug|Buprenorphine|
45771059|NCT00000208|Drug|Buprenorphine|
45771060|NCT00001930|Drug|Amantadine|
45771061|NCT00000964|Drug|Ranitidine hydrochloride|
45771062|NCT00000964|Drug|Foscarnet sodium|
45771063|NCT00000976|Drug|CD4-IgG|
45771064|NCT00000976|Drug|Zidovudine|
45771065|NCT00000226|Drug|Buprenorphine|
45771066|NCT00000982|Drug|Zidovudine|
45771067|NCT00000982|Drug|Didanosine|
45771068|NCT04818814|Behavioral|Mindfulness Meditation App|Listening to audio-guided meditation sessions using a mobile app.
45771069|NCT04818814|Behavioral|Engagement and Distraction App|Listening to engaging and distracting videos of interest to the participant using a mobile app.
45771070|NCT02549196|Drug|Donepezil|Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
45771071|NCT02549196|Drug|Solifenacin|Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
45771072|NCT00000988|Drug|Stavudine|
45913571|NCT02024139|Other|Using Mouthwash|Rinse mouth with plax sensitive fluoridated mouthwash for 30 seconds, three times per day
45913572|NCT02024152|Drug|JDP-205 IV high dose|
45913573|NCT02024152|Drug|JDP-205 IV low dose|
45913574|NCT02024152|Drug|JDP-205 IM|
45913575|NCT02024152|Drug|Control: Zyrtec|
45631657|NCT02372435|Procedure|Shortening of the interval of two-stage prosthesis exchange|The Intervention consist in shortening of the interval between Explantation and re-implantation in patients undergoing a two-stage prosthesis Exchange. Comparison between arms is performed between short and long interval before re-implantation.
45631658|NCT02369627|Device|Rapid HIV Self-Test (OraQuick® In-home HIV Test)|The participant will utilize materials and directions contained within the OraQuick In-Home HIV Test kit to properly perform a rapid HIV self-test. The participant will first swab his upper and lower gums using an Oral Swab Test Stick. The participant will then place this device in a test tube, and the results will be displayed in the Test Window within 20 minutes. Test results expire after 40 minutes.
45631659|NCT02369627|Device|Conventional Home-Based HIV Test (Home Access Express)|The participant will utilize materials and directions contained within the Home Access Express HIV-1 Test System to properly perform a conventional home-based HIV test. The participant is required to gather a blood sample by lancing his finger. Blood samples are collected by placing drops of blood on a packaged specimen card. The participant will then mail his blood sample to the Home Access laboratory using a self-addressed, pre-paid shipping envelope. The Home Access laboratory will process the blood sample, and the participant is required to call the facility to learn his HIV test result.
45631660|NCT02369627|Other|Community/Medical-Based HIV Test|The participant will receive a link to a CDC website (https://gettested.cdc.gov) to search for HIV testing locations in his surroudning community. This resource website will provide the participant with places that offer HIV testing for free or at a low cost. The participant also has the option of going to places that can use his insurance or charge for testing. The pariticant is responsible to pay for any testing costs.
45631661|NCT02369549|Drug|Micro-particle Curcumin|as described in Arm
45631662|NCT02369549|Drug|Placebo|Looks, smells, tastes and feels exactly like the Curcumin capsules.
45631663|NCT02372123|Other|lifestyle advice|Investigators will give lifestyle advice to patients such as exercising regularly, limiting caffeine, sugar and alcohol intake, reduction or cessation of smoking
45631664|NCT02372123|Other|connective tissue manipulation|Investigators will apply connective tissue manipulation on lumbosacral, lower thoracic, and anterior pelvic regions starting from the estimated time of ovulation until the next period begins
45631665|NCT02660489|Drug|OC459|
45631666|NCT02660489|Drug|Placebo|
45631667|NCT02660489|Other|Rhinovirus|Inoculation with rhinovirus serotype 16
45631668|NCT02372201|Other|Hydro Colon Therapy plus probiotic|Probiotic intervention was done after 2-5 cycles of hydro colon therapy.
45631669|NCT02369393|Behavioral|Behavioral Activation|Behavioral Activation intervention promotes the involvement in meaningful activities close to personal values.
45631670|NCT02369393|Behavioral|Physical Activity|Physical Activity intervention promotes the gradual increase of the frequency and intensity of PA levels, with special attention to motivational strategies.
45631671|NCT02369315|Behavioral|Treatment (Invited entry 2012)|Entry to music program offered in September 2012
45631672|NCT02369315|Behavioral|Control (Invited entry 2013)|Entry to music program offered in September 2013
45631673|NCT02365259|Device|Phototherapy|Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.
45631674|NCT02365415|Drug|Sirolimus|8 weeks oral sirolimus, following drug levels
45631675|NCT02369081|Drug|Spironolactone|Spironolactone 25mg tablet orally once daily for 6 weeks, followed by Spironolactone 50mg tablet orally once daily for a further 6 weeks.
45913576|NCT02024178|Procedure|Ultrasound Imaging|
45913577|NCT02024191|Dietary Supplement|Glutamine|
45913578|NCT02024217|Radiation|S1，oxaliplatin，radiation|Radiation: 180 (cGy) /day, D1-5;S1: 50mg/m2,D1-5;
45447757|NCT02113540|Drug|Atorvastatin|
45447758|NCT02113618|Behavioral|Cogmed training|Cogmed® working memory training session consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks (i.e. total training time approximately 12,5 hours). In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program adjusts the difficulty of the different tasks trial-by-trial, which allows for each subject to train at a level adjusted to his or her current Working memory capacity
45631676|NCT02369081|Drug|Bisoprolol|Bisoprolol 5mg tablet orally once each day for 6 weeks, followed by Bisoprolol 10mg tablet orally once each day for a further 6 weeks.
45631677|NCT02369081|Drug|Doxazosin|Doxazosin 4mg tablet orally once daily for 6 weeks, followed by Doxazosin 8mg tablet orally once daily for a further 6 weeks.
45631678|NCT02369081|Drug|Placebo|Placebo treatment for 12 weeks.
45631679|NCT02368769|Device|During Tele-expertise|
45631680|NCT02365493|Drug|Beta-Lactam|
45631681|NCT02368925|Device|Ultherapy™ System|The Investigator will apply to the eligible subject the Study Device Ultherapy™ System with 200~260 lines of 3.0 and 4.5 probe respectively on the subject's neck.
45631682|NCT02365103|Other|Test meal I (given with water)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
45631683|NCT02365103|Other|Test meal II (simultaneously with tea)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
45631684|NCT02365103|Other|Test meal III (1 hour after test meal)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
45631685|NCT02365103|Other|Reference iron dose|3 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled and administered in the study, enrichment in the system will take approximately 14 days post dosing
45771073|NCT00000232|Drug|Buprenorphine|
45771074|NCT00000238|Drug|Buprenorphine|
45771075|NCT00000244|Drug|Dynorphin 1 - 13|
45771076|NCT00000994|Drug|Zidovudine|
45771077|NCT00001006|Drug|AS-101|
45771078|NCT00001012|Drug|AL 721|
45771079|NCT00001954|Drug|Etanercept|
45771080|NCT00001018|Drug|Letrazuril|
45771081|NCT02904954|Drug|Durvalumab|Intravenously
45771082|NCT02904954|Other|Durvalumab plus SBRT|Intravenously plus radiotherapy
45771083|NCT00000250|Drug|0% N2O|Subjects will inhale 100% oxygen with no N2O for 25 min then immerse forearm in warm water and cold water
45771084|NCT00000250|Drug|40% N2O|Subjects will inhale 40% N2O then immerse forearm in warm water and cold water
45771085|NCT00001960|Device|Pacemaker therapy|
45447759|NCT02113618|Behavioral|Standard Training|Standard training session in an online training and also consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks. In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program does not increase in difficultly level
45771086|NCT03244020|Drug|Aspirin 325mg|Aspirin 325 mg by mouth once daily
45771087|NCT03244020|Drug|Enoxaparin 40Mg/0.4mL Prefilled Syringe|Enoxaparin 40 mg subcutaneous injection once daily
45771088|NCT00000262|Drug|30% Nitrous oxide|
45913579|NCT02024256|Other|Cold pads soaked in Magnesium sulfate solution|
45771089|NCT00000262|Drug|0.4% Sevoflurane|
45771090|NCT00000262|Drug|0.2% sevoflurane|
45771091|NCT00000262|Other|Placebo|
45771092|NCT01188499|Drug|Birinapant|
45913580|NCT02024256|Other|Cold pads soaked in water|
45913581|NCT02024269|Biological|Adipose Derived Stem Cells|
45771093|NCT02891538|Drug|Epigallocatechin gallate (EGCG)|Teavigo™ is a natural, caffeine-free, highly purified and refined green tea extract providing 94% epigallocatechin gallate (EGCG).*
45771094|NCT00001024|Drug|Zidovudine|
45771095|NCT00001024|Drug|Didanosine|
45447760|NCT03552484|Behavioral|Home Visit Program|Informed consent discussion, documentation; UPDRS I-IV, medical history, vitals, medication reconciliation, patient medical history and comorbidities; home safety assessment; psychosocial assessment of dyad, resource utilization questionnaire, caregiver medical history and comorbidities, MCSI; patient and caregiver short MoCA, satisfaction surveys, EQ5D; counseling, summarizing plan of care
45771096|NCT05468970|Other|NO Intervention|NO Intervention
45771097|NCT00000268|Drug|Bupropion|
45771098|NCT02847624|Drug|tolvaptan|
45771099|NCT00001966|Drug|Mind-body therapy|
45771100|NCT02830152|Device|LAAO|The left atrial appendage is occluded with the AMPLATZER™ Amulet™ device, which offers a conformable disc and lobe designed for complete occlusion of the left atrial appendage.
45771101|NCT02830152|Drug|Medical Therapy|Available options included in Medical therapy are: anticoagulation with OAC or NOAC, antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
45771102|NCT00001042|Biological|Aluminum hydroxide|
45771103|NCT00001042|Biological|Lipid A, Monophosphoryl|
45771104|NCT00001042|Biological|Lipid A, Liposome-encapsulated monophosphoryl|
45771105|NCT00001042|Biological|Syntex adjuvant formulation|
45771106|NCT00001042|Biological|MF59|
45771107|NCT00001042|Biological|Threonyl Muramyl Dipeptide|
45771108|NCT00001042|Biological|rgp120/HIV-1 SF-2|
45771109|NCT00001042|Biological|MTP-PE/MF59|
45771110|NCT00982865|Drug|MSC1936369B|
45913582|NCT02024282|Device|Use of C-reactive protein (CRP) point of care test|
45771111|NCT00982865|Drug|MSC1936369B|
45771112|NCT00982865|Drug|MSC1936369B|
45771113|NCT00982865|Drug|MSC1936369B|
45771114|NCT05475756|Device|Intrauterine Biological Barrier|after Hysteroscopic adhesiolysis，use of Intrauterine Biological Barrier to repair uterine cavity
45771115|NCT05475756|Device|Intrauterine Adhesion Barrier Gel|after Hysteroscopic adhesiolysis，use of Intrauterine Adhesion Barrier Gel to repair uterine cavity
45771116|NCT00001972|Drug|15 O Water|
45771117|NCT02522468|Procedure|Radioactive Seed Localization|
45771118|NCT02522468|Procedure|Wire Localization|
45771119|NCT00001054|Drug|Valacyclovir hydrochloride|
45771120|NCT02521844|Drug|ETC-1922159|Oral administration
45771121|NCT02521844|Drug|Pembrolizumab|IV administration
45771122|NCT00380536|Behavioral|Peer-Led Health Education Class|Participants will participate in group sessions once a week for 6 weeks. Sessions will focus on medical self-management, healthy behaviors, and effective use of the general medical system.
45771123|NCT01226719|Drug|Panitumumab|6 mg/kg, 60-90 minute IV infusion every 2 weeks
45771124|NCT01226719|Drug|Oxaliplatin|85 mg/m2, 2-hour IV infusion every 2 weeks
45771125|NCT01226719|Drug|Irinotecan|125 mg/m2, 1-hour IV infusion every 2 weeks
45771126|NCT01226719|Drug|Leucovorin|200 mg/m2, 2-hour IV infusion every 2 weeks
45771127|NCT01226719|Drug|5-Fluorouracil|3200 mg/m2 IV, 48-hour continuous infusion every two weeks
45771128|NCT00001060|Biological|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
45771129|NCT02518256|Procedure|Lavage of the Cavum uteri and proximal fallopian tubes|
45771130|NCT00001072|Biological|ALVAC-HIV MN120TMGNP (vCP300)|
45935303|NCT00220753|Device|IQAir Allergen 100 Air cleaners|Two air cleaners are installed in the patient's room, one in his bedroom, and one in the living room. The cleaners can be run at 5 different speeds: Speed 1 filtrates 60m3 of air per hour, speed 2 filtrates 90 m3 per hour, speed 3 filtrates 130 m3 per hour, speed 4 filtrates 240 m3 per hour, and speed 5 filtrates 380 m3 per hour. A timer-on period can be pre-set for every day of the week, but the cleaner can be run even in the timer-off period, at a speed pre-set and different from the timer-on period. Different timer-on off periods cannot be selected for different days, but the different days of the week can be pre-set to apply timer-on periods or not.
45935304|NCT00220792|Behavioral|Brief supportive-expressive group therapy|
45447761|NCT03552484|Behavioral|Usual Care/Online Survey|Patients and caregivers, if available, will be asked to complete an online survey that asks about demographics, disease history, resource utilization, and unmet needs. The will be asked to complete a follow-up survey 12 months after completion of the initial survey.
45447762|NCT02122978|Behavioral|Mindfulness Based Cognitive Therapy|MBCT 8 week course delivered by trained facilitator
45631686|NCT02365181|Procedure|intra-articular local anesthetic infiltration|intra-articular local anesthetic infiltration with 20 ml of Ropivacaine 2 % and catheter
45631687|NCT02365181|Procedure|inter-scalene block|inter-scalene block with 20 ml of Ropivacaine 2 % and catheter
45631688|NCT02365181|Drug|Ropivacaine 2 %|20 ml of Ropivacaine 2 %
45631689|NCT05653895|Dietary Supplement|Resveratrol|Resveratrol
45631690|NCT05653895|Drug|Metformin|Metformin
45631691|NCT05653895|Combination Product|Acetyl-L-Carnitin, L Arginine, Co-Q10|Treatment of PCOS with combination of Acetyl-L-Carnitin, L Arginine, Co-Q10
45631692|NCT02368847|Device|Diagnostic tests|C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine C Reactive Protein level in the blood
45631693|NCT02368847|Device|Diagnostic tests|Uricult dipslide: Easy-to-perform bacterial culture test for dectecting urinary tract infections in point of care settings
45447763|NCT02122978|Behavioral|MBSC - minimal contact|8 week course in Mindfulness Based Self Compassion delivered remotely by audio guided MP3
45447764|NCT02122978|Behavioral|Mindfulness Based Self Compassion Therapy|Mindfulness Based Self Compassion Therapy - 8 wee course delivered by trained facilitator
45631694|NCT03589703|Other|Target ear points related to chronic low back pain (T-APA)|Light touch using vaccaria seeds on specific points of the ear.
45631695|NCT03589703|Other|Non-Target ear Points not related to chronic low back pain (NT-APA)|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
45631696|NCT03589703|Other|Enhanced Educational Control Group (CG-2)|No contact with the subject. Participants in the enhanced educational control group will be given the cLBP educational booklet.
45631697|NCT02368535|Other|Survey|25-item questionnaire on pereception of interdisciplinary rounds
45631698|NCT02365025|Other|Meetings guides by experts in sleeping disorders.|meetings guides by experts in sleeping disorders. In those meeting the parents will be exposed to sleep disturbances, the importance of sleep habits and the influence of electronic media on sleep and learning.
45631699|NCT02364869|Dietary Supplement|Fructooligosaccharide|Patients will be evaluated at baseline, week 6 and 12.
45631700|NCT02364869|Dietary Supplement|Maltodextrin|Placebo Comparator. Patients will be evaluated at baseline, week 6 and 12.
45631701|NCT02368613|Drug|DW-3102|
45631702|NCT02364479|Drug|50mg Yisaipu|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
45631703|NCT02364479|Drug|25mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
45631704|NCT02364479|Drug|Placebo|The injection method and frequency of placebo is the same as the other arms.
45631705|NCT05653817|Drug|Carrilizumab|Carrilizumab 200mg Q3W d1
45631706|NCT05653817|Drug|Albumin-bound paclitaxel|Albumin-bound paclitaxel 125 mg/m2 d1,8
45771131|NCT00001072|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
45771132|NCT00001072|Biological|rgp120/HIV-1 SF-2|
45771133|NCT02194868|Biological|Recipients|"Adult recipient:~collected 20 ml pre-transplant~collected 30 ml for adults on day 20 post-transplant at engraftment for cell phenotype,~collected 30 ml on days 30, 60, 90, 180, 360 days post-HSCT for cell phenotyping at all time points, functional INKT at day 60 or 90 depending on the number of cells collected and anti-viral ELISPOT studies on days 180 and 360~Children recipients~collected residual blood pre-transplant~collected residual blood on day 20 post-transplant at engraftment for cell phenotype,~collected residual blood on days 20, 30, 90, 180 and 360 post-HSCT"
45935305|NCT00220831|Drug|Natural source Vitamin E 400IU/day|
45935306|NCT00073632|Behavioral|Acceptance Based Behavioral Therapy|
45447765|NCT02117518|Other|blood drawing|
45447766|NCT02123056|Drug|Metoprolol|the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
45447767|NCT02123056|Drug|Matching Placebo|the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
45447768|NCT02120092|Drug|Clopidogrel|1x Loading dose 600 mg 6x maintenance dose 150 mg
45447769|NCT02120092|Drug|Ticagrelor|1x Loading dose: 180 mg 6x Maintenance dose: 90 mg bid
45631707|NCT05653817|Drug|Apatinib|Apatinib mesylate tablets for treatment: 250mg
45631708|NCT02364635|Drug|icosabutate|Single dose at each dose levet
45631709|NCT02052310|Drug|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm.
45631710|NCT02052310|Drug|Epoetin Alfa|Epoetin alfa will be administered TIW according to the epoetin alfa USPI or SmPC, or local SOC.
45631711|NCT02364245|Device|Kinect|Receive computer games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
45631712|NCT02364245|Other|Traditional OT(30 Mins)|Receive Traditional Occupational Therapy training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
45631713|NCT02364245|Other|Traditional OT(60 Mins)|Receive Traditional Occupational Therapy training for 60 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
45631714|NCT02368379|Other|Low dose (1 mcg) ACTH stimulation test|Subjects will have baseline cortisol and ACTH drawn followed by administration of 1 mcg/m2 (max 1 mcg) of cortrosyn. Blood will be drawn at 20 and 40 minutes post cortrosyn for peak cortisol assessment of central adrenal insufficiency.
45631715|NCT02368379|Other|Overnight metyrapone test|Subjects will receive metyrapone 30 mg/kg (max 3 grams) by mouth at midnight. Blood will be drawn at 0800 AM the following morning for ACTH, cortisol and 11 deoxycortisol for assessment of central adrenal insufficiency.
45631716|NCT02367989|Dietary Supplement|0g barley β-glucan no fibre|Food containing no barley β-glucan and no additional fibre
45631717|NCT02367989|Dietary Supplement|2g barley β-glucan|Food containing low amounts of barley β-glucan
45631718|NCT02367989|Dietary Supplement|4g barley β-glucan|Food containing medium amounts of barley β-glucan
45631719|NCT02367989|Dietary Supplement|6g barley β-glucan|Food containing high amounts of barley β-glucan
45935307|NCT00220870|Behavioral|Decision aid|
45631720|NCT02367989|Dietary Supplement|0g barley β-glucan with fibre|Food containing no barley β-glucan, but matches fibre content in β-glucan treatments
45631721|NCT02368067|Procedure|Standard of Care Sentinal Node Dye|Delivery of sentinal node dye by different routes
45631722|NCT02368067|Procedure|Study Sentinal Node Dye|Patients will receive different types of dye by different routes of administration
45771134|NCT02194868|Biological|Donors|"Adult donors :~collected 20 ml of blood, (if possible before granulocyte colony-stimulating factor (GCSF) administration)~collected 1 ml of the stem cell graft for adult recipient or 2 ml of bone marrow for children recipients These samples will be collected at the same time of those needed for transplant.~Children donors samples~collected residual blood~2ml of bone marrow (bottom of tube)"
45771135|NCT04331470|Drug|Levamisole Pill + Budesonide+Formoterol inhaler|Levamisole 50 mg tablet has to be taken 1-2 tablets every 8 hours Budesonide+Formoterol has to be inhaled 1-2 puff every 12 hours
45771136|NCT04331470|Drug|Lopinavir/Ritonavir + hydoxychloroquine|Hydroxy Chloroquine 200mg single dise Lopinavir/Ritonavir 2 tablets every 12 hours
45771137|NCT02743910|Other|ptDNA|Pre-operative blood samples for ptDNA will be collected at the time of diagnosis/prior to NAT, post-cycle 1/pre-cycle 2 of NAT, after all NAT/immediately before surgery, and post-operatively at 6, 12, 24, and 36 months, and annually thereafter if funding allows.
45631723|NCT02051764|Drug|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
45631724|NCT02051764|Drug|Florbetapir F 18|370 megabecquerel (MBq) IV single-dose
45631725|NCT02051764|Procedure|Brain PET Scan|positron emission tomography (PET) scan of the brain
45631726|NCT02364401|Device|Ablation|Catheter ablation for atrial fibrillation
45631727|NCT02368223|Device|YouGrabber|2 weeks of home-based therapy with a virtual-reality enhanced upper limb training system
45771138|NCT02743910|Other|Tissue sample|Representative tissue sample will be collected from the diagnostic biopsy (in all participants) and definitive surgery (if available)
45771139|NCT00001078|Biological|Hepatitis A Vaccine (Inactivated)|
45631728|NCT02051296|Drug|Minocycline|RCT blinded placebo trial
45771140|NCT00983489|Behavioral|video demonstration|video will be shown to mothers
45771141|NCT00983489|Behavioral|counselling|breast feeding counselling
45771142|NCT02743832|Procedure|Resection for primary lesion and cervical lymph node dissection|Resection for primary lesion and cervical lymph node dissection are performed in the early-stage oral squamous cell carcinoma.
45771143|NCT02743832|Procedure|Resection for primary lesion only|Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma.
45771144|NCT02179736|Device|Restylane|
45771145|NCT00001090|Biological|APL 400-047|
45771146|NCT00001090|Biological|ALVAC-HIV MN120TMG (vCP205)|
45771147|NCT00001090|Drug|Sargramostim|
45771148|NCT01147627|Drug|exenatide injection|Patients in exenatide group will be treated with exenatide (Byetta®, Eli Lilly and Company) 5 µg BID for the first 4 weeks and then 10 µg BID thereafter.
45771149|NCT01147627|Drug|Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R|Patients in insulin group will be treated with premixed insulin analog (Humalog Mix 25, Eli Lilly and Company). The initial insulin doses are 0.4 IU/kg per day(50% before breakfast and 50% before dinner). Insulin doses are titrated following a forced schedule according to blood glucose before breakfast and dinner.
45771150|NCT01147627|Drug|Pioglitazone|Patients in thiazolidinedione group will be treated with Pioglitazone 30mg daily as single dose. The dose will be increased to 45mg daily after 4 weeks.
45771151|NCT02548962|Drug|Ibrutinib|
45771152|NCT02548962|Drug|Pomalidomide|
45771153|NCT02548962|Drug|Dexamethasone|
45771154|NCT02548962|Drug|Placebo|
45771155|NCT00000274|Drug|Flupenthixol|
45771156|NCT04921072|Behavioral|Constant practice conditions|CG will be practicing only one specific pattern of step isometric contractions (SPSIC) scheme. It means that 90 trials in all training sessions will consist only of SPSIC 1.
45771157|NCT04921072|Behavioral|Variable practice conditions|VG will practice three SPSIC's (1-3). Each SPSIC will be practiced 30 times per session, which means that each session will consist of 90 SPSIC like CG.
45771158|NCT02743598|Drug|Liraglutide|
45771159|NCT00000280|Drug|Nimodipine|
45771160|NCT00983801|Drug|Ixabepilone|Vial, Injection, Intravenous (IV), 40 mg/m^2, Every 21 days, Up to 8 cycles or until disease progression or intolerable toxicity. Additional treatment was given in agreement by both the investigator and sponsor. Ixabepilone 40 mg/m^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day (3 week) cycle provided the participant met the retreatment criteria.
45935308|NCT00042770|Other|talc|Given intrapleurally
45935309|NCT00042770|Procedure|dyspnea management|No talc
45935310|NCT00220909|Drug|Lansoprazole|
45631729|NCT02051296|Drug|placebo|RCT blinded placebo trial
45631730|NCT02364167|Drug|Standard therapy|Standard therapy includes pharmacologic treatment of postoperative pain according to the standards of our University hospital
45631731|NCT02364167|Device|Verum acupuncture|"Verum acupuncture will be performed using indwelling permanent acupuncture needles New Pyonex with 1,5 mm length, manufactured by Seirin Corp. Japan"
45631732|NCT02364167|Other|Placebo acupuncture|"Placebo acupuncture will be performed using the placebo New Pyonex adhesive tapes, mimicking the needles, manufactured by Seirin Corp. Japan"
45631733|NCT02367677|Other|Method comparison|
45631734|NCT02367755|Drug|Propofol|Propofol use during therapeutic hypothermia
45631735|NCT02367755|Drug|Lorazepam|Lorazepam use during therapeutic hypothermia
45631736|NCT02050048|Other|Administration of Lactated Ringer's (LR) Solution|"Patients will be randomized to low volume or high volume group. Patient in the low volume group will receive fluids via infusion at a rate of 1.5 cc/kg/hr. Fluid administration may be continued through the 90 minute post-procedure observation period. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:~initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour~LR fluid infusion during the procedure at 5 cc/kg/hr~Post-procedure bolus of 20 cc/kg over 90 minutes"
45631737|NCT02364089|Procedure|Laparoscopic surgical removal of the adrenal tumor|
45935311|NCT00220948|Procedure|CERSR Myoelectric monitoring during standardized tasks|
45935312|NCT00220987|Other|Intensive Insulin Therapy|Maintain blood glucose 4.5 - 6.o mmol/L
45631738|NCT02364089|Drug|Standardized medical treatment of hypertension by SAHR|"Standardized anti-hypertensive drug regimen has been established according to international recommendations and includes the following steps:~step 1: Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor antagonist (ARBs) at half-dose (Ranipril 5mg or Ibesartan 150 mg )~step 2: CEI or ARA2 at full dose (Ranipril 10 mg or Ibesartan 300 mg)~step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg~step 4: Add-on of Indapamide LP 1.5 mg~step 5: Add-on of Spironolactone 25 mg~step 6: Add-on of Bisoprolol 10 mg~step 7: Add-on of Prazosine LP 5mg/day."
45631739|NCT02363777|Procedure|Epidural|A mid thoracic epidural is placed preoperatively and a local anesthetic and opioid infusion is run postoperatively
45631740|NCT02363777|Procedure|Paravertebral catheters|Bilateral paravertebral catheters are placed and a local anesthetic infusion via an elastomeric pump is run postoperatively
45447770|NCT02120092|Drug|ASA|"7x 100mg acetylsalicylic acid (clopidogrel arm)~1x 300 mg acetylsalicylic acid (ticagrelor arm)"
45631741|NCT02363699|Drug|Lidocaine|Lidocaine was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure. Solution of 0,3% lidocaine was used, so that the infusion rate was equal to the weight of the patient.
45631742|NCT02363699|Drug|Saline solution|Saline solution was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure.
45631743|NCT02049814|Drug|Metformin|Metformin tablets
45771161|NCT02510456|Device|Diffuse Optical Spectroscopy Imaging (DOSI) - Neoadjuvant Chemo (NAC) Cohort|Subjects will have up to 9 DOSI scans at 6 different time points during the course of their neoadjuvant chemotherapy. The time course of chemotherapy may vary between 3-9 months depending on the type chemotherapy subjects receive. Depending on chemotherapy schedule, subjects may or may not be asked to participate in all the 6 measurement time points. The number of DOSI scans each subject requires will be decided during consent. Each DOSI scan will take about 30-60 minutes, although scans at infusion time point will take longer in total due to repeated or continuous measurements.
45771162|NCT02510456|Device|Diffuse Optical Spectroscopy Imaging (DOSI) - Non-NAC Cohort|Subjects will have 1 DOSI scan at baseline. The DOSI scan will take about 30-60 minutes.
45771163|NCT00000286|Drug|Nefazodone|
45771164|NCT01188577|Drug|Epinephrine Inhalation Aerosol, HFA|10 inhalations of epinephrine inhalation aerosol, 125 mcg/inhalation
45771165|NCT01188577|Drug|Epinephrine Inhalation Aerosol|Epinephrine Inhalation Aerosol, 220 mcg/ inhalation, 10 inhalations
45771166|NCT03948672|Device|CleanHands System|All participants who regularly access the ICUs will wear the CleanHands system wristband while at work for 5 months and the reminding functionality is turned on.
45771167|NCT02507336|Drug|Thalidomide|100-300 mg capsule taken by mouth once daily.
45771168|NCT00000292|Procedure|Cocaine|
45771169|NCT02763384|Drug|BL-8040|
45771170|NCT02763384|Drug|Nelarabine|
45771171|NCT02734550|Other|Standard of care|Patients are treated according to the ESCMID guidelines. Antifungal therapy is started if fungi are detected in the blood culture or other primary sterile body fluids.
45913583|NCT02024282|Other|Brief intervention and parent leaflet|"Brief interventions are commonly used to give opportunistic advice, discussion, negotiation or encouragement. Mostly they take between 5 to 10 minutes. We developed a brief intervention: we'll ask the clinicians to ask 3 specific questions, namely Are you concerned?, What exactly concerns you? and Why does this concern you?. This intervention is easy to implement in daily practice and no additional training is required.~We developed a parent information leaflet that gives information about what they can do when their child is ill, which signs are important to follow up and when they really should get advice from a clinician. This could make it easier for them to cope with an ill child. The clinician could use this leaflet to give advice and make clear when they have to re-consult their physician to re-evaluate the child. Our hypothesis is that through creating this safety net, the improper demand for antibiotics could be reduced."
45913584|NCT02024282|Device|Finger Pulse Oximeter|All physicians will be asked to perform a measurement of the oxygen saturation on all children and enter the results on the case report form. The selected device is a clip-on system suitable for use in children, which measures oxygen saturation in the capillary blood as well as the pulse rate.
45913585|NCT02024295|Drug|Ademethionine|ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.
45913586|NCT02024295|Drug|Polyene Phosphatidyl choline|Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.
45913587|NCT02024295|Drug|Ademethionine|after 6 weeks of core treatment stage, then ademethionine 1000mg bid or qd orally for 42 weeks
45913588|NCT02024308|Drug|Fludarabine|50 mg/m2, IV (in the vein) in combination with cytarabine 1.4mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
45913589|NCT02024308|Drug|Cytarabine|2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
45913590|NCT02024334|Drug|Leflunomide|
45913591|NCT02024373|Drug|Atorvastatin|20 mg (every evening orally) for 8 weeks
45913592|NCT02024373|Drug|placebo|20 mg (every evening orally) for 8 weeks
45913593|NCT02024399|Other|Exercise|Strength training, aerobic exercise and core strengthening, running
45913594|NCT02024412|Drug|monosialotetrahexosylganglioside Sodium|it is a component extract from pig's brain,shenjie is the brand name
45913595|NCT02024412|Other|placebo|saline of the same appearance as monosialotetrahexosylganglioside Sodium
45447771|NCT02120092|Drug|Placebo|7x 300mg acetylsalicylic acid placebo
45631744|NCT02049814|Drug|Voglibose|Voglibose tablets
45631745|NCT02049814|Drug|Acarbose|Acarbose tablets
45631746|NCT02363855|Drug|BAY 1841788(ODM-201)|Cohort 1: Single dose 300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks Cohort 2: Single dose 2x300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks.
45631747|NCT04059809|Device|Photobiomodulation|Photobiomodulation will be with the Cicatrillux (Cosmedical®) LED that contains 36 red light emitters in a 10x12 cm neoprene plate with 650 nm LED wave length whose optical spot diameter is 5 mm and with an average wave length of 2 ~ 5 mw for 10 minutes that will be placed over the area that will be irradiated for 10 minutes;
45631748|NCT02363543|Device|Hyalomatrix|
45631749|NCT02363543|Device|Integra|
45913596|NCT02024425|Dietary Supplement|Functional bioactive supplement|1,25g of antioxidant extracted from rosemary, 18g of oligosaccharides derived from lactulosa and 1,25g of bioactive peptides
45631750|NCT02363387|Behavioral|Incentives for Viral Suppression|Incentive group participants will receive incentives for maintaining suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years.
45631751|NCT02363387|Behavioral|Standard HIV Medical Care|The best HIV medical care available in each participant's medical clinic.
45631752|NCT03458975|Radiation|MRI|Magnetic Resonance Imaging
45631753|NCT03458975|Radiation|Perfusion CT scan|Perfusion Computerized tomography scan
45631754|NCT03458975|Other|Contrast enhanced ultrasound|Contrast enhanced ultrasound
45913597|NCT02024425|Dietary Supplement|Control supplement|
45771172|NCT02734550|Other|(1,3)-β-D-glucan guided therapy|Serum for (1,3)-β-D-glucan measurement is obtained after enrollment and 24 hours later. Antifungal therapy is started if at least one sample is 80 pg/ml or higher. If concomitantly taken microbiological cultures remain negative, antifungal therapy is continued only, if both (1,3)-β-D-glucan were at least 80 pg/ml. Blood cultures or other samples from primary sterile body fluids positive for fungi are treated with antifungals irrespective the (1,3)-β-D-glucan results.
45631755|NCT03458975|Drug|Sonoporation|Gaseous microbubbles (Sonovue) combinated with Ultrasounds
45631756|NCT03344159|Drug|Spironolactone|Spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated for a total duration of 12 weeks.
45771173|NCT00000298|Drug|Buprenorphine/naloxone|
45771174|NCT00984815|Drug|HZT-501|Fixed-dose combination oral tablet 800mg Ibuprofen/26.6 mg Famotidine taken three times per day
45771175|NCT00000304|Drug|Dextroamphetamine|15 mg for first 8 weeks and 30 mg for 2nd 8 weeks
45771176|NCT00000304|Drug|D-Amphetamine|30 mg for the first 8 weeks and 60 for the second 8 weeks (16 weeks total)
45771177|NCT00000304|Drug|Placebo|Placebo
45771178|NCT02548650|Drug|Vorapaxar|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
45771179|NCT02548650|Drug|Clopidogrel|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
45771180|NCT02548650|Drug|Aspirin|Triple therapy with DAPT plus vorapaxar(vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
45913598|NCT02024438|Drug|monosialotetrahexosylganglioside Sodium|it is extracted from pig's brain,shenjie is the brand name
45631757|NCT03344159|Drug|Placebo|Placebo daily for a total of duration of 12 weeks
46070019|NCT00799201|Drug|Naloxone and Docusate|Naloxone 6mg (15 mL) every 6 hours plus docusate sodium liquid 10 mL (100mg) every 12 hours
45771181|NCT02734394|Behavioral|Exercise|Cardiovascular and resistance exercise training
45771182|NCT05394077|Diagnostic Test|Active Release Technique|Using Active Release Technique
45771183|NCT05394077|Diagnostic Test|Abdominal Drawing-Maneuver|Using Abdominal Drawing-Maneuver Technique
45771184|NCT00000310|Drug|Risperidone|
45771185|NCT02734004|Drug|Olaparib|Olaparib
45771186|NCT02734004|Drug|MEDI4736|MEDI4736
45771187|NCT02734004|Drug|Bevacizumab|Bevacizumab
45771188|NCT05468424|Other|tablet (iPad or android) based role-playing game|The intervention is a tablet (iPad or android) based role-playing game called FarmVille. In FarmVille the player assumes the role of a farmer tasked with tending to crops and farm animals and using what is produced to craft goods which can be sold to expand the farm. The participant is required to play FarmVille for 5 or more hours a week for 8 weeks.Their study partner can remind them to play the game each week and can assist them with issues related to using the tablet and navigating menus in the game.
45771189|NCT05468424|Other|tablet (iPad or android) based word puzzles and image puzzles|"This intervention is a selection of tablet (iPad or android) word puzzles and image puzzles. One word puzzle involves word making (i.e., making words from a set of random letters), and the other word searching (i.e., finding words on a grid of letters). One image puzzle is Flow Free, a game that requires the player to connect pairs of same coloured dots positioned on a grid ranging from 5x5 to 9x9. The other image puzzle is a jigsaw. The participant is required to play these games for 5 or more hours a week for 8 weeks.Their study partner can remind them to play the games each week and can assist them with issues related to using the tablet and navigating menus in the games."
45771190|NCT01227655|Drug|BIA 9-1067|Capsules will be used.
45913599|NCT02024438|Other|placebo|saline of the same appearance as monosialotetrahexosylganglioside Sodium
45913600|NCT02024451|Device|Radial shock wave|radial shock wave: Treatment point is the origin attachment of upper trapezius at the external occipital protuberance. Radial shock wave therapy will be performed once per week, and will be continued for 3 weeks. Acetaminophen will be prescribed as rescue medication, and the amount given will be recorded at the end of the study.
45913601|NCT02024451|Device|Acupuncture|Acupuncture is performed at Fenfchi (GB20) point over upper back by the same physiatrist to all patients.
45631758|NCT03344159|Radiation|PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82|At baseline and 12 weeks, all participants will undergo rest perfusion PET imaging according to standard protocols with either 82-Rb or N-13 NH3, followed by C-11 HED PET.
45631759|NCT03344159|Diagnostic Test|Cardiac MRI (Gadolinium enhanced)|At baseline and 12 weeks all participants will undergo cMR to assess RV function and structure. We will acquire precontrast T2 and native T1 maps, and post gadolinium T1 maps.
45631760|NCT02363465|Other|Echographic measurement of skin thickness|"(Epi)Dermal thickness at the proximal forearm and the deltoid region will be measured using imaging technology, more specifically high-frequency ultrasound (20-40 MHz) in B-mode (VEVO 2100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid region and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging."
45631761|NCT03324113|Drug|SAR408701|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45631762|NCT03324113|Drug|dexamethasone|"Pharmaceutical form: solution for eye drop~Route of administration: eye drop"
45631763|NCT03324113|Drug|naphazoline|"Pharmaceutical form: solution for eye drop~Route of administration: eye drop"
45631764|NCT03324113|Drug|diphenhydramine|"Pharmaceutical form: tablet~Route of administration: oral"
45631765|NCT02079844|Drug|Roflumilast|Roflumilast tablets
45771191|NCT01227655|Drug|Placebo|comparator
45771192|NCT01227655|Drug|Levodopa|
45771193|NCT01227655|Drug|Carbidopa|DOPA decarboxylase inhibitor (DDCI)
45631766|NCT02079844|Drug|Placebo|Roflumilast placebo-matching tablets
45771194|NCT01227655|Drug|Benserazide|DOPA decarboxylase inhibitor
45771195|NCT00000316|Drug|Cocaine|
45771196|NCT05459532|Drug|Molnupiravir 200 mg|The drug is orally bioavailable (and is indicated for treatment of mild to moderate COVID-19 in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness. The recommended dose is 800 mg (four 200 mg capsules) taken orally 12-hourly for five days, and should be administered as soon as possible after diagnosis of COVID-19 has been made and within five days of symptom onset.
45771197|NCT02506556|Drug|BYl719|"Treatment: BYL719 350mg orally daily Treatment will be given daily until progression, undue adverse events or withdrawal of consent.~Dose reductions (two levels) are allowed. Each cycle is 28 days"
45631767|NCT02079844|Drug|Second generation antipsychotic|Second Generation Antipsychotic (SGA) medication for standard of care therapy will be sourced and managed locally by the site.
45631768|NCT02367365|Other|No Intervention|No intervention
45631769|NCT02367365|Other|No Intervention|No intervention
45771198|NCT00001990|Drug|Atovaquone|
45771199|NCT05468190|Biological|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
45771200|NCT05468190|Biological|CD70 CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
45771201|NCT00000322|Behavioral|Tyrosine|
45631770|NCT02363153|Other|Diet and Exercise|"Exercise will consist of 2x/week aerobic exercise, 2x/week strength training and 1x/week core-stabilizing exercise.~Diet will be constructed so that 30% of the daily caloric goal will be protein, 35% fat, and 35% carbohydrates."
45771202|NCT01189123|Biological|High dose influenza vaccine Sanofi-Pasteur|High dose influenza vaccine Sanofi-Pasteur at standard dosing intramuscular injection
45771203|NCT01189123|Biological|fluzone by sanofi pasteur|standard dose fluzone
45771204|NCT04423224|Other|GDFM|Stroke volume variation fluid management
45771205|NCT04423224|Other|USUAL CARE - CONTROL|Usual care fluid management
45771206|NCT00001096|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
45771207|NCT00001096|Biological|QS-21|
45771208|NCT00001096|Biological|rgp120/HIV-1MN|
45771209|NCT01026623|Biological|Cixutumumab|Given IV
45771210|NCT01026623|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
45771211|NCT01026623|Drug|Temsirolimus|Given IV
45913602|NCT02024464|Device|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
45913603|NCT02024464|Device|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
45771212|NCT00001996|Drug|Atovaquone|
45771213|NCT00001996|Drug|Pentamidine isethionate|
45771214|NCT05433870|Other|Whether the PE or E patient combined with PRES|According to the Diagnostic criteria of PRES, all the patients grouped into two groups.
45771215|NCT02725424|Drug|S-1|Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA <1.25m2) , 100mg(BSA ≥1.25m2, <1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
45913604|NCT02024516|Other|50 gr concentrated pomegranate juice|
45913605|NCT02024555|Drug|Levofloxacin|
45913606|NCT02024555|Drug|Ethambutol|
45913607|NCT02024555|Drug|Azithromycin|
45771216|NCT02725424|Drug|Trastuzumab|Her-2 positive patients with SOXT Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA <1.25m2) , 100mg(BSA ≥1.25m2, <1.5 m2), 120 mg(BSA≥ 1.5m2), Trastuzumab: 8mg/kg (loading dose), 6mg/kg subsequently ivgtt d1 Every 3 weeks.
45771217|NCT02725424|Drug|Oxaliplatin|Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA <1.25m2) , 100mg(BSA ≥1.25m2, <1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
45771218|NCT02725424|Drug|Docetaxel|Her-2 Negative patients with DOS Docetaxel： 60 mg/m2, iv, d1 Oxaliplatin：100 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA <1.25m2) , 100mg(BSA ≥1.25m2, <1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks
45913608|NCT02024555|Drug|Rifampin|
45913609|NCT02024555|Drug|Placebo|This will serve as a placebo to the antibiotics used in antimycobacterial therapy.
45913610|NCT02024568|Drug|Pregabalin|See arm description
45913611|NCT02024568|Drug|Placebo|See arm description
45913612|NCT02024581|Drug|10% East Indian sandalwood oil cream|A topical oil/water emulsion cream containing 10% East Indian sandalwood oil (EISO)
45913613|NCT02024581|Drug|Placebo Cream|A sandalwood-scented oil/water emulsion topical cream matching the appearance of the active comparator creams
45771219|NCT01189279|Drug|bimatoprost Formulation A|bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
45913614|NCT02024594|Drug|Nitrous Oxide-Oxygen conscious sedation|
45631771|NCT02363075|Drug|Dexamfetamine sulphate|10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
45631772|NCT02363075|Drug|placebo|10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
45771220|NCT01189279|Drug|bimatoprost Formulation B|bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
45771221|NCT01189279|Drug|bimatoprost Formulation C|bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
45771222|NCT00001108|Drug|Ritonavir|
45631773|NCT02367443|Radiation|Radiation|Radiation: Accelerated Hypofractionated radiotherapy with full dose Chemotherapy
45631774|NCT03307343|Behavioral|Intervention|The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
45771223|NCT00001108|Drug|Nelfinavir mesylate|
45771224|NCT00001108|Drug|Saquinavir|
45771225|NCT00001108|Drug|Nevirapine|
45771226|NCT00001108|Drug|Lamivudine|
45771227|NCT00001108|Drug|Stavudine|
45771228|NCT00001108|Drug|Didanosine|
45771229|NCT02157974|Drug|Byetta 5Mcg Pen Injection|10 participants will receive 2 doses of Byetta, one at 7 PM the night prior to metabolic study and the second 30 min before ingestion of glucola
45771230|NCT00000328|Drug|Opioid-Related Disorders|
46070020|NCT00799279|Behavioral|Smoking cessation training, support, and telephone follow-up|The CF group will receive the same smoking cessation training and practice support tools delivered to the PS group. In addition, patients in the FC group who are smokers and are willing to set a quit date within the next 30 days and who have set a quit date will be enrolled in an interactive voice response (IVR)-mediated telephone follow-up and counselling system. The IVR system will automatically contact patients via telephone 7 days before their TQD, and 5, 14, 30, and 60 days after their TQD to check the patients' smoking status, potential concerns, and their risk of relapse.
45771231|NCT03213990|Other|Continuous infusion|Clinician prescribed beta-lactam antibiotic will be administered via continuous infusion for as long as prescribed whilst in the ICU
45771232|NCT03213990|Other|Intermittent infusion|Clinician prescribed beta-lactam antibiotic will be administered via intermittent infusion for as long as prescribed whilst in the ICU
45771233|NCT01148563|Device|Tele-health Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
45771234|NCT00380224|Drug|bifeprunox, olanzapine|
45771235|NCT02155946|Device|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Active brain stimulation
45771236|NCT02155946|Device|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Sham (placebo)
45771237|NCT03010189|Device|Actigraphy|A small computer in the shape of a wristwatch, that registers movement and assesses sleep quality.
45913615|NCT02024594|Behavioral|cognitive-behavioral therapy|
45771238|NCT03010189|Device|Heart-rate variability monitoring|A small computer that registers variation in heart rate, which reflects cardiac autonomic tone.
45771239|NCT03010189|Device|Pupillometry|A handheld infrared camera that sends out a light flash and records the pupil as it contracts and dilates, as a measure of pupillary autonomic tone.
45771240|NCT05458440|Other|Generation of a biobank allowing the cryopreservation of leucocytes from COVID19 convalescent donors|The investigators aim to demonstrate that it is possible to implement a biobank of leucocytes from convalescent donors that could be used as raw material to generate anti-SARS COV-2 viral specific T cells. The protocol will be explained during hospitalisation for each donor. If they agree, they will be included before they leave hospital. Few weeks later, if they have no exclusion criteria, they will consult in the hemapheresis department of the Nancy University hospital. After medical exams, a whole blood bag and blood samples will be taken with the aim to establish a bank of cryopreserved human leucocytes as a raw material for the generation of a T-Lymphocyte immunotherapy.
45771241|NCT01228435|Drug|IPI-504|Given intravenously twice weekly for 2 weeks followed by 10 day off treatment
45771242|NCT00002002|Drug|Trimethoprim|
45913616|NCT02024620|Behavioral|Behavioral activation plus mobile app|
45913617|NCT02024620|Behavioral|Standard behavioral activation|
45771243|NCT00002002|Drug|Sulfamethoxazole|
45913618|NCT02024633|Drug|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
45913619|NCT02024633|Drug|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
45913620|NCT02024659|Drug|budesonide|Patients receive 1mg/2ml budesonide twice daily via transnasal nebulization for 14 days.
45771244|NCT00002002|Drug|Leucovorin calcium|
45771245|NCT00380302|Drug|AVE1625|
45771246|NCT02535000|Drug|Duloxetine|duloxetine 60 mg
45771247|NCT02535000|Drug|Placebo|placebo
45771248|NCT00380380|Drug|Vildagliptin|
45771249|NCT01228903|Drug|Allopurinol|Xanthine oxidase inhibitor- effective at lowering uric acid levels.
45771250|NCT01228903|Other|Placebo|Placebo tablets with no active ingredient
46070021|NCT00799279|Behavioral|smoking cessation intervention|Intervention practices will be provided with training in smoking cessation, and will be supported with integrating a waiting room screener for smoking and smoking consult form and patient quit plan into their practice routines.
45631775|NCT02362763|Procedure|Acupuncture|Patients randomized to the study group received five sessions of acupuncture in a series of points in the lower abdomen, lower back, hands, and feet. This combination of acupoints is believed to impact on the genital area, raise the pain threshold, and counteract inflammation. Control group patients received five sessions of acupuncture at acupoints that are believed to have no influence on the genital area, but are believed to have a general sedative effect.
45447772|NCT05296408|Behavioral|motor learning based therapy|Motor learning based therapy will include functional task/task component training and will be employed to practice hand-to-mouth, forward reach, grasp-release, and object manipulation. Training will include high repetition both in the clinic and during home exercise practice. Tasks will be decomposed into component parts and practiced in this manner with the goal of returning to full task performance as skill develops Training will be tailored to each individual subject's capability and progressed according to a motor control hierarchy to ensure adequate challenge. Training is always started at the appropriate level of challenge for an individual to ensure adequate challenge is delivered whether the individual is higher or lower functioning.
45771251|NCT05440552|Diagnostic Test|Qualitative Fecal immunochemical test + APCS score|Risk stratification using Qualitative Fecal immunochemical test and APCS score
45447773|NCT05296408|Behavioral|MyoPro|The MyoPro supports motor learning-based training by reinforcing coordinated movement practice, allowing for finely incrementalized training progression, and encouraging high repetition of movement. Importantly, the device assists the user to move the paretic limb in a manner they may otherwise be unable to do. This further motivates the user to continue attempts to move the paretic limb. When a user attempts to volitionally contract a weak muscle, sensors embedded within the MyoPro detect the EMG signal, which triggers activation of a motor within the device. The motor assists the user to complete the desired movement (e.g. opening of the hand).Subjects experience real-time biofeedback through their ability to sense and see movement of the target joint(s) and via their interface with the software on a computer that provides visual feedback of the EMG level of the contracting muscle
45771252|NCT05440552|Diagnostic Test|Quantitative Fecal immunochemical test|Use Quantitative Fecal immunochemical only for risk stratification
45771253|NCT01189747|Biological|onabotulinumtoxinA|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1
45771254|NCT01189747|Drug|normal saline|Injected into bilateral Crow's Feet Line areas on Day 1
45771255|NCT00001126|Drug|Cidofovir|
45771256|NCT00002008|Drug|Sargramostim|
45771257|NCT00001132|Drug|Abacavir sulfate|
45631776|NCT03097757|Radiation|Ultrasound - guided fracture reduction|Ultrasound will be used as a real-time imaging modality to guide forearm fracture reduction.
45631777|NCT03097757|Procedure|Standard of care fracture reduction|Closed reduction of a fractured bone.
45631778|NCT02367053|Drug|ZP4207|
45631779|NCT02367053|Drug|Glucagon|
45631780|NCT02048722|Drug|regorafenib|Given PO
45631781|NCT02366897|Device|Manus Sensor Pen|Manus Sensor Pen as made by Manus Neurodynamica Ltd
45631782|NCT04417114|Drug|Rosuvastatin|Statin
45631783|NCT02366975|Drug|Testosterone gel 2%|testosterone gel 2% (50mg/die).
45631784|NCT02366975|Other|Placebo|placebo gel
45771258|NCT01149733|Drug|Tamsulosin|Test 0.4 mg Capsule
45771259|NCT01149733|Drug|Tamsulosin|Reference Listed 0.4 Capsule
45771260|NCT02498912|Procedure|Production of Genetically-modified T cells|
45771261|NCT02498912|Drug|Cyclophosphamide|
45771262|NCT02498912|Device|IP Catheter Insertion|
45771263|NCT02498912|Genetic|Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells|Patients who do not have sufficient CAR T cells for the assigned dose cohort will be treated in the cohort for which cells are available.
45771264|NCT02498912|Drug|Fludarabine|fludarabine dose 25-30 mg/m2 x 3 days
45771265|NCT00002014|Drug|Zidovudine|
45771266|NCT00002014|Drug|Didanosine|
45771267|NCT01893866|Drug|1 x 30 mg/mL pegvisomant|Subcutaneous injection, 30 mg, single dose.
45771268|NCT01893866|Drug|2 x 15 mg/mL pegvisomant|Subcutaneous injection, 2 injections of 15 mg, single dose.
45771269|NCT00000334|Drug|Buprenorphine|
45771270|NCT00000340|Drug|Pemoline|
45771271|NCT00000346|Behavioral|counseling|
45631785|NCT04417504|Other|MobFood breakfast kit|Cereal biscuit with orange fruit, cheese with fruit preparation and beverage based on oat, milk and mocha (without added sugar), specifically developed for the project MobFood_PPS4.
45631786|NCT04417504|Other|Control isocaloric breakfast|White bread, butter and milk.
45771272|NCT01190527|Radiation|FDG-PET|This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) before treatment and again during treatment to see if it helps predict how well the treatment works for the cancer. The standard of care for patients with stage III unresectable NSCLC is combined chemoradiotherapy. This study will seek to determine 2 year local-regional progression free survival in patients with non-small cell lung cancer (NSCLC) when an adaptive plan is applied based on repeat PET-CT imaging during the course of radiation therapy (during RT), and investigate if there is an improvement compared to those treated with conventional radiation therapy without field and/or dose modification. The investigators hypothesize that during-RT, PET-CT-based adaptive therapy will allow them to dose escalate in the majority of patients and meet the dose limits of normal structures, thus improving local tumor control without increasing toxicity.
45771273|NCT00002020|Drug|Zidovudine|
45771274|NCT04352023|Procedure|Patient-controlled analgesia|Intravenous patient-controlled analgesia Patient-controlled epidural analgesia
45771275|NCT00002026|Drug|Acyclovir|
45771276|NCT00000352|Drug|Dextromethorphan|
45771277|NCT00002032|Drug|Rifabutin|
45771278|NCT01229527|Drug|Remifentanil|Patient receive a bolus of Remifentanil (0,5 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,5 mcg/Kg every time the patient presses its button.
45631787|NCT03009539|Behavioral|eHealth Familias Unidas Primary Care|"The experimental condition will consist of eHealth Familias Unidas Primary Care. eHealth Familias Unidas Primary Care is an adaptation of the face-to-face version of Familias Unidas. As with face-to-face Familias Unidas, eHealth Familias Unidas Primary Care aims to prevent drug use, sexual risk behaviors, and STIs by improving family functioning. Similar to face-to-face Familias Unidas, eHealth Familias Unidas is a multi-level intervention that targets risk and protective factors at the multiple systems affecting the youth and youths' family."
45631788|NCT04711486|Drug|Contraloid acetate|Oral administration of drug substance capsules
45771279|NCT01229527|Drug|Remifentanil|Patient receive a bolus of Remifentanil (0,8 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,8 mcg/Kg every time the patient presses its button.
45771280|NCT01229527|Drug|Meperidine|Patient receive a bolus of Meperidine (0,7 mg/Kg) before the procedure and the PCSA pump with saline (sham PCSA) is connected.
45771281|NCT02723162|Drug|Varenicline (VRN)|VRN will be provided at the standard recommended dose (0.5 mg daily for 3 days, then 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for the remaining 21 days of active treatment.
45771282|NCT02723162|Drug|N-Acetylcysteine (NAC)|NAC will be dosed at 1200 mg twice daily throughout the 28-day active treatment
45771283|NCT02723162|Drug|Placebo|Matched placebo
45631789|NCT04711486|Drug|Placebo|Oral administration of placebo without any exipients.
45631790|NCT01696721|Other|No intervention|
45631791|NCT04686292|Diagnostic Test|urine flow cytometry|Diagnostic test of urine flow cytometry. A urine sample will be collected according to routine procedure by a study assistant. The sample will be divided into two aliquots; half for routine urine culturing, and half for Point-of-care Urine Flow cytometry (POC-UFC) analysis (UF-5000, Sysmex, Kobe, Japan). The analysis will be performed according to manufacturer's instruction and conducted by laboratory staff. Laboratory staff will be blinded to the participants diagnosis and outcome. The results of the POC-UFC analysis will not be visible to the treating physician.
45631792|NCT01288235|Radiation|Proton radiotherapy|5 days a week
45631793|NCT02030002|Device|APC Flash-Free Adhesive Coated Appliance System|APC Flash-Free Adhesive Coated Appliance System
45631794|NCT02030002|Device|APC II Adhesive Coated Appliance System|APC II Adhesive Coated Appliance System
45631795|NCT04479371|Drug|Liposomal bupivacaine|Injecting liposomal bupivacaine for a penile block for analgesia for hypospadias repair
45771284|NCT00000358|Drug|Lofexidine|
45631796|NCT04479371|Drug|Bupivacaine|Standard bupivacaine
45631797|NCT02079610|Behavioral|real-time fMRI neurofeedback: Amygdala|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
45631798|NCT02079610|Behavioral|real-time fMRI neurofeedback: HIPS|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
45771285|NCT00000370|Behavioral|Cognitive behavior therapy|
45771286|NCT00000370|Behavioral|Performance-based exposure therapy|
45771287|NCT00000370|Behavioral|Psychosocial intervention|
45771288|NCT04757558|Device|C-MAC video-stylet|Patients will be randomly assigned two group 40 patients each, C-MAC-VS group (VS group) (Karl Storz GmbHand Co.KG, Germany), and control group (C group). This will be done using a closed envelope technique using a computer-generated block randomization method.
45771289|NCT04757558|Device|Macintosh laryngoscope|Patients will be randomly assigned two group 40 patients each, C-MAC-VS group (VS group) (Karl Storz GmbHand Co.KG, Germany), and control group (C group). This will be done using a closed envelope technique using a computer-generated block randomization method.
45631799|NCT03112733|Diagnostic Test|TFF3, SFRP4, Romo1, NFKB|Blood samples of all participants will be collected.
45631800|NCT02366741|Radiation|Whole brain radiotherapy with reduced dose to the hippocampi|VMAT plan to treat the whole brain while reducing the dose to the hippocampi.
45631801|NCT03112655|Diagnostic Test|RNA and neopterin detection|Detection of spliced leader RNA will be performed on blood and cerebrospinal fluid taken before treatment, 11 days after treatment, 6, 12 and 18 months after treatment. Neopterin and 5-hydroxytryptophan will be quantified in cerebrospinal fluid taken at the same time points.
45771290|NCT00000376|Behavioral|Cognitive therapy|
45771291|NCT00000376|Drug|Desipramine|
45771292|NCT02721680|Other|Internal Awareness Training Program|
45771293|NCT02721680|Other|External Awareness Training Program|
45771294|NCT00000382|Behavioral|Infant-Parent Psychotherapy|
45771295|NCT00000382|Behavioral|Child Protective Services|
45771296|NCT00000382|Behavioral|Psychoeducational Home Visitation|
45631802|NCT02366585|Drug|Ciclosporin|Ciclosporin gel applied to two periodontal pockets
45631803|NCT02362685|Device|functional test|subjects perform a metabolic exercise testing
45631804|NCT02362685|Genetic|matching genotype with phenotype|
45631805|NCT02366429|Behavioral|ICBT for antenatal depression|Participants receives active therapist support via the internet to go through a 10-week self-help treatment on a secure web platform
45631806|NCT02366429|Other|TAU|Treatment as usual provided at antenatal clinics and other health care instances
45631807|NCT02079532|Drug|rituximab [MabThera]|1 g was given by intravenous infusion on Days 1 and 15
45631808|NCT02372279|Other|Embryo observation|In EO group, conventional observations will be made.
45631809|NCT02366351|Drug|SHR3824|Once daily, 12 weeks
45631810|NCT02366351|Drug|Placebo|Once daily, 12 weeks
45771297|NCT00000382|Behavioral|Parent Education|
45771298|NCT02143388|Drug|IMRT combine with cisplatin concurrent chemotherapy|Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT.
45771299|NCT02143388|Drug|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy|Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles.
45631811|NCT02366117|Behavioral|Training|Adapted training on the patients active participation, rehabilitation, independence, rights and wellbeing.
45631812|NCT02038673|Drug|ASP5878|oral
45631813|NCT02958917|Drug|Pirfenidone|This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
45631814|NCT02958917|Other|Placebo controlled|This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
45631815|NCT02362529|Drug|Minocycline|50 mg and 100 mg capsule, oral administration
45447774|NCT05296408|Behavioral|Home Exercise Program|Every subject will be assigned an individualized HEP. Therapy staff will create written handouts for the user to follow. The HEP will include photographs of the study participant performing his/her exercises/functional tasks along with written instructions. Each individual will have their own personalized HEP that will be created during their study participation and will be dispensed only to them. The HEP will reinforce in-clinic therapy. The HEP will be progressed regularly, and individuals will log practice time. The HEP for M+ML will include practice with and without the MyoPro; the HEP for ML-alone will include practice without MyoPro. Each HEP session will require approximately 90 minutes to complete.
45631816|NCT02362529|Drug|Placebo|Lactose monohydrate in identical gel capsules to minocycline, oral administration.
45631817|NCT02362529|Drug|Celecoxib|100 mg and 200 mg capsules, oral administration.
45631818|NCT02836067|Behavioral|Counseling|Smoking cessation counseling
45447775|NCT02117596|Drug|Sirolimus|"Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours)."
45447776|NCT02120170|Procedure|Colon polypectomy|
45447777|NCT02117674|Procedure|standard forward-viewing colonoscopy|examination of the colon with a conventional colonoscope
45631819|NCT02836067|Other|Smoking Cessation drugs|Medication to aid smoking cessation
45631820|NCT02836067|Procedure|Bronchoscopy|Bronchoscopy
45631821|NCT02836067|Procedure|Blood Draw|Screening and research blood draws
45631822|NCT02836067|Behavioral|Questionnaires|Behavioral questionnaires
45447778|NCT02117674|Procedure|full-spectrum colonoscopy|examination of the colon with full-spectrum colonoscope
45631823|NCT02362607|Behavioral|Integrated Diabetes Management Protocol|
45631824|NCT02362607|Behavioral|Standard Diabetes Management Protocol|
45631825|NCT02362295|Other|qualitative interview|some patient are interviewed.
45631826|NCT02794571|Drug|Atezolizumab|Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle or as 1680 mg via IV infusion on Day 1 of each 28-day cycle.
45631827|NCT02794571|Drug|Tiragolumab|Several dose levels will be evaluated for tiragolumab administered as a single agent and in combination with atezolizumab and/or other anti-cancer therapies. Tiragolumab will be given via IV infusion on Day 1 of each cycle (21-day or 28-day depending on study cohort and phase) until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent tiragolumab may receive combination treatment with tiragolumab and atezolizumab and/or other anti-cancer therapies. Combination treatment may continue until disease progression or loss of clinical benefit.
45631828|NCT02794571|Drug|Carboplatin|Carboplatin, AUC of 6 milligram per milliliter per minute (mg/ml/min) for Cohorts A and B and AUC of 5 mg/ml/min for Cohort C, IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab IV infusion.
45631829|NCT02794571|Drug|Cisplatin|Cisplatin 75 milligram per square meter (mg/m^2) IV infusion will be administered on day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.
45631830|NCT02794571|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 IV infusion will be administered on Day 1 of each 21-day cycle after carboplatin or cisplatin IV infusion with combination treatment of atezolizumab and tiragolumab.
45631831|NCT02794571|Drug|Paclitaxel|Paclitaxel 200 mg/m^2 IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment with atezolizumab and tiragolumab.
45447779|NCT02117674|Procedure|right colon retroflexion|examination of the right colon with scope retroflexion (both with conventional and fuse scope)
45631832|NCT02794571|Drug|Etoposide|Etoposide 100 mg/m^2 IV infusion will be administered on Days 1, 2, and 3 of each 21-day cycle with combination treatment of atezolizumab and tiragolumab.
45631833|NCT02794571|Drug|Capecitabine|Capecitabine 1250 mg/m^2 oral dose will be administered twice daily (BID) on Days 1 through 14 of each 21-day cycle. On Day 1 of Cycle 1, the first dose of capecitabine will be administered prior to the atezolizumab and tiragolumab infusion.
45631834|NCT02794571|Drug|Bevacizumab|Bevacizumab 15 mg/kg IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.
45631835|NCT02794571|Drug|Pembrolizumab|Pembrolizumab 200 mg IV infusion will be administered on Day 1 of each 21-day cycle after treatment with tiragolumab.
45631836|NCT02769689|Drug|Methylprednisolone|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
45631837|NCT02769689|Drug|Placebo|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
45631838|NCT02769689|Drug|natalizumab (NTZ)|Patients with MS receiving NTZ for at least 18 months and without any disease activity during the previous year will be eligible. Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
45631839|NCT02769689|Drug|fingolimob (FTY)|Every patient will initiate a treatment with FTY 7 weeks after the last NTZ perfusion. Methylprednisolone or placebo will be taken 4, 8 and 12 weeks (W4, W8 and W12) after NTZ discontinuation.
45631840|NCT02362061|Radiation|3D ultrasound|ultrasound to measure the thickness of the junctional zone at day 21 of the cycle
45771300|NCT04757480|Procedure|Thoracolumbar Interfascial Plane Block (TLIP)|(20ml) (plain bupivacaine 0.25% on each side toward the LG-MF interface.
45631841|NCT02362139|Drug|The study group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation<4cm).
45447780|NCT02117752|Drug|dapsone gel|Patches containing dapsone gel will be applied to the skin.
45631842|NCT02365571|Drug|LY3154207|Administered orally
45631843|NCT02365571|Drug|Placebo|Administered orally
45631844|NCT02365571|Drug|Itraconazole|Administered orally (twice daily on Day 3 and then once daily to Day 12) as a 10 mg/mL solution
45631845|NCT02362217|Biological|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
45631846|NCT02362217|Biological|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
45631847|NCT02362217|Biological|ChAdV63.HIVconsv|Genetic vaccine against HIV-1 infection
46070022|NCT02554201|Device|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. Needles of 0.40 Х 100 mm are inserted perpendicularly to the upper points to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The two lower points are about 1 cm bilateral to the tip of the coccyx. Needles of 0.40 Х 100 or 125 mm are inserted obliquely to the lower points towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally needles.
46070023|NCT02554201|Device|Transvaginal electrical stimulation|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
45631848|NCT02362217|Biological|MVA.HIVconsv|Genetic vaccine against HIV-1 infection
45631849|NCT02361983|Device|DLT versus bronchial blockers|Safety and efficacy of the double-lumen tubes (DLT) and bronchial blockers (BB) for lung isolation in patients undergoing thoracic surgery have been extensively studied and most of the results show similar rates of successful placement and lung collapse. DLT and BB are more frequently inserted by anesthetists who are expert in thoracic anesthesia, with dedicated but different training.
45631850|NCT02361827|Procedure|Embryo transfer|For patients in each group, they will have embryo transferred 3 or 5 days after oocyte retrieval.
45631851|NCT02365727|Drug|Liposomal bupivacaine|
45631852|NCT02365727|Drug|Ropivacaine|
45631853|NCT02365727|Drug|Epinephrine|
45631854|NCT02365727|Drug|Clonidine|
45631855|NCT02365727|Drug|Saline|
45631856|NCT02361593|Procedure|assistance of a transparent cap|Patients will receive endoscopic injection of lauromacrogol with assistance of a transparent cap.
45631857|NCT02361593|Procedure|without a transparent cap|Patients will receive routine endoscopic injection of lauromacrogol without use of transparent cap.
45631858|NCT02365805|Drug|Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel|Epirubicin 90 mg/m2 + Ciclofosfamide 600 mg/m2 + 5-Fluorouracil 600 mg/m2 intravenous infusion on day 1 every three weeks, for four cycles; followed by Paclitaxel 100 mg/m2 weekly for eight weeks.
45631859|NCT02365805|Drug|Epirubicin + Cisplatin + Fluorouracil|Epirubicin 60 mg/m2 + Cisplatin 60 mg/m2 intravenous infusion on day 1 every three weeks and 5-Fluorouracil 200 mg/m2/day for eight cycles.
45447781|NCT02117752|Drug|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
45447782|NCT02117752|Drug|sodium lauryl sulfate|Patches containing sodium lauryl sulfate (Positive Control) will be applied to the skin.
45631860|NCT02365805|Drug|Docetaxel + Ciclofosfamide|Docetaxel 75 mg/m2 + Ciclofosfamide 600 mg/m2, intravenous infusion on day 1 every three weeks, for eight cycles.
45631861|NCT03112889|Drug|Sodium Valproate|Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
45631862|NCT04478825|Drug|BBT-401-1S|BBT-401-1S, 8 weeks, once a day
45631863|NCT04479059|Other|follicular fluid flushing|Follicular fluid obtained during OPU will be used for endometrial cavity flushing.
45631864|NCT04438889|Other|Non-interventional|Only routine clinical data, which has already been recorded in the patient's medical chart, will be documented. Any other data assessments (e.g. quality of life analyses such as EQ-5D and QLQ-C30 have been approved by the Ehtikkommission für das Bundesland Salzburg and are optional.
45631865|NCT03112577|Drug|REGN3500|Intravenous (IV) use
45631866|NCT03112577|Drug|Dupilumab|Subcutaneous (SC) use
45631867|NCT03112577|Drug|Placebo|Matching placebo
45631868|NCT03112577|Drug|Fluticasone propionate|Inhalation use
45913621|NCT02024659|Other|placebo|patients receive placebo (saline solution) 2ml twice daily for 14 days.
45631869|NCT02361905|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later
45631870|NCT02361905|Drug|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
45447783|NCT02117752|Drug|Normal saline|Patches containing normal saline (Negative Control) will be applied to the skin.
45447784|NCT03553030|Device|coronary artery angiography|In all patients authors performed a coronary artery angiography for detection of coronary artery stenosis.
45447785|NCT02123212|Other|Mailer|Henry Ford intentifies patients meeting birth cohort screening criteria and then sends mailers to those individuals. Mailers contained HCV guidelines, the importance of screening, laboratory slips and locations for patients to act directly on their own behalf. If patients do not respond to the initial mailer, Henry Ford sends additional mailers.
45631871|NCT02361749|Drug|Botulinum Toxin|Injection of Botulinum toxin under general anesthesia. Four injections will be given into the anal sphincter into the four quadrants in one session.
45631872|NCT02361749|Procedure|Anal Myectomy|Longitudinal anal myectomy will be performed under general anesthesia as a day case.
45631873|NCT02361671|Other|Optic Nerve Sheath Diameter using an ultrasound|Optic nerve sheath diameter will be measured by ultrasound preoperatively on the day of surgery, Immediate postoperative period (within 24 hours) or 6-8 weeks after surgery on the follow-up visit.
45631874|NCT04372433|Biological|IO-202|IO-202 as monotherapy
45631875|NCT04372433|Biological|IO-202 and Azacitidine|IO-202 and azacitidine combination therapy
45631876|NCT04372433|Biological|IO-202 and Azacitidine + Venetoclax|IO-202 and azacitidine + venetoclax combination therapy
45631877|NCT04372433|Biological|IO-202 and Azacitidine|IO-202 and azacitidine combination therapy
45631878|NCT02361203|Behavioral|Exercise|30 minutes of aerobic exercise on a treadmill at 80% of participant's heart rate reserve.
45631879|NCT02361359|Other|Psychological questionnaires|
45631880|NCT02361437|Dietary Supplement|Vasculera|Vasculera 630 mg b.i.d.
45631881|NCT02359409|Device|goggle balloon|Colonoscopy will be performed using the water immersion technique.
45631882|NCT02359409|Other|water immersion only|Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique.
45631883|NCT04349735|Other|Assessment of inhalation technique|Assessment of inhalation technique by 3 methods in every patient
45631884|NCT03160469|Device|intragastric Elipse Device|"Obesity prevalence is increasing worldwide, and Kuwait is currently considered to be the country with the most obese population1. Accordingly, standardization of the weight loss procedures has been made according to the Body Mass Index (BMI), keeping the more advanced surgeries for class II obesity (BMI 35- 39.9) and above, with consideration of other factors like, for example, obesity-related comorbidities. For those patients whom considered in the category of overweight (BMI = 25- 29.9) & class I obesity (BMI 30- 34.9), after failure of diet attempts, the weight loss options are limited. Of the highly requested options are the various types of intra-gastric balloons. Conventional endoscopic gastric balloons have proven to be safe and effective, with Excess Weight Loss (%EWL) of 25-50%2. A new swallowable gastric balloon, named Elipse, has been launched recently in Kuwait and became highly popular due to its unique concept of being procedure-less."
45631885|NCT02358941|Behavioral|Neurofeedback training|In neurofeedback training, EEG-activity is visualized and fed back to the participant online on a computer screen. Successful regulation is rewarded by bonus points. The aim is to gain control over one's brain activity and to be able to switch to or to maintain a more wakeful, alert or focussed state.
45631886|NCT02358941|Behavioral|Computerized cognitive training|In computerized cognitive training, impaired neuropsychological functions, such as inhibition, working memory, distractibility, are directly trained by adaptive computerized software programs. We use training programs from a scientifically based training system for patients presenting problems with sustained, focussed or selective attention, working memory, inhibition, processing speed. Good performance / improvements are rewarded with bonus points.
45631887|NCT03160313|Behavioral|InFuSE|Each session includes a 45-minute education and group discussion. A 60-minute exercise component then completes the session. Each topic was specifically picked and tailored to benefit Veterans with TBI. The education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities. The activities are included to help improve understanding and promote group discussion. The exercise piece consists of a warm-up, endurance training (20-30 minutes), strengthening (15 minutes), balance/cognitive training (15 minutes), and a cool-down.
45771301|NCT04757480|Procedure|Bilateral Erector Spinae plane Block (ESB)|Will receive (20ml) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the eighth thoracic segment (T8).
45771302|NCT00001228|Drug|Interferon|
45771303|NCT01191541|Drug|DNR:|DNR：45mg/m2 d1-3
45771304|NCT01191541|Drug|Ara-c|DNR+ARA-C：DNR：45mg/m2 d1-3;Ara-C :1g/m2 d1-3
45771305|NCT02141906|Other|Oncozene-DEB-TACE|ONCOZENE microspheres are the newly available microspheres for DEB-TACE. It appears (based on the preliminary bench tests) that these microspheres may allow more efficient drug loading, and slow elution and equivalent vascular occlusion(12). In this pilot study, we aim to assess the safety of these microspheres when used for chemoembolization of unresectable hepatocellular carcinoma.
45771306|NCT02483936|Drug|Olmesartan medoxomil 40mg + chlorthalidone 12,5mg|1 tablet a day
45771307|NCT02483936|Drug|Olmesartan medoxomil 40mg + chlorthalidone 25mg|1 tablet a day
45771308|NCT02483936|Drug|Olmesartan 40mg + Hydrochlorothiazide 12,5mg|1 tablet a day
45631888|NCT03160313|Behavioral|Patient Education/Group Discussion|Each week you will participate in a 1 hour health education class with other Veterans. Each topic was specifically picked and tailored for Veterans with TBI. These education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities which are included to help improve understanding and promote group discussion.
45631889|NCT02358785|Device|ECHELON FLEX™ Powered Plus Stapler|ECHELON FLEX™ Powered Plus Stapler using ENDOPATH ECHELON™ Reloads with Gripping Surface Technology (GST). The combination of stapler plus reload is referred to as the ECHELON FLEX™ GST System.
45631890|NCT02358707|Other|Ibuprofen phonophoresis|
45631891|NCT02358551|Device|Placement of electrode lead through axillary vein puncture|
45771309|NCT02483936|Drug|Olmesartan 40mg + Hydrochlorothiazide 25mg|1 tablet a day
45771310|NCT00002038|Drug|Fluconazole|
45771311|NCT01150903|Other|no intervention|non-interventional study
45631892|NCT02358551|Device|Placement of electrode lead through subclavian vein puncture|
45631893|NCT02358317|Behavioral|Video Game Motor Training|
45631894|NCT02358317|Behavioral|Sedentary Video Game Training|
45771312|NCT01150903|Other|no intervention|non-interventional study
45771313|NCT01894334|Drug|Ulinastatin|
45771314|NCT01894334|Drug|Tranexamic acid|
45771315|NCT01894334|Drug|Edaravone|
45771316|NCT00002044|Drug|Zidovudine|
45771317|NCT00001270|Drug|interleukin-1|
45771318|NCT02715518|Device|PCI using 2nd generation drug-eluting stent|"Percutaneous coronary intervention (PCI) using 2nd generation drug-eluting stent for non-IRA stenosis will be decided according to the allocated arms.~FFR-guided strategy arm~Angiography-guided strategy arm"
45771319|NCT00001282|Drug|Zidovudine (AZT) & Interleukin-2 (IL2)|
45771320|NCT02478320|Drug|Ilorasertib|200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.
45771321|NCT01150981|Drug|Rosiglitazone|One 8mg capsule daily for 6 weeks.
45771322|NCT01150981|Drug|Placebo|One capsule daily for 6 weeks.
45771323|NCT00001288|Drug|15 O Water|
45631895|NCT02360969|Other|Examination of the eye|"Before planed surgery, an ophthalmologist measures the patient's visual acuity and realise an oculomotor examination. Measurement the refraction and the axial length of the eye is performed. Photographs wakefulness are performed.~During surgery, participation in this study does not involve any change in the course of anesthesia and surgery.~Pictures of the eye will be performed under general anesthesia.~Timing photos will be dictated by the values of BIS and train-of-four (TOF). Photos will be conducted at different times, with the top given by the anesthetist under the following conditions:~Deep anesthesia: BIS <50 Deep anesthesia and muscle relaxation: BIS <50 and TOF 0/4"
45771324|NCT00001288|Drug|FDG|
45631896|NCT02361047|Behavioral|Phone Coaching Program|Participants in this group will receive a 10-session nutrition and physical activity program delivered via phone by a health behavior coach to promote healthy lifestyle changes. Participants will also receive standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
45771325|NCT02132858|Other|cytology specimen collection procedure|Correlative studies
45447786|NCT02123212|Other|In-person recruitment|UAB used study coordinators to actively screen and recruit patients who met the inclusion criteria for birth-cohort screening. Study coordinators were located at two internal medicine clinics, where they approached eligible participants in person. A control group was pulled from an additional two internal medicine clinics, which screened using a risk-based strategy. A cross-over approach was used, so that the intervention and control clinics switched at the midpoint of data collection, allowing all four clinics to participate in both arms of the study.
45631897|NCT02358239|Procedure|acupuncture|Experiment group received acupuncture at Zusanli (ST36) and Neiguan (PC6) acupuncture points
45631898|NCT02360813|Behavioral|Cognitive Remediation Therapy|Fifty-six sessions of principle driven cognitive remediation therapy. Three individual sessions and one group session each week for approximately fourteen weeks.
45631899|NCT02360813|Other|Treatment as usual|Keep getting usual care.
45631900|NCT02360657|Drug|JNJ-54861911, 10 mg|JNJ-54861911, 10 mg (2*5 mg tablet) orally once daily for 4 weeks.
45631901|NCT02360657|Drug|JNJ-54861911, 50 mg|JNJ-54861911, 50 mg (2*25 mg tablet) orally once daily for 4 weeks.
45631902|NCT02360657|Drug|Placebo|Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
45631903|NCT02360735|Other|Manual Lymphatic Drainage|Manual Lymphatic Drainage (MLD) is a specialized massage technique utilized to decrease various forms of edema. This technique promotes reuptake of interstitial fluid along the pathways of the lymphatic system. This technique promotes healing, decrease swelling, and decrease pain.
45631904|NCT02360735|Other|Physical Therapy|All patients will participate in joint physical therapy classes during their inpatient stay.
45771326|NCT02132858|Other|laboratory biomarker analysis|Correlative studies
45771327|NCT00001300|Drug|doxorubicin|
45447787|NCT02123212|Other|EHR Alert|EHR include a Best Practice Alert (BPA) prompting the Medical Assistant and/or clinican to order a Hepatitis C lab test for patients in the birth cohort.
45631905|NCT02358005|Procedure|Extracorporeal shock wave therapy 60mj|
45631906|NCT02358005|Procedure|Extracorporeal shock wave therapy 120mj|
45631907|NCT02358005|Procedure|non extracorporeal shock wave therapy|
45631908|NCT02360501|Drug|Docetaxel|75mg/㎡,d1
45771328|NCT00001300|Drug|ifosfamide|
45771329|NCT00001300|Drug|mesna|
45771330|NCT01230931|Device|Vitagel|Vitagel (by Stryker) is a topical surgical hemostat spray that results in coagulation. The components are as follows: autogenous blood is drawn and centrifuged to produce a sample of platelets and growth factors; this is combined with a bovine thrombin and collagen solution. When the two are applied together, it produces the hemostatic effect.
45771331|NCT01230931|Procedure|Standard of care|Standard of care for hemostasis in acetabular surgery includes electrocautery/ligation of bleeding vessels, fracture reduction and stabilization, cell-saver, lap packing.
45771332|NCT00000394|Procedure|Acupuncture therapy|
45771333|NCT00000400|Drug|Human parathyroid hormone [hPTH-(1-34)]|37 mcg once daily by self-administered sc injection
45771334|NCT00000400|Drug|alendronate|70 mg/week by oral route
45771335|NCT02477774|Device|ARISTA|According to the manufacturer, Arista uses Microporous Polysaccharide Hemospheres (MPH) technology to catalyze the clotting cascade and effectively dehydrate tissue to initiate hemostasis in broad areas. Major advantages of Arista are that it has been shown to be safe and effective across multiple surgical disciplines, is completely absorbed in 24-48 hours, and contains no human or animal components
45913622|NCT02024672|Other|Immediate postpartum placement of IUD|pelvic exam, transvaginal ultrasound (3 during the course of the study), bleeding and symptom diary
45447788|NCT02120248|Other|Telephone-based breastfeeding peer counseling|
45447789|NCT02251522|Device|ConforMIS Total Knee Replacement System|Total knee replacement system using a patient specific implant.
45447790|NCT02251522|Device|Off-the-Shelf Knee Replacement System|Total knee replacement system not using a patient specific implant.
45631909|NCT02360501|Drug|Cisplatin|25mg/㎡,d1-3
45631910|NCT02360501|Drug|Capecitabine|2000mg/㎡,d1-14
45631911|NCT02358629|Device|NovaCross™ microcatheter|successful delivery, crossing, and retrieval of the investigational device as identified by confirmation of guidewire placement in the distal true lumen confirmed by angiography
45631912|NCT02360423|Device|CRE8 sirolimus-eluting stent|The CRE8 stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium alloy and is coated with i-carbofilm.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
45631913|NCT02360423|Device|RESOLUTE zotarolimus-eluting stent|The RESOLUTE stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium tungsten alloy. It has been approved by CFDA in 2009 and commercially available in Chinese market
45935313|NCT00220987|Other|Conventional Insulin therapy|Maintain blood glucose 8-10mmol/L
45631914|NCT02358083|Behavioral|Provider Communication about Vaccination|There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
45631915|NCT02358161|Drug|gemcitabine and nab paclitaxel|DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer
45631916|NCT02357927|Behavioral|Mini-AFTERc|20-30 minute structured conversation following guidelines and instruction within the Mini-AFTERc 20 page manual
45631917|NCT02357927|Behavioral|telephone call|this consists of a 20-30 minute conversation about the general well-being of the patient with no specific reference to recurrence fears unless raised by the patient explicitly themselves
45631918|NCT02360345|Drug|ONX-0801|
45631919|NCT02360579|Biological|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2.
45631920|NCT02357849|Drug|Aripiprazole|see arm description
45631921|NCT02357849|Drug|Fluoxetine|see arm description
45631922|NCT02357693|Drug|Aprepitant|Aprepitant or placebo will be administered to the patient before surgery
45631923|NCT02360033|Behavioral|Systemic Therapy for Social Anxiety Disorder|
45631924|NCT02360033|Behavioral|Cognitive Behavioral Therapy for Social Anxiety Disorder|
45631925|NCT02357771|Drug|Probiotic (L. brevis CD2 lozenges)|Each Lactobacillus brevis CD2 lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2
45631926|NCT02357771|Drug|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
45631927|NCT02357537|Behavioral|Combined Anti-inflammatory Diet (CAID)|The CAID requires participants to modify their diet to include certain types of foods that may have anti-inflammatory properties. Participants on the CAID will be required to abstain from red meat and alcoholic beverages.
45913623|NCT02024685|Behavioral|Personalized Treatment Recommendations|This is a psychosocial/behavioral study. It will use a randomized trial to test the hypothesis that a decision analysis model that provides individualized estimates of quality-adjusted disease-free survival for each of the treatment options for clinically localized prostate cancer will lead to higher quality treatment decisions congruent with a patient's values leading to improved decisional regret and treatment satisfaction. In this trial, all patients would be evaluated at baseline for their utilities for various clinically important health states. The primary endpoint of this study will be regret-free survival at 2 years after treatment. There will be a 1:1 randomization. A random permuted design will be used to assure approximate balanced number of patients in the two groups over time.
45913624|NCT02024685|Behavioral|Standard patient-physician counseling interaction|Both patients and physicians will be unaware of the decision analysis recommendation and the patients will receive standard treatment counseling alone. After the patient has made a treatment decision he will be given a short questionnaire to assess decisional conflict. If after one month no treatment decision information is available, a letter and form requesting treatment information along with the decisional conflict questionnaire will be sent to patients.
45935314|NCT02966067|Device|Microneedle Device (Experimental)|Injection of 1.2ml of a standard local dental anaesthetic solution [1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)] at a rate of 1 mL/min.
45935315|NCT02966067|Device|30-gauge Short Hypodermic Needle|Injection of 1.2ml of a standard local dental anaesthetic solution [1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)] at a rate of 1 mL/min.
45631928|NCT02357615|Drug|nifedipine CR tablets (Xin Ran)|
45631929|NCT02357615|Drug|Adalat|
45631930|NCT03160001|Drug|Placebo|Patients with active RA and receive Etanercept for 8 weeks.: Placebo lactose 500mg cap twice daily
45631931|NCT03160001|Drug|Niclosamide|Patients with active RA and receive etanercept with niclosamide cap 500mg twice daily orally as adjuvant therapy for 8 weeks
45631932|NCT03160001|Drug|Etanercept|Etanercept 50mg weekly
45631933|NCT02359643|Drug|Aspirin|"This study was conduct to investigate the role of high dose aspirin in acute stage of KD via a multi-center randomized control trail, and we plan to achieve the followings in the coming 4 years:~Enroll 300 KD patients from multiple medical centers of Taiwan and China in 4 years. Randomize group patients as group 1: with high dose aspirin (more than 30/mg/kd/day) until fever subsided and shift to low dose aspirin (3-5mg/kg/day, N=150); and group 2: without high dose aspirin during acute febrile stage, only use low dose aspirin (N=150).~Compare data including fever days, admission duration, laboratory data (CBC/DC, GOT/GPT, BUN/Cr, Alb, ESR, CRP, 2D echo), IVIG treatment response and CAL formation rate (followed at least 1 year)."
45935316|NCT00221026|Drug|Methoxsalen +ECP|ECP + Uvadex given at weeks 1-12 weeks.
45935317|NCT00221026|Procedure|Extracorporeal Photopheresis|ECP given at weeks 1 through 12.
45631934|NCT02038985|Other|Participants will receive ICG Dye|Participants will receive ICG Dye preoperatively for use in the Visual Diagnosis of Endometriosis
45631935|NCT02359721|Drug|tablet clarithromycin 500 mg (Clarino-500) orally|orally
45771336|NCT01195597|Device|E-Cigarette 7.2 mg nicotine|"Participants were given a free e-Cigarette kit containing two rechargeable batteries, a charger, and two atomizers and instructed on how to charge, activate and use the e-Cigarette. Key troubleshooting were addressed and phone numbers were supplied for both technical and medical assistance. A full 4-weeks supply of 7.2 mg nicotine cartridges (Original cartridges; Arbi Group Srl, Milano, Italy) was also provided and participants were trained on how to load them onto the e-Cigarette's atomizer"
45771337|NCT00000406|Procedure|Progressive resistance exercise|
45771338|NCT02127398|Biological|fecal microbiota|fecal microbiota in capsule form
45771339|NCT00002050|Drug|Thymopentin|
45771340|NCT04389866|Device|JUVÉDERM VOLUMA™ XC|Injectable gel
45771341|NCT00000412|Drug|Alendronate|
45771342|NCT00000412|Drug|Calcitriol|
45771343|NCT00000412|Drug|Placebo Alendronate|
45771344|NCT00000412|Drug|Placebo Calcitriol|
45771345|NCT04390256|Other|Clove water extract|natural product
45771346|NCT04390256|Other|Carbopol|Bioadhesive polymer
45771347|NCT04390256|Other|Carboxymethyle cellulose|Bioadhesive polymer
45771348|NCT00002056|Drug|Pentamidine isethionate|
45771349|NCT03110562|Drug|Selinexor|oral 100 mg dose
45913625|NCT02024737|Other|MRI lung imaging (not an intervention per se but the focus of the study)|"The purpose of this pilot study is to determine short and long term reproducibility of a comprehensive set of functional imaging data; using hyperpolarised gas MRI, conventional MRI and lung physiology measurements in patients with moderate to severe COPD. In addition,how sensitive the imaging techniques are to changes in lung function after treatment with a standard (bronchodilator) inhaler will also be assessed (the bronchodilator foradil is a non-investigative medicinal product as it is a medicine with a known effect which will be used to induce a known response).~This pilot study will serve as a platform for future larger scale studies, aimed at better understanding of and intervention in early COPD."
45913626|NCT02024763|Behavioral|Educational Intervention|Intervention was applied to classroom teachers by the multidisciplinary team of the RRIDA Project. Training lasted six weeks, 12 hours devoted to physical activity and 18 hours to nutritional content. Modules of educational activities to classroom teachers were to be replicated at PE classes to children from 1st and 2nd grades of three exposed schools. The physical activity module was based on a theoretical approach of physical activity benefits and risks for health, children's physical fitness and activity patterns, physical education and change behavior models.
45631936|NCT04299191|Drug|LAM561|"Once a patient is allocated a dose of LAM561, they will receive the same dose on a daily basis in treatment cycles of 21 days (3 weeks), which may be repeated without therapy interruption until a criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general criterion) is met.~The starting dose will be 2.8 g/m2 twice daily. If tolerated, doses will be escalated to 3.5 g/m2 twice daily and then to a third dose level of 4.2 g/m2 twice daily. These dose levels correspond to 80%, 100%, and 120% of the maximum tolerated dose of LAM561 in adult patients when adjusted for body surface area. A total of 3 dose cohorts are anticipated for the dose escalation phase of the study, with up to 6 patients enrolled at each dose level according to a standard 3+3 design. During each dose cohort, at least 1 week must elapse between the first and subsequent patients receiving treatment with LAM561."
45631937|NCT02359487|Behavioral|Alcohol-HIV Risk Reduction Counseling|The intervention consists of a 1-hour individual counseling session relating to alcohol consumption and HIV sexual risk behaviors. Intervention counselors will assess alcohol-related sexual risk behaviors through the use of job aids that include a flip chart, guided scripts, activities, role plays, and a take home booklet. Counselors use motivational interviewing and interactive activities to discuss alcohol and HIV myths and facts, participants personal risk behaviors, and a decision-making activity that assists participants in weighing the pros and cons of engaging in risky behavior. Counselors also facilitate role plays to improve communication skills in risky situations, as well as a condom demonstration and skills session, and goal setting. In addition, men in the intervention arm will also receive two cell phone text messages 1-month and 4-months following enrollment to reiterate risk reduction messages.
45631938|NCT02359487|Behavioral|Placebo Intervention|Participants assigned to the control arm will be given a general alcohol information booklet and an alcohol abuse support services brochure. The alcohol information booklet contains information about responsible drinking, signs and symptoms of alcohol abuse, advice and guidance to reduce alcohol intake, and resources for assistance. The alcohol support services brochure contains times, dates, and locations of peer support and counseling services in the Windhoek region.
45631939|NCT02357303|Drug|Simethicone|100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
45631940|NCT02357303|Drug|Acetylcysteine|100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy
45631941|NCT02357303|Other|Placebo|100mL of water
45631942|NCT03112811|Device|Autogenic drainage|The manual technique of the chest physiotherapy to move the secretions
45631943|NCT03112811|Device|Intrapulmonary percussive ventilation|The instrumental technique of the chest physiotherapy to move the secretions
45631944|NCT02352857|Other|Sugar|100g of sponge cakes made with 24g of dextrose.
45631945|NCT02352857|Other|FOS|100g of sponge cakes made with 19.4g of dextrose and 9.1g of FOS.
45631946|NCT02352935|Device|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
45631947|NCT02357225|Drug|Pyridostigmine Bromide|Pyridostigmine is an acetylcholinesterase inhibitor, which increases the amount of acetylcholine at the neuromuscular junction. It will be taken orally, either as a tablet or as a syrup.
45631948|NCT04478903|Other|Questionnaire|Zarit Burden Inventory French version and SF12
45631949|NCT02357381|Device|eNeura SpringTMS|Single pulse magnetic stimulation for prevention and/or treatment of migraine headache with or without aura.
45631950|NCT02356991|Drug|Famitinib|
45913627|NCT02024776|Behavioral|Prehabilitation|Tailored exercise training program
45913628|NCT02024789|Drug|Placebo|Orally twice daily, 26 weeks
45913629|NCT02024789|Drug|RG1662|120 mg (80 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
45913630|NCT02024789|Drug|RG1662|240 mg (160 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
45913631|NCT02024815|Radiation|External Beam radiotherapy|External Beam radiotherapy
45913632|NCT02024828|Other|Early/Slow|
45913633|NCT02024828|Other|Early/Fast|
45913634|NCT02024828|Other|Late/Slow|
45913635|NCT02024828|Other|Late/Fast|
45631951|NCT02356991|Drug|Placebo|
45771350|NCT03110562|Drug|Bortezomib|subcutaneous dose of 1.3 mg/m2
45771351|NCT03110562|Drug|Dexamethasone|oral dose of 20mg
45771352|NCT00380614|Drug|Lamivudine|
45771353|NCT00000430|Drug|Alendronate|
45771354|NCT00000430|Drug|Estrogen/progestin therapy|
45771355|NCT00380770|Drug|Generic HAART Triomune : d4T, 3TC, NVP|Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
45771356|NCT00380770|Drug|Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV|Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks) Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
45771357|NCT01231399|Drug|fluorouracil|Given IV
45771358|NCT01231399|Drug|leucovorin calcium|Given IV
45771359|NCT01231399|Drug|oxaliplatin|Given IV
45631952|NCT03112265|Behavioral|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
45631953|NCT03112265|Other|Monitoring and Feedback System|For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Emotions Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.
45631954|NCT03112265|Behavioral|Treatment as usual|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective.
45631955|NCT03112343|Device|Algorithm-based feedback messages|ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
45771360|NCT01231399|Drug|everolimus|Given orally
45913636|NCT02024841|Drug|Intraperitoneal docetaxel|Intraperitoneal docetaxel, intravenous cisplatin and oral TS-ONE every 3 weeks for 3 cycles then stop
45631956|NCT03112343|Device|Personal Health Record|Subjects will save and send their health information to the server via the personal health record app
45631957|NCT02357069|Drug|Enbrel|Etanercept
45771361|NCT01231399|Other|laboratory biomarker analysis|Correlative studies
45913637|NCT02024880|Device|Protective catheter group|The tip of this catheter is protected on insertion of the catheter.
45913638|NCT02024880|Device|Conventional catheter group|A standard embryo catheter
45913639|NCT02024893|Other|Observational study|"Observation and type of data collected are listged in detail under 'description"
45913640|NCT02024906|Dietary Supplement|soy protein isolate (SPI)|
45913641|NCT02024906|Dietary Supplement|milk protein isolate (MPI)|
45631958|NCT02357069|Drug|LBEC0101|Etanercept
45631959|NCT02356913|Drug|Nicotine gum|
45631960|NCT02352545|Drug|Montelukast|Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
45631961|NCT02356835|Device|APT001|APT001, is a portable device that uses plasma energy to deliver nitric oxide to the tissues.
45631962|NCT02356835|Device|SHAM|Portable device that uses warmed room air to mimic delivery of the APT001 treatment.
45631963|NCT02352701|Drug|Noltec tab. 10mg|Ilaprazole 10mg BID dosage form : delayed release tablet
45631964|NCT02352701|Drug|Chongkundang Amoxicillin Cap. 500mg|Amoxicillin 1000mg, BID dosage form : capsule
45631965|NCT02352701|Drug|Cravit Tab. 500mg|Levofloxacin 500mg, BID dosage form : film coated tablet
45631966|NCT02352623|Radiation|DXA scan|DXA scan
45631967|NCT02352623|Procedure|Clinical examination|Clinical examination
45631968|NCT02352467|Device|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
45631969|NCT02356445|Other|Cytotoxic drug|Observe patients versus treatment type
45631970|NCT02356679|Drug|Eupasidin-s Tab|three times per day, 1 tab for each time, PO, during 2weeks
45631971|NCT02356679|Drug|Stillen Tab.|three times per day, 1 tab for each time, PO, during 2weeks
45631972|NCT02352233|Procedure|RETROVIEW colonoscope|withdrawal in retro vision and forward vision was performed by segments (right, transverse, left, sigmoid colon and rectum). Retroflexed therapeutics procedures were executed when needed.
45631973|NCT02356289|Drug|Placebo|
45631974|NCT02356289|Drug|MYK-461|
45631975|NCT02356367|Other|telemonitoring|
45771362|NCT01231399|Other|immunohistochemistry staining method|Correlative studies
45771363|NCT01231399|Genetic|microarray analysis|Correlative studies
45771364|NCT00002062|Drug|Spiramycin|
45771365|NCT00000436|Behavioral|Self-efficacy and muscle strength training|
45771366|NCT00000436|Procedure|High-intensity strength training|
45771367|NCT05432154|Device|Film forming silicone gel (7-0940)|"Film forming silicone gel (7-0940) is an innovative gel that forms a full contact, flexible wound dressing for supporting mucosal conditions of the genital, rectal and perineal areas.~Film forming silicone gel (7-0940) is a semi-occlusive, non-resorbable, self-drying and transparent gel.~Film forming silicone gel (7-0940) may be directly applied to dry, wet, cracked and sensitive mucosal tissue.~Film forming silicone gel (7-0940) gel is bacteriostatic and inert. It contains no alcohols, parabens or fragrances."
45771368|NCT01231633|Drug|Ozurdex|Ozurdex, 0.7mg dexamethasone
45771369|NCT01231633|Drug|Avastin|Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.
45771370|NCT00000442|Drug|naltrexone (Revia)|
45913642|NCT02024919|Drug|intracoronary administration of diltiazem|
45913643|NCT02024919|Drug|intracoronary injection of 5 mL saline|
45913644|NCT02024945|Drug|Propiverine|Propiverine 15 mg tablets or 30 mg regulated release capsules
45913645|NCT02024984|Drug|Clomiphene Citrate|"Group A (study group) 'Luteal Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting on day 2 of the cycle induced by MPA for another menstrual cycle.~Group B (control group)'Follicular Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting on day 2 of the cycle induced by MPA, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days for another menstrual cycle."
45631976|NCT02351999|Device|TSP Crosser Transseptal Access System|for transseptal puncture, left atrial access and catheter navigation.
45771371|NCT05431686|Behavioral|SMA visits|SMA visit once every 3 months over a 12 month period
45631977|NCT02352155|Procedure|epinephrine injection or heater probe or hemoclips|Elective Second look endoscopy in the following morning with re-treatment to the bleeding vessel using epinephrine injection or heater probe or hemoclips
45631978|NCT02352155|Other|Observation only|Observation for rebleeding, unscheduled endoscopy only when rebleeding criteria fulfilled
45631979|NCT02355899|Drug|PD P 506 A|PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm².
45631980|NCT02351921|Device|Transcranial magnetic stimulation|Intermittent theta-burst stimulation is a form of repetitive Transcranial magnetic stimulation. ITBS is a non-invasive, non-painful procedure being used worldwide to study brain function and promote short-term changes (~1 hour) in neural activity in the brain. The delivery of cTBS requires ~ 40 seconds in total.
45631981|NCT02352311|Drug|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg
45631982|NCT02352311|Drug|AVODART|Dutasteride 0.5 mg
45771372|NCT00002068|Drug|Fluconazole|
45913646|NCT02024997|Other|Magnetic Resonance Imaging (MRI)|
45913647|NCT02025023|Drug|5-fluorouracil Injection|If the chalazion is present at follow-up visit, another injection of 5-FU will be given.
45447791|NCT02120326|Device|Transcranial direct current stimulation of the motor cortex|"The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.~Stimulation parameters:~2 mA intensity~Continuous stimulation for 20 min with rise times and fall times of 10 seconds each"
45771373|NCT00002068|Drug|Amphotericin B|
45771374|NCT02247037|Other|Chemotherapy|Patients are treated with neoadjuvant chemotherapy as according to the standard of care guidelines. Patients with metastatic disease are treated according to standard of care guidelines.
45771375|NCT00000448|Drug|naltrexone|Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence.
45771376|NCT00000448|Drug|Placebo|A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient.
45631983|NCT02352311|Drug|CIALIS|Tadalafil 5 mg
45631984|NCT02352077|Biological|NeuroRegen scaffold with BMMCs or MSCs transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
45631985|NCT02356055|Behavioral|STOMP (Skill-building through Task-Oriented Motor Practice)|The STOMP intervention is a package including family-centered goals, task-specific training delivered through motor learning and errorless learning principles. It is unique in the use of massed practice (high-dosage) therapy.
45631986|NCT03153215|Other|treatment|We will offer Sildenafil citrate (20 mg per os three times daily until delivery) as innovative therapy to 23 women with severe IUGR ('Sildenafil-treated') in addition to fish oil and zinc supplementation.
45631987|NCT03153215|Other|Placebo|Placebo tablets similar to Sildenafil will be given to control group in addition to fish oil and zinc supplementation.
45631988|NCT03152357|Device|ConforMIS iUni, iDuo, or iTotal (CR)|ConforMIS iUni, iDuo, or iTotal (CR)
45631989|NCT02355431|Drug|Itacitinib|tablets to be administered by mouth once daily at dose selected from safety run-in phase
45631990|NCT02355431|Drug|erlotinib|150 mg tablets administered by mouth once daily at total daily dose of 150 mg
45631991|NCT02355431|Drug|placebo|matching placebo tablets to be administered by mouth at dose selected from safety run-in phase
45771377|NCT01234207|Device|Standard, non-free-form, non-customized PAL spectacles|Control spectacles include several different PAL brands as selected by patients in the UC Berkeley Optometry Clinic and purchased in the Eyewear Center; after successful fitting and purchase, potential subjects were recruited for the trial.
45771378|NCT01234207|Device|Individually customized free-form surfaced PAL spectacles|Test spectacles are Zeiss Individual, free-form surfaced, and customized using the iTerminal device to account for individual back vertex distance, wrap angle and pantoscopic tilt
45771379|NCT00001318|Drug|interferon gamma|
45771380|NCT00002074|Drug|Fluconazole|
45771381|NCT00002074|Drug|Amphotericin B|
45771382|NCT01234831|Device|nucleic acid amplification of nasal swab; nasal swab culture|Nasal swab is performed and analyzed using nucleic acid amplification to determine the presence or absence of MRSA DNA. One nasal swab is performed each day for three consecutive days during hospitalization.
45771383|NCT01234831|Other|Nasal swab culture|Nasal swabs are obtained if the clinician caring for the patient identifies the patient as eligible to be screened for colonization. An algorithm for screening eligible patients is available electronically as part of the patient's standard medical record to the clinicians providing care.
45771384|NCT00001354|Drug|Interleukin-2/Zidovudine (AZT)|
45913648|NCT02025023|Drug|Triamcinolone Acetonide|If chalazion present at follow-up, another Triamcinolone injection will be done.
45913649|NCT02025023|Procedure|Incision and Curettage|If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.
45913650|NCT02025023|Drug|Triamcinolone Acetonide/5-fluorouracil mixture|If chalazion persists at follow-up visit, another injection of triamcinolone/5-FU mixture will be done.
45913651|NCT02025049|Drug|DP-b99|DP-b99 is a lipophilic analog of the divalent metal ion chelator O,O'-Bis(2-aminophenyl) ethyleneglycol-N,N,N',N'-tetraacetic acid (BAPTA)
45913652|NCT02025049|Drug|Placebo|mannitol-based DP-b99 look-alike
45935318|NCT00042809|Drug|paclitaxel|Given IV
45935319|NCT00042809|Biological|trastuzumab|Given IV
45935320|NCT00042809|Drug|erlotinib hydrochloride|Given orally
45935321|NCT00042809|Other|laboratory biomarker analysis|Correlative studies
45935322|NCT00042809|Other|pharmacological study|Correlative studies
45771385|NCT02546856|Other|Heart Failure (HF) nurse up-titration|"Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure De Novo patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines with cardiologist prescription and support."
45631992|NCT02355353|Other|Experimental: imaging arm|DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 6 cycles of chemotherapy
45631993|NCT02351687|Dietary Supplement|Lipid Nutrient Supplement|
45913653|NCT02025062|Other|CGA and geriatric follow-up|The CGA is a multidimensional assessment of general health status, using validated scales. It produces an inventory of problems which can then serve to develop an individualized geriatric intervention plan of care and follow-up
45631994|NCT02351687|Drug|Sulfadoxine-pyrimethamine|
45631995|NCT02351687|Drug|Albendazole|
45631996|NCT02351687|Drug|Zinc|
45913654|NCT02025088|Procedure|Laser|Patients of this arm will undergo three sessions of laser treatment with an interval of six weeks between them. In each laser session, the non-ablative fractional erbium laser 1340 nm ProDeep (Etheria ® platform/Industra) with tip 100mtz/cm ² will be applied across the face, with a power of 120mJ/mtz time and pulse time of 5ms.
45631997|NCT02351687|Other|Insecticide-treated bednet|
45631998|NCT02351843|Device|MECTA Spectrum 5000Q|
45631999|NCT02355509|Drug|Acarbose|"Acarbose dose was progressively titrated (50 mg/day per week up to 150 mg/day) to reduce the known adverse effects of acarbose such as flatulence, bloating, diarrhea, abdominal pain.~The treatment for three months"
45632000|NCT02355509|Drug|Placebo|Placebo pills are given instead of acarbose in this group
45771386|NCT02546856|Other|Heart Failure (HF) cardiologist up-titration|"Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure De Novo patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines. Drugs are prescribed and titrated by the cardiologist."
45447792|NCT02120326|Device|simulation of Transcranial direct current stimulation of the motor cortex|"The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.~Stimulation parameters:~The intensity of the stimulation current is 2 mA~The current is applied during the first 30 seconds with rise times and fall times of 10 seconds each. Then the session will be continued without actual stimulation."
45447793|NCT02120560|Procedure|Atrial Fibrillation Ablation|Both treatment arms will undergo atrial fibrillation ablation.
45447794|NCT02117830|Drug|Androxal 25 mg capsules|
45447795|NCT02117830|Drug|Androxal 250 Capsules|
45447796|NCT02117830|Drug|Placebo Capsules|
45447797|NCT02117830|Drug|Moxifloxacin 400 mg|
45632001|NCT02355197|Drug|L-ascorbic acid|1 gram L-ascorbic acid (vitamin C …..) per day from the time of diagnosis until the time of delivery
45632002|NCT02351609|Behavioral|Intervention|"Intervention patients will be introduced to the patient navigator either in person or by telephone. The intervention patients will receive navigation from one of two trained navigators, based centrally in the Section of General Internal Medicine. The purpose of the patient navigation interactions is to 1) connect patients to existing yet underutilized smoking cessation resources and 2) increase patient commitment to follow through with existing treatment services.~Financial incentives: $250 for biochemically confirmed abstinence within six months after study enrollment, and $500 for biochemically confirmed abstinence for an additional six months after the initial cessation."
45632003|NCT02351609|Other|Enhanced Traditional Care control|List of smoking cessation resources and educational brochure.
45771387|NCT00000454|Drug|nicotine replacement patch|
45632004|NCT02351531|Dietary Supplement|Extensively Hydrolyzed formula|
45632005|NCT02351297|Dietary Supplement|casein supplementation|After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
45632006|NCT02351297|Dietary Supplement|soy protein supplementation|After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
45632007|NCT02351297|Dietary Supplement|maltodextrin supplementation|After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
45632008|NCT02355119|Drug|FOLFOXIRI|Combination of 5-Fluorouracil/Folinic Acid, Irinotecan, Oxaliplatin
45632009|NCT02355119|Drug|Gemcitabine|
45771388|NCT03011437|Other|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy is an examining method for upper gastrointestinal disease.
45913655|NCT02025088|Procedure|Microneedling|"Patients in this arm will undergo three sessions with microneedling, with an interval of six weeks between them. In the microneedling sessions, the instrument contains 192 microneedles with 2 mm depth, which will be applied to the face in four different directions, making up about 20 movements of coming and going in each direction."
45913656|NCT02025114|Drug|selumetinib|The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).
45913657|NCT02025127|Other|Enteral nutrition|Enteral nutrition introduced via a feeding tube
45913658|NCT02025140|Device|Computer controlled anesthesia|The IANB by the computer controlled local anesthetic device CCLAD and periodontal ligament anesthesia by the CCLAD
45913659|NCT02025140|Device|conventional anesthesia syringe|Active control
45632010|NCT02355041|Behavioral|Meal Replacement-based Weight Loss Diet|
45632011|NCT02355041|Behavioral|Educational Video|Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web.
45632012|NCT03149939|Drug|Febuxostat 40 milligramsTablet|Febuxostat 40 milligramsTablet every other day for 3 months
45632013|NCT03149783|Drug|Ropivacaine HCL|Ropivacaine injected after placement of catheters, then infused during the operation
45632014|NCT03149783|Drug|sodium chloride|Placebo
45632015|NCT02354885|Drug|Tranexamic Acid|Coagulation Management / Efficiency
45632016|NCT02354807|Drug|Mirabegron|One-time dose of 100mg of Mirabegron
45632017|NCT02354807|Other|Cold exposure|Exposure of subjects to cold temperature to induce non-shivering thermogenesis
45632018|NCT03159845|Drug|Zinc Sulfate Oral Product|
45632019|NCT03159845|Drug|Levofloxacin 500Mg Oral Tablet|once daily from day +10 until day +30 after stem cell transplantation
45771389|NCT00002080|Drug|Rifabutin|
45632020|NCT03159845|Drug|Fluconazole 200mg tab|twice daily from day +10 until day +30 after stem cell transplantation
45632021|NCT03159845|Drug|Acyclovir 400 MG|twice daily from day +10 until day +30 after stem cell transplantation
45632022|NCT02351375|Other|diet|A controlled diet will be provided to participants which consists of either high protein/low carbohydrate, or of low protein/high carbohydrate.
45632023|NCT02351375|Device|IntelliCap® system|
45632024|NCT03159065|Other|Bilberry|Fruit beverage with bilberry and fermented oatmeal
45632025|NCT03159065|Other|Blackcurrant|Fruit beverage with blackcurrant and fermented oatmeal
46070024|NCT00658879|Drug|Somavert (Pegvisomant)|"Somavert (Pegvisomant) 10, 15 or 20mg powder and solvent for solution for injection.~Dosage, Frequency : According to Japanese LPD.~Duration : According to the protocol of A6291023, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 5 years after the first administration."
46070025|NCT00806611|Procedure|Alcohol Block|Operating surgeon by injecting 20 ml of either 50% ethanol or saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
45632026|NCT03159065|Other|Mango|Fruit beverage with mango and fermented oatmeal
45632027|NCT03159065|Other|Beetroot|Fruit beverage with beetroot and fermented oatmeal
45632028|NCT03159065|Other|Rose hip|Fruit beverage with rose hip and fermented oatmeal
45632029|NCT03159065|Other|Glucose drink|A reference glucose drink
45632030|NCT02351219|Drug|FOLFOXIRI|
45632031|NCT02354963|Procedure|In vitro fragmentation of the ovarian tissue|Unilateral ovarian cortex extraction, in vitro fragmentation and reimplantation.
45771390|NCT00000484|Drug|chlorothiazide|
45771391|NCT00000484|Drug|Rauwolfia alkaloids|
45632032|NCT02350751|Drug|MEDI8852|
46070026|NCT00806689|Procedure|Cardiac rhythm monitor implantation|post surgical procedure implantation of insertable event recorder for long time heart rhythm surveillance afte ablation therapy
45632033|NCT02350751|Drug|Placebo|
45632034|NCT02350829|Other|Cardiac magnetic resonance sequence T1 mapping|Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
45632035|NCT02354729|Other|Behavioral Economics|Use financial incentives to promote epinephrine-carrying.
45632036|NCT02354573|Drug|Ivabradine|All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
45632037|NCT02350985|Drug|Propranolol|Propranolol was given in a flexible dose between 40 mg to 160 mg with an escalating fashion starting at 40 mg PO AM for one week and followed by 40 mg AM and 40 mg PM for a total dose up to 160 mg daily
45632038|NCT02350985|Drug|Venlafaxine|Venlafaxine treatment was followed as: 37.5 mg qhs for two weeks and followed 75 mg qhs with an escalating dose with 2 weeks periods up to 150 mg daily
45632039|NCT02354495|Dietary Supplement|Changes in energy and protein intake|Energy intake will be based on accurate measurements of energy expenditure. Protein intake will be matched to age-based recommended values if necessary.
45632040|NCT02354261|Drug|SUBA-Itraconazole|Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily.
45632041|NCT02350439|Drug|Adenosine infusion at 200μg/Kg/min|Assessment of fractional flow reserve (FFR) under high adenosine intravenous infusion dose (200mg/kg/min)
45632042|NCT02350673|Drug|Atezolizumab|Participants will receive atezolizumab IV infusion at doses of 800 mg q2w or 1200 mg q3w.
45632043|NCT02350673|Drug|Cergutuzumab Amunaleukin|Participants will receive cergutuzumab amunaleukin IV infusion at escalated doses and at different dosing schedules in Part I and at MTD (or recommended dose) in Part II.
45632044|NCT02350361|Drug|Recombinant human endostatin|Recombinant human endostatin 7.5mg/m2
45632045|NCT02350361|Drug|Placebo|Placebo
45771392|NCT01151371|Device|narafilcon B contact lens|Silicone Hydrogel Daily Disposable Contact Lenses
45771393|NCT01151371|Device|nelfilcon A contact lens|Conventional Hydrogel Daily Disposable Contact Lenses
45771394|NCT01151371|Device|lotrafilcon B contact lens|Silicone Hydrogel Monthly Replacement Contact Lenses
45771395|NCT00000496|Drug|aspirin|
45771396|NCT00000496|Drug|dipyridamole|
45913660|NCT02025153|Other|pain testing|physical testing, psychological testing, genetics testing and functional brain imaging
45913661|NCT02025166|Drug|Paracetamol|"Pain treatment with aniline analgesics (paracetamol) at the time of the procedure"
45913662|NCT02025166|Drug|lornoxicam|"Pain treatment with NSAID (lornoxicam) at the time of the procedure"
45632046|NCT02353949|Drug|Flutemetamol (Vizamyl)|PET-MR Scan using the radiotracer Flutemetamol (Vizamyl) for diagnostic purpose
45632047|NCT02354027|Drug|SHR3824 metformin|"Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.~Drug: SHR3824 + Metformin"
45632048|NCT02354183|Behavioral|DBT Skills Training|Based on Linehan's (1993) manualized DBT approach, the brief DBT skills training group covers will cover five skills: wise mind, TIP skills, distraction, mindfulness of the current emotion, and opposite to emotion action.
45632049|NCT03149471|Diagnostic Test|Endothelial dysfunction test|The endothelial function test will be assessed after 48 hours post admission and 1 year post discharge using the non-invasive Endo-PAT2000 device. The device is intended for use as a diagnostic aid in the detection of coronary artery endothelial dysfunction (positive or negative) using a reactive hyperemia procedure. It is based on the use of Peripheral Arterial Tone (PAT) signal technology, during a clinically established procedure, which measure post-ischemic vascular responsiveness following upper arm blood flow occlusion.
45632050|NCT02353793|Device|ReadyHeat® blanket|Using ReadyHeat® blanket for patient warming
45632051|NCT02353793|Device|Cotton wool blanket|Using cotton wool blanket for patient warming
45632052|NCT03149549|Drug|CX-2009|CX-2009 Monotherapy
45632053|NCT02350283|Device|Interventional treatment with Solitaire|Patients will be treated for mechanical recanalization with Solitaire within 12 hours after stroke onset plus standard medical management.
45632054|NCT03149627|Other|Estimates - prevalence of lifetime/chronic HBV infection|Estimation of the prevalence and correlates of lifetime HBV infection defined as hepatitis B core antibody (HBcAb) positivity and chronic HBV infection defined as HBsAg positivity.
45632055|NCT03149393|Drug|Qizhi Weitong Granules|Patients in this group will take Qizhi Weitong Granules 2.5g,3 times/day,30 minutes before dinner for 8 weeks.
45632056|NCT03149393|Drug|Mosapride Citrate Tablets|Patients in this group will take mosapride citrate tablets 5mg,3 times/day,30 minutes before dinner for 8 weeks.
45632057|NCT03149315|Drug|Ibrutinib|Ibrutinib 420mg, PO once daily for 2-7 days
45632058|NCT02353559|Behavioral|EASE|EASE includes psychotherapeutic (EASE-psy) and physical symptom control (EASE-phys) components.
45632059|NCT02353637|Dietary Supplement|Partial Meal Replacements|The use of partial meal replacements will be utilized in conjunction with a high protein, restricted carbohydrate diet
45632060|NCT02353715|Drug|Enzalutamide|
45771397|NCT03011359|Other|Optimizing B.I (New) PCA mode|In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: ~ 6 hr: 1.5 - 3.5 ml, 6-24 hr: 1 - 3 ml, 24 hr ~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 3.5 ml (or 0.5 ml).
45771398|NCT03011359|Other|Conventional PCA mode|(Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes)
46070027|NCT00806689|Device|Reveal® XT 9525|During cardiac surgery after stand alone or concomitant ablation procedure, an insertable loop recorder will be implanted subcutaneously in left pectoral region. After surgery, patients will be monitored regularly in a quarterly basis by performing telemetry of the device in the outpatient clinic. Furthermore, home telemetry will be performed once a month for optimal heart rhythm observation.
45447798|NCT02120638|Drug|Pyrazinamide containing regimen|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, >70kg 2000-2500mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, >70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, >50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily All treatment is taken daily, for a duration of up to 12 months depending on treatment arm.
45632061|NCT02353715|Drug|Abiraterone acetate|
45632062|NCT02353715|Drug|Sipuleucel-T|
45632063|NCT02353403|Other|Sugar|A 210g chocolate dairy dessert made with 35g of dextrose.
45632064|NCT02353403|Other|FOS|A 210g chocolate dairy dessert made with 24g of dextrose and 11.2g of FOS.
45632065|NCT02349737|Other|Exposure to BIA interference with the ICD|Exposure to BIA interference with the ICD
45632066|NCT02353325|Dietary Supplement|non-encapsulated FeSO4|
45632067|NCT02353325|Dietary Supplement|encapsulated FeSO4, before cooking|
45632068|NCT02353325|Dietary Supplement|encapsulated FeSO4, after cooking|
45632069|NCT02353325|Dietary Supplement|non-encapsulated FeSO4 + ascorbic acid|
45632070|NCT02353325|Dietary Supplement|encapsulated FeSO4 + ascorbic acid, before cooking|
45632071|NCT02353325|Dietary Supplement|encapsulated FeSO4 + ascorbic acid, after cooking|
45632072|NCT02353481|Other|Heart Failure Management|
45632073|NCT03157895|Behavioral|Connecting|Connecting was adapted for use within the child welfare system from the Staying Connected With Your Teen program that has been demonstrated to prevent substance abuse, risky sexual behavior, and violence during adolescence.
45632074|NCT02349503|Drug|NBI-77860|
45632075|NCT02349503|Drug|NBI-77860|
45632076|NCT02349503|Drug|NBI-77860|
45632077|NCT02349659|Device|Implantation with the commercially available Axium neurostimulator|
45632078|NCT03157505|Drug|Purethal Birch immunotherapy|Purethal birch was administered as perennial therapy: 24 months
45771399|NCT00002086|Drug|Zidovudine|
45771400|NCT00002086|Drug|Zalcitabine|
45771401|NCT00002086|Drug|Interferon alfa-n1|
45771402|NCT04713436|Drug|Differentiation Markers|Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.
45771403|NCT01151449|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
45771404|NCT01151449|Other|laboratory biomarker analysis|Correlative studies
45771405|NCT00001384|Drug|Adriamycin|
45771406|NCT00001384|Drug|cyclophosphamide|
45771407|NCT00001384|Drug|G-CSF|
45447799|NCT02120638|Drug|Regimen without Pyrazinamide|Isoniazid 600mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, >70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, >50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily All treatment is taken daily, for a duration of up to 18 months depending on treatment arm.
45447800|NCT02117908|Device|RESMED AUTOSET S9|Continuous positive pressure during surgery
45632079|NCT03157505|Other|Placebo and symptomatic treatment|symptomatic treatment including: antihitamine drug, nasal dropps and placebo injection
45632080|NCT03157193|Drug|Hyaluronic Acid|Hyaluronic acid gel application as coadjuvant in the treatment of perimplantitis.
45632081|NCT03157193|Drug|Hydroxypropyl Guar|Hydroxypropyl Guar gel application as sham comparator
45913663|NCT02025192|Drug|Tucatinib|Administered twice per day, orally.
45632082|NCT03149159|Drug|Nivolumab|Nivolumab will be given every 21 days for the first 12 weeks at a dose of 3mg/kg. After 12 weeks, the dose will be 240mg and will be given every 14 days.
45913664|NCT02025192|Drug|Capecitabine|1000mg/m^2 administered twice per day, orally in Days 1-14 of each 21-day cycle.
45632083|NCT03149159|Drug|Ipilimumab|Ipilimumab will be given at a dose of 1mg/kg every 21 days for up to 12 weeks.
45771408|NCT00001384|Drug|paclitaxel|
45771409|NCT02122952|Biological|AVXS-101|Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
45447801|NCT03768232|Other|ultrasound asessment|US diaphragm measurements within 36 hours of initiation of MV. Measurements will be repeated daily for the duration of MV for the first week, then every 48 hours and 24 hours after the extubation.
45447802|NCT03552406|Biological|ISU104|Intravenous Infusion for 1 hour.
45632084|NCT03149159|Radiation|Steriotactic radiation therapy|The dose of radiation will be 6 Gy daily x 5 days. Radiation will be given between the first and second doses of ipilimumab plus nivolumab.
45632085|NCT03156959|Behavioral|EMDR|The Eye Movement Desensitization and Reprocessing (EMDR) is a psychotherapy developed by Francine Shapiro (2001) that emphasizes disturbing memories as the cause of psychopathology. These memories and associated stimuli are inadequately processed and stored in an isolated memory network (Shapiro and Laliotis, 2010). The goal of EMDR is to reduce the long-lasting effects of distressing memories by developing more adaptive coping mechanisms.
45632086|NCT03156959|Behavioral|CBT-Eb|"The broad form of Enhanced Cognitive Behavioural Therapy (CBT-Eb; Fairburn and colleagues, 2009) addresses psychopathological processes external to the eating disorder, such as clinical perfectionism, low self-esteem or interpersonal difficulties, which interact with the disorder itself."
45632087|NCT03156803|Behavioral|Healthy eating blog|For a 6-month period, mothers randomised to the HEB group will receive a weekly blog post discussing various positive aspects of healthy eating and presenting recipes and strategies to increase dairy product intakes and vegetable and fruit intakes. The posts will be developed with an emphasis of food skills acquisition.
45632088|NCT03156569|Diagnostic Test|Analysis of the saliva|IFN-, IL-10, IL-1b, IL-4 and IL-6
45632089|NCT03155477|Dietary Supplement|"Cholecalciferol and C. Xanthorrhiza"|Cholecalciferol are given 400 IU 3 times daily for 3 months C. Xanthorrhiza are given 200 mg 3 times daily for 3 months
45632090|NCT03155477|Dietary Supplement|"Cholecalciferol and placebo"|Cholecalciferol are given 400 IU 3 times daily for 3 months Placebo are given 3 times daily for 3 months
45632091|NCT03148925|Biological|SELA-070|Sub-cutaneous injection, multiple dose
45771410|NCT00000508|Behavioral|smoking cessation|
45771411|NCT00000508|Behavioral|diet, reducing|
45771412|NCT00000508|Behavioral|exercise|
45447803|NCT03552406|Drug|Cetuximab|Intravenous Infusion for 1 hour (2 hours at initial dose)
45447804|NCT02123290|Drug|DSM265 400mg|
45632092|NCT03148925|Biological|Saline|Sub-cutaneous injection, multiple dose
45632093|NCT03148847|Other|Baseline care|
45632094|NCT03148847|Other|Referential's dissemination|
45771413|NCT00000508|Behavioral|diet, fat-restricted|
45771414|NCT01151761|Procedure|Stereotactic Body Radiotherapy|Standard of care
45771415|NCT01151761|Drug|Gemcitabine|100 mg/m2, IV
45771416|NCT01151761|Drug|Cisplatin|25 mg/m2, IV
45771417|NCT01151761|Drug|Carboplatin|AUC 2, based on Calvert formula, IV
45771418|NCT01151761|Drug|Capecitabine|1000 mg/m2, PO
45771419|NCT01151761|Drug|5FU|200 mg/m2
45771420|NCT01151761|Procedure|Liver transplantation|
45771421|NCT00002092|Drug|Cimetidine|
45771422|NCT02122562|Drug|Ketamine|Treatment
45632095|NCT02349581|Procedure|PECS block|Ultrasound guided delivery of local anesthetic between the pectoral muscles
45632096|NCT02349581|Drug|Bupivacaine|
45771423|NCT02122562|Other|Alcohol Infusion|Biomarker
45771424|NCT00380458|Device|Coblation (radiofrequency-based device)|
45771425|NCT00002098|Drug|Lentinan|
45771426|NCT00002098|Drug|Didanosine|
45771427|NCT02705300|Drug|Irinotecan 165 mg/m2 iv|Max. 4 months
45771428|NCT02705300|Drug|Oxaliplatin 85 mg/m2 iv|Max. 4 months
45771429|NCT02705300|Drug|Calcium folinate 200 mg/m2 iv|Max. 6 months
45771430|NCT02705300|Drug|5-fluorouracil 3200 mg/m2|Max. 6 months
45913665|NCT02025192|Drug|Trastuzumab|Administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
45913666|NCT02025218|Drug|Gefitinib standard dose|
45913667|NCT02025231|Radiation|External beam radiotherapy|Study group 1: 3.5 Gray x 10, 5 fractions per week. Study group 2: 3.5 Gray x 10 + 7 Gray boost to biological target volume, 5 fractions per week. Study group 3: 5.9 Gray x 10, 5 fractions per week. Study group 4 (planning target volumes: 100 millilitres - 300 millilitres): 3.5 Gray x 10, 5 fractions per week. Phase II dosis: to be chosen based on results of phase I study.
45913668|NCT02025244|Procedure|Key Hole Biopsy ( KHB)|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are, according to randomization, allocated to undergo esophagogastroduodenoscopy with Key Hole Biopsy consisting of forceps biopsy through mucosal incision by a needle knife, with subsequent cytological /histological and immunohistochemical evaluation of specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
45935323|NCT00221065|Device|Nasal Continuous positive airway pressure - Tyco 420G|CPAP at determined pressure nightly for 1 month
45632097|NCT03155633|Other|Athletics track|Running at 95-105% aerobic Threshold on athletics track 48h, 96h, 144h after the race. Control heart devices
45913669|NCT02025244|Procedure|EUS-FNA|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine mitotic activity is evaluated. In case of failure of this method, the second one is performed.
45771431|NCT02705300|Dietary Supplement|Tocotrienol|Max. 2 years or at the discretion of the investigator
45632098|NCT03155633|Other|Elliptical machine|Running at 95-105% aerobic Threshold on elliptical machine 48h, 96h, 144h after the race. Control heart devices
45632099|NCT03155711|Procedure|HFNC group|Positive pressure plus supplemental oxygen through a high flow nasal oxygen device
45632100|NCT03155711|Procedure|Standard group|Supplemental oxygen through venturi mask
45632101|NCT03155165|Device|Retroview™ colonoscope|The colonoscopy will be performed twice, with 2 different scopes, in tandem, by 2 endoscopists trained on retroflex withdrawal. First a conventional HD colonoscope with I-Scan will be used following the standard withdrawal technique and then the second endoscopist blinded to the first colonoscopy results, will perform the second colonoscopy using the Retroview™ scope with a combining withdrawal (retroflexed + standard withdrawal). The endoscopist that will perform each colonoscopy will be chosen randomly. After the examination, the endoscopist will fill a questionnaire detailing each polyp / adenoma found including the size and location.
45771432|NCT02705300|Drug|Placebo|Max. 2 years or at the discretion of the investigator
45771433|NCT01196377|Drug|Albuterol|Nebulized albuterol
45771434|NCT00001426|Drug|Cyclophosphamide|
45771435|NCT00001426|Drug|Paclitaxel|
45771436|NCT00001426|Drug|Cisplatin|
45771437|NCT00001426|Drug|G-CSF|
45771438|NCT02463266|Behavioral|SUSTAIN Monitoring and Care Management|Program participants are offered clinical services based on symptom severity and clinical need. Follow-up Monitoring consists of up to 4 brief, structured assessments following the baseline clinical assessment. These follow-up contacts are conducted over the telephone by the HT/BHP and take place during the initial 12 weeks of pharmaceutical treatment. These brief interviews monitor symptoms, adherence, side effects, and response to treatment. Care Management incorporates the use of a BHP who has expertise in mental health assessment and is well versed in the delivery of algorithm-based management strategies. The BHP monitors and encourages patient acceptance and adherence to treatment recommendations through support, education, and motivational engagement.
45913670|NCT02025283|Procedure|Group Decompression or Group Nucleoplasty|Group Decompression: Decompression with flexible intradiscal decompression catheter (SpineCATH®, Smith & Nephew, Memphis, TN) Group Nucleoplasty: Nucleoplasty with radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM [ArthroCare Spine, Sunnyvale, CA]
45913671|NCT02025296|Device|U-healthcare|use of a public switched telephone network (PSTN)-connected glucometer to measure their blood glucose level at the same frequency as the SMBG group
45913672|NCT02025309|Device|Neuromuscular monitorisation|
45935324|NCT00221143|Genetic|Autologous peripheral blood CD34 positive cell therapy|
45771439|NCT00002104|Drug|Thalidomide|
45771440|NCT01152307|Behavioral|DVD/Booklet: Coping with Symptoms of Depression|DVD and booklet that provides information about treatment choices for depression symptoms
45771441|NCT00001438|Drug|all-trans-retinoic acid with IFN-alpha2a|
45771442|NCT01235377|Other|Favor one of two thiazides for new prescriptions & attempt target dose|Providers will be randomized to either Favor Chlorthalidone or Favor Hydrochlorothiazide for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. Providers will have agreed to adhere to their assignment for patients for whom there is equipoise, but they are free to deviate if medically indicated for individual patients. There is no requirement to maintain the initial thiazide therapy; it is expected that the regimen may require adjustment over time. The cluster assignment is simply to favor a particular thiazide on initiation of thiazide therapy and attempt to reach the target dose.
45771443|NCT00001444|Drug|7-hydroxystaurosporine (UCN-01)|
45771444|NCT02700386|Combination Product|Adjuvant Hypofractionated Radiation|Hypofractionation is the delivery of radiotherapy in single daily doses greater than the 180-200 cGy. Hypofractionation, through use of larger doses per fraction and fewer total treatments, is a method of shortening overall treatment time in breast cancer therapy.
45935325|NCT00073710|Drug|Zemplar|
45935326|NCT00073710|Procedure|42 Ca carbonate absorption via single tracer method|
45935327|NCT00073710|Drug|Calcijex|
45935328|NCT00221182|Genetic|Autologous peripheral blood CD34 positive cell therapy|
45935329|NCT00042848|Drug|modafinil|
45935330|NCT00221221|Device|Pedometer|
45935331|NCT00221221|Device|Exercise guidebook|
45935332|NCT00221260|Procedure|anesthesia|Intraoperative general anesthesia AND postoperative IV narcotic analgesia.
45935333|NCT00402259|Drug|Esomeprazole IV|
45632102|NCT02349191|Procedure|Omental transposition for mild Alzheimers disease|An omental pedicle is brought from the abdomen underneath the skin and sewn to the dura matter of the brain via a craniotomy.
45632103|NCT03154385|Drug|Rituximab (Mabthera ®) Belimumab (Benlysta ®)|Rituximab (Mabthera ®): 1g IV at W0 and W2 Belimumab (Benlysta ®) : 10mg/kg IV, W0 + 2days, W2 + 2 days, W4, W8, W12
45632104|NCT03154463|Procedure|TAP Blocks|TAP blocks were performed using ultrasound as a guide and injected on three points on trans abdominal plane using 100 mm stimuplex needle and 0.25% bupivacaine with total volume of 20 ml in each point (with total of 60 ml in three points)
45632105|NCT03154463|Procedure|continuous epidural infusion|Continuous epidural infusion was given with epidural regimen of 0.25% bupivacaine without any adjuvant
45632106|NCT03112187|Drug|Iron Supplement|Ferfer® is a multi-ingredient supplement containing micro-encapsulated iron pyrophosphate (to form liposomes), vitamin C and vitamin B12 which are valuable for the control of nutritional deficiencies or increased organic needs of iron.
45632107|NCT02353013|Dietary Supplement|Protein supplementation|Standard fortification of human milk may not have enough protein for optimal growth of premature infants. The investigators will add extra protein to this group to increase the protein consumed.
45632108|NCT02353013|Dietary Supplement|Standard fortification|Standard fortification of human milk involves adding a commercially available human milk fortifier to human milk in order to increase several nutrients.
45632109|NCT03147677|Drug|Alfacalcidol|
45632110|NCT03147677|Drug|Irbesartan|
45771445|NCT00000544|Behavioral|diet therapy|
45771446|NCT01196533|Device|Non invasive peripheral blood monitoring|non invasive monitoring
45771447|NCT02700308|Device|Kyphoplasty|Placement and inflation of balloon prior to cement injection
45913673|NCT02025322|Behavioral|Peer Mentoring|"Participants in the Peer Mentoring arm will be paired with a Peer Mentor for the duration of the 4-month intervention. Peer Mentors are HIV-positive patients who demonstrate high levels of medication and treatment adherence and are knowledgeable about HIV/AIDS and barriers to care. During the 4-month intervention, Peer Mentors will contact participants weekly via in-person, phone, or email, with the option to provide more frequent contact, if needed. Peer Mentors will provide social support and remind participants to take their medications and attend upcoming medical appointments.~Study participants will also attend four monthly, one hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness, which will be developed and co-facilitated by Peer Mentors."
45632111|NCT03148535|Drug|Lithium Carbonate|bipolar depression recieve lithium Carbonate treatment
45632112|NCT03148535|Drug|lithium carbonate combined with SSRI antidepressant treatment|lithium carbonate combined with SSRI antidepressant treatment
45632113|NCT03148301|Other|Survey|Survey
45632114|NCT03147599|Drug|Coloverin|Mebeverine hydrochloride 135 mg
45447805|NCT02123290|Drug|DSM265 xmg|Dose of DSM265 to be determined based on the results of the first cohort
45913674|NCT02025348|Drug|IntelliCap|Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.
45913675|NCT02025361|Drug|intrarectal lidocaine gel|intrarectal local anesthetic application
45913676|NCT02025361|Drug|periprostatic nerve blockade|periprostatic local anesthetic application
45913677|NCT02025374|Drug|Hyperbaric levobupivacaine|
45447806|NCT02123290|Drug|DSM265 ymg|Dose of DSM265 to be determined based on the results of the second cohort
45447807|NCT02123368|Drug|Hyaluronic acid|Single intraarticular injection of Hyaluronic acid (Hyal One)
45632115|NCT03147599|Drug|Placebo|Placebo
45632116|NCT03147443|Drug|Individualized Decoction|Applied in the Tested Drug Observation Period. It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
45632117|NCT03147443|Drug|placebo|Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
45632118|NCT03147443|Drug|Tested drug minus heat-clearing herbs|It is the decoction of the Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.
45632119|NCT03147521|Other|Care bundle|Risk fall assessment at hospital admission with Conley scale or with findings of specific risk characteristics (previous falls, cognitive impairment, neuropsychological damage, increased need to go to the bathroom for increased evacuative needs, neuroleptic or cardiovascular drugs assumption); if risk is found shear the information with the team, writing it in patient chart, and positioning a specific symbol on patient bed. Inform patient and family about fall risk and ask, if possible, a continuous caregiver presence. Universal strategy application for the environmental safety and patient safety. Periodic assessment of drugs therapy, with the aim of reduce those that acts on central nervous system and cardiovascular system. If patient is at risk and alone, verify each 2 hours the need to go to the bathroom, change position or drink.
45632120|NCT03148223|Device|auriculotherapy|The participants will be submitted to a session per week with duration of 20 minutes, for three consecutive months, to fix the adhesives. The points selected for stimulation, according to Chinese atrial mapping, are: uterus, endocrine, ovary, pituitary, shen men, sympathetic, and liver. Participants will be advised to remain with the stickers fixed to the auricle for six days.
45632121|NCT03148145|Behavioral|Step Goal Delivery by Smartphone|Step Goal Delivery by Smartphone
45771448|NCT02700308|Device|Conventional vertebroplasty|Conventional vertebroplasty
45771449|NCT00000562|Procedure|extracorporeal membrane oxygenation|
45771450|NCT01196923|Device|Endoscopically Guided Ablation|Visually Guided Ablation using EAS-AC
45771451|NCT00000574|Drug|ibuprofen|
45771452|NCT00002110|Drug|Cysteamine|
45771453|NCT00002110|Drug|Zidovudine|
45771454|NCT00001450|Drug|paclitaxel|
45771455|NCT00001450|Drug|cisplatin|
45771456|NCT00381082|Drug|1) MOOV Head Lice Treatment (Ego Pharmaceutical).|
45771457|NCT00381082|Drug|Banlice Mousse Aerosol (Pfizer, Australia)|
45771458|NCT00381082|Drug|3) KP24 Medicated Foam (Nelson Laboratories)|
45771459|NCT00000580|Drug|immunoglobulins, intravenous|
45771460|NCT00381160|Behavioral|Reduction of sugar-sweetened beverage consumption|Multi-component intervention aimed at reducing sugar-sweetened beverage consumption. Components include delivery of non-caloric beverages to home in combination with behavioral modification (telephone counseling with parent; check in visit with participant).
45632122|NCT03148145|Behavioral|Message Delivery by Smartphone|Message Delivery by Smartphone
45771461|NCT00985517|Biological|CERE-120: Adeno-Associated Virus Delivery of Neurturin|
45771462|NCT00985517|Procedure|Sham Surgery|
45771463|NCT00002116|Drug|Cidofovir|
45771464|NCT02451176|Device|Davol Bard Soft Mesh synthetic|soft mesh synthetic
45771465|NCT02451176|Device|LifeCell Strattice Reconstructive Tissue Biologic|biologic mesh
45771466|NCT00001498|Drug|methotrexate|
45771467|NCT00001498|Drug|leucovorin|
45771468|NCT00001498|Drug|5-fluorouracil|
45771469|NCT00001498|Drug|cyclophosphamide|
45632123|NCT02348411|Device|ExAblate|
45771470|NCT00001498|Procedure|peripheral blood progenitor cell|
45913678|NCT02025374|Drug|Hyperbaric bupivacaine % 0.5|
45913679|NCT02025387|Behavioral|Physical activity feedback|
45913680|NCT02025387|Behavioral|Usual care except physical activity measurement|
46070028|NCT00799513|Drug|Lenalidomide|single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.
45632124|NCT03147365|Behavioral|Aerobic exercises|Aerobic exercises will do by using treadmill for children of study group A. it will consist of (max.incline15% - max. speed - heart rate grips and wireless chest strap - smooth virtual fitness trainer - smooth drop folding frame - impression shock absorption cushioning system).
45771471|NCT00001498|Drug|paclitaxel|
46070029|NCT00570037|Biological|Trivalent inactivated influenza vaccine|Intramuscular injection, 0.5 mL or 0.25 mL depending on age of vaccine recipient, one or two doses administered a month apart depending on age and prior influenza vaccination history of recipient
45632125|NCT03147365|Behavioral|Modified strength training|Dumbbells will be used to conduct the modified strength training program for children of group B. This exercises included five exercises for the main muscle groups: bench press, leg press, seat row, leg extension and lat pull down.
45632126|NCT02348879|Drug|AMG 403|AMG 403 is for treatment of subjects with chronic pain
45632127|NCT02348879|Drug|Placebo|contains no active drug
45771472|NCT00001498|Drug|doxorubicin|
45771473|NCT02696616|Drug|BI 655088|
45771474|NCT02696616|Drug|Placebo|
45771475|NCT00001504|Drug|9-cis-Retinoic Acid|
45771476|NCT02688140|Drug|Arsenic trioxide|
45771477|NCT02688140|Drug|Idarubicin|
45771478|NCT02688140|Drug|Cytarabine|
45913681|NCT02025400|Other|eRehab|"Growth in e-Health applications, defined as any computer or Internet application integrated into health services, has resulted in the development of treatment strategies to improve healthcare while reducing costs. The utilization of e-Health to provide a rehabilitative intervention has recently been identified in the cardiac literature as e-rehabilitation or eRehab. This study specifically compares an orthopedic eRehab Internet application to standard outpatient physical therapy as an adjunct in the treatment of non-complicated knee and shoulder disorders."
45913682|NCT02025400|Other|Formal Physical Therapy|This intervention involves referral to a licensed physical therapist or supervised ATC-L.
45913683|NCT02025413|Device|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)|
45913684|NCT02025452|Other|Rapid diagnostic|Specimens from rectal mucosa will be obtained using flocked swabs at enrolment. Those in 'rapid diagnostic' groups will have them tested using multiplex PCR the day of enrolment and participants with treatable pathogens will have antimicrobials provided. Those in 'delayed diagnostic' groups will have the swabs batched at tested at the conclusion of the study, being treated as per standard of care.
45913685|NCT02025452|Dietary Supplement|Probiotic|Lactobacillus reuteri suspended in vegetable oil, 5 drops/day (1 x 10e8 CFU) x 2 months
45771479|NCT02688140|Drug|Tretinoin|
45771480|NCT02688140|Drug|Mitoxantrone|
45771481|NCT02688140|Drug|Mercaptopurine|
45771482|NCT02688140|Drug|Methotrexate|
45771483|NCT00000616|Behavioral|diet, sodium-restricted|
46070030|NCT00804661|Device|SENTEC device|Nocturnal recording SAO2 and PtcCO2 and wrist movements by means of actigraphy
45771484|NCT00000616|Behavioral|diet, fat-restricted|
45771485|NCT00000616|Behavioral|exercise|
45771486|NCT00000616|Behavioral|diet, reducing|
45771487|NCT00000616|Behavioral|alcohol drinking|
45771488|NCT00002122|Drug|Azithromycin|
45771489|NCT00002122|Drug|Rifabutin|
45771490|NCT00002122|Drug|Fluconazole|
45771491|NCT05456334|Device|Pulsed-dye laser|Comparance of pulsed-dye laser-mediated and conventional photodynamic therapy in a split-head design
45771492|NCT05456334|Device|Fractional CO2-laser|Comparance of fractional CO2-laser-mediated or plain daylight photodynamic therapy in a split-head design
45771493|NCT05456334|Drug|Metvix cream|Metvix-cream was used for photodynamic therapy in all experimental arms
45771494|NCT00001534|Drug|Losartan|
45771495|NCT01027559|Drug|Sertraline|Depressed participants will be randomized to SRT or CBT treatment. For those in the SRT treatment condition, visits will involve dispensing medications, checking for side effects and administering the Hamilton Depression rating scale occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response. Depressed subjects will start their SRT treatment once their first MRI and computer testing sessions are completed.
45935334|NCT00402259|Drug|Omeprazole IV|
45935335|NCT02965677|Device|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter
45935336|NCT02965677|Device|Peripheral Balloon Dilatation Catheter|in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter
45935337|NCT00402376|Drug|Pravastatin, Carvedilol, Perindopril|
45935338|NCT00402376|Device|Biventricular assist device (Thoratec paracorporeal assist device)|
45935339|NCT00042887|Drug|mitomycin C|
46070031|NCT00806767|Biological|therapeutic immune globulin|
46070032|NCT00806767|Drug|busulfan|
45632128|NCT03147209|Behavioral|Health Coaching|This intervention will consist of health coaching, goal setting and self directed activities to improve strength and balance.
45632129|NCT02349035|Device|Compare control of multifunction transradial prosthesis|Subjects practice control methods using a VR system. EMG data and virtual games are used and provide data to assess control methods without prosthesis. Subjects are fit with commercially available multifunctional hand system. They receive 1-3 days of training for conventional or pattern recognition control. They return home for an 8 week trial. They use the prosthesis for 2 hours a day across the 8 week trial. They keep a log of use and check with a therapist about usage and performance. After the 8 week trial, data from the prosthesis is downloaded. The subject will complete 1-3 days of outcomes testing. They perform a series of tests and data is recorded. The subject will repeat the 1-3 days of training, 8 week home trial, and 1-3 days of outcomes testing with either type of control.
45632130|NCT02349035|Procedure|Perform TMR surgery and evaluate transradial TMR pattern recognition control of multifunctional prostheses.|Subject has Targeted Muscle Reinnervation surgery. The surgery transfers median nerve to flexor digitorum superficialis muscle and ulnar nerve to flexor carpi ulnaris muscle. Two weeks after surgery, exercises start for muscle recovery. Then return to prosthesis from Phase 1 for 6 months. If they have pattern recognition control, usage and performance will be tracked for 6 months. If they return to conventional control, they will not complete tests, track usage, or performance. Six months after surgery, they return to pattern recognition control. Receive 1-3 days of training. Take prosthesis home for 8 week trial. Log use of device, note issues, and follow up with therapist. After home trial, 1-3 days of outcomes testing are completed and usage data downloaded. Continue using their prostheses for an additional 3-4 months. At 12 months after surgery, a final round of 1-3 days of testing and data are downloaded.
45632131|NCT03147053|Drug|Jiedu Tongluo granules|Patients in this group were administered the Jiedu Tongluo granules, 3.9mg/bag, 2 times/day for 8 weeks.
45632132|NCT03147053|Drug|Placebo|Patients in this group were administered the placebo, 3.9mg/bag, 2 times/day for 8 weeks.
45632133|NCT03147131|Procedure|Total Hip Arthroplasty|Total hip arthroplasty was randomly performed wither either a Fitmore short or a CLS straight stem.
45632134|NCT03146975|Procedure|Non-surgical periodontal treatment|Quadrant-wise ultrasonic debridement followed by manual scaling and root planing under local anesthesia provided in weekly sections. Oral hygiene instructions.
45632135|NCT02349113|Drug|Estrogens (Climara)|Treatment with estrogens: Estradiol dermal patch 0.1mg/d transdermally
45632136|NCT04183205|Diagnostic Test|LDAEP|This is an ERP task in which participants hear a series of tones ranging from 74dB to 104dB and electrophysiological activity is measured throughout. For each participant average P2 scores are derived for the 74dB tones, 84dB tones, 94dB tones, and 104dB tones. Then, LDAEP is defined as the slope of these average P2 scores.
45632137|NCT04183205|Drug|Placebo|placebo pills of the same size, color and taste as the active drug will be administered
45632138|NCT04183205|Drug|sertraline|Sertraline is an FDA approved SSRI for treatment of PTSD.
45771496|NCT01027559|Behavioral|Cognitive Behavioral Therapy|Depressed participants will be randomized to SRT or CBT treatment. For those in the CBT treatment condition, visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed subjects will start their CBT treatment once their first MRI and computer testing sessions are completed.
45771497|NCT00002128|Drug|Adefovir dipivoxil|
45771498|NCT05466084|Procedure|tissue Glue for mesh fixation|one arm of the study had their mesh fixed with tissue glue applied at multiple sites
45771499|NCT05466084|Procedure|Metallic Tackers for mesh fixation|in the other arm mesh was fixed with tackers applied avoiding the triangle of pain and the triangle of doom using a three point fixation technique; Cooper's ligament, medial cranial edge of the mesh and just lateral to the inferior epigastric vessels.
45771500|NCT00001570|Drug|PSC 833|
45771501|NCT00001570|Drug|vinblastine|
45771502|NCT02099864|Drug|Enzalutamide|Given PO
45771503|NCT05454696|Other|Exercise|Patients in the exercise group will participate in online clinical pilates exercise sessions under the supervision of a physiotherapist twice a week. The exercises will be done via the Zoom application and will continue for 6 weeks. The exercise program will last one hour with a warm-up and cool-down period. The exercises will be done by adhering to the basic principles of clinical pilates. The exercise program includes mat exercises that provide general body strengthening and stretching. Progression will be provided according to the health status of the patients and their compliance with exercise. The intensity of exercise will be planned as medium according to the Rating of perceived exertion (RPE) Scale.
45771504|NCT05454696|Other|online physical activity counselling|CG will receive online physical activity counselling by a physiotherapist only once. The importance of physical activity after surgery and the points to be considered during physical activity will be explained to the patients.
45771505|NCT00985829|Radiation|photodynamic therapy|treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
45771506|NCT00000628|Drug|L-697,661|
45771507|NCT00000628|Drug|Zidovudine|
45771508|NCT00000634|Drug|Nevirapine|
45913686|NCT02025452|Other|Placebo|Identical in appearance to L. reuteri probiotic (same bottle), but simply vegetable oil. Dose is 5 drops/day x 2 months.
45935340|NCT00042887|Procedure|conventional surgery|
45935341|NCT00122746|Radiation|Radiotherapy alone|EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A
45935342|NCT00122746|Radiation|Radiotherapy with cisplatin|EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT
46070033|NCT00806767|Drug|fludarabine phosphate|
46070034|NCT00806767|Procedure|allogeneic hematopoietic stem cell transplantation|
45447808|NCT02123368|Biological|10 million Bone marrow mesenchimal stem cells|10 million of Bone marrow mesenchimal stem cells
45632139|NCT02348801|Behavioral|Weight loss and Exercise|"Group behavior therapy sessions designed to acquire positive weight-control skills and attitudes, and practice weight-maintenance skills. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.~Exercise sessions of ~90 min duration 15 min warm-up of flexibility exercise, followed by ~30 min of aerobic exercise, and, after a brief rest period, ~30 min of resistance training, and finally ~15 min balance exercise) conducted three times weekly supervised at our exercise facility for first six months, and regular exercises continued at community-fitness centers and at home for the following six months."
45771509|NCT01661790|Drug|Bevacizumab|Bevacizumab300mg&Cispltin30mg by intrapleural administration of each 2 week
45632140|NCT02348801|Behavioral|Healthy lifestyle|Diabetes support and education
45632141|NCT02348567|Other|Unannounced hospital surveys|This is a cluster-randomised controlled trial performed at hospital level. We hypothesise that unannounced surveys produce less successful assessments of patient safety compared to announced surveys (conventional/control). This study defines less successful as less compliance with the included standards and performance indicators.
45632142|NCT02348567|Other|announced hospital surveys|
45632143|NCT04151849|Drug|GLP-1 receptor agonist|Treatment with GLP-1 agonist for up to 1 year.
45771510|NCT01661790|Drug|Cisplatin|Cisplatin 30mg,intrapleural administration,each 2 week
45632144|NCT04151849|Drug|SGLT2 inhibitor|Treatment with SGLT2 inhibitor for up to 1 year
45447809|NCT02123368|Biological|100 million Bone marrow mesenchimal stem cells|100 million of Bone marrow mesenchimal stem cells
45771511|NCT05576246|Diagnostic Test|airway pressure occlusion measurement|Flow, airway pressure (Paw), and esophageal pressure (Pes) will be recorded for 10 minutes on different NIV settings: during each one, three end-expiratory airway occlusions will be applied at random intervals. Each occlusion was maintained for the duration of a single breath deflection in Paw from PEEP, confirmed by the return of Paw to baseline.
45447810|NCT02123524|Drug|Rivaroxaban|
45632145|NCT03147989|Drug|MultiHance|gadolinium contrast agent
45632146|NCT02348177|Drug|lopinavir with ritonavir in 1:1 ratio|During co-treatment of rifampicin containing tuberculosis treatment and lopinavir/ritonavir (4:1) based therapy, additional ritonavir is given to make lopinavir/ritonavir 1:1 ratio
45771512|NCT00002134|Drug|Ganciclovir|
45771513|NCT00985907|Drug|Doxil, melphalan, bortezomib|"Doxil®: IV over 30-60 min, Day 1 q28d~Melphalan: IV over 30 min, Day 1 q28d~Velcade®: IV bolus, Day 1, 4, 8, 11 q28d~Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2~Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2"
45771514|NCT00002140|Drug|Ethambutol hydrochloride|
45771515|NCT00002140|Drug|Clarithromycin|
45632147|NCT02348177|Drug|Lopinavir/ritonavir 4:1|This is the conventional dosing of LPV/r 4:1 for HIV when TB treatment has not been started or has been stopped
45771516|NCT00002140|Drug|Azithromycin|
45447811|NCT02123524|Drug|Placebo|
45771517|NCT02685332|Radiation|Stereotactic Radiation|"Stereotactic Body Partial Breast irradiation Step No. Fractions Dose per fraction~-1 1 20 0 (starting) 1 22.5~1 26.5~1 30"
45771518|NCT00986453|Device|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
45771519|NCT00986453|Procedure|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
45771520|NCT05465928|Device|Active rTMS|rTMS is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each rTMS treatment, the magnetic field is generated by a coil which is placed on the head near the brain region of interest, and further, an electrical current is induced to modulate brain activity.
45771521|NCT05465928|Device|Sham rTMS|The sham rTMS stimulation is performed based on a sham coil which will mimic scalp sensations and the acoustic artifact of the active stimulation, without delivering any magnetic pulse.
45771522|NCT00000658|Drug|Bleomycin sulfate|
45771523|NCT00000658|Drug|Vincristine sulfate|
45771524|NCT00000658|Drug|Doxorubicin hydrochloride|
45771525|NCT00000658|Drug|Cyclophosphamide|
45771526|NCT00000658|Drug|Allopurinol|
45447812|NCT02117986|Drug|colistin|One arm will receive a loading dose of colistin (6 million international units), and a maintenance dose of 3 million every 8 hours. The other arm will receive a maintenance dose of 3 million international units every 8 hours.
45447813|NCT02118064|Biological|G17DT-Irinotecan|500µg dose of G17DT intramuscular injection in combination with 125 mg/m^2 intravenous infusion of Irinotecan over 90 minutes.
45632148|NCT02348255|Procedure|Electric Field Therapy|Undergo NovoTTF-100A
45632149|NCT02348255|Biological|Bevacizumab|Given IV
45632150|NCT02348255|Drug|Carmustine|Given IV
45632151|NCT02348255|Other|Quality-of-Life Assessment|Ancillary studies
45632152|NCT02348333|Drug|FYU-981, (Oral daily dosing for 7 days)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
45632153|NCT02348333|Drug|Placebo, (Oral daily dosing for 7 days)|Subjects randomized to the placebo arm receive placebo.
45632154|NCT02348021|Procedure|Percutaneous coronary intervention (PCI)|
45632155|NCT02348021|Drug|Dual Anti Platelet Therapy|All patients will receive Dual Anti Platelet Therapy for one month
45632156|NCT03146819|Device|iTotal PS Knee Replacement System|Total Knee Replacement systems (Patient Specific)
45632157|NCT03146819|Device|Off-the-Shelf Knee Replacement System|Total Knee Replacement systems (Off-the-shelf)
45771527|NCT00000658|Drug|Methotrexate|
45771528|NCT00000658|Drug|Cytarabine|
45771529|NCT00000658|Drug|Leucovorin calcium|
45771530|NCT00000658|Drug|Sargramostim|
45771531|NCT00000658|Drug|Dexamethasone|
45771532|NCT02684474|Biological|HBOC-201|Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.
45771533|NCT02085980|Device|Laser treatment|The laser handpiece (probe) will be deposited in the vaginal canal and the laser energy will be delivered through the handpiece
45935343|NCT00122785|Drug|dexamethasone|
45935344|NCT00122824|Drug|duloxetine hydrochloride|
45935345|NCT00122824|Drug|placebo|
45632158|NCT03147755|Other|No intervention|No intervention
45632159|NCT03147833|Dietary Supplement|Sport beverages Protein|Beverage ingested before each night sleep during the intervention
45632160|NCT03147833|Dietary Supplement|Sport beverages Carbohydrate|Beverage ingested before each night sleep during the intervention
45632161|NCT05255627|Other|Control|"Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using written educational material prepared in line with the literature."
45771534|NCT03016247|Behavioral|TRUST Intervention|The TRUST intervention will be guided by Rotenberg's Framework of Interpersonal Trust 3. The TRUST group will meet with an interventionist trained in weight self-management for eight 90-minute weekly sessions. Each session will include adolescent/parent trust-building exercises (honesty, reliability, emotional connection), didactic content, experiential skills developing (nutrition label reading), behavior-change goal-setting, and problem-solving.
45771535|NCT03016247|Behavioral|Enhanced Usual Care|Single meeting with a Nutritionist for physical activity and eating counseling.
45771536|NCT02546544|Drug|Linsitinib|
45632162|NCT05255627|Other|Mobile application group (Experimental Group)|"A mobile application program was installed on the phones of the experimental group students for their benefit. Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using a mobile application program prepared in line with the literature."
46070035|NCT00804739|Other|Mother-Infant Treatment Team|This is a treatment team approach that allows for outreach. The clinical team will be a nurse practitioner of psychiatry and a social worker. The nurse practitioner will provide either interpersonal psychotherapy, sertraline or both as indicated.
45632163|NCT05255549|Procedure|ESWT + Stretching|"3 weeks intervention:~3 sessions of ESWT, once a week~6 sessions of passive stretching, twice a week"
45632164|NCT05255549|Procedure|ESWT and SHAM + Stretching|"3 weeks intervention:~1 sessions of ESWT + 2 sessions of Sham, once a week~6 sessions of passive stretching, twice a week"
45632165|NCT02343653|Behavioral|Nutrition and strength training|"All participants will receive professional dietary guidance and a protein supplement. At the beginning and end of the intervention every participant will be part of a program consisting of:~Test of muscle strength, blood samples, assessment of nutritional status, MRi scan, test of Quality of life by questionnaire and test of the ammonium metabolism. After one year readmissions will by registered.~The intervention group will receive supervised training."
45632166|NCT02343653|Behavioral|Nutrition|"All participants will receive professional dietary guidance and a protein supplement. At the beginning and end of the intervention every participant will be part of a program consisting of:~Test of muscle strength, blood samples, assessment of nutritional status, MRi scan, test of Quality of life by questionnaire and test of the ammonium metabolism. After one year readmissions will by registered."
45632167|NCT02343497|Dietary Supplement|Astaxanthin|
45632168|NCT02343497|Dietary Supplement|Placebo|
45771537|NCT00380848|Procedure|Hemodiafiltration|
45771538|NCT01027793|Drug|Tretinoin cream 0.005%|Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
45771539|NCT01027793|Device|Superficial Dermabrasion|Group 2 will receive 16 sessions of dermabrasion that would be held in the research center
45771540|NCT00002146|Drug|Magnesium sulfate|
45632169|NCT02343419|Other|Methacholine Challenge Test|"Forced oscillation technique test, plethysmography, interrupter technique test and spirometry will be performed in a row before any intervention and after inhalation of aerosols - normal saline, followed by increasing concentrations of methacholine: 0.03 mg/ml; 0.06 mg/ml; 0.125 mg/ml; 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 4 mg/ml, 8 mg/ml, 16 mg/ml.~In case of FEV1 decrease of ≥ 20% of the initial value methacholine challenge test will be ceased and patient will be administered 200 µg of salbutamol in inhalation. Then, pulmonary function tests will be performed after 15 minutes."
45632170|NCT02343341|Behavioral|Preschool Health Promotion Education Program|
45632171|NCT02343107|Behavioral|e-coaching|connexion to a website and interaction with an automatizes system which delivers tailored recommendations over a 4 month period.
45632172|NCT02348099|Other|Ultrasound|Abdomen scanned with portable ultrasound to determine presence of subclinical lipohypertrophy.
45632173|NCT02343029|Other|Individualised aerobic exercise training|During the first 4 weeks of intervention two of the three weekly training sessions are offered as group training supervised by the respective qualified exercise physiologist of the Department of Sports Medicine. After 4 weeks, participants' physical performance is reassessed at the Department of Sports Medicine. If necessary, workload is readjusted to achieve the initially defined exercise intensity.
45771541|NCT00002146|Drug|Foscarnet sodium|
45771542|NCT04389554|Other|Blood D-dimer assay|Blood samples will be taken from the patients and will be examined by the ELISA method.
45771543|NCT00380926|Drug|polyunsatturated fatty acids (fish oil)|
45771544|NCT05427552|Device|Intermittent theta-burst stimulation (iTBS)|The iTBS will be applied over lDLPFC with three different intensities. The investigators put the NIRS probe under the TMS coil to detect the hemodynamic signal simultaneously, and the applied rMT was adjusted based on Stokes et al., 2007. The equation is AdjMT% = MT + 2.8 * (Dsitex - Dm1), and the thickness of the probe is 6mm, therefore, 2.8*6=16.8(%) were added to the normal intensity.
45771545|NCT02444390|Procedure|Biopsy|biopsy of a metastasis
45771546|NCT03051516|Other|Laboratory Biomarker Analysis|Correlative studies
45771547|NCT03051516|Other|Placebo Administration|Given IM
45771548|NCT03051516|Other|Questionnaire Administration|Ancillary studies
45771549|NCT03051516|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
45771550|NCT01029587|Drug|Eculizumab|Eculizumab will be administered by intravenous infusion. Eculizumab will be administered at a dose of 1200mg by intravenous (IV) infusion on the day of or on the day prior to kidney transplantation, and at a dose of 900mg IV on post-operative day 1. Subsequently, the post-operative dosing regimen would be comprised of an induction phase of weekly doses of 900mg IV per dose followed by a maintenance phase of every other week dosing of 1200mg IV per dose. The weekly induction dosing regimen would begin on postoperative day 8, and would continue for three doses (specifically, doses of 900mg IV would be given on postoperative days 8, 15, and 22). The maintenance phase of dosing would begin with a dose of 1200mg on postoperative day 29, and would continue for a total of 5 doses (specifically, doses of 1200mg IV would be given on postoperative days 29, 43, 47, 72, and 85). In most cases, eculizumab would be discontinued after the 5th maintenance dose.
45632174|NCT02343029|Other|Waiting Control|After waiting for 12 weeks with normal daily activity, patients are allocated to a individualised aerobic exercise training, too.
45771551|NCT00000664|Drug|Interleukin-2, Polyethylene Glycolated|
45771552|NCT00000664|Drug|Zidovudine|
45632175|NCT03146897|Dietary Supplement|Supplementary Food|Supplementary food for treating MAM
45771553|NCT02444078|Other|Exercise|Exercise training will take place in the NH, twice weekly, around 60 minutes per session (session duration can be shorter during the first weeks of intervention according with participants' physical capacity), during 6 months; interval between two exercise sessions will be of at least 48 hours. The exercise program will be a multicomponent training, with exercises specifically developed to improve participants' flexibility (10 minutes), coordination and balance (10 minutes), muscle toning (10 minutes), and cardiorespiratory capacity (25 minutes). The exercise intensity targeted will be moderate. All exercise sessions will be accompanied by music.
45771554|NCT02444078|Other|Social Activity|Interventionists will be health professionals external to the NH, preferentially psychologists. Interventions will take place in the NHs, at the same frequency and duration than the exercise intervention (twice weekly, 60 minutes per session, during 6 months).
45771555|NCT05427396|Drug|JS004|Usage and dosage: Inject 200mg once every 3 weeks
45771556|NCT05427396|Drug|Toripalimab Injection|Usage and dosage: Inject 240mg once every 3 weeks
45632176|NCT02343185|Other|manual therapy with diaphragmatic treatment|Subjects receive five sesions of manual therapy for low back pain combined with diaphragmatic treatment.
45632177|NCT02343185|Other|Placebo treatment|Subjects receive five sesions of manual therapy for low back pain combined with a sham diaphragmatic treatment.
45632178|NCT02342951|Other|Lung clearance index determination|Lung clearance index determination
45632179|NCT02342717|Drug|BI 425809|single dose BI 425809 tablet
45771557|NCT05440630|Dietary Supplement|Probiotics|Participants in this arm will receive a daily dose of 1x10^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria) for 16 weeks.
45632180|NCT02342717|Drug|Itraconazole|multiple doses of Itraconazole capsules
45632181|NCT02342717|Drug|BI 425809|single dose BI 425809 tablet
45632182|NCT02342795|Other|e-cigarette|
45771558|NCT05440630|Dietary Supplement|Postbiotic|Participants in this arm will receive a daily dose of 1x10^10 Colony Forming Unit (CFU) of a single strain postbiotic (Heat treated bacteria) for 16 weeks.
45771559|NCT05440630|Dietary Supplement|Placebo|Participants in this arm will receive an equivalent placebo for 16 weeks.
45771560|NCT01893944|Other|virtual reality|customized applications using virtual and augmented reality to be developed.
45632183|NCT02342795|Other|cigarette substitute|
45771561|NCT05465538|Drug|[11C]UCB-J PET|Single PET scan using the radioligand [11C]UCB-J
45771562|NCT00000670|Drug|Probenecid|
45771563|NCT00000670|Drug|Zidovudine|
45771564|NCT00002152|Drug|WF10|
45771565|NCT00001630|Device|Isolex 300i|
45771566|NCT00988013|Radiation|IM-TMI (3Gy)|Patients will receive 3Gy per day for 1 day.
45771567|NCT00988013|Radiation|IM-TMI (6Gy)|Patients will receive 3Gy per day for 2 days.
45771568|NCT00988013|Radiation|IM-TMI (9Gy)|Patients will receive 3Gy per day for 3 days.
45935346|NCT00077532|Biological|gp100 antigen|
45935347|NCT00077532|Biological|incomplete Freund's adjuvant|
45632184|NCT02342873|Procedure|NS-guided interscalene block|Patients received a standard single injection interscalene block using the modified lateral approach of Borgeat. The interscalene brachial plexus was identified using an insulated needle connected to a nerve stimulator. An insulated needle attached to a nerve stimulator was used to identify the brachial plexus. Placement of the needle was considered adequate if the deltoid, triceps, pectoralis, or biceps muscle motor response was still present at 0.2 - 0.5mA. Ropivacine 0.75% 20ml was used.
45632185|NCT02342873|Procedure|US-guided interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.75% ropivacaine is injected
45632186|NCT02347553|Other|This is not an interventional study|Participants will act as their own controls and will undergo the study procedure once in a hypoglycaemic state and once in a euglycaemic state. Therefore there is no intervention being studied as such.
45632187|NCT04478435|Other|glucose loaded clear fluid|Ultrasound assessment of gastric antrum is done at different time interval following glucose loaded clear fluid ingestion
45632188|NCT04478357|Drug|4 mg Fesoterodine ER tablet from Zwickau|Manufactured at Zwickau
45632189|NCT04478357|Drug|4 mg fesoterodine ER tablet from Freiburg|Manufactured at Freiburg
45632190|NCT04478357|Drug|8 mg fesoterodine ER tablet from Zwickau|Manufactured at Zwickau
45632191|NCT04478357|Drug|8 mg fesoterodine ER tablet from Freiburg|Manufactured at Freiburg
45632192|NCT04478513|Drug|AZD4635|During each treatment period subjects will receive a single dose of AZD4635 under fasting conditions.
45632193|NCT04478513|Drug|Fluvoxamine|Daily oral single doses of fluvoxamine are planned to be administered to healthy volunteers in Treatment Period 2.
45771569|NCT00988013|Radiation|IM-TMI (12Gy)|Patients will receive 3Gy per day for 4 days.
45771570|NCT02020070|Drug|Degarelix|
45771571|NCT02020070|Drug|Ipilimumab|
45771572|NCT02020070|Procedure|Radical Prostatectomy|
45771573|NCT00002158|Drug|Nitazoxanide|
45632194|NCT02342483|Dietary Supplement|MSM|
45632195|NCT02342405|Other|80% oxygen|
45771574|NCT00000694|Drug|Interferon alfa-2b|
45771575|NCT00000694|Drug|Zidovudine|
45771576|NCT00000694|Drug|Sargramostim|
45771577|NCT01894412|Biological|Etanercept (Enbrel)|
45771578|NCT01894412|Biological|HD203|
45771579|NCT00000700|Drug|Zidovudine|
45771580|NCT02440646|Radiation|Coronary computed tomography angiography|The coronary arteries will be visualized with the MSCT scan CT 5000 Ingenuity (Philips, The Netherlands) or systems from any other vendors.
45771581|NCT02440646|Radiation|Quantitative coronary angiography, intravascular imaging with percutaneous intervention|Coronaries will be shot with Artis zee (Siemens, Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (FFR, QFR, OCT, IVUS, VH-IVUS) and/ or percutaneous intervention (with implantation of the medical device).
45771582|NCT00002164|Drug|Nelfinavir mesylate|
45771583|NCT02003690|Behavioral|Dialectical Behavior Therapy|Dialectical Behavior Therapy
45771584|NCT02003690|Behavioral|Standard of Care Psychotherapy|Standard of Care Psychotherapy
45771585|NCT02003690|Other|Pharmacotherapy|Standard of Care Pharmacotherapy
45771586|NCT00000706|Drug|Quinine sulfate|
45771587|NCT00000706|Drug|Probenecid|
45771588|NCT00000706|Drug|Zidovudine|
45771589|NCT00988325|Drug|Tamiflu|oral repeating dose
45771590|NCT00002296|Drug|Inosine pranobex|
45913687|NCT02025465|Drug|Metoprolol|"The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF/FL rate control.~Conversion of intravenous to oral, chronic management will be left to the discretion of the ED or managing medical team."
46070036|NCT00804817|Behavioral|Control Group|Control: Care as usual, i.e. standard physical activity enhancement, oral mucositis prevention and treatment and mal nutrition prevention
45632196|NCT02342405|Other|30% oxygen|
45632197|NCT04478591|Other|Questionnaires|All participants will fill in two questionnaires before or during their next treatment with ocrelizumab: the MSIS-29 questionnaire and a wearing-off questionnaire. After two weeks, participants fill in two digital questionnaires (MSIS-29, additional wearing-off questionnaire).
45632198|NCT02347475|Other|Observational Study|Ultrasound and NIRS
45632199|NCT02342093|Drug|30EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months
45632200|NCT02342093|Drug|20EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
45632201|NCT02347319|Drug|Pennel|Pennel 2 Tablet, Legalon Placebo 1 tablet, Tid
45632202|NCT02347319|Drug|Legalon|Pennel Placebo 2 Tablet, Legalon 1 tablet, Tid
45632203|NCT02347319|Drug|Placebo|Pennel Placebo 2 Tablet, Legalon Placebo 1 tablet, Tid
45771591|NCT00002302|Drug|Epoetin alfa|
45771592|NCT00002170|Drug|Nelfinavir mesylate|
45771593|NCT00002308|Drug|Stavudine|
45771594|NCT00002314|Drug|Ro 24-7429|
45771595|NCT00000724|Drug|Trimetrexate glucuronate|
45771596|NCT00000724|Drug|Leucovorin calcium|
45771597|NCT00000730|Drug|Trimetrexate glucuronate|
45771598|NCT00000730|Drug|Methylprednisolone|
45771599|NCT00000730|Drug|Pentamidine isethionate|
45771600|NCT00000730|Drug|Sulfamethoxazole-Trimethoprim|
45771601|NCT00000730|Drug|Leucovorin calcium|
45771602|NCT02435264|Other|Healthier Dining Program Intervention|The food environment at the intervention centers will be modified to increase the availability of healthier foods and low calorie meals.
45771603|NCT00002176|Drug|Hydroxyurea|
45771604|NCT00002176|Drug|Nelfinavir mesylate|
45771605|NCT00002176|Drug|Stavudine|
45771606|NCT00002176|Drug|Didanosine|
45771607|NCT01990196|Drug|degarelix|"Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
45771608|NCT01990196|Drug|enzalutamide|"Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
45771609|NCT01990196|Drug|trametinib|"Once Daily Treatment: If randomized into Group 2, then 2mg of Trametinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
45771610|NCT01990196|Drug|dasatinib|"Once Daily Treatment: If randomized into Group 3, then 100mg of Dasatinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
45771611|NCT00381316|Drug|Technetium Tc99m Tetrofosmin injections|Single Isotope: be 555 to 888 MBq (15 to 24 mCi) MYOVIEW at Rest/i.v./bolus.
45771612|NCT00381316|Drug|Thallous Chloride T1-201|Myoview SPECT Imaging
45771613|NCT04708834|Drug|Troriluzole (BHV-4157)|200 mg daily first 2 weeks, 280 daily for following 46 weeks
45771614|NCT02161133|Behavioral|Problem-Solving Therapy|Problem-Solving Therapy is a treatment approach that teaches patients strategies to address real-life problems.
45771615|NCT02161133|Behavioral|Health Education|Health Education provides didactic information about Gulf War Illness
45632204|NCT03146351|Other|Family based early intervention program (NDT-Bobath based)|Family based early intervention program is NDT - Bobath based home program. Physiotherapist teaches principles of the treatment to infants' family. Family applies the program at home.
45632205|NCT02341937|Other|Diagnostic tests for suspected deep vein thrombosis|Pre-test clinical probability (Wells score), D-dimer, compression ultrasonography
45632206|NCT02347397|Device|SS Bipolar Head + SL-TWIN Stem|Subject will undergo hemiarthroplasty surgery with SS Bipolar Head & SL-TWIN Stem
45632207|NCT02347397|Device|Bipolar Head + SL-PLUS Stem|Subject will undergo hemiarthroplasty surgery with Bipolar Head & SL-PLUS Stem
45632208|NCT03146273|Dietary Supplement|Multivitamins|"After the study product administration blood tests will be performed in order to calculate the AUC for each mineral and vitamin - Vit A Vit E Folic Acid Vit C Calcium Magnesium~After the washout period, the same procedure will be done for the additional formulation of the multivitamins."
45632209|NCT02347241|Other|Educational intervention|Educational Debriefings and High frequency training and team reflection
45771616|NCT02432690|Drug|BBI503|BBI503 will be administered orally, once daily. Dosing will begin at 200 mg once daily, preferably at bedtime and 2 hours after a meal. Dose modification in case of adverse events is allowed according to the schedule below; Full dose: 200 mg daily, Modification Level-1: 100 mg daily, Modification Level-2: 50 mg daily.
45771617|NCT03830177|Drug|Natural Treatment|The participant will be given the treatment, which contains all natural ingredients, and a kit of all necessary materials to take home with them, which will include a set of instructions. The kit will contain the instruction handout and their treatment. They will be instructed to apply the treatment to their scalp, wait seven minutes, and then rinse their scalp. They will perform this entire procedure once per day for 14 days.
45913688|NCT02025465|Drug|Diltiazem|"The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF rate control.~Conversion of intravenous to oral medication for rate control for chronic management will be left to the discretion of the ED or managing medical team."
45913689|NCT02025478|Dietary Supplement|Breastmilk|"A registered dietician will supervise milk provision, and additional calories will be provided by addition of the supplement Prolacta. To make 28 kcal/oz milk, 40 ml of Prolacta will be mixed with 60 ml human milk to make a total volume of 100 ml.~If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible, with Prolacta supplementation if clinically indicated and recommended by the registered dietician."
45913690|NCT02025491|Drug|Liposomal Amphotericin B|Liposomal Amphotericin B will be administered by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment. Complete hemogram, aminotransferases (AST, ALT), blood urea and creatinine will be determined in all patients on days -1, and three times/week up to the end of therapy. Patients will bemonitored for side effects daily. Patients will be followed-up at 1, 2, 3, 4 and 6 months post-therapy. Clinical and laboratory adverse events will be graded according to the Common Toxicity Criteria (CTC) of the National Cancer Institute.
45913691|NCT02025504|Device|ColoWrap|ColoWrap is an abdominal binder intended as an accessory to facilitate colonoscopy.
45913692|NCT02025517|Other|Cognitive Tasks.|The Experimental Group underwent treadmill gait training simultaneously to a protocol of cognitive tasks created specifically for this study, based on cognitive activities proposed in previous studies. The training sessions lasted 20 minutes. The first three minutes allowed subjects to familiarize themselves with the treadmill. From the 4th minute onward, the volunteer walked for 1 minute while performing cognitive tasks, and in the following minute, only walked. Thus, the 17 remaining minutes on the treadmill alternated between one minute of treadmill training combined with a cognitive task and the following minute only treadmill training. Treadmill gait speed was that reported by the patient as the fastest possible speed while maintaining a suitable comfort level.
45913693|NCT02025569|Other|Strain Counterstrain|
45913694|NCT02025569|Other|Sham strain counterstrain|
45913695|NCT02025582|Device|Kinesio Tape of the Ankle|Tibialis anterior facilitation/ gastrocnemius inhibition: Taping to be worn 3-5 days and repeated x 1
45632210|NCT02347163|Drug|Zoledronate|Patients fulfilling the eligibility criteria will be registered using a centralized system and will receive a pre-operative, single administration of zol (4mg i.v.), 7 days before definitive breast surgery .
45632211|NCT02341703|Drug|letrozole-metformin|letrozole 2.5 mg will be given daily from day 3 of the cycle for 5 days + metformin 500 mg three times daily continuously for 3 months unless pregnancy occurred
45632212|NCT02341703|Drug|letrozole-metformin-pioglitazone|letrozole will be given daily from day 3 of the cycle for 5 days + (metformin 850 mg + pioglitazone 15 mg) from the first day of the cycle for 10 days.
45913696|NCT02025608|Drug|Pramipexole|
45913697|NCT02025608|Drug|Placebo|
45913698|NCT02025660|Drug|Mw, 0.3ml x three days sc|
45632213|NCT02341703|Radiation|transvaginal ultrasound|transvaginal ultrasound will be done from day 10 of the cycle and every other day for monitoring of follicular enlargement.
45632214|NCT02341703|Other|laboratory investigations|day 3: FSH, LH, TSH, and total testosterone day 12 serum E2 day 21 serum progesterone
45632215|NCT02346851|Procedure|Functional Electrical Stimulation (FES) treatment|This study is randomized controlled trial performed by Random permuted blocks. This study has 2 experimental groups and 1 control group. Both experimental group receive FES treatment of their posterior deltoid and supraspinatus. Experimental group 1(Acceleration group) uses Novastim CU FS1 once a day for 30 minutes during 3 weeks. During treatment patient give a maximal effort for shoulder abduction. Experimental group 2 (Convention group) receive cyclic FES treatment for reducing shoulder subluxation. All patients have evaluation pre-intervention, post-intervention, 3 weeks after intervention and 9 weeks after intervention including physical examination and x-ray.
45771618|NCT01030289|Device|real tDCS|transcranial direct current stimulation
45771619|NCT01030289|Device|sham tDCS|transcranial direct current stimulation
45771620|NCT00002182|Drug|Megestrol acetate|
45771621|NCT04756934|Drug|HX008|HX008: 200mg, Q3W
45913699|NCT02025660|Drug|Placebo|
45771622|NCT04756934|Drug|LP002|LP002: 1mg/kg, or 3mg/kg, or 5mg/kg, Q3W
45771623|NCT00002320|Drug|Lamivudine|
45771624|NCT00002320|Drug|Zidovudine|
45771625|NCT01236391|Drug|PCI-32765|560 mg daily
45771626|NCT04675840|Procedure|Robotic-assisted hysterectomy|Robotic-assisted surgery
45632216|NCT02341469|Other|integrated ediagnostic approach (IeDA)|"IeDA is a package of several interventions with the objective of improving the quality of child health care in health centres to ultimately decrease child morbidity and mortality. The components of IedA are described as follows:~REC: the IMCI protocol translated into a computer-based tool that aims to guide nurses during consultations.~The training of nurses on IMCI and REC.~A quality assurance mechanism through which each district and health centre is encouraged to find appropriate solutions in response to their local needs.~A supervision system conducted implemented by district managers to provide support and guidance to health centres.~A health information system based on data collected through the REC and fed back to the district managers and Heads of health centres."
45632217|NCT02341547|Drug|a Biosimilar Epoetin Alfa|End Stage Renal Failure patients stable on Eprex switched to Binocrit
45632218|NCT02347007|Dietary Supplement|Almond|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from almonds daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily almond supplement as a mid-afternoon snack and the rest at a meal of their choice.
45632219|NCT02347007|Dietary Supplement|Cereal Bar|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from cereal bars daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily cereal bar supplement as a mid-afternoon snack and the rest at a meal of their choice.
45632220|NCT02346929|Other|ultrasound guide|Patients randomized to this arm will have the hematoma block of the distal radial fracture with the guidance of a bedside ultrasound
45632221|NCT02341391|Biological|TissueGene-C(Low dose)|3.0 x 10^6 cells
45632222|NCT02341391|Biological|TissueGene-C(Medium dose)|1.0 x 10^7 cells
45632223|NCT02341391|Biological|TissueGene-C(High dose)|3.0 x 10^7 cells
45632224|NCT02341235|Behavioral|Game intervention|The game will target motivation via narrative and game mechanics. It will also encourage self-regulation by providing monitoring and feedback of activity. Counseling will be adapted to specifically reference concepts related to narrative and games.
45771627|NCT02167217|Drug|Prednisolone|Prednisolone (5mg per kg) will be taken on two consecutive days, Friday and Saturday mornings each week with breakfast
45913700|NCT02025686|Drug|Hyperbaric Oxygen|Subjects will breathe oxygen (FIO2 = 1.0) at 2.4 ATA in a hyperbaric chamber after the tonic heat stimulations. The duration of oxygen exposure is 90 min.
45632225|NCT02341235|Behavioral|Standard intervention|The electronic activity monitor will monitor steps, and the mobile device will provide basic feedback on progress toward goals. Counseling will be standard and concentrate on self-regulatory skill-building.
45632226|NCT02346773|Dietary Supplement|ω-3 LC-PUFA|The intervention product was a full fat (80%) margarine.Participants were provided with one-month supply of the intervention product (including reserve products) at the onset of the intervention and received a new supply monthly. The intervention products were provided in neutral serving-sized cups, each containing 10 grams of margarine.The child's parents were instructed to have their child consume one complete portion pack (10 g) of margarine per day. The margarine had to be consumed as spread on sandwiches, crackers or bread rolls.The intervention product could be consumed on various periods over the day or all at one occasion. Every day a new portion pack had to be used, even if there was margarine left in the package of the previous day.
45632227|NCT02346773|Other|Placebo|The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
45632228|NCT03146429|Diagnostic Test|I-123 FP-CIT Single photon emission tomography|Brain scan for dopamine transporter
45632229|NCT02346617|Biological|IFN-γ positive selected T-cells|No intervention
45632230|NCT02341079|Drug|Bupivacaine Liposome Injection|Intraoperative intracapsular injection of 266mg of bupivacaine liposome injection diluted to 60mL with 0.9% normal saline.
45632231|NCT02341079|Drug|Indwelling femoral nerve block|Femoral nerve block delivered via indwelling femoral nerve catheter with 0.125% bupivacaine.
45913701|NCT02025686|Other|Normal ambient conditions|Normal ambient conditions (1 ATA, FIO2 = 0.21)
45913702|NCT02025712|Drug|Exemestane|Commercially available exemestane was supplied to sites as 25-mg tablets according to local regulations.
45632232|NCT02346539|Drug|Nicotine polacrilex|Single Acute dose
45913703|NCT02025712|Drug|Everolimus|Everolimus was administered by continuous oral dosing of two 5-mg tablets or one 10-mg tablets.
45913704|NCT02025738|Device|MAGNET APPLICATION|
45913705|NCT02025738|Device|REPROGRAMING|
45771628|NCT00002326|Drug|Adefovir|
45771629|NCT00002326|Drug|Zidovudine|
45771630|NCT01152697|Drug|haloperidol decanoate|Drug is in in injectable form and will be administered approximately every four weeks through Week 25 of the study. A participant may continue on the drug after Week 25 at the discretion of his or her treating psychiatrist. Dosage is per package insert or at the discretion of the psychiatrist.
45913706|NCT02025738|Device|NO ACTION|
45913707|NCT02025777|Device|Capsule Endoscopy|
45913708|NCT02025790|Procedure|Per Oral Endoscopic Myotomy (POEM)|"Mucosal incision - After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 12 cm proximal to the gastroesophageal junction (GEJ).~Submucosal tunneling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.~Long endoscopic myotomy is performed 10 cm proximal to GEJ extending~Closure of mucosal entry: the mucosal incision is closed using hemostatic clips"
45913709|NCT02025790|Procedure|Pneumatic Dilatation|Pneumatic dilatation using a Rigiflex balloon up to 35 mm at 8 psi for 1 minute.
45935348|NCT00077532|Biological|ipilimumab|
45935349|NCT00122863|Drug|Duloxetine Hydrochloride|
45935350|NCT00122863|Drug|placebo|
45935351|NCT00042926|Other|immunohistochemistry staining method|
45935352|NCT00042926|Procedure|conventional surgery|
45771631|NCT01152697|Drug|haloperidol|Drug will be administered in oral form to participants not already taking oral haloperidol and then transitioned to the injectable version. Dosage and frequency is at the discretion of the psychiatrist.
45913710|NCT02025803|Drug|TAS-114/capecitabine|"Part 1 (dose-escalation phase):~Treatment cycles of TAS-114 and capecitabine orally BID for 14 days followed by 7 days rest until at least one of the discontinuation criteria are met TAS-114 dose starting at 20mg/m2/day with capecitabine dose of 760 mg/m2/day. TAS-114 doses will be escalated for each cohort up to 480mg/m2/day. If MTD is not reached by TAS-114 dose of 480mg/m2/day, the capecitabine dose will be escalated~Part 2 (expansion phase):~TAS-114 and capecitabine MTD established in Part 1 administered BID for 14 days followed by 7-day recovery period (21-day cycle)."
45632233|NCT02340689|Other|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic analysis.
45632234|NCT04018859|Device|Platelet Rich Plasma Prep System|intradermal injections of platelet rich plasma to the eyebrows
45913711|NCT02025855|Drug|Methadone|
45632235|NCT04018859|Drug|Saline|intradermal injections to the eyebrows
45632236|NCT02346149|Other|glucose 20%|Intravenous infusion (0.75 ml / kg) over 1 min
45632237|NCT04091243|Drug|Romosozumab|Experimental drug for the treatment of glucocorticoid induced osteoporosis
45632238|NCT05254691|Procedure|Sprinting|"The ventilator mode is switched to PS ventilation. The level of PS is set to meet the level of PS set when the patient is ventilated in the SIMV-PS mode. The patient will be in the PS mode until he or she clinically shows increased work-of-breathing (tachypnoea and the presence of nasal flaring and intercostal and/or interjugular retractions indicate increased work of breathing). This sprinting is performed on the theory that the respiratory muscles can be slowly trained to sustain complete spontaneous breathing. Also, theoretically this sprinting allows a better global and regional distribution of the tidal volume in the lung."
45913712|NCT02025855|Drug|Placebo|
45632239|NCT02346227|Drug|AV2|"The virucide AV2 consists of a spray. It is a mixture of natural essential oil components (Carvone, Eugenol, Geraniol, Nerolidol) in equal volumes diluted 50% in olive oil (Olea europaea).~It is administered as a topical spray to the cervix while the subject is in the lithotomic position and fitted with a speculum. The manual spray applicator is positioned inside the anterior of the vagina and two pumps are applied. Each pump delivers 100 microliters of the solution."
45632240|NCT02346227|Drug|Placebo|"The placebo consists of 10% lemon (citrus limon) and 10% lime (citrus aurantifolia) in 80% olive oil.~It is administered as a one time (2 puffs) topical spray of 100 microliters on the cervix."
45771632|NCT01152697|Behavioral|Customized Adherence Enhancement|CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
45771633|NCT05161793|Device|Tele-Monitor DM|Remote monitoring of CGM data to identify, contact, and provide diabetes management for patients who are having episodes of hypoglycemia, hyperglycemia and/or difficulty using their CGM device.
45913713|NCT02025868|Behavioral|adherence reinforcement|Directly observed treatment at home (family or relatives DOT); pillboxes; phone calls; SMS; home visits; adherence reinforcement sessions by trained health workers.
45913714|NCT02025868|Drug|Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)|"Second-line ART regimen : ongoing regimen at the time of inclusion will be continued.~Third-line ART regimen : Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)"
45771634|NCT00002188|Drug|Alitretinoin|
45771635|NCT04637230|Diagnostic Test|Electrocardiogram analysis by Artificial Intelligence|1-channel electrocardiograms are collected to train an Artificial Intelligence in the automatic diagnosis of regular and irregular heart rhythms
45771636|NCT02421380|Drug|Hyperpolarized Pyruvate|
45771637|NCT01197547|Device|Genesys HTA|Genesys HTA Endometrial Ablation
45771638|NCT05105477|Device|AcumenTM HPI Software Feature|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
45771639|NCT05105477|Other|Non-protocolized Standard of Care|Non-protocolized standard of care to treat subjects
45913715|NCT02025881|Drug|Carboplatin + etoposide|"Carboplatin 160 mg/m2 Day 1 to day 5 As an intravenous infusion over 1 hour. Dilution in 5 % glucose saline or sodium chloride 9 mg/ml (0.9%).~Etoposide 100 mg/m2 D ay 1 to day 5 As an intravenous infusion over 1 hour. Dilution in physiological saline or 5 % glucose saline while not exceeding a concentration of 0.4 mg/ml etoposide in the infusion bottle."
45913716|NCT02025881|Drug|Thiotepa|Thiotepa 200 mg/m² Day-3 to day-1 As an intravenously infusion over 1 hour dilution in 200 ml/m² of 5% glucose saline or sodium chloride 9 mg/ml (0.9%)
45771640|NCT00002332|Drug|Thymopentin|
45913717|NCT02025881|Drug|Cyclophosphamide + Busilvex|"Cyclophosphamide Level 1 20 mg/kg/day Level 2 30 mg/kg/day Level 3 40 mg/kg/day Level 4 50 mg/kg/day~Busilvex < 9 kgs 0.8 mg/kg/dose - 3.2 mg/kg/day 9 à < 16 kgs 0.96 mg/kg/dose - 3.84 mg/kg/day 16 à 23 kgs 0.88 mg/kg/dose - 3.52 mg/kg/day > 23 à 34 kgs 0.76 mg/kg/dose - 3.04 mg/kg/day > 34 kgs 0.64 mg/kg/dose"
45913718|NCT02025920|Other|Salmon Group|
45913719|NCT02025920|Other|Cod Group|
45913720|NCT02025920|Other|Meat Group|
45913721|NCT02025933|Other|Salmon Group|The children are advised to eat at least 75g of salmon per serving, but no more than 150g
45913722|NCT02025933|Other|Cod Group|The children are advised to eat at least 75g of cod per serving, but no more than 150g
45771641|NCT05571644|Drug|mFOLFOXIRI + Cadonilimab|Cadonilimab（AK104）6mg/kg, intravenous d for 60 minutes, followed by mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
45632241|NCT03146039|Radiation|Radiation Therapy|"Whole pelvis radiation therapy will be delivered according to institutional standard of care.~SBRT is delivered with 5 fractions of 5.5-8 Gy prescribed to the high-risk CTV, with dose constraints identical to those for high dose rate, volume-directed brachytherapy. The patient will undergo arc therapy with a minimum of two arcs. On-line kV CBCT will be used to verify the isocenter prior to each arc delivery. Patients will be resimulated for SBRT boost planning."
45632242|NCT03146195|Other|Dynamic Magnetic resonance imaging|
45632243|NCT05254223|Other|Antiinflammatory Diet|The intervention group is recommended to follow a diet, inspired in mediterranean diet, rich in anti-inflammatory foods. They are provided with a table with the recommended foods as well as the frequency of daily/weekly/biweekly consumption.
45632244|NCT05254223|Other|Control Diet|The control group is recommended to follow their usual diet. Only in the case of detecting a serious nutritional problem the participant is recommended to correct it with the appropriate advice of the nutritionist.
45632245|NCT05254145|Diagnostic Test|Next Generation Sequencing|During the participants surgical procedure, a total of 3 ml of synovial fluid (joint fluid collected from the knee) will be collected per joint. Upon collection, the samples will be deidentified, stored on ice and shipped with a study ID number to MicroGenDx for Next Generation Sequencing.
45632246|NCT05254067|Device|Codman Enterprise 2 Vascular Reconstruction Device|a self-expanding nitinol, compliant, closed-cell, recapturable design that can be deployed by a single operator designed to assist in the stent-assisted coil embolization of intracranial aneurysms, specifically those that have a wide neck that would not otherwise maintain the coil embolization material within the aneurysm because of the wide opening at the base of the aneurysm.
45632247|NCT02345915|Other|Blood sample|
45632248|NCT02345915|Other|Electrocardiogram|
45632249|NCT02341001|Other|Daily text message of support|
45632250|NCT02340845|Biological|Bromelain and Comosain|Treatment of solid tumors in advanced stage of lung, breast, colon, ovary, cervix, uterus, prostatic, and liver
45632251|NCT02340533|Procedure|hysteroscopic endo-myometrial biopsy|
45771642|NCT05571644|Drug|mFOLFOX6|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycels before surgery
45771643|NCT03011281|Drug|Tofacitinib|
45771644|NCT00002194|Drug|Erythromycin|
45771645|NCT00002194|Drug|Nevirapine|
45771646|NCT00002194|Drug|Clarithromycin|
45771647|NCT02413736|Drug|Imatinib|Imatinib 400 mg/day
45771648|NCT00990509|Drug|Albumin|Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.
45771649|NCT00990509|Drug|Placebo|Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment
45913723|NCT02025933|Other|Meat Group|The children are advised to eat at least 75g of meat per serving, but no more than 150g
45913724|NCT02025959|Behavioral|Educating hospital staff on good sleep hygiene for patients and screening for sleep disorders|
45913725|NCT02025972|Procedure|Allogeneic umbilical cord blood therapy|
45771650|NCT00990509|Procedure|Brain MRI with and without contrast|"All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.~MRIs will be with and without contrast will be performed at:~Baseline~48 hours after enrollment(approximately Day 3)~96 hours after drug treatment begins (approximately Day 5)"
45771651|NCT00002338|Drug|Raluridine|
45771652|NCT01238341|Procedure|Endoscopic Retrograde Cholangiopancreatography (ERCP)|An Endoscopic Retrograde Cholangiopancreatography (ERCP) performed with an overtube in the evaluation of pancreatobiliary disease in patients with altered gastric anatomy
45771653|NCT04756622|Drug|N acetyl cysteine|N acetyl cysteine dissolved in water at a dose of 600 mg three times daily from day of transplant until neutrophil engraftment, or upon resolution of OM, whichever appears later.
45771654|NCT00002344|Drug|Azithromycin|
45913726|NCT02025998|Drug|Ibudilast|Ibudilast is a glial cell modulator that inhibits phosphodiesterases -4 and -10 and macrophage migration inhibitory factor.
45913727|NCT02025998|Other|Matched placebo|A matched placebo (suggar pill) will be administered as a control condition.
45771655|NCT04756778|Procedure|Aortic surgery +/- aortic valve replacement|Replacement of aneurysmal proximal thoracic aorta +/- replacement of diseased bicuspid aortic valve
45632252|NCT02340533|Device|ultrasound|two dimensional trans-vaginal ultrasonography
45632253|NCT02340455|Drug|Pregabalin_male|Pregabalin 150mg bid 1day Men
45632254|NCT02340455|Drug|Pregabalin_female|Pregabalin 150mg bid 1day Women
45632255|NCT02340455|Drug|Placebo_Men|Placebo durg
45632256|NCT02340455|Drug|Placebo_Women|Placebo_Women
45632257|NCT02345837|Device|endometrial sampling|injury to the endometrium
45632258|NCT02345837|Drug|clomiphene citrate|ovulation induction by 100mg clomiphene citrate
45771656|NCT00992927|Procedure|Capsule-Preserving Intra-articular Hydraulic Distension|Capsule-Preserving Intra-articular Hydraulic Distension (CPIHD) infuses as much volume as possible during the distension without rupturing the capsule.
45771657|NCT00992927|Procedure|Capsule-Rupturing Intra-articular Hydraulic Distension|Capsule-Rupturing Intra-articular Hydraulic Distension (CRIHD) infuses fluid into the joint space until the rupture of the capsule is observed.
45935353|NCT00042926|Procedure|lymphangiography|
45935354|NCT00042926|Procedure|radionuclide imaging|
45632259|NCT02346071|Behavioral|Acceptance and Commitment Therapy|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The ACT treatment is manualized and given in groups of 7-8 patients with 9 3-hour sessions (i.e. 27 hours in total) over a period of 3 months and one follow up meeting (3 hours) three months after end of treatment. The parents and other relevant close relatives (e.g. siblings, boy/girlfriends) to the patient participate in a workshop where ACT principles are applied. One individual consultation with the adolescent and parents will be offered at the end of 8 sessions of group therapy."
45632260|NCT02346071|Other|Enhanced Usual Care (EUC)|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The consultation is according to a manual and includes psycho-education related to the diagnosis of multiorgan BDS, health promoting recommendations and counselling regarding existing medicine or other treatment. An individualized treatment plan will be sent to the patient's general practitioner, to optimize management in primary care and support by social services."
45632261|NCT02345993|Drug|Extra fine Formoterol/Beclomethasone|"standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40, 60 minutes"
45632262|NCT02345447|Drug|Herbal-based medication|Aconitum napellus, Capsicum annuum; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum; Hydrastis canadensis; Iodum; Natrium tetraboracicum; Sambucus nigra; Sanguinaria canadensis
45632263|NCT02345447|Drug|Placebo|Aqueous ethanol solution non-distinguishable from verum
45632264|NCT05253989|Device|VR Intervention|VR Device that allows a patient to play games based on the EMG activity in the upper limb.
45632265|NCT05253989|Device|FES|Functional Electrical Stimulation used to increase motor excitability whilst engaging in VR rehabilitation
45632266|NCT05253599|Device|Isokinetic training|The knees were flexed slightly at 15 degrees, and the fixation straps were tied around the popliteus, thigh, pelvis, chest and scapula to prevent the tricky movements.
45632267|NCT05253599|Device|Virtual reality training|"Training was given in the sitting position which provides challenges to the balance activities of the participant. The game which was used in the current study was a shooting game, which consists of the subject sitting on the virtual platform and visualizing the game on the display screen. The game was executed and controlled by moving the trunk back and forth and left and right according to the signs. Participants can perform all the six movements of their spine within their pain limits.~The level of difficulty of the exercises was increased by graded activity, in which the activities were gradually getting difficult and harder as participants required more muscle activity and movement."
45632268|NCT05253599|Other|Exercises|They performed these exercises 10-15 reps/day for 5 days per week for 4 weeks. Stretching was focused on each muscle group for 3 repetitions for 10 seconds per muscle group (Hamstring, Hip flexors and Lumbar Extensors).7 A home-based exercise protocol was prescribed to all the subjects to perform at home. All the subjects in three groups were undergone hot pack therapy for 20 mins and ultrasound with a frequency of 1 Mhz and intensity of 1.5 W/cm2 in continuous form for five minutes.
45632269|NCT02345681|Drug|Furosemide|
45632270|NCT02345525|Behavioral|mCIMT|"This intervention is based on 3 main aspects:~intensive training of functional tasks with the affected arm (massed practice)~constraint of the un-affected hand through a mitt~shaping techniques designed to transfer gains to the real world activities~The 2 hours massed practice will be performed in a outpatient clinic with a supervision of PT."
45632271|NCT02345525|Behavioral|hCIMT|"This intervention is based on 3 main aspects:~intensive training of functional tasks with the affected arm (massed practice)~constraint of the un-affected hand through a mitt~shaping techniques designed to transfer gains to the real world activities~In this group, a comprehensive set of the material necessary to perform the training at home and a booklet containing an explanation of the exercises that can be done will be provided to subjects.~In addition, 2 hospital visits will be scheduled to instruct subjects and caregivers on the training and to update activities (1 visit at the beginning + 1 visit after 1 week)."
45632272|NCT02345291|Drug|NRD135S.E1|A small chemical entity for treatment of neuropathic pain NRD135S.E1
45632273|NCT02345291|Drug|Placebo to match NRD135S.E1|Placebo capsule to match NRD135S.E1 capsules
45632274|NCT02340611|Drug|Olaparib|Polyadenosine 5'diphosphoribose polymerase (PARP) Inhibitor
45632275|NCT02340611|Drug|Cediranib|Vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor that is a potent inhibitor of all three VEGF receptors (VEGFR-1, -2 and -3)
45771658|NCT04756466|Dietary Supplement|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
45771659|NCT04756466|Dietary Supplement|Lactobacillus|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
45771660|NCT01198327|Drug|ranibizumab|Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart.
45771661|NCT01198327|Other|Peripheral Laser|Areas of nonperfusion identified on wide field angiograms will receive laser, if the patient is continuing to require ranibizumab injections.
45771662|NCT00002200|Drug|Abacavir sulfate|
45771663|NCT02408588|Other|Pulse oximeter|Place a pulse oximeter on the subject which will record the pulse oximeter waveform.
45771664|NCT02407808|Drug|THC|Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.
45771665|NCT02407808|Drug|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
45771666|NCT00002350|Biological|APL 400-003|
45771667|NCT04694950|Procedure|Usual care|Intravenous morphine according to clinician´s discretion.
45771668|NCT02405234|Device|Carbon Modular Radial Head replacement|'Carbon Modular Radial Head replacement: The Ascension Radial Head is made of pyrocarbon, a material that testing has shown to be both wear resistant and biocompatible and has been used in surgical implants for years. The introduction of the pyrocarbon head should alleviate the problems associated with wear debris and fragmentation experienced with the silicone radial spacer.
45632276|NCT02340377|Device|ELITE 3 HQ|The pill is about the size of a multivitamin, is coated with special medical plastic, and is easy to swallow. The pill sends radio signals to a small recording device that participants wear that send a signal to a monitor and records the participant's internal body temperature. The pill will exit the participant's body in one of his/her bowel movements approximately 1-5 days after ingestion. Pills are not reused.
45771669|NCT02405234|Device|Metal Radial Head replacement|Metal Radial Head replacement:The Ascension® Modular Radial Head (MRH) is an anatomically designed, single-use, modular prosthesis designed for replacement of the proximal end of the radius. FDA cleared this device for commercial distribution under 510(k) K032686. It is made from medical grade cobalt chromium alloy meeting ASTM F1537. Head components are available in six sizes and stem components are available in four sizes are interchangeable and assembled with a taper connection.
45771670|NCT00002356|Drug|Fomivirsen sodium|
45771671|NCT00994175|Drug|Pioglitazone|
45771672|NCT00994175|Drug|Placebo|
45771673|NCT00002206|Drug|Adefovir dipivoxil|
45771674|NCT02403986|Device|Restylane Vital Skinboosters Lidocaine|
45632277|NCT02345603|Procedure|Cryo-therapy|Cryo-therapy for about 60 seconds applied circumpherentially to each renal artery
45632278|NCT02340143|Other|Control|Marketed partially hydrolyzed cow's milk protein infant formula
45632279|NCT02340143|Other|Investigational|Partially hydrolyzed cow's milk protein infant formula with a probiotic
45632280|NCT03145883|Other|Home-Based Aerobic Exercise|
45771675|NCT01239355|Drug|Akt Inhibitor MK2206|Given PO
45771676|NCT01239355|Other|Laboratory Biomarker Analysis|Correlative studies
45771677|NCT02168153|Other|Chiropractic Manipulative Therapy|Participants will receive chiropractic spinal manipulative therapy consisting of High velocity low amplitude (HVLA) spinal manipulative procedures. These procedures are typically associated with a quick manual thrust and a cavitation sound. For the cervical spine, a procedure called a cervical index pillar push, thoracic manipulation will occur with unilateral or bimanual contacts in the prone or supine positions and lumbar/pelvis manipulation will be performed with a procedure referred to as side-lying or side-posture.
45632281|NCT02340065|Procedure|standard colonoscopy|examination of the colon with a conventional colonoscope
45771678|NCT02168153|Other|Wait-list|Participants randomized to the wait-list control group will complete questionnaires and perform the same study procedures as those randomized to the chiropractic manipulative therapy arm. After completing the required 2-week waiting period, those who wish to receive chiropractic manipulative therapy will be eligible to schedule treatment visits.
45771679|NCT04389476|Other|Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19)|"Establish standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19) for the different tiers of medical staff, patients, and community residents.~Then explore the psychological impact and mental disabilities under the intervention and controlling related factors."
45771680|NCT00002212|Drug|Bexarotene|
45771681|NCT03011203|Other|physical exercise|In session II and III participants will perform an exercise test on a bicycle inside and outside the MR scanner.
45913728|NCT02026037|Behavioral|Brief Treatment for Acutely Burned Patients (BTBP)|Brief Treatment for Acutely Burned Patients (BTBP) adapts CBT principles that have been validated with non-burn trauma survivors to the treatment of hospitalized burn patients. BTBP consists of three 1 to 1½ hour sessions per week for two weeks, as well as two sessions for family members or partners/spouses.
45913729|NCT02026050|Procedure|intraarticular dexamethasone|2ml 8 mg dexamethasone administration for intraarticular
45913730|NCT02026050|Procedure|interscalene dexamethasone|2ml 8 mg dexamethasone administration interscalene brachial plexus added 30 ml 0.5 % bupivacaine
45913731|NCT02026050|Procedure|serum phsyologic|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2ml serum phsyologic and after surgery 10 ml serum phsyologic administration for intraarticular
45913732|NCT02026076|Other|mechanical lumbar traction|15 minutes at up to 50% body weight lumbar traction in supine hooklying with split table open
45913733|NCT02026089|Biological|Varicella vaccine|Varivax 0.5ml subcutaneous injection
45913734|NCT02026102|Behavioral|ICD Decision Aid Toolkit|Research assistants will provide patients with a toolkit of decision aids. Participants will have the option of using all of the decision aids or just some of the decision aids.
45935355|NCT00042926|Procedure|sentinel lymph node biopsy|
45632282|NCT02340065|Procedure|Endocuff-assisted colonoscopy|examination of the colon with Endocuff-assisted colonoscopy
45632283|NCT03145649|Other|Dietary therapy or insulin injection|
45632284|NCT04086329|Device|Nanosensor|"The purpose of the study is to test a device called a nanosensor, which measures oxygen levels (a proxy of mitochondrial function) in muscle. The nanosensor has not been tested in humans nor has it been approved by the FDA.~The study nanosensor measures 1.8 mm width x 6 mm length x 0.3 mm depth. Placement of the sterilized nanosensor involves a small incision for manual placement of the nanosensor in muscle forearm tissue."
45632285|NCT02345213|Drug|E2020|E2020 tablets will be orally administered once daily after breakfast
45632286|NCT02345213|Drug|Placebo|Matching placebo tablets will be orally administered once daily after breakfast
45632287|NCT02339753|Drug|Carboplatin|Blood sampling will be done at the time before administration (0hr pre-dose), 1hr, 2hr, 5hr for pharmacokinetic study.
45632288|NCT02345135|Procedure|Blood collection|In all patients with Ataxia telangiectasia blood was collected at each visit date to determine blood count, lymphocyte subpopulation count and immunoglobulin levels in serum (IgA, IgG, IgM, IgE), as well as alpha feto protein (AFP).
45632289|NCT02345135|Procedure|Lung function measurement|In all patients - Ataxia telangiectasia and healthy controls - a lung function measurement was done to determine vital capacity (VC), forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF) and Tiffenau index.
45771682|NCT02402192|Drug|Corifollitropin alfa|
45771683|NCT00002362|Drug|Abacavir sulfate|
45771684|NCT00002362|Drug|Efavirenz|
45771685|NCT00002362|Drug|Emtricitabine|
45771686|NCT00002362|Drug|Stavudine|
45771687|NCT02168309|Drug|Labetalol|Titrate up for blood pressure control
45632290|NCT02345135|Behavioral|Symptom diary|All patients - Ataxia telangiectasia and healthy controls - were requested to keep a symptom diary for the months September to March of the years 2012/2013 and 2013/2014 to determine days with symptoms as coughing during day and night, cold and fever, as well missing days at kindergarten/school/work, intake of medication (especially antibiotic treatment) and hospitalisations.
45632291|NCT02345057|Drug|CS-3150|
45632292|NCT02345057|Drug|placebo|
45632293|NCT02339597|Procedure|Automatic Positive Airway Pressure (APAP) initiation|
45632294|NCT02339675|Other|conventional MS rehabilitation|assessment pre and post conventional MS rehabilitation
45632295|NCT02339519|Device|LMA CLASSIC|Classic LMA consists of a mask with a surrounding inflatable bag compatible to the shape of the hypopharynx and a tube that has a 30° angle with a mask.
45632296|NCT02339519|Device|LMA FASTRACH|Fastrach LMA has similar features to the LMA Classic, but it is designed to provide upper airway during intubation via blind intubation or fiberoptic assistance. It has a rigid handle that allows one-handed insertion, removal or adjustment.
45632297|NCT02339519|Device|LMA SUPREME|Supreme LMA is a novel, sterile, single use, new generation supraglottic airway device which provides more rapid and higher volume gas passage through airway and can be inserted in a rapid and safe manner.
45632298|NCT02339441|Drug|Methotrexate|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, either oral or subcutaneous with a target dose of 20-25mg weekly.
45632299|NCT02339441|Drug|Mycophenolate mofetil|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study,recommended dose 500 mg twice daily for 2 weeks increasing to 1gm twice daily.
45632300|NCT02339441|Drug|Cyclophosphamide|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, recommend use (i) IV. Minimum monthly dose 500mg/m2 with a recommended duration of 6-12 months. (ii) Oral. 1-2mg/day with a recommended duration of 12 months.
45632301|NCT02344823|Drug|Vardenafil|per oral intake of 10mg Vardenafil once daily
45632302|NCT02344823|Procedure|HVPG (Hepatic venous pressure measurement) baseline|HVPG measurement day 1
45632303|NCT02344823|Procedure|HVPG (Hepatic venous pressure measurement) day 7|HVPG measurement day 7
45632304|NCT02344823|Behavioral|IIEF 5 (International Index of Erectile Function) questionaire baseline|IIEF 5 questionaire to define level of erectile dysfunction at baseline
45632305|NCT02344823|Behavioral|IIEF 5 (International Index of Erectile Function) questionnaire at study phase end|IIEF 5 questionaire to define level of erectile dysfunction at end of study phase
45632306|NCT02344823|Drug|Placebo intake once daily|
45771688|NCT02168309|Drug|Nifedipine|Titrate up to achieve blood pressure control
45632307|NCT03145961|Drug|Pembrolizumab|200mg intravenous infusion
45632308|NCT02339207|Drug|AL-335 matching placebo|
45632309|NCT02339207|Drug|AL-335|
45632310|NCT02339363|Behavioral|Sitting Meditation|4 weeks Sitting Meditation
45632311|NCT02339363|Behavioral|Hatha yoga|4 weeks of Hatha yoga
45632312|NCT03145727|Device|Placebo Group|In this group, the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the opposite arm of the chemotherapy infusion, but in this group the electrical stimulation will be performed just by 10 seconds and turn off for all reminiscent time of the protocol.
45632313|NCT03145727|Device|Low Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
45632314|NCT03145727|Device|High Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
45632315|NCT02339051|Behavioral|Jumping on one leg|
45632316|NCT02338895|Device|Ultrasound|Ultrasound of inferior vena cava and kidneys
45632317|NCT02344511|Drug|Dalbavancin|Drug
45632318|NCT02344511|Drug|cefazolin, nafcillin, oxacillin or vancomycin|Standard of Care
45632319|NCT02344589|Drug|Lidocaine|used for the active blocks
45771689|NCT00002368|Drug|Nevirapine|
45771690|NCT00002368|Drug|Lamivudine|
45632320|NCT02344589|Drug|Saline|used for the placebo-block
45632321|NCT02344667|Radiation|Stereotactic Body Radiotherapy|
45632322|NCT02338583|Device|Echelon Flex™ 45 and 60 Powered ENDOPATH® Stapler Articulating Endoscopic Linear Cutter|
45632323|NCT02338661|Device|SBG hip stem|
45771691|NCT01894724|Device|NeuroSave device|
45771692|NCT01895582|Other|Blood samples|"4 blood tubes of lithium heparinate (5ml) 3 blood tubes of QTF-G-IT (1ml)~1 blood dry tube (5ml)"
45771693|NCT04746014|Diagnostic Test|Clearblue Pregnancy Test|Urine Pregnancy Test
45771694|NCT00002218|Drug|CI-1012|
45771695|NCT01199965|Drug|MAP0004|1.0mg MAP0004 via inhalation at Visit 2 or 3 as per protocol
45771696|NCT01199965|Drug|IV DHE|IV DHE administered at Visit 2 or 3 as per protocol
45632324|NCT02338739|Behavioral|REC; Outreach if Failure|Routine education and counseling (REC) services, delivered per Kenya Ministry of Health Guidelines; followed by standard of care (SOC) outreach to encourage return to clinic for patients 14 days late for a scheduled visit in year 1.
45632325|NCT02338739|Behavioral|REC; SMS + Voucher if Failure|Routine education and counseling services, delivered per Kenya Ministry of Health (MOH) Guidelines; followed by SMS text messages for patients and reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
45632326|NCT02338739|Behavioral|REC; Navigator if Failure|REC services, delivered per Kenya MOH Guidelines; followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
45632327|NCT02338739|Behavioral|SMS; Outreach if Failure|SMS text messages for patients; followed by SOC outreach for patients 14 days late for a scheduled visit
45771697|NCT00995501|Drug|Dexamethasone Sodium Sulfate|8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
45771698|NCT00995501|Drug|Insulin|Insulin to maintain blood glucose 80-110 mg/dl.
45632328|NCT02338739|Behavioral|SMS; Outreach if Failure; Stop SMS if Success|SMS text messages for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
45632329|NCT02338739|Behavioral|SMS; SMS+Voucher if Failure|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
45632330|NCT02338739|Behavioral|SMS; SMS+Voucher if Failure; Stop SMS if Success|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1, and discontinuation of SMS text messages if never 14 days late
45632331|NCT02338739|Behavioral|SMS; Navigator if Failure|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
45632332|NCT02338739|Behavioral|SMS; Navigator if Failure; Stop SMS if Success|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
45632333|NCT02338739|Behavioral|Voucher; Outreach if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit
45447814|NCT03552328|Other|Lunch with Medical Student|Each student will bring provided lunches once a week to their elder participant's residence, and they will share lunch together for an hour once a week for six weeks. Students will enroll as Meals on Wheels volunteers and participate in the Meals on Wheels pre-program training. On the day of their scheduled lunch, students will first arrive at the Meals on Wheels designated meal-drop location and pick up two lunches, one for them and one for their assigned elder. They will then drive to their assigned elder's residence and eat lunch with them for one hour.
45632334|NCT02338739|Behavioral|Voucher; Outreach if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
45632335|NCT02338739|Behavioral|Voucher; SMS+Voucher if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit
45632336|NCT02338739|Behavioral|Voucher; SMS+Voucher if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
45632337|NCT02338739|Behavioral|Voucher; Navigator if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
45632338|NCT02338739|Behavioral|Voucher; Navigator if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
45632339|NCT02338817|Device|Diabetes Sentry|The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
45632340|NCT03145337|Biological|FlexHD ADM (Cohort A)|Tissue assisted breast reconstruction with FlexHD pliable perforated ADM
45632341|NCT03145337|Biological|AlloDerm RTU ADM (Cohort B)|Tissue assisted breast reconstruction with AlloDerm RTU perforated ADM
45632342|NCT02344433|Behavioral|VICKY|Relational agent/virtual counselor
45632343|NCT02344433|Behavioral|MFHP|US Surgeon General's family history tool
45632344|NCT02338505|Device|Telelap ALF-X|"Patients placed in the dorsal lithotomic position with both legs supported in Allen stirrups with a Trendelenburg tilt. After achieving pneumoperitoneum (12mmHg) through a trans umbilical open access technique, intra-abdominal visualization was obtained with a 10mm 0° HD 3D telescope. During the trocar placement the operative room nurses supported the surgeon in the docking procedures approaching the robotic arms to the operative table, in places established for pelvic surgery. The cockpit is located in one corner of our square shape room; the operative table is surrounded by the three robotic arms unit.~Through the teleassisted operative ports we could make use of several type of instruments. Movements of both instruments and optic were completely carried out by the surgeon from the cockpit according to the needs of the procedure."
45632345|NCT02338427|Other|Immunohistochemistry|
45632346|NCT02338427|Other|Proteomic analysis|
45632347|NCT02344277|Device|S-ICD System (implantable defibrillator)|"The subjects will be symptomatic or asymptomatic Brugada patients with Indication for ICD replacement. Patients should be follow first at 1 month and then every 6 months according to the recent ACC/AHA/HRS guidelines60, for a period of 5 years until remote monitoring became available for S-ICD.~Visit to 4 week post-implantation: Vital status, Clinical assessment data: weight; height; blood pressure; NYHA class, Exercise test will be performed to control sensing vectors during exercise, Electrocardiogram, Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form. Visit every 6 months post-implantation to 5 years follow-up visit: Vital status, Clinical status (e.g.NYHA) , Electrocardiogram , Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form, Current status of S-ICD system."
45632348|NCT05002595|Drug|H. pylori eradication|Antimicrobial agents for H. pylori eradication
45632349|NCT02343965|Other|Touch-massage|
45632350|NCT03145493|Device|drainage|Administration of IV tranexamic acid at the moment of anesthetic induction (1g) and at tourniquet release (1g), installing a suction drain
45447815|NCT03552328|Other|Control|Students will not bring provided lunches to an elder participant's residence. The elder participants in this arm will simply continue receiving daily meals from Meals on Wheels with no accompanying student.
45447816|NCT03552952|Other|No intervention|No intervention
45447817|NCT02123602|Other|core stabilization|
45771699|NCT00995501|Drug|anesthesia management|Light anesthesia to maintain BIS about 55
45771700|NCT00995501|Other|Dexamethasone - placebo|8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
45771701|NCT00995501|Other|Insulin - Placebo|Insulin to maintain blood glucose 180-200 mg/dl.
45771702|NCT00995501|Other|Anesthesia management -Placebo|Deep anesthesia to maintain BIS about 35
45771703|NCT02397200|Dietary Supplement|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
45632351|NCT02338271|Other|autologous adipose derived mesenchymal stem cell|autologous adipose derived mesenchymal stem cell (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) and Tissuefill (hyaluronic acid derivatives) 1mL/syringe
45632352|NCT02344043|Device|Near infrared spectroscopy|This device uses near infrared spectroscopy to measure tissue oxygen levels (0-100%). The sensors are placed on the subjects' forehead to measure brain tissue oxygenation
45632353|NCT02343887|Other|neuropsychological tests|
45632354|NCT02343887|Other|STAI-Y scale for anxiety|
45632355|NCT02343887|Other|Beck scale for depression|
45632356|NCT02343887|Other|without intervention|
45632357|NCT02338115|Drug|Paclitaxel 80mg/m2 weekly x 12 weeks|
45632358|NCT02343809|Other|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. The hook is deeply applied following the intermuscular septum between the muscles with an anatomical of functional relationship with the painful structure in order to release adherences between musculoskeletal structures.
45632359|NCT02343809|Other|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
45771704|NCT02397200|Dietary Supplement|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals
45771705|NCT00002374|Drug|Ritonavir|
45447818|NCT02123602|Other|lower extremity training only|
45632360|NCT02343809|Other|Protocolized Physiotherapy|Protocolized physiotherapeutic treatment: Three weeks fo daily stretching exercises, ultrasound and analgesic electrotherapy
45632361|NCT03112109|Other|'New care'|Frail elderly receiving care within new organisational models delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform) as provided by pilot sites individually.
45632362|NCT02039297|Other|Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation|Computer aided checklist and rounding tool implemented in the Intensive care unit environment
45632363|NCT02343731|Other|Introduction of a dog into the home|Participants will foster dogs from the HSSA for three months while they are in the study.
45771706|NCT00002374|Drug|Nelfinavir mesylate|
45447819|NCT02120872|Drug|Platelet rich fibrin and simvastatin|Three wall intrabony defect sites treated with Open Flap Debridement. 0.1 mL prepared SMV gel (1.2 mg/0.1 mL) was mixed with PRF. The PRF - SMV mixture was delivered to the defect.
45447820|NCT02120872|Biological|Platelet rich fibrin|Three wall intrabony defect sites treated with Open Flap Debridement. PRF was placed into the intrabony defect.
45632364|NCT02337803|Behavioral|Strength Training Program|The strength training program consists of 6 exercises using resistance bands three times a week
45632365|NCT02337803|Behavioral|Usual Care|Will continue daily physical activity and complete surveys online
45632366|NCT02337881|Drug|nifedipen|The protocol for nifedipen in our units consists of 20 mg orally stat, followed by 10 mg orally every 6-8 hours for 48 to 72 hours as needed
45632367|NCT02337881|Drug|Sildenafil|sildenafil citrate will be administered vaginally in a dose of 25mg at 8 hourly intervals and both medications will be continued for 48-72 hours as indicated.
45632368|NCT02337257|Drug|Cholecalciferol|subjects will receive one pill per day which contains 4000 IU/d for 16 weeks
45632369|NCT02337257|Drug|Placebo|subjects will receive placebo one pill per day for 16 weeks
45632370|NCT02337569|Drug|NPC-02|
45632371|NCT02337569|Drug|Placebos|
45632372|NCT02337179|Procedure|Voluntary medical male circumcision|Male Circumcision Under Local Anesthesia using the Forceps Guided Method
45632373|NCT02337647|Other|DCDC App|The DCDC app is an experimental software that allows users to map their visual distortions on a tablet computer.
45632374|NCT02337101|Other|Enhanced Usual Care (EUC)|All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.
45771707|NCT00002374|Drug|Saquinavir|
45771708|NCT00002374|Drug|Stavudine|
45771709|NCT03011047|Procedure|endoscopic trans-antral approach|new surgical approach to repair the orbital floor fractures through the maxillary sinus
45771710|NCT03011047|Procedure|trans-orbital surgical approach|through the lower eyelid below the eyelashes ,then down to bone the herniated orbital content will be reduced through this incision traditional surgical approach to repair orbital floor fractures
45771711|NCT01508390|Radiation|CyberKnife Boost|21 Gy in 7 Gy per day, 3 fractions, Every other day
45771712|NCT00002380|Drug|Nelfinavir mesylate|
45771713|NCT00002380|Drug|Saquinavir|
45771714|NCT00002386|Drug|Indinavir sulfate|
45771715|NCT00002386|Drug|Lamivudine|
45771716|NCT00002386|Drug|Stavudine|
45771717|NCT00002386|Drug|Zidovudine|
45771718|NCT00002386|Drug|Zalcitabine|
45447821|NCT02120872|Procedure|Open Flap Debridement alone|Three wall intrabony defect sites treated with Open Flap Debridement only. No PRF or SMV was delivered to the defect.
45447822|NCT03552016|Drug|Oral Riboflavin|The intervention doses will be 200 mg oral riboflavin and 400 mg oral riboflavin doses; the placebo dose will be 0 mg of oral riboflavin
45447823|NCT02788474|Drug|nintedanib|
45447824|NCT02788474|Drug|placebo|
45447825|NCT02123836|Biological|NK cells|"7 days of preparatory treatment are given before the NK cell infusion. Chemotherapy will be given over 6 days. This chemotherapy will promote donor NK cells engraftment. After which, a drug called Interleukin-2 (IL-2) will be given as an injection just under the skin three times per week for at least 2 weeks (total of 6 doses). This treatment is used to help keep the donor NK cells alive.~Blood cells will be collected from an eligible and suitable family donor 10 days before infusion. The collection sample will be processed to remove red blood cells and as many T-cells as possible. T-cells from the donor might cause these donor cells to attack the body, usually the skin, liver, and intestines.~NK cells will be activated in the National University Hospital lab and ready for infusion on Day 0.~The NK cells will then be infused into the vein, through a peripheral catheter."
45447826|NCT02118142|Dietary Supplement|Betaine|6 gram one-time dose of betaine delivered in encapsulated form with an unsweetened beverage
45632375|NCT02337101|Behavioral|EUC + Early intervention programme|"All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.~The early intervention programme will be interdisciplinary and will mainly be provided by an occupational therapist and a physiotherapist under supervision of a neuropsychologist. It will be based on psychoeducation and principles from Cognitive Behavioral Therapy and Graded Exercise Therapy and targeted to patients' individual goals.~Patients will receive 8 weekly treatment sessions (3 group based and 5 individual sessions). Intervention will start approximately 4-5 months after the concussion."
45632376|NCT02337413|Drug|Polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and then will be stepped down to 0.8gr/kg subsequently and tapered accoriding to stool consistency and frequency.
45632377|NCT02337413|Behavioral|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavioral therapy including active sitting on the toilet to attempt defaction following meals.
45632378|NCT02337413|Behavioral|Urotherapy|Patients will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
45447827|NCT02118142|Dietary Supplement|Dextrose|6 gram one-time dose of dextrose delivered in encapsulated form with an unsweetened beverage
45632379|NCT02332265|Other|Support to Able-Bodied Vulnerable groups to Achieve Food Security (SAFE)|The SAFE program was developed & implemented from Jan. 2008-Dec. 2010 by CARE-Malawi, a country office of CARE International, a large NGO. SAFE participants were selected by CARE-Malawi. SAFE was designed to address intertwined structural issues contributing to HIV susceptibility: food insecurity, poverty, gender inequity and ineffective governance. SAFE was implemented in 3 geographic subdivisions (Njombwa, Kaomba, & Mwase) of Kasungu District, located in west-central Malawi. It was funded primarily by the European Commission & partially by the Austrian Development Cooperation. SAFE had 4 main components: 1) improving farming practices & sustainable agriculture through Farmer Field Schools, 2) increasing access to savings and investment through Village Savings & Loans Groups, 3) building capacity of local governance structures & 4) integrating HIV education & gender empowerment into programs through training & education. Details: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082534/.
45771719|NCT00002386|Drug|Didanosine|
45771720|NCT01942694|Dietary Supplement|Vitamin D (Cholecalciferol)|Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.
45771721|NCT01942694|Other|Placebo|Administered as one soft-gel pill daily by mouth
45771722|NCT01153711|Drug|BI 1744|10 mcg solution for oral inhalation
45771723|NCT01153711|Drug|BI 1744|10 mcg solution for oral inhalation
45447828|NCT02118220|Other|Concussion Questionnaire|
45771724|NCT01153711|Drug|Ketoconazole|400 mg tablet
45771725|NCT01153711|Drug|Ketoconazole|400 mg tablet
45771726|NCT05752006|Other|Repeated trunk flexion|A 60-min intermittent trunk flexion protocol. Participants will sit on a standard height sit, with their knees bent at approximately 90° with their hands crossed on their chest. They will perform 40 sets of 60 s of maintaining a flexed position, interspersed with 30 s of rest. Participants will achieve the flexed position by tilting the pelvis posteriorly and leaning forward. During rest, participants will sit up straight without leaning on the support.
45771727|NCT02168855|Drug|active nicotine gum|2 mg, standard over-the-counter nicotine replacement therapy gum
45771728|NCT02168855|Behavioral|Standard behavioral therapy|Standard behavioral therapy for smoking cessation
45771729|NCT01938326|Procedure|Approach Method|SIDG : 1 incision (umbilicus 2.5cm) TLDG : 5 incisions (12mm ports X 3, 5mm ports X 2, umbilicus extension up to 3cm for specimen delivery)
45771730|NCT05751850|Drug|HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate|HR070803 in combination with oxaliplatin, 5-fluorouracil, calcium folinate
45771731|NCT05751850|Drug|nab-paclitaxel; gemcitabine|nab-paclitaxel in combination with gemcitabine
45447829|NCT03552874|Other|The Performance of Upper Limb Questionnaire (PUL)|
45447830|NCT02118376|Drug|Exenatide|5ug bid,Subcutaneous injection
45447831|NCT02118454|Behavioral|Daily IVR Calls Intervention|
45447832|NCT02118454|Behavioral|Weekly IVR Survey Only|
45935356|NCT00042926|Radiation|technetium Tc 99m sulfur colloid|
45935357|NCT00122941|Dietary Supplement|multiple micronutrients|
45935358|NCT00077688|Drug|TOCOSOL Paclitaxel|
45935359|NCT00397319|Drug|Growth Hormone|
45935360|NCT00123019|Behavioral|Exercise and diet|Advice and measurement only
45935361|NCT00123019|Behavioral|Diet, Weight Reducing|Measurement, advice, environmental and behavioral group interventions
45935362|NCT00123019|Behavioral|Level 1|Annual assessment of weight and waist circumference, questionnaire on work, health issues, advice on diet, physical activity and other health issues.
45771732|NCT01938248|Drug|Apixaban|apixaban at a dose of 5 mg twice daily (2.5 mg twice daily if 2 or more of: age > 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)
45632380|NCT02332109|Device|ODM 5|ODM 5 is a CE-certified, preservative-free, hyperosmolar ophthalmological solution containing 5% sodium chloride and 0.15% sodium hyaluronate recommended for the reduction of corneal edema. The patient will use ODM 5 on a daily basis in accordance with the instructions for use and as recommended by the investigator over a period of 8 weeks.
45632381|NCT02332343|Other|No intervention - Natural history study|
45632382|NCT02337023|Radiation|Brain scintigraphy with injection of Neurolite® (ECD)|Brain scintigraphy with injection of Neurolite® (ECD) 1 injection
45632383|NCT04477811|Drug|Vitamin K1|vitamin k1 tablets
45771733|NCT01938248|Drug|aspirin|aspirin 81 mg once daily
45632384|NCT04477811|Drug|Vitamin k2|vitamin k2 45 ug tablets twice daily
45632385|NCT04477811|Other|placebo|placebo tablets
45632386|NCT02332031|Drug|Sorafenib (Nexavar, BAY43-9006)|Single dose of 400 mg orally on Period 1 Day 1 and Period 2 Day 11
45771734|NCT02168933|Device|308 nm excimer laser|Biweekly treatments with 308 nm excimer laser for a total of 8 weeks
45771735|NCT02168933|Device|Sham laser|Sham laser treatment to the control side biweekly for a total of 8 weeks.
45771736|NCT00002230|Drug|Hydroxyurea|
46070037|NCT00804817|Behavioral|SCION-HSCT program|"Intervention: Patients receive SCION-HSCT program a multi-modular somatic-psycho-social care intervention. consisting of 3 modules: Activity Enhancement, Oral Mucositis Prevention and Mal-Nutrition Avoidance.~The intervention will be conducted by specially trained oncology nurses and will include components of knowledge, skills training, and coaching to improve self management. The intervention starts at admission followed by booster sessions during the period of hospitalization. Patients will be scheduled to an individualized physical activity program incl. endurance training on light level 60-80% of max heart rate. Additionally the patient will be counselled to follow a mouth care protocol based on self assessment of the mouth to prevent oral mucositis. Both interventions are accompanied by a systematic screening of the nutritional situation. All three interventions are aimed to improve patients' adherence to self management strategies of side effects."
45447833|NCT02123914|Other|Aerobic exercise with Vit. C|"walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week combined with taking vitamin C supplemented daily with an oral dose of 2,000 mg 2 times/day for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
45632387|NCT02332031|Drug|Levothyroxine|Single dose of 300 mcq orally from Period 2 Day 1 to Period 2 Day 14
45632388|NCT03112031|Drug|Tamoxifen|Tamoxifen will be given orally in a dose of 300mg/day for the first 14 days following randomization. It will be administered by nasogastric tube where patients are unconscious. The Tamoxifen will be administered in the morning combined with amphotericin and fluconazole dose.
45632389|NCT03112031|Drug|Amphotericin B|Patients will receive amphotericin 1mg/kg/day i.v. once daily orally for the first 2 weeks.
45771737|NCT00002230|Drug|Efavirenz|
45771738|NCT00002230|Drug|Stavudine|
45771739|NCT00002230|Drug|Didanosine|
45771740|NCT01239511|Drug|green tea polyphenols (STA-2)|2 capsules t.i.d., after meal
45771741|NCT05751772|Other|Patient therapeutic education|"The pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients is made by a clinical pharmacist and includes:~Targeted education on patient needs related to heart failure, heart failure medications and self-care;~a pre-discharge interview to consolidate key teaching messages and prepare the patient for their discharge treatment plan;~a telephone call the week of discharge to ensure pharmaceutical follow-up between hospital care and return home (continuity of care, transition of care)."
45771742|NCT03009877|Device|Optiflow F&P 850™ System|"Optiflow™ (Fisher & Paykel Healthcare Limited, East Tamaki, Auckland-New Zealand) offers the ability to comfortably deliver a complete range of oxygen concentrations and flows to extend the traditional boundaries of oxygen therapy.~This will be placed on the patient immediately upon entering the operating room for 5 minutes, at 50 liters per minute then increased to 70 liters per minute after induction."
45771743|NCT03009877|Device|facemask|We will apply the facemask to the patient immediately upon entering the operating room to pre-oxygenate for five minutes.
45771744|NCT03009877|Drug|Rocuronium|Rocuronium will be administered after the ability to mask ventilate is determined.
45771745|NCT03009877|Drug|Propofol|Propofol infusion 50 micrograms to 150 micrograms will be administered immediately on induction to maintain sedation throughout apneic oxygenation.
45771746|NCT03009877|Drug|Fentanyl|Fentanyl will be administered at the beginning of induction, 2 micrograms per kilogram.
45771747|NCT03009877|Drug|Midazolam|midazolam will be given upon induction, 1-2 milligrams at the anesthesiologist's discretion.
45632390|NCT03112031|Drug|Fluconazole|Patients will receive fluconazole 800mg once daily orally for the first 2 weeks. Amphotericin and fluconazole will be administered simultaneously. After the first 2 weeks of study treatment, all patients will receive fluconazole 800mg/day for 8 further weeks, until the study end.
45632391|NCT03111797|Drug|Morphine|we observe the self-patient controlled morphine consumption during the first 48h after surgery
45632392|NCT03111797|Other|Cardiac output measure|we observe the cardiac output during surgical procedure using a non-invasive cardiac output monitoring device (ClearSight from Edwards lifescience laboratory )
45632393|NCT03111953|Procedure|Roux-en-Y Gastric Bypass Surgery|"In Roux-en-Y Gastric Bypass Surgery a small gastric pouch is created and connected to a segment of jejunum. Bowel continuity is restored by reconnecting the Roux limb and the biliopancreatic limb approximately ~75-150 cm distal to the gastrojejunostomy. Therefore, ingested food bypasses most of the stomach, the entire duodenum, and a short segment of the jejunum."
45771748|NCT03009877|Device|C-MAC Premium Video Intubation Platform-KARL STORZ|After patient is induced, the 5.5mm flexible intubation video scope (C-MAC Premium Video Intubation Platform-KARL STORZ) will then be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope (3 or 4 blade based on anesthesiologist's discretion).
45771749|NCT00002392|Drug|Thalidomide|
45771750|NCT00002398|Drug|Levocarnitine|
45771751|NCT00002398|Drug|Adefovir dipivoxil|
45771752|NCT02394860|Other|echo Doppler lower limbs|
45771753|NCT00997139|Drug|Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)|2 1/32oz packages will be dispensed. If positive nasal swab for S. aureus, subjects will apply a small amount to anterior nares twice daily for 5 days.
45771754|NCT00002236|Drug|Indinavir sulfate|
45771755|NCT00002236|Drug|Delavirdine mesylate|
45632394|NCT03111953|Procedure|Biliopancreatic Diversion Surgery|In Biliopancreatic Diversion Surgery a horizontal gastrectomy is conducted leaving a portion of the stomach, which is connected to the small intestine, ~250 cm from the ileocecal valve and the biliopancreatic limb is connected to the ileum, ~50 cm from the ileocecal valve. Digestive secretions from the biliopancreatic limb mix in the common channel, where ingested food is also delivered by the alimentary limb.
45632395|NCT02336867|Device|Closure clip (OTSC® Proctology)|
45632396|NCT02938013|Drug|Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]|antiviral therapy for HCV
45632397|NCT02938013|Drug|Sofosbuvir/Velpatasvir (SOF/VEL)|antiviral therapy for HCV
45632398|NCT02331875|Drug|IPH2201|The first 6 patients will receive IPH2201, IV, at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4.
45632399|NCT02331875|Procedure|Standard Surgery|After the end of treatment with IPH2201, according to standard recommendations in the relevant country .
45632400|NCT02331875|Radiation|Postsurgical Adjuvant Therapy|After the standard surgery, according to standard recommendations in the relevant country
45632401|NCT02331797|Device|Endoscopic Technique|Endoscopic Technique; endoscopic transcanal lateral graft tympanoplasty using An endoscope (Karl Storz, Tuttlingen, Germany) and A microdrill (Skeeter Otologic Drill System; Medtronic Xom ed Surgical Products, Inc., Jacksonville, FL, USA)
45632402|NCT02331797|Device|Microscopic Technique|Microsopic surgical approach using a Zeiss Opmi 111 (Carl Zeiss, Jena, Germany) operating microscope
45771756|NCT00002236|Drug|Zidovudine|
45771757|NCT01241539|Drug|Dabigatran etexilate|150 mg capsule
45771758|NCT01241539|Drug|Dabigatran etexilate|75 mg capsule
45771759|NCT01241539|Drug|Dabigatran etexilate|110 mg capsule
45632403|NCT02336945|Device|Abbott Sensor Based Glucose Monitoring System-Professional|Subjects will wear 2 glucose sensors while going about daily activities and adhering to establish diabetes treatment plan. This is not a treatment study.
45632404|NCT02336711|Radiation|dose escalation|molecular imaging based radiotherapy dose escalation
45447834|NCT02123914|Other|Aerobic exercise|"walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
45447835|NCT02123914|Other|No exercise|"Sedentary control.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
45447836|NCT02123992|Device|Elevate Apical and Posterior|
45447837|NCT02123992|Procedure|Native Tissue Repair for pelvic organ prolapse|
45632405|NCT02820311|Drug|TD-4208 175 mcg|via nebulizer
45632406|NCT02820311|Drug|TD-4208 700 mcg|via nebulizer
45632407|NCT02820311|Drug|Placebo for TD-4208|via nebulizer
45632408|NCT02820311|Drug|Moxifloxacin 400 mg|oral
45632409|NCT02336633|Dietary Supplement|Resveratrol|2 capsules of 20mg in the morning and in the evening (4 capsules in total/day = 80mg/day) every day during 1 year
45632410|NCT02336633|Other|Placebo|
45632411|NCT02336477|Drug|Mexiletine|"Blisters of 10 capsules of 200 mg mexiletine hydrochloride.~Patients will receive gradual dose of the treatment as it would be done in clinical practice.~Mexiletine will be started at 200 mg / day (1 capsule to be taken at the beginning of the meal) and will be increased by 200mg every 3 days to reach a maximum of 600mg / day in 3 taken in 1 week.~The duration of each treatment period is 18 days minimum (maximum 22 days)."
45632412|NCT02336477|Drug|placebo|
45632413|NCT02336789|Other|fecal material|. All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
45771760|NCT04998617|Other|Toothpaste with curcumin|Subjects will be given toothpaste to be used during this study with 0.5% curcumin
45771761|NCT04998617|Other|Toothpaste without curcumin|Subjects will be given toothpaste to be used during this study without curcumin
45771762|NCT00002404|Drug|Valacyclovir hydrochloride|
45771763|NCT05593757|Drug|Quinidine|Oral quinidine
45771764|NCT05593757|Drug|Verapamil|Oral verapamil
45771765|NCT01242241|Drug|Propofol|Each Obese child/subject in this group will receive a predetermined dose of propofol ranging from 1.0mg/kg to 4.25mg/kg to induce loss of consciousness depending on the response (presence or absence of lash reflex) of the preceding patient to his/her assigned dose (biased coin design)
45771766|NCT01242241|Drug|Propofol|This arm of patients(non-obese)will act as the control group for the obese children. Each non-obese child/subject will receive a predetermined dose of propofol from a range of 1.0mg/kg to 4.25mg/kg depending on the response of the previous patient to their assigned dose( biased coin design)
45771767|NCT00002248|Drug|Cryptosporidium Immune Whey Protein Concentrate (Bovine)|
45447838|NCT02124070|Drug|rh Growth Hormone|
45447839|NCT02121106|Behavioral|Cognitive Remediation|
45447840|NCT02121106|Behavioral|Sham Cognitive Remediation|
45447841|NCT02121340|Behavioral|Behavioral Activation|
45771768|NCT04962113|Other|TUBE BATH|Wrap Tube Baht (immersion)
45771769|NCT02393690|Radiation|Iodine I-131|Given PO
45771770|NCT02393690|Other|Placebo Administration|Given PO
45771771|NCT02393690|Drug|Selumetinib|Given PO
45771772|NCT05751616|Other|Laminate veneers with speed sintering|Zirconia specimens will be sintered using speed sintering cycle in a conventional furnace according to the manufacturer instructions.
45771773|NCT05751616|Other|Laminate veneers with conventional sintering|Zirconia specimens will be sintered using conventional sintering cycle in a conventional furnace according to the manufacturer instructions.
45771774|NCT05593679|Diagnostic Test|Tc-99m PYP Cardiac scan|Tc-99m PYP Cardiac scan
45771775|NCT02189161|Device|Radiofrequency Ablation (Barrx™)|Anal canal RFA is performed to the full anal canal, 3 cm above the dentate line to the anocutaneous line proximal to the verge. The procedure entails Barrx60 ablation device, introducing the device into the anus through the anoscope, placing the electrode surface in contact with the target tissue and delivering 3 bursts of energy in rapid succession at an energy density setting of 12 J/cm2.
45632414|NCT02336789|Other|normal saline|All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
45447842|NCT03551860|Procedure|TQL|"For the intervention of TQL peripheral nerve block the needle tip will be advanced by in-plane technique and local anaesthetic will be deposited between psoas major and quadratus lumborum muscles. 20 ml of 0.25% bupivacaine will be administered under ultrasound guidance following careful intermittent aspiration. The needle tip will not be repositioned unless the patient complains of paraesthesia.~For the intervention of spinal neuraxial blockade the needle will be advanced into the subarachnoid space. Once clear CSF is visualised 3.2ml 0.5% plain bupivacaine will be infiltrated."
45632415|NCT04700891|Diagnostic Test|Olfactory identification test|"Burghart Sniffin' Sticks Screening 12 Test Olfactory function will be evaluated through the Sniffin' Sticks test which is a validated psychophysical testing method. Sniffin' Sticks test is based on pen-like odor dispensing devices that will be presented to the patients. The short version of this test will be used and will consist solely of a test of odor identification function."
45447843|NCT03551860|Procedure|FIB|"The needle tip will be advanced by in-plane technique and local anaesthetic will be deposited deep to the fascia iliaca. 20ml of 0.25% bupivacaine will be administered under ultrasound guidance following careful intermittent aspiration. The needle tip will not be repositioned unless the patient complains of paraesthesia.~For the intervention of spinal neuraxial blockade the needle will be advanced into the subarachnoid space. Once clear CSF is visualised 3.2ml 0.5% plain bupivacaine will be infiltrated."
45632416|NCT04700891|Diagnostic Test|Edmonton Frail Scale|The Edmonton Frail Scale (EFS) involves nine domains of frailty : functional performance, cognitive function, general health, functional independence, social support, used medications, nutrition, mood and continence. It has been validated with respect to comprehensive geriatric assessment and to other screening tools related to frail state. EFS test is considered most appropriate for use in routine preoperative screening and only requires 5 minutes.
45771776|NCT04631302|Behavioral|Be Mindful|"Be mindful is an online course run by the Mental Health Foundation and Wellmind Media. It was developed together with British mindfulness instructors and offers access to its course materials and instructional videos through a website (http://www.bemindfulonline.com).~The course consists of 11 sessions led by two mindfulness teachers, one female, one male. Using a variety of media (videos, assignments, audio tracks and e-mails), participants are taught to use formal as well as informal mindfulness techniques. The course lasts 4 weeks. For each week, participants are asked to do a daily formal mediation practice (up to 30 minutes but it varies from week to week) and one or two informal exercises."
45771777|NCT04631302|Behavioral|Light exercise course|"The control condition involves light physical exercises aimed at increasing mobility, reducing stiffness, improving circulation, and avoiding pain or repetitive strain injuries that may result from sedentary or repetitive tasks common in office environments. The exercises will include simple whole-body slightly aerobic exercises such as rotation of limbs and stretching. The course was developed by Dr Julieta Galante, a public health doctor, together with an expert in body posture re-education and body techniques.~The course is designed to match with the mindfulness intervention condition in duration and media (length of videos, amount of written instructions). It also replicates the encouraged use of short breaks (of seconds or minutes) throughout the workday to focus on wellbeing, as occurs in mindfulness."
45771778|NCT02246959|Behavioral|Process Incentive|Daily sweepstake conditional on daily medication adherence
45771779|NCT02246959|Behavioral|Outcome Incentive|Incentives conditional on LDL cholesterol reduction
45771780|NCT04788953|Drug|Solriamfetol Oral Tablet|The administered drug is SUNOSI (solriamfetol) tablets for oral use. Initial U.S. Approval: 2019
46070038|NCT00799669|Behavioral|smoking cessation intervention|Standard quit-smoking counseling to help decrease their risk of cancer.
46070039|NCT00799669|Other|counseling intervention|Counseling focusing on decreasing risk of getting cancer by decreasing smoking and alcohol use.
46070040|NCT00799669|Other|preventive intervention|
46070041|NCT00799669|Other|questionnaire administration|
45632417|NCT04700891|Diagnostic Test|Handgrip strength|Handgrip strength is a simple and reliable measurement technique for the assessment of maximal voluntary hand force. Handgrip strength is used as a reflect of nutritional status and muscle mass, physical function and health status. Measurement will be realized using a digital handgrip dynamometer. Patients will be asked to grip the dynamometer with the second finger node at 90° angle to the handle and to grab the handle as strongly as they can. Maximal grip strength will be checked with the forearm away from the body in standing position.
45632418|NCT02331485|Device|PICO + Acticoat group|Comparison between Pico and Acticoat dressing change after 3 and 7 days with standard Mepor dressing change on daily basis.
45632419|NCT03111563|Other|Warm saline distension media in office hysteroscopy|warm saline distension media in office hysteroscopy
45632420|NCT04624451|Drug|Dalbavancin|Dalbavancin 1500 mg intravenously x 1 dose
45632421|NCT03105167|Procedure|cortical bone trajectory screws|cortical bone trajectory screws fixation takes the place of traditional pedicle screws fixation will be used in transforaminal lumbar interbody fusion.
45632422|NCT03105167|Procedure|pedicle screws|traditional pedicle screws fixation will be used in transforaminal lumbar interbody fusion.
45771781|NCT04788953|Drug|Placebo|Control subjects will receive placebo tablets for oral use.
45632423|NCT02642315|Drug|Horizant|"Phase1: During phase 1 therapy, Horizant will be added on as an adjunct to all subjects taking part in the study along with stable dose of their current dopaminergic (DA) agent and both medication will be continued for a total period of 90 days from day 0 to day 90. Subjects will be evaluated for three visits (days 0, 30 and 90) during Phase I.~Phase 2: At the 90th day follow-up visit, with initiation of phase 2 therapy, all subjects will be tapered off (by 50% reduction in dose each week) of their current dopaminergic agents while maintaining the same dose of Horizant and will be on Horizant monotherapy. All subjects will be evaluated for additional three clinic visits (days 120, 180, 360)."
45632424|NCT02518139|Drug|TD-4208|Subjects receiving TD-4208 are blinded to one of two doses of 4208.
45632425|NCT02518139|Drug|Tiotropium|There is not a placebo, there is an active comparator (Tiotropium) arm.
45771782|NCT05751538|Other|No intervention|No intervention
45771783|NCT05593211|Device|Kronos Electrocautery Device|The Kronos Electrocautery Device is a disposable electrocautery device that can cauterize deep tissue through a standard biopsy procedure guide needle. This device is intended to coagulate the tissue surrounding the core biopsy channel during withdrawal to reduce or eliminate significant post-procedural bleeding. Currently, the Kronos Electrocautery Device consists of one (1) size. As such, the existing Kronos Electrocautery Device is chosen as the worst-case condition
45632426|NCT02336321|Device|BNCI controlled hand exoskeleton|The BNCI system fuses and translates bio-signals related to user intention into control signals of an assistive device performing grasping motions
45632427|NCT04477655|Procedure|Awake prone positioning|Patients will be asked to remain in prone position or lateral decubitus throughout the day as long as possible.
45632428|NCT04477655|Procedure|Standard oxygen therapy|Oxygen therapy through high flow nasal cannula (HFNC). Inspired fraction of oxygen will be titrated to maintain a capillary saturation of ≥92%
45632429|NCT02709889|Drug|Rovalpituzumab tesirine|
45632430|NCT02709889|Drug|Dexamethasone|Dexamethasone will be provided through a participant's local prescription by Investigator or other provider (i.e., dexamethasone will not be provided by the Sponsor).
45632431|NCT03189901|Drug|Regular management+Levosimendan|Patients are treated with regular management recommended in guidelines and levosimendan.
45632432|NCT02711995|Drug|RenuGel|Injection augmentation is the injection of a filler material (Brand: RenuGel; generic: Carboxymethylcellulose) into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. The flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. It is the routine diagnostic evaluation technique of voice disorders.
45771784|NCT01200433|Drug|dexmedetomidine|Patients assigned to dexmedetomidine will be given a mg/kg bolus over 10-20 minutes; subsequently, an infusion will be titrated to between 0.4-0.6 mcg/kg/hr to maintain an adequate level of sedation during the procedure.
45771785|NCT01200433|Drug|propofol|Patients assigned to propofol will be given an infusion dose of 50-75 µ/kg/min which will be titrated to the patient's response
45771786|NCT02973022|Other|CC&S|Three educational modules -- Cancer Basics, Cancer Prevention, and Cancer Screening -- intended to increase cancer awareness. The full CC&S curriculum is currently available at http://chdi.wisc.edu/cancer-clear-simple-curriculum-rural-adaptation.
45913735|NCT02026115|Behavioral|PAINReportIt|PAINReportIt is a software program first developed with an electronic MPQ (1970 version) and now includes questions about analgesics used by the patient and a shortened version of the pain Barriers Questionnaire (BQ). PAINReportIt is designed as an interactive, touch screen method for assessment of pain. It can be self-administered and requires little or no patient computer experience and minimal or no provider time for administration. Directions for self-administration allow the patient to read instructions on-screen and practice making all types of selection responses that are available in the program. Directions from the paper and pencil tools were modified to address the touch screen method of recording patient responses. The copyright is owned by Dr. Ronald Melzack for the MPQ and Dr. Sandra Ward for the BQ. Both of these individuals have authorized the modifications, presentation format, and computerized use of their tools.
45935363|NCT00123019|Behavioral|Level 2|All Level 1 activities plus ongoing environmental interventions in worksite and weight management groups in worksite over a 24 month period.
46070042|NCT00799747|Drug|AZD4017|ascending single doses (start dose 2 mg), oral suspension
45935364|NCT00123058|Behavioral|Nurse administered|Subjects received a nurse administered behavioral intervention via telephone every 8 weeks for 24 months.
46070043|NCT00799747|Drug|Placebo|placebo
45913736|NCT02026115|Behavioral|PAINConsultN|PAINConsultN for hospice nurses. Our previous studies support the feasibility and clinical effect of PAINConsultN. This narrative and graphic tool provides decision support for the nurse's clinical decisions regarding management of the patient's pain. Based on the PAINReportIt output and published cancer pain guidelines, PAINConsultN generates an algorithm-based consultation report with a list of recommendations that could be useful to provide improved pain relief. If the patient's PAINReportIt output indicates the pain level is consistent with the patient's goals for pain management and represents no pain or a mild pain level, the consultation report acknowledges the therapy plan and reinforces its consistency with pain guidelines.
45935365|NCT00123058|Device|BP Monitor|Subjects received a study provided home BP monitor and recorded home BP 3 times per week for 24 months.
45935366|NCT00123097|Combination Product|Chlorinated polyethylene elastomer|Chlorinated polyethylene
45935367|NCT02965443|Drug|Dapagliflozin 10 mg + Saxagliptin 5 mg|24 weeks intervention with Dapagliflozin 10 mg + Saxagliptin 5 mg
45632433|NCT02711995|Drug|Botulinum Toxin|Botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. This is identical to the injections you may have received in the past for your disorder.
45632434|NCT02438605|Device|Nellix|
45632435|NCT02438449|Procedure|Breast Reconstruction Surgery|AAT-based orTE/I reconstruction in all patients undergoing breast reconstruction following mastectomy
45632436|NCT02443051|Behavioral|Attention Bias Modification|Computer delivered modification in 80% of trials
45632437|NCT02443129|Device|DRI-1 Swept source OCT, Atlantis, Topcon|Fundus imaging
45632438|NCT02438215|Drug|IRX4204|IRX4204 is a potent and highly selective orally available and brain penetrant RXR nuclear receptor agonist small compound administered as gel capsules.
45632439|NCT03193723|Procedure|US guided five step field block|"Ultrasound will guide needle insertion in the following layers (except intradermic injection):~Subdermic infiltration. Approximately 8 milliliters~Intradermic injection (making of the skin wheal). of approximately 6 milliliters.~Deep subcutaneous injection. 8 milliliters of the mixture will be injected deep into the subcutaneous adipose~Subfascial infiltration. Approximately eight milliliters of the anesthetic mixture will be injected immediately underneath the aponeurosis of the external oblique.~Pubic tubercle and hernia sac injection. Occasionally, infiltration of ten milliliters of the mixture at the level of the pubic tubercle, around the neck and inside the indirect hernia sac"
45632440|NCT03193723|Procedure|Spinal anesthesia|Spinal anesthesia will be administered in sitting position, with 25 gauge Quincke spinal needle in L3-L4 intervertebral space, under all aseptic precautions and local infiltration, with 3.0 ml of 0.5% bupivacaine (heavy) after ensuring free, clear and adequate flow of cerebrospinal fluid. After giving spinal anesthesia, patient will be made to lie supine.
45632441|NCT04483609|Other|Questionnaire administration pre test|After the translation and cultural adaptation of the SF-Qualiveen scale is completed, face-to-face pre-test will be performed on 10 patients with multiple sclerosis.
45632442|NCT04483609|Other|Questionnaire administration validation and reliability|After the pre-test is completed, if necessary, arrangements will be made, and then the validity and reliability of SF-Qualiveen will be made in 80 individuals with Multiple Sclerosis.First of all, participants will be asked to complete two questionnaires (SF-Qualiveen and Urinary Distress Inventory). Two weeks after this assessment, they will be asked to respond to SF-Qualiveen again.
45771787|NCT04755686|Procedure|Fast-tracking|
45771788|NCT00002410|Drug|Indinavir sulfate|
45771789|NCT00002410|Drug|Lamivudine|
45935368|NCT02965443|Drug|Placebo 1 10 mg + Placebo 2 5 mg|24 weeks intervention with Placebo 1 10 mg + Placebo 2 5 mg
45935369|NCT00123136|Device|foot energizer|
45935370|NCT00042965|Drug|capecitabine|
45632443|NCT03194035|Biological|blood sample|Study per and post-exertional changes in proinflammatory biological (IL1, IL6, TNF alpha, HMG beta1 and CRP) and anti inflammatory parameters (IL4, IL10 and IL13, TGF beta, LPS, lipoproteins, lipids) during an ultra endurance race.
45632444|NCT04483453|Other|EXPL feeding regimen|EXPL FUF (lower protein and 100% lactose) + EXPL IC (whole grains and legumes)
45632445|NCT04483453|Other|CTRL feeding regimen|CTRL FUF (standard protein content and carbohydrate profile) + CTRL IC (refined grains)
45935371|NCT00042965|Drug|gemcitabine hydrochloride|
45632446|NCT02438293|Other|rhinovirus diagnostics|rhinovirus PCR on a nasopharyngeal swab
45632447|NCT03193411|Device|Visumax femtosecond laser|
45632448|NCT03193411|Device|Moria M2 microkeratome (MK)|
45632449|NCT02437825|Drug|octreotide|Octreotide has been in clinical use for thirty years and approved for use in Israel in acromegaly and functional gastroenteropancreatic tumours. It is currently being used extensively in surgical patients to prevent pancreatic fistulae1, and in lymphorrhea (both lymphatic malformations and leaks from the thoracic duct)
45632450|NCT02437825|Other|placebo|placebo ( saline) act as comperator in this study.
45632451|NCT03192319|Biological|Zostavax|Zostavax will be administrated by subcutaneous injection
45771790|NCT00002410|Drug|Zidovudine|
45771791|NCT01894880|Procedure|early SSC|bonding straight after birth
45771792|NCT01894880|Procedure|late SSC|bonding after termination of operation
45771793|NCT01243333|Radiation|[F-18]fluorodeoxyglucose|Undergo PET scans with [F-18]fluorodeoxyglucose
45771794|NCT01243333|Radiation|[F-18]fluorothymidine|Undergo PET scans with fluorine [F-18]fluorothymidine
45771795|NCT01243333|Procedure|Positron Emission Tomography|Undergo PET scans with 3 radiotracers (fludeoxyglucose F 18, fluorine F 18 fluorothymidine, and water O-15)
45632452|NCT02442583|Other|Brochure regarding sedentary behavior|This pilot will occur in two phases. Phase 1 will occur in two steps. In Step 1, we will conduct one-on-one telephone interviews with 15 early stage CRC (colorectal cancer) survivors to obtain their knowledge and insights about sedentary behaviors and ways to reduce them. Their input will be used to help create a brochure on sedentary behaviors. In Step 2, we will conduct one-on-one telephone interviews with 5 early stage CRC survivors to provide feedback about the brochure. In Phase 2, we will recruit 15 CRC survivors. After completing a baseline survey, they will be asked to both wear an ActiGraph and self-report their daily sedentary behaviors for one week. They will receive tailored feedback as to their average weakly levels of sedentary behaviors and receive the brochure. One month post-intervention, they will be asked to take part in telephone survey assessing sedentary behaviors, PA (physical activity), and use of brochure.
45632453|NCT02438059|Behavioral|SoSu-liv website and app|A 38 weeks web- and app-based tool for lifestyle changes intervention.
45632454|NCT03193489|Other|Follow-up|
45632455|NCT03193489|Other|Post-treatment control|After 3 weeks of intensive treatment, no special exercises are performed as a control.
45632456|NCT03193489|Other|Control Parkinson group|No treatment.
45632457|NCT03192163|Other|Survey|31 question survey with questions regarding non-identifying demographic information such as age and gender. This survey also contains questions about acne treatment preferences, racial/ethnic background, and cultural identity in addition to a few Willingness to Pay questions.
45632458|NCT03193255|Device|OPHTECS cleadew GP|Povidone-iodine based disinfecting solutions for rigid contact lenses
45632459|NCT02442817|Drug|Linagliptin|12 weeks of treatment and week for assessment. Linagliptin, 5 mg by mouth once per day for 12 weeks, in combination with continued antipsychotic treatment.
45632460|NCT02437747|Drug|SRP + Aloe|Scaling and root planing along with aloe vera application was done
45771796|NCT01243333|Radiation|Water O-15|Undergo PET scans with water O-15 tracers
45632461|NCT02437747|Procedure|SRP|Scaling and root planing was done
45632462|NCT02437357|Other|Metacognitive Training|8 group sessions á 60 min
45632463|NCT02437357|Other|Positivity Training|8 group sessions á 60 min
45632464|NCT03193177|Other|the 21-day fasting-like diet|a fasting-like diet with 400 KJ energy intake per day for 21 days
45447844|NCT05287048|Diagnostic Test|MCM5 ELISA|ADXGYNAE is a non-invasive ELISA utilising a combination of two monoclonal antibodies for the detection of MCM5 in urine sediment. It is intended to aid in the detection of endometrial cancer in women with postmenopausal bleeding who are suspected of having endometrial cancer. Participants will be asked to provide a urine specimen, which will be centrifuged before the sediment is lysed. The lysed sample will then be tested with the MCM5 ELISA.
45447845|NCT02118532|Device|IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter|IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter originally developed, approved and commercialized by Invatec Technology Center GmbH is the investigational medical device used in the study. Medtronic Inc. acquired Invatec on April 21, 2010. Medtronic
45447846|NCT02118688|Drug|Risperidone|
45447847|NCT02118688|Drug|Trazodone|
45632465|NCT03503617|Device|RehabTouch|Exercise using the motion sensing devices and a computer
45771797|NCT05593133|Other|Pnf exercises|"PNF techniques will comprise of Warm up, Rhythmic stabilization, Hold Relax, Contract Relax and light exercises and performed on three muscle groups ( Hamstring, Quad and Calf).~20 participants will be followed up with the therapist regularly twice a week for 30 minutes session each for a duration of 8 weeks."
45771798|NCT05593133|Other|Gait training exercises|gait Training exercises comprised of one foot balancing, leg raises, heel raises, tight-rope walking. 20 participants will be followed up with the therapist regularly twice a week for 30 minutes session each for a duration of 8 weeks.
45447848|NCT02118688|Drug|Placebo|
45447849|NCT02126722|Procedure|Gastroscopy|Gastroscopy with multiple biopsies will be performed in all patients enrolled
45632466|NCT03503617|Other|Conventional tabletop exercise program|Exercise following printed sheets of exercises
45632467|NCT02437591|Drug|fidaxomicin|oral
45632468|NCT02442739|Drug|Ketamine|Ketamine 0.5 mg/kg mixed with syrup will be given by mouth once a week for 12 weeks.
45632469|NCT02442739|Other|Placebo|Placebo syrup will be given by mouth once a week for 12 weeks.
45632470|NCT02442505|Device|Microlife WatchBP03 device|Microlife WatchBP03 device which is an automated oscillometric device using a new algorithm to detect atrial fibrillation
45632471|NCT03189667|Device|Vessel preparation with angioplasty|"Vessel preparation with Pre dilatation:~All lesions to be predilated with high pressure balloons until waist is obliterated.~At least two minutes dilatation.~Balloon sizing: not to exceed the average diameter of adjacent normal appearing non-aneurysmal segments by more than 25%.~Multiple lesions:~To be treated with single balloon if possible.~To be treated with multiple inflation if cannot be covered with single balloon."
45935372|NCT00123175|Device|Intrauterine Device|Mirena and Provera
45935373|NCT00123214|Drug|Controlled Dietary Intervention|
45935374|NCT00077727|Drug|Extended-release galantamine hydrobromide|
45447850|NCT02126722|Device|EndoFaster test|During the gastroscopy the EndoFaster test will be carried out in all patients enrolled.
45447851|NCT02126722|Other|Clo test|During the gastroscopy the Clo test will be carried out in all patients enrolled.
45447852|NCT02126722|Other|Faecal Helicobacter pylori antigen|On the day of the endoscopic procedure all the enrolled patients will bring a stool sample for the detection of Helicobacter pylori antigen.
45447853|NCT03248492|Drug|DS-8201a|DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.
45935375|NCT00123292|Drug|Microplasmin|An infusion of 0.45, 0.60 and 0.90 mg/kg/hr will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).
45935376|NCT00123292|Drug|Microplasmin|An infusion of 0.45 mg/kg/hr in conjunction with distal protection device will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).
45632472|NCT03189667|Device|Plain balloon angioplasty|"Plain balloon angioplasty~Vessel treatment with additional Plain balloon angioplasty:~Inflation to nominal pressure for at least 1 minute.~Balloon size: similar to predilation balloon."
45632473|NCT03189667|Device|Drug coated balloon angioplasty|"Lutonix® Drug Coated Balloon: The balloon is coated with a specialized formulation that includes the drug, paclitaxel. The paclitaxel coating is evenly distributed across the working length of the balloon at a surface concentration of 2 μg/mm2. The key functional characteristic of the formulation is to allow for release of paclitaxel to the tissue of the vascular wall during inflation.~Inflation to nominal pressure for at least 1 minute.~Balloon size: similar to the predilation balloon.~New drug coated balloon will be required for each lesion."
45632474|NCT02437201|Behavioral|Liberty Program|
45632475|NCT02437123|Behavioral|The Cedar Project mHealth intervention|
45632476|NCT03022903|Procedure|Aminolevulinic Acid (ALA)|Photosensitizing
45632477|NCT02442037|Biological|UCMSC group|Human umbilical cord MSCs are transplanted three times by intravenous infusion(1×10^6/kg) ,once every week，a total of three times.
45632478|NCT02442037|Other|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
45632479|NCT02914951|Behavioral|Cognitive-Behavioral Therapy|CBT is a behavioral intervention that consists of 12 60- to 90-minute-long weekly sessions. A modified, principles-based form of CBT will be used in this study to reduce complexity of activities during therapy sessions while retaining all key elements and principles of CBT.
45632480|NCT02914951|Other|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI). There will be two fMRI visits, 60 to 90 minute each, one before and the other after CBT. fMRI is a technique that uses magnetism to measure activity of the brain as participants perform simple tasks such as pressing the button in response to pictures. During this study, children will be asked to look at pictures of objects and press or not press the button in response to specific instruction. Participants will also look at pictures of faces and light-point displays depicted biological motion. fMRI is used as an outcome measure to explore if change in irritability is associated with change in brain responses to these tasks during fMRI.
45632481|NCT02442427|Drug|Palivizumab|A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg). The study medication will be given by IV infusion over 30 minutes using a syringe infusion pump.
45452481|NCT01093391|Device|DRUG ELUTING STENT|Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
45632482|NCT02442427|Other|Placebo|An equal volume of 0.9% normal saline
45632483|NCT02442193|Other|Individual Placement and Support|Individual Placement and Support is a form of supported employment.
45632484|NCT03189511|Drug|Fluvastatin|Fluvastatin 40 mg twice daily per mouth for 14 days.
45632485|NCT04483687|Drug|Filgotinib|Tablets administered orally once daily
45632486|NCT04483687|Drug|Placebo to Match Filgotinib|Tablets administered orally once daily
45632487|NCT02065141|Other|sip feeding with stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
45632488|NCT03189043|Device|Antimicrobial Surface|Antimicrobial Surface
45632489|NCT02436967|Other|Carotid endarterectomy in clinical healthcare.|For the this study itself there is no intervention caused by the extra CT or MRI. The patients are scheduled for surgery as the routine intervention to reduce the risk of a new stroke in clinical practice. The performed extra diagnostic CT and MRI in this study before surgery will compare the vessel wall images with histology regardless of the patients status or medication.
45632490|NCT01654315|Device|Myomo Robotic Arm|"Patients are administered rehabilitative therapy (repetitive task specific therapy,, also known as RTP' in this study) using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period. These patients engage in RTP, which consists of a battery of activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion."
45632491|NCT01654315|Behavioral|RTP Standard Therapy|Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period. In this condition, patients engage in activities that emphasize use of their affected arms repetitively, with the therapist providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the therapist during the activities is reduced.
45632492|NCT03188575|Behavioral|SilverCloud Internet-delivered Cognitive Behavioural Therapy|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).
46070044|NCT00863655|Drug|Everolimus|Everolimus was formulated as tablets of 5-mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
46070045|NCT00863655|Drug|Exemestane|Exemestane 25 mg orally daily.
45632493|NCT03188575|Other|Waiting List|8 week waiting list period.
45771799|NCT01924052|Drug|CGRP|Calcitonin-gene-related-peptide (CGRP)
45632494|NCT05233735|Other|Enhanced Transcutaneous Delivery of Topical Betamethasone after the treatment with Tixel|Tixel Parameters: exposure time 6-8 milliseconds, 400-600 μm protrusion
45632495|NCT05233735|Other|Topical treatment|betamethasone ointment treatment once per day
45771800|NCT00002416|Drug|Emtricitabine|
45632496|NCT03188341|Other|vascular surgery procedure|"an elective open vascular surgery procedure~ECG Holter recording during the procedure and 24 hours after operation (continuous electrocardiographic tracing (digital Holter ECG monitor)"
45632497|NCT02441959|Procedure|Lumbar discectomy Open|Open Discectomy
45632498|NCT02441959|Procedure|Lumbar discectomy Endoscopic|Endoscopic Discectomy
45632499|NCT02436499|Drug|Botulinum Toxin-A|
45632500|NCT02434315|Device|FreeStyle Libre Pro 4 sensor wears, 2 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 2 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
45771801|NCT00002416|Drug|Lamivudine|
45771802|NCT00381394|Drug|sitamaquine|
45771803|NCT00002254|Drug|Alovudine|
45771804|NCT01897454|Drug|Fluorouracil|Given IV
45771805|NCT01897454|Drug|Gemcitabine Hydrochloride|Given IV
45935377|NCT00123292|Drug|Microplasmin|An infusion of 20 or 40 mg (20 mg for the 15 cm treatment length device; 40 mg for the 30 cm treatment length device) over 10 minutes via the Trellis-8 Peripheral Infusion System catheter, in accordance with the Trellis-8 Instructions for Use. For occlusive lesions that are longer than the treatment length of the Trellis-8 device, a repeat infusion of the same dose and duration may be administered.
45935378|NCT00043004|Biological|bevacizumab|
45632501|NCT02434315|Device|FreeStyle Libre Pro 6 sensor wears, 4 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 4 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
45632502|NCT02434315|Device|FreeStyle Libre Pro 3 sensor wears|Subjects will wear the FreeStyle Libre Pro System for 14 days. 3 periods of Sensor wear for time in range measurement over a period of approximately 8 months.
45771806|NCT01897454|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45771807|NCT01897454|Drug|Irinotecan Hydrochloride|Given IV
45771808|NCT01897454|Drug|Leucovorin Calcium|Given IV
45771809|NCT01897454|Drug|Oxaliplatin|Given IV
46070046|NCT00863655|Drug|Everolimus Placebo|Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
46070047|NCT00806923|Drug|Cisplatin|80mg/m2 iv on day 1 of each 3 week cycle, for a maximum of 6 cycles
46070048|NCT00806923|Drug|Gemcitabine|1250mg/m2 on days 1 and 8 of each 3 week cycle for a maximum of 6 cycles
46070049|NCT00806923|Drug|Placebo|iv on day 1 of each 3 week cycle until disease progression
45632503|NCT02514239|Drug|BI 836909|Intravenous Infusion of BI 836909.
45632504|NCT02436421|Other|Best Practice Alert based in the Electronic Medical Record|
45771810|NCT01243567|Drug|bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution|Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
45771811|NCT01243567|Drug|latanoprost 0.005% ophthalmic solution|Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
45771812|NCT01001195|Drug|AGN-210669 ophthalmic solution, 0.1%|One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
45771813|NCT01001195|Drug|AGN-210669 ophthalmic solution, 0.075%|One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
45771814|NCT01001195|Drug|AGN-210669 ophthalmic solution, 0.05%|One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
45771815|NCT01001195|Drug|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
45771816|NCT00381472|Drug|Ropinirole|
45771817|NCT02185729|Drug|Intralipid|Infusion of Intralipid (soybean-derived fat)
45771818|NCT02185729|Drug|ClinOleic|Infusion of ClinOleic (olive oil-based)
45771819|NCT02185729|Drug|Dextrose|Infusion of dextrose (sugar) without fat
45771820|NCT02185729|Other|Saline (control)|Infusion of 0.9% normal saline
45935379|NCT00043004|Drug|FOLFOX regimen|
45935380|NCT00043004|Drug|fluorouracil|
45935381|NCT00043004|Drug|leucovorin calcium|
45935382|NCT00043004|Drug|oxaliplatin|
45632505|NCT03189355|Procedure|Blood sampling|"D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube~D4 zonulin"
45632506|NCT03189355|Procedure|Bioelectrical impedance vector analysis|"D1~D4"
45771821|NCT01460654|Drug|Testosterone|Testosterone Gel (Fortesta) 40mg daily.
45632507|NCT03189355|Procedure|Muscular echography|"D1~D4"
45632508|NCT02441881|Device|Venefit|Endovenous radiofrequency device
45632509|NCT02441881|Device|Radiofrequency Induced Thermal Therapy|Endovenous radiofrequency device
45632510|NCT02441881|Device|Endovenous Radiofrequency|Endovenous radiofrequency device
45632511|NCT02441647|Device|KL029 Intimate Lubricant Gel|
45632512|NCT02441725|Other|1-minute sit-to-stand test|Validation of the 1-minute sit-to-stand test in a COPD patient population
45771822|NCT01460654|Drug|Alendronate|Alendronate (Fosamax) 70mg every week.
45632513|NCT04483271|Dietary Supplement|300 mg of omega3-FA|"The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.~Baseline and follow-up serum levels of IL-1,IL-6, and TNF will be measured."
45632514|NCT02336009|Device|total wrist arthroplasty, Trimed|A new total wrist arthroplasty design. A pilot study.
45632515|NCT03117283|Procedure|Laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach|Patients with advanced posterior gastric wall cancer including in the laparoscopic total gastrectomy (LTG) with bursectomy group will undergo laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach.
45632516|NCT03117283|Procedure|Laparoscopic D2 radical total gastrectomy without bursectomy|Patients who are included in the laparoscopic total gastrectomy (LTG) without bursectomy group will undergo laparoscopic D2 radical total gastrectomy without bursectomy in a conventional manner.
45632517|NCT02331329|Device|NICOM cardiac output measurement|
45771823|NCT01460654|Drug|Placebo Alendronate|A placebo alendronate tablet will be taken every week by subjects in the Testosterone and Placebo Alendronate Group.
45771824|NCT01460654|Drug|Placebo Testosterone|Placebo testosterone gel will be applied daily by subjects in the Alendronate and Placebo Testosterone group.
45771825|NCT01001975|Drug|Sunscreen Test Code: V53-028|Sunscreen formula containing 15% Zinc Oxide, 3% Avobenzone, and 1% Ensulizole
45771826|NCT01001975|Drug|Sunscreen Test Code: V53-030|Sunscreen formula containing 15% Zinc Oxide and 3% Avobenzone
45771827|NCT01001975|Drug|Standard SPF 4 Sunscreen|8% Homosalate Standard SPF 4 Sunscreen
45632518|NCT02331329|Device|Cardiac MRT cardiac output measurement|
45771828|NCT05751460|Other|Straight leg raise|Diagnostic test, tool for *g*
45771829|NCT01459484|Drug|Mifamurtide arm|"PRE SUGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~POST SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN~Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)~POST SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN~Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)~All the product are used as commercial formulation"
45771830|NCT01459484|Other|3 drugs arm|"High grade osteosarcoma who do not over express ABCB1/P-glycoprotein will be treated with a standard 3-drugs regimen~PRE-SUGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~POST SURGERY TREATMENT:~Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2~Total lenght 34 weeks~All the product are used as commercial formulation"
45771831|NCT01201057|Drug|0.5% SPL7013 Gel|Vaginal gel
45771832|NCT01201057|Drug|1.0% SPL7013 Gel|Vaginal gel
45771833|NCT01201057|Drug|3.0% SPL7013 Gel|Vaginal gel
45771834|NCT01201057|Other|Placebo Gel|Vaginal gel
45771835|NCT00002260|Drug|Alovudine|
45771836|NCT01444040|Device|iStent inject|Implantation of two iStent inject devices
45771837|NCT01444040|Drug|Travoprost|Travoprost drops
45632519|NCT02331563|Drug|Dexmedetomidine|ultrasound guided transvers abdominis plane block
45632520|NCT02331563|Drug|0.25 % bupivacaine|ultrasound guided transvers abdominis plane block
45632521|NCT03188107|Other|Video based assessment|All the infants included in this study will be assessed with Infant Motor Profile based on video recording.
45632522|NCT02336243|Dietary Supplement|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA), 600 mg per day. Each woman will take three DHA capsules per day (200 mg each), as early in gestation as possible and until the end of pregnancy.
45632523|NCT02336243|Dietary Supplement|Placebo (for Docosahexaenoic acid (DHA))|Each women allocated to the placebo group, will receive three placebo capsules per day. The placebo capsules will have same size, aspect and flavor than the DHA capsules.
45632524|NCT02331641|Procedure|Hepatectomy|Removal of a part of the liver
45632525|NCT02436343|Other|echocardiogram|"At each echocardiographic evaluation, the investigator will obtain the following parameters:~Left ventricular internal dimensions at end diastole Left ventricular posterior wall thickness Left ventricular end systolic stress Left ventricular fractional shortening Velocity of circumferential shortening Left ventricular mass Contractility and indices of preload Stroke volume"
45632526|NCT02330939|Other|Low fat- Low glycemic index meal|
45771838|NCT05751382|Device|Surefil one|Restorative material (Dentsply Sirona). Used for direct restoration of class V NCCL.
45771839|NCT05751382|Device|Venus Pearl|Restorative material. Traditional paste composite employed in combination with iBond universal adhesive.
45771840|NCT01002287|Device|SprayShield Adhesion Barrier System|Adhesion Barrier Device
45771841|NCT01002287|Procedure|Good Surgical Technique Alone|Good Surgical Technique Alone
45771842|NCT04294862|Drug|TNP-2092|TNP-2092 for injection 100mg/vial
45935383|NCT00043004|Procedure|conventional surgery|
45632527|NCT02330939|Other|MUFA- Low glycemic index meal|
45632528|NCT02330939|Other|SAFA- Low glycemic index meal|
45632529|NCT02330939|Other|Low fat- High glycemic index meal|
45632530|NCT02330939|Other|MUFA- High glycemic index meal|
45632531|NCT02330939|Other|SAFA- High glycemic index meal|
45632532|NCT02331017|Behavioral|Speech perception tests and self-rating questionnaire|Speech perception test results and self-rating questionnaire scores will be analyzed by means of non-parametric statistical tests. The statistical tests will be chosen in accordance with the number and type of variables in each test. Correlation between audiological variables (aided and unaided hearing thresholds in the non implanted ear, aided speech perception abilities in the HA-alone condition) and the bilateral-bimodal benefit will be examined. Moreover, possible relationship between self-rating questionnaire scores and speech perception test results will be assessed.
45632533|NCT02331173|Drug|Dorzolamide 2% TID or brinzolamide 1% TID|"Dosing of all medications will be based upon standard of care. Standard dosing for the treatment of pediatric and adult patients with XLRS is as follows:~Topical dorzolamide 2% three times per day~Topical brinzolamide 1% three times per day"
45632534|NCT04461899|Biological|Blood test|additional blood test will be done 3 and 12 months after endometrioma sclerotherapy.
45632535|NCT02709109|Drug|VX-371 + HS|
45632536|NCT02709109|Drug|Hypertonic saline|
45632537|NCT02709109|Drug|Placebo|
45632538|NCT02709109|Drug|Orkambi|
46070050|NCT00806923|Drug|bevacizumab [Avastin]|15mg/kg 1v on day 1 of each 3 week cycle until disease progression
45632539|NCT02709109|Drug|VX-371|
45632540|NCT04337489|Device|SensiumVitals wearable sensor|A waterproof, light, wearable sensor measuring vital signs (heart rate, respiratory rate, temperature) continuously.
45632541|NCT01979003|Drug|Fluorescein|
45632542|NCT02436109|Device|Ultrasound|Parturients backs will be scanned using 3D ultrasound to measure the depth to the epidural space
45632543|NCT01827761|Behavioral|Questionnaire|After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
45771843|NCT04769791|Device|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
45771844|NCT04769791|Device|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
45771845|NCT04769791|Device|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
45632544|NCT03188029|Diagnostic Test|adrenocortical function|"Blood samples for cortisol dosage are performed and 24 hours after the sixth session. All blood samples are performed at 9 and collected in normal tube.~Blood samples for glycaemia, sodium, potassium and bicarbonates are performed at the same rate."
45632545|NCT02441569|Behavioral|Common factors engagement training for provider|Primary care providers have received brief training in communication skills designed to promote family engagement in care including understanding of treatment and empowerment.
45632546|NCT02441569|Behavioral|Standard pediatric advice for childhood anxiety|Providers will be free to use their existing knowledge of anxiety problems to offer routine counseling.
45632547|NCT04289051|Device|HYDRAL Oral Rinse|Application 4 times a day for two weeks
45632548|NCT04289051|Device|BIOTENE® Oral Rinse|Application 4 times a day for two weeks
45632549|NCT04289051|Device|Placebo Oral Rinse|Application 4 times a day for two weeks
45632550|NCT02441413|Radiation|High Resolution Computed Tomography scans|"A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1."
45632551|NCT03117595|Drug|Bupivacaine-fentanyl|Dosages as previously written
45632552|NCT03117595|Drug|Bupivacaine-fentanyl morphine|Dosage as previously written
45632553|NCT02434159|Other|Heart scan|
45632554|NCT02039531|Biological|Plasma rich in growth factors|
45632555|NCT02039531|Drug|Hyaluronic Acid|
45632556|NCT02435875|Other|no intervention|Antihypertensive drug as intervention is used to see if it can improve baroreflex sensitivity to stable perioperative hemodynamic
45632557|NCT02331251|Drug|Pembrolizumab|
45632558|NCT02331251|Drug|Gemcitabine|
45632559|NCT02331251|Drug|Docetaxel|
45632560|NCT02331251|Drug|Nab-paclitaxel|
45771846|NCT00002266|Drug|AS-101|
45632561|NCT02331251|Drug|Vinorelbine|
45632562|NCT02331251|Drug|Irinotecan|
45632563|NCT02331251|Drug|Liposomal Doxorubicin|
45632564|NCT02435953|Procedure|TACE|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
45632565|NCT02435953|Procedure|RFA|For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
45632566|NCT02335619|Behavioral|Early palliative care|
45771847|NCT01437176|Device|new type of intramedullary nail|This is a new fixation treat for intertrochanteric fracture.
45771848|NCT01437176|Device|The intramedullary nail of PFNA|It was used very common in treat with intertrochanteric fracture.
45771849|NCT05751304|Drug|Dexmedetomidine|(50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 5μg Dexametomidine.
45771850|NCT05751304|Drug|Ketamine|(50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 0.1 mg/kg ketamine.
45935384|NCT00043004|Procedure|radiofrequency ablation|
45935385|NCT00123331|Drug|Cyclosporine discontinuation|
45935386|NCT00123331|Drug|Rapamycin medication|
45935387|NCT00073788|Procedure|PET Scans|PET Scan to look for coronary flow reserve, heart rate variability, and carotid ultrasound measures (mean intermediate thickness of the far fall of the carotid artery).
45632567|NCT02435797|Drug|Nicorandil|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Subjects in the NicorandilGroup were then given 2 mg intracoronary nicorandil through the lesions via thrombus aspiration catheter, and an additional intracoronary dose of 2 mg nicorandil before stent implantation. A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects.
45632568|NCT02435797|Drug|normal saline|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Normal saline in the Placebo Group were then given 2 ml through the lesions via thrombus aspiration catheter,and an additional intracoronary dose of 2 ml before stent implantation. A minimum 5-min interval occurred between the first and second injection.
45632569|NCT02330861|Device|combowire and IVUS|
45632570|NCT02335697|Behavioral|Attitude change towards female circumcision|The intervention comprises of a series of meetings between newly arrived Somalis and established Somalis. At each meeting, a pre-determined topic relating to FC will be discussed. The topics include culture, religion, health, children's rights, and Swedish laws. Different experts, chosen to match the specific topic of the meeting will be invited to each meeting to facilitate the interactive discussions between the participants. Somalis who are both familiar with the Swedish and Somali culture will facilitate the meetings. The intervention spans over a time period of six months. The intervention meetings will be held during the first five months of the intervention period; one meeting scheduled per month. Thereafter, there will be a 'wash-out' period of one month to allow for reflections and to minimize the risk of courtesy bias.
45632571|NCT02335697|Other|No intervention|
45771851|NCT01202071|Drug|Rabeprazole sodium, 5 mg Tablets|"Rabeprazole sodium Tablets, 5 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water >= 2 hours after the completion of breakfast."
45771852|NCT01202071|Drug|Rabeprazole sodium, 10 mg Tablets|"Rabeprazole sodium Tablets, 10 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water >= 2 hours after the completion of breakfast."
45771853|NCT01202071|Drug|Rabeprazole sodium, 20 mg Tablets|"Rabeprazole sodium Tablets, 20 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water >= 2 hours after the completion of breakfast."
45771854|NCT01202071|Drug|Rabeprazole sodium, 40 mg Tablets (two 20 mg Tablets)|"Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets) administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water, >=2 hours after the completion of breakfast."
45771855|NCT05592821|Procedure|dental implant placement|In both groups, dental implants of the same brand will be placed into the bone with the same protocol.
45771856|NCT04284488|Drug|APG-1387 for Injection|APG-1387 IV on Days 1 and 8 of each 21-Day Cycle. The following doses of APG-1387 to be studied: 20, 30, and 45mg. In the phase II, the assigned recommended phase two dose will be administered in all cohorts.
45771857|NCT04284488|Drug|Toripalimab|240 mg toripalimab IV on Day 1 of each 21-Day Cycle
45913737|NCT02026115|Behavioral|PAINUCope|We tested the prototype of the PAINUCope component of the intervention in three completed studies. PAINUCope is a multimedia, computer generated tool that provides tailored patient information to overcome their misconceptions about pain and to help them engage in self-care activities that contribute to reducing their pain. PAINUCope focuses on two crucial aspects of pain management: 1) reporting cancer pain; and 2) safe and effective use of pain medicines. All the educational materials were written at a 6th grade reading level and presented as 21st Century best-practices, evidence-based facts or scripts for the person living with cancer or sickle cell disease (in one study). The facts or scripts are customized to the patient's need for this type of health information. The patient's responses on PAINReportIt govern the specific health information that is shared with the patient via PAINUCope.
45913738|NCT02026167|Behavioral|Collaborative Care|Addition of a Health Care Assistant to treatment team, case review by expert panel of supervisors, non-medical interventions
45935388|NCT00123370|Drug|Modafinil|
45771858|NCT00002422|Drug|HE2000|
45447854|NCT02121496|Behavioral|Resources for Postpartum Parenting|The intervention includes four-sessions that targets maternal caregiving of young infants to increase infant sleep and reduce fuss/cry behavior and thereby simultaneously consolidate women's enjoyment of and confidence in their maternal role, this, in turn, promotes a cycle of a mutually re- warding engagement in the mother-infant dyad - the antithesis of a 'toxic' experience, and a strong foundation for improving the chances of a successful psychosocial adjustment, including adequate employment. Investigators believe PREPP holds tremendous promise as an intervention to fill the science-practice gap in the promotion of an optimal emotional environment for the developing infant, particularly for women and children living in poverty and/or facing significant psychosocial hardship.
45632572|NCT04477967|Other|No intervention|There are no interventions because it is a protocol study
45632573|NCT05230745|Device|ContraBand implants|Percutaneous implantation of the ContraBand devices by right heart catheterization
45632574|NCT02330705|Drug|HCG|Women will be given HCG before IUI
45632575|NCT04174625|Dietary Supplement|Dietary Supplement: Omega3-FA|Dietary Supplement: Omega3-FA 300 mg of omega3-FA once daily for 8 weeks
45632576|NCT02330783|Drug|Bevacizumab|5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
45632577|NCT02330783|Drug|Sorafenib|400mg twice daily by oral of each 4-week cycle
45632578|NCT03105089|Procedure|ischemic preconditioning|) ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
45447855|NCT02126956|Drug|ACT-128800|ACT-128800 was supplied as a powder mix in hard gelatin capsules for oral administration. The capsules contained a co-precipitated mixture of non-radiolabeled and 14C-labeled ACT-128800 formulated at a dose strength of 40 mg with a maximum radioactive content of 102 μCi (3.79 MBq).
45771859|NCT00002428|Biological|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
45771860|NCT00002428|Biological|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
45771861|NCT01422746|Drug|Metformin|500-1000 mg PO BID (X12 weeks)
45771862|NCT00002272|Drug|Foscarnet sodium|
45771863|NCT01002755|Drug|Lenalidomide|Given PO
45771864|NCT01002755|Biological|Ofatumumab|Given IV
45771865|NCT04331314|Device|Use of Symbios Bone Graft Material|Patients will receive Symbios Bone Graft Material according to randomization Group.
45771866|NCT04331314|Device|Algipore Bone Substitution Material|Patients will receive Algipore Bone Substitution Material according to randomization Group.
45632579|NCT02330315|Device|transcranial direct current stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
45632580|NCT02330315|Device|transcranial ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
45771867|NCT01887860|Other|Cetaphil Daily Facial Moisturizer SPF 50|Other: Cetaphil Daily Advance Ultra Hydrating Lotion 0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
45771868|NCT00539162|Behavioral|Questionnaire|Questionnaires completed at baseline and during each follow up visit.
45447856|NCT02124148|Drug|Prexasertib|Administered IV
45632581|NCT02335307|Genetic|CYP2D6 genotyping|CYP2D6 genotype results and an interpretive report will be placed in the electronic medical record to assist the physician with prescribing medication for pain management.
45632582|NCT02335307|Other|Pain assessment questionnaire|A pain assessment questionnaire will be administered at baseline and 3 months.
45632583|NCT02335307|Other|Physician assessment|20-item survey administered to physicians treating patients enrolled in the study
45632584|NCT02335385|Procedure|single incision laparoscopic varicocelectomy|bilateral and unilateral varicocelectomy was performed through a single transumbilical flexible SILS port.
45771869|NCT01003067|Device|Mesh implementation|Prophylactic intraperitoneal mesh implantation in laparoscopic surgery to prevent incisional hernia.
45632585|NCT02335385|Procedure|conventional transperitoneal laparoscopic varicocelectomy|bilateral and unilateral varicocelectomy was performed through a conventional 3-ports transperitoneal varicoceletomy
45771870|NCT00002434|Drug|Trimetrexate glucuronate|
45771871|NCT00002434|Drug|Leucovorin calcium|
45447857|NCT02124148|Drug|Cisplatin|Administered IV
45632586|NCT02335151|Drug|Desflurane|Apply desflurane as anesthetic
45632587|NCT02330237|Drug|natural gels|whole fruits and vegetables
45632588|NCT02330237|Drug|Placebo|
45771872|NCT00002278|Drug|Diclazuril|
45771873|NCT01885130|Other|Cetaphil Daily Advance Ultra Hydrating Lotion|0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
45771874|NCT01003301|Drug|Omalizumab|Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
45771875|NCT01003301|Drug|Placebo|Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
45447858|NCT02124148|Drug|Cetuximab|Administered IV
45447859|NCT02124148|Drug|G-CSF|Administered SC
45447860|NCT02124148|Drug|Pemetrexed|Administered IV
45447861|NCT02124148|Drug|Fluorouracil|Administered IV
45447862|NCT02124148|Drug|LY3023414|Administered PO
45447863|NCT02124148|Drug|Leucovorin|Administered IV
45632589|NCT03890237|Behavioral|Her Spaces|Her Spaces will comprise a set of activities leveraging the Her Spaces curriculum and program model which includes curriculum-based sessions for 11-13 year old girls, with 40 sessions delivered weekly over the course of 10 months
45771876|NCT00002440|Drug|Indinavir sulfate|
45771877|NCT00002440|Drug|Ritonavir|
45771878|NCT00002440|Drug|Abacavir sulfate|
45771879|NCT00002440|Drug|Amprenavir|
45771880|NCT00002440|Drug|Nelfinavir mesylate|
45771881|NCT00002440|Drug|Saquinavir|
45771882|NCT01421810|Drug|Dexamethasone|1 mg PO
45771883|NCT01421810|Drug|rhCG|25 mcg IV
45771884|NCT00002284|Drug|Zidovudine|
45771885|NCT01243957|Drug|LY2216684|LY2216684: 18 mg po QD on Days 1, 2, and 3 and Days 25-27
45771886|NCT01243957|Drug|Fluoxetine|Fluoxetine: 60 mg po QD for 7 days (Days 4-10) then 20 mg po QD for 17 days (Days 11-27)
45771887|NCT00002446|Drug|Posaconazole|
45771888|NCT00002446|Drug|Fluconazole|
45935389|NCT02958085|Drug|NNC0174-0833|Doses of NNC0174-0833, dosed either once daily or once weekly
45632590|NCT03890237|Behavioral|Act With Her|Act With Her was designed to facilitate adolescent transitions to adulthood via improvements across the six GAGE domains (education, bodily integrity, health, psychosocial well-being, voice and agency, and economic empowerment). Project activities fall into three main categories: curriculum-based programming with adolescent girls and boys, community transformation, and systems strengthening. Act With Her will work with 10-13 year old girls and boys for 10 months and implement community-level and high-level system strengthening work up to 24 months (in rural and pastoralist areas).
45632591|NCT03890237|Behavioral|Act With Her + Asset Transfer|This arm will implement the Act With Her program described above, using program curricula with 10-13-year-old girls and boys over 10 months and conducting community-level systems strengthening up to 24 months. Additionally, the girls participating in this arm will receive one of three asset transfer options. The packages will be of equal value (115 USD) - one will include school supplies, one will include hygiene supplies, and will be a combination of both. Each adolescent girl will choose which package she would like to receive and will receive components of the package at 3 timepoints over the course of the first 10 months of the project.
45632592|NCT03890237|Behavioral|Act With Her (simple)|This arm will implement the Act With Her curricula described above with 10-13 year old girls and boys over 10 months. The adolescent groups will follow the same model (near-peer, same-sex mentors, 40 weekly meetings for girls, 18 meetings for boys, 4 of which are joint sessions for boys and girls, 6 sessions for parents), but will not include community-level systems strengthening activities
45632593|NCT02330003|Biological|IL-YANG FLU Vaccine Prefilled Syringe INJ.|Second vaccination (only for the test group) of IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL
45771889|NCT01895816|Dietary Supplement|coated tablet|this supplement contains 700 mg of 8 natural herbals: Citrus & ZINGIBER OFFICINALE & Onion & Ocimum basilicum & Cinnamomum zelanicum & Citrullus lanatus & Citrullus vulgaris & Daucus carota
45771890|NCT05589233|Biological|Vaccionation eighter started or full course|Vaccination against SARS-CoV-2 at any number of doses
45771891|NCT02979847|Procedure|hybrid approach|Before transseptal puncture, epicardial puncture is performed through subxyphoid approach. Atrial epicardial potentials are recorded using multi-electrode catheter, leading an activation map for atrial tachycardia and map for continuous fractionated atrial electrograms during atrial fibrillation. Endocardial potentials are also recorded in the same fashion. Procedural endpoint is a tachycardia termination or a noninducibility of tachycardia.
45913739|NCT02026180|Device|Micropuncture Access|Femoral arterial access will be obtained either with a 21G micropuncture needle kit or an 18G standard access needle.
45913740|NCT02026219|Drug|Clopidogrel|Clopidogrel 600mg loading
46070051|NCT00806923|Drug|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of each 3 week cycle until disease progression
45447864|NCT03753854|Diagnostic Test|polysomnography and oxygen saturation exam|Measurement of the Apnea/hypopnea index (AHI) and oxygen saturation
45447865|NCT03753854|Biological|calculation of VOC frequency between the first polysomnography and the end of the first year of continuous positive airway pressure treatment|calculation of VOC rate within the two previous years or between first polysomnography and one year of continuous positive airway pressure treatment
45447866|NCT03753854|Biological|Blood samples|Blood samples with measurements of hematological, hemorheological, inflammatory and blood coagulation markers
45447867|NCT03753854|Other|Physiological measurements|Evaluation of microvascular reactivity and autonomic nervous system activity
45632594|NCT02330003|Biological|Fluarix Prefilled Syringe|Fluarix Prefilled Syringe 0.5mL
45632595|NCT02335073|Other|Venous blood|
45632596|NCT02330159|Procedure|Novel Wound Healing Protocol|All patients will undergo surgical excision of the pilonidal disease and application of the novel wound healing protocol. After excision, MatriStem MicroMatrix powder will be applied to the wound bed. A MatriStem Multilayer Wound Matrix sheet will then be placed over the MatriStem MicroMatrix, secured in place, then covered with surface dressings. The wound should be left undisturbed for 10-14 days (until the 1st follow-up visit). At the 1st postoperative visit, the wound will reassessed, and a second application of the MicroMatrix to the wound bed may be performed. At subsequent follow-up visits at 1, 3, and 6 months, the wound bed will be measured, photo documentation will be captured, and patients will complete a survey to assess quality of life.
45771892|NCT02979847|Procedure|conventional endocardial approach|Atrial endocardial potentials are recorded using multi-electrode catheter, leading an activation map for atrial tachycardia and map for continuous fractionated atrial electrograms during atrial fibrillation. Procedural endpoint is a tachycardia termination or a noninducibility of tachycardia.
45771893|NCT01884740|Drug|SIACI of Erbitux and Bevacizumab|Subjects will receive a single intra-arterial dose of Cetuximab (200 mg/m^2) and Bevacizumab (15 mg/kg) via Superselective Intraarterial Cerebral Infusion (SIACI).
45771894|NCT00002290|Drug|Zidovudine|
45771895|NCT00002290|Drug|Acyclovir|
45771896|NCT01003769|Drug|Lenalidomide|Given PO
45771897|NCT01003769|Drug|R-(-)-Gossypol Acetic Acid|Given PO
45771898|NCT01003769|Other|Laboratory Biomarker Analysis|Correlative studies
45771899|NCT00002452|Drug|L-756423|
45771900|NCT00002452|Drug|Indinavir sulfate|
45913741|NCT02026219|Drug|Ticagrelor|Ticagrelor 180mg loading
45913742|NCT02026245|Device|Data gloves to perform movements|"Using the electronic data gloves to perform a set routine of movements:~5DT 'dataglove 14 Ultra' Electronic glove (commercially available)~New 'Tyndall/UU' developmental dataglove"
45913743|NCT02026271|Biological|Ad-RTS-hIL-12|"2.0 x 10^11 viral particles (vp) per injection or 1.0 x 10^12 viral particles (vp) per injection~one intratumoral injection of Ad-RTS-hIL-12"
45913744|NCT02026271|Drug|veledimex|"4 doses (20mg/day, 40mg/day, 80mg/day, and 120mg/day)~14 oral daily doses of veledimex~1 Expansion cohort at a single dose level at or below MTD"
46070052|NCT04125537|Behavioral|IHI Breakthrough Collaborative Model|Staff participants participate in a quality improvement/collaborative learning model that includes three in-person learning sessions, and three activity sessions during which staff teams at each site use quality improvement processes to implement best practices from the change package. Technical assistance, education, and quality improvement coaching are provided to the site staff teams throughout the project.
46070053|NCT04125147|Device|Experimental: Montage Bone Hemostat|Use of Montage bone hemostat on the cut surfaces of bone at the osteotomy site
46070054|NCT00698607|Device|Everolimus-eluting stent (Xience or Promus)|Use everolimus-eluting stent in the treatment of coronary stenosis
45771901|NCT01244503|Drug|Sodium Octanoate Breath Test|100 mg of 13-C labeled sodium octanoate (Octanoate for short) is to be dissolved in 1 cup of tap water and administered to subject after baseline breath collection is completed.
45632597|NCT02334839|Other|Observational only|Endothelial function will be assessed using ENDO-PAT (Itamar medical LTD, Caesarea, Israel) device, which evaluates the change in peripheral vascular tone in reaction to temporal ischemia in a process called Reactive Hyperemia (RH) .The RH-PAT is a blood pressure measurement-like cuff which is placed on the non-dominant arm. A pneumatic probe is placed on the index finger bilaterally (one serves as a control). After a baseline assessment for a 5 minutes period, the cuff is inflated to a 60mm Hg pressure above the systolic pressure in order to occlude the arterial flow distal to the brachial artery. After 5 minutes of occlusion, a prompt deflation of the cuff results in a RH response and vasodilatation in the distal arteries including those monitored in the index finger. The sensor translates the change in vascular tone and the ENDO-PAT V3.0.4 device analyzes the data automatically. The results are given in a RH index scale that reflects the level of reactive hyperemia.
45632598|NCT02329769|Drug|PRO044 SC 6 mg/kg|
45632599|NCT02329769|Drug|PRO044 IV 6 mg/kg|
45913745|NCT02026284|Other|Questionnaire|A questionnaire was performed to gravid women who are to deliver, regarding theri anesthesia preferences.
45632600|NCT02329769|Drug|PRO044 IV 9 mg/kg|
45632601|NCT02441803|Drug|Busulfan|Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3.
45632602|NCT02441803|Drug|Fludarabine|Fludarabine 10 mg/m2 by vein on Days -6 to -3.
45632603|NCT02441803|Drug|Clofarabine|"Salvage Chemotherapy Before Transplant: Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Clofarabine 40 mg/m2 by vein on Days -6 to -3."
45632604|NCT02441803|Radiation|Total Body Irradiation (TBI)|Total body irradiation (TBI) delivered at 2Gy on Day -2.
45632605|NCT02441803|Drug|Thymoglobulin|Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2.
45632606|NCT02441803|Biological|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood (PB) progenitor cells infused on Day 0. Goal is to infuse 4 X 106 CD34+ cells/kg if PB or >3.0 X 108 marrow mononuclear cells/kg if bone marrow.
45632607|NCT02441803|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg by vein on Days +3 and +4.
45632608|NCT02441803|Drug|Tacrolimus|Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5.
45771902|NCT00515372|Other|Telephone Counseling|Weekly phone calls lasting about 30 minutes.
45771903|NCT00515372|Other|Usual Care|Lists of professional resources and referral recommendations will be provided.
45771904|NCT05720884|Device|acupuncture|Acupuncture of a disposable, sterilized, stainless steel needle of 0.20 mm * 30 mm size (Dongbang medical, Boryeong, Rep of Korea) will be used.
45771905|NCT05720884|Device|placebo acupuncture|Acupuncture of a disposable, sterilized, stainless steel needle of 0.20 mm * 30 mm size (Dongbang medical, Boryeong, Rep of Korea) will be used but in differene location.
45771906|NCT01004393|Drug|Methylnaltrexone bromide|Methylnaltrexone bromide, dosage based on weight (0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg), single dose
45771907|NCT00002458|Biological|monoclonal antibody 3F8|
45771908|NCT00002470|Biological|recombinant interferon alfa|
45771909|NCT00002470|Drug|fluorouracil|
45913746|NCT02026310|Drug|glimepiride|on the basis of metformin and glargine, glimepiride is added; with the maximun dose of glimepiride, if the targeted FPG is not reached, glargine dose will be increased.
45913747|NCT02026310|Drug|glargine and metformin|
45913748|NCT02026323|Other|acupuncture|acupuncture
45913749|NCT02026336|Other|electronic nose|"Exhaled gas to assess e-nose VOC profiles was collected as described. Briefly, patients breathed through a mouthpiece into a 2-way nonrebreathing valve (Hans rudolph 2700, Hans rudolph, Kansas City, Mo) with an inspiratory VOC filter and an expiratory silica reservoir to dry the expired air. Expiratory air was collected in a 10-L Tedlar bag. Within not more than 10 minutes, the bag was connected to the e-nose device (Cyranose 320®; Smith Detections, Pasadena, CA), provided with a 32 organic polymeric nano-composite sensor array, for 5 minutes and changes in the nano-sensor electrical resistance generated a breath-print VOC profile."
45913750|NCT02026362|Biological|MASCT:Multiple Antigens Specific Cellular Therapy|autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens .
45913751|NCT02026362|Other|The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment|
45913752|NCT02026479|Drug|Dexamethasone Phosphate|5mg; postauricular injection
45632609|NCT02441803|Drug|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100.
45632610|NCT02441803|Drug|Decitabine|20 mg/m2 by vein on Days 1 - 5.
45632611|NCT02441803|Drug|Cytarabine|1 g/m2 by vein on Days 6 - 10.
45632612|NCT02441803|Drug|Idarubicin|10 mg/m2 by vein on Days 6 - 8.
45632613|NCT02334917|Procedure|Surgical wound closure with superficial absorbable sutures|Different superficial absorbable sutures will be used in the closure of skin wounds after Mohs surgery. No drugs or devices are being compared, only the two different absorbable sutures (Vicryl Rapide and Fast Absorbing Gut).
45632614|NCT02329457|Biological|Zostavax|varicella zoster vaccine
45632615|NCT02329457|Biological|Normal Saline|normal saline placebo vaccine
45632616|NCT02709655|Drug|Vortioxetine 10 mg/day|"10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"
45632617|NCT02709655|Drug|Vortioxetine 20 mg/day|"20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"
45771910|NCT01878344|Drug|NAC|
45771911|NCT01878344|Drug|Saline|
45771912|NCT00002476|Biological|bleomycin sulfate|
45771913|NCT00002476|Drug|fluorouracil|
45632618|NCT02709655|Drug|Fluoxetine 20mg/day|"20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"
45632619|NCT02709655|Other|Placebo|Encapsulated tablet, orally
45632620|NCT02334605|Other|cold dry air|"Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.~Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%."
45632621|NCT02334605|Device|hyperosmolar discs|A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.
45632622|NCT02334605|Device|capsaicin nasal spray|1 puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
45632623|NCT02329613|Other|Standard evening meals.|Patients will receive usual evening meals.
45632624|NCT02329613|Other|Improved evening meal|Patients will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.
45632625|NCT02334449|Drug|LML134|LML134 will be administered first as single doses and then as multiple doses
45632626|NCT02334449|Drug|Placebo|All study cohorts (except food effect cohort) are placebo controlled
45632627|NCT02441101|Device|RV DDD(R)-60 with AV optimization|Device to be programmed for RV pacing with AV interval optimization at the bedside to produce QRS fusion with the native conduction down the native left bundle on surface EKG
45632628|NCT02441101|Device|RV DDD(R)-60|AV settings programmed to minimize RV pacing - standard demand pacing programming.
45632629|NCT02329535|Drug|Micronized progesterone|vaginal caps 400 mg daily up to 36 weeks of gestation
45632630|NCT03187795|Drug|Oxybutynin Chloride IR|Oxybutynin chloride immediate release (IR) 5 mg three times daily for 6 weeks
45632631|NCT03187795|Drug|Mirabegron|Mirabegron 25 mg tablet once daily for 2 weeks, followed by mirabegron 50 mg once daily for 4 weeks (Note: Placebo twice daily will be included with mirabegron once daily to match the three-time daily dosing of oxybutynin IR in the other intervention).
45632632|NCT02329379|Drug|Levothyroxine|
45632633|NCT02334293|Drug|Omegaven|Omegaven® fat emulsion will be used as a Compassionate Use treatment for critically ill infants with PN associated liver injury.
45632634|NCT02441257|Procedure|control ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
45771914|NCT00002476|Drug|leucovorin calcium|
45771915|NCT00002476|Drug|methotrexate|
45913753|NCT02026479|Drug|Dexamethasone Phosphate|10mg; postauricular injection
45447868|NCT03753854|Other|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure during 1 year
45447869|NCT02124226|Drug|Methotrexate|7.5 mg/week + folic acid the day after
45632635|NCT02441257|Procedure|spontaneous ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
45632636|NCT02329067|Other|walnuts|consumption of 43 g walnuts per day
45632637|NCT02334137|Behavioral|iPad app|"Provided by the Patient Education Institute, the X-plain iPad app includes modules on healthy eating for diabetics, eye complications, foot care, and others."
45632638|NCT02334137|Behavioral|Educator sessions|A certified diabetes educator and/or registered dietitian will meet with patients for 30-60 minutes prior to their ophthalmology visits, when scheduling permits.
45632639|NCT02334137|Behavioral|Retinal photos|A resident ophthalmologist will spend approximately 5 minutes showing patient their own retinal photos, compared to a normal retina, and explaining the pathology present (if applicable).
45632640|NCT03189199|Other|a cohort using Dazhuhongjingtian injection|All patients will be measured and assessed at the time Dazhuhongjingtian Injection is administered to them until they discharge. Patients using Dazhuhongjingtian Injection will be registered on a registration form including disease background, Dazhuhongjingtian Injection's administration, and extraction information from hospital information system. An adverse event or drug adverse reaction form also will be used to describe any doubted symptoms or signs from patients. A judgment will be made by doctors directly and a further analysis will be conducted by researchers to decide those potential side effects of Dazhuhongjingtian Injection.
45632641|NCT02329145|Procedure|renal denervation|
45632642|NCT02435563|Drug|ticagrelor 180 mg administrated alone|
45771916|NCT00002476|Drug|vincristine sulfate|
45771917|NCT00002476|Radiation|low-LET cobalt-60 gamma ray therapy|
45771918|NCT00002476|Radiation|low-LET photon therapy|
45447870|NCT02124226|Drug|Placebo|matched placebo
45447871|NCT02127034|Drug|Mirabegron|oral
45447872|NCT02127034|Drug|Solifenacin|oral
45447873|NCT02127034|Drug|Digoxin|oral
45447874|NCT02251678|Dietary Supplement|Elimune Capsules|2 capsules BID for 28 days
45632643|NCT02435563|Drug|Ticagrelor adjusted dose + ritonavir 100mg|
45632644|NCT02329301|Drug|MDA with DHAp (Eurartesim)|Eurartesim is the brand name.
45632645|NCT02329301|Drug|Focal MDA with DHAp (Eurartesim)|Eurartesim is the brand name.
45771919|NCT00002476|Radiation|radiation therapy|
45771920|NCT01245439|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
45771921|NCT01876628|Drug|Flucloxacillin|Intravenous or oral Flucloxacillin. Minimum dose 500mg four times each day. Target duration 5 days less pre-recruitment beta-lactam duration.
45771922|NCT01876628|Drug|Clindamycin|Clindamycin dose 300mg four times each day for 2 days, within 48 hours of commencing flucloxacillin. Clindamycin is over-encapsulated and externally identical to placebo.
45771923|NCT01876628|Drug|Placebo oral capsule|Placebo is externally identical to the over-encapsulated clindamycin and is taken four times each day for 2 days
45771924|NCT01004705|Drug|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 12 weeks.
45771925|NCT01004705|Drug|Simvastatin|A once daily oral dose of simvastatin for 12 weeks.
45771926|NCT00002482|Biological|antibody therapy|
45771927|NCT00002482|Biological|biological therapy|
45771928|NCT00002482|Biological|muromonab-CD3|
45771929|NCT00002482|Drug|cyclophosphamide|
45913754|NCT02026479|Drug|Ginaton|40mg/pill, 3times/day,oral
45632646|NCT03187639|Diagnostic Test|FFRct|In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis of equal or > 40% data in at least one major epicardial vessel of stentable/graftable diameter will be referred for FFRct. (NB Lesions in distal vessels or vessels of a diameter not suitable for stenting/grafting will not qualify for FFRct if there are no other more significant lesions). In patients in whom FFRct analysis is performed, FFR will be derived for all vessels. The data derived from this test will determine their management strategy. The patients in this arm will not follow the NICE guideline algorithm. Those patients randomised to FFRct with contraindications for CTA will be asked to take part in a trial registry.
45632647|NCT03187639|Diagnostic Test|Standard care|All patients in the standard care group will be assessed according to their current conventional pathways that are based upon NICE guidelines for Chest Pain of Recent Onset. The trial will encourage the routine and standard assessment and management of all patients at these sites… (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance), in accordance with the local application of the NICE guideline for chest pain of recent onset.
45632648|NCT02328989|Device|Pessary|The device will be placed in the vagina during the consultation. It is rinsed in sterile water for lubrification and left in place until delivery or remove at 36 weeks in case of no delivery before. There is no need to use any analgesia. The good position of the pessary is checking in the same time than the placement with digital examination.
45632649|NCT03187873|Behavioral|Chama cha MamaToto|Chamas are a community-led model of peer support for women in pregnancy and infancy. Chamas are highly gendered institutions that women have relied on for survival to pool resources. Using this existing cultural script, chamas have been tailored to the needs of pregnant women. Central to the approach is the integration of health, social and financial literacy education with a savings/loans program. Chamas are designed to improve MNCH by generating positive peer support for women to advocate for themselves and account for the care they receive.
46070055|NCT00698607|Device|Sirolimus-eluting stent (Cypher)|Use sirolimus-eluting stent in the treatment of coronary stenosis
46070056|NCT00698607|Drug|6-month clopidogrel therapy|Use clopidogrel for 6 months
45447875|NCT01389050|Radiation|Intensity-Modulated Radiotherapy|Radiotherapy for the treatment of retroperitoneal sarcoma. IMRT will be 50.4 Gy given in 28 fractions.
45447876|NCT01389050|Radiation|Daily Cone Beam CT|Images and information from the daily CT will be used for the repositioning of the patient prior to their treatments as per standard procedures.
45632650|NCT02435485|Device|Biodex balance training|1.weight shift training, 2. random control training with Biodex balance system.
45632651|NCT02435485|Other|Rehabilitation including core spinal stabilization exercise|Rehabilitation: 2-3 times a week, up to 8 weeks, 15 sessions in total. Each session will include hot packing, interferential therapy, core spine stablilzation exercise and low extremity strengthening exercise.
45771930|NCT01417286|Radiation|External beam radiation therapy|Hypofractionated accelerated radiation therapy over 11 days
45771931|NCT01417208|Device|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
45771932|NCT00505310|Behavioral|Writing|20 minutes of writing on different topics at four different times.
45771933|NCT00505310|Behavioral|Questionnaire|Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
45771934|NCT01004939|Drug|fondaparinux|fondaparinux
45771935|NCT05750836|Other|Specific nursing support|"3 mandatory on-site nursing consultations with the patient's caregiver at inclusion, 6 months and 12 months post-randomisation.The caregivers will complete the questionnaires (Zarit scale, Hospital Anxiety and Depression scale, Medical Outcome Study Short Form - 36, Caregiver's satisfaction).~interviews once a month with a nurse either by phone, on-site consultation or teleconsultation.~Nurses assess the general health of the caregiver and Identify the socio-professional situation of the caregiver"
45771936|NCT05750836|Other|Non-specific nursing support|Caregivers will only have to complete on site Health indicators, Zarit scale, Hospital Anxiety and Depression scale, Medical Outcome Study Short Form - 36 at inclusion, 6 months and 12 months post-randomisation.
45771937|NCT04389710|Drug|Convalescent Plasma|One to two units (200-600 mL) of ABO compatible COVID-19 convalescent plasma
45771938|NCT04239248|Dietary Supplement|Tasty&Healthy intervention group|"patients will receive dietary advice to exclude pro-inflammatory dietary components based on the book Tasty&Healthy."
45771939|NCT04239248|Dietary Supplement|EEN intervention group|Oral exclusive feeding of formulated food (EEN), using Modulen formula only, for 8 weeks in amount based on the Daily Recommendations Intake. Those not tolerating oral EEN can receive EEN via a nasogastric tube.
45771940|NCT05750758|Drug|rivaroxaban|rivaroxaban 2.5mg bid for 1m
45771941|NCT00002488|Drug|cisplatin|
45771942|NCT00002488|Drug|cyclophosphamide|
45771943|NCT00002488|Drug|etoposide|
45771944|NCT01864850|Radiation|Standard RT|70 Gy / 7 weeks / 2 Gy per fraction
45771945|NCT01864850|Radiation|Hypofractionated RT|55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
45771946|NCT03015389|Procedure|Diagnostic Test|WATS3D brush biopsy
45771947|NCT01245595|Drug|Aminophylline|5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
45771948|NCT01245595|Drug|Placebo|Normal Saline
45913755|NCT02026492|Other|Exercise challenge in a cold chamber|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
46070057|NCT00698607|Drug|12-month clopidogrel therapy|Use clopidogrel for 12 months
46070058|NCT04124757|Other|Deep neuromuscular block|Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count
46070059|NCT04123041|Other|JUUL ENDS, Combustible cigarette, comparator e-cigarette, Nicorette gum|JUUL ENDS and comparator e-cigarette will be used for 5 minutes ad libitum, one combustible cigarette will be used ad libitum, Nicorette gum will be used for 30 minutes ad libitum
46070060|NCT04122495|Dietary Supplement|Probiotic|Oral administration of B. lactis M8 at 10 log CFU/day for 4-weeks
46070061|NCT04122495|Dietary Supplement|Placebo|Oral administration of maltodextrin daily for 4-weeks
46070062|NCT00698763|Drug|Levosimendan|from 0.125 mg to 2 mg in escalating doses
46070063|NCT00698763|Drug|Placebo|Placebo capsules are identical in appearance to active capsules
45632652|NCT02334371|Radiation|MR-PET|The MR-PET will be performed with the Biograph mMR system (Siemens Healthcare, Erlangen, Germany). This system integrates a 3Tesla MRI and PET scan which makes simultaneous acquisition of whole-body MRI and PET images possible. The Biograph mMR holds the CE mark and was FDA approved in June 2011. The Biograph mMR is intended to be used in the Academical hospita! Maastricht for standard patient care. The radiotracer that will be used is 18F-Iabeled fluorodeoxyglucose (18F-FDG), according to standard PET -protocol.
45632653|NCT02435641|Other|Questionnaires|All subjects (patients and caregivers) will complete a battery of psychological questionnaires at baseline (ICU admission), 3 months post-baseline, and 6 months post-baseline.
45632654|NCT04031729|Drug|Aspirin 81 mg|Aspirin 81mg tablets will be given once daily, for the duration of the clinical trial.
45632655|NCT04031729|Drug|Placebo oral tablet|Identical, blinded placebo tablets will be given once daily, for the duration of the clinical trial.
45632656|NCT02708485|Other|Physical exercise|A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
45632657|NCT02435407|Behavioral|SOS|Ten (10) children will be randomized to participate in the SOS intervention arm. The intervention will be divided into two groups of 5 children with 2 therapists assigned. The children will attend 1 hour intervention sessions once a week for 12 weeks. Here they will be introduced to different types of foods that they would not have typically eaten in a play based group session. The SOS intervention utilizes the principle of hierarchal desensitization.
45632658|NCT02435407|Other|Education|Parents will be given three 1 hour educational talks around the aetiology and management of feeding difficulties in children with autism spectrum disorder. This will be administered at 3 distinct time points; baseline, week 6 and week 12 of the study.
45771949|NCT01864772|Drug|Carbo, 5FU, Cetuximab|"6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)~Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity"
45771950|NCT03010891|Behavioral|The bundle of supportive interventions|usual NICU care +positioning + gentle touch + modulating infant states + facilitated tucking + NNS+ oral sucrose+ routine KMC > 45 minutes
45771951|NCT03010891|Behavioral|Usual NICU care|usual NICU care + positioning + gentle touch +routine KMC < 20 minutes
46070064|NCT00658723|Drug|Fibrin Pad|Fibrin Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
46070065|NCT00658723|Device|SURGICEL™|Absorbable hemostat
46070066|NCT00800059|Radiation|Total Marrow Irradiation|Total Marrow Irradiation delivered by chemotherapy delivered to cohorts of patients in a dose escalation. The initial cohort will receive 14 Gy. If tolerated subsequent cohorts will receive an additional 2 Gy until the maximum tolerated dose or 28 Gy is reached.
46070067|NCT00804895|Drug|ALTIM, cortivazol injections|ALTIM, cortivazol in greater occipital nerve injection separated by 2 or 3 days each.
45447877|NCT02251756|Device|Actinica, 0.8 mg/cm2, 1 application|
45632659|NCT02333903|Other|Personalized Physical Activity|"1.5 hours physical training sessions, twice a week for 1 year, under the supervision of a dedicated coach specialized in supporting overweighted patients.~Typical training session organized for small groups (5 patients) will consist of aerobic exercises, muscular strengthening (4 peripheral members and abdominal muscular belt), followed by stretching exercises."
45632660|NCT02441023|Behavioral|Nutritional therapy and education|"Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.~Education with multimedia application: Patients were exposed to the multimedia application previous to the nutritional counseling. Multimedia application comprises the following modules: 1) Introduction, 2) Nutrition, 3) Physical Exercise, 4) Diabetes myths 5) Metabolic control indicators 6) Knowing diabetes, 7) Diabetes complications including testimonials."
45771952|NCT00002494|Drug|cyclophosphamide|
45771953|NCT00002494|Drug|cytarabine|
45771954|NCT00002494|Drug|dexamethasone|
45771955|NCT00002494|Drug|doxorubicin hydrochloride|
45771956|NCT00002494|Drug|etoposide|
45771957|NCT00002494|Drug|ifosfamide|
45771958|NCT00002494|Drug|leucovorin calcium|
45771959|NCT00002494|Drug|mesna|
45771960|NCT00002494|Drug|methotrexate|
45771961|NCT00002494|Drug|prednisone|
45771962|NCT00002494|Drug|therapeutic hydrocortisone|
45771963|NCT00002494|Drug|vincristine sulfate|
45771964|NCT00002494|Radiation|low-LET cobalt-60 gamma ray therapy|
45771965|NCT00002494|Radiation|low-LET photon therapy|
45771966|NCT02164721|Device|Three-lead CRT-D (Defibrillator)|The three-lead CRT-D (Defibrillator) will consist of a pulse generator, a right atrial lead, a right ventricular lead and a left ventricular lead.
45771967|NCT00002506|Biological|recombinant interferon alfa|
45771968|NCT00002506|Drug|isotretinoin|
45771969|NCT01895894|Drug|Mycophenolate mofetil|Mycophenolate mofetil 20~30mg/kg/day PO until nephrotic syndrome relapse (max. 1 year)
45771970|NCT02165111|Drug|Onabotulinumtoxin A|
46070068|NCT00804895|Drug|PROAMP, subcutaneous serum physiological saline|Three injections will be performed at the level of the greater occipital nerve with a suboccipital approach. Injection will be separated by two or three days each.
46070069|NCT00804895|Drug|Verapamil|standard prophylactic treatment
45632661|NCT02441023|Behavioral|Nutritional therapy|Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association Standards for medical care in diabetes.
45632662|NCT02333981|Device|passive oral motor therapy for drooling|7 subjects aged 7-19 yrs were taken . All subjects received passive treatment which included light touch, stroking, vibration with (mechanical vibrator), tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
45632663|NCT02433847|Drug|Mosapride|
45632664|NCT02328833|Other|Experimental strategies of guidelines implementation|Experimental strategies of Depression Guidelines implementation in Primary Care Centers. The active process includes the establishment of local implementation teams, seminars, regular feedback and follow-up visits for four months.
45632665|NCT02435329|Other|Baseline comparison of microcirculation and bone metabolism|Baseline comparison of microcirculation and bone metabolism among the 5 different groups
45632666|NCT02435251|Device|dual energy X-ray absorptiometry|
45632667|NCT03187483|Procedure|orthodontic treatment|orthodontic treatment in maxillary crowding
45632668|NCT02328911|Device|Laser treatment|Laser energy will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits therapeutic dual-wavelength infrared laser energy as well as red visible light.
45632669|NCT02328911|Device|Sham treatment|A sham treatment will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits only red visible light.
45632670|NCT02435095|Drug|Maintenance treatment|"Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) for at least 12 months.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole)."
45632671|NCT02435095|Drug|Intermittent treatment|"Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) only for first episode of schizophrenia, tapering-off medication after remission of positive symptoms, reinstatement of treatment only in case of recurrence of positive symptoms.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole)."
45632672|NCT04477421|Procedure|FS-SMILE|Femtosecond small incision lenticule extraction
45632673|NCT04477421|Procedure|S-LASIK|Femtosecond laser Insitu keratomileusis
45632674|NCT01307813|Device|Overstitch Endoscopic Suturing System|"Assess the safety and effectiveness of the Apollo endoscopic suturing device (Overstitch) and cinching device for placement of sutures and surgical knots in a segment of colon under laparoscopic or open visualization of the operative area.~Patients will already require resection of segments of colon for treatment of benign or malignant disease and this will therefore be a treat and resect model"
45632675|NCT03111251|Behavioral|Provider assessment and feedback|Tailored immunization reports highlighting adolescent vaccination rates at the individual, clinic and network levels are distributed by clinic champions every quarter. Reports track vaccination rates over time and allow physicians to compare their rates to the national goal.
45632676|NCT03111251|Behavioral|Provider reminders|An EHR-based reminder system informs providers when patients are due or overdue for HPV vaccination.
45632677|NCT03111251|Behavioral|Provider education|Provider education is being delivered through a comprehensive online continuing education activity that is tailored specifically to physicians, nurses, and clinical staff at TCP practices. It focuses on HPV vaccination best practices and communicating with parents about the HPV vaccine.
45632678|NCT03111251|Behavioral|Patient reminders|Patient reminders are delivered through MyChart, the clinics' online personal health record system, to inform patients (parents) that they are due or overdue for HPV vaccination.
45632679|NCT03111251|Behavioral|Parent education|The parent education intervention (currently in development) will employ innovative strategies to identify and overcome barriers to HPV vaccination.
45632680|NCT02333669|Other|no intervention|no intervention
45632681|NCT02333747|Device|the Hans electronic acupuncture apparatus|TEAS was performed with a dense-disperse frequency of 2/10 Hz and an intensity of 6-9 mA for 30 min using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China).
45632682|NCT02333591|Drug|GlucagonLikePeptide-1 (7-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
45632683|NCT02333591|Drug|GlucagonLikePeptide-1 (9-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
45632684|NCT02333591|Drug|Saline|Infused intravenously for 2,5 hours.
45632685|NCT02709577|Device|EndoBarrier Gastrointestinal Liner|The EndoBarrier is a single use, implant consisting of a tube of composite material which is placed in the proximal section of the duodenum. The implant is fixed in place with the aid of a metal anchor. The device is delivered via an endoscope. The implant facilitates the passage of food from the stomach through the tube to the proximal section of the jejunum.
45632686|NCT02709577|Other|Sham: endoscopy and standard of care|Sham subjects had an endoscopic procedure and then received standard of care treatment of their diabetes
45632687|NCT02328521|Drug|Nicorandil|Nicorandil is given once before PCI and given 3 times daily for 30 days after PCI.
45632688|NCT02328521|Drug|nicorandil placebo|Nicorandil placebo is given once before PCI and given 3 times daily for 30 days after PCI.
45632689|NCT03192241|Other|Pump|Intervention is providing mothers with a manual breast pump and instructions for when it could be used.
45632690|NCT03192241|Other|Book|Active control intervention is providing mother's with a children's book and information about reading to baby.
45632691|NCT03831503|Biological|INO-A002|Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).
45632692|NCT03831503|Device|CELLECTRA® 2000|Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.
45632693|NCT03831503|Device|Dengue Fever Antibodies (IgG)|To determine if the subject is Dengue seronegative at baseline
45447878|NCT02251756|Device|Actinica, 0.8 mg/cm2, 2 applications|
45771971|NCT02165111|Drug|sterile saline solution|
45771972|NCT05750680|Drug|DOACs|outpatients visited in anticoagulation clinics with a prescription of DOAC for atrial fibrillation and venous thromboembolism and concomitant antiepileptic drug will perform a blood draw for measurement of dabigatran, rivaroxaban, apixaban and edoxaban
45771973|NCT05750602|Dietary Supplement|LIMICOL|Suplementation with LIMICOL, 3 tablets per day, together with supervised physical activity (3 times per week) for 12 weeks.
45632694|NCT03187093|Drug|Vortioxetine|10-20 mg once daily for 8 weeks
45771974|NCT05750602|Dietary Supplement|PLACEBO|Suplementation with PLACEBO, 3 tablets per day, together with supervised physical activity (3 times per week) for 12 weeks.
45771975|NCT04755374|Other|Discharged ≤ 21 days|Discharged from palliative care unit in equal less than 21 days
45771976|NCT04755374|Other|Prolonged discharge|Discharged from palliative care unit in longer than 21 days
45771977|NCT04389788|Device|carboxy therapy|6 sessions of carboxy therapy every 2 weeks
45771978|NCT04389788|Device|Dermapen with topical glutathione|6 sessions of Dermapen microneedling with topical glutathione every 2 weeks
45913756|NCT02026492|Other|Methacholine challenge|nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
45632695|NCT03187093|Drug|Escitalopram|10-20 mg once daily for 8 weeks
45632696|NCT02039999|Other|Nebulised citric acid in serial dilutions|Citric acid will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
45632697|NCT02039999|Other|Nebulised ATP solution in serial dilutions|ATP solution will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
45913757|NCT02026492|Other|Exercise challenge in room temperature|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in room temperature.
45632698|NCT02039999|Other|Nebulised TRPA1 agonist solution in serial dilutions|TRPA1 agonist will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
45632699|NCT02078752|Drug|PF-06647263|Part 1- PF-06647263 will be administered intravenously in either a 21 day cycle or weekly in cohorts of 2 or more patients starting at a dose of 0.015 mg/kg. Increases in dose will continue until MTD is determined.
45632700|NCT02078752|Drug|PF-06647263|Part 2- Patients with triple negative breast cancer will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
45632701|NCT03187249|Behavioral|Cognitive Behavioral Therapy|12 weeks cognitive-behavioral lessons, once a week
45632702|NCT03187249|Behavioral|Pulmonary Rehabilitation Therapy|12 weeks pulmonary rehabilitation exercise
45771979|NCT03998657|Device|Exablate Prostate Treatment|The Exablate system is a non-invasive thermal ablation device that is being used to ablate tissue. The system combines a focused ultrasound surgery (FUS) delivery system and MRI scanner.
45771980|NCT01357772|Drug|Tamoxifen|
45771981|NCT01357772|Drug|placebo|
45771982|NCT05750524|Other|reflexology hand massage|Reflexology massage methods applied randomly to both trial groups.
45771983|NCT05750524|Other|classical hand massage|Classical hand massage methods applied randomly to both trial groups.
45771984|NCT02246387|Procedure|Manchester Operation|A 3- compartment native tissue repair procedure for Pelvic Organ Prolapse.
45913758|NCT02026505|Drug|Bortezomib|
45913759|NCT02026518|Dietary Supplement|Soy isoflavones|
45913760|NCT02026518|Dietary Supplement|cholecalciferol|
45913761|NCT02026518|Dietary Supplement|Placebo of soy isoflavones|
45447879|NCT02251756|Device|Actinica, 2 mg/cm2, 1 application|
45447880|NCT02251756|Device|Actinica, 2 mg/cm2, 2 applications|
45447881|NCT01072370|Biological|Cord Blood Infusion|red-cell depleted, mononuclear cell enriched cord blood unit prepared for infusion
45447882|NCT01072370|Biological|Intravenous Sham|intravenous infusion of 5% dextrose, ¼ normal saline solution
45447883|NCT03247556|Drug|Placebo|Placebo was administered once daily
45447884|NCT03247556|Drug|400mg SPN-812|400mg SPN-812 was administered once daily and compared to Placebo
45447885|NCT03247556|Drug|600mg SPN-812|600mg SPN-812 was administered once daily and compared to Placebo
45913762|NCT02026518|Dietary Supplement|placebo of cholecalciferol|
45913763|NCT02026531|Other|3-Helium gas|3-Helium gas for MRI contrast
45913764|NCT02026544|Device|Low Frequency Therapeutic Ultrasound|29 kHz (kilohertz) low frequency therapeutic ultrasound delivered transcutaneously
45913765|NCT02026570|Behavioral|Internal Focus of Attention|Providing instructions for the user to manipulate their residual limb in space during standing and walking tasks.
45913766|NCT02026570|Behavioral|External Focus of Attention|Providing instructions for the user to manipulate their prosthetic foot in space during standing and walking tasks.
45913767|NCT02026583|Drug|Simvastatin|
45632703|NCT03187249|Behavioral|Combined Therapy|cognitive-behavioral lessons and pulmonary rehabilitation exercise for 12 weeks
45632704|NCT03191851|Device|standard device|paracentesis using standard
45632705|NCT03191851|Device|Melody Device|paracentesis using Melody Device
45632706|NCT03191851|Device|Melody Device with Pump|paracentesis using Melody Device with Pump
45632707|NCT03145571|Procedure|Continuity of midwifery care|Pre-natal care in rural villages performed by the midwives from the local hospital
45632708|NCT02434627|Drug|Sodium Nitrate|Patients will be given sodium nitrate daily in the form of beetroot juice.
45632709|NCT03145103|Device|CT ASPHINA 409|intraocular lens
45632710|NCT03187171|Other|Allograft Fusion|ACDF is a surgical technique used to treat a variety of cervical spine disorders, such as nerve root or spinal cord compression, cervical spondylosis, and cervical spinal stenosis. The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft was first described by Robinson and Smith in 1955. In 1958, Cloward described a wide anterior cylindrical discectomy performed with a special reamer combined with anterior fusion by the insertion of autologous iliac bone graft of the same shape. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
45632711|NCT03187171|Device|Cohere PEEK Fusion Group|Bagby et al. developed the first interbody fusion cage. Cages of different shapes and materials are used to perform ACDF which, in some cases, could be associated with plate fixation. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
45632712|NCT02434861|Drug|Rolapitant|
45632713|NCT02434861|Drug|Digoxin|P-gp substrate
45632714|NCT02434861|Drug|Sulfasalazine|BCRP substrate
45632715|NCT02434861|Drug|Cooperstown Cocktail|Midazolam, omeprazole, warfarin, caffeine, and dextromethorphan
45632716|NCT02328365|Other|Structured medical follow-up after operation|Patients in the intervention arm are seen by a physician on the 4th or 5th postoperative day before discharge to pick up and manage any medical problems, and are furthermore seen in the cardiology clinic 1 month after operation, and in the pulmonary medicine clinic 1 and 3 months after operation
45632717|NCT03187015|Drug|Entinostat|HDAC (histone deacetylase inhibitor)
45632718|NCT03187015|Drug|Midazolam|benzodiazepine central nervous system (CNS) depressant
45632719|NCT02328053|Procedure|collagen crosslinking group|collagen crosslinking with riboflavin and Ultraviolet A
45632720|NCT02328053|Drug|Topical anti-fungal therapy|topical antifungal medications like natamycin eye drops and voriconazole eye drops
45632721|NCT03186937|Dietary Supplement|hominex-2|Hominex-2 is a methionine-free amino acid modified medical supplement
45632722|NCT02022748|Drug|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 1, subjects will receive treatment A in Period 1 and treatment B in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 1. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
45632723|NCT02022748|Drug|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 2, subjects will receive treatment B in Period 1 and treatment A in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 2. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
45632724|NCT02022748|Drug|ticagrelor|Group B is healthy subjects. Group B healthy subjects will receive oral 90 mg ticagrelor referred to as Treatment H.
45632725|NCT02333513|Drug|Lomustine/Vincristine/Procarbazine|
45771985|NCT01357460|Device|Implantation of intrabronchial valves (IBV) (Spiration IBV)|"In advanced emphysema due to alpha1 antitrypsin deficiency even optimum treatment including drugs, physical training and possibly oxygen therapy is unable to influence exercise dyspnoea and exercise capacity.Implantation of intrabronchial valves in the most destroyed and hyperinflated lung lobe can improve the elastic recoil of the small airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function.The one-way mechanism of these valves allows air to escape from the downstream lung segment without any influx of new air during inspiration."
45771986|NCT03866837|Dietary Supplement|Galacto-oligosaccharides|Galacto-oligosaccharides are classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, are components of cow's milk and have been used repeatedly in clinical trials without adverse effects.
45771987|NCT03866837|Dietary Supplement|Bovine lactoferrin|Bovine lactoferrin is classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, is a component of cow's milk and has been used repeatedly in clinical trials without adverse effects.
45913768|NCT02026596|Procedure|Magnetic resonance imaging|
45935390|NCT02958085|Drug|Placebo|Dosed either once daily or once weekly
45935391|NCT00123526|Behavioral|Diet|Participants will also follow a healthy diet, characterized by higher intakes of fruits, vegetables, fish, poultry, legumes, and whole grains. Participants will consume less high fat foods and refined grains, and reduce their total caloric intake through smaller portion sizes.
45632726|NCT02434549|Drug|Dysport®|Intramuscular injections in spastic muscle with regional muscle-related pain
45632727|NCT02434549|Drug|Normal saline|Intramuscular injections in spastic muscle with regional muscle-related pain
45935392|NCT00123526|Behavioral|Physical Activity|The intervention will promote active living, in which physical activity is incorporated into each participants' daily routine.
45935393|NCT00043043|Drug|celecoxib|
45935394|NCT00123565|Drug|Hexadecasaccharide (SR123781A)|
45935395|NCT00123760|Procedure|Positron Emission Tomography (PET) scan|
45771988|NCT03866837|Dietary Supplement|Multiple micronutrient powders with 5 mg iron|The multiple micronutrient powders are composed of Vitamin A, 400 μg; Vitamin D, 5 μg; Tocopherol Equivalents, 5 mg; Thiamine, 0.5 mg; Riboflavin, 0.5 mg; Vitamin B6, 0.5 mg; Folic Acid, 90 μg; Niacin, 6 mg; Vitamin B12, 0.9 μg; Vitamin C, 30 mg; Copper, 0.56 mg; Iodine, 90 μg; Selenium, 17 μg; Zinc, 4.1 mg; Phytase, 190 FTU; Iron, 5 mg [(as Ferrous fumarate, 2.5 mg and sodium iron ethylenediaminetetraacetate (NaFeEDTA), 2.5 mg].
45771989|NCT05750446|Drug|Riociguat (BAY 63-2521)|A selective stimulator of soluble guanylate cyclase (sGC)
45771990|NCT05750446|Other|Placebo|Placebo
45632728|NCT03191773|Combination Product|Drugs and anti-CD19 CAR transduced T cells|"Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 (IV) will be infused over 30 minutes.~Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300-500mg/m2 IV will be infused over 60 minutes followed by fludarabine.~Biological: Anti-CD19-CAR T cells On day 0, cells will be infused intravenously IV over 20 - 30 minutes."
45632729|NCT02328287|Drug|ALLOB®|Each patient will undergo a single administration of ALLOB® into the failed fusion lumbar level under anesthesia.
45632730|NCT02328209|Drug|ranibizumab|0.5mg/0.05ml, intravitreal injection, frequency: each 8 or 12 weeks
45632731|NCT02022670|Drug|Placebo|Sugar pill manufactured to mimic sodium nitrite capsules
45632732|NCT02022670|Drug|Sodium Nitrite|80 mg/d or 160 mg/d
45632733|NCT02433769|Device|TOFscan|"Data from the TOFscan will be compared to simultaneously measured data from the TOF-Watch-SX (gold standard)"
45632734|NCT02433769|Device|TOF-Watch-SX|Data from the TOF-Watch-SX will be compared to simultaneously measured data from the TOFscan
45632735|NCT02328443|Drug|Midazolam|
45771991|NCT04756310|Dietary Supplement|Retilut|antioxidants, antiangiogenic, antiinflammatory micronutrients
45632736|NCT02328443|Drug|itraconazole|
45632737|NCT02328443|Drug|rifampicin|
45632738|NCT02076334|Other|Far Infrared Fabric|
45632739|NCT02076334|Other|Spandex|
45771992|NCT04756310|Dietary Supplement|Theavit|antioxidants micronutrients
45771993|NCT05750290|Drug|CKD-702 in combination with irinotecan|CKD-702 and irinotecan will be intravenously administered every 2 weeks.
45771994|NCT03845621|Device|Conventional Mouthguard|Use of a conventional custom-made mouthguard while playing water polo
45771995|NCT03845621|Device|Occlusal-adjusted Mouthguard|Use of an occlusal-adjusted custom-made mouthguard while playing water polo
45913769|NCT02026596|Procedure|Cerebral microdialysis catheter insertion|Is inserted only when invasive intracranial pressure monitoring is required. The same route with pressure probe is used for insertion.
45913770|NCT02026609|Other|Oral glutamine challenge|Blood ammonia determination before, 30-, 60-, and 90-minute, after intake of 10 g of L-glutamine
45632740|NCT05150197|Device|VisuALL|Virtual Reality Visual Field Device
45632741|NCT05150197|Device|Humphrey Visual Field|Standard of care Visual Field test
45632742|NCT02039765|Drug|Brimonidine tartrate|
45632743|NCT03191539|Drug|Apremilast|30 mg twice a day during 52 weeks. In the first 6 days will be a dose escalation
45632744|NCT03188809|Procedure|Adductor Canal Block|Adductor channel is roughly triangular in cross section and is bounded by three muscles: quadriceps anterolaterally (specifically vastusmedialis), sartorius medially and adductor magnus posteriorly. Within this canal is the femoral artery, femoral vein, the posterior branch of the obturator nerve, and branches of the femoral nerve; specifically the saphenous nerve and nerve to vastus medialis. When the femoral artery is shown by ultrasonography 21 gauge, 50 mm needle in-plane technique and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
45632745|NCT03188809|Procedure|femoral nerve block|The probe is placed just below the inguinal crease , when the femoral artery is shown by ultrasonography, the femoral nerve stays in the lateral direction and 21 gauge, 50 mm needle will be advanced from the anterior to the posteriomedial with an in-plane technique and the catheter will be inserted by the peripheral nerve stimulator in the lateral femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
45632746|NCT02327975|Other|Training group|"The main part of the session included a whole-body strength training, which incorporated chest press, shoulder press, lateral pull-down, seated row, shoulder flexion, chest pulley, hammer curl, biceps curl, triceps curl, triceps pushdown, leg extension, leg curl, lunge, squat, abdominal crunch. To control and equate the intensity between the TG and MG, a method based on the combined use of the prescribed number of repetitions and the OMNI Resistance Scale for the active muscles was used. Previous studies have described the method used for controlling exercise intensity (Colado et al., 2012; Colado et al., 2014).~During 1-3 weeks subjects performed 25 min of exercise at 60% maximum heart rate (HRmax), during weeks 4-6 subjects performed 30 min of exercise at 70% HRmax and during weeks 7-10 subjects performed 35 min of exercise at 80% HRmax."
45771996|NCT05750212|Diagnostic Test|Tone|Tone is a binary measurement of the pelvic floor muscle on physical examination
45771997|NCT05750212|Diagnostic Test|Tenderness|Tenderness is a binary measurement of the pelvic floor muscle on physical examination
45771998|NCT05750212|Diagnostic Test|Contraction|Contraction is a binary measurement of the pelvic floor muscle on physical examination
45771999|NCT05750212|Diagnostic Test|Relaxation|Relaxation is a binary measurement of the pelvic floor muscle on physical examination
45772000|NCT05750212|Diagnostic Test|Electromyography|Electromyography is a measurement of the pelvic floor muscle in microvolts
45772001|NCT05750212|Diagnostic Test|Transperineal|Transperineal measurements (in millimeters) of the pelvic floor muscle using an ultrasound
45913771|NCT02026609|Other|Psychometric Tests|PHES (portosystemic hepatic encephalopathy score) and ICT (inhibitory control test)
45913772|NCT02026622|Behavioral|psychometric tests|NEO-PI, MADRS, MINI depression, MMSE, STAI-E, ERD, Anhedonia
45913773|NCT02026622|Device|MRI|ASL, rest f-MRI, FLAIR, white matter hyper intensities load
45913774|NCT02026622|Device|transcranial doppler and TPI|transcranial doppler TPI
45913775|NCT02026622|Behavioral|explicitative interview|
45913776|NCT02026674|Device|FloRite|Disposable home use urine flow meter.
45935396|NCT00123799|Procedure|Positron Emission Tomography Imaging|
45632747|NCT02327975|Other|Mobile group|The subjects in this group received the same intervention that trainning group but through a mobile application (whatsapp).
45632748|NCT02327975|Other|Control group|No received intervention.
45632749|NCT02433925|Dietary Supplement|Resveratrol|
45632750|NCT02433925|Dietary Supplement|Placebo|
45632751|NCT02332967|Other|Whey predominant starter formula|Milk powder product given to babies between 1 week and 4 months
45632752|NCT02332967|Other|Whey predominant starter formula + 40% palmitic acid|Milk powder product containing 40% of palmitic acid
45632753|NCT02332967|Other|Whey predominant starter formula + 50% palmitic acid|Milk powder product containing 50% of palmitic acid
45632754|NCT02433691|Other|simultaneous aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes while receiving memory training.
45632755|NCT02433691|Other|sequential aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes followed by memory training.
45632756|NCT02433691|Other|stretching and toning|anaerobic stretching and toning followed by memory training.
45913777|NCT02026700|Device|bariederm cream|patients are asked to apply twice a day a barrier cream on their hands for 3 weeks only
45632757|NCT02327663|Drug|Emtricitabine|emtricitabine were given to each patients at baseline and respoonse guided therapy was adopted according HBV DNA level at week 24
45632758|NCT02440867|Device|Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
45632759|NCT02440867|Device|Sham TBS|Sham stimulation
45632760|NCT02021812|Device|GORE® TAG® Thoracic Branch Endoprosthesis|
45632761|NCT03191929|Other|HIT Intervention|"Patients in the HIT intervention completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider. Patients' scores were transmitted to the provider prior to their clinic visit.~Providers in the HIT intervention received a web-based training developed by the Harvard Program in Refugee Trauma to train providers in delivering culturally competent, trauma-informed care to address mental health problems and other trauma-related medical issues in patients who experienced extreme war trauma. Providers also received ongoing clinical decision support through a mobile application to support the diagnosis and initiation of treatment for depression and/or PTSD."
45632762|NCT03191929|Other|Minimal Intervention Control Arm|"Patients in the Minimal Intervention Control Arm completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider; however, patients' scores in the Minimal Intervention Control Arm were only transmitted to the provider prior to their clinic visit if they showed evidence of being at risk to harm either themselves or others.~Providers in the Minimal Intervention Control Arm completed the online tutorial, A physician's practical guide to culturally competent care, which was provided by The Office of Minority Health, US Department of Health and Human Services Website."
45632763|NCT02333123|Drug|Aspirin|Each 300mg aspirin capsule will contain over-encapsulated 4 x Aspirin 75mg tablets.
45632764|NCT02333123|Drug|Placebo (for Aspirin)|Each placebo capsule will contain a lactose and magnesium stearate blend, and will appear identical in weight, colour and size to the matched aspirin capsules.
45632765|NCT03188887|Drug|corticotherapy|3 IV pulses steroids followed by oral steroids for 4 months
45632766|NCT03188887|Drug|Renin Angiotensin system (RAS) blockade or Inhibitors of sodium glucose transporter 2 (SGLT2i)|treatment with Renin angiotensin system (RAS) blockade or SGLT2i
45632767|NCT02332811|Drug|sevelamer carbonate 800mg|"Pharmaceutical form:tablet~Route of administration: oral"
45632768|NCT02332811|Drug|sevelamer carbonate 2.4 g|"Pharmaceutical form:powder~Route of administration: oral"
45632769|NCT02433457|Drug|CC-292|
45632770|NCT02433457|Drug|Oral Omeprazole (OMP)|
45632771|NCT02021656|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily without regard to food
45632772|NCT03188653|Other|CeraVe® Eczema Soothing Body Wash|One of the 7 arm locations will be selected to receive CeraVe® Eczema Soothing Body Wash
45772002|NCT05750212|Diagnostic Test|Pressure|Pressure measurements (in millimeters) of the pelvic floor muscle using an algometer
45772003|NCT03015467|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation and the traditional treatments for Acute Pancreatitis with gut mucosal barrier dysfunction and unbalance of gut microflora in part 1
45913778|NCT02026713|Other|quit smoking for a 2 weeks period|evaluate the platelet reactivity after 15 days by quit smoking
45913779|NCT02026739|Procedure|low supplemental oxygen concentration|low supplemental oxygen concentration would be used during the surgery
45913780|NCT02026739|Procedure|high supplemental oxygen concentration (conventional)|high supplemental oxygen concentration would be used during the surgery
45913781|NCT02026765|Device|traditional lens|A random eyes with traditional lens
45632773|NCT03188653|Other|Cetaphil® RestoraDerm® Eczema Calming Body Wash|One of the 7 arm locations will be selected to receive Cetaphil® RestoraDerm® Eczema Calming Body Wash
45632774|NCT03188653|Other|Dove® Sensitive Skin Body Wash|One of the 7 arm locations will be selected to receive Dove® Sensitive Skin Body Wash
45632775|NCT03188653|Other|Eucerin® Skin Calming Body Wash|One of the 7 arm locations will be selected to receive Eucerin® Skin Calming Body Wash
45632776|NCT03188653|Other|Aveeno® Skin Relief Body Wash|One of the 7 arm locations will be selected to receive Aveeno® Skin Relief Body Wash
45632777|NCT03188653|Other|MooGoo® Milk Wash|One of the 7 arm locations will be selected to receive MooGoo® Milk Wash
45632778|NCT03188653|Other|Free & Clear Liquid Cleanser|One of the 7 arm locations will be selected to receive Free & Clear Liquid Cleanser
45632779|NCT03145025|Device|Retisert|Intravitreal Implant
45632780|NCT03145025|Drug|Fluocinolone Acetonide Intravitreal Implant|Intravitreal Implant
45772004|NCT03015467|Other|normal saline|normal saline and the traditional treatments for Acute Pancreatitis with gut mucosal barrier dysfunction and unbalance of gut microflora in part 2
45913782|NCT02026765|Device|heparin surface modified aspheric lens|the other eye implant heparin surface modified aspheric lens
45913783|NCT02026778|Drug|ondansetron|"The ondansetron group is given placebo (pyridoxin) instead of betahistine.~The ondansetron group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA."
45632781|NCT03144947|Biological|Trastuzumab IV|"Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2; cyclophosphamide 500 mg/m2) x 3 cycles~Post-randomization phase:~Group A: Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.~by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.~*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase."
45632782|NCT03144947|Biological|Trastuzumab SC|"Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2;~Group B: Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.~*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase."
45632783|NCT03144947|Biological|Pertuzumab|pertuzumab IV (840 mg loading dose, followed by 420 mg) weeks for 4 cycles (both arms)
45632784|NCT03144947|Drug|Docetaxel|docetaxel (75 mg/m2), every 3 weeks for 4 cycles (both arms). The dose of docetaxel may be escalated to 100 mg/m2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated.
45632785|NCT02440555|Other|fulfill the self-administered questionnaire|Patients viewed in a pharmacy or a hospital fulfill the self-administered questionnaire before having a capillary blood glucose measurement.
45632786|NCT02433535|Drug|Simvastatin|Simvastatin is used to lower cholesterol, however, it also possess anti-inflammatory and immunomodulatory properties that may also alleviate allergic airway inflammation in asthma.
45632787|NCT02433535|Other|Placebo|A placebo pill will be given to the placebo group. There will be no detectible differences between study drug pill and placebo pill.
45632788|NCT02039843|Other|Service Dog or Emotional Support Dog|"Emotional Support Dog. Service Dog - an assistance dog specifically trained to perform tasks that are specific to the person's disability and has public access privileges.~-Emotional Support Dog - a dog that has earned AKC Good Canine Citizen certification and provides emotional support and comfort to the Veteran."
45632789|NCT02039843|Other|Emotional Support Dog|-Emotional Support Dog - a dog that has earned AKC Good Canine Citizen certification and provides emotional support and comfort to the Veteran.
45632790|NCT03191695|Other|Assessment via questionnaire|All the children will be assessed via assessment questionnaires.
45632791|NCT03144713|Drug|Terlipressin|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
45632792|NCT03144713|Drug|Midodrine|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
45913784|NCT02026778|Drug|ondansetron-betahistine|"The ondansetron-betahistine group is given betahistine 18mg orally in the morning of surgery and postoperative day 1.~The ondansetron-betahistine group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA."
45632793|NCT03144713|Drug|Albumin|Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.
45632794|NCT03191617|Dietary Supplement|Human milk fortifier|Fortification of breastmilk with liquid human milk fortifier in premature infants
45632795|NCT02076022|Device|Enhanced Fat Grafting|"The stromal vascular fraction (SVF) cell suspension (device output) will be processed using the Tissue Genesis Cell Isolation System™~The Standard graft material and the stromal vascular fraction cells will be mixed and subsequently injected into the amputated stump at a concentration of 2.0 - 3.0 x 10 6 stromal vascular cells/ml of injected fat graft to each site. The volume of each injected fat graft will depend on the volume requirements for each injured extremity.~To manually combine the standard fat graft material and the SVF suspension (device output), each of the syringes will be connected via luer to luer lock. The contents of the lipoaspirate syringe are transferred to the SVF syringe and the cell suspension will be injected slowly back and forth between the two (2) syringes. The final 1 mL SVF-fat graft syringe is now considered cell-enriched and ready for injection into the subject."
45772005|NCT04755296|Device|Low level laser therapy|Low level laser therapy was applied immediately before each aerobic exercise training session by using a multidiode cluster (with four diode spots; Polaris2, manufactured by Astar ABR, Poland) )on 12 sites on the lower limb (6 on quadriceps ( 2 centrally on rectus femoris and vastus intermedius,2 laterally on vastus lateralis, and two medially on vastus medialis), 4 on hamstrings and 2 on gastrocnemius) with the following parameters: 808 nm, continous output, 200 mW each diode (total of 800 mW) power output, 24 J energy on each site (6 J for each spot) , 40 seconds at each site (8 minutes of total treatment time in lower limb) and 288 J total energy delivered per lower limb, 48 irradiation points per lower limb ,3 sessions weekly for 12 weeks.
45913785|NCT02026791|Device|I-gel|"The patient was monitored at 1-5 minute intervals.~While supplying oxygen through a mask, propofol 1.0mg/kg and remifentanil 0.5ug/kg were intravenously injected to induce anesthesia. When consciousness was not lost, propofol 0.5mg/kg was additionally injected. After consciousness was lost and spontaneous respiration disappeared, rocuronium 0.3 mg/kg was intravenously injected while performing manual ventilation.~After injecting an anesthetic and muscle relaxant, the injection concentration of fresh gas including 6 L/min oxygen and desflurane was regulated to maintain BIS between 40 and 60. A train of four (TOF) was performed with a nerve stimulator for muscle relaxation monitoring to verify that a muscular contraction did not take place (TOF=0).~Then, with the assistance of another anesthesiologist, I-gel prepared in advance was inserted."
45913786|NCT02026791|Device|Supreme-LMA|"The patient was monitored at 1-5 minute intervals.~While supplying oxygen through a mask, propofol 1.0mg/kg and remifentanil 0.5ug/kg were intravenously injected to induce anesthesia. When consciousness was not lost, propofol 0.5mg/kg was additionally injected. After consciousness was lost and spontaneous respiration disappeared, rocuronium 0.3 mg/kg was intravenously injected while performing manual ventilation.~After injecting an anesthetic and muscle relaxant, the injection concentration of fresh gas including 6 L/min oxygen and desflurane was regulated to maintain BIS between 40 and 60. A train of four (TOF) was performed with a nerve stimulator for muscle relaxation monitoring to verify that a muscular contraction did not take place (TOF=0).~Then, with the assistance of another anesthesiologist, Supreme LMA prepared in advance was inserted."
45935397|NCT00077805|Drug|Enoxaparin sodium|
45913787|NCT02026817|Drug|HCP1201 750/10mg|750mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
45632796|NCT02076022|Procedure|Standard fat graft|Aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
45632797|NCT03191383|Biological|RSV vaccine (GSK3003891A) formulation 1|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
45632798|NCT03191383|Biological|RSV vaccine (GSK3003891A) formulation 2|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
45632799|NCT03191383|Biological|RSV vaccine (GSK3003891A) formulation 3|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
45632800|NCT03191383|Drug|Placebo (Formulation buffer S9b)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
45632801|NCT03111641|Diagnostic Test|Lung ultrasonography|Lung ultrasound scan during preoperative anaesthesia consultation
45632802|NCT04682392|Device|Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction Group|A Delphi Personal Tourniquet system for blood flow restriction (BFR) therapy will be applied to each treatment session for this group. They will do 3-5 exercises with the BFR system on the surgical or both lower extremities for bilateral or unilateral movements.
45632803|NCT04682392|Other|Standard ACL rehab|Standard accelerated ACL protocol
45632804|NCT02332733|Biological|TV003|10^3 plaque forming units (PFU) of rDEN1 delta 30, 10^3 PFU of rDEN2/4 delta 30(ME), 10^3 PFU of rDEN3 delta 30/31-7164, and 10^3 PFU of rDEN4 delta 30 to be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
45632805|NCT02332733|Biological|Placebo for TV003|To be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
46070070|NCT00800137|Drug|low molecular weight heparin or unfractionated heparin|"For elective patients with greater than 5 days pre-implant; discontinue oral anti-coagulation (coumadin) 5 days before the procedure. Full therapeutic doses of subcutaneous LMWH 3 days before the procedure.~Patients with less than 5 days to implant can be given vitamin K (up to 2 mg) at the investigator discretion and start full therapeutic doses of either subcutaneous LMWH or IV Unfractionated Heparin (choice is at investigator's discretion) when INR is below the upper limit of the prescribed therapeutic range for the patient (usually greater than or equal to 2; 2.5 for some valve patients) and surgery to proceed when INR is less than 1.6.~Last dose given in the morning(ie. > 24 hours)of the day prior to the procedure.~Oral anti-coagulation (coumadin) will be resumed on the evening of the procedure.~Full dose LMWH or full dose IV heparin will be restarted 24 hours after surgery."
45632806|NCT03191071|Diagnostic Test|UltraPro|"First, procalcitonin will be measured using a rapid point-of-care test. In case of elevated procalcitonin result (≥0.25 µg/L), a lung ultrasound will be performed to look for the presence of a lung infiltrate or consolidation suggesting the presence of community acquired pneumonia. A portable ultrasound machine with a convex probe, that will be provided to the general practitioner by the study, will be used.~The lung ultrasound will be done following international evidence-based recommendations for point-of-care lung ultrasound using the basic eight-region sonographic technique and the criteria for positive scan and positive examination for the diagnosis of pneumonia ."
46070071|NCT00800137|Drug|Warfarin or coumadin|Continue on oral anti-coagulant (coumadin). INR on the day of surgery will be < 3.0
45632807|NCT03191071|Diagnostic Test|Procalcitonin|Procalcitonin will be measured using a rapid point-of-care test
46070072|NCT00807079|Drug|carboplatin|
46070073|NCT00807079|Drug|topotecan hydrochloride|
45632808|NCT03191071|Diagnostic Test|Blood sampling|A venous blood sample (17.5 mL) will be collected. Whole blood and plasma will be stored at - 80°C. Further analysis will be performed in order to identify novel biomarkers and gene transcription patterns that could predict the necessity of antibiotic prescription or the severity of disease.
45632809|NCT03191071|Diagnostic Test|Naso-pharyngeal swab and sputum culture|A pooled nasal swab will be performed and sputum will be collected. Samples will be stored at -80°C. Further analysis of the naso-pharyngeal swab and cultures of sputum will be performed to identify by molecular techniques pathogens implicated in the clinical presentation.
45632810|NCT03111329|Other|No aspiration of gastric residuals|No assessment of gastric residuals will be performed prior to administering 3-hourly feeds with increasing amounts of the feeds given as per a predefined plan
45632811|NCT03188497|Drug|Lobaplatin|Lobaplatin for Injection
45913788|NCT02026817|Drug|Metformin SR 750mg|Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
45913789|NCT02026817|Drug|Rosuvastatin 10mg|Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
45913790|NCT02026856|Drug|sodium selenite pentahydrate|
45913791|NCT02026856|Other|placebo - continuous saline NaCl 50 ml|
45913792|NCT02026869|Drug|Metformin|Metformin is taken either orally or vaginally every 12 hours
45913793|NCT02026882|Device|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.
45913794|NCT02026895|Genetic|Genetic blood sample|
45632812|NCT03188497|Device|linear accelerator|Medical linear accelerator
45632813|NCT02332421|Device|modified dentoalveolar distractor|Here, the modified distractor is going to be used when retracting the canine.
45913795|NCT02026921|Drug|Carboplatin|Carboplatin, AUC5, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops
45935398|NCT00123838|Device|Calypso® 4D Localization System|Localization of prostate irradiation.
45935399|NCT00043082|Drug|carboplatin|intravenous q 4 weeks
45935400|NCT00043082|Drug|pegylated liposomal doxorubicin hydrochloride|intravenous q 4 weeks
45935401|NCT00123877|Drug|GPX-100 (13-deoxydoxorubicin)|
45935402|NCT00123916|Drug|Benznidazole|Daily po Benznidazole or placebo (weight based) during 40 - 80 days (depending on body weight)
45772006|NCT04755296|Other|Aerobic exercises|Aerobic exercise program consisted of walking on the treadmill at a rate of 3 sessions/week for 12 weeks, with each session lasting for 40 minutes in the form of warming up for 5 minutes at intensity of <50% of the previously determined VO2max of each participant, 30 minutes of treadmill exercises at intensity of (70-85%) of the previously determined VO2max of each participant then 5 minutes cooling down at intensity of<50% of the previously determined VO2max of each participant.
45632814|NCT02075632|Drug|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% (15 g)
45632815|NCT02430259|Drug|Weekly INH / RRT given by DOT|weekly oral Rifapentine 15 mg/kg (up to 900mg) plus Isoniazid 15 mg/kg (up to 900mg) for 12 doses
45632816|NCT02332499|Drug|Anlotinib|Anlotinib p.o. qd
45632817|NCT02332499|Drug|Placebo|Placebo p.o. qd
45632818|NCT02075554|Device|CALIBER|Expandable interbody spacer
45632819|NCT02327819|Dietary Supplement|Branched-chain amoni acids (BCAA)|
45632820|NCT02327819|Dietary Supplement|non-BCAA protein supplement|
45632821|NCT02075476|Procedure|Hemiarthroplasty|
45632822|NCT02075476|Procedure|reverse arthroplasty|
45772007|NCT04755296|Other|Traditional physical therapy program|Patients were received traditional physical therapy program in the form of (stretching and strengthening exercises for all affected areas, diaphragmatic breathing exercises and activities of daily living).
45447886|NCT03216746|Behavioral|Oral orientation and App for smartphone|66 adolescents aged between 14 and 19 years. Participants enrolled in this group received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. This intervention was carried out in a classroom, in a group with approximately 20 participants, providing an environment of discussions about the subjects covered. The duration was approximately 15 minutes. The participants also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
45447887|NCT03216746|Behavioral|Oral orientation|71 adolescents aged between 14 and 19 years. Participants enrolled in this group received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. This intervention was carried out in a classroom, in a group with approximately 20 participants, providing an environment of discussions about the subjects covered. The duration was approximately 15 minutes.
45632823|NCT02327585|Behavioral|A randomized controlled study of Executive Function training for children with ADHD|Children diagnosis of ADHD are randomized to the experimental condition(Executive Function therapy) or waiting group experimental:participants will receive 12 sessions of executive function therapy weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
45632824|NCT02326961|Device|Celution Device|ADRCs Prepared using the Celution Device
45632825|NCT02326961|Other|Placebo|Inactive Placebo
45913796|NCT02026921|Drug|Docetaxel|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
45632826|NCT02075320|Device|Stationary Digital Chest Tomosynthesis|"The study scan, s-DCT, will be performed within two weeks of his/her clinical evaluations by chest CT and CR. There cannot be any intervening therapies or procedures (i.e. biopsy or excision of lesions) done in between the SOC imaging and the s-DCT. In the event that CRs are not included in the SOC imaging or are unusable (outside of acceptable window or poor quality), the scout image acquired by CT will be used in place of a CR.~Images will be acquired by a trained radiologist technologist. The technologist will comfortably position the patient in the supine position on the imaging table. Then, all patients will have a breath held s-DCT scan in an anterior-posterior direction."
45632827|NCT02327273|Drug|BMS-963272|
45632828|NCT02327273|Drug|Placebo|
45632829|NCT02327507|Behavioral|Toothpaste & Telephone Support|Mailed toothpaste, messages and telephone support.
45632830|NCT03144869|Behavioral|physical activity monitor and feedback|Children will wear a Runscribe accelerometer for two weeks (children in Arm 2 will also wear a CGM). Runscribe will measure activity levels. Activity data will be downloaded by a researcher, analysed and graphs of daily activity levels prepared. At the child's next routine clinic appointment, child and parent will have 1:1 session with researcher acting as 'physical activity champion'. Session content will be informed by Phase 1, but will involve educational support around PA (including barriers and facilitators to participation) and individualised feedback on PA level). Individualised feedback will involve review of daily PA graphs - addressing times of high and low activity levels. For participants in Arm 2, there will also be review of daily line graphs showing BG trends. As part of standard clinical care, CGM data gets downloaded at routine clinic appointments and is visible on the patient's clinic notes in daily graph form.
45632831|NCT02708095|Drug|Baricitinib|Administered orally
45632832|NCT02708095|Drug|Placebo|Administered orally
45632833|NCT02327039|Drug|Dapagliflozin|Sodium glucose cotransporter-2 inhibitor
45632834|NCT02327039|Drug|Placebo|Tables of Dapagliflozin placebo
45632835|NCT03142607|Drug|Metronidazole gel|1% Metronidazole gel
45632836|NCT03142607|Drug|Chlorhexidine Gluconate|0.2% Chlorhexidene gluconate gel
45632837|NCT05078099|Device|CureSight|Binocular eye-tracking-based passive home treatment system delivering personalized amblyopia therapy
45632838|NCT02440711|Device|Energy storing foot (ESF)|A commercially-available energy storing prosthetic foot
45632839|NCT02440711|Device|Modified running specific foot (mRSF)|A running specific prosthetic foot customized for both running and walking activities
45632840|NCT03144557|Other|Education|Education protocol included 4 individual sessions of verbal and graphic instructions to correct inhalation technique in patients with COPD
45772008|NCT04456517|Drug|Ranolazine|500 mg tablet
45772009|NCT04456517|Drug|Placebo|Ranolazine-matched placebo tablet
45772010|NCT01840046|Drug|Interleukin-2|"The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:~5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9.~The dosage is as follows:~S1: 1.5 mille-International unit / day (D1 to D5), S3, S6 and S9: 3 mille-International unit /Jour (D1 to D5)."
45772011|NCT05533463|Drug|HRS-4642|HRS-4642 will be administrated per dose level in which the patients are assigned.
45772012|NCT00437216|Drug|Clobetasol Propionate, 0.05%|Apply twice daily for 2 or 4 weeks as monotherapy
45772013|NCT00437216|Drug|Clobetasol propionate, 0.05% Spray|Apply twice daily for 2 or 4 weeks as add-on therapy
45772014|NCT00002524|Biological|Bleomycin Sulfate|
45772015|NCT00002524|Biological|Filgrastim|
45632841|NCT03186547|Drug|Botulinum Toxin A Injection|adult patients with gummy smile due to hypermobile upper lip will receive Botulinum Toxin A Injection with a single injection1 cm lateral to the ala horizontally and 3 cm above the lip line vertically.
45632842|NCT03186547|Procedure|Modified Lip Repositioning Surgery|the surgical procedure will be done by removal of strip of epithelium by careful dissection and stabilizing the new mucosal margin to the gingiva to improve the gingival display in adult patients with gummy smile.
45632843|NCT03144323|Behavioral|Reminders|"Four reminders will be set on the patient's mobile phone's Calendar-type app, saying Don't forget to wear your elastics, at 08:00, 13:00, 17:00 and 22:00."
45632844|NCT02440477|Other|clinical shoulder tests|Three clinical shoulder tests (Neer impingement sign,Hawkins-kennedy, empty can) performed in three different sitting positions: normal resting posture, slouched posture, and upright posture with scapular retraction and shoulder. and in addition shoulder muscle strength test with handheld dynamometer
45632845|NCT05077475|Drug|C52R1H Tab. and C52R2 Tab.|Single oral dose C52R1H(FDC, Valsartan/Amlodipine) 160/10 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
45632846|NCT05077475|Drug|AJU-C52L|Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 80/5/12.5 mg FDC 2 tablet
45632847|NCT02433067|Other|Physical activity intervention|Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
45632848|NCT02433067|Other|Control Group|standard oncologic care
45632849|NCT02326727|Drug|Ropivacaine|Epidural analgesia
45632850|NCT02326727|Drug|Fentanyl|General Anesthesia
45632851|NCT02326727|Drug|Propofol|General Anesthesia
45632852|NCT02326727|Drug|Isoflurane|General Anesthesia
45632853|NCT02326727|Drug|Nitrous Oxide|General Anesthesia
45632854|NCT02432911|Drug|CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF)|Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
45632855|NCT02432911|Drug|low dose cytarabine|cytarabine 20mg bid for 10 days.
45632856|NCT03588767|Drug|Vitamin D3 + anabolic substance|Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance
45632857|NCT03588767|Other|No Vitamin D3 + anabolic substance|Retrospectively analyzed group of patients, no Vitamin D3 + anabolic substance administration
45632858|NCT02440321|Behavioral|Parent-child interactive program|
45632859|NCT02440321|Other|written materials|
45632860|NCT02440399|Drug|Tramadol hydrochloride|Please see arm description
45632861|NCT02440399|Drug|Morphine|Please see arm description
45632862|NCT02440399|Drug|Paracetamol|
45632863|NCT02440399|Drug|Diclofenac|
45632864|NCT02440399|Drug|TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)|
45632865|NCT03574571|Drug|Docetaxel 75 mg/m2|Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses.
45772016|NCT00002524|Drug|Cisplatin|
45772017|NCT00002524|Drug|Cyclophosphamide|
45772018|NCT00002524|Drug|Cytarabine|
45772019|NCT00002524|Drug|Doxorubicin Hydrochloride (DOX)|
45772020|NCT00002524|Drug|Etoposide|
45772021|NCT00002524|Drug|Fluorouracil|
45772022|NCT00002524|Drug|Ifosfamide|
45772023|NCT00002524|Drug|Leucovorin calcium|
45772024|NCT00002524|Drug|Methotrexate|
45772025|NCT00002524|Drug|Methylprednisolone|
45772026|NCT00002524|Drug|Pentamidine|
45772027|NCT00002524|Drug|Prednisone|
45772028|NCT00002524|Drug|Trimethoprim-Sulfamethoxazole|
45772029|NCT00002524|Drug|Vincristine Sulfate|
45772030|NCT00002524|Drug|Zidovudine (AZT)|
45772031|NCT00002524|Radiation|Radiation Therapy|
45772032|NCT05531357|Diagnostic Test|Transvaginal ultrasound scans|"Transvaginal ultrasound scans to map ovarian follicle growth and ovulation, finger-prick blood sampling for dried blood spot (DBS) hormonal assays and urine sampling for hormone metabolites, every consecutive day for an interovulatory interval.~Weekly venipuncture samples will be taken for standard ELISA hormonal assays. The hormones of interest are FSH, LH, estradiol, progesterone, AMH, inhibins A and B, GDF-9 and BMP-15."
45772033|NCT03736811|Device|Polyglactin 910 or polydioxanone|Vicryl or PDS II
45772034|NCT03736811|Device|Polyester or polypropylene|Ethibond Excel or prolene
46070074|NCT00800293|Drug|Betamethasone Dipropionate 0.05% Cream|Small amount applied and evaluated over the course of several hours
45632866|NCT03574571|Drug|Docetaxel 60 mg/m2|Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses.
45632867|NCT03574571|Drug|Radium-223|Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
45632868|NCT02432989|Behavioral|Exercise|Light-moderate exercise on a stationary bike and leisurely walks.
45632869|NCT03186625|Drug|Compound Panax Notoginseng Granule|"Dosage form:granule. Composition: Panax notoginseng,Codonopsis pilosula,Salvia miltiorrhiza,Pinellia ternata,Medicated Leaven,Coptis chinensis,Citrus reticulata Blanco,etc.~Frequency:two times a day, one package per time. Duration:three months."
45632870|NCT03186625|Drug|Placebo Granule|Placebo granule has the same as Compound Panax Notoginseng Granule in the appearance, shape,colour,taste,frequency and duration.
45632871|NCT03184909|Drug|Ocimum Sanctum|Active capsules containing leaves of organically prepared ocimum sanctum
45632872|NCT03184909|Drug|Placebo|Placebo capsules of look alike inert substance for control
45632873|NCT02429635|Behavioral|My exercise|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshop.~Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan"
45632874|NCT03110939|Other|hyperthermic perfusion|hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after surgery of advanced lung cancer/esophageal cancer)
45632875|NCT02429713|Procedure|Short-duration tourniquet|Short-duration tourniquet group:inflate the tourniquet immediately before cement application and deflated after its hardening
45632876|NCT02429713|Procedure|Long-duration tourniquet|Long-duration tourniquet group: inflate the tourniquet immediately before incision and deflated after the hardening of the cement
45632877|NCT03144479|Procedure|right-sided double lumen tube|Verification of a new technique to assess the correct positioning of a right-sided double-lumen tube for left thoracic surgeries, using a central venous catheter wire guide and a radioscopy
45632878|NCT03186703|Behavioral|Tailored knowledge translation|Tailored knowledge translation strategies specific to evidence-based cancer prevention recommendations
45632879|NCT03142529|Drug|colon lotion|The colon lotion used in this clinic trial is a kind of hospital preparation. It is brown liquid,which consists of Rhubarb, Concha ostreae and some other traditional Chinese medicine.The colon lotion is diluted from 30ml to 150ml each time and will be used once a day for 10 days.
45632880|NCT03191305|Drug|Coumadin|Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day. The total duration Of coumadin would be six months.
45632881|NCT03191305|Drug|Rivoroxaban|The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, Then 20 mg PO qDay for 6 months.
45632882|NCT03144401|Drug|Misoprostol|mesotac
45913797|NCT02026934|Device|CliniMACS CD34 Reagent System|Following screening and enrollment, peripheral blood or bone marrow collection will be performed on the donor followed by subsequent CD34+ cell selection using the Miltenyi CliniMACS device. There is no limit to the number of CD34+ progenitors that can be administered. The CD34+ selected cells will be infused within 12 hours of the initiation of processing.
45632883|NCT03144401|Other|Placebo|Placebo tablet identical to the misoprostol tablet but without the active ingredient
45632884|NCT04483765|Procedure|spinal anesthesia|patients undergoing transurethral resection of the prostate (TURP) and transurethral resection of the bladder (TURB) surgery under spinal anesthesia.
45632885|NCT05054231|Other|Blood sample collection|Blood samples collection: at Day (D)-6 and D0 before CAR-T cells injection, post injection at Day (D)3, D5,D7, D9, D11, D14, D18, D 21, Month 2 and Month 12 post injection.
45632886|NCT03186391|Other|Data collected|Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
45632887|NCT03186469|Behavioral|Safety Baby shower|"A Safety Baby Shower using didactic and experiential teaching methods to educate participants on safety topics focused on reducing infant mortality. Participants receive safety products as their shower gifts with education on appropriate use of the products. The relaxed setting also encourages participants to seek answers and clarify myths from credible sources not otherwise available among family and friends. For intervention provides information on the infant's sleep position, bedding, co-sleeping, and tobacco exposure, all of which, alone or in combination, are risk factors for sleep-related deaths in infants. Breastfeeding, a protective factor for SIDS, will be encouraged."
45913798|NCT02026947|Drug|Sodium Benzoate|0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.
45913799|NCT02026947|Drug|Placebo|
45632888|NCT03186469|Behavioral|Standard of Care|Participants will received standard of care in regards to infant injury prevention. Written material on car seat safety, prevention of abusive head trauma, and safe sleep environments will be provide to participants.
45632889|NCT03142217|Other|Study of dysarthria in patients with Huntington's disease|Study of dysarthria in patients with Huntington's disease
45632890|NCT02326415|Other|"Clinical Pathway with Fast-Track"|Care described in the critical pathway during postoperative like the moment when the patients can eat, can move or are discharged.
45632891|NCT02326415|Other|Postoperative Usual Protocol|Cares step by step as sugery responsable thinks are the best for patients until discharge.
45632892|NCT02429245|Other|Retrospective study|
45632893|NCT03142295|Procedure|urine transfusion|Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
45632894|NCT03186313|Drug|Dactavira Plus|1 Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
45632895|NCT03186313|Drug|Sofosbuvir + Daclatasvir + Ribavirin|Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg & Ribavirin 800 mg for 12 weeks.
45632896|NCT03186313|Drug|Dactavira|Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks
45913800|NCT02026960|Device|RNA extraction and amplification from biopsy specimens|
45913801|NCT02026973|Drug|Fulvestrant|
45632897|NCT03186313|Drug|Sofosbuvir + Daclatasvir|Daily dose Sofosbuvir 400 mg & Daclatasvir 60 mg for 12 weeks
45632898|NCT03144245|Biological|AMV564|AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing
45632899|NCT03144245|Combination Product|AMV564 in combination with pembrolizumab|AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing.in combination with pembrolizumab given IV every 21 days
45632900|NCT02429479|Behavioral|Making Your Wishes Known|Making Your Wishes Known provides tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a healthcare team.
45772035|NCT05525741|Other|Non segmental vitiligo|"The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~Inform the subject of the goals, constraints and risks of the study and obtain written consent.~Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken."
45913802|NCT02026973|Drug|Anastrozole|
45913803|NCT02026973|Drug|Placebo|
45913804|NCT02026973|Drug|Somatostatin|
45913805|NCT02026986|Behavioral|sleep deprivation|sleep deprivation for one night
45913806|NCT02027012|Device|Percutaneous renal denervation with the Vessix™ Renal Denervation System|
45447888|NCT03216746|Behavioral|Video orientation and App for smartphone|63 adolescentes aged between 14 and 19 years. Participants enrolled in this group received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The elaboration counted with the participation of three actors, two acting as adolescents and the third as a dental surgeon. The video had a total duration of 14 minutes. The participants also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
45913807|NCT02027038|Device|Pelvic belt application|
45913808|NCT02027064|Drug|Interferon-alpha|
45632901|NCT02429479|Behavioral|Standard advance care planning|This is a online simple living will form.
45632902|NCT02326493|Device|Cardiac Resynchronization Therapy|A CRT device will be implanted while performing extra hemodynamic (LV dP/dtmax) and electrical (LVLED, VCG, and D-VCG) measurements. Devices and leads from various vendors will be used.
45632903|NCT03186079|Drug|Xiaojidaozhi Decoction oral capsules|Capsules with mixture of twelve Chinese herbal medicines granule inside
45632904|NCT03186079|Drug|Placebo oral capsules|Capsules with flour granule inside
45632905|NCT03186079|Drug|Fiberform|Fiberform is a low-phytate wheat fibre which can increase the gastrointestinal motility.
45632906|NCT03186079|Behavioral|Toilet training|Toilet training has been considered a routine method in treatment of constipation
45913809|NCT02027077|Behavioral|Control group|No prescribed intervention/ Participants asked to follow normal initiatives to engage in physical activity a healthful diet behaviors for the duration of the intervention
45913810|NCT02027077|Behavioral|Lifestyle counselling|Participants will follow a prescribed behavioral intervention program seeking small changes in both physical activity and diet for the duration of the intervention.
45913811|NCT02027090|Drug|Routine dose icotinib|Icotinib is administered 125 mg three times daily.
45913812|NCT02027090|Drug|Higher dose icotinib|After 8-week induction of icotinib with a dose of 125 mg three times daily, icotinib is administered 375 mg three times per day.
45913813|NCT02027103|Drug|Metformin|Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
45913814|NCT02027103|Drug|Pioglitazone|Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
46070075|NCT00800371|Procedure|intra-articular steroid injection|Steroid injection into otherwise noncontrollable arthritis.
46070076|NCT00593385|Device|iCAST covered stent|Iliac stent implantation
45632907|NCT04996199|Drug|Oxcarbazepine|oxcarbazepine 150mg BD initial dose , followup will be done at 15days, 6weeks, 10 weeks interval
45632908|NCT04996199|Drug|Carbamazepine|carbamazepine 100mg BD initial dose, follow up will be done 2weeks, 6 weeks & 10weeks
45632909|NCT02432833|Drug|ENVARSUS®|Envarsus® tablets, once daily, oral formulation. Prolonged -release formulation of tacrolimus
45632910|NCT02432833|Drug|PROGRAF®|Prograf® hard capsules, twice daily, oral formulation
45632911|NCT02432833|Drug|ADVAGRAF®|Advagraf® prolonged-release hard capsules, once daily, oral formulation
45632912|NCT02326337|Device|TWO2 Device|Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
45632913|NCT02326337|Device|Placebo Device|Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
45632914|NCT02429323|Drug|Sevoflurane|use of 8% sevoflurane in compared to incremental dose increased each few breaths from 1% to 8%
45632915|NCT02326103|Drug|Ciprofloxacin|Comparison of ciprofloxacin with placebo in alcoholic hepatitis
45632916|NCT02326103|Drug|Placebo|
45632917|NCT04984733|Drug|Temozolomide|"Metronomic TMZ 50mg/m2/day orally for 3 months then nivolumab 240mg IV +/- TMZ until progression.~Patients who don't progress on TMZ will commence with combination treatment; TMZ + Nivolumab at 3 mths. Patients who progress on TMZ will start monotherapy with nivolumab. Patients will remain on monotherapy with nivolumab or combination therapy until progression or up to a maximum of 24mths."
45632918|NCT04984733|Drug|Temozolomide 50mg/m2/day|Metronomic TMZ 50mg/m2/day orally until progression then nivolumab 240mg IV until progression
45632919|NCT04984733|Drug|Temozolomide 3 month|Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV and TMZ until progression.
45632920|NCT04984733|Drug|Temozolomide 24month|Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV and TMZ until a maximum of 24 months
45632921|NCT02707861|Drug|ibalizumab|Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry
45632922|NCT02707861|Drug|Optimized Background Regimen|An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).
45632923|NCT04908137|Drug|2-octyl cyanoacrylate|Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D & C Violet No. 2. It is provided as a single use applicator in a blister package
45632924|NCT02432599|Radiation|F18-choline PET examination|F18-choline PET examination will be performed before surgery
46070077|NCT00658021|Drug|Placebo|Subcutaneous injection, twice a day
45632925|NCT02326181|Device|inspiratory pressure training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) .
45632926|NCT02326181|Device|mixed training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) and expiration(EMST).
45632927|NCT02432755|Behavioral|home-based MTOT|The home-based MTOT group will receive 30 minutes of MT followed by 30 minutes of TOT per session. The intervention will take place in the participant's home environment. During the mirror practices, the patient will seat close to a table which the mirror box will be placed at the mid-sagittal plane. During MT, the participant will be encouraged to actively move their paretic arm and hand concurrently with the mirror reflection of the movement of the nonparetic arm and hand as possible as they can. If necessary, the therapist will assist the participant in moving the paretic hand to synchronize the movement with the nonparetic hand.
45632928|NCT02432755|Behavioral|hospital-based therapy|The control group will receive a dose-matched, individualized occupational therapy at a hospital. The participants will receive customary rehabilitation programs as usual performed at hospitals for 1 hour per session. The treatment protocol will include: (a) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques, (b) fine motor or dexterity training, (c) arm exercises or gross motor training, (d) muscle strengthening of the affected upper limb, and (e) activities of daily living training or functional task practice.
45632929|NCT02432755|Behavioral|hospital-based MTOT|The hospital-based MTOT group will also receive 30 minutes of MT followed by 30 minutes of TOT per session at a hospital. The intervention will take place in the occupational therapy clinic. The treatment modalities in the hospital will be selected and provided for this group. Most of the treatment principles and components are the same as aforementioned in the home-based MTOT. However, the major differences between home-based and hospital-based MTOT are the treatment contexts, environments and functional modalities used.
45913815|NCT02027116|Biological|VGX-6150|Plasmid DNA delivered via IM injection with electroporation
46070078|NCT00658021|Drug|Exenatide|Subcutaneous injection, 5 µg, twice a day
45913816|NCT02027129|Other|High Frequency Oscillation|Comparison of low frequency HFO/HFO-TGI with cuff leak and high frequency HFO without cuff leak on right ventricular function
46070079|NCT00658021|Drug|Exenatide|Subcutaneous injection,10 µg, twice a day
46070080|NCT00698919|Other|Observational study|"This is not an interventional studies. We will just compare two methods of bacterial diagnosis. Of note the physicians will care of their patients with the classic bacterial analysis tools; so there is no modification of the care.~The new techniques used (DNA detection) will done later on and thus won't modify their decision."
45632930|NCT04904705|Other|The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach|"The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach is a cognitive-based approach. This is a person-oriented, performance-solving problem-solving approach that enables strategy acquisition and guided exploration for the acquisition and learning of new skills.~The main objectives of this approach are; define and transfer domain-specific strategies to other motor-based tasks to gain skills, learn problem-solving strategy (goal, plan, do, check) and adapt to other environments (such as home, school)."
45632931|NCT04904705|Other|Home Program|Home Program are activities that a participant can apply at home to improve their skills.
45632932|NCT02429401|Behavioral|Non-adapted brief motivational interview|1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
45632933|NCT02429401|Behavioral|Culturally adapted brief motivational interview|Addresses impact of acculturative stress and drinking norms based on screening results and 1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
45632934|NCT05076851|Other|placebo|placebo+ADT（Androgen Deprivation Therapy） ，Route of placebo administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
45772036|NCT05525741|Other|Health Volunteers|"The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. The family control subjects will be recruited from the vitiligos patients coming into our department. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~Inform the subject of the goals, constraints and risks of the study and obtain written consent.~Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken."
45632935|NCT05076851|Drug|Proxalutamide|Proxalutamide +ADT（Androgen Deprivation Therapy） ，Route of Proxalutamide administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
45913817|NCT02027142|Other|Pittsburgh Sleep Quality Index.|"Pittsburgh Sleep Quality Index is an effective instrument used to measure the quality and patterns of sleep of patients. It allows evaluating poor from good sleep by assessing seven domains. A total score ≤ 5 indicated good sleep quality while a total score > 5 was indicated poor sleep quality."
45913818|NCT02027142|Other|Epworth sleepiness scale.|Epworth sleepiness scale is an 8-item questionnaire developed to measure average daytime sleepiness. A total score ≥ 10 indicates excessive daytime sleepiness.
45632936|NCT04890509|Drug|Bemcentinib|Bemcentinib capsules will be administered orally.
45772037|NCT05700994|Behavioral|Peer Contingency Management|Participants allocated to peer-facilitated contingency management will receive incentives for achieving self-identified harm reduction goals set with peer specialists using a participant-driven harm reduction goal-setting process (e.g. completing overdose prevention and supply training, daily life goals, treatment and care goals, relationship and social support goals)
45772038|NCT05700994|Behavioral|Standard of Care Contingency Management|Participants allocated to standard of care contingency management will receive incentives for peer encounters.
45772039|NCT03678467|Combination Product|EB-CMF|Autologous, anatomically shaped bone graft
45772040|NCT01349894|Device|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
45772041|NCT00002536|Drug|cisplatin|
45447889|NCT03216746|Behavioral|Video orientation|63 adolescentes aged between 14 and 19 years. Participants enrolled in this group received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The elaboration counted with the participation of three actors, two acting as adolescents and the third as a dental surgeon. The video had a total duration of 14 minutes.
45772042|NCT00002536|Drug|vincristine sulfate|
45772043|NCT00002536|Procedure|surgical procedure|
45913819|NCT02027142|Other|Insomnia Severity Index.|Insomnia Severity Index is a 7-item questionnaire developed to measure insomnia. A total score between 0 and 7 correspond to not clinically significant insomnia, between 8 and 14 to subthreshold insomnia, between 15 and 21 to clinical insomnia (moderate), between 22 and 28 to clinical insomnia (severe).
45913820|NCT02027142|Other|The Endometriosis Health Profile.|The Endometriosis Health Profile is a patient generated instrument that evaluates disease-specific health-related quality of life in patients with endometriosis. The questionnaire is administrable to all patients with endometriosis and it consists in 30 items divided in 5 domains (pain, control and powerlessness, emotional well-being, social support and self-image). Each scale for each domain is comprised between 0 (indicating the best health status) and 100 (indicating the worst health status).
45913821|NCT02027168|Other|CPA|Site specific, patient centered manual physical therapy regimen focused on restoring function to the entire body
45913822|NCT02027181|Device|Device FreeO2 v2.0|"Automatic adjustment of oxygen through the Free O2 device.~FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
45913823|NCT02027181|Device|Device FreeO2 v2.0|"Manual adjustment of oxygen without the assistance of the FreeO2 device.~Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
45913824|NCT02027194|Drug|Cure-Allergic Rhinitis Syrup|Delivered one bottle for two weeks to the participants twice
45447890|NCT02787304|Drug|SHP626|5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion
45632937|NCT04890509|Other|SoC|The SoC will be administered based on local guidelines.
45772044|NCT00002536|Radiation|radiation therapy|
45632938|NCT02432521|Other|Conventional rehabilitation program from IMREA|The IMREA rehabilitation program lasts about 18 weeks and consists of two weekly sessions of 60 minutes of physical therapy, occupational therapy, as well as weekly sessions of speech therapy, nursing, nutrition, psychology and social work. Conventional therapies are typically composed of stretching and strengthening exercises both upper and lower limbs, mobilizations, functional training. The only fact that differ the subjects from the protocol from the patients from the IMREA Institute are the clinical and neurophysiological evaluations that will be performed before and after the end of the conventional rehabilitation program previously described.
45632939|NCT03185143|Drug|Naltrexone and Acetaminophen Combination|Treat a single Qualified Migraine attack.
45772045|NCT01203319|Biological|60mcg/1.0ml recombinant hepatitis B vaccine|to receive 60mcg/1.0ml recombinant HBV vaccines on day 0, 30 and 60
45632940|NCT03185143|Drug|Sumatriptan 100 mg|One capsule contains Sumatriptan 100 mg and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
45632941|NCT03185143|Drug|Placebo|One capsule contains a sham for component A and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
45632942|NCT05076773|Procedure|Ultrasound guided block|Giving one regional block
45772046|NCT01203319|Biological|30mcg/1.0ml recombinant hepatitis B vaccine|to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
45913825|NCT02027194|Drug|Yu-ping-fung San|Delivered one bottle for 2-week usage to the participants twice
45913826|NCT02027194|Drug|Placebo|Delivered one bottle (wheat power with favors) for 2-week usage to the participants twice
45913827|NCT02027207|Biological|Shanchol|"We will use the killed whole cell oral cholera vaccine, Shanchol that will be manufactured by Shantha Biotechnics, in Hyderabad, India for the study. The vaccine is registered in India and is prequalified by the WHO. Shanchol is available in a single dose vial. Vaccine will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive vaccine.Pregnancy status will be enquired verbally for all married women of child bearing age during the census update as well as before vaccination to exclude them from the study.~Prior to vaccination, informed consent will be taken from the adults and guardians of minor participants .Each dose of vaccine will be 1.5 ml in volume."
45632943|NCT05076773|Drug|IV morphine|given when VAS>3
45632944|NCT02432677|Drug|Remifentanil|Remifentanil (IV infusion): 0,06mcg.kg.min. The infusion starts 10min before tDCSThe infusion will be stopped in the event of: a decrease in respiratory rate below 7 breaths / min, a peripheral oxygen saturation below 85%, a lower heart rate of 40 beats per minute, a lower mean arterial pressure of 60 mmHg, sedation causing inadequate management switch stimuli tests and occurrence of vomiting.
45447891|NCT02787304|Drug|Placebo|Matching placebo
45632945|NCT02432677|Device|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
45772047|NCT01203319|Biological|10mcg/1.0ml recombinant hepatitis B vaccine|to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60
45772048|NCT01344200|Drug|Celecoxib|In Phase I twenty (20) children will receive either celecoxib 14 or 7 mg/kg 120-180 minutes prior to lumbar puncture (LP). In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
45772049|NCT01344200|Drug|Placebo|In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
45913828|NCT02027207|Biological|Placebo|Placebo will be transported from the manufacturer and will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive placebo.Each dose of placebo will be 1.5 ml in volume.Placebo will be dispensed in liquid form in identical vials.
45913829|NCT02027220|Drug|G-CSF|G-CSF Intracutaneous injection (IC) on days 0, 1, 7, 8, 14, 15, 21 and 22, every four weeks.
45632946|NCT02432677|Device|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
45772050|NCT05521217|Diagnostic Test|MyotonPRO|"Evaluation of biomechanics and viscoelastic properties of posture muscle in children with Spinal Muscular Atrophy.~The biomechanical and viscoelastic properties of the posture muscle in children with Spinal Muscular Atrophy. will be measured with the MyotonPRO device."
45447892|NCT00574496|Drug|cyclophosphamide|
45632947|NCT02432677|Drug|Placebo|Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests.
45447893|NCT00574496|Drug|cyclosporine|
45447894|NCT00574496|Drug|fludarabine phosphate|
45447895|NCT00574496|Drug|gemcitabine hydrochloride|
45447896|NCT00574496|Drug|ifosfamide|
45447897|NCT00574496|Drug|mechlorethamine hydrochloride|
45447898|NCT00574496|Drug|melphalan|
45447899|NCT00574496|Drug|methotrexate|
45447900|NCT00574496|Drug|mycophenolate mofetil|
45632948|NCT03144167|Other|Analysis of spectroscopic biomarkers of proliferation for six-month survival|Analysis of spectroscopic biomarkers of proliferation, glial reaction, infiltration and glutaminergic metabolism or glycolytic metabolism for six-month survival
45772051|NCT05696314|Diagnostic Test|Transoral Ultrasound|The oropharynx is scanned using high-frequency, small-footprint ultrasound transducers placed onto the suspected oropharynx sub-locations (e.g. tonsils or tongue base). Lidocaine spray or gel will be applied prior to scanning to reduce the gag reflex.
45772052|NCT05696314|Diagnostic Test|Transcervical Ultrasound|Curved low-frequency ultrasound transducers will be placed on the submental region on the skin of the neck, and the tongue base will be visualized in the midline in transverse and sagittal planes. The tonsils will be visualized adjacent to the tongue base on either side in oblique transverse and oblique sagittal planes, deep to the submandibular glands.
45772053|NCT01204255|Drug|lorazepam|Given topically
45772054|NCT01204255|Drug|diphenhydramine hydrochloride|Given topically
45632949|NCT04777799|Device|URGOnight|"URGOnight is a daytime brain training solution (CE marked) aim at improve the quality of sleep. The device consists of an electroencephalographic (EEG) measuring strip connected to a mobile application. The latter is available free of charge on Android and iOS in various mobile application stores (Google Play Store and App Store).~URGOnight is a wireless device, it connects via Bluetooth® Low Energy (BLE) to the URGOnight mobile application running on a smartphone. The EEG data is broadcast via a BLE protocol, and the standard Bluetooth® operating distance has a range of 10 meters.~To use the URGOnight solution, the user must authorize the application to access his phone's memory to store his usage data and must also authorize the geolocation of his phone to enable BLE connection. This data is not recorded but is necessary for the proper functioning of the solution."
45772055|NCT01204255|Drug|haloperidol|Given topically
45913830|NCT02027220|Drug|Bortezomib|Bortezomib Intravenous injection (IV) on days 1, 8, 15 and 22, every four weeks.
45913831|NCT02027220|Drug|Cyclophosphamide|Cyclophosphamide, Continuously Intravenous injection (CIV) on days 1, 8, 15 and 22, every four weeks.
45913832|NCT02027220|Drug|Dexamethasone|Dexamethasone Intravenous injection (IV) on days 1, 2, 8, 9, 15, 16, 22 and 23, every four weeks.
45913833|NCT02027246|Biological|Autologous bone marrow mononuclear cell transplantation|Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
45913834|NCT02027259|Behavioral|Behavioral activation (BA)|The addition of Behavioral activation (BA) to our group visits in patients with DM and depression will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
45772056|NCT01204255|Other|questionnaire administration|Ancillary studies
45772057|NCT01204255|Other|laboratory biomarker analysis|Correlative studies
45772058|NCT01343342|Dietary Supplement|n-3 PUFA supplementation|3g per day of n-3 PUFA supplementation (1.9g EPA, 1.1g DHA). 5 capsules per day (1g fish oil each, 5g of fish oil/day)
45772059|NCT00002542|Drug|CMF regimen|
45772060|NCT00002542|Drug|cyclophosphamide|
45913835|NCT02027285|Dietary Supplement|fortified milk|"FortifiedUltra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose <0.5%) produced by Granarolo s.p.a. supplemented with long chain unsaturated fatty acids DHA (Docosahexaenoic acid) +EPA (Eicosapentaenoic acid), vitamin D, B12, B6, B9, E,C, Zinc and Selenium versus placebo Ultra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose <0.5%) of the same manufacturer.~The nutrients added are: DHA + EPA 1.4 mg/ml; vitamin D3 0.068 mcg/ml; B6 6.4 mcg/ml; B12 0.01 mcg/ml; B9 (folic acid) 0.80 mcg/ml; vitamin E 0.05 mg/ml; vitamin C 0.19 mg/ml; Zinc 0.04 mg/ml; Selenium 0.22 mcg/ml. The protein content of the milk is 0.04 g/ml."
45913836|NCT02027298|Drug|Abatacept|by SC injection of 125 mg weekly for 6 months
45913837|NCT02027324|Drug|Chlorhexidine-alcohol group|2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
45913838|NCT02027324|Drug|Povidone-Iodine Group|10% Povidone-Iodine for surgical antisepsis according to manufacturer's instructions.
45913839|NCT02027337|Drug|20 mcg ethinylestradiol /3 mg drospirenone|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
45913840|NCT02027337|Drug|20 mcg ethinylestradiol/3 mg drospirenone and Selmevit|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
45913841|NCT02027337|Drug|30 mcg ethinylestradiol/3 mg drospirenone|One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12
45447901|NCT00574496|Drug|prednisone|
45447902|NCT00574496|Drug|procarbazine hydrochloride|
45772061|NCT00002542|Drug|doxorubicin hydrochloride|
45772062|NCT00002542|Drug|epirubicin hydrochloride|
45772063|NCT00002542|Drug|fluorouracil|
45772064|NCT00002542|Drug|methotrexate|
45772065|NCT00002542|Drug|tamoxifen citrate|
45772066|NCT00002542|Radiation|radiation therapy|
45913842|NCT02027337|Drug|30 mcg ethinylestradiol/3 mg drospirenone and Selmevit|One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12 Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
45913843|NCT02027337|Drug|35 mcg ethinylestradiol/2 mg cyproterone|1 contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
45913844|NCT02027337|Drug|35 mcg ethinylestradiol/2 mg cyproterone and Selmevit|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
45913845|NCT02027350|Device|CD Leycom/Millar Instruments conductance catheter|Conductance catheter-Pressure volume relationship
45447903|NCT00574496|Drug|vincristine sulfate|
45447904|NCT00574496|Drug|vinorelbine tartrate|
45447905|NCT00574496|Procedure|allogeneic bone marrow transplantation|
45447906|NCT00574496|Procedure|allogeneic hematopoietic stem cell transplantation|
45447907|NCT00574496|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
45447908|NCT00574496|Procedure|peripheral blood stem cell transplantation|
45772067|NCT01333826|Behavioral|Zomba Cash Transfer Program|Cash transfers were provided monthly to a randomly selected sample of school aged girls. Amounts were also varied in both treatment arms.
45772068|NCT02246465|Drug|RXI-109|
45772069|NCT01156597|Drug|pioglitazone|30 mg daily for three weeks increase to 45 mg daily for 21 more weeks
45632950|NCT02432443|Behavioral|Motor and pre-literacy program|The program will run for 60 minutes once per week for 10 consecutive weeks and will consist of three components: direct FMS instruction, unstructured exploratory free-play, and an interactive storybook reading activity. The curriculum and teaching strategies to be used for the first two segments of our intervention have been successfully implemented in previous research to improve the motor skills of 4 year old children with autism (Bremer, Balogh, & Lloyd, 2014). Specific strategies and books were selected from an existing evidence-based curriculum (Justice & McGuinty, 2009). There will be active involvement of at least one parent in the direct instruction and reading components.
45632951|NCT02432443|Other|Wait-list Comparison|The participants will not participate in the motor and pre-literacy program for 10 weeks after enrollment and will continue with their normal daily life without any intervention. After the experimental arm completes the motor and pre-literacy program, the wait-list group will receive the exact same motor and pre-literacy intervention.
45632952|NCT03442673|Drug|Vinorelbine|Stimulation with vinorelbine together with G-CSF for mobilization of autologous stem cells
45632953|NCT03442673|Drug|Gemcitabine|Stimulation with gemcitabine together with G-CSF for mobilization of autologous stem cells
45913846|NCT02027363|Drug|Capecitabine|maintenance with apecitabine，1,000 mg/m2 twice a day， days1-15，every 3 weeks，until progression, unacceptable toxicity, or patient withdrawal.
45632954|NCT03442673|Drug|G-CSF|Cytokine stimulation with G-CSF for mobilization of autologous stem cells
45632955|NCT03184831|Procedure|sinus lift, implant placement, sole bovine bone|sinus lift augmentation with a sole deproteinized bovine bone with simultaneous implant placement
45632956|NCT03184831|Procedure|sinus lift, implant placement, injectable PRF + bovine bone|sinus lift augmentation with a mixture of injectable platelet rich fibrin plus a deproteinized bovine bone with simultaneous implant placement
45632957|NCT03185299|Other|Video|Patients randomized to the intervention arm will be contacted 48-72h before their procedure via telephone using a standardized script and will be provided a link to a website allowing posting of videos for public viewing
45632958|NCT03185299|Other|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
45632959|NCT03117673|Other|transesophageal echocardiography measurements|transesophageal echocardiography will be done routinely during the procedure. We will do additional measurements of the maximal TR velocity
45772070|NCT03015623|Biological|SBI-101|SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.
45772071|NCT03015623|Device|Sham|The sham control is an FDA-approved plasmapheresis device, without MSCs, which is integrated into a Continuous Renal Replacement Therapy circuit.
45632960|NCT04741841|Dietary Supplement|GutMagnific™ H.|Vegan Capsules with active product, GutMagnific™ high dose
45772072|NCT01331408|Device|Macrolane VRF30|Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject
45772073|NCT01823198|Biological|Aldesleukin|Given SC
45913847|NCT02027363|Other|Observation|Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy would stop the chemotherapy and observation
45632961|NCT04741841|Dietary Supplement|GutMagnific™ L.|Vegan Capsules with active product, GutMagnific™ low dose
45632962|NCT04741841|Dietary Supplement|Placebo|Vegan capsules identical to active product in taste and appearance but without probiotic
45913848|NCT02027415|Dietary Supplement|Beet juice|2 cups of beet juice will be given before the car ride
45632963|NCT02432365|Drug|paclitaxel|7-day cycle schedule of paclitaxel (60 mg/m2)
45913849|NCT02027415|Dietary Supplement|Orange juice|2 cups of orange juice will be given before the car ride
45913850|NCT02027441|Other|Standard Counseling and Testing|"Individuals who opt for standard counseling and testing will complete the following procedures:~• Standardized pre- and post-test counseling and HIV testing using HIV rapid test per approved national guidelines"
45632964|NCT02432365|Drug|cisplatin|7-day cycle schedule of cisplatin (40 mg/m2)
45913851|NCT02027454|Drug|GSK1265744|White to slightly colored film coated tablet with unit dose strength of 30 mg and dose level of 150mg (5 tablets of 3 mg) administered orally every 12hours for 3 doses.
45632965|NCT02432365|Procedure|Radical hysterectomy and bilateral pelvic lymphadenectomy|2 weeks after last course of neoadjuvant chemotherapy
45772074|NCT01823198|Biological|Allogeneic CD56-positive CD3-negative Natural Killer Cells|Given IV
45772075|NCT01823198|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC transplant
45772076|NCT01823198|Drug|Busulfan|Given IV
45913852|NCT02027454|Drug|GSK1265744 matching placebo|GSK1265744 matching placebo tablets administered orally every 12hours for 3 doses (5 tablets per dose).
45913853|NCT02027454|Drug|Moxifloxacin|Dull red, oblong, convex film coated tablets with unit dose strength of 400 mg administered orally as a single dose.
45913854|NCT02027467|Dietary Supplement|StemAlive®|
45913855|NCT02027467|Dietary Supplement|Placebo (For StemAlive®)|
45913856|NCT02027493|Drug|Reiferon R|subcutaneous injection of 100 μg/m2
45447909|NCT00574496|Procedure|umbilical cord blood transplantation|
45447910|NCT00574496|Radiation|total-body irradiation|
45632966|NCT05076695|Drug|Palbociclib|Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles)
45632967|NCT05076695|Drug|trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg IV, every 3 weeks for a total of 6 administrations.
45632968|NCT05076695|Drug|pyrotinib|Pyrotinib 400mg, PO daily, continuously
45772077|NCT01823198|Drug|Fludarabine Phosphate|Given IV
45913857|NCT02027493|Drug|Ribavirin|15 mg/kg daily on two divided doses
45632969|NCT05076695|Drug|fulvestrant|Fulvestrant will be administered according to local prescription guidelines and will be given intramuscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose.
45632970|NCT03143933|Drug|Propofol|I.V propofol
45772078|NCT01823198|Other|Laboratory Biomarker Analysis|Correlative studies
45632971|NCT03143933|Drug|Fentanyl|
45632972|NCT02440243|Drug|Purethal|prerseasonal course of SCIT - three years
45632973|NCT02440243|Drug|Purethal -placebo|preseasonal course of SCIT - three years
45632974|NCT04723043|Device|mechanical ventilation modes|ventilation with pressure controlled mode in laparoscopic abdominal surgery ventilation with volume controlled mode in laparoscopic abdominal surgery
45632975|NCT02440165|Behavioral|Nursing nutrition intervention|"The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:~Information and advice;~Examples of energy and protein rich meals;~patients will be asked to register their nutritional intake for two days at home;~after a week, the nurse will call the patients to answer questions and to give advice.~This nutrition care plan will be tailored to the individual patient requirements.~Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care."
45632976|NCT04705259|Behavioral|Antimicrobial Stewardship ENGAGEMENT bundle|"Given that a single intervention is unlikely to be effective in stewardship programs, nor in care improvement processes at RACFs [7], this trial will deliver a set of multimodal, multidisciplinary interventions to optimise antibiotic use in RACFs. This RACF AMS ENGAGEMENT bundle will comprise the following key interventions:~Education and engagement of prescribers, nurses, pharmacists and residents and family members~Nursing initiatives to improve UTI diagnosis and reduce inappropriate urine testing~Guideline development specific to antibiotic use in RACF residents~Antimicrobial stewardship team creation in RACF with GP involvement~EMergency department liaison and use of clinical pathways to ensure consistency of practice across the care continuum~ElectroNic decision support to guide RACF urine testing and GP antibiotic prescribing~Telehealth support for key intervention components"
45632977|NCT05076461|Drug|Ondansetron|Ondansetron group received oral suspension of ondansetron as 0.15mg per body weight
45632978|NCT02428933|Drug|Bromocriptine|The investigators will look at the physiological effect of dopamine on BAT activity rather than on the effect of the drug itself
45632979|NCT05076305|Other|No specific intervention; cases are retrospective and patients have already been treated.|To assess the geographic variation that exists in the management of locally advanced and recurrent rectal cancers.
45632980|NCT02428777|Drug|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure.
45772079|NCT01823198|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
45772080|NCT01823198|Other|Pharmacological Study|Correlative studies
45913858|NCT02027519|Other|HIV Self-testing with Standard Counseling and Testing (SCT) Confirmation|"Partners of the index participants and other household members will be offered HIV self-testing by the mobile testing team. Those who consent to HIV self-testing with SCT confirmation will complete the following procedures:~Undergo standardized pre-test counseling and demonstration of use of HIV rapid test kit by trained study staff, including how to determine test results~Self-administer HIV rapid test and read test results~Provide study staff with self-testing result~Undergo confirmatory testing as well as post-test counseling by study staff (SCT) if the initial self-test is positive, there is any doubt about the results, or the test reveals couple discordance"
45913859|NCT02027532|Drug|Cefazolin|
45913860|NCT02027532|Drug|Vancomycin|
45447911|NCT02251834|Behavioral|Community Health Worker (CHW)|The primary mechanism used by the Community Health Worker (CHW) for delivering interventions will be a) home visits b) phone based contacts c) group level activities d) mobile technology. Ideally, each subject will have, at a minimum, 4 home visits and ten phone calls during months 3-12. Group visits will held twice a month. The Community Health Worker (CHW) intervention will be highly individualized and tailored to unique circumstances of each patient and we expect home visits, calls, ProMobile usage and group visits to vary by patient.
45447912|NCT02251834|Other|usual care and health education brochures every 4 months.|Patients randomized to the control group will receive usual care.
45447913|NCT02127112|Procedure|Block Allograft plus Matrix Allograft|A cancellous block allograft plus a demineralized bone matrix allograft will be used as the positive control treatment.
45632981|NCT02428777|Drug|Diclofenac|Women will receive oral diclofenac 100 mg 1 hour before the procedure
45632982|NCT02428777|Drug|Placebo|Women will receive an oral placebo 1 hour before the procedure
45632983|NCT03142373|Other|CV4 technique|
45632984|NCT03142373|Other|RR technique|
45632985|NCT03142373|Other|Placebo treatment|
45632986|NCT05076071|Genetic|NGS|Next Generation Sequencing
45632987|NCT05233657|Drug|JX11502MA|Oral capsule
45632988|NCT05233657|Drug|Placebo|Oral capsule
45772081|NCT01156987|Device|Magnetic resonance imaging|"Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:~an IV line is placed by nurse,~patient is placed in the 4 T MRI scanner at CMRR,~initial scout images and manual linear shims are adjusted,~Pre-contrast SWIFT T1 weighted images and T1 map are obtained,~continuous SWIFT acquisition begins immediately before contrast injection,~contrast injection,~continuous SWIFT acquisition continues for 12 min after contrast,~late enhancement images may also be obtained.~10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods."
45772082|NCT05750056|Drug|lidocaine|Patients received an intravenous bolus injection of lidocaine 1.5 mg/kg over 10 min before induction of anesthesia, followed by a continuous infusion of 2 mg/kg/h until the end of the procedure.
45772083|NCT05750056|Drug|0.9% saline|Patients received a perioperative saline infusion at the same rate and volume as the lidocaine infusion.
45632989|NCT03142139|Biological|RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib|"Children will be categorized as timely vaccinated if they receive the 1st dose within the month of scheduled vaccination:~timely vaccinated: received 1st dose of DTaP-IPV-Hib before 4 months of age~delayed vaccinated: did not receive the first dose of DTaP-IPV-Hib before 4 months of age."
45632990|NCT03142139|Biological|RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib|"Children will be categorized as timely vaccinated if they receive the 2nd dose within the month of scheduled vaccination:~timely vaccinated: received 2nd dose of DTaP-IPV-Hib before 6 months of age~delayed vaccinated: did not receive the 2nd dose of DTaP-IPV-Hib before 6 months of age."
45772084|NCT05750056|Drug|Propofol|An i.v. bolus injection of propofol 1 mg/kg was given to all patients. Propofol was then titrated if necessary to produce unconsciousness during the introduction of the endoscope. Afterward, the anesthesiologist determined the dose of propofol and titrated to effect.
45913861|NCT02027571|Behavioral|Intensive Lifestyle Intervention (ILI)|ILI consists of weight loss ( > 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.
46070081|NCT04121637|Other|Aerobic Exercise|"Each exercise session;~5 min warm-up = 30% of VO2 max~20 min exercise = 50-60% of VO2 max~5 minutes cooling in the form. The goal of aerobic exercise is to increase physical capacity, which is represented by maximum oxygen uptake (VO2max) and mechanical power generated during exercise. Training programs should be conducted at least 2 to 3 times per week (60-80% maximum work rate or 60% VO2max) for 30 to 60 minutes at moderate concentrations. These programs are effective in increasing aerobic capacity and power output in MS."
45632991|NCT03142139|Biological|RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated|"• Vaccination status will be assessed as a time dependent exposure, whereby children will be categorized as unvaccinated until date of vaccination where they will shift exposure group to vaccinated."
45632992|NCT02432053|Drug|Advagraf|
45632993|NCT04624919|Other|Hot/Dry|Work is completed in a hot/dry environment.
45632994|NCT04624919|Other|Warm/Humid|Work is completed in a warm/humid environment
45632995|NCT03186157|Procedure|Decompressive craniectomy|Decompressive craniectomy is a surgical procedure used to treat patients with acute intractable intracranial hypertension. It includes removing a large portion of lateral skull wall in order to alleviate the effects of increased intracranial pressure and allow the brain to expand.
45632996|NCT03186157|Procedure|Cranioplasty|Cranioplasty is a routine neurosurgical procedure to repair the continuity of the bone tissue of the skull with autologous bone or synthetic bone flap from heterologous material.
45632997|NCT02429089|Drug|LEE011|"The first 12 patients will receive cetuximab associated with LEE011 at doses of 400 mg and 600 mg daily to determine the DLTs and safety.~In the expansion part, besides safety, objective response rate, progression-free survival and overall survival will be calculated with the inclusion of 14 patients."
45632998|NCT03141827|Drug|Insulin|Insulin 40 IU, nasal spray, single dose
45447914|NCT02127112|Procedure|Moldable Matrix Allograft|The test arm of this study will include a demineralized bone matrix allograft placed over resorbable bone pins.
45447915|NCT02121574|Device|Zero flux and ingestible thermometers|
45632999|NCT03141827|Drug|Placebo|Placebo, nasal spray, single dose
45633000|NCT03190681|Drug|Ritalin 10Mg Tablet|ingestion of an oral single-dose
45633001|NCT03143777|Device|Sara Combilizer|Combined tilt table and stretcher chair
45633002|NCT04604405|Radiation|photobiomodulation|650nm low energy red light eye irradiation
45633003|NCT03186235|Other|Flow cytometry|Isolation of T regulatory cells from blood
45633004|NCT05068115|Procedure|Clinical characteristics, diagnosis and treatment, survival status|Describe the clinical characteristics, diagnosis and treatment, survival status and the trends of young breast cancer
45633005|NCT03186001|Drug|Abobotulinum toxin A|The purpose of this study is to describe two safe and reproducible techniques upper face botulinum toxin injection. It will also describe the effect of both techniques on the eyebrow shape and height using quantitative, objective measurements and subjective scales
45633006|NCT04593563|Drug|Psilocybin|Single 5 capsule oral psilocybin dose: 25mg: 5 x 5 mg capsules.
45772085|NCT05750056|Drug|Sufentanil|Sufentail 0.1 ug/kg was administered for sedation induction.
45772086|NCT03015311|Drug|Intensive BP control|For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
45633007|NCT03185923|Drug|TCM plus conventional drug|"All patients were treated with antibiotics according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.~qingfeijieduhuatan granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome in 28 treatment days.~zaoshihuatanxiefei granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome in 28 treatment days.~qingxinkaiqiao granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome in 28 treatment days.~shenmai injection（Sichuan chuanda west China Pharmaceutical Co., Ltd.）,15ml/ ampulla, 10～60ml each time (when needed), for yin exhausted syndrome in 28 treatment days.~shenfu injection（Sanjiu Medical & Pharmaceutical Co., Ltd.）,10ml/ ampulla, 50～100ml each time (when needed), for yang exhausted syndrome in 28 treatment days."
45913862|NCT02027584|Other|collection of remnant of clinically indicated blood sample|collection of remnant of clinically indicated blood sample
45913863|NCT02027597|Other|Attack of the S. Mutans|A research assistant led groups of students through the Attack of the S. Mutans exhibit. All participants played all the games and viewed all the graphical content of the exhibit.
45913864|NCT02027597|Other|Follow-up|This group experienced the Attack of the S. Mutans! exhibit and 3 doses of follow-up booster content at a web site.
45913865|NCT02027597|Other|SnowWorld|SnowWorld is a 3D first-person-shooter game developed by Firsthand Technology. In SnowWorld, the player shoots snowballs at penguins, polar bears, and other features of a frozen landscape. The game is designed to help burn victims cope with pain, and has no oral health messages.
45633008|NCT03185923|Drug|TCM placebo plus conventional drug|"All patients were treated with antibiotics according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.~placebo qingfeijieduhuatan granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome every day in 28 treatment days.~placebo zaoshihuatanxiefei granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome every day in 28 treatment days.~placebo qingxinkaiqiao granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome every day in 28 treatment days."
45633009|NCT04551911|Drug|Rayaldee 30Mcg Extended-Release (ER) Capsule|Rayaldee 30Mcg Extended-Release (ER) Capsule
45633010|NCT04551911|Drug|Placebo|0Mcg Extended-Release (ER) Capsule
45772087|NCT03015311|Drug|Standard BP control|For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
45772088|NCT03011125|Drug|dexlansoprazole injection|
45772089|NCT03011125|Other|placebo|
45772090|NCT05749978|Behavioral|Asana adjustment|Adjust the operating table to 15° head height and foot low in advance. The patient is then slowly turned over from the transport table to the operating table and completed in the prone position. After the patient's hemodynamic stability is smooth, adjust the operating table to the level.
45772091|NCT03015545|Device|paretic leg-control|standing on the vibration platform, with no vibration signals delivered.
45772092|NCT03015545|Device|paretic leg-WBV|standing on the vibration platform, with WBV at 30Hz, 1.5mm.
45772093|NCT03015545|Device|non-paretic leg-control|standing on the vibration platform, with no vibration signals delivered.
45772094|NCT03015545|Device|non-paretic leg-WBV|standing on the vibration platform, with WBV at 30Hz, 1.5mm.
45772095|NCT05749900|Drug|Trastuzumab+Nivolumab+Gemcitabine+Cisplatin|Phase Ib Nivolumab 360mg IV q 3weeks Gemcitabine 1000mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks Level -1 Nivolumab 360mg IV q 3weeks Gemcitabine 800mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks
45772096|NCT03541577|Device|TruePhysioTM Microcatheter|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
45772097|NCT03541577|Device|Pressure Wire|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
45772098|NCT02973178|Device|Scanadu Urine Device|Device to allow lay user to perform urinalysis test at home.
45633011|NCT02428465|Behavioral|Purposeful Parenting|Purposeful Parenting reinforces responsive interactions that help promote emerging developmental skills. This information is presented over the course of a child's first 12 months, such that core lessons are the same but specific skills are designed to be developmentally appropriate. This repetitiveness, along with the provision of age-appropriate behavioral guidance, will allow parents to successfully engage in responsive interactions with their children.
45633012|NCT03143387|Other|Caries removal using only manual instruments|Caries removal using only manual instruments according to Atraumatic Restorative Treatment
45633013|NCT03143387|Other|Caries removal using Papacarie gel|Caries removal using a chemical-mechanical method - Papacarie gel and manual instruments.
45633014|NCT02431975|Drug|Nevirapine|"Standard medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medication.~The initial dose of NVP will be 6 mg per kg per dose orally twice daily until 42 weeks gestational age (2 weeks of age for infants born at term) which is the dosing selected by the NIH International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Network."
45772099|NCT03442751|Drug|Paracel 1|Two drops every 60 seconds for 4 minutes
45772100|NCT03442751|Drug|Paracel Placebo|Two drops of Paracel Placebo every 60 seconds for 4 minutes followed by two drops every 30 seconds for 6 minutes
45772101|NCT03442751|Drug|Paracel 2 R0185|Two drops every 30 seconds for 6 minutes
45772102|NCT03442751|Device|KXL High Power System (2 J)|6 mW/cm2 for 11 minutes 6 seconds with an on/off cycle of 1 second UVA on/1 second UVA off (total UVA does of 2 J/cm2)
45772103|NCT03442751|Device|KXL High Power System (10 J)|30 mW/cm2 for 11 minutes 6 seconds with an on/off cycle of 1 second UVA on/1 second UVA off (total UVA does of 10 J/cm2)
45772104|NCT05673226|Other|Surface disinfection with Organosilane|Organosilane will be sprayed on the surfaces, using an atomizer. When the environment has been completely covered (i.e., when all surfaces and equipment have a slightly damp film), we will proceed with the second phase of the disinfection of all heavily touched surfaces. surfaces of the bed, with a microfiber cloth with organosilane.
45913866|NCT02027636|Behavioral|Engagement and Counseling for Latinos (ECLA-F)|The Engagement and Counseling for Latinos - Face-to-face (ECLA-F) intervention is a cognitive behavioral therapy (CBT) plus care-management intervention delivered in person. The CBT component consists of 6-8 sessions, delivered by a Master's level clinician, and focusing on self-management techniques, problem-solving, and techniques for managing depression and stress. The care-management component of the intervention consisted of monitoring, assistance in scheduling appointments, and help with transportation. This intervention was identical to the telephone (ECLA-F) intervention, except for the delivery method.
45633015|NCT02431975|Drug|Zidovudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretroviral.~ZDV will be dosed as per standard guideline and routine practices."
45633016|NCT02431975|Drug|Lamivudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is effective against both HIV-1 and HIV-2.~3TC will be dosed as per standard guideline and routine practices."
45633017|NCT02431975|Drug|LPV/r|"Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.~LPV/r will be dosed as per standard guideline and routine practices."
45913867|NCT02027636|Behavioral|Engagement and Counseling for Latinos (ECLA-T)|The Engagement and Counseling for Latinos - Telephone (ECLA-T) intervention is a cognitive behavioral therapy (CBT) plus care-management intervention delivered via telephone. The CBT component consists of 6-8 sessions, delivered by a Master's level clinician, and focusing on self-management techniques, problem-solving, and techniques for managing depression and stress. The care-management component of the intervention consisted of monitoring, assistance in scheduling appointments, and technical assistance. This intervention was identical to the face-to-face (ECLA-F) intervention, except for the delivery method.
45913868|NCT02027662|Drug|Osvaren Granules|
45913869|NCT02027662|Drug|Osvaren film-coated tablets|
45633018|NCT03143465|Drug|Calcitonin Gene-Related Peptide|
45633019|NCT03143465|Drug|Sildenafil|
45913870|NCT02027675|Other|High fat poor micronutrient meal|The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an high fat poor micronutrient meal.
46070082|NCT04121637|Other|Frenkel coordination exercises|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. 1 minute break between each exercise set
45633020|NCT03143465|Drug|Placebo|
45633021|NCT02431819|Device|contention socks|Patients wear contention socks during 15 days.
45633022|NCT05034809|Drug|Melatonin 20 MG|Melatonin, also known as N-acetyl-5-methoxytryptamine will be the main intervention given to participating patients of this study. This study will use a dose of 20mg/day using the commercially available 5mg/tablet20-21. If a patient cannot be tolerate swallowing the whole tablet, it will be crushed and mixed with milk. According to the study done by Shah et al. there was no degradation in the active component of melatonin when mixed with milk or food as a medium for drug delivery.
45633023|NCT02428543|Drug|Ponatinib and Cytarabine|Prospective, non-randomized, open-label, multicenter, dose-escalation phase I-II trial; an adaptive Bayesian logistic regression dose-escalation model incorporating escalation with overdose control will be used (Babb 1998, Tighiouart 2005). Each cohort will consist of 3 evaluable patients
45633024|NCT04428203|Drug|Epidiolex Oral Liquid Product|patients with rising PSA after failure of localized therapy will receive Epidiolex PO once daily for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients receive an Epidiolex taper for 7-10 days after withdrawing from study for any reason or completion of the study period.
45633025|NCT04381325|Drug|MSB0254 Injection|"An intravenous infusion with concentration from 4 mg/kg to 16 mg/kg every 2 weeks (Q2W).~An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W)."
45633026|NCT02431663|Drug|Ketamine|Intravenous administration in continuous
45633027|NCT05014217|Behavioral|Mentalization-based Treatment|An empirically-validated intervention for personality disorders based on the attachment theory and on knowledge from developmental psychology and cognitive neuroscience (Bateman and Fonagy, 2004). Patients assist psychoeducative group meetings beforehand, along with a pretreatment of four to six individual meetings (over four to eight weeks), followed by bi-weekly individual follow-ups and weekly group follow-ups. The treatment lasts two years. Patients have an assessment meeting with their individual therapist and one of the group therapists at the end of each session. Psychiatric follow-up appointments are on an as-needed basis and every patient has a treatment contract with specific and measurable treatment objectives.
45633028|NCT05014217|Behavioral|Dialectical Behavior Therapy-inspired Treatment|A psychotherapy developed by M. Linehan for patients with borderline personality disorder that combines cognitive behavioral therapy techniques (emotional regulation, practical exercises) with Buddhist meditation principles (stress tolerance, acceptance, open-mindedness) (Linehan, M. M. & Dimeff, L., 2001). As opposed to Linehan's model, individual meetings are bi-weekly, no emergency phone service is offered, the mindful meditation module is reorganized into life habits modules, and every module includes mindfulness exercises. Patients assist psychoeducative group meetings beforehand, along with a pre-treatment of 4-6 individual meetings (over 4-8 weeks), followed by bi-weekly individual follow-ups and weekly group follow-ups. The treatment lasts one year, but can be extended to two years for eligible patients who are interested. Psychiatric follow-up appointments are on an as-needed basis. Every every patient has a treatment contract with specific and measurable treatment objectives.
45913871|NCT02027675|Other|Mediterranean meal|The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an Mediterranean meal
45913872|NCT02027688|Other|q6 hour oral feeding schedule|The intervention is the schedule under which stable infants are offered oral feeding attempts: every 6 hours.
46070083|NCT00920816|Drug|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg BID with continuous dosing
46070084|NCT00920816|Drug|Sorafenib|sorafenib will be given at a dose of 400 mg BID continuous dosing
45772105|NCT05485181|Behavioral|Spiritual Intervention|The Intervention is a CBT- based psychotherapeutic process that occurs in a group setting with two cohorts of 8 subjects each. It will occur in an introductory 3-hour session followed by 9 weekly 1 ½ hour sessions. In this process, self-worth (self-confidence, self-esteem, self-competence) and dignity (reason, compassion, courage) as operationally defined are strengthened through an interpersonal, psychological process including mindful self-awareness training, attitude transformation with self-compassion, forgiveness, and self-acceptance, and opens to a new level of awareness. This awareness opens to spiritual / numinous features of connectedness, vitality, wholeness, meaning, and serenity that are predicted to be associated with greater well-being and relief of anxiety and depression symptoms.
45772106|NCT05749666|Drug|Tofacitinib 5 MG|Tofacitinib 5 MG BID taken orally for 24 weeks
45772107|NCT05749666|Drug|Prednisolone|Prednisolone taken daily according to preset tapering protocol
45772108|NCT05749666|Other|Placebo of tofacitinib 5mg|Placebo of tofacitinib 5mg BID taken orally for 24 weeks
45772109|NCT05749666|Other|Placebo of prednisolone|Placebo of prednisolone taken daily according to preset tapering protocol for 24 weeks
45633029|NCT02428621|Device|Twicare® appliance|"Early orthodontic treatment with the Twicare®. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Twicare® is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
45772110|NCT03295799|Other|Patient Self-Management|Patient will manage their own warfarin therapy.
45633030|NCT02428621|Device|Removable Herbst appliance|"Early orthodontic treatment with the removable Herbst appliance. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Herbst appliance is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
45633031|NCT04956029|Other|There are no any interventions. This is to observe and test hospital cleanliness.|There are no any interventions. This is to observe and test hospital cleanliness.
45772111|NCT05449535|Drug|JYB1904|Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
45772112|NCT05449535|Drug|Omalizumab|Dosage form: injection, powder, lyophilized, for solution； Usage and dosage matching:dose 1; single-dose; subcutaneous injection in the deltoid region of the upper arm.
45772113|NCT05449535|Drug|JYB1904 Placebo|Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
45772114|NCT05749588|Drug|A1: SHR-A1811|A1: an anti-HER2 antibody-drug conjugate (ADC)
45772115|NCT05749588|Drug|A2: SHR-A1811 with Camrelizumab|"A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~Camrelizumab: an anti-programmed death-1 (PD-1) antibody"
45772116|NCT05749588|Drug|B1: TROP2 ADC|B1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
45772117|NCT05749588|Drug|B2: TROP2 ADC with Camrelizumab|"B2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~Camrelizumab: an anti-programmed death-1 (PD-1) antibody"
46070085|NCT04254224|Procedure|colon resection, stoma|oral or intravenous antibiotics treatment with or without percutanous or transrectal or transvaginal drainage
45633032|NCT02428387|Behavioral|My Tools 4 Care|On-line self-administered (My Tools 4 Care) transition toolkit includes interactive activities and resources to help caregivers deal with their transitions
45633033|NCT02431585|Dietary Supplement|gluten|
45633034|NCT02431585|Dietary Supplement|placebo|
45633035|NCT03143231|Other|Normal saline|The normal saline will be divided in 3ml aliquots that will be preserved in the pharmacy refrigerator between 2 and 60[0]C. Once a patient had been randomized, 6 aliquots would be prepared daily until the end of the trial.
45633036|NCT03143231|Other|Hypertonic saline|The mixture (500 ml Sodium Chloride 0.9% with 60 ml Sodium chloride 20%) will be divided in 3ml aliquots that will be preserved in the pharmacy refrigerator between 2 and 60[0]C. Once a patient had been randomized, 6 aliquots would be prepared daily until the end of the trial.
45772118|NCT05749588|Drug|C1: SHR-A1811|C1: an anti-HER2 antibody-drug conjugate (ADC)
45772119|NCT05749588|Drug|C2: SHR-A1811 with BP102|"C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)"
45772120|NCT05749588|Drug|D1: TROP2 ADC|D1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
45772121|NCT05749588|Drug|D2: TROP2 ADC with BP102|"D2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)"
45772122|NCT05749588|Drug|E1: SHR-A1811|E1: an anti-HER2 antibody-drug conjugate (ADC)
45633037|NCT03185845|Drug|Warfarin|tailored dose according to international normalized ratio (INR) for 3 months
46070086|NCT04254146|Other|Aerobic exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.
45633038|NCT04336787|Other|Survey|A Google Survey which included that consent form, demographic information form, International Physical Activity Questionnaire, Pittsburgh Sleep Quality Index, Perceived Stress Scale and The Numeric Rating Scale will be created. Then the survey link will be shared via social media such as Whatsapp, Facebook, etc.
45633039|NCT03184597|Diagnostic Test|HLA screening before commencing aromatic AEDs|When the risk HLA alleles are tested positive for the patients, aromatic AEDs were avoided or administrated with caution according to the risk level.
45772123|NCT05749588|Drug|F1: TROP2 ADC|F1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
45633040|NCT04327193|Procedure|Titrated PEEP based on driving pressure|Alveolar recruitment and PEEP titration is performed at three time points: after intubation, after Trendelenburg, and after supine after CO2 deflation. The level of PEEP which makes the driving pressure lowest is selected and applied during the operation.
45633041|NCT04327193|Procedure|Conventional PEEP|Alveolar recruitment is performed at three time points: after intubation, after Trendelenburg, and after supine after CO2 deflation. Conventional PEEP (5cmH2O) is applied during the operation.
45633042|NCT04293029|Drug|SHR0302|SHR0302
45772124|NCT05749588|Drug|G1: SHR-A1811|G1: an anti-HER2 antibody-drug conjugate (ADC)
45772125|NCT05749588|Drug|H1: TROP2 ADC|H1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
45913873|NCT02027688|Other|q3 hour oral feeding schedule|The intervention is the schedule under which stable infants are offered oral feeding attempts: every 3 hours.
45913874|NCT02027727|Other|No Intervention|no intervention- tihs is an observational study
45913875|NCT02027740|Dietary Supplement|almond|
45913876|NCT02027753|Drug|INSULIN GLARGINE|Pharmaceutical form: solution Route of administration: subcutaneous
45913877|NCT02027753|Drug|Metformin|Pharmaceutical form: tablet Route of administration: oral
45913878|NCT02027753|Drug|DPP-4 inhibitor|Pharmaceutical form: tablet Route of administration: oral
45633043|NCT03184753|Biological|OC-IgT cells|Autologous human OC-IgT cells.
45913879|NCT02027753|Drug|Sulphonylurea|Pharmaceutical form: tablet Route of administration: oral
45913880|NCT02027766|Other|Calf muscle stretching|
45633044|NCT04261127|Genetic|Genetic diagnosis (PMDA panel)|Blood samples for DNA study
45633045|NCT04261127|Diagnostic Test|Use of RADIAL algorithm|RADIAL card filling (contains clinical and biological data)
45633046|NCT03185767|Other|blood sampling|blood sampling
45772126|NCT05670418|Device|Quantitative Electroencephalography|Each qEEG examination of one person lasted about 20 minutes and included two stages: the first-recording of brain waves with eyes closed (5 min), the other with eyes open (5 min)
45772127|NCT05749510|Other|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
45772128|NCT05749432|Drug|Hemay181|Hemay181 will be given intravenously on the first day per cycle, and the treatment cycle is 21-days.
45772129|NCT05416307|Drug|ELA026|Single or multiple daily doses of ELA026
45772130|NCT04222985|Biological|HSV 2 Formulation 1|Route of administration: Intramuscular
45772131|NCT04222985|Biological|HSV 2 Formulation 2|Route of administration: Intramuscular
45772132|NCT04222985|Biological|HSV 2 Formulation 3|Route of administration: Intramuscular
45913881|NCT02027779|Biological|GreenGene™ F|"Prophylaxis safety and efficacy substudy:~intra venous infusion, 30 ± 10 IU/kg infusions 3 times per week with dose escalation to 45 ± 10 IU/kg if appropriate, for 50 exposure days"
45913882|NCT02027779|Biological|GreenGene™ F|"On-demand safety and efficacy substudy:~minor bleed = 20 ± 10 IU/kg moderate bleed = 30 ± 10 IU/kg major bleed = 30 - 50 IU/kg"
45913883|NCT02027792|Other|Cabbage leave wraps|
45913884|NCT02027792|Drug|Diclofenac Gel|
45913885|NCT02027805|Biological|T-Guard|
45913886|NCT02027818|Drug|Indocyanine Green|Observation of the correlation between fluorescence and margins of the tumour after IV injection of ICG
45913887|NCT02027831|Drug|Indocyanine Green|
45913888|NCT02027857|Device|EIT monitoring|
45913889|NCT02027857|Device|non-invasive ICP monitoring|
45913890|NCT02027870|Device|EXCEL-II biodegradable polymer sirolimus-eluting stent|EXCEL-II biodegradable polymer sirolimus-eluting stent implantation
45913891|NCT02027909|Device|Reprogramming dual chamber pacemaker|Reprogramming rate response feature in the Medtronic pacemaker to each arm with crossover
45913892|NCT02027922|Other|Fluor Protector S|Fluor Protector S intervention group A (25 ml) Duraphat group B (25ml)
45913893|NCT02027961|Biological|Durvalumab|Intravenous dose of 3 or 10 mg/kg durvalumab.
45913894|NCT02027961|Drug|Dabrafenib|Oral dose of 150 mg dabrafenib capsule.
45913895|NCT02027961|Drug|Trametinib|Oral dose of 2 mg trametinib tablet.
45913896|NCT02027974|Device|Iconacy Hip System|Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
45913897|NCT02027974|Device|Stryker Accolade Hip System|Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
45913898|NCT02027987|Drug|valproate acid|valproate acid is a common drug which is applied for epilepsy prevention and treatment.
45913899|NCT02028000|Procedure|Insorb staples skin closure|Patients will be randomized to Insorb staples skin closure and compared to Monocryl and Vicryl group.
45913900|NCT02028000|Procedure|Monocryl skin closure|Patients will be randomized to Monocryl skin closure and compared to Insorb skin closure and Vicryl skin closure.
45633047|NCT03184675|Other|Functional action observation training|the Four Square Step Test (FSST) performance video for enhancing the dynamic balance and the video including participants' daily activities to increase the gait ability such as walking in a corridor, walking around the hospital, walking to the therapy room, coming out of the ward after opening and closing the door of it, coming in and out of toilet, shifting their blue plate. and bringing something from a refrigerator were produced and watched.
45633048|NCT03184675|Other|General action observation training|step 1, looking at the front, while walking comfortably; step 2, looking left and right, while walking; step 3, looking up and down, while walking; step 4, looking at the front, left and right, up and down while walking. After 15 minutes of watching the video, the exercise program with a therapist was conducted to increase the gait ability, for 15 minutes.
45633049|NCT04747457|Device|Research FibroScan|"After having obtained the patient's Informed Consent Form signature, the following 3 examinations will be done:~Standard examination [Reference CE-marked FibroScan]: the operator will need to find an optimal measurement area, and perform 10 valid measurements.~Standard examination [Research FibroScan]: the operator must take 15 valid measurements at the same measurement point as the one used for the examination with the Reference FibroScan.~Exploratory examination [Research FibroScan]: the operator needs to perform15 invalid measurements to acquire data in non-optimal regions of measurement (lungs, vessels, intestines, ribs, edges of the liver)."
45633050|NCT03182803|Biological|CTLA-4/PD-1 antibodies expressing mesoCAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing mesothelin-targeted CAR-T cells at (2-5) ×10^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
45633051|NCT04596917|Behavioral|Preferred music listening|The preferred music listening group will receive 15 minute patient-preferred music listening selection intervention in the Prep Room and unlimited music listening selection intervention in the PACU once cognitively ready until discharge criteria met.
45633052|NCT04596917|Behavioral|Relaxation breathing narrative over hypnotic music listening|The relaxation breathing group will receive the relaxation and breathing instructions over soft monotone hypnotic music in the PreOp unit before surgery and then in the PACU once cognitively ready to listen to the hypnotic music until discharge criteria met.
45913901|NCT02028000|Procedure|Vicryl skin closure|Patients will be randomized to Vicryl skin closure and compared to Insorb and Monocryl skin closure groups.
45913902|NCT02028026|Drug|Vilazodone|10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks.
45633053|NCT03185689|Behavioral|Effectiveness of an intensified DSME in T2D adult patients|
45633054|NCT04199897|Dietary Supplement|Succrose rinsing|Sucrose rinsing 7-8 times a day for 14 days
45913903|NCT02028026|Drug|Citalopram|20 mg/day for 2 weeks and then 40 mg/day for 6 weeks
45913904|NCT02028039|Drug|IPI-145|75 mg orally twice daily for 4 weeks.
45633055|NCT04199897|Dietary Supplement|Probiotic lozenges|Probiotic lozenges 2 times a day for 35 days
45633056|NCT04199897|Other|xylitol rinsing|Xylitol rinsing 7-8 times a day for 14 days
45633057|NCT04199897|Other|Placebo tablets|Placebo lozenges 2 times a day for 35 days
45633058|NCT03185611|Drug|Rifaximin|Antibiotics
45633059|NCT03185611|Drug|Azathioprine|immunomodulator
45633060|NCT03185533|Behavioral|Quality improvement (QI) interventions|"1. The ED admissions exhibited prolonged length of stay.~2. The Interventions for Reducing Medical Decision Time:~The ED director created QI education sessions and reported monthly QI outcomes.~The ED nurses reported the current number of ED admission patients twice a day to the director. The director summarized the bed requests to the administrative personnel.~The nurses reported the in-scene complicated cases to the ED director. The director would give an assistance in managing these cases.~3. The Interventions for Reducing Boarding Time~The ED patients could be admitted before 8 a.m. if the bed was vacant.~The ED director initiated an on-line meeting at 8 a.m. and 4 p.m.~Monthly QI outcomes were reported in the hospital affairs meeting."
45633061|NCT03182959|Drug|Avmacol®|Avmacol® tablets
45633062|NCT02431429|Drug|Miltefosine|
45633063|NCT04158245|Drug|18F-fluciclovine PET Scan|The use of 18F-fluciclovine PET scanning will allow a more sensitive assessment of mCRPC patients at the initiation of systemic therapy and changes observed in 18F-fluciclovine PET will correlate better with the serologic changes in PSA, allowing superior disease monitoring, as compared to conventional imaging modalities. In addition, 18F-fluciclovine PET will detect heterogeneity in disease response and thus identify potential lesions amenable to targeted therapy.
45633064|NCT03182881|Other|Lymphatic Drainage|It was applied with the patient in a supine position with 30º elevation of the arm and very superficial and smooth maneuvers were performed in the axillary lymph nodes, the chest region and the arm.
45772133|NCT04222985|Biological|HSV 2 Formulation 4|Route of administration: Intramuscular
45772134|NCT04222985|Biological|HSV 2 Formulation 5|Route of administration: Intramuscular
45772135|NCT04222985|Biological|HSV 2 Formulation 6|Route of administration: Intramuscular
45772136|NCT04222985|Biological|Sodium Chloride 0.9%|Route of administration: Intramuscular
45913905|NCT02028039|Behavioral|Follow-up Visit/Call|Follow-up visit 30 days after last dose of study drug. If patient cannot make it to the clinic for this visit, they may speak by phone with a member of the study staff. This phone call should last about 10 minutes.
45913906|NCT02028052|Procedure|ROSE|The procedure will proceed with conventional EBUS-TBNA sampling of the target lesion with 22 gauge Vizishot needles. Each subject will be randomized to either ROSE by cytopathologist or no ROSE.
45913907|NCT02028052|Device|22 gauge Vizishot needles|
45913908|NCT02028078|Drug|Insulin human|Induces hypoglycaemia
45913909|NCT02028104|Biological|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in traumatic brain injury patients
45913910|NCT02028117|Biological|Enadenotucirev|Oncolytic Virus
45913911|NCT02028130|Procedure|LAA electrical isolation + occlusion|LAA electrical isolation + Watchman device implantation to occlude LAA
45772137|NCT05749354|Other|electroacupuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675.~For non-acupoint group,the internal wire of the electroacupuncture instrument will be interrupted, no current passed through."
45447916|NCT02127190|Drug|CXA-10 emulsion|CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
45633065|NCT03182881|Other|Myofascial Release|For the use of the treatment the bases of Pilat, A. 2016 were followed. The global and specific techniques for the periganglionar and upper thoracic region were chosen. The application of each smooth maneuver three-dimensional fascial movement has been carried out has an approximate duration of about 10 minutes and a total of 50 minutes.
45447917|NCT02127190|Drug|Placebo|
45633066|NCT03143543|Drug|Group A Lorcaserin (10mg)|10 mg lorcaserin orally for 7 days
45633067|NCT03143543|Drug|Group A2 Lorcaserin (20 mg)|20 mg lorcaserin orally for 7 days
45633068|NCT03143543|Other|Group B Parallel Placebo|Oral placebo vs 10 mg lorcaserin
45633069|NCT03143543|Other|Group B2 Parallel Placebo|Oral placebo vs 20 mg lorcaserin
45633070|NCT02428075|Behavioral|FCHV visit|Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages and measure the blood pressure
45633071|NCT02428153|Other|stretching exercises|static stretching exercise of 5 repetitions, with a duration of 45 seconds to the right gastrocnemius muscle and dynamic stretching exercise of 5 repetitions, with a duration of 45 seconds to the cases' left gastrocnemius muscles
45633072|NCT03142061|Procedure|Electrochemotherapy|Bleomycin plus local electroporation of cutan accessible tumor tissue in patients with advanced inoperable vulva carcinoma
45633073|NCT04402307|Other|Chin Tuck Against Resistance|Training in 6 weeks 3 times a day.
45633074|NCT02427919|Drug|G-CSF|Comparison of the effect of G-CSF use
45633075|NCT03110783|Biological|Bioseal|Upon completion of the sutured dural repair, the closure will be evaluated for intra-operative CSF leakage with a baseline Valsalva maneuver to 10-20 cm H2O for 5-10 seconds. Subjects who have a CSF leak will be enrolled into the study. If randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds.
45772138|NCT05749276|Drug|Darzalex|"DARZALEX® = Daratumumab. Solution for injection, 1800 mg/15 mL, single vial. Sub-cutaneous administration.~Dose level 1 : 1800 mg Day 1~Dose level 2 : 1800 mg Day 1 and 8 (+/- 2 days)~Dose level 3 : 1800 mg à Day 1, 8 (+/- 2 days) and D15 (+/- 2 days)"
45772139|NCT04206605|Drug|Lanadelumab|Participants will receive 300 mg of lanadelumab solution in a PFS SC injection once q2w for 26 weeks.
45633076|NCT02027428|Drug|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
45633077|NCT02027428|Drug|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion
45772140|NCT04206605|Other|Placebo|Participants will receive placebo matched to lanadelumab SC injection once q2w for 26 weeks.
45935403|NCT00123916|Drug|Placebo|a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 - 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)
45447918|NCT02127268|Drug|Thymosin-α1|with Thymosin-α1 1.6mg twice a week
45633078|NCT02027428|Drug|Abraxane (Maintenance)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, administered as standard of care
45633079|NCT02027428|Other|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
45633080|NCT02027428|Drug|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
45633081|NCT02027428|Drug|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion, administered as standard of care
45633082|NCT02027428|Other|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
45633083|NCT03182647|Procedure|Surgically treatment of the ACL|Surgical initial ACL treatment
45447919|NCT03551704|Behavioral|CBT + EFT|"The CBT treatment will be implemented in 8-week group-based sessions (maximum 4 patients). Sessions will be carried out once a week over an 8-week period, with quit date occurring at fifth session. Patients will be asked to gradually reduce their nicotine intake (i.e., 25% each week). CBT components include: psychoeducation, self-monitoring, physiological feedback, training in stimulus control and strategies for controlling negative discomfort, and relapse prevention strategies.~As part of the EFT, participants will be asked to select future smoking-related events that would occur within the following time periods: 2 weeks, 1, and 6 months. They will be instructed to generate personal audio recordings that will be used to help them think about future decision-making choices."
45633084|NCT03182647|Other|Non surgical initial ACL treatment|Non surgical initial ACL treatment
45935404|NCT00073827|Drug|levalbuterol tartrate MDI|levalbuterol 90 mcg QID
45935405|NCT00073827|Drug|racemic albuterol MDI|racemic albuterol 180 mcg QID
45633085|NCT03143699|Other|Immediate Feedback|Students will be trained to measure blood pressure in the same way, with a brief 4-hour theoretical-practical intervention. After the training, students will measure the blood pressure of a standardized patient and observers will evaluate them using a checklist. After that, students from the intervention group will receive an immediate feedback based on the previous literature. Briefly, feedback will be based on what was directly observed and will be phrased in non-judgmental language, following the Pendleton model.
45633086|NCT04016363|Other|ProbeFix|ProbeFix vs. manual hold of the ultrasound probe during pharmacological stress-echocardiography examinations
45633087|NCT04016363|Other|Manual hold|ProbeFix vs. manual hold of the ultrasound probe during pharmacological stress-echocardiography examinations
45633088|NCT03399071|Drug|FLOT-A|This is a single-arm study with all patients receiving combination FLOT-A
45633089|NCT02425033|Procedure|POEM|Under general anesthesia, patient undergoes upper endoscopy and a small longitudinal submucosal incision is created and a dilating balloon is inserted submucosally via the created incision. The balloon is slightly inflated to allow entrance of the endoscope. The gastroscope is advanced into the submucosal space and the tunnel is created via endoscopic or blunt dissection as appropriate. The tunnel is created distally and is stopped several centimeters beyond the lower esophageal sphincter (LES), which can easily be identified using endoscopic landmarks. Using a dissection knife, the clearly visible circular muscles are divided. The longitudinal layer is left intact and the mucosal entry is closed.
45633090|NCT03857165|Drug|SAP-001|SAP-001 or placebo treatment in a 3:1 randomization ratio.
45633091|NCT03184363|Drug|Clostridium Botulinum A Toxin|Clostridium Botulinum A Toxin
45633092|NCT02431039|Device|NEOSORB PLUS|Fascia and subcutaneous tissue repaired by antibacterial suture materials (Chlorhexidine diacetate coated PGLA910)
45633093|NCT02431039|Device|NEOSORB|Fascia and subcutaneous tissue repaired by non-antibacterial suture materials (PGLA910)
45633094|NCT04346693|Procedure|Standard therapy recommended by the Ministry of Health of the Russian Federation.|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days"
45633095|NCT04346693|Procedure|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days"
45633096|NCT04346693|Procedure|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin inhalation|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional inhalation of the drug Leitragin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased."
45772141|NCT05749198|Diagnostic Test|MRE|MRE was performed using a 3T system (Magnetom Skyra; Siemens, Erlangen, Germany) equipped with a combination of a 30-channel body and a 32-channel spine matrix coil.
45772142|NCT04197869|Drug|Polyethylene Glycol Powder|Polyethylene Glycol 3350 17g should be mixed in 8 ounces of fluid for administration. Polyethylene glycol is a high molecular weight, water soluble polymer which can form hydrogen bonds with water molecules. It is an osmotic laxative solution which stimulates bowel movements by increasing the amount of water absorbed in the GI tract. It decreases feces consistency and increases their volume by promoting peristalsis and evacuation. The side effects of polyethylene glycol are bloating, gas or diarrhea. The half-life of polyethylene glycol is 4-6 hours and after 18 hours the concentration declines to non-quantifiable levels.
45772143|NCT05749042|Drug|Sintilimab|Concurrent Chemoradiotherapy Based of Cisplatin Plus Sintilimab.
45772144|NCT05749042|Radiation|Radiotherapy|Concurrent Chemoradiotherapy Based of Cisplatin
45772145|NCT03015077|Dietary Supplement|oral glutamine|L-Glutamine and maltodextrin are both nutritional supplements. In the glutamine arm: 10 g L-Glutamine and 5 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
45772146|NCT03015077|Dietary Supplement|placebo|in the placebo arm: 15 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
45772147|NCT03015077|Radiation|Radiotherapy|All patients undergo radiotherapy. 5 days a week. All patients had a dental evaluation for good oral hygiene prior to computed tomography simulation for radiotherapy. Post-operative patients received planned course of adjuvant treatment of 60 to 66 Gy in 2-Gy fractions to the surgical bed. The course of radiation was initiated no more than 6 weeks after resection. Patients without operation received definitive treatment to 70 Gy in 2-Gy fractions.
45935406|NCT00073827|Drug|Placebo|Placebo MDI QID
45935407|NCT00123994|Behavioral|Tai Chi classes|
45935408|NCT00123994|Behavioral|Hydrotherapy classes|
45935409|NCT00124033|Procedure|Transcystic Stenting (Facilitated ERCP)|
45935410|NCT02970539|Drug|Oraxol|Oraxol (Paclitaxel and HM30181A) will be dosed orally. Paclitaxel will be supplied as capsules and HM30181A will be supplied as tablets.
45633097|NCT04346693|Procedure|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection combined with Leitragin inhalation|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional inhalation of the drug Leitragin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased.~Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days"
45633098|NCT02430805|Other|dna extraction and genotyping|blood and urine sample
45633099|NCT01995136|Drug|Travoprost Ophthalmic Solution 0.004%|benzalkonium chloride (BAC) free
45633100|NCT04290299|Other|Data collection|Cancer (response, relapse) and fertility (pregnancy, delivery) outcomes
45633101|NCT04483141|Diagnostic Test|Abbey Pain Scale|Hetero-assessment of pain
45633102|NCT02430883|Procedure|Retrograde Intrarenal Surgery|endoscopic treatment of kidney stones with flexible renoscopy
45633103|NCT03141593|Drug|Vitamin D: liquid form, start weekly|Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
45633104|NCT03141593|Drug|Vitamin D: liquid form, start monthly|Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
45633105|NCT03141593|Drug|Vitamin D: solid form, start weekly|Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
45633106|NCT03141593|Drug|Vitamin D: solid form, start monthly|Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
45633107|NCT04680832|Diagnostic Test|Electronic nose|First, patients will be asked to rinse their mouth thoroughly with water three times. Subsequently, exhaled breath analysis will be performed in duplicate with a 1-minute interval. An eNose measurement consists of five tidal breaths, followed by an inspiratory capacity maneuver to total lung capacity, a five second breath hold, and subsequently a slow expiration (flow <0.4L/s) to residual volume. The measurements are non-invasive and will cost approximately 5-10 minutes in total, including explanation and informed consent procedure. There are no risks associated with this study and the burden for patients is minimal.
45633108|NCT03183973|Biological|PRF|patients who will receive PRF suspension
45633109|NCT03183973|Biological|placebo group|patients who will receive Placebo
45633110|NCT03143309|Behavioral|Intervention|Brief introductory session, pedometer instruction, daily pedometer use, and health messages delivered via WhatsApp 2-3 times per week.
45633111|NCT03143309|Other|Control|Non-health related messages delivered via WhatsApp 2-3 times per week.
45633112|NCT04102241|Drug|15mg Hemay005|Hemay005 is a small molecule PDE4 inhibitor.
45633113|NCT04102241|Drug|Placebos|Placebos are the same as drugs, but contain no Hemay005.
45633114|NCT01994902|Device|Coloplast test product|The Coloplast test product is a newly developed ostomy appliance
45633115|NCT01994902|Device|SenSura Convex Light|The comparator product is SenSura Convex Light, which is CE-marked and commercially available.
45633116|NCT03111095|Other|Mobile Health|Subjects will submit blood pressure and weight measurements daily for 6 weeks postpartum. Subjects will have a video telehealth visit with the mobile health nurse at 48 hours and 7 days after discharge from the hospital.
46070087|NCT05251688|Other|Cryoanalgesia|"On the first day of the study, the PI met the participants and assessed their level of consciousness using the Modified Glasgow Coma Scale to ensure that they were unconscious and reviewed the medical records to collect their sociodemographic data. After that, the participants received routine care before the arterial puncture. The PI assessed their pain scores during the puncture.~In the second meeting (on the same day or the following day), the PI prepared the ice packs by crushing small pieces of ice and wrapping them in smooth gauze to avoid skin damage and moisture in the puncture area. Before the arterial puncture, the ice pack was applied over the selected puncture site (radial, brachial, or femoral artery) for 5 minutes in addition to the routine care. After removing the ice pack, the nurse palpated the artery, wiped of the residue of ice vapor present on the skin, and took the arterial blood sample. During the puncture, the PI assessed the participants' pain scores."
45633117|NCT02425267|Other|Rehabilitation (Physiotherapy)|The training program will be carried out twice a day, and at every day during the eight-week program, either by telerehabilitation or in the clinic or by autonomous unsupervised way. During weeks 1, 3 and 5, the patient will perform his/her exercises twice a week by telerehabilitation/clinic and the other without supervision. During the other weeks (2, 4, 6, 7, 8), the patient will benefit from one exercise session by telerehabilitation/clinic per week and will perform all other without supervision. Supervised sessions allow the therapist and the patient to adjust the program in case of problems and to ensure a smooth implementation of the program.
45633118|NCT03777137|Behavioral|TMS (Rapid2, Magstim Corp)|Volunteers will take a telephone screening questionnaire and those meeting inclusion criteria will attend their first visit. Those signing the consent will have a T1 weighted MRI scan to localize sites in the brain to be stimulated with TMS. The subjects will then have four visits at intervals of two weeks; each visit will have a TMS intervention including SITE1, SITE2, SITE3, and SITE4. The sequence of the testing TMS four different visits (SITE1 to SITE4) will be randomly assigned among stimulation sites Medial Frontal (MF), Dorsal Lateral Frontal (DL), Primary motor cortex (M1) and Interparietal Sulcus (Sham) and counterbalanced across subjects (see Diagram below). During each of visits 2 to 5, each participant will undergo baseline Quantitative Sensory Testing (QST), followed by a TMS intervention, and then by repeat QST. QST will consist of pain thresholds for contact heat.
45772148|NCT05659420|Behavioral|Cardiac rehabilitation comprised aerobic exercise on a treadmill accompanied by an electrocardiogram monitoring device and a blood pressure monitor|aerobic exercise on a treadmill (T7M, Motus, Paju, South Korea) accompanied by an electrocardiogram monitoring device (Q-Tel Rehabilitation Management System, Mortara Inc., Milwaukee, WI, USA) and a blood pressure monitor
45772149|NCT05653726|Other|Telemonitoring follow-up using medical devices and telematic consultations|Home telemonitoring of blood pressure, heart rate and peripheral oxygen saturation on a daily basis during 12 months
45633119|NCT02026258|Procedure|Piezotome-Corticision|Local anesthetic will be administered to the labial sulcus of the mandibular incisors. A scalpel will be used to make three vertical incisions through the gingiva, 4mm below the interdental papilla, interproximally between mandibular canines and lateral incisors, and central incisors on the labial aspect of the mandible. The incisions will be 4mm in length. A piezosurgery knife will be used to create the cortical alveolar incisions to a depth of 1mm within the cortical bone. The depth of the cortical incision will be limited to 1mm for a safety margin. Postoperatively, subjects will be advised to rinse with chlorhexidine mouthwash twice a day for one week and take acetaminophen as needed.
45633120|NCT02026258|Device|Orthodontics|Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment.
45772150|NCT02940509|Drug|Ketamine plus Magnesium sulfate|"Patients will receive 2 IV infusions:~Ketamine (0.5mg/kg)~Magnesium sulfate (2g)"
45633121|NCT05129683|Other|Anodal tDCS cerebellar stimulation group|Single-session ctDCS (2 mA, 20 min). The active (anode) and the returning (cathode) electrodes will be placed bilaterally over the cerebellum (1 -2 cm below inion of occipital bone) and the right buccinator muscle, respectively Xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins will also be given
45772151|NCT02940509|Drug|Placebo|Patients will receive 2 IV infusions, both of NaCl 0.9%, as placebos for Ketamine and magnesium sulfate
45633122|NCT05129683|Other|Anodal tDCS cerebral (M1) stimulation group|Single-session ctDCS (2 mA, 20 min) In the M1 a-tDCS group, the anode will be positioned over the left (dominant) M1 (C3, International 10-20 system) and the cathode Would be located over the right contralateral supraorbital area. Xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins will also be given
45772152|NCT05748964|Procedure|Laparoscopic pyeloplasty|Twenty patients presented with ureteropelvic junction obstruction [UPJO] will be divided into two equal groups. The first was subjected to trans-peritoneal pyeloplasty while the second was subjected to retroperitoneal pyeloplasty.
45772153|NCT02786615|Behavioral|Peer Unity|A 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
45633123|NCT05129683|Other|sham group|Single-session a-tDCS (2 mA, 20 min), Sham tDCS followed a similar protocol as Anodal tDCS cerebral (M1) stimulation and arrangement but stimulation for 30 s, after which the current was ramped-down and turned off for the rest of the treatment. Xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins will also be given
45772154|NCT05652088|Procedure|Colonoscopy|Colonoscopy is a procedure where an instrument called colonoscope is inserted through the rectum to look at the entire internal surface of the intestine. Participants will be placed on a stretcher on the left side. A colonoscope will be advanced into the colon and into the terminal ileum. The entire procedure should take approximately 40 minutes
45772155|NCT05328713|Diagnostic Test|Cardiac MRI|This study will use Cardiac MRI to identify subclinical cardiac dysfunction.
45772156|NCT02530697|Drug|Meglumine antimoniate|20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days.
45772157|NCT02530697|Drug|Miltefosine|Miltefosine 2,5mg/kg/day up to 50mg 2x/daily.
45772158|NCT02530697|Drug|Pentoxifylline|Pentoxifylline 20mg/kg/day up to 400mg 3x/daily for 28 days.
45772159|NCT02246075|Drug|EVP-6124|
45772160|NCT02246153|Procedure|Laparoscopic gastrectomy|"After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy."
45772161|NCT02246153|Procedure|Open gastrectomy|"After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~The type of reconstruction will be selected according to the surgeon's experience."
45772162|NCT05650294|Dietary Supplement|PL+ omega 3 fatty acids|PL+ omega 3 fatty acids is a food supplement that combines krill oil and FO EE. The dose will be around 1250 mg EPA+DHA.
45772163|NCT05650294|Dietary Supplement|FO EE fatty acids|A conventional fish oil food supplement containing EPA and DHA in the EE form. The dose will be 1250 mg EPA+DHA.
45913912|NCT02028143|Device|Biosense Webster irrigated tip catheter|The second group (study group) will have the ICE catheter placed through one of two existing 8F sheaths already in the left atrium. The ICE catheter will be exchanged in the sheath utilizing the lasso multipolar mapping catheter during left pulmonary vein ablation lines. During exchange, suction and irrigation techniques will be utilized to avoid any air or thrombus embolization. All patients will have standard anticoagulation during the procedure with heparin infusion adjusted to an activated clotting time (ACT) of 350-400. The left sided ICE catheter will be adjusted to visualize left sided structures, ablation tip and tissue interface, and adjacent noncardiac structures such as the esophagus during radiofrequency ablation of the left pulmonary vein system.
45913913|NCT02028143|Device|Biosense Webster irrigated tip catheter|Group 1 will receive standard pulmonary vein isolation (PVI) procedure utilizing intracardiac guided ultrasound (ICE) placed within the right atrium via the femoral vein.
45913914|NCT02028143|Procedure|Pulmonary vein isolation|
45913915|NCT02028143|Procedure|ICE catheter placed through one of two existing 8F sheaths|
45913916|NCT02028156|Other|Partially Hydrolyzed Infant Formula|Commercially available infant formula
45913917|NCT02028195|Other|Health check|"The program includes four components:~Invitation: All participants receive invitation by mail and a prefixed appointment time. A web-based questionnaire including self-reported health (SF12), physical activity, smoking habits and alcohol use/behaviour has to be answered before Health Examination (HE).~The HE include: Blood pressure, waist, weight, lung function test, lipid profile, HbA1c and fitness (Aastrand).~Health profile pamphlet: The participant receives a pamphlet with the results. The persons are stratified into three groups (I) referral to a consultation in general practice (GP) (II) targeted behavioural programs at the health centre (HC) or (III ) no identified need for health promoting follow-up.~Follow-up according to risk-profile: If referred to GP treatment of risk conditions or diseases will follow national guidelines. The GPs were paid 50 Euros per health interview."
45913918|NCT02028234|Drug|Pantoprazole,|os, 20 mg, once per day, for 30 days
45772164|NCT03014999|Device|High frequency rTMS (repetitive Transcranial Magnetic Stimulation)|Higher cortical representation area of first right dorsal interosseous muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold by finding the lowest stimulator output that elicit motor evoked potential at least 50μV. After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 10Hz, 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28s, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
45772165|NCT03014999|Device|Low frequency rTMS (repetitive Transcranial Magnetic Stimulation)|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline, will be placed over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold (RMT) by finding the lowest stimulator output that elicit motor evoked potential (MEP) at least 50 microvolts (μV). After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed
45633124|NCT03576443|Drug|Idelalisib|Idelalisib 150 mg x 2 p o
45633125|NCT03141515|Device|Lung ultrasound|Lung ultrasound examination at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
45633126|NCT02427685|Device|Pulse Co-Ox|Comparison of pulse co-oximeter to blood gas analyzer.
45633127|NCT02427529|Drug|Human Chorionic Gonadotropin|The addition of hormone to a daily low calorie diet to potentially aid in selective fat loss, or muscle-sparing.
45633128|NCT02427529|Drug|Placebo|
45633129|NCT02427529|Other|Low calorie diet|
45633130|NCT03336671|Procedure|Endoscopic Sinus surgery|Endoscopic sinus surgery would be tailored to abnormal findings in the CT scan, as is the standard of care. Radiologists typically examine sinonasal disease of the sinuses, and they would also be requested to comment on the patency of the osteo-meatal unit, as this is a component of the Lund-McKay score. The Lund-McKay score is an objective radiologic grade of the severity of sinusitis. If there is sinus thickening, or narrowing of the OMU, endoscopic sinus surgery would be tailored to this using either balloon sinuplasty or traditional antrostomy. Patient undergoing endoscopic sinus surgery will likely have at least a maxillary antrostomy and anterior ethmoidectomy performed, with frontal sinusotomy, posterior ethmoidectomy, and sphenoidotomy performed depending on CT or endoscopy findings.
45633131|NCT03336671|Procedure|Adenoidectomy|Adenoidectomy performed, routine, as a singular procedure not combined with any sinus surgery.
45633132|NCT04667572|Combination Product|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
45633133|NCT03552341|Other|Maternal iodine status|Urinary iodine concentration during pregnancy at 26 weeks' gestation (Bord in Bradford study) and at 12, 26 and 36 weeks' gestation, 6, 18 and 30 weeks postpartum (Hiba longitudinal study). This is primarily in the form of Iodine to Creatinine ratio, to take spot urine volume into account. There is no intervention in this observational study.
45633134|NCT02427763|Device|hours of use (Essix)|the patient will use de thermoplastic device during the night or during all day
45633135|NCT02427763|Other|collect saliva|the patient spit during 30 seconds in a small bottle
45633136|NCT02427763|Other|collect biofilm|a sterile swab is rubbed at the buccal surface of the upper teeth
45633137|NCT02427763|Other|collect epithelium|a sterile cytobrush is rubbed at the buccal surface of gingiva at the upper arch
45633138|NCT04438733|Drug|test-anastrozole tablet (Salutas Pharma GmbH)|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
45633139|NCT04438733|Drug|reference-anastrozole tablet (Arimidex)|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
45633140|NCT04438811|Other|delivery of the spinal anesthetic by a trained medical officer|The delivery of spinal anesthesia by the trained medical officers in 3 rural Indian hospitals will be compared to those delivered by consultant anesthetists in the same hospitals in a non-inferiority analysis.
45633141|NCT04438811|Other|delivery of spinal anesthetic by a consultant anesthetist|The delivery of spinal anesthesia by the trained medical officers in 3 rural Indian hospitals will be compared to those delivered by consultant anesthetists in the same hospitals in a non-inferiority analysis.
45633142|NCT02427295|Drug|Sandostatin (Octreotide Acetate)|"For the patients outlined above (refer to 2), subjects who are not able to be treated by surgery alone:~Dose: Sandostatin LAR® 20mg per 4 weeks for 3 months -> If serum IFG-1 levels fails to normalize, the dose of LAR will be increased to 30 mg.~Frequency: every 4 weeks.~Route of administration: IM injection."
45633143|NCT01994590|Drug|Dovitinib|Starting dose will be 400 mg by mouth daily on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle.
45633144|NCT01994590|Drug|Abiraterone Acetate|4 tablets (250 mg each) by mouth daily.
45633145|NCT01994590|Drug|Prednisone|5 mg by mouth twice daily.
45633146|NCT02427373|Dietary Supplement|fish oil ethyl ester|
45633147|NCT02427373|Dietary Supplement|fish oil triglyceride|
45913919|NCT02028234|Drug|Omeprazole|os, 20 mg, once per day, for 30 days
45913920|NCT02028260|Drug|Modafinil|200 mg daily
45633148|NCT02427373|Dietary Supplement|krill oil|
45633149|NCT02427061|Behavioral|Intervention Program (Manhood 2.0)|
45633150|NCT02427061|Behavioral|Control Program (Job Skills Training)|
45913921|NCT02028260|Drug|Placebo|similar appearing inert tablet
45913922|NCT02028286|Drug|CLS001|
45913923|NCT02028299|Procedure|2D doppler echo with Definity solution|Correlate right heart catheterization results with results from 2D doppler echo with Definity Solution
45913924|NCT02028312|Drug|Loteprednol etabonate|
45913925|NCT02028312|Drug|Artificial Tears|
45913926|NCT02028312|Drug|Restasis|
45772166|NCT03014999|Device|sham rTMS (repetitive Transcranial Magnetic Stimulation)|The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over primary motor area Cz. After each rTMS session, presence of adverse effects will be computed.
45913927|NCT02028377|Procedure|PET/MRI|PET/MRI
45447920|NCT03551704|Behavioral|CBT + EFT + CM|This intervention includes the abovementioned treatment components and a CM procedure reinforcing abstinence. This arm will consist on delivering CBT and EFT and providing patients incentives to promote and reinforce abstinence contingent on abstinence. The schedule will incorporate an increasing magnitude of reinforcement.
45633151|NCT05387603|Drug|177Lu-DOTATOC|"The investigational medicinal product (IMP) is 177Lu-DOTATOC which is registered as an orphan drug by the EMA ( European Medicines Agency) for the treatment of GEP-NEN (gastro-entero-pancreatic neuroendocrine tumor).~The IMP will be administered to participants both in the control arm and the experimental arms, but with different intervals, but the same activity; 7.5 Gbq per dosing."
45633152|NCT05387603|Drug|Capecitabine|Will be given orally with a dose of 825/m2 twice daily, starting on day 1 of each of the 4 first treatment cycles, cycle length 3 weeks.
45633153|NCT03182569|Device|FLEXIBLE CATHETER|
45633154|NCT03182569|Device|hourly rigid needle puncture|
45633155|NCT03306173|Other|Commercially available cigarette|Commercially available cigarette with either ~0% or ~25% filter ventilation. Menthol flavor will be available in both types.
45633156|NCT02019550|Device|Rebif Rebidose|Rebif 44 mcg will be injected subcutaneously three times a week using Rebif Rebidose self-injector device.
45633157|NCT02019550|Device|Rebiject II|Rebif 44 mcg will be injected subcutaneously three times a week using Rebiject II self-injector device.
45633158|NCT03182413|Drug|Placebo|
45633159|NCT03182413|Drug|Modafinil|
45633160|NCT03182413|Drug|THN102|
45447921|NCT03552250|Behavioral|Parenting for Lifelong Health for Young Children|In this study, the 12 sessions-PLH version for parents of young children (2-9 years) will be delivered. The PLH (2 - 9) programme is delivered in groups of parents and includes the following general content 1) One-on-one time, 2) Say what you see, 3) Talking about feelings, 4) Praising and rewarding our children, 5) Giving positive, specific, and realistic instructions, 6) Establishing household rules and routines, 7) Redirecting negative behavior, 8) Ignoring negative attention seeking and demanding behavior, 9) Using consequences to support compliance, 10) Using Cool-down as a consequence for aggressive behavior, 11) Avoiding and resolving conflicts, 12) Reflection celebration, and moving on.
45447922|NCT02121886|Procedure|venous reconstruction with the parietal peritoneum|
45633161|NCT02430649|Procedure|Irreversible electroporation (IRE)|
45633162|NCT02430649|Device|NanoKnife|
45633163|NCT03182257|Drug|ONO-7579|ONO-7579 Tablets
45633164|NCT03166631|Drug|BI 891065|Part A, B & C
45633165|NCT03166631|Drug|BI 754091|Part B & C
45633166|NCT05117827|Device|Power Wheelchair Standing Device|A power wheelchair standing device is a power wheelchair that allows a child to electronically move between sitting and standing. It can be driven in either position. The Permobil F5 Corpus VS is the specific power wheelchair standing device to be used in this study.
45913928|NCT02028390|Device|Scout takes visual and thermal images of external wounds|All images are taken after the wound has acclimated.
45913929|NCT02028390|Device|ImageReview's visual perimeter trace of the external wound|Trace is drawn by the study staff using the ImageReview software.
45633167|NCT03159377|Device|Ultra low dose chest CT|Performing an ultra low dose chest CT (ULDCT) in addition to a clinically indicated chest CT and assessing nodule detection with a recently developed denoising algorithm
45913930|NCT02028390|Device|ImageReview's External Wound Trace Overlay|Study staff overlay the trace of the visual external wound's perimeter onto the corresponding thermal image of the external wound.
45913931|NCT02028390|Device|ImageReview's unaffected reference area selected|Study Staff select an unaffected reference area of an adjacent body surface.
45913932|NCT02028390|Device|Adjacent tissue trace of the wound trace overlay|Study staff select an adjacent tissue trace of the wound trace overlay
45913933|NCT02028403|Drug|BMS-936559|0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg of BMS-936559, depending on which cohort participants are enrolled in, administered as an intravenous (IV) infusion
45633168|NCT02980367|Other|Non-Surgical Management (Rehabilitation)|Routine ACL rehabilitation protocols used at the participating site will be followed. As part of the site selection process, documentary evidence of the use of or willingness to adopt a rehabilitation protocol that reflects the guidelines of the mandatory aims/goals set for the study rehabilitation intervention will be required.
45633169|NCT02980367|Procedure|Surgical Management (Reconstruction)|All surgical reconstructions will be patella tendon or hamstrings tendon depending on the surgeon's preference. All other care will be routine, including immediate post-operative care.
45633170|NCT03185221|Device|Cordimax|One rapamycin eluting stent for treating the adapted coronary patients
45633171|NCT03185221|Device|XIENCE V|One everolimus eluting stent for treating the adapted coronary patients
45633172|NCT03184129|Device|trial group|Patients with knee disease who will undergo knee arthroplasty will be randomized into trial group. The patients from the trial group will receive newly developed knee arthroplasty with knee prostheses purchased from Wuhan Yijiabao Biomaterial Co., Ltd..
45633173|NCT03184129|Device|control group|Patients with knee disease who will undergo knee arthroplasty will be randomized into control group. The patients from the control group will receive knee arthroplasty with knee prostheses purchased from Beijing AKEC Medical Co., Ltd., Beijing, China (approved by China Food and Drug Administration).
45633174|NCT02507765|Other|Laboratory Biomarker Analysis|Correlative studies
45913934|NCT02028403|Drug|Placebo for BMS-936559|Sodium chloride for injection 0.9%, USP, administered as an IV infusion
45447923|NCT02124694|Behavioral|HTUG|HTUG is a group psychotherapy...
45447924|NCT02127424|Procedure|Nurse-driven HIV targeted screening|
45447925|NCT02127424|Procedure|Current practice|
45633175|NCT02507765|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45772167|NCT05647252|Drug|Whole Body and nasal decolonization with octenidin (Octenisan Set)|"Octenidin body lotion once a day during the five consecutive days preceding the elective orthopedic surgery, including for the hair.~Octenidin nasal creme 2-3 times a day in both nasal orifices during the same period"
45772168|NCT05647252|Behavioral|Questionnaire for study participants immediately after the decolonization|"A questionnaire in GErman language will be handed out to decolonized patients with five questions: Practical difficulties of decolonization, the completeness of scheduled decolonization actions, all adverse events during decolonization and surgery, and two questions regarding the comprehension of the science (indication for decolonization, potential benefit expected in the individual case).~The questionnaire is handmade and validated by the Investigators."
45772169|NCT02170649|Drug|BIA 2-093|
45772170|NCT05288699|Behavioral|Aliento|Aliento is a culturally adapted, brief, personalized feedback intervention (PFI) to address alcohol misuse in the context of clinical anxiety delivered via a mobile application.
45772171|NCT05646160|Other|Ischemic Compression of Myofascial Trigger Points (IC-MTRPs)|IC-MTrPs intervention was made first on the right side and then on the left side and this order was the same in each patient. Before starting the therapeutic procedure, the MTrPs localizations were identified by palpation and pinch pressure in patients lying back on the couch. During the procedure, a qualified physiotherapist sat behind the subject's head. The pressure was sustained for about 5 seconds with a 2-3 seconds pause. In each subject, the intervention lasted 15 minutes on the same measurement day in the morning. The subjects underwent cycle of seven IC-MTrPs therapeutic sessions, with 3 days brakes between each session, that lasted in total about a 3-weeks (25 days).
45772172|NCT02316470|Biological|VLA84|a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
45772173|NCT02316470|Biological|Placebo|phosphate buffered saline (PBS) solution
45633176|NCT02507765|Procedure|Transarterial Chemoembolization|Undergo TACE
45772174|NCT03014921|Other|iron injection|Injection of a 250mL saline solution added with 500mg of iron (Ferinject)
45772175|NCT03014921|Other|saline solution injection|Injection of a 250mL saline solution
45633177|NCT03184285|Procedure|baseline alert 1|measurement in supine position
45772176|NCT04094207|Drug|Placebo oral tablet|Placebo tablets PLUS Risperidone 2 mg tablet up to 6 mg/day
45772177|NCT04094207|Drug|Pentoxifylline|Pentoxifylline tablet PLUS Risperidone 2 mg tablet up to 6 mg/day
45772178|NCT05645614|Other|EVALUATION OF PAIN|PAIN EVALUATION THANKS TO SCALES
45772179|NCT02144831|Drug|anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)|comparisson of what is the efficacy and safety of 10 days to 30 day treatment of aspirin (ASA)+Clopidogrel
45772180|NCT05634538|Device|Robotic-assisted PCI with Corpath GRX® System|The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary interventions (PCI).
45772181|NCT05634538|Procedure|Standard PCI|Percutaneous coronary intervention (PCI) is a procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart. This arm will be completed without robotic assistance.
45772182|NCT05276219|Drug|Furosemide Injection|A diuretic (iv furosemide) strategy for decongestion in acute heart failure
45913935|NCT02028416|Drug|ATG-fresenius|"we will create 2 arms as per randomization table. Both arms will receive ATG-Fresenius but with 2 different regimens.~the first arm will receive ATG-F @10mg/kg for 3 days and second arm will receive ATG-F same dose but for 5 days"
45633178|NCT03184285|Procedure|Anti-Trendelenburg-position (ATB)|measurement under ATB
45772183|NCT05276219|Drug|Isosorbide Dinitrate|Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure
45772184|NCT05276219|Drug|Furosemide and isosorbide dinitrate|Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure AND A diuretic (iv furosemide) strategy for decongestion in acute heart failure
45772185|NCT01810250|Device|Endurant Stent Graft|
45913936|NCT02028429|Drug|Sildenafil.|Arm 1 :Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
45633179|NCT03184285|Procedure|ATB in narcosis|measurement under ATB in narcosis
45633180|NCT03184285|Procedure|baseline in narcosis 1|measurement in supine position in narcosis
45633181|NCT03184285|Procedure|passive leg raising|measurement under passive leg raising
45633182|NCT03184285|Procedure|volume bolus substitution|measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
45633183|NCT03184285|Procedure|baseline in narcosis 2|measurement in supine position
45633184|NCT03184285|Procedure|start capnoperitoneum|measurement in supine position
45633185|NCT03184285|Procedure|ATB plus capnoperitoneum|measurement under ATB plus capnoperitoneum
45772186|NCT05232461|Drug|PrimeC-ER 748 mg|PrimeC-ER is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
45772187|NCT05232461|Drug|Ciprofloxacin 750 MG|Ciprofloxacin
45772188|NCT05232461|Drug|Celecoxib 200mg|Celecoxib
45772189|NCT05748106|Device|Ultrasound-based imaging|Ultrasound-based imaging
45913937|NCT02028442|Biological|Enadenotucirev|Oncolytic virus
45633186|NCT03184285|Procedure|ATB plus capnoperitoneum plus volume bolus substitution|measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
45633187|NCT03184285|Procedure|ATB loss of capnoperitoneum|measurement under ATB
45633188|NCT03184285|Procedure|baseline|measurement in supine position
45633189|NCT03184285|Procedure|baseline alert 2|measurement in supine position
45633190|NCT03184285|Procedure|torso position rising 30° at the beginning|measurement in the recovery unit
45633191|NCT03184285|Procedure|torso position rising 30° at the end|measurement in the recovery unit
45633192|NCT03183817|Behavioral|Person-centred care at distance|Person-centred care at distance through an eHealth platform
45633193|NCT03183739|Drug|ASP8062|ASP8062 will be administered orally.
45633194|NCT03183739|Drug|Placebo|Placebo will be administered orally.
45633195|NCT02862119|Procedure|FFR Treatment Arm|Fractional Flow Reserve-guided PCI of non-culprit lesions during index hospital admission
45633196|NCT02862119|Other|Conservative Treatment Arm|Initial Conservative management of non-culprit lesions during index hospital admission
45633197|NCT05080361|Drug|BRAF inhibitor|Reports of adverse events occurring in patients treated with at least one BRAFi or MEKi as reported in the individual case safety reports.
45633198|NCT02430415|Device|laryngoscope-assisted lightwand intubation|laryngoscope-assisted lightwand intubation
45633199|NCT02430415|Device|traditional lightwand intubation|traditional lightwand intubation
45633200|NCT05080205|Procedure|Bariatric surgery|Roux-en-Y gastric bypass or sleeve gastrectomy, chosen based on routine evaluation process
45633201|NCT03117439|Other|duration of antifungal therapy|Patients in the study group will stop antifungals in presence of a negative result of Beta Glucan Test
45772190|NCT01804790|Drug|mFolfirinox|Investigational arm: Neoadjuvant chemotherapy mFolfirinox, 4 cycles: oxaliplatin: 85 mg/m² in 2 hours at D1 irinotecan: 180 mg/m² in 90 min at D1 folinic acid: 400 mg/m² simultaneously in 2 hours at D1 during the irinotecan infusion 5-FU: 2400 mg/m² continuous infusion during 48 hours (1200 mg/m² at D1 and D2), every 14 days during 2 months (4 cycles), then CRT (50 Gy (2 Gy/session, 25 fractions) + capecitabine 800 mg/m² twice a day 5 days/7), then surgery with TME 6-8 weeks after chemoradiation, and 4 months of adjuvant CT depending on the center's choice.
45772191|NCT01804790|Radiation|Radiotherapy 50 Gy|5 radiations per week of 2 Gy for 5 weeks
45913938|NCT02028481|Procedure|Postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
45633202|NCT02741141|Other|New partograph based on the studies of Neal and Lowe|"The partograph designed by Neal and Lowe includes an action line which if crossed permits an active management of labour.~Eventually, the only difference between the two arms is the moment when the active management of labour is started.~The oxytocin is administrated according to the department protocol."
45633203|NCT02741141|Other|Classical partograph|Classical partograph used as standard care
45633204|NCT05079971|Diagnostic Test|Group B: aEEG with concurrent multichannel (full) continuous cEEG review by clinical neurophysiology|In group B, the standart-care equivalent aEEG review is undertaken by NICU staff via a 2-channel display. In addition to the standard care, concurrent full EEG is reviewed remotely with regular feedback by a specialist trained clinical neurophysiologist. The clinical neurophysiology reports only on seizure burden, no information or direction is provided regarding clinical management.
45633205|NCT02616263|Other|Foot exercise|
45633206|NCT02616263|Other|Shoulder exercise|
45633207|NCT02427139|Device|ANSiStim|ANSiStim allows continuous point stimulation over a period of several days while offering the patient a high degree of comfort and mobility at the same time. Use of the ANSiSTIM therapy provides overwhelming advantage over drug therapy minimizing possible side-effects caused by pain medications (i.e. opioid) such as, for example, impaired reactions. In most cases, the patient continues to lead its life as normal, without side effects or any loss of quality of life.
45633208|NCT02544035|Other|Type of Toy|Children will be presented with one of three (counterbalanced) toys targeted for their age group. When presented, each target toy will be paired with two additional toys from the same toy category;
45772192|NCT01804790|Drug|Capecitabine|1600 mg/m² (800 mg/m² twice daily) for 5 weeks
45772193|NCT01804790|Procedure|TME surgery|
45913939|NCT02028494|Drug|Capecitabine|Two dosages comparison
45913940|NCT02028507|Drug|Palbociclib|
45913941|NCT02028507|Drug|Capecitabine|
45913942|NCT02028507|Drug|Exemestane|
45913943|NCT02028507|Drug|Fulvestrant|
45633209|NCT02544035|Other|Play Partner|Each child will first play alone then play with parent.
45772194|NCT01804790|Drug|mFolfox6 or capecitabine|oxaliplatine 85 mg/m² (day 1 of cycle; perfusion in 2h), folinic acid 400 mg/m² (day 1 of cycle perfusion in 2h), 5-FU (bolus 400 mg/m² in 10 min and 2400 mg/m² perfusion continuous 46h). Arm A - 12 cycles ; Arm B - 6 cycles OR Capecitabine 2500 mg/m²/day (Each cycle consists of 1250 mg/m² twice daily for D1-14 then pause therapeutic from D15-21). Arm A - 8 cycles; Arm B 4 cycles.
45772195|NCT05747248|Device|Ultrasonography|Tracheal, diaphragmatic and lung ultrasonography
45913944|NCT02028533|Drug|Oxytocin|
45913945|NCT02028533|Drug|Placebo|
45633210|NCT02426905|Drug|trientine dihydrochloride|A retrospective review of patients' medical records
45633211|NCT05079893|Other|Case control study|Observational case control study
45772196|NCT05623774|Drug|Imatinib Mesylate|400mg tablet
45772197|NCT05623774|Drug|IkT-001Pro|100mg or 400mg tablet
45772198|NCT05745922|Behavioral|Moderate intensity exercise|Treadmill walking/running with moderate intensity
45913946|NCT02028546|Procedure|bathing and moisturizer application|"regimen 1: soaking an arm for 10 minutes, no moisturizer application regimen 2: soaking an arm for 10 minutes,immediate moisturizer application regimen 3: soaking an arm for 10 minutes, delayed moisturizer application for 30 min.~regimen 4: wait for 10 minutes,no soaking, moisturizer application (moisturizer alone) (All regimens were completed in all patients with 2 visits (7 days interval))"
45913947|NCT02028585|Dietary Supplement|Low-fat milk group|
45913948|NCT02028598|Drug|Treatment 1|An oral single dose administration
45913949|NCT02028598|Drug|Treatment 2|An oral single dose administration
45913950|NCT02028598|Drug|Treatment 3|Co-administration of oral single doses
45633212|NCT03183661|Biological|ALLO-ASC-CD|ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore their immunomodulatory effects are significant for treating immune-related disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease. This study is a follow-up study without intervention.
45772199|NCT05745922|Behavioral|High intensity exercise|Treadmill walking/running with high intensity
45633213|NCT05079737|Other|Mutation Burden|Subjects will have their facial samples analyzed for DNA mutation burden.
45633214|NCT03181945|Other|Group 4 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 4 weeks followed by taper in 10-14days
45633215|NCT03181945|Other|Group 12 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 12 weeks followed by taper in 10-14days
45633216|NCT02031107|Device|cTBS|
45633217|NCT02031107|Device|cathodal tDCS|
45633218|NCT02031107|Device|sham stimulation|
45633219|NCT02421523|Procedure|Aim 2 Exercise group|The experimental group will participate in an isometric exercise strengthening intervention with a frequency of ~three times/week for 12 weeks. Training will include using a custom-built exercise set-up and a live monitoring system for all of the subjects who participate in the experimental group. Progression of the exercise program will only occur after safety assessments at weeks 3, 6, and 9. The safety assessments to occur at baseline, 1 week, 6 weeks, and 12 weeks include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. The safety assessments to occur at 3 weeks and 9 weeks include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
45633220|NCT02421523|Procedure|Aim 1 Exercise Dosing|The maximal voluntary contraction (MVC) will be determined for each subject. The first four subjects will exercise at an intensity of ~30% of the subject's MVC. Subjects will be asked to perform ~4 sets of 6 reps of knee extension and knee flexion contractions. 48hs after the exercise is completed a safety assessment will be performed for muscle damage. If none has occurred, four additional subjects will perform the exercise at the next level of intensity (~50% MVC). Similarly, if no damage has occurred at ~50% MVC, four more subjects exercise at ~70% MVC. All safety measures will be performed 48hrs after the exercise has been completed at each of the levels. These safety assessments include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels.
45633221|NCT02421523|Procedure|Aim 2 Control group|This group will receive safety assessments at baseline, 1 week, 6 weeks, and 12 weeks including T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. They will also receive safety assessments at 3 weeks and 9 weeks that will include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
45633222|NCT02421289|Drug|Efavirenz|There will be adjusted dose of efavirenz in CYP2B6 guide group
45772200|NCT01317134|Device|EndoPAT measurement|EndoPAT (Itamar Medical Ltd, Ceasarea, Isreal) quantifies the endothelium-mediated changes in vascular tone, elicited by a 5-minute occlusion of the brachial artery (using a standard blood pressure cuff). When the cuff is released, the surge of blood flow causes an endothelium-dependent Flow Mediated Dilatation (FMD). The dilatation, manifested as Reactive Hyperemia, is captured by EndoPAT as an increase in the PAT Signal amplitude. A post-occlusion to pre-occlusion ratio is calculated by the EndoPAT software, providing the EndoPAT index. EndoPAT is FDA-cleared and CE-marked.
45772201|NCT01317134|Biological|Blood Test|It is hypothesized that L-arginine/NO-metabolites are altered in pulmonary hypertension depending on disease severity. Moreover, polymorphisms in L-arginine/NO-metabolism modifying factors may influence disease severity. Analysis will be performed following established/published protocols after isolation from whole blood.
45772202|NCT01315340|Procedure|Ocular rigidity, outflow facility and intraocular pressure measurement|The measurement procedure includes cannulation of the anterior chamber of the eye, under sterile conditions. Infusion of the eye with microvolumes of a saline solution is performed, followed by manometric measurement of intraocular pressure, in order to quantify ocular rigidity. Outflow facility is estimated from recordings of intraocular pressure after the infusion is stopped.
45772203|NCT05622136|Drug|Regorafenib Oral Product|Dose escalation strategy
45772204|NCT01313702|Drug|polipillV1|polipill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg
45772205|NCT01313702|Drug|polipillV2|Polipill version 2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.
45772206|NCT01313702|Drug|usual care|the drugs used in clinical practice, defined by physician
45772207|NCT04983446|Drug|Foralumab|Foralumab is a second generation fully human anti-CD3 antibody
45633223|NCT02421289|Drug|Efavirenz|If the patients was diagnosed as hypersensitivity to EFV, they will receive boosted-PI instead.
45633224|NCT02421289|Other|CYP450 2B6|All patients will be monitored drug level which should be in therapeutic level.
45772208|NCT04983446|Other|Placebo|Placebo will be the vehicle for the foralumab nasal solution without active drug (25 mM sodium acetate/125 mM sodium chloride/0.02% polysorbate 80, pH 5.5 buffer).
45913951|NCT02028624|Behavioral|Nutrition counseling|Patients received nutrition counseling, through one-to-one sessions conducted once a month, until the 6-month evaluation. Nutrition counseling was based on goal-setting and aimed at increasing adherence to Mediterannean diet.
45913952|NCT02028637|Other|TLRs|Recently it has involved the role of TLR (toll-like receptors) in the pathogenesis of asthma.The possible role that TLRs play in the asthma and its recognition as a new endotype asthma, could open new therapeutic expectations.
45447926|NCT03551158|Diagnostic Test|Echocardiography|Cardiac imaging for the assessment of the left atrium anatomy and function.
45913953|NCT02028650|Biological|the first donor's stem cell|HLA-matched stem cell infusion
45913954|NCT02028650|Biological|the second donor's stem cell|HLA-mismatched, the second donor's stem cell infusion
45447927|NCT02121964|Procedure|Capsulectomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulectomy during total hip arthroplasty.
45447928|NCT02121964|Procedure|Capsulotomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulotomy during total hip arthroplasty. Surgeon will repair the joint capsule.
45447929|NCT02127580|Procedure|BAV|
45447930|NCT02127580|Procedure|without BAV|
45633225|NCT03142997|Diagnostic Test|Lung ultrasound|we will perform lung ultrasound for both groups to calculate lung score.
45633226|NCT02424643|Behavioral|Monetary Incentive|$20 Amazon.com gift card
45633227|NCT02424643|Behavioral|Altruistic Incentive|"A preliminary statement of the importance of participation, and periodic inspirational messages throughout the length of the survey emphasizing the value to men's health by completing the survey"
45633228|NCT02424643|Behavioral|Dashboard Incentive|"A sample dashboard will compare data subjects enter in their survey to the data already collected from other men who have taken the survey. For the dashboard, men who complete the survey will be shown how their own reported data about certain topics compared to other men's data."
45772209|NCT00365690|Behavioral|Telephone-administered coping improvement therapy|Telephone-administered coping improvement therapy is aimed to improve coping in older adults living with HIV/AIDS. Participants will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. Cognitive behavioral principles will be used to evaluate stressor severity, develop problem- and emotion-focused coping skills, determine the relationship between coping strategies and stressor controllability, and optimize coping through use of social support resources. Between weekly sessions, participants will also work to improve coping abilities on their own.
45633229|NCT03142685|Device|Bowel Ultrasound|Subjects randomized to Arm B will undergo a bowel ultrasound q24 for 48 hours after time of clinical suspicion of NEC. This is in addition to the standard of care KUBs which patients in both arms will get.
45633230|NCT02424877|Procedure|SandRA|SandRA software sends SMS messages to a patient asking questions about the usage and adverse effects of prescribed drugs and about the severity of rheumatoid arthritis. The answer messages are interpreted automatically.
45633231|NCT05079503|Drug|GEN-001|GEN-001, Lactobacillus lactis is a live, purified facultative anaerobic gram-positive probiotic lactic acid bacterial strain. GEN-001 is orally administered once daily during total TNT periods.
45633232|NCT02424487|Procedure|Intracuff pressure measurement in one-lung ventilation during thoracic surgery|
45772210|NCT00365690|Behavioral|Telephone-administered supportive-expressive therapy|Telephone-administered supportive-expressive therapy is aimed to improve relationships with friends, family members, and health care providers. Participants in will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. The first 60 minutes of each session will focus on discussing topics believed to be of interest to older adults with HIV and providing up-to-date information related to living with HIV/AIDS. The last 30 minutes of each session will be devoted to discussing topics raised by the group.
45772211|NCT00365690|Behavioral|Individual therapy|Participants will receive no active treatment, but will have access to community-based support services that are commonly available to people living with HIV/AIDS. Additionally, participants who experience pronounced periods of emotional crisis and request assistance will be provided with brief, individual, telephone-based therapy by study clinicians.
45772212|NCT04331392|Behavioral|Spatial Navigation Intervention|"The 16-week intervention is completed daily, 5 days/week, remotely from home on a designated study website. Each week participants learn a new city through navigation tasks which increase in difficulty day-to-day and have a total of 4 levels of difficulty, with the goal of being able to independently navigate the city by the end of the week via Google Street View. Participants complete end-of-day multiple-choice tasks, testing what they learned with 3 types of allocentric questions: 1) predicting the next street/landmark, 2) distance judgement and 3) vector mapping. Participants also complete a map placement task, which involves reporting the locations of all studied landmarks/streets.~Participants are presented with auditory rewards in the forms of short audio clips about landmarks, written encouragement in the form pop-ups (e.g., Good work, keep it up!), and coffee card rewards based on adherence to the intervention (e.g.,$5 bi-weekly if 100% of intervention is completed)."
45913955|NCT02028663|Drug|CJ-12420|Once daily, Oral administration
45913956|NCT02028663|Drug|Esomeprazole|Once daily, Oral administration
45633233|NCT03141125|Other|Physalis angulata ethanol extract|Ethanol extract of physalis angulate Linn with dosage of 3x250 mg/day given orally for 3 months
45633234|NCT03141125|Other|Placebo|No active component at the same dosage of 3x250 mg/day given orally for 3 months
45633235|NCT02427217|Biological|FCH|FCH is a heat-treated, lyophilized fibrinogen (coagulation factor I) powder made from pooled human plasma. FCH is administered as an IV infusion.
45913957|NCT02028689|Drug|Lesinurad 400 mg|
45913958|NCT02028689|Drug|Metformin 850 mg|
45913959|NCT02028689|Drug|Furosemide 40 mg|
45913960|NCT02028702|Dietary Supplement|Placebo|water with color
45913961|NCT02028702|Dietary Supplement|Red Clover extract|Red Clover extract containing 80 mg Isoflavones. Dosage: 2 X 75 ml/day
45447931|NCT02127658|Other|Hygiene education|Participants will receive specific hygiene instructions according to existing recommendations.
45913962|NCT02028741|Other|Transverse vertebral pressures|Graded transverse mobilization directed to the thoracic spine
45633236|NCT02426983|Device|Direct Current Stimulation|"Comparison between active Direct Current Stimulation (2 mA, 20 minutes) and Sham stimulation (the device is set up, but only turned on for 30 seconds).~Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks. For 'sham' stimulation, the device will only be turned on for 30 seconds. This will occur in two separate sessions, occurring within weeks."
45633237|NCT02426983|Drug|Dextromethorphan|Comparison between Dextromethorphan and a no-sugar placebo. Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON), which has high dose of DMO (15 mg/5 ml) with no other major additives. Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks. Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks.
45772213|NCT04331392|Behavioral|Educational Videos|The 16-week active control, remote video intervention is completed daily, 5 days a week by participants on a designated website. Participants placed in the active control group are trained on educational topics by watching videos of Ted Talks, to control for the effects of generalized environmental enrichment of the same dose as targeted navigation training. For each day of training, participants are asked to select between an option of 2 possible videos, watching a total of three videos per day. To ensure compliance and sufficient attention to the videos, at the end of each video, participants are asked to rate 5 aspects of the content (relevance, interest, comprehensibility, complexity, informative), and speaker (persuasiveness, quality of delivery, facial expression, convincingness, captivation), on a scale of 1 (lowest) to 5 (highest). Additionally, as with remote navigation participants, they are given written and monetary rewards.
45772214|NCT00301184|Biological|pGA2/JS7 DNA|DNA Vaccine
45633238|NCT02426827|Device|Spinal Cord Stimulation|
45633239|NCT05078801|Procedure|Endoscopic drainage|ERCP and/or EUS-guided biliary drainage
45633240|NCT05078801|Procedure|Percutaneous transhepatic biliary drainage|US or CT-guided percutaneous drainage
45633241|NCT03183583|Procedure|Tissue adhesive in primary Total Hip and Total Knee arthroplasty|Use of tissue adhesive in primary Total Hip and Total Knee arthroplasty
45633242|NCT03141047|Other|Lifespan Integration|A protocol based psychological treatment method
45633243|NCT03183349|Procedure|deprotienized bovine bone (tutogen)|
45633244|NCT03183349|Procedure|platelet rich fibrin|
45633245|NCT03142763|Other|Eggs|Consumption of 3 eggs per day for breakfast, 4 weeks
45633246|NCT03142763|Dietary Supplement|Choline Supplement|Consumption of choline supplement, 1 1/2 tablet (395mg choline), with breakfast for 4 weeks
45633247|NCT03183271|Radiation|external beam proton radiation therapy.|Treatment of irradiation with protons beam The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, or at referral Hospitals enrolling head and neck patients for treatment with photon IMRT.
45633248|NCT03511391|Drug|Nivolumab or Pembrolizumab or Atezolizumab|per national standard of care
45633249|NCT03511391|Radiation|SBRT|Stereotactic body radiotherapy is administered to maximally 3 lesions in 3 fractions of 8Gy prior to the second/third cycle of checkpoint inhibitors.
45772215|NCT00301184|Biological|Modified vaccinia Ankara/HIV62|Recombinant Modified Ankara Vaccine
45913963|NCT02028819|Drug|Dolutegravir Sodium Monohydrate|Dolutegravir taken 50mg orally twice daily
45633250|NCT03183193|Other|Control diet|The participants follow a conventional and balanced distribution of macronutrients (30% fat, 15% protein, 55% carbohydrates), adequate fiber (25-30 g/day) and dietary cholesterol (<250 mg/day) intake according to AHA guidelines. This strategy was included within a personalized energy-restricted diet (-30% individual needs) under healthy lifestyle advice in order to achieve the objectives of AASLD (loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation).
45633251|NCT03183193|Other|FLiO diet|The participants follow a strategy based on a distribution of macronutrients 30-35% lipid (extra virgin olive oil and fatty acids Ω3 in detriment of saturated, trans and cholesterol)/ protein 25% (vegetable against animal)/carbohydrates 40-45% (low glycaemic index, fiber 30-35 g/day); high adherence to the Mediterranean diet and natural antioxidants; meal frequency of 7 meals/day; size/composition of the ration suitable for each moment; including traditional foods with no additional economic cost that will allow diet adherence without abandonment; avoid inappropriate mealtimes and the eating manners as the eating rate. The participants are instructed to follow this strategy within a personalized energy-restricted diet (-30%) and under healthy lifestyle advice to achieve AASLD objectives.
45633252|NCT05653505|Other|Remote Ischemic Conditioning|Remote ischaemic conditioning (RIC) refers to a process whereby periods of intermittent ischemia, typically via the cyclical application of a blood pressure cuff to a limb at above systolic pressure, confers systemic protection against ischemia in spatially distinct vascular territories.
45633253|NCT03179059|Diagnostic Test|Pregnancy test at Baseline|Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.
45633254|NCT03179059|Diagnostic Test|Pregnancy test at follow up survey|We will provide a free pregnancy tests in for the future use, they are randomly selected from intervention #1 treatment group.
45772216|NCT05740462|Behavioral|Recipes consumption|Participants will eat two recipes a day for 17 weeks
45633255|NCT05078645|Device|Maya|The Maya is a cover which can be placed over the end of the patients bed. The Maya aims to reduce light and sound nuisances and enhance patients' privacy
45633256|NCT02426593|Device|IMED-4|Non-invasive novel lung hydration status sensor.
45633257|NCT05078567|Device|5% Natural Lactic Acid-enriched Cream|The subjects were required to topically apply natural lactic acid-enriched cream twice daily in the morning and evening for the treatment duration of 12 weeks.
45633258|NCT02426515|Device|Hilotherm® cooling device and face mask|Hilotherm® is an external cooling device and facial mask through which water circulates at a controlled temperature This allows continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
45772217|NCT05740462|Behavioral|Hydroponic unit|Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.
45772218|NCT05374694|Diagnostic Test|Physiological invasive coronary evaluation|Performance of FFR, IMR and acetylcholine test (Only patients in groups 3 and 4 will undergo the acetylcholine test)
45772219|NCT04868708|Biological|AK104|Subjects will receive AK104 intravenously.
45772220|NCT04868708|Biological|Bevacizumab|Subjects will receive Bevacizumab intravenously.
45633259|NCT05081765|Drug|Lynparza® (AstraZeneca Pharma Poland Sp. z o.o.)|correlation between C through and taken drug
45633260|NCT05081765|Device|Lynparza|correlation between C through and taken drug
45633261|NCT04482829|Drug|Jing-yan-kang Granule|Jing-yuan-kang granule will be administered 6 days on and 1 days off for 12weeks.
45633262|NCT04482829|Drug|PC chemotherapy and symptomatic treatment|"Drugs used in PC chemotherapy includes Pemetrexed and Cisplatin. Pemetrexed disodium for injection 500 mg per square meter, intravenous drip on day 1 in each treatment cycle.~Cisplatin injection 75 mg per square meter, intravenous drip from day 1 to day 3 in each treatment cycle. One treatment cycle will be continued for 21 days and 4 cycles will be performed.~If necessary, symptomatic treatment will also be used."
45633263|NCT02426359|Drug|Q301 Cream|
45633264|NCT02426359|Drug|Placebo|
45772221|NCT04868708|Drug|Paclitaxel|Subjects will receive Paclitaxel intravenously.
45633265|NCT05078177|Drug|Rituximab|All patients receive AHSCT with RIC (Cyclophosphamide, Antithymocyte globulin/Rituximab). After resolution of cytopenia (approximately from about D+12 to D+14 AHSCT), patients will receive intrathecal Rituximab.
45633266|NCT03183427|Diagnostic Test|MR of the brain|MR of the brain without gadolinium, incl. T2-weighted image
45633267|NCT05081687|Drug|Folfirinox|5-FU 2400mg/m2; Oxaliplatin 85 mg/m2, Irinotecan 150mg/m2
45633268|NCT05387369|Drug|Paxlovid|The study is a real-world study. According to the actual medical history of patients, the usage of paxlovid will be collected.
45633269|NCT05387213|Behavioral|Team Huddles|Brief multidisciplinary meeting occurring twice a week for staff working at a LTC home led by a Nurse Practitioner. Huddles focused on discussing resident-care and staff-wellbeing.
45633270|NCT05387135|Device|Transcutaneous Vagus Nerve Stimulation|Afferents of the Auricular branch of vagus nerve (ABVN) were stimulated using a t-VNS device (TENS 7000TM made by Roscoe Medical Inc., will be used. TENS 7000TM device was labeled as nerve stimulator and low-risk medical device (Instruction manual for TENS 7000).
45633271|NCT05080985|Procedure|TPVB|20 ml 0.375 % bupivacaine was injected between superior costotransverse ligament and pleura.
45633272|NCT05080985|Procedure|ESPB|20 ml 0.375 % bupivacaine was injected between deep fascia of the erector spinae muscle and transverse process.
45633273|NCT05080985|Drug|Bupivacain|20 ml 0.375 % bupivacaine was injected
45633274|NCT05080829|Diagnostic Test|Myeloid mutations measurement|Measure of myeloid mutations by NGS when detection of refractory or relapsed CML is done
45633275|NCT05267639|Device|Power Knee|Newest version of the commercially-available Power Knee developed by Ossur.
45633276|NCT05258591|Device|Axem Home|Rehabilitation system comprised of functional near-infrared spectroscopy headband (measuring from the motor cortex), as well as tablet-based software application (guiding stroke survivors through rehabilitation exercises for their hands/arms).
45772222|NCT04868708|Drug|Cisplatin or Carboplatin|Subjects will receive Cisplatin or Carboplatin intravenously.
45772223|NCT05609110|Device|Remote ischemic conditioning|Remote ischemic conditioning is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
45772224|NCT05609110|Device|Sham remote ischemic conditioning|Remote ischemic conditioning is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
45772225|NCT05604274|Other|App to monitor stool consistency and symptoms|App to monitor stool consistency and symptoms
45772226|NCT05732272|Drug|Bupropion|150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.
45772227|NCT05513872|Drug|Nicotine Replacement Therapy (NRT) Sampling|Participants randomized to this condition will receive a 4-week nicotine replacement therapy (NRT) starter kit containing both nicotine lozenges and patches in their original packaging.
45772228|NCT05513872|Behavioral|Practice Quitting (PQ) Counseling|Practice Quitting (PQ) counseling will consist of four weekly treatment sessions, with an initial 45-minute session followed by three 20-minute sessions. The goals of the counseling sessions are 1) to gradually expose patients to nicotine withdrawal symptoms through practice quitting, and 2) to reduce fear and avoidance of the physical sensations associated with nicotine withdrawal.
45772229|NCT05513872|Behavioral|Motivational Interviewing (MI) Counseling|Motivational Interviewing (MI) counseling will consist of four weekly treatment sessions, with an initial 45-minute session followed by three 20-minute sessions. Counseling content will incorporate MI-consistent principles, such as open questions, simple and complex reflections, and affirmations to facilitate participant statements in favor of behavior change. Discussion will focus on the motivational topics outlined in the USPHS guidelines for smokers not ready to quit: 1) relevance of smoking cessation or reduction to the individual, 2) risks of continued heavy smoking, 3) rewards of quitting and reduction, and 4) roadblocks to success, on a 5) repeated basis.
45772230|NCT05492110|Device|Coronary sinus reducer|The Neovasc coronary sinus reducer is an hourglass-shaped stainless steel device inserted percutaneously into the coronary sinus and currently indicated for the treatment of refractory angina.
45772231|NCT05492110|Other|Sham-procedure|Implantation procedure with no device implanted
45633277|NCT05258357|Device|Ultrasound-assisted bone marrow biopsy|"After the usual landmark technique is performed and the potential site has been marked, the ultrasound machine fine tunes the drill site location. The probe is placed over the marked site in the transverse orientation. In this view, the location where the sacrum articulates near the ilium is visualized. The physician then searches for the location of the PSIS at its most superficial location, then the PSIS is centered. The probe is then rocked back and forth to determine the optimal drill angle.The skin is marked at the probe indicators on both long sides. In the sagittal orientation the PSIS is visualized and centered. The skin is then marked at the probe indicators on both long sides. The marker is then used to connect the marks, creating an X that marks the desired skin entry point"
45633278|NCT05258357|Procedure|Landmark palpation bone marrow biopsy|The lateral, superior iliac crest is palpated and an attempt is made to follow the course of the posterior iliac crest until the posterior superior iliac spine (PSIS) is palpated. Additionally, the gluteal cleft is visualized indicating the patient midline. The area over the sacrum at midline is then palpated, proceeding laterally until the PSIS can be felt. The skin is marked with a marker at the estimated PSIS and point of entry.
45633279|NCT03139643|Other|Cognitive Dissonance|After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
45633280|NCT03139643|Other|Action Planning|After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
45633281|NCT03139643|Other|Reflection (Control Condition)|After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
45633282|NCT05072171|Procedure|Inguinal hernia repair with dynamic prosthesis|Tissue specimens excised at the above defined postoperative stages were fixed in neutral-buffered 10% formalin and routinely processed to paraffin wax. Sections (4 μm thick) were cut and stored at room temperature until use. Sections were stained with hematoxylin and eosin (H&E) for histological analysis and Azan trichrome (Bioptica) staining to evaluate muscular tissue in the implant fabric.
45633283|NCT03139487|Drug|Rivaroxaban|15 mg q12 hours for 3 weeks followed by 20mg q24 hours for 21 weeks
45633284|NCT03139487|Drug|Dalteparin|200 IU/kg q24 hours for 4 weeks followed by 150 IU/kg q24 hours for 20 weeks
45633285|NCT03139487|Drug|apixaban|10 mg q12 hours for 7days followed by 5mg q12 hours for 21 weeks
45633286|NCT04976387|Drug|Hydrocodone/Acetaminophen 5 Mg-325 Mg ORAL TABLET|Patients are instructed to take Hydrocodone/acetaminophen 5 mg-325 mg oral tablets every 6 hours as needed for treatment of severe pain
45633287|NCT04976387|Drug|Ibuprofen 600 mg|Patients will take ibuprofen 600 mg every 6 hours as needed
45633288|NCT04976387|Drug|Acetaminophen 650 MG|Patients will take Tylenol 650mg every 6 hours as needed
45633289|NCT03139253|Drug|amoxicillin|amoxicillin 1000 mg bid. for 14 days
45633290|NCT03139253|Drug|clarithromycin|clarithromycin 500 mg bid. for 14 days.
45633291|NCT03139253|Drug|tinidazole|tinidazole 500 mg bid. for 14 days.
45633292|NCT03139253|Drug|levofloxacin|levofloxacin 500 mg qd. for 14 days.
45633293|NCT03139253|Drug|furazolidone|furazolidone 100 mg bid. for 14 days.
45633294|NCT03139253|Drug|tetracycline|tetracycline 750 mg bid. for 14 days.
45633295|NCT03139253|Drug|Ilaprazole|Ilaprazole 5 mg bid. for 14 days.
45633296|NCT03139409|Procedure|adhesive bond with chlorhexidine|Peak® Universal Bond (ultradent, 505 West 10200 South, South Jordan, UT 84095،USA ) light-Cured Adhesive with Chlorhexidine (0.2%), 7.5% filler, phosphate and containing hydroxyethyl methacrylate with ethyl alcohol as the carrier. its viscosity has been optimized for minimal film thickness (2μm) and superior strength. using self etch adhesive with chlorexidine as one step in the bonding component may give chance to proper penetration of resin tags, decrease the micro-organisms due to the antibacterial effect of chlorexidine (Bin-Shuwaish, 2016) and also the addition of chlorexidine in bonding system may be an excellent tool to increase the stability of collagen fibrils within the hybrid layer against host-derived metaloproteinases (MMP) without the need for additional steps for the bonding protocol (Stanislawczuk, et al., 2009), which results in better durability and good restorations with decreasing the incidence of recurrent caries
45633297|NCT03139409|Other|Time variable|Diagnosis and follow up will be immediate , 6 months later and 1 year
45633298|NCT02019472|Biological|adalimumab 40 mg|SC injections
45633299|NCT02019472|Biological|sirukumab 100 mg|SC injections
45633300|NCT02019472|Biological|sirukumab 50 mg|SC injections
45633301|NCT02019472|Drug|Placebo|SC injections
45633302|NCT05095649|Biological|Regulatory T-cell enriched infusion|Enrichment of CD25hi regulatory T cells from cluster of differentiation antigen 8 and/or cluster of differentiation antigen19 pre-depleted leukapheresis products.
45633303|NCT03140891|Device|NHFOV|NHFOV is used as the noninvasive mode after extubation
45633304|NCT03140891|Device|NCPAP|NCPAP is used as the noninvasive mode after extubation
45772232|NCT05492110|Diagnostic Test|Invasive coronary physiology|Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy
45772233|NCT05445856|Drug|Methadone|Methadone is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery
45772234|NCT05445856|Drug|Fentanyl|Fentanyl is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery
45772235|NCT05488444|Behavioral|Navigator Phone Calls|"The patient navigator will call you every week as described above in Study Groups. These phone calls will continue until you begin receiving chemotherapy."
45772236|NCT05488444|Behavioral|Exit Interview|Participants will be asked to complete an exit interview either in person or by phone
45913964|NCT02028819|Drug|Ibalizumab|Ibalizumab will be administered intravenously at a dose of 800mg once every two weeks.
45772237|NCT05481112|Drug|Extended-Release Buprenorphine Injection|Extended-release buprenorphine (XR-B, Sublocade) is manufactured by Indivior. XR-B consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades.
45772238|NCT05477212|Dietary Supplement|Ketogenic Diet|all patients will receive a very low calorie ketogenic diet
45633305|NCT04665557|Behavioral|Dove Confident Me Indonesia Single Session|"Dove Confident Me Indonesia Single Session is an adaptation of Dove Confident Me Global Single Session, designed to be facilitated by schoolteachers or school counsellors. Dove Confident Me Indonesia includes four interactive activities (to be delivered in a single 90-minute session) as well as a homework challenge and commitment pledge. The programme incorporates three primary techniques to improve Indonesian adolescents' body confidence and self-esteem: (1) psychoeducation, (2) media literacy, and (3) cognitive dissonance as well as two secondary techniques: (4) self-affirmation and (5) cognitive reframing. As the curriculum was adapted to be delivered in Indonesian schools with limited resources, videos or PowerPoint presentations are not included. Instead, a detailed teacher guide and student worksheets are provided.~Due to COVID-19, the intervention will be delivered online via video conferencing platform."
45633306|NCT04587245|Other|Online questionnaire and interviews|Online questionnaire, financial statements (one month per quarter in 2020) submitted electronically, interview with professional accounting firm and review of data and exit Interview
45633307|NCT05092061|Other|Moderate-repetition resistance training|Will undertake resistance training with moderate loads, and moderate repetitions 3 times per week for 7 weeks.
45633308|NCT05092061|Other|High-repetition resistance training|Will undertake resistance training with low loads, and high repetitions 3 times per week for 7 weeks.
45633309|NCT00157937|Drug|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
45633310|NCT00157937|Drug|Comparator: theophylline ER/Duration of Treatment: 16 weeks|
45633311|NCT03139565|Biological|Fluzone High-dose Influenza Vaccine|This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
45633312|NCT03139565|Biological|Standard 2016-2017 Flu vaccine|The intramuscular preparation of the vaccine used for the control group will be the Standard influenza vaccine made available by public health. The intramuscular dose (standard 0.5 mL) will contain 15 microgram antigen from each strain and delivered in the deltoid muscle by trained personnel.
45633313|NCT04566185|Other|FDG PET|"IV application of F Dopa, 2 MBq per Kg, with a scout view (angle of view 90 °, 120 kV, 30 mAs), then an X-ray scan is performed for the attenuation correction ( 120 kV - 5mAs - pitch 0.531 - thickness // increment: 3.75mm//3.27mm -QAC filter - DFOV 25).~PET acquisition: static in 3D mode for 20 minutes, 8 minutes after the injection of 18 F Dopa, the axial field of view is 25, the matrix in 256 x 256. After OSEM reconstruction 6 iterations and 24 subsets, with correction of attenuation and diffusion, then Gaussian filter of frequency 4, 47 contiguous axial sections of 3.26 mm are obtained."
45633314|NCT04566185|Other|CT scan|"Localization propeller without injection: 120kV - mA regulation (Noise Index 15) - pitch 0.969 - thickness // increment: 5mm // 5mm - Soft filter - Asir 60% - DFOV 25.~Acquisition begins 5 seconds after the start of the injection of 60 ml of contrast product (VISIPAQUE) at 4 cc / second without (acquisition characteristics: 80 kV - 100 mAs -- thickness: 5mm // 8 images / rotation - STD filter - Asir 50% display field of view (DFOV) 25 - phase1: 5s then phase2 15s).~Diagnostic quality CT: 120kV - Regulation of mA (Noise Index 15) - pitch 0.531 - thickness // increment: 1.25 // 0.625mm - Soft filter - Asir 60% - DFOV 25."
45772239|NCT05473936|Behavioral|Community Health Worker led curriculum|The intervention arm will consist of a CHW-based health educational program via Zoom, where participants will be provided with information about COVID-19, COVID-19 resources and services in Los Angeles County, and engagement with Los Angeles County Department of Health Services CHWs who will lead the curriculum and be available to answer questions of the intervention arm patients.
45772240|NCT05554666|Biological|ASKG315|Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.
45772241|NCT05553574|Behavioral|Stop signal food task|The participants need to classify pictures of food and not food. They were asked to hold their response if they see a white frame around the picture.
45772242|NCT05544994|Other|Aerobic Exercise Training|Aerobic training will be performed 3 days a week for 12 weeks at 60%-%75 of their maximum hearth rate with 30 minutes total duration consisting of 5 min warm up and 5 min cool down period in treatment group.
45772243|NCT05544994|Other|Home exercise program|Home exercise program will be given. This home program will include stretching, breathing, normal joint movement, for 3 to 5 days a week.
45772244|NCT00382330|Drug|Ciclopirox|
45772245|NCT05449834|Drug|Fibrinogen Concentrate|3g Fibrinogen Concentrate
45772246|NCT05449834|Other|Cryoprecipitate|10U WB or 4U Apheresis Cryoprecipitate
45772247|NCT05443750|Behavioral|Motivational Behavioral Economic Alcohol Intervention|The intervention combines an alcohol brief motivational intervention (US-THRIVE [Tertiary Health Research Intervention via Email]) with the Substance-Free Activity Session (SFAS), shown to reduce drinking and related negative consequences by increasing future orientation and engagement in pro-social alternatives to drinking. The intervention will be delivered using a web-based platform appropriate for the young adult target population whose social networks operate through such communications.
45772248|NCT05443750|Behavioral|Health Education|Participants view web-based health educational material about alcohol, sleep, and nutrition of a similar length and style to the experimental intervention materials.
45772249|NCT05520892|Drug|intravenous immunoglobulin|To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia
45772250|NCT04567498|Other|exhaled breath sampling|The participants are requested to quietly sit and breathe to the air collecting bag until the collecting bag is full. The collecting bag is sealed and connected to the e-nose machine via a collecting hose and HEPA-filter. The data are read and stored in the e-nose machine.
45772251|NCT04567498|Other|exhaled breath sampling|The participants are requested to quietly sit and breathe to the air collecting bag until the collecting bag is full. The collecting bag is sealed and connected to the e-nose machine via a collecting hose and HEPA-filter. The data are read and stored in the e-nose machine.
45772252|NCT04436692|Behavioral|Nudging|Use nudging approach by using smaller plates and glasses and increasing the availability of fruits and vegetables
45633315|NCT04566185|Other|Magnetic resonance imaging (MRI)|"If the examination is performed on the SIEMENS SKYRA 3T device: 32 channel head coil antenna, if on the PHILIPPS INGENIA 1.5 T device: DStream HeadSpine Coil antenna.~The sequence begins with an axial, coronal and sagittal Survey topogram, lasting 1 minute.~Then axial sequence T1, Axial T2 *, Axial cerebral perfusion (Injection of gadolinium (0.1 mmol / kg, 5 cc / second), coronal T2, Axial T2 Flair, Axial DWI b100, Axial 3D T1 gadolinium"
45633316|NCT03139175|Device|balance assessment with Biodex balance system|All subjects of three groups will be assessed with the evaluation device( balance system).
45633317|NCT03139331|Drug|Pazopanib|Pazopanib will be administered orally as a tablet according to an assigned dose level per protocol. A cycle will be defined as 21 days. Drug dosing for the tablet formulation will be determined using a study-specific nomogram.
45633318|NCT03139331|Drug|Irinotecan|"Patients will be given irinotecan at a dose of 25 mg/m2/dose IV on days 1-5 of a 21-day cycle during Cycle 1. In subsequent cycles, irinotecan may be given intravenously at a dose of 25 to 37.5 mg/m2/dose or orally at a dose of 45 to 67.5 mg/m2/dose on days 1-5 of a 21-day cycle.~Note that some patients enrolled on an earlier protocol version received 50 mg/m2/dose IV on days 1-5 of the first 21-day cycle and then either 50 mg/m2/dose IV or 90 mg/m2/dose orally for subsequent 21-day cycles. This higher dose level is no longer being given to newly enrolled subjects."
45633319|NCT03139331|Drug|Temozolomide|Temozolomide will be given at a dose of 100 mg/m2/dose orally on days 1-5 of each 21-day cycle.
45633320|NCT04423601|Drug|SHR6390 tablet|single oral dose of SHR6390 or co-administered with itraconazole.
45633321|NCT04423601|Drug|Itraconazole capsule|200 mg itraconazole was administered in the morning.
45633322|NCT04418141|Drug|CN1|Participants will receive CN1 by IV infusion on Day 1 of each cycle (every 3 weeks). The 5 planned dose levels are 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg.
45633323|NCT05022563|Drug|Parenteral anticoagulant|Parenteral anticoagulant only
45633324|NCT05022563|Drug|Warfarin|Warfarin-based
45633325|NCT05022563|Drug|Apixaban|Apixaban
45633326|NCT05022563|Drug|Rivaroxaban|Rivaroxaban
45633327|NCT05022563|Drug|Dabigatran|Dabigatran
45633328|NCT05022563|Drug|Edoxaban|Edoxaban
45633329|NCT04345991|Drug|Transfusion of COVID-19 convalescent plasma|Two convalescent plasma units of 200 to 220 ml each will be transfused i.v. as early as possible and no later than 10 days after onset of clinical symptoms. In the absence of acute unforeseen adverse events in the first 3 patients, an additional 2 plasma units of 200/220 ml each will be transfused 24 hours after first 2 units: a total of 4 units / patient
45633330|NCT03139019|Behavioral|Process incentives|Participants will receive cash based incentives for achieving process based measures (class attendance).
45772253|NCT05432752|Device|Concussion Pen|Device will measure the distance from the eye to the Concussion Pen for ocular motor functions.
45772254|NCT05235412|Other|Not applicable: Observational study without any interventions.|Exposures of interest: Maternal diet and lifestyle, demographics, anthropometrics, infant's health outcomes
45772255|NCT05422378|Drug|STP705|STP705 composed of 2 siRNA targeting TGF-B1and COX-2 individually.
45772256|NCT05447572|Other|FIT + FC|FIT + FC
45772257|NCT05413408|Other|Education and contact|"The intervention consists of three phases, including investigative learning activity (this section will last about one week), higher-order thinking activity (this section will last about two hours), collaborative activity (this section will last about two hours). Both the intervention group and the control group will be interns in the hospital simultaneously. The study outcomes include nursing students' knowledge, attitude, and behavioral intentions regarding stigma towards schizophrenia. The intervention effect will be evaluated by the researcher, comparing results between and within the two groups from baseline (T0) to immediately after first and second session intervention (T1), immediately after third session intervention (T2), and three months follow-up (T3).~The control group only has one session and will be given a book of schizophrenia knowledge, and they will be asked to finish reading it in four weeks."
45772258|NCT05210920|Other|Nail polish application|After application of nail polish as described, participants will have bacterial swabs collected from the under the fingernail and from the nail bed of the three assigned fingers on their dominant hand, both before and after scrubbing with a chlorhexidine surgical scrubbing brush.
45772259|NCT05397964|Device|Radiopaque Calcium Hydroxide Composition|Treatment of exposed pulp tissue with radiopaque calcium hydroxide composition as a direct pulp capping material
45772260|NCT04330924|Other|Create Real-life Experience And Teamwork In Virtual Environment (CREATIVE)|3D virtual hospital environment where participants can perform physical and social interaction and presence using avatars.
45772261|NCT05200702|Device|Knee-hip Powered Soft Exoskeleton (MyoSuit, MyoSwiss, Zurich, Switzerland)|Patients and healthy subjects will wear the movement assistance device to perform different standardised physical evaluations.
45772262|NCT00002548|Biological|recombinant interferon alfa|"3 million units/m2 SQ Monday-Wednesday~-Friday (3 times a week)"
45772263|NCT00002548|Drug|carmustine|20 mg/m2 I.V. day 1 q 35 days
45772264|NCT00002548|Drug|cyclophosphamide|1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)
45772265|NCT00002548|Drug|dexamethasone|40 mg/day PO or IVPB days 1-4, 9-12, 17-20 q 5 weeks
45772266|NCT00002548|Drug|doxorubicin hydrochloride|10 mg/m2/day continuous 1 - 4 q 5 weeks
45772267|NCT00002548|Drug|melphalan|140 mg/m2 is given IV within 30 minutes of constitution on Day -5
45772268|NCT00002548|Drug|prednisone|40 mg/m2 PO days 1-7 q 35 days
45633331|NCT03139019|Behavioral|Outcome incentives|Participants will receive cash based incentives for outcome based measures (weight loss).
45633332|NCT03139019|Behavioral|Process and Outcome incentives|Participants will receive cash based incentives for both achieving process based measures (class attendance) and outcome based measures (weight loss).
45633333|NCT04085705|Diagnostic Test|PATCH test|The PATCH test is a method used to determine whether a specific substance causes allergic inflammation of a patient's skin, in this case contact allergy for wound dressings. Two days after PATCH test is applied, the patches are removed. The next day, the presence of a contact allergy is determined.
45772269|NCT00002548|Drug|vincristine sulfate|0.5 mg/day continuous 1 - 4 q 5 weeks
45772270|NCT00002548|Procedure|allogeneic bone marrow transplantation|day 0
45772271|NCT00002548|Procedure|autologous bone marrow transplantation|day 0
45772272|NCT00002548|Procedure|peripheral blood stem cell transplantation|day 0
46070088|NCT04253990|Procedure|Precut EMR|"For treating of 10~20mm colon polyp, patient will be randomly divided into two groups, a Precut-EMR group and a EMR group.~In Precut-EMR, endoscopist submucosally inject with saline around a polyp. Subsequently, circumferential incision/precutting was made with the tip of the snare around 2 mm outside the tumor. After that, the snare was positioned in the cut groove and tightend, and the tumor was resected using electrical current."
45772273|NCT00002548|Radiation|radiation therapy|administered in fractionated doses of 150 cGy, 6 - 10 hours apart bid, on Days -4, -3, -2, and -1 (Total 1,200 cGy)
45633334|NCT04983095|Radiation|stereotactic body radiotherapy|30 Gy in 3 fractions alternatively 40 Gy in 5 fractions delivered with stereotactic radiotherapy-principles
45633335|NCT04983095|Drug|androgen deprivation therapy|Medical castration
45772274|NCT02087306|Drug|Brincidofovir|BCV administered twice weekly, dose depending on weight.
45772275|NCT05196334|Other|No intervention|No intervention
45772276|NCT00002554|Drug|busulfan|
45772277|NCT00002554|Drug|cyclophosphamide|
45772278|NCT00002554|Drug|methotrexate|
45772279|NCT00002554|Procedure|allogeneic bone marrow transplantation|
45772280|NCT00002554|Radiation|radioimmunotherapy|
45772281|NCT05190172|Radiation|Radiation therapy|Radiation therapy either with protons or photons
45772282|NCT00289094|Device|Total Knee Replacement|Rotating Platform (RP) Cruciate Retaining Knee System
45633336|NCT04983095|Radiation|Radiotherapy|RT to the prostate for de novo patients
45633337|NCT04902287|Behavioral|Training Intervention for the Engagement of Families (TIES)|This intervention involves training service personnel in a method of communication that elicits a person's intrinsic motivation for change.
45633338|NCT04880759|Other|bike desks in the classroom|Children will use bike desks for 13 weeks during school time
45633339|NCT04877405|Other|No intervention|This observational study is not focused on therapeutic intervention
45633340|NCT03495479|Drug|OMN54|Twice daily, self administered, oral dosing of OMN54. A daily diary log will be prepared by each participant and reviewed by the Investigator.
45633341|NCT03140813|Drug|AZD7325 (High-Dose)|15mg PO BID
45633342|NCT03140813|Drug|AZD7325 (Low-Dose)|5mg PO BID
45633343|NCT03140813|Drug|Placebo oral capsule|Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.
45633344|NCT04870307|Other|Dissemination and Implementation Research|Dissemination and Implementation research involves assisting primary care practices to address SARS-CoV-2 testing using evidence-based practices as well as increased testing in mobile-based community settings. The D&I model also involves Practice Assessment, Academic Detailing, Practice Facilitation, Health Information Technology Support, Performance Feedback and Benchmarking, and a Virtual Learning Community.
45772283|NCT00289094|Device|Total knee replacement|Fixed Cruciate Retaining Knee System
45772284|NCT05169580|Drug|FTX-6058 oral capsule(s)|Subjects will receive FTX-6058
45772285|NCT05169580|Drug|FTX-6058 oral capsule(s)|Subjects will receive FTX-6058
45772286|NCT01293578|Other|Diabetes Medication Choice Cards|Clinician uses the Diabetes Medication Choice Cards to inform and engage patient in discussing the issues they find relevant in choosing a new diabetes medication.
45772287|NCT00002560|Biological|monoclonal antibody 3F8|
45772288|NCT00002560|Biological|sargramostim|
45772289|NCT00254384|Drug|Cisplatin|Given IV
45772290|NCT00254384|Drug|Docetaxel|Given IV
45772291|NCT00254384|Drug|Erlotinib|Given PO
45633345|NCT04792931|Other|description of adult autoimmune myopathies|description of adult autoimmune myopathies
45772292|NCT00254384|Drug|Erlotinib Hydrochloride|Given PO
46070089|NCT04253990|Procedure|Conventional MER|EMR had been widely used technique. Endoscopist submucosally inject with saline around a polyp. After that, snare is positioned around a polyp, and polyp was resected using electrical current.
46070090|NCT00631592|Drug|GSK1349572|
45633346|NCT02936687|Drug|NOS Inhibition|NOS inhibition: L - NMMA is a potent non-selective NOS inhibitor used to study vascular physiology. L-NMMA will be infused at 3 mg/kg body weight/hr bolus (over 10min ) followed by a maintenance infusion of 1 mg/kg/hr for the duration of the experiment. Systemic delivery of L - NMMA has been shown to elevate blood pressure ~8-15 mmHg that is within the range observed during exercise.
45772293|NCT00254384|Other|Laboratory Biomarker Analysis|Correlative studies
45772294|NCT05163028|Drug|HBI-2376|SHP2 Inhibitor
45772295|NCT00002566|Drug|carboplatin|
45772296|NCT00002566|Drug|cisplatin|
45772297|NCT00002566|Drug|cyclophosphamide|
45772298|NCT00002566|Drug|etoposide|
45772299|NCT00002566|Drug|ifosfamide|
45772300|NCT00002566|Drug|vinblastine sulfate|
45772301|NCT00002566|Procedure|autologous bone marrow transplantation|
45772302|NCT00002566|Procedure|conventional surgery|
45772303|NCT00002566|Procedure|peripheral blood stem cell transplantation|
45772304|NCT01284686|Other|subthalamo-cortical loops stimulation in a one-sided and bipolar way|Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
45772305|NCT01284686|Other|subthalamo-cortical loops stimulation in a one-sided and bipolar way|Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
45772306|NCT01800500|Behavioral|smoking cessation intervention|Purchase ST products using a fixed rate of product prices
45772307|NCT01800500|Behavioral|smoking cessation intervention|Purchase ST products using escalating product prices
45772308|NCT01800500|Other|questionnaire administration|Ancillary studies
45772309|NCT01800500|Other|quality-of-life assessment|Ancillary studies
45772310|NCT01800500|Other|laboratory biomarker analysis|Correlative studies
45772311|NCT01800500|Other|ecigarettes|Purchase ST products using escalating product prices nicotine replacement therapy
45772312|NCT01800500|Other|ecigarettes|Purchase ST products using a fixed rate of product prices nicotine replacement therapy
45772313|NCT00002572|Biological|aldesleukin|
45772314|NCT00002572|Biological|muromonab-CD3|
45772315|NCT00002572|Biological|therapeutic tumor infiltrating lymphocytes|
45772316|NCT00002572|Procedure|conventional surgery|
45772317|NCT05154916|Other|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program
45633347|NCT02936687|Drug|ET-1 Inhibition|ET-1 inhibition: Ambrisentan is an antagonist of the ETA receptor. Subjects will receive 10 mg of Ambrisentan in a pill form 90-150 minutes prior to the OGTT. This class of drugs have been used to research ET-1 signaling in diabetes, obesity, and hypertension. ETA receptors are the most likely to mediate excessive constriction in MetSyn patients. Ambrisentan will be taken orally. Systemic delivery of endothelin antagonist have been shown at chronic dosing to decrease systolic blood pressure 4.5±10 mmHg and diastolic 3 ± 7.5 mmHg in hypertensives, and not alter mean arterial pressure in obesity.
45633348|NCT02936687|Drug|NOS Inhibition Placebo|Saline will be infused at the same rate and quantity as the corresponding drug visit.
45633349|NCT02936687|Device|3 Tesla MRI|A 3 Tesla MRI will be used to quantify cerebral blood flow and capture cerebral vessel structure at designated time points throughout the study visits (at baseline and during treatment conditions).
45633350|NCT02936687|Device|Intravenous Catheter|A blood sampling IV catheter will be used to draw up to 15 mL blood samples at specific time points throughout each study visit to measure concentrations of glucose and insulin as well as for markers of inflammation and oxidative stress.
45633351|NCT02936687|Other|Oral Glucose Tolerance Test|The subject will drink distilled deionized water (300ml) containing 75 grams glucose within 5 minutes.
45633352|NCT02936687|Drug|ET-1 Inhibition Placebo|Placebo pill similar in size and shape to Ambrisentan will be used as placebo control.
45633353|NCT04728737|Other|swallowing therapy|oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
45633354|NCT04728737|Other|IOPI therapy|tongue muscle strengthening and endurance exercises by using 15-min IOPI biofeedback program. The biofeedback will be 50%-60% of maximal strength. (total 1 hour/session for 10 sessions)
45633355|NCT04728737|Other|neuromuscular electrical stimulation (NMES) therapy|"The neuromuscular electrical stimulation (NMES) therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the clinical swallowing disorders with for oropharyngeal muscles~(1 hour/session for 10 sessions)"
45633356|NCT04722809|Drug|Botulinum toxin injection|Injection in the temporal and masseter muscles: in 3 points in the masseter muscles and in 2 points in the temporal muscles.
45633357|NCT04722809|Other|QOL-Brux|Questionnaire evaluating the symptoms of bruxism Inclusion and 3 months post-injection
45633358|NCT04722809|Other|Muscular strength of the jaw|"Measurement in the jaw with a dynamometer connected to a sensor placed on the 1st molar on the right side.~At inclusion and 1 month post-injection."
45633359|NCT04722809|Other|Intensity and frequency of episodes of nocturnal bruxism|Measurements via a portable electromyography system, coupled with a heartbeat sensor (Bruxoff®). Measurements performed during normal sleeping conditions at home before injection and 1 month after.
45633360|NCT04722809|Other|visual analogue pain scale|Evaluation of jaw pain. At inclusion and 3 months post-injection
45633361|NCT04722809|Other|Endobuccal and linea alba photographs|"anonymous endobuccal and linea alba photographs (line on the inner face of the cheeks as the result of chronic friction).~At inclusion"
45633362|NCT04654013|Device|Spectacles|Intervention group workers receive free glasses within one week of undergoing vision assessment (April 2021). The duration of the treatment for the Intervention participants will depend on when they leave employment at the factor. If they stayed for the full duration of the trial, they will have undergone a maximum of 18 months (October 2022).
45633363|NCT05083793|Drug|Pregabalin 150mg|The effect of pregabalin on post-operative pain
45633364|NCT05083793|Other|Placebo|patients will receive placebo one hour before operation
45633365|NCT03139097|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
45633366|NCT04561193|Other|Observational|Observational
45633367|NCT03140657|Drug|Nanocurcumin|Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months
45633368|NCT03140657|Drug|Placebo|Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months
45633369|NCT04525703|Behavioral|Pathways for Parents after Incarceration|The Pathways for Parents after Incarceration program uses eight key lessons, including topics on effective listening, speaking, and problem-solving skills, lessons on emotion regulation, and issues surrounding family engagement. The program (both classroom and therapeutic peer support) will be offered virtually and weekly for 8 continuous weeks.
45633370|NCT04427345|Other|Predictive factors for clinical response in patients with COVID-19.|Identify the risk factors for intra-hospital mortality in patients hospitalized in the COVID + hospital wards of the San Gerardo hospital and build a prognostic score through which it is possible to define a stratification that immediately guides the therapeutic choices and the intensity of care .
45772318|NCT00002578|Drug|cytarabine|
45772319|NCT00002578|Drug|gallium nitrate|
45772320|NCT00002578|Drug|leucovorin calcium|
45772321|NCT00002578|Drug|methotrexate|
45772322|NCT04668742|Device|DYNAtraq|Tracheostomy alignment with DYNAtraq
45772323|NCT05153356|Device|Personal Kinetigraph, Kinesia 360|10 patients will be assigned to each technology with a crossover at 3 months for a total of 20 patients over 6 months, 6 timepoints with data collected every 2 weeks.
45772324|NCT05143138|Device|GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis|Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent
45772325|NCT05355454|Device|STYLAGE® XXL|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face."
45913965|NCT02028832|Procedure|PIM consult and service provision|If service is requested, treatment options include acupuncture/acupressure, massage, and reiki
45913966|NCT02028832|Procedure|Usual care|Usual care consists of all conventional care options in pediatric oncology including medication and other therapies.
45772326|NCT05355454|Device|STYLAGE® XXL|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face."
45772327|NCT00002590|Biological|filgrastim|
45772328|NCT00002590|Drug|cyclophosphamide|
45913967|NCT02028845|Device|Biliary cannulation with loop guidewire|Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
45447932|NCT02127658|Other|Hygiene education and Decolonization|Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite [Clorox; The Clorox Company] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupiricin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
45633371|NCT03140501|Device|"Mobile application (app)"|"The self-management app has 3 main features: 1) SCI-specific education modules; 2) a circle-of-care in which the users select health allies (formal and informal caregivers); and 3) a variety of tools to assist with goal identification, symptom/behaviour tracking, etc. The intervention will involve 5-6 contacts that occur over a 3-month period and ongoing use of the app. There will be 1 to 2 in-person sessions, where the principles of self-management are reviewed, self-management goals are identified, and features of the app are explained. Over the next month, there will be 2 follow-up contacts to review any questions/issues participants have. Participants can set additional goals during this time. Over the last 2 months, there will be monthly contacts to address the same issues."
45633372|NCT04415021|Other|Experimental: Diaphragmatic and İliopsoas Myofascial Release Techniques|Subjects in this arm will receive different myofascial release techniques aimed to relaxation the myofascial tension of the diaphragmatic and iliopsoas muscles.
45633373|NCT04415021|Other|Sham Comparator: Sham Myofascial Release Techniques|Subjects in this arm will receive the same manual techniques of the diaphragmatic and iliopsoas myofascial release group, but without the myofascial stimulus.
45633374|NCT04332029|Behavioral|CBT + WGP + CM|The intervention will be implemented in 8-week group-based sessions and includes: 1) A Cognitive Behavioral Treatment (CBT) for smoking cessation with quit date occurring at sixth session. Patients will be asked to reduce their nicotine intake gradually (i.e., 20% each week); 2) A Weight Gain Prevention module (WGP) which will consist on providing CBT and Dialectical-Behavioral Therapy (DBT) techniques targeting weight stability and associated disordered eating, and 3) a Contingency Management procedure reinforcing smoking abstinence. This component will consist on providing vouchers to reinforce abstinence contingent on biochemical verification. The schedule will incorporate an increasing magnitude of reinforcement.
45633375|NCT04332029|Behavioral|CBT + WGP|The intervention will be implemented in 8-week group-based sessions and will include only the first two components of the experimental intervention: 1) A Cognitive Behavioral Treatment (CBT) for smoking cessation with quit date occurring at sixth session. Patients will be asked to reduce their nicotine intake gradually (i.e., 20% each week); 2) A Weight Gain Prevention module (WGP) which will consist on providing CBT and Dialectical-Behavioral Therapy (DBT) techniques targeting weight stability and associated disordered eating.
45913968|NCT02028845|Device|Biliary cannulation with straight guidewire|Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
45633376|NCT05083013|Diagnostic Test|Reverse transcription polymerase chain reaction (RT-PCR)|For SARS Corona Virus 2 (COV2) confirmation
45772329|NCT00002590|Drug|cytarabine|
45772330|NCT00002590|Drug|daunorubicin hydrochloride|
45772331|NCT00002590|Drug|doxorubicin hydrochloride|
45772332|NCT00002590|Drug|etoposide|
45772333|NCT00002590|Drug|leucovorin calcium|
45772334|NCT00002590|Drug|methotrexate|
45772335|NCT00002590|Drug|pegaspargase|
45772336|NCT00002590|Drug|prednisone|
45772337|NCT00002590|Drug|thioguanine|
45772338|NCT00002590|Drug|vincristine sulfate|
45772339|NCT00002590|Radiation|radiation therapy|
45772340|NCT00002596|Biological|bleomycin sulfate|
45772341|NCT00002596|Biological|filgrastim|
45772342|NCT00002596|Drug|carboplatin|
45772343|NCT00002596|Drug|cisplatin|
45772344|NCT00002596|Drug|cyclophosphamide|
45772345|NCT00002596|Drug|etoposide|
45772346|NCT00002596|Procedure|autologous bone marrow transplantation|
45913969|NCT02028897|Other|Conventional embryo culture|
45447933|NCT02932904|Drug|Vortioxetine|Vortioxetine Overencapsulated Tablet
45772347|NCT00002596|Procedure|bone marrow ablation with stem cell support|
45772348|NCT00002596|Procedure|conventional surgery|
45772349|NCT00002596|Procedure|peripheral blood stem cell transplantation|
45772350|NCT00002596|Radiation|radiation therapy|
45772351|NCT00199082|Drug|Adriamycin|
45772352|NCT00199082|Drug|Cyclophosphamide|
45772353|NCT00199082|Drug|Cytarabine|
45772354|NCT00199082|Drug|Dexamethasone/Prednisolone|
45772355|NCT00199082|Drug|VP16|
45772356|NCT00199082|Drug|Ifosfamide|
45772357|NCT00199082|Drug|Methotrexate|
45772358|NCT00199082|Drug|G-CSF|
45772359|NCT00199082|Drug|Rituximab|
45913970|NCT02028897|Other|Enclosed embryo culture|
45913971|NCT02028910|Drug|Ondansetron|"The treatment is administered orally in a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed the maximum dose of 10mg. A second dose, the same dose is given back if the child vomits within 15 minutes after the first administration.~The bottle contains at least 2 doses of up to 10 mg for a second dose can be given back in case of vomiting within 15 minutes after the first dose in children weighing more than 25 kg.~The dosage should be adjusted according to the weight of the child"
45913972|NCT02028923|Drug|Morphine gel|Topical
45913973|NCT02028923|Other|Neutral gel|Topical
45913974|NCT02028936|Other|Grape juice R@isol|
45913975|NCT02028936|Other|Commercially-available grape juice|
45913976|NCT02028949|Drug|Zavedos®|
45633377|NCT05083013|Diagnostic Test|Glycated haemoglobin (HbA1C)|Diabetic patients' group will be categorized according to their glycemic control by using their glycated haemoglobin (HBA1C) into good control, fair control and poor control
45633378|NCT05083013|Radiation|High Resolution Computed Tomography (HRCT)|with the coronavirus disease 2019 Reporting and Data System (CO-RADS) classification grade 5 for SARS COV2 confirmation
45633379|NCT05083013|Diagnostic Test|Routine Laboratory investigations|"Arterial blood gases (ABGs)~Routine Laboratory investigations (Urea, Creatinine, Liver function tests, Serum Electrolytes, Prothrombin Concentration)"
45633380|NCT05083013|Diagnostic Test|Random Blood Sugar (RBS)|Blood Sugar will be measured before each meal and before bed time during hospitalization.
45633381|NCT03140735|Other|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction
45772360|NCT00199082|Drug|Vincristine/Vindesine|
45772361|NCT00199082|Procedure|Irradiation (in specific conditions)|
45633382|NCT03140735|Other|Control group without heart disease|Control group without heart disease
45633383|NCT05082623|Other|Music|Music medicine
45633384|NCT05082623|Other|Earplug|Earplug with noise cancelling
45772362|NCT04755998|Other|Use of virtual reality glasses during vaccination applications in children|"To the experimental group:~Before the vaccine administration;~Children's Fear Scale, and Children's Anxiety Scale-State Scale was applied to the student.~Cartoons and virtual reality glasses that the student wanted to watch were prepared.~While the nurse was preparing the vaccines, the student was put on virtual reality glasses and the distance settings of the lenses were adjusted and the cartoons he chose to watch during the vaccination applications started to be shown. Since virtual reality glasses can cause anxiety attacks manifested by nausea in some children, this was also tested beforehand. It took about two minutes to administer the vaccine and watch cartoons.~Those applied after the vaccine administration;~- Children's Fear Scale, and Children's Anxiety Scale-State Scale was applied to the student."
45633385|NCT04139837|Behavioral|Health screening, community health talks or activities on frailty|Screening for frailty using the FRAIL scale to categorize participant's status as robust, prefrail and frail. A series of community health talks or activities on frailty will be provided to each category of participants for the prevention or management of frailty.
45633386|NCT03111017|Other|Exercise Training|HFpEF patients randomized to either 16 weeks of exercise training or attention control group.
45633387|NCT02705755|Drug|TD-9855|Administered orally.
45772363|NCT01797458|Procedure|Hall Technique|"Technique:~Removal of dental plaque and rest of aliments from the cavity~Selection of the SSC~If the contact points are very tight, orthodontic separator elastics could be placed through the mesial and distal contacts and the SSC has to be fitted at a subsequent appointment~Dry the crown and fill with glass-ionomer luting cement~Place the crown over the tooth~Removal of cement excesses from the crown margins~The child should be asked to keep biting on the crown until the cement has set"
45772364|NCT01797458|Procedure|Non-Restorative Caries Treatment|"Technique:~A high-speed bur should be used to remove the undermined enamel and make the cavity accessible for plaque removal. Do not remove the contact area~Clean, dry the cavity and apply Duraphat® varnish fluoride (50/mg/ml)~Show the cavity to patient/parents and give them tooth-brushing instructions~Tell to parents that good plaque control is the key for this treatment~The recall interval for these patients is every 3 months."
45772365|NCT01797458|Procedure|Conventional Restoration|"Technique:~Local anesthesia should be used when needed~Perform complete caries removal and cavity preparation~Use a matrix band and a wedge to tightly hold the band against the tooth~Place the material (Compomer)~Check contacts and occlusion, and polish the restoration"
45772366|NCT00002602|Radiation|3D-CRT|3 dimensional conformal radiation therapy
45772367|NCT00194090|Drug|celecoxib|
45772368|NCT00002608|Drug|cisplatin|
45772369|NCT00002608|Drug|doxorubicin hydrochloride|
45772370|NCT00002608|Drug|tamoxifen citrate|
45772371|NCT00002608|Procedure|conventional surgery|
45772372|NCT00002608|Radiation|radiation therapy|
45633388|NCT02705755|Drug|Placebo|Administered orally.
45633389|NCT05073653|Diagnostic Test|68Ga-PSMA PET/CT|Exploratory, Single-institution Study, Comparing 68Ga-GRP PET/CT Versus 68Ga-PSMA PET/CT in Patients Diagnosed With Prostate Cancer of Low and Intermediate Risk for Radical Prostatectomy
45633390|NCT05073653|Diagnostic Test|68Ga-GRP PET/CT|Exploratory, Single-institution Study, Comparing 68Ga-GRP PET/CT Versus 68Ga-PSMA PET/CT in Patients Diagnosed With Prostate Cancer of Low and Intermediate Risk for Radical Prostatectomy
45633391|NCT02024932|Drug|BVS857|BVS857 lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
45633392|NCT02024932|Drug|Placebo|Placebo lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
45633393|NCT02034149|Behavioral|general management|All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.
45633394|NCT02034149|Behavioral|self-management|Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with DVD courses. We negotiated their behavior change set goals for them etc.
45633395|NCT02034149|Behavioral|peer-assisted management|The peer-assisted management group received similar program for 3 months, the peer oriented group activities followed, including group discussions to share experience and sports map etc.
45633396|NCT03223883|Drug|Curcumin|Oral supplement for 12 months
45633397|NCT03223883|Other|Placebo|Oral placebo for 12 months
45772373|NCT00002620|Drug|carmustine|
45772374|NCT00002620|Drug|chemotherapy|
45633398|NCT02420899|Drug|rosuvastatin|10mg/d or 20mg/d,po
45772375|NCT00002620|Drug|mitolactol|
45772376|NCT00002620|Radiation|low-LET cobalt-60 gamma ray therapy|
45772377|NCT00002620|Radiation|low-LET photon therapy|
45913977|NCT02028949|Other|Blood samples|
45913978|NCT02028962|Behavioral|Lifestyle counseling|
45633399|NCT05048069|Drug|Mucosta®SR Tablets 150mg(Rebamipide)|adult patients with gastric mucosal lesions (erosion, bleeding, redness, and edema) of acute gastritis or acute exacerbation of chronic gastritis prescribed with Mucosta®SR Tab. according to the medical considerations of the investigator.
45633400|NCT03179137|Other|Standard therapy|Patients with therapy prescribed independent of the study
45633401|NCT05042141|Dietary Supplement|KOVIR oral capsule|KOVIR is a hard capsule containing fine powder mixed medicinal herbs 600 mg
45633402|NCT05042141|Dietary Supplement|Placebo oral capsule|Placebo
45772378|NCT05342896|Behavioral|MIND diet|MIND diet intervention will be a 3-month nutrition programme consisting of 4 face-to-face nutrition counselling sessions (one session per week, 60 min per session) in the activity room of each participating community centre. All intervention sessions will be conducted by a registered nutritionist and trained student helpers. In the nutrition sessions, the participants will learn to modify their diet to meet MIND diet guidelines.
45633403|NCT02426203|Procedure|Pulmonary endarterectomy|Echocardiographic assessment right ventricular function prior to, during, and following Pulmonary Endarterectomy surgery.
45633404|NCT03194165|Biological|Dolutegravir|Dosage
45633405|NCT03194165|Biological|Raltegravir|Dosage
45633406|NCT03194165|Biological|Rilpivirine|Dosage
45633407|NCT03194165|Biological|Nevirapine|Dosage
45772379|NCT05342896|Behavioral|Mind diet plus Forest Bathing|MIND diet intervention will be a 3-month nutrition programme consisting of 4 face-to-face nutrition counselling sessions (one session per week, 60 min per session) in the activity room of each participating community centre. All intervention sessions will be conducted by a registered nutritionist and trained student helpers. In the nutrition sessions, the participants will learn to modify their diet to meet MIND diet guidelines. Forest Bathing will be another session per week, 2 hours forest bathing sessions on 4-consecutive weekends in a country park at daytime with sunny, cloudy or drizzling conditions. The walking distance for each forest bathing is one to two kilometres. The coach-to-participant ratio is approximately 1:16. Participants will then be required to self-practice 2h FB in the country park at daytime at the weekends of 8th week and 12th week of the intervention.
45633408|NCT03194165|Biological|Atazanavir|Dosage
45633409|NCT03194165|Biological|Darunavir|Dosage
45772380|NCT05121142|Drug|Ruxolitinib|Ruxolitinib will be given by mouth or enteral tube (if applicable).
45772381|NCT01895192|Other|Assessment of sperm morphology (contrast microscopy).|Sperm head vacuoles were analyzed on 100 spermatozoa that were randomly photographed and separately analyzed using digital imaging system software. Interactive Measurement module allows measurement of sperm head areas and vacuole areas by manually depicting their outline. The area and position of each vacuole were recorded. Relative vacuole area is the ratio of the area of all the vacuoles of a spermatozoon to the area of its head.
45772382|NCT04160000|Device|Catheter ablation|Delivery of physical energy from external energy source via percutaneously inserted electrophysiologic catheter to destroy heart tissue in the human atrium and adjoining vasculature
45913979|NCT02028975|Other|Measure the threshold of detection for linoleic acid|
45913980|NCT02028975|Other|Oral stimulation tests|
45913981|NCT02028975|Other|Venous blood samples|
45913982|NCT02028975|Other|Samples for genetic studies (ancillary study)|
45913983|NCT02029014|Device|LAA closure system|
45913984|NCT02029027|Device|GYNEFFIK(R)|Vaginal electro-stimulation medical device
45913985|NCT02029027|Other|Usual Care|Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation
45913986|NCT02029053|Device|Vaginal Lubrication Ring for Vaginal Dryness|"Participants will be asked to complete 4 study visits and one final follow-up phone call. Each study visit will include a brief vaginal exam where vaginal fluid levels and pH levels are checked and questionnaires are completed. Daily diaries will be completed at home and returned to the study staff at subsequent visits.~Participants will self-insert the Intravaginal ring on the 1st study visit. The 2nd study visit will occur 3-4 days later.~The 3rd study visit will occur approximately 7 days after the 1st visit. Participants will remove the device and self-insert a new intravaginal ring.~The 4th study visit will occur approximately 14 days after the first visit. Participants will remove the intravaginal ring and undergo a final vaginal exam.~Participants will be called approximately 7 days after the last visit and will be asked about their current vaginal dryness symptoms and how they felt about the device during the study."
45913987|NCT02029066|Drug|SR-T100 gel|2g of SR-T100 will topical apply on 100 cm^2 once for 24 hours.
45633410|NCT03194165|Biological|Ritonavir|Dosage
45633411|NCT02426437|Other|Pulmonary Rehabilitation (PR)|Patients enrolled in PR will undergo a 6-8 week rehabilitation program.
45633412|NCT02426437|Other|Usual Care|Patients enrolled in usual care will be followed-up by their most responsible physician as determined by the admitting team.
45633413|NCT03117205|Other|Application of Kinesio Taping®|The technique was applied following the methods described in the original method for patellofemoral instability
45633414|NCT03117205|Other|Kinesio Taping® placebo application|Simulation of the application of the Kinesio Taping® technique.
45633415|NCT04065113|Procedure|Middle Meningeal Artery Embolization with polyvinyl alcohol particles (PVA)|Seal off blood supply to the middle meningeal artery to prevent growth of subdural hematoma
45633416|NCT04065113|Procedure|Drainage of Subdural Hematoma|Drainage of subdural hematoma via burrhole or craniotomy
45633417|NCT03178903|Other|tDCS|Participants in transcranial direct current stimulation (tDCS) will receive tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.
45633418|NCT03178903|Other|Sham tDCS|Participants in sham transcranial direct current stimulation (tDCS) will receive shame tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.
45633419|NCT03178903|Behavioral|Aerobic Exercise (AE)|Participants will engage in supervised, 30-minute bouts of moderate-intensity exercise 3x/week for 8 weeks.
45633420|NCT05005871|Other|Quadratus lumborum block after C-section surgery as postoperative pain management|To manage postoperative pain, the subjects will be allocated to either QLB or QLTB group to receive the respective intervention.
45633421|NCT02425969|Procedure|PCI|Patients will have balloon angioplasty and coronary stent insertion for their grey-zone FFR lesion.
45772383|NCT04160000|Drug|Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation|Administration of antiarrhythmic drug to achieve either rate control or restoration of sinus rhythm for management of atrial fibrillation
45633422|NCT02425969|Drug|Optimal Medical Therapy|Optimal Medical therapy consists of secondary prevention which will include high dose statin and aspirin as well as anti-anginal therapy according to ESC 2013 international treatment guidelines for stable angina as follows; B-Blocker or Calcium channel blocker as first line agents and Nicorandil or Nitrates or Ranolazine as second line treatment titrated against symptoms to maximum tolerated dose. ACE inhibitors or Angiotensin Receptor Blockers will be prescribed if patients also have a diagnosis of hypertension, LVEF ≤40%, diabetes or CKD where appropriate.
45633423|NCT04029155|Device|Lung biopsy|Transbronchial Needle Aspiration performed via a ultra thin bronchoscope
45633424|NCT03116737|Drug|Benzocaine Otic Solution|
45772384|NCT04160000|Device|Insertion of CardioMems Hemodynamic monitor|Insertion of wireless hemodynamic monitor to provide hemodynamic data to guide heart failure therapy to achieve heart failure improvement.
45772385|NCT04160000|Drug|Empiric heart failure drug therapy|Administration of heart failure drug therapy based on clinical evaluation to achieve heart failure improvement.
45772386|NCT00002638|Biological|filgrastim|
45772387|NCT00002638|Biological|sargramostim|
45772388|NCT00002638|Drug|carmustine|
45772389|NCT00002638|Drug|cyclophosphamide|
45772390|NCT00002638|Drug|cytarabine|
45772391|NCT00002638|Drug|etoposide|
45913988|NCT02029079|Dietary Supplement|E+|300 ml E+ per day (525 kcal, 22.5 gram protein) for 35 days.
45913989|NCT02029105|Biological|Mesothelin, hyaluronan, osteopontin, syndecan-1|We compere the serum levels of the tumor markers in patients with pleural diseases according to the groups for the diagnosis and differential diagnosis of the diseases.
45913990|NCT02029118|Drug|Herbal plaster ( styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech)|Application containing herbal medicine that mainly include styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech and other herbal medicine.
45913991|NCT02029118|Device|acupoint|select acupoint according to traditional Chinese medicine
45913992|NCT02029118|Drug|Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.|foundation treatment
45772392|NCT00002638|Procedure|peripheral blood stem cell transplantation|
45772393|NCT00002638|Radiation|radiation therapy|
45772394|NCT05120362|Drug|Cream containing JAK Inhibitor|The study drug is a cream containing JAK Inhibitor.
45913993|NCT02029131|Behavioral|Exercise|Educated exercise training for the trunk 3 times per week, each for 20 min. Recommendation of additional fitness courses as offered by the local healthy insurance company.
45913994|NCT02029157|Drug|ARQ197|
45913995|NCT02029157|Drug|Placebo|
45913996|NCT02029170|Procedure|Early weightbearing|Patients allocated to early weightbearing group are allowed to weightbear after stitch out and application of a walking cast
45633425|NCT03116737|Drug|Placebo|
45633426|NCT03138707|Other|patients who die|
45633427|NCT02426047|Dietary Supplement|betaquik®|Participants will add betaquik® (a liquid emulsion of medium chain triglycerides) for a 10 day time interval starting 2 days prior to and encompassing the primary catamenial pattern.
45633428|NCT04910243|Other|Questionnaire Survey|Physicians providing care to patients with COVID-19 admitted at ICU in period of COVID-19 pandemic will be questioned by electronic web-based survey within Masaryk University information system.
45633429|NCT03116659|Drug|Doxycycline|Doxycycline 100 mg PO BID x 14 days
45633430|NCT03116659|Drug|Imiquimod|up to 2 packs 3/ week x 28 days
45633431|NCT04889573|Genetic|Blood sample|The blood samples will be collected from healthy volunteers : 7 tubes of 7 ml with anti-coagulant Héparine Lithium and 1 tube of 7ml with anti-coagulant EDTA
45633432|NCT01993888|Biological|EVARREST® Fibrin Sealant Patch|
45633433|NCT01993888|Other|Standard of Care (SoC)|
45633434|NCT02425813|Drug|Budesonide|Given PO
45633435|NCT02425813|Drug|Methylprednisolone Sodium Succinate|Given IA and IV
45772395|NCT04330768|Procedure|PRF pulp capping|PRF is injected in the site of exposure
45772396|NCT04330768|Procedure|MTA pulp capping|conventional pulp capping procedure
45772397|NCT01896440|Drug|Ondansetron|There will be two doses investigated in each arm - standard dose (0.15 mg/kg) and high dose (0.3 mg/kg)
45772398|NCT01217216|Behavioral|Group-based Intervention|compared effects of a group-based intervention on weight loss and physical activity.
45772399|NCT01217216|Behavioral|Telephone-based Intervention|compared telephone-based intervention to weight loss and physical activity.
45772400|NCT00086762|Behavioral|MR Therapy|Arm I: Participants receive Mindfulness Relaxation (MR) therapy as in the pilot phase. Instructions given on breathing techniques and other practices to help relax mind and body.
45772401|NCT00086762|Behavioral|Relaxing Music (RM) Therapy|Participants listen to relaxing music (with no instructions on relaxation techniques) for 30 minutes before and during each chemotherapy session AND at least once daily for the entire duration of chemotherapy treatment
45772402|NCT00086762|Behavioral|Standard Symptom Management|Participants receive standard symptom management education. General information received about how to manage symptoms that develop due to the chemotherapy.
45772403|NCT00086762|Behavioral|Questionnaires|Questionnaire completion at baseline, during the middle of chemotherapy treatment, and at chemotherapy completion.
45772404|NCT00002656|Drug|pyrazoloacridine|"Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.~Depending on the prior cycle toxicity the dose should be escalated, maintained or reduced, utilizing levels: -1, 0 (initial dose level), 1 - Level +1 (820mg/m2); Level 0 (750mg/m2); Level -1 (600mg/m2)"
45772405|NCT00002662|Drug|docetaxel|
45772406|NCT00002662|Drug|paclitaxel|
45772407|NCT01750112|Device|Macrolane VRF20|Injection treatment with Macrolane VRF20
45772408|NCT00054314|Drug|ortataxel|
45913997|NCT02029170|Procedure|Non-weightbearing|Patients allocated to non-weightbearing group are kept non-weightbearing till 6 weeks post-operative
45913998|NCT02029183|Device|Bi level positive pressure ventilation|Bi level positive pressure ventilation should be given for subject for 6 hours per night ，total 7 times.
45633436|NCT04862429|Other|Contrast enhanced mammography guided biopsy (diagnostic procedure)|With visible contrast-enhancement, stereotactic biopsy will be performed under CESM guidance. After administration of an additional dose of iodized contrast-enhancement (Omnipaque), the insertion of the biopsy needle and the biopsy sampling will be targeted on the area of greatest enhancement in the context of calcifications. In the absence of contrast-enhancement, stereotactic biopsy Mammotome will be performed, using X-ray guidance. The insertion of the biopsy needle and biopsy will be targeted on the most suspicious calcification cluster or area. At the end of the procedure, a metal clip marker will be placed in the biopsy site; the placement will be verified with dual orthogonal mammography projection (as regular clinical practice).
45633437|NCT04862429|Other|Mammography guided biopsy (diagnostic procedure)|"For all lesions, stereotactic biopsy Mammotome will be performed, using X-ray guidance. The insertion of the biopsy needle and biopsy will be targeted on the most suspicious calcification cluster or area.~At the end of the procedure, a metal clip marker will be placed in the biopsy site; the placement will be verified with dual orthogonal mammography projection (as regular clinical practice)."
45633438|NCT03181555|Other|Exploratory|
45772409|NCT02973334|Other|Ingestion of artificially-sweetened beverages|From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing non nutritive sweeteners (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
45633439|NCT04852133|Other|Burn subjects|see eligibility criteria
45633440|NCT04683562|Other|Pregnant women at 28-32 weeks|Pregnant women at gestational age 28-32 weeks
45633441|NCT04683562|Other|at delivery|women delivered at term
45633442|NCT04804787|Diagnostic Test|Carrying out a tests and questionnaires battery|The attendees will carry out different questionnaires and tests to evaluate their potential cognitive disorders
45633443|NCT03116581|Other|Behavior|"Random-dots tasks: dots appear and move, most have a random trajectory but a given proportion of them move coherently to the same direction.~Vicarious reward Each trial begins with a cue, showing 'me' or 'him' and filled rectangle filled proportionally to the payoff. The cue and the square are depicted in yellow (oneself) or blue (other), depending on the beneficiary. The moving dots are then presented and the subjects respond. At the end of dots motion, the feedback is presented. If the response was correct, a pile of coins proportional to the payoff is shown. For incorrect responses and misses, a red-colored cross is displayed.~Audience effect Each trial begins with the display of two eyes (public) or a padlock (private). The moving dots are shown and the participant answers. Audience condition changes the information available on accuracy when submitting comments. In the observed condition, an arrow shows the response. In the observed condition, no feedback is displayed."
45633444|NCT03116581|Other|fMRI (functional Magnetic Resonance Imagery)|"Both behavioral task (audience effect and vicarious reward) will be studied in fMRI (functional Magnetic Resonance Imagery). The same paradigms used in the behavioral experiment will be adapted for fMRI.~Audience Effect experiment: trials will last for 10 seconds maximum. With 80 trials for each condition (public easy, public difficult, private easy and private difficult), the task will count a total of 320 trials and have a 54 minutes duration, in 3 runs of 17 minutes each.~Vicarious Reward experiment: trials will have a 10 seconds maximum duration. Using 40 trials for each condition (other low payoff, other high payoff, self low payoff, self high payoff, control condition), the task will have a total of 200 trials and last for 54 minutes, in 6 runs of 9 minutes each."
45652952|NCT05092893|Other|Online parental questionnaires|"The SRS-2 is a parental 65-item questionnaire to detect difficulties in social responsiveness in children with autism spectrum disorder. Four different forms are available: preschoolers (2.5-4.5 years), school-aged children (4-18 years), adults (≥ 19 years) and adults self-report. In this study, only the form for school-aged children will be used.~The DCDQ'07 is a parental 15-item questionnaire to detect the risk of DCD in children between 5 and 15 years of age. Parents are asked to compare their child's motor performance to his/her peers using a 5-point Likert scale. The total sum score is compared to age-specific cut-off scores to determine the risk of DCD. Belgian norms are available since 2007."
45772410|NCT02973334|Other|Ingestion of sugar-sweetened beverages|From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing sugar (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
45772411|NCT02973334|Other|Ingestion of water|From t=60 to the end of the metabolic test, volunteers will ingest 7 water beverages (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
45772412|NCT01744418|Device|HAVG graft implantation|Patients will be implanted with a Human Acellular Vascular Graft (HAVG) in the forearm or upper arm (arterial anastomosis to the radial or brachial artery, venous anastomosis to either the brachial, cephalic or very central basilica vein) using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration in the first 10 patients. Loop grafts may be permitted in subsequent patients subject to acceptable graft performance at the interim safety review. Placing the graft across the elbow will be avoided.
45772413|NCT01743950|Drug|Bevacizumab|10mg/kg every 2weeks.
45772414|NCT01743950|Radiation|PRDR|Daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions. In the rare instance of the presence of extensive disease requiring essentially whole brain radiation, a total daily dose of 1.8 Gy delivered in .2 Gy pulses for 23 fractions to a total dose of 41.4 Gy will be utilized.
45772415|NCT00381784|Behavioral|Printed materials|"Role model stories comprise the heart of printed materials distributed throughout the target community. The role model stories are brief publications that depict personal accounts from individuals in the population of focus who have made or are planning to make a risk-reducing behavioral change. Depending on the population they are meant to reach and what behavior they are trying to influence, the stories may include examples of people who now carry condoms with them, talked to a partner about condom use, use condoms consistently, avoid sharing needles, or exhibited other risk reduction behaviors."
45913999|NCT02029183|Device|bi-level positive airway pressure|
45914000|NCT02029209|Drug|Anlotinib|Anlotinib QD
45914001|NCT02029209|Drug|Placebo Capsule|Placebo capsule QD
45914002|NCT02029248|Other|Quality of life questionnaire|
45914003|NCT02029287|Other|Hospital-Community-Family-Care Management Platform Online|Hospital-Community-Family-Care Management Platform Online: the remote monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital
45935411|NCT02970539|Drug|Ramucirumab|Ramucirumab will be administered by iv infusion and supplied as a solution at a concentration of 10 mg/mL
45633445|NCT03116581|Other|MEG (MagnetoEncephaloGraphy)|"Both behavioral task (audience effect and vicarious reward) will be studied in MEG (MagnetoEncephaloGraphy). The same paradigms used in the behavioral experiment will be used in MEG.~Audience Effect experiment: trials will last for 7 seconds maximum. With 100 trials for each condition (public easy, public difficult, private easy and private difficult), the task will count a total of 400 trials and have a 47 minutes duration. Every 100 trials (about 12 minutes of tasks), a break will be proposed to the participants.~Vicarious Reward experiment: trials will have a 7.2 seconds maximum duration. Using 75 trials for each condition (other low payoff, other high payoff, self low payoff, self high payoff, control condition), the task will have a total of 375 trials and last for 45 minutes. Every 125 trials (every 15 minutes), a break will be proposed to the participants."
45914004|NCT02029287|Other|Subjects with CHF via conventional clinic visit according to the latest relevant guidelines|Subjects with CHF via conventional clinic visit according to the latest relevant guidelines
45633446|NCT02024698|Device|omafilcon A|contact lens
45633447|NCT02024698|Device|etafilcon A|contact lens
45633448|NCT03106831|Drug|Pituitrin infusion|To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
45633449|NCT03106831|Drug|Norepinephrine infusion|To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
45633450|NCT03891875|Combination Product|Subcutaneous elamipretide through the elamipretide delivery system|Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
45633451|NCT03891875|Combination Product|Subcutaneos placebo through the elamipretide delivery system|Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
45633452|NCT02425735|Biological|DC-CIK cells|DC-CIK cells will be used against tumor cells.
45633453|NCT02425735|Biological|γδ T cells|γδ T cells will be used against breast tumor.
45914005|NCT02029300|Other|Fiberoptic Intubation through the nasal route|
45633454|NCT02425735|Biological|γδ T/DC-CIK cells|γδ T/DC-CIK cells will be used against breast tumor.
45633455|NCT03106675|Device|Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T|"Procedure is performed under proper analgesia (general or local anesthesia). The intervention can be performed in areas accessible with ultrasound with no critical structures (nerves, vasculature, bowels) in proximity. Limbs and pelvis are most usually accepted locations.~Patient is adjusted on top of the HIFU-transducer connected to MRI. First a MR-scan is performed and the treatment procedure is planned on consol. Then under MRI-guidance a point by point ablation of the target tumor is performed. During the treatment a real-time thermometry is obtained in order to avoid unwanted heating of related structures and to observe sufficient effect on treatment zone. After treatment MR-scan with gadolinium is performed to evaluate the size of ablated area."
45633456|NCT03106675|Device|Varian Truebeam Radiotherapy System|Conventional radiotherapy focused on bone tumor. Pretreatment planning images acquired with computer tomography
45633457|NCT03138785|Drug|topical voriconazole / levofloxacin systemic itraconazole|starting topical voriconazole every hour tapering after 4 days , levofloxacin every 6 hours, Itraconazole 100mg /BD for 2 weeks
45914006|NCT02029300|Other|Fiberoptic intubation through the oral route|
46070091|NCT05251610|Drug|20mg oral propranolol and oxytocin|Participants will receive 20mg of oral propranolol 10minutes prior to initiation of augmentation or induction of labor with oxytocin
46070092|NCT05251610|Drug|Oxytocin only|Participants will have outright augmentation or induction of labor with oxytocin
45633458|NCT03138785|Radiation|CXL|30 min Riboflavin prescription to the cornea followed by 30 min UV-A radiation at 3mW/cm2 associated with Riboflavin administration
45633459|NCT02424331|Other|Pursed Lips Breathing|Pursed Lips Breathing for six minutes.
45633460|NCT02424331|Other|Quiet Breathing|
45633461|NCT05393843|Dietary Supplement|omega-3 fatty acids, anthocyanins and alpha-cyclodextrins|administration for 12 weeks
45914007|NCT02029313|Drug|Montelukast|
45914008|NCT02029313|Drug|Montelukast sodium|
45914009|NCT02029339|Device|Continuous topical triple-tube irrigation and suction|"The triple-tube device was continuous operated: instilled the topical solution through the washing tube, delivered negative pressure therapy at 100 - 125 mmHg continuously through the inner tube of sleeve tubes through the central negative pressure device in the wall of the ward. The outer tube was used for normalize and balance the distribution of the negative pressure around the inner tube to allow the solution to penetrate through the dressing to cover the wound, and protecting the inner tube from getting stuck with the sucked tissue. All tubes are all commercially available (Medical Silicone Tubing, Forbest Manufacturing Co., Ltd, China)."
45914010|NCT02029339|Device|SOC|Debridement, offloading, standard moist wound care, and conventional NPWT without continuous irrigation are the fundamental SOC for Open Abdomen with complicated abdominal infections.
45914011|NCT02029352|Drug|Sinecatechins 10%|
45914012|NCT02029352|Drug|Placebo|Composition, apart from the active substance, is otherwise identical to the investigational medical product.
45914013|NCT02029365|Other|Autoquestionnary|autoquestionnary completed during the consultation for infertility
45914014|NCT02029365|Other|semi-structured interview|phone interview
45914015|NCT02029378|Drug|Eculizumab|
45914016|NCT02029391|Other|Manual pressure release|Therapist applied non-painful pressure with slowly increase over the myofascial trigger point until he felts a tissue resistance barrier.
45914017|NCT02029391|Other|Kinesio tape|Kinesio tape was adhered from insertion to origin of the upper trapezius muscle
45935412|NCT00124111|Drug|pegfilgrastim|
46070093|NCT00657709|Biological|Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)|One dose of rMenB Lot concomitantly with the routinely administered infant vaccines
46070094|NCT00657709|Biological|Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)|One dose of rMenB concomitantly with the routinely administered infant vaccines
46070095|NCT00657709|Biological|Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)|One dose of rMenB concomitantly with the routinely administered infant vaccines
46070096|NCT00657709|Biological|Infanrix Hexa|Routine vaccination
46070097|NCT00657709|Biological|Menjugate|One dose of the routinely administered infant vaccines + MenC vaccine
46070098|NCT00657709|Biological|Prevenar|Routine vaccination
45633462|NCT05393843|Behavioral|diet|12 weeks of personalized diet according to the Mediterranean standard diet referrals, the Healthy Eating Plate recommendations of Harvard University School of Public Health, and the reference intake levels of nutrients and energy for the Italian population (LARN) for pregnant women
45633463|NCT05393843|Other|placebo|sunflower oil as placebo for Omega3 fatty acids; isomaltulosio as placebo for Anthocyanins and Alpha-cyclodextrins; administration for 12 weeks
45633464|NCT03106597|Drug|Manidipine 20mg|"After a 1~2-week run-in period, patents will be randomized to receive manidipine (20 mg/day; n=50) for a 8-week open-labeled phase. Study drugs will be administered orally and once daily between 8:00am and 10:00am.~BP, heart rate, adverse events and concomitant therapy are assessed and a physical examination is performed at each visit. A 12-lead standard ECG is obtained and hematology, clinical biochemistry and urine analysis investigations performed at the screening visit. A Bioelectrical Impedance Analysis (BIA) is undertaken at the screening visit and at the end of the 8-week treatment course. Patients have to attend the clinic visit every 4 weeks during the treatment period."
45633465|NCT03106597|Drug|Amlodipine 10mg|"After a 1~2-week run-in period, patents will be randomized to receive amlodipine (10 mg/day; n=50) for a 8-week open-labeled phase. Study drugs will be administered orally and once daily between 8:00am and 10:00am.~BP, heart rate, adverse events and concomitant therapy are assessed and a physical examination is performed at each visit. A 12-lead standard ECG is obtained and hematology, clinical biochemistry and urine analysis investigations performed at the screening visit. A Bioelectrical Impedance Analysis (BIA) is undertaken at the screening visit and at the end of the 8-week treatment course. Patients have to attend the clinic visit every 4 weeks during the treatment period."
45772416|NCT00381784|Behavioral|Peer advocates|"Core Element 1 Core group of young gay men and additional volunteers recruited from the community. The core group and volunteers comprise the peer advocates who design and carry out all program activities.~Core Element 2 Designated space where most social events and meetings are held; also serves as a drop in center where young men can meet and socialize during specified hours.~Core Element 3 Social events to attract young gay men and to promote safer sex. Core Element 4 Teams of young gay men go to locations frequented by young gay men to discuss and promote safer sex, deliver appealing informational literature on HIV risk reduction and distribute condoms.~Core Element 5 Meetings of eight to 10 young gay men to discuss factors contributing to unsafe sex among men. Men practice safer sex negotiation and correct condom use skills.~Core Element 6 Publicity campaigns that attract men to the program by word of mouth and through articles and advertisements in gay newspapers."
45772417|NCT00002674|Biological|filgrastim|
45772418|NCT00002674|Drug|cytarabine|
45772419|NCT00002674|Drug|etoposide|
45772420|NCT00002674|Drug|hydroxyurea|
45772421|NCT00002674|Drug|mitoxantrone hydrochloride|
45772422|NCT00002674|Procedure|peripheral blood stem cell transplantation|
45772423|NCT01743872|Procedure|Contrast Injection|Media #1: IV Contrast (Omnipaque 350) will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml) Intervention protocol will be followed per Cross-Reference Intervention.
45772424|NCT01743872|Procedure|Dextran Injection|Media #2: Dextran 40 Solution will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml. Intervention protocol will be followed per Cross-Reference Intervention.
45772425|NCT01743872|Procedure|CO2 Injection|Media #3: Carbon Dioxide (CO2) will be injected with large volume hand injection syringe as per the usual protocol. This be done with particular attention to avoid air in the closed system. In addition to supine, there is also an option that the patient's distal limb may be elevated to improve the flow of CO2 during injection. The surgeon will also wait at least 2 minutes between each CO2 injection to allow any potentially trapped CO2 to dissolve. A range of 20-60 ml will be used with each hand injection based on the data from the initial 5-10 pilot patients. Intervention protocol will be followed per Cross-Reference Intervention.
45914018|NCT02029404|Procedure|Tibial nerve group|"After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution, Micrel Medical Devices) with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be > 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.~An information sheet will be released at the discharge and the medical indication for any rescue doses at home.~The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump"
45914019|NCT02029404|Procedure|Tibial peroneal nerve group|"After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution ,Micrel Medical Devices )with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be > 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.~An information sheet will be released at the discharge and the medical indication for any rescue doses at home.~The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump"
45652953|NCT01667549|Other|Timing of Diet and Flavor Experience|Groups differ in the timing and duration of exposure to flavored food experience.
45772426|NCT01743872|Procedure|Heparinized Normal Saline Injection|Media #4: Heparinized Normal Saline (Heparin NS) will be hand injected using 20 mL (2 U/mL) in antegrade fashion.
45772427|NCT00002680|Biological|filgrastim|
45914020|NCT02029456|Drug|25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours|
45935413|NCT00124111|Drug|cyclophosphamide|
45772428|NCT00002680|Drug|cyclophosphamide|
45772429|NCT00002680|Drug|megestrol acetate|
45772430|NCT00002680|Drug|melphalan|
45772431|NCT00002680|Drug|tamoxifen citrate|
45772432|NCT00002680|Drug|thiotepa|
45772433|NCT00002680|Procedure|conventional surgery|
45772434|NCT00002680|Procedure|peripheral blood stem cell transplantation|
45447934|NCT02932904|Drug|Paroxetine|Paroxetine Overencapsulated Tablets.
45772435|NCT00002680|Radiation|radiation therapy|
45772436|NCT00002692|Drug|fluorouracil|
45772437|NCT00002692|Drug|isolated perfusion|
45772438|NCT00002692|Drug|leucovorin calcium|
45447935|NCT02932904|Drug|Placebo|Vortioxetine Placebo-matching Capsules.
45633466|NCT03140267|Diagnostic Test|Difficult to wean patients|Subjects will be following during 18 hours in an invasive mechanical ventilation in a controlled mode. After failure of first single breath trial during 2 hours and presence of sevrability criterias defined by the European consensus conference in 2007, Maximal Inspiratory Pressure and Peak Pressure will be measure.
45633467|NCT03178825|Device|Hybrid Fractional Laser|Consecutive and coincident fractional 2940 nm and 1470 nm lasers
45772439|NCT01182506|Behavioral|Cogmed Working Memory Training Program|"Women will be randomized to one of two 5-week rehabilitation software training programs that train working memory called Cogmed Working Memory Training Program.~The training software will be provided to each participant. For each group, training occurs for 30 minutes a day, 5 days a week for 5 weeks. As part of the set-up, training data is uploaded to the internet at a minimum of every 3 days. This function allows the coach (in this case, the PI and RSA) to review the training. A weekly coach phone call is made to review the training results, answer questions, troubleshoot, and motivate the participant. Participants can load the software onto multiple computers to provide flexibility for them to do training at home, after work, when they are away from home."
45633468|NCT02018458|Biological|LA TNBC: DC vaccine+Preop chemo|LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.
45914021|NCT02029469|Device|Ascension HRA device|Patients who are treated with the Ascension® HRA for resurfacing of humeral head.
45914022|NCT02029482|Drug|ACT-128800|
45914023|NCT02029482|Drug|Placebo|
45914024|NCT02029508|Procedure|Modified Epley maneuver|For Modified Epley maneuver, the patient was placed in the upright position with the head turned 45 degrees toward the affected ear. And then the patient was rapidly laid back to the supine head-hanging position for 1 minute. Next, the head was turned 90 degrees toward the other (unaffected) side for 1 minute. Next, the head is turned a further 90 degrees (usually necessitating the patient's body to also move from the supine position to the lateral decubitus position) such that the patient' head is nearly in the facedown position for 1 minute. The patient is then brought into the upright sitting position for 1 minute, completing the maneuver.
45914025|NCT02029508|Procedure|Semont maneuver|Patient's head was turned 45 degrees toward the healthy side. And then patient was rapidly moved to affected side-lying position and sustained for 2 minutes. Next, Patient is rapidly taken to the opposite side-lying position without pausing in the sitting position or changing the head position relative to the shoulder for 2 minutes. Next, Patient returns slowly with the head still tilted and fixed until the seated position for 1 minute.
45914026|NCT02029508|Procedure|Reverse Epley maneuver|Like the modified Epley maneuver, but the direction was reverse.
45914027|NCT02029534|Drug|Atorvastatin 20 mg|
45633469|NCT02018458|Biological|ER+/HER2-BC:DC vaccine+Preop chemo|ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.
45633470|NCT03613103|Device|Video laryngoscopy|Intubation with videolaryngoscopy with highly curved blade
45633471|NCT03613103|Device|Direct laryngoscopy|Intubation with direct laryngoscopy with macintosh blade
45652954|NCT05092581|Drug|casirivimab+imdevimab|Single dose weight-based equivalent administered intravenously (IV)
45772440|NCT04747340|Behavioral|Training for Awareness Resilience and Action (TARA)|See arm-description
45914028|NCT02029534|Drug|Atorvastatin 80 mg|
45914029|NCT02029547|Drug|Florbetapir (18F)|No Florbetapir (18F) will be administered in this study.
45914030|NCT02029573|Drug|Atorvastatin|80 mg po daily until disease progression or unacceptable toxicity. (starting dose of 40 mg po daily for the first 21 days)
45914031|NCT02029573|Drug|Temozolomide|75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
45914032|NCT02029573|Radiation|Radiotherapy|60 Gy in 30 fractions
45914033|NCT02029586|Drug|MB12066 200mg|oral administration, 100mg bid
46070099|NCT00915356|Drug|AZD1305|Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
45447936|NCT02127736|Drug|Amitriptyline|
45447937|NCT02127736|Drug|Placebo|
45447938|NCT03552172|Other|Physical activity|PHYSICAL ACTIVITY: Rhythm of meetings, number of meetings, place of meetings
45447939|NCT03552172|Other|Absence of or suspended physical activity|the brakes responsible for a stop or lack of practice
45447940|NCT02122042|Biological|HBOT|
45447941|NCT02124850|Drug|Motolimod|
45447942|NCT02124850|Drug|Cetuximab|
45447943|NCT02124850|Drug|Nivolumab|
45914034|NCT02029586|Drug|Placebo|oral administration, 100mg bid
45914035|NCT02029599|Drug|Fang yi qing feng shi granule|10g, Oral,Three each time, 3 times a day,for 3 months;
45914036|NCT02029599|Drug|placebo|10g, Oral,Three each time, 3 times a day,for 3 months
45914037|NCT02029599|Drug|Methotrexate|7.5-15mg per week，All patients should be used
45914038|NCT02029599|Drug|Acetaminophen tablets|Oral,0.5g, 1~2 times a day, when vas=10
45633472|NCT03183037|Procedure|Acupuncture|The acupuncture group will undergo 8 weeks of outpatient acupuncture or sham acupuncture treatments (twice weekly for 2 weeks, then weekly for 6 weeks, 10 treatments in total). The investigators have designed this approach to standardize acupuncture treatment for future broad use; it is based on the understanding that CIPN is a global symptom complex rather than individual isolated or local symptoms.
45633473|NCT03183037|Procedure|Sham Acupuncture|Subjects in this group will receive the sham acupuncture procedure on the same schedule as subjects in the real acupuncture group. In both groups, patients' eyes will be covered with patches so they cannot observe the treatment procedure. To improve incentive to join and stay in the study, we will unblind all patients at Week 12, and offer those randomized to the Sham group 8 weeks of Acu (real) treatment. All points used will be documented.
45633474|NCT03183037|Other|Usual Care Group|Patients go to clinic three times during the study, at Baseline, Week 8, and Week 12 to undergo QST and CPM tests. Patients will complete all questionnaires (CIPN severity by 0-10 11-point numeric rating scale, FACT/GOG-Ntx-11, NPS) and their pain medication use at these time points. Week 4 questionnaires can be completed over the phone. As an incentive for patients to join the study - and for those randomized to control to stay in the study - controls will be offered 8 weeks of Acu (real) treatment once they have completed Week 12 assessments.
45633475|NCT03183037|Behavioral|questionnaires|FACT/GOG-Ntx, Neuropathic Pain Scale (NPS),Treatment Expectancy Scale (TES), Quantitative Sensory Testing (QST), Insomnia Severity Index (ISI), Hospital Anxiety and Depression Scale (HADS), Brief Fatigue Inventory (BFI)
45772441|NCT04747340|Other|Standard treatment|See arm-description
45633476|NCT02017522|Device|11C-PBR PET|"Subjects will have a positron emission tomography (PET) CT scan using 11C-PBR28 as a radiotracer. This study will evaluate inflammation due to cardiac sarcoidosis. The CT scan will improve the images. The total scan time will be about 30 minutes. There will also be some time required for prep, such as inserting an intravenous (IV) catheter in an arm or forearm. Including prep time, the scan will take approximately two hours.~Subjects will also undergo a cardiac MRI. Cardiac MRI uses strong magnetic fields to make pictures of the heart. We will use gadolinium containing contrast material, given through an intravenous (IV) catheter to highlight areas of scar in your heart which may be due to cardiac sarcoidosis. This scan will take about 60 minutes."
45633477|NCT05393687|Other|Eccentric exercise|progressive eccentric exercise with elastic band
45633478|NCT03183505|Drug|Anyu Peibo|Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
45633479|NCT03183505|Drug|Placebo|Placebo Capsule, twice per day, oral after breakfast and supper
45633480|NCT05393609|Procedure|Sigmoidectomy|Conventional laparoscopic resection of the sigmoid colon
45633481|NCT05393609|Dietary Supplement|Conservative|According to current practice including advice on supplementary dietary fiber, analgetics, or laxatives when indicated.
45633482|NCT02423083|Drug|Guanabenz|
45633483|NCT05393531|Device|Mandibular advancement device (MAD)|Active therapy
45633484|NCT05393531|Device|Continuous positive airway pressure (CPAP)|Active therapy
45914039|NCT02029612|Drug|Nicotine Patch|10 week supply of nicotine patches given to participants at baseline.
45914040|NCT02029612|Behavioral|Phone Counseling|Each participant counseled on quitting smoking at baseline.
45914041|NCT02029612|Behavioral|Questionnaires|Questionnaires completed at baseline, 3 months, and at 6 months.
45914042|NCT02029612|Behavioral|Breath Test|Breath test performed at 3 month and 6 month visit.
45914043|NCT02029612|Behavioral|Proactive Cell Phone Smoking Cessation Counseling|Participant receives 11 phone calls from study staff over a 6-month period.
45633485|NCT02017444|Drug|AZD4017|
45633486|NCT02017444|Other|Placebo|Matched placebo (matched to AZD4017 arm)
45633487|NCT02423941|Procedure|Retrogade reperfusion|Retrogade caval reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
45633488|NCT02423941|Procedure|Antegrade reperfusion|Antegrade conventional portal reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
45633489|NCT03138395|Diagnostic Test|droplet digital PCR|This study will use our droplet digital PCR (ddPCR) method to quantify and track peripheral blood plasma MAF in MDS and AML patients before, during and after chemotherapy treatment. Quantification of MAF from fingersticks and saliva samples will also be performed to determine feasibility of obtaining adequate circulating tumor DNA (ctDNA) for ddPCR. Results from this project will generate a non-invasive means to monitor cancer response and progression months before current clinical methods, and provide an opportunity to intervene before the patient relapses.
45772442|NCT00382486|Procedure|Reduce the risk of allograft rejection|
45772443|NCT05293210|Drug|Dexamethasone|"A daily dose of dexamethasone 20 mg intravenous for 3 days, followed by a daily dose of dexamethasone 6 mg intravenous or oral for 7 days.~Dexamethasone 6 mg orally or intravenously for 10 days (with the possibility of escalation to doses of 20 mg daily of oral or intravenous dexamethasone for 3 days if clinical criteria of respiratory distress develop despite treatment with doses of dexamethasone 6 mg daily)."
45772444|NCT01895348|Drug|Propofol|Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes
45772445|NCT01895348|Drug|propofol-remifentanil|Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
45914044|NCT02029612|Behavioral|Text Message Smoking Cessation Support|Participants receive text messages for support about quitting smoking over a 6 month period.
45914045|NCT02029625|Drug|NVP-1205|rosuvastatin/ezetimibe fixed dose combination orally, once daily on Period 1 or Period 2
45914046|NCT02029625|Drug|rosuvastatin and ezetimibe|coadministration of rosuvastatin and ezetimibe orally, once daily on Period 1 or Period 2
45914047|NCT02029651|Device|E-glove system|Novel rehabilitation system using game for upper extremity rehabilitation for patients with stroke
45914048|NCT02029651|Procedure|Conventional occupational therapy|conventional occupational therapy
45914049|NCT02029664|Device|Visual distortion increment based on the gait pattern|
45914050|NCT02029690|Drug|ADI-PEG 20|
45914051|NCT02029716|Drug|RTA 408 Lotion 0.5%, 1%, 3%|
45914052|NCT02029716|Drug|Lotion vehicle/placebo|
45633490|NCT02421367|Biological|TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.|Tetravalent dengue virus purified inactivated vaccine (1 µg/virus type)
45633491|NCT05393063|Drug|AK127|Subjects will receive AK127 by intravenous administration（administered on Day 1 of each cycle, Q3W）
45633492|NCT02420587|Drug|AMG 208|Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles.
45633493|NCT02420587|Behavioral|Questionnaire|Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
45633494|NCT02425657|Behavioral|Training of junior doctors|Training program
45633495|NCT03138551|Behavioral|Mealtime PREP (Promoting Routines of Exploration and Play)|
45633496|NCT03140111|Device|LAMELLEYE|Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
45633497|NCT03140111|Device|OPTIVE FUSION|Multi-dose sterile solution which contains sodium hyaluronate 0.1%, sodium carboxymethylcellulose 0.5%, glycerine 0.9%, erythritol, boric acid, sodium citrate dihydrate, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, and is preserved with PURITE® 0.01% which breaks down into natural tear components on the eye.
45633498|NCT02420743|Procedure|serum ferritin|serum ferritin will be measured serially at 26, 30 and 34 weeks gestation.
45772446|NCT01895348|Drug|Dexmedetomidine-remifentanil|Dexmedetomidine infusion: After the loading dose (1 mcg/kg for 10 minutes), the continuous infusion was done (0.2 mcg/kg/hr) and the infusion rate was increased by 0.2 mcg/kg/hr every five minutes (maximum infusion rate: 1.4 mcg/kg/hr) Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
45772447|NCT04070534|Other|PALS|patient activated learning system
45633499|NCT02420743|Procedure|MCA Doppler|MCA peak systolic value will be assessed at 26, 30 and 34 weeks gestation.
45633500|NCT02423863|Biological|Hiltonol|"Wk 1 Days 1, 3 and 5: Poly-ICLC (Hiltonol®) 1 mg (0. 5 ml) IntraTumoral (priming treatment course). Weeks 2-25 Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM twice a week with a 48-72 hour interval between the two injections, AND either:~No additional immunotherapy OR~ONLY ONE of the Anti-PD1 or anti-PDL-1 regimens will be administered, per manufacturer's dosing and clinical oncologist's discretion as follows: (Not to be Administered on the same day as Poly-ICLC [Hiltonol®]) Either Nivolumab, OR Pembrolizumab, OR Atezolizumab, OR Cemiplimab, OR Durvalumab"
45772448|NCT05292040|Drug|LY3857210|Administered orally.
45772449|NCT01734122|Other|Questionnaires / Observational Assessments|Includes QUEST, PDQ-39, FTM, and Neuropsych evaluation
45772450|NCT05280184|Behavioral|Coin2Dose|Behavioral Economics incentive intervention that also combines automated text message reminders to dose for insulin
45772451|NCT04271852|Device|bio-feedback treatment|50 patients will treated with phenix u2 and phenix u4 treating equipment。
45772452|NCT05278546|Drug|ILB2109|ILB2109 tablets by mouth once per day at dosages prespecified by the protocol
45633501|NCT03178747|Diagnostic Test|Methylene blue|working solution methylene blue
45772453|NCT04784078|Procedure|Coronary Angiography and Intervention|Transradial access puncture site
45772454|NCT04194554|Drug|Niraparib|given PO per dose escalation schedule
45914053|NCT02029729|Drug|omaveloxolone|
45914054|NCT02029742|Behavioral|Community Health Worker (CHW)|CHWs will have scheduled interactions with subjects at home, by telephone or at Community League of the Heights (CLOTH), our partner community-based organization (CBO). CHWs will customize text messaging jointly with each youth and parent (Month 3) and text message reminders to both parent and youth will be implemented during Months 4-6. Subjects lacking a mobile phone or sufficient cell phone plan will be compensated to purchase or upgrade plans to accommodate texts.
45633502|NCT03178747|Diagnostic Test|Giemsa stain|working solution Giemsa stain (Wolbach's modification)
45633503|NCT03181321|Behavioral|The First Twenty|The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
45633504|NCT02425423|Dietary Supplement|New thickened formula|
45633505|NCT05392673|Other|KM-8800 plasma exchange device (Kuraray, Tokyo, Japan)|Artificial liver scavenges inflammatory factors.
45633506|NCT02425579|Drug|Inhaled Carbon Monoxide at 100ppm (4 participants)|Inhaled Carbon Monoxide at 100ppm for up to 90 minutes daily for 5 days
45633507|NCT02425579|Drug|Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants)|Inhaled Medical Air for up to 90 minutes daily for 5 days
45633508|NCT02425579|Drug|Inhaled Carbon Monoxide at 200ppm (4 participants)|Inhaled Carbon Monoxide at 200ppm for 90 minutes daily for 5 days
45772455|NCT04194554|Drug|Leuprolide|22.5 mg q3 month
45772456|NCT04194554|Drug|Abiraterone Acetate|1000 mg daily
45772457|NCT04194554|Radiation|Stereotactic body radiotherapy (SBRT)|5-6 fraction SBRT (total dose: 37.5-40 Gy)
45772458|NCT05073718|Drug|Low-dose acetylsalicylic acid|In case of being positive for SARS-CoV-2 PCR or antigen test, she will be randomised 1:1 to receive daily LDASA (125 mg) or placebo, up to 36 weeks of pregnancy.
45772459|NCT05073718|Drug|Placebo|Placebo
45772460|NCT04784000|Drug|Period 1: AT-527 550 mg|AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 1
45772461|NCT04784000|Drug|Period 2: carbamazepine|Carbamazepine 100 mg twice daily (BID) Days 3 to 6, 200 mg BID on Days 9 to 11, 300 mg BID on Days 12 to 25
45935414|NCT00124111|Drug|methotrexate|
45935415|NCT00124111|Drug|5-fluorouracil|
45772462|NCT04784000|Drug|Period 3: AT-527 550 mg + carbamazepine|AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26
45772463|NCT04784000|Drug|Period 3: AT-527 1100 mg + carbamazepine|AT-527 1100 mg tablet (2 x 550 mg tablets, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26
45772464|NCT05271292|Drug|Chiauranib|"Phase 1b: Each patient will undergo both a single-dose period (6 days) and a consecutive-dose (1 cycle of 28 days) period~Phase 2: Patients will take the RP2D once daily for 28-day cycles continuously with no interruption between cycles"
45935416|NCT00124150|Drug|Intravenous magnesium sulfate infusion|80mg per day
45633509|NCT02425579|Drug|Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants)|Inhaled Medical Air for up to 90 minutes daily for 5 days
45633510|NCT05392595|Other|Cawthrone and cooksey exercises,Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.|"Epley repositioning maneuver will be performed, also cervical stretches and Basic Balance exercises Following Exercises will be performed by patient in next session. Caw-Thorne and Cooksey exercise program. Participants will receive CRM for 6 weeks as needed in each evaluation. Frequency: These exercises will be performed thrice a week on alternate days for 40 min sessions. Post-Intervention Assessment: The patients will be assessed 6 weeks after the beginning of the intervention"
45633511|NCT05392595|Other|Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.|"Conventional treatment: Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.~Frequency: Participants will receive CRM for 6 weeks as needed in each evaluation. Frequency: These exercises will be performed thrice a week on alternate days for 40 min sessions. Post-Intervention Assessment: The patients will be assessed 6 weeks after the beginning of the intervention"
45633512|NCT03178591|Drug|vildagliptin|
45633513|NCT03178591|Drug|Dapagliflozin|
45633514|NCT01993186|Drug|UX007|oral liquid
45633515|NCT01993186|Drug|Placebo|oral liquid
45633516|NCT03181243|Procedure|Madajet|The spermatic cord is firmly trapped between the middle finger, index finger and thumb of the left hand. The injector's sheath is placed over the spermatic cord with gentle pressure adjacent to the external inguinal ring. Depending upon the thickness of spermatic cord, three or four injections are consecutively administered around it, beginning from proximal to distal points.
45633517|NCT03181243|Procedure|Needle injection|The pubic tubercle is palpated on the side that is going to be blocked. The spermatic cord is then immobilised with the non-dominant hand between the thumb and index finger. Right after needle puncture with attached syringe and local anaesthetic solution is conducted at a point that is 1 cm inferior to and 1 cm medial to the pubic tubercle, pass the needle directly downward in a vertical fashion, which leads it into the spermatic cord. After a check-up (negative aspiration) for bleeding, approximately 3 mL of solution (Lidocaine 2%) is injected into the cord.
45633518|NCT03139955|Device|Bodytrak|Bodytrak is a wireless earpiece which can monitor the user's vital signs such as tympanic (ear) temperature and heart rate. The earpiece is non-invasive and should fit comfortably within the right ear, similar to an earphone with an over-the-ear hook. Bodytrak is currently in a prototype stage. For further information please visit http://www.bodytrak.co
45772465|NCT05266846|Drug|Pembrolizumab Combined With Bevacizumab and Chemotherapy|Pembrolizumab + Bevacizumab + Chemotherapy
45772466|NCT04783688|Other|Full Face Snorkel Mask (FFSM)|A mask used for snorkeling that covers the entire face, as opposed to a conventional snorkel, which is held in the mouth only.
45772467|NCT05261620|Dietary Supplement|red wine|Subjects in the intervention arm (SoC+WISE) will be assigned to consume exclusively during meals one glass (around 150 ml at lunch and 150 ml at dinner) of red wine containing ethanol (˜13% EtOH v/v) with a high content of phenolic compounds (800 mg of Gallic acid equivalent) both for woman and men. Total polyphenolic contents and antioxidant activity (Folin-Ciocalteu method with calibration curve in gallic acid), antioxidant/radical scavenger capacity [DPPH (2,2-diphenyl-1-picrylhydrazyl) test] and phenolic profiles [HPLC (High Performance Liquid Chromatography)/DAD (diode-array detector) /ESI-MS (Electrospray Ionisation Mass Spectrometry) analysis] will be performed for wine selection for the clinical trial.
45772468|NCT04783844|Diagnostic Test|Virtual modelization.|3D-MSP technology is used to make virtual 3D models based on conventional CT.
45772469|NCT01113476|Drug|Nab-paclitaxel|Starting dose of 50 mg/m^2 on Day 1, 8 + 15 every 28 days (+/- 2 days)
45772470|NCT01113476|Drug|Bevacizumab|Starting dose of 5 mg/m^2 on Day 1 + 15 every 28 days (+/- 2 days)
45772471|NCT01113476|Drug|Gemcitabine|1000 mg/kg Day 1, 8 + 15 every 28 days (+/- 2 days)
45772472|NCT01718600|Behavioral|Neuropsychological testing|
45772473|NCT04839718|Behavioral|ADAPT|The Achieving Depression and Anxiety Patient Centered Treatment (ADAPT) Program is a novel collaborative psychiatric care model that is designed to unburden PCPs and psychiatrists, increase access to quality specialty mental healthcare for Kaiser Permanente members, and improve patient depression and anxiety treatment outcomes by utilizing technology-driven appointments. This program uses principles of collaborative care, including patient-centered care, population-based care, evidence-based care, measurement-based treatment to target, and accountable care.
45772474|NCT04783766|Drug|CK-3773274|CK-3773274- Tablets
45772475|NCT04783766|Drug|Placebo|Placebo- Tablets
46070100|NCT00915356|Drug|Placebo|iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
45772476|NCT01107236|Drug|IW-6118|Single dose
45772477|NCT01107236|Drug|Matching Placebo|Single dose of matching placebo for IW-6118 and/or matching placebo for naproxen sodium
45772478|NCT01107236|Drug|Naproxen Sodium|Single dose
46070101|NCT05218070|Drug|EgyVax Vaccine Candidate|EgyVax Inactivated SARS-CoV-2 vaccine candidate, equivalent to 70 mcg inactivated SARS-CoV-2 total protein. Alum adjuvant 2% 50 µl (equivalent to 0.5 mg AlOH). Equivalent volume of Saline 0.9% to each vaccine dose. Each vial contains 0.5 ml representing one dose 70 mcg of inactivated SARS-CoV-2 virus with alum adjuvant or two doses of 35 mcg of inactivated SARS-CoV-2 virus with alum adjuvant
45633519|NCT03178435|Other|Measures to prevent AKI among critically ill patients|"Meticulous optimization of the fluid balance~Avoidance of nephrotoxic medications where possible~Optimisation of the hemodynamic status~Avoidance of blood transfusion unless marked acute blood loss or symptomatic anemia~Optimization of the underlying medical condition~Seek expert renal advise when necessary"
45633520|NCT03110705|Behavioral|sport|recreaational sport : diving or multisport
45633521|NCT02420665|Drug|Proflavine|0.01% Proflavine applied topically to the cervix after colposcopy and HRME cervical images obtained.
45633522|NCT02420665|Device|HRME Imaging|HRME images obtained from one visually normal cervical site, and from up to 3 visually abnormal lesions based on exam and/or colposcopic findings.
45633523|NCT02420665|Behavioral|Phone Call|Study staff follow up with participant by phone one month after procedure.
45633524|NCT02420665|Procedure|Colposcopy|Colposcopy performed after visual inspection of cervix.
45772479|NCT00002704|Biological|filgrastim|
45772480|NCT00002704|Drug|asparaginase|
45772481|NCT00002704|Drug|cyclophosphamide|
45772482|NCT00002704|Drug|daunorubicin hydrochloride|
45633525|NCT02420665|Drug|Acetic Acid|3 - 5% added to cervix before visual inspection.
45772483|NCT00002704|Drug|dexamethasone|
45772484|NCT00002704|Drug|etoposide|
45772485|NCT00002704|Drug|leucovorin calcium|
45772486|NCT00002704|Drug|liposomal cytarabine|
45772487|NCT00002704|Drug|mercaptopurine|
45772488|NCT00002704|Drug|mesna|
45772489|NCT00002704|Drug|methotrexate|
45772490|NCT00002704|Drug|therapeutic hydrocortisone|
45772491|NCT00002704|Drug|thiotepa|
45772492|NCT00002704|Drug|vincristine sulfate|
45772493|NCT00002704|Radiation|low-LET electron therapy|
45772494|NCT00002704|Radiation|low-LET photon therapy|
45772495|NCT00002716|Drug|dexamethasone|
45772496|NCT00002716|Drug|floxuridine|
45772497|NCT00002716|Drug|fluorouracil|
45772498|NCT00002716|Drug|leucovorin calcium|
45772499|NCT00002716|Procedure|laparotomy|
45772500|NCT00002716|Procedure|conventional surgery|
45772501|NCT02533674|Drug|Gemcitabine plus PM060184|
45772502|NCT04756544|Dietary Supplement|Lactobacillus helveticus Rosell®-52, Bifidobacterium longum Rosell®-175|probiotic
45772503|NCT04756544|Other|placebo|placebo
45772504|NCT00002722|Drug|cisplatin|
45633526|NCT02016898|Procedure|Placement of the sponge|
45633527|NCT02016898|Drug|Mitomycin-C|
45772505|NCT00002722|Drug|fluorouracil|
45772506|NCT00002722|Drug|leucovorin calcium|
45772507|NCT04756154|Drug|CHG/IPA Surgical skin preparation|Apply topically
45772508|NCT04756154|Drug|Normal saline|Apply topically
45633528|NCT04482907|Dietary Supplement|Giving dill by mouth capsule to the study group and placebo capsule by mouth to the control group.|Tests from intravenous blood: TSH, fT3, fT4, anti-TPO, Anti-Tg, CRP
45633529|NCT03110627|Device|VDD ICD (experimental group)|"Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications."
45652955|NCT04790357|Other|Current guidelines|doppler ultrasound and/or angio CT-scan of the cervical arteries, angio CT-scan of the intracranial arteries, TTE wich can be supplemented by a TEE at the discretion of the investigator. The TEE is not mandatory
45772509|NCT00002734|Biological|recombinant interferon alfa|
45772510|NCT00002734|Drug|chemotherapy|
45772511|NCT00002734|Drug|paclitaxel|
45772512|NCT00002734|Drug|topotecan hydrochloride|
45772513|NCT00002734|Radiation|lutetium Lu 177 monoclonal antibody CC49|
45772514|NCT00002734|Radiation|yttrium Y 90 monoclonal antibody CC49|
45772515|NCT04783610|Other|Ethanol|Ethanol will be administered via oral route.
45772516|NCT05465382|Device|Saline Lavage|Three rounds of 10cc of sterile 0.9% normal saline will be injected into the injured ankle joint and withdrawn from the joint using an anteromedial 16-gauge needle attached to a 10cc syringe.
45772517|NCT00002740|Biological|filgrastim|
45772518|NCT00002740|Drug|carboplatin|
45772519|NCT00002740|Drug|cyclophosphamide|
45772520|NCT00002740|Drug|doxorubicin hydrochloride|
45772521|NCT00002740|Drug|etoposide|
45772522|NCT00002740|Drug|mesna|
45772523|NCT00002740|Drug|vincristine sulfate|
45772524|NCT00002740|Procedure|conventional surgery|
45772525|NCT00002740|Procedure|peripheral blood stem cell transplantation|
45772526|NCT00002740|Radiation|low-LET cobalt-60 gamma ray therapy|
45772527|NCT00002740|Radiation|low-LET photon therapy|
45772528|NCT04572230|Device|Endovascular treatment of intracranial aneurysms using a flow-diverting stent|The flow diverter brings about a reduction of blood flow to the aneurysm, which progresses over time into forming a stable thrombus within the aneurysm, as well as eventual aneurysm scarring and retraction. The flow diverter also acts as a scaffold for tissue growth across the neck of the aneurysm, which blocks the aneurysm from the artery blood flow.
45772529|NCT00002746|Biological|aldesleukin|
45772530|NCT05453292|Procedure|Endoscopic ultrasound guided radiofrequency ablation|Patients will be first assessed by DFI-EUS and CE-EUS. Then. EUS guided RFA will be performed using the 19G electrode ablation needle connected to the Starmed radiofrequency generator (Taewong Medical, Seoul, South Korea). After EUS identification of the GIST, a place without interposing vessels will be found by the endosonographer. Puncture of the tumor will be performed directly with the ablation probe inserted through the working channel of the echoendoscope. Time - seconds will depend by the tumor dimension, localization, distance from vital structures (e.g., aorta) and EUS appearance (e.g., hyperechoic). Power will be set at no more than 30W. If the tumor is in contact with vital structures a 10mm safe margin will be kept from these to avoid thermal injury. Multiple applications can be performed in the same or separate session depending on the residual tumor tissue evaluated with DFI-EUSor CE-EUS immediately after procedure.
45772531|NCT05073406|Other|Altitude exposure in hypobaric normoxic condition|Altitude exposure with oxygen supplementation to achieve normoxia at altitude
45772532|NCT05073406|Other|Altitude exposure in hypobaric hypoxic condition|Altitude exposure with air supplementation to obtain a sham comparator arm
45772533|NCT05071768|Behavioral|Focused ACT|Brief acceptance and commitment therapy
45772534|NCT01662024|Device|Endoscopic gastric restrictive procedure|Endoluminal gastric tissue approximation using an incisionless/per-oral endoscopic suturing device for primary gastric restrictive procedures
45772535|NCT04783298|Other|App|An application to deliver a series of behavioral questionnaires and decision-making game
45772536|NCT01049945|Drug|bendamustine hydrochloride|Given IV
45772537|NCT01049945|Drug|lenalidomide|Given orally
45633530|NCT03110627|Device|Single chamber VVI ICD (control group)|"Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications."
45633531|NCT02416297|Procedure|Micro-osteoperforation|Flapless cortical perforations will be made 8 months minimum after dental extraction. Surgical protocol will be flapless to preserve periodontal health. After local anesthesia, 3 micro osteoperforations will be done with manual instrument, between apex to the contour of free gum between the canine and second pre-molar. Perforations near each tooth will have 6-8 mm depth
45633532|NCT03110549|Drug|TMB-607|
45633533|NCT03110549|Drug|Placebo|
45633534|NCT02420509|Drug|systemic chemotherapy|twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery
45633535|NCT01993030|Device|HQ® Matrix Medical Wound Dressing|
45633536|NCT01993030|Device|Sidaiyi® wound dressing|
45633537|NCT02416531|Drug|Clobetasol propionate|Clobetasol propionate 0.05% ointment applied once daily at a dose of 1 g/application (1 g sachets) for 4 weeks.
45633538|NCT02416531|Radiation|Photodynamic therapy|Methylene blue 0.01% intralesional, λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
45633539|NCT02416531|Radiation|Low level laser therapy|λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
45633540|NCT03138317|Biological|PRP|This group will receive a knee injection with 6 ml of platelet rich plasma (PRP)
45633541|NCT03138317|Biological|Plasma|This group will receive a knee injection with 6 ml of plasma.
45633542|NCT03138317|Biological|Placebo|This group will receive a knee injection with 6 ml saline solution.
45633543|NCT04483063|Drug|2% chlorhexidine gluconate skin cleanser|2% chlorhexidine gluconate skin cleanser over shoulder region before shoulder surgery
45633544|NCT03110393|Device|Ambu AuraGain|Insert and intubation of an Ambu® AuraGain™ laryngeal mask
45772538|NCT01049945|Drug|dexamethasone|Given orally or IV
45772539|NCT00002752|Radiation|iodine I 131 monoclonal antibody 81C6|
45772540|NCT04525196|Other|Physical activity.|"The procedure under study (physical activity program) will include, each week for 12 months, two sessions dedicated to the development of aerobic capacity and a muscle building session.~The experimental group will therefore be offered 3 sessions of Physical Activity (PA) per week. The PA will be positioned in the first two hours after the start of the dialysis session. Each session will include 5 minutes of general warm-up, then 15 minutes of PA itself and finally 5 minutes of cool down period. The PA time itself will be increased as the sessions progress, according to the progress and improvement of physical capabilities of patients."
45914055|NCT02029742|Behavioral|Education|Dyads randomized to the control group will continue usual clinic-based care, including monitoring and review of HbF levels, and similar frequency of clinic visits and access to sickle cell team staff. They will be provided with educational materials about sickle cell disease and hydroxyurea use for children.
45914056|NCT02029781|Procedure|LAPP score|Use of the LAPP score during a diagnostic laparoscopy.
45935417|NCT02958046|Drug|Lansoprazole/Domperidone|DUOLANS 30/30 mg SR tablet per oral, one tablet daily
46070102|NCT05218070|Drug|Placebo|0.5ml Saline (0.9%)
45633545|NCT03110393|Device|Intersurgical i-gel|Insert and intubation of an Intersurgical i-gel®
45633546|NCT03181165|Behavioral|Low-carbohydrate Therapeutic Nutrition|The pharmacist or pharmacy lifestyle coach will work with the participant to develop a diet plan that is low in carbohydrate and energy-restricted based on personal preferences and characteristics. A combination of pre-packaged low-carbohydrate foods and whole foods from pre-specified lists will be used.
45633547|NCT02936453|Procedure|Device implantation|"Implantation of Specify 5-6-5 lead or Go-2 lead in epidural space~Implantation of Activa RC neurostimulator"
45633548|NCT05392049|Other|Bowen's therapy|Bowens technique will be apply on patients of TMJ for 2 repetitions in 1 set, 4 sets in each session for 4 weeks.
45633549|NCT05392049|Other|Post isometric relaxation|post isometric relaxation technique and jaw exercises (strengthen the weakened muscles, stretch the shortened muscles) with dosage 5 times/session, 5 sec rest and 2times/week for 4 weeks will apply on patients.
45633550|NCT02416141|Drug|fast release oro dispersible tramadol 50 mg|idem arm 1
45633551|NCT03138239|Radiation|Ga-68-PSMA scan, and PET -CT F-18-FDG|"The patient will do tow mappings on two different days. It should be noted that there is no importance to the order between the two tests on the condition that they be performed within 7-10 days of each other.~Both tests will be performed with the Discovery 690 camera, which is located at the Nuclear Medicine Institute.~First test PET-CT with F-18-FDG PET-CT second test with Ga-68-PSMA"
45633552|NCT02001233|Biological|EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
45633553|NCT02420197|Behavioral|High-intensity resistance training|
45633554|NCT02420197|Behavioral|General physical activity|
45633555|NCT02420197|Behavioral|Multidisciplinary rehabilitation program|
45633556|NCT05391659|Device|deep learning|a form of artificial intelligence (AI), has been introduced for automated analysis of images
45772541|NCT04460586|Drug|Omadacycline Injection [Nuzyra]|Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
45772542|NCT04460586|Drug|Omadacycline Oral Tablet [Nuzyra]|Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
45772543|NCT04500080|Behavioral|PE Intervention|"Each single exercise session will last for one hour and will consist of a combination of the following elements:~Aerobic Exercise (AE): 20-30 minutes at moderate-high intensity, from 60 to 80% of the maximum heart rate (% HRmax).~Resistance Exercise (RE): 30 minutes of strength activity of the major muscle groups.~Neuromotor Exercise (NE): will be integrated with strength exercises and will consist of jumping, balance and coordination activities"
45772544|NCT01050647|Drug|17-Hydroxyprogesterone Caproate|Weekly injections of 17-hydroxyprogesterone caproate.
45772545|NCT01050647|Other|Caster Oil injections|Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.
45772546|NCT04825678|Drug|Erenumab|Administered as a subcutaneous injection via the SureClick® Autoinjector Pen (AI/Pen).
45633557|NCT05391659|Diagnostic Test|remote grading of fundus images|referrable cases identified by DR AI tool will be remotely graded by a human
45633558|NCT05391659|Diagnostic Test|gold standard|examination by ophthalmologist
45633559|NCT02416219|Procedure|Cricoid pressure|participants will ask to mark the place where they will apply cricoid pressure if the patients was undergoing rapid sequence induction. US will be used to confirm how accurate they are in their estimation.
45633560|NCT02416219|Device|Ultrasound|
45633561|NCT02416063|Drug|Caudal Dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg~Drug: Caudal dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline~sevoflurane Induction and maintenance of anesthesia"
45633562|NCT02416063|Drug|Intravenous dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg.~Drug:Intravenous dexmedetomidine1 μg /kg in a total volume of 10 ml~sevoflurane Induction and maintenance of anesthesia"
45633563|NCT02416063|Drug|Placebo|"Drug:Caudal bupivacaine 0.25% 1ml/kg~Intravenous: Normal saline 10 ml~sevoflurane Induction and maintenance of anesthesia"
45633564|NCT01828697|Drug|Low dose nadroparin|"Fixed low dose nadroparin:~< 100 kg: 2850 IU subcutaneously once-daily~100 kg and above: 3800 IU subcutaneously once-daily"
45633565|NCT01828697|Drug|Intermediate dose nadroparin|"Intermediate weight-adjusted dose nadroparin:~< 50 kg: 3800 IU subcutaneously once-daily;~50 to < 70 kg: 5700 IU subcutaneously once-daily;~70 to < 100 kg: 7600 IU subcutaneously once-daily;~100 kg or above: 9500 IU subcutaneously once-daily."
45772547|NCT01689584|Genetic|salivary kit|The saliva samples will be made of selected related (DNA).
45772548|NCT03987035|Device|BeGraft Peripheral (BGP) Stent Graft System as bridging stent|BGP Stent Graft System as bridging stent
45772549|NCT05058196|Radiation|Whole breast radiotherapy|Whole breast radiotherapy after surgery
45772550|NCT05058196|Radiation|Intra Operative Radiotherapy|Intra Operative Radiotherapy
45772551|NCT03968393|Drug|Non-vitamin K oral anticoagulant (NOAC)|Participants randomized to the intervention arm will be prescribed one of the following NOACs for 24 months: edoxaban 60 mg daily (dose reduction to 30 mg, if applicable), apixaban 5 mg twice daily (dose reduction to 2.5 mg, if applicable), dabigatran 110 mg twice daily, or rivaroxaban 20 mg daily (dose reduction to 15 mg, if applicable). The choice of NOAC will be left up to the participant's prescribing physician.
45772552|NCT00002764|Biological|filgrastim|
45772553|NCT00002764|Drug|doxorubicin hydrochloride|
45633566|NCT01828697|Drug|Low dose enoxaparin|"Fixed low dose enoxaparin:~< 100 kg: 40 mg subcutaneously once-daily~100 kg and above: 60 mg subcutaneously once-daily"
45772554|NCT00002764|Drug|ifosfamide|
45772555|NCT00002764|Procedure|conventional surgery|
45772556|NCT05045326|Behavioral|Smoking cessation program|"Participants will receive intensive treatment for smoking cessation during day hospital admission.~The intervention is carried out individually and in an open-ended group. The treatment, provided by trained and multidisciplinary professionals (nursing, psychiatry, psychologist, occupational therapist, social work), includes psychological, psycho-educational support, and pharmacological treatment advice.~The group intervention takes place once a week and is divided into six structured sessions that are repeated. Sessions include nicotine addiction and withdrawal, health consequences, benefits of quitting, motivation for change, triggers, coping responses, social support, decision making, pharmacological treatment advice and healthy lifestyle habits."
45772557|NCT05045326|Behavioral|Placebo Comparator: Brief Counselling|Participants will receive brief counseling on smoking cessation during their hospital stay. This brief intervention is based on motivational techniques to increase motivation to reduce tobacco use or to initiate treatment.
45772558|NCT01688492|Drug|Ipilimumab|Abiraterone acetate (JanssenBiotech, Inc/Johnson & Johnson) 1000 mg orally daily plus prednisone 5 mg orally twice daily will be administered continuously during the duration of the trial. Starting at cycle 3 (Combination Therapy), Ipilimumab (Bristol-Myers Squibb) will be infused intravenously (IV) once every 3 weeks for a total of 4 infusions.
45772559|NCT05035732|Radiation|18F-fluciclovine|IV
45772560|NCT05167175|Drug|Olaparib tablet|Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily.
45772561|NCT05167175|Drug|Abiraterone acetate|Qingkeshu (Abiraterone acetate tablets) 1000 mg should be taken orally once daily.
45772562|NCT05167175|Drug|Prednisone tablet|Prednisone Tablets should be taken 5 mg once daily.
45633567|NCT01828697|Drug|Intermediate dose enoxaparin|"Intermediate weight-adjusted dose enoxaparin:~< 50 kg: 60 mg subcutaneously once-daily, or;~50 kg to < 70 kg: 80 mg subcutaneously once-daily, or;~70 kg to < 100 kg: 100 mg subcutaneously once-daily, or;~100 kg or above: 120 mg subcutaneously once-daily."
45772563|NCT04782908|Device|Transcatheter tricuspid valve edge-to-edge repair|Transcatheter tricuspid valve edge-to-edge repair is an interventional approach to treat severe tricuspid regurgitation. Under general anesthesia a clip delivery system is forwarded through the vena femoralis and right atrium in the right ventricle. A clip is deployed to clamp the tricuspid valve and reduce tricuspid valve regurgitation.
45772564|NCT00002788|Biological|filgrastim|
45772565|NCT00002788|Drug|cyclophosphamide|
45772566|NCT00002788|Drug|dexamethasone|
45772567|NCT00002788|Drug|etoposide|
45772568|NCT00002788|Procedure|peripheral blood stem cell transplantation|
45772569|NCT00002788|Radiation|radiation therapy|
45935418|NCT00073905|Drug|capecitabine plus gemcitabine|capecitabine plus gemcitabine
45935419|NCT00124189|Drug|GRN163L|Weekly intravenous infusion
45772570|NCT04352933|Drug|Hydroxychloroquine - Daily dosing|"Active HCQ:~Days 1-2: Loading phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 200mg (1 x 200mg capsule) taken ONCE A DAY, every day for 90 days (~3 months),~Matched Placebo HCQ:~Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (~3 months)"
45633568|NCT01828697|Drug|Low dose dalteparin|"Fixed low dose dalteparin:~< 100 kg: 5000 IU subcutaneously once-daily~100 kg and above: 7500 IU subcutaneously once-daily"
45633569|NCT01828697|Drug|Intermediate dose dalteparin|"Intermediate weight-adjusted dose dalteparin:~< 50 kg: 7500 IU subcutaneously once-daily, or;~50 kg to < 70 kg: 10000 IU subcutaneously once-daily, or;~70 kg to < 100 kg: 12500 IU subcutaneously once-daily, or;~100 kg or above: 15000 IU subcutaneously once-daily."
45633570|NCT01828697|Drug|Fixed low dose tinzaparin|"Fixed low dose tinzaparin:~< 100 kg: 3500 IU subcutaneously once-daily~100 kg and above: 4500 IU subcutaneously once-daily"
45633571|NCT01828697|Drug|Intermediate dose tinzaparin|"Intermediate weight-adjusted dose tinzaparin:~< 50 kg: 4500 IU subcutaneously once-daily, or;~50 kg to < 70 kg: 7000 IU subcutaneously once-daily, or;~70 kg to < 100 kg: 10000 IU subcutaneously once-daily, or;~100 kg or above: 12000 IU subcutaneously once-daily."
45633572|NCT02420275|Other|placebo|THIS GROUP WILL RECEIVE NO BRIGHT LIGHT
45633573|NCT02420275|Device|"Luminette,Lucimed Belgium"|THIS GROUP WILL RECEIVE BLEU LIGHT ENRICHIDED IN WITHE BRIGHT LIGHT
45633574|NCT02419963|Procedure|endoscopy for tissue biopsy|endoscopy to obtain tissue biopsy for analysis of biomarker status
45633575|NCT02419963|Other|Blood Sample|Blood draw to evaluate serotonin and Vit D level.
45633576|NCT02419963|Other|Stool Sample|Stool sample to evaluate microbiome fingerprint.
45633577|NCT02415985|Drug|Lopinavir/r will be supplied by NHSO/GPO|200/50 mg tablet LPV/rtv
45633578|NCT02415985|Drug|Rifabutin|
45633579|NCT02415907|Drug|[ethyl-1-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67708 ([ethyl-1-14C]-idalopirdine) in one capsule for oral administration, single dose
45633580|NCT02415907|Drug|[benzyl-7-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67709 ([benzyl-7-14C]-idalopirdine) in one capsule for oral administration, single dose
45633581|NCT03138083|Drug|OMO-1|OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase
45633582|NCT02415829|Drug|capecitabine plus oxaliplatin|The neoadjuvant chemotherapy consisted of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen)
45633583|NCT03180931|Device|Bioresorbable vascular scaffold|"No study specific procedures will be applied. Optical coherence tomography recordings at the time of very late scaffold thrombosis were obtained during clinical routine with one of the commercially available and approved optical coherence tomography consoles and catheters. The analysis will be conducted at the Core laboratory at Bern University Hospital, Bern, Switzerland using a systematic and validated approach.~Every participant will be coded by getting a number (pseudonym) in the local institutes. In the Core Laboratory, data will be further coded to ensure anonymity of the participants."
45633584|NCT04631393|Drug|Propofol Alfentanil|Propofol and Alfentanil are self-administered by the participant.
45633585|NCT04482725|Other|Trial product 1|Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL
45633586|NCT04482725|Other|Trial product 2|Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL
45633587|NCT04482725|Other|Trial product 3|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL
45633588|NCT04482725|Other|Trial product 4|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Glycerol 22.0 mg/mL
45633589|NCT04482725|Other|Trial product 5|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Mannitol 44.0 mg/mL
45633590|NCT04482725|Other|Trial product 6|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL
45633591|NCT04482725|Other|Trial product 7|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: a,a-Trehalose, dihydrate 90.0 mg/mL
45633592|NCT04482725|Other|Trial product 8|Buffering agent: Disodium hydrogen phosphate dihydrate 5.34 mg/mL Isotonic agent: NaCl 6.72 mg/mL
45633593|NCT04482725|Other|Trial product 9|Buffering agent: Tris 2.4 mg/mL Isotonic agent: Propylene glycol 19 mg/mL
45633594|NCT04482725|Other|Trial product 10|Buffering agent: Glutamic acid 0.74 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
45772571|NCT04352933|Drug|Hydroxychloroquine - Weekly Dosing|"Active HCQ:~Days 1-2: Loading Phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 400mg (2 x 200mg capsules) taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (~3 months)~Matched Placebo HCQ:~Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (~3 months)"
45633595|NCT04482725|Other|Trial product 10|Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
45633596|NCT04482725|Other|Trial product 12|Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL
45633597|NCT03180775|Other|Cellulose (control)|Cellulose (a vegetal product, in powder form, used as dietary fiber, that is not digested or absorbed in the intestines), will be supplemented in the form of water soluble powder.
45633598|NCT03180775|Dietary Supplement|Glycine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glycine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
45652956|NCT04790357|Other|cc-MRI|of one-shot cardiac-cervical-intracranial MRI: cardiac MRI with late-enhancement, angio-MRI of the cervical and intracranial arteries
45935420|NCT00124228|Drug|Human Albumin|albumin 1.5g/kg body weight the first day of inclusion plus 1g/kg/body weight the 3th day of inclusion.
45772572|NCT04352933|Other|Matched Placebo Hydroxychloroquine|"Matched placebo HCQ - daily dosing:~Days 1-2: Loading Phase - 2 capsules taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (~3 months) Matched placebo HCQ - weekly dosing Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (~3 months)"
45633599|NCT03180775|Dietary Supplement|Alanine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Alanine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
45633600|NCT03180775|Dietary Supplement|Leucine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Leucine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
45633601|NCT03180775|Dietary Supplement|Isoleucine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Isoleucine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
45633602|NCT03180775|Dietary Supplement|Valine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Valine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
45633603|NCT03180775|Dietary Supplement|Cysteine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Cysteine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
45633604|NCT03180775|Dietary Supplement|Arginine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Arginine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
45633605|NCT03180775|Dietary Supplement|Methionine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Methionine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
45633606|NCT03180775|Dietary Supplement|Glutamate|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glutamate will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
45652957|NCT04756193|Diagnostic Test|Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound|Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound, ECG, pulse oximetry, blood draw, spirometry
45772573|NCT05246696|Other|BodyBabe questionnaire|assessment of young mothers' perceptions using self-questionnaires
45772574|NCT04783792|Dietary Supplement|Ascorbic acid / phytochemical supplement|Ascorbic acid / phytochemical supplement
45772575|NCT04783792|Dietary Supplement|Ascorbic acid|Ascorbic acid
45772576|NCT02981381|Device|NEST-1|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be NEST-1 compatible.
45914057|NCT02029794|Procedure|HPV self-colleciton|Women will self-collect a cervical sample that will be provided to an outreach worker and then labelled and sent to laboratories in Kampala for HPV testing. Women who test positive for HPV will be contacted by phone and provided with follow-up instructions.
45772577|NCT02981381|Device|SHAM|The SHAM NeoSync EEG Synchronized TMS (NEST) is a device, identical to the active NEST-1 device, that is configured to simulate the delivery of active treatment without actively delivering sTMS therapy. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be SHAM compatible.
45633607|NCT03180775|Dietary Supplement|Glutamine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glutamine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
45633608|NCT03180697|Diagnostic Test|APT MR Imaging|Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will obtain routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy. We will observe the change of tumor after target therapy using APT imaging. We will compare the change of tumor between Gd-enhanced and APT Imaging before and after therapy.
45633609|NCT03178357|Other|Cardiac rehabilitation + standard therapy|Patients with HCM subjected to cardiological rehabilitation
45633610|NCT03178357|Other|Standard therapy|Standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling
45633611|NCT04441775|Other|AI-assisted RT modelling|Artificial Intelligence assisted Radiation Treatment
45633612|NCT03180541|Behavioral|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
45633613|NCT05391425|Other|no intervention|no intervention planned, since it is an observational study
45633614|NCT02415673|Device|Fixed orthodontics appliance and arch wire|Two nickel-titanium alignment and leveling sequences were employed
45633615|NCT05390099|Drug|Moringa oleifera leaf|Moringa toothpaste
45633616|NCT02415751|Behavioral|heart failure self-care education|It is defined as a naturalistic decision-making process that patients use in the choice of behaviors that maintain physiological stability (symptom monitoring and treatment adherence) and the response to symptoms when they occur (Riegel 2004). This includes following advice regarding medications, sodium and water consumption, alcohol restriction, exercise, preventive behaviors, and monitoring of signs and symptoms.
45633617|NCT03137927|Biological|Vaccine GamLPV|live intranasal vaccine for whooping cough prevention
45633618|NCT03137927|Other|Placebo|Placebo
45633619|NCT04482985|Drug|Meclizine Hydrochloride|Meclzine is given to all study participants to prevent seasickness. Meclizine plasma levels are determined from both the meclizine responders and non responders group.
45633620|NCT05388305|Biological|CAR--γδT cells|Biological: CAR-γδT; Drug:
45633621|NCT03178513|Other|Home visit|"The visit will be entirely patient tailored, last approximately one hour, and at a minimum will entail:~Medical assessment~Psychosocial assessment~Medication reconciliation~Follow-up of inpatient primary team's specific recommendations~Follow-up, as needed, with primary care team or inpatient team"
45633622|NCT03178279|Other|Physical Health Plan|Use of a Physical Health Plan by service users
45633623|NCT04286789|Drug|Low dose ORTD-1|Once weekly, single subcutaneous injection of ORTD-1 at a volume of 0.45 mL. Six weekly treatments; 28-day follow-up period.
45633624|NCT04286789|Drug|Low dose vehicle control|Once weekly subcutaneous injection of vehicle at a volume of 0.45 mL. Six weekly treatments; 28-day follow-up period.
45633625|NCT04286789|Drug|High dose ORTD-1|Two subcutaneous injections of ORTD-1 at two injection sites once weekly; 0.90 mL of ORTD-1 per each subcutaneous injection. Six weekly treatments; 28-day follow-up period.
45633626|NCT04286789|Drug|High dose vehicle control|Two subcutaneous injections of vehicle at two injection sites once weekly; 0.90 mL of vehicle per each subcutaneous injection. Six weekly treatments; 28-day follow-up period.
45633627|NCT02415517|Behavioral|Cognitive training|"Cognitive training on computer. Six sessions with different tasks: Tiere merken & Räumlich visuelles Training (application BrainTwister) and Taskswitching (programmed with eprime)"
45633628|NCT02415517|Behavioral|Test of general knowledge|Training of general knowledge on computer. Six sessions with different topics.
45633629|NCT05385263|Drug|Nivolumab Injection [Opdivo]|Nivolumab ( 3mg/kg IV) on day +5. If CAR-T expansion<100 cells/microL on day +7 one additional dose of nivolumab (3mg/kg IV) will be given on day +19
45772578|NCT02981381|Device|NEST-2|The open-label NeoSync EEG Synchronized TMS (NEST) that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device is distinct in both color and sound both SHAM and NEST-1 devices. PPMs corresponding with both SHAM and NEST-1 devices are compatible with the NEST-2 device.
45772579|NCT01680302|Behavioral|High intensity exercise|
45772580|NCT01680302|Behavioral|Moderate intensity exercise|
45772581|NCT01680302|Behavioral|Control|Advised to follow current guidelines for physical activity, but exercise on their own.
45914058|NCT02029794|Procedure|visual inspection with acetic acid (VIA)|
45633630|NCT00706147|Drug|Arimoclomol|Drug: Arimoclomol capsules given three times per day
45633631|NCT00706147|Drug|Placebo|Drug: Placebo capsules given three times per day
45633632|NCT05384561|Other|Smell training|For 12 weeks, morning and evening, smell four different odors or four odorless substances for a total of five minutes per session.
45914059|NCT02029794|Drug|3-5% acetic acid|
45914060|NCT02029820|Device|RenalGuard|Intravenous saline hydration matched with urine output, using the device Renalguard
45914061|NCT02029859|Procedure|Polygraphic examination|Polygraphic examination between 30 and 36 weeks of amenorhea
45914062|NCT02029885|Device|Investigational Therapy (Surround Sound)|
45914063|NCT02029885|Device|Sham Control|
45914064|NCT02029898|Drug|Remifentanil|
45633633|NCT03180229|Drug|Granisetron 1 Mg/mL Intravenous Solution|1 milligram (mg) will use on group Granisetron before 5 min induction
45633634|NCT03137849|Other|Yoga Poses|Yoga poses routine including specific muscles contractions known as bandhas (pelvic floor, core and throat/neck contraction) within each pose, which are advised to be done with steadiness and comfort.
45633635|NCT03137849|Other|Breath Control|"Ujjayi pranayama (Victorious breath) Inhalation and exhalation are both done through the nose. The ocean sound is created by moving the glottis as air passes in and out. As the throat passage is narrowed so, too, is the airway, the passage of air through which creates a rushing sound. The length and speed of the breath is controlled by the diaphragm, the Strengthening of which is, in part, the purpose of ujjayi. The inhalations and exhalations are equal in duration."
45633636|NCT03137849|Other|Stretching exercises|Stretching exercises routine based on dynamic and static exercises excluding those similar to yoga poses. This routine works on great range of motion of all body joints and main muscles groups/ chains.
45772582|NCT05002816|Drug|Elotuzumab|Elotuzumab will be administered via intravenous infusion at an established dose of 10 mg/kg on days 1, 8, 15, 22 every 28 days for cycles 1 and 2, followed by 20mg/kg on day 1 of each cycle thereafter, cycles repeated every 28 days.
45772583|NCT05002816|Drug|Belantamab mafodotin|Belantamab mafodotin will be administered via IV infusion. There will be 2 dose levels for belantamab mafodotin, with the starting dose of 1.9 mg/kg IV at every 4 week interval. Up to 12 subjects will be treated at this dose level. If the initial dose is found to be too toxic, dose of belantamab mafodotin 1.9 mg/kg every 8 weeks will be teste
45772584|NCT01676402|Biological|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 4 mg dosage is administered as a 1 mL volume.
45772585|NCT01676402|Biological|TIV|2012/13, 2013/14 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
45772586|NCT01670006|Device|Cochlear Nucleus Cochlear Implant System|
45772587|NCT01052831|Drug|Naltrexone|50-100 mg qd for 8 weeks
45772588|NCT01052831|Drug|Placebo|50-100 mg qd for 8 weeks
45914065|NCT02029898|Drug|sodium chloride 0,9%|
45633637|NCT03180151|Procedure|piezotome assisted orthodontic tooth movement|"Surgical procedure~After local anesthesia, vertical interproximal incisions will be done under the interdental papilla, on the labial aspect of upper arch using a blade No. 15.~The incisions will be kept minimal.~The incisions go though the periosteum, which permit the blade to reach to the alveolar bone.~A Piezo surgical knife will be used to make the cortical alveolar incision through the gingival incisions to a depth of approximately 3mm.~As we will not use bone graft so we don't need use suturing after cortication.~We give patient antibiotic and analgesic cover."
45633638|NCT05375435|Drug|triple therapy|high-dose glucocorticoids + cyclophosphamide + calcineurin inhibitor
45633639|NCT05375435|Drug|dual-therapy|high-dose glucocorticoids + cyclophosphamide/calcineurin inhibitor
45633640|NCT03178123|Biological|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
45633641|NCT03178123|Biological|high-dose recombinant interferon a-2B|15*10^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 15*10^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
45633642|NCT02423551|Other|MRE|MRE consumption
45633643|NCT03820817|Drug|Rifaximin|Given PO
45633644|NCT05111197|Radiation|SRT|"Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy are treated with SRT, in addition to their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.~A maximum of 3 Brain metastases treatable in stereotactic radiotherapy will be included among these hypermetabolic lesions.~Each lesion is treated with a total dose of 24 Gy delivered in 3 fractions of 8 Gy (isodose surface)."
45652958|NCT05138991|Procedure|Echocardiogram Recording|Undergo assessment via echo
45772589|NCT01005368|Genetic|fluorescence in situ hybridization|
45772590|NCT01005368|Genetic|mutation analysis|
45772591|NCT01005368|Genetic|nucleic acid sequencing|
45772592|NCT01005368|Genetic|polymerase chain reaction|
45772593|NCT01005368|Genetic|western blotting|
45772594|NCT01005368|Other|flow cytometry|
45772595|NCT01005368|Other|laboratory biomarker analysis|
45772596|NCT04330300|Drug|Thiazide or Thiazide-like diuretics|Anti-hypertensive (Active Arm)
45772597|NCT04330300|Drug|Calcium Channel Blockers|Anti-hypertensive (Active Arm)
45772598|NCT04330300|Drug|ACE inhibitor|Anti-hypertensive (Control Arm)
45772599|NCT04330300|Drug|Angiotensin receptor blocker|Anti-hypertensive (Control Arm)
45772600|NCT04352855|Drug|Ceftolozane/tazobactam|Administration
45772601|NCT04782128|Biological|RC28-E injection|a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
45772602|NCT05100875|Behavioral|"Social Skills and Emotion Regulation Training SSERT"|The SSERT intervention will broadly consist of the following 10 modules: (1) Introducing the Participant to Treatment; (2-3) Emotional Awareness and Recognition; (4-5) Emotion Regulation and Understanding Emotions in the Context of Psychotic Experiences; (6) Living an Emotionally Engaged Life; (7) Understanding Relationship Patterns in the Context of Psychosis; (8) Changing Undesirable Relationship Patterns; (9) Learning to have agency in Relationships; and (10) Flexibility in Relationships and Transitioning to Trauma-Focused Therapy.
45772603|NCT00995150|Drug|LNG20|levonorgestrel-releasing intrauterine system for contraception
45772604|NCT00995150|Drug|Mirena|Mirena intrauterine system
45772605|NCT00382642|Drug|Ondansetron + Cognitive Behavioral Therapy|13 week outpatient trial
45772606|NCT00382642|Drug|Placebo + Cognitive Behavioral Therapy|13 week outpatient trial
45772607|NCT01054079|Other|laboratory biomarker analysis|Correlative study
45772608|NCT01054079|Procedure|quality-of-life assessment|Ancillary study
45914066|NCT02029924|Drug|BioChaperone insulin lispro|Single dose of 0.2 U/Kg body weight injected subcutaneously (under the skin)
45633645|NCT05111197|Drug|Immunotherapy|Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy continue their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.
45633646|NCT03138005|Other|target SpO2 98-100%|Prehospital, post-ROSC oxygen maintained at ≥10L/minute of oxygen (equivalent to ~100% oxygen) into SGA/ETT if hand ventilated or 100% (i.e. FiO2 of 1.0) oxygen settings if mechanically ventilated. Patients will continue on treatment to handover in the ED. Between arrival at ED and first ABG in ICU, the oxygen setting may then be decreased provided SpO2 is maintained between 98-100%.
45633647|NCT03138005|Other|target SpO2 90-94%|Prehospital, post-ROSC oxygen reduced initially to 4L/minute (i.e. approximately 70% oxygen) into SGA/ETT if hand ventilated or an air mix setting if mechanically ventilated. If oxygen saturation remains ≥94% for 5 minutes, the oxygen flow rate will be further reduced to 2L/minute (i.e. approximately 46% oxygen) and hand ventilated to target an oxygen saturation between 90-94%. This treatment will continue to patient handover in the emergency department. Between arrival at ED and first ABG in ICU, oxygen will be titrated to target a oxygen saturation of 90-94%.
45633648|NCT05106517|Drug|Denosumab|Denosumab 60mg/6 months subcutaneously + placebo iv
45633649|NCT05106517|Drug|Zoledronic acid|Iv zoledronic acid and placebo /6 months subcutaneously
45633650|NCT02415361|Other|Cleft lip and palate|Comparison between Arm A who will receive standard care and Arm B who will receive systematic follow up performed by a special trained nurse will be performed.
45633651|NCT03140033|Drug|Misoprostol Oral Tablet|at cord clamping the patient will recieve 400 micrograms of misoprostol sublingually
45633652|NCT03140033|Drug|Ranitidine Oral Tablet|at cord clamping the patient will recieve ranitidine sublingually
45633653|NCT02415283|Device|¹³C-Octanoate Breath Test|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
45633654|NCT03622697|Behavioral|Mindfulness Meditation Phone Application|Mindfulness meditation intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for at least 4 weeks with periodic survey assessments using validated psychometric tools.
45633655|NCT01992094|Biological|QIVc|Novartis Investigational Quadrivalent Vaccine
45633656|NCT01992094|Biological|TIV1c|Licensed Influenza Vaccine
45633657|NCT01992094|Biological|TIV2c|Novartis Investigational Vaccine
45633658|NCT05347043|Other|Montreal cognitive assessment|Montreal cognitive assessment and standardized neuropsychological evaluation (Test of Attentional Performance of Zimmermann and Fimm ; Wechsler Adult Intelligence Scale 4th version digit span ; Wechsler memory scale III, spatial span ; Wisconsin Card Scoring Test, GREFEX version ; Wechsler Adult Intelligence Scale 4th version block design ; Six elements test GREFEX version; free and cued selective reminding test, 16 items, B version ; Behavioral Rating Inventory of Executive Function ; Modified Fatigue Impact Scale)
45633659|NCT03177967|Behavioral|Sleep Restriction Therapy/Stimulus Control|Sleep Restriction Therapy focuses on forcing your available sleep time into a fixed window. The sleeper sets a bedtime and wake-up time and sticks to those times closely. The time allocated for being allowed in bed is determined from an estimate of how long the patient in average has been sleeping during the night, in the week before treatment. The goal is to have the patient sleeping the entire time he or she is in bed by making this period so restricted that the patient has no chance of sleeping enough. Once this goal is achieved, the time allocated for bed can be slowly increased, for example by 15 minutes at a time. After enough iterations, an equilibrium is achieved that the patient can keep maintaining after treatment has completed.
45633660|NCT03177967|Other|Discussions about adverse cognitions about sleep|Group discussions about insomnia, CBT-i treatment and it's effects
45633661|NCT03177967|Other|Psychoeducative advice about how to improve sleep|Learning about sleep and sleep hygiene tips. It also includes learning about stimulus control and sleep restriction.
45633662|NCT05338931|Drug|AT101(Anti-CD19 Chimeric Antigen Receptor T cell)|Anti-CD19 Chimeric Antigen Receptor T cell
45633663|NCT02414893|Procedure|Sleeve gastrectomy|Laparoscopic vertical gastrectomy as a bariatric procedure.
45633664|NCT03507101|Other|No intervention|No particular intervention or exposure is of particular interest
45633665|NCT02706691|Drug|BGJ398|Given by mouth (oral)
46070103|NCT04676672|Device|Open repair|Open repair of the aortic arch and descending aorta with or without involvment of the ascending aorta using a hybrid graft.
46070104|NCT00657553|Drug|Bortezomib|Year 1:1.0 mg/m2. IV. Days 1, 4, 8, 11 every 4 weeks Year 2: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 8 weeks Year 3: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 12 weeks
46070105|NCT04675970|Other|Observational|Product in a Institute of Bio-Stem Cell rehabilitation UAB - sponsored clinical trial who agree to participate in this study
46070106|NCT05150977|Other|Polysomnography|Reviewing collected data
45633666|NCT03504137|Other|mHealth Intervention|The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
46070107|NCT04254068|Behavioral|Parent-based prevention|Parent-based prevention is a 12 session program for parents with eating disorders and their partners. Most sessions occur on a weekly basis, most of the sessions involve both partners.
45652959|NCT05138991|Other|Questionnaire Administration|Ancillary Studies
45652960|NCT05138991|Procedure|Stress Cardiac Magnetic Resonance Imaging|Undergo assessment via CMR
45772609|NCT01054079|Other|questionnaire administration|Ancillary study
46070108|NCT00807157|Dietary Supplement|PROBIOSTICK® during 30 days|Every morning subjects will consume a stick of PROBIOSTICK® during 30 days
46070109|NCT00807157|Dietary Supplement|Placebo during 30 days|Every morning subjects will consume a stick of placebo during 30 days
46070110|NCT04253912|Drug|VBP-245|2% Povidone-Iodine Gel
46070111|NCT04253912|Drug|Placebo Gel (no Povidone-Iodine)|Placebo Gel (no Povidone-Iodine)
45633667|NCT03177889|Combination Product|Traditional Chinese Medicine (TCM)|"Traditional Chinese Medicine plus oral mucolytics [ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid];~Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g~Optional formulae: bile arisaema 15g, polygala tenuifolia 15g, Mangnolia officinalis 10g, Fructus aurantii immaturus 10g; Magnetite 15-30g and reddle15-30g"
45633668|NCT02419729|Device|CO2 laser|SMARTXIDE2 V2LR (DEKA-Pulse) was used in each application using minimal parameters suggested by the laser's software ( Power of 30 W, 1000us emission time, 1000um spacing and a level of SmartStack 2)
45772610|NCT01054079|Drug|cinacalcet hydrochloride|Given PO
45772611|NCT00991094|Other|Quality-of-Life Assessment|Complete questionnaires
45772612|NCT00991094|Other|Questionnaire Administration|Complete questionnaires
45772613|NCT04338022|Drug|Evobrutinib|Evobrutinib twice daily (BID) in double-blind (DB) treatment period.
45772614|NCT04338022|Drug|Placebo (match to Teriflunomide)|Placebo match to Teriflunomide once daily in double-blind treatment period.
45772615|NCT04338022|Drug|Teriflunomide|Teriflunomide once daily in double-blind treatment period.
45633669|NCT02419729|Drug|Estrogen|Topical estrogen cream treatment: Estriol 1mg daily.
45772616|NCT04338022|Drug|Placebo (match to Evobrutinib)|Placebo match to Evobrutinib BID in double-blind treatment period.
45772617|NCT00975338|Other|LIFEspan|Rehabilitation services provided by an inter-disciplinary team of health professionals addressing the transfer of care to adult services and emerging needs related to transition to adulthood. LIFEspan staff are cross-appointed to both a pediatric and an adult hospital through a formally linked model of care.
45772618|NCT00975338|Other|Non-LIFEspan|Standard of care in the absence of a formal partnership between a pediatric and an adult hospital.
45633670|NCT02419729|Drug|Placebo of Estrogen|Placebo of topical estrogen cream.
45633671|NCT02419729|Device|Placebo of CO2 laser|SMARTXIDE2 V2LR (DEKA-Pulse) was used in each applications using minimal parameters suggested by the laser's software but power of 0.5 W was stipulated for the placebo intervention and other parameters remained unchanged.
45772619|NCT01054625|Biological|zalutumumab|Zalutumumab is a clear to opalescent liquid. It is intended for intravenous infusion following dilution in sterile, pyrogen free, 0.9% NaCl. Patients will be treated at a specified dose of Zalutumumab over a period of 7 weeks. The dose will be 4mg/kg, 8mg/kg or 16mg/kg depending on when they enter the study. The study will begin with 6 patients on 4mg/kg, then 10 patients on 8mg/kg and lastly 10 patients on 16mg/kg.
45772620|NCT01054703|Device|Ethmoid Sinus Spacer|Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
45914067|NCT02029924|Drug|Humalog®|Single dose of 0.2 /Kg body weight injected subcutaneously (under the skin)
45633672|NCT03136757|Other|Transcriptomic analysis of GVHD biopsies|"The transcriptomic analysis of GVHD biopsies aims at:~to demonstrate an evocative or even specific molecular profile, making the diagnosis of GVHD easier~to identify new intracellular signaling pathways that could lead to new therapeutic"
45652961|NCT05138991|Device|Wireless Synchronized Cardiac Function Monitoring Device|SphygmoCor® Xcel Oscar 2™ Ambulatory Blood Pressure Monitor
45772621|NCT02544750|Drug|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
45772622|NCT01662050|Drug|Rituximab, Bendamustine, Cytarabine.|6 cycles of 28 days with Rituximab, Bendamustine and Cytarabine (R-BAC). Rituximab 375mg/mq; Bendamustine 70mg/mq; Cytarabine 500mg/mq.
45772623|NCT04330456|Radiation|Preoperative stereotactic radiation therapy in hypofractionation mode|"At the first step patient undergoes preoperative stereotactic radiation therapy in hypofractionation mode. Radiation therapy plan is based on topometric MRI and CT scans. Radiation therapy plan are performed after MRI and CT fusion, contouring of the target and surrounding normal tissues.~At first step only tumor and, if necessary, the surrounding normal tissues, which will be removed during surgery, are exposed to radiation.~GTV - determined in with the boundaries of the tumor visualised by topometric MRI and CT CTV1 - match GTV CTV2 - formed inward (to the tumor center) from GTV by 0.5-1 cm (depending on the proximity of functionally significant normal tissues (neurovascular bundles, bone tissue, skin and subcutaneous fat, etc.) PTV - 3-5 mm indent from CTV1, taking into account the proximity of functionally significant normal tissues and the planned surgery Preoperative radiation therapy is carried in 5 fractions with a single dose on PTV - 5 Gy, a single dose on CTV2 - 7 Gy."
45772624|NCT04330456|Procedure|Surgery|In 14-21 days after preoperative stereotactic radiation therapy radical surgery will be performed
45772625|NCT04330456|Radiation|Postoperative conformal radiation therapy in normofractionation mode|"In 25-35 days after the surgery postoperative conformal radiation therapy is performed according to the standard protocol GTV (tumor bed) - based on the volume of the primary tumor, including the swelling zone (T2-weighted images on preoperative MRI) СTV - formed with an indent of 4 cm from GTV (without going beyond the boundaries of the involved compartment), in the transverse direction the indent could be reduced to 2 cm.~PTV - formed with an indent of 0.5-1cm from CTV An important condition for planning radiation therapy is to limit the dose absorbed during both stages of radiation therapy in surrounding normal tissues that are not removed during surgery."
45772626|NCT02654028|Procedure|Autotransfusion|These group of patients will receive autotransfusion before liver resection.
45772627|NCT02654028|Other|Control group|These group of patients will not receive autotransfusion before liver resection.
45772628|NCT04751734|Biological|Covid vaccines|women within Priority groups for coronavirus (COVID-19) vaccination
45772629|NCT02592330|Procedure|Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft|Cultivated autologous limbal epithelial cell (CALEC) therapy utilizes a bio-engineered composite of ex vivo expanded autologous corneal epithelial cells and an FDA-approved amniotic membrane (AmnioGraft®, Bio-Tissue, Inc.) to reconstruct the ocular surface. A small biopsy (2-3 mm2) from the patient's contralateral eye serves as a source epithelial (stem) cells that are expanded on the amniotic membrane in culture and the resulting product is surgically transplanted onto the cornea after excision of the fibrovascular pannus.
45935421|NCT00124267|Drug|Intrarectal quinine|
45935422|NCT00077844|Drug|Enoxaparin sodium|
45633673|NCT03176719|Other|Venipuncture|"Full blood count and leukocyte differentiation.~Detection of malaria parasites and parasite differentiation to trophozoites, gametocytes and ringstages (XN-30)~Detection of anemia, thallasemia and sickle cell anemia (XN-20)~Ex-vivo stimulation of wholeblood with various stimuli. Read-out will be a spectrum of cytokines (ELISA)~Circulating cytokines and inflammatory markers (ELIZA)~DNA analysis to assess genetic variations determining pro- versus anti inflammatory response including mTOR, HK2, PFKP, GLS, and GLUD1/2.~pan-Salmonella PCR~Gametocyte PCR"
45633674|NCT03697031|Drug|Follitropin Delta|"The Intervention (solution for injection) is delivered with an injection pen. For women with AMH <15 pmol/L the daily dose is 12 micrograms, irrespective of body weight. For women with AMH ≥15 pmol/L the daily dose decreases from 0.19 to 0.10 micrograms/kg by increasing AMH concentration. The maximum daily dose for the first treatment cycle is 12 micrograms.~For subsequent treatment cycles, the daily dose of REKOVELLE® should be maintained or modified according to the patient's ovarian response in the previous cycle. Based on the ovarian hypo/hyper-response in the previous cycle, the daily dose in the subsequent cycle should be increased (by 25% or 50%) or decreased (by 20% or 33%). The maximum daily dose is 24 micrograms."
45633675|NCT02414971|Other|There is no intervention|There is no intervention
45633676|NCT02729207|Drug|Esflurbiprofen Hydrogel Patch|One patch per day for 7 days
45772630|NCT02592330|Biological|Cultivation of Limbal epithelial cells into a graft|A graft is manufactured for transplant
45772631|NCT02592330|Procedure|CALEC Transplant|Limbal epithelial cells are obtained from the healthy fellow eye and cultivated in a lab for later transplantation into the diseased eye.
45633677|NCT02415049|Other|Incremental Feeds|This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
45633678|NCT02415049|Other|Ad lib feeds|This arm of patients will be fed ad lib following pyloromyotomy. They will be allowed to eat as frequently as they desire based on infant cues to a goal of 12.5ml/kg/feed
45772632|NCT02536092|Device|755nm and 1064nm Nd:YAG laser|Dual wavelength 755nm and 1064nm Nd:YAG laser
46070112|NCT02552797|Behavioral|Shared Decision Making tool|
45633679|NCT02709239|Dietary Supplement|DHA 200mg|4 50mg capsules of DHA to be taken by mouth daily
45633680|NCT02709239|Dietary Supplement|DHA 800mg|4 200mg capsules of DHA to be taken by mouth daily
45772633|NCT04748848|Drug|CC-90011|CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle. The dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design.
45772634|NCT04748848|Drug|Venetoclax|Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle with a brief dose ramp-up for Cycle 1 with the dosing of 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Venetoclax should be administered at 400 mg on subsequent days.
45772635|NCT04748848|Drug|Azacitidine|Azacitidine is administered on Days 1 to 7 of each 28-day cycle as an IV infusion or SC injection at 75 mg/m2
45633681|NCT01991470|Device|Enlite sensors|Subject wears enlite sensor first and followed by enlite 3 sensor.
45633682|NCT02419651|Drug|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
45633683|NCT02419651|Drug|Diclofenac|Women will receive 100 mg diclofenac 1 hour before the procedure
45633684|NCT02419651|Drug|Placebo|Women will receive a placebo 1 hour before the procedure
45633685|NCT02488655|Device|Echopulse|HIFU Under ultrasound guidance
45633686|NCT02414815|Device|Monophasic action potential(MAP) catheter|After ordinary procedure for electrophysiologic study or catheter ablation, the investigators will replace conventional catheter to monophasic action potential (MAP) recording catheter through right femoral sheath. MAP recording catheter is introduced to endocardial surface of atrium, and we record atrial MAP at variable pacing cycle lengths: steady state cycle lengths of 600, 400, 300, 240, 220, 240, 260, 300, 400 and 600 ms. At each cycle length, pacing was applied for 20 sec. It takes less than 5 min to acquire MAP recordings.
45633687|NCT05088239|Drug|prophylactic antibiotics duration|Prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative care. Different discontinued duration of antibiotics was divided to 3 groups in one day, 3 days and until to drain removal.
45633688|NCT02419261|Drug|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade for Arthroscopic surgical repair of the anterior cruciate ligament
45633689|NCT02419261|Procedure|Arthroscopic surgical repair of the anterior cruciate ligament|
45633690|NCT01991314|Drug|Ferrous sulphate|200mg tablets.
45633691|NCT03176641|Other|platelet-rich plasma|Autologous platelet-rich plasma gel applied during meniscus repair surgery
45633692|NCT03176641|Other|control|Meniscus repair surgery only
45652962|NCT04953767|Device|Blue light therapy|Blue light therapy has been proved its efficacy and safety is treatment circadian rhythm disorder as well as other diseases.
45652963|NCT04953767|Other|White light|White light is used as sham control.
45772636|NCT04748848|Drug|Venetoclax|Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle
45772637|NCT04748848|Drug|CC-90011|CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle at the recommended phase to dose of CC-90011 confirmed in dose escalation.
45772638|NCT04782206|Procedure|superior hypogastric plexus block|superior hypogastric plexus chemical neurolysis
45772639|NCT04782206|Procedure|pulsed radiofrequency at S3 root plus superior hypogastric plexus block|pulsed radiofrequency neuromodulation at S3 root plus superior hypogastric plexus chemical neurolysis
45772640|NCT02526342|Device|V.A.C. UltraTM (KCI®,San Antonio, Texas, USA)|Free muscle flaps are treated with Negative Pressure Wound Therapy (V.A.C. Ultra (KCI®,San Antonio, Texas, USA)) for five days following surgery with a continuous subatmospheric pressure of 125 mmHg.
45772641|NCT02171195|Drug|BIA 2-093|BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg
46070113|NCT04253600|Behavioral|Risk profile screening questionnaire|Families will be asked to complete a LimeSurvey questionnaire that aims at evaluating general risk profiles associated with DLD (e.g., no elevated risk, behavioral risk, environmental risk, familial risk), as well as our exclusion criteria (e.g., hearing deficit).
45633693|NCT03500471|Procedure|Robotic-assisted Total Gastrectomy|Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
45633694|NCT03500471|Procedure|Laparoscopic-assisted Total Gastrectomy|Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
45633695|NCT02414503|Drug|8IU intranasal oxytocin|
45633696|NCT02414503|Drug|24IU intranasal oxytocin|
45633697|NCT02414503|Drug|Placebo|
45633698|NCT02414503|Device|OptiNose Breath Powered Bi|
45633699|NCT03137615|Procedure|Pituitary surgery|Trans-sphenoidal resection of a pituitary gland lesion.
45633700|NCT03137615|Drug|local anaesthetic injection|The surgeon infiltrates the nasal septum with local anaesthesia as per usual practice. This consists of Moffet's solution and lidocaine with adrenaline (1:200,000).
45633701|NCT03137147|Behavioral|Intervention for Sleep and Pain in Youth|See arm description.
45633702|NCT03415061|Drug|Regular Insulin, Human 100 UNT/ML|40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
45633703|NCT03415061|Drug|Normal Saline Flush, 0.9% Injectable Solution|Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
45633704|NCT03136211|Behavioral|EIRA intervention|Individual intervention has an average intensity between 2 and 3 visits; if necessary, professionals have the freedom to make a greater number of visits. Group intervention is carried out through health education workshops. These workshops take place 15-20 days after initiating the individual intervention and they are conducted by primary care providers in the health center. A group of 12-15 people attend in each workshop. Community intervention focuses mainly on the social prescription of resources and activities that are carried out in the community where the participant person resides. In addition the intervention has the support of information and communication technologies, such as a web addressed to the participant, a mobile app or the sending personalized text messages.
45633705|NCT03275831|Device|PluroGel|Surfactant based gel
45772642|NCT02171195|Drug|Placebo|Identical placebo administered as oral tablets with 200 ml potable water.
45772643|NCT04739878|Procedure|Airway Ultrasound|Comparison between Airway ultrasound and CT cervical
45772644|NCT04782440|Other|Telerehabilitaton|Patients will receive telerehabilitation sessions that include strengthening, stretching and range of motion exercises
45772645|NCT04782440|Other|Home exercise|Patients will be given a home-based exercise program without telerehabilitation supervision
45772646|NCT05453058|Diagnostic Test|plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort|"Biomarker assessments are mandated in this protocol (i.e., they are not expected to be done as part of routine clinical practice).~These assessments will be conducted within the same time window as the observational assessments (at approx. 6-month intervals) and are mandated by protocol if not conducted as per clinical practice."
45772647|NCT00382798|Drug|RO5024048|
45772648|NCT04781738|Diagnostic Test|Cardiopulmonary exercise test|"CPET using a cycle ergometer (COSMED, Rome, Italy) beginning with no resistance warmup lasting 1-3 minutes followed with an incrementing resistance adapted to the patient's functional capacities according to the examiner's free judgment by successive stages~Six minute walk test - patients will be instructed to walk as far as possible for six minutes in a 30-meter long enclosed corridor with a flat and hard surface, marked at every meter. Meters will be calculated at the end of the test.~SF-36 is a questionnaire that contains eight domains - physical functioning (10 items); role limitations due to physical functioning (4 items); role limitations due to emotional problems (3 items); energy and vitality (4 items); mental health (5 items); social functioning (2 items); bodily pain (2 items); and general health perceptions (5 items).~Scores are summed for each domain and were transformed into scores of between 0 (worst possible health state) to 100 (best possible health state)."
45772649|NCT03015155|Procedure|Infusion of Cold Saline into Local Infarction Myocardium.|Infusion of Cold Saline into the Area of Ischemic Myocardium by Using Aspirated Catheter Before the Ischemia/reperfusion.
45772650|NCT01620788|Drug|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 50mg, oral, a day
45772651|NCT01620788|Drug|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 100mg, oral, a day
45772652|NCT01620788|Drug|Hyzaar®|1 tablet of Hyzaar®, oral, a day
45772653|NCT01620788|Drug|Hyzaar®|1 tablet of Hyzaar®, oral, a day
45772654|NCT04983628|Other|Tumor molecular profiling|targeted DNA NGS
45772655|NCT03014843|Drug|Naloxone|20µg/kg/h intravenous infusion after 0.4mg bolus of Naloxone and 0.6mL IM NaCl (0.9%) injection (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
45633706|NCT03275831|Device|Intrasite gel|Hydrogel
45633707|NCT03160235|Radiation|Magnetic resonance imaging|
45772656|NCT03014843|Drug|Methylnaltrexone Bromide|12mg/0.6mL subcutaneous injection and 1mL bolus of NaCl (0.9%) followed by intravenous infusion (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
45772657|NCT03014843|Other|Placebo|0.6 mL of NaCl 0.9% will be injected IM and 1mL bolus injection of NaCl(0.9%) will be administered IV followed by IV NaCl 0.9% infusion
45772658|NCT02540538|Biological|HBVaxPro|3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.
45772659|NCT02540538|Biological|HBAI20|2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.
45772660|NCT05081375|Drug|Enoxaparin Injectable Product|Not holding prophylaxis dose prior to surgical procedure
45772661|NCT05081375|Drug|Sodium chloride|Holding prophylaxis dose of Enoxaparin replacing with placebo
45633708|NCT03160235|Device|EEG|
45633709|NCT03160235|Device|NIRS|
45633710|NCT05088083|Device|Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon|After predilation, using drug-coated balloon catheter to cover the whole treated segment
45633711|NCT03110159|Drug|Levulan® Kerastick®|Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light
45633712|NCT03110159|Drug|BLU-U Blue Light Photodynamic Therapy|3 hours after Levulan® Kerastick® for Topical Solution is applied blue light illumination of designated area will be performed using the standard FDA approved treatment time of 16 minutes 40 seconds.
45633713|NCT05088005|Procedure|Hyperbaric oxygen therapy|Patients with any symptoms and signs were treated with HBO2. During the first HBO2, initial compression was performed to 2.8 atmospheres absolute (ATA) for 45 min, followed by 2.0 ATA for 60 min. If an additional HBO2 was possible within 24 h, then 2.0 ATA was administered for 90 min.
45633714|NCT01990768|Drug|1 gram Tranexamic Acid (TXA)|TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
45772662|NCT02201628|Device|Nasopharyngeal and oesophageal temperature probes|
45772663|NCT04980898|Device|WoundEL medical device|"The WoundEl system is composed by: a class IIa device , a class IIb dressing electrode and a class I disperser electrode.~Applied to the leg ulcer, WoundEL® reproduces the endogenous electrical current to stimulate all the factors contributing to healing. Electrical current is evenly spread over the Dressing Electrode which also maintains a moist wound healing environment."
45772664|NCT04980898|Other|Standard cares|Cleaning and monitoring
45772665|NCT04755062|Behavioral|Micronutrient-dense plant-rich Intervention|"The mNDPR dietary protocol is designed to be (1) micronutrient rich (i.e., high in plant-derived phytochemicals, antioxidants, vitamins, and minerals); (2) nutritionally adequate and diverse; (3) hormonally favorable, avoiding carbohydrates with a high glycemic index that could elevate levels of serum insulin and minimizing animal protein that may invoke an inflammatory response; and (4) encourage intake of regular meals, limited consumption of snacks, and an overnight fast of at least 12 hours. The calorie breakdown of the diet is derived from approximately: 30-60% vegetables, 10-40% beans/legumes, 10-40% fruit, 10-40% seeds/nuts, 20% whole grains, no more than 10% naturally raised and wild animal products, poultry, eggs, fish, dairy, oil and white potatoes."
45772666|NCT03911531|Diagnostic Test|Whole Exome Sequencing|Whole exome sequencing (WES) provides more detailed information through greater resolution, identifying single base-pair changes and small insertions and deletions. WES performs sequencing on the protein-coding exons, which are contained in 1-2% of the genome but make up over 85% of all known pathogenic mutations.
45772667|NCT03911531|Diagnostic Test|Whole Genome Sequencing|Whole Genome Sequencing (WGS) has emerged in recent years as a diagnostic tool that sequences the entire genome and can pick up insertions or deletion of bases, structural variants and intronic single nucleotide variations.
46070114|NCT04253600|Procedure|Investigation of the neural correlates of DLD using Magnetic Resonance Imagery (MRI)|MRI data acquisition will take place during natural sleep in infants aged from 6 to 12 months. First, families will have to complete a security questionnaire to make sure that neither the children nor the accompanying parent have any known contraindication preventing the MRI session and that none of them is wearing any ferro-magnetic elements. Then, families will be welcomed in a calm and child-friendly environment where we will propose them some preparatory games known to facilitate sleep in children. MRI protocol will comprise structural and functional images and won't exceed 30 minutes.
46070115|NCT04253600|Behavioral|Online investigation of predictive factors associated with DLD and LANCOM app development|Parents will be asked to complete a series of online questionnaires every six months. Questionnaires will be created on LimeSurvey and will include different questionnaires, scales, and observations that aim at evaluating children's development, and especially language development, as well as parental and environmental characteristics.
45633715|NCT01990768|Drug|2 grams TXA|TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
45633716|NCT01990768|Drug|0.9% Sodium Chloride injectable|Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival. No active drug is added to the solution.
45633717|NCT03002207|Device|Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
45772668|NCT04284436|Behavioral|Treadmill walking|Treadmill walking 4 days per week for 30 minutes in the target heart rate
45772669|NCT03014531|Other|almond|
45772670|NCT03014531|Other|high-carbohydrate control food|
45772671|NCT04754906|Other|Sequence 1|perform arm movements towards a target
45772672|NCT04754906|Other|Sequence 2|judge the verticality of an object
45772673|NCT04754906|Other|Sequence 3|In standing position, point as quickly as possible with the right arm at the diode that will light up in front of the participant.
45772674|NCT04754906|Other|Sequence 4|Composed of 5 sessions of about 15 minutes each (5 consecutive days), it will be required to perform a walking test (10 meters) in 3 different conditions and a manual dexterity test. Participants will be asked to imagine carrying out these tests during the training sessions.
45772675|NCT04754906|Other|Sequence 5|Composed of 5 sessions of about 20 minutes each (5 consecutive days), it will be asked to perform pointing movements of the arm. It will be asked to imagine these movements during training sessions.
45633718|NCT03002207|Procedure|The defect is sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect is sutured after discectomy.
45652964|NCT05614427|Diagnostic Test|Innova Lateral Flow Test|Lateral flow test performed on anterior nasal or buccal swabs
45633719|NCT05087459|Drug|Avatrombopag|On the basis of conventional treatment, Avatrombopag was added, 30×10^9/L < platelet count < 50×10^9/L patients received Avatrombopag 60mg/d, 50×10^9/L≤ platelet count < 75×10^9/L patients received Avatrombopag 40mg/d for 5 consecutive days, and waited for a period of time after drug withdrawal.Surgery is expected to take place on day 10-13 of the initial dose.
45633720|NCT01990612|Procedure|Elective Induction of Labor|Women randomized to induction of labor will undergo induction via oxytocin at 39 weeks 0 days to 39 weeks 4 days. Those with an unfavorable cervix (modified Bishop score < 5) will first undergo cervical ripening (method left to the discretion of the patient's physician) in conjunction with or followed by oxytocin stimulation unless a contraindication arises.
45633721|NCT02851511|Behavioral|Cognitive Training|Cognitive Training employs an eight component, PositScience BrainHQ suite via its researcher portal.
45633722|NCT02851511|Device|tDCS (active stimulation)|A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm x 7cm sponges (8cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (10-20 system).
45633723|NCT02851511|Device|tDCS (sham stimulation)|Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
45633724|NCT02851511|Behavioral|Educational Training|Educational training involves watching educational videos produced by the National Geographic Channel, which cover a range of topics such as history, nature, and wildlife. Participants will be asked to complete questions on the content of the videos to ensure sustained attention.
45633725|NCT05086991|Other|Follow up|like group descriptions
45633726|NCT05228327|Device|Occlusal splint treatment|Occlusal splint was made for 16 patients and they used just this occlusal splint for 3 months.
45633727|NCT05228327|Procedure|Masticatory muscle injection|Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Injection was repeated 3 times, once a week.
45633728|NCT05228327|Combination Product|Combination of occlusal splint and masticatory muscle injection treatments|Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Occlusal splint was also made and they started to use the day which first injection was made. And continue to use the occlusal splint for 3 months. Injection was repeated 3 times, once a week.
45633729|NCT05086601|Procedure|colorectal cancer surgery|Any surgery for primary tumor of colorectal cancer, including palliative resection, simple bowel stoma and exploratory surgery.
45633730|NCT02624765|Drug|Digoxin (monotherapy)|Oral or IV loading dose: 0.5 mg q 12 h (total 4 doses over 48 hours) followed by Oral maintenance dose: 0.25 mg-1mg/day
45633731|NCT02624765|Drug|Sotalol (monotherapy)|Oral dose: 80 mg TID or 120 mg BID (240 mg/day)
45633732|NCT02624765|Drug|Flecainide (monotherapy)|Oral dose: 100 mg TID (300 mg/day)
45633733|NCT02624765|Drug|Digoxin (dual therapy)|Oral or IV loading dose: 0.5 mg q 8 h (total 4 doses over 32 hours) followed by oral maintenance dose: 0.25 mg-1mg/day
45633734|NCT02624765|Drug|Sotalol (dual therapy)|Oral dose: 160 mg BID (320 mg/day)
45633735|NCT02624765|Drug|Flecainide (dual therapy)|Oral dose:100 mg TID (300 mg/day)
45633736|NCT05086367|Other|Diaphragmatic and pursed lip breathing|Breathing exercises were performed. Two breathing techniques were applied to the participants. Diaphragmatic and pursed lip breathing were intervened along with routine physical therapy.
45633737|NCT05086367|Other|Routine Physical Therapy|Routine physical therapy exercises were performed in which neck isometrics and neck range of motion exercises were performed
45772676|NCT03908879|Procedure|Standard intraosseous (IO) catheter confirmation procedure|The physician will evaluate the ability or inability of the intraosseous (IO) catheter to stand upright unassisted, the ability or inability to aspirate blood or bone marrow from the IO catheter, and whether or not there is visible or palpable extravasation of infusate from the IO catheter insertion site or surrounding subcutaneous tissue during IO catheter use.
45772677|NCT03908879|Procedure|Color flow Doppler intraosseous (IO) catheter confirmation procedure|The high frequency probe of a portable ultrasound with color flow Doppler is placed adjacent to the intraosseous (IO) catheter, visualizing the IO space in long or short axis. Color flow Doppler signal will be turned on during IO use and the physician will determine if the Doppler signal is in the intraosseous space or the extraosseous space. Saved data of the ultrasound image will be reviewed independently by at least two blinded reviewers. If the conclusions from the blinded reviewers are discordant then a third blinded reviewer will evaluate the saved data.
45772678|NCT03908879|Procedure|Pressure transduction intraosseous (IO) catheter confirmation procedure|The intraosseous (IO) catheter will be attached to a pressure transducer to demonstrate a waveform on the telemetry monitor. Physicians will evaluate for the presence of a pulsatile waveform with objective measurements of a systolic pressure, diastolic pressure and mean pressure. Saved data of the waveform image will be reviewed independently by at least two blinded reviewers. If the conclusions from the blinded reviewers are discordant then a third blinded reviewer will evaluate the saved data.
45772679|NCT01895504|Device|ColoAssist|Screening colonoscopy with the test instrument
45772680|NCT01895504|Device|MEI|Colonoscopy with Olympus colonoscopes and MEI guidance
45772681|NCT03852797|Drug|Oxytocin|Oxytocin solution, 20nM concentration
45772682|NCT03852797|Drug|Ketamine|Ketamine in solution, 10-4M to 10-7M
45914068|NCT02029937|Drug|Proflavine, high resolution imaging|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
45914069|NCT02029950|Drug|Cytarabine|Given IV
45914070|NCT02029950|Drug|Daunorubicin Hydrochloride|Given IV
45914071|NCT02029950|Drug|Etoposide|Given IV
45914072|NCT02029950|Drug|Idarubicin Hydrochloride|Given IV
45914073|NCT02029950|Other|Laboratory Biomarker Analysis|Correlative studies
45914074|NCT02029950|Other|Pharmacological Study|Correlative studies
45914075|NCT02029950|Drug|Pomalidomide|Given PO
45914076|NCT02030171|Other|functionnal reeducation|Specific functionnal reeducation for chronic low back pain
45633738|NCT05090189|Other|Exercise Training|"The present intervention will consist of a 6-month long, twice-weekly, home-based, monitored exercise training program, with training sessions lasting around 40 minutes, with 48 sessions in total. The program will be delivered in the form of 6 x 4-week blocks, which will progressively increase in intensity and complexity, as the participants physical capacities develop. Additionally, and in addition with current physical activity guidelines, participants will be instructed to perform at least an additional 70 minutes of purposeful activities per week. Study trainers will discuss the content of these activities with each individual participant to facilitate selection of suitable activities (e.g., brisk walking, jogging, stair climbing or bike riding), but their selection will be left to the discretion of the individual participants, and activity logs will be maintained throughout the study period."
45633739|NCT05086211|Other|proprioceptive neuromuscular facilitation|"Each session including three proprioceptive neuromuscular facilitation techniques:~Balance training exercises,participants will be treated for 20 minutes with PNF techniques that included;Rhythmic initiation, slow reversal techniques practiced with D1 and D2 pattern in lower limb,repeated contraction and Resisted PNF.The Technique will be performed for 3 days per week in same order on all subjects."
45633740|NCT05086211|Other|pertubation based balance training|Each session will include a 5-10min warm-up,voluntary tasks intended to induce internal perturbations,voluntary tasks combined with external perturbations and a 5-10mins cool down.The technique will be performed for 2 sets of 10 repetitions on all subjects
45633741|NCT05085587|Drug|Test|2 inhalations of Test and Reference product in each study period
45633742|NCT05085587|Drug|Reference|2 inhalations of Test and Reference product in each study period
45633743|NCT01990534|Drug|Brentuximab Vedotin|Brentuximab vedotin IV infusion
45633744|NCT05085509|Procedure|US guidance and MB staining|Ultrasound guidance and methylene blue staining
45633745|NCT05085431|Biological|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
45633746|NCT05085353|Procedure|non-obstetric acute general surgical disease|non-obstetric acute general surgical disease
45633747|NCT05084807|Other|Endoscopy|"A dyspepsia test will be performed to avoid selection bias. In subjects strictly asymptomatic, a blood analysis will be proposed.~Subjects who present strictly normal laboratory tests (including celiac serology and negative H Pylori tests) and no genetic risk of celiac disease will be invited to perform an upper gastrointestinal endoscopy.~During gastroscopy, samples of normal mucosa will be taken for histological and lymphocyte subpopulations analysis. The percentage of lymphocyte subpopulations will be assessed by flow cytometry.~To compare whether there are differences between the lymphocyte subpopulations related to the age and sex of the healthy individuals, a student's t test, ANOVA or the corresponding non-parametric test will be used. The values will be expressed according to: mean +/- 2DS or median and interquartile range."
45633748|NCT05089097|Other|evaluation of delirium with CAM-ICU Score|the CAM-ICU score is an evaluation tool to verify the presence or absence of delirium in a subject
45633749|NCT02414659|Procedure|Umbilical cord blood collection, in-utero|Umbilical cord blood was collected during cesarean, after delivery of the baby and after clamping of the cord. Blood was collected into a standard blood donation bag with (Capacity: 450 mL) a 16 G venipuncture needle. Needle was left in place after umbilical vein is collapsed and no more blood flow happens spontaneously.
45633750|NCT05085743|Diagnostic Test|Deep convolutional neural networks analysis|using Deep convolutional neural networks to analyze pre-intubation chest radiographs along with patients' data to predict the proper depth of ETT fixation
45633751|NCT05084573|Drug|Liposomal bupivacaine|Single bolus injection 10mL 1.33% LB
45633752|NCT05084573|Drug|Standard bupivacaine|Single bolus 10mL 0.25% SB + continuous 300mL 0.2% SB @5mL/hr
45633753|NCT03136289|Behavioral|Family Consumer Behaviors|The relationship between family consumer behaviours (healthy food availability and supermarket spending) and adolescent prediabetes and diabetes.
45633754|NCT05069753|Procedure|Immediate sequential bilateral cataract surgery (ISBCS)|Surgery on both eyes will be performed on the same day as separate procedures: Once surgery on the first eye is completed, a new sterile procedure on the second eye will commence.
45772683|NCT03852797|Drug|Propofol|Propofol in solution, 10-4M to 10-7M
45772684|NCT03852797|Drug|Etomidate|Etomidate in solution, 10-4M to 10-7M
45633755|NCT05069753|Procedure|Delayed sequential bilateral cataract surgery (DSBCS)|The group will undergo bilateral cataract surgery on two separate days with a time period of one week between the two procedures.
45633756|NCT05088707|Drug|sublingual misoprostol|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
45772685|NCT00900224|Genetic|DNA analysis|
45772686|NCT00900224|Genetic|DNA methylation analysis|
45772687|NCT00900224|Genetic|gene expression analysis|
45772688|NCT00900224|Genetic|mutation analysis|
45772689|NCT00900224|Genetic|polymerase chain reaction|
45772690|NCT00900224|Genetic|reverse transcriptase-polymerase chain reaction|
45772691|NCT00900224|Other|high performance liquid chromatography|
45772692|NCT00900224|Other|laboratory biomarker analysis|
45772693|NCT01055171|Drug|Propranolol|40 mg; Single Administration.
45772694|NCT01055171|Drug|Placebo|40 mg; Single Dose.
45772695|NCT04941053|Diagnostic Test|laboratory test|seroprevalnce
45772696|NCT04714996|Drug|ES-481|"Treatment Period Week 1 - 25 mg qd, Week 2 - 25 mg bid, Week 3 - 50 mg bid, Week 4 - 75 mg bid.~Step-down and Washout Period Day 1 - 125 mg, Day 2 - 100 mg, Day 3 - 75 mg, Day 4 - 50 mg, Day 5 - 50 mg, Day 6 - 25 mg, Day 7 - 25 mg, Days 8 to 14 - 0 mg"
45772697|NCT04714996|Drug|Placebo|Placebo on Week 1, Week 2, Week 3 and Week 4
45772698|NCT04714996|Drug|Open-Label Extension Study|Dosing will be at the discretion of the Investigator with a minimum dose of 25 mg/day (25 mg qd) to a maximum dose of 150 mg/day (75 mg bid).
45633757|NCT05088707|Drug|vaginal misoprostol|"All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic"
45633758|NCT01967134|Biological|H56:IC31|H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
45633759|NCT05028257|Biological|COVID-19 Vaccines|Pursuit of vaccination in case of anaphylactic reaction
45633760|NCT04678882|Drug|Placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous (SC)
45633761|NCT04678882|Drug|Dupilumab SAR231893|Pharmaceutical form:solution for injection Route of administration: subcutaneous (SC)
45633762|NCT05075057|Biological|Inactivated COVID-19 vaccine|three doses of inactivated COVID-19 vaccine
45633763|NCT01990300|Drug|Alogliptin/Pioglitazone|Alogliptin/Pioglitazone combination tablets
45633764|NCT05072639|Behavioral|Guided Meditation|23 minute audio recording
45633765|NCT03135977|Drug|Apatinib, Etoposide|Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
45633766|NCT01966432|Behavioral|Referral to Treatment|Patients receive a referral to treatment for substance abuse, with up to 2 follow-up phone calls. Patients are re-screened at followup visits.
45633767|NCT01966432|Behavioral|Brief Intervention|Patients receive a brief intervention aimed at reducing substance use, and are re-screened at followup visits.
45633768|NCT04937231|Other|Aerobic exercises|"For Week 1 and 2 : Treadmill 3-5days/weeks~Intensity:~50-70 vo2 peak Or HRR 60-80% Duration of 10-20 minutes For Week 3 and 4; Cycle ergometer 3-5days/weeks~Intensity:~50-70 vo2 peak Or HRR 60-80% Duration of 30-40 minutes"
45633769|NCT04937231|Other|Resistance exercises|"For Week 1 and 2; 2 x 10 rep (unilateral leg press) 4x 12 reps (Bilateral leg press~1 x 8 rep ( unilateral arm curls For Week 3 and 4; 1 x 10 reps Shoulder press~1 x15 rep Bilateral knee extension~1 x 10 reps Bilateral arm curls"
45633770|NCT04937231|Other|Combined training|For Week 1 and 2; Aerobic exercise on Treadmill along with dumbbell to perform upper limb exercises (biceps curls, side curls extensions, upright row, back fly) and used Thera band to perform lower limb exercises for 10-20 minutes For Week 3 and 4; Aerobic exercise on Treadmill along with dumbbell and Thera band to perform upper limb and lower limb exercises for 30-40 minutes
45633771|NCT03136133|Dietary Supplement|Active protein drink|Fish protein from cod to be used for man after Heavy excercise to restitute
45633772|NCT05036291|Drug|NB004 tablets|NB004 tablets will be administered orally once daily for repeated 28-day cycles until discontinuation criteria are met.
45633773|NCT05002439|Other|Multicomponent physical exercise program and a nutritional intervention|The exercise program will be delivered by trained experts in groups of 6 participants, and will be based on the recommendations presented in the Spanish Healthcare Ministry document. This program includes balance, flexibility, and strength and power exercises. The program will be realized twice a week, during 45 minutes time, for 16 weeks, twice a year. Nutritional intervention will be based on the results of MNA-SF. If the results of this instrument show normal nutrition status, general nutritional recommendations will de presented by a nutritionist twice a year before the physical exercise program. If MNA-SF shows nutritional risk or malnutrition, oral nutritional supplementation will be offered. Primary Care Physicians will have the opportunity of referring high risk participants to their Geriatrics Department Participants when appropriate, following Healthcare Ministry algorithm
45633774|NCT01966120|Drug|BF-200 ALA gel|BF-200 ALA was applied over 1-2 fields of approximately 20 cm² in total, allowed to dry for approximately 10 minutes, and covered with occlusive tape material for 3 h.
45633775|NCT01966120|Drug|Placebo to BF-200 ALA gel|The reference product was a placebo (a nanoemulsion gel formulation similar to the Investigational Medicinal Product (IMP), but without the active ingredient). The placebo was packaged, assigned to each patient, and administered in the same way as the IMP.
45633776|NCT01966120|Procedure|Photodynamic therapy with BF-RhodoLED|After cleaning the lesions, the entire treatment field(s) were illuminated using the novel narrow spectrum BF-RhodoLED lamp, a red light illumination source (approximately 635 nm) developed by Biofrontera, until a total light dose of 37 J/cm² (per treated field) was achieved.
45652965|NCT04089371|Device|ReUnion Total Shoulder Arthroplasty (TSA)|The ReUnion RFX System includes a Reversible Fracture Stem (RFX Stem) that can utilize either the ReUnion Total Shoulder Arthroplasty (TSA) or ReUnion Reverse Shoulder Arthroplasty (RSA) humeral and glenoid components and is indicated for use as a hemi, total or reverse shoulder replacement. The ReUnion RFX stem is intended for cemented use only.
45652966|NCT04089371|Device|ReUnion Reverse Shoulder Arthroplasty (RSA)|The ReUnion RFX System includes a Reversible Fracture Stem (RFX Stem) that can utilize either the ReUnion Total Shoulder Arthroplasty (TSA) or ReUnion Reverse Shoulder Arthroplasty (RSA) humeral and glenoid components and is indicated for use as a hemi, total or reverse shoulder replacement. The ReUnion RFX stem is intended for cemented use only.
45772699|NCT00888290|Drug|Sodium bicarbonate|Sodium bicarbonate at 3 different doses or placebo. The different doses tested will be: 0.3 mEq/kg of ideal body weight, 0.6 mEq/kg of ideal body weight and 1 mEq/kg pf ideal body weight
45772700|NCT00888290|Drug|Placebos|Placebo at 3 different doses to match Sodium bicarbonate dosing
45772701|NCT01057277|Drug|RAD001(Afinitor)|Rad001 in combination withCisplatin and Concurrent RT
45772702|NCT04697056|Drug|Imsidolimab|Humanized Monoclonal Antibody
45772703|NCT04697056|Biological|placebo|placebo
45772704|NCT00866840|Drug|riluzole|100 mg orally twice daily
45772705|NCT01057901|Drug|Flibanserin|Flibanserin 100mg administered at bedtime for 24 weeks
45772706|NCT01057901|Drug|Placebo|This is the matched placebo which will be administered two tablets daily at bedtime.
45914077|NCT02030236|Device|Cooling|Temperature reached Duration of exposure to cold.
45935423|NCT00043121|Drug|oxaliplatin|Given IV
45772707|NCT04755608|Other|Low Intensity Exercises with Blood Flow Restriction|In the exercise protocol, people exercised resistance between 20% and 30% of 1 MaxRepetition with free weight. In addition, blood flow was restricted in 70% of the arterial occlusion pressure of the individual with the help of a cuff during exercise.
45633777|NCT05378087|Radiation|Concurrent chemoradiation|Standard concurrent chemoradiation: A point/HCR-CTV D90 ≥80Gy (+20%) by using IMRT or TOMO technics. Patients with image-positive common iliac lymph nodes or para-aortic lymph nodes receive extended-field EBRT. Brachytherapy should begin after 15-20F external radiotherapy. A radiation dose for the image-positive nodes can range from 55Gy to 60Gy. Five cycles of concurrent platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period one week) and CCRT should be completed within 56 days. CCRT one week later, if the cervix biopsy shows residual tumour and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes in the pelvic and abdominal cavity, three cycles of adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy will be performed (A point/HR-CTV D90 ≤ 96Gy).
45633778|NCT05378087|Procedure|Open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation|Open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation. (height of lymph node dissection: At least the inferior mesenteric artery. Chemoradiation should be performed postoperatively within 28 days.) The chemoradiation is consistent with the image staging group, except for extended-field EBRT determined by pathological positive para-aortic lymph nodes.
45633779|NCT04928729|Other|Pursed Lip Breathing|PLB with frequency of three times daily for First 3 days of week for a duration of 5-10 mins is perform.
45633780|NCT04928729|Other|Pursed Lip Breathing +DB|PLB+DB with frequency of three times daily for Last three days of week for a duration of 10-15 mins is perform.
45633781|NCT04928729|Other|Conservative care|Participants will be having different dose as per tolerance 5 times daily.
45633782|NCT04850651|Drug|Pyrotinib；Fluconazole|"Drug: Pyrotinib Participants received a single oral dose of Pyrotinib tablet on the morning of day1 in treatment period 1.~Drug: Pyrotinib/Fluconazole In treatment period 2, Participants received a single oral dose of pyrotinib tablet on the morning of day9, and received a loading dose of fluconazole capsule on day6 followed by single dose of fluconazole for oral administration from D7 to D18."
45633783|NCT04837235|Drug|Hemay005|oral
45633784|NCT04767971|Device|Standard Colonoscopy|Colonoscopy with a standard colonoscope
45633785|NCT04767971|Device|G-EYE Colonoscopy|Colonoscopy with a G-EYE Colonoscope
45633786|NCT04829981|Device|SAFEWATER systems for drinking water disinfection|A domestic water purification technology, consisting of a raw water storage tank, a pump, a filtration unit (2 cartridge filters), a UVC disinfection unit (UV lamp), a storage tank for drinking water (treated and safe water), and a distribution network inside the house for drinking water.
45633787|NCT04829981|Behavioral|Behaviour change interventions|Targeting behaviors around the use of the technology and water more generally. Behavioral interventions will be data-driven (i.e., dependent on the problems that arise) but are likely to include household and community-level activities.
45633788|NCT02702401|Biological|Pembrolizumab|IV infusion
45633789|NCT02702401|Drug|Placebo|0.90% w/v sodium chloride IV infusion
45633790|NCT02702401|Other|Best Supportive Care|Best supportive care will include pain management and management of other potential complications including ascites per local standards of care.
45633791|NCT04736615|Device|SAFEWATER systems for drinking water disinfection|A domestic water purification technology, consisting of a raw water storage tank, a pump, a filtration unit (2 cartridge filters), a UVC disinfection unit (UV lamp), a storage tank for drinking water (treated and safe water), and a distribution network inside the house for drinking water.
45633792|NCT04736615|Behavioral|Behavior change interventions|Targeting behaviors around the use of the technology and water more generally. Behavioral interventions will be data-driven (i.e., dependent on the problems that arise) but are likely to include household and community-level activities.
45633793|NCT05738213|Device|Thermal stimuli|The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
45633794|NCT05738213|Device|Pressure stimuli|Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
45633795|NCT05738213|Behavioral|Pain ratings|Pain intensity and pain unpleasantness ratings will be assessed.
45633796|NCT05738213|Behavioral|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
45633797|NCT05738213|Behavioral|Conditioned pain modulation (CPM) response|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency. CPM testing includes the application of a test stimulus without conditioning (control run, pressure pain thresholds) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run, a 60 second of foot immersion in cold water). The CPM response is the difference in the pressure pain thresholds between the control and the conditioning runs."
45652967|NCT04010981|Other|study group|The treatment protocol will consist of Nintendo wii fit virtual reality exercises (yoga,aerobic exercises,muscle strengthening exercises)
45652968|NCT04010981|Other|control group|The treatment protocol will consist of home based video exercises ;yoga,aerobic exercises,muscle strengthening exercises
45772708|NCT04755608|Other|High Intensity Resistant Exercise|People included in the study did resistance exercise with free weight at 70-80% of 1 MT.
45772709|NCT04686916|Drug|IP2018|Test drug
45772710|NCT04686916|Drug|Placebo|Placebo
45772711|NCT04349722|Drug|Hyoscine Butylbromide|Intervention is given once a participant is in established labor
45772712|NCT04349722|Other|Placebo|Intervention is given once a participant is in established labor
45935424|NCT00043121|Drug|leucovorin calcium|Given IV
45935425|NCT00043121|Drug|fluorouracil|Given IV
45935426|NCT00043121|Drug|capecitabine|Given orally
45633798|NCT05738213|Behavioral|PedMIDAS (Pediatric Migraine Disability Assessment)|Adolescents with migraine will complete questions regarding their headache frequency. Migraine disability will be assessed using PedMIDAS (Pediatric Migraine Disability Assessment). This self-reported questionnaire assesses the number of days that headaches affect participant's daily activities. This is a widely used, reliable and validated tool to assess migraine disability.
45633799|NCT05738213|Diagnostic Test|Hormonal assessment|Blood samples (approximetly 2 tablespoons) will be collected for analyses of sex hormone levels (e.g., testosterone, estradiol, progesterone).
45633800|NCT05738213|Other|Pubertal status|Pubertal status will be assessed using the self-reported Physical Developmental Scale-Wave 3 survey, which allows for differentiation between pre-, early-, late-, and post-pubertal status. Early puberty is defined as a score of 3 and no menarche, mid-puberty is defined as 4 and no menarche, late pubertal is defined as a score of 7 points or less and with menarche, and post pubertal is defined as a score of 8 and menarche. For boys, pubertal maturation status will be determined by the Physical Development Scale using the body hair growth voice change and facial hair questions. Early puberty is defined as a score of 4-5, mid-puberty is defined as a score of 6-8, late pubertal is defined as a score of 9-11 points, and post pubertal is defined as a score of 12.
45633801|NCT02423707|Drug|ALK Alutard Birch and/or 5-grasses|"3 intralymphatic injections of 1000 SQ-U birch and/or grass allergen with 4 weeks interval.~The substance used for the three intralymphatic injections is ALK-alutard SQ Betula verrucosa® and ALK-alutard SQ 5-grasses ® under ATC-code V01AA, V04CL and V07AB which is a depot formulation for subcutaneous use."
45633802|NCT02423707|Drug|ALK Diluent|This placebo group will receive 3 injections of 0.3% human albumin instead of active substance
45772713|NCT01058993|Drug|AMD3100 or plerixafor|The study will examine the hematological effects/safety of plerixafor in patients with myelokathexis attributable to mutations of CXCR4. Plerixafor will be administered on days 1, 3, 5, 8, and 10. Five intrapatient escalating doses of AMD 3100, 20 micrograms per kilogram (mcg/kg), 40 micrograms per kilogram (mcg/kg), 80 micrograms per kilogram (mcg/kg), and 240 micrograms per kilogram (mcg/kg) will be examined in the patients at University of Washington General Clinical Research Center for up to 10 days, requiring subjects be available up to 14 days. Patients will be monitored for hematological effects of plerixafor and observed for adverse effects. If normal blood neutrophil count is achieved and maintained for at least 24 hours prior to highest dose, we will stop at that level.
45772714|NCT04677322|Drug|Adult patients diagnosed and treated for high blood pressure|Educational program interventions conducted by primary care staff to encourage adherence to a low-sodium diet consisting of direct action on the patient and provision of educational materials will be assessed. Compliance and follow-up of the low sodium diet will be done by monitoring the sodium in urine in the target population, selected according to the selection criteria described in the protocol.
45633803|NCT02423629|Device|Agili-C™ implantation procedure|Candidates for Agili-C™ implantation will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
45633804|NCT04729829|Behavioral|Social and behaviour change communication|Each SBC treatment community will receive nutrition content and learning through savings groups. The group members will participate in skill-building activities that promote five key behaviours about fish nutrition and household decision making on fish consumption as part of facilitated discussions, interactive learning sessions, and a video-based facilitated dialogue. Increased fish consumption through SBC mass attendance events through marketing of fish vendors, interactive learning, and edu-tainment competitions promoting fish consumption. SBC will raise awareness of the benefits of eating fish as part of a balanced diet, with a particular focus on pregnant and lactating mothers, and children under 5 years of age.
45914078|NCT02030249|Behavioral|Low calorie diet administered from 0 to 2 months|The 2-month low calorie diet is administered from the 0 months to the 2 months time point. It is designed to elicit a weight loss of 8% of initial body weight. Please see parent study for further intervention details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview&rank=1
45914079|NCT02030249|Behavioral|High Protein / Low Glycaemic Index|Please see description of the Arm by the same name.
45914080|NCT02030249|Behavioral|Moderate Protein / High Glycaemic Index|Please see description of the Arm by the same name.
45652969|NCT05191017|Drug|NUV-422|NUV-422 is an investigational drug for oral dosing.
46070116|NCT04253600|Behavioral|Individual behavioral and cognitive assessment|Individual cognitive and behavioral assessment will be scheduled once a year, around the child's birth date, and will comprise an extensive battery of standardized evaluation appropriate for the child's age. This individual evaluation will focus on several developmental aspects including language, psychomotor, behavioral and cognitive development, as well as executive and socio-emotional functioning, depending on the age of the children. Evaluations will be adapted to each child's specific profile, while respecting the following administration rules: (1) we will prioritize language development testing, (2) testing sessions will be adapted to each child's pace and possibilities, (3) if a child does not want to take part in the assessment, feels tired, or does not seem to be comfortable with the investigator, tests won't be administered.
45772715|NCT04652518|Drug|LYT-100|oral administration
45772716|NCT04652518|Other|Placebo|oral administration
45914081|NCT02030470|Other|Fotosan®630. LED lamp. Toluidinblue. Photoactivated disinfection|
45914082|NCT02030561|Drug|Trastuzumab + NK cells|
45772717|NCT01059305|Drug|Erlotinib|150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).
45914083|NCT02030730|Behavioral|Triple P Seminar Series|The intervention was delivered by the researcher and an accredited TripleP practitioner. The seminars took place in a conference room located within a bookshop. The seminars were re-offered for parents who could not attend the scheduled day.
45914084|NCT02031224|Behavioral|Conventional low protein diet|
45633805|NCT04729829|Other|Fish aggregating device|This is a moored line attached to buoys in coastal waters that attracts oceanic fish to it, to make it easier for small-scale fishers to catch them using their existing gear and boats. This FAD will work to increase the catch rate and hence, the availability of fish for sale in upland community markets.
45633806|NCT02419339|Procedure|Extravesical ureteral reimplantation|Extravesical ureteral reimplantation with or without tapering
45633807|NCT04719533|Other|Pre-marking of episiotomy location|A template marking the pre-determined correct location of episiotomy will be used to mark to women in the interventional group
45633808|NCT02419183|Other|SAMSTAR|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
45633809|NCT02419183|Other|RAVLT|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
45633810|NCT05737979|Other|Study chart review|Evaluation of the IVF cycle using the prescribed medication
45633811|NCT02419027|Dietary Supplement|GI Flora|
45633812|NCT02419027|Dietary Supplement|Placebo|
45633813|NCT04708301|Diagnostic Test|T1 mapping|T1 mapping is a specialised heart scan that measures the magnetic properties of heart tissue and displays them as an image or map
45633814|NCT03116971|Drug|M3814|Participants received M3814 PiC or hot melt extrusion (HME) tablet orally once daily in combination with etoposide (intravenously) and cisplatin for 6 cycles with each cycle lasting 3 weeks (21 days).
45633815|NCT03116971|Drug|Cisplatin|Cisplatin 75 milligram per square meter (mg/m^2) was administered over a 60-minute intravenous infusion on Day 1.
45633816|NCT03116971|Drug|Etoposide|Etoposide 100 mg/m^2 over a 60 minute IV infusion on Days 1-3 was administered for 6 cycles with each cycle lasting 3 weeks (21 days).
45772718|NCT04650490|Radiation|Stereotactic Radiosurgery|Timing of stereotactic radiosurgery relative to immunotherapy
45772719|NCT04650490|Drug|Immunotherapy|Physician's choice of immunotherapy per standard of care
45772720|NCT03850379|Drug|Levofloxacin|This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC >1000
45772721|NCT03850379|Drug|Ciprofloxacin|This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC >1000
45772722|NCT04649788|Device|Ultrasound-guided axillary vein access|Venous access is performed through ultrasound-guided axillary vein puncture and Seldinger technique. After venous access is obtained, a guide-wire is advanced through the access needle, and the tip of the guide-wire is positioned in the right cardiac atrium.
45633817|NCT05737901|Other|Education Booklet|"Training titles and contents were created by listing the most common complications and needs of patients after CABG surgery. In the General Information section of the booklet, the definition of CAD, how CABG surgery is performed, the length of hospital stay, and what can be experienced in the hospital after surgery and in the home environment after discharge were discussed. In the Postoperative Self-Care Practices section, information about the healing process of the breastbone, pain management, medication, respiratory exercises, early nutrition, personal hygiene, protection from coronavirus-19, pulse control, postoperative heart attack, conditions to be reported, compression stockings use for varicose veins, physical activity, travel, sleep and rest, sexual life, and coping with stress and depression was presented. In the Postoperative Life section, training topics on exercise, nutrition, smoking, and alcohol use were included."
45772723|NCT04649788|Device|Cephalic vein access|Venous access is performed through a cephalic vein cutdown approach. After venous access is obtained, a guide-wire is advanced and the tip of the guide-wire is positioned in the right cardiac atrium.
45633818|NCT05737901|Other|Mobile application|"The logo and content of the Bypass e-Discharge application was visually designed, and the software was developed. In-app transactions were secured with end-to-end encryption by entering the username and password, and internet access was not required to use the application. The application was presented for expert opinion (3 patients, 1 academician, 2 nurses, 2 physicians) in order to investigate the user experience, and edits were made on its interface (such as adding the acceleration feature in videos, an additional button for stopping and starting videos, displaying video total time on the screen, and magnification of all buttons)."
45633819|NCT03135743|Other|Show an increase in incidence of cancers in patients with synchronous lymphoma|Show an increase in incidence of cancers in patients with synchronous lymphoma
45633820|NCT02414581|Drug|chlorhexidine 0.12%/Ethyl alcohol 7%|Mouth rinses with chlorhexidine 0.12%-based solution
45633821|NCT02414581|Drug|Ethyl Alcohol 7%|Mouth rinses with Ethyl Alcohol 7%-based solution
45633822|NCT02414581|Drug|Chlorhexidine 2%/Ethyl alcohol 7%|Mouth rinses with chlorhexidine 2%-based solution
45633823|NCT04700267|Drug|GLPG3970 film-coated tablet|GLPG3970 for oral administration
45633824|NCT04700267|Drug|Placebo film-coated tablet|Placebo for oral administration
45772724|NCT04641832|Other|Soccer heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
45772725|NCT03014687|Drug|Placebo|PO BID placebo for 7 days. Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
45914085|NCT02031224|Dietary Supplement|Very low protein diet supplemented with Ketosteril|
45633825|NCT02419105|Drug|Testosterone|transdermal gel, 75 mg daily
45633826|NCT02419105|Drug|Colecalciferol|drink solution, 24000 IU once per month
45772726|NCT03014687|Drug|Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole|Oral antibiotics (cefdinir [Omnicef®] 300 mg PO BID or trimethoprim/sulfamethoxazole [Bactrim DS™] PO BID for cephalosporin intolerant patients) for 7 days.Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
45772727|NCT04296292|Other|In-depth interviews|In-depth interviews following a narrative line of enquiry and direct observation at each of the research sites
45772728|NCT04629274|Procedure|Blood sampling|The patients will be asked to provide at least 2 peripheral blood samples of approximately 100 milliliters each time, with a minimum of 14 days interval between these 2 samples.If the results obtained with the 2 initial samples would be of interest to the Sponsor, the patient will be asked to come back for additional samplings with a maximum of 6 additional blood draws
45772729|NCT03824405|Drug|BTX 1204|BTX 1204 liquid formulation
45633827|NCT02419105|Drug|Placebo drink solution|drink solution, 0 IU Colecalciferol once per month
45633828|NCT02419105|Drug|Placebo transdermal gel|transdermal gel, 0 mg testosterone daily
45633829|NCT03136991|Drug|AZD4831|Participants will receive AZD4831 once daily, orally, for a period of 10 days. Note: Additional doses (for cohorts 2,3&4) are provisional and could be adjusted based on the emerging data after the review of all available safety or other pertinent data from the previous dose by the Safety Review Committee (SRC).
45914086|NCT02031367|Drug|Triamcinolone Acetonide|Corticosteroid arm
45633830|NCT03136991|Drug|Placebo|Participants will receive placebo matching the AZD4831 dose, once daily, orally, for a period of 10 days.
45633831|NCT02414737|Drug|corifollitrophin alfa|use of a single dose of corifollitrophin alfa to provide adequate controlled ovarian hyperstimulation during IVF treatment
45633832|NCT04643249|Drug|KL1333|Tablet
45633833|NCT04643249|Drug|Flurbiprofen|Tablet
45633834|NCT04643249|Drug|Dextromethorphan|Syrap
45914087|NCT02031367|Other|Platelet Rich Plasma|Platelet Rich Plasma
45633835|NCT04643249|Drug|Bupropion|Tablet
45914088|NCT02031497|Dietary Supplement|Drink with sweeteners|Subjects will have to consume a 330ml can of a drink with sweeteners twice per day as part of their usual fluid intake for 12 weeks.
45914089|NCT02031497|Dietary Supplement|Drink without sweeteners|Subjects will have to consume a 330ml can of a drink without sweeteners twice per day as part of their usual fluid intake for 12 weeks.
45914090|NCT02031692|Drug|400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate|The patients allocated to the intervention group will have a test for serum vitamin D, and receive 800 IU of vitamin D and 1000 mg of calcium as calcium carbonate when the serum vitamin D is decreased. The patients in the control group will be followed up without intervention for one year.
45914091|NCT02031991|Biological|PF-06439535|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
45633836|NCT04643249|Drug|Midazolam injection|solution for injection
45633837|NCT04643249|Drug|Omeprazole|Capsule
45633838|NCT04643249|Drug|Caffeine|Tablet or capsule
45633839|NCT04643249|Drug|Repaglinide|Tablet
45633840|NCT04482517|Other|Density Gradient Centrifugation|Semen processing is done by double layer density gradient method.
45633841|NCT04482517|Other|Physiological ICSI|Sperm selection by PICSI dishes depending on hyaluronan binding of sperm head
45633842|NCT04482517|Other|Magnetic activated cell sorting|Sperm selection by using Annexin V micro-beads and separation columns
45633843|NCT04482517|Other|Testicular sperm|Using testicular sperm retrieved by TESA or TESE
45633844|NCT02418871|Device|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject. An improved injector system was used.
45633845|NCT02418871|Procedure|Cataract surgery|Performed using standard microsurgical techniques
45633846|NCT02414425|Procedure|Rectoscopy|A rectoscopy will be performed for Botulinum toxin A or physiologic serum injection
45633847|NCT02414425|Procedure|Anorectal manometry|Anorectal manometry will be performed to evaluate efficacy of Botulinum toxin A or physiologic serum rectal injection
45633848|NCT02414425|Drug|Botulinum toxin A or physiologic serum injection|Botulinum toxin A or physiologic serum injection is performed during rectoscopy
45633849|NCT04524143|Other|cervical mobilization|"Cervical mobilization techniques were applied in the study. Within the scope of application; rotation with traction, lateral gliding, anterior-posterior gliding with traction, bridging and stroking techniques to the paravertebral muscles were used. Mobilization were performed at grade A (mobilization in painless joint range) and grade B (continuous stretching at the end of the joint range). The mobilization were applied during 10 minutes.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise"
45652970|NCT05191017|Drug|Enzalutamide|Enzalutamide
45772730|NCT03824405|Drug|Vehicle|Vehicle liquid formulation
45772731|NCT04244266|Other|NO INTERVENTION, it is an observational study|No intervention
45772732|NCT02246699|Device|KiOnutrime®-Cs|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules of 500mg, 3 times per day.
45772733|NCT02246699|Other|Placebo|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules, 3 times per day.
45772734|NCT04234204|Drug|Fezolinetant|Oral
45772735|NCT04234204|Drug|Placebo|Oral
45633850|NCT04524143|Other|control|There was no intervention in the control group during study. At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise
45633851|NCT02414191|Behavioral|Benchmarked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of benchmarked feedback, which is the measure of their performance in comparison the standard set by the hospital.
45633852|NCT02414191|Behavioral|Ranked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of ranked feedback, which is the measure of their performance in comparison to their peers.
45772736|NCT04925921|Device|SR-1 Laser|3-4 treatments at 4-6 week intervals
45772737|NCT04199572|Drug|Diclofenac and Paracetamol|analgesic effect of diclofenac along with either Oral versus Intravenous paracetamol versus placebo
45772738|NCT04177966|Behavioral|pre-prepared video describing the cesarean surgery|a pre-prepared video, approximately 10 minutes in length, showing in detail the course of events around the operation - from the woman's perspective - from the time they were admitted to the department, preparation for surgery, entrance to the operating r
45772739|NCT04177966|Behavioral|general information|In the control group - women will receive general information about the surgery as part of informed consent, without watching a pre-prepared film.
45772740|NCT00383032|Drug|mifepristone|
45772741|NCT02169479|Drug|BIA 9-1067|OPC, Opicapone
45772742|NCT02169479|Drug|Placebo|PLC, Placebo
45772743|NCT02169479|Drug|Sinemet® 100/25|Immediate-release levodopa/carbidopa 100/25 mg
45772744|NCT04313530|Device|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS treatment fatigue is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks connectivity changes involved in the processing of fatigue signals.
45772745|NCT04302454|Radiation|Radiotherapy|Radiotherapy
45914092|NCT02031991|Biological|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
45935427|NCT00043121|Other|pharmacological study|Correlative studies
45633853|NCT05737589|Radiation|Whole-brain radiotherapy|Radiotherapy is administered to the patient's brain lesions, and the subject's specific treatment plan is developed by two specialized physicians.
45633854|NCT03116893|Drug|BI 685509 After Standardised Breakfast|High-fat high calorie breakfast
45633855|NCT03116893|Drug|Itraconazole|Administration of itraconazole together with BI 685509
45633856|NCT03116893|Drug|Rifampin|Administration of rifampicin together with BI 685509
45772746|NCT04302454|Drug|Leuprorelin|Hormonal therapy
45772747|NCT01059851|Drug|Suvorexant|single oral dose of 20 mg (administered as 2 x 10 mg tablets) of suvorexant administered with ~240 mL of water after an 8 hour fast
45772748|NCT02169869|Device|Mirena|A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.
45772749|NCT02169869|Device|Paragard|A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
45772750|NCT04912817|Other|Off the Shelf VR|"Operates using Oculus quest VR HMD and uses auditory and visual stimuli during the pain rehabilitation treatment. The Off-the-shelf VR program for Oculus Quest VR features a suite of off-the shelf applications that can be tailored by the PT and used with participants including. PR-VR sessions will be 30 minutes in total with approximately 20 minutes in the virtual experience and 10 minutes for set-up, screening, instructions, and rest breaks. The Off-the-shelf VR intervention group will also receive 30 minutes of usual care, and Standard Virtual Physiotherapy Treatment (SVPT) during the same appointment, for a total 1-hour usual care session length."
45772751|NCT04912817|Other|Custom VR|Operates using Oculus Quest VR HMD with PR-VR software developed with two gaming options: Fruity Feet and Space Burgers 2. Game settings are manipulated by the physiotherapist in session to target specific limb movements and intensity and also motivates participants to cycle using a leg ergometer. Motion sensors on the ergometer track the participants revolutions per minute. For participants in this study arm, a leg ergometer (DeskCycle) will be provided to them during the study phase alongside the Actigraph and Oculus Quest HMD. During the 30min VR portion of the session, 20 minutes will be dedicated to gaming and exercise, and 10 minutes dedicated for set up, tear down, and rest breaks. During the 20 minutes gaming time, a minimum of 15 minutes will be dedicated to Custom VR, with 5 minutes for 'free play' where the participant can opt to try an off-the-shelf VR game.
45772752|NCT01059929|Drug|Dexmedetomidine|continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
45772753|NCT01059929|Drug|Propofol|continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
45772754|NCT01059929|Drug|Fentanyl|25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
45772755|NCT01059929|Drug|Midazolam|0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS>+2)
45772756|NCT01059929|Behavioral|Physical and Occupational Therapy|Daily therapy sessions targeting range of motion, strength, and mobility
45772757|NCT04353011|Other|questionnaire assesment|questionnaire assesment
45772758|NCT04866953|Other|Blood transfusion|Number of units of blood received within 24 hours of admission
45772759|NCT03579641|Device|HeartLogic Sensors|HeartLogic Sensors
45772760|NCT04828031|Drug|Vitamin D|Patient with inflammatory bowel disease who have low vitamin D (25(OH)D less than or equal to 25 ng/mL) will take Vitamin D 50,000 IU by mouth every week for 12 weeks. Patients will fill out questionnaires to document disease activity score (HBI or Mayo score and sIBDQ) and have blood and stool samples collected before (Week 0), during (Week 8) and after (Week 12) vitamin D intervention.
45633857|NCT03116893|Drug|BI 685509 Fasted Conditions|BI 685509, given alone
45772761|NCT04162522|Drug|Escitalopram|Participants are given escitalopram for 8 weeks. At week 8, those classified as responders will continue on escitalopram until the end of study.
45772762|NCT04162522|Drug|Brexpiprazole|Participants who are classified as non-responders are given 8 weeks add-on brexpiprazole, in addition to escitalopram, for the remainder of the study.
45633858|NCT05737511|Drug|Hydroxyzine|Oral tablet of hydroxyzine 25mg at night which could be increased to TID or QID
45633859|NCT05737511|Drug|Escitalopram Oxalate|The treatment as usual can include first-line, second-line and third-line recommendations
45633860|NCT03117127|Behavioral|Resistance Exercise|Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites
45633861|NCT03117127|Other|Whole Eggs|Participants will ingestion whole eggs immediately after resistance exercise
45633862|NCT03117127|Other|Egg Whites|Participants will ingestion whole eggs immediately after resistance exercise
45633863|NCT04310423|Drug|Placebo|Matched to endotoxin
45633864|NCT04310423|Biological|Endotoxin|Bolus dose of 0.8 ng/kg
45633865|NCT03180073|Diagnostic Test|Ziopatch Pre discharge|Ziopatch applied 2 weeks prior to procedure
45633866|NCT03180073|Diagnostic Test|Ziopatch at Discharge|Ziopatch applied at discharge from hospital to be worn for 2 weeks
45633867|NCT03180073|Diagnostic Test|Ziopatch at 2 months|Ziopatch applied 2 months from procedure to be worn for 2 weeks
45633868|NCT05737277|Drug|Gabapral|"This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period."
45633869|NCT05737277|Drug|Placebo|"This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period"
45633870|NCT02418637|Other|Worksite screening for DM, HTN and hyperlipidemia|Six monthly visits to worksite to perform screenings
45633871|NCT04187027|Device|pulsed electromagnetic field therapy device|magnetic field stimulation (MFS) is a novel technique for stimulating the nervous system non-invasively, which can activate deep neural structures via induced electric currents, without pain and discomfort. Also, several clinical trials including placebo-controlled studies have shown that MFS of the pelvic floor and sacral roots is effective for overactive bladder (OAB). MFS induces inhibitory effects on detrusor overactivity in a similar manner to electrical stimulation, with significant clinical advantages. MFS of the sacral nerve roots could be a promising alternative treatment for OAB.
45652971|NCT05190159|Device|Monster Screw System|Subjects who have undergone a foot and/or ankle procedure involving the index device
45772763|NCT04896658|Drug|Belantamab Mafodotin, Cyclophosphamide and Dexamethasone|Study drug
45772764|NCT01062269|Drug|Cholestyramine|Cholestyramine 4 grams one time dose
45772765|NCT01062269|Drug|Cholestyramine|Cholestyramine 12 grams one dose, one day
45772766|NCT01062269|Drug|Tang|Tang one dose one day
45772767|NCT04156828|Drug|Copanlisib|Given IV
45772768|NCT04156828|Drug|Gemcitabine|Given IV
45772769|NCT04156828|Drug|Carboplatin|Given IV
45772770|NCT04156828|Drug|Dexamethasone|Given PO
45772771|NCT04156828|Biological|Rituximab|Given IV
45772772|NCT04156828|Biological|Pegfilgrastim|Given SC
45772773|NCT01062893|Other|Sterile normal saline 0 mls|at time of epidural needle placement there will not be any saline injected into the epidural space prior to placement of the spinal needle to administer the CSE dose of standard analgesic medications. Instead a pause will be done as by the investigator to maintain blind for the assessor.
45772774|NCT01062893|Other|15 mls sterile normal saline|After the epidural needle is placed, 15 mls of sterile normal saline will be injected into the epidural space, then the spinal needle will be placed to administer the CSE dose of standard analgesic medications.
45772775|NCT01063049|Drug|Gatorade/Miralax|Gatorade 64 oz (1/2 gallon), Miralax 306 g to be consumed the day before your colonoscopy as follows: Miralax 51 g at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
45772776|NCT01063049|Drug|NuLytely|Nulytely (or Trilyte) 128 oz (1 gallon) to be consumed from about 5 PM to 9 PM the night before the colonoscopy.
45772777|NCT01063049|Drug|Bisacodyl|Bisacodyl 10 mg (two 5 mg pills) to be consumed the day before the colonoscopy at 12 noon.
45772778|NCT01063049|Drug|Placebo|Placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy
45772779|NCT04620070|Procedure|ECPR|Application of prehospital ECPR
45772780|NCT04617262|Behavioral|Remote Problem Management Plus|Five sessions of low-intensity, trans-diagnostic psychological intervention including the teaching and practice of the following strategies: stress management, problem solving, behavioral activation, and strengthening social support
45772781|NCT04883242|Drug|Carfilzomib|Given IV
45772782|NCT04883242|Drug|Dexamethasone|Given PO or IV
45772783|NCT04883242|Biological|Isatuximab|Given IV
45772784|NCT04883242|Drug|Pomalidomide|Given PO
45772785|NCT04104178|Drug|Clindamycin|Investigating whether a significantly higher number of MRSA throat carriers succeed in becoming MRSA free, when using Clindamycin on top of our general recommended topical treatment of Mupirocin nasal ointment + chorhexidin baths
45772786|NCT04104178|Drug|Placebo|Placebo
45633872|NCT03179839|Behavioral|Mindfulness-based Cognitive Therapy|"The intervention will be carried out according to the handbook of the Dr. Didonna. There is a Session Agenda from Dr. Didonna for the use of the Instructor and session handouts for the participants. Some records of mindfulness practices will be given to participants for facilitating practice between sessions. Before each session, the instructor needs to review the session agenda and prepare copies of handouts for participants.~MBCT instructors were experienced psychotherapists and psychiatrists with several years' expertise in OCD treatment. They had been trained by one of the founders of MBCT, Mark Williams and the founder of MBCT for OCD, Fabrizio Didonna. Supervision will be provided by Dr.Didonna."
45772787|NCT03661138|Drug|Upadacitinib|Upadacitinib is administered orally.
45772788|NCT03661138|Drug|Placebo for upadacitinib|Placebo is administered orally.
46070117|NCT04253600|Behavioral|Automated analysis of language development and environment|"Following the individual assessment, families will be asked to record their child's language environment over a 2-days' timeframe using the LENA® device, a small wearable device allowing for large-scale all-day audio recording and automated vocal analyses of speech segments. An automatic analysis of the recordings, performed by the LENA pro software algorithms, will provide amongst others, a direct and natural measure of the child's number of vocalizations, adult word counts, conversational turns, duration of exposure to electronic media versus to meaningful language. Data acquisition will take place once a year following our sample selection, with a required recording time per day ranging from 12 to 16 hours."
45772789|NCT03661138|Drug|Topical Corticosteroids (TCS)|It is administered concomitantly with upadacitinib or placebo.
45772790|NCT04588792|Drug|Nebulized Furosemide|Furosemide administered by nebulization through the ventilator circuit
46070118|NCT00800527|Drug|Gabapentin|Gabapentin 800 mg one a day up to 30 day
45772791|NCT04588792|Drug|Nebulized Saline|Saline administered by nebulization through the ventilator circuit
45772792|NCT04086160|Device|Transcranial direct current stimulation device (Soterix Medical, New York, NY)|Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.
45772793|NCT04081792|Procedure|Antibiotic therapy|Postoperative randomizations regarding the duration of systemic antibiotics
45914093|NCT02031991|Biological|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
45772794|NCT04075396|Drug|Lazertinib|Participants will receive Lazertinib tablets once daily.
45772795|NCT04053088|Device|INSPIRIS RESILIA Aortic Valve™|Collection of patient data from patients undergoing Surgical Aortic Valve Replacement (SAVR) by usage of the INSPIRIS RESILIA aortic valve™
45772796|NCT04562038|Behavioral|Young Children's Participation and Environment Measure (YC-PEM) electronic patient-reported outcome (e-PRO)|The Young Children's Participation in Environment Measure (YC-PEM) is an evidence-based option for comprehensive proxy assessment of a young child's current and desired participation in occupations across home, daycare, and community settings. The YC-PEM is an electronic patient-reported outcome (e-PRO) that provides individual caregivers a valid, reliable, and feasible way to communicate information about their child's current participation in home and community activities and areas of participation need. The gained information is then summarized and shared with the child's EI provide team to identify intervention priorities and goal attainment strategies in partnership with families. For quality improvement, EI programs can aggregate the YC-PEM e-PRO data to examine trends in participation as a function of EI service use. It is therefore a promising electronic health systems intervention to enhance the parent-practitioner relationship, and an NIH common data element for trials.
45772797|NCT04041778|Other|Catheter ablation|Substrate ablation. Pulmonary vein isolation.
45772798|NCT04038970|Biological|KN019, 5mg/kg|Solution, intravenous, 5 mg/kg
45772799|NCT04038970|Biological|KN019, 10 mg/kg|Solution, intravenous, 10 mg/kg
45772800|NCT04038970|Biological|Placebo|Solution, intravenous, Placebo
45772801|NCT04038970|Combination Product|Methotrexate|Tablets, oral, 7.5-25 mg weekly to be adjusted according to patient condition
45914094|NCT02032043|Drug|Annual versus Semiannual Albendazole plus Ivermectin MDA|Annual or semiannual Albendazole plus Ivermectin, administered by the Ivorian Ministry of Health.
45914095|NCT02032134|Biological|Transfusion of Pooled Platelets Cryopreserved In DMSO|"Patients with severe thrombocytopenia will be admitted as in patients at the Hematology Unit of the Policlinic P. Giaccone- Palermo, if they require platelet transfusion (for bleeding, in preparation for surgery, after chemotherapy); they will receive buffy coat derived cryopreserved platelets,after thawing"
45935428|NCT00402415|Drug|Sunitinib malate|C1: 50 mg po days 1-15, 2 weeks off C2: 50 mg po x 4 weeks, 2 weeks off
45935429|NCT00402415|Drug|Rapamycin|"Dose escalation until MTD as follows:~C1: not given C2: 4 mg weekly, 8 mg weekly, 12 mg weekly, 20 mg weekly"
45772802|NCT03533686|Device|Adhear Bone Conduction System|Non-invasive bone conduction hearing device using adhesive
45772803|NCT03533686|Device|Bone anchored hearing aid (BAHA)|Non-invasive bone conduction hearing device using a headband
45772804|NCT02181738|Drug|Nivolumab|Specified dose on specified days
45772805|NCT02181738|Drug|Doxorubicin|Specified dose on specified days
45772806|NCT02181738|Drug|Vinblastine|Specified dose on specified days
45772807|NCT02181738|Drug|Dacarbazine|Specified dose on specified days
45772808|NCT03512470|Device|Sistema Prevena ™(TVAC)|The medications with a negative topical pressure system (Sistema Prevena ™) will be applied directly in the Operating Room. Thereafter medication will be checked in the inpatient ward after 48 h from the intervention, evaluating the possible absorption of exudate on the surface. If no absorption are detected within 48 hours, the medication won't be removed and renewed in the 7th day (± 2 days) post-operative; and to follow every 7 (± 2 days) until the points are removed. If the wound continues to progress towards recovery, the protocol will continue until discharge and / or rehabilitation and / or surgery.
45772809|NCT03512470|Other|Standard medication|standard medication in use (sterile gauze and TNT patch or medicated patches).
45772810|NCT05426304|Drug|Agomelatine|agomelatine 25 mg/day for 180 days
45772811|NCT05426304|Drug|Placebo Tablets|placebo 25 mg/day for 180 days
45935430|NCT04727476|Drug|Lisdexamfetamine|Prescription of lisdexamfetamine sometime during til period from 1 April 2013 to 5 November 2019.
45914096|NCT02032186|Drug|Magnesium citrate|Oral Mg++citrate, 160 mg twice daily. Each capsule will contained 160 mg of elemental magnesium citrate. The participants will be instructed to take one capsule twice daily until delivery.
45633873|NCT03179839|Behavioral|Psycho-education Program|As a widely used placebo control condition, the Psycho-Education Program can play an active role through the psychological suggestion and forward thinking mostly. It is designed to be similar with MBCT in level of structure, setting and other non-specific effects of psychological intervention. All instructors will be qualified graduate students who major in clinical psychology with training in cognitive behavioral therapy and psychodynamic therapy.
45633874|NCT03179839|Drug|sertraline, fluvoxamine|The participants can be adjustable once a week dose and the maximum dose does not exceed the maximum amount of instructions. And benzodiazepine drugs also can be used by the OCD patients with sleep disorders, but not be used continuously for more than two weeks. Besides this, other psychotropic drugs are not allowed to use. The use of drugs in this study are commonly used drugs with good safety, and its common adverse reactions include dry mouth, constipation, nausea, indigestion, dizziness, fatigue, sweating and so on.
45633875|NCT05737043|Diagnostic Test|prenatal diagnose|we will do a fetal echo in pregnant women with polyhidramnios
45633876|NCT03106909|Radiation|pulmonary computed tomography (CT)|Pulmonary CT imaging
45633877|NCT03135821|Diagnostic Test|TCM|
45772812|NCT03955198|Combination Product|Radiotherapy + durvalumab|Radiotherapy will be administered in combination with Durvalumab
45772813|NCT03952156|Genetic|HMI-102|HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene
45633878|NCT05021497|Other|Global Positional Re-education|A series of gentle active movements and postures aimed at realigning joints and stretching shortened muscles. GPR includes 8 therapeutic postures in lying, sitting and standing.
45772814|NCT03952156|Genetic|HMI-102|"Control subjects will generally have the same assessments as treated subjects.~Control subjects will undergo pre-baseline procedures to confirm that they are eligible to receive treatment with HMI-102. Once eligible control subjects are dosed with HMI-102, they will initiate the same post-dose procedures as subjects who received HMI-102."
45772815|NCT04510714|Device|Image guided percutaneous microwave ablation|Lung metastasis from sarcoma will be treated with microwave antennas (SOLERO) and Ablation System and microwave generators (Angiodynamics), with power settings of 35-45W and an average ablation time of 15 minutes (range 10-30 minutes). The ablation time will be recorded for all procedures. The manufacturer's recommendations will be observed in all cases, since it is assured that patients are able to tolerate the total ablation time.
45914097|NCT02032446|Biological|UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)|"pentostatin, dose 1 mg/m2~§ MSC doses:~3 patients → 3 infusions of 1x106 cells /kg~3 patients → 3 infusions of 2x106 cells /kg~3 patients → 3 infusions of 3x106 cells /kg"
45914098|NCT02032537|Drug|Callmax cream application over affected skin|Callmax cream application over affected skin Callmax cream or topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity.
45772816|NCT02991144|Genetic|scAAV8OTC|non-replicating, recombinant scAAV8 encoding human ornithine transcarbamylase (OTC)
45772817|NCT02991144|Drug|Reactive Corticosteroid Taper Regimen|"Oral prednisone [or oral prednisolone] 60 mg/day week 1, 40 mg/day Week 2, 30 mg/day Weeks 3 and 4, tapered by 5 mg/week Week 5 and beyond until liver enzymes return to baseline levels.~Corticosteroid treatment will be considered when a participant's alanine aminotransferase (ALT) level exceeded the upper limit of normal (ULN) and the ALT increase was considered by the Investigator to be related to DTX301."
45772818|NCT02991144|Drug|Prophylactic Corticosteroid Taper Regimen|"Oral prednisone [or oral prednisolone] 60 mg/day at least 5 days prior to DTX301 administration, tapered over 9 weeks.~A prophylactic corticosteroid taper regimen will be administered to prevent or minimize transient vector-induced hepatic effects."
45772819|NCT03493282|Drug|Active Treatment- CT1812 100 mg|CT1812
45772820|NCT03493282|Drug|Active Treatment- CT1812 300 mg|CT1812
45772821|NCT03493282|Drug|Placebo|Matching Placebo
45772822|NCT05426226|Device|laser acupuncture|using laser acupuncture device on sleep acupoints during sleep
45772823|NCT05426226|Device|sham device|using sham device on sleep acupoints during sleep
45772824|NCT03468166|Other|Chronic stroke|The data for motor function and gait pattern analysis was obtained.
45772825|NCT05452122|Other|Auditory and Electrical Stimulation|Electrical and auditory stimulation will be applied during sleep.
45772826|NCT04499092|Behavioral|Neuropsychological treatment|Neuropsychological treatment
45914099|NCT02032537|Drug|Placebo|Topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity. The data on efficacy, duration of effect and frequency of application will be collected.during the study.
45772827|NCT04781660|Device|Implantable Alginate Hydrogel|"Implantable Alginate Hydrogel is a single use, multiple component device. It is expected to be used as a space-occupying material implanted into the myocardium to affect the shape of the left ventricle and reduce the clinical symptoms of patients with left ventricular ischemia and non-ischemic cardiomyopathy.~The hydrogel serves as an artificial myocardial filler to stop the continuous expansion of the ventricle and restore it to a more favorable shape and size. The expected clinical effect of the Implanted Alginate Hydrogel is to reduce the clinical symptoms of patients and improve the quality of life by improving the structure and function of the failing heart."
45772828|NCT02973750|Procedure|Baseline Biopsy|Baseline biopsy (and ascites fluid sampling if applicable). This is done during the normal work-up procedures.
45772829|NCT02973750|Procedure|Tissue Collection|Tissue collection during debulking surgery.
45914100|NCT02032576|Device|ECT for depressed patients|electroconvulsive therapy with a bipolar brief pulse square wave
45914101|NCT02032628|Behavioral|Exercise|The investigators will measure changes in DNA methylation as a result of four different intervention groups, i.e, high/longer, low/longer, high/shorter, low/shorter.
45914102|NCT02032667|Behavioral|Multi-player condition|Children in the multi-player condition will be able to play with and compete against other children in real time.
46070119|NCT00800527|Drug|Diclofenac|Diclofenac 75 mg one a day up to 30 day
45772830|NCT02973750|Procedure|Blood Draws|Blood samples for paclitaxel and carboplatin plasma levels will be collected in the study. Paclitaxel will be measured on cycle 1 day 1 at predose and then at the end of the infusion, followed by 1, 2, 4, 8 hours after the end of infusion, then on cycle 1 day 2 at 24 hours after the end of infusion. Carboplatin will be sampled for on cycle 1 day 1 at predose and then at the end of the infusion, followed by 0.5, 1.5, 3.5, 7.5 hours after the end of infusion, then on cycle 1 day 2 at 23.5 hours after the end of infusion.
45772831|NCT03946618|Device|Medtronic Summit System, Olympus|Electrical brain stimulation with an implantable pulse generator
45633879|NCT05021497|Other|Conventional Physical Therapy Program|Axial traction will be given for 5 minutes, followed by mobilization of the muscle fascia along with static stretching of the scalene, levator scapulae, upper trapezius, sternocleidomastoid and pectoralis minor muscles.
45772832|NCT05425680|Other|Core muscle training|Combining virtual reality technology and waist wearable sensors, training the pelvis and lumbar spine movements as the main training goal, it is estimated that two 1-hour training sessions per week, a total of 6 weeks of training, to improve the core muscle of patients with lumbar degenerative diseases muscle strength.
45772833|NCT03934606|Behavioral|Genetic testing for hereditary predisposition|Change in distress levels (HADS-Anxiety) from Baseline to Assessments #2 and #3, measured as an effect size among participants who receive a pathogenic variant(s), no pathogenic variant(s), and variant(s) of uncertain significance
45772834|NCT05464758|Other|Repeated cold exposure|8 consecutive days of exposure to 8°C air for 120 minutes each day
45772835|NCT03458728|Drug|BAY806946|Copanlisib will be dosed on Day 1, Day 8, and Day 15 of every 28-day cycle. Phase 1: 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Phase 2: RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
45772836|NCT04494958|Drug|Combination, Palbociclib + Binimetinib|"Patients will then start treatment with continuous oral binimetinib 45 mg/BID and palbociclib 100 mg daily, 21 days on / 7 days off, until disease progression. Study treatment will continue until disease progression.~If treatment tolerance is good, after a full cycle patients will be allowed to escalate palbociclib to 125 mg, according to the study investigators' decision. Alternatively, patients with non tolerable grade 2 events will resume at 30 mg/BID of binimetinib upon recovery, maintaining palbociclib at 100 mg 21-on/7-off. Depending on the side-effects, in case of clear relationship with palbociclib is established, palbociclib -instead of binimetinib - will be reduced to 75 mg daily."
45772837|NCT02532972|Device|Med-el MAESTRO Cochlear Implant with Flex 28 electrode array|Cochlear Implant (CI) surgery followed by device activation, testing, and clinical assessment for 12 months following surgery.
45914103|NCT02033044|Other|cognitive remediation|Cognitive Rehabilitation (CR). Consisted on group sessions (5 individuals per group) of 120-minutes, twice a week during a total period of 16 weeks (32 sessions). The exercises addressed neurocognitive issues related to sustained attention, processing speed, memory and executive functioning. The whole program aimed at getting new strategies to improve functional adaptation, thus tasks were carried out in the clinical setting and at home. Some homework tasks were based on their daily life difficulties and problems. The main objective of this program was the generalization of rehabilitated cognitive functions to daily life activities. Most of the techniques were based on a previous program for bipolar disorder.
45914104|NCT02033044|Other|Psychoeducation|Psychoeducation (PE). The psychoeducation intervention consisted of 16 weekly group sessions of 5 individuals of 120 minutes each (16 sessions). This therapy aimed at improving illness' consciousness , interpersonal abilities, family balance, therapeutical adherence, emotional management in frustrating situations, problems resolutions, and lifestyle regularity. On this intervention, no homework tasks were required. This intervention was based on the Systems Training for Emotional Predictability and Problem Solving (STEPPS) program therapy.
45914105|NCT02033122|Other|Aerobic training|the intervention will be an aerobic training program. For the TG subjects, breathing exercises will have duration of 30 minutes and will be always followed by aerobic training sessions that will consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months.
45914106|NCT02033122|Other|Breathing exercise|Patients from the control group will be taught breathing exercises with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .
45914107|NCT02033356|Procedure|Adductor canal block with lidocaine 1%|US-guided adductor canal block
45914108|NCT02033356|Drug|Lidocaine|
45914109|NCT02033720|Other|No treatment|No therapeutic hypothermia was induced.
45914110|NCT02033720|Other|Therapeutic hypothermia|Hypothermia was induced after successful resuscitation from cardiac arrest.
45914111|NCT02033733|Drug|Cisatracurium infusion|"This group will include postcardiac arrest patients that have received a cisatracurium infusion as part of their therapeutic hypothermia protocol. It will only include patients that had their infusion started within 2 hours from protocol initiation. Patients that received an infusion as a rescue measure (beyond the first 2 hours) or did not receive and infusion at all will not be included in this group.~Most patients admitted to our ICU postcardiac arrest prior to October 2011, will likely belong to this group (the cisatracurium infusion group)."
45633880|NCT02418793|Drug|MOD-5014|Long Acting Factor VIIa
45633881|NCT03136601|Other|PTNS maintenance|The intervention is the timing of PTNS for maintenance (monthly treatment versus as patient needs)
45633882|NCT05736887|Drug|N-Acetylcysteine|N-Acetylcysteine in 600mg tablets
45633883|NCT05736887|Drug|Placebo|Placebo in 600mg tablets
45633884|NCT04074083|Behavioral|electronic IMCI|Participants will be trained to use an electronic version of the Integrated Management of Childhood Illness (IMCI) guidelines
45633885|NCT04074083|Behavioral|paper IMCI|Participants will be trained to use routine paper version of Integrated Management of Childhood Illness (IMCI) guidelines
45633886|NCT02703337|Drug|LY900014|Administered subcutaneously (SC)
45633887|NCT02703337|Drug|Insulin Lispro|Administered SC
45633888|NCT03110081|Procedure|Quadratus lumborum block|Quadratus lumborum (QL) block for open partial nephrectomy.
45772838|NCT05450406|Other|Physical activity|The participants will receive the possibility to attend weekly endurance, resistance and yoga exercise sessions administered by the Healthy Life Center. They will also receive personalized follow-up from the Healthy Life Center, and have the possibility to exercise at the local gym.
45914112|NCT02033733|Drug|Cisatracurium prn bolus|Patients that have not received a cisatracurium infusion within the first 2 hours from protocol initiation will be in this group. These are likely to be patients admitted to our ICU after October 2011 (when the protocol change happened).
45772839|NCT03921502|Procedure|Gall bladder transmural drainage with LAMS|Placing a PAL Axios (Boston Scientific) usually 15x10 mm or 10x10 mm to allow direct cholecystoscopy with a conventional gastroscope or transnasal gastroscope. The placement of the drainage will be performed in the same endoscopic act, by means of an Olympus® sectorial echoendoscope, assisted with X-rays, which allows puncturing the vesicle from the gastric antrum or the duodenal bulb to generate a cholecysto-gastrostomy or cholecysto-duodenostomy respectively. After the puncture of the vesicle from the most optimal anatomical point, it will be tutored with guidance and a Hot Axios® PAL 15x10 mm or 10x10 mm will be *placed on it to generate the anastomosis between the aforementioned structures.
45772840|NCT03919396|Device|Breath-O orthokeratology lenses|"Specially designed rigid gas permeable lenses which~reshapes corneal profile for myopia control~has higher elasticity compared to traditional lens material."
45772841|NCT03351712|Behavioral|ACT-Based Intervention and Activity Tracker WITH Feedback|Combining ACT and Behavioral Change
45772842|NCT03351712|Behavioral|Gold Standard Intervention + Activity Tracker WITHOUT Feedback|Medical Rehabilitation, Motivational Support and Psycho-Education
45772843|NCT03351712|Behavioral|Gold Standard Intervention and Activity Tracker WITH Feedback|Behavioral Change Condition - Activity Tracker
45772844|NCT03351712|Behavioral|ACT-Based Intervention and Activity Tracker WITHOUT Feedback|ACT-Based Intervention Standalone
45772845|NCT00382954|Drug|Velcade|velcade (4 original dosing levels with 3 modified dosing levels) I.V. on days 1, 4, 8, 11, 15, 18, 22, and 25 for 4 weeks concurrent with the Idarubicin
45772846|NCT00382954|Drug|Idarubicin|I.V., 8, or 10 or 12 mg/m^2 weekly (days 1, 8, 15, and 22) for 4 weeks
45633889|NCT03110081|Procedure|Epidural analgesia|Epidural analgesia for open partial nephrectomy.
45633890|NCT05736809|Other|Low-dye taping|Low-dye taing using 4 tapes around calcaneam
45633891|NCT05736809|Other|Plantar fascia stretching|out of 21 participants 7 will be included in the study design as an active participants group using plantar fscia stretching in acute stage
45633892|NCT05736809|Other|sham taping|out of 21 participants 7 will be included in the study design as an plecebo group using sham taping in acute stage
45772847|NCT03314584|Device|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the left motor cortex.
45772848|NCT03314584|Device|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation to the left motor cortex due to the use of a double sided Active/Sham coil used specifically for research studies.
45772849|NCT03879070|Device|Ankle active and passive mobilization using an Ankle mobilization device|The treatment consists in 20 rehabilitation sessions, 5 times/week for 4 weeks. The device is capable of generating ankle dorsi/plantarflexion movements using two activation modes: passive and assistive. In the passive mode the device generates a movement pattern which the patient follows passively without exerting any force on the device. During the assistive mode, the device follows the active movement of the patient. During the intervention, these two modes will be alternated.
45772850|NCT04440592|Drug|MT-7117|MT-7117
45772851|NCT04440592|Drug|Placebo|Placebo
45633893|NCT02418715|Other|Water Aerobics Training|
45633894|NCT03976895|Procedure|Supine position (SP)|"Infants under high flow nasal cannula (HFNC) will be positioned in the supine position.~Patients may be positioned temporarily in lateral position between periods of supine position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis."
45633895|NCT03976895|Procedure|Prone position (PP)|"Infants under high flow nasal cannula (HFNC) will be placed in the prone position during at least 24 hours over the first 48 hours. The positioning will be standardized (chest on the bed plan and abdomen cleared) and children should be placed in the prone position immediately after randomization.~Patients may be positioned temporarily in lateral position between periods of prone position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis."
45633896|NCT02413723|Device|Videolaryngoscope|McGrath Mac videolaryngoscope will be use for first attempt of intratracheal intubation.
45633897|NCT02413723|Device|Standard laryngoscope|Macintosh laryngoscope will be use for first attempt of intratracheal intubation.
45772852|NCT03234556|Procedure|Biopsy of Prostate|Undergo SR-Bx
45772853|NCT03234556|Other|Laboratory Biomarker Analysis|Correlative studies
45772854|NCT03234556|Diagnostic Test|Magnetic Resonance Imaging|Undergo MRI
45772855|NCT03234556|Diagnostic Test|MRI Ultrasound Fusion Guided Biopsy|Undergo MRUS-Bx
45772856|NCT04420078|Procedure|Catheter Ablation|Ventricular fibrillation substrate
45772857|NCT01246063|Drug|carfilzomib|
45772858|NCT01246063|Drug|pegylated liposomal doxorubicin (PLD)|
45772859|NCT01246063|Drug|Dexamethasone|
45772860|NCT04236154|Other|Pedometer|Participants will wear a pedometer for 4 days at baseline, and 4-6 weeks later. Baseline readings will be used to derive an individualized exercise program for each participant based on their assigned experimental arm.
45772861|NCT04236154|Other|Actigraph|Participants will wear a Actigraph for 4 days at baseline and 4-6 weeks later. Baseline readings will be used to derive an individualized exercise program for each participant based on their assigned experimental arm.
45772862|NCT04236154|Other|Perturbation Treadmill|Participants will walk on an instrumented treadmill while wearing a safety harness at baseline and 4-6 weeks later. The perturbation treadmill will assess an individual's risk for falling. Baseline readings will be used to derive an individualized exercise program for each participant based on their assigned experimental arm.
45772863|NCT04330612|Other|Perioperative Updates|In the intervention group, the families received additional standardized electronic updates via pagers at three pivotal moments: 1) Initial skin incision has been made; 2) Critical part of the case is completed and closure has begun; and, 3) Closure is complete, and patient will be transferred to the recovery room when ready.
45772864|NCT03836014|Combination Product|Daratumumab/Lenalidomide/Dexamethasone for 24 months|"Conditioning regimen: 16 mg/kg IV :~Weekly (Cycles 1 and C2)~Every two weeks (C3 to C6)~Monthly from C7 up to 24 months in total (Arm 1)~Infusion reaction prophylaxis :~Acetaminophen (paracetamol) 650-1000 mg IV or orally (PO) approximately 1 hour or less prior to infusion~An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but avoid IV use of promethazine) approximately 1hour prior to infusion; after Cycle 6, if a subject has not developed an infusion-related reaction and is intolerant to antihistamines, modifications are acceptable as per investigator discretion~Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior infusion.~Lenalidomide:~Conditioning regimen: 25 mg per os. From day 1 to day 21 of each cycle up to 24 months in total (Arm 1)~Dexamethasone:~Conditioning regimen: 40 mg at day 1 (preinfusion medication IV preferred), day 8, day 15 and day 22 per os of each cycle up to 24 months in total (Arm 1)"
45633898|NCT03179683|Device|Diode laser application|an 630-660 nm aluminum gallium indium phosphide (AlGalnP) laser device (Scorpion Dental Optima Model 405-7A; Optica Laser, Sofia, Bulgaria) was used immediately after surgery, third day, fifth day and seventh day only for one operation side. Treatment side were randomly selected by another surgeon who applied LLLT. Tissue was irradiated at 25mW power for total six minutes, two minutes for each point (buccal, palatal, crestal). 72J /cm2 energy density was deposited in one session.
45633899|NCT05735639|Drug|Dalteparin Sodium|Low molecular weight heparin
45633900|NCT05735639|Drug|Tinzaparin Sodium|Low molecular weight heparin
45633901|NCT05735639|Drug|Enoxaparin Sodium|Low molecular weight heparin
45633902|NCT05735639|Drug|Rivaroxaban|Direct oral anticoagulant
45772865|NCT03836014|Combination Product|Daratumumab/Lenalidomide/Dexamethasone until progression|"Conditioning regimen: 16 mg/kg IV :~Weekly (Cycles 1 and C2)~Every two weeks (C3 to C6)~Monthly from C7 until disease progression (Arm 2).~Infusion reaction prophylaxis :~Acetaminophen (paracetamol) 650-1000 mg IV or orally (PO) approximately 1 hour or less prior to infusion~An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but avoid IV use of promethazine) approximately 1hour prior to infusion; after Cycle 6, if a subject has not developed an infusion-related reaction and is intolerant to antihistamines, modifications are acceptable as per investigator discretion~Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior infusion.~Lenalidomide:~Conditioning regimen: 25 mg per os. From day 1 to day 21 of each cycle until disease progression (Arm 2).~Dexamethasone:~Conditioning regimen: 40 mg at day 1 (preinfusion medication IV preferred), day 8, day 15 and day 22 per os of each cycle until disease progression (Arm 2)."
45772866|NCT04403620|Radiation|Intensity-modulated Radiation Therapy (IMRT)|Patients will receive adjuvant radiation therapy using intensity-modulated radiation therapy (IMRT) within 8 weeks of surgical resection
45772867|NCT04398160|Other|HVLA C3/C4 manipulation|The investigator will apply an anterior and lateral translation associated with extension, homolateral inclination and contralateral rotation of the cervical. This procedure will increase the tension of the soft tissues to reduce the remaining slack and, finally, the thrust will be applied in pure rotation. Subsequently the head of the volunteer will be repositioned in the neutral position without applying any pressure and will wait 10 seconds in this position. Finally, the previous procedure will be repeated to the opposite side.
45772868|NCT04398160|Other|Sham technique|The investigator will apply an anterior and lateral translation associated with extension, homolateral inclination and contralateral rotation of the cervical until the perception of tissue tension at the point of contact, holding this position for 10 seconds. The investigator then repositions the head of the volunteer in the neutral position without applying pressure, holding again this position for 10 seconds. Finally, the previous procedure will be repeated for the opposite side.
45914113|NCT02034045|Other|Community Paramedicine|
45914114|NCT02034045|Other|Usual Care|
45633903|NCT05735639|Drug|Apixaban|Direct oral anticoagulant
45633904|NCT05735639|Drug|Dabigatran Etexilate|Direct oral anticoagulant
45633905|NCT02418559|Drug|JNJ-63623872 (300 mg)|Participants will receive JNJ-63623872 300 mg tablet orally once on Day 1 under fasted conditions.
45633906|NCT02418559|Drug|JNJ-63623872 (600 mg)|Participants will receive JNJ-63623872 600 mg (2*300 mg) tablet orally once on Day 1 under fasted conditions.
45633907|NCT02418559|Drug|JNJ-63623872 (1200 mg)|Participants will receive JNJ-63623872 1200 mg (4*300 mg) tablet orally once on Day 1 under fasted conditions.
45914115|NCT02034136|Dietary Supplement|Ginsenoside|3.0 g/ d for 28 days
45914116|NCT02034136|Dietary Supplement|Dietary fiber fill|3g/day, 28days
45935431|NCT00124306|Drug|Amitriptyline|Amitriptyline will be titrated over a 6-week period as tolerated, to a maximum dose of 75mg. During the 6-week titration period, the patient who cannot tolerate a scheduled increased dose may adjust the medication dose for tolerance by tapering down one 25mg tablet.
45633908|NCT02418559|Drug|Placebo|Participants will receive placebo tablet orally once on Day 1 under fasted conditions.
45633909|NCT03135665|Device|Ultrasound|"Scolioscan, the ultrasound system reported to be reliable and valid for spinal deformity assessment, will be used. The system composes of an ultrasound scanner with a linear probe of 100 mm in width and frequency range of 4-10MHz, a frame structure and a spatial sensor which is attached to the ultrasound probe for spatial data capture. Daily calibration will be performed using a phantom to assure accuracy of spine image formation and subsequent angle measurement.~Subjects will stand on the Scolioscan platform with a standardized posture kept stable with pegs throughout the scanning process.. After adjusting the ultrasound scanner setting, the probe will be steered from L5 to T1 spinous process for scanning.~SPA will be used to determine the ultrasound-based Referral Status through predicting whether the Cobb angle is beyond the referral threshold of ≥20° or not. There are two values for the Referral Status: either for specialist referral or not for specialist referral."
45633910|NCT02413645|Biological|TriMix_100|100 μg of TriMix in
45633911|NCT02413645|Biological|TriMix_300|300 μg of TriMix in
45633912|NCT02413645|Biological|600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)|600 μg of mRNA (300 μg TriMix + 300 μg HIVACAT)
45633913|NCT02413645|Biological|900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)|900 μg of mRNA (300 μg TriMix + 600 μg HIVACAT)
45633914|NCT02413645|Biological|1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA)|1200 μg of mRNA (300 μg TriMix + 900 μg HIVACAT)
45633915|NCT05733377|Diagnostic Test|Arrow Test|It consists of taking the widest measurement between the rope of a plumb bob on her upper and lower back.
45772869|NCT04394650|Biological|CC-98633|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC-98633.~During CC-98633 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC-98633 product, subjects will receive treatment with CC-98633 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of CC-98633 administered by intravenous (IV) injection."
45772870|NCT01205503|Drug|Mesna|Mesna: 360 mg/m2 in 50 mL normal saline (NS) either on cycle 2 or cycle 1, day 1. Infused over 15 minutes
45772871|NCT01205503|Drug|Saline|Saline (used as a placebo) infused over the same time as mesna intervention
45772872|NCT01205503|Drug|Doxorubicin|60mg/m2 given IV over 15 minutes after receiving mesna or saline. Can allow for premedications of Ondansetron 8 mg orally, dexamethasone 12 mg orally, Aprepitant 125 mg orally.
45772873|NCT01205503|Drug|Cyclophosphamide|600 mg/m2 IV over 30 minutes. Start 6 hours after doxorubicin started.
45772874|NCT01158157|Biological|ACAM2000|Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.
45772875|NCT03187834|Drug|Azithromycin|Children in this arm will receive Azithromycin once a day.
45772876|NCT03187834|Drug|Amoxicillin|Children in this arm will receive Amoxicillin twice a day.
45772877|NCT03187834|Drug|Cotrimoxazole|Children in this arm will receive co-trimoxazole once a day.
45772878|NCT03187834|Drug|Placebo|Children in this arm will receive Placebo once a day.
45914117|NCT02034214|Behavioral|Life skills education|The life skills curriculum drew upon Stepping Stones and CDC-Zimbabwe Talk Time, developed with input from the target population. It consisted of 14 modules delivered to groups of 25 over 4-6 weeks on: HIV/STI and reproductive health; relationship negotiation; strategies to avoid violence;and identification of safe and risky places in the community. Participants also attended a six-weeks-long home-based care training conducted through Red Cross Zimbabwe, to gain skills on safely caring for people living with HIV.
45772879|NCT01206595|Drug|SKY0402|Single dose of SKY0402 administered as a nerve block
45772880|NCT01206595|Drug|Bupivacaine HCl|Single dose of 125 mg administered as a nerve block
45772881|NCT04385992|Drug|177Lu-Dotatate|Peptide Receptor Radionuclide Therapy (PRRT) is based on specific somatostatin receptor targeting with radiolabelled analogues 90Y-DOTATOC and 177Lu-DOTATATE
45772882|NCT01158703|Drug|clopidogrel|clopidogrel 75mg daily by mouth daily for 12 months
45772883|NCT01158703|Drug|sugar pill|sugar pill by mouth daily for 12 months
45914118|NCT02034214|Other|Reproductive health services|All participants were provided a health screening at every study visit and were treated for treatable STIs and minor ailments. They received condoms, and contraceptive pills or injectable free upon request. Participants who tested positive for HIV were referred to local clinics, where the study team assisted with ART registration including payment for CD4 tests required for enrolment.
45914119|NCT02034214|Behavioral|Economic livelihoods|The Livelihoods intervention consisted of financial literacy and a choice of vocational training at local training institutes. Courses were 6-months-long, conducted in English, with a practical and a theoretical component. In spite of encouragement to venture outside of accepted gender norms, the most popular courses were hairdressing, garment-making, and receptionist/secretarial and nurse-aid training. Participants who passed developed business plans that were supported with a micro-grant valued at $100US in the form of capital equipment, supplies or additional training.
45914120|NCT02034253|Drug|Risperidone|Patients with psychosis will be provided a 16 week regimen of the antipsychotic drug Risperidone in accordance with standard care.
45914121|NCT02034279|Drug|Albumin|Intravenous infusion of 20% albumin
45633916|NCT05733377|Diagnostic Test|Angle measurement by imaging device|First, three anatomical landmarks are located, and a sticker is placed on each of them: the 12th thoracic vertebra at its intersection with the midline descending from the axilla, the greater trochanter, and the anterior superior iliac spine. After this, the woman will be asked to stand in a normal position facing forward with her hands crossed over her shoulders, and a picture will be taken and pixelated with anything that could identify her. The angle formed by the three stickers will be measured with this image and the software.
45633917|NCT03116815|Other|Direct input of home blood pressure readings via MyChart|Participants will record home blood pressure readings directly into the electronic health record via the MyChart application
45633918|NCT03200483|Other|Control Protocol|In this period the volunteers were at rest, in the supine position for 15 minutes, followed by 30 minutes of aerobic exercise on a treadmill (five minutes at a speed of 6.0 km / h followed by 25 minutes with 60% of Vmax + 1% grade) and then a recovery period lasting 60 minutes (three minutes standing on the treadmill followed by 57 minutes in the supine position). The volunteers were instructed to remain awake during all the protocol and this was verified and monitored by one of the researchers.
45772884|NCT01158703|Drug|Aspirin|aspirin 81 mg daily by mouth for 12 months ( Standard of care in both arms)
45772885|NCT03010969|Procedure|Acute abdominal surgery|Acute abdominal surgery within 72 hours of admission to the department of surgery
45772886|NCT01159015|Drug|KetoNaph|Ophthalmic Solution administered BID for 6 weeks
45772887|NCT01159015|Drug|Vehicle|Vehicle of KetoNaph ophthalmic solution administered bid for six weeks
45772888|NCT03009643|Drug|Inhaled Nitric Oxide|Patients are treated with iNO for 3-5 days.The concentration of inhaled Nitric Oxide is around 5-10ppm.
45772889|NCT03009643|Device|lung protective mechanical ventilation|Mechanical ventilation in the SIMV mode (ventilators Evita 2 or 4,Dräger, Lübeck, Germany) with VT 6-8ml/kg
45772890|NCT03009643|Device|Hemodynamic monitoring|Flotrac/Vigileo (Edwards Lifesciences) are used to guide the fluid management.
45772891|NCT04275232|Biological|Allogenic plasma aliquots, a source of plasminogen|Plasma eye drops, a source of plasminogen
45772892|NCT04274296|Device|Activation of Advisory|Advisory is activated which will show if driving pressure is greater or equal 15
45772893|NCT01207765|Drug|indium-111-ibritumomab tiuxetan|1.5mg of 111In Zevalin (containing 5 mCi of 111In) will be used for radioimaging. 111In Zevalin will be administered by a 10 minute slow IV push injection immediately following completion of the rituximab infusion. 111In Zevalin may be injected by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the drug infusion port and the patient. The line must be flushed with at least 10cc of normal saline after 111In Zevalin has been injected.
45772894|NCT01207765|Drug|90Y Zevalin|Each patient will receive a single therapeutic dose of 90Y Zevalin at a dose of 0.4 mCi/kg, capped at a maximum dose of 32 mCi. 90Y Zevalin will be administered intravenously as a slow IV push over 10 minutes. 90Y Zevalin may be directly infused by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the syringe and the infusion port. The line must be flushed with at least 10cc normal saline after 90Y Zevalin has been infused.
45633919|NCT03200483|Other|Classical Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to classical music during exercise and recovery.
45633920|NCT03200483|Other|Rock Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to rocky musical style during exercise and recovery.
45772895|NCT03157258|Behavioral|Social Network Training|Members of HIV+ social networks randomized to this arm will be trained to endorse compliance with medical guidelines and adherence to medical treatment regimens to their friends.
45772896|NCT03157258|Behavioral|Single Care-Related Counseling Session and Referral to Care|Members of HIV+ social networks randomized to this arm will attend a single, brief care-related counseling session and referral to care at baseline.
45633921|NCT02418403|Behavioral|Financial incentive|Offer of money designed to overcome barriers to advance care planning.
45633922|NCT02418403|Behavioral|Educational website|"Research-verson of the Prepare for your care website (www.prepareforyourcare.org)"
45633923|NCT02418247|Drug|I131|
45633924|NCT02418247|Drug|I123|
45633925|NCT04483219|Drug|TKI ± anti-PD-1 antibody|"After one cycle of TKI, evaluations would be performed according to RECIST v 1.1. (1) obvious response (A): CR, PR or shrunken SD, or cavitation in metastatic lung lesions, or decrease in the density of liver metastatic targets ≥15%; (2) general response (B): enlarged SD; (3) poor response (C): PD. TKI ＋ anti-PD-1 antibody will be administered in group A. The subjects in group C will exit the study. The subjects in group B will continue TKI for another one cycle, the obvious response subjects will entered group A, the general response subjects will keep in arm B and continue the TKI monotherapy, and the poor response subjects will exit the study.~Fruquintinib 5mg or regorafenib 120mg, qd po, 3 weeks, Q4w. (The investigators decide to choose fruquintinib or regorafenib)~Toripalimab injection 240mg, Q3w, until the disease progresses or lasts for two years."
45633926|NCT03975179|Procedure|Omission of intraoperative frozen section biopsy for margin status|Omitting intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery
45633927|NCT03975179|Procedure|Frozen section biopsy for margin status|Performing intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery
45633928|NCT02413957|Other|Medication Reconciliation|Pharmacist take the best possible medication history (BPMH), comparison of the BPMH with the admission order (AMO), clarify and solve al discrepancies between the BPMH and the AMO.
45633929|NCT02413957|Other|Pharmaceutical Care|Checking medication under safety considerations (medication at admission, during hospital stay, at discharge); recommendations for inappropriate medication (e.g. contraindications or interactions) or medication related problems. Pharmaceutical care includes Medication Reconciliation.
45633930|NCT03176563|Drug|Arctuvan|application of a herbal drug in the clinical trial REGATTA (NCT03151603)
45633931|NCT03176563|Drug|Placebo to Fosfomycin|application of Placebo to Fosfomycin in the clinical trial REGATTA (NCT03151603)
45633932|NCT03176563|Drug|Fosfomycin|application of an antibiotic drug in the clinical trial REGATTA (NCT03151603)
45633933|NCT03176563|Drug|Placebo to Arctuvan|application of Placebo to Arctuvan in the clinical trial REGATTA (NCT03151603)
45633934|NCT03955835|Device|Treatment with Credo® stent together with the NeuroSpeed® PTA balloon catheter.|Self-expandable Credo® stent together with NeuroSpeed® PTA balloon catheter. Credo® and NeuroSpeed® are already CE approved products, for which within ACUTE an additional new indication shall be examined.
45772897|NCT04385368|Drug|Durvalumab + SoC chemotherapy|Experimental Treatment
45772898|NCT04385368|Other|Placebo + SoC chemotherapy|Placebo Comparator
45772899|NCT03786796|Drug|Olaparib|Olaparib is a crystalline solid, is non-chiral and shows pH-independent solubility of approximately 0.1 mg/mL across the physiological range. Olaparib is presented for oral administration as a green, film-coated tablet containing 25 mg, 100 mg or 150 mg of drug substance. The 100 mg strength is also available as a yellow, film-coated tablet. The 25 mg, 100 mg and 150 mg strengths of olaparib tablets are composed of the same constituents. The tablet cores comprise: olaparib, copovidone, colloidal silicon dioxide, mannitol and sodium stearyl fumarate. The composition of the green tablet film coating is: hydroxypropyl methylcellulose (hypromellose), macrogol 400 (polyethylene glycol 400), titanium dioxide, iron oxide yellow and iron oxide black. The yellow tablet film coating only differs from the green film coating with the omission of iron oxide black.
45772900|NCT03779854|Radiation|Total-Body Irradiation|Undergo TBI
45772901|NCT03779854|Drug|Thiotepa|Given IV
45772902|NCT03779854|Drug|Fludarabine|Given IV
45772903|NCT03779854|Drug|Cyclophosphamide|Given IV
45772904|NCT03779854|Drug|Busulfan|Given IV
45914122|NCT02034370|Device|Lung-function spirometry test|5 minute lung function test performed once preoperatively and once postoperatively
45633935|NCT03925961|Other|Preoperative education|The intervention is focused around providing patients with educational information in the pre-operative setting and determine if this improves patients' surgical experience.
45772905|NCT03779854|Procedure|Allogeneic Bone Marrow Transplantation|Receive unmanipulated T cell replete BM
45772906|NCT03779854|Drug|Tacrolimus|Given IV
45772907|NCT03779854|Drug|Methotrexate|Given IV
45772908|NCT03779854|Procedure|Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation|Receive naive T-cell depleted PBSCs
45772909|NCT03089866|Drug|Midazolam (0.02mg/kg)|Quantify the effects of sedation with midazolam on auditory activation and cognitive performance (mini Mental State exam and complex reaction time).
45772910|NCT00002890|Biological|lintuzumab|
45772911|NCT03081910|Genetic|Autologous CD5.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~Dose level one: 1×10^7 cells/m2~Dose level two: 5×10^7 cells/m2~Dose level three: 1×10^8 cells/m2"
45914123|NCT02034370|Device|Overnight sleep test|Somte sleep monitor to be worn two nights before and the night of surgery.
45935432|NCT00124306|Other|Placebo|Placebo will be dosed exactly as active arm.
45772912|NCT03081910|Genetic|Allogeneic CD5.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~Dose level one: 1×10^7 cells/m2~Dose level two: 5×10^7 cells/m2~Dose level three: 1×10^8 cells/m2"
45633936|NCT03176485|Other|Solar Simulator|A Multiport UV Solar Simulator Model 600 (Solar Light Co., Inc., Philadelphia, PA) will be used to administer Solar Simulated Light (SSL) exposures to formerly unexposed buttock skin.The device is equipped with six 8mm liquid light guides (LLG), allowing for 6 simultaneously conducted exposures.A large 3x2 endplate places the LLGs several centimeters apart and is specifically designed for Sun Protection Factor (SPF) and photo patch testing. The dose of emission from each LLG can be precisely regulated and the spectrum of emission can be limited to UVA (320-390 nm) or UVB+UVA (290-390 nm). The operator can select between UVA only and a combined Ultraviolet-A (UVA)/ Ultraviolet-B (UVB) spectrum by placement of an optical filter. The spectral output (indicated below) follows the distribution of sunlight from 290 to 390 nm.
45633937|NCT05731193|Other|Exposed group (EXP) - 35 students. EXP group will learn pathological and nonpathological sounds for 3 days.|After 3 days students will take 3 tests with different levels of white noise pollution added ( signal-to-noise ratio (SNR) 20, 40 and none added)
45633938|NCT03176251|Other|Gamified-Integrated Curriculum|The experimental group will receive identical training compared to the control group, with the additional incorporation of several elements of gamification, as outlined in the Arm/Group descriptions.
45633939|NCT03909503|Device|Porcine-derived collagen wound dressing|Patients who meet the inclusion criteria will be treated with porcine-derived collagen dressings. The dressing will be used in accordance with its label. After cleansing the wound, the dressing will be placed on the wound. Appropriate primary and secondary dressings will be placed over the intervention product. Patients will visit the clinic once per week to have their dressings re-applied. Wound evaluations will take place once per week with the intervention lasting up to twelve weeks. Concomitant standard of care such as compression for venous ulcers will be provided according to individual patient needs.
45633940|NCT05088551|Other|Patient Education|The education was divided into three parts. The information in the first part of the booklet (general information, preoperative preparation, and operation day) is given in the preoperative period. In the postoperative period, the patients were visited and the information in the second part (postoperative hospital stay, first, second, and third-day goals after surgery) was given. Before the patients were discharged, the information in the third section (things to be considered in the recovery process at home) was presented. According to the physical conditions of the clinic, patient education was carried out in an area suitable for teaching as much as possible.
45633941|NCT02418325|Biological|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
45633942|NCT02418325|Other|Liberation therapy|
45633943|NCT03877133|Device|Near-infrared spectroscopy|Regional oxygen saturation probe is applied to the skin near the kidney bilaterally and is connected to the regional oxygen saturation monitor.
45633944|NCT02418481|Biological|DC-CIK|DC-CIK cells will be used against tumor cells.
45633945|NCT02418481|Biological|γδ T Cell|γδ T cells will be used against breast tumor.
45633946|NCT02418481|Biological|Combination|γδ T/DC-CIK cells will be used against breast tumor.
45633947|NCT03827447|Drug|Vancomycin Oral Capsule|125 mg capsules every 6 hours for 14 days.
45633948|NCT03827447|Drug|Placebo Oral Capsule|Gelatin pill manufactured to mimic 125 mg Vancomycin oral capsule
45633949|NCT01680497|Device|Crosslinked hyaluronic acid dermal filler|All treatment details are at the discretion of the Investigator and should be guided by the Directions for Use. Up to 3 treatments will be administered: Initial treatment, optional top-up treatment at Day 14 post-initial treatment, and optional repeat treatment at Month 12 post-initial treatment.
45633950|NCT02423473|Procedure|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
45633951|NCT02423473|Procedure|Composite resin restoration (Filtek Supreme - 3M)|Restorative procedure do treat tooth structure loss
45633952|NCT02417857|Procedure|Laparoscopic Cholecystectomy (Single Incision)|We performed Single Incision Laparoscopic Cholecystectomy (SILC) operation to the group-1
45633953|NCT02417857|Procedure|Laparoscopic Cholecystectomy (Conventional)|We performed Conventional Laparoscopic Cholecystectomy (CLC) to group-2
45772913|NCT00002896|Drug|chemotherapy|
45772914|NCT00002896|Drug|fluorouracil|
45772915|NCT00002896|Drug|leucovorin calcium|
45772916|NCT00002896|Procedure|conventional surgery|
45772917|NCT00002896|Radiation|low-LET cobalt-60 gamma ray therapy|
45772918|NCT00002896|Radiation|low-LET photon therapy|
45633954|NCT05717777|Other|There is no intervention, only observational study|There is no intervention, only observational study
45633955|NCT02423395|Drug|orphenadrine|Orphenadrine in muscle cramps in cirrhotic patients
45772919|NCT03778060|Device|Cala TWO stimulator|Treatment intervention will consist of subjects undergoing 40 minute sessions of transcutaneous stimulation with the Cala TWO stimulator twice daily for 3 months to reduce hand tremors prior to their undergoing deep brain stimulation 'surgery for treatment of essential tremor at Mayo Clinic.
45772920|NCT03056638|Drug|Degarelix|Degarelix monthly for 6 months
45772921|NCT03056638|Radiation|stereotactic body radiosurgery (SBRT)|SBRT 8 Gy x 5
45772922|NCT01249027|Device|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|Patients who receive XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)will be invited to participate in the study.
45633956|NCT02423395|Drug|Placebo|calcium in muscle cramps in cirrhotic patients
45772923|NCT03046342|Diagnostic Test|Molecular method (PCR)|"Stool samples are being processed through molecular method (PCR) for children with GE.~Epidemiology of acute Gastroenteritis in the pediatric population in Qatar"
45772924|NCT00002902|Drug|irinotecan hydrochloride|
45772925|NCT00002902|Drug|raltitrexed|
45633957|NCT05712083|Drug|BCMA CAR-T cells|Each subject receive BCMA CAR T-cells by intravenous infusion
45633958|NCT02418091|Behavioral|Telehealth|Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
45633959|NCT05711147|Procedure|Abutment removal|4 times healing abutment removal during prosthesis making (impressions, metal try-in, ceramic try-in, prosthesis loading)
45633960|NCT05711147|Procedure|Placement of definitive abutment|Placement of the final prosthetic abutment at the moment of implantation
45633961|NCT05694689|Dietary Supplement|Placebo|Placebo is normal saline, given in the first 28 days after birth, prepared to have the same volume and appearance as vitamin D, which is a clear odorless solution.
45633962|NCT05694689|Dietary Supplement|800 IU/day vitamin D supplementation with feedings in the first 28 days after birth|800 IU/day Vitamin D supplementation until 400 IU/ day are provided as part of usual care. At that point the intervention becomes a supplement of 400 IU/day above that given with usual care. In this way all infants in the intervention group receive 800 IU/day of vitamin D total supplementation in the first 28 days after birth with feedings.
45633963|NCT05694689|Other|Usual Care|Co-interventions will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices
45772926|NCT02992756|Drug|Growth Factors|one dose 3-6 mL of PRP obtained by PRGF Endoret
45772927|NCT01250899|Dietary Supplement|Vitamin D|50,000 IU vitamin D3 twice weekly for 5 weeks, followed by 2000 IU daily maintenance supplementation to complete 12 weeks. At the end of the 12-week period, 25(OH)D levels will be checked. If the subject is still deficient, he/she may undergo a second period of supplementation (at the discretion of their provider) to complete a total of 24 weeks. After 24 weeks, we anticipate all subjects will be kept on daily maintenance supplementation by their primary physicians.
45772928|NCT03716830|Device|verum acupuncture|Participants will receive real acupuncture treatment.
45772929|NCT03716830|Device|sham acupuncture|Participants will receive sham acupuncture treatment.
45772930|NCT03716830|Device|real tDCS|Participants will receive real transcranial direct current stimulation.
45633964|NCT02423239|Drug|Dexanabinol|Patients will receive dexanabinol given once a week, as a slow intravenous infusion (i.v.) over a 3 hour period
45633965|NCT02423239|Drug|Sorafenib|Patients will receive Sorafenib at a dose of 400 mg bid (oral administration)
45633966|NCT02423239|Drug|Nab-paclitaxel|Patients will receive Nab-paclitaxel at a dose of 125mg/m2 intravenous infusion
45633967|NCT02423239|Drug|Gemcitabine|Patients will receive Gemcitabine at a dose of 1000mg/m2 intravenous infusion
45633968|NCT02449733|Behavioral|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
45633969|NCT02449733|Behavioral|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
45772931|NCT03716830|Device|sham tDCS|Participants will receive sham transcranial direct current stimulation.
45772932|NCT01212445|Drug|PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)|13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes
45772933|NCT00002908|Drug|bryostatin 1|
45772934|NCT00002908|Drug|vincristine sulfate|
45772935|NCT00002920|Drug|medroxyprogesterone|
45772936|NCT00002920|Drug|tamoxifen citrate|
45772937|NCT00002920|Procedure|adjuvant therapy|
45772938|NCT01250977|Drug|Donepezil|
45772939|NCT01250977|Drug|Placebo|
45772940|NCT01251757|Other|Interactive Voice Recognition (IVR) phone calls|"The IVR intervention consisted of automated phone calls designed to educate participants about their medications and to assist them in refilling their prescriptions. The calls fell into two basic types: simple refill reminders and tardy calls for those who were overdue for a refill. Calls occured monthly and were triggered by dispensing information in the electronic medical record (EMR). Call features included the ability to transfer individuals to Kaiser's automated prescription refill service as well as to care managers. Although the calls were triggered by and focused on use of ACE inhibitors, ARBs and statins, they also included reminders to use aspirin, which is known to also be effective for secondary prevention in this patient population."
45772941|NCT01251757|Other|Educational mailings and follow-up for nonadherence|Participants received bimonthly educational materials by mail. In addition, patients received mailed refill reminder letters and their providers were notified electronically if the patients failed to refill in response to the automated calls. The educational mailings included personalized health information such as the participant's cholesterol and blood pressure readings, as well as tools for improving adherence such as frequently asked questions (FAQs) about their medications, a pocket-sized calendar for tracking refills with pertinent phone numbers and web site information and space for them to write their medical record number and prescription numbers.
45772942|NCT01252147|Other|No treatment|No treatment (intervention) will be provided in this study
45914124|NCT02034812|Other|Decipher Questionnaire|Pathological data from 12 de-identified patient cases will be reviewed by at least 25 Radiation Oncologists before and after exposure to the Decipher test results. Given the number of patient cases, reviewed by each participant, this allows for assessment of decision making based on 300 patient case reviews at each time point, immediately following RP and at the time of PSA rise.
45914125|NCT02034825|Other|Decipher Questionnaire|Each participant will complete the pre and post-Decipher eCRQs for a minimum of 5 cases, and a maximum of 25 cases.
45914126|NCT02034864|Other|Osteopathic manipulative treatment|A standardized manipulative treatment according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized manipulative treatment.
45633970|NCT02449733|Behavioral|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
45772943|NCT01161121|Drug|adenosine|Measuring FFR and Coronary Flow Reserve after administration of IV adenosine 140 mcg/kg/min for 2 minutes.
45772944|NCT01161121|Drug|regadenoson|Measuring FFR and Coronary Flow Reserve after administration of IV regadenoson 0.4 mg over 10 seconds.
45772945|NCT03010579|Drug|erythropoietin|Erythropoietin will be administered subcutaneously (s.c.) at the dose of 10 000 IU, three times a week. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.
45772946|NCT03010579|Drug|iron supplementation|If necessary, oral ferrous succinate, vitamins B12 and folic acid will be administered.
45772947|NCT01214083|Drug|N-acetylcysteine + high-dose naltrexone (150 mg)|All subjects will be evaluated weekly for 12 weeks.
45772948|NCT01214083|Drug|High-dose naltrexone (150 mg) alone|All subjects will be evaluated weekly for 12 weeks.
45772949|NCT01214083|Drug|Low-dose naltrexone (50 mg) alone|All subjects will be evaluated weekly for 12 weeks.
45772950|NCT03010813|Procedure|Robotic single port surgery and NOTES|Robotic single port colorectal surgery; Robotic transanal surgery; Robotic single port urologic surgery; Transoral robotic surgery
45772951|NCT03010735|Dietary Supplement|probiotics|Daily take 4.0E+10 CFU of probiotics
45772952|NCT03010735|Dietary Supplement|Placebo|
45772953|NCT01254877|Drug|ondansetron|ondansetron 0.2 mg bid, oral preparation, 16 weeks
45772954|NCT01254877|Drug|placebo ondansetron|Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.
45772955|NCT01254877|Drug|Ondansetron|Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration
45772956|NCT02189317|Drug|Exparel|For the treatment group a total of 40 cc consisting of 20 cc of 1.3% Exparel® and 20 cc of 0.5 % marcaine will be administered to the ACL harvest site, into the periosteum surrounding the distal tibial tunnel site, and in the proximity of the skin incisions. No infiltration of Exparel will be provided intra-articularly.
45772957|NCT03713944|Drug|Carboplatin|Carboplatin, AUC 5
45772958|NCT03713944|Drug|Pemetrexed|Pemetrexed 500mg/m2
45772959|NCT03713944|Drug|Atezolizumab|Atezolizumab 1200mg
45772960|NCT03713944|Drug|Bevacizumab|Bevacizumab 15mg/kg
45772961|NCT01256983|Behavioral|Bright Light Therapy|10000 Lux for 30 Minutes according to sleep wake rhythm
45772962|NCT01256983|Behavioral|Wait-list intervention|10000 Lux for 30 Minutes according to sleep wake rhythm
45633971|NCT02449733|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|"FTC/TDF is a once daily oral tablet taken with or without food. The tablet includes 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF).~For men who meet eligibility criteria, Pre-exposure prophylaxis (PrEP) with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit."
45633972|NCT02449733|Other|HIV Testing|Rapid HIV testing at multiple time points
45772963|NCT02986048|Other|Proton Beam Therapy|Intervention is not assigned. Only patient data is being collected
45914127|NCT02034864|Other|Placebo of osteopathic manipulative treatment|"A standardized placebo of manipulative treatment consisting in light touch and according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized placebo of manipulative treatment."
45914128|NCT02034942|Other|Non-sedation|
45914129|NCT02034942|Other|Sedation, control|
45914130|NCT02035020|Drug|gamma interferon|IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
45914131|NCT02035046|Procedure|Samplings of blood|
45914132|NCT02035046|Procedure|Sampling of urine|
45772964|NCT01214161|Drug|2% lidocaine gel|"Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control group with an inert gel similar in appearance, color and consistency to the lidocaine gel.~Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room."
45914133|NCT02035046|Procedure|Measure of the blood pressure|
45914134|NCT02035046|Procedure|glycemia test|
45914135|NCT02035540|Other|Decellularized human valves|
45935433|NCT00073944|Drug|forodesine hydrochloride|
46070120|NCT00809263|Drug|homeopathic remedy|Homeopathic remedy 12C potency, 10 drops TID X 7 days
45633973|NCT02449733|Other|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for sexually transmitted infections (STIs )will be treated at the clinic site.
45447944|NCT02124928|Procedure|Carotid endarterectomy|Carotid endarterectomy is a surgery used to reduce the risk of stroke, by correcting stenosis in the carotid artery. Endarterectomy is the removal of material on the inside (end-) of an artery.An incision is made on the midline side of the Sternocleidomastoid muscle. The incision is between 5 and 10 cm in length. Then the patients get 5000 IU heparin by the anesthesia. The internal, common and external carotid arteries are carefully identified, controlled with vessel loops, and clamped. The lumen of the internal carotid artery is opened, and the atheromatous plaque removed. The artery is closed using suture. The procedure is performed under local anesthesia. Local anesthesia, opposite to general, allows for direct monitoring of neurological status by intra-operative verbal contact and testing of grip strength.
45633974|NCT02449733|Procedure|Post-exposure prophylaxis (PEP)|Two to three antiretroviral medicines as soon as possible (recommended is emtricitabine/tenofovir disoproxil fumarate plus either raltegravir or dolutegravir), but no more than 72 hours (3 days) after one may have been exposed to HIV, to try to reduce the chance of becoming HIV-positive. They must be taken for 28 days.
45633975|NCT02449733|Behavioral|Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
45633976|NCT03176329|Other|Nursing 1 : INTELLIVENT-ASV|
45772965|NCT01214161|Other|placebo|"Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control/placebo group with an inert gel similar in appearance, color and consistency to the lidocaine gel.~Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room."
45633977|NCT03176329|Other|Nursing 2 : INTELLIVENT-ASV|
45772966|NCT02984410|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|IMRT (Simultaneous Integrated Boost (SIB) and accelerated regimen) with selective neck node dissection
45772967|NCT02984410|Procedure|Trans Oral Surgery (TOS)|TOS (Trans Oral Laser Microsurgery (TLM), Trans Oral Robotic Surgery (TORS), conventional) with selective neck node dissection
45772968|NCT01257217|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1|Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
45772969|NCT01257217|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
45772970|NCT01257217|Device|Acri.LISA® 366D IOL|Aspheric diffractive IOL with +3.75 D add power implanted for long-term use over the lifetime of the cataract patient
45914136|NCT02035670|Other|Two-step diagnostic strategy|"The first step is to differentiate FUO according to the onset of disease and invasive pathogens. Apart from collecting detailed present medical history and careful physical examination, it focuses on seeking the clues of bacterial invasion two weeks before the fever onset from five aspects.To finish this part, the doctor needs to ask for informations following a list we already made, which covers more than forty definite items. If some of these items were proved existed, result of first step would be positive.~The second step is calculating the integral score of inflammatory biomarkers and vital diagnostic clues, WBC& N, ESR, CRP, LDH, SF, ANCA, ANA, RF, PCT and T-Spot, as well as the clinical findings were included in this integrating system.The results of these items will be recorded and calculated with certain interval of time. If the score were more than nine, this part would be considered. positive."
45935434|NCT00124345|Device|MR730|humidity measurement inside the helmet by a capacitative hygrometer and evaluation of patients' comfort
45772971|NCT01257217|Device|Acri.LISA® 466TD Toric IOL|Aspheric diffractive IOL with +3.75 D add power and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
45772972|NCT02945800|Drug|nab-Paclitaxel|nab-Paclitaxel: 125 mg/m^2 intravenously (IV)
45772973|NCT02945800|Drug|Gemcitabine|Gemcitabine: 1000 mg/m^2 intravenously (IV)
45633978|NCT03176329|Other|Nursing 1 : Conventional mode|
45633979|NCT03176329|Other|Nursing 2 : Conventional mode|
45772974|NCT02981329|Drug|Metformin|Metfomin will be taken daily. The metformin dose will be increased during two time points per subject if protocol dose escalation criteria is met.
45772975|NCT02981329|Behavioral|Questionnaires|Questionnaires will be completed to assess the impact quality of life
45772976|NCT00383656|Drug|GnRH|75 ng/kg GnRH IV
45772977|NCT00383656|Device|Pump|portable, infusion pump for GnRH
45772978|NCT01214317|Procedure|plasmapheresis|3 courses of plasmapheresis are performed before mitoxantrone injection in first 3 months to investigate the efficacy of plasmapheresis in comparison with the other arm that are only treated with mitoxantrone
45772979|NCT00383734|Device|Newfill|1 to 7 injections of drug
45772980|NCT00383734|Device|Eutrophill|1 to 7 injections of drug
45772981|NCT00383812|Drug|Intravitreal Bevacizumab|
45935435|NCT00043199|Drug|Aroplatin (Liposomal NDDP, L-NDDP)|
45772982|NCT02912104|Biological|human amniotic epithelial cells (hAECs) transplantation|hAECs are prepared and cultured using GMP(Good Manufacturing Practice, GMP) rules, 3×10^7 hAECs in 4.5ml is separately injected into ovarian tissue by bilateral ovarian artery infusion.
45772983|NCT02189629|Drug|CD5789 (trifarotene)|
45772984|NCT04330066|Diagnostic Test|Abdominal ultrasound measurement of the endometrial lining|On the day of the participants frozen embryo transfer, an endometrial thickness measurement (T2) will obtained from an abdominal ultrasound during the embryo transfer.
45772985|NCT00002926|Drug|cytarabine|
45772986|NCT00002926|Drug|etoposide|
45772987|NCT00002926|Drug|idarubicin|
45633980|NCT05082493|Drug|Berubicin Hydrochloride|Berubicin will be administered as 1-hour infusions each day for 3 consecutive days followed by 18 days off drug (ie, 21-day cycles). The starting dose is based on population PK modeling of data from adult studies and will be 1.20 mg/m2 (Dose Level 1). During the study, PK data will be incorporated into a PK model on an ongoing basis and may be used to inform dose escalation decisions
45772988|NCT00002926|Procedure|allogeneic bone marrow transplantation|
45772989|NCT00002926|Procedure|peripheral blood stem cell transplantation|
45772990|NCT01281007|Drug|Famciclovir|Famciclovir 125 mg every 12 hours for 5 days
45772991|NCT01281007|Drug|Aciclovir|Aciclovir 200 mg every 4 hours fo 5 days
45633981|NCT05377853|Behavioral|Cognitive-Kinesthetic Navigational Training|Training with tactile maps to improve spatial memory capability for enhanced navigational capabilities.
45633982|NCT02418013|Other|Fresh cord blood(experimental group A)|"Cord blood is administered through intravenous at CHA clinical trail institute.~Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered prior to the treatment."
45914137|NCT02035709|Drug|Hydromorphone|Hydromorphone is given by PCA or TCI-PCA. The TCI-PCA System steer the hydromorphone infusion pump to achieve plasma concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma concentration range, lock times and infusion speed.
45914138|NCT02035774|Procedure|LSIB + SSNB|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml) or LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml placebo, saline)
45914139|NCT02035839|Device|Target Temperature Management of 34°C|In hospital target temperature management to achieve core body temperature of 34°C for 24 hours.
45633983|NCT02418013|Other|Frozen cord blood(experimental group B)|"Cord blood is administered through intravenous at CHA clinical trail institute.~Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered"
45633984|NCT02418013|Other|Frozen plasma(experimental group C)|"Cord blood is administered through intravenous at CHA clinical trail institute.~Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered"
45633985|NCT02418013|Other|Placebo group|"A placebo agent is administered through intravenous at CHA clinical trail institute.~It should be certain that when administered, participants are not aware of which treatments are preformed."
45633986|NCT05377775|Device|Iliac Stenting|Conventional Implantation of mesh stent in iliac stenosis with high-risk plaques
45633987|NCT02413411|Behavioral|DA/MI Intervention|Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
45772992|NCT02898610|Drug|Colchicine|
45772993|NCT01281475|Drug|Levodopa|"Levodopa/Carbidopa (4:1)~Dosages are based on levodopa.~Subjects randomized to the levodopa arm will receive a levodopa dose of 5 mg/kg/day in the first 2 weeks of the study, a levodopa dose of 10 mg/kg/day in the second 2 weeks of the study, and a levodopa dose of 15 mg/kg/day (up to a maximum of 800 mg per day) for the remaining duration of the study.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
45772994|NCT01281475|Drug|Placebo Oral Capsule|The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa.
45772995|NCT03009721|Drug|Other: Not applicable-observational study|
45772996|NCT01587092|Behavioral|WorkStation|Participants will be asked to attend 2 scheduled sessions per day of treadmill walking, which will replace their sitting desk time. Participants will complete 2 sessions per day for 6 months.
45772997|NCT01587092|Behavioral|Usual Working Condition|Participants will be asked to continue working at their desk in their usual manner.
45914140|NCT02035839|Device|Target Temperature Management of 32°C|In hospital target temperature management to achieve core body temperature of 32°C for 24 hours.
45633988|NCT02413411|Behavioral|an educational program (an NIH-developed booklet)|
45633989|NCT01826591|Behavioral|Low-Carbohydrate Diet|Counseling/instruction on how to follow a low-carbohydrate diet.
45633990|NCT01826591|Behavioral|Low-Fat Diet|Counseling/instruction on how to follow a low-fat diet.
45772998|NCT05052944|Device|Cochlear implantation|Patients who receive cochlear implant for single-sided deafness
45772999|NCT00002932|Drug|cisplatin|
45773000|NCT00002932|Radiation|radiation therapy|
45773001|NCT01572662|Drug|Fludarabine monophosphate|40 mg/m2 by vein on Days -6 through -3.
45773002|NCT01572662|Drug|Busulfan|First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies.
45773003|NCT01572662|Procedure|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood progenitor cells infused on Day 0.
45773004|NCT01572662|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as 24 hour continuous infusion daily adjusted to achieve therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
45773005|NCT01572662|Drug|Methotrexate|5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
45914141|NCT02035839|Device|Target Temperature Management of 33°C|In hospital target temperature management to achieve core body temperature of 33°C for 24 hours.
45914142|NCT02035878|Other|Probiotics|probiotic intervention: 400mg of probiotic capsule
45914143|NCT02035878|Drug|Placebo|placebo comparator
45914144|NCT02035891|Drug|colchicine 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
45914145|NCT02035891|Drug|placebo 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
45935436|NCT00124384|Behavioral|CBT-I|
45935437|NCT00124384|Drug|modafinil|
45633991|NCT01826591|Behavioral|Mobile App|Mobile app to increase vegetable consumption. Participants with iPhones will be re-randomized to receive a mobile app beginning at either months 4-5 or months 7-8. The first phase during months 4-7 will be used to compare the effect of a mobile app (intervention) vs. no mobile app (waiting-list control). The a priori hypothesis is that vegetable consumption will increase among those who receive the app in both diet groups.
45773006|NCT01572662|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
45773007|NCT02884102|Genetic|genetic sequencing|
45773008|NCT04781582|Procedure|Lung volume reduction surgery|Surgical lung volume reduction
45914146|NCT02035956|Biological|IVAC MUTANOME, RBL001/RBL002|Each patient will receive multiple repeated intranodal injections of IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002.
45914147|NCT02036151|Drug|xylitol|Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month
45633992|NCT02413567|Device|DMR Procedure (Fractyl)|Endoscopic procedure
45633993|NCT05377931|Diagnostic Test|Changes in heart pulse rate|Measuring heart pulse rate using a wrest smart watch.
45633994|NCT05377931|Diagnostic Test|Changes in eye strain|Changes in Accommodation measured by auto refractometer before and after mobile battle ground gaming.
45633995|NCT02417623|Behavioral|Smartphone Application group|Intervention group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline, complemented with a smartphone app
45633996|NCT04543331|Drug|brolucizumab|There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
45633997|NCT02422849|Other|hospital specialist|
45633998|NCT02422849|Other|General Practitioner|
45633999|NCT02417467|Other|Nicotine E-Cigarette|
45773009|NCT04781582|Procedure|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction by endobronchial valves
45773010|NCT02822092|Drug|Risperidone or Aripiprazole (patients only)|Inpatients deemed eligible for the study, we be put on open-label risperidone
45773011|NCT01258153|Drug|Nepadutant oral solution|Oral administration once daily for 7 days
45773012|NCT01258153|Drug|Nepadutant oral solution|Oral administration once daily for 7 days
45773013|NCT01258153|Drug|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
45773014|NCT01555268|Biological|trebananib|Given IV
45634000|NCT02417467|Other|Non-Nicotine E-Cigarette|
45634001|NCT02417467|Behavioral|Counseling|
45634002|NCT02422771|Other|FIFA 11+ warm-up|A sequence of 15 exercises performed before soccer practices and games. The exercises include strength, agility, balance and motor control components and take about 15-20 minutes to perform. The intervention replaces any previous warm-up the athletes may have done.
45634003|NCT03199937|Behavioral|Flexible Futures|Flexible Futures is a novel and innovative cognitive-behavioral treatment that directly addresses executive function and self-regulation deficits in ASD. Flexible futures targets flexibility and planning through self-regulatory scripts that are consistently modeled and reinforced. Scripts compensate for the inner speech and organization/integration deficits in ASD, and are practiced repeatedly to achieve automaticity. Content focuses on key functions needed for college success, such as: intrinsic motivation, how to implement skills socially, self-advocacy skills application of flexibility and organization scripts and strategies in the service of a long-term goal, and management of time and priorities.
45634004|NCT03199937|Other|Current standard of care|Flexible Futures will be compared to a social skills treatment as usual that capitalizes on current standard of care provided by local school districts.
45773015|NCT01555268|Drug|cytarabine|Given SC
45773016|NCT01555268|Other|laboratory biomarker analysis|Correlative studies
45773017|NCT01555268|Other|pharmacological study|Correlative studies
45773018|NCT00002938|Procedure|conventional surgery|Salvage prostatectomy
45773019|NCT00840944|Drug|somatropin|somatropin 0.050 mg/kg/day
45773020|NCT00840944|Drug|triptorelin|triptorelin 3.75 mg each month
45773021|NCT04781270|Drug|mFOLFOXIRI regimen|oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1
45773022|NCT04781270|Drug|mFOLFOX regimen|oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1
45773023|NCT04781270|Drug|Bevacizumab|5 mg/kg on day 1
45773024|NCT02745028|Dietary Supplement|Monosodium glutamate|A single dose of weight adjusted monosodium glutamate will be added at the time of a repeat radionuclide gastric emptying study
45773025|NCT00003394|Drug|carboplatin|
45773026|NCT00003394|Drug|endocrine-modulating drug therapy|
45773027|NCT00003394|Drug|estramustine phosphate sodium|
45773028|NCT00003394|Drug|goserelin acetate|
45773029|NCT00003394|Drug|leuprolide acetate|
45773030|NCT00003394|Drug|paclitaxel|
45773031|NCT00003400|Biological|filgrastim|
45914148|NCT02036151|Drug|fluoride varnish application|The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
45914149|NCT02036255|Drug|Taurolidine Urokinase|
45914150|NCT02036255|Drug|Taurolidine Heparin|
45935438|NCT00124423|Procedure|Megavoltage CT scan|
45935439|NCT00124501|Behavioral|Biofeedback-assisted relaxation training|10 sessions BART
45935440|NCT00077883|Drug|TLK286, cisplatin|TLK286 administered once every 3 weeks (± 2 days) at two dose-ranging levels (750 mg/m²) and 1,000 mg/²) in combination with two dose levels of cisplatin (75 mg/m² and 100 mg/m²) of cisplatin once every 3 weeks (± 2 days).
45935441|NCT00124540|Drug|misoprostol|
45935442|NCT00124540|Drug|placebo|placebo resembling misoprosotl
45773032|NCT00003400|Drug|carmustine|
45773033|NCT00003400|Drug|cisplatin|
45773034|NCT00003400|Drug|melphalan|
45773035|NCT00003400|Drug|vinorelbine tartrate|
45773036|NCT00003400|Procedure|peripheral blood stem cell transplantation|
45773037|NCT04348370|Biological|BCG Vaccine|BCG vaccine will be administered by research nurses. Participants and investigators will be blinded.
45773038|NCT04348370|Biological|Placebo Vaccine|Placebo vaccine will be administered by research nurses. Participants and investigators will be blinded.
45773039|NCT00002944|Drug|carboplatin|Given IV
45634005|NCT02422927|Dietary Supplement|Nutraceutical Combination|red yeast rice extract 200 mg (equivalent to 3 mg monacolins), policosanol 10 mg, berberine 500 mg, 0.2 mg folic acid, coenzyme Q10 2 mg, and astaxanthin 0.5 mg once daily
45773040|NCT00002944|Drug|lomustine|Given IV
45773041|NCT00002944|Drug|procarbazine hydrochloride|Given PO
45773042|NCT00002944|Drug|thioguanine|Given PO
45634006|NCT02422927|Other|Standard of Care|low-cholesterol/low-saturated fat diet and regular aerobic physical activity schedule
45773043|NCT00002944|Drug|vincristine sulfate|Given PO and IV
45773044|NCT04778306|Procedure|Transoral Laser Surgery|Remove of the laryngeal tumour via diode laser
45773045|NCT04778072|Dietary Supplement|Ferrous sulfate 14mg once daily|ACTIVE IRON™ (ferrous sulfate) 14 mg elemental iron once daily with matching placebo
45773046|NCT04778072|Dietary Supplement|Ferrous sulfate 25mg once daily|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron once daily with matching placebo
45773047|NCT04778072|Dietary Supplement|Ferrous sulfate 25mg twice daily|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron twice daily
45935443|NCT00124696|Drug|Cocaethylene|
46070121|NCT00862719|Drug|Sitagliptin|600 mg sitagliptin taken orally per the schedule listed in each of the three separate arms.
45447945|NCT02122120|Dietary Supplement|HEN|Patients with tube feeding with FSMP for at least twelve months
45634007|NCT02422927|Other|Placebo|placebo
45634008|NCT02423005|Device|Neurotech Vital Compact|Neuromuscular electrical stimulation of the pelvic floor via an arrangement of external electrodes held in place by a garment.
45634009|NCT02423005|Device|itouch Sure Pelvic Floor Exerciser|Vaginal probe with electrodes designed to deliver electrical stimulation to the pelvic floor muscles.
45634010|NCT03199703|Device|Baylis transseptal system group|
45634011|NCT03199703|Device|Standard conventional transseptal group|
45634012|NCT05233501|Procedure|low level laser therapy|adjunctive application of low level laser therapy to non-surgical periodontal treatment
45634013|NCT05233501|Procedure|non-surgical periodontal treatment|standart periodontal therapy
45773048|NCT04778462|Device|extracorporeal shock wave and conventional treament|"Extracorporeal shock wave for 700 impulses of 0.056 mJ/mm at a frequency of 10 Hz to the taut band and 300 impulses surrounding the taut band will be applied as low energy 2 sessions per week for 2 weeks The will be used as a radial type of shock wave therapy.~Strengthening, stretching exercises and ischemic compression:~Isometric neck extensor exercise:~Isometric neck flexor exercise:~Isometric neck side bending muscle exercise:~Stretching exercise:~Passive stretching for the neck extensor muscles:~Passive stretching of the neck side-bending muscles:~Ischemic compression"
45773049|NCT04778462|Device|high pain threshold ultrasound and conventional treatment for myofascial pain syndrome trigger points|"will be applied in continuous mode, with the probe placed directly on the TrP and held motionless. To elicit threshold pain, the US probe will be kept static on the TrP. Intensity gradually will be increased to the level of maximum pain the patient could bear. It will be kept at that level for 3 to 4 seconds, then will be reduced to the half-intensity level for another 15 seconds. This procedure was repeated 3 times.the intensity of US will be dependent on the patient's level of pain. intensity will be applied in the range of 0.5 to 2.0 Watt per/cm2. Patients continually report their pain level and its localization and nature High-power pain threshold US will be applied 4 times, with a 3-day interval 2 sessions per week for 2 weeks .~1)Isometric neck extensor exercise2)Isometric neck flexor exercise3)Isometric neck side bending muscle exercise,Stretching exercise:Passive stretching for the neck extensor muscles ,stretching of the neck side-bending muscles,Ischemic compression"
45773050|NCT04778462|Other|conventional treatment for myofascial pain trigger point|"Strengthening, stretching exercises and ischemic compression:~Isometric neck extensor exercise:~Isometric neck flexor exercise:~Isometric neck side bending muscle exercise:~Stretching exercise:~Passive stretching for the neck extensor muscles:~Passive stretching of the neck side-bending muscles:~Ischemic compression"
45773051|NCT04778228|Device|mechanical ventilation|"critically ill patients requiring mechanical ventilation (MV) were ventilated using high tidal volumes (Vt) and high airway pressures, until the pivotal ARDS net randomized controlled trial (RCT) demonstrated that a lung-protective MV strategy using a Vt of 4-8 mL/kg predicted body weight (PBW) and moderate levels of positive end-expiratory pressure (PEEP) improved survival (2). Since then, limitation of Vt to 4-8 mL/kg PBW, plateau pressures (Pplat) to a maximum of 30 cm H2O, and application of PEEP 10 -16 cm H2O represent the standard for MV in ARDS patients."
45773052|NCT00002950|Biological|sargramostim|
45773053|NCT00002950|Drug|topotecan hydrochloride|
45773054|NCT04780646|Behavioral|Nature therapy in urban nature|Nature therapy means visits in nature, actively perceiving the flora and fauna
45773055|NCT04780646|Behavioral|City Walk|City Walk means walking through urban surroundings (houses, streets, concrete..) with as little as possible contact to nature
45773056|NCT02739022|Behavioral|Early Psychological Support for the Critically Ill (EPSCI)|early psychological support based on positive therapeutic suggestion
45773057|NCT03726554|Device|Comprehensive Reverse Porous Augmented Glenoid|Three glenoid baseplate options designed for various severities of glenoid erosion and deformity, the device promotes bony ingrowth while restoring natural human anatomy.
45773058|NCT03726554|Device|Comprehensive Mini Humeral Tray|The mini humeral tray offers additional sizing options to the Comprehensive Shoulder line. The mini tray is designed to fit smaller anatomies.
45773059|NCT00002956|Biological|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
45935444|NCT00124774|Procedure|Nucleoplasty|
45935445|NCT00043277|Drug|Angiomax (bivalirudin)|
45634014|NCT03199781|Device|Motorized mechanical massage with the Dermothonus Slim® Ibramed with cosmetics|Patients will be treated with motorized mechanical massage with the Dermothonus Slim® electromedical equipment (Ibramed- Brazilian Industry of Electrical Equipment) associated with cosmetics with lipolytic active principle, being performed twice a week totaling 10 sessions by a dermato-functional physiotherapist.
45773060|NCT00777140|Drug|Deferoxamine|"Intravenous deferoxamine: bolus 10mg/Kg (initiated during thrombolytic infusion, iv tPA), followed by intravenous perfusion of 20/40/60mg/Kg during 72h. It's a dose-finding study with 3 different doses of deferoxamine, with 20 patients (15 active:5 placebo) in each step.~Bolus + 72h perfusion of saline solution for the placebo group."
45914151|NCT02036450|Device|Implantable loop recorder (Medtronic Reveal LINQ(TM))|The patients in the experimental arm receive an implantable loop recorder (Medtronic Reveal LINQ(TM)) with continuous monitoring, and are followed by daily automated remote transmissions. New arrhythmia episodes are reviewed daily by an experienced medical doctor. If AF lasting ≥6 minutes is detected and confirmed by at least two senior cardiologists, OAC is initiated. Decision about specific type of OAC, and possible further clinical work-up or treatment, is left to the treating physician and the patient. The remote monitoring continues until end of service of the device, patient withdrawal or other end-of-study.
45914152|NCT02037022|Behavioral|Pivotal Response Treatment Package (PRT-P)|
45914153|NCT02037282|Drug|Anti-influenza IVIG|
45914154|NCT02037542|Behavioral|Diet and exercise|Upon enrollment, the patient will be asked to meet with a dietitian to assess the individual patient's current diet and exercise routines. In the first session, the dietitian will provide individual counseling and together with the patient devise weight loss / exercise strategies that fit the patients' lifestyle. Following the initial assessment, patients will embark on a weekly program, with weekly meetings lasting 30min - 1h. Patients will be asked to record meal portions weekly in a Food Log (Appendix B), according to the established goal. At each meeting, the dietitian will review the Food Log with the patient and evaluate progress.
45634015|NCT02413177|Behavioral|EEG-no RTNF|All EEG sessions are done on an individual basis. Group 2 will receive EEG (no RTNF) at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
45634016|NCT02413177|Behavioral|EEG-RTNF|All EEG sessions are done on an individual basis. Group 1 will receive EEG-RTNF training from the PCC at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
45634017|NCT04542707|Procedure|joint manipulation|Thrust manipulation to the spine, hand, and foot
45634018|NCT04542707|Procedure|Exercise|Strength training, bike aerobic training, and yoga exercise
45634019|NCT04542707|Device|Soft tissue massage|Graston tool
45634020|NCT02413099|Drug|KBMSI-2|The KBMSI-2 capsules (6gm/capsule) and placebo were provided by Korean Bio Medical Science Institute (Seoul, Korea). KBMSI-2 was analyzed by high-performance liquid chromatography. KBMSI-2 contained major ginsenoside-Rb1: 260.53ug/g, -Rb2: 543.91ug/g, -Rc: 424.92ug/g, -Re: 377.32ug/g, -Rf: 1160.55ug/g, -Rg1: 703.97ug/g, Curcumin 60.73ug/g, Allantoin 98.66ug.g, and Loganin 744.13ug/g. During the study period, two capsules were taken daily for 8 weeks. The placebo capsules were identical in shape, color, and taste.
45634021|NCT02607449|Drug|FS-1|FS-1 is a liquid solution for internal intake and has antimicrobial and antibacterial activities.
45914155|NCT02038062|Procedure|Sevoflurane preconditioning|Preconditioning by transient application of sevoflurane
45935446|NCT00074022|Biological|GTI-2040|Given IV
45935447|NCT00074022|Drug|docetaxel|Given IV
45935448|NCT00074022|Other|laboratory biomarker analysis|Correlative studies
45935449|NCT00074022|Other|pharmacological study|Correlative studies
45447946|NCT02125006|Behavioral|Mindfulness-Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups. To assess therapist adherence to the protocol, sessions will be recorded. A random selection of 50% of sessions will be rated by an MBSR trainer who completed the University of Massachusetts Centre for Mindfulness in Medicine, Health Care and Society Teacher Development Intensive using a checklist of specified treatment components. A percentage score for each session rated will be calculated to determine therapist adherence.
45447947|NCT02127814|Dietary Supplement|Lactobacillus reuteri|One chewable tablet of 1E8 CFU L. reuteri, once per day
45634022|NCT02607449|Drug|Placebo|Placebo without any active pharmaceutical ingredients
45935450|NCT00124813|Drug|thalidomide|
45634023|NCT02417389|Drug|cinacalcet|During Phase 1 (months 1-12): oral administration; 30 mg twice/day (dose to be increased if needed).
45634024|NCT02417389|Drug|Alendronate|During Phase 2 (months 13-24): oral administration; 70 mg once/week (in addition to cinacalcet 30 mg twice/day as during Phase 1).
45634025|NCT04928963|Dietary Supplement|Prolon - FMD|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides ~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide ~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
45634026|NCT02412943|Other|Fresh Frozen Plasma|Liquid portion of human blood that was centrifuged, separated, and frozen solid within 6 hours of collection
45935451|NCT00124813|Drug|idarubicin|oral idarubicin
45634027|NCT03177655|Other|Guided Imagery|Guided Imagery meditation
45634028|NCT03177655|Other|Journaling|Keeping a journal
45773061|NCT00003406|Drug|carboplatin|
45773062|NCT00003406|Drug|docetaxel|
45773063|NCT00003406|Drug|ifosfamide|
45773064|NCT00003406|Procedure|autologous bone marrow transplantation|
45773065|NCT00003406|Procedure|bone marrow ablation with stem cell support|
45773066|NCT00003406|Procedure|peripheral blood stem cell transplantation|
45634029|NCT02413021|Drug|Cytarabine|20 mg/m^2 , SC, two times a day for 10 days every 30 days for 1 cycle
45634030|NCT02413021|Drug|Deferasirox|20 mg/kg ,oral, per day
45634031|NCT01680341|Drug|insulin degludec/insulin aspart|Twice weekly self-titration at intervals of 3-4 days, based upon a single pre-breakfast and pre-dinner SMPG (self-measured plasma glucose) value. For subcutaneous (s.c., under the skin) administration.
45634032|NCT01680341|Drug|insulin degludec/insulin aspart|Once weekly self-titration based upon the lowest of 3 pre-breakfast and 3 pre-dinner SMPG (self-measured plasma glucose) values. For subcutaneous (s.c., under the skin) administration.
45634033|NCT03177811|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
45773067|NCT04304768|Biological|Fluzone Quadrivalent|0.5 ml prefilled syringe administrated intramuscularly
45634034|NCT03177811|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
45447948|NCT02122276|Procedure|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch exercise on ankle.
45634035|NCT03177733|Procedure|Evaluation of a breast double block|"we made an association of the serratus block and the PIF block, which allows for a complete block of both the laterals branches of intercostal nerves (with the serratus block) and of anterior branches of intercostal nerves (with the PIF block). Therefore, this association of blocks may lead to a complete analgesia of the breast, while the serratus block alone only allows for an analgesia of the lateral part of the breast.~The objective is to analyze this technique through a collection form that evaluates the satisfaction and post-operative morphine consumption of women receiving this association before a general anesthesia for a unilateral mastectomy with homolateral total lymphadenectomy.~This is a purely observational study that assesses our current practice in this type of surgery."
45634036|NCT03175939|Radiation|Radiotherapy|External beam radiotherapy with curative intent, at least 66 Gy
45634037|NCT03175939|Drug|Cisplatin|cisplatin IV injection over 3 hours
45634038|NCT03175939|Drug|5-FU|5-FU IV 24 hours continuous infusion
45634039|NCT02602145|Other|follow-up CTA|All patients will receive PAD stents as their normal standard of care determined by their treating physician. If the patient would decide to enroll in the study, we will perform a post-operative contrast-enhanced CTA of the lower extremities at 6-12 months after stenting.
45634040|NCT03176017|Procedure|Ejaculatory sparing TUIP|The bladder neck will be incised and vaporized at the 5 or 7-o'clock position. The incision will start near the ureteral orifice and carry downward to about 0.5-1.0 cm proximal to the verumontanum
45634041|NCT03176017|Procedure|Conventional TUIP|the bladder neck will be incised by Collins knife at the 5 or 7-o'clock position till the verumontanum.
45634042|NCT03199625|Behavioral|Cognitive therapy|
45634043|NCT03199625|Behavioral|Behavior therapy|
45634044|NCT03199625|Drug|SSRI antidepressants|
45634045|NCT02417077|Other|Photographic Review|Photographic review of subjects who received treatment with onabotulinumtoxinA for crow's feet lines.
45634046|NCT02412865|Behavioral|Quit4Baby|
45634047|NCT02412865|Behavioral|Text4Baby|
45773068|NCT02732080|Device|deferred coronary stenting|Final coronary stenting will be performed when coronary auto regulation was recovered (approximately 30 minutes after establishment of TIMI III flow şn the infarct related artery)
45634048|NCT03199313|Drug|Sutezolid|Sutezolid supplied as tablets and matching placebo for oral administration.
45773069|NCT02732080|Device|immediate stenting|Stent implantation will be performed immediately after balloon angioplasty (or thrombectomy or wire crossing) as it is performed in daily routine.
45773070|NCT00003412|Biological|recombinant interleukin-12|
45773071|NCT02715622|Procedure|Hernia repair|Patient undergoing Hernia repair using different surgical modalities as per the surgeon's standard of care practice
45447949|NCT02125084|Drug|Everolimus|
45447950|NCT02125084|Drug|Enzalutamide|
45634049|NCT03199313|Drug|Placebo|Matching Sutezolid placebo
45634050|NCT02412709|Device|QTScreen ECG Recorder|Subjects will be randomly assigned to the: Parents Performing ECG (PPE) group or Staff Performing ECG (SPE) group. This will assess whether parents are able to use QTScreen on babies at home.
45634051|NCT03199235|Device|Lucky Iron Fish|200g iron ingot that is placed in boiling water for 10+ minutes, and then removed. The water is then used to eating and drinking.
45634052|NCT03199235|Other|enhanced standard of care|parents of subjects are provided oral iron supplementation per usual clinical care at clinic and followed for their anemia in addition to study visits
45634053|NCT03179527|Drug|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc
45773072|NCT02682316|Other|dry gauze|
45773073|NCT02682316|Device|The Prevena Incision Management System|
45914156|NCT02038855|Behavioral|Integrated Intervention for Dual Problems and Early Action|Integrated Intervention for Dual Problems and Early Action (IIDEA) includes psycho-education, Cognitive Behavioral Therapy and mindfulness; identifies triggers and challenging thoughts; provides motivational techniques for reducing substance use and/or smoking cravings; incorporates cognitive restructuring to identify and correct negative thinking patterns influenced by depression, anxiety and/or trauma; and includes self-monitoring of thoughts and risk behaviors that contribute to substance use, smoking and increased HIV risk.
45935452|NCT00124852|Behavioral|n-3 Fatty Acid Supplementation|
45773074|NCT04780958|Other|Serum retinol and RBP levels were determined by enzyme-linked immunosorbent assay.|Umbilical cord blood was drawn at birth in all babies included in the study by experienced individuals using a vacutainer. Approximately 6 ml of venous blood was also drawn from the antecubital region of the mothers immediately after the birth in a biochemistry tube.In the serum samples, the retinol levels were analyzed using ELISA kits from the Bioassay Technology Laboratory ( E1548 Hu Jiaxing, Zhejiang, China), RBP levels were analyzed using ELISA kits of Elabscience (E-EL-H1581 Texas USA) following the standard protocol suggested by the manufacturer at the Dynex automated ELISA reading device (Dynex Technologies Headquarters, Chantilly, USA)
45634054|NCT03179527|Drug|Lipid Regulating Drugs|Mainly including statins
45634055|NCT03179527|Drug|Coronary Vasodilator|Mainly including nitrates
45634056|NCT03179527|Drug|Shuanghe Decoction|Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
45634057|NCT02412475|Drug|Decitabine|Dosing per protocol starting at hour 0 IV infusion over 1 hour on Days 1-5
45773075|NCT00759434|Procedure|Surgery - Saphenofemoral ligation, saphenous strip and avulsions|Patients undergo Saphenofemoral ligation, inversion stripping of the Long Saphenous Vein and avulsion of varicosities if necessary under a general anaesthetic.
45634058|NCT02412475|Drug|Vorinostat|180 mg per meter squared per day for those under age 18, 300mg BID for those age 18 and older. Given after the decitabine infusion by mouth on Days 1-5
45634059|NCT02412475|Drug|Fludarabine|30 mg per meter squared per day starting at hour 0 given immediately after G-CSF by IV infusion over 30 minutes on days 6-10
45773076|NCT00759434|Procedure|EVLT|Patients undergo endovenous laser treatment, using a 810nm laser aiming to occlude the incompetent long saphenous vein from the saphenofemoral junction to the knee. This may then be followed by ambulatory phlebectomy as appropriate. All procedures are to be performed under a local anaesthetic.
45773077|NCT00002968|Biological|edrecolomab|Given IV
45634060|NCT02412475|Drug|Cytarabine|2000 mg per meter squared per day starting at hour 4 by IV over 3 hours on days 6-10
45773078|NCT00002968|Other|laboratory biomarker analysis|Correlative studies
45773079|NCT04780412|Drug|Misoprostol|Vaginal Misoprostol tablets in a dose of 50 microgram given 90-120 minutes before an elective caesarian section.
45773080|NCT04780412|Drug|Placebo|Vaginal placebo pills given 90-120 minutes before an elective caesarian section.
45773081|NCT00754598|Device|Tomosynthesis digital mammography imaging system|a full-field digital mammography system where multiple images are acquired at various angles near the normal to the detector. Breast compression is performed in a standard geometry. The acquired images are reconstructed using mathematical algorithms, not unlike CT reconstructions, to generate a set of thin slices parallel to the breast platform. The reconstructed slices can be viewed individually or in a movie format.
45773082|NCT00002974|Drug|carboplatin|
45914157|NCT02039141|Other|Every Little Step Counts Intervention|"Youth participants randomized to participate in the experimental group will attend weekly healthy lifestyles education session with their parent(s)/guardian(s) and will also attend exercise sessions 3 times a week for 12 weeks. The education sessions will cover topics such as healthy eating choices, roles and responsibilities of both parents and youth in the realm of the family unit as well as in youth's own health, and self esteem among other topics. The exercise sessions will incorporate both aerobic and resistance training as well as other free-play physical activities i.e. basketball, volleyball etc."
45914158|NCT02039193|Behavioral|Cognitive behavioral therapy|CBT-manual (Zinbarg et al., 2006): Traditional cognitive-behavioral therapy (CBT) for GAD typically consists of psycho education of generalized anxiety disorder, relaxation training (RT), cognitive restructuring (CR) and with some in-vivo situational exposure for patients with overt behavioral avoidance (e.g., Barlow, Rapee, & Brown, 1992; Borkovec & Costello, 1993). Furthermore, imagery exposure as a GAD-specific form of in-sensu exposition will be applied to reduce experiential avoidance based on a well-introduced CBT-manual (Zinbarg et al., 2006). The manualized therapy follows an usual treatment format of 14 sessions to 50 minutes and a booster session after 6-months.
45634061|NCT02412475|Drug|Filgrastim|5 μ/kg/dose starting at hour 0 immediately before fludarabine by IV or SQ on days 5-12
45634062|NCT02412475|Drug|Cytarabine|"Patient Age (years) IT Cytarabine Dose > 1 30 mg~2 and < 3 50 mg~3 and ≤ 18 70 mg > 18 100 mg~given IT on day 0 or -1"
45773083|NCT00002974|Drug|etoposide|
45773084|NCT00002974|Drug|ifosfamide|
45773085|NCT00002974|Procedure|hyperthermia treatment|
45773086|NCT00754364|Drug|Pemetrexed/Carboplatin|"Patients will receive Pemetrexed intravenous infusion (i.v.) via infusion pump or gravity drip, at a dose of 500 mg/m2 (over a target of 10 minutes). Pemetrexed should be administered every 21 days on the same day.~Patients will receive carboplatin intravenous continuous infusion (i.v.) over 30 minutes via infusion pump or gravity drip, at a dose of AUC5. Carboplatin should be administered every 21 days on the same day."
45773087|NCT00754364|Drug|Gemcitabine|Patients will receive gemcitabine 1250 mg/m2 as a 30 minutes intravenous infusion on days 1 and 8 and of a 21-day cycle.Patients may continue to receive gemcitabine for up to a maximum of 6 cycles.
45773088|NCT02612896|Drug|Mass drug administration, praziquantel 10mg/kg|see previous, in elimination study arm only
45773089|NCT02612896|Behavioral|Health education|in all study arms, using village meetings, posters, pamphlets.
45773090|NCT00002980|Drug|decitabine|
45634063|NCT02412475|Drug|Sorafenib|150 mg/m2/dose twice daily by mouth on days 11-28
45634064|NCT02417311|Other|Skin biopsy, genotyping and disease phenotyping|Major steps of the project are (i) in depths clinical phenotyping and follow-up of the clinical course of probands (ii) genotyping of candidate genes involved in heart disease development and (iii) in vitro functional tests of engineered heart tissue (EHT), miniature beating heart muscles. These EHTs are generated from hiPSC (human induced pluripotent stem cells) lines derived from skin biopsies of each participant.
45634065|NCT04543643|Drug|Carvedilol|As the third generation of NSBB, carvedilol is more effective in reducing HVPG than propranolol, which is recommended by Baveno VI as the first-line drug for EVB primary prevention.
45634066|NCT04543643|Drug|Berberine|Berberine can regulate the intestinal flora, which is safe and effective in clinical application.
45773091|NCT04777682|Procedure|ultrasound, double balloon enteroscopy|compare intestinal ultrasound versus double-balloon enteroscopy in diagnosis of malabsorption syndrome
45773092|NCT00002986|Drug|carmustine|
45773093|NCT00002986|Drug|topotecan hydrochloride|
45773094|NCT04780256|Procedure|Endoscopic resection|"The endoscopic resection is the procedure that allows to remove cancerous or precancerous conditions of digestive tract. Endoscopic resection can be preformed by several techniques:~Endoscopic mucosal resection (EMR): it allows to remove mucosal lesions~Endoscopic submucosal dissection: it allows to remove mucosal lesions that involved submucosal layer and large lesions~Full-thickness resection: it allows to remove infiltrating lesions by the resection of a little piece of the entire gastrointestinal wall"
45773095|NCT00003418|Drug|exemestane|
45447951|NCT02122432|Other|Teledermatology|"General practitioner takes 3 photographs per dermatologic lesion using either a telephone with a 3Mega Pixel minimum camera or a standard camera following recommendations of the practice guidelines for teledermatology (2007) of the American Telemedicine Association.~Photographs are sent by email using a secured mail server with at least the following information=date of symptoms, symptomatology, topography of lesions, description of lesions, extension, recent drug intakes)~Photographs are read and analyzed by a single dermatologist who gives an expert answer (diagnosis and/or treatment). Answer is sent back to the general practitioner by email (using a secured mail server). Answer contains at least the following information= are photographs usable? What is the diagnosis? If necessary, which treatment should the general practitioner begin ? If necessary, does the patient need a consultation with a dermatologist ?"
45634067|NCT02417155|Behavioral|Hyper/hypoventilation|"Subjects are asked to hyperventilate for an average of 30 breaths. Subsequently, the subjects exhaled and hold their breath for approximately 2 minutes (retention phase). The duration of breath retention will be entirely at the discretion of the subject himself. Breath retention is followed by a deep inhalation breath, that will be held for 10 s. Subsequently a new cycle of hyper/hypoventilation begins."
45773096|NCT00003418|Drug|tamoxifen citrate|
45773097|NCT04777526|Other|Proprioception exercises|Exercises for recognition of thumb position and thumb force sense.
45773098|NCT04777526|Other|Joint protection program|Reeducation in the activities daily life
45634068|NCT02417155|Behavioral|Strength ventilation|This exercise consists of deep inhalations and exhalations in which every inhalation and exhalation is followed by breath holding for 10 s, during which the subject tightens all his body muscles.
45634069|NCT03177499|Procedure|Invasive PPG|Invasive PPG obtained by means of catheterization.
45773099|NCT04777526|Other|Thumb orthosis|Thumb night orthosis
45773100|NCT04777526|Other|Manual distraction|Manual distraction of CMC joint
45634070|NCT05377619|Drug|Prucalopride|prucalopride 2 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
45634071|NCT05377619|Drug|Buspirone|buspirone 10 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
45634072|NCT05377619|Drug|Placebo|placebo 1 hour before the challenge with intake of wine (200 ml) and a dinner
45773101|NCT04777604|Other|Organoid|The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as neoadjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within patients with resectable pancreatic cancer after neoadjuvant chemotherapy, the investigators aim to strategize appropriate neoadjuvant chemotherapy before surgery, thus developing a platform to predict the outcomes of each patient.
45773102|NCT04777838|Drug|Citalopram 10 MG|10 mg of citalopram every day
45773103|NCT04777838|Drug|Amitriptyline|25mg of Amitriptyline every
45773104|NCT04777838|Device|Bite Splint|Night use of occlusal splint
45773105|NCT04777448|Procedure|telerehabilitation|24 sessions (less Thant 1h hour each) of tele rehabilitation. Patients can choose among several activities (gym, dance, cardio training, ...)
45773106|NCT00003424|Drug|tamoxifen citrate|
45773107|NCT04779944|Other|other|questionnaire
45773108|NCT02572024|Device|BAT|Baroreflex activation therapy device ON
45914159|NCT02039453|Drug|fentanyl doses|fentanyl doses 50μg (37.5kg to 62.5kg), 75μg (62.5kg to 87.5kg), 100μg (>87.5kg), single use Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
45914160|NCT02039453|Drug|pethidine dose|pethidine dose 50mg, IV bolus (25mg if < 50kg or >70 years or significant co-morbidity), Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
45447952|NCT03551080|Biological|Lipopolysaccharide|Endotoxin at 0.8 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)
45447953|NCT03551080|Biological|Placebo|Saline administered intravenously
45634073|NCT02412319|Drug|Anti-HBV placenta transfer factor injection|Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
45773109|NCT02572024|Other|Placebo|Baroreflex activation therapy device OFF
45773110|NCT04777370|Other|posterior glide mobilization|The participant will be positioned supine on a plinth, with their scapula stabilized against a firm wedge on the table, and the shoulder joint in the resting position (approx. 55 degrees abduction, 30 degrees horizontal adduction, and slight external rotation). With the extremity held in the same position, the researcher will then apply a grade III (into tissue stretch) PG mobilization. This will consist of five 30-second bouts of sustained gr III posterior glide mobilizations.
45773111|NCT04777370|Other|Sleeper stretch|All participants randomized to the stretching group will perform five 30-second holds of the sleeper stretch. This is performed by lying on the side to be stretched, elevating the upper arm to 90° on the support surface with the elbow bent 90°, then passively internally rotating the shoulder with force provided by with the opposite arm.
45773112|NCT04777370|Other|thoracic manipulation|"Individuals will then undergo a single supine grade V thrust manipulation. All manipulations will take place at the T3-4 segment. If a cavitation (pop) is not heard or felt by either the subject or examiner, a second thrust will be performed."
45773113|NCT04777136|Other|Home visit and comprehensive geriatric assessment|Home-visit from the geriatric team, who will do a full geriatric assessment and targeted interventions
45773114|NCT04777136|Other|Control group, no designated follow up|Only follow-up on patients own initiative with contact to the general practitioner
45634074|NCT02412319|Other|Placebo|Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
45773115|NCT00003430|Drug|L-778,123|
45773116|NCT00002998|Drug|cisplatin|
45773117|NCT00002998|Drug|gemcitabine hydrochloride|
45773118|NCT02088788|Device|Board|Also has radio-dense pelvic shielding
45773119|NCT02088788|Device|No Board|Radio-lucent armboard for radial access with radio-dense drape across pelvis
45773120|NCT00003004|Drug|alvocidib|
45773121|NCT00003004|Drug|cisplatin|
45773122|NCT00003004|Drug|paclitaxel|
45773123|NCT04776512|Procedure|ESP Block With Bupivacain|bilateral lumbar ESP block using 0.375% Bupivacain
45773124|NCT04776512|Procedure|Epidural Analgesia|Continuous Lumbar Epidural analgesia With 0,125% Bupivacain+0,25 mcg/ml Sufentanil
45773125|NCT04329910|Other|no intervention|no intervention - observational only
45773126|NCT04776590|Drug|Tislelizumab|neoadjuvant immunotherapy
45773127|NCT00637676|Procedure|VATS, Talc-Pleurodesis, tunneled pleural drainage|poudrage of 4 gr talc into the pleural cavity implantation of tunneled pleural catheter
45773128|NCT00637676|Procedure|VATS, Talc-pleurodesis|poudrage of 4 gr. talc into the pleural cavity no tunneled pleural catheter
45773129|NCT00003436|Drug|amsacrine|
45773130|NCT00003436|Drug|asparaginase|
45773131|NCT00003436|Drug|cytarabine|
45773132|NCT00003436|Drug|daunorubicin hydrochloride|
45773133|NCT00003436|Drug|etoposide|
45773134|NCT00003436|Drug|methotrexate|
45773135|NCT00003436|Drug|mitoxantrone hydrochloride|
45773136|NCT00003436|Drug|therapeutic hydrocortisone|
45773137|NCT00003436|Procedure|allogeneic bone marrow transplantation|
45773138|NCT02469662|Device|Nexel Total Elbow|Nexel Total Elbow used in primary or revision total elbow arthroplasty
45773139|NCT02325154|Device|Cerebral Oximeter|Use of cerebral oximeter to monitor cerebral oxygenation for occurence of desaturation events.
45634075|NCT04393337|Other|Gestational Age Chart Method|The endotracheal tube insertion depth is obtained by the gestational age chart
45634076|NCT04393337|Other|Nasal-Tragus Length Method|The endotracheal tube insertion depth is obtained by the nasal-tragus method formula
45634077|NCT02412397|Procedure|Total Shoulder Arthroplasty|
45634078|NCT04322513|Diagnostic Test|Biomarkers expression|Evaluation in biomarkers expression between 2 groups
45634079|NCT00703573|Drug|S-777469 400 mg|S-777469 400 mg BID
45634080|NCT00703573|Drug|S-777469 800 mg|S-777469 800 mg BID
45634081|NCT00703573|Drug|Placebo|Placebo BID
45773140|NCT02432378|Biological|Cisplatin + celecoxib + DC vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle
45773141|NCT02432378|Biological|Cisplatin + CKM + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle
45773142|NCT00003454|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Breast Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45773143|NCT04779788|Device|I-125 seeds loaded stent (self-expanded metal stent with I-125 seeds, Micro-Tech, Nanjing, China)|An I-125 seeds loaded stent consisted of two overlapped parts: an inner normal bare stent and an outer seeds-loaded stent
45773144|NCT04779788|Device|Normal stent (self-expanded metal stent without I-125 seeds, Micro-Tech, Nanjing, China)|Bare self-expanded metal stent
45773145|NCT00003466|Drug|temozolomide|
45773146|NCT05605652|Procedure|microosteoperforations|"Flapless micro-osteoperforations will be performed interproximally on the alveolar bone equidistant between upper right canine to upper left canine at every interdental alveolar bone except at the midline~alveolar bone to prevent trauma to the soft tissue frenum before placing the initial leveling archwire."
45773147|NCT00003478|Procedure|conventional surgery|
45773148|NCT00003478|Radiation|iodine I 131 monoclonal antibody 81C6|
45773149|NCT00003478|Radiation|radiation therapy|
45773150|NCT05605418|Behavioral|CHESS intervention|The multi-faceted CHESS intervention includes: (1) home blood pressure monitoring (HBPM) for patients, and the data will be uploaded to central electronic health records (EHR) automatically; (2) a Smart Reminder and Alert System (SRAS) to send educational messages and reminders to support patients on HBPM, improve blood pressure medication adherence and lifestyle modification; (3) a decision support system (DSS) to provide physicians with antihypertensive medications prescriptions and referral recommendations; (4) regular quality assessment reports will be provided to health care providers automatically to improve the quality of hypertension management at PHC level.
45773151|NCT00003016|Drug|tamoxifen citrate|
45773152|NCT00003016|Procedure|adjuvant therapy|
45773153|NCT00003022|Radiation|iodine I 131 monoclonal antibody 3F8|
45773154|NCT04779632|Dietary Supplement|Experimental: Fish Oil|Participants are provided with fish oil capsules and asked to take 4 capsules of 1000 mg twice a day (in total 5.2 mg/day of long-chain n-3 fatty acids hereof 2400 mg of eicosapentaenoic acid and 1600 mg of docosahexaenoic acid) for 4 weeks.
45773155|NCT04779632|Dietary Supplement|Comparator: Safflower Oil|Participants are provided with fish oil capsules and asked to take 4 capsules of 500 mg twice a day (containing ~ 3000 mg of linoleic acid) for 4 weeks.
45773156|NCT00383344|Procedure|FDG PET/CT|
45773157|NCT00003028|Drug|sabarubicin|
45773158|NCT04776122|Device|Therapy|Device-assisted breathing for relaxation
45773159|NCT04776122|Other|No device|Breathing platform without device
45773160|NCT01258387|Drug|Glial growth factor 2/ Neuregulin 1β3|
45773161|NCT01258387|Other|Placebo|
45773162|NCT00003484|Drug|carmustine|
45773163|NCT00003484|Drug|irinotecan hydrochloride|
45773164|NCT00003484|Procedure|surgical procedure|
45773165|NCT00003484|Radiation|iodine I 131 monoclonal antibody 81C6|
45773166|NCT05605262|Drug|Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey|After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
45773167|NCT02227654|Procedure|Abnormal Ovarian Ultrasound|Ultrasound
45914161|NCT02039492|Procedure|Sympathetic Renal Denervation|
45914162|NCT02039492|Drug|Treatment with aldactone|
45634082|NCT02412241|Other|LEF measures|Patient-reported outcome measure; clinician-reported outcome measures
45634083|NCT02412241|Procedure|Technical measure|Undergo standard CT scan
45914163|NCT02030769|Drug|Pronase|use pronase to improve visibility during endoscopical iodine staining
45634084|NCT02412241|Procedure|Technical measure|Undergo standard ultrasound
45634085|NCT03199157|Drug|Fentanyl transdermal patch|Patients received fentanyl 12 mcg transdermal patch group 8 hours preoperatively and until 24 hours after the surgery
45634086|NCT02412163|Device|Ellipse IM HTO Nail|
45634087|NCT00641381|Drug|carmustine|150 mg/m2 day -7, -6,and -5 prior to stem cell reinfusion
45634088|NCT00641381|Drug|cyclophosphamide|100 mg/kg on day -2 prior to stem cell reinfusion
45634089|NCT00641381|Drug|etoposide|60 mg/kg on day -4 prior to stem cell reinfusion
45634090|NCT00641381|Other|pharmacological study|Prior to start of etoposide infusion, 2 hours after start of infusion, just prior to the end of infusion, then at 0.5, 1, 2, 4, 24 and 48 hours after the end of infusion
45634091|NCT00641381|Procedure|autologous hematopoietic stem cell transplantation|Reinfusion of autologous stem cells
45634092|NCT00641381|Procedure|peripheral blood stem cell transplantation|Reinfusion of autologous stem cells
45773168|NCT05605184|Other|Survey|Survey
45773169|NCT00003490|Biological|sargramostim|
45914164|NCT02030769|Drug|Control|No pronase plus Dimethicone and sodium bicarbonate. use without pronase to compare visibility during endoscopical iodiine staining
45914165|NCT02039583|Other|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces were by law required to be smoke-free. More detail can be found via the link provided at the end of this protocol.
45914166|NCT02039596|Other|Diet|
45914167|NCT02039869|Device|Confocal endomicroscopy|The probe allows microscopic evaluation of tissue in real time during endoscopy.
45914168|NCT02039869|Drug|Proton pump inhibitor|Acid suppressing medication (over the counter)
45914169|NCT02039869|Drug|Sucralfate|Coating agent for damaged intestinal lining.
45634093|NCT02422537|Dietary Supplement|Unmodified wheat bran|
45634094|NCT02422537|Dietary Supplement|Wheat bran with reduced particle size|
45634095|NCT02422537|Dietary Supplement|Destarched pericarp-enriched wheat bran|
45634096|NCT02422537|Dietary Supplement|No wheat bran fraction|
45634097|NCT02416999|Drug|Ultra-low dose Bevacizumab|
45634098|NCT02416999|Drug|Temozolomide|
45634099|NCT04194671|Biological|Mesenchymal stem cells|In experimental group, patients receive standard treatment and allogeneic human umbilical cord derived-mesenchymal stem cells (MSCs) is administered via intravenous infusion on day 0 and day 7
45634100|NCT04194671|Other|Saline|In placebo control group, patients receive standard treatment and saline is administered via intravenous infusion on day 0 and day 7
45634101|NCT02422693|Other|Aquatic Exercises|Exercises performed in the water.
45634102|NCT02422693|Other|Deep-water running|It is a non-impact form of running executed in place in (higher than 2 meters) the water wearing a flotation belt. Heart rate is controlled by heart rate watch
45914170|NCT02040012|Drug|AZP-531|
45914171|NCT02040012|Drug|Placebo|
45914172|NCT02040038|Behavioral|LIVE|3-D Virtual Environment for DSMT/S
45914173|NCT02040038|Behavioral|Website|2-D Website participation for DSMT/S
45652972|NCT04848857|Drug|Colchicine|colchicine is a potent anti-inflammatory drug which is currently recommended for the treatment of pericarditis and acute gout attacks, but also familial Mediterranean fever and Behçet disease. This drug acts on inflammation through inhibition of microtubule polymerization by binding free tubule dimers. Colchicine blunts monocyte and neutrophil invasion at the site of inflammation and reduces intracellular trafficking and thus the release of cytokine and production of reactive oxygen species and a variety of proteolytic enzymes.
45773170|NCT00003490|Drug|cyclophosphamide|
45773171|NCT00003490|Drug|prednisone|
45773172|NCT00003490|Drug|vincristine sulfate|
45773173|NCT05605106|Diagnostic Test|speckle tracking echocardiography|"Speckle tracking is a recent development in image processing that uses proprietary software to automatically determine the movements of these points, which appear sonographically as speckles, within the myocardium over time. Tracking the movements of these speckles throughout the cardiac cycle yields positive values when the two points are moving away from one another, as in diastole, and negative values when they are moving towards one another, as in systole"
45914174|NCT02040051|Behavioral|Sound isolation / Music therapy|"Sound isolation: we will used headphones Noise Candelling HI-FI Polk Audio UF 8000 Control Talk for sound isolation.~Music therapy: we will used relaxing Zen music. Light Reiki Touch (Album: Merlin's Magic; Composer: Andreas Mock. Published in 1995 by Inner Worl Music)"
45914175|NCT02040064|Drug|Gefitinib|Oral tablet
45914176|NCT02040064|Drug|Tremelimumab|IV
45914177|NCT02040103|Device|pneumatic compression|All IPC devices intended for DVT prophylaxis are acceptable in the study. Sequential devices (cuffs have several chambers) are preferred, but non-sequential (cuffs have single chambers) are acceptable.
45914178|NCT02040129|Device|Acrysof Toric IOL|Lens implantation following cataract surgery
45914179|NCT02040142|Procedure|HIPEC|
45914180|NCT02040142|Drug|Mitomycin C|
45935453|NCT00124930|Drug|Olanzapine|
45935454|NCT00124930|Drug|Haldol|
45935455|NCT00124969|Drug|Amlodipine|10mg
45935456|NCT00124969|Drug|Placebo|10mg
45634103|NCT02465333|Procedure|Heel Fat Grafting|"Fat grafting is widely used by plastic surgeons and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested with a small liposuction cannula. The fat is then centrifuged, cleaned, and loaded into 1cc syringes and injected into the heel fat pad using specialized cannulas.~Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity."
45652973|NCT04848857|Drug|Placebo|the placebo is a drug with no chemical effects but with the same physical characteristics as the experiment drug colchine.
45652974|NCT03973385|Device|Cryotherapy|patients recieving cryotherapy for skin anesthesia for artérial blood gas
45773174|NCT05605106|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention refers to a family of minimally invasive procedures used to open clogged coronary arteries (those that deliver blood to the heart). By restoring blood flow, the treatment can improve symptoms of blocked arteries, such as chest pain or shortness of breath.
45773175|NCT00003496|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Recurrent or Extensive-Stage Small Cell Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45914181|NCT02040155|Device|Novel nano-scintillator fiber-optic dosimeter (nanoFOD)|This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter (nanoFOD) for the real time dosimetric monitoring of brachytherapy treatment.
45914182|NCT02040194|Drug|AM-101|AM-101 gel for intratympanic injection
45914183|NCT02040194|Drug|Placebo|Placebo gel for intratympanic injection
45914184|NCT02040207|Drug|AM-101|AM-101 gel for intratympanic injection
45652975|NCT05137431|Other|HFNO and NIV|"Patients meeting the inclusion criteria will be treated alternately with 2 hours of HFNO and 1 hour of NIV (HFNO-NIV for the same patient in turn). In 24 hours, there will be 16 hours of HFNO, 8 hours of NIV.~Parameters to record~Respiratory parameters (respiratory rate)~SpO2~Ventilator settings~Patient's tolerance (VAS; between 0-100)~Arterial blood gas (HFNO and NIV at 1 hour)~Clinical parameters (D dimer, CRP, ROX index)~Intubation criteria~Loss of consciousness~Agitation~Persistent hypotension~Need for fluid resuscitation~Need for vasopressor~Respiration rate ≥40/min~SpO2 <92~pH<7.30"
45652976|NCT05135871|Drug|Mavacamten|Single fasted oral dose of Mavacamten 15/25 mg on Day 1
45652977|NCT03909347|Behavioral|PLAN|The study intervention, PLAN is a multifaceted intervention led by trained CHW. It consists of two main components: dementia literacy education and phone counseling with navigation assistance through (1) 1-hour visit for dementia literacy education and (2)monthly counseling with navigation assistance
45652978|NCT03909347|Behavioral|Standard of Care|The investigators will refer control group participants to participants' primary physicians for follow-up and provide an Alzheimer's Association brochure about signs of dementia and dementia treatment, which is publicly available in Korean.
45652979|NCT05091957|Other|Community Support Worker|structured review of participant income supports with a trained CSW, to identify financial needs and benefits for which the family is eligible, including assessment of income and food security, affordability of medications, housing and energy insecurity, and dental care. The visits will be conducted in person, by telephone or by videoconferencing, according to participant preference and to ensure adherence to COVID-19 pandemic-related criteria.
45652980|NCT05091957|Other|Usual Care|Participants in both groups will receive a written summary of available resources
45652981|NCT04338659|Biological|IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection|IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection
45652982|NCT05190003|Other|Experimental Study|On the basis of neurosurgical examination and MRI imaging, 40 patients aged 20-65 years with pains in the lumbar spine will be referred for the first-time single-level microdiscectomy procedure. Microdiscectomy patients will begin a rehabilitation program that will be includes exercises to reduce pain and strengthen the stabilizing muscles of the lumbar spine. From week to week, exercises will be difficult, among others due to the change of initial positions, the number of repetitions of exercises, or a longer duration of isometric exercises.
45652983|NCT05189535|Drug|Pentoxifylline|Pentoxifylline 400 mg oral tablet twice daily for 12 weeks.
45652984|NCT05189535|Drug|Paclitaxel|Paclitaxel I.V 80 mg/m2 weekly
45652985|NCT05189535|Drug|Placebo|placebo
45652986|NCT03744611|Dietary Supplement|CE|550mg capsule (Eucommia ulmoides Oliver extract)
45652987|NCT03744611|Dietary Supplement|Placebo|550mg capsule (Placebo)
45652988|NCT05135169|Drug|Definity Suspension for Injection|Administration of Definity
45773176|NCT00003502|Drug|antineoplaston A10|
45773177|NCT00003502|Drug|antineoplaston AS2-1|
45773178|NCT00003502|Procedure|alternative product therapy|
45773179|NCT00003502|Procedure|biological therapy|
45773180|NCT00003502|Procedure|biologically based therapies|
45773181|NCT00003502|Procedure|cancer prevention intervention|
45773182|NCT00003502|Procedure|complementary and alternative therapy|
45773183|NCT00003502|Procedure|differentiation therapy|
45773184|NCT00003034|Drug|doxorubicin hydrochloride|Given IV
45773185|NCT00003034|Drug|ranpirnase|Given IV
45773186|NCT03862352|Device|Covered coronary stent|Insertion of covered coronary stent as part of standard care
45773187|NCT00003040|Procedure|laser surgery|CO2 supraglottic laryngectomy within 28 days following registration with neck dissection as needed
45914185|NCT02040220|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|2 mg of Eylea will be treated per one injection at more than one months interval usually.
45914186|NCT02040233|Drug|BAY1067197 (10 mg)|10 mg BAY1067197 for 7 d treatment once daily as oral application
45914187|NCT02040233|Drug|BAY1067197|The dose escalation to the second dose step will proceed only if the previous dose step has shown acceptable safety and tolerability 5 mg / or 10 mg / or 20 mg BAY1067197 for 7 d treatment as oral application.
45914188|NCT02040233|Drug|Placebo (10 mg)|10 mg Placebo for 7 d treatment once daily as oral application
45914189|NCT02040233|Drug|Placebo|5 mg / or 10 mg / or 20 mg Placebo for 7 d treatment once daily as oral application
45773188|NCT00003040|Radiation|radiation therapy|200 cGy per day, five days per week for approximately 6 weeks, to begin 14 days after laser surgery
45773189|NCT04389398|Device|pocket compression fixation belt|Pocket compression fixation belt to is used to compress the postoperative wounds of CIEDS patients, and its effect of preventing hematoma is evaluated.
45773190|NCT00383890|Drug|Dexmedetomidine HCL Injection|
45773191|NCT00383890|Drug|Placebo|
45773192|NCT00003046|Biological|Recombinant Interleukin-12|Intraperitoneal over 30 minutes once weekly for 4 weeks, repeats every 4 weeks for up to 6 courses
45773193|NCT00003052|Drug|doxorubicin hydrochloride|
45773194|NCT00003052|Drug|etoposide|
45773195|NCT00003052|Drug|ifosfamide|
45773196|NCT00003052|Procedure|conventional surgery|
45634104|NCT02412007|Other|Individualized comprehensive home centred activity based programme|"Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to~Standing up from squatting position to catch an object of interest.~Squatting from standing position to pick an object of interest.~Walking to reach an object of interest.~Climbing up steps to get an object of interest.~Climbing down steps to keep the above object of interest.~Cycling~Kicking a football~Dancing"
45634105|NCT02412085|Drug|Golimumab|"Subcutaneous golimumab. Induction regimen: 200 mg (week 0), 100 mg (week 2)~Maintenance regimen:~body weight < 80kg: 50 mg every 4 weeks~body weight ≥ 80 kg: 100 mg every 4 weeks"
45634106|NCT03176797|Diagnostic Test|Liver MRI|Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
45634107|NCT01679405|Drug|BIBW 2992|once daily per os
45634108|NCT03175861|Other|Stereotactic radiotherapy|"The patient will have an initial pre-therapeutic assessment in the 8 weeks before the start of radiotherapy Then, radiation therapy planning with 3 free breathing 4D (4 dimensions) scanners performed over 8 days without injection of iodinated contrast agent.~Then the patient will receive his treatment by conventional stereotactic radiotherapy"
45634109|NCT03175705|Biological|HCC antigens-specific CD8+ T lymphocytes|"Three different dosing schedules will be evaluated. Three patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~Loading Dose 1: 3x10^7/m2 Loading Dose 2: 6x10^7/m2 Loading Dose 3: 9x10^7/m2 The doses are calculated according to the actual number of GPC3/NY-ESO-1/AFP specific cytotoxic lymphocytes (CTLs)"
45773197|NCT00003052|Procedure|hyperthermia treatment|
45914190|NCT02040246|Drug|Repaglinide|Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.
45634110|NCT03175705|Drug|IL-2|IL-2 will be given at a dose of 25000 IU/kg/day for 5-14 days.
45634111|NCT03175705|Drug|Tegafur|Tegafur will be given at a dose of 40~60 mg bis in die (BID) 2 weeks.
45634112|NCT00301457|Drug|Anastrozole|1 mg once daily oral dose
45634113|NCT03175783|Device|Fitbit Zip Activity Tracker|Subjects from both treatment and control group will be put on wristband starting from one week before the scheduled operation until 7 post-operative days. Patients will be instructed to wear the wristband continuously 24 hours per day except during water based activity. The treatment group will receive normal wristband with indicator showing steps count, distance, and calories. Meanwhile, the control group will receive Fitbit Zip with a display covered with adhesive tape and will not receive automatic feedback on the mobility from the device.
45773198|NCT00003052|Radiation|radiation therapy|
45773199|NCT03843944|Drug|Safinamide|Overnight switch from rasagiline 1 mg OD to safinamide 50 mg OD
45773200|NCT04754828|Other|Assigned to a rounding style|Team rounded on new admissions either in hallway or at the bedside
45773201|NCT00003058|Drug|troglitazone|
45773202|NCT04775732|Biological|infliximab therapeutic drug monitoring|dose optimization of infliximab based on a predefined dosing algorithm
45773203|NCT00003514|Drug|antineoplaston A10|
45773204|NCT00003514|Drug|antineoplaston AS2-1|
45914191|NCT02040246|Drug|Metformin|Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.
45914192|NCT02040272|Procedure|(Extended) pleurectomy decortication|
45773205|NCT00003514|Procedure|alternative product therapy|
45773206|NCT00003514|Procedure|biological therapy|
45773207|NCT00003514|Procedure|biologically based therapies|
45773208|NCT00003514|Procedure|cancer prevention intervention|
45773209|NCT00003514|Procedure|complementary and alternative therapy|
45773210|NCT00003514|Procedure|differentiation therapy|
45773211|NCT04775498|Behavioral|Face-to-face psychoeducation group|All of the investigation centers participating in this study have a psychoeducation programme on bipolar disorders labeled and monitored by their Regional Health Agency. For this, he must respect the decree of January 14, 2015 relating to the specifications of therapeutic education programs for the patient. Patients will be receive by an investigator, for inclusion and baseline evaluation and at 6 and 12 months after inclusion. During this meeting, investigator and patient will be complete 7 questionnaires (about disease, treatment observance and quality of life), investigator will collect treatment, style life and adverse event(s).
45773212|NCT04775498|Behavioral|SIMPLe mobile application|The experimental intervention consists of 12 months use SIMPLe smartphone application who has been developed by the Barcelona Institute of neuroscience. The purpose of this application is to deliver individualized psychoeducation messages to the patient's clinical condition. The psychoeducational messages correspond to the contents of the different modules and sessions carried out in face-to-face psychoeducation groups (Colomm & Vieta ; 2015). Patients will be receive by an investigator for inclusion and baseline evaluation, at 6 and 12 months after inclusion. During this meeting, investigator and patient will be complete 7 questionnaires (about disease, treatment observance and quality of life), investigator will collect treatment, style life and adverse event(s).
45914193|NCT02040285|Drug|Bisacodyl & PEG-CS|"the day before the CTC:~low fiber diet~at 15.00: 2 tablets of bisacodyl (5 mg)~at 17.00: 1 litre of PEG-CS~liquid diet~the day of the exam:~at home: 2 tablets of bisacodyl (5 mg)~at the Hospital (3 hours after tablets intake): 90 ml of Iopamidol in 500 ml of water~at the Hospital (5 minutes after Iopamidol intake): 10 mg of Metoclopramide mono chlorohydrate monohydrate im"
45634114|NCT03175393|Device|coronary angiography|per cutaneous coronary intervention to identify severity of coronary artery disease by syntx score
45634115|NCT02422459|Behavioral|COMMENCE|ChrOnic pain self-ManageMent support with pain science Education and exerCisE (COMMENCE) consists of two visits with a physiotherapist per week over six weeks. One of the two visits is in a group setting, where the emphasis is on pain neurophysiology education and provision of self-management strategies. The second visit each week is an individualized, one-to-one session in which the focus is on providing support for implementing self-management strategies and developing of an individualized, goal-oriented exercise program.
45634116|NCT03270527|Other|High SFA diet (Diet 1)|'Diet 1' will contain ~18% of its total energy as SFA .
45634117|NCT03270527|Other|Low SFA diet (Diet 2)|'Diet 2' will contain ~10% of its total energy as SFA. The SFA-replacement fats will be mixture of PUFA/MUFA.
45634118|NCT03198845|Other|video game|20-min per session for 3 times per week for a 4-week duration
45634119|NCT03198845|Other|exercise|20-min per session for 3 times per week for a 4-week duration
45634120|NCT02422225|Device|Eldith DC-STIMULATOR|"Transcranical direct current stimulator (Neuroconn GmbH, Ilmenau, Germany) approved by Conformity European as safe treatment device for stroke patients~tDCS intervention]~Intensity: 1.5mA for 20min Device: Neuroconn GmbH, Ilmenau, Germany~Stimulation site <Experimental group>~Anode-Anode dual stimulation group Anode: affected pharyngeal motor cortex / Cathode: affected supraorbit Anode: non-affected pharyngeal motor cortex / Cathode: non-affected supraorbit~Anode-Cathode dual stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected pharyngeal motor cortex~Single stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected supraorbit <Control group> Sham stimulation"
45634121|NCT02422225|Device|Sham Eldith DC-STIMULATOR|
45634122|NCT03177109|Drug|5% fluoride varnish|Applied topically as a coating at single point in time
45634123|NCT03177109|Drug|8% arginine containing paste|Applied topically as a coating at single point in time
45634124|NCT03177109|Drug|Self-adhesive resin|Applied topically as a coating at single point in time and light cured for 20 seconds
45634125|NCT03198923|Biological|natural killer and natural killer T cell|The eligible patients are infused with 10 doses of (2-2.5)x10^9 NK and NKT cells in one course of treatment.
45634126|NCT03198455|Dietary Supplement|Agaricus blazei Murill-based mushroom extract, Andosan™|Dietary Supplement: Agaricus blazei Murill-based mushroom extract, Andosan™
45634127|NCT03198455|Other|Placebo|Drinking water with food coloring and salt
45634128|NCT02422147|Procedure|Ablation of PCL|All procedures are standard of care and will be undertaken using a curvilinear echoendoscope. The cyst will be punctured using a 22G needle and after subtotal evacuation of the cyst, injection is performed with a volume of alcohol that is equal to the quantity aspirated, and the cyst will be lavaged for 3 to 5 minutes. The injected ethanol will then be evacuated at the end of lavage, leaving just enough fluid to outline the cavity. A second ablative agent such as paclitaxel is then injected and left in the cyst cavity. At the completion of the procedure, the needle will be removed from the cyst cavity.
45634129|NCT03198611|Diagnostic Test|Echocardiography|Usual echocardiographic studies in patients suffering septic shock
45634130|NCT03176875|Other|ALICALM (75% of daily caloric requirements)|PEN group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and 25% of daily dietary needs (1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
45634131|NCT03176875|Other|ALICALM (100% of daily caloric requirements)|EEN group will receive 100% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) for 6 weeks.
45634132|NCT03185897|Other|Non-treatment, seroprevalence|Non-treatment study examining the prevalence of preexisting immunity to adeno-associated virus (AAV)
45634133|NCT02421991|Behavioral|Telephone Delivered Intervention|
45634134|NCT03175627|Device|Filtek One|Restoring a posterior permanent tooth in need of a filling applying Filtek One using bulk fill technique.
45634135|NCT03175627|Device|Filtek Z250|Restoring a posterior permanent tooth in need of a filling applying Filtek Z250 using incremental filling technique.
45634136|NCT01603355|Drug|Tocilizumab|"Intravenous tocilizumab:~Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks"
45634137|NCT03177031|Device|Stay Safe Link (SSL)|CAPD system produced in Malaysia by Fresenius Medical Care
45634138|NCT03177031|Device|Stay Safe (STS)|CAPD system produce in Germany by Fresenius Medical Care
45634139|NCT02416843|Other|Consumption of a mixed meal|Participants will consume a mixed meal and postprandial responses in blood and adipose tissue will be investigated over 6 hours and compared to baseline.
45634140|NCT02411851|Drug|ingenol mebutate 0.015%|one cycle of ingenol mebutate 0.015% on two 25 cm2 treatment areas
45634141|NCT02411851|Other|dermasil lotion|Dermasil lotion has 1% dimethicone as its active ingredient - part of the family of silicone oils, is a hypoallergenic, noncomedogenic, and nonacnegenic agent
45634142|NCT05094947|Procedure|intermittent catheterization|clean intermittent catheterization with catheter Nelaton
45634143|NCT05094947|Procedure|trial without catheter|catheter Foley
45914194|NCT02040285|Drug|Iopamidol|"the day before CTC:~low fiber diet~at 15.00: 90 ml of Iopamidol in 250 ml of water~at 17.00: 90 ml of Iopamidol in 250 ml of water~at 20.00: start liquid diet"
45634144|NCT05094947|Drug|alpha-blockers|tamsulosin, alfuzosin, doxazosin, silodosin
45634145|NCT02421913|Drug|S(+)-Ketamine|S(+)-Ketamine 0,3mg/kg/hr intraoperative
45634146|NCT05094869|Behavioral|Use of mobile health application|The APP would regularly send messages including the medication reminder, health education knowledge, etc.
45634147|NCT05094869|Behavioral|Online interaction|The patients would be able to upload their examination results in the APP and then the doctors will evaluate their disease progression every six months through the APP and guide patients' clinical practice accordingly.
45914195|NCT02040311|Drug|Topiramate 96 mg daily|
45634148|NCT05094869|Behavioral|Self follow-up reminders|The APP would regularly send messages including the follow-up reminder (manually set up by the patient on the APP)
45634149|NCT05094869|Behavioral|Intelligent follow-up reminders|The APP would regularly send messages including the follow-up reminder (automatically set up by the APP)
45634150|NCT03179293|Drug|Propofol|propofol 1 mg/kg IV bolus will be given to the patient with a further 2 mg/kg administered manually over the next 3 min prior to the patient leaving the OR
45634151|NCT03179293|Drug|Normal saline|Normal saline will be administered manually over the next 3 min prior to the patient leaving the OR
45634152|NCT02416765|Other|15-hour intervention|Interventions will be conducted in outpatient settings. Subject's usual insulin will be used. Meals will not be standardized. Subjects will be allowed to eat whatever and when they want and will be allowed to drink alcohol. Subjects will be allowed to exercise, but they will be asked to do the same amount and intensity of exercise on all intervention visits. Subjects will be accompanied all the time by a member from the research team during closed-loop visits to implement hormonal infusions.
45634153|NCT02416765|Drug|Insulin (Lispro, Aspart or guilisine)|Patient's usual insulin (Lispro, Aspart or guilisine) will be used in all interventions.
45634154|NCT02416765|Drug|Glucagon (Eli Lilly)|In the dual-hormone CLS interventions, glucagon (Eli Lilly) will be used.
45634155|NCT02416765|Other|Closed-loop strategy|Every 10 minutes, the glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates. The computer generated recommendations are based on a predictive algorithm.
45634156|NCT05094479|Behavioral|Health information delivered via health app|Intervention group will use a health app with non-personalized information on health-promoting lifestyle habits during pregnancy. Control group will use a health app without health information. Intervention effects on the lifestyle habits (gestational weight gain, diet quality, physical activity) will be investigated.
45634157|NCT02703259|Drug|Gabapentin|
45634158|NCT02703259|Drug|Acetaminophen|
45634159|NCT02703259|Drug|Celecoxib|
45634160|NCT02366273|Other|PASI and HOMA index|
45634161|NCT05094167|Other|V9|one times a day during the whole treatment
45634162|NCT05094167|Other|placebo|placebo
45634163|NCT02416687|Device|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant was inserted in the first 48 h postpartum
45634164|NCT05093465|Behavioral|Technology Intervention|"Participants were provided with sleep hygiene and stimulus control procedure plus procedures to reduce technology usage in bed (i.e., technology usage stimulus control).~In addition to the sleep hygiene and stimulus control procedures, participants were also given a set of procedures aimed at changing technology usage behavior at bedtime and throughout the day."
45634165|NCT05093465|Other|Active Control|Participants were provided with sleep hygiene and stimulus control procedures.
45634166|NCT02411695|Drug|Brexpiprazole (OPC-34712)|Subjects who are deemed eligible for the trial will be assigned to a dosing cohort and will enter a Dose Titration Phase during which they will receive a starting dose of brexpiprazole for 2 to 10 days based on their assigned titration schedule. The Dose Titration Phase may be extended up to a maximum of 14 days, based on the observed safety and tolerability profile of the previous cohort's Dose Titration Phase. Following the Dose Titration Phase, subjects will enter the Fixed Dose Phase and will be administered the assigned dose for that cohort for 14 days.
45634167|NCT05093309|Behavioral|Educational Webinar|At month 1 of the study period, the educational webinar was presented by expert speakers and consisted of 3 modules: 1) naloxone basics; 2) naloxone service implementation strategies; and 3) naloxone recommendation communication strategies. Participants were mailed naloxone nasal spray and auto-injector training devices prior to attending the online webinar so that they could follow along during demonstrations.
45634168|NCT05093309|Behavioral|Resources|After completing the baseline survey, both control and intervention groups were provided with a basic publicly available flyer about naloxone dosage forms in order to ensure all participants could provide adequate patient care.
45634169|NCT05093309|Behavioral|Reminders|Reminders consisted of monthly emails from investigators for the purpose of retaining study engagement.
45634170|NCT02416921|Behavioral|Weight-gain Prevention|A 4-week weight-gain prevention curriculum will be delivered via Facebook. Participants will be provided tips to prevent weight-gain and will be given the opportunity to engage with the peer coaches and other participants in the group.
45634171|NCT02416921|Behavioral|Women's Health|A 4-week women's health curriculum will be delivered via Facebook. Participants will be provided tips for staying healthy and will be given the opportunity to engage with the peer coaches and other participants in the group.
45634172|NCT05093231|Drug|Pembrolizumab|Pembrolizumab is a highly selective immunoglobulin G4-kappa humanised monoclonal antibody against Programmed cell death protein 1 (PD-1) receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing Serine 228 to Proline Fc mutation.
45634173|NCT05093231|Drug|Olaparib|Olaparib is a potent inhibitor of polyadenosine 5'diphosphoribose polymerase (PARP) developed as a monotherapy as well as for combination with chemotherapy, ionising radiation and other anti-cancer agents including novel agents and immunotherapy.
45634174|NCT02411617|Device|Drain|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
45634175|NCT03198533|Device|Triathlon PA|Implantation of Knee Prosthesis
45634176|NCT03198533|Device|Triathlon Pressfit|Implantation of Knee Prosthesis
45634177|NCT02410525|Drug|[11C]PF-06427878|Single administration via intravenous infusion of 20 ug [11C]PF-06427878 on Day 1 of all 3 Periods
45634178|NCT02410525|Drug|PF-06427878 10 mg|Single oral administration of 10 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to [11C]PF-06427878 administration
45634179|NCT02410525|Drug|PF-06427878 600 mg|Single oral administration of 600 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to [11C]PF-06427878 administration
45634180|NCT03198377|Device|TENS: Randomized frequency modulation|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Frequency modulation: randomized pattern (from 80 to 120 Hz) Pulse width 200 microseconds"
45914196|NCT02040311|Drug|Topiramate 192 mg daily|
45914197|NCT02040311|Drug|Placebo|
45914198|NCT02040324|Device|Laryngeal mask with gastric access|
45914199|NCT02040324|Device|Endotracheal tube|
45634181|NCT03198377|Device|TENS: Scan 6/6 of frequency modulation|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Frequency modulation: Scan of frequency from 80 to 120 Hz in 6/6 mode (frequency sweep from 80 Hz to 120 Hz in 6 seconds and from 120 to 80 Hz in 6 secons) Pulse width 200 microseconds"
45634182|NCT03198377|Device|TENS: Fixed frequency|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Fixed frequency at 100 Hz Pulse width 200 microseconds"
45634183|NCT03198377|Device|Sham Stimulation|Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
45634184|NCT02411383|Device|NeuRx Diaphragm Pacing System|NeuRx Diaphragm Pacing System electrodes are placed in the diaphragm during lung transplant surgery. The diaphragm will be continually paced until the patient is free from the ventilator or the patient is discharged from the ICU whichever. Diaphragm measurements are taken daily to assess tolerability and pacing success.
45773213|NCT00003520|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Kidney Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45634185|NCT03198299|Device|MEI BIN insoles|wearing insoles for 12 weeks
45773214|NCT04754750|Drug|Paliperidone Palmitate 156 MG/ML Prefilled Syringe [Invega]|
45634186|NCT02421835|Dietary Supplement|Olive leaf extract|132 mg of oleuropein per day suspended in olive leaf extract 700 mg
45634187|NCT02421835|Dietary Supplement|Placebo|700 mg Maltodextrin per day
45634188|NCT04542395|Behavioral|Increasing Willingness and Uptake of COVID-19 Testing and Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 related risk and challenges and increase willingness and uptake in COVID-19 testing and vaccination.
45773215|NCT04754750|Drug|Paliperidone Palmitate 546 MG Intramuscular Suspension, Extended Release [INVEGA TRINZA]|
45773216|NCT00003532|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage III or IV Ovarian Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45773217|NCT00003538|Biological|graft versus host disease prophylaxis/therapy|
45773218|NCT00003538|Procedure|allogeneic bone marrow transplantation|
45773219|NCT04779164|Diagnostic Test|knee ultrasonography|The knees of all patients were screened with ultrasonography device for the measurement of femoral cartilage thicknesses.
45773220|NCT01958086|Device|Neural Communication System|NeuroPort Arrays allow for the local recording of cerebral cortex. The Neural Communication system is primarily composed of two NeuroPort Arrays. The two arrays of one MultiPort device will be placed in the primary motor cortex for recording (Platinum-tipped electrodes); and the two arrays of the additional MultiPort device be placed in the superior parietal lobule for recording (Platinum-tipped electrodes). Each MultiPort device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D) or 4 mm x 4 mm x 1.0 mm, and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array.
45773221|NCT05589662|Other|Clinical and functional assessment|The dependent variables (muscle strength, muscle activation, pressure pain threshold and joint status) and the outcome measures used to measure these variables will be: pressure dynamometer, surface electromyography, pressure algometer and Hemophilia Joint Health Score
46070122|NCT04120779|Device|The EMPOWER-SUSTAIN e-Health Self-Management Intervention|Multifaceted chronic disease management strategies involving web-based self-management intervention mobile apps based on chronic care model and persuasive technology theory to improve patient activation and self-management behaviours among patients with metabolic syndrome.
46070123|NCT00862641|Drug|Regadenoson|IV
46070124|NCT00862641|Drug|Placebo|IV
45634189|NCT02410447|Device|Defocused shock wave therapy (DUOLITH® SD1)|
46070125|NCT04120857|Behavioral|Gentle Stretching|60 minutes fo gentle stretching twice weekly for 8 weeks
46070126|NCT02614053|Device|Masimo Radical-7™ Pulse CO-Oximeter|a device collecting data regarding PVI, PI & spHB
45773222|NCT00003064|Biological|filgrastim|
45773223|NCT00003064|Drug|carboplatin|
45773224|NCT00003064|Drug|etoposide phosphate|
45773225|NCT00003064|Drug|paclitaxel|
45773226|NCT00003064|Drug|thiotepa|
45773227|NCT00003064|Drug|topotecan hydrochloride|
45773228|NCT00003064|Procedure|peripheral blood stem cell transplantation|
45773229|NCT00003544|Drug|irinotecan hydrochloride|
45773230|NCT00003544|Procedure|surgical procedure|
45773231|NCT03475394|Other|Chlorhexidine gel|0.1 ml of Chlorhexidine gel was administered into the periodontal pocket
45773232|NCT03475394|Other|Morus alba gel|0.1 ml of Morus alba gel was administered into the periodontal pocket
45773233|NCT03475394|Other|Placebo|0.1 ml of Placebo gel was administered into the periodontal pocket
45773234|NCT01269424|Biological|MGMTP140K-encoding retroviral vector|
45773235|NCT01269424|Drug|O6-benzylguanine|
45773236|NCT01269424|Drug|temozolomide|
45773237|NCT01269424|Other|laboratory biomarker analysis|
45773238|NCT01269424|Procedure|autologous hematopoietic stem cell transplantation|
46070127|NCT04119921|Drug|prescription topical ketorolac in group 1|topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
45634190|NCT02410681|Device|Electromyographic recording of temporalis muscle activity during sleep|"Electromyographic recording of temporalis muscle activity during sleep. In total, 9 sleep recordings will be done at the home setting of each participant.~3 recordings after the baseline visit~3 recordings 6 weeks after the baseline visit~3 recordings one year after the baseline visit"
45634191|NCT02410681|Radiation|Vertical bitewing radiograph|An intraoral vertical bitewing radiograph will be performed with the assistance of individually modified plate positioning devices at each visit (in total 8 visits during the 2-year follow-up period).
45634192|NCT02410681|Other|Collection of biofilm sample|"Collection of peri-implant intrasulcular biofilm sample for DNA analysis of the biofilm composition. In total, samples will be collected three times:~At the baseline visit~Three months after the baseline visit~One year after the baseline visit"
45634193|NCT03197909|Other|Determination of pro-inflammatory plasma factors|Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old
45634194|NCT02411227|Behavioral|VR Driving|Baseline: Tactical A3 scenario, composite score Post-Assessment: Tactical A4 scenario composite score
45634195|NCT05093075|Other|Therapeutic Plasma Exchange|TPE procedures will be performed using a Spectra Optia ® apheresis machine (Terumo BCT, Lakewood, USA) according to usual-care procedures for apheresis. Venous access for the TPE procedures will be obtained through a double lumen dialysis catheter to provide adequate flow rates required for TPE. Regional citrate anticoagulation will be used for anticoagulation within the apheresis circuit. One to two grams of calcium chloride will be infused as per standard during TPE to prevent symptomatic hypocalcemia. Plasma volume will be calculated as per a standard formula whereby estimated plasma volume (in liters) = 0.07 x weight (kg) x (1 - hematocrit). In patients on dialysis, dialysis will be interrupted for the duration of the procedure. Antibiotics will be given after TPE to avoid clearance of the antibiotics. On the first day of TPE, a repeat dose of antibiotics will be administered after completion of TPE. Nurse clinicians trained in TPE will perform the TPE procedures.
45634196|NCT02411149|Drug|Adductor Canal Block|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine.
45634197|NCT02411149|Drug|Adductor Canal Block with Morphine|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine and 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)
45634198|NCT02411149|Drug|Local Infiltration|30 ml normal saline in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine, in addition to the local infiltration.
45634199|NCT04413227|Drug|Pegylated Recombinant Human Endostatin（PEG-ENDO）|PEG-ENDO 1 mg/kg or 2 mg/kg or 4 mg/kg or 6 mg/kg or 8 mg/kg+Docetaxel 75 mg/m2，once every 3 weeks at day 1
45634200|NCT03175315|Behavioral|Treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH)|Treatment and education program based on the self-management theory of behavioral medicine. The program is delivered by certified and specially trained diabetes educators.
45634201|NCT02410369|Drug|S-588410|Following randomization, subjects with HLA-A*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
45634202|NCT02410369|Drug|Placebo|Following randomization, subjects with HLA-A*2402 in the investigational arm will receive the subcutaneous administration of Placebo.
45634203|NCT03198143|Drug|Ghrelin|Subjects will receive a subcutaneous injection of synthetic acyl ghrelin (12 µg/kg) at the start of the study.
45634204|NCT03198143|Drug|Saline|Subjects will receive a subcutaneous injection of saline (0.9%) at the start of the study.
45634205|NCT03179215|Diagnostic Test|fluid challange|A set of hemodynamic measurements will be obtained at baseline and after infusing a fluid challenge (FC) of 150-250 ml normal saline over 5-10 minutes.Fluid-responders are patients with a SV increase ≥10% after fluid challenge
45634206|NCT03198065|Procedure|Hand-made glove setting|The patients receive Hand-made glove setting for single-incision laparoscopic appendectomy
45634207|NCT03198065|Procedure|Commercialized single-incision multiport setting|The patients receive commercialized single-incision multiport setting for single-incision laparoscopic appendectomy
45634208|NCT05233423|Device|compressed cold therapy bandage|Compressed cold therapy bandage was applied by wrapping the operated knee of the patients. The patients in the intervention group received 9 cold applications with 30 mmHg pressure for 20 minutes and 40 minutes of rest.
45634209|NCT03197987|Device|Endocuff|Endocuff-assisted colonoscopy
45634210|NCT03197987|Device|cap|Cap-assisted colonoscopy
45634211|NCT03175237|Other|Mirror Therapy|
45634212|NCT02410993|Procedure|CABG surgery|
45634213|NCT02410135|Drug|Mirabegron|25 mg PO per day for four weeks. if tolerated then uptitrated to 50 mg PO per day for the remaining 8 weeks
45634214|NCT05080127|Combination Product|application of the allergenic food|a small amount of the allergenic fresh food will be placed on the forearm using a patch test sticker for 15 minutes. the skin reaction will be measured.
46070128|NCT04119921|Drug|prescription artificial tear in group 2|artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
46070129|NCT04119921|Drug|prescription topical ketorolac in group 2|artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
45634215|NCT02410915|Device|Hybrid Assistive Limb (HAL); gait training|Training with HAL is performed in 1 session per day, 4 days per week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective time). Training with HAL is performed in combination with body-weight support system and on a treadmill. The training program is performed by 2 physiotherapists, who have been trained in the HAL method.
45634216|NCT02410915|Other|Control Group; Conventional gait training|Conventional gait training is individualized and performed according to current practice (approximately 30-60 minutes/session, 5 days a week) and may include standing, weight shifting, stepping, over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support. Conventional gait training is offered to both study groups.
46070130|NCT04119921|Drug|prescription artificial tear in group1|topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
46070131|NCT02613663|Procedure|Immediate implants with nanobone graft|Extraction of unrestorable tooth replaced with immediate implant and use nanobone graft to fill the gap.
45634217|NCT05054621|Biological|Heterologous prime-boost schedule with AZD1222 and MVC-COV1901|Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.
45634218|NCT05054621|Biological|Homologous prime-boost schedule with two doses of AZD1222|Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.
45634219|NCT02410759|Drug|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm IM
45634220|NCT02410759|Drug|Ergometrine|100 women with atonic PPH will receive Ergometrine 0.5 µgm IM
45773239|NCT01269424|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45773240|NCT01269424|Radiation|radiation therapy|
45773241|NCT03395912|Drug|Intervention|After closing the fascia above the rectus muscles, and before closing the skin, the subcutaneous layer will be infiltrated on both sides of the incision (top and bottom) by 30 ml of 0.25% BUPIVACAINE and ADRENALIN at 1: 200,000 concentration and then closing the skin.
45773242|NCT00003556|Biological|ALVAC-hB7.1|
45773243|NCT00003556|Biological|canarypox-hIL-12 melanoma vaccine|
45634221|NCT04459091|Dietary Supplement|Amino Essential Acid|8 gr die in two administration
45634222|NCT04459091|Dietary Supplement|placebo|8 gr die in two administration
45773244|NCT03393338|Behavioral|DM I-TEAM|DM I-TEAM is a home-based behavioral intervention that involve 9 treatment visits with a community health worker (CHW) over 12 months. During the treatment visits, the CHW provides culturally-relevant diabetes education, and facilitates telehealth visits with a diabetes nurse educator and participants' primary care physicians (PCPs). In addition, a clinical pharmacist reviews participants' medication regimens to identify potentially inappropriate medications (PIMS), and to simply regimens when indicated to facilitate medication adherence.
45773245|NCT00384436|Drug|escitalopram|
45773246|NCT04778696|Procedure|PASO Pacemapping|Using the PASO pacemapping visualisation module of CARTO3
45773247|NCT04778696|Procedure|Conventional Pacemapping|without visualisation in 3D mapping
45447954|NCT02125162|Drug|BCX4161|Each subject will receive Treatments A, B, and C in an open-label, randomized sequence with a washout period of at least 7 days between each dose
45773248|NCT00384514|Device|VesCell (TM)-Autologous EPCs/Angiogenic Cell Precursors|
45447955|NCT02122510|Drug|Bupivacine group|Bupivacaine group(n=30) will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
45634223|NCT03175081|Drug|Ropivacaine|Patient undergo elective laparoscopic sleeve gastrectomy will receive 20mL of 150mg ropivacaine (0.75%) diluted in 180mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
45634224|NCT03175081|Drug|Normal saline|Patient undergo elective laparoscopic sleeve gastrectomy will receive 200mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
45634225|NCT05016479|Device|Accelerated repetitive Transcranial Magnetic Stimulation|arTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with a Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
45634226|NCT03175003|Other|Food Product|Each food product will provide similar calories, but a different micro- and macro-nutrient composition
45634227|NCT02406625|Behavioral|Behavioral Therapy|16 therapeutic group sessions are delivered to both parents and adolescents; according to the assigned group for each family.
45634228|NCT02409979|Other|Carbon dioxide method|Insufflation with CO2 during insertion and withdrawal phases of colonoscopy.
45773249|NCT00003562|Drug|carboplatin|
45773250|NCT00003562|Drug|docetaxel|
45773251|NCT04775576|Other|Pleth Variability Index|Conventional fluid management is widely used in clinical practice. In this method, the fluid need of the patient is decided according to pulse, arterial blood pressure, central venous pressure, urine output and clinical condition. In the targeted fluid therapy method, besides static parameters such as pulse, arterial blood pressure, central venous pressure; Dynamic parameters such as Stroke volume variability (SVV), pulse pressure variability (PPV), pleth variability index (PVI), continuous hemoglobin (SpHb) are also used noninvasively.
45773252|NCT04775576|Other|Conventional fluid theraphy|8-10 ml / kg / hour iv fluid maintenance will be started for the control group. If the mean arterial pressure (MAP) is <65 mmHg or the decrease in MAP is more than 20%, 250 ml iv colloid will be applied. If the decrease in MAP continues despite the colloid bolus or if the MAP is below 65 mmHg, noradrenaline infusion will be started.
45773253|NCT04775576|Other|Anesthesia method|All patients included in the study will be premedicated with 1mg of midazolam after monitoring with pulse, non-invasive blood pressure, oxygen saturation. Then, invasive arterial cannulation will be applied and continuous blood pressure monitoring will be done. In the PVI group, non-invasive PVI and SpHb monitoring will also be performed from the other upper extremity without arterial cannulation. After two minutes of preoxygenation, anesthesia induction will be started. Anesthesia induction doses used routinely in our clinic include iv 2 mg / kg propofol, 0.6 mg / kg rocuronium and 2 μg / kg fentanyl. Sevoflurane will be administered by inhalation during anesthesia maintenance after tracheal intubation.
45773254|NCT00003568|Biological|aldesleukin|
45773255|NCT00003568|Biological|gp100 antigen|
45773256|NCT00003568|Biological|incomplete Freund's adjuvant|
45914200|NCT02040350|Drug|Pralidoxime|Pralidoxime was compared to placebo to study the effects of the drug on mortatlity
45773257|NCT04775108|Device|Epygon™ Transcatheter Mitral Valve System|"The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedure by means of a dedicated implant device.~The EPYGON VALVE is a bio prosthesis, composed by a functional assembly of bovine pericardium on a NiTinol stent."
45773258|NCT00003070|Drug|enalapril maleate|
45634229|NCT02409979|Other|Water Exchange-CO2|Insertion using water exchange, withdrawal using CO2 insufflation.
45447956|NCT02122510|Drug|Dexmedetomidine|Dexamedtomedine group will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
45773259|NCT00003070|Procedure|quality-of-life assessment|
45773260|NCT03240536|Other|Choosing Wisely form|"The investigators will fax a Choosing Wisely form to ordering physicians that will include information from the Canadian Rheumatology Association Canada Choosing Wisely Guidelines. Three points will be included with some additional explanation of why these are important.~The three guidelines included will be:~Don't order an ANA as a screening test in patients without specific signs or symptoms of systemic lupus erythematous (SLE) or another connective tissue disorder (CTD).~Don't routinely image patients with low back pain regardless of the duration of symptoms unless that are clinical reasons to suspect serious underlying pathology~Don' routinely order a shoulder ultrasound as it is likely to indicate a tear in many people over the age of 50 years and will not change the initial management."
45773261|NCT00003076|Drug|eflornithine|
45773262|NCT01896518|Drug|Nicotine polacrilex|
45773263|NCT01896518|Drug|Tobacco lozenge|
45773264|NCT00003082|Biological|monoclonal antibody A27.15|
45773265|NCT00003082|Biological|monoclonal antibody E2.3|
45634230|NCT02409979|Other|Water Exchange-AI|Insertion using water exchange, withdrawal using air insufflation.
45773266|NCT04775186|Procedure|Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)|Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)
45773267|NCT00003088|Drug|cyclophosphamide|given IV
45447957|NCT02125240|Drug|Icotinib|125 mg three times daily (375 mg per day) by mouth
45634231|NCT02409901|Behavioral|Exercise Rehabilitation|12 month personalized exercise rehabilitation in addition to standard clinical care
45634232|NCT03171961|Behavioral|online visit group|subjects has online visit with dietitian every 2 weeks+diet
45634233|NCT03171961|Behavioral|Clinic visit group|Clinic visit group ,subjects has every 2 weeks in person visit at clinic+diet
45634234|NCT03171961|Behavioral|self-directed group|self-directed group receives nutritional information via web and their energy needs for weight loss
45634235|NCT02409823|Drug|Atypical Antipsychotics|any atypical antipsychotic
45634236|NCT02409511|Other|non intervention|
45634237|NCT02406469|Dietary Supplement|Oral consumption milk Tetra Pak|Oral consumption of assigned products in the form of Tetra Pak (A1 or A2 milk according to randomization), 250 ml/time, 2 times daily after meal, for a total of 28 days (14 days in each intervention phase).
45773268|NCT00003088|Drug|doxorubicin hydrochloride|given IV
45773269|NCT00003088|Drug|paclitaxel|given IV
45447958|NCT02125240|Drug|Placebo|1 tablet three times daily by mouth
45914201|NCT02040363|Procedure|Muscular biopsy|
45447959|NCT02125318|Drug|Anagrelide CR|Starting dose of 0.5 mg b.i.d. (1.0 mg/day) titrated at weekly intervals, on an individual basis, to achieve the lowest dose required to achieve and maintain a target platelet count of 150 - 400 x 10e9/L, tolerability permitting. The dose will be increased at weekly intervals in steps not exceeding 0.5 mg/day; the rate of dose titration may be reduced (i.e., up to once every 2 weeks) at the discretion of the Investigator.
45447960|NCT02128048|Device|Assessment of body composition and muscle function|Assessment of body composition by DEXA and BIA Measurement of muscle function by hand-grip dynamometer and physical tests Comparison between quitters and continued smokers
45634238|NCT02406313|Other|CTS|Standardized Thermal Cure
45634239|NCT02406313|Other|ETP|Patient Therapeutic Education
45634240|NCT04481269|Device|Surface-modified composite coated orthopedic implants|The surface-modified composite coated orthopedic implants have the capacity of high binding strength, high tissue-inducing activity and intelligent bacteria-resistance. The implant devices are expected to be used in the prevention and treatment of plant-related infections in orthopedic surgeries.
45634241|NCT04481269|Device|conventional orthopedic implants|conventional orthopedic implants
45634242|NCT02401477|Drug|Ilaprazole + Amoxicillin|Ilaprazole 40mg BID, dosage form : delayed release tablet Amoxicillin 750mg QID, dosage form : capsule
45634243|NCT03174769|Other|Normal protein|Following a two week baseline assessment period, subjects will consume a diet with normal protein diet while undergoing weight loss for 12 wk.
45634244|NCT03174769|Other|High protien|Following a two week baseline assessment period, subjects will consume a diet with high protein diet while undergoing weight loss for 12 wk.
45634245|NCT02401399|Dietary Supplement|Regular diet|The patients receive regular diet 900 Kcal/day during 15 days before surgery
45634246|NCT02401399|Dietary Supplement|High protein formula|The patients receive high protein formula during 15 days before surgery
45634247|NCT02401399|Dietary Supplement|Immunonutrition|The patients receive Immunonutrition formula during 15 days before surgery
45773270|NCT04774874|Drug|Topical formulation|Topical administration on the scalp once daily for 16 weeks
45773271|NCT04774640|Device|MaterniT GENOME|
45773272|NCT00003094|Other|preventative dietary intervention|
45773273|NCT04775030|Drug|CBD occlusal appliance|Occlusal appliance manufactured with CBD molecules released from material to patients oral cavity during sleep time
45773274|NCT04775030|Device|Acrylic resin occlusal appliance|Acrylic resin occlusal appliance during sleep time
45773275|NCT00003100|Dietary Supplement|soy isoflavones|
45773276|NCT05423210|Combination Product|Atezolizumab + FSRT radiation|Atezolizumab 840mg IV every 2 weeks Fractionated Stereotactic Radiotherapy
45773277|NCT00755560|Drug|Albendazole|Albendazole 10 - 15 mg/kg/day BID for 15 days
45773278|NCT00755560|Drug|Placebo|Placebo BID for 15 days
45914202|NCT02040363|Other|5-10 weeks sport training|
45914203|NCT02040389|Behavioral|Picture book|Arm with showing and explaining for parents about perioperative typical surgery site/wound view by study's team
45773279|NCT05412602|Procedure|full spine corrective protocol|36 chiropractic adjustments over 12 weeks (3 visits per week) with in office spinal traction on the 3D Denneroll Traction Table, as well as supplemental home exercises
45634248|NCT03174691|Diagnostic Test|Blood collection|"A total of ten (10) blood samples (2ml/each) will be collected during the study.~Blood samples will be collected on the following days for subsequent analysis of LH, Estradiol, hCG, progesterone and 17-Hydroxyprogesterone."
45634249|NCT02406157|Device|577-MPL|Device for 577nm micropulse treatment of the diabetic macular edema with the following parameters:100 microns spot size,5% duty cycle of 0.2 seconds,power is tested on micropulse mode and then reduce power to 50% of visible
45634250|NCT02406157|Device|532-SLP|Device for 532nm subthreshold treatment of the diabetic macular edema, by decomposing a subthreshold short pulse, with 10 milliseconds, 100 microns, and power(100-1000mW) adjusted according to patient's diopter transparency and pigmentation
45773280|NCT05405894|Drug|Zoledronic acid|Once-yearly infusion of zoledronic acid following denosumab discontinuation
45634251|NCT03174457|Drug|Micafungin|Intravenous
45634252|NCT00701701|Biological|Myozyme® (alglucosidase alfa)|Myozyme®: IV infusion of 20 mg/kg qow; Cyclophosphamide: 250 mg/m^2 IV q4w after Myozyme infusion for 6 months.
45634253|NCT00701701|Biological|Myozyme® (alglucosidase alfa)|Myozyme®: IV infusion of 20 mg/kg qow; Rituximab: 375 mg/m^2 IV weekly beginning the day after Myozyme infusion for 4 weeks (an optional additional 2nd cycle could be administered at the discretion of the investigator); Methotrexate: 15 mg/m^2 subcutaneous qow on the day after Myozyme infusion for 6 months.
45634254|NCT02401711|Behavioral|Education - BIPS course|The guiding principles behind the BIPS program include: (1) explaining how complex systems cause human error and how human error can lead to patient harm in complex systems; (2) diagnosing human error and identifying a prevention behavior for each of the three types: skill, rule, and knowledge; and (3) preventing error by promoting safety behaviors, such as having attention to detail, communicating clearly, having a questioning attitude, and speaking up for safety
45634255|NCT02401711|Behavioral|Formal safety curriculum|The educational program is designed to improve patient safety by informing residents about safe operating room behaviors.
45773281|NCT00003118|Drug|cisplatin|
45447961|NCT02128126|Drug|ISA101/ISA101b|Four dose levels ISA101/ISA101b
45634256|NCT02401711|Behavioral|Ongoing evaluation and feedback|The feedback program is designed to encourage the use of safe behaviors and to discourage unsafe behaviors taught in the workshops.
45634257|NCT03174613|Drug|LC51-0255|0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
45634258|NCT03174613|Drug|Placebo|0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
45634259|NCT02409745|Procedure|endometrial scratch|local injury to the endometrium by Pipelle
45634260|NCT02401321|Behavioral|Telephone-Based Intervention|Complete Taking Care of Her program
45634261|NCT02401321|Other|Caregiver-Assisted Training|Complete Taking Care of Her program
45634262|NCT02401321|Other|Questionnaire Administration|Ancillary studies
45634263|NCT02401321|Other|Quality-of-Life Assessment|Ancillary studies
45634264|NCT03174145|Behavioral|Positive behaviour|Information about T4P1010 treatment
45634265|NCT03174145|Drug|T4P1010 administration|Provide treatment to be taken twice a day between Visit 2 and Visit 5 as add-on therapy to patient's regular analgesic treatment
45447962|NCT02128204|Device|lidocaine contained hyaluronate facial dermal filler|HYADERMIS LA Facial Dermal Implant contains 20 mg/ml hyaluronate and 0.3 % lidocaine.
45634266|NCT03174145|Genetic|Pharmacogenetic|Blood sample of 10 millilitres maximum
45634267|NCT03174145|Other|Questionnaires and diary completion|Personality, pain and disease questionnaires completion during the study Diary completion between Visit 1 and Visit 5
45634268|NCT04480957|Biological|ARCT-021 Dose 1|ARCT-021 Dose 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP)
45634269|NCT04480957|Biological|ARCT-021 Dose 2|ARCT-021 Dose 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
45634270|NCT04480957|Biological|ARCT-021 Dose 3|ARCT-021 Dose 3 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
45773282|NCT00003118|Drug|fluorouracil|
45447963|NCT02128204|Device|hyaluronate facial dermal filler|Hya-Dermis Facial Dermal Implant contains 20 mg/ml hyaluronate.
45447964|NCT02125474|Radiation|[177Lu] DOTA-TATE|We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-[DOTA 0, Tyr 3] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
45447965|NCT02125552|Procedure|Ultrasound guidance|The ultrasound machine will be used to guide intravenous line placement in patients randomized to the ultrasound guided intravenous line group
45447966|NCT02125552|Procedure|Traditional intravenous access|Placement by experienced nurse using standard IV techniques
45447967|NCT02128282|Drug|CX-4945|API powder-in-capsule in 200 mg strength.
45447968|NCT02128282|Drug|Cisplatin|25 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
45447969|NCT02128282|Drug|Gemcitabine|1,000 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
45634271|NCT04480957|Biological|ARCT-021 Dose 4|ARCT-021 Dose 4 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
45773283|NCT00003118|Procedure|surgical procedure|
45773284|NCT00003118|Radiation|radiation therapy|
45773285|NCT00003124|Drug|flutamide|
45773286|NCT00003124|Drug|leuprolide acetate|
45773287|NCT00003124|Radiation|radiation therapy|
45773288|NCT00003574|Procedure|surgical procedure|
45773289|NCT00003574|Radiation|brachytherapy|
45773290|NCT00003574|Radiation|intraoperative radiation therapy|
45773291|NCT00003574|Radiation|iodine I 125|
45773292|NCT00003580|Drug|amifostine trihydrate|
45773293|NCT00003580|Drug|cisplatin|
45773294|NCT00003580|Radiation|radiation therapy|
45773295|NCT00056498|Drug|Placebo|Placebo capsule daily for 16 weeks
45914204|NCT02040389|Behavioral|Standard preoperative education|Arm with standard, verbal explaining for a parents about perioperative site/wound view
45634272|NCT04480957|Biological|ARCT-021 Dose Regimen 1|ARCT-021 dose regimen 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
45773296|NCT00056498|Drug|Risperdal|Risperdal 4 mg per day for 16 weeks
45773297|NCT03066050|Other|MV Repair|Participants underwent mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.
45773298|NCT03066050|Other|MV Replacement|Participants underwent mitral valve replacement and complete preservation of the sub-valvular apparatus.
45634273|NCT04480957|Biological|ARCT-021 Dose Regimen 2|ARCT-021 dose regimen 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
45773299|NCT03066050|Other|CABG|Participants underwent coronary artery bypass grafting
45634274|NCT04480957|Other|Placebo|Sterile 0.9% saline
45634275|NCT02401243|Drug|INSULIN GLARGINE (U300)|"Pharmaceutical form: pre-filled disposable pen~Route of administration: subcutaneous"
45773300|NCT04330144|Drug|Hydroxychloroquine as post exposure prophylaxis|1day: Hydroxychloroquine 800mg Qd po 2-5dy: Hydroxychloroquine 400mg Qd po
45773301|NCT04330144|Other|Others(No intervention)|No treatment. Close monitoring and quarantine.
45634276|NCT02406079|Procedure|tracheotomy|Tracheotomy is one of most performed surgical procedures to assure airway by making a hole in front of the trachea in ICU.
45773302|NCT00003130|Drug|paclitaxel|
45773303|NCT00058370|Drug|cisplatin|
45773304|NCT00058370|Drug|lomustine|
45773305|NCT00058370|Drug|vincristine sulfate|
45773306|NCT00058370|Procedure|adjuvant therapy|
45773307|NCT00058370|Radiation|iodine I 131 monoclonal antibody 3F8|
45634277|NCT02406001|Device|Tigran PTG|Open Flap Debridement
45634278|NCT02406001|Procedure|Surgical intervention|Open Flap Debridement
45634279|NCT02409433|Drug|lacosamide|"Comparison of patients treated with IV lacosamide to those treated with phenytoin in the intensive care unit setting.~The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours."
45634280|NCT02409433|Drug|Phenytoin|the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day.
45914205|NCT02040402|Biological|7-valent pneumococcal conjugated vaccine|Pneumococcal vaccine 3+1 and 2+1 schedule comparison
45914206|NCT02040402|Biological|7-valent pneumococcal conjugated vaccine|3+1 doses vs 2+1 doses
45914207|NCT02040415|Drug|DW-1030(eperisone HCl) 75mg|
45634281|NCT01989754|Drug|Placebo|One placebo capsule taken orally (by mouth) once daily for 156 weeks
45634282|NCT01989754|Drug|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily
45914208|NCT02040415|Drug|Myonal Tab.(eperisone HCl) 50mg|
45634283|NCT01989754|Drug|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily
45773308|NCT00058370|Radiation|radiation therapy|
45773309|NCT00059228|Drug|17beta Estradiol|Alora 100 microgram per day by skin patch for 6 weeks.
45773310|NCT00059228|Drug|Placebos|Placebo skin patch for 6 weeks
45773311|NCT00060008|Radiation|fludeoxyglucose F 18|
45773312|NCT00060008|Radiation|gadopentetate dimeglumine|
45773313|NCT00062738|Drug|paroxetine|Paroxetine CR 12.5 - 25 mg q hs
45773314|NCT00062738|Drug|Nortriptyline|nortriptyline 25 - 75 mg q hs
45773315|NCT00062738|Other|placebo|matching placebo
45773316|NCT05278520|Procedure|Total hip arthroplasty|Hip joint replacement surgery. Elective for RA and OA cases.
45773317|NCT00063362|Drug|Lithium|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over three weeks to a minimum blood level of 0.5 milliequivalent /L (mEq/L).
45773318|NCT00063362|Drug|Lamotrigine|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
45773319|NCT00063362|Drug|Divalproex|Divalproex was then initiated at 250 mg twice daily and increased slowly over five weeks to a minimum blood level of 50 μg/mL.
45773320|NCT00063362|Drug|Placebo|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
45914209|NCT02040415|Drug|Placebo drug of DW-1030|
45914210|NCT02040415|Drug|Placebo drug of Myonal Tab.|
45914211|NCT02040441|Drug|Spironolactone|
45914212|NCT02040441|Drug|Placebo|
45914213|NCT02040441|Drug|Standard care|Standard diabetes care
45914214|NCT02040454|Drug|Paclitaxel|
45914215|NCT02040454|Procedure|Standard Therapy|
45914216|NCT02040480|Drug|GSK2110183 Gelatin Capsule|White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration
45914217|NCT02040480|Drug|GSK2110183 IR Tablet|White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration
45914218|NCT02040493|Radiation|Intra-operative radiation therapy (IORT)|All subjects will receive IORT at the time of lumpectomy.
45914219|NCT02040506|Drug|IGN523|Given intravenously every week for 8 weeks. Dosing beyond 8 weeks will be permitted for subjects meeting criteria for ongoing clinical benefit and acceptable safety.
45914220|NCT02040519|Behavioral|Filling out voiding diaries.|
45634284|NCT01619878|Drug|Artemether-lumefantrine (COA566)|One dispersible tablet taken orally twice a day during 3 days.
45634285|NCT02015104|Biological|BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))|TICE BCG for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis
45634286|NCT02015104|Biological|PANVAC|A recombinant virus vector vaccine containing genes for human carcinoembryonic antigen (CEA), mucin-1 (MUC-1) and three co-stimulatory molecules (designated Triad of costimulatory molecules (TRICOM): B7.1, intercellular adhesion molecule-1 (ICAM-1), and leukocyte function-associated antigen-3 (LFA-3).
45634287|NCT04178746|Device|Artemis Neuro Evacuation Device|"The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump.~The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.~The Artemis Device will be evaluated by descriptive statistics in this registry to assess its efficiency and reliability in minimally invasive, mechanical evacuation of hematoma in patients with intracranial hemorrhage under direct visualization and control using a neuroendoscope."
45773321|NCT00064844|Behavioral|Cognitive Behavior Therapy for alcohol and smoking cessation|Individual 60-minute treatment sessions were scheduled weekly for the first 3 months, then monthly for the next 3 months for a total of 16 sessions. Alcohol treatment was based on the cognitive behavioral therapy manual developed for Project MATCH, with approximately 40-45 minutes of each session devoted to alcohol treatment. Components of this intervention included identifying alcohol antecedents, coping with alcohol urges, managing thoughts about alcohol, problem solving, drink refusal skills, planning for emergencies, communication and assertiveness training and enhancing social support networks for alcohol abstinence. The smoking cessation intervention was delivered in the same sessions as the alcohol treatment, with approximately 15-20 minutes of each session devoted to smoking cessation. Treatment employed behavioral elements that have been supported empirically according to the USDHHS smoking cessation practice guideline.
45447970|NCT02122744|Device|Super Rapid Magstim Stimulator|"The repetitive transcranial magnetic stimulation (rTMS) is able to modify cortical excitability and reactivity. 1Hz rTMS inhibits the cortex, 10Hz excites it. In particular, a new paradigm of rTMS, the rTMS quadri pulse has a more lasting and effective activity.~The side effects are rare and transient: migraine,contractions of the muscles of the neck due to muscle stimulation by the electromagnetic field of the coil."
45447971|NCT02122744|Device|Super Rapid Magstim Stimulator (sham)|coil perpendicular to the scalp
45634288|NCT01619800|Device|Blended Sensor Optimization (BSO)|"At wound check (POD#1 and 1 Week F/U), histograms from device interrogation obtained from patients in the BSO group are assessed, and these patients undergo optimization. A hall walk and stair climbing exercise will be performed and MV optimized using trending data to hit the following targets:~HR at Rest: 60 HR upon slow walking: 100 HR upon brisk walking: 115-120 HR upon climbing stairs: 130-135 Patients will undergo optimization, and be instructed that their device may have been optimized."
45634289|NCT01619800|Device|Accelerometer Alone (AA)|Patients in the AA group will also undergo device interrogation, and will perform a hall walk and stair climbing exercise. Afterwards, these patients will undergo a sham optimization by placing the PPM interrogation laptop device over there pacemaker, and instructing the patients that their device may have been optimized.
45634290|NCT01989208|Other|SG1002|200 mg capsules will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
45634291|NCT01989208|Other|Placebo|200 mg capsules containing placebo will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
45634292|NCT01619410|Biological|Linezolid|Linezolid 600 mg every 12 hours for 7 days
45634293|NCT01619410|Biological|Clindamycin|Clindamycin 300 mg po every 6 hours for 7 days
45634294|NCT01966042|Procedure|Local sedation|All subjects enrolled in the study underwent local sedation for bone marrow aspiration.
45634295|NCT01966042|Procedure|Bone Marrow Aspiration|All subjects enrolled in the study underwent bone marrow aspiration after they had been anesthetized from the posterior iliac crest. The sample was aspirated into a series of sterile syringes and brought to the cell processing room/laboratory. The processing was in accordance to the Standard Operating Procedure developed observing Good Practice Guidelines.
45634296|NCT01966042|Procedure|Minithoracotomy|The surgical procedure used as cardiac access route was the left anterolateral thoracotomy or left anterior minithoracotomy, depending on the segment of the left ventricle to be treated, allowing the good access to the viable myocardial areas.
45773322|NCT00064844|Drug|Nicoderm CQ nicotine patch|Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy.
45914221|NCT02040558|Drug|MNK-010|
45935457|NCT00043316|Drug|interferon gamma-1b|500 or 1000 mcg, inhalation, 3x per week
45447972|NCT02125630|Procedure|Surgery|Surgery to primary tumor
45447973|NCT02125630|Drug|Systemic therapy|Systemic therapy based on tumor phenotype
45447974|NCT02122822|Biological|gp96|vaccination of autologous gp96 derived from tumor tissue + basal treatment
45634297|NCT01966042|Biological|Autologous bone marrow mononuclear cells infusion|Once the subject had his or her chest opened and the coronary anatomy reviewed by examination of the pre-operatory nuclear scan to define the area of ischemia, the surgeon drew up the cells into a series of syringes and injected the entire contents of the cell preparation in a series of injections directly into the myocardium.
45634298|NCT04416724|Procedure|Phacoemulsification|Lens removal by Phacoemulsification
45634299|NCT04416724|Device|Selective Laser Trabeculoplasty|Laser application in trabecular meshwork
45634300|NCT02014480|Device|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via NDPI.
45634301|NCT02014480|Device|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via NDPI.
45634302|NCT02014480|Device|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via NDPI.
45634303|NCT04666714|Drug|Praga formulation|Praga formulation tablet
45634304|NCT04666714|Other|Placebo pregabalin 75mg|Placebo pregabalin 75mg tablet
45634305|NCT04666714|Other|Placebo Pregabalin 150mg|Placebo Pregabalin 150mg tablet
45634306|NCT04666714|Drug|Pregabalin 75mg|Pregabalin 75mg tablet
45773323|NCT00064844|Drug|Placebo gum|Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.
45634307|NCT04666714|Drug|Pregabalin 150mg|Pregabalin 150mg tablet
45634308|NCT04666714|Other|Placebo Praga formulation|Placebo Praga formulation tablet
45914222|NCT02040571|Device|Closed Loop|A total of 24 participants with T1 Diabetes with sensor augmented insulin pump therapy (SAPT) experience will be recruited from four tertiary hospitals and will enter an un-masked randomised-control crossover trial, with a run-in period followed by two phases (in-hospital and at-home) in each of two stages (Closed Loop and Open Loop in random order). Closed Loop will be the intervention for this study, and its performance will be assessed compared to Open Loop (control treatment).
45773324|NCT00064844|Drug|Nicotine gum - Nicorette®|Nicotine gum (2 mg uncoated mint Nicorette®) was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. Use of the gum was encouraged for 24 weeks.
45634309|NCT05016167|Procedure|Replacement every 24 hours|"Processing Steps:~The monitoring electrodes were not replaced for 24 hours, the electrodes were removed at the end of 24 hours. During the 24-hour follow-up, patients whose electrodes were removed for any reason were excluded from the sample.~Immediately after the drying, skin moisture measurement was made in the right 2nd intercostal space (ICA), left 2nd ICA, and midclavicular 5th ICA regions.~The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~The data were recorded."
45773325|NCT01896908|Other|Sodium restriction|"Patients that are eligible and fulfill the inclusion criteria will be invited to participate while hospitalized, and then sign the informed consent form. Then, the dietitian on call will be notified in order to change the dietary map of the patients. The prescription diet for both the intervention and control group will be the same: DIET AS RESEARCH PROTOCOL. PATIENT WILL RECEIVE THE DIET UNTIL DAY __ / __ OR DISCHARGE. PLEASE DO NOT CHANGE IT. This will be combined with the medical staff and with the Nutrition and Dietetics service.~The evaluation of outcomes after hospital discharge will be held in the institution of reference when will be performed clinical evaluation and blood samples collection for neurohormonal activation analysis."
45773326|NCT01897376|Procedure|Pfannenstiel incision|Pfannenstiel incision at time of cesarean section
45773327|NCT01897376|Procedure|vertical skin incision|vertical skin incision at time of cesarean section
45773328|NCT02668562|Procedure|Early CABG (Day 2-3 after ticagrelor discontinuation)|Timing for CABG after ticagrelor discontinuation
45773329|NCT02668562|Procedure|Delayed CABG (Day 5-7 after ticagrelor discontinuation)|Timing for CABG after ticagrelor discontinuation
45914223|NCT02040571|Device|Open Loop|"The performance of closed loop system will be compared to open loop system (Sensor Augmented Pump Therapy). Therefore, the Open Loop system will be the control treatment.~In stage 1 of study, participants are randomized to either closed loop (CL) or open loop (OL). In stage 2, all participants will be crossed to the opposite study arm.~Throughout the study, those who randomised to OL will receive exactly the same medical attention as the CL participants."
45914224|NCT02040584|Drug|Minimisation of TAC|•EVR: Treatment started at a total daily dose of 2 mg within 24 hours after randomisation. The dose of EVR was adjusted upon reaching trough levels (C-0h) in whole blood of 3-8 ng/mL. The daily dose (in two administrations) of EVR may have been modified to maintain trough levels (C-0h) in whole blood of 3-8 ng/mL until Week 52 post-transplant. •TAC: Once confirmation was obtained, beginning in Week 5, that trough levels (C-0h) in whole blood of EVR were between 3-8 ng/mL, minimisation of TAC began, in order to reach trough levels (C-0h) of TAC in whole blood of ≤5 ng/mL no later than four weeks after randomisation (Week 8), which were levels that should have been maintained until Week 52 post-transplant. •MMF was withdrawn at the same time that EVR was introduced. •oral corticosteroids was administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids was permitted
45914225|NCT02040584|Drug|TAC + MMF + corticosteroids|•Dose of TAC: Trough levels (C-0h) of TAC in whole blood should have been maintained between 6-10 ng/mL until Week 52 post-transplant. •Dose of MMF: Doses of 500-1000 mg/12 hrs was maintained until Week 52. •Corticosteroids: During the study, oral corticosteroids was administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids was permitted (e.g. in patients with a history of HCV). It was recommended in any case that corticosteroids not be administered beyond Week 24 post-transplant except in cases of hepatopathy of autoimmune origin. At each centre all patients should have followed the same administration protocol for corticosteroids based on history of HCV.
45447975|NCT03551548|Drug|Spironolactone 25mg|25 mg oral spironolactone once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
45447976|NCT03551548|Drug|Placebo oral capsule|oral placebo once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
45447977|NCT03551470|Procedure|Robotic one-stage colorectal and liver resection|
45447978|NCT02125708|Device|OvulaRing®|The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. It was originally invented to assess the moment of ovulation and optimize fertility. This plastic ring including a high-tech-sensor thermometer should be placed into the vaginal fornix for a maximum of 30 days, measuring the intravaginal core-temperature 288 times a day.
45447979|NCT02128360|Drug|Letrozole, Gonadotropins|
45447980|NCT02128360|Drug|Gonadotropins|
45652989|NCT04755179|Procedure|Laparoscopic appendectomy|"Laparoscopic appendectomy is performed according to daily practice but with the following standardized key points:~Conventional laparoscopy (three-trocar technique)~In case of purulent fluid: Suction and no peritoneal lavage procedure~Skelletizing of the mesoappendix (coagulation/clips according to routine practice locally)~Appendiceal stump closure: with two endoloops and dissected between the endoloops. In case of involvement of the appendiceal base, the use of endostapler is recommended.~Withdrawal of appendix: principle of abdominal wall protection is followed (trocar technique / endobag)~No drain placement, no nasogastric tube, and no urinary catheter routinely, only on indication.~Closure of wounds as appropriate"
45773330|NCT04774562|Behavioral|Video-Assisted Discharge Education (VADE)|Video-Assisted Discharge Education (VADE): Information about THR, preventive rehabilitation approaches, transfer activities, using stairs, self-care activities.
45634310|NCT05016167|Procedure|Replacement every 12 hours|"Processing Steps:~Monitoring electrodes were removed at the end of the 12th hour. When removing the monitoring electrodes, the area was first wetted using a disinfectant and dried using a sponge after removing the electrodes.~Immediately after the drying, skin moisture measurement was made in the right 2nd ICA, left 2nd ICA and midclavicular 5th ICA regions.~The skin condition was evaluated from these areas monitored using the skin condition score by the researcher and another independent observer.~Monitored again.~Monitoring electrodes were removed at the end of the 24th hour. Cleaning and drying were done immediately after removal.~Immediately after drying, skin moisture was measured from the monitored areas.~The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~The data were recorded."
45634311|NCT01261247|Drug|panobinostat|Given orally
45634312|NCT01261247|Other|laboratory biomarker analysis|Correlative studies
45634313|NCT01261247|Genetic|western blotting|Correlative studies
45634314|NCT01261247|Genetic|DNA analysis|Correlative studies
45773331|NCT04774562|Behavioral|Physiotherapy (PT) Program|Physiotherapy (PT): Breathing exercises, positioning, hip range of motion and strengthening exercises, and information about walking and ambulation.
45773332|NCT04753502|Procedure|Laparoscopy|laparoscopic removal of pathologic appendix
45773333|NCT00067028|Drug|Clofarabine 40mg/m^2|40 mg/m^2 by vein over 1 hour daily for 5 days.
45773334|NCT00067028|Drug|Idarubicin 10mg/m^2|"10 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.~Clofarabine + Idarubicin plus Ara-C:~6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle."
45773335|NCT00067028|Drug|Ara-C 0.75 g/m^2|0.75 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
45773336|NCT00067028|Drug|Clofarabine 22.5mg/m^2|22.5 mg/m^2 by vein over 1 hour daily for 5 days.
45773337|NCT00067028|Drug|Ara-C 1 g/m^2|1 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
45773338|NCT00067028|Drug|Idarubicin 6 mg/m^2|6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.
45773339|NCT05194748|Other|No intervention, observational only|No intervention, observational only
45773340|NCT00067808|Drug|Decitabine|10 mg/m^2 by vein over 1 hour daily for 10 days
45914226|NCT02040597|Drug|Beclometasone/Formoterol/Glycopyrrolate|
45914227|NCT02040610|Radiation|Hypofractionated Proton Therapy|
45914228|NCT02040636|Biological|Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV|0.5 mL, Intramuscular
45914229|NCT02040636|Biological|Hepatitis B vaccine|0.5 ml, Intramuscular
45914230|NCT02040649|Other|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
45914231|NCT02040649|Other|Control, sedation (propofol, midazolam)|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
45447981|NCT05300620|Device|Custom Foot Orthotics EVA|these are custom foot orthotics made out of Ethyl Vinyl Acetate material
45447982|NCT05300620|Device|Original Liner|these are original shoe liners
45447983|NCT05300620|Device|Custom Foot Orthotics PU|these are custom foot orthotics made out of Expanded Poly Urethane Material
45447984|NCT05300620|Device|Custom Hybrid Foot Orthotics|these are custom foot orthotics made out of a combination of Ethyl Vinyl Acetate and Expanded Poly Urethane Material
45447985|NCT02128516|Other|oral powder in sachet|
45447986|NCT02125942|Behavioral|Central Meditation and Imagery Therapy|mindfulness, guided imagery, meditation
45447987|NCT02126020|Drug|topical infliximab|topical infliximab administered QID for 3 months followed by BID for 9 months
45634315|NCT01261247|Other|flow cytometry|Correlative studies
45634316|NCT01261247|Other|pharmacological study|Correlative studies
45634317|NCT01261247|Other|immunohistochemistry staining method|Optional correlative studies
45634318|NCT02449577|Other|Beverage sequence ABCD|Participants receive test beverages in the randomised order ABCD
45634319|NCT02449577|Other|Beverage sequence CADB|Participants receive test beverages in the randomised order CADB
45634320|NCT02449577|Other|Beverage sequence DACB|Participants receive test beverages in the randomised order DACB
45634321|NCT02449577|Other|Beverage sequence CBAD|Participants receive test beverages in the randomised order CBAD
45634322|NCT02449577|Other|Beverage sequence ABDC|Participants receive test beverages in the randomised order ABDC
45634323|NCT02449577|Other|Beverage sequence DABC|Participants receive test beverages in the randomised order DABC
45634324|NCT02449577|Other|Beverage sequence DCAB|Participants receive test beverages in the randomised order DCAB
45634325|NCT02449577|Other|Beverage sequence DBCA|Participants receive test beverages in the randomised order BDCA
45634326|NCT02449577|Other|Beverage sequence ADCB|Participants receive test beverages in the randomised order ADCB
45634327|NCT02449577|Other|Beverage sequence BADC|Participants receive test beverages in the randomised order BADC
45773341|NCT00067808|Drug|Decitabine|20 mg/m2 by vein (IV) over 1 hour daily x 5 days
45773342|NCT00067808|Drug|Decitabine|20 mg/m2 subcutaneous (SQ) daily x 5 days
45773343|NCT05174312|Device|Reprieve Decongestion Management System|The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
45773344|NCT05174312|Drug|Diuretic|Subjects will receive diuretic therapy per the high dose of arm of the DOSE trial when randomized to the control group.
45914232|NCT02040662|Procedure|Continuous Thoracic Epidural Block|Before anesthesia, continuous thoracic epidural block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (air). A catheter is advanced ca. 3-5 cm, and test dose with 2 ml of lidocaine 2% i injected. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 6 ml bolus is injected, followed by an infusion of the same mixture at 0,06 ml/kg/h for postoperative pain management.
45935458|NCT00077961|Drug|CAMPATH (alemtuzumab)|
45914233|NCT02040662|Procedure|Continuous Thoracic Paravertebral Block|Before anesthesia, continuous thoracic paravertebral block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (normal saline). After injection of 5-10 ml of normal saline a catheter is advanced medially ca. 5 cm. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 20 ml bolus is injected, followed by an infusion of the same mixture at 0,08 ml/kg/h for postoperative pain management
45914234|NCT02040662|Procedure|Patient-Controlled Analgesia with Morphine|"Once arrived at the PACU all patients are placed on a postoperative analgesia regimen, that include:~patient-controlled analgesia with morphine (bolus dose 2 mg, lockout time 10 min)~paracetamol 1000 mg iv every 8 hrs~ketoprofen 100 mg iv every 12 hrs"
45914235|NCT02040727|Behavioral|Resistance Training|Supervised strength training 3 days per week for 24 weeks
45914236|NCT02040727|Behavioral|No Resistance Training|No supervised strength training throughout the study
45914237|NCT02040753|Behavioral|Intensive Lifestyle Intervention|Intensive Lifestyle intervention at Ubberup Folk High School for 10-14 weeks. Daily exercise for 1-3hrs. Calorie restriction. Education within Nutrition, exercise and healthy living in general.
45914238|NCT02040818|Drug|tigecycline, N-acetylcysteine, heparin combination|
45914239|NCT02040818|Device|guide-wire exchange|
45914240|NCT02040831|Biological|RSV LID ΔM2-2 Vaccine|10^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
45914241|NCT02040831|Biological|Placebo Vaccine|0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
45914242|NCT02040883|Drug|Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole|Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.
45914243|NCT02040883|Drug|Tandospirone|Tandospirone，30mg per day
45914244|NCT02040909|Drug|Propofol|Propofol, an anesthetic agent, is used to sedate the patients before endotracheal intubation. The propofol starting dose in all age groups will be 1.0 mg propofol/kg. After 5 patients per age group the next dose will be determined. Dose will be increased or decreased with 0.5 mg/kg for the next 5 patients. The study will be continued untill an adequate dose, that results in adequate sedation, good intubation conditions without hypotension, is determined. That dose will be valideted in another 5 patients per age group.
45914245|NCT02040935|Drug|Trastuzumab|600 mg SC Q3W by SID
45914246|NCT02040948|Device|- Nexfin (Pulse Pressure Variation) - Radical 7 (Pleth Variability Index) - CardioQ (stroke volume)|
45447988|NCT00688376|Drug|Donepezil hydrochloride|"During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets starting at a dose of 3 mg once daily. Doses will be increased incrementally at successive 3-week intervals on the basis of weight and tolerability. The final daily dose will be 3, 5, or 10 mg depending on body weight.~During the Blinded Extension Phase, all subjects will receive active treatment (donepezil)."
45447989|NCT00688376|Drug|Placebo|"During the 12-week Double-Blind Phase, subjects will receive matching placebo tablets (3, 5, of 10 mg) once daily.~During the 12-week Blinded Extension Phase, all subjects will receive active treatment (donepezil)."
45634328|NCT02449577|Other|Beverage sequence ACDB|Participants receive test beverages in the randomised order ACDB
45634329|NCT03233243|Drug|Rosuvastatin Oral Tablet|Patients with 18F-NaF-positive plaques will be treated with 20 mg of rosuvastatin daily for six months, except in patients who need a 55% LDL reduction to achieve recommended targets (rosuvastatin 40 mg). A second visit (visit 2) will take place eight weeks after therapy initiation to monitor for compliance and adverse events report: therapy will be discontinued if there is an elevation of creatine kinase over five times the ULN with myalgia or alanine amino-transferase three times the ULN.
45634330|NCT02449655|Drug|AZD5363|AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week
45773345|NCT05157620|Other|Yoga-based Exercise (YE)|The Yoga-based Exercise (YE) intervention is a series of yoga-based poses that consists of sitting, standing, kneeling, and lying postures as well as breathing exercises. The duration of the intervention will be 12 months. Participants will engage in yoga-based exercise sessions lasting 60 minutes twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in yoga-based exercises once a week. The remainder of the study (6 months), participants will engage in yoga-based exercises once a month.
45447990|NCT02131090|Device|Tegaderm TM|This is a generic adhesive dressing which is commonly used to secure epidural catheters.
45914247|NCT02040961|Device|ETView Double-Lumen Tube|Tracheal intubation is performed using a ETView Double-Lumen Tube
45914248|NCT02040987|Drug|AZD3293|AZD3293 oral solution - one single dose (low dose).
45914249|NCT02040987|Drug|AZD3293|AZD3293 oral solution - one single dose (high dose).
45914250|NCT02040987|Drug|Placebo|Placebo oral solution - one single dose
45447991|NCT02131090|Device|Lock-it Plus|This dressing is specifically designed for securing epidural catheters. It is adhesive to the patient's back and has a plastic clamp through which the epidural catheter passes. Once closed, the clamp secures the catheter.
45447992|NCT02131090|Device|Epifix|This dressing is specifically designed to secure epidural catheters. It is adhesive to the patient's back and has a foam, moulded mechanism through which the catheter is passed. An adhesive flap folds over the whole mechanism to secure the catheter.
45914251|NCT02040987|Drug|Moxifloxacin|Moxifloxacin tablet - one single dose
45914252|NCT02041000|Other|Adipose Derived Stem Cells|
45914253|NCT02041013|Other|Taking Card|Recordable greeting card-style discharge instruction card
45914254|NCT02041026|Dietary Supplement|probiotic yoghurt|The probiotic yoghurt will be prepared using lactobacillus NN20 isolated from Kimere (a traditional fermented food product) consumed in eastern part of kenya
45914255|NCT02041052|Procedure|Subtotal gastrectomy as an adjunct to traditional whipple procedure.|Subtotal gastrectomy as an adjunct to traditional whipple procedure.
45914256|NCT02041052|Procedure|Conventional whipple procedure|All patients undergoing whipple procedure without risk for pancreaticojejunal anastomosis leakage.
45914257|NCT02041065|Device|Waterjet induced dissection|Waterjet induced dissection of the liver during resection.Waterjet dissection device mechanically separates hepatic tissue from bile ducts and vessels, the latter two to be separately ligated.
45914258|NCT02041065|Device|CUSA induced dissection|Ultrasound based destruction of the liver
45634331|NCT02449655|Drug|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
45634332|NCT02449655|Drug|AZD2014|AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle
45914259|NCT02041078|Procedure|Intrahepatic division of the right hepatic vein.|Ligation and division of the entrance of the right hepatic vein into the suprarenal cava vein are done at the end of transection of the liver parenchyma with CUSA.
45634333|NCT02449655|Drug|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
45634334|NCT04400123|Drug|Famitinib malate|"TR group:~The first period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h.~RT group:~The first period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h."
45914260|NCT02041078|Procedure|Extrahepatic vein division|Standard surgical procedure with extrahepatic ligation/division of the right hepatic vein prior to parenchymal division with CUSA.
45634335|NCT03197753|Device|Laryngeal mask airway|Laryngeal mask airway
45634336|NCT03197753|Device|Nasotracheal intubation|Nasotracheal intubation
45634337|NCT04916795|Drug|Vupanorsen|80 mg subcutaneous injection
45914261|NCT02041117|Drug|Rosuvastatin|Rosuvastatin, 10mg for 4-weeks, then according to the results of the LDL-C, adjust dose of rosuvastatin, maximum to 20 mg/d, to reduce LDL-C under 70 mg/dl for two years.
45634338|NCT04916795|Drug|Vupanorsen|80 mg subcutaneous injection
45914262|NCT02041130|Device|Renal Denervation|
45634339|NCT04373837|Behavioral|Prismatic googles inducing prismatic adaptation (PA) associated to Virtual Reality (VR)|"The experimental condition consists of PA procedure associated to VR task: the pointing task will be followed by 5 sessions of VR task.~Pointing task. Patients will perform a session of 90 pointing movements toward a visual target presented in a variety of positions on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a rightward shift of the visual field (experimental condition). After lenses removal, a leftward shift of spatial attention will be produced.~Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Patients will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action."
45914263|NCT02041143|Dietary Supplement|Milk protein|Study product will provide 25 g of protein to subjects.
45914264|NCT02041143|Dietary Supplement|Placebo|Product with no protein
45914265|NCT02041156|Other|aerobic and resistance training|
45914266|NCT02041156|Other|aerobic combined with balance training|
45914267|NCT02041182|Behavioral|Pre-Visit Questionnaire|
45447993|NCT02126332|Other|ropivacaine and sufentanil|Thoracic epidural analgesia will be performed using ropivacaine (2 mg/ml), sufentanil (0.5 microg/ml) administered through a patient-controlled deviced (PCEA : patient-controlled epidural analgesia). PCEA parameters will be fixed as follows : continuous administration of 5 to 15 ml/h and bolus of 3 to 10 ml every 10 minutes. Iterative epidural administration of clonidine (1 mckg/kg) will be allowed to achieve analgesia goals.
45652990|NCT04755179|Procedure|Open appendectomy|"Open appendectomy will be performed according to the following standardized key points:~Gridiron incision at the right lower quadrant. (McBurney's point)~After obtaining access to the abdominal cavity the principle of abdominal wall protection will be followed.~The appendiceal stump will be closed by ligation, not a purse string suture.~Closure of wounds as appropriate"
45914268|NCT02041208|Procedure|kidney transplantation|kidney transplantation
45914269|NCT02041247|Biological|VAC-3S|VAC-3S is administered via intra-muscular route in the arm.
45914270|NCT02041260|Drug|Cabozantinib|
45914271|NCT02041273|Drug|palbociclib isethionate (phase 1 and 2 studies)|125 mg palbociclib isethionate salt under overnight fasting conditions
45914272|NCT02041273|Drug|palbociclib isethionate (phase 1 and 2 studies)|125 mg palbociclib isethionate salt under minimal fasting conditions (1 hr before palbociclib administration and 2 hrs post dose)
45652991|NCT04755179|Procedure|Non-operative treatment|"Non-operative treatment consisting of administration of intravenous antibiotics with or without drainage procedures (in case of an abscess), reserving an appendectomy for those not responding or with recurrent disease.~One of the two antibiotic regiments:~Combination A:~Amoxicillin/clavulanic acid 25/2.5mg/kg 6 hourly (total 100/10 mg/kg daily. Maximum 6000/600mg a day) for children <40 kg OR Amoxicillin/clavulanic acid 1000/200mg/kg 8 hourly (total 3000/6000 mg/kg daily) for children > 40 kg~Gentamicin 7mg/kg once daily~Combination B:~Cefuroxim 25 mg/kg 6 hourly (total 100 mg/kg/day. Maximum 6gram/day)~Metronidazole 10mg/kg 8hourly (total 30 mg/kg/day. Maximum 4000 mg/day) In case of peri-appendicular abscess the decision can be made to perform a drainage procedure either percutaneously or surgical."
45652992|NCT04755179|Procedure|Direct appendectomy|laparoscopic or open appendectomy as described
45652993|NCT05133999|Biological|Plasma determination of iron, transferrin and ferritin|Iron, transferrin and ferritin levels in plasma
45652994|NCT05133999|Other|Fundus Examination by wide field digital imaging camera (PanocamTM camera)|ROP screening using wide field digital retinal imaging according to current recommendations.
45652995|NCT04732871|Biological|RSVPreF3 OA investigational vaccine|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
45652996|NCT05133219|Other|Occupational Therapy|Occupational therapy is the only profession that helps people across the lifespan to do the things they want and need to do through the therapeutic use of daily activities (occupations). Occupational therapy practitioners enable people of all ages to live life to its fullest by helping them promote health, and prevent-or live better with-injury, illness, or disability.
45652997|NCT02633059|Drug|Dexamethasone|Given PO
45652998|NCT02633059|Drug|Idasanutlin|Given PO
45652999|NCT02633059|Drug|Ixazomib Citrate|Given PO
45653000|NCT02633059|Other|Laboratory Biomarker Analysis|Correlative studies
45653001|NCT02633059|Other|Pharmacological Study|Correlative studies
45773346|NCT05157620|Other|Wellness Lifestyle Program (WLP)|The Wellness Lifestyle Program (WLP) is a comprehensive lifestyle program that consists of 30 minutes of educational information covering various topics, such as nutrition, healthy living, stress reduction, and more will be followed by 30 minutes of low-intensity exercise such as walking. The duration of the intervention will be 12 months. Participants will engage in the 60 minute WLP session twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in WLP sessions once a week. The remainder of the study (6 months), participants will engage in WLP sessions once a month.
45773347|NCT00493870|Drug|Docetaxel|Docetaxel 75 mg/m2 IV over 1 hour on Day 1 followed by cyclophosphamide
45773348|NCT00493870|Drug|Doxorubicin|• Doxorubicin 50 mg/m2 IV push over 5-15 minutes via sidearm through a running IV line on Day 1, followed by cyclophosphamide 500 mg/m2 IV over 15-30 minutes on Day 1, followed by docetaxel 75 mg/m2 IV over 1 hour on Day 1. Administer pegfilgrastim 6 mg SC on Day 2 (or filgrastim 5 mcg/kg SC per standard of care).
45773349|NCT00493870|Drug|Cyclophosphamide|600 mg/m2 IV over 15-30 minutes on Day 1.
45773350|NCT05146622|Behavioral|Workplaces in the World|Formative research activities to better understand attitudes and behaviors of outdoor workers with respect to UV safety.
45773351|NCT03287336|Drug|Tranexamic Acid|Tranexamic acid dosage (5 mg/kg, 10 mg/kg and 15 mg/kg) administered in a dose escalating fashion by cohort with the lowest dose first.
45773352|NCT00003136|Biological|filgrastim|
45773353|NCT00003136|Drug|amifostine trihydrate|
45773354|NCT00003136|Drug|carboplatin|
45634340|NCT04373837|Other|Neutral googles inducing no-adaptation (NA) associated to Virtual Reality (VR)|"The sham condition of this study consists of NA procedure associated to VR task: the pointing task will be followed by 5 sessions of VR task.~Pointing task. Patients will perform a session of 90 pointing movements toward a visual target presented in a variety of positions on the right, the left or at the center of the visual field. This pointing task will be performed with neutral goggles (control condition), which should not induce a shift of the visual field and of spatial attention.~Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Patients will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action."
45773355|NCT00003136|Drug|cyclophosphamide|
45773356|NCT00003136|Procedure|peripheral blood stem cell transplantation|
45773357|NCT00003598|Drug|tretinoin|
45773358|NCT00003604|Biological|aldesleukin|
45773359|NCT00002794|Drug|carboplatin|
45773360|NCT00002794|Drug|vincristine sulfate|
45773361|NCT00003610|Dietary Supplement|capsaicin|
45773362|NCT00003610|Other|placebo|
45773363|NCT00003610|Radiation|radiation therapy|
45773364|NCT00003616|Drug|irinotecan hydrochloride|
45773365|NCT01063829|Drug|60 mg AIC246|Oral administration
45773366|NCT01063829|Drug|120 mg AIC246|Oral administration
45773367|NCT01063829|Drug|240 mg AIC246|Oral administration
45773368|NCT01063829|Other|Placebo|Oral administration
45914273|NCT02041273|Drug|palbociclib commercial free base capsule|125 mg palbociclib commercial free base capsule under fed conditions ( moderate fat meal)
45773369|NCT00072566|Biological|Bevacizumab|Given IV
45773370|NCT00072566|Drug|Cyclophosphamide|Given PO
45773371|NCT00072566|Other|Laboratory Biomarker Analysis|Correlative studies
45773372|NCT00003622|Drug|paclitaxel|
45773373|NCT00003622|Drug|vinorelbine tartrate|
45773374|NCT00003148|Biological|aldesleukin|
45914274|NCT02041312|Other|No intervention|No intervention will be needed.
45914275|NCT02041338|Drug|Paclitaxel and carboplatin|
45773375|NCT00003154|Drug|aminocamptothecin colloidal dispersion|120 hour continuous infusion of aminocamptothecin colloidal dispersion (AC/CD) once a week for 2 weeks, followed by 1 week of rest. Patients are assessed after every 2 courses of therapy. Treatment with aminocamptothecin continues indefinitely if there is tumor shrinkage or stable disease and no significant toxicity is experienced. Patients are followed every 3 months.
45773376|NCT04773860|Other|Muscle Energy Techniques|A 4 week intervention will be carried out consisting of Muscle Energy Techniques on the accessory muscle of respiration. That is, Pectoralis Minor, Sternocleidomastoid, Upper trapezius, Scalene muscles and Latissimus Dorsi
45773377|NCT00384046|Drug|Testosterone|patch, 300 mcg/day testosterone, patch changed every 3-4 days, 24 weeks
45773378|NCT00384046|Drug|Placebo|patch, placebo, patch changed every 3-4 days, 24 weeks
45773379|NCT05074862|Dietary Supplement|KetoneAid KE4 Pro Monoester|A dietary supplement containing ketone monoester.
45773380|NCT05074862|Dietary Supplement|Maltodextrin and fat-based placebo|Dosis isocaloric to the KetoneAid Arm
45773381|NCT00002800|Biological|filgrastim|
45773382|NCT00002800|Biological|lintuzumab|
45773383|NCT00002800|Drug|cytarabine|
45773384|NCT00002800|Drug|etoposide|
45773385|NCT00002800|Drug|idarubicin|
45773386|NCT05061992|Drug|Lactulose|"Participants will take 20 grams (dissolved in 4ounces of water/beverage) doses of lactulose twice daily (upon awakening and then 4 hours later) for 28 days.~In addition, outcome measurements will be completed at baseline and day 28."
45773387|NCT00002806|Drug|lomustine|
45773388|NCT00002806|Drug|procarbazine hydrochloride|
45773389|NCT00002806|Drug|vincristine sulfate|
45773390|NCT00002806|Radiation|low-LET photon therapy|
45773391|NCT00003160|Drug|paclitaxel|
45773392|NCT00002812|Drug|asparaginase|Given IV
45773393|NCT00002812|Drug|cyclophosphamide|Given IV
45773394|NCT00002812|Drug|cytarabine|Given IV
45773395|NCT00002812|Drug|daunorubicin hydrochloride|Given IV
45773396|NCT00002812|Drug|dexamethasone|Given IV
45773397|NCT00002812|Drug|doxorubicin hydrochloride|Given IV
45914276|NCT02041338|Drug|Paclitaxel|
45914277|NCT02041338|Drug|Epirubicin and Paclitaxel|
45914278|NCT02041351|Drug|Docetaxel|evaluate the activity of docetaxel on, metastatic lesions when measured after 4 cycles of chemotherapy
45935459|NCT00125008|Biological|Typhoid Vi vaccine|single 0.5ml dose (25ug of purified Vi polysaccharide of S. typhi)
45634341|NCT03197519|Behavioral|TCApp|During these 12 weeks, in addition to TAU, the patient from the experimental group should use TCApp at least once a day, completing at least one self-record daily and/or contacting his/her therapist via chat when needed. The therapist responsible for the online monitoring should, at least once a week, connect to the online platform and perform the following actions: follow the patient's daily self-records, generate personalized reports or graphs and communicate with him/her via chat. After a 12-week period, patients from the experimental group and their therapists will stop using the TCApp application (they will be discharged).
45634342|NCT03197519|Behavioral|TAU|The TAU control group will receive treatment as usual, that is to say, the standard face-to-face CBT, offered by the different ED units in Spain.
45634343|NCT04897295|Device|Active transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
45634344|NCT04897295|Device|Sham transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
45634345|NCT03189563|Drug|DA-9805 45mg|DA-9805 15mg tid
45634346|NCT03189563|Drug|DA-9805 90mg|DA-9805 30mg tid
45634347|NCT03189563|Other|Placebo|Placebo, tid
45634348|NCT04254731|Drug|Same individuals treated with racemic methadone and switched to levomethadone (R-methadone)|
45634349|NCT01603277|Biological|Anti-GM-CSF Monoclonal Antibody 400mg|Anti-GM-CSF Monoclonal Antibody 400mg
45634350|NCT01603277|Other|Placebo|Normal Saline
45634351|NCT04192487|Drug|Crofelemer delayed-release tablets 125mg|1 crofelemer delayed-release tablet twice daily at least 8 hours apart for 30 days with or without meals.
45773398|NCT00002812|Drug|idarubicin|Given IV
45634352|NCT04107623|Diagnostic Test|Indocyanine Green|Using Q-ICG perfusion of the remaining Gastric Conduit will be compared
45634353|NCT03197597|Other|Strain isolation from the nasopharynx|B. pertussis strains has been collected from the nasopharynx of the patients during the clinical visit
45634354|NCT04655027|Drug|Roxadustat|The starting dose of roxadustat will be in accordance with the China package insert, and will depend on the body weight of the patient: 100 mg (45 to < 60 kg) or 120 mg (≥ 60 kg) in patients on dialysis; 70 mg (40 to < 60 kg) or 100 mg (≥ 60 kg) in non-dialysis patients.
45634355|NCT04655027|Drug|rHuEPO|The starting dose of rHuEPO will be in accordance to the dosage approved in rHuEPO China package insert (patients on weekly dose of 6000 IU [dosing will BIW], and patients on weekly dose of >6000 IU [dosing will TIW]) and on patient's haemoglobin levels.
45634356|NCT04032743|Other|ICU treatment|any treatment available by ICU
45634357|NCT04631705|Biological|DZIF-10c|Inhaled administration of the human monoclonal antibody DZIF-10c
45773399|NCT00002812|Drug|mercaptopurine|Given IV
45773400|NCT00002812|Drug|methotrexate|Given PO
45773401|NCT00002812|Drug|pegaspargase|Given IV
45935460|NCT00125008|Biological|Hepatitis A vaccine|720 EL.U. of inactivated hepatitis A viral antigen for children 1440 EL.U. of inactivated hepatitis A viral antigen for adults
46070132|NCT02613663|Procedure|immediate implants with autogenous bone graft|Extraction of unrestorable tooth replaced with immediate implant and use autogenous bone graft to fill the gap.
45634358|NCT04631705|Biological|DZIF-10c|Intravenous administration of the human monoclonal antibody DZIF-10c
45634359|NCT04631705|Drug|Placebo|Inhalation of DZIF-10c diluent as placebo
45634360|NCT04631705|Drug|Placebo|Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
45634361|NCT03197285|Other|EYE-CERVICAL RE-EDUCATION PROGRAM|"Subjects received a total of ten sessions on alternate days.~This includes a total of 10 exercises that has proprioceptive reprogramming in the cervical area with the following phases:~To stimulate ocular mobility without including the cervical movement. The patient was placed in the supine position and the physiotherapist seated, at the height of the head.~To exercise cervical mobility with restricted eye movement. The patient is placed on a rotating stool. The ocular mobility is excluded with opaque glasses that allowed exclusively the foveal vision~Finally we stimulate eye and neck movement coordination. The patient continued to sit on the stool, this time without the glasses."
45634362|NCT03197285|Other|Combined Physiotherapy Protocol|Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful).
45634363|NCT03876977|Procedure|Robotic laparoscopic decompression of pudendal nerve entrapment|"Robotic laparoscopic decompression of pudendal nerve entrapment.~Transperitoneal Laparoscopic Robotic assistance"
45634364|NCT04508933|Device|Extravascular Lung Water Index|Measurement of the EVLWI
45634365|NCT04508933|Device|Pulmonary Vascular Permeability Index|Measurement of the PVPI
45634366|NCT03197441|Other|Platelet-rich plasma|Intraoperative platelet-rich plasma injection during arthroscopic knee surgery
45634367|NCT01678313|Drug|Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)|Study group
45634368|NCT01678313|Drug|Doxazosin 4 mg every day (QD)|Control group
45773402|NCT00002812|Drug|prednisone|Given PO
45773403|NCT00002812|Drug|thioguanine|Given IV
45773404|NCT00002812|Drug|vincristine sulfate|Given IV
46070133|NCT00861471|Drug|Docetaxel|"One treatment cycle is defined as 21 days.~Docetaxel: 70 mg/m^2 (60 mg/m^2 was tested in Phase I as well), Intravenous, every 21 days."
46070134|NCT00861471|Drug|Imatinib Mesylate|"One treatment cycle is defined as 21 days.~Imatinib Mesylate: 24-36 hours after Docetaxel, 600 mg (400 mg was tested in Phase I as well), orally, daily x 14 days."
45773405|NCT00002812|Radiation|radiation therapy|
45773406|NCT01258855|Biological|Aldesleukin|Given IV
45773407|NCT01258855|Other|Laboratory Biomarker Analysis|Correlative studies
45773408|NCT01258855|Biological|Ziv-Aflibercept|Given IV
45773409|NCT00003166|Drug|bryostatin 1|Given IV
45773410|NCT00003166|Drug|vincristine sulfate|Given IV
45773411|NCT00003166|Other|laboratory biomarker analysis|Correlative studies
45773412|NCT00003172|Biological|filgrastim|
45773413|NCT00003172|Biological|recombinant interferon alfa|
45773414|NCT00003172|Drug|docetaxel|
45634369|NCT03197207|Procedure|"Dragon and Tiger warring in lifting and thrusting"|"Tight press slow insert in each acupoint through the superficial,intermediate, deep layer, then tight lifting slow withdraw needle through the deep, intermediate, superficial layer . Two acupoints (GB34, GB39) are manipulation in the process three times each during one minute, then let patients lift shoulder up and down for three times, then draw out the needle 20 minutes later."
45634370|NCT03197207|Procedure|"Dragon and Tiger warring in twisting-rotating"|When needle insert in each acupoint through the superficial,intermediate, deep layer, within each layer twisting thumb forward nine times, then twisting backward six times. Two acupoints (GB34, GB39) are manipulation in the process during one minute, then let patients lift shoulder up and down for three times, then draw out the needle 20 minutes later.
45634371|NCT03409991|Behavioral|Opening Doors|This project is designed as a three-stage mixed methods study to test the efficacy of a career guidance intervention for individuals with psychiatric disabilities. We are using both a randomized clinical trial design coupled with a small qualitative sub-study.
45634372|NCT04435379|Biological|VPM1002|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
45634373|NCT04435379|Biological|Placebo|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
45634374|NCT03407495|Drug|IOP Injection (MPB-1523)|one dose, once IV injection at Day 1
45914279|NCT02041390|Other|SMS reminder|Each month after stent implantation, one investigator sent a text massage by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date back to the hospital for stent management. Patients were requested to response by SMS and were encouraged to contact with the investigator if they had any questions about stent management.
45634375|NCT01603121|Drug|Lisofylline|Lisofylline single dose of 9 mg/kg continuous intravenous infusion over a 10 hour period, and lisofylline single dose of 12 mg/kg continuous subcutaneous infusion over a 10 hour period during the alternate period 1 week apart.
45634376|NCT04365803|Procedure|vacuum-assisted breast biopsy|patient with radiological complete response after neoadjuvant chemotherapy undergo to vacuum assisted breast biopsy and the to definitive surgery
45634377|NCT04413383|Other|Traditional Curved Iris Scissors|Aesculap Curved Iris Scissors
45634378|NCT04413383|Other|Wuennenberg Modified Curved Iris Scissors|Modified Silent Curved Iris Scissors
45634379|NCT04413383|Other|Comparative Experience of Traditional and Wuennenberg Modified Curved Iris Scissors|Patients experience both types of scissors
45634380|NCT03246425|Other|Ventilator mode change|The enrolled subjects will be moved from the baseline mode to another mode of ventilation and the changes in the arterial pulse will be observed
45634381|NCT03246425|Device|Monitoring of blood pressure variation|The changes in the blood pressure will be measured in the form of Stroke Volume Variation using SVV using Vigileo (Edward Life sciences) monitor
45634382|NCT03139721|Device|Mosaic model 305, model 310, and ultra model 305|Aortic or mitral valve replacement
45634383|NCT04325789|Device|nanofiber scaffold|Utilization of the interpositional nanofiber scaffold to augment the rotator cuff repair.
45634384|NCT02356757|Behavioral|Personalized Behavioral Intervention|The PBI is based on self-regulation theory, the Transtheoretical Model and Prospect Theory, and will be delivered using Motivational Interviewing principles and the teach-back method. Participants will receive monthly calls targeting foot self-care, foot self-monitoring, diet, medication and physical activity for 6 months. Call/mailing frequency during the next 6 months will depend on adherence level to foot self-care and self-monitoring at 6 months.
45634385|NCT02356757|Behavioral|Current Best Practice|CBP will include monthly calls from a counselor focusing on preventing conditions like colorectal cancer, flu, insomnia, vision problems, memory loss and oral disease for the first 6 months. Frequency of calls and mailings from counselors during the next 6 months will be determined by level of adherence to preventive strategies during the first 6 months.
45634386|NCT03196895|Behavioral|Weight reduction training|6 one-hour sessions of conventional weight reduction training
45634387|NCT03196895|Behavioral|PPG training|Four 90-minute sessions of glycemic load and exercise training
45634388|NCT03196895|Behavioral|discrete BG feedback|Blood glucose feedback from structured self-monitoring of blood glucose
45634389|NCT03196895|Behavioral|continuous BG feedback|blood glucose feedback from continuous glucose monitoring
45634390|NCT02449265|Radiation|Consolidation involved-site radiotherapy (ISRT)|"6 cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~The general dose had been guided that 30-36Gy in 15~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20~25 fractions of 2 Gy 5 days per week for partial response (PR)."
45634391|NCT02449265|Radiation|Consolidation involved-field radiotherapy (IFRT)|"6 cycles modern CHOP chemotherapy. Radiotherapy field of IFRT defined by CALGB is encompassed the prechemotherapy gross tumor.~The general dose had been guided that 30-36Gy in 15~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 15~18 fractions of 2 Gy 5 days per week for partial response (PR)."
45634392|NCT02449265|Drug|cyclophosphamide|Patients in both arms will be given cyclophpsphamide chemotherapy.
45634393|NCT02449265|Drug|doxorubicin|Patients in both arms will be given doxorubicin chemotherapy.
45634394|NCT02449265|Drug|vincristine|Patients in both arms will be given vincristine chemotherapy.
45634395|NCT02449265|Drug|prednisone|Patients in both arms will be given prednisone chemotherapy.
45634396|NCT05092685|Genetic|AAVLK03hOTC|Peripheral intravenous infusion of AAVLK03hOTC.
46070135|NCT00699231|Biological|HBV-MPL vaccine 208129|IM injection
45634397|NCT04143035|Other|No Intervention|No Intervention
45773415|NCT00003172|Drug|doxorubicin hydrochloride|
45773416|NCT00003172|Drug|fluorouracil|
45773417|NCT00003172|Drug|hydroxyurea|
45935461|NCT00125047|Biological|Typhoid Vi vaccine|Single 0.5ml dose containing 25ug purified Vi polysaccharide of S. typhi.
46070136|NCT00699231|Biological|Engerix™-B|IM injection
45634398|NCT05092217|Drug|Tirelizumab|Tirelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); Tirelizumab should be applied since 2-6 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
45634399|NCT05092217|Procedure|salvage surgery|Endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor
45634400|NCT04031807|Procedure|Single-Incision Sling|The women with stress urinary incontinence underwent single-incision sling procedure.
45634401|NCT04413305|Other|screen of CRKP and infection control measure|For intervention group, we screen admitted patients for carbapenem-resistant Klebsiella pneumoniae and carry out 'Bundle' infection and control measures. When outbreak or tranmission of CRKP was observed, we take whole-genome sequencing to track origin and transmission route to decease CRKP rate.
45914280|NCT02041390|Other|Conventional reminder|After stent implantation, all patients received oral instruction about further management. If single or multiple plastic stents were inserted, patients were informed back to our hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed back to the hospital at 6 months.
45914281|NCT02041455|Drug|Melatonin and Placebo|
45634402|NCT03854747|Other|cervical spinal stabilization exercise|The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
45634403|NCT03196817|Drug|betamethasone dipropionate, betamethasone disodium phosphate and lidocaine 2%|6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%
45634404|NCT03196817|Device|Wrist splinting|Splinting only at night to maintain the wrist positioned in 15 degrees of extensionin.
45634405|NCT03118661|Other|For Step 2: Structured treatment interruption|-Accepted tool in the evaluation of immunological interventions, gene therapy, or therapeutic vaccines for the treatment of HIV infection
45634406|NCT03118661|Procedure|Peripheral blood draw|-Screening, entry for Step 1, Step 1 visit 2, entry for Step 2, weekly, week 16, monthly through week 52, week 52, quarterly through year 5, year 5, and viral relapse
45634407|NCT01603043|Drug|Al-78898A|0.400 milligrams (mg) per 50 microliters (μL) administered as an intravitreal injection
45634408|NCT01603043|Drug|Sham injection|Mock injection administered as an empty hub without needle
45634409|NCT05091515|Other|Personal protective equipment from biological hazard|Includes: isolation clothing, mask, eyewear, overshoes
45634410|NCT05091359|Device|Study group with absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate paste|Application of absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate in paste for prevent loosening of Dynamic Hip Screw implant
45773418|NCT01259011|Behavioral|the SPIRIT intervention|the SPIRIT intervention (Sharing the Patient's Illness Representation to Increase Trust) to improve discussions about end-of-life care between patients and their surrogate decision makers
45773419|NCT00003634|Biological|oregovomab|
45773420|NCT03010111|Other|QFT-IT Test and other blood sampling|In all enrolled health care workers, QFT-IT Test and other blood sampling were performed.
45773421|NCT04712578|Dietary Supplement|Caffeinated pre-workout supplement|The intervention will consist of consuming a standardized meal followed by one serving of the commercially available Pulse caffeinated pre-workout supplement (Legion Athletics, Inc.).
45773422|NCT04712578|Dietary Supplement|Non-caffeinated pre-workout supplement|The intervention will consist of consuming a standardized meal followed by one serving of the commercially available Pulse non-caffeinated pre-workout supplement (Legion Athletics, Inc.).
45914282|NCT02041455|Drug|Amitriptyline and Placebo|
45914283|NCT02041455|Drug|Melatonin and Amitriptylin|
45634411|NCT03670745|Behavioral|An electronic self-administered pre-visit planning tool.|An electronic self-administered pre-visit planning tool allowing adolescents to list areas of concern to support shared decision-making during an office visit.
45634412|NCT03670745|Behavioral|Control group|No planning tool
45634413|NCT03196739|Device|Virtual rehabilitation|A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for upper limb rehabilitation using immersive virtual reality under the assistance of an occupational therapist.
45634414|NCT05091125|Diagnostic Test|Diagnostic performance of the S100B protein dosage|Dosage of the S100B protein in patients with mild head trauma with complication risks
45773423|NCT04712578|Dietary Supplement|Placebo|The intervention will consist of consuming a standardized meal followed by a placebo beverage.
45773424|NCT02191033|Behavioral|Smoking counseling|
45914284|NCT02041481|Drug|MEK inhibitor MEK162|Given PO
45914285|NCT02041481|Drug|leucovorin calcium|Given IV
45914286|NCT02041481|Drug|fluorouracil|Given IV
45914287|NCT02041481|Drug|oxaliplatin|Given IV
45914288|NCT02041481|Other|pharmacological study|Correlative studies
45914289|NCT02041481|Other|Laboratory Biomarker Analysis|Correlative Studies
45914290|NCT02041507|Other|Air insufflation method.|Air insufflation colonoscopy.
45914291|NCT02041507|Other|Water Immersion method.|Water Immersion during insertion, air insufflation during withdrawal.
45914292|NCT02041507|Other|Water Exchange method.|Water Exchange during insertion, air insufflation during withdrawal.
45773425|NCT02191033|Behavioral|Text messaging|
45773426|NCT02191033|Drug|Nicotine patch|
45634415|NCT03196583|Device|Velo-Lingual Bite (BVL)|The administration of the device will proceed according to both the essential requirements of the European directives concerning medical devices (Annex I and X of directive 93/42/EEC) and the clinical practice standards and guidelines provided by the AASM and AASDM. These include the obtainment of alginate impression of both jaws and an interocclusal record, with the mandible at 50% of its maximal protrusive position. Since no single standard titration protocol is available, progressive mandibular advancement will be conducted according to the best available medical standard.
45634416|NCT03593759|Drug|Prednisone or Prednisolone|Oral prednisone/prednisolone tablet
45773427|NCT00002818|Drug|cytarabine|
45773428|NCT00002818|Drug|deoxycytidine|
45914293|NCT02041546|Drug|Lung lavage with surfactant|
45914294|NCT02041546|Drug|Bolus surfactant|
45914295|NCT02041572|Behavioral|Attentional bias retraining|Participants complete a computer-based intervention, which is designed to correct cognitive biases associated with PTSD by training to attend to neutral information rather than the trauma-related cue words.
45914296|NCT02041598|Other|CHW Intervention|5 group educational sessions, 2 1v1 Visits with a CHW, Phone Calls as needed during 6-month study period
45914297|NCT02041611|Procedure|Blood collections|pts will have 6 blood collections (30ml/collection) throughout course of standard treatment
45634417|NCT03593759|Drug|Methotrexate|Oral, subcutaneous, or intramuscular methotrexate
45914298|NCT02041650|Drug|Ticagrelor|
45634418|NCT03564821|Drug|Ivosidenib|Ivosidenib is an inhibitor of the protein IDH1
45634419|NCT03364283|Procedure|Surgical position|
45634420|NCT02014402|Biological|Human thrombin|Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
45634421|NCT02014402|Biological|Bovine thrombin|Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
45634422|NCT01988662|Procedure|Neovascular Age-related Macular Degeneration|Blood measurement
45634423|NCT02839343|Radiation|radiation therapy|
45914299|NCT02041663|Biological|BNP|Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5
45914300|NCT02041676|Procedure|Chest physiotherapy|
45914301|NCT02041676|Procedure|Usual surveillance|Usual surveillance of the non invasive ventilation without chest physiotherapy.
45914302|NCT02041689|Behavioral|Interview|Each participant will complete two interview sessions with the primary investigator. Each interview will be conducted in a private, quiet room. Parents may choose to remain with the child during the interview if they would like, but only the responses of the child will be analyzed. Each interview session will last no more than one hour; if the child is not able to respond to each of the primary interview questions during this time, a second follow-up session will be scheduled so that the remainder of the questions can be answered. All interviews will be audio-recorded and transcribed.
45914303|NCT02041689|Behavioral|Observations|Observations help to give insights about interpersonal interactions, actions, non-verbal cues, and the activities and function of areas within the hospital. Three kinds of observation will be used: participant observation, non-participant observation, and guided activities. These observations will be conducted to learn more about the hospital environment as it intersects with the learning experiences of the participants.
45447994|NCT02126332|Other|acetaminophen, nefopam, tramadol, opidoids|Conventional analgesia will include enteral and/or parental administration of usual analgesics, ranging from step 1 to step 3 drugs according to WHO classification (including acetaminophen, nefopam, tramadol, opidoids). The route, dose and frequency of analgesics administrations will be based on participating ICUs protocols.
45634424|NCT02839343|Procedure|surgery|
45634425|NCT02839343|Drug|mFOLFIRINOX|oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV
45634426|NCT02839343|Drug|FOLFOX|oxaliplatin IV, leucovorin IV and 5-FU IV
45634427|NCT00127673|Drug|Sertraline|The dose of sertraline will be up to 200 mg daily for 10 weeks. There will also be weekly meetings with study psychiatrist.
45634428|NCT00127673|Behavioral|Cognitive behavioral therapy (CBT)|CBT will include 10 weekly sessions of individual cognitive behavioral therapy.
45634429|NCT05377073|Other|Hatha Yoga|Patients in the yoga group performed warm-up exercises for 10 minutes, standing, sitting and supine positions of Hatha yoga (30 minutes), and relaxation and breathing exercises (20 minutes). The program consisted of one weekly session for a total of eight weeks.
45634430|NCT05377073|Other|Stretching|Patients in the stretching group performed warm-up activities (10 minutes), and analytic stretching exercises targeting the following muscles: sternocleidomastoid, splenius, trapeze, triceps, posterior shoulder capsule, paravertebralis, hamstrings, quadriceps, gastrocnemius, soleus and tibialis anterior (40 minutes). Two repetitions of 15 seconds of each stretch were performed, with a 15 seconds interval between repetitions. The sessions ended with diaphragmatic breathing exercises (10 minutes). The program consisted of one weekly session for a total of eight weeks.
45634431|NCT03196661|Biological|Influenza A (H7N9) virus vaccine|To prevent the infection of H7N9 virus.
45773429|NCT00003640|Biological|filgrastim|
45773430|NCT00003640|Drug|cisplatin|
45447995|NCT02128594|Behavioral|Serosorting Intervention|Single session, behavioral intervention
45447996|NCT05158790|Other|Questionnaire|Administration of a questionnaire
45447997|NCT02128672|Procedure|Spinal Cord Stimulator Lead Placement|
45773431|NCT00003640|Drug|doxorubicin hydrochloride|
45773432|NCT00003640|Drug|methotrexate|
45773433|NCT00003640|Drug|vinblastine sulfate|
45773434|NCT00003640|Procedure|surgical procedure|
45773435|NCT00003640|Radiation|radiation therapy|
45773436|NCT01260493|Other|integrated health care chain|Geriatric assessment at ED, case manager with multiprofessional team in the community, support for informal caregivers
45773437|NCT00002824|Biological|gene therapy|
45773438|NCT00002824|Drug|chemotherapy|
45773439|NCT00002824|Drug|ganciclovir|
45773440|NCT00002824|Procedure|conventional surgery|
45634432|NCT05376995|Diagnostic Test|Graston technique|Graston technique among patient of knee osteoarthritis
45634433|NCT05376995|Diagnostic Test|muscle energy technique|muscle energy technique among patient of knee osteoarthritis
45634434|NCT05090735|Procedure|SPIP and TAP Block|Injection of Bupivacaine 0.25% for SPIP Block and TAP Block.
45634435|NCT05090735|Procedure|SPIP Block|Injection of Bupivacaine 0.25% for SPIP Block
45634436|NCT02379611|Procedure|fNIRS (Functional Near Infrared Spectroscopy)|fNIRS is a non-invasive imaging method involving the quantification of chromophore concentration resolved from the measurement of near infrared (NIR) light attenuation, temporal or phasic changes. NIR spectrum light takes advantage of the optical window in which skin, tissue, and bone are mostly transparent to NIR light in the spectrum of 700-900 nm, while hemoglobin (Hb) and deoxygenated-hemoglobin (deoxy-Hb) are stronger absorbers of light. Differences in the absorption spectra of deoxy-Hb and oxy-Hb allow the measurement of relative changes in hemoglobin concentration through the use of light attenuation at multiple wavelengths.
45634437|NCT05376605|Other|assessment|Evaluations of the patients will be made with scales, questionnaires and physical tests.
45634438|NCT02449187|Drug|JLP-1310, Fasted followed by fed|"In period 1, the subjects will receive an oral pill of JLP-1310 under fasted condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fed condition."
45634439|NCT02449187|Drug|JLP-1310, Fed followed by fasted|"In period 1, the subjects will receive an oral pill of JLP-1310 under fed condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fasted condition."
45634440|NCT02449343|Drug|Anlotinib|Anlotinib p.o. qd
45634441|NCT02449343|Drug|Placebo|Placebo p.o. qd
45634442|NCT05376527|Biological|Double Recombinant Vaccinia Virus VV-GMCSF-Lact|"Intratumoral injections:~1*107 PFU (calculated at minimal ED on mice); 2*107 PFU; 4*107 PFU; 6*107 PFU; 8*107 PFU; 10*107 PFU;"
45634443|NCT05090579|Procedure|Group I (BN10)|patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine, 1 mL of 10 mg of nalbuphine plus 4 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
45634444|NCT05090579|Procedure|Active Comparator:Group ll (BN20)|patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine, 2 mL of 20 mg of nalbuphine plus 3 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
45634445|NCT05090579|Procedure|Active Comparator:Group lll (B)|patients will receive 20 mL of 0.25%bupivacaine plus 5 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
45634446|NCT02449109|Procedure|interventional therapy|Liver cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）
45634447|NCT05087537|Procedure|Valve ablation|Valve ablation
45634448|NCT05087537|Procedure|Valve ablation and bladder neck incision|Valve ablation and bladder neck incision
45634449|NCT05095571|Dietary Supplement|EH301 (Nicotinamide Riboside/Pterostilbene)|For this study EH301 is defined as Investigational Product(s) (IP). The ALS extension study is an open label study with active treatment of all patients thet have passed through the NO-ALS trial.
45634450|NCT05095493|Dietary Supplement|Zinc Acetate|50 mg tablet
45634451|NCT05095493|Dietary Supplement|Placebo|Zinc Acetate matched placebo tablet
45634452|NCT05095415|Other|Occupational Therapy Pre-operative Consult|Preoperative education will be given by the treating orthopedic surgeon first and will then be followed by a consult with a final semester, occupational therapy student. The pre-operative education will include the importance of attending therapy, what to expect at therapy, typical duration of therapy for their specific diagnosis, and address any questions of ther participant. Participants will be given educational materials and access to education videos to watch if they so choose.
45634453|NCT05095415|Other|Typical Pre-Operative Education|Participants will receive all preoperative education from their orthopedic surgeon and will not be spoken to directly about the therapeutic process until their first scheduled therapy appointment.
45634454|NCT01965652|Drug|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
45634455|NCT01965652|Drug|Placebo|Placebo tablet taken orally once a day
45634456|NCT02677181|Drug|ATG|rabbit ATG（Sanofi）
45634457|NCT02677181|Drug|CsA|cyclosporine (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered.
45773441|NCT00003646|Drug|allovectin-7|
45773442|NCT00003178|Biological|filgrastim|
45773443|NCT00003178|Drug|cladribine|
45634458|NCT02677181|Drug|mycophenolate mofetil|From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30 for MSD-PBSCT.
45634459|NCT02677181|Drug|Methotrexate|short-term methotrexate
45634460|NCT01602965|Procedure|Counseling Monthly Phone Calls|the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviors that need to be changed, problem-solving as to how to make the changes and physical activity levels.
45773444|NCT00003178|Drug|idarubicin|
45773445|NCT01260649|Drug|ketamine|eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care
45634461|NCT01602965|Procedure|Self Help Informative Booklet|Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies
45773446|NCT01260649|Other|IV Saline|eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care
45773447|NCT01260649|Procedure|ECT|ECT will be administered as per standard of care
45773448|NCT01260649|Drug|Muscle Relaxant|All participant will receive routine course of muscle relaxant with ECT as per standard of care
45773449|NCT01260649|Drug|Anesthetic Agents|All participant will receive routine course of anesthetic agents with ECT as per standard of care
45773450|NCT01260883|Drug|Ketorolac Tromethamine 1 mg/kg|Ketorolac Tromethamine 1 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling in for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
45773451|NCT01260883|Drug|Ketorolac Tromethamine 0.5 mg/kg|Ketorolac Tromethamine 0.5 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
45634462|NCT05095025|Drug|Bupivacaine Hydrochloride 20ml injectate|Sequential dosing, starting at 50mg with 5mg increments based on the outcome of the preceding participant
45634463|NCT03196271|Dietary Supplement|Ketocal 2.5:1|A ketogenic feed for the dietary management of intractable epilepsy is given over a period of four weeks, after a control period of 4 weeks. The amount of the feed given is determined by the Dietitian and/or Doctor responsible for the patient's care (at least one carton per day).
45634464|NCT05065073|Drug|Iodixanol|Iso-osmolar Contrast Media
45634465|NCT05065073|Drug|Iohexol|Low-Osmolar Contrast Media
45634466|NCT05059379|Radiation|Entire supraclavicular lymph node radiotherapy|Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node. Entire supraclavicular lymph node includes medial supraclavicular and posterior neck lymph node.
45634467|NCT05059379|Radiation|Medial supraclavicular lymph node radiotherapy|Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node.
45773452|NCT01260883|Drug|Placebo|Dextrose in water (D5W) infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
45773453|NCT00076622|Drug|Antidepressant medication|Participants assigned to continue current medication will be monitored over a period of one year for recurrence of depression and related symptoms.
45773454|NCT00076622|Drug|No antidepressant medication|Participants assigned to discontinue current medication (no antidepressant medication) will be monitored over a period of one year for recurrence of depression and related symptoms.
45773455|NCT00423202|Drug|ambrisentan|
45773456|NCT00003184|Biological|BCG vaccine|
45773457|NCT00003184|Biological|CD80 breast cancer vaccine|
45773458|NCT00003184|Biological|sargramostim|
45773459|NCT00003190|Drug|cytarabine|Given IV
45773460|NCT00003190|Drug|daunorubicin hydrochloride|Given IV
45773461|NCT00003190|Drug|etoposide|Given IV
45773462|NCT00003190|Drug|valspodar|Given IV
45773463|NCT00003652|Drug|cisplatin|
45634468|NCT05056259|Device|18F-FDG PET/CT|"The PET/CT procedure will be performed according to the institutional standard with 18F-FDG (0.8-1.2 mCi /kg) injection following 6 h fasting. Blood glucose was controlled to be <150 mg/dl. PET/CT from the vertex to the middle femur will be obtained 60 min after FDG injection.~MDCT examination without IV contrast will be done for attenuation correction and anatomic localization followed by PET images from the skull vault to the mid-thigh region.~Images of CT and corresponding functional PET images are displayed in axial, coronal and sagittal planes.~PET/CT data will include tumor size and extension, LN invasion& distant metastasis SUVmax will be calculated for all positive lesions, Metabolic parameters including SUVmax, SUVmean, TLG & MTV will be calculated for primary tumor.~Data of PET will be compared with other diagnostic imaging and postoperative pathologic data."
45634469|NCT01987960|Drug|Placebo|Once daily, tablets, orally
45634470|NCT01987960|Drug|Brexpiprazole|1 to 3 mg/day, once daily dose, tablets, orally
45634471|NCT05084027|Combination Product|venetoclax combining with fludarabine and melphalan|Venetoclax 400mg/day，oral，day-8～day-2; Fludarabine, 30mg/m2/day，intravenous，d-7～d-3；Melphalan, 140mg/ m2/d，intravenous，day-2
45634472|NCT02013778|Drug|HCQ|
45634473|NCT05374889|Other|Open Kinetic Chain Proprioception Exercises|basketball-specific target shooting in open kinetic chain
45634474|NCT04676308|Other|Artificial Intelligence|Artificial intelligence
45634475|NCT05074745|Diagnostic Test|ELISA POCT vs RT-PCR|3 swabs taken, buccal for RT-PCR and ELISA POCT, nasopharyngeal for RT-PCR
45634476|NCT05374811|Other|Neuropathic Pain|Neuropathic pain degrees of the patients will be evaluated with the Douleur Neuropathic-4 (DN4) questionnaire.
45634477|NCT02013622|Drug|Brexpiprazole|Treatment (16 weeks) Up to 4 mg/day, once daily dose, tablets, orally
45773464|NCT00003652|Drug|fluorouracil|
45773465|NCT00003652|Procedure|neoadjuvant therapy|
45773466|NCT00003652|Radiation|radiation therapy|
45773467|NCT04389164|Procedure|Tissue-engineered skin grafts of autologous scar dermal scaffolds|"scar excision. The thickness of scar tissue in the middle of scar is removed with a roller cutter and the thickness is about 0.01 -- 0.02mm.~take autologous skin slices of the patient with an electric skin knife, cut out a small piece of skin, and prepare autologous epidermal basal cell suspension for use;The rest of the skin should be the same size as the wound.~the prepared autogenous scar dermal stent was grafted onto the scar resection wound surface, and the prepared autoepidermal basal cells were sprayed between the mesh and on the dermal stent, and autologous skin slices were grafted onto the wound surface and fixed with pressure bandaging;~after the operation, the outer dressing should be changed regularly according to the conventional treatment, and the wound surface condition should be observed and recorded according to the experimental scheme."
45773468|NCT04773236|Drug|sodium bicarbonate 8.4%|mixing the sodium bicarbonate with 2%lidocaine and 1:80.000 epinphrine using mixing pen (onset buffering system)
45773469|NCT04773236|Drug|2%lidocaine with 1:80.000 epinphrine|injection
45773470|NCT04773236|Device|Mixing pen (onset buffering system)|Premixing of the two solutions sodium bicarbonate and lidocaine with epinphrine before the local anesthesia adminstration to the patient
45773471|NCT00003658|Biological|filgrastim|
45773472|NCT00003658|Biological|rituximab|
45773473|NCT00003658|Drug|cyclophosphamide|
45773474|NCT00003658|Drug|pentostatin|
45773475|NCT00078728|Behavioral|Family-Based Anxiety Prevention Program|Participants in the prevention program will have weekly sessions with a therapist and will learn skills to help reduce anxiety for 8 weeks. The intervention will begin immediately after randomization to the study.
45773476|NCT00078728|Behavioral|Evaluation only|Participants will undergo evaluations without active treatment for 8 weeks.
45935462|NCT00125047|Biological|Hepatitis A vaccine|single 0.5ml dose contains 720 EL.U. of inactivated hepatitis A viral antigen
45935463|NCT00125086|Device|autologous platelet gel|
45447998|NCT03550612|Diagnostic Test|magnetic resonant imaging,cranial ultrasound.|Magnetic resonant image performed at term gestation neonate suffer of hypoxic ischemic encephalopathy and its results will be analysed in details and classified according to global score of magnetic resonant image injury.Cranial ultrasound results will be analysed regards (periventricular - interventricular haemorrhage-Ventricular size-basal ganglia, thalamus and cerebellum affection) and Doppler (peak systolic flow velocity-end diastolic peak flow velocity-mean velocity and resistance index).Cerebral bleeding will be diagnosed be cranial ultrasound and confirmed be standard magnetic resonant image in term equivalent age.
45634478|NCT02448797|Drug|Icotinib|125 mg three times daily (375 mg per day) orally for two years.
45634479|NCT02448797|Drug|Chemotherapy|Vinorelbine 25 mg/m^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles, cisplatin 75 mg/m^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles. For adenocarcinoma: pemetrexed (500 mg/m^2, day 1)/cisplatin (75 mg/m^2, day 1) for 4 cycles.
45634480|NCT05374733|Diagnostic Test|Coronary Physiology assessment|"Pd/Pa, diastolic pressure ratio (dPR), resting full cycle ratio (RFR), FFR, coronary flow reserve (CFR), and index of microvascular resistance (IMR) measurements in the coronary of interest before the valvular intervention.~Pd/Pa, dPR, RFR, FFR, vFFR, CFR and IMR measurements in the coronary of interest after the valvular intervention."
45634481|NCT04438421|Drug|Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid|Subjects will then be given the test product, BMG0703, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
45634482|NCT04438421|Drug|Chlorhexidine mouthwash|Subjects will then be given Chlorhexidine 0.2%mouthwash, as an active comparator, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
45634483|NCT04438421|Drug|Placebo|Subjects will then be given a placebo product to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
45634484|NCT05099081|Procedure|diode laser application|Local anesthesia will be applied Lesion will be excised with diode laser (Medency, Italy) continuous wave mode 980 nm wave length with an output power 3 W in contact mode
45634485|NCT05099081|Procedure|intra-lesional injection of ethanolamine oleate|"Local anesthesia will be applied Injection of ethanolamine oleate (sclerosing gent) with concentration 5% diluted in distilled water to form 2.5% ethanolamine oleate According to lesion size range from 1.5 to 3 ml of solution will be injected slowly into lesion using gauge needle until leaked from lesion.~Lesion will be compressed for 5 minutes. Lesion will be observed once a week after injection until it becomes necrotic and falls off spontaneously.~Repeated injection may be needed."
45634486|NCT04438577|Drug|Lidocaine mucilage-ICG|Lidocaine mucilage-ICG as an agent for intraoperative tumor delineation
45634487|NCT04846439|Biological|CAR-T infusion|Sequential infusion of CD19 and BCMA autologous chimeric antigen receptor T cells, the infusion dose was determined according to the body weight of the subject and the effective content of cell preparation.
45634488|NCT03196037|Behavioral|Tai Chi|An 8-week Tai Chi intervention consisting of 75-minute group sessions held twice a week, over 8 weeks (i.e., total of 16 sessions).
45634489|NCT05087615|Drug|Metoclopramide|This groups only received metoclopramide 0.2 mg/kg IV Bid as antiemetic in the postoperative period.
45634490|NCT05087615|Drug|Ondansetron|This groups only received ondansetron 8 mg IV Bid as antiemetic in the postoperative period.
45634491|NCT05087615|Drug|Metoclopramide and Ondanteron|This groups received both metoclopramide 0.2 mg IV Bid and ondansetron 8 mg IV/Bid as antiemetics in the postoperative period.
45773477|NCT00002836|Biological|Filgrastim (G-CSF)|For group one (Filgrastim + Chemotherapy), given under the skin (SC) on day 4 every 12 hours until completion of apheresis; for group two (Filgrastim alone), beginning on day of reinfusion twice a day (bid) until white blood count (WBC) reaches a safe level.
45773478|NCT00002836|Drug|Carmustine|Upon recovery of hematopoiesis patients then receive high by vein (IV) doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days
45634492|NCT05087615|Drug|Granisetron|This groups only received granisetron 2 mg IV Bid as antiemetic in the postoperative period.
45634493|NCT01987102|Drug|Calcium Folinate|"The enrolled patients will be treated according to the MAP schedule and will receive the study drug Calcium Folinate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and [6R] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) [6R] 5,10-methylenetetrahydrofolate dose cohort groups: with [6R] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort."
45773479|NCT00002836|Drug|Cisplatin|As part of CVP chemotherapy treatment by vein (IV) on days 1-3.
45773480|NCT00002836|Drug|Cyclophosphamide (CTX)|In group one (Filgrastim + Chemotherapy) as part of CVP chemotherapy treatment by vein (IV) on days 1-3; and group two (Filgrastim alone), upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
45773481|NCT00002836|Drug|Etoposide|CVP chemotherapy treatment IV on days 1-3, with cyclophosphamide (CTX), etoposide, and cisplatin.
45773482|NCT00002836|Drug|Thiotepa|Upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
45773483|NCT00002836|Procedure|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
45773484|NCT04773548|Other|VR-JIT|Job interview with virtual interviewer
45773485|NCT00003664|Biological|aldesleukin|
45773486|NCT00003664|Biological|recombinant interferon alfa|
45773487|NCT00003664|Drug|fluorouracil|
45773488|NCT00003664|Drug|gemcitabine hydrochloride|
45773489|NCT04797104|Drug|lerodalcibep|300 mg Q4W
45773490|NCT00003196|Drug|chemotherapy|Undergo cytoreductive chemotherapy
45773491|NCT00003196|Radiation|total-body irradiation|Undergo TBI
45773492|NCT00003196|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
45773493|NCT00003196|Drug|cyclosporine|Given IV or PO
45634494|NCT01987102|Drug|[6R] 5,10-methylenetetrahydrofolate (arfolitixorin)|"The enrolled patients will be treated according to the MAP schedule and will receive the study drug [6R] 5,10-methylenetetrahydrofolate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and [6R] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) [6R] 5,10-methylenetetrahydrofolate® dose cohort groups: with [6R] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort."
45773494|NCT00003196|Drug|mycophenolate mofetil|Given PO
45773495|NCT00003196|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
45773496|NCT00003196|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
45773497|NCT04777292|Device|Use of a mobile health application until app completion|Participants are asked to use esTOCma app approximately during 10 days, until app completion. This app has been designed to increase knowledge about obsessive-compulsive disorder (OCD), help seeking attitudes, and reduce stigmatizing attitudes. It consists in a game in which participants are asked to fight against the OCD stigma monster through ten missions. Participants have to liberate 10 characters who are prisoners of EsTOCma monster.
45773498|NCT00002848|Procedure|psychosocial assessment and care|
45773499|NCT00002848|Procedure|quality-of-life assessment|
45773500|NCT00080912|Radiation|radiation therapy|Given in a single fraction or multiple fractions
45773501|NCT00003202|Drug|cisplatin|
45773502|NCT00003202|Drug|gemcitabine hydrochloride|
45773503|NCT00003202|Radiation|radiation therapy|
45773504|NCT00003670|Drug|arzoxifene hydrochloride|
45773505|NCT04738682|Other|Digital dietary registration|"The purpose of the intervention is to test whether digital dietary registration can yield more precise and consistent data, than conventional pen and paper based registration.~Furthermore a subjective evaluation of the use of digital registration will be conducted by the staff upon completion of the intervention. The format will be individual interviews held by the investigators."
45773506|NCT04738682|Other|Conventional dietary registration|The conventional way of doing dietary registration. This is done by a paper form, with the dietary options listed. The form is then filled in and logged by staff working in the afternoon.
45773507|NCT00002854|Biological|filgrastim|
45773508|NCT00002854|Drug|carboplatin|
45773509|NCT00002854|Drug|cisplatin|
45773510|NCT00002854|Drug|cyclophosphamide|
45634495|NCT05374577|Other|pulmonary vascular dysfunction|Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, left heart function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity. Further examinations will be performed in patients with still unclear cause of persistent shortness of breath after 3 months of follow-up (subgroup RHC)
45773511|NCT00002854|Drug|etoposide|
45773512|NCT00002854|Drug|ifosfamide|
45773513|NCT00002854|Drug|mesna|
45773514|NCT00002854|Drug|paclitaxel|
45773515|NCT00002854|Procedure|peripheral blood stem cell transplantation|
45773516|NCT02308202|Drug|doxazosin|
45773517|NCT02308202|Drug|Perindopril|
45773518|NCT02308202|Drug|Placebo|
45773519|NCT00003214|Drug|carboplatin|
45773520|NCT00003214|Drug|cisplatin|
45773521|NCT00003214|Drug|cyclophosphamide|
45773522|NCT00003214|Drug|doxorubicin hydrochloride|
45773523|NCT00003214|Drug|in vitro sensitivity-directed chemotherapy|
45773524|NCT00003214|Drug|paclitaxel|
45773525|NCT00002860|Procedure|Surgery|Complete surgical resection of metastatic melanoma
45773526|NCT03148964|Biological|blood sampling|Blood Sampling at J0, M1, M3, M6, M12, M24 and every 12 months until the end of the study
45773527|NCT00384592|Drug|Esomeprazole|
45773528|NCT00384592|Procedure|Physical exam|
45773529|NCT00384592|Procedure|Pregnancy test if applicable|
45773530|NCT00003220|Drug|bryostatin 1|
45773531|NCT00002866|Biological|filgrastim|
45773532|NCT00002866|Drug|docetaxel|
45773533|NCT00002866|Drug|epirubicin hydrochloride|
45773534|NCT00003232|Drug|clodronate disodium|
45773535|NCT00003232|Drug|mitoxantrone hydrochloride|
45773536|NCT00003232|Drug|prednisone|
45773537|NCT00003232|Procedure|quality-of-life assessment|
45773538|NCT00003238|Drug|perillyl alcohol|
45773539|NCT04329052|Behavioral|Adventure-based training with health educational talk|Participants need to attend an adventure-based training with various experiential learning activities with a health educational talk on mental health.
45773540|NCT00002884|Drug|chemotherapy|
45773541|NCT00002884|Drug|cisplatin|
45773542|NCT00002884|Drug|fluorouracil|
45773543|NCT00002884|Radiation|brachytherapy|
45773544|NCT00002884|Radiation|radiation therapy|
45914304|NCT02041689|Behavioral|Guided Activities|"This study will use three different types of arts and play-based activities to give participants a variety of ways to express their thoughts and perceptions of what it is like to learn about their cancer diagnosis and treatment.~The first activity will be a guided medical play opportunity that prompts the child to use actual medical equipment while taking care of a doll.~For the second activity, the child will be given a digital camera to use and a prompt that asks them to photograph things and individuals in the hospital that have helped them to learn about their diagnosis and treatment.~The third activity will be an open-ended art prompt in which the child will create an artistic representation of what it means to have cancer and get treatment."
45634496|NCT05374577|Other|pulmonary vascular function|Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity.
45634497|NCT02448953|Procedure|Two-field lymphadenectomy|Thoracic-upper abdominal two-field lymphadenectomy
45634498|NCT02448953|Procedure|Three-field lymphadenectomy|Cervical-thoracic-upper abdominal three-field completely lymphadenectomy
45773545|NCT00003682|Drug|doxorubicin hydrochloride|
45773546|NCT00003682|Drug|methylprednisolone|
45914305|NCT02041715|Drug|TKM-100802 for Injection|IV infusion
45773547|NCT00003688|Biological|dactinomycin|
45914306|NCT02041715|Drug|Placebo|IV infusion
45914307|NCT02041741|Behavioral|Weekly tips|Participants in this condition receive weekly a more in-depth tip to increase feelings of happiness involving a (doing and experiencing) task
45773548|NCT00083174|Drug|exemestane|one 25 mg tablet daily in am
45773549|NCT00003934|Drug|tretinoin|Given orally
45773550|NCT00003934|Drug|daunorubicin hydrochloride|Given IV
45773551|NCT00003934|Drug|cytarabine|Given IV
45773552|NCT00003934|Drug|mercaptopurine|Given IV
45773553|NCT00003934|Drug|methotrexate|Given IV
45773554|NCT00003934|Drug|arsenic trioxide|Given IV
45773555|NCT00003694|Drug|omacetaxine mepesuccinate|Given IV
45914308|NCT02041741|Behavioral|Daily Tips|Participants in this condition receive daily a set of small tips aimed at increasing happiness
45914309|NCT02041754|Device|IQP-AK-102|
45914310|NCT02041754|Device|Placebo|
45634499|NCT04570007|Procedure|Pars Plana Vitrectomy|removal of vitreous with vitreous cutter
45634500|NCT02013544|Drug|Placebo|
45634501|NCT02013544|Drug|Prasterone (DHEA)|
45634502|NCT04284605|Other|Aerobic exercise combined with strength training|30 minute aerobic exercise training with warm-up and cool down followed by 30 minute strength training for specific muscles.
45634503|NCT04284605|Other|Yoga|60 minute yoga intervention including different asanas, breath control and meditation
45634504|NCT03968939|Drug|Diphenhydramine (Benadryl)|Oral Diphenhydramine (Benadryl), 25 mg
45634505|NCT03968939|Dietary Supplement|Melatonin|Oral Melatonin, 3 mg
45773556|NCT00003694|Drug|cytarabine|Given IV
45773557|NCT00003694|Other|laboratory biomarker analysis|Correlative studies
45773558|NCT00003250|Drug|fenretinide|
45773559|NCT01896596|Biological|Menjugate|Administered with routine vaccinations at 3 months of age
45773560|NCT01896596|Biological|Menitorix|Administered with routine vaccinations at 3 months
45773561|NCT01896596|Biological|NeisVac-C|Administered with routine vaccinations at 3 months
45773562|NCT00003256|Drug|alvocidib|
45773563|NCT04772846|Drug|Oral tablet|Oral 250mg chloroquine tablets
45773564|NCT04772846|Drug|Placebo|Oral placebo tablets
45773565|NCT00003946|Drug|danazol|
45773566|NCT04695002|Behavioral|MIRA|Based on the initial assessment, the citizen and professional agree what outcomes the citizen should report in MIRA. This could be pain, mood, sleep quality, energy level, dependent on the priorities of the citizen. Similarly, different activities are reported, e.g. exercise, social activities, prolonged sitting or work-related tasks. The citizen and the professional agree how often the citizen reports the outcomes and tasks, and the citizen is notified by the MIRA-app when it's time for reporting. The data will be visualized in a graph for the professional in the back-end of the system, making it possible for the citizen and the professional to view the same, real-time reported data. This provides the base for discussing and adjusting the course of rehabilitation as symptoms change over time. At the same time, this increases the citizen's knowledge of how symptoms, mood, sleep and activities all interact, thereby giving them the tools better cope with their health condition.
45914311|NCT02041767|Drug|Ertapenem|One single injection of 1g of ertapenem before surgery
45914312|NCT02041780|Procedure|Shearwave electrography|
45914313|NCT02041793|Procedure|Laparoscopic cystogastrostomy|Patients undergo drainage of pseudocyst by laparoscopic technique
45914314|NCT02041793|Procedure|Endoscopic cystogastrostomy|Endoscopic cystogastrostomy or cystoduodenostomy will be performed either under direct endoscopic or endosonography guidance
45914315|NCT02041819|Drug|Nimotuzumab|Nimotuzumab: 200mg,IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).
45914316|NCT02041832|Other|Conventional Holter monitoring|Patients undergo 72h Holter monitoring
45914317|NCT02041832|Device|Implantable loop recorder|Implantation of loop recorder with follow-up by remote monitoring
45914318|NCT02041858|Other|Altered Alarm Settings|An altered set of alarm parameter settings
45634506|NCT03968939|Behavioral|Sleep Hygiene Education|"Brochure containing information about getting a good night's sleep."
45634507|NCT03856619|Drug|TERIFLUNOMIDE HMR1726|"Pharmaceutical form: Tablet~Route of administration: Oral"
45634508|NCT02448407|Biological|Platelet rich plasma|Three intraarticular injections of platelet-rich plasma, one each fifteen days
45634509|NCT02448407|Drug|Hyaluronic acid|Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1% solution, administered by intraarticular injections (three doses, one each fifteen days)
45634510|NCT04484597|Diagnostic Test|Rt PCR|positive COVID-19 by PCR and tested for other ancillary tests and CT chest to compare them and analyse which is the most sensitive in both moderate and severe clinical condition
45773567|NCT04695002|Behavioral|Control|Citizens in the control group participate in the standard course of vocational rehabilitation, without the use of MIRA app. Citizens are referred from the jobcenter if the case manager assesses that a health condition limits the citizen's ability to resume work. The typical course of rehabilitation lasts 4-12 weeks, and is managed by a physiotherapist, a psychologist and a physician. Depending on the condition of the citizen, the rehabilitation may be managed by only two of the three professionals. During the course of rehabilitation, the citizen may consult the team with varying frequency. If physical rehabilitation is part of the prescribed rehabilitation, the citizen shows up twice per week for several weeks of supervised exercise, whereas rehabilitation courses where self-management is in focus, only biweekly consultations may be provided. The decisions and planning of contents and duration of the rehabilitation programme is done in collaboration with the citizen.
45773568|NCT04679480|Drug|Cemiplimab Injection [Libtayo]|"Investigational product: a combination of an anti-PD1 antibody (Cemiplimab) and a HHI (Sonidegib).~Cemiplimab will be supplied as a liquid in a sterile, single-use 10 ml vial. Each vial will contain a volume of 7ml at a concentration of 50mg/ml. Cemiplimab will be prepared for infusion (as described in SmPC (Fachinformation Swissmedic) Libtayo, see Appendix) at the trial site and administered as a flat 350mg dose in 100ml NaCl 0.9% as an IV infusion over approximately 30 minutes (±10 minutes) in an outpatient setting. Each patient's dose will be administered as a flat 350mg dose in every 3 weeks, starting from week 2 of the trial.~The Hedgehog Inhibitor used for the trial will be Sonidegib. Sonidegib is a white 200mg capsule, orally administered once daily. Sonidegib will be administered in a 2 week cycle every 4 weeks (pulsed therapy: 2 weeks on, 2 weeks off), starting from week 0 of the trial."
45773569|NCT00003262|Biological|bleomycin sulfate|
45773570|NCT00003262|Biological|filgrastim|
45773571|NCT00003262|Drug|Stanford V regimen|
45773572|NCT00003262|Drug|doxorubicin hydrochloride|
45773573|NCT00003262|Drug|epirubicin hydrochloride|
45773574|NCT00003262|Drug|etoposide|
45773575|NCT00003262|Drug|mechlorethamine hydrochloride|
45773576|NCT00003262|Drug|prednisone|
45773577|NCT00003262|Drug|vinblastine sulfate|
45773578|NCT00003262|Drug|vincristine sulfate|
45773579|NCT02092610|Device|Novel Implant BI300|The Novel Implant BI300 was the new titanium implant and abutment for the Baha system developed by Cochlear Bone Anchored Solutions AB. The novel implant is 4.5 mm wide and 4.0 mm long.
45634511|NCT03195647|Drug|Potassium|"The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol."
45773580|NCT02092610|Device|Standard Implant BI300|The Standard Implant BI300 was the standard titanium implant and abutment in the Baha system developed by Cochlear Bone Anchored Solutions AB. The implant is 3.75 mm wide and 4.0 mm long
45634512|NCT05374343|Drug|pyroglutamate rongliflozin capsules|Subjects will receive one 50mg capsule orally (by mouth) on Day 1
45773581|NCT00003700|Biological|G-CSF|Courses I, II, IV, V: 5 ug/kg/d subQ injection Day 4 until ANC > 5,000 uL after nadir: 7 day minimum for Courses I & IV
45634513|NCT05374265|Other|Cardiovascular Magnetic Resonance Scan|Patients will receive a baseline CMR scan to detect viability within 7 days of index admission
45634514|NCT02013388|Drug|N91115|Given PO daily for 14 days
45634515|NCT02013388|Drug|Placebo|Given PO daily for 14 days
45634516|NCT02013388|Drug|N91115|Given PO only on Day 1
45773582|NCT00003700|Drug|asparaginase|6000 U/sq m subQ or IM injection 2X/wk for 6 doses starting on Day 5: Courses I & IV
45773583|NCT00003700|Drug|cyclophosphamide|1200 mg/sq m IV infusion over 15-30 min Day 1 Courses I & IV (pts < 60y/o) 1000 mg/sq m IV infusion over 15-30 min Day 1 Courses II & V
45773584|NCT00003700|Drug|cytarabine|2000 mg/sq m IV infusion over 3 hrs Days 1,2, & 3: Courses II & V
45773585|NCT00003700|Drug|daunorubicin hydrochloride|80mg/sq m (pts<60y/o)OR 60mg/sq m (pts =/>60y/o) IV infusion over 5-10 min Days 1,2,& 3: Courses I & IV
45634517|NCT02013388|Drug|Placebo-Day 1 only|Given PO- only on Day 1 (single dosed to match single dose treatments)
45634518|NCT05200715|Other|No intervention is foreseen by the protocol.|Patients will be observed for 10 years at least. Demographic, genetic, clinical, clinimetric, laboratory, radiologic and therapeutic data will be collected both retrospectively and prospectively during routine follow-up visits.
45634519|NCT02012686|Device|TENS|transcutaneous electric nerve stimulation frequency of 100 Hz pulse duration of 200 µs wih stimulation intensity of feeling strong but non-painful paresthesia in the upper trapezius
45634520|NCT02012452|Behavioral|Tobacco treatment|participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
45773586|NCT00003700|Drug|leucovorin calcium|"Courses III & VI:~25mg/sq m IV infusion Days 2, 9, and 16 5mg/sq m PO q 6 hr for 8 doses or until serum MTX <0.05 uM after ea IV dose"
45773587|NCT00003700|Drug|mercaptopurine|60mg/sq m/d PO every day Course VII
45773588|NCT00003700|Drug|methotrexate|15mg intrathecal Day 1 Courses II & V 1000mg/sq m IV infusion over 3 hrs Days 1, 8, & 15 and 25mg/sq m PO q 6hr x 4 doses after ea IV dose: Courses III & VI.
45773589|NCT00003700|Drug|prednisone|60mg/sq m/day PO Days 1-21 (pts<60y/o) OR Days 1-7 (pts >/= 60y/o) Courses I & IV and Days 1-5 of ea 4 cycle in Course VII
45773590|NCT00003700|Drug|vincristine sulfate|2 mg total IV infusion Days 1,8,15,& 22 Courses I & IV and Days 1, 8, & 15 Courses III & VI, and Day 1 of ea 4 wk cycle in Course VII
45773591|NCT00003700|Drug|Allopurinol|300mg PO q day Days 1-14 Course I
45634521|NCT02012452|Behavioral|Health Education|Participants will be provided education on a variety of health topics and will set health goals around each topic
45634522|NCT05098847|Drug|Sintilimab|Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks.
45773592|NCT02093234|Behavioral|mobile health care application|mobile health application for cell phones to assist patients in managing their diabetes.
45914319|NCT02041871|Dietary Supplement|Oral immunonutrition|Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
45914320|NCT02041871|Dietary Supplement|Placebo|Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
45914321|NCT02041884|Behavioral|iCBT for Adults with ADHD|A skill training internet-based treatment program based on CBT and DBT interventions .
45914322|NCT02041884|Behavioral|Internet stress-reduction|Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
45634523|NCT05098847|Drug|Lenvatinib|Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) was given orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
45634524|NCT05098847|Drug|Cryoablation|Cryoablation treatment starts at day 0. Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
45653002|NCT05131659|Behavioral|Executive function group therapy|This executive function group therapy curriculum for adolescents uses cognitive behavioral therapy techniques, and focuses on key functions needed for adult success, such as: self-advocacy, flexibility, time management, motivation, goal setting, developing plans, monitoring progress. Guided practice begins with concrete interventionist support and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support.
45653003|NCT05131503|Other|Survey Research|Non-applicable. There is no intervention. This study is descriptive research.
45653004|NCT04627493|Behavioral|Online exercise|Participants will participate in an online exercise program on Zoom delivered by Registered Kinesiologists and Physiotherapists three times a week.
45653005|NCT05090553|Procedure|Lumbar Spinal Fusion Surgery|During surgery will be collected five disc fragments and five fragments of muscle-ligament tissue adjacent to the collected disc.
45653006|NCT05090553|Biological|Bacterial culture|Samples will be seeded on blood agar and anaerobic blood agar plates. After sowing in solid media, the swab will be inoculated in thioglycolate medium, where it will remain for 14 days
45653007|NCT05090553|Genetic|Phenotypic and genotypic characterization|"The phenotypic identification of the species will be carried out through mass spectrometry, with the MALDI-TOF equipment.~PCR analyzes performed in two phases, the first to confirm the presence of bacteria (target and non-target) using primers capable of amplifying eubacteria ribosomal deoxyribonucleic acid (rDNA) 16s and the second directed to confirm C. acnes through specific rDNA 16s primers."
45653008|NCT05090553|Genetic|Multiomics analysis|Whole Genome Sequencing, proteomics and metabolomics analysis
45653009|NCT04789811|Other|Stretching exercise|Stretching exercise: Stretching exercises were planned for 30 seconds, ten repetitions for each stretching, 10 minutes in total, four days a week, for two weeks.
45653010|NCT04789811|Other|Dry needling|Dry needling: A total of 3 sessions of dry needling, once a week, were applied to the gastrocnemius muscle.
45653011|NCT05089461|Drug|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV), 20 mg/m^2. Solid tumors: every 3 weeks (q3w, 1 cycle), Lymphoma: every 4 weeks (q4w, 1 cycle).
45653012|NCT02434705|Other|Antigen (wheat base soy sauce) spray|Patients having a clinically indicated endoscopy for Eosinphilic Esophagitis will have two biopsies from the esophageal body, 10 cm above the gastroesophageal junction. After biopsies are taken, approximately 10 cc of wheat based soy sauce will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and Two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction.
45653013|NCT04789343|Other|Root canal treatment|The patient usually takes anaesthesia before treatment and access cavity was prepared on the tooth and root canal removed and instrumented and obturated. However, in the present study, previously done root canal was retreated. Usually no anaesthesia was used because all root canals were done before. So just instrumentation and obturation was done.
45653014|NCT05186415|Drug|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]|The patient will receive the weight-based dose of Lumason of 0.03 mL/kg per injection, not to exceed 2.4 mL per injection per the FDA and manufacturer recommendations.
45653015|NCT05730439|Procedure|Biospecimen Collection|Undergo collection of blood
45653016|NCT05730439|Drug|Nicotine Oral Pouch|Receive ZYN brand NP
45653017|NCT05730439|Drug|Nicotine Oral Pouch|Receive Rogue brand NP
45653018|NCT05730439|Other|Questionnaire Administration|Ancillary studies
45653019|NCT05730439|Drug|Smokeless Tobacco|Receive usual SLT
45653020|NCT03683147|Other|Laboratory Biomarker Analysis|Correlative studies
45653021|NCT03683147|Behavioral|Meditation-Based Stress Reduction Program|Participate in 6-week online program
45653022|NCT03683147|Other|Quality-of-Life Assessment|Ancillary studies
45653023|NCT03683147|Other|Questionnaire Administration|Ancillary studies
45653024|NCT05182125|Biological|AdC6-HIVgp140|"The product is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS [tris(hydroxymethyl)aminomethane], pH 8.0 formulation buffer to a concentration of 1.2 x 10^11 vp/mL and filled at 0.3 mL for AdC6-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC6-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the Investigator's Brochure (IB)."
45447999|NCT03550612|Diagnostic Test|Amplitude integrated electroencephalogram|"Amplitude integrated electroencephalogram before and during cooling will be assessed and classified according to Hellstrom Westas et al 2006 and it will be compared with the results of cranial ultrasound and magnetic resonant imaging.~Neurodevelopment study at 12 and 14 month age using Bayley ɪɪɪ score will be compared with the results of cranial ultrasound,magnetic resonant imaging and Amplitude integrated electroencephalogram."
45448000|NCT03214952|Drug|Vonoprazan|Vonoprazan tablets
45634525|NCT01676909|Behavioral|Living Well|This study will involve a clinical trial of Living Well (LW), a 12-session, peer co-led, group intervention designed to help veterans with co-occurring Serious Mental Illnesses and Chronic Medical Conditions learn techniques for better health management and ways to live a healthier lifestyle. Key topics that will be discussed are medication side effects, how symptoms of mental illness may affect veterans' ability to manage their medical conditions, effects of substance use on medical and mental health functioning, learning ways to eat healthier and exercise, and how to communicate more effectively with care providers. There will be 3 booster sessions after the 12 sessions, once a month for 3 months.
45634526|NCT01676909|Behavioral|Medical Illness Education & Support Group|The comparison condition will be a general Medical Illness Education and Support (MIES) group that will discuss common challenges experienced by those living with a wide range of chronic illnesses and behavioral and lifestyle management techniques that may help veterans to better handle chronic medical conditions that also meets for 12 weeks.
45634527|NCT04437953|Drug|Avatrombopag|"Patients will receive an initial dose of Avatrombopag 60 mg on Day 1. Starting on Day 2, the dose will be Avatrombopag 20 mg daily. Once a patient has reached a platelet target of > 100,000/mcL patients can initiate systemic cancer therapy. Avatrombopag will be continued as maintenance (subscript m) and titrated weekly with a goal to maintain a platelet count of ≥ 100,000/mcL during administration of systemic cancer therapy. Duration of maintenance therapy will be at least 12 weeks (indicated by Week 1m, Week 2m, … 12m) starting from time of platelet correction and resumption of systemic cancer therapy. End of Treatment (EOT) is up to 15 weeks on study Week 12m."
45634528|NCT03051971|Device|Vibrating Mesh Nebulizer|short-acting bronchodilator medication delivered with a vibrating mesh nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
45634529|NCT03051971|Device|Jet Nebulizer|short-acting bronchodilator medication delivered with a jet nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
45634530|NCT04517357|Drug|Fluzoparib+Apatinib|Fluzoparib-Apatinib combination
45634531|NCT04517357|Drug|Fluzoparib|Fluzoparib monotherapy
45634532|NCT04517357|Drug|Fluzoparib+Apatinib|Fluzoparib-Apatinib combination
45634533|NCT02012296|Drug|enzalutamide|Given PO
45634534|NCT02012296|Drug|mifepristone|Given PO
45634535|NCT02012296|Other|laboratory biomarker analysis|Correlative studies
45634536|NCT02012296|Other|pharmacological study|Correlative studies
45634537|NCT02012218|Drug|ADT|
45634538|NCT02012218|Drug|Brexpiprazole|
45634539|NCT04177498|Drug|Rigosertib Sodium|given PO or 72 hour continuous infusion
45634540|NCT04177498|Other|Quality-of-Life Assessment|Ancillary studies
45634541|NCT04658836|Drug|Triamcinolone Acetonide 40mg/mL|Intratympanic application of triamcinolone acetonide
45634542|NCT01965262|Device|Hema-copolymer Lens|contact lens
45634543|NCT01965262|Device|etafilcon A Lens|contact lens
45634544|NCT01677377|Drug|Risperidone|Oral risperidone was supplied as 2, 3, or 4 mg tablets in blister packs or bottles and taken daily only during the oral dosing periods of the study, days -14 through -8 (if applicable), days -7 through -1, and days 85 through 87.
45634545|NCT01677377|Drug|RBP-7000|RBP-7000 60 mg, 90 mg, and 120 mg were a mixture of the ATRIGEL® Delivery System and 60 mg, 90 mg, or 120 mg risperidone, respectively. Treatment was delivered as subcutaneous injections on study days 1, 29 and 57.
45914323|NCT02041884|Other|Treatment as usual (TAU)/waiting list|Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
45448001|NCT02126488|Behavioral|treadmill slip perturbation|Group A will receive perturbation training on a treadmill with precisely controlled slip-like displacements and then encounter an unannounced novel slip during over-ground walking.
45634546|NCT02893865|Device|Continuous positive airway pressure|Continuous positive airway pressure treatment during three months with adherence recording
45634547|NCT02893865|Device|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
45634548|NCT05104151|Dietary Supplement|Nutritional bar|Protein-based nutritional bar, providing 155 calories per bar
45634549|NCT05104151|Behavioral|Healthy Habits Intervention|The participants included, will receive a nutritional intervention providing a caloric deficit of 500 calories, depending on their daily requirements, these daily requirements calculated according to the formula BMR (Basic Metabolic Rate). Also prescription of moderate physical activity from 60 to 90 minutes daily will be made.
45634550|NCT02492009|Behavioral|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
45634551|NCT02492009|Behavioral|Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
45634552|NCT04458623|Diagnostic Test|Air Test|.The Air-Test may represent an accurate, simple, inexpensive and non-invasive method for diagnosing postoperative atelectasis.
45634553|NCT05098691|Diagnostic Test|serum marker levels|two groups comparisons
45773593|NCT02093234|Behavioral|CHWs and mobile health care application|CHWs will assist diabetic patients in managing their health in conjunction with the mobile health care application.
45634554|NCT04430387|Device|The saliva ejector|A thin suction tube that draws water, saliva, blood, and debris from the mouth to provide patient comfort, preventing patient from constantly having to sit up and spit while maintain a clear operative field. It is connected through the low-volume suction hose in the dental chair. It can be held by the dental assistant, the dental provider or by the patient. In practice, it can be also contoured and hang by the cheek of the patient due to its light weight.
45773594|NCT02093234|Behavioral|Community Health Worker (CHW)|CHWs assist patients in managing their diabetes in various ways.
45634555|NCT04430387|Device|The high-volume evacuator|The high-velocity air evacuation device. It is connected through the high-volume suction hose in the dental chair. It is operated by a dental assistant during the dental treatment, owing to the challenge posed by the rigid disposable attachment and bulky high-volume suction hose.
45634556|NCT04430387|Device|The DryShield|The device is attached to the high-volume suction hose to provide continuous suction of intraoral fluid and debris, and also simultaneous isolation to both maxillary and mandibular quadrants on the same side. Other advantages of these devices include retracting the tongue and cheek, and prevention of aspiration.
45634557|NCT04066205|Behavioral|SLEEPSAMRT|SLEEPSMART will be designed to improve sleep by providing guidance and structure to assist JIA children and their parent in adhering to the intervention protocol. The intervention will be interactive and personalized; users will interface with three primary components:1) monitoring: daily records of sleep and symptoms; 2) skill building modules: sleep education, sleep skills training, relaxation techniques, positive coping skills, and reward systems for activity participation for reducing sleep deficiency; and 3) assignment review and personalized feedback via behavioral assignments for skill implementation and tailored feedback. Modules will take an estimated 30 minutes each week to complete and will include multimedia elements to enhance learning.
45773595|NCT00003706|Drug|pemetrexed disodium|
45634558|NCT05098535|Other|Visual Aid|"The visual aid will include a graphic display of 100 individuals with number of individuals anticipated to suffer a myocardial injury highlighted by being filled in in red. There will also be a textual description stating the anticipated risk.~For example in a patient with an rCRI score = 2 the text will state 10 out of 100 patients will have a myocardial injury (MINS) and 90 out of 100 patients will have no myocardial injury and 10 of the patients will be shaded red on the visual aid. The patients in this intervention will also received the scripted discussion of perioperative risk of MINS."
45634559|NCT05098535|Other|Scripted Risk Discussion|The patients seen in PSS will have a standardized discussion of perioperative risk of myocardial injury read to them by the anesthesiologist in the PSS clinic.
45773596|NCT00003958|Biological|dactinomycin|Given IV
45773597|NCT00003958|Drug|vincristine sulfate|Given IV
45773598|NCT00003958|Drug|cyclophosphamide|Given IV
45773599|NCT00003958|Procedure|therapeutic conventional surgery|Undergo surgery
45773600|NCT00003958|Radiation|radiation therapy|Undergo radiotherapy
45448002|NCT02126488|Behavioral|treadmill training placebo|An age-matched control group (Group B) will receive only placebo training (on the same treadmill for the same duration but without perturbation) but encounter an identical novel slip during their over-ground walking.
45773601|NCT00003958|Drug|topotecan hydrochloride|Given IV
45773602|NCT00003958|Biological|filgrastim|Given SC
45773603|NCT00003958|Biological|sargramostim|Given SC
45773604|NCT00003958|Other|laboratory biomarker analysis|Correlative studies
45773605|NCT03044054|Device|ECHOPULSE|HIFU Under ultrasound guidance
45448003|NCT02126488|Behavioral|observation training|An age-matched observation-training group (Group C) will watch a training video and slides. When exposed to an identical novel slip in over-ground walking, they will know where and how the slip is going to occur and how to resist a fall.
45448004|NCT02126566|Device|Administration of light therapy - measurement of results before and after therapy|
45448005|NCT02128750|Other|contrast echographie with hexafluorur of sulfur|Echography of contrast after injection of product of contrast (sonovue (r))
45773606|NCT04101292|Other|Characterization of tumor tissue by fluorescence|"HSI Imaging of the resected specimen, from the serum and the mucous side~FF-OCT imaging of the tumor and the healthy tissue biopsies~Local application of Bevacizumab-IRDye800CW and visualization with the Surgvision Explorer system~Standard anti-VEGF Immunohistochemistry and pathology"
45914324|NCT02041897|Procedure|EUS-FNA|Only one puncture will be performed. First the fluid will be aspirated out for biochemical analysis and cytology. Then the tissue will be aspirated out from the solid part of the lesion for pathology.
45914325|NCT02041910|Biological|Stem Cells|MSCs injection intratesticular
45914326|NCT02041910|Biological|Stem Cells|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into testis.
45914327|NCT02041975|Dietary Supplement|Nutriose FB06|Wheat dextrin soluble fibre
45634560|NCT05375513|Other|PMI@Home|"Personalized multidomain interventional program by combining tailored lifestyle interventions that targets 5 domains: physical activity, cognition, diet, sleep, and vascular risk factors. These interventions are tailored based on participants' baseline profile and progress in intensity following the principles of personalized medicine. All aspects of the PMI@home will be delivered remotely, at participants' homes, using a digital platform with scheduled bi-weekly 1-to1 coaching sessions. Delivery of interventions and assessments are centralized with 5 trained staff at the sponsor site (London) to assure logistics, standardization, and quality control."
45773607|NCT00003712|Drug|temsirolimus|"•Part I: Patients receive CCI-779 IV over 30 minutes on days 1-5, followed by a 9 day rest period. Treatment courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.~The maximum tolerated dose for part I is defined as the dose level at which 33% of patients experience dose limiting toxicity.~•Part II: Patients receive the same treatment schedule as part I. Three patients with CNS tumors are entered at the dose of CCI-779 determined to be the MTD in Part I. At least 3 patients are entered at each dose level in part II."
45773608|NCT00003268|Drug|amifostine trihydrate|
45773609|NCT00003268|Drug|cytarabine|
45773610|NCT00003268|Drug|idarubicin|
45773611|NCT00083720|Biological|cetuximab|Initial dose of 400 mg/m2 intravenously (i.v.) over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes
45773612|NCT00003274|Biological|gp100 antigen|
45773613|NCT00003274|Biological|incomplete Freund's adjuvant|
45773614|NCT00003274|Biological|sargramostim|
45773615|NCT00003274|Biological|tyrosinase peptide|
45773616|NCT00003280|Biological|rituximab|
45773617|NCT04772924|Behavioral|fasting|more than 12 hour of fasting as ceremony of Ramadan
45773618|NCT04772924|Behavioral|not fasting|preferred not to take long term fasting
45773619|NCT02972710|Other|Supine thoracic spine thrust manipulation|The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
45773620|NCT02972710|Other|Seated thoracic spine thrust manipulation|The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
45448006|NCT02131246|Drug|Faster-acting insulin aspart|Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
45634561|NCT05375513|Other|Brain Health Pro|"Online Modules:~Motivation, Self-Efficacy, Positive Health, Environment and Genetic risk~Physical Activity~Cognitively Stimulating Activities~Diet~Sleep~Social and Psychological Health~Vascular health~Vision and Hearing~Lifestyle Risk Impact Surveys~Goal Setting"
45634562|NCT05103995|Other|no intervention|no intervention, just observation
45773621|NCT00384124|Drug|Imiquimod|Imiquimod application M-F for six weeks (total of 30 applications) followed by surgical excision of site
45773622|NCT00003718|Drug|temozolomide|
45773623|NCT02024360|Behavioral|Patient navigation|16 session (25 hour) home-based intervention with patient navigators encouraging families to adopt healthy eating, active living and parental skill building
45773624|NCT00003970|Drug|irinotecan hydrochloride|Given IV
45773625|NCT00085436|Biological|Aldesleukin,|Recombinant human interleukin-2 (Proleukin, Chiron Therapeutics) will be administered as a five day (120 hr) continuous intravenous infusion at a dose of 18x106 IU per square meter of body surface area per day as per the Negrier regimen (21). The treatment schedule consists of two induction cycles and three maintenance cycles. Each induction cycle consists of two five-day courses of interleukin-2 infusion separated by a nine-day break. Each maintenance cycle consists of a five-day infusion followed by 23-day rest period of no therapy.
45773626|NCT00085436|Biological|autologous tumor cell vaccine|we will administer 1 X 107 DC cells. The autologous tumor cell vaccine (1 X 107 cells/1cc) in lactated ringers solution and injected into one (or two if clinically necessary) inguinal lymph nodes under ultrasound guidance. Each cycle of DC vaccine will be administered alternately in the right and left inguinal lymph nodes.
45773627|NCT00085436|Biological|recombinant interferon alfa|Recombinant human interferon alfa-2a (Roferon, Roche), at a dose of 6 million IU per day three times a week subcutaneously will be given during the two interleukin-2 induction cycles and during each interleukin-2 maintenance cycle
45773628|NCT00003724|Procedure|surgical procedure|
45773629|NCT00384202|Drug|Tacrolimus|Immunosuppression
45914328|NCT02041975|Dietary Supplement|Placebo|
45914329|NCT02042001|Drug|Immediate switch to TDF/FTC/RPV|
45914330|NCT02042001|Drug|Switch to TDF/FTC/RPV after 24 weeks|Patients will continue current EFV-containing regimen up to week 24 and then will be switched to TDF/FTC/RPV
45914331|NCT02042027|Drug|Gamunex-C|Patients will receive 50 mg (0.5 mL) subconjunctival Gamunex-C injection in addition to standard of care treatment (steroids and cyclosporine)
45914332|NCT02042053|Device|PET/CT|
45914333|NCT02042053|Device|PET/MRI|
45634563|NCT05103917|Drug|X4P-001|CXCR4 inhibitor
45773630|NCT00086138|Drug|Sertraline (Zoloft)|Sertraline: range of 25 to 125 mg per day for 24 weeks
45773631|NCT00086138|Drug|Placebo|Placebo designed to mimic sertraline taken daily for 24 weeks
45914334|NCT02042066|Device|Omnispec model Vascuspec|Energy Density: 0.09 - 0.1 mJ/mm2 Extracorporeal Shockwave Therapy
45914335|NCT02042079|Procedure|EFTR with LA|(Endoscopic full-thickness resection with laparoscopic assistance)
45914336|NCT02042092|Device|Ultrasound|
45914337|NCT02042092|Device|MRA|
45634564|NCT03861221|Device|CBBCT|To compare the differences between various lesions' presentation on CBBCT and on other approaches under diverse breast conditions.
45773632|NCT04329130|Drug|Chidamide, Lenalidomide|All patients enrolled in the study will accept Chidamide combination with lenalidomide regimen.
45773633|NCT00384280|Drug|Rifampin|
45773634|NCT00003976|Drug|indisulam|
45634565|NCT05098223|Behavioral|Intervention to remove price promotions on unhealthy foods when online shopping|Removal of price promotions on unhealthy foods
45773635|NCT00003730|Drug|fluorouracil|
45773636|NCT00003730|Drug|vinorelbine tartrate|
45773637|NCT01881308|Drug|TNF inhibitors|
45773638|NCT01881308|Drug|Synthetic DMARD(s)|
45773639|NCT01881308|Drug|Co-medication: Synthetic DMARDs|Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.
45773640|NCT00003982|Drug|sabarubicin|
45773641|NCT00003292|Drug|ifosfamide|
45773642|NCT00088634|Drug|Lurasidone|80 mg AM dosing once daily
45773643|NCT00088634|Drug|Placebo|Matching Placebo to 40mg lurasidone tablets
45773644|NCT00003736|Drug|motexafin gadolinium|
45773645|NCT00003736|Procedure|biopsy|
45773646|NCT00003736|Procedure|breast imaging study|
45773647|NCT00003736|Procedure|comparison of screening methods|
45448007|NCT02131246|Drug|insulin aspart|Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
45634566|NCT05097911|Drug|MTL-CEBPA|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
45773648|NCT00003736|Procedure|magnetic resonance imaging|
45773649|NCT00003736|Procedure|study of high risk factors|
45773650|NCT04772066|Other|Measure of medication adherence|Measure of medication adherence
45773651|NCT00003994|Procedure|therapeutic conventional surgery|Undergo surgical resection
45773652|NCT00003994|Drug|cisplatin|Given IV
45773653|NCT00003994|Drug|vincristine sulfate|Given IV
45773654|NCT00003994|Drug|fluorouracil|Given IV
45773655|NCT00003994|Drug|amifostine trihydrate|Given IV
45914338|NCT02042118|Device|Laryngeal Mask Airway|Laryngeal mask airway (LMA) ventilation will be provided for newborns in this arm during the first 2.5 minutes.
45914339|NCT02042118|Device|Face mask ventilation|Face-mask ventilation (FMV) will be provided for newborns in this arm during the first 2.5 minutes.
45773656|NCT00003994|Drug|carboplatin|Given IV
45773657|NCT00003742|Drug|cisplatin|
45773658|NCT00003742|Drug|irinotecan hydrochloride|
45773659|NCT00003742|Drug|paclitaxel|
45773660|NCT01636544|Procedure|contralateral healthy tissue biopsy|At the time of surgery, a part of the specimen, plus a biopsy of the healthy (control) contralateral mucosa (i.e. right border of the tongue for a SCC of the left border, left cheek for a dysplasia of the right cheek and so on) will be harvested for research and immediately frozen at -80°C first in dry ice, then in a -80°C freezer.
45773661|NCT00003304|Drug|temozolomide|
45773662|NCT00004006|Biological|filgrastim|
45773663|NCT00004006|Drug|carboplatin|
45773664|NCT00004006|Drug|cyclophosphamide|
45773665|NCT00004006|Drug|doxorubicin hydrochloride|
45773666|NCT00004006|Drug|etoposide|
45773667|NCT00004006|Drug|topotecan hydrochloride|
45773668|NCT00004006|Procedure|autologous bone marrow transplantation|
45773669|NCT00004006|Radiation|radiation therapy|
45773670|NCT00003316|Drug|gemcitabine hydrochloride|
45773671|NCT00089024|Drug|fluorouracil|2700 mg/m5 IV over 24 hr after gemcitabine weeks 1 & 2; Repeat one 3-week cycle starting day 22
45773672|NCT00089024|Drug|gemcitabine hydrochloride|750 (females) or 900 (males) mg/m5 IV over 30 min (day 2)weeks 1 & 2; Repeat one 3-week cycle starting day 22
45773673|NCT00089024|Drug|leucovorin calcium|20 mg/m5 PO (day 1) and 20 mg/m5 IV (day 2) weeks 1 and 2; Repeat one 3-week cycle starting day 22
45773674|NCT00089024|Drug|oxaliplatin|48 mg/m5 IV over 2 hr weeks 1, 2, 4, and 5
45773675|NCT00089024|Procedure|adjuvant therapy|"Patients who have undergone surgical resection, after post-operative recovery, will receive two additional cycles of gemcitabine/5-FU/leucovorin. Patients will then be followed at 3 month intervals with a history and physical exam, CT scan of the chest/abdomen/pelvis, and tumor markers.~If surgical resection is not possible, patients with stable or responsive disease will resume gemcitabine/5-FU/leucovorin and continue on it indefinitely until disease progression provided the patient tolerates it and wishes to remain on therapy."
45773676|NCT00089024|Procedure|conventional surgery|Restaging with repeat imaging studies will be performed four weeks after completion of the chemo-radiation. If no contraindication for surgical resection is identified, resection will be performed six to eight weeks after completing chemoradiation. At the time of surgical resection, an extensive examination of the abdomen will be performed to exclude the presence of metastatic disease. All operations will be performed with curative intent with resection of all gross tumor (ie R0 [negative margins] or R1 [positive microscopic margins]). Resection of adjacent involved organs or vascular structures will be performed as clinically indicated.
45773677|NCT00089024|Procedure|neoadjuvant therapy|Eligible patients will receive an initial two cycles of chemotherapy with gemcitabine 750 (females) or 900 (males) mg/m5 over 30 minutes followed by a 24-hour infusion of fluorouracil 2700 mg/m5 on days 2 and 9 of a 21-day cycle . Calcium leucovorin 20 mg/m5 will be given orally on days 1 and 8 and by IV push on days 2 and 9 prior to the 5-FU. A window of -2 up to +7 days will be allowed to start planned cycles of therapy provided all other criteria to restart the new cycle has been met. Patients will require a central venous catheter (Port, Hickman or Groshong catheter) for the administration of 5-FU.
45773678|NCT00089024|Radiation|radiation therapy|A re-staging CT scan, which will be obtained as part of the radiation simulation, will be used to assess any possible response to the initial two cycles of chemotherapy. Unless the patient has developed evidence of metastatic disease, chemoradiation will proceed. Patients who required no treatment delays will commence chemoradiation on day 42. If a one-week delay is needed before cycle 2 of neo-adjuvant chemotherapy can be delivered, the patient will begin chemoradiation on day 49 provided treatment-related toxicity has resolved. If cycle 2 could not be given (2 or more week delay for resolution of treatment-related toxicity), then chemoradiation will begin once toxicity has resolved (may be earlier than day 42).
45773679|NCT00003322|Drug|cisplatin|
45634567|NCT05097911|Drug|Atezolizumab|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
45634568|NCT05097911|Drug|Bevacizumab|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
45634569|NCT03739775|Procedure|Blood sampling|Patients will have a blood draw at each visit to the hospital and at least 6 months (+/- 1 month) intervals.
45634570|NCT03732209|Behavioral|Episodic future thinking|Participants will engage in episodic future thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
45634571|NCT03732209|Behavioral|Control Thinking|Participants will engage in non-future-oriented control thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
45773680|NCT00003322|Drug|paclitaxel|
45773681|NCT00003322|Procedure|quality-of-life assessment|
45634572|NCT05097365|Dietary Supplement|Vitamin B12 + folic acid supplementation|A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a vitamin B12 and folic acid supplementation, in addition to the usual therapy. The dietary supplementation will be by capsules, which will content 400 mcg of folic acid and 2000 mcg of vitamin B12 each.
45634573|NCT05097365|Dietary Supplement|Placebo supplementation|A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a placebo supplementation.The placebo and vitamin B12 + folic acid supplement will be indistinguishable in terms of taste, smell, and appearance.
45773682|NCT00519818|Drug|Chronocort|Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration
45773683|NCT00519818|Drug|Cortef|Cortef 3 times daily(total dose 30 mg)for minimum of 7 days
45773684|NCT00003748|Drug|irinotecan hydrochloride|One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
45634574|NCT01964716|Biological|13-valent pneumococcal conjugate vaccine|Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (multidose vial formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
45634575|NCT01964716|Biological|13-valent pneumococcal conjugate vaccine|Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (single-dose syringe formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
45634576|NCT01964560|Drug|Lacosamide|"Pharmaceutical form: oral solution~Concentration: 1 mg/kg - 6 mg/kg BID (2 mg/kg/day - 12 mg/ kg/day)~Route of administration: oral use"
45634577|NCT01964560|Drug|Lacosamide|"Pharmaceutical form: tablet~Concentration: 50 mg - 300 mg BID (100 mg/day - 600 mg/day)~Route of administration: oral use"
45773685|NCT00089102|Drug|gemcitabine hydrochloride|1,000 mg/m2/dose in 250 cc of NS IV over 30 minutes on Days 1 and 8 of each 21 day cycle
45773686|NCT00089102|Drug|irinotecan hydrochloride|100mg/m2/dose in 500 cc of D5W or NS IV over 90 minutes on days 1 and 8 of each 21 day cycle
45773687|NCT00004012|Drug|capecitabine|
45773688|NCT04771988|Radiation|yttrium-90 radioembolization|selective/superselective treatment using resin microspheres labeled with Yttrium-90
45773689|NCT04753736|Procedure|Intrauterine administration of hCG-activated peripheral blood mononuclear cells|Intrauterine administration of hCG-activated peripheral blood mononuclear cells
45773690|NCT00086450|Procedure|Coronary Artery Bypass Graft|For CABG, participants will receive general anesthesia and will have a breathing tube placed in their throat and they will be unconscious during the operation. An incision is made through the chest bone and muscle, which allows the surgeon access to the heart and diseased vessels. The surgeon will use one or more healthy vessels (either from an artery in the shoulder or a vein in the leg) and will bypass the diseased vessel with the healthy vessel(s). This bypass will provide needed blood supply to the heart.
45914340|NCT02042144|Drug|Stivarga (Regorafenib, BAY73-4506)|Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib
45914341|NCT02042157|Behavioral|Bidet use|Participants used a bidet, a device installed on the toilet that provides fresh water to help clean the bottom and genitalia after having a bowel movement or urinating.
45634578|NCT02659943|Biological|Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells|Dose-escalation trial starting dose: 0.66x10^6 CAR+ T cells/kg(weight based dosing)(up to a maximum dose of 18x10^6 CAR+ T cells/kg) infuse on day 0
45634579|NCT02659943|Drug|Cyclophosphamide|300 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
45773691|NCT00086450|Device|Percutaneous Coronary Intervention|"For PCI, the participant will have two or more drug-eluting stents permanently implanted in their clogged arteries. Drug-eluting stents are coated with a drug that may prevent the disease in the vessel from coming back. The brand names of the stents used in this study are TAXUS and CYPHER.~The participant will receive a local anesthetic. A small puncture will be made and a balloon-tipped catheter is introduced through the small puncture in the leg/arm and advanced through the artery to the diseased heart vessel. The balloon is then inflated to enlarge the opening in the vessel. After enlarging the vessel, the drug-eluting stent will be placed using a similar balloon catheter. This balloon will be inflated, expanding the stent and placing it in the diseased vessel. Once the stent is fully expanded, the balloon is deflated and removed, leaving the stent in place in the artery."
45773692|NCT00003754|Drug|cyclophosphamide|
45773693|NCT00003754|Drug|thalidomide|
45634580|NCT02659943|Drug|Fludarabine|30 mg/m^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
45773694|NCT04771910|Other|Topical cream with live probiotic bacteria|Application of the probiotic cream once a day, for approximately 8 weeks on one side of the body (elbow or knee cavity; decided by doctor in advance, same as placebo cream). Assessment before product use (T0), after 4 and 8 weeks of product use (T4w and T8w, respectively) and after 4 weeks without product use (T12w).
45773695|NCT04771910|Other|Placebo cream|Application of the placebo cream (same formulation as probiotic cream except live probiotic bacteria) once a day, for approximately 8 weeks on one side of the body (elbow or knee cavity; decided by doctor in advance, same as probiotic cream). Assessment before product use (T0), after 4 and 8 weeks of product use (T4w and T8w, respectively) and after 4 weeks without product use (T12w).
45773696|NCT00003328|Drug|porfiromycin|
45773697|NCT00003328|Radiation|radiation therapy|
45634581|NCT03257969|Behavioral|The DROP program of pharmaceutical interventions|Multidisciplinary program that includes informative sessions with a hospital pharmacist about the oral anticancer drug: information is given to the patient on adverse events occurrence and there management; and optimizing drug dosage plan, including drug-drug interactions.
45634582|NCT03257969|Behavioral|Standard of care|In the group with standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessment.
45773698|NCT04771832|Procedure|ERAS|Enhanced Recovery After Surgery (ERAS) protocol is an evidence-based multimodal perioperative protocol focused on stress reduction and the promotion of a return to function
45773699|NCT00004024|Biological|aldesleukin|
45634583|NCT05103371|Behavioral|"Experiment: Millie prevention program, adolescents and active parents"|"Prevention program: Millie, with the participation of adolescents and parents"
45634584|NCT05103371|Behavioral|"Experiment: Millie prevention program, adolescents only"|"Prevention program: Millie, with the participation of adolescents only, no parental involvement in the program"
45634585|NCT05103293|Diagnostic Test|patient-derived tumor-like cell clusters drug sensitivity test|Intervention Description：Neoadjuvant therapy regimen of patients in the PTC group is guided by PTC drug sensitivity results. After operation, adjuvant targeted therapy for pCR patients is based on original treatment, adjuvant targeted therapy for non-pCR patients is based on a secondary PTC drug sensitivity results.
45773700|NCT00004024|Biological|autologous tumor cell vaccine|
45773701|NCT00004024|Biological|muromonab-CD3|
45773702|NCT00004024|Biological|sargramostim|
45773703|NCT00004024|Biological|therapeutic autologous lymphocytes|
45773704|NCT00004024|Procedure|surgical procedure|
45773705|NCT00004024|Radiation|radiation therapy|
45773706|NCT00003334|Drug|paclitaxel|
45773707|NCT00003334|Drug|pegylated liposomal doxorubicin hydrochloride|
45773708|NCT00093782|Drug|temsirolimus|Given IV
45773709|NCT00093782|Other|laboratory biomarker analysis|Correlative studies
45634586|NCT05369663|Device|mask use|face mask use
45634587|NCT05083325|Drug|Oseltamivir 75mg Test Drug capsules|Investigational Medicinal Product
45634588|NCT05083325|Drug|Oseltamivir 75mg capsules Reference Product capsules|Tamiflu (Roche Pharma (Switzerland) AG, Basel)
45773710|NCT00003760|Drug|irofulven|Patients receive 6-hydroxymethylacylfulvene (MGI 114) IV over 5 minutes on days 1-5. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for up to 1 year after therapy initiation.
45773711|NCT04771754|Drug|Dolutegravir|50 mg once daily orally
45773712|NCT00003766|Drug|O6-benzylguanine|
45773713|NCT00004030|Drug|VX-853|
45773714|NCT00004030|Drug|pegylated liposomal doxorubicin hydrochloride|
45773715|NCT04389320|Drug|Hydroxychloroquine|assess its role in the coarse of covid 19 virus infection
45773716|NCT00003340|Drug|cyclophosphamide|
45773717|NCT00003340|Drug|topotecan hydrochloride|
45773718|NCT04624100|Procedure|Hernia repair|Primary or mesh repair of primary ventral or incisional hernia
45773719|NCT00004036|Biological|sargramostim|
45773720|NCT00004036|Drug|amifostine trihydrate|
45773721|NCT00004036|Drug|carboplatin|
45773722|NCT00004036|Drug|cyclophosphamide|
45773723|NCT00003346|Drug|acetaminophen|
45773724|NCT00003346|Drug|acetylcysteine|
45773725|NCT00003346|Drug|carmustine|
45773726|NCT00003772|Procedure|quality-of-life assessment|
45773727|NCT00096122|Drug|cytarabine|Given IV
45773728|NCT00096122|Drug|idarubicin|Given IV
45773729|NCT00096122|Drug|tipifarnib|Given orally
45773730|NCT00003778|Drug|dolastatin 10|
45773731|NCT00004042|Biological|monoclonal antibody F19|
45773732|NCT00004042|Radiation|iodine I 131 monoclonal antibody F19|
45773733|NCT00003784|Drug|CHOP regimen|
45634589|NCT01677299|Drug|EFB0027 (metformin delayed release)|Comparison of enteric-coating to assess effect on PK
45634590|NCT01677299|Drug|EFB0026 (metformin immediate-release)|Active comparator
45773734|NCT00003784|Drug|cyclophosphamide|
45773735|NCT00003784|Drug|doxorubicin hydrochloride|
45773736|NCT00003784|Drug|prednisone|
45773737|NCT00003784|Drug|vincristine sulfate|
45773738|NCT00003784|Radiation|tositumomab and iodine I 131 tositumomab|
45773739|NCT00003352|Drug|cyclophosphamide|600 mg/m2, IV, every 3 weeks
45773740|NCT00003352|Drug|Taxotere|60 mg/m2, IV, every 3 weeks
45773741|NCT00003352|Drug|Adriamycin|60 mg/m2, IV, every 3 weeks
45773742|NCT00004048|Biological|filgrastim|
45773743|NCT00004048|Drug|doxorubicin hydrochloride|
45773744|NCT00004048|Procedure|autologous bone marrow transplantation|
45773745|NCT00004048|Procedure|peripheral blood stem cell transplantation|
45773746|NCT00004048|Radiation|indium In 111 monoclonal antibody MN-14|
45773747|NCT00004048|Radiation|yttrium Y 90 monoclonal antibody MN-14|
45773748|NCT00003358|Drug|chemotherapy|
45773749|NCT00003358|Drug|cisplatin|
45634591|NCT05103059|Diagnostic Test|BMI|Patients with cancer cachexia will be enrolled in the study, and the following data will be collected: age, sex, total protein, albumin, hemoglobin (Hb), white blood cell (WBC) count, neutrophil count, lymphocyte count, red blood cell (RBC) count, platelet (PLT) count, body mass index (BMI), mid-arm circumference (MAC), thickness of triceps skinfold (TSF), handgrip strength (HGS), and calf circumference (CC)
45773750|NCT00003358|Drug|gemcitabine hydrochloride|
45773751|NCT00003790|Genetic|polymerase chain reaction|
45773752|NCT00003790|Other|flow cytometry|
45773753|NCT00004060|Drug|exatecan mesylate|
45773754|NCT00384826|Drug|erlotinib|Erlotinib 150 mg/day (until progression)
45773755|NCT00384826|Drug|paclitaxel + carboplatine|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D28, until progression) Carboplatine AUC 6 D1 (D1=D28, 6 cycles)
45773756|NCT00003364|Drug|cisplatin|
45634592|NCT04436783|Device|Virtual Reality Epley Maneuver System (VREMS)|The VREMS system includes a smartphone placed inside virtual reality goggles worn by the participant. On the smartphone there is a virtual reality application. When viewed through the VR goggles the participants see a three-dimensional environment. Audio and text cues are presented in a 3D environment to help guide the patient through the Epley maneuver.
45773757|NCT00003364|Drug|cyclophosphamide|
45773758|NCT00003364|Drug|doxorubicin hydrochloride|
45773759|NCT00003364|Drug|etoposide|
45773760|NCT00003364|Drug|vincristine sulfate|
45773761|NCT00003364|Radiation|radiation therapy|
45773762|NCT00384982|Procedure|Bone marrow-derived stem cells implantation|percutaneous BM-derived cell therapy
45773763|NCT00004066|Biological|filgrastim|
45773764|NCT00004066|Drug|docetaxel|
45773765|NCT00004066|Drug|gemcitabine hydrochloride|
45773766|NCT00003370|Drug|irofulven|
45773767|NCT00003382|Biological|filgrastim|
45773768|NCT00003382|Drug|gemcitabine hydrochloride|
45773769|NCT00003382|Drug|topotecan hydrochloride|
45773770|NCT00004828|Drug|liothyronine I 131|
45773771|NCT00004834|Drug|imipramine|
45773772|NCT00004834|Behavioral|cognitive-behavioral therapy|
45773773|NCT00004840|Drug|thyrotropin-releasing hormone|
45773774|NCT00004846|Drug|ABC/Gen-Probe/Chiron HIV-1/HCV 001|
45773775|NCT00004852|Drug|Efavirenz|
45773776|NCT00004852|Drug|Lamivudine|
45773777|NCT00004852|Drug|Zidovudine|
45773778|NCT00004858|Biological|B43-genistein immunoconjugate|
45773779|NCT00004864|Drug|GEM 231|
45773780|NCT00004864|Drug|docetaxel|
45773781|NCT00003796|Drug|irofulven|
45773782|NCT00003802|Drug|pyrazoloacridine|
45773783|NCT02972866|Drug|Budesonide|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
45773784|NCT00003814|Drug|eflornithine|
45773785|NCT00003832|Drug|bromodeoxyuridine|Given IV
45773786|NCT00003832|Procedure|conventional surgery|Undergo surgery
45773787|NCT00003832|Other|laboratory biomarker analysis|Correlative studies
45773788|NCT00003850|Drug|thalidomide|
45773789|NCT00004072|Drug|O6-benzylguanine|Patients receive O6-benzylguanine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
45773790|NCT00004072|Drug|carmustine|Followed 1 hour later by carmustine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
45773791|NCT00004078|Drug|irinotecan hydrochloride|Given IV
45773792|NCT00003856|Drug|temoporfin|
45773793|NCT00014222|Biological|epoetin alfa|40,000 IU
45773794|NCT00014222|Biological|filgrastim|5 mg/kg/d - days 2-13
45773795|NCT00014222|Drug|cyclophosphamide|75, 600 and 830 mg/m2
45773796|NCT00014222|Drug|doxorubicin hydrochloride|60 mg/m2
45773797|NCT00014222|Drug|epirubicin hydrochloride|60 mg/m2
45773798|NCT00014222|Drug|fluorouracil|500mg/m2
45773799|NCT00014222|Drug|paclitaxel|175 mg/m2
45773800|NCT00004870|Biological|oblimersen sodium|
45773801|NCT00004870|Drug|irinotecan hydrochloride|
45773802|NCT00004084|Radiation|indium In 111 LL2 IgG|single dose, intravenous infusion over 30 minutes
45773803|NCT00004084|Radiation|yttrium Y 90 epratuzumab|single dose, intravenous infusion over 30 minutes
45634593|NCT04436783|Other|Instructional Handout (IH)|Patients randomized to the IH group will be given an instructional handout with image and text-based instructions on the steps involved in performing the Epley maneuver. They will then be given the chance to perform the Epley maneuver.
45634594|NCT05102825|Diagnostic Test|1H and Xe-129 MRI|Traditional 1H-MRI (room air inhalation) and Xe-129 MRI (requires inhalation of Xenon 129 gas).
45634595|NCT05012267|Other|16-hour PP|PP according to previous study
45773804|NCT00004876|Drug|carboplatin|
45773805|NCT00004876|Drug|thalidomide|
45773806|NCT00003862|Drug|cisplatin|
45773807|NCT00003862|Drug|fluorouracil|
45634596|NCT04999631|Drug|Squaric Acid Dibutyl Ester|Topical squaric acid dibutyl ester (SADBE) dissolved in ethanol at 0.2% concentration.
45634597|NCT04999631|Drug|Ethanol Solution|Control
45634598|NCT05337761|Behavioral|Peer-led training on lifejacket wear|Training on proper lifejacket wear will be given to peers who will be the change agents amongst their fellow boaters
45634599|NCT04437875|Biological|Gam-COVID-Vac Lyo|adenoviral-based vaccine against SARS-CoV-2
45773808|NCT00003862|Drug|leucovorin calcium|
45773809|NCT00003862|Drug|paclitaxel|
45773810|NCT00003862|Procedure|conventional surgery|
45773811|NCT00003862|Procedure|neoadjuvant therapy|
45773812|NCT00003862|Radiation|radiation therapy|
45773813|NCT00003868|Drug|cyclophosphamide|
45773814|NCT00003868|Drug|methotrexate|
45773815|NCT00003868|Procedure|allogeneic bone marrow transplantation|
45773816|NCT00003868|Procedure|peripheral blood stem cell transplantation|
45773817|NCT00003868|Radiation|iodine I 131 monoclonal antibody BC8|
45773818|NCT00003868|Radiation|radiation therapy|
45773819|NCT00003874|Biological|monoclonal antibody CD19|
45634600|NCT02718833|Drug|Elotuzumab|
45634601|NCT02718833|Drug|Pomalidomide|
45634602|NCT02718833|Drug|Bortezomib|
45634603|NCT02718833|Drug|Dexamethasone|
45634604|NCT04908293|Other|Biorepair toothpaste|Use of New Biorepair Advanced Sensitive for home oral care.
45634605|NCT04908293|Other|Colgate toothpaste|Use of Colgate toothpaste for home oral care.
45634606|NCT04437797|Procedure|Surgical Extrusion|The next step will be atraumatic extraction which will be initiated by using straight periotome until it is sufficiently luxated and gently pulled out to the amount of sufficient ferrule effect without encroaching the biological width. 90- or 180-degrees rotation of the tooth will be done if needed. The tooth will be supported from palatal side, etching will be done using 37% phosphoric acid, rinsing, drying, bonding agent and then application of 3M Filtek flowable composite on rounded 16mm stainless steel wire for splinting in the middle of the tooth without extension of flowable composite neither to the mesial nor to the distal. This procedure should be followed by occlusal adjustment if needed. Splint will be removed after 2 weeks.
45773820|NCT00003874|Biological|monoclonal antibody CD20|
45773821|NCT00003874|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45773822|NCT00004090|Drug|cisplatin|
45773823|NCT00004090|Drug|gemcitabine hydrochloride|
45773824|NCT00004102|Drug|FOLFOX regimen|
45773825|NCT00004102|Drug|fluorouracil|
45773826|NCT00004102|Drug|leucovorin calcium|
45773827|NCT00004102|Drug|oxaliplatin|
45773828|NCT00003880|Biological|recombinant adenovirus-p53 SCH-58500|
45773829|NCT00003880|Drug|carboplatin|
45773830|NCT00003880|Drug|paclitaxel|
45773831|NCT00004108|Drug|exatecan mesylate|
45773832|NCT00004900|Biological|filgrastim|
45773833|NCT00004900|Drug|anastrozole|
45773834|NCT00004900|Drug|carboplatin|
45773835|NCT00004900|Drug|cisplatin|
45773836|NCT00004900|Drug|cyclophosphamide|
45773837|NCT00004900|Drug|etoposide|
45773838|NCT00004900|Drug|thiotepa|
45773839|NCT00004900|Procedure|peripheral blood stem cell transplantation|
45773840|NCT00004900|Radiation|radiation therapy|
45773841|NCT00004114|Biological|filgrastim|
45773842|NCT00004114|Drug|cyclophosphamide|
45773843|NCT00004114|Drug|cytarabine|
45773844|NCT00004114|Drug|fludarabine phosphate|
45773845|NCT00004114|Procedure|peripheral blood stem cell transplantation|
45773846|NCT04394156|Behavioral|Brief cognitive intervention|See the information provided in the experimental arm description.
45773847|NCT00004906|Biological|filgrastim|
45773848|NCT00004906|Drug|anastrozole|
45773849|NCT00004906|Drug|carboplatin|
45773850|NCT00004906|Drug|cisplatin|
45773851|NCT00004906|Drug|cyclophosphamide|
45773852|NCT00004906|Drug|docetaxel|
45773853|NCT00004906|Drug|doxorubicin hydrochloride|
45773854|NCT00004906|Drug|etoposide|
45773855|NCT00004906|Drug|pamidronate disodium|
45773856|NCT00004906|Drug|thiotepa|
45773857|NCT00004906|Procedure|peripheral blood stem cell transplantation|
45773858|NCT00004918|Biological|PR1 leukemia peptide vaccine|Given SC
45773859|NCT00004918|Drug|Montanide ISA 51 VG|Given SC
45773860|NCT00004918|Biological|sargramostim|Given SC
45773861|NCT00004918|Other|laboratory biomarker analysis|Correlative studies
45773862|NCT00003892|Drug|ISIS 5132|4mg/kg/day IV for 21 days every 4 weeks.
45773863|NCT00003898|Dietary Supplement|glutamine|Oral
45773864|NCT00004132|Biological|filgrastim|
45773865|NCT00004132|Biological|palifermin|
45773866|NCT00004132|Drug|cyclophosphamide|
45448008|NCT01367704|Behavioral|"Coaching Boys Into Men program"|Coaching Boys into Men (CBIM) program consists of a 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rationale for CBIM and the CBIM Coaches Kit. The Coaches use this CBIM toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth.
45634607|NCT04437797|Procedure|Immediate Implant Placement|The patient is anaesthetized. Atraumatic extraction of the badly broken-down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, 11 to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed. Jumping gap occurring subsequent to atraumatic extraction and immediate implant placement more than 2 mm will be grafted using Xenograft.
45634608|NCT01964326|Drug|Atorvastatin calcium 10 mg|Atorvastatin calcium 10 mg tablet to be administered orally every day
45634609|NCT04786457|Biological|Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)|one subcutaneous injection of Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) at 0.5 mL of 6.5 x 10^3 PFU/mL
45634610|NCT05047757|Dietary Supplement|Test meal with 15N labeled favabean|Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).
45634611|NCT04436705|Other|Progressive Muscle Relaxation (PMR) technique|The PMR technique utilized in this study was based on the original technique designed by Jacobson (1938) and subsequently modified by Bernstein and Borkovec (1973). The PMR technique involves tensing the individual muscle groups for about 5 seconds for each muscle. Then, allowing them to relax for about 10 seconds, and notice how the muscle feels when it is relaxed in contrast to how it felt when it was tensed. The technique is accompanied by breathing exercises in order to feel the sense of relaxation. In this study, the PMR technique refers to tensing and relaxing the muscles from the forehead to the feet one by one, including the eleven muscle groups (right arm, left arm, forehead, jaw and neck, back and shoulders, stomach, thighs, right calf, left calf, right foot and left foot). The total procedure takes around 20 minutes.
45634612|NCT05102045|Device|Repetitive Transcranial Magnetic Stimulation|TMS is a non-invasive application that induces changes in neuronal polarization and activity by causing the induction of weak electric currents in a rapidly changing magnetic field. Repetitive TMS (rTMS) refers to the application of regular TMS pulses at fixed intervals.
45634613|NCT05102045|Other|Aerobic Exercise|Brisk exercise that promotes the circulation of oxygen through the blood and is associated with an increased rate of breathing.
45634614|NCT05102045|Drug|Acetylcholinesterase Inhibitors|Donepezil, Rivastigmine, Galantamine were given in combination for Alzheimer's disease.
45634615|NCT05102045|Drug|Memantine|Memantine were given for Alzheimer's disease. .
45653025|NCT05182125|Biological|AdC7-HIVgp140|"The products is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS [tris(hydroxymethyl)aminomethane], pH 8.0 formulation buffer to a concentration of 1.2 x 10^11 vp/mL and filled at 0.6 mL for AdC7-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC7-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the IB."
45773867|NCT00004132|Drug|etoposide|
45773868|NCT00004132|Drug|ifosfamide|
45773869|NCT00004132|Procedure|quality-of-life assessment|
45773870|NCT00004132|Radiation|radiation therapy|
45773871|NCT00004138|Procedure|positron emission tomography|
45773872|NCT00004138|Procedure|radionuclide imaging|
45773873|NCT00004138|Radiation|fludeoxyglucose F 18|
45773874|NCT04712500|Drug|AND017|AND017 oral capsule
45773875|NCT05777057|Diagnostic Test|Diagnodent|using DIAGNDENT depends on the principle that when 655nm wavelength of Diode laser is irradiated on dental surface, intraoral bacteria metabolites will absorb it and then metabolites emit a red fluorescence. The dental surface will reflect this fluorescence and gives number between 0 and 99 on the screen of the DIAGNdent.
45448009|NCT05268172|Drug|IFN-γ and CIK cells, Tcm cells or CAR T cells|A 50ng/ mL IFN-γ solution was prepared, and the required volume of IFN-γ solution was calculated according to the final concentration of 5ng/ mL according to the volume of pleural fluid or ascites of the patient. CIK cells were injected 1.0-2.0×109 on the second day and review three days later.T cells and CAR T cells were selected sequentially according to the re-examination of pleural fluid or ascites.
45448010|NCT03214094|Drug|Vonoprazan|Vonoprazan tablets
45448011|NCT02126644|Drug|70% glycolic acid|
45773876|NCT05777044|Behavioral|Yoga|Participation in Hatha Yoga twice a week for 45 minutes for 10 weeks. The total potential dose is 900 minutes over the course of the intervention.
45448012|NCT03550534|Drug|Calcium Carbonate|Calcium carbonate was obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.
45914342|NCT02042157|Other|Regular toileting|Patients in the control arm will toilet as usual.
45914343|NCT02042170|Drug|human growth hormone self-injection|
45634616|NCT04934267|Other|Eccentric Exercise for subjects with JHS|There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1-RM), which is the highest amount of weight that they can lift concentrically once. The independent variables are the two groups and the dependent variables are girth, resting arm angle, Pain, McGill Pain Questionnaire, and pressure pain threshold. This groups will perform 1 set of standing eccentric bicep curls order to induce DOMS.Each rep will include a timed 5 second long eccentric component without an concentric component,. The exercise will stop when the participant cannot volitionally keep up with the 5 second count. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
45448013|NCT03550534|Drug|Placebo oral capsule|Placebo oral capsule was also obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.
45634617|NCT04934267|Other|Eccentric Exercise for Controls|There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1-RM), which is the highest amount of weight that they can lift concentrically once. The independent variables are the two groups and the dependent variables are girth, resting arm angle, Pain, McGill Pain Questionnaire, and pressure pain threshold. This groups will perform 1 set of standing eccentric bicep curls order to induce DOMS.Each rep will include a timed 5 second long eccentric component without an concentric component,. The exercise will stop when the participant cannot volitionally keep up with the 5 second count. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
45634618|NCT04867655|Other|Orange Juice|Approximately 500 ml of orange juice will be consumed and then blood and urine samples will be collected for 24 hours
45634619|NCT04867655|Other|Orange juice with either 6g or 3 g of β-Glucan|Approximately 500 ml of orange juice mixed with either 6g or 3 g of β-Glucan will be consumed and then blood and urine samples will be collected for 24 hours
45634620|NCT04855019|Procedure|shoulder periarticular injection, suprascapular and axillary nerve block|"In the PI group, a mixture of 30 ml bupivacaine 0.5% and 30 ml saline solution will be injected by the orthopedist after the wound is closed.~In the CSAB group, a total of 20 ml 0.5% bupivacaine, 10 ml to the suprascapular notch, 10 ml to the axillary nerve, will be administered preoperatively by the anesthesiologist under ultrasound guidance."
45634621|NCT04414241|Drug|Hydroxychloroquine|A loading dose of 600mg of hydroxychloroquine orally on the first day, followed by 400mg of hydroxychloroquine orally every-other-day and use of standard measures of personal protection provided from the hospital for 8 weeks.
45634622|NCT05101967|Procedure|Dynamic Cervical Implant|Cervical discectomy through anterior approach with replacement of disc by dynamic implant
45634623|NCT05101967|Procedure|Anterior Cervical Discectomt and Fusion|Cervical discectomy through anterior approach with putting of cervical cage.
45634624|NCT04779905|Diagnostic Test|urinary albumbin/creatinine ratio|detection of microalbuminuria in nafld patients
45634625|NCT04764773|Other|No intervention|No intervention
45634626|NCT04758377|Procedure|Magnetic resonance imaging (MRI)|Serial MRI scans of patients with acute cervical SCI to quantify hemorrhage.
45634627|NCT05101889|Dietary Supplement|Oral Impact®|3 ready-to-drink bottles/day
45634628|NCT04532177|Radiation|Stereotactic Body Radiation Therapy (SBRT)|fractionated linear accelerator based SBRT to 40 Gy in 5 fractions
45634629|NCT04531553|Procedure|Thoracic epidural analgesia|Patients will preoperatively receive thoracic epidural at the level T5 & T6 with bolus 20 ml of levobupivacaine 0.25% then levobupivacaine 0.1% infused at a rate of 0.1 mL/Kg/hr until chest tube removal ( 5-6 days).
45634630|NCT04531553|Procedure|ESPB with levobupivacaine and dexmedetomedine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% plus 0.5mic/Kg dexmedetomidine on the deep aspect of erector spinae muscle then catheter inserted. 20 ml bolus of levobupivacaine 0.1% with dexmedetomidine 0.5 μg/Kg was injected every 6 hours until chest tube removal.
45634631|NCT04531553|Procedure|ESPB with levobupivacaine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% on the deep aspect of erector spinae muscle then catheter inserted.A 20 ml bolus of levobupivacaine 0.1% is injected every 6 hours until chest tube removal.
45634632|NCT05101811|Drug|Vitamin D Levels measurement using chemiluminescent assay|Measurement of serum vitamin D levels
45634633|NCT05101811|Device|Vitamin D level assessment|Using lIAISON DEVICE
45634634|NCT05323409|Behavioral|OPTIMISE|OPTIMISE is a multilevel intervention that seeks to improve patient activation for comorbidity self-management during cancer treatment and coordination of care between oncologists and primary care physicians from point of diagnosis through the first year of post-treatment survivorship.
45634635|NCT04088123|Drug|Ticagrelor Oral Tablet [Brilinta]|A single loading dose of ticagrelor (180 mg) will be administered to each participant in this study.
45634636|NCT05307419|Procedure|Rectal suction biopsy.|Suction biopsy performed
45914344|NCT02042196|Drug|KUVAN|KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.
45914345|NCT02042196|Drug|Placebo|Placebo pills designed to match the dissolvable KUVAN pills
45448014|NCT03551314|Other|Nasal Intermittent Positive Pressure|"- NIPPV The following parameters: inspiratory pressure = 15 cmH2O / final expiratory positive pressure = 6 cmH2O / inspiratory time = 0.40 / flow = 6-8 L.min-1 / respiratory rate = 24.~Respiratory inductive plethysmography is used to evaluate breathing pattern (tidal volume, respiratory rate, minute ventilation, mean inspiratory flow) and chest wall motion (labor breathing index - LBI, phase relation in inspiratory breathing - PhRIB, phase relation in expiratory breathing - PhREB, total phase relation - PhRTB and phase angle)."
45634637|NCT05307419|Procedure|Full-thickness rectal biopsy.|Full-thickness biopsy performed
45634638|NCT05199779|Behavioral|Single Session Intervention Leveraging an Ultra-Brief Self-Compassion Exercise|This 20-second contemplative exercise includes draws from the science of habit formation and includes elements of self-soothing touch, somatic experiencing, and mindful self-compassion.
45634639|NCT05199779|Behavioral|Finger-Tapping Active Control|This 20-second finger tapping exercise involves touching each finger to the thumb on one hand and repeating for twenty seconds. This intervention was designed to control for the potential effect of assessment on outcomes, the effect of having an activity to do for the duration of the intervention (4 weeks), regression to the mean, time, or other nonspecific factors.
45773877|NCT05777018|Procedure|conventional recruitment maneuvers|"The recruitment maneuver will be performed at 3 predefined time points: 5 minutes after induction of GA (T2), 5 minutes after insufflation of the capnoperitoneum (T3), After the end of surgery and before recovery from anesthesia (T4).~by pressure controlled mode starting with an airway pressure of 15 cmH2O the subsquently changed ( decrease or increase) to provide targeted tidal volume according to each patient, maintaining end-tidal carbon dioxide between 35 to 45 mmHg with 5 cmH2O increments in PEEP until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 s. The peak airway pressure will be maintained for 10 s or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings"
45773878|NCT05777018|Procedure|ultrasound-guided recruitment maneuvers|"Ultrasound guided maneuver will be performed at T2, T3 and T4.~The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area is visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit will be 40 cmH2O. The Recruitment maneuvers (RM) will be started searching the pressure level at which the consolidation pattern disappears and progressive lung re-aeration is observed and will be recorded for all patients (the lung's opening pressure).(14) Lung ultrasound examination will be performed every 5 cmH2O increments in PEEP to detect the lung's opening pressure."
45634640|NCT05164367|Drug|Atropine sulfate gel (0.01%)|A research nurse will measure 1 gram of gel using a calibrated measuring spoon and will provide it to the participant for self-administration.
45634641|NCT03847181|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban at a dose of 15 or 20 mg once daily
45634642|NCT03847181|Drug|Apixaban (Eliquis)|Apixaban at a dose of 2.5 or 5 mg twice daily
45634643|NCT03847181|Drug|Warfarin|Warfarin dose as prescribed by medical practitioner
45634644|NCT03825107|Other|patching|covering the fellow eye with an eyepatch to force use of the amblyopic eye
45773879|NCT05777005|Behavioral|5A's/5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
45773880|NCT05777005|Other|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
45773881|NCT05777005|Other|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
45773882|NCT05777005|Behavioral|Chat-based support|Participants will receive three months of chat-based support via WeChat. The regular messages and instant messaging on psychosocial support aim to provide cessation advice, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
45914346|NCT02042196|Drug|Cetrotide|Cetrotide (0.25mg/d) will be taken daily for 10 days via abdominal subcutaneous injection.
45914347|NCT02042196|Drug|Climara|0.075mg/d transdermal patch will be placed on skin.
45448015|NCT03551314|Other|Continuous Positive Airway Pressure|"- CPAP The following parameters: pressure of 6 cmH2O, with flow of 6-8L/min.~Respiratory inductive plethysmography is used to evaluate breathing pattern (tidal volume, respiratory rate, minute ventilation, mean inspiratory flow) and chest wall motion (labor breathing index - LBI, phase relation in inspiratory breathing - PhRIB, phase relation in expiratory breathing - PhREB, total phase relation - PhRTB and phase angle)."
45448016|NCT03550924|Procedure|low flow passive oxygenation|low flow passive oxygenation during laryngoscopy with 10l/min oxygen via standard nasal prongs
45914348|NCT02042196|Drug|Placebo transdermal patch|Inactive transdermal patch
45914349|NCT02042222|Drug|Hydroxyurea|
45914350|NCT02042235|Behavioral|Parent-implemented intervention|In order to achieve the programme of parent-implemented language intervention, a detailed protocol for speech therapists recruited and trained for the present study has been established. The techniques and attitudes favouring use of oral language will be taught to the parents during 15 sessions with the parent(s) and child.
45914351|NCT02042248|Biological|AGS-004|All participants in both arms will receive the same treatment and doses of AGS-004 in Step 2 at weeks 0, 4, 8, and 12.
45914352|NCT02042313|Other|continuous epidural infusion|
45914353|NCT02042313|Other|combined paravertebral infusion and single shot of TAP block|
45448017|NCT03550924|Procedure|high flow passive oxygenation|high flow passive oxygenation during laryngoscopy with 120l/min oxygen via THRIVE system
45448018|NCT02131480|Drug|Doxorubicin|60 mg/m²
45448019|NCT02131480|Drug|Trabectedin|1,1 mg/m²
45448020|NCT02128906|Drug|Cisplatin|Cisplatin 40 mg/m2 weekly x 7
45448021|NCT02128906|Radiation|IMRT|IMRT: once daily, M-F, 7 weeks (70 Gy)
45448022|NCT02128906|Drug|Docetaxel|Docetaxel 15 mg/m2 weekly x 7
45634645|NCT03825107|Other|Dichoptic videos|watching contrast-rebalanced dichoptic videos to allow the two eyes to work together
45653026|NCT05182125|Biological|CH505TF gp120|"CH505TF gp120 is formulated in 20 mM sodium phosphate, 150 mM NaCl, 0.02% polysorbate 80 (PS80), pH 6.5, supplied as a frozen liquid in 2 mL glass vials. Each 2 mL vial contains 0.75 mL of formulated gp120 at a concentration of 0.8 mg/mL and is stored at ≤ -65°C.~The study product is described in further detail in the IB."
45935464|NCT02970656|Behavioral|Teens.Connect|Teens.Connect combines two internet psycho-educational programs, TEENCOPE™, an internet version of coping skills training using a graphic novel format combined with social media, and an internet diabetes problem-solving educational program (Managing Diabetes)
45935465|NCT00125125|Drug|Fluvastatin|
45935466|NCT00078000|Drug|SU011248|
45773883|NCT05777005|Behavioral|WeChat group support|Participants will receive three months of group support via WeChat.
45773884|NCT05776940|Drug|Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules combined with Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab|Naive al amyloidosis patients receive Bortezomib+Dexamethasone, Bortezomib+Dexamethasone+Daratumumab or single Daratumumab therapy combined with Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules(250mg/time, bid,up to 3 months).
45914354|NCT02042339|Drug|Hyperbaric oxygen|The treatment will be applied in a large walk-in drive-in hyperbaric chamber. Depending on their general condition, the patients will sit in comfortable chairs or remain in their own wheelchair or bed in relaxed position. They will be accompanied by a medical attendant or by a hyperbaric physician if necessary due to their general condition. Oxygen 100% will be distributed over a tight fitting oxygen-mask connected to the overboard-dumping system. The treatment will be administered according to the so-called problem-wound schedule once a day for six consecutive weeks. On weekends and on public holidays the patients will be off therapy.
45634646|NCT05101499|Procedure|AKIN osteotomy with screw fixation|"A simple skin speck is made on the medial aspect of the hallux, in the metaphyseal area, using a 3 mm beaver blade. The tissue is lifted from the bone using an elevator medially and dorsally on the phalanx. A Shannon 2x12 mm burr is then positioned transversely by making the osteotomy which must preserve a lateral hinge, a guarantee of stability in the event of non-fixation.~Fixation with a screw will be effected by another skin speckle allowing access to the infero-medial area of the phalangeal base. A pre-hole can be made with the same bur to facilitate the introduction of the guide wire for osteosynthesis, which is not specific."
45634647|NCT05101499|Procedure|AKIN osteotomy without screw fixation|This is the same procedure as the procedure under study, without the fixation by a target: a simple skin speck is performed on the medial face of the hallux, in the metaphyseal area using a beaver blade. of 3 mm. The tissue is lifted from the bone using an elevator medially and dorsally on the phalanx. A Shannon 2x12 mm burr is then positioned transversely by making the osteotomy which must preserve a lateral hinge, a guarantee of stability in the event of non-fixation.
45448023|NCT02128906|Drug|Cetuximab|Cetuximab 400 mg/m2 load, one week prior to IMRT Cetuximab 250 mg/m2 weekly x 7
45634648|NCT03477851|Drug|Tramadol Hydrochloride|Tramadol i.m. simultaneous with sciatic nerve block
45634649|NCT03477851|Drug|Placebo|0,9%NaCl i.m. simultaneous with sciatic nerve block
45914355|NCT02042352|Other|pH glove|
45914356|NCT02042365|Procedure|ERAS (Enhanced recovery after surgery)|
45634650|NCT05101343|Behavioral|Breathing meditation|Daily, 5-minute breathing meditation for one week.
45634651|NCT05122871|Other|Scape Room|Practical training through scape-room with simulator
45914357|NCT02042417|Device|INRatio2 and CoaguChek|
45914358|NCT02042456|Device|Digital Breast Tomosynthesis|digital breast tomosynthesis technology
45914359|NCT02042456|Device|Automated Whole Breast Ultrasound|Automated Whole Breast Ultrasound
46070137|NCT02613585|Other|Permethrin Impregnated Clothing|Uniforms and work clothing treated with permethrin according to proprietary process used by Insect Shield, Inc.
45634652|NCT05122871|Other|Simulation|Practical training through simulator
45634653|NCT04437407|Device|PB2-1 prototype|PB2-1 prototype is a belt-like wearable device similar to the original PrenaBelt designed for pregnant women that permits supine positioning of the pelvis but, when in this position, provides subtle pressure points to the user's body and thereby activates the body's natural mechanism to reposition itself to relieve discomfort. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
45634654|NCT04437407|Device|PB2-2 prototype|PB2-2 prototype is a belt-like wearable device designed for pregnant women. When placed on the woman's back, this device prevents the pelvis from achieving a supine orientation by maintaining at least fifteen degrees of right or left lateral pelvic tilt. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
45773885|NCT05776940|Drug|Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab|Naive al amyloidosis patients receive Bortezomib+Dexamethasone, Bortezomib+Dexamethasone+Daratumumab or single Daratumumab therapy without any probiotics (Blank Control).
45773886|NCT05776901|Device|C-STRESS|Participants were asked to use the C-STRESS app daily for 6 weeks to participate in CBCT lessons, watch guided meditation videos, complete short reflective exercises, and engage with other content provided in C-STRESS (i.e., attending drop-in sessions, journaling, completing mood and wellbeing check-ins, and reading educational articles on depression, anxiety, and stress)
45773887|NCT05776888|Other|Ofatumumab|There is no treatment allocation. For both cohorts, only patients that have received Ofatumumab treatment for at least 3 months prior to inclusion in the study will be enrolled.
45914360|NCT02042456|Device|Full Field Digital Mammography|
45914361|NCT02042482|Dietary Supplement|Coenzyme Q10U, L-carnitine|
45914362|NCT02042495|Drug|Metformin|
45448024|NCT02131558|Procedure|ICG Dye|ICG Dye injections
45914363|NCT02042508|Other|strengthening|
45448025|NCT02128984|Dietary Supplement|Symbiotic Formula with DHA and antioxidants|6 months intervention.
45448026|NCT02128984|Dietary Supplement|Standard Formula|6 months intervention.
45914364|NCT02042508|Other|hybrid training programme|
45935467|NCT00125203|Drug|Botulinum toxin type B (Myobloc)|
45935468|NCT00125203|Procedure|Injection of salivary glands|
45935469|NCT00125281|Drug|S-adenosyl-methionine (SAMe) capsules|
45935470|NCT00043355|Drug|interferon gamma-1b|500 mcg, oral, three times weekly
45935471|NCT00125320|Drug|RSD1235|
45935472|NCT00125398|Drug|AQUAVAN (fospropofol disodium; GPI 15715 )|
45935473|NCT04729998|Drug|Rivaroxaban film-coated tablet 20 mg|Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 20 mg of rivaroxaban.
45935474|NCT04729998|Drug|Xarelto® film-coated tablet 20 mg|Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 20 mg of rivaroxaban.
45935475|NCT00125437|Drug|spironolactone|
45935476|NCT00125476|Behavioral|Exercise|
45935477|NCT00125554|Drug|Metyrapone|
45773888|NCT05776862|Drug|Ursolic Acid|Subjects will take an oral 400mg (8 capsules - 4 in the morning/200mg and 4 at night/200mg) supplement of UA every day for 12 weeks.
45773889|NCT05776862|Other|Strength Training|Subjects will perform 3 sets of 10 repetitions of concentric and eccentric upper body exercises (bicep curls and tricep extensions) each session. Each session will last approximately 10-15 minutes of weightlifting with a 2-minute rest period between sets. The arm selected for exercise will be randomized.
45634655|NCT04437407|Device|PB2-3 prototype|PB2-3 prototype is a belt-like wearable device designed for pregnant women. When placed on the woman's back, this device prevents the pelvis from achieving a supine orientation by maintaining at least fifteen degrees of right or left lateral pelvic tilt. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
45773890|NCT05776810|Diagnostic Test|Diagnostic Test: Head Up Tilt Table (HUT)|"Participant randomized to open-label diagnostic strategy. Results and all follow-up care to be in the hands of treating cardiologist as this is a pragmatic study.~the early HUT [protocol: supine pre-tilt phase 5 min, un-medicated HUT to 70 degrees for 20 minutes; if response negative then 400 μg of sublingual nitroglycerin and continued 70 degree tilt for 20 minutes]"
45634656|NCT04437407|Device|PB2-4 prototype|PB2-4 prototype is a belt-like wearable device designed for pregnant women that prevents the user from achieving a supine position as the device allows right and left lateral pelvic tilt but prevents the user's pelvis from settling supine due to virtue of its design. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
45634657|NCT04437407|Device|PB2-5 prototype|PB2-5 prototype is a belt-like wearable device designed for pregnant women that does not provide positional therapy. It can be worn anytime as a maternity support belt.
45773891|NCT05776810|Device|Device: Implantable Loop Recorder|ILR is a small subcutaneously implanted device, lasting up to 3 years, that records heart rhythms, and which may be either auto-triggered or patientactivated.
45773892|NCT05776784|Procedure|dental procedure|questionnaire for patient with dental procedure
45773893|NCT05776758|Drug|cisplatin based neoadjuvant chemotherapy|cisplatin based neoadjuvant chemotherapy
45773894|NCT05776758|Procedure|Radical cystectomy alone|RC alone
45773895|NCT05776745|Behavioral|Speech|Patients read specific words and sentences
45773896|NCT05776745|Device|Stereoelectroencephalography|Using stereoelectroencephalography to record the Intracranial EEG of the patient
45773897|NCT05776732|Other|3M CaviionTM|3M CaviionTM is mainly composed of acrylate trimer, non-toxic, alcohol-free, and compatible with chlorhexidine gluconate and povidone iodine.
45634658|NCT04437407|Device|Ajuvia-Active|Ajuvia Sleep Monitor senses the user's body position and can be used in passive or active mode with or without the PB2 prototypes. In the active mode, it alerts the woman when her pelvis is in the supine position through a gentle vibratory alarm.
45634659|NCT04437407|Device|Ajuvia-Passive|Ajuvia Sleep Monitor senses the user's body position and can be used in passive or active mode with or without the PB2 prototypes. In the passive mode, it measures and records the position of the pelvis but does not alert the woman.
45634660|NCT05101265|Drug|Lurbinectedin|"Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 3.2 mg/m² dose."
45773898|NCT05776680|Other|Psychological support|60-minute once or twice a week for 6 months of Initial Remote Psychological Support Course .
45773899|NCT05776654|Device|Biometric wearable devices|Passive data collection using biometric wearable devices.
45773900|NCT05776628|Device|Plenum® Tissue ortho membrane (polydioxanone membrane)|Membrane addition after flavectomy and spinal nerve and dura mater manipulation.
45773901|NCT05776615|Other|mobile application|"In the collection of Mobile Application group data, they will be asked to fill out the forms.The mobile application will be introduced, the application will be downloaded from the virtual market (Google Play Store or App Store) to the phone, login will be provided by giving a user name and password, and how to use the application will be explained. Nursing Diagnosis Perception Scale with nurses at the end of the 1st month and at the end of the 3rd month;  MıssCare Questionnaire in the Neonatal Intensive Care Unit(NICU); System Availability Scale will be applied."
45773902|NCT05776589|Device|The mechanical ventilation mode|Changing the mechanical ventilation mode
45773903|NCT05776563|Other|Magnetic Resonance Spectroscopy Imaging (MRSI)|baseline 1HMRSI imaging study, then will undergo intensification of their diabetes management for a period of 12-week and at the end of the intervention they will undergo 1H MRSI scanning to measure intracerebral and plasma glucose levels at euglycemia and following 2 hours of hyperglycemia using the clamp technique (target glucose 220 mg/dl) in the occipital region
45448027|NCT02252302|Other|Rest (Sitting on chair)|Study participants will sit on a chair for 60min. This is to simulate physical resting condition.
45773904|NCT05776537|Device|Fibreoptic bronchoscopy|different endoscopies used for confirmation of diagnosis
45773905|NCT05776485|Other|Progressive resistance training|Only the control group: 3 exercise bouts within the study period. Comparison between exercised and non-exercised leg.
45773906|NCT05776485|Other|Cross-sectional comparison between healthy and tendinopathic group|Comparison of primary and secondary outcomes.
45773907|NCT05776472|Drug|Pegcetacoplan|Pegcetacoplan will be prescribed according to the label in patients with PNH.
45773908|NCT05776407|Drug|ThisCART19A|Single dose of Allogeneic Anti-CD19 CAR T cells (ThisCART19A) will be infused after the lymphodepletion conditioning of Fludarabine, Cyclophosphamide and Etoposide.
45773909|NCT05776407|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
45773910|NCT05776407|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
45634661|NCT05101265|Drug|Lurbinectedin|"Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 1.6 mg/m² dose"
45914365|NCT02042521|Drug|Dietary Supplement|The active evening dietary supplement is taken at 22:00. The active morning dietary supplement is taken at 8:00-8:15. The active evening dietary supplement is taken first. The active morning and evening dietary supplements are taken within 12 hours in time points as specified above.
45914366|NCT02042521|Drug|Lactose Placebo|This research study involves a placebo dietary supplement that does not have any of or only partial of the active ingredients in the active dietary supplement. The placebo dietary supplement will be given in identical time points to match that of the active dietary supplements.
45914367|NCT02042547|Other|Tissue samples from the right atrium|
45914368|NCT02042547|Other|Blood samples|
45914369|NCT02042560|Other|Blood samples|
45914370|NCT02042560|Other|Spleen samples|
45914371|NCT02042573|Device|rTMS|
45914372|NCT02042573|Drug|SSRI (SEROPLEX ou ZOLOFT)|
45914373|NCT02042573|Other|Genetic samples|
45914374|NCT02042586|Other|Analysis of movement before total hip replacement|
45634662|NCT05375045|Device|dental implantation|an implant is surgically inserted into the maxilla or mandible, and then an abutment is connected to this implant to support the dental prosthesis.
45773911|NCT05776407|Drug|Etoposide|Etoposide is used for lymphodepletion.
45914375|NCT02042586|Other|Analysis of movement after total hip replacement|
45914376|NCT02042599|Drug|Sedation with sevoflurane during 48-hr in ICU|
45914377|NCT02042612|Drug|Sedation with sevoflurane during 48-hr in ICU|
45914378|NCT02042625|Procedure|Nasopharyngeal|
45914379|NCT02042638|Drug|hCG 1500 IU three times a week|
45914380|NCT02042638|Drug|Pregnyl (hCG) ampule 1500 IU/three times a week|
45914381|NCT02042651|Device|Low intensity extracorporeal shockwave therapy|Shockwaves will be applied to the perineum a total of 6 times once per week. The energy level applied will range between 0.25 and 0.40 mJ/mm2 with a frequency of 3 Hz for a total of 3000 shockwaves per treatment session
45914382|NCT02042651|Device|Sham low intensity extracorporeal shockwave therapy|Shockwaves will be applied to the perineum a total of 6 times once per week. The shockwaves will be blocked by a medium on the handheld applicator.
45914383|NCT02042664|Drug|BYETTA treatment|
45914384|NCT02042664|Drug|Metformine|
45914385|NCT02041442|Procedure|Electrical mapping of the urinary bladder|
45914386|NCT02042690|Procedure|Haplo-identical HSCT|Haplo-identical Protocol: myeloablative human leukocyte antigen (HLA) haploidentical stem cell transplantation (haplo-SCT) using pretransplant ATG and granulocyte colony-stimulating factor (G-CSF)-stimulated grafts (ATG+G-CSF) GVHD prevention regimen: CSA/MMF/MTX, CSA 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HRD-HSC and then gradually tapered. Every 12h, 0.5g MMF(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. MTX was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11.
45914387|NCT02042690|Drug|Chemotherapy|Patients receive 6 cycles of consolidation chemotherapy after randomization, including Hyper-CVAD-B regimen-Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen.Maintenance treatment includes MTX 20mg/m2/w，po，6-mercaptopurine 60 mg/m2/d，po，d1-d28，VP（VDS 4mg,d1, Prednisone 1mg/kg d1-7) every one month for 2 years.
45914388|NCT02042703|Device|anterior segment OCT|
45914389|NCT02042716|Other|diagnosis of white matter damage in preterm infants|Added value of supersonic shear imaging in the diagnosis of white matter damage in preterm infants
45773912|NCT05776277|Biological|Iltamiocel|Single external anal sphincter (EAS) injection of 300 x 10^6 cells.
45773913|NCT05776277|Other|Placebo|Placebo control is the vehicle solution used for the study product.
45773914|NCT05776251|Device|taVNS|"Includes the use of Soterix Medical Device, which consists of a handheld smart-phone size device. There are two electrodes (designed for studies in infants) with small patches that the participant places on the external ear (the cymbals conchae and the tragus). The stimulation intensity is personalized for each participant based on perceptual threshold."
45773915|NCT05776225|Procedure|Right heart catheterization (RHC)|RHC to evaluate pulmonary hemodynamics
45773916|NCT05776212|Radiation|18F-fluoride PET|Positron emission tomography using 18F-fluoride as a tracer
45773917|NCT05776186|Drug|Spinal anesthesia with heavy bupivacaine|Spinal anesthesia
45773918|NCT05776173|Genetic|BD211|Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
45773919|NCT05776121|Drug|ZB001 for injection|Dose Cohort1 (3 mg/kg) ZB001 four IV injections
45914390|NCT02042729|Drug|E2022- Current Formula Tape|"Cohort I: E2022 current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 current formula tape administered to skin application site and evaluated for 20 days."
45914391|NCT02042729|Drug|E2022- New Formula Tape|"Cohort I: E2022 new formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 new formula tape administered to skin application site and evaluated for 20 days."
45914392|NCT02042729|Drug|E2022 Matching Placebo- Current Formula Tape|
45914393|NCT02042729|Drug|E2022 Matching Placebo- New Formula Tape|
45914394|NCT02042742|Dietary Supplement|punicalagin and hydroxytyrosol mixture|Antioxidant Supplement (punicalagin and hydroxytyrosol mixture) During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
45914395|NCT02042742|Dietary Supplement|Control supplement (maltodextrin)|During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
45634663|NCT04437251|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is an non-invasive, low-intensity direct current stimulation. The stimulation intensity is very low (0- 2 mA) to only produce tingling sensation on the scalp. From literature, there were no serious adverse effects reported after 20-minute stimulation. The main temporary side effect is skill irritation, itching sensation at the stimulation site during or after stimulation.
45634664|NCT05094635|Diagnostic Test|SARS-CoV-2 IgG II Quant|3ml of blood samples are collected, contained in heparin-free tubes, and centrifuged. Blood serum samples are collected and stored at the -80 Celcius degree. SARS-CoV-2 IgG antibodies in human serum and plasma are detected using chemiluminescent microparticle immunoassay (CMIA) technology on the ARCHITECT I 1000r System. Quality Control procedures will take place once daily, with three levels: one negative control and two positive controls. Sample, SARS-CoV-2 antigen-coated paramagnetic microparticles, and assay diluent are combined and incubated. The SARS-CoV-2 IgG antibodies present in the sample bind to the antigen-coated microparticles. The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the titres of IgG antibodies to SARS-CoV-2 in the sample and the RLU detected by the system optics. Interpretation of Results: < 50.0 AU/mL, Negative, ≥ 50.0 AU/mL, Positive
45634665|NCT03310697|Other|Collection of blood and urine samples|For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand.
45773920|NCT05776121|Drug|ZB001 for injection|Dose Cohort2 (10 mg/kg) ZB001 four IV injections
45448028|NCT02252302|Other|Cycling exercise|Study participants will exercise on a cycle ergometer for 45min. Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention. The exercise test will be set to a resistance of 50% of the maximal wattage that was reached on the graded exercise test on the screening day. The cycling exercise intervention will follow the rest-intervention.
45634666|NCT03310697|Other|Clinical examination|The other clinical data, any other biological samples or additional examinations are done under the opinion of the clinician or the neuropediatrics.
45634667|NCT05281211|Dietary Supplement|Nutrition|6 weeks nutrition implementation in the form of branched chain amino acids and immune-system boosters twice daily for 4 weeks and once daily for 2 weeks
45634668|NCT05281211|Behavioral|Exercise|6 weeks exercise 30 minutes' walk/day or 2000 extra steps daily
45634669|NCT02699749|Drug|TAK-931|TAK-931 oral capsules.
45634670|NCT02409199|Drug|Docetaxel|
45634671|NCT02409199|Drug|apatinib|
45773921|NCT05776121|Drug|ZB001 for injection|Dose Cohort3 (20 mg/kg) ZB001 four IV injections
45773922|NCT05776082|Other|Questionnaire survey and specimen collection|Questionnaire survey, clinical follow-up and specimens collection.
45773923|NCT05776056|Drug|Methylphenidate|Methylphenidate 10mg will be taken twice daily.
45773924|NCT05776056|Drug|Placebo|An inactive pill (placebo) will be taken twice daily.
45773925|NCT05776043|Drug|Empagliflozin 10 MG|once daily for 6 or 9 months
45773926|NCT05776043|Drug|Dapagliflozin 10 MG|once daily for 6 or 9 months
45773927|NCT05776043|Drug|Placebo|once daily for 3 months
45773928|NCT05776030|Device|Single Speed Ergonomic Wheelchair|"Ergonomic wheelchair. The ergonomic wheelchair was developed by the MADE program and has anterior placed hand rims that are connected with a bicycle chain. In Aim 1, Participants will use the ergonomic wheelchair to test 3 different gear ratios.~2:3~1:1~3:2"
45914396|NCT02042755|Device|trifocal intraocular lens|Standard cataract surgery
45773929|NCT05776030|Device|Multi-Speed Ergonomic Wheelchair|The multi-speed ergonomic wheelchair will be developed by the MADE program and will use a two-hand rim design so the participant can change gears by changing hand rims.
45773930|NCT05775978|Behavioral|Más Presente, the UGRComp program|Más Presente, the UGRComp program is based upon the European LifeComp framework (Sala, Punie, Garkov and Cabrera Giraldez 2020) and covers intra and interpersonal, emotional, cognitive and metacognitive aspects. Created at the University of Granada by an interdisciplinary group of experts, it focuses on three core elements (self-regulation, empathy and growth mindset) as they are the pre-requisites for developing all other elements across framework areas. It consists of 8 weekly classes, 2 hours each, together with a day of intensive practice. The program is structured along the following topics: The Underpinnings of Más Presente; Awareness and Concentration: our Body; Managing our Emotional Laberynth; Walking with Directionality, Sense and Conscience; Empathy, Presence and Connection; Empathic Listening and Honest Expression: Non-violent communication; Growth Mindset, Creativity and Divergent Thinking; And Now what? The First Day of the Rest of My Life.
45773931|NCT05775978|Behavioral|The MBSR program|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA. It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction), together with a day of intensive practice. The program is structured along the following topics: The Underpinnings of MBSR; The Perception of Reality; Power in Being Present; Understanding Stress: The Mind-Body Relation; Responding to Stress; Communication and Personal Relations; Daily Life Management; My Personal Plan: What lies ahead."
45914397|NCT02042781|Drug|PG545|PG545 will be administered once weekly, as a one hour IV infusion. Patients will be treated until they exhibit disease progression, withdraw due to poor tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 250 mg anticipated.
45914398|NCT02042807|Drug|Placebo|
45914399|NCT02042807|Drug|MCS®|
46070138|NCT04119297|Other|Routine care|"Routine care was applied to the periorbital area by clinical nurses.~Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara & Gokalan's Scale"
45634672|NCT02405923|Other|HRF|The subject will take the formula for a period of 12 months.
45773932|NCT05775978|Behavioral|Neuro-muscular stimulation|Subjects will receive weekly sessions with a combination of educational sessions and specific physical exercises to enhance physical wellbeing and prevent neuro-degeneration . After spotting the therapeutic targets for each subject, a 4-phase program will be designed for each subject aimed at improving lifestyle habits and general wellbeing.
45773933|NCT05775965|Drug|Rivaroxaban 10mg|Rivaroxaban 10mg daily for 35 days post hip fracture surgery
45634673|NCT02405923|Other|eHF|The subject will take the formula for a period of 12 months.
45773934|NCT05775965|Drug|acetylsalicylic acid (ASA) 81mg Oral Tablet|acetylsalicylic acid (ASA) 81mg daily for 35 days post hip fracture surgery
45773935|NCT05775952|Biological|HRV-39|We will use a US Food and Drug Administration (FDA) approved Good Manufacturing Practices (GMP)-grade HRV-39 for our proposed study. Use of this GMP-grade HRV-39 viral stock ensures compliance with recent regulatory agency requirements which, beginning in 2001, have mandated that HRV preparations used for human inoculation be made under Good Manufacturing Practices (GMP). This proposed clinical study will allow us to address fundamental questions regarding the nature, kinetics and potential mechanisms of upper and lower airway inflammatory responses in subjects with well-controlled mild-moderate asthma and in healthy, non-asthmatic control subjects; a better understanding of these mechanisms may lead to new paradigms in the treatment of virally-induced airway remodeling and asthma exacerbations.
45773936|NCT05775939|Other|Fludeoxyglucose F-18|Given FDG
45773937|NCT05775939|Procedure|Positron Emission Tomography|Undergo PET-CT
45773938|NCT05775939|Procedure|Computed Tomography|Undergo PET-CT
45773939|NCT05775939|Other|Questionnaire Administration|Ancillary studies
45773940|NCT05775926|Other|Education|Nursing Care and Challenges Training for Nurses Caring for Dying Cancer Patients and Their Families was given in 4 modules and 2 days.
45773941|NCT05775913|Device|Tubal Selective Delivery System (TSDS)|A novel tubal selective delivery catheter system for selective delivery of administered agents to the fallopian tubes without entry of any portion of the catheter into the tubes.
45773942|NCT05775900|Drug|Cetuximab|Cetuximab will be given triweekly at a dose from 400mg/m2 to 700mg/m2.
45773943|NCT05775900|Drug|Capecitabine|Capecitabine will be given 2 weeks on/1 week off (1000mg/m2 BID po.)
45773944|NCT05775874|Drug|AZD4547|Initiation dose: 80mg BID,po.
45773945|NCT05775874|Drug|Tislelizumab|Tislelizumab:200mg Q3W
45914400|NCT02042820|Other|In vivo confocal microscopy (IVCM)|IVCM is a sensitive tool for detecting dry eye-associated subclinical inflammation.
45914401|NCT02042846|Device|SportWelding Fiji Anchor|
45773946|NCT05775861|Drug|single shot interscalene brachial plexus block group with dexmedetomidine added to ropivacaine group|"For the single shot group with dexmedetomidine added to ropivacaine group (Group D), after local analgesia with 3 mL of 1% lidocaine, the block will be performed under ultrasound guidance using an in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany).~The perineural solution will be pre-mixed in a 30 mL syringe before the realization of the block.~A total of 150 mg of ropivacaine 0.5% will be prepared, 125 mg (25mL) will be mixed with a dose of 2 mcg/kg IBW of dexmedetomidine (100 mcg/mL dexmedetomidine hydrochloride; Precedex, Hospira Inc, Lake Forest, IL). The total of 25 mL (125 mg or ropivacaine 0.5%) with dexmedetomidine will be injected perineurally at the level of the roots and a 5 mL (25 mg) will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block."
45773947|NCT05775861|Drug|continuous interscalene brachial plexus block|The block will be performed under ultrasound guidance using an in-plane approach with a 17G Tuohy needle (Arrow FlexBlock). A total of 100 mg (20 mL) of ropivacaine 0,5% will be injected perineurally at the level of the roots using the Tuohy needle. The 19 G arrow catheter will then be introduced through the Tuohy needle and we will leave 4 cm of the catheter perineurally. An additional 25 mg (5 mL) of ropivacaine 0,5% will be injected using the catheter to make sure the catheter is in a correct position. An additional 5 mL (25 mg) of ropivacaine 0.5 % will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block using an ultrasound in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany) or with a standard 25G 1 1/2 inches needle. After the surgery, an infusion of ropivacaine 0,2% at a standard rate of 5 mL/h will be started using an elastomeric pump of 300 mL (Baxter Corporation, Mississauga, Ontario).
45914402|NCT02042859|Device|Endoscopic Bipolar RadioFrequency Probe used to remove tumors in bile duct to manage Pancreatic Cancer|
45914403|NCT02042885|Drug|OPB-111001|
45914404|NCT02042898|Other|Restrictive Transfusion Strategy|
45914405|NCT02042898|Other|Liberal transfusion strategy|
45914406|NCT02042937|Other|Exercise|Exercise to improve gluteus maximus recruitment
45448029|NCT02252302|Drug|Salbutamol inhalation|Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.
45914407|NCT02042976|Behavioral|Mindfulness-based cognitive therapy|
45914408|NCT02042976|Behavioral|Pulmonary rehabilitation|
45448030|NCT02252302|Drug|Placebo inhalation|Study participants will inhale a placebo (placebo for salbutamol) prior to entering the air pollution chamber
45914409|NCT02043002|Procedure|18F-FDG-PET scan|
45914410|NCT02043028|Device|Chest compression with a step stool|Participants compress the chest of a manikin with a standing posture using a step stool during 5 minutes
45914411|NCT02043028|Device|Chest compression with a kneeling stool|Participants compress the chest of a manikin with kneeling posture using a kneeling stool during 5 minutes
45935478|NCT00125632|Procedure|Eccentric Viewing Training for Reading|
45448031|NCT02252302|Other|Diesel Exhaust Exposure|Participants will be exposed to PM2.5 of 300 μg/m3
45448032|NCT02252302|Other|Filtered air|Participants will be breathing filtered air
45634674|NCT02409121|Behavioral|Education information system|Participants will receive a mobile tablet as an educational intervention during the patient's inpatient hospitalization
45634675|NCT02405611|Behavioral|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
45773948|NCT05775835|Other|Whole body vibration and strengthening exercise|Prior to commencing training, all subjects will undergo a pre-screening that includes a thorough history and physical examination to monitor compliance with the inclusion criteria. Evaluation parameters will be evaluated before and after 6 weeks of exercise. Training sessions will be held 3 days a week for 6 weeks, with a minimum of 48 hours between training sessions. All exercise groups include a warm-up period and a cool-down period (stretching exercises). Stretching exercises for the hamstring, gastrocnemius, soleus, and quadriceps muscles will be performed for 15-30 seconds and 3-5 repetitions. The total average application time (including warm-up and cool-down exercises), consisting of exercise and rest periods, was planned as 45-60 minutes for the WBV, SE, and WBV+SE groups.
45773949|NCT05775835|Other|Whole body vibration exercise|The application will be carried out with a whole body vibration device that gives 35 Hz constant vertical vibration. The exercises will be performed on the vibration platform in a standing position and with vibration. 5 static squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squat on the fingertip (120 degrees knee extension), right and left lunge positions, which will be accepted as 180 degrees full knee extension exercise protocol. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For static exercises, the duration will be 3 sets of 30-60 seconds in each practice position. There will be 30-60 second rest breaks between sets.
45773950|NCT05775835|Other|Strengthening exercise|"The exercises will be performed on the vibration platform but without vibration. Patients will be asked to hold a body bar corresponding to 10% of their body weight during exercises. 5 dynamics including squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squats on the toe tip (120 degrees knee extension), right and left lunge exercises, which will be accepted as 180 degrees full knee extension will perform an exercise protocol consisting of exercise. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For dynamic exercise, the duration will be 3 sets of 10 repetitions. Dynamic exercises will be performed with slow and controlled movements, consisting of 3 seconds of eccentric and 2 seconds of concentric phases."
45773951|NCT05775822|Diagnostic Test|CT scan and blood sample collection|"Each enrolled patient performs:~preventive clinical cardiology assessment visit, addressed to individualized risk profile assessment and addressed to chest CT scan.~a blood sampling (1 citrate tube of 5 ml) will be done the same day just the chest CT scan and analyzed locally also for future research of biomarker discovery (single sample, for those patients who agree in ICF)~CT scan"
45773952|NCT05775783|Procedure|Transvenous lead extraction|Each TLE procedure was started using the single traction method. If this attempt was not sufficient to extract the lead, then the following methods were used: mechanical extraction sheaths (Byrd, Cook Vascular Inc., Leechburg, PA, USA), locking and nonlocking stylets (Liberator® Beacon® Tip Locking Stylet, Cook® Medical, Leechburg, PA, USA), powered extraction sheaths (Evolution or Evolution II Mechanical Dilator Sheath, Cook® Medical, Leechburg, PA, USA). A side retrieval snare loop (Needle's Eye Snare, Cook® Medical, Leechburg, PA, USA) was used for the femoral approach when the subclavian-only approach was insufficient.
45773953|NCT05775770|Drug|Insulin|insulin therapy
45773954|NCT05775757|Radiation|Hypofractionated radiation therapy|Both 3-week and 1-week hypofractioanted radiation therapy are allowed. (simultaneous or sequential tumor bed boost is allowed.) A 3-week regimen includes 42.4 Gy in 16 fractions. A 1-week regimen includes 26 Gy in 5 fractions or 28.5 Gy in 3 fractions, 30 Gy in 5 fractions.
45773955|NCT05775731|Diagnostic Test|Tests for markers of inflammation and activated hemostasis|Volunteers who do not have exclusion criteria, are invited to complete the three questionnaires and to choose a date for blood drawing based on whether they are shift workers or not. Blood is immediately processed for platelet markers, and stored for inflammation and coagulation markers
45773956|NCT05775705|Drug|L-DEP and PD-1 antibody|Doxorubicin (doxorubicin hydrochloride liposome injection) 35 mg/m2 day 1; etoposide 75 mg/m2 day1; methylprednisolone 1.5mg/kg days 1 to 3, 0.25mg/kg day 4 to 14; PEG-aspargase 6000iu/m2 day2, day4; PD-1 antibody injection 200mg day 5.
45634676|NCT02405611|Behavioral|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
45448033|NCT02131714|Behavioral|counseling and exercises|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character. They also had to perform once daily application of hot packs on both sides of the face for 20 minutes and after that they must perform active free therapeutic exercise of mouth opening for 10 times
45448034|NCT02131714|Behavioral|lifestyle counseling|
45448035|NCT02135926|Device|Thrombectomy|Stent retriever are intended to restore blood flow in patients with acute ischemic stroke secondary to intracranial occlusive vessel disease by providing temporary bypass across the occlusion and/or by the non-surgical removal of emboli and thrombi. They may be used with aspiration and with the injection or infusion of contrast media and/or other fluids. For subjects enrolled in this protocol who are randomly assigned to undergo the thrombectomy procedure, the device will be used according to the Instructions-for-Use (IFU) that is packaged with the device.
45448036|NCT02135926|Other|Best medical care|Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.).
45634677|NCT02405611|Behavioral|primary eduction|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
45773957|NCT05775692|Drug|fluconazole|According to the models of population pharmacokinetics,the investigators and want to correlate use of fluconazole with treatment effectiveness and safety in newborns
45634678|NCT03169465|Procedure|open approach|open excision of the bursa and deformity then debridement of Achilles tendon
45634679|NCT03169465|Procedure|endoscopic approach|excision of the bursa and deformity then debridement of Achilles tendon through endoscopy
45634680|NCT03169543|Behavioral|Sleep deprivation|36-hours total sleep deprivation
45773958|NCT05775666|Biological|UCLM802 Cell Injection|Anti-mesothelin CAR-T cells are autologous genetically modified T cells. A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by UCLM802 cell injection.
45773959|NCT05775653|Other|ADAPT program|The ADAPT program is a structured and individualized group-based program, in which two occupational therapists teach groups of people the skills of problem-solving more efficiently as means to overcome ADL task performance problems. The ADAPT program 3.0 includes 10 two-hour sessions and is followed by two booster sessions to support sustainable gains.
45773960|NCT05775653|Other|UOT|UOT is delivered by one occupational therapist. Sessions are individualised and focus on improving ADL ability e.g. by practicing the performance of ADL task. UOT typiccally includes 7 one-to-one sessions of 60 minutes, delivered over a 10-week period in the clients´ homes. The dose is however not fixed but based on the occupational therapists´ clinical judgement.
45773961|NCT05775640|Behavioral|serious game|The forms were applied to the children in the experimental group and the parents of the children on the 0th day of hospitalization. After the forms were applied, a serious game developed by the researchers was played. Children were given access to the game by giving a game link. The game can be played on digital platforms such as computers, tablets, etc. For children who do not have an electronic device, the game was downloaded to the computer in the hospital and the children were allowed to play. On the third day of hospitalization, the children and their parents were surveyed again and the Game Evaluation Questionnaire was filled. Access to the game will be closed at the end of the study.
45773962|NCT05775627|Behavioral|Chronic Sleep Restriction|Participants are randomized into either a group (n=10) that is sleep restricted or the control (n=10) group who experiences non-restricted sleeping conditions. Both arms are fed 3 meals and have access to ad libitum food between meals. Both groups will also undergo up to 3 mixed-meal tolerance tests to measure glucose tolerance.
45773963|NCT05775614|Device|UroTainer®|Clinical effect of preventive treatment - catheter flushing with UroTainer®
45773964|NCT05775614|Device|Saline|Clinical effect of preventive treatment - catheter flushing with saline solution
45773965|NCT05775588|Procedure|Lung volume reduction surgery with endobronchial valve implantation|the patient would undergo Lung volume reduction surgery with endobronchial valve implantation
45773966|NCT05775575|Drug|TQB3909 tablets|TQB3909 is an inhibitor targeting BCL-2 protein
45773967|NCT05775562|Diagnostic Test|Pre and post dive examinations|"Performing pre-dive examinations:~- EFR by plethysmography cabin~Realization of the examinations the day of the dive:~Portable Spirometry~Pulmonary ultrasound~Cardiac ultrasound~Measurement of circulating bubbles~ECG~Venous blood sampling (biological collection)~Water balance (Δweight/water intake)~EFR by plethysmography cabin~Weight measurement~Realization of the examinations the day after the dive:~Venous blood sample (biological collection)~Portable Spirometry~Pulmonary ultrasound~Cardiac ultrasound~Weight measurement"
45634681|NCT03115489|Drug|Traditional Treatment (Group T)|Patients will receive traditional drug infusions
45634682|NCT03115489|Drug|Ketamine Infusion (Group K)|Patients will receive loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached
45634683|NCT02405533|Dietary Supplement|AHCC 3 grams once a day|AHCC supplementation x 6 months with Placebo x 6 months
45634684|NCT02405533|Other|Placebo|Placebo supplementation x 12 months
45634685|NCT02409043|Other|Blood draw|Blood drawn for comparison with other groups
45634686|NCT02409043|Other|Stroke blood draw|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, blood pressure, MRI infarct volumes, and hospital length of stay taken from the medical records. 3 month modified Rankin scale score collected by phone interview.
45773968|NCT05775549|Other|None (Observational Study)|Not Applicable since observational study
45773969|NCT05775536|Drug|Aspirin 500Mg Tab|Dose: 1 tablet per day starting from visit 2 until visit 3, intake in the evening
45634687|NCT02699593|Device|Test Contact Lens|
45634688|NCT02699593|Device|Control Contact Lens|
45773970|NCT05775536|Dietary Supplement|Dr. Böhm® Omega 3 complex 870 mg|Dose: 2 tablets per day starting from visit 2 until visit 3, intake in the evening
45773971|NCT05775497|Behavioral|Behavioral weight loss intervention (Online; Rx Weight Loss)|Rx Weight Loss is a fully automated online behavioral obesity treatment that includes 3 core components: weekly online video lessons, submission of self-monitored weight, calorie intake, and activity data, and personalized automated feedback. Participants set goals for weight loss (e.g., 10%), daily calorie intake, and activity (e.g., 200 mins/week of moderate-to-vigorous intensity physical activity). Online lessons discuss healthy eating, physical activity, and behavioral skills (e.g., stimulus control, goal-setting, problem solving). To maintain participant engagement, lessons are interactive, use audio and video, and include experiential learning opportunities. Based on their progress, participants receive automated feedback that provides encouragement, praise for meeting goals, and constructive feedback. To enhance adherence, participants who do not view the weekly lesson or enter monitoring data receive e-mail reminders to re-engage.
45914412|NCT02043041|Other|Number of DBS Spots|The number of DBS spots on the card constitutes the experimental condition.
45634689|NCT02408731|Drug|PMZ-2010 (Centhaquin)|As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.
45448037|NCT02131792|Procedure|Slanted recession of the lateral rectus muscle|All patients who had intermittent exotropia with convergence weakness was enrolled to the slanted lateral rectus muscle recession group.
45935479|NCT00043394|Drug|0.04 mg/kg CpG 7909|0.04 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
45634690|NCT03169309|Device|Brain Entrainment Technology|Brain Entrainment Technology (BET), also known as Binaural Beat Technology (BBT), is a sound technology where two slightly different tones are present to each ear and the brain produces a third tone. This third tone impacts the reticular activating system which alters the action potentials of the thalamus and cerebral cortex in turn changing the brain wave frequency to alter the state of consciousness of the listener.
45773972|NCT05775497|Behavioral|Minority stress intervention|The Minority Stress Intervention will teach cognitive and behavioral strategies for coping with minority stress with a focus on how minority stress impacts weight loss behaviors. The treatment will primarily address stressors due to sexuality and weight but will also cover how minority stress intersects with other facets of identity. The intervention, while innovative, is adapted from evidence-based treatments using cognitive behavioral therapy (CBT) to address minority stress.Lessons will provide psychoeducation on minority stress related to sexuality, gender, and weight, how it intersects with other aspects of identity, and how it can interfere with weight loss (e.g., unhealthy eating, avoiding exercise and healthcare, reduced motivation, disengaging from the program).The treatment will be delivered in 12 8-10-min lessons/week (a duration comparable to previous treatments) viewed directly after Rx Weight Loss lessons in Wks 1-12.
45773973|NCT05775497|Behavioral|Social support intervention|The Social Support Intervention will provide sexual minority women with online opportunities to give and receive real-time social support for weight loss efforts. The treatment is based on Social Learning Theory and evidence-based online social support programs used in behavioral weight loss. The intervention will include one video lesson outlining the value of social support for weight loss and well-being, strategies for eliciting support, and an orientation to using the online platform (hosted within Rx Weight Loss). The platform will feature a private forum where participants can post to provide support and discuss their weight loss goals, challenges, and successes. To foster engagement, discussion topics will be automated to post 4 times/week and those who do not participate will be reminded via e-mail to engage (1x/month).
45634691|NCT03168997|Drug|Memantine Hydrochloride|Memantine Hydrochloride treatment according to clinical routine treatment
45773974|NCT05775497|Behavioral|Negative body image intervention|The Negative Body Image Intervention will teach CBT skills for improving negative body image and reducing its impact on weight loss behaviors. The treatment is derived from evidence-based CBT interventions targeting body image for women with obesity during behavioral weight loss and will be adapted to reflect the unique body image ideals and concerns of sexual minority women. Lessons will teach CBT strategies for coping with negative body image and reducing interference with weight loss efforts. The intervention will be delivered in 12 weekly 8-10-minute lessons, a treatment duration comparable to previous treatments and will be viewed immediately following Rx Weight Loss lessons during Weeks 1-12.
45773975|NCT05775458|Diagnostic Test|Blood, CSF and tumor samples|Blood, CSF and brain tissue sampling of Glu and Glu regulatory proteins.
45773976|NCT05775445|Procedure|Blood draw|2 6ml blood tubes will be collected from patient
45773977|NCT05775419|Combination Product|Consolidation chemotherapy (4 courses)|Consolidation chemotherapy (4 courses): After the concurrent chemoradiotherapy is over, after 2-3 weeks of rest, the patients in the consolidation chemotherapy group will be given 4 cycles of consolidation chemotherapy, and the chemotherapy regimen is the same as the concurrent chemotherapy regimen;
45773978|NCT05775419|Combination Product|Concurrent chemotherapy (2 courses)|Lipusu (T) + Cisplatin (DDP) program: T 135mg/m2 ivgtt, d1, 3week*2cycles; DDP 75mg/m2 ivgtt, d2, 3week*2cycles;
46070139|NCT04119297|Other|Cold gel pack|"Cold application was applied to the periorbital area for 20 minutes per hour beginning 3rd hour following craniotomy, except from 10pm-7 am, and for three days using gel pack cooled to -14ºC.~Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara & Gokalan's Scale"
45773979|NCT05775393|Procedure|Serratus anterior plane block for MRM|"They will randomly assigned to two groups of 30 patients each, at 1:1 allocation ratio using computer-generated random numbers concealed in sealed opaque envelopes.~Group (A):~Patients will receive ultrasound-guided serratus anterior block using 30ml of (bupivacaine 0 .25 % and dexamethasone 4 mg).~Group (B):~Patients will receive ultrasound-guided serratus anterior block using 30ml of (bupivacaine 0.25% and dexamethasone 4mg with ketamine 50 mg).~All the medications were prepared by an anesthesiologist not participating in the study."
45773980|NCT05775354|Diagnostic Test|Early diagnosis strategy|RED-CVD early diagnosis questionnaire, physical examination, laboratory testing, electrocardiography, echocardiography
45773981|NCT05775341|Other|No Intervention|This is purely an observational study.
45935480|NCT00043394|Drug|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
45935481|NCT00043394|Drug|0.08 mg/kg CpG 7909|0.08 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
45935482|NCT00043394|Drug|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
45935483|NCT00043394|Drug|0.12 mg/kg CpG 7909|0.12 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
45448038|NCT02136082|Behavioral|Asha Support + Training|
45448039|NCT02136082|Behavioral|Asha Support + Food|
45448040|NCT02136082|Behavioral|Asha Support + Training + Food|
45448041|NCT02136082|Behavioral|Asha Support Only|
45448042|NCT02129140|Device|Hernia graft/mesh|observational group
45448043|NCT02131870|Dietary Supplement|L plantarum DSM 9843 or placebo|
45634692|NCT02405767|Other|Foot ulcer impedance|lmpedence measured using ECG electrodes placed at the periphery of the wound (when the wound dressing is changed as part of standard care).
45634693|NCT02408809|Behavioral|General Smoking Cessation Discussion|This group receives the 5 A's of smoking cessation counseling incorporating how cigarette smoking negatively impacts general health (cancer, MI). 10 minutes in length.
45634694|NCT02408809|Behavioral|Orthopaedic Related Smoking Cessation Discussion|The participants in this group receive a discussion including the 5 A's of smoking cessation counseling incorporating an orthopaedic related smoking cessation discussion about the effects of smoking cigarettes on the musculoskeletal system. 10 minutes in length.
45634695|NCT02408575|Device|Notched filtering (verum)|Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3 The Hearing aid with notched amplification filters frequences in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.
45634696|NCT02408575|Device|No filtering (placebo)|"Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3~No notched filtering"
45634697|NCT03171727|Drug|low molecular weight heparin|After TIPS procedure was performed, low molecular weight heparin was given for three days.
45634698|NCT02401165|Other|Blood test|blood test
45914413|NCT02043054|Drug|Liraglutide|"Liraglutide (Victoza®, Novo Nordisk) is a stable analogue of the natural hormone glucagon-like peptide-1 (GLP-1). Liraglutide is licensed for use within the United Kingdom and recommended by NICE in combination with metformin, and/or sulphonylurea and/or thiazolidinedione if the following conditions are satisfied.~BMI ≥ 35 kg/m2 in those of European descent (with appropriate adjustment for other ethnic groups) and specific psychological or medical problems associated with high body weight, or~BMI < 35 kg/m2, and therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities."
46070140|NCT04119297|Drug|Heparinoids Topical Cream|"Heparinoid cream was applied to the periorbital area once at 3rd and 9th hours following craniotomy, and 4 times daily in the following 3 days.~Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara & Gokalan's Scale"
45634699|NCT02401087|Procedure|Anaesthesiological procedure|
45634700|NCT02400931|Procedure|mask ventilation|In mask ventilation group, rocuronium of 0.6 mg/kg will be administered after the loss of consciousness. Mask ventilation wil be performed until there is no response on the train-of-four stimulus. No mask ventilation - In no mask ventilation group, rocuronium of 1.2 mg/kg will be administered after the loss of consciousness. Tracheal intubation will be performed after confirmation of no response on the train-of-four stimulus. The mask ventilation will not be performed before the tracheal intubation.
46070141|NCT00860067|Biological|Q/LAIV (MEDI3250)|0.2 mL dose at Day 0
46070142|NCT00860067|Biological|FluMist/B/Yamagata|0.2 mL dose at Day 0
46070143|NCT00860067|Biological|FluMist/B/Victoria|0.2 mL dose at Day 0
46070144|NCT00699387|Drug|Benznidazole|benznidazole (RADANIL®, Roche) 5-8 mg/kg/d bid PO for 60 days
45634701|NCT02400931|Procedure|no mask ventilation|
45634702|NCT02400931|Drug|Rocuronium|
45634703|NCT02408653|Device|EEG|
45634704|NCT03169387|Behavioral|Virtual Reality|For the VRG training, Microsoft's Xbox 360® will be used with Kinect™, which features an infrared camera sensor that recognizes user movements without a controller. The games used will be YourShape™(Fitness Evolved) and Dance Central 3™, which will be played for 25 minutes each; the former will be associated with the use of Velcro weights on the ankles and dumbbells in the hands to provide resistance.
45634705|NCT03169387|Behavioral|Conventional Training|treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training, which will be carried out in 3 sets of 10 repetitions, with a recovery interval of 1 minute between sets.
45634706|NCT03116191|Drug|SK-1404|4 weeks of repeated administration of SK-1404 to the patients of nocturia
45634707|NCT03116191|Drug|Placebo|4 weeks of repeated administration of Placebo to the patients of nocturia
45634708|NCT03116503|Other|diagnosis of bipolar disorder and comorbid depression|Evaluation of the number of diagnosis of bipolar disorder and comorbid depression
45653027|NCT05182125|Biological|GLA-SE (glucopyranosyl lipid A - stable emulsion; [labeled as AP 10-201])|The GLA-SE adjuvant will be provided as vials containing 20 mcg/mL GLA in a 4% oil-in-water emulsion. Each sterile, single use vial contains 0.4 mL of product. Product appears as a milky-white liquid. GLA-SE must be stored at 2° to 8°C and must not be frozen. The study product is described in further detail within the IB.
45653028|NCT05182125|Biological|Placebo|Placebo will be Sodium Chloride for Injection, 0.9%, will be used as the placebo. It must be stored as recommended by the manufacturer.
45653029|NCT05730361|Biological|ScTIL injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and superamplification factor, and cell number are amplified. The obtained ScTIL is used for one-time intravenous infusion."
45653030|NCT05730361|Biological|ScTIL injection and B lymphocytes adjuvant|B lymphocyte are also isolated from PBMCs. If the percentage of subject's B lymphocyte in total lymphocytes is > 5%, the autologous B lymphocyte adjuvant will be prepared. If this percentage is ≤ 5%, PBMCs will be collected from haploidentical donor of the subject via apheresis, and B lymphocyte will be isolated for preparation of allogeneic B lymphocyte adjuvant.
45653031|NCT04789187|Procedure|High-Intensity-Interval-Training|Defined exercise program up to four times per week including high-intensity-interval-training for one year of active study intervention.
45653032|NCT04789187|Procedure|General Physical Activity Recommendations|Patients will be given general physical activity recommendations during chemotherapy.
45653033|NCT05550493|Behavioral|Cognitive Behavioral Therapy|The cognitive behavioral therapy program consisted of eight interactive sessions, each requiring approximately 15 minutes to complete. Each ICBT session includes interactive multimedia modules (videos, pictures, and texts), the contents of which were based on the community reinforcement approach. The ICBT sessions covered the following topics: (1) introduction to digital therapeutics and CBT, (2) recognizing the triggers of craving, (3) coping with craving, (4) refusing skills/assertiveness, (5) problem-solving skills, (6) changing thoughts about drugs, (7) seemingly irrelevant decisions, and (8) HIV risks and prevention.
45653034|NCT05550493|Behavioral|Counseling|Counseling provided by social workers and psychotherapists on topics including work, family, stress management, and drug craving suppression.
45773982|NCT05775315|Other|Action Observation Therapy|"Exercises of AO protocol MOVEMENT TOTAL VIDEO TIME PATIENT TIME Upright the pelvis 1 minute 5 minutes Move weight forward 1 minute 5 minutes Move weight to the left and right 1 minute 5 minutes Rotate right and left 1 minute 5 minutes Upright the pelvis in sitting position 1 minute 5 minutes Move weight forward from a sitting position 1 minute 5 minutes Stand up from a sitting position 1 minute 5 minutes Move weight right and left 1 minute 5 minutes Forward weight shift with right foot and left foot 1 minute 5 minutes Walking sideways to left 1 minute 5 minutes Walking sideways to right 1 minute 5 minutes~Rest time between watching and performing each video will be 1 minute. the exercises will be done 3 times a week."
45634709|NCT03171649|Device|RETRAINER-S1|"It consists of the execution of different exercises with the affected arm supported by the RETRAINER-S1 device. The subject is actively involved in the exercises and the system provides two types of support: weight relief and FES. The following exercises can be performed:~anterior reaching (in a plane or in the space)~lateral elevation of the arm~hand to mouth movements with or without an object in the hand~moving objects on a plane or in the space. A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise."
45773983|NCT05775315|Other|Action Observation Therapy along with visual feedback|"Exercises of AO protocol in front of a mirror MOVEMENT TOTAL VIDEO TIME PATIENT TIME Upright the pelvis 1 minute 5 minutes Move weight forward 1 minute 5 minutes Move weight to the left and right 1 minute 5 minutes Rotate right and left 1 minute 5 minutes Upright the pelvis in sitting position 1 minute 5 minutes Move weight forward from a sitting position 1 minute 5 minutes Stand up from a sitting position 1 minute 5 minutes Move weight right and left 1 minute 5 minutes Forward weight shift with right foot and left foot 1 minute 5 minutes Walking sideways to left 1 minute 5 minutes Walking sideways to right 1 minute 5 minutes~Rest time between watching and performing each video will be 1 minute. the exercises will be done 3 times a week."
45773984|NCT05775302|Other|IASTM of Gastrocnemius + Conventional therapy|The SWEEP technique will be performed downwards from the popliteal region to the Achilles tendon for 60 seconds, 30 times 12 sessions over a time frame of 4 weeks at a frequency of 3 sessions per week.
45773985|NCT05775302|Other|IASTM of AchillesTendon + Conventional Therapy|Participants will receive a maximum of 60 seconds<30 times 12 sessions over a time frame of 4 weeks at a frequency of 3 sessions per week.
45773986|NCT05775276|Procedure|Proline mesh in hernioplasty|Hernioplasty using proline mesh then follow up for incidence of infection
45773987|NCT05775211|Biological|Intrauterine administration of PBMC immunomodulated with IFNt|Standard density gradient centrifugation will be performed to obtain autologous PBMC from patients' peripheral blood (9 ml). Isolated cells will be suspended in RPMI 1640 supplemented with 10% HSA (human serum albumin) and incubated in the presence of 500 IU/ml IFNt for 24 h at 37˚C. The cultured cell suspension will be introduced into the uterine cavity via a catheter.
45773988|NCT05775198|Biological|PBMC immunomodulated with IFNt|Autologous peripheral blood mononuclear cells (PBMC) isolated using a standard protocol will be cultured in the presence of interferon tau (IFNt) for 24 hours at 37 ˚C and administered in the uterine cavity of patients 1 day prior to embryo transfer.
45773989|NCT05775185|Radiation|Orbital radiotherapy|Low dose fractionated orbital radiotherapy, total dose 20 Gy in 2-week period.
45914414|NCT02043054|Drug|Sitagliptin|Sitagliptin (Januvia®, Merck & Co) is an enzyme-inhibiting drug used to inhibit the natural enzyme dipeptidyl peptidase-4 (DPP-4). It is an oral antihyperglycaemic agent used in the treatment of T2DM. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea) and is recommended by NICE as a second line therapy.
45773990|NCT05775172|Procedure|Sleeve gastrectomy|laparoscopic sleeve gastrectomy was done under general anesthesia by the same surgeon in the SBAHC. Routine preoperative, and postoperative care (including early post-operative dietary management) were done. Baseline assessment was taken within the last week before the surgery during the preoperative preparation and the final assessment was recorded 6 months after the surgery date.
45914415|NCT02043067|Other|Comprehensive TB screening|All enrollees will receive a comprehensive TB screening regardless of symptom presentation.
45914416|NCT02043080|Other|Xpert MTB/RIF Tuberculosis diagnostic tool|This is s new diagnostic tool that has been approved by WHO for the diagnosis of TB in HIV-infected patients in resource limited settings
45448044|NCT03550768|Other|MDP|evaluate the anatomy of each major duodenal papilla before selective cannulation during ERCP
45773991|NCT05775172|Dietary Supplement|Lifestyle intervention|balanced 500 to 1000-calorie-deficit diet, personalized physical activity plan, and customized behavioral modification
45773992|NCT05775172|Other|Control|No interventions were applied
45773993|NCT05775159|Drug|MEDI5752|CTLA-4/Anti-PD-1 Bispecific Antibody
45773994|NCT05775159|Drug|Bevacizumab|15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
45448045|NCT01367236|Drug|standard care|"atazanavir 300 mg daily~ritonavir 100 mg daily~tenofovir 245 mg daily*~emtricitabine 200 mg daily*"
45448046|NCT01367236|Drug|novel treatment|"darunavir 800 mg daily~ritonavir 100 mg daily~lamivudine 300 mg daily** and abacavir 600mgs daily**~maraviroc 150 mg once daily"
45773995|NCT05775159|Drug|Lenvatinib|Daily use per oral (8 mg capsules/day for participants < 60 kg or 12 mg/day for participants ≥ 60 kg) of 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
45914417|NCT02043093|Behavioral|Sources of Strength|"Sources of Strength (http://www.sourcesofstrength.com/) has three phases:~Introduction to school and community partners. Staff advisors for the program are identified and trained.~A standard process is used for nominating student peer leaders, who are trained through a 4-hour interactive workshop. A major focus is on increasing knowledge of 'sources of strength' and skills for increasing use of those resources for themselves and other students.~Peer Leaders plan and conduct messaging with Adult Advisor mentoring. A school-wide messaging phase involves presentations; media campaigns through posters, public service announcements, videos."
45914418|NCT02043106|Other|plantar vibration|
45914419|NCT02043119|Behavioral|Breastfeeding Clinic|
45914420|NCT02043171|Dietary Supplement|Placebo|A Placebo comparator
45914421|NCT02043171|Drug|HMB plus Vitamin D|Active comparator of HMB (3 g/d) plus Vitamin D (2,000 IU/d)
45773996|NCT05775146|Radiation|stereotactic body radiation treatment (SBRT)|SBRT uses 3D imaging to target high doses of radiation to the affected area. There is very little damage to the surrounding healthy tissue. SBRT works by damaging the DNA of the targeted cells. Then, the affected cells can't reproduce, which causes tumors to shrink.
45914422|NCT02043171|Behavioral|Non-Exercise|This group will not participate in 3 times per week strength training
45448047|NCT02129218|Other|questionnaire administration|Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.
45634710|NCT03171649|Other|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the petient's specific needs:~Upper limb passive motion~Arm Cycle ergometer with or without FES~Neuro Muscular Electrical Stimulation~Upper limb exercises using augmented or virtual reality environment~Occupational therapy exercises~Constraint induced movement therapy~Upper limb active movement (reaching, grasping, elevation, spatial orientation)~Repetitive task training~Mirror therapy~Writing training~Chemodenervation Therapy"
45773997|NCT05775133|Device|ICG|"Patient will receive a standard dose of indocyanine green (ICG) 45 minutes prior to surgery. ActivSight will be used during laparoscopic cholecystectomy - the surgeon will perform the procedure in their standard fashion.~Video data will be analyzed in real-time by Activ Surgical's ActivInsight surgical artificial intelligence platform to identify anatomic structures and surgical phase. The surgeon will be blinded to this information, and will see the standard screens and information they do when performing the procedure in a non-study setting."
45773998|NCT05775120|Diagnostic Test|OLGA and H.pylori culture|Upper endoscopy will be performed by endoscopists using modern endoscopes (Fujinon EG-590WR, Olimpus GIF-H190 and others) while patient is sedated. Using sterile biopsy forceps, biopsy specimens will be taken from five areas of the stomach (two biopsy specimens - greater and lesser curvature of the antrum of the stomach; two biopsy specimens - lesser and greater curvature (or anterior and posterior wall) of the body of the stomach and one from the corner of the stomach) for pathology assessment. Pathology assessment of the gastritis stage and degree will be conducted according to the OLGA system developed by the international group of gastroenterologists and pathologists (Atrophy Club).
45634711|NCT03116269|Drug|Cilostazol 100mg|
45773999|NCT05775094|Drug|Romosozumab|Romosozumab will be administered 210 mg SC as two 105 mg prefilled syringes once every 4 weeks x 12 months. No dose adjustments for romosozumab will be permitted. All efforts will be made to administer romosozumab within the defined study visit windows (+/- 14 days).
45634712|NCT03116269|Drug|Aspirin|
45774000|NCT00004126|Drug|oxaliplatin|
45774001|NCT00004126|Drug|paclitaxel|
45774002|NCT05775055|Other|Composition of oral rehydration solutions|Investigate the efficacy of an amino acid-based oral rehydration solution compared to two current commercially available glucose-based oral rehydration solutions.
45774003|NCT05775042|Biological|CM338|CM338 injection
45774004|NCT05774977|Other|Aviation Noise Only (AN)|The aviation noise (AN) night will expose subjects to a pre-programmed recording of aviation noise during sleep from 2300-0700.
45774005|NCT05774977|Other|Pink noise, 50 dBA only (BN50)|The BN50 night will consist of exposure to continuous pink noise throughout the sleep period at a level of 50 A-weighted decibels (dBA).
45774006|NCT05774977|Other|Aviation noise plus earplugs (AN+EP)|The AN + EP night will consist of the aviation noise (AN) exposure with the addition of wearing earplugs overnight.
45774007|NCT05774977|Other|Aviation noise plus white noise 40 dBA (AN+BN40)|The AN + BN40 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 40 dBA.
45774008|NCT05774977|Other|Aviation noise plus white noise 50 dBA (AN+BN50)|The AN + BN50 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 50 dBA.
45774009|NCT05774977|Other|Control Night (CTRL)|Control night (CTRL) without noise exposure and without earplugs.
45774010|NCT05774964|Drug|Oxaliplatin|Oxaliplatin via intravenous drip on d1 at a dose of 130 mg/m2 × patient 's body surface area
45774011|NCT05774964|Drug|S1|Orally on d2-d15 at 20 mg three times daily
45774012|NCT05774964|Drug|Cetuximab|Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.
45634713|NCT03168763|Behavioral|Video|Participants shown Video 1A or 1B, then shown Video 2A or 2B.
45774013|NCT05774964|Drug|Metronidazole|Metronidazole 0.4g/time, qd
45774014|NCT05774964|Drug|Vitamin A|Vitamin A 5,000 units/time, qd
45774015|NCT05774964|Drug|Folic acid|Folic acid 5 mg/time, qd
45774016|NCT05774938|Procedure|Standard Endovascular aneurysm repair (sEVAR)|Standard EVAR treatment with Medtronic Endurant IIs (Medtronic, Inc. - Minneapolis, Minnesota), Gore Excluder AAA (W. L. Gore & Associates, Inc. - Newark, Delaware), Gore Excluder Conformable AAA (W. L. Gore & Associates, Inc. - Newark, Delaware), Cook Zenith Flex (Cook Medical, Inc. - Bloomington, Indiana).
45774017|NCT05774938|Procedure|Complex Endovascular Aneurysm Repair (cEVAR)|Complex EVAR treatment with custom made devices (CMD's) from Cook Medical (Cook Medical, Inc. - Bloomington, Indiana) including fenestrated or branched devices or off-the-shelf T-branch device (Cook Medical, Inc. - Bloomington, Indiana).
45774018|NCT05774912|Other|Ultrasound evaluation|Fetal ultrasound evaluation will be collected longitudinally during the prenatal period from the weeks 14 every 4-5 weeks, for a total of maximum 6 ultrasound scans
45914423|NCT02043171|Behavioral|Exercise|This group will participate in a supervised 3 times per week strength training program
45914424|NCT02043184|Behavioral|Interactive Voice Response (IVR) Reminders|Reminders tailored to the oral cancer medication(s) the patients are receiving delivered by interactive voice response system with referral to a self-management guide when symptoms exceed thresholds.
45448048|NCT02129218|Other|laboratory biomarker analysis|Correlative studies
45634714|NCT03168763|Behavioral|Questionnaires|Questionnaires completed at baseline, after each video viewing, and at completion.
45634715|NCT03174223|Drug|deep neuromuscular block|a continuous dosing of rocuronium is used to achieve neuromuscular block of 1-2 twitches post tetanic count
45634716|NCT03174067|Drug|Buprenorphine|The participant receives buprenorphine
45634717|NCT03174067|Drug|Clonidine|The participant receives clonidine
45774019|NCT05774873|Drug|IBI334|Subjects will receive IBI334 once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
45774020|NCT05774821|Procedure|Tricuspid valve surgery|Surgical repair or valve prosthesis implant to treath the regurgitation of the tricuspid valve
45774021|NCT05774808|Procedure|Aortic valve replacement|An aortic valve prosthesis is surgically implanted to treat AR
45774022|NCT05774808|Procedure|Mitral valve annuloplasty|Surgical repair of the mitral valve in which a prosthetic ring is implanted to treat MR
45774023|NCT05774795|Procedure|Mitral valve surgery|Mitral valve repair or replacement to treat mitral regurgitation
45774024|NCT05774795|Procedure|Aortic valve surgery|Aortic valve replacement to treat aortic regurgitation
45774025|NCT05774769|Procedure|Commissural edge to edge mitral valve repair|Edge to edge is the suture of mitral valve leaflets tissue in the regurgitant spot. If the regurgitant jet is near a mitral commissure, it is called a commissural edge to edge.
45774026|NCT05774691|Drug|Protamine sulfate|Routine protamine administration in a ratio of 1 mg per 100 IU of unfractionated heparin
45774027|NCT05774691|Drug|Protamine sulfate|Selective protamine administration, in case of (threatening) bleeding
45774028|NCT05774678|Radiation|Group 1 (preoperative radiation hypofractionated)|radiation schedules/regimens before your scheduled breast surgery
45774029|NCT05774678|Other|Group 2 (preoperative radiation conventionally fractionated)|radiation schedules/regimens before your scheduled breast surgery
45774030|NCT05773976|Device|Afomill Refreshing Soothing, Afomill Anti-redness Eye Drops, Iridil|"At baseline visit (V0), as per clinical practice, only one of the below reported IPs products can be dispensed to the enrolled subject, depending on investigator clinical evaluation and decision:~Afomill Refreshing Soothing~Afomill Anti-redness Eye Drops~Iridil"
45774031|NCT05773963|Device|Irilens; Iridina; Afomill Lubricating Eye Drops|"Irilens (with 0.4% HA as key ingredient);~Iridina (with 0.4% HA as key ingredient);~Afomill Lubricating Eye Drops (with 0.2% HA as key ingredient and distilled water of Chamomile)."
45774032|NCT05773950|Drug|fosaprepitant|"The subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered.~In the experimental group, the subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered."
45774033|NCT05773950|Drug|normal saline|"On the day of surgery, in the preoperative holding area, the principal investigator administers the study drug to the participants. During the study drug administration period, the principal investigator observes the presence of specific symptoms and abnormalities at the injection site of participants.~In the case of the control group, the study drug is 150 ml of normal saline, which is visually indistinguishable from the dilute solution of the fosaprepitant, administered over 30 minutes."
45774034|NCT05773872|Other|Questionary|"In addition to the usual care, the patient will complete the following validated questionnaires :~SART (Sustained Attention to Response Task), IGT (Iowa Gambling Task), UPPS (Impulsive Behaviour Scale), TAS (Toronto Alexithymia Scale), BES (Basic Empathy Scale), FRET (Facial Emotions Recognition Task), ERF-CS, MASC (Movie for the Assessment of Social Cognition)"
45774035|NCT05773677|Dietary Supplement|Specific Diet|"A specific diet will be developed for each patient, which will also take into account any food allergies or intolerances.~Each diet will be then eventually modified and revised throughout the pregnancy, according to the evolution of the same."
45774036|NCT05773404|Other|Passive Neurodynamics and Passive axial hip mobilisation/distraction|The physiotherapist performs passive techniques on the hamstring muscles and the nerve that innervates the hamstring muscles.
45774037|NCT05773404|Other|Active therapy|Active lumbopelvic CORE control exercises and active stretching of the ischiopelvic nerves
45774038|NCT05773404|Other|2.5.3. Combined therapy|The physiotherapist performs passive techniques on the hamstring muscles and the nerve that innervates the hamstring muscles and active lumbopelvic CORE control exercises and active stretching of the ischiopelvic nerves.
45634718|NCT03171571|Other|Coaching procedure|"In this study, the volunteers will be followed during one year. The wellbeing will be followed with :~survey like FFQ, SF36, dietary habits.~actimetry measurement~one year follow-up of weight, waist measurement~nutritional biomarkers"
45634719|NCT03168685|Device|SureSource Engage application|"Eligible patients who choose to participate in the study will be asked to wear an actigraphy device [ActiGraph GT9X Link Actigraph Link] on their wrist continuously during both 4-week study phases.~The ActiGraph Link is a small (3.5 X 3.5 X 1 cm) wristwatch like device weighing approximately 14 grams that measures indicators of the wearer's activity and sleep patterns, including: acceleration, energy expenditure, steps, basal metabolic rate, activity intensity, sleep time, sleep efficiency, sleep latency, and body position.~The application being utilized is SureSource Engage application from Clinical Ink. The application is compatible to most Android and iOS devices.~Participants will also use a basic Bluetooth-enabled weight scale that syncs with the application."
45634720|NCT03168607|Drug|FOLFIRI Protocol|Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
45774039|NCT05773352|Device|Tornier Perform® Humeral System - Fracture|"A replacement of shoulder joints for anatomic and reverse shoulder arthroplasty.~A replacement of other shoulder joints devices in case of revisions if sufficient bone stock remains."
45774040|NCT05773222|Drug|Apixaban|Single Group Assignment
45774041|NCT05772754|Genetic|study of molecular and protein pathways|42 ml peripheral venous blood sample.
45774042|NCT05772325|Other|Individually tailored diet counseling|Participants in the intervention group will receive a 60 min individually tailored heart-friendly diet consultation by a dietitian
45774043|NCT05772325|Other|The brief standardized 4-minute heart healthy dietary advice|The brief standardized 4-minute heart healthy dietary advice will be provided by an experienced cardiologist or rheumatologists
45634721|NCT02408185|Drug|Colistin 6 million units + 240mg/8h|240 mg of colistin methanesulfonate (CMS) every 8 hours, 3 million units (MU); 90 mg colistin base activity, (CBA)
45774044|NCT05769556|Other|Brain Gym Exercises|Brain gym exercises is a collection of simple movements that function to stimulate the development of all parts of the brain synergistically.
45774045|NCT05769556|Other|Traditional physiotherapy|A Group of exercises
45634722|NCT02408185|Drug|Colistin 6 million units + 360mg/12h|360 mg CMS every 12 hours (4.5 MU; 135 mg CBA)
45774046|NCT05769244|Other|near-infrared spectroscopy (NIRS)|NIRS measurements will be performed on each testicle on a group of healthy boys and on a group of boys under 18 years consulting to emergency for scrotal pain
45634723|NCT02400541|Behavioral|Cognitive remediation therapy|"Our scheme comprises 10 biweekly sessions ( 5 in group and 5 single) . Each session last about 45 minutes.~Individual sessions will be held with the patient and a therapist trained in the CRT; group sessions will be led by two therapists trained in CRT and regroup the maximum 5 patients."
45774047|NCT05768594|Other|Blood sample|After blood sampling, patients will undergo a Color Doppler Echocardiogram, a non-invasive method
45774048|NCT05767762|Other|scale Idiopathic Clubfoot|The Dimeglo and the muscle activity scale will be performed at 3, 6 and 12 months with patient with idiopathic clubfoot
45634724|NCT02400541|Other|relaxation therapy|Our scheme comprises 10 biweekly sessions. Each session last about 45 minutes.
45634725|NCT02408419|Drug|Bupivacaine|Bupivacaine is injected proximally to anesthetize the obturator nerve
45774049|NCT05763524|Procedure|Adrenalectomy with or without lymphadenectomy|Regarding lymphadenectomy extent, it will be described as locoregional or systematic depending on availability of data in the Eurocrine database.
45774050|NCT05762393|Biological|Sm-p80 + GLA-SE|Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.
45774051|NCT05761626|Other|MP < 17 J/min|assessment of the ventilatory variables according to the MP value (< or >= 17 J/min)
45774052|NCT05760443|Behavioral|Learning to BREATHE|"Learning 2 BREATHE (L2B) is an empirically-supported, manualized mindfulness-based group program (Broderick, 2021). Participants attend 6 sessions of approximately 1.5 hours per session. BREATHE is an acronym: Body, Reflections, Emotions, Attention, Tenderness, Habits, Empowerment; each week's lesson is centered around one of the letters (week 1 encompasses both Body and the overall theme of the sessions, Empowerment). Sample activities of L2B include psycho-education on emotion and self-regulation, body scanning, sitting meditation, non-aerobic yoga, and walking meditation, designed to promote moment-to-moment awareness of mind-body experiences. In between sessions, participants are encouraged to practice brief mindfulness skills in their daily lives and to complete the homework assignments, such as an audio-guided body scan. Participants will have access to home-practice audio-recordings and will be queried about their completion of home-practice assignments."
45774053|NCT05756634|Behavioral|Care Coordination after Preterm Birth (CCAPB)|For participants randomized to CCAPB, the care coordinator will follow a manulized intervention to support care planning, health care access, and wellbeing. Contact with participants will be initiated as soon as possible after enrollment, and will continue until six months after enrollment.
45774054|NCT05753982|Other|Kinesiotape placement|Placement of kinesiotapes, using ligament techniques on the injured side of chest, focusing on the point of maximal pain.
45774055|NCT05753891|Device|Suture Tape Reconstruction|This intervention will utilize a suture tape to suspend the 1st and 2nd metacarpal post trapeziectomy compared to the standard procedure of a trapeziectomy followed by ligament reconstruction and tendon interposition.
45774056|NCT05746247|Behavioral|Testing centralized referral mechanisms for PCPs|"For patients with a Penn PCP, we are testing the two different centralized referral mechanisms to increase the number of referrals to preventive cardiology (active choice vs default/opt out referrals)~For active choice: A non-interruptive In Basket alert will be delivered to PCPs that have patients that have been screened as positive with the FIND FH tool and recommends a referral to a lipid specialist. PCPs will have the choice of either accepting the referral or declining the referral. If they do not take action on the In Basket alert, the referral will stay in their In Basket.~For default/opt out: A non-interruptive In Basket alert will be delivered to PCPs that have patients that have been screened as positive with the FIND FH tool and recommends a referral to a lipid specialist. Not interacting with the BPA or accepting the BPA will indicate that the referral to a lipid specialist should be placed."
45774057|NCT05746247|Behavioral|Testing out patient outreach methods|Testing health care system mediated outreach vs Family Heart Foundation mediated outreach to see which type of outreach might be most effective at getting patients to schedule an appointment with a lipid specialist
45914425|NCT02043210|Behavioral|Standard Treatment as Usual|Treatment normally offered at this clinic which could include individual or group substance use counseling sessions one time per week lasting one hour each time.
45634726|NCT02408419|Drug|Saline|Saline is injected as a placebo
45634727|NCT00708097|Drug|NaF|Fluoride
45634728|NCT00708097|Drug|Placebo|Placebo
45634729|NCT00708097|Drug|NaMFP|Fluoride
45914426|NCT02043210|Behavioral|CBT4CBT plus Standard treatment as usual|Subjects work with a computerized program in Spanish that teaches skills for stopping substance use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus Standard treatment as usual
45914427|NCT02043223|Dietary Supplement|Vitamin A (<3-day postpartum)|Single dose 200,000 IU vitamin A supplementation at <3-day and placebo supplementation at 6-wk postpartum.
45634730|NCT02400697|Other|<30 wks gestation or 1500 grams|Outcomes of preterm infants recorded
45634731|NCT02400775|Drug|Azilsartan|Azilsartan tablets
45634732|NCT02405689|Drug|Remifentanil|
45634733|NCT02405689|Drug|Dexmedetomidine|
45634734|NCT02405689|Drug|Sevoflurane|
45634735|NCT03173989|Device|Orthosis Exercises Orientation|Use of orthosis, exercises and orientation for home.
45634736|NCT03173989|Behavioral|Orientation|Orientation for home.
45634737|NCT02405455|Procedure|Cerclage|Surgical procedure which consists of a strong suture being inserted into and around the cervix to close it.
45634738|NCT02405455|Device|Cervical pessary|The Arabin cervical pessary, which is CE-certified for preventing spontaneous preterm birth (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC). It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
45634739|NCT02400619|Device|shock waves|Swiss dolorclast smart EMS Registration: EN-60601-1 Type BF IP40. 93/42 CEE
45774058|NCT05743426|Other|Survey|Patient Reported Outcome (PRO) questionnaire
45774059|NCT05743426|Other|Toxicity Assessments|Toxicity Assessments will be performed using the National Cancer Institute Common Terminology Criteria (NCI-CTCAE).
45774060|NCT05737550|Device|Previct Drugs|Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
45634740|NCT02400619|Drug|Botulinum Toxin Type A|Botulinum toxin type A Botox
45634741|NCT02400853|Device|Standard cranial echography|Standard cranial echography will be done at day 5 day 7 post-birth looking for radiological finding of intraventricular hemorrhage
45634742|NCT02400853|Procedure|Cord blood analysis|Cord blood will be collected during deliverance and analysed
45634743|NCT02659631|Drug|PF-06671008|Dose Escalation Phase - Part 1
45774061|NCT05735912|Procedure|Endoscopic ultrasound-guided radio frequency ablation|Radiofrequency ablation performed under endoscopic ultrasound guidance of pancreatic insulinoma
45774062|NCT05735912|Procedure|Surgery|Surgical resection of pancreatic insulinoma
45634744|NCT02659631|Drug|PF-06671008|Dose Expansion Phase - Part 2
45774063|NCT05729516|Behavioral|Hope App immersive learning and telehealth platform|As part of the Hope App intervention, participants attend 10 skills sessions related to diabetes self-management. ITG participants will also receive monthly health coaching calls. After 6 months of active participation, participants enter a maintenance period, during which programming concludes but continued access to the program materials remains.
45774064|NCT05728723|Device|Android Application|Android Application for 3 months
45774065|NCT05728723|Behavioral|Pharmacy education|Pharmacy education in hypertensive patients
45774066|NCT05727839|Drug|JCXH-211 Injection|JCXH-211 administered once every 28 days
45774067|NCT05719194|Other|Standard SBT|Weaning strategy in accordance with the care practices of the department, regarding the assessment of weaning criteria, SBT and extubation modalities.
45774068|NCT05719194|Other|SBT with T-piece or PSV|"- Risk factors of WIPO~Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.~Step 2 : Spontaneous breathing trial with T-piece for an hour. Measure of protein and haemoglobin by blood sample before and after the trial.~If it increase by more then 5% then it signs a weaning induced pulmonary oedema.~Step 3 : Reconnect the patient to the ventilator for 1 hour and then extubate if SBT is successful.~If SBT failed or WIPO : no extubation and new SBT the next day. Optimization of cardiac function or fluid overload will be in charge of the investigator.~- No risk factors of WIPO~Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.~Step 2 : Spontaneous breathing trial with pressure support ventilation (pressure support from 5 to 8 cmH20 - PEEP at 0 cmH20) for an hour.~Step 3 : Reconnect the patient to the ventilator for 1 hour and then extubate if SBT is successful."
45774069|NCT05716477|Procedure|Biospecimen Collection|Undergo blood sample collection
45774070|NCT05716477|Other|Survey Administration|Complete survey
45774071|NCT05692011|Device|blood purification(PS)|After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with PS membrane, 24 hours per day, for 3 consecutive days
45774072|NCT05692011|Device|blood purification(AN69ST)|After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with AN69ST membrane, 24 hours per day, for 3 consecutive days
45774073|NCT05677659|Drug|VGL101|Solution administered via Intravenous Infusion (IV)
45774074|NCT05676658|Behavioral|Coherent breathing|Guided audio of coherent breathing pre-recorded by trained breathwork facilitator: ~5.5bcpm (with equal inhalation/exhalation durations of ~5.5secs each) for ~10mins/day over four weeks / 28 days. Delivered remotely through audio link.
45774075|NCT05676658|Behavioral|Placebo coherent breathing|Same audio of coherent breathing but paced at: ~12bcpm (with equal inhalation/exhalation durations of 2.5secs each) for ~10mins/day over four weeks / 28 days.
45774076|NCT05666011|Device|M22 IPL|IPL is an attractive option in the treatment of KP as the provider can utilize cut-off filters to target both melanin for hair removal and erythema with a single device. An added benefit of IPL is the larger crystal size, allowing for efficient coverage of a larger body surface area. IPL has been utilized in the treatment of KP and KP variants, with outcomes showing reductions in both erythema and texture.
45914428|NCT02043223|Dietary Supplement|Vitamin A (6 wk postpartum)|Placebo supplementation at <3-day and single dose 200,000 IU vitamin A supplementation at 6-wk postpartum.
45914429|NCT02043223|Dietary Supplement|Vitamin A (<3-day and 6 wk postpartum)|200,000 IU vitamin A supplementation, both at <3-day and 6-wk postpartum
45914430|NCT02043223|Dietary Supplement|Placebo|Placebo supplementation, both at <3-day and 6-wk postpartum.
45914431|NCT02043236|Behavioral|Healthy bones pamphlet|written educational material
45914432|NCT02043236|Behavioral|Bone Health Care Coordinator|The Bone Health Care Coordinator reviews educational materials with participant and facilitates ordering BMD.
45634745|NCT03173833|Other|CAGO questionnaire outcome|Every time when cancer patients fulfill the following questionnaires, SDS, PTGI, CNS, PedsQL, the outcome of the questionnaires will be provided to the experimental group of the participants by using a computer assessment with graphic outcome.
45634746|NCT02405143|Device|Active tACS using DC-Stimulator MC|Transcranial alternating current stimulation (tACS) is administered using DC-Stimulator MC (NeuroConn GmbH, Ilmenau Germany). Stimulation is administered through two 5 cm2 saline-soaked electrodes placed in the Fpz position and on the right arm. Stimulation will consist of short blocks, during which stimulation frequency will be ramped up to 30Hz with maximum current of 1.5mA. Stimulation will be administered for 20 minutes on 10 consecutive weekdays.
45634747|NCT02405143|Device|Sham stimulation using DC-Stimulator MC|Patients in the sham group will undergo the same preparations as the treatment group. This includes using an identical electrode placement and session duration as for the experimental arm. In order to create the effect of phosphenes, one 5Hz current burst per minute will be administered using the individual phosphene threshold of the patient. This is not expected to have therapeutic effects.
45634748|NCT03173911|Device|Bandage|Application of Elastic Bandage Therapy by the Therapy Taping method
45774077|NCT05658237|Procedure|Pars plana vitrectomy|One sheet of PAL-222 is implanted into the subretinal space of either of eyes through pars plana vitrectomy.
45914433|NCT02043236|Behavioral|Letter to GP|The letter to the General Practitioner contains information about the study, recommendations for bone health, guidelines of Osteoporosis Canada, and the identical educational material that the participant received.
45914434|NCT02043249|Other|CORD MILKING|MILKING OF UMBILICAL CORD OF THE BABY
45914435|NCT02043262|Behavioral|Reablement|The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.
45914436|NCT02043262|Behavioral|Standard treatment|The control intervention is standard home-based treatment/care in Norway.
45634749|NCT02408107|Behavioral|Physical activity|Physical activity (PA) intervention participants received a 30-45 min face-to-face consultation (1st visit), followed by 15-20 min support telephone calls (end of months 1, 2 and 3). During months 4 and 5 patients received reminder leaflets. Consultations were conducted by the primary researcher after baseline measurements and were based on the four core motivational interviewing principles. The topics covered in the consultation (e.g. goal setting, overcoming barriers, health and safety advice) were similar to other trials that incorporated a PA counselling component. The focus of the follow-up phone calls (end of months 1-3) was to prevent relapse and/or improve maintenance of PA. The intervention participants were encouraged to work towards accumulating at least 30min of moderate-intensity PA on 5-7 days/week.
45634750|NCT04459247|Drug|Vit D|Oral liquid formulation of 60000 IU
45634751|NCT02405377|Procedure|hydration|Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration in all patients. Investigator monitored the central venous pressure (CVP) by placing an 5-French catheter in the jugular vein in the intervention group, and administration fluid rate was adjusted according to the CVP as follows: 3 ml/kg/h for CVP lower than 6 mmHg, 1.5 ml/kg/h for pressure of 6-12 mmHg, and 1ml/kg/h for pressure higher than 12 mmHg. The control group was hydrated with 0.9% sodium chloride at 1 ml/kg/h, continued for the duration of 12 h post-procedure in both groups. Thus, both study groups received intravenous fluids for the same duration but at different rates. All study participants received intra-arterial Visipaque(320 mg I/ml; GE Healthcare) iso-osmolar contrast medium.
45774078|NCT05656469|Other|Personalised medication advice based on pharmacogenetic testing|Pharmacogenetic genotyping provides personalised medication advice on dosage and choice of currently available and legally approved medication based on the patient's pharmacogenetic profile
45774079|NCT05644756|Behavioral|IMPACT Methods to Identify and Prioritize Determinants (Challenge I), Challenge and Match strategies to Prioritized Determinants (Challenge II)|IMPACT Center developed two methods for identifying determinants that involved providers, staff, and youth at community mental health centers in site visit 1: Rapid Ethnographic Assessment, Design Probes. Then, practice partners engage in a facilitated group activity to rate the criticality, chronicity, and ubiquity of the list of determinants in Site Visit 2. Finally, practice partners engage in a third site visit where they create Causal Pathway Diagrams that allow them to match strategies to prioritize determinants and create Implementation Plans.
45774080|NCT05638594|Drug|Pyrotinib|320mg, qd
45774081|NCT05638594|Drug|Trastuzumab|8 mg/kg first dose, then 6 mg/kg，q3w
45774082|NCT05638594|Drug|Dalpiciclib|125mg , qd，d1-21, q4w
45774083|NCT05638594|Drug|Letrozole|2.5mg，qd
45774084|NCT05638594|Drug|Pertuzumab|840 mg first dose, then 420 mg, q3w
45774085|NCT05638594|Drug|Docetaxel|75 mg/m2, q3w
45774086|NCT05638594|Drug|Carboplatin|AUC 6, q3w
45774087|NCT05638594|Drug|Gonadotropin-releasing hormone agonist|Every 4 weeks for 5 cycles, premenopausal patients only
45774088|NCT05638152|Other|implementation of a bundle of non-pharmacological interventions aimed at stress reduction|"The bundle consists of 4 interventions:~natural imagery in the PACU (wall length decorations and lighted ceiling panels with sky views~Aromatherapy with fragrances selected for anxiolytic and antiemetic properties~Music available to patients~Comfort Talk communication course for PACU nurses"
45774089|NCT05636241|Other|conventional physiotherapy program|The conventional physiotherapy program consists of stretching exercises for lower extremities, strength exercises for core, upper, and lower extremity muscles, sit to stand exercises, and balance exercises.
45774090|NCT05636241|Other|whole body vibration training program|The whole body vibration training program sessions consisted of three 3-min bouts of vibration of 20 Hz and a peak-to-peak amplitude of 2mm with a 3-min rest in between, in addition to conventional physiotherapy exercises for children with cerebral palsy.
45774091|NCT05635227|Drug|Tocilizumab|See description of arms
45774092|NCT05635227|Drug|Isotonic sodium chloride (0.9%)|See description of arms
45774093|NCT05635227|Drug|Dexamethasone phosphate|See description of arms
45774094|NCT05635227|Drug|Isotonic sodium chloride (0.9%)|See description of arms
45774095|NCT05635227|Drug|Olanzapine 10 MG|Olanzapine tablet pre-hidden in capsule identical to the placebo tablet
45774096|NCT05635227|Drug|Placebo capsule|capsule identical to capsule containing olanzapine
45774097|NCT05635227|Procedure|Flow-targeted hemodynamic management|See description of arms
45914437|NCT02043275|Other|Leg training|Lower body resistance training twice per week for one hour each time.
45774098|NCT05635227|Procedure|Pressure-targeted hemodynamic management|See description of arms
45774099|NCT05635227|Procedure|Low tidal-volume ventilation|See description of arms
45774100|NCT05635227|Procedure|No ventilation|See description of arms
45774101|NCT05620368|Behavioral|Mindfulness and Compassionate Living Course (MCLC)|"The course will be held online (using the Zoom platform) with weekly sessions lasting 2.5 hours each, as well as a day of silent practice (mini-retreat of 4 hours) between sessions 6 and 7.~On the structural level, every course session consists of four elements: (1) an educational input, (2) mindfulness and compassion exercises (eg, sitting meditation, body scan, mindful walking, self-compassion break), (3) a reflection of one's practice (inquiry), (4) and home assignments."
45774102|NCT05620368|Behavioral|Usual care intervention|"If necessary, psychological support is organized at the request of the parent.~Support includes individual support of a psychologist (1h / week), consultation with a teacher (special pedagogue and early school education teacher, 1h / week), individual consultation with observation of a child with a Venetian mirror (1h / week)."
45774103|NCT05612672|Other|GeoHAI|A Geographic healthcare-associated infection (HAI) visualization and assessment tool (GeoHAI) which uses spatio-temporal Bayesian models to identify clusters of National Healthcare Safety Network (NHSN)-defined hospital onset Clostridium difficile (CDI) and multidrug resistant organisms (MDRO), and predict potential high risk areas given hospital and patient risk factors.
45774104|NCT05607147|Device|Testing for SARS CoV2 Antigen and Antibody|Antigen testing: Rapid Antigen testing (Point-of-care) Antibody testing: ELISA testing of microsampling 'finger-prick' specimen DHCW Survey for adoption of risk mitigation practices and for perceptions of safety
45774105|NCT05598359|Dietary Supplement|TA-65|TA-65 is a purified small molecule extracted from Astragalus root
45774106|NCT05598359|Other|Placebo|Inactive formulation
45774107|NCT05595239|Device|blood purification(CVVH)|After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode, 24 hours per day, for 3 consecutive days
45774108|NCT05595239|Device|blood purification(TPE+CVVH)|After the sepsis patients were enrolled, they were treated with blood purification in TPE mode 2 hours at first and then in CVVH mode 22 hours in the first two days, and then in CVVH mode 24 hours
45774109|NCT05595239|Device|blood purification(HP+CVVH)|After the sepsis patients were enrolled, they were treated with blood purification in HP mode 2 hours at first and then in CVVH mode 22 hours in the first two days, and then in CVVH mode 24 hours
45774110|NCT05590702|Drug|First line therapy|"Patient with CLL or SLL requiring a therapeutic strategy according to iwCLL criteria or investigator evaluation will be identified in MCM (multidisciplinary collegial meeting).~Patients will be treated and managed according to the decision of their physicians and the related MDM. No treatment plan is recommended in the setting of this non-interventional study."
45774111|NCT05585684|Other|Non-invasive Comprehensive Genomic Profiling for Cancer Treatment Selection|Use of liquid biopsy to evaluate the clinical utility of non-invasive comprehensive genomic profiling for cancer treatment selection.
45774112|NCT05585242|Behavioral|Infertility ACTion Program|Seven 15-minutes videos of Acceptance and commitment therapy adapted for women with infertility with assigned homework and summaries of the videos.
45774113|NCT05570617|Behavioral|Transition Coach Intervention|The Transition Coach Intervention will include 8, 1-hour sessions over 6-months. The transition coach will independently meet one-on-one with each youth using an individualized, patient-centred approach beginning with an introductory session, followed by 5 sessions covering each topic in the Youth Transition Roadmap. These topics include: Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation. The clinical psychologist will lead 2 sessions beginning with the Patient Health Questionnaire for Anxiety and Depression as a screening tool. The clinical psychologist will discuss psychological and social well-being in the context of their disease covering personally relevant issues/concerns.
45774114|NCT05570617|Behavioral|Standard of Care- Youth Transition Roadmap|All participants will receive the Youth Transition Roadmap (standard of care) which discusses 5 domains of healthcare transition; Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation. This is an informational pamphlet and will not require any additional meetings with the patient beyond their normal healthcare interactions
45774115|NCT05563909|Other|Exercise|Patients participating in the study will not receive any intervention other than exercise and splint.
45774116|NCT05563909|Other|Wrist Splint|Patients participating in the study will not receive any intervention other than exercise and splint.
45774117|NCT05563909|Other|Virtual Reality Mediated Exercise|Patients participating in the study will not receive any intervention other than exercise and splint.
45774118|NCT05553470|Drug|Miricorilant|600 mg miricorilant
45774119|NCT05545839|Behavioral|Transition coaching|Transition coaching sessions (8 sessions), covering paediatric to adult care, self-advocacy, medication management, general health, lifestyle and behaviours, future planning, screening for mood disorders and coping skills.
45774120|NCT05519254|Dietary Supplement|Lactoferrin|Caregivers of children will be instructed to provide 41.5g of lactoferrin daily mixed with 125 mL of porridge or other complimentary food.
45774121|NCT05519254|Dietary Supplement|Lysosyme|Caregivers of children will be instructed to provide 41.5g of lysosyme daily mixed with 125 mL of porridge or other complimentary food.
45774122|NCT05519254|Combination Product|Lactoferrin + Lysosyme|Caregivers of children will be instructed to provide 40 grams of Lysosure with 1.5 grams of bovine lactoferrin daily mixed with 125 mL of porridge or other complimentary food.
45774123|NCT05519254|Other|Placebo|Caregivers of children will be instructed to provide 41.5 grams of unmodified rice powder produced by Ventria Bioscience Inc daily mixed with 125 mL of porridge or other complimentary food.
45914438|NCT02043275|Other|Arm training|Upper body resistance training twice per week for one hour each time.
45914439|NCT02043288|Drug|NC-6004|"Study group (3 week/cycle):~NC-6004 90 mg/m2 i.v. inf. over 60 min on Day 1"
45634752|NCT02405377|Drug|Visipaque|All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
45634753|NCT02405377|Drug|0.9% sodium chloride ﬂuid administration|
45634754|NCT02405377|Device|5-French catheter|
45634755|NCT04402463|Other|Global Postural Reeducation|"The participants will receive treatment along 4 weeks, 2 sessions per week, and 40-45 minutes each session.~In the treatment 3 of the therapeutic postures of GPR method to will carry out following Souchard's principles of Global Postural Reeducation"
45774124|NCT05516771|Device|Tcore™ system|"The Tcore sensor is a double-sensor-heat-flux (DHF) thermometer and consist of two sensors separated by a known thermal resistance. One side is placed directly at the patient's skin and the other is facing the environment. After some equilibration time the core temperature can then be calculated. The sensors are placed above the eye and the sinus frontalis.~Intended use The Tcore system is a thermometer intended for non-invasive, continuous measurement of the core body temperature of children from 5 years of age, adolescents, and adults. The Tcore system consists of a sensor and an adapter. The adapter is reusable. The sensor is intended for single use. The Tcore system works in adjusted mode, i.e., the core body temperature is determined by a dual sensor.~Off-Label/Investigational Use In context of this clinical study the Tcore-system will be investigated outside its approved and intended use, namely in children below the age of five and toddlers."
45914440|NCT02043288|Drug|Gemcitabine|"Study group (3 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1 and Day 8 (follow by administration of NC-6004)~Control group (4 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1, Day 8 and Day 15"
45634756|NCT04402463|Other|Exercise Therapeutic|"The participants will receive treatment along 4 weeks, 2 sessions per week, and 40-45 minutes each session.~The treatment will be divided into 3 phases, where it initially starts with phase 1 (3 treatments) and progresses to phase 2 (3 treatments) until reaching stage 3 (2 treatments)."
45634757|NCT02405299|Other|experimental groupe|exercices of cognitive and neuropsychological stimulation of inhibition (paper and pencil exercises and computerized exercises) created for the experience: cognitive stimulation exercises for children in the form of cognitive and metacognitive games with rehabilitation objective disorder of inhibition
45634758|NCT04342871|Behavioral|Fam-CT|Customized communication guidance to help parents with cancer talk about their cancer with their children.
45634759|NCT04480879|Drug|AZD8154 nebuliser|Nebuliser suspension
45634760|NCT04480879|Drug|AZD8154 Monodose DPI presented in capsules|AZD8154 Monodose DPI formulation delivered dose
45634761|NCT04480879|Drug|AZD8154 Placebo Monodose DPI presented in capsules|The dose correspond to AZD8154 Monodose DPI formulation
45634762|NCT05088317|Diagnostic Test|Exercise capacity|The incremental shuttle walking test at increasing speed (ISWT) is one of the field tests used to evaluate exercise capacity. It has been shown that ISWT is a valid and reliable assessment tool that can be used to evaluate exercise capacity in obese individuals. This test is an exercise test in which walking between two cones 10 m apart at increasing speed for 12 minutes is counted as one sit-up for each 10-meter walk between the two cones. It is continued until the patient is unable to continue the test due to shortness of breath, the heart rate reaches 85% of the maximum expected heart rate, or completes the 12-minute test. In this test, the primary measure is the distance walked, and the result is calculated based on the number of shuttles completed.
45634763|NCT05083949|Drug|empagliflozin/metformin|empagliflozin/metformin
45634764|NCT05083949|Drug|Jardiance®|Jardiance®
45634765|NCT05083949|Drug|Glifage®|Glifage®
45634766|NCT02400229|Procedure|Computed tomography angiography (cardiac CT)|Clinical management/treatment decisions based on cardiac computed tomography including coronary calcium scoring and coronary computed tomography angiography
45914441|NCT02043314|Drug|Isoniazida|
45634767|NCT02400229|Procedure|Invasive coronary angiography (ICA)|Clinical management/treatment decisions based on invasive coronary angiography
45634768|NCT02717663|Behavioral|Adaptive Goals|Prescribed goals change daily based on participant's performance
45634769|NCT02717663|Behavioral|Static Goals|Prescribed goals remain the same throughout study
45634770|NCT02717663|Behavioral|Delayed (non-contingent) Incentives|Incentives are provided on bi-monthly basis for participation
45914442|NCT02043340|Drug|indocyanine green|ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
45634771|NCT02717663|Behavioral|Immediate Micro-Incentives|Incentives are provided immediately for each goal attained
45634772|NCT02699125|Drug|Guanfacine|Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.
45634773|NCT02699125|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks
45634774|NCT04279535|Drug|Topical Ascorbic Acid|Twice daily application of 300 microliters of 30% ascorbic acid solution with a small cuticle brush.
45914443|NCT02043340|Device|LASER|LASER group - scaling and root planing with application of 810 nm diode laser Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
45914444|NCT02043340|Procedure|Scaling and Root Planing|SRP group - scaling and root planning. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
45914445|NCT02043444|Radiation|FDG PET-CT|
45914446|NCT02043496|Behavioral|Integrative Cognitive-Affective Therapy|Integrative Cognitive-Affective Therapy is a psychotherapy treatment for binge eating that focuses on changing behaviors, feelings, thoughts, and relationships
45634775|NCT05049317|Procedure|Laparoscopic FTME surgery|Nerve plane was defined as the overlying tiny membranous tissue including the nerves, the adipose tissue and the extremely tiny capillaries around the nerve. Following the TME principles, the surgical procedure of FTME was guided by the nerve plane and dissected between the proper fascia of the rectum and nerve plane (the first gap), which could ensure completeness of the nerve plane and the proper fascia of the rectum.
45634776|NCT02400151|Drug|Vitamin D supplementation|Patients randomized to this group will receive 4000 UI of Vitamin D3 per day for 90 days.
45634777|NCT02400151|Drug|Placebo|Patients randomized to this group will receive placebo for 90 days.
45774125|NCT05513443|Procedure|Irreversible electroporation, IRE|IRE involves the use of high voltage electrical pulses to treat solid tumors by increasing membrane permeability and inducing membrane disruption, leading to cell death. The technique is used in Sweden today in radical ablative therapies in the treatment of tumors in the liver, kidney and pancreas. Prior to treatment a Foley catheter is placed. During the treatment, which takes place under anesthesia, the patient is placed in gynecological position and the tumour lesion is located with BK transrectal fusion ultrasound. Thereafter the needles are placed transperineal around the tumor in the prostate using a brachytherapy grid (17Ga Civco brachytherapy grid), guided by the ultrasound/MRI fusion images. Through the needles electrical pulses are then sent to treat the tumor in the center using the Nanoknife technique. After treatment patients are treated with diuretics to flush the kidneys post treatment.
45774126|NCT05513443|Procedure|Radical prostatectomy|Radical prostatectomy
45774127|NCT05513443|Radiation|Radiation therapy|Radiation therapy for prostate cancer
45774128|NCT05507814|Behavioral|Episodic Future Thinking (EFT)|Participants will generate descriptions of vivid positive future events.
45634778|NCT02400151|Other|3 months lifestyle and dietary management|Lifestyle and dietary management at the Saint Pierre Institute (Palavas-les-Flots, France) occurs for three months. Nutritionally speaking, each child or adolescent receives a controlled and balanced diet, consistent with the recommendations appropriate for his/her age, slightly hypocaloric or normocaloric. This dietary approach is complemented by a nutrition education program and supervision by a doctor and a dietician. Three hours of exercise training per week are scheduled; these sessions include adapted aerobic activities supervised by instructors and educators at the center.
45774129|NCT05507814|Behavioral|Control Episodic Thinking|Participants will generate descriptions of vivid positive future events.
45774130|NCT05500144|Other|Not applicable- no intervention administered|Not applicable- no intervention administered
45634779|NCT02400151|Other|Normal control|Patients in this group do not have experimental intervention in order to provide measures of a real-life control group.
45774131|NCT05493475|Behavioral|Fentanyl Test Strips|A brief fentanyl test strip (FTS) education intervention will be given to participants at court sites in the intervention arm after enrollment and collecting baseline data. It will be offered one-on-one with participants and will include the purpose, benefits, and limitations of FTS testing, and information on how to use FTS, interpret the results, what to do if the FTS is positive, and how to use FTS for different drug delivery methods. Participants will practice and demonstrate use of the FTS, and the short video on how to interpret the FTS will include an on-camera statement on the importance of testing for fentanyl. The video will be accessible to participants after study enrollment. Participants will be advised of the possibility of both false positive/negative results, and that the drugs may be mixed with other substances not detectable with FTS. Participants will be encouraged to practice other harm reduction strategies.
45774132|NCT05488964|Behavioral|Exercise|Supervised endurance training with moderate-to-high intensity 3-4 times weekly.
45774133|NCT05471596|Device|NeuWave Microwave Ablation System|The NEUWAVE System supports target ablation or linear coagulation in surgical liver resection procedures. The System offers a versatile probe portfolio, multi-probe synchrony and CO2 cooling to help control the shape, size and burn pattern of your ablations.
45774134|NCT05463341|Behavioral|Fentanyl Test Strips|A brief fentanyl test strip (FTS) education intervention will be given to participants at Project DAWN sites in the intervention arm after enrollment and collecting baseline data. It will be offered one-on-one with participants and will include the purpose, benefits, and limitations of FTS testing, and information on how to use FTS, interpret the results, what to do if the FTS is positive, and how to use FTS for different drug delivery methods. Participants will practice and demonstrate use of the FTS, and the short video on how to interpret the FTS will include an on-camera statement on the importance of testing for fentanyl. The video will be accessible to participants after study enrollment. Participants will be advised of the possibility of both false positive/negative results, and that the drugs may be mixed with other substances not detectable with FTS. Participants will be encouraged to practice other harm reduction strategies.
45774135|NCT05462821|Device|Eye Patch|adhesive patch to cover eye
45774136|NCT05453708|Other|Survey|One 15-20-minute survey
45774137|NCT05446298|Drug|ONC-392|ONC-392, either in 3 mg/kg or in 6 mg/kg, will be given by IV infusion, q3w.
45774138|NCT05446298|Drug|Pembrolizumab|Pembrolizumab in fixed dose of 200 mg will be given by IV infusion, q3w.
45774139|NCT05433506|Drug|HU6 Tablet|Six subjects will receive a tablet formulation.
45774140|NCT05433506|Drug|HU6 Capsule|Six subjects will receive the capsule formulation
45774141|NCT05429970|Behavioral|Mind-body resilience training|MBRT is a meditation technique used to achieve relaxation)
45774142|NCT05429970|Behavioral|Music therapy|Music listening was found, in multiple trials, to significantly reduce self-reported anxiety, physiologic indicators of anxiety, and/or sedation requirements
45774143|NCT05429970|Drug|Propofol|Pre-op: 20 mg BID p.o. (preop D7 - preop D1) Day of Surgery: total intravenous anesthesia/TIVA using propofol as the main anesthetic drug Post-op: 20 mg BID p.o. (until POD 14)
45914447|NCT02043496|Behavioral|CBT-Guided Self Help|CBT-Guided Self Help focuses on changing behavior patterns through the use of reading and homework assignments along with sessions with a therapist.
45914448|NCT02043522|Drug|Radioisotope|One dose of 10 mCi (370 mBq:± 10%, calibrated to time of injection) of 123I-mIBG (AdreView) administered as a single intravenous bolus over 1 or 2 minutes, followed by a saline flush.
45634780|NCT04845893|Other|Treatment of Ewings Sarcoma of bone according clinical practice (includes drugs, surgery, radiotherapy or any other received treatments)|This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments
45774144|NCT05429970|Drug|Etodolac|Pre-op: 400 mg BID p.o. (preop D7 - preop D1) Post-op: 400 mg BID p.o. (until POD 14)
45774145|NCT05406973|Device|SBK microkeratome versus femtosecond laser in flap creation|prospective comparative non randomized interventional clinical study
45774146|NCT05406908|Biological|tozinameran|Pfizer-BioNTech COVID-19 vaccine (Trade name: Comirnaty)
45774147|NCT05400512|Behavioral|Cognitive Training|Computerized cognitive training targeting the underlying cerebral networks associated with depression.
45935484|NCT00043394|Drug|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
45653035|NCT05550493|Behavioral|Approach Bias Modification|In an ApBM session, users were instructed to swipe upward (downward) when they saw portrait (landscape) format images. A shrinking (growing) animation comes after swiping upward (downward) to simulate the visual effect of moving away (moving towards). The images were related to methamphetamine usage (methamphetamine crystals, powders, and paraphernalia) or healthy lifestyles (wealth, sports, gourmet, family activities, etc.). Each ApBM session was composed of presenting each one of the healthy lifestyle (methamphetamine) cues 12 times in landscape (portrait) and once in portrait (landscape).
45774148|NCT05400512|Device|tDCS (active stimulation)|A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0 milliamps (mA) direct current through two bicarbon rubber electrodes encased in saline soaked 5 cm x 7 cm sponges (8 cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (via 10-20 system).
45774149|NCT05400512|Device|tDCS (sham stimulation)|Sham stimulation will be performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
45774150|NCT05396079|Other|tahini and bread|Fifthy grams of tahini with 2 slices of white bread
45774151|NCT05396079|Other|margarine, cheese and bread|46 g of margarine and 38 g of cheese with 2 slices of white bread
45774152|NCT05376904|Drug|HR18034|HR18034 low dose
45774153|NCT05376904|Drug|HR18034|HR18034 midium dose
45774154|NCT05376904|Drug|HR18034|HR18034 high dose
45774155|NCT05376904|Drug|ropivacaine HCl.|ropivacaine HCl.
45774156|NCT05348291|Device|ventilation tubes|Transtympanic pressure equalising devices.
45774157|NCT05333497|Device|the fourth programmed generation of low-frequency acupoint electric stimulation therapy instrument|Conventional electrical stimulation does not produce coordinated movement of multiple joints by stimulating several locally generated single ones simultaneously. The stimulation after the improved program, through different time output electrical stimulation on different parts of the muscles or muscle groups, forming the programmed motion. The purpose of this study is to achieve the rehabilitation goal of single joint - multiple joint - extensive movement, promote the coordination recovery of affected limb movement and relieve muscle fatigue.
45774158|NCT05333497|Device|the fourth generation of low-frequency acupoint electric stimulation therapy instrument|In this study, the instrument of alternate acupoint electrical stimulation of flexor and extensor muscles combines traditional acupoint therapy with modern low-frequency electric stimulation technology, has the advantages of non-invasive and convenient application, and has a good effect on improving the range of motion of joints, relieving spasm, enhancing muscle strength, promoting the recovery of the central nervous system and other aspects.
45774159|NCT05329740|Drug|Methylprednisolone Injection|All eligible patients randomised to the glucocorticoid group will receive intravenous Methylprednisolone for 3 days after surgery. The dosage is 2mg/kg/d on post-operative day 1, 1mg/kg/d on post-operative day 2, and 0.5mg/kg/d on post-operative day 3. The daily dosage will be administered with two injections (12h interval).
45774160|NCT05323448|Device|Control Group|During the surgical procedure, hemostasis will be achieved using the standard of care (electrocautery, pressure, ligature or any hemostatic agent).
45774161|NCT05323448|Device|ARISTA|"During the surgical procedure, hemostasis will be achieved using the standard of care (electrocautery, pressure, ligature or any hemostatic agent). Before surgical wound closure, the corresponding amount of ARISTA-AH will be applied to completely cover the bleeding site :~5g for 5 to 8 instrumented vertebra~10g fo 9 or more instrumented vertebra"
45774162|NCT05318222|Diagnostic Test|Whole genome sequencing (WGS)|WGS will identify copy number variations (CNVs), single nucleotide variants (SNVs), as well as triplet repeat disorders in children with rare diseases
45774163|NCT05301335|Device|SCONE|The Spinal COrd NEuromodulation(SCONE) device delivers a sufficient electrical signal non-invasively to activate the neural structures of the spinal cord without cutaneous discomfort. Rather than relying on stimulation of peripheral nerves, SCONE modulates the CNS directly via the spinal cord. Importantly, SCONE is a technique that enables electrical stimulation of the spinal cord without the need for insertion or implantation of stimulating electrodes
45774164|NCT05298670|Drug|MetFORMIN 1000 Mg Oral Tablet|Antidiabetic agent used to treat type 2 diabetes, and to prevent type 2 diabetes.
45774165|NCT05298670|Drug|Interferon beta-1a|Disease Modifying Therapies (DMTs)
45774166|NCT05297851|Drug|Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin)|10 ml diluted to 100-200 ml of 5-10% dextroseor 0.9% sodium chloride solution. The rate of administration is 3-4 ml / min. The drug is administered in a volume of 10 ml per injection with an interval of 8-12 hours for 10 days. In severe cases of the disease, a single dose is increased to 20 ml.
45774167|NCT05297851|Drug|Control|Standard treatment accordind to the routine clinical practice
45653036|NCT05550493|Behavioral|Cognitive Training|The DTx application incorporated a game-based cognitive function training module for improving working memory. In this game, a matrix of squares is displayed at the center of the screen. Between 3 and 5 target symbols are randomly placed in the matrix and displayed for 2 seconds. Next, the symbols disappear, and the matrix randomly rotates. The participants were asked to click the correct locations of the target symbols within the prescribed time limit. The game becomes more difficult as the size of the matrix, the number of target symbols, and the complexity of the matrix rotation change at each level. Each cognitive function training session lasted between 3 and 5 minutes.
45774168|NCT05297279|Behavioral|Home delivery Omega-3 rich Food|The active treatment arm will receive voucher (with a specified amount) weekly home delivery omega-3 rich food for the 12-weeks (3 months) intervention. Participants will be limited to purchasing foods rich in omega-3 only.
45774169|NCT05297279|Behavioral|Dietary Motivational Coaching|The active treatment arm will receive weekly personalize dietary couching by a dietary coach on omega-3 rich food for the 12-weeks intervention. Participant will also receive educational materials and guidance about what kind of food to order, how to cook, prepare (recipes) and store omega-3 rich foods.
45774170|NCT05297279|Behavioral|Home delivery Food|The control treatment arm will receive voucher (with a specified amount) weekly home delivery food (any kind of food) for the 12-weeks (3 months) intervention. Participant will not receive dietary coaching on food choices and will not be limited to purchasing foods rich in omega-3.
45634781|NCT02407951|Behavioral|CBIT group|"Child group: 8 weekly group sessions lasting 90 mins, additional three monthly booster sessions.~During sessions, children create a tic hierarchy from most to least distressing, with more distressing tics addressed earlier in the treatment. Awareness training and competing response training is implemented and practiced. Competing response training is added, involving engagement in a voluntary behavior physically incompatible with the tic, contingent on the premonitory urge or other signs of impeding tic occurrence. Relaxation training addresses situations that sustained or worsened tics, training focuses on developing individual behavioral strategies to reduce the influence of these factor.~Parallel parent-group sessions simultaneously run during first 4 sessions of child-group. parents-group includes psycho-education and use of reward strategies.~Meetings executed by two trained clinicians."
45634782|NCT02407951|Behavioral|Psycho-Educational group|"Child group: 8 weekly group sessions lasting 90 mins each, as well as additional three monthly booster sessions afterwards.~During the educational group sessions, each session will focus on educating the participants in regard to a specific subject: Tourette syndrome, Self-esteem, Anger, OCD (obssesive compulsive disorder), School and bullying, Anxiety, Attention, and a final session Quiz.~Parent group: Parent-group sessions will simultaneously run during the first 4 sessions of the child-group. The parents-group will include psycho-education and the use of reward strategies.~All group meetings will be executed and managed by two trained clinicians."
45634783|NCT02400385|Drug|sunitinib|sunitinib 50mg/day po, 4 weeks on 2 weeks off
45634784|NCT02400385|Drug|nivolumab|nivolumab 3mg/kg IV ever 2 weeks
45634785|NCT03173677|Dietary Supplement|Lipid Intake|90 grams whipping cream, 31.5 grams fat, 1.7 grams protein, and 2.25 grams carbohydrate
45634786|NCT03173677|Dietary Supplement|Glucose intake|300 calories of glucose
45634787|NCT03173677|Dietary Supplement|Protein intake|Isopure unflavored Whey proteins isolate (WPI) powder containing 26 grams per serving of 100% WPI, stripped of fat, carbs, fillers, sugars, and lactose
45634788|NCT02405065|Drug|HM95573|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
45774171|NCT05295589|Procedure|Computed Tomography|Undergo CT scan
45914449|NCT02043535|Device|Delivery of precise levels of carbon dioxide with the RA-MR™ Virtual Sequential Gas Delivery System.|"All participants will undergo a baseline rest Rb-82 positron emission tomography (PET) myocardial perfusion imaging scan (MPI) with low-dose computed tomography. Following this baseline study, serial Rb-82 PET MPI using a target level of carbon dioxide (CO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A rest/stress Rb-82 PET MPI will be performed after return to normal CO2 levels (normocapnea) using persantine as the stress agent.~Myocardial perfusion stress testing"
45634789|NCT03173599|Drug|PNA 40mg|The beginning dose is 40mg.
45634790|NCT03173599|Drug|PNA 80mg|The single dose is 80mg.
45634791|NCT03173599|Drug|PNA 160mg|The single dose is 160mg.
45634792|NCT03173599|Drug|PNA 240mg|The single dose is 240mg.
45634793|NCT03173599|Drug|PNA 360mg|The single dose is 360mg.
45634794|NCT03173599|Drug|PNA 480mg|The single dose is 480mg.
45914450|NCT02043535|Device|Delivery of rubidium radioisotope (Rb-82) using the automated pump/elution system|All participants will undergo a baseline rest Rb-82 positron emission tomography myocardial perfusion imaging scan (PET MPI) with low-dose CT. Following this baseline study, serial Rb-82 PET MPI using three target levels of pulmonary end-tidal carbon dioxide tension (PetCO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A second rest Rb-82 PET MPI will be performed after return to normocapnea, followed by a pharmacologic persantine stress Rb-82 PET MPI.
45914451|NCT02043561|Other|induction of urge by rectal distension|
45634795|NCT03173599|Drug|PNA Placebo|The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg.
45774172|NCT05295589|Drug|Copanlisib Hydrochloride|Given IV
45774173|NCT05295589|Procedure|Magnetic Resonance Imaging|Undergo MRI
45774174|NCT05295589|Drug|Olaparib|Given PO
45774175|NCT05295589|Drug|Paclitaxel|Given IV
45774176|NCT05295589|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
45774177|NCT05295589|Drug|Topotecan Hydrochloride|Given IV
45774178|NCT05286294|Biological|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT)
45914452|NCT02043600|Behavioral|Yoga|12-week Hatha Yoga intervention 90 minutes once a week
45634796|NCT03173287|Procedure|Quantification of liver fibrosis|Procedure MRI and liver biopsy
45634797|NCT02425787|Behavioral|Interview|"This is a prospective study with a semi-structured in-depth qualitative interview. Interviews will be conducted by the study PI or designee. However, in order to ensure that the interviews are conducted sensitively, the first 10 interviews will be observed and supervised by a clinically credentialed St. Jude faculty member, and an additional 10% of the interviews will be observed after that.~In order to ensure that the interviewer does not lead the participant, or in turn, that the participant does not feel limited in regards to what they believe is an appropriate or desired response, the semi-structured interview questions are general and intended to produce broad responses in regards to participant experiences."
45634798|NCT02425787|Behavioral|Focus Group|"Focus groups will be conducted with a two-fold purpose in mind:~With bereaved parents: to validate the findings of the preliminary analyses of the initial interviews &/or to suggest avenues of further inquiry to expand and more deeply define the grief journey of bereaved parents.~With Hematology/Oncology Fellows: to receive input regarding the applicability and use of the findings during the training and future careers of these medical providers."
45634799|NCT02425787|Behavioral|Interview|The interview will be conducted by study team members and will center around legacy item-related questions.
45914453|NCT02043600|Behavioral|Self-care|Self-care books are provided for self-directed use
45634800|NCT03173365|Drug|Brimonidine Tartrate|1 gram of Brimonidine 3 mg/g gel (Mirvaso®) in 24 hours on the randomized palm equal to a finger tip unit (FTU) of 0.5 gram , topical application under occlusion twice per day, every 12 hours.
45634801|NCT05100953|Behavioral|Physical Activity Counseling|Physical activity counseling will be provided under supervision by the researcher physiotherapist via video conference and an individual physical activity program will be organized weekly for two months.
45634802|NCT03171337|Device|Acupuncture|Acupuncture at acupoints for CTTH according to TCM theory using stainless filiform needle.
45774179|NCT05284955|Device|CardioMEMS HF System|The CardioMEMS HF System is a wireless pulmonary artery pressure monitor. We will use measurements from the device to guide medical heart failure therapy.
45774180|NCT05284955|Drug|Standard heart failure medical therapy|Standard heart failure medical therapy as recommended by guidelines.
45914454|NCT02043613|Other|Contextually enhanced physical surroundings of exercise|"Different physical surroundings of exercise may affects the patients differently and consequently influence the effect of exercise. The exercise rooms are different from each other on parameters such as source of lighting, acoustics, materials and decorations.~The differences with the physical surroundings of exercise is the primary intervention for this study."
45634803|NCT03171337|Device|Fu's Subcutaneous Needling (FSN)|Fu's subcutaneous needling at specific points for CTTH using soft casing needle.
45914455|NCT02043613|Other|Neuromuscular exercise|The neuromuscular exercise program is the same across the two exercise groups. Consequently, this intervention is not the primary intervention of this study. The exercise program is based on the previously reported NEMEX program designed for patients with hip or knee osteoarthritis, originally published by Ageberg et al, 2010 in BMCMusculoskeletal Disorders.
45914456|NCT02043626|Other|DISTRICT WELLNESS COMMITTEE|Three Targeted Schools (N+PA) will expand the District's school based wellness initiative, PAW-Physical Activity and Wellness. With District support, PAW schools develop School Wellness Teams (SWTs) to identify school health priorities, implement and sustain health initiatives through school campaigns, promote healthy behavior, and support wellness policies. Results from a 3-year evaluation suggest significant and sustained positive impact on school health culture, student behavior, time-on-task, and increased physical activity among students.
45634804|NCT03171337|Device|Sham acupuncture|Sham acupuncture at non-acupoints using Steinberger placebo needles
45634805|NCT05374967|Behavioral|Lifestyle intervention: Live with IBD|"A digital lifestyle intervention divided into two phases:~An intensive phase lasting six months~a facultative phase lasting six months~During the Intensive Phase, participants will receive regular counseling by a nutritionist and a lifestyle coach in groups of 25 people. Participants will also follow five online meetings focusing on either nutrition, exercise, sleep, and stress. In addition, participants will have 24/7 access to an online platform that contains additional information, challenges, recipes, and peer-support groups. Finally, during the facultative phase, participants can attend smaller group sessions for additional counseling by a nutritionist or a lifestyle coach; these sessions will be organized every six to 12 weeks."
45634806|NCT05374967|Other|Control group|The standard of care for patients with IBD suffering from chronic fatigue.
45634807|NCT05100719|Drug|alverine-citrate + simethicone and lactase|Patients who randomized in the first arm are treated with alverine-citrate + simethicone and lactase.
45634808|NCT05100719|Drug|alverin-citrate + simethicone with placebo|Patients in the second arm receive alverin-citrate + simethicone with placebo without lactase.
45634809|NCT05100563|Drug|50 mg naltrexone|Medication combined with twice a week psychotherapy
45634810|NCT04828109|Device|Virtual Reality|Use of any virtual reality experiences available
45634811|NCT04828109|Device|Fitbit|Use of a Fitbit wearable activity device to track daily step goals.
45634812|NCT05100329|Drug|Mitoxantrone Hydrochloride Liposome injection|20 mg/m^2, IV, on day 1 of every 3 weeks (q3w, a cycle)
45634813|NCT04530539|Dietary Supplement|Vitamin C|1000mg Vitamin C, at bedtime
45634814|NCT04530539|Dietary Supplement|melatonin|10mg melatonin, at bedtime
45634815|NCT04530539|Dietary Supplement|Placebo|Placebo at bedtime
45774181|NCT05277558|Other|Observational|Investigators are observing brain health over time (21 months) in these groups
45774182|NCT05271318|Biological|TILT-123|Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123
45774183|NCT05271318|Biological|Pembrolizumab|Pembrolizumab, a monoclonal antibody binding PD-1
45774184|NCT05264038|Drug|OC514 (Low dose)|Low dose level of OC514
45774185|NCT05264038|Drug|OC514 (Mid dose)|Mid dose level of OC514
45774186|NCT05264038|Drug|OC514 (High dose)|High dose level of OC514
45774187|NCT05264038|Other|Placebo|Placebo to match
45774188|NCT05263440|Device|Transcranial direct current stimulation (tDCS)|Participants will complete a single 30 minutes tDCS session targeting the left DLPFC while sitting in a comfortable position. At the end of the tDCS session possible side effects experienced during the tDCS session will be recorded along with their intensity (rated using the visual analogue scale, 0-10) and duration. The session can be aborted at any time for any reason if the participant wishes.The MINDD STIM tDCS system is composed of a management component, treatment module, single-use sponge patches and supporting patches, a headband to hold in position the sponge patches, and 2 cables. A trained study technician will program the stimulation device through the management component setting to the following stimulation parameters:Stimulation intensity: 2.0 mA or 1.5 mA; Stimulation duration: 30 minutes;Ramp up duration: 30 seconds (beginning of stimulation);Ramp down duration: 30 seconds (end of stimulation)
45774189|NCT05252598|Drug|Psilocybin|1mg encapsulated psilocybin
45634816|NCT04530539|Other|Symptom Survey|Daily symptom survey to be completed by patient electronically
45774190|NCT05252598|Drug|Inonotus Obliquus Whole Extract|1mg encapsulated chaga mushroom
45774191|NCT05245526|Device|STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS|Reprocessed noninvasive pulse oximeter sensors.
45634817|NCT02698891|Drug|Paclitaxel|
45634818|NCT02698891|Drug|Neulasta|
45634819|NCT04719065|Drug|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|Subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/ m2, IV, on day 1 of each cycle for a maximum of 8 cycles.
45774192|NCT05243888|Diagnostic Test|self-sampling|eligible women receive at their home address a self-sampling kit in addition to the conventional invitation letter
45774193|NCT05241990|Behavioral|Practice Facilitation|A practice coach will offer tools, resources, hands-on guidance, and content expertise to assist sites in offering a stepped care model of alcohol treatment to patients with unhealthy alcohol use.
45634820|NCT03171181|Other|Vestibular reeducation|Balance quality was registered with static and dynamic posturography. For spatial orientation is was registered Visual vertical and visual orientation perception. Vestibular disability was also assessed. Variables were registered at the beginning and at the end of a vestibular rehabilitation in UPVD participants. Vestibular rehabilitation consisted of 10 sessions of vestibular rehabilitation using dynamic posturography and visual reeducation. Duration of each session: 40 minutes. Twice a week.
45774194|NCT05241990|Behavioral|Alcohol Stepped Care|Based on severity of alcohol use, individuals receive brief alcohol intervention delivered in person or by computer, cognitive behavioral therapy by person or computer, or pharmacotherapy for alcohol use disorder
45634821|NCT04567745|Diagnostic Test|Retinal fundus photography|Fundus photographs
45634822|NCT03173443|Device|single lumen tube and bronchial blocker|fiberoptic intubation with single lumen tube and bronchial blocker
45634823|NCT03173443|Device|double lumen tube|fiberoptic intubation with double umen tube
45634824|NCT05087147|Device|0.7 mm stainless steel orthodontic wire|0.7 mm stainless steel orthodontic wire
45634825|NCT05087147|Device|Banded space maintainer|band and loop space maintainer
45634826|NCT03173209|Behavioral|professional development in Calm Moments Cards program|Professional development (lecture and coaching)was used in combination with informal coaching by occupational therapy practitioners to educate school personnel on signs of stress and how to embed evidence based strategies (cognitive behavioral, mindfulness, and sensory) throughout the school day to reduce stress and enhance emotional well-being in students using the Calm Moments Cards program.
45634827|NCT05099627|Other|"The questionnaire Cervical myelopathy treatment outcome questionnaire"|"Information gathered through clinical examination and questionnaires performed retrospectively over the phone, pre-operation and at 3- and 6-months post-operation. The questionnaire Cervical myelopathy treatment outcome questionnaire attached records information relating to co-morbidities and symptomology. The examination will be a thorough neurological examination in addition to a focused cardiovascular examination. Biochemical blood markers from existing blood markers or from GP records, which have been or would have been performed regardless of this trial. Radiological findings will be taken from routine MRI and cervical spine X-rays performed as part of the CSM diagnostic work-up"
45774195|NCT05236920|Device|Resuscitative Endovascular balloon occlusion of the aorta using a REBOA catheter device|In-hospital use of a REBOA catheter device during advanced cardiac life support
45634828|NCT05099627|Other|"The retrospective questionnaire CSM early diagnosis questionnaire"|To identify early clinical predictors of cervical myelopathy diagnosis based on individual patient-reported symptoms by using a questionnaire and patient characteristics as well as co-morbities, as well as clinical examination findings provided by community musculoskeletal teams.
45774196|NCT05236439|Device|Interposition supraciliary implant|Surgical placement of SV22 interposition supraciliary implant in the supraciliary space
45774197|NCT05230550|Drug|Somapacitan|Sogroya® therapy in participants with AGHD (only severe case) under normal clinical practice conditions
45774198|NCT05223829|Drug|Brexanolone|Brexanolone will be administered as a continuous IV infusion over 20 hours under medical observation
45634829|NCT05099627|Other|JOACMEQ questionnaire and mJOA|Used for prospective cohort via telephone at 3, 6 and 12-months post-operatively to assess treatment outcomes.
45634830|NCT02399683|Biological|Trichuris trichiura eggs|Live eggs from human whipworm, Trichuris trichiura
45634831|NCT02407873|Other|Non|
45634832|NCT02399605|Other|Stimulation|Subcutaneous abdominal electrical stimulation
45634833|NCT05076383|Other|Study Group (Motor relearning program)|Task-specific training based on motor relearning program will be performed for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each training session will consist of five training tasks: (1) bed mobility and sitting up over the side of the bed; (2) balanced sitting; (3) standing up and sitting down; (4) balanced standing; and (5) practice of walking.
45634834|NCT05076383|Other|Control Group (Conventional physical therapy program)|The conventional physical therapy program (CPT) exercises will be performed following a standard stroke rehabilitation program for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each CPT rehabilitation session will include the following exercises: (1) passive and active-assisted range of motion; (2) stretching; (3) strengthening exercises; (4) balance exercises; and (5) walking.
45634835|NCT02408029|Other|Observational study - no intervention|
45634836|NCT05108207|Other|Prevention software|The software is installed on an Alcatel OneTouch Pixi-3 10 tablet and is delivered every day to each patient between 9:00 am and 8:00 pm, with nighttime pickup (8:00 pm to 09:00 am), so the patient can rest and to charge the device. The first day, a previously trained health professional delivers the tablet and trains the older adults in its use, taking 10 to 15 minutes. The day after the tablet is delivered, the same person goes to the patient's room to check if he or she has any doubts or problems with its use. Both groups are advised to use the tablet 3 times a day, at least 10 minutes each time.
45634837|NCT05108207|Other|Placebo|All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.
45774199|NCT05223491|Procedure|En Bloc resection|Tumour is resected and removed from the bladder in one piece, if possible.
45774200|NCT05223491|Procedure|Conventional TURB|Tumour is resected piecemeal.
45774201|NCT05218096|Drug|ALXN2050|Oral tablet.
45774202|NCT05218096|Drug|Placebo|Oral tablet.
45935485|NCT00043394|Drug|0.16 mg/kg CpG 7909|0.16 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
45935486|NCT00043394|Drug|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
45935487|NCT00125671|Drug|Warfarin|
45935488|NCT00125749|Biological|Dendritic cell vaccination|Autologous Dendritic Cells Derived from PBMC, Cultured with Cytokines, Pulsed Ex Vivo with Irradiated Allogeneic (Colo 829) Melanoma Cells
45634838|NCT05108207|Other|Implement a program of non-pharmacological interventions to prevent delirium|Three months before the start of the clinical trial, an intervention is carried out in the Internal Medicine, Geriatrics and Intermediate Care Unit services of the 4 participating centers in order to establish a homogeneous plan of nPPD and assess adherence. The implementation methodology in the first stage will be according to the Consolidated Framework for Advancing Implementation Science (CFIR) model, used in a local pilot study.
45634839|NCT02399059|Procedure|Antibiotic lavage|Peritoneal irrigation with gentamycin-clindamycin solution
45634840|NCT02399059|Procedure|Normal saline lavage|Peritoneal irrigation with normal saline
45774203|NCT05214209|Behavioral|Digital health supported|Participants will be issued a fitness tracker, a Bluetooth enabled glucometer, and a custom developed app which they can communicate digitally to the study investigators either as a group or individually. In the beginning of the study, participants will be taught on how to use the program, how to interact with their coach, and the importance of maintaining motivation throughout the program. Participants will have access to a pharmacist-participant messaging, group messaging, daily challenges for behavior change, education articles (weekly bite-sized content over 4 weeks), food logging, steps and exercise logging, and feedback. They will be asked to log their weight, meals, and physical activity within the program on a weekly basis. Pharmacist will monitor participant progress through a web-based dashboard. Community pharmacist will be assisting users in setting specific, measurable, attainable, realistic, and time-based goals on a weekly basis.
45774204|NCT05214209|Behavioral|Usual care|Participants will be issued a fitness tracker and Bluetooth enabled glucometer but these functions will not be enabled or linked to any app. All participants will be given physical tracking sheets to log in their food intake, blood glucose levels and food diary but will not have access to a personal coaching. Participants are free to seek any assistance for their medical care during the study period.
45774205|NCT05212922|Drug|YH001 + Toripalimab|YH001 + Toripalimab
45634841|NCT05108051|Drug|ZSP1273|ZSP1273 tablets 600mg administered orally once daily
45634842|NCT05108051|Drug|Oseltamivir|Oseltamivir 75mg administered orally twice daily
45774206|NCT05199415|Behavioral|Health and Well-being Committee|Health and Well-being Committees (HaWCs) will be introduced in treatment sites as a means to facilitate on-going problem identification and collaborative processes for developing action plans, implementing small-scale, site-based improvements. HaWCs will involve 10-14 workers and frontline supervisors, with a worker and manager co-chair. HaWCs will identify challenges to safety, health, and well-being spanning physical hazards, COVID-19 protocols as relevant, other conditions of work (e.g., schedules, pace of work), and policies (e.g., absenteeism, performance management). They will then design and implement mitigating solutions and track outcomes. As such, HaWCs have a broader scope than traditional safety committees and will actively solicit worker voice regarding policies and practices that are not labeled as health and safety policies.
45634843|NCT02404909|Other|IVC diameters evaluation by intraoperative ultrasound|Out of consecutive patients who underwent hepatectomy for primary and secondary liver tumors, patients in whom IVC diameters were intraoperatively measured for clinical reasons were retrospectively selected and analyzed
45634844|NCT03765359|Drug|metforminhydrochloride|metformin 500 mg tablets and insulin
45774207|NCT05199025|Diagnostic Test|Biomarker|Perioperative biomarker analyses
45634845|NCT03765359|Drug|Placebo Oral Tablet|Placebo tablets mimic metformin 500 mg tablets and insulin
45634846|NCT02407483|Device|Laser Visual Guidance|Laparoscopic simulator training, tested with laser visual guidance
45634847|NCT02407483|Device|2 D vision|Laparoscopic simulator training, tested without laser visual guidance
45634848|NCT02404987|Other|Nutritional Supplement|
45634849|NCT04351295|Drug|Favipiravir|Favipiravir
45634850|NCT04351295|Drug|Chloroquine|chloroquine oral tablets
45634851|NCT05107895|Behavioral|online coping skills training|Young people with high levels of stress were given online coping trainings. The content of this training was primarily aimed at raising awareness about stress by giving information about stress, and then information about coping methods with stress was shared and training on problem solving skills was provided.
45774208|NCT05197725|Device|Face mask|Individuals in intervention communities will be given surgical or KF94 face masks.
45774209|NCT05197725|Behavioral|Face mask awareness|Intervention individuals will be told about the importance of wearing face masks that cover the nose, mouth, and chin. Mask by mask promoters and community and religious leaders will encourage mask wearing.
45634852|NCT02407639|Other|CO2|gas
45634853|NCT02407639|Other|air|air
45634854|NCT04344587|Other|Self-prone position recommendation|"The Qualtrics self-prone position recommendation intervention website will include the following sections:~Welcome message~Educational review of the potential benefits of prone positioning~How-To guide to safely prone in a hospital bed~A recommendation to prone while lying in bed (4 times for 1-2 hours each during the day and at night every 24 hours).~A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking"
45634855|NCT04344587|Other|Usual care|"The Qualtrics usual care website will include the following sections:~Welcome message~A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking"
45634856|NCT02399137|Drug|MM-141|
45634857|NCT02399137|Drug|Placebo|
45634858|NCT02399137|Drug|Gemcitabine|
45634859|NCT02399137|Drug|Nab-Paclitaxel|
45634860|NCT05236205|Procedure|Caries removal with a lowspeed drill|"Initial periapical and interproximal radiographs;~Prophylaxis with toothbrush and fluoride toothpaste;~Relative isolation with lip bumper, cotton roll, and aspirator;~Microbiological sampling with ear curette for standardization of volume of carious tissue;~Removal of carious dentin with carbide burs and manual instruments;~Additional microbiological sampling;~Clinical inspection of texture of remaining dentin with an exploratory probe;~Restoration with glass ionomer cement (Ketac Molar Easy Mix - 3M ESPE);~Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months."
45774210|NCT05197725|Behavioral|Face mask promotion through community values or individual information|"In intervention communities randomized to mask promotion through community values, promotional discussions and media will focus on encouraging groups of people to wear masks as a reflection of their values.~In intervention communities randomized to mask promotion through individual information, promotional discussions and media will target individuals and focus on the instrumental value of wearing masks (preventing the inhalation of viral particles)"
45774211|NCT05195827|Drug|PRM-125|Antihypertensive
45774212|NCT05180734|Biological|JS001/Placebo|JS001/placebo combine with Postoperative Adjuvant Chemotherapy
45774213|NCT05180734|Biological|JS001/placebo combine with Postoperative Adjuvant Chemotherapy|JS001/placebo combine with Postoperative Adjuvant Chemotherapy
45774214|NCT05180006|Drug|Atezolizumab Injection|Patients randomized to an atezolizumab arm will receive atezolizumab 840 mg IV on D1 (15 days +/- 48 h before the surgery date or the biopsy prior to the start of standard of care neoadjuvant systemic treatment.).
45774215|NCT05180006|Drug|Ipatasertib|Patients in the atezolizumab plus ipatasertib arm will receive treatment (ipatasertib) for 2 weeks unless unacceptable toxicity occurs. Patients will receive ipatasertib at a dose of 400 mg orally once a day on Days 1-14 until the day before the surgery or the biopsy before start standard of care neoadjuvant systemic treatment..
45774216|NCT05180006|Drug|Bevacizumab|Patients in the atezolizumab plus bevacizumab arm will receive a unique dose of bevacizumab as 10 mg/kg administered by IV infusion over 60 mins on day 1 cycle 1 (15 days before surgery +/- 48 h), the same day as atezolizumab.
45634861|NCT05236205|Procedure|Partial removal of carious tissue with the administration of Papacarie™|"Initial radiographs;~Relative isolation;~Microbiological sample with otoscope curette to standardize volume of carious tissue;~Application of Papacarie™ for 5 m inutes, removal of carious tissue around lateral walls of the cavity with noncutting curette and no removal of carious tissue on pulp floor;~Second microbiological sample of remaining dentin with curette;~Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~Restoration with glass ionomer cement;~Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment."
45634862|NCT05236205|Procedure|Partial removal of carious tissue with the administration of Papacarie™ and application of Bixa Orellana extract (20%)|"Initial radiographs;~Relative isolation;~Microbiological sample with otoscope curette to standardize volume of carious tissue;~Application of Papacarie™ with Bixa Orellana extract (20%) for 5 minutes, removal of carious tissue around lateral walls of the cavity with noncutting curette;~Irradiation of dental tissue for 1 minute on a single point;~Second microbiological sample of remaining dentin with curette;~Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~Restoration with glass ionomer cement;~Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment."
45774217|NCT05180006|Drug|Pertuzumab|Patients in the atezolizumab plus trastuzumab plus pertuzumab arm will receive single doses of pertuzumab on day 1 administered IV. Pertuzumab will be administered IV at a loading dose of 840 mg.
45774218|NCT05180006|Drug|Trastuzumab|Patients in the atezolizumab plus trastuzumab plus pertuzumab arm will receive single doses of Trastuzumab on day 1 administered IV. Trastuzumab will be given at a loading dose of 8 mg/kg.
45774219|NCT05179928|Procedure|Erector Spinae Plane Block (ESPB)|Postoperative Bilateral Ultrasound-guided ESPB
45774220|NCT05179928|Procedure|Rectus Sheath Block (RSB)|Postoperative Bilateral Ultrasound-guided RSB
45774221|NCT05168943|Device|Nylon (Polyamide) Epidural Catheter|Nylon (Polyamide) Epidural Catheter
45774222|NCT05168943|Device|Polyurethane Epidural Catheter|Polyurethane Epidural Catheter
45774223|NCT05162911|Behavioral|Ask, advise, Assist and refer to the Quitline|A nurse will ask, advise, assist and refer patient to the Quitline
45774224|NCT05162911|Behavioral|Ask, advise, Assist and referral to onsite counselor|A nurse will ask, advise, assist and refer patient to a counselor
45774225|NCT05162911|Behavioral|Ask, advise, Assist and referral to onsite counselor and NRT|A nurse will ask, advise, assist and refer patient to a counselor and provide nicotine replacement therapy in the form of gum
45774226|NCT05149144|Diagnostic Test|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule
45774227|NCT05149144|Behavioral|audio signal dataset creation and validation; machine learning analysis, empirical evaluations|The project tests and adapts the technology developed at MIT for vocalization collection and labeling, and contributes to data gathering among Italian subjects (and their quality validation) in order to create a multi-cultural dataset and to enable cross-cultural studies and analyses. Next, the focus is placed on the analysis of harmonic features of the audio in the vocalizations of the dataset to identify recurring individual features and patterns corresponding to specific communications purposes or emotional states. Supervised and unsupervised machine learning approaches are developed and different machine learning algorithms will be compared to identify the most accurate ones for the project goal. Last, an exploratory evaluation of the vocalization-understanding machine learning model is conducted to test the usability and utility of the tool for vocalization interpretation.
45774228|NCT05148884|Drug|NLX-112|NLX-112 will be supplied as tablets containing 0.25 mg NLX-112. NLX-112 is a structurally novel centrally acting, high-efficacy selective 5-HT1A receptor agonist with nanomolar affinity for 5-HT1A receptors. Proposed as a treatment for L-DOPA-induced-dyskinesia in Parkinson's disease.
45774229|NCT05148884|Drug|Placebo|Placebo will be matching tablets (identical weight, shape and color) without NLX-112.
45774230|NCT05144854|Drug|ONO-4538|Specified dose on specified days
45774231|NCT05144854|Drug|Ipilimumab|Specified dose on specified days
45774232|NCT05144854|Drug|Oxaliplatin|Specified dose on specified days
45774233|NCT05144854|Drug|Capecitabine|Specified dose on specified days
45774234|NCT05144854|Drug|S-1|Specified dose on specified days
45935489|NCT00125827|Drug|clofarabine (oral formulation)|Cohorts of 3 patients each were to receive oral clofarabine administered daily for 5 days followed by 23 days of rest (1 cycle) and repeated every 28 days depending on toxicity and response. The starting dose of clofarabine was to be 1 mg/m2/day with subsequent dose escalation to occur in increments of 50% for the first 5 dose levels (1.5, 2.25, 3.5, and 5.0 mg/m2/day) and in increments of 25% thereafter until the MTD/RP2D was determined.
45935490|NCT00078039|Drug|Paliperidone ER|
45935491|NCT00043433|Drug|intravenous T900607-sodium|
45774235|NCT05128578|Behavioral|Liver Education About Pain (LEAP)|The study team plans to recruit patients at UPMC for participation in the Liver Education About Pain (LEAP) intervention program. LEAP is a modular 12-week pain self-management intervention with alternating group and individual sessions. Group sessions allow participants to practice skills, set goals with the group, seek social support, and learn together. Individual sessions serve the purpose of individualizing the program to the needs of the patients. The purpose of the LEAP program is to make pain better, help patients reach their personal goals (things that may be hard to do because of pain), and add to the care patients' medical team is providing.
45774236|NCT05128578|Behavioral|Usual Care|"Patients can continue to use other pain management strategies (usual care) in order to mimic real-life conditions."
45774237|NCT05121064|Behavioral|Alcohol Brief Intervention|The alcohol brief intervention (BI) was based on CETA'S substance use module and was designed for one-on-one delivery. It is comprised of 6 elements (i.e. assessment, understanding impacts, exploring possibilities of change, goal setting, identifying reasons for alcohol use and skill building) including a 2-week alcohol timeline follow back assessment completed by provider. The alcohol brief intervention (BI) will be conducted by a trained counselor.
45774238|NCT05121064|Behavioral|Common Elements Treatment Approach|CETA is a multisession cognitive behavioral therapy (CBT)-based model. CETA consists of elements: engagement, safety assessment, psychoeducation, substance use reduction, behavioral activation, cognitive coping, relaxation, exposure and problem solving. During a weekly clinic meeting, newly enrolled participants who are assigned to get CETA will be assigned to a specific counselor. The counsellor, together with their supervisor, will design an individualized treatment plan including type and order of Common Elements Treatment Approach (CETA) for each participant. The counsellor will contact participants by phone or home visit to schedule CETA session. CETA sessions will begin with standardized clinical monitoring form to track progress of treatment and each session will last 45-90 minutes.
45774239|NCT05121064|Behavioral|Standard of Care|Standard of Care (SOC) at HIV clinics in Zambia consist of Antiretroviral Treatment (ART) adherence counselling. All participants will receive Standard of Care (SOC), but for participants in Arm C it will be the only alcohol treatment. The ART adherence counseling includes brief unstructured discussion of substance use and mental health issues with a focus on issues that reduce adherence and retention issues. ART adherence counseling is delivered in a one-on-one format between patient and counsellor and it usually lasts 5-10 minutes.
45774240|NCT05110430|Other|Deep learning based detection of metastatic bone disease on bone scintigraphy scans.|The aim is to investigate whether deep learning algorithms can detect bone metastasis with high accuracy and specificity.
45935492|NCT00125866|Behavioral|Flavonoid rich or flavonoid depleted chocolate drink|
45634863|NCT05236205|Procedure|Partial removal of carious tissue with the administration of Papacarie™, application of Bixa Orellana extract (20%) and LED (aPDT)|"Initial radiographs;~Relative isolation;~Microbiological sample with otoscope curette to standardize volume of carious tissue;~Application of Papacarie™ with Bixa Orellana extract (20%) for 5 minutes and the blue light-emitting diode (LED) irradiation with 440-480 nm. Removal of carious tissue around lateral walls of the cavity with noncutting curette;~Irradiation of dental tissue for 1 minute on a single point;~Second microbiological sample of remaining dentin with curette;~Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);~Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment."
45634864|NCT05093387|Drug|Carboplatin|Given IV
45634865|NCT05093387|Biological|Pembrolizumab|Given IV
45935493|NCT00125905|Behavioral|Advice|
45634866|NCT05093387|Genetic|Transferrin Receptor-Targeted Liposomal p53 cDNA|Given IV
45634867|NCT02407171|Drug|MK-3475|200 mg every 2 weeks by IV infusion
45634868|NCT02407171|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction).
45634869|NCT05107349|Procedure|Muscle biopsy|A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
45634870|NCT03493295|Drug|Levonogestrel IntraUterine System (LNG-IUS)|At the routine clinical practice. Jaydess, Mirena, Kyleena Or any other levonogestrel intrauterine system (LNG-IUS) commercialized in Spain at the start of the study, only for contraception indication.
45634871|NCT02399293|Behavioral|N-back|"The N-back task required patients to monitor a continuous sequence of stimuli (in this experiment audio and visual stimuli). Press a button if the current stimulus is the same as that shown N back in the sequence. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
45634872|NCT02399293|Behavioral|Visual Search|"The Visual Search task consists of a NxN array of shapes. Press the button if a certain target stimulus is present in this array. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
45935494|NCT00125905|Behavioral|Motivational Interviewing|
45634873|NCT03952793|Other|extended biopsy|Additional sample are performed during a biopsy to provide tumor tissues for the organoid technique development
45634874|NCT02698423|Device|Cobas HPV DNA Test|Women will receive a home-sent sample for HPV self-testing
45634875|NCT02698423|Other|Papanicolau test|Women will be invited to come in for a physician-performed Pap test
45634876|NCT02967965|Other|Imagery|MRI at year 3
45634877|NCT02850263|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept for the treatment of DMO by the patient.according to the prescribing physician.
45634878|NCT02850263|Drug|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent [Ophthalmologicals / Antineovascularisation agents (S01LA05)] for the treatment of DMO by the patient.according to the prescribing physician.
45774241|NCT05099926|Behavioral|Reducing Exercise Sensitivity with Exposure Training|"Participants complete 2, home-based intervention visits on a secure video visit platform. Video visits include psychoeducation, interoceptive exposure, and interoceptive counseling. For homework, participants are asked to document their weekly physical activity and exercise sensations in a journal.~Psychoeducation: Participants are educated about the benefits and safety of exercise and cardiac rehabilitation, the role of fear and anxiety in exercise avoidance, and the concept of interoceptive exposure.~Interoceptive Exposure: A gradual six-minute walk (G6MW) serves as a low-risk form of interoceptive exposure. Exercise sensations and ratings of perceived intensity and distress are collected before and after the G6MW.~Interoceptive Counseling: Participants review and reflect upon their pre-walking and post-walking physical sensations and ratings (intensity and distress) with a research team member. Homework is also reviewed."
45774242|NCT05099666|Drug|Lurbinectedin|Dosage per protocol, escalation per protocol, IV over 60 minutes (± 5 minute infusion window), schedule per protocol
45774243|NCT05099666|Drug|Doxorubicin|Dosage per protocol, IV per institutional standards of practice and the FDA package insert, schedule per protocol
45774244|NCT05070065|Device|Cognitive remedy intervention with virtual reality (CEREBRUM)|Cognitive Remedial method Virtual Reality (CEREBRUM)
45774245|NCT05049135|Device|Somnofy® sleep monitor|Registration of sleep score and apneas with radar sensor technology at time of primary investigation and 12 weeks after treatment initiation with continuous positive airway pressure (CPAP)
45774246|NCT05042817|Drug|100 mcg morphine|The effect of intrathecal morphine on vesical function and the need for bladder re-catheterization after a cesarean delivery
45774247|NCT05042817|Drug|0.9% NaCl|NaCl 0.9%
45774248|NCT05042817|Drug|50 mg prilocaine + 2.5 mcg sufentanil|50 mg prilocaine + 2.5 mcg sufentanil
45634879|NCT02850263|Drug|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent [Ophthalmologicals / Antineovascularisation agents (S01LA05)] for the treatment of DMO by the patient.according to the prescribing physician.
45774249|NCT05042817|Procedure|bilateral transverse abdominal plane block|20 mL of ropicavaine 0.375% on each side
45774250|NCT05042505|Drug|Dapagliflozin 10Mg Tab|Dapa group (n = 50): Patients with diabetes mellitus will receive Dapagliflozin 10 mg
45774251|NCT05042505|Drug|Sitagliptin 100mg|Sita group (n = 50): Patients with diabetes mellitus will receive sitagliptin 100 mg once daily
45774252|NCT05030337|Device|Closed-loop automated oxygen control (Oxygenie, SLE 6000)|The OxyGenie closed-loop oxygen saturation monitoring software (SLE) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
45774253|NCT05030012|Device|Automated Control|The purpose of this intervention is to evaluate that the efficacy and safety during the automated performance of the Vapotherm OAM are not inferior to standard care practice (manual control) in maintaining SpO2 levels of 90-95% in preterm infants requiring oxygen adjustments while being treated with high velocity nasal insufflation (HVNI) therapy.
45774254|NCT05030012|Device|Manual Control|The purpose of this intervention is to establish an active comparator via standard care practice against which to evaluate the efficacy and safety of the automated arm of the study, for determination of non-inferiority of that automated control arm to manual control in maintaining SpO2 levels of 90-95% in preterm infants being treated with high velocity nasal insufflation (HVNI) therapy.
45774255|NCT05017675|Other|High fructose diet|"4 week high fructose diet.~Intended composition (En%):~Carbohydrates: 60-70 Fat: 20-30 Protein: 10-15 Fructose: 20 SFA: 5"
45774256|NCT05017675|Other|High saturated fat diet|"4 week high saturated fat diet.~Intended composition (En%):~Carbohydrates: 35-45 Fat: 40-50 Protein: 10-15 Fructose: 5 SFA: 20"
45774257|NCT04982926|Drug|TAS2940|Study participants with solid tumors and EGFR or HER2 aberrations will receive TAS2940 tablets daily at increasing doses until MTD is reached.
45774258|NCT04982926|Drug|TAS2940|Study subjects with select solid tumors characterized by EGFR or HER2 aberrations will receive TAS2940 at the dose identified during Dose Escalation phase.
45774259|NCT04965675|Drug|Eptinezumab|Eptinezumab will be administered per dose and schedule specified in the arm.
45774260|NCT04965675|Drug|Placebo|Placebo matching to eptinezumab will be administered per schedule specified in the arm.
45774261|NCT04955821|Diagnostic Test|mNGS diagnose of VAP|This study is an observational study to evaluate the accuracy of pathogens in children with VAP tested by mNGS with no intervention. All patients from the cohort accept mNGS test and bacterial culture or virus PCR detection. A double sputum specimens are used for test.The reference standard is bacterial culture or virus PCR detection.
45774262|NCT04952909|Device|ShortCut™|Splitting bioprosthetic aortic valve leaflets
45774263|NCT04939051|Biological|Obeticholic Acid|Given PO
45774264|NCT04939051|Drug|Placebo Administration|Given PO
45935495|NCT00125905|Drug|Nicotine Gum and Patch|
45935496|NCT00125905|Drug|Bupropion|
45935497|NCT00125944|Biological|FluMist|
45935498|NCT00078117|Drug|Buprenorphine|
45935499|NCT02970617|Other|Memory Intervention|Ring bell after final radiation treatment
45935500|NCT02970617|Other|Questionnaire Administration|Ancillary studies
45935501|NCT02970617|Radiation|Radiation therapy|Radiation therapy with or without chemotherapy
45935502|NCT00125983|Drug|Lopinavir/ritonavir|
45935503|NCT00125983|Drug|Ortho Novum 1/35|
45935504|NCT00125983|Drug|Ortho Evra|
45935505|NCT00126022|Drug|Tedisamil sesquifumarate|
45935506|NCT00078156|Behavioral|Behavior Therapy|
45935507|NCT00043511|Biological|pGA2/JS2 Plasmid DNA Vaccine|
45634880|NCT04481815|Drug|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 375mg/m2 intravenous infusion d1, every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
45634881|NCT04481815|Drug|Lenalidomide|25mg orally d1-10 every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 25mg orally d1-14,d29-42 every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
45774265|NCT04926675|Behavioral|Psychological Therapy|Participants will be receiving their one-to-one psychological therapy from IAPT as usual. They typically receive between 6 and 12 sessions with a psychological practitioner.
45774266|NCT04926675|Behavioral|Debt Advice|Participants will receive one-to-one support from a Citizen's Advice (CA) money advisor for as long as needed to resolve any money worries currently affecting their mental health.
45774267|NCT04914234|Drug|Atenolol Succinate Oral Tablet|Atenolol 50 mg
45774268|NCT04914234|Drug|Metoprolol Succinate Oral Tablet|Metoprolol 100 mg
45774269|NCT04913649|Drug|Ferric Derisomaltose 100 MG/ML|Postoperative treatment with a single dose IVI (ferric derisomaltose), with a dose of 20mg/kg in approximately 60 minutes.
45634882|NCT04481815|Drug|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
45634883|NCT05107037|Drug|TQ-B3234 capsule|TQ-B3234 is an anti-tumor molecular targeted drug, which is a selective Mitogen-activated protein kinase kinase（MEK）1/2 inhibitor
45634884|NCT02407093|Behavioral|High-Intensity Functional Training|Constantly varied functional movements performed at a high intensity and incorporating monostructural (aerobic), gymnastics (body weight) and/or weightlifting movements. CrossFit is a good model of HIFT for the military because of its emphasis on general physical preparedness and functional movements and because it is open source and programming is available at no cost (see www.crossfit.com). Sixty-minute HIFT sessions will include a warm-up, workout and cool down. Workouts will average 15 minutes in duration (range = 5-45 minutes) for a total of 50-100 minutes per week.
45634885|NCT02407093|Behavioral|Army Physical Readiness Training|Usual physical training program for Army personnel from directive FM 7-22, using the Reset phase. Exercises will address strength, endurance, and mobility training. APRT is designed to be completed in 60-90 minute sessions, 5 days/week for a total dose of 300-450 minutes per week.
45634886|NCT05106959|Behavioral|Motivational Interviewing Informed Shame Resilience Training|Shame resilience involves four elements. Understating shame, normalizing shame thoughts, reaching out, and speaking shame. Motivational interviewing will be used to elicit and guide participants through these four elements.
45774270|NCT04913649|Drug|Sodium chloride|Postoperative treatment with a single dose NaCl 0.9% in approximately 60 minutes.
45774271|NCT04896398|Device|ESWT|In the study group, a total of 5 sessions of focused ESWT (1000 shock, 1.6 bar, 5 Hz) will be applied to the affected wrist within 2 weeks.
45634887|NCT02404831|Other|Web-based PR|Participants will undertake web-based PR twice/week for 6 weeks in their own home. They will be given individual log-in details to access the website with access to exercises and education pages. Participants will be provided with a standardised exercise programme at the start of the study. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Participant log-ins and diaries will be monitored remotely and participants will be telephone at weeks 2 and 4 by their physiotherapist to discuss their progress and, at this time, exercises may be progressed by changing the level of difficulty/intensity. This is done remotely by physiotherapy staff.
45774272|NCT04895566|Biological|Monoclonal antibody (Mab) sB24M|200 mg monoclonal antibody (Mab) sB24 by injection into the affected areas.
45774273|NCT04889937|Device|PointCheck|PointCheckTM is intended for use to aid in the assessment of severe neutropenia in the home or clinic setting in subjects receiving myelosuppressive chemotherapy with intermediate to high febrile neutropenia risk. The device non-invasively captures real-time videos of blood flow in the nailfold microcirculation and utilizes visible light, a microscope and a computer vision software to provide a qualitative result. The device is limited to use as a preliminary assessment tool in conjunction with standard of care, including temperature monitoring and clinical assessment. It is not to be used as a stand-alone determinant of severe neutropenia or for any other diagnostic purpose
45774274|NCT04880538|Procedure|Endoscopic procedure|Endoscopic biopsy of one or more of the following: esophagus, stomach, small bowel, colon, or rectum as part of patient clinical care. Biopsies will be performed during endoscopy or colonoscopy and will be transported to the research laboratory for evaluation.
45935508|NCT00402454|Drug|isoniazid, rifampin + isoniazid or rifampin + pyrazinamide|
45448049|NCT02129218|Behavioral|Standard Dietary Intervention|Participants will be contacted by a nutritionist, in person every 2 weeks with phone contact on the alternating weeks. At the initial visit, each participant will be given verbal and written patient education materials, including low glycemic load diet recipes, meal plans, food preparation, and grocery shopping information. Individual instruction will be tailored to their baseline dietary preferences (e.g. vegan, allergies, etc).
45634888|NCT02404831|Other|Hospital-based PR|Participants allocated to this group will undertake hospital-based PR twice per week for 6 weeks in. Participants attend PR classes and complete a circuit based exercise class. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Following each class they will receive educational information about their condition.
45634889|NCT05106803|Drug|ciprofloxacin|Antibiotics used in vitro n the study
45634890|NCT02404753|Drug|Neoadjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 3 courses.
45774275|NCT04864561|Biological|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide 2 vaccinations 28 days apart
45774276|NCT04864561|Biological|AZD1222|2 vaccinations 28 days apart AZD1222 is a recombinant, replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 S surface glycoprotein.
45774277|NCT04864561|Biological|VLA2001 - adolescent part|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxid 2 vaccinations 28 days apart and with a booster vaccination on day 208. Placebo group will receive VLA2001 on day 208 and following second vaccination 28 days later.
45774278|NCT04864561|Biological|Placebo|2 vaccinations 28 days apart with placebo (PBS buffer based on Dulbecco's PBS media formulation without Calcium and Magnesium )
45935509|NCT00402493|Drug|ibuprofen, latanoprost, brimonidine|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
45935510|NCT00402493|Drug|Ibuprofen, brimonidine, latanoprost|to determine whether commonly used OTC non-steroidal anti-inflammatory agentsn(200mg ibuprofen) taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
45774279|NCT04848298|Behavioral|mHealth Intervention|"The Mobile Health Arm will receive standard of care including tailored prescription of physical activity as well as the mobile health intervention, which will have the following features:~Goal setting for frequency and duration of exercise sessions~Graphic feedback and reinforcement with educational and motivational messages tailored to user's exercise adherence.~Problem-solving support~Library with educational tips and information regarding physical exercise."
45774280|NCT04832685|Device|BrainSonix Pulsar 1002|Device that delivers low intensity focused ultrasound
45774281|NCT04826835|Behavioral|Prehabilitation intervention|"Participants will:~Receive four supervised exercise classes (twice per week for two weeks);~Practice six sessions of home-based exercise (three times per week for two weeks);~Practice unsupervised respiratory muscle training (daily for two weeks);~Receive usual care."
45774282|NCT04826835|Behavioral|Health education control|"Participants will:~Receive four health education talks (twice per week for two weeks)~Receive usual care."
45634891|NCT02404753|Procedure|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy with D2 lymph node dissection
45634892|NCT02404753|Procedure|Open gastrectomy|Open distal gastrectomy with D2 lymph node dissection
45634893|NCT02404753|Drug|Adjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 5 courses.
45634894|NCT03780803|Other|home cardiac rehabilitation and respiratory rehabilitation|
45448050|NCT02129218|Behavioral|Intensified Dietary Intervention|Patients will be contacted weekly, in person, by a nutritionist . Participants will take part in a cooking demonstration at the time of their initial visit. The demonstration will be hands-on and participants will be able to sample foods and recipes. In addition to grocery shopping information, participants will be accompanied by a nutritionist to their local grocery store to practice new shopping habits for their target dietary glycemic load. Each participant will also receive weekly random phone calls to assess his or her progress.
45774283|NCT04820309|Drug|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
45774284|NCT04816721|Drug|EDP-938|Oral suspension
45774285|NCT04816721|Drug|Placebo|Placebo oral suspension to match EDP-938
45774286|NCT04806113|Biological|Moderna COVID-19 vaccine|Two doses from the Moderna vaccine will be administered intramuscularly. The time between dose 1 and dose 2 of the vaccine will be 28 days.
45774287|NCT04795843|Other|Exercise and patient education|Over a period of 6-months, patients will be offered eight one-to-one supervised training sessions. In these sessions, patients will be instructed in a home-based exercise programme and given patient education. The programme includes four exercises covering strength and stability training. The exercises will be performed in sets of three with a minimum of 5 repetitions, and patients will be instructed to perform a minimum of three training sessions each week. Each of the exercises can be progressed through three levels of difficulty, allowing for individualised treatment with regard to exercise quality and perceived exertion according to the Borg CR10 scale. Exercises will be performed on a perceived exertion level from somewhat hard (level 5) to very hard (level 7). Patient education includes pain management, a focus on exercise adherence and progression, and advice on physical activity.
45774288|NCT04795843|Other|Usual Care|Patients will follow usual care, including an individual consultation on self-management of hip symptoms and general advice on exercise and physical activity.
45774289|NCT04794972|Drug|GNC-039|Administration by intravenous infusion.
45774290|NCT04779320|Drug|Vedolizumab IV|Vedolizumab IV
45774291|NCT04779307|Drug|Vedolizumab|Vedolizumab IV infusion.
45634895|NCT02404675|Drug|icotinib|
45634896|NCT05025761|Other|Personal protection package|The personal protection package will be distributed to mobile and migrant peoples in each village according to the stepped wedge design.
45634897|NCT03106441|Device|High flow oxygen therapy by nasal cannula. Optiflow®|Patients randomized in interventional group will received a four minutes preoxygenation period with High Flow nasal cannula (60 l/mn FiO2 = 1) before orotracheal intubation. The device will be maintained in place throughout the intubation procedure in order to achieve apnoeic oxygenation.
45634898|NCT03106441|Device|Facial mask oxygenation in BIPAP ventilation|Patients randomized in BIPAP group will receive a four minutes preoxygenation with EPAP 5, IPAP 15 FiO2 = 1 for a pressure support of 10 cm H2O. The facial mask with be removed after before crash induction enabling laryngoscopic vision
45634899|NCT05017883|Drug|TAA05 cell injection|"Chimeric antigen receptor T cells (car-t)~Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner,which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells."
45774292|NCT04770246|Drug|TAS-117|TAS-117 will be dosed orally every day on a 21-day cycle
45774293|NCT04770246|Drug|TAS-117|TAS-117 will be dosed intermittently on a 21-day cycle
45774294|NCT04770246|Drug|TAS-117|TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
45774295|NCT04770246|Drug|TAS-117|TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
45774296|NCT04769869|Drug|AZD4604 for inhalation via DPI|Healthy volunteers will receive AZD4604 administered with a DPI. The dose is expected to be administered between 10 to 45 minutes, depending upon dose. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
45448051|NCT02129218|Behavioral|Low glycemic load|
45634900|NCT05008991|Device|Spirometry|Spirometry assesses the integrated mechanical function of the lung, chest wall, respiratory muscles, and airways by measuring the total volume of air exhaled from a full lung (total lung capacity [TLC]) to maximal expiration (residual volume [RV]). This volume, the forced vital capacity (FVC) and the forced expiratory volume in the first second of the forceful exhalation (FEV1), should be repeatable to within 0.15 L upon repeat efforts in the same measurement unless the largest value for either parameter is less than 1 L. In this case, the expected repeatability is to within 0.1 L of the largest value.
45774297|NCT04769869|Drug|Placebo for AZD4604 for inhalation via DPI|"Part 1a: An additional cohort of healthy volunteers will receive a placebo administered with a DPI.~Part 2: Healthy volunteers will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 6, and a single dose will be administered on Day 7.~Part 3: Patients will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 9, and a single dose will be administered on Day 10."
45774298|NCT04769869|Drug|AZD4604 for IV administration|Healthy volunteers will receive a single IV dose of AZD4604 administered over 20 minutes. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
45774299|NCT04769869|Drug|AZD4604 for oral administration|Healthy volunteers will receive a single PO dose of AZD4604. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
45774300|NCT04769869|Drug|AZD4604 for inhalation via DPI|Patients with mild asthma will also receive AZD4604 administered with a DPI. Patients will receive BID doses on Day 1 to Day 9 (morning and evening with 12-hour intervals between doses), and a single morning dose will be administered on Day 10. On Day 1 and Day 10, the morning dose will be administered after an overnight fast of 10 hours. For all other doses, the dose will be administered after a 1-hour fast.
45774301|NCT04769011|Diagnostic Test|Clinical evaluation|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule, Social Responsiveness Scale, Children Behavior Check List, Conners' Scale
45774302|NCT04769011|Diagnostic Test|Neuropsychological evaluation|The participants' motor skills are measured using the Movement Assessment Battery for Children 2 (MABC2) (Henderson et al., 2007), the Developmental Coordination Disorder Questionnaire (DCDQ) (Wilson et al., 2007), and the kinematic analysis of a reach-to-drop task (Forti et al., 2011; Crippa et al., 2015).Sensorimotor domain will be also further investigated with NEPSY-II (Korkman et al., 2007) (Fingertip Tapping, Imitating Hand Positions, Manual Motor Sequences, and Visuomotor Precision).
45774303|NCT04769011|Diagnostic Test|Neurophysiological evaluation|Magnetic Resonance Imaging (structural MRI and DTI)
45774304|NCT04769011|Diagnostic Test|Genetic evaluation|Either blood or saliva will be obtained for participants for DNA collection. DNA will be extracted in the Molecular Biology Laboratory at the Scientific Institute IRCCS Medea. Captured exome libraries will be sequenced using the Illumina NextSeq 500 in 100 bp paired end reads. Postsequencing reads will be aligned using BWA Enrichment application on BaseSpace. VCF file will be then marked using wANNOVAR (Wang Genomics Lab). The analysis will be focused on non-synonymous variants enrichment in Gene Ontology and Human Phenotype.
45774305|NCT04762199|Drug|Flt3/MerTK Inhibitor MRX-2843|Given PO
45774306|NCT04762199|Drug|Osimertinib|Given PO
45774307|NCT04755881|Other|Occurence of biphasic reaction following anaphylaxis|Prospective observation for biphasic reaction following anaphylaxis and subsequent analysis (comparison between usual care and the care that would have been suggested by the three proposed clinical decision rules).
45774308|NCT04750720|Other|Sampling by venipuncture (and eventually by nasopharyngeal swab)|"Biological samples :~Serum and plasma from each donor for the purpose of performing (if applicable) the SARS-CoV-2 serologic test~PBMC (peripheral blood mononuclear cells)~Nasopharyngeal samples (not mandatory)~Associated data :~Demographic data~Description of clinical manifestations related to SARS-CoV-2 infection~Notion of hospitalization/ambulatory follow-up~Blood Fractioning~Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)~Separation of PBMC on Lymphoprep and freezing in liquid nitrogen for subsequent analysis of immune system cells"
45774309|NCT04737330|Drug|Secukinumab|Secukinumab 300 mg s.c. at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12
45774310|NCT04737330|Drug|Placebo|Placebo s.c. at Baseline, Weeks 1, Week 2, Week 3, Week 4, Week 8, Week 12
45774311|NCT04737187|Drug|Trifluridine/Tipiracil|Taken by mouth two times a day, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest
45774312|NCT04737187|Drug|Bevacizumab|administered every 2 weeks (Day 1 and Day 15)
45774313|NCT04734951|Other|Power/resistance exercise program|participants will complete a power/resistance program during 14 weeks. The exercise program will consist of training to improve muscle strength, neuromotor skills, flexibility, endurance, and a greater emphasis on maximum strength and power. The intensity will be set according the estimated repetition to failure.
45774314|NCT04734951|Dietary Supplement|HMB supplementation|Daily oral supplementation with 237 ml of a polymeric nutritional formula added with 1.5 g of HMB (Ensure Advance®)
45774315|NCT04733157|Drug|Tranexamic acid injection|Tranexamic 1g administered intravenously at the onset of skin incision at caesarean section
45774316|NCT04733157|Other|Normal saline placebo|10ml of normal saline will be administered intravenously at onset of skin incision at caesarean section to the placebo group
45774317|NCT04723147|Drug|Carbidopa Levodopa|Patients will receive L-DOPA at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA. Starting dose is 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day
45935511|NCT00402493|Drug|Ibuprofen|ibuprofen 200mg
45935512|NCT00402532|Drug|Everolimus|Initial dosage 2 x 0.75 mg/d
45448052|NCT02129218|Behavioral|Medium Glycemic Load|
45634901|NCT02700997|Device|Vascular Clip|Application of a titanium vascular clip (size small) to the base of each delayed absorbable suture placed at the vaginal apex on the internal vaginal side to help in identification by imaging
45448053|NCT02252614|Drug|naproxen sodium codein|Pain intensity, contramal consumption
45448054|NCT02252614|Drug|paracetamol codein|Pain intensity, contramal consumption
45448055|NCT02252614|Drug|Placebo|Pain intensity, contramal consumption
45448056|NCT02260570|Drug|Tolcapone|COMT Inhibitor
45634902|NCT02407015|Other|Nintendo 3DS gameplay|
45634903|NCT02404597|Device|NICOM (non-invasive cardiac output monitor)|"The non-invasive cardiac output monitor (NICOM) will be used to tailor fluid management to optimize resuscitation if the patient has an episode of hypotension (defined as systolic blood pressure <100 or mean arterial pressure <65). NICOM consists of two electrodes placed on the patient's chest and back and uses bioreactance technology to transduce signals to compute hemodynamic parameters on an associated monitor.~The electrodes will remain on the patient for twenty minutes. Once the electrodes are in place the patient's leg will be raised to 45 degrees and the monitor to which the electrodes are attached will generate a number that reflects stroke volume of the heart. The electrodes will be removed once this number is determined."
45634904|NCT04481659|Procedure|Lap partial ISR|A direct laparoscopic surgery with completely abdominal approach laparoscopic partial intersphincteric resection
45634905|NCT04481659|Combination Product|NCRT+Lap partial ISR|Preoperative radiation and chemotherapy + laparoscopic completely abdominal approach laparoscopic partial intersphincteric resection
45634906|NCT03115645|Other|Dynamic Work|The intervention consists of the introduction of sit-stand workstations and desk bikes in the participants work environment in a ratio of 1:2 with traditional desks and chairs. Employees will receive a half hour intervention session at the start of the intervention from an occupational physiotherapist, who will provide further intervention support in the ensuing 12 weeks. Intervention participants will also receive an activity tracker which provides feedback on sitting time and physical activity levels.
45634907|NCT03218423|Device|Epi proColon|Plasma cell free DNA SEPT9 promoter methylation test for colorectal cancer screening.
45634908|NCT02398981|Other|Clinical decision support tool|
45634909|NCT04826081|Other|data collection|data collection
45634910|NCT02398903|Other|Blood samples for measurement of drug Css|Blood samples for measurement of drug Css
45634911|NCT02398903|Other|DXA and impedancemetry|Body composition by DXA and impedancemetry
45634912|NCT04923971|Other|Purdue Pegboard|Participants will assemble the pegboard with their left, right, and both hands in each environmental condition.
45634913|NCT02398669|Drug|Lorcaserin hydrochloride|A single 10 mg dose of oral tablet formulation of lorcaserin hydrochloride will be administered with 240 mL of water.
45634914|NCT05041751|Procedure|Acupuncture Point Injection|Receive trigger point injections
45634915|NCT05041751|Procedure|Massage Therapy|Perform myofascial release
45634916|NCT05041751|Other|Quality-of-Life Assessment|Ancillary studies
45634917|NCT05041751|Other|Questionnaire Administration|Ancillary studies
45634918|NCT02398591|Drug|JNJ 53718678|JNJ 53718678 will be orally administered once in a dose of 250, 500 or 1000 mg on Day 1.
45634919|NCT02398591|Drug|Placebo|Placebo matching to JNJ 53718678 will be orally administered once on Day 1.
45634920|NCT02398357|Drug|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,alone with Nadroparin Calcium 4100IU／d，subcutaneous, when taking endoscopy therapy .
45634921|NCT04437641|Other|Tobacco questionnaire|"A questionnaire on smoking habits was given to all parents of children being followed in consultation for cystic fibrosis or type 1 diabetes, or whose child was hospitalized for the first time for bronchiolitis.~Provision of minimal advice (oral and a leaflet from the anti-smoking centre) to parents who smoke by the paediatrician following the child.~For parents who smoke, evaluation at 3 months of the impact of this minimal advice by another questionnaire during the usual follow-up of the patient at 3 months or by telephone contact."
45634922|NCT02398435|Biological|Tadekinig alfa (recombinant human IL-18 binding protein)|Patients received the study treatment three times a week subcutaneously.
45634923|NCT05090111|Drug|ALG-055009|Single or multiple doses of ALG-055009
45634924|NCT05090111|Drug|Placebo|Single or multiple doses of Placebo
45634925|NCT02398513|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg per oral
45634926|NCT04436939|Device|Dental implant|Following dental implant installation, PEEK or Ti healing abutments were placed according to the split mouth study design.
45634927|NCT02398279|Dietary Supplement|L-Arginine|Experimental supplement
45634928|NCT02398279|Other|Placebo|Placebo capsules in the same color and shape with the experimental supplement
45774318|NCT04723147|Drug|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the Carbidopa Levodopa tablet.
45774319|NCT04717635|Biological|Canakinumab|Provide as 150 mg/1 mL solution for subcutaneous injection and administer 4mg/kg every 4 weeks.
45774320|NCT04711239|Diagnostic Test|PGT-A / niPGT-A|PGT-A and niPGT-A will be performed using next generation sequencing (NGS) analysis for chromosome copy number variation (CNV). Embryo transfers will rely solely on the results of PGT-A for trophectoderm biopsies.
45634929|NCT04611425|Drug|Remimazolam|Patients will receive an infusion of Remimazolam for a maximum duration of 48 hours. The dose of Remimazolam will be adapted according to the ICU units protocol of analgesia-sedation management, based on validated scale (Richmond Assessment Sedation Scale). Owing to previous data gathered through a previous study in Japan, the initial dose of infusion will be within a 0.2-0.5 mg/min range. The dose of Remimazolam can be increased or decreased by 0.1mg/min when needed. The maximum dose of Remimazolam will be set at 1 mg/min.
45774321|NCT04691141|Drug|ATG-016|59 patients enrolled will be treated with 5 mg (QD×Days 1-5/week), orally, each 4 week (28-day) a cycle
45774322|NCT04688047|Behavioral|Nursing care based on the transtheoretical model|Nursing care consists of urinary incontinence training, motivational interview and telephone/mail counseling processes.
45774323|NCT04685044|Device|IH 1Tx32Rx Head Array|BrainPET insert
45774324|NCT04662710|Biological|Pembrolizumab|400 mg Q6W by IV infusion
45774325|NCT04662710|Biological|Lenvatinib|Administered PO QD, 8 mg induction/20 mg consolidation.
45935513|NCT00402532|Drug|Mycophenolatmofetil|Initial dosage 2 x 500 mg/d intravenous
45448057|NCT02260570|Drug|Placebo|A pill that contains no active ingredient
45634930|NCT04436471|Biological|Gam-COVID-Vac|adenoviral-based vaccine against SARS-CoV-2
45634931|NCT02398201|Drug|Bezafibrate|Bezafibrate 200mg-600mg three times daily for 12 weeks.
45634932|NCT05106179|Drug|Atenolol Pill|Atenolol is a second-generation hydrophilic β-1-selective adrenergic antagonist, which is primarily metabolised by the kidneys.
45935514|NCT00126061|Drug|Tedisamil sesquifumarate|
45935515|NCT00043589|Drug|donepezil|
45448058|NCT03681951|Drug|GSK3145095|GSK3145095 will be available as capsule (size 1 containing 5 to 25 mg GSK3145095 and size 0 containing 25 to 75 mg GSK3145095) or tablet (25, 50, 200 mg white to slightly covered round/oval shaped coated) for oral administration in the fasted stated with approximately 200 milliliters (mL) of water.
45448059|NCT03681951|Drug|Pembrolizumab|Pembrolizumab will be available as solution for infusion (100 milligrams/ 4 milliliter) at a dose of 200 mg via IV infusion for 30 minutes (given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted i.e., infusion time is 25 to 40 minutes).
45634933|NCT05106179|Drug|Propranolol Pill|Propranolol is highly lipophilic, nonselective β-blockers, which is primarily metabolised by the liver.
45634934|NCT04480567|Drug|BMN 307|AAV Gene Therapy Infusion
45634935|NCT04670471|Drug|Remimazolam|Remimazolam is an intravenous anaesthetic and sedative drug. Remimazolam exhibits its anaesthetic effects via the benzodiazepine binding site at the GABAA receptor.
45634936|NCT04670471|Drug|Remifentanil|Remifentanil is a commonly used opioid in anaesthetic practice. It is a potent and fast-acting analgesic.
45634937|NCT02406781|Drug|Combination of MK3475 with Metronomic CP|"Combination of MK3475 with Metronomic CP. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intraveinously, and given every 3 weeks on day 8. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
45634938|NCT02406781|Drug|Combination of MK3475 with Metronomic CP and G100|"Combination of MK3475 with Metronomic CP and G100. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intravenously (200 mg), and given every 3 weeks on day 8.~G100 will be administered by intra-tumoral injection (20µg), one weekly injection for at least 6 weeks and for a maximum of 12 weeks. G100 will start one week before CP administration (impregnation phase).~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
45634939|NCT05106023|Drug|SHR-1701|SHR-1701 combined with temozolomide
45634940|NCT05106023|Drug|Temozolomide|SHR-1701 combined with temozolomide
45634941|NCT02398123|Other|Transversus abdominis plane block|Children who received transversus aAbdominis plane block with 0.25% bupivacaine with epinephrine 1 mL/kg guided by ultrasound
45634942|NCT02398123|Other|Caudal block|Children who received caudal 0.25% bupivacaine 1 mL/kg
45634943|NCT02398123|Drug|Bupivacaine|
45634944|NCT05105945|Procedure|Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery|"Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery dissects, dissociates and removes the esophagus in the mediastinum through an inflatable endoscopy. Detailed surgical procedures and related instructions have been published in Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery for Radical Esophagectomy Is an Effective and Safe Treatment for Esophageal Cancer J Gastrointest Surg. 2019 Aug;23(8):1533-1540. doi: 10.1007/s11605-018-04069-w. Epub 2019 Jan 11."
45634945|NCT05105945|Procedure|Thoracoscopy Combined With Laparoscopic Surgery|Patients will receive a standardized thoracoscopy and laparoscopy combined radical esophageal cancer surgery
45634946|NCT04480801|Other|Thermal Evaluation and Foot Care|Participants in the experimental group will be given foot care and thermal evaluation in the clinic and will be taught to the patient and / or their relatives. Thermal evaluation and foot care video will be uploaded to the patient and / or relative's phone.
45634947|NCT04480801|Other|Foot Care|Participants in the control group will be given foot care in the clinic and will be taught to the patient and / or their relatives. Foot care video will be uploaded to the patient and / or relative's phone.
45634948|NCT04486625|Drug|Aztreonam-Avibactam|500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours
45634949|NCT04486625|Drug|Aztreonam-Avibactam|675/225 mg ATM/AVI loading infusion, followed by 675/225 mg ATM/AVI extended loading infusion, then 675/225 mg ATM/AVI maintenance dose infusion every 8 hours
45634950|NCT02397967|Other|Neuropsychological assessments|"Neuropsychological assessments:~Intelligence Quotient (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette test, Lobrot test, Odedys test. Visio-spatial skill (JLO, Thurston, Corsi tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)"
45634951|NCT04458077|Behavioral|Discover Learning (SEIL)|This mobile-phone-based intervention will assess the effectiveness of 10 SEIL sessions conducted at the household level with VYAs. Activities were designed to be done individually, with siblings/peers, and with parents/caregivers. This intervention will look at how household composition and types of practice that can enhance SEIL learning.
45634952|NCT02404363|Drug|Clopidogrel|"Clopidogrel tablets 75 mg for six months:~In case of treatment with aspirin < or = 75 mg/d or prophylactic LMWH --> clopidogrel 75 mg/d If aspirin = 0 + LMWH = 0 --> clopidogrel 150 mg/d x 7days then 75mg/d"
45634953|NCT02404363|Drug|Placebo|"Placebo tablets 75 mg for six months:~In case of treatment with aspirin < or = 75 mg/d or prophylactic LMWH --> placebo 75 mg/d If aspirin = 0 + LMWH = 0 --> placebo 150 mg/d x 7days then 75mg/d"
45634954|NCT04872569|Behavioral|Decision-making tool|"Participants will be directed to use the decision tool for 3 months using it at their own pace.~The tool covers topics relevant to women with disabilities in considering or planning a pregnancy and reflects core elements of decision making tools based on the Ottawa Framework for Decision Support."
45634955|NCT02404519|Dietary Supplement|Menaquinone-7|1 tablet containing 180 micrograms MK-7 taken orally every day during 1 year
45634956|NCT02404519|Dietary Supplement|Placebo|1 tablet without MK-7 taken orally every day during 1 year
45634957|NCT03173131|Behavioral|Pre-operative opioid counseling|Patients will be randomized to receive counseling regarding opioid medication and post operative pain control.
45634958|NCT04524611|Drug|Risankizumab|Intravenous (IV) Infusion
45634959|NCT04524611|Drug|Risankizumab|Subcutaneous (SC) Injection
45935516|NCT00043589|Procedure|Memory-training class|
45935517|NCT00399399|Drug|azathioprine|
45935518|NCT00399399|Drug|cyclophosphamide|
45448060|NCT02131948|Drug|Intranasal insulin|Intranasal spray
45448061|NCT02131948|Drug|Intranasal placebo|Intranasal spray
45448062|NCT02129296|Device|Air filled balloon|Balloon filled with air according to the manufacturing company orders
45634960|NCT04524611|Drug|Ustekinumab|Intravenous (IV) infusion
45634961|NCT04524611|Drug|Ustekinumab|Subcutaneous (SC) injection
45634962|NCT02398045|Other|Computerised CBT for OCD|Computerised CBT for OCD
45634963|NCT02658149|Drug|Ropivacaine with NaCl|50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment
45634964|NCT02658149|Drug|Epinephrine|"0.15 mg Epinephrine are injected as part of the drug cocktail"
45634965|NCT02658149|Drug|Morphine|"4 mg Morphine are injected as part of the drug cocktail"
45634966|NCT02658149|Drug|Ketorolac Tromethamine|"30 mg morphine are injected as part of the drug cocktail"
45634967|NCT02658149|Drug|Ropivacaine|"30 mL 0.5% Ropivicaine are injected as part of the drug cocktail"
45634968|NCT03701711|Drug|Lenalidomide|"Dose Escalation~Patients in the dose escalation phase will receive oral treatment with:~Lenalidomide: 10, 15, or 25 mg on Days 1-21 of every 28-day cycle Dexamethasone: 20mg on Days 1,8,15 and 22~Starting doses of Lenalidomide will be assigned at the time of registration.~Dose Expansion~Once the MTD has been established or determined, 8 additional patients will be treated at the MTD of lenalidomide at the same schedule as above. Dexamethasone will be given at the same dose as in the dose escalation portion of the study."
45774326|NCT04662710|Drug|Oxaliplatin|130 mg/m^2 administered by IV infusion on Day 1 of Weeks 1 and 4 of each Q6W cycle as part of CAPOX chemotherapy, or 85 mg/m^2 administered by IV infusion on Day 1 and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.
45774327|NCT04662710|Drug|Capecitabine|1000 mg/m^2 administered PO twice daily (BID) on Days 1-14, 22-35 of each Q6W cycle as part of CAPOX chemotherapy.
45774328|NCT04662710|Drug|Leucovorin (or Levoleucovorin)|Administered by IV infusion at 400 mg/m^2 (leucovorin) or 200 mg/m^2 (levoleucovorin) on Day 1, and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.
45774329|NCT04662710|Drug|5-FU|400 mg/m^2 bolus IV infusion followed by 2400 mg/m^2 continuous IV infusion administered on Day 1, and Week 1, 3, 5, of each Q2W cycle as part of mFOLFOX6 chemotherapy.
45774330|NCT04662034|Device|CMIC|The C-MIC System consists of three implantable parts: a transvenous and an epicardial lead which are both connected to an implanted power source, and an external programing device. The patch lead is placed over the free wall of the left ventricle and fixated with sutures. When lead placement is achieved, the leads are then tunneled subcutaneously to the infraclavicular region and connected to the power source.
45774331|NCT04662034|Drug|Standard of Care (SOC)|Patients receive optimal SOC based defined in pertinent guideline and at the discretion of the investigator
45774332|NCT04659174|Drug|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
45774333|NCT04653662|Device|Earol|Treated with Earol on both ears and subsequent removal after 6 days of application
45774334|NCT04643405|Drug|APG-1387 for Injection|APG1387 will be administered IV days 1， 8, 15 and 22 of a 28 day cycle.
45774335|NCT04643405|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
45448063|NCT02129296|Device|Bioenteric BIB® balloon|Balloon filled with saline and methylene blue according to the manufacturing company orders
45634969|NCT04522895|Drug|Enasidenib|Participants receive up to 12 cycles of Enasidenib.
45634970|NCT03511079|Behavioral|Music|Music will be delivered through Pandora Plus radio via patient's computer or smartphone. The patient will choose a favorite song to create a playlist which will be used for the duration of the entire study. The subgenre of the initial song will be recorded.
45634971|NCT03458195|Other|bio-banking collection|blood samples, biopsies, and surgical specimen collected in addition to usual practice
45634972|NCT05111873|Other|multimodal treatment|combination of medical consultations, psychological therapy, physiotherapy, occupational therapy, disease specific education und progressive muscle relaxation
45634973|NCT05111405|Procedure|CMC Arthroplasty|Surgical intervention to treat CMC arthritis
45634974|NCT05105321|Drug|Berberine|The tablet of berberine and placebo are both coated with white sugar and had the same appearance. Berberine tablet will be orally taken with a dose of 500mg twice daily
45634975|NCT05105321|Behavioral|Healthy lifestyle intervention|"Healthy lifestyle intervention will be launched according to the Chinese guidelines on prevention of cardiovascular and metabolic diseases by Chinese Preventive Medical Association in 2019, including health lectures, health information promotion, health manual and so on."
45634976|NCT02698189|Drug|Birabresib Dose 20 mg|Administered as an oral capsule twice a day for 21 consecutive days per cycle.
45634977|NCT03172663|Device|pure tone audiometry|for estimate the type and degree of hearing loss
45634978|NCT02397733|Radiation|Prophylactic cranial irradiation (PCI)|Prophylactic cranial irradiation (PCI): 25 Gy in 10 daily fractions, five times a week
45634979|NCT02397733|Radiation|Hippocampal avoidance PCI|Hippocampal avoidance prophylactic cranial irradiation 25 Gy in 10 daily fractions, five times a week
45634980|NCT04482127|Other|SubEpithelial connective graft|Connective tissue graft harvested from hard palate, to be placed buccal to extraction sockets in the intervention group
45448064|NCT02136316|Drug|ASP7962|Oral
45448065|NCT02136316|Drug|Placebo|Oral
45448066|NCT02136394|Other|Gastro-esophageal reflux|This is an observational study. The exposure is the gastro-esophageal reflux.
45448067|NCT02132026|Drug|Denosumab|
45634981|NCT02397811|Dietary Supplement|Enteric Coated Softgels|Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose
45634982|NCT02397811|Dietary Supplement|Liposomal astaxanthin|Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 3.66 grams per dose
45634983|NCT02397811|Dietary Supplement|Standard Softgel|Standard softgel containing 4 mg astaxanthin per softgel. 3 softgels per dose
45634984|NCT02397811|Dietary Supplement|Astaxanthin Water Soluble Emulsion|Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose
45634985|NCT02397811|Dietary Supplement|Astaxanthin Water Dispersible Powder|Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose
45634986|NCT02397811|Dietary Supplement|Standard Softgel with Astaxanthin Gel|Standard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 soft gels per dose
45774336|NCT04643405|Drug|Nab paclitaxel|Nab-Paclitaxel 125mg/m^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
45774337|NCT04636190|Device|Triathlon All-Polyethylene Tibia Knee|Triathlon All-Polyethylene Tibia Knee is an all polyethylene resurfacing knee device using either a condylar stabilizing (CS) and posterior stabilizing (PS) device.
45634987|NCT04481971|Drug|Prednisolone|Tablets
45634988|NCT04481971|Drug|lactose in capsules gelatin|Tablets
45634989|NCT03170791|Device|vagal nerve stimulation intervention|During exercise sessions the therapist will the therapist will press a switch to trigger a run of vagal nerve stimulation in time with the patient's activity. No further activity involved.
45634990|NCT03172741|Drug|Medical Marijuana|1-gram marijuana cigarette smoked once per day for 3 months
45774338|NCT04633122|Drug|Ripretinib|Oral kinase inhibitor
45774339|NCT04633122|Drug|Sunitinib|second-line therapy in GIST patients who have progressed after imatinib treatment or are intolerant to imatinib
45914457|NCT02043626|Other|NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS|Policy changes will focus on 6 target schools. District will expand nutrition education by integrating other opportunities to learn and practice healthy behaviors across disciplines. Farm-to-School programs will include school visits by farmers to teach students about agriculture, healthy foods and nutrition, coinciding with Farmer's Market Menu Days. Schools will receive four 45 minute nutrition workshops per year. Community educators will offer culturally appropriate, interactive nutrition workshops and cooking demonstrations. Cafeterias will receive youth friendly nutritional messaging, regular promotion of new menu foods, and a variety of monthly nutrition-focused activities. The goals are to: increase number of students who try new menu items regularly, increase acceptance of healthy foods, and improve nutrition literacy. Policy states schools will limit celebrations that involve food to no more than 1 per class/month: 6 schools will pilot alternatives to food for celebrations.
45448068|NCT02132026|Drug|Alendronic Acid|
45634991|NCT03172741|Drug|Placebo|Matching 1 gram placebo cigarette smoked once per day for 3 months
45634992|NCT02702011|Drug|empagliflozin medium dose|
45634993|NCT02702011|Drug|empagliflozin low dose|
45634994|NCT02702011|Drug|empagliflozin high dose|
45634995|NCT02702011|Drug|placebo|
45634996|NCT03170713|Drug|arveles|800 mg ibuprofen and 50 mg dexketoprofen in 150 cc normal saline before operation will be given in 30 minutes. The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
45634997|NCT03170713|Drug|intrafen|800 mg ibuprofen in 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
45634998|NCT03170713|Other|placebos|150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
45634999|NCT02404207|Other|Soybean oil|Participants will be fed soybean oil as part of a controlled (typical American) diet.
45914458|NCT02043626|Other|HEALTH PROMOTION AND MARKETING|SWP addresses health promotion and marketing by limiting product marketing in schools, expanding nutrition education and broadening health communication with parents. In 3 targeted schools, we expand to include Staff Wellness Promotion. Adults in schools are trusted and influential role models for students; by increasing their positive health behaviors, students may be influenced to adopt similar behaviors. The District will work with the City's Employee Wellness Program to increase school staff participation.
45935519|NCT00126100|Drug|G-CSF Granulocyte-Colony Stimulating Factor|Patients were randomly assigned to receive subcutaneously a daily dose of 10 microg/kg of G-CSF for 5 days.
45935520|NCT00126100|Other|Placebo|Patients were randomly assigned to receive subcutaneously either a daily dose of 10 microg/kg of G-CSF or placebo for 5 days.
45935521|NCT00123253|Drug|TH9507|
45935522|NCT00126139|Drug|Abciximab|
45448069|NCT02132026|Drug|Denosumab Placebo|subcutaneous injection of 0.9%Saline at baseline, 6 months, 12 months and 18 months
45448070|NCT02132026|Drug|Alendronic Acid Placebo|Inert Capsule containing lactose monohydrate manufactured and labelled by Investigational Supplies Group (ISG) University of Edinburgh.
45448071|NCT02540811|Device|dCELL® ACL Scaffold|
45448072|NCT03735771|Drug|Bupivacaine|0.25% bupivacaine plus fentanyl 8 mcg/ml
45635000|NCT02404207|Other|High-oleic soybean oil|Participants will be fed high-oleic soybean oil as part of a controlled (typical American) diet.
45635001|NCT02404207|Other|High-oleic soybean oil + fully hydrogenated soybean oil|Participants will be fed a blend of high-oleic soybean oil and fully hydrogenated soybean oil as part of a controlled (typical American) diet.
45635002|NCT02404207|Other|Palm olein + palm stearin|Participants will be fed a blend of palm olein + palm stearin as part of a controlled (typical American) diet.
45635003|NCT02657369|Drug|Lenvatinib 24 mg|
45635004|NCT02397421|Drug|Dapagliflozin|Sodium Glucose Linked Transporter Type 2 (SGLT-2) Inhibitor
45635005|NCT02397421|Drug|Placebo|Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
45774340|NCT04630379|Other|Palliative Therapy|Visit with palliative care team
45774341|NCT04630379|Other|Quality-of-Life Assessment|Ancillary studies
45774342|NCT04630379|Other|Supportive Care|Visit with neuro-oncologist
45774343|NCT04630379|Other|Survey Administration|Complete survey
45774344|NCT04629924|Device|sleeper one|anesthesic injection with sleeper one device
45774345|NCT04629924|Device|conventional technis|anesthesic injection with the conventional technic
45774346|NCT04626609|Other|Biopsy samples|Esophageal mucosal biopsies are collected during gastroscopy
45774347|NCT04626609|Other|Blood samples|Blood will be drawn by venipuncture into citrate- or ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tubes and into serum tubes
45774348|NCT04605666|Biological|CD19-CAR-T2 Cells|CD19-CAR-T2 T cells will be infused over 10-15 minutes on Day 0.
45774349|NCT04591171|Procedure|n-of-1 trial guided clinical decision making|The n-of-1 trial will, on the level of the individual patient, test which treatment strategy produces superior blood pressure reduction without unacceptable side effects. After discussion with the patient/caregiver dyad to identify whether they have specific concerns about particular medications, the nephrologist (clinician) will decide which two drugs and dosages will be tested in the n-of-1 trial (the protocol does not determine drug or dose). The two drugs chosen by the clinician will be assessed at clinician-selected dosing in a randomized treatment order (e.g., ABAB) for two weeks per treatment period and two treatment periods per drug.
45774350|NCT04569747|Combination Product|Pertuzumab+TRASTUZUMAB|Trastuzumab + pertuzumab SC FDC (PHESGO) will be administered on Day 1 of each 21-day cycle , subcutaneous, fixed dose
45774351|NCT04569747|Drug|ADJUVANT ENDOCRINE THERAPY|Oral, daily per cycle
45774352|NCT04543942|Drug|Alcohol|Alcohol will be administered by IV infusion (60mg%). Brain activation during response inhibition (BARI) will be assessed using fMRI during performance of the stop signal task.
45774353|NCT04538950|Diagnostic Test|PET/CT|Positron emission tomography-computed tomography is an image test that helps show detail about how tissues and organs are functioning.
45774354|NCT04538950|Drug|radioactive drug (tracer)|A radioactive drug (tracer) is used in the PET scan.
45774355|NCT04535050|Device|Renal denervation|Renal Denervation: DENEX system
45774356|NCT04535050|Procedure|Renal angiography|Renal angiography
45635006|NCT04952779|Drug|Xultophy® (insulin degludec/liraglutide)|"Xultophy® is a fixed ratio combination of the long-acting basal insulin, insulin degludec, and the glucagon-like peptide 1 receptor agonist (GLP-1 RA), liraglutide, administered under the skin.~Patients will be treated according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS.~The assignment of the patient to Xultophy® is not decided in advance by the protocol but falls within current practice and the prescription of Xultophy® is clearly separated from the decision to include the patient in the study."
45774357|NCT04531046|Drug|axicabtagene ciloleucel|Patient-specific (autologous) product cryopreserved in cryostorage bag
45635007|NCT04862507|Other|Telephone call on day 90|telephone call on day 90 to assess the primary outcome (mRs 90)
45635008|NCT04862507|Diagnostic Test|Quantification of lesion water uptake by CT densitometry|Retrospective quantification of lesion water uptake by CT densitometry in admission and follow-up imaging
45774358|NCT04529343|Other|Virtual reality mediated upper extremity rehabilitation|"Game-based exercise will be applied for different range of motion of the upper extremity. Gamified exercise program consisting of 4 different scenarios will be applied 3 days a week for 6 weeks to the patients in the virtual reality group. A session takes an average of 45 minutes.~Games to be applied;~Finger flexion-extension (10 minutes / session)~Wrist flexion, extension, ulnar and radial deviation (10 minutes / session)~Forearm pronation and supination (10 minutes / session)~Elbow flexion-extension-shoulder internal and external rotation (15 minutes / session) will have scenarios controlled with. All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes."
45774359|NCT04529343|Other|Classical exercise therapy for upper extremities|All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes.
45774360|NCT04519983|Drug|Aumolertinib Oral Tablet|Aumolertinib 110 mg p.o. qd+ SRT(32Gy/4fx)
45774361|NCT04500158|Drug|Lidocaine|2% Lidocaine with 1:100,000 epi
45774362|NCT04466852|Other|telemedicine-guided consultation|Educational material is provided as short audiovisual films for understanding heart failure condition and management, how medicines work and their side effects, general advise on diets, exercise and importance of refraining from toxic exposure (smoke, alcohol, narcotics and damaging illegal medicines). Additionally, the patient (eventually assisted by their relatives and caregivers) can use this platform for learning basic important warning signs or cardiac decompensation based on feedback on recording regular measurements (weight, blood pressure and pulse and blood tests when needed) and symptoms. The cardiologist guides the patient and their Family/Basic doctors on the need for follow-up based on the parameters recorded. Videoconsultations with participation of the cardiologist, the Family/Basic doctor and the patient and relatives are used on demand.
45935523|NCT00043628|Procedure|Stem Cell Mobilization|
45448073|NCT02136550|Behavioral|Smoking cessation|Smoking cessation is a program that gives all the support to the subject: orientation, medications, exams, etc
45448074|NCT02132104|Procedure|Uterine application of amnion membrane|Uterine application of amnion membrane following hysteroscopic adhesiolysis.
45448075|NCT02132104|Device|Foley balloon|Uterine application of Foley balloon
45448076|NCT02132104|Drug|Femoston|Hormones treatment after surgery.
45774363|NCT04448314|Diagnostic Test|PointCheck|This is a usability study on PointCheck, a new technology to detect chemotherapy-induced neutropenia
45635009|NCT03168451|Behavioral|Culturally Tailored Text Messages|Members of the intervention group receive culturally tailored messages on the following schedule: 4 messages per day for 1 week prior to target quit date, 4 messages per day for 4 weeks following target quit date, 3 messages per week for 20 weeks following weeks.
45635010|NCT05110859|Other|in-depth individual interviews|in-depth individual interviews to explore their perspectives on their first work experience during covid-19 pandemic
45635011|NCT02397343|Drug|Hyperbaric oxygen|
45635012|NCT04850339|Biological|ANXV|Intravenous infusion
45635013|NCT04850339|Other|Placebo|Intravenous infusion
45635014|NCT02403973|Other|IN2005E|IN2005E is a validated questionnaire that measures patient satisfaction
45635015|NCT04832009|Drug|Dextrose 20 % in 500 ML Injection|Dextrose (20% intravenous solution) will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, dextrose will be administered via antecubital vein at a standard rate of 4 mg/kg/min for 2 hours.
45635016|NCT04832009|Drug|Intralipid|Intralipid ® 20% will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, Intralipid ® 20% will be administered via antecubital vein at 0.75 mL/min for 2 hours Increases in circulating markers of oxidative stress peak within 2 hours of Intralipid ® 20% infusion in healthy adults (42). An initial heparin bolus of 1000 UL followed by 200 U/hr infusion will be included to activate endothelial lipoprotein lipase and accelerate hydrolysis of fatty acids.
45774364|NCT04439344|Drug|Binimetinib|Given PO
45774365|NCT04439279|Drug|Trametinib Dimethyl Sulfoxide|Given PO
45774366|NCT04439201|Drug|Palbociclib|Given PO
45448077|NCT02136628|Procedure|Method RTL|"The method consists of two lines of suture, each, over the fascial wound edge. It starts with a suture strand (in this study was used PDS number 0) in one end of the fascial wound where the suture is run longitudinally and parallel to the aponeurotic edge. The needle should go in and out at intervals of 1 cm away and always kept at 0.5 cm from the edge of the fascia. Upon reaching the opposite angle of the wound suture strand another repeating the same process on the fascial edge otherwise used. The ends of the two suture strands are tied in fascial angles.~Thus the fascial wound is sutured with two lines of strengthening its edges. Then proceed to close the wound with continuous súrgete always ensuring that the suture lines remain anchored on suture reinforcement."
45635017|NCT04832009|Drug|Saline|Saline will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. Will be administered via antecubital vein at 75 to 150 mL/hour for 2 hours.
45635018|NCT04832009|Drug|Ascorbic acid|"(ASCOR) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min. The KU Investigational Pharmacy will randomize ascorbic acid or placebo (saline) for each participant."
45635019|NCT03115957|Other|Parenteral Nutrition|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 or at day 8 after abdominal surgery.
45635020|NCT03129113|Drug|Maraviroc|1:1:1:1 randomisation to one of four arms for 48 weeks
45635021|NCT03129113|Drug|Metformin|1:1:1:1 randomisation to one of four arms for 48 weeks
45635022|NCT03116035|Other|Web-based decision aid|Patients were randomized to receive links to a commercially available decision aid.
45774367|NCT04439175|Drug|Taselisib|Given PO
45774368|NCT04426838|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBTi) via Videoconference|The CBTi protocol will include stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring which will be done over 4 weeks with one session weekly delivered via videoconference.
45774369|NCT04396834|Drug|Lorcaserin Oral Tablet|Lorcasering 10mg Oral Tablet (BID)
45774370|NCT04396834|Drug|Placebo oral tablet|Placebo Oral Tablet (BID)
45774371|NCT04396262|Other|Food-1|HTD-blueberry beverage with white bread.
45774372|NCT04396262|Other|Food-2|Sweetened water with white bread as a control.
45774373|NCT04349891|Device|Transcutaneous Electroacupuncture|Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions.
45448078|NCT03681405|Other|Informational Intervention|Given information about mindful movement and breathing
45448079|NCT03681405|Other|Questionnaire Administration|Ancillary studies
45448080|NCT03681405|Behavioral|Telephone-Based Intervention|Receive caring attention phone call
45774374|NCT04349891|Device|Sham TEA|Sham will be delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions.
45774375|NCT04339517|Procedure|Aspiration of seroma fluid|Fluid will be collected from the lumpectomy site of patients between one to six weeks post-surgery and tested for the presence of persistent tumor cells (PTCs).
45774376|NCT04332471|Procedure|Radial shockwave therapy|Target intensity will be within a range of 3.5-5.0 bar at maximum Hz, titrated up to patient tolerance within 100 pulses. Total of 3000 pulses.
45774377|NCT04332471|Procedure|Focused shockwave therapy|Target intensity will be within a range of 0.15-0.25 mJ/mm2 at maximum Hz, titrated up to patient tolerance within 100 pulses. Total of 3000 pulses.
45774378|NCT04332471|Device|Shockwave therapy device|The shockwave therapy device will be used to administer either radial or focused shockwave therapy.
45448081|NCT02129374|Procedure|Direct repair of pars defect|Direct repair at pars defect was performed with 4.5mm cortical screw in young spondylolytic patients.
45635023|NCT03116035|Other|Standard websites|Patients were randomized to receive links to standard, high-quality websites.
45635024|NCT05105165|Diagnostic Test|Enzyme linked immunosorbent assay|Determination of serum β 1-aa content
45635025|NCT03170635|Behavioral|Refreshing Recess program|6-week program integrated into recess in order to build capacity of recess supervisors to foster active play and socialization so that all students enjoy recess and socialization with peers.
45635026|NCT05110547|Biological|blood collection|2 additional 5ml EDTA tubes, with assays for the following markers: 24S and 27 hydroxycholesterol (gas chromatography-mass spectrometry, GC-MS), Neurofilaments (SIMOA), oxydative phosphorylation (OXPHOS) and quantitative measurement of intracellular ATP (ELISA), Very long chain fatty acids (GC-MS), Octanoyl CoA (HPLC), Uric acid, MDA assay (TBAR assay kit), and Lipid panel.
45635027|NCT02397577|Other|Solid test meal, liquid test meal on two separate occations|13C labeld solid test meal, 13C labeld liquid test meal on two separate occations
45635028|NCT05105009|Drug|Furosemide|"Furosemide Stress Test ( 1mg/kg in non diuretic users and 1.5 mg/kg in diuretic users).~Oral creatinine load using 5 grams of creatinine"
45635029|NCT03168529|Drug|Ivabradine|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
45635030|NCT03168529|Drug|Placebo|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules not containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
45635031|NCT03115879|Other|Hip mobilization|High velocity low amplitude hip mobilization of the experimental group
45635032|NCT03115879|Other|Hip manipulation simulation|Hip manipulation simulation
45635033|NCT05104931|Drug|Nanoformed Piroxicam IR Tablet|Orally delivered Nanoformed Piroxicam
45635034|NCT05104931|Drug|Felden (piroxicam) Tablets|orally delivered Felden (reference) tablets
45635035|NCT05104931|Drug|Brexidol (piroxicam) Tablets|orally delivered Brexidol (reference) tablets
45635036|NCT02397499|Drug|LIPO-202|
45635037|NCT02397499|Drug|Placebo|
45774379|NCT04332471|Other|Home therapy|Stretching and ice massage
45774380|NCT04320810|Other|no intervention|It's only observational study. No interventions.
45774381|NCT04304755|Drug|Zoledronic Acid 5 MG in 5 ML Injection|Zoledronic acid
45774382|NCT04304755|Drug|Placebos|NaCl 0.9%
45774383|NCT04302428|Biological|Serum Zn|The investigators will obtain an additional 2 mL of blood in an extra tube. This will be collected at the same time blood is collected for the participant's yearly CF screening labs so as to minimize additional needle sticks.
45774384|NCT04302428|Biological|Red Blood Cell Zn|If the participant is greater or equal than 5 kg, an additional 2 mL of blood will be obtained in an extra tube. This will be collected at the same time blood is collected for the participant's yearly CF screening labs so as to minimize additional needle sticks.
45448082|NCT00174785|Drug|dronedarone (SR33589)|oral administration (tablets)
45448083|NCT00174785|Drug|placebo|oral administration (tablets)
45448084|NCT03681093|Drug|Fevipiprant 150 mg|Fevipiprant (QAW039) 150 mg once daily administered orally as tablet
45448085|NCT03681093|Drug|Fevipiprant 450 mg|Fevipiprant (QAW039) 450 mg once daily administered orally as tablet
45448086|NCT03681093|Drug|Placebo|Placebo once daily administered orally as tablet
45635038|NCT02847689|Behavioral|Language Treatment|Recording of a mother's voice reading a children's storybook.
45635039|NCT02847689|Behavioral|Control Treatment|Standard of Care
45635040|NCT02406703|Drug|Chloroprocaine|
45635041|NCT02406703|Drug|Mepivacaine|
45635042|NCT02682641|Drug|IBRUTINIB|Ibrutinib 560 mg daily po for 28 days (cycle one). Continuous cycles until disease progression or unacceptable toxicity.
45635043|NCT02682641|Drug|Rituximab|Rituximab 375 mg/m2 iv day 1,8, 15 and 22 (cycle 1, 4 doses). Rituximab 375 mg/m2 iv, day one of every other cycle for 4 doses (cycle 3, 5, 7 and 9).
45635044|NCT02397031|Behavioral|Mindfulness|weekly psychotherapy sessions for 10 weeks (120 min each)
45635045|NCT02397031|Behavioral|interpersonal effectiveness|weekly psychotherapy sessions for 10 weeks (120 min each)
45635046|NCT05110469|Drug|Magnesium sulfate|"IV Magnesium sulphate 30 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression."
45635047|NCT05110469|Drug|Meperidine|"IV Meperidine 0.5 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression."
45635048|NCT02404129|Other|Turn 180 test|"The purpose of this study is to explore the TURN180 test ability to evaluate the risk of falling in the elderly population and compare it to the known gold standard clinical tests. The independent elderly subjects will be divided into three groups according to their falls history and undergo four balance tests: Timed Up and Go test (TUG), Tinetti Balance Test (Tinetti), Berg Balance Scale (BBS). The participants will be videotaped while performing the TUG test. Basic temporospatial aspects of turning during walking such as the number of steps taken during the turn and the time taken to accomplish the turn will be measured using both the slow-motion and stop-action capabilities of the VCR system and a time-code processor."
45635049|NCT04831775|Behavioral|Memory, Attention, and Problem Solving Skills for Diabetes|The intervention is composed of 4 small-group webinar classes and home-based individual online cognitive skills practice and will be held over 8 weeks. The classes will be taught by a GRA. Classes 1 & 2 will focus on common cognitive problems in T2DM and strategies to improve cognitive skills. Classes 3 & 4 focus on lifestyle changes to support cognitive functioning and DM-SM skills. Each online class will follow the same format: (1) introduction/revisiting content from the previous class; (2) review of progress on computer exercises; (3) practicing cognitive strategies in class; and (4) a weekly topic. The GRA will also prescribe exercises for the following weeks.
45935524|NCT00126178|Biological|HSPPC-96|
45635050|NCT04831775|Behavioral|Brain Games|The computer-training component uses a model for cognitive training that adapts to the user through an integrated hierarchical structure. The BrainHQ website houses the interactive program that runs on standard web browsers. Participants will only need a computer, smart phone, or tablet with Internet access to securely log onto the website. Each participant will be registered by the project staff using anonymous ID numbers that will allow unlimited access during the study. The website stores each session completed, and participants can start subsequent sessions wherever they stopped the last time logged on.
45774385|NCT04294745|Procedure|Buccal infiltration|Injection of local anaesthetic parallel to the Long axis of the tooth in the depth of buccal sulcus
45774386|NCT04294745|Procedure|Inferior alveolar nerve block|Standard technique of mandibular nerve block
45774387|NCT04273165|Drug|Etravirine Tablets|Daily etravirine BID with 100 or 200 tablets for 4 months
45774388|NCT04236414|Drug|Olaparib|Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. 25 and 100 mg tablet strengths available for ages ≥3 to <18 years. AAF available for ≥0.5 to <6 years; The AAF is a sprinkle capsule formulation, available in dose strengths of 15 mg and 19.5 mg. The sprinkle capsules contain 1.5 mg granules which are to be dispersed onto a food vehicle prior to dosing.
45914459|NCT02043626|Other|OPPORTUNITIES FOR PHYSICAL ACTIVITY|District-wide policies include mandates for daily physical activity and PE and development of policies that prohibit withholding PE for punitive reasons. To further increase physical activity, the School Wellness Policy specifies expanding programs/activities that meet need, interest, and abilities of students. Exer-gaming consoles will be provided to 6 schools and will be integrated into 5th-8th grade PE classes and after-school programs. New and innovate gym equipment will be purchased for the 6 target schools for use in gym class and after school programming. Various pedometer and interactive programs encouraging physical activity in and outside of school are planned for the 6th grade.
46070145|NCT04030923|Device|repetitive transcranial magnetic stimulation|By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor Pollicis Brevis (APB), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for the left DLPFC (coil placed tangential over the optimal position of 7 cm anterior to hand motor hotspot area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
46070146|NCT00699465|Drug|enoxaparin|20 mg enoxaparin (2 000 IU) s.c. will be given twice daily starting 24-48 h after onset of the stroke. Intermittent pneumatic compression will be started immediately after admission.
45774389|NCT04188457|Other|Usual follow-up|2 medical consultations (nurse and doctor) over 24 months
45774390|NCT04188457|Other|Intensive follow-up|10 medical visits (nurse, doctor, pharmacist) over 24 months
45448087|NCT03735615|Behavioral|sprint interval training|Each training session will be performed 3 times per week for 3 weeks. Each session consists of 3-5x20 sec all-out cycling efforts against a load corresponding to 0.05-0.07 kg/kg body mass, separated by 3-5 min of low intensity cycling (20-50 W), on a lode bicycle ergometer (Excalibur Sport V2.0, Groningen, the Netherlands). All training sessions includes a 5 min warm-up and 3 min cool-down.
45635051|NCT02404051|Drug|Everolimus|10 mg daily tablets
45635052|NCT02404051|Drug|Exemestane|25 mg daily tablets
45635053|NCT02404051|Drug|Fulvestrant|500 mg i.m. on Days 1, 15 and 29 and every 28 days thereafter
45635054|NCT05102357|Procedure|Conservative Treatment (splint)|splint 6 weeks
45774391|NCT04179968|Drug|68Ga PSMA-11 injection|Injection of 68Ga PSMA-11
45774392|NCT04179968|Procedure|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
45774393|NCT04169529|Device|Reveal LINQ|Insertion of Reveal LINQ device to characterize collected data from patients with COPD.
45774394|NCT04140526|Drug|ONC-392|ONC-392 will be given by intravenous infusion, once every 21 days (Q3W). In Part C Arm M and in Part D, ONC-392 will be given Q4W.
45774395|NCT04140526|Drug|Pembrolizumab|Pembrolizumab will be given intravenous (IV) infusion at 200 mg/cycle, once every 21 days (Q3W).
45774396|NCT04115371|Behavioral|Intervention|Geriatric assessment and care coordination provided by a multidisciplinary team in the emergency department including transitional care nurses, social workers, pharmacists, occupational therapists, and physical therapists.
45774397|NCT04110236|Behavioral|PriCARE|PriCARE is a group caregiver training program designed to improve child behaviors, caregiver-child relationships, parenting capacity, and reduce caregiver stress. Sessions occur in the primary care clinic or virtually. PriCARE uses the 3 P skills (Praise, Paraphrase and Point-out-Behavior). The training starts with skills on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second part of the training teaches skills for giving effective commands in order to set age-appropriate limits and increase compliance. PriCARE includes a stress education section that contextualizes the use of these skills with the types of behaviors and problems exhibited by many children living with psychosocial adversity and familial stress. Caregivers are encouraged to practice the skills with their child in between sessions. Since PriCARE's initial and successful pilot, the intervention has been enhanced in order to increase engagement and effectiveness.
45914460|NCT02043717|Dietary Supplement|Vitamin D|"Supplementing oral cholecalciferol according to the new guidelines by:~Tangpricha V, Kelly a, Stephenson a, Maguiness K, Enders J, Robinson K a, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. The Journal of clinical endocrinology and metabolism [Internet]. 2012 May [cited 2012 Oct 31];97(4):1082-93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22399505"
45914461|NCT02043730|Drug|Nab-paclitaxel and Gemcitabine|Chemotherapy will consist of nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
45635055|NCT05101109|Drug|ABL501|ABL501 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
45635056|NCT02406547|Device|NBI|Withdrawal from cecum to sigmoid colon with Narrow Band Imaging (NBI, Evis Exera III, Olympus)
45635057|NCT02406547|Device|WLE|Withdrawal from cecum to sigmoid colon with High Definition White Light Endoscopy (WLE)
45635058|NCT04436549|Procedure|Stab Avulsion of varicose veins|Stab avulsion is a technique to remove varicose veins. In this procedure, several tiny cuts (incisions) are made in the skin through which the varicosed vein is removed. Removed varicose veins will be collected and analyzed.
45774398|NCT04110236|Behavioral|Positive Discipline Module|The PriCARE Positive Discipline Module is a pilot group caregiver training program designed to teach caregivers positive discipline techniques, including appropriate timeout procedures. The sessions are offered in the primary care setting or virtually. This training will supplement the content of the main PriCARE intervention and provide caregivers with skills for addressing difficult behaviors not reduced through positive attention and strategic ignoring. This module will be offered to a subset of CHOP participants who were randomized to the intervention arm, successfully completed the main study interviews, and attended at least 4 out of the 6 PriCARE sessions.
45774399|NCT04097717|Behavioral|"My Decision tubal sterilization decision aid"|"The My Decision tubal sterilization decision aid is a web-based decision aid designed to help women make informed decisions about tubal sterilization."
46070147|NCT00699465|Drug|enoxaparin placebo|Placebo will be given s.c. twice daily starting 24-48 h after onset of the stroke for 2 days. Thereafter, 20 mg enoxaparin (2 000 IU) s.c. will be given twice daily. Intermittent pneumatic compression will be started immediately after admission.
46070148|NCT00858117|Biological|Alemtuzumab|Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks
45774400|NCT04097717|Other|Usual Care|Usual medical care will vary among participants.
45914462|NCT02043730|Drug|Gemcitabine|gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
45914463|NCT02043743|Biological|Biological: Stem Cells|Biological: Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally 3-5 million MSCs injected into ovarian tissue.
45914464|NCT02043756|Drug|Mitoxantrone Hydrochloride Liposome|6-16mg/m2, IV ,one time of each 28 day cycle,3 cycles
45914465|NCT02043756|Drug|Mitoxantrone|10mg/m2, IV ,on day 1 of each 28 day,3 cycles
45914466|NCT02043795|Device|BVS, Abbott Vascular|The aim of this study is to study the safety and clinical efficacy of a novel Bioabsorbable Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS, Abbott Vascular).
45914467|NCT02043821|Drug|Capecitabine|14days
45914468|NCT02043821|Other|placebo|14 days
45914469|NCT02043834|Other|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
45914470|NCT02043886|Drug|Acarbose|Acarbose 50 mg by mouth given during Meal Test
45635059|NCT04436549|Diagnostic Test|Histopathologic evaluation of varicose veins|Sample obtained from varicose veins of lower limbs of patients will be collected and immediately fixed in formalin. The tissue fragments will be taken from varicose veins. Subsequently the tissue will be embedded in paraffin and 3-to-4 mm thick sections will be prepared by a microtome. The tissue sections will be processed for histological and immunohistochemical studies of VEGF, MM9, PGP 9.5 AND FRIBRONECTIN. For antibodies the EnVision staining system (Dako EnVision™) will be used. For the analysis of the positive structures detected by immunohistochemistry, a semiquantitative evaluation method will be used.
45914471|NCT02043886|Drug|Placebo|Non active substance matched to look like Acarbose 50 mg tablets. Taken by mouth during Meal Test.
45914472|NCT02043912|Drug|Haloperidol|
46070149|NCT00858117|Biological|Rituximab|Rituximab administered intravenously at 375mg/m2 every 2 weeks for 18 weeks
45635060|NCT03172585|Other|High resolution computed tomography|High resolution computed tomography of the chest is the gold standard imaging modality for most pulmonary diseases
45635061|NCT03172585|Other|trans thoracic ultrasonography|Trans thoracic ultrasonograghy is used progressively for evaluation of pulmonary diseases . Its non invasive nature , relatively low price ,portability for bedside use, and high reproducible of results allows for incorporation of imaging findings with clinical data
45635062|NCT05094323|Drug|Ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine|Patients will receive ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine.
45635063|NCT05094323|Drug|Local wound infiltration with isobaric bupivacaine|Patients will receive local wound infiltration with isobaric bupivacaine.
45635064|NCT05094323|Drug|Ultrasound-guided thoracic paravertebral block with isobaric bupivacaine|Patients will receive ultrasound-guided thoracic paravertebral block with isobaric bupivacaine.
45914473|NCT02043925|Drug|drugs linked with QT-prolongation|all the drugs that are mentioned in the lists of QT-prolonging drugs of CredibleMeds (www.crediblemeds.org)
45914474|NCT02043951|Device|Lutonix Drug Coated Balloon Catheter|
45914475|NCT02043964|Procedure|tears and cerebrospinal fluid sampling|All patients recruited in this study will undergo a cerebrospinal fluid sampling which is an invasive procedure included in the actual routine practice. In addition a sampling from eyes will be obtain using the Schirmer test to get tears from the lacrimal gland.
45914476|NCT02043977|Drug|propofol injectable emulsion|
45914477|NCT02043990|Device|Noninvasive NAVA ventilation|Noninvasive NAVA Ventilation versus conventional noninvasive Pressure Support Ventilation
45914478|NCT02044003|Device|Innovasc Tack Intravascular Staple System (Tack)|Tack-It Dissection repair
45935525|NCT00126217|Biological|Bacille Calmette Guerin (BCG)|0,1 ml, revaccination at 19 months of age
45935526|NCT00074100|Drug|amonafide dihydrochloride|
45935527|NCT00126256|Drug|5-fluorouracil|
45935528|NCT00126256|Drug|leucovorin|
45935529|NCT00126256|Drug|irinotecan|
45935530|NCT00126256|Drug|oxaliplatin|
45935531|NCT00126295|Device|'What you need to know about stroke' education package|
45635065|NCT03170323|Drug|Mycophenolate Mofetil|steroid 1mg/kg/d and Mycophenolate mofetil 500mg bid
45774401|NCT04091347|Behavioral|DAPPER|The DAPPER program is person directed and will consist of 8 nurse visits during which the nurse assesses each participant for pain, depression and frailty and then implements a manualized individually tailored intervention. Participants will be randomized into either the intervention or the wait list control group. Once the intervention group has completed the intervention group's visits, the wait list control group will begin the waitlist control group's visits. All participants will all be offered the same information and format of nurse visits. The nurses will systematically tailor the content of the visits to the participants' risk profile and goals based on protocols. All participants will be assessed at the start of the study, at 12 weeks and 24 weeks.
45774402|NCT04072055|Device|MOTO Medial|MOTO medial unicompartmental knee system
45635066|NCT03170323|Drug|Cyclosporins|steroid 0.15mg/kg/d and Cyclosporin 3-5mg/kg/d
45774403|NCT04041128|Drug|Lynparza|Lynparza taken orally at a dose of 300mg twice daily for 7 days
45774404|NCT04030962|Drug|AGN-242428|Ophthalmic solution administered as a topical eye drop
45774405|NCT04030962|Drug|AGN-231868|Ophthalmic solution administered as a topical eye drop
45914479|NCT02044107|Behavioral|Co-packaging and counseling messages|The intervention involves co-packaging in 2 distinct packages: 1) for diarrhea treatment to package zinc & ORS for the treatment of diarrhea using a plastic bag with printed messages that were pre-tested in formative research; and 2) for pneumonia treatment to co-package zinc & antibiotics in a plastic bag with printed messages that were pre-tested in a formative research phase. Pre-tested zinc treatment messages will be on posters displayed in the intervention health centers. Orientation will be provided to health facility staff in control and intervention areas.
45774406|NCT04030962|Other|AGN-242428 Vehicle|Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop
45774407|NCT04030962|Other|AGN-231868 Vehicle|Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop
45448088|NCT00166517|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
45774408|NCT04030962|Drug|Lifitegrast|Ophthalmic solution administered as a topical eye drop
45774409|NCT04024059|Behavioral|Contingency Management for adherence|Incentives contingent on buprenorphine adherence
45774410|NCT04024059|Behavioral|Contingency Management for abstinence|Incentives contingent on opiate abstinence
45774411|NCT04022590|Device|E-clothes|The E-clothes could prove heart rate or heart rate variability(HRV) information to the participants' smart phone by blue tooth. Then the smart phone will calculate and provide the suitable aerobic training intensity by the microphone when the participants do aerobic training.
45774412|NCT04022590|Behavioral|Healthy consultation|Healthy consultation will educate the participants do aerobic training three times a week for 3 months. And the each training period is at least 30 minutes.
45774413|NCT04009837|Behavioral|Hip-focused rehabilitation intervention|The hip-focused intervention includes a blend of hip-focused rehabilitative techniques and some basic lumbar spine-directed techniques. The hip-focused arm includes tailored manual therapy, progressive strengthening exercises, and flexibility exercises for the hip, as well as spinal flexibility and trunk muscle training exercises. The intervention will be delivered by licensed physical therapists in one-hour sessions, twice per week, for 8 weeks.
45448089|NCT00166517|Biological|Comparator: Placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
45448090|NCT00166439|Drug|Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)|"rituximab 375 mg/m2 IV Weekly x 4 1 cycle only~dexamethasone 40 mg PO/IV Days 2-5 q 21 days 2 cycles~oxaliplatin 130 mg/m2 IV Day 2 q 21 days 2 cycles~cytosine arabinoside 2000 mg/m2 x 2 doses IV Days 2-3 q 21 days 2 cycles~pegfilgrastim 6 mg SQ Day 4 q21 days 2 cycles"
45635067|NCT05087225|Biological|polyethelyene glycol|the excipients at covid-19 vaccines
45635068|NCT04480489|Other|VR|"Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive VR instructions on how to navigate Route 1 (i.e. they will watch a 360-degree immersive video using Samsung VR headset).~Task 2: After completing the Route 1 walkthrough, the same group will be given traditional instructions (2D video) on navigating Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR"
45774414|NCT04009837|Behavioral|Spine-focused rehabilitation intervention|The spine-focused rehabilitation intervention is a direct and comprehensive lumbar spine rehabilitative program, but it does not include hip treatment. The spine-focused arm includes spinal manual therapy, spinal flexibility exercises, and trunk muscle training exercises. The intervention will be delivered by licensed physical therapists in one-hour sessions, twice per week, for 8 weeks.
45774415|NCT03997162|Other|Best Practice|Complete standard of care enhanced recovery after surgery protocol
45774416|NCT03997162|Other|Quality-of-Life Assessment|Ancillary studies
45774417|NCT03997162|Other|Questionnaire Administration|Ancillary studies
45774418|NCT03991962|Drug|mFOLFIRINOX|Patients will receive 6-12 cycles of mFOLFIRINOX every 2 weeks
45774419|NCT03991962|Radiation|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved lymph nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
45774420|NCT03951753|Drug|Tirzepatide|Administered SC
45774421|NCT03951753|Drug|Semaglutide|Administered SC
45774422|NCT03951753|Drug|Placebo|Administered SC
45774423|NCT03947671|Device|Rapr Rounds Hyper/Hypothermia Wraps|Rapr Round® vest and leg wraps will placed around the torso and legs of the participant and will be adjusted to maintain normal body temperature
45774424|NCT03947671|Drug|Acetaminophen|Acetaminophen will be administered as it would be per standard of care
45774425|NCT03947346|Other|Urine sample|The urine collected from the first morning void will be used to assess urine creatinine and microalbumin. The fresh urine specimen will be analyzed for novel urinary biomarkers of (urinary NGAL, TGF-β1, IL-18 and KIM-1). Serum BUN, creatinine, and cystatin-C will be assessed using serum samples drawn for routine clinical care.
45914480|NCT02044120|Drug|niraparib|
45914481|NCT02044120|Drug|Temozolomide|
45914482|NCT02044120|Drug|Irinotecan|
45635069|NCT04480489|Other|Traditional|"Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive traditional instructions (2D video) on how to navigate Route 1.~Task 2: After completing the Route 1 walkthrough, the same group will be given VR instructions on how to navigate Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR"
45635070|NCT04961177|Other|EITC & ACEs Training|We will deliver up to 56 trainings to 65 frontline health workers and 25 staff of our partner organizations. The training will include: 1.) Information about what ACEs are, and the risk and protective factors associated with ACEs and 2.) Information regarding EITC benefits, eligibility, application procedure and logistics, referrals for free tax preparation assistance, and use of EITC tools., and 3.) frontline health workers will receive additional training in protocols for reporting to support Objective #2.
45635071|NCT04961177|Other|EITC Outreach & Screening|"Our partners will screen and refer a minimum of 5200 clients (65 CHWs x 10 clients per quarter x 2 years) for EITC. Our evaluation team will track the number of individuals screened, the number found to be eligible/not eligible, the number referred out and to which free tax prep service, and if available, the number who use the free tax prep service, the number who file a tax claim for EITC, the number who receive EITC benefits, and the amount of the benefit.~We will conduct community-level EIT outreach by integrating EITC outreach and education into planned community events in the neighborhoods and service areas of our partners. The events will provide information about the EITC to the public. We will have a minimum of 48 events to reach a minimum of 480 potential filers (48 events x 10 participants each)."
45774426|NCT03944499|Drug|FS-1502|"Dose-Escalation Phase (Phase 1a)： FS-1502 dose-escalation will be proceeded on standard 3+3 design with starting dose of 0.1 mg/kg, IV, once per 28 days, 28 days as a cycle in the V1.2 and V2.0 regimens; IV, once per 21 days, 21 days as a cycle in the V3.0 regimens..~Dose level 1: 0.1 mg/kg; Dose level 2: 0.2 mg/kg; Dose level 3: 0.4 mg/kg; Dose level 4: 0.6 mg/kg; Dose level 5: 0.8 mg/kg; Dose level 6: 1.0 mg/kg; Dose level 7: 1.3 mg/kg. If 1.3mg/kg is still tolerated safely and in line with linear kinetic characteristics, and combined with the results of PK, PD, safety and effectiveness, a comprehensive assessment is made to determine whether to continue the dose escalating. The subsequent dose increase ratio is 33% (the dose increase ratio can be adjusted according to the previous data results) until MTD or RP2D.~Dose-expansion Phase (Phase 1b) : RP2D determined in phase 1a, IV."
45653037|NCT04224987|Drug|Azithromycin|"Azithromycin will be administered as a directly observed dose in oral suspension form for children:~Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~For children 1-11 months of age, weight or age-based dosing will be used~For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program"
45774427|NCT03941964|Drug|Venetoclax|Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing. On the days that the participant received either azacitidine or decitabine, venetoclax was dosed in clinic and administered prior to these agents.
45774428|NCT03941964|Drug|Azacitidine|The azacitidine infusion was prepared and administered per the package insert and given either subcutaneously or intravenously, per institutional practice.
45774429|NCT03941964|Drug|Decitabine|The decitabine infusion was prepared and administered per the package insert and given intravenously, per institutional practice.
45914483|NCT02044133|Other|Dosage Vitamine D|
45914484|NCT02044146|Drug|Ticagrelor, Prasugrel, Clopidogrel|
45914485|NCT02044185|Drug|salvage chemotherapy, total body irradiation|there are no direct interventions to our patients.
45774430|NCT03935100|Procedure|Endoscopic clipping|Endoscopic clips fired to close mucosa over diverticular defects.
45774431|NCT03935100|Other|Placebo - colonoscopy without clipping|Colonoscopy performed, no clipping of diverticula
45774432|NCT03932240|Drug|Fibrinogen Concentrate (FC)|The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.
45774433|NCT03932240|Drug|Cryoprecipitate|Standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 345mg/dL
45774434|NCT03931772|Behavioral|Automated Self-Hypnosis|Self-Hypnosis will be delivered through an interactive application administered through Amazon Alexa or Reveri.com.
45448091|NCT01074671|Device|CG Future Annuloplasty Ring/Band|A CG Future Annuloplasty Ring or Band will be implanted, following standard care
45774435|NCT03931746|Device|Porcine xenograft|The EZ-DERM™ porcine xenograft is a biosynthetic dressing made from porcine collagen containing aldehyde crosslinking. It has been most commonly applied to the management of 2nd degree burns, both partial-thickness and full-thickness defects. This dressing can be used for two healing purposes, either for primary healing or as an intermediate in the preparation for a skin graft
45774436|NCT03920410|Other|serotonergic stimulation|Increase of serotonergic activity by a single oral administration of 10 mg Escitalopram, a Selective Serotonin Reuptake Inhibitor (SSRI), packed in a coloured hydroxypropylmethylcellulose capsule.
45914486|NCT02044198|Biological|FMP2.1/AS01B|50 µg FMP2.1 in 0.5 mL of the adjuvant AS01B (containing 50 mcg MPL + 50 mcg QS21) is administered via intramuscular (IM) injection in the deltoid region of the non-dominant arm
45914487|NCT02044211|Behavioral|Collaborative Care for Heart Failure|"Nurse care managers will provide patients with education for their heart failure to facilitate self-management for their condition. In addition, the nurse will telephone the patient to review with their medical history, medications, diet, activity and sleep patterns, and plans for follow-up medical appointments, and offer basic care coordination relative to heart failure care including assistance attaining authorization for home health services in concert with the patient's primary care physician (PCP), and follow-up appointments.~After case review with a study internist, the care manager may send treatment recommendations to the patient's physician(s) regarding guideline-indicated care. Afterwards, the care manager will telephone the patient approximately every other week to monitor and promote adherence with recommended care, and suggest adjustments in treatment as applicable following discussion with the clinical team and notification of the patient's PCP and cardiologist."
45935532|NCT00043667|Drug|Daclizumab|
45935533|NCT00126334|Procedure|Packed Red Blood Cell Transfusion|transfusion of 1 unit of PRBCs
45935534|NCT00074139|Drug|cyclophosphamide|
45935535|NCT00074139|Drug|docetaxel|
45635072|NCT04961177|Other|Assistance with EITC|"We will conduct a statistical analysis of the impact of EITC funds on ACEs risk and protective factors in the lives of EITC benefit recipients. Project CHW team members will invite 200 clients who qualify to receive EITC benefits to participate in the study using an approved recruitment script. With those who agree to participate, the CHW team member will obtain consent and administer a baseline survey. A post-survey will be administered at 4 months.~In addition, we will gather qualitative data to help us understand impacts of this project. The post-survey will contain an open/qualitative response question asking participants to describe how the EITC benefit impacted them, how they felt when they received it, how important it was, and what they did with the funds. In Y2, the Research Team will conduct interviews with a subset of 20 clients who participated in the pre/post survey."
45635073|NCT02396797|Behavioral|The new atWork intervention|"atWork is a cognitive intervention, and uses a nondirective delivery approach. It does not prescribe any change in lifestyle, but aims at establishing an understanding of common complaints and what to do when pain and health complaints occur. All information is based on the non-injury model, where pain and complaints are not signs of injury caused by wrongdoing or inappropriate behavior. The consistent take home message from all parts of the intervention is that keeping up usual activities, including going to work, is beneficial for health and recovery. This group will receive one management course, two workplace courses for all employees targeting mild mental disorders and nonspecific musculoskeletal complaints, and one reflection and review meeting."
45635074|NCT02396797|Behavioral|The original atWork intervention|This group will receive three workplace courses for all employees targeting nonspecific musculoskeletal complaints, and peer support. Peer support involves selecting a peer advisor at the workplace. A peer advisor is a fellow worker without former medical training who as part of the atWork intervention receive more in-depth medical knowledge and training about nonspecific musculoskeletal complaints. The peer advisors role is to give social support and to use their local knowledge of the work place to facilitate staying at work for colleagues with health complaints.
45635075|NCT04788875|Procedure|Small bite suturing Technique|Small bite suturing technique with PDS 2.0
45635076|NCT04788875|Procedure|Standardised Large Bites Technique|Standardised large bite suturing technique with PDS 2.0
45635077|NCT02396875|Procedure|Blood sampling and exercise protocol pre and post CRT implant|
45635078|NCT02396875|Procedure|Peripheral blood sampling|
45635079|NCT02396875|Procedure|Central blood sampling pre and post CRT implant|
45635080|NCT02396875|Procedure|Central blood sampling on one occasion and exercise protocol and 6 month peripheral sampling|
45774437|NCT03920410|Other|no serotonergic stimulation|Oral administration of a placebo. The placebo will consist of a coloured hydroxypropylmethylcellulose capsule filled with microcrystalline cellulose.
45774438|NCT03888053|Biological|BB-101|Within each cohort, 8 subjects will be randomized to receive BB-101 and 4 subjects to receive placebo.
45774439|NCT03878030|Drug|nusinersen|Subjects will receive nusinersen and be observed with motor assessments for 24 months
45774440|NCT03837509|Drug|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined starting dose, with dose escalation/de-escalation based on protocol-defined toxicity criteria to determine the maximum tolerated dose. INCB001158 is administered in combination with daratumumab SC. Phase 2: INCB001158 administered orally at the recommended dose from Phase 1 either as a monotherapy or in combination with daratumumab SC.
45914488|NCT02044211|Behavioral|Collaborative Care for Depression|"The care manager will telephone patients randomized to blended care patient to review their psychiatric history including use of antidepressant pharmacotherapy, herbal supplements, and alcohol possibly used to self-medicate depressive symptoms; provide basic psychoeducation about depression and its impact on cardiac disease; recommend various self-management strategies (e.g., sufficient rest and exercise); and describe treatment options. They will include: (1) use of a workbook or computer program to enhance patients' understanding and ability to self-care; (2) initiation or adjustment of antidepressant pharmacotherapy prescribed under their primary care physicians' direction; or (3) referral to a local mental health specialist. The nurse will then telephone the patient to monitor symptoms and pharmacotherapy use, practice skills imparted through workbook assignments, promote adherence with recommended care, and suggest adjustments in treatment as applicable."
45914489|NCT02044224|Drug|Dexmedetomidine|"Dexmedetomidine 0.4 µg/kg/hr infusion (from the start of anaesthesia until the end of anaesthesia).~Anaesthesia induction: propofol 2 mg/kg, rocuronium 0.6 mg/kg iv, and fentanyl 2-3 mikrogram/kg.~Anaesthesia maintenance: sevoflurane and oxygen 50%, rocuronium 0.1-0.2 mg/kg iv, fentanyl 1 mikrogram/kg as required"
45914490|NCT02044237|Behavioral|Decoupling|
45914491|NCT02044237|Behavioral|Progressive relaxation|
45914492|NCT02044250|Drug|Clopidogrel|Clopidogrel 75mg 1tab P.O. daily
45914493|NCT02044250|Drug|Aspirin|Aspirin 100~200mg 1~2tab P.O. daily
45448092|NCT01075997|Device|cell phone delivered tele-educational|This group will receive a cell phone and cell phone service for 1 year. This group will receive a daily video reminders and tips for the first 6 months of the study. For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent. The group will be instructed on how to use the cell phone.
45448093|NCT01075997|Device|cell phone|This group will receive a cell phone and cell phone service for 1 year. For the second 6 months this group will be seen by their providers at least every 3 months. The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by your provider. The groups will have blood sugars downloaded from from the glucometer by your provider at every visit and reviewed.
45635081|NCT02396641|Other|Best Supportive Care Checklist|
45774441|NCT03837509|Biological|Daratumumab SC|Daratumumab 1800 mg co-formulated with rHuPH20 (2000 U/mL) and administered subcutaneously once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and then once every 4 weeks. Daratumumab will be administered either as monotherapy or in combination with INCB001158.
45774442|NCT03822117|Drug|Pemigatinib|Pemigatinib administered orally once daily (QD).
45914494|NCT02044263|Behavioral|Internet CBT-i SHUTi|Computer program SHUTi is based on the same theoretical model of insomnia and involves the same interventions as ordinary CBT-I: a structured treatment focusing on education, behaviors and cognitions. Specifically, CBT-I usually consists of one or more of the following: psychoeducation about sleep, sleep restriction therapy, stimulus control, relaxation techniques, and challenging beliefs and perception of sleep.
45774443|NCT03810404|Dietary Supplement|Sodium bicarbonate supplementation|"Interventions:~The experimental procedure for each athlete included an acute SB supplementation in a different-dose regimen in order to assess whether the dose affects the actual physical and exercise capacity (doses: 0.15-, 0.25-, 0.35- and 0.50 g/kgFFM (0.12-, 0.20-, 0.28- and 0.40 g/kgBM), respectively). SB (Alkala, SANUM, Poland) will be administered as dissolved form in a 750 ml of fluid (water + fruit juice). On testing days the SB will be taken before physical and exercise capacity tests session.~Between the SB and PLA or a PLA and SB treatments, a minimum 7-day washout period will be introduced."
45774444|NCT03810404|Dietary Supplement|Placebo treatment|"Interventions:~The experimental procedure for each athlete will be included an PLA supplementation. Placebo will be administered in a form of 750 ml of fluid (water + fruit juice). On testing days the PLA will be taken before physical and exercise capacity tests session.~Between the PLA and SB or a SB and PLA treatments, a minimum 7-day washout period will be introduced."
45774445|NCT03808454|Drug|PRP|The investigators draw 10cc of blood and concentrate the blood to get the platelet rich plasma
45774446|NCT03808454|Other|Rehabilitation|strengthening ex, posture training,...
45774447|NCT03808454|Combination Product|PRP+Rehabilitation|combine PRP and Rehabilitation
45774448|NCT03808077|Drug|Rocuronium 0.3mg/kg/hr|The Moderate NMB group (Control ) will have rocuronium infusion titrated to moderate paralysis defined as TOF of 1-2 (infusion start rate 0.005mg/kg/min or 0.3mg/kg/hr).
45774449|NCT03808077|Drug|Rocuronium 1.5mg/kg/hr|The Deep NMB group (Intervention) will have rocuronium infusion titrated to deep paralysis defined as PTC of 1-2 (infusion start rate 0.025mg/kg/min or 1.5mg/kg/hr).
45774450|NCT03775954|Diagnostic Test|Fetal Magnetocardiogram and Neonatal Electrocardiogram|Fetal Magnetocardiography (fMCG) is a new non-invasive diagnostic procedure that records tiny fetal cardiac signals similar to an Electrocardiogram or Holter monitor. The magnetometer has FDA clearance, and does not emit magnetic, electric or other energies. This is not an MRI. Examples of fetal MCG's can be found in the Links. The American Heart Association Scientific Statement on Fetal Diagnosis and Treatment (Circulation, 2014) has declared fMCG to be Class IIa for fetal heart rhythm abnormalities, meaning that benefit far exceeds risk. As part of this study, a neonatal electrocardiogram (nECG) will be obtained for comparison after the baby is born.
45774451|NCT03737500|Device|B-Lite® light weight breast implant|Definitive breast reconstruction after total mastectomy by the use of B-Lite® light weight breast implant
45774452|NCT03737500|Device|Standard silicone-based breast implant|Definitive breast reconstruction after total mastectomy by the use of silicone-based breast implants commonly used in our institution
45774453|NCT03710928|Other|very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement as needed with each meal to support digestive health, and a daily multi-vitamin, magnesium and omega-three supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 70% fat, 20% protein."
45774454|NCT03710928|Other|standard carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein."
45774455|NCT03681132|Other|Stop of therapy|The active intervention is to stop antiviral therapy, and delay re-start in the high-threshold group.
45774456|NCT03676647|Other|Diagnostic DNA Methylation Signature|Undergo collection of tissue samples
45774457|NCT03630705|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form: Liquid solution Route of administration : Intramuscular
45914495|NCT02044263|Behavioral|face-to-face CBT-i|
45914496|NCT02044315|Device|ICD programming|
45914497|NCT02044354|Drug|Taxotere|
45914498|NCT02044354|Drug|Jevtana|
45914499|NCT02044406|Drug|BI 1181181|single dose (low to high dose)
45914500|NCT02044406|Drug|BI 1181181, R|powder for oral solution
45914501|NCT02044406|Drug|BI 1181181, T2|tablet, fasted
45914502|NCT02044406|Drug|Placebo to BI 1181181|Placebo to BI 1181181
45914503|NCT02044406|Drug|BI 1181181, T1|tablet, fed
45914504|NCT02044432|Other|ginger compress|Kidney ginger compress
45448094|NCT01074749|Device|Accent Pacemaker|Implantation of pacemaker
45448095|NCT02531555|Device|810 Nanometer Wavelenght GaAlAs Diode Laser|FDA approved 810 nanometer GaAlAs Diode Laser
45914505|NCT02044445|Procedure|Oocyte retrieval will be performed 36 h or 38 h after hCG administration|Oocyte retrieval will be performed 36 h or 38 h after hCG administration
45914506|NCT02044471|Other|Remote Ischemic Conditioning (using Sphygmomanometer)|"Patients in experimental arm will have validated protocol of Remote Ischemic Conditioning (using Sphygmomanometer): 5 minutes with blood pressure cuff inflated at 200 mmHg, then deflated for 5 minutes; repeated for 3 cycles.~Patient in control group will not perform this."
45914507|NCT02044484|Behavioral|Multi-component intervention|"The computer-based intervention (CBI) is offered to patients whose viral load exceeds 1000 copies/mL at enrollment.~Counseling is offered to patients whose viral load does not drop 1-log after the first CBI or remains above 200 copies/mL after completing two CBIs.~The behavioral screener will be conducted of all patients at primary care visits. The patient completes the screener before seeing the provider. Responses are given to their provider who can use it in clinical care of the patient.~At primary care visits, all patients are given a palm card containing 1 of 15 empowering messages before they leave the clinic. Messages cover three domains: adhering to antiretroviral therapy, regular care, and safer sex."
45914508|NCT02044523|Device|Transient elastography, acoustic radiation force impulse, magnetic resonance elastography|Transient elastography (Fibroscan) Acoustic Radiation Force Impulse (ARFI) Magnetic Resonance Elastography (MRE)
45448096|NCT02531555|Device|Gracey curettes|
45448097|NCT01074827|Other|Strength training and treadmill training|Eight weeks of intensive strength training or treadmill training
45448098|NCT01074905|Drug|Artesunate|2 mg/kg/day as single daily dose given for 5 days; maximum dose range is 1.6 to 2.4 mg/kg/day or a total of 8 to 12 mg/kg.
45448099|NCT01074905|Drug|Chloroquine|25 mg base/kg given in divided doses (10,10,5) over 3 days; Absolute range 20-30 mg/kg.
45774458|NCT03630705|Biological|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|Pharmaceutical form: Lyophilized powder combined with liquid component Route of administration : Intramuscular
45774459|NCT03630705|Biological|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form: Lyophilized live virus vaccine Route of administration : Subcutaneous
45774460|NCT03630705|Biological|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
45774461|NCT03630705|Biological|Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine, and Haemophilus influenza type b Conjugate Vaccine|Pharmaceutical form: Powder and suspension for injection Route of administration: Intramuscular
45774462|NCT03630705|Biological|Hepatitis B Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
45774463|NCT03630705|Biological|Rotavirus Vaccine, Live, Pentavalent|Pharmaceutical form: Oral solution Route of administration: Oral
45635082|NCT05109923|Dietary Supplement|Multi-Ingredient Herbal Supplement|Weeks 0-2 all participants consumed a placebo lead-in period and weeks 2-6 were intervention weeks. Throughout the 8 weeks (2 weeks placebo lead-in and 6 weeks intervention) participants were asked to consume 2 capsules (multi-ingredient supplement) upon waking in the morning and 2 capsules (multi-ingredient supplement) before bed.
45635083|NCT05109923|Dietary Supplement|Placebo Supplement|Weeks 0-8 all participants consumed a placebo. Throughout the 8 weeks participants were asked to consume 2 capsules (placebo) upon waking in the morning and 2 capsules (placebo) before bed.
45774464|NCT03630705|Biological|Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
45774465|NCT03603184|Drug|Atezolizumab|Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).
45774466|NCT03603184|Drug|Placebos|Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).
45774467|NCT03603184|Drug|Paclitaxel|Paclitaxel 175 mg/m2 will be administered every 21 days for 6-8 cycles or until progression of disease.
45774468|NCT03603184|Drug|Carboplatin|Carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or until progression of disease.
45774469|NCT03586999|Drug|Nivolumab and EPOCH|Nivolumab injection is to be administered as an IV infusion. DA-EPOCH dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a >10% weight gain or loss. Patients receive six 21 day cycles of the medications.
45774470|NCT03527498|Device|Baby treadmill|The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.
45774471|NCT03527498|Behavioral|Physical rehabilitation training|Suitable for general physical rehabilitation training of all infants with cerebral palsy.
45774472|NCT03519009|Behavioral|IPS Plus Abstinence-Contingent Wage Supplement|Participants are offered abstinence-contingent wage supplements if they obtain and maintain competitive employment. The wage supplements are designed to promote employment while reinforcing drug abstinence. To help participants obtain and maintain competitive employment, participants will receive Individual Placement and Support (IPS) supported employment. IPS is a supported employment intervention that has been proven effective in promoting employment in adults with severe mental illness. To promote employment and prevent relapse to drug use, participants will receive IPS Plus Abstinence-Contingent Wage Supplements.
45774473|NCT03507452|Drug|BAY2287411|"Dose Escalation part:~A single dose will be administered intravenously on Day 1 of each cycle lasting 6 weeks (42 days)."
45774474|NCT03507452|Drug|BAY2287411|"Dose Expansion part:~The selection of the dose level(s) /regimen(s) to be evaluated will be based on the overall benefit / risk and PK profile observed in the dose escalation."
45774475|NCT03497897|Drug|LYS006 20 mg|LYS006 20 mg, capsules, oral administration, BID, for 12 weeks
45635084|NCT02396563|Procedure|epidural analgesia|
45635085|NCT02396563|Drug|Ropivacaine|
45635086|NCT05109767|Device|Virtual reality|The Virtual Reality Glass game application reduces anxiety by distracting attention..The virtual reality glass game was played to intervention group for 15 minutes before surgery.
45635087|NCT05109767|Device|Smartphone|The Smartphone game application reduces anxiety by distracting attention. Smartphone game was played to intervention group for 15 minutes before surgery.
45635088|NCT03170245|Diagnostic Test|Interleukin-6|serum samples used for doing the test by ELISA
45635089|NCT03170245|Diagnostic Test|HsC-RP|serum samples used for doing the test by ELISA
45774476|NCT03497897|Drug|LYS006 2 mg|LYS006 2 mg, capsules, oral administration, BID, for 12 weeks
45774477|NCT03497897|Drug|Placebo|Matching placebo, capsules, oral administration, BID, for 12 weeks
45774478|NCT03493490|Drug|Neodolpasse|Patients will receive two infusions containing 75 mg diclofenac and 30 mg orphenadrine citrate 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
45774479|NCT03493490|Drug|Diclofenac|Patients will receive two infusions containing 75 mg diclofenac 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
45774480|NCT03493490|Drug|Placebo|Patients will receive two physiologic saline infusions 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
45774481|NCT03489746|Other|ICS withdrawal protocol|A primary care intervention to support switch from ICS containing regimen to non-ICS containing regimen in appropriate patients.
45774482|NCT03489746|Other|Standard care|Normal clinically indicated inhaled therapy
45774483|NCT03477513|Radiation|Radation Therapy|Personalized Radiation Therapy
45774484|NCT03428217|Drug|CB-839|Oral glutaminase inhibitor
45774485|NCT03428217|Drug|Cabozantinib|Oral receptor tyrosine kinase inhibitor
45774486|NCT03428217|Drug|Placebo|Placebo tablets
45774487|NCT03414658|Drug|Vinorelbine|work by interfering with cell division, which leaves the tumor unable to grow and spread
45774488|NCT03414658|Drug|Trastuzumab|trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2.
45774489|NCT03414658|Drug|Avelumab|monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein
45774490|NCT03414658|Drug|Utomilumab|Utomilumab is an antibody designed to stimulate the body's immune system to fight cancer cells
45774491|NCT03410927|Drug|TAS0728|TAS0728 is an oral HER2 covalent inhibitor investigated in patients with advanced solid tumor harboring HER2 or HER3 abnormalities. It will be administered orally at a starting dose of 50 mg BID each morning and evening and escalated to the DLT. The MTD will be used for the phase 2 arms of the study.
45774492|NCT03399851|Device|Amplatzer Amulet for left atrial appendage closure|The closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the Amplatzer Amulet will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
45774493|NCT03399851|Device|Watchman/FLX for left atrial appendage closure|The closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the Watchman/FLX will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
45774494|NCT03389698|Device|GRASP Dynamic Contrast-Enhanced (DCE) MRI|Golden-angle Radial Sparse Parallel (GRASP) DCE MRI is an MRI sequence designed to improve spatial and temporal resolution while enabling retrospective reconstruction with flexible temporal resolution.
45774495|NCT03389698|Device|3T Brain Scan|Up to 60 minutes, a portion of which uses the GRASP DCE-MRI sequence.
45774496|NCT03389698|Drug|Gadolinium-based Contrast Agent (GBCA) for MRI|Gadavist/Gadobutrol is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.
45774497|NCT03377491|Device|NovoTTF-200T|Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
45774498|NCT03377491|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 over 30 minute infusion will be administered immediately after nab-paclitaxel on Days 1, 8 and 15 of each 28-day cycle.
45774499|NCT03377491|Drug|nab paclitaxel|nab-paclitaxel 125 mg/m^2 administered as an intravenous infusion over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle.
45774500|NCT03341403|Dietary Supplement|Probiotical®|"Probiotical is composed of: Lactobacillus, Bifidobacterium et Streptococcus thermophilus, 18 billion of bacteria per pill."
45774501|NCT03341403|Other|Placebo|pills containing placebo
45774502|NCT03331250|Drug|Eribulin|It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die
45774503|NCT03307044|Procedure|Laser Therapy|Undergo fractional CO2 laser therapy
45774504|NCT03307044|Other|Questionnaire Administration|Ancillary studies
45774505|NCT03298087|Procedure|radical prostatectomy|surgical removal of the prostate
45914509|NCT02044536|Other|No intervention|retrospective data review
45774506|NCT03298087|Radiation|stereotactic body radiotherapy|Highly targeted radiation
45774507|NCT03298087|Drug|Leuprolide|Lowers serum testosterone
45774508|NCT03298087|Drug|apalutamide|antiandrogen
45774509|NCT03298087|Drug|abiraterone|Inhibits androgen synthesis
45774510|NCT03297359|Biological|Dalteparin|daily subcutaneous injection of weight-adjusted dalteparin
45914510|NCT02044549|Drug|carbetocin|Oxycontin analogue
45774511|NCT03189719|Biological|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
45914511|NCT02044549|Drug|Syntometrine|Uterotonins
45914512|NCT02044562|Dietary Supplement|nitrate supplementation|A 70 ml beetroot juice containing 0.45g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
45914513|NCT02044562|Dietary Supplement|Placebo|A 70 ml placebo containing 0 g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
45914514|NCT02044588|Biological|HBsAg positive kidney allograft donor|
45914515|NCT02044601|Drug|Onartuzumab|"Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle.~Phase II: Maximum tolerated dose from Phase I."
45935536|NCT00074139|Drug|doxorubicin hydrochloride|
45774512|NCT03189719|Drug|Placebo|Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
45774513|NCT03189719|Drug|Cisplatin|80 mg/m^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
45774514|NCT03189719|Drug|5-FU|800 mg/m^2/day (4000 mg/m^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration, up to 35 administrations.
45774515|NCT03126630|Biological|Anetumab Ravtansine|Given IV
45774516|NCT03126630|Other|Laboratory Biomarker Analysis|Correlative studies
45774517|NCT03126630|Biological|Pembrolizumab|Given IV
45774518|NCT03126630|Other|Pharmacological Study|Correlative studies
45774519|NCT03114462|Radiation|Stereotactic Hypofractionated Radioablation|Starting dose is 8.0 Gy per fraction for 5 fractions (total dose = 40.0 Gy). Subsequent cohorts of participants receive an additional 0.5 Gy per fraction.
45774520|NCT03114462|Behavioral|Questionnaires|Quality of life and symptom questionnaires completed at: Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years.
45774521|NCT03070340|Diagnostic Test|Breast Magnetic Resonance Imaging (MRI)|All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.
45635090|NCT03170245|Diagnostic Test|Adiponectin level|serum samples used for doing the test by ELISA
45635091|NCT03170245|Diagnostic Test|Carotid intima media thickness|Done by carotid doppler
45774522|NCT03070340|Diagnostic Test|Contrast Enhanced Mammography (CEDM)|All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.
45774523|NCT02969525|Other|Placebo|
45774524|NCT02969525|Drug|Bimekizumab|Bimekizumab in different dosage regimens.
45774525|NCT02889081|Other|maternal biological folate level|supplementation status and serum level
45635092|NCT05109689|Behavioral|ACT-P|ACT-P consists of five modules. The Big Picture sessions are interwoven throughout the 24 sessions to introduce the main concepts of the curriculum, such as values identification and awareness of criminal behaviors. The Emotion Regulation and Cognitive Skills modules focus on awareness of internal experiences; learning new ways to respond to internal experiences; identifying and stepping back from problematic/criminal thoughts and beliefs; awareness of behaviors in service of values versus behaviors in service of control/avoidance; and identifying steps for behavior change. The Behavioral Skills module focuses on practicing prosocial behaviors, such as speaking and listening effectively and conflict resolution. Finally, the Barriers to Change module addresses environmental or life circumstances that can hinder successful behavior change (e.g., toxic masculinity, substance use, and parenting difficulties).
45774526|NCT02889081|Other|maternal biological Vitamin D level|supplementation status and serum level
45774527|NCT02866578|Procedure|Open lung protective ventilation strategy|
45774528|NCT02856594|Drug|Dexmedetomidine|Dexmedetomidine
45774529|NCT02856594|Drug|Placebo|Placebo
45774530|NCT04232215|Device|HeraBEAT™|A wireless Smart Fetal Ultrasound Doppler measuring device designed to be self-administered by the expectant mother throughout the different stages of pregnancy
45774531|NCT04232215|Device|Doppler fetal heart rate monitor|A hand-held ultrasound transducer that uses the Doppler Effect to provide an audible simulation of the heart beat and displays the number of beats per minute.
45914516|NCT02044601|Drug|Erlotinib|Phase I and II: 150 mg by mouth every day throughout radiation, except for chemotherapy day.
45914517|NCT02044601|Drug|Paclitaxel|Phase I and II: 45 mg/m2 by vein once a week throughout radiation for 7 weeks.
45914518|NCT02044601|Drug|Carboplatin|Phase I and II: AUC 2 by vein once a week throughout radiation for 7 weeks.
45448100|NCT01074905|Drug|Chloroquine/Primaquine|Chloroquine 3 days and Primaquine 14 days
45774532|NCT02840539|Drug|Bortezomib, Cytarabine, Dexamethasone, Pegteograstim|"Bortezomib: 1.3mg/m2 per day, SC (mixed with normal saline 1.4ml) on day 1, 4, 8, and 11 of each 28-day cycle~Cytarabine: 1.5g/m2 per day, IV (in the vein) over 3 hours on day 2 and 3 of each 28-day cycle for subjects aged less than 65 and 1g/m2 with the same route and schedule for those aged 65 or older~Dexamethasone: 20mg per day, IV (in the vein) or PO on day 1, 4, 8, and 11 of each 28-day cycle~Pegfilgrastim: 6mg once, SC on day 13 of each 28-day cycle Number of cycles: 6 unless progression or unacceptable toxicity develops within 6 cycles"
45774533|NCT02774954|Behavioral|Change the Cycle|See previous response
45774534|NCT02671448|Behavioral|Home monitoring teleconsult visits|A tablet will be provided to both the patient and the caregiver during the homecare portion of the study. The tablet will remain at the home, to be used by the patient and the caregiver during daily homecare visits to complete instruments/surveys and video diary recording sessions.
45448101|NCT02126254|Device|Hemodynamic group|NICAS guided treatment
45635093|NCT05109689|Behavioral|T4C|T4C is an integrated cognitive behavioral change program authored by Drs. Jack Bush, Barry Glick, and Juliana Taymans under a cooperative agreement with the National Institute of Corrections (NIC). The program is based on the principle that thinking controls how people act, and that to change the way people act, they have to control their thinking. T4C systematically presents the concept that thoughts cause one's behavior, and offenders learn to identify their own thought patterns that lead to risky behavior, and then to replace those maladaptive thoughts with new ones. T4C incorporates research from cognitive restructuring theory, social skills development, and the learning and use of problem solving skills.
45635094|NCT02701777|Other|STDP|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.
45635095|NCT02701777|Behavioral|Training|The participant will be asked to perform exercises using their hands and arms.
45448102|NCT02136160|Behavioral|attitude change, behavioral change|
45448103|NCT02136160|Behavioral|prevention program|
45448104|NCT01076387|Procedure|open radical cystectomy|Open radical cystectomy, pelvic lymph node dissection and open urinary diversion.
45448105|NCT01076387|Procedure|robotic-assisted radical cystectomy|Robotic radical cystectomy, pelvic lymph node dissection and open urinary diversion. Robotic radical cystectomy is routinely performed by robotically trained and experienced minimally invasive surgeons.
45448106|NCT03968237|Drug|Buprenorphine/Naloxone|Controlled substances
45635096|NCT02701777|Other|Sham STDP|Sham or fake paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined times.
45635097|NCT02701777|Other|Multisite-STDP|Paired stimulation will be given to the brain bilaterally, thoracic spine, and several peripheral nerve so that the messages are received at the spinal cord at predetermined time.
45774535|NCT02671448|Behavioral|Patient Reported Outcomes (PRO)|Distress Thermometer, MSK-Modified M.D. Anderson Symptom Inventory (MDASI) Instrument, FACT-G Instrument, FACT-BMT Instrument
45448107|NCT00138671|Drug|Subcutaneous Insulin|Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
45635098|NCT05109533|Other|Lactobacillus rhamnosus BMX 54, Lactobacillus reuteri RC-14, Lactobacillus rhamnosus GR-1|Probiotics implementation
45914519|NCT02044601|Radiation|Radiation Therapy|Phase I and II: Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.
45914520|NCT02044614|Other|Adjuvant Peritoneal Dialysis in the context of ongoing Hemodialysis|
45914521|NCT02044627|Drug|[14C-ETC-1002]|
45914522|NCT02044640|Procedure|Appendectomy|
45774536|NCT02671448|Behavioral|Caregiver Reported Outcomes instruments|Distress Thermometer, Caregiver Reaction Assessment (CRA) Instrument, The Caregiver Quality of Life Index-Cancer (CQOLC) Scale, Satisfaction Questionnaire, Video Diary Entries
45635099|NCT05109377|Diagnostic Test|Endocan|Endocan will measured before and after treatment
45635100|NCT05109377|Drug|tadalafil|tadalafil
45635101|NCT05109299|Other|Miswak toothpaste|Dabur Meswak is scientifically formulated herbal toothpaste with pure extract of the Miswak plant 'Salvadore Persica'
45774537|NCT02639442|Device|ClearRing™|
45635102|NCT05109299|Other|Fluoride toothpaste|1450 ppm fluoride toothpaste
45774538|NCT02603341|Radiation|Photon|Photon Therapy:once a day, 5 days a week, for 5 to 7 weeks
45635103|NCT03172351|Device|EDoF1|extended depth of focus IOL - EDoF1
45635104|NCT03172351|Device|Monofocal|Monofocal IOL
45635105|NCT03172351|Device|EDoF2|Comparison EDoF2 IOL
45635106|NCT05108753|Other|Procedure/Surgery|Transanal Total Mesorectal Excision
45774539|NCT02603341|Radiation|Proton|Proton Therapy: once a day, 5 days a week, for 5 to 7 weeks
45635107|NCT03170089|Behavioral|Oral Health Educational Program|Oral Hygiene methods learned
45774540|NCT02583113|Device|Total and Unicompartment Knee Replacement|Patients who have undergone a primary TKA on one side and primary UKA on the opposite side and are at a minimum of two years post-surgery.
45774541|NCT02551003|Drug|Autologous cord blood|Autologous cord blood will be collected after birth and administered in divided aliquots during the first 3 days of life. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
45635108|NCT02396719|Device|LenSx® Laser|Used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
45635109|NCT04673591|Drug|Tregalizumab|a monoclonal antibody designed for the treatment of allergic asthma indication
45635110|NCT04673591|Other|Placebo|Matched Placebo
45774542|NCT02551003|Device|Hypothermia|Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
45774543|NCT02550054|Drug|Epo|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, subcutaneously 400 U/Kg per injection and 3 doses per week until at corrected age of 34 weeks.
45635111|NCT05108597|Drug|Misoprostol|400ug misoprostol will be administered through rectal route, 1 hour before surgery to assess its effect on intra-operative blood loss during myomectomy
45774544|NCT02550054|Drug|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
45774545|NCT02544100|Other|Database Entry/Biospecimen Collection|blood, urine, CFS samples and medical data collected
45774546|NCT02457845|Biological|G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
45774547|NCT02453594|Biological|pembrolizumab|IV infusion
45774548|NCT02399813|Drug|Axalimogene filolisbac|
45635112|NCT02397187|Behavioral|LOOP|"The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes."
45774549|NCT02362802|Device|Implantable Cardioverter Defibrillator|
45774550|NCT02342782|Biological|Yttrium Y 90 Basiliximab|Given IV
45774551|NCT02342782|Drug|Carmustine|Given IV
45774552|NCT02342782|Drug|Etoposide|Given IV
45774553|NCT02342782|Drug|Cytarabine|Given IV
45774554|NCT02342782|Drug|Melphalan|Given IV
45774555|NCT02342782|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo AHCT
45774556|NCT02342782|Other|Laboratory Biomarker Analysis|Correlative studies
45774557|NCT02342782|Other|Pharmacological Study|Correlative studies
45774558|NCT02341924|Other|Portfolio of functional foods|
45774559|NCT02341924|Other|Control foods|
45774560|NCT02291055|Drug|ADXS11-001|
45774561|NCT02291055|Drug|MEDI4736|
45774562|NCT02112864|Drug|Dexamethasone|10 mg (2.5 ml)
45774563|NCT02112864|Drug|Normal Saline|2.5 mL normal saline
45774564|NCT02106988|Radiation|Radiation Therapy|Radiation therapy delivered for a total dose of 50.4 to 54 Gy 5 days a week for 28 to 30 treatments.
45774565|NCT02106988|Drug|Dexamethasone|40 mg by vein Days 1-3 in a 21 day cycle.
45774566|NCT02106988|Drug|Etoposide phosphate|67 mg/m2 by vein on Days 1-3 of a 21 day cycle.
45774567|NCT02106988|Drug|Ifosfamide|1 g/m2 by vein on Days 1-3 of a 21 day cycle.
45774568|NCT02106988|Drug|Mesna|0.4 g/m2 by vein on Days 1-3 with Ifosfamide, 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump.
45774569|NCT02106988|Drug|Carboplatin|200 mg/m2 by vein on Day 1 of a 21 day cycle.
45774570|NCT02022436|Drug|contrast ultrasound|Definity® is the contrast agent that will be administered by intravenous injection by a registered nurse during the ultrasound (contrast enhanced ultrasound (CUS). The purpose is to assist in identifying differences in AAA characteristics based on gender and AAA stability and growth.
45774571|NCT01981837|Drug|ALN-TTRSC (revusiran) for subcutaneous administration|
45774572|NCT01897558|Device|Pacemaker implantation|
45774573|NCT01854229|Device|Prometra Programmable Intrathecal Infusion Pump|There are two enrollment groups (arms). One is for new patients who are going to have a Prometra Pump implanted. The other arm is for patients who were part of the IDE study prior to FDA approval of the pump, and are willing to continue to be followed as part of a study.
45774574|NCT01847625|Other|simulator|
45774575|NCT01267500|Procedure|Non surgical therapy|patching or fusion exercises
45774576|NCT01237457|Drug|177Lu-DOTATATE|Patients will receive 200mCi dose of 177Lu Dotatate
45774577|NCT00723697|Drug|buprenorphine|0.4, 2, or 8 mg sublingual tablets
45774578|NCT00684073|Drug|buprenorphine|2 mg buprenorphine and 8 mg buprenorphine tablets at doses from 2 to 16 mg buprenorphine daily for first two days of study
45635113|NCT02396485|Other|Regular diet within 6hrs postoperative|Patients will be randomized to regular diet within 6 hrs postoperative (Early group) versus remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs (Routine Group) as standard postoperative protocol in the investigators' institution.
45635114|NCT03167593|Dietary Supplement|Lactobacillus coryniformis K8 CECT5711|Lactobacillus coryniformis CECT5711
45635115|NCT03167593|Other|Control placebo|Maltodextrin
45774579|NCT00684073|Drug|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone tablets at doses from 2/0.5 mg buprenorphine/naloxone to 16/4 mg buprenorphine/naloxone daily for last 3 days of study
45635116|NCT05108519|Other|Electronic Health Record Review|Medical records are reviewed
45635117|NCT02396173|Other|Risk Score for non-return to work|"The WORRK tool will be filled in for all patients, even the patients in the control group. However, the probability score will only be accessible for the medical doctors in the intervention group, along with guidelines for interpretation (1. With a probability score over 50% (not to return to work), patient's allocation to the Evaluation Pathway should be considered 2. With a probability score over 70% (not to return to work), the Evaluation Pathway is probably the most suitable choice)."
45635118|NCT04524767|Behavioral|SBIRT|Screening Brief Intervention and Referral to Treatment (SBIRT) is an evidence-based approach designed to provide screening, brief intervention, and referral to more intensive treatment for people at risk of developing mental disorders, including depression. SBIRT is composed of three core components: screening with a validated instrument, brief intervention, referral to treatment. Motivational Interviewing (MI) is the brief intervention most commonly used in SBIRT. MI is an empirically tested, person-centered, behavior change intervention designed to guide, elicit, and strengthen motivation for change. Subjects enrolled in the experimental SBIRT arm will receive up to a maximum of six sessions of MI.
45774580|NCT00603109|Drug|rimonabant|rimonabant capsule 20 mg per day PO for 6 months
45774581|NCT00603109|Drug|placebo|Subjects take 20 mg placebo capsule one a day PO for 6 months
45774582|NCT00199095|Drug|Adriamycin|
45774583|NCT00199095|Drug|Cyclophosphamide|
45774584|NCT00199095|Drug|Cytarabine|
45774585|NCT00199095|Drug|Dexamethasone|
45774586|NCT00199095|Drug|Idarubicin|
45774587|NCT00199095|Drug|Ifosfamide|
45774588|NCT00199095|Drug|Methotrexate|
45774589|NCT00199095|Drug|Mercaptopurine|
45774590|NCT00199095|Drug|VM26|
46070150|NCT04119141|Diagnostic Test|X ray imaging|"Acquisition:~140 kVp,~1/2 mAs/kg,~Pitch: 1.35,~Rotation time: 0.5 sec.~Reconstruction:~I70f filter, 3 iteration loops,~Cutting thickness 1 mm/0.7 mm~Fenestration: C -600/W 1600~Field of view (Size, x & y coordinates) identical on both acquisitions."
45774591|NCT00199095|Drug|Vincristine|
45774592|NCT00199056|Drug|Dexamethasone / Prednisolone|
45774593|NCT00199056|Drug|Cyclophosphamide|
45774594|NCT00199056|Drug|Methotrexate|
45774595|NCT00199056|Drug|Vincristine / Vindesine|
45774596|NCT00199056|Drug|Daunorubicin|
45774597|NCT00199056|Drug|Asparaginase|
45774598|NCT00199056|Drug|G-CSF|
45774599|NCT00199056|Drug|Cytarabine|
45774600|NCT00199056|Drug|6-Mercaptopurine|
45774601|NCT00199056|Drug|VP16|
45774602|NCT00199056|Drug|Adriamycin|
45774603|NCT00199056|Drug|Thioguanine|
45774604|NCT00199056|Drug|VM26|
45774605|NCT00199056|Drug|Idarubicin|
45774606|NCT00199056|Drug|Fludarabine|
45774607|NCT00199056|Drug|Ifosfamide|
45774608|NCT00199056|Procedure|CNS irradiation|
45774609|NCT00199056|Procedure|Mediastinal irradiation (if residual tumor)|
45774610|NCT00199056|Procedure|stem cell transplantation|
45774611|NCT00199030|Drug|Alemtuzumab (MabCampath)|
45774612|NCT00199030|Drug|Cladribine|
45774613|NCT00198978|Drug|Cyclophosphamide|
45774614|NCT00198978|Drug|Dexamethasone / Prednisolone|
45774615|NCT00198978|Drug|Cytarabine|
45774616|NCT00198978|Drug|Idarubicin|
45774617|NCT00198978|Drug|Granulocyte-Colony-Stimulating Factor|
45774618|NCT00198978|Drug|Mercaptopurine|
45774619|NCT00198978|Drug|Methotrexate|
45774620|NCT00198978|Drug|Rituximab|
45774621|NCT00198978|Drug|HDARAC|
45774622|NCT00198978|Drug|Vincristine|
45774623|NCT00198978|Drug|Depocyte|
45774624|NCT00198978|Drug|Asparaginase|
45774625|NCT00109395|Drug|Lorazepam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
45774626|NCT00109395|Drug|Midazolam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
45774627|NCT00109395|Drug|Lorazepam CI|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
45774628|NCT00003916|Radiation|radiation therapy|
45774629|NCT00003916|Radiation|stereotactic radiosurgery|
45774630|NCT01215643|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
45774631|NCT01215643|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
45774632|NCT01215643|Drug|Ribavirin|RBV 400 mg (2 x 200 mg tablets) administered orally twice daily (BID)
45774633|NCT00004924|Drug|irinotecan hydrochloride|
45774634|NCT00004924|Drug|paclitaxel|
45774635|NCT00004144|Drug|bryostatin 1|
45774636|NCT00004144|Drug|gemcitabine hydrochloride|
45774637|NCT00004150|Drug|fluorouracil|
45774638|NCT00004150|Drug|leucovorin calcium|
45774639|NCT00004150|Procedure|adjuvant therapy|
45774640|NCT00004930|Drug|doxorubicin hydrochloride|
45774641|NCT00004936|Drug|iodinated contrast dye|
45774642|NCT00004936|Procedure|computed tomography|
45774643|NCT00004936|Procedure|magnetic resonance imaging|
45774644|NCT00004936|Radiation|gadopentetate dimeglumine|
45635119|NCT04524767|Behavioral|Referral as Usual|We will utilize depression educational brochures describing the nine hallmark symptoms of depression symptoms and the importance of seeking treatment from pamphlets from the National Institute of Mental Health (NIMH). Subjects will also receive a list of referral sites in the study's catchment area of Upper Manhattan
45774645|NCT01261819|Device|cystoscopy|
45635120|NCT02396407|Behavioral|Combined water, sanitation, and hygiene|"Water: Free chlorine tablets (Aquatabs; NaDCC) and safe storage vessel to treat and store drinking water.~Sanitation: Free child potties, sani-scoop hoes to remove feces from household, and latrine upgrades to a dual pit latrine for all households in study compounds.~Handwashing: Handwashing stations including soapy water bottles and detergent soap.~Local promoters visit study compounds at least monthly to deliver behavior change messages that focus on (1) treating drinking water for children < 36 months of age, (2) use of latrines for defecation and the removal of human and animal feces from the compound, and (3) handwashing with soap at critical times around food preparation, defecation, and contact with feces."
45635121|NCT02403739|Other|No Intervention|No Intervention
45635122|NCT05080907|Other|Observational|Subjects for observational study Various conditions & healthy subjects
45635123|NCT03170011|Behavioral|Exercise using the Biodex Sit2Stand Trainer|Week 1-2 - Focused on lower intensity, higher volume, comfortable/self-selected velocity Week 3-4 - Focus on higher intensity, lower volume, comfortable/self-selected velocity Week 5 - Focus on moderate intensity, moderate volume, transitioning to higher velocity Week 6 - Focus on moderate intensity, moderate volume, high velocity
45635124|NCT05086913|Other|Lifestyle medicine smartphone booklets|Participants will receive a pocket size 6-page booklet weekly over 8 weeks that covers 8 lifestyle medicine, mental health and CBT themes including stress, relaxation, diet, exercise, sleep hygiene, worry management, mindfulness, and positive psychology, and guides participants to set and meet short term and long-term goals.
45635125|NCT05086913|Other|Lifestyle medicine smartphone app|The lifestyle medicine app offers 8 modules with identical content as the wellness booklets, in addition to videos, relaxation, exercise and cooking demonstrations, daily challenges, record of goals, and ecological momentary assessments of diet, physical activity, sleep, stress and mood.
45635126|NCT05086913|Other|Waitlist control|The waitlist control group will receive access to the lifestyle medicine app and booklets at the end of the study.
45635127|NCT05745805|Device|Simultaneous cortico-spinal magnetic resonance imaging, Serum|Simultaneous cortico-spinal magnetic resonance imaging data were collected in a strong magnetic field and collected the serum of participants.
45774646|NCT00003928|Drug|cisplatin|Cisplatin IV over 60 minutes on day 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
45774647|NCT00003928|Drug|gemcitabine hydrochloride|Gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
45774648|NCT00004156|Biological|MUC1-KLH vaccine/QS21|
45635128|NCT03169855|Diagnostic Test|Slit lamp (LOCS III Score)|Diagnostic procedure only
45774649|NCT01262131|Device|magnetic therapy protocol A|Application of magnetic fields using the Resonator device Protocol A
45774650|NCT01262131|Device|magnetic therapy Protocol B|Application of magnetic fields using the Resonator device Protocol B
45774651|NCT01262131|Device|placebo therapy|Application of inactive magnetic fields using the Resonator device
45774652|NCT00004162|Biological|sargramostim|
45774653|NCT00004162|Drug|methotrexate|
45774654|NCT00004162|Drug|pegylated liposomal doxorubicin hydrochloride|
45774655|NCT00004162|Drug|vincristine sulfate|
45774656|NCT01262599|Device|Sham PEMF Device|Inactive device placed in the same manner as the active device; does not deliver pulsed electromagnetic fields
45448108|NCT00138671|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
45774657|NCT01262599|Device|Ivivi Torino II PEMF Device|"The PEMF device to be employed in this study is FDA cleared for adjunctive use in the palliative treatment of postoperative pain and edema in superficial soft tissue (510(k) number: K903675). The PEMF device will be taped over the affected breast and abdomen. The PEMF signal will consist of a 2 msec burst of 27.12 MHz sinusoidal waves repeating at 2 bursts/sec. The device will automatically provide a 15 minute treatment every 2 hours. Supplied by Ivivi Health Sciences, LLC."
45774658|NCT01262755|Behavioral|Structured Interview|Subjects underwent a structured interview using a laptop computer and answered over 200 standardized questions. All patient had their height, weight, and waist circumference measured.
45774659|NCT00004984|Drug|Parenteral Insulin|Subcutaneous injections of recombinant human ultralente insulin in the morning and in the evening; the initial dose for each injection was 0.125 U per kilogram of body weight.
45774660|NCT00004984|Other|Close Observation|Study visits every 6 months including an oral glucose tolerance test
45774661|NCT00004984|Drug|Oral Insulin|Capsules oral insulin, 7.5 mg of recombinant human insulin crystals
45774662|NCT00004984|Drug|Placebo|Placebo for oral insulin
45774663|NCT00004174|Biological|filgrastim|
45774664|NCT00004174|Drug|cyclophosphamide|
45774665|NCT00004174|Drug|paclitaxel|
45774666|NCT00004174|Drug|thiotepa|
45774667|NCT00004174|Procedure|peripheral blood stem cell transplantation|
45774668|NCT00004174|Radiation|radiation therapy|
45774669|NCT01284517|Drug|Lurasidone|Tablets 20-120 mg, PM dosing,daily for 6 weeks
45774670|NCT01284517|Drug|Placebo|Equivalent to Lurasidone dosing
45774671|NCT00004990|Drug|Dexamethasone|
45774672|NCT01216735|Drug|Fluticasone|220 ug twice a day for 3 weeks
45774673|NCT01216735|Drug|Placebo|Placebo for 3 weeks
45774674|NCT00004186|Drug|carboplatin|
45774675|NCT00004186|Drug|etoposide|
45774676|NCT00004186|Drug|ifosfamide|
45774677|NCT00004186|Drug|topotecan hydrochloride|
45774678|NCT00004186|Radiation|radiation therapy|
45774679|NCT01285843|Procedure|Anterior Minimally Invasive Approach (AMIS)|
45774680|NCT00004192|Biological|filgrastim|
45774681|NCT00004192|Biological|pegfilgrastim|
45774682|NCT00004192|Drug|cisplatin|
45774683|NCT00004192|Drug|cytarabine|
45774684|NCT00004192|Drug|etoposide|
45635129|NCT04436627|Device|Amadeo-assisted training-1|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes active assistive training mode, followed by 20 minutes RT functional games (grasp and release) and 20 minutes RT finger coordination training.
45635130|NCT04436627|Device|Amadeo-assisted training-2|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 10 minutes continuous passive motion mode followed by 20 minutes active assistive training mode, and 30 minutes RT functional games (grasp and release).
45635131|NCT04436627|Device|Amadeo-assisted training-3|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes continuous passive motion mode followed by 20 minutes active assistive training mode. After 40 minutes of RT, 20 minutes functional tasks without robot.
45635132|NCT02396329|Drug|Chlorhexidine|
45635133|NCT02396329|Drug|Povidone-Iodine|
45635134|NCT04964921|Other|Device: ANSiScope Plus|Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
45635135|NCT05745727|Drug|PRX-115|Escalating doses of PRX-115 will be given in different cohorts i.e., Cohorts 1 through 7
45635136|NCT05745727|Drug|Placebo|Escalating doses of Placebo will be given in different cohorts i.e., Cohorts 1 through 7
45635137|NCT04053049|Other|Diet|Meals composed of either high fat vs. high carbohydrate and semi-solid vs. solid
45635138|NCT04648553|Behavioral|Task-Based Grounding|Three 50 minutes sessions with an interventionist that includes 6 non-punitive components of treatment common in Behavioral Parent Trainings: Education on behavior change, positive one-on-one time between parents and their children, differential attending to positive and negative behaviors, effective praise, giving effective instructions, and using a point and reward system to encourage prosocial behaviors. These components are distilled into 5 skill modules and paired with Task-Based Grounding, which involves a brief restriction of privileges and provides children with the opportunity to end the restriction by completing a prosocial task.
45635139|NCT04648553|Behavioral|Connected Care (Enhanced Treatment as usual)|Two sessions with a facilitator. The facilitator does NOT provide any guidance to the parent on managing their child's behavior, but provides empathy and problem solving to help them find a resource that best fits their needs. It is particularly geared towards helping parents connect with Behavioral Parent Trainings to address the needs of children with oppositional, defiant, or aggressive behaviors.
45774685|NCT00004192|Drug|methylprednisolone|
45635140|NCT03167515|Device|074-6751 Lotion|Apply lotion once in the morning and once in the evening daily at approximately the same time every day with 12 hours between doses. Apply the lotion only to the active psoriatic lesions, as instructed by your study doctor.
45635141|NCT03168139|Drug|Olaptesed pegol - Monotherapy|"Monotherapy (MT) period:~Treatment with 300 mg olaptesed pegol only, weekly on MT D1 and MT D4 for up to 2 weeks"
45635142|NCT03168139|Drug|Olaptesed pegol + Pembrolizumab - Combination Therapy|"Combination therapy (CT) period:~Treatment with 300 mg olaptesed pegol in combination with 200 mg pembrolizumab every three weeks (Q3W) until progressive disease or limiting toxicity, for a maximum of 24 months in total"
45635143|NCT02396017|Device|Capsule endoscopy|Endoscopic device
45635144|NCT02396017|Drug|Polyethylene Glycol|Bowel purgative
45635145|NCT04515407|Other|PAS at Rest|Paired Associative Stimulation will be delivered while the participant is seated and resting.
45774686|NCT00005002|Drug|Lamivudine/Zidovudine|
45774687|NCT00005002|Biological|HIV-1 Immunogen|
45774688|NCT00005002|Drug|Nelfinavir mesylate|
45774689|NCT01263301|Device|carotid duplex|Carotid duplex in the differential diagnosis of subclavian steal syndrome due to Arteriovenous Hemodialysis access in the Ipsilateral arm
45774690|NCT00004198|Biological|keyhole limpet hemocyanin|
45774691|NCT00004198|Biological|sargramostim|
45774692|NCT00004198|Biological|tumor cell-based vaccine therapy|
45774693|NCT01264705|Drug|bavituximab (0.3 mg/kg) and sorafenib|Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily
45774694|NCT01264705|Drug|bavituximab (1.0 mg/kg ) and sorafenib|Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily
45774695|NCT01264705|Drug|bavituximab (3.0 mg/kg) and sorafenib|Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily
45914523|NCT02044653|Drug|GX-E2|Each Group of Peritoneal dialysis patients (n=10) will be administered GX-E2 3ug/kg to 8ug/kg
45635146|NCT04515407|Other|PAS - Active|Paired Associative Stimulation will be delivered while the participant is seated and producing submaximal background activity in the plantarflexor muscles.
45914524|NCT02044653|Drug|GX-E2|Each Group of Peritoneal dialysis patients (n=24) will be administered GX-E2 5ug/kg to 8ug/kg
45914525|NCT02044653|Drug|GX-E2|Each Group of Hemodialysis patients (n=30) will be administered GX-E2 5ug/kg to 8ug/kg
45635147|NCT04515407|Other|PAS - Walking|Paired Associative Stimulation will be delivered while the participant is walking, during the late stance phase of the gait cycle.
45914526|NCT02044653|Drug|NESP|Each Group of Hemodialysis (n=30) will be administered NESP 30ug
45448109|NCT01075061|Other|healthy volunteers|morphological and functional brain MRI; transcranial magnetic stimulation
45774696|NCT00004204|Drug|temozolomide|
45774697|NCT01217515|Drug|Diltiazem hydrochloride 4% cream|3 times daily
45774698|NCT01217515|Drug|Diltiazem hydrochloride 2% cream|3 times daily
45774699|NCT01217515|Other|Placebo|3 times daily
45774700|NCT00005014|Drug|Risperidone|
45774701|NCT03009799|Drug|Iota-Carrageenan|One drop in each eye 8 times per day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until Day 21
45774702|NCT03009799|Drug|Carmellose|1 drop in each eye 8 times/day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until day 21
45774703|NCT00005026|Drug|carboplatin|
45774704|NCT00005026|Drug|paclitaxel|
45914527|NCT02044653|Drug|MIRCERA|Each Group of Peritoneal dialysis (n=24) will be administered MIRCERA 0.6ug/kg
45914528|NCT02044666|Device|Micronized Small Intestinal Submucosa (SIS)|Micronized Small Intestinal Submucosa (SIS)
45914529|NCT02044679|Other|Water|
45774705|NCT00005026|Drug|topotecan hydrochloride|
45635148|NCT02395939|Procedure|CT guided core biopsy|CT guided biopsy will be performed by a trained interventional radiologist using core biopsy.
45635149|NCT02395939|Procedure|Cryo-biopsy via Radial EBUS navigation|Cryo-biopsy will be performed via R-EBUS guidance. Cryo biopsy probe will be applied for 4 seconds for each biopsy and a minimum of 3 biopsies will be performed . Each patient will also have 3 forceps biopsies. The order of forceps biopsy or cryo biopsy will be randomly allocated.
45635150|NCT02395783|Drug|Melatonin 10 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
45635151|NCT02395783|Drug|Melatonin 20 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
45635152|NCT02395783|Other|Placebo|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
45635153|NCT04604015|Diagnostic Test|NeuralBot Investigational System|The NeuralBot Investigational System when used with the Lucid M1 System is a medical ultrasound device which assists the user in the setup and acquisition of cerebral blood flow velocity via the patient's temporal windows. It is intended for use as an adjunct to standard clinical practices for measuring and displaying cerebral blood flow velocity and the occurrence of transient emboli within the blood stream.
45635154|NCT04569383|Biological|MVA-SARS-2-S vaccinations (days 0 & 28)|Vaccination with MVA-SARS-2-S in two escalating dose regimens
45635155|NCT04569383|Biological|Comirnaty|Vaccination with Comirnaty (21 day interval)
45635156|NCT04555343|Drug|Tranexamic acid|1gm instilled instravesically
45914530|NCT02044679|Other|No intervention|
45635157|NCT04450667|Dietary Supplement|Nutricia PreOp|Oral rehydration 2 hours before the scheduled cesarean section under spinal anesthesia
45635158|NCT04436237|Other|Virtual reality foot placement training|The training is conducted in sitting and standing, and involves both the affected and unaffected foot placement. In the total immersive virtual environment, a target will be presented and the participants are required to move one foot to the target. The location of the moving foot is not seen by the participant in this training.
45635159|NCT04466657|Dietary Supplement|Antioxidation Therapy|Two proprietary formulations composed of reduced glutathione, N-acetylcysteine, superoxide dismutase, and bovine lactoferrin and immunoglobulins.
45635160|NCT04466657|Other|Standard of Care|SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
45914531|NCT02044705|Behavioral|Active and Healthy Families|Pediatric obesity intervention delivered through five bi-weekly Active and Healthy Families family-based group medical appointments (i.e., sessions).
46070151|NCT04030689|Other|data collected from patient file|socio-demographics, previous HIV testing history, history of HIV contamination, clinics HIV related data will be collected for each patient who notified his non-objection to participate to this non interventional study.
46070152|NCT00700947|Drug|Beta-blocker therapy (TOPROL-XL® )|Patients who are asymptomatic with normal left ventricular systolic function and wish to be medically treated for severe primary mitral regurgitation with Beta-blocker.
45635161|NCT04392323|Diagnostic Test|COVID-19 PCR and Serology|PCR for COVID entails obtaining a nasopharyngeal swab (a cotton tip introduced via the nose to obtain a sample) to determine whether there is active viral replication and viral shedding. They will then have a second test with serology and PCR for COVID-19 infection 12-16 days after discharge from the hospital. Serology implies that a blood sample will be obtained by venipuncture. A volume of 50 ml (about 4 tablespoons) or less of blood will be obtained.
45774706|NCT00004210|Other|loss of heterozygosity analysis|
45774707|NCT00004210|Other|microsatellite instability analysis|
45448110|NCT01075061|Other|Kallmann|morphological and functional brain MRI; transcranial magnetic stimulation
45448111|NCT01075061|Other|Congenital Mirror Movement|morphological and functional brain MRI; transcranial magnetic stimulation
45448112|NCT01075139|Behavioral|Brief Motivational Intervention|30 minute one-on-one meeting
45448113|NCT01075139|Behavioral|Educational information|Educational handouts/brochures
45635162|NCT04528667|Drug|STI-5656|STI-5656 (abivertinib maleate) is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor.
45635163|NCT04528667|Drug|Placebo|Placebo capsules
45635164|NCT04383119|Drug|Trabectedin|Trabectedin in monotherapy
45635165|NCT04383119|Drug|Gemcitabine|Gemcitabine, control arm
45635166|NCT04383119|Drug|No Intervention: Observational Cohort|Treatment according clinical practice
45635167|NCT04522739|Drug|Spironolactone|The initial dose of spironolactone will be 25mg and will be increased to 50 mg after 2 weeks provided the following criteria are present: 1) systolic blood pressure (SBP) >110 mm Hg, 2) diastolic blood pressure (DBP) > 60 mm Hg, and no reported symptoms of hypotension (dizziness or weakness). Participants will take one capsule by mouth per day.
45635168|NCT04522739|Drug|Placebo|A placebo to match spironolactone will be taken orally once per day.
45635169|NCT04309877|Drug|Theophylline ER|Capsules of theophylline ER
45635170|NCT04309877|Other|PO placebo|Capsules of methylcellulose
45635171|NCT04309877|Biological|Lipopolysaccharide (LPS)|Purified bacterial wall component as an inflammatory challenge
45635172|NCT04309877|Other|IV placebo|Normal (0.9%) saline
45774708|NCT00004210|Other|mutation analysis|
45774709|NCT00004210|Other|counseling intervention|
45774710|NCT00016718|Drug|Didanosine (ddI)|Antiretroviral Didanosine (ddI) : 240 mg/m^2 up to a maximum of 400 mg once daily
45774711|NCT00016718|Drug|Efavirenz (EFV)|Antiretroviral For Age Group 1 Efavirenz (EFV): dose adjusted for body size and for Age Groups 2 and 3 Efavirenz (EFV): up to a maximum of 600 mg once daily as a capsule ot 720 mg as an oral solution
45914532|NCT02044731|Behavioral|Active and Healthy Families|A pediatric overweight/obesity intervention delivered through five bi-weekly family-based group sessions.
45635173|NCT04367909|Drug|Nimotuzumab|Nimotuzumab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
46070153|NCT04116333|Device|Endotracheal tube introducer|Use of endotracheal tube introducer with the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
45635174|NCT04367909|Drug|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m^2) will be administered intravenously on Day 1 of each 21-day cycle.
45635175|NCT04367909|Drug|Carboplatin|Carboplatin AUC 5 will be administered intravenously on Day 1 of each 21-day cycle.
45635176|NCT04221425|Procedure|virtual reality rehabilitation system (VRRS)|experimental group is equipped with a telerehabilitation system which comprises a tablet (VRRS tablet) and a set of inertial magnetic sensors. participants are invited to follow a daily rehabilitation exercise program provided via VRRS tablet
45635177|NCT04221425|Procedure|standard care|participants in the control group are invited to follow a daily rehabilitation exercise program and indications for the recovery as illustrated in the dimission booklets drawn up by the rehabilitation unit
45635178|NCT04058873|Drug|Levonorgestrel 1.5mg|Levonorgestrel 1.5mg for pericoital use
45635179|NCT04203953|Other|Early mobilization program|Early mobilization will be defined as any active exercise where the patients could assist with the activity using their own muscle strength and control that occurred within the first 7 days of trauma ICU admission and will be intended to maintain or restore overall function as well as being scored using the ICU mobility scale.15 The ICU mobility scale includes rolling, bridging, sitting, standing and walking, and upper and lower limb flexion and extension. In-bed therapies will include active or active-assist range of motion, bridge exercise, quadriceps setting, straight leg raising, rolling exercises and facilitation.
45774712|NCT00016718|Drug|Emtricitabine (FTC)|Antiretroviral Emtricitabine (FTC): 6 mg/Kg up to a maximum of 200 mg once daily
45774713|NCT00004216|Biological|salmonella VNP20009|
45774714|NCT00004216|Drug|cefixime|
46070154|NCT04116333|Device|Macintosh laryngoscope|Use of the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
46070155|NCT04116177|Device|Deep brain stimulation|Stimulation using VerciseTM system
46070156|NCT00652951|Biological|GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)|Intramuscular injection, 3 doses in the primary vaccination and 1 dose in the booster vaccination
46070157|NCT00652951|Biological|Infanrix™ hexa.|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
46070158|NCT00652951|Biological|Pediacel™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
45635180|NCT04196075|Drug|Andrographis Paniculata|AP as palliative treatment
45635181|NCT04142255|Biological|FMT|FMT administration starts on the first week of enrollment. Age-based dose of FMT is taken once a day for the first three days of the first week. Then once a week for 3 weeks.
45635182|NCT03863483|Drug|Sintilimab|Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
45635183|NCT03863483|Drug|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m^2) will be administered intravenously on Day 1 of each 21-day cycle.
45635184|NCT03863483|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
45774715|NCT00004216|Drug|ceftriaxone sodium|
45774716|NCT00004216|Drug|ciprofloxacin|
45774717|NCT00004216|Drug|trimethoprim-sulfamethoxazole|
45774718|NCT00005566|Behavioral|Desperation Scale|
45774719|NCT01897064|Behavioral|Aerobic Exercise|36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric care.
45774720|NCT01897064|Other|Standard Psychiatric Treatment|Standard psychiatric treatment.
46070159|NCT00652951|Biological|Prevenar™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
46070160|NCT00848211|Other|Placebo|Subcutaneous injection on Day 0, Day 28, and Day 84
45774721|NCT00005032|Biological|oblimersen sodium|
45774722|NCT00005032|Drug|paclitaxel|
45774723|NCT04613414|Other|Early Management|Scheduled for sleep physician appointment within 1 month of home sleep apnea test/triage
45774724|NCT00004234|Procedure|management of therapy complications|
45774725|NCT00004234|Radiation|radiation therapy|
45774726|NCT00005038|Biological|aldesleukin|
45774727|NCT00005038|Drug|histamine dihydrochloride|
45774728|NCT00019682|Biological|Aldesleukin|Given IV
45774729|NCT00019682|Biological|gp100 Antigen|Given SC
46070161|NCT00848211|Biological|TUTI-16 (0.03mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
46070162|NCT00848211|Biological|TUTI-16 (0.1mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
45635185|NCT03863483|Drug|Placebo|0.9% sodium chloride injection as placebo will be administered intravenously at a fixed dose of 100 milliliters (mL) on Day 1 of each 21-day cycle.
45635186|NCT04010045|Device|Endovascular Treatment of PAD|PAD endovascular treatment using the DABRA Laser System + other FDA cleared/ approved devices for the treatment of PAD.
45635187|NCT04000763|Device|superficial peroneal nerve stimulation|A commercially available FDA-approved transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes will be used to stimulate the foot. The electrodes will be attached to the dorsal surface of the foot and a sock will be placed over the foot to prevent detachment of the electrodes. Based on our animal studies, foot stimulation parameters of 2 Hz frequency and 0.2 ms pulse width will be used at the maximal intensity comfortable for each patient. It is expected that superficial peroneal nerve stimulation in patients can increase bladder sensation so that micturition can be initiated at a small bladder volume, or it can initiate bladder contraction at a small bladder volume and enhance the contraction or prolong the duration of contraction. Any of these excitatory effects, if occurs in human patients, will certainly improve the condition of non-obstructive urinary retention.
45635188|NCT03871595|Drug|BI 894416|Oral
45635189|NCT03840005|Drug|Ursonorm|Ursodeoxycholic acid
45635190|NCT03780725|Drug|BI 754111|Solution for infusion
45635191|NCT03780725|Drug|[89Zr]Zr-BI 754111|Solution for infusion
45774730|NCT00019682|Drug|Montanide ISA 51 VG|Given SC
45774731|NCT00019682|Other|Quality-of-Life Assessment|Ancillary studies
45774732|NCT00019682|Other|Questionnaire Administration|Ancillary studies
45774733|NCT00019682|Other|Laboratory Biomarker Analysis|Correlative studies
45774734|NCT00005050|Drug|ethynyluracil|
45774735|NCT00005050|Drug|fluorouracil|
45774736|NCT00005050|Drug|oxaliplatin|
45914533|NCT02044744|Behavioral|Physical activity referral|Provision of a primary care referral to at least one community-based physical activity program that is a good match for the participant's needs and preferences and patient follow-up on enrollment.
45914534|NCT02044757|Behavioral|SSB withdrawal|During days 1-5, participants will drink the beverages they normally consume (no intervention). On days 6-8, participants will be instructed to drink only water and unflavored milk during the withdrawal period (days 6-8).
45914535|NCT02044783|Behavioral|Behavioral Counseling|
45914536|NCT02044809|Drug|Cannabidiol|
45635192|NCT03780725|Drug|BI 754091|Solution for infusion
45635193|NCT03830411|Drug|Sintilimab|Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
45635194|NCT03830411|Drug|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m^2) will be administered intravenously on Day 1 of each 21-day cycle.
45635195|NCT03830411|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
45635196|NCT03300479|Drug|Clevidipine|Intravenous antihypertensive therapy with Clevidipine for the first 24 hours in patients with nontraumatic intracerebral hemorrhage (ICH).
45635197|NCT03300479|Drug|Urapidil|We compare the therapy with Urapidil to Clevidipine for the acute phase (24 hours) in patients with ICH. We would like to show the efficacy and safety of Clevidipine in this special situation.
45635198|NCT04718987|Radiation|Low dose rate (LDR) brachytherapy|Low dose rate (LDR) brachytherapy is a type of radiation treatment where doctor places the radioactive implants (seeds) inside patient's prostate gland and these seeds emits low dose radiation over a certain period of time. During low-dose-rate brachytherapy, a continuous low dose of radiation is released over time -from several hours to several days.
45635199|NCT04708379|Behavioral|Lifestyle intervention|Nutrition and physical activity education.
45635200|NCT04698785|Drug|Treatment by regorafenib and best supportive care|"Treatment for 13 cycles (12 months) maximum.~During each cycle :~patients ≥ 16 years old and patients <16 old with Body Surface Area (BSA) ≥ 1,70 m2 will take 3 tablets, once a day, corresponding to a total of 120 mg Regorafenib, during 21 days, followed by 7 days without treatment.~patients < 16 years old with a 1,30 m2 ≤ BSA ≥ 1,70 m2 will take 2 tablets, once a day, corresponding to a total of 80 mg Regorafenib, during 21 days, followed by 7 days without treatment"
45635201|NCT04698785|Drug|Treatment by placebo and best supportive care|"Treatment for 13 cycles (12 months) maximum.~During each cycle :~patients ≥ 16 years old and patients <16 old with Body Surface Area (BSA) ≥ 1,70 m2 will take 3 tablets, once a day, corresponding to a total of 120 mg Placebo, during 21 days, followed by 7 days without treatment.~patients < 16 years old with a 1,30 m2 ≤ BSA ≥ 1,70 m2 will take 2 tablets, once a day, corresponding to a total of 80 mg Placebo, during 21 days, followed by 7 days without treatment"
45774737|NCT00005578|Biological|bleomycin sulfate|
45774738|NCT00005578|Biological|filgrastim|
45774739|NCT00005578|Drug|cyclophosphamide|
45774740|NCT00005578|Drug|dexrazoxane hydrochloride|
45774741|NCT00005578|Drug|doxorubicin hydrochloride|
45774742|NCT00005578|Drug|etoposide|
45774743|NCT00005578|Drug|prednisone|
45774744|NCT00005578|Drug|vincristine sulfate|
45774745|NCT00005578|Radiation|radiation therapy|
45774746|NCT00022490|Drug|cytarabine|Once daily subcutaneous injection of Ara-C (Cytarabine) at a dose of 20 mg (10 mg or 5 mg if they have been dose reduced) per square meter of calculated body surface area, on days 15-28 of each sequential 28 day cycle
45774747|NCT00022490|Drug|imatinib mesylate|Once daily oral administration of STI571 (Imatinib Mesylate) at a dose of 400 mg for 12 months.
45774748|NCT00386230|Drug|ZDV Short (mother)-Short (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Sinfant)
45914537|NCT02044809|Drug|Placebo|
45914538|NCT02044835|Drug|Fu-zheng-qu-zhuo oral liquid|Fu-zheng-qu-zhuo oral liquid was composed of Ginseng, Astragalus, Angelica root, Tuckahoe, Rhubarb, etc. It was producted by manufacturing laboratory of Guang'anmen Hospital, China Academy of Chinese Medical Science (License code: 京药制字Z20063242)
45914539|NCT02044861|Drug|PFK-158|IV dose escalation
45935537|NCT00126373|Drug|Wellbutrin (bupropion)|bupropion 150mg-300mg daily
45935538|NCT00126412|Drug|123I-mIBG (meta-iodobenzylguanidine)|
45935539|NCT00043706|Drug|Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody|
45635202|NCT03702569|Diagnostic Test|Left ventricular global longitudinal strain measure|Left ventricular global longitudinal strain value measured before and immediately after volume expansion (500mL crystalloid) using speckle tracking images with echocardiography
45635203|NCT04685447|Procedure|Expanded Hemodialysis for Covid19 maintenance hemodialysis patients|After Covid19 diagnosis participants are randomized to receive Expanded Hemodialysis for two weeks
45635204|NCT04685447|Procedure|Hemodialysis by protein-leaking dialyzer for Covid19 maintenance hemodialysis patients|After Covid19 diagnosis participants are randomized to receive hemodialysis by protein-leaking dialyzer for two weeks
45635205|NCT03012425|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
45635206|NCT03012425|Procedure|Acupuncture|
45635207|NCT03012425|Behavioral|questionnaires|
45635208|NCT03012425|Other|Diurnal Cortisol|saliva test
45635209|NCT03587675|Diagnostic Test|EVH test|
45635210|NCT03540875|Device|Closed loop anesthesia|"Propofol and Remifentanil are administered automatically using a closed-loop system.~The goal of this study is to compare manual titration versus automated titration of propofol and remifentanil in adult patients undergoing surgery guided by the electro-cortical activity. The aim in both group is to maintain the qCon in the range 40-60 during induction and maintenance of general anesthesia using the propofol in TCI mode. But also the qNox in the range 40-60 using remifentanil. The controller is based on a Proportional-Integral-derivative algorithm which steers a target to the pumps during induction and maintenance of general anesthesia."
45635211|NCT03540875|Drug|Propofol|The dosage is modified automatically by the device or according to the new medical prescription.
45635212|NCT03540875|Drug|Remifentanil|The dosage is modified automatically by the device or according to the new medical prescription.
45635213|NCT03536507|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
45635214|NCT03536507|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
45635215|NCT03220685|Biological|Stool analysis|Bacterial extraction in faeces by repeated fractional centrifugation to obtain bacterial mass and DNA sequencing.
45635216|NCT04765787|Drug|Combination of Paracetamol 650mg + Orphenadrine 50mg|In routine practice for pain , combination of Paracetamol 650 mg + Orphenadrine 50mg prescribed for 7-10 days with follow up and as per physician discretion
45635217|NCT05115539|Other|doppler US of portal vein, hepatic veins, intrarenal veins|"Hepatic Vein Doppler : To obtain the HV PW, a phased array transducer is used with cardiac pre-sets. ECG leads are placed to assist in the interpretation of HVD in sinus rhythm as well as atrial fibrillation. The middle hepatic vein is identified from mid-subcostal or lateral views during the end-expiratory phase of the patients respiratory cycle.~Portal vein Doppler: From a lateral costal or subcostal window, the portal vein is identified in the coronal plane using a phased-array transducer. The PV were considered abnormal if the pulsatilty index was greater than 30%. The portal pulsatility index was defined as: (VMax - VMin/VMax) * 100%. Here, VMax is the maximal velocity and VMin is the minimal velocity during the cardiac cycle.~Intra-renal venous Doppler: From lateral costal window, the kidney is located in the coronal plane and a color flow box placed over the distal renal calyceal junction to cortex."
45635218|NCT04672967|Diagnostic Test|BioROSA MAP test|The BioROSA MAP test is a blood test that is being developed to predict ASD risk
45635219|NCT04663217|Other|Exercise|After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion
45914540|NCT02044913|Behavioral|Phone-based Aftercare-Coordination|After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention is case-management orientated and aims at supporting the patients in finding and organising an adequate aftercare treatment.
45914541|NCT02044939|Other|Pulmonary rehabilitation program|Pulmonary rehabilitation program should follow ATS/ERS Guidelines (2006)
45635220|NCT02944799|Drug|Placebo|Discontinuation of alendronate treatment
45635221|NCT02944799|Drug|Alendronate|
45635222|NCT02944799|Drug|Calcium|Daily dietary supplement of 800mg calcium
45635223|NCT02944799|Drug|Vitamin D|Daily dietary supplement of 38 micrograms vitamin D
45635224|NCT02749331|Drug|AdVince|Virus solution for infusion in intrahepatic artery
45635225|NCT05115149|Device|VIBRAINT RehUp robotic orthosis|VIBRAINT RehUp robotic orthosis is a robotic arm that supports movement of a paralyzed arm. The robotic device is connected to a BCI. VIBRAINT RehUp software decodes imagery of a movement of the paralyzed arm and/or selective attention to the target of movement.
45635226|NCT05115149|Procedure|tSCS during the exercise|"During the exercise transcutaneous stimulation of the spinal cord and, in some cases, peripheral nerves is also performed.~tSCS is performed with the localization of electrodes between the spinous processes of the vertebrae C2-C3 and C5-C6, anodes - above the clavicles or above the crests of the iliac bones, bipolar or monopolar pulses with a frequency of 30 Hz, modulated with a frequency of 5 Hz."
45774749|NCT00386230|Drug|ZDV Short (mother)-Long (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Linfant)
45774750|NCT00386230|Drug|ZDV Long (mother)-Short (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Sinfant)
45774751|NCT00386230|Drug|ZDV Long (mother)-Long (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Linfant)
45774752|NCT00097448|Drug|prednisone|Oral, 19 days
45774753|NCT00097448|Drug|methylprednisolone sodium succinate|Four intratympanic injections delivered to the middle ear over 2 weeks
45774754|NCT00004246|Drug|Fludarabine Phosphate|IV on days 1-5 of weeks 6 and 7 of radiotherapy, administered 3-4 hours prior to daily radiotherapy.
45635227|NCT05115149|Procedure|tSCS prior to the exercise|"Prior to the exercise transcutaneous stimulation of the spinal cord and, in some cases, peripheral nerves is also performed.~tSCS is performed with the localization of electrodes between the spinous processes of the vertebrae C2-C3 and C5-C6, anodes - above the clavicles or above the crests of the iliac bones, bipolar or monopolar pulses with a frequency of 30 Hz, modulated with a frequency of 5 Hz."
45635228|NCT05115149|Device|Neostim-5|Neostim-5 is intended for the transcutaneous spinal cord noninvasive stimulation from 0 up to 250 2 mA (step 1mA). Neostim allows to stimulate up to five different segments of spinal cord. The device can be synchronised with other devices.
45635229|NCT05115149|Procedure|Exercise|The partcipant recieves a mental task - to imagine a movement or to concentrate on the goal. Upon successful completion of the given mental task, the VIBRAINT RehUp robotic exerciser moves the paralyzed limb. In the presence of muscular activity in a limb, an additional condition for the start of movement can be EMG activity in an agonist muscle assisting the robot movement.
45635230|NCT05112341|Radiation|radiation therapy|the patient first is simulated then delineation is done
45635231|NCT04638803|Drug|PRX-P4-003, (-)-FCF|sequential study
45635232|NCT05114681|Other|Assessment of Oral care as per patient personal choice|We just inquire from patients or attendants about products used, the timing for oral care.
45635233|NCT04592783|Drug|Antihypertensive Agents|Antihypertensive medications will be initialed once BP is at predetermined threshold
45635234|NCT05114525|Behavioral|Survey questionnaire|The survey questionnaire will include semi-structured questions about patient demographics and patient understanding of the risks and benefits of radiation, different treatment options, the treatment process, utility of visual aid presentation and information gathering preference using a semi-structured questionnaire
45635235|NCT05112107|Behavioral|Culinary workshops|Approved ketogenic recipes will be applied in educational cooking workshops at the ketogenic diet clinic at Instituto da Criança HCFMUSP.
45635236|NCT04521881|Drug|Tranexamic Acid 500 MG|given once as an intramuscular injection
45774755|NCT00004246|Radiation|Radiation Therapy (RT)|Days 1-5 for 7 weeks
45774756|NCT00423280|Drug|6R-BH4|6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
45774757|NCT00028262|Drug|Cystagon|
45774758|NCT04771286|Drug|BI 1015550 (C-14)|BI 1015550 (C-14)
45774759|NCT00005056|Drug|bryostatin 1|
45774760|NCT00004252|Drug|fluorouracil|
45914542|NCT02044952|Drug|Mesalazine, Tripterygium glycosides|tripterygium glycosides: 2mg/kg/d, oral Mesalazine: 4g/d, oral
45774761|NCT00004252|Drug|leucovorin calcium|
45774762|NCT00004252|Drug|semaxanib|
45774763|NCT00005062|Radiation|radiation therapy|
45774764|NCT00005590|Drug|levofloxacin|
45914543|NCT02044965|Other|Antibiotic|2 mg/kg per day via oral ingestion.
45914544|NCT02044965|Drug|Probiotic|2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule
45914545|NCT02044978|Device|Zoledronate-coated dental implant|
45914546|NCT02045017|Drug|Pomalidomide and Dexamethasone|
45914547|NCT02045030|Drug|aflibercept + FOLFIRI|Aflibercept (Sanofi and Regeneron) targets the Vascular endothelial growth factor (VEGF) pathway that is a composite decoy receptor based on VEGFR-1 and VEGFR-2 fused to an Fc segment of IgG1. In pre-clinical assessments, aflibercept results in stronger angiogenesis inhibition than bevacizumab, exhibiting at least 100-1000 times higher affinity to the circulating VEGFs. It is postulated that in vivo, the binding of these ligands to aflibercept results in the blockade of tumor angiogenesis along with pruning of existing tumor vascular elements and reduction of VEGF-driven vascular permeability. The expected outcome is reduced growth of primary and metastatic tumors by impeding the density of tumor vasculature and diminishing the abnormal leakiness of tumor vessels that supply matrix components to the cancer.
45914548|NCT02045056|Drug|Gemfibrozil|
45914549|NCT02045056|Drug|Placebo|
45914550|NCT02045069|Drug|2 days Ivermectin|200-400 µg/kg once daily for 2 days and placebo once daily at D3
45914551|NCT02045069|Drug|3 days Ivermectin|200 -400 µg/kg once daily for 3 days
45635237|NCT04570787|Procedure|Urinary bladder catheterisation|Installation of Foley catheter into the urinary bladder
45635238|NCT05114369|Procedure|Curative surgery|
45774765|NCT00004258|Drug|cilengitide|dose escalation of cilengitide
45774766|NCT00005596|Drug|cyclophosphamide|
45774767|NCT00005596|Drug|cytarabine|
45774768|NCT00005596|Drug|daunorubicin hydrochloride|30 mg/m2 IV Day 1 of weeks 16, 17, and 18. Give Week 16 dose if ANC ≥ 500/μL and platelets ≥ 75,000/μL. Continue to give during Weeks 17 and 18, even in the face of uncomplicated myelosuppression
45774769|NCT00005596|Drug|dexamethasone|6 mg/m2/day divided BID for 7 days during weeks 8 and 17.
45774770|NCT00005596|Drug|leucovorin calcium|5 mg/m2/dose of leucovorin will be given PO q12h x 2 doses beginning 48 hours after the start of the MTX.
45914552|NCT02045069|Drug|Placebo|Placebo once daily for 3 days
45914553|NCT02045082|Procedure|Corneal sampling|Slit lamp corneal sampling with a Swab
45635239|NCT04316585|Drug|GSK2982772|GSK2982772 will be available as MR tablet at a unit dose strength of 480 mg.
45635240|NCT04316585|Drug|Placebo|GSK2982772 matching placebo tablets will be administered via the oral route.
45635241|NCT04305899|Drug|BMS-986165 Tablet formulation 1|Specified dose on specified days
45635242|NCT04305899|Drug|BMS-986165 Tablet formulation 2|Specified dose on specified days
45635243|NCT01675661|Drug|N-Acetylcysteine|Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
45914554|NCT02045121|Device|Indwelling Pleural Catheter|
45635244|NCT01675661|Drug|Placebo|Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
45635245|NCT05113823|Procedure|Simulation Training|Simulation Training using High and Low Fidelity Simulator
45635246|NCT04425395|Behavioral|Cold pressor task (CPT)|"The cold pressor test is among the most common and established methods for studying human reactions to pain and pain tolerance. Participants submerge a hand in cold water (approx. 5°C) and are asked to keep their hand submerged for as long as can (until the sensation is intolerable), up to a maximum of 5 min. The procedure is safe because the hand is removed before adverse effects can occur. The participant will be given a break of 5 min in between trials, and will interchange hands between trials. During this break hand may to be place in warm water (25-35°C) for up to 4 min to normalise hand temperature, which will be measured before and after each trial using a digital thermometer held firmly in the palm of the hand.~Each participant will complete no more than three trials (conditions) in a randomised order."
45635247|NCT04425395|Behavioral|Acoustic Recordings|During the experiment, the vocalizations produced will be systematically recorded for each participant and an analysis of the acoustic structure of these vocalizations will be carried out.
45635248|NCT04425395|Diagnostic Test|Index measurement NOL™|Four sensors placed non-invasively on one finger. of the participants will be able to calculate a dozen physiological parameters converts in real time into a pain index called NOL (for Nociception Level Index).
45635249|NCT04425395|Diagnostic Test|Video pupillometry|This technique is based on the observation of the dilatation of the pupil during the perception of a nociceptive stimulus in test persons.
45914555|NCT02045121|Procedure|Talc Pleurodesis|
45914556|NCT02045134|Dietary Supplement|Placebo|Soluble corn flour not rich in anthocyanins
45635250|NCT04003493|Other|Nutrition and oral health intervention|The interventions included individualised nutrition and oral health care.
45635251|NCT03956849|Other|Training COACH Conversationstarter|"After elaborating perceived barriers and facilitators via surveys and semi-structured focusgroups, a short training with the COACH Conversationstarter will be provided to a part of the participants. The COACH Conversationstarter will be provided to the participants attending the training, which they can use in the next couple of months. After a period of time all participants will be provided with a second questionnaire, and results of the group that received the COACH Conversationstarter will be compared with the group that didn't receive the COACH Conversationstarter. (A part of) the participants that used the COACH Conversationstarter will be interviewed about their experiences.~However, the study will have an observational design, since the decision if a professional is attending the training is not based on the investigator / protocol, but depending on the professional, for example logistic reasons. This is part of routine education."
45635252|NCT05113511|Drug|SCT510|Subjects received a single intravenous infusion (3 mg/kg) of SCT510 for 90 minutes , and the volume of administration was calculated based on the subject's weight.
45774771|NCT00005596|Drug|mercaptopurine|50 mg/m2 dose po qhs Weeks 5 through 13 (total 9 wks) and from Week 24 until the end of consolidation. Only hold for uncomplicated myelosuppression, only if IV MTX course is delayed, until ANC > 500/μL and platelets > 75,000/uL
45774772|NCT00005596|Drug|methotrexate|"IV: 1 gm/m2 given as a 200 mg/m2 bolus over 20 min followed by 800 mg/m2 over 23.6 hours given during Weeks 7, 10, 13, 16, 19, and 22.~IT: Doses by age, Weeks 7, 10, 13, 16, 19 and 22."
45774773|NCT00005596|Drug|pegaspargase|2,500 IU/m2 will be given IM x 1 on Days 2,3,or 4 of Week 16; > or = 1 day after the IT MTX
45774774|NCT00005596|Drug|thioguanine|60 mg/m2 po qhs during Weeks 20 and 21 (total 14 days). Start week 20 when ANC > or = 500/ul and platelets > or = 75,000/uL. Continue to give all 14 doses despite uncomplicated myelosuppression.
45774775|NCT00005596|Drug|vincristine sulfate|1.5 mg/m2 IV on Day 1 of Weeks 8, 9, 17 and 18 (max 2 mg)
45774776|NCT00005068|Drug|fluorouracil|
45914557|NCT02045134|Dietary Supplement|High-anthocyanin rich corn flour|Soluble corn flour at high content in anthocyanins
45914558|NCT02045147|Behavioral|Grp 1 Low Cognition, Low Activation|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation."
45914559|NCT02045147|Behavioral|Grp 2 Low Cognition, High Activation|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation and handling stressful situations."
45935540|NCT00126451|Drug|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)|
45635253|NCT05113511|Drug|Bevacizumab|Subjects received a single intravenous infusion (3 mg/kg) of bevacizumab for 90 minutes , and the volume of administration was calculated based on the subject's weight.
45635254|NCT04506515|Diagnostic Test|Psychological stress and adaptation at work score (PSAS)|completing a survey based on PSAS
45635255|NCT05113433|Other|conventional physical therapy|"muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session."
45914560|NCT02045147|Behavioral|Grp 3 Normal Cognition, Low Activation|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided for areas of misunderstanding. The teach back method is used to validate knowledge, skills and confidence. Interventions are focused on motivation and developing personal behavioral goals."
45635256|NCT05113433|Other|standing frame.|"muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session. sanding on standing frame for different time period according to group with upper limb activities lie box and blocks , cones and theraputty ."
45635257|NCT05112887|Other|Osteopathic Manipulative Therapy|Osteopathic Manipulative Therapy is a type of hands-on manipulative medicine where the physician uses their hands and knowledge of anatomy to encourage the human body to reattain homeostasis.
45635258|NCT01602341|Drug|AN2728 Topical Ointment, 2% QD|AN2728 Topical Ointment, 2% QD
45635259|NCT01602341|Drug|AN2728 Topical Ointment, 0.5% QD|AN2728 Topical Ointment, 0.5% QD
45635260|NCT01602341|Drug|AN2728 Topical Ointment, 2% BID|AN2728 Topical Ointment, 2% BID
45635261|NCT01602341|Drug|AN2728 Topical Ointment, 0.5% BID|AN2728 Topical Ointment, 0.5% BID
45635262|NCT03539393|Drug|Fremanezumab|quarterly 675 mg dose (3 subcutaneous [SC] injections of 225 mg each).
45914561|NCT02045147|Behavioral|Grp 4 Normal Cognition, High Activation|The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Focus is on maintaining behaviors during hardship and stress. Empowering, motivating and validating are strategies utilized.
45635263|NCT05111171|Device|sheath|Senior interventional doctors interpret the CAG results and group according to their clinical experience: (1) No PCI is required, only diagnostic CAG is required, which is group ①6F sheath CAG group; (2) PCI is required, simple lesions are group ②6F sheath PCI group, the 6F sheath is still used for PCI; (3) PCI is required for the complicated disease and use 7F sheath, as the 7F sheath PCI group is the group ③, and the 7F sheath is replaced for PCI.
45635264|NCT03330197|Biological|Ad-RTS-hIL-12|2.0 x 10^11 viral particles (vp) per injection, one intratumoral injection of Ad-RTS-hIL-12
45635265|NCT03330197|Drug|Oral Veledimex - Arm 1 (Pediatric Brain Tumor)|1 dose level (10mg/day) 15 oral daily doses of veledimex
45914562|NCT02045173|Other|Apneascan TM|Autoscoring algorithms with automatical detection of sleep apnea by the Apneascan TM
45914563|NCT02045173|Device|Polysomnography/polygraphy|1 night polysomnography/polygraphy
45935541|NCT00126451|Drug|Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles|
45935542|NCT00126607|Biological|trastuzumab|Given IV
45635266|NCT03330197|Drug|Oral Veledimex - Arm 2 (DIPG)|2 dose levels (10mg/day, 20mg/day) 14 oral daily doses of veledimex
45635267|NCT03169985|Drug|Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day|After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months by clinical judgement.
45635268|NCT03169985|Drug|Rosuvastatin 20 mg orally once a day|After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months based by clinical judgement.
45635269|NCT03155399|Other|Proprioceptive based training (PBT)|During the PBT patient will stay in supine position with the upper limbs positioned in symmetric posture. He/She will be asked to move both limbs with the same frequency performing bilateral flexion-extension of one of the upper limb districts according to the available free ROM of the target joint. The movement execution of the affected arm will be supported by the physiotherapist performing passive movement at the same rhythm, as the one executed with the unaffected side. Patient will be asked to focus the attention on the movement performed against gravity, which will be reinforced by a verbal command. Afterwards, the physiotherapist will fully support movement execution coherently with the patient's movement initialization. The active movement performed voluntarily by the patient with unaffected limb will be considered as the reference movement, that the physiotherapist has to emulate passively, by synchronization of passive movement executed in phase with the affected side.
45774777|NCT00005068|Drug|irinotecan hydrochloride|
45935543|NCT00126607|Other|laboratory biomarker analysis|Correlative studies
45935544|NCT00074178|Biological|filgrastim|
45774778|NCT00005068|Drug|leucovorin calcium|
45935545|NCT00074178|Biological|pegfilgrastim|
45774779|NCT00005068|Drug|oxaliplatin|
45774780|NCT00004264|Drug|amifostine trihydrate|
45774781|NCT00004264|Drug|cisplatin|
45774782|NCT00004264|Drug|docetaxel|
45774783|NCT00005074|Drug|alvocidib|
45774784|NCT00005602|Drug|carboplatin|
45774785|NCT00005602|Drug|cereport|
45774786|NCT00005602|Radiation|radiation therapy|
45774787|NCT00004276|Drug|thalidomide|
45774788|NCT00005080|Drug|nelarabine|Given IV
45774789|NCT00004288|Drug|olsalazine|
45774790|NCT00005086|Drug|cisplatin|
45774791|NCT00005086|Drug|docetaxel|
45774792|NCT00005086|Drug|gemcitabine hydrochloride|
45774793|NCT00005086|Drug|methotrexate|
45774794|NCT00385372|Procedure|elimination diet|
45774795|NCT00385372|Procedure|provocation diet|
45774796|NCT00005614|Drug|Gemcitabine hydrochloride|Gemcitabine via IV
45774797|NCT00101036|Drug|lapatinib ditosylate|Given PO
45774798|NCT00101036|Other|laboratory biomarker analysis|Correlative studies
45774799|NCT00004294|Genetic|human glucocerebrosidase gene into autologous peripheral blood stem cells|
45635270|NCT03155399|Other|Conventional neuromotor treatment (CNT).|The patients randomized to the CNT group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity.
45635271|NCT05108363|Behavioral|Lifestyle modification program|Participants will attend dietary consultation sessions weekly in the first 4 months during the intensive phase , and monthly in the subsequent 8 months in the maintenance phase of LMP either face-to-face or via telephone. Participants will be given an individualized menu plan aiming at achieving a varied balanced diet with an emphasis on fiber intake and moderate-carbohydrate, low-fat, low-glycemic index products in appropriate portions. The diet will aim for a calorie reduction of 10-20%, at least 10% body weight reduction or body mass index less than 23 kg/m2.Participants will see an exercise instructor a minimum of four times starting at the 2nd month. The exercise instructor will design a suitable exercise regime. Participants will first be advised to increase daily physical activities or to do moderate intensity aerobic exercise, with the goal of 30 minutes for 3 to 5 days a week.
45635272|NCT05065307|Diagnostic Test|Venipuncture|Diagnostic venipuncture
45635273|NCT05104385|Other|Observational, prospective, follow-up of the recipients of CoronaVac (inactivated), Pfizer-Biontech (mRNA) vaccines|Based on the Turkish Ministry of Health regulations, any research protocol involving use of any drug/vaccine needs to be presented in a clinical trial format, and is presented to the clinical research ethical boards accordingly. Otherwise, the study has no intervention (to the exposure status) involved. Selection, administration, number of doses applied and the period between vaccine doses are beyond the capacity the study team.
45635274|NCT01013129|Genetic|DNA analysis|saliva samples will be collected from men (probands) who join the study.
45635275|NCT01013129|Genetic|polymorphism analysis|we will genotype DNA samples (buccal) from all probands and conduct a traditional case-control analysis
45635276|NCT01013129|Other|laboratory biomarker analysis|10ml blood specimen will be obtained and processed (on probands locally-consented and/or those who have an appointment at the VA in Portland, Oregon) to allow for analyses of erythrocyte fatty acids and future nutrient and DNA analyses
45635277|NCT01013129|Other|medical chart review|PSA results, prostate biopsy pathology reports and clinician notes related to the biopsy are reviewed for final data analysis
45635278|NCT01013129|Other|questionnaire administration|probands are asked to complete questionnaires on 1) family history of cancer, 2) diet history over the past year, 3) employment environment and risk factors and/or 4) changes to diet, medications since enrollment in originating case control study
45635279|NCT01013129|Procedure|evaluation of cancer risk factors|pathology reports will be reviewed for probands whose prostate biopsies reveal cancer; these factors will be evaluated for cancer risk factors
45635280|NCT01013129|Procedure|study of high risk factors|prostate biopsy pathology reports will be reviewed for high risk factors
45635281|NCT05103761|Other|Study diet|A low carbohydrate diet (<20g/day) is administered to achieve diet-induced ketosis.
45774800|NCT00004300|Drug|bromocriptine|
45774801|NCT00004300|Drug|sertraline hydrochloride|
45774802|NCT04770818|Device|Modified Brostrum procedure with Internal Brace Augmentation|Open, anatomic repair of the anterior talofibular and calcaneofibular ligaments for lateral ankle stability with InternalBrace augmentation.
45774803|NCT04770818|Device|Modified Brostrum procedure|Open, anatomic repair of the anterior talofibular and calcaneofibular ligaments for lateral ankle stability
45774804|NCT00005626|Drug|Irinotecan|Irinotecan as outlined in treatment arm
45774805|NCT00005092|Drug|Cyclophosphamide|IV over 2 hours on days 2 and 3
45774806|NCT00005092|Drug|Psoralen|Psoralen treated T-cell allogeneic transplant on day 9
45774807|NCT00005092|Drug|Thiotepa|IV over 2 hours on day 1
45774808|NCT00005092|Procedure|Allogeneic bone marrow transplantation|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
45774809|NCT00005092|Procedure|In vitro-treated peripheral blood stem cell transplantation (PBSCT)|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
45774810|NCT00005092|Radiation|Radiation Therapy (RT)|Whole body radiotherapy on days 5-8.
45774811|NCT00005632|Biological|MUC1-KLH vaccine/QS21|
45635282|NCT05103761|Other|Low glycemic index treatment diet|A diet matched with the study diet with added carbohydrates (40-60g/day) to avoid ketosis.
45635283|NCT02700919|Drug|BCT197|Capsules will be taken orally with fluids over a 5 day period after randomization
45635284|NCT02700919|Drug|Placebo|Capsules will be taken orally with fluids over a 5 day period after randomization
45635285|NCT05103137|Other|Questionnaire|Questionnaires concerning assesment of quality of life with 3 different questionnaires ( SF36, HAQ and pre-established questionnaire for the study) during a phone interview
45774812|NCT00005638|Drug|cisplatin|
45774813|NCT00005638|Drug|irinotecan hydrochloride|
45774814|NCT00005638|Radiation|radiation therapy|
45774815|NCT00005104|Drug|clomiphene citrate|
45774816|NCT00005104|Drug|metformin|
45774817|NCT00005110|Drug|Salmeterol|
45774818|NCT00005110|Drug|Albuterol|
45774819|NCT00004330|Drug|luteinizing hormone-releasing factor|
45774820|NCT00005116|Behavioral|psychotherapy|
45774821|NCT00005668|Drug|Itraconazole oral solution|
45774822|NCT00030992|Drug|BMS-247550|One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m^2/day for a total per cycle dose of 30 mg/m^2
45774823|NCT00030992|Drug|Ranitidine|50 mg 30-60 minutes prior to Ixabepilone (BMS-247550)
45774824|NCT00030992|Drug|Diphenhydramine|50 mg intravenously 30-60 minutes prior to Ixabepilone (BMS-247550)
45774825|NCT00032630|Procedure|Coronary artery bypass - on-pump|CABG procedure performed on heart lung machine
45774826|NCT00032630|Procedure|Coronary artery bypass - off-pump|CABG procedure performed without the use of the heart lung machine
45774827|NCT00005674|Drug|Creatine|
45774828|NCT00004360|Drug|chlorothiazide|
45774829|NCT00004366|Procedure|Physical therapy|
45774830|NCT00004378|Procedure|Stem Cell Transplantation|
45774831|NCT00385450|Drug|Nelfinavir/placebo|1250mg/twice each day/four days.
45774832|NCT02972788|Drug|Enamel Matrix Proteins Derivative|Enamel matrix proteins derivative will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
45635286|NCT05088473|Other|Biological collection|Collection of cerebrospinal fluid kappa and lambda free light chains and indexes
45635287|NCT05119127|Device|Alcon Vivity toric intra ocular lens|implanting vivity toric IOL to asses rotational stability. IOL is already FDA approved for implantation at time of cataract surger. Intervention is to assess rotational stability and visual outcome.
45635288|NCT04161989|Drug|omega-3 fatty acids|. The Omega 3 plus capsule contains 1000 mg Fish Oil (contains Eicosapentaenoic acid 13% & Docosahexaenoic acid 9%) plus 100 mg Wheat Germ Oil (Linoleic acid 52- 59%) as a natural source of Vitamin E.
45635289|NCT04161989|Drug|vaginal progesterone|Prontogest 400 mg vaginal suppository contains progesterone 400 mg.
45635290|NCT01986010|Biological|V160 Low Dose IM|V160 administered as a 0.75 mL intramuscular injection
45635291|NCT01986010|Biological|V160 Medium Dose IM|V160 administered as a 0.75 mL intramuscular injection
45635292|NCT01986010|Biological|V160 High Dose IM|V160 administered as a 0.75 mL intramuscular injection
45635293|NCT01986010|Biological|V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
45635294|NCT01986010|Biological|V160 High Dose plus MAPA 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
45635295|NCT01986010|Biological|V160 Maximum Dose IM|V160 administered as a 0.75 mL intramuscular injection
45774833|NCT02972788|Other|Saline|Saline will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
45774834|NCT00004390|Drug|desipramine|
45774835|NCT00004390|Drug|methadone|
45774836|NCT00004390|Drug|morphine|
45914564|NCT02045186|Other|Assessment of Oral HPV Infection|"Saliva and exfoliated oral epithelial cells will be collected with collection supplies provided by OralDNA Labs. Patients will swish and gargle a saline solution for 30 seconds and expectorate it into a funneled collection tube. The collected specimen will be sent to OralDNA Labs. Three diagnostic tests will be performed on each sample to assess oral HPV infection:~Polymerase chain reaction (PCR) for HPV DNA.~Fluorescent in-situ hybridization (FISH).~Viral expression: The test is based on the measurement of the viral RNA levels by methods of detection of the fluorochrome labeled HPV probes by flow cytometry."
45914565|NCT02045199|Device|Tested product : V0111 cream|Application twice a day during 28 days
45914566|NCT02045199|Device|Placebo|Application twice a day during 28 days
45935546|NCT00074178|Drug|cyclophosphamide|
45452482|NCT01093391|Device|BARE METAL STENT|Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
45935547|NCT00074178|Drug|cytarabine|
45935548|NCT00074178|Drug|dexamethasone|
45635296|NCT01986010|Other|Placebo IM|Placebo administered as a 0.75 mL intramuscular injection
45635297|NCT01986010|Biological|V160 Medium Dose ID|V160 administered as a 0.1 mL intradermal injection
45935549|NCT00074178|Drug|etoposide phosphate|
45935550|NCT00074178|Drug|methotrexate|
45935551|NCT00126646|Drug|BL22 immunotoxin|
45935552|NCT00126646|Procedure|antibody-drug conjugate therapy|
45635298|NCT01986010|Other|Placebo ID|Placebo administered as a 0.1 mL intradermal injection
45635299|NCT04160117|Drug|Colchicine 0.6 mg|p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
45635300|NCT04160117|Drug|Matching placebo|p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
45635301|NCT04414631|Drug|Conestat alfa|Conestat alfa (8400 Units (U) followed by 4200 U every 8 hours, 9 administrations in total) will be administered as a slow intravenous injection (5-10 minutes) over a 72 hour period.
45635302|NCT03115255|Drug|intravitreal ranibizumab|0.25 mg intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases)
45635303|NCT02403583|Behavioral|Intervention- Home Visits|If a woman has been randomized to the intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the woman about optimal times for a home visit. The woman will be given a letter for her male partner to inform him about the study and potential upcoming visits, given that our preliminary research revealed that notifying the male partner beforehand is important. As described above, the intervention arm will consist of three home visits conducted by one female and one male lay health worker.
45653038|NCT04224987|Other|Placebo|"Placebo will be administered as a directly observed dose in oral suspension form for children:~Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~For children 1-11 months of age, weight-based dosing will be used~For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program"
45774837|NCT00004390|Drug|nortriptyline|
45774838|NCT00004396|Drug|heme arginate|
45774839|NCT00004396|Drug|tin mesoporphyrin|
45774840|NCT00004402|Drug|calcitriol|
45774841|NCT00004402|Drug|interferon gamma|
45774842|NCT00004408|Drug|poloxamer 188|
45774843|NCT00004414|Drug|sincalide|
45774844|NCT00004420|Drug|gamma-Linolenic acid|
45774845|NCT00004426|Drug|gonadotropin releasing hormone|
45774846|NCT00004426|Drug|leuprolide|
45774847|NCT00004438|Drug|leuprolide|
45774848|NCT01217749|Drug|PCI-32765|420 mg PO daily
45774849|NCT01217749|Drug|ofatumumab|per package insert as an IV infusion
45774850|NCT01217827|Behavioral|Clinical Reminder|
45935553|NCT00126646|Procedure|immunotoxin therapy|
45935554|NCT00126685|Biological|autologous tumor cell vaccine|
45935555|NCT00126685|Biological|therapeutic autologous dendritic cells|
45935556|NCT00126724|Genetic|tgAAC94 gene therapy vector|Single Dose 1x10^11 DRP/mL
45635304|NCT05042063|Device|Hyfe Cough Tracker|"Hyfe Cough Tracker is a digital acoustic surveillance system that uses an artificial intelligence system to discriminate cough from non-cough sounds. Hyfe is an AI-enabled mobile app that records short snippets (<0.5 seconds) of putative cough explosive sounds and then classifies them as cough or non-cough using a convolutional neural network (CNN) model. Briefly, the acoustic characteristics of recorded sounds are converted into an image file, which is then processed by an algorithm trained to identify graphical differences in images. This creates an adjustable prediction score, with values above it, resulting in a sound being classified as cough, and those below being classified as non-cough."
45635305|NCT05042063|Device|Hyfe Air|Hyfe Air is a wearable device with an incorporated wireless lapel microphone. The device´s recordings can be run through the same cough-detection algorithm used by Hyfe Cough Tracker, while its results are directly stored in a remote database and are not displayed to participants.
45635306|NCT03168061|Drug|NC 6300|Part 1: NC-6300 at escalating doses starting at a fixed dose Part 2: NC-6300 at the RPII dose
45635307|NCT01963780|Device|OCS Lung Preservation|
45635308|NCT02009878|Drug|tolvaptan|Subjects will receive a single dose of 3.75, 7.5 or 15 mg of tolvaptan on study Day 1
45635309|NCT04439968|Other|Clinical algorithm|In order to maintain cerebral saturations within targeted range, subjects in the targeted Csat arm will undergo clinical interventions based on clinical algorithm. Interventions may include administration of inotropes, fluid resuscitation, transfusion of blood products, and/or adjustment to respiratory support.
45635310|NCT02009722|Drug|Morphine|Duramorph is administered as part of spinal anesthesia for post-operative pain relief.
45635311|NCT02009722|Drug|Hydromorphone|Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control
45635312|NCT04416880|Device|Press Tack Needle Acupuncture|Seirin Pyonex Press Tack Needle 0.20 x 0.60 mm for SI1 Shaoze acupuncture point Seirin Pyonex Press Tack Needle 0.20 x 0.90 mm for CV17 Danzhong acupuncture point
45635313|NCT02655419|Drug|ATM-AVI|"Cohort 1:~(Creatinine clearance > 50 mL/min)6500mg ATM/1777mg AVI on day 1 followed by total daily dose of 6000mg ATM/1640mg AVI~Cohorts 2 and 3:~(Creatinine clearance > 50 mL/min) As above, or: 6500 mg ATM/2167 mg on Day 1 followed by a total daily dose of 6000 mg ATM/2000 m AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1162 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/820 mg AVI, or:~4250 mg ATM/1417 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/1000 mg AVI"
45635314|NCT02655419|Drug|Metronidazole|Metronidazole 500mg infused over 1 hour every 8 hours
45635315|NCT01962922|Drug|LCP-Tacro|once-daily extended release tablet
45635316|NCT01962922|Drug|Tacrolimus -IR|twice daily capsules
45635317|NCT04198961|Other|opioid prescribing|Individualized taper and safety recommendations will be communicated to prescribers via an electronic medical record encrypted message.
45935557|NCT00126724|Genetic|tgAAC94 gene therapy vector|Second dose of 1x10^11 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
45635318|NCT05118971|Diagnostic Test|muscle activation of the vastus lateralis, vastus medialis, gluteus medius, tibialis anterior, rectus abdominis and paravertebral muscles|understand the pattern of muscle activation during modalities used in this study with the selected population, it becomes extremely important, allowing the quantification of muscle functions and, therefore, prescribing exercises more adequately to achieve therapeutic goals.
45635319|NCT04436315|Device|Motor-cognitive training device|Motor-cognitive training device
45635320|NCT04436315|Other|Active control condition|Physical activity program
45635321|NCT01984684|Drug|delafloxacin|
45774851|NCT02197273|Drug|Liposomal bupivacaine|
45935558|NCT00126724|Genetic|tgAAC94 placebo|placebo
45452483|NCT05160662|Procedure|New guidlines|New guidelines for this group are being developed using NICE guidelines (evidence-based recommendations for health and care in England) as a model and will be tested in clinical practice
45635322|NCT01984684|Drug|vancomycin|
45635323|NCT01984684|Drug|aztreonam|
45635324|NCT05029739|Device|A PAD-specific smartphone application (e-intervention) developed for patients with Peripheral Artery Disease|See description of the e-intervention group as above.
45635325|NCT05118659|Procedure|sustained natural apophyseal glides|It consists on a sustained apophyseal glides in a postero-anterior direction on C2 with a dose of three series of ten repetitions each
45635326|NCT05118659|Procedure|SHAM SNAG|Subjects on SNAG group received a simulation of the contact used for the SNAGs, without any vertebral glide, and with an active cervical extension
45635327|NCT04999553|Device|Repetitive Transcranial Magnetic Stimulation|rTMS will employ the MagPro X100/R30 stimulator equipped with the cool-B70 as we used a cool-B70 in our past non-inferiority trial. The dose will be a 120% rMT in accordance to our latest trial using iTBS. The target area to stimulate will be the right dorsolateral prefrontal cortex (DLPFC) for LFR and the left DLPFC for iTBS as established in prior clinical trials. The localization of both targets will follow the well-established procedures for either R-DLPFC or L-DLPFC using a heuristic method.
45635328|NCT04999553|Device|Intermittent Theta Burst Stimulation (iTBS)|Intermittent Theta Burst Stimulation (iTBS)
45635329|NCT04999553|Device|Low Frequency Right (LFR)|Low Frequency Right (LFR)
45635330|NCT04657588|Device|myMiracle anal insert|The myMiracle device is a single-use, pre-lubricated, liquid-filled rectal insert with a plastic applicator. The insert is filled with liquid mineral oil. The primary advantage of this new instrument is the fact that the liquid-filled insert will move and adapt as the fluid is transferred throughout the device making it easy to insert/remove and comfortable to wear. The design is intended to adjust to the contours of the individual anatomy to prevent leakage.
45635331|NCT04657588|Other|Care as usual|Care as usual means participants are to continue their usual treatment for FI, like they would if they would not have participated in this study.
45774852|NCT02197273|Drug|Standard of care analgesia|
45635332|NCT04589663|Drug|Mometasone furoate|Single inhaled dose of 100 µg mometasone furoate (MF) administered via Twisthaler® on Day 1
45635333|NCT04589663|Drug|QMF149|Single inhaled dose of QMF149 (75/40 µg indacaterol acetate/MF fixed dose combination) administered via Concept 1 device on Day 6
45635334|NCT05118347|Other|Buteyko Breathing Technique|An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. This helps prevent lung problems, such as pneumonia. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
45635335|NCT05109845|Diagnostic Test|Spheres & Shield Maze Task|"A VR environment that consists of a maze that the user must solve by moving through space. The movement is done by combining a touchpad with front-facing orientation.~Different hazards will present throughout the maze, with time penalty, energy loss, and certain consequences, such as narrow walkways from which the player can fall (Figure 1) lightning clouds that strike in intervals, flying insects (Figure 2), or locked rooms (Figure 3). The user can also make use of a shield that allows moving through lightning and insects without penalty at the cost of being unable to gather green orbs (Figure 2). When used, the shield requires a recharge time, so it is a limited resource that the player must optimize. Hazards may also be avoided completely by choosing another path through the labyrinth, however completion of the maze requires traversal of a minimum number of hazards."
45635336|NCT04585841|Drug|Cannabidiol|Patients will receive cannabidiol in the period of time they receive chemotherapy.
45635337|NCT02694523|Drug|risankizumab|Risankizumab administered by subcutaneous (SC) injection
45635338|NCT02694523|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
45635339|NCT02694523|Drug|placebo for risankizumab|Placebo risankizumab administered by subcutaneous (SC) injection
45635340|NCT02694523|Biological|placebo for adalimumab|Placebo for adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
45635341|NCT04959617|Device|Quantitative Fecal Immunochemical Test (qFIT)|The study only included quantitative FIT examination in the general physical examination population over 30 years old.
45635342|NCT05038475|Diagnostic Test|COVID-19 antibody test|FDA-approved Immunoassays were used in the study. At the beginning of the study, up to 3 months, ELISA and CLIA immunoassays were adopted to analyze the antibody titers. Thereafter, CLIA was used for longitudinal analysis of antibody titers for consecutive months. Anti
45635343|NCT02395861|Other|neuro-electrophysiologic analyses|mismatch negativity (MMN) cognitive evoked potentials (CEP) auditory evoked potentials (AEP)
45774853|NCT00004444|Drug|paromomycin|
45635344|NCT04848935|Device|CURATE.AI|CURATE.AI will be utilised to provide personalised training intensity recommendations (low, medium or high) to the patients during the digital cognitive test battery DI session. The difficulty of each task will be modulated by CURATE.AI by adjusting the frequency of critical events that demand evaluation and/or response.
45635345|NCT04827095|Other|Web-Based Support and Education Program 1|The classes will discuss topics related to caregiving for someone with a spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about one hour per week that relate to the topics discussed in class.
45635346|NCT04827095|Other|Web-Based Support and Education Program 2|The classes will discuss topics related to caregiving for someone with a spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about one hour per week that relate to the topics discussed in class.
45635347|NCT01353703|Biological|Infanrix hexa™|Intramuscular, three doses
45635348|NCT04096703|Procedure|Pneumatic dilation|The patients randomized to the pneumatic dilation cohort will undergo an initial pneumatic dilation with a 30mm Rigiflex (Boston Scientific). If the Eckardt score four weeks after initial dilation is > 4, then the patient will be scheduled for a second dilation with a 35mm Rigiflex balloon (Boston Scientific).
45635349|NCT02009332|Drug|ABI-009|ABI-009 is a nanoparticle albumin-bound (nab®) formulation of the mammalian Target of Rapamycin ( mTOR) inhibitor, sirolimus. Specifically, ABI-009 is a sterile lyophilized powder of albumin-bound sirolimus nanoparticles with a mean particle size of less than 100 nm.
45635350|NCT02009332|Drug|Gemcitabine|Gemcitabine is administered after ABI-009 in the Phase 2 study.
45774854|NCT00004444|Drug|streptomycin|
45774855|NCT00004450|Drug|glyceryl trierucate|
45774856|NCT00004450|Drug|glyceryl trioleate|
45774857|NCT00004450|Drug|interferon beta|
45452484|NCT00894868|Drug|vildagliptin|
45452485|NCT00894868|Drug|placebo of vildagliptin|
45774858|NCT00004450|Drug|thalidomide|
45774859|NCT01288027|Biological|Alglucosidase Alfa|Alglucosidase alfa intravenous infusion 20 milligram per kilogram (mg/kg) every other week for 24 weeks.
45774860|NCT00004468|Drug|calcitriol|
45774861|NCT00005758|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
45774862|NCT00005758|Biological|HIV-1 Immunogen|
45774863|NCT01288807|Drug|Milnacipram|Titration to 200mg PO daily
45774864|NCT00005764|Drug|Lamivudine/Zidovudine|
45774865|NCT00005764|Drug|Abacavir sulfate|
45774866|NCT00005764|Drug|Lamivudine|
45774867|NCT01289275|Drug|Nicotine Patches|Subjects randomized into the patch condition will receive 8 weeks of nicotine patches at discharge. The kit will contain 4 weeks of 21mg patches, 2 weeks of 14mg, and 2 weeks of 7mg.
45774868|NCT01289275|Behavioral|Telephone Counseling|Up to 5 proactive counseling sessions from California Smokers' Helpline.
45935559|NCT00126724|Genetic|tgAAC94 gene therapy vector|Single Dose 1x10^12 DRP/mL tgAAC94
45635351|NCT04518293|Drug|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg|Single pill
45635352|NCT04518293|Drug|telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg|Signle pill
45635353|NCT04518293|Drug|Telmisartan 20 mg/amlodipine 2.5 mg .|oral tablet
45635354|NCT04518293|Drug|telmisartan 40 mg/amlodipine 5 mg|oral tablet
45635355|NCT04518293|Drug|Telmisartan 20 mg/indapamide 1.25 mg|oral tablet
45635356|NCT04518293|Drug|telmisartan 40 mg/indapamide 2.5 mg|oral tablet
45635357|NCT04518293|Drug|Amlodipine 2.5 mg/indapamide 1.25 mg|oral tablet
45635358|NCT04518293|Drug|amlodipine 5 mg/indapamide 2.5 mg|oral tablet
45635359|NCT04480021|Behavioral|MITHRA|A mobile based application (app) in CBOs to screen, track and treat mild to moderate depression among low income women using Healthy Activity Program (HAP),a WHO-recommended evidence-based intervention.
45635360|NCT04480021|Behavioral|EUC|Group education on depression by community health workers
45635361|NCT04480177|Device|foot insole|the subject was instructed to wear foot insole for 8 hours.
45635362|NCT04480177|Other|short foot exercise|the subject was instructed to perform exercise once a day 30 repetitions.
45635363|NCT03166969|Procedure|Holter 21 days|
45635364|NCT01984294|Drug|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg FDC tablet administered orally once daily
45635365|NCT01984294|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45774869|NCT01289275|Behavioral|Brief Hospital Counseling|All subjects receive bedside counseling either from Respiratory Therapists or nurses according to the hospital's particular practices.
45635366|NCT01984294|Drug|GS-9669|GS-9669 tablet(s) administered orally once daily
45635367|NCT04932707|Other|sub-occipital muscle inhibition technique|this technique will be conducted from a supine lying position. The therapist stretches the suboccipital, placing the hands beneath the patient head applying pressure up and backward, pressure was maintained till tissue relaxation was occurred flexes the head of the patient to get the chin to the manibiurim sternii, plus the passive stretch exercise
45935560|NCT00126724|Genetic|tgAAC94 gene therapy vector|Second dose of 1x10^12 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
45635368|NCT04932707|Other|Neural slump sliding stretch|Patient in a comfortable short sitting position at the edge of the bed with the trunk in an military straight position then ask the patient to slump; flex her neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot plus the passive stretch exercise
45635369|NCT04932707|Other|control (passive stretch exercises)|The patient in a comfortable supine lying position, the patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side
45635370|NCT03170479|Dietary Supplement|Vitamin D|Two doses of Vitamin D supplementation in ampoules form (ED3) were procured. Ampoule contains Cholecalciferol in 200,000 IU both for oral and intra muscular use.
45635371|NCT03170479|Dietary Supplement|Ready to Use Therapeutic Food (RUTF)|RUTF is recommended by WHO for sever malnourished children in community settings as a therapeutic diet. The quantity depends upon the child body weight.
45635372|NCT03953027|Other|Survey Administration|Ancillary studies
45635373|NCT05745493|Behavioral|Social Engage Coaching (S-ENG)|Social Engage Coaching (S-ENG) involves 10 individual coaching sessions focused on increasing social connection. S-ENG is a stepped, modular intervention that was developed to allow personalization to a given subject's needs, preferences, and individualized barriers to social connection. Early sessions include psychoeducation on the importance of social connection; a values clarification exercise on aspects of connection most important to subjects; and assessment of current social networks and social activities. Together, the coach and subject create a conceptualization of reasons for loneliness and identify personalized activities most likely to impact loneliness. The primary activity is 'action planning,' which involves selecting a social goal for the week, brainstorming ways to meet the goal, identifying barriers, and selecting specific actions to take before the next session. The first 8 sessions are offered weekly and the final two are monthly booster sessions.
45635374|NCT01962298|Drug|sugammadex 2mg/kg|
45635375|NCT01962298|Drug|neostigmine|
45635376|NCT01962298|Drug|sugammadex 4mg/kg|
45635377|NCT01962298|Drug|placebo|
45635378|NCT01962298|Drug|Single rocuronium dose|
45635379|NCT01962298|Drug|Repeated rocuronium dose|
45635380|NCT01962298|Drug|Continuous rocuronium infusion|
45635381|NCT04418921|Behavioral|Self-regulation: MRehab - Un colegio emocionante, clinical trial with non-immersive virtual reality|The principles of the programme will be based on the following premises for children with ASD: 1) Strengthening communicative attempts; 2) Choose the most natural contexts possible; 3) Establish structured and predictable routines and environments; 4)Visually support information; 5) Adapting our language to the understanding level of the child. On the difficulty of interpreting and responding to social emotions and cues, games of perspectives are of great interest, where the child and therapist describe the same object from different perspectives, beliefs (guess that may be in this box), games with social stories, which are short stories that use pictograms, to help understand especially situations with social ambiguity: 1) describing what happens; 2) orienting the action, indicating to the child what to do in that situation; 3) anticipating and explaining what can happen and how you can feel; 4) developing a strategy that can be applied in similar situations.
45774870|NCT00004474|Drug|Anti-thymocyte globulin|Given via IV over 4 hours
45774871|NCT00004474|Drug|Cyclophosphamide|Given via IV over 60 minutes on Days -5 to -2
45774872|NCT00004474|Procedure|Bone marrow transplantation|Given on Day 0
45774873|NCT01289431|Drug|Mapracorat|administered daily to each eye for 2 weeks following allergen challenge using a CAC model
45935561|NCT00126724|Genetic|tgAAC94 gene therapy vector|Single Dose 1x10^13 DRP/mL tgAAC94
45935562|NCT00126724|Genetic|tgAAC94 gene therapy vector|Second dose of 1x10^13 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
45935563|NCT02970461|Other|Gamified Group|See Gamified Group in Arms description.
45935564|NCT02970461|Other|Control Group|See Control Group in Arms description.
45635382|NCT04418921|Behavioral|Traditional self-regulation program|The children from control group will follow a program of emotional education of Primary Schools, though group activities in the classroom .The content of the sessions will include 5 sessions of emotional awareness and 5 sessions of emotional and cognitive regulation.Each session will last 50 minutes
45635383|NCT03169933|Radiation|Combined, intensified and modulated adjuvant radiotherapy|
45635384|NCT03169621|Procedure|Endometrial Biopsy and endometrial fluid collection|"On day 5 of the Hormonal Replacement Therapy (after 5 days of progesterone administration), the doctor will perform endometrial fluid aspiration (EF) followed by an endometrial biopsy (EB) the same day of hysteroscopy that is performed as usual clinical practice. EF sample will be analyzed by molecular techniques (Next Generation Sequencing) for the detection of infectious agents and the EB sample will be divided into three parts, one of them will be used for molecular analysis (as control of the bacterial content present in the EF) and the others will be used for microbiological analysis and histological techniques respectively.~The Assisted Reproductive Treatment (ART) will be performed once the specialist considers it appropriated according to the clinical standard practice and the reproductive rates will be correlated with the diagnosis of CE comparing the results of ART before and after its diagnosis of CE."
45635385|NCT04416334|Drug|Colchicine plus symptomatic treatment (paracetamol)|Colchicine plus symptomatic treatment (paracetamol).
45635386|NCT04416334|Drug|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
45635387|NCT02403349|Drug|Fimasartan|
45635388|NCT02403349|Drug|Valsartan|
45635389|NCT02403349|Drug|Atenolol|
45635390|NCT04735822|Drug|Part 1: Belumosudil 40 mg/mL Sequence ABFCED|Oral suspension belumosudil 40 mg/mL in sequence Regimen A, then Regimen B, then Regimen F, then Regimen C, then Regimen E, then Regimen D
45635391|NCT04735822|Drug|Part 1: Belumosudil 40 mg/mL Sequence BCADFE|Oral suspension belumosudil 40 mg/mL in sequence Regimen B, then Regimen C, then Regimen A, then Regimen D, then Regimen F, then Regimen E
45635392|NCT04735822|Drug|Part 1: Belumosudil 40 mg/mL Sequence CDBEAF|Oral suspension belumosudil 40 mg/mL in sequence Regimen C, then Regimen D, then Regimen B, then Regimen E, then Regimen A, then Regimen F
45635393|NCT04735822|Drug|Part 1: Belumosudil 40 mg/mL Sequence DECFBA|Oral suspension of belumosudil 40 mg/mL in sequence Regimen D, then Regimen E, then Regimen C, then Regimen F, then Regimen B, then Regimen A
45635394|NCT04735822|Drug|Part 1: Belumosudil 40 mg/mL Sequence EFDACB|Oral suspension of belumosudil 40 mg/mL in sequence Regimen E, then Regimen F, then Regimen D, then Regimen A, then Regimen C, then Regimen C
45635395|NCT04735822|Drug|Part 1: Belumosudil 40 mg/mL Sequence FAEBDC|Oral suspension of belumosudil 40 mg/mL in sequence Regimen F, then Regimen A, then Regimen E, then Regimen B, then Regimen D, then Regimen C
45635396|NCT04735822|Drug|Part 2: Belumosudil 200 mg Sequence GHI|1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed)
45635397|NCT04735822|Drug|Part 2: Belumosudil 200 mg Sequence HIG|1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed), then Regimen G (tablet)
45635398|NCT04735822|Drug|Part 2: Belumosudil 200 mg Sequence IGH|1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen G (tablet), then Regimen H (oral suspension, subject fasted)
45635399|NCT04735822|Drug|Part 2: Belumosudil 200 mg Sequence IHG|1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted), then Regimen G (tablet)
45635400|NCT04735822|Drug|Part 2: Belumosudil 200 mg Sequence GIH|1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted)
45774874|NCT01289431|Drug|Vehicle|administered daily to each eye for 2 weeks following allergen challenge using a CAC model
45774875|NCT00005770|Device|Acupuncture|
45935565|NCT00126763|Drug|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and was available in 25, 50,75 and 100 mcg/hr patches. For patients who were using transdermal fentanyl (ie,Duragesic®), the initial dose of ZR-02-01 was the same as their current Duragesic dose. For patients who were taking oral opioids, the initial dose of ZR-02-01 was determined by the investigator using sponsor-provided conversion guidelines. The patches were worn on the chest or upper arm and an overlay was placed over the patch. Patches (and overlays) were replaced every 3 days
45635401|NCT04735822|Drug|Part 2: Belumosudil 200 mg Sequence HGI|1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen G (tablet), then Regimen I (oral suspension; subject fed)
45774876|NCT00004480|Drug|botulinum toxin type A|
45774877|NCT01289665|Procedure|Lubricating gel used during speculum insertion.|Examiner will use 0.5 mL of sterile lubricating gel to lubricate standard-sized plastic speculum during clinically indicated vaginal speculum examination. Patients will mark visual analog scale immediately following insertion.
45635402|NCT02395393|Device|Alveoflex Confocal MiniprobeTM|-Alveolar imaging
45774878|NCT01289665|Procedure|Water used during speculum examination.|Patients will under vaginal speculum examination using 3 mL of water as a lubricant and will mark a visual analog scale immediately after speculum insertion.
45774879|NCT00004486|Drug|fluoxetine|
45774880|NCT00004492|Drug|clotrimazole|
45774881|NCT00004492|Drug|hydroxyurea|
45774882|NCT00005776|Drug|Inhaled nitric oxide|Inhaled Nitric oxide at a concentration of 20 ppm
45774883|NCT00005776|Drug|Placebo|100% Oxygen
45774884|NCT01290445|Drug|varenicline|This is a non-interventional study. Exposure in utero to varenicline is observed, not assigned.
45935566|NCT00399438|Drug|Placebo|Tablets, Oral, once daily, 2 weeks
45774885|NCT01290445|Behavioral|cigarette smoke from maternal smoking|This is a non-interventional study. Exposure in utero to cigarette smoke from maternal smoking is observed, not assigned.
45774886|NCT01290445|Other|Non-Exposure|This is a non-interventional study. Non-exposure in utero to varenicline and cigarette smoke from maternal smoking is observed, not assigned.
45774887|NCT00005782|Drug|Granulocyte colony-stimulating factor|
45774888|NCT00005782|Procedure|Leukapheresis|
45774889|NCT01290913|Drug|Omalizumab|Omalizumab is an antibody that helps decrease allergic responses in the body
45935567|NCT00399438|Drug|BMS-562086|Tablets, Oral, once daily, 2 weeks
45448114|NCT01075295|Behavioral|Behavioural Intervention for the Prevention of Weight Gain|"The intervention consists of four steps:~STEP 1 (Watchful Waiting): Measurement of body weight and Waist Circumference at the start (1 visit). Subjects that have a weight gain greater then or equal to 2% of their baseline weight will progress to Step 2~STEP 2 (Self monitoring): Self-monitoring of daily weight, daily food intake & physical activity (1 visit) Subjects that have a weight gain greater then or equal to 2% (from STEP 2) will progress to Step 3~STEP 3 (Nutrition & Exercise Counseling): Counseling for nutrition and physical activity (4 visits; 2 in-clinic, 2 telephone) Subjects that have a weight gain greater then or equal to 2% (from STEP 3) will progress to Step 4~STEP 4 (Intensive): Intensive behavioral training geared towards reducing caloric intake (4 in-clinic visits)"
45635403|NCT01984138|Drug|ESTRING|ESTRING (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days. ESTRING has the following dimensions: outer diameter 55 mm; cross-sectional diameter 9 mm; core diameter 2 mm. One ESTRING should be inserted into the upper third of the vaginal vault, to be worn continuously for three months.
45635404|NCT01984138|Drug|Replens|Replens should be applied vaginally, with a supplied applicator, three times each week.
45635405|NCT02693743|Device|repetitive transcranial magnetic stimulation (rTMS)|A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.
45635406|NCT02655887|Device|VENOVO™ Venous Stent|VENOVO™ Venous stent placement
45448115|NCT01075295|Other|TAU|Treatment as provided by individuals' existing healthcare providers
45448116|NCT01367158|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine|The lyophilized Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine reconstituted with one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
45635407|NCT02008318|Drug|Galunisertib|Administered orally
45635408|NCT02008318|Drug|Placebo|Administered orally
45635409|NCT04009265|Combination Product|adjuvant treatment|adjuvant treatments include chemotherapy or chemoradiotherapy
45448117|NCT01367158|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine|Liquid Meningococcal (group B) multicomponent recombinant adsorbed vaccine
45635410|NCT01982812|Drug|Oral Levetiracetam|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days
45635411|NCT01982812|Drug|Standard AED|Active comparitor, Standard AED
45774890|NCT01267045|Behavioral|Mindfulness-based stress reduction|Mindfulness-Based Stress Reduction (MBSR) teaches mindfulness as a non-religious practice of self-observation and self-awareness. Kabat-Zinn developed MBSR in 1979 in response to a growing awareness that medical interventions were often inadequate at addressing chronic pain issues and restoring function and life satisfaction. He drew on his meditation and yoga training to develop this program as a complement to traditional medicine that could help patients live fully despite their chronic medical and psychiatric conditions. Through MBSR an individual's emphasis shifts from a preoccupation with what is wrong to a growing appreciation for what is right and what can be built upon.
45774891|NCT00004498|Genetic|Adenoviral Vector-Mediated Gene Transfer|
45935568|NCT00126802|Procedure|Tomotherapy|Standard 45 Gy in 25 fractions in 5 weeks
45935569|NCT00402571|Drug|acetaminophen|
45448118|NCT01367158|Biological|Tdap|Sterile liquid suspension of tetanus and diphtheria toxoids and acellular pertussis components intended for intramuscular injection
45448119|NCT00130637|Drug|Daclizumab|
45448120|NCT03550456|Other|ECC|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
45448121|NCT03550456|Other|ECC with CLE|Continuous Laryngoscopy is endoscopy of the larynx used to obtain a view of laryngeal obstruction during exercise.
45448122|NCT03550456|Other|Speech therapy|Patients with diagnosis of EILO will be sent to a speech therapist for at least 6 training sessions.
45448123|NCT01077245|Drug|MIYA-BM Fine Granules (CBM588)|MIYA-BM Fine Granules (CBM588)
45448124|NCT01077245|Drug|Placebo Fine Granules (without CBM588)|Placebo Fine Granules (without CBM588)
45448125|NCT02136706|Procedure|Myocardial Perfusion imaging with 10 minute waiting period|After the Myocardial Perfusion Imaging testing the investigators will wait 10 minutes to take images and then wait the 30 minute standard of care time to take images.
45448126|NCT01077479|Drug|Metformin|Metformin 1500mg nocte for 6 months
45635412|NCT03996785|Behavioral|Walking in Urban setting|Walking for 60 minutes as described above
45635413|NCT03996785|Behavioral|Walking in nature setting|Walking for 60 minutes as described above
45635414|NCT04541693|Device|Full revision|Both cup and stem require revision
45635415|NCT04541693|Device|Cup revision|Only the cup requires revision
45635416|NCT04541693|Device|Stem revision|Only the stem requires revision
45635417|NCT04910087|Diagnostic Test|Sonographic optic nerve sheath diameter measurement|With the linear ultrasound probe operating at 11 MHz in B mode, it will be measured in 2 planes, 3.0 mm behind the optic disc, the transverse plane where the probe is placed horizontally and the sagittal plane where the probe is placed vertically. Then, the average of these measurements will be recorded for both eyes every 10 minutes.
45635418|NCT02007070|Biological|Pembrolizumab|Intravenous infusion
45774892|NCT00004552|Drug|acamprosate (Campral)|
45774893|NCT00101660|Drug|Dasatinib|Tablets; oral; 70 mg BID, depending on response
45774894|NCT01267279|Drug|Zoledronic acid|Zoledronic acid per protocol
45774895|NCT01267279|Other|Placebo|Placebo
45774896|NCT00005794|Drug|perifosine|
45774897|NCT00004558|Behavioral|dietary n-3 polyunsaturated fatty acids|
45774898|NCT00005800|Biological|Filgrastim|
45774899|NCT00005800|Drug|Docetaxel|
45774900|NCT00005800|Drug|Doxorubicin|
45935570|NCT00126841|Procedure|CT and MR fusion|
46070163|NCT00848211|Biological|TUTI-16 (0.6mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
45635419|NCT03906617|Drug|Intercostal nerve block and wound infiltration with liposomal bupivacaine|Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 266mg of liposomal bupivacaine with 24 ml of 0.5% bupivacaine will be used.
45635420|NCT03906617|Drug|Intercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone|Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 42 ml of 0.5% Bupivacaine/epinephrine with 8mg dexamethasone will be used.
45774901|NCT00005800|Procedure|Surgery|Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
45774902|NCT00004564|Drug|Clopidogrel|
45774903|NCT00004564|Drug|Atorvastatin|
45914567|NCT02045225|Behavioral|Reduction of social anxiety & substance use in gay/bi men|The study will provide Phase I trial data for a novel and innovative HIV prevention intervention for MSM built upon empirically supported interventions to reduce HIV risk among MSM and cognitive-behavioural therapy to reduce social anxiety. This study will test a novel integrated HIV prevention intervention that combines empirically supported treatments for social anxiety with HIV risk reduction counseling to reduce HIV sexual risk behaviour. Study objectives: 1) to provide data on the acceptability/feasibility of the intervention, 2) to provide data to test the intervention, and 3) to provide data that will allow for a RCT that will test intervention efficacy relative to HIV prevention interventions that do not reduce social anxiety or substance use in sexual situations.
45914568|NCT02045251|Drug|Pylera based reduced regimen|Patients with H. pylori infection will be treated with a 10 day course of reduced Pylera based regimen.
45914569|NCT02045290|Drug|Metformin|The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in the morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
45635421|NCT03897725|Other|Telehealth Coaching|Telehealth coaching to promote adherence
45635422|NCT03844919|Device|rTMS + CBIT|"Repetitive Transcranial Magnetic Stimulation (rTMS) parameters are: intensity 100% resting motor threshold (RMT), frequency 1Hz, duration = 30 minutes (1800 stimulations; 900 per side), target - the supplementary motor area (SMA). Treatments occur on weekdays (T - F) for four weeks (20 total).~The Comprehensive Behavioral Intervention for Tics (CBIT) will be completed over eight sessions that will average 60 minutes in duration. First, participants will undergo awareness training. Participants will then be introduced to competing response training, which involves performing a voluntary behaviour designed to disrupt the execution of the tic. The eight sessions will occur on Mondays, once a week for six weeks and then on weeks 8 and 10."
45914570|NCT02045290|Drug|Placebo|
45635423|NCT03844919|Behavioral|Sham rTMS + CBIT|Sham rTMS (sham coil) will be paired with CBIT. Sham rTMS will be delivered over the same time-frame as above. CBIT will be identical to the above.
45635424|NCT02006758|Device|EnligHTN™ Renal Denervation System|The EnligHTN™ Renal Denervation System is designed to deliver radiofrequency (RF) energy to the renal nerves to achieve targeted denervation. The system consists of the EnligHTN™ RF Ablation Generator (generator), the EnligHTN™ Renal Artery Ablation Catheter (ablation catheter), and the EnligHTN™ Guiding Catheter (optional).
45635425|NCT01960816|Device|Procedure: thermal coagulation of tissue in the nasal airway|The Vivaer Stylus is used to deliver low-power, temperature-controlled, radiofrequency energy to tissues of the nasal airway to cause coagulation of soft tissues and submucosal tissue shrinkage.
45635426|NCT01602419|Other|Patients using Wilate as standard of care|Patients with von Willebrand Disease using Wilate for a period of 2 years.
45914571|NCT02045342|Other|Carbohydrate drink|Ingest 500ml (1g/kg) prior to metabolic measures.
45914572|NCT02045342|Other|Placebo|Ingest 500ml of placebo prior to metabolic measures.
45914573|NCT02045355|Other|Fish intervention|The intervention will compare fish intake with a correspondent amount of meat. The basis for the comparison will be the estimated protein intake from fish and meat and should be almost similar both from fish and from meat. To ensure compliance and to add more variety to the diet, different fish types will be included in the intervention group and different meat sources in the control group. The types of fish (and that of meat in the control diet) that will be used will be accurately documented and will be similar for all participants included.
45914574|NCT02045368|Drug|IGF-Methotrexate conjugate|IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle. Up to 7 dose levels will be tested, starting with 0.05 microequivalents per kg and up to 2.5 microequivalents per kg.
45914575|NCT02045394|Other|Chest X-ray|
45914576|NCT02045394|Other|computed tomography of the chest|
45448127|NCT03549676|Biological|Fecal Microbiota Transplantation|For patients who do not respond or partial respond for first time FMT treatment, a second time FMT treatment using different donor should be considered.
45774904|NCT00386386|Other|hypodermoclysis via recombinant hyaluronidase-facilitated subcutaneous infusion|Above
45774905|NCT00385528|Behavioral|Multi-faceted psychiatric intervention|
45774906|NCT01268527|Drug|0.03% E6201|Topical 0.03% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
45774907|NCT01268527|Drug|0.1% E6201|Topical 0.1% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
45774908|NCT01268527|Drug|0.2% E6201|Topical 0.2% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
45774909|NCT01268527|Drug|0.005% E6201|Topical 0.005% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
45774910|NCT01268527|Drug|0.01% E6201|Topical 0.01% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
45774911|NCT01268527|Drug|0.05% E6201|Topical 0.05% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
45448128|NCT02136784|Drug|morphine sulfate|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
45774912|NCT01268527|Other|Placebo - 0.03% gel vehicle|Topical 0.03% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
45774913|NCT01268527|Other|Placebo - 0.1% gel vehicle|Topical 0.1% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
45774914|NCT01268527|Other|Placebo - 0.2% gel vehicle|Topical 0.2% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
45914577|NCT02045394|Procedure|Bronchoscopy|In patients with haemoptysis bronchoscopy will be performed with flexible bronchoscope. A systemic research of bleeding site and causes will be done. Microbiological or pathological sampling will be executed if clinically required. In selected patients, bronchoscopy might be performed with the rigid instrument or the flexible bronchoscope in intubated patients.
45635427|NCT04655482|Drug|Aflibercept Injection|"Intravitreal injection of aflibercept using treat-and-extend regimen~:Three monthly loading injections followed by proactive treatment using TAE regimen. Extension of injection interval by 2 weeks. The maximum injection interval was set as 16 weeks."
45635428|NCT04866173|Other|Dog|Subjection to standardised stress situations in the presence of a dog and a person
45635429|NCT04866173|Other|No Dog|Subjection to standardised stress situations in the presence of a person
45914578|NCT02045459|Behavioral|Exercise Program|Subject will be exercising on a treadmill 3x/week. Subjects progress will dictate increases/decreases in time of exercise and pace.
45635430|NCT04515797|Drug|Glecaprevir and Pibrentasvir|4 weeks of treatment starting within 24 hrs of kidney transplant
45635431|NCT03571841|Behavioral|Group Session|The 4-hour group session will be structured around three 60-minute modules and creation of a personal action plan
45635432|NCT03571841|Behavioral|Telephone Booster|One month following the group session, women will receive a telephone booster session (<15 minutes). This brief telephone check-in is intended to help women review progress with their individualized action-plan, problem-solve around continuing problems, and plan for maintenance moving forward.
45635433|NCT04866095|Device|Transthoracic echocardiogram|Transthoracic echocardiogram (TTE) is a widely used and validated imaging technique which involves the study of the heart and great vessels through multiple examination windows. In particular, the subcostal window represents the gold standard for evaluating the diameter of the inferior vena cava (IVC) and its compliance, allowing the physician to obtain valuable information on the volume status of patients. Acquiring images in the subcostal window with a transthoracic echocardiogram (TTE) can be, in some cases, difficult or impossible due to the presence of drainages or surgical wounds: in such cases an alternative could be represented by the trans-hepatic window. This has not been validated in the scientific litterature.
45635434|NCT04866095|Device|Clear Sight system|"The Clear Sight System is a non-invasive blood pressure (BP) monitoring system, where the CO is determined analysing the photo-plethysmography curve by a miniaturized pressure cuff and infrared LEDs.~Its main advantage is to assess CO continuously in a completely non-invasive way, following its variations and thereby contributing to the detection of hypovolaemia. Other visualized parameters are: the stroke volume (SV), the systemic vascular resistance (SVR) as well as the BP and the heart rate (HR)."
45635435|NCT02184767|Drug|ADASUVE®|ADASUVE® 2.5, 5, or 10 mg
45635436|NCT01981954|Drug|Solifenacin succinate|Oral suspension
45635437|NCT04248413|Device|Blood Flow Restriction Therapy|The blood flow restriction cuff, which is regulated by the FDA under 878.5910 and is registered under number 9681444, is manufactured by Delfi Medical. The cuff will be used as recommended by the manufacturer and Owens Recovery Science, the company who provides certificating of blood flow restriction training.
45635438|NCT04248413|Other|Standard physical rehabilitation|Patients diagnosed with non-operative rotator cuff or biceps tendinopathy will undergo physical rehabilitation under the supervision of the same physical therapists who will be performing the BFR therapy.
45635439|NCT03727139|Drug|Rasagiline|Rasagiline Tablets
45774915|NCT01268527|Other|Placebo - 0.05% gel vehicle|Topical 0.005% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
45635440|NCT05122403|Procedure|MRgFUS central lateral thalamotomy|MRgFUS central lateral thalamotomy is a minimally invasive and effective procedure for medication-refractory neuropathic pain patients.
45635441|NCT05120687|Drug|noncorticosteroid systemic immunomodulatory therapy (NCSIT)|Patients in corticosteroid + NCSIT group will receive systemic corticosteroids combined with Methotrexate 15mg/week or Adalimumab 40mg /2weeks or Mycophenolate Mofetil 1g/day or Cyclosporin 50mg-100mg/day or cyclophosphamide 10mg/kg on two consecutive days every 2 weeks.
45914579|NCT02045472|Drug|VIS410|
45914580|NCT02045472|Drug|Placebo|
45914581|NCT02045498|Device|capnography feedback|capnography feedback was used for management of the resuscitation and quality of cpr performance in rescuers and outcomes of the patients was measured.
45914582|NCT02045524|Other|Deep muscle injection|
45914583|NCT02045524|Other|Sub-Q Injection|
45635442|NCT05122325|Device|Transcutaneous tibial nerve stimulation TENS® EMS NMS60 device|"Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week at 10 Hz, with a pulse width of 200 μs and an intensity between 0 and 100 mA, which will be individually adjusted to each participant.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the frequency is raised to what has been established between 10Hz and there the intensity is increased without having to now reach the excitomotor threshold, as long as the physiotherapist notice it is enough (it must be tolerable)."
45774916|NCT01268527|Other|Placebo - 0.01% gel vehicle|Topical 0.01% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
45774917|NCT01268527|Other|Placebo - 0.05% gel vehicle|Topical 0.05% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
45774918|NCT01268527|Drug|Calcipotriene|Topical 0.005% calcipotriene (positive control) was applied once daily to individual specific regions of the psoriatic plaque.
45774919|NCT00005806|Drug|carboplatin|
45774920|NCT00005806|Drug|gefitinib|
45914584|NCT02045550|Drug|Prospan Syrup|2.5 ml twice daily for 4 weeks
45635443|NCT05122325|Device|Genital vibration with Ferticare 2.0® vibrator|Women will be instructed in the use of the Ferticare 2.0® vibrator. Initially, a practice will be carried out , indicating that the frequency of use will be 70 Hz with an amplitude of 1.5 mm. It will be recommended to gradually increase its use over time, with a limit of 30 minutes a day.
45635444|NCT05122325|Device|TENS® EMS NMS60 device_sham intervention|"Sham of TTNS intervention with Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the intensity is decreased to lower the sensitive threshold of treatment."
45774921|NCT00005806|Drug|paclitaxel|
45635445|NCT05120609|Device|Parkinson's Application|The application delivers at-home, tailored allied health exercises (physiotherapy, speech and language therapy, and occupational therapy) for the gait, speech, and manual dexterity symptoms associated with Parkinson's disease.
45635446|NCT05120609|Device|Digital Placebo Application|The application is designed to provide a method of capturing outcome measures without providing access to the therapy exercises.
45635447|NCT03416855|Drug|Insulin degludec /insulin aspart|Commercially available Insulin degludec /insulin aspart (Ryzodeg® FlexTouch®) according to routine clinical practice at the discretion of the treating physician.
45635448|NCT05121779|Drug|68Ga-FAPI|Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of pulmonary fibrosis by PET/CT.
45774922|NCT04351789|Other|Psychoeducational intervention|"The written and verbal information provided at discharge to patients in the intervention arm will consist of:~An explanation of the normal recovery period after hospitalization due to COVID-19. What can the patient expect physically, psychologically and emotionally, and what coping mechanism might be appropriate Social support in the recovery period and how this can be used constructively. In case of worsening of symptoms - physically or psychologically, where can the patient get help after discharge from hospital.~These points are based on crisis psychology, enhancing the patients empowerment and self-management after discharge from hospital."
45914585|NCT02045563|Other|prise de sang|
45914586|NCT02045563|Other|magnetic resonance imaging and magnetic resonance spectroscopy|
45635449|NCT05121779|Drug|18F-FDG|Intravenous injection of one dosage of 4.44-5.55 MBq(0.12-0.15mCi)/Kg 18F-FDG. Tracer doses of 18F-FDG will be used to image lesions of pulmonary fibrosis by PET/CT.
45635450|NCT05120063|Device|SPS monoblock stem, Symbios|hip prosthesis
45635451|NCT05120063|Device|Quadra-H, Medacta|hip prosthesis
45635452|NCT05120063|Procedure|3D planning of THR|primary total-hip replacement (THR) planned on 3-dimensional images (computer tomography)
45635453|NCT05120063|Procedure|2D planning of THR|primary total-hip replacement (THR) planned on 2-dimensional images (anteroposteiros pelciv x-ray)
45914587|NCT02045576|Device|sleep position trainer|
45448129|NCT02136784|Drug|hydrocodone|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
45448130|NCT02136784|Drug|hydromorphone HCI|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
45448131|NCT02136784|Drug|oxycodone|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
45448132|NCT02136784|Drug|buprenorphine|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
45448133|NCT02136784|Drug|oral tablet placebo|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
45448134|NCT02136784|Drug|sublingual tablet placebo|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
45635454|NCT02693119|Drug|elamipretide (MTP-131) 1% topical ophthalmic solution|
45635455|NCT02693119|Drug|Vehicle topical ophthalmic solution|
45914588|NCT02045576|Device|Oral Appliance Therapy|
45914589|NCT02045589|Genetic|VCN-01|Genetically modified human adenovirus encoding human PH20 hyaluronidase
45914590|NCT02045589|Drug|Gemcitabine|1000 mg/m2 intravenous administration
45635456|NCT04224545|Drug|Colchicine Pill|Colchicine at a dose of 1 mg a day before surgery, 2, 3, 4, 5 days after surgery.
45635457|NCT04224545|Drug|Placebo|Placebo started a day before surgery, 2, 3, 4, 5 days after surgery.
45635458|NCT04224311|Biological|Menactra|0.5 mL dosage of Menactra will be administered by intramuscular injection in the deltoid muscle on day 0.
45635459|NCT05121389|Drug|normal saline|Normal saline is injected intravenously, using a infusion rate control device to control the drip rate.
45774923|NCT00004576|Drug|LY300164|
45774924|NCT00005812|Drug|temozolomide|
45774925|NCT01270555|Drug|Bupropion SR|100mg capsules Initial dosing 100mgSR every morning, to be titrated to 200mgSR twice daily maximum
45774926|NCT00004582|Drug|Lopinavir/Ritonavir|
45774927|NCT00004582|Drug|Efavirenz|
45914591|NCT02045589|Drug|Abraxane®|125 mg/m2 intravenous administration
45914592|NCT02045602|Genetic|VCN-01|Genetically modified human adenovirus encoding human PH20 hyaluronidase
45914593|NCT02045602|Drug|Gemcitabine|1000 mg/m2 intravenous administration
45914594|NCT02045602|Drug|Abraxane®|125 mg/m2 intravenous administration
45914595|NCT02045615|Procedure|Proposed technique for removal of the Wichita Fusion Nail|
45635460|NCT02395549|Drug|0.375% (w/w) MTC896 Gel|0.375% (w/w) MTC896 Gel
45635461|NCT02395549|Drug|0.75% (w/w) MTC896 Gel|0.75% (w/w) MTC896 Gel
45635462|NCT02395549|Drug|1.5% (w/w) MTC896 Gel|1.5% (w/w) MTC896 Gel
45635463|NCT02395549|Drug|Vehicle Control Gel|
45635464|NCT05121233|Drug|Diclofenac|a single dose 75 mg IV diclofenac by infusion prior to the procedure
45635465|NCT05121233|Drug|Placebo|single dose iv placebo (saline ) by infusion prior to the procedure
45448135|NCT02136940|Drug|AMA0076|
45635466|NCT02403427|Device|VoiceDiab expert system|"Decision support system VoiceDiab this is computer-based system constructed for mobile phone devices working on the server.~Patients in experimental arm get the mobile phone application for 4 days. Glucose control will be done by two methods SMPG and CGM. Before every study's meal insulin dose with type of bolus will be indicate by VoiceDiab."
45635467|NCT05121155|Device|ICP wave morphology comparison between a non-invasive (Brain4care) and a invasive method|We prospectively collected data of adults admitted to an intensive care unit (ICU) with subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH) or ischemic stroke (IS) in whom invasive ICP monitoring placed. Measures had been simultaneously collected from the following non-invasive indices: optic nerve sheath diameter (ONSD), pulsatility index (PI) using transcranial Doppler (TCD), a 5-point visual scale designed for Computed Tomography (CT) and two parameters (time-to-peak [TTP] and P2/P1 ratio) of a non-invasive ICP wave morphology monitor (Brain4care[B4c]). Intracranial hypertension was defined as an invasively measured ICP > 20 mmHg for at least five minutes
45635468|NCT05120921|Other|Osteopathic Manual Treatment|includes touch, joint manipulations, stretching and massage
45635469|NCT05120921|Other|Self-management|Providing rehabilitative exercises to patients to do at home
45635470|NCT05120921|Other|Reassurance|Reassuring patients on their symptoms, diagnosis and prognosis.
45635471|NCT05120921|Other|Biopsychosocial management|Giving a central place to the patient in the decision-making to help them to get back to valued activities.
45635472|NCT05745259|Drug|Alteplase|Alteplase 0.9mg/kg are being used.
45448136|NCT02136940|Drug|Placebo|
45448137|NCT02137018|Device|PPL fixation by BP|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by BP patch. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable stitches on the cutaneous layer.
45635473|NCT05745259|Drug|Tenecteplase|Tenecteplase 0.25mg/kg are being used.
45914596|NCT02045628|Behavioral|Investment intervention|Those in the investment group will complete carefully framed questions designed to raise the salience of the investment they have made in their procedure at baseline and 3 months follow up. The content of this intervention will be tailored to the recent experiences of the patient (ie pre or post surgery).
45448138|NCT02137018|Device|PPL mesh|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by absorbable stichtes. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable suture on the cutaneous layer.
45448139|NCT03679767|Drug|Retifanlimab|Retifanlimab administered intravenously at 500 mg every 4 weeks
45448140|NCT02129530|Behavioral|Community Social Mobilization program|
45448141|NCT02129686|Procedure|Immediate Acupuncture Group|
45635474|NCT05118581|Device|ultrasound guided vascular access|Arterial or venous catheterization guided by ultrasound
45635475|NCT02928107|Other|Tele-HS|Patients will be given information on the Tele-HS and given access to take the screening at home or in-office, depending on arm.
45914597|NCT02045641|Procedure|pleuracentesis|Direct needle drainage of pleural effusions with dynamic ultrasound technique
45935571|NCT02970695|Device|magneto-auriculotherapy (MAT)|Subjects will then receive MAT. The magnetic pellets will have ~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm.The experimental object will be applied to the seven selected acupoints as detected by an acupoint detector. Only one ear will receive treatment at a time, and the pellets will remain in situ for two days before the next change.
45448142|NCT02129686|Procedure|Delayed Acupuncture Group|
45448143|NCT02129764|Drug|Prednisone|
45635476|NCT02928107|Other|PCP encouragement|Patients will or will not either receive PCP encouragement to do the Tele-HS.
45635477|NCT02893241|Drug|Cafedrine/theodrenaline|
45448144|NCT02129764|Drug|Allopurinol|
45635478|NCT02893241|Drug|Ephedrine|
45635479|NCT02395237|Drug|: Amaryl® M IR 2/1000|
45635480|NCT02394847|Drug|propofol|
45635481|NCT03167125|Other|Automated Prompts|This intervention is an automated data-driven program, using automated phone calls, text messages, and/or emails, for delivering FIT kit prompts to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
45635482|NCT03167125|Other|Automated Plus Live Prompts|This intervention is a higher-intensity program, using automated data-driven prompts plus linguistically and culturally tailored live prompts, for delivering FIT kit messages to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
45635483|NCT04509479|Procedure|Valve replacement|Description of valve replacements
45635484|NCT05745181|Biological|CAR-T Cell Infusion|Peripheral blood mononuclear cells were isolated, amplified and cultured in vitro, pretreated with FC regimen, and Anti-CD1a CAR-T cells were transfused.
45635485|NCT05745103|Behavioral|Cognitive behavioral therapy with AI|Cognitive behavioral therapy is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders. The Eleos Health platform provides real-time data that optimizes this therapy and helps the provider tailor the intervention to the specific client.
45635486|NCT05745103|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders.
45635487|NCT01960348|Drug|patisiran (ALN-TTR02)|administered by intravenous (IV) infusion
45448145|NCT00130247|Drug|Ethambutol|Mycobacteriostatic agent given to prevent emergence of drug resistance to other 1st line drugs; dosages are 15-25 milligram (mg)/ kilogram (kg)/day (d).
45635488|NCT01960348|Drug|Sterile Normal Saline (0.9% NaCl)|administered by intravenous (IV) infusion
45635489|NCT04508699|Other|semantic learning|Experimental semantic learning from linguistic context task
45635490|NCT02395159|Device|Prevena™ IMS|"Prevena™ IMS is intended for the management of the surgical incision environment and surrounding healthy skin in patients with a risk of postoperative complications such as infections. This entails the maintenance of a closed environment around the incision by applying a negative pressure wound therapy system.~The corresponding dressing is known under the name Prevena™ Dressing. The layer closest to the skin comprises silver foil, which reduces the microbial colonisation of cells."
45635491|NCT02395159|Other|sterile plaster dressings|standard wound management method of sterile plaster dressings
45774928|NCT01270711|Drug|Study Drug|non interventional study - usage as per usual care
45774929|NCT00004642|Drug|SDZ MSL-109|
45914598|NCT02045667|Drug|Mexiletine|"Mexiletine is a lidocaine-derivate and belongs to the class of 1B antiarrhythmic agents (Vaughan-Williams Classification of Antiarrhytmica). Class I antiarrhythmics have membrane-stabilizing properties. Drugs in this class work by interfering with the fast influx of sodium by inhibition of sodium ionchannels during the fast depolarization phase, thereby decreasing the maximal voltage and upshoot phase of the action potential.~Mexiletine study-medication will be purchased from Stabilimento Chimico Farmaceutico Militare, Firenze, Italy."
45914599|NCT02045667|Drug|Placebo|Placebo tablets do not contain any active medicinal component.
45448146|NCT00130247|Drug|Isoniazid|Hydrazide of isonicotininc acid; antimicrobial activity is limited to mycobacteria where it inhibits the synthesis of mycolic acids.
45448147|NCT00130247|Drug|Pyrazinamide|1st line bactericidal agent; dosages are 15-30 mg/kg/d, up to 2 grams (gm)/d.
45448148|NCT00130247|Drug|Rifampin|1st line bactericidal agent which inhibits deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase; dosages are 10 mg/kg/d (up to 600 mg/d).
45914600|NCT02045693|Drug|Methadone|
45914601|NCT02045693|Drug|DCV 3DAA FDC|
45448149|NCT03678285|Other|HIFRT Workout|A single high intensity functional resistance training (HIFRT) exercise bout.
45448150|NCT02129920|Other|This is an observational study|
45448151|NCT02129998|Other|IVF/ICSI treatment|
45448152|NCT03735459|Behavioral|Patient reminders and accountability questionnaires|Participants who are assigned to the patient reminder arm will receive text messages 1, 2, and 4 weeks after enrollment. These text messages will encourage participants to adhere to the provided treatment plan, and ask participants to complete questionnaires to assess their adherence to treatment (in-house Adherence Questionnaire) and severity of eczema (PO-SCORAD) for that week.
45635492|NCT05021861|Drug|Cyproterone Acetate, Ethinyl Estradiol Drug Combination|FEMALE PATIENTS WITH PCOS ON CPA/EE DRUG REGIMEN FOR ATLEAST 6 MONTHS
45635493|NCT05021861|Diagnostic Test|FEMALE PATIENTS WITH PCOS|FEMALE PATIENTS WITH PCOS( NEWLY DIAGNOSED) ,NOT ON ANY MEDICATION,
45448153|NCT02252926|Drug|Bupivacaine|25 mg bupivacaine lozenge
45635494|NCT05021861|Diagnostic Test|Control group|SYSTEMICALLY HEALTHY FEMALES
45635495|NCT02403115|Other|Serum collection|Clinical tests (renal function, complete blood count, CRP, ANA, dsDNA, urinalysis) will be performed at fixed time intervals (6, 12, 24 and 36 months) and the surplus of blood sample will form the serum bank used for the study
45635496|NCT05230355|Device|360 degrees subthreshold diode laser cyclophotocoagulation|cyclophotocoagulation is applied along 360 degrees over pars plana
45635497|NCT05230355|Device|180 degrees subthreshold diode laser cyclophotocoagulation|cyclophotocoagulation is applied over one hemisphere only along 180 degrees in a double arc fashion
45635498|NCT04664062|Behavioral|Medication Assisted Treatment|All subjects will undergo MAT induction with buprenorphine. Participants will be randomized to the behavioral aspects of induction, specifically comparing office induction vs home vs synchronous telehealth induction.
45635499|NCT02403037|Device|True auricular acupressure|A 5-day auricular acupressure at the specific ear acupoints using vaccaria seeds.
45635500|NCT02403037|Device|Sham auricular acupressure|A 5-day sham auricular acupressure at the same acupoints as in the true auricular acupressure arm using Junci Medulla but no pressure will be applied.
45635501|NCT02403037|Drug|Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)|5-HT3 receptor antagonists and/or Dexamethasone will be administered to manage chemotherapy-induced nausea and vomiting.
45774930|NCT01340053|Drug|RDX5791|Capsule, QD
45774931|NCT00004654|Drug|soy protein isolate|
45774932|NCT00004660|Radiation|Radiotherapy|
45774933|NCT00004660|Radiation|Sham treatment|
45774934|NCT00004690|Drug|monolaurin cream|
45774935|NCT01270867|Device|Mechanical Thrombectomy|Each arm will use either Merci or Trevo as the primary Mechanical Thrombectomy device.
45774936|NCT00004696|Drug|morphine|
45774937|NCT00004744|Drug|immune globulin|
45774938|NCT01271413|Behavioral|Computerized cognitively stimulating activities|The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
45774939|NCT03009565|Other|coronary artery disease|
45774940|NCT01292005|Drug|Pentoxifylline|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
45914602|NCT02045693|Drug|BMS-791325|
45914603|NCT02045693|Drug|Buprenorphine|
45914604|NCT02045693|Drug|Naloxone|
45914605|NCT02045706|Other|Community Health Worker Trainings|
45914606|NCT02045719|Drug|uncaria tomentosa (cat´s claw)|
45914607|NCT02045745|Biological|"Implantation of autologous mesenchymal stem cells (CSM) expanded in vitro and administered directly into the lung suture line"|Patients at risk of prolonged postoperative air leak will be treated by local administration of autologous mesenchymal cells expanded in vitro
45914608|NCT02045758|Device|Fingerstick|
45774941|NCT01292005|Drug|Placebo|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
45774942|NCT00004756|Procedure|Tailored educational program|
45774943|NCT00004756|Procedure|Educational materials|
45914609|NCT02045758|Device|TAP20-C|
45914610|NCT02045771|Behavioral|Behavioral Activation|"Behavioral activation is a therapy, which has been shown to be quite effective in the treatment of depression (Kanter, Manos et al. 2010; Martell, Dimidjian et al. 2010). Although previous therapies have focused more on the cognitive element, behavioural activation on its own has also been significantly effective for depression treatment (Jacobson, Dobson et al. 1996). The treatment works by increasing behaviours that help a patient with depression interact with an environment and providing consequences to positively reinforce antidepressant behaviour (Martell, Dimidjian et al. 2010)."
45914611|NCT02045771|Behavioral|Support Group|In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
45653039|NCT03671291|Behavioral|self-administrated questionnaire|Persons who the biological parameters or past screening show that they were recently infected with HIV cf. eligibility criteria, will, after obtaining his consent, answer a series of questions through a self-administrated questionnaire that will take approximately 40 minutes.
45653040|NCT05532007|Dietary Supplement|Peanuts|2-3 ounces of peanuts to replace 20% of total daily energy intake
45774944|NCT00004762|Drug|cladribine|
45448154|NCT02252926|Drug|Standard treatment (lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin)|Standard treatment includes lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin
45774945|NCT01292629|Device|iSert 251 intraocular lens|aphakic intraocular lens
45774946|NCT00004786|Drug|iloprost|
45774947|NCT01272583|Drug|Sitagliptin|100 mg once daily for six weeks
45774948|NCT01272583|Drug|Placebo|placebo, once daily for six weeks
45774949|NCT00004804|Drug|interferon alfa|
45448155|NCT02253004|Drug|Cilostazol|Single oral administration of active or placebo one week apart
45448156|NCT02253004|Drug|Placebo|
45653041|NCT05532007|Other|Habitual Diet|continue with habitual diet and abstain from eating peanuts
45653042|NCT05730283|Drug|ORC-13661|High-dose intervention (30mg daily)
45653043|NCT05730283|Drug|ORC-13661|Low-dose intervention (12mg daily)
45774950|NCT00386074|Drug|NaFeEDTA, Electrolytic Iron|
45774951|NCT00004810|Drug|-aminosalicylic acid|
45774952|NCT00004816|Drug|monoclonal antibody M-T412|
45774953|NCT01341301|Radiation|Total Body Irradiation|Undergo TBI
45774954|NCT01341301|Biological|Donor Lymphocyte Infusion (DLI)|Undergo DLI
45774955|NCT01341301|Drug|Cyclophosphamide|Given IV
45774956|NCT01341301|Drug|Tacrolimus|Given IV or PO
45774957|NCT01341301|Drug|Mycophenolate mofetil|Given IV or PO
45774958|NCT01341301|Procedure|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
45774959|NCT01341301|Other|Laboratory biomarker analysis|Correlative studies
45774960|NCT01342471|Behavioral|TV commercial stepping|"Participants were instructed to stand and briskly step in place, or briskly walk continuously around the room/house for the duration of each commercial break during at least 90 min of TV programming on at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention"
45774961|NCT01342471|Behavioral|30-min walk|"Participants were instructed to use brisk walking (at least 30 min/day in bouts of at least 10 min) at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention"
45774962|NCT01273207|Drug|Cyclosporine Inhalation Solution (CIS)|CIS is a sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
45774963|NCT02195713|Device|Accuryn|Accuryn is a novel electronic urine output monitor
45774964|NCT01342549|Drug|Valproate|250mg per day 30 minutes after a meal. Dosages will be increase as tolerated to a maximum recommended dosage of 60 mg per kg per day. Usual dosage is between 1250mg to 2000mg per day
45774965|NCT01342549|Drug|Naltrexone|25mg per day, taken by mouth for 7 days, then 50mg per day
45635502|NCT04652908|Biological|Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix|As in the current standard fetal surgery, under sonographic guidance, initial uterine entry will be accomplished by uterine stapling device or similar. The fetus will be given an intramuscular injection of pain medications and paralytic. The myelomeningocele will be closed in a standardized manner under magnification. As in the standard fetal operation, the spinal cord will be dissected from surrounding tissue and allowed to drop into the spinal canal. The PMSC-ECM product will then be tailored to the size of the spinal cord and applied topically, cell side down. The PMSC-ECM product will be sutured in place to the dura. Finally, the fetal skin will be closed in the standard fashion. The amniotic fluid volume will be replaced and antibiotics will be added. The uterus will be closed. The abdominal fascial layer and skin will be closed in routine fashion.
45635503|NCT04652908|Other|Untreated contemporaneous cohort|The addition of a non-PMSC treated cohort, the untreated contemporaneous cohort, has been added at the request of the FDA to provide contemporaneous patients for validation of the continued relevance of use of the outcomes of the MOMS trial as the comparison arm for the Phase 2a portion of the study.
45635504|NCT02653625|Drug|Cenicriviroc 150 mg|One tablet of CVC 150 mg once daily taken with food in the morning.
45635505|NCT05745025|Device|Repeated Transcranial Magnetic Stimulation|rTMS will be delivered using a commercially available magnetic stimulator (Rapid2, Magstim Inc., Eden Prairie, MN) with a figure-of-8 Air Film coil at 10 Hz. Coil orientation will be optimized for stimulation of the abductor pollicis brevis. Stimulation targeting will be identified using motor evoked potentials (MEP) of the abductor pollicis brevis that will be monitored using electromyography (EMG) (Motion Lab Systems Inc., Baton Rouge, LA). The motor threshold (MT) of the muscle will then be identified by systematically adjusting the pulse intensity. The MT will be considered the lowest stimulation intensity at which 5 out of 10 MEPs have a peak-to-peak amplitude of at least 50 microvolts. rTMS will be performed at the identified optimal location at 10Hz using an intensity that is 80% of the MT. Pulse trains will be delivered for 10 seconds, with a 30-second rest for 20 repetitions.
45635506|NCT05745025|Device|Sham Repeated Transcranial Magnetic Stimulation|Sham rTMS will be performed using the same coil and delivery device used in the real rTMS group. The sham group will start with the same localization procedure as the real rTMS group. The magnet will then be moved over the vertex of the skull and angled 30-45 degrees away from the skull. The intensity will be dropped to half of the treatment intensity (40% of MT) used in the real rTMS group. Subjects in both groups will be told that after localization, the stimulation intensity will be lowered for the treatment.
45635507|NCT05745025|Other|Rehabilitation|"o Rehabilitation will consist of education, value-based goal setting, Graded Motor Imagery (GMI) (3 components described below), and graded activity. Subjects will complete activities at treatment sessions and be asked to perform certain treatment activities at home.~Week 1: Pain education, functional value-based goal setting, laterality training (first component of GMI), one task for graded activity (task-based on patient goals)~Week 2: Continue week 1 activity, add graded motor imagery (second component of GMI), progress 1st graded activity, and initiate 2nd graded activity exercise.~Week 3- Mirror therapy (third component of GMI), assess knowledge and update education as needed, progress graded activity 1 and 2, and add 3rd graded activity if appropriate based on patient goals.~Week 4- Continue with week 3 activities. Discuss experience with meditation and progress graded activity as tolerated"
45635508|NCT01981096|Behavioral|Fibromyalgia integrative training|Combined intervention with neuromuscular exercise training and cognitive behavioral therapy
45635509|NCT01981096|Behavioral|Cognitive Behavioral Therapy|Therapy focused on training in behavioral pain coping skills
45635510|NCT02394613|Drug|ANX776|Single intravenous injection
45774966|NCT01343095|Device|Foam Earplugs|Standard Foam Earplugs applied from 10pm-6am nightly. (Sperian Technologies, manufacturer)
45635511|NCT02394691|Device|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
45635512|NCT02652767|Biological|GS010|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
45653044|NCT05730283|Drug|Placebo|Placebo intervention
45653045|NCT05087667|Device|Implantation of Ortholoop cerclage|implantation of Sterile Self Locking Polymer Cerclage System named OrthoLoop to the patient and follow up for 36 months post-intervention
45653046|NCT05087667|Device|Implantation of Cerclage used in current practice|implantation of Cerclage used in current practice to patients and follow up for 36 months post-intervention
45774967|NCT01343095|Device|Noise Canceling Headphones|Noise Canceling headphones applied over the ears between 10pm-6am nightly. Model is Bose QuietComfort 15, manufactured by Bose Technologies.
45774968|NCT01343485|Behavioral|Computer reminder system|Intervention sites will receive computer kiosk with study specific software to assist in reminding study participants to return for HPV vaccine series
45774969|NCT01345513|Other|Sample Collection for Genome-Wide Sequencing|Collection of archival tumor tissue, fresh tumor biopsy, blood sample, and pleural effusion (if available)or ascites (if available)
45635513|NCT02652767|Device|Sham Intravitreal Injection|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
45635514|NCT04480333|Drug|Drug: NA-831 - 0.10 mg/kg|NA-831 in nanoparticle inhalation formulation
45635515|NCT04480333|Drug|Placebo- 0.10 mg/kg|Placebo in nanoparticle inhalation formulation
45635516|NCT04480333|Drug|Drug: NA-831 - 0.20 mg/kg|NA-831 in nanoparticle inhalation formulation
45635517|NCT04480333|Drug|Placebo- 0.20 mg/kg|Placebo in nanoparticle inhalation formulation
45635518|NCT04480333|Drug|Drug: GS-5734 - 1.00 mg/kg|GS-5734 in nanoparticle inhaled formulation
45635519|NCT04480333|Drug|Placebo- 1.00 mg/kg|Placebo in nanoparticle inhalation formulation
45635520|NCT04480333|Drug|Drug: GS-5734 - 2.00 mg/kg|GS-5734 in nanoparticle inhaled formulation
45635521|NCT04480333|Drug|Placebo- 2.00 mg/kg|Placebo in nanoparticle inhaled formulation
45635522|NCT04480333|Combination Product|Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)|The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation
45635523|NCT04480333|Combination Product|Placebo 0.10 mg + 1.00 mg/kg|The combined placebo are in nanoparticle inhaled formulation
45635524|NCT04480333|Combination Product|Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)|The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation
45635525|NCT04480333|Combination Product|Placebo 0.20 mg + 2.00 mg/kg|Placebo 0.10 mg + 1.00 mg/kg
45635526|NCT03166891|Drug|Chiauranib|Take 50mg orally once daily
45635527|NCT04969601|Biological|vaccine COMIRNATY® (BNT162b2)|two injections of COMIRNATY® (BNT162b2) vaccine 21-28 days apart, of either 10, 20, 30 µg of vaccine, depending on the observed responses of previous children
45635528|NCT05744869|Behavioral|SB-CAP|SB-CAP
45635529|NCT01980940|Drug|Etoricoxib 75 mg 4% DMSO Gel|Etoricoxib 75 mg 4% DMSO gel applied topically.
45635530|NCT01980940|Drug|Etoricoxib 75 mg 4% PG Gel|Etoricoxib 75 4% PG gel applied topically.
45635531|NCT01980940|Drug|Etoricoxib 150 mg 4% DMSO Gel|Etoricoxib 150 mg 4% DMSO gel applied topically.
45635532|NCT01980940|Drug|Etoricoxib 150 mg 4% PG Gel|Etoricoxib 150 mg 4% PG gel applied topically.
45635533|NCT01980940|Drug|Etoricoxib 163 mg 4% DMSO gel|Etoricoxib 163 mg 4% DMSO gel applied topically
45774970|NCT01294267|Device|Circulatory Support System|Femoral angiography will be performed, and if the anatomy is suitable, the femoral artery preclosure technique will be employed. The Impella 2.5 will be inserted through th femoral artery into the left ventricle. Anti-coagulation will be titrated to achieve a therapeutic ACT level. Organ perfusion and Hemodynamic data will be collected during simulated VTs and throughout the course of the case. The performance level of the device may be adjusted during the case to quantify hemodynamic effects
45774971|NCT01276171|Procedure|Ultrasound|Participants will place arterial line using ultrasound technique
45635534|NCT01980940|Drug|Placebo|Placebo gel applied topically.
45635535|NCT01980940|Drug|Etoricoxib 50 mg 4% DMSO|Etoricoxib 50 mg 4% DMSO gel applied topically.
45635536|NCT01980940|Drug|Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel|Matching Placebo to Etoricoxib 50 mg 4% DMSO gel applied topically.
45635537|NCT02394223|Procedure|Full Field Optical Coherence Tomography (FFOCT) procedure|TRUS Prostate biopsy are performed under the care procedure Pathological examination of these prostate biopsy with FFOCT procedure, as compared to standard pathological evaluation
45635538|NCT04857437|Drug|PF-07202954 Repeat Dose|10, 30, 100, 300, 600, 1200 milligrams (mg)
45774972|NCT01276171|Procedure|Doppler|Participants will place arterial line using doppler technique
45635539|NCT04857437|Drug|PF-07202954 Single Dose|10, 30, 100, 300, 600, 900, 1200 milligrams (mg)
45635540|NCT04857437|Drug|Placebo|Matching Placebo
45635541|NCT02394379|Device|Trulign™ Toric IOL|Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
45635542|NCT05229575|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
45635543|NCT04842929|Device|Transcranial magnetic stimulation|The coil will be positioned in the prefrontal dorsolateral cortex, with intermintent TBS (TBSi) mode on the left and continuous TBS (TBSc) on the right. 1800 pulses will be used on each side, totaling 10 minutes of total duration. There will be 20 consecutive sessions, one per day, except on weekends and holidays, totaling around 4 weeks. A day of stimulation with the same technique will be done in the 6th week, 8th week and 12th week.
45635544|NCT02699983|Behavioral|Behavioral Dietary Intervention|Use SparkPeople web-based program
45635545|NCT02699983|Behavioral|Exercise Intervention|Use Fitbit monitor and SparkPeople web-based program
45635546|NCT02699983|Device|Activity Monitoring Device|Wear Fitbit activity monitoring device
45635547|NCT01960114|Drug|Acetaminophen ER|Single dose (2 tablets) Acetaminophen ER 750 mg
45635548|NCT01960114|Drug|Placebo|Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
45635549|NCT04752527|Drug|venetoclax combined with decitabine|combination of venetoclax plus decitabine, and sorafenib for patients with high FLT3-ITD allelic ratio. (On day 1 of cycle 1, decitabine 20 mg/m2 will be given intravenously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 28 day cycle is finished. For patients with high FLT3-ITD allelic ratio, sorafenib was administered at a dose of 400mg orally twice daily, on days 3 through 28.
45635550|NCT05229497|Drug|AK112|IV infusion,Specified dose on specified days
45635551|NCT05229497|Drug|AK117|IV infusion,Specified dose on specified days
45635552|NCT05229497|Drug|Carboplatin|IV infusion,Specified dose on specified days
45635553|NCT05229497|Drug|Cisplatin|IV infusion,Specified dose on specified days
45635554|NCT05229497|Drug|5-Fluorouracil|IV infusion,Specified dose on specified days
45653047|NCT05613959|Device|Veress +|The Veress+ safety mechanism was used
45774973|NCT01276171|Procedure|Palpation|Participants will place arterial line using Palpation technique
45774974|NCT01346683|Device|OsseoSpeed TX|OsseoSpeed TX implants of lengths 8-17 mm
45774975|NCT01295515|Drug|Pegylated Interferon Alpha 2b (PEGINTRON)|pegylated preparation of interferon alpha 2b
45635555|NCT02005276|Behavioral|Basic Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day.
45635556|NCT02005276|Behavioral|Combined Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day.
45448157|NCT03735381|Device|Pedometer watch 'Xiomi mi band2'|"They receive information on the use of the pedometer.~Carry the pedometer (Xiaomi Mi Band 2 ™) from 12 to 32GW.~Prescription of benefits of walking in pregnancy:~Receive information about the goal of steps / day to be reached: 10,000-11,000 steps / day (Only the intervention 2 group).~Receive information on the adequacy of walking with moderate intensity.~They will receive messages on the mobile phone remembering the goal to achieve and a notification that the researching staff will proceed to collect the average count of steps / day of the week prior to 20 and 32 gestation weeks (only for the intervention 2 group)."
45635557|NCT02005276|Behavioral|Jackpot Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day.
45635558|NCT03169777|Biological|avelumab|Fully human anti-programmed death-ligand 1 (PD-L1) immunoglobulin (Ig)G1 lambda monoclonal antibody
45635559|NCT03169777|Biological|bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
45448158|NCT02252458|Drug|Fentanyl|
45448159|NCT02132182|Biological|Blood draw|The patient population for this study will be comprised of individuals who present to clinic with newly diagnosed osteosarcoma with or without infection and without known metastasis to the lung. These patients would have a standard-of-care blood draw. For the study we will be drawing an additional 15-20mL of blood (no additional needle stick).
45914612|NCT02045784|Dietary Supplement|Infant formula|To establish dose-response relationships, formula-fed infants will be randomly allocated to three 11-day cross-over periods of exclusive consumption of infant formula providing different amounts of iodine. All iodine levels are within the required iodine levels for infant formula following the regulations of the United States, the European Union, Switzerland and New Zealand.
45635560|NCT03169777|Drug|capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
45635561|NCT03169777|Biological|cetuximab|Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
45635562|NCT03169777|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
45448160|NCT04032171|Drug|Evobrutinib|Participants received evobrutinib twice daily (BID).
45635563|NCT03169777|Drug|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
45448161|NCT04032171|Drug|Avonex®|Participants received avonex® IM injection once a week.
45635564|NCT03169777|Drug|fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
45635565|NCT03169777|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
45635566|NCT03169777|Drug|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
45635567|NCT03169777|Biological|nivolumab|Human anti-programmed cell death protein 1 (PD-1) IgG4 kappa monoclonal antibody
45635568|NCT03169777|Drug|Lovaza|Omega-3-acid ethyl esters
45448162|NCT04032171|Drug|Avonex® matched Placebo|Participants received IM injection of placebo matched to avonex® once a week.
45448163|NCT04032171|Drug|Evobrutinib matched Placebo|Participants received placebo matched to evobrutinib twice a day.
45635569|NCT03169777|Drug|oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
45635570|NCT03169777|Radiation|Stereotactic Body Radiation Therapy|(SBRT)
45448164|NCT02137174|Other|Home and school visits|Each child in the intervention group received, in addition to the standard care at the diabetic clinic, home and school visits by a multidisciplinary team during one year.
45635571|NCT03169777|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
45635572|NCT03169777|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine
45635573|NCT03169777|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
45635574|NCT03169777|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
45635575|NCT03169777|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine
45635576|NCT03169777|Biological|GI-4000|RAS yeast vaccine
45635577|NCT03169777|Biological|GI-6207|CEA yeast vaccine
45635578|NCT03169777|Biological|GI-6301|Brachyury yeast vaccine
45635579|NCT03169777|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion
45635580|NCT02306915|Drug|lipegfilgrastim|lipegfilgrastim 30 μg/kg, 60 μg/kg, 100 μg/kg
45635581|NCT04105907|Device|GentleWave|Subject teeth will receive a partial root canal treatment with the Sonendo GentleWave system followed by extraction of the tooth and histological evaluation of the tooth
45635582|NCT03167047|Procedure|Caudal block|Caudal epidural
45635583|NCT03167047|Procedure|Nerve Block|Peripheral nerve block
45635584|NCT03167047|Drug|Standarising intraoperative pain relief|All patients will receive a standarised dose of paracetamol 15mg/kg and fentanyl 2mcg/kg.
45635585|NCT01980706|Drug|Baclofen|Baclofen is a GABA-B agonist
45635586|NCT01980706|Drug|Placebo|Pill containing no pharmacologically active substance.
45635587|NCT05229029|Drug|TCM Formula|TCM herbs：White peony 10g, angelica 10g, Astragalus 20g, Atractylodes macrocephala 10g, tangerine peel 6g, Poria cocos 10g, raw land 10g, cinnamon 3g, Polygala tenuifolia 6g, Schisandra chinensis 6g, raw licorice 6g.
45635588|NCT05229029|Drug|Placebo|Placebo made of dextrin and caramel
45653048|NCT05613959|Device|Conventional Veress|The Conventional Veress Needle was used
45774976|NCT03008941|Biological|FMT|Capsules with fecal microbiota from healthy donors
45914613|NCT02045784|Other|Breast milk|Unlimited breast feeding
45914614|NCT02045797|Drug|GSK2140944 Lyophile|GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.
45635589|NCT02402803|Other|Dried blood spot testing and phlebotomy|At baseline and 4-6 week follow-up, a phlebotomy serum sample (5 ml) will be collected in one golden-top tube for clinical laboratory measurement of cholesterol (total cholesterol, LDL-C, triglycerides, HDL-C) . During the same phlebotomy, a fingerprick dried blood spot (DBS) sample and two lavender EDTA plasma tubes (5 ml each) will be collected for analysis of CVD protein markers
45635590|NCT02092571|Drug|Progesterone vaginal ring,|Participants will be randomized to receive treatments in 1 of 2 treatment sequences (AB or BA)
45635591|NCT02402959|Other|individualized treatment|Individualized treatment includes anything no matter what kind of interventions, like medicine, herbs, acupuncture, massage, behaviour therapy, diet and exercise therapy. The TCM experts should choose the intervention in accordance to the patients' preference, best existed evidence and their empirical knowledge.
45635592|NCT02085863|Drug|laquinimod|Oral laquinimod 0.6 mg capsules (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
45635593|NCT02085863|Drug|Placebo|Placebo (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
45635594|NCT02402725|Drug|Dexamethasone|(1 cycle = 28 days) D1: Dexamethasone 100mg IV; Dex 24mg PO every 6 hrs (begin immediately after IV dex) D2: Dex 24mg PO every 6 hrs D3: Dex 24mg PO every 6 hrs
45635595|NCT02054351|Drug|IMAB027|Stage 1 (Intrapatient dose escalation): The starting dose is set to 1 mg/m2, followed by 10 mg/m2, 30 mg/m2 and 100 mg/m2 Stage 2 (Interpatient dose escalation): 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2 Extension period: 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2
45635596|NCT02394145|Drug|Ticagrelor|Patients with normal kidney function and ESRD on hemodialysis will be treated by ticagrelor 90mg twice a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
45635597|NCT02394145|Drug|Clopidogrel|Patients with normal kidney function and ESRD on hemodialysis will be treated by clopidogrel 75mg or 150mg once a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
45635598|NCT03167827|Other|Exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
45635599|NCT03167827|Other|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
45635600|NCT03167827|Other|placebo|Daily supplementation in 1 capsule per day containing starch of corn.
45635601|NCT04101695|Device|tDCS|Ybrain tDCS System (Ybrain, Korea) is used for anodal stimulation of cerebellar hemisphere. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on right buccinator muscle.
45774977|NCT03008941|Other|Placebo|Placebo capsules
45774978|NCT01277341|Drug|Bepotastine Besilate Nasal Spray 2% Twice a day|nasal spray
45635602|NCT03166657|Procedure|office hysteroscopy|A speculum is first inserted into the vagina. The hysteroscope is then inserted and gently moved through the cervix into uterus. Carbon dioxide gas or a fluid, such as saline will be put through the hysteroscope into uterus to expand it. The gas or fluid helps see the lining more clearly. The amount of fluid used is carefully checked throughout the procedure
45635603|NCT04103099|Dietary Supplement|HLNatural Immune|Vitamin C, Echinacea, Ivy Extract, Zinc, Ginger and Turmeric in a powder form mixed with water
45635604|NCT02692417|Device|Transcutaneous Electrical Nerve Stimulation|Both arms will receive stimulation from the same TENS (transcutaneous electrical nerve stimulation) unit with identical stimulation frequency, but potentially different amplitudes depending on the subject's stimulation threshold.
45774979|NCT01277341|Drug|Bepotastine Besilate Nasal Spray 3% Twice a day|nasal spray
45774980|NCT01277341|Drug|Bepotastine Besilate Nasal Spray 4% Twice a day|nasal spray
45774981|NCT01277341|Drug|Placebo Nasal Spray|nasal spray
45774982|NCT01346839|Behavioral|Contact Intervention|The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
45774983|NCT04769635|Device|CPAP therapy|All studied patients were received CPAP therapy with average cumulative adherence ⩾4 h/day of >70% nights [380] obtained from device download with AHI<5 /hr
45774984|NCT04351477|Device|Massage chair|Mechanical massage chair
45635605|NCT04091555|Dietary Supplement|HLNatural Tension|Understand the impact of the supplement on Tension Headaches
45635606|NCT02393911|Dietary Supplement|Low Oxalate Diet|Low oxalate diet is a diet where products with oxalate will be eliminated, such as: tomatoes, berries, coffee, nuts
45635607|NCT02004886|Drug|MK-0893|10 mg and 100 mg tablets
45635608|NCT02004886|Drug|Metformin|500 mg metformin tablets
45635609|NCT02004886|Drug|Placebo|Placebo tablets matching MK-0893
45635610|NCT02004886|Drug|Placebo|Placebo tablets matching metformin
45635611|NCT02393989|Procedure|posterior restoration|restorations for caries effected teeth
45635612|NCT04065893|Procedure|Catheter ablation of ventricular arrhythmia|PVC or VT ablation
45774985|NCT00101816|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or intolerable toxicity, switch to the roll-over study or study closure.
45774986|NCT00102518|Drug|Aripiprazole|2 to 30 mg/day orally (2, 5, 10, 15, 20, 25, or 30 mg/day); tablets in strengths of 2, 5, 10, and 15 mg were used to achieve desired doses
45774987|NCT02090894|Device|UV Light (Laser Genesis)|
45774988|NCT00103376|Drug|Velcade|"Part A: 1.3 mg/m2 administered on days 1, 4, 8 and 11 followed by 10 days rest. A second cycle will be given at the same schedule. Cycle 3 will include 3 weekly injections.~Part B: 1.3mg/m2 administered weekly for 3 weeks followed by 1 week break"
45774989|NCT00103376|Drug|LH-RH Agonist|given as a 3 month depo-injection
45774990|NCT00103376|Drug|Androgen Receptor Antagonists|given orally daily for 3 months
45774991|NCT00042224|Procedure|Electroconvulsive Therapy (ECT)|ECT will be used to augment clozapine in schizophrenic patients who continue to have psychotic symptoms despite optimal treatment with clozapine.
45774992|NCT00042224|Drug|Clozapine|Patients with psychotic symptoms will receive clozapine
45635613|NCT04065893|Drug|Intensified medical therapy|Dosage increase / new onset of Betablocker / medical antiarrhythmic medication according to guideline and clinical practice
45774993|NCT01296763|Drug|Irinotecan|Irinotecan 70 mg/m2 IV, Days 1 and 8
45774994|NCT01296763|Drug|Cisplatin|Cisplatin 25 mg/m2 IV, Days 1 and 8
45635614|NCT05744713|Other|Observational|Observational
45635615|NCT05228561|Other|Mobile Application Supported Nutrition and Diabetes Education|With this intervention, the difference between the mobile application supported nutrition diabetes education created with written and visual (video) and face-to-face nutrition and diabetes education will be found.
45635616|NCT05228483|Device|CO2 fractional laser|CO2 fraction laser
45635617|NCT05228483|Combination Product|5-aminolevulinic acid (5-ALA) with red light illumination|5-aminolevulinic acid (5-ALA) is a photosensitizing agent which can induce photochemical reactions in tissues in response to an appropriate wavelength of light (red light 630-635nm).
45635618|NCT05228483|Drug|Mometasone furoate (MMF) 0.1% ointment|0.1% Mometasone furoate ointment is a potent steroid and has been proven to result as efficacious and well tolerated as clobetasol propionate which represent the recomended first-line treatment of vulvar lichen sclerosus.
45774995|NCT01296763|Drug|Olaparib (for levels 1 and 5)|Olaparib 100 mg bid oral, Days 1 and 8
45914615|NCT02045797|Drug|GSK2140944 Capsules|GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.
45635619|NCT01959880|Device|The Contour Profile Gel (CPG) breast implants|"The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement.~The Contour Profile Gel is available in sizes 125cc - 690cc and 4 styles with various projection and height options in this study."
45635620|NCT05228405|Other|All of the disabled children's caregivers will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness|All of the different type of disabled children's caregivers (cerebral palsy, muscular dystrophy, spina bifida and down syndrome) will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness
45635621|NCT04259801|Drug|NNC0480-0389|Part 1: A single dose of NNC0480-0389, dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of NNC0480-0389, dose increased in each cohort.
45635622|NCT04259801|Drug|Semaglutide|Part 1: Single dose of semaglutide (0.5 mg). Part 2: Weekly doses of semaglutide alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
45635623|NCT04259801|Drug|Placebo (NNC0480-0389)|Placebo for NNC0480-0389. Part 1: A single dose of placebo (NNC0480-0389), dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of placebo A, dose increased in each cohort.
45635624|NCT04259801|Drug|Placebo (semaglutide)|Part 1: Single dose of placebo (semaglutide) (0.5 mg). Part 2: Weekly doses of placebo (semaglutide) alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
45635625|NCT04255277|Drug|Combined oral contraceptives (COC)|A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.
45448165|NCT03549988|Other|Fecal Calprotectin (FC) measurements with IBDocTM|"Each IBDocTM kit measure one fecal calprotectin value. The IBDoc® is an in-vitro diagnostic immunoassay analyzed by a downloadable smartphone application (CalApp®). A patient is able to process their stool at home using a test cassette.~The IBDocTM test results are displayed in a light signal system as three titre categories; normal <100 µg/g (green), 100-300 µg/g (yellow), >300 µg/g (high). Patients' results will be sent directly to the central research coordinator through the IBDoc® Web Portal. If the FC is >250 µg/g a second FC will be performed within 2 weeks. If this result is <250 µg/g patients will continue to monitor their FC every 2 months. If the second result is >250 µg/g, the attending physician will review the patient either by telephone or in the office within 7 days."
45774996|NCT01296763|Drug|Olaparib (for dose level 2)|Olaparib 100mg bid oral, Day 1-3, Day 8-10
45774997|NCT01296763|Drug|Mitomycin-C|Mitomycin 5 mg/m2 IV, Day 1
45448166|NCT03735303|Dietary Supplement|VD3 group|VD3 50000 IU/ week for 8 weeks
45774998|NCT01347541|Behavioral|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
45774999|NCT01347541|Behavioral|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
45448167|NCT03735303|Dietary Supplement|omega 3 FA group|omega 3 FA group 300 mg once daily for 8 weeks
45775000|NCT01347541|Drug|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
45775001|NCT01347541|Behavioral|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors
45775002|NCT01296841|Device|Collaborative Imaging|Hardware and software communication tools to provide clinical care from a distance.
45914616|NCT02045810|Drug|Levobupivacaine|
45914617|NCT02045810|Drug|Saline|
45914618|NCT02045849|Drug|GSK2140944 capsule|Immediate release capsule containing GSK2140944 and inactive formulation excipients with a unit dose strength of 500 mg
45914619|NCT02045849|Drug|GSK2140944 tablet|Immediate release tablet containing GSK2140944 and inactive formulation excipients with a unit dose strength of 750 mg
45914620|NCT02045849|Drug|Itraconazole capsule|Capsule containing Itraconazole with a unit dose strength of 100 mg
45775003|NCT01349491|Drug|Ranolazine|Patients will be started on ranolazine 500mg twice daily. The first dose will be administered the day of cardioversion. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated for a total of six months.
45775004|NCT01349491|Drug|Matching placebo|Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion and continued for a total of six months.
45775005|NCT01298167|Device|Cyanoacrylate tissue glue versus Fast absorbing gut|All wounds will be closed using a linear, bilayered closure method, where the buried intradermal absorbing suture (5-0, Polysorb) will be placed along the length of the incision, consistent with standard surgical procedure. Only patients with wounds with a length of 3cm or greater will be enrolled. Each wound will be measured, and the length divided in half. Half of the surgical wound will be randomly selected (by coin toss) for epidermal reapproximation with cyanoacrylate, whereas the other half will be repaired with 6-0 fast absorbing gut suture in standard running fashion.
45775006|NCT01280695|Drug|Placebo|Placebo Capsules
45775007|NCT01280695|Drug|MSDC-0602 100 mg|MSDC-0602 100 mg Capsules
45635626|NCT04255277|Drug|Moxifloxacin 400mg|A commercially available formulation of moxifloxacin 400 mg will be used and administered open-label. All tablets will be from the same batch.
45635627|NCT04255277|Drug|Cenerimod 0.5 mg|This will be administered orally as a film-coated tablet in the morning.
45635628|NCT04255277|Drug|Cenerimod 4 mg|This will be administered orally as a film-coated tablet in the morning.
45635629|NCT04255277|Other|Charcoal, activated|Granules for oral suspension will be used and administered open-label.
45635630|NCT04255277|Drug|Matching Placebo|Cenerimod matching placebo tablets will be administered once daily orally in the morning.
45635631|NCT05228093|Procedure|Curative-intent endoscopic necrectomy followed by reconstruction using the posterior pedicle nasal septum and floor mucoperiosteum flap|"Radical endoscopic necrectomy was performed under general anesthesia using the endoscopic endonasal approach. And the reconstruction of the nasopharyngeal defect use the nasal septum and floor mucoperiosteum flap. Antibiotic therapy based on the result of bacterial cultivation before the surgery was administered for 5-7 days after surgery. Patients are prescribed regional perfusion with recombinant human epidermal growth factor derivative liquid (Watsin Genetech Ltd, Shenzhen, Guangdong, P.R. China) to keep the wound humid, and endoscopic nasal cleanup was performed every 2-4 weeks until the flap was completely epithelialized and the entire defect was relined.~Patients who were assessed as non-healing at 3 months after treatment will underwent salvage surgery."
45635632|NCT05228093|Procedure|Conservative treatment|"Debridement guided by nasopharyngeal endoscopy and excision of the radiation-induced necrotic tissues were performed every 1 or 2 weeks. Patients are prescribed regional perfusion with recombinant human epidermal growth factor derivative liquid (Watsin Genetech Ltd, Shenzhen, Guangdong, P.R. China) to keep the wound humid. Other conservative treatment included daily nasopharynx rinsing with 2% aquae hydrogeniidioxide (5-10 mL each time) or saline (50-100 mL each time) and antibiotic therapy (metronidazole or ornidazole) guided by the culture results was also performed synchronously. Intravenous nutrition and systematic antibiotic therapy were also performed if indicated and necessary. In addition, patients can receive hyperbaric oxygen therapy when conditions permit.~Patients who were assessed as non-healing at 3 months after treatment will underwent salvage surgery."
45635633|NCT01980628|Drug|ibrutinib|
45775008|NCT01280695|Drug|MSDC-0602 250 mg|MSDC-0602 250 mg Capsules
45635634|NCT01255943|Behavioral|healthcare staff processes for infection prevention|Toyota lean and positive deviance discovery and action dialogues to facilitate process improvement
45635635|NCT05057975|Device|Sunrise|Use of the Sunrise device for three nights to register mandibular movements that will be automatically analysed using artificial intelligence.
45635636|NCT05057975|Device|polysomnography|Reference protocol to diagnose OSA (in-lab or outpatient PSG)
45635637|NCT04237727|Device|Fluxmed GrH will be used to measure the ventilation parameters|The study will be a prospective descriptive multicenter study where measurement of ventilation data will be sampled during CPR by EMS treating patients with OHCA.
45448168|NCT03735303|Dietary Supplement|VD3 and omega- 3FA group|50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks
45448169|NCT03735303|Other|control group|no intervention was given
45448170|NCT02137330|Device|Swallowable Obalon® Gastric Balloon|
45448171|NCT02137408|Dietary Supplement|Docosahexaenoic acid 200 mg|Participants will be randomized to 200 mg docosahexaenoic acid daily (1-200mg capsule) PO beginning at 18-20 weeks gestation through 6 weeks post-partum.
45635638|NCT04007705|Behavioral|Anti-inflammatory and low FODMAPs diet|Exemption of the intake of potentially inflammatory foods, namely gluten, dairy and processed foods, over a consecutive period of 3 months. During the first month, a low FODMAPs diet will be implemented, along with the anti-inflammatory diet, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months.
45635639|NCT04007705|Behavioral|General healthy eating|Healthy eating counseling according to the World Health Organization
45775009|NCT01280695|Drug|MSDC-0602 250 mg|MSDC-0602 500 mg Capsules
45775010|NCT01280695|Drug|Pioglitazone|Pioglitazone 45 mg Capsules
45448172|NCT02137408|Drug|Docosahexaenoic acid 1000 mg|Participants will be randomized to 1000 mg (5-200mg capsules) docosahexaenoic acid PO daily beginning at 18-20 weeks gestation through 6 weeks post-partum.
45448173|NCT02130154|Other|18-FDG PET CT scan and 123I-MIBG SPECT scan|
45635640|NCT03978533|Behavioral|Family Support Group|Family Support Groups will be piloted with families in community and clinical sites. Each pair of facilitators will pilot two groups of 6 families each. Each group is 4 sessions lasting 2 hours each. Each of the sessions incorporates didactic talks, family discussion, and separate breakout groups for adolescents and adults. Family Support intervention incorporates cognitive-behavioral theory of PM+ which underlies evidence-based techniques focused on stress management and behavioral activation. Family support intervention also incorporates resilience theory, which explains family protective processes that can ameliorate the negative consequences of hardships and challenges and enable healing and growth in families.
45635641|NCT03840707|Behavioral|LIFEwithIBD|"LIFEwithIBD programme is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients~Treatment as Usual (TAU): Standard personalized treatment of inflammatory bowel disease"
45635642|NCT04221893|Radiation|Radiation Therapy (RT)|Undergo radiation therapy
45635643|NCT03670121|Device|Bronchoscopic Thermal Vapor Ablation (BTVA)|Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
45635644|NCT04435925|Drug|Remifentanil|Loading dose: 0.5 mcg/kg Maintenance dose: 1 mcg/kg/minute
45635645|NCT04435925|Drug|Fentanyl|Loading dose: 2 mcg/kg Maintenance dose: 0.4 mcg/kg/30-minutes
45635646|NCT03648281|Drug|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
45635647|NCT01979614|Drug|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
45635648|NCT01979614|Other|Placebo|5% v/v glucose solution
45635649|NCT05205707|Diagnostic Test|ACE serum levels|Circulating ACE2 level will be measured
45635650|NCT04649476|Drug|Camrelizumab|The participants will receive camrelizumab (200 mg) intravenous infusion each 2-week cycle for 3 cycles prior to surgery.
45635651|NCT04649476|Drug|Camrelizumanb plus TPF|The participants will receive camrelizumab (200 mg) through intravenous infusion each 2-week cycle, and docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2, 5-Fluorouracil (F) 750 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
45635652|NCT04671784|Other|EUS-E|EUS-E
45635653|NCT05117957|Drug|Sorafenib|Subjects will receive sorafenib 600mg orally daily. When dose reduction is necessary during the treatment of HCC, the sorafenib dose should be reduced to 400mg once daily. Escalation of sorafenib from a daily dose of 600mg to 800mg (400mg twice daily) is allowed if the subject who is tolerating the 600mg sorafenib dose level well. Treatment will continue until progression, unacceptable toxicity, withdrawal of consent, or study end, whichever occurs first.
45635654|NCT04671628|Behavioral|Relaxing music|Participants will be asked to listen to relaxing music for 30 minutes each day. They will allowed to choose between several playlists based on their preference.
45635655|NCT04671238|Device|SPECT CT|SPECT/CT scan of the spine as part of a vertebroplasty
45635656|NCT02654717|Drug|DFD-07 Cream|
45635657|NCT02654717|Drug|Placebo Cream|
45635658|NCT05117879|Procedure|Cold snaring polypectomy/ Cold EMR/Hot EMR|"Cold snaring polypectomy: The technique of cold snare polypectomy is used to remove [small colonic polyps] without diathermy, which implies that a polyp is transected by a snare along with a rim of surrounding normal mucosa.~Cold EMR: Cold EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal cold snare resection of target polyp with a margin of normal tissue.~Hot EMR: Hot EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal electrocautery snare resection of target polyp with a margin of normal tissue."
45635659|NCT05117801|Device|Petale|The child sits on the companion's lap between the two enclosures, and the investigator observes whether or not he is attracted to a familiar calibrated noise coming from one side or the other.
45448174|NCT02130232|Behavioral|Lifestyle Intervention|
45448175|NCT02130232|Other|Usual Care|
45635660|NCT03094871|Behavioral|FACE-PC|
45635661|NCT04236167|Device|Fractional CO2 laser treatment -|UltraPulse CO2 Laser (Lumenis, Israel). Patients will receive laser treatments at 4 to 8-week intervals for a total of 3 sessions. A combination of the SCAAR FX and Deep FX treatment modes, with or without Active FX treatment mode, will be used according to individual patient and scar characteristics. For SCAAR FX, the settings include energy (70-150mJ), density (1-5%), and frequency (150-250Hz).For Deep FX, the settings include energy (12.5-22.5mJ), density (5-15%) and frequency (300-600Hz). For Active FX, the settings include energy (80-125mJ), density (2-3%) and frequency (100-150Hz)
45448176|NCT02132260|Drug|Naftifine Hydrochloride Cream 2%|Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.) applied once-daily for two weeks
45775011|NCT03008785|Other|exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
45775012|NCT03008785|Other|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
45775013|NCT03008785|Other|Placebo|Daily supplementation in 1 capsule per day containing starch of corn.
45775014|NCT00103844|Drug|Dasatinib|Tablets, oral, 20 mg and 50mg, twice daily, up to 96 weeks
45775015|NCT00103844|Drug|Imatinib|Tablets, Oral, 400mg and 100mg, twice daily, up to 96 weeks
45775016|NCT01402141|Dietary Supplement|Chungkookjang|Chungkookjang(35g/say)for 12 weeks
45448177|NCT02132260|Drug|Naftin® (Naftifine Hydrochloride) Cream 2%|Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) applied once-daily for two weeks.
45635662|NCT05191043|Other|Kinesio Taping Technique|Kinesio taping is a thin, stretchy, elastic cotton strip with an acrylic adhesive that is approximately the same thickness as the epidermis of the skin. When the taping method is followed correctly, the tape effects on the muscle by facilitating a weakened muscle or relaxing an over-used muscle,decreasing pain, fatigue and increasing tissue recovery. Kinesio Taping facilitation technique will be used with fifty percent stretch on rhomboids bilaterally.
45635663|NCT05191043|Other|Routine Physical Therapy|"routine physical therapy includes thermotherapy and Transcutaneous electrical nerve stimulation (TENS), the strengthening exercises of lower and middle trapezius, rhomboids and deep neck flexors. Stretching exercises of upper trapezius, pectoralis major and minor. Mobilization of cervicothoracic junction and postural education.~Thermotherapy and transcutaneous electrical nerve stimulation will be used for 10 minutes in each session. Each exercise will be performed in 3 sets of 10 repetitions. Treatment session will have a duration of 30-45 minutes."
45635664|NCT05190029|Diagnostic Test|Series of questions to parents of children in a virtual form.|A questionnaire of 5 questions was provided in an online format addressed to the parents or legal representatives of each child. These questions were related to the child's own aspects (behavioral, psychomotor and cognitive parameters), as well as parameters oriented to the mother (pregnancy and childbirth).
45635665|NCT05190029|Other|Intervention by teachers|"The school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which assesses five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-50%), normal (50-80%) and high (80-100%). Low and high values are considered impairments in one or more of the evaluated areas."
45775017|NCT01402141|Dietary Supplement|Placebo|Placebo(35g/day) for 12 weeks
45775018|NCT01402375|Drug|Hydrocodone (first trial)|Patients will take 1 dose of Hydrocodone 5mg / Acetaminophen 500mg every 4 hours as needed for pain
45775019|NCT01402375|Drug|Codeine (first trial)|Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
45775020|NCT01402375|Drug|Oxycodone (for second trial)|Patients will take 1 dose of Oxycodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain
45775021|NCT01402375|Drug|Codeine (for second trial)|Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
45775022|NCT01402375|Drug|Oxycodone (third trial)|Patients will take 1 dose of Oxycodone 5mg / Acetaminophen 325 mg every 4 hours as needed for pain
45775023|NCT01402375|Drug|Hydrocodone (third trial)|Patients will take 1 dose of Hydrocodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain.
45775024|NCT01299103|Device|Pelleve Wrinkle Treatment System|comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System
45775025|NCT01302379|Drug|Metformin|Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
45775026|NCT01302379|Drug|Placebo|Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
45914621|NCT02045888|Device|ADRCs prepared by investigational Celution Device|ADRCs (low dose and high dose) to be used in investigational treatment will be prepared using the investigational Celution Device which is being investigated under IDE 15363
45448178|NCT02132260|Drug|Placebo Topical Cream|Placebo Topical Cream (Taro Pharmaceuticals Inc.) applied once-daily for two weeks.
45448179|NCT02130310|Biological|CureXcell®|CureXcell® is a cell based therapy obtained from donated whole blood. The blood is collected from healthy young adults, the white blood cells are separated and then activated by hypo-osmotic shock.
45448180|NCT02130310|Other|Placebo injection|Normal saline injected at each centimeter of ulcer bed
45448181|NCT02130388|Dietary Supplement|Zinc|
45448182|NCT02137564|Drug|gamma secretase inhibitor PF-03084014|Given PO
45914622|NCT02045888|Biological|Placebo|Placebo is visually matched solution
45914623|NCT02045914|Other|calcium ionophore solution|After microinjection of sperm into the oocyte, oocytes are incubated for 15 minutes in a 30 microlitre droplet of calcium ionomycin solution
45914624|NCT02045927|Other|sedation monitoring with RASS score|
45914625|NCT02045927|Other|sedation monitoring with BIS-Guided monitoring|
45775027|NCT01302379|Behavioral|Lifestyle intervention|Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.
45775028|NCT01302379|Behavioral|Standard printed dietary guidelines|Set of standard health education materials provided to participants at single time point (immediately after randomization)
45775029|NCT01404559|Device|Ossur Variflex prosthetic foot|Lightweight energy-storing prosthetic foot
45775030|NCT01404559|Device|Ossur Ceterus prosthetic foot|Shock-absorbing prosthetic foot
45635666|NCT05190029|Procedure|Physiotherapeutic evaluation|"A physiotherapeutic evaluation of the state of the RP and craniosacral system was performed according to the method of Andrzej Pilat and John E. Upledger.~The 14 primitive reflexes explored were: Moro reflex, cervical asymmetric, supine labyrinthine tonic, prone labyrinthine tonic, palmar grasp, plantar grasp, lateral trunk propulsion, parachute, Galant, search, cervical symmetric, Babinski, cochleo-palpebral and acoustic. These reflexes were considered as: inactive (0), or active (1).~In the evaluation of the craniosacral system, the following parameters were explored: dura mater sway, frontal bone, parietal bones, temporal bones, temporomandibular joint and sphenoid bone. These parameters were considered as: normal (0), or blockage (1)."
45635667|NCT04508543|Other|Non-verbal communication score|1. To compare nonverbal communication score (NCS, range 0 - 4) between minority and Caucasian non-Hispanic patients. The score is a sum of four components, each contribute to a score range 0 - 1. The four components are: percent time spent with open body language, percent time spent interacting with the patient or surrogate, distance from the patient along the long axis of the patient's body (distance from the head), and distance from the patient along the axis perpendicular to the patient's body (distance from the handrail).
45448183|NCT02137564|Other|pharmacological study|Correlative studies
45635668|NCT05117645|Diagnostic Test|Computed tomography|All patients will be examined by multislice CT scanner,Light speed 5X GE 8 detector elements scanner or GE Revolution Evo 128 multidetector elements scanner (GE Healthcare, Chicago, Illinois, United state) or Toshibe Alexion 16 detector elements scanner (Aplio 500, Toshiba Medical Systems, Otawara-shi, Tochigi 324-8550, Japan). Axial scanns will be done commences at 1 cm above the diaphragm and ending at lesser trochanters then coronal and sagittal reconstruction images will be exposed.
45635669|NCT03343301|Biological|Bemarituzumab|Administered by intravenous infusion over approximately 30 minutes
45635670|NCT03343301|Drug|Modified FOLFOX6|"Modified FOLFOX6 regimen consists of the following:~Oxaliplatin 85 mg/m² IV infusion over 120 minutes~Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours."
45635671|NCT03930251|Behavioral|Clinic-Based Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led twice weekly by a clinician in small groups.
45635672|NCT03930251|Behavioral|Partial-Remote Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led once weekly by a clinician in small groups and clients gain additional practice by accessing clinician-assigned computer-based exercises independently.
45635673|NCT03297827|Other|Serum and Urine measurement of cytokines.|To evaluate serum cytokine levels and identifying serum inflammatory markers (serum interleukin-33, IL-37, IL-36, IL-4, IL-6, IL-10, IL-17, IL-23, IL-1, TNF, PDGF, VEGFM TNFa, ANNULIN, MMP-9, MMP-12, NFk-B levels plus metabolic products like MPO, etc and glial factors like GMF, SI000B, GM6001) in patients with acute ischemic & hemorrhagic stroke.
45635674|NCT04507919|Drug|Dabrafenib|150 mg
45635675|NCT04507919|Drug|Trametininb|2.0 mg
45775031|NCT01404559|Device|Endolite Elite Blade prosthetic foot|Multi-axial prosthetic foot
45775032|NCT01351753|Drug|Metformin|
45775033|NCT01351753|Drug|Orlistat|
45775034|NCT01351753|Drug|Topiramate|
45775035|NCT01351753|Drug|Placebo|Placebo pills and capsules for metformin, orlistat and topiramate
45775036|NCT01353079|Biological|Short Ragweed Pollen Allergenic Extract|Daily sublingual administration of Short Ragweed Pollen Allergenic Extract up to 42 U Amb a 1 for a minimum of 8 weeks prior to the ragweed pollen season.
45775037|NCT01353079|Biological|Placebo|Placebo: Glycero-COCAs sublingual
45775038|NCT00104234|Drug|N-acetylgalactosamine 4-sulfatase|
45775039|NCT00104234|Drug|Placebo/rhASB|
45775040|NCT01303939|Diagnostic Test|magnetic resonance imaging (MRI) of the brain|High resolution three-dimensional T1-weighted magnetic resonance imaging (MRI) was obtained from each participant at one visit.
45775041|NCT00104858|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
45775042|NCT00104858|Drug|Cyclosporine|Given PO
45775043|NCT00104858|Drug|Fludarabine Phosphate|Given IV
45448184|NCT02137564|Other|laboratory biomarker analysis|Correlative studies
45448185|NCT02137642|Drug|RM-131|Double blind RM-131 (100 ug) will be delivered once by injection during study procedure.
45448186|NCT02137642|Drug|Placebo|Double blind placebo will be delivered once by injection during study procedure.
45775044|NCT00104858|Other|Laboratory Biomarker Analysis|Correlative studies
45775045|NCT00104858|Drug|Mycophenolate Mofetil|Given PO
45775046|NCT00104858|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo HSCT
45775047|NCT00104858|Other|Pharmacological Study|Correlative studies
45775048|NCT00104858|Biological|Rituximab|Given IV
45775049|NCT00104858|Radiation|Total-Body Irradiation|Undergo TBI
45775050|NCT01354015|Device|DRMS|USE OF TEXT MESSAGING SYSTEM
45775051|NCT01407523|Drug|Levetiracetam|"Formulation: concentrate for solution for infusion~Strength: Levetiracetam injection (100 mg/mL) will be packed in 5 mL glass vials (500 mg/5 mL)~Dosage: 1000 mg/day, 1500 mg/day, 2000 mg/day, 2500 mg/day or 3000 mg/day~Frequency: twice daily"
45775052|NCT00047060|Other|A matched peripheral donor stem cells|A matched peripheral donor stem cells
45775053|NCT00047060|Drug|cyclosporine|cyclosporine
45775054|NCT00047060|Drug|fludarabine|fludarabine
45775055|NCT00047060|Drug|Campath|Campath
45635676|NCT05136365|Drug|Xiongdan Wan|Xiongdan Wan is used as 450mg three times a day after meals with water for 8 weeks. The daily dose (e.g. 450mg/bag, 3 times/day) should be strictly controlled according to the experimental design. Patients should take medicine regularly every day under the guidance of doctors.
45635677|NCT03251729|Procedure|Cervical cerclage|Transvaginal cervical cerclage placed between 18 0/7 - 23 6/7 weeks
45448187|NCT02132338|Behavioral|The Education Health Program|The operation of the educational program for the group under intervention will consist of groups operating with the triad of diabetes mellitus (pathophysiology of the disease, physical activity and diet), to be held in five times (cycles) approach, an interval of three months being held between them . In each session, participants will be the same (under multidisciplinary team intervention), the content will also be the same, however, using different educational strategies. During the intervals between cycles these users will be monitored by phone by equity and / or nursing students of the Federal University of São João Del Rei properly trained to do so. The educational program will be developed in five times (T0, T3, T6, T9, T12) and with an interval of three months. At every moment the educational process will be conducted with three consecutive meetings with one week interval. In summary, 15 educational sessions with the experimental group will be held.
45448188|NCT02132416|Drug|NSAID|Will be used if tolerated.
45448189|NCT02132416|Drug|Opioids|Initially intravenous administration and when tolerated oral slow-release pils will be used.
45448190|NCT02132416|Drug|Thoracic Epidural anaesthesia|Given by specialists in anaesthesiology and intensive care.
45914626|NCT02045940|Drug|GSK2881078|Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg
45914627|NCT02045940|Drug|Placebo|Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.
45448191|NCT02132416|Drug|Paracetamol|1g QID will be given to all patients unless allergies.
45448192|NCT02132416|Procedure|Surgical management|Fracture stabilization
45775056|NCT01304407|Other|Calcium stable isotope|Subjects consume breakfast and 180 ml of calcium-fortified orange juice to which 20 mg of 46Ca stable isotope was added. Immediately after breakfast, subjects receive 5 mg of 42Ca intravenously.
45448193|NCT00137423|Drug|SU011248 (sunitinib)|37.5 mg/day, oral, continuous daily dosing
45775057|NCT00106106|Procedure|NMR-spectroscopy|Scans were performed on a 3T scanner using the echo-time-averaged PRESS sequence previously published to detect glutamate's resonance line at 2.35 ppm and average out the interferences from glutamine, NAA and the macromolecules.
45775058|NCT00106106|Drug|Oral acamprosate|For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
45775059|NCT01304641|Other|Atorvastatin Initiators|Retrospective database analysis no intervention performed.
45775060|NCT01304641|Other|Simvastatin Initiators|Retrospective database analysis no intervention performed.
46070164|NCT04116255|Other|Mandibular oral occlusal splint|The panoramic open-mouth and close-mouth radiographs of the first group(splint group) were taken, and intraoral and extraoral examinations were performed by an experienced dentist that also examined the radiographs. The upper jaw of the patients was measured with an alginate impression material, to obtain a hard plaster model. Then, using these models, a vacuum plate machine made a customized mandibular oral occlusal splint suitable for each patient's teeth. The suitability of the splints was checked and confirmed by the dentist on the first and seventh days of use. The patients were asked to use these splints at night (for at least six hours) throughout the study.
45448194|NCT02137720|Behavioral|Telephonic Diabetes Self-Management Support|
45448195|NCT02137720|Other|Educational Print Materials|
45448196|NCT02137798|Device|Radio-frequency catheter ablation|Radio-frequency atrial fibrillation catheter ablation includes circumferential PV isolation and voltage-map guided substrate modification, which means low voltage zone (amplitude < o.5 mV) will also be ablated.
45448197|NCT02137876|Procedure|Blood Draws|Patients will be asked to provide blood for immune tests.Patients will not take any study medications, all the research will be performed on blood donated for the study.Patients will donate about 20mls of blood (2 tbls)to be used to determine the subject's blood group and tissue typing (genetic).Results and the patient's contact information will be maintained in a database that is accessible only by the investigators and study personnel conducting the study.For the duration of this study, the investigator will contact patients by phone to request additional samples when needed. Study staff may ask patients donate more blood on short notice (1 day). This will consist of 60-120 ml (6-12 tbls) of blood.The frequency of blood collection will not exceed more than 2 times per week.The total amount of blood collected from subjects will not exceed 360 ml (1.5 cups) within any eight week period throughout the two year timespan patients may be asked to participate in this study.
45448198|NCT01077557|Other|No Antiretroviral (ARV) Drug Exposure|No pharmacy dispensing of an ARV drug
45448199|NCT01077557|Drug|Any Antiretroviral (ARV) Drug Exposure|Pharmacy dispensing claim for any ARV drug
45448200|NCT02132494|Behavioral|Physical activity|
45448201|NCT02130700|Drug|VT-464: given orally twice daily in 28-day cycles|Oral VT-464 given twice daily, in continuous 28-day cycles at the recommended Phase 2 dose
45448202|NCT02130700|Drug|VT-464: given orally once daily in 28-day cycles|Oral VT-464 given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
45448203|NCT02130778|Drug|Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline|infusion of synthetic GLP-1 (1.5 pmol/kg/min) saline
45448204|NCT02130778|Other|500 ml 0.9% saline|infusion of saline
45448205|NCT02137954|Drug|Lidocaine|
45635678|NCT03251729|Drug|Vaginal progesterone|Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks
45635679|NCT03248843|Drug|KN035|Four cohorts dosed at 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg, and 10 mg/kg weekly. All cohorts are administered by subcutaneous injection (SC).
45635680|NCT02696785|Drug|Ixekizumab|Administered SC
45635681|NCT02696785|Drug|Placebo|Administered SC
45635682|NCT02696785|Drug|Adalimumab|Administered SC
45914628|NCT02045953|Device|VENTOLIN Mini-Spacer|VENTOLIN mini-spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
45448206|NCT02137954|Drug|Placebo|
45775061|NCT01305265|Device|cuff manometer|endotracheal tube cuff will be inflated to 22-26 cm H20 using cuff manometer
45775062|NCT04545320|Behavioral|Usual care control group|Health education
45635683|NCT05117567|Combination Product|Personal protection package|A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and MMP-tailored behavioural change communication (BCC) package
45635684|NCT02004262|Biological|GVAX Pancreas Vaccine|
45635685|NCT02004262|Biological|CRS-207|
45635686|NCT02004262|Drug|Chemotherapy|Investigator's choice of one of the following commercially available products: gemcitabine; capecitabine; fluorouracil with or without leucovorin; irinotecan; or erlotinib.
45635687|NCT02004262|Drug|cyclophosphamide|
45635688|NCT05117411|Diagnostic Test|OCTA and pseudophakin cystoid edema|Patients underwent OCT angiografia after cataract surgery
45635689|NCT01675427|Other|Interleukin 28B testing|Blood sampling for ILB28 genotyping
45635690|NCT02394067|Other|Radiological Imaging|magnetic resonance imaging and magnetic resonance venography scans
45635691|NCT03166267|Device|External fixator|Tibia fracture (AO 41-43) treated with external fracture fixation (large external fixator)
45635692|NCT02393833|Procedure|Blood samples collection|"Blood samples to be collected at the following time points:~Baseline, (after the completion of induction chemotherapy and, if randomized to CM maintenance, before start of CM maintenance.)~Months 12, 18 and 36 after start of induction chemotherapy~At time of confirmatory evidence of progression"
45448207|NCT02138032|Behavioral|Gains Framed Message|
45448208|NCT02138032|Behavioral|Loss Framed Message|
45635693|NCT02393599|Drug|Lorcaserin|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
45635694|NCT02393599|Drug|Placebo|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
45635695|NCT02393599|Drug|Cocaine Infusion|Screening / Session 1, Study Day -2: 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine Baseline/ Session 2, Study Day 1: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Baseline / Session 3, Study Day 2: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline Treatment / Session 4, Study Day 9: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Treatment / Session 5, Study Day10: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline
45448209|NCT02786836|Drug|13C-Methacetin|"The test substrate in this study, ¹³C-methacetin solution for single-use oral administration (75 mg in 150 ml purified water), is administered orally or via feeding tube, rapidly absorbed, exclusively metabolized by hepatic mixed function oxidase via O-demethylation, mainly by cytochrome P450 enzyme, subtype 1A2, into acetaminophen and formaldehyde. The formaldehyde is then transformed through two successive oxidative steps to ¹³carbon dioxide, the quantity of which is measured in exhaled breath as a ratio of 13C to 12C.~The nasal or intubated breath sampling investigational device (ID) circuit continuously transports the breath sample from the patient to the BreathID® MCS device before and following administration of the 13C-methylacetanilide test substrate."
45775063|NCT04545320|Behavioral|HIIT group|Once-a-week HIIT
45775064|NCT04545320|Behavioral|MICT group|Once-a-week MICT
45775065|NCT01305655|Drug|Glucarpidase|Patients treated with Glucarpidase if the 24 hour levels of MTX is >250 µM, 36 hour levels >30 µM or 42 hours levels >10 µM together with a reduced kidney function will be compared with patients in just below the tricking values.
45775066|NCT04442438|Other|Monthly moral case deliberation|Once per month, ICU professionals will take part in moral case deliberation. As part of the intervention, two or three ICU professionals (physicians and nurses) are tasked with selecting a case for moral discussion. Moral case deliberation is attended by around thirty individuals per month per unit. A feedback system will be developed used to spread the knowledge/insights from the case deliberation to all professionals in the unit.
45635696|NCT02393365|Other|Questionnaire|All patients admitted to the one day clinic for surgery and gastroenterology will be asked, after signing an informed consent, to fill in a questionnaire about HCV risk factors.
45635697|NCT02393365|Procedure|HCV serology|"In case of a pre-operative blood sample an HCV serology will also be done as part of a routine pre-operative screening.~In patients where no pre-operative blood sample is done an additional consent will be asked to perform a blood sample for HCV serology. This qualifies the study as 'interventional' according to the Belgian legislation."
45635698|NCT02402491|Drug|12 months of P2Y12 receptor antagonist|All subjects will be received 12 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
45635699|NCT02402491|Drug|24 months of P2Y12 receptor antagonist|All subjects will be received 24 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
45635700|NCT02402491|Drug|Aspirin|The maintenance dose of aspirin is 100 mg daily, to be taken indefinitely.
45635701|NCT03166423|Drug|MU001 patches (Investigational)|Patches containing snail slime, calendula extract and propolis extract
45775067|NCT04753112|Drug|Sacubitril / Valsartan Oral Tablet [Entresto]|Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor
45775068|NCT01305811|Device|Acupuncture|Sterile insertive needles are applied by licensed, experienced practitioners.
45775069|NCT04770194|Drug|SP-8008 Prototype Capsule A|Oral
45775070|NCT04770194|Drug|SP-8008 Prototype Capsule B|Oral
45775071|NCT04770194|Drug|Placebo|Oral
45914629|NCT02045953|Device|Aerochamber Plus spacer|Aerochamber Plus spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
45914630|NCT02045966|Drug|Cocktail|Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg
45914631|NCT02045966|Drug|DCV 3DAA FDC|DCV 30 mg + ASV 200 mg + BMS-791325 75 mg
45914632|NCT02045966|Drug|BMS-791325|
45914633|NCT02045992|Dietary Supplement|caffeine|Five doses of 100mg of caffeine diluted in 100 ml of decaffeinated coffee. One dose every hour for five hours
45914634|NCT02046018|Other|ICCM delivered by VHT|VHT's deliver ICCM to children under five in their communities
45914635|NCT02046018|Other|ICCM delivered by VHT with Cell Phone|ICCM delivered to children under 5 by VHT trained in ICCM and given cell phones
45914636|NCT02046018|Other|No intervention|VHT's selected by no ICCM training given and no drugs or cell phones.
45635702|NCT03166423|Device|Conventional patches (Control)|Patches containing conventional formulations in medical devices for ulcers (hydrocolloids, activated charcoal silver, alginate, carboxymethylcellulose or hydrogel).
45635703|NCT02402569|Device|32 channels Deep Brain Stimulator|
45635704|NCT02402413|Procedure|Ultrasound|The patients will be subjected to ultrasound bi-dimensional or three-dimensional. Will Be calculated the ratio stroma/volume with both methods
45635705|NCT02402413|Procedure|Determination of concentrations of androgens|Determination of concentrations of serum levels of circulating androgens
45775072|NCT05606588|Behavioral|Playful sensorimotor training|"For the max. duration of the first in-hospital phase (3weeks), all children will receive supervised training. When children go home they will be supplied with a manual, specific exercises and the necessary training devices. Regular supervision will allow to ensure that the training is performed at maximum benefit. Each session will last for about 20 to 30 minutes in total, including a child-specific warm-up and cool-down. The children will be asked to maintain balance in a previously acquired short-foot-position, knees slightly flexed (30°), without shoes. Training will consist of 5 playful balance exercises chosen from a standardized pool of exercises according to the child's age, with increasing difficulty in order to allow for individual, optimal progression. Each of the 5 exercises will contain of 5 repetitions for 10sec. allowing for a 20sec. rest in between each set and a 1min rest between each exercise in order to avoid neural fatigue."
45775073|NCT01409239|Drug|Intravenous insulin|24 hr IV insulin administered according to hospital guideline
45635706|NCT02402413|Device|Three dimensional ultrasound probe|Capture of ovarian three dimensional volumes
45635707|NCT04440241|Procedure|regenerative treatment periimplantitis|"Full thickness buccal and lingual flaps will be performed. After debridement of the defect using hand and ultrasonic instruments and implant surface decontamination using titanium brushes (TiBrush®) and saline Regenerative treatment will be performed only in the intrabony component of type 1 peri-implant defects. Guided bone regeneration using a bone substitute (Bio-oss®) and a resorbable membrane (bio-gide®) will be performed in the intrabony and dehiscenses areas of the defect.~The surgeon will be blinded to the assignment of treatment until it is time to close the flaps."
45635708|NCT03166501|Drug|Lanicemine|Three 60 min parenteral infusions over a 5 day period
45635709|NCT03166501|Drug|Placebo|Three 60 min parenteral infusions over a 5 day period
45635710|NCT02402257|Behavioral|CVC Train the Trainer|Trainees receive a simulation-based mastery learning intervention and train-the-trainer program on central venous catheter insertion
45635711|NCT03166579|Behavioral|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
45635712|NCT01978912|Drug|KTP-001|KTP-001 is one time dose intradiscally.
45635713|NCT02393443|Drug|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
45635714|NCT02393443|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
45635715|NCT01977898|Drug|Morphine|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
45635716|NCT01977898|Drug|Saline|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
45635717|NCT02393287|Other|Eribulin (ReProLine)|this is an observational trial ; there is no intervention
45775074|NCT01409239|Drug|Subcutaneous Insulin|basal bolus insulin using carb counting technique and insulin analogues
45775075|NCT00108524|Behavioral|Low carbohydrate ketogenic diet|A low-carb diet limits carbohydrates - such as grains, starchy vegetables and fruit - and emphasizes dietary protein and fat.
45635718|NCT02392975|Procedure|Fast MR|Enrolled subjects will undergo fast MR within 24 hours of CT completion. Subjects will be scanned using one of 2 Philips Ingenia MR 3T scanners. The estimated duration of the fast MR is less than 5 minutes, even if up to 2 sequences are repeated for motion.
45914637|NCT02046031|Drug|Ginkgolides Meglumine Injection|25 mg, ivdrip, once.
45914638|NCT02046044|Drug|Digoxin|
45635719|NCT02392975|Procedure|Computed Tomography|The Investigator will recruit children in whom a head CT is ordered as standard of care for TBI. Consenting subjects will undergo fast MR shortly after CT and results will be compared.
45635720|NCT05744479|Drug|Metformin|Metformin oral, 2000mg/day, for 24 weeks.
45635721|NCT05744479|Drug|Placebo|Oral placebo for 24 weeks
45914639|NCT02046044|Drug|Ivabradine|
45775076|NCT00108524|Drug|Orlistat|In addition to the low fat diet, Orlistat is taken 3 times daily.
45775077|NCT00108524|Behavioral|Low-fat diet|Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake
45635722|NCT05744479|Behavioral|Lifestyle Intervention|Participants from both groups will meet a dietician and a diabetes educator at the study start to obtain advice regarding healthy diet, portion size, and meal planning to improve physical health. All participants will be invited to monthly group meetings to learn skills which will help them in a variety of wellness areas such as physical exercises and diet. Attendance in these sessions will be encouraged but not mandatory, and attendance will be recorded. Fidelity with these interventions will be captured using diet and physical activity questionnaires at RCT start, midpoint and end, and end of open label phase.
45775078|NCT01410097|Behavioral|Lifestyle intervention|Intensive Lifestyle Intervention that includes diet, physical activity, and behavior modification. The goal of the ILI intervention was for individuals to achieve and maintain a loss of at least 7% of initial body weight.
45775079|NCT01410097|Behavioral|Diabetes Support Education|It offers an educational program to participants including developing support groups. Providing such benefits helps retain these participants in the trial.
45775080|NCT05606354|Other|Intervention group|Experimental
45635723|NCT02003638|Drug|Niacin|Niacin titrated to 6000 mg daily
45635724|NCT02003638|Drug|Placebo|Placebo provided in the same pill quantity as niacin arm
45635725|NCT05232253|Device|Cystoelastometer - Urodynamics Testing|The non-invasive cystoelastometer device connects to the drainage end of urinary catheter that the patient uses for routine daily catheterization. Once urine flows into the device a pressure measurement is recorded and stored in the device along with the time and date. The remaining urine is then evacuated through the catheter and device and the cystoelastometer records the volume of urine evacuated. The measurement(s) of bladder pressure and volume as well as the time and date can later be transmitted wirelessly to a smart phone that contains an app for the device.
45635726|NCT02393131|Radiation|Hippocampal avoidance WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
45635727|NCT02393131|Radiation|Conformal WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
45635728|NCT04670536|Device|PASS LP implants|Thoraco lumbar arthrodesis
45635729|NCT04670536|Device|PASS DEGEN|Thoraco lumbar arthrodesis
45635730|NCT04670536|Device|PASS TULIP PRIME|Thoraco lumbar arthrodesis
45635731|NCT04649398|Drug|Nimodipine|If application of nimodipine is clinically indicated patients will be enrolled in the study protocol according to the inclusion and exclusion criteria. The clinically appropriate route of administration will be administered according to the recommended regimen of the study drug; i.e. within the first 10-14 days intra-venous infusion and thereafter oral administration. Intra-arterial infusion will be performed due to severe cerebral vasospasm with impending stroke.
45635732|NCT02696317|Device|Senofilcon A contact lenses with HydraLuxe™|Contact lenses worn during Period 1 or 2, as randomized
45635733|NCT02696317|Device|Senofilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
45635734|NCT02393053|Procedure|Treatment with subepithelial connective tissue graft (SCTG)|Miller Class I or II gingival recessions were treated with subepithelial connective tissue graft (SCTG)
45635735|NCT02393053|Procedure|Treatment with non-pedicled buccal fat pad graft (BFPG)|Miller Class I or II gingival recessions were treated with non-pedicled buccal fat pad graft (BFPG)
45635736|NCT01959412|Drug|Indacaterol 27.5 mcg|indacaterol 27.5 mcg twice daily inhaled once via inhaler
45635737|NCT01959412|Drug|Indacaterol 37.5|Indacaterol 37.5 mcg once daily, inhaled once via inhaler
45775081|NCT02093702|Behavioral|Physical activity and exercise education and behaviour counseling from a Registered Kinesiologist and a YMCA Wellness Coach|
45775082|NCT02093702|Behavioral|Unstructured Physical Activity and Exercise Education|
45775083|NCT04404530|Drug|Palynziq|Participants will take Palynziq as prescribed by their genetics doctor. In accordance with the Palynziq Risk Evaluation and Mitigation Strategy (REMS) protocol, patients will have their first injection of Palynziq at the Emory Genetics Clinic under the supervision of a physician. After initiating therapy, patients will continue to mail in blood spot filter papers and 3-day dietary records to their clinic providers as standard components of clinical care.
45775084|NCT00052442|Drug|pralatrexate|
45775085|NCT01410409|Other|Neuromuscular training (NEMEX-TJR)|60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
45914640|NCT02046083|Drug|arachid|
45775086|NCT01410409|Drug|Paracetamol|1 g x 4/day
45775087|NCT01410409|Drug|Burana|400 mg x 3/day for three weeks
45775088|NCT01410409|Drug|Pantoprazol|20mg x 1/day for three weeks
45775089|NCT01410409|Behavioral|Dietary counseling|For participants with a BMI equal to or >25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
45775090|NCT01410409|Behavioral|Patient education|"The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden."
45914641|NCT02046109|Procedure|Repair|
45914642|NCT02046109|Procedure|Replace|
45914643|NCT02046161|Procedure|colonoscopic examination in colon cleansing room|All patients drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
45635738|NCT01959412|Drug|Indacaterol 55 mcg|Indacaterol 55 mcg once daily, inhaled once via inhaler
45635739|NCT01959412|Drug|Indacaterol 75 mcg|Indacaterol 75 mcg once daily, inhaled once via inhaler
45635740|NCT01959412|Drug|Indacaterol 150 mcg|Indacaterol 150 mcg once daily, inhaled once via inhaler
45635741|NCT01959412|Drug|Placebo|Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher
45635742|NCT02402101|Device|Procedure: active tDCS|Intensity 2 mA during 20 minutes
45635743|NCT02402101|Device|Procedure: sham tDCS|sham condition as delivered by the stimulator
45635744|NCT02402179|Other|Tryptophan|Tryptophan will be supplied at 13.2, 26.4, 39.7, or 52.9% of requirement; sourced from crystalline amino acid and white cornmeal maize.
45635745|NCT02401945|Drug|DE-120|
45635746|NCT02401945|Drug|Aflibercept|
45635747|NCT01977820|Drug|Sapropterin|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and 24-Week study period.
45448210|NCT02130856|Device|Neonatal kit|"Contents of the neonatal kit:~Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.~4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.~Sunflower oil emollient (50 mL)~ThermoSpot~Mylar infant sleeve~Click to heat warmer (http://www.heatinaclick.ca/products/pocket_size.html) in a fitted cloth pouch.~Handheld electric scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Lady Health Worker."
45775091|NCT01410409|Procedure|TKR|Surgical treatment with insertion of total knee replacement following standard procedures.
45775092|NCT01410409|Other|Insoles|"The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).~The participants will be advised to use the insoles in all shoes."
45635748|NCT01977820|Drug|Placebo|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and Placebo tablets matching to sapropterin will be administered orally once daily during the 24-Week study period.
45635749|NCT02402023|Behavioral|Contingency Management (CM)|CM is standard care plus monetary payment delivered contingent on abstinence.
45635750|NCT02402023|Behavioral|Standard of Care (SC)|Standard of care consists of smoking cessation counseling sessions and nicotine patches.
45635751|NCT05744401|Drug|AL002|Administered via intravenous (IV) infusion
45635752|NCT02392897|Behavioral|High Eating Frequency|Free-living participants will complete a 21-day high eating frequency (high EF) Phase in which consume all daily energy at 6 eating occasions.
45635753|NCT02392897|Behavioral|Low Eating Frequency|Free-living participants will complete a 21-day low eating frequency (low EF) Phase
45635754|NCT02003014|Drug|Pioglitazone|Pioglitazone Tablets
45635755|NCT03166345|Other|Treatment of Thin Endometrium|This is a trial to improve endometrial thickness by autologous injection of PRP into the Uterine Cavity compared with CSF or no treatment.
45635756|NCT04411498|Diagnostic Test|Fibromyalgia diagnosis in patients with SSc|American College of Rheumatology (ACR) FMS diagnostic criteria set:It is evaluated by the common pain index [WPI] and symptom severity (SS) scale [19]. Diffuse pain index [WPI]; It is a scale that can be scored between 0-19 and obtained by indicating the aching regions of the patient during the last 1 week. Right shoulder, left shoulder, right hip [gluteal region], left hip [gluteal region], left chin, right chin, left upper arm, left lower arm, right upper arm, right lower arm, left upper leg, left lower leg, includes right upper leg, right lower leg, chest, neck, abdomen, upper back, lower back. Symptom Severity Scale [SSS]; evaluates weakness, tired awakening and cognitive functions. In addition, muscle pain, weakness, irritable bowel syndrome, memory problems, headache, abdominal pain, numbness, dizziness, insomnia, depression, constipation, irritability, dry mouth etc. It also evaluates somatic symptoms.
45635757|NCT02392819|Dietary Supplement|Panax ginseng|Pananx ginseng is provided prior to a standardised breakfast, effects on test variables are determined at fasting and repeatedly postprandially the breakfast
45635758|NCT02392819|Dietary Supplement|Placebo|
45635759|NCT01977352|Drug|Liposomal bupivacaine|liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)
45635760|NCT01977352|Drug|Bupivacaine 0.25%|20 cc of bupivacaine 0.25%
45635761|NCT03166033|Other|the disease|Observation the patients and non-patients
45635762|NCT03166189|Biological|bone marrow-derived MSC and HRT|"Transplantation procedure to endometrial cavity is performed with ultrasound guidance on menstrual cycle day 5-6 through uterine cervix using cater for embryo transfer with 1 ml of suspension containing 5 millions of autologous bone marrow-derived mesenchymal stem cells~Three cycles of HRT following MSC transplantation;~Pipelle-biopsy of endometrium on day 20 of hormonal replacement therapy of the last (third) cycle;~Frozen/thawed embryo transfer 3-6 months after transplantation."
45635763|NCT03166189|Other|hormonal replacement therapy|"standard treatment of hypoplastic endometrium or Asherman's syndrome:~Three cycles of HRT preceding frozen/thawed embryo transfer;~Frozen/thawed embryo transfer."
45635764|NCT03166111|Drug|lidocaine gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
45635765|NCT03166111|Drug|placebo gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
45635766|NCT02001688|Drug|Kamada-AAT for Inhalation, 80mg|
45635767|NCT02001688|Drug|Placebo|
45635768|NCT02001688|Drug|Kamada-AAT for Inhalation, 160mg|
45775093|NCT01356277|Behavioral|Action-focused problem-solving|"Adherence Support Team (patient, parent, Coach)~standardized education on immunosuppressive medications~identification of adherence barriers~'Action-Focused Problem-Solving' to address barriers selected as most important by the patient"
45775094|NCT01356277|Device|Electronic pillbox monitoring, dose reminders, and feedback|"Electronic adherence monitoring with feedback of past 3 months of electronic monitoring data at 3-month intervals~text message, email, or visual cue dose reminders"
45635769|NCT05668507|Behavioral|REACHOUT Virtual Mental Health Support|"REACHOUT is a mobile app which delivers peer-led mental health support to adults with type 1 diabetes. The mobile app has three support features:~One-on-one support delivered by a Peer Supporter. Participants will be able to review Peer Supporter profiles and connect with one of their choosing.~Group support delivered via a 24/7 chat room~Face to face support delivered via virtual happy hours"
45635770|NCT02392741|Other|Physical exercise program|The intervention consists to an exercise program composed by a daily post prandial, 10' after breakfast, lunch and dinner, totaling 150' weekly, for eight weeks.
45775095|NCT01410565|Drug|Apaziquone|Apaziquone 4 mg in 40 mL diluent
45635771|NCT03114943|Biological|NBP608|Preparation of the Oka/SK strain of live, attenuated varicella virus
45635772|NCT03114943|Biological|Varivax|Preparation of the Oka/Merck strain of live, attenuated varicella virus
45775096|NCT01410565|Drug|Placebo|Placebo for Double Blind Phase
45635773|NCT05117021|Drug|Caudal Epidural Block using 0.25% plain bupivacaine dose 1 ml / kg and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine dose 0.5 ml / kg|Caudal Epidural Block and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine
45635774|NCT02001064|Behavioral|Care4Today v2.0 mobile application + electronic monitoring of adherence|Care4Today mobile application will send automated medication alert messages to HIV-infected persons. The alert messages are customizable and automated, and real-time results are viewable within the application. The Care4Today intervention is designed to improve adherence to ART medications among HIV-infected persons who experience adherence difficulties over standard of care.
45635775|NCT02392585|Procedure|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
45635776|NCT02392585|Procedure|Triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
45635777|NCT03068273|Device|Real-time CGM data|
45635778|NCT02392663|Other|Hypertonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
45635779|NCT02392663|Other|Hyaneb solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
45635780|NCT02392663|Other|Isotonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
45635781|NCT02000752|Device|Acupuncture|
45635782|NCT02000752|Device|Sham acupuncture|Sham point acupuncture
45635783|NCT02982941|Drug|Enoblituzumab|enoblituzumab administered IV weekly for up to 96 weeks
45635784|NCT02392117|Drug|insulin degludec|Tresiba® will be prescribed by the physician under normal clinical practice conditions and will be obtained/ purchased from the chemist based on physician prescription. No treatment given.
45635785|NCT02812433|Drug|Sildenafil|sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
45635786|NCT02812433|Drug|Ora-Blend|Ora-Blend, 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
45635787|NCT02392039|Drug|Pegfilgrastim|6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.
45775097|NCT01357135|Drug|Metformin|
45775098|NCT01357135|Drug|Sitagliptin|
45775099|NCT01357135|Drug|Sulfonylurea|
45775100|NCT01357135|Drug|Antihyperglycemic Medication|
45775101|NCT02324335|Drug|Brilacidin|Oral Rinse used 3 times daily for 7 weeks
45775102|NCT02324335|Other|Placebo|
45775103|NCT01411501|Other|acupuncture|"Thrust and lift the needle to achieve De Qi. After being needled, the points will be punctured again using auxiliary needles 2 mm lateral to the first needle, and to a depth of 2 mm without manual stimulation. Put the electric stimulator on the pair of needles with a continuous wave, 20Hz. The current intensity is increased to the patients' maximum tolerance and then slightly reduced to a bearable level (0.1-1.0 mA).~Huatuo Brand needle (φ0.30×25mm,φ0.30×40mm,φ0.30×50mm, produced by Suzhou Medical Appliance Factory) and G6805-1A electro-acupuncture apparatus(produced by Shanghai Huayi Medical Instrument Co. Ltd.) will be used.~Five sessions/week in the first 2 weeks, three sessions/week for in the last 2 weeks."
45775104|NCT01411501|Drug|mosapride citrate|4-week oral use of mosapride citrate, 5mg, three times daily 0.5 hour before meal
45775105|NCT03008473|Device|video laryngoscope and chest CT iminge|
45775106|NCT03008473|Device|Conventional intubation of uniblocker|
45635788|NCT02392039|Drug|Loratadine|"Group 1 - Cycles 1 and 3: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 2 and 4: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days."
45635789|NCT02392039|Other|Placebo|"Group 1 - Cycle 2 and 4: Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 1 and 3 : Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days."
45635790|NCT02392039|Behavioral|Questionnaires|Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs.
45635791|NCT03995693|Dietary Supplement|Solution ingestion|Two ingestion modalities will be attributed (participant is blinded) in random order: a placebo and a glucose solution. The placebo contains water and a non-caloric sweetener (stevia) in order to reproduce the taste of the glucose solution. The glucose solution contains 6% glucose per volume, labelled with 13C. Both solutions will be administered in 8 doses: a bolus (333 mL) at rest, 30 minutes before the start of exercise, 167 mL immediately before exercise, 167 mL every 15 minutes during arm cranking, 125 mL immediately before concentric or eccentric pedalling and at 15 and 25 minutes of this last exercise period. In total, 1250 mL of solution will be administered during the experimental protocol.
45775107|NCT01309867|Device|Investigational Toric Lens|Bausch & Lomb investigational toric contact lens worn on a daily wear basis for 2 weeks.
45914644|NCT02046187|Dietary Supplement|Ketogenic Diet|Patients/families meet with the study dietician after surgery to discuss the ketogenic diet (KD), ask questions and plan clinic visits. Before radiation and chemotherapy begins, training takes place about the diet, meal planning and ketone/glucose monitoring. Ketosis will begin with the help of the dietitian one week before radiation begins. The patient will follow a classic 4/1 KD during chemo-radiation, followed by a modified Atkins diet during monthly chemotherapy. At the end of this period patients will follow a normal low carbohydrate diet similar to a Diabetic diet. The dietitian will follow the patient over the course of treatment. The patient will take and record ketone and glucose blood levels daily from start to end of treatment MRI scan, and meet with the dietitian weekly during radiation, at follow-up visits and on an as-needed basis.
45914645|NCT02046187|Radiation|Radiation therapy|Patients receive standard dose (60Gy/30 fractions) external beam radiation
45635792|NCT03995693|Behavioral|Constant load arm cranking|The participants will perform 45 minutes of arm cranking on a specialized ergometer at a power output corresponding to 30% of their concentric cycling VO2max, previously measured.
45635793|NCT03995693|Procedure|Expired gas sampling|Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution.
45635794|NCT03995693|Procedure|Indirect respiratory calorimetry|A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution.
45635795|NCT03995693|Procedure|Blood sampling|A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain vein open. 10 mL of blood will be collected immediately before ingesting the solution for a total of 80 mL.
45635796|NCT03995693|Behavioral|Measure of maximal voluntary contraction force production|Maximal voluntary bilateral knee extensions (3 trials of 3-4 seconds each) will be performed on a chair equipped with force sensors to measure peak force production. These measurements will be done before the first ingestion, immediately before exercise, during the transition between arm cranking and concentric or eccentric cycling, and at the end of the exercise protocol.
45635797|NCT03995693|Diagnostic Test|Measure of muscle electrical activity (EMG)|Surface electrodes will be placed on the biceps and quadriceps to measure EMG throughout the exercise protocol.
45635798|NCT03995693|Diagnostic Test|Measure of central and cutaneous temperatures|Wireless sensors will be placed on the skin of the arm, chest, back, abdomen, thigh and calf using adhesive tape. A wireless thermometric pill will be ingested the morning of the experiment. These will allow the measurement of skin and central temperatures throughout the exercise protocol.
45635799|NCT03995693|Diagnostic Test|Measure of perceived exertion, pain perception and affective response|"100 points scales (CR100) will be used to measure perceived exertion and pain perception immediately before ingesting the gas sampling. At the same time, affective responses will be assessed using the Feeling scale."
45775108|NCT01309867|Device|PureVision Toric Lens|Currently marked Bausch & Lomb PureVision Toric Lens worn on a daily wear basis for 2 weeks.
45775109|NCT04351633|Other|questionnaire assesment|questionnaire assesment
45775110|NCT01357525|Radiation|Stereotactic Body Radiation Therapy (SBRT)|"An SBRT plan will be created by a medical physicist based on the PTV contoured on the CT scan. The plan will be to deliver fractionated SBRT to the isodose line best encompassing the PTV:~12 Gy x 3 fractions (36 Gy total)"
45775111|NCT01310179|Genetic|Ad/PNP and fludarabine monophosphate|Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
45775112|NCT01412281|Biological|Virosomal influenza vaccine (AdImmune HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA Antigen) 2011/2012, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
45914646|NCT02046187|Drug|Temozolomide|patients receive standard dose (75 mg/kg/day) temozolomide by mouth daily with radiation for 6 weeks. patients will also have standard maintenance dose (150-200 mg/kg/day) for five days each month for 12 cycles following radiation course.
45635800|NCT03995693|Procedure|Measure of sweat and urine production|Sweat production and sampling will be performed by measuring body weight before and after exercise, after voiding the bladder. Mass loss through the urine and gases will be accounted for in order to compute sweat production. A sweat sample will be collected using a cotton gauze placed into a plastic collector affixed in the upper back of the participants. A urine sample will be taken from the urine collected at the end of the exercise period. Urine and sweat volumes along with respective urea concentrations will be used to compute protein oxidation during exercise.
45635801|NCT02000440|Drug|Losmapimod|Losmapimod (micronized GW856553X) will be supplied as a film coated white, 7 mm round, biconvex, plain faced, tablet. Oral doses of losmapimod, 7.5 mg (1 tablet) or 15 mg (2 tablets), will be taken twice daily (BID) with food and swallowed whole (not chewed or crushed)
45635802|NCT02781701|Device|Tongue Trainer|"The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.~Therefore, participants will work out about 20 minutes a day for 6 weeks."
45635803|NCT03106363|Drug|delta 9 tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
45775113|NCT01412281|Biological|Virosomal influenza vaccine (CSL HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using CSL HA antigen) 2011/2012 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
45635804|NCT03106363|Drug|placebo delta 9 tetrahydrocannabinol|A single placebo cannabis cigarette (<0.03% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the placebo cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
45635805|NCT03106363|Drug|Alcohol|A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol to tonic water to obtain a target blood alcohol content of 0.08mg%.
45635806|NCT03106363|Drug|Placebo alcohol|A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
45775114|NCT01359007|Drug|Irinotecan, Oxaliplatin, Leucovorin, 5-FU|5-FU 2400 mg/m2 IV continuous infusion for 46-48 hours Days 1-3 for 2 weeks 5-FU 400 mg/m2 IV Bolus Day 1 Oxaliplatin 85 mg/m2 IV over 120min +/-30 min. Day 1 Irinotecan 180 mg/m2 IV to run over 90 min +/- 30 min Day 1 Leucovorin (Before bolus 5-FU) 400 mg/m2 IV over 120 min. +/- 30 Day 1 May give oxaliplatin and leucovorin concurrently
45914647|NCT02046213|Drug|E2006|Single oral 10mg dose of 100 uCi [14C]E2006
45775115|NCT01361113|Drug|Pazopanib|800 mg orally once daily for 8 weeks, prior to nephrectomy
45775116|NCT01414153|Drug|4.0 mg iSONEP|4.0 mg iSONEP given monthly intravitreously for 4 months
45775117|NCT01414153|Drug|0.5 mg iSONEP|0.5 mg iSONEP given monthly intravitreously for 4 months
45775118|NCT01414153|Drug|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea given monthly intravitreously for 4 months
45775119|NCT01414153|Drug|sham injection|administered monthly for 4 months
45914648|NCT02046239|Procedure|Suture Group|
45635807|NCT04413071|Other|Passed infection of SARS-CoV-2|This is an observational design. Participants have passed infection from SARS-CoV-2 and a cardiac assessment is performed.
45635808|NCT03106519|Drug|Liposome bupivacaine + bupivacaine|
45635809|NCT05657587|Device|SPRINT PNS|Each subject will have 2 leads placed for 60 days. The Sprint system delivers mild electrical stimulation to the shoulder. The Sprint system includes up to two leads (small wires) that are placed through your skin in your shoulder. The leads attach to devices worn on your body that delivers stimulation (stimulators).
45775120|NCT03008629|Device|Podofix nail brace|Podofix nail brace
45775121|NCT03008629|Device|Combiped nail brace|Combiped nail brace
45775122|NCT03008629|Device|Podofix and then Combiped nail brace|Podofix and then Combiped nail brace
45775123|NCT01311895|Drug|H2O|2 mg IV hydromorphone
45775124|NCT01311895|Drug|1+1|"1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
45775125|NCT03009175|Device|Implantable Cardiac Defibrillator, Cardiac Resynchronization Therapy Defibrillator/Pacemaker|
45775126|NCT01362127|Drug|Chemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
45914649|NCT02046239|Biological|Staple Group (control)|
45914650|NCT02046278|Device|LifeSeal™ Kit|
45914651|NCT02046291|Drug|Romiplostim|Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks. The dose will be assigned at the time of subject registration. This is a dose escalation to determine the maximum tolerated dose. The doses include 4 mcg/kg/dose, 6 mcg/kg/dose, 8 mcg/kg/dose, and 10 mcg/kg/dose.
45914652|NCT02046304|Drug|Gemcitabine|Starting dose: 400 mg/m2 by vein on days 1, 8, 22, 29, 43, and 50.
45914653|NCT02046304|Radiation|Radiation Therapy|Radiation therapy dose of 50 Gy in 25 fractions at 2.0 Gy per fraction. Radiotherapy given once daily (Monday through Friday) for 5 weeks.
45914654|NCT02046343|Behavioral|Health education|Group health education sessions delivered by a promotora approximately 90 minutes in length. In the PA arm, health education incorporates at least 30 minutes group exercise.
45914655|NCT02046343|Behavioral|Telephone Counseling|Brief (10 minute) telephone counseling calls delivered by promotoras using motivational interviewing techniques. The counseling calls will emphasize behavior change strategies, including self-monitoring, goal setting, reinforcement, problem solving, stimulus control, and enlisting social support.
45914656|NCT02046343|Other|Newsletter|Educational, motivational and informational newsletters tailored for each community and hand-delivered by promotoras to participant homes.
45914657|NCT02046343|Other|Environmental Change|Create a site atmosphere that promotes PA and increases the number of PA program offerings.
45914658|NCT02046356|Procedure|MESS-RFA|
45635810|NCT02687815|Drug|vitamin D3 4000 IU|The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.
45635811|NCT02687815|Drug|Placebo|The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.
45635812|NCT05742451|Other|kids yoga|"The kids yoga was applied to the intervention group for 8 weeks, once a week (8 sessions), 40 minutes per session, by a yoga instructor occupational therapist.~Kids yoga training included: 5-minute warm-up consisting of jogging, jumping, stretching, relaxation exercises; 20 minutes of asanas (positions) consisting of standing, sitting, prone, supine postures and pranayamas (breathing exercises) consisting of vigorous inspiration and expiration, slow and rhythmic alternating nostril breathing; 10-minute yogic games about balance, reaction time and agility; meditation with focus for 5 minutes with resuscitation techniques."
45635813|NCT03916133|Diagnostic Test|Intervention group|6s PBV mapping will be conducted
45635814|NCT05654701|Drug|Palopegteriparatide (TransCon PTH)|The investigational drug Palopegteriparatide (TransCon PTH) is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
45635815|NCT03915665|Drug|Chlorhexidine|Chlorhexidine gel 1% one single application after mechanical biofilm removal through manual instruments
45448211|NCT02132728|Other|Flaxseed or rice raw powder ingestion|The experimental groups received isocaloric diets and different proportions of carbohydrates, and the introduction of 60g of brown flaxseed or rice raw powder. Flaxseed and raw rice were crushed weekly by minimal particle type mill and appropriate sieves for fine grinding grain with a degree to 250 mm/micrometers. After crushing flaxseed and raw rice, they were weighed in semi-analytical balance. The addition of flaxseed or raw rice powder was made in the collation (40 g added to milk) and lunch (20 g added to baked beans). The volunteers received flaxseed or rice raw powder, portioned to be used for 42 days, including the weekends.
45635816|NCT03915665|Device|Air-powder|Erythritol powder using air-powder device
45635817|NCT01959334|Drug|Nasal Glucagon (NG)|
45635818|NCT01959334|Drug|Glucagon IM|
45635819|NCT04722419|Other|Probe meal|The probe meal will be served in 112 Kcal portions (16 g white bread, 10 g cheese, 10 g jam, 3.25 g butter, and 50 mL orange juice) up to the level of maximal satiation.
45635820|NCT02687581|Device|IO-therapy Glasses|12-hour of 50% intermittent occlusion therapy on the fellow eye.
45635821|NCT02687581|Device|patch|6-hour of eye patch on the fellow eye
45635822|NCT04173754|Procedure|Motion Style Acupuncture Treatment(MSAT)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
45635823|NCT02248805|Drug|MGD007|MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent.
45635824|NCT05737849|Other|No Intervention|As this is an observational study, no intervention will be administered in this study.
45635825|NCT02021279|Device|MatriStem Pelvic Floor Matrix|
45635826|NCT02021279|Procedure|native tissue repair|
45775127|NCT01362127|Radiation|Radiochemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
45635827|NCT05652439|Other|Observational retrospective data collection|Observational retrospective data collection of the incidence of adverse cardiovascular and cerebrovascular outcomes
45914659|NCT02046408|Other|Computer Tablet|
45914660|NCT02046421|Drug|mifepristone|Given PO
45635828|NCT02392273|Drug|Ausanil|Patients with Primary Headache disorders will receive Ausanil in the context of usual and routine clinical care.
45635829|NCT04813705|Radiation|Reduced dose|The patients with CMR and more than 70% PMR at 25th fraction will receive reduced-dose radiotherapy for 30 fractions.
45914661|NCT02046421|Drug|carboplatin|Given IV
45635830|NCT04813705|Radiation|Conventional dose|The patients who do not achieve CMR or 70% PMR at 25th fraction will receive conventional dose radiotherapy for 33 fractions.
45635831|NCT04813705|Drug|Chemotherapy|The patients with stage II will receive concurrent cisplatin during Intensity modulated radiotherapy (IMRT), and stage III-IVA patients will receive platinum based induction chemotherapy every 21 days for at least two cycles followed by concurrent cisplatin during IMRT.
45775128|NCT01312519|Device|OnControl Bone Marrow Biopsy and Aspiration System|Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest for the purpose of aspiration and core biopsy collection.
45775129|NCT01312519|Device|Manual bone marrow sampling device|Hollow needle with a t-shaped handle that is pushed into the bone for the purpose of collecting bone marrow aspiration and core biopsy samples.
45775130|NCT01312675|Device|S.A.F.E.BT|Five (5) S.A.F.E.BT treatments within a 7 day treatment period.
45775131|NCT01362205|Drug|Dexmedetomidine|
45775132|NCT01362205|Drug|Placebos|Inactive placebo (normal saline)
45775133|NCT01362907|Device|Delefilcon A contact lens|Investigational, silicone hydrogel, single vision, soft contact lens for daily disposable wear
45914662|NCT02046421|Drug|gemcitabine hydrochloride|Given IV
45914663|NCT02046421|Other|laboratory biomarker analysis|Correlative studies
45914664|NCT02046421|Other|pharmacological study|Correlative studies
45635832|NCT01958476|Drug|Neonatal Morphine Solution|"Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than 12. Dosing will be weight and symptom based. A double dummy design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose."
45635833|NCT01958476|Drug|Methadone|"Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a double dummy design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose."
45635834|NCT01958476|Drug|Phenobarbital|"A second line medication will be added once the infant reaches maximum doses of the study drug (morphine or methadone) for continued scores generally >8. Infants will be loaded with 20mg/kg of phenobarbital with the option to re-load with 10mg/kg q8-12 hours for 2 more doses if needed for continued high scores. Maintenance therapy of 5mg/kg/day will be initiated 12 - 24 hours after the last loading dose. Phenobarbital trough levels will be monitored with goal levels of 20 - 30 mcg/mL.~Phenobarbital will be weaned only after the infant has been weaned off of the study drug. Weaning will begin 48 hours after the study drug has been stopped by 20% of the maximum total daily dose every 3 days for scores <8. An infant may be discharged home 48 - 72 hours after the first wean. The remaining wean will be outlined in the discharge prescription, and followed up on by study staff with the goal of the phenobarbital discontinuation within a 2 week period."
45635835|NCT04809181|Drug|Azacitidine in Combination With Venetoclax|Azacitidine in combination with venetoclax
45635836|NCT05737381|Other|Differential oxygen tension|By culturing the embryos in a differential O2 set-up, changing the O2 tension from reduced (5% O2) to ultralow (2% O2) from day 3 to day 5 of embryo development in vitro, we mimic the physiological differential changes in O2 as the embryo migrate from the oviduct to the uterus and develops in vivo.
45775134|NCT01362907|Device|Etafilcon A contact lens|Commercially marketed, HEMA-based, single vision, soft contact lens for daily disposable wear
45775135|NCT00052910|Drug|cisplatin|Given IV
45775136|NCT00052910|Drug|epirubicin hydrochloride|Given IV
45775137|NCT00052910|Drug|fluorouracil|Given IV
45775138|NCT00052910|Drug|leucovorin calcium|Given IV
45775139|NCT00052910|Radiation|radiation therapy|Given 5 days a week for 5 weeks
45775140|NCT01416025|Drug|Prospective TDM Arm|Voriconazole dose will be adjusted based on per protocol obtained TDM levels
45775141|NCT01363843|Drug|FOLFOX6|FOLFOX6
45775142|NCT01363843|Radiation|RT with concurrent chemotherapy|IMRT 50.4Gy with chemotherapy
45775143|NCT01363843|Procedure|Surgery|
45775144|NCT01417741|Device|Acupuncture Needle|A small 1.8 mm needle to be placed in the P6 acupuncture point on the wrist
45635837|NCT05736679|Device|In2Care EaveTube|In2Care® EaveTubes (ETs) comprise 15 cm diameter, 20 cm long ventilation tubes with removable netting inserts that are placed in the wall under the roof of houses where they attract malaria mosquitoes at night, block them from entering the house, and contaminate them with a lethal dose of insecticide. In2Care® ET netting inserts have an electrostatically charged coating treated with bio-actives in powder form, which kills insecticide-resistant mosquitoes through high active ingredient dose transfer.
45635838|NCT05734807|Drug|Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs)|Subjects will receive NrtIs therapy for 24 weeks.
45635839|NCT05734807|Drug|HH-003 and NrtIs|Subjects will receive HH-003 20 mg/kg intravenously Q2W and NrtIs therapy for 24 weeks.
45635840|NCT05734807|Drug|HH-003, NrtIs and PEG-IFN-α|Subjects will receive HH-003 20 mg/kg intravenously Q2W, NrtIs therapy and PEG-IFN-α 180μg SC QW for 24 weeks.
45635841|NCT05746585|Behavioral|The Talk Web-based resources|Educational videos and podcasts for parents and their sons
45635842|NCT01057121|Drug|Lenalidomide|Lenalidomide is administered daily on days 1-21 of a 28-day cycle. The maximum duration of treatment is 12 28-day cycles. Sequential cohorts were entered at 10 mg/day, 15 mg/day, 20 mg/day and 25 mg/day using a 3+3 design to determine the MTD
45635843|NCT02695537|Drug|Epidiolex|Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
45635844|NCT04692389|Device|Jalosome soothing gel|This study has not got other intervention
45635845|NCT04679909|Biological|AdCOVID|Administered intranasally
45775145|NCT00112112|Biological|FluMist|"The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.~brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm."
45775146|NCT00112112|Biological|Placebo|Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
45635846|NCT04679909|Other|Placebo|Administered intranasally
45635847|NCT04620941|Diagnostic Test|reticulocyte/hemoglobin (Ret-He) ratio|Ret-He values will be studied on the day (1st day), 4th and 7th days of the diagnosis of ventilator-associated pneumonia in patients hospitalized in the intensive care unit.
45635848|NCT04615871|Drug|semaglutide|semaglutide 0.25 mg s.c. on Day 0 after randomization, then semaglutide 0.5 mg s.c. on Day 7, Day 14 and Day 21
45635849|NCT04210349|Biological|Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
45635850|NCT04210349|Biological|Trivalent Influenza Vaccine 1 SP Shz TIV1|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
45635851|NCT04210349|Biological|Trivalent Influenza Vaccine 2 SP Shz TIV2|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
45775147|NCT02092298|Drug|Mitomycin C|Mitomycin C 30 mg delivered laparoscopically for 60 minutes.
45775148|NCT02092298|Drug|Cisplatin|Cisplatin 200 mg delivered laparoscopically 60 minutes, 2-8 weeks after completion of systemic chemotherapy.
45635852|NCT01353313|Drug|Hydrocortisone|"Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents), to be administered either intravenously or orally if no intravenous line is available at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
45635853|NCT01353313|Drug|Placebo|"Saline placebo to be administered either intravenously or orally if no intravenous line is available, at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
45635854|NCT04991129|Drug|WJ01024|5mg: WJ01024, Q4W, twice per week
45635855|NCT04991129|Drug|WJ01024|10mg: WJ01024, Q4W, twice per week
45635856|NCT04991129|Drug|WJ01024|20mg: WJ01024, Q4W, twice per week
45635857|NCT04991129|Drug|WJ01024|40mg: WJ01024, Q4W, twice per week
45635858|NCT04991129|Drug|WJ01024|60mg: WJ01024, Q4W, twice per week
45635859|NCT04991129|Drug|WJ01024|80mg: WJ01024, Q4W, twice per week
45635860|NCT04991129|Drug|WJ01024|100mg: WJ01024, Q4W, twice per week
45635861|NCT04991129|Drug|WJ01024|120mg: WJ01024, Q4W, twice per week
45635862|NCT04991129|Drug|WJ01024|140mg: WJ01024, Q4W, twice per week
45635863|NCT04991129|Drug|WJ01024|1600mg: WJ01024, Q4W, twice per week
45635864|NCT04888793|Diagnostic Test|Serologic immune response evaluation|Detection of total and neutralizing antibodies against SARS-CoV-2
45635865|NCT04802447|Drug|SurVaxM|Each participant will receive 4 doses of SVN53-67/M57-KLH (SurVaxM) spaced two weeks apart. This phase of treatment is known as the prime-boost phase and will take 6 weeks to complete. After completion of the prime-boost phase of treatment, the participant will receive a dose ofSVN53-67/M57-KLH (SurVaxM) every 3 months for up to two years
45635866|NCT04746989|Drug|Probenecid|Probenecid claim is used as the exposure group.
45635867|NCT04746989|Drug|Allopurinol|Allopurinol claim is used as the reference group.
45635868|NCT04446221|Other|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
45448212|NCT02130934|Procedure|Cardiac 3D MRI|
45635869|NCT02691247|Biological|CLBS03 Low Dose|
45635870|NCT02691247|Biological|CLBS03 High Dose|
45635871|NCT02691247|Biological|Placebo|
45635872|NCT04412915|Other|Labor induction|Labor induction with oxytocin or prostagladin
45635873|NCT04383821|Device|Double-Trunk Mask|The DTM (oxygen delivery system) is worn by the patient for 30 minutes.
45448213|NCT02131012|Drug|Intravitreal Celecoxib|1-4 mg intravitreal celecoxib
45448214|NCT03550690|Device|Large Volume Paracentesis|Insertion of a plastic tube into the abdomen and draining off ascitic fluid under local anaesthetic, removing the drain afterwards
45448215|NCT03550690|Device|Rocket Indwelling Pleural Catheter|A small plastic tube under the skin which is left in place so that the fluid can be drained if it builds up again
45635874|NCT04383821|Device|Non-Rebreather mask|The NRM (standard oxygen delivery system) is worn by the patient for 30 minutes.
45635875|NCT04520009|Behavioral|Activity Restriction|Standard post-operative activity instructions (i.e., no bending, twisting, or lifting more than 10 lbs for 4 weeks, no return to work until cleared to do so).
45635876|NCT04520009|Behavioral|Activity as Tolerated|Instructions advising activity as tolerated and return to work based on patient discretion
45635877|NCT04349423|Behavioral|Social Media Usage Manipulation|Behavioral Intervention of social media usage.
45635878|NCT03988985|Other|Patient-targeted feedback|The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
45635879|NCT03988985|Other|GP-targeted feedback|The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
45635880|NCT04163393|Procedure|Percutaneous Coronary Intervention|PCI with robotic assistance
45635881|NCT04163393|Device|Percutaneous Coronary Intervention using R-One assistance|PCI with robotic assistance
45635882|NCT04428749|Diagnostic Test|Yale Swallow Protocol|The YSP is a three-step method consisting of an assessment of the patient's awareness, the patient's ability to follow simple instructions and finally the patient's ability to drink 90 ml water from a cup or by straw without stopping, choking or coughing.
45635883|NCT04428749|Diagnostic Test|FEES (fiberoptic endoscopic evaluation of swallowing)|"The FEES will be performed bedside by an experienced occupational therapists. The patient will be sitting upright in a chair and be given 1) 2 spoons of applesauce, 2) 2 spoons of water, 3) several sips of water, 4) 90 ml of water. All items colored blue.~The FEES will use a single-use AMBU rhino-laryngo scope slim and the AMBU monitor. the examination will be terminated in case of aspiration below the vocal cords."
45775149|NCT02092298|Drug|Sodium Thiosulfate|Loading dose of 7.5 gm/M2 of Sodium Thiosulfate infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by continuous infusion pump over 12 hours.
45775150|NCT02568566|Other|Laboratory Biomarker Analysis|Correlative studies
45635884|NCT04393103|Drug|Intralipid, 20% Intravenous Emulsion|"Atropine will be administered to ALL PATIENTS by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till com-plete atropinization. Following this an infusion of 10-20% of the atropinizing dose was given every hour.~Group A (Control Group) : Follow Up of 30 patients.~Group B (Study Group): 30 patients will receive intralipid AS AN ADJUVANT Three boluses of IFE 15 mg/kg were given over 3 minutes, 20 minutes apart."
45914665|NCT02046447|Drug|Primary Cervical Dystonia (Trihexyphenidyl)|After the baseline testing these subjects will receive a dose of trihexyphenidyl 2 mg an hour prior to the second functional magnetic resonance imaging (fMRI) scan. This is to test the change in cerebral blood flow based on blood-oxygen-level dependent (BOLD) contrast during a precision gripping task after administration of trihexyphenidyl compared to change in BOLD contrast during a precision gripping task. The subjects will be done with the study after the second MRI scan has been completed.
45635885|NCT04393103|Drug|Intravenous Atropine Sulfate|Atropine will be administered to ALL PATIENTS in Group A and group B by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till complete atropinization. Following this, an infusion of 10-20% of the atropinizing dose was given every hour.
45635886|NCT03868475|Procedure|Vacuum-assisted percutaneous excision|The intervention group will undergo the vacuum assisted percutaneous excision (VAPE). All VAPE procedures will be performed on a digital supine table using the ATEC© Breast Biopsy System hand piece (Hologic) with a 9-gauge needle and a 10 or 20 mm aperture providing 6-mmHg of suction strength to completely excise the breast lesion.
45635887|NCT03868475|Procedure|Open surgical excision|The control group will undergo standard open surgical excision of the breast lesion. This will be done in the operating room using preoperative image-guided localization with radioactive seed (I-125) or in the procedure room of the Breast Care Centre if appropriate (i.e. lesion is palpable and localization is not required).
45448216|NCT02132806|Procedure|Piezosurgery with biomaterial mp3 + bracket|
45448217|NCT02132806|Procedure|Piezosurgery with biomaterial mp3|
45448218|NCT02132806|Procedure|Piezosurgery|
45448219|NCT00137267|Behavioral|Time limited case management|This group will receive treatment as usual on Acute Psychiatry and at the Day Treatment Center along with an enhanced Time Limited Case Management community linkage intervention (TLC). Patients assigned to TLC will be offered enhanced services that begin on Acute Psychiatry and continue for a total of eight weeks through the community and Day Treatment Center transition.
45448220|NCT00137267|Behavioral|Health Education|This group will receive treatment as usual in Acute Psychiatry and at the Day Treatment Center in addition to participating in four group and one individual health education sessions (i.e., the attention control group). The length of the health education sessions (four group sessions and one individual session) will match the amount of attention provided to the treatment group. The health education sessions will cover topics such as nutrition, disease prevention, injury prevention, and healthy aging.
45448221|NCT03549910|Procedure|APRVplus protocol|Physiology-driven APRVplus protocol
45448222|NCT03549910|Procedure|Low tidal volume ventilation|Low tidal volume lung protective ventilation
45448223|NCT01077635|Drug|Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)|HIV-1 infected children currently or having ever been exposed to FPV (+/- 20% of 18mg/kg BID + RTV)
45635888|NCT04238585|Behavioral|Mobile messaging|Mobile health messages
45635889|NCT04677803|Drug|BT200|BT200 is a PEGylated synthetic RNA oligonucleotide
45775151|NCT02568566|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
45775152|NCT00115076|Drug|Efalizumab|24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection
45775153|NCT05605808|Other|Aerobic exercises|Aerobic exercise by using the treadmill, two times per week. Its intensity was equivalent to 60-85% of each patient's maximum heart rate and lasted 20 minutes in the first week and 30 minutes in weeks 2-12.
45775154|NCT05605808|Other|Diet protocol|A specific diet for three months is designed to boost the immune system through edible seeds and nuts which are rich in proteins, fats, fibers, minerals, and vitamins.
45635890|NCT04671953|Drug|BMS-986165|Specified dose on specified days
45635891|NCT04671953|Drug|Metformin|Specified dose on specified days
45775155|NCT00254072|Procedure|3.5 mm vs 4.8 mm Stapler During Laparoscopic Gastric Bypass|The procedure consists of a creation of a small gastric pouch and rerouting the small bowel to bypass the stomach and duodenum. There are two anastomoses in this procedure: the gastrojejunostomy and the jejunojejunostomy.
45775156|NCT00151814|Drug|Olmesartan medoxomil|Children less than 6 years old: oral suspension or tablets equal to 0.3 mg/kg; 20 mg or 40 mg tablets for older children depending on weight.
45775157|NCT00153842|Drug|Bexarotene (targretin)|"Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).~Level 1: 300 mg"
45775158|NCT00153842|Drug|Bexarotene (targretin)|"Bexarotene oral capsules will be administered daily beginning on the intitial day of chemotherapy (Day 1).~Level 2: 400 mg"
45775159|NCT01314001|Drug|Varenicline|Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
45775160|NCT01314001|Drug|Placebo|"Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally~Week 1 - 6: 21mg placebo patch Week 7 - 8: 14mg placebo patch Week 9 - 11: 7mg placebo patch"
45775161|NCT01314001|Drug|Transdermal Nicotine|Week 1-6: 21mg nicotine patch Week 7-8: 14mg nicotine patch Week 9-11: 7mg nicotine patch
45635892|NCT04640753|Procedure|Endoscopic procedure for achalasia|POEM procedure will have a high technical feasibility, with effective clinical resolution of symptoms both in the short and long term.
45635893|NCT04616105|Drug|REGN6490|Single dose of REGN6490
45635894|NCT04616105|Drug|Placebo|Placebo matching single dose of REGN6490
45635895|NCT04585061|Drug|Lidocaine Hydrochloride|1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle
45635896|NCT04585061|Device|Virtual reality device (Harga Miniso Vr Glass 3d terbaru)|"Virtual reality device (Harga Miniso Vr Glass 3d terbaru) is placed on the face of the patient, playing a video of Tom and Jerry cartoon.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized"
45635897|NCT04585061|Dietary Supplement|Xylitol|Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized while xylitol tablet putted under tongue
45635898|NCT04531007|Diagnostic Test|iFR/ FFR/ IVUS/ OCT|intermediate lesion evaluation with intracoronary physiology and imaging
45635899|NCT03902717|Procedure|Minimally invasive cardiac surgery|Patients will undergo minimally invasive cardiac surgery
45775162|NCT00154466|Behavioral|cardiac rehabilitation|Those in the training group participated in a 3-month rehabilitation training program at an exercise intensity of 55% to 70% of peak oxygen uptake (VO2); those in the nontraining group continued their usual lifestyle.
45775163|NCT00117806|Behavioral|Arm 1|SCI-VIP: Supported employment implemented for veterans with spinal cord injury.
45775164|NCT00117806|Behavioral|Arm 2|Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center
45635900|NCT04349501|Other|Restriction Spectrum Imaging Magnetic Resonance Imaging|RSI is a multicompartment model of diffusion MRI that uses data acquired at multiple b-values to distinguish varied diffusion speeds (restricted intracellular, hindered extracellular, and approximately free diffusion).
45635901|NCT03874091|Procedure|bilateral ESP block with 0,25% Bupivacaine+ Adrenaline|Regional anaesthesia technique performed under ultrasound guidance before surgery
45635902|NCT03874091|Procedure|ESP block continuous infusion with 0,125% Bupivacaine+Adrenaline|Continous infusion of Local Anaesthetic (LA) given postoperatively via the catheter.
45635903|NCT03874091|Drug|Morphine PCA pump|Morphine given postoperatively.
45448224|NCT02138422|Biological|Xilonix|
45448225|NCT02138422|Biological|Placebo|
45635904|NCT03786965|Other|On-pump CABG|On-pump CABG
45635905|NCT03786965|Other|Off-pump CABG|Off-pump CABG
45635906|NCT03786965|Other|Pump-assisted CABG|Pump-assisted CABG
45775165|NCT01363999|Drug|atorvastatin|single dose of atorvastatin on day 1
45775166|NCT01363999|Drug|dalcetrapib|single dose of dalcetrapib on day 1
45635907|NCT03786965|Other|Valve Repair Procedure without CABG.|Valve Repair Procedure without CABG (open heart procedure).
45635908|NCT03786965|Other|Valve Repair Procedure with CABG.|Valve Repair Procedure with CABG (open heart procedure).
45635909|NCT03735017|Other|Non-Interactive Virtual Reality Walking|"Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
45635910|NCT03735017|Other|Interactive Virtual Reality Walking|"Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
45635911|NCT03729557|Procedure|Nephrectomy|Unilateral nephrectomy
45635912|NCT03722693|Device|Functional electrical stimulation based treatment|Two types of multi-pad electrodes will be used during this study. Both were designed for covering the extrinsic muscles of the hand. Electrodes are comprised of 8 pads that act as anodes and 32 pads that acted as cathodes. The shape and distribution of the conductive pads within the electrodes were designed considering the motor points for achieving different movement primitives (wrist extension, wrist flexion, fingers extension, fingers flexion, index extension, index flexion, thumb extension, and thumb flexion). Each participant will receive 5 assessment sessions:1. before starting the interventions, 2. after the 7 days of standard care, 3. after 7 days of first FES based protocol, 4.after another 7 days of standard care and 5. after seven days of the other FES based intervention
45775167|NCT04388930|Other|Pre-operative assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing"
45635913|NCT01362491|Drug|Ibuprofen Sodium|Single-dose of ibuprofen sodium tablets (equal to 400 mg ibuprofen)
45635914|NCT01362491|Drug|Standard Ibuprofen|Single-dose of standard ibuprofen tablets (400mg)
45775168|NCT04388930|Other|Post-operative day 3 assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
45635915|NCT01362491|Drug|Placebo|Single-dose of placebo
45635916|NCT02687191|Biological|PF-05230907|PF-05230907 IV bolus injection
45635917|NCT02687035|Device|SAPIEN S3 valve|Transcatheter aortic valve replacement
45635918|NCT04515563|Behavioral|Stretching exercise|Control Group
45635919|NCT04515563|Behavioral|Low-frequency, moderate-intensity walking group|once-a-week walking exercise at moderate intensity
45635920|NCT04515563|Behavioral|High-frequency, moderate-intensity walking group|thrice-a-week walking exercise at moderate intensity
45635921|NCT04515563|Behavioral|Low-frequency, vigorous-intensity walking group|once-a-week walking exercise at vigorous intensity
45775169|NCT04388930|Other|Post-operative week 4-6 assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
45775170|NCT04388930|Other|Post-operative 3 month assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
45775171|NCT04388930|Other|Pre-operative 6 month assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
45775172|NCT04388930|Other|Post-operative month 12 recipient assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
45775173|NCT00257894|Drug|Baclofen|Dosing taken orally for a total of 12 days: 40mg/day vs. 0mg/day (placebo tabs). The 40mg condition will receive 15mg/day the first 3 days(Days 1,2,3), 30mg/day for 3 days(Days 4,5,6), and 40mg/day for 3 days(Days 7,8,9). Downward titration: 40mg/day condition will receive 40mg/day(Day 10), 20mg/day(Day 11), and 10mg/day(Day 12).
45775174|NCT00257894|Drug|Placebo|Matched placebo capsules containing inert filler taken orally for a total of 12 days
45635922|NCT04515563|Behavioral|High-frequency, vigorous-intensity walking group|thrice-a-week walking exercise at vigorous intensity
45635923|NCT05746507|Behavioral|Night Respite Care|(see description above)
45635924|NCT04477889|Other|Treatment for COVID-19|Patients treated for COVID-19
45635925|NCT03167749|Diagnostic Test|Laboratory test|Semen analysis and reproductive hormonal assay (free and total testosterone, luteinizing hormone, follicle-stimulating hormone , estradiol and prolactin hormone) for both patients and control group
45775175|NCT00258128|Drug|Salsalate|Active
45775176|NCT00258128|Drug|Placebo|Placebo for salslate, used only in the third trial
45775177|NCT01364623|Drug|Low dose testosterone nasal gel, single dose|Low dose testosterone nasal gel, single dose
45635926|NCT03684473|Behavioral|Online Mindfulness-Based CBT & Trauma-Informed Yoga Intervention|"8 Weekly Online modules consisting of one weekly video of yoga postures combined with breath awareness and daily guided meditation audios, and a breath technique manual form the foundation of the intervention. The trauma-informed component of the program uses specific language, movement cues, teacher qualities, and physical assists. The yoga intervention will emphasize full choice and control of the participant through invitational language such as, when you are ready, if you like before each body posture cue. Based on trauma-informed yoga best practices, a predictable foundation of yoga postures (with variations) will be followed in a consistent order each session to allow participants to anchor to the series."
45635927|NCT05726461|Device|AndroidAPS-rt-CGM;|Insulin therapy (aspart, lispro or glulisine) with AndroidAPS-rt-CGM.AndroidAPS-rt-CGM consists of three components:1) AiDEX G7 continuous glucose monitoring (an rt-CGM);2) Equil® insulin patch pump;3) AndroidAPS algorithm implemented in Android smartphone.
45635928|NCT05726461|Device|sensor augmented pump(SAP);|Insulin therapy (aspart, lispro or glulisine) with sensor augmented pump(SAP).SAP includes only Equil® insulin patch pump and AiDEX G7 continuous glucose monitoring.
45635929|NCT03560297|Behavioral|SeRenade Parent-Child Music Class|Parent-Child Music Class involving parent training, peer inclusion, and musical play
45635930|NCT03560297|Behavioral|Delayed Intervention|Participants receive intervention after delay
45635931|NCT02691013|Drug|Ramelteon|
45635932|NCT02691013|Drug|Placebo|
45635933|NCT03423407|Device|Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)|FDA approved scanner
45635934|NCT04256759|Drug|Dupilumab 300Mg Solution for Injection|Subcutaneous (SC) dupilumab selected for this study is 300 mg every 2 weeks for 18 weeks.
45635935|NCT03342989|Behavioral|Speed of Processing Training|This intervention is based on computer-administered tasks that are used to evaluate Useful Field of View test, which measures discrimination between visually presented stimuli in the presence of distractors
45635936|NCT03342989|Behavioral|Internet-Based Contact Control|This intervention provides social contact and mentally stimulating activities that do not target speed of processing
45635937|NCT03274505|Other|Questionnaires|"Questionnaires about excessive daytime sleepiness (Epworth scale), insomnia (Severity of Insomnia Scale), Restless Legs Syndrome, Chronotype (Horne and Ostberg questionnaire), Sleep apnoea syndrome (Berlin questionnaire)~Clinical evaluation~Routine neuropsychological evaluation (for stroke patients)~Routine Polysomnography for patients with high suspicion of sleep apnoea syndrome (SOS score (Epworth + Berlin) > 10)"
45775178|NCT01364623|Drug|Medium dose testosterone nasal gel, single dose|Medium dose testosterone nasal gel, single dose
45775179|NCT01364623|Drug|High dose testosterone nasal gel, single dose|High dose testosterone nasal gel, single dose
45914666|NCT02046447|Other|Controls Primary Cervical Dystonia (Trihexyphenidyl)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
45448226|NCT02132962|Dietary Supplement|Amino acid infusion|
45448227|NCT02132962|Other|Bloodsamples, Biopsies.|
45775180|NCT01364623|Drug|Medium dose testosterone nasal gel, multiple dose|Medium dose testosterone nasal gel, multiple dose
45775181|NCT00258206|Biological|rituximab|
45775182|NCT00258206|Drug|cyclophosphamide|
45775183|NCT01063907|Drug|KW-2478|Administered Days 1, 4, 8 and 11 of a 21 day cycle
45914667|NCT02046447|Other|DYT 1 Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
45448228|NCT02138500|Drug|PF-06372865|Single, oral dose administration of 10 mg PF-06372865 using tablet formulation.
45775184|NCT01063907|Drug|Bortezomib|Administered on Days 1, 4, 8 and 11 of a 21 day cycle
45775185|NCT01316263|Biological|Olaratumab|Administered IV
45775186|NCT03014765|Other|EDOP|no intervention
45775187|NCT03015857|Drug|phenylephrine|- phenylephrine; a vasopressor drug given to prevent post spinal hypotension
45635938|NCT02690701|Drug|Secukinumab 300 mg|"Secukinumab 300 mg was provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab consisted of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occurred on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home."
45635939|NCT02690701|Biological|Placebo|"Placebo was provided in 1 mL prefilled syringe. Each placebo dose consisted of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3, 4), then after four weeks at Week 8. At Week 12, patients were switched to receive 300 mg secukinumab once weekly for five weeks (Weeks 12, 13, 14, 15, 16) followed by monthly dosing through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occured on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home."
45635940|NCT04965389|Drug|Oral solution|Specified dose on specified days
45635941|NCT04965389|Drug|[14C]BMS-986177 Solution for Infusion|Specified dose on specified days.
45635942|NCT04965389|Drug|BMS-986177 Spray-dried Dispersion Capsules|Specified dose on specified days
45635943|NCT04957745|Other|Visual confusion|We will show peripheral target images on a background motion in a stereoscopic display. For the binocular visual confusion condition, the target peripheral image will be displayed on only one eye. For unilateral and bilateral monocular visual confusion conditions, the half-transparent peripheral image will be displayed on only one eye and both eyes, respectively.
45635944|NCT04122287|Drug|Levofloxacin|levofloxacinn-tetracycline-containing quadruple regimens
45635945|NCT04122287|Drug|tinidazole|tinidazole-tetracycline-containing quadruple regimens
45635946|NCT05746351|Drug|Dexmedetomidine|a group will receive epidural Bupivacaine with Dexmedetomidine in normal labor
45635947|NCT05746351|Drug|fentanyl|a group will receive epidural Bupivacaine with fentanyl in normal labor
45635948|NCT05746351|Drug|Nalbuphine|a group will receive epidural Bupivacaine with Nalbuphine in normal labor
45635949|NCT05403437|Other|Evaluation of pain|Painful areas will be marked on the body chart. The presence and severity of pelvic girdle pain will be determined by the Visual Analog Scale (VAS).
45635950|NCT05403437|Diagnostic Test|Evaluation of pelvic girdle pain diagnostic tests|Pelvic girdle pain diagnostic tests will be applied. The severity of the pain that occurs in positive tests will be evaluated with VAS.
45635951|NCT05403437|Other|Evaluation of activity limitation|The Pelvic Girdle Questionnaire will be filled.
45775188|NCT03015857|Drug|Norepinephrine|- norepinephrine; a vasopressor drug given to prevent post spinal hypotension
45635952|NCT02694757|Device|Ostom-i device|The Ostom-i alert (OIA) is a discrete novel device which clips onto any ostomy bag from edge to edge and measures the horizontal tension between the edges over time, as a result of stool volume in the ostomy. It is an FDA approved medical device.
45635953|NCT04760795|Other|PTSD Check List (PCL) scale|PTSD Check List (PCL) scale will be realized to evaluated post-traumatic stress disorder.
45775189|NCT03015857|Drug|Bupivacaine|intrathecal bupivacaine 10 mg will be given in both groups
45775190|NCT03015857|Drug|Fentanyl|intrathecal fentanyl 20 mcg will be given in both groups
45775191|NCT03015857|Drug|Placebo (normal saline)|
45775192|NCT03295487|Procedure|TVT-O|transobturator tape has been applied to all the patients in the study,and local estrogen vaginal cream is only applied to patients in group A
45775193|NCT03015935|Procedure|visual-assisted entry|First trocar entry will be performed with visual-assisted trocar
45775194|NCT03015935|Procedure|Veress entry|First trocar entry will be performed with Veress
45775195|NCT03016091|Drug|Pembrolizumab|anti PD-L1
45775196|NCT03206489|Device|noninvasive high-frequency ventilation (nHFOV)|noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in one of the preterm twins infants with respiratory distress syndrome
45635954|NCT04760795|Other|Brief COPE scale|Brief COPE scale dispositional version will be realized to evaluated usual coping strategies. It was assessed during the teleconsultations and post containment.
45635955|NCT04760795|Other|GAD-7 (Generalized Anxiety Disorder) scale (during containment)|GAD 7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.
45635956|NCT04760795|Other|Analog scale|Analog scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.
45635957|NCT04760795|Other|GAD-7 (Generalized Anxiety Disorder) scale (post containment)|GAD-7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during post containment.
45635958|NCT04760795|Other|Big Five Inventory (BFI) scale|Big Five Inventory (BFI) will be realized to evaluated personality.
45635959|NCT04760795|Other|Relationship Scales Questionnaire (RSQ)|Relationship Scales Questionnaire (RSQ) will be realized to evaluated attachment style.
45635960|NCT05720611|Behavioral|Digitally delivered gardening and healthy eating course|The intervention group will consist of a digitally delivered course designed to teach gardening, cooking and nutrition education to adults with risk factors for CVD. Participants will be invited to participate in 10 Zoom-based gardening and cooking education sessions. Zoom meetings will be facilitated by members of the study team, will present information to participants and will allow participants to ask questions and share their experiences with others. The materials will walk the participant through various aspects of starting and tending a garden.
45775197|NCT03206489|Device|nasal continuous positive airway pressure (nCPAP)|nasal continuous positive airway pressure (nCPAP) as a primary mode of ventilation in another of the preterm twins infants with respiratory distress syndrome
45775198|NCT03015779|Other|cultured autologous oral mucosal epithelial cell sheet|a prospective study,Before and after self control
45775199|NCT03015701|Drug|Mifepristone|a 19 norsteroid with anti-progesterone and anti glucocorticoid activity which competitively inhibits binding of the hormone to its receptor
45775200|NCT03015701|Other|Placebo|placebo matching mifepristone
45775201|NCT03047135|Drug|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until the patient completes the study, withdraws from the study or closure of the study.
45775202|NCT04353089|Other|Basic life support courses|4 hours certified basic life support courses
45775203|NCT01068821|Other|Gel pad|A gel pad (mattress) (approximately 3cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
45775204|NCT01068821|Other|Egg crate foam mattress|An egg-crate foam mattress (approximately 5cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
45775205|NCT03830021|Behavioral|Salt reduction program|Dietary and behavioural change program, led by nutritionists, including low sodium dietary advice; use of aromatic herbs and spices in food instead of salt; motivational activities; food diaries; restrict salty processed foods; eat more fresh foods and seasoning advice; problem solving exercises; digital bulletins; individual counselling reinforced at each clinic visit and shopping counselling at local supermarket.
45775206|NCT03830021|Behavioral|Healthy lifestyle program|Participants receive an educational healthy lifestyle program that includes 1) methods to cook healthier and the Mediterranean diet based on a high intake of fresh fruit and, vegetables, beans, grain legumes, lentils, nuts, cereals, and olive oil as source of fat; moderate intake of fish, poultry, yoghurt and cheese, low intake of salt, red meat, processed meats and sugar; 2) physical activity; 3) drink more water and reducing alcohol consumption; and 4) sleep education.
45775207|NCT04780061|Drug|Vitamin D3 50,000 IU|This is a loading dose of Vitamin D. Vitamin D (cholecalciferol [vitamin D3]) is a fat-soluble vitamin that is synthesized following ultraviolet radiation to the skin, naturally occurs in a few dietary sources and is available as a dietary supplement.
45635961|NCT05403281|Drug|DW6012|"Drug: DW6012 Single oral administration of DW6012 after an overnight fast~Drug: Dapagliflozin and Sitagliptin Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast"
45775208|NCT04780061|Dietary Supplement|Vitamin C/Zinc|This is a combination of Vitamin C and Zinc. Vitamin C (ascorbic acid, ascorbate) is a water-soluble vitamin that naturally occurs in many foods and is sold as a dietary supplement. It is required for the functioning of several enzymes and is important for the immune system. Zinc is one of the most abundant essential trace elements in the human body and is required for the function of several hundred enzymes and transcription factors.
45775209|NCT04780061|Dietary Supplement|Vitamin K2/D|This is a combination of Vitamin K2 (menaquinone-7) and vitamin D. Vitamin K (menaquinone-7 [vitamin K2]) is a fat-soluble vitamin found in foods and sold as a dietary supplement. Vitamin K plays a large role in synthesizing coagulation factors in the blood, and vitamin K deficiency has been associated with uncontrolled bleeding. Vitamin K1 (phylloquinone) is an alternate form of vitamin K found in foods and supplements; however, vitamin K2 has a better absorption profile50 and additionally plays a role in bone metabolism controlling the binding of calcium, especially in older adults, where it attenuates the rate of bone loss
45448229|NCT02138500|Drug|PF-06372865|Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
45448230|NCT02138500|Drug|PF-06372865|Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
45635962|NCT03158831|Drug|Placebo-Controlled Graded Drug Challenge|All patients receive a placebo followed by 30 minutes of observation. Patients then receive 1/10 of the treatment dose of the challenge drug followed by 30 minutes of observation. If no reaction, they will then receive a full dose of their challenge drug followed by 1 hour of observation. If they do not experience any reactions, they are deemed not to be allergic. All patients are asked to monitor for delayed reactions after the challenge. Patients are also called within 1 month of the challenge to determine if any delayed reactions occurred. Patients are called again within 1 year of the challenge to determine if they have subsequently taken the challenge drug and experienced any reactions.
45635963|NCT03165877|Other|Low-glycemic index|Subjects ate low-glycemic index lunches and dinners (<55%),consisting of salad, main course and dessert, respectively.
45635964|NCT03165877|Other|Control|Subjects ate standard lunches and dinners (>60%),consisting of salad, main course and dessert, respectively.
45775210|NCT04780061|Other|Microcrystalline Cellulose Capsule|Placebo equivalent of Vitamin C/Zinc and Vitamin D3.
45775211|NCT04780061|Other|Medium Chain Triglyceride Oil|Placebo equivalent of Vitamin K2/D
45775212|NCT04644731|Device|Aquadex™ System|Ultrafiltration for fluid removal
45635965|NCT03115099|Drug|LY3325656|Administered orally
45448231|NCT01561768|Biological|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: low dose; intramuscular injection, deltoid
45775213|NCT01070693|Procedure|Open mesh inguinal hernia repair|Inguinal hernia repair either with the bilayer mesh or the Lichtenstein technique
45775214|NCT01070693|Device|Prolene Hernia System|Prolene Hernia System
45775215|NCT01070693|Procedure|Lichtenstein technique|Lichtenstein technique
45775216|NCT02171819|Biological|IVACFLU-A/H5N1, 7.5 mcg|Contains 7.5 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose.
45775217|NCT02171819|Biological|IVACFLU-A/H5N1, 15 mcg|Contains 15 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose
45775218|NCT02171819|Other|Placebo Comparator|PBS, pH 7.2 in 0.5 mL single-dose vials.
45775219|NCT02172755|Drug|BIA 2-093|During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
45775220|NCT02173535|Device|etafilcon test contact lens Variant AP|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
45914668|NCT02046447|Other|DYT 1 Dystonia|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
45914669|NCT02046460|Drug|Acetylsalicylic acid|Acetylsalicylic acid, 300mg o.p.d.
45914670|NCT02046460|Drug|Vitamin K antagonist|Vitamin K-antagonists, target INR 2.0-3.0
45914671|NCT02046473|Procedure|Volumetric Flow in TIPS|Subjects who have a TIPS (transjugular intrahepatic portal-systemic shunt) for portal hypertension will undergo a clinical 3D ultrasound to determine if the TIPS is working properly. Additional ultrasounds will be obtained during the subject's clinically ordered ultrasound(s). These measurements will be taken by using a second ultrasound probe (plastic hand held device that is rubbed along the subject's abdomen). 15 minutes will be added to your clinically ordered exams that are completed 4 times a year.
45914672|NCT02046486|Drug|Ticagrelor 180mg whole tablets|
45914673|NCT02046486|Drug|Ticagrelor 180mg crushed and dispersed|
45448232|NCT01561768|Biological|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: medium dose; intramuscular injection, deltoid
45448233|NCT01561768|Biological|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: high dose; intramuscular injection, deltoid
45448234|NCT01561768|Biological|Novavax Trivalent vaccine|Trivalent Dose; intramuscular injection, deltoid
45448235|NCT01561768|Biological|cTIV|Preconfigured dose; intramuscular injection, deltoid
45448236|NCT01561690|Drug|ARRY-502, CRTh2 antagonist; oral|multiple dose, single schedule
45448237|NCT01561690|Drug|Placebo; oral|matching placebo
45635966|NCT03115099|Drug|Placebo|Administered orally
45635967|NCT03115099|Drug|Liraglutide|Administered subcutaneously
45635968|NCT03115099|Drug|Sitagliptin|Administered orally
45775221|NCT02173535|Device|etafilcon test contact lens Variant JG|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
45775222|NCT02173535|Device|etafilcon test contact lens Variant CS|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
45775223|NCT02173535|Device|etafilcon test contact lens Variant VC|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
45775224|NCT02173535|Device|etafilcon test contact lens Variant LA|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
45775225|NCT04621175|Dietary Supplement|EAA+W & Carbohydrate|Essential amino acid plus whey beverage with added carbohydrate
45775226|NCT04621175|Dietary Supplement|EAA+W & EAA|Essential amino acid plus whey beverage with added essential amino acid
45775227|NCT02987387|Device|SAPIEN XT THV|SAPIEN XT THV will be implanted in the pulmonic position.
45775228|NCT02986217|Other|regular structured assessment of surgical performance|
45775229|NCT02973737|Drug|pyrotinib|400 mg once daily
45775230|NCT02973737|Drug|placebo|400 mg once daily
45775231|NCT02973737|Drug|Capecitabine|1000 mg/m2 per day on day 1 through 14, every 21 days.
45775232|NCT02872025|Drug|Pembrolizumab|Injected intralesionally
45775233|NCT02872025|Biological|Intralesional mRNA 2752|Injected intralesionally
45775234|NCT02762669|Drug|Oxytocin|Oxytocin, 10-7mol/L to 10-5mol/L
45775235|NCT01072331|Drug|MP-513|MP-513 10 mg, once a day, for 4 weeks
45775236|NCT01072331|Drug|MP-513|MP-513 20 mg, once a day, for 4 weeks
45775237|NCT01072331|Drug|Placebo of MP-513|MP-513 placebo, once a day, for 4 weeks
45775238|NCT01072409|Device|Nucleus 5 Cochlear implant|Cochlear implant surgery
45775239|NCT01072409|Device|Cochlear implantation|Implantation
45775240|NCT01072643|Drug|Dexmedetomidine|This is a single center, dose escalation study of Dexmedetomidine in pediatric subjects with pulmonary hypertension (PVR>4WU) undergoing hemodynamic cardiac catheterization and vasoreactivity drug testing. Cohorts of 8 evaluable subjects will receive dose level 1, dose level 2, or dose level 3 of Dexmedetomidine.
45775241|NCT04352543|Behavioral|Active Video Game Exercise|Play during 30 minutes in the easy level
45775242|NCT04352543|Behavioral|Treadmill walking exercise|30 minutes (65 - 75% heart rate maximal)
45775243|NCT04352543|Behavioral|Sedentary Behavior|Quiet Rest: 30 minutes
45635969|NCT05746117|Device|Aktiia Device|The Aktiia Bracelet is a CE-marked medical device that will be used in accordance with its instructions for use. The bracelet non-invasively measures optical signals at the wrist, which are used to determine blood pressure. The bracelet comes with a bluetooth enabled upper arm cuff that can be used to take on-demand blood pressure measurements. All measurements are transmitted to a dashboard that a clinical pharmacist monitors during the participant's enrollment in the study.
45448238|NCT00137111|Drug|Prednisone, Dexamethasone, Vincristine, Daunorubicin|See Detailed Description sections for details on treatment interventions.
45635970|NCT05746117|Device|Upper arm cuff|A standard upper arm oscillometric cuff that can be used to take blood pressure at home.
45635971|NCT03165097|Drug|ACT-709478|Hard gelatine capsules for oral administration
45635972|NCT03165097|Drug|Placebo|Placebo capsules matching ACT-709478 capsules
45635973|NCT03165097|Drug|Midazolam|Midazolam oral solution (2 mg/mL) applied with a syringe
45635974|NCT03165097|Drug|ACT-709478 combined with midazolam|Hard gelatine capsules for oral administration (ACT-709478) to be taken first followed by Midazolam oral solution (2 mg/mL) applied with a syringe
45635975|NCT03165799|Behavioral|Mindfulness Education|Mindfulness Education
45635976|NCT05745961|Radiation|TSPO PET scan (11C-PBR28)|PET scan
45635977|NCT03165643|Diagnostic Test|OGTT|75 g glucose tolerance test was provided to all pregnant women during 24-28 weeks.
45635978|NCT04436003|Behavioral|Muscle and articulation chains GDS method|"A physiotherapy method adapting treatment to patient's terrain, or psychomorphology, using chosen techniques to balance tension between muscle chains, thus optimalizing posture and mouvement."
45635979|NCT04436159|Procedure|Addition of 360 fundoplication after crural closure|A total fundoplication was constructed in which the right and left part of the wrap was brought together in front of, and slightly to the right of the esophagus, and sutured with three interrupted stitches of 2-0 unabsorbable sutures from the GEJ and cranially to attain a length between the top and bottom sutures of at the most 2 cm. At least one wrap suture included the esophageal muscle-wall.
45775244|NCT04590209|Other|Blood sampling|Recruited patients will be subjected to 2 blood samples of 7 mL at day 0 for serological analysis and cell collection and to an additional blood sample of 7 mL at day 15 for serological analysis
45775245|NCT04590209|Other|Skin biopsy|Recruited patients will be subjected to a single skin biopsy at day 0 for histological and transcriptomic analysis
45775246|NCT01073657|Other|Supported Education|Rehabilitation counseling using peers to achieve educational goals
45775247|NCT01073657|Other|General Peer Support|Matched peer support for any personal goal other than education
45448239|NCT00137111|Drug|Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase|See Detailed Description sections for details on treatment interventions.
45448240|NCT00137111|Drug|Methotrexate, Cyclophosphamide, Cytarabine, Etoposide|See Detailed Description sections for details on treatment interventions.
45448241|NCT00137111|Drug|Mercaptopurine, Imatinib|See Detailed Description sections for details on treatment interventions.
45635980|NCT04436159|Procedure|Addition of 180 posterior fundoplication after crural closure|"The wrap was pulled dorsally around the distal part of the esophagus and GEJ, which was encircled approximately 180-200 degrees. First, the wrap was anchored with Gore-tex sutures, dorsally to the left crus with 3 sutures and then to the right crus with another 3 sutures.~Finally, the wrap was completed with 3-4 sutures, between the edges of the wrap and the right and left side of the esophageal wall, respectively."
45635981|NCT03165409|Biological|Nivolumab|Melanoma intervention
45635982|NCT03165409|Biological|Ipilimumab|Melanoma intervention
45635983|NCT05403125|Device|silver diamine fluoride, 38%|Topical application to all surfaces of the teeth
45635984|NCT05403125|Device|Sodium fluoride gel, 5000 PPM|Gel applied after application of silver diamine fluoride and dispensed for home use
45635985|NCT05701423|Drug|Natalizumab|Administered as specified in the treatment arm.
45635986|NCT02795351|Drug|Sildenafil|Single oral administration of active or placebo one week apart
45635987|NCT02795351|Drug|Placebo|
45448242|NCT00137111|Procedure|chemotherapy, intrathecal chemotherapy|See Detailed Description sections for details on treatment interventions.
45635988|NCT05403047|Drug|Fumarate, Tenofovir Disoproxil|all participants receive the intervention
45635989|NCT04626713|Device|Brain-Computer Interface|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. Our technology will deliver a mindfulness-based anxiety regulation intervention through a neuro-/ bio-feedback-based game interface that is driven by an EEG algorithm.
45635990|NCT05399303|Procedure|obturation|obturation using different types of sealers
45635991|NCT04563845|Drug|GSK3640254|GSK3640254 will be available as 100 mg oral tablet for therapeutic dose. The Supratherapeutic dose will be determined based on the results of preliminary data from sentinel cohort(s).
45635992|NCT04563845|Drug|Placebo|Placebo will be available as GSK3640254 matching oral tablets.
45775248|NCT01074125|Drug|ferric citrate|1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days
45775249|NCT02641145|Radiation|F-18 florbetapir/C-11 acetate PET|F-18 florbetapir PET scan, C-11 acetate PET scan
45775250|NCT02641145|Device|MRI|Cardiac MRI with gadolinium contrast.
45775251|NCT02641145|Radiation|N-13 ammonia PET|N-13 ammonia PET scan following supine bicycle stress.
45775252|NCT02618213|Device|Optiflow Junior|Humified air are dispensed through the system. Airflow, FiO2 (Fraction of inspired oxygen) , SpO2 (peripheral capillary Oxygen saturation) and respiratory rate are noted each hour. Progression of condition might lead to change of system og mechanical ventilation. poor tolerance might lead to change of system
45775253|NCT02618213|Device|Continous Positive Airway Pressure|Humified air are dispensed throug the system. Airflow, FiO2, SpO2 and respiratory rate are noted each hour. Progression of condition might lead to change of system or mechanical ventilation. Poor tolerance might lead to change of system.
45635993|NCT04563845|Drug|Moxifloxacin|Moxifloxacin will be available as 400 mg oral capsule.
45635994|NCT03927443|Drug|SDP-133|one drop
45635995|NCT03927443|Drug|Lumigan|one drop
45775254|NCT01108835|Other|Comprehensive care programme|"Intervention group:~Patients will be interviewed by a respiratory nurse and given education in 1-2 sessions~Physiotherapist assessment and training (individualized physical training programme to perform at home or a short course out-patient pulmonary rehabilitation)~Respiratory physician assessment and optimization of treatment~Patients will also be taught about a personalized action plan by the physician and respiratory nurse.~Subsequent intervention: Patients will receive monthly telephone calls by a respiratory nurse for a period of 1 year to assess their conditions and also answer their queries."
45635996|NCT02872493|Procedure|Small bowel length measurement|The total length of the small bowel with be measured at the time of the bariatric surgical operation.
45635997|NCT05124353|Drug|Cerebrolysin|Cerebrolysin 30ml i.v., administrated in first 6 hours after stroke onset and fo 10 day afterwards in Neurology Department or ICU conditions.
45635998|NCT02222831|Procedure|Day 0 denudation and time lapse culture on IVF-oocytes.|
45775255|NCT02601755|Behavioral|iCanCope app and website|"In addition to standard medical care, adolescents and young adults in the experimental group will receive access to the iCanCope with Pain smartphone app and website for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component. The website provides chronic pain-specific education, self-management strategies, and resources."
45775256|NCT02601755|Behavioral|Attention control group|"The control group is designed to control for the potential effects on outcomes of time, attention, smartphone and computer use during the intervention. In addition to standard medical care, adolescents and young adults in the attention control group will receive access to the iCanCope with Pain smartphone app (control version, with limited functionality), and a pain resource website without access to self-management strategies."
45635999|NCT05124197|Other|prone position|extension of prone position duration
45636000|NCT03913247|Other|Size Measurement using a measuring tape, a caliper and a metric|Each patient will have the following measure: measure of the span, the tibia, the ulna, the distance between the hill and the knee, the head, the trunk and the leg. The different measures will be done using a measuring tape and with a caliper. Before leaving the intensive care unit, each patients will be measured according to the WHO standard, that is to say strictly lengthened, using a metric for patient younger than 2 and stand up using a stadiometer for patient older than 2.
45636001|NCT03805841|Drug|tarloxotinib bromide|weekly intravenous infusion
45636002|NCT02816099|Biological|Prise de sang|
45636003|NCT02815943|Procedure|biliopancreatic diversion with duodenal switch|
45636004|NCT02815943|Procedure|sleeve gastrectomy|
45636005|NCT02815943|Other|liquid meal|will be consumed over 30 minutes with [U-13C]-palmitate (0.2 g mixed in the liquid meal) and H2-glucose
45636006|NCT02815943|Radiation|PET/scan|a dynamic and whole body PET acquisition will be performed on a thoraco-abdominal segment, 150 minutes after an oral administration of 18FTHA
45775257|NCT03014141|Other|Oat bran (Oatwell 28)|11 g oat bran containing 3.1 gram oat beta-glucan
45775258|NCT03014141|Other|Maltodextrin|11 g of Maltodextrin
45775259|NCT01076231|Radiation|proton beam radiation therapy|
45775260|NCT01076231|Drug|cisplatin|Given IV
45775261|NCT01076231|Drug|etoposide|Given IV
45775262|NCT01076231|Procedure|therapeutic conventional surgery|
45775263|NCT00117962|Biological|cetuximab|400 mg/sq m IV over 120 min: Day 1; Week 1 250 mg/sq m IV over 60 min weekly for 6 more weeks.
45775264|NCT00117962|Drug|carboplatin|AUC = 5 q 21 days for 4 cycles
45448243|NCT00137111|Procedure|steroid therapy, hematopoietic stem cell transplantation|See Detailed Description sections for details on treatment interventions.
45636007|NCT02815943|Other|[7,7,8,8-2H]-palmitate|i.v. administration of [7,7,8,8-2H]-palmitate (in 25% human albumin) from time -60 to 360 min.
45636008|NCT02815943|Device|indirect calorimetry|will be performed every hour throughout the protocol along with exhaled breath collection
45636009|NCT04440995|Procedure|pectoral nerve block|Patients received standardized general anesthesia. PECS block were applied under vision using blunted tip cannula(27G, 30mm) after surgical resection of breast by operator. 0.25% ropivacaine 10ml was injected into fascia between pectoralis major and minor muscles. 0.25% ropivacaine 20ml was injected into fascia between pectoralis minor and serratus anterior muscles at the level of the third rib. Breast reconstruction is performed after PECS block
45775265|NCT00117962|Drug|pemetrexed disodium|500 mg/sq m IV q 21 days during chemoradiation and consolidation chemotherapy phases
45775266|NCT00117962|Radiation|radiation therapy|Thoracic radiotherapy: 70 Gy for 7 weeks beginning on Day 1.
45775267|NCT01109069|Drug|PCI-32765|Dose based on parent protocol
45636010|NCT03563651|Procedure|Biopsy|Undergo biopsy
45636011|NCT03563651|Procedure|Biospecimen Collection|Undergo collection of blood, urine, and stool
45636012|NCT03563651|Other|Laboratory Biomarker Analysis|Correlative studies
45636013|NCT03563651|Other|Questionnaire Administration|Ancillary studies
45636014|NCT03560765|Device|MED|Training in the use of mainstream electronic devices with accessibility options
45636015|NCT03560765|Other|Buddy|A buddy who will meet with the participant regularly for social interaction, and assistance with use of any MED purchased
45636016|NCT04207073|Device|Mobilization of median nerve|Neural mobilization
45636017|NCT04435847|Biological|HST 001|Participants will receive intradermal injections at 3 timepoints only: week 0, week 6 and week 12. At each of these 3 interventional visits they will receive 0.1 mL X 20 injections spaced approximately 0.8 - 1.2 cm apart from one another of active treatment (HST 001).
45636018|NCT04435847|Other|Phosphate Buffered Saline|Participants will receive intradermal injections at 3 timepoints only: week 0, week 6 and week 12. At each of these 3 interventional visits they will receive 0.1 mL X 20 injections spaced approximately 0.8 - 1.2 cm apart from one another of placebo control (Phosphate Buffered Saline).
45636019|NCT03057743|Device|Positron emission tomography (PET/CT) imaging|
45775268|NCT00118274|Biological|incomplete Freund's adjuvant|Given intradermally and subcutaneously
45775269|NCT00118274|Biological|melanoma helper peptide vaccine|Given intradermally and subcutaneously
45775270|NCT00118274|Biological|multi-epitope melanoma peptide vaccine|Given intradermally and subcutaneously
45775271|NCT00118274|Biological|tetanus toxoid helper peptide|Given intradermally and subcutaneously
45636020|NCT03057743|Device|radiotracer [18F]ISO-1|
45636021|NCT05123651|Biological|Lactobacillus rhamnosus X253|Every two weeks, all volunteers were given the number of probiotic lozenges to be used within two weeks. Edible method: 3 times a day, 1 tablet every time (0.8g/tablet). Put the tablet in the mouth and keep it in the mouth for at least 2-3 minutes before swallowing. Take it once every 30 minutes after breakfast, lunch and dinner. Do not brush your teeth, eat foods, or rinse your mouth within half an hour of consumption. Maintain oral hygiene according to the original habits during consumption, and do not use fluoride toothpaste during consumption.
45775272|NCT00118274|Drug|cyclophosphamide|Given IV
45775273|NCT01109147|Other|Imagery|All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.
45775274|NCT01109147|Genetic|pharmacogenetic sampling|A pharmacogenetic sample will be done with an additional consentment.
45775275|NCT01898000|Behavioral|Triphala mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
45448244|NCT02138656|Other|Chiropractic|Chiropractic treatment delivered in accordance with clinical protocols developed and agreed with the participant clinicians
45448245|NCT02138656|Other|Best Standard Care|Counselling and advice delivered in accordance with the Map of Medicine care pathway for Infantile colic
45448246|NCT02133118|Drug|individual SUs, insulin, pioglitazone|
45448247|NCT02138812|Drug|BAY1161909|Given orally, with a starting dose of 0.75 mg twice daily from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in 28-day cycles. For single-dose PK cohort: a single oral dose on C1D1
45448248|NCT02138812|Drug|Paclitaxel|75 mg/m^2 (initial dose escalation) or 90 mg/m^2 (second dose escalation), weekly intravenously (IV) infusion on D1, D8, and D15 of the 28-day cycles from C2D1
45775276|NCT01898000|Behavioral|Chlorhexidine mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
45775277|NCT01109381|Drug|GT08|GT08 is the combination of omeprazole 40mg daily, lauric acid 150-300mg daily, NAC 1.2 - 2g daily
45775278|NCT01110395|Diagnostic Test|MR Spectroscopy|MR spectroscopy of myocardial
45775279|NCT00166166|Drug|Tetraethylammonium (TEA)|5 minute intra-arterial infusion of Tetraethylammonium at 1 mg/min
45775280|NCT00166166|Drug|L-NG-monomethyl Arginine (L-NMMA)|5 minute intra-arterial infusion of L-NMMA 8 μmol/min
45775281|NCT00166166|Drug|Bradykinin|Intra-arterial infusion of bradykinin at 100, 200, and 400 ng/min. Each dose will be given for 5 minutes.
45775282|NCT00166166|Drug|Sodium nitroprusside|Intra-arterial infusion of sodium nitroprusside at 1.6 and 3.2 mg/min. Each dose will be given for 5 minutes.
45775283|NCT00166166|Drug|Acetylcholine|Intra-arterial infusion of acetylcholine at 7.5, 15 and 30 μg/min. Each dose will be given for 5 minutes.
45636022|NCT05123573|Behavioral|Clinical Skills|We will evaluate the students' ability to demonstrate essential clinical skills, clinical reasoning and problem-solving skills, management of life-threatening medical conditions, management of common medical problems, and placing the patients' needs and safety at the center of the care process.
45636023|NCT02811887|Behavioral|Supervised exercise|A 12 week supervised and facility-based exercise training program. The program is facility based and supervised by a physiotherapist. The program runs 3 times weekly for 12 weeks. The exercise is group-based. The exercise program lasts approximately 1 hour and consists of a brief warm-up phase (bicycle ergometer at moderate intensity) followed by a circuit training program focusing on strength and endurance exercises of the large muscle groups (e.g. quadriceps).
45636024|NCT02811887|Other|Usual Care|Participants allocated to usual care will receive instructions related to healthy living, alcohol absenteeism, and benefits of increased physical activity. The instructions will be provided by a physical therapist and/or a nurse, and will be given according to recommendations and local and national guidance. The participants are offered continued regular visits at the rehabilitation clinic, but no supervised physical exercise.
45636025|NCT02811887|Behavioral|SMS-messages|"Participants allocated to SMS-messages will receive the same intervention as usual care (see above) AND regular text messages via SMS over a 12-week period.~The text messages will be unidirectional and will serve as motivational information but will not allow two-way communication with a researcher or health professional about clinical management. The messages will provide information, motivation, and support to adhere to a healthy lifestyle, alcohol absenteeism, and physical activity and will reinforce the information and instructions received at the face-to-face information (usual care)."
45636026|NCT03995303|Other|NCP and home-delivered meals|The dietitian (Ph.D. student) will perform an individual nutritional assessment focusing on dietary intake, activity level and weight of each participant, as a basis for developing an individualized nutrition care plan consistent with estimated nutritional requirements and nutritional rehabilitation goals. Total fluid, energy- and protein requirements will be estimated for each patient. Giving the group free food to fulfill protein-and energy needs.
45636027|NCT03957707|Procedure|stereotactic surgery plus thrombolysis|stereotactic puncture and aspiration to evacuate basal ganglion hematoma with or without thrombolytic agent
45636028|NCT02739659|Device|carbon-ion radiotherapy|
45636029|NCT05123261|Behavioral|the mindfulness-based elder care (MBEC) therapy|According to the mindfulness-based elder care (MBEC) therapy developed by McBee (2008), the experimental group was offered eight 50-minute courses once a week.
45448249|NCT02133274|Behavioral|Brief Psychosocial Intervention|Five weekly sessions of a Brief Psychosocial Intervention based of Behavioral Cognitive Therapy designed specifically for the present study.
45448250|NCT02133274|Other|Early Palliative Care|Early integration of Palliative Care into the standard oncologic care. Patients starting first line chemotherapy will receive immediately evaluation by the board-certified palliative care physicians.
45636030|NCT05123105|Other|1) cupping therapy|The participant lay on his front on a couch. The examiner applied a plastic cup on a pre-marked trigger point, suctioned it with a mechanical pump and left it for 2 minutes. This was a stationary application with medium suction force. Therapy was performed on both sides. Measurements were taken before and 2 minutes after the therapy.
45636031|NCT05123105|Other|2) control test (no intervention)|The participant lay on his front on a couch for 4 minutes without any activity and without anyy intervention. Measurements were taken before and after the session.
45775284|NCT00166166|Drug|Saline|5 minute intra-arterial infusion of 0.9% saline at 2.5ml/min
45775285|NCT00166166|Drug|Fluconazole|5 minute intra-arterial infusion of fluconazole at 0.4 mg/L/min
45775286|NCT02276417|Other|Blood collection|Blood will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Blood will also be collected at the one year appointment.
45775287|NCT02276417|Other|Urine collection|Urine will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Urine will also be collected at the one year appointment.
45775288|NCT02276417|Other|Bioimpedance Analysis|The bioimpedance analysis will be performed at baseline, day 14 or discharge from hospitalization, month 3, month 6, and month 12.
45775289|NCT02276417|Other|Cognitive Function Tests|Cognitive function tests will be administered at 3, 6 and 12 months.
45775290|NCT02276417|Other|Quality-of-life Questionnaires|Quality-of-life questionnaires will be administered at baseline, 3, 6 and 12 months.
45775291|NCT02276417|Other|Physical Function Tests|Physical function tests will be administered at baseline, day 14 or discharge from hospital 3, 6 and 12 months.
45775292|NCT02276417|Other|Blood Collection|The healthy volunteer participants will donate a blood sample. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
45775293|NCT03014219|Drug|Only 1 arm: treatment with MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell. Drug study. Single dose of 20 million cells.
45775294|NCT04265378|Device|anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)
45914674|NCT02046499|Drug|Oxytocin|Oxytocin will be administered intravenously as per standard protocol
45914675|NCT02046499|Drug|Oxytocin ergometrine|Oxytocin ergometrine will be administered intra-musculalry
45775295|NCT04265378|Behavioral|Intensive cognitive training|Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
45636032|NCT05123105|Other|3) ischemic compression|The participant lay on his front on a couch. The researcher applied pressure to a pre-marked trigger point using the thumb for 2 minutes until tissue resistance was felt. This included 60-second compression and after a break of a few seconds, another 60 seconds of compression. Therapies were performed on each side. Measurements were taken before and 2 minutes after the therapy.
45636033|NCT05122949|Device|3D Printed Ankle-Foot Orthosis|3D Printed (Fused Deposition Modelling) Ankle-Foot Orthosis with Polyamide Nylon-12 material
45636034|NCT05122949|Device|Thermoformed Ankle-Foot Orthosis|Thermoformed Ankle-Foot Orthosis with homopolymer polypropylene
45636035|NCT02684617|Biological|pembrolizumab|200 mg administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35. Each cycle is 21 days.
45636036|NCT02684617|Drug|dinaciclib|dinaciclib 7 mg/m^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35. Each cycle is 21 days.
45636037|NCT01999972|Drug|axitinib|Axitinib: tablets, dosage range 2 - 5 mg, given orally twice daily on a continuous dosing schedule in 28 days cycles.
45636038|NCT01999972|Drug|crizotinib|Crizotinib: capsules, dosage range 200-250 mg, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
45636039|NCT01999972|Drug|axitinib|Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
45636040|NCT01999972|Drug|crizotinib|Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
45775296|NCT00118352|Biological|alemtuzumab|Given IV
45775297|NCT00118352|Radiation|total-body irradiation|Undergo low-dose TBI
45775298|NCT00118352|Drug|fludarabine phosphate|Given IV
45775299|NCT00118352|Drug|cyclosporine|Given PO or IV
45775300|NCT00118352|Drug|mycophenolate mofetil|Given PO
45775301|NCT00118352|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
45775302|NCT00118352|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
45636041|NCT01999972|Drug|axitinib|Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
45636042|NCT01999972|Drug|crizotinib|Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
45636043|NCT04055389|Drug|Antithrombin III|"Patients with reversal of flow or sluggish flow in the main portal vein (<15 cm/s by Doppler ultrasound exam) will be enrolled and randomized to either weekly infusions of AT-III (half-life ~4 days) at a weight-based dosage according to the following formula:~[Desired level of AT (100%) - Subject level of AT (%)] * subject weight (kg) 1.4~or placebo for 24 weeks of therapy."
45775303|NCT00118352|Biological|graft versus host disease prophylaxis/therapy|Undergo GVHD prophylaxis/therapy
45775304|NCT00118352|Other|laboratory biomarker analysis|Correlative studies
45636044|NCT04055389|Other|Placebo|No study drug
45636045|NCT03106207|Procedure|Upper gastric endoscopy (UGE)|UGE will be performed before the gastric bypass surgery and post-surgery at two, six and 12 months of clinical visit.
45775305|NCT01111331|Drug|BI 10773 25 mg|25 mg BI 10773 qd for 5 days
45775306|NCT01111331|Drug|Warfarin 25 mg|25 mg Warfarin single dose
45775307|NCT01111331|Drug|BI 10773 25 mg|25 mg BI 10773 qd for 12 days
45775308|NCT01111331|Drug|Warfarin|25 mg warfarin single dose with and without 50 mg BI 10773
45914676|NCT02046538|Drug|Leucovorin|400 mg/m2 IV over two hours (or administered concurrently with oxaliplatin or irinotecan, depending on the assigned regimen)
45636046|NCT05697055|Drug|Azvudine|5mg orally, once a day, for no more than 14 days
45636047|NCT05697055|Drug|Nirmatrelvir-Ritonavir|Nirmatrelvir 300mg combined with Ritonavir 100mg every 12 hours for 5 days. For patients with 30≤ eGFR < 60 ml/min, it should be reduced to150mg/100mg Nirmatrelvir-Ritonavir every 12 hours for 5 days
45775309|NCT00167102|Drug|Alefacept|Study participants will receive weekly IM administration of placebo or 15 mg of alefacept for 12 weeks, to be followed by a 12-week post-treatment period during which the safety, efficacy, and durability of effect in treatment responders will be assessed on weeks 2, 4, 8 and 12.
45775310|NCT03014375|Drug|BIA-5-453|Each subject will receive a single oral dose of 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 (600 mg).
45775311|NCT01859819|Drug|Rituximab|
45775312|NCT01859819|Drug|IT Cytarabine|
45775313|NCT01795313|Biological|HLA-A2 restricted synthetic tumor antigen|
45775314|NCT01795313|Drug|Imiquimod|
45775315|NCT01795313|Other|enzyme-linked immunosorbent assay|
45775316|NCT01795313|Other|flow cytometry|
45775317|NCT01795313|Other|immunohistochemistry staining method|
45775318|NCT01795313|Other|laboratory biomarker analysis|
45775319|NCT02176031|Drug|Natalizumab|
45775320|NCT02176031|Drug|Methylprednisolone|
45914677|NCT02046538|Drug|Oxaliplatin|85 mg/m2 IV over two hours
45448251|NCT02138968|Other|Multidisciplinary intervention|Multidimensional intervention based on: good control of baseline diseases, review of medication adequacy, exercise program, nutritional assessment and control, social assessment and control.
45636048|NCT04053361|Procedure|Catheter ablation|Catheter ablation of atrial fibrillation or atrial tachykardie related to atrial fibrillation with use of radiofrequency energy.
45636049|NCT03162367|Biological|Autologous epidermal cell suspension|First skin samples taken from normal skin by 4mm punch will be send to laboratory for preparation of epidermal cell suspension and this suspension transfer to one area of second degree burn
45636050|NCT03162367|Drug|Silver sulfadiazine ointment|the area with second degree burn dresses by silver sulfadiazine ointment and dressing change each 12 hour till 10 day
45636051|NCT01999894|Drug|Memantine HCl|Memantine extended release 3- and 6-mg capsules; dose ranging 3 - 18 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for 48 weeks.
45636052|NCT03165565|Behavioral|Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT)|Participants will receive Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).
45636053|NCT03165565|Behavioral|Conventional Care|Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
45636054|NCT02679235|Drug|POST Triheptanoin|The target daily dose of triheptanoin will be 1 g/kg/d, or approximately 70 g/d during 28±2 days. It will be divided into four daily doses, one of which will be consumed at each meal and one with an evening snack.
45636055|NCT01976806|Drug|Aspirin|
45636056|NCT01976806|Drug|Docosahexaenoic acid|
45636057|NCT01976806|Drug|Placebo (for Docosahexaenoic acid)|Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules
45636058|NCT02679079|Drug|NBI-98854|
45636059|NCT02679079|Drug|Placebo|
45636060|NCT02678923|Drug|MDCO-216|
45636061|NCT02678923|Drug|Placebo|
45636062|NCT01976728|Drug|Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump|
45636063|NCT01976728|Drug|Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump|
45636064|NCT01976728|Drug|Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump|
45914678|NCT02046538|Drug|5-FU|400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
45914679|NCT02046538|Drug|Irinotecan|180 mg/m2 IV over 90 minutes
45914680|NCT02046551|Drug|Atomoxetine|
45914681|NCT02046551|Drug|Placebo|
45914682|NCT02046577|Dietary Supplement|Vitamin D3|Cholecalciferol administration
45914683|NCT02046577|Dietary Supplement|Placebo|Placebo liquid
45914684|NCT02046629|Drug|Teriflunomide HMR1726|Pharmaceutical form:tablet Route of administration: oral
45914685|NCT02046629|Drug|cholestyramine|Pharmaceutical form:power Route of administration: oral
45448252|NCT02253082|Drug|OctaplasLG®|OctaplasLG® is an industrial donor plasma product pooled from approximately 400 single donor units. It possess' unique features when compared to standard FFP, such as having standardized concentrations of natural pro- and anti-coagulation factors, standardized volume and as being pathogen free. Very importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation.
45448253|NCT02253082|Biological|Fresh frozen plasma|Standard FFP from the Blood Bank
45448254|NCT00136955|Drug|Irinotecan|An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan (60mg/sqm, D1, 8, 15) Plus Cisplatin (60mg/sqm, D1) As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix
45636065|NCT01976728|Drug|Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)|
45636066|NCT02689219|Drug|Brentuximab Vedotin|Both cohorts will be treated similarly and in parallel but analyzed separately.
45636067|NCT03162133|Other|Baduanjin exercise|
45636068|NCT05673733|Other|scapular stabilization exercises with exergaming training|Group A will receive scapular stabilization exercises with exergaming training
45636069|NCT05673733|Other|exergaming training|Group B will receive only exergaming training
45636070|NCT05550727|Other|PorchLight|The PorchLight Project intervention consists of three components: 1) CARES® Dementia Care Specialist online training modules; 2) a PorchLight Project training course; and 3) monthly check-in sessions.
45636071|NCT05673421|Other|Exergaming Training|VR game-assisted intervention will perform for 30-45 min, 5 sessions per week for a duration of 8 weeks
45775321|NCT02176343|Device|AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
45775322|NCT02177201|Other|Group 1|Intravenous access was established and 10 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
45775323|NCT02177201|Other|Group 2|Intravenous access was established and 20 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
45775324|NCT03013361|Drug|Bupivacaine|Post operative pain control
45775325|NCT03013361|Drug|Ropivacaine|Post operative pain control
45775326|NCT03013361|Other|Normal Saline|Acts as comparator
45636072|NCT05673421|Other|Visual Feedback Training|During the visual feedback practices, patients will be seated or in a standing phase close to a table on which a mirror would be placed vertically. The practice would be consisted of nonparetic-side shoulder, elbow, wrist and finger flexion, extension, abduction, adduction movements, task oriented activities like, unscrewing lid of jar ,card stacking, moving coins or marbles from one box to another, Folding towels and stacking them, picking glass, while patient will look into the mirror, -watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. After watching the practices on the uninvolved side, patient will be asked to try to do the same movements with the paretic limb while they will be moving the nonparetic limb.Each activity will be performed for 4 min, with a 1 min preparation time between tasks.
45636073|NCT03165253|Drug|Bifidobacterium Animalis Oral Product|The synbiotic group will receive this product.
45636074|NCT03165253|Drug|Amoxicillin Oral Tablet|50mg/kg/day B.I.D.
45636075|NCT03165253|Drug|Clarithromycin Oral Tablet|15 mg/kg/day B.I.D.
45448255|NCT02261038|Other|Kanekasu radiographs|No interventions are performed here. All patients undergo CT and special radiographs of the knee to assess femoral TKA rotation.
45448256|NCT02133430|Device|Bispectral index, as measured by a BIS processor|Comparisons of incidence of postoperative delirium.
45636076|NCT03165253|Drug|Omeprazole|1 mg/kg/day
45636077|NCT05543317|Diagnostic Test|18F-FDG PET/CT, 68Ga-FAPI-RGD PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-RGD, and undergo PET/CT imaging within the specified time. A part of participants will undergo additional 68Ga-FAPI-46 PET/CT for comparison.
45636078|NCT03114241|Behavioral|Intervention|Patients allocated to the intervention group receive a pedometer. They are encouraged to be more active by using the pedometer to measure the number of steps walked daily. An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient. Monthly telephone calls are indicated to encourage compliance with the protocol and motivate patients to enhance their level of activity. The coached program ends after three months but patients keep their pedometer and are encouraged to sustain an increased level of daily physical activity for additional 9 months (end of study).
45636079|NCT04718389|Biological|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be provided in a single-use prefilled syringe (PFS).
45636080|NCT04718389|Biological|Mepolizumab|Mepolizumab will be provided in a single-use PFS.
45636081|NCT04718389|Biological|Benralizumab|Benralizumab will be provided in a single-use PFS.
45636082|NCT04718389|Biological|Placebo|Placebo will be a sterile liquid formulation.
45636083|NCT04718389|Drug|Standard of care (SoC)|Non-biologic SoC will include inhaled corticosteroid (ICS) plus at least one other controller, long-acting beta-2-agonist (LABA), long-acting muscarinic antagonist (LAMA), with or without maintenance oral corticosteroids (OCS).
45636084|NCT04718389|Device|Pre-filled Syringes (PFS)|PFS will include glass barrel with pre-staked needle and plunger.
45636085|NCT03161977|Other|Mannitol|Mannitol was intravenous infused within 15-20 mins when drilling skull
45636086|NCT02683525|Drug|Sitagliptin|600 mg ever 12 hours by mouth will be given starting the day before transplant through day +14 after transplant
45636087|NCT01976338|Drug|Ranibizumab 0.5 mg|intravitreal injection of 0.05 ml
45636088|NCT01976338|Other|Sham injection|Sham intravitreal injection
45775327|NCT01365793|Drug|0.45% saline replacement fluid|10cc/Kg bolus of 0.9% saline followed by 0.45% saline used as the replacement fluid
45636089|NCT02674633|Device|AKL-T01|Videogame-like digital therapy
45636090|NCT02674633|Device|AKL-T09|Videogame-like digital therapy
45636091|NCT02651987|Drug|Lanreotide autogel 120 mg|
45775328|NCT01365793|Drug|0.9% saline replacement fluid|10cc/Kg bolus of 0.9% saline followed by 0.9% saline used as the replacement fluid.
45775329|NCT01365793|Drug|0.45% saline intravenous fluid|0.45% saline fluid
45636092|NCT05676307|Behavioral|Vestibular Rehabilitation|Cawthorne Cooksey Based Vestibular Rehabilitation Exercises (Oculomotor exercise, Vestibulo-ocular Exercise, posture exercise, balance training, etc)
45636093|NCT05115773|Procedure|Intraligamentary anaesthesia|one tooth anaesthesia by 2 or 4 points intraligamentary injection
45636094|NCT05115773|Procedure|Mandibular anaesthesia|Inferior alveolar nerve block by direct standart method
45636095|NCT05108285|Diagnostic Test|Optical Coherence Tomography Angiography (OCTA) and indocyanine green angiography (ICGA)|OCTA and ICGA is able to detect the dark halo as a area of reduced perfusion around MVN
45636096|NCT02677987|Device|Intervention systematic light exposure|Bright light using Litebook device.
45636097|NCT02677987|Device|Comparison systematic light exposure|Dim light using modified Litebook device.
45636098|NCT02506517|Drug|Afatinib|
45636099|NCT02463773|Device|Ultrasound|Diaphragmatic excursion ultrasound assessment
45636100|NCT05676151|Behavioral|Music Therapy|20-minute music-therapy-informed interventions (musical bingo, songwriting, lyric scramble) guided by a music therapist
45636101|NCT04701853|Other|Specific abdominal muscle training|Specific abdominal muscle training
45636102|NCT04701853|Other|Usual care|Care according to each center.
45775330|NCT01365793|Drug|0.9% saline Intravenous fluid|0.9% saline fluid
45775331|NCT01077401|Drug|Ranibizumab|Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
45636103|NCT03049397|Other|Communication Intervention|Complete Enhancing Connections program
45636104|NCT03049397|Other|Questionnaire Administration|Ancillary studies
45636105|NCT04657939|Drug|Liraglutide|Liraglutide 0.6mg once daily by subcutaneous injection escalated to 1.2mg after 2 weeks.
45636106|NCT04657939|Drug|Pioglitazone|Pioglitazone 15mg once daily tablets taken orally escalated to 30mg after 2 weeks then escalated to 45mg after another 2 weeks.
45636107|NCT01999114|Drug|Buprenorphine transdermal patch|Buprenorphine patch applied transdermally
45636108|NCT01999114|Drug|Naltrexone tablet|Naltrexone tablet; 1 tablet taken orally every 12 hours
45636109|NCT01999114|Drug|Placebos (for TDS and for naltrexone and for moxifloxacin)|Matching placebos
45636110|NCT01999114|Drug|Moxifloxacin tablet|Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17
45636111|NCT02968355|Other|Observational study|Observational study
45636112|NCT04500275|Drug|Vancomycin Hydrochloride|Vancomycin will be spread on sternal edge immediately after sternotomy and before sternal closure
45775332|NCT01077401|Drug|ranibizumab|Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
45636113|NCT04500275|Other|Normal Saline|2 ml normal saline will be spread on sternal edge immediately after sternotomy and before sternal closure
45636114|NCT03161743|Procedure|venipuncture|blood draw for the purpose of determining the platelet concentration in PRP
45636115|NCT02783105|Other|Musical intervention|
45775333|NCT01316341|Drug|BI10773|patient to receive a tablet containing high dose BI10773 p.o. plus one placebo
45636116|NCT02783105|Other|Control|Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham
45636117|NCT03161665|Other|BMT Roadmap|The BMT Roadmap is a health IT System that has been developed for use on the Apple iPad® to give the patient and caregivers easy access to test results, current treatment and contact information to hopefully increase active participation and engagement in transplant care.
45636118|NCT04499963|Drug|Theracurmin HP|The intervention is based on the twice daily dosage of Theracurmin 90 mg capsules used in a trial of patients with mild cognitive impairment
45636119|NCT02666339|Other|Usual care|Usual care : drug therapy, nurse and physician consultations.
45448257|NCT05579002|Other|Questionnaires and tests|"Application of three questionnaires:~Canadian Occupational Performance Measure (CORM),~a version of the Disabilities of the Arm Shoulder and Hand (DASH) modified for the child~a questionnaire developed by CEREFAM~Two analytical and functional tests:~1) the Action Research Arm Test (ARAT) 2) modified 400-point assessment."
45636120|NCT02666339|Behavioral|Hortitherapy|2 hortitherapy sessions/week during 4 weeks, added at the usual care.
45636121|NCT02382497|Device|AN Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
45636122|NCT02382497|Device|AN Sham tDCS|The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
45636123|NCT02382497|Device|BED Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~For the OW/OB with diagnosis of BE, or food craving, the anode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
45775334|NCT01316341|Drug|Placebo|patient to receive two placebos
45775335|NCT01316341|Drug|Placebo|patient to receive two placebos
45775336|NCT01316341|Drug|Placebo|patient to receive two placebos
45636124|NCT02382497|Device|BED Sham tDCS|The same electrode placement will be used as in the stimulation conditions (right anodal/left cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
45636125|NCT04503161|Device|Duragen with Collagen Hydrodel and ASCs|Duragen combined with collagen hydrogel and patient's stem cells
45775337|NCT01316341|Drug|BI10773|patient to receive a tablet containing low dose BI10773 p.o. plus one placebo
45636126|NCT02214407|Drug|Decitabine|"Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Hydroxyurea may be added during the first 3 cycles if WBC counts > 30 G/L, and mandatory if WBC > 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
45775338|NCT01112735|Biological|FS VH S/D 4 s-apr (= two-component fibrin sealant, double virus inactivated, made from pooled human plasma)|Dosage form: spray (aerosolized sealant), Dosage frequency: once (1 layer). ARTISS will be applied onto the fascia or the wound bed.
45775339|NCT01112735|Procedure|Standard of care|Standard of care
45448258|NCT02133586|Other|Ozone|Exposure to 300ppb ozone with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or nitrogen dioxide) in a two-exposure series.
45636127|NCT02214407|Drug|HYDROXYUREA|"Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
45636128|NCT02682823|Device|AI-1000 G2|Tocilizumab will be administered using the AI-1000 G2.
45775340|NCT01366417|Drug|ChloraPrep One-Step|1.5 ml applicator patient preoperative skin preparation
45775341|NCT01366417|Drug|70% isopropyl alcohol|Curity Alcohol Prep Pads
45775342|NCT03014297|Drug|everolimus|everolimus
45775343|NCT03014297|Drug|fosbretabulin|fosbretabulin
45775344|NCT01113983|Device|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation via transapical and transfemoral approach
45775345|NCT01034111|Drug|Sitagliptin phosphate|Sitagliptin 100 mg tablet by mouth once daily for 4 weeks.
45775346|NCT01034111|Drug|Metformin|Stable dose of metformin tablet(s) by mouth (at least 1000 mg/day) for 4 weeks.
45775347|NCT01114997|Drug|Lidocaine|Pre-Induction: Lidocaine Loading: 1 mg/kg After Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)
45775348|NCT01114997|Drug|Esmolol|Esmolol Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Esmolol Post Induction: Infusion dose 7.5 - 15 mcg /kg/min
45914686|NCT02046642|Behavioral|Maternal rest in left lateral position|After initial amniotic fluid index measurements, the participating pregnant women were instructed to turn their left sides and rest in that position for 15 minutes before a second amniotic fluid index measurement
45448259|NCT02133586|Other|Nitrogen dioxide|Exposure to 500ppb nitrogen dioxide with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or ozone) in a two-exposure series.
45448260|NCT02139202|Behavioral|Social Influence|
45448261|NCT02139202|Behavioral|Electronic Pill Bottles|
45448262|NCT02139202|Behavioral|Financial Incentives|
45448263|NCT02260726|Procedure|Magnetic resonance imaging|
45448264|NCT02260726|Procedure|Ultrasound|
45448265|NCT00135707|Drug|Dietary Supplement/Vitamins|Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
45448266|NCT00135707|Drug|Placebo for Vitamin C and Vitamin E|Placebo two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
45636129|NCT02682823|Drug|Tocilizumab|Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28). The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
45636130|NCT01899989|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
45636131|NCT01899989|Drug|cisplatin or carboplatin-based|Standard chemotherapy with a histology-selected cisplatin or carboplatin-based doublet will be administered intravenously as adjuvant therapy. Gemcitabine will be used for squamous cell carcinomas and pemetrexed will be used for non-squamous non-small cell lung cancer. Cisplatin or carboplatin will be used in combination with the histology-selected agent. The choice of cisplatin or carboplatin will be at the discretion of the treating medical oncologist.
45636132|NCT01634711|Device|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
45636133|NCT05008601|Device|Wrist-word optical heart rate and ECG measurement device|Aino ECG: wrist-word optical heart rate and ECG measurement device
45636134|NCT01478555|Drug|ISV 101|Bromfenac in DuraSite
45636135|NCT02261285|Drug|ONO-4538|
45636136|NCT01422083|Procedure|home stretching program|A home stretching program (sleeper's stretch): 3 x 30 seconds, once a day for 6 weeks.
45636137|NCT05130125|Drug|rFSH|rFSH or HP-hMG or rFSH and HP-hMG
45636138|NCT01288625|Drug|Amifostine|500 mg sc, qod, 3 times per week
45636139|NCT01288625|Radiation|Amifostine|500mg rinsing wash, qod, 3 times per week
45636140|NCT05041829|Other|Dietary sodium|Low sodium diet with sodium of <2.3 g/day (<100 mmol/day) and high sodium diet with sodium of ≥4 - <6 g/day (≥174 - <261 mmo/day)
45775349|NCT01114997|Drug|Lidocaine + Esmolol (Combo)|"Pre-induction: Lidocaine Loading dose(1 mg/kg) + Esmolol Loading dose(750 mcg/Kg)~Maintenance Infusion rate after Induction:~Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)"
45775350|NCT00118742|Drug|mycophenolate mofetil [CellCept]|1-1.5 g orally or intravenously twice daily
45775351|NCT00118742|Drug|Tacrolimus|As prescribed, for 12 months
45448267|NCT03548818|Drug|Interferon Gamma-1B|Study function and biochemistry of neutrophils off the drug for one week and then 12 hours after first dose and fourth dose.
45448268|NCT05578768|Other|No intervention|Patients will receive standard of care.
45636141|NCT05129813|Behavioral|Recovery Guide Counseling|Recovery Guide Counseling is a 12-session psychoeducational and behavioral counseling intended for delivery by Peer Recovery Specialists, community health workers, or other personnel without advanced training in counseling
45636142|NCT05129579|Behavioral|Mindfulness Based Stress Reduction Intervention|Mindfulness Based Stress Reduction intervention is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 90 minute sessions, once per week for eight weeks.
45636143|NCT05129579|Other|no intervention|No intervention will be made in the control group.
45636144|NCT05129267|Other|Group B|Scaling and Root debridement + iPRF
45636145|NCT05129267|Other|Group C|Scaling and Root debridement + iPRF together with vitamin C
45636146|NCT01374451|Drug|Everolimus|Everolimus was supplied as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets
45636147|NCT01374451|Drug|Pasireotide LAR|Pasireotide LAR intra-muscular depot injections were supplied as a powder in vials containing 20 mg and 40 mg with ampoules containing 2 mL of vehicle (for reconstitution).
45775352|NCT00118742|Drug|Cyclosporine|As prescribed, for 12 months
45775353|NCT00118742|Drug|Sirolimus|2-4 mg orally once daily for 9-11 months
45448269|NCT03548740|Biological|Human Papillomavirus|women with high-risk Human Papillomavirus or not
45448270|NCT02252692|Drug|Enalapril|oral administration
45448271|NCT03548662|Biological|Platelet-Rich Plasma|Platelet-Rich Plasma prepared by RegenKit® PRP, Regenlab SA
45448272|NCT03548662|Drug|Hyaluronic Acid|Hyruan Plus Inj. produced by LG Life Sciences, Ltd.
45775354|NCT01034579|Other|Blood sampling|Subjects who had received Rebif® 44 microgram (mcg) three times a week for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
45448273|NCT03548662|Other|Exercise|passive range of motion (PROM) exercise, active-assisted range of motion (AAROM) exercise, active range of motion (AROM) exercise, rotator cuff strengthening exercise, and peri-scapular muscle strengthening exercise
45448274|NCT02139514|Behavioral|Virtual Reality Social Cognition Training|Social skills training via virtual reality with trained therapist.
45448275|NCT03966209|Drug|JS001(PD-1 inhibitor)|240mg I.V. Q3W
45636148|NCT02674477|Device|Therapeutic Education System (TES)|The TES program is made of modules about ways to prevent substance use, such as how to refuse drugs and alcohol, how to cope with thoughts about using, and how to make the best possible decisions for a person's mental health. Each module takes less than 30 minutes to complete. Modules may contain videos or other interactive media. At the end of each module, there are questions about the material.
45636149|NCT02674477|Other|Treatment as Usual (TAU)|Standard treatment comprises a psychiatrist-led interdisciplinary team as well as face-to-face group counseling for substance use and skills for improving general mental health. There will be no change to the routine care (treatment at usual [TAU]) provided to patients on the service.
45636150|NCT03164863|Diagnostic Test|Onco4D Biodynamic Chemotherapy Selection Assay|The Onco4D Biodynamic Chemotherapy Selection Assay uses Motility Contrast Tomography (MCT) to measure ex-vivo fresh tumor biopsy response when challenged by an array of chemotherapeutic agents. A machine learning algorithm uses the MCT datastream to predict in vivo tumor response or non response to chemotherapy.
45636151|NCT03164941|Procedure|Selective Laser Trabeculoplasty|Laser treatment for glaucoma.
45636152|NCT03164707|Diagnostic Test|Blood Glucose Level|ON Admission Blood Glucose Level Fasting Blood Glucose Level
45636153|NCT01352845|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months
45636154|NCT01352845|Other|Placebo|0.5 mL dose, given at 0, 2 and 6 months
45636155|NCT05675995|Behavioral|External Qigong|6 sessions of external qigong delivered in a group-based format once a week.
45636156|NCT02674399|Drug|JointStem|
45636157|NCT02674399|Drug|Synvisc-One|
45636158|NCT03164785|Drug|Jinshuibao Capsule|1.98g t.i.d. p.o. for 6 months
45636159|NCT05675839|Other|Film (Wit) and a documentary (First Turkish Nurse-Safiye Hüseyin Elbi's Life)|Film (Wit) (https://www.youtube.com/watch?v=2s4ozvI_hzY&t=160s) and a documentary (First Turkish Nurse-Safiye Hüseyin Elbi's Life) (https://www.youtube.com/watch?v=XsabHOiF0CY&t=284s)
45636160|NCT03161509|Drug|Paracetamol|single dose of 1 gr paracetamol
45636161|NCT03161509|Drug|Antiepileptic (either carbamazepine, lamotrigine, phenytoin or valproic acid)|Single dose of antiepileptic drug (either carbamazepine, lamotrigine, phenytoin or valproic acid) for which the participant is taking chronically in stable dose
45636162|NCT04587193|Device|Robotic-assist gait training device|PD participants will walk while wearing a robotic-assist gait training device
45636163|NCT02676895|Biological|GVGH S. sonnei (1790GAHB) vaccine 25 μg|Two injections of the study vaccine were administered 28 days apart.
45636164|NCT02676895|Biological|GVGH S. sonnei (1790GAHB) vaccine 100 μg|Two injections of the study vaccine were administered 28 days apart.
45636165|NCT02676895|Biological|Menveo|One injection of Menveo was administered in subjects in the Control Group.
45636166|NCT02676895|Biological|Boostrix|One injection of Boostrix was administered in subjects in the Control Group.
45636167|NCT05235451|Other|Human-Animal Interactions|Human-animal interactions (HAI) is a powerful and cost-effective strategy to improve reading fluencies and comprehension of children with learning differences. Emerging data suggest that HAI help promote classroom behaviors and learning, including effects on cognition, emotional functioning, and motor skills for children with and without learning differences. The HAI reading group will receive reading instruction as usual plus visits from a registered therapy dog team (dog + animal handler) twice a week over 12 weeks.
45636168|NCT05461495|Behavioral|Treatment Group|"This intervention is unique in its emphasis on family support and in providing ongoing availability of the counselor. While the NYUCI is being implemented in several communities, its effectiveness in Chinese and Korean American dementia caregivers has not been tested. The first component of the intervention consists of two individual and four family counseling sessions that include relatives suggested by the caregiver. The second component of the intervention is participation in a support group to provide the caregiver with continuous emotional support and education. The third component of the treatment is participation in an on-line chat group to provide peer support. The fourth component of the treatment is ad hoc counseling the continuous availability of counselors to caregivers and families to help them deal with crises and with the changing nature and severity of their relatives' symptoms over the course of the disease."
45636169|NCT05675683|Drug|Capmatinib|Patients receiving Capmatinib
45636170|NCT04691999|Behavioral|Intermittent Fasting|16-18 hour fasting period four times per week
45448276|NCT00129701|Procedure|Telephone consultation|
45448277|NCT02252770|Dietary Supplement|Nitric oxide supplement|Each active comparator supplement is an all natural nitric oxide supplement. Subjects will take one lozenge twice a day.
45448278|NCT02252770|Dietary Supplement|Placebo|Placebo will not contain nitric oxide supplement.
45448279|NCT01077791|Behavioral|original cognitive therapy|12 weekly sequences of an original cognitive therapy based on videos involving the learning of a better use of contextual information to infer others' intention. Group of 5 patients trained by 2 therapeutics. Comparison with a non-cognitive psychoeducational training (same organisational design).
45448280|NCT05578456|Drug|Prednisone and Aspirin|prednisone 10 mg and aspirin 75-100mg per day per os
45636171|NCT01680809|Device|Compression stocking 15-20mmHg|Compression stocking with 15-20mmHg of compression
45636172|NCT01680809|Device|Compression stocking 20-30mmHg|Compression stocking with 20-30mmHg of compression
45636173|NCT04440085|Drug|Midodrine Hydrochloride|All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Midodrine will be administered according to the evolution of the patient's mean pressure.
45636174|NCT04440085|Drug|Placebo|All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Placebo will be administered according to the evolution of the patient's mean pressure.
45636175|NCT05129033|Drug|Prednisone tablet|Basic medication for allergic airway inflammation such as asthma and ABPA, to relieve inflammation. Reduction may failed if disease exacerbate.
45448281|NCT05578456|Drug|Placebo|placebo 2 starch tablets per day per os
45448282|NCT02133820|Drug|4 mg 12 hourly capsule - strong pain killer fasted|
45448283|NCT02133820|Drug|4 mg 12 hourly capsule - strong pain killer fed|
45636176|NCT05129033|Drug|itraconazole|Anti-fungal medication to reduce fugal load.
45636177|NCT05129033|Biological|Omalizumab|Anti-IgE monoclonal antibody, used for high IgE allergic disease.
45636178|NCT05675605|Drug|TY-1091|TY-1091(10mg,100mg) , once a day, oral administration Dose level is from 20mg to 800mg
45636179|NCT04780399|Drug|Yangxue Qingnao pills|72 subjects in the Yangxue Qingnao pills group take 7.5g of Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
45636180|NCT04780399|Drug|Yangxue Qingnao pills|72 subjects in the Yangxue Qingnao pills group take 5g of Yangxue Qingnao pills and 2.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
45636181|NCT04780399|Drug|Placebo|72 subjects in the placebo group take 7.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
45775355|NCT01034579|Other|Blood sampling|Subjects who had received Copaxone® (Glatiramer Acetate) 20 milligram once daily for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
45775356|NCT01317667|Biological|RVEc|
45775357|NCT00167180|Procedure|Donor Lymphocyte Infusion|donor cells infused over 2 hrs at cell dose of 0.5 dx 10^8 CD3+T-cells/kg
45914687|NCT02046642|Behavioral|Maternal rest in right lateral position|After initial amniotic fluid index measurements, the participating pregnant women were instructed to turn their right sides and rest in that position for 15 minutes before a second amniotic fluid index measurement
45636182|NCT05404997|Device|Shockwave Therapy|"Subjects in Group A will receive conventional physical therapy treatment that involves lumbar stretching exercises (bridges, knee to chest, press-up back extensions, bird dogs) and core strengthening exercises (partial crunches, pelvic tilts, wall sits, hip stretches) for ten minutes. After the conventional therapy, this group will be given shockwave therapy treatment twice a week for four weeks.~After exposing and cleaning the treated area with alcohol, adequate amount of gel will be placed on the lower back region, and the machine will be adjusted at (2000 shock per session, 8 sessions 2 per week for 4 weeks, energy flux density 0,18mJ per mm square, 2 bars of pressure, frequency 10hz), with using 20mm D-Actor head."
45636183|NCT05404997|Other|Maitland's lumbar mobilizations|"Subjects in Group B will receive conventional physical therapy treatment that involves lumbar stretching exercises (bridges, knee to chest, press-up back extensions, bird dogs) and core strengthening exercises (partial crunches, pelvic tilts, wall sits, hip stretches) for ten minutes.~After the conventional treatment, Group B will be given Maitland's lumbar postero-anterior glide mobilizations initiating from Grade 1, with 3-4 sets of oscillations of 40 counts in each set, 2 sets of oscillations will be given below and above the affected joint level.This whole mobilization treatment will also be given twice a week for 10 minutes."
45636184|NCT03114007|Behavioral|Preventure program|Personality-targeted interventions conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural components. They include real life 'scenarios' shared by local youth with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
45775358|NCT00167180|Drug|Induction Chemotherapy|Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV
45775359|NCT01035047|Other|Clinical decision unit care, coupled with cardiac MRI|After ED evaluation, patients are randomized to clinical decision unit care or inpatient care. Patients in the clinical decision unit will also undergo a stress cardiac MRI. Patients in the inpatient care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
45914688|NCT02046655|Drug|Corifollitropin alfa|
45448284|NCT02133820|Drug|12 hourly capsule strong painkiller with antagonist fasted)|
45448285|NCT02133820|Drug|4 mg 12 hourly capsule strong painkiller with antagonist fed|
45448286|NCT05578378|Drug|Cladribine|Cladribine combine with cytarabine will be intravenous on days 1-5; G-CSF will be hypodermic injection on day0-5,4 weeks per cycle.
45448287|NCT05578378|Drug|Fludarabine|"Control arm~Patients in the control arm received the investigator's choice of one of the following three regimens:~FLAG:Fludarabine(30mg/m2)should be intravenous use on day 1-5, granulocyte colony-stimulating factor will be hypodermic injection using 300 μg per day on days 0-5,cytarabine (1.5 mg/m2) every 12 hours, intravenous infusion on day1-5,4 weeks per cycle.~a high-dose cytosine arabinoside-based regimen; a high-dose methotrexate-based regimen"
45775360|NCT01317901|Drug|TRU-016|100 mg TRU-016 lyophilized solution for infusion at 10 or 20 mg/kg (or 6 mg/kg, if necessary) on Days 1 and 15 of each 28 day cycle
45775361|NCT01317901|Drug|Bendamustine|Bendamustine by IV administration on Days 1 and 2 of each 28 day cycle.
45775362|NCT01317901|Drug|Rituximab|Rituximab by IV administration at 375 mg/m^2 on Day 2 of each 28 day cycle.
45448288|NCT00129623|Drug|Placebo|po monthly for 1 year
45448289|NCT00129623|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 1 year
45914689|NCT02046655|Drug|rFSH|
45775363|NCT03008551|Drug|Empagliflozin|Each participant will receive empagliflozin 25mg daily for 3 months.
45775364|NCT03008551|Drug|Metformin|Each participant will receive metformin 1500mg daily for 3 months.
45775365|NCT01366495|Behavioral|Project Bridge|Project Bridge provides intensive case management for individuals with HIV as they transition back into the community from incarceration. The primary goal of the program is to increase continuity of medical care through social stabilization.
45775366|NCT01366885|Drug|Vitamin D3|5000 IU D3 capsule oral/day for entire pregnancy. 7000 IU D3/day during breastfeeding. If not breast feeding, baby gets 400 IU D3/day. Baby increased to 1000 IU D3/day at one year of age.
45914690|NCT02046668|Drug|spironolactone|spironolactone 25mg daily for 12 weeks
45914691|NCT02046707|Other|initial evaluation|
45914692|NCT02046707|Other|Period of cardiac rehabilitation|
45914693|NCT02046707|Other|final evaluation|
45448290|NCT02139748|Procedure|Dental Implant & ADM|A dental implant will be placed and the buccal soft tissue will be grafted using an acellular dermal matrix allograft.
45914694|NCT02046707|Other|Concentric and eccentric exercise sessions|
45636185|NCT03114007|Behavioral|Equipe program|"Parent training program designed to be delivered in community settings accessible to large groups of parents of 13 to 18 year olds. It uses a coping modeling problem solving process in which parents are the key players in developing problem solving strategies.~Parents participate in group workshops with themes related to communication, conflict resolution, cooperative transitions, negotiating, house rules, monitoring, consequences for serious problems and problem solving. Parents are guides to establish solutions to common problems. Readings and videotapes are used in the workshops to guide parents in identifying common challenges in child management, parenting errors, discussing possible consequences and alternative strategies as well as rationales supporting these strategies."
45636186|NCT03114007|Behavioral|Inter-Action services|An intervention model designed to provide integrated services for youth with significant symptoms of mental health problems, substance misuse and/or psychosocial difficulties. Young people with such difficulties will benefit from stepped and collaborative care involving interventions of varied intensity adapted to their needs and the severity of their problems. These will include cognitive behavioral therapy, motivational interviews, dialectic behavioral therapy and family interventions provided by multidisciplinary teams of professionals. A case navigator will be in charge of initiating service provision and ensuring a fast and smooth flow of information between indicated services providers.
45636187|NCT04588025|Device|Point-of-care Portable Perfusion Phantom, P4|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
45636188|NCT04557709|Other|Medical Chart Review|Review of medical charts
45636189|NCT05128721|Biological|Covi Vax|Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection. NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials. Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.
45636190|NCT03161119|Device|Ultrasound guided embryotransfer with Cook K-Jets-551910-S|"On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias."
45636191|NCT03161119|Device|Ultrasound guided embryotransfer with Cook k-soft-5000 (or K-J-SP-681710 and K-J-SPPE-681710)|"On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias."
45636192|NCT04373525|Other|Genome analysis|Venous blood will be obtained for later genome analysis
45636193|NCT04496609|Device|Stimulation and automated rehabilitation / automated rehabilitation|Stimulation and automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
45636194|NCT04496609|Device|Automated rehabilitation / Stimulation and automated rehabilitation|Automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
45636195|NCT05128175|Drug|WD-1603 Carbidopa-Levodopa Extended-Release Tablets|For fasting conditions in the morning, a single oral dose will be administered to each subject under fasting conditions before 5 minutes of serving a standardized vegetarian breakfast as per the randomization schedule; for fasting conditions in the afternoon and evening, a single oral dose will be administered to each subject under fasting condition before 5 minutes of serving standardized vegetarian lunch and dinner as per randomization schedule. For fed condition, single oral dose will be administered to each subject after 30 minutes of serving standardized vegetarian breakfast, lunch and dinner as per randomization schedule. Dosing interval between two subsequent dosing should be 5 hours in each period. There will be one tablet for A, B, C, D and E.
45636196|NCT05341427|Device|electromagnetic device|electromagnetic waves for burn wound
45636197|NCT05119205|Diagnostic Test|Bone marrow biopsy and compete blood count|Bone marrow biopsy and compete blood count will be done for follow up in patients with multiple myeloma
45636198|NCT04184453|Drug|Deferiprone treated|Deferiprone (25 mg/kg/day) was given to the enrolled patients.
45636199|NCT05127707|Behavioral|Words Matter - Visual Campaign|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings.
45636200|NCT05127707|Behavioral|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder) Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a person with opioid use disorder
45636201|NCT05127707|Behavioral|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a clinician working with patients with opioid use disorder
45636202|NCT05127707|Behavioral|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a health system administrator/leader
45636203|NCT05127707|Behavioral|Medication Treatment for Opioid Use Disorder Works - Visual Campaign|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives
45775367|NCT01424215|Drug|Indocyanine Green (ICG)|Injection of ICG intravenously then intraoperative imaging of the biliary anatomy during laparoscopic cholecystectomy using a near infrared (NIRF) imaging camera(Spy scope, Novadaq Canada)
45775368|NCT01370629|Drug|Vernakalant|Prescribed at the discretion of the physician in accordance with their usual practice
45775369|NCT02094872|Other|cytology specimen collection procedure|Undergo collection of tissue and blood samples
45636204|NCT05127707|Behavioral|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a person with opioid use disorder
45636205|NCT05127707|Behavioral|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a clinician who treats people with opioid use disorder
45636206|NCT05127707|Behavioral|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a health system administrator/leader
45636207|NCT05018975|Drug|Tazemetostat|Tazemetostat 800mg BID PO dosing for 15 days
45636208|NCT03741881|Other|No treatment given|Participants are treated with their usual prescribed treatment, either given regularly as a prevention (prophylaxis) or when needed (on-demand).
45636209|NCT05217667|Drug|ARO-ANG 3 Injection|Participants will be randomized to receive ARO-ANG3 SC on Day 1 and Day 84 during the initial 36 Weeks of the study and on Day1 and Months 3, 6, 9, 12, 15, 18, and 21 of the extension period
45636210|NCT05216029|Other|Best Practice|Receive standard of care
45636211|NCT05216029|Other|Informational Intervention|View oncology dashboard
45636212|NCT05216029|Other|Questionnaire Administration|Ancillary studies
45636213|NCT03111173|Device|Holter Device|MyECG E3.80 Holter Recorder
45636214|NCT02673697|Device|Perceval valve|Sutureless Aortic Biological Valve
45636215|NCT02673697|Device|other stented biological valve|Any biological stented valves available on the market (Edwards, Medtronic, St.Jude, LivaNova, Labcor)
45636216|NCT02891993|Other|IMPROVED|"The electronic symptom monitoring intervention, Improving Management of Patient-Reported Outcomes Via Electronic Data (IMPROVED), consists of patients self-reporting their symptoms each day using a tablet computer. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden."
45636217|NCT02891993|Other|Usual Care|Participants receiving usual care will also self-report their symptoms each day using tablet computers. However, these patients' clinicians will not receive their symptom reports. Patients randomized to usual care will report their symptoms to their clinicians as they usually would, at their own discretion.
45636218|NCT02433509|Other|HUCB monocyte cells|"The cord blood need to be infusion within less than 10 days after the onset of stroke, and the cord blood mononuclear cells 200 million ~ 500 million will used.~20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion ."
45636219|NCT05205109|Drug|ATG-037|"Part I : ATG-037 will be administered orally once a day (QD) on D-2, then multiple doses of ATG-037 will be administered orally BID for every day from C1D1. A treatment cycle will be defined as 21 days.~Part II: ATG-037 will be administered orally BID for every day from C1D1."
45636220|NCT05205109|Drug|Pembrolizumab|"Part I: After 2 cycles of ATG-037 monotherapy, eligible participants will receive ATG-037 combination therapy with pembrolizumab 200mg/Q3W fixed dose for up to 35 administrations (approximately 2 years).~Part II: Pembrolizumab will be administered from C1."
45636221|NCT02207465|Radiation|Radiotherapy|
45636222|NCT02207465|Drug|Abraxane|Dose varies within subtrial 1 to determine maximum dose. All patients in subtrial 2 receive 125mg Abraxane
45636223|NCT04533919|Procedure|Biospecimen Collection|Undergo collection of dorsal root ganglia
45636224|NCT05168579|Behavioral|Deliberate practice|As above
45636225|NCT00719225|Drug|Belatacept|IV, 5 mg/kg, once monthly, until BMS terminates trial or Belatacept is available commercially
45636226|NCT05404607|Other|Fascial distortion method with neuromuscular inhibition technique|27 participants will receive FDM with INIT followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
45636227|NCT05404607|Other|Fascial distortion method|27 participants will receive FDM followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
45636228|NCT05404451|Diagnostic Test|Mulligan Mobilization|Using the Technique of Mulligan Mobilization
45636229|NCT05404451|Diagnostic Test|Mckenzie Exercises|Using Mckenzie Exercises
45636230|NCT05127239|Behavioral|Smartphone Application with lifestyle modification Intervention|The study will introduce a health-promoting lifestyle through the combination of a smartphone app (MyFitnessPal) for the experimental group, emphasizing the use of behavior change techniques to reduce weight, thereby improving the obstructive sleep apnea with overweight and obese employees in the workplace. The self-monitoring, instant feedback, and social support, as well as individualized tailor-made functions are used in intervention programs. The intervention process adopts a healthy weight reduction plan, focusing on a balanced diet, moderately reducing the calories of the food, and combining weight loss methods such as increasing exercise as the main axis, emphasizing the concept of self-monitoring of weight, calorie intake, and exercise .
45636231|NCT05127083|Radiation|Patients will be treated with localized PBM with a diode laser|Toluidine blue was applied on the lesions.The tissue were irradiated with a 660-nm diode laser InGaAlP
45636232|NCT04566497|Other|No stress testing|No stress testing during the patient follow up (up to 48 months) if the patient remains asymptomatic
45636233|NCT04566497|Procedure|stress testing|Systematic annual stress testing during the patient follow up (up to 48 months)
45636234|NCT05134337|Drug|LOXO-305|Oral LOXO-305
45636235|NCT05134337|Drug|Itraconazole|Oral itraconazole
45636236|NCT05134337|Drug|Rifampin|Oral rifampin
45636237|NCT04535219|Other|Exercise|60 minutes of moderate-intensity treadmill exercise (70% of maximal heart rate determined from the maximal graded exercise test)
45636238|NCT04535219|Other|Supervised Total Sleep Deprivation|Laboratory-monitored total sleep deprivation
45636239|NCT04499495|Other|PENTASA (mesalamine/ 5-Aminosalicylic acid (5-ASA)|"The 5-ASAs of interest in the study are mesalazine (5-ASA); sulfasalazine (5-ASA+sulfapyridine); and balsalazide (5-ASA) and will be grouped together as 5-ASA. For sulfasalazine and balsalazide, the equivalent dose to 5-ASA will be calculated as: balsalazide 6.75g is equivalent to 2.4g of mesalamine; and Sulfasalazine 4g is equivalent to 1.6g of mesalamine.~The dose will be stratified by oral monotherapy, rectal monotherapy, oral and rectal combination therapy."
45636240|NCT05134181|Drug|sacroiliac joint injection|"Intervention will be done at complete aseptic conditions by ultrasound at frequency of 4-5 MHz patient in prone position. The ultrasound transducer will be oriented in a transverse orientation at the level of the sacral hiatus. Here the sacral cornuae are identified. Moving the transducer laterally from here, the lateral edge of the sacrum is now identified. This bony edge is~followed in a cephalad direction with the transducer maintained in a transverse orientation. A second bony contour, the ileum, is now identified. The cleft between both bony contours represented the sacroiliac joint. This will be found at 4.5 cm depth. Real-time imaging will be used to direct a 22G spinal needle into the SIJ, where 2% lidocaine and triamcinolone or methylprednisolone will be injected under direct vision.The needle will be removed, a sterile dressing will be applied"
45636241|NCT05323175|Drug|Ropivacaine injection|Local anesthesia injected under ultrasound guidance
45636242|NCT05323175|Other|Standard of care medications|Whatever the ED clinicians normally give for renal colic pain
45636243|NCT02673619|Drug|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colourless solution, free from visible particulates, for topical application. Each subject total daily dose will be calculated as per study reference manual (SRM) using subject's hand area. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm^2. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects.
45636244|NCT02673619|Drug|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application.This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm^2
45636245|NCT05126849|Other|Allogenic transplantation|"Conditioning regimen Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day-1)~Stem cell source Bone Marrow~GVHD Prophylaxis Rabbit ATG dosed at 0.5 mg/kg on day -9 and 2 mg/kg on days -8 and -7, Cyclophosphamide 50 mg/Kg/day at D+3 and D+4, Tacrolimus (residual 8-12 microg/L) and mycophenolate (MMF) from D+5. In absence of GvHD, MMF will be stopped at D35 and tacrolimus at day 365.~Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT, Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine."
45775370|NCT02094872|Drug|MEK 162 therapy or molecularly targeted therapy|molecularly targeted therapy, MEK 162 therapy
45775371|NCT02094872|Procedure|therapeutic procedure|
45775372|NCT02094872|Other|laboratory biomarker analysis|Correlative studies
45754190|NCT03590353|Device|His Bundle Pacemaker|1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
45775373|NCT02094872|Other|quality-of-life assessment|Ancillary studies
45775374|NCT01424293|Device|Indocyanine Green|1ml of intravenous ICG and imaging transanally using the Spyscope system
45775375|NCT01424293|Device|The SPY® Intraoperative Imaging System|
45775376|NCT01899170|Procedure|Deep brain stimulation|Implantation of a deep brain stimulation electrode into pain processing brain areas
45775377|NCT01899170|Device|Cervel Neurotech, Multi-coil TMS|Non-invasive selective stimulation of deep brain areas using magnetic fields.
45775378|NCT01899170|Drug|11C-Carfentanil|PET-radioligand for functional brain imaging to assess opioid binding. The compound is a potent synthetic opioid.
45775379|NCT01425229|Drug|Bosentan|"Administration of bosentan: 1 x 125 mg p.o. on day 1, 2 x 125 mg p.o. on day 2-14~Administration of clarithromycin: 2 x 500 mg p.o. on day 11-14"
45775380|NCT00258362|Drug|carboplatin|Dose = Area-under-the-curve 6 on Day 1 every 3 weeks for 3 cycles.
45775381|NCT00258362|Drug|docetaxel|75 mg/m^2 on Day 1 of each course
45775382|NCT00258362|Radiation|radiation therapy|Weekly, 5 days/week over 6-7 weeks (tailored 4500 cGy)
45636246|NCT05279963|Procedure|electroacupuncture|"The prespecified acupoints applied here will include bilateral Sanyinjiao(SP6), Shenshu(BL23), Ciliao(BL32), Zhongliao(BL33), Zhibian(BL54) .~Acupuncture treatment is carried out by acupuncturists who have been well trained. Acupuncture will be performed with disposable and sterile needles in the specification of 0.25 ×40 mm(diameter: 0.25mm; Suzhou Medical Products Factory Co., Ltd, China). Electroacupuncture procedures will be performed with electronic instruments (Hans-100A, Nanjing Jisheng Medical TechnologyCo., Ltd, China). Two paired of acupoints (i.e., two Shenshu(BL23) and two Ciliao(BL32), respectively) are connected to the EA apparatus. Alternating-frequency mode is selected and frequency is 2/100 Hz. EA intensity is determined in accordance with patients' endurance. EA will last for 30 min for each treatment. Patients will receive a total number of 12 EA sessions, with the frequency of 3 sessions per week for 4 weeks."
45636247|NCT05279963|Drug|Amitriptyline|Participants in the medication group will be merely treated with oral administration of amitriptyline capsule. The dosage of amitriptyline is 25mg bid, for 4 weeks. Any changes in the medications of individual participants will be recorded on diary cards.
45636248|NCT05279963|Procedure|sham electroacupuncture|"In the trunk region, the points are 5 cm away from respective acupoints. In the lower limb region, the point is 3 cm away from Sanyinjiao(SP6). All points will only receive shallow insertion.~Acupuncture will be performed with disposable and sterile needles in the specification of 0.25 ×40 mm(diameter: 0.25mm; Suzhou Medical Products Factory Co., Ltd, China).The needles are shallowly inserted to the subcutaneous area, and acupoints are connected to the EA apparatus without electricity. The frequency, intensity and duration of treatment will be the same as the electric needle group."
45775383|NCT00258830|Biological|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
45636249|NCT03161197|Behavioral|Mindfulness-Based Stress Reduction|The intervention consists of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, the intervention subjects, during every point of contact, will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
45636250|NCT03160963|Other|Power Testing|Chair stand, vertical jump, computerized squat
45636251|NCT05158543|Other|conventional therapy|The conventional group will receive active and passive range of motion exercises, balance, and strength training for upper and lower limbs. One session per day, three sessions/week for total of 12 weeks.
45636252|NCT05158543|Other|Task oriented training (moderate intensity)|In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Single session/day, 4 sessions/week for 12 weeks.
45636253|NCT05158543|Other|Task oriented training (high intensity)|In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Two sessions/day, 5 sessions/week for 12 weeks.
45636254|NCT05235659|Behavioral|Basic modules|Caregivers will only have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child.
45775384|NCT00258830|Biological|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
45775385|NCT02095340|Other|Positive Interpretation Bias Training|
45775386|NCT02095340|Other|Neutral Interpretation Bias Training|
45775387|NCT02539368|Drug|CT-P13|biosimilar infliximab
45775388|NCT02539368|Drug|Remicade|infliximab
45775389|NCT01425307|Drug|Hydroxyurea|Capsules (300 mg, 400 mg, or 500 mg) taken once daily liquid formulation (100 mg/mL)
45775390|NCT01035749|Biological|GSK Biologicals' Influenza investigational vaccine GSK2340274A|One or two doses administered intramuscularly
45775391|NCT01035749|Biological|GSK Biologicals' Influenza investigational vaccine GSK2340273A|Two doses intramuscularly
45775392|NCT01035749|Biological|Placebo (saline)|One dose intramuscularly
45775393|NCT00123110|Drug|metformin|Initiated on 500 mg daily and titrated up to 1000 mg twice a day during the first four weeks, remaining at that dose until 12 weeks
45775394|NCT00123110|Drug|leuprolide injection|3.75 mg injection every 4 weeks (e.g. at baseline, 4, and 8 weeks)
45775395|NCT00123110|Drug|placebo pill|matching pill twice a day for 12 weeks
45775396|NCT00123110|Drug|placebo injection|matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)
45775397|NCT01898156|Drug|BIW-8962|"Phase 1 -With a standard 3+3 dose escalation design, the enrollment in Phase 1 will proceed until the MTD has been defined or the highest dose level has been reached. BIW-8962 will be administered intravenously on day 1 of each 21 day cycle.~Phase 2 - RP2D of BIW-8962 determined in phase 1 portion will be administered until progression or unacceptable toxicity develops."
45775398|NCT02096276|Other|Data collection|Initial and follow-up data will be collected using questionnaires.
45775399|NCT01425853|Drug|Chondroitin/Glucosamine (Droglican)|Experimental
45775400|NCT01425853|Drug|Celecoxib|Active comparator
45775401|NCT01426867|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
45775402|NCT01426867|Drug|Brinzolamide ophthalmic suspension, 1%|
45775403|NCT01426867|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
45775404|NCT02203747|Other|Administration of patient self-assessment|
45775405|NCT00168428|Biological|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
45636255|NCT05235659|Behavioral|"Basic modules and experimental condition My coach"|Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Professional support of the caregiver will be provided. Caregivers will receive one phone call (50 minutes) to support processing of information from module 1 and 2. Finally, they will receive text messages or emails with the core message of the modules.
45636256|NCT05235659|Behavioral|"Basic modules and experimental module Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
45636257|NCT05235659|Behavioral|"Basic modules and experimental modules Who am I and where do I belong? and My coach"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 5. Finally, they will receive text messages or emails with the core message of the modules."
45636258|NCT05235659|Behavioral|"Basic modules and experimental module You are safe here"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers."
45636259|NCT05235659|Behavioral|"Basic modules and experimental modules You are safe here and My coach"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 4. Finally, they will receive text messages or emails with the core message of the modules."
45636260|NCT05235659|Behavioral|"Basic modules and experimental modules You are safe here and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
45636261|NCT05235659|Behavioral|"Basic modules and experimental modules You are safe here, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 4, and 5. Finally, they will receive text messages or emails with the core message of the modules."
45775406|NCT00168428|Other|placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
45775407|NCT01427881|Drug|cyclophosphamide|Given IV
45775408|NCT01427881|Drug|cyclosporine|Given IV
45775409|NCT01427881|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSCT
45775410|NCT01427881|Radiation|total-body irradiation|Undergo TBI
45775411|NCT01427881|Drug|fludarabine phosphate|Given IV
45775412|NCT01427881|Drug|busulfan|Given IV
45775413|NCT01427881|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
45775414|NCT00258908|Biological|Diphteria, tetanus, and Acellular Pertussis vaccine|0.5 mL, Intramuscular
45775415|NCT02112734|Drug|Vitamin D|400 IU/daily until age 12 months
45775416|NCT02112734|Drug|placebo|identical placebo daily
45775417|NCT01319539|Drug|Akt Inhibitor MK2206|Given PO
45775418|NCT01319539|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45775419|NCT01319539|Other|Pharmacological Study|Correlative studies
45775420|NCT01319539|Other|Laboratory Biomarker Analysis|Correlative studies
45775421|NCT01319617|Device|SENSIMED Triggerfish|Soft contact lens-based device intended for continuous recording of relative changes in IOP
45775422|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation A|One drop of cyclosporine ophthalmic emulsion Formulation A administered to each eye twice daily for 2 days and once in the morning of Day 3.
45775423|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation B administered to each eye twice daily for 2 days and once in the morning of Day 3.
45448291|NCT02139748|Procedure|Dental Implant & ADM & bone xenograft|A dental implant will be placed along with a buccal acellular dermal matrix allograft which will cover a bone xenograft.
45636262|NCT05235659|Behavioral|"Basic modules and experimental module Watch out!"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior."
45636263|NCT05235659|Behavioral|"Basic modules and experimental modules Watch out! and My coach"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 3. Finally, they will receive text messages or emails with the core message of the modules."
45636264|NCT05235659|Behavioral|"Basic modules and experimental modules Watch out! and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
45636265|NCT05235659|Behavioral|"Basic modules and experimental modules Watch out!, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, and 5. Finally, they will receive text messages or emails with the core message of the modules."
45636266|NCT05235659|Behavioral|"Basic modules and experimental modules Watch out! and You are safe here"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers."
45636267|NCT05235659|Behavioral|"Basic modules and experimental modules Watch out!, You are safe here, and My coach"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, and 4. Finally, they will receive text messages or emails with the core message of the modules."
45636268|NCT05235659|Behavioral|"Basic modules and experimental modules Watch out!, You are safe here, and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
45754191|NCT05581628|Diagnostic Test|Pain location inventory (PLI)|PLI is obtained by questioning the pain in 28 regions in the last 7 days. Total score is between 0-28
45775424|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
45775425|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation B administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
45775426|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion Formulation B administered to the opposite eye, twice daily for 1 day.
45775427|NCT01319851|Drug|Alefacept|0.25 mg/kg IV on day -40 and day -39 0.5 mg/kg IV on days -33, -26, -19 and -12 Alefacept was diluted in sterile water (2 ml total volume) and administered via i.v. push followed by a normal saline flush per package insert.
45775428|NCT04351867|Drug|docetaxel plus oxaliplatin and capecitabine|docetaxel 50mg/㎡ ivgtt. d1+oxaliplatin 100mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
45775429|NCT04351867|Drug|oxaliplatin plus capecitabine|oxaliplatin 130mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
45775430|NCT02539134|Drug|TAK-935|TAK-935 oral solution
45448292|NCT02139904|Drug|Vinorelbine|Vinorelbine was first licensed in the UK for Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer in 1997. Vinorelbine (Navelbine®) is a semi-synthetic, third generation, vinca alkaloid. The cytotoxic effect of vinorelbine is through the disruption of mitotic spindle formation, blocking mitosis at the G2-M stage resulting in cell death.
45636269|NCT05235659|Behavioral|"Basic modules and experimental modules Watch out!, You are safe here, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation. They will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Further access will be provided to module 4 You are safe here on improving children´s relationship-related safety and facilitating solid relationships. Access to module 5 Who am I and where do I belong? will support caregivers in helping their child develop an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support will be provided. They will receive four phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, 4, and 5. Text messages or emails with the core message of the modules will be provided."
45636270|NCT05146297|Behavioral|Clinical trial match-list|Creation and dissemination educational materials designed to inform and empower patients' participation in their cancer treatment including the consideration of clinical trial participation and provide clinical trials' patient navigators (CTPN) to further aid with education about clinical trials.
45636271|NCT05146297|Behavioral|Match-list intervention|Providers by intervening at the clinical and systems levels to provide them with tools and processes and informational and practical support to facilitate CT consideration, discussion, and offer to aid with education about clinical trials and facilitate CT consideration at a treatment decision node.
45636272|NCT05133869|Device|Metacognitive training + direct training|"The intervention will consist of a combination of direct training of the impaired cognitive function(s) and metacognitive strategy training for 42 days (6 weeks). Direct training will be done with the computer program Rehacom for 20 minutes, 5 times a week. Metacognitive strategy training will be given on a weekly or biweekly basis (6-10 sessions) by a trained therapist at Adelante.~Rehacom is a brain training program developed to improve a variety of cognitive functions with the use of game-like cognitive training modules. During the intervention the participant should train with Rehacom for approximately 600 minutes in total.~In addition to the direct training, the participant receives six to ten sessions of metacognitive strategy training. During this training they are taught strategies by a therapist to improve their performance on the Rehacom modules and on daily life functioning. Each metacognitive strategy is linked to one of the Rehacom modules."
45636273|NCT05231863|Drug|TKIs|tyrosine kinase inhibitors based therapy
45636274|NCT05126693|Other|Botulinum Toxin treatment combined with a post-BoNT intensive physical therapy period guided by individualized treatment goals.|BoNT treatment combined with a follow-up period of intensive physical therapy of 8-10 weeks. During this intensive physical therapy post BoNT injections, the children in the intervention group will work on individualized treatment goals, which will be defined based on the baseline measurements during a multidisciplinary discussion with the treating physician (planned prior to the BoNT injections).
45636275|NCT03164317|Other|Intervention|A trained nurse care coordinator enabled with a electronic decision support system placed at the CHCs to share the task of management of hypertension.
45636276|NCT03164317|Other|Control|No NCC or EDSS will be placed in the CHCs. Doctors working in the CHCs will be given training (one day) on evidence based management of hypertension
45636277|NCT04442087|Biological|Serology SARS-CoV2|Collect serum for Serology SARS-CoV2 at inclusion
45636278|NCT04442087|Behavioral|Data collection|Collect clinical and demographic data, habitus, Lifestyle Counseling at inclusion
45636279|NCT05133791|Drug|Annexin A5|Annexin A5 coupled to IRDye800CW as a potential treatment for RVO
45636280|NCT03164239|Behavioral|Intervention group - telephone and print exercise intervention|Intervention has previously been described.
45636281|NCT05133635|Drug|Methylprednisolone|Patients with the clinical and laboratory diagnosis of cytokine storm will receive methylprednisolone 250 mg for 3 days.
45775431|NCT02539134|Drug|Placebo|TAK-935 placebo-matching oral solution
45775432|NCT00262730|Drug|poly ICLC|20 mcg/kg 3x each week (Maintenance cycles)
45636282|NCT05133635|Drug|Tocilizumab|Patients with the clinical and laboratory diagnosis of cytokine storm will receive tocilizumab 400-800 mg for one time.
45775433|NCT00262730|Drug|temozolomide|daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)
45775434|NCT00262730|Radiation|radiation therapy|RT: 60 Gy (6 weeks) concomitant therapy
45775435|NCT01320553|Drug|SPARC1102 I|SPARC1102 I will be administered in both eyes
45775436|NCT01320553|Drug|SPARC1102 II|SPARC1102 II will be administered in both eyes
45775437|NCT01320553|Drug|SPARC1102 III|SPARC1102 III will be administered in both eyes
45775438|NCT01320553|Drug|Vehicle|Vehicle will be administered in both eyes
45775439|NCT04262934|Drug|Cholecalciferol 100.000 UI administration|One oral Administration - Every month
45775440|NCT04262934|Other|No vitamin D administration|No vitamin D administration
45914695|NCT02046720|Drug|Propofol induced sedation|"Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.~The BIS index was compared between a young population (18 to 64 years old) and an elderly population (65 and more)"
45636283|NCT05133557|Other|Chewing gum containing xylitol and blackberry extract (BBE)|On the day of gum chewing, four pieces of gum were provided per the assigned group, and each volunteer was requested to chew the gum four times daily (i.e., at 9 am, 11 am, 1 pm and 3 pm). Each gum chewing interval was for 20 minutes.
45636284|NCT04253587|Device|LabyrinthVR|Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, immersive regimen of wayfinding in novel urban and village neighborhoods.
45636285|NCT04253587|Device|Placebo Games|Commercially-available, narrative computer games marketed as cognitively enriching.
45636286|NCT04253587|Device|Coherence|Head-mounted display virtual reality game designed to present an adaptive rhythm training routine.
45636287|NCT04253587|Device|Tablet|Tablet computer playing Labyrinth VR game but in 2.5D
45636288|NCT05133167|Procedure|Balloon Tamponade or B-Lynch|In group A, balloon tamponade (using Foley catheter 28 Fr) was used intra-operatively to prevent post-partum hemorrhage. Post-operative blood loss within first 24 hours was estimated by measuring the amount of blood collected in Foley balloon tamponade bag, in milliliters. In group B, B lynch suture was used intra-operatively to prevent post-partum hemorrhage. Post-operative blood loss within first 24 hours was estimated by the weight difference of the pads before and after patient use (1-gram weight difference = 1 ml blood volume lost). Mean blood loss within first 24 hours post procedure, was compared in both the groups for outcome measurement.
45636289|NCT05118529|Other|Routine care|Mobilization to chair
45636290|NCT04219969|Drug|Fludeoxyglucose F-18|Given IV
45636291|NCT04219969|Device|Magnetic Resonance Imaging|Undergo PET-MRI
45636292|NCT04219969|Procedure|Positron Emission Tomography|Undergo PET-MRI
45636293|NCT05132933|Procedure|PEEP trial - Electrical Impedance Tomography|Three different levels of PEEP and two different levels of FiO2 will be tested without changing anything else in the baseline patient ventilation
45636294|NCT05132777|Drug|JMT101|JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
45636295|NCT05132777|Drug|Osimertinib Mesylate Tablets|Osimertinib, 160 mg, Oral administration once daily (one treatment cycle is 4 weeks).
45636296|NCT02680639|Device|BiPAP Synchrony ventilator|The BiPAP Synchrony ventilator will be used to determine Expiratory Positive Airway Pressure (EPAP). The ventilator will be used with varying pressure supports and oscillations depending on what arm of the study the participant is in.
45636297|NCT05126615|Drug|Auriculotherapy|Application of a bolus of 5 μ of liquid nitrogen via a cryospray on the auriculotherapy points A4, C18, D9, C9, DIX, H13, G14 and FXVII, chosen according to a neurophysiological reasoning taking into account the surgical intervention performed and innervation of the anatomical region affected by the intervention.
45636298|NCT05126615|Behavioral|Chronic Post-Surgical Pain evaluation|"Different questionnaires :~BPI : Brief Pain Inventory DN4"
45636299|NCT05126069|Device|Ab interno gelatin microstent|Ab interno gelatin microstent
45636300|NCT05126069|Procedure|Trabeculectomy|Trabeculectomy
45636301|NCT05422027|Drug|Selinexor|"Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Selinexor dose escalation: 40, 60mg respectively on day 1,8,15 for 21 days cycles"
45636302|NCT05422027|Drug|Bortezomib|"The investigators gave patients subcutaneous bortezomib 1.3mg/sqm on days 1, 8,15 of a 21- day cycle.~standard bortezomib-lenalidomide-dexamethasone"
45636303|NCT05422027|Drug|Lenalidomide|"The investigators gave patients oral lenalidomide 25mg on days 1 to 14 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone"
45636304|NCT05422027|Drug|Dexamethasone|"The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone"
45636305|NCT05132621|Diagnostic Test|Smear|A smear of the posterior vaginal fornix collected with a gynecological speculum.
45636306|NCT05080777|Behavioral|Tele-Savvy|A low-risk, psychoeducational, group-based intervention, is grounded in social learning and stress process theory and its main goal is to produce improved caregiver mastery over the symptom management skills commonly encountered when supervising and caring at home for an older adult living with ADRD. Over the 7-week program, there are synchronous and asynchronous activities each week. The synchronous portion includes weekly scheduled videoconferences (60-80 min) that serve as an online classroom in which facilitators lead lectures and discussions. Daily, caregivers access online 6- to 15-min prerecorded videos, each focused on one main learning objective. Caregivers can watch the lessons whenever and as often as they wish.
45636307|NCT05080777|Behavioral|Caregiving During Crisis (Educational Program)|The attention control group will receive the self-guided Caregiving During Crisis program. Caregiving During Crisis is a fully online, asynchronous, professionally designed continuing education course aimed at developing the competency of informal caregivers of community-dwelling persons living with dementia to ensure the safety of that person and themselves during this time of the COVID-19 pandemic. The course, readily accessible by home computer or smartphone, describes methods of home infection control and prevention to create a Safe Home space, strategies for safely leaving and re-entering the home (e.g., to shop), additional strategies for safely allowing service personnel (e.g., home health aides or electricians) and select family members to enter the Safe Home space, and risk management strategies to frame decisions when/if COVID restrictions are relaxed or revoked.
45636308|NCT05132309|Combination Product|enzyme replacement therapy|Correction of the previously prescribed dose of enzyme replacement therapy (ERT)/first time selection of ERT according to the severity of pancreatic exocrine insufficiency
45448293|NCT02139904|Other|Active Symptom Control|
45448294|NCT02133976|Behavioral|cognitive therapy|
45636309|NCT05072821|Drug|Botulinum Toxin Type A Injection [Botox]|After the whole surgical procedures of keloid revision are done, the participants will receive Botulinum Toxin type A (BTA) injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Vials containing 100 units of BTA (BotoxⓇ, Allergan) are mixed with 2mL 0.9% injectable saline. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was treated, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 8 units / cm based on aforementioned studies. The maximal dose won't exceed 100 units.
45636310|NCT05072821|Drug|0.9% Sodium Chloride Injection|After the whole surgical procedures of keloid revision are done, the participants will receive 0.9% saline injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Only 0.9% saline is injected on the control side. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was injected, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 0.16 mL / cm.
45636311|NCT05125991|Procedure|Prepectoral reconstruction|Prepectoral breast reconstruction
45636312|NCT05125991|Procedure|Submuscolar reconstruction|Submuscolar breast reconstruction
45636313|NCT04149691|Drug|CPL304110|CPL304110 is to be administered orally as hard gelatine capsules once daily in 28-day cycles.
45636314|NCT01674725|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
45636315|NCT01674725|Drug|Ribavirin|Tablet
45636316|NCT03164083|Biological|Mesenchymal stem cell|intra articular injection of mesenchymal stem cell Other Name: stem cell transplantation
45636317|NCT03164083|Biological|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
45636318|NCT03164395|Procedure|Internal Cardioversion|Internal Cardioversion with device maximum output shock from RV coil to Can versus external cardioversion per institutional protocol
45636319|NCT03164395|Procedure|External Cardioversion|External Cardioversion per institutional protocol
45636320|NCT05404061|Other|Gut hormones|"Their first visit will act as an acclimatisation visit and participants will be infused subcutaneously with a triple gut hormone infusion (GLP-1, PYY and OXM). This will not only allow us to acclimatise the study volunteer to the study visits, but also allow us to test for subject tolerability of the gut hormones.~For the next two visits participants will be randomised in a single-blinded fashion to a subcutaneous infusion of either:~0.9% saline,~GLP-1"
45636321|NCT05051293|Other|serum concentration of estrogen (E1 and E2) and testosterone ratio measurement|To measure the serum concentration of estrogen (E1 and E2) and testosterone ratio in all male cirrhosis patients
45636322|NCT03161041|Procedure|Cytoreductive surgery combined with HIPEC|Procedure/Surgery: Cytoreductive surgery combined with HIPEC (Oxaliplatin 360 mg/m2).
45636323|NCT03161041|Drug|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
45636324|NCT05123495|Behavioral|Device Briefing Tool|A 4-item supplement to the WHO Surgical Safety Checklist designed to improve teamwork and communication around new/complex surgical devices
46070165|NCT04116255|Other|Temporomandibular joint Exercises|This program was created by combining patient training and a home exercise program. The exercise program consisted of slow passive and active mouth opening and closing exercises, isometric masseter exercises, mouth stretching exercises, and resistant mouth opening and closing exercises. Each exercise set was administered twice a day, and each movement was undertaken for 10 seconds and repeated 15 times. The training was given by an experienced physical medicine and rehabilitation expert over approximately 45 minutes. The exercise program was demonstrated for the patients in front of a mirror, and each exercise was performed by a set of patients under the supervision of a doctor. A training document including the written exercise program was to the patients in the exercises group.
46070166|NCT02553031|Device|The imaging biomarkers determined by MR-PET|This study will explore the potential value in proper therapeutic decision and clinical outcome prediction by using integrated MR-PET system and advanced MR techniques in patients with colorectal cancer.
46070167|NCT00809419|Device|NeoVista Ophthalmic System|A single procedure with the NeoVista Ophthalmic System, with Lucentis (0.5mg) administered on an as needed basis for three years.
45775441|NCT03009253|Other|order of treatment|the 2 arms have different orders of treatment,participants in arm A accept concurrent chemoradiotherapy at first and then accept evalution for surgery.In arm B,participants accept concurrent chemoradiotherapy at first and then accept evalution for surgery.
46070168|NCT00805519|Drug|Glucosamine and chondroitin sulfate|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients, daily.
45636325|NCT05123495|Behavioral|Surgical Safety Checklist|Reimplementation of the WHO Surgical Safety Checklist to improve adherence and utility of the checklist
45636326|NCT04139317|Drug|Capmatinib|Oral tablet
45636327|NCT04139317|Biological|Pembrolizumab|IV infusion
45636328|NCT03138629|Drug|VAL-083|VAL-083 will be administered intravenously
45636329|NCT05120219|Drug|FDC tablet|single HR20033 FDC tablet fed, take orally on an empty stomach and then after meals
45636330|NCT05120219|Drug|FDC tablet|single HR20033 FDC tablet fasted, take orally after meals and then on an empty stomach
45636331|NCT05120219|Drug|FDC tablet|single and multiple doses of HR20033 FDC tablet
45636332|NCT05119517|Other|Osteopathic manipulative medicine pedal pump|In this 7 minute intervention, the patient receives 2 minutes of myofascial release of the thoracic inlet and then 5 minutes of the pedal pump technique
45775442|NCT00262964|Drug|Niacin|Subjects randomized to Niacin therapy will be treated with Niacin at night for 16 wks to reduce plasma free fatty acid concentrations. The dose of medication will be gradually increased: 500 mg/day during week 1, 1000 mg/day during week 2, 1500 mg/day during week 3, and 2000mg/day during weeks 4-16.
45775443|NCT00262964|Drug|fenofibrate|Subjects randomized to fenofibrate will be treated with 200 mgs per day for eight weeks.
45775444|NCT00262964|Drug|placebo|Subjects randomized to placebo will be treated with one placebo pill per day for eight weeks.
45775445|NCT01321177|Behavioral|Integrated Treatment|"Integrated program of treatments and services delivered by a coordinated team of providers that includes:~education about schizophrenia and its treatment for the participants and their family members~medication for symptoms and preventing relapse that uses a computerized decision support system~strategies for managing the illness and building personal resilience~help getting back to school or work using a supported employment/education model"
45636333|NCT05119049|Other|Exercise guideline|The experimental group underwent 20 sessions with an aquatic exercise plan in the pool at the rehabilitation department. The control group did the same exercises in one of the rooms in the rehabilitation department, with the same number of sessions. Both groups were guided by a physiotherapist. The main outcome variables were assessed at the start of the study, at the end of the 20 sessions, and at 3 months after completing the sessions.
45636334|NCT05113355|Drug|Chidamide|30mg; administered orally; twice a week (d1, d4, d8, d11, d15, d18). Repeat every 3 weeks for up to 24 months.
46070169|NCT00805519|Drug|glucosamine and chondroitin sulfate plus Prednisolone|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive Prednisolone 5 mg/day
45636335|NCT05113355|Drug|Sintilimab|200mg; intravenous infusion; d1. Repeat every 3 weeks for up to 24 months.
45636336|NCT03163693|Drug|dexmedetomidine|receive dexmedetomidine 0.5 μg/kg
45636337|NCT03163693|Other|normal saline|receive equal volume of normal saline
45636338|NCT05054543|Drug|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
45636339|NCT05054543|Drug|Placebo|0.9% Sodium Chloride
45636340|NCT05044507|Device|BQ 2.0|frequency and intensity parameters will be set to zero so that no stimulation is delivered
45636341|NCT05044507|Device|BQ 2.0|The BQ 2.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; up to 1 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
45636342|NCT05125757|Other|lifestyle modification|for 12 week, the patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)
45636343|NCT05125757|Other|usual lifestyle|the patients will receive the usual immuno-modulating therapy with continued usual diet and activities
45636344|NCT04439617|Biological|blood examination|use of the remaining 1-2 ml of blood in samples taken as part of routine care to study mitochondrial function
45775446|NCT01321177|Behavioral|Community Care|"Standard mental health treatments and services offered at the local agency that may include :~medication for symptoms and preventing relapse~psychosocial therapy which may include a range of behavioral treatments and supportive services~Case management"
46070170|NCT00805519|Drug|Glucosamine and Chondroitin sulfate plus Chloroquine|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive chloroquine 150 mg every two days.
46070171|NCT00805519|Drug|Glucosamine,Chondroitin sulfate,Prednisolone,Chloroquine|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive prednisolone 5 mg/day and chloroquine 150 mg every two days.
46070172|NCT00592683|Drug|Aripiprazole|tablet, start at 2mg and increase/decrease each week, taken daily for 12 weeks
46070173|NCT00592683|Dietary Supplement|fish oil|1600mg (4 capsules) daily for 12 weeks
46070174|NCT00592683|Drug|Placebo|Placebo
46070175|NCT00805597|Radiation|radiation|radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region
45636345|NCT05030545|Drug|Eplerenone|After baseline cardiac imaging with PET and echocardiogram, participants will be treated with eplerenone for 6 months at a starting dose of 50mg daily and up to a maximally tolerated dose of 100mg daily, followed by repeat imaging with PET and echocardiogram.
45636346|NCT03163927|Other|Simulation-based training|See arm description
45636347|NCT03106805|Procedure|early insertion|insertion at 4th postpartum week
45636348|NCT03106805|Procedure|late insertion|insertion at 6th postpartum week
45636349|NCT03164161|Device|Cold pressor test|Described before.
46070176|NCT00805597|Radiation|no radiation|no radiotherapy
45636350|NCT03164161|Other|β-endorphins evaluation in saliva|Described before.
45636351|NCT03164161|Other|β-endorphins evaluation in blood plasma|Described before.
45636352|NCT02627183|Procedure|Catheter ablation|Subjects undergoing catheter ablation for the first time for atrial fibrillation as part of their regular care (regardless of involvement in this study).
45775447|NCT01372813|Drug|vandetanib|Daily dose 300mg/day by mouth, 28 day cycle
45636353|NCT02627183|Behavioral|Exercise training|Subjects participating in supervised exercise classes for up to 60 minutes in length 2 times/week as part of their involvement in another study (NCT02602457).
45636354|NCT04960475|Other|Hospital Anxious and Depression(HADS)|The assessment content in the scale is divided into two parts: anxiety and depression. Anxiety is an unexplained state of restlessness, manifested as tension, fear, and panic all day long. Depression is manifested as depression, slow thinking, decreased volition and physical symptoms. The two parts are scored separately. A total score of 0-7 means normal, a total score of 8-10 means mild depression/anxiety, a total score of 11-14 means moderate depression/anxiety, and a total score of 15-21 means severe depression/ anxiety.
45636355|NCT04960475|Other|Fear-Avoidance Belief Questionnaire (FABQ)|FABQ is a self-assessment questionnaire with 16 options. Each option has 7 levels of 0-6 points, representing totally disagree, uncertain, and totally agree; there are 2 subscales, and one subscale measures the fear-avoidance in physical activity, another subscale measures fear-avoidance of work. The final score of FABQ is the superposition of the value of each item. A high score indicates a high level of fear-avoidance beliefs.
45636356|NCT04960475|Other|The MOS 36-Item Short From Health Survey (SF-36)|The SF-36 is a multi-purpose survey designed to capture adult patients' perceptions of their own health and well-being. The SF-36 has 36 items grouped in 8 dimensions: physical functoning, physicial and emotional limitations, social functioning, bodily pain, general and mental health.
45636357|NCT03163615|Drug|Tibet Rhodiola Capsule|4 capsules, po, from admission up to 84 days
45636358|NCT03163615|Drug|Placebo oral capsule|4 capsules, po, from admission up to 84 days
45636359|NCT04439695|Biological|Low dose|Low dose of KBP-V001
45636360|NCT04439695|Biological|Intermediate dose|Intermediate dose of KBP-V001
45636361|NCT04439695|Biological|High dose|High dose of KBP-V001
45636362|NCT04439695|Biological|Placebo|Buffered Saline Solution
45636363|NCT05675215|Diagnostic Test|Psychopathology screening tests|"The assessment phase includes the SCID-5 (First et al., 2017), the D-PSY questionnaire and standardized questionnaires. The D-PSY questionnaire and the SCID-5 (First et al., 2017) will be counterbalanced in terms of the order of administration, with half of the participants taking the SCID-5 (First et al., 2017) first and then the D-PSY questionnaire and the others standardized; the other half will take the D-PSY first and then the SCID-5 (First et al., 2017) and the other questionnaires.~The other standardised questionnaires will be randomised for order of administration. These standardised questionnaires measure social desirability (Balanced Inventory of Desirable Responding, BIDR, Paulhus, 1985, 1991; in French: Cournoyer & Sabourin, 1991), dissociation (DIS-Q, Vanderlinden et al., 1993), phobia (the Fear Questionnaire, F.Q., Marks & Mathews, 1979; in French Cottraux et al., 1987) and autism (AQ, Baron-Cohen et al., 2001; in French, translation by Braun & Kempenaers, 2007)."
45636364|NCT03114787|Other|Study on patients with respiratory resuscitation|Patient intubated with mechanical ventilation in VS-AI mode, whose weaning is difficult
45636365|NCT05125445|Procedure|Implants placed at bone crest|"Mid crestal incision will be performed and full-thickness envelope flap will be elevated to expose the alveolar ridge (no releasing incisions will be made).~Implant site will be prepared according to the manufacturer's instructions under sterile copious irrigation Implants will be placed at crestal level"
45636366|NCT05125445|Procedure|Implants placed 1mm Subcrestally|Implants will be placed 1mm subcrestally
45636367|NCT03114475|Radiation|CO2 laser irradiation|CO2 laser irradiation will be applied onto the enamel surrounding the orthodontic bracket
45636368|NCT03114475|Other|Placebo|No irradiation is going to be applied in the intervention. Just a red light will be used as placebo.
45636369|NCT00754949|Drug|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
46070177|NCT02613039|Drug|Combined Estrogen-Progestin Oral Contraceptives|All patients enrolled will undergo Combined Estrogen-Progestin Oral Contraceptives. Different compounds will be chosen according to the approved indications and clinical practice. Therefore it is not possible to provide a specific trade and/or generic name.
45448295|NCT02133976|Behavioral|mindfulness training|
45636370|NCT00754949|Drug|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
45636371|NCT00754949|Drug|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
45636372|NCT03114709|Other|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social support in mindfulness practices and physical activity.
45636373|NCT03114709|Other|10 Keys to Health & Wellbeing|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
45636374|NCT05022121|Behavioral|Supported Biopsychosocial Self-Management (SBSM)|Participants receive training and instruction in skills to engage in healthy physical, psychological, and social self-management behaviors. This will be accomplished through 6-12 sessions with a trained chiropractor or physical therapist. Patients will receive training and instruction in exercises targeting posture, strength, stabilization, and mobility based on their individual needs. They will learn psychological strategies including problem solving and cognitive restructuring to address unhelpful thoughts and emotions. Social strategies include pleasant activity planning with a social focus, and communication techniques for navigating relationships to garner support for self-sufficiency. Other elements include providing key evidence based information about BRLP and spinal manipulation therapies (SMT). SMT will include manipulation, mobilization and soft-tissue treatment. Other intervention elements include enablement, persuasion, and resources and materials to support the patient.
45754192|NCT05581628|Diagnostic Test|Symptom Impact Questionnaire (SIQR)|The SIQR score includes a total of 10 different evaluations in the last 7 days, including pain, energy, stiffness, sleep, depression, memory problems, anxiety, sensitivity to touch, balance problems, sensitivity to loud sounds-bright light-smells-cold. Each item is scored between 0-10 and the total score is obtained between 0-100. This total score is divided by 2 to get the SIQR score
45775448|NCT00124514|Drug|Triptorelin pamoate|IM injection given monthly
45448296|NCT02133976|Behavioral|behavioral therapy|
45636375|NCT05022121|Drug|Medical Care|Medical care will be comprised of primarily medication management, which is a standard first-line approach for back-related leg pain in primary care. Choice of medications is informed by the current evidence and the American College of Physicians guidelines on noninvasive treatment for LBP which balances evidence for risks and benefits when making recommendations. Decisions regarding medication selection will be made collaboratively between the study provider and patient after a discussion of risk/benefit profiles and patient preferences, including prior response. Study providers licensed to prescribe FDA-approved medications will call-in the prescription for the medication of choice to the participant's preferred pharmacy, as is typical in clinical practice.
45636376|NCT05011045|Procedure|Magnetic Resonance Imaging|Undergo MRI
45636377|NCT05011045|Other|Neurocognitive Assessment|Undergo neurocognitive function assessment
45636378|NCT05011045|Other|Quality-of-Life Assessment|Complete questionnaires
45636379|NCT05011045|Other|Questionnaire Administration|Complete questionnaires
45636380|NCT05675137|Device|mobile-based|Participants who were randomly assigned to the mobile-based intervention group were provided multidomain programs based on scientific evidence of ways to improve brain-health and reduce dementia risk for 10 minutes per day and at least 50 minutes per week.
45636381|NCT05675137|Other|paper-based|Participants who were randomly assigned to the paper-based intervention group were provided with the Korean version of the dementia prevention booklet published by the WHO.
45636382|NCT04620707|Device|RGS based training and monitoring|The RGS treatment will consist in a variable number of sessions per week of RGS-based training. Each session consists of cognitive and motor training involving reaching, grasping, placing virtual objects. The duration of the training period will be variable. Patients will use the RGS@Clinic from admission to discharge, and will have the RGS@Home during the first 3 months of the outpatient stage after recruitment. After this period of time, the patient will be evaluated by clinicians and the RGS@Home system will be collected. The RGS-Wear will be kept by the patient also during the follow-up period, up to 1 year post-recruitment.
45636383|NCT04620707|Behavioral|Therapy as usual|The patients will follow treatment as usual, including conventional rehabilitation and physical therapy when corresponding. The exact treatment that the patients will receive will depend on the local medical guidelines.
45636384|NCT03160807|Drug|Levofloxacin|Levolet 500 mg OD for 5 days
45636385|NCT03160807|Drug|Levofloxacin|Levolet 500 OD for 10 days
45636386|NCT01674569|Drug|X-82 oral|X-82 oral for 24 weeks or until unacceptable toxicity develops
45636387|NCT01674569|Drug|ranibizumab (Lucentis)|Rescue treatment with intravitreal ranibizumab (Lucentis) as needed
45636388|NCT03160729|Drug|Dexamethasone|pre-operative, single-shot injection
45636389|NCT04589117|Behavioral|Expressive writing|"The 4-week study intervention will invite participants through a progression of expressive writing exercises designed to support emotional expression and enhance personal resilience. Weekly instruction writing sessions will be conducted via Zoom. The sessions will not be recorded, but participants who cannot attend the sessions live (or prefer not to, for any reason) will receive each week's instructions and prompts via email.~The progression of writing exercises flows as follows:~Week 1: Writing to expressive difficult emotions~Week 2: Writing to cultivate compassion & forgiveness~Week 3: Writing to nurture positive emotions~Week 4: Writing to invite insight, perspective, & growth"
45636390|NCT04439929|Biological|TUR01|Administered as a single 40 mg, subcutaneous dose
45636391|NCT04439929|Biological|Adalimumab-EU|Administered as a single 40 mg, subcutaneous dose
45636392|NCT05131841|Drug|Cipterbin Combined With Vinorelbine|"Cipterbin combined with Vinorelbine Injection every week in the treatment of patients with HER2-positive metastatic breast cancer~Cipterbin combined with Vinorelbine Injection every three weeks in the treatment of patients with HER2-positive metastatic breast cancer"
45636393|NCT03163849|Drug|Sofosbuvir , daclatasvir|Tablets
45636394|NCT03163849|Drug|Placebos|oral tablets
45636395|NCT04520867|Other|STRENGTH|Patients with esophageal (EC) and gastroesophageal junction (GEJC) cancers who are seen in the Esophageal and Gastric Multidisciplinary Clinic (EGMDC) for treatment planning and are recommended to receive neoadjuvant therapy and plan to receive treatment at UCCC Metro will be offered enrollment into the study. Patients will complete the patient reported assessments focused on QOL and physical activity on provided tablet computers during UCCC visits at specified time points. If unable to complete assessments in person they will be e-mailed to the patient via REDCap to complete. Additional data regarding dosing of chemotherapy, radiation, nutrition and surgical outcomes will be collected.
45636396|NCT05674903|Device|Verum stimulation with Diadem prototype|Diadem prototype device delivers focused low-intensity ultrasound stimulation
45636397|NCT05674903|Device|Sham stimulation with Diadem prototype|Diadem prototype device delivers active sham, unfocused low-intensity ultrasound stimulation
45636398|NCT04509947|Biological|Ad26.COV2.S|Ad26.COV2.S will be administered as IM injection at 2-dose (high and low) levels.
45636399|NCT04509947|Biological|Placebo|Placebo will be administered as IM injection.
45636400|NCT04087057|Other|Interview|Participate in interview
45636401|NCT04087057|Other|Medical Chart Review|Patients' medical records are reviewed
45636402|NCT04087057|Behavioral|Questionnaire|Complete questionnaires
45636403|NCT05131763|Biological|NKG2D-based CAR T-cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
45636404|NCT05131685|Procedure|Reduction|closed reduction under conscious sedation followed by casting
45636405|NCT05131685|Procedure|Immobilization|immobilization in cast without reduction
45636406|NCT03160495|Other|All patients|All patients are scanned with PET/MR prior to surgery.
45775449|NCT00124514|Drug|Triptorelin Pamoate|IM injection given monthly
45448297|NCT02133976|Other|treatment as usual|
45448298|NCT05578222|Drug|Pembrolizumab|Pembrolizumab, 200mg i.v. gtt,D1,Q3W,
45636407|NCT04160039|Device|Cycle ergometry|Lower extremity cycle ergometry, passive and/or active, up to 20 minutes per session, up to 5 sessions per week
45636408|NCT05676853|Drug|Pegzilarginase|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
45636409|NCT05178641|Device|Ninjamas Pyjama Pants|Disposable, absorbent underwear-like pyjama pant specifically designed to manage nocturnal enuresis in children by absorbing involuntary urine loss overnight and keeping the child's bed and clothing dry.
45636410|NCT05178641|Other|Participant's Overnight Current Standard of Care|Any disposable or reusable absorbent diaper or pant product available on the US market that is used to absorb involuntary urine loss for children who are wetting the bed at night.
45636411|NCT05676775|Other|No intervenetion|Observational inception cohort, with remote follow-up via participants and data record linkage
45775450|NCT00124514|Drug|Triptorelin Pamoate|IM injection given monthly
45636412|NCT04501913|Procedure|Patient Monitoring|Undergo remote perioperative telemonitoring
45914696|NCT02046733|Drug|Ipilimumab|Induction phase: i.v. 3 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation)
45914697|NCT02046733|Drug|Nivolumab|Induction phase: Nivolumab i.v. 1 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation) Maintenance Phase: Nivolumab 240 mg i.v once every 2 weeks for a maximum of 12 months from start of maintenance (the first dose of maintenance nivolumab will be administered 3 weeks after the last IMP doses of induction Phase).
45448299|NCT05578144|Other|Patients Decision Aids (PDA)|Patient Decision Aids (PDA) administer to case group
45448300|NCT02134132|Biological|Platelet Gel|Application of platelet gel in patients suffering from diabetic foot ulcers.
45448301|NCT02134132|Other|Placebo|The patients with Diabetic foot ulcer who receive placebo instead of PL Gel.
45448302|NCT03548506|Device|Omnidirectional Deep Brain Stimulation of STN|Deep Brain Stimulation
45636413|NCT04501913|Other|Questionnaire Administration|Complete questionnaires
45636414|NCT03163537|Device|HealthPatch|Smart patch that is able to measure stress real time using an algorithm between HR and HRV
45636415|NCT03163381|Drug|Apatinib|Apatinib 500mg,po,qd,medicine to disease progression.
45448303|NCT03548506|Device|Directional Deep Brain Stimulation of STN|Deep Brain Stimulation
45448304|NCT05578066|Other|Developing teams of Local Leaders|A team of local leaders, consisting of 3-5 PHC providers and 1-2 users at each CESFAM will be developed in months 1-3 of the intervention.The teams will comprise some individuals who have provided critical support and input, including participating in the exploratory research phase and the Community-Based Participatory Research (CBPR) adaptation of the intervention framework for the Chilean context developed previously. The teams will assist with the data collection process throughout the study by encouraging colleagues to complete questionnaires and recruit users, as well as oversee and implement the intervention at their respective CESFAM. They will receive training to develop their skills as leaders and support the implementation process at their respective CESFAM.
45448305|NCT05578066|Other|Analysis of Internal Policies, Procedures and Protocols|This component involves evaluating CESFAM policies, procedures, and protocols using an anti-stigma/pro-recovery approach to identify strengths and areas for improvement in service delivery for individuals affected by MISUI. This will be completed using a policy analysis tool based on existing frameworks, such as the Health Equity Impact Assessment Tool (PHO & OMHLTC, 2012) and the QualityRights Toolkit (WHO, 2012). At least 5 policies, procedures, or protocols to be analyzed will be selected by the local leaders at intervention CESFAM during months 3-6 of the intervention. Recommendations concerning health equity, prevention of stigma, and promotion of recoveryoriented practices for individuals with MISUI will be developed and shared following analysis. Each intervention CESFAM will be expected to implement at least one recommendation and make the necessary efforts to educate PHC providers about the policy change in months 7-18 of the intervention.
45636416|NCT05131295|Drug|Dapsone|Dapsone is a drug that has been used clinically for several decades due to its anti-infective effect. It has an anti-inflammatory effect due to its inhibitory action on neutrophils. Neuroprotective effects have been found experimentally with the use of dapsone, predominantly through its glutamate receptors antagonistic effect; these are the main receptors involved in neuronal excitotoxicity.
45636417|NCT05131295|Drug|Aluminum Hydroxide Gel|Aluminum Hydroxide Gel is an antacid that works quickly to lower the acid in the stomach
45636418|NCT04028167|Drug|Sequential FLOT followed by chemoradiation|Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/ Leucovorin
45754193|NCT05581628|Diagnostic Test|Fibromyalgia Impact Questionnaire (FIQ)|FIQ measures 10 different features, including physical function, well-being, absenteeism, difficulty at work, pain, fatigue, morning fatigue, stiffness, anxiety and depression. With the exception of the well-being trait, low scores indicate recovery or less affliction. The maximum possible score of each sub-title is 10. Thus, the total maximum score is 100.
45754194|NCT03558373|Drug|Immunosuppressive|Immunosuppressive therapies
45775451|NCT00124514|Drug|Triptorelin Pamoate|IM injection given monthly
45775452|NCT00124514|Other|placebo|placebo 0.9% normal saline IM injection
45775453|NCT01373671|Device|SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM|DBT scan
45754195|NCT04064957|Biological|HB-adMSCs|
45775454|NCT02538900|Behavioral|Exercise|Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.
45914698|NCT02046746|Other|Oral Nutritional Supplement (ONS)|renal specific commercially available ONS
45914699|NCT02046759|Other|Pharmacist- Intervention|Patients received additional education on basic facts about asthma, role of medications, the difference between long-term control medications and quick-relief medications, as well as patient skills in the first visit then reinforcement every two weeks.. The importance of proper inhaler technique, avoidance of asthma triggers and self-monitoring of asthma were also highlighted. Visual aids, physical demonstration as well as written information resources were supplied. Asthma care plans were tailored to patient needs and preferences. Patients were informed how to detect early signs of worsening asthma, when and how to seek medical care as appropriate.
45448306|NCT05578066|Other|Raising Awareness|Various forms of media will be used to raise awareness about stigma related to MISUI among PHC providers and users. Local leaders at intervention CESFAM will determine the type of media they would like to use; this may include images, film, music, or a combination of media. The research team will work with local leaders to develop messaging to include in the media and assist with showcasing these pieces within each intervention CESFAM. This component will be implemented throughout the intervention (intervention months 1-18). Depending on the type of media, instances of use will be tracked accordingly. For example with posters, data on the number of posters posted at a CESFAM over what time period and an estimation of the number of PHC providers and users who have viewed the posters will be collected.
45636419|NCT05130905|Dietary Supplement|RiteStart Supplement|RiteStart is a comprehensive multivitamin, multimineral, all-in-one daily supplement. Besides having comprehensive and balanced amounts of essential vitamins and minerals that the human body needs, RS includes many other health-promoting ingredients. For example, RS contains potent antioxidants, including vitamins A, C, and E, oligomeric proanthocyanidins from pinebark and grapeseed extracts, lutein, CoQ10, alpha-lipoic acid, and green tea. It is also a source of essential fatty acids from fish and plant oils. RS contains transfer factor (bovine colostrum and egg yolk extracts) that support immunity [6, 7, 8]. RS also includes a blend of maitake mushrooms, shiitake mushrooms, cordyceps, inositol hexaphosphate, olive leaf extract, and other ingredients that aim to further support immune function and overall health.
45636420|NCT03163459|Drug|selective brain cooling by cold saline perfusion|During the procedure, a microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
45636421|NCT03163459|Device|mechanical thrombectomy|conventional mechanical thrombectomy using Solitaire
45636422|NCT05130749|Other|Questionnaire|The questionnaire's first section asked for demographic information such as gender, age, the name of the primary healthcare centre, and level of education. The second section comprised sources of knowledge on COVID-19; respondents replied on a scale of 1 least used (1), occasionally (2), more frequently (3), and most used (4). The third section had six items pertaining to nurses' infection prevention and control methods with reference to COVID-19, and respondents replied on a scale of yes (2), occasionally (1), and no (0). Permission to use the questionnaire has been requested from the author and is awaited.
45636423|NCT05130203|Behavioral|MouvMat Exergaming|Sessions engaging with exergaming device.
45636424|NCT05130203|Behavioral|Standard Recreational Programming|Conducted by recreational therapists.
45636425|NCT05124587|Other|No intervention group|No intervention group
45636426|NCT03981809|Diagnostic Test|"Diagnostic test (PainsCan) for the identification of the dominant pain mechanisms in cancer survivers with persistent pain"|Easy-to-use screening tool to identify the dominant pain mechanism by using quick clinical tests and compare their accuracy and validity with complicated reference tests.
45636427|NCT01374217|Drug|Tadalafil|Tadalafil will be administered at a dose of 20 mg orally daily starting with day 1 of the first cycle. Each cycle will last for 28 days
45636428|NCT01374217|Drug|Lenalidomide|Lenalidomide will be administered as it was prior to study entry.
45636429|NCT01374217|Drug|Dexamethasone|Dexamethasone will be administered as it was prior to study entry.
45636430|NCT01374217|Drug|Clarithromycin|Clarithromycin will be administered as it was prior to study entry.
45636431|NCT04494815|Drug|SR419|Each participant will receive 1 dose of 20 mg SR419 oral suspension.
45636432|NCT04494815|Drug|active control|Each participant will receive 1 dose of 300 mg active control capsule.
45636433|NCT04494815|Drug|SR419 placebo|Each participant will receive 2 doses of SR419 placebo oral suspension.
45636434|NCT04494815|Drug|active control placebo|Each participant will receive 2 doses of active control placebo capsule.
45636435|NCT04494737|Behavioral|Active Comparator: Program 1|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
45636436|NCT04494737|Behavioral|Active Comparator: Program 2|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
45636437|NCT04494503|Drug|APG-2575|APG-2575 orally once daily, every 28 days as a cycle.
45636438|NCT04494503|Drug|Rituximab|Rituximab 375mg/m2 ivgtt on C1D8 and 500mg/m2 ivgtt on C2-6D1.
45636439|NCT04494503|Drug|Ibrutinib|Ibrutinib 420mg orally once daily during C1D8-28 and following cycles.
45636440|NCT05676541|Other|Complex intervention to enhance care for patients with multimorbidity in general practice consisting of an extended overview consultation and supporting elements|The intervention consists of 1) an extended overview consultation lasting 30-45 minutes in general practice, 2) access to cross-sectoral video conferences with secondary care specialists and 3) an instruction material for GPs on how to organize the intervention and 4) an adaptive toolbox to support elements in the intervention (not yet developed)
46070178|NCT02612961|Other|3mL of normal saline from the pink sodium chloride bullet|
46070179|NCT02612961|Other|Sham Comparator of 3mL normal saline|
46070180|NCT00813475|Drug|Basal bolus insulin regimen (tight glucose control)|Basal bolus insulin regimen
45636441|NCT04012567|Device|Investigational device: Biosure Regenesorb Interference Screw|The Biosure Regenesorb Interference Screw, an absorbable screw designed with an open structure and made of biocomposite material made of PLGA, β-TCP and calcium sulfate, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery. Its open structural design enables rapid bone ingrowth to make the screw integrated with bone tissues so as to promote healing.
45636442|NCT04012567|Device|Control device: BIOSURE HA Interference Screw|BIOSURE HA Interference Screws and Drivers are designed for durability and reduced screw breakage. Both the screws and driver have been enhanced to allow screws to fully seat on the driver all the way to the tip of the screw, helping stress distribution and force transfer. The screw design also incorporates a consistent wall thickness throughout the length of the screw for added durability and features a tapered body for ideal ease of insertion.
45636443|NCT03688763|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-i)|CBT-i is an evidence-based treatment for insomnia. Participants will receive CBT-i via online program (Sleepio).
45636444|NCT03906253|Device|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
45636445|NCT03278249|Other|Modified Atkins Ketogenic Diet|Less than 20 grams of carbohydrates per day
45636446|NCT04941937|Drug|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg/d QW
45636447|NCT04941937|Drug|Thalidomide|100mg/d, Po. on day1-28
45636448|NCT04941937|Drug|Lenalidomide|PO,Lenalidomide 25mg once daily from D1-21
45636449|NCT04941937|Drug|Pomalidomide|Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle, PO.
45636450|NCT04941937|Drug|Dexamethasone|Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
45636451|NCT02959619|Drug|Ensartinib|Oral ensartinib was given daily at escalating doses in a 28-day cycle
45636452|NCT04935931|Drug|Naltrexone|naltrexone 50 mg PO x 1
45636453|NCT05124431|Drug|Anlotinib hydrochloride|Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor.
45775455|NCT02538900|Other|Attention control|Our attention control group controls for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention. Participants randomized to the control group will attend weekly one-hour educational sessions at Northwestern University for the first four weeks of the intervention (Phase I). These sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, and cancer screening. During Phase II (weeks 5-52), the attention control group will receive weekly telephone calls, lasting 5-15 minutes, with information on a health-related topic.
45775456|NCT01899248|Drug|Sevoflurane|
45775457|NCT01899248|Drug|Desflurane|
45775458|NCT01322815|Drug|chemotherapy and GI-4000|"Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.~maintenance of GI-4000 injection and bevacizumab every 2 weeks"
45775459|NCT01322815|Drug|GI-4000|40 YU GI-4000 every 2 weeks Bevacizumab every 2 weeks
45636454|NCT05124431|Drug|everolimus|5mg po，qd
45636455|NCT04435613|Other|protective mechanical ventilation strategies|1. Reduce tidal volume from 7 ml/kg to 5 ml/kg. 2 Set end-inspiratory pausa. 3 respiratory rate reduction until 20% of the basal condition
45636456|NCT04877275|Drug|Selinexor (80mg/d)|"Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm I：80mg/d QW ;"
45775460|NCT05463432|Drug|HR19024|Intravenous infusion
45775461|NCT00265538|Behavioral|Patient educational letter to engage provider in hypertension rx discussion|Patients will receive a customized/tailored letter (education) including most recent clinic blood pressure, current blood pressure medications and suggested htn medication(s). All the intervention arms (A, B and C) receive the letter.
45775462|NCT00265538|Behavioral|Financial incentive (Arms B and C) and health educator phone call (Arm C)|Patients may receive a financial incentive for discussing the intervention letter with their provider and 6 months copay reimbursement and/or the financial incentive discussion incentive, 6 months copay reimbursement as well as a phone call reminder 1-2 days prior to their primary care appt. The Financial incentive is part of both Arms B and C. The health educator phone call is only in Arm C.
45775463|NCT05449002|Behavioral|Practicing the Opposite (PTO)|This 30-45-minute digital program is designed to help youths on the waitlist feel better prior to treatment and may also improve their treatment engagement and outcomes.
45775464|NCT05449002|Other|Usual Clinical Care|Usual care provided by a local Boston-area youth mental health clinic.
46070181|NCT00813475|Drug|Basal bolus insulin regimen (standard control)|basal bolus insulin regimen
46070182|NCT04115943|Other|Treatment protocol for neck pain|The protocol to be used in the study is in accordance with the latest guidelines for the treatment of neck pain associated with limited mobility for patients in the chronic phase. The followed techniques will be performed: i) manual therapy - manipulation or mobilization of the upper cervical spine, manipulation or mobilization of the cervical, cervicothoracic and thoracic regions, manual cervical traction, release of the cervical muscles and muscles of the scapulothoracic region; ii) exercises - strengthening and resistance exercises for the muscles of the scapular girdle, coordination, proprioception and postural training of the cervical and scapulothoracic regions.
45636457|NCT04877275|Drug|Selinexor (100mg/d)|"Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm II：100mg/d QW ;"
45636458|NCT04877275|Drug|Pegylated liposomal doxorubicin|25 mg/m^2 intravenously on day 1 , QW
45636459|NCT04877275|Drug|Dexamethasone|Dexamethasone 40mg/d QW
45636460|NCT04877275|Drug|Cyclophosphamide|Cyclophosphamide：300mg/m2, d1 QW，
45636461|NCT04955249|Drug|Dexmedetomidine|Patients in this group receive dexmedetomidine-supplemented patient-controlled analgesia for up to 3 days after surgery. The formula is a mixture of dexmedetomidine (1 microgram/ml) and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is programmed to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
45636462|NCT04955249|Drug|Placebo|Patients in this group receive routine patient-controlled intravenous analgesia for up to 3 days after surgery. The formula is a mixture of placebo and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
45636463|NCT04876417|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
45636464|NCT04876417|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
45636465|NCT05097443|Drug|Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies|"Orelabrutinib+R-CHOP： Orelabrutinib 150mg qd; R-CHOP：Rituximab 375mg/m2 d0, Cyclophosphamide 750mg /m2 d1, Doxorubicin 50mg /m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg /m2 or Vindesine 3mg /m2 d1, Prednisone 100mg d1-5.~Orelabrutinib+R-DA-EPOCH： Orelabrutinib 150mg qd； R-DA-EPOCH：Rituximab 375mg/m2 d0, Etoposide 50mg/ m2, Epirubicin 15mg/ m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5.~Orelabrutinib+R-HD-MTX: Orelabrutinib 150mg qd; R-HD-MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/ｍ2 d1.~Orelabrutinib+ R+other regimens: Orelabrutinib 150mg qd； R+other regimens: Rituximab 375mg/m2 d0. The dose of other drugs depends on the regimen.~All regimens follow every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance.~Dose adjustments of Orelabrutinib are allowed. The initial dose is 150 mg, QD, while the first adjustment is 100 mg, QD and the second adjustment is 50 mg, QD."
45636466|NCT05676463|Procedure|MRI-guided Intensity-Modulated Radiation Therapy|Undergo MRI-guided IMRT
45636467|NCT05676463|Drug|Antiandrogen Therapy|Receive SOC ADT
45636468|NCT05676463|Procedure|PSMA PET Scan|Undergo PSMA PET scan
45636469|NCT05676463|Procedure|Computed Tomography|Undergo CT
45636470|NCT05676463|Procedure|Magnetic Resonance Imaging|Undergo MRI
45636471|NCT05676463|Procedure|Bone Scan|Undergo bone scan
45636472|NCT05676463|Procedure|Biospecimen Collection|Undergo blood sample collection
45914700|NCT02046759|Other|Routine Care|Patients received usual care delivered by physician without pharmacist intervention. Patients were prescribed asthma medication with summarized basic information on asthma and medication use. Follow-up visits were not planned on consistent basis, but rather individually according to the disease status. No asthma action plans were provided.
45914701|NCT02046785|Other|0.9% saline solution|comparing values obtained before and after administration of 500 ml of 0.9% salin
45636473|NCT05676463|Other|Quality-of-Life Assessment|Ancillary studies
45914702|NCT02046798|Drug|ASP3652|oral
45914703|NCT02046811|Behavioral|Patient activation and education (PAE)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface)
45636474|NCT02285621|Other|Optimized brace versus conventional Boston brace|Surface topography using Inspeck cameras allows production of a 3D reconstruction of the patient's trunk, this reconstruction will help to produce the optimized brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between time points. All radiographs will be taken with an EOS imaging system to allow 3D reconstructions. The SRS-22r will be collected at all clinical visits. Study questions will be aligned as much as possible with other prospective scoliosis protocols so as to minimize patient and surgeon response burden. The study protocol requires no additional visits or radiographs beyond standard of care. Ibuttons are installed in each brace and used to measure the compliance of the patient.
45636475|NCT00197873|Dietary Supplement|Lactobacillus Rhamnosus supplementation|Lactophilus supplementation is administered during chemotherapy.
45636476|NCT00197873|Other|Placebo administration.|Placebo is administered during chemotherapy.
45636477|NCT03114085|Drug|Capecitabine|Capecitabine 1000mg/m2 po bid, d1-d14, every 21 days for a cycle;
45636478|NCT03114085|Drug|Apatinib|Apatinib 500 mg po qd, d1-d21, every 21 days for one cycle
45636479|NCT04854317|Procedure|Endoscopic gastroplasty or Intragastric balloon placement|Endoscopic bariatric procedures
45636480|NCT04440553|Behavioral|Uniform random message delivery|The uniform random intervention group receives feedback and motivational messages chosen from the messaging banks with equal probabilities.
45636481|NCT04440553|Behavioral|Reinforcement learning message delivery|The adaptive intervention group receives messages chosen from the messaging banks by a reinforcement learning algorithm.
45636482|NCT04993261|Procedure|Dual-Energy Computed Tomography|Undergo dual energy CT scan
45636483|NCT03114631|Biological|Dendritic cells pulsed with tumor lysate|
45636484|NCT03114631|Biological|Dendritic cells pulsed with MUC-1/WT-1 peptides|
45636485|NCT05403983|Behavioral|Yoga movement intervention|Mixture of yoga, tai chi, pilates. Will be delivered in person (experimental) and online (active comparator)
45636486|NCT05403983|Other|Education booklet|Recently published postpartum physical activity guidebook through the Sport Information Resource Center of Canada
45636487|NCT03162835|Other|Pain Neuroscience Education|Children as well as their parents will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
45636488|NCT04918511|Drug|OPD5|OPD5 solution for i.v. infusion
45636489|NCT03162757|Procedure|Central venous catheterization|Central venous catheterization via either internal jugular vein or subclavian vein up to a maximum of two attempts.
45636490|NCT03162991|Other|Aerobic Exercise Intervention|Aerobic Exercise Intervention- 12-weeks, exercise 3 non-consecutive days/week for ~30-55 minutes per exercise session.
45636491|NCT05056415|Other|Everyday Life Rehabilitation (ELR)|"Everyday Life Rehabilitation (ELR) is an intervention model for integrated occupational therapy in close collaboration with housing staff in sheltered and supported housing facilities (Lindström, 2007; 2011), aiming at personal recovery and engagement in meaningful everyday activities for persons with SPD. The mediators are: personcentred, motivational, recovery- and activity-based methods, negotiation of user goal priority and expected outcome; methods for training in real-life situations; devices for collaboration; support from staff on an everyday basis; and an educational package including web-sections, manuals, and collegiate tutorial.~The language and actions of professionals promote hope, self-discovery and shared-decision making, shaped in partnership with residents. The resident is also encouraged to access different resources outside of health and social care such as family, peer and social support, out-of-housing strategies, and sources in the open society."
45636492|NCT05056415|Other|Treatment as usual (TAU)|No standardized instructions about the efforts is given to staff at the accommodations. Usually, only short terms efforts are offered to residents, such as prescribing technical aids.
45636493|NCT03163069|Combination Product|in-office bleaching with the conventional whitening dentifrice|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the conventional whitening dentifrice.
45636494|NCT03163069|Combination Product|in-office bleaching with the whitening dentifrice containing blue covarine|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the whitening dentifrice containing blue covarine.
45775465|NCT05422560|Procedure|Embolization of the inferior mesenteric artery|"The procedure is performed in a dedicated angiography room. After local anesthesia, a common femoral arterial approach is performed according to the Seldinger technique with the placement of a 4 French valve introducer.~Catheterization of the superior mesenteric artery with a Cobra 4F catheter and angiography to confirm patency of the border arcade.~Catheterization of the inferior mesenteric artery with a 4F cobra/shepherd hook catheter and angiography. Microcatheterization of the artery with a 2.7F or 2.8F microcatheter and embolization with microcoil leaving the first centimeters of the IMA in order not to interfere with the surgery.~Catheterization of the superior mesenteric artery and final angiography to confirm the reinjection of the inferior mesenteric by the border arcade.~Removal of the material and manual compression of femoral access. Clinical monitoring for 6 hours and discharge the same day of the procedure."
46070183|NCT04115943|Other|Protocol for release of tongue muscles|. The aim is the relaxation of the suprahyoid muscles (mylohyoid, geniohyoid, digastric and stylohyoid) as well as the cervical fascia of the anterior region and soft tissues of the region of the pharynx and larynx.
46070184|NCT00809497|Drug|Propionyl-L-carnitine Tablets|500mg tablets, oral administration of 2g daily
46070185|NCT04016857|Procedure|RIPC|4 cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of arm cuff
46070186|NCT04016857|Procedure|Control|deflated cuff placed on the left arm for 40 min
46070187|NCT00809575|Other|questionnaire administration|
46070188|NCT00809575|Other|fatigue assessment and management|
46070189|NCT00809575|Other|observation|
46070190|NCT00809575|Other|quality-of-life assessment|
45452486|NCT05158010|Other|HELIX's follow-up|"Visit 1 (Day 0): clinical examination (anthropometry, bioimpedance, blood pressure,spirometry), neurodevelopment computer testing, questionnaires (Physical activity,diet, psychological distress, tobacco exposure, pubertal development, sleeping patterns, light exposure before going to sleep, outdoor environment (green spaces, noise), address history, home environment, socio-economic status, noise, psychological distress, medical history, medication use) 7 consecutive days (minimum) of personal exposure monitoring including wearing an actigraph, a Smartphone (GPS data), carrying a NO2 diffusion tube, collection of hair, stool, urines (2 urines during 6 consecutive days) and filling a sleep and physical activity diary~Visit 2 (Day 8): blood collection early in the morning and collection of all the 7- days personal monitoring material, and stools and urines samples."
46070191|NCT00847665|Other|repositioning|Turning every 4 or 2 hours
45636495|NCT03163069|Combination Product|in-office bleaching with the regular dentifrice|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the regular dentifrice.
45636496|NCT05136599|Biological|Bordetella pertussis D420|Intranasal inoculation of Bordetella pertussis D420 in each naris on Day 0 of the study.
45775466|NCT00176228|Drug|Lamotrigine|"It is a mood stabilizer that is clinically the first choice if patients present with depression and is effective in adults for mania in maintenance phase. So it is administered to see how effective it is in children and adolescents.~The dose of lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg."
45775467|NCT00176306|Drug|Levofloxacin 750 mg IV|PK in obesity
45636497|NCT03162679|Behavioral|Skills training of Affect-Regulation - A culture-sensitive approach: STARK|Emotion Regulation Group Therapy, 14 sessions, 1.5 hour sessions, group therapy, meeting weekly.
45636498|NCT04886453|Drug|Balanced general anesthesia without morphine|Balanced general anesthesia without morphine
45636499|NCT04886453|Drug|Standard general anesthesia balanced with morphine|Standard general anesthesia balanced with morphine
45636500|NCT04886453|Other|Data collection|Data collection
45636501|NCT04886453|Other|Assessment of pain|visual analog scale
45636502|NCT04886453|Other|Recovery quality score|QoR15 questionnaire
45636503|NCT03162601|Procedure|Neurovascular percutaneous intervention|Patient will receive one extra CACT scan while they are receiving percutaneous neurovascular intervention.
45636504|NCT05136521|Drug|Trazodone HCl - new polymer|A single 300 mg dose of the test (T) and of the reference (R) products will be administered to the study subjects in two consecutive periods, according to a randomised 2-sequence cross-over design. A wash-out interval of at least 10 days will elapse between the two administrations. The two investigational products will be administered with 240 mL of still mineral water on day 1 of the two study periods, at 08:00±1 h after an overnight fasting.
45636505|NCT05136521|Drug|Trazodone HCl - Contramid®|A single 300 mg dose of the test (T) and of the reference (R) products will be administered to the study subjects in two consecutive periods, according to a randomised 2-sequence cross-over design. A wash-out interval of at least 10 days will elapse between the two administrations. The two investigational products will be administered with 240 mL of still mineral water on day 1 of the two study periods, at 08:00±1 h after an overnight fasting.
45636506|NCT03162523|Radiation|High-Dose Rate Brachytherapy|
45636507|NCT03330067|Device|Cold and dry CO2 pneumoperitoneum|In this arm, patients undergo pneumoperitoneum by the insufflation of cold (19-21°C) and nonhumidified (0%) CO2.
45775468|NCT01429987|Drug|plecanatide|Subjects receive experimental study drug for 12 weeks.
45775469|NCT01429987|Other|Placebo|Subjects receive experimental study drug for 12 weeks.
45775470|NCT00265616|Drug|propofol|liquid, mg/kg.h, titrated after EEG
46070192|NCT00809653|Device|No Face Mask|Subjects will not wear a face mask to reduce their personal air pollution exposure
45636508|NCT03330067|Device|Warm and humidified CO2 pneumoperitoneum|In this arm, patients undergo pneumoperitoneum by the insufflation of warmed (95° F) and humidified (95% relative humidity) CO2, using a Lexion Insuflow device.
45636509|NCT05136209|Procedure|PCCC procedure without A-vit|In this randomized clinical trial, patients receive cataract surgery on both eyes on the same day. For each patient, one eye is randomly assigned to undergo PCCC+A-Vit procedure, while the fellow eye is undergoing PCCC procedure without A-Vit.
45636510|NCT05136209|Procedure|PCCC+A-Vit procedure|PCCC+A-Vit procedure
45636511|NCT05135897|Device|Electroconvulsive therapy|Treatment with Electroconvulsive therapy
45636512|NCT05135897|Device|rTMS|repetitive Transcranial Magnetic Stimulation
45754196|NCT05581550|Radiation|FDG-PET|Patients will be fasted for 6 hours prior to intravenous injection of 370MBq +/- 10% (18)F-fluorodeoxyglucose. Scanning will be performed at an interval of at least 60 minutes following the injection.
45754197|NCT05581550|Radiation|Galium-68 DOTATATE|200MBq +/- 10% Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection.
45775471|NCT00265616|Drug|thiopental/pentobarbital|liquid, mg/kg.h, titrated after EEG
45775472|NCT04351399|Other|questionnaire assesment|The questionnaire will ask questions around their socio-demographic characteristics,quality of life, painful, using analgesic , since they are in quarantine
45775473|NCT01430299|Device|Demineralized Bone Matrix|Accell Evo3 in posteriolateral fusion (prospective cohort)
45636513|NCT03850171|Other|Exercise Training|Participants from the experimental study arm are assigned to a 12-week exercise training programme integrated in a multidisciplinary oncology rehabilitation programme at the Inselspital Bern, Spital AG Thun, or Bürgerspital Solothurn. The exercise programme will comprise 2 weekly exercise sessions lasting 90 min, supervised by experienced exercise therapists. The sessions start with approximately 40 min cycling on an ergometer at moderate intensity, increasing on a weekly basis if possible. After the cycling training, patients continue the exercise session with 40 min of strength training, stretching, relaxation, coordination and balance training. In addition, patients will be instructed to perform at least one additional endurance-related activity per week in their own time with a duration of 30-60 min at moderate intensity levels (e.g. walking, bicycling).
45636514|NCT04937465|Other|No intervention done|No intervention was done. This was an observational study.
45636515|NCT04725877|Biological|VIR-1111|VIR-1111 is administered as a 1 mL subcutaneous injection in the deltoid area of the upper arm on Day 1 and Day 57.
45636516|NCT04725877|Drug|Placebo|A placebo (Tris NaCl Sucrose formulation buffer) given by subcutaneous injection.
45636517|NCT02388529|Drug|MTP-131|MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
45636518|NCT02388529|Drug|MTP-131|MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
45636519|NCT02388529|Drug|MTP-131|MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
45636520|NCT02388529|Drug|Placebo|Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
45636521|NCT03819985|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
45636522|NCT03819985|Other|Quality-of-Life Assessment|Ancillary studies
45636523|NCT03819985|Other|Questionnaire Administration|Ancillary studies
45636524|NCT05343013|Drug|TAS-102|GIven by PO
45636525|NCT02388373|Drug|Fluticasone 250/formoterol 10|
45636526|NCT02388373|Drug|Fluticasone 250/salmeterol 25|
45636527|NCT02388373|Drug|Fluticasone 125/formoterol 5|
45775474|NCT01430299|Device|rh-BMP2|rh-BMP2 in posterolateral fusion (retrospective cohort)
45636528|NCT05231239|Device|tDCS : Transcranial direct current stimulation|Transcranial direct current stimulation
45636529|NCT02388451|Device|Feuerstein Program|The IE activity is administered by instructors in groups of 10 to 15 participants. The intervention comprises 30 twice weekly meetings of 90 minutes duration per group.
45636530|NCT03239587|Behavioral|Musical Intervention|Participants wait for 30 minutes in waiting area with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.
45636531|NCT03239587|Procedure|Blood Draws|"No Musical Intervention - Control Group: Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.~Musical Intervention Group: Blood drawn before, and about 30 minutes after in waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music."
45636532|NCT03239587|Behavioral|Questionnaires|Participants complete 2 questionnaires about anxiety and stress levels. It should take about 20-30 minutes to complete.
45636533|NCT01674647|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg orally once daily; subjects with moderate renal impairment (ie, CrCl of 30 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily in the study
45636534|NCT01674647|Drug|Vitamin K antagonist (VKA)|VKA orally once daily titrated to a target international normalized ratio (INR) of 2.5 (range 2.0-3.0, inclusive); the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards
45636535|NCT02669407|Procedure|splanchnic nerve anesthesia with a local anesthetic|regional nerve block of the splanchnic nerve
46070193|NCT00809653|Device|Face Mask|Subjects will be asked to wear a simple face mask to reduce personal exposure to particulate air pollution. Subjects will be asked to wear the mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask at all times when outdoors and as much as possible when indoors.
46070194|NCT00701259|Drug|Lansoprazole|Lansoprazole 15 mg once per day for 14 days
46070195|NCT00701259|Drug|Lansoprazole|Lansoprazole 30 mg once per day for 14 days
45636536|NCT02669407|Drug|regional nerve block with a local anesthetic (Lidocaine)|
45636537|NCT02388139|Procedure|renal artery angiography|preprocedural renal arteriogram is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
45636538|NCT02388139|Procedure|coronarography|
45636539|NCT02388139|Procedure|coronary angioplasty|
45775475|NCT01431313|Drug|Inhaled Nitrite|Each patient will receive a starting dose of 45 mg of inhaled nitrite, with one planned subsequent planned dose of 90 mg of inhaled nitrite
45775476|NCT00176852|Drug|Busulfan, Fludarabine, ATG, TLI|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -8 and -7 Fludarabine 35 mg/m2 IV Days -6 through -2 Antithymocyte globulin (ATG) 30 mg/kg IV Days -2 and -1 Total lymphoid radiation 300 cGy
45636540|NCT02388139|Procedure|pulse wave velocity measurement|is a measure of arterial stiffness with Sphigmocore device.
45636541|NCT02388139|Procedure|body composition monitoring|using Fresenius device
45636542|NCT04776005|Other|Data collection|Assessment of the efficacy and immunogenicity of the anti-Sars-COv2 vaccines in patients treated for malignant pathology.
45636543|NCT04909853|Drug|PF-07321332/ritonavir|PF-07321332 in combination with the PK boosting agent, ritonavir, being developed for the treatment of COVID-19
45636544|NCT05135819|Behavioral|Cyber School for Grandparents|Educational program for secondary school students to become cyber tutors for their grandparents or for senior citizens, who are interested to learn new digital use and skills.
45636545|NCT03182335|Other|sedation awakening trial|vital signs and delirium assessment (CAM-ICU) at baseline then following routine sedation awakening trial. Patient will thus serve as their own control for these interventions
45636546|NCT05135741|Device|pressure bio feedback|The pressure biofeedback unit was placed between the plinth and the posterior aspect of the neck just below the occiput and inflated to a baseline of 20 mmHg. A trained physiotherapist was observing and correcting any substitution movements to ensure that all subjects could perform the exercises correctly. All exercise protocols and programs were taken from previously published studies8-10. A conventional DCF exercise protocol was performed three times a week for four weeks in both groups. The duration of the conventional DCF exercise protocol was 20-30 minutes, once a day in the control group, and 15-20 minutes, once a day in the experimental group
45636547|NCT02667457|Radiation|99mTc-rhAnnexin V-128|
45636548|NCT05135507|Behavioral|An integrated parenting intervention for families of children with developmental disabilities|Deliver three training modules to parent and track program usage, psychological flexibility, parents' stress, parents mindfulness, and child behavior
45636549|NCT05135429|Other|Bathing|The data of the study were obtained from premature newborns born at 34 weeks and above, who were hospitalized.
45636550|NCT05403905|Procedure|non surgical treatment|Conservative treatment is required to use a curved splint for 6 weeks to keep the feet on the ground, bathing and sleeping without loosening the utensils and taking no steroids during the period. Physical examination and magnetic resonance imaging were performed after 6 weeks. If laxity remained unsatisfactory, the outcome was recorded as failure and surgery was changed.
45636551|NCT05403905|Procedure|surgical treatment|The patient underwent knee arthroscopic anterior cruciate ligament surgery at the Institute of Sports Medicine of the Third Hospital of Peking University. The surgical methods were all anatomical single-bundle.
45636552|NCT04893707|Biological|CM310|"adults and teenagers (12 ~ 18 years) with weight ≥60 kg : 600mg for 1st dose, and then 300 mg, every 2 weeks and up to 1 year, SC.~teenagers (12 ~ 18 years) with weight ≥30 kg and <60kg : 400mg for 1st dose, and then 200 mg, every 2 weeks and up to 1 year, SC."
45636553|NCT02669095|Device|Investigational Contact Lenses (Test)|
45636554|NCT02669095|Device|Marketed Contact Lenses (Control)|
45636555|NCT04637555|Drug|sacubitril/valsartan|LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
45636556|NCT02388061|Drug|Tenecteplase|
45636557|NCT02388061|Drug|Tissue Plasminogen Activator|
45636558|NCT04598789|Other|no intervention|no intervention, observational study
45636559|NCT05134961|Procedure|Pancreaduodenectomy and possible adjuvant therapy|Adjuvant therapy was generally offered to patients with T4 or lymph node positive disease. As no national Danish guidelines exist, patients were treated based on the oncologists' preference.
45636560|NCT04587635|Dietary Supplement|PHGG|PHGG
45636561|NCT04587635|Dietary Supplement|Placebo|Maltodextrin
45636562|NCT02387827|Behavioral|Diet+ short term versus long -term physical activity|
45636563|NCT04556357|Drug|Phenylephrine|A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
45636564|NCT04556357|Drug|Norepinephrine|A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
45636565|NCT02933281|Biological|MTBVAC|Escalating dose levels (5 x 10^3 CFU, 5 x 10^4 CFU, 5 x 10^5 CFU, and 5 x 10^6 CFU
45636566|NCT02933281|Biological|BCG|BCG 5 x 10^5 CFU
45636567|NCT05134883|Other|PNF|A PNF stretching protocol will be performed with each participant assuming a long sitting position on a plinth with the knee maintained as extended as possible. At this moment, the participant will be asked to perform a maximum isometric hamstring muscle contraction for 5 seconds followed by 5 seconds of relaxation and 20 seconds of stretching. The therapist will show the participant how to maintain this isometric contraction with the flexion of the hip and ankle. Each participant will undergo 4 repetitions of PNF stretching (30 seconds/rep).
45636568|NCT05134883|Other|SMR|For the application of self-myofascial release, the subjects will assume a long sitting position on a firm and even surface by placing the arms backward and transferring their body weight to their palms. The roller foam, applied bilaterally, will be placed under the hamstrings and slowly moved back and forth from the ischial tuberosity to the popliteal fossa by applying pressure for 2 minutes.
45636569|NCT05134805|Procedure|Bipolar hemiarthroplasty , proximal femoral nail|"Removal of head of femur , greater trochanter , and lesser trochanter and use bioplar hemiarthroplasty (BHA).~Intra-medullary fixation of intertrchanteric femoral fracture by proximal femoral nail (PFN) Fixation of the fracture by using intramedullary nail(proximal femoral nail)."
45636570|NCT02667301|Device|EMG recording|1.3X0.4 mm, sterile subdermal monopolar needle electrodes along with the same type of reference needle electrodes were inserted mTVP and mLVP muscles submucosally through the soft palate trans orally. The point of insertion for mTVP was one mm inferior and lateral of the pterygoid hamulus which is palpable at the posterior-medial of the upper alveolus. The active electrode was fully inserted horizontally into the superior belly of mTVP on the tested side. The reference electrode for mTVP was inserted into the palatine aponeurosis at one centimeter apart from the active electrode. The point of insertion for the mLVP active electrode was one centimeter medial and five mm inferior to the hamulus pterygoideus. Reference electrode of mLVP was inserted into one cm apart of medial side of the passive electrode of the mTVP at palatine aponeurosis.
45636571|NCT02667301|Device|Tympanic Cavity Air Exchange Test|Tympanic cavity air exchange test is done by placing a sensitive pressure sensor in the ear canal and another pressure sensor on one of the nostrils. Patient is asked to to obstruct the other nostril with his/her index finger while holding the probe in place securely and asked to swallow the water during the next ten seconds. Both ear canal and nasal pressure values were simultaneously recorded on tympanic cavity air exchange sensor computer for subsequent analyses. The swallowing action triggers the ET opening and causes a momentary increase of pressure in the nasal cavity. ET opening moves the tympanic membrane which is sensed by the sensors.
45775477|NCT00176852|Drug|Busulfan, Cyclophosphamide, ATG, GCSF|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -9 through -6 Cyclophosphamide 50 mg/kg IV Days -5 through -2 ATG 30 mg/kg IV Day -1 GCSF 5 mcg/kg/day IV until ANC >2500 x 2 days.
45775478|NCT00176852|Drug|Campath, Fludarabine, Cyclophosphamide|Receives Campath-1H 0.2 mg/kg Days -10 through -6, Fludarabine 35 mg/m2 intravenous (IV) Days -6 through -2, total body irradiation (TBI) 300 cGy Day -1.
45914704|NCT02046811|Behavioral|PAE plus physician activation (PAE + MD)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface), physician activation/educational materials about: (1) survivors' increased skin cancer risk; (2) the benefits of and the skills needed to conduct full-body skin exams; and (3) the importance of recommending routine SSE to patients
45914705|NCT02046811|Behavioral|PAE physician activation, plus teledermoscopy (PAE +MD +TD)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface), physician activation/educational materials about: (1) survivors' increased skin cancer risk; (2) the benefits of and the skills needed to conduct full-body skin exams; and (3) the importance of recommending routine SSE to patients, and participant receipt of a dermoscopic lens
45914706|NCT02046824|Device|Xtra®, Sorin cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
45914707|NCT02046824|Device|C.A.T.S.®, Fresenius cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
45914708|NCT02046824|Device|CardioPAT®, Haemonetics, cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
45914709|NCT02046824|Other|no use of cell saver|When less than 750 ml of wound blood is collected in the reservoir at the end of the operation, patients will be automatically allocated to the control group. The collected blood will be cast away according to daily clinical practice and recommendations of the manufacturers.
45636572|NCT02667301|Device|Tympanometer test|Patient is subjected to tympanometry test on the specific ear and information is recorded.
45775479|NCT00176852|Radiation|Total Body Irradiation|300 cGY Day -1
45775480|NCT00176852|Procedure|Stem cell infusion|Given Day 0
45636573|NCT04180709|Device|Sleepio|Sleepio is an online cognitive behavioural therapy (CBT) based intervention designed to treat insomnia, conducted is 6 sessions. The program is an automated media-rich web-based application that is driven dynamically by baseline, adherence, performance and progress data. At the beginning of each session The Prof conducts a progressive review with the participant exploring the diary data submitted the week prior that includes sleep status and pattern, as well as progress based on goals previously set by the participant. The information, support and advice are personally tailored based on underlying algorithms.
45775481|NCT01323517|Drug|Ipilimumab, Melphalan and Dactinomycin|Isolated limb infusion ((ILI) with Melphalan and Dactinomycin- MSKCC operating room. Ipilimumab- IV administration in outpatient chemotherapy clinic. Induction therapy with Ipilimumab will start 1-3 weeks after ILI in the standard dose of 10mg/kg every 3 weeks for a total of 4 doses. Patients will then receive chronic therapy every 3 months. Patients will be followed every 3 months for 2 years.
45775482|NCT01323595|Drug|Celecoxib|Celecoxib 200mg PO BID x 6 days
45775483|NCT01323595|Drug|Sugar Pill|Sugar pill PO BID x 6 days
45775484|NCT01324453|Procedure|Post Conditioning + Primary PCI|Four, 30-second PTCA balloon occlusions followed by 30-seconds of reperfusion over a total of 4 minutes, in addition to Percutaneous Coronary Intervention as clinically indicated.
45775485|NCT01324453|Procedure|Standard Primary PCI|Routine Percutaneous Coronary Intervention as clinically indicated.
45914710|NCT02046837|Behavioral|Supervised 1:1 exercise|The exercise program will be delivered in a personal training (1:1) format by a certified exercise specialist.
46070196|NCT00701259|Drug|placebo|
45636574|NCT02803333|Other|No Intervention|No intervention
45636575|NCT04553939|Drug|Toripalimab|Toripalimab 3mg/m2 ivgtt, D1 every 14 days for 2-4 cycles.
45636576|NCT04553939|Drug|Gemcitabine|Gemcitabine 800mg/m2 ivgtt, D1 every 14 days for 2-4 cycles.
45775486|NCT01376557|Drug|75 mg LX4211|Subjects will receive 75 mg LX4211 once daily
45775487|NCT01376557|Drug|200 mg LX4211|Subjects will receive 200 mg LX4211 once daily.
45775488|NCT01376557|Drug|400 mg LX4211|Subjects will receive 400 mg LX4211 once daily.
45775489|NCT01376557|Drug|200 mg LX4211|Subjects will receive 200 mg LX4211 twice daily.
45775490|NCT01376557|Drug|Placebo|Subjects will receive placebo once daily.
45775491|NCT01324687|Other|Telemedicine care|Availability of telemedicine
45775492|NCT01431391|Biological|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
45775493|NCT01431391|Drug|leuprolide acetate|45.0 mg depot injection, 2 doses 6 months apart
45775494|NCT04346641|Diagnostic Test|Facial Measurements and Tooth Size and Pulp Volume|Radiographic images of patients who have been indicated for cone-beam computed tomography for the upper jaw for various reasons (such as impacted teeth, sinusitis, skeletal anomalies) will be reviewed retrospectively. Facial measurements (lower face height, midface height, inter-zygomatic distance, inter-pupillary distance, inter alar distance, epicanthus distance, the distance between commissures) of the patients who received cone beam computed tomography will be measured in the clinic. Mesiodistal distance, buccal palatal distance, root length, pulp volume of maxillary sixth tooth will be measured using cone beam computed tomography. The data obtained will be compared.
45775495|NCT03009097|Biological|DFDBA|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA)
45636577|NCT02790853|Procedure|Biopsy|Undergo brush biopsy and incisional biopsy
45636578|NCT02790853|Procedure|Fluorescence Imaging|Undergo PS2.1/PS3 imaging
45636579|NCT02790853|Procedure|High-Resolution Microendoscopy|Undergo HRME imaging
45452487|NCT03956693|Behavioral|HEADS: UP|"HEADS: UP comprises 9 x 2.5 hour mindfulness teaching sessions and a silent retreat in week 7. Course materials include accessible information packs and resources to complement class-based sessions.~The first week of the 9-week course is an introductory class. The purpose of the introductory class is to give participants the opportunity to meet the trainers and to decide if they want to learn more about mindfulness. The introductory session also allows participants to meet other people on the course and to share their (stroke) stories."
45452488|NCT05160272|Drug|AP-325|Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.
45636580|NCT02790853|Drug|Proflavine Hemisulfate|Applied on mucosa
45636581|NCT03113773|Drug|Proleukin|Patients will be treated with subcutaneous injections of IL-2 (range 0.3 X 10^6 - 3.0 X 10^6 IU) or placebo once daily for five consecutive days during the trial.A maximum dose of 3.0 X 10^6 IU will be allowed per day.
45636582|NCT03113773|Drug|Placebo Injection|Dextrose 5%
45636583|NCT05306041|Drug|Inavolisib|daily application of 9 mg (may be decreased to 6 mg and to 3 mg)
45636584|NCT05306041|Drug|PHESGO|fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase s.c. (PH-FDC SC) q3w beginning on day 1 of cycle 1 for 6 cycles (18 weeks)
45636585|NCT05306041|Drug|Endocrine therapy|Endocrine therapy per physician´s choice with either tamoxifen 20mg or an aromatase inhibitor +/- GnRH analogue for premenopausal women and men
45636586|NCT04874831|Drug|domatinostat in combination with avelumab|domatinostat tablets and avelumab infusion
45636587|NCT04454879|Drug|Roxadustat|Patients in the standard dosage group will receive starting dosage of roxadustat 100 mg, three times per week for weight 45-60kg and 120 mg, three times per week for weight greater than 60kg. Patients in the lower dosage group will receive the starting dosage of roxadustat 50 mg, three times per week for weight lower than 50kg, 70 mg, three times per week for weight 50-70kg, 90 mg, three times per week for weight 70-90kg and 110 mg, three times per week for weight 90-110kg, respectively.
45452489|NCT05160272|Drug|Placebo matching AP-325|Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.
45636588|NCT04859153|Diagnostic Test|central nerve sensory, motor control and various muscle mechanical characteristic and sport-related fitness test|To explore the sports performance of the adolescent sprinters, including analyzing the correlations between the results and central nerve sensory, and also between motor control and various muscle mechanical characteristic and sport-related fitness factor.
45636589|NCT05122169|Drug|Povidone-Iodine|Skin preparation with povidone-iodine pre-vaginal delivery skin preparation.
45636590|NCT05122169|Drug|Chlorhexidine|Skin preparation with chlorhexidine-alcohol pre-vaginal delivery skin preparation.
45636591|NCT04387955|Diagnostic Test|Biological Sample Collection|"Diagnostic test : biological sample collection at Day 0~Two skin biopsies on chilblain at Day 0 (one biopsy for histological analysis, one biopsy for basic research)~Anal swabbing at Day 0~Blood test at Day 0~Blood test at Month 1~Blood test at Month 2"
45636592|NCT04359329|Drug|Estradiol patch|Participant receives estradiol 100 micrograms/day for 7 days through a patch applied on the skin
45636593|NCT04326101|Other|Transmission of adherence records|Electronic transmission of patient adherence records by pharmacists into medical EHR (Electronic Health Records)
45636594|NCT04494035|Device|CAPERE Thrombectomy System|Arteriovenous graft thrombectomy
45636595|NCT03041285|Drug|idronoxil (NOX66) suppository|"Patients in Group 1 will be given 400mg of Idronoxil suppository (NOX66) (1 suppository) daily from Day 0(1 day before radiotherapy) until 7 days after radiotherapy. Group 2 will be given Idronoxil (NOX66) 800mg (2 suppositories) daily from Day 0 until 7 days after radiotherapy.~All patients will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 fractions.~Radiotherapy session will involve irradiation of 1-2 lesions.~."
45636596|NCT03041285|Radiation|Stereotactic Body Radiation Therapy|All patients (Group 1 and Group 2) will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 daily fractions on consecutive days. Radiotherapy session (week 1) will involve irradiation to 1-2 lesions.
45636597|NCT04794023|Device|Corneal Ablation|Corneal ablation for the treatment of myopia with/without astigmatism following flap creation using femtosecond laser.
45636598|NCT04256681|Other|SNAP questionnaire|The SNAP questionnaire will be administered 2 times in 2 consecutive days to evaluate its reliability. The questionnaire will be self-filled by the patient. Then the SPRS scale and, where possible, the 6MWT will be administered.
45636599|NCT05403749|Biological|dose 1 IBI302|After 4 loading monthly intravitreal injections of dose 1 IBI302，the following IBI302 IVT is given as descript in protocol.
45636600|NCT05403749|Drug|Aflibercept|Three consecutive monthly intravitreal injections of 2.0mg Aflibercept followed by injection every other month
45636601|NCT05403749|Biological|dose 2 IBI302|After 4 loading monthly intravitreal injections of dose 2 IBI302，the following IBI302 IVT is given as descript in protocol
45636602|NCT04766645|Device|Robotic assisted intervention|Conventional rehabilitation and Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
45636603|NCT04766645|Genetic|epigenetic analyses|Epigenetic study: evaluation of methylation levels of ACE2 promoter and miR-200c-3p levels.
45636604|NCT04766645|Diagnostic Test|biochemical analyses|Biochemical analysis: the evaluation of serum levels of angiotensin II, ACE2 and Vitamin D.
46070197|NCT00807391|Procedure|TBCA, TBNA|One arm, in random order first transbronchial catheter aspiration and second transbronchial needle aspiration or vice verse, both techniques routinely used in the diagnosis of peripheral pulmonary lesions; the cytological specimens of TBCA and TBNA are in random order examined by two independent cytologists, all cytological specimens are afterwards examined by a third, supervising cytologist.
45636605|NCT05301725|Other|PPI regimen|All patients received PPI regimen( lansoprazole or esomeprazole,bismuth amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
45636606|NCT05301725|Other|P-CAB regimen|All patients received P-CAB regimen(vonoprazan,bismuth ,amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
45775496|NCT03009097|Drug|DFDBA with atorvastatin|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA) in combination with atorvastatin gel
45636607|NCT05301647|Diagnostic Test|Nasal cytology|The cytological technique involves the following moments: sampling, processing, which includes fixation, staining and microscopic observation. Cytological sampling consists in the collection of superficial cells of the nasal mucosa with the help of a sterile swab or a small curette (scraping) in disposable plastic material (Rhino-probe).
45636608|NCT05301647|Other|The validated Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)|The validated Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) consists of 23 questions in 5 domains (nasal symptoms, ocular symptoms, practical issues, limitation of activities, other symptoms) that are answered on a 7-point scale (0-6), where 0 represents the absence of problems and 6 the greatest symptom distress. Children will complete the questionnaire together with a parent at baseline and during the study. A Total Score was calculated as the mean of the 5 domains.
45636609|NCT05301647|Other|Total symptom score (TSS)|Total symptom score was the sum of 3 domains: i) nasal symptoms (TNSS) included itching, sneezing, rhinorrhea, nasal congestion; ii) ocular symptoms (TOSS): itching, hyperemia of the conjunctiva, tearing; and iii) throat symptoms (TTSS): itching, coughing. With the help of their parents, patients scored symptoms severity on a 4-point scale: 0 = absent or irrelevant, 1 = mild, 2 = moderate, 3 = severe. Total symptom score was assessed at 12 hours (TTS 12h) and two weeks (TTS 2W) before the visits. TSS represents the doctor's point of view of symptom severity
45636610|NCT05301647|Other|Visual analogic scale (VAS)|A visual analogic scale (VAS) measured the parental perception of symptom severity (0=no symptom; 10=very severe symptoms).
45636611|NCT05403671|Other|Increasing Exercise and Physical Activity in Those Rehablilitating From Cancer|Intervention includes exercising and relaxation in a group
45636612|NCT04412759|Other|microbial cellulose|polymer dressing synthesized in abundance with Acetobacter Xylinum
45636613|NCT04203875|Drug|Orencia® (Abatacept)|Orencia® (Abatacept) will be administered once a week for 6 months subcutaneously (injection under the skin) with an option to continue to receive Abatacept weekly injections for an additional 6 months, for a total of 12 months if there is a positive response.
45636614|NCT05285111|Behavioral|Reconnecting to Internal Sensations and Experiences|The intervention consists of four modules that focus on multiple aspects of interoception including: body awareness, body sensations/movement, eating, health and self-care, emotional awareness, and understanding the self in relation to others.
45636615|NCT05285111|Behavioral|Healthy Habits|"The comparator condition is called Health Habits and is matched for time and attention; participants complete modules related to healthy habits such as financial planning, hygiene, stretching, and healthy eating."
45636616|NCT05283785|Procedure|End To End or End to side sutures|End to end or End to side sutures of ulnar nerve by nerve to quadratus muscle ( branch of anterior interosseous nerve )
45636617|NCT04491461|Dietary Supplement|Herbal tea blend|1 cup of freshly brewed tea from an herbal tea blend.
45636618|NCT04491461|Dietary Supplement|Warm water|1 cup of warm water
45775497|NCT01325311|Drug|Cholecalciferol|Given PO
45775498|NCT01325311|Drug|Genistein|Given PO
45775499|NCT01325311|Other|Laboratory Biomarker Analysis|Correlative studies
45775500|NCT01325311|Other|Pharmacological Study|Correlative studies
45775501|NCT01325311|Other|Placebo|Given PO
45636619|NCT04151927|Device|Normobaric Hypoxia|Low oxygen exposure to mimic ~8500 feet elevation.
45636620|NCT04151927|Device|Normobaric Normoxia|Normal oxygen exposure to mimic ~1000 feet elevation (sham comparator).
45636621|NCT04491383|Drug|Tocovid Suprabio (HOV-12020)|Dietary supplement: Tocotrienol (HOV-12020) Palm oil-derived vitamin E, tocotrienol
45775502|NCT01432015|Drug|fosaprepitant|Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Patient will receive standard pre-medications
45775503|NCT01432015|Drug|aprepitant|Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. patient will receive standard pre-medications
45775504|NCT01432015|Other|Oral Placebo|One pill administered on days 1-3 in conjunction with Fosaprepitant.
46070198|NCT00701337|Drug|oestradiol|oestradiol 2 mg oral route 30 days
45636622|NCT04491383|Other|Placebo|Dietary supplement: Placebo. Placebo.
45775505|NCT01432015|Other|IV placebo|100 cc of IV placebo administered on day in conjunction with Aprepitant
45775506|NCT01080209|Drug|Brimo PS DDS®|Patients who received Brimo PS DDS® intravitreal implant in a previous study.
45775507|NCT01080209|Other|Sham|Patients who recieved sham in a previous study.
45775508|NCT01080677|Drug|caffeine/propranolol combination tablet|caffeine/propranolol combination tablet administered orally once daily
45775509|NCT01080677|Drug|placebo|placebo to match caffeine/propranolol combination tablet administered orally once daily
45775510|NCT01378273|Drug|Epo|Enrollment will occur within 24 hours of birth. Study drug will be administered intravenously for the first 6 doses. Subjects in the Epo arm will then receive 400 U/kg/dose three times a week until they reach 32-6/7 weeks postmenstrual age. Control infants will receive sham injections.
46070199|NCT00701337|Drug|oestradiol|oestradio transdermal patch 60ug by 24 hours 30 days
45775511|NCT01378273|Other|Control|Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
45636623|NCT04142645|Device|OptiMEDs|"The OptiMEDs intervention is a multi-faceted intervention combining:~an ICT platform:~automatic and secure capture of individual prescribing information from the electronic medication administration records in the nursing home~a tool for structured nurse observations of side effects, derived from the existing Pharmanurse application (20) (used to list potential medication side effects, based on the individual medication chart of the nursing home residents) to support monitoring of medication safety by nurses.~an electronic decision support tool for the appraisal of potentially inappropriate medication (explicit criteria of misuse and underused of medication, based on existing lists of explicit criteria (PIMs)), use of medication with anticholinergic properties and medication inappropriate in view of the limited life expectancy.~a multidisciplinary medication review with the input of GPs, trained community-pharmacists and nurses."
45636624|NCT04089917|Device|Q Aspiration Catheter|The Q Aspiration Catheter is indicated for use in the removal of fresh, soft emboli and thrombi in the neurovascular system.
45636625|NCT05900700|Behavioral|eYST website|The website is a psychoeducational, social support program for adolescents at risk for suicide
45636626|NCT05900687|Behavioral|Use of mHealth Question Prompt List app|mHealth Question Prompt List app that facilitates in asking questions with a physician during a consultation specific to GERD
45636627|NCT05900674|Drug|Reteplase Injection|To test the single dose of reteplase (9 U) and Maximum dose (18 U) in acute ischemic stroke patients.
45636628|NCT05900661|Drug|myo-inositol|myo-inositol 600µgm + folic acid 0.2 mg) 2 capsules at the morning and 2 capsules at the evening on empty stomach for 12 weeks produced by a Lo.Li pharma international ,Rome.Italy .
45636629|NCT05900661|Drug|Somatropin|growth hormone 2:Somatropin (4 IU for 1month), SEDICO ,6th of october .Egypt. 1 s.c injection every 3 days for at least 1 month.
45636630|NCT05900661|Drug|Dehydroepiandrosterone|DHEA 50 mg twice per day for 12 weeks in the last group , NATROL UK.Ltd.
45636631|NCT05900648|Drug|Regorafenib|Given by PO
45636632|NCT05900648|Drug|XmAb20717|Given by (IV) vein
45636633|NCT05900635|Drug|Lactoferrin|Effect of adding Lactoferrin to Oral Iron Supplementation for the treatment of Iron Deficiency Anemia in Chronic Kidney Disease Patients
45636634|NCT05900635|Drug|Ferrous Glycine Sulfate|Effect of adding Lactoferrin to Oral Iron Supplementation for the treatment of Iron Deficiency Anemia in Chronic Kidney Disease Patients
45636635|NCT05900622|Other|Reduced postoperative braking and bed rest time.Lower extremity on the puncture side with a 2-hour brake+Get out of bed after 4 hours|Braking time is defined as the time from the start of postoperative lying down until the patient sits up in bed and can move the lower limbs Bed rest is the time from when the patient is lying down to when they are on the floor after the procedure, but it has been identified as the most difficult part of post-vascular puncture intervention care
45636636|NCT05900622|Other|Significantly reduce postoperative braking and bed rest time.No braking of the lower limb on the side of the puncture+Get out of bed after 2 hours|Braking time is defined as the time from the start of postoperative lying down until the patient sits up in bed and can move the lower limbs Bed rest is the time from when the patient is lying down to when they are on the floor after the procedure, but it has been identified as the most difficult part of post-vascular puncture intervention care
45636637|NCT05900609|Dietary Supplement|WholeFiber|"WholeFiberTM is a product with high levels of prebiotic dietary fibers (~85%) mainly consisting of inulin, and some pectin, hemi-cellulose and cellulose that is derived from the root vegetable, chicory roots.~Fiber guidelines:~Subjects receive a booklet with recipes high in fiber. Subjects are recommended to use 2 recipes per day + a snack. Estimated average intake via the recipes in the recipe booklet is 24 grams/day.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation)."
45636638|NCT05900609|Dietary Supplement|Kombucha|"The kombucha is produced by a minimum three-month long fermentation process. It is a live fermented herbal drink essence, without refined sugar, and an unpasteurized, organic product.~Fermented food guidelines:~Study participants in the fermented foods arm are asked to use 3 additional servings of fermented food per day, using the fermented food list / recipe booklet.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation)."
45636639|NCT05900609|Dietary Supplement|Maltodextrin DE19/21|"Maltodextrin DE19/21 is a digestible carbohydrate, that is completely digested and does not reach the colon, which makes it a suitable placebo dietary compound and the reason why it is frequently used in comparable studies.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation)."
45636640|NCT05900570|Diagnostic Test|Urodynamic testing with and without pudendal nerve stimulation|A urodynamic test with and without neurostimulation will be conducted. The external neurostimulator device settings will be adjusted to deliver acute nerve stimulation per the individual tolerance level to assess the effect on urethral pressure. A leak point pressure (LLP) during Valsalva maneuver will be assessed with and without acute nerve stimulation.
45636641|NCT05900557|Diagnostic Test|ECoG monitoring|Brief (1-5 days) of post operative ECoG monitoring to detect spreading depolarization.
45636642|NCT05900544|Other|System implementation of patient-centered incidental findings report|For three lung cancer screening programs a system level implementation for a patient-centered incidental findings report
45775512|NCT01432405|Drug|Exenatide|Type 2 diabetic subjects will be randomized to receive exenatide 10 micrograms injected subcutaneously twice daily for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
46070200|NCT00916370|Device|Core size Xience Prime|Core size includes a range of stent sizes.
45636643|NCT05900531|Drug|K-757|administered orally
45636644|NCT05900531|Drug|K-757 and open-label sitagliptin|both administered orally
45636645|NCT05900531|Drug|Matching placebo to K-757|administered orally
45636646|NCT05900531|Drug|Matching placebo to K-757 and matching placebo to K-833|both administered orally
45636647|NCT05900531|Drug|K-757 and K-833|both administered orally
45636648|NCT05900531|Drug|Matching placebo to K-757, open-label sitagliptin|both administered orally
45636649|NCT05900453|Other|Clinical decision support (CDS) tool|"The web-based clinical decision support (CDS) tool uses patient information (e.g., age, sex, BMI, perioperative status) to create personalized predictions of recovery following knee replacement. The CDS tool predicts range of motion, physical function, and pain recovery. Clinicians can use these predictions to (1) inform patients of their expected prognosis, (2) monitor patients' recovery against their predicted recovery, and (3) tailor treatments according to individual patients' needs.~Clinicians were provided with basic training for how to use the CDS tool, and were given examples of how to integrate it into clinical care. However, the CDS tool did not dictate any treatment decisions; clinicians were free to use the CDS tool at their discretion to inform decision making."
45636650|NCT05900440|Other|Ultrasound with Artificial Inteligence Engabled|Participants shall be randomized 1:1 to receive personal access to a handheld ultrasound device with artificial intelligence vs a device with no artificial intelligence. The groups shall not cross over in which intervention they received.
45636651|NCT05900440|Other|Ultrasound without Artificial Intelligence Enabled|Participants shall be randomized 1:1 to receive personal access to a handheld ultrasound device with artificial intelligence vs a device with no artificial intelligence. The groups shall not cross over in which intervention they received.
45636652|NCT05900414|Behavioral|Electronic patient decision aid|Link to website with information about atrial fibrillation treatments, plus access to the web-based patient decision aid to enable shared decision making between patients and their physicians for atrial fibrillation stroke prevention treatments
45636653|NCT05900414|Other|Information|Link to website with information about atrial fibrillation treatments
45636654|NCT05900401|Other|Bone Marrow Transplant|Months-Years after standard transplant, patients will undergo bone marrow transplant (either from prospective collection of stem cells from their living donor, or from bone marrow collected at the time of deceased donation)
45636655|NCT05900401|Procedure|Peripheral Blood Stem Cell Collection|PBSC will be collected from the LD via leukapheresis 1-4 weeks before the scheduled HSCT. The donor will first undergo standard GCSF mobilization: GCSF (can be TBO-GCSF) dosed at 10 mcg/kg/d (rounded to nearest pre-filled syringe) administered subcutaneously daily for 5 consecutive days. On the 5th day, the donor will undergo standard large volume leukapheresis. The target yield will be 2-3 x 106 CD34+ cells / kg of actual recipient body weight. A maximum of 3 days of pheresis will be allowed. A minimum of 2 x 106 CD34+ cells / kg of actual recipient body weight will be required to proceed.
45636656|NCT05900401|Drug|Combination of Fludarabine, Cyclophosphamide, Rituximab & Siplizumab|Combination of Fludarabine, Cyclophosphamide, Rituximab & Siplizumab
45775513|NCT01432405|Drug|Pioglitazone|Type 2 diabetic subjects will be randomized to receive pioglitazone 45 mg daily orally for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
45775514|NCT01082159|Procedure|lumbar decompression|The mild® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
45775515|NCT01432561|Drug|Cysteamine bitartrate|500 mg total, single dose taken orally on visits 2, 3 & 4 which must occur within a 14 day period.
45775516|NCT01116401|Drug|leuprolide|Leuprolide acetate is a widely used GnRH agonist. In this protocol, leuprolide will be administered at a dose routinely used for treatment of endometriosis and uterine fibroids in women (one 3.75-mg intramuscular injection).
45775517|NCT03008317|Device|PEEK|a metallic denture base
45775518|NCT01433107|Drug|Terbinafine|1% single application
45775519|NCT01433107|Drug|Terbinafine Placebo|single application
45775520|NCT01082939|Drug|Fludarabine|25 mg/m^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
45775521|NCT01082939|Drug|Cyclophosphamide|250 mg/m^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
45775522|NCT01082939|Drug|Alemtuzumab|30 mg IV on Days 1, 3 and 5 over 2-4 hours; repeated every four weeks for a total of 6 planned cycles.
45775523|NCT01082939|Drug|Rituximab|"Cycle 1 (Week 1): 375 mg/m^2/day IV on Day 2 over 4- 6 hours~Cycle 2 - 6 (Week 1): 500 mg/m^2/day IV on Day 2 over 4- 6 hours"
45775524|NCT01327963|Device|Transoral Incisionless Fundoplication|Transoral incisionless esophago-gastric fundoplication performed using the EsophyX (brand name) system with SerosaFuse (brand name) fasteners (EndoGastric Solutions, Inc., Redmond, Washington, USA) and following the standardized Transoral Incisionless Fundoplication 2.0 technique iteration (TIF2.0) protocol.
45775525|NCT01381471|Drug|fluticasone propionate/salmeterol xinafoate combination|fluticasone propionate/salmeterol xinafoate combination
45775526|NCT01328743|Behavioral|Brief alcohol intervention|3 sessions of individual face-to-face counseling at baseline, 3 and 6 months. Sessions are motivationally focused including discussion of pros and cons of drinking and feedback on health and its relation to heavy drinking
45775527|NCT01329679|Dietary Supplement|Energy Drink|Energy drink, 2oz twice daily for 7 days
46070201|NCT00916370|Device|Xience Prime Long Lesion (LL)|Long lesion stent sizes include a range of sizes.
45636657|NCT05900388|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain
45636658|NCT05900388|Drug|Standard of care (SOC)|Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain. SOC including heparins, Vitamin K antagonists (VKAs) and Other Direct oral anticoagulants (DOACs).
45636659|NCT05900349|Other|Carbohydrate mouth rinsing|the carbohydrate solution was prepared by dissolving 6.4 g of colorless and odorless maltodextrin in 93.6 mL of water; the mixtures were then adjusted to a 6.4% maltodextrin solution for the participants to rinse their mouths for 20 seconds
45636660|NCT05900349|Other|200 mg caffeine gum|Chewing caffeinated gum for 20 minutes
45636661|NCT05900336|Drug|Sodium Naproxen|One dose of 550mg sodium naproxen taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).
45636662|NCT05900336|Drug|Placebo|One dose of placebo capsule taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).
45636663|NCT05900323|Combination Product|enteral nutrition guidelines|The nurses will be educated about the enteral nutrition guidelines. Then they will apply these guidelines on the participants during enteral nutrition procedure. After conducting the guidelines, the researcher will assess the effect of the guidelines on patients' outcomes.
45636664|NCT05900310|Diagnostic Test|Core Cognitive Evaluation (CCE)|The Linus Health Core Cognitive Evaluation (CCE) is an easy-to-use but powerful tool to augment and facilitate cognitive health assessment during a patient's visit to their PCP. As a digital assessment solution, the CCE combines objective insights into cognitive ability with patient-reported insights to detect early signs of cognitive impairment and reveal specific modifiable risk factors earlier than the existing status quo assessments. The CCE is an FDA-listed Class II 510k exempt software as a medical device. The CCE has two components: The Digital Clock and Recall (DCR™) test and the Life and Health Questionnaire (LHQ).
45636665|NCT05900284|Drug|Metformin low dose|If randomized to the 500 mg. Metformin arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
45636666|NCT05900284|Drug|Metformin high dose|If randomized to the 1000 mg. Metformin arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
45775528|NCT01329679|Other|Placebo|Water, lime juice and cherry flavoring
45775529|NCT01331083|Drug|PX-866|PX-866: 8mg orally taken daily
45775530|NCT05422092|Drug|Canagliflozin|40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive canagliflozin on top of metformin as experimental group.
45775531|NCT05422092|Drug|Pioglitazone|40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive pioglitazone 45mg on top of metformin as placebo comparator group.
45775532|NCT05420844|Other|Kintsugi voice journaling application|Participants will use the Kintsugi voice journaling phone application for three months.
45775533|NCT05448456|Drug|Tranexamic acid|1 gram of tranexamic acid in 100 ml of 0.9% normal saline
45775534|NCT05448456|Drug|Placebo|100 ml of 0.9% normal saline
45775535|NCT01433731|Drug|placebo for SHAPE (SHP-141)|topical gelled solution
45775536|NCT01433731|Drug|SHAPE (SHP-141) 0.1% BID|topical gelled solution
45775537|NCT01433731|Drug|SHAPE (SHP-141) 0.5% BID|topical gelled solution
45775538|NCT01433731|Drug|SHAPE (SHP-141) 1.0% BID|topical gelled solution
45775539|NCT05448378|Dietary Supplement|D-chiro-inositol|D-chiro-inositol 600 mg twice per day on an empty stomach for one month
45775540|NCT05447130|Procedure|phacoemulsification|phacoemulsification with corneal endothelial evaluation by specular microscopy
45775541|NCT01434121|Drug|Ascorbic Acid|The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo
45775542|NCT01434121|Drug|Placebo|
45775543|NCT01435603|Behavioral|Standard Lifestyle Advice|Standard clinical education is offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits and are provided with clinical recommendations for lifestyle and cardiovascular risk factor management. Brief lifestyle advice is delivered by a study Research Assistant at baseline, 6, 12, and 24 months.
45775544|NCT01435603|Behavioral|Advice Plus Lifestyle Intervention|Standard clinical education offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits for lifestyle and cardiovascular risk factor management. Brief lifestyle advice delivered by a study research assistant at baseline, 6, 12, and 24 months. AND, participant offered free of charge access to an intensive lifestyle intervention offered in a community setting. Lifestyle interventions are delivered in community settings by lay instructors from community organizations who are centrally trained by the study team.
45636667|NCT05900284|Drug|Placebo|If randomized to the Placebo arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
45775545|NCT02438202|Device|Thymatron IV device (Somatics)|Patients will be treated with a modified routine ECT/maintenance ECT series.
45775546|NCT01381861|Biological|Carotuximab (TRC105)|Carotuximab (TRC105) 10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
45775547|NCT01382719|Drug|bremelanotide|"Subjects will administer drug on an as needed basis, prior to anticipated sexual activity.~Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.~Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product."
45636668|NCT05900258|Drug|Tirbanibulin|Klisyri® 10 mg/g Ointment (Tirbanibulin) patients receive Tirbanibulin on sun-damaged areas of the face for five days, according to the SmPC.
45636669|NCT05900245|Other|Index of consciousness+Anesthetic（propofol）+Muscle relaxant（Succinylcholine）|EEG monitoring is performed before induction of electrical shock anesthesia（propofol1.5mg/kg+Succinylcholine1mg/kg）, and the timing of electrical stimulation is determined based on the level of consciousness index 1 displayed on the EEG.
45636670|NCT05900232|Diagnostic Test|Anti _KU antibodies|aim of the work is to determine the relationship between Anti_Ku antibodies and SLE manifestations the study will include 60 SLE cases diagnosed by SLICC criteria and the activity of SLE will be calculated by SELDAI criteria, which is tool composed of 24 clinical and laboratory variables.
45636671|NCT05900219|Drug|HL-085+Vemurafenib|The treatment regimen was HL-085 9mg BID+ Vemurafenib 720mg BID oral administration for 21 days per cycle. The primary efficacy endpoint in this study was the ORR assessed by the Independent Review Committee (IRC) according to the RECIST 1.1
45914711|NCT02046837|Behavioral|Supervised group exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
45914712|NCT02046837|Behavioral|Home-based exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
45914713|NCT02046850|Drug|selumetinib|Volunteers will receive a single oral dose of 75 mg selumetinib on day 1 (Treatment A).
45914714|NCT02046850|Drug|rifampicin|Volunteers will receive single, daily, oral doses of 600 mg rifampicin on Days 4 to 11 (Treatment B).
45914715|NCT02046850|Drug|selumetinib|On day 12 volunteers will receive a single oral dose of 75 mg selumetinib (Treatment C).
45775548|NCT01037309|Drug|PRO044 SC|Subcutaneous injection, once a week, for five weeks
45775549|NCT01037309|Drug|PRO044 IV|Intravenous injection, once a week, for five weeks
45775550|NCT01038557|Biological|RBC units|When a transfusion is ordered, enrolled subjects will receive RBC units 1) up to 14 days old, 2) 14-42 days old, or 3) that are frozen when stored.
45914716|NCT02046850|Drug|rifampicin|On day 12 volunteers will receive a single oral dose of 600 mg rifampicin. Once daily rifampicin administrations will continue through to Day 14 (Treatment C).
45914717|NCT02046876|Other|Multimodal Physiotherapy Program|Multimodal Physiotherapy Program integrates: physical land-based therapeutic exercise, adapted swimming and health education
45914718|NCT02046889|Behavioral|Bicycle Training Intervention|
45914719|NCT02046915|Drug|Imnovid (pomalidomide)|
45914720|NCT02046915|Drug|Dexamethasone|
45636672|NCT05900206|Drug|Trastuzumab deruxtecan|Experimental drug. Provided in 100mg vials. IV infusion.
45914721|NCT02046915|Drug|Endoxan (Cyclophosphamide)|
45914722|NCT02046928|Drug|A6|A6 is self-administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).
45914723|NCT02046967|Procedure|Endovenous laser ablation with 940 nm bare fiber|Endovenous laser ablation with 940 nm Diode laser using a bare fiber for treating the Great Saphenous Vein.
45914724|NCT02046967|Procedure|Endovenous steam ablation with steam vein sclerosis system.|Endovenous steam ablation with steam vein sclerosis.
45914725|NCT02047006|Drug|Rivaroxaban 10 mg|"Measurement of AUC of rivaroxaban and effect on coagulation assays:~Venous blood samples (8.5 ml) are collected immediately before (t=0) and at t= 0,5, 1, 2, 4, 8, 12, 24, 36 and 44 hours after administration of rivaroxaban.~Effect of dialysis on levels of rivaroxaban:~Venous blood samples (8.5 ml) are collected at the start of dialysis (t=0) and at t=1, 2, 3 and 4 hours."
45914726|NCT02047019|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 30/16 mg, tablet, orally, once daily
45914727|NCT02047019|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16 mg, tablet, orally, once daily
45636673|NCT05900206|Drug|Docetaxel|Active comparator. IV infusion.
45636674|NCT05900206|Drug|Paclitaxel|Active comparator. IV infusion.
45636675|NCT05900206|Drug|Carboplatin|Active comparator. IV infusion.
45914728|NCT02047019|Drug|Candesartan Cilexetil|Candesartan Cilexetil, 16 mg, capsule, orally, once daily
45914729|NCT02047019|Drug|Candesartan matching placebo|Candesartan matching placebo, capsule, orally, once daily
45914730|NCT02047019|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo, tablet, orally, once daily
45914731|NCT02047019|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16mg matching placebo, tablet, orally, once daily
45636676|NCT05900206|Drug|Trastuzumab|Active comparator. IV infusion.
45636677|NCT05900206|Drug|Pertuzumab|Active comparator. IV infusion.
45636678|NCT05900206|Drug|Ribociclib|Experimental drug. Tablets.
45636679|NCT05900206|Drug|Letrozole|Experimental drug. Tablets.
45636680|NCT05900206|Drug|Epirubicin|Active comparator. IV infusion.
45636681|NCT05900206|Drug|Cyclophosphamide|Active comparator. IV infusion.
45636682|NCT05900193|Dietary Supplement|TAS1R2/3 agonist or antagoinst admixture to oral glucose tolerance test|Participants drank a glucose beverage for an oral glucose tolerance test along or with admixture with the TAS1R2/3 agonist sucralose or the TAS1R2/3 antagonist lactisole.
45636683|NCT05900180|Behavioral|Speech Therapy|Delivery of speech therapy services
45636684|NCT05900167|Behavioral|enteral nutrition|The nutritional status of the patient is assessed by the physician to determine the need for enteral nutrition
45636685|NCT05900154|Biological|RSVpreF 120 µg|RSVpreF standard dose level
45636686|NCT05900154|Biological|RSVpreF 60 µg|RSVpreF low dose level
45636687|NCT05900154|Other|placebo|Placebo
45636688|NCT05900141|Drug|Pelacarsen|Pelacarsen 80mg s.c. monthly
45636689|NCT05900128|Behavioral|workshop|Patients will receive workshops and they will encourage to practice physical activity
45636690|NCT05900128|Other|no workshop|patients won't receive educative workshops
45636691|NCT05900115|Behavioral|Media Ready Parent|The intervention is a web-based resource that provides parents with media literacy and media mediation skills, knowledge about adolescent development and substance use, and practice in high quality parent-child communication.
45636692|NCT05900115|Behavioral|Active Control Program|The active control is a web-based resource that contains PDFs of medically accurate information about adolescent substance use.
45636693|NCT05900089|Drug|SHR0302|SHR0302 will be administered orally as tablet. SHR0302 treatment will be continued until disease progression or intolerant adverse reactions
45636694|NCT05900050|Drug|VS-01 on top of SOC|Patients will receive VS-01 intraperitoneally on four consecutive days on top of SOC
45636695|NCT05900050|Other|SOC (Control Group)|Patients will receive SOC for decompensated cirrhosis and ACLF
45636696|NCT05900037|Device|GATT-Patch|"GATT-Patch is a sterile, flexible and resorbable hemostatic sealing patch. It presents as a blue, soft, flexible, porcine gelatin fiber-based carrier impregnated with an NHS-POx / NU-POx granulate. GATT-Patch measures 10 cm long by 5 cm wide. GATT-Patch is active and can be applied on both sides. Blue color is an aid to visualize GATT-Patch when applied onto a bleeding location.~GATT-Patch is indicated for use as an adjunct to hemostasis in surgery for minimal, mild or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. GATT-Patch is intended to be used for management of hemorrhage during surgeries on the liver."
45636697|NCT05900037|Device|SURGICEL® Original|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is indicated for use in surgical procedures to assist in the control of capillary, venous and small arterial hemorrhage when ligation or other conventional methods of control are impractical or ineffective.
45636698|NCT05900024|Other|Funk It Cycle Bites|The intervention product contains: Organic Pumpkin Seed Butter, Prebiotic Agave Inulin, Organic Flax Seed, Organic Oat Flour, Organic Ginger, Quinoa Sprouts, Crispy Red Rice, Organic Cacao Nibs, Sunflower Seed Butter, Organic Reishi Mushroom, Organic Amaranth Seeds, Dates, Organic Button Mushroom, Acai Berry, Amla Fruit, Goji Berry, Pomegranate, Cranberry, Acerola (Cherry Juice), Rosemary Extract, Vitamin E (Mixed Tocopherols), Organic Vanilla Extract, Sea Salt, Cinnamon, Naturally Sourced Potassium Sorbate.
45636699|NCT05900011|Behavioral|Quality of life questionnaire|Measurement of the quality of life of patients with eosinophilic esophagitis by the PedsQL questionnaire eosinophilic esophagitis module
45636700|NCT05899998|Behavioral|Bright IDEAS|Bright IDEAS® (Identify, Define, Evaluate, Act, See) is a problem-solving skills training program that was originally developed to alleviate distress in caregivers of children recently diagnosed with cancer. Intervention materials include instructor and user manuals, a brochure, and worksheets to be completed by the parent caregiver, initially with the help of the interventionist and then with increasing independence.
45636701|NCT05899985|Combination Product|FerroTrace® and FerroMag Sentinel Lymph Node Mapping (SLNM) System|"FerroTrace will be injected peri-tumorally during the surgeons staging endoscopy, with an MRI conducted 12h to 28 days after injection. The MRI will be blinded to the clinical team and will assess the location of the primary draining lymph nodes (sentinel lymph nodes or SLNs).~Patients will proceed to standard of care neoadjuvant therapy and/or surgery. During surgery, indocyanine green (ICG) will be used to identify draining lymph nodes. Following surgery, pathologists will use FerroMag to identify SLNs which will undergo standard H&E assessment, and if negative ultras-staging (fine serial slice and immunochemistry)."
45636702|NCT05899959|Device|Corsano CardioWatch 287-2|Patients receive either an EKG holter or an automatic blood pressure cuff, as prescribed by their cardiologist. The readings from these devices (atrial fibrillation detection and blood pressure) will be compared to the readings from the CardioWatch 287-2.
45914732|NCT02047071|Device|Continuous positive airways pressure|Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
45636703|NCT05899946|Other|A community-based network training program|A 3-phase program including establishing a community-based network, video competition, and Video promotions will be conducted.
45636704|NCT05899933|Procedure|Non-surgical peri-implant therapy|"2 weeks after baseline examination, non surgical therapy will be applied in implants diagnosed with peri-implantitis prior to enrollment in surgical therapy.~Firstly, participants will be instructed in oral hygiene. Professional supragingival and subgingival debridement of implants/ teeth, including the selected for the study implants, will be performed. Local anesthesia will be performed, when needed. Targeted implants will be treated with PEEK-coating ultrasonic tips (Instrument PI; EMS), titanium curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy), rubber cup and polishing paste. Possible adjustments to implant-borne prostheses will be considered, whenever possible. Re-evaluation of non-surgical therapy will be performed after 6 weeks.~At the 6-week reevaluation, participants with peri-implant probing pocket depth ≥5 mm and bleeding on probing and/or suppuration in patients with full mouth plaque score ≤20% will proceed to surgical therapy."
45636705|NCT05899933|Procedure|Implantoplasty|"Screw-retained supraconstructions and, when possible, cement-retained restorations will be removed.~Following local anesthesia, intrasulcular incisions will be performed and full-thickness flaps will be elevated on the buccal and lingual aspects of affected implants. Granulation tissue will be removed, and titanium-coated curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy) and NiTi brushes (NEGRIN IN DENTAL) will be applied to remove hard deposits on implants. Osseous recontouring will be performed when indicated followed by irrigations with saline. Implantoplasty will be applied using tungsten carbide burs of various shapes and sizes (Peri-implantitis Kit; Meisinger) followed by irrigations with saline. Flaps will be readjusted and closed with sutures in order to allow a non-submerged healing. Supraconstructions will be reconnected after the surgery."
45636706|NCT05899933|Procedure|Erythritol Air-abrasive device|"Screw-retained supraconstructions and, when possible, cement-retained restorations will be removed.~Following local anesthesia, intrasulcular incisions will be performed and full-thickness flaps will be elevated on the buccal and lingual aspects of affected implants. Granulation tissue will be removed, and titanium-coated curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy), and NiTi brushes (NEGRIN IN DENTAL) will be applied to remove hard deposits on implants. Osseous recontouring will be performed when indicated followed by irrigations with saline. Implant surface decontamination with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS) will be applied followed by irrigations with saline. Flaps will be readjusted and closed with sutures in order to allow a non-submerged healing. Supraconstructions will be reconnected after the surgery."
45636707|NCT05899933|Procedure|Prophylaxis|Supramucosal biofilm removal of implants/ teeth will be performed at, 3, 6, 9 and 12 months after surgical therapy for the Implantoplasty group and the Erythritol Air-abrasive device group and at 2 weeks, 3, 6, 9 and 12 months after baseline examination for the control group. Targeted implants will be treated with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS). During these appointments, patients will be re-motivated and re-instructed to oral-hygiene measures.
45636708|NCT05899920|Diagnostic Test|Blood samples will be taken for pharmacokinetics and pharmacogenetics|To assess antihypertensive drugs concentration (lisinopril, valsartan, amlodipine, indapamide
45636709|NCT05899907|Drug|Telitacicept|160mg once a week for 48 weeks
45636710|NCT05899907|Drug|Standard of Care|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
45636711|NCT05899894|Device|Neurally Adjusted Ventilatory Assist|NAVA mode will be titrated as per protocol alongside titration of PEEP levels. Peep will be titrated for all NAVA levels in a descending order 10,5,0 NAVA level will be titrated in an ascending order 0.5, 1.0, 1.5, 2.0 at each PEEP level
45636712|NCT05899881|Behavioral|Yoga intervention|10 weeks of Hatha yoga, once per week, 60 minutes per class
45636713|NCT05899868|Device|Time to Intubation using FASTER device|Time from fiberoptic placement onto airway to documentation of end-tidal carbon dioxide waveform through the endotracheal tube.
45636714|NCT05899855|Other|No intervention|No intervention
45636715|NCT05899842|Drug|Protein pump inhibitor therapy systematically|Lansoprazole 30mg once per day
45636716|NCT05899829|Drug|Camlipixant + Rifampin|Camlipixant will be administered alone as well as in co-administration with rifampin
45636717|NCT05899829|Drug|Camlipixant + Rabeprazole|Camlipixant will be administered alone as well as in co-administration with rabeprazole
45775551|NCT04352387|Behavioral|Montessori Method for Dementia|The Montessori Method highlights the importance of considering the past experiences, identifying interests and maximizing spared capacity and abilities of each individual.
45775552|NCT04352387|Behavioral|Usual care|Activities delivered regularly in the usual care, such as reading out newspapers, physical activities, and watching videos, in the 1-hour sessions.
45775553|NCT01117727|Device|Brain Computer Interface Switch|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 14-20 sessions.
45775554|NCT01040819|Drug|Pioglitazone|Patients will receive PIO 15 mg/d for one month, then 55 patients continue with the same dose for one additional month, and in 55 patients the dose will be increased to 30 mg/d for an additional one month. Other non-diabetes drugs should not be changed. Other hypoglycemic agents, including insulin may be adjusted, if clinically indicated. NSAID, COX2 inhibitors, aspirin >162 mg/d, steroids and prostaglandin analogs will be prohibited.
45775555|NCT01041209|Behavioral|Strategy based on BPS guided antibiotic use|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
45775556|NCT01041209|Behavioral|Enforced Guidelines|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
45775557|NCT01084265|Drug|Recombinant human luteinizing hormone (r-hLH)|One r-hLH (75 International Units [IU]) injection s.c. once daily.
45775558|NCT01084265|Drug|Recombinant human follicle-stimulating hormone (r-hFSH)|One r-hFSH (150 IU) injection s.c. once daily.
45775559|NCT01084265|Drug|Human chorionic gonadotropin (hCG)|After adequate follicular response, ovulation induction was triggered by an injection of 10,000 IU hCG.
45775560|NCT01084499|Drug|Femara (Sequence 1)|Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.
46070202|NCT04116021|Other|PECS block|Ultrasound-guided PECS block before surgical incision with 30 mL bupivacaine 0.5 %
45636718|NCT05899803|Diagnostic Test|Posture Analysis|This analysis consists of 13 different body parts and evaluates the body in terms of current posture changes. Our study evaluated children from two angles: posterior (head, shoulders, back, hips, feet, and arches) and lateral (neck, chest, shoulders, upper back, trunk, abdomen, and waist). In the scoring system, correct posture was recorded as five points, a moderate amount of deformity posture as three points, and severe deformity posture as one point. The total score calculated at the end of the questionnaire was a maximum of 65 points and a minimum of 13 points. The results of the analysis were evaluated as follows: ≥ 45 points, very good, 40-44 points good, 30-39 points moderate, 20-29 points poor, and a total score of ≤ 19 points.
45636719|NCT05899803|Diagnostic Test|Physical activity level|This questionnaire, administered to children aged 4-14, evaluates the activities performed during a week. The questionnaire consisted of nine questions, each of which was evaluated on a 5 points. One point indicated a low physical activity level and five points indicated a high physical activity level. Dividing the total score of the selected items by the number of items gives a summary score for the PAQ-C questionnaire. In our study, we used the Turkish version of the questionnaire, which was found to be reliable and valid.
45636720|NCT05899803|Diagnostic Test|Muscle strength|"Our study objectively measured muscle strength using the JTech Commander PowerTrack Muscle Dynamometer.~Right and left muscle tests: Hip flexors/hyperextensors/adductors/abductors/internal rotators/external retractors, knee flexors/extensors, and foot plantar flexors/dorsiflexors were evaluated. The measurement results were recorded in Newtons, the measurements were repeated three times, and the average of these three repetitions was recorded."
45636721|NCT05899790|Other|VR|"The first interview with the patients in the intervention group will be held in the afternoon, the day before the surgery. After completing the forms and scale the video containing information about the operating room environment will be applied to the patients through SG glasses and headphones.~Before the surgical intervention, patients admitted to the pre-operative waiting area from the clinic, the video containing information about the operating room environment will be watched by the patients through SG glasses and headphones."
45636722|NCT05899777|Other|Yizhi Baduanjin|Yizhi Baduanjin is a newly compiled routine developed on the foundation of the traditional Baduanjin, aiming at the mental and cerebral health of middle-aged and elderly population, which combining the preliminary research result and principles of the traditional routine. It could be practiced in long term to prevent MCI and AD, or simply as a general health exercise for elders.
45636723|NCT05899764|Drug|Brivaracetam|"Intravenous administration: 25 mg or 50 mg will be administered depending on its effects on epileptic activity during a hospital stay where simultaneous EEG and depth electrode recordings will be measuring epileptic activity.~Oral administration: Subjects will take 25mg or 50mg twice a day for 12 months. The dosage will depend on its effects on epileptic activity. Brivaracetam levels will be measured on months 3, 6 and 12."
45636724|NCT05899751|Drug|High-dose methotrexate|High-dose methotrexate
45636725|NCT05899751|Drug|Glucarpidase|Glucarpidase
45636726|NCT05899738|Drug|Iberdomide|Specified dose on specified days
45636727|NCT05899712|Other|Removable Partial Denture Construction|Construction of class I Removable partial denture by digital workflow
45775561|NCT01084499|Drug|Peratra (Sequence 1)|Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.
46070203|NCT04116021|Other|Local infiltration|Wound infiltration at the end of surgery with with 30 mL bupivacaine 0.5 %
46070204|NCT00847197|Drug|MK1903|Three 50 mg capsules MK1903 by mouth every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
46070205|NCT00847197|Drug|Comparator: Placebo|Three 50 mg capsules placebo to MK1903 every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
46070206|NCT00654901|Biological|DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)|0.5 mL, Intramuscular
45452490|NCT01098149|Other|BD and BVC, AFB|Some patients are randomized into the AFB, the others into the BD and BVC
45636728|NCT05899686|Device|Tetanic Stimulus|5 second 100 Hz 70 mA tetanic stimulus will be applied to three different locations in a random order
45636729|NCT05899660|Dietary Supplement|Active Comparator: Omega-3|It is a dietary supplement made of fish oil rich in n-3 PUFA.
45636730|NCT05899660|Dietary Supplement|Placebo Comparator: olive oil|Refined olive oil is the usual placebo used in studies with n-3 PUFA.
45775562|NCT01084499|Drug|Femara (Sequence 2)|Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
45775563|NCT01084499|Drug|Peratra (Sequence 2)|Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
45775564|NCT01085513|Device|PillCam SB2|The disposable, ingestible PillCam SB 2 Capsule, part no. FGS-0180, is designed to acquire video images during natural propulsion through the small bowel. The capsule transmits acquired images via RF communication channel to the DataRecorder located outside the body.
45775565|NCT01986348|Drug|Selinexor|One cycle is 28 days (4 weeks).
46070207|NCT00654901|Biological|DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)|0.5 mL, Intramuscular
46070208|NCT00654901|Biological|DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)|0.5 mL, Intramuscular
46070209|NCT00654901|Biological|Infanrix Hexa™|0.5 mL, Intramuscular
46070210|NCT00701493|Drug|Topiramate oral liquid formulation;Topiramate Sprinkle formulation|
46070211|NCT00813553|Dietary Supplement|placebo|daily
46070212|NCT00813553|Dietary Supplement|beta-alanine|daily
45452491|NCT01122784|Biological|rF1V vaccine (with Adjuvant)|80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182
45452492|NCT01122784|Biological|rF1V vaccine (without Adjuvant)|80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182
45452493|NCT01122784|Biological|rF1V vaccine (with Adjuvant)|80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121
46070213|NCT00813553|Dietary Supplement|beta-alanine|daily
46070214|NCT04253678|Drug|Vortioxetine|Flexible dosing from 5mg to 20mg based on attending psychiatrist's discretion
46070215|NCT02551939|Procedure|Autologous Fat Grafting|Autologous Fat Grafting
45636731|NCT05899647|Diagnostic Test|Ultraviolet Microscopic Analysis|"Data to be collected from subjects at the time of their clinical visit; or upon chart review by the research team; will include demographic information, whether the subject is presenting for a routine screen or for a follow-up, and the subject's most recent cervical cytology result. Data to be collected from the standard-of-care cytology will include the cytologic diagnosis and the presence or absence of human papilloma virus (HPV), if applicable based on the subject's age. The Pap results of each subject will be reviewed and classified as screen negative (NIL), screen positive (LSIL, HSIL), or indeterminate (ASCUS, ASC-H). Subjects with a positive screen, or an indeterminate result, who undergo colposcopy will have their colposcopy results recorded as well. The UV microscopy imaging features will be coded and collected."
45636732|NCT05899621|Drug|Obinutuzumab|Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.
45636733|NCT05899621|Drug|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
45636734|NCT05899621|Drug|Bendamustine|Bendamustine IV infusion will be administered as per the schedule specified in the respective arm.
45636735|NCT05899621|Drug|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
45636736|NCT05899621|Drug|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
45636737|NCT05899621|Drug|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
45636738|NCT05899621|Drug|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
45636739|NCT05899582|Procedure|Extracranial-Intracranial Bypass Surgery|Extracranial-intracranial bypass surgery plus medical treatment
45636740|NCT05899582|Other|Medical treatment alone|Best medical treatment alone according to current clinical guidelines, including antiplatelet drugs (e.g. aspirin) and risk factor controls.
45636741|NCT05899569|Device|Fistura® Procedure|"The Fistura® procedure is performed using a sterile Fistura® catheter (F Care Systems), intended to be connected to an F Care Systems radiofrequency generator (MedRF4000®) (both CE-marked).~The flexible Fistura® catheters used during the procedure allow it to follow the path of the anal fistula, facilitating the closure of the fistula along its entire length. To allow closure, the tip of the catheter will heat the fistula and cause coagulation. The thermal effect around the catheter tip has a 3 mm radius, avoiding damage to surrounding tissue or muscle. The catheter is available in different sizes depending on the diameter of the anal fistula (6F, 7F, 8F, 9F). One Fistura® catheter will be used per patient, a total of 50 Fistura® catheters in this study.~As the catheter can treat fistulas involving the sphincter complex, but without cutting or damaging it, it is expected to be effective in term of continence maintenance."
45636742|NCT05899517|Drug|oral lollipop with oxytocin (24IU)|For oral oxytocin administration, participants will be instructed to suck the lollipop medicated with 24IU oxytocin for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to rate their mood (PANAS). Participants then start the self versus other touch task around 53 minutes after oxytocin administration.
45636743|NCT05899517|Drug|oral lollipop with placebo|For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to rate their mood (PANAS). Participants then start the self versus other touch task around 53 minutes after placebo administration.
45636744|NCT05899504|Device|Over-The-Scope-Clip (OTSC) Stent Fix|A stent that of at least 4 cm longer than the stricture will be used to allow at least a 2-cm extension above and below the proximal and distal tumor margins. The stent positioned over a guidewire and deployed under fluoroscopy guidance and, in some cases, also under endoscopy guidance. Subsequently, the OTSC system will be loaded onto the scope and part of the upper rim of the stent will be suctioned into the transparent cap before releasing the OTSC, grasping both the SEMS and esophageal wall. We will avoid deploying the OTSC in areas of pulsations to prevent potential grasping of the vasculature structure
45636745|NCT05899491|Procedure|ARMA|Patients will be instructed to fast for 6 hours pre-ARMA, the Procedure will be performed under propofol-based sedation. Patients will be in the left lateral decubitus position. The stomach will be insufflated with CO2 to visualize the cardia in retroflex view.
45636746|NCT05899491|Procedure|UGI Endoscopy|"UGI Endoscopy will be performed under propofol based sedation with scope kept inside for atleast 5 minutes.~Follow up will include objective evaluation of reflux disease with: upper endoscopy, esophageal manometry, pHmetry, reflux questionnaire."
45775566|NCT01118273|Drug|Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg|Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
45775567|NCT01118273|Drug|Naproxen Sodium 440 mg (BAYH6689)|Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.
45452494|NCT01122784|Biological|rF1V vaccine (without Adjuvant)|80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121
45636747|NCT05899478|Device|Tyknot® Suture-Mediated Closure System|Arterial closure to ensure hemostasis at femoral artery puncture points
45636748|NCT05899478|Device|Perclose® ProGlide Suture-Mediated Closure System|Arterial closure to ensure hemostasis at femoral artery puncture points
45636749|NCT05899465|Drug|Tranexamic acid|A single preoperative intravenous dose and per os treatment postoperatively day 1 through 4
45636750|NCT05899465|Drug|Saline|A single preoperative intravenous dose and per os treatment postoperatively day 1 through 4
45636751|NCT05899452|Behavioral|Bubble blowing (active)|Bubble blowing as a method of active distraction during painful procedure (insertion of an IV cannula)
45636752|NCT05899452|Behavioral|Video distraction (passive)|Video on a tablet computer as a method of passive distraction during painful procedure (insertion of an IV cannula)
45636753|NCT05899426|Other|motor learning based clinical pilates|The exercises will be created as function and goal. At least one stimulus will be given during each exercise (visual, tactile, auditory or vestibular). 3 different levels were determined for 3 months of treatment, according to the months. As the level increased, the intensity of the exercise increased. In general, the exercise intensity was increased according to the against gravity and the decreasing in the support area.
45775568|NCT01118273|Drug|Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg|One dose of naproxen sodium 220 mg plus diphenhydramine 50 mg
45452495|NCT03208244|Drug|Clinically prescribed direct acting antiviral|HCV treatment for 12 weeks
45636754|NCT05899426|Other|Conventional Physiotherapy|This exercise program will include strengthening, stretching, posture exercises, balance and gait exercises. Aim is to improve muscle strength and prevent shortness of muscles. Also, balance and gait exercise aim to improve walking capacity.
45636755|NCT05899400|Diagnostic Test|Diascopic iON Image Analysis System|A scanning digital optical train that images sputum slides for automated analysis by a tuberculosis detecting algorithm
45636756|NCT05899387|Procedure|Swap collection|"Performing the surgery (Mastectomy with or without implant reconstruction; Insertion of Breast implants for control group 3) according to valid standards.~In addition, taking swabs intraoperatively according to protocol from skin and surgical site."
45636757|NCT05899387|Procedure|Seroma punction|Puncturing of a seroma in case of occurence and clinical need
45636758|NCT05899387|Procedure|Blood sampling|Blood sampling at defined time points according to protocol
45636759|NCT05899374|Behavioral|KindMap|The KindMap is a stand-alone, cost-free e-mental health tool presenting a low-intensive psychological intervention adapted from the MBPI to fit a web app format. KindMap is to be used at users' own time and pace, and includes ten modules addressing psychoeducation, mindfulness and compassion guided practices, and ACT-based experiential exercises. These components are delivered through text, videos, audio, experiential exercises, and interactive contents.
45636760|NCT05899361|Device|Electromagnetic Guided Laparoscopy|Standard Care
45636761|NCT05899361|Device|Ultrasound|Standard Care
45636762|NCT05899348|Behavioral|iTEST|iTEST is a computerized training intervention delivered on a mobile device that is coupled with individual contacts with a therapist/coach. The mobile components train in improving participant's ability to form accurate judgments about their performance and their rate of functional activities. The intervention involves coaching coupled with automated training that is delivered on a mobile device. The automated training involves daily cognitive tests in which the goal for treatment is to improve judgments of accuracy of self-assessment, and coaching is aimed at applying improving metacognitive awareness to every day activities.
45636763|NCT05899335|Device|SmartCP (mobile phone app)|As described
45636764|NCT05899322|Behavioral|Primary Care Intervention for PTSD Spanish Speaking Adolescents|This treatment ranges from 1-3 sessions which last 30-50 minutes per session. The first session will cover psychoeducation about PTSD symptoms in children that can be delivered to the adolescent with optional parent involvement. The first session will also teach the adolescent a breathing technique to combat the physiological impact of PTSD in children. The subsequent sessions will be tailored to meet the needs of the adolescent's most distressing PTSD symptom cluster including hyper arousal, negative changes in cognition and mood, avoidance, re-experiencing. Each session contains coping skills that address the adolescent's symptoms. This treatment will be delivered via telehealth and all materials have been developed in both Spanish and English.
45636765|NCT05899322|Behavioral|Waitlist Treatment as Usual|Will receive treatment as usual at local clinic and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
45636766|NCT05899309|Diagnostic Test|liver and spleen stiffness test and laboratory test|Diagnosis of cirrhosis can be based on liver biopsy,radiological ,clinical or liver stiffness measurement (LMS)
45636767|NCT05899296|Device|dental syringe ( NumBee)|assess the capability of NumBee to reduce anxiety and pain during injection
45636768|NCT05899296|Device|Traditional dental syringe|compare the level of anxiety of the traditional dental syringe and the Number dental syringe
45636769|NCT05899283|Device|OCI-HF160|OCI-HF160 are used in patients for hemofiltration, hemodialysis and hemodiafiltration, to correct solute and fluid imbalances in patients' blood.
45636770|NCT05899283|Device|FX800HDF|FX800HDF are used in patients for hemofiltration, hemodialysis and hemodiafiltration, to correct solute and fluid imbalances in patients' blood.
45636771|NCT05899270|Other|3D reconstruction automatic matching system|it is an automatic comparison software for 3D reconstruction based on CT data (3DRACS). It reconstructs the trachea and bronchus and compares them with the DLT, predicting the most suitable size and depth of the DLT for lung isolation.
45636772|NCT05899270|Other|traditional method for selecting double lumen tube|In control group, the size of DLT is based on patient's sex and weight and the height is used to guide the depth of DLT insertion.
45636773|NCT05899244|Other|muscle streching exercice|"For this exercice the participant will have to place the foot of the stretched leg on a step while maintaining his knee in extension.~From this starting position the patient will have to do a pelvic anterior tilt while keeping is back straight and his gaze horizontal until the movement induce a feeling of stretching in the posterior part of the thigh."
45775569|NCT01118273|Drug|Naproxen Sodium 220 mg (BAYH6689)|Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.
45636774|NCT05899244|Other|Slider|"In order to define the starting position for a slider, the participant will be positioned in lateral decubitus with the knee extended and will perform a hip flexion until a sensation of pain or stretching feeling appears on the posterior part of the thigh or of the knee. If the hip flexion does not induce a stretching sensation or pain, a dorsal ankle flexion is added. Once this position is defined the patient slightly reduces the amount of hip flexion until the stretching/pain sensation disappears.~From this starting position, to perform the slider: the subject performs a hip flexion movement and simultaneously a cervical extension movement, this corresponds to the outward movement. For the return movement the patient performs a hip extension and at the same time a cervical flexion. The slider technique must be pain free."
45775570|NCT01118273|Drug|DPH 50mg|Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.
45775571|NCT01118273|Drug|Ibuprofen 400 mg / Diphenhydramine citrate 76 mg|Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.
45452496|NCT05162326|Biological|BC-101|Human umbilical cord tissue derived mesenchymal stem cells (hUC-MSC) suspension at concentration of 2, 4, or 6 million cells/mL.
45636775|NCT05899244|Other|Tensioner|"The participant will be positioned in lateral decubitus with the knee extended and the hip, the cervical, thoracic and lumbar spine placed in neutral position.~For the outward movement, the participant will perform a hip flexion associated with a simultaneous movement of cervical extension until a sensation of pain or a stretching feeling appears on the posterior part of the thigh or of the knee.If this combined movements do not induce a stretching sensation or pain, a dorsal flexion of the ankle is added.~For the return movement, the participant will realize a hip extension simultaneously associated to a movement of extension of the cervical spine. If the dorsal flexion of the ankle was used during the outward movement, a movement plantar flexion of the ankle must be used in association to the movement of hip extension."
45636776|NCT05899179|Biological|Recombinant Mycobacterium Tuberculosis Fusion Protein|"Dosage form:injection. Main ingredients and contents: Recombinant Mycobacterium tuberculosis fusion protein, 0.3ml, 0.5ml, 1.0ml per bottle.~1. This product is used alone: 0.1ml (5U) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method. 2. This product combined with TB-PPD: 0.1ml(5U) of this product and 0.1ml(5U) of TB-PPD were inhaled respectively, and the product was injected intradermally into the volar side of the left forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the right forearm."
45452497|NCT01088165|Drug|Adalimumab treatment arm|Adalimumab: day 1: 2x40 mg s.c., day 8: 40 mg s.c., thereafter 40 mg s.c. in biweekly intervals
45914733|NCT02047123|Dietary Supplement|Raw Flaxseed|The participants were randomly single blind controlled trial distributed into three groups: (1, n =30), (2, n =32), (3, n =27). For 30 days, participants in group 1 took with 15g flaxseed mixed with yoghurt and diet,(the 15g of flaxseed that was provided in addition to the linen package spoon so all would take far it) group 2 took yoghurt and diet, and group 3 only received the diet.
45636777|NCT05899179|Biological|Purified Protein Derivative of Tuberculin|"Dosage form:injection. Main ingredients and contents:Pure protein derivatives of tuberculin,0.1ml per bottle.~Usage:0.1ml (5IU) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method."
45636778|NCT05899166|Other|Ketogenic diet, food delivery and education|Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.
45636779|NCT05899166|Other|Standard diet, food delivery and education|Groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.
45636780|NCT05899153|Device|Biomotum Spark: Robotic ankle resistance|Robotic ankle exoskeleton that provides resistance to ankle plantarflexion.
45914734|NCT02047136|Other|Treatment group (on low histamine diet)|78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
45636781|NCT05899153|Device|Audiovisual Biofeedback|Electromyography recordings from the plantarflexor muscles are used to provide audio feedback via a sound that plays when muscle activity is above target and a visual bar that displays real-time muscle activity.
45914735|NCT02047136|Other|Well-balanced diet|Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
45914736|NCT02047149|Drug|Zileuton (Zyflo®) Dasatinib (Sprycel®)|To determine the maximum dose of zileuton/dasatinib in subjects with CML
45636782|NCT05899127|Drug|Lidocaine|1.5mg/kg induction，1.5 mg/kg/h maintenance
45636783|NCT05899127|Drug|0.9%NaCl|2mg/kg induction，1.5 mg/kg/h maintenance
45636784|NCT05899114|Other|Transitional Multidisciplinary Pharmacotherapeutic Care|"A structured medication review with improved transitional care and multidisciplinary collaboration.~TMPC consists of the following four elements:~A structured pharmacotherapeutic analysis~A transitional multidisciplinary discussion.The treating physician in the hospital will be involved. The general practitioner and community pharmacist will be consulted.~An interview and discussion with the patient and/or legal representative by a member of the Pharmacotherapy-team, which will be performed before the patient is discharged from the hospital.~A discharge note with the pharmacotherapeutic care plan. This will be sent to the community pharmacist and the general practitioner."
45636785|NCT05899088|Other|Mindful Movement|Mindful Movement Program with Researcher Follow-up
45636786|NCT05899075|Other|xylitol wipes|group A will receive xylitol wipes and group B will receive placebo wipes
45636787|NCT05899075|Other|placebo wipes|group A will receive xylitol wipes and group B will receive placebo wipes
45636788|NCT05899062|Other|"Education with the telerehabilitation method. In addition, a Constipation Training Booklet will be sent via e-mail or WhatsApp"|"The patients in the control group will be given education about constipation, which lasts about 45-60 minutes, with the telerehabilitation method. In addition, a Constipation Training Booklet will be sent via e-mail or WhatsApp, related to the training content given to all patients and to reinforce the training. Definition of constipation in education, its causes, medications that cause constipation, risk factors, suggestions for prevention of constipation (such as regular defecation, not delaying defecation, best position for defecation, not straining for a long time), constipation treatment and the importance of individual management, healthy and balanced diet, nutrition Types, adequate fluid intake, benefits of exercise and appropriate exercise selection, abdominal massage, toilet training and individual methods of preventing constipation will be included."
45914737|NCT02047149|Drug|Dosing with Zileuton/Dasatinib in CML|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
45914738|NCT02047149|Drug|Daily dosing of Zileuton/Dasatinib|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
45914739|NCT02047149|Drug|Daily dosing with Zileuton/Dasatinib for CML|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
45914740|NCT02047162|Drug|Bismuth subsalicylate|
45914741|NCT02047162|Other|Placebo|Chewable tablets identical to intervention tablets, but missing the bismuth subsalicylate
45914742|NCT02047175|Drug|Telmisartan/S-Amlodipine|Telmisartan/S-Amlodipine 40/2.5mg 2T PO, QD for 9days
45636789|NCT05899062|Other|Training and exercise practices with the telerehabilitation method.|The patients in this group will be given an exercise program in addition to all the practices in the control group. Training and exercise practices will be carried out with the telerehabilitation method. Exercise training, which will last 40-60 minutes, 3 days a week for 6 weeks, will consist of warm-up and breathing exercises, exercises for constipation and cooling movements. Patients will be asked to walk for at least 30 minutes, 2 days a week, on days without exercise training.
45775572|NCT05420142|Dietary Supplement|Net peripheral AA appearance following ingestion of 3 selected PPF products compared to whey|The intervention will assess the effects of three difference varieties of plant-based protein and fibre supplements on net peripheral amino acid appearance in blood compared to whey protein with matched fibre content as a control arm.
45775573|NCT02931240|Device|Revivent TC|Treatment of LV scar
45636790|NCT05899049|Biological|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
45636791|NCT05899049|Drug|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
45775574|NCT04423848|Other|Home Hospital for Lymphoma|Remote monitoring and home-based care designed for hospitalized patients with lymphoma
45775575|NCT01085825|Procedure|D & C abortion|Participants will be randomized to receive their abortion using either manual vacuum aspiration or electric vacuum aspiration.
45914743|NCT02047175|Drug|Rosuvastatin|Rosuvastatin 20mg 1T PO, QD for 5days
45636792|NCT05899049|Biological|Pembrolizumab/Quavonlimab|Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion
45636793|NCT05899049|Drug|Lenvatinib|Lenvatinib 20 mg administered QD via oral capsule
45636794|NCT05899023|Other|Telehealth Bridge Visits|Patients will be scheduled for a telemedicine visit staffed by a family or internal medicine trained physician who will assess their understanding and answer any questions about the new diagnosis of diabetes, start initial conversations about how to improve their habits around diet and exercise, and discuss medication options for diabetes and, if appropriate, initiate treatment. At the end of the telemedicine visit, providers will attempt to address any difficulties that patients are experiencing in accessing primary care by providing an alternative contact for care or reaching out to a primary care doctor as necessary. If the patient experiences difficulties accessing a primary care provider based on their first telemedicine visit, then an additional telemedicine visit can be scheduled for the patient.
45636795|NCT05899023|Other|Standard of Care|Standard of care currently includes calls from the site's follow-up center to see if patients received their HbA1c result, understood what their result meant, had any problems accessing medications prescribed or any difficulty scheduling an outpatient follow-up visit.
45775576|NCT05419908|Drug|Fezolinetant|Oral Capsule
45775577|NCT05419908|Drug|Placebo|Oral Capsule
45914744|NCT02047175|Drug|Telmisartan/S-Amlodipine + Rosuvastatin|Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 5days
45914745|NCT02047175|Drug|Telmisartan/S-Amlodipine + Rosuvastatin|Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 9days
45914746|NCT02047201|Radiation|IMRT|IMRT treatment planning using FDG-PET/CT images after induction chemotherapy (IC).
45914747|NCT02047201|Radiation|PET/CT|Assessing tumor response using FDG-PET/CT.
45914748|NCT02047201|Drug|Docetaxel|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
45914749|NCT02047201|Drug|Fluorouracil|750 mg/m2 continuous infusion for 120 h IV (in the vein) every 3 weeks. Number of cycles: 3.
45914750|NCT02047201|Drug|Cisplatin|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
45914751|NCT02047266|Procedure|MICS CABG|Minimally invasive coronary artery bypass grafting - beating heart multi-vessel procedure in which the anastomoses are performed under direct vision through a lateral left mini-thoracotomy. The left internal thoracic artery is used to graft the left anterior descending artery or circumflex artery territories. Radial artery or saphenous vein are used (Y - grafts) to graft another myocardial territories. Right internal thoracic artery can be used as free Y-graft, as in-situ graft with radial artery (extension technique) or as in-situ graft without composite technique. Right gastroepiploic artery can be used to graft right coronary artery territory. Hybrid approach (MICS CABG + PCI), parallel transfemoral extracorporeal circulation without cardioplegia and CABG from the ascending aorta are acceptable for achievement of the complete revascularization.
45914752|NCT02047266|Procedure|OPCABG|Off-pump coronary artery bypass grafting via sternotomy (aortocoronary bypass grafting or aortic no-touch technique composite grafting). Mechanical Devices are used for coronary artery stabilization and heart positioning. Pericardial traction sutures are used to position the heart where appropriate. Blowers and Intracoronary shunts are used routinely. Anticoagulation is obtained using sodium heparin at a dose of 2mg/kg with supplemental doses to maintain adequate heparinisation (Activated clotting time>250seconds).
45775578|NCT04265742|Radiation|bone densitometry|Bone Mineral Density (BMD), body composition, vertebral fractures
45775579|NCT04265742|Radiation|High resolution peripheral QCT|High resolution peripheral QCT (HR-pQCT): bone microarchitecture and bone strength
45775580|NCT04265742|Diagnostic Test|Collection of biological samples|Peripheral blood and urine samples to assess bone turnover markers and cytokines; and faeces to assess gut microbiota composition
45775581|NCT04265742|Other|questionnaires|Epidemiologic and nutritional questionnaire and physical activity scale
45775582|NCT04265742|Other|clinical tests|physical performance tests and grip strenght measurement
45775583|NCT01085903|Drug|Modafinil|200 mg once daily with morning meal for three days administered only to stroke patients
45775584|NCT01085903|Drug|Placebo|Subjects will receive a placebo designed to look like 200 mg dose of modafinil. The dose will be taken once daily with the morning meal for three days and will only be administered to stroke patients
45775585|NCT01085903|Behavioral|Baseline|Observations made at baseline before any intervention
45775586|NCT01085903|Behavioral|CPS|Submerging each participant's foot into ice water (36-44 F) for 50 seconds.
45775587|NCT01085903|Behavioral|Post CPS|20 minutes following the CPS condition.
45775588|NCT01085903|Behavioral|Follow up|Follow up testing occurred at 3 months
45636796|NCT05899010|Drug|Vaginal progesterone 600mg daily|If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH <7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone <10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
45636797|NCT05899010|Drug|Vaginal progesterone 800mg daily|If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH <7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone <10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
45448307|NCT05578066|Other|Innovative Contact-Based Education|Educational workshops will include anti-stigma and recovery principles, along with specific MISUI topics relevant to PHC providers. This will be determined by findings from the exploratory phase, current research, best practices, and the perspectives of local leaders. It may include (1) supporting CESFAM PHC providers in preventing stigma and promoting recovery in their practice and (2) enhancing the competencies of CESFAM PHC providers for discussing MISUI with their users, identifying MISUI signs and symptoms, and referring users to psychosocial centres for treatment. The key feature of these workshops is the contact-based educational element, where people with lived experience participate in developing and delivering the curriculum to CESFAM PHC providers. Four three-hour workshops will be held at each intervention CESFAM and will be facilitated by two academic/clinical trainers with expertise in stigma research and practice, and one person with lived experience.
45636798|NCT05898997|Behavioral|Acupressure|Massage the following acupoints in order: Jing Ming, Zan Zhu, Mei Chong, Yu Yao, and Si Zhu Kong. Use the joint of your thumb to massage each acupoint for 30 times, and repeat the cycle at least once. Then, continue to promote the circulation of qi by gently making a fist and using the four fingers to scrape along the upper eye socket from inside to outside. Scrape each side 30 times, and do it separately for the left and right sides. It is recommended to do this process at least once in the morning and once in the evening.
45636799|NCT05898984|Drug|Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI|"CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI with HFA 134a propellant (fixed combination of BDP [200 μg], FF [6 μg] and GB [12.5 μg] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a total daily dose (TDD) of BDP/FF/GB: 800/24/50 µg.~Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI with HFA 134a propellant (fixed combination of BDP [100 μg], FF [6 μg] and GB [12.5 μg] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a TDD of BDP/FF/GB: 400/24/50 µg.~Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg): pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve)."
45636800|NCT05898984|Drug|Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI|with HFA 134a propellant (fixed combination of BDP [100 μg], FF [6 μg] and GB [12.5 μg] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a TDD of BDP/FF/GB: 400/24/50 µg
45636801|NCT05898984|Drug|Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg)|pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve).
45636802|NCT05898971|Other|Robotic|Patients receive robotic training (grasp and grip)
45636803|NCT05898971|Other|Traditional Physical Therapy|Traditional exercise and Neurophysiological approaches
45775589|NCT05419128|Behavioral|PartnerCHESS|"The following ABCT services, from PartnerCHESS, will be available in the FamCHESS-C app but not in ACHESS-C:~ABCT tutorials. Interactive e-learning modules explaining key ABCT skills. Agreements between drinker and partner to follow key principles. Trigger identification and removal. Cravings discussion. Relapse plan. Reminders."
45448308|NCT05578066|Other|Recovery-Based Arts|Local leaders at CESFAM will select one PHC provider member and recruit one artist to develop an arts curriculum and facilitate the art sessions. The facilitators will select an art form to use throughout the sessions, and in collaboration with local leaders they will determine themes related to MISUI to cover in each session (planning process will be completed in intervention months 7-8). Arts workshops will be held for 10 weeks, with each session lasting up to three hours (during intervention months 9-12). Ten users affected by MISUI and at least three CESFAM PHC providers will participate in the workshops each week. At the end of the 10-week program, each CESFAM will host an exhibition to showcase the artwork that has been produced (during intervention months 13-18). All PHC providers and users, as well as community members, will be invited to attend the exhibition. PHC providers and users will be invited to speak about their experiences learning and working together to create art.
45448309|NCT05201638|Drug|IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
45448310|NCT05201638|Drug|Placebo matching IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
45448311|NCT00129545|Device|WATCHMAN Left Atrial Appendage Closure Technology|Implant of WATCHMAN Left Atrial Appendage Closure Technology
45636804|NCT05898958|Procedure|thoracic paravertebral block|The block will be performed in the lateral position.After skin sterilization,the ultrasound transducerprobe (6-13-MHz high-frequency linear transducer) is positioned in the vertical plane ∼2.5 cm lateral tomarked spinous process with its orientation directedcranially. T.After local anesthetic infiltration, an 18-gauge Tuohy needle will be inserted into the paravertebral spacein an 'in plane' technique. After a negativeaspiration through the needle, 20 ml of 0.25%bupivacaine with 1: 200 000 epinephrine will be injected slowly over 3 min.A20-G epidural catheter will be threaded through Tuohyneedle and advanced 2-3 cm into the paravertebral space.Anyprocedure-related adverse effects will be noted, and thedermatomal loss of pin prick sensation will be testedover both sides.
45636805|NCT05898958|Procedure|rhomboid intercostal and subserratus block|The ultrasound probe will be placed in the obliquesagittal plane orientation, 1-2 cm medial to the medial scapula at theT5-T6 level. The trapezius muscle, rhomboid major muscle, ribs, intercostal muscle and pleura will be visualized respectively using ultrasound.After local anesthetic infiltration, needle will be inserted from the cranial to the caudal direction using the in-plane technique. The needle will be advanced between the rhomboid major and intercostal muscle fascia. The location of the needle will be confirmed with 2 mL saline solution, 10 ml of 0.25% bupivacaine with 1 : 200 000 epinephrine will beinjected slowly over 3min.for the subserratus block 10 ml of 0.25%bupivacaine with 1 : 200 000 epinephrine will be injected betweenthe serratus and intercostal muscle fascia at level of t9.
45636806|NCT05898932|Other|Medical Management|Participants will be managing condition with medication
45636807|NCT05898932|Other|Surgical Management|Participants will be managing condition with a surgery
45636808|NCT05898893|Device|Microport NeuroTech Tubridge Plus flow-diverter Stent|Intracranial stent for wide-necked aneurysms
45636809|NCT05898880|Other|Self-acupressure|In the self-acupressure group, before the application, the tissue sensitivity will be reduced by heating and rubbing for 20 seconds without direct pressure on the acupressure points, and the points will be made ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point. Afterwards, acupressure will be applied to themselves by participants
45636810|NCT05898880|Other|Acupressure by therapists|In the acupressure group applied by therapist, before the application, the tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point.
45636811|NCT05898880|Other|Control group|No intervention will be made in the control group.
45636812|NCT05898867|Other|Saline|Open label intra-articular injection of isotonic saline.
45636813|NCT05898815|Diagnostic Test|Medical record collection|Medical record collection
45636814|NCT05898802|Dietary Supplement|Kimchi|Two different kimchi, one traditional kimchi and one fermented with a lactic acid bacteria having anti-obesity effect, hereafter starter kimchi, are flash freeze dried, powdered and encapsulated.
45636815|NCT05898802|Dietary Supplement|Placebo|Lactose with kimchi flavor
45636816|NCT05898789|Behavioral|CaRE@Home intervention|participants randomized to the intervention arm will complete a virtual 8 week exercise and education program.
45636817|NCT05898776|Device|Lung transplantation after 10°C donor lung preservation|When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to 10°C preservation will be stored, transported and preserved in the X°Port Lung Transport Device (Traferox Technologies Inc.) until implant with a maximum time of 12 hours between the donor and recipient surgeries.
45636818|NCT05898776|Device|Lung transplantation after standard ice cooler donor lung preservation|When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to standard preservation will be will be stored, transported and preserved in an ice cooler (~4°C, standard of care) until implant with a maximum time of 6 hours between the donor and recipient surgeries.
45636819|NCT05898763|Drug|TEIPP24 (LRPAP7-30V-SLP vaccine in Montanide ISA-51)|Patients will receive three rounds of vaccination three weeks apart via one subcutaneous (SC) injection in an alternating limb. Patients in the extension cohort will receive the highest safest dose in combination with pembrolizumab (a CPI).These patients will receive three rounds of combination treatment with TEIPP24 vaccination and pembrolizumab every three weeks. Pembrolizumab will be administered as per standard of care.
45636820|NCT05898750|Dietary Supplement|MorDom|oral powder in tea bags contains 4gm twice daily (equal concentration of each drugs)
45636821|NCT05898724|Procedure|Blank group|include six orthodontic patients, which have a surgical procedure to install two orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed orthodontic titanium miniscrews.
45636822|NCT05898724|Procedure|Silver hydroxyapatite|include six orthodontic patients, which have a surgical procedure to install two silver hydroxyapatite nano-coated orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed silver hydroxyapatite nano-coated orthodontic titanium miniscrews.
45636823|NCT05898724|Procedure|Zinc oxide|include six orthodontic patients, which have a surgical procedure to install two zinc oxide nano-coated orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed zinc oxide nano-coated orthodontic titanium miniscrews.
45636824|NCT05898685|Behavioral|Intermittent hypoxia|The intermittent hypoxia protocol will consist of eight 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with normoxic cycles to resaturation.
45636825|NCT05898685|Behavioral|Intermittent normoxia|The intermittent normoxia protocol will consist of eight 4-minute normoxic cycles (compressed air) interspersed with 1-minute normoxic cycles (room air)
45636826|NCT05898672|Drug|Rosuvastatin|Single oral dose of rosuvastatin tablets
45636827|NCT05898672|Drug|Nirmatrelvir/ritonavir|Twice daily oral doses of nirmatrelvir/ritonavir tablets
45775590|NCT05419128|Behavioral|ACHESS|ACHESS-C offers the following, which are also available in FamCHESS-C: Covid content, Instant Library, Discussion Groups, Personal Stories, Location Monitor, Surveys and Ecological Momentary Assessments, Guided Relaxation, Healthy Activities, Crisis Button, Skills Reminders
45775591|NCT01439035|Device|MGH OFDI Imaging|Imaging of Duodenum with OFDI system
45775592|NCT05446350|Procedure|transcranial alternating current stimulation (tACS)|transcranial alternating current stimulation (tACS) used to manipulate how neural activity aligns to speech rhythm, leading to changes in speech perception
45636828|NCT05898659|Device|ABFnoS then ABFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting without synchronization with the contralateral hearing-aid then with synchronization with the contralateral hearing-aid
45636829|NCT05898659|Device|ABFS then ABFnoS (Cochlear implant)|Cochlear implant with tonotopy-based fitting with synchronization with the contralateral hearing-aid then without synchronization with the contralateral hearing-aid
45775593|NCT05446350|Procedure|electroencephalography (EEG)|analyse rhythmic electroencephalography responses that outlast the stimulation
45914753|NCT02047266|Procedure|ONCABG|On-pump coronary artery bypass grafting via sternotomy (aortocoronary bypass grafting or aortic no-touch technique composite grafting). Normothermic cardiopulmonary bypass and complex blood ante-retrograde cardioplegia are used. All patients are cannulated with an proximal aortic cannula and two-stage right atrial cannula. Extracorporeal circulation is provided by the Terumo System-1 heart-lung machine using cardiopulmonary bypass systems with physiological surfaces and opened venous reservoirs. The left internal thoracic artery is used to graft the left anterior descending artery, and radial artery or saphenous vein segments are used to graft another myocardial territories. Anticoagulation is obtained using sodium heparin at a dose of 3mg/kg (ACT, activated clotting time>450seconds).
45775594|NCT05446350|Procedure|brain imaging (fMRI)|Using brain imaging (fMRI) to predict optimal stimulation protocols for individual participants
45775595|NCT05446350|Procedure|electroencephalography (EEG) with neurofeedback|Using neurofeedback to teach participants to enhance their own neural entrainment
45775596|NCT01118741|Drug|Disulfiram|Cohort 1: 250mg PO daily for 28 days Cohort 2: 500mg PO daily for 28 days
45775597|NCT01439581|Device|Mapping System|Pressure Sensing coverlet on ICU bed and provides real time feedback to assist in effective patient repositioning
45775598|NCT01439581|Device|Non-Mapping System|Standard ICU bed with no mapping system
45636835|NCT05898633|Drug|Recombinant fragment of human surfactant protein D (rfhSP-D)|Administration of rfhSP-D
45636836|NCT05898568|Device|virtual reality|In addition to the routine hand rehabilitation programs for 4 weeks, 5 days, 40 minutes a day, 20 sessions (4 weeks, 5 days a week, 20 minutes) virtual reality based movement therapy program will be applied.
45636837|NCT05898568|Behavioral|routine treatment|20 sessions (4 weeks, 5 days a week, 60 minutes) routine hand rehabilitation program will be applied.
45775599|NCT01439815|Drug|Fluticasone Propionate Nasal Spray|two sprays in each nostril once daily
45775600|NCT01439815|Drug|Saline Nasal Spray|two sprays in each nostril once daily
45775601|NCT01332253|Drug|Intravenous ibuprofen|Participants will receive a single 10mg/kg dose of intravenous ibuprofen diluted in normal saline at the induction of anesthesia.
45775602|NCT01332253|Other|Normal Saline|Participants will receive a comparable weight based volume of normal saline as a placebo comparator at the induction of anesthesia.
45775603|NCT01332487|Drug|5ARI + AB|5ARI: Dutasteride or Finasteride and any AB: Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
45775604|NCT01332721|Drug|TRC105 and Bevacizumab|Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
45448312|NCT00129545|Drug|Warfarin|Subjects receive warfarin
45636838|NCT05898555|Device|Skiin garment and pods|"Participants will be asked to wear a Skiin smart garment over their own clothes.~Small motion capture markers will be placed on their body and pressure-sensitive insoles placed into their shoes to measure the pressure underneath their feet during the study tasks.~Once the sensors are ready for collection, participants will be asked to complete 5 tasks associated with their daily activities: 1. Locomotion; 2. Lower limb strength - repeated sit-to-stand-to-sit transitions; 3. Lower limb strength and locomotion - Timed Up and Go; 4. Free walking during a 2min walk; 5. Standing balance, postural control."
45636839|NCT05898542|Procedure|Nature-based therapy|Therapy sessions conducted outdoors
45636840|NCT05898529|Diagnostic Test|Rapid antigen test|COVID-19 rapid antigen testing of nasal swab
45636841|NCT05898503|Behavioral|Walking exercise + resistance training|Walking exercise and resistance training for 12 weeks
45636842|NCT05898503|Behavioral|Resistance training|Resistance training for 12 weeks
45636843|NCT05898503|Behavioral|Walking exercise|Walking exercise for 12 weeks
45636844|NCT05898503|Behavioral|Health promotion|Health promotion for 12 weeks
45636845|NCT05898490|Behavioral|Animation Therapy|The process of shooting a stop-motion animation film, is designed according to the interests and leading of the participant.
45636846|NCT05898464|Biological|Recombinant zoster vaccination|Two doses of recombinant zoster vaccine(Shingrix®), 2 months apart
45775605|NCT01384591|Drug|N-acetylcysteine|50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
45775606|NCT01384591|Drug|Losartan|25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
45775607|NCT01384591|Drug|Placebo losartan|Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
45775608|NCT01384591|Drug|Placebo N-acetylcysteine|Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.
45775609|NCT01086605|Drug|pixantrone dimaleate|Given IV
45775610|NCT00265850|Biological|bevacizumab|Given IV
45775611|NCT00265850|Biological|cetuximab|Given IV
45914754|NCT02047266|Device|Octopus® Nuvo, Starfish® Non-Sternotomy, thoracic retractor (ThoraTrak®)|Octopus® Nuvo - MICS CABG tissue stabilizer available for minimally invasive procedures. It minimizes the motion of a small area of the heart while the rest of the heart continues to beat normally and allows to perform anastomosis through a small incision. Starfish® Non-Sternotomy (NS) - MICS CABG heart positioner available for minimally invasive procedures. It allows for the positioning of the beating heart through a small incision, bringing coronary targets into the operative thoracotomy window. ThoraTrak® - a reusable, stainless steel MICS thoracic retractor system for minimally invasive heart surgery with multiple interchangeable blades, which allows to harvest left internal thoracic artery and to perform anastomosis through a small left thoracotomy(Medtronic, Inc., Minneapolis, MN).
45636847|NCT05898451|Drug|Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T)|has a direct antitumor effect in vitro and in vivo on various tumor cell lines
45636848|NCT05898451|Drug|Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T) and chemotherapy|Refnot has a direct antitumor effect in vitro and in vivo on various tumor cell lines, chemotherapy has a cytostatic and cytotoxic effect.
45636849|NCT05898399|Drug|ART6043|Patients will orally receive ART6043.
45636850|NCT05898399|Drug|Olaparib|Patients will orally receive ART6043 in combination with Olaparib.
45636851|NCT05898399|Drug|Talazoparib|Patients will orally receive ART6043 combination with Talazoparib.
45636852|NCT05898399|Drug|Olaparib|Patients will orally receive Olaparib.
45636853|NCT05898399|Drug|Talazoparib|Patients will orally receive Talazoparib.
45636854|NCT05898373|Drug|vedicitumomab (Edisil, RC48）|intravenously for 6-8 cycles before surgery and postoperative radiotherapy, followed by Treatment with injectable recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent vedicitumomab (Edisil, RC48) until 1 year or disease progression or intolerable toxicity in locally advanced patients , and until disease progression or intolerable toxicity in metastatic patients .
45636855|NCT05898373|Drug|vedicitumomab in combination with pyrrolizidine|vedicitumomab in combination with pyrrolizidine
45636856|NCT05898373|Drug|RC48 in combination with a platinum-based chemotherapeutic agent|RC48 in combination with a platinum-based chemotherapeutic agent
45636857|NCT05898373|Drug|RC48 in combination with teraplizumab|RC48 in combination with teraplizumab
45636858|NCT05898360|Combination Product|Time Restricted Eating|time restricted eating
45636859|NCT05898360|Other|normal diet|normal diet
45636860|NCT05898347|Other|Active surveillance|"Skin lesions clinically compatible with nevoid basal cell carcinomas are documented with measurements, clinical description, clinical photos and dermatoscopy photos every eight months for two years. Three representative skin lesions are selected at the first visit to be removed by skin biopsy at the end of the observation period (two years) for histopathological analyses.~If a nevoid basal cell carcinoma shows a certain increases in size (according to pre-specified criteria of the study protocol), ulcerates, gets unevenly demarcated or give functional complaints during the observation period, the skin lesion will be excised."
45636861|NCT05898334|Device|Active Biophoton Generators|The whole body, including brain, of the study participant will be sleeping inside of the strong biophoton field so her/his entire body will be energized to promote self-healing.
45636862|NCT05898334|Device|Inactive Biophoton Generators|The whole body, including brain, of the study participant will be sleeping inside of the normal hotel bed and the participant will not receive any biophotons.
45636863|NCT05898321|Drug|Zoladex|Patients with fibroid remained will be enrolled and divided into three groups. one group wii be administrated with Zoladex (3.60mg/28 days) for three to six months.
45636864|NCT05898321|Drug|Mifepristone Oral Tablet|Patients with fibroid remained will be enrolled and divided into three groups. one group will be administrated with mifepristone(10.0mg/d) for three to six months.
45636865|NCT05898308|Drug|RiTUXimab Injection|"Patients assigned to the personalized maintenance treatment will be treated by additional RITUXIMAB injection depending on anti-Dsg Abs levels."
45636866|NCT05898295|Other|no intervention|No intervention: only observation of the child behavior
45636867|NCT05898282|Other|observation|since this is a cross sectional observational study any form of intervention was not applicable
45636868|NCT05898269|Diagnostic Test|Trendelenburg maneuver|Bed tilting from the +13° position to the -13° position for 60 seconds. Evaluator: relative change in continuous cardiac index between baseline, and the highest value observed during the maneuver
45775612|NCT00265850|Drug|FOLFOX or|Patients receive oxaliplatin 85 mg/m^2 IV infused over two hours followed by leucovorin 400 mg/m^2 IV over 2 hours followed by 5-FU 400 mg/m^2 IV bolus, then 2400 mg/m^2 continuous IV infusion over 46-48 hours
45775613|NCT00265850|Drug|FOLFIRI|Patients receive irinotecan 180 mg/m^2 IV infused over 90 minutes followed by leucovorin 400 mg/m^2 IV over 2 hours followed by 5-FU 400 mg/m^2 IV bolus following leucovorin then 2400 mg/m^2 continuous IV infusion over 46-48 hours.
45775614|NCT01385137|Dietary Supplement|omega-3 fatty acid|Given orally
45775615|NCT01385137|Other|placebo|Given orally
45775616|NCT01086761|Biological|MP0112|Single intravitreal injection of MP0112 in the study eye.
45775617|NCT00125372|Drug|erlotinib (Tarceva) and bexarotene (Targretin)|Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy
45775618|NCT01087541|Behavioral|Educational program 6-hour standardized|6-hour standardized program for adults ( doctors and nurses )
45775619|NCT01385293|Drug|BKM120|BKM120 at the maximum tolerated dose (MTD) of 100mg orally daily
45775620|NCT00125528|Drug|D-cycloserine|D-cycloserine 50 mg bid; D-cycloserine 100 mg bid; D-cycloserine 200 mg bid
45775621|NCT00125528|Drug|placebo|placebo bid
45775622|NCT00125762|Device|FibroScan|
45636869|NCT05898269|Diagnostic Test|End-expiratory occlusion test (EE OCC)|"End-expiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause"
45636870|NCT05898269|Diagnostic Test|End-expiratory and end-inspiratory occlusion test (EI OCC)|"End-inspiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause. The evaluator is calculated as the sum of the relative change in cardiac index observed during the end-expiratory pause and that of the end-inspiratory pause. Hence, for this test, the evaluator will be coupled with that of intervention 2 (end-expiratory occlusion test)."
45636871|NCT05898269|Diagnostic Test|Tidal volume challenge|"Increase in tidal volume set on the ventilator from 6 ml.kg-1 of predicted body weight, to 8 ml.kg-1 for 60 seconds.~Evaluator: difference in the pulse pressure variation measured at 6 ml.kg-1 and at 8 ml.kg-1."
45775623|NCT01333813|Biological|Engerix-B™ Kinder|Intramuscular, single dose
45775624|NCT04346485|Procedure|SP TFL RIRS with 145 mcm fiber|retrograde intrarenal surgery
45775625|NCT04346485|Procedure|SP TFL RIRS with 200 mcm fiber|retrograde intrarenal surgery
45775626|NCT04346485|Procedure|Ho:YAG RIRS with 200 mcm fiber|retrograde intrarenal surgery
45775627|NCT01390909|Drug|Anti-epileptic drug (AED)|Prescription claim for at least one AED including lamotrigine, tiagabine, pregabalin, ethosuximide, lacosamide, phenytoin, carbamazepine, valproic acid, felbamate, levetiracetam, zonisamide, primidone, oxcarbazepine, vigabatrin, phenobarbital, gabapentin, topiramate.
45636872|NCT05898269|Diagnostic Test|Fluid bolus (reference diagnostic method)|"After the 4 tests, the patient will receive a 500-ml fluid bolus of crystalloids in less than 15 minutes.~Evaluator (reference method): cardiac index measured by transpulmonary thermodilution before and immediately after the fluid bolus. Patients with a relative change in cardiac index > 15% will be identified as being fluid responders, and the others as non-responders."
45636873|NCT05898256|Drug|Cadonilimab|10mg/kg administered intravenously (IV)
45636874|NCT05898256|Drug|Gemcitabine|1 g/m2, administered as an IV infusion within 30 minutes
45636875|NCT05898256|Drug|Cisplatin|80 mg/m2, administered as an IV infusion over 4 hours
45636876|NCT05898230|Device|Mitral Valve Replacement|Mitral Valve Replacement with Carbomedics OptiForm Mitral Heart Valve
45636877|NCT05898217|Other|Dairy Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
45636878|NCT05898217|Other|Soy Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
45636879|NCT05898217|Other|Almond Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
45775628|NCT01041521|Drug|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 24 months
45775629|NCT01042145|Drug|Prednisone|2 mgs/kg for 3 days
45775630|NCT01042145|Drug|Dexamethasone|0.6 mgs for one day, then placebo for 2 days
45775631|NCT01334827|Other|high volume gel|4 mL HEC
45775632|NCT01334827|Other|low volume gel|2 mL HEC
45775633|NCT01334827|Other|vaginal film|"1 x 2 intravaginal quick-dissolving film"
45775634|NCT01042613|Procedure|Cannulation using Accuvein device|If the research participant has been randomized to the AV300 device group A, then intravenous cannulation will be attempted using the AV300 device following manufacturer's instructions by four anesthesiologists.
46070216|NCT00813631|Other|silver-releasing dressings|Experimental group are accepted primary dressing the AQUACEL Ag. control group are provided with the AQUACEL on the wound surface. Wound specialist or primary nurses undertaking wound care are informed by inclusion criteria that the treatment shall be adhered to during the two-week study period.All wounds are cleansed with sterile saline prior to assessment and dressing application.The sterile, non-woven sodium carboxymethylcellulose primary AQUACEL Ag with 1.2% ionic silver.Each secondary dressing is covered a sterile gauze.Dressings are changed between daily assessments when judged necessary.Patients attended the wound ward weekly for treatment evaluation. All participating clinics used the same wound management guidelines and data collection forms.
46070217|NCT02551861|Drug|Daclatasvir|
46070218|NCT02551861|Drug|Sofosbuvir|
45636880|NCT05898217|Other|Oat Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
45636881|NCT05898204|Other|Ketogenic diet|Prescription of a ketogenic diet, 1200 Kcal/die. Patients are encouraged to walk 30 minutes every day.
45636882|NCT05898204|Other|Balanced diet|Prescription of a balanced diet, 1200 Kcal/die. Patients are encouraged to walk 30 minutes every day.
45636883|NCT05898191|Other|vaginal laser treatment|non-ablative vaginal laser application
45636884|NCT05898178|Other|Experimental intervention: 8-5-2% oxygen gradient concentration in the incubator|After oocyte retrieval and insemination, half of a given patient's embryos will be randomly allocated in an incubator set at a gradient of oxygen tension (8-5-2%). The embryos will remain in the incubator until their developmental assessments on day 5.
45775635|NCT01042613|Procedure|Standard Cannulation method|If the research participant has been randomized to the standard treatment group B then cannulation will be attempted in the standard manner. A research team member will time cannulation access for all participants. Participation ends once successful cannulation is achieved or when a maximum of 4 skin punctures have been made.
45775636|NCT01043393|Drug|Desoximetasone 0.25% spray|Desoximetasone spray applied to affected areas twice daily for 28 days
45775637|NCT01335061|Biological|Nonacog alfa|Period 1: During on-demand period, dosing at the discretion of investigator.
45775638|NCT01335061|Biological|Nonacog alfa|Period 2: During the prophylaxis period, 100 IU/kg once weekly
45775639|NCT01087931|Drug|Bupivacaine|Single application of 10ml of bupivacaine 0.5% into the iliac crest bone harvest surgical site.
45775640|NCT01087931|Other|Normal Saline|Normal saline 0.9%, 10ml, single application directly into iliac crest bone harvest surgical site.
45775641|NCT01336933|Drug|prednisone|Given PO
45775642|NCT01336933|Drug|cyclophosphamide|Given IV
45775643|NCT01336933|Drug|etoposide|Given PO or IV
45775644|NCT01336933|Drug|Vincristine|Given IV
45775645|NCT01336933|Drug|pralatrexate|Given IV
45636885|NCT05898165|Other|Development of an algorithm|Prospective verification of a developed algorithm to predict the risk of a new onset Atrial Fibrillation
45775646|NCT01336933|Other|laboratory biomarker analysis|Correlative studies
45636886|NCT05898152|Other|Data collection|A collection about patient's data demographic, neurologic and gynecologic follow-up and satisfaction will be review by questionnaire. And a calendar of epileptic seizures will be completed by patients on 4 months
45636887|NCT05898113|Other|EXTRA VIRGIN OLIVE OIL|Participants will consume a daily amount of extra virgin olive oil. Can consume the oil either raw or cooked
45636888|NCT05898113|Other|OLIVE OIL LOW POLYPHENOL|Participants will consume a daily amount of olive oil low polyphenol. Can consume the oil either raw or cooked
45775647|NCT01336933|Genetic|comparative genomic hybridization|Correlative studies
45636889|NCT05898087|Drug|Marcaine 0.25 % Injectable Solution|Patients in this arm will receive an injection of 20cc of injectable 0.25% bupivacaine solution. It will be injected in a fan-like pattern beneath the pectoralis fascia
45636890|NCT05898087|Drug|Saline|Patients in this arm will receive an injection of 20cc of injectable saline. It will be injected in a fan-like pattern beneath the pectoralis fascia
45935572|NCT02970695|Device|Laser auriculotherapy (LAT)|A laser device (Pointer Pulse™)15 will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm,2 and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. 16, 17 This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the selected acupoints. Laser protective goggles will be provided to the subjects and the researcher for eyes protection
45636891|NCT05898074|Device|Non-Absorbable Packing (Silastic Splint)|Participant will have silastic splint applied to nasoseptal flap harvest site
45636892|NCT05898074|Device|PuraGel (RADA16) Hydrogel|Participant will have PuraGel (RADA16) Hydrogel applied to the nasoseptal flap harvest site
45775648|NCT01336933|Genetic|gene expression analysis|Correlative studies
46070219|NCT02551861|Drug|Ribavirin|
45636893|NCT05898035|Procedure|Endodontic Microsurgery|Osteotomy will be done either with air motor high speed hand-piece and round bur with copious irrigation or with Piezosurgery touch. After the soft tissue curettage and uncovering the root apex , the last 3 mm of the root apex will be resected perpendicular to the long axis of the tooth at ( 0 - 10) degree bevel , using either conventional dental hand-piece or piezotome (Piezotome Cube by ACTEON ).The resected root will be rinsed , dried and and stained with 1% methylene blue dye after which , it will be inspected carefully under high magnification, to identify possible reasons for the non surgical root canal treatment failure. Subsequently, ultrasonic apical preparation will be performed. After achieving adequate haemostasis with Epinephrine pellets. Biodentine®retrograde filling material will be placed. The flap will be re-approximated and interrupted suture using non-absorbable monofilament size 5-0 suture will be applied. Finally, Post-operative parallel Digital view.
45636894|NCT05898022|Drug|Furosemide (plus potassium chloride)|Furosemide is a loop diuretic that inhibits the reabsorption of sodium and chloride in the proximal and distal tubules as well as the loop of Henle. Participants will receive 2 mg/kg enteral furosemide daily during treatment periods when they receive study drug. To prevent hypokalemia and hypochloremia associated with furosemide use, participants will also receive 1 mg/kg of potassium chloride enterally twice per day when receiving furosemide. Each patient will have 14 days of total exposure to furosemide over the 28-day N-of-1 trial.
45636895|NCT05898022|Drug|Placebo (plus placebo electrolyte solution)|During treatment periods when participants receive placebo, they will receive a volume of sterile water equivalent to the study drug dose. Participants will also receive a placebo electrolyte solution equivalent to the volume of potassium chloride that would be given.
45636896|NCT05898009|Genetic|blood sample for BRCA2 mutation detection|blood sample
45636897|NCT05897996|Device|creation of vascular access for hemodialysis|endo-AVfs created with Wavelinq
45636898|NCT05897970|Diagnostic Test|Return-to-sport (RTS) follow-up|All sports patients who had a muscle evaluation at 3-4 months after ACLR since January 2017
45636899|NCT05897944|Other|COPD|A data set consisting of information from COPD and HC groups will be used to experiment with the classification performance of several Machine Learning techniques.
45636900|NCT05897918|Drug|Tranexamic Acid 500 MG|Each patient received treatment on both sides of the face, one side treated by micro needling with 10% topical tranexamic acid, and othert side treated by 10% topical tranexamic acid alone every 2 weeks for 3 sessions
45636901|NCT05897697|Other|Interview|Structured interview
45636902|NCT05897450|Other|Transversus abdominis plane (TAP) block|Transversus abdominis plane (TAP) block: injection of a local anesthetic into a region between the internal oblique and transversus abdominis muscles.
45636903|NCT05897099|Behavioral|Comprehensive Tele-harm Reduction|Comprehensive Tele-Harm Reduction is on-demand services including low-barrier access to PrEP, medications for substance use disorder and hepatitis C treatment. It includes mobile phlebotomy, peer harm reduction counseling, medication management, telehealth mental health/substance use disorder services-- all delivered via an syringe services program.
45775649|NCT01336933|Genetic|nucleic acid sequencing|Correlative studies
45775650|NCT01336933|Genetic|mutation analysis|Correlative studies
45775651|NCT01336933|Other|immunohistochemistry staining method|Correlative studies
45775652|NCT01336933|Genetic|microarray analysis|Correlative studies
45935573|NCT00126880|Drug|AVX754|apricitabine, 600mg BID or 800mg BID
45775653|NCT01336933|Genetic|RNA analysis|Correlative studies
45775654|NCT03009409|Drug|Ketamine Injectable Solution|"Once IV access has been obtained and a facemask has been applied for pre-oxygenation, the loading dose (0.25 mg/kg) of the study drug will be given over 60 seconds and the fixed infusion (5 mcg/kg/min to a maximum of 60 mg/hour) will be initiated by the anesthetist through the pump interface.~The study drug will be infused at a constant rate of 5 mcg/kg/min throughout the maintenance phase, until the end of the procedure (last suture), up to a maximum cumulative dose of 100 mg. If at any point the anesthesiologist feels that it is clinically necessary to reduce the amount of study drug infusion rate, they may opt to reduce the infusion rate by 50% (to 2.5 mcg/kg/min), or stop the infusion entirely."
45636904|NCT05897099|Behavioral|Off-site Linkage to HIV Prevention|The community engagement team is comprised of peers and social workers and provides the wraparound support needed.The team will assist participants in scheduling appointments at community health clinics. The community engagement team provides active clinic referral- that is, a member of the team will accompany patients to the first clinic visit.
45636905|NCT05897034|Drug|Doxycyclin|Doxycycline is a moderate-spectrum, second-generation tetracycline that is generally well tolerated
45636906|NCT05897034|Drug|Pentoxifylline|Pentoxifylline is a vasoactive agent that improves the flow of blood by reducing its viscosity
45636907|NCT05897034|Drug|Nitazoxanide 500Mg Oral Tablet|Nitazoxanide is a broad-spectrum antiparasitic and broad-spectrum antiviral medication that is used in medicine for the treatment of various helminthic, protozoal, and viral infections
45636908|NCT05897021|Behavioral|Expressive Writing on Minority Stressors|The EWMS protocol will consist of 3 sessions delivered by a therapist (either in-person or remotely via telehealth platform) to sexual minority Veterans. The intervention will begin with an overview of the intervention, brief psychoeducation about expressive writing, and a review of the potential benefits of expressive writing. The initial session will also consist of psychoeducation on sexual minority stressors and common reactions to these stressors (i.e., universal stress reactions and minority-identity specific reactions) and how this relates to psychological outcomes, such as depression and anxiety, and high-risk behaviors, such as substance use and suicidal ideation. The initial session will be 60 minutes (introduction, psychoeducation, and first writing exercise) and the following two sessions (feedback, writing exercises, and check-ins) will take approximately 40 minutes.
45636909|NCT05897021|Behavioral|Neutral Writing|To be comparable to EWMS, the control intervention will also be a 3-session individual intervention involving engaging in a writing exercise per session. For the control writing exercises, participants will be asked to write for 30 minutes about their daily activities since waking up that day based on Pennebaker's standard writing paradigm (Pennebaker & Beall, 1987). Individuals in the control condition will also be given information about the purpose of the writing exercises to be comparable to the psychoeducation information provided in EWMS. Similar to EWMS, the clinician will check in with the participant about the writing session, such as asking how the session went and how it felt to do the writing, following the 30 minutes of writing.
45636910|NCT05897008|Biological|CMAB007|for subcutaneous injection only
45636911|NCT05897008|Biological|Xolair|for subcutaneous injection only
45636912|NCT05896865|Radiation|Whole breast / chest wall & regional lymph node irradiation|Whole breast / chest wall and corresponding regional lymph node irradiation with dose of 42.4 Gy in 16 fractions
45636913|NCT05896865|Radiation|Internal mammary or supraclavicular lymph node boost|Simultaneous boost to Internal mammary or supraclavicular lymph node area with dose of total 53.6 Gy or 56.0 Gy in 16 fractions, depending on the response after neoadjuvant chemotherapy
45636914|NCT05896423|Behavioral|PrEP awareness materials|Community-designed PrEP awareness materials - developed in the formative portion of this study
45636915|NCT05896410|Device|splint (orthosis)|3D printed splint (orthosis) help prevent the joint from shifting during pinch activities. This reduces improper joint loading and helps reduce pain and the progression of degenerative change in patients with OA.
45636916|NCT05895825|Drug|EOC237|EOC237 for orally
45636917|NCT05895747|Drug|Low Dose 5-hydroxytryptophan|5-hydroxytryptophan 100mg PO BID
45636918|NCT05895747|Drug|High Dose 5-hydroxytryptophan|5-hydroxytryptophan 200mg PO BID
45636919|NCT05895747|Drug|Low Dose Creatine Monohydrate|Creatine monohydrate 5g PO qday
45636920|NCT05895747|Drug|High Dose Creatine Monohydrate|Creatine monohydrate 10g PO qday
45636921|NCT05895747|Drug|Placebo|Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)
45636922|NCT05894395|Biological|MMR booster vaccination (as M-M-R-VaxPro)|a single dose of MMR-containing vaccine (as M-M-R-VaxPro), in adults having previously received 2 lifetime doses of MMR-containing vaccine
45636923|NCT05894304|Device|Suspension system|suspended from the handles of the straps by either their hands or feet while the non-suspended pair of extremities are in contact with the ground leading to muscle activation due to unstable base of support
45636924|NCT05894304|Other|Scapular training exercises|Scapular muscle strength by resistance
45636925|NCT05893667|Diagnostic Test|Inflammatory markers|analysis of inflammatory scores
45636926|NCT05893498|Device|FFRangio|A 3D image-base software device (CathWorks, Ltd, Kfar Saba, Israel) using three (3) angiographic views to provide a quantitative analysis of the functional significance of coronary lesions.
45636927|NCT05893498|Device|FFR or NHPR|Using an invasive pressure-wire to assess functional significance of coronary lesions either under hyperemic conditions (FFR) or utilizing Non-hyperemic pressure ratios (NHPR).
45636928|NCT05893264|Other|Data collection|"Several data will be collected such as:~Age, weight, height, gender, previous spine surgery, skoliosis (Y/N), palpable spinous process (Y/N), experience in years of anesthesiologist, spine level of epidural placement~and the following sonographic parameters at the level of epidural placement: skin-spinous process distance (cm), skin-transversous process distance (cm), erector spinae plane distance (cm), superior to inferior spinous process distance (cm)"
45636929|NCT05893251|Other|Manual therapy|"Within the manual therapy protocol carried out in the experimental group, we performed a series of passive maneuvers. The patient remains in supine position on a treatment table throughout the treatment, while the therapist sits at the head of the patient on a stool. The sequence of application is as follows:~Suboccipital inhibition technique Cervical spinal mobilization Posterior fascia stretching"
45636930|NCT05893251|Other|Postural exercises|The treatment plan includes active postural exercises for the cervical spine.
45636931|NCT05892939|Drug|intranasal Oxytocin(24IU)|Administration of intranasal Oxytocin(24IU)
45636932|NCT05892939|Drug|intranasal Placebo|Administration of intranasal Placebo
45636933|NCT05892861|Behavioral|cognitive stimulation|video education, board games, and 24-hour dietary recall record
45636934|NCT05892861|Other|as usual care|history taking, explain data, and discuss how to control healthy condition
45636935|NCT05891834|Drug|INV-202|tablet, once daily, oral
45636936|NCT05891834|Drug|Placebo|tablet, once daily, oral
45775655|NCT03009409|Other|Placebo|Participants in the control group will receive an equivalent volume bolus and infusion of normal saline to mimic the ketamine infusion in the ketamine group.
45636937|NCT05890924|Other|WAST questionnaire|"WAST questionnaire, designed and validated as a screening tool for violence against women and intimate partner violence.~(ref: Brown JB, Lent B, Brett PJ, Sas G, Pederson LL. Development of the Woman Abuse Screening Tool for use in family practice. Fam Med. 1996 Jun;28(6):422-8.)"
45636938|NCT05890534|Drug|Pycnogenol®|Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
45636939|NCT05890534|Drug|Placebo|Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
45636940|NCT05888896|Other|methyldopa tablets 250mg|patients will be taken methyldopa tablets 250mg in the morning orally with a lot of water after breakfast daily and this medication continues for 8 weeks
45636941|NCT05888896|Other|methyldopa tablets 250mg + foot reflexology|patients will receive methyldopa tablets 250mg in oral way once daily per 8 weeks and patients will receive foot reflexology two sessions per week, every session will last for 30 minutes and sessions will last for 8 weeks.
45636942|NCT05888571|Procedure|prepectoral breast reconstruction|Patients receive immediate prepectoral breast reconstruction
45636943|NCT05888571|Procedure|Tiloop Mesh implantation|Patients receive immediate prepectoral breast reconstruction with Tiloop Mesh
46070220|NCT00701571|Procedure|Virtual Reality distraction|"Virtual Reality involves the participant wearing a helmet with sight and sound. the visual provided is a type of immersive video game, the game used is Snow World. In some cases the participant will be exposed to 3D representation of the game, and in other cases a lower tech version with less immersive qualities."
45636944|NCT05888545|Device|anti-adhesion diaphragm|Participants will be asked to place an anti-adhesion diaphragm in the uterus for 3-7 days after the abortion procedure.
45636945|NCT05886049|Procedure|Biospecimen Collection|Undergo collection of blood
45636946|NCT05886049|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
45636947|NCT05886049|Procedure|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
45636948|NCT05886049|Drug|Cytarabine|Given IV
45636949|NCT05886049|Drug|Daunorubicin|Given IV
45636950|NCT05886049|Procedure|Multigated Acquisition Scan|Undergo MUGA
45636951|NCT05886049|Drug|Revumenib|Given PO
45636952|NCT05886049|Procedure|Transthoracic Echocardiography|Undergo transthoracic ECHO
45636953|NCT05886036|Procedure|Biopsy|Undergo tissue biopsy
45636954|NCT05886036|Procedure|Biospecimen Collection|Undergo blood sample collection
45935574|NCT00126880|Drug|3TC|3TC, 150mg BID
45636955|NCT05886036|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
45636956|NCT05886036|Procedure|Computed Tomography|Undergo PET/CT
45636957|NCT05886036|Other|Fludeoxyglucose F-18|Receive FDG
45636958|NCT05886036|Procedure|Magnetic Resonance Imaging|Undergo MRI
45636959|NCT05886036|Biological|Mosunetuzumab|Given SC
45636960|NCT05886036|Procedure|Positron Emission Tomography|Undergo PET/CT
45636961|NCT05886036|Biological|Rituximab|Given IV
45636962|NCT05886036|Biological|Rituximab and Hyaluronidase Human|Given SC
45636963|NCT05885061|Device|Spinal cord stimulation turned on (suggestions: off)|Spinal cord stimulation turned on with verbal suggestions of treatment off
45636964|NCT05885061|Device|Spinal cord stimulation turned off (suggestions: on)|Spinal cord stimulation turned off with verbal suggestions of treatment on
45636965|NCT05885061|Device|Spinal cord stimulation turned on with suggestions (suggestions on)|Spinal cord stimulation turned on with verbal suggestions of treatment on
45636966|NCT05881083|Behavioral|1-week nicotine replacement therapy sampling|Participants will be given an 1-week sample of nicotine replacement therapy (patch or gum) with brief instructions on how to use the product
45636967|NCT05881083|Behavioral|Brief cessation advice|"Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again"
45636968|NCT05880966|Behavioral|Functional Fitness|Six month, thrice weekly functional fitness sessions will include a warm-up (15 minutes), skill or strength work (30 minutes) and a cool down (15 minutes)
45636969|NCT05879757|Other|No Intervention|As this is an observational study, no intervention will be administered in this study.
45636970|NCT05878301|Other|vegetable and protein first followed by carbohydrates (VPF) meal sequence|vegetable and protein first followed10 min later by carbohydrates (VPF) meal sequence
45636971|NCT05878223|Device|Extracorporeal shock waves|Both group received extracorporeal shock waves therapy
45636972|NCT05876754|Drug|Ivosidenib Oral Tablet|Ivosidenib 500 mg
45636973|NCT05876338|Other|CRCaSSM|The intervention group will receive face-to-face training, giving patient education booklet and telephone counseling based on the symptom management model. After the training, it is planned to provide telephone counseling for a total of 6 times, once every 2 weeks for 3 months.
45636974|NCT05876065|Drug|XC|Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days
45636975|NCT05876065|Drug|TPC|Any physician's choice as maintenance therapy (except for XC regimen)
45636976|NCT05875974|Drug|JZP258 (XYWAV)|Narcolepsy Cohort: Initiate dosage per XYWAV label and titrate to effect. IH Cohort: Initiate dosage per XYWAV label and titrate to effect.
45636977|NCT05875454|Diagnostic Test|Histopathological examination of tru-cut needle biopsy|Renal biopsies fixed in formalin from patients with suspected medical renal disease will be processed and examined for histopathological diagnosis.
45935575|NCT02965911|Drug|Fenofibrate|Fenofibrate is a drug of the fibrate class. it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels.
45935576|NCT02965911|Drug|UDCA|Ursodeoxycholic acid，the abbreviation UDCA, is one of the secondary bile acids, which are metabolic byproducts of intestinal bacteria，it is the only FDA approved drug to treat PBC.
45935577|NCT00126919|Device|SonoPrep|
45935578|NCT00126958|Procedure|urinary analysis|
45935579|NCT00126997|Biological|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
45636978|NCT05874713|Biological|aH5N8c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
45636979|NCT05874713|Biological|aH5N6c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular administration, containing intermediate dose H5N6 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
45636980|NCT05874713|Biological|aH5N8c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
45636981|NCT05874713|Biological|aH5N6c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular administration, containing intermediate dose H5N6 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
45636982|NCT05874713|Biological|aH5N8c on Day 202|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
45636983|NCT05873582|Device|Robotic-assisted inguinal hernia repair|Primary transperitoneal unilateral or bilateral inguinal hernia repair with the Dexter robotic system
45636984|NCT05867836|Dietary Supplement|IFA vs. MMS during pregnancy|Iron and folic acid, or multiple micronutrient supplements provided during pregnancy
45636985|NCT05867147|Drug|Vanzacaftor|Tablets for oral administration.
45636986|NCT05867147|Drug|Vanzacaftor Placebo|Placebo for oral administration.
45636987|NCT05867147|Drug|Moxifloxacin|Tablets for oral administration.
45636988|NCT05867147|Drug|Moxifloxacin Placebo|Tablets for oral administration.
45636989|NCT05861765|Drug|Papaverine Hydrochloride|Slowly inject 10ml of papaverine hydrochloride solution (30mg/10ml) through the successfully implanted radial artery sheath, and continuously drip papaverine hydrochloride solution (60mg/500ml, 4ml/min) through the artery sheath during the operation. The compatible solutions are normal saline(0.9%);
45636990|NCT05861765|Drug|normal saline|After inserting the radial artery sheath, slowly inject 10ml normal saline(0.9%) through the artery sheath, then continuously drip normal saline(0.9%, 500ml, 4ml/min) through the artery sheath during the operation.
45636991|NCT05860595|Genetic|KL003 cell injection Drug Product|Transplant of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene.
45636992|NCT05859698|Drug|Valbenazine|Valbenazine capsules for oral administration
45636993|NCT05855837|Other|Ready to Eat Cereal|Cereal products available in retail stores
45636994|NCT05849207|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 50, 40, 32, or 25 mg/k/d intravenous infusion (IV) continuously for two days starting 60-72 hours after transplant.
45636995|NCT05843890|Behavioral|Structured and tailored PainGuide|"Participants will receive specific instruction to complete one module a week over the first 4 weeks. Participants will then receive tailored messaging using scores from the assessments completed during T1(baseline visit) from the PROMIS 29+2.~Participants will be asked to complete surveys over 24 weeks.~All participants will also be registered with a Fitbit device that is linked to the PainGuide to capture movement data (daily step counts)."
45636996|NCT05843890|Behavioral|Standard PainGuide|"Participants in the control group will not receive any messaging once enrolled. Participants will be asked to complete surveys over 24 weeks.~All participants will also be registered with a Fitbit device that is linked to the PainGuide to capture movement data (daily step counts)."
45636997|NCT05842304|Device|active cTBS|Each patient will receive three 600-pulse cTBS stimulations per day, parted by two 15-minute rest periods (a total of 1800 pulses daily), for 21 consecutive days (3 weeks).
45636998|NCT05842304|Device|sham cTBS|Each patient will receive three 600-pulse sham cTBS stimulations per day, parted by two 15-minute rest periods (a total of 1800 pulses daily), for 21 consecutive days (3 weeks).
45636999|NCT05836454|Other|Progressive Muscle Relaxation Group:|Progressive muscle relaxation is a relaxation technique that involves regular and sequential contraction and relaxation of muscles until the whole body is relaxed.
45637000|NCT05836454|Other|Myofascial Release Technique Group|It is a physiotherapy technique based on soft tissue mobilization. All enveloping fascia sale prices are positive for mobility, a user used for adhesions and pain.
45637001|NCT05823259|Other|Hybrid Telehealth Program: Respiratory Muscle Training and Patient Education|"A testing session will be held where subjects will undergo respiratory muscle testing using the Pro2Fit device to measure PIMax and PEmax. During this session, subjects will be instructed in a respiratory muscle training home program utilizing a provided device call the Breather. They will be instructed to perform this program consisting of breathing exercises for 2 sets of 10 repetitions, twice a day at a difficulty level of 5-7 on the Visual Analogue Scale (VAS) scale for 8 weeks. Subjects will be shown how to follow a training program every day utilizing the free companion application to the device Breather Coach. If subjects have issues with using technology, they will be provided a physical log to record when they complete sessions. Ten to fifteen-minute Zoom sessions with the study coordinator will be held once a week to check in on how the program is progressing, compliance, and if the resistance can be increased."
45637002|NCT05823259|Other|Standard Physical Therapy Care|A group of patients who receive standard physical therapy care for chronic constipation at the University of Miami that consists of biofeedback therapy, manual therapy, therapeutic exercise, and patient education.
45637003|NCT05819827|Other|Blood and Tissue|"Patients will collect stool for microbiome analysis at baseline (i.e., 3 +2 days prior to chemotherapy) and again 5-7 days following initiation of chemotherapy.~Blood samples will be collected prior to their first chemotherapy treatment, and in the second week after chemotherapy."
45637004|NCT05818618|Drug|Clobetasol Topical Gel|Topic Clobetasol gel applied locally on OLP lesions.
45637005|NCT05818618|Drug|Placebo|Placebo oral gel applied locally on OLP lesions.
45935580|NCT00043745|Dietary Supplement|Soy isoflavones|Soy isoflavones extracted from soy protein, compressed into tablets; three tablets taken daily
45935581|NCT00043745|Dietary Supplement|Extract tablets|Extract from soy protein, but devoid of isoflavones; three tablets taken once daily
45935582|NCT00074295|Biological|GVAX lung cancer vaccine|6-7 injections per week in rotating locations for five weeks
45935583|NCT00127075|Drug|nomegestrol acetate|10 mg/day
45637006|NCT05814653|Behavioral|Family Based Treatment-Primary Care|Novel treatment that borrows key intervention strategies from standard family-based treatment. It uses trained primary care providers (PCPs), in consultation with a mental health provider, to deliver family-based treatment strategies in community-based clinics to increase caregiver self-efficacy to reverse their child's dietary restriction and weight loss.
45637007|NCT05814653|Behavioral|Family-Based Treatment|Delivered by a mental health provider in a traditional mental health or eating disorder specialty setting. First-line evidence-based treatment for adolescent eating disorders that targets caregiver self-efficacy as a mechanism to facilitate weight restoration and ultimately symptom remission in adolescents.
45637008|NCT05814016|Drug|Danavorexton|Danavorexton IV infusion.
45637009|NCT05814016|Drug|Placebo|Placebo matching danavorexton IV infusion.
45637010|NCT05811702|Other|A randomized acute controlled trial of twenty-eight healthy overweight or obese women|A randomized acute controlled trial of twenty-eight healthy overweight or obese women in Saudi Arabia, aged between 18 and 40 with a body mass index between 25 and 34.5 kg m2 and fat parentage above 30% . The participants have followed ether HFKD or LFD for 12 weeks. Our primary outcome of this study to investigated the effective diets HFKD and LFD on reduction of body weight, the percentage of body fat
45637011|NCT05809921|Drug|alteplase|Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg) with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes.
45637012|NCT05809921|Drug|Alteplase + possible complementary IVT with tenecteplase|Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg, with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes) and depending on the MRI-2 results, an additional IVT with tenecteplase (0.25mg/kg, maximum 25 mg, with 100% of the dose given as a bolus) could be given in case of persistent occlusion and with no contraindication according to the study protocol.
45637013|NCT05808309|Other|Salivary sampling|Salivary sampling for genomic material (DNA and RNA (for primary outcome measures); proteins and DNA methylation (for secondary outcome measures)
45914755|NCT02047266|Device|Starfish®, Octopus®, Clearview® blower, ClearView® Shunt|Starfish® - heart positioner is designed to position and to hold the heart to give the surgeon easy access to the vessel requiring the bypass graft. Octopus® - tissue stabilizer minimizes / limits the motion of a small area of the heart while the rest of the heart continues to beat normally. This allows the surgeon to perform CABG surgery without stopping of the heart and without using the heart-lung machine. ClearView® Blower is designed to improve visualization of the surgical site. An irrigation mist gently clears blood from the site, improving visualization without drying or desiccating delicate tissue. The ClearView® shunt - Intracoronary shunt provides a clear anastomotic site during the procedure while providing blood flow to the distal myocardium (Medtronic, Inc., Minneapolis, MN)
45935584|NCT00127075|Drug|estradiol|75 mcg, once a week
45637014|NCT05804513|Drug|Placebo|s/c injection
45637015|NCT05804513|Drug|Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector|s/c injection
45637016|NCT05802615|Behavioral|PARITY|The PARITY program reinforces strengths through consistent, community-based Black doula support and protective asset (personal strengths) focused messaging. PARITY promotes wellness-related behaviors (nutrition, physical activity, sleep, and healthcare adherence) and promotes and builds empowered strengths (self-efficacy, social support, motivation, resilience, problem-solving, and self-regulation) through mobile technology and doula support.
45637017|NCT05802615|Other|Usual Care|Participants will obtain prenatal care from their usual care provider and a handout on healthy pregnancy.
45637018|NCT05799989|Procedure|Surgical fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with surgical fixation
45637019|NCT05799989|Procedure|Atraumatic fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with atraumatic fixation
45637020|NCT05794087|Other|Clean Air|Subjects will be exposed to clean air for 3 hours.
45637021|NCT05794087|Other|Ozone|Subjects will be exposed to 0.2 ppm ozone for 3 hours.
45637022|NCT05783219|Drug|Lidocaine patch|4% lidocaine patch placed over the sacrum 30 minutes prior to PNE procedure
45637023|NCT05783219|Other|Placebo|Adhesive patch placed over the sacrum 30 minutes prior to PNE procedure
45637024|NCT05782868|Other|Expressive writing in response to vignette|Participants will read a vignette, which describes the experience and response of a young adult who experiences rejection from a close friend after a first disclosure of their gender identity. Participants will then be asked to write in response to three prompts: 1) identify expressions of internalized transphobia in the vignette character, 2) reflect on times the participant has experienced similar feelings, 3) identify thoughts and feelings that promote and support a positive and affirming identity in contrast to negative emotions and thoughts.
45637025|NCT05782868|Other|Expressive writing about events of the day|Participants in the control condition will be asked to write about the events of their day and thoughts and feelings that occurred in response to those events.
45637026|NCT05782868|Other|Letter of Gratitude|Participants will be directed to compose a brief letter of gratitude to an individual to whom they have not previously expressed gratitude, and who has provided meaningful and affirming support to them as a TNB person.
45637027|NCT05771246|Diagnostic Test|Radiographic evaluation|Panoramic and lateral cephalometric radiographs with cephalometric analysis will be performed.
45637028|NCT05770570|Behavioral|Counseling|In-person individual diet and physical activity (PA) counseling
45637029|NCT05770570|Behavioral|Text Messages|Thrice-weekly diet/physical activity(PA) text messages
45637030|NCT05770570|Behavioral|Phone calls|Weekly telephone support
45637031|NCT05770570|Behavioral|Self-monitoring tools|Self-monitoring tools
45637032|NCT05769608|Drug|Placebo|Placebo once daily for 12 weeks
45637033|NCT05769608|Drug|lorundrostat Dose 1|lorundrostat Dose 1 once daily for 12 weeks
45637034|NCT05769608|Drug|lorundrostat Dose 2|lorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks
45935585|NCT00127075|Drug|placebo|matching placebo treatments
45637036|NCT05766878|Device|implants placement|The intervention will consist of placement of two types of short implants (one with traditional machined collar and one with anodized collar). After their healing period, the prosthetic rehabilitation will be made.
45775656|NCT00176930|Biological|Stem Cell Transplant|Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover. (Allowable sources of stem cells = related or unrelated bone marrow or peripheral blood, for Busulfan/cyclophosphamide/ATG preparative chemo only, umbilical cord blood is also permitted.)
45775657|NCT00176930|Drug|Cyclophosphamide|60 mg/kg intravenously (IV) Days -6 and -5 or 50 mg/kg/day IV Days -5 through -2.
45775658|NCT00176930|Radiation|Total Body Irradiation|On Day -4, -3, -2, -1 total body irradiation is given twice daily.
45775659|NCT00176930|Drug|Busulfan|When not receiving total body irradiation, administered Days -9 through -6, 0.8 mg/kg/dose by intravenous dosing every 6 hours.
45775660|NCT00176930|Drug|Equine ATG (ATGAM)|UCB recipients who have not had chemotherapy in the preceding 3 months will also receive Equine ATG (ATGAM) 15 mg/kg IV will be administered every 12 hours for 6 doses beginning on day -3 per institutional guidelines
45775661|NCT00176930|Biological|CD4+/CD25+ cells|On days -2, patients will receive CD4+/CD25+ cells intravenously.
45775662|NCT01473745|Procedure|conventional alar base cinch|The conventional suture began from the bilateral alar part of the nasalis muscle and passed through a hole drilled on the anterior nasal spine.
45775663|NCT01473745|Procedure|modified alar base cinch|The modified suture began from the bilateral alar part of the nasalis muscle and dermis tissue over the alar base, and then passed through a hole drilled on the anterior nasal spine.
45637037|NCT05765851|Drug|DS-1103a|One IV infusion Q3W on Day 1 of each 21-day cycle
45637038|NCT05765851|Drug|T-DXd|One IV infusion Q3W on Day 1 of each 21-day cycle
45914756|NCT02047279|Procedure|maze procedure|"The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp. The left atrial appendage was excluded in all cases."
45914757|NCT02047279|Procedure|mitral valve surgery|For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.
45914758|NCT02047279|Procedure|left atrial reduction|The enlarged left atria are plicated (suture technique) between the left and right pulmonary vein down to the inferior end of left atrial incision on the half-moon shape.
45637042|NCT05756725|Other|Practice-Level Implementation Strategies|The intervention is implementation of new population health management tools that may better leverage patient navigation and other staff resources to ensure timely abnormal follow up of breast and colorectal cancer screening. The research team will work with CHCs to select implementation strategies that will best facilitate integration of the new tools into practice. The team will use electronic health record data (analyzed at the population level) to determine the impact of the new tools on screening outcomes and qualitative data from up to 3 staff and 2 patients per CHC to evaluate integration of the tools into practice.
45637043|NCT05756114|Behavioral|Support Group|Support Group condition, meetings will be held online via HIPAA-compliant Zoom and run by a trained SMART Recovery meeting facilitator
45637044|NCT05756114|Other|Psychoeducational Email|Participants receive a weekly email with a Qualtrics survey link containing psychoeducational content.
45637045|NCT05755958|Device|HIFU treatment in rectal Endometriosis|HIFU treatment of rectal endometriosis
45637046|NCT05755958|Device|SHAM HIFU procedure|SHAM HIFU procedure
45637047|NCT05755165|Behavioral|Depression|~90-second selfie video of an adolescent discussing her history of depression, treatment, and recovery
45637048|NCT05755165|Behavioral|Depression, adjusted|~90-second selfie video of an adolescent discussing her history of depression, treatment, and recovery - and including explicit reference to the role of anti-Black racism as a contributing factor
45775664|NCT01088711|Drug|Omarigliptin|Once-weekly 50 mg capsule
45775665|NCT01088711|Drug|Placebo|Once-weekly placebo capsule
45637049|NCT05755165|Behavioral|Control|~90-second selfie video of an adolescent discussing everyday activities and interests, with no reference to depression or racism.
45637050|NCT05754580|Radiation|High Dose Brachytherapy|This technique involves transient insertion of a stronger (i.e. more active) source (Ir-192) into the prostate, with dose delivery over the course of several minutes followed by immediate removal.
45637051|NCT05754580|Radiation|Stereostatic Body Radiation Therapy|ultra-hypofractionation radiation therapy.
45637052|NCT05747352|Other|closed-loop hybrid insulin administration|observational non-interventional study
45637053|NCT05746520|Other|Antibiotic|Type of antibiotic is per clinical judgement with the duration being the experimental aspect of this study.
45775666|NCT00127790|Behavioral|CBT for Insomnia (CBT-I)|
45775667|NCT00127790|Behavioral|CBT for Pain (CBT-P)|
45775668|NCT03008395|Behavioral|EMMA|Dialogue tools will be used to develop personally relevant behavioural goals consistent with diabetes self-management
45775669|NCT03008395|Other|Treatment as Usual|Participants randomized to this intervention will receive standard diabetes education sessions. These include group education session and follow up session based on clinician-generated recommendations.
45775670|NCT01120223|Drug|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|Once daily application
45775671|NCT00178178|Device|Breg Pain Care 3000 Catheter|Device: Breg Pain Care 3000 Catheter
45775672|NCT00178178|Drug|Bupivicaine 0.5%|Drug: Bupivicaine 0.5 %
45775673|NCT00178178|Drug|Placebo|Drug: Placebo
45914759|NCT02047292|Device|THA Corail PinnacleCoC28|Uncemented THA with Corail stem and Pinnacle acetabular cup with CoC 28 mm head
45637054|NCT05745636|Dietary Supplement|Broccoli, mustard, vitamin C|2 capsules per day for 4 weeks
45637055|NCT05745636|Dietary Supplement|Placebo|2 capsules per day for 4 weeks.
45637056|NCT05741060|Drug|S-equol|Experimental drug
45637057|NCT05741060|Drug|Placebo|Placebo - 10 mg per day for 24 months of tablets that will be the same size/shape/color as the s-equol tablets.
45637058|NCT05740124|Behavioral|slip recovery training|Participants practice volitional and reactive stepping responses that mimic those needed when recovering balance after slipping.
45637059|NCT05740124|Behavioral|alternative balance training|Participants practice standing and walking under varied sensory conditions.
45637060|NCT05738161|Drug|Magrolimab|Magrolimab in combination with cytotoxic chemotherapy in advanced urothelial carcinoma
45637061|NCT05738161|Drug|Cisplatin|Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
45637062|NCT05738161|Drug|Gemcitabine|Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
45637063|NCT05735483|Drug|Lebrikizumab|Administered SC
45637064|NCT05735483|Drug|Placebo|Administered SC
45448313|NCT03549364|Behavioral|Endurance Race|1 CT and lab tests, 2 CT and lab tests within 24h of a race, 3 follow up investigations 1-2 weeks after the race with CT and lab tests
45914760|NCT02047292|Device|THA Corail DeltaMotion36|Uncemented THA with Corail stem and DeltaMotion acetabular cup with 36 mm head
45914761|NCT02047292|Device|THA Corail DeltaMotion40|Uncemented THA with Corail stem and DeltaMotion acetabular cup with 40 mm head
45637065|NCT05734040|Biological|OVX836 480µg|One single administration intramuscularly at Day 1
45914762|NCT02047331|Procedure|periarticular injection|patients were performed bupivacaine solution to the periarticular soft tissues during surgery by the surgeon.
45914763|NCT02047331|Procedure|fascia iliaca block|patients were performed fascia iliaca block with bupivacaine solution before surgery.
45637066|NCT05734040|Biological|Fluarix Tetra|One single administration intramuscularly at Day 1
45637067|NCT05734040|Biological|Afluria Quad|One single administration intramuscularly at Day 1
45637068|NCT05734040|Biological|Placebo|One single administration intramuscularly at Day 1
45637069|NCT05733598|Biological|RP3|Genetically modified herpes simplex type 1 virus
45637070|NCT05733598|Biological|atezolizumab|anti-PD-L1 monoclonal antibody
45637071|NCT05733598|Biological|bevacizumab|anti-VEGF therapy
45637072|NCT05733507|Procedure|IVT with tenecteplase or alteplase|Patients received intravenous tenecteplase 0.25mg/kg (maximum dose: 25mg), administered as a bolus over 5 to 10 seconds or intravenous alteplase 0.9 mg/kg (maximum dose: 90mg), 10% as bolus and the remainder as continuous perfusion over 1 hour.
45637073|NCT05733507|Procedure|Intervention Name : Tirofiban and IVT with tenecteplase or alteplase|IVT with tenecteplase or alteplase with continuous infusion of tirofiban 0.4µg/kg/min continued for 24 to 48 hours.
45637074|NCT05724134|Drug|Insulin human|Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).
45637075|NCT05724134|Drug|Octreotide Acetate|Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
45637076|NCT05724134|Drug|Glucagon|Glucagon will be replaced at a constant rate of 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
45637077|NCT05724134|Drug|Growth Hormone, Human|Recombinant human growth hormone (rhGH) will be replaced at a constant rate of 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
45637078|NCT05724134|Other|[6,6-2H2] D-glucose|Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.
45637079|NCT05724134|Drug|20% D-glucose (aq)|20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.
45637080|NCT05724134|Dietary Supplement|BOOST Plus|"Nutritional supplement will be administered to provide three standardized mixed meals on the day before the pancreatic clamp."
45637081|NCT05724134|Device|Harvard Apparatus PHD ULTRA CP syringe pump|Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.
45637082|NCT05724134|Device|Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer|Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.
45637083|NCT05723198|Drug|Baricitinib|Administered orally
45637084|NCT05723198|Drug|Placebo|Administered orally
45637085|NCT05721157|Other|AI-enabled Chest X-ray-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-Chest X-ray result was positive or negative.The system will send a message to corresponding physicians if positive finding.
45914764|NCT02047357|Other|Learning Through Play Plus|Learning Through Play (LTP) Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
45914765|NCT02047370|Other|Diaphragm stretching|The therapist stands behind the patient and passes his hands around the thoracic cage, carefully introducing fingers under the costal margins. The patient slightly rounds the trunk in order to relax rectus abdominis. During the exhalation of the patient the therapist grasps the lower ribs and costal margin and eases the hands caudally. This traction was maintained during 5-7 minutes.
45448314|NCT03549286|Other|Questionnaire passation|Questionnaires assessing general knowledge about Down's syndrome screening, specific knowledge of NIPT for Down's syndrome and patient's satisfaction about provided information.
45448315|NCT02134288|Drug|Belatacept|
45914766|NCT02047370|Other|Placebo|The same therapist, patient position and duration of the technique, but using disconnected ultrasound
45448316|NCT02134288|Drug|Everolimus|
45914767|NCT00005817|Drug|becatecarin|Given IV
45448317|NCT00129467|Drug|Methylphenidate|"Subjects will take methylphenidate 5 mg twice daily (bid) for 3 days, then 10 mg bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of methylphenidate, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%. During the 18-day blinded treatment period the total daily dose will not exceed 20 mg.~If subjects have side effects when increasing to 10 mg bid, they will drop back to 5 mg bid. If the participant develops psychosis or cardiac events, they will be discontinued from methylphenidate.~Subjects who receive methylphenidate and respond with a 50% reduction in MADRS score will have the option to continue in the open label portion of the study for up to 6 weeks. For patients taking methylphenidate 10 mg bid whose MADRS score is > 10 at day 18, the dose may be increased to 15 mg bid."
45637088|NCT05709444|Drug|Bremelanotide|Bremelanotide is a cyclic, heptapeptide analog of the endogenous peptide alpha melanocortin stimulating hormone (αMSH).
45637089|NCT05709444|Drug|RAAS inhibition therapy|RAS-acting agents are medicines acting on a hormone system that helps to control blood pressure and the amount of fluid in the body.
45637090|NCT05704036|Drug|Transdermal estrogen|Transdermal estradiol 0.1 mg/day, applied once weekly
45637091|NCT05704036|Drug|Placebo patch|Placebo patch, applied once weekly
45637092|NCT05704036|Drug|Progesterone|Progesterone 200 mg daily for 10 days/month, if participant is not on progesterone-containing contraceptive
45637093|NCT05704036|Drug|Placebo pill|Placebo pill daily for 10 days/month, if participant is not on progesterone-containing contraceptive
45637094|NCT05695716|Device|CSI pVAD System|The CSI percutaneous ventricular assist device (pVAD) is being investigated as a temporary left ventricular system intended to support and/or provide hemodynamic stability during high-risk percutaneous coronary interventions.
45637095|NCT05683223|Behavioral|Group CBT for Social Anxiety Disorder|Initial CBT will consist of 12 weekly, 2.5-hour group sessions. Later sessions (after session 7) become more individualized as the exposure practices are tailored to the individual participant's concerns. Most often, the exposures are completed outside the group environment. Session content includes various cognitive behavioral strategies tailored to SAD, such as psychoeducation, examining and challenging cognitive distortions, and exposure exercises.
45637096|NCT05683223|Drug|Sertraline|Non-responders will initiate sertraline at baseline (week 0) with 25 mg/day followed by a dose increase to 50 mg/day at week 1, 100 mg at week 4, 150 mg at week 6, and 200 mg at week 8. Upward dose titration may be slowed and the dose decreased if necessary due to side effects, but the clinician will attempt to titrate all symptomatic participants up to 200 mg/day if tolerated by week 8, with the last dose increase allowed at week 10. Participants will be assessed at each visit by the study psychiatrist for purposes of dose titration and monitoring. Symptomatic participants unable to reach 200 mg/day of sertraline due to side effects will be maintained in the trial if they are on at least 50 mg/day by week 8; all symptomatic participants will be titrated to their maximally tolerated dose (< 200 mg/day sertraline). Any participant unable to tolerate sertraline will be discontinued and referred for clinical treatment.
45637097|NCT05683223|Behavioral|Individual CBT for Social Anxiety Disorder|Participants who show no or only partial response to the initial group CBT will continue with an individual, tailored form of CBT plus adjunctive SSRI. The format of CBT will include
45637098|NCT05682482|Drug|LT3 (liothyronine)|Addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy. To investigate whether addition of LT3 is effective in relieving tiredness.
45637099|NCT05682482|Drug|Placebo|Addition of placebo (LT4 monotherapy) in patients with persistent tiredness on LT4 monotherapy.
45637100|NCT05681715|Drug|Rozanolixizumab|Rozanolixizumab self-administration via Syringe Driver or Manual Push.
45637101|NCT05678010|Drug|AZD1390|Dose level 1: 20 Dose level 2: 40 Dose level 3: 60 Dose level 4: 80
45637102|NCT05678010|Radiation|Stereotactic Body Radiotherapy|Participants will receive Stereotactic Body Radiotherapy/SBRT to 2 sites of metastatic tumors consecutively. The two treatment sites will be randomized to SBRT to one site and SBRT + AZD1390 to the other site. Both sites will receive 30Gy in 5 fractions.
45775674|NCT03008239|Device|FiberSense sensor|The FiberSense system is a glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients ages 18 and older with insulin dependent diabetes mellitus for the purpose of improving diabetes management.
45775675|NCT03008239|Device|Dexcom Sensor|Dexcom is a continuous glucose monitoring (CGM) system. The display device shows the glucose readings and the trend.
45775676|NCT01441843|Drug|Lorazepam|Once 1mg <75kg body weight, 1.5mg 75kg and >75kg body weight, IV, before surgery
45914768|NCT00005817|Other|laboratory biomarker analysis|Correlative studies
45914769|NCT00005820|Drug|nitrocamptothecin|
45914770|NCT00005823|Drug|cytarabine|
45914771|NCT00005823|Drug|daunorubicin hydrochloride|
45637103|NCT05673057|Drug|MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)|"Phase 1 comprises the dose-escalation part of the study and is designed to determine the recommended phase 2a dose regimen (RP2D-R) and/or the maximum tolerated dose-regimen (MTD-R) for MP0533 monotherapy.~Once the RP2D-R or MTD-R has been selected based on the dose escalation part, the study will proceed into the phase 2 expansion part and up to 30 additional patients will be treated."
45637104|NCT05672329|Other|0.2 L/kg/min, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 0.2 L/kg/min using OptiFlow system by Fisher&Paykel and an oxygen inspiration concentration FiO2 of 1.0
45637105|NCT05672329|Other|2 L/kg/min, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 2 L/kg/min using OptiFlow system by Fisher&Paykel and an oxygen inspiration concentration FiO2 of 1.0
45637106|NCT05672329|Other|4 L/kg/min, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 4 L/kg/min using OptiFlow system by Fisher&Paykel and an oxygen inspiration concentration FiO2 of 1.0
45775677|NCT01441843|Drug|NaCl 0.9% (Sodium Chloride)|Once 1ml <75kg body weight, 1.5ml 75kg or >75kg body weight, IV, before surgery
45637107|NCT05672329|Other|2 L/kg/min using OptiFlow-Switch system, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 2 L/kg/min using OptiFlow-Switch system by Fisher&Paykel and an oxygen inspiration concentration FiO2 of 1.0
45637108|NCT05670288|Other|Gut Microbiome|Observe the changes in microbial community, such as bacteria, in the gut within the first year of spinal cord injury
45637109|NCT05668585|Drug|CFT1946|Specified oral dose on specified day
45637110|NCT05668585|Drug|Trametinib|Specified oral dose on specified day
45637111|NCT05667532|Diagnostic Test|Contrast Enhanced Mammography|Screening Modality
45775678|NCT00178646|Drug|Botox|Botox 75-150 units, single treatment only
45448318|NCT00129467|Drug|Placebo|"Subjects assigned to placebo will receive 1 capsule of placebo twice per day (bid) for 3 days and then 2 capsules bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of placebo, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%.~If subjects have side effects when increasing the dose to 2 capsules bid, they will drop back to 1 capsule bid. If the participant develops psychosis or cardiac events, they will be discontinued from the intervention."
45598066|NCT04479423|Procedure|Soda-water instead of pure water to observe gastric filling|All patients underwent a bowel preparation that consisted of a low-residue diet for 24 hours, fluid intake, and ingestion of 2L polyethylene glycol-based electrolyte solution 12 hours before the examination. On the examination day, patients arrived at hospital in the morning after an over night fast (>8hours). Then they would be randomly assigned to controll group or soda group. 40 minutes before capsule ingestion, all patients swallowed 100ml clear water containing 50mg simethicone. During the period, patients were asked to have a proper walk to wash out bubbles. An additional 900ml pure water or 400ml soda-water was drunk to obtain good vision before undergoing MCE examination.
45637112|NCT05662332|Drug|Insulin Efsitora Alfa|Administered SC
45637113|NCT05662332|Drug|Insulin Glargine|Administered SC
45637114|NCT05662241|Drug|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
45637115|NCT05662241|Other|Placebo|Placebo
45637116|NCT05660434|Other|Aroma Inhaler with Bergamot essential oil|The intervention group will receive an aroma inhaler and logbook to use three times a day for 7 days and complete pre and post surveys for comfort, ease, and stress.
45775679|NCT02204761|Radiation|Proton Beam Radiation Therapy|Undergo proton beam re-irradiation therapy
45775680|NCT01089569|Drug|Exenatide|5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
45775681|NCT01089569|Drug|Insulin Glargine|.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
45914772|NCT00005823|Drug|etoposide|
45914773|NCT00005823|Drug|hydroxyurea|
45914774|NCT00005823|Drug|idarubicin|
45914775|NCT00005823|Drug|mitoxantrone hydrochloride|
45914776|NCT00005823|Drug|thioguanine|
45637117|NCT05658575|Drug|Dapansutrile|An initial loading dose of 2000 mg dapansutrile on Day 1 followed by a maintenance regimen of 1000 mg dapansutrile twice daily starting 12 hours later through the second dose on Day 7, inclusive.
45775682|NCT01898234|Device|Revaclear|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
45914777|NCT00005823|Drug|tretinoin|
45914778|NCT00005823|Drug|valspodar|
45914779|NCT00005826|Drug|rubitecan|
45914780|NCT00005829|Drug|gemcitabine hydrochloride|
45914781|NCT00005832|Drug|R115777|300mg/dose BID, PO, Days 1-21, q 28days
45914782|NCT00005838|Drug|shark cartilage extract AE-941|Given orally
45914783|NCT00005838|Other|placebo|Given orally
45914784|NCT00005838|Drug|cisplatin|Given IV
45914785|NCT00005838|Drug|vinorelbine tartrate|Given IV
45914786|NCT00005838|Drug|carboplatin|Given IV
45914787|NCT00005838|Drug|paclitaxel|Given IV
45914788|NCT00005838|Radiation|radiation therapy|Undergo radiotherapy
45775683|NCT01898234|Device|Helixone high flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
45775684|NCT01898234|Device|Xevonta|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
45637118|NCT05658575|Other|Placebo Tablet|An initial loading dose of matching placebo (to mimic dapansutrile dosing) on Day 1 followed by a maintenance regimen of matching placebo twice daily starting 12 hours later through the second dose on Day 7, inclusive.
45775685|NCT01898234|Device|Helixone low flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
45775686|NCT01043939|Other|Purple Grape Juice|6 ounces of purple grape juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
45775687|NCT01043939|Other|Apple Juice|6 ounces of clear apple juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
45775688|NCT01899482|Other|Manual Lymphatic Drainage|
45775689|NCT01899482|Behavioral|Education|Behavioral education.
45775690|NCT03013907|Behavioral|UPLIFT|Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping & Relaxing Session 4: Attention & Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure & the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks
45775691|NCT03013907|Behavioral|Usual care|Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study
45775692|NCT00128180|Drug|Methylprednisolone|Intravenous methylprednisolone 16 mg/kg/day for 3 days as follows: 8 mg/kg (up to 500 mg) given over first hour followed by 8 mg/kg over the next 23 hours; then 16 mg/kg (up to 1000 mg) on days 2 and 3 administered over 24 hours.
45775693|NCT00128180|Drug|Placebo|Placebo
45775694|NCT01899560|Procedure|Measure lung and chest wall elastance with esophageal catheter|"Patients will be in supine position with 30-45° head of bed elevation. The cuff of the endotracheal tube will be transiently overinflated to 60 cmH2O to ensure there will be no air leaks. NMBA (cisatracurium) will be administrated [9]. The fraction of inspired oxygen (FiO2) will be adjusted for continuously monitored oxygen saturation (SpO2) between 90 to 94%. Patients will be ventilated in pressure control with 15 cmH2O of driving pressure.~A low flow pressure/volume curve from 0 to 40 cmH2O will be performed."
45775695|NCT01899560|Other|non-invasive method for measuring the lung elastance|by measuring volume recruited during a change of pressure (∆PEEP/∆EELV)
45914789|NCT00005841|Biological|MART-1 antigen|
45637119|NCT05652725|Dietary Supplement|Clarity Active Study Product 1.1 Usage|Participants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks.
45637120|NCT05652725|Dietary Supplement|Clarity Active Study Product 2.1 Usage|Participants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks.
45775696|NCT01121939|Drug|Bevacizumab|"15 mg/kg IV Day 1. The first dose should be administered over~90 minutes. If no adverse reactions occur after the initial dose, the second dose should~be administered over a minimum of 60 minutes. If no adverse reactions occur after the~second dose, all subsequent doses should be administered over a minimum of 30~minutes. Bevacizumab will be infused prior to pertuzumab."
45914790|NCT00005841|Biological|gp100 antigen|
45598067|NCT02205593|Behavioral|Control|Regular follow-up and treatment WITHOUT behavioural intervention
45598068|NCT02365701|Drug|Motilitone 30mg|30mg of Motilitone in tablet form, to be taken 3 times daily for 4 weeks
45598069|NCT02365701|Drug|Placebo|Placebo, in tablet form, to be taken 3 times daily for 4 weeks. The placebo is the same formulation as Motilitone except that it does not contain the active pharmaceutical ingredient.
45598070|NCT02209415|Behavioral|standard follow-up|Outpatient clinic visits
45598071|NCT02209415|Procedure|PET/CT and EUS|PET/CT and EUS
45914791|NCT00005841|Biological|incomplete Freund's adjuvant|
45914792|NCT00005841|Biological|progenipoietin|
45914793|NCT00005841|Biological|tyrosinase peptide|
45914794|NCT00005844|Drug|oxaliplatin|
45914795|NCT00005850|Drug|cisplatin|80 mg/m2 administered by intravenous (IV) over 30 minutes on Day 1 following the gemcitabine infusion. Treatment repeated every 21 days for a total of 6 cycles.
45637121|NCT05652725|Dietary Supplement|Clarity Active Study Product 3.1 Usage|Participants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks.
45637122|NCT05652725|Dietary Supplement|Clarity Active Study Product 4.1 Usage|Participants will use their Radicle Clarity Active Study Product 4.1 as directed for a period of 6 weeks.
45637123|NCT05652725|Dietary Supplement|Clarity Active Study Product 4.2 Usage|Participants will use their Radicle Clarity Active Study Product 4.2 as directed for a period of 6 weeks.
45637124|NCT05652725|Dietary Supplement|Clarity Active Study Product 4.3 Usage|Participants will use their Radicle Clarity Active Study Product 4.3 as directed for a period of 6 weeks.
45637125|NCT05652725|Dietary Supplement|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
45637126|NCT05652725|Dietary Supplement|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
45637127|NCT05652725|Dietary Supplement|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
45637128|NCT05652725|Dietary Supplement|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
45637129|NCT05644002|Behavioral|Puff Topography Biofeedback Training|"Visit 1: Participants will be asked to smoke their usual brand cigarette using the CReSS smoking topography device. Participants will be instructed on how to follow visual and auditory puffing prompts provided to them by a computer program in order to control puffing behavior for a duration of five minutes.~Visit 2: Participants will be instructed to smoke their cigarette using the CReSS device and instructions provided during Visit 1 after undergoing a brief laboratory stress induction."
45637130|NCT05644002|Behavioral|Control|"Visit 1: Participants will be instructed to smoke their usual brand cigarette using the CReSS smoking topography device while passively viewing time-matched control stimulus presented to them on a computer monitor for a duration of five minutes.~Visit 2: Participants will be instructed to smoke their cigarette using the CReSS device and instructions provided during Visit 1 after undergoing a brief laboratory stress induction."
45637131|NCT05642611|Procedure|Biospecimen Collection|Undergo collection of blood, plasma, and serum
45637132|NCT05642611|Procedure|Cryocompression Therapy|Undergo cryocompression
45637133|NCT05642611|Procedure|Pneumatic Compression Therapy|Undergo continuous compression
45637134|NCT05642611|Procedure|Pneumatic Compression Therapy|Undergo low cyclic compression
45637135|NCT05642611|Other|Quality-of-Life Assessment|Ancillary studies
45637136|NCT05642611|Other|Questionnaire Administration|Ancillary studies
45637137|NCT05641948|Other|MRI scan|Participants will undergo brain MRI scan at 3 intervals
45637138|NCT05636176|Drug|Ziltivekimab|Participants will receive ziltivekimab 15 milligrams (mg) subcutaneous (s.c.) injection once-monthly and added to standard of care for up to 4 years.
45637139|NCT05636176|Drug|Placebo|Participants will receive ziltivekimab placebo subcutaneous (s.c.) injection once-monthly and added to standard of care for up to 4 years.
45637140|NCT05629962|Drug|Bemnifosbuvir (BEM)|BEM tablets administered orally every 12 hours (twice a day) for a total of 5 days
45637141|NCT05629962|Drug|Placebo|Placebo tablets administered orally every 12 hours (twice a day) for a total of 5 days
45637142|NCT05628649|Behavioral|Teaching Kitchen Collaborative Curriculum|"Participants in the intervention arm will first attend 16 weeks of intensive 2-hour classes covering hands-on cooking skills, dietary recommendations (as described within the Harvard Healthy Eating Plate), mindfulness and stress reduction skills, activity and movement techniques, and tools for behavior change. Next, they will attend monthly booster classes for 8 months, with a final assessment for the sustainability of outcomes at 18 months. Sessions will be taught by a combination of a chef educator, dietitian, health coach, or medical doctor.~The study will consist of 2 cohorts of individuals from 4 teaching kitchen program institutions. Each institution will run one-two cycles of the program with each cycle including both a treatment and control group. Each individual cohort will consist of a maximum of 80 individuals; with 40 block-randomized to the intervention and 40 in the control group receiving normal standard of care (followed by their PCP)."
45637143|NCT05627102|Other|Experimental Group|Therapeutic Percutaneous Electrolysis an neuromodulation associated with eccentric exercises devices at home.
45637144|NCT05627102|Other|Conventional group|Ultrasound pulsatil therapy (US), transcutaneous electric nerve stimulation (TENS) for 20 minutes and associated with eccentric exercises devices at home.
45637145|NCT05626777|Drug|Pre-filled syringe, mepolizumab 100 mg/month|Pre-filled syringe, mepolizumab, 100 mg/month, 6 first months of treatment administered by nurse, 6 last months of treatment administered by patient
45637146|NCT05626777|Drug|Auto-injector pen, mepolizumab 100 mg/month|Auto-injector pen, mepolizumab, 100 mg/month 12 months of treatment administered by patient
45637147|NCT05623306|Device|PMT Stereoencephalography (SEEG)|For Stage 1 of this study, we will be implanting depth electrodes to record stereoencephalography across a network of brain regions.
45637148|NCT05623306|Device|Vercise Genus™ Deep Brain Stimulation (DBS) System|For Stages 2 and 3 of this study, we intend to use the DBS system to treat patients with severe symptoms of chronic, treatment-refractory OCD by targeting stimulation to sites that have been determined to have therapeutic benefit during our SEEG Invasive Monitoring phase.
45637149|NCT05617599|Device|SUPRAFLEX CRUZ|Patients in whom treatment with SUPRAFLEX CRUZ has been attempted
45637150|NCT05614024|Other|Real fNIRS Neurofeedback|Participants will be instructed to use real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
45914796|NCT00005850|Drug|fluoxetine|10 mg PO QD (by mouth once daily) starting on week 2 (day 8) and continuing for 7 weeks (days 8-57). After 7 weeks of fluoxetine treatment (day 57), further use of fluoxetine is at the discretion of the patient and physician.
45935586|NCT00127114|Drug|Amantadine|
45935587|NCT00127114|Drug|Placebo|
45637151|NCT05614024|Other|Sham-Control fNIRS Neurofeedback|Participants will be instructed to use sham real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
45775697|NCT01121939|Drug|Pertuzumab|"840 mg IV loading dose infused over 60 minutes. The loading dose is given on Cycle 1, Day 1 or as below. Subsequent doses of pertuzumab are 420 mg IV. If the patient tolerates the initial infusion over 60 minutes, the patient may receive subsequent infusions over 30 minutes. Otherwise, pertuzumab should be infused over 60 minutes. Patients should be observed for 30 minutes after completing the pertuzumab infusion.~If a patient misses a dose of pertuzumab for 1 cycle (i.e., 2 sequential cycles or administrations are 6 weeks or more apart), a re-loading dose (840 mg) of pertuzumab should be given. If re-loading pertuzumab is administered, subsequent doses of 420 mg will then be given every 3 weeks, starting 3 weeks later."
45775698|NCT01121939|Drug|Sandostatin LAR® Depot|30 mg will be given every 28 days by IM injection. The dose of sandostatin may be increased, at the discretion of the treating physician, if necessary to control symptoms related to tumor secretion of vasoactive peptides.
45637152|NCT05613088|Drug|MORAb-202|Specified dose on specified days
45637153|NCT05613088|Drug|Paclitaxel|Specified dose on specified days
45775699|NCT00181610|Drug|Recombinant Human Prolactin|60 mcg/kg every 12 hours
45775700|NCT00181610|Biological|Recombinant human prolactin|60 mcg/kg given every 12 hours or every 24 hours
45637154|NCT05613088|Drug|Pegylated Liposomal Doxorubicin (PLD)|Specified dose on specified days
45637155|NCT05613088|Drug|Topotecan|Specified dose on specified days
45637156|NCT05612971|Behavioral|iAmHealthy Parents First|iAmHealthy Parents first is a 3-month adult obesity treatment program targeting the unique needs of adults with school-age children. Following the iAmHealthy Parents First program, these dyads will take part in a 6-month family-based healthy lifestyles program.
45637157|NCT05612971|Behavioral|Self-Guided|The Self-Guided group will receive newsletters for 3 months. Following this period, these dyads will take part in a 6-month family-based healthy lifestyles program.
45637158|NCT05611957|Drug|LY3437943|Administered SC.
45637159|NCT05611671|Drug|MORF-057|MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
45637160|NCT05611671|Drug|Placebo|Matching placebo (identical appearance to MORF-057) administered orally.
45775701|NCT00181610|Biological|Normal Saline|twice per day
45775702|NCT03013751|Drug|Udenafil|Active drug
45775703|NCT02205307|Device|PINPOINT|
45775704|NCT02205307|Device|SPY Elite|
45914797|NCT00005850|Drug|gemcitabine hydrochloride|1000 mg/m2 intravenous (IV) administered by IV over 30 minutes on days 1 and 8. Repeat treatment every 21 days for a total of 6 cycles.
45637161|NCT05610176|Device|Amvia Sky pacemaker or CRT-P device|Subjects with an indication for a pacemaker or CRT-P device will be implanted with an Amvia Sky device of the Amvia/Solvia pacemaker family according to standard pacemaker implantation procedures. Device programming will be done according to the medical needs of the subjects.
45914798|NCT00005853|Biological|anti-thymocyte globulin|
45637162|NCT05607056|Dietary Supplement|Sinquanon|"This probiotic food supplement includes fourteen probiotic bacterial strains of Lactobacillus Spp, Bifidobacterium Spp., Bacillus coagulans, Saccharomyces boulardii, three prebiotics and Vitamin-B complex - B1, B2, B3, B6, B7, B9 in an enterosolvent cellulose capsule. The product includes supplementary substances: maltodextrin and magnesium stearate.~2 capsules once a day during the antibiotic dosing. 1 capsule a day for 14 days following completion of antibiotic dosing."
45637163|NCT05607056|Dietary Supplement|Placebo|The placebo product will have the same appearance as the active product and the same composition but without the live bacteria, prebiotics, and vitamin-B complex. 2 capsules once a day during the antibiotic dosing. 1 capsule a day for 14 days following completion of antibiotic dosing.
45637164|NCT05606042|Device|IM Implant|Patients that have had surgical interventions with one or more IM Implant as part of standard of care for a pelvic and/or acetabular fracture
45637165|NCT05602454|Other|Digital Heart Failure Medication Titration|Story Health Platform, which is a remote, digital tool that provides treating clinicians collected data to make clinical decisions regarding heart failure medication titration.
45637166|NCT05597748|Device|Modified Herbst Approach|A modified hybrid Herbst appliance approach (same hybrid Herbst appliance approach but with the addition of temporary anchorage devices (TADs) in both arches) will be used (alternative treatment). In the upper arch, the TADs would be inserted in the paramedical palatal area. In the lower arch, they would be inserted buccally between the roots of the lower second premolar and the first permanent molar. Elastomeric chains will be used to link these TADs to the first molars in the upper arch and to a buccal bottom on the lower canines. Upper brackets will be initially bonded and upper incisors proclined until normal inclination values are attained.
45775705|NCT01897844|Drug|ITF2984 (100, 2000, 3000 mcg bid)|
45775706|NCT01897844|Drug|Placebo|
45775707|NCT00131378|Drug|Nutropin AQ growth hormone|Participants will give themselves injections of growth hormone every night for 6 months.
45775708|NCT00131378|Drug|Placebo Growth Hormone|Participants will give themselves injections of placebo growth hormone every night for 6 months.
45775709|NCT01445821|Biological|Peripheral Blood Stem Cells|Mobilized leukapheresis product
45914799|NCT00005853|Biological|etanercept|
45914800|NCT00005856|Drug|oxaliplatin|Given IV
45914801|NCT00005856|Other|pharmacological study|Correlative studies
45914802|NCT00005859|Drug|tipifarnib|
45914803|NCT00005862|Drug|semaxanib|
45914804|NCT00005865|Drug|vinorelbine tartrate|
45914805|NCT00005868|Drug|cisplatin|
45914806|NCT00005868|Drug|docetaxel|
45914807|NCT00005871|Drug|fluorouracil|
45914808|NCT00005871|Drug|rubitecan|
45914809|NCT00005874|Drug|rubitecan|
45914810|NCT00005877|Drug|rubitecan|
45914811|NCT00005880|Drug|budesonide|
45914812|NCT00005883|Drug|phenethyl isothiocyanate|
45914813|NCT00005886|Drug|arzoxifene hydrochloride|
45914814|NCT00005886|Drug|tamoxifen citrate|
45914815|NCT00005889|Drug|alanine|
45914816|NCT00005889|Drug|amino acids|
45914817|NCT00005889|Drug|glucagon|
45914818|NCT00005889|Drug|glucose|
45637167|NCT05597748|Device|Conventional Herbst Approach|A hybrid Herbst appliance approach will be used (current available conventional treatment). The upper jaw component will be a maxillary expander secured on the first molar bands. The lower arch would have an uncemented lower acrylic full-coverage splint-type. In between Herbst-type pistons will be used.
45637168|NCT05596916|Other|High frequency of stretching exercise|"After the randomization and evaluations, the selected postural stretching exercises will be taught to both groups in the clinic, and then a brochure will be given to the participants and they will be asked to practice these exercises at home.~In the experimental group, the exercises will be applied at the specified time and frequency, 5 days a week.~Participants will be given an Exercise Diary and exercise tracking will be provided by calling the participants once a week. The exercises will be done for 6 weeks. Participants will be evaluated twice, before and end of the treatment."
45637169|NCT05596916|Other|Low frequency of stretching exercise|"After the randomization and evaluations, the selected postural stretching exercises will be taught to both groups in the clinic, and then a brochure will be given to the participants and they will be asked to practice these exercises at home.~In the experimental group, the exercises will be applied at the specified time and frequency, 3 days a week.~Participants will be given an Exercise Diary and exercise tracking will be provided by calling the participants once a week. The exercises will be done for 6 weeks. Participants will be evaluated twice, before and end of the treatment."
45775710|NCT01445821|Drug|Cyclophosphamide|An alkylating agent which causes prevention of cell division by forming adducts with DNA
45775711|NCT01445821|Drug|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
45775712|NCT01445821|Drug|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
45914819|NCT00005889|Drug|glutamine|
45637170|NCT05586308|Behavioral|Text-massaging suport|Text-messaging quitting support program (i.e., This is Quitting) is an evidence-based, free mobile program from Truth Initiative designed to help young people quit vaping. The program is fully automated and interactive. To establish or reinforce perceived social norms and social support around quitting, a majority of messages come from other users who have submitted them to the program.
45637171|NCT05586308|Behavioral|Financial incentive|"Participants will earn $3 for each saliva cotinine sample submission regardless of positive or negative results after the quit day (an assessments at Week 6, Week 8, Week 10, and Week 12, during the abstinence phase)~Participants will earn additional escalating rewards for each negative sample- $7 for Week 6, $12 for Week 8, $17 for Week 10, and $22 for Week 12 (2 months after the target quit date). The bonus starts at $7 and increase by $5 for each subsequent negative cotinine sample (i.e., $7, $12, $17, and $22).~A reset contingency will be used. That is the reward amount will be returned back to original $7 if there is a missing or positive saliva cotinine sample"
45637172|NCT05586308|Behavioral|Media literacy|Media literacy e-learning lessons cover topics regarding what e-cigarettes are and how they work, how nicotine and nicotine addiction affects the brain and behavior, how to prepare to quit vaping, developing a quit plan and how to deal with cravings and relapse. The program focuses on changing knowledge, attitudes and beliefs related to e-cigarette use, as well as emphasizing vaping related media literacy.
45637173|NCT05583721|Drug|[13N]NH3|Ammonia N 13 (a radioactive tracer) will be given per intravenous (IV) injection for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.
45775713|NCT01445821|Drug|Methylprednisolone|Steroid
45637174|NCT05583721|Drug|Lexiscan|Given IV prior to PET stress test
45637175|NCT05583721|Diagnostic Test|Positron emission tomography|Participants will complete a onetime PET (stress-rest) myocardial perfusion scan.
45775714|NCT01445821|Drug|Filgrastim|Granulocyte-colony stimulating factor (G-CSF); a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
45775715|NCT01445821|Drug|Fludarabine|Purine analog which inhibits DNA synthesis or repair
45775716|NCT01092767|Device|Valiant Thoracic Stent Graft with the Captivia Delivery System|All subjects will be implanted with this device
45775717|NCT02543892|Biological|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide
45775718|NCT02543892|Biological|Placebo|Normal Saline
45775719|NCT00182000|Drug|seromycin|100mg tablet administered 1 hour prior to each therapy session
45775720|NCT00182000|Behavioral|Behavior Therapy|10 weekly hour-long behavior therapy sessions
45775721|NCT01092923|Drug|sevoflurane on air/O2|sevoflurane on air/O2
45775722|NCT01092923|Drug|sevoflurane in N2O/O2|sevoflurane in N2O/O2
45914820|NCT00005889|Drug|glycerol|
45914821|NCT00005889|Drug|insulin|
45914822|NCT00005889|Drug|leucine|
45914823|NCT00005889|Drug|lipids|
45914824|NCT00005889|Drug|urea|
45914825|NCT00005892|Drug|cyclophosphamide|
45914826|NCT00005892|Procedure|Allogeneic Bone Marrow Transplantation|
45914827|NCT00005898|Drug|anti-thymocyte globulin|
45914828|NCT00005898|Drug|cyclophosphamide|
45914829|NCT00005898|Drug|cyclosporine|
45914830|NCT00005898|Drug|filgrastim|
45914831|NCT00005898|Drug|fludarabine|
45914832|NCT00005898|Drug|methylprednisolone|
45914833|NCT00005910|Procedure|Intraoperative ultrasound|
45914834|NCT00005916|Drug|rV-PSA|
45914835|NCT00005916|Drug|rF-PSA|
45914836|NCT00005916|Drug|rV-B7.1|
45914837|NCT00386412|Drug|Valganciclovir|900 mg/ 12 h oral, 2 weeks 900 mg/ 24 h oral, 2 weeks
45914838|NCT00386451|Device|Catheter locking systems|
45637176|NCT05583110|Drug|Tucatinib|"Run-in Phase:~Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity [DLT] is seen) on days 1 and 8, every 3 weeks.~Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~Oral tucatinib 300 mg BID on a continuous dosing schedule."
45637177|NCT05583110|Drug|Trastuzumab|"Run-in Phase:~Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity [DLT] is seen) on days 1 and 8, every 3 weeks.~Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~Oral tucatinib 300 mg BID on a continuous dosing schedule."
46070221|NCT00701649|Biological|CYT006-AngQb|s.c.
46070222|NCT00701649|Biological|Placebo|s.c.
45637178|NCT05583110|Drug|Vinorelbine|"Run-in Phase:~Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity [DLT] is seen) on days 1 and 8, every 3 weeks.~Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~Oral tucatinib 300 mg BID on a continuous dosing schedule."
45637179|NCT05579899|Drug|EVO101|Topical Cream
45637180|NCT05573126|Drug|EP0062|EP0062 is an orally administered investigational selective androgen receptor modulator (SARM)
45637181|NCT05572671|Behavioral|Laboratory task modeling smoking lapse behavior|Participants will complete a task (the behavioral intervention) designed to model smoking lapse behavior in the laboratory; during the task, they will be given the option of delaying smoking in exchange for monetary reinforcement.
45637182|NCT05570604|Behavioral|Sweep Seeker|The person is asked to clear the rows of blocks presented on the screen, either by moving them into horizontal or vertical blocks that have identical color. The goal is to refine and increase the response of primary visual cortex neurons and to enable the person to increase speed and accuracy of visual processing (executive function) and visual memory.
45637183|NCT05570604|Behavioral|Bird Safari|The user is first presented with a target bird. Subsequently, a group of birds is presented in the peripheral vision and then disappears when the trial begins. The user selects the section of the screen where the target bird appeared. The presentation speed adapts with user performance (i.e. better performance = faster presentation). The goal is to improve speed and accuracy of object identification in peripheral vision and improve visual precision important for improving memory.
45637184|NCT05570604|Behavioral|Jewel Diver|The person is first presented objects (jewels) on the screen. The objects are then covered with occluders (bubbles) and then identical distracters are presented. The objects move around in screen and when the movement stops, the user chooses the occluders that cover the jewels. The number of jewels adapts to performance (more jewels = better performance). The goal is to improve divided visual attention, sustained visual attention, visual working memory, and visual precision.
45637185|NCT05570604|Behavioral|Master Gardener|The person is presented a series of target stimuli and distracters which are presented at one time and then disappear. The locations of the stimuli are marked by icons, and the user chooses the icons where the target stimuli were once located. The goal is to increase speed and accuracy as well as the ability to extract information accurately.
45775723|NCT03013049|Procedure|Non cultured epidermal cell suspension|Non cultured epidermal cell suspension Split thickness skin specimen will be transferred under aseptic conditions to a container with normal salineand transferred to laboratory. There, the skin graft will be transferred to Trypsin-EDTA solution (0.25% trypsin and 0.02% EDTA) in a Petri dish and incubated overnight at 4°C in 5% CO2 to separate the epidermis from the dermis.Afterwards, the Trypsin-EDTA solution will be removed and PBS will be added and pipetted well so as to separate the cells from the tissue.The suspension will be centrifuged at 1000 rpm for 5 minutes.The supernatant will then be discarded and Phosphate buffer saline is added to make suspension of non-cultured epidermal cells.
45914839|NCT00386490|Drug|larazotide acetate|capsule for oral administration
45935588|NCT00043784|Drug|enoxaparin|
45935589|NCT00127153|Biological|V110, pneumococcal vaccine polyvalent|
45935590|NCT00399477|Drug|rasagiline mesylate|Azilect®
45935591|NCT00399477|Drug|Rasagiline mesylate plus Mirapex|Mirapex, Azilect®
45935592|NCT00399477|Drug|Rasagiline mesylate with Levodopa|Azilect®, Levodopa
45935593|NCT00399477|Drug|Rasagiline mesylate with Requip|Azilect®, Requip
45935594|NCT00127270|Drug|Darifenacin|Darifenacin tablets 7,5 mg once daily with the possibility to up-titrate to 15 mg once daily
45935595|NCT00127270|Drug|Darifenacin|Darifenacin tablets 7,5 mg or 15 mg once daily
45935596|NCT00127270|Behavioral|Behavioral therapy|Behavioral Modification Programme for symptoms of overactive bladder
46070223|NCT00846495|Drug|topiramate|topiramate 25mg 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 2 tabs in PM x 1 week topiramate 25mg 2 tabs in AM / 2 tabs in PM x 5 weeks
45637186|NCT05570604|Behavioral|Road Tour|The person is presented with a target vehicle briefly in both the center of the screen and in one of eight locations in the periphery. Two vehicles are then presented briefly in the center of the screen, one of which is the target vehicle. The user must identify the location of the target vehicle in the periphery as well as identify which was the target vehicle that appeared in the center. The goal of this activity is to improve divided attention and ability to extract information and discard irrelevant information from peripheral vision.
45637187|NCT05570604|Behavioral|Computerized Crossword Puzzles|The program offers a pre-determined set of computerized crossword puzzles. The site has over 100,000 puzzles and can be accessed easily via the web and are free to users. The computerized crossword puzzles do not provide for progressive challenges of increasing speed, visual field size, number of distractors or degree of difficulty of targeted stimulus differentiation.
45637188|NCT05565937|Device|BL-3100-NBR03 multi-purpose solution|BL-3100-NBR03 multi-purpose solution used to clean and disinfect contact lenses
45637189|NCT05565937|Device|renu® Advanced Formula multi-purpose solution|renu® Advanced Formula multi-purpose solution used to clean and disinfect contact lenses
45637190|NCT05564039|Drug|Tirzepatide|Administered SC
45637191|NCT05564039|Drug|Dulaglutide|Administered SC
45637192|NCT05556265|Drug|Deucravacitinib|Specified dose on specified days
45637193|NCT05556265|Other|Placebo|Specified dose on specified days
45637194|NCT05552118|Procedure|Cochlear™ Remote care|"Cochlear™ Remote Check is a virtual assessment tool which helps the clinician to monitor the participant hearing progress remotely. It allows the participant to complete a series of hearing tests using the Cochlear™ Nucleus® Smart App then electronically send the results to the clinician for review.~Cochlear™ Remote Assist enables a video call appointment through the Cochlear™ Custom Sound® Pro software and the Nucleus® Smart App. When remote check requires further follow-up, it allows the clinician to make programming adjustments and sound processor settings without a clinic visit."
45637195|NCT05552118|Procedure|Standard of care|Routine in clinic face-to-face care and sound processor programming using Cochlear™ Custom Sound® Pro
45637196|NCT05552118|Device|Cochlear Implant CI600 Series, CI500 Series or Freedom Series and Sound processor Nucleus 7 or Kanso 2 (or latest compatible Sound Processor)|CI600 Series (CI612, CI622, CI632), CI500 Series (CI512, CI522, CI532), Freedom Series (CI24RE(CA), CI24RE(ST), CI422). Nucleus 7 (CP1000) or Kanso 2 (CP1050)
45637197|NCT05545111|Drug|NBI-1117568|Active treatment with orally administered NBI-1117568
45775724|NCT03013049|Procedure|Non cultured dermal cell suspension|Non-cultured Dermal Cell Suspension Skin punch will be collected in phosphate buffer saline (PBS) with antibiotics (penicillin and streptomycin). The epidermis will be cut off from dermis carefully using a surgical blade (Epidermal part will be used for the epidermal cell suspension). Dermis will be then cut into small pieces and incubated in collagenase (1mg/ml) overnight at room temperature. Next day content will be diluted with PBS and centrifuged at 1000rpm for 5 minutes. Pellet will be washed three times with PBS to remove collagenase activity. Phosphate buffer saline is added to make suspension of non-cultured dermal cells and will be used for the autologous transplantation.
45775725|NCT03013439|Drug|Iron Isomaltoside|The trial is a dose escalating trial.
45775726|NCT00131456|Drug|Venlafaxine|375mg/day
45914840|NCT00386529|Drug|Aspirin enteric coated pellests 100mg|
45637198|NCT05545111|Drug|Placebo|Placebo matching NBI-1117568
45775727|NCT00131456|Drug|Placebo|Placebo
45775728|NCT05461872|Other|No intervention|No intervention
45775729|NCT05418816|Device|SelfWrap Bioabsorbable Perivascular Wrap|SelfWrap is applied during the normal arteriovenous fistula (AVF) creation procedure. It provides mechanical support to the vein and induces outward remodeling to improve maturation and patency of AVFs.
45775730|NCT01897922|Other|An investigational infant formula containing a probiotic source|
45775731|NCT01897922|Other|Control: Marketed routine infant formula|
45914841|NCT00005922|Behavioral|Partial schedule of pharmacotherapeutic reinforcement|Dose of 0.1% of Aristocort A on 1-2 of every 4 days for a period of up to 14 weeks.
45914842|NCT00005922|Drug|Dose control for Arm B|Dose of 0.025-0.05% of Aristocort A 2 times per day for a period of up to 14 weeks.
46070224|NCT00846495|Drug|frovatriptan|frovatriptan 5mg tab during premonitory phase of migraine
45637199|NCT05537935|Drug|Low Dose Naltrexone|Subjects will be started with 3mg LDN orally administered daily for one week with a planned increase to 4 mg/day beginning week two, if tolerated. They will be provided a 4 week supply of study medication. The most common side effects are difficulty sleeping and vivid dreams, which is seen more frequently with nighttime dosing, so LDN will be given as a daytime dose.
45637200|NCT05526248|Drug|Darolutamide(BAY1841788, Nubeqa)|tablet, oral
45637201|NCT05526248|Drug|Enzalutamide|tablet, oral
45637202|NCT05522673|Drug|11(R)-rolipram|Injected IV followed by PET scanning
45637203|NCT05516758|Drug|Peresolimab|Administered subcutaneously (SC)
45637204|NCT05516758|Drug|Placebo|Administered SC
45637205|NCT05508789|Drug|Donanemab|Administered IV
45637206|NCT05508789|Drug|Placebo|Administered IV
45637207|NCT05496998|Device|Medtronic Intrepid™ TMVR TF System|Patients with moderate-to-severe or severe symptomatic mitral regurgitation will have a Transcatheter Mitral Valve Replacement with the Medtronic Intrepid™ TMVR Transfemoral System
45637208|NCT05483933|Drug|Pegylated Liposomal Doxorubicin + SL-172154|The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
45775732|NCT01093469|Drug|Atopiclair Nonsteroidal Cream|
45775733|NCT01093469|Other|Aquaphor Healing Ointment|
45775734|NCT01093469|Drug|EpiCeram|
45914843|NCT00005922|Other|Standard pharmacotherapeutic protocol|Full dose of Aristicort A (0.1%) 2 times per day for a period of up to 14 weeks.
45914844|NCT00005925|Drug|Muscimol|
45914845|NCT00005928|Drug|Ramipril|
45914846|NCT00005931|Drug|SU5416|
45914847|NCT00005934|Drug|5-Azacytidine|
45914848|NCT00005940|Radiation|iodine I 131 monoclonal antibody BC8|Given IV
45914849|NCT00005940|Drug|busulfan|Given PO
45914850|NCT00005940|Drug|cyclophosphamide|Given IV
45775735|NCT05461482|Other|Pre-procedural consultation and audiovisual tools|In addition to the information provided by the referring physician, an interventional radiologist will assist the patient in a consultation before the intervention to inform him, explaining the objective of the intervention, its risks and benefits, and possible alternatives and doubts related to the intervention. In this group, educational videos will be used, one for each type of intervention, which will complement the explanations of the physician. The videos will aim to present in an understandable way the preparation for the intervention, its objective, the benefits and risks that derive from it and what you can expect once it has been carried out. Patients will have access to the videos before attending the consultation and will view them before being seen by the interventional radiologist.
45637209|NCT05483933|Drug|Mirvetuximab + SL-172154|The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
45637210|NCT05478499|Drug|Deucravacitinib|Specified dose on specified days
45775736|NCT01045187|Radiation|brachytherapy|Electronic brachytherapy dose 21 Gy or 22 Gy in 3-4 fractions prescribed to 5mm depth, or electronic brachytherapy 16-18 Gy if EBRT is administered.
45775737|NCT01045187|Radiation|Xoft Axxent Electronic Brachytherapy System|21-22 Gy in 3-4 fractions to 5mm or 16-18 Gy in 3 fractions prescribed to the surface.
45775738|NCT02543658|Drug|Neostigmine Methylsulfate 1 MG/ML|The initial dose was 1mg, intramuscular injection(IM) once every 12 hours. If there is no defecation after 12 hours, the dose is increased to 1mg IM once every 8 hours; if there is no defecation after 24 hours, the dose is increased to 1mg IM once every 6 hours. If the abdominal pressure drops below 12mmhg, neostigmine will be stopped, otherwise it will be used continuously for 7 days.
45775739|NCT02543658|Combination Product|Conservative treatment|Intragastric administration of paraffin oil, 50ml,once every 8 hours；gastrointestinal decompression with nasogastric tube and rectal tub; lycerin enema promotes defecation; patients with ascites undergo percutaneous puncture drainage. Other conservative medical treatment recommended by the guidelines.
45637211|NCT05478499|Other|Placebo|Specified dose on specified days
45775740|NCT01045265|Other|Seminal plasma pharmacokinetics|Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.
45775741|NCT00183092|Drug|Quinacrine|100mg by mouth three times a day
45775742|NCT00183092|Drug|Placebo|100mg by mouth three times a day
45775743|NCT05445258|Device|InnoCath AB® hyper-compliant balloon catheter|endovascular treatment of lesions in the superficial femoral artery (SFA) and/or popliteal artery pars I/II without further luminal widening, and/or for short-term interruption of blood flow with the InnoCath AB® hyper-compliant balloon cathe-ters (100 or 200 mm length)
45775744|NCT01045499|Device|Laparoscopic adjustable gastric banding (Allergan Lap Band)|Pre-op evaluation, surgical placement of a gastric band, and follow-up for a minimum of 5 years after surgery. Surgery is laparoscopic adjustable gastric band placement using a single brand of gastric band. Evaluations before and after surgery include but are not limited to history and physical examination, serum chemistry studies, imaging, sleep studies, and pulmonary function testing.
45775745|NCT00132002|Drug|vorinostat|Given PO
45775746|NCT00132002|Other|laboratory biomarker analysis|Correlative studies
45914851|NCT00005940|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic PBSC or bone marrow transplant
45914852|NCT00005940|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC or bone marrow transplant
45914853|NCT00005940|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC or bone marrow transplant
45914854|NCT00005940|Drug|cyclosporine|Given IV or PO
45914855|NCT00005940|Drug|methotrexate|Given IV
46070225|NCT02612805|Other|Aerobic training|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.
45637212|NCT05477134|Other|Stable isotope infusion, oral glucose ingestion, intravenous arginine bolus|On separate study days, each participant will have a stable isotope infusion, ingest oral glucose, and be given an intravenous arginine bolus.
45637213|NCT05469802|Biological|Purified Inactivated Zika Virus Vaccine (PIZV)|PIZV vaccine with aluminium hydroxide adjuvant IM injection.
45637214|NCT05469802|Other|Placebo|Placebo (normal saline (0.9% NaCl) IM injection.
45637215|NCT05461014|Behavioral|dCBI|"The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation. The coaches are trained to provide assistance with adult care transition readiness."
45914856|NCT00005940|Other|laboratory biomarker analysis|Correlative studies
45914857|NCT00005943|Biological|aldesleukin|
45775747|NCT00183794|Drug|Docetaxel and Gemcitabine|Docetaxel 75 mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8 of each 3 weeks (21 days) cycle.
45775748|NCT00270296|Drug|Trizivir|300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
45775749|NCT00270296|Drug|Lamivudine/Zidovudine|150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
45775750|NCT00270296|Drug|Lopinavir/Ritonavir|400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
45775751|NCT00270296|Drug|Nevirapine|200 mg tablet taken orally daily for the first 14 days before receiving 200 mg tablet taken orally twice daily
45775752|NCT00270842|Behavioral|Tai Chi|This intervention is a 10 week Tai Chi group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
45775753|NCT00270842|Behavioral|Functional Balance|This intervention is a 10 week Functional Balance group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
45637216|NCT05459233|Procedure|Doppler-echocardiography|The TAVR (valve-in-valve) procedure will be performed with the SAPIEN 3 Ultra valve, with valve sizing according to current manufacturer recommendations. Following valve implantation, further intervention will be based on Doppler-echocardiographic measurements. Balloon post-dilation with a non-compliant balloon will be performed in the presence of a residual mean gradient ≥20 mmHg as assessed by Doppler-echocardiography.
45775754|NCT00270842|Behavioral|Education Control group|This control group participated in 10 weeks of general health education classes.
45775755|NCT01046669|Device|TORAYMYXIN PMX-20R (PMX cartridge)|TORAYMYXIN PMX-20R (PMX cartridge), Extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
45637217|NCT05459233|Procedure|Invasive hemodynamic measurements|The TAVR (valve-in-valve) procedure will be performed with the SAPIEN 3 Ultra valve, with valve sizing according to current manufacturer recommendations. Following valve implantation, further interventions will be based on invasive hemodynamic measurements (with simultaneous aortic and ventricular pressure recording). Balloon post-dilation will be performed with a non-compliant balloon in the presence of a mean residual gradient ≥20 mmHg as assessed by hemodynamic measurements.
45775756|NCT01046669|Other|Standard medical care for septic shock|Standard medical care for septic shock
45775757|NCT01047527|Drug|Transdermal nicotine patch|Transdermal nicotine, 21mg/day
45775758|NCT03013127|Drug|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy.
45775759|NCT01047839|Biological|IC51|0.25 ml, 2 i.m. vaccinations at Day 0 and 28
45775760|NCT01047839|Biological|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
46070226|NCT02612805|Other|Combined training|"Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic more resistance training.~Aerobic component (between 30 and 40 minutes of the sessions): Method: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.~Resistance component (Between 10 and 20 minutes of the sessions): Method: Multiple sets (2 to 4 sets of 30 to 15 seconds) in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: Maximum execution speed."
45775761|NCT01047839|Biological|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
45775762|NCT03013829|Behavioral|KPD Educational Video|LKDs and recipients assigned to the video-based KPD education group will receive the same living donation and KPD educational materials as those in the UC group. Also, as in the UC group, they will be encouraged by the site coordinator to review the educational materials. In addition, following randomization to this group, participants will be sent an email encouraging them to watch an embedded KPD education video. This video will be professionally designed and will highlight the operational features of KPD and address the specific barriers highlighted in our formative research. The primary goal of these sessions is to increase living donation and KPD knowledge of risks and benefits and to reduce specific concerns that are based on inaccurate information. The intent is not to persuade LKDs or recipients to pursue living donation or KPD, but to ensure that they have sufficient information to make an informed choice that is consistent with their own values and preferences.
45775763|NCT01048697|Drug|Ethambutol|"All volunteers in each category will receive a single dose of oral ethambutol based on American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American (ATS/CDC/IDSA) TB treatment guidelines.1 We will not use any doses higher than the maximum dose recommended for daily administration by the current ATS/CDC/IDSA TB guidelines (which use ideal body weight for dosing):~40-55kg: 800 mg (two 400 mg tablets) 56-75kg: 1,200 mg (three 400 mg tablets) 76-90kg: 1,600 mg (four 400 mg tablets) > 90 kg: No dosage recommendations so these volunteers will only receive 1,600 mg (four 400 mg tablets)"
45775764|NCT01049243|Drug|Fluocinonide Cream 0.1%|0.1% Cream, One Application, Twice Daily, 14 Days
45775765|NCT03013205|Procedure|Intraarticular triamcinolone injection|triamcinolone 10mg/mL
45637218|NCT05456893|Procedure|Procedure: endoscopic biopsy|Per-endoscopic biopsies
45637219|NCT05456893|Procedure|Blood sampling|Blood sampling
45637220|NCT05456893|Procedure|stool sampling|stool sampling
45775766|NCT03013205|Procedure|Intraarticular Xylocaine injection|Xylocaine 1% 4ml
45775767|NCT03013205|Procedure|Coracohumeral ligament triamcinolone injection|triamcinolone 10mg/mL
45775768|NCT03013205|Procedure|Physiotherapy|
45775769|NCT03013283|Other|self questionnaire|"Interface side effects and degree of satisfaction of the patients~Technician evaluation and device measures."
45775770|NCT01094717|Drug|Acitretin 25Mg Oral Capsule|Acitretin 25 mg oral daily for 12 weeks
45775771|NCT01094717|Device|Excimer laser|Lesions on randomly assigned left or right side of body were treated with 308nm excimer laser.
45775772|NCT01094717|Drug|Tazarotene 0.1% Gel,Top|Topical tazarotene 0.1% gel was applied daily to active lesions.
45914858|NCT00005943|Biological|staphylococcal enterotoxin B|
45914859|NCT00005946|Biological|filgrastim|
45637221|NCT05456256|Drug|LP-300|LP-300: 18.4 g/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
45914860|NCT00005946|Biological|therapeutic allogeneic lymphocytes|
45914861|NCT00005946|Drug|cyclophosphamide|
45637222|NCT05456256|Drug|Pemetrexed|Pemetrexed: 500 mg/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. After completion of the 4 to 6 cycles, patients will have the option to continue pemetrexed maintenance therapy until disease progression, unacceptable toxicity, or patient preference/physician discretion. The number of treatment cycles will be determined by PI discretion.
45637223|NCT05456256|Drug|Carboplatin|Carboplatin: area under the concentration-time curve 5 mg/mL per minute (AUC5) by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
45775773|NCT01094717|Device|Sham excimer laser|Lesions on randomly assigned left or right side of body were treated with sham excimer laser (opaque cover on the laser device).
45637224|NCT05455697|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
45637225|NCT05455697|Drug|Cyclophosphamide|Given IV
45637226|NCT05455697|Drug|Doxorubicin|Given IV
45637227|NCT05455697|Drug|Prednisone|Given PO
45637228|NCT05455697|Biological|Retifanlimab|Given IV
45637229|NCT05455697|Biological|Rituximab and Hyaluronidase Human|Given SC
45637230|NCT05455697|Biological|Tafasitamab|Given IV
45637231|NCT05455697|Drug|Vincristine|Given vincristine
45637232|NCT05455697|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
45775774|NCT01095497|Biological|CINRYZE|C1 esterase inhibitor (human)
45637233|NCT05455697|Procedure|Multigated Acquisition Scan|Undergo MUGA
45637234|NCT05455697|Other|Fludeoxyglucose F-18|Undergo FDG-PET/CT
45775775|NCT05308121|Other|Evaluation of biomechanics and viscoelastic properties of Achilles tendon|The biomechanical and viscoelastic properties of the Achilles tendon will be measured in the side lying position. Measurements will be taken from three different points with the ankle in the neutral position.
45914862|NCT00005946|Drug|etoposide|
45637235|NCT05455697|Procedure|Positron Emission Tomography|Undergo FDG-PET
45914863|NCT00005949|Biological|aldesleukin|Given SC
46070227|NCT02612805|Other|Training placebo|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Activities performed in main part: Stretching and relaxation in aquatic environment.
45637236|NCT05455697|Procedure|Computed Tomography|Undergo FDG-CT
45637237|NCT05455697|Procedure|Biospecimen Collection|Undergo collection of blood samples
45637238|NCT05447897|Other|Qualitative Group Interviews|One time interview, 60-90 minutes
45637239|NCT05447897|Other|Stakeholder advisory group|The team will meet with the stakeholder advisory group four times for 1-2 hours each
45637240|NCT05440851|Other|Ultra-Protective Ventilation Facilitated by Extracorporeal Support|Patients randomized to the intervention group will receive VV-ECMO with the ventilator set to minimize driving pressure and respiratory rate for ultra-protective ventilation.
45914864|NCT00005949|Biological|gp100:209-217(210M) peptide vaccine|Given SC
45914865|NCT00005949|Other|laboratory biomarker analysis|Correlative studies
45914866|NCT00005952|Biological|filgrastim|
45914867|NCT00005952|Drug|temozolomide|
45637241|NCT05440851|Other|Lung-Protective Ventilation (LPV)|Patients randomized to LPV will receive standard of care lung-protective ventilation with conventional limits on tidal volume and plateau airway pressure.
45637242|NCT05440851|Other|Driving Pressure-Limited Ventilation (DPL)|Patients randomized to DPL will receive mechanical ventilation set to maintain a safe limit on driving pressure and plateau airway pressure, without less for the tidal volume.
45637243|NCT05440851|Other|Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS)|Patients randomized to LDPVS will have ventilation and sedation adjusted to maintain lung-distending pressure and respiratory effort in a safe target range.
45637244|NCT05440851|Drug|Early Cohort corticosteroid dose|Patients randomized to receive corticosteroids will receive dexamethasone 20mg daily for 5 days and then 10mg for an additional 5 days, for a total of 10 days from the time of randomization (or until ICU discharge or death, whichever comes first); after 10 days dexamethasone will be stopped without a taper.
45914868|NCT00005952|Procedure|peripheral blood stem cell transplantation|
45914869|NCT00005955|Drug|temozolomide|
45914870|NCT00005958|Biological|filgrastim|
45914871|NCT00005958|Drug|docetaxel|
45914872|NCT00005958|Drug|gemcitabine hydrochloride|
45914873|NCT00005961|Drug|O6-benzylguanine|
45914874|NCT00005961|Drug|carmustine|
45914875|NCT00005964|Biological|filgrastim|
45914876|NCT00005964|Drug|cyclophosphamide|
45914877|NCT00005964|Drug|doxorubicin hydrochloride|
45914878|NCT00005964|Drug|etoposide|
45914879|NCT00005964|Drug|prednisone|
45914880|NCT00005964|Drug|vincristine sulfate|
45914881|NCT00005967|Drug|tipifarnib|
45914882|NCT00005970|Drug|Aromatase Inhibition Therapy|Given orally
45914883|NCT00005970|Drug|Cyclophosphamide|Given IV
45914884|NCT00005970|Drug|Doxorubicin Hydrochloride|Given IV
45914885|NCT00005970|Other|Laboratory Biomarker Analysis|Correlative studies
45914886|NCT00005970|Drug|Paclitaxel|Given IV
45914887|NCT00005970|Drug|Tamoxifen Citrate|Given orally
45914888|NCT00005970|Biological|Trastuzumab|Given IV
45914889|NCT00005973|Drug|BMS-214662|Given IV
45914890|NCT00005973|Other|laboratory biomarker analysis|Correlative studies
45914891|NCT00005976|Drug|carboplatin|
45637245|NCT05440851|Drug|Extended Cohort corticosteroid dose|Patients randomized to receive extended corticosteroids will receive dexamethasone 10mg for an additional 10 days. At the end of the additional 10 days (day 20 of corticosteroids), the dexamethasone dose will be halved to 5mg for another 5 days (to reduce the risk of adrenal insufficiency) and then stopped (a total of 25 days or until ICU discharge or death, whichever comes first).
45637246|NCT05440851|Drug|Usual care without routine corticosteroids|Patients randomized to this arm will be managed according to usual care. They will receive corticosteroids only if prescribed by the clinician.
45637247|NCT05440851|Drug|Usual care without extending corticosteroids|Corticosteroids will stop after 10 days. Other management will be according to usual care. Patients will receive corticosteroids only if prescribed by the clinician.
45637248|NCT05440786|Drug|Abemaciclib|Orally
45637249|NCT05440786|Drug|Irinotecan|IV
45637250|NCT05440786|Drug|Temozolomide|Orally
45637251|NCT05419076|Radiation|Stereotactic Radiosurgery|All participants will undergo MSK standard SRS. A CT simulation will be performed per institutional standards, typically with contrast unless a contraindication exists. A contrast-enhanced MRI with 1mm slices will be fused to the CT simulation scan for the purposes of SRS planning. The SRS GTV will be considered the visible tumor on MRI and CT contrast enhanced studies. An expansion of 1-2mm will be used to create the PTV. Radiation dose may be between 16Gy and 30Gy in 1 to 5 fractions, per the discretion of the treating radiation oncologist. Participants with multiple lesions may receive different doses to each lesion per the discretion of the treating radiation oncologist. Concurrent treatment to other body sites is permitted.
45637252|NCT05419076|Procedure|Cerebrospinal fluid collection|All participants will undergo lumbar puncture for CSF collection at study enrollment.. Lumbar punctures will be performed by clinical staff in neurology or neuroradiology, per the discretion of the treating radiation oncologist, as dictated by scheduling limitations and expected clinical difficulty in obtaining a sample (e.g. requiring fluoroscopic guidance), with input from the PI, neurology, and/or neuroradiology as necessary. Participants will be encouraged to undergo repeat lumbar puncture for CSF collection at 3 months (+/- 4 weeks), and at the time of CNS disease progression, though these latter timepoints are not required. CSF cytology will be evaluated.
45637253|NCT05411679|Drug|EP0057|EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously
45637254|NCT05411679|Drug|Olaparib tablets|Olaparib is a PARP inhibitor (poly [adenosine diphosphate-ribose] polymerase inhibitor) Other names: Lynparza
45637255|NCT05409105|Dietary Supplement|Mangoes|Frozen mangoes, 2 cups per day, 2 weeks
45637256|NCT05409105|Dietary Supplement|Water|2 cups/day bottled water, 2 weeks
45637257|NCT05407636|Genetic|RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)
45637258|NCT05407636|Genetic|RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)
45637259|NCT05407636|Biological|Aflibercept (EYLEA®)|"2.0 mg (0.05 mLsolution) administered by intravitreal injection approximately every 8 weeks after 3 monthly injections~Other Names:~• Eylea (anti-VEGF agent)"
45637260|NCT05406479|Drug|BE-PEP (Bedaquiline)|Single dose of Bedaquiline
45637261|NCT05406479|Drug|SDR-PEP|Single dose of Rifampicin
45637262|NCT05406479|Drug|BE-PEP (Rifampicine)|Single dose of Rifampicin
45775776|NCT05308043|Diagnostic Test|Deep learning algorism|A deep learning algorism that was developed previous would be applied to identify retinoblastoma tumours on Retcam images and distinguish between active and inactive retinoblastoma tumours. The decision of two different senior ophthalmologists would be the gold standard.
45775777|NCT01095887|Drug|Eculizumab|Subjects received eculizumab intravenously at the time of transplant, on the day after transplant, then weekly for four weeks. At four weeks post transplant, anti-blood group antibody levels were determined. Subjects may have potentially received eculizumab every two weeks for one year depending on antibody levels.
45637263|NCT05400837|Combination Product|Corrie Virtual Atrial Fibrillation Management Program|Intervention aims to implement guideline-recommended Afib care
45637264|NCT05399888|Drug|BIIB080|Administered as specified in the treatment arm.
45637265|NCT05399888|Drug|BIIB080-matching placebo|Administered as specified in the treatment arm.
45637266|NCT05398341|Device|The BEAR® Implant|"The BEAR Implant is a bovine collagen-based implant. The bovine tissue is sourced from countries that are free of bovine spongiform encephalopathy [BSE] and is further treated to remove bovine cell fragments and DNA.~The BEAR® (Bridge Enhanced ACL Restoration) Implant is a bovine extracellular matrix collagen-based implant for treatment of anterior cruciate ligament (ACL) injuries. The BEAR® Implant is indicated for skeletally mature subjects at least 14 years of age with a complete rupture of the ACL. Subjects must have an ACL stump attached to the tibia to construct the repair."
45775778|NCT05307731|Drug|Fingolimod|0.5mg daily for 90-180 days, in addition to guideline-based treatment for DM
45775779|NCT05307731|Drug|guideline-based treatment for DM|guideline-based treatment for DM
45775780|NCT01096823|Behavioral|Iyengar Yoga|Iyengar Yoga classes twice a week for six weeks
45775781|NCT03110315|Drug|Suvorexant|See detailed information in associated Arm Description.
45775782|NCT03110315|Drug|Placebo|Sugar pill manufactured to mimic suvorexant 10 mg tablet.
45775783|NCT02983487|Procedure|Nasopharyngeal sampling|Nasopharyngeal sample by aspiration or swabbing
45775784|NCT02983487|Procedure|Blood Sampling|Blood sample by the tip of a finger (fingerprick)
45637267|NCT05384665|Drug|Remifentanil|REMIFENTANIL, 5 µg/cc, solution for injection, 0.5 µg/kg, parenteral (intravenous) route, injection delay of 30 seconds, once only
45637268|NCT05384665|Drug|Sufentanil|SUFENTANIL, 5 µg/cc, solution for injection, 0.2 µg/kg, parenteral (intravenous) route, bolus over 5 seconds, once
45637269|NCT05384665|Drug|Placebo|PLACEBO contains 0.9% NaCl, parenteral (intravenous), bolus, one-time
45637270|NCT05380505|Behavioral|Racially Congruent Ads|Facebook food ads that are racially congruent.
45637271|NCT05380505|Behavioral|Racially Incongruent Ads|Facebook food ads that are racially incongruent.
45637272|NCT05379829|Drug|Ziltivekimab|Participants will be administered 3 doses subcutaneously (s.c.) every four weeks (Q4W).
45775785|NCT03013595|Behavioral|TRAM feedback|
45775786|NCT05307341|Drug|sufentanil|One dose of sufentanil 30 mcg sublingual pre-operatively upon entry to operating room and one dose of sufentanil 30 mcg sublingual in the PACU.
45914892|NCT00005976|Drug|pyrazoloacridine|
45637273|NCT05379829|Drug|Placebo|Participants will be administered 3 doses s.c. Q4W.
45637274|NCT05377359|Device|Recordings of Hearing Aids with Open Domes|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled to open domes. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
45637275|NCT05377359|Device|Recordings of Hearing Aids with Closed Domes|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with closed domes. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
45637276|NCT05377359|Device|Recordings of Hearing Aids with Novel State 1|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with the new coupling method in its first state. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
45637277|NCT05377359|Device|Recordings of Hearing Aids with Novel State 2|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with the new coupling method in its second state. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
45637278|NCT05372419|Drug|Lebrikizumab|Administered SC
45637279|NCT05371717|Other|Domiciliary use of Biorepair Total Protection + Biorepair Shock Treatment|Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.
45637280|NCT05371717|Other|Biorepair Total Protection|Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.
45637281|NCT05364502|Device|Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter|The Embrace Hydrogel Embolic System (HES) is indicated for embolization of peripheral arterial bleeds in vessels ≤6mm
45637282|NCT05363319|Drug|Cemiplimab|solution for injection via intravenous (IV) infusion
45637283|NCT05357989|Drug|Buntanetap|HPMC (vegetarian source) capsule shells
45637284|NCT05357989|Drug|Placebo|HPMC (vegetarian source) capsule shells
45637285|NCT05355753|Drug|CFT8634|Oral dose of CFT8634
45637286|NCT05354544|Biological|Autologous adipose derived SVF|A single dose of autologous adipose derived SVF isolated from adipose tissue will be administered to scarred vocal folds.
45637287|NCT05354453|Drug|BI 1839100|BI 1839100
45637288|NCT05354453|Drug|Placebo|Placebo
45637289|NCT05354453|Drug|allyl isothiocyanate (AITC)|allyl isothiocyanate (AITC)
45637290|NCT05353998|Other|CDS with Sleep Navigation|The Sleep Navigation program will involve 1-3 meetings between the Sleep Navigator (SN) and the participating family. Participants will also complete baseline and post-intervention assessments, and about 10 to 15 caregivers will be randomly invited to participate in an interview on the acceptability and feasibility of the program. The SN will provide: SDB and sleep health psychoeducation using Patient-Family Education handouts and videos that are currently part of usual care practices; Care coordination for scheduling of specialty care referral(s) for clinical SDB evaluation; Problem-solving for family-identified barriers to accessing specialty care; and Motivational interviewing to enhance family engagement, communication, and collaboration with the family's medical team.
45637291|NCT05353998|Other|CDS-only|Participants will complete baseline and post-intervention assessments. Participants will be able to follow-up with their primary care clinician as needed.
45637292|NCT05344092|Behavioral|VetEd Mobile Application|Participants be provided with the VetEd mobile app, with instructions on how to utilize the app at home over a four-week period
45637293|NCT05337033|Drug|MPL-001|"CBD50 plus is a medical cannabis oil with flavouring agent produced under Good Manufacturing Practice by MediPharm Labs and purchased for this study. Each ml of oil contains 2 mg/ml of delta-9-THC and 50 mg/ml of CBD.~Participants will receive escalating doses from 0.2-0.4 mg/kg/day of CBD to 0.8-1 mg/kg of CBD per day for four months, with dose increases monthly in 0.2mg/kg increments. Participants will following a weekly weaning protocol."
45637294|NCT05333458|Biological|Atezolizumab|Given IV
45637295|NCT05333458|Procedure|Biopsy|Undergo biopsy
45637296|NCT05333458|Procedure|Biospecimen Collection|Undergo collection of blood samples
45775787|NCT02912351|Other|Patient record review, Radiographs, and questionaires.|KSS-Objective Knee Scores, KSS Subsets, Radiographs and Patient Satisfaction
45775788|NCT01099475|Procedure|Pringle manoeuvre 15 minutes|During parenchymal transection, the hepatoduodenal ligament will be clamped by a rubber band for 2-times 15 minutes with 5 minutes reperfusion
45914893|NCT00005979|Drug|FOLFIRI regimen|
45637297|NCT05333458|Procedure|Computed Tomography|Undergo CT
45637298|NCT05333458|Procedure|Magnetic Resonance Imaging|Undergo MRI
45637299|NCT05333458|Drug|Selinexor|Given PO
45637300|NCT05325281|Drug|CPI-613® (Dose level -1.0 250 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
45637301|NCT05325281|Drug|CPI-613® (Dose level 1.0 500 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
45637302|NCT05325281|Drug|CPI-613® (Dose level 2.0 1,000 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
45637303|NCT05325281|Drug|CPI-613® (Dose level 3.0 1,500 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
45914894|NCT00005979|Drug|fluorouracil|
45637304|NCT05325281|Drug|CPI-613® Maximum Tolerated Dose (MTD)|MTD will be determined by testing increasing doses of CPI-613®, starting from 500 mg/m^2 and up to 1,500 mg/m^2, on dose escalation cohorts of three patients (maximum 24 patients) in combination with Gem-RT therapy. MTD reflects the highest drug dose that does not cause unacceptable adverse effects, with a target dose-limiting toxicity (DLT) rate of 30%. Final dose will be revised as appropriate.
45637305|NCT05325281|Drug|Gemcitabine|Subjects will be administered 400 mg/m^2 gemcitabine once per week by IV infusion over approximately 30 minutes for six weeks.
45637306|NCT05325281|Radiation|Intensity-modulated Radiation Therapy|1.8 Gy per fraction, 5 fractions per week, 30 fractions total (54 Gy) across six weeks.
45637307|NCT05304390|Behavioral|Patient Navigation|Receive patient navigation intervention
45637308|NCT05304390|Other|Questionnaire Administration|Ancillary studies
45637309|NCT05304390|Behavioral|Smoking Cessation Intervention|Receive an intervention for smoking cessation
45637310|NCT05301062|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Treatment with Radium-223 should follow the approved local product information according to National Medical Products Administration (NMPA) approved label
45637311|NCT05289934|Behavioral|Music Stimuli|Nine-minute-long Mozart K.448 (1st movement) and instrumental age-appropriate songs will be played via single-use earbuds with 10 minutes wash-out in between music stimuli.
45637312|NCT05289505|Device|MUSIC-CARE|This device allows the listening of music using different sequences of instrumental music created specifically, and using principles based on hypno-analgesia, that is to say the association of hypnotic techniques and approaches to help or analgesic, medicated or not. It consists of a tablet application containing instrumental music pieces, specially created and recorded for Music-Care. Each piece is at least 20 minutes long. The music can be played through headphones or speakers.
45637313|NCT05285202|Other|Active TB case finding with linkage to preventive therapy (ACF/TPT)|ACF/TPT in both intervention arms will consist of TB screening by mobile chest X-ray (with artificial intelligence-based reading, followed by confirmatory sputum testing with Xpert MTB/RIF Ultra for participants with abnormal x-rays), and linkage to preventive therapy for those who are TB-negative for eligible for TPT (interested after counseling and either positive tuberculin skin test or known HIV infection).
45637314|NCT05282264|Other|device|closed-loop insulin
45637315|NCT05276063|Drug|Linsitinib|Study medication taken twice daily by mouth
45637316|NCT05276063|Drug|Placebo|Placebo taken twice daily by mouth
45637317|NCT05274165|Device|Lyric Hearing Aid- Experimental Design|Extended wear hearing aid with a fitting modification that is currently not available
45637318|NCT05274165|Device|Lyric Hearing Aid- Commercially Available|Extended wear hearing aid that is currently available
45637319|NCT05267574|Drug|REN001|Once daily dosing
45637320|NCT05260008|Drug|ATX-101|ATX-101 (bupivacaine) implant, one-time administration into the surgical site
45637321|NCT05260008|Drug|ATX-101|ATX-101 (bupivacaine) implant, one-time administration into the surgical site
45637322|NCT05260008|Drug|bupivacaine hydrochloride without epinephrine|bupivacaine hydrochloride (125 mg) without epinephrine via local infiltration and/or nerve block
45637323|NCT05258916|Procedure|Nurse consultation|nurse consultation carried out within two weeks after maternity discharged
45637324|NCT05255601|Drug|Relatlimab|Specified Dose on Specified Days
45637325|NCT05255601|Drug|Nivolumab|Specified Dose on Specified Days
45637326|NCT05254275|Other|Ozoral Pro and Ozoral gel administration|Peri-implant mucositis sites will receive in-office Ozoral Pro administration after non-surgical therapy. Patients will use Ozoral Gel for the domiciliary administration once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
45637327|NCT05254275|Other|Curasept chlorhexidine gel 1%|Peri-implant mucositis sites will receive in-office Curasept chlorhexidine gel 1% administration after non-surgical therapy. Patients will use chlorhexidine gel 1% for the domiciliary application once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
45637328|NCT05252442|Other|Pre-COVID-19|Pre-COVID-19 period
45914895|NCT00005979|Drug|irinotecan hydrochloride|
45914896|NCT00005979|Drug|leucovorin calcium|
46070228|NCT02612493|Other|Obese patients with type I diabetes|Postsurgical follow - up in obese patients with type I diabetes
45637329|NCT05252442|Other|COVID-19|COVID-19 period
45637330|NCT05252442|Other|COVID-19 vaccination roll-out|COVID-19 vaccination roll-out period
45637331|NCT05248438|Behavioral|Questionnaire|Questionnaire
45637332|NCT05245097|Device|Tango Belt|The Tango Belt is a patient-contacting electronic device made out of medical grade plastics and biocompatible fabrics worn around the waist. The Tango Belt contains a fall-in-progress detection algorithm which can detect a serious hip-impacting fall-in-progress using built-in sensors and deploy an automotive-grade cold-gas airbag to protect the hips from ground impact forces. When connected to Wi-Fi, the Tango Belt can send automated fall and impact alerts to caregivers and Healthcare Providers (HCPs) while recording motion and event data, which can then be analyzed for usage-based metrics viewable via a companion mobile app and/or desktop app. Alerts are sent in the form of short message service (SMS) texts and emails to alert recipients designated in the mobile or desktop Companion App. The Tango Belt can also detect non-serious hip-impacting or non-hip impacting falls in which the wearer may have incurred a minor injury (i.e., not a major hip injury) and/or may be unable to get up.
45637333|NCT05244629|Device|BMS vs. CS|Patients will be randomized to treatment with either BeSmooth (BMS, Bentley Innomed GmBh) or BeGraft (CS, Bentley Innomed Gmbh)
45914897|NCT00005982|Drug|nelarabine|Given IV
45914898|NCT00005982|Other|pharmacological study|Correlative studies
45914899|NCT00005985|Biological|filgrastim|
45914900|NCT00005985|Drug|carmustine|
45914901|NCT00005985|Drug|cyclophosphamide|
45914902|NCT00005985|Drug|cytarabine|
45914903|NCT00005985|Drug|dexamethasone|
46070229|NCT00654745|Drug|Amlodipine|Amlodipine 5 mg tablets , Daily for 3 weeks;
46070230|NCT00654745|Drug|amlodipine / olmesartan medoxomil combination|amlodipine / olmesartan medoxomil combination tablets 5 mg/20 mg or 5 mg/40 mg or 10 mg/40 mg
46070231|NCT00654745|Drug|Hydrochlorothiazide|hydrochlorothiazide tablets, 12.5 mg or 25 mg.
46070232|NCT00809887|Drug|Micafungin lock therapy|
45637334|NCT05242809|Behavioral|Group-based PFMT group|The intervention group receives PFMT supervision in groups of about 6-8 women
45637335|NCT05232916|Biological|Placebo|0.9% Normal Saline
45637336|NCT05232916|Biological|GLSI-100|500 mcg/mL GP2 and 125 mcg/mL GM-CSF
45637337|NCT05220046|Drug|Psilocybin|Psilocybin, 25mg administered orally drug during an 8-hour monitored session with supportive pre- and post- session counseling
45637338|NCT05206565|Procedure|Neurotization - Autologous Reconstruction with DIEP/TRAM|"Transverse Rectus Abdominis Muscle/Deep Inferior Epigastric Artery Flap Harvest - Prior to elevation of flaps in the suprafascial plane from using loupe magnification to identify medial and lateral row of perforators bilaterally, sensory nerves T10-12 are identified and dissected into the muscle bilaterally to prepare for nerve coaptation, nerves are divided at the level of the fascia where they are pure sensory nerves.~Chest Intercostal Nerve Harvest - During standard of care chest vessel dissection, intercostal nerves T3-4 are identified. After completion of vein coupling it will be determined whether neurotization can be performed or if autograft. Primary nerve coaptation will be performed if there is adequate length for direct end to end apposition.~Coaptation of nerve or nerve graft endings will be performed using 9-0 nylon suture in an interrupted fashion."
45637339|NCT05204927|Drug|177Lu-PSMA-I&T|Radioligand therapy
45637340|NCT05204927|Drug|Abiraterone with Prednisone or Enzalutamide|Hormone Therapy
45637341|NCT05193994|Drug|Dolutegravir, Abacavir and Lamivudine|Dolutegravir 50mg, Abacavir 600mg and Lamivudine 300mg.
45637342|NCT05193994|Drug|Placebo|Matching placebo.
45637343|NCT05191784|Drug|GX-I7|Administered by intramuscular (IM) injection
45637344|NCT05191784|Drug|Bevacizumab|Administered by intravenous (IV) injection
45637345|NCT05177263|Other|Placebo|Sterile Water
45637346|NCT05177263|Drug|10% Oral Dextrose Solution|10% Oral Dextrose Solution
45637347|NCT05177263|Drug|20% Oral Dextrose Solution|20% Oral Dextrose Solution
45637348|NCT05177263|Drug|30% Oral Dextrose Solution|30% Oral Dextrose Solution
45637349|NCT05174221|Drug|Mezagitamab|TAK-079 subcutaneous injection.
45637350|NCT05161715|Drug|Obicetrapib|10mg obicetrapib
45637351|NCT05159934|Drug|0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine|Determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
45637352|NCT05159934|Drug|Saline|Saline will be use to determine if smokers can discriminate from the nicotine/pulse of nicotine and saline
45637353|NCT05159908|Drug|NBI-921352|Tablets for oral administration
45637354|NCT05159908|Drug|Placebo|Matching placebo tablets for oral administration
45637355|NCT05147974|Behavioral|DOZE app|"Complete DOZE app: Delivering Online ZZZ's with Empirical support (DOZE) app plus a Consensus Sleep Diary (CSD).~The DOZE app, is a web-based app optimized for desktop, smartphone, or tablet use. It is a self-management program for adolescents and young adults with sleep problems. The intervention will be delivered on restricted password-protected applications that will allow tracking of adherence (number of logins to app and website using Google Analytics). Participants will be encouraged to log onto the sleep dairy (via automated alerts) once a day over a 10-week period to complete sleep diary entries, develop and track their goals, and receive sleep health education/tailored sleep health interventions.~1-week pre- and post- intervention, participants will complete a battery of baseline study questionnaires and have the option of using a Geneactiv actigraphy device along with a CSD."
45637356|NCT05146024|Behavioral|Way To Serve Plus: Improving Responsible Alcohol Service|Improving responsible alcohol service of owners, managers, and employees of alcohol-serving establishments by developing professional development components to enhance their responsible beverage service skills.
45637357|NCT05145595|Device|Thermal Sensory Analyzer|Thermal stimuli: The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
45637358|NCT05145595|Device|Pressure Stimuli|Pressure stimuli: Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
45637359|NCT05145595|Device|Mechanical Stimuli|Mechanical stimuli: A set of standardised von Frey filaments (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128 and 256mN). The contact area of the hairs with the skin is of uniform size (<1 mm²) and texture.
45637360|NCT05145595|Behavioral|Pain Ratings|Pain intensity and pain unpleasantness ratings will be assessed by numerical rating scale (ranging from 0- no pain/unpleasantness to- 100 the most intense/unpleasantness pain imaginable) and by mechanical and computerized visual analog scales (VAS which ranges between ''no pain sensation'' and ''most intense pain imaginable'').
45637361|NCT05145595|Behavioral|Thermal pain thresholds|Cold and heat pain thresholds (CPT and HPT, respectively) will be determined [22; 55]. Thresholds are determined by continuous ramping of temperature from 32°C baseline temperature until the participant press a button at the first moment he/she feels pain from the stimulus. Cut-off temperatures are 0°C and 50°C, to minimize potential damage to the skin. The baseline temperature to which the thermode returns before each test is 32°C. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
45637362|NCT05145595|Behavioral|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
45775789|NCT01099475|Procedure|Pringle manoeuvre 30 minutes|During parenchymal transection, the hepatoduodenal ligament will be clamped by a rubber band for 30 minutes with 5 minutes reperfusion
45914904|NCT00005985|Drug|etoposide|
45914905|NCT00005985|Drug|mitoxantrone hydrochloride|
45637363|NCT05145595|Behavioral|Mechanical temporal summation|A pinprick stimulus with standardised intensity (#6.10 or #6.45 von Frey filament) and a flat contact area of 0.25mm diameter will be used. In this test, participants will rate the pain evoked by a single pinprick stimulus and by a series of 10 identical pinprick stimuli. The 10 identical pinprick stimuli are applied with a frequency of 1 s-1 within an area of 1 cm2. Immediately following the single stimulus and series of stimuli, an evaluation of the pain will be collected. The difference in pain ratings evoked with the one stimuli vs. the 10 stimuli is the temporal summation value.
45637364|NCT05145595|Behavioral|Conditioned pain modulation (CPM) efficiency|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency related to spatial filtering of nociceptive information. CPM testing includes the application of a test stimulus without conditioning (control run) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run). Heat-CPM and pressure-CPM. Heat and pressure CPM will be tested in random order.~The difference between the pain ratings/thresholds of the test stimulus with vs. without the concomitant conditioning stimulus is the CPM magnitude. CPM<0 (reduction in pain) implies efficient inhibitory pain modulation of spatial filtering."
45637365|NCT05145595|Behavioral|Offset analgesia efficiency|"Offset analgesia (OA) paradigm assesses endogenous inhibitory pain modulation efficiency of temporal filtering of nociceptive information. The mechanisms underlying OA are distinct from the CPM mechanisms [41]. OA is characterized by a disproportionately large reduction in pain perception after a small decrease in temperature during noxious thermal stimulation.~Offset analgesia will be assessed using the three-temperature method (T1°C 5s, T1+1°C 5s, T1°C 20s). The T1 will be noxious heat (44-48°C) delivered to the hand or leg. During the OA paradigm, real time pain intensity ratings will be obtained using the computerized VAS.~The difference between the pain ratings of the 10-20 seconds noxious stimulus in the OA paradigm compared to a control paradigm (30 seconds of T1) is the OA magnitude. OA<0 (reduction in pain) implies efficient inhibitory pain modulation of temporal filtering."
45637366|NCT05145595|Behavioral|Cold pain tolerance|Cold pain tolerance will be assessed by having participants immerse their hand or foot in a cold (4-12°C) water bath. Tolerance will be defined by the time of hand withdrawal. VAS ratings of cold pain intensity might be obtained periodically, and both pain intensity and pain unpleasantness will be recorded upon hand withdrawal. Limb immersion in the cold water bath will be terminated after 120 s if participants do not withdraw their hand before then.
45637367|NCT05144555|Other|Fixed orthodontic treatment with stainless steel brackets|"Stainless steel brackets (Queen Series Low Profile Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth to perform orthodontic treatment."
45637368|NCT05144555|Other|Fixed orthodontic treatment with ceramic brackets|"Ceramic brackets (Super Clear Series Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth to perform orthodontic treatment."
45637369|NCT05140434|Diagnostic Test|Exercise test|exercise test on an exercise bike with increasing load
45637370|NCT05140434|Diagnostic Test|Cardiac CT|cardiac CT scan
45637371|NCT05139498|Procedure|Conservative management for placenta accreta spectrum (PAS)|Subjects who are randomized to to conservative management will undergo a cesarean delivery followed by a period of close observation in the operating room for 30-45 minutes to be sure there is no excessive bleeding or risk to keep the placenta inside
45637372|NCT05139498|Procedure|Cesarean hysterectomy for placenta accreta spectrum (PAS)|Subjects who are randomized to cesarean hysterectomy will undergo a cesarean delivery followed immediately by hysterectomy to remove the placenta and uterus together
45637373|NCT05138601|Other|Virtual Collaborative Care Clinic|Trained clinical pharmacists will monitor BP, prescribe and adjust medications and monitor for side effects of medications under the license of, and in communication with, the patient's physician.
45637374|NCT05137717|Drug|Maribavir|Maribavir tablets
45637375|NCT05126758|Biological|CAP-1002|CAP-1002 is a cell therapy consisting of human allogeneic cardiosphere-derived cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
45637376|NCT05126758|Drug|Placebo|Placebo
45637377|NCT05123586|Drug|LY3361237|Administered SC
45637378|NCT05123586|Drug|Placebo|Administered SC
45637379|NCT05123482|Drug|AZD8205|AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, and endometrial cancers
45637380|NCT05119179|Drug|Semaglutide|Glucagon-like Peptide 1 Receptor Agonist
45637381|NCT05099159|Drug|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
45637382|NCT05099159|Drug|Placebo|Matching placebo orally once daily
45914906|NCT00005985|Procedure|peripheral blood stem cell transplantation|
46070233|NCT00807547|Biological|Allergy vaccination (Alutard SQ)|Alutard SQ grasses and rye, 8 subcutaneous injections, updosing to 10.000 SQ-U, duration of treatment 50 days
45914907|NCT00005985|Radiation|radiation therapy|
46070234|NCT00846027|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
46070235|NCT00846027|Drug|Paclitaxel|Paclitaxel was supplied as a sterile liquid in glass vials.
45637383|NCT05091112|Procedure|Spinal surgery|In participants who undergo elective lumbar spinal surgery and consented for research, the medial branch and dorsal rami will be harvested for histological analysis.
45637384|NCT05091112|Other|Histology|The harvested nerves will be fixed, cut into smaller sections. Analysis of macroscopic and light microscopic sections will be carried out
45637385|NCT05089084|Drug|ARO-APOC3|ARO-APOC3 injection
45637386|NCT05089084|Drug|Placebo|sterile normal saline (0.9% NaCl)
45637387|NCT05079230|Drug|Magrolimab|Administered intravenously (IV)
45637388|NCT05079230|Drug|Venetoclax|Tablets administered orally
45637389|NCT05079230|Drug|Azacitidine|Administered according to region-specific drug labeling, either subcutaneously (SC) or intravenously (IV)
45637390|NCT05079230|Drug|Magrolimab Placebo|Administered intravenously (IV)
45637391|NCT05077709|Drug|IO102-IO103 in combination with pembrolizumab|The experimental drug IO102-IO103 is for SC injection and consist of IDO and PD-L1 peptides
45637392|NCT05077124|Device|CytoSorb|Sorbent hemoperfusion system
45637393|NCT05076370|Drug|CBD Day 1|CBD 400mg
45637394|NCT05076370|Drug|CBD Day 2|CBD 800mg
45637395|NCT05076370|Drug|CBD Day 3|CBD 1200mg
45637396|NCT05073471|Behavioral|Patterned Sensory Enhancement (PSE)|"Patterned Sensory Enhancement (PSE) is one of Neurologic Music Therapy (NMT) techniques. NMT is a research-guided clinical model that is driven by advances in neuroscience and the understanding of the perception, production, and performance of music and how music can influence and change non-musical brain and behavior function.~PSE is a technique that uses the rhythmic, melodic, harmonic, and dynamic-acoustical elements of music to provide temporal, spatial, and. force cues for movements which reflect functional movements of activities of daily."
45637397|NCT05073471|Device|Transcranial Direct Current Stimulation (tDCS)|"We will apply five small electrodes to participant's head. Once the electrodes are in place, a small electrical current will be passed between the electrodes. Participants will also get sham tDCS, which means they will not receive any real stimulation from the electrodes. Most individuals do not find the procedure uncomfortable, and there are no known long-term risks of tDCS. When the current goes through the electrodes, you may feel an itching or tingling sensation under the electrodes or see brief flashes of light, or you may not feel anything at all. If the sensation is unpleasant, participant can report to co-investigator immediately. If participant finds the procedures too uncomfortable, they may stop it at any time. A trained staff member will be present throughout the procedure."
45637398|NCT05071287|Other|mHealth + low-fat diet|A restricted total calorie and reduced total fat consumption.
45775790|NCT05307263|Procedure|Combination therapy of atherectomy and DCB|The target lesion in femoropopliteal artery will be treated with atherectomy folloewd by DCB. The choice of atherectomy devices (HawkOne, Jectstream, or Rotarex)and DCBs (IN.PACT or Ranger) will be left to the operator's decision. In presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of bare nitinol stents is recommended. Implantational of drug-eluting stents is not allowed.
45775791|NCT05307263|Procedure|DCB alone|The target lesion in femoropopliteal artery will be treated with DCB. The choice of DCBs (IN.PACT or Ranger) will be left to the operator's decision. In presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of bare nitinol stents is recommended. Implantational of drug-eluting stents is not allowed.
45914908|NCT00005988|Drug|cyclophosphamide|
45914909|NCT00005988|Drug|cyclosporine|
45914910|NCT00005988|Drug|leucovorin calcium|
45914911|NCT00005988|Drug|methotrexate|
45914912|NCT00005988|Drug|methylprednisolone|
45914913|NCT00005988|Procedure|in vitro-treated bone marrow transplantation|
45637399|NCT05071287|Other|mHealth + low-carb/ketogenic diet|A low-carb/ketogenic diet
45914914|NCT00005988|Radiation|radiation therapy|
45914915|NCT00005991|Drug|gemcitabine hydrochloride|
45914916|NCT00005991|Drug|pegylated liposomal doxorubicin hydrochloride|
45914917|NCT00005994|Drug|ondansetron|
45914918|NCT00005997|Drug|becatecarin|Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue until the maximum tolerated dose (MTD) is determined.
45914919|NCT00006000|Drug|cisplatin|
45914920|NCT00006000|Drug|irinotecan hydrochloride|
45914921|NCT00006000|Drug|semaxanib|
45914922|NCT00006003|Drug|semaxanib|Given IV
45637409|NCT05057676|Behavioral|Immediate Autoimmune Intervention Mastery Course (AIM)|Immediate access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
45914923|NCT00006003|Other|laboratory biomarker analysis|Correlative studies
45914924|NCT00006006|Biological|recombinant interferon alfa|
45914925|NCT00006006|Drug|thalidomide|
45914926|NCT00006009|Biological|visilizumab|
45914927|NCT00006012|Biological|filgrastim|
45914928|NCT00006012|Drug|amifostine trihydrate|
45914929|NCT00006012|Drug|cisplatin|
45914930|NCT00006012|Drug|etoposide|
45914931|NCT00006012|Drug|paclitaxel|
45914932|NCT00006012|Drug|topotecan hydrochloride|
45914933|NCT00006012|Radiation|radiation therapy|
45914934|NCT00006015|Biological|trastuzumab|4 mg/kg IV infusion Day 1, then weekly 2 mg/kg IV infusion (on Days 8, 15, & 22)
45914935|NCT00006015|Drug|fluorouracil|500 mg/sq m IV push weekly for 3 weeks, followed by a 1 wk break
45914936|NCT00006015|Drug|leucovorin calcium|500 mg/sq m IV infusion over 2 hours weekly for 3 weeks, then a 1 wk break
45914937|NCT00006015|Drug|oxaliplatin|85 mg/sq m IV infusion over 2 hours Days 1 & 15 of each cycle
45914938|NCT00006018|Drug|BMS-214662|This is a dose-escalation study of BMS-214662. BMS-214662 IV over 1 hour on day 3 of course 1. For all subsequent courses, patients receive BMS-214662 IV over 1 hour on day 1 (30 minutes after paclitaxel). Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
45914939|NCT00006018|Drug|paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 of course 1. For all subsequent courses, patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
45637410|NCT05057676|Behavioral|Immediate Question and Answer sessions. (AIM Q and A sessions)|Immediate access to videos answering common questions about the course concepts. One video released each week, 7 videos total.
45775792|NCT01099631|Biological|Salmonella typhimurium|Attenuated Salmonella typhimurium (virulent strain x4550) will be given orally in escalating dose groups: Level 1 = 10^5, Level 2 = 10^6, Level 3 = 10^7, Level 4 = 10^8, Level 5 = 10^9, Level 6 = 10^10.
45775793|NCT05307029|Procedure|rehabilitation with fixed full-arch prosthesis|
45637411|NCT05057676|Behavioral|Delayed Autoimmune Intervention Mastery Course (delayed AIM course)|Delayed access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
45637412|NCT05057676|Behavioral|Delayed AIM Question and Answer sessions|Delayed access to videos answering common questions about the course concepts. One video released each week, 7 videos total.
45637413|NCT05047705|Behavioral|Distress Tolerance Skills Training|Individuals with TS will receive distress tolerance skill training. Therapeutic skill training will consist of 4 weekly 1-hour sessions. Skill training will occur either in-person or remotely via videoconferencing software. Sessions will focus on building participants' distress tolerance skills with strategies drawn from third-wave CBT.
45637414|NCT05026866|Drug|Donanemab|Administered intravenously
45637415|NCT05026866|Drug|Placebo|Administered intravenously
45637416|NCT05025787|Drug|CNTX-6970|CNTX-6970, a novel potent antagonist of CCR2 with lesser effects on CCR5, is being developed as a new treatment for chronic pain, including painful osteoarthritis of the knee.
45637417|NCT05025787|Drug|Placebo|BID
45637418|NCT05020821|Procedure|Single-shot superior trunk block with intravenous dexmedetomidine|During surgery, dexmedetomidine will be administered. After intravenous administration of 2 mcg/kg for 30 minutes, 0.5 mcg/kg/hr will be administered until the end of surgery. After surgery, a single-shot superior trunk block will be performed under ultrasound guidance. 15 mL of 0.5% ropivacaine with 1:200,000 epinephrine will be administered.
45637419|NCT05020821|Procedure|Continuous superior trunk block|Continuous superior trunk block will be performed under ultrasound guidance and utilize patient-controlled analgesia infusion pump with a 300 mL reservoir of ropivacaine 0.2%, and programmed the pump to deliver 5 mL per hour with an optional patient-controlled analgesia bolus of 4 mL at 30-minute lockout intervals. Patients were typically discharged home on POD 1, and block was continued until reservoir completion.
45637420|NCT05020665|Drug|Entospletinib|Orally as tablets
45637421|NCT05020665|Drug|Placebo|Orally as tablets
45775794|NCT01100255|Drug|Ketamine infusion|0.5mg/kg IV over 40 minutes
45775795|NCT01100255|Other|Saline|saline infusion
45914940|NCT00006021|Dietary Supplement|ascorbic acid|
45637422|NCT05020665|Drug|Cytarabine|Continuous infusion
45637423|NCT05020665|Drug|Anthracycline|Either daunorubicin or idarubicin will be administered via slow intravenous (IV) push
45914941|NCT00006021|Drug|arsenic trioxide|
45637424|NCT05020470|Device|Virtual Auricular Point Acupressure (APA)|Participants will learn how to self-administer APA by themselves.
45637425|NCT05020470|Other|In-Person Training|Participants will receive in-person training to self-administer APA.
45637426|NCT05020470|Other|Usual Care|Participants will continue to do whatever they are instructed by theirs physicians.
45637427|NCT04996264|Drug|Varespladib Methyl|Varespladib-methyl (LY333013) is an IR, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration. Scaled pediatric doses of varespladib-methyl (LY333013) are supplied as 50 mg IR capsules for oral administration.
45637428|NCT04996264|Drug|Placebo|"The oral placebo is supplied as a white film-coated oval tablet to match the appearance of the varespladib-methyl 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~Placebo for scaled pediatric dosing is supplied as an IR capsule to match the varespladib-methyl 50 mg capsule, and contains the excipients lactose monohydrate, microcrystalline cellulose, and magnesium stearate."
45637429|NCT04996264|Drug|Standard of care (SOC)|SOC (including antivenom) will continue to be administered throughout the subject's participation in the study according to the protocol and the judgment of the Investigator.
45637430|NCT04992065|Drug|NNC0385-0434 A 15 mg|15 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
45775796|NCT03012347|Drug|BAY987517|Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity. (Formulation: RB# Y73-161)
45775797|NCT03012347|Drug|BullFrog Gel Sunscreen Land Sport SPF-50|Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity.
45775798|NCT03012737|Device|Trilogy 100 ® (Philips Respironics)|Trilogy 100 ® (Philips Respironics) on MPV mode.
45775799|NCT01100723|Other|Cinacalcet, active vitamin D analogue|Patients will have their mineral and bone disorders managed by the computer directed algorithm. Cinacalcet will be dose increased starting at 30 mg/day as indicated by protocol along with active vitamin D based on values of serum calcium, phosphorus and parathyroid hormone.
45775800|NCT05306561|Procedure|Systane iLux thermal pulsation treatment|Systane iLux thermal pulsation uses light emitting diode (LED) technology to emit light that is absorbed by pigments (melanin and hemoglobin) in the eyelid. The pigments convert the light energy to heat, which is then transferred to the surrounding tissues, including the meibomian glands. The device heats the eyelid to 40-42°C and maintains it above 40°C during the heating period, which can be 40 seconds or more. This helps melt the meibum. After the heating phase, the meibomian glands are expressed with the built in expression system.
45914942|NCT00006024|Drug|lomustine|
45914943|NCT00006024|Drug|temozolomide|
45914944|NCT00006027|Drug|cisplatin|
45914945|NCT00006027|Drug|paclitaxel|
45914946|NCT00006027|Procedure|adjuvant therapy|
45914947|NCT00006027|Radiation|radiation therapy|
45914948|NCT00386646|Drug|0.5% carboxymethylcellulose (CMC) with purite and CMC alone|
45637431|NCT04992065|Drug|NNC0385-0434 A 40 mg|40 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
45637432|NCT04992065|Other|Placebo I A (for NNC0385-0434 A 15 mg)|Placebo administered as 1 tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces). placebo tablets are sized match to the active arm within dose level
45637433|NCT04992065|Drug|NNC0385-0434 A 100 mg|"100 mg administered as one oral tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces)."
45637434|NCT04992065|Other|Placebo I A (for NNC0385-0434 A 40 mg)|"Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level"
45637435|NCT04992065|Other|Placebo II A (for NNC0385-0434 A 100 mg)|"Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level"
45637436|NCT04992065|Drug|Evolocumab 140 mg/mL, Repatha®|"Every 2 weeks subcutaneous (s.c.) injection of 140 mg into areas of the abdomen, thigh, or upper arm that are not tender, bruised, red, or indurated. Administered using a pre-filled SureClick® autoinjector (single-use).~Dose volume: 1 mL"
45637437|NCT04971993|Device|Wearable Cardiac Monitor|Participants will be fitted with a wearable cardiac monitor placed on their skin that measures physiological signals.
45637438|NCT04969822|Device|iDAScore®|A system that studies time lapse images obtained from the embryo culture system, Embryoscope, throughout the development to blastocyst. The system uses data acquired from a sequence of embryo images and has taught itself to identify the embryos with the highest likelihood of implanting and leading to fetal heart-beat detection.
45637439|NCT04957134|Device|Electro-acupuncture|The acupoints of electro-acupuncture will be selected as Zusanli ,Sanyinjiao ,Zhongwan , Tianshu , Shuifen , Daheng ,Daimai , Shuidao ,Huaroumen and Fujie . We will deliver electrical stimulation with dense-disperse waves at 50 Hz and 10 V through the electrical acupuncture stimulation instrument to the abdominal points. The bodily needles will be retained for 30 minutes . Electro-acupuncture treatment will be applied 3 times a week, once every other day, for 8 consecutive weeks.
45637440|NCT04957134|Device|Sham electro-acupuncture|The acupoints of sham electro-acupuncture will be selected as nonacupoints . The internal output power cord of the electrical acupuncture stimulation instrument will be interrupted. The bodily needles will be retained for 30 minutes . Sham acupuncture treatment will be applied 3 times a week, once every other day, for 8 consecutive weeks.
45637441|NCT04950725|Behavioral|Strength RMT|2 sets of 10 breaths twice per day using the breather or 3 sets of 10 breaths, twice per day using the Breather Fit
45637442|NCT04950725|Behavioral|Strength RMT and nasal breathing|2 sets of 10 breaths twice per day using the Breather or 3 sets of 10 breaths twice per day using the Breather Fit. Subjects will also be asked to complete 2 sets of 10 nasal breathing exercises either before or after the RMT exercise.
45637443|NCT04950725|Behavioral|Endurance RMT|15 breaths twice per day using the Breather or 20 breaths twice per day using the Breather Fit
45637444|NCT04950725|Behavioral|Endurance RMT and nasal breathing|15 breaths twice per day using the Breather or 20 breaths twice per day using the Breather Fit at a lower intensity for a longer duration without break. Subjects will also perform 2 sets of 10 nasal breathing exercises either before or after the RMT exercise.
45637445|NCT04950725|Behavioral|Low dose RMT|10 breaths, 3 times per week, at an intensity of 3 to 4 out of 10 using the Breather device.
45637446|NCT04941716|Drug|Acalabrutinib|Given PO
45637447|NCT04941716|Drug|Venetoclax|Given PO
45754254|NCT03588104|Device|POWER2DM system|This system consists of two components: 1) the web-based Shared Decision Making Dashboard, used to set self-management goals together with a health care professional with the use of both short- and long-term predictive computer simulation models, and 2) the POWER2DM Self-Management Support System as a mobile application and webpage, used to support behavioural change in DM self-management. The system is fed with data from an activity tracker, a glucose monitor and manual data entry. Power2DM support will be provided as an adjunct to usual care
45914949|NCT00386685|Drug|larotaxel (XRP9881)|intravenous administration
45914950|NCT00386685|Drug|trastuzumab|intravenous administration
45914951|NCT00006030|Drug|tamoxifen citrate|
45914952|NCT00006030|Procedure|conventional surgery|
45914953|NCT00006030|Radiation|radiation therapy|
45914954|NCT00006033|Biological|gene therapy|
45914955|NCT00006033|Biological|interleukin-2 gene|
45637448|NCT04931953|Other|Intermittent theta burst stimulation (iTBS)|The localisation of the left dorsolateral prefrontal cortex (DLPFC) target will be identified using effective connectivity of the left caudate to identify the maximally-connected locus in the left DLFPC. Following this the iTBS will be administered to the target coordinates identified using the neuronavigation software available with the system. Connectivity-guided iTBS is then administered using a 70mm Double Air Film Coil (Magstim, Whitland, Dyfed, UK), connected to a Magstim Super Rapid-2 Plus-1 stimulator. The administration comprises bursts of 3 pulses at 50Hz with a power of 80% motor threshold at a burst frequency of 5 Hz (i.e., every 200ms) for 2 seconds, repeated every 10 seconds for a total of 190 seconds (600 pulses). Blocks are repeated a total of 3 times, with 5-minute rest intervals between blocks. During left DLPFC stimulation, the TBS coil is held by a support tangentially to the skull, with the axis of the coil angled approximately 90 degrees from the midsagittal axis.
45637449|NCT04931953|Other|Sham Intermittent theta burst stimulation (iTBS)|The sham iTBS administration is performed under the same conditions and with an identical protocol and equipment to the full administration, except that it uses a commercially available sham iTBS coil designed for use in double-blind trials. This sham coil looks like the real coil and connects to the iTBS unit but delivers only a very weak and shallow stimulation thus simulating the sounds made by the real iTBS coil.
45452498|NCT01088165|Drug|Fumaric acid esters treatment group|"First week:FAE mite (DIMETHYL FUMARATE 30mg, ETHYL FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg):day 1 and 2: 0-0-1, day 3 and 4: 1-0-1, day 5-7: 1-1-1).~Week 2: FAE forte (DIMETHYL FUMARATE 120mg ETHYL, FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg)starting with 0-0-1 capsule daily, thereafter weekly increases by on capsule until maximum daily dose 2-2-2. In the event of side effects (in particular, gastrointestinal disturbances or flushing) adaption of the dose (reduction or no increase) depending on the type and severity of the side effect will be performed. If remission occurs at a lower than the maximum dose that dose will be maintained throughout the rest of the study period."
45637450|NCT04924712|Other|Measurement of blood immune populations and microbiota distribution.|Measurement of peripheral cell populations by spectral cytometry and in parallel, sequencing of intestinal and urinary bacterial 16S RNA of each patient.
45637451|NCT04911062|Drug|Bupivacaine HCI without epinephrine|100 mg administered via injection into the surgical site.
45637452|NCT04911062|Drug|HTX-011|HTX-011 (bupivacaine/meloxicam) dose up to 200 mg/6 mg administered via application into the surgical site.
45637453|NCT04911062|Device|Luer Lock Applicator|Applicator for instillation.
45637454|NCT04906395|Drug|TOL2506|Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months.
45637455|NCT04906395|Drug|Tamoxifen|20 mg once daily or 10 mg 2 times daily - either tablet or solution
45637456|NCT04906395|Drug|Letrozole Tablets|One 2.5 mg tablet taken orally once daily
45637457|NCT04906395|Drug|Anastrozole Tablets|One 1 mg tablet taken orally once daily
45637458|NCT04906395|Drug|Exemestane Tablets|One 25 mg tablet taken orally once daily
45637459|NCT04903626|Drug|Glecaprevir/Pibrentasvir (GLE/PIB)|Oral tablets
45637460|NCT04899180|Drug|99mTc-PYP|Radioisotope used by SPECT/CT imaging
45775801|NCT01101971|Other|Pelvic exam video tutorial|Bryden Magee (Meds 2010) and Dr. Robert Reid created an educational DVD © 2009 that outlines a step-by-step approach to the pelvic exam; utilizing real patient video clips and illustrations. Endorsed by the Association of Professors of Obstetrics and Gynaecology of Canada (APOG), this innovation has been shown to improve both knowledge and confidence in medical students learning these skills (Magee 2009). The video content has been posted on the Queen's streaming server and incorporated into a MEdTech community accessible to all Queen's faculty and students affiliated with the School of Medicine (in MEdTech Central see OBGYN Pelvic Exam Module under community courses).
45775802|NCT05306405|Drug|Vaginal Tablet|"Misoprostol alone will be repeated every 4 h in both groups for a maximum of 5 doses, reaching Bishop score >8, rupture of membranes or occurrence of labor pain.~Cervical evaluation will be done using Bishop's score. A score < 5 will be taken as unfavorable Cervix will be termed as ripped when Bishop's score equal 8 or more.~The endpoint of the study will be initiation of active phase of 1st stage of labor which commence from 6cm to full cervical dilatation"
45637461|NCT04899089|Behavioral|Cognitive Training|The computerized training exercises and brain games help stimulate cognitive functions while providing real-time monitoring on the evolution of participants' skills.
45637462|NCT04899089|Behavioral|Trivia Training|The computerized trivia training asks participants to answer general questions related to pop culture, science, geography, etc. Participants can use online sources to search for answers and will be provided feedback on their accuracy.
45637463|NCT04892472|Device|NovoTTF-200T|All patients enrolled in this group will receive TTFields treatment, delivered for at an average of least 18 hours a day using NovoTTF-200T concomitant with pembrolizumab, a standard immunotherapy agent, which is delivered intravenously.
45637464|NCT04892472|Drug|Pembrolizumab (MK-3475) 200 mg|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
45637465|NCT04890834|Other|Best Practice|Receive standard care
45637466|NCT04890834|Other|Exercise Intervention|Participate in yoga sessions
45914956|NCT00006033|Drug|methotrexate|
45914957|NCT00006036|Drug|cisplatin|
45914958|NCT00006036|Drug|lurtotecan liposome|
45914959|NCT00006039|Biological|pegylated interferon alfa|
45914960|NCT00006042|Biological|filgrastim|
45914961|NCT00006042|Drug|cyclophosphamide|
45914962|NCT00006042|Drug|fludarabine phosphate|
46070236|NCT00846027|Drug|Gemcitabine|Gemcitabine was supplied as a sterile liquid in glass vials.
45914963|NCT00006042|Drug|mycophenolate mofetil|
45914964|NCT00006042|Drug|tacrolimus|
45637467|NCT04890834|Other|Questionnaire Administration|Ancillary studies
45637468|NCT04879043|Drug|HDP-101|HDP-101 is available as lyophilized white powder for preparation of infusion.
45914965|NCT00006042|Procedure|allogeneic bone marrow transplantation|
45914966|NCT00006042|Radiation|radiation therapy|
46070237|NCT00807625|Drug|Depo Provera|Depo Provera administered by injection at randomization visit and the 12-week study visit.
45637469|NCT04877990|Drug|Deucravacitinib|Specified dose on specified days
45637470|NCT04873037|Device|BTL Emsella Chair|The Emsella Chair is a novel high-intensity focused electromagnetic (HIFEM) technology for the treatment of pelvic floor related disorders. HIFEM technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes. The treatment paradigm consists of 3 different phases. The phases consist of an intense stimulation of the pelvic floor muscles (PFM), which consists of stimulation and relaxation. The repetition of the phases and focused electromagnetic energy delivery leads to pelvic floor stimulation, adaptation, and remodelation.
45637471|NCT04873037|Device|Sham BTL Emsella Chair|The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (less than 10%) power.
45637472|NCT04841226|Device|Long-term indwelling Foley catheter|Foley Catheter inserted for up to 28-days
45637473|NCT04836195|Drug|PCLX-001|To ensure maximal safety in this first-in-human trial, the starting dose level was chosen to be 20 mg daily on a 28-day cycle.
45637474|NCT04823858|Procedure|Lumbar Interbody Fusion|The TLIF/PLIF system includes a TLIF/PLIF interbody cage and a pedicle screw system (4 screws with 2 rods). Any FDA cleared TLIF/PLIF interbody cage and pedicle screw system is acceptable for this study (with the exception of PEEK rods) as long as it is implanted per the package insert. No subjects implanted with an off-label use of a device are permitted for this study.
45637475|NCT04818749|Drug|Saline|Saline (placebo) will be administered intravenously before block performance and after the induction of general anaesthesia.
45637476|NCT04818749|Drug|Dexamethasone 12 mg|Dexamethasone 12 mg will be administered intravenously before block performance and saline (placebo) will be administered intravenously after the induction of general anaesthesia.
45637477|NCT04818749|Drug|Dexamethasone 12 mg + dexmedetomidine 1 mcg/kg|Dexamethasone 12 mg will be administered intravenously before block performance and dexmedetomidine 1 mcg/kg will be administered intravenously after the induction of general anaesthesia.
45637478|NCT04817137|Device|CareTaker PDA Device|Non-invasive blood pressure monitoring
45637479|NCT04815551|Drug|AV-380|AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
45637480|NCT04815551|Drug|Placebo|Placebo is sterile liquid for IV infusion.
45637481|NCT04813692|Procedure|Surgical repair|Surgical repair of post-infarction LVFWR or VSR
45452499|NCT01088165|Other|Narrow band UVB radiation|"No reduction of 50% minimum of baseline psoriasis severity index by week 12: additional narrow band UVB radiation, 3x/week until the patients achieve PASI reduction of 75% or greater or over a maximum period of another 12 weeks.~Initial dosage: Fitzpatrick skin phototype I and II: 0,4 J/cm2, III and IV: 0,6), 10% Increments after each radiation"
45637482|NCT04813692|Procedure|Percutaneous treatment|Percutaneous closure of post-infarction VSR (or treatment for LVFWR)
45637483|NCT04813692|Procedure|Mitral valve surgery|Mitral valve repair or replacement for post-infarction PMR
45637484|NCT04797611|Device|Non-invasive brainstem stimulation|Study participants will self-administer ~19-minute treatments twice daily in the home setting over 12 weeks using a non-invasive brainstem modulation device. The device has been deemed to be a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
45637485|NCT04795960|Dietary Supplement|Low serine diet|Participants will be on this diet 1 week prior to initiation and 1 week after initiation of Ustekinumab (standard of care medication). The meals will be prepared in the Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System and given to the participants.
45637486|NCT04795960|Dietary Supplement|High serine diet|Participants will be on this diet 1 week prior to initiation and 1 week after initiation of Ustekinumab (standard of care medication). The meals will be prepared in the Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System and given to the participants.
45637487|NCT04790903|Drug|Venetoclax|Participants will self-administer Venetoclax, as described in the Arm Descriptions.
45637488|NCT04790903|Drug|Polatuzumab Vedotin|Participants will receive Polatuzumab Vedotin at a dose of 1.8 mg/kg by intravenous (IV) infusion on Day 1 of Cycles 1-6.
45637489|NCT04790903|Drug|Rituximab|Participants will receive Rituximab at a dose of 375 mg/m^2 by IV infusion on Day 1 of Cycles 1-6.
45637490|NCT04790903|Drug|Cyclophosphamide|Participants will receive Cyclophosphamide at a dose of 750 mg/m^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
45637491|NCT04790903|Drug|Doxorubicin|Participants will receive Doxorubicin at a dose of 50 mg/m^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
45637492|NCT04790903|Drug|Prednisone|Participants will receive Prednisone orally (PO) at a dose of 100 mg/day on Days 1-5 of Cycles 1-6.
45637493|NCT04790071|Other|Conventional physical therapy|Conventional physical therapy: The patients received physical therapy to the shoulder, transcutaneous electrical nerve stimulation, and stretching and strengthening exercises (5 days per week for three weeks in a total of 15 sessions).
45637494|NCT04790071|Other|Conventional physical therapy plus dry needling|Conventional physical therapy plus dry needling: The patients received physical therapy to the shoulder, including transcutaneous electrical nerve stimulation, stretching, and strengthening exercise (5 days per week for three weeks in a total of 15 sessions). And also, a total of 3 dry needling sessions were applied at 7-day intervals.
45637495|NCT04781309|Drug|NT-I7|NT-I7 is a recombinant human interleukin-7 fused to a hybrid fragment crystallizable region of a human antibody (hyFc). NT-I6 has a molecular weight of 104 kD. The active moiety of NT-I7 is recombinant human interleukin-7 (rhIL-7), containing human IL-7 (amino acids 4 through 155) and exhibiting all known functions of endogenous human IL-7.
45452500|NCT00892762|Drug|Travoprost APS 40 micrograms/ml eye drop solution|non-BAK (benzalkonium chloride) medication
46070238|NCT00807625|Device|Copper T Intrauterine contraception device|IUCD inserted upon randomization to this study arm
45452501|NCT00892762|Drug|Latanoprost 50 micrograms/ml eye drop solution|BAK-preserved medication
45637496|NCT04777396|Drug|Semagludtide|Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
45637497|NCT04777396|Drug|Placebo (semaglutide)|Oral placebo (semaglutide) once-daily, The study will last for up to 173 weeks
45637498|NCT04776395|Drug|Dexamethasone|Given PO
45637499|NCT04776395|Drug|Iberdomide Hydrochloride|Given PO
45637500|NCT04776395|Other|Quality-of-Life Assessment|Ancillary studies
45637501|NCT04772079|Drug|Deucravacitinib|Specified dose on specified days
45637502|NCT04772079|Other|Placebo matching deucravacitinib|Specified dose on specified days
45637503|NCT04754165|Other|Virtual Reality Immersive Relaxation|The VR software developed allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
45637504|NCT04751383|Procedure|Biospecimen Collection|Undergo collection of blood samples
45637505|NCT04751383|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
45637506|NCT04751383|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
45637507|NCT04751383|Procedure|Computed Tomography|Undergo CT
45637508|NCT04751383|Biological|Dinutuximab|Given IV
45637509|NCT04751383|Procedure|Magnetic Resonance Imaging|Undergo MRI
45637510|NCT04751383|Biological|Magrolimab|Given IV
45637511|NCT04751383|Procedure|Resection|Undergo surgical resection
45637512|NCT04748549|Other|Virtual Reality Immersive Relaxation|The VR software developed allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
45637513|NCT04748549|Other|Immersive Audio Experience|A study team member will play from a library of music or other audible content (audiobook, podcast) that was preselected by the patient.
45775803|NCT03012893|Device|Ultrasound sagittal scan|Convex transducer will be placed at patient's neck using paramedian sagittal scan and pointing toward the chest apex aiming to identify the first rib. Then move the transducer medially to identify the transverse process along with identify C7 transverse process will appear on the image as a hyperechoic shadow without continue to the rib laterally. Place the C7 spinous process on the midpoint of the probe and the spinous process correspondence to the midline will be marked as C7.
45775804|NCT03012893|Device|Ultrasound transverse scan|Linear transducer will be placed at patient's lateral neck using transverse scan. The unique characteristic of sonography of transvers process of C6 and C7 will be used to identify the transverse process of C6 and C7. C6 transverse process has a very prominence anterior tubercle (known as Chassaignac tubercle). While anterior tubercle of C7 is absent. After identifying the C7 transverse process, simultaneously the color Doppler mode will be activated to identify the vertebral artery for double confirmation.
45775805|NCT03012893|Procedure|Fluoroscopic technique|C7 spinous process will be identified by counting down from C1 vertebral body and spinous process.
45914967|NCT05681013|Behavioral|Laughter Therapy|The effect of the Laughter Therapy on nursing students
45637514|NCT04748549|Other|Sham Virtual Reality Experience|Subjects will wear VR headsets and headphones but will not view any content or listen to any audible content.
45637515|NCT04743141|Drug|Rimegepant / BHV3000|BHV3000 (rimegepant) 75 mg or 50 mg ODT
45637516|NCT04738643|Other|Tobacco Use Treatment Service and Varenicline Management|The VM intervention builds upon the established TUT Service process. In addition to connecting the patient to TUT Service via electronic referral, it activates a medication management protocol that: 1) actively confirms no evidence of renal failure or pregnancy with oncology provider, 2) automates a referral to prescribing providers within the TUT Service team, prompting a call-back to patient within 24 hours, 3) provides written AVS instructions to contact TUT Service for initiation instructions and clinic appointment, and 4) pends a varenicline prescription to the medication list, ready for reconciliation by TUT Service prescribing clinicians. The protocol formalizes standard management principles for varenicline, including follow-up evaluation, pre-quit period duration, and side effect amelioration.
45637517|NCT04733534|Drug|Dasatinib plus Quercetin|Dasatinib (100 mg/day) plus Quercetin (500 mg twice daily) on days 1, 2, 3, 30, 31, 32 taken orally under observation of the study nurse.
45637518|NCT04733534|Drug|Fisetin|Fisetin (20mg/kg/day) on days 1, 2, 30 and 31 taken orally under observation of the study nurse. Fisetin will be dispensed based on weight of 20 mg/kg/day on the four separate days.
45637519|NCT04726748|Procedure|Comparisons between the Prostatic urethral lift (PUL) and the TURP/Laser cohorts|"Comparison between the PUL and the TURP/Laser cohorts will be performed after 1 year and 3 years of follow-up in a intention-to-treat analysis using:~a linear regression model when it involves quantitative variables,~a logistic regression model adjusted on potential confounding when it involves qualitative variables."
45637520|NCT04726748|Procedure|Comparison between the Prostatic urethral lift (PUL) and the SNDS cohorts|"Comparison between the PUL and the SNDS cohorts will be performed after 1 year and 3 years of follow-up in a intention-to-treat analysis using:~a linear regression model when it involves quantitative variables,~a logistic regression model adjusted on potential confounding when it involves qualitative variables."
45637521|NCT04716231|Biological|Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
45637522|NCT04716231|Other|Placebo to match Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
45935597|NCT00043823|Drug|Avastin|7.5 mg/kg By Vein on Day 1 of Every 21 Day Cycle
45935598|NCT00043823|Drug|Tarceva|100 mg By Mouth Daily for 3 Weeks
45935599|NCT00127309|Drug|Glutathione|
45935600|NCT00074334|Biological|TGFa-PE38 immunotoxin|
46070239|NCT00807703|Procedure|Select Stim|Select Stim: see summary
46070240|NCT02551549|Drug|CD101 IV|antifungal
46070241|NCT02551549|Drug|Placebo|Normal saline
46070242|NCT00646399|Drug|Placebo|Phosphate Buffered Saline on Days 0, 1, 2, 9, 16 and 23.
45775806|NCT04352621|Drug|intranasal ketamine|Ketamine 0.5 mg/kg will be administered intranasally using an atomization device with a maximum dose of 40 mg followed by 6 weeks of rTMS treatment. .
45775807|NCT04352621|Device|rTMS treatment|patients will begin the open label trial of rTMS per the FDA-approved method on day 1 (the day after the Baseline Visit).
45775808|NCT02246855|Biological|Gammaplex® (Human Normal Immunoglobulin)|
45775809|NCT05272397|Drug|Methylphenidate 20 Mg Oral Tablet|20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
45637523|NCT04716036|Other|Alcohol beverage|Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.
45637524|NCT04716036|Other|Placebo beverage|placebo beverage condition.
45637525|NCT04712552|Procedure|deep brain stimulation|"On the day of surgery, under general anesthesia, a Fischer ZD frame will be attached to the skull. A T1-weighted 3D MRI with gadolinium will be performed.~Investigators will plan on this MRI, anatomical targets and deep brain trajectories using the NeuroInspire surgical planning software.~The patient will be attached to the base of the robot through the frame. Registration will be performed using the Neurolocate method after the acquisition of 3D CT images using the O-arm. The Neurolocate recording is based on radiographic images.The 3D MRI will be merged with the 3D tomography images taken with the O-arm to co-register the trajectories planned on the MRI in the robot space The surgical procedure will be performed as usual by milling the bone at the entry point and inserting under robotic guidance an electrode through a guide tube to the intended target."
45775810|NCT05272397|Drug|Placebo|20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
45775811|NCT05272397|Behavioral|Language Task|The core part of the experiment is the language task, in which the aim is to investigate two critical aspects of language processing: semantic and syntactic processing. In this task, participants will be asked to read a list of sentences.
45775812|NCT05272397|Behavioral|Rest Recording|Brain activity in the EEG is recorded at rest with eyes open and eyes closed to obtain baseline measures of alpha power as a proxy for attention and control under conditions of drug and placebo.
45775813|NCT05272397|Behavioral|Go/No-Go Task|A Go/No-Go task will be implemented in the study design to investigate the functional properties of spatial selective attention and response inhibition. An adapted cued Go/No-Go paradigm from Randall & Smith (2011) will be employed.
45775814|NCT05272397|Behavioral|Processing Speed|A speeded button response task will be included to measure participants' general processing speed. In this task, participants will be instructed to respond to a simple shape presented in the centre of the screen as fast and accurately as possible through pressing a corresponding button.
45775815|NCT05272397|Behavioral|Operation Span|In the operation span task, participants are instructed to solve math operations (e.g., (1*2) +1=?) as soon as possible and then remember a single letter. This to-be-remembered letter is followed by either another math-word combination or a recall screen, which will show up at the end of each set. When the recall screen is presented, participants have to recall all the letters in the correct order they were presented. The experimental trials contain three sets at each set size (i.e., the number of math-word pairs), with set sizes ranging from 3 to 7 items. This results in a total of 75 sets with 75 letters and 75 math problems. The order of set sizes is random for each participant. Participants' operation span will be evaluated by the total number of letters recalled in the correct serial position regardless of whether the entire trial was recalled correctly.
45775816|NCT05272397|Behavioral|Reading Span|Participants are instructed to judge whether a presented sentence makes sense or not. After each sentence, a to-be-remembered letter will be shown on the screen, which is followed by either another sentence-word combination or the final recall screen. The set size ranges from 3 to 7 items. At the end of each set of sentences, participants will be required to recall all the letters in the current set in order. There will be a total of 75 letters and 75 sentence judgements. The order of the set sizes will be at random for each participant. Participants' performance will be evaluated by calculating the total number of correctly recalled letter sets.
45775817|NCT05272397|Behavioral|Barratt Impulsiveness Scale|The Barratt impulsiveness scale (BIS-11) will be used in the experiment to measure participants' trait impulsivity. Participants will be required to rate themselves on 30 items that are related to attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness.
45775818|NCT00481403|Behavioral|Microarray analysis|Microarray analysis
45775819|NCT00481403|Behavioral|Microarray|Microarray
45775820|NCT01127087|Drug|Oxazyme|"Oxazyme (registered trademark) is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase (OxDC). It is formulated to enzymatically degrade available dietary oxalate prior to its absorption.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
45935601|NCT00074334|Procedure|conventional surgery|
45935602|NCT00127348|Device|CPAP (Continuous Positive Airway Pressure)|
45637526|NCT04704661|Drug|Ceralasertib|Given PO
45935603|NCT00127387|Drug|Enbrel|
45637527|NCT04704661|Biological|Trastuzumab Deruxtecan|Given IV
45637528|NCT04691154|Combination Product|L606 inhalation suspension|L606 inhalation suspension, twice daily dosing
45637529|NCT04671771|Device|InnAVasc arteriovenous graft surgical implant|The InnAVasc AVG is a hemodialysis vascular access graft, intended for implantation in the lower or upper arm using standard vascular techniques, in patients requiring hemodialysis
45637530|NCT04663308|Drug|Volixibat|Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.
45637531|NCT04663308|Drug|Placebo|Capsules matched to study drug minus active substance
45775821|NCT00271154|Device|Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT|All randomized patients will be implanted with a market-released Medtronic CRT or CRT/ICD device.
45914968|NCT05680974|Other|If a targetable cytokine is increased in the lesional skin of a patient, this patient is treated with the respective antibody therapy (off-label use of approved drug).|If a targetable cytokine is increased in the lesional skin of a patient, this patient is treated with the respective antibody therapy (off-label use of approved drug).
45637532|NCT04657549|Procedure|Tonsillectomy|Tonsillectomy is done by monopolar electrocautery, bipolar scissors or cold instruments. First the mucosa of the anterior palatinal arch is incised and tonsillar capsule identified, then tonsillar tissue is removed along the capsule. Any bleeding is coagulated either with monopolar or bipolar electrocautery.
45914969|NCT05680935|Diagnostic Test|blood microRNA|all patients will receive blood (20 ml) from the cubital vein for microRNA isolation.
45637533|NCT04657549|Procedure|Tonsillotomy|Tonsillotomy is done using monopolar electrosurgery, bipolar scissors or coblator device. Most of the tonsillar tissue is removed, exceeding the removal behind the line between anterior and posterior palatinal arch so that only thin layer of tonsil tissue is left over the tonsillar capsule.
45448319|NCT00129467|Drug|Selective Serotonin Uptake Inhibitor (SSRI)|"Each subject will be treated with a SSRI. Patients who are taking an SSRI at the time of enrollment will continue on the same medication during the 18-day blind treatment period. The prescribed dose will only be adjusted if it is more than the highest dose in the recommended range (fluoxetine to 40 mg, paroxetine to 40 mg, citalopram to 40 mg, sertraline to 150 mg). Patients who are not on a SSRI at the time of enrollment will be prescribed citalopram 10 mg per day for 2 weeks, then 20 mg per day.~A subject's SSRI may be discontinued if the subject experiences moderate to severe side effects likely attributable to a SSRI. If subjects experience similar symptoms when increasing their citalopram dose to 20 mg per day, they will drop back to 10 mg per day. During the open label extension, the SSRI may be increased, decreased, or changed to a different SSRI or other antidepressant with the exception of venlafaxine and bupropion"
45448320|NCT02140138|Biological|CV9104|
45637534|NCT04652726|Drug|Inclisiran|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection
45637535|NCT04652726|Drug|Placebo|Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
45637536|NCT04649242|Drug|Rimegepant/BHV3000|BHV3000 (rimegepant) 75 mg or 50 mg ODT
45637537|NCT04649242|Drug|Matching placebo|Matching 75 mg or 50 mg ODT placebo
45637538|NCT04616326|Drug|Galcanezumab|Administered SQ
45448321|NCT02140138|Device|needle free injection device (Tropis®)|
45637539|NCT04616326|Drug|Placebo|Administered SQ
45637540|NCT04612049|Device|Immersive virtual reality visuo-motor skill assessment|Visuo-motor skill assessment in an immersive 3D virtual environment using a head-mounted display.
45637541|NCT04588688|Drug|Mifepristone|Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor.
45637542|NCT04587830|Drug|ADI-PEG20|Investigational Medicine
45637543|NCT04587830|Drug|Temozolomide|Radiotherapy and TMZ are standard front-line therapy for newly diagnosed GBM.
45637544|NCT04568369|Device|rTMS|See treatment arm description.
45637545|NCT04558281|Drug|Active ropivacaine 0.3% erector spinae plane perineural administration|Ropivacaine 0.3% administration via an erector spinae plane perineural catheter
45637546|NCT04558281|Drug|Placebo erector spinae plane perineural administration|Normal saline administration via an erector spinae plane perineural catheter
45637547|NCT04539964|Procedure|Implant Procedure|The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
45637548|NCT04539964|Drug|Conventional Synthetic DMARD|All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent
45637549|NCT04539964|Device|Active stimulation|Active stimulation for 1 min once per day
45637550|NCT04539964|Device|Non-active stimulation|Non-active stimulation for 1 min once per day
45637551|NCT04520607|Drug|Placebo|Healthcare professional-administered intra-articular injection of vehicle.
45637552|NCT04520607|Drug|Lorecivivint|Healthcare professional-administered intra-articular injections of lorecivivint.
45637553|NCT04510090|Drug|EP547|EP547
45637554|NCT04510090|Drug|Placebo|Placebo
45637555|NCT04498468|Drug|Sustained Release Dexamethasone, 0.4 mg|dexamethasone 0.4mg lacrimal insert
45775822|NCT00136214|Diagnostic Test|MR brain and neuropsychiatric tests|
45775823|NCT01127321|Other|Placebo|A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
45775824|NCT01127321|Biological|MEDI-570 0.03 MG|A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
45775825|NCT01127321|Biological|MEDI-570 0.1 MG|A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
45914970|NCT05680935|Diagnostic Test|plaque and intima microRNA|The resulting surgical material will be sent for microRNA isolation.
45914971|NCT05680935|Diagnostic Test|histological examination of the plaque|The resulting surgical material (atherosclerotic plaque) will be sent for histological examination.
45914972|NCT05680935|Diagnostic Test|blood level trimethyl N-oxide|all patients will receive blood (20 ml) from the cubital vein for determination of plasma trimethyl N-oxide (TMAO) content.
45914973|NCT05680896|Biological|inactivated COVID-19 vaccines; orally aerosolized Ad5-nCoV|the protection of COVID-19 vaccines on breakthrough infection
45914974|NCT05680857|Other|Placebo|Product doesn't have active ingredients i.e. marine collagen peptide and Coenzyme Q10.
45914975|NCT05680857|Other|Product containing marine collagen peptide and Coenzyme Q10.|Product containing marine collagen peptide and Coenzyme Q10.
45914976|NCT00386763|Drug|Artemether-lumefantrine|
45914977|NCT05680701|Other|real tACS|The participant will receive one session of 10 Hz tACS for 20-minutes
45914978|NCT05680701|Other|sham tACS|The participant will receive one session of active-sham tACS for 20-minutes
45637556|NCT04498468|Other|E-Caprolactone-L-Lactide copolymer (PCL) punctal plug|Control eye will receive a tear duct plug without the dexamethasone (EXTENDED WEAR SYNTHETIC ABSORBABLE PUNCTAL PLUG made of E-Caprolactone-L-Lactide copolymer (PCL). Absorbs in 60 to 180 days. Size 0.5mm which is comparable to the study treatment)
45775826|NCT01127321|Biological|MEDI-570 0.3 MG|A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
45637557|NCT04491006|Drug|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
45637558|NCT04491006|Drug|Placebo|Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
45637559|NCT04486391|Drug|Tislelizumab|200 mg administered via intravenous (IV) infusion once every 3 weeks
45637560|NCT04486391|Drug|Salvage Chemotherapy|Salvage chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE (dexamethasone, ifosfamide, carboplatin, etoposide), ICE (ifosfamide, carboplatin, etoposide), IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone), GVD (gemcitabine, vinorelbine, liposomal doxorubicin), and MINE (etoposide, ifosfamide, mesna, mitoxantrone)
45637561|NCT04473222|Behavioral|Sleep Well!|Sleep Well! is a brief, behavioral sleep intervention. The intervention was originally comprised of healthy sleep advice and tested in the context of a sleep health education campaign for impoverished children. Based on preliminary research regarding the need for sleep intervention in primary care, Investigators have expanded the intervention to more comprehensively address poor sleep health behaviors (e.g., use of electronics at bedtime; inconsistent and variable sleep schedules; lack of a bedtime routine) as well as insomnia (difficulty falling and staying asleep; the need for caregiver presence at bedtime) and insufficient sleep in toddlers and preschoolers who are living in disadvantaged contexts. Intervention components are based on effective pediatric behavioral sleep treatments.
45637562|NCT04473222|Behavioral|Sleep education|Sleep education for caregivers of toddlers and preschoolers is provided via a Parent Family Education handout available to families and clinicians in the CHOP primary care network. The handout contains evidence-based advice about healthy sleep in early childhood.
45637563|NCT04451408|Drug|LY3372993|Administered IV or SC.
45637564|NCT04451408|Drug|Placebo|Administered IV or SC.
45637565|NCT04437511|Drug|Donanemab|Given IV
45637566|NCT04437511|Drug|Placebo|Given IV
45637567|NCT04436510|Drug|Matching Placebo|"Drug: Matching Placebo~Administration: Oral~Dose: two tablets twice daily"
45637568|NCT04436510|Drug|Verdiperstat|"Drug: Verdiperstat~Administration: Oral~Dose: 600mg twice daily"
45637569|NCT04434092|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight >=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight >=100kg). Dosing schedule will be as described above.
45637570|NCT04434092|Drug|Eculizumab|Eculizumab will be administered at a dose of 600 mg for the first 4 weeks, followed by maintenance doses of 900 mg starting on Week 5, as per the dosing schedule described above.
45637571|NCT04433052|Behavioral|personalised prevention program (PPP)|Study subjects in the PPP arm will be invited to return to the study site six times over a three-year period (at V2/start of the study, V3/mo2, V4/mo6, V5/mo12, V6/mo18 and V7/mo36) to receive lifestyle coaching and exercise prescriptions led by a delegated member of the site staff and supervised by the investigator. Information on drug treatment will also be given by the investigator. These activities will be assisted by digital tools specifically designed for this study, the CoroPrevention Tool Suite.
45775827|NCT01127321|Biological|MEDI-570 1 MG|A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
45775828|NCT00272168|Behavioral|Maryland Program for Vocational Effectiveness|psychosocial intervention that combines elements of cognitive-behavioral therapy (CBT) with work-related social skills training and basic problem solving training (SST)
45775829|NCT00272168|Other|Supportive Treatment for SMI|Sessions are interactive, supportive, flexible, and unstructured, and are intended to help patients adjust to their new jobs and understand how working affects their lives. The therapist stance is non-directive, and there is an emphasis on having patients share with one another, rather than having the therapists dictate the content of group sessions. The primary goals of the therapists are to engage patients in treatment and to generate discussion among members.
45775830|NCT00185900|Drug|Magnesium Sulfate|Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.
45775831|NCT00185900|Drug|Nifedipine|Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.
45775832|NCT00186056|Drug|Mifepristone|Glucocorticoid antagonist
45775833|NCT00186056|Drug|Placebo Oral Tablet|Inactive placebo tab
45775834|NCT00186446|Drug|bupropion and smoking cessation behavioral intervention|
45448322|NCT02140216|Biological|No blood transfusion|No blood transfusion
45775835|NCT01899638|Drug|UMEC/VI 125/25 mcg|Combination in high dose
45775836|NCT01899638|Drug|UMEC/VI 62.5/25 mcg|Combination in low dose
45775837|NCT01899638|Drug|UMEC 125 mcg|LAMA mono in high dose
45775838|NCT01899638|Drug|UMEC 62.5 mcg|LAMA mono in low dose
45775839|NCT01899638|Drug|VI 25 mcg|LABA mono
45448323|NCT02140216|Biological|Day 0 blood transfusion|Patients undergoing elective spine surgery receiving intra- or immediate-postoperative red cell blood transfusion.
45775840|NCT00136760|Drug|Bupropion|Contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
45935604|NCT00127465|Procedure|Issue of information booklet|
45637572|NCT04432584|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight >=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight >=100kg). Dosing schedule will be as described above.
45637573|NCT04432584|Drug|Eculizumab|Eculizumab will be administered at a dose of 900 mg every 2 weeks, as per the dosing schedule described above.
45637574|NCT04401267|Drug|Intensive Antihypertensive Therapy|Receives intensive antihypertensive therapy
45637575|NCT04401267|Drug|Conventional Antihypertensive Therapy|Receives conventional antihypertensive therapy
45637576|NCT04401267|Other|Symptom Survey|The symptom survey is comprised of the PROMIS Ped 25 profile, PROMIS pain interference 8a, PROMIS physical activity 8a, and PROMIS mobility 8a during induction (day 23-28), during week 17 of continuation (+/- 2 weeks), and continuation week 49 (+/- 3 weeks).
45637577|NCT04401267|Other|Semi-structured interview|Patients will be interviewed by a trained examiner about their treatment and symptom burden on Week 49 of TOT17 Continuation Therapy. The interview will be recorded and will take about 30-45 minutes.
45637578|NCT04396574|Drug|Lasmiditan|Administered orally
45637579|NCT04396236|Drug|Lasmiditan|Administered orally
45637580|NCT04396236|Drug|Placebo|Administered orally
45637581|NCT04365400|Drug|DS102|DS102 Epeleuton capsules
45637582|NCT04365400|Drug|Placebo|Placebo capsules
45637583|NCT04361240|Radiation|Proton vs Photon Radiation|Assignment to proton vs photon by randomization on RadComp parent study.
45637584|NCT04345913|Procedure|Biopsy|Undergo biopsy
45637585|NCT04345913|Procedure|Biospecimen Collection|Undergo blood sample collection
45637586|NCT04345913|Procedure|Computed Tomography|Undergo CT scan
45637587|NCT04345913|Drug|Copanlisib Hydrochloride|Given IV
45637588|NCT04345913|Drug|Eribulin Mesylate|Given IV
45637589|NCT04345913|Procedure|Magnetic Resonance Imaging|Undergo MRI
45775841|NCT00136760|Drug|Contingent reinforcement plus placebo|contingent reinforcement plus placebo (3 weeks)
45775842|NCT00136760|Drug|non-contingent reinforcement plus bupropion|non-contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
45637590|NCT04344470|Device|EMG|EMG will be recorded from two electrodes placed on both extensor carpi radialis (ECR) muscles
45637591|NCT04344470|Device|EEG|EEG electrodes will be positioned according to 10-20 International System, with every impedance kept under 5 kOhm. EEG data will be amplified, filtered (DC-100 Hz), digitized at 1000 Hz, and stored on a computer for offline analysis.
45637592|NCT04343222|Drug|Bromfenac|An NSAID used to treat eye pain and swelling
45775843|NCT00136760|Drug|Non-contingent reinforcement plus placebo|Non-contingent reinforcement plus placebo
45775844|NCT00136838|Behavioral|Neutral or active cigarette cues|Packets of cigarettes or cigarette smoke.
45637593|NCT04343222|Drug|Artificial tears|eye drops to lubricate the eye and maintain moisture
45637594|NCT04342039|Drug|Budesonide Nasal|budesonide 64 mcg/spray; 2 sprays each nostril once daily on days as indicated in the timeline
45637595|NCT04342039|Other|Placebo|2 sprays each nostril daily on days as indicated in the timeline
45637596|NCT04311671|Drug|Moxidectin|2mg tablets, encapsulated for blinding
45637597|NCT04311671|Drug|Ivermectin|3mg tablets, encapsulated for blinding
45775845|NCT00189098|Drug|Sulfamethoxazole-trimethoprim|18 mg/kg, two times a day
45637598|NCT04311671|Drug|Albendazole|400 mg tablets
45637599|NCT04303169|Biological|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
45637600|NCT04303169|Biological|Vibostolimab|Administered via IV infusion at a specified dose on specified days
45637601|NCT04303169|Biological|Gebasaxturev|Administered via IT injection at a specified dose on specified days
45637602|NCT04303169|Biological|MK-4830|Administered via IV infusion at a specified dose on specified days
45637603|NCT04303169|Biological|Favezelimab + Pembrolizumab|Administered via IV infusion at a specified dose on specified days
45637604|NCT04303169|Drug|ATRA|Administered via oral capsules at a specified dose on specified days
45637605|NCT04281108|Drug|APT-1011|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
45637606|NCT04281108|Drug|Placebo oral tablet|Placebo orally disintegrating tablet.
45637607|NCT04281108|Procedure|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus.
45637608|NCT04268849|Drug|Ferumoxytol|Ferumoxytol (30 mg/mL) intravenous injection in single use vials.
45637609|NCT04268849|Drug|Saline|Placebo for Ferumoxytol
45637610|NCT04268849|Drug|Ferrous sulfate tablets|ferrous sulfate tablets containing 60 mg elemental iron
45637611|NCT04268849|Drug|Vitamin C|Placebo: Vitamin C, 250 mg, given in the same bottle as the oral iron
45637612|NCT04258046|Drug|Trametinib tablet|Drug is supplied in 0.5 mg and 2 mg tablets
45637613|NCT04255199|Behavioral|Control|Clinicians randomized to the control group will receive a single visit with a standardized patient instructor (SPI) scheduled during usual office hours. SPIs will portray a patients with acute back pain but will deliver no formative training or feedback to the primary care physicians randomized to the control arm.
45637614|NCT04255199|Behavioral|Intervention|Clinicians randomized to the intervention group will receive 2-3 visits with a standardized patient instructor (SPI) scheduled during usual office hours over ~3 month period. For intervention physicians, SPIs will portray patients with acute back pain and will provide formative feedback to physicians and specific instruction in communication techniques to facilitate patient acceptance of a watchful waiting strategy with respect to spinal imaging. The specific communication techniques and sequence will be determined based on pre-trial literature review, patient focus groups, and interviews of primary care physicians who will not participate in the trial.
45775846|NCT00189098|Drug|Placebo|
45775847|NCT00145418|Drug|Oxaliplatin + Docetaxel|Oxaliplatin 85mg/m2 Docetaxel 30mg.m2
45775848|NCT04751474|Other|Motivational messages|Participants in the motivational group were sent to motivational messages to their mobile phones for 21 days.
45637615|NCT04248829|Drug|Lazertinib 240 mg/160 mg|The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
45637616|NCT04248829|Drug|Gefitinib 250 mg|The initial dose for Gefitinib (250 mg once daily) cannot be reduced to a lower dose
45637617|NCT04248829|Drug|Lazertinib-matching placebo 240 mg/160 mg|The initial dose of lazertinib-matching placebo 240 mg (3 tablets of 80 mg lazertinib-matching placebo) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib-matching placebo) under specific circumstances
45775849|NCT04751318|Drug|Duloxetine 60mg Test Drug Enteric Coated Granules|Investigational Medicinal Product
45775850|NCT04751318|Drug|Duloxetine 60mg Reference Product Enteric Coated Granules|Cymbalta (Eli Lilly)
45637618|NCT04248829|Drug|Gefitinib-matching placebo 250 mg|The initial dose for Gefitinib-matching placebo (250 mg once daily) cannot be reduced to a lower dose
45637619|NCT04236986|Drug|Lipopolysaccharide|LPS will be administered intravenously (1.0ng/kg; IV)
45448324|NCT02140216|Biological|Day 1 or 2 blood transfusion|Patients undergoing elective spine surgery receiving first red cell blood transfusion on day 1 or 2 after surgery.
45775851|NCT01105247|Drug|PCI-32765|420 mg daily or 840 mg daily
45775852|NCT01107665|Drug|Pazopanib and Paclitaxel|Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
45775853|NCT05272007|Procedure|EUS-biliary drainage|EUS-GBD with LAMS
45448325|NCT00129311|Drug|Selegiline|5 mg capsules taken by mouth. Participants take 5 mg once a day for the first week of the study, then increase the dose to 5 mg twice a day for 6 weeks, then take 5 mg once a day during the last week of the study. Participants receiving the placebo pill take 1 pill per day for the first week of the study and 1 pill twice a day for the other weeks.
45775854|NCT03012659|Behavioral|Contraceptive Counseling Training|"Intervention sites will receive:~In person training: All staff at an intervention health center will participate in a one-day counseling training.~On-site shadowing: Trainers will shadow staff in-clinic the day following the training to observe the counseling implementation and provide additional coaching and support.~Technical assistance: A Planned Parenthood clinic operations expert will provide follow-up technical assistance."
45775855|NCT01447225|Drug|MM-121|MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV
45775856|NCT01447225|Drug|Carboplatin|administered at AUC 6
45775857|NCT01447225|Drug|Pemetrexed|administered IV at 500 mg/m2
45775858|NCT01447225|Drug|Cabazitaxel|administered IV at 20 mg/m2 or 25 mg/m2
45775859|NCT01447225|Drug|Gemcitabine|administered IV at 1000 mg/m2 or 1250 mg/m2
45775860|NCT01447849|Drug|lubiprostone|24mcg twice a day (BID) 1 week
45775861|NCT01447849|Drug|placebo|Placebo pills twice a day for one week.
45775862|NCT00277394|Drug|innohep®|175 anti-Xa IU/kg administered subcutaneously (SC) once daily
45448326|NCT00129311|Drug|Placebo|
45448327|NCT03548350|Behavioral|HealthyKidz physical activity programme|A 24 week physical activity intervention to promote fitness and wellbeing in primary schools
45448328|NCT01076621|Drug|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|Data collection of the use of 0.5 mg estradiol and 0.1 mg norethisterone acetate (NETA) in women in connection to a daily clinical practice.
45448329|NCT05577832|Procedure|Helfer Skin Tap Technique|In a single-group design, 3 technique injections will be administered to the patients, 1 technique per week, to be randomized. The HST technique will be applied to patients in any one of 3 weeks in a randomized fashion.
45637620|NCT04232761|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Drug administration as determined by treating physician
45637621|NCT04230265|Drug|Cyclophosphamide (Non-IMP)|Intravenous infusion over 3 days
45637622|NCT04230265|Drug|Fludarabine (Non-IMP)|Intravenous infusion over 3 days
45637623|NCT04230265|Drug|TM123 (IMP)|Intravenous Infusion for 20 days
45637624|NCT04230265|Drug|UniCAR02-T (IMP)|Intravenous infusion of single dose
45637625|NCT04227587|Other|Zero Time Exercise|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
45637626|NCT04227587|Other|Sleep hygiene education|We offer a 2-session education course to teach the subjects about sleep hygiene practice.
45637627|NCT04217161|Device|Dexcom G6 Continuous Glucose Monitor|Eligible patients will undergo DDexcom G6 Continuous Glucose Monitor device placement
45637628|NCT04215978|Drug|BGB-A445|Administered as specified in the treatment arm
45637629|NCT04215978|Drug|tislelizumab|Administered as specified in the treatment arm
45637630|NCT04210115|Biological|pembrolizumab|IV infusion
45637631|NCT04210115|Drug|placebo|IV infusion
45775863|NCT00277394|Drug|Heparin|Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
45775864|NCT01450189|Behavioral|Standard HIV prevention messages|A single session of standard HIV prevention messages during HIV post-test counseling with supplemental information regarding the acute stage of their infection.
45775865|NCT01450189|Behavioral|BI: Information-Motivation-Behavioral Skills Model|The behavioral intervention consists of five counselor-delivered sessions based on the Information-Motivation-Behavioral Skills (IMB) Model. The sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
45775866|NCT01450189|Drug|Raltegravir|raltegravir (400 mg) administered orally twice daily for 12 weeks
45775867|NCT01450189|Drug|emtricitabine/tenofovir disoproxil fumarate|emtricitabine/tenofovir (200/300 mg daily) in a fixed dose combination administered orally for 12 weeks
45775868|NCT00278876|Drug|Imatinib mesylate (Glivec)|Imatinib mesylate 400mg/day per oral (day 1-28) every 4 weeks
45637632|NCT04210115|Drug|cisplatin|IV infusion
45637633|NCT04210115|Drug|5-FU|IV infusion
45637634|NCT04210115|Radiation|radiotherapy|external radiation
45637635|NCT04210115|Drug|leucovorin|IV infusion
45637636|NCT04210115|Drug|levoleucovorin|IV infusion
45637637|NCT04210115|Drug|oxaliplatin|IV infusion
45637638|NCT04192227|Behavioral|EnHAncing BehavIors through wellness TreatmentS (HABITS)|Six 75-minute sessions via live video conference wherein participants will receive training in areas of health, wellness and quality of life. Classes will be supplemented with independent homework assignments and discussion on a closed social media forum with peers and facilitators.
45637639|NCT04189055|Drug|Cetuximab|Cetuximab 500mg/m² IV, day 1
45775869|NCT01474213|Drug|dexmedetomidine group|1-1.5cmg/kg dexmedetomidine infusion within 10 minutes, while followed by maintainly infusing 0.7cmg/kg/min dexmedetomidine
45775870|NCT01474213|Drug|remifentanil group|target controlled 3.5-4ng/ml remifentanil infused(blood plasma concentration)
45775871|NCT04752410|Procedure|Selective Brachial Plexus Block|It is one type of peripheral nerve blocks for upper extremity surgery. In this study, the block will be done under the ultrasound guidance and the local anesthetic agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 25ml) will be injected at the trunks of the brachial plexus in order to produce the surgical anesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries.
45775872|NCT03008863|Other|Education|
45775873|NCT00147212|Drug|ET 743|ET-743 administered IV by 24-hr infusion every 3 weeks
45775874|NCT01474915|Drug|Aprepitant|Subject will receive 40 mg of Aprepitant versus placebo PO before anesthesia induction
45775875|NCT01474915|Drug|Ondansetron|Subject will receive 4 mg of Ondansetron IV versus placebo around anesthesia induction
45775876|NCT01474915|Drug|Promethazine|Subject will receive 25 mg of Promethazine IV around anesthesia induction
45775877|NCT01474915|Drug|Dexamethasone|Subject will receive 10 mg of Dexamethasone IV around anesthesia induction
45775878|NCT00280826|Drug|Efalizumab|Participants who qualified for the study received weekly subcutaneous treatments of efalizumab, with the first dose being a test dose of 0.7 mg/kg and subsequent doses of 1 mg/kg (not to exceed 200 mg per dose), for a total treatment duration of 16 weeks.
45775879|NCT01899794|Procedure|TVT-O/Oxytrol|
45775880|NCT01899794|Device|TVT-O|
45775881|NCT01899794|Drug|Oxytrol|
45775882|NCT00147446|Behavioral|Individual Stress Management|Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
45775883|NCT00147446|Other|Wait List Control|Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
45775884|NCT01475305|Drug|Placebo|Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.
45775885|NCT01475305|Drug|MEDI-557|Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.
45775886|NCT00280904|Device|Shunt catheter|standard of care implantation of shunt (any brand). Subjects are followed for 90 days to obtain information about whether or not an infection occurred.
45775887|NCT02103218|Behavioral|Education, activities, empowerment, racial pride building|Intervention focuses on information aimed toward reducing or preventing risky sex behaviors of minority adolescent females.
45775888|NCT02103218|Behavioral|General Health education, activities|Intervention focuses on information regarding general health knowledge and healthy behaviors (not including sex).
45775889|NCT01391299|Biological|botulinum toxin Type A|Botulinum toxin Type A (total dose 30 Units or 40 Units) injected into bilateral forehead and frown line areas on Day 1.
45775890|NCT01391299|Drug|Normal Saline|Normal Saline (placebo) injected into bilateral forehead and frown line areas on Day 1.
45775891|NCT02099084|Drug|Teduglutide|Participants will receive Teduglutide 0.05 mg/kg/d administered subcutaneously.
45637640|NCT04189055|Drug|Irinotecan|Irinotecan 180mg/m² IV, day 1
45637641|NCT04184622|Drug|Tirzepatide|Administered SC
45637642|NCT04184622|Drug|Placebo|Administered SC
45637643|NCT04183595|Drug|(N1, N3-bis(2- mercaptoethyl)isophthalamide)|600mg / day NBMI treatment for 14 days, administered as four capsules of 100 mg of NBMI every 24 hours, at the start of treatment, the principal investigator or his delegate will verify the intake of the first dose and deliver a blister pack corresponding to the remaining NBMI capsules, at visit day 14 research subjects will be asked to return the packaging with the remaining capsules or not, in order to estimate adherence to treatment.
45637644|NCT04183595|Other|Excipients microcrystalline cellulose, silica and magnesium stearate|6 Capsules will be administered every 24 hours for 14 days.
45637645|NCT04165291|Behavioral|F4C|Fathers for Change (F4C) focuses on: 1) the fathering role to facilitate engagement, 2) RF to understand self, partner and children and emotion regulation skills to reduce IPV and child maltreatment. F4C focuses on understanding of emotional experiences, how they impact thinking and behaviors related to partners, co-parents and children. F4C clients will meet individually with their F4C therapist for 50 minutes per week over 16 weeks.
45775892|NCT02099084|Drug|Placebo|Participants will receive placebo matching study drug, administered subcutaneously.
45775893|NCT02099786|Other|COMP-VA|Hearing testing at each treatment interval by the comp-va audiologist
45775894|NCT02099786|Other|Standard of care|Hearing testing done in the audiology clinic after oncology referral or patient self referral
45775895|NCT02100410|Device|Delefilcon A toric contact lens T1|Iteration 2-87-1 with embossed mark
45935605|NCT00043862|Drug|topotecan|
45637646|NCT04165291|Behavioral|BIP|The Batterer Intervention Program (BIP) is a psychoeducational intervention that will be delivered in 50- minute individual weekly sessions over 16 weeks. The intervention focuses on the impact of violence on victims, power and control tactics, and societal influences supporting men's violence toward women. The intervention includes didactics and experiential exercises including role plays to teach anger management skills.
45637647|NCT04162470|Drug|REGN3918|Subcutaneous (SC) every week (QW) over the treatment period
45637648|NCT04147806|Radiation|IGRT 45 Gy in 5 fractions of 9 Gy|Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
45637649|NCT04147806|Radiation|IGRT 24 Gy single dose|Administration of a single dose of 24 Gy in one session
45775896|NCT02100410|Device|Delefilcon A toric contact lens T2|Iteration 2-87-1 without embossed mark
45775897|NCT02100410|Device|Delefilcon A toric contact lens T3|Iteration 2-87-2 with embossed mark
45637650|NCT04147806|Drug|Dexamethasone|4 mg by mouth on treatment days only
45637651|NCT04147806|Drug|Tamsulosin|0.4 mg by mouth daily starting the day of simulation and until 2 weeks post-treatment.
45637652|NCT04131361|Other|Ultrasound-guided Inferior vena cava diameter dependent colloid challenge versus routine crystalloid strategy Fluid replacement|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region.
45775898|NCT02100410|Device|Delefilcon A toric contact lens T4|Iteration 2-87-2 without embossed mark
45775899|NCT02100410|Device|Delefilcon A toric contact lens T5|Iteration 2-87-3 with embossed mark
45775900|NCT02100410|Device|Delefilcon A toric contact lens T6|Iteration 2-87-3 without embossed mark
45775901|NCT01477567|Drug|LY3009385|
45775902|NCT01477567|Drug|Placebo|
45775903|NCT01391611|Drug|Pazopanib|800 mg; PO
45775904|NCT00281918|Drug|Rituximab|Intravenous repeating dose
45775905|NCT00281918|Drug|Cyclophosphamide|Intravenous repeating dose
45775906|NCT00281918|Drug|Fludarabine Phosphate|Intravenous repeating dose
45775907|NCT00201734|Drug|Capecitabine|Level 1: 500 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 2: 750 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 3 - 5: 1000mg/m2 orally twice daily Days 8 - 21 of each cycle.
45775908|NCT00201734|Drug|Carboplatin|Levels 1-5: AUC of 6 every 4 weeks.
45775909|NCT00201734|Drug|Paclitaxel|Level 1-3: 60 mg/m2/week. Level 4: 80 mg/m2/week. Level 5: 100 mg/m2/week.
45637653|NCT04122625|Drug|Debio 1143|Administered as capsules.
45775910|NCT01898468|Procedure|Pericostal Closure Technique|
45637654|NCT04122625|Drug|Nivolumab|Administered as IV infusion.
45637655|NCT04117945|Biological|Cetuximab|Given IV
45637656|NCT04117945|Drug|Irinotecan|Given IV
45637657|NCT04117945|Biological|Panitumumab|Given IV
45637658|NCT04117945|Drug|Regorafenib|Given PO
45637659|NCT04097561|Biological|Belimumab|Belimumab 10 mg/kg once every 2 weeks for 3 doses, and then once every 4 weeks for 5 doses, delivered via 1-hour intravenous (IV) infusion.
45637660|NCT04091984|Diagnostic Test|Prospera|No Interventions, this is an observational study.
45637661|NCT04088188|Drug|Cisplatin|Given IV
45637662|NCT04088188|Drug|Gemcitabine|Given IV
45637663|NCT04088188|Drug|Ivosidenib|Given PO
45637664|NCT04088188|Drug|Pemigatinib|Given PO
45637665|NCT04077346|Device|Biostim-5 transcutaneous spinal stimulator|"Transcutaneous spinal stimulation (TcStim): The 5-channel stimulator capable of generating (41) pain-free biphasic rectangular waveform of 0.3- to 1.0-ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels.~TcStim will be delivered in combination with activity based locomotor training in 5 - 10 minute of stimulation at sub-motor threshold daily (5x/week) for 60 sessions"
45637666|NCT04077346|Other|Transcutaneous Spinal Stimulator + Activity Based Locomotor Training|Participants will receive a combination of Activity-based locomotor training (AB-LT)+TcStim daily (5x/week) for 60 sessions and will consist of a minimum of 55-60 min on the TM for facilitated standing/stepping followed by 30 min of activities off TM in sitting, standing, or stepping.
45637667|NCT04076462|Drug|CAM2029 (octreotide subcutaneous depot)|Octreotide subcutaneous depot for monthly injections in acromegaly patients
45637668|NCT04076462|Drug|Matching placebo|Matching placebo for CAM2029
45637669|NCT04066348|Biological|Etanercept|To treat blast or noise induced tinnitus
45637670|NCT04066348|Other|Saline|Placebo
45754255|NCT03588104|Other|Usual care|Usual care as given to diabetes patients by the patient's diabetes care team.
45754256|NCT04838041|Drug|Asciminib|40 mg by mouth (PO) twice a day (BID).
45775911|NCT01898468|Procedure|Intracostal Closure Technique|
45775912|NCT04752956|Other|"Total nasal symptom score (TNSS)"|TNSS contains 4 parameters in assessing the severity of allergic rhinitis: nasal congestion, runny nose, nasal itching, and sneezing. Each symptom is scored out of 4 points, from 0 to 3. 0, none- there are no complaints 1- mild- any symptom that exists but is not particularly annoying; 2, moderate, - any annoying symptom but does not interfere with daily activities or sleep; 3, severe - any symptom preventing daily activities or disturbing during sleeping. The total score is calculated by summing all the scores of 4 fields, which vary ranges from 0 to 15 .In our study, all patients will be instructed to record their TNSS symptom scores on their diary cards each morning before taking the drug. Patients will be graded on baseline TNSS parameters compared to 4 weeks before starting treatment.
45935606|NCT00127504|Drug|Rifampin|
45935607|NCT00127504|Drug|Azithromycin|
45775913|NCT04752956|Behavioral|"Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)"|"PRQLQ, is a self-administered, disease-specific questionnaire, evaluating physical, emotional, and social status of individuals with AR. It contains 23 items in 5 domains: nose symptoms (RS), eye symptoms (ES), practical problems (PF), activity limitation (RL) and other symptoms (OS). One score is given to each domain. 7-point scale (from 0, not problematic; to 6, very problematic). The overall score is derived from the average score of all items (20). In our study, the Turkish validated form of PRQLQ was used~Patients will be asked to answer PRQLQ questions at the end of each week during treatment. At the end of the treatment, an average of 4 weeks will be taken as the PRQLQ score. Basal PRQLQ questions will be evaluated by the participants based on 4 weeks prior to treatment."
45637671|NCT04064060|Drug|Luspatercept|Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the human immunoglobin G 1 (IgG1) Fc domain. ActRIIB receptor and its ligands are members of the transforming growth factor-β (TGF-β) superfamily. Members of the TGF-β superfamily ligands, through their binding to activin receptors, are involved in modulating the differentiation of late-stage erythrocyte precursors (normoblasts) in the bone marrow. Luspatercept for injection is formulated as a sterile, preservative-free, lyophilized cake/powder. Luspatercept for injection is available in 25 mg and 75 mg vials and when reconstituted with water for injection, each consists of 50 mg/mL luspatercept in a 10 mM citrate buffer-based solution
45637672|NCT04060966|Behavioral|Cold-Pressor Task (CPT)|The CPT involves participants submerging their dominant forearm in ice-water (0-4°C) for 3 minutes.
45637673|NCT04060966|Behavioral|Control CPT|The control CPT involves participants submerging their dominant forearm in warm water (~30°C) for 3 minutes.
45637674|NCT04060966|Device|fMRI|Participants in the neuroimaging cohort will complete up to two fMRI experimental sessions on different days, with at least a day between sessions, each lasting approximately 2 hours. Imaging data will be collected with a Prisma 3T head- only scanner equipped with a head coil from Nova Medical.
45637675|NCT04058288|Device|High-definition Transcranial Direct Current Stimulation|Stimulation sessions will be conducted on 2 different visits separated by 2-week gap. In a crossover design, Anodal HD-tDCS will be delivered either in Active/Sham mode (during the first visit) and Sham/Active during the second visit in a 4x1 ring configuration (center electrode being Anode and the surrounding 4 electrodes being cathodes) over the affected motor area.
45775914|NCT04752956|Diagnostic Test|Nasal cytology|In anterior rhinoscopy, nasal cytology will be scraped off the middle part of the lower turbinate with the help of a small sterile cotton swab. The cellular material obtained will be fixed by air drying on a glass slide and then stained by the May-Grünwald-Giemsa method. Preparations that do not contain respiratory epithelium or contain less than 10 epithelium at high magnification will be excluded from the study. A percentage of cells per 100 cells will be reported. NECs (nasal eosinophilic count) will be evaluated according to the quantitative classification of Gelardi et al. An experienced cytologist who is blind to the study groups will perform this test. Eosinophil percentages in nasal smears of all patients will be evaluated before and after the treatment.
45775915|NCT04752956|Diagnostic Test|anterior rhinomanometry|Children's right, left and total nasal airway resistance (NAR) and nasal airflow (NAF) will be measured with active anterior rhinomanometry ZAN 100 USB Rhinomanometry (Longmont, Colo., USA). In the evaluation, the NAR- pressure difference / air flow (R = P / V) formula will be used at a constant 150 Pascal prescribed by the European Rinomanometry Standardization Committee in 1984. After the patient is rested for 20 minutes, measurements will be made at 20-22 ° C and the nasal secretion will be cleared. NAR and NAF values of the participants will be measured before starting treatment and 4 weeks after treatment.
45775916|NCT00203216|Drug|levetiracetam|Daily dose of open label levatiracetam was 3000 mg. or maximally tolerated dose. (Maximum daily dose: 3000 mg. Minimum daily dose allowed for study participation:1000 mg)
45775917|NCT00203216|Procedure|Transcranial Magnetic Stimulation|
45775918|NCT05156060|Drug|Gabapentin|Taken by mouth 3 times per day
45775919|NCT05156060|Drug|Ketamine|Administered intranasally 3 times per day
45775920|NCT00204932|Drug|conjugated linoleic acid|4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA, and 22% safflower oil for 6 months
45775921|NCT00206336|Drug|Topiramate (drug)|Topiramate 25 mg to 200 mg
45775922|NCT00210470|Biological|IRX-2|IRX-2 for 10 days (2 s.c. injections of 1 mL each day) into bilateral mastoid insertion regions.
45775923|NCT00210470|Drug|Cyclophosphamide|Single i.v. injection of low-dose (300 mg/m2) on Day 1
45775924|NCT00210470|Drug|Indomethacin|21 days of oral indomethacin, 25 mg. 3 times daily
45775925|NCT00210470|Drug|Zinc|21 days of zinc gluconate (65 mg) as part of an oral multivitamin
45775926|NCT00210470|Drug|Omeprazole|21 days of 20 mg. orally
45775927|NCT00212264|Behavioral|Behavioral Therapy|Pelvic Floor Muscle Exercises and Bladder control strategies
45775928|NCT00212264|Device|Pelvic Floor Electrical Stimulation|Pelvic Floor Electrical Stimulation daily for 8 weeks
45637676|NCT04057898|Drug|MN-166|Subjects will take MN-166 for 12 months followed by a 6-month open-label extension phase.
45637677|NCT04057898|Drug|placebo|Subjects will take matching placebo for 12 months followed by a 6-month open-label extension phase.
45637678|NCT04057105|Device|Active High-definition Transcranial Direct Current Stimulation (HD-tDCS)|Stimulation sessions will be conducted once a day on 10 weekdays over a period of 2-3 weeks. Anodal HD-tDCS will be delivered either in Active or Sham mode (as per the randomized order) in a 4x1 ring configuration (center electrode being Anode and the surrounding 4 electrodes being cathodes) over the affected motor area.
45637679|NCT04057105|Device|MusicGlove|Both groups will undergo MusicGlove video-game based hand exercises.
45637680|NCT04044313|Procedure|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
45637681|NCT04044313|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
45637682|NCT04044313|Drug|Toripalimab|240mg intravenously every 3 weeks
45637683|NCT04042337|Behavioral|Pivotal Response Treatment|PRT will target functional communication abilities
45637684|NCT04032990|Device|Biostim-5 transcutaneous spinal stimulator|Safety and feasibility will be monitored during transcutaneous spinal stimulation in children with spinal cord injury
45637685|NCT04017351|Other|Artificial Intelligence Virtual Assistant|Virtual assistance application for subjects to ask questions and get information regarding planned surgery
45637686|NCT03999983|Other|Observational Prospective Registry|This is a prospective registry looking at patients admitted for stroke with evidence of Vertebral Artery Origin Stenosis. Patients clinical outcomes will be collected at 30 days and 1-year post-treatment and angiographic outcomes at 1-year post-treatment
45637687|NCT03993873|Drug|elzovantinib (TPX-0022)|Oral elzovantinib (TPX-0022) capsules
45637688|NCT03975634|Device|Transcutaneous Spinal Stimulation|Safety and feasibility will be monitored during transcutaneous spinal stimulation in children with spinal cord injury
45637689|NCT03968757|Device|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Device for creation of anastomoses during laparoscopic RYGB surgery manufactured by Ezisurg Medical.
45637690|NCT03941756|Drug|Indocyanine Green|Given IV
45637691|NCT03941756|Procedure|Lymphangiography|Undergo lymphangiography
45637692|NCT03941756|Procedure|Lymphovenous Bypass|Undergo LVB
45637693|NCT03938922|Drug|Active Investigational Treatment ENT-01|"ENT-01 will be administered in tablet form, once daily.~Other Names:~ENT-01"
45637694|NCT03888612|Drug|ARV-110|"Part A: Daily oral dosages are predetermined by cohort review committee after the initial starting dose cohort after the first 28 days of treatment~Part B: Daily oral dosage and schedule at a recommended Phase 2 dose based on data from Part A"
45637695|NCT03887455|Drug|Lecanemab|10 milligram per kilogram (mg/kg) biweekly (once every 2 weeks) administered as i.v. infusion.
45637696|NCT03887455|Drug|Placebo|Biweekly (once every 2 weeks) administered as i.v. infusion.
45637697|NCT03887455|Drug|Lecanemab|720 milligram (mg) weekly administered as subcutaneous injection.
45775929|NCT00212264|Behavioral|Biofeedback|Pelvic Floor Muscle training via biofeedback
45775930|NCT00212264|Other|No Treatment|No treatment
45775931|NCT01108445|Drug|Everolimus|Subjects in this treatment arm will receive everolimusRAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
45637698|NCT03878121|Biological|Ad4-Env145NFL|10^8 vp doses of Ad4-Env145NFL formulated as a liquid for intranasal administration.
45637699|NCT03878121|Biological|Ad4-Env150KN|10^8 vp doses of Ad4-Env150KN formulated as a liquid for intranasal administration.
45637700|NCT03878121|Biological|VRC-HIVRGP096-00-VP (Trimer 4571) with alum|500-mcg dose of protein boost vaccine formulated for intramuscular administration.
45637701|NCT03873870|Diagnostic Test|68Ga -DOTATATE PET scans|PET scan using 68Ga-DOTATATE contrast
45637702|NCT03847428|Drug|Durvalumab|Durvalumab IV (intravenous)
45637703|NCT03847428|Drug|Bevacizumab|Bevacizumab IV (intravenous)
45637704|NCT03847428|Other|Placebo|Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous) or Dextrose for Durvalumab masking
45637705|NCT03836976|Other|Auditory gamma sensory stimulation|"Gamma-conditioning stimulation will be~administered in 2 blocks of 3 min each. During each block, participants will be presented with a continuous~tone at the CF (500 or 1200 Hz) that will be amplitude modulated at 40 H"
45637706|NCT03828201|Drug|Delamanid|"Frequency: daily Route of administration: oral~Delamanid is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth."
45637707|NCT03828201|Drug|Levofloxacin|"Frequency: daily Route of administration: oral~Levofloxacin is an antibiotic used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis."
45637708|NCT03828201|Drug|Bedaquiline|"Frequency: daily Route of administration: oral~Bedaquiline is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability."
45637709|NCT03828201|Drug|Clofazimine|"Frequency: daily Route of administration: oral~Clofazimine has shown activity against multidrug-resistant tuberculosis (MDR-TB) and is now recommended by the World Health Organization (WHO) to treat drug resistant tuberculosis as a Group B drug. It is thought that clofazimine acts by inhibiting the formation of matrixes within the DNA and thus delaying the growth of the bacterium. Clofazimine first received FDA approval in 1986, although its use in the treatment of MDR-TB has not been approved by any stringent regulatory authorities and it is therefore used off-label for this function."
45637710|NCT03828201|Drug|Linezolid|"Frequency: daily Route of administration: oral~Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics."
45637711|NCT03824704|Drug|Rucaparib|Oral rucaparib will be administered twice daily
45775932|NCT01108445|Drug|Sunitinib|50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
45775933|NCT00212888|Biological|Remune and ALVAC|"Group 1) Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20);~Group 2) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20; or~Group 3) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20."
45775934|NCT01607892|Drug|KPT-330|
45914979|NCT05680662|Combination Product|quercetin, EGCG, metformin , zinc|this intervention target many mechanisms at tumorigenesis, metastasis autophagy, apoptosis, interleukin 6, cathepsin L, and also epigenetic DNA methylation
45914980|NCT05680545|Other|Sevoflurane vaporized in ECMO machines|Sevoflurane will be directly vaporized into the ECMO machine through the sweep gas.
45637712|NCT03824704|Drug|Nivolumab|IV nivolumab will be administered once every 4 weeks
45637713|NCT03800537|Device|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
45637714|NCT03798106|Drug|Durvalumab, pazopanib|Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks
45637715|NCT03773965|Drug|Baricitinib|Administered orally.
45637716|NCT03767075|Drug|Atezolizumab|1200 mg, administered IV, once every 3 weeks
45775935|NCT01108757|Drug|Bactrim|Bactrim DS BID for 3 days
45775936|NCT01108757|Other|Placebo|Corn starch capsules
45775937|NCT04352153|Drug|Febuxostat|Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
45775938|NCT04352153|Drug|Uralyt-U|Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
45775939|NCT05215067|Drug|AK104|IV infusion,Specified dose on specified days
45775940|NCT05215067|Drug|Docetaxel|IV infusion,Specified dose on specified days
45775941|NCT05214833|Behavioral|Real Neurofeedback|During neurofeedback, the brain activity in response to a motor task is recorded in real-time and displayed back to the participants.
45775942|NCT05214833|Behavioral|Sham Neurofeedback|During sham neurofeedback, a signal which resembles the participant's brain activity is used instead of the actual brain activity.
45775943|NCT05184569|Drug|Verdiperstat|Oral, extended release (ER) tablet
45775944|NCT05176301|Radiation|computed tomography, Magnetic resonance image|Investigators measured the cervical cord and canal diameter by using CT and MRI that were previously taken.
45775945|NCT01162733|Drug|Vancomycin|15mg/kg
45775946|NCT01162733|Drug|Vancomycin|30mg/kg
45775947|NCT02530242|Device|End-tidal Carbon Monoxide Subjects|ETCO monitor will be used to measure CO levels in subjects and controls.
45775948|NCT02530242|Device|End-tidal Carbon Monoxide Controls|ETCO monitor will be used to measure CO levels in subjects and controls.
45775949|NCT05121623|Other|Questionnaire|Online auto-administered Questionnaire
45775950|NCT05444010|Behavioral|mandala painting|nurse painted mandala for relaksing
45775951|NCT05410860|Drug|Etripamil NS 70 mg|Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
45775952|NCT05410860|Drug|Placebo|Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
45775953|NCT01131065|Drug|Hepatitis B immune globulin|Daily doses of 10,000 IU of intravenous hepatitis B immune globulin during the first week post-transplantation (anhepatic phase + days 1-7), followed by weekly and monthly doses of 5,000 IU during weeks 2,3, and 4 and months 2,3,4,5,6,7,8,9,10,11 and 12, respectively.
45914981|NCT05680506|Procedure|Pain neuroscience education|Pain neuroscience education will be given in form videos,pictures, stories and metaphors for 2 times per week for 4 weeks.
45637717|NCT03767075|Drug|Futibatinib|20 mg administered orally, once daily (QD) continuously in 28-day cycles.
45637718|NCT03767075|Drug|Amivantamab|1050 mg administered IV for body weight < 80 kg and 1400 mg for body weight >= 80 kg mg once weekly in Cycle 1 (with a split dose on Days 1-2) and then every 2 weeks in subsequent cycles (28-day cycles)
45637719|NCT03766581|Drug|BMS-986177|Oral administration
45637720|NCT03766581|Other|Placebo|Oral Administration
45637721|NCT03766581|Drug|Clopidogrel|Oral administration
45637722|NCT03766581|Drug|Aspirin|Oral administration
45775954|NCT00214526|Procedure|Bronchial thermoplasty with the Alair System|Conventional therapy with ICS+LABA plus bronchial thermoplasty with the Alair System.
45637723|NCT03743129|Drug|Anlotinib|Anlotinib 12mg p.o, qd
45637724|NCT03729115|Procedure|Magnetic Resonance Imaging (MRI)|Patients will have MRI scans every 6 months.
45637725|NCT03723850|Device|Active tDCS|The brain is stimulated for 20 minutes with mild electrical current (maximum 2 mA) with two 7 cm x 5 cm electrodes placed on the scalp, using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.
45637726|NCT03723850|Device|Sham tDCS|The brain is not stimulated for 20 minutes with mild electrical current, but instead a sham procedure is administered using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.
45637727|NCT03721393|Device|Wearable heart monitor|Participants will be fitted with a wearable heart monitor placed on the skin that measures physiologic signals. There is no intervention or treatment.
45775955|NCT00214526|Drug|Conventional therapy with ICS+LABA|Conventional therapy with ICS+LABA.
45775956|NCT02537574|Drug|NTX/BUP|Daily doses
45775957|NCT02537574|Drug|NTX/PBO-B|Daily doses
45775958|NCT02537574|Drug|PBO-N/PBO-B|Daily doses
45775959|NCT05098925|Other|Biological testing|Blood sampling, microcapillary sampling, temperature monitoring, saliva testing, EHI questionnaire
45775960|NCT03011801|Behavioral|Interpersonal Therapy|reducing conflict in relationships, increasing social support in relationships, improving communication, reducing depressive symptoms
45775961|NCT03011801|Behavioral|Enhanced usual care|Treatment as Usual, including eclectic and supportive therapy, as well as psychiatric medication
45775962|NCT03010241|Drug|Tangbi (prescription)|A kind of Granule(Tang bi fang) was made from five kind of Chinese herbs. Other: Standard medical care Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
45775963|NCT03010241|Drug|Placebo|"Granule(Placebo) is in accordance with Tangbi prescription in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013)."
45775964|NCT01164137|Behavioral|Medication Reconciliation|A pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at correcting and identifying medication discrepancies.
45775965|NCT01165541|Drug|Mirtazapine|mirtazapine (7.5-45mg)
45914982|NCT05680506|Procedure|Standard Therapy|Hot pack,TENS, Kaltenborn grade 1 and 2 mobilizations, stretchings and lumbar stabilization exercises
45914983|NCT05680389|Drug|Minocycline|100 mg twice daily for 3 months
45637728|NCT03716778|Other|Eccentric rehabilitation sessions|"ECC cycling will be conducted using a commercially available ECC motor-driven ergometer. Intensity and duration are progressively increased during the first five sessions in order to minimize the extent of exercise-induced muscle soreness.~The subjects will perform five sessions of endurance training on cycle ergometer per week. Each session lasting 30 minutes will be achieved at an intensity corresponding to the pre-determined CON ventilatory threshold. In the ECC group, 3 sessions of ECC (Monday, Wednesday and Friday) and two session of concentric (Tuesday and Thursday) cycling will be carried out each week. In the control group CON all sessions will be achieved using the traditional pedaling mode."
45775966|NCT01165541|Drug|Quetiapine fumarate extended release (Quetiapine XR)|Quetiapine fumarate extended release 50-400mg/d
45775967|NCT00284180|Drug|Vinflunine|Novel second generation vinca alkaloid
45637729|NCT03702725|Drug|Ibrutinib|Ibrutinib administered on every day of each 28 day cycle. Dosage depends on timing of patient enrollment and dosage tolerance by patients already enrolled.
45637730|NCT03702725|Drug|Lenalidomide|Lenalidomide administered on days 1-21 of each 28 day cycle. Dosage depends on findings from Dose Escalation phase.
45775968|NCT00284180|Drug|Trastuzumab|Anti-HER2 monoclonal antibody
45775969|NCT01165775|Device|Dexcom Seven Plus Continuous Glucose Monitoring System|Soft sensor for continuous glucose monitoring inserted for up to 24 hours prior to administration of betamethasone. Device to be worn for duration of hospitalization or up to 7 days total, whichever time period is shorter.
45775970|NCT01899872|Behavioral|Resistance exercise session|Resistance exercise session consisting of 4 lower-limb exercises, with 4 sets, 12 repetitions per set, at an intensity of 60% of maximal strength.
45637731|NCT03702725|Drug|Dexamethasone|Dexamethasone administered on days 1, 8, 15, and 22 of every 28 day cycle. Dosage depends on findings from Dose Escalation phase.
45775971|NCT01899872|Behavioral|Aerobic exercise session|Aerobic exercise session consisting of 40 minutes of lower-limb bicycle.
45775972|NCT04087460|Biological|Protein based pneumococcal vaccine(Low dose)|0.2mL,Intramuscular other name:PBPV
45775973|NCT04087460|Biological|Protein based pneumococcal vaccine placebo(Low dose)|0.2mL,Intramuscular other name:PBPV placebo
45775974|NCT04087460|Biological|Protein based pneumococcal vaccine(Middle dose)|0.5mL,Intramuscular other name:PBPV
45775975|NCT04087460|Biological|Protein based pneumococcal vaccine placebo(Middle dose)|0.5mL,Intramuscular other name:PBPV placebo
45775976|NCT04087460|Biological|Protein based pneumococcal vaccine(High dose)|1.0mL,Intramuscular other name:PBPV
45775977|NCT04087460|Biological|Protein based pneumococcal vaccine placebo(High dose)|1.0mL,Intramuscular other name:PBPV placebo
45775978|NCT02044172|Procedure|Radical prostatectomy|radical prostatectomy
45775979|NCT02044172|Radiation|Conformal radiation therapy|Conformal radiation therapy, external beam
45775980|NCT02044172|Other|Active monitoring|Active monitoring of Prostate specific antigen levels and disease surveillance
45775981|NCT05031806|Drug|iNexin™ (0.08% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.randomized 7:3 for each active concentration to Vehicle.
45775982|NCT05031806|Drug|iNexin™ (0.4% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.
45775983|NCT05031806|Drug|iNexin™ (2.0% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.
45775984|NCT05031806|Drug|Vehicle (eye drop formulation without aCT1)|"36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.~During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2)."
45775985|NCT01899404|Biological|18-FDG PET/CT, DWI, DCE-MRI|All patients on this study will receive a Diffuse Weighted MRI and Dynamic Contrast Enhancing MRI during the routine MRI session on the day of brachytherapy (additional 10 minutes), and a FDG PET/CT scanning session on the day of brachytherapy.
45775986|NCT01898546|Procedure|Primary angioplasty|Primary angioplasty preceded by 300 mg aspirin plus 600 mg clopidogrel oral load doses. The radial approach and the use of thrombus aspiration catheters will be recommended. Stent will be implanted in all cases. Balloon pre-dilatation or direct stenting will be decided according to lesion characteristics.
45775987|NCT01898546|Procedure|Postconditioning|1 min after stent deployment, the angioplasty balloon will be re-inflated 4 times during 1 min at low-pressure (4 to 6 atmospheres), each separated by 1 min of reflow.
45775988|NCT04389008|Other|no interventions|no interventions
45775989|NCT00216320|Device|WalkAide|Arm 1 - Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks
45775990|NCT00216320|Device|AFO|Arm 2 - Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks
45775991|NCT00216320|Device|AFO|Arm 3 - Subjects wear AFO for entire 12 weeks with no crossover
45775992|NCT00217490|Behavioral|dietary counseling via computer|An interactive computer program that addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
45754257|NCT04838041|Drug|Imatinib|400 mg by mouth (PO) once daily
45775993|NCT00217490|Behavioral|dietary counseling via nutritionist|A one on one counseling sessions to addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
45775994|NCT00217490|Behavioral|combined computer and nutritionist|An interactive computer program plus one on one nutrition counseling that addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
45775995|NCT00217490|Other|physical activity counseling via computer|An interactive computer program that addresses increase to physical activity, barriers to change and possible solution to barriers to develop an action plan
45775996|NCT00217724|Dietary Supplement|glutamine|Given orally
45775997|NCT00217724|Other|placebo|Given orally
45637732|NCT03681535|Radiation|Radiation Therapy|This phase II study will evaluate whether a reduction in the RT dose, concomitant with a decrease in the RT field size, in patients that achieve complete response and have a negative post-chemotherapy PET scan following 3 to 6 cycles of rituximab containing chemotherapy, will be associated with a low risk of in-field failure. The goal of this approach is to maintain excellent control rates while minimizing the risk of acute and late toxicity.
45637733|NCT03675321|Device|Active Auricular Neurostimulation|Active auricular neurostimulation for 4 weeks. Subjects in Active group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy.
45637734|NCT03675321|Device|Sham Auricular Neurostimulation|"Sham auricular neurostimulation for 4 weeks with identical device as the active but lacking the electrical charge.~Subjects in Sham group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy."
45637735|NCT03670966|Biological|Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10|Given via infusion
45637736|NCT03670966|Drug|Cyclophosphamide|Given IV
45637737|NCT03670966|Radiation|Total-Body Irradiation|Undergo TBI
45637738|NCT03670966|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplantation
45637739|NCT03670966|Procedure|Bone Marrow Transplantation|Undergo bone marrow transplant
45637740|NCT03670966|Drug|Mycophenolate Mofetil|Given IV or PO
45637741|NCT03670966|Biological|Recombinant Granulocyte Colony-Stimulating Factor|Given IV or SC
45637742|NCT03670966|Drug|Fludarabine Phosphate|Given IV
45637743|NCT03670966|Drug|Tacrolimus|Given IV or PO
45637744|NCT03655132|Behavioral|Veteran Acceptance and Commitment Therapy for Chronic Pain|Seven online modules based on the theoretical framework of ACT for chronic pain, provided as weekly sessions that will feature an ECA (virtual therapist) as a treatment guide. The initial module is devoted to an explanation of the treatment rationale, initial psychoeducation on pain-related symptoms, pain interference, and focal concepts of ACT, and assessment of individual pain symptoms. Modules 2-4 will focus on values clarification, acceptance and willingness, mindfulness, with an emphasis on tolerance of pain-related experiences. Modules 5-7 will continue to this focus, and incorporate goal-creation and committed action exercises. Module 8 will consolidate and provide feedback on goal-related achievements, and will focus on planning for the future.
45637745|NCT03653247|Biological|Plerixafor|Plerixafor subcutaneous injection will be administered prior to apheresis.
45637746|NCT03653247|Drug|Busulfan|Busulfan IV infusion will be administered as myeloablative conditioning therapy.
45637747|NCT03653247|Genetic|BIVV003|BIVV003 will be administered as an IV infusion following myeloablative conditioning with busulfan.
45637748|NCT03638596|Behavioral|Contingency Management|Incentive provided for changing alcohol drinking patterns based on ankle monitor
45637749|NCT03638596|Behavioral|Control|Incentive provided is not contingent on alcohol drinking patterns based on ankle monitor
45637750|NCT03635983|Biological|NKTR-214|Specified dose on specified days
45637751|NCT03635983|Biological|Nivolumab|Specified dose on specified days
45637752|NCT03613363|Device|Helix Ventilator|The Helix ventilator is a non-FDA cleared ventilator device. The Helix ventilator has similar modalities to the Trilogy ventilator, which has FDA clearance. The Helix device has improved algorithms, controls, and features to enhance the therapy delivery. Additionally, Helix has an updated hardware platform which has been adequately tested to ensure that the device specifications are met. No pre-clinical or developmental clinical work was required because of Trilogy being the established predicate.
45637753|NCT03527745|Drug|Albendazole|Single dose of albendazole (200mg, dependent on treatment cohort)
45637754|NCT03527745|Drug|Albendazole|Single dose of albendazole (400mg, dependent on treatment cohort)
45637755|NCT03527745|Drug|Albendazole|Single dose of albendazole (600mg, dependent on treatment cohort)
45637756|NCT03527745|Drug|Albendazole|Single dose of albendazole (800mg, dependent on treatment cohort)
45637757|NCT03527745|Drug|Placebo|Matching placebo tablets will be obtained from Fagron, Germany.
45637758|NCT03524534|Other|Telephone Call|A phone call will take place within 7 days of discharge by a Kaiser Permanente Heart Failure Care Manager from the Kaiser Permanente Heart Failure Chronic Care Management Program.
45637759|NCT03524534|Other|In-Person Primary Care Clinical Follow-Up Visit|This will be a standard in-person clinic visit with the subject's primary care physician within 7 days of discharge, with no structured heart failure protocol.
45637760|NCT03522584|Biological|Durvalumab|Given IV
45637761|NCT03522584|Other|Laboratory Biomarker Analysis|Correlative studies
45637762|NCT03522584|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45637763|NCT03522584|Biological|Tremelimumab|Given IV
45637764|NCT03522584|Procedure|Hypofractionated Image-Guided Radiation Therapy|Undergo HIGRT
45637765|NCT03515083|Device|Alive Cor Kardia mobile electrocardiogram monitor|Mobile ECG monitor paired with smart phone application
45637766|NCT03496883|Biological|Recombinant Activated Factor VII (rFVIIa)|Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
45637767|NCT03496883|Biological|Placebo|Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
45637768|NCT03495115|Device|MRI|A MRI uses a strong magnet to produce detailed pictures of the inside of your body.
45637769|NCT03495115|Device|RSI|RSI is a technique that aims to improve the pictures produced during a MRI exam.
45914984|NCT05680389|Drug|Placebo|twice daily for 3 months
45637770|NCT03482557|Device|CESM|Contrast enhanced mammography is a new type of mammogram. It uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone
45637771|NCT03482557|Device|MRI|MRI uses magnets to create a detailed image of the tissues and bones inside of the body
45637772|NCT03474588|Behavioral|Standard treatment (ST) PLUS web-based CBT4CBT|Participants will have access to the CBT4CBT website in Spanish as an add-on to treatment. In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on
45637773|NCT03474588|Behavioral|Standard Treatment (ST)|ST includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks
45637774|NCT03383445|Procedure|Edwards|The TAVR procedure will be performed with the Edwards SAPIEN XT or SAPIEN 3 valve (20 0r 23 mm).
45637775|NCT03383445|Procedure|CoreValve|The TAVR procedure will be performed with the CoreValve Evolut R valve system (23 or 26 mm).
45637776|NCT03383445|Procedure|Standard|The choice of the type and size of valve, utilization of additional procedures such as root enlargement will be left at the discretion of heart team of the treating the patient.
45775998|NCT04752644|Biological|MVA-mBN294B|MVA-BN-RSV (nominal titre 5 x10*8 Inf.U per 0.5 mL) as intramuscular injections. Liquid frozen suspension, single dose of 0.5ml.
45775999|NCT04752644|Drug|Placebo|TBS (Placebo) as intramuscular injections (0.5ml)
45776000|NCT01893710|Procedure|biopsy sampling|"Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained.~Biopsy sampling will be performed in all groups. This is an observational not an interventional trial."
45776001|NCT00287222|Drug|Bevacizumab|15 mg/KG I.V. every 21 days
45776002|NCT00287222|Drug|Erlotinib|150 mg orally every day
45776003|NCT04751240|Behavioral|SIT and resistance training|Participants complete 30 sessions of sprints and resistance training. Outcomes are assessed acutely and at 6 months.
45776004|NCT00218426|Drug|naltrexone implant|naltrexone implant is 1000 mg naltrexone
45776005|NCT00218426|Drug|oral naltrexone|oral naltrexone 50 mg/day
45637777|NCT03377361|Biological|Nivolumab|Specified dose on specified days
45637778|NCT03377361|Drug|Trametinib|Specified dose on specified days
45637779|NCT03377361|Biological|Ipilimumab|Specified dose on specified days
45637780|NCT03377361|Drug|Regorafenib|Specified dose on specified days
45637781|NCT03366116|Drug|aza-TdC|Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. The nucleoside analog 5-aza-4'-thio-2'- deoxycytidine (Aza-TdC) is incorporated into DNA, where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to hypermethylation and silencing of tumor suppressor genes. Aza-TdC offers an improvement over traditional DNMT inhibitors via higher incorporation into DNA and lower cytotoxicity; Aza-TdC has greater antitumor activity than another recently developed DNMT1 inhibitor, TdCyd, in some solid tumor xenograft models. Treatment with Aza-TdC is anticipated to yield inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules.
45637782|NCT03330405|Drug|Avelumab Phase 1b|Avelumab
45637783|NCT03330405|Drug|Talazoparib Phase 1b|Talazoparib
45776006|NCT00218426|Drug|oral placebo naltrexone|oral placebo naltrexone resembles active medication
45776007|NCT00218426|Drug|placebo implant|placebo implant resembles active medication
45776008|NCT01134575|Drug|CMC-544 (Inotuzumab Ozogamycin)|"First patients > 16 years and < 16 years receive CMC-544 at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle.~Part 2 CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2."
45776009|NCT01134575|Drug|Rituximab|With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
45776010|NCT01790672|Dietary Supplement|Ethanol|Vodka Absolut
45776011|NCT01790672|Other|Water|Lemon-flavored water
45776012|NCT01790672|Dietary Supplement|Alcoholized wine|Wine 13º or wine 8º
45776013|NCT01790672|Dietary Supplement|De-alcoholized wine|Wine 0º
45776014|NCT01134887|Other|Informational Guide for Patients|"Veterans received a copy of the NIA guide for Talking with Your Doctor. This pamphlet was specifically developed for this purpose (updated in 2002). It has pictorials and is written at an 8th grade level."
45914985|NCT05680350|Procedure|Laparoscopic Exploration|Laparoscopic Exploration to diagnose & grade endometriosis
45637784|NCT03330405|Drug|Avelumab Phase 2|The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.
45637785|NCT03330405|Drug|Talazoparib Phase 2|The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.
45637786|NCT03284463|Drug|Glibenclamide|Glibenclamide is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
45754258|NCT03106285|Dietary Supplement|Lactobacillus reuteri DSM17938|5 drops of active oil drops. The active dose consists of 10^8 CFU L retueri DSM17938
45914986|NCT05680350|Diagnostic Test|Estimation of Plasma Expression level of MICRO RNA 203 & 210|"estimation of Plasma Expression level for GeneMicro RNA 203 & 210 by qRT-PCR"
45935608|NCT00127543|Behavioral|Medication Education for Children|
45935609|NCT00127582|Procedure|Electrophysiological study|
45935610|NCT00127582|Device|pacemaker (PM) implant, internal cardiac defibrillator (ICD) implant, loop-recorder implant|
45935611|NCT00127621|Procedure|early tracheotomy|
45637787|NCT03284463|Drug|Placebo|Placebo is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
45637788|NCT03244995|Procedure|Mind-Body Intervention Procedure|Undergo CBMB program
45637789|NCT03244995|Other|Quality-of-Life Assessment|Ancillary studies
45776015|NCT01134887|Behavioral|Video-Assisted Coaching|Physicians participated in an audiotaped intensive 30 minute, one-on-one educational intervention with PI Frankel after their first set of visits from their three participating patients, but before seeing them for follow-ups. The main goal of this video-assisted coaching session was to review and discuss the analysis of the physician's videotaped visits using the Four Habits framework, with a particular focus on improving communication about self-management.
45776016|NCT01134887|Other|Monograph for Physicians|"Primary care providers randomly assigned to the Intervention-Physicians arm of this study received a copy of the Four Habits of Highly Effective Physicians. The Four Habits provided practical evidence-based advice for improving patient-physician communication."
45776017|NCT01134887|Behavioral|Educational Coaching|an educator met with each Veteran in the intervention arm individually for 20-30 minutes to review the material in the pamphlet and develop a plan for enhancing communication about self-management of hypertension with their doctor [Coaching]. To facilitate communication change, the educator assisted the patient in setting a goal to achieve during their visit. The educator also provided telephone follow-up within 24 hours to review satisfaction and effectiveness of the visit and assess barriers and facilitators to communicating about self-management.
45776018|NCT01134887|Other|Control|"The primary care providers randomly assigned to the Control-Physicians arm did not receive any additional coaching or resources and conducted their practice as usual."
45637790|NCT03244995|Other|Questionnaire Administration|Ancillary studies
45637791|NCT03223103|Drug|Poly-ICLC|Poly-ICLC 100mcg per peptide per dose
45637792|NCT03223103|Device|Tumor Treating Fields|an FDA approved treatment for patients with recurrent GBM and newly diagnosed GBM
45637793|NCT03223103|Biological|Peptides|synthetic long peptides (SLP) as vaccine substrate
45776019|NCT00223262|Drug|Lamotrigine (Drug)|
45776020|NCT03011879|Other|clinical pathway|
45776021|NCT00223652|Behavioral|Telephone cognitive behavioral therapy|An initial treatment phase consisting of 12 weekly sessions aimed at reducing symptoms of depression, and a booster phase in which 4 sessions are provided at increasingly greater intervals to target maintenance of treatment gains.
45935612|NCT00127621|Procedure|prolonged endotracheal intubation|
45637794|NCT03215030|Drug|Modakafusp alfa|Modakafusp alfa intravenous infusion.
45637795|NCT03215030|Drug|Dexamethasone|Dexamethasone.
45637796|NCT03208907|Drug|CQ coadministered with PQ|113 subjects in a 3-day regimen treatment with the schizonticidal drug Chloroquine concomitantly to 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day.
45637797|NCT03208907|Drug|DHA-PQP coadministered with PQ|In this treatment group, 112 subjects took DHA-PQP for three days and Primaquine for 14 days in the following dose: 0.50 mg/kg/day.
45637798|NCT03208907|Drug|CQ and PQ starting on Day 42|98 subjects in a 3-day regimen treatment with Chloroquine with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
45637799|NCT03208907|Drug|DHA-PQP and PQ starting on Day 42|95 subjects in a 3-day regimen treatment with DHA-PQP with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
45637800|NCT03194646|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen).
45637801|NCT03194646|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 24 weeks, 2 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen).
45637802|NCT03194646|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen).
45637803|NCT03194646|Other|Standard of care|Standard of care as determined by the investigators (including watch and wait, symptomatic nonhormonal)
45637804|NCT03194646|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 8 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen)
45637805|NCT03194646|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 24 weeks, 4 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen)
45637806|NCT03194646|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 6 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen)
45637807|NCT03191058|Device|Magnetic Seizure Therapy|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
45776022|NCT03012035|Other|positive treatment expectations|Before participants undergo the exposure training their expectation of treatment efficacy is manipulated with different information regarding the following treatment. The experimental group will get positive treatment expectations induced with the accurate information, that exposure training refers to the gold standard in psychotherapy to reduce spider fear (= open administration of treatment).
45776023|NCT03012035|Other|neutral treatment expectations|The comparator group will get neutral expectations regarding treatment outcome. To induce neutral treatment expectations about the following exposure training, it is necessary to tell them they are in the comparator group and that they will receive a comparator condition exposure training for diagnostic purposes only (= hidden administration of treatment).
45935613|NCT00043901|Drug|lamotrigine|
45637808|NCT03191058|Device|Electroconvulsive Therapy|In the ECT arm treatment, the MECTA spectrum 5000Q or the MECTA Sigma devices will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes
45637809|NCT03187860|Procedure|Bronchial Biopsy|Bronchial biopsies will be performed on all subjects.
45637810|NCT03187860|Other|ALI culture|Air-liquid-interface cell cultures will be derived from bronchial biopsy specimens. We are expecting several replicate cell lines from each biopsy specimen.
45637811|NCT03174782|Drug|Bupivacaine|Patients randomized to the treatment group will receive regional nerve blocks (sciatic and femoral) with bupivacaine at the dose of 1 mg/kg.
45637812|NCT03174782|Drug|Saline Solution|Patients randomized to the control group will receive two needle sticks (in the sciatic and femoral distributions) with normal saline to maintain the double-blinded investigation.
45637813|NCT03145298|Biological|Allogeneic Human Cardiosphere-Derived Stem Cells|Human Allogeneic Cardiosphere-Derived Cells is a biologic product consisting largely of cells grown from donated human heart muscle tissue
45914987|NCT05680272|Behavioral|empathic communication-based education|The study will consist of two stages. The first stage will be methodological in order to develop the Positive Birth Perception Awareness Scale based on Empathic Communication, and the second stage will be a trial model with a pretest-posttest control group in order to determine the effect of the training given to pregnant women based on empathic communication on positive birth perception awareness and birth experience.
45776024|NCT05080673|Procedure|5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy|The five- and ten-year colonoscopies, in addition to any unscheduled colonoscopies, will be performed according to currently accepted guidelines for the performance of quality colonoscopy. Participants will be given the standardized colonoscopy preparation instructions per institutional standards.
45637814|NCT03145298|Biological|Placebo|For use in Phase 1b - Double-blind randomized control portion of the study
45637815|NCT03128034|Drug|Cyclosporine|Given PO or IV
45637816|NCT03128034|Drug|Fludarabine Phosphate|Given IV
45637817|NCT03128034|Other|Laboratory Biomarker Analysis|Correlative studies
45637818|NCT03128034|Drug|Mycophenolate Mofetil|Given PO or IV
45637819|NCT03128034|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
45637820|NCT03128034|Other|Pharmacological Study|Correlative studies
45637821|NCT03128034|Radiation|Pretargeted Radioimmunotherapy|Given 211^At-BC8-B10 IV
45637822|NCT03128034|Radiation|Total-Body Irradiation|Undergo TBI
45637823|NCT03115333|Diagnostic Test|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
45776025|NCT00289718|Biological|Twinrix™ adult|Intramuscular administration
45776026|NCT00290654|Drug|Tamoxifen|Tamoxifen may be used postoperatively at the discretion of the treating physicians and patient
45776027|NCT00290654|Procedure|Lumpectomy|A standard lumpectomy will be performed with an attempt to remove at least 1 cm of gross margin around the DCIS.
45776028|NCT00290654|Radiation|brachytherapy|Treatment will be given in 10 fractions of 3.4 Gy per fraction twice a day, with a minimum of 6 hours between fractions. In general, brachytherapy will start between 2 - 5 days of implant. All treatments will be done using a commercially available HDR and 192Ir radioactive sources.
45776029|NCT00290810|Biological|bevacizumab|Given IV
45914988|NCT05680194|Procedure|operation|operation methods: breast-conserving surgery, mastectomy, axillary lymph node dissection, sentinal lymphnodes biopsy; chemotherapy regimens: AC, TC, AC-T/P, TCrb, TAC, capecitabine; ovarian protection:GnRHa; endocrine therapy: Aromatase inhibitor, TAM, Fulvestrant, CDK4/6 inhibitors; target therapy: trastuzumab，patuzumab, Pyrotinib.
45637824|NCT03110523|Drug|X0002|All subjects who provide informed consent will initiate the Screening Period of at least 14 (±3) days for the assessment of eligibility including radiographic evaluation of the lumbar spine. X-ray images must be collected within 4-11 hours after the subject wakes up. Those subjects who meet preliminary eligibility criteria will be treated with placebo in a subject-blind manner for 14(±3) days from Screening Visit to Day 1. Subjects with a placebo response exceeding 25% improvement in the average NPRS score over the previous 7 days will be excluded. Subjects with a Lane grading of 1 or 2 on their neutral lateral lumbar spine film per the central radiologist are eligible to be enrolled. At Day 1, eligible subjects will be randomly assigned to 1 of 2 treatment groups in a 1:1 ratio with a 1:1 ratio of active:placebo within each treatment group, and stratified evenly according to Lane Radiographic Grading Scale summary score (1 or 2) and gender.
45637825|NCT03090659|Biological|LCAR-B38M CAR-T cell injection|
45637826|NCT03081364|Other|Initiate ACLS protocol if lethal arrythmia develops|Cardiac Rhythm Management
45637827|NCT03064490|Drug|Pembrolizumab|Neoadjuvant Pembrolizumab ( 3 cycles) administered concurrently with weekly Carboplatin and Paclitaxel and daily radiation therapy; followed by surgical resection and adjuvant Pembrolizumab ( 3 cycles)
45637828|NCT02973685|Procedure|Hepatic arterial infusion chemotherapy|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially.
45776030|NCT04042142|Other|glucagon|Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers.
45776031|NCT04364750|Dietary Supplement|L-Histidine|1 capsule (0.6g) twice daily
45776032|NCT04364750|Dietary Supplement|High-FODMAP beverage|High-FODMAP beverage (10g of fermentable carbohydrates) consumed twice daily.
45776033|NCT04364750|Dietary Supplement|Low-FODMAP beverage|Low-FODMAP beverage (10g glucose) consumed twice daily.
45637829|NCT02973685|Procedure|Transarterial chemoembolization|Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.
45914989|NCT05680194|Drug|Bisphosphonate|Bisphosphonate
45637830|NCT02973685|Drug|Folfox Protocol|oxaliplatin,leucovorin and 5-FU
45637831|NCT02973685|Drug|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, with or without MMC) followed by polyvinyl alcohol particles (PVA)
45637832|NCT02953509|Drug|Magrolimab|Administered intravenously
45637833|NCT02953509|Drug|Rituximab|Administered intravenously on Days 8, 15, and 22 during Cycle 1, followed by 1 dose on Day 1 for Cycles 2 through 6, and Day 1 for every other cycle until Cycle 13
45914990|NCT05680077|Diagnostic Test|KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)|Blood samples from participants in both groups were collected and methylation tests were performed according to the kit instructions.
45637834|NCT02953509|Drug|Gemcitabine|Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
45637835|NCT02953509|Drug|Oxaliplatin|Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
45637836|NCT02919969|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
45637837|NCT02905812|Other|RGI & Massage|A trained intervention nurse will administer a 15 min moderate pressure massage as well as guided imagery with music once daily for up to five consecutive days.
45637838|NCT02840656|Other|oropharyngeal swabbing|microbiological sampling will be performed on buccal mucosa with standard swab. only one sample will be done
45637839|NCT02840656|Other|rectal swabbing|same process as oropharyngeal swabbing will be used to collect rectal microbiological sample
45776034|NCT04364750|Dietary Supplement|Lactobacillus acidophilus CL1285, L. casei LBC80R and L. rhamnosus CLR2.|Total of 50 billion CFU/capsule taken twice daily.
45776035|NCT04364750|Other|Placebo|Enteric coated capsule with no active ingredient, taken twice daily
45776036|NCT01137539|Device|Gynecare TVT-SECUR system|All patients in the study will receive the Gynecare TVT-SECUR to treat stress urinary incontinence
45776037|NCT01892930|Radiation|stereotactic body radiation therapy|Undergo SBRT
45776038|NCT01892930|Procedure|therapeutic conventional surgery|Undergo partial or radical nephrectomy
45776039|NCT01892930|Other|laboratory biomarker analysis|Correlative studies
45776040|NCT01138475|Drug|Paricalcitol|1 microgram by mouth daily for 6 weeks
45776041|NCT01138475|Drug|Cholecalciferol|5000 IU (international units) by mouth daily for 6 weeks
45914991|NCT05680038|Drug|Penpulimab|Penpulimab is a modified PD1 inhibitor, which innovated the use of IgG1 subtype. On the basis of ensuring the stability of the antibody, it eliminated ADCC, ADCP, CDC and other effects that were not conducive to the efficacy of T cells and reduced the effect of ADCR by modifying the Fc segment
45448330|NCT05577832|Procedure|ShotBlocker Technique|In a single-group design, 3 technique injections will be administered to the patients, 1 technique per week, to be randomized. The ShotBlocker technique will be applied to patients in any one of 3 weeks in a randomized manner.
45637840|NCT02837263|Radiation|Stereotactic body radiotherapy (SBRT)|"SBRT treatment will consist of 40-60 Gy delivered in five fractions prescribed to the planning target volume (PVT). Image guidance with MRI, megavoltage CT or cone beam CT scans would be required.~SBRT will be initiated on Day 0. This should be initiated within 4 weeks of signing informed consent. An additional 2 weeks will be allowed if necessary due to SBRT treatment planning."
45637841|NCT02837263|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. KeytrudaTM (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilumumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
45637842|NCT02823262|Other|Breast Cancer Treatment Decision Aid for women 70+|We developed a decision aid on breast cancer treatment for women 70 years or older newly diagnosed with estrogen receptor positive (ER+), clinically lymph node negative (LN-), HER2 negative (HER2-), breast cancers that are 3 centimeters or less. The DA was written using low literacy principles and provides information on the benefits and risks of mastectomy vs. breast conserving surgery (BCS), radiotherapy after BCS, and of hormonal therapies (e.g., anastrozole). It also considers the impact of competing health issues on older women's treatment choices.
45776042|NCT01138475|Drug|Placebo|Inactive substance, one capsule daily for 6 weeks
45776043|NCT01896830|Biological|Clostridium difficile Toxoid Vaccine|0.5 mL, intramuscular
45776044|NCT01896830|Biological|0.9% normal saline|0.5 mL, intramuscular
45776045|NCT05076539|Other|Garmin GPS activity tracker|50 patients will be issued a Garmin GPS-activity tracker where they will be required to wear for 24 hours for 1 week, prior to each timepoint (pre-operatively and 6 months post surgery).
45776046|NCT01894958|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials or 3g in 30mL bottles) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
45776047|NCT01894958|Drug|Placebo|Strawberry flavored solution
45935614|NCT00399594|Procedure|A|LV lead placement in region of latest mechanical velocity (tissue doppler)
45935615|NCT00399594|Procedure|B|LV lead placement in standard (lateral / posterolateral) position.
45935616|NCT00127699|Procedure|Alcohol swab of umbilical cord|
45776048|NCT05073497|Other|Finger puppets|In the experimental group, for distraction the researcher will put finger puppets consisting of various animal figures on his finger, and will ask the child to imitate these sounds by making animal-specific sounds that he moves with his finger. The researcher will also draw the child's attention to finger puppets by using methods such as making animals talk to each other and singing before and during venipuncture.
45776049|NCT05045807|Dietary Supplement|Meat with added nitrate|Prosciutto/pancetta/Parma ham/salami (all derived from pork) prepared by a commercial butcher with the sodium nitrate and nitrite as an additive.
45776050|NCT05045807|Dietary Supplement|Meat with added nitrate plus vegetables|"The same intervention as of intervention meat with added nitrate consumed together with mixed vegetables."
45776051|NCT00293540|Procedure|oophorectomy|Excision of an ovary
45776052|NCT00293540|Drug|Tamoxifen|20 mg orally every day
45637843|NCT02823262|Other|Usual Care|
45637844|NCT02777762|Behavioral|Fun First|8 weekly interactive small-group sessions with a health coach
45637845|NCT02777762|Behavioral|Close at Hand|8 weekly check-ins with a state of the art, engaging mobile app
45914992|NCT05679921|Drug|pembrolizumab, pazopanib|Pembrolizumab will be given for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing. Participants who complete study intervention after 2 years of pembrolizumab can be treated with pazopanib monotherapy based on physician's judgement. The duration of optional pembrolizumab crossover treatment will be maximum of 2 years i.e. a total of 35 cycles of pembrolizumab for patients progressing on pazopanib.
45914993|NCT05679804|Other|validity and realibility of scale|Turkish validity and realibility of Bipolar Recovery Questionnare
45637848|NCT02729350|Behavioral|Guided Relaxation video clip|This intervention is a 12-minute guided relaxation intervention for reducing pain and stress in adult inpatients with sickle cell disease.
45637849|NCT02729350|Behavioral|Sickle Cell Disease Experience Discussion|This intervention is a 12-minute sickle cell disease experience discussion.
45637850|NCT02694055|Other|Proactive Community Case Management|CHWs will be trained and deployed to conduct daily active case finding home visits door-to-door for at least two hours each day, with the goal of visiting each household at least two times each month. At these active case finding home visits, CHWs will screen each household of sick children and will offer home pregnancy testing and family planning services to reproductive aged women. For patients they identify, they will offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package.
45776053|NCT03012113|Drug|Mirabegron|
45776054|NCT03012113|Other|Short term mild cooling|
45776055|NCT03012113|Drug|Placebo Oral Capsule|
45914994|NCT05679687|Drug|Treatment|In this study, allogeneic anti-CD19 CAR T cells (ThisCART19A) infusion is used as a bridge therapy to hematopoietic stem cell transplantation to treat patients with refractory or relapsed CD19 positive B cell acute lymphoblastic leukemia. Lymphodepletion conditioning before CAR T cell infusion consists of fludarabine, CTX and VP-16.
45914995|NCT05679609|Device|incentive spirometry|It is flow-oriented that has 3 chambers, (600, 900, and 1200 cc/s) and it has a mouthpiece and a ball in each chamber. After a quiet exhalation, each participant was instructed to take slow full inspirations and to keep as long as he can for at least 5 seconds, then he slowly expires. The device is used every hour at least 5 to 10 times in the session during wake time.
45914996|NCT00386802|Drug|Antifungal drug. VORICONAZOL. (VFEND®)|I.V charge dose 6 mg/kg/12h (2 doses) Maintenance iv treatment 4 mg/kg/12h during 6 days, followed by oral treatment (200 mg/12h)
45914997|NCT00386841|Drug|Escitalopram|Escitalopram 10 mg p.o. per day
45637851|NCT02694055|Other|Integrated Community Case Management|CHWs will be trained offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package to patients that visit them at their work post.
45637852|NCT02694055|Other|Removal of point-of-care user fees|User fees will be removed across the catchment areas for both study and control villages. No fees will be charged for care by CHWs or at all primary care centres.
45637853|NCT02694055|Other|Infrastructure improvements at primary health centre|Targeted infrastructure improvements to rehabilitate, expand and equip the capacity of the seven government primary care centres in the study area. Each health center will be equipped with solar power.
45637854|NCT02694055|Other|Training of primary health centre staff|"Health center staff will receive targeted training in~Integrated management of childhood illness~Diagnosis and treatment of simple and severe cases of malaria~Helping babies breathe~Managing post-partum haemorrhage~Gestational dating using frontal height, last menstrual period and ultrasound~Family planning counselling and administration of long-acting contraceptives~Pharmacy stock management~Health center management"
45637855|NCT02670707|Drug|Cytarabine|Cytarabine 100 mg/m^2/day IV for five consecutive days. This five-day cycle will be repeated every 21 days for a total of four cycles for all patients regardless of response. Each new cycle may not begin until absolute neutrophil count (ANC) is ≥ 750/mcL and platelet count is ≥ 75,000/mcL.
45754259|NCT03106285|Dietary Supplement|Placebo|5 drops of placebo drops
45776056|NCT05008133|Behavioral|Bicycle exercise|Stepwise increased exercise for 5 minutes at 0, 50, 100 and 150 Watts. One series lying flat in prone position, after 15 minutes of rest, series repeated at 70 degrees head up tilt.
45914998|NCT00386841|Drug|Placebo|Placebo
45914999|NCT05679453|Drug|Lornoxicam 8 Mg Oral Tablet|Lornoxicam is a oxicam grup non-steroid antiinflamatuar drug
45915000|NCT05679414|Diagnostic Test|RT- PCR of 2 ml EDTA blood sample to determine MTHFR C677T genotypes|Venous blood sample
45776057|NCT01139411|Behavioral|Behavioral Weight Control with Enhanced Parent Involvement|
45776058|NCT01139411|Behavioral|Behavioral Weight Control with Minimal Parent Involvement|
45776059|NCT01139801|Drug|Oxytocin|Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute.
45915001|NCT05679375|Drug|Intrathecal ketamine|Patients will receive intrathecal Ketamine 0.1mg/kg added to bupivacaine and morphine
45776060|NCT01139801|Drug|Misoprostol|Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement
45776061|NCT05444712|Procedure|Chemotherapy + follow up|"Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices.~An intermediate evaluation will be performed after four cycles by PET-CT (or CT-Scan for non-avid PTCL)~A post-induction evaluation by PET-CT or CT-Scan will be done between 3 and 5 weeks after the last chemotherapy drug administration for all patients~A last evaluation by PET-CT or CT-Scan will be done between 08 and 12 weeks after the post-induction for all patients"
45776062|NCT05444712|Procedure|Chemotherapy + ASCT + follow up|"Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices.~An intermediate evaluation will be performed after four cycles by PET-CT (or CT-Scan for non-avid PTCL)~The fifth or sixth cycles should be used as stem-cell mobilizing chemotherapy for patients with ASCT strategy~A post-induction evaluation by PET-CT or CT-Scan will be done between 3 and 5 weeks after the last chemotherapy drug administration for all patients~Patients with in Complete Response after 6 cycles will receive a High Dose Therapy as conditioning regimen before transplantation~A last evaluation by PET-CT or CT-Scan will be done between 08 and 12 weeks after the post-induction for all patients"
45776063|NCT01139879|Device|P400 mattress|The P400 mattress will be placed for a period of 12 weeks.
45776064|NCT05004467|Other|Mobilization With Movement Technique|The researcher explains cervical movements to the patient to be done while the technique is performed. This movements will be the painful and limited movements detected in goniometric intervention before the treatment and movements done actively and in all range of motion.
45776065|NCT00294632|Drug|Lenalidomide|Starting Dose 10 mg By Mouth Daily on Days 1-21
45776066|NCT00294632|Drug|Rituximab|375 mg/m^2 By Vein Weekly for 4 Weeks
45776067|NCT01898624|Drug|mirabegron|oral
45776068|NCT01140191|Drug|WR 279,396|Topical application of WR 279,396 cream (15% paromomycin + 0.5% gentamicin)once daily for 20 days
45637856|NCT02670707|Drug|Vinblastine/prednisone|"Vinblastine/Prednisone +/- 6-mercaptopurine based on risk category. Patients with high-risk organ involvement (liver, spleen, hematopoeitic system) will receive 6-mercaptopurine during Continuation Therapy as this is the current standard of care treatment.~Vinblastine 6 mg/m^2/dose IV push weekly for patients ≥ 12 months of age. Vinblastine will be dosed at 3 mg/m^2/dose for patients under 6 months of age, and dosed at 4.5 mg/m^2/dose for patients 6 months of age to 11.99 months of age.~Prednisone (or prednisolone) 20 mg/m2/dose by mouth twice a day"
45637857|NCT02632994|Drug|LY2503029|Administered orally.
45637858|NCT02632994|Drug|LY3023414|Administered orally.
45637859|NCT02616640|Drug|Durvalumab|
45637860|NCT02616640|Drug|Pomalidomide|
45637861|NCT02616640|Drug|Dexamethasone|
45637862|NCT02446249|Biological|AAV2hAQP1|Infusion of gene therapy
45637863|NCT02416622|Biological|rAAV2tYF-CB-hRS1|adeno-associated virus vector expressing retinoschisin
45776069|NCT04752176|Device|ØREBLUE® Method|"The ØREBLUE® Method combines 2 inseparable therapeutic approaches that will be personalized, one dedicated to the auditory symptom (personalized sound therapy based on music and delivered through a helmet as part of the device), the other dedicated to the psychology of the subject.~Sound rehabilitation will be based on successive treatment sequences. The 1st sequence includes 30 hours of listening, at a rate of 2 hours / day, 5 days a week. A period of 4 to 6 weeks is necessary before carrying out a new sequence. The second sequence (and subsequent ones when necessary, respecting a 4-to-6-weeks window in between) of sound rehabilitation consists of 20 hours distributed as for the first sequence."
45776070|NCT01140815|Device|Total Knee Replacement|Smith and Nephew Total Knee Replacement
45776071|NCT01140815|Device|Deuce|Smith and Nephew Bicompartmental Knee Replacement
45776072|NCT01141049|Drug|Gabapentin|During week 1 the dosage will be increased 3 times. Days 1 and 2, participants will receive 400 mg of Gabapentin three times daily. During days 3 and 4 the dosage will be increased to 800 mg three times daily. On day 5 through 7, participants will receive a dose of 1200 mg three times daily, which will continue from week 2 through 8. During week 9 patients will be tapered off for the duration of the week.
45776073|NCT01141049|Other|Placebo|Placebo, TID
45776074|NCT01141595|Drug|sapropterin dihydrochloride|Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
45915002|NCT05679375|Drug|Intravenous ketamine|Patients will receive IV Ketamine 0.25mg/kg after spinal
45935617|NCT00127738|Procedure|Angiographic renal revascularization|
45935618|NCT00127777|Drug|Amantadine sulphate (in addition to standard treatment)|
45935619|NCT00127816|Procedure|Permanent prostate implant|
45637864|NCT02352883|Procedure|Magnetic Resonance Imaging|Undergo MRI
45637865|NCT02352883|Procedure|Therapeutic Conventional Surgery|Undergo mastectomy
45637866|NCT02352883|Procedure|Therapeutic Surgical Procedure|Undergo wide local excision
45637867|NCT02352883|Radiation|Radiation Therapy|Undergo radiation therapy
45637868|NCT02352883|Drug|Endocrine Therapy|Undergo endocrine therapy
45637869|NCT02352883|Other|Quality-of-Life Assessment|Ancillary studies
45637870|NCT02352883|Other|Laboratory Biomarker Analysis|Correlative studies
45637871|NCT02352883|Other|Cytology Specimen Collection Procedure|Correlative studies
45637872|NCT02312960|Other|Data Collection|No study treatment will be provided in this long term follow up study.
45637873|NCT02307812|Drug|Ramucirumab|Administered intravenously (IV)
45637874|NCT02307812|Drug|Paclitaxel|Administered IV
45637875|NCT02270632|Drug|F8IL10|F8IL10 will be administered once a week for 8 weeks (or until withdrawn from the study).
45637876|NCT02270632|Drug|MTX|All patients enrolled in the study will receive as concomitant therapy MTX at stable dose (10-25 mg/week), and the corresponding fixed dose of folic acid.
45637877|NCT02270632|Drug|Placebo|Placebo will be administered once a week for 8 weeks (or until withdrawn from the study).
45637878|NCT02231749|Biological|Nivolumab|
45637879|NCT02231749|Biological|Ipilimumab|
45637880|NCT02231749|Drug|Sunitinib|
45637881|NCT02065765|Biological|Ramucirumab|Administered intravenously (IV)
45935620|NCT00399633|Drug|sumatriptan|
45935621|NCT04727008|Biological|CXCR4 modified anti-BCMA CAR T cells|intravenous infusion
45637882|NCT02003209|Drug|Aromatase Inhibition Therapy|Given at the investigator's discretion
45776075|NCT01141907|Behavioral|Heart Failure Self Care Support|The intervention is aimed at preventing HF exacerbations and hospitalizations by improving self management with the support of the Home Automated Telemonitoring (HAT) system. The intervention was delivered by a RN-community health navigator (CHN) team over three months to HF patients and their caregivers in their home and via telephone and HAT system. The intervention was initiated during the index hospitalization. The RN-CHN team collaborated with participants, caregivers, and their usual source of HF care. Intervention strategies included tracking of weight and HF symptoms to provide feedback regarding self management and plan of care, enhancing medication and symptom self management, promoting HF care follow up, and promoting communication with providers.
45776076|NCT01141907|Other|Usual heart failure care|Participants assigned to usual care are treated by their usual source of HF care in the usual manner and in accordance with the American College of Cardiology/American Heart Association Guidelines for the management of HF. Usual care for HF patients admitted to Johns Hopkins Hospital also includes the following: 1) Referral to HF clinic if the patient has no usual source of care and 2) HF patient education booklet.
45776077|NCT01142297|Device|dental implant and modified dental implant|standard SLA surface and chemically modified surface
45776078|NCT03011723|Behavioral|Resource oriented music therapy|"10 weeks of tailored individual music therapy for PWD and a caregiver. Pre and post assessment in addition.~The music therapy consists of one or more of the following activities:~Singing~Listening to live music~Listening to recorded music~Dancing~Conversations about memories/reminiscence~Exercising to music~Breathing exercises and relaxing exercises~The treatment is following the principles of resource oriented music therapy as described by Rolvsjord et al (2005)"
45776079|NCT01143701|Other|ADHD Collaborative|The ADHD Collaborative intervention model includes academic detailing, quality improvement methods, and innovative tools (e.g., web portal) designed to promote and support the systematic use of the AAP guidelines.
45776080|NCT03012503|Drug|BioFreeze|The estimated surface area of the average adult's neck is 350cm and the standard dose of Biofreeze® to achieve a clinically significant effect has been sited to be 1ml/200cm2 of skin surface area. Using this data approximately 1.75 ml of the assigned gel was applied to each participant's neck (posterior, anterior, left lateral and right lateral) by the same member of the research team, 5 minutes prior to an independent practitioner performing cervical manipulation on the participant.
45776081|NCT03012503|Drug|Placebos|control gel with a similar packaging, texture, and scent as Brand X but without the active ingredient of menthol
45637883|NCT02003209|Drug|Carboplatin|Given IV
45776082|NCT01167569|Drug|Ascorbic Acid|Ascorbic Acid/Placebo 10mg/kg body weight X2 in Operating Room followed by Ascorbic Acid/Placebo 5mg/kg x 48 hours.
45637884|NCT02003209|Other|Cytology Specimen Collection Procedure|Undergo 2 core biopsies
45776083|NCT01167569|Other|5 % Dextrose Water or Normal Saline|100 ml D5W or NS X 2 in operating room and then every 4 hours for 48 hours.
45776084|NCT00296192|Drug|Rotigotine nasal spray|Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries
45776085|NCT00296192|Other|Placebo|placebo nasal spray 1, 2 3, and 4 puffs
45637885|NCT02003209|Drug|Docetaxel|Given IV
45935622|NCT04726657|Drug|Premixed Human Isophane Insulin Suspension + Human Insulin Injection|premixed human insulin
45935623|NCT04726657|Drug|Premixed Insulin|Premixed Insulin Analog Biphasic Aspart 30
45935624|NCT04726735|Biological|Samples of bladder tissue|Samples of bladder tissue collected between 2007 and 2011.
45448331|NCT05577832|Procedure|Standard Technique|Standard Technique In a single-group design, 3 technique injections will be administered to the patients, 1 technique per week, to be randomized. The standard technique will be applied to patients in any one of 3 weeks in a randomized fashion.
45637886|NCT02003209|Drug|Goserelin Acetate|Given SC
45637887|NCT02003209|Other|Laboratory Biomarker Analysis|Correlative studies
45637888|NCT02003209|Biological|Pertuzumab|Given IV
45637889|NCT02003209|Other|Quality-of-Life Assessment|Ancillary studies
45637890|NCT02003209|Procedure|Therapeutic Conventional Surgery|Undergo lumpectomy or mastectomy
45637891|NCT02003209|Biological|Trastuzumab|Given IV
45637892|NCT02003209|Radiation|Whole Breast Irradiation|Undergo whole breast irradiation
45448332|NCT01077869|Procedure|endoscopic examination|on a weekly basis during 7 weeks
45637893|NCT01968109|Biological|Relatlimab|
45776086|NCT04312139|Diagnostic Test|Echocardiography|Baseline and prospective follow-up echocardiography
45935625|NCT00402610|Drug|isoniazid, rifampin + isoniazid, rifampin + pyrazinamide or not treatment|
45935626|NCT00402766|Drug|Cisplatin|Starting Dose: 60 mg/m^2 by vein, Over 2 Hours
45935627|NCT00402766|Drug|Imatinib Mesylate|Starting Dose: 300 mg PO Daily
45637894|NCT01968109|Biological|Nivolumab|
45637895|NCT01968109|Biological|BMS-986213|Relatlimab + Nivolumab
45637896|NCT01891344|Drug|Oral rucaparib|600 mg BID
45637897|NCT01828099|Drug|Ceritinib|Ceritinib was administered orally once-daily fasted at a dose of 750 mg capsules on a continuous dosing schedule. Ceritinib (LDK378) was the investigational treatment and is referred to as the investigational study treatment/drug.
45637898|NCT01828099|Drug|Pemetrexed|Pemetrexed was administered at a dose of 500 mg/m2 as an iv infusion on Day 1 of each 21-day cycle to patients randomized to the chemotherapy arm.
45637899|NCT01828099|Drug|Cisplatin|Cisplatin was administered by IV at a dose of 75 mg/m2 every 21 days for up to 4 cycles.
45637900|NCT01828099|Drug|Carboplatin|Carboplatin was administered as iv infusion (AUC 5-6) every 21 days up to 4 cycles
45637901|NCT01724580|Drug|Baricitinib|Administered orally
45637902|NCT01399138|Dietary Supplement|Blueberry Powder|The groups will be randomized to receive 45g of blueberry powder or control (i.e., placebo) per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The second smoothie will be consumed at least 6 hours from the first smoothie. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients
45637903|NCT01188096|Drug|Poly ICLC|Children will receive poly-ICLC 20 mcg/kg twice weekly IM (using Monday/Wednesday schedule if possible). The first 2 doses will be administered in the clinic under supervision.
45776087|NCT04312139|Diagnostic Test|Computerized Tomography Aortic Valve Calcium Score|Baseline and prospective follow-up CT calcium score of aortic valve
45776088|NCT04312139|Other|Untargeted LC/MS and LC-MS/MS|Serum samples untargeted proteomics and metabolomics
45448333|NCT01077869|Procedure|FDG-PET|once pre-radiotherapy and once 2 weeks after initiation of radiotherapy
45637904|NCT01176006|Procedure|Reduced-intensity hematopoietic stem cell|stem cell transplant
45637905|NCT01176006|Drug|Fludarabine(Fludara, Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
45637906|NCT01176006|Drug|Cyclophosphamide(CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 min on days -6, and -5
45637907|NCT01176006|Procedure|Total Body Irradiation (TBI)|200 cGy on Day -1
45637908|NCT01176006|Drug|Busulfan (Busulfex)|3.2 mg/kg IV (in the vein) over 2 hours once daily on Days -6, -5, -4 and -3 (weight based dosing) or on days -4, -3 and -2
45637909|NCT01176006|Procedure|Donor peripheral blood stem cell mobiliation and collection|Donors undergo peripheral blood stem cell (PBSC) collection by apheresis will have their CD34 cells mobilized into the blood with filgrastim (Neupogen, Amgen)
45637910|NCT01176006|Procedure|Bone Marrow Harvest Procedure|Bone marrow from haploidentical related donors, and, in some cases, matched related donors will be harvested under routine conditions in the operating room. General or spinal anesthesia will be employed.
45637911|NCT01121588|Drug|Crizotinib|Crizotinib tablets, 250 mg BID, will be administered orally on a continuous dosing schedule
45637912|NCT01094691|Procedure|Renal Allograft Biopsy|A renal allograft biopsy will be performed when the urine is determined to be Haufen negative.
45637913|NCT01005420|Dietary Supplement|Blueberry Powder|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
45637914|NCT01005420|Dietary Supplement|Placebo|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
45637915|NCT00632853|Radiation|Standard Radiation Dose Therapy|45 Gy
45637916|NCT00632853|Drug|cisplatin|IV
45637917|NCT00632853|Drug|etoposide|IV
45776089|NCT04312139|Other|Targeted LC/MS and LC-MS/MS|Serum samples targeted proteomics and metabolomics
45776090|NCT04312139|Diagnostic Test|multiplex ELISA|Implementation of novel multiplex ELISA assay on serum samples of aortic valve stenosis prospective cohort.
45776091|NCT04161950|Other|Assessment of the safety and validity of echoendoscope|"Ultrasonic and endoscopic image quality assessment~Device controllability assessment~System safety assessment~System stability assessment"
45776092|NCT00297596|Drug|Trastuzumab|Trastuzumab will be administered as an 8 mg/kg loading dose by intravenous (IV) infusion over 90 minutes on day 1 of cycle 1. Subsequent doses will be administered as a 6 mg/kg IV dose over 30 minutes.
45776093|NCT00297596|Drug|Oxaliplatin|"Oxaliplatin will be administered at a dose of 130 mg/ m2 over 120 minutes on day 1 of each cycle, following standard antiemetic premedications. 21 day cycles.~For the first cycle, trastuzumab will be administered before oxaliplatin; however for subsequent cycles, oxaliplatin will be infused prior to trastuzumab"
45776094|NCT01144637|Biological|IMVAMUNE®|0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)
45637918|NCT00632853|Radiation|High Radiation Dose Therapy|70 Gy
45448334|NCT02140294|Dietary Supplement|Polymeric nutritional supplements|
45448335|NCT02140294|Dietary Supplement|Standard Nutrional Treatment|
45448336|NCT03965819|Dietary Supplement|Pain Bloc-R|Herbal Supplement containing Vit D3, Vit B6, Vit B12, White Willow Bark, Angelica Root, Acetyl L-carnitine HCl, Caffeine, L-Theanine, Benfotiamine, and L-Tetrahydropalmatine
45448337|NCT03965819|Other|Active Comparator - Acetaminophen|DIN 02447479 Encapsulated for Blinding Purposes
45448338|NCT03965819|Other|Placebo|No active ingredients
45448339|NCT02134366|Drug|Clobazam|Comparison of AED use in Epilepsia Partialis Continua
45448340|NCT02134366|Drug|Clonazepam|Comparison of AED use in Epilepsia Partialis Continua
45448341|NCT02134366|Drug|Lorazepam|Comparison of AED use in Epilepsia Partialis Continua
45448342|NCT03965975|Device|Lab Gold Standard|"First intervention (assigned to the All participants arm)."
45448343|NCT03965975|Device|S-There|"Second intervention (assigned to the All participants arm)."
45637919|NCT00632853|Drug|carboplatin|IV
45754260|NCT03895502|Drug|12-month Edoxaban|Prescription of Edoxaban for 12 months
45754261|NCT03895502|Drug|3-month Edoxaban|Prescription of Edoxaban for 3 months
45754262|NCT03588026|Drug|rVA576|6 months of treatment, rVA576 plus SOC. Followed by a further 3 months of rVA576 plus SOC. In total, 9 months on rVA576 plus SOC.
45776095|NCT01144637|Other|Placebo|0.5 ml TBS
45776096|NCT00298610|Drug|Artesunate|Intravenous Artesunate (2.4 mg/kg) once a day for three days
45776097|NCT00298610|Drug|Malarone|(proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)
45935628|NCT00402766|Drug|Pemetrexed|Starting Dose: 500 mg/m^2 by vein, Over 40 Minutes
45935629|NCT00402766|Drug|Dexamethasone|20 mg by vein given prior to Pemetrexed therapy and 4 mg given orally on Day 2 of each cycle.
45935630|NCT00402805|Biological|Trivalent Inactivated Influenza Vaccine|
45754263|NCT03588026|Other|Standard of care (SOC)|6 months on SOC followed by 3 months of treatment with rVA576 plus SOC. In total, 3 months on rVA576 plus SOC.
45754264|NCT03587948|Diagnostic Test|Diabetes mellitus|Children and adolescents who is diagnosed with diabetes will be involved in case-group, and others will be involved in control-group.
45935631|NCT00127972|Drug|stavudine|
45935632|NCT00127972|Drug|lamivudine|
45935633|NCT00127972|Drug|nevirapine|
45935634|NCT00127972|Drug|efavirenz|
45776098|NCT04236947|Behavioral|SCPP-YA|SCPP-YA includes two modules. In the first module of ten sessions, students will learn to employ a 6-step social information processing framework for solving a wide range of real-life problems. The six-step process consists of 1) stop, clam down, and think before you act; 2) say the problem and how you feel; 3) set a positive goal; 4) think of many solutions; 5) think ahead to the consequences and 6) go ahead and try the best plan. The second module offers 1) current and accurate information about the health, social, and legal consequences of substance use, 2) correct mistaken beliefs that students have about substance use, 3) enhances awareness of social and media influences; and 4) teachers assertiveness and critical thinking skills to resist peer pressure.
45637920|NCT00581334|Procedure|Robotic-assisted laparoscopic sacrocolpopexy|4 abdominal incisions will be made: 1 infraumbilical port and 3 lateral ports. The peritoneum overlaying the sacrum is entered and the anterior longitudinal ligament is exposed. 3 permanent sutures are placed through the ligament at the S2-S3. Then a vaginal obturator is placed transvaginally and the apex of vagina is elevated into the operative field. The peritoneum overlying the anterior and posterior vaginal epithelium is reflected and the bladder is dissected off the underlying vagina to expose 4cm of apical vagina. 2 segments of polypropylene mesh are prepared and one segment is anchored along the anterior vagina with a series of interrupted permanent suture and the second segment is anchored along the posterior vagina. These 2 segments are brought together to the previously placed sutures within the anterior longitudinal ligament of the sacrum. The peritoneum is then closed over the graft complex and the pelvis irrigated. The 4 robotic ports are removed and the abdomen closed.
45776099|NCT00299000|Drug|Naglazyme|Weekly infusion for minimum of 52 weeks. Naglazyme is diluted in sterile 0.9% sodium chloride solution
45776100|NCT01144949|Drug|silodosin|one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks
45776101|NCT01144949|Drug|placebo|one placebo capsule orally, once daily, with food for up to 4 weeks
45776102|NCT00215930|Drug|Vinorelbine|Ribonucleotide reductase subunit 1(RRM1)above 16.5 and Excision repair cross-complementing group 1 gene(ERCC1)above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.
45776103|NCT00215930|Drug|Docetaxel|"RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days."
45776104|NCT00215930|Drug|Gemcitabine|"Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve [AUC] of 5 on day 1) every 21 days.~RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days."
45776105|NCT00215930|Drug|Carboplatin|"Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve [AUC] of 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days."
45776106|NCT01145183|Drug|Doxazosin|Doxazosin is initiated at 4 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 2 weeks. Participants will be maintained on 6mg-8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
45776107|NCT01145183|Drug|Placebo|Matched placebo daily dosing
45776108|NCT04183673|Procedure|Laser therapy-cryo thermal therapy|5 days per week, 3 weeks, sessions including laser therapy + cryo therapy followed by usual rehabilitation
45776109|NCT04183673|Procedure|Usual care|5 days per week, 3 weeks, sessions of usual rehabilitation
45637921|NCT00581334|Procedure|Open sacrocolpopexy|mesh augmented repair for post-hysterectomy prolapse performed via open laparotomy
45776110|NCT00230126|Drug|erlotinib|Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.
45776111|NCT04128722|Drug|Sirolimus Oral Liquid Product 1mg/mL|0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation
45776112|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.125mg/kg injection over 20min
45915003|NCT05679336|Drug|Rituximab, Cyclophosphamide, and Corticosteroids|"Rituximab (RTX) will be given as a single intravenous (IV) dose of 375 mg/m2. Extra RTX infusion at the same dose will be administered on weeks 12, 24, and 36 in the absence of remission and the occurrence of peripheral B-cell reconstitution. Peripheral B-cell reconstitution is defined as total CD19+ cell count >5 cells/μL;~Concurrent with RTX initiation, a single IV infusion of methylprednisolone 500 mg will be administrated, followed by oral prednisolone 1 mg/kg daily but not exceeding 60 mg daily during week 1. The dosage will be rapidly decreased by 10 mg/weekly as follows: week 2, 50 mg daily; week 3, 40 mg daily; week 4, 30 mg daily; week 5, 20 mg daily; weeks 6-7, 10 mg daily; weeks 8-48, 5 mg daily; week 49, stop;~Four IV infusions of Cyclophosphamide will be administered at a dose of 7.5 mg/kg every other week (on weeks 1, 3, 5, and 7)."
45448344|NCT05189938|Diagnostic Test|HBA1c data and glucose levels|All subjects will wear the professional FreeStyle Libre Pro for glucose data and HbA1c data will be collected at different time points over the participation period.
45448345|NCT03966131|Device|Tongue pressure recordings with the PRESLA prothesis for the Arm1 (patients wearing the complete denture for the first time)|Tongue pressure recordings during speech production, wet and dry swallowing tasks planned in 3 sessions, when the complete denture is worn for the first time, after 3 weeks, then after 3 months in order to characterise the adaptation to this new prosthesis.
45637922|NCT00579826|Drug|Letrozole|Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.
45776113|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.25mg/kg injection over 20min
45637923|NCT00579826|Drug|Placebo|Placebo tablet daily for 6 months then optional open label letrozole for 6 months.
45637924|NCT00106691|Drug|Toremifene 20 mg|The subject takes one dose by mouth of the 20mg Toremifine Citrate tablet once a day for the length of the trial (360 days).
45637925|NCT00106691|Drug|Placebo|The subject takes a placebo tablet identical in appearance to the toremifene 20mg tablet, administered by mouth daily for 360 days.
45637926|NCT00071708|Drug|Duloxetine Hydrochloride|
45637927|NCT04089137|Behavioral|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. This intervention targets alcohol use, sexual assault victimization risk, sexual assault perpetration, and bystander intervention and is tailored by gender and sexual orientation.
45637928|NCT04004429|Drug|50 mg AP1189|50 mg AP1189 powder in bottle
45637929|NCT04004429|Drug|AP1189|100 mg AP1189 powder in bottle
45448346|NCT03966131|Device|Tongue pressure recordings with the PRESLA prothesis for the Arm2 (patients used to wear the complete denture)|These measures provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during speech production in patients used to their prosthesis. They also provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during swallowing) in these patients. The measurement is made at once when the new denture which replaces the old one is placed in the mouth.
45637930|NCT04004429|Drug|Placebo|Placebo powder in bottle
45637931|NCT05260073|Drug|Tirbanibulin (Klisyri®)|Participants will be treated with tirbanibulin ointment 1% (2.5 mg tirbanibulin in 250 mg) as 1 single-dose packet per application, for 5 consecutive days
45637932|NCT03882203|Drug|CLAGE-FluBu|Cladribine combined with cytarabine and VP16 sequential with Fludarabine combined with busulifan
45637933|NCT03826901|Drug|delgocitinib|Cream for topical application
45637934|NCT04590443|Other|NMP|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
45637935|NCT03476759|Procedure|Tubal adhesiolysis|125 patients will undergo tubal adhesiolysis or tuboplasty
45637936|NCT03476759|Drug|IVF/ICSI|125 patients will undergo IVF-ICSI procedures.
45637937|NCT04582643|Behavioral|6P intervention|6P assessment targeting on diet, activity and mentality, along with education provided based on the 6P components. The 6P tool serves the functions to help the women to self-monitor and be aware of their negative lifestyle choices.
45637938|NCT04576325|Drug|Voriconazole Inhalation Powder|For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules for a given dose must be inhaled over a maximum 10-minute period. Cohort 1 will receive 40 mg BID and Cohort 2 will receive 80 mg BID. Both Cohorts will administer study drug for 3.5 days (7 days total).
45637939|NCT04576325|Drug|Placebo|For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules must be inhaled over a maximum 10-minute period. Cohort 1 will receive 4 capsules of inactive BID and Cohort 2 will receive 8 capsules of inactive BID. Both Cohorts will administer placebo capsules for 3.5 days (7 days total).
45637940|NCT04566263|Device|Neuroform EZ Stent System|The Stryker Neuroform EZ Stent System is a self-expanding nitinol, compliant, open-cell design that can be deployed by a single operator. The Neuroform EZ Stent System is packaged sterile as a single unit with an introducer sheath and a detachable push wire.
45637941|NCT04564625|Other|Vitamin D Assessment|index admission vitamin D assessment
45637942|NCT04564625|Other|Fracture|rate of nonunion (i.e., failure of a fractured bone to heal)
45637943|NCT05231993|Procedure|Conization|A cone biopsy to remove abnormal tissue.
45637944|NCT05231993|Procedure|Colposcopy|"Colposcopy with biopsy within 3 months,endocervical sample, ultrasound and endometrial biopsy if the woman is ≥40~Colposcopy after 12 months if the first colposcopy and biopsies are normal~Cytology and HPV testing at 12 and 24 months if the second colposcopy is normal"
45637945|NCT05223257|Other|AOT|Observation of video sequences showing unimanual and bimanual goal-directed actions followed by the execution of the observed actions with upper limbs for unimanual and bimanual actions.
45637946|NCT04534361|Other|CBCT measurements|No intervention will be performed on patients for this study. Based on the CBCTs already done previously of the patients in the sample, linear measurements will be taken in order to assess dimensional changes of the alveolar ridge at 1, 3, 5 and 7 mm from the bone crest in the CBCTs taken before and after implant explantation, 4-6 months apart.
45776114|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.35mg/kg by injection over 20min
45776115|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.45mg/kg by injection over 20min
45776116|NCT02103608|Device|Glide|6 facial hair reduction treatments with the Glide device, two weeks apart.
45776117|NCT04071977|Drug|Combined antioxidant therapy|It consists of a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1 mg), vitamin C (L-ascorbic acid 180 mg), vitamin E (DL-alpha tocopherol 30 mg), zinc (zinc oxide 20 mg), copper (copper sulfate 1 mg), taken once a day for 12 months
45776118|NCT04071977|Other|Placebo|It consists in a capsule with 100 mg of magnesium oxide
45776119|NCT02101190|Drug|BIA 9-1067|Opicapone, OPC
45776120|NCT01170533|Drug|omeprazole and pantoprazole|The clopidogrel dose will be a 600mg loading dose followed by a 75mg daily maintenance dose, starting the next day for 7 days. Omeprazole will be used at a daily dose of 40mg and pantoprazole at 80mg.
45915004|NCT05677191|Device|Proximal Femoral Nail|open reduction
45935635|NCT00127972|Drug|trizivir|
46070243|NCT00646399|Drug|Pagibaximab 50 mg/mL|Pagibaximab 100 mg/kg dosed on Days 0, 1, 2, 9, 16 and 23
46070244|NCT00807781|Biological|Mammaglobin-A DNA vaccine|
45637947|NCT03390491|Behavioral|OnTrack>TheGame (OTG)|OTG clients will be informed that the game can be played on a computer or a tablet and the time estimate for completing the game is approximately 5-8 hours. OnTrack>The Game offers players the opportunity to immerse in a fictional neighborhood that centers around four domains for supportive recovery as defined by SAMHSA: health, home, purpose and community. The player interacts with other game characters including new acquaintances, friends/peers, a family member, and a treatment team, allowing the player to practice social and communication skills, while fostering personal relationships and building a support network. Additionally, the game provides players with helpful resources including psychoeducation materials and videos of real people who have experienced a first episode of psychosis, sharing their stories of hope and recovery. As a whole, the game provides a safe environment to promote goal attainment and recovery.
46070245|NCT00810121|Drug|ketoprofen 100 mg|100 mg b.i.d. for 5 days
45754265|NCT04766060|Other|Fluorescent Imaging|Fluorescense imaging used to evaluate blood perfusion
45776121|NCT01790906|Procedure|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD .once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster,Diamond Bar,California)was introduced into each renal artery.then was maneuvered within the renal artery to allow energy delivery in a circumferential,longitudinally staggered manner to minimize the chance of renal artery stenosis.About six to nine ablation at 10W for 1 min each were performed in both renal arteries.during ablation, the catheter system monitored tip temperature and impedance,altering radiofrequency energy delivery in response to predetermined algorithm.
45776122|NCT01790906|Other|Conventional therapy|Optimizing drug therapy,included angiotensin-converting enzyme inhibitors,aldosterone antagonist,beta-receptor blockers,diuretic,digoxin and so on.The patients with chronic heart failure ,whos'condition need for CRT-D(cardiac resynchronization therapy )/ICD(implantable cardioverter-defibrillator),are considered to implant CRT/ICD .CRT is abbreviation for cardiac resynchronization therapy ,ICD is defined for Implantable Cardioverter defibrillator.
45776123|NCT01147601|Drug|topical 0.5% Timolol|topical 0.5% Timolol aqueous solution, 2-3 drops to cover the hemangioma, twice daily
45776124|NCT01147601|Drug|Control (placebo) group|Control (placebo) group
45776125|NCT03011645|Drug|Ziprasidone|Given by mouth, single dose of 60 mg.
45776126|NCT03011645|Drug|Lorcaserin|Given by mouth, single dose of 20 mg.
45776127|NCT03011645|Drug|Placebo Oral Tablet|Given by mouth, single dose.
45776128|NCT03012269|Behavioral|Working memory training|
45776129|NCT01149785|Drug|crizotinib|Treatment A: a single 150-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
45776130|NCT01149785|Drug|ketoconazole|Treatment B: 200 mg twice a day (approximately 12 hrs apart) doses of ketoconazole will be administered orally on an empty stomach from Day 1 to Day 16.
45776131|NCT01149785|Drug|crizotinib|Treatment B: A single 150-mg dose of crizotinib will be administered in the fasted state on Day 4 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
45776132|NCT02182115|Drug|antiseptic bundle|"Chlorhexidine gluconate liquid soap for bathing daily.~Chlorhexidine gluconate mouthrinse to use twice daily.~Nasal mupirocin to apply twice daily."
45776133|NCT02182115|Drug|standard of care|Surgeon's instructions may include advising patients to use an antiseptic soap prior to surgery.
45776134|NCT03011567|Drug|Acetaminophen|Participants will receive acetaminophen for postpartum mild pain relief
45776135|NCT03011567|Drug|Ibuprofen|Participants will receive ibuprofen for postpartum mild pain relief
45776136|NCT01151189|Biological|MVA85A/AERAS-485|Subjects received intradermal injection of MVA85A/AERAS-485 on Study Day 0, followed 6-9 months later by a booster injection of MVA85A/AERAS-485.
45915005|NCT05677191|Combination Product|Dual Mobility Arthroplasty|Hip Arthroplasty Surgery
45915006|NCT05677152|Drug|Intravenous Infusion of Aclasta®|Intravenous Infusion of Aclasta® (Verum) or physiological saline solution 0.9% (Placebo)
45915007|NCT05677035|Drug|LINO-1713 1 tablet|LINO-1713 1 tablet is administered once. Oral administration with 200mL of water
45915008|NCT05677035|Drug|LINO-1713 once a day for 24 days|Oral administration is performed with 200 mL of water. Instruct subjects to take the drug at the same time as possible.
45915009|NCT05676957|Device|Thermogard XP3|Patients received endovascular hypothermia for 12 hours following endovascular treatment and recanalization.
45915010|NCT05675280|Other|Gluten free diet|All subjects initiated a gluten free diet as mandated by their diagnosis of Celiac disease, regardless of the study
45915011|NCT05670522|Device|Transcranial direct current stimulation|"Transcranial direct-current stimulation (tDCS), over the motor cortex, is a potential therapy option for motor control deficits in children with CP. The application of tDCS involves positioning 2 rubber electrodes sheathed in saline-soaked pads onto the scalp, held in place by a rubber strap. Low-intensity, direct-current, of 1 to 2 mA, is delivered to cortical areas from the device.~The standard-of-care gait training included various gait training and balance tasks as well as resistive exercises and passive stretching as necessary. Task-specific gait exercises included: walking in a closed indoor environment, walking in an open indoor environment, walking on various floor surfaces, and climbing stairs up and down without assistance. The children also performed dynamic balance exercises by walking on a balance board."
46070246|NCT00810121|Drug|ketoprofen|150 mg b.i.d. for 5 days
46070247|NCT02552875|Other|Tetanic stimulation|50 Hz tetanic stimulation before TOF-twitch stabilization with the aim to eliminate the staircase phenomenon
46070248|NCT02552875|Other|Staircase Stimulation|TOF-twitch stabilization without 50 Hz tetanic stimulation with the aim to verify the staircase phenomenon
46070249|NCT00652327|Drug|Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin)|ezetimibe 10 mg plus ongoing statin (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) once daily for 8 weeks
46070250|NCT00652327|Drug|Double Statin (simvastatin, atorvastatin, or pravastatin)|simvastatin 40 mg or atorvastatin 20 mg or pravastatin 40 mg once daily for 8 weeks
46070251|NCT00814021|Drug|sunitinib malate|
46070252|NCT02551627|Dietary Supplement|Test Product|MMN fortified beverage powder.
46070253|NCT02551627|Dietary Supplement|Control|Isocaloric beverage powder without micronutrient fortification.
45637948|NCT03390491|Behavioral|Recovery Videos (RV)|As described, RV clients will have access to a website that includes recovery videos and static psychoeducation materials. In this condition, mental health providers will also ask about possible reactions to viewing the recovery videos and information on the website.
45776137|NCT01151189|Biological|Placebo|Subjects received an intradermal injection placebo on Study Day 0, followed 6-9 months later by a booster injection of placebo.
45776138|NCT01173029|Drug|Anti-hypertensive drug treatment|Anti-hypertensive drug treatment was non-investigational. Drug regimen, including which drug and the number of drugs prescribed, was left at discretion of the physician who carried primary assistance.
45915012|NCT05670522|Device|Virtual reality|"Virtual reality rehabilitation is an emerging therapy for motor rehabilitation of children with CP. The therapy is provided through a computer-simulated environment where they interact with real-world-like objects and events through sight, sound, and touch. The Wii Remote was used as the interactive interface, and standard computer/television screens were used as the display hardware. Therefore, VR therapy was of the non-immersive type.~The standard-of-care gait training included various gait training and balance tasks as well as resistive exercises and passive stretching as necessary. Task-specific gait exercises included: walking in a closed indoor environment, walking in an open indoor environment, walking on various floor surfaces, and climbing stairs up and down without assistance. The children also performed dynamic balance exercises by walking on a balance board."
45915013|NCT04005456|Dietary Supplement|Supplements and/or medical foods|Personalized dietary supplementation (e.g., multivitamins/minerals, probiotics, specialized pro-resolving mediators, marine oil, vitamin D, hormone support, methylation support, protein drink, phytochemicals, neurocognitive support, targeted ingredients)
45637949|NCT03126617|Biological|Elotuzumab|Elotuzumab (Emplicitii) is a Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) directed immunostimulatory antibody approved by the US Food and Drug Administration (FDA) and indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Please contact your physician for more details.
45637950|NCT03052985|Procedure|urinary incontinence, pelvic organ or rectal prolapse surgery|The observatory is planned for following women after surgery for urinary incontinence, pelvic organ prolapse, or rectal prolapse whatever the type of surgery (by laparoscopy, laparotomy or vginal route) or the use of a mesh
45637951|NCT04422743|Dietary Supplement|Citicoline 500 mg plus Homotaurine 50 mg|Citicoline 500 mg plus Homotaurine 50 mg was added to topical therapy
45637952|NCT04421417|Procedure|Microfracture + Standard Arthroscopic Rotator Cuff Repair|drilling of rotator cuff footprint area on humerus and standard arthroscopic rotator cuff repair
45637953|NCT04421417|Procedure|Standard Arthroscopic Rotator Cuff Repair|Standard Arthroscopic Rotator Cuff Repair
45637954|NCT04639973|Diagnostic Test|Group 1 (First trimester ultrasound)|A detailed first trimester anatomy ultrasound will be performed,at the visit when the subject is confirmed to be of eligible gestational age. After this detailed research ultrasound, which will be limited to 15 minutes, subject will then receive the clinically indicated dating ultrasound or nuchal translucency measurement. The patient will complete a survey about her satisfaction with this technique via email.as a safety measure, if an anomaly is suspected on the day of the detailed first trimester anatomy scan, the patient will be unblinded. Patients in this arm are later scheduled for a second trimester ultrasound by the clinical team, as this is part of standard obstetrical care.
45637955|NCT04639973|Diagnostic Test|Group 2 (Second trimester anatomy ultrasound)|Patients do not undergo a detailed first trimester ultrasound , but will receive the clinically indicated limited ultrasound for dating or for nuchal translucency. Patient will then undergoes a second trimester ultrasound by the clinical team as part of standard obstetrical care and completes a survey regarding her satisfaction with this technique via email.
45637956|NCT05403515|Other|foot massage|foot massage
45637957|NCT05403515|Other|Foot massage +Aromatherapy group|foot massage and lavender oil inhalation
45637958|NCT05140421|Behavioral|Data to Suppression (D2S)|Intervention components include (1) reporting and (2) capacity building to facilitate identification of and follow-up with PWH who are in care but virally unsuppressed. The NYC Health Department will send client-level, surveillance-based reports on individual clients' viral suppression status to those clients' current Ryan White Part A behavioral health and housing service providers. The Health Department will also provide capacity building and technical assistance (TA) support to service providers on following up with clients flagged as unsuppressed, and on addressing barriers to viral suppression through root cause analyses and the development and implementation of D2S quality improvement projects. The intervention components are all delivered to Ryan White Part A providers by the Health Department, in order to enhance program resources to achieve and maintain viral suppression in the Ryan White Part A client population in NYC.
45637959|NCT05127629|Procedure|Immediate implant placement|After tooth extraction, a dental implant is placed immediately.
45637960|NCT05127629|Procedure|Guided bone regeneration|After implant placement, the gap between implant and the buccal bone wall is filled with Bio-oss collagen.
45776139|NCT01174823|Drug|bepotastine besilate ophthalmic solution|sterile ophthalmic solution
45776140|NCT01174823|Drug|placebo comparator ophthalmic solution|sterile ophthalmic solution
45637961|NCT05127629|Procedure|Wound closure with gelatin sponge|After guided bone regeneration, patient in the control group receive gelatin sponge for wound closure.
45637962|NCT05127629|Procedure|Wound closure with collagen matrix|After guided bone regeneration, patient in the control group receive collagen matrix (Mucograft Seal) for wound closure.
45637963|NCT02535221|Drug|Goserelin+TAM+AI|Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.
45637964|NCT02535221|Drug|Epirubicin+CTX+5-Fu|Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.
45776141|NCT03011489|Device|Vacuum formed aligners|Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is a modified step in Figueroa's technique.
45776142|NCT03886649|Drug|Copanlisib|Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The only dose level 1 (DL1) is 60 mg copanlisib.
45637965|NCT04574609|Device|Oncomfort® clinical virtual reality|"hypnotherapy arm, patients will receive in addition to the care provided by the usual :~for PAC insertion: a 45-minute hypnotherapy session 2 hours before the procedure in a room of the outpatient surgery unit (UCA).~during the entire duration of chemotherapy (and/or immunotherapy for HER2+ patients) : one hypnotherapy session before the first treatment and then every 3 weeks. One hypnotherapy session before the first treatment and then every 3 weeks. Thus, sessions will take place before each treatment for 3-week inter-course regimens and every 3 treatments for chemotherapy administered on a weekly. Each session will last 20 minutes."
45776143|NCT03886649|Drug|Venetoclax|Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The starting dose is dose level 1 (DL1): 600 mg venetoclax.
45776144|NCT01151813|Drug|Varenicline|Varenicline, oral target dose of 1.0 mg BID, one week titration.
45776145|NCT01151813|Drug|Placebo|Placebo
45776146|NCT01175369|Behavioral|School-based Care|The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).
45776147|NCT03877991|Drug|CBD-sesame oil capsule|A capsule containing cannabidiol dissolved in sesame oil and surfactant vehicle.
45915014|NCT04005456|Behavioral|Behavioral change support program|Program to implement lifestyle and behavioral change according to individuals' need.
45915015|NCT04005456|Other|Food plan|Personalized food plan (e.g., basic wellness food plan, cardiometabolic food plan, high protein high phytonutrient food plan, ketogenic food plan, detoxification food plan, anti-inflammatory food plan, neuro food plan)
45915016|NCT05632770|Behavioral|Stepped Collaborative Care|Case management, behavioral intervention elements, psychopharmacologic medication recommendations and 24/7 cell phone coverage for 6 months post-injury.
45915017|NCT05632770|Behavioral|American College of Surgeons (ACS) Required Screening and Referral (Usual Care)|The study will contribute to usual care with the study 10-domain electronic health record (EHR) screen and the posttraumatic stress disorder (PTSD) evaluation. The study team may also collaborate with hospital providers on the referral process and/or inform a member of the patient's care team of distress patients are experiencing as identified by a DSM-5 PTSD Checklist (PCL) score of ≥ 30 or a DSM-IV PTSD Checklist (PCL) score of ≥ 35.
45915018|NCT05626725|Device|Automated insulin delivery system|This is an outpatient prospective observational study to evaluate the effect of DIY-AID use on maintaining glucose levels in physically active adult people living with T1D.
45915019|NCT05611203|Procedure|An Oropharyngeal swab|An Oropharyngeal swab performed for diagnostic purposes
45915020|NCT05597163|Drug|low concentration atropine (0.01%)|0.01% atropine eye drop
45448347|NCT01077947|Procedure|Functional anesthetic discography|Functional anesthetic discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
45637966|NCT01071941|Biological|administration of rRp450 into the hepatic artery|Administration of rRp450 into the hepatic artery either as a single infusion, or as four infusions administered every one to two weeks.
45637967|NCT00000587|Procedure|erythropoietin, recombinant|
45637968|NCT05138237|Procedure|endoscopy or surgery|"we choose the proper intervention surgery or endoscopy for management of the indeterminate common bile duct stricture according to its nature benign or malignant"
45754266|NCT03587792|Procedure|stapedectomy|Stapedectomy as described in literature with stapes removal, Carbon Dioxide (CO2) laser platinectomy and placement of a prothesis(piston) between the incus long process and the stapes footplate
45754267|NCT04862923|Drug|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to treat the participant with a given product is independent of the decision to include him/her in the study.
45754268|NCT04143620|Procedure|Procedure|Triple procedure
45776148|NCT03877991|Drug|CBD-LNL capsule|A capsule containing Cannabidiol dissolved in self nano emulsifying formulation
45776149|NCT03877991|Drug|CBD powder form capsule|Powder of Cannabidiol filled in a hard gelatin capsule, without formulation.
45776150|NCT03835949|Drug|TJ004309|Antibody to CD73
45776151|NCT03835949|Drug|Atezolizumab|Humanized monoclonal antibody to PD-L1
45776152|NCT01176617|Device|Reveal XT implantable loop recorder|All study participants will receive the Reveal XT implantable loop recorder immediately after completion of the ablation procedure.
45776153|NCT01177709|Drug|Metformin|metformin 500- 2500 mg/day. Patient received variable doses of metformin starting at 500 mg/day and increasing up to maximum of 2500 mg/day over 3-4 weeks. Dose was titrated on tolerability and side effects, especially development of hypoglycemia. This explains why different patients received different maximum doses.
45776154|NCT01179113|Drug|Esmolol|Esmolol group: Will receive 0.5 mg/kg IV bolus of esmolol during induction, and an infusion of esmolol at 0.3 mg/kg/hr intraoperatively.
45776155|NCT01179113|Drug|Saline|Loading: an equivalent volume for the Esmolol group Infusion: an equivalent volume for the Esmolol group
45915021|NCT05597163|Drug|low concentration atropine (0.025%)|0.025% atropine eye drop
45915022|NCT05597163|Drug|low concentration atropine (0.05%)|0.05% atropine eye drop
45915023|NCT05597163|Drug|Placebo|Placebo eye drop
45915024|NCT05595837|Other|Standard organ transplant|Standard organ transplant procedures and follow up care
45915025|NCT03983772|Dietary Supplement|RS blend|The intervention is a proprietary resistant starch blend.
45915026|NCT03983772|Other|Placebo|The placebo is starch.
45915027|NCT03981471|Behavioral|Exercise|Elderly people with or without fall history receive exercise to improve balance. Exercise interevention will be given 6 months in 2020. Outcomes (incidence of fall and biological tests) between two arms will be compared.
45915028|NCT05565885|Other|Sampling|4 blood sampling per patient and an additional one in case of relapse
45915029|NCT05550129|Drug|AMG 510|Oral tablet
45776156|NCT01152359|Behavioral|Choice|Participants are allowed to choose between a low-carbohydrate or a low-fat diet for weight loss after receiving information about these diets and their food preferences (Choice arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm have the option to switch diets at 12 weeks.
45776157|NCT01152359|Behavioral|Control|Participants are randomly assigned to (rather than getting to choose, as in the experimental arm) a low-carbohydrate or a low-fat diet for weight loss (Control arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm do not have the option to switch diets at 12 weeks.
45776158|NCT01152515|Drug|Remifentanil|Control group : stopping of propofol and remifentanil infusion Remifentanil group : stopping of propofol and maintenance of remifentanil infusion
45776159|NCT03011255|Biological|peptide specific CTL|Radiation: RT to 60 Gy, 5 x per week，for 6 weeks Biological: Peptide specific CTL Peptide specific CTL will be administered by intravenous injection on day 28 of radiation.
45776160|NCT01153685|Biological|Fluviral®|Intramuscular injection, one dose
45776161|NCT03011177|Drug|Teneligliptin|teneligliptin 20mg qd
45776162|NCT03011177|Drug|Linagliptin|linagliptin 5mg qd
45448348|NCT01077947|Procedure|Provocative Discography|Provocative Discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
45776163|NCT03599297|Procedure|Bilateral synchronous simultaneous stone surgery|Patients undergoing Bilateral synchronous simultaneous stone surgery (one kidney undergoing percutaneous nephrolithotomy, other kidney undergoing ureteroscopy at the same time in a single patient)
45776164|NCT01154699|Device|Bilevel PAP (4 weeks)|Subjects will use bilevel PAP each night for 4 weeks. The pressure levels will be adjusted by the investigators to increase lung volumes during the night.
45776165|NCT01154699|Other|Usual Care (4 weeks)|Subjects will continue with their usual asthma care. Investigators will make no changes to their medications or other habits.
45776166|NCT01154699|Other|Washout Period (4 weeks)|Subjects will continue with their usual asthma care in between the Usual Care and Bilevel PAP periods. Investigators will make no changes to their medications or other habits.
45776167|NCT03465527|Drug|PrednisoLONE 50 MG|Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days
45776168|NCT03010943|Device|Virtual reality headset|Feasibility and tolerance
45776169|NCT01180127|Dietary Supplement|Flavanol containing food product|12 weeks, 2X/day, 20g serving
45776170|NCT01180127|Behavioral|Aerobic training|4X/week, 1 hour/session at 75% maximum HR
45915030|NCT05550129|Drug|Metformin|Oral tablet
45915031|NCT05523726|Behavioral|pCBT-I|Telehealth coaching
45915032|NCT05508204|Drug|BION-1301|A solution for SC injection administered as a single dose
45915033|NCT05500716|Other|Auricular Non-Invazive Vagus Nerve Stimulation + Traditional Rehabilitation Program for TMD|"In this application, vagus nerve stimulation is applied to the patients in addition to the traditional rehabilitation program. In our research, vagal nerve stimulation will be applied with the Vagustim Device and all applications will be applied at a frequency of 10 Hz, a pulse amplitude of 300 microseconds and for 20 minutes."
45915034|NCT05500716|Other|Traditional Rehabilitation Program|This intervention includes: Deep Friction Massage, Myofascial Trigger Point Compression Therapy, Temporomandibular Joint Mobilization, Rocabado Exercises, Muscle-Energy Techniques.
45754269|NCT04143854|Drug|MBA-P01(Botulinum toxin A)|Intramuscular injection; Dose varies by group
45754270|NCT04143854|Drug|Placebo|Intramuscular injection; normal saline
45754271|NCT04765670|Other|Instrument Assisted Soft Tissue Mobilization|Bilateral Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
45754272|NCT04765670|Other|Kinesiotape Application|Bilateral Kinesiotape application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
45754273|NCT03587714|Diagnostic Test|HCV RT-PCR|HCV ribonucleic acid by reverse transcriptase polymerase chain reaction (RT-PCR)
45776171|NCT01180127|Dietary Supplement|Food product lacking flavanol|20 g serving, 2X/day, food additive lacking flavonol
45776172|NCT01180127|Behavioral|Wait list control|12 week wait list control condition during which participants abstain from aerobic exercise
45776173|NCT03418805|Drug|Advil Ibuprofen table 200 mg|"Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration."
45776174|NCT03418805|Drug|Motrin IB Ibuprofen Tablets 200 mg|"Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration."
45915035|NCT05489835|Behavioral|Nutritional counseling|Nutritional counseling
45915036|NCT05482698|Drug|MC2-25 cream|Topical application
45915037|NCT05482698|Drug|MC2-25 vehicle|Topical application
45915038|NCT05470101|Drug|ITI-333|ITI-333 oral solution
45915039|NCT00386919|Procedure|CyberKnife|
45915040|NCT00386958|Drug|Povidone-Iodine|
45776175|NCT03418805|Drug|Ibuprofen CR Tablets 600 mg|"Administration of the investigational product:~Single oral dose of IBUCR, followed by 28 and 32 hours after the dose administration for fasted and fed studies, respectively"
45637969|NCT05089253|Other|Dry Needling|"The subject will be in the supine position and receive dry needling. The first point will be at the medial femoral condyle of the knee joint line in vastus medialis muscles. The second point will be at the lateral femoral condyle of the knee joint line in vastus lateralis muscles. The third point will be above the base of the patella in the rectus femoris muscle. The fourth point will be 2cm above the third point in rectus femoris muscles. These four points were the most common places of trigger point at quadriceps muscles. Dry needling is affected on A-delta fibers. Therefore when superficial dry needling with a noxious stimulation leads to stimulation on A-delta fibers, the excitation remains almost 72 hours and gradually decreases.~The standard 9- point dry needling technique will be applied for 20 minutes per session 3 times a week for 4 weeks."
45637970|NCT05089253|Other|Kinesio tapping|"The subject will be in the supine position and receive Kinesio taping. The Kinesio tape application with no tension one Y strip with a length of 20 cm, an anchor of 2 cm.~The Kinesio tape will be applied to the participants in supine with the knee in 90 flexions. Two Y-shaped tapes are applied above and below the patella. The tape will be removed after 48 hours after application. The Kinesio tape will be applied 3 times a week for 4 weeks."
45637971|NCT04567121|Behavioral|Intensive intervention group|Establish a team of chronic disease prevention managers (5 people), with each educator responsible for the intervention of 200 people. For sub-health population and chronic disease patients, there would be conducted health education interview twice, 4 calls, online communication 50 times once a year, controlling risk factors and making treatment plan.
45776176|NCT01156571|Drug|cangrelor P2Y12 (platelet) inhibitor|
45915041|NCT00386997|Drug|liposomal amphotericin B (AmBisome®)|
45915042|NCT00387114|Drug|Vitamin C|
46070254|NCT00814099|Behavioral|Team approach to sedation management|"The team approach to sedation management includes the following:~Team education and consensus on the use of sedatives~Team identification of the patient's trajectory of illness and daily prescription of a sedation goal~A nurse-implemented goal-directed comfort algorithm that guides moment-to-moment titration of opioids and benzodiazepines~Team feedback on sedation management performance"
46070255|NCT00814099|Behavioral|Usual approach to sedation management|The pediatric ICU will continue its usual approach to sedation management.
45776177|NCT01156571|Drug|Clopidogrel - 300 or 600 mg (study arm)|Over encapsulated tablets.
45776178|NCT01156571|Drug|Clopidogrel 600 mg post cangrelor|over-encapsulated clopidogrel (600 mg)
45776179|NCT01220687|Drug|iNO|Immediately after birth, subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
45776180|NCT01220687|Other|Nitrogen|Subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
45776181|NCT03010865|Drug|Sodium Butyrate|Sodium butyrate is being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) in 730 mg capsules. The company asserts that their material is 98% pure and food grade. We will have identical placebo capsules. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 4380 mg/day.
45776182|NCT03010865|Drug|Placebo Oral Capsule|Placebo Oral Capsule is also being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) and there is no difference from appearance, smell and taste. It contains 1.5 mg sodium butyrate per capsule. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 9 mg/day.
45776183|NCT01156805|Other|Educational program|The intervention consisted of the promotion of healthy eating habits and physical activity by means of the educational methodology Investigation, Vision, Action and Change (IVAC). At the beginning and at the end of 1st phase of the study (2006 and 2008) the weight and height of each child was measured in situ, while the families were given a self-report physical activity questionnaire and the Krece Plus quick test
45776184|NCT02531802|Biological|ETVAX|"Varying dosages of liquid ETVAX vaccine (Batch BX1003574). A full dose consisted of:~Hybrid protein between the B-subunit of the E. coli heat-labile enterotoxin and the B-subunit of the cholera toxin (LCTBA): 1 mg~E. coli ETEX 21 formalin inactivated: 1.3 mg colonization factor 1 (CFA/I)~E. coli ETEX 22 formalin inactivated: 6.4 mg coli surface antigen 3 (CS3)~E. coli ETEX 23 formalin inactivated: 1.1 mg coli surface antigen 5 (CS5)~E. coli ETEX 24 phenol inactivated: 0.5 mg coli surface antigen 6 (CS6)~The vaccine was given together with sodium bicarbonate effervescent granules (Recip), which was dissolved in water and mixed with the vaccine suspension prior to oral administration. The buffer was used to prevent degradation of LCTBA hybrid protein by the gastric acid."
45776185|NCT02531802|Biological|dmLT|Varying dosages of dmLT, a derivative of wild-type enterotoxigenic Escherichia coli LT that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
45776186|NCT02531802|Other|Bicarbonate Buffer|Sodium bicarbonate buffer dissolved in 150 ml of potable water
45776187|NCT01157429|Drug|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
45915043|NCT05419479|Drug|ZIMBERELIMAB|Via IV on two days per cycle, dosage per protocol
45915044|NCT05419479|Drug|DOMVANALIMAB|Via IV on two days per cycle, dosage per protocol
45915045|NCT05419479|Drug|APX005M|Via IV on two days per cycle, dosage per protocol
45915046|NCT05419479|Drug|FOLFIRI|every two weeks through an infusion at a dose determined by physician
45915047|NCT05320770|Procedure|US guided TMJ intra articular injection|therapeutic TMJ intra articulatr injection of blood under sonography guidance to reduce joint hyper mobility
45915048|NCT00387192|Drug|Optivate|Plasma-derived Factor VIII
46070256|NCT00808093|Drug|GSK256073|GSK256073 100 mg study drug
46070257|NCT00645853|Drug|AZD0837|Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od
45776188|NCT01157429|Drug|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of teh 12-session CBT protocol.
45776189|NCT01157429|Behavioral|CBT|12-session CBT protocol, called Youth PTSD Treatment.
45776190|NCT01158521|Drug|pazopanib hydrochloride|Oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity.
45776191|NCT01158521|Procedure|therapeutic conventional surgery|Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride.
45776192|NCT02246933|Other|PUFA Diet|The 7-day diet will consist of 50% carbohydrate, 15% protein, and 35% fat. 21% of total energy will be poly-unsaturated fatty acids, 9% mono-unsaturated fatty acids, and 5% saturated fatty acids.
45776193|NCT02246933|Other|Control Diet|The 7-day diet will consist of 50% carbohydrate, 35% fat, and 15% protein. Furthermore, 7% of total energy will be poly-unsaturated fatty acids, 15% of total energy will be mono-unsaturated fatty acids, and 13% of total energy will be saturated fatty acids.
45776194|NCT01221311|Device|Fully covered Metallic Stent|Covered Wallflex Biliary (TM)
45776195|NCT01221311|Device|Plastic Stent|Patients randomized to the PS group will be treated using a standard algorithm. Specifically, the stricture will be dilated using a passage dilator and/or dilation balloon catheter, and one or two PS will be deployed depending on the baseline characteristics of the stricture as well as the diameter of the proximal and distal bile duct (standard of care). The endoscopist will sequentially dilate and upsize the cumulative stent diameter on ensuing ERCPs, until the stricture has been obliterated using clinical and fluoroscopic criteria.
45776196|NCT04352075|Drug|Autologous biologic drug of innovative therapy /cell therapy drug|Articular knee injection of microfat associated with a dose of 3 billions of platelets or associated with a dose of 1 billion of platelets or with saline solution
45776197|NCT05410080|Diagnostic Test|Fasting blood sugar, 2 hours postprandial, HBA1C ,Ultrasound and Doppler study|Fasting blood sugar, 2 hours postprandial, HBA1C ,Ultrasound and Doppler study
45776198|NCT00234884|Biological|adalimumab|commercial adalimumab as prescribed by the rheumatologist in a normal clinical setting and in accordance with the Summary of Product Characteristics (SmPC)
45776199|NCT04388774|Drug|Ketamine|A single 40-minute intravenous infusion
45776200|NCT01602666|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
45776201|NCT01602666|Drug|Carboplatin|Given IV
45637972|NCT04567121|Behavioral|standard intervention group|Conduct general health education without active management
45637973|NCT05083403|Device|AcumenTM HPI Software Feature|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
45637974|NCT05083403|Other|Non-protocolized Standard of Care|Non-protocolized standard of care to treat subjects
45637975|NCT04493411|Procedure|WBMRI|"WBMRI will be performed either at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points.~Baseline: (before or after 1-2 cycles of induction therapy)~Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy)~Between Week 24 - 36 (before starting maintenance therapy)~Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)"
45776202|NCT01602666|Drug|Etoposide|Given IV
45776203|NCT01602666|Drug|Ifosfamide|Given IV
45776204|NCT01602666|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45776205|NCT01552356|Other|Laboratory Biomarker Analysis|Correlative studies
45776206|NCT01552356|Drug|Pazopanib Hydrochloride|Given PO
45776207|NCT01552356|Other|Pharmacological Study|Correlative studies
45776208|NCT04423380|Drug|SH3051 capsule treatment|Starting dose 20mg,oral administered twice daily.If tolerated subsequent cohorts will test increasing doses (40mg,60mg,80mg,100mg) of SH3051.
45776209|NCT05442060|Biological|30 μg OBI-833/100 μg OBI-821|Each subject in the OBI-833/OBI-821 + erlotinib combination arm will be treated with OBI-833/OBI-821 weekly for 4 doses (Weeks 1, 2, 3, 4), then every 2 weeks for 2 doses (Weeks 6, 8), then every 4 weeks for 4 doses (Weeks 12, 16, 20, 24), and then every 8 weeks until documented disease progression, intolerable adverse events (AEs)/toxicity, consent withdrawal, death, loss to follow-up, or up to 80 weeks from randomization.
45776210|NCT05442060|Drug|Erlotinib (150 mg daily)|All subjects in both arms will continue to receive erlotinib as the background therapy (150 mg daily).
45776211|NCT05441592|Drug|Tranexamic acid injection|The breast pockets will additionally be irrigated with 150 cc of 2.67% TXA (75 cc in each breast). The TXA solution will be allowed to be sit in the breast pocket for 15 minutes and then removed after 15 minutes.
45776212|NCT05441592|Other|No additional irrigation|There will be no additional irrigation after the standard surgical procedure.
45776213|NCT02531646|Radiation|Radiation|Radiation - Each human subject will receive one standard of care x-ray and one Duel Energy exposure or one standard of care x-ray and one Digital Tomosynthesis exposure. Phantoms were imaged using linear tomography and digital tomography.
45776214|NCT04259970|Drug|Initiation of CFTR Modulator|Inhaled contrast for MRI occurring at each 4 visits.
45776215|NCT01451502|Biological|Umbilical Cord Blood (UCB)|Infusion of Minimally Manipulated UCB Units - the UCB unit will be infused through a central line according to institutional guidelines.
45776216|NCT05415618|Other|Manual lymphatic drainage|Manual lymphatic drainage will be applied 5 days a week for about 15 minutes every day for 4 weeks.
45776217|NCT05415618|Device|splint|In splint treatment, a volar-supported splint that keeps the wrist in a neutral position will be preferred and it will be recommended to both groups to be used only at night for 4 weeks.
45776218|NCT05415462|Biological|mRNA-1010|Sterile liquid for injection
45637976|NCT04493411|Procedure|Positron Emission Tomography/Computed Tomography (PET/CT)|"PET/CT will be performed at at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points.~Baseline: (before or after 1-2 cycles of induction therapy)~Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy)~Between Week 24 - 36 (before starting maintenance therapy)~Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)"
45637977|NCT05081921|Drug|MesoCellA-Ortho administration|"Single dose of MesoCellA-Ortho product consisting of 20 mln of autologous adipose tissue-derived mesenchymal stem/ stromal cells (AT-MSCs) will be administrated intraarticularly in patients enrolled in MesoCellA-Ortho- treated groups."
45637978|NCT05081921|Drug|HA administration|"Single dose of hyaluronic acid (HA) will be administrated intraarticularly as an active control in patients enrolled in Control Patients groups."
45637979|NCT04492007|Behavioral|Patient-Reported Outcomes-Informed Symptom Management System (PRISMS)|Participants will receive personalized self-care information and guidance based on their symptoms and signs of complications (e.g., skin infection, fatigue) from the web-based telehealth PRISMS program. They will also have access through this website a peer support online forum that is moderated by a research nurse as well as professional support through videoconferencing/telephone from the research nurse and also their healthcare providers at the hospital(s) if they experience moderate to severe symptoms and/or abnormal sign (e.g., body temperature is greater than 98.6 C
45637980|NCT04561661|Procedure|Percutaneous pinning|Closed reduction, percutaneous pinning and plaster
45776219|NCT05415462|Biological|Licensed quadrivalent inactivated seasonal influenza vaccine|Sterile suspension for injection
45776220|NCT00300482|Drug|ABT-335|135 mg, daily, 12 weeks
45637981|NCT04561661|Procedure|Conservative treatment|Closed reduction, custom made orthosis and early mobilization
45776221|NCT00300482|Drug|Rosuvastatin Calcium|Daily, 12 weeks, see Arm Description for dosage information
45776222|NCT00300482|Drug|Placebo|Daily, 12 weeks, see Arm Description for information regarding placebo type
45637982|NCT05138159|Drug|Donafenib|Donafenib: 200mg po bid.
45637983|NCT05138159|Drug|S1|S-1 capsule: According to the body surface area <1.25m2 40mg/d, 1.25 ~ 1.5 m2 50 mg/d, > 1.5m2 60mg/d po bid, taking 14 days, stopping for 7 days, 21 days for 1 cycle.
45776223|NCT05439876|Drug|Melatonin|Melatonin 2 mg daily for 4 weeks
45637984|NCT05066087|Behavioral|DAHLIA treatment|6 weeks; CBT/ ACT/ process-based treatment; micro-learning format with 4 digital micro-sessions per week; exposure as the core process; guidance to be OPEN, AWARE, ACTIVE; weekly contact with therapist; booster sessions after 2- and 4 months;
45637985|NCT05066087|Other|Treatment as usual|Usual pain treatment; defined post-hoc based on what patients receive
45754274|NCT03022058|Device|Ear-EEG system|Measurement of the neural activity in the brain by use of the Ear-EEG device, which is a customized earplug containing 6 embedded dry electrodes placed inside the ear canal and in the concha of the ear.
45776224|NCT05439876|Drug|Placebo|Placebo daily for 4 weeks
45776225|NCT01791062|Device|HYTOP®|HYTOP® will be implanted once during surgery.
45915049|NCT03940131|Drug|Panitumumab|FOLFOX6 regimen consists of 2-hour infusion of oxaliplatin (85 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2 ) on Day l, followed by 5-fluorouracil bolus (400 mg/m2) on Day 1 and 46-hour infusion (2.4 g/m2). FOLFOX6 regimen will be repeated at 2-week intervals. FOLFIRI regimen consists of 2-hour infusion of irinotecan (180 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2 ) on Day l, followed by 5-fluorouracil bolus (400 mg/m2) on Day 1 and 46-hour infusion (2.4 g/m2). FOLFIRI regimen will be repeated at 2-week intervals.
45915050|NCT05257044|Drug|Cannabigerol|Participants will ingest CBG and placebo in a double-blind randomized cross-over design
45915051|NCT05257044|Other|Placebo|Placebo
45915052|NCT03939390|Drug|time of administration of Corifollitropin Alfa|The treatment will be identical in both arms. The difference between the arms is the moment of the Administration of Corifollitropin Alfa: follicular phase of the menstrual cycle (control group) vs. luteal phase of the menstrual cycle (study group).
45754275|NCT03587558|Drug|Carvedilol|Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT.
45754276|NCT03587558|Drug|Flecainide|Patients in this group are taking flecainide to inhibit outflow tract PVC/VT.
45754277|NCT03021512|Procedure|Phaco with Restor|Phacoemulsification with bilateral bifocal intraocular lenses implantation
45776226|NCT04261686|Device|Covera Vascular Covered Stent|This is a single-arm study. All subjects will receive the Covera Vascular Covered Stent
45776227|NCT00301028|Biological|Cetuximab|Beginning weekly dose 400 mg/m^2 IV over 1-2 hours, and 250 mg/m^2 weeks 2-6.
45776228|NCT00301028|Drug|Carboplatin|AUC 2 weekly for 6 courses.
45776229|NCT00301028|Drug|Paclitaxel|135 mg/m^2 weekly for 6 courses.
45776230|NCT00301028|Procedure|Conventional Surgery|Following induction in second part of study.
45776231|NCT00301028|Radiation|Radiation Therapy|Following induction in second part of study.
45915053|NCT05230173|Other|Pragmatic|"Patients randomized to a strategy of switching TIM will be switched to one of the preferred agents recommended by clinical guidelines and covered by the patients' insurance formulary as part of routine care, and at the discretion of the site investigator and treating provider. No study-related medications will be provided.~Patients (and their providers) in either treatment arm will be allowed to stop or start new TIMs and other IBD-directed therapies in case of symptomatic relapse or intolerance to therapies, at the discretion of the treating provider-patient team."
46070258|NCT00645853|Drug|VKA INR 2-3|Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5
45776232|NCT05404230|Dietary Supplement|Fish oil|Fish oil containing poly unsaturated fatty acids.
45776233|NCT05404230|Dietary Supplement|Corn oil|Corn oil
45776234|NCT00301418|Drug|Erlotinib|Tarceva®: Will be given at a starting dose of 150mg QD dose for the first cycle which is 28 days. This will be followed by 14 days of 100mg PO on a bid schedule and 150mg PO on a bid schedule for the final 14 days of the second cycle. Assuming no dose limiting toxicity, 150 mg PO tid will be continued for up to 10 more cycles. This is an outpatient regimen, in which the drug is admininistered orally. Tumor response will be assessed after every 2nd treatment cycle. Patients may receive a maximum of 12 cycles of treatment under this research protocol.
45637986|NCT05064293|Behavioral|Navigation Arm|Families will be offered a formal assessment to ascertain the primary mental health diagnosis and any co-occurring mental health disorders. After completing the online parent/guardian self-assessment, parents/guardians will meet with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to the navigator for connection to care or study-provided tele-video visits. Navigators will outreach families monthly during the 6-month study period. The navigator will inquire about the child's status and re-evaluate barriers to access. When barriers exist, the navigator will help in facilitating specialty treatment initiation and assess appropriateness of tele-video therapy sessions until ongoing MH services can be arranged. Families/patients reporting that index symptoms have resolved will be offered a 'watchful waiting' approach. Subjects accepting 'watchful waiting' will be outreached quarterly, but not beyond the end of the 6-month follow-up period.
45776235|NCT05414838|Dietary Supplement|Curcumin, Omega-3 and Vitamin-D (COD)|"Acumin™ Turmeric Complex (Dr. D's Ultra BioTurmeric) 500 mg daily (NPN 80087842)~Omega-3 supplements (combination of DHA and EPA) 900 mg daily (NPN 80019234)~Vitamin D3 supplements 2500 IU daily (NPN 80108995)"
45776236|NCT00302042|Behavioral|Brief counseling plus group diabetes prevention in community|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk, Group diabetes prevention in community: 16 weekly group lifestyle behavior change visits followed by monthly group lifestyle behavior change visits.
45637987|NCT05064293|Behavioral|Control Arm|Families who agree to participate will first be offered a formal assessment in order to ascertain the primary mental health diagnosis and any co-occurring mental health disorders (e.g., substance use). After completing the online parent/guardian self-assessment, parents/guardians will meet for 30 minutes with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to their primary care provider. Control arm participants do not receive navigation.
45776237|NCT00302042|Behavioral|Brief Counseling for pre-diabetes alone|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk.
45637988|NCT04592159|Drug|Nabiximols|oromucosal spray
45637989|NCT04592159|Drug|Placebo|oromucosal spray
45637990|NCT05061485|Other|Sucrose|The participants consume A) water with 75 g sucrose
45637991|NCT05061485|Other|Sucrose + protein|The participants consume B) water with 75 g sucrose + approx. 100 kcal protein
45637992|NCT05061485|Other|Sucrose + fat|The participants C) water with 75 g sucrose + approx. 100 kcal fat
45776238|NCT01892228|Behavioral|Immediate post-screening treatment education|immediate treatment education after screening to decrease time from initial HIV screening to treatment implementation
45915054|NCT05214963|Device|NTX100 Neuromodulation System - Active|Noninvasive peripheral nerve stimulation device programmed to active mode
45915055|NCT05214963|Device|NTX100 Neuromodulation System - Sham|Noninvasive peripheral nerve stimulation device programmed to sham mode
45776239|NCT01898702|Behavioral|Diabetes expert patients programme|Nine-weekly informative and educational sessions by a teaching patient who has experience on diabetes
45776240|NCT05414604|Diagnostic Test|3D spine CT|CT scan of the spine
45776241|NCT01898780|Procedure|pancreaticojejunostomy with horizontal mattress suture|
45637993|NCT05138081|Other|PNF stretching|"Neck flexion pattern The therapist slightly pulled the chin so that it was lifted and causing the neck to extend. Commands such as pull your chin in and look at your left hip were given to the patient. Resistance was given against left rotation, flexion and lateral flexion along with the traction to the patient's chin.Neck extension pattern The therapists lightly pulled the chin so that the neck was flexed; head was rotated and tilted to the left. Commands such as lift your chin and then lift your head to look above were given to the patient. Passive resistance was provided against right rotation, extension and lateral flexion."
45637994|NCT05138081|Other|Stabilization|Stabilization exercises are shoulder rolls, shrugging, chin tuck, scapular retraction, cervical extension. This was done for 15 repetition
45637995|NCT05137613|Other|One visit root canal retreatment|The teeth were treated in one-visit (OV) root canal retreatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation
45637996|NCT05137613|Other|Two visit root canal retreatment|The teeth were treated in two visit (TV) root canal retreatment. After completion of root canal instrumentation, calcium hydroxide (CH) paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
45776242|NCT01898780|Procedure|pancreaticojejunostomy with interrupted suture|
45776243|NCT05414214|Procedure|Thyromental Height Test|Thyromental Height Test (TMHT) : will be measured while a patient is lying supine with the head and neck are maintained in a neutral position using a pillow under the head. By using a digital depth gauge, the TMH is the vertical distance measured between the anterior border of the thyroid cartilage directly on the thyroid notch and the anterior border of the mentum.
45776244|NCT05414214|Procedure|Sternomental displacement|Sternomental displacement (SMDD): While the patient is sitting with the head in a neutral position, SMD-neutral will be measured using a tape as the distance between upper borders of the manubrium sterni and the mentum. The SMD-extension will then be measured in the same way with the head extended on the neck. The difference between SMD-extension and SMD-neutral will then be calculated as SMDD.
45915056|NCT05196828|Device|NTX100 Neuromodulation System|Active Noninvasive peripheral nerve stimulation device programmed to active mode
45915057|NCT05178810|Drug|FAB122|Daily dose 100 mg
45915058|NCT05178810|Drug|Placebo|Daily dose
45915059|NCT05173935|Procedure|Percutaneous endoscopic gastrostomy|Gastrostomy tube placement using an endoscopic camera inserted via the mouth into the stomach to place the tube.
45915060|NCT05173935|Procedure|Radiologically-inserted gastrostomy|Gastrostomy tube placement using a temporary nasogastric tube placed from nose to stomach and fluoroscopy (x-rays).
45776245|NCT05414214|Procedure|General anesthesia|patients will be pre-oxygenated with 100% oxygen for 3 minutes, anesthesia will be then induced intravenously using fentanyl 2 μg/kg, propofol 1 -1.5 mg/kg, and succinylcholine 1 mg/kg lean body weight. Mask ventilation will be maintained till complete muscle relaxation guided by a peripheral nerve stimulator. Using Macintosh laryngoscopy, an anesthetist who has at least three years experience and who will be blinded to the preoperative tests' results, determined the best laryngeal view by using Cormack-Lehane (CL) grading system from I-IV. External neck manipulation will be used when needed to obtain the best laryngoscopic view. Endotracheal intubation will then be accomplished. The number and duration of intubation attempts will be recorded.
45637997|NCT05137535|Other|Questionnaire|Family-based questionnaire
45637998|NCT05137457|Other|"Delivering Online ZZZ's with Empirical support (DOZE) app"|"The DOZE app is a unique digital CBTi intervention that can be used on any mobile phone, tablet or computer, using the iPhone Operating System (iOS) or Android software. It is an innovative program that consists of an integrated smart phone app and web self-management system (DOZE) to help adolescents and young adults to sleep better. It allows data capture through entries in a sleep diary and calculation of specific clinical indices. The acquisition of baseline sleep health data over a two-week period is then used to provide personalized targets and tailored therapeutic interventions during the treatment phase. The app also includes a self-monitoring tool that fosters goal setting and provides feedback on sleep and goal attainment. DOZE allows for real time assessment of sleep related behaviors and customized reports and graphs from the young adults' data. The app provides reminders about specific goals and positive feedback (increasing scores) for each step towards a goal."
45637999|NCT05137457|Other|Sleep diary|The control group will receive the control version of the DOZE app where the patients will be able to access the sleep diary only, without the CBTi intervention. Participants will simply use the app to input entries into their sleep diary as an attention control over a 10-week period.
45638000|NCT05137145|Drug|Linaclotide|The observation group 1 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine, and the observation group 2 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. observation group 3 was given Linaclotide in 3 day combined with 3L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. Intestinal cleanliness and the incidence of adverse reactions of patients in each group were compared.
45638001|NCT05137145|Drug|Compound Polyethylene Glycol Electrolyte Powder|The control group was given Compound Polyethylene Glycol Electrolyte Powder to clear the intestines,
45638002|NCT05136989|Behavioral|Individual and collective semi-structured interviews|Individual and collective semi-structured interviews will be performed with professionals to identify levers (practices, knowledge, tools, regulations) which, at the level of services and establishments, enable the development of a policy of less recourse to coercion
45638003|NCT05136989|Behavioral|Individual semi-structured interviews with ex-patients|Individual semi-structured interviews will be performed with ex-patients in order to gather their experiences in the seven institutions concerned and to better understand the impact of their hospitalization in these institutions on their lives
45638004|NCT05136989|Behavioral|Observations out in the services|Observations will be carried out in the services in order to measure the gap between rhetoric and practice, and to observe the effective implementation of lesser use practices
45776246|NCT01898858|Device|Hypercapnia inhalation (Altitrainer NP 190)|Hypercapnia inhalation using an Altitrainer NP 190
45776247|NCT01898858|Device|Hypoxia and hypercapnia (Altitrainer NP 190)|Hypoxia and hypercapnia inhalation using an Altitrainer NP 190
45776248|NCT01898858|Device|Hypoxia inhalation (Altitrainer NP 190)|Hypoxia inhalation using an Altitrainer NP 190
45776249|NCT05014230|Dietary Supplement|Open Placebo|Zeebo
45776250|NCT05014230|Other|Opioid medication as part of standard care|Opioid medication as prescribed by prescriber. This is not impacted by being in the research study.
45776251|NCT00237770|Drug|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
45776252|NCT00237770|Procedure|Head-up Tilt maneuver|Participant will be placed onto tilt table and brought to 15 degrees of head up tilt for 60 minutes (intravenous infusion time). After this time, a progressive increase to 45 degrees will be completed with a 10 degree increase every 5 minutes. Participant will remain at 45 degrees for 45 minutes or until symptom onset.
45776253|NCT04228484|Other|Placebo|Placebo infusion
45776254|NCT04228484|Other|GIP receptor antagonization|GIP(3-30)NH2 infusion
45776255|NCT01895738|Behavioral|WrapAround Care|Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
45915061|NCT05173116|Other|Medical Outcomes Study Short Form 36 (SF 36)|completion of questionnaire quality of life SF 36 (inclusion, Month 3, Month 6).
45915062|NCT05173116|Other|observationnal study|data collection
45915063|NCT05160597|Procedure|Biopsy of Prostate|Undergo image-guided prostate biopsy
45776256|NCT01896284|Drug|0.5mg aflibercept|0.5mg aflibercept intravitreal injection will be performed every 4 weeks from baseline to week 8 (3 doses) and every 8 weeks until week 32.
45776257|NCT02536404|Drug|Etrasimod|
45776258|NCT02536404|Drug|Placebo|
45776259|NCT04271618|Other|TheraTogs Orthotic Undergarment|Strapping undergarment made from a lightweight, breathable fabric that is velcro sensitive. It consists of sleeveless vest (tank-Top), two shorts (Hipster) each with two thigh cuffs and limb cuffs
45776260|NCT05438160|Device|Digital therapeutics app CT-155|Patients to be treated with digital therapeutics app CT-155 downloadable into personal smartphones
45915064|NCT05160597|Other|Gallium Ga 68 Gozetotide|Given IV
45915065|NCT05160597|Procedure|Transrectal Ultrasonography Guided Biopsy|Undergo standard of care TRUS
45935636|NCT00043940|Drug|bivalirudin|Bivalirudin therapy will be given as a 0.75-mg/kg intravenous bolus and 1.75-mg/kg/h intravenous infusion during procedure and up to 4 hours.
45935637|NCT00128011|Biological|killed oral cholera vaccine|
45935638|NCT00128050|Drug|rFactor VIIa (Eptacog alfa, NovoNordisk)|rFVIIa will be admistered as single bolus at the dosage of 100 mcg/Kg b.w.
45935639|NCT00128050|Drug|rFVIIa|Patients with spontaneous supratentorial ICH will be treated with rFVII after hematoma evacuation
45776261|NCT05435820|Device|Near-infrared Transcranial Laser Therapy|The treatment consists in exposing bilaterally the frontal brain to Transcranial Laser Therapy, which may enhance ATP production in depressed subjects.
45776262|NCT03954990|Drug|Metronidazole Oral|4 tablets (2 g of metronidazole)
45638005|NCT05136911|Behavioral|SALT-Intervention|Participants in the intervention group will have access to all standard care as provided to the usual care group participants. In addition, participants in the intervention group will receive the SALT-intervention developed by the principal investigator in the form of a SALT-intervention consist of the Salt Intervention manual, five online modules which include a virtual cooking demonstration and five ten-minute weekly telephone calls delivered by the principal investigator.These strategies aim to increase knowledge, enhance self-management abilities and provide social support.
45776263|NCT03954990|Drug|Placebo Oral Tablet|4 tablets
45776264|NCT01478581|Drug|PCI-32765|
45776265|NCT01478581|Drug|Dexamethasone|
45776266|NCT00239642|Drug|Venofer (iron sucrose injection)|0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
45638006|NCT05121467|Other|Pain Assessment|Visual Analogue Scale (VAS) were included in the study
45776267|NCT00239642|Drug|Venofer (iron sucrose injection)|1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
45638007|NCT05121467|Other|Assessment of Muscular Endurance|The endurance of the 9 muscles/muscle groups including cervical flexor, extensor, deep flexor muscles, trunk flexor, extensor, lateral flexor, and stabilizer muscles, upper extremity, and scapular muscles (mm. serratus anterior and trapezius) were evaluated based on the assessment instructions given in the studies of Edmonston et al., Grimmer et al., Evans et al., Reece et al., ACSM guideline
45638008|NCT05121467|Other|Assessment of Neck Awareness|The Turkish version of the Fremantle Neck Awareness Questionnaire (FreNAQ) which was developed by Wand et al. to assess neck awareness in patients with chronic neck pain was used in this study
45638009|NCT05121467|Other|Assessment of Fear of Movement|The fear of movement was assessed by the Turkish version of the Tampa Scale of Kinesiophobia which originally developed by Kori et al.
45638010|NCT05306171|Behavioral|Online training for healthcare professionals|"The online training (4 modules) will use the technique of hybrid learning, combining meetings that will require the presence of participants and mediator at the same time and platform (live) with recorded meetings (interviews with experts) that will be watched by the participants at any time (from a distance).~Module 1: Self Care; Module 2: Stress and anxiety management; Module 3: Relationships; Module 4: Communication."
45638011|NCT05305937|Device|MRI scan|All patients will be scanned twice during the same MRI session, before and 2 hours after taking glucosamine orally. In addition to the CEST scans with glucosamine, patients will undergo MRI scans with the standard contrast agent of gadolinium. This procedure will be done following the CEST scan
45638012|NCT05305703|Other|cervical stretching|Heating therapy for 10 minutes Passive stretching of neck muscles including Sub-occipital muscles, Trapezius upper boarder and Sternocleidomastoid muscle with 10 reps each
45776268|NCT00239642|Drug|Venofer (iron sucrose injection)|2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
45776269|NCT04041830|Behavioral|Visit 1|the participants will fill in the LFPQ questionnaire before and after a lunch test meal
45638013|NCT05305703|Other|soft tissue mobilization|Heating therapy for 10 minutes Soft tissue mobilization for 8 minutes and trigger point release of sub-occiptal muscles with 5 repetitions each.
45638014|NCT05305625|Procedure|remote ischemic postcondioning|remote ischemic postcondioning twice daily, for three consecutive days，the upper arm of the lighter paralyzed side was pressurized to 200mmHg, pressurized 5min and relaxed for 5 minutes for 4 cycles as a complete remote ischemic postcondioning
45638015|NCT05305625|Drug|standard therapy|received standardized treatment
45638016|NCT04938791|Other|Isometric activity|Participants will do elevation of upper limbs and mantain a 90º degree flexion position in an unsupported way.
45776270|NCT04041830|Behavioral|Visit 2|this is a replication of Visit 1, testing the reproducibility of the LFPQ and of its response to a meal.
45776271|NCT01351896|Other|Laboratory Biomarker Analysis|Correlative studies
45776272|NCT01351896|Drug|Lenalidomide|Given PO
45776273|NCT01351896|Other|Pharmacological Study|Correlative studies
45776274|NCT01351896|Biological|Pneumococcal Polyvalent Vaccine|Given IM (concurrently or sequentially)
45776275|NCT04271462|Other|Comparing two CO2 absorbers in the ventilator circuit|"General anaesthesia will be induced with a standardised regimen (propofol 0.8-2.5 mg·kg-1, sufentanil 0.2 - 0.5 µg·kg-1 and rocuronium 0.5 - 1 mg·kg-1). After tracheal intubation, anaesthesia will be maintained with sevoflurane targeted at 1 MAC end tidal concentration (corrected for age using the formula by Mapleson) in 40% O2. Different ventilator settings will be compared for 30 minutes (in randomised order):~I. Sodalime, FGF 2.0 L min-1. II. Amsorb Plus®, FGF 2.0 L min-1. III. Soda lime, FGF, 0.5 L min-1. IV. Amsorb Plus®, FGF 0.5 L min-1. FGF=fresh gas flow."
45776276|NCT05267522|Other|Egg diet|30% fat [6% saturated fat], 20% protein, 40% carbohydrate, 600 mg cholesterol
45776277|NCT05267522|Other|Egg-free Diet|30% fat [12% saturated fat], 25% protein, 40% carbohydrate, 300 mg cholesterol
45776278|NCT05267522|Other|Control Diet|30% fat [12% saturated fat], 25% protein, 40% carbohydrate, 600 mg cholesterol
45776279|NCT01791218|Procedure|CABG, AVR or CABG+AVR and PVI|
45915066|NCT05160519|Radiation|Class IV Laser|"30 participants will be irradiated with Class IV laser therapy over the left parasternal area to examine the efficacy of class IV laser on ejection fraction, Cardiac Biomarker and functional outcomes.~Device: Litecure LCT-1000C Class IV laser will be used in contact method over the left parasternal area in 2nd, 3rd intercostal space and apex. Dosage and Parameters for the irradiation will be calculated. Parameters: 1. Wavelength: 980nm, 2. Power/ Energy density: 6W/6J/cm2 3. Frequency: CW 4. Energy delivered at each spot: 360J 5. irradiation spots: 3 6. Irradiation time: 60 sec at each spot.~Both the patient and laser giver will use the laser protected eye wears to ensure standard practice for the laser."
45776280|NCT01791218|Procedure|CABG, AVR or CABG+AVR|
45776281|NCT00241904|Behavioral|Lifestyle Changes|Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise
45776282|NCT00241904|Drug|Antiplatelet Agents|Aspirin 81 mg q day
45776283|NCT00241904|Drug|Beta Blocker|Oral medication
45776284|NCT00241904|Drug|ACE Inhibitors|Oral medications, received 1-2 times per day
45776285|NCT01791296|Drug|Dexmedetomidine|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
45776286|NCT01791296|Other|Placebo|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
45776287|NCT01479127|Drug|ABT-SLV187|
45776288|NCT01479127|Drug|Oral Levodopa/Carbidopa|Tablet; contains 100 mg levodopa and 10 mg carbidopa
45776289|NCT01479127|Device|Infusion Pump: CADD-Legacy® 1400 Pump|General infusion pump, manufactured by Smiths Medical (US)
45776290|NCT01479127|Device|NJ-Tube: Silicon ED Tube|Device used to deliver nutrition/drug to stomach/intestine or to aspirate stomach fluid, manufactured by Create Medic Co., Ltd. (Japan)
45776291|NCT01479127|Device|Adaptor: Hakko Adaptor|Accessory set for fluid infusion set, consisting of caps, connectors and adapters, etc, manufactured by Hakko Medical (Japan)
45776292|NCT03917966|Drug|SHR-1210+docetaxel+nedaplatin|neoadjuvant chemotherapy:SHR-1210, 200mg,q2w, a total of 3 times; docetaxel 75mg/m2 ivgtt d1, nedaplatin 75mg/m2 ivgtt d1, q3w, for 2 cycles.The patient was evaluated after 2 cycles of neoadjuvant chemotherapy. The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
45776293|NCT03917966|Drug|SHR-1210+Apatinib|SHR-1210, 200 mg, q2w; Apatinib, 250mg, qd; 4 weeks is a cycle, a total of 2 cycles
45776294|NCT00243152|Drug|Lamotrigine|: 25mg and 50mg tablets
45776295|NCT00243152|Drug|Placebo (for Lamotrigine)|Sugar pill manufactured to mimic Lamotrigine tablets
45776296|NCT01453075|Drug|Valacyclovir|Valacyclovir 1.5 mg po bid
45776297|NCT01453075|Drug|Placebo|Matching placebo twice daily
45776298|NCT01899092|Drug|TT-034|The study drug will be given as a single dose IV infusion on Day 1. 5 different dose levels corresponding to the 5 cohorts of the study will be given.
45638017|NCT04457141|Combination Product|Effect of pelvic floor for the use of minimalist shoes versus shod in woman.|Measure the activity of the pelvic floor and others muscles with EMG during treadmill running with different speeds and different shoes: minimalist and shod.
45638018|NCT04419389|Drug|APR-246 (eprenetapopt) + Acalabrutinib in CLL|APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule
45638019|NCT04419389|Drug|APR-246 (eprenetapopt) + Venetoclax + Rituximab in CLL|APR-246 D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule
45638020|NCT04419389|Drug|APR-246 (eprenetapopt) + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT|APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule Venetoclax and Rituxiab will be given at a standard dose and schedule
45776299|NCT05267210|Other|Questionnaire|"Back Pain and Body Posture Assessment Instrument for Adults (BackPDE-Y) This questionnaire assesses pain and risk factors associated with back pain. The questionnaire includes questions that include demographic, socio-economic, hereditary and behavioral risk factors. The questionarie consists of 20 questions in total.~Musculoskeletal Health Questionnaire (CIS-SS) The questionnaire included pain/stiffness (during the day and night), physical function (walking and dressing), physical activity level, involvement of symptom-related work/daily life and social activities/hobbies, difficulty sleeping, fatigue, emotional well-being, diagnosis and It consists of a total of 14 questions evaluating the understanding of the treatment and the overall effect of the disease."
45638021|NCT04419389|Drug|APR-246 (eprenetapopt) + Venetoclax + Rituximab in RT|APR-246 D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule
45776300|NCT01891760|Device|Dermagraft|Dermagraft treatment regimen of one application applied topically to the ulcer, weekly, for a maximum of 8 weeks (8 application maximum).
45776301|NCT01891760|Device|Profore|Four-layer compression bandaging therapy.
46070259|NCT02551783|Procedure|Urethroplasty with buccal mucosa graft|A surgery to correct urethral stricture
45638022|NCT05304845|Drug|DWP14012|Potassium-competitive acid blocker
45776302|NCT01791374|Drug|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
45776303|NCT01791374|Drug|Rilotumumab|Drug: Rilotumumab Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells. Drug: Cisplatin A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death). Drug: Capecitabine A chemo-therapy prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
45776304|NCT03783416|Drug|Ixazomib (NINLARO®) capsules / Matching placebo capsules|Participants will be treated for a maximum of 24 months
45638023|NCT05304845|Drug|Aspirin|acetylsalicylic acid
45638024|NCT04407143|Diagnostic Test|IgG test|IgG+ blood test by ELISA method.
45638025|NCT04385927|Behavioral|e-Net for Parents of Neurodiverse Children|One-on-one distance coached intervention; approx. 12 sessions at 60-90 minutes.
45638026|NCT05304299|Dietary Supplement|Cordyceps Cicadae Mycelia|Cordyceps Cicadae Mycelia will be given to test its potential for alleviation of high intraocular pressure.
45638027|NCT04936451|Device|TENS (transcutaneous electrical nerve stimulation)|"Patients will benefit from screening for refractory pain, neuropathic or not, with myofascial syndrome, between 3 and 12 months after surgery.~The healthcare professional will determine 4 trigger points. TENS is applied twice 45 min every day for 2 months. Pain treatment will be done by using the P6 program in alternative mode: 2hz / 100Hz.~The time between 2 electrostimulations will be a minimum of 4 hours and a maximum of 15 hours."
45638028|NCT04936451|Device|TENS (transcutaneous electrical nerve stimulation) ECOMODYN|"TENS ECOMODYN® is applied to 4 treatment points, 5 minutes per point 2 times a day for 2 months.~A minimum rest period of 4 hours between 2 sessions on the same point must be respected Stimulation is performed directly with the bipolar probe of the TENS ECOMODYN® device on the painful area by fixed stimulation of 4 active pain points in 77Hz mode."
45638029|NCT04924517|Behavioral|Extended Evening Fasting|Participants will undertake 4 days of extended evening fasting (feeding between 8am-4pm). The participants will visit the laboratory on day 1, following a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory. The participant will continue to adhere to the feeding window on day 2 and day 3, although this will be in free-living conditions. On day 4, the participant will arrive back to the lab for post-intervention assessment, identical in format to day 1 with a metabolic assessment and energy intake assessment via a ad-libitum meal.
45638030|NCT04924517|Behavioral|Control|Participants will undertake 4 days of a standard western feeding pattern (feeding between 8am-8pm). The participants will visit the laboratory on day 1, following a 12 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory. The participant will continue to adhere to the feeding window on day 2 and day 3, although this will be in free-living conditions. On day 4, the participant will arrive back to the lab for post-intervention assessment, identical in format to day 1 with a metabolic assessment and energy intake assessment via a ad-libitum meal.
45638031|NCT05303597|Diagnostic Test|ultrasound-guided diagnostic nerve block with lidocaine|Patients with a trigger point in the posterior iliac crest will be evaluated by a second physician and diagnostic nerve block will be performed ultrasound-guided with the preliminary diagnosis of superior cluneal nerve entrapment. General Electric LogiqP5 model ultrasound device will be used and lidocaine will be applied between the posterior iliac crest and thoracolumbar fascia, which is viewed under the guidance of ultrasonography, for diagnosis and treatment.
45754278|NCT03021512|Procedure|Phaco with Panoptix|Phacoemulsification with bilateral trifocal intraocular lenses implantation
45776305|NCT00248534|Biological|rituximab|given IV days 1,8, 15 and 22
45776306|NCT00248534|Drug|methylprednisolone|2hr IV every 28 days post consolidation cycles of Temozolomide (TMZ) (6 cycles TMZ = Consolidation cycles)
45776307|NCT00248534|Drug|temozolomide|Induction Days 1-7 and 15-21 (150mg/m2 PO) Consolidation days 1-5 every 28 days X 6 cycles
45776308|NCT00248612|Drug|Venlafaxine|Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
45776309|NCT00248612|Behavioral|CBT|CBT is Cognitive Behavioral Therapy. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
45915067|NCT05160519|Radiation|Sham Class IV Laser|"30 participants in sham control group will be suppose to irradiate with Class IV laser therapy over the left parasternal area, but the radiation will not be delivered.~Device: Litecure LCT-1000C Class IV laser will be placed over the left parasternal area in 2nd, 3rd intercostal space and apex without switching on the instrument.~Both the patient and laser giver will use the laser protected eye wears to ensure standard practice for the laser."
45915068|NCT05146167|Behavioral|Bodhi AIM (intervention group)|"Bodhi AIM (Action In Mindfulness) is a smartphone-based app that teaches users to establish a daily meditation practice via a 30-day path, with each day consisting of a brief audio- or video-guided file. In addition to the 30 daily path files, users have access to a menu of to go audio-guided meditation practices that they may access any time to prepare for particular situations (e.g., attending a party)."
45915069|NCT05146167|Behavioral|HIB (control group)|"HIB (Health In Balance) is a smartphone-based app that is matched to Bodhi AIM for time and structure, but includes health promotion content (e.g., educational information on substance use) in place of the meditation content featured in Bodhi AIM. Like Bodhi AIM, HIB includes a 30-day path of audio and video files, along with a menu of to go audio files that users may access any time to review key intervention concepts."
45915070|NCT05145816|Drug|Belantamab mafodotin 2.5 mg/kg (6 weeks)|Belantamab mafodotin 2.5 mg/kg on Day 1 every 6 weeks for Part 1
45915071|NCT05145816|Drug|Belantamab mafodotin 2.5 mg/kg (4 weeks)|Belantamab mafodotin 2.5 mg/kg on Day 1 every 4 weeks for Part 1
45915072|NCT05145816|Drug|Belantamab mafodotin 2.5 mg/kg (8 weeks)|Belantamab mafodotin 2.5 mg/kg on Day 1 every 8 weeks for Part 1
45638032|NCT04892459|Biological|Recombinant SARS-CoV-2 Ad5 vectored vaccine|This vaccine contains 5×10^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
45776310|NCT00248612|Other|Progressive muscle relaxation therapy (PMR)|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
45638033|NCT04892459|Biological|Inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research & Development Co., Ltd. 0.5 ml / bottle.
45638034|NCT04890431|Drug|Oxygen|oxygen treatment (5 L/minute for 30 minutes by nasal cannula, twice/day)
45638035|NCT04890431|Drug|Placebo|ambient air not enriched with oxygen (5 L/minute for 30 minutes by nasal cannula, twice/day)
45638036|NCT04881539|Dietary Supplement|Cannabidiol (CBD)|This group will receive an oral dose of CBD (Six Degrees Wellness).
45776311|NCT00248612|Other|Placebo medication|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
45638037|NCT05303519|Drug|safusidenib|safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity.
45776312|NCT03774992|Device|Orthokeratology lenses|Custom fit, form stable contact lenses
45776313|NCT03951584|Other|ISSNHL with vertigo|Participants who suffered from ISSNHL with vertigo will be included in this study. Participants will undergo vestibular function tests including caloric test, sensory organization test, video head impulse test and vestibular evoked myogenic potentials at baseline and 2 months after onset as primary outcome, to evaluate the damage and prognosis of vestibular function.
45776314|NCT03924128|Device|Photobiomodulation|The Photobiomodulation device should cover the entire knee junction, with time of application from 6 to 8 minutes and device turned on.
45776315|NCT00249470|Behavioral|Abstinence & Work|Participants in the Abstinence & Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.
45776316|NCT00249470|Behavioral|Work Only|Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
45776317|NCT05266820|Drug|Thalidomide|For the experimental group, the intervention was thalidomide（100mg PO Bid)
45776318|NCT05266820|Drug|TAS-102|TAS-102
45776319|NCT05266742|Other|web based education|"An educative website was created for our study. The content of the website was accessible from www.diyabet.mumcu.net and the content of the website was brought together by scanning the literature. The content text was quoted from publicly available information and guides as ADA and IDF."
45776320|NCT01790204|Dietary Supplement|Watercress Juice|The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
45776321|NCT00250484|Device|Transcranial Magnetic Stimulation|1Hz transcranial Magnetic Stimulation for 10 days for 26 minutes each day
45776322|NCT00250484|Device|Sham Transcranial Magnetic Stimulation|Sham procedure of transcranial Magnetic Stimulation for 10 days for 26 minutes each day
45776323|NCT03549650|Drug|Pentosan Polysulfate Na 100Mg Cap|"Participants will be randomly assigned to receive Pentosan Polysulfate Na 100Mg Cap TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped."
45776324|NCT03549650|Drug|Placebo oral capsule|"Participants will be randomly assigned to receive Placebo oral capsule TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped."
45915073|NCT05145816|Drug|Belantamab mafodotin 1.9 mg/kg (8 weeks)|Belantamab mafodotin 1.9 mg/kg on Day 1 every 8 weeks for Part 1
45915074|NCT05145816|Drug|Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages|Belantamab mafodotin Dose 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages.
45915075|NCT05142540|Procedure|blood and saliva samples will be taken|"For serology, 8 ml of blood and 1.5 ml saliva samples will be taken at every visit.~For testing cellular immunity, additional 24 ml of blood will be drawn at visits 1 and 2."
45935640|NCT00128050|Other|Sodiun chloride 0.9%|Bolus injection of sodium chloride 0.9% after surgical hematoma removal
45935641|NCT00128089|Behavioral|Dietary treatment|
45638038|NCT04854083|Drug|Semaglutide, 1.34 mg/mL|The low-calorie diet (LCD) has a phase run-in period for 13 weeks for all participants including 8 weeks of total LCD followed 5-week gradual re-introduction of food (replacement of the VLCD products by one meal/week). During re-introduction of food, the subjects will be randomly assigned to semaglutide 1.34mg/ml (subcutaneous administration, dose escalation 0.25 mg once weekly for 4 weeks, 0.5 mg once weekly for 4 weeks, where after 1.0 mg once weekly) until the end of the study (12 months). The participants will receive lifestyle counselling throughout the study.
45776325|NCT00252512|Behavioral|Contingency Management|Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are both negative, the participant receives a chance to draw tokens from a bowl. Some tokens are social reinforcement (Good Job!). Other have monetary value.
45776326|NCT00252512|Other|Placebo|Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.
45776327|NCT00252590|Behavioral|Health Motivational Feedback|Personalized feedback on health status
45776328|NCT00252590|Behavioral|Health Education|Generalized health education related to alcohol use
45638039|NCT04854083|Drug|Placebo|The low-calorie diet (LCD) has a phase run-in period for 13 weeks for all participants including 8 weeks of total LCD followed 5-week gradual re-introduction of food (replacement of the VLCD products by one meal/week). During re-introduction of food, the subjects will be randomly assigned to placebo (subcutaneous administration, dose escalation 0.25 mg once weekly for 4 weeks, 0.5 mg once weekly for 4 weeks, where after 1.0 mg once weekly) until the end of the study (12 months). The participants will receive lifestyle counselling throughout the study.
45638040|NCT05303441|Procedure|percutaneous coronary intervention|conventional coronary angiography
45638041|NCT03050879|Drug|Indocyanine Green Tracer|Laparoscopic gastrectomy with lymph node dissection for gastric cancer using Indocyanine Green Tracer
45638042|NCT05303363|Device|VV-ECMO|VV-ECMO is indicated in case of severe respiratory failure refractory to other therapies. Indications for VV-ECMO include severe pneumonia, acute respiratory distress syndrome (ARDS) (a.o. due to COVID-19) or near-drowning. ECMO is considered a 'last resort' therapy, in which other maneuvers - such as prone positioning and neuromuscular blockage - have shown to be insufficient. Patients are generally receiving invasive mechanical ventilation and are almost always unconscious, since due to the severe respiratory failure, high doses of sedatives and neuromuscular blockage are often applied to prevent further ventilator-induced damage. After the decision for VV-ECMO is made, the patient is directly cannulated in the ICU or OR following standard protocols.
45638043|NCT05303285|Drug|Secukinumab 300mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 300 mg secukinumab s.c. every 4 weeks
45776329|NCT00252590|Behavioral|Control - treatment as usual|Control group with no additional intervention
45776330|NCT01453387|Drug|MSC2015103B|Schedule 1: MSC2015103B will be administered orally once weekly on Days 1, 8, and 15 of a 21-day cycle until MTD establishment. Starting dose will be 150 microgram (mcg), which will be escalated to 200 mcg, 300 mcg, 450 mcg, 650 mcg, 1000 mcg and 1500 mcg subsequently.
45776331|NCT01453387|Drug|MSC2015103B|Schedule 2: MSC2015103B will be administered orally thrice weekly on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19 of a 21-day cycle until MTD was established. Starting dose will be 150 mcg, and will be escalated to 200 mcg subsequently.
45776332|NCT04751864|Device|Cranial Electrotherapy Stimulator (CES) Device|Fisher Wallace Cranial Electrotherapy Stimulator (CES) Device
45776333|NCT03419702|Dietary Supplement|Almonds|During the intervention period of 5 months, subjects will receive daily 50 gr almonds. Subjects are free to consume the almonds during the day whenever they want to, i.e. there will not be guidelines when to consume the almonds.
45776334|NCT02097992|Drug|Roflumilast Placebo|Placebo pill
45776335|NCT02097992|Drug|Roflumilast|500 Ug ORAL TABLET
45776336|NCT02098304|Device|Calcivis Caries Activity Imaging System|Teeth imaged with the Calcivis Caries Activity Imaging System
45776337|NCT01392625|Biological|Autologous hMSCs|"Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
45776338|NCT01392625|Biological|Allogeneic hMSCs|"Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
45776339|NCT02114294|Other|Isolated hip strengthening|Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Hip strengthening group will train hip abduction, hip external rotation and hip extension.
45638044|NCT05303285|Drug|Secukinumab 150mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 150 mg secukinumab s.c. every 4 weeks
45935642|NCT00128167|Drug|Liquid CAIV-T|
45638045|NCT05302973|Other|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
45638046|NCT05302973|Other|Aerobic exercise|30 min/day of aerobic exercise added to 1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
45776340|NCT02114294|Other|Quadriceps based training|Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Quadriceps group will train mini-squat, straight leg raising, terminal extensions.
45776341|NCT02114294|Other|Active control|Patients receive standardised information concerning patellofemoral pain syndrome, but receive no prescribed exercise regime. They are encouraged to remain active.
45776342|NCT01454791|Drug|diclofenac sodium topical gel|diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks either preceded by or followed by two weeks of placebo
45776343|NCT01454791|Other|Placebo|a placebo gel is applied 1-4 times per day for two weeks.
45776344|NCT02099006|Drug|Amitriptyline|Topical application of the drug at a 2% concentration in combination with 2% Baclofen
45776345|NCT02099006|Drug|Baclofen|Used topically at 2% concentration in combination with 2% amitriptyline
45776346|NCT02099006|Drug|Ketoprofen|To be applied topically at a 10% concentration
45776347|NCT02099006|Drug|Ketamine|To be applied topically at a 10% concentration
45935643|NCT00044018|Drug|CDC-501|
45935644|NCT04711434|Drug|PD-1 Antibody|Toripalimab: 240mg IV every 3 months for a year
45935645|NCT00128245|Drug|Pimecrolimus|
45935646|NCT00128245|Drug|Vehicle|Placebo
45935647|NCT04711629|Other|Clinical Tests|Respiratory function test, arterial blood gas analysis, six-minute walking test (6-MWT), mMRC Dyspnea Scale, St George Quality of Life Questionnaire and Hospital Anxiety Depression Scale
45935648|NCT00044057|Drug|YM872 (zonampanel), t-PA (alteplase)|
45776348|NCT02099006|Drug|Loperamide|To be applied topically at a 5% concentration
45776349|NCT02099006|Drug|Gabapentin|To be applied topically at a 6% concentration
45776350|NCT02099006|Drug|placebo|Compounding base to be used alone as a placebo
45638047|NCT04288661|Procedure|No drain placement|The need of perianastomotic drain placement after Roux-en-Y reconstruction in total gastrectomy operations is investigated. As intervention, no drain placement is considered
45776351|NCT01454947|Behavioral|Clinical Decision Support (CDS): Accountable Justifications|Accountable Justifications triggered by discordant prescriptions that populate the electronic health record (EHR) note with provider's rationale for guideline exceptions (AJ).
45638048|NCT04280939|Procedure|spinal anesthesia|prospective randomized double-blind study of patients undergoing total hip or knee replacement, as well as partial knee replacements (medial, lateral, patellafemoral, or bilateral). All groups will be matched for age, sex, American Society of Anesthesiologists class, and type of surgery. An attempt will be made to achieve a similar proportion of THA, TKA, and partial knee replacements in each group. We will randomize patients to one group of spinal anesthesia protocole.
45638049|NCT04276571|Device|exergames with GRAIL virtual immersive reality environment|The participants will perform exergames on GRAIL immersive virtual reality to improve balance (e.g. load shifts, exercises with adaptations to motor perturbations). GRAIL can provide proprioceptive and visual feedback to participants.
45638050|NCT04831385|Behavioral|Cognitive Behavioural Therapy|CBT is a first line therapy for insomnia
45638051|NCT05302817|Combination Product|Hyperpolarized xenon MRI|Patients with non-small cell lung cancer scheduled for radiation therapy willing to take part in this study will undergo hyperpolarized xenon MRI at several time points prior and post RT. Images will be used to determine maps for functional lung avoidance and post-RT changes in the lung function and compared to standard-of-care assessment methods.
45638052|NCT04489589|Drug|Midodrine|10mg PO/NG q8h
45638053|NCT04489589|Drug|Placebo|10mg PO/NG q8h
45638054|NCT04328441|Drug|BCG Vaccine|Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis
45638055|NCT04328441|Drug|Placebo|Intracutaneously 0.1ml NaCl 0,9%
45638056|NCT04485611|Behavioral|Supervised aerobic + resistance training and nutritional support|The intervention will consist of individualized exercise training delivered remotely using VA telehealth technology, combined with nutritional support consisting of tailored nutritional advice, protein supplementation, multivitamin and vitamin D supplements]]. Adherence to the intervention will be enhanced by use of automated text messages and monitored using activity trackers.
45638057|NCT05302739|Other|Facial cooling|30 s of water mist sprayed onto the face during breaks in a simulated fencing competition
45638058|NCT05302661|Behavioral|re-education|Contact patients by phone or wechat and guide them
45638059|NCT04314713|Drug|Scopolamine Hydrobromide Trihydrate|Scopolamine Hydrobromide Trihydrate Intramuscular Injection
45776352|NCT01454947|Behavioral|Audit and Feedback: Peer Comparison|Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
45915076|NCT05129709|Behavioral|"My Health Priorities Identification Program"|"The web-based My Health Priorities Identification Program may improve values solicitation and operationalization skills in primary care, but has not been optimized for AAs with MCCs and their FCGs. The Program is a facilitator-led evidence- and values-based care communication model for patients, clinicians, and caregivers that has reduced patient-reported treatment burden by aligning value-based priorities with treatment. The web-based program assists patients in identifying their health priorities as they complete t four online modules that help them to identify specific and actionable health goals and preferences. The final result can be printed and brought to the clinic or uploaded to the Electronic Medical Record to inform subsequent healthcare decision making. Unrecognized cultural preferences of AAs, including the important role of R/S beliefs and family-centered values, can interfere with adequate healthcare communication resulting in healthcare disparities and inequities."
45638060|NCT05302193|Other|Calm measurement of blood pressure and heart rate (before physical activity)|Simultaneous blood pressure and heart rate measurements at minutes 2 and 5.5 of the experiment.
45638061|NCT05302193|Other|Physical activity|Five minutes of physical activity, between times 7.5 min and 12.5 min of the experimental part. Riding on a spinning ergometer with a standardized load of 1 W/kg.
45638062|NCT05302193|Other|Calm measurement of blood pressure and heart rate (after physical activity)|Simultaneous blood pressure and heart rate measurements at times 15.5, 17, 20.5 and 22 minutes of the experimental part.
45638063|NCT04777253|Other|Biofeedback method|"Patients in the study group will participate in training with visual biofeedback, aimed to improve motor function of the arm. The exercise will be performed using a Biometrics device. The biofeedback training will be carried out for 30 minutes per day.~Health-resort based rehabilitation The patients will participate in a three-week rehabilitation program (from Monday to Friday), with the treatments and therapies continued for up to two hours per day.~The program will include: group and individual exercise (active and assisted exercises, manipulation exercise, PNF-based practice, balance and breathing exercise), manual massage, physical treatments, such as: laser, whirlpool therapy, mud compress therapy, carbonic acid therapy, TENS therapy, BIO-V lamp, and localized cryotherapy."
45448349|NCT02134444|Behavioral|Experimental group|Experimental group will receive a game-based exercise program delivered at home. This includes provision of a head-mounted motion mouse. This provides a treatment tool applied to gaze control, and allows incorporation of balance exercises. It also allows many different therapeutic exercises to be coupled to a wide range of inexpensive commercial computer games. Participants will attend 3 clinical sessions during which time the home therapy programs will be established and training in the use of the motion mouse and games will be provided. The treating physiotherapist will attend the participant's home to ensure proper set-up and operation of the computer applications. Participants will be asked to perform their respective home programs four times per week for 20 minutes per session.
45776353|NCT01454947|Behavioral|CDS Order Sets: Suggested Alternatives|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
45915077|NCT05120037|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) uses a mild electrical current to make small (or subtle) changes to how the brain works (or functions).
45935649|NCT05562505|Other|Venovenous ECMO|ECMO therapy for patients with hypoxic respiratory failure.
45638064|NCT04777253|Other|Health-resort based rehabilitation|"The patients will participate in a three-week rehabilitation program (from Monday to Friday), with the treatments and therapies continued for up to two hours per day.~The program will include: group and individual exercise (active and assisted exercises, manipulation exercise, PNF-based practice, balance and breathing exercise), manual massage, physical treatments, such as: laser, whirlpool therapy, mud compress therapy, carbonic acid therapy, TENS therapy, BIO-V lamp, and localized cryotherapy"
45638065|NCT04775771|Behavioral|Animal Assisted Practice|The children, who were planned to be hospitalized for at least three days and were randomized to the experimental and control groups, were asked by the researcher using the face-to-face interview technique, and the questions in the patient information form were filled in on the form. Then, pre-test data were recorded by determining their anxiety levels with the State Anxiety Scale for Children, levels of fear with the Child Fear Scale, emotional and psychological well-being with the Stirling Children's Emotional and Psychological Well-being Scale. Unlike the other scales, the anxiety levels were assessed twice with one-hour intervals on the first day with the Children's State Anxiety Scale. On the third day, the anxiety levels were evaluated twice with one-hour intervals on the first day using the State Anxiety Scale for Children. The second group, the children in the control group, had the same procedure except for the intervention; but no intervention was made.
45638066|NCT05302037|Biological|Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)|In the production of CTM-N2D, blood cells from healthy donors are used as starting materials. Through a proprietary expansion technology, γδ T cells of high-purity can be obtained. These γδ T cells are further grafted with NKG2DL-targeting CARs using mRNA electroporation to enhance its anticancer potency. The finished product (CTM-N2D) are then infused allogeneically into cancer patients.
45638067|NCT04121507|Drug|High dose chemotherapy before allogeneic stem cell transplantation (alloSCT)|High-dose therapy (HDT) prior to alloSCT will consist of FTC
45638068|NCT04121507|Procedure|Bone marrow histology|Bone marrow histology at staging and restaging is only mandatory if the bone marrow was initially involved
45638069|NCT04121507|Diagnostic Test|clinical and laboratory parameters|During staging and restaging examinations, all clinical and laboratory parameters relevant for therapy.
45638070|NCT04121507|Diagnostic Test|PET-CT or CT|Metabolic CR in a PET-CT scan after the last cycle of therapy prior to planned SCT. Consists preferably of a PET-CT or a CT scan according to local practice and other appropriate diagnostic procedures with respect to the sites of primary involvement.
45638071|NCT04762043|Device|MyoVoice|Person-centric AAC system comprising a user-specific set of wearable sensors for capturing articulatory muscle activity and mobile software that provides real-time audible speech outputs.
45638072|NCT04762043|Device|Electrolarynx|Hand-operated electromechanical device that operates as an artificial larynx to enable a person after laryngectomy to produce speech.
45638073|NCT04261595|Other|Dates fruit as functional Food|Two groups will receive Dates; The number per group is dependant on the child age. For children aged 3-6 years; they will receive the minimum numbers of dates (3 pieces). For children aged more than 6-12 years will receive 5 pieces of Dates the choice of the minimum numbers of dates (3 pieces) in this current trial is based on a study that was done by Al Jaouni and his colleagues, 2019 which proved the effects of three pieces of Ajwa on infection, hospitalization, and survival among 26 pediatric cancer patients in a university hospital; for which their treatment outcome was improved due to their intake of this amount of Ajwa during their standard treatment
45638074|NCT04261595|Behavioral|behavioral modification and stimulation|Behavioral modification applied to the autistic children that is based on applied behavior analysis (ABA), a widely accepted approach that tracks a child's progress in improving his or her skills. We use Positive Behavioral and Support (PBS)
45776354|NCT05266274|Drug|CD47 monoclonal antibody|patients who meet the criteria are selected, CD47 monoclonal antibody combined with azacitidine is used for the treatment of patients with recurrent AML after transplantation
45776355|NCT05266196|Drug|Seclidemstat|Treatment assigned as per parent protocol
45776356|NCT03225404|Other|Epte group|Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
45776357|NCT03225404|Other|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.
45776358|NCT05265962|Drug|Decitabine plus Penpulimab|Pts received decitabine 10mg/d IV daily x5 every 3 weeks and penpulimab(AK-105) 200 mg intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
45776359|NCT01455181|Drug|NPSP558|50, 75, 100 μg
45776360|NCT00324896|Drug|eszopiclone|eszopiclone
45915078|NCT05075850|Device|Neuroblate System|"All subjects will undergo comprehensive neuropsychological assessment post-LITT per standard of care practice.~Visual field testing will be conducted in a subset of enrolled patients."
45915079|NCT03935178|Diagnostic Test|Measuring Right Ventricular Size and Function|This study focuses on evaluating different approaches to evaluation of right ventricular size and function using the Upper Valley Right Ventricle Algorithm and novel imaging modalities
45915080|NCT05031468|Biological|Licensed or EUA SARS-CoV-2 vaccine|Several SARS-CoV-2 vaccines utilizing different platforms (e.g., mRNA, viral vector, etc.), are available under EUA (and soon to be licensed) and are being administered to individuals who are pregnant or postpartum who belong to high-risk priority groups for vaccination. Participants will receive the SARS-CoV-2 vaccine of their choice or the type that is available to them. The researchers anticipate including up to 3 vaccines, whether given as part of the primary series or additional doses, as part of this non-interventional study.
45915081|NCT05004012|Device|Magnetically Controlled Capsule Endoscopy|This is a diagnostic device for gastric disorders used to diagnose mucosal abnormalities. In this study it will be evaluated for use in gastric motility.
45776361|NCT00324896|Other|placebo|matching placebo administered at night
45776362|NCT01479517|Drug|Kovacaine Mist 0.1 mL x 4 sprays|Dose = 4 intranasal sprays of study drug delivered at 4-minute intervals.
45776363|NCT01479517|Drug|Kovacaine Mist 0.2 mL x 2 sprays|Dose = 2 intranasal sprays of study drug delivered at 4-minute intervals.
45776364|NCT01479517|Drug|Kovacaine Mist 0.2 mL x 1 spray|Dose = 1 intranasal spray of study drug
45776365|NCT01480219|Drug|voriconazole (Vfend)|Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
45776366|NCT01480219|Other|no voriconazole (Vfend)|Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
45776367|NCT01480297|Drug|Salsalate|Salsalate 3 grams daily (1 gram TID with meals)
45776368|NCT01480843|Drug|Glargine|Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults
45638075|NCT04261595|Other|nutritional Guidance|The nutritional education sessions are based on educating parents on providing their autistic children with a nutritious, balanced diet. Because children with ASD often have restricted diets as well as difficulty sitting through meal times, they may not be getting all the nutrients they need, particularly calcium and protein
45638076|NCT04209725|Drug|CPX-351|Given during the induction and consildation phase and will consist of 44 mg/m^2 daunorubicin with 100 mg/m^2 cytarabine administered intravenously on Days 1, 3, and 5 during induction phase and Days 1 and 3 of consolidation phase.
45638077|NCT04209725|Drug|Quizartinib|Given during induction, consolidation, and maintenance phases and will be taken orally at a dose of 30mg on Days 8-21 of induction phase, Days 6-21 of consolidation phase, and daily in maintenance phase.
45638078|NCT04156373|Behavioral|Fuerte|Fuerte is a prevention program targeting youth at risk for psychological trauma who are recent immigrants to the United States. The program is evidence-informed using cognitive-behavioral principles and the Attachment, Regulation, and Competency (ARC) model for treating psychological trauma.
45776369|NCT01392703|Drug|Dasatinib as tablets|2 50-mg tablets plus 240 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
45638079|NCT04743167|Procedure|Surgery|Laparoscopic treatment of endometriotic lesions
45776370|NCT01392703|Drug|Dasatinib as liquid|100 mg administered as 10 mL of liquid drug (10 mg/mL) plus 230 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
45776371|NCT01392703|Drug|Dasatinib as dispersed tablets|2 50-mg dispersed tablets in 30 mL of 100% orange juice followed by 15 mL of orange juice plus 195 mL noncarbonated, nonrefrigerated water. Liquid (oral solution), single dose, 1 day.
45776372|NCT01392859|Drug|Levocetirizine 0.5 Mg/mL Oral Solution|Subjects in two arms, will be enrolled in a classical, randomized, double blind, crossover, placebo controlled trial of Levocetirizine(LCT) with determination of the PD response to LCT as determined by suppression of histamine microvasculature response via HILD.
45776373|NCT01457521|Drug|Ibuprofen|Ibuprofen
45638080|NCT04743167|Procedure|IVF|Up to three completed cycles of IVF
45638081|NCT04082117|Behavioral|Educational video|Educational genetic counseling video
45776374|NCT00325442|Drug|Oral treprostinil (UT-15C) sustained release tablets|UT-15C 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
45776375|NCT00325442|Drug|Placebo|Placebo 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
45776376|NCT01393717|Drug|brentuximab vedotin|Given IV
45638082|NCT01449149|Radiation|Proton Therapy|
45638083|NCT04719221|Drug|Evolocumab|The maximum dose of combined cholesterol therapy (Statin + Ezetimibe) is prescribed for 2 months, and a cholesterol test is performed in an outpatient clinic to ensure that LDL-Cholesterol <70mg/dL is met. Patients who do not meet the criteria are randomized to maintain current treatment or receive additional Evolocumab according to randomization.
45638084|NCT04719221|Device|NIRS IVUS|near-infrared spectroscopy
45776377|NCT01459705|Behavioral|Prolonged Exposure Therapy (PE)|Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
45776378|NCT01459705|Behavioral|Virtual Reality Exposure Therapy (VRET)|Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
45776379|NCT01459705|Behavioral|Waitlist|This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
45776380|NCT01460875|Biological|recombinant interferon alfa-2b|Given SC
45776381|NCT01460875|Other|laboratory biomarker analysis|Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.
45638085|NCT00905957|Procedure|TAP block|TAP block using 20 ml of a local anaesthetic agent will be used in the treatment group
45638086|NCT00905957|Procedure|TAP block with placebo|TAP block using a placebo after induction of anaesthesia
45638087|NCT04704479|Device|Russian current|For application of Russian current, 2 channels with 2 electrodes each will positioned on the oblique muscles and rectus abdominis motor points using wet spongy pads to enhance electrical activity. Russian current will be a carrier frequency 2500 Hz with frequency of 5 Hz for 5 minutes of muscular conditioning, 40 Hz for 10 minutes for training of slow contraction muscular fibers and 120 Hz for 5 minutes for training of fast contraction muscular fibers with On time (contraction time) 4 secs and Off time (relaxation time) 2 secs. The contraction phase will be at time of patient's expiration while relaxation will be at time of patient's inspiration
45776382|NCT01481545|Radiation|Radiation therapy|Radiation therapy will be administered at the total dose of 45 Gy, given with five weekly fractions over a period of 5 weeks. The daily fraction dose will be 1.8 Gy
45776383|NCT01481545|Drug|Oxaliplatin|100 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
45776384|NCT01481545|Drug|Raltitrexed|2.5 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1) , an additional 2 cycles of chemotherapy will be given after radiation therapy)
45776385|NCT01481545|Drug|levofolinic acid|250 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
45915082|NCT05000307|Diagnostic Test|Blood sample|Analysing blood samples for the presence of antibody against SARS-CoV2. When impossible to collect sufficient B-cells for further typing, leucapheresis will be performed if the patient agrees.
45915083|NCT00387231|Procedure|Percutaneous coronary angioplasty/intervention (PCI)|
45776386|NCT01481545|Drug|5-fluorouracil|800 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
45915084|NCT00387231|Drug|Anti-ischemic drug therapy|
45915085|NCT00387270|Drug|Dimebon|Dimebon 10 or 20 mg TID x 7 days
45638088|NCT04704479|Device|EMT|patients in both groups trained 3 times a week, each session consisting of 1/2 h by the end of sessions. Initially, repeated cycles of 3 min of work followed by 2 min of rest were conducted (total work- time 18 min). The length of work intervals was increased on a weekly basis while rest periods were shortened to obtain a total work time of 30 min in the last week of the program. The valve opening pressure was continuously monitored at the mouthpiece to ensure the achievement of the target pressure. Patients will receive EMT with a threshold expiratory muscle trainer (Threshold; HealthScan), started breathing through the expiratory port of the threshold muscle trainer at a resistance equal to 15% of their Pemax for 1 week. The resistance will then increase incrementally, 5 to 10% each session, to reach 60% of their baseline Pemax at the end of the first month then continued at 60% of the Pemax, will be adjusted weekly to the new Pemax achieved
45776387|NCT01481545|Drug|Bevacizumab|will be given by intravenous infusion at the dose of 5 mg/kg concurrent with chemotherapy and radiotherapy every 2 weeks for 4 cycles from -14 days to start chemo-radiotherapy (classical schedule) or 4 days before the concurrent administration of chemotherapy and radiation therapy for 2 cycles if the number of TRG1 was not reached in the first stage (statistical design) with the classical schedule (for patients with resectable organ metastases (M1), one additional administration of bevacizumab will be given after radiation therapy)
45776388|NCT01482091|Drug|Fentanyl Citrate|A single dose of fentanyl citrate (2 mcg/kg; max 100mcg) administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device
45776389|NCT01482091|Drug|Normal Saline|A single dose of equivalent volume of 0.9% Normal Saline will be administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device.
45776390|NCT00325598|Radiation|Partial Breast Irradiation (PBI)|
45776391|NCT05265884|Device|Kinesiotaping|The tape is waterproof, porous, and adhesive. The width is 5 cm and thickness of 0.5 mm will be used in this study. This tape is with elastic core wrapped within cotton and capable of stretching up to 140-150%, applies heat-sensitive acrylic adhesive to avoid risk of latex allergy .The tape without medicinal properties is water resistant and can remain on the skin for 3 to 5 days. It will be applied two times per week for one month
45776392|NCT05265884|Behavioral|traditional therapy intervention|traditional treatment (ROM exercises, stretching exercises, and Deep friction message) 3 times per week for one month.
45776393|NCT03111758|Device|Flow augmentation|Augmenting venous flow following deep venous stenting in patients with Postthrombotic syndrome
45776394|NCT05261360|Drug|SF-MSC-EX|Intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes
45776395|NCT05261360|Drug|SF-MSC|Intra-articular administration of synovial fluid-derived mesenchymal stem cells
45776396|NCT05242094|Procedure|Pulmonary Rehabilitation Program|An in-patients 3-week high intensity rehabilitation program, five times a week, was used as the intervention treatment. The author's pulmonary rehabilitation program was programmed based on previous experience in patients with COPD. A holistic pulmonary rehabilitation program with combined treatment focused on increasing exercise capacity, restoring lung function, and supporting mental health, developed by a multidisciplinary team, was introduced. Based on the patient's submaximal exercise tolerance test results, the qualification for one of the respiratory physiotherapy models differing in therapy intensity was performed. Rehabilitation models included exercise capacity training on a cycle ergometer, breathing exercises, general fitness exercises, resistance training, and relaxation.
45776397|NCT00326924|Biological|Transfusion|PRBC blood transfusions.
45776398|NCT00327392|Drug|AQUAVAN® (fospropofol disodium) Injection|
45776399|NCT00328016|Behavioral|Guided Breathing|The participant will engage in daily 15 min sessions of meditative relaxation that involves quiet attention to breathing pattern with no attempt to manipulate breathing pattern
45776400|NCT00328016|Device|RESPeRATE|The participant will be trained to perform a guided breathing task that involves a chest expansion sensor, battery-powered microcomputer, and earphones
45638089|NCT04039763|Device|Dexcom G6|Realtime Continous Glucose Monitoring
45776401|NCT01791608|Dietary Supplement|Zinc sulfate as dietary supplementation|Zinc sulfate as dietary supplementation
45776402|NCT01791608|Dietary Supplement|Zinc amino acid chelate as dietary supplementation|Zinc amino acid chelate as dietary supplementation
45776403|NCT01791608|Dietary Supplement|Milk without fortification without zinc|Milk without fortification
45776404|NCT04346030|Drug|Triamcinolone Acetonide|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
45776405|NCT04346030|Drug|lidocaine hydrochloride|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
45776406|NCT04346030|Drug|normal saline|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
45915086|NCT00387309|Drug|Methylnaltrexone (MOA-728)|
45448350|NCT02134444|Behavioral|Control group|Control group will receive a vestibular exercise program which will include the Herdman gaze stabilization exercises and balance training program. This program is presently a standard of vestibular care. Participants will attend an out-patient physical therapy clinic once a week for 12 weeks. The program also includes a 20 minute home exercise program prescribed 4 times per week.
45448351|NCT01078025|Procedure|Smear test vaginally, intraabdominally|Pre- and intraoperative smear tests of the vagina and douglas are performed.
45638090|NCT04039763|Device|Self monitoring of blood glucose|Finger prick self monitoring of blood glucose
45915087|NCT00387387|Drug|Pazopanib|Pazopanib is an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases
45915088|NCT00387387|Drug|FOLFOX 6|FOLFOX 6 treatment consists of intravenous (IV) oxaliplatin (100 milligram per meter^2[mg/m^2]), and folinic acid (400 mg/m^2), IV 5-fluorouracil bolus (400 mg/m^2) followed by IV 5-fluorouracil (2400 to 3000 mg/m^2) infusion over 48 hours on Day 1 of every 14-day cycle.
45915089|NCT00387387|Drug|CapeOx|CapeOx treatment consists of IV oxaliplatin (130 mg/m^2) on Day 1 plus oral capecitabine (1000 mg/m^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment will be administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine will be reduced to 850 mg/m^2 twice daily.
45776407|NCT05095844|Biological|vaccinated|Pfizer-BioNTech COVID-19 Vaccine, Moderna or J&J/Janssen COVID-19 Vaccine, Diphtheria (e.g., DTP, DTaP, Tdap, DT, Td, TT) Haemophilus influenza type b polysaccharide conjugate vaccines (e.g., Hib) Hepatitis A (e.g., HAV) Hepatitis B (e.g., HBV) Human papillomavirus (e.g., HPV) Seasonal influenza (e.g., Flu) Measles (e.g., MMR) Mumps (e.g., MMR, MR, M) Meningococcal (e.g., MCV4, MPSV4, MenB-FHbp, MenB-4C) Pertussis (e.g., DTP, DTaP, Tdap) Pneumococcal conjugate (e.g., PCV) Polio (e.g., OPV or IPV) Rotavirus (e.g., RV) Rubella (e.g., MMR, MR, R) Tetanus (e.g., Td) Varicella (e.g., VAR)
45776408|NCT05087264|Drug|Indocyanine green|ICG retention test and clearance test: intravenous injection, 0.5mg/l. Liver blood flow measurement: intravenous drip, dissolve 25mg ICG in 100ml injection water, and drip at a constant speed for about 50min to make the ICG concentration reach equilibrium.
45776409|NCT05075330|Behavioral|Opioid Use Disorder Stigma Reduction|Billboards with destigmatizing language regarding opioid use disorder placed in the community.
45638091|NCT04033679|Other|Active TDCS|Participants will receive active TDCS stimulation.
45638092|NCT04033679|Other|Sham TDCS|Participants will receive sham TDCS stimulation.
45638093|NCT03982043|Behavioral|Text2Connect|Text2Connect is a personalized text messaging intervention for patients and parents that targets self-identified barriers to engaging in treatment to increase the likelihood that a depressed or suicidal patient will initiate recommended services.
45638094|NCT03982979|Device|HM3 LVAS|HeartMate® 3 (HM3) Left Ventricular Assist System (LVAS)
45776410|NCT02208362|Biological|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given via intratumoral or intraventricular catheter
45776411|NCT02208362|Biological|IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Given via intratumoral, intracavitary, or intraventricular catheter
45776412|NCT02208362|Other|Laboratory Biomarker Analysis|Correlative studies
45776413|NCT02208362|Procedure|Magnetic Resonance Imaging|Correlative studies
45776414|NCT02208362|Procedure|Magnetic Resonance Spectroscopic Imaging|Correlative studies
45776415|NCT02208362|Other|Quality-of-Life Assessment|Ancillary studies
45776416|NCT05005286|Other|Past history of vaginal Infections|With or without vaginal infection during pregnancy
45776417|NCT01793558|Procedure|Forced-air warming|In the intervention group a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the upper body of the patients laying on the operating table just beginning after the spinal block.
45448352|NCT01078025|Procedure|Smear test vaginally, intraabdominally|Pre- and intraoperative smear tests of the vagina and douglas are performed.
45776418|NCT02108288|Drug|OPC-1085EL ophthalmic solution|
45448353|NCT00133991|Biological|Filgrastim|5 mcg/kg/day starting on Day 3 after each R-CVP cycle and on Day 6 after HiCy.
45448354|NCT00133991|Biological|Rituximab|375 mg/m^2 on Day 1 and Day 8 of each R-CVP cycle. 375 mg/m^2 on Day -4 of HiCy and weekly for four weeks after HiCy.
45448355|NCT00133991|Drug|Cyclophosphamide|1500 mg/m^2 on Day 1 of each R-CVP cycle. 50 mg/kg/day on Days -3, -2, -1, and 0 of HiCy.
45448356|NCT00133991|Drug|Cytarabine|100 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
45448357|NCT00133991|Drug|Methotrexate|3 g/m^2 on Day 8 of each cycle of R-CVP.
45638095|NCT03948503|Procedure|Mulligan concept|Mobilization with movement during an active dorsi-flexion of the ankle
45915090|NCT03865719|Behavioral|Healthy Habits for Life|Healthy Habits for Life: 11-session, 6 month, one-on-one, dietician-lead weight management manualized treatment.
45776419|NCT02108288|Drug|Carteolol long-acting ophthalmic solution|
45776420|NCT02108288|Drug|Latanoprost ophthalmic solution|
45776421|NCT02108522|Biological|Multivirus Specific T cells|
45776422|NCT02106494|Drug|APF530|
45776423|NCT02106494|Drug|Ondansetron|
45915091|NCT04965636|Drug|Mepolizumab|Mepolizumab will be provided in pre-filled safety syringe
46070260|NCT02551783|Procedure|Ventral Buccal|Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.
45448358|NCT00133991|Drug|Prednisone|100 mg on Days 1-5 of each cycle of R-CVP.
45638096|NCT03948503|Procedure|Placebo|Sham mobilization with movement during an active dorsi-flexion of the ankle
45776424|NCT02106494|Drug|Ondansetron placebo|
45776425|NCT02106494|Drug|APF530 placebo|
45776426|NCT02106494|Drug|Fosaprepitant|
45776427|NCT02106494|Drug|Dexamethasone|
45776428|NCT01931852|Procedure|Cardiac MRI|Participants in the CMR-guided care group will receive a cardiac MRI.
45776429|NCT01931852|Other|ACC/AHA Guideline adherent care|Participants in the invasive-based guideline-adherent care group will receive care adherent with current American College of Cardiology / American Heart Association (ACC/AHA) guideline recommendations. ( ACC/AHA Guideline adherent care )
45776430|NCT00333710|Behavioral|Individual psychotherapy|Individual face-to-face contact with educational and goal setting components
45776431|NCT00333710|Behavioral|Telehealth Intervention|Individual telephone contact with educational and goal setting components
45776432|NCT00335504|Drug|oligofructose-enriched inulin|Given orally
45776433|NCT00335504|Drug|sulindac|Given orally
45776434|NCT00335504|Drug|placebo|Given orally
45776435|NCT00335504|Drug|atorvastatin calcium|Given orally
45776436|NCT00335504|Other|laboratory biomarker analysis|Correlative studies
45776437|NCT01183169|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
45776438|NCT01183169|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
45776439|NCT01183169|Drug|Ribavirin|RBV 200 mg tablets (weight-based dose: < 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
45776440|NCT01183169|Drug|Placebo|ALV placebo soft gel capsules administered orally
45638097|NCT03920189|Diagnostic Test|echocariographic ultrasound|left ventricular diastolic function description
45776441|NCT01183481|Drug|Aprepitant|Patients will be given a single dose of Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the radiation treatment.
45776442|NCT01183481|Radiation|Palliative radiation therapy|Moderately emetogenic palliative radiation therapy (RT) will be administered to all patients on the study.
45776443|NCT01183481|Drug|Granisetron|Patients will be given a single dose of both Granisetron 2 mg orally on Day 0 (at least one hour before on the day of RT).
45776444|NCT01183559|Drug|Vandetanib|Vandetanib 100mg orally escalating to doses of 200 mg daily 7 days a week until completion of radiation therapy
45776445|NCT01183559|Drug|5 Fluorouracil (FU)|5-FU 225 mg/m2/day continuous infusion over96 hours during radiation therapy
45776446|NCT01183559|Drug|Carboplatin|Carboplatin AUC=5 days 1 and 29 during radiation therapy
45776447|NCT01183559|Drug|Paclitaxel|Paclitaxel 50 mg/m2 days 1, 8, 15, 22, 29 during radiation therapy
45776448|NCT01183559|Radiation|External Beam Radiation Therapy (RT)|External Beam Radiation Therapy(XRT)to a total dose of 4,500 centiGray (cGy) (180 cGy fractions daily) Monday through Friday for five weeks
45776449|NCT01184417|Drug|10 mg/kg IV phenobarbital in 100 ml saline|10 mg/kg IV phenobarbital in 100 ml saline
45776450|NCT01184417|Drug|placebo|100 m l saline
45776451|NCT01159067|Drug|deferasirox|Given orally
45776452|NCT01221857|Drug|NiCord®|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
45776453|NCT01159535|Behavioral|Mindfulness Based Relapse Prevention|The MBRP intervention comprises 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists (Bowen, et al., 2009). In MBRP, therapists facilitate discussions and exercises and introduce the meditation practice component.Group sessions include discussions of mindfulness as a means of coping with craving and painful cognitions/sensations that precipitate relapse, role-playing exercises, meditation practice, and homework assignments.
45776454|NCT01159535|Behavioral|Relapse Prevention|intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants)
45776455|NCT01159535|Behavioral|Treatment as Usual|All participants will be enrolled in continuing care services (including attendance at AA, NA, or other self-help groups) as recommended by their treatment providers. Thus, TAU participants will have ongoing support and monitoring by their continuing care providers on a regular basis.
45776456|NCT02980055|Procedure|collagen matrix|Surgical procedure for root coverage using collagen matrix
45776457|NCT02980055|Procedure|connective tissue graft|Surgical procedure for root coverage using connective tissue graft
45915092|NCT04921722|Drug|Percutaneous sirolimus|We compare topical and oral use of sirolimus in the treatment of superficial complicted vascular anomalies. In experimental group, we administrate percutaneous sirolimus. Drop 5 ml of sirolimus oral solution and 5 g of dressing into the mixed bottle. Apply mixed gel of topical sirolimus to affected area. Use it twice a day for 6 months.
45448359|NCT00133991|Drug|Hydrocortisone|50 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
45448360|NCT00133991|Drug|Vincristine|1.4 mg/m^2 on Day 1 of each cycle of R-CVP.
45448361|NCT00133991|Drug|Leucovorin|25 mg four times daily after methotrexate administration. Dosing continues until adequate methotrexate levels are reached.
45638098|NCT03867773|Behavioral|Time restricted feeding|TRF subjects will consume food ad libitum during the feeding window (4-h or 6-h window), and refrain from eating during the fasting window (20-h or 18-h window)
45638099|NCT03790397|Drug|Osimertinib|Patients treated with Osimertinib within the Special Use medication Program (SUMP).
45638100|NCT03780101|Diagnostic Test|Multi-parametric renal MRI|Multi-parametric functional magnetic resonance imaging of a transplant kidney including sequences for T1, T2, diffusion-weighted imaging, diffusion tensor imaging and arterial spin labelling.
45638101|NCT03800771|Device|Cycléo BRAU|Practice dual-task tests.
45638102|NCT03800771|Device|GAITRITE®|Routine practice dual-task tests.
45638103|NCT04699565|Diagnostic Test|Cardiac magnetic resonance|Evaluate the predictive value of myocardial viability measured with cardiac magnetic resonance for the identification of LV REM 6 months after STEMI
45638104|NCT03718559|Drug|Edoxaban|Taking edoxaban (Lixiana™, Daiichi-Sankyo Inc.) 60mg once daily. The dose of edoxaban will be reduced to 30mg once daily in patients with estimated creatinine clearance 15≤CrCL≤50mL/min by Cockcroft-Gault equation or weight is ≤60kg.
45776458|NCT01222091|Drug|Propranolol|Propranolol administered intravenously, initially set to target plasma concentration of 5 ng/mL, titrated upward in 5 ng/mL intervals until a final concentration of 15 ng/mL is achieved.
45776459|NCT01222091|Drug|Placebo to Match Propranolol|
45776460|NCT01222091|Drug|Remifentanil|Remifentanil administered intravenously at a plasma concentration of 3 ng/mL.
45776461|NCT01225055|Drug|Teriparatide|20 ug daily over 12 months
45776462|NCT01225055|Device|vibration|10 min/day for 12 months
45776463|NCT05399082|Device|Cryoprobe biopsy|A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue
45776464|NCT05399082|Procedure|Forceps biopsy|Biopsy forceps used to collect tissue
45776465|NCT05412654|Dietary Supplement|High potassium water|High potassium water Potassium 6.2 mg/100ml
45776466|NCT05412654|Dietary Supplement|Control low potassium water|Control water Potassium 0.2 mg/100ml
45776467|NCT05412420|Other|Patient Self-Reporting of Symptoms|"At baseline, clinical research staff will:~verify the possibility of an internet connection at the patient's home~help the patient to fill in the 1st questionnaire (baseline questionnaire - frailty)~Every two weeks for 3 months:~patients complete questionnaires via app (toxicity; quality of life, medication adherence)~responses are verified by clinical research staff~In case of severe symptoms, the clinician contacts the patient and arranges for management.~At the end of the study :~- patients answer a satisfaction questionnaire"
45638105|NCT03718559|Drug|Single Antiplatelet Agents|Type of antiplatelet agent is dependant upon the investigator's discretion, but aspirin 100mg once daily is recommended.
45638106|NCT04677257|Procedure|PCI, invasive coronary physiology and CMR|Patients with acute STEMI will undergo invasive assessment of coronary physiology (IMR and CFR) following successful primary PCI and CMR within a week of the acute event
45638107|NCT01228331|Drug|Amsacrine|one block amsacrine together with etoposide and methylprednisolone for very high risk patients
45638108|NCT01228331|Drug|Clofarabine|one block clofarabine with Asparaginase for MRD positive patients after induction
45915093|NCT04921722|Drug|Oral sirolimus|We compare topical and oral use of sirolimus in the treatment of superficial complicted vascular anomalies. In active comparator group, we administrate oral sirolimus. Oral dose of sirolimus is calculated according to body surface area. Take it twice a day for 6 months. Maintain the blood concentration of sirolimus at 5-15ng/ml.
45638109|NCT01228331|Drug|Cyclophosphamide|together wit MTX and ASP in consolidation and together with cytarabine and 6-TG in reinduction
45638110|NCT01228331|Drug|Cytarabine|part of different chemotherapy blocks in consolidation and reinduction
45638111|NCT01228331|Drug|Daunorubicin hydrochloride|part of induction and reinduction therapy
45638112|NCT01228331|Drug|Dexamethasone|part of reinduction therapy
45638113|NCT01228331|Drug|Doxorubicin hydrochloride|part of reinduction therapy
45638114|NCT01228331|Drug|Etoposide phosphate|part of different chemotherapy blocks
45776468|NCT01160237|Biological|PandemrixTM|One dose intramuscular injection
45776469|NCT01160237|Biological|FluarixTM/ Influsplit SSW® 2010/2011|One dose intramuscular injection
45776470|NCT05379426|Other|Impact COVID-19 pandemic|Battery of screening tests and the semi-structured interview focusing on the difficulties experienced by the older adult during the pandemic period.
45776471|NCT03010787|Drug|V565|single ascending dose of V565
45776472|NCT03010787|Drug|V565|Multiple dose
45776473|NCT03010787|Drug|Placebo|Single and multiple dose
45776474|NCT03010787|Drug|V565|Open-label single dose
45915094|NCT04920825|Dietary Supplement|Sacha Inchi Oil softgel supplement|A twice daily supplementation of Sacha Inchi Oil softgel for 12 weeks
45915095|NCT04920825|Dietary Supplement|Corn oil softgel|A twice daily supplementation of Corn Oil softgel for 12 weeks (Placebo)
45448362|NCT02784106|Drug|Placebo|Participants received placebo matched to M2951 twice daily up to Day 84 during the double-blind treatment period.
45448363|NCT02784106|Drug|M2951|Participants received 50 milligrams (mg) M2951 orally twice daily up to Day 84 during the double-blind treatment period.
45448364|NCT02784106|Drug|M2951|Participants who received placebo matched to M2951 or M2951 in double-blind treatment period, received 50 mg M2951 orally twice daily up to 26-weeks during the open label extension period.
45638115|NCT01228331|Drug|Mercaptopurine|part of different chemotherapy blocks
45638116|NCT01228331|Drug|Methotrexate|part of different chemotherapy blocks
45638117|NCT01228331|Drug|Methylprednisolone|part of different chemotherapy blocks
45638118|NCT01228331|Drug|Pegaspargase|part of different chemotherapy blocks
45638119|NCT01228331|Drug|Thioguanine|part of different chemotherapy blocks
45638120|NCT01228331|Drug|Vincristine sulfate|part of intravenous chemotherapy
45638121|NCT01228331|Radiation|Whole-brain radiation therapy|patients with initial cns involvement receive cranial irradiation
45638122|NCT03428165|Other|HCG|250 μg/0.5ml choriogonadotropine alpha, Ovitrelle, Merck Serono
45638123|NCT01171937|Drug|Risperidone|children get randomized to either placebo or active risperidone
45776475|NCT03010787|Drug|V565|Open-label single ascending dose
45776476|NCT05598294|Procedure|Mobilization recommendations|Standard mobilization recommendations will be given to all patients, and feedback will be given to the intervention group to increase the number of steps 4 times a day according to the daily targeted number of steps.
45776477|NCT01336140|Drug|Aminophylline|75 mg of intravenous aminophylline
45776478|NCT01336140|Drug|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
45776479|NCT05398926|Biological|COVID-19 Vaccine (Vero cell), Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.
45915096|NCT04860336|Other|Observational|Observational
45915097|NCT04833387|Drug|PD-1 antibody|Capecitabine:Dose of 1650mg/m2,14days; Radiation:50Gy/25 fractions;IBI308: 200mg on day1 of each cycle, 3 cycles; Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
45915098|NCT04831008|Other|Figure-of-eight suture|Using the figure-of-eight closure technique when closing access for structural heart therapies.
45915099|NCT04831008|Other|Perclose Device|Using the Perclose device when closing access for structural heart therapies.
45915100|NCT04804293|Device|FDA approved ultrasound system with shear wave elastography capability|The investigators will acquire at least 4 acquisitions for each of 2 locations on the wrist. The objective is to correlate SWE measurements with patient-reported measures of symptom severity and functional status scores and severity of pre-operative electrodiagnostic tests (EDX). Evaluate the treatment response to surgical decompression or corticosteroid injection, using quantitative SWE and correlate the results to repeated patient reported outcomes with Boston CTQ, and objective clinical improvement with Semmes-Weinstein monofilament evaluation for recovery of sensibility, and grip and lateral pinch strength.
45915101|NCT04803084|Other|Tempus assay|Blood collection
45915102|NCT04803084|Other|Advanced pathology 1|Tissue procurement (from diagnostic biopsy)
45638124|NCT01171937|Drug|Placebo|Children get randomized to either placebo or risperidone
45915103|NCT04803084|Other|Advanced pathology 2|Tissue procurement (from research biopsy)
45776480|NCT05398068|Other|Exercises and Diet|"Non-Invasive Ventilation (NIV) will be included in the treatment program of all patients participating in the study. For the Mediterranean diet protocol planned in training groups; each patient will be evaluated by a dietitian at the beginning of the study and individual diet programs will be planned.~A 10-week exercise training will be planned for the training group.~Aerobic exercise sessions will be planned as a 5-minute warm-up - 20-minute bicycle ergometer - 5-minute cooling-down program. The intensity of exercise will be planned to be of medium intensity according to the heart rate reserve (40-50%). According to the Modified Borg Scale, walking will be given 3 days a week at a intensity of 4-6, also as a home exercise.~Strengthening exercises will be planned with reference to 10 RM (repetition maximum) with theraband for large muscle groups (10 repetitions-3 sets)."
45638125|NCT03416933|Other|Blood sampling|2x10 ml of patient peripherical blood will be collected at D0, D15, D30, D90, D180, D270 and with progression or at the end of the follow-up at the 12th month.
45638126|NCT03102905|Other|Measurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied.|To evaluate the prevalence of the positivity of HHV6 PCR in the skin, during the exanthema in patients hospitalized for haemopathy.
45638127|NCT03136445|Drug|Tranexamic acid (TXA).|IV or oral preparation. IV tranexamic acid or Oral tablet of tranexamic acid.
45638128|NCT03136445|Drug|Placebo|IV (saline) or oral placebo tablets
45638129|NCT04481399|Behavioral|Family Strengthening Intervention for Early Childhood Development|The Family Strengthening Intervention for Early Childhood Development (FSI-ECD) is an evidence-based home-visiting behavioral intervention for vulnerable families with children aged 6-36 months. The FSI-ECD targets improving parental emotion regulation and parent-child interactions to improve parental mental health and child development outcomes and reduce family violence. FSI-ECD compromises five core components delivered in 12 modules delivered in weekly sessions via active coaching by community health workers. Core components include coaching on: a) nutrition, health and hygiene; b) early stimulation and playful parenting; c) building resilience and coping skills; d) building problem-solving skills; and d) building emotion regulation and conflict resolution skills.
45915104|NCT04793685|Drug|Prazosin|Prazosin (16mg/day) versus Placebo comparator, with a 2 week titration period, 9 weeks at full dose and a 5-day taper in week 12.
45448365|NCT03549208|Biological|LBVE01|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
45653049|NCT05730049|Device|Transcutaneous auricular vagus nerve stimulation|Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA(3). Pulse width will be set at 100μs and frequency will be set at 25Hz as performed in a previous protocol in stroke patients(3). The control group will receive the same stimulation parameters but will have the earpiece placed in the sham position such that stimulation is applied to the earlobe and does not activate the vagus nerve(4).
45776481|NCT05398068|Other|Diet|Non-Invasive Ventilation (NIV) will be included in the treatment program of all patients participating in the study. A regular diet program will be planned for 10 weeks for the control group. . For the Mediterranean diet protocol planned in control groups; each patient will be evaluated by a dietitian at the beginning of the study and individual diet programs will be planned. After that, after 1 week, patients will be re-evaluated for compliance by a dietitian. And than, each patient included in the study will be evaluated for 2 weeks during the treatment period.
45776482|NCT01184885|Drug|Hyper-CVAD|"Cycle A: Cyclophosphamide 300mg/m2 every 12 hours on days 3-5; Vincristine 2mg/day on days 6 and 13; Doxorubicin 50mg/m2 on day 6; Decadron 40mg/ day po on days 3-6 and 13-16; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~Cycle B: Methotrexate 1000mg/m2 on day 3; Leucovorin 50mg every 6 hours starting 24 hours from the beginning of the MTX infusion until MTX levels are < 0.1 umol/L; Ara-C 3000mg/m2 every 12 hours on days 4 and 5; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~Rituximab (if given) will be 375 mg/m2 on Days 3 and 13 of Cycle A and on Days 4 and 9 of cycle B, for a total of 8 doses over the first 4 courses."
45776483|NCT01184885|Drug|Sirolimus|Sirolimus loading dose of 12mg on day 1 followed by a single daily dose of 4 mg/ day on days 2 through 7 (Cycle A) and on days 2 through 6 (Cycle B)
45915105|NCT04793685|Behavioral|12-Step Facilitation with Relapse Prevention and Contingency Management|12-Step Facilitation and relapse prevention weekly support and Contingency Management with vouchers for each weekly appointment to support treatment attendance for all subjects.
45915106|NCT04787991|Drug|Nivolumab (Cohort A)|Nivolumab will be administered intravenously at 360 mg every 3 weeks for up to 2 years.
45915107|NCT04787991|Drug|Ipilimumab (Cohort A, B and C)|For Cohort A and B, ipilimumab will be administered intravenously at 1mg/kg every 6 weeks for up to 2 cycles. For Cohort C, ipilimumab will be administered intravenously at 1mg/kg on C2D1 and C4D1.
45915108|NCT04787991|Drug|Hydroxychloroquine (HCQ) (Cohort B)|Hydroxychloroquine will be administered orally daily for up to 2 years.
45915109|NCT04787991|Drug|Nab-paclitaxel (nP) (Cohort A, B and C)|Nab-paclitaxel will be administered intravenously at 125 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.
45448366|NCT03549208|Biological|LBVE02|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
45448367|NCT03549208|Biological|Prevnar13|13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
45448368|NCT02134600|Dietary Supplement|Omega-3 enriched fruit juice|"Different doses of omega-3 will be administered to five different groups:~400, 800, 1200, 2400 and 3000 mg/m2."
45448369|NCT02140450|Drug|Timolol|2 drops of timolol, 10 minutes apart, 1-2 hours before intravitreal injection
45448370|NCT02140450|Drug|Brimonidine|Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
45448371|NCT02140450|Drug|Acetazolamide|Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection
45776484|NCT02187887|Behavioral|Personalized normative feedback|Participants receive behavioral norms feedback based on their response to items in a baseline survey. Personal responses are presented along with perceptions of other same gender veterans and actual drinking norms of same gender veterans.
45638130|NCT04481399|Other|Community Health Worker Routine|Standard CHW care involves three home visiting sessions delivered to families following childbirth with weekly supervision via phone or face-to-face. Topics of home visiting sessions include: skilled post-natal care for mothers, early initiation of breastfeeding and exclusive breastfeeding practices, adequate nutrition, immunization services and timely use of these services, hand washing and hygiene practices (including waste disposal and food hygiene), building the capacity of family members to appropriately take care of newborns and children under age 5, and building the capacity of family members to recognize and act on postnatal danger signs for newborns, mothers, and children under 5. CHWs also conduct screenings for acute malnutrition and growth monitoring to identify early referrals, and they can provide family planning methods, deworming tablets and other vitamins for acute malnutrition, dehydration, and anti-malaria treatment. Each home-visiting session lasts about 60 minutes.
45638131|NCT03102983|Other|MRI functional|vowels records and MRI session
45776485|NCT04346771|Behavioral|Working memory training|Participants complete 10 sessions of maintaining positive working memory training during a two-week period. Each session consists of 15 blocks.
45776486|NCT04346771|Behavioral|Positive ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes.
45638132|NCT05302349|Other|Core Exercise Group|"Core Exercise Group Procedure:~Weeks 1-4 (Five days a week)~Hotpack ultrasound, conventional TENS, stretching exercises and strengthening exercises for low back pain.~Core stabilization exercise :~Active pelvic floor exercise (supine position)~Bridge exercise (supine position)~Back Extension and Ball Back Extension exercises (prone position)~Abdominal and Oblique Crunch exercises (supin position)~Leg lift exercise (prone position)~Plank and Side Plank exercise~Superman exercise~Weeks 5-8 (Three days a week)~Stretching exercises and strengthening exercises for low back pain.~Core stabilization exercise :~The same exercises as for Weeks 1-4 will perform."
45776487|NCT01187381|Drug|Trastuzumab|Trastuzumab according to local standard of care and in line with the current summary of product characteristics/ local guidelines
45776488|NCT01187771|Procedure|Laparoscopic Gastric Banding|Those randomized to surgery would meet with the bariatric surgeon and the dietitian during the 3 month weight management period and based on insurance requirements, would undergo LGB surgery after 3 months of weight management. PAP therapy would be utilized for the 3 week peri-operative period (1 week prior to 2 weeks post-operatively) given evidence that this might reduce peri-operative respiratory complications. Routine surgical follow-up will occur 2 weeks post-operatively and then every 4-6 weeks to assess weight loss trajectory and adjust the band as needed.
45776489|NCT01187771|Procedure|Continuous Positive Airway Pressure|Participants randomized to the CPAP arm will undergo a CPAP titration within 2 weeks of enrollment unless a split-night study was already performed as part of their diagnostic polysomnogram (PSG) providing a reliable CPAP therapeutic pressure. As soon as an appropriate pressure is identified, CPAP therapy will begin with routinely scheduled follow-up visits to maximize CPAP adherence. All participants will be offered a 12 month supervised weight loss program in addition to OSA-specific therapy.
45776490|NCT01225289|Dietary Supplement|Vitamin A|25000 IU/day (one capsule per day) Vitamin A for 6 months
45776491|NCT01225289|Drug|Placebo|1 capsule per day for six months
45776492|NCT01161329|Other|High-Intensity Functional Exercise Programmes (HIFE)|Hife include functional exercises consisting of everyday tasks challenging leg strength, postural stability, and gait ability. All exercise shall be performed in weight-bearing positions, eg squats and walking over obstacles. HIFE are performed twice a week during 1 h. for three months in a group with 6-7 seven patients with stroke. Two physiotherapists lead the group and one physiotherapist select exercises for each participant according to their functional deficits. The exercises will be progressively increased in load and difficulty.
45776493|NCT01227005|Biological|Transfusion of blood products|The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).
45776494|NCT01161563|Drug|Triptorelin pamoate|Triptorelin pamoate for injectable suspension 22.5 mg administered as a single intramuscular injection in either buttock
45776495|NCT01161563|Drug|Leuprolide acetate|Leuprolide acetate for injectable suspension 45 mg administered as a single subcutaneous injection in the upper- or mid-abdominal area.
45776496|NCT03010085|Procedure|Open left-sided hepatectomy|Open left-sided hepatectomy Laparotomy (upper midline, inverted 'L', or Benz incision) Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
45776497|NCT03010085|Procedure|Laparoscopic left-sided hepatectomy|Trocar insertion Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
45776498|NCT01189409|Drug|PEG then Senna|Stepped bowel protocol with PEG for 3 weeks followed by senna for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
45776499|NCT01189409|Drug|Senna then PEG|Stepped bowel protocol with senna for 3 weeks followed by PEG for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
45915110|NCT04787991|Drug|Gemcitabine (gem) (Cohort A, B and C)|Gemcitabine will be administered intravenously at 1000 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.
45915111|NCT04787991|Drug|NG350A (Cohort C)|NG-350A will be administered intravenously on Cycle 1 Days 15 (1e12 viral particles), 17 (3e12 viral particles), and 19 (3e12 viral particles).
45448372|NCT02140450|Drug|Mannitol|Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection
45638133|NCT05302349|Other|Routine Therapy Group|"Routine Therapy Group Procedure:~Weeks 1-4 (Five days a week)~1. Hotpack ultrasound, conventional TENS, stretching exercises and strengthening exercises for low back pain.~Weeks 5-8 (Three days a week)~1.Stretching exercises and strengthening exercises for low back pain."
45638134|NCT04483349|Other|Survey Administration|Complete survey
45638135|NCT03350711|Other|Microbiota Enrichment Program (MEP)|"Registry participants will provide demographic and medical information and may take part in general screening procedures to facilitate enrolling into an appropriate FMT study.~Once determined to be eligible for study entry, study-specific screening procedures may include:~Health history and physical examination~Urinalysis~Urine or serum pregnancy test~Blood tests for Hepatitis B, Hepatitis C, HIV, chemistry panel (which includes liver function, kidney function), complete blood count with differential, platelet count, partial thromboplastin time (PTT), international normalized ratio (INR)~Electrocardiogram (EKG or ECG)~Stool studies~Participants will be re-screened every 6 months and will remain in follow-up indefinitely or until they are rendered ineligible, participate in a MEP study, or withdraw consent to be included in the database."
45638136|NCT00887783|Drug|Navelbine|Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks
45638137|NCT00887783|Radiation|66 Gy/33F|irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)
45638138|NCT00887783|Radiation|60 Gy/30F|irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)
45915112|NCT04745676|Behavioral|Telehealth|Telehealth ACP intervention advance care planning intervention
45915113|NCT04726410|Biological|Cold Stored Platelets|early infusion of urgent release CSP
45915114|NCT04726410|Biological|Standard Care|standard care including room temperature platelets
45638139|NCT03287843|Procedure|Total mesorectal excision before 56 days (4-8 weeks)|Low anterior resection or abdominoperineal resection
45638140|NCT03287843|Procedure|Total mesorectal excision after 56 days (8-12 weeks)|Low anterior resection or abdominoperineal resection
45638141|NCT02156609|Device|Percutaneous ventricular support with the HeartMate PHP|The HeartMate PHP device will be inserted percutaneously prior to the start of high risk coronary interventions (complex disease, reduced ejection fraction, etc.) to provide hemodynamic support,
45776500|NCT01227551|Biological|Coxsackievirus A21 (CVA21)|CVA21 is a live oncolytic virus preparation derived from the non-genetically altered prototype Kuykendall strain of Coxsackievirus A21.
45776501|NCT03010475|Drug|Furosemide|Oral administration A total of three single doses.
45776502|NCT03010475|Drug|Rosuvastatin|Oral administration. A total of three single doses.
45776503|NCT03010475|Drug|SNAC|Oral administration. A total of five single doses.
45776504|NCT03010475|Drug|Semaglutide|Oral administration. Once daily.
45776505|NCT03010553|Procedure|Detection and resection of sentinel lymph node|
45776506|NCT01227785|Device|INCEPTA ICD or CRT-D|
45776507|NCT02191865|Drug|Nintedanib|Soft gelatine capsule
45776508|NCT02191865|Drug|Nintedanib|Soft gelatine capsule
45776509|NCT02191865|Drug|Nintedanib|Soft gelatine capsule
45915115|NCT04677738|Dietary Supplement|B. breve|Probiotic capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of B. breve B-3 in the morning before breakfast for 12 weeks.
45638142|NCT02047097|Drug|dimethyl fumarate|Provided under routine clinical care
45638143|NCT01125371|Behavioral|Computerized brief alcohol intervention + IVR booster calls|1) Computerized brief alcohol intervention + IVR booster calls: Clinic-based computerized brief alcohol intervention (delivered once) followed by three booster phone calls using interactive voice response technology + text messages
45915116|NCT04677738|Dietary Supplement|Placebo|Placebo capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of placebo in the morning before breakfast for 12 weeks.
45776510|NCT04352465|Drug|Methotrexate|Phase A: Subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).
45776511|NCT04352465|Drug|Methotrexate|Phase B: Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).
45776512|NCT04352465|Drug|Methotrexate|Phase C: Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).
45776513|NCT01191749|Drug|Alemtuzumab|10 mg by vein over 2 hours on Days 1 to 10 of a 28 day cycle.
45915117|NCT04604418|Other|No intervention. It is observational|No intervention. It is observational
45915118|NCT04552080|Drug|Amoxicillin|Preoperatively antibiotics of 2 g amoxicillin 1 hour prior to standard implant placement and sinus floor Elevation will be administered. An additional single dose of 500 mg of amoxicillin will be administered 8 hours after surgery and 500 mg thrice daily (8 hourly) on days 1 to 3 following implant placement and sinus floor elevation.
45915119|NCT04552080|Other|Placebo|Preoperatively a placebo of 2 g will be administered. An additional single dose of 500 mg of placebo will be administered 8 hours after surgery and 500 mg thrice daily (8 hourly) on days 1 to 3 following implant placement and sinus floor elevation.
45448373|NCT02140450|Drug|Placebo|Artificial tears, 2 drops, 1-2 hours before intravitreal injection
45776514|NCT00343460|Drug|APF530|Given subcutanously
45776515|NCT00343460|Drug|dexamethasone|Given IV and orally
45776516|NCT00343460|Drug|Palonosetron Hydrochloride|Given IV
45776517|NCT00343460|Other|placebo|Given subcutanously or IV
45776518|NCT04934696|Drug|BMS-986166|Specified dose on specified days
45776519|NCT04934696|Drug|Oral contraceptive|Specified dose on specified days
45776520|NCT01192139|Drug|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
45776521|NCT01192139|Drug|metformin XR|Tablets, Oral, 500 mg. once daily, Single dose
45776522|NCT01192139|Drug|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 500 mg), once daily, Single dose
45638144|NCT01125371|Behavioral|Computerized brief alcohol intervention|Computerized brief alcohol intervention: Clinic based computer delivered brief alcohol intervention delivered one time
45638145|NCT01125371|Behavioral|Attention Control|Attention Control: 20 minute attention control condition focused on dental hygiene delivered once
45776523|NCT04924400|Behavioral|CHIP Program|"GHP members randomized to the intervention arm will participate in the following activities:~Attend 2 group meetings per week over 6 weeks, followed by one group meeting per week for 6 weeks (12 weeks total); each meeting will last about one hour. CHIP classes for weeks 1-4 and week 12 require in-person attendance, while week 5-11 classes can be attended either virtually or in-person.~Receive a copy of The Optimal Diet, The Official CHIP Cookbook.~The following data will be collected at weeks 1,12 and 26:~Biometrics: weight, BMI, waist circumference, systolic and diastolic blood pressure~Biomarkers (blood tests): HbA1c, LDL-C~Psychometrics: Wellbeing360 survey"
45776524|NCT04924400|Behavioral|Usual Care|"GHP members assigned to the control arm will receive the routine standard of care for GHP members. Members will receive a summary of diabetes-related benefits available to members with type 2 diabetes.~The following data will be collected at weeks 1,12 and 26:~Biometrics: Weight, BMI, waist circumference, systolic and diastolic blood pressure~Biomarkers (blood tests): HbA1c, LDL-C~Psychometrics: Wellbeing360 survey"
45776525|NCT04919954|Drug|Tebipenem Pivoxil Hydrobromide|Tebipenem 300 mg or 600 mg will be administered orally every 8 hours for total of 3 to 7 doses
45776526|NCT04892186|Drug|Myo-inositol|"30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used myo-inositol 2g twice daily for 6 months, having a re-evaluation every 3 months.~Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference."
45776527|NCT04892186|Drug|Metformin|"30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used metformin three times a day for 6 months, having a re-evaluation every 3 months.~Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference."
45776528|NCT01684904|Radiation|Proton radiation|
45776529|NCT01229423|Drug|bimatoprost 0.03%|One drop of bimatoprost 0.03% (LATISSE®) applied evenly to each upper eyelid in the evening. Treatment is once daily for up to 40 weeks.
45776530|NCT01283321|Drug|Human fibrinogen concentrate|4 g IV once, within 30 minutes of ACT < 155 seconds, post CPB, with evidence of significant microvascular bleeding
45776531|NCT01283321|Other|apheresis platelets|A single apheresis platelet unit will be administered as an initial therapy within 30 minutes of ACT <155 seconds post CPB with evidence of significant microvascular bleeding.
45776532|NCT01229891|Dietary Supplement|plain yogurt drink|daily intake of two bottle of plain yogurt drink
45776533|NCT01229891|Dietary Supplement|vitamin D fortified yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D/250 mL
45776534|NCT01229891|Dietary Supplement|vitamin D-calcium yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 ml package
45776535|NCT01283555|Drug|Tenofovir|Delivered using prefilled and user-filled applicator
45776536|NCT00345176|Dietary Supplement|Lutein/zeaxanthin|10 mg lutein and 2 mg zeaxanthin (1 tablet) Placebo-DHA/EPA (2 soft-gel capsules)
45776537|NCT00345176|Dietary Supplement|DHA/EPA|Placebo-lutein/zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
45776538|NCT00345176|Drug|Lutein/zeaxanthin and DHA/EPA|10 mg lutein and 2 mg zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
45776539|NCT01194089|Drug|Nasal Nicotine Spray|Single 3 mg dose of nasal nicotine spray
45776540|NCT01194089|Drug|Nasal Normal Saline Spray|An isotonic solution of sodium chloride 0.65% in deionized water
45776541|NCT00345254|Procedure|severing cord|The cord was cut intentionally after delivery of the anterior shoulder and prior to extraction of the body.
45776542|NCT00345332|Drug|Botox|Injected
45776543|NCT00345332|Drug|Placebo|Injected
45776544|NCT01650350|Drug|Naltrexone|"4.1 Low Dose Naltrexone (LDN) LDN, 5 mg/day, at approximately 9pm, on an empty stomach, until disease progression, unacceptable toxicity, need for initiation of narcotic analgesia, or removal from protocol treatment according to section 12.0. (1 cycle = 28 days).~LDN, 5mg/ml, will be prepared by the Lifespan hospital pharmacy for patient use for this study."
45776545|NCT00505466|Behavioral|Genetic Counseling|Genetic counseling conducted in person, by telephone with an M. D. Anderson Genetic Counselor, or with a local Genetic Counselor in conference with the M. D. Anderson Genetic Counselor.
45776546|NCT00349388|Drug|Asacol|Asacol is given once a day versus twice or three times a day
45776547|NCT00349778|Drug|Cyclophosphamide|Cyclophosphamide as a white powder in 100 mg, 200 mg and 500 mg vials, to be dissolved in ~250 mL of saline or D5W and infused IV over 2 hours
45776548|NCT00349778|Drug|Etoposide|100 mg etoposide as 5 mL solution in clear ampules for injection.
45776549|NCT00349778|Drug|Melphalan|Melphalan as single-use glass vials of freeze-dried melphalan hydrochloride (equivalent to 50 mg of melphalan), to be reconstituted in 0.9% sodium chloride solution to not greater than 0.45 mg/mL, and administered within 1 hour of constitution.
45776550|NCT00349778|Drug|Carmustine|Carmustine as a powder for reconstitution in 100 mg vials, to be reconstituted with 3 mL sterile dehydrated ethanol and D5W. Carmustine should be dissolved in 500 mL of 5% dextrose in water (D5W) and infused IV over 2 hours.
45915120|NCT03834909|Drug|Standard dose Truvada®|TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, one tablet each day
45915121|NCT03834909|Drug|Pregnancy-adjusted dose Truvada®|TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, two tablets each day
45638146|NCT03199547|Drug|Azithromycin|The women will be randomized to receive a single dose of Azithromycin or Placebo
45638147|NCT03199547|Drug|Placebo Oral Tablet|The women will be randomized to receive a single dose of Azithromycin or Placebo
45638148|NCT03189641|Device|Cilostazol eluting stent system (CES-1)|Implantation of drug eluting stent
45638149|NCT03180905|Device|ImPACT Online/Paper Pencil Tests|Compare ImPACT Online versus Paper and Pencil Neurocognitive Tests
45638150|NCT03180905|Device|ImPACT Online|ImPACT Online will be administered at 2 time points.
45776551|NCT00349778|Drug|Filgrastim|Filgrastim in vials of 300 µg or 480 µg at a concentration of 300 µg/mL, to be given as a daily subcutaneous injection.
45776552|NCT00305084|Drug|NGR-hTNF|0.2, 0.4, 0.8 and 1.6 μg/m²as 60-minute intravenous infusion every 3 weeks
45915122|NCT04380480|Combination Product|Concurrent chemoradiotherapy combined with enteral feeding by percutaneous endoscopic gastrostomy|"One or two weeks before CCRT, all patients will undergo a percutaneous endoscopic gastrostomy (PEG) to be administered enteral nutrition support(30-35 kcal/kg of energy, 1.2-1.5g/kg of protein and electrolyte supplementation each day). Nutritional supplements will be administered till 1 month after CCRT.~All patients will receive definitive radiotherapy combined with three cycles of S-1 (40mg/2, BID, po) on D1-14, D22-35, D43-56."
45638151|NCT04042571|Device|Cerebral oxymetry monitoring (NIRS)|Near-InfraRed Spectroscopy (NIRS) is a non-invasive method measuring tissue oxygenation by regional saturation of capillary-oxygenated hemoglobin (rSO2). Starting on day 4 after aneurismal rupture NIRS electrods will be placed and maintained until day 12 permanently and blindly recording rSO2. Patients will be monitored following daily practice recommandations inclunding vasospasm detection and treatment.
45776553|NCT00305084|Drug|Doxorubicin|75 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion)
45776554|NCT00305162|Drug|Cangrelor (P2Y12 inhibitor)|IV bolus (30 mcg/kg) & infusion (4 mcg/kg/min) initiated prior to PCI, as soon as possible following randomization (after need for PCI is confirmed) but not more than 30 minutes prior to placement of arterial access. Infusion is to continue for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion).
45776555|NCT00305162|Drug|clopidogrel (oral P2Y12 inhibitor)|600 mg active clopidogrel administered as soon as possible following randomization (after need for PCI confirmed), but not more than 30 minutes prior to the placement of the arterial access.
45776556|NCT00305162|Drug|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) & placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
45776557|NCT00305162|Drug|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
45776558|NCT00305162|Drug|Placebo capsules - as soon as possible after randomization|Placebo capsules given as soon as possible after randomization to mimic 600mg clopidogrel dosing
45915123|NCT04360473|Other|General anesthesia|Balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.
45915124|NCT04360473|Drug|Ketamine plus general anesthesia|ketamine 0.3 mg / kg 15 minutes before balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.
45915125|NCT04360473|Drug|Magnesium sulfate plus general anesthesia|Magnesium sulfate 40 mg / kg 15 minutes before balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.
45915126|NCT04360473|Drug|ketamine plus magnesium sulfate plus general anesthesia|Ketamine 0.15 mg/kg plus magnesium sulfate 20 mg/kg 15 minutes before balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane
45638152|NCT04038593|Other|Youtube© relaxation music|Use of non standardized relaxation music with Youtube© during cares
45776559|NCT01791686|Drug|CDX-1135|
45638153|NCT04038593|Device|MUSIC CARE© intervention|Use of MUSIC CARE© during cares
45638154|NCT00416351|Drug|clofarabine|
45653050|NCT04226937|Other|Not Applicable as this is a translational, sample collection study.|"Patients will take their normal standard of care treatment for their lymphoma, as per agreed with the patient's doctor.~Blood samples will be collected at Baseline, during the first 3 cycles of Treatment, at End of Treatment, at 6- and 12-months after End of Treatment and at relapse/progression if applicable.~Surplus Tissue biopsy will be collected at Baseline and at relapse/progression if applicable. In rare cases research-specific tissue biopsy may be collected if appropriate."
45776560|NCT00351416|Drug|Letrozole|Letrozole 20 mg orally one time
45776561|NCT00351416|Drug|NAL-GLU GnRH antagonist|5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously
45776562|NCT00305942|Drug|Topotecan|Topotecan 4mg/m2 IV on days 1, 8.
45776563|NCT00305942|Drug|carboplatin|Carboplatin AUC=5 IV day 1 only .
45638155|NCT03104777|Behavioral|Behaviourally Informed Intervention Materials|"The intervention consists of 7 separate components. The intervention components are to be delivered at three time-points (referred to as bundles). The bundles consist of:~Bundle 1a - Letter to parents of children bringing a packed lunch to school, 'spot the difference' lunch box tag (attached to all lunchboxes) and a Handy Swaps Card.~Bundle 1b - Letter to parents of children only having school meals and a Handy Swaps Card.~Bundle 2 - Lunch box mixer with ideas for creating nutritious packed lunches. Bundle 3 - Shopping list, packed lunch planner and reward chart to support planning and monitoring progress."
45638156|NCT03105011|Behavioral|EpxDiabetes software|Subjects will interact daily with a commercially available telemedicine product, Epharmix Diabetes (EpxDiabetes). They will each undergo a baseline blood draw to establish the control HgbA1C associated with standard of care. Three months later they will undergo an experimental blood draw to establish the HgbA1C associated with the use of EpxDiabetes. Between those procedures, the patient will interact with the intervention daily.
45638157|NCT03965273|Behavioral|Full TP|The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Community and Social Norms Change Component; iv) Facilitated sessions with mothers' groups and (separate) fathers' groups; v) 2-days intensive facilitated workshop with selected religious leaders and influential people; vi) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vii) Trainings of girls, boys and parents with special interest in activism.
45638158|NCT03965273|Behavioral|Light TP|The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Facilitated sessions with mothers' groups and (separate) fathers' groups; iv) 2-days intensive facilitated workshop with selected religious leaders and influential people; v) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vi) Trainings of girls, boys and parents with special interest in activism.
45638159|NCT03102827|Drug|Oxygen|Patients will receive oxygen with humidified air, fully saturated at 37° C at a flow rate of 20- 50 L/min. The ratio of oxygen and ambient air (FiO2) will be increased stepwise depending on patient's oxygen saturation.
45638160|NCT03102827|Other|Placebo|Ambient air without high-flow therapy administered during first night
45638161|NCT03102515|Drug|USG-TAP block|
45638162|NCT03102515|Drug|CIC|
45776564|NCT04737668|Other|Intrathecal pump refill with Virtual Reality|VR game
45776565|NCT04737668|Other|Intrathecal pump refill with distraction|Video
45776566|NCT04737668|Other|Intrathecal pump refill|daily routine care for pump refill
45915127|NCT04330989|Behavioral|iNSC and Adherence supporter training|"Integrated next step counseling: iNSC is a structured, patient-centered approach informed by motivational interviewing techniques, which aims to foster an environment for joint-problem solving in order that the participant may identify their individual needs to increase or sustain sexual health through biomedical and non-biomedical approaches. iNSC frames the counselling sessions as a non-judgmental discussion to explore the facilitators and challenges to sexual health and medication adherence.~Adherence supporter training: Participants will be asked to identify a partner, family member, or friend to whom they are willing to disclose their HIV status (for HIV-positive women) or their intent to initiate PrEP (for HIV-negative women). Participants may also select a clinic-based peer to serve this adherence supporter role. Trainings will emphasize basic HIV knowledge, importance of antiretroviral adherence, potential drug side effects, and practical strategies for supporting adherence."
45915128|NCT03816735|Device|Cikatridina|Women are asked to insert the suppositories according to the manufacturer's protocol.
45776567|NCT02527200|Drug|liraglutide|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
45776568|NCT02527200|Drug|placebo|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
45776569|NCT00352976|Drug|Cyclophosphamide|Day -5 through Day -2, subjects will receive chemotherapy of Cyclophosphamide via central line (i.e. Hickman or Broviac),10 mg/kg intravenously (IV)
45776570|NCT00352976|Drug|Fludarabine|Day -5 through Day -2 prior to transplant; subjects will receive chemotherapy of Fludarabine via central line (i.e. Hickman or Broviac),35 mg/m^2 intravenous (IV)
45915129|NCT03816735|Device|Juliet Feminine Laser|Women will receive the laser treatment twice during the study period.
45915130|NCT04329975|Drug|Desmopressin|Desmopressin (MINIRINMELT OD tablet) 25μg or 50μg, orally.
45915131|NCT04305795|Biological|200 mg Pembrolizumab|every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.
45448374|NCT05577676|Drug|Ultrasound-guided Hydrodissection of the Median Nerve|Hydrodissection for CTS includes injecting fluid around the median nerve (MN) with 5 ml volume, 3 ml of which is given in between the transverse carpal ligament & MN, and 2 ml below the MN under Ultrasound guidance in-plane ulnar approach.
45448375|NCT05577598|Device|Implantation of a DBS therapy system|"The system is called Reclaim DBS Therapy for OCD und is marketed by Medtronic (Minneapolis, Minnesota). It has a HDE status by the FDA. The system consists of two quadripolar electrodes (Medtronic Reclaim DBS) as well as a generator (Medtronic Activa PC), which will be implanted into a subcutaneous pocket below the clavicula."
45915132|NCT04305795|Biological|350 mg Cemiplimab|every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.
45915133|NCT04305795|Combination Product|ASP-1929|"ASP-1929 IV on Day 8 of each 6-week cycle for up to 24 months.~Photoimmunotherapy Light Treatment on Day 9 of each 6-week cycle for up to 24 months."
45915134|NCT04203303|Other|Observational|Observational
45638163|NCT03102749|Other|metacholine provocation test and CT-scan low dose|Investigators perform a metacholine provocation test where expiratory CT slices were acquired at each dose
45638164|NCT03947333|Other|My Diabetes Care|The My Diabetes Care is embedded within an existing patient web portal (My Health at Vanderbilt) and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy-level sensitive educational resources, and contains secure-messaging capability.
45638165|NCT03938831|Drug|Dexmedetomidine|dexmedetomidine 0.5 micg/kg/hr infusion during operation and followed by 0.2 mic/kg/hr with fentanyl-based PCA mixture for 2 days
45638166|NCT03938831|Drug|Fentanyl-based PCA infusion|Fentanyl-based PCA infusion
45638167|NCT03909815|Device|Dual mobility cup|Patients with a displaced femoral neck fracture eligible for THA receive a dual mobility cup, as opposed to a standard cup in the control group.
45915135|NCT00423384|Drug|Placebo|Placebo
45638168|NCT03909815|Device|Standard cup|Patients with a displaced femoral neck fracture eligible for THA receive a standard cup, as opposed to a dual mobility cup in the experimental group.
45638169|NCT03875183|Drug|INL1|Capsules
45776571|NCT00352976|Procedure|Total Body Irradiation|total body irradiation (300 cGy) with thymic shielding will be given six days before the stem cells are given (day -6). Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
45776572|NCT00352976|Procedure|Bone Marrow Transplantation|A target of 5 * 10^6/kg and a minimum of 4 * 10^6 CD34+ cell/kg recipient weight will be collected by apheresis and used for transplant. In most cases this dose will be recovered in a single apheresis; however, a second or rarely third apheresis performed on the following days may be required to achieve the minimum dose.
45638170|NCT03875183|Other|Placebo|Capsules
45638171|NCT03872375|Dietary Supplement|Meal-Replacement Therapy|The meal replacement shake, consumed once per day on two consecutive days, will over a given week lead to negative energy balance and induce weight loss.
45638172|NCT03872375|Behavioral|Dietary Counseling|A Registered Dietitian of Nutrition will provide consultation on how to induce moderate weight loss.
45638173|NCT02592707|Drug|Satoreotide tetraxetan|Satoreotide tetraxetan will be administered in 3 cycles at intervals of 8 weeks (+ up to 2 additional optional cycles)
45638174|NCT02592707|Other|Amino acid solution|"Given as an auxiliary product the day of the IMP infusion for safety reasons to protect the renal function.~Centres can use their established amino acid infusion or Ipsen amino acid solution (auxiliary medical product OPS301)"
45776573|NCT00352976|Drug|Mycophenolate Mofetil|Patients will receive MMF therapy beginning on day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute graft-versus-host disease (GVHD). Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count [ANC] > 0.5 * 10^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours by mouth(to a maximum dose of 1 gram).
45915136|NCT00423384|Drug|Ibandronate|I.v.
45638175|NCT02592707|Other|Antiemetic|To counteract the known side effects of the amino acid infusion, such as nausea, dexamethasone (antiemetic) and as-required ondansetron will be administered 15 to 30 minutes before the start of the amino acid infusion (unless there are contraindications for these drugs).
45776574|NCT00352976|Drug|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC). Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
45915137|NCT04175613|Drug|Apremilast|Apremilast dose will be increased from 20 mg BID to 30 mg BID for those subjects that reach a weight of 50 kg or more during the study
45915138|NCT04062552|Other|Behavioral, Psychological or Informational Intervention|Receive ENABLE palliative care information
45915139|NCT04062552|Other|Educational Intervention|Participate in VLC group-based learning sessions
45915140|NCT04062552|Other|Educational Intervention|Participate in consultation with ENABLE/TA expert
45915141|NCT04062552|Procedure|Medical Examination|Undergo palliative care assessment
45915142|NCT04062552|Other|Quality-of-Life Assessment|Ancillary studies
45915143|NCT04062552|Other|Survey Administration|Complete surveys
45915144|NCT04062552|Behavioral|Telephone-Based Intervention|Receive monthly phone calls
45448376|NCT05577520|Procedure|Sinus floor augmentation|
45448377|NCT02134678|Behavioral|self-system therapy|
45448378|NCT02134678|Behavioral|cognitive therapy|
45638176|NCT03102671|Other|Use of HeartHab application followed by usual care|use of a mobile, app based multidisciplinary telerehabilitation program (2 months) followed by usual care (two months)
45638177|NCT03102671|Other|Usual care followed by the use of HeartHab application|Usual care (2 months) followed by the use of HeartHab application (two months)
45638178|NCT03855917|Drug|Sofosbuvir 400mg [Sovaldi]|Four weeks.
45638179|NCT03855917|Drug|Glecaprevir/pibrentasvir (300mg/120mg)|Four weeks.
45638180|NCT03104855|Drug|d6-25-hydroxyvitamin D3|intravenous administration of stable isotope-labeled D6-25(OH)D3
45638181|NCT02431091|Other|Optical Coherence Tomography|Optical Coherence Tomography provides a non invasive evaluation of the thickness of different layers of the retina
45638182|NCT03104621|Drug|Benzalkonium chloride (BAK)|Benzalkonium chloride (BAK) is the most used preservative and is excellent for safety and stability of drug. However, it causes dry eye, corneal oedema, corneal erosion, and corneal toxicities, thus lowering the long-term tolerability for patients. A critical component when managing glaucoma patients is ensuring compliance.
45638183|NCT03104621|Drug|0.0015% tafluprost|Tafluprost (trade names Taflotan or Taflotan-S by Santen Pharmaceutical) is a prostaglandin analogue. It is used topically (as eye drops) to control the progression of open-angle glaucoma and in the management of ocular hypertension. In this study, tafluprost was used in all experimental group with equally concentration(0.0015%), only measured whether BAK was included or not.
45638184|NCT03102593|Drug|ARGX-113|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
45638185|NCT03102593|Other|Placebo|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
45638186|NCT03104387|Other|Electric train|Exposure to air with low level of ultrafine particles (Electric train)
45776575|NCT00306488|Drug|OT-551 antioxidant eye drop|0.45% concentration of OT-551 eye drops were given three times a day on participants with geographic atrophy area for up to three years. Participants had one eye randomized to receive the eye drop and the fellow eye was observed.
45776576|NCT04751006|Other|Gaze Stabilization Exercises|Gaze group performed balance exercises with gaze stability exercise.Gaze stability exercises included two types of exercises vestibular adaptation and substitution exercises. In Adaptation exercises individual need to fixate on a visual target during horizontal and vertical head movement with a purpose of increasing gaze stability and a long term gain to vestibular system. Subsitution exercises are planned to use other eye movement stratigies to substitute vestibular function and sustained visual fixation. During Substitution exercises individual need to perfomed eye head movement between target with a purpose of clear sighting during these tasks. Balance exercises consist of both static and dynamic balance exercises with weekly progression making balance exercises more challenging.
45776577|NCT04751006|Other|Balance Training|Participants performed balance training with saccade eye exercises.balance exercises included both static and dynamic balance exercises with a purpose of increasing mobility and stability of a posture by weekly progression. These exercises included standing on firm and foam surface with eyes open or close, heel stand, toe stand, marching on firm surface, forward and backward walking with normal base of support with weekly progression. Each task was performed for 5 repetitions with weekly progression in each task.
45776578|NCT05378334|Drug|ICI|PD-1 inhibitors selected by clinicians based on patients' condition
45776579|NCT05378334|Drug|Chemotherapy|AP regimen（Pemetrexed 500mg/m2+carboplatin AUC=5,q3w） for non-squamous cancer patientsor or TP regimen（Paclitaxel 175mg/m2+carboplatin AUC=5, or albumin paclitaxel 100mg/m2+carboplatin AUC=5,q3w）for Squamous cancer patients.
45776580|NCT05378334|Drug|Placebo|The particle size and color are similar to the HGXJT, and the smell and taste are close to the HGXJT, and the bacteria test is qualified
45776581|NCT05378334|Drug|Bone-protecting and Mass-dispersesing Decoction|Chinese Herbal Formula,also named as HGXJT
45776582|NCT01793636|Drug|AZD2014|AZD2014 vs Everolimus
45776583|NCT01793636|Drug|Everolimus|comparing PFS in patients treated with AZD2014 vs Everolimus
45776584|NCT05345418|Biological|Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency|Patients will receive two administrations at a dose of 1.5 million cells/kg patient bodyweight via the IV route with a 3-month intervening interval. A validated umbilical cord blood mesenchymal stem cells (UC-MSC) line was selected from the Vinmec Tissue Bank and cultured under xeno-free, serum-free and antibiotic-free conditions as previously described. To prepare UC-MSCs for therapy, aliquots of Passage 3 (P3) UC-MSCs will be thawed and cultured to P5 to get approximately 500 million cells and dispensed to 10 million UC-MSCs/ml/vial for cryopreservation. Upon request from the clinical team, aliquots of P5 UC-MSCs will be thawed in a temperature control water bath or incubator on the infusion day. The UC-MSCs will be washed and suspended in Ringer Lactate.
45776585|NCT00308282|Drug|LY2127399|30 mg, 60 mg or 160 mg, IV (in the vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
45776586|NCT00308282|Drug|Placebo|IV (in vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
45776587|NCT01659996|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
45915145|NCT04027647|Drug|Dacomitinib|30mg of oral dacomitinib is administered daily for one cycle. After one cycle, a toxicity assessment will be conducted. Subjects will then continue dacomitinib at either 30mg or 45mg.
45915146|NCT03993054|Behavioral|Cognitive behavioral stress management|The SmartManage CBSM intervention includes content that is of clinical relevance to sexual minority men dually diagnosed with HIV and cancer. Intervention content includes: co-management of HIV and cancer, strategies for self-advocacy, partnering with the health system and health providers, intimacy and disclosure concerns regarding both conditions, and contextual stressors (e.g., racial/ethnic minority status), stigmatization, assertiveness and communication skills, and self-efficacy in care coordination. Participants receive weekly 1.5 hour interactive group sessions online that focus on stress and self-management skill-building, and also receive access to didactic information regarding intervention content via the intervention website. Intervention length is 4 weeks.
45915147|NCT03993054|Behavioral|Culturally-tailored cognitive behavioral stress management|This intervention will be a version of SmartManage that is culturally-tailored for Latino populations.
45935650|NCT04711551|Combination Product|PRP and related devices to abtain platelet concentrate from whole blood, medullary and adipose tissue and related devices|PRP and related devices to abtain platelet concentrate from whole blood, medullary and adipose tissue and related devices
45448379|NCT03549832|Drug|Sofosbuvir|Sofosbuvir 400 mg oral pills
45448380|NCT03549832|Drug|Simeprevir|Simeprevir 150 mg oral pills
45448381|NCT03549832|Drug|Daclatasvir|Daclatasvir 60 mg oral pills
45448382|NCT03549832|Drug|Ribavirin|Ribavirin 200 mg oral pills
45448383|NCT03549832|Drug|Ombitasvir/paritaprevir/ritonavir|Ombitasvir/paritaprevir/ritonavir oral pills
45448384|NCT03548974|Behavioral|Treatment group 1|The ms-intakt/MOTOmed-intervention is a home-based program using the MOTOmed movement trainer: 12 week passive, motor-driven movement therapy followed by 12 weeks of intermittent active and passive training after the 3month assessment. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. Therapists aimed at eliciting a BORG Feedback of between 10 (fairly light) and 15 (hard). The exercise training was home-based and supervised via the internet.
45448385|NCT03548974|Behavioral|Treatment group 2|The subjects assigned to interventiongroup2 started with 12 weeks intermittent active and passive training followed by 12 weeks of no intervention (Wash out phase)
45638187|NCT03104387|Other|Diesel train|Exposure to air with high level of ultrafine particles (Diesel train)
45638188|NCT03104465|Behavioral|Mindfulness Training|interactive. web-based mindfulness training complemented with mobile application
45638189|NCT03102359|Drug|Dexmedetomidine|Using dexmedetomidine at anesthesia induction and maintain until the end of the surgery
45638190|NCT03102359|Device|Cooling Helmet|Using cooling helmet for selective head cooling group and Selective Head Cooling and Dexmedetomidine group
45638191|NCT03104231|Other|three-dimensional (3D) movie|Brief VR-3D will be shown using the oculus glasses and a smartphone. Then, patients will be asked several questions from the prepared questionnaire.
45776588|NCT01659996|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
45776589|NCT01659996|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate|0.5 mL, Intramuscular
45776590|NCT00309140|Drug|enzastaurin|500 milligrams (mg), oral, daily, six 42-day cycle and subsequent cycles or until participants met study discontinuation criteria of progressive disease or unacceptable toxicity
45448386|NCT03548272|Procedure|Percutaneous Coronary Intervention with stent implantation|PCI with BiOSS LIM C or rDES depending on the randomization
45776591|NCT05395806|Other|Health App|The intervention will include training health teams and patients in accessing and using a gamified health App 2-3 times a week. The App is based on a gamified character that improves its health if a patient checks its App, complies with her therapy, does regular exercise, and introduces normal levels of blood pressure, lipids level, and HbA1c levels. On the other hand, the character gets sick if the patient does not comply with her therapy or does not achieve certain levels of physical activity (i.e. 30 min moderate exercise 5 times a week or 2.5 hs a week or more than 9000 steps/day).
45776592|NCT05395806|Other|Usual Care|In this group, participants will receive their usual cardiovascular care according to the national guidelines. All patients receive free care at the primary care clinics and also receive free medications prescribed according to the national guidelines at the clinics. In addition, participants in this group will receive specific written information to improve their medication compliance, level of physical activity, blood pressure, HbA1c, and lipids level control.
45776593|NCT00353522|Drug|Placebo|po daily for 24 weeks
45776594|NCT00353522|Drug|dalcetrapib|900mg po daily for 24 weeks
45776595|NCT05597046|Other|Interview|Interviews
45776596|NCT05595486|Other|Baby2Home Mobile Application|Baby2Home is a digital health intervention designed to bridge the resultant gaps in obstetrics and pediatrics healthcare services for new families over the first year of life.
45776597|NCT05376774|Other|Admitted to intensive care units|Admitted to intensive care units
45776598|NCT00310076|Drug|thalidomide|Patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
45776599|NCT00310076|Procedure|surgery|Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy
45776600|NCT05540028|Biological|IVT PCV-25|25 valent pneumococcal conjugate vaccine
45776601|NCT05540028|Biological|PCV 20|20 valent pneumococcal conjugate vaccine
45776602|NCT05540028|Biological|PCV 13|13 valent pneumococcal conjugate vaccine
45448387|NCT02134834|Drug|OP0595|Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
45448388|NCT02134834|Drug|Placebo|Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
45448389|NCT05577052|Radiation|Metastatic vertebrae treated with SBRT|High-dose SBRT treatment
45776603|NCT05344716|Device|Laser|Intraurethral and vaginal laser treatment
45776604|NCT00353834|Drug|Exenatide|Exenetide 5ug twice daily for 4 weeks, then 10ug twice daily for 8 weeks
45935651|NCT05562271|Radiation|low-dose radiation therapy|low-dose radiation therapy to involved knee joint
45448390|NCT03548194|Drug|BNC210|BNC210 300 mg b.i.d
45448391|NCT03548194|Drug|Placebo|Placebo b.i.d.
45448392|NCT02140528|Biological|Mesenchymal stem cell injection|Injection of adipose derived mesenchymal stem cell in the site of tibia fracture .
45448393|NCT02140528|Biological|Placebo|
45448394|NCT02134990|Drug|Oshadi D and Oshadi R|Anti cancer agents
45448395|NCT02134990|Drug|Docetaxel|Chemotheraphy
45448396|NCT02140606|Drug|Cafusertib Hydrochloride|Drug: Cafusertib Hydrochloride (d1 and 15) Cafusertib (d1 and 15 - one hour iv.v) Drug: Cytarabine Cytarabine 2 x 20 mg/d s.c. d1-15.
45448397|NCT05576818|Drug|Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers|Two sachets daily of synbiotic preparation containing Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers
45448398|NCT02260960|Dietary Supplement|Omega-3 (Triglyceride form)|
45638192|NCT03104309|Device|Levonorgestrel intrauterine system|Levonorgestrel intrauterine system for adenomyosis
45638193|NCT03832049|Biological|9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses|0.5mL intramuscular dose - 3 doses (0, 2 and 6 months)
45638194|NCT03832049|Biological|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses|0.5mL intramuscular dose - 2 doses (0 and 6 months)
45776605|NCT00353834|Drug|Glargine Insulin|Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve a fasting glucose of 100mg/dl and avoid hypoglycemia.
45776606|NCT05344404|Dietary Supplement|Nicotinamide Riboside|3000mg total daily. Administered in capsule form in doses of 1500mg twice daily for the duration of the trial (4 weeks).
45776607|NCT05344404|Dietary Supplement|Placebo|Placebo drug. Administered in tablet form twice daily for the duration of the trial (4 weeks).
45776608|NCT00354224|Drug|capecitabine|
45776609|NCT00354224|Drug|oxaliplatin|
45776610|NCT05539716|Device|PAP Therapy|Auto-PAP device (ResMed AirsenseTM Autoset) with a heated humidifier will be provided along with an appropriate mask and connecting hose for nightly use
45935652|NCT05562271|Radiation|sham radiation therapy|sham radiation therapy to involved knee joint
45776611|NCT05539716|Behavioral|Lifestyle Counseling Intervention|Lifestyle intervention will include counseling on (a) education on nutrition and exercise; and (b) behavioral support for identifying lifestyle change strategies and problem-solving barriers to improve the regularity and duration of sleep. This will be conducted using brochures on weight loss and sleep hygiene
45776612|NCT05395260|Drug|FL-101|FL-101 200mg IV
45776613|NCT00310310|Behavioral|Sleep Apnea Self-Management Program|Sleep apnea self-management program - 4 sessions, group-based.
45776614|NCT00310310|Behavioral|Usual care|Usual sleep apnea and cpap care
45776615|NCT01792388|Dietary Supplement|Vitamin D|Capsule Form
45776616|NCT01792388|Dietary Supplement|Soya Bean oil|Capsule form
45776617|NCT05395104|Drug|Midazolam|Syrup for oral administration
45638195|NCT03832049|Biological|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose|0.5mL intramuscular dose - 1 doses (0 months)
45776618|NCT05395104|Drug|Cefiderocol|Liquid for IV infusion
45776619|NCT05394558|Drug|AsiDNA|Administration of AsiDNA followed by radiotherapy
45776620|NCT01793870|Drug|Tab carvedilol 25 mg|Carvedilol 25 mg immediate release tablet
45776621|NCT01793870|Drug|Tab carvedilol 6.25 mg|Carvedilol 6.25 mg immediate release tablet
45776622|NCT01793870|Drug|Powder carvedilol up to 2.5 mg|Carvedilol up to 2.5 mg isotopically enriched drug substance powder
45776623|NCT01793948|Drug|metformin hydrochloride|Given PO
45776624|NCT01793948|Other|placebo|Given PO
45915148|NCT03988257|Dietary Supplement|Imunoglukan PH4|Children allocated to experimental group will receive Imunoglukan PH4 syrup (10 mg of pleuran and 10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day in the morning, before the first meal, until signs of AGE subside (< 3 stools / 24 hours and normalization of stool consistency - grade 2-5 according to Bristol Stool Form Scale) or until the 14th day of the intervention.
45776625|NCT01793948|Other|laboratory biomarker analysis|Correlative studies
45776626|NCT04623320|Diagnostic Test|euglycaemic clamp test|clamp test (golden standard) to determine insulin resistance
45638196|NCT02281175|Behavioral|Psychosocial intervention|Based on a cognitive-behavioral approach, the psychosocial intervention (PASSE-65+) is specifically designed to help older BZD users to better manage their withdrawal symptoms, to stop their medication, and to improve their general psychological well-being
45776627|NCT04623320|Diagnostic Test|13C glucose breath test|13C glucose breath test to compare with the golden standard
45776628|NCT05342298|Other|prediction model|Data will be pre-processed prior to final analysis, including data cleaning, imputation of missing values, dimensionality reduction, and removal of outliers. Data will be utilized as Xi and Yi where Xi presents input (features) and Yi presents dependent variables (outcomes). Different classification algorithms will be tested for accuracy to build the final model including logistic regression, SVM, XGboost and random forest algorithms. Data will be split at 0.8:0.2 for model training and testing, respectively.
45776629|NCT05394402|Drug|SHR0410 Injection|SHR0410 Injection
45776630|NCT05394402|Drug|Placebo for SHR0410 Injection|SHR0410 Injection blank preparation
45776631|NCT04256850|Behavioral|Acceptance and Commitment Therapy (ACT)|Teaches acceptance, mindfulness, and values-based skills
45776632|NCT04256850|Behavioral|Self-Regulation (SR)|Teaches monitoring and reinforcement strategies designed to improve motivation and adherence to positive weight loss behavioral prescriptions.
45915149|NCT03988257|Dietary Supplement|Placebo (vitamin C syrup)|Children allocated to control group will receive a placebo: a vitamin C syrup (10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day in the morning, before the first meal, until signs of AGE subside (< 3 stools / 24 hours and normalization of stool consistency - grade 2-5 according to Bristol Stool Form Scale) or until the 14th day of the intervention.
45915150|NCT03957954|Biological|cLSC|Transplantation of cLSC
45915151|NCT03957954|Device|Scleral contact lens (SCL)|Scleral contact lens device (SCL) will be used to stabilize and improve ocular surface.
45915152|NCT03945357|Drug|Gemcitabine/ clindamycin|Comparison of saline solution rinse vs antibiotic rinse
45638197|NCT02281175|Behavioral|a weekly physician intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
45638198|NCT02102477|Procedure|Prostatectomy/Surgery|Radical prostatectomy with or without adjuvant or salvage radiotherapy
45638199|NCT02102477|Other|Radiotherapy with adjuvant androgen deprivation therapy|Radiotherapy with adjuvant androgen deprivation therapy
45776633|NCT05535270|Diagnostic Test|Oxford Depression Questionnaire (ODQ)|"The Oxford Depression Questionnaire (ODQ)is a patient-centered questionnaire. The scale contains three sections: i) the patient's experience in the past week; ii) the patient's experience before the illness worsened, and iii) the patient's emotional feelings about receiving antidepressant treatment. The 26-item questionnaire contains four dimensions of emotional blunting: not caring (NC), emotional detachment from others (ED), reduction in positive emotions (RP), and general reduction in emotions (GR). Patients not taking antidepressants were only required to rate the first two sections ."
45776634|NCT05374434|Other|Conventional irrigation|The participant will be treated by manual irrigation with sodium hypochlorite NaOCl.
45776635|NCT05374434|Device|Inertial cavitation|The participant will be treated by inertial cavitation-generating device, that generates hydraulic cavitation to clean root canals deeper and more effectively than other existing systems.
45776636|NCT05374200|Other|Mind-body intervention with 1-1 support from study personnel|"The multicomponent intervention will consist of the following core components: (1) A choice between three different types of low-intensity, mindful movement videos - chair fitness, standing fitness, or standing tai chi (15-30 minutes/session); (2) Breathwork and theme-of-the-week based mindfulness meditations (5-10 minutes/session); (3) A once weekly positive psychology/behavior change activity presented as a point-and-click interactive storybook within the online site; (4) A once weekly disease management tip from a PBC physician.~Weekly brief (~10-minute) motivational interview style telephone check-ins taking place during the intervention period will be conducted by a member of the study team. During these check-ins, progress will be reviewed, motivation provided, and questions answered."
45915153|NCT03945357|Drug|Normal saline|Comparison of saline solution rinse vs antibiotic rinse
45935653|NCT05562232|Dietary Supplement|Creatine Monohydrate|Follows
45915154|NCT03937128|Behavioral|Virtual Reality Job Interview Training|Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout the training.
45915155|NCT03937128|Behavioral|Services as usual|Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
45915156|NCT03913221|Drug|Caffeine Citrate 5 mg/kg|Loading dose of caffeine 20 mg/kg IV followed by two daily doses of 5 mg/kg IV.
45638200|NCT03104153|Procedure|Early-drain removal|Drain removal at hospital discharge
45776637|NCT05393310|Other|post isometric relaxation|The therapist will apply Post isometric relaxation ensure that foot will not actually move and only a static muscle contraction apply and held for 20 seconds. This will be followed by 2-3 second of relaxation, and then the foot passively stretched to dorsiflexion up to the palpated barrier and/or tolerance to stretch. This will continue until no further gains achieved 2 sets of 5 repetitions a day for 3 days a week for 4 weeks
45915157|NCT03913221|Drug|Caffeine Citrate 10 mg/kg|Loading dose of caffeine 20 mg/kg IV followed by two daily doses of 10 mg/kg IV.
45915158|NCT03903549|Drug|[18F]P17-059|Injection of < 10 mCi [18F]P17-059 followed by PET/CT scanning
45915159|NCT03869736|Drug|Nitrous Oxide|1-hour sessions of inhaled nitrous oxide at concentrations of 25% or 50% (randomly assigned) to be administered weekly for 4 weeks.
45915160|NCT03869736|Drug|Placebo|1-hour sessions of inhaled oxygen-air mixture (inspired oxygen concentration ~23-30%) to be administered weekly for 4 weeks.
45638201|NCT04482413|Drug|AstroStem|Treatment group receive AstroStem(Autologous adipose tissue derived mesenchymal stem cells, AdMSCs) every 4 weeks from Week 0 to Week 36.
45776638|NCT05393310|Other|MWM group|MWM group will receive inferior tibiofibular, talocrural, or cubometatarsal MWM 2-8 treatment sessions over 4 weeks.
45776639|NCT00310466|Biological|Sublingual immunotherapy|once daily intake of sublingual drops
45776640|NCT00310466|Biological|Placebo|once daily intake of sublingual drops
45776641|NCT00355394|Drug|Metoclopramide|Intravenous bolus administration.
45776642|NCT00355394|Other|Placebo|Standard care including intravenous fluid, but no metoclopramide.
45776643|NCT00355706|Procedure|Thoracic facet joint nerve blocks|Thoracic medial branch blocks
45776644|NCT00311246|Drug|Adalimumab|Subjects will give themselves a dose of Adalimumab at 40 mg/every week by subcutaneous injection for a total of 45 weeks.
45776645|NCT02105246|Behavioral|Referral to home-based cardiac rehab|Home-based cardiac rehab is a 12 week, home-based lifestyle intervention that includes counseling regarding heart healthy lifestyle changes.
45776646|NCT02105246|Behavioral|Referral to center-based cardiac rehab|Center-based cardiac rehab is a health center-based cardiac rehabilitation program that involves counseling in healthy heart behaviors and exercise delivered in a clinical setting.
45776647|NCT01792466|Procedure|Transpancreatic sphincterotomy|A sphinctertome will be placed into the pancreatic duct over a guidewire and the sphincter will be cut in the direction of the bile duct
45776648|NCT02105324|Device|Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
45915161|NCT03786081|Drug|Tisotumab Vedotin|Given into the vein (IV)
45915162|NCT03786081|Drug|Bevacizumab|Given via IV
45915163|NCT03786081|Drug|Pembrolizumab|Given via IV
45638202|NCT04482413|Drug|Placebo|Placebo control group receive 20 mL of Saline and auto serum every 4 weeks from Week 0 to Week 36.
45638203|NCT03103997|Procedure|EUS-guided liver biopsy|EUS-guided liver biopsy using needles with various preparations
45638204|NCT04435223|Biological|biological assays in particular on the lipid metabolism|bioassays carried out on samples already collected and conserved
45776649|NCT02105324|Other|Usual Care|As a comparator control, usual diabetes camp care with the participant's own insulin pump.
45915164|NCT03786081|Drug|Carboplatin|Given via IV
45915165|NCT03782259|Drug|dapagliflozin|Subjects will either receive 10mg tabs of dapagliflozin or identical looking placebo - inactive medication. Subjects have an equal chance of receiving dapagliflozin or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects nor the Study Site personnel will know which treatment subjects are assigned to. The study drug must be taken daily. The subject's other medications will not be changed by the study.
45915166|NCT03782259|Other|Placebo|Placebo
45915167|NCT03741933|Drug|Apremilast 30mg|Apremilast 30 mg tablet
45915168|NCT03598530|Procedure|Surgery|Surgical fracture fixation, using osteosynthesis, including single or multiple staged procedures (e.g. primary External Fixation and later conversion to internal fixation).
45915169|NCT03584646|Device|Nokia GO Wearable StepTracker|All participants will be provided with a Nokia GO step tracker to monitor daily step counts. The device is not subject to FDA regulation.
45915170|NCT03584646|Other|Medication Reminder|Medication reminders are sent to participants in Arm 2 on a daily basis.
45915171|NCT03584646|Other|Weekly Check-in appointment with study team or provider|Virtual meeting or telephone call between participants and study team to assess study involvement, adherence to procedures, and following of medical care recommendations.
45915172|NCT03408717|Other|Questionnaires|Questionnaires including Pain catastrophizing scale (PCS), Central Sensitisation Inventory (CSI), Coping Strategies Questionnaire-Revised (CSQ-R), Brief Symptom Inventory-18 (BSI-18), Perceived Stress Scale (PSS), EQ-5D-3L and Eysenck Personality Questionnaire (EPQ) will be administered to the patient.
45935654|NCT04730505|Device|MyHOPE™ for Multiple Myeloma|The MyHOPE for MM Platform is designed to provide patients with tools and resources to support them in their overall experience with MM. Patients can share their data through a PDF or by showing their device to their care team at clinic visits.
45638205|NCT04412603|Other|Conventional Mirror Therapy|The Conventional Mirror Therapy was carried out with a mirror box and the Mirror Therapy Virtual Reality was carried out with virtual reality glasses and mobile application: Mirror Therapy VR.
45638206|NCT03817229|Behavioral|Education microlearning sessions|mHealth education microlearning sessions
45638207|NCT03817229|Behavioral|Automated digital reminders|reminders from electronic monitors based on texts or lights/chimes
45638208|NCT03817229|Behavioral|Problem-solving mHealth module|mhealht problem solving module with 2 telehealth sessions with a therapist
45638209|NCT03817229|Behavioral|Individualized Adherence Feedback Report|Individual Adherence Feedback reports sent to parents weekly
45776650|NCT02105558|Drug|Epidural anesthesia|"￼An epidural involves injecting pain-blocking medication into a space between the vertebrae and the spinal fluid; it usually takes about 15 minutes to work.~Epidurals will be placed in a sterile fashion using a 17g Tuohy needle to locate the epidural space via loss-of-resistance to saline at the lumbar vertebral level. 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine will then be used for test dose to exclude intrathecal or intravenous placement of the catheter. Epidural solution composed of 5ml of 0.2% ropivacaine and another 5 ml of 0.2% ropivacaine will then be administered."
45776651|NCT02105558|Drug|Combined spinal and epidural anesthesia|"A spinal is an injection directly into the spinal fluid; it is given in addition to the epidural technique and takes effect in five minutes.~The epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr."
45776652|NCT00312884|Device|HomMed Telemonitoring System|The HomMed telemonitoring system allows for patients to monitor their weight, blood pressure, oxygen saturation and symptoms of dyspnoea on a daily basis from their home
45638210|NCT03103685|Drug|Clopidogrel|The patient s in experimental arm will not be ask to stop P2Y12 inhibitor such as Clopidogrel, Prasugrel or Ticagrelor
45915173|NCT03408717|Other|Mechanical Temporal Summation assessment|A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.
45915174|NCT03408717|Other|Pain threshold assessment|Pressure is applied 90 degree straight down force on the subject's right/left centre of the trapezius muscle using an algometer, with a speed of pressure ~ 1kgf/s. The above procedure is then repeated 3 times at each site (left/right) which is indicated on the pressure mark with each time having the reading recorded. When patient shows no response ≥ 6kgf, the threshold is recorded as 6kgf. The patient upon feeling pain will say stop or raise the hand to terminate the test. The mean value is obtained by averaging the readings and will then be recorded as the threshold estimate.
45776653|NCT02106728|Behavioral|Multi-Family Therapy|Multi-Family Therapy is conducted once per week over the course of 8 weeks for 1.5 hours per session. Therapy is provided to a minimum of 3 families and a maximum of 6 families with the aid of two to three therapist group leaders. Group topics are set and cover material on eating disorder psychoeducation, care-giving styles, meal support, and relapse prevention.
45776654|NCT02106728|Behavioral|Supportive Family Therapy|Supportive Family Therapy is treatment as usual in the eating disorders program at TGH. Families meet independently with a therapist once per week for 1 hour per session. The length of the therapy and the topics of therapy are decided upon collaboratively with the therapist and the family.
45776655|NCT02106962|Drug|Topical Tranexamic Acid 5% with bacitracin|Selected participants received a fixed amount of tranexamic acid 5 %and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
45776656|NCT02106962|Other|Topical Tranexamic Acid 25% with bacitracin|Selected participants received a fixed amount of tranexamic acid 25%and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
45915175|NCT03385239|Drug|ISIS 678354|ISIS 678354 solution for SC injection.
45915176|NCT03385239|Drug|Placebo|Sterile Normal Saline (0.9% NaCl).
45915177|NCT03079401|Biological|MPC; rexlemestrocel-L|MPCs will be injected into the patient's myocardium during planned surgical procedures.
45915178|NCT03073395|Drug|[68Ga]P16-093|Imaging by Positron Emission Tomography after iv injection of [68Ga]P16-093
45915179|NCT03020160|Drug|Emicizumab|Emicizumab will be administered according to dose and schedule described in respective arms. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol Version 5 (20-Dec-2019), treatment duration was extended. During this study prolongation, participants had the opportunity to switch to a preferred emicizumab dosing regimen (1.5 mg/kg weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks) in order to provide them the same flexibility as with commercial product.
45915180|NCT03002259|Drug|Dexamethasone|Dexamethasone administered as a single IV injection after induction of anaesthesia, but before initiation of CPB. Prepare as a 20 mg/mL dexamethasone solution, made up with 0.9% saline to 10 ml.
45915181|NCT03000387|Drug|Nicotine Patch|Active nicotine patch of 21 mg, 14 mg and 7 mg
45638211|NCT00999011|Procedure|once daily mobility activity|in bed and out-of-bed activity including range of motion, chair sitting, sitting at edge of bed without weightbearing, standing, walking.
45915182|NCT03000387|Drug|Placebos|Matching placebo patches of 21 mg, 14 mg and 7 mg
45915183|NCT00387504|Drug|fenretinide|4-HPR (Fenretinide) is given as a continuous intravenous infusion (CIV) for five consecutive days. Cycle is repeated every 3 weeks, if PR, CR or stable disease for 6 cycles.
45915184|NCT00387504|Other|pharmacological study|samples drawn per protocol
45638212|NCT00999011|Procedure|twice daily mobility activity|as with once daily. Goal is to progress intensity and duration of activity over time as patient condition improves for both arms
45638213|NCT03748433|Device|Dexcom G6 CGM|Commercially available Dexcom G6 Continuous Glucose Monitoring
45638214|NCT03748433|Device|Tandem t:slim X2 Insulin Pump|sensor augmented insulin pump with predictive low glucose suspend
45638215|NCT03103529|Other|Active Rehabilitation|
45638216|NCT00540995|Drug|busulfan|Given IV
45638217|NCT00540995|Drug|etoposide|Given IV
45915185|NCT02936505|Drug|Cyclosporine|"Cyclosporin A (Sandimmun Neoral® or similar):~Cyclosporin A given orally pretransplant in the dose of 2-3 mg/kg.~Continued postop day 1 in the dose of 3mg/kgx2, according to local practice and blood concentration: 0-3 months 250-300; 3-6 months 200-250; 6-12 months 150-200; >12 months 100-150 ng/ml. Cyclosporine A will be administered twice daily."
45776657|NCT00315146|Drug|Pioglitazone|
45915186|NCT02936505|Drug|Mycophenolate mofetil (MMF)|"MMF target dose: 2000 mg/day (1gx2):~o Controlled by a single Area Under the Curve (AUC) measurement day 90 with a target AUC between 40 and 60 mg.h/L and corrected accordingly."
45638218|NCT00540995|Radiation|intensity-modulated radiation therapy|Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
45638219|NCT00540995|Procedure|allogeneic hematopoietic stem cell transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
45638220|NCT00540995|Procedure|allogeneic bone marrow transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
45638221|NCT00540995|Procedure|peripheral blood stem cell transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
45638222|NCT00540995|Radiation|tomotherapy|Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
45638223|NCT03103607|Diagnostic Test|Ophthalmological evaluation|exophthalmometry, evaluation of the Clinical Activity Score (CAS), assessment of diplopia, measurement of visual acuity, assessment of the corneal status; examination of the fundi
45638224|NCT03103607|Diagnostic Test|Questionnaire|Patients were asked to fill a questionnaire on self-perception related to GO with the following questions: i) are your eyes identical to the way they were before GO appeared?; ii) are your eyes normal? iii) do you have any limitations in daily activities related to your eyes?; iv) do you have any limitations in social life related to your eyes?
45638225|NCT00418301|Other|Precision Spinal Cord Stimulation and PET Scan|Imaging procedure to assess spinal Cord Stimulation.
45638226|NCT03101969|Other|Call|not called, not reached, and spoken to
45638227|NCT03103451|Drug|BCD-121|
45776658|NCT00315146|Behavioral|Resistance exercise training to maximize muscle power|
45776659|NCT00315146|Behavioral|Hypocaloric diet|
45638228|NCT03103451|Other|Placebo|
45638229|NCT03103295|Biological|3D-Tissue Engineered Bone Equivalent|Administrated for operative delivery of 3D-Tissue Engineered Bone Equivalent
45638230|NCT05103215|Drug|Lidocaine HCl 2%|Intravenous injection of 1.5 mg/kg lidocaine at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
45638231|NCT05103215|Drug|Normal saline|Intravenous injection of 1.5 mg/kg normal saline at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
45638232|NCT03656159|Behavioral|Cognitive-Behavioral group therapy|Intervention will consist of eight weekly sessions of two hours each with a break of 15 minutes. The CBT will be delivered by a clinical psychologist and a clinical neuropsychologist previously trained in this therapeutic approach.
45638233|NCT03656159|Behavioral|Non directive support Group|Intervention will consist of eight weekly sessions of two hours each with a break of 15 minutes. The support group will be delivered by Ph.D. students having no experience with CBT.
45638234|NCT05001815|Device|Continuous subcutaneous insulin infusion (CSII)|The CSII device used in this study has access to mobile phone, however, without CGM enhanced function
45638235|NCT05001815|Device|Multiple daily insulin injection (MDI)|Patients with indication will receive MDI treatment with at least one basal insulin injection plus 2 to 3 prandial insulin injection.
45638236|NCT02644967|Drug|IMO-2125|Drug: IMO-2125 Intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 17, 23, and 29.
45638237|NCT02644967|Drug|Ipilimumab|4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 2, 5, 8, and 11.
45638238|NCT04435535|Procedure|PEP|Positive expiratory pressure 10 cmH2O 15 min
45638239|NCT04964453|Drug|BI 474121|BI 474121
45776660|NCT00315146|Drug|Placebo|
45776661|NCT04462562|Diagnostic Test|Quantitative US (Samsung Medison, RS85A)|In each patients, measurements of tissue attenuation imagine (TAI), tissue scatter-distribution imaging (TSI) parameters, hepatorenal index (EzHRI) will be performed
45776662|NCT04428164|Other|The Richards-Campbell Sleep Questionnaire (R-CSQ)|"Tool developed to assess patient satisfaction and comfort in the hospital setting.~The R-CSQ is a scale used to measure different aspects of sleep quality. This scale allows the patient to rate their quality and amount of sleep on a scale of 0-100. The R-CSQ allows the patient to rate six different components of their sleep, including sleep depth, sleep latency, awakenings, returning to sleep, sleep quality, and noise."
45776663|NCT04428164|Other|Revised American Pain Society Outcome Questionnaire (APS-POQ-R)|The APS-POQ-R can be utilized to measure perceived levels of pain in patients. The APS-POQ-R scale is a validated scale that is used in the hospital setting with reliable and consistent results. This scale measures five aspects of a patient's perception and experiences with pain and a sixth aspect including nonpharmacological interventions.
45776664|NCT01792544|Other|Statement|
45776665|NCT01792544|Other|No Statement|
45776666|NCT01792700|Drug|esomeprazole|
45776667|NCT01792700|Drug|tripotassium dicitrate bismuthate|
45776668|NCT01792700|Drug|metronidazole|
45776669|NCT01792700|Drug|tetracycline|
45776670|NCT01792700|Drug|moxifloxacin|
45776671|NCT01792700|Drug|amoxicillin|
45776672|NCT00315302|Drug|Atropine|Atropine 1% once each weekend day
45776673|NCT00315302|Device|Plano Lens|Plano lens for the sound eye
45915187|NCT02936505|Drug|Rabbit Anti thymocyte globulin|Induction therapy: Thymoglobulin® (Rabbit Anti thymocyte globulin)(1.5 mg/kg given immediately postoperatively).
45776674|NCT00315614|Biological|Islet Transplantation and Bone Marrow|Islet transplantation and CD34 Bone Marrow infusion in subjects with type 1 diabetes.
45776675|NCT01792778|Device|ViaValve Safety IV Catheter|Insertion of the peripheral intravenous catheters into both upper extremities of subjects
45638240|NCT04964453|Drug|Placebo|Placebo matching BI 474121
45776676|NCT01792778|Device|Insyte Autoguard BC [Blood Control] Shielded IV Catheter|
45776677|NCT04389242|Other|REST Online（Reduce Stress Tour Online）|Different cognitive behavioral skills are introduced and practiced in a 8 weekly online program, which includes animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, online assessment and reminder. One face-to-face session and one telephone follow-up provided by an experienced CBT therapist are also provided to clients.
45776678|NCT01794026|Procedure|diffusion weighted magnetic resonance imaging|for diagnostic purposes, diffusion weighted magnetic resonance imaging in all patients
45776679|NCT00316862|Drug|cisplatin|Given IV
45776680|NCT00316862|Drug|irinotecan hydrochloride|Given IV
45776681|NCT00316862|Procedure|therapeutic conventional surgery|Undergo Surgery
45776682|NCT00316862|Radiation|radiation therapy|Undergo radiation
45776683|NCT00317720|Drug|Trastuzumab|"Loading dose = 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle.~If participant on trastuzumab at time of registration, loading dose deferred and received maintenance dose (6 mg/kg every 3 weeks). If the last trastuzumab dose was given 1 week (for participants receiving 2 mg/kg/week), or 3 weeks before registration (for participants receiving 6 mg/kg every 3 weeks), a loading dose (8 mg/kg) was given followed by maintenance dose."
45915188|NCT02936505|Drug|Corticosteroids|"Corticosteroids:~Day 0 (day of lung transplantation); 500+500mg methylprednisolone iv. before reperfusion, i.e. restoration of blood flow into the transplanted allograft.~From day 1: Initiated at 0.2 mg/kg/day; tapered to 0.1 mg/kg 3-6 months; less than 0,1 mg/kg > 6 months."
45638241|NCT04945109|Other|Mankai beverage|Recommended background healthy diet with Mankai supplementation after main meal (300 ml)
45638242|NCT04945109|Other|Water (control)|Recommended background healthy diet with water supplementation after main meal (300 ml)
45638243|NCT04896749|Other|Nerve mobilization|"Moist pack all over cervical spine for 10 minutes. TENS for 10 minutes at frequency of 60 Hz with 2 electrodes. Cervical traction for 10 minutes with 7 sec hold and 5 sec rest time. Cervical isometric exercises with 7 sec hold and 30 repetitions in each direction twice a day.~Median, ulnar and radial nerve stretch with 3 sets of 10 repetitions , with 3 sec hold at final stretched position.~Following nerve mobilizations are used in experimental group/group A:~Median Nerve: Glenohumeral abduction, wrist extension, supination, glenohumeral lateral rotation, elbow extension, neck lateral bending to opposite side. Radial Nerve: Glenohumeral depression, elbow extension, whole arm internal rotation, wrist flexion Ulnar Nerve: Wrist extension, forearm pronation elbow flexion, glenohumeral lateral rotation, glenohumeral depression, shoulder abduction each with 3 sets of 10 repetitions , with 3 sec hold at final stretched position."
45638244|NCT04896749|Other|Conventional physical therapy|Moist pack for 10 minutes. TENS for 10 minutes at frequency of 60 Hz with 2 electrodes. Cervical traction for 10 minutes with 7 sec hold and 5 sec rest time. Cervical isometric exercises with 7 sec hold and 30 repetitions in each direction twice a day.
45776684|NCT00317720|Drug|RAD001|Starting dose 10 mg by mouth daily. Phase I dose finding from two dose levels of daily RAD001 (5 and 10 mg).
45776685|NCT00357032|Drug|belinostat|Given IV
45776686|NCT00357032|Other|laboratory biomarker analysis|Correlative studies
45776687|NCT00357734|Drug|Gefitinib|ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
45776688|NCT01791842|Drug|Tocilizumab|8 mg/kg/month
45776689|NCT01791842|Drug|Placebo|
45915189|NCT02936505|Drug|Tacrolimus|"Tacrolimus should be given orally pretransplant in the dose of 0.1 mg/kg.~Continued postop day 1 according to local practice and blood concentration: 0-3 months 10-14, 3-6 months 8-12, 6-12 months 8-10, >12 months 6-8 ng/ml. Tacrolimus will be administered once daily."
45638245|NCT04890821|Device|CI Percutaneous Ring Annuloplasty System|Percutaneous transcatheter implant and adjustment of the CI ring annuloplasty system.
45638246|NCT03594383|Device|ULTRASOUND|Lung ultrasound done through POCUS to diagnose pneumonia
45638247|NCT04771637|Drug|Dexmedetomidine|The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrolyte and quality of recovery of the patients
45638248|NCT04771637|Drug|Dexmedetomidine|The loading dose with 1.0 μg/kg, maintenance dose with 0.25 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology and quality of recovery of the patient
45776690|NCT01791998|Procedure|magnetic resonance thermal imaging|Undergo MR-thermal image guided LITT
45776691|NCT01791998|Procedure|laser interstitial thermal therapy|Undergo MR-thermal image guided LITT
45776692|NCT00318812|Drug|Heme Iron Polypeptide (Proferrin)|Heme iron polypeptide 11mg po tid for 6 months
45776693|NCT00318812|Drug|Iron sucrose (Venofer)|Iron sucrose infusion IV q month x 6 months
45915190|NCT02931903|Other|Vita Enamic (hybrid dental ceramic)|Vita Enamic (hybrid dental ceramic) are provided as blocks to be milled using Computer aided design/Computer aided manufacturer (CAD/CAM) technology,
45915191|NCT02931903|Other|lithium disilicate glass-ceramic|All ceramic crowns (Lithium disilicate glass ceramic) milled by Computer aided design/Computer aided manufacturer (CAD/CAM) technology
45915192|NCT02851758|Other|autologous mitochondria transplantation|Autologous mitochondria obtained from the subject's own skeletal muscle will be injected or infused into the ischemic myocardium
45915193|NCT02793921|Behavioral|Moderate-Intensity Aerobic Exercise Intervention|The intervention is moderate-intensity aerobic exercise. Walking on a motorized treadmill will be the encouraged mode of exercise; however participants may use other equipment or home exercise. Participants will begin by exercising 10-15 minutes for 3 days/week during the first 2 weeks and gradually increase the duration for the following 4 weeks until they reach 40-50 minutes per session/3 days per week. This level is then maintained for the remainder of the 6 months. The rate of increase will be tailored based on baseline cardiorespiratory fitness and response to exercise. All sessions start and end with a vital sign check (in-person) and 5-10 minutes warm-up/cool-down. Trained exercise physiologists will supervise all exercise sessions and closely monitor adherence, intensity, and safety when sessions are completed in-person, or through regular communication when home-based exercise is warranted (due to COVID-19).
45638249|NCT04771637|Drug|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology and quality of recovery of the patients
45915194|NCT02648997|Drug|Nivolumab - 240 mg|240 mg every 2 weeks
45915195|NCT02648997|Drug|Ipilimumab - 1 mg/kg|1 mg/kg every 3 weeks
45915196|NCT02648997|Drug|Nivolumab - 480 mg|480 mg once every 4 weeks
45915197|NCT02648997|Drug|Nivolumab - 3 mg/kg|3 mg/kg every 3 weeks
45776694|NCT02109458|Device|Navigation guided bronchoscopy|Navigation guided transthoracic needle aspiration (N-TTNA) and navigation guided bronchoscopy (NB); guidance system is by Veran Medical Technologies, Inc.
45776695|NCT00319748|Drug|852A|0.2% 852a subcutaneous injection, 2 times per week for 12 weeks (24 doses) starting at 0.6 mg/m2; subsequent dose escalation for additional courses may be increased by 0.2 mg/m2 not to exceed 1.2 mg/m2.
45776696|NCT01794260|Drug|Cream from Zingiber cassumunar Roxb. extract|
45638250|NCT04771637|Drug|Normal saline|Normal saline is used to observe the effect on the electrophysiology and quality of recovery of the patients
45776697|NCT01794260|Drug|Placebo cream|
45776698|NCT00361712|Procedure|Preemptive epidural analgesia|Parturients will receive early epidural analgesia before onset of painful contractions as oppose to standard of care in which parturients receive epidural analgesia with onset of painful contractions.
45776699|NCT00361712|Drug|Standard of care|Epidural analgesia with parturients with cervical dilatation and painful labor (VAS >5)
45776700|NCT04008056|Other|Patient Reported Outcome questionnaire|34 question form to assess patient symptoms
45776701|NCT03710096|Device|macGrath|in the mac grath group we use the videolaryngoscope macGrath as first-line for the insertion of double lumen tube
45776702|NCT03710096|Device|Macintosh's|in the macintosh group we use the laryngoscope with Macintosh's blade as first-line for the insertion of double lumen tube
45915198|NCT02648997|Radiation|External Beam RT|IMRT, 3D-CRT, or proton-beam radiation therapy
45915199|NCT02593110|Behavioral|Supervised Treadmill Exercise Therapy|Participants randomized to the exercise intervention will receive supervised treadmill exercise three times weekly for six months.
45915200|NCT02593110|Drug|Telmisartan|Participants randomized to the telmisartan arm of the study will take 20 mg or 40 mg of telmisartan daily based on the results of their study run-in. Participants will have their dose increased to up to 80 mg as tolerated.
45638251|NCT04751591|Procedure|Endoscopic resection|Endoscopic submucosal dissection (ESD) or endoscopic full-thickness resection (EFTR) for patients with 2-5cm gastric GISTs
45776703|NCT03993002|Other|Normoxia with Normocarbia|PaO2 < 100 (FiO2 >= 21%) PaCO2 of 30-40
45776704|NCT03993002|Other|Normoxia with Hypercarbia|PaO2 < 100 (FiO2 >= 21%) PaCO2 of 50-60
45776705|NCT03993002|Other|Hyperoxia with Normocarbia|PaO2 > 250 (FiO2 >= 70%) PaCO2 of 30-40
45776706|NCT03993002|Other|Hyperoxia with Hypercarbia|PaO2 > 250 (FiO2 >= 70%) PaCO2 of 50-60
45776707|NCT00362882|Drug|docetaxel|Given IV
45776708|NCT00362882|Drug|bortezomib|Given IV
45638252|NCT04751591|Procedure|Laparoscopic partial gastrectomy|Laparoscopic partial gastrectomy for patients with 2-5cm gastric GISTs
45638253|NCT04731389|Behavioral|internet-based cognitive-behavioral therapy|Composed of 4 modules: the first module will address psychoeducation on dermatillomania, self-monitoring of symptoms and habit reversal techniques; the second module works with anxiety coping techniques (diaphragmatic breathing and muscle relaxation); module 3 addresses cognitive correction techniques, such as stopping thinking, analyzing evidence, reassigning severity and responsibilities; the last module reviews the techniques learned and addresses techniques for preventing symptom relapse. The modules will be applied by the patient in an online format, each module lasts an average of 30 minutes. The platform will send notice by email through automation tools, SMS or message by application to patients to remind them to complete 1 module per week.
45776709|NCT00362882|Other|laboratory biomarker analysis|correlative study
45776710|NCT00362882|Other|immunoenzyme technique|correlative study
45776711|NCT00362882|Other|immunohistochemistry staining method|correlative study
45776712|NCT00362882|Other|pharmacological study|correlative study
45776713|NCT05578326|Drug|Trilaciclib|240 mg/m2 intravenous, over 30 minutes at day 1 of each cycle
45776714|NCT05578326|Drug|Lurbinectedin|3.2 mg/m2, over 60 minutes at day 1 of each cycle
45776715|NCT05577312|Drug|BRL-101|BRL-101 autologous hematopoietic stem and progenitor cells injection
45776716|NCT05532384|Behavioral|Early resumption of oral intake|as above
45776717|NCT05532384|Behavioral|Late resumption of oral intake|as above
45776718|NCT05389488|Device|OsciPulse system|The OsciPulse system is a pneumatic compression system designed to provide intermittent compression to the limbs to augment venous blood flow.
45776719|NCT05389488|Device|Flowtron ACS900|The Arjo Flowtron ACS900 intermittent pneumatic compression system provides compression the calf to augment venous blood flow.
45776720|NCT05339568|Other|Patients' whole process follow-up and management platform|Patients' whole process follow-up and management platform is a software for the patients and investigators. This platform will use to collect patients' information when they are out of patients and will provide the patients' education materials.
45776721|NCT00365144|Biological|bevacizumab|
45638254|NCT04731389|Behavioral|Quality of life improving intervention|consisting of videos with guidance on quality of life, with a total of 4 videos of 2 minutes, each being made available in 1 week, consisting of: guidance on sleep hygiene; guidance on healthy eating; guidelines on the practice of physical activity and guidelines on the excessive use of social networks.
45638255|NCT03588377|Device|Pulse Oximetry|"Intervention clusters:~On LHW's regular visits to households of their catchment area, they will daily screen for severe pneumonia and check oxygen level in blood using a pulse oximeter in all under <5 children with symptoms of cough or difficulty breathing~Case definition:~Birth - 6 days: Fast breathing +/- Low oxygen in blood <92% (Hypoxemia)~7 days - 59 months: Fast breathing and/or Chest In-drawing + Any one danger sign: (Low oxygen in blood <92% (Hypoxemia), Refusing to eat, Vomiting continuously, Convulsions, Lethargy/ Unconsciousness, Stridor."
45776722|NCT00365144|Drug|erlotinib hydrochloride|
45638256|NCT03103217|Behavioral|brief CBT for anxious pregnant women|one off 3 hour session including psychoeducation, exploration of cognitions and experiential practice of behavioural techniques.
45776723|NCT00365144|Other|laboratory biomarker analysis|
45638257|NCT04166591|Behavioral|Overheard Speech|New words are introduced with the child as a bystander rather directly taught.
45776724|NCT05339022|Other|Best Practice|Receive standard of care
45915201|NCT02593110|Other|"No exercise control group"|Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months.
45915202|NCT02593110|Drug|Placebo|
45915203|NCT02373813|Drug|etanercept pre-filled syringe subcutaneous injection|etanercept for injection in pre-filled syringes
45915204|NCT02373813|Drug|Oral methotrexate|"During the open-label run-in period, methotrexate will be provided as 2.5 mg tablets.~During the double-blind treatment period, methotrexate will be provided as 2.5 mg capsules."
46070261|NCT00652093|Drug|opana then darvocet then placebo|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
46070262|NCT00652093|Drug|opana then placebo then darvocet|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
45915205|NCT02373813|Drug|Placebo for etanercept subcutaneous injection|etanercept placebo for injection in pre-filled syringes
45915206|NCT02373813|Drug|Placebo for methotrexate|methotrexate placebo capsules
46070263|NCT00652093|Drug|placebo then opana then darvocet|Placebo tablet tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
46070264|NCT00652093|Drug|Placebo then darvocet then opana|Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
45638258|NCT04166591|Behavioral|Addressed Speech|New words are introduced directly to the child by an experimenter.
45638259|NCT03103373|Device|Conventional monitor|Patients underwent non-cardiac surgery will be monitoring by regular monitors
45638260|NCT03103373|Device|Echocardiography|Patients will be monitoring by regular monitors plus echocardiography
45638261|NCT04695041|Drug|PBI-4050/ Placebo|Participants receive either 800mg PBI-4050 capsules or placebo, twice a day for 14 days
45638262|NCT04695041|Drug|PBI-4050/ Placebo|Participants receive either 1200mg PBI-4050 capsules or placebo, once a day for 14 days
45776725|NCT05339022|Other|Exercise Intervention|Undergo exercise intervention
45776726|NCT05339022|Procedure|Physical Therapy|Undergo physical therapy
45776727|NCT05339022|Other|Quality-of-Life Assessment|Ancillary studies
45776728|NCT05339022|Other|Questionnaire Administration|Ancillary studies
45776729|NCT05339022|Procedure|Relaxation Therapy|Undergo progressive muscles relaxation exercises
45776730|NCT00365768|Drug|Glutamine|Administered orally twice daily for 21 days
45776731|NCT00365768|Other|Placebo|Administered orally twice daily for 21 days
45776732|NCT05336994|Dietary Supplement|Multivitamin/mineral supplement A|Oral administration of Supplement A
45915207|NCT02373813|Dietary Supplement|Folic acid (non-investigational product)|Folic acid 5 to 7 mg per week as per investigator judgment or according to local standard of care.
45638263|NCT04695041|Drug|PBI-4050/ Placebo|Participants receive either 1000 mg PBI-4050 capsules or placebo, twice a day for 14 days
45776733|NCT05336994|Dietary Supplement|Multivitamin/mineral supplement B|Oral administration of Supplement B
45776734|NCT05372640|Drug|Abemaciclib|Given PO
45776735|NCT05372640|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
45776736|NCT05372640|Procedure|Biopsy|Undergo biopsy
45776737|NCT05372640|Procedure|Diagnostic Imaging|Undergo imaging evaluation
45776738|NCT00366626|Drug|Naltrexone|Naltrexone (25 mg/day for days 1-2 and 50 mg/day for days 3-7)
45776739|NCT00366626|Drug|Placebo|Placebo for 7 days matched to Naltrexone
45776740|NCT00367016|Drug|Omalizumab|Xolair (Omalizumab) will be given by subcutaneous injection according to Ige level and weight calculation.
45638264|NCT04695041|Drug|PBI-4050/ Placebo|Participants receive either 1200 mg PBI-4050 capsules or placebo, twice a day for 14 days
45638265|NCT04695041|Drug|PBI-4050/ Placebo|Participants receive either 800 mg PBI-4050 capsules or placebo, three times a day for 14 days
45638266|NCT04626869|Other|Evaluation of Diaphragm Movement|Diaphragmatic movement will be evaluated with ultrasonography and a 5-2 MHz convex transducer will be used. The ultrasound probe is placed between the mid-clavicular line and the anterior axillary line by directing it vertically and slightly cranially. During quiet breathing and deep breathing, diaphragm movement will be measured. The reduction in diaphragm motion will be calculated as the difference (in percent) in diaphragm motion measured before and 30 minutes after the block. Each test will be done 3 times and the values will be averaged. A decrease between 75% and 100% will be defined as complete paresis, a decrease between 25% and 75% as partial paresis, and less than 25% decrease in diaphragmatic movement will be defined as no paresis. In order to investigate the effect of continuous local anesthetic drug administration on diaphragm movement via nerve catheter, the same procedure will be repeated 24 hours after surgery.
45638267|NCT04435145|Behavioral|Sugar-sweetened beverage warning label|A sugar-sweetened beverage warning label appropriate for the college-aged population was developed and applied to beverage stations at one large campus dining hall
45638268|NCT04435301|Device|DC-Stimulator, NeuroConn, Germany|Neurostimulation device
45638269|NCT03471221|Behavioral|Therapy Dog Visit|"Animal Assisted Activities (AAA) provide opportunities for motivational, educational, recreational, and/or therapeutic benefits to enhance quality of life. AAA are delivered in a variety of environments by specially trained professionals, paraprofessionals, and/or volunteers, in association with animals that meet specific criteria.~Key features of AAA are as follows:~Specific treatment goals are not planned for each visit.~Volunteers and treatment providers are not required to take detailed notes.~Visit content and activities are spontaneous.~Visit length can be as long or as short as needed."
45638270|NCT03464669|Other|Prenatal education|Observational study : natural distribution of participants between groups
45638271|NCT05244863|Other|Test|Measurements
45776741|NCT00367016|Drug|Placebo|Placebo, given by subcutaneous injection.
45776742|NCT05372250|Other|Measurement of the diaphragmatic excursion according to the position of the body by ultrasound|Measurement of the diaphragmatic excursion according to the position of the body by ultrasound
45638272|NCT03449069|Drug|MSC-AFP|Patients will have a mesenchymal stromal cell coated anal fistula plug placed in their Crohn's perianal fistula tract.
45776743|NCT04422678|Drug|Imatinib Mesylate|Adding treatment by imatinib oral tablet into the standard treatment for moderate to severe COVID-19 pneumonia.
45776744|NCT04422678|Drug|Standard of Care|Standard of Care for the Moderate to Severe COVID-19 Pneumonia as per the Egyptian National Protocol by the Ministry of Health.
45776745|NCT01794416|Procedure|Thoracoscopic epicardial ablation|
45776746|NCT01794416|Procedure|Endocardial catheter ablation|
45915208|NCT02324907|Device|Procedure/Surgery|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
45915209|NCT01959204|Drug|Oxycodone|Pain
45915210|NCT01853748|Drug|Trastuzumab|
46070265|NCT00652093|Drug|Darvocet then opana then placebo|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
45653051|NCT04517279|Behavioral|Invest in My Recovery Bank|The intervention has not be fully developed. It will be created in partnership with individuals serving in peer provider roles.
45776747|NCT01794416|Device|Implantable loop recorder|
45776748|NCT05371314|Diagnostic Test|P/FP ratio|PaO2/FiO2 X PEEP, SpO2/FiO2 X PEEP
45776749|NCT05370768|Behavioral|Parenting Mindfully Intervention|Includes meditation and using meditation and mindfulness in everyday life and in parenting interactions.
45776750|NCT00587886|Behavioral|Questionnaire|The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.
45776751|NCT00587886|Behavioral|Questionnaire|"The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.~We will conduct interviews mainly by telephone but also in person (at home or another convenient place)if the participant prefers."
45915211|NCT01853748|Drug|Paclitaxel|
45915212|NCT01853748|Drug|Trastuzumab emtansine|
45915213|NCT03795870|Dietary Supplement|Polymeric Tube Feeds|Polymeric tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with blenderized tube feeds
45915214|NCT03795870|Dietary Supplement|Blenderized Tube Feeds|Blenderized tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with polymeric tube feeds
45915215|NCT04712331|Other|Graduated abdominal strengthening exercises|"Graduated abdominal strengthening exercises~In this study the following equipments will be used to achieve treatment approaches:~Exercise mat and inflatable Swiss ball 55 cm & 65 cm diameter. Wall bar, wedges, elastic tubing (Thera-band) with resistance ranges from light to very heavy (yellow, red, blue, green, and gray colors)."
45915216|NCT04712331|Device|The Russian current stimulation|The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation.
45915217|NCT04712331|Other|Combination Product: Graduated abdominal strengthening exercises and the Russian current stimulation|"Graduated abdominal strengthening exercises and the Russian current stimulation~In this study the following equipments will be used to achieve treatment approaches:~Exercise mat and inflatable Swiss ball 55 cm & 65 cm diameter. Wall bar, wedges, elastic tubing (Thera-band) with resistance ranges from light to very heavy (yellow, red, blue, green, and gray colors).~The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation."
45915218|NCT00734838|Device|High Resolution Microendoscope|Using core biopsy and reduction mammoplasty tissue
45915219|NCT00006045|Biological|lintuzumab|
45638273|NCT03101735|Drug|Dimethyl Fumarate (DMF)|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
45915220|NCT00006045|Drug|cytarabine|
45915221|NCT00006045|Drug|etoposide|
45915222|NCT00006045|Drug|mitoxantrone hydrochloride|
45915223|NCT00006048|Drug|cisplatin|
45915224|NCT00006048|Drug|gefitinib|
45915225|NCT00006048|Drug|gemcitabine hydrochloride|
45915226|NCT00006051|Drug|cisplatin|
45776752|NCT00573378|Drug|PEG-IFN-a2b|Patients will receive pegylated interferon α-2b (Pegintron®) (PEG-IFN-α2b) 150 µg subcutaneously, once a week. Patients and/or caregivers identified by the patient will be taught how to perform subcutaneous injections of the PEG-IFN-α2b by trained nurses in the chemotherapy infusion center at the University of Michigan Comprehensive Cancer Center. Those patients who do not feel comfortable receiving the injections outside of the cancer center, or are deemed unreliable in administering injections per the training nurse, will return to the cancer center infusion room on a weekly basis to receive subsequent injections.
45776753|NCT05334654|Drug|Enoxaparin Sodium|Enoxaparin will be subcutaneously administered at a dosage from 4000 to 8000 twice daily according
45776754|NCT05334654|Drug|Bivalirudin|Bivalirudin will be intravenously administered to obtain an activated prothrombin time (aPTT) of 1.5 fold of the normal values.
45776755|NCT03561584|Drug|Sulfasalazine|Patients will be initiated on a low dose of sulfasalazine (500 mg) twice daily (bid). Dosage will be increased throughout the study.
45776756|NCT03561584|Drug|Placebo|Patients will be initiated on 1 placebo tablet twice daily (bid). Dosage will be increased throughout the study.
45915227|NCT00006051|Drug|fluorouracil|
45915228|NCT00006051|Radiation|radiation therapy|
45915229|NCT00006054|Drug|anti-thymocyte globulin|
45915230|NCT00006054|Drug|busulfan|
45915231|NCT00006054|Drug|cyclophosphamide|
45915232|NCT00006054|Drug|cyclosporine|
45638274|NCT03446027|Device|NMES|NMES device to be used for up to 3 hours daily in 30 minute sessions for 3 months.
45638275|NCT04482179|Device|Active TMS|Active TMS will be delivered at 100% motor threshold
45638276|NCT04482179|Behavioral|CILT|60-90 minutes of CILT will be administered during each treatment session
45638277|NCT04482179|Device|Sham TMS|Sham TMS will be administered
45638278|NCT05244707|Behavioral|Mediterranean style diet|The intervention will consist of an intensive food and nutrition intervention program to improve adherence to the Mediterranean dietary pattern. In addition to individual and face-to-face nutrition consultations, other strategies will be used, such as telephone contacts, short text messages, consultation support tools, podcasts, short open access videos, nutrition workshops and nutrition sessions for caregivers of participants in the study.
45638279|NCT05244707|Behavioral|Standard of care|The usual care group will only have access to face-to-face and individual nutrition consultations in order to improve adherence to the Mediterranean dietary pattern.
45638280|NCT04479995|Behavioral|Horizon Program|Telehealth videoconferencing sessions and questionnaires.
45776757|NCT00389610|Biological|GVAX pancreas vaccine|Given intradermally
45776758|NCT00369512|Drug|Erlotinib|Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
45915233|NCT00006054|Drug|etoposide|
45915234|NCT00006054|Drug|methotrexate|
45915235|NCT00006054|Drug|methylprednisolone|
45915236|NCT00006054|Drug|prednisone|
45915237|NCT00006054|Procedure|Allogeneic Bone Marrow Transplantation|
45915238|NCT00006060|Drug|standard gadolinium contrast|
45915239|NCT00006063|Drug|pancrelipase with bicarbonate|
45915240|NCT00006066|Biological|Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed|
45915241|NCT00006066|Biological|Diphtheria and Tetanus Toxoids Adsorbed|
45915242|NCT00006066|Biological|Tetanus and Diphtheria Toxoids Adsorbed|
45915243|NCT00006066|Drug|Bacteriophage phi X 174|
45915244|NCT00006066|Drug|Aldesleukin|
45915245|NCT00006072|Drug|Rituxan|
45915246|NCT00006075|Drug|Chlorhexidine gluconate|
45915247|NCT00006078|Dietary Supplement|lycopene|
45915248|NCT00006081|Drug|Bryostatin-1|40 mcg/m2 one-hour infusion 24 hours after each dose of paclitaxel (i.e., day 2, 9, 16).
45915249|NCT00006081|Drug|Paclitaxel (Taxol)|80 mg/m^2 one-hour infusion weekly x 3 every 4 weeks
45915250|NCT00006084|Biological|lintuzumab|
45915251|NCT00006087|Procedure|annual screening|
45915252|NCT00006087|Procedure|bronchoscopic and lung imaging studies|
45915253|NCT00006087|Procedure|comparison of screening methods|
45915254|NCT00006087|Procedure|computed tomography|
45915255|NCT00006087|Procedure|radiography|
45915256|NCT00006087|Procedure|study of high risk factors|
45915257|NCT00006090|Drug|arsenic trioxide|
45915258|NCT00006093|Drug|cilengitide|
45915259|NCT00006096|Drug|cisplatin|
45638281|NCT04479995|Behavioral|Usual Care|Standard medical visits with additional paper or electronic booklet.
45638282|NCT05244317|Device|cast|the cast of the upper limb from just below elbow joint to the knuckle of fingers
45776759|NCT05368350|Device|Transcranial direct current stimulation|"Other Names:~tDCS~1 milliamp tDCS High definition tDCS High definition transcranial direct current stimulator, Neuroelectrics Starstim tES, SN E20200930-10 Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds."
45638283|NCT05244317|Device|splint|Removable splint
45638284|NCT04479683|Other|FTH then DH support|"FTH output and DH relay one day a week until the minimum healthy weight. This treatment combines over one day a medical evaluation by a senior psychiatrist, family work (parents group and multi-family therapy session), a therapeutic education group, a cognitive remediation group and a dietary follow-up with therapeutic meals.~During this phase, all children are evaluated once a week on a somatic level."
45638285|NCT04479683|Other|standard care|continuation of full-time hospitalization until the minimum healthy weight is reached, defined as the weight corresponding to the return to the previous BMI corridor (previous BMI +/- 1 BMI corridor, e.g. change from 25th to 10th percentile). This management combines bi-weekly medical follow-up by a senior psychiatrist, weekly family work, weekly therapeutic education group, weekly cognitive remediation group and bi-weekly dietary follow-up with therapeutic meals.
45638286|NCT05244161|Behavioral|RMV-ECD|Combined radio messaging, video job aids (primarily for CHWs), Care for Childhood Development package
45638287|NCT05243927|Other|Aerobic exercise program|Aerobic exercise will be performed under the supervision of a physiotherapist with a treadmill during 40-60 minutes 3 days a week for 8 weeks
45638288|NCT05243927|Other|Spinal stabilization exercise program|Spinal stabilization exercises will be performed with a physiotherapist during 40-60 minutes 3 days a week for 8 weeks.
45776760|NCT03459482|Other|Food Elimination Diet|Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms
45776761|NCT05528484|Procedure|ERAS nursing|Patients were given education before surgery, fluid and anesthetic drug management during surgery, early ambulation, fluid management and early feeding after surgery, etc
45776762|NCT05528484|Procedure|non eras nursing|Patients were under the routine management without eras protocol
45776763|NCT05386134|Device|Adaptive Optics Retinal Camera|The rtx1 is a non-invasive device functions without making contact with the eye. The fundus of the patient's eye is illuminated with the IR light emitted from the illumination optical system. The device is comprised of an optoelectronic sensor (OES) that measures the optical defects, software that calculates the necessary corrections and a deformable mirror (DM) that constantly adapts its shape to restore the image's clarity. The digital camera, which is built into the instrument, receives the images and then the images are recorded in the computer hard disk. The AO image software registers and averages the captured image series in order to reduce noise and produce a final enhanced image. The rtx1 integrates AO technology in a flood illumination imaging system and enables visualizing the retina with a high transverse optical resolution of 250 line-pairs per millimeter.
45776764|NCT00324272|Drug|Fibrin Sealant (Tisseel) used in the Experimental Arm.|"For patients in the Experimental (Treatment) Arm, 4 ml of Tisseel fibrin sealant were instilled into the wound using the Duploject™ spray delivery system prior to wound closure. Tisseel™ fibrin sealant was provided by Baxter Healthcare Ltd., Newbury, Berkshire, UK.~For patients in the Active Comparator (Control) Arm, no fibrin sealant was used during wound closure (with the surgical procedure being identical in all other respects)."
45776765|NCT05332158|Behavioral|Questionnaires to report barriers to medication adherence|One questionnaire specific to DOACs and one specific to statins have been integrated within the medical records system and will be sent to eligible patients to respond to following written informed consent.
45776766|NCT00369590|Biological|ziv-aflibercept|Given IV
45776767|NCT00369590|Other|pharmacological study|correlative studies
45638289|NCT04961879|Procedure|Reversed Cross Finger Flap|"distal dorsal finger defect will be reconstructed by reversed cross finger flap~- reversed cross finger flap is a modified cross finger flap harvested from an adjacent finger ."
45638290|NCT04961879|Procedure|reversed island homo-digital flap|"distal dorsal finger defect will be reconstructed by reversed island homo-digital flap~- this flap is harvested from the same finger ."
45638291|NCT05243849|Device|Optical Coherence Tomography Angiography|Optical coherence tomography angiography (OCTA) is a novel non-invasive, non-dye and high-resolution imaging technique, allowing real-time quantitative evaluation of retinal vasculature and the structure of foveal avascular zone (FAZ).
45638292|NCT04937075|Other|No intervention|No intervention
45638293|NCT05243771|Procedure|Rectal resection with diverting stoma|Patients in this group will receive a rectal resection with an anastomosis and also a diverting stoma will be created
45638294|NCT05243771|Procedure|Rectal resection without diverting stoma|Patients in this group will receive a rectal resection with an anastomosis and no diverting stoma will be created
45638295|NCT05243771|Procedure|Rectal resection with permanent colostomy|Patients in this group will receive a rectal resection and a permanent colostomy will be created
45638296|NCT04701593|Drug|Triamcinolone Acetonide 40mg/mL|Sub-tenon irrigation 1cc
45638297|NCT05243693|Drug|Brentuximab vedotin|3 cycles of Brentuximab vedotin and DHAP
45638298|NCT05243459|Behavioral|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention away from threat face stimuli.
45638299|NCT05243459|Behavioral|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
45776768|NCT00369590|Other|laboratory biomarker analysis|correlative studies
45776769|NCT03367910|Drug|Fecal microbiota transplant|150mL of FMT product RBX2660 delivered via enema
45776770|NCT03932136|Dietary Supplement|Sulforaphane|Sulforaphane (SFN) is a natural compound extracts from cruciferous vegetables, especially broccoli, with cytoprotective, anti-inflammatory, and antioxidant effects.
45776771|NCT03932136|Combination Product|Placebo|The placebo is safe, with no therapeutical effect, and has same appearance and similar smell and taste with active tablet.
45776772|NCT00324350|Drug|hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents|type 2 diabetes treatments, per standard of care
45776773|NCT00390182|Drug|Gemcitabine|"Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.~Radiation:External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy.~**Radiation is the experimental part of the study."
45776774|NCT05366868|Drug|Imeglimin|Imeglimin 1000 mg orally twice daily in the morning and evening (2000 mg daily).
45776775|NCT05366868|Drug|Metformin|Metformin 500 mg orally twice daily in the morning and evening (1000 mg daily). However, until 2 weeks after the start of treatment, 250 mg should be administered orally twice daily in the morning and evening. Thereafter, after 4, 8, or 12 weeks, the dose may be increased up to 750 mg twice daily (1500 mg daily) if the physician determines that the hypoglycemic effect is inadequate.
45776776|NCT05366868|Drug|Vildagliptin|Vildagliptin 50 mg orally twice daily in the morning and evening (100 mg daily).
45776777|NCT01793246|Device|probe based laser endomicroscopy (pCLE)|pCLE will be added to standard bronchoscopy for the purpose of characterizing lung cancer or for characterizing of acute rejection in transplanted lungs.
45776778|NCT05366712|Device|Stryker Trident® II HA coated cementless acetabula component|New acetabula component.
45776779|NCT05366556|Behavioral|Virtual reality|"The patient, whose blood will be drawn, will be asked to wear virtual reality glasses after sitting in the blood collection chair. One minute before the start of the blood collection process, Nature Hiking will be watched from the virtual reality. Meanwhile, the researcher will complete the preparations for blood collection and will start the blood collection process. It is thought that the blood collection process takes 2-3 minutes on average. During this period, virtual reality will be applied. While blood is being drawn from the patient, the researcher will assess the patient's level of pain with the VAS during the procedure. After the blood draw is completed, the virtual reality glasses will be removed. Then, the patient will be taken to the waiting area and the state anxiety scale will be applied."
45776780|NCT00369746|Drug|citalopram|tablets, 60 mg maximum, daily, 12 weeks
45776781|NCT05366478|Drug|Autologous tumor infiltrating lymphocytes (TILs)|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients will be infused with LM103 Injection followed by IL-2.
45776782|NCT00392054|Procedure|Pulmonary Vein Isolation performed by Catheter Ablation|Ablation will be done to achieve entrance block into all pulmonary veins.
45776783|NCT00392054|Drug|Conventional Antiarrhythmic Drug Therapy|Anti-Arrhythmic Drugs per ACC/AHA 2006 Guidelines for the Management of Patients with AF
45776784|NCT02525874|Drug|dimethyl fumarate|Initial oral dose for 7 days with maintenance dose thereafter
45776785|NCT05288036|Other|Proprioceptive Neuromuscular Rehabilitation group|The PNF technique was performed in the supine position with the hip joints of the patients in 30° flexion and the lower extremities in semi-flexion. The application was performed in 2 different diagonal and 4 different patterns (flexion-abduction-external rotation/extension-abduction-internal rotation, and flexion-adduction-external rotation/extension-abduction-internal rotation) of the upper extremity. When starting the exercise, the muscles were first brought to their longest position and the patient was asked to move in the direction of the pattern with resistance (concentric contraction) and to maintain this position for 6 seconds at the end of the pattern (isometric contraction). Then, while the therapist was taking the patient's arm to the starting position, the patient was asked to prevent movement (eccentric contraction). All of these moves counted as one repetition. 3 sets of 8-12 repetitions were performed for each pattern.
45915260|NCT00006096|Radiation|radiation therapy|
45915261|NCT00006102|Drug|becatecarin|
45915262|NCT00006105|Drug|amifostine trihydrate|
45915263|NCT00006105|Drug|cisplatin|
45915264|NCT00006105|Drug|gemcitabine hydrochloride|
45915265|NCT00006105|Procedure|adjuvant therapy|
45915266|NCT00006108|Biological|trastuzumab|
45915267|NCT00006108|Drug|capecitabine|
45915268|NCT00006108|Drug|paclitaxel|
45915269|NCT00006111|Drug|cisplatin|
45915270|NCT00006111|Drug|fluorouracil|
45915271|NCT00006111|Procedure|conventional surgery|
45915272|NCT00006111|Radiation|radiation therapy|
45638300|NCT05243459|Behavioral|Non-Contingent Feedback Training|Participants listen to a musical track they chose while viewing the face matrices. The music is played throughout and is not contingent upon gaze behavior.
45915273|NCT00006114|Drug|mitoxantrone hydrochloride|
45638301|NCT05243225|Procedure|Laparoscopic versus open surgical management of post cholecystectomy bile duct injury|Comparison between laparoscopic and open surgical management of post cholecystectomy bile duct injury.
45638302|NCT04640987|Biological|Allogeneic Stem Cell Transplant|The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.
45638303|NCT04640987|Device|CliniMACS Prodigy System|Device used for production of T-allo10 cells.
45638304|NCT04640987|Drug|T-allo10 cells addback|T-allo10 cells are made by manipulating the participant's stem cell donor's white blood cells (CD4+ T cells) in the presence of their (participant's) CD14+ monocytes.
45638305|NCT02644343|Device|Custom Sound|Custom Sound is the programming software used to program Nucleus cochlear implants.
45638306|NCT04552847|Drug|Al18F-NOTA-octreotide|One intravenous injection of 4 MBq/kg
45638307|NCT04552847|Device|PET/CT|Patients in part A of the trial will undergo a whole-body PET/CT scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The CT-scan is a low-dose CT that will be acquired for both PET attenuation correction and anatomical information.
45638308|NCT04552847|Device|PET/MR|Patients in part B of the trial will undergo a whole-body PET/MR scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The MR scan is a fully diagnostic MR requiring intravenous contrast (Dotarem®) injection and Buscopan® administration to minimize bowel movement.
45638309|NCT05183321|Procedure|periodontal therapy|periodontal cleaning
45638310|NCT05167331|Drug|Nitrous Oxide inhalation|use of Nitrous Oxide inhalation on children's anxiety during a dental treatment
45638311|NCT05167331|Device|Dispositif de RV - HYPNO VR|use of Virtual Reality on children's anxiety during a dental treatment
45638312|NCT04509401|Drug|Vitamin B 6 with Magnesium|Patients of intervention group will receive high dose of vitamin B6 with magnesium. This group will receive high dose of vitamin B6 with magnesium orally for 12 weeks.
45638313|NCT04509401|Drug|placebo of vitamin B6 and magnesium|Patients of control group will receive oral placebo tablet in the same manner, schedule for 12 weeks.
45638314|NCT05155007|Drug|Rilematovir|Rilematovir will be administered orally as per assigned treatment sequence.
45638315|NCT05155007|Drug|Ciclosporin|Ciclosporin will be administered orally as per assigned treatment sequence.
45638316|NCT01641107|Drug|Ponatinib|"Treatment:~Patients will receive daily oral administration of Ponatinib at a dose of 45 mg/day for 6 weeks (defined as one course) for 8 courses, same dose and schedule, for a total of 48 weeks. Each patient will be followed for the subsequent 24 months, every 3 month, providing survival information and monitoring serious adverse event. Each patient should be treated for a minimum of 6 weeks. Patients must be discontinued from the trial in the event of myocardial infarction or stroke, or for development or progression of arterial disease necessitating revascularization. Once a complete hematologic response has been achieved, with a platelet count ≥ 50x109/L, patients can be treated with aspirin and/or a statin as clinically indicated, at investigator discretion."
45776786|NCT05288036|Other|Progressive Resistance Exercise Group|"Strengthening exercises targeting the upper extremity main muscles were applied to the PRE group with progressive resistance. Dumbbells and sandbags were used as resistance equipment. resistance intensity; 50-80% of a repetition maximum (RM) was determined according to the patient's tolerance. The exercises were applied as 8-12 repetitions and 3 sets. A rest period of 60-90 seconds was allowed between each set. After the 4th week of the training, 1 RM was measured again and the resistance density was updated. The 8 strengthening exercises to be applied were created by taking examples from the literature and in accordance with the Guidelines for implementing exercise programs exercise programs for cancer patients. These exercises are: dumbbell fly, triceps extension, biceps curl up, one-arm bent over row, dumbbell sides rise, lifting the arm forward, wrist curl and side lying shoulder internal -external rotation."
45776787|NCT05288036|Other|Control Group|The patients in the control group were instructed to continue their usual daily lives (not changing their physical activity levels, diet, drug use, etc.) until the date of re-evaluation after the initial evaluation. Information was given about the upper extremity normal range of motion exercises that they could apply at home, and a brochure was given.
45776788|NCT05287880|Diagnostic Test|Dynamic PET/CT|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FAPI intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained. And then underwent whole body static PET scan.
45915274|NCT00006114|Drug|vinorelbine tartrate|
45915275|NCT00006117|Drug|gemcitabine hydrochloride|
45915276|NCT00006117|Drug|oxaliplatin|
45915277|NCT00006120|Drug|docetaxel|
45915278|NCT00006120|Drug|paclitaxel|
45915279|NCT00006123|Biological|trastuzumab|
45915280|NCT00006123|Drug|carboplatin|
45915281|NCT00006123|Drug|carmustine|
45915282|NCT00006123|Drug|cisplatin|
45915283|NCT00006123|Drug|cyclophosphamide|
45915284|NCT00006123|Drug|thiotepa|
45638317|NCT04425317|Diagnostic Test|Blood sample|Blood sample and endometrial biopsy on the moment of oocyte retrieval
45915285|NCT00006123|Procedure|peripheral blood stem cell transplantation|
45915286|NCT00006126|Drug|busulfan|
45915287|NCT00006126|Drug|cyclophosphamide|
45915288|NCT00006126|Drug|etoposide|
45915289|NCT00006126|Drug|fludarabine phosphate|
45915290|NCT00006126|Procedure|peripheral blood stem cell transplantation|
45638318|NCT04411511|Other|Exposure to the Dutch measures due to the Covid-19 pandemic.|Several measures are taken in The Netherlands, due to the Covid-19 virus and pandemic. For example, closure of schools and sportclubs, and advices to stay at home as much as possible. During the pandemic, several measures also will be scaled down.
45638319|NCT03101423|Drug|Interleukin-2|On +60 day after transplantation,check patients with STR more than or equal to 90%. transplantat interleukin-2 treatment per month
45638320|NCT03101423|Drug|Donor Regulatory T-Lymphocytes|On +60 day after transplantation,check patients with STR less than 90%. Donor Regulatory T-Lymphocytes infusion (DLI) treatment per month
45638321|NCT04309799|Device|Tear Restore Mask|The Tear Restore Mask will be used for 10 minutes
45915291|NCT00006126|Radiation|radiation therapy|
45915292|NCT00006129|Drug|testosterone|
45776789|NCT05287880|Diagnostic Test|Dynamic PET/CT|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FAPI intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained. And then underwent whole body static PET scan.
45776790|NCT05329662|Biological|Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency|"Patients in the two groups will receive two autologous AD-MSC administrations: the group A on day 0 and day 90 ± 7; the group B on day 180 ± 14 and day 270 ± 14.~Dose: 1.0 x 106 cells/kg patient bodyweight.~Route: intravenous infusion~ADSCs were collected after the third passage. On the day of transplantation, the ADSCs were harvested, washed twice with NaCl 0.9%, counted and resuspended in NaCl 0.9% in a total volume of 20 ml. Each participant received a dose of 1x10^6 cells/kg body weight infused through the intravenous route within 30 minutes before being discharged after 24 hours"
45776791|NCT05287802|Other|Balance and proprioception exercises|Balance and proprioception exercises using two different methods (classical balance training and Biodex) in addition to strengthening exercises
45638322|NCT05073029|Other|nutrition program and modification of physical activity|nutrition program developed by a gastroenterologist-nutritionist and modification of physical activity (8000-10000 steps daily)
45638323|NCT05073029|Dietary Supplement|synbiotic (Fructooligosaccharides+Lactobacillus rhamnosus GG ATCC 53103, 4.0х109 colony forming units - CFU)|one synbiotic sachet (3g), BID, for 3 month traetment
45638324|NCT05073029|Dietary Supplement|vitamin D3|vitamin D3, oral, 2000IU BID, for 3 month treatment
45638325|NCT02644109|Dietary Supplement|Phytosterol|"Day 1: Anthropometry, laboratory test, dietary intake (24 hour recall and food frequency questionnaire) and presence of symptoms and side effects will be determined, a logbook will be provided to record product consumption, symptoms, medications and side effects. Then will be randomly assigned to one of the groups.~Days 7 & 21: 24 hour recall, review of symptoms, side effects and adherence as registered in the logbook.~Days 15 & 30: Anthropometry, vital signs, venous blood sample, review of symptoms, side effects and adherence to intervention as registered on logbook, dietary intake (24-hour recall), delivery of monetary compensation proportional to the study days will be given before being discharged."
45638326|NCT02644109|Dietary Supplement|Placebo|"Day 1: Anthropometry, laboratory test, dietary intake (24 hour recall and food frequency questionnaire) and presence of symptoms and side effects will be determined, a logbook will be provided to record product consumption, symptoms, medications and side effects. Then will be randomly assigned to one of the groups.~Days 7 & 21: 24 hour recall, review of symptoms, side effects and adherence as registered in the logbook.~Days 15 & 30: Anthropometry, vital signs, venous blood sample, review of symptoms, side effects and adherence to intervention as registered on logbook, dietary intake (24-hour recall), delivery of monetary compensation proportional to the study days will be given before being discharged."
45638327|NCT05072951|Diagnostic Test|Urine Biomarker for Kidney Transplant Rejection|Biomarker for active kidney transplant rejection.
45638328|NCT04145843|Procedure|endoscopic retrograde cholangiopancreatography|ERCP is a procedure that enables the physician to examine the pancreatic and bile ducts and remove gallstones.
45776792|NCT05287802|Other|Home exercises program|Isometric exercises for the quadriceps and hamstrings at home
45776793|NCT05329428|Dietary Supplement|Vitamin D Supplementation 20 µg/day|At a routine visit at the antenatal care in early pregnancy (gestational week <15) women will be provided with with vitamin D3 (cholecalciferol) supplements. Two tablets, with a total content of 20 µg (800 IE), are taken daily throughout pregnancy.
45776794|NCT05329428|Dietary Supplement|Vitamin D Supplementation 40 µg/day|At a routine visit at the antenatal care in early pregnancy (gestational week <15) women will be provided with with vitamin D3 (cholecalciferol) supplements. Two tablets, with a total content of 40 µg (1600 IE), are taken daily throughout pregnancy.
45776795|NCT05329428|Other|Usual Antenatal Care|In early pregnancy (gestational week <15) women are advised by the regular midwife to take a daily supplement of Vitamin D throughout pregnancy, according to usual antenatal care routines.
45776796|NCT01794572|Drug|Melphalan|Melphalan: 140 mg/m²is infused intravenously in 30 minutes on day -2 after IV anti-emetics (5-HT3 antagonists).
45776797|NCT01794572|Biological|Autologous Hematopoietic Stem cell|"Autologous Peripheral Stem Cell Rescue : 2.5 10^6 CD-34/Kg are re-infused in the central line on day 0 after adequate premedication."
45776798|NCT05385666|Other|collaborative cares|coordinate care between city medicine and specialized psychiatric care to improve the management of common mental disorders
45638329|NCT02642159|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
45776799|NCT01794650|Dietary Supplement|Meal composition|
45776800|NCT05365776|Behavioral|Graded Exposure Therapy|Graded exposure therapy is delivered by a psychologist over 12 individual (1:1) secure videoconference sessions. The core active ingredient is graded situational exposure to foster habituation and challenge beliefs that the avoided activities are dangerous. Homework exercises involve planned exposure exercises in the home and community to support generalization.
45776801|NCT05365776|Behavioral|Prescribed aerobic exercise|Participants will be asked to complete 30 minutes of aerobic exercise on 5 days/week for a 12-week period. Participants select the mode (e.g., swimming, jogging, bicycling) and location of exercise (e.g., outdoors, a gym or community centre, at home). The initial exercise intensity target will be based on the Buffalo Concussion Bike Test. The target progression will be 3-5 beats per minute every two weeks.
45776802|NCT05365776|Other|Enhanced usual care|Usual care (education about concussion from the website: concussion.vch.ca/) will be enhanced through text message support.
45776803|NCT05364684|Drug|LUM-201|LUM-201 (ibutamoren mesylate) is an oral growth hormone secretagogue.
45915293|NCT00006132|Drug|acyclovir|
45638330|NCT02642159|Drug|Statins|Statins at stable dose without other LMT as clinically indicated.
45638331|NCT02642159|Drug|Ezetimibe|Pharmaceutical form: tablet Route of administration: oral
45638332|NCT02642159|Drug|Fenofibrate|Pharmaceutical form: tablet Route of administration: oral
45638333|NCT02642159|Drug|Nicotinic acid|Pharmaceutical form: tablet Route of administration: oral
45638334|NCT02642159|Drug|Omega-3 fatty acids|Pharmaceutical form: tablet Route of administration: oral
45915294|NCT00006135|Drug|acyclovir|
45915295|NCT00006144|Drug|Lopinavir/Ritonavir|
45776804|NCT05385432|Drug|Rabbit Anti thymocyte globulin (rATG)|The infusion of rTAG (Thymoglobulin® (1.5mg/kg/day, maximum daily dose: 100 mg)) starts just after the randomization pre-operatively on a functional arteriovenous fistula or a high-flow venous catheter during 3 to 7 days until efficient tacrolimus level is obtained.
45776805|NCT05385432|Drug|Basiliximab|Simulect® IV 40mg D0 and D4
45776806|NCT00392444|Drug|sunitinib malate|Given orally
45776807|NCT02528214|Drug|Dupilumab|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
45776808|NCT02528214|Drug|Placebo|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
45915296|NCT00006144|Drug|Emtricitabine|
45776809|NCT02528214|Drug|Oral corticosteroid therapy (prednisone/prednisolone)|Oral administration.
45776810|NCT02528214|Drug|Inhaled corticosteroid (ICS) therapy|Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy).
45776811|NCT02528214|Drug|Albuterol/Salbutamol|Oral inhalation as needed.
45776812|NCT02528214|Drug|Levalbuterol/Levosalbutamol|Oral inhalation as needed.
45776813|NCT00392678|Drug|Salsalate|Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided
45776814|NCT00392678|Drug|Placebo|Placebo to Salsalate
45776815|NCT05610540|Device|TECNIS Synergy IOL|Implanted in one eye
45776816|NCT05610540|Device|AcrySof PanOptix Trifocal IOL|Implanted in one eye
45776817|NCT05902312|Device|transcranial magnetic stimulation|Participants will receive either rTMS or dTMS
46070266|NCT00652093|Drug|Darvocet then placebo then opana|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
45915297|NCT00006144|Drug|Stavudine|
45915298|NCT00006153|Biological|HIV-1 Immunogen|
45915299|NCT00006159|Behavioral|lifestyle (exercise, diet, and family and community support)|
45915300|NCT00006162|Behavioral|exercise and diet|
45915301|NCT00006165|Behavioral|'Ohana (Family) Support Lifestyle Intervention|
45915302|NCT00006168|Drug|Methotrexate|
45915303|NCT00006174|Drug|Letrozole|
45915304|NCT00006180|Drug|Alendronate|
45915305|NCT00006183|Procedure|Cardiopulmonary Bypass with Two Different Intra-Operative Hematocrits|
45915306|NCT00006183|Procedure|Thoracic Surgery|
45915307|NCT00006186|Procedure|Autologous fresh whole blood|
45915308|NCT00006195|Drug|risperidone|
45776818|NCT05902299|Drug|Antibiotic|Evaluate the choice of antibiotic therapy prescribed for P. aeruginosa ou S. aureus infection
45776819|NCT05902286|Behavioral|OSC+|The first session of the HRVB intervention will focus on introducing the client to HRVB and calculating the participant's resonance frequency which typically range from 4.5-7 breaths per minute. Participants will first complete a five-minute baseline breathing condition. Following the breathing condition, the participants will complete five conditions for five minutes each. Specifically, each condition will have the person breath at 6, 6.5, 5.5, 5, and 4.5 breaths per minute with a minute break between. Session two will focus on practicing resonance frequency breathing and solidifying the correct resonance frequency for the participant. Additionally, this session will introduce the technique of breathing through pursed lips and abdominal breathing. For sessions three through five, participants will practice resonance frequency breathing and review previous strategies.
45776820|NCT05902286|Behavioral|OSC-|During the first week, the baseline will be assessed and resonance frequency. Specifically, during their first intervention session the participants will be told that the goal of the sessions includes decreasing heart rate variability and avoiding slow and steady breathing. The participants will then be asked to choose five strategies to lower their heart rate oscillations. Participants will be told to avoid slow breathing as it causes large heart rate oscillations. For the second session, the therapist will check in with the participant and discuss how the practice went. Participants will then select three strategies that they will practice for three five-minute conditions following a five-minute baseline. Sessions three, four, and five will include three conditions: a five-minute baseline and two strategies of their choice. For each session, the best strategy will be calculated and written on the assignment sheets to be used during the week for their four homework sessions.
45915309|NCT00006195|Drug|olanzapine|
45915310|NCT00006198|Drug|thalidomide|
45915311|NCT00006198|Procedure|chemoembolization with doxorubicin/collagen|
45915312|NCT00006204|Drug|naltrexone (Revia)|
45915313|NCT00006204|Drug|fluoxetine (Prozac)|
45915314|NCT00006207|Drug|PRO 2000|
45915315|NCT00006213|Drug|BMS-214662|Given IV
45915316|NCT00006213|Other|pharmacological study|Correlative studies
45915317|NCT00006213|Other|laboratory biomarker analysis|Correlative studies
45915318|NCT00006216|Biological|PA-1-STK ovarian carcinoma vaccine|
45915319|NCT00006216|Drug|ganciclovir|
45915320|NCT00006219|Drug|clarithromycin|
45915321|NCT00006219|Drug|prasterone|
45915322|NCT00006222|Drug|cilengitide|
45915323|NCT00387582|Drug|Ranibizumab (Lucentis)|Lucentis 0.5 mg monthly for the first three months and then per protocol for the duration of the trial.
45915324|NCT00387582|Procedure|Argon Laser|Argon laser at entry to trial and then per protocol for the duration of the study.
45915325|NCT03765177|Biological|CLIC-1901|Participants will undergo (a) lymphodepletion with cyclophosphamide and fludarabine, followed by (b) infusion of autologous CLIC-1901 CAR-T cells. All treatments will be delivered intravenously.
45915326|NCT00006228|Biological|trastuzumab|Given IV
45638335|NCT02642159|Drug|Antihyperglycemic Drug|Insulin (injectable or inhaled) or other antihyperglycemic drugs as clinically indicated.
45638336|NCT05072873|Drug|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
45638337|NCT05072873|Other|normal saline|temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
45638338|NCT03970967|Device|Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
45776821|NCT05902273|Diagnostic Test|hemodynamic monitoring|Baxter Starling Monitor for measuring cardiac output and systemic vascular resistance (SVRI) which is using bioreactance technology. We need to place four electrodes on chest wall (upper left, upper right, down left, down right) and input monitor demographic parameters. Also enter mean arterial pressure (MAP) for calculating SVRI so we input MAP every minute.Patient bed set as 45 degree head elevated and legs 0 degree. Just after start measuring, monitor needs to synchronize itself for patient. After synchronisation we start fluid challenge with passive leg raising option. This test has two stages. First stage calculating baseline parameters which takes 3 minutes and second stage is measuring difference with fluid challenge which also takes 3 minutes. At the end of first stage monitor shows to perform passive leg raise and we perform trendelenburg maneuver till head comes to 0 degree. After second stage measurement has finished.
45776822|NCT05902273|Diagnostic Test|resistive index|We use ultrasonography at the same time with cardiac output monitor in both stages. First we determine the location of radial artery at wrist snuffbox at 1.5 centimeters depth with linear probe and confirm pulsatile flow with color mode. In Starling's baseline stage we measure and calculate resistive index with doppler P-mode in triplex setting 3 times. When received 3 same result successively we noted as SBRI-1. Second measurement is initiated at last 30 seconds of passive leg raising as described before and we noted our measurement as SBRI-2
45776823|NCT05902273|Diagnostic Test|Pleth variability index|During all stages Masimo Rad-87 rainbow probe is placed patients index or middle finger and we note PVI-1 and PVI-2 at the same time with SBRI-1 and SBRI-2
45776824|NCT05902260|Dietary Supplement|Nutritional intervention|Subjects should consume two 200 mL bottles of study product per day next to their cancer treatment (immunotherapy)
45776825|NCT05902260|Drug|Immunotherapy|Pembrolizumab monotherapy with or without combination chemotherapy according to standard of care
45776826|NCT05902247|Radiation|Radionuclide Therapy|To evaluate the tolerability and safety of 225Ac-PSMA I&T in patients with metastatic prostate cancer
45776827|NCT05902234|Behavioral|interdiciplinary treatment|Normal interdiciplinary treatment path
45776828|NCT05902221|Drug|amoxicillin or moxifloxacin|Antibiotic treatment back bone during 12 weeks
45776829|NCT05902221|Drug|amoxicillin or moxifloxacin + rifampicin|Antibiotic treatment back bone during 12 weeks + rifampicin
45915327|NCT00006228|Biological|aldesleukin|Given SC
45915328|NCT00006228|Other|laboratory biomarker analysis|Correlative studies
45638339|NCT05072405|Drug|Simvastatin 20 mg (Zocor®, MSD)|Simvastatin 20 mg given once alone, once with green tea extract and once with soy isoflavones extract.
45638340|NCT05072405|Drug|rosuvastatin 10 mg (Crestor®, Astra Zeneca)|rosuvastatin 10 mg are given once alone, once with green tea extract and once with soy isoflavones extract.
45638341|NCT05072327|Procedure|Mohs surgery|Mohs surgery of eyelid
45638342|NCT05072327|Procedure|cryotherapy|cryotherapy of eyelid
45638343|NCT03101579|Drug|Pemetrexed|Pemetrexed,10-15 mg, intrathecal injection via lumbar puncture, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
45915329|NCT00006228|Other|pharmacological study|Correlative studies
45915330|NCT00006231|Procedure|quality-of-life assessment|
45638344|NCT03101579|Drug|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
45638345|NCT03101579|Drug|Folic Acid|Folic acid, 400 μg, oral, once per day, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
45776830|NCT05902208|Drug|Antiviral treatment with conventional non-surgical treatment|Valaciclovir, a antiviral treatment will be added to the conventional non-surgical treatment of generalized periodontitis. One gram per day will be administered during 28 days.
45915331|NCT00006231|Procedure|standard follow-up care|
45915332|NCT00006231|Radiation|radiation therapy|
45638346|NCT03101579|Drug|Vitamin B12|A single dose of vitamin B12 1000 μg, intramuscular injection, before the first intrathecal pemetrexed.
45638347|NCT05071547|Behavioral|Guided internet-delivered acceptance and commitment therapy (ACT)|ACT builds on cognitive behavioral therapy (CBT), and includes methods for experiential learning and focus on psychological flexibility
45776831|NCT05902208|Drug|Placebo with conventional non-surgical treatment|Placebo of valaciclovir (same composition, without active substance) will be added to the conventional non-surgical treatment of generalized periodontitis. One gram a day will be administered during 28 days.
45915333|NCT00006234|Procedure|peripheral blood stem cell transplantation|
45915334|NCT00006234|Radiation|holmium Ho 166 DOTMP|
45915335|NCT03751800|Drug|Chronic hormonal treatment|Drugs used in this study are described by the physicians during routine gynecological visits
45915336|NCT00006240|Biological|sargramostim|
45915337|NCT00006240|Drug|dexamethasone|
45915338|NCT00006240|Drug|oral sodium phenylbutyrate|
45915339|NCT02972463|Dietary Supplement|Immunoglobulin Y|
45915340|NCT02972463|Other|Placebo|
45776832|NCT05902195|Behavioral|Personal Resource Building and Inclusive Volunteering Intervention (PVI)|PVI is a 6-week virtual programme aimed at building up young stroke survivors' personal resources for work through engaging in inclusive volunteering activities.
45638348|NCT05071547|Other|Interdisciplinary Pain Rehabilitation Program (IPRP)|Multimodal treatment where physio therapists, occupational therapists, psychologists and physicians give synchronized treatments to raise physical and psychological function and promote return to work
45638349|NCT05071625|Procedure|percutaneous vertebroplasty|percutaneous vertebroplasty under combined CT/fluoroscopy guidance for non-union after posterior fixation performed for a traumatic non-neurologic thoraco-lumbar vertebral fracture.
45915341|NCT00006243|Biological|tyrosinase peptide|Given SC
45915342|NCT00006243|Biological|MART-1:27-35 peptide vaccine|Given SC
45915343|NCT00006243|Biological|gp100 antigen|Given SC
45915344|NCT00006243|Biological|incomplete Freund's adjuvant|Given SC
45638350|NCT03101345|Other|Peptamen® 1.5 vanilla|Administration orally
45638351|NCT05071391|Procedure|Roux-en-Y gastric bypass|"Gastric bypass, also called Roux-en-Y gastric bypass, is a type of weight-loss surgery that involves creating a small pouch from the stomach and connecting the newly created pouch directly to the small intestine. After gastric bypass, swallowed food will go into this small pouch of stomach and then directly into the small intestine, thereby bypassing most of your stomach and the first section of your small intestine.~Gastric bypass is one of the most commonly performed types of bariatric surgery. Gastric bypass is done when diet and exercise haven't worked or when you have serious health problems because of your weight."
45638352|NCT05071781|Drug|Corticotropin-release hormone|intravenous CRH (100 µg)
45638353|NCT05071781|Drug|Corticotropin-release hormone|a bolus dose (CRH 100 µg or placebo) will be administered, followed by a continuous infusion (CRH 1 µg/kg/h or placebo)
45638354|NCT05071001|Procedure|MRI|"This assessment will be planned in the year after the consent signAll patients will have one brain MRI performed in Henri Mondor Hospital on a 3T MR unit (Skyra, Siemens, Erlangen). The procedure will include:~a 3D-FLAIR imaging~a morphometric study based on a 3DT1 MPRAGE gradient echo sequence (TR / TI / TE = 2300/900 /2.9 ms)~an analysis of the anatomic connectivity of the patient's brain assessed using a 1.5mm isotopic DTI with a high number of directions (HARDI / 65 directions / b=1500s/mm2).~An evaluation of neuronal dysfunction using MR Spectroscopy. Spectroscopic data will be collected using a 2D CSI laser with a short TE technique.~Magnetization transfer imaging providing information about integrity of membranes."
45776833|NCT05902195|Other|Usual care|Usual stroke care services include medical and health services offered by the hospitals or community-based organisations.
45776834|NCT05902182|Device|ConvaFoam|ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ non-adhesive dressings are designed to provide a moist wound healing environment and removing dead-space between the wound and dressing interface. These dressings are designed to manage excess exudate levels which may further damage the wound bed and surrounding skin. In addition, the dressings are designed to protect fragile skin from moisture, shear, and friction damage. These will be used in line with the patients pressure injury mitigation protocol for a 2 week period, with daily inspections of the skin area.
45776835|NCT05902169|Device|SonoCloud-9 (SC9)|Implantation of SC9 device and repeat activation at constant acoustic pressure
45776836|NCT05902169|Drug|Carboplatin|"Dose of carboplatin AUC 5 mg/ml.min-1 calculated using Calvert's formula:~Dose (mg) = target AUC (mg/mL x minute) x [glomerular filtration rate (GFR) mL/minute + 25]."
45776837|NCT05902169|Drug|Lomustine|Dosed and administered per labelling.
45776838|NCT05902169|Drug|Temozolomide|Dosed and administered per labelling.
45776839|NCT05902130|Other|symptoms of a myocardial infarction|Analysis of the differences in symptoms of a myocardial infarction between a man and a woman
45776840|NCT05902117|Diagnostic Test|Troponin and Copeptin assay|Collection of an additional blood tube for copeptin determination during blood collection for troponin testing as part of care.
45776841|NCT05902091|Behavioral|Neurophysiology-based intervention|
45776842|NCT05902078|Drug|Eldecalcitol capsules|Oral eldecalcitol 0.75μg daily
45915345|NCT00006243|Biological|sargramostim|Given SC
45915346|NCT00006243|Other|laboratory biomarker analysis|Correlative studies
45915347|NCT00006246|Drug|busulfan|
45638355|NCT03882905|Drug|Ezetimibe|10 mg tablet, oral, once daily
45638356|NCT03882905|Drug|Placebo|one tablet, oral, once daily
45638357|NCT03882905|Drug|Simivastatin|Once daily administration at dose to be determined
45638358|NCT03882905|Drug|Statin|Statin administered orally once daily at dose determined by treatment prior to enrollment by personal physician
45776843|NCT05902078|Drug|Calcitriol capsules|Oral calcitriol 0.5μg daily
45915348|NCT00006249|Biological|pegylated interferon alfa|
45915349|NCT00006249|Procedure|adjuvant therapy|
45915350|NCT00006252|Drug|fludarabine phosphate|30 mg/sq m/day IV infusion for 5 days (Days -7 thru -3)
45915351|NCT00006252|Drug|Cyclophosphamide|1 g/sq m/day IV infusion x 3 days (Days -5 thru -3)
45915352|NCT00006252|Biological|PBSC|2-8,000,000/kg CD34+ cells via infusion on Day 0
45915353|NCT00006252|Drug|G-CSF|5 ug/kg/day subQ injection until ANC > 1000/uL for 3 days beginning Day 5
45915354|NCT00006252|Biological|Donor lymphocytes|10,000,000 CD3+ cells/kg via infusion
45915355|NCT00006255|Procedure|radiofrequency ablation|Undergo thermal ablation by radiofrequency energy under magnetic resonance guidance.Thermal ablation continues until the entire tumor is treated.
45915356|NCT00006255|Procedure|thermal ablation therapy|Undergo thermal ablation by radiofrequency energy under magnetic resonance guidance.Thermal ablation continues until the entire tumor is treated.
45915357|NCT00006258|Biological|filgrastim|
45915358|NCT00006258|Drug|cisplatin|
45915359|NCT00006258|Drug|cyclophosphamide|
45915360|NCT00006258|Drug|etoposide|
45915361|NCT00006258|Drug|methotrexate|
45915362|NCT00006258|Drug|vincristine sulfate|
45915363|NCT00006258|Procedure|adjuvant therapy|
45776844|NCT05902065|Device|AVR Treadmill training with C-Mill|The protocol will include three sessions per week for 8 weeks of gait training using C-Mill with AVR applications. An anchoring system will prevent possible falls, activities will be stopped on patient request, or when a heart rate considered safe will be exceeded. The patient will be supervised by a physical therapist and asked not to use lateral bars. Treatment is planned to be progressive and will be individualized to the participant's level of performance. Progression in gait speed: at the training start, gait speed will be set at 80% of the individual's overground walking speed and weekly increased by 10%, to a maximum of 120%; progression in trial duration: at the training start the duration will be set at 25' and every two weeks increased by 5'; the maximum duration of a session will reach 45'; progression in difficulty: the protocol has 5 levels for each AVR application, and the transition among levels will be set at 80% success achievement.
45638359|NCT03572543|Device|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
45915364|NCT00006258|Radiation|radiation therapy|
45776845|NCT05902065|Device|Conventional Treadmill training with C-Mill|The protocol will include three sessions per week for 8 weeks of gait training using C-Mill without AVR applications, walking on the treadmill. An anchoring system will prevent possible falls, activities will be stopped on patient request, or when a heart rate considered safe will be exceeded. All sessions will be supervised by a physical therapist, who will give guidance and standardized cues on walking patterns (e.g., step length). The patient will be asked not to use the lateral bars. Treatment is planned to be progressive and will be individualized to the participant's level of performance: progression in gait speed: at the training start, gait speed will be set at 80% of the individual's overground walking speed and weekly increased by 10%, to a maximum of 120%; progression in trial duration: at the training start the duration will be set at 25' and every two weeks increased by 5'; the maximum duration of a session will reach 45'.
45915365|NCT00006261|Biological|therapeutic allogeneic lymphocytes|Beginning on day 120 after PBSC transplantation, eligible patients receive unmobilized donor lymphocyte infusion (DLI) over 15-30 minutes. Treatment continues monthly for a total of 3 DLIs in the absence of grade III or IV graft versus host disease or marrow aplasia.
45915366|NCT00006261|Drug|cyclophosphamide|4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of cyclophosphamide IV over 2 hours on days -3 and -2.
45915367|NCT00006261|Drug|docetaxel|Docetaxel IV over 1 hour. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
45638360|NCT02669017|Drug|ADCT-402|intravenous infusion
45638361|NCT02387671|Behavioral|Device: FitBit Flex wrist band|Participants will track their daily steps walked and hours of sleep by wearing the FitBit Flex wrist band during the 8 week study period. The data collected from the wrist band will be synced to participants' FitBit smart phone application and monitored by the study team.
45915368|NCT00006261|Drug|doxorubicin hydrochloride|Doxorubicin IV over several minutes on day 1. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
45915369|NCT00006261|Drug|fludarabine phosphate|4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of fludarabine IV over 30 minutes on days -8 to -4.
45915370|NCT00006261|Procedure|peripheral blood stem cell transplantation|Filgrastim (G-CSF) and sargramostim (GM-CSF) mobilized allogeneic peripheral blood stem cells (PBSC) IV on day 0.
45915371|NCT00006264|Biological|aldesleukin|
45915372|NCT00006264|Drug|ganciclovir|
45915373|NCT00006264|Drug|zidovudine|
45915374|NCT00006267|Drug|rubitecan|
45915375|NCT00006270|Drug|cosyntropin|
45638362|NCT02387671|Behavioral|Device: FitBit Aria weight scale|Participants will record their daily body weight during the 8 week study period by stepping on the FitBit Aria weight scale. The data collected from the scale will be synced to participants' FitBit smart phone application accounts and monitored by the study team.
45638363|NCT02387671|Behavioral|Diet Intake Messages|The study team will send participants daily text messages regarding their dietary intake. Each message will contain five questions that yield a yes, or no response. Messages will be sent daily during the 8 week study period. Responses from the messages will be recorded and monitored by the study team to enhance the behavioral counseling intervention.
45915376|NCT00006270|Drug|metyrapone|
45915377|NCT00006276|Drug|Micellar Paclitaxel|
45653052|NCT04517279|Behavioral|Usual Care Peer Services|Usual peer services involves supporting the process of change for individuals with mental health disorder to improve their health and wellness, live a self-directed life, and strive to reach their full potential.
45915378|NCT00006279|Drug|Nevirapine|
45915379|NCT00006291|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
45915380|NCT00006291|Drug|Aldesleukin|
45915381|NCT00006294|Drug|Chlorthalidone|participant's drug dose will be titrated from 12.5mg to 25mg over the course of the study
45915382|NCT00006294|Drug|Lisinopril|participant's drug dose will be titrated from 10mg to 40mg over the course of the study
45915383|NCT00006294|Drug|Amlodipine|participant's drug dose will be titrated from 10mg to 40mg over the course of the study
45915384|NCT00006294|Drug|Doxazosin|participant's drug dose will be titrated from 2mg to 8mg over the course of the study
45915385|NCT03728595|Diagnostic Test|Venepuncture|A blood sample will be taken for serum bicarbonate
45915386|NCT03728595|Diagnostic Test|Spirometry|All patients who have not had a spirometry in the 12 months prior to the HAST will undergo one on the day of the HAST.
45915387|NCT03728595|Diagnostic Test|Hypoxic altitude simulation test (HAST)|HAST will be performed as per clinical team request. No changes to this intervention will be made for research purposes.
45915388|NCT00005818|Drug|irinotecan hydrochloride|Given IV
45915389|NCT00005818|Drug|semaxanib|Given IV
45915390|NCT00005818|Other|laboratory biomarker analysis|Correlative studies
45915391|NCT00006324|Drug|Ethinyl estradiol/levonorgestrel|
45915392|NCT00006324|Drug|Medroxyprogesterone acetate|
45915393|NCT00005821|Drug|patent blue V dye|
45915394|NCT00005821|Procedure|conventional surgery|
45638364|NCT02387671|Behavioral|Behavioral Counseling|Participants will engage in four phone calls with the study counselor to discuss behavioral several topics (physical activity, sleep, fatigue & dietary patterns) and to reflect on their data recorded by the FitBit devices. The calls will take place on a bi-weekly basis. During the weeks between calls, the counselor will maintain contact with the participants through asynchronous text messages to monitor their progress in the study.
45638365|NCT04479865|Drug|Aricept 5mg Tablet|1 tablet once daily
45638366|NCT04479865|Drug|Aricept 10mg Tablet|1 tablet once daily
45638367|NCT04479865|Drug|DA-5207 150mg|1 patch once weekly
45638368|NCT04479865|Drug|DA-5207 170mg|1 patch once weekly
45638369|NCT02255773|Behavioral|Computerized Tasks|3 computerized tasks completed to assess motivation, learning of goal-directed and habitual behavior, and flexibility in switching between behavior strategies. It should take about 60 minutes to complete all three tasks.
45638370|NCT02255773|Behavioral|Questionnaires|Completion of 8 questionnaires about mood, fatigue, sleep quality, and other symptoms. It should take about 30 minutes to complete these questionnaires.
45776846|NCT05902039|Other|MRI|All participants underwent an MR examination on a 3T whole-body Prisma MRI system (Siemens, Erlangen, Germany) with a 64-channel head coil, and a 7T whole-body MAGNETOM MR system (Siemens, Erlangen, Germany) using a 32-channel receive/birdcage transmit head coil (NOVA medical). DP-pCASL, Multi-delay pCASL (MD-pCASL) was acquired to evaluate BBB function and cerebral perfusion. T1-weighted magnetization-prepared rapid gradient echo (T1w-MPRAGE) was scanned at both 3T and 7T for registration in the post-processing workflow. T2-weighted fluid-attenuated inversion recovery (T2w-FLAIR) and T2*-weighted gradient echo (T2*w-GRE) were acquired at 7T for high-resolution structural images and evaluation of lesions.
45776847|NCT05902013|Device|laryngoscopy|laryngoscopy for nasotracheal intubation
45776848|NCT05901948|Other|Classification|Novel Asherman Scoring Classification
45776849|NCT05901935|Drug|DP303c|DP303c injection, 3.0 mg/kg, Q3W.
45776850|NCT05901935|Drug|Trastuzumab|IV, 6 mg/kg, D1, Q3W
45776851|NCT05901935|Drug|Vinorelbine Tartrate|IV, 25 mg/m^2，D1、D8，Q3W
45776852|NCT05901935|Drug|Capecitabine tablets|PO 1000 mg/m^2, bid, D1-D14, Q3W
45776853|NCT05901922|Behavioral|Social skills training|In this training, role-playing will be done in groups of six. In these role playing, the importance and application of the social skill specified before the session will be studied.
45776854|NCT05901896|Other|there are no intervention|no intervention
45776855|NCT05901870|Other|Questionnaire administration|All study participants will be surveyed with the questionnaire, which includes such instruments as EQ-5D-3L and WG-SS, to assess their health-related quality of life, health-related behavior, and health care utilization indicators.
45776856|NCT05901857|Diagnostic Test|convolutional neural network|A deep learning model for dental age classification from panoramic images
45776857|NCT05901844|Diagnostic Test|Paraffin pathological diagnosis|Perform two diagnostic methods on the same sample
45776858|NCT05901805|Other|questionnaire application|"Participants will be asked to fill in the Occupational Sitting and Physical Activity Questionnaire adapted into Turkish. Correlation of the scale with the International Physical Activity Questionnaire-Short Form, VAS and YİBT-SF, Buss-Perry Aggression Scale will be tested. The questionnaire will be repeated every 7-14 days in order to perform the test-retest analysis of the questionnaire."
45776859|NCT05901779|Drug|live combined Bifidobacteriun, Lactobacillus and Enterococcus capsules|Probiotics capsules containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. Each capsule contained>10,000,000 colony-forming units (CFUs). This drug can treat endoxemia caused by imbalance of intestinal flora.
45776860|NCT05901766|Dietary Supplement|UNIMAP Multiple Micronutrient Supplement|Iodine Containing Multiple Micronutrient Supplement once daily
45776861|NCT05901727|Other|No intervention|Observational data collection only.
45776862|NCT05901714|Drug|Afimetoran|Specified dose on specified days
45776863|NCT05901714|Drug|Phenytoin|Specified dose on specified days
45776864|NCT05901714|Drug|Midazolam|Specified dose on specified days
45776865|NCT05901701|Radiation|Low Level LASER therapy|using semiconductor InGaAsp diode LASER type 940 nm with continuous mode of operation, with time of application 180 sec per session for 12 sessions.
45776866|NCT05901701|Device|Hard occlusal splint|2 mm thickness occlusal splint constructed over the maxillary arch using CAD/CAM technology.
45776867|NCT05901688|Other|Umbilical cord measurements & observations|"In the screening study of an unselected population at 20-22 weeks' and 35-37 weeks' gestation, women are offered an ultrasound scan as part of standard care and will be invited to take part in the study which will involve taking the following additional ultrasound measurements:~Umbilical cord coiling index (UCI)~Transverse diameter of umbilical cord (UC)~Transverse diameter of umbilical vein (UV) and artery (UA)~Umbilical vein (UV) Doppler flow characteristics~Presence of nuchal cord"
45776868|NCT05901649|Drug|Apalutamide|No interventions will be administered as a part of this study. Participants will receive apalutamide as per their routine clinical practice.
45638371|NCT03494335|Other|Online surveys|The investigators are recruiting health care providers for these surveys that are involved in or use imaging.
45638372|NCT02153047|Behavioral|Spirometry|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured 20-minutes visit with details of the spirometry data (values of respiratory capacity and volumes referring on the theoretical)
45638373|NCT02387515|Other|intensive rehabilitation program|Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology. The technological system consists out of motion tracking sensors that register the movements and position of the lumbar spine.
45776869|NCT05901649|Drug|Enzalutamide|No interventions will be administered as a part of this study. Participants will receive enzalutamide as per their routine clinical practice.
45776870|NCT05901636|Biological|INFLUENZA G1 mHA|INFLUENZA G1 mHA will be administered intramuscularly.
45776871|NCT05901636|Biological|Placebo|Placebo will be administered intramuscularly.
45776872|NCT05901636|Biological|Al(OH)3|Al(OH)3 will be administered intramuscularly.
45915395|NCT00005821|Procedure|lymphangiography|
45915396|NCT00005821|Procedure|radionuclide imaging|
45915397|NCT00005821|Procedure|sentinel lymph node biopsy|
45638374|NCT03113539|Other|Modified Low-dose, EKG-gated CT without contrast for the evaluation of aortic aneurysm|"On the same day, the subject will do :~Modified low-dose, EKG-gated CT without contrast~Usual high-dose, EKG-gated CT with contrast~Comparing aortic diameters from the two protocols."
45915398|NCT00005821|Radiation|Technetium Tc 99m human serum albumin colloid|
45776873|NCT05901610|Behavioral|Episodic Future Thinking|Participants will generate descriptions of vivid positive future events.
45776874|NCT05901610|Behavioral|Episodic Recent Thinking|Participants will generate descriptions of vivid positive past events.
45776875|NCT05901610|Device|Low-intensity Focused Ultrasound|A transducer device will use focused ultrasound energy to neuromodulate the insular cortex. The participant's brain will be mapped based on information from the CT and MRI scans, and the transducer will deliver brief ultrasound pulses to the insular cortex.
45776876|NCT05901610|Device|Sham Low-intensity Focused Ultrasound|All of the same actions done during LIFU will be performed, but the device will be inactive.
45776877|NCT05901597|Device|Clareon PanOptix and AcrySof Vivity IOL implantation Alcon Vision Suite and Argos biometer|Clareon PanOptix and AcrySof Vivity IOL implantation Alcon Vision Suite and Argos biometer
45776878|NCT05901571|Other|acupuncture|"The acupuncture group will receive treatment with needles inserted at the specified acupoints. Selected by acupuncture experts, these acupoints include SP4 (Gongsun) , PC6 (Neiguan) , PC5 (Jianshi) and LV 3 (Taichong) bilaterally. All acupoints are localized according to the WHO Standard Acupuncture Locations.After needle insertion, the acupuncture needles will be manipulated using either the twirling-rotating or lifting-thrusting methods to achieve the De Qi sensation."
45776879|NCT05901571|Other|escitalopram|Patients will receive 10 mg/day of escitalopram for the first 3 weeks and 20mg/day for the remaining 7 weeks.
45776880|NCT05901571|Other|sham-acupuncure|In the sham acupuncture group, superficial skin penetration (2 to 3 mm in depth) at nonacupoints will be done without De Qi manipulations. Nonacupoints are away from conventional acupoints or meridians. The choice of sham acupuncture points, which are points located in an emplacement different than the meridian points. The sham acupoints are not standard acupoints and will be about 1cun ( ≈20 mm) lateral from the real acupoints in the experimental group.
45776881|NCT05901571|Other|escitalopram placebo|Patients will receive 10 mg/day of escitalopram placebo for the first 3 weeks and 20mg/day for the remaining 7 weeks.
45776882|NCT05901558|Behavioral|Strategies for Toddler ASD with Remote-therapy (STAR)|The intervention strategies in STAR model are designed under the Naturalistic Developmental Behavioral Intervention (NDBI) framework which are implemented in natural settings targeting at improving social and communicational capabilities
45776883|NCT05901558|Behavioral|Community intervention|Regular community intervention
45776884|NCT05901545|Biological|Panitumumab|Given by IV
45776885|NCT05901545|Other|Indium In 111 Panitumumab|Given by IV
45776886|NCT05901545|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
45776887|NCT05901545|Procedure|Computed Tomography|Undergo SPECT/CT
45776888|NCT05901545|Procedure|Surgical Procedure|Undergo standard of care surgery
45776889|NCT05901545|Other|Imaging agent|Receive local injection of optical dye
45776890|NCT05901545|Procedure|Intraoperative Imaging|Undergo Intraoperative Imaging
45776891|NCT05901545|Procedure|Near Infrared Imaging|Undergo Near Infrared Imaging
45776892|NCT05901545|Procedure|Electrocardiography|Undergo Electrocardiography
45776893|NCT05901545|Procedure|Biospecimen Collection|Undergo blood sample collection
45776894|NCT05901519|Drug|Prednisone|Patients will be treated with PO prednisone, once a day, at a dose of 60 mg/day
45776895|NCT05901480|Genetic|OTOV101N+OTOV101C Injections|The gene therapy of OTOV101N+OTOV101C injection via intracochlear injection.
45776896|NCT05901467|Drug|kisspeptin 112-121|One IV bolus of kisspeptin 112-121
45915399|NCT00005824|Biological|filgrastim|
45638377|NCT02668393|Drug|Docetaxel|
45638378|NCT02668393|Drug|Nintedanib|Low Dose
45638379|NCT02668393|Drug|Nintedanib|Medium dose
45638380|NCT02668393|Drug|Nintedanib|High dose
45776897|NCT05901467|Drug|GnRH|One IV bolus of gonadotropin-releasing hormone
45776898|NCT05901454|Drug|Yellow Fever Vaccine|vaccination according to manufacturers manual (0.5mL subcutaneously in the arm)
45776899|NCT05901441|Drug|Hydromorphone|For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone
45776900|NCT05901441|Drug|Sufentanil|For those in SF group: they will be administered with 40 ug/ml sufentanil
45776901|NCT05901441|Drug|Ropivacaine|0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
45776902|NCT05901415|Procedure|Combined anterior lumbar plexus and lateral sacral plexus block in a semi-supine position|We proposed a modified approach of combined anterior LPB and lateral SPB with the patients posed in a semi-supine position aiming to reduce the pain and discomfort induced by position changing effectively.
45915400|NCT00005824|Drug|busulfan|
45638381|NCT02668393|Drug|Nintedanib|Continuous high dose
45638382|NCT03105739|Other|LMA removal|According to randomization, LMA device was removed at the end of surgery, either in deeply anesthetised patients or after consciousness recovery.
45638383|NCT03105895|Procedure|Mesh group|An onlay PDVF mesh will be placed as abdominal wall reinforcement
45776903|NCT05901415|Procedure|Combined anterior lumbar plexus and lateral sacral plexus block in a classical position.|Patients posed in a classical position and received combined anterior LPB and lateral SPB.
45776904|NCT05901402|Behavioral|aerobic and resistance exercise|The experimental group performed aerobic resistance exercise during pregnancy every day.
45776905|NCT05901389|Drug|Lidocaine|After the thoracoscopic surgery, lidocaine will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
45915401|NCT00005824|Drug|cyclophosphamide|
45915402|NCT00005824|Procedure|peripheral blood stem cell transplantation|
45915403|NCT00005827|Dietary Supplement|genistein|
45776906|NCT05901389|Drug|normal saline|After the thoracoscopic surgery, normal saline will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
45776907|NCT05901376|Diagnostic Test|MicroRNA|MiR-20a, MiR-21, MiR-106b, MiR-199a, MiR-223
45776908|NCT05901363|Procedure|Endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy|laparoscopic removal of gallbladder and endoscopic extraction of common bile duct stones
45776909|NCT05901363|Procedure|aparoscopic common bile duct exploration and laparoscopic cholecystectomy|laparoscopic removal of gallbladder and laparoscopic extraction of common bile duct stones
45776910|NCT05901350|Drug|Levodopa|Some patients did not reduced the dose of levodopa after STN-DBS comparing to some without reducing the dose.
45776911|NCT05901337|Combination Product|Cupping therapy with convential medical treatment|"Device:Cupping therapy device~Group A participants received Dry cupping therapy one session per week for 8 weeks with 6 days intervals between sessions and with cups applied to the skin for around 8 minutes. (In addition to convential medical treatment for 8 weeks in the form of :~Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day for adults 70 and younger .~Vitamine C: The recommended dietary dose 200 mg/day vitamin c~Anticoagulation drugs (blood thinners)Doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours ."
45776912|NCT05901337|Drug|Convential medical treatment|"Group B participants received convential medical treatment for 8 weeks in the form of :~Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day for adults 70 and younger .~Vitamine C: The recommended dietary dose 200 mg/day vitamin C~Anticoagulation drugs (blood thinners)Doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours ."
45776913|NCT05901324|Radiation|intensity-modulated radiotherapy (IMRT)|1.8 Gy of 4-6 MV X-ray to a total dose of 23.4 Gy (13 fractions) will be delivered.
45776914|NCT05901311|Drug|LY3537982|Administered orally.
45776915|NCT05901311|Drug|[¹⁴C]-LY3537982|Administered orally.
45776916|NCT05901311|Drug|[¹⁴C]-LY3537982|Administered IV.
45776917|NCT05901298|Device|My Breastfeeding Guide|Development of the content of the mobile nursing application had began with a literature review on breastfeeding, Dennis' Breastfeeding Self-Efficacy Theory and Pender's Health Promotion Model and after content is created. The mobile nursing application can be download via the Google Play Store® and the Apple Store®. The application consist of three parts. In the first part includes mother and baby information which is asked with scales and forms, the second part includes literature knowledge and the third section includes the expert consultation and blog section. Mothers receive notifications consisting of sentences every two days to increase their breastfeeding self-efficacy. The application web page can allow the mothers' information to be kept in the system.
45776918|NCT05901285|Drug|VAX014|Intratumorally administered oncolytic agent comprised of recombinant bacterial minicells. VAX014 is not infectious and is not capable of replication
45776919|NCT05901272|Other|Local clinical champion|A clinical champion is a local provider who serves as a liaison between local clinics and local or regional leadership or national program offices (e.g., HHRC) and advocates for the HITIDES intervention with their local peers. A clinical champion can provide ongoing promotion of and education about HITIDES and remind care providers of its presence and value either formally (e.g., presentations at staff meetings) or informally (e.g., individual conversations about HITIDES benefits). Clinical champions can also engage middle managers or local leadership to buy in to and support intervention uptake. Clinical champions may also work with Veterans in quality improvement efforts to garner their ideas for how to outreach to other Veteran patients, plan quality improvement cycles, or consult in an advisory capacity. Potential champions will be approached about participation after consultation with site HIV care providers and HHRC.
45776920|NCT05901272|Other|Learning collaborative|Learning Collaboratives are groups of providers or provider organizations and foster a collaborative learning environment to improve implementation of the clinical innovation (HITIDES). There are several approaches to this in the literature including peer consultation networks, online communities of practice, quality circles, and learning collaboratives. Groups will meet virtually using a wide variety of media. Participation will be monitored by research staff and recorded by participants in a time-tracking log but not controlled. The learning collaboratives will be comprised of a group of site clinical champions, HIV care providers, and other VHA HIV care representatives, potentially including Veterans who are engaged in implementation activities, to foster a learning environment to improve the implementation of HITIDES through consultation.
45776921|NCT05901272|Other|External facilitation|. External facilitation will be provided by a trained external facilitator who is given the HITIDES Operations Guide and Consumer Voice tools for Veteran engagement in quality improvement. Facilitation is a process to enable sites to increase uptake of HITIDES through supportive relationships and strategies to navigate the implementation process. Virtual external facilitation is a recognized modality of facilitation delivery in VHA. The external facilitator will work with the clinical champion, site personnel, and Veterans-not conducting research activities but engaging in quality improvement processes with these individuals. The addition of a facilitator allows problem identification and problem-solving, using processes based on supportive relationships.
45915404|NCT00005830|Drug|Doxorubicin Hydrochloride|Given IV
45638384|NCT03473821|Behavioral|MOTIFS|o MOTor Imagery to Facilitate Sensorimotor re-learning (MOTIFS) is an individualized and physical activity-specific integrated model that includes aspects of both neuromuscular training, as used in rehabilitation practices, and Dynamic Motor Imagery (DMI). DMI is a form of mental training in which the participant images him-/herself performing a task from a first-person perspective in order to maximize functional equivalence to the task in question. This includes dynamic, physical movement, as well as mental imaging. The intervention provides a framework for designing individualized, physical activity-specific rehabilitation exercises for knee-injured people.
45638385|NCT05263843|Diagnostic Test|Biological markers of myocardial fibrosis|Blood sample for measurements of NET activation and collagen biomarkers
45915405|NCT00005830|Drug|Cisplatin|Given IV
45915406|NCT00005830|Radiation|Radiation Therapy|Undergo radiation therapy
45915407|NCT00006327|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
45915408|NCT00005833|Drug|R115777|300mg P.O. BID.
45915409|NCT00005836|Drug|oxaliplatin|
45915410|NCT00006330|Drug|Digoxin|
45915411|NCT00006330|Drug|Hawthorn|
45915412|NCT00005839|Drug|capecitabine|
45915413|NCT00005839|Drug|oxaliplatin|
45915414|NCT00005842|Biological|trastuzumab|
45448399|NCT02135068|Device|Medtronic MiniMed Closed Loop (CL) System|The Medtronic MiniMed Closed Loop (CL) System is an investigational system that uses some commercially available products. An investigational Enlite 2 glucose sensor measures the sensor glucose. The glucose sensor signal is sent to the insulin pump. From the insulin pump the sensor glucose is sent through the translator, which then relays the signal on to a controller. An Android Mobile Device (off the shelf) has the control algorithm installed. This device is known as the controller. The controller serves as the control center for the Android system, receiving data from the sensor and pump components, feeding the data to its control algorithm, issuing delivery commands to the pump to apply the algorithm's recommend therapy, and providing a means to monitor the system.
45915415|NCT00005842|Drug|tipifarnib|
45915416|NCT00005845|Drug|tipifarnib|Given PO
45915417|NCT00005845|Other|laboratory biomarker analysis|Correlative studies
45776922|NCT05901259|Device|Exopulse Mollii Suit|The registry is designed to demonstrate the impact of Exopulse Mollii Suit on improvement of muscle relaxation, muscle activation, local blood circulation and/or chronic pain relief. The subjects included use the suit for 60 minutes every other day, unless other is specified by the Investigator, in their home environment for up to a maximum of 12 consecutive weeks. Qualitative and quantitative measures will be collected at baseline (T0), after 60 minutes stimulation (T1), after 4 weeks (T4) and at the end of the 12-week intervention period (T12).
45776923|NCT05901246|Dietary Supplement|PS-containing dietary supplement|Sachet containing a powdered ingredient source of microencapsulated free plant sterols (2,25 g ingredient/day)
45776924|NCT05901246|Other|Placebo|Sachet containing the excipients of the ingredient (2,25 g placebo/day)
45776925|NCT05901233|Device|Remotely supervised Transcranial Direct Current Stimulation (RS-tDCS)|tDCS is a type of non-invasive brain stimulation. 1.5 milliamp (mA) of current will be delivered via electrodes in saline-soaked sponges placed on the left side of the head and right upper arm. The stimulation will be delivered for 20 minutes, 5 times weekly, in the participant's home setting while the participant engages in computer-delivered speech-language training. Sessions are monitored by study personnel.
45915418|NCT00005845|Other|pharmacological study|Correlative studies
45915419|NCT00005848|Drug|chemotherapy|
45915420|NCT00005848|Drug|tipifarnib|
45915421|NCT00005851|Drug|fludarabine phosphate|Given IV
45915422|NCT00005851|Radiation|total-body irradiation|Undergo TBI
45915423|NCT00005851|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
45915424|NCT00005851|Drug|cyclosporine|Given PO or IV
45448400|NCT02135068|Other|Snacking|Up to 45 g of oral glucose via Gatorade
45448401|NCT05214118|Behavioral|technology-based program|Participants will be asked to complete three 25-minute modules covering the transition from pregnancy to postpartum, possible neonatal abstinence syndrome (NAS) or neonatal withdrawal syndrome (NOWS), and interactions with child welfare.
45448402|NCT02135224|Drug|Fentanyl|
45448403|NCT02135224|Drug|Normal saline|
45915425|NCT00005851|Drug|mycophenolate mofetil|Given PO or IV
45915426|NCT00005851|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
45638391|NCT05251129|Drug|Atorvastatin 80 Mg Oral Tablet|Higher intensity statin
45915427|NCT00005851|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
45915428|NCT00005851|Other|laboratory biomarker analysis|Correlative studies
45915429|NCT00005854|Drug|cyclophosphamide|
45915430|NCT00005854|Drug|cyclosporine|
45915431|NCT00005854|Drug|methotrexate|
45915432|NCT00005854|Procedure|allogeneic bone marrow transplantation|
45915433|NCT00005854|Procedure|in vitro-treated bone marrow transplantation|
45915434|NCT00005854|Radiation|radiation therapy|
45915435|NCT00005857|Biological|trastuzumab|
45915436|NCT00005857|Drug|docetaxel|
45915437|NCT00005860|Drug|floxuridine|
45915438|NCT00005860|Drug|leucovorin calcium|
45915439|NCT00005860|Drug|oxaliplatin|
45915440|NCT00005863|Biological|filgrastim|
45915441|NCT00005863|Drug|cytarabine|
45915442|NCT00005863|Drug|daunorubicin hydrochloride|
45915443|NCT00005863|Drug|etoposide|
45915444|NCT00005863|Drug|fludarabine phosphate|
45915445|NCT00005863|Drug|tretinoin|
45915446|NCT00005866|Drug|busulfan|arm 1: 0.44 mg/kg every 6 hours, IV over 2 hours, day -7 to -4
45915447|NCT00005866|Drug|cyclophosphamide|arm 2: 60 mg/kg every 24 hrs for 2 doses, IV over 2 hrs, days -5 and -4
45915448|NCT00005866|Drug|cyclosporine|both arms per published schedule
45915449|NCT00005866|Drug|methotrexate|GVHD: 15 mg/m2 day 1, 10 mg/m2 day 3, 6 and 11 by IV
45915450|NCT00005866|Procedure|allogeneic bone marrow transplantation|day 0
45915451|NCT00005866|Radiation|radiation therapy|both arms: 1200 cGy total dose (6 x 200 fractions)
45915452|NCT00005869|Drug|gemcitabine hydrochloride|
45915453|NCT00005869|Drug|rubitecan|
45915454|NCT00005872|Drug|rubitecan|
45915455|NCT00005875|Drug|rubitecan|
45915456|NCT00005878|Drug|celecoxib|
45915457|NCT00005881|Other|Quality of Life Forms|Completion of the instrument [Minneapolis-Manchester Quality of Life (MM-QOL)] that measures HRQOL in the survivors of childhood cancer in a standardized, valid way and to assess the feasibility of incorporating this endpoint in a variety of clinical trials.
45915458|NCT00005884|Drug|eflornithine|
45915459|NCT00005887|Drug|efaproxiral|
45915460|NCT00005887|Radiation|radiation therapy|
45915461|NCT00006339|Drug|Indinavir sulfate|
45915462|NCT00006339|Drug|Ritonavir|
45915463|NCT00006339|Drug|Hydroxyurea|
45915464|NCT00006339|Drug|Stavudine|
45915465|NCT00006339|Drug|Didanosine|
45915466|NCT00005890|Drug|corticotropin|
45915467|NCT00005893|Drug|anti-thymocyte globulin|
45915468|NCT00005893|Drug|busulfan|
45915469|NCT00005893|Drug|cyclophosphamide|
45915470|NCT00005893|Procedure|Bone marrow transplantation|
45915471|NCT00005896|Drug|filgrastim|
45638392|NCT01797523|Drug|Metformin|500 mg by mouth daily for 4 days on Days 1 - 4 of Cycle 0 and then 2 times a day (about 12 hours apart) every day after that. Metformin taken for 7 - 10 days in Cycle 0 before Cycle 1 begins.
45638393|NCT01797523|Drug|Letrozole|2.5 mg tablet by mouth once daily in a 28 day cycle.
45638394|NCT01797523|Drug|Everolimus|10 mg by mouth once daily in a 28 day cycle.
45638395|NCT03412591|Drug|Suvorexant 20 mg|Suvorexant 20 mg is an orexin 1/2receptor antagonist approved for the treatment of sleep disturbance in subjects with Primary Insomnia.
45776926|NCT05901233|Device|Remotely supervised sham tDCS (RS-sham-tDCS)|tDCS is a type of non-invasive brain stimulation. During sham stimulation 1.5 milliamp (mA) of current will be delivered for a brief period and then turned off. Current will be delivered via electrodes in saline-soaked sponges placed on the left side of the head and right upper arm. Sham will be delivered for 20 minutes, 5 times weekly, in the participant's home setting while the participant engages in computer-delivered speech-language training. Sessions are monitored by study personnel.
45776927|NCT05901233|Behavioral|Lexical Retrieval Training (LRT)|Participants work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) teletherapy sessions per week with a clinician plus 30 minutes of additional independent, computer-based practice exercises 3 times per week.
45776928|NCT05901233|Behavioral|Video Implemented Script Training in Aphasia (VISTA)|Participants work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes two (one hour each) teletherapy sessions per week with a clinician targeting clear and accurate script production, script memorization, and conversational usage of scripts. The participant completes 30 minutes of independent, computer-based practice 3 times per week, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts.
45776929|NCT05901220|Behavioral|Healthy lifestyle|An educational programme to promote healthy lifestyle will be performed.
45776930|NCT05901207|Diagnostic Test|blood test|blood test
45776931|NCT05901194|Drug|Lenvatinib|Lenvatinib will be administred orally and daily at the usual dose ( 8 or 12 mg per day depending on the weight < or ≥ 60kg) in the 25 patients of the study from TACE failure until LT
45776932|NCT05901181|Behavioral|Laughter Yoga|"Laughter yoga is a childlike practice where group members make eye contact with each other.~It is a breath yoga practiced by imitating games and fake laughing. Brain the effects of real laughter on the body, as it cannot distinguish between fake and real laughter.~showing positive effects. It consists of sessions lasting at least 20 minutes and an average of 45 minutes."
45776933|NCT05901168|Other|Active Video Games Intervention|Participants will complete active video games in the same order until they fill 20 minutes after the first 5 minutes of warm-up. In addition, during the change between games (lasting approximately 20 seconds), patients will be instructed by a therapist to perform combined exercises to minimize immobility time. These exercises are: elbow flexion and foot flexion, shoulder flexion and unilateral hip extension, and arm abduction and squat exercises that will prevent the patient from cooling down.
45776934|NCT05901168|Other|Traditional Exercise Intervention|"Active exercises for the upper extremities (without support): Shoulder flexion, Shoulder abduction, Elbow flexion at shoulder 90° flexion.~Active exercises for the lower extremities: Ankle-foot movements (ankle pumping exercise), heel raise, Knee extension in sitting high, Hip-knee flexion while lying supine~Body: Bridging, Trunk rotations in sitting~These exercises will be done in 1 set of 8-10 repetitions.~It will take about 20 minutes."
45776935|NCT05901155|Device|MedAL-mentor|MedAL-mentor is a near real-time monitoring and benchmarking dashboard based on data collected through ePOCT+, providing direct feedback on several clinical indicators (antibiotic prescription, performance of key measurements, signs, and diagnostic tests).
45776936|NCT05901142|Behavioral|Exercise-based multi-phasic, multi-modal intervention|"Pre-op: 2*60min supervised; 1*30min unsupervised walking sessions per week Supervised session: Aerobic: 8*60secs star jump, squat thrust, high knees with 90sec rest. Elastic resistance: 2*10-12reps of chest press, seated row, leg press, 'lat' pulldown, and either abdominal flexion or lumbar extension-alternated, with 60-90sec rest. Targeted physiotherapy: general breathing exercises, active-assisted range of motion (RoM) exercises, and active-resisted RoM exercises~Postop: 1*60min supervised exercise; unsupervised walking [2*30min weeks 1-2; 3*30min week 3; 4*30min weeks 4-6] session per week Supervised session: Aerobic: As above using full body extension, squat jump, static sprint in week 1-4. Progressed to those performed preoperatively from week 5. Elastic resistance: As above from week 4, performed 3*week. Targeted physiotherapy: As above, with active-assisted RoM progressing from 1*10reps in week 1, to 2*10reps in weeks 2-4, and 3*10reps in weeks 4-6"
45448404|NCT03548896|Procedure|Post extraction socket|**Dental implant will be placed 3 months after tooth extraction
45448405|NCT02135380|Biological|Autologous Stromal Vascular Fraction (SVF)|Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.
45448406|NCT02135380|Biological|Autologous Adipose Derived MSCs (ADMSCs)|Study arm B subjects will receive total 3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals.
45638396|NCT03377023|Drug|Nivolumab|Intravenous nivolumab every 2 weeks.
45638397|NCT03377023|Drug|Ipilimumab|Intravenous ipilimumab every 6 weeks.
45915472|NCT00005896|Genetic|Autologous stem cells transduced with FACC retroviral vector|
45915473|NCT00005896|Procedure|Autologous Stem Cell Transplantation|
45448407|NCT02135380|Other|Control|Standard Therapy
45638398|NCT03377023|Drug|Nintedanib|Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles.
45638399|NCT02383147|Device|Tomographic Neurofeedback|EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex and deliver feedback for the patient
45638400|NCT02383147|Device|Non Tomographic Neurofeedback|EEG-electrodes are placed on the patients head, but only 4 electrodes (Fc1, Fc2, F3 and F4 of a 10-10 EEG-system) record the surface activity and generate the feedback for the patient.
45638401|NCT05206591|Biological|Secukinumab|Secukinumab 300 s.c.
45638402|NCT05206591|Other|Placebo|Placebo
45638403|NCT05168449|Other|Mobile Application|mobile phone applications directed to chronic kidney disease patients to improve their medication.
45638404|NCT02383069|Other|Intervention Group|Aerobic training
45638405|NCT02383069|Other|Control Group|Chest physiotherapy: Flutter and muscle stretching
45776937|NCT05901129|Other|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
45638406|NCT02387593|Device|ENDOCUFF|One endocuff device is placed at the tip of colonoscope prior to colonoscopy baseline
45638407|NCT02383303|Behavioral|Individual Development Account and financial education|The Program intervention includes a matched savings account (Individual Development Account) and financial education.
45638408|NCT02383225|Behavioral|Lakota Language enhancement|This intervention component includes more extensive adaptation for Lakota families, focusing on use of Lakota language specifically around relationship/kinship terms. Study arms without this component will include the same adapted intervention but with use of English language rather than Lakota.
45638409|NCT02383225|Behavioral|Facebook Supplement|This intervention component includes a social media supplement to engage families outside of weekly intervention sessions and will include postings and polls for participating parents/other caregivers to complete between sessions.
45638410|NCT02383225|Behavioral|Substance Use Resistance Skills|This intervention component consists of the original substance use resistance skills training from the Iowa Strengthening Families Program for Parents and Youth 10-14; arms without this component will include a session on healthy eating and exercise (attention control).
45638411|NCT02387437|Behavioral|SI recruitment|SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.
45915474|NCT00005905|Drug|hu Leptin (A-100)|
45915475|NCT00386464|Device|noninvasive positive pressure ventilation|
45915476|NCT00006342|Genetic|chromosomal translocation analysis|
45638412|NCT02387437|Behavioral|IP recruitment|Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).
45638413|NCT02387437|Behavioral|PCV recruitment|PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min
45915477|NCT00006342|Genetic|gene rearrangement analysis|
45915478|NCT00006342|Genetic|mutation analysis|
45915479|NCT00386503|Drug|Artesunate + Amodiaquine|
45915480|NCT00386542|Biological|Vaxigrip® trivalent inactivated influenza vaccine|See full description elsewhere in this record.
45448408|NCT05509270|Behavioral|Letter|Mailed letter about flu vaccination
45638414|NCT02383615|Procedure|Saphenous nerve block|Ultrasound guided saphenous nerve blocks with 0.5% Ropivacaine for patients undergoing elective foot and ankle surgery for post-operative pain relief.
45638415|NCT01226563|Device|IK-5001|4 mL (+/- 0.2 mL) administered through intracoronary slow bolus injection over 15 to 30 seconds at least 2 days after PCI but within 5 days of onset of symptoms.
45638416|NCT01226563|Device|Saline Solution|4 mL (+/- 0.2 mL) slow bolus, intracoronary injection of saline solution will be administered over 15 to 30 seconds at least 2 days after percutaneous coronary intervention (PCI) but within 5 days of onset of symptoms.
45638417|NCT02382757|Drug|insulin human|Children will receive conventional treatment with human insulin according to standard medical practice.
45638418|NCT02382679|Dietary Supplement|Experimental: Vitamin Mixture|Vitamins: B2 (riboflavin), magnesium, co-enzyme Q10, Omega 3 fatty acids
45638419|NCT02382679|Dietary Supplement|Placebo|Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
45638420|NCT02387125|Biological|CMB305|
45638421|NCT02387125|Biological|G100|
45638422|NCT02387125|Drug|Metronomic CPA|
45638423|NCT02386891|Other|Thermal Environment|
45638424|NCT02386969|Device|active rTMS then sham rTMS|A first period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months
45915481|NCT00386542|Device|Intradermal spacer on Biojector® 2000 jet injector|See elsewhere in this record for full description.
45915482|NCT00386581|Drug|atomoxetine|
45915483|NCT00386581|Drug|placebo|
45915484|NCT00006345|Biological|denileukin diftitox|
45915485|NCT00006345|Drug|dexamethasone|
45915486|NCT00386620|Behavioral|Questionnaire|45 minute survey about health, pain and relationships
45915487|NCT00386620|Behavioral|Interview|Feedback on use of handheld computer electronic diaries (ED).
45915488|NCT00005920|Drug|L-743,872|
45915489|NCT00005926|Drug|Gemcitabine|
45915490|NCT00005926|Drug|Herceptin|
45915491|NCT00005926|Procedure|Radiation therapy|
45915492|NCT00005935|Drug|Mycophenolate mofetil|
45915493|NCT00005935|Drug|Cyclosporine|
45915494|NCT00006348|Drug|ondansetron|
45915495|NCT00006348|Other|placebo|
45915496|NCT00005938|Drug|exatecan mesylate|
45638425|NCT02386969|Device|sham rTMS then active rTMS|A first period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months
45638426|NCT02386657|Other|Satisfaction|Satisfaction questionnaire to be filled in
45776938|NCT05901116|Other|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
45638427|NCT02386657|Other|Biological parameters|Measure of standard routine biological parameters (Hb, GB, Plaq, LDH, CRP, TCA, INR, D Dimers) and dosage of nitrous albumin (PNA).
45638428|NCT02386657|Other|Pain management|Validated pain scale questionnaire to be filled in
45638429|NCT00916747|Drug|Lonafarnib, Zoledronic Acid, and Pravastatin|"Lonafarnib: Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Lonafarnib will be orally administered without planned breaks, approximately every 12 hours, for a period of 24 months. For patients unable to swallow capsules, the capsules can be opened and dissolved into Ora Blend SF or Ora-Plus.~Zoledronic Acid: Zoledronic acid will be administered intravenously at week one, and months 6, 12, 18 and 24 of this treatment trial. Treatment will consist of one infusion over a 30 minute period.~Pravastatin: Pravastatin will be orally administered once daily without planned breaks, approximately every 24 hours, for a period of 24 months. The drug may be taken with meals. For patients unable to swallow pills, pills can be crushed into food. Pravastatin will be dosed according to the patient weight. Patients less than 10 kg will receive 5 mg pravastatin orally, once daily. Patients weighing 10 kg or greater will receive 10 mg pravastatin daily."
45638430|NCT05231317|Other|Plant-based diet|16 days with all foods provided
45638431|NCT05231317|Other|Western diet|16 days with all foods provided
45776939|NCT05901103|Other|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
46070267|NCT00651937|Drug|Melphalan|100 mg/m^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion.
46070268|NCT00651937|Procedure|Stem Cell Infusion|"Stem Cell Infusion is Day 0.~Standard Dose (Arm 1) = Stem cell dose of between 4-6 x 10^6 CD34/kg On Day 0~High Dose (Arm 2) = Stem cell dose of between 10-15 x 10^6 CD34/kg On Day 0."
46070269|NCT00651937|Behavioral|Questionnaires|Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
46070270|NCT00651937|Drug|Granulocyte-colony stimulating factor (G-CSF)|5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days.
46070271|NCT00651937|Procedure|Apheresis|Collection of stem cells from blood collected either through CVC or from a vein in one arm.
46070272|NCT00654355|Drug|tacrolimus ointment|tacrolimus ointment to be applied twice daily to affected areas during duration of study
46070273|NCT00651313|Drug|Lidocaine|Lidocaine vaginal gel 10% (150mg) administered once daily for 4 days
45638432|NCT02391883|Drug|Clopidogrel|
45638433|NCT02386423|Device|RESTIFFIC™ Brand Pressure Application System|The device, RESTIFFIC™, was administered intermittently through the course of the study: one-week baseline period without the device (days 1-7), three weeks of initial testing with the device (days 8-28), a subsequent one-week period without the device (days 29-35), and three weeks of subsequent testing with the device (days 36-56).
45638434|NCT02386267|Drug|L-leucine|L-leucine pills per os for 6 months
45653053|NCT04789031|Dietary Supplement|Oral nutritional supplementation (ONS)|Patients received a renal specific ONS (Novasource Renal, Nestle) providing 475 kcal and 21.7g of protein per serving on a daily basis for 6 months. This was a ready-to- drink formula available in a tetrabrik pack. Patients consumed the product 30 minutes after commencing their dialysis session or at home after completion of dialysis.
45653054|NCT05126745|Device|color flow Doppler ultrasonography|Doppler ultrasonography
45653055|NCT04789421|Device|Clinical, dermoscopy and Reflective confocal microscopy evaluations|Adjunctive reflective confocal microscopy to dermoscopy and clinical dermatological evaluation.
46070274|NCT00651313|Drug|Placebo|Placebo vaginal gel administered once daily for 4 days
46070275|NCT02551705|Other|functional Imaging|Brain responses associated with emotional memory will be investigated
45638435|NCT02382523|Drug|Acthar 80 unit injection|"Subjects not responding after 3 months of therapy (increasing creatinine; proteinuria not lower by 30%), will continue therapy at a dose 120 U SC x2/wk. Treatment will be discontinued if improvement is not observed 6 months after initiation of therapy.~If partial remission is achieved with Acthar 80 U SC x2/wk or x3/wk then Acthar will be increased to 120 U SCx2/wk; if remission is achieved, treatment will be continued at this dose for a total of 12 months; otherwise, if response is not observed after 3 months of treatment with the higher dose, we will resume therapy with the original dose/schedule. We will check anti-ACTH antibodies in non-responders.~If relapse occurs during the follow-up period, a 6 month treatment with Acthar at 120 U SC x2/wk will be started (not for partial responders), and the response will be assessed."
45638436|NCT02386501|Drug|ADXS31-164|
45638437|NCT05547841|Device|Echocardiography acquisition|Echocardiography examination of all participants using PHILIPS. Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of six echocardiographic examinations will be performed in the first trimester (11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester (29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), 6 weeks and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
45638438|NCT02391727|Biological|SYN004|subjects who have received effective treatment for their cancers are eligible
45638439|NCT02391805|Drug|Entecavir|Entecavir will be administered as per local labeling.
45776940|NCT05901090|Other|M-TAPA block|Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. M-TAPA block with the same standard technique and drug dose was applied to the contralateral side for each group of M-TAPA patients.
45638440|NCT02391805|Drug|Placebo|Participants will be administered PO placebo capsules matched to RO6864018, either QOD or QWk for 12 weeks of treatment.
45776941|NCT05901090|Other|TAP block|After the necessary sterilization conditions were established, the linear ultrasound probe was sterilely coated and placed in the middle of the iliac crest with the end limit of the ribs. Starting with skin, the layers in descending order, subcutaneous adipose tissue, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum were identified. As the tip of the 80 mm sonovisible needle passed through the muscular layers and fascia, a fascial click was felt and the needle was advanced with ultrasound in a controlled manner. After receiving the second click sensation (passage of the fascia of the internal oblique muscle), the location of the needle was fixed and frequently aspirated and applied to the plane so that 20 ml of 0.25% bupivacaine was applied to each side. (40 ml in total)
45776942|NCT05901064|Procedure|Axillary clearance|Evaluating the use of Harmonic Focus in axillary clearance due to metastasis of breast cancer in axilla
45776943|NCT05901051|Drug|vonoprazan|Proton pump inhibitor
45776944|NCT05901051|Drug|Amoxicillin|Antibiotics for H. pylori eradication
45776945|NCT05901038|Device|Wearing heart rate monitors|Participants will use 2 consumer wearable heart rate monitors: Polar H10 chest strap and Fitbit Inspire 2 fitness tracker.
45776946|NCT05901012|Drug|N,N-Dimethyltryptamine|DMT will be administered using a vaporizer device in a placebo-controlled, double-blind, randomized, monocentric clinical trial design.
45776947|NCT05901012|Drug|Placebo|DMT will be administered using a vaporizer device in a placebo-controlled, double-blind, randomized, monocentric clinical trial design.
45915497|NCT00005941|Biological|therapeutic allogeneic lymphocytes|
45915498|NCT00005941|Drug|cyclosporine|
45915499|NCT00005941|Drug|fludarabine phosphate|
45915500|NCT00005941|Drug|mycophenolate mofetil|
45915501|NCT00005941|Procedure|peripheral blood stem cell transplantation|
45915502|NCT00005941|Radiation|radiation therapy|
45915503|NCT00005944|Drug|chemotherapy|
45915504|NCT00005944|Drug|fluorouracil|
45915505|NCT00005944|Drug|leucovorin calcium|
45915506|NCT00005944|Drug|mitomycin C|
45915507|NCT00005944|Procedure|conventional surgery|
45915508|NCT00005944|Procedure|laparoscopic surgery|
45653056|NCT04789421|Device|Clinical, dermoscopy evaluations|Dermoscopy and clinical dermatological evaluation only
45915509|NCT00387699|Biological|bevacizumab|
45915510|NCT00387699|Drug|cisplatin|
45448409|NCT05509270|Behavioral|Patient portal|Patient portal message about flu vaccination
45448410|NCT05509270|Behavioral|SMS|SMS about flu vaccination
45915511|NCT00387699|Drug|etoposide|
45915512|NCT00387699|Radiation|radiation therapy|
45915513|NCT00005950|Drug|nelarabine|Given IV
45915514|NCT00005956|Biological|HER-2/neu intracellular domain protein|
45915515|NCT00005956|Biological|therapeutic autologous dendritic cells|
45915516|NCT00005959|Biological|filgrastim|
45915517|NCT00005959|Biological|rituximab|
45915518|NCT00005959|Drug|cyclophosphamide|
45915519|NCT00005959|Drug|doxorubicin hydrochloride|
45915520|NCT00005959|Drug|prednisone|
45915521|NCT00005959|Drug|vincristine sulfate|
45915522|NCT00387738|Biological|Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate|Escalating doses, 6 weekly subcutaneous (under the skin) injections
45915523|NCT00387738|Biological|Histamine base|Escalating doses, 6 weekly subcutaneous (under the skin) injections
45915524|NCT00005965|Drug|bryostatin 1|
45915525|NCT00005965|Drug|cisplatin|
45915526|NCT00005968|Drug|irofulven|
45915527|NCT00387777|Drug|Patch with centrally acting analgesic|
45915528|NCT00387777|Drug|Transtec(R) PRO (buprenorphine)|
45915529|NCT00005971|Drug|alvocidib|
45915530|NCT00005974|Drug|alvocidib|Flavopiridol 50 mg/m2 IV over 1 hour daily x 3 days every 3 weeks
46070276|NCT00808171|Drug|Livopan|Inhalation of oxygen and nitrous oxide 50%
45776948|NCT05900999|Behavioral|Feasibility of idle time exercise|The experiments in this proposal will assess the utility and subjective patient experience performing idle time exercise intervention designed to reduce learned non-use of the hemiparetic arm in the days, and weeks immediately following stroke. Exercise will be cued by wearable technology that provides vibrotactile cues similar to those provided by FitBit devices. Participants will be asked to perform simple exercises after receiving a vibration cue. In the first four sessions they will tap the more-involved wrist; in the second four sessions they will passively move the more-involved elbow through a range of motion; in the final four sessions they will actively move the more-involved elbow through a range of motion. Accelerometers in the wearable devices will monitor motion of the wrist during the exercise sessions. We will interview the participants two months later regarding how well they use the more-involved arm to perform daily activities.
45776949|NCT05900986|Drug|LS301-IT 0.025 mg/kg|The dose of LS301-IT planned to be administered to the first cohort of patients is 0.025 mg/kg. Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased (by 50% as necessary). The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
45915531|NCT03658551|Diagnostic Test|Fluorescein|Measurement of intensity in the gastrointestinal mucosa after intravenous administration of fluorescein by confocal endoscopy
45915532|NCT00005977|Biological|filgrastim|Given IV
45915533|NCT00005977|Drug|cyclophosphamide|Given IV
45915534|NCT00005977|Drug|cytarabine|Given IV
45915535|NCT00005977|Drug|dexamethasone|Given IV
45638441|NCT02391805|Drug|RO6864018|Participants will be administered RO6864018 as 200-mg PO capsules at a dose of 800 mg or 1200 mg, either QOD or QWk for 12 weeks of treatment.
45638442|NCT02391805|Drug|Tenofovir|Tenofovir will be administered as per local labeling.
45638443|NCT02391649|Behavioral|Self-learning program|The PSBBP in this study consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the [psychosocial] effects of the illness; and Module 5:Dealing with [physical and mental health] effects of the illness), helping each caregiver from developing a positive attitude to caregiving, identifying caring related problems and obstacles, predicting positive and negative implications of each alternative, to trying out the solution and monitor if it worked.
45915536|NCT00005977|Drug|doxorubicin hydrochloride|Given IV
45638444|NCT02391649|Behavioral|Psycho-education program (in Phase 2)|The program consists of 12 two-hour sessions held weekly/biweekly completed in 5 months, with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and 'review and future plan'.
45638445|NCT02382289|Procedure|radiofrequency ablation for sacroiliac joint arthropathy|comparing bipolar RF at 6 points with monopolar RF at 3 and 6 points for the treatment of SI arthropathy
45638446|NCT02386579|Procedure|Blood sample measurements|Blood samples are drawn in the feet and arms (a/v) before and after cooling the feet with ice water
45638447|NCT02382367|Other|Blood sampling|Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
45638448|NCT02381977|Other|No intervention|
45638449|NCT05146453|Procedure|Pectointercostal fascia blocks|PIF blocks will be placed at the conclusion of surgery with the surgical drapes in place. The blocks are performed using a high frequency linear transducer with aseptic technique. The ultrasound probe is placed longitudinally 3 cm from the sternum at the level of the 4th-6th intercostal space. Using an in-plane approach, an echogenic needle will be advanced into the fascial plane between pectoralis major and the external intercostal muscles. Peripheral nerve block catheters will then be inserted and secured to the skin surface with tegaderm. For patients weighing over 70 kg, 20 mL of 0.5% ropivacaine will be administered. This will be reduced to 15mL per side for patients weighing less than 70 kg. A CADD™ pump will be connected to each catheter and programmed to deliver 20 mL boluses of ropivacaine 0.2% starting at postoperative hour 2. The boluses will be staggered every 2 hours on alternate sides until hour 24. The catheters will be removed 24 hours post-operatively.
45915537|NCT00005977|Drug|etoposide|Given IV
45915538|NCT00005977|Drug|ifosfamide|Given IV
45915539|NCT00005977|Drug|leucovorin calcium|Given IV
45915540|NCT00005977|Drug|methotrexate|Given IV
45915541|NCT00005977|Drug|vincristine sulfate|Given IV
45915542|NCT00387855|Behavioral|SOS program|screening and didactic programming to raise awareness of depression suicidality
45915543|NCT00005980|Drug|pegylated liposomal doxorubicin hydrochloride|
45915544|NCT00005983|Radiation|radiation therapy|
45915545|NCT00005983|Procedure|surgery|surgery
45915546|NCT00005986|Drug|busulfan|
45915547|NCT00005986|Drug|cyclophosphamide|
45915548|NCT00005986|Drug|filgrastim|
45915549|NCT00005986|Drug|recombinant interferon alfa|
45915550|NCT00005986|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45915551|NCT00005986|Procedure|peripheral blood stem cell transplantation|
45915552|NCT00005986|Procedure|radiation therapy|
45915553|NCT00005989|Drug|tipifarnib|
45915554|NCT00005992|Biological|PSA prostate cancer vaccine|
45915555|NCT00005992|Biological|therapeutic autologous dendritic cells|
45448411|NCT03548038|Other|taste test|All subjects will complete a procedure to determine their taste sensitivity to sweet tastants.
45448412|NCT02135458|Other|Telemonitoring|
45915556|NCT00005995|Drug|shark cartilage extract AE-941|
45915557|NCT00005998|Drug|carmustine|
45915558|NCT00005998|Drug|cyclophosphamide|
45915559|NCT00005998|Drug|cytarabine|
45915560|NCT00005998|Drug|dexamethasone|
45915561|NCT00005998|Drug|etoposide|
45915562|NCT00005998|Drug|filgrastim|
45915563|NCT00005998|Drug|mitoxantrone hydrochloride|
45915564|NCT00005998|Drug|retrovirus vector LN|
45915565|NCT00005998|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45915566|NCT00005998|Procedure|peripheral blood stem cell transplantation|
45915567|NCT00005998|Procedure|radiation therapy|
45915568|NCT00006351|Drug|gemcitabine hydrochloride|
45915569|NCT00006351|Drug|lonafarnib|
45638450|NCT05146453|Other|Placebo|The control group patients will receive the same intraoperative analgesia management. A PIF block will not be performed, instead, a peripheral nerve block catheter will be secured to the skin surface and connected to a CADD™ pump. As the catheter is taped to the skin surface the control group patients will not be exposed to the risks of peripheral nerve block placement.
45638451|NCT05104489|Biological|AdimrSC-2f|IM injection
45638452|NCT02391493|Device|functional magnetic resonance imaging|"Stimuli will be presented in 3 language conditions, French, English and switch in which the participant alternates between English and French every trial. A block design will be used, with 7 line drawings per language condition. Four 9-minute runs will be performed, there being 2 action runs and 2 object runs. In each run, there are 6 blocks of each language condition, presented in a fixed random order. No drawings are repeated. Each stimulus is preceded either by an English or a French prompt word (to or faire for actions and, say or dire for objects) for 450 msec; stimuli are presented for 1.5 seconds and followed by a blank screen for 1 second. Language blocks are separated by a variable duration (from 8 to 10 seconds)."
45638453|NCT02391415|Biological|VPM1002|Tuberculosis vaccine
45638454|NCT02391415|Biological|BCG|commercially available live vaccine BCG
45638455|NCT02391415|Biological|VPM1002(Hyg+)|Tuberculosis vaccine
45638456|NCT02382055|Behavioral|REACH|REACH is a 12-session intervention, delivered 2-3 times per week for 45 minutes. The treatment focuses on identifying and changing behaviors and routines that have become entrenched and help perpetuate the illness.
45638457|NCT02382055|Behavioral|Supportive Psychotherapy|The Supportive Psychotherapy is based on the Specialist Supportive Care (McIntosh et al, 2005), and modified for the current research procedures. Supportive Psychotherapy is a 12-session intervention, delivered 2-3 times per week as 45 minute sessions, focusing on symptoms of anorexia nervosa during the transition to the inpatient unit.
45638458|NCT02382055|Behavioral|Inpatient Behavioral Treatment|Inpatient treatment at the NYSPI is a behaviorally-based treatment program for anorexia nervosa. This is a non-research, clinical intervention for individuals with anorexia nervosa.
45915570|NCT00006001|Drug|semaxanib|
45638459|NCT02391181|Drug|Iron Sucrose Azad|Test product Iron Sucrose Azad will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
45776950|NCT05900986|Drug|LS301-IT 0.05 mg/kg|Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
45915571|NCT00006354|Dietary Supplement|mistletoe extract|
45915572|NCT00006007|Drug|gemcitabine hydrochloride|
45915573|NCT00006007|Drug|pemetrexed disodium|
45915574|NCT00006010|Drug|docetaxel|
45915575|NCT00006010|Drug|gemcitabine hydrochloride|
45638460|NCT02391181|Drug|Venofer®|Reference product Venofer® will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of reference product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
45776951|NCT05900986|Drug|LS301-IT 0.075 mg/kg|Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
45638461|NCT02381821|Other|3 D ultrasound and Doppler examination|Endometrial thickness was measured in the longitudinal plane at the widest anteroposterior diameter with a trans-vaginal 2D ultrasound, and then 3D mode was then activated with power Doppler setting for this study standardized using a frequency at 4-9 MHZ pulse repetition frequency at 0.5KHz gain at-3.0 and wall motion filter at 1. The sub-endometrial region was considered to be within 3 mm of the originally defined myometrial-endometrial contour. The endometrial volume (EV) and 3D power Doppler indices below the endometrium were measured using the automated VOCAL™ for the 3D power Doppler histogram analysis
45754279|NCT02943265|Other|Care Coordination Strategies|Co-located Care coordinator will use EMR-driven registry to facilitate patient transitions between primary care and oncology care and enhance teamwork through coaching and technical assistance.
45776952|NCT05900986|Drug|LS301-IT 0.1 mg/kg|Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
45776953|NCT05900947|Other|analysis of carotid atherosclerotic plaque|To assess the presence of air pollutants (benzene, toluene, xylene, and ethylbenzene) within tissues from atherosclerotic plaques by Chromatographic analyses.
45915576|NCT00006013|Drug|semaxanib|
45915577|NCT00006357|Drug|imatinib mesylate|
45915578|NCT00006016|Drug|thalidomide|Given orally
45915579|NCT00006016|Drug|doxorubicin hydrochloride|Given transarterially (chemoembolization)
45915580|NCT00006016|Other|laboratory biomarker analysis|Correlative studies
45915581|NCT00006019|Drug|azacitidine|
45915582|NCT00006019|Drug|sodium phenylbutyrate|
45915583|NCT00006022|Biological|aldesleukin|
45915584|NCT00006022|Drug|bryostatin 1|
45915585|NCT00006025|Drug|irinotecan hydrochloride|
45915586|NCT00006025|Drug|temozolomide|
45915587|NCT00386659|Drug|tenofovir + abacavir + lopinavir/ritonavir|
45448413|NCT02135458|Other|Conventional care|
45638462|NCT02381821|Drug|GnRH agonist|All women received daily subcutaneous 0.1 mg triptorelin injection started from day 21) of the cycle preceding stimulation. Downregulation of the pituitary gonadotropins was confirmed after 12 days , gonadotropin (Gn) induction was started using Human menopausal gonadotropins for ovarian stimulation. The starting dose was 225 to 300 IU . Ultrasound Folliculometry was done every other day . When two or more follicles reached a minimum mean diameter of 18 mm, triggering of ovulation trigger was done using Human chorionic gonadotropin (hCG) 10,000 IU and ovum pick up was scheduled 36 hours later
45638463|NCT02381899|Drug|Bendamustine and Rituximab|Patients receive bendamustine and rituximab. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
45638464|NCT01998958|Drug|Esketamine 14 mg|1 to 6 sprays of esketamine 14 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable during the optional open-label phase for up to 4 days
45638465|NCT01998958|Drug|Esketamine 28 mg|1 to 6 sprays of esketamine 28 mg self-administered as an intranasal formulation for 4 days (Days 1,4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
45638466|NCT01998958|Drug|Esketamine 56 mg|1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
45638467|NCT01998958|Drug|Esketamine 84 mg|1 to 6 sprays of esketamine 84 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
45638468|NCT01998958|Drug|Placebo|1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase
45448414|NCT05508100|Biological|IO-108|IO-108 will be administrated at RP2D selected from US study IO-108-CL-001, intravenously, on Day 1 of each 21-day cycle.
45638469|NCT02386111|Drug|Combination of varlilumab and sunitinib|"During the treatment phase of the study, eligible patients will receive varlilumab for up to 8 cycles. Treatment cycles are 6 weeks each with varlilumab administered once every 3 weeks and sunitinib administered daily for 4 weeks followed by a 2 week rest. There is no limit on the number of cycles of sunitinib. Patients may be discontinued from receiving study treatment (sunitinib or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg or 3 mg/kg.~The Study was terminated prior to initiation of Phase II.~All patients will receive sunitinib at a dose of 50 mg."
45638470|NCT02381743|Behavioral|Group 2 intervention daily SMS bullet point|Group 2 subjects receive a daily SMS bullet point, summarizing a key clinical point pertinent to the CBPA's daily work.
45638471|NCT02381743|Behavioral|Group 3 intervention daily SMS bullet point|Group 3 subjects receive a c phrased as a multiple choice question. The content mirrors that of group 2, but is presented as a question to render it interactive
45638472|NCT02386033|Drug|Atorvastatin (ATV)|After SRP, ATV gel was delivered subgingivally into the pocket
45638473|NCT02386033|Drug|Placebo Gel|After SRP, placebo gel was delivered subgingivally into the pocket
45776954|NCT05900934|Other|Myofascial Releasing Group|Using a subjective 7/10 target numeric rating scale rating (0 representing no discomfort and 10 representing maximum discomfort), the intensity of foam roller application can be determined. This intensity defines an application intensity that is mildly painful for the participant and appropriate according to previous literature.
45776955|NCT05900934|Other|Sham Myofascial Releasing Group|The severity of the application is not felt at all according to the numerical rating scale of 0/10.
45776956|NCT05900921|Drug|Trilaciclib|IV infusion, d1
45776957|NCT05900921|Drug|Carboplatin|IV infusion, d1
45915588|NCT00386659|Drug|tenofovir + abacavir + efavirenz|
45776958|NCT05900921|Drug|Paclitaxel|IV infusion, d1
45776959|NCT05900921|Drug|Tislelizumab|IV infusion, d1
45776960|NCT05900908|Device|Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)|GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile
45776961|NCT05900908|Radiation|Stereotactic Radiation Therapy|External Beam Radiation Therapy
45776962|NCT05900895|Drug|Olaparib|Participants will be treated with olaparib at the approved doses for the treatment of subtypes of breast cancer or at reduced dose/frequency for participants with moderate renal impairment.
45776963|NCT05900895|Drug|17b-estradiol|17b-estradiol will be taken orally three times per day.
45776964|NCT05900882|Drug|Selinexor|Selinexor 60 mg/day, orally on d1,8,15,22
45915589|NCT00006360|Drug|radioprotection|
45638474|NCT05233345|Behavioral|Occupational Therapy|online occupational therapy sessions are based on the activity training
45754280|NCT03895346|Behavioral|Mindfulness|Mindfulness meditation is a technique of sustained attention and focus, involving preventing the mind from wandering from the meditative object (i.e. breath or body sensations)
45754281|NCT03895346|Behavioral|Brain Games and Puzzles|Intervention will include the instruction and practice of puzzles such as word searches, crossword puzzles, Sudoku, and KenKen.
45776965|NCT05900882|Drug|Bortezomib|Bortezomib 1.3mg/m2 intravenously on d1,8,15,22
45776966|NCT05900882|Drug|Lenalidomide|Lenalidomide 25 mg/d (the dose will be adjusted according to creatinine clearance)
45915590|NCT00006360|Radiation|radiation therapy|
45915591|NCT00386698|Biological|Fluarix|
45915592|NCT00386698|Biological|adjuvanted influenza vaccine|
45915593|NCT00006028|Drug|cisplatin|
45915594|NCT00006028|Drug|gemcitabine hydrochloride|
45915595|NCT00387933|Drug|hydroxyurea|
45915596|NCT00387933|Drug|imatinib mesylate|
45915597|NCT00387933|Drug|vatalanib|
45915598|NCT00006031|Procedure|Needle localized breast biopsy with specimen x-ray|
45915599|NCT00006031|Procedure|Low dose radioactive seed followed by surgery and mammogram|either iodine I 125 or palladium Pd 103
45915600|NCT00006034|Biological|keyhole limpet hemocyanin|Given intradermally and IV
45915601|NCT00006034|Drug|doxorubicin hydrochloride|Given IV
45915602|NCT00006037|Drug|fluorouracil|
45915603|NCT00006037|Drug|irinotecan hydrochloride|
45638475|NCT02385955|Procedure|Myeloablative double unit cord blood transplantation|Two myeloablative conditioning regimens will be used in this study: (1) total body irradation (TBI, 12Gy), followed by cyclophosphamide (60 mg/kg/day on day -3 and -2) and cytarabine (3 g/m2 every 12 hours on day -5 and -4), or (2) thiotepa (5 mg/kg/day on day -7 and -6), busulfan (3.2 mg/kg/day on day -5, -4, and -3), and fludarabine (50 mg/m2/day on day -5, -4, and -3).
45776967|NCT05900882|Drug|Dexamethasone|Dexamethasone 20 mg/day orally on d1-2, d8-9,d15-16,d22-23
45638476|NCT02381665|Device|Flexstim IF|Patient enrolled will receive a device for effective interferential current stimulation
45776968|NCT05900869|Other|FSFI|Female Sexual Function Index questionnaire
45776969|NCT05900869|Other|BES|Body Esteem Scale questionnaire
45638477|NCT02381665|Device|Flexstim IF faked|Patient enrolled will receive a sham device.
45638478|NCT02381587|Other|Retrospective study|no interventional study - Retrospective study that valuate The effect of HCQ treatment in cardiovascular AVENTS IN patients with primary sjogren syndrome
45638479|NCT01958164|Drug|Actilyse|Actilyse 2mg/2ml will be given if the CVAD has not been restored at time 120min.
45638480|NCT01958164|Drug|Saline solution|Instil Saline solution 2 ml into the disfunctional CVAD once at time O only for patients enrolled in Group II
45776970|NCT05900856|Other|low caloric diet regimen|lipids approximately (20: 35%) of total caloric intake, protein approximately (10: 35%) of total caloric intake and high complexed carbohydrate intake approximately (45: 65%) of total caloric intake (with increased fiber-rich whole grain breads, cereals, fruits and vegetables), for eight weeks.
45776971|NCT05900856|Device|ultrasound cavitation|patients will assume standing position, the abdominal area will be divided vertically into 2 equal sections, right and left segment, extending bilaterally from the line stretching between the mid axilla above and the iliac crest below, and upward from center of diaphragm to the midpoint extending between two iliac crest below, then from supine lying position the cavitation head will be applied on each abdominal segment for 15 minutes with total treatment time 30 minutes twice per week for eight weeks
45776972|NCT05900830|Other|play therapy|A combined program based on physical and occupational therapy techniques within a play context
45776973|NCT05900830|Other|common educational methods|the child will receive his education in a passive manner
45915604|NCT00006037|Drug|oglufanide disodium|
45776974|NCT05900817|Other|antivet|A material used for micro abrasion of teeth
45915605|NCT00006040|Biological|filgrastim|
45915606|NCT00006040|Drug|etoposide|
45915607|NCT00006040|Procedure|autologous bone marrow transplantation|
45915608|NCT00006040|Procedure|peripheral blood stem cell transplantation|
45638481|NCT01958164|Drug|Actilyse|Instil Actilyse 2 mg/ 2 ml into the dysfunctional CVAD at time O.
45638482|NCT01958164|Drug|Actilyse|Second dose of Actilyse 2mg/2ml will be given if CVAD has not been restored at time 120min.
45915609|NCT00006040|Radiation|yttrium Y 90 monoclonal antibody M195|
45638483|NCT02381275|Drug|Tenofovir Disoproxil Fumarate|Observe long-term outcomes of patients using Tenofovir based antiretroviral therapy at the Lighthouse Clinics
45638484|NCT04821154|Device|Persona Revision Knee System|Patients in this cohort will have been previously implanted with the Persona Revision Knee system in the described configuration per standard of care. The Persona Revision knee system is a total knee system that is widely available for use in the United States and is designed for use in primary and revision knee surgical interventions.
45638485|NCT05069623|Biological|VB10.2129|0.3 mg, 1 mg or 3 mg on Day 0 and Day 21 or 3 mg on Day 0
45638486|NCT05069623|Biological|VB10.2210|3 doses (dose to be determined) on Day 0 and Day 21 or highest dose (TBD) on Day 0
45638487|NCT02381431|Device|FLIR ONE|
45638488|NCT02385877|Drug|[18F]4F-MHPG|IV injection of [18F]4F-MHPG
45638489|NCT02385877|Drug|[18F]3F-PHPG|IV injection of [18F]3F-PHPG
45638490|NCT01976104|Drug|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
45638491|NCT01976104|Drug|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
45638492|NCT01976104|Drug|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
45638493|NCT01976104|Drug|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
45776975|NCT05900817|Other|Oplsture|A material used for micro abrasion of teeth
45776976|NCT05900804|Other|Training Prepared in Line with the Fracture Liaison Service Model|The Effect of Education Prepared in Line with Fracture Liaison Service Model on Patients' Frailty Level, Care Dependency and Fear of Movement in Hip Surgery Patients
45915610|NCT00006363|Drug|cytarabine|Given IV
45915611|NCT00006363|Drug|daunorubicin hydrochloride|Given IV
45915612|NCT00006363|Drug|etoposide|Given IV
45915613|NCT00006363|Drug|valspodar|Given IV
45915614|NCT00006363|Biological|filgrastim|Given SC
45915615|NCT00006363|Drug|busulfan|Given orally
45776977|NCT05900791|Procedure|Primary knee arthroplasty|All patients surveyed have undergone primary knee arthroplasty approximately 1 year prior to survey distribution
45776978|NCT05900752|Dietary Supplement|QiMeiYan Probiotics|consume one sachet of the assigned product, once a day after meals.
45776979|NCT05900752|Dietary Supplement|Placebo product|consume one sachet of the assigned product, once a day after meals.
45915616|NCT00006363|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
45915617|NCT00006363|Procedure|peripheral blood stem cell transplantation|Undergo autologous PBSCT
45915618|NCT00006363|Biological|aldesleukin|Given SC
45915619|NCT00006363|Other|clinical observation|Undergo clinical observation
45915620|NCT00006363|Other|pharmacological study|Correlative studies
45915621|NCT05681065|Device|TeNDER tool|"The TeNDER intervention consists of the use of the TeNDER technological tool. It is a web application that integrates all the functionalities of biosensors to facilitate patient self-monitoring, caregiver care and monitoring and management in the daily work of healthcare professionals. Each participant will use the sensor that suits their needs:~Sleep quality detector; Position sensor; Smart band; Smart watch; Microphone and speaker; rgb (real sense) sensor; Binary door and window sensor; Environmental sensor."
45915622|NCT05681026|Behavioral|Yoga Sessions|Participants will have up to 12 sessions, 3 sessions per week, over the first 30 days of your hospitalization.
45638494|NCT01372501|Device|Endobarrier Liner|Medical device placed endoscopically in the duodenum
45638495|NCT02391259|Drug|AMG 557|AMG 557 is for the treatment of sybjects with systemic lupus erythematosus
45638496|NCT02391259|Drug|Placebo|contains no active drug
45638497|NCT02385643|Behavioral|SmartPhone Support System|
45638498|NCT02385565|Other|high fat diet|high fat diet as 10 % proteins, 30 % lipids, 60 % carbohydrates
45638499|NCT02385565|Other|normal fat diet|high fat diet as 10 % proteins, 45 % lipids,45 % carbohydrates
45638500|NCT02391103|Device|Compex 3 Professional (CefarCompex Medical AB) stimulator|NMES
45638501|NCT02391103|Device|sham-stimulation|no electricity applied
45638502|NCT01958008|Drug|Placebo to BI 113608 high dose b.i.d.|Film-coated tablet
45776980|NCT05900739|Behavioral|Increase of fruit and vegetable consumption|"Week 1 Presentation of the program. Healthy eating Week 2 Fruit and vegetable: nutritional value, types, seasonality, benefits for health Week 3 Shopping Fruit and vegetable: tips, places, conservation methods Week 4 Healthy menu planning with My Plate Week 5 How to cook Fruit and Vegetable avoiding food waste Week 6 Healthy snacks using Fruit and vegetable Week 7 Batch cooking"
45776981|NCT05900726|Diagnostic Test|High Resolution Anorectal Manometry|A test used to measure the strength of the muscles in the anal canal
45776982|NCT05900726|Diagnostic Test|Endoanal Ultrasound|An examination of the anal canal (back passage) that allows us to see the muscles involved in passing stool and the tissues that surround these.
45776983|NCT05900726|Other|Bowel diary|A daily diary to assess episodes of faecal incontinence
45776984|NCT05900726|Other|MYMOP2|Questionnaire to assess individual symptoms, general wellbeing and activity in faecal incontinence
45776985|NCT05900726|Other|FIQOL|Questionnaire to assess the quality of life with faecal incontinence
45638503|NCT01958008|Drug|Placebo to BI 113608 low dose b.i.d.|Film-coated tablet
45638504|NCT01958008|Drug|BI 113608 high dose b.i.d.|Film-coated tablet
45638505|NCT01958008|Drug|Placebo to BI 113608 medium dose b.i.d.|Film-coated tablet
45638506|NCT01958008|Drug|BI 113608 low dose b.i.d.|Film-coated tablet
45638507|NCT01958008|Drug|BI 113608 medium dose b.i.d.|Film-coated tablet
45638508|NCT04479163|Biological|Convalescent Plasma|250 ml Convalescent plasma with an IgG titer against SARS CoV2
45638509|NCT04479163|Other|Placebo|Normal Saline 0.9%
45638510|NCT04645264|Device|Foley Catheter|The patient is catheterized during surgery.
45638511|NCT02380963|Dietary Supplement|Colorado Diet with soy protein foods.|"Phase 1 (week 1-2): Participants will be given soy protein powder and asked to consume 3 protein shakes per day.~Phase 2 (week 3-8): Participants will be given both protein powder and soy patties designed to be similar to other phase 2 acceptable foods and will be asked to consume 2 soy protein shakes and 1 soy patty per day.~Phase 3 (week 9-16): Participants will be given protein powder, soy patties, and protein bars designed to be similar to other phase 3 acceptable foods and will be asked to consume 1 soy protein shake, 1 soy patty and 1 soy protein bar per day.~Maintenance Phase (month 5-12): Participants will continue to receive study food products (protein powder, patties and protein bars)"
45638512|NCT02380963|Behavioral|Colorado Diet with monetary payments|"Phase 1 (week 1-2): Participants will be given monetary stipend and asked to consume 3 non-soy protein shakes per day.~Phase 2 (week 3-8): Participants will be given monetary stipends and asked to consume 2 non-soy protein shakes per day.~Phase 3 (week 9-16): Participants will be given monetary stipend and asked to consume 1 non-soy protein shake and 1 non-soy protein bar per day.~Maintenance Phase (month 5-12): Participants will continue to receive monetary stipend."
45638513|NCT02381509|Device|IVC Filter|
45638514|NCT02381197|Device|Congo Red Dot test|The Congo Red Dot test is a simple dye test that detects unfolded or misfolded proteins
45638515|NCT04694287|Diagnostic Test|Percutaneous DUS volume flow measurements|Volume flow measurements of the AFV will be obtained using intraprocedural DUS just prior to sheath insertion and at the end of the final balloon dilation, before sheath removal.
45638516|NCT02385253|Behavioral|Educational training program|"The educational training program (intervention) consists of four sequential phases:~Knowledge Acquisition~Skills Assessment~Deliberate Practice~Clinical Proficiency"
45638517|NCT02390947|Drug|Famitinib|25 mg p.o. qd
45638518|NCT02390947|Drug|Placebo|25 mg p.o. qd
45638519|NCT04693507|Drug|teverelix TFA 120 mg|Teverelix TFA 240 mg Day 0 and 120 mg every 6 weeks from week 6 to week 24
45638520|NCT04693507|Drug|teverelix TFA 180 mg|Teverelix TFA 360 mg Day 0 and 180 mg every 6 weeks from week 6 to week 24
45638521|NCT03105661|Drug|Labetalol Hydrochloride 200 mg|Anti-hypertensive prescribed for increased cardiac output as determined by Impedance Cardiography
45638522|NCT03105661|Drug|NIFEdipine 60 mg|Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by Impedance Cardiography
45776986|NCT05900726|Other|FISI|Questionnaire to assess the severity of faecal incontinence
45776987|NCT05900726|Other|Follow up call|At 28 days and 3 months post final pelvipower or sham session to assess faecal incontience after study period
45776988|NCT05900726|Other|St Mark's incontinence score|A score of incontinence
45776989|NCT05900492|Procedure|cesarean section|caesarean delivery, is the surgical procedure by which one or more babies are delivered through an incision in the mother's abdomen
45776990|NCT05899725|Drug|Corticosteroids|Initial dosage of corticosteroids is more than predinisone 1mg/kg/d or other corticosteroids with equal equivalence
45776991|NCT05899725|Drug|Corticosteroids and Ruxolitinib|Initial dosage of corticosteroids is more than predinisone 1mg/kg/d or other corticosteroids with equal equivalence, add-on oral Ruxolitinib 5mg twice a day for 2 weeks, following with Ruxolitinib
45776992|NCT05899699|Drug|DAP-FLU ME|Combination therapy of topical anti-inflammatory agent (Dapsone 5%) and anti-androgenic agent (Flutamide 2.5%) with anti-bacterial agent of micro-emulsion component (tea tree oil 5%)
45776993|NCT05899699|Drug|Adapalene .1% gel|Adapalene .1% gel
45915623|NCT05681026|Behavioral|Questionnaries|Participants will complete 4 questionnaires about any symptoms you may be having, any anxiety and/or depression you may be having, your quality of life, and your expectations about your treatment.
45638523|NCT03105661|Drug|Atenolol 25 mg|Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
45638524|NCT03105817|Device|Asymmetric cellulose triacetate (ATA™)|Each patient underwent 12 sessions of haemodialysis with the usual schedule, changing the usual dialyzer
45638525|NCT02381119|Behavioral|Personalized Dietary Advice Services|"This Personalized Dietary Advice is based on markers for nutrition status and SNPs (single nucleotide polymorphisms).~This advice is given via Personalized Dietary Advice Services, in which health data of the client can be entered and will be translated into advice on intake of specific nutrients or food categories."
45776994|NCT05899608|Biological|Ivonescimab Injection|Subject will receive ivonescimab and chemotherapy as an IV injection
45776995|NCT05899608|Biological|Pembrolizumab Injection|Subject will receive pembrolizumab and chemotherapy as an IV injection
45776996|NCT05899530|Device|Invisalign|Expansion using Invisalign versus conventional expander
45776997|NCT05899530|Device|Conventional expander|conventional expander
45776998|NCT05899439|Other|blood draw|a peripheral blood draw
45915624|NCT05681026|Behavioral|Interviews|Participants will have an exit interview last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom, FaceTime, or other approved video call methods.). The interview will be audio and video recorded and transcribed (typed).
45915625|NCT05680987|Procedure|RFN-Advanced Retrograde Femoral Nailing System|RFN-Advanced Retrograde Femoral Nailing System for patients with a distal femur or femoral shaft fracture requiring surgery
45448415|NCT05508100|Biological|IO-108 + pembrolizumab|IO-108 will be administrated at RP2D selected from US study IO-108-CL-001, intravenously, on Day 1 of each 21-day cycle. Pembrolizumab 200 mg will be administered intravenously on Day 1 of each 21-day cycle.
45915626|NCT05680870|Drug|Omeprazole|Omeprazole 40 mg 3 times daily for 5 days ..to start 2 days before chemotherapy cycles
45915627|NCT00006366|Drug|fluorouracil|
45915628|NCT00006366|Drug|irinotecan hydrochloride|
45915629|NCT00006366|Procedure|conventional surgery|
45915630|NCT00006366|Radiation|radiation therapy|
45448416|NCT02785900|Drug|33A|33A, 10 mcg/kg, every 4 weeks via intravenous (IV) push
45448417|NCT02785900|Drug|placebo|Volume equivalent to 10 mcg/kg, every 4 weeks via IV push
45448418|NCT02785900|Drug|azacitidine|75 mg/m2 given subcutaneously (SC) or IV x 7 days, every 4 weeks
45448419|NCT02785900|Drug|decitabine|20 mg/m2 given IV x 5 days, every 4 weeks
45638526|NCT02381119|Behavioral|Regular care|The control group will receive usual advice for diabetes type 2 from the dietician. However, after the end of the study participants in the control group will be offered the opportunity to receive the Personalized Dietary Advice from their dietician, as based on the parameters measured during the study.
45638527|NCT02385175|Other|Different objective clinical tests of Eustachian tube function|
45638528|NCT02385175|Other|Different patient-completed questionnaires relating to Eustachian tube dysfunction|
45638529|NCT02384785|Device|Transcutaneous Electric Nerve Stimulation|Electric currents: 'Transcutaneous Electric Nerve Stimulation' and Transcranial Direct Current Stimulation will be applied on the back of the patients in parallel to the implanted electrodes. Implanted electrode will measure voltages that generated near the spinal cord tissue.
45638530|NCT02390713|Device|MID-AVR|"Phase A (4 patients): After laparotomy and dissection of hepatic pedicle, feasibility of MID-AVR positioning around the portal vein by hepato-biliary surgeon and visual evaluation of potential spatial conflict with hepatic artery and choledochal. Mid-AVR is removed at the end of surgery. Each procedure will be filmed.~Phase B (12 patients): Mid-AVR is maintained at the end of surgery, and during 48 hours to evaluate the persistence of an hepatopetal portal flow without portal vein thrombosis upstream MID-AVR during the 48 hours after the liver surgery at bi-daily ultrasonography."
45638531|NCT02380885|Behavioral|SCIT|psychosocial group intervention
45638532|NCT02380885|Behavioral|TAFT|psychosocial group intervention
45638533|NCT02380729|Genetic|Gene Panel Sequencing|Enrichment for and panel sequencing of 2942 disease genes listed in the Online Mendelian Inheritance of Man (OMIM) database.
45638534|NCT02380729|Genetic|Whole Genome Sequencing (WGS)|Whole Genome Sequencing of the index case and of both parents in the event that Gene Panel Sequencing did not identify a disease-causing mutation.
45638535|NCT02390401|Device|Vacuum-assisted closure|Prevena (VAC) device at the time of primary closure for a cesarean section, left in place for 5-7 days postoperatively.
45754282|NCT04415905|Drug|Propofol|The participants in the group P are anesthetized with propofol
45915631|NCT05680831|Biological|0.070 ppm ozone concentration|The concentration of ozone a subject will randomly receive on a visit for 6.6 hours in a controlled atmospheric chamber while performing moderate intermittent exercise.
45915632|NCT05680831|Biological|Clean air (0.0 ppm ozone)|Same subject will randomly receive clean air on another visit separated by at least one week for 6.6 hours in the same controlled atmospheric chamber while performing moderate intermittent exercise.
45915633|NCT05680792|Drug|Nitazoxanide|1000 mg nitazoxanide tablets twice daily. The drug will be administered after meal for 5 days
45915634|NCT05680792|Drug|"Nitazoxanide and atazanavir/ritonavir separately"|1000 mg nitazoxanide tablets twice daily and 300/100 mg atazanavir/ritonavir tablets once daily (i.e., nitazoxanide plus atazanavir-r in the morning and nitazoxanide alone in the evening). The drugs will be administered after meal for 5 days
45915635|NCT05680753|Behavioral|Physiotherapy|Physiotherapy
45915636|NCT05680714|Other|Implement coordination of care with multifactorial falls- and fracture risk assessment and tailored intervention|
45935655|NCT04730505|Device|MyHope HCP Portal|Is designed to provide HCPs with the ability to view patient data and symptom notifications (Cohort 1 only) to provide support between clinic visits and to facilitate dialogue during clinic visits.
45935656|NCT05562154|Procedure|Total Ankle Replacement|Participants will undergo either lateral approach or anterior approach when having a total ankle replacement
45638536|NCT02390401|Device|Standard sterile dressing|Standard sterile dressing at the time of primary closure for a cesarean section, left in place for 1-2 days postoperatively.
45448420|NCT00127205|Drug|clodronate disodium|Given orally
45638537|NCT04903327|Biological|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
45638538|NCT04903327|Drug|Placebo|Excipient solution
45935657|NCT05562076|Device|the spot stent(ZENFLEX ® Pinto) system|the spot stent(ZENFLEX ® Pinto) system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
45638539|NCT04897009|Procedure|Biospecimen Collection|Undergo blood and tissue collection
45638540|NCT02380807|Device|Dry Needling|"Dry needling is the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, sometimes also known as intramuscular stimulation (IMS). Although dry needling originally utilized only hypodermic needles due to the concern that solid filiform needles had neither the strength or tactile feedback that hypodermic needles provided and that the solid filiform needle could be deflected by dense contraction knots."
45638541|NCT02380807|Other|Cross Tape Therapy|The tape consists of cross bands or strips mesh cross, nonelastic and without any medication, forming a grid-shaped patch. The cross tape will be applied on trigger points.
45638542|NCT02380651|Procedure|Limb salvage|Local or free flaps
45638543|NCT02390479|Other|non surgical periodontal treatment|"SRP under local anaesthesia, in a total of four clinical visits~Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
45638544|NCT02380495|Other|Data Collection|
45638545|NCT01998880|Drug|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
45638546|NCT01998880|Drug|rituximab|375 mg/m^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6.
45638547|NCT01998880|Drug|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
45638548|NCT04747561|Drug|18F-PEG3-FPN|For clinically suspected or confirmed melanoma patients and healthy volunteers, integrated PET/MR imaging was performed using targeted melanin-specific imaging agent 18F-PEG3-FPN. Meanwhile, the general imaging agent 18F-FDG was compared with MR multi-sequence and multi-parameters
45638549|NCT04745221|Other|autologous fecal bacteria|autologous fecal bacteria transplantation
45638550|NCT02385019|Biological|Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease|"Regulatory T cells selected by a sequential 2 step procedure:~- Negative selection of CD8 and CD19 cells~- Positive selection of CD25 cells"
45638551|NCT02384629|Device|OCT-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
45776999|NCT05899231|Behavioral|Prehabilitation Programming|"12-weeks of online prehabilitation programming including:~1.12 weeks of nutrition programming focused on achieving a guideline- based protein intake of 1.2-1.5 g/kg/day. Participants will participate in a dietitian assessment and 0-2 dietitian follow-ups stratified by risk and 5 virtual group nutrition classes. Participants will be provided with a whey protein powder supplement - dosing stratified by risk.~2.10 weeks of exercise programming focused on completion of 3 full- body resistance/aerobic exercise sessions weekly (1 or 2 virtual group classes as per patient preference + 1 or 2 pre-recorded home exercise videos).~3.12 weeks of acceptance and commitment therapy based educational videos and online activities focused on reducing stress and anxiety and improving motivation and adherence."
45777000|NCT05898919|Other|Acupuncture|Acupuncture is a technique that inserts a needle into the acupuncture point to treat a condition. In this trial, we will use acupuncture to treat postoperative urinary retention.
45777001|NCT05898919|Other|Sham acupuncture|Participants will receive sham acupuncture at sham points.
45777002|NCT05898919|Drug|Neostigmine Injectable Product|Neostigmine was injected once after postoperative urinary retention.
45777003|NCT05898854|Drug|68Ga-FAPi-46|Gastric or gatro-esophageal junction cancer patients undergo 68Ga-FAPi-46 PET/CT at primary staging and at restaging
45638552|NCT02384629|Device|OCT-guided PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
45754283|NCT04415905|Drug|Sevoflurane|The participants in the group S are anesthetized with sevoflurane.
45777004|NCT05898737|Device|NOL-Index|NOL Index monitoring with the PMD100™ (Medasense Biometrics Ltd.)
45935658|NCT05562076|Device|the bare stent( Everflex) system|the bare stent( Everflex) system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
45448421|NCT00127205|Drug|ibandronate sodium|Given orally
45448422|NCT00127205|Drug|zoledronic acid|Given IV
45754284|NCT03021356|Device|Aortic xenograft|After randomization, the aortic xenograft is implanted in the standard fashion
45777005|NCT05898594|Procedure|Low-dose Computed Tomography|Per standard care
45777006|NCT05898516|Behavioral|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
45638553|NCT02384629|Device|Angio-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. We use the conventional coronary angiography.
45638554|NCT02384629|Device|Angio-guided PCI with PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. We use the conventional coronary angiography.
45777007|NCT05898412|Drug|Andexanet alfa|Patients treated with andexanet alfa
45638555|NCT02384707|Other|allegic food|"Reintroduction procedure for small doses :~Administration of the first dose~Clinical monitoring for 45 minutes~Administration of the second dose"
45638556|NCT02384707|Other|Placebo|
45638557|NCT02380417|Procedure|paravertebral catheter placement|a thoracic paravertebral catheter was placed and connected to an elastomeric pump with a continuous infusion of 0.2% ropivacaine
45638558|NCT02380417|Drug|0.2% ropivacaine|0.2% ropivacaine was infused through the elastomeric device
45638559|NCT02380417|Device|Elastomeric pump|An elastomeric pump was connected to the paravertebral catheter
45638560|NCT02380339|Behavioral|Psych-Educational session and virtual reality|Psych-Educational session and virtual reality
45638561|NCT02380339|Behavioral|Psych-Educational and BF sessions|Psych-Educational and BF sessions
45638562|NCT01975948|Other|Mental Health Practice Support Program|"training and (2) practice support.~Three half day workshop sessions over a 24 week period.~Practice support:~3 evidence based Supported Self Management tools (Cognitive Behavioral Interpersonal Skills Manual,Bounceback program, Antidepressant Skills Workbook), and Practice support coordinator provides guidance to incorporate newly acquired tools, skills, and processes"
45777008|NCT05897983|Other|Rocabado exercises plus TENS device|Rocabado exercises form of 2 parts , 6×6×6 exercises part are repeated 6 times a day for 20 minutes for each repetition and mobilization exercises exercises is done by the therapist 3 times a week for 20 min ,each mobilization is performed for 10-15 times and repeated for 5-6 times. TENS is used, with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 mA and the pulse width is between 50-200 microseconds, The TENS will be applied for 20 min 3 sessions/week for 8 weeks, Traditional exercises are passive , active Rom exercises and massage, these exercises are performed for 30 minutes and repeated 2 times daily
45638563|NCT01975948|Other|Treatment as Usual|Physicians manage patients with depression as usual
45777009|NCT05897671|Other|retrospective data analysis|Macular hole closure rate, visual acuity and OCT
45777010|NCT05897190|Biological|SARS-CoV-2 mRNA vaccine (RBMRNA)|Dose A
45777011|NCT05897190|Biological|CoronaVac®|Dose B
45777012|NCT05897151|Drug|Continuous spinal anesthesia|"Preservative free 0.5% Hyperbaric bupivacaine (AstraZeneca) 5mg + 25mcg fentanyl for the initial dose will be followed by top up doses of 2.5 mg boluses of 0.5% Hyperbaric bupivacaine every 10 minutes until the desired block height is obtained considering patient hemodynamics.~Norepinephrine starting. dose 0.01 micg/kg/min will be ready for both groups if needed (Mean arterial pressure < 70 or Mean arterial pressure decreased more than 20% of preoperative value). The infusion will be through a wide bore Intravenous line. The dose will be titrated up or down according to the patient hemodynamics."
45915637|NCT05680675|Diagnostic Test|Single-Tracer FDG PET/CT Exam|"The PET technologist will administer approximately 15 mCi (millicuries) of FDG intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
45777013|NCT05897151|Drug|General anesthesia|After establishing of ASA monitoring, a wide bore cannula (18 G) will be inserted. Induction will be done by fentanyl ( 2 mcg/kg ) , titrating dose of propofol according to patient hemodynamic response and atracurium ( 0.5 mg/kg ) to facilitate tracheal intubation maintaining End tidal Co2 between 30-40 mmHg.
45777014|NCT05897138|Drug|Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle|"Drug: Lenvatinib Capsules administered orally once daily~Drug: Tislelizumab 200 mg intravenous (IV) infusion administered on Day 1 of each cycle"
45777015|NCT05896917|Device|3D Printed Foot Orthosis|3D printed foot orthoses designed and fabricated at the Taibah University
45777016|NCT05896917|Device|Prefabricated Foot Orthosis|Generic foot orthoses available commercially
45915638|NCT05680675|Diagnostic Test|Single-Tracer Cu64-DOTATATE PET/CT Exam|"The PET technologist will administer with approximately 4 mCi Cu64-DOTATATE intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
45935659|NCT00044135|Drug|clevudine (drug)|
46070277|NCT00808171|Drug|Livopan|equimolar mixture of N2O/O2
46070278|NCT00808171|Drug|EMLA|Lidocaine-prilocain cream
45638564|NCT02380105|Behavioral|Counseling|Patients were informed of their condition and possible etiological factors contributing to the pathology. They were also educated about the postural rest position of the mandible and instructed to perform bilateral chewing and not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions for future reference, as a way of reinforcing the information provided during the initial consultation.
45638565|NCT02380105|Device|Interocclusal Appliances|Patients were treated using interocclusal appliances
45448423|NCT05575960|Behavioral|Interpersonal Psychotherapy for Adolescents (IPT-A)|Interpersonal Psychotherapy (IPT) is a psychotherapeutic treatment originally developed for treating depression in adults. It is a brief, structured treatment based on the idea of mobilizing the patient's social network, increasing his/her capacity to accept and seek support from others, and to process interpersonal difficulties, in order to improve depressive symptoms. Interpersonal psychotherapy for adolescents (IPT-A) is a version of IPT designed for young people between the age of 12-18 years with depression (Mufson, 2004), and is in many respects similar to IPT although with some modifications (e.g., a few scheduled meetings with parents during the course of treatment).
45448424|NCT02785588|Device|3.0 T Neonatal MRI scanner|eligible subjects will undergo neonatal MRI scan procedure
45638566|NCT02384317|Drug|CCX168|BID for 84 days
45638567|NCT04645030|Diagnostic Test|Ultra low-dose computer thermography|The ULD-CT scan will be executed according to a standardized predeveloped technical protocol. The technical protocol will differentiate between patients with BMI <25 and >25 to insure optimal ULD-CT image quality.
45638568|NCT04645030|Diagnostic Test|lung ultrasound|"LUS will be performed by trained researchers. Before inclusion researchers preforming LUS scans, will undergo a training program and will complete 25 supervised LUS scans to be certified in LUS. At the end of the training program, researchers will be tested to insure proficiency in LUS.~LUS will be performed according to LUS protocol with seven scanning's zones on each side; 2 anterior, 2 lateral and 3 posterior."
45638569|NCT02390089|Drug|Capsaicin vapor|Single-breath and continuous inhalation paradigm to induce cough.
45638570|NCT02390089|Other|fog|Continuous inhalation of fog until a cough is produced, or up to 60 seconds (whichever is shortest)
45638571|NCT02390089|Radiation|Videofluoroscopic swallow evaluation|Fluoroscopic evaluation of oropharyngeal swallowing function.
45638572|NCT02390089|Device|Nebulizer|A hand-held nebulizer will be used to aerosolize the capsaicin and water solutions. Participants will inhale through the device's mouthpiece, and cough if they need to.
45638573|NCT04644874|Diagnostic Test|Geriatric 8|The G8 is an eight-item screening tool, developed for older cancer patients. The G8 score ranges from 0 (heavily impaired) to 17 (not at all impaired), with a cut-off for potential frailty of ≤14.
45638574|NCT04644874|Diagnostic Test|modified Geriatric 8|The mG8 is a modified version of the Geriatric 8 screening tool, consisting of 6-items. The mG8 score ranges from 0 (not at all impaired) to 35 (heavily impaired), with a cut-off for potential frailty at ≥6.
45638575|NCT04644874|Diagnostic Test|30 second chair stand test|Repetitions within 30 seconds
45638576|NCT04644874|Diagnostic Test|Handgrip Strength Test|Measured in kilograms
45638577|NCT02379871|Other|Experimental Group|Supine mid-thoracic spinal manipulation to the T4/5 region
45638578|NCT02379871|Other|Sham Group|Subject will be positioned in supine identical to the experimental group, but no spinal manipulation will be delivered.
45638579|NCT03521986|Procedure|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections
45638580|NCT03521986|Procedure|Intercostal uniportal VATS|The surgical procedures followed principles of pulmonary resections
45638581|NCT02379793|Drug|LEO 80185 gel, vehicle, liquid paraffin|Each subject has all 3 treatments applied at the same time. Each treatment is applied once to 2 locations on the subject.
45638582|NCT01975246|Drug|Telmisartan + amlodipine|FDC tablet
45638583|NCT01975246|Drug|hydrochlorothiazide|tablet
45638584|NCT01975246|Drug|Telmisartan + amlodipine|FDC tablet
45638585|NCT01975246|Drug|Placebo|placebo matching hydrochlorothiazide tablet
45638586|NCT02389933|Drug|LCZ696|immediate release film coated tablet in 50 mg, 100 mg, 200 mg, and 400 mg strengths for oral administration.
45638587|NCT04669834|Other|a traditional therapeutic knee rehabilitation program|mini-squatting exercise and clamshell exercise
45638588|NCT04669834|Other|core stability exercise|the principles of core stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
45638589|NCT01621126|Device|Intra-operative neuromonitoring (XLTEK/NATUS EP Protektor)|Device: Intra-operative neuromonitoring A XLTEK/NATUS EP Protektor machine (at MGH) or a Cadwell Cascade Elite neuromonitoring machine (at BWH), both FDA approved for intra-operative neuromonitoring, will deliver the electrical stimulus applied transcranially to stimulate the motor cortex, while motor evoked responses will be recorded from different myotomes from both upper limbs. Also the same equipment will deliver electrical stimulus to stimulate peripherally the median and ulnar nerves at the wrists, with recording of the thalamocortical potentials in the scalp channels.
45638590|NCT02389855|Procedure|NeuroBlate® System Therapy|
45638591|NCT02389699|Radiation|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
45638592|NCT02389699|Radiation|Whole breast radiation|whole breast radiation after BCS with 46-50 Gy
45638593|NCT01973998|Drug|Roflumilast|PDE4 inhibitor
45638594|NCT01973998|Drug|Placebo|Inactive substance.
45638595|NCT02380027|Device|MRI|This will be a multi-parametric MRI of the prostate
45638596|NCT02380027|Procedure|MRI-targeted biopsy|This will be a biopsy targeted to suspicious areas on the MRI
45638597|NCT02380027|Procedure|TRUS-biopsy|This will be a standard 12 core trans-rectal prostate biopsy
45638598|NCT05406739|Other|Test Meals|"For the first meal, Participants will be fasted for 8 hours and will consume a test meal of 255 calories (120 g egg substitute [60 kcal]; 2 slices of bread [120 kcal] with 30 g strawberry jam [75 kcal]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 120 mL of water.~After five to seven days, participants will be fasted for 10 hours and will consume a second test meal of 510 calories (240 g egg substitute [120 kcal]; 4 slices of bread [240 kcal] with 60 g strawberry jam [150 kcal]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 240 mL of water."
45638599|NCT02384161|Other|Isometric exercise Intermittent|Intermittent isometric exercise is characterized by an interval muscle contraction (one period and another relaxed contracted period) in which there is no generation of voltage change in the length of the muscle fiber.
45638600|NCT02384005|Other|Self-anal exam arm|After a short pre-test the clinician will use a model to show a normal and diseased anal canal and then use pictures to show a self-DAE. The clinician will describe how to do a self-DAE for single men and partners. Next, the clinician will ask the participant to lower his pants for collection of anal human papillomavirus (HPV) DNA and cytology. The clinician will conduct a DAE and then participants will do self-DAE done in private. Then the research assistant will demonstrate the computer-assisted self-interview. When participants return to the clinician to receive the DAE results, the clinician will conduct a safety-related interview. The clinician will treat external anal disease, triage internal anal disease, and ask to be notified if a participant has any anus-related concerns in the following week. A complete appointment will require 70 minutes for singles and 105 minutes for couples. The PI will later conduct 3 focus groups.
45638601|NCT02379949|Behavioral|Virtual Reality Exposure Therapy|During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
45448425|NCT05575882|Other|Skin hydration|Skin hydration outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
45638602|NCT02379949|Behavioral|Exposure Group Therapy|Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
45638603|NCT04849741|Drug|ION373|ION373 will be administered by ITB injection.
45638604|NCT04849741|Drug|Placebo|ION373-matching placebo will be administered by ITB injection.
45638605|NCT02379715|Drug|Remifentanil|
45638606|NCT02379715|Drug|Desflurane|
45638607|NCT02379559|Behavioral|Exercise|For the first 12-weeks, participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise. Exercise duration will increase from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, men will maintain 150 min/wk of moderate-intensity physical activity.
45638608|NCT02379559|Behavioral|Attention Control|We will provide weekly healthy lifestyle tips via text messages, and will include tips such as managing stressors in life and getting better sleep.
45777017|NCT05896878|Dietary Supplement|Root.Health Dietary Supplement|The Root.Health supplement is composed of six plant-based compounds with established roles in supporting innate physiological processes which are implicated in pain: tetrohydrocurcumin, ergothioneine, dihydroberberine, trans-resveratrol, ginger root extract, and methylcobalamin. Participants will take the provided supplement twice per day for the entire study duration in addition to pain management treatment protocols the participants currently follow.
45777018|NCT05896735|Procedure|Ultrasound-guided axillary vein catheterization|All axillary vein catheterizations were performed according to standard central venous catheterization procedures, which were performed under ultrasound guidance at the bedside. Before the operation, patients were placed in a supine position with the upper limb placed in a natural position, and the ultrasound probe and wires were wrapped with a sterile protective sheath. Ultrasound pre-scanning the axillary artery and axillary vein, and pay attention to using the minimum pressure to control the ultrasound probe to avoid crushing the blood vessels. The operator holds the ultrasound probe and puncture needle to puncture the axillary vein under the guidance of ultrasound. After drawing out of the dark red blood, the guide wire was inserted and the puncture needle was withdrawn. The three-lumen CVC catheter was then inserted using the Seldinger technique.
45777019|NCT05896592|Diagnostic Test|Invasive electrophysiological study|Invasive electrophysiological study consists in inserting two electrodes into the heart through femoral vein puncture into the right atrium and right ventricle. Then the following measurements are taken: SNRT- sinus rhythm recovery time, cSNRT- corrected sinus rhythm recovery time, Wenckebach point, AH and HV time and HRV-rhythm variability after SNRT measurement. The examination will be performed under general anesthesia.
45448426|NCT05575882|Other|Barrier function measurement|TEWL measurement outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
45638609|NCT04823923|Other|blood sampling for ITK dosage|Blood sample for ITK dosage at visit 1 (1 month +/- 1 week after the start of treatment) and at visit 2 (3 months +/- 1 month after the start of treatment)
45638610|NCT04820023|Drug|BBT-176|BBT-176 given orally alone
45638611|NCT02379481|Dietary Supplement|NS 550mg|
46070279|NCT00814411|Behavioral|group family planning counseling|group family planning counseling for gynecological patients with unmet need
45638612|NCT02379481|Dietary Supplement|NS 1100mg|
45638613|NCT02379481|Dietary Supplement|placebo|
45638614|NCT02389153|Behavioral|collaborative care CHD|Over a time span of 6 months participants receive individualized treatment to reduce risk factors and improve quality of life, based on their preferences following a health plan, which they developed with their health coach.
45638615|NCT04439773|Drug|placebo|the control group will be given the same volume of saline.
45638616|NCT04439773|Drug|Lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
45638617|NCT02664415|Biological|VRC01|40 mg/kg; administered IV
45638618|NCT02664415|Biological|Placebo for VRC01|Sodium Chloride for Injection 0.9%, USP; administered IV
45638619|NCT05387083|Drug|Low Dose TP-05|Healthy Volunteers will receive a single low dose of TP-05 on Day 1.
45638620|NCT05387083|Drug|High Dose TP-05|Healthy Volunteers will receive a single high dose of TP-05 on Day 1.
45638621|NCT05387083|Drug|Placebo Comparator|Healthy Volunteers will receive a single dose of placebo on Day 1.
45638622|NCT02389231|Drug|Interleukine-2|"Four courses of IL2 ( [Proleukin, Novartis]) will be administered subcutaneously for 5 days.~The first course will be limited to a dose of 1.5 million IU per day and followed by a 9 day wash-out.~The other courses of 3 million IU per day will be initiated after a 16 day wash-out."
45638623|NCT02383927|Drug|Tipifarnib|FTase inhibitor
45638624|NCT02383693|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation
45638625|NCT02379325|Behavioral|Lets Quit|"Five tracks were created including Not Ready, Beginner, Advance, Relapse, and Distraction. The Distraction track was combined with all of the other remaining 4 tracks. It was aimed as a distraction (as the name indicated) method to lighten the participants mood. It consisted of general information such as sports, fashion, dining, movies, and travelling."
45638626|NCT02379325|Behavioral|pamphlets material|Given pamphlets material on smoking and complication
45638627|NCT02383771|Drug|Ticagrelor|(Ticagrelor 90mg Bid) x 7days
45638628|NCT02383771|Drug|Aspirin + Ticagrelor|(Aspirin 100mg daily + Ticagrelor 90mg Bid) x 7days
45638629|NCT02383771|Drug|Control|No Anti-platelet Therapy
45638630|NCT02383771|Drug|Aspirin + Ticagrelor|Dual anti-platelet therapy (Aspirin 100mg daily + Ticagrelor 90mg Bid) after percutaneous coronary intervention (PCI)
45915639|NCT05680675|Diagnostic Test|Single-Tracer Ga68-DOTATATE PET/CT Exam|"The PET technologist will administer with with approximately 5 mCi Ga68-DOTATATE intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
45638631|NCT02388919|Drug|Anlotinib|Basic dosage, take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
45638632|NCT02388919|Drug|Placebo|Basic dosage, take once when limosis in the morning.
45638633|NCT02383537|Other|Diabetes|the trial is observational with no intervention
45638634|NCT04685317|Device|Sentinel® Cerebral Protection System|A percutaneously delivered dual-filter protection device, designed to capture and remove debris dislodged during transcatheter aortic valve replacement procedures.
45638635|NCT04685317|Diagnostic Test|Magnetic Resonance Imaging|Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation
45638636|NCT02388841|Radiation|Pulmonary embolism|the thrombus were assessed with Computed tomographic pulmonary angiography
45638637|NCT02379013|Procedure|Volunteer with MRI|functional MRI
45915640|NCT05680675|Diagnostic Test|Single-Tracer PSMA PET/CT Exam|"The PET technologist will administer with with approximately 7 mCi Ga68-PSMA-11 intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
45777020|NCT05896592|Diagnostic Test|Extracardiac vagal stimulation|"Extracardiac vagal stimulation consists in leading the electrode through the puncture of the femoral vein, successively to both internal jugular veins and stimulating the vagus nerve at the level of its cranial orifice and lower at the level of the angle of the mandible. Stimulation is performed using the Extra-Cardiac Autonomic NeuroStimulatorPachon.~Induction of a sinus pause or AV block during vagal stimulation is considered a positive test result. Absence of sinus pause and AV block during vagal stimulation indicates parasympathetic denervation of the heart. The examination is performed under general anesthesia."
45777021|NCT05896592|Procedure|Cardioneuroablation|CNA consists in complete parasympathetic denervation of the heart or in its deep neuromodulation by destroying the postganglionic nerve fibers of the vagus nerve, located in the epicardium in the vicinity of the pulmonary veins to the left atrium and in the area of the interatrial septum. It consists in inserting the electrode into the left atrium through puncture of the femoral vein, and then the interatrial septum, and performing ablation in the vicinity of the pulmonary vein orifices and on the interatrial septum at the level of the mitral annulus. Then the electrode is withdrawn into the right atrium and subsequent applications are made in the area of the coronary sinus opening and the roof of the right atrium and the upper part of the interatrial septum. The procedure is performed under general anesthesia. In group 1, CNA will be performed 1 month after randomization. In group 2, CNA will be performed 4 months after randomization.
45777022|NCT05896592|Procedure|Redo cardioneuroablation|It consists in re-performing the CNA if full parasympathetic parasympathetic denervation of the heart is not confirmed by ECVS.
45777023|NCT05896592|Procedure|Implantation of the implantable loop recorder|Implantation of the implantable loop recorder consists in subcutaneous implantation of the ECG loop recorder in the sternum area.
45777024|NCT05896592|Diagnostic Test|Pacemaker check|It consists in evaluating the reliability of the PM system. And the assessment of pacing percentage and recorded arrhythmias. After successful cardioneuroablation in groups 1 and 2, 4 months after randomization, the PM will be programmed to the VVI 30/min mode and after 6 months to the OAO/OVO mode. In group 3 patients and in the case of unsuccessful cardioneuroablation, the pacemaker will be set to the optimal mode for the patient. During the PM control, a non-invasive electrophysiological study (NIEPS) is also performed, in which the SNRT, cSNRT, Wenckebach point and HRV after SNRT measurement are assessed. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
45915641|NCT05680636|Diagnostic Test|temperature measurement|Differential Leg Skin Temperature Measured With Handheld Low-cost Infrared Thermometers.
45915642|NCT00006369|Drug|ERA-923|
45915643|NCT05680402|Other|Soft Tissue mobilization|mobilization of soft tissues of body
45915644|NCT05680402|Other|Piriformis Syndrome (Piriformis muscle stretching)|Stretching of Piriformis muscle
45915645|NCT05680363|Device|HyperSperm|Multi-step sperm preparation
45638638|NCT02383381|Procedure|lateral rectus recession|typical surgery for correcting intermittent exotropia
45638639|NCT02377297|Procedure|Restoration with Fuji IX|The cavities will be restored with Fuji IX (GC Europe, Leuven, BE).
45638640|NCT02377297|Procedure|Restoration with Vitro Molar|The cavities will be restored with Vitro Molar (DHL, Rio de Janeiro, BR).
45638641|NCT02377297|Procedure|Restoration with Maxxion R|The cavities will be restored with Maxxion R (FGM, Rio de Janeiro, BR).
45638642|NCT02377375|Procedure|Micro-assisted technique|Medtronic DBS lead 3391-28cm Medtronic electrode array microrecording 22670
45638643|NCT02377375|Procedure|Standard technique|Medtronic DBS lead 3391-28cm
45638644|NCT02379169|Dietary Supplement|Sea buckthorn oil & lutein|Standardised sea buckthorn seed and pulp oil complemented with lutein
45638645|NCT02379169|Dietary Supplement|Placebo|Triglycerides of medium chain fatty acids
45638646|NCT02377219|Other|hormonal and blood analysis|
45638647|NCT02388607|Other|measurements|performance measurements
45638648|NCT02377141|Procedure|Endoscopic Variceal Band Ligation|Standard care: Endoscopic application of rubber bands to varices (swollen veins) in the oesophagus this is repeated on 4-5 occasions until the varices are eradicated.
45638649|NCT02377141|Procedure|Transjugular Intrahepatic Porto-Systemic Stent Shunt|Within 72 hours of the initial endoscopy to apply bands to the bleeding varices the patient undergoes a Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure. Under x-ray guidance a shunt is created in the liver between the hepatic vein and portal vein via a catheter introduced via the jugular vein. It may require a check once or twice per year to ensure it remains patent.
45638650|NCT02378623|Drug|Apixaban|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
45638651|NCT02378623|Drug|Placebo|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
45638652|NCT04305925|Device|Focal Laser Ablation|Orion system to deploy and monitor thermal energy in cancerous regions of the prostate, identified by MRI and confirmed by targeted biopsy. MRI guidance will be achieved by MRI/ultrasound fusion, overlaying stored MRI images upon real-time ultrasound images. Interstitial laser treatments would be achieved by inserting the fiber into the cancerous regions guided by the Artemis image-fusion device. Applications of laser energy up to 15 watts of power will be used to treat the target region.
45638653|NCT02372149|Drug|10% intravenous immunoglobulin (IVIg)|
45638654|NCT02372149|Drug|0.9% sodium chloride|
45915646|NCT05680363|Device|Standard Sperm Preparation|Standard sperm preparation
45638655|NCT02372305|Biological|FlexHD|Patients will be randomized to receive FlexHD.
45638656|NCT02372305|Biological|Alloderm|Patient will be randomized to receive Alloderm.
45638657|NCT02661061|Drug|Ketamine|A sub-anaesthetic dose of ketamine will be administered in four infusions, each two weeks apart.
45638658|NCT02661061|Drug|Midazolam|A sub-anaesthetic dose of midazolam will be administered in four infusions, each two weeks apart.
45777025|NCT05896592|Diagnostic Test|Implantable loop recorder check|Assessment of arrhythmias recorded in the ILR. The procedure will be repeated at subsequent visits 3, 4, 6, 9, 12, 15, 18 months after randomization.
45915647|NCT00006372|Drug|gemcitabine hydrochloride|Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
45915648|NCT00006372|Drug|pegylated liposomal doxorubicin hydrochloride|Patients receive doxorubicin HCl liposome IV over 1-2.5 hours on day 1. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
45638659|NCT02371915|Other|Videoconference follow-up|Rheumatology visits to take place video videoconference with a physiotherapist present
45638660|NCT02371837|Other|Pilates and fall prevention|A 2 days per week during 6 week Pilates practice will be performed in experimental group in order to check the effectiveness in fall prevention
45777026|NCT05896592|Diagnostic Test|Holter ECG|24 hour ECG recording. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
45777027|NCT05896592|Diagnostic Test|Anamnesis|Medical history assessing symptoms of bradycardia, MAS, paraMAS and complications of performed procedures. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
45777028|NCT05896501|Device|Fractional Flow Reserve|Functional assessement of anatomical stenosis of coronary artery
45777029|NCT05895903|Device|Screw expander|threadform screw expanders with special condensing burs for lateralization and compaction of bone
45448427|NCT05575882|Other|Potential of hydrogen measurement (pH)|pH measurement outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
45638661|NCT02376985|Procedure|Oral management|
45638662|NCT02376985|Drug|Everolimus|
45638663|NCT02376907|Procedure|Biliary drainage|EUS-BD or ERCP
45638664|NCT02376751|Drug|sebelipase alfa|
45638665|NCT02371993|Dietary Supplement|Choline|
45638666|NCT02371993|Other|Placebo|
45638667|NCT02378779|Other|Questionary SF12 and PEDT (Premature Ejaculation Diagnostic Tool)|The SF-12 was designed to measure general health status from the patient's point of view (12 questions are asking to the patients) and the PEDT questionnaire is a self-assessment questionnaire to diagnose premature ejaculation (5 questions are asking to the patients).
45777030|NCT05895903|Device|Osseodensification drills|special drills to expand narrow alveolar ridges.
45638668|NCT02378779|Other|Total attention|Total attention of the GP to approach the subject of premature ejaculation during all the consultation
45638669|NCT02378779|Other|Humour|Use the humour to approach the subject of premature ejaculation
45638670|NCT02378779|Other|Take the drama out|Take the drama out to approach the subject of premature ejaculation
45638671|NCT02378779|Other|Question about premature ejaculation|Question about premature ejaculation during the GP consultation
45638672|NCT02378779|Other|Symptoms of premature ejaculation|GP's observation about signs of premature ejaculation
45638673|NCT02378779|Other|Help to verbalize|Help for the patient to speak about premature ejaculation
45638674|NCT02371603|Drug|GSK1278863 25 mg Tablet|A round, biconvex, white film coated tablet to be taken orally in the fasted state in the morning
45777031|NCT05895253|Device|vibrotactile ground-contact feedback|Suralis®, Saphenus Medical Technology (Baden, Lower Austria, Austria)
45915649|NCT00006372|Drug|vinorelbine ditartrate|Patients receive vinorelbine IV over 6-10 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
45915650|NCT05680324|Procedure|Monsplasty|liposuction assisted monsplasty
45915651|NCT05680285|Device|diode lazer|diode laser was applied during the pulpotomy procedure
45777032|NCT05895162|Drug|JUVIA zinc containing vaginal gel treatment|Women receive a single oral dose of fluconazole (150mg) followed by treatment with JUVIA zinc containing vaginal gel (daily for 2 weeks and twice per week thereafter).
45638675|NCT02371603|Drug|Pioglitazone 15 mg Tablet|"White to off-white, round, convex, non scored tablet with ACTOS on one side, and 15 on the other, to be taken orally in the fasted state in the morning"
45638676|NCT02371603|Drug|Rosuvastatin 10 mg Tablet|"Pink, round, biconvex, coated tablets. Debossed CRESTOR and 10 on one side, to be taken orally in the fasted state in the morning"
45638677|NCT02371603|Drug|Trimethoprim 100 mg Tablet|"White, round, scored, convex tablet, debossed 93 above the score and debossed 2159 below the score on one side and plain on the other, to be taken orally as two tablets once in the morning and once in the evening"
45638678|NCT02371525|Behavioral|Prepmate|A novel multi-modal, technology-based intervention for pre-exposure prophylaxis (PrEP) adherence support .
45638679|NCT04230109|Drug|Sacituzumab Govitecan|Sacituzumab Govitecan via iv, predetermined dosage per protocol, two days per 21-day cycle, for 4 cycles (monotherapy cohort)
45638680|NCT04230109|Drug|Pembrolizumab|Pembrolizumab via iv, predetermined dosage per protocol, per 21-day cycle, for 4 cycles (combination cohort)
45638681|NCT02378545|Drug|Oxygen|"On the Hyperoxia arm: Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose.~On the Normoxia arm: In many cases oxygen will not be administered. If required the minimum percentage required to reach the target saturations will be administered. In a majority of cases this will be via a venturi mask."
45777033|NCT05895162|Drug|Fluconazole 150Mg Tab|Women receive oral fluconazole treatment with a single dose of oral fluconazole (150 mg).
45777034|NCT05894603|Drug|Nirmatrelvir/ritonavir|Nirmatrelvir/ritonavir
45638682|NCT04149145|Drug|M4344+Niraparib|The first phase will be a 3+3 design of fixed dose Niraparib by mouth (PO) every day (QD) and M4344 will be escalated from 100-200 mg PO QD (28-day cycle). There will be a 4-week lead in with niraparib only.
45638683|NCT04149145|Drug|M4344+Niraparib|In the second phase eligible patients will receive combination Niraparib + the determined dose of M4344 from the first phase.
45638684|NCT02378389|Drug|Pyrotinib/Pyrotinib with Docetaxel|Pyrotinib oral daily, 240 mg, 320 mg, 400 mg.... Docetaxel i.v. once every 21 days.
45638685|NCT02376595|Drug|Rocuronium Bromide|Rocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus.
45777035|NCT05894603|Drug|Molnupiravir|Molnupiravir
45777036|NCT05891951|Other|Fluid therapy under the guide of Carotid ultrasound|Participants will use carotid ultrasound to assess volume status. If volume is insufficient, fluid therapy will be selected until volume is sufficient. If volume is sufficient, no fluid therapy will be given.
45777037|NCT05889793|Drug|Emetine Hydrochloride|To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic Covid-19 patients.
45777038|NCT05889793|Drug|Placebo|Participant takes a placebo for 10 consecutive days.
45777039|NCT05886335|Drug|Cyclophosphamide|Time of administration
45777040|NCT05885217|Other|measure serum MicroRNA in acne vulgaris|Quantitively assay of serum microRNA level will be measured control by performing an enzyme-linked immune sorbent assay (E LISA)
45915652|NCT05680285|Device|low level diode laser|Low-dose diode laser was applied during the pulpotomy procedure
45638686|NCT02371213|Other|social networking on mobile phone|Audio-video media about serious complications such as labor pain, vaginal bleeding, water breaking and fewer fetal movement via social networking application on mobile phone to antenatal women from the first ANC visit four times every month and four times biweekly
45638687|NCT02378155|Device|SenSmart Model X-100, Nonin Medical|Device to measure cerebral tissue oxygen saturation
45638688|NCT02378467|Drug|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
45638689|NCT02378467|Drug|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
45638690|NCT02371291|Behavioral|Memory Flexibility Training|As in experimental arm description.
45638691|NCT02371291|Behavioral|Psychoeducation|As in experimental arm description.
45638692|NCT02370979|Biological|Blood samples|
45638693|NCT02376517|Behavioral|Educational program|The educational program consists of a short (13 pages) read-along book in English and Spanish. This book presents sun protective practices at an appropriate level for 2-6 year old children to read with their parent or caregiver. A sun protective swim shirt, which provides a sun-protection factor (SPF) of over 50, for the child will be provided. Additionally, the parent will receive weekly text message reminders to practice sun protection.
45777041|NCT05884125|Device|Checkpoint BEST System|Single use medical device, consisting of electric stimulator and intraoperative lead. Therapy consists of single, 10 minute dose delivered proximal to site of decompression/repair
45915653|NCT05680207|Behavioral|Diabetes self- management education (DSME) program|We offered a two-hour course each week, comprising of two sessions of lectures (40 minutes each), two breaks (10 min each) and interactive session (20 min). In the interactive session, patients could communicate with each other in groups or raise any questions to the investigators.
45638694|NCT02378077|Procedure|Fat biopsy during scheduled abdominal surgery|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Fat tissue biopsy during a scheduled abdominal surgery.
45638695|NCT02378077|Procedure|Fat Aspiration|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Subcutaneous fat tissue biopsy.
45638696|NCT02378077|Dietary Supplement|Fish Oil Supplement|Fish Oil supplementation for three months.
45777042|NCT05883267|Device|Virtual reality glasses|"PICO model neo 2 VR glasses"
45777043|NCT05883267|Device|Vocal-guided affective imagery|Audio via telephone
45777044|NCT05882058|Drug|BI 764532|BI 764532
45777045|NCT05882045|Drug|Retatrutide|Administered SC
45777046|NCT05882045|Drug|Placebo|Administered SC
45777047|NCT05879991|Drug|BI 1810631 (C-14) formulation 1|BI 1810631 (C-14) formulation 1
45777048|NCT05879991|Drug|BI 1810631|BI 1810631
45777049|NCT05879991|Drug|BI 1810631 (C-14) formulation 2|BI 1810631 (C-14) formulation 2
45638697|NCT02376439|Other|Kool-aid|Participant drank two different types of kool-aid (sugar free and regular)
45448428|NCT05575882|Other|Clinical evaluation of atopic dermatitis|EASI score on each visit. Non invasive technique.
45448429|NCT05575882|Other|Quality of life assessment|Cardiff questionnaires to assess quality of life of subjects and their family members.
45448430|NCT05575882|Other|Assessment of the effect on itching and sleep disturbances|Visual analogue scale from 0 to 10
45448431|NCT05575882|Other|Assessment of the tolerance of the study product or placebo|By collection of Adverse Events (AEs) on daily log and electronic Case Report Form (eCRF).
45777050|NCT05879731|Other|EEG-hd (high density electroencephalogram)|"Once in the operating room, the investigators will place a 128-channel Hd-EEG (high density electroencephalogram) saline net referenced to Cz on the patient's head. Impedances will be verified and maintained <50 kΩ for the duration of the study. The patient will be positioned supine and all routine monitors will be installed. A 5 minutes baseline resting-state Hd-EEG with eyes closed will be performed before induction. Once under general anesthesia and intubated, a no pain period of 5 minutes will take place. During this 5-min period, resting-state Hd-EEG recording will be recorded. A standardized tetanic stimulation to the ulnar nerve of the non-dominant forearm delivered by a routine nerve stimulator (100 Hz, 70 mA) for a duration of 30 seconds will then be applied. Hd-EEG recording will take place during this 30 seconds and will continue during the 5 minutes after. Once this period will be over, the Hd-EEG net will be removed and the investigators will exit the operating room."
45638698|NCT02377843|Behavioral|Participatory|"The participatory intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~Skills building on how to recommend HPV vaccine using a participatory communication strategy based in shared decision making~Practice using the communication strategy via role play~Discussion on applying the communication strategy to medical practice"
45638699|NCT02377843|Behavioral|Efficient|"The efficient intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~Skills building on how to recommend HPV vaccine using an efficient communication strategy based on first announcing the child is due for 3 vaccines~Practice using the communication strategy via role play~Discussion on applying the communication strategy to medical practice"
45638700|NCT02376673|Other|Children's Book|A specially-designed, illustrated (full color) children's book written at a first-grade level, conveying American Academy of Pediatrics safe sleep guidelines through the story. Expanded guidelines are listed on the back cover, at a 4th grade reading level. This book will be exclusively used for safe sleep education at 3 study home visits: prenatal between 32 weeks and term, 1 week postnatal, and 2 months postnatal. The mother will be encouraged to share the book with her baby.
45638701|NCT02376673|Other|Standard Brochures|An assortment of standard safe sleep educational brochures provided by home visitors during prescribed home visits, covering various recommendations for safe sleep.
45638702|NCT02370745|Drug|GLP-1|GLP-1 effects on skeletal muscle glucose and amino acid metabolism and microvascular blood flow will be scrutinised under the specified insulin concentrations. It will also be used to test the effect of intravenous feed on insulin secretion.
45638703|NCT02370745|Drug|Insulin Actrapid|Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1
45638704|NCT02370745|Dietary Supplement|Oral amino acids|Oral amino acids containing 15 g of amino acids
45777051|NCT05877326|Drug|General anesthesia with propofol or sevoflurane|General anesthesia
45777052|NCT05877326|Behavioral|CAM-ICU (Confusion Assesment Method ICU) at day 3 post-operative|The presence of mental confusion will be determined by CAM-ICU at J3 post intervention.
45777053|NCT05871489|Drug|Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)|Bdq, Lzd, Lfx, Dlm, Cfz for nine months, with extension to 12 months as needed
45777054|NCT05871489|Drug|Bdq, Lzd, Lfx, Cfz, Cs (9-12 months)|Bdq, Lzd, Lfx, Cfz, Cs for nine months, with extension to 12 months as needed
45777055|NCT05871489|Drug|Bdq, Lzd, Lfx, Z, Dlm (9-12 months)|Bdq, Lzd, Lfx, Z, Dlm for nine months, with extension to 12 months as needed
45777056|NCT05871346|Behavioral|Complementary feeding counseling|Complementary Feeding Counseling to Improve Appropriate Complementary Feeding Practices and Reduce Child Undernutrition
45448432|NCT02135770|Drug|Unfractionated heparin|10 unit/kgBW/hour continuous infusion for 72 hours
45448433|NCT05575336|Other|ADLIFE intervention|"The ADLIFE toolbox will be deployed, used and evaluated in seven healthcare environments to demonstrate the effectiveness of the ADLIFE intervention in clinical real conditions. Patients participating in ADLIFE will have a personalised care plan, created in the ADLIFE toolbox, developed and managed together with their healthcare professionals. PCPMP will be used within clinical sites´ ICT systems to create patient care plans based on most recent clinical data, following clinical evidence. The main task of patients and informal caregivers will be to use the ADLIFE toolbox as part of their healthcare process together with their healthcare professionals.~Patients recruited will use the ADLIFE system during the pilot study (a year). If the proposed sample size is not reached by the start date (Dec. 2022), the recruitment period could be expanded to a maximum of three additional months. Patient's follow-up may range between 9 (March-Nov. 2023) and 12 (Dec. 2022 - Nov. 2023) months."
45638705|NCT02370745|Drug|GIP|This will be co infused with GLP-1 and intravenous amino acids
45638706|NCT02370745|Drug|Intravenous amino acids|This will aim to deliver iso equivalent amount to the amino acids administered orally
45638707|NCT02377999|Drug|Picato|
45777057|NCT05870956|Drug|Nintedanib|Nintedanib
45915654|NCT00006375|Drug|LY293111|
45915655|NCT05680090|Diagnostic Test|Artificial intelligent system for eye emergency triage and primary diagnosis|An intelligent triage and diagnostic system for ophthalmic emergencies has been developed. In the prospective test, patients with acute ocular symptoms can achieve remote self-triage and primary diagnosis after uploading metadata and ocular images.
45777058|NCT05868694|Diagnostic Test|polysomnography|Polysomnography is mainly used to diagnose sleep breathing disorders, including sleep apnea syndrome, snoring, upper airway resistance syndrome, and also used for the auxiliary diagnosis of other sleep disorders, such as: narcolepsy, restless legs syndrome, insomnia classification, etc.
45638708|NCT04072783|Diagnostic Test|MRI,DTI, functional MRI|"Patients will undergo testing with Pre- and and post-surgical MRI. The protocol will be Sagittal T1, Axial inversion recovery, T2, fluid-attenuated inversion recovery, susceptibility weighted image, diffusion weighted images, diffusion tensor imaging, resting state fMRI, sagittal 3D GRE / FFE or 3D T1 VIBE and tractography.~Once patients are identified, surgery is planned.The standard of care procedures fall into two categories based on age of presentation, clinician judgement and family preference all other things being equal. Both the endoscopic-assisted craniectomy and open CVR are standard of care procedures. Patients self-select into these groups. None of the surgery nor any aspect of it is experimental.~Patients are routinely examined for neurodevelopment pre- and post-operatively as part of American Cleft Palate Craniofacial Association guidelines.The Vineland Adaptive Behavior Scales are used up to and including age 4."
45638709|NCT01995838|Drug|E2006|E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
45638710|NCT01995838|Drug|Placebo|E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
45638711|NCT02377765|Device|Transcutaneous Stimulation|TPTNS through a TENS unit is a non-invasive technique, easily manageable by patients, which lacks some adverse side effects reported with the use of PTNS, such as bleeding and/or pain at the site of needle insertion. As the technique is self-administered, the associated costs might be substantially lower when compared to PTNS, which involves repeated Hospital appointments for maintenance therapy.
45638712|NCT02377765|Procedure|Percutaneus Stimulation|PTNS aims to stimulate the sacral nerve plexus (origin to the parasympathetic innervations to the bladder) through the afferent fibres of the posterior tibial nerve, a mixed nerve containing L5-S3 fibres (Slovak, Chapple and Barker, 2014). This is achieved by a needle electrode inserted above the medial malleolus. Interestingly, this anatomical area is known as acupuncture point Spleen6 (Sp6).
45638713|NCT04019275|Behavioral|ENGAGE|ENGAGE blends social learning, guided discovery and skill training focused on community participation
45638714|NCT02370823|Procedure|Regenexx SD|stem cell treatment
45638715|NCT04589377|Behavioral|Mindfulness Training|Training is focused on learning the principle of RAIN (recognize, accept, investigate, non-identify) in the context of physics learning.
45638716|NCT02376049|Drug|Pimecrolimus cream|
45638717|NCT02376049|Drug|Betamethasone dipropionate cream|
45638718|NCT02376049|Drug|Clobetasol propionate cream|
45638719|NCT02376049|Drug|Glaxal Base cream vehicle|
45638720|NCT02376205|Drug|bupivacaine hydrochloride 0.5% solution|10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
45638721|NCT02376205|Drug|0.9% NaCl solution|10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
45638722|NCT01957462|Device|Coloplast Test V|Coloplast Test product V is a newly developed 1-piece ostomy appliance
45638723|NCT01957462|Device|Coloplast Test X|Coloplast Test X is a newly developed 1-piece ostomy appliance
45638724|NCT03611335|Behavioral|CATCH Interviews|Baseline interviews are conducted with CATCH staff (5/site); while Post-implementation interviews are conducted 9-12 months after introduction of CATCH, with CATCH staff (5/site) and patients (5/site)
45638725|NCT04567771|Other|Quality-of-Life Assessment|Complete quality of life questionnaires
45638726|NCT04567771|Other|Questionnaire Administration|Complete adverse event assessments
45638727|NCT04567771|Radiation|Radiation Therapy|Undergo proton or intensity modulated radiation therapy
45638728|NCT02370433|Drug|Intravenous Neostigmine and Glycopyrrolate|
45638729|NCT02370433|Drug|Transdermal Neostigmine and Glycopyrrolate|
45638730|NCT01957150|Drug|Fluticasone Furoate/Vilanterol|Dry white powder containing 100 mcg of Fluticasone Furoate blended with lactose per blister was administered by NDPI. Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
45638731|NCT01957150|Drug|Vilanterol|Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
45638732|NCT01955122|Device|Tandem Colonoscopy|Each patient will undergo a double procedure: standard colonoscopy using the EndoRings™ add-on device and Standard colonoscopy (without using the EndoRings™ add-on device) in a randomized order.
45638733|NCT01995526|Drug|Insulin Peglispro|
45777059|NCT05865678|Other|Not an intervention study|This is a study administering questionnaire and interviews using mixed quantitative and qualitative methodology with the aim to describe and evaluate musculoskeletal health of adult haematological cancer survivors and its impact to survivors.
45638734|NCT01955044|Dietary Supplement|LCPUFA supplement|
45638735|NCT01955044|Dietary Supplement|placebo|
45638736|NCT01973218|Biological|Meningococcal B Recombinant vaccine rMenB+OMV NZ|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) vaccination with two doses of rMenV+OMV NZ vaccine (0.5 mL) in the non-dominant arm, one month apart. Subjects were followed for two months.
45638737|NCT01973218|Biological|Placebo|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
45638738|NCT01973218|Biological|Meningococcal ACWY-CRM conjugate vaccine|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
45915656|NCT00006378|Drug|carboplatin|
45448434|NCT05478850|Procedure|radiotherapy under anesthesia|Body temperature change will be investigated before the procedure and during recovery in Radiotherapy patients who need anesthesia due to childhood malignancies.
45754285|NCT02979704|Drug|Rosuvastatin|45 patients will be treated with rosuvastatin at a dose of (5-10) mg orally once daily dose for 08 weeks
45915657|NCT00006378|Drug|paclitaxel|
45915658|NCT00006378|Radiation|radiation therapy|
45638739|NCT04174924|Procedure|Phakic intraocular lens (pIOL) explantation|"Phakic intraocular lens (pIOL) explantation is a surgical procedure to remove the pIOL which needs to be done after cataract formation.~Cataract extraction is a surgical procedure to remove a lens in the eye that has become cloudy over time, affecting vision in that eye."
45638740|NCT01972438|Drug|ASEDs|Experimental Intervention
45638741|NCT01972438|Drug|Saline|Control Intervention
45638742|NCT01946152|Drug|Dexamethasone|Given PO
45638743|NCT01946152|Biological|Filgrastim-sndz|Given SC
45638744|NCT01946152|Other|Laboratory Biomarker Analysis|Correlative studies
45638745|NCT01946152|Drug|Pomalidomide|Given PO
45638746|NCT01945996|Behavioral|TExT MED|educational , motivational, medication reminder and healthy living challenge text messages sent to patient's cell phone
45638747|NCT01945996|Behavioral|FANS|supporter curriculum of messages, consisting of educational/motivational messages, and support challenges
45638748|NCT01971346|Drug|etanercept|100 mg Etanercept injections per week (2 separate single-use pre-filled 50 mg subcutaneous injections taken on two separate days) for 3 months
45638749|NCT01945216|Drug|Alogliptin|Alogliptin tablets
45638750|NCT02641379|Drug|Peginterferon alfa-2a|PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\n
45638751|NCT02641379|Drug|Ribavirin|Ribavirin is available as 200 mg tablets
45638752|NCT02660983|Drug|Donepezil hydrochloride|
45638753|NCT02660983|Drug|Donepezil matching placebo|
45638754|NCT02660983|Drug|Donepezil hydrochloride|
45638755|NCT05070611|Device|IPL-MGX|One week after lesion incision, the E-Eye machine (E-SWIN company, France) IPL treatment was administered to the skin area below the lower eyelid.13 Before treatment, the eyes were protected with opaque goggles and ultrasound gel was applied on the patient's face from tragus to tragus including the nose to conduct the light.
45638756|NCT05070221|Drug|Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)|less than 8mL/time，Q2W，i.t.；
45638757|NCT05070221|Drug|Recombinant humanized anti-PD-1 monoclonal antibody for injection|200mg/time，Q3W，i.v.；
45638758|NCT05070221|Drug|Axitinib|5mg，bid，p.o.；
45638759|NCT05069909|Procedure|Denture Fabrication technique|Each patient received two sets of dentures fabricated using the two different techniques and their satisfaction and OHIP-EDENT were compared
45638760|NCT02962115|Behavioral|Decision Aid Invitation|electronic invitation to complete web-based decision aid
45638761|NCT02370355|Other|Cytology Specimen Collection Procedure|Undergo collection of blood samples
45638762|NCT02370355|Other|Laboratory Biomarker Analysis|Correlative studies
45638763|NCT03099941|Other|Biofeedback|The aim of this study is to investigate effects of a biofeedback application that is alternative to physical therapist feedback in core stabilization training of patients with CNLBP.
45638764|NCT04479397|Procedure|Latarjet Surgery for anterior shoulder instability|Bone block procedure for anterior shoulder instability
45638765|NCT04479397|Procedure|No sling in postoperative care|No sling will be used in postoperative care.
45638766|NCT03099629|Behavioral|inspiratory muscle training|inspiratory muscle training will start with an intensity of 30% of maximal inspiratory pressure, 15 times/set, 3 sets/day, 7 days/week and training will continue until surgery is scheduled or 2 weeks after the completion of treatment if surgery is not suitable.
45915659|NCT05679973|Device|Polybutester suture|After third molar surgery this suture used for primary closure.
45638767|NCT02370277|Other|Cytology Specimen Collection Procedure|Undergo collection of stool samples
45638768|NCT02370277|Other|Laboratory Biomarker Analysis|Correlative studies
45638769|NCT02370277|Other|Questionnaire Administration|Ancillary studies
45638770|NCT05068895|Other|liquid chromatography-mass spectrometry|Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography-mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and repro- ducibility.
45638771|NCT02375815|Other|Statin Choice Implementation|
45638772|NCT02375737|Behavioral|m-health|Patients will receive e-reminders via text message and email. A message library that allows us to disseminate constant and reliable information has been created. Messages will contain not only medication reminders, but information about issues related to self-management and medication adherence for CVD risk including messages on side-effects, risks/benefits of medication treatment, and barriers to medication adherence. In addition to these messages, patients will also receive tailored information via telephone by trained research staff.
45638773|NCT05067881|Procedure|Pulmonary resection|Resection of pneumohematocele
45638774|NCT04404439|Drug|Nortriptyline + topiramate|Treatment group 1
45638775|NCT04404439|Drug|Verapamil + paroxetine|Treatment group 2
45638776|NCT04404439|Other|Placebo|Placebo comparator
45638777|NCT01953328|Drug|Atorvastatin|Administered orally once a day
45638778|NCT01953328|Biological|Evolocumab|Administered by subcutaneous injection
45638779|NCT01953328|Other|Placebo to Evolocumab|Administered by subcutaneous injection
45638780|NCT05067959|Biological|Covid-19 vaccine|blood tests and questioners before 1st vaccine, 3 weeks before 2nd vaccine, 4 weeks after 2nd vaccine, 6 months after 1st vaccine, and 12 months after 2nd vaccine
45638781|NCT02375893|Other|No intervention|Collecting blood and feces samples
45638782|NCT02375893|Other|Healthy subject|Collecting blood and feces samples
45638783|NCT02370199|Device|670 nm light|670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2.
45754286|NCT02979704|Drug|Atorvastatin|45 patients will be treated with atorvastatin at a dose of (10-20) mg orally once daily dose for 08 weeks
45638784|NCT02370199|Drug|octafluropropane|Octofluoropropane will be administered as a continuous infusion prior to the initiation of 670 nm light in order to measure skeletal muscle blood flow.
45638785|NCT03100955|Drug|cisplatin, etoposide|The recommended regimen is cisplatin plus etoposide. cisplatin 75 mg/m2 iv on day 1, etoposide 120 mg/m2 iv on day 1-3, 3 weeks a cycle, total for 6 cycles is allowed.
45638786|NCT03100955|Drug|cisplatin, etoposide, apatinib|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatin and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI apatinib oral daily after chemotherapy treatment. Apatinib 500mg oral, once a day, until disease progression or death or un-tolerated toxicites.
45638787|NCT02377609|Drug|Tacrolimus|oral
45777060|NCT05860647|Device|Intermittent theta burst stimulation|MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
45777061|NCT05855304|Other|manual therapy|The leg length was measured while the subjects were lying on their stomachs. Then, by grasping the lateral malleolus, the knees are bent 90 degrees and changes in leg length were observed, the positions of the SI joints were noted. Afterwards, the person
45777062|NCT05855304|Other|Kinesiology taping|As part of the tape (kinesio tex brand) kinesio protocol used in this study, the starting position of the kinesio tape is the site of lumbar spine flexion. Kinesio tape was applied transversely to the bilateral sacroiliac joint area as a long I-shaped piece of tape with 80% tension and no tension was applied to the ends of the tape. Another short tape will be adhered to the SI joint with 80% tension at a right angle to the hip, and no tension is applied to the ends of the tape.
45777063|NCT05851326|Device|Active Sonodyn|Sonodyn emits ultrasound, electrical and magnetic stimulation signals with a pre-defined, fixed set of parameters for each of the independently operated power sources.
45777064|NCT05851326|Device|Sham|Non-functional Sonodyn device that cannot convey any energy signals to the device output, however, looks and behaves fully identical as the active Sonodyn device.
45777065|NCT05850793|Behavioral|Sensorimotor Exercise|Balance, perturbation , aging and strengthing exercise will be performed for knee
45777066|NCT05850793|Behavioral|Conventional Exercise|Range of motion, strengthing and stretching exercise will be performed for knee
45777067|NCT05850793|Behavioral|Progressive Motor Imagery Exercise|Different types of exercises will be applied targeting muscle strength, proprioceptive sense or brain neurons for knee
45777068|NCT05847933|Device|rTMS (cTBS experiment)|"rTMS using cTBS protocol with the following characteristics:~Frequency: trains of 50 Hz (3 pulses) every 200ms (frequency of 5 Hz, in the range of theta band)~Intensity: 80% of resting motor threshold (rMT)~Location: consecutively on the left and right temporo-occipital cortex (MNI coordinates: left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~Duration: 40 seconds for each hemisphere, 80 seconds in total.~Timing: Immediately before viewing pictures in pictorial memory task (off-line)"
45777069|NCT05847933|Device|rTMS (cTBS sham)|"rTMS using cTBS protocol with the following characteristics:~Frequency: trains of 50 Hz (3 pulses) every 200ms (frequency of 5 Hz, in the range of theta band)~Intensity: 0%~Location: consecutively on the left and right temporo-occipital cortex (MNI coordinates: left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~Duration: 40 seconds for each hemisphere, 80 seconds in total.~Timing: Immediately before viewing pictures in pictorial memory task (off-line)"
45777070|NCT05847933|Device|rTMS (cTBS active control)|"rTMS using cTBS protocol with the following characteristics:~Frequency: trains of 50 Hz (3 pulses) every 200ms (frequency of 5 Hz, in the range of theta band)~Intensity: 80% of resting motor threshold (rMT)~Location: Right superior frontal cortex~Duration: 40 seconds for each hemisphere, 80 seconds in total.~Timing: Immediately before viewing pictures in pictorial memory task (off-line)"
45777071|NCT05847933|Device|rTMS (high frequency)|"rTMS using high frequency protocol with the following characteristics: Frequency: 5 Hz~Intensity: 100% of rMT~Location: bilateral temporo-occipital cortex (MNI coordinates: left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~Duration: 2.5 seconds during the presentation of pictures (3 minutes in total)~Timing: Only during the picture viewing part of memory task (On-line)"
45915660|NCT05679973|Device|Polypropylene suture|After third molar surgery this suture used for primary closure.
45915661|NCT05679934|Other|Exercise Program|Stretching and strengthening exercises will be applied to the participants
45915662|NCT05679856|Radiation|Hypofractionated single vocal cord irradiation|Only the affected vocal cord with additional margin to account for motion and setup errors will receive 58.08Gy/16 fractions using IMRT/VMAT technique
45915663|NCT05679856|Radiation|Whole laryngeal radiotherapy|The whole larynx from lower border of hyoid bone to lower border of cricoid cartilage will receive 63Gy/28 fractions using IMRT/VMAT technique
45935660|NCT05561998|Device|TalkingMats|TalkingMats is a low-technology communication framework, to help people with communication difficulties to express their views. It uses a simple system of picture symbols, placed on a textured mat, that allow people to indicate their feelings about various options within a topic by placing the relevant image below a visual scale. Three sets of symbols are used, one set for the topics of the conversation, one set for the options within each topic and one set consisting of the value scale under which the options are placed.
45638788|NCT05067413|Procedure|Transanterior obturator nerve gateway approach|Distal rectal transection of cases in the experimental group will be performed using transanterior obturator nerve gateway approach
45638789|NCT05067413|Procedure|Total mesorectal excision approach|Distal rectal transection of cases in the control group will be performed using total mesorectal excision approach
45638790|NCT02375581|Drug|Icotinib|125mg, Po, TID during RT
45638791|NCT02375581|Radiation|Thoracic radiotherapy|involved-Field irradiaton without elective nodal irradiation
45754287|NCT05580224|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed for peripherally located small hepatocellular carcinoma using combined energy delivery mode and triple cooled-wet electrodes. One of three electrodes is placed across the 4th or 5th portal vein branches near the target tumor which enables anatomical ablation of tumor.
45754288|NCT05580146|Dietary Supplement|Zynamite® 15% 150mg|leaves of the mango food plant
45754289|NCT05580146|Dietary Supplement|Zynamite® 15% 300mg|leaves of the mango food plant
45638792|NCT04435067|Genetic|Analysis of genetic mutations and the gene expression profile of lung metastasis and primary neoplasia|The mutational analysis of the main oncogenes and tumor suppressor genes involved in the genesis and tumor progression will be performed on the genomic DNA extracted from each sample using the Ion Torrent TM Oncomine TM Comprehensive Assay version 3 (OCAv3) kit. This panel includes 161 cancer-related genes and allows the identification of all genomic alterations affecting oncogenes and recurrently altered tumor suppressor genes in solid tumors. The study of gene expression will be carried out using Nanostring Technology using the Pancancer IO 360 TM panel which allows simultaneous analysis for each sample of multiple mRNAs associated with crucial pathways in carcinogenesis and the immunological profile of the tumor, defining its up and down conditions gene regulation.
46070280|NCT00814411|Behavioral|Individual family planning counseling|Individual family planning counseling with gynecological patients - the current standard of care
45638793|NCT04435067|Other|Radiomics analysis on TAC imaging at diagnosis of lung metastasis and, if possible, of the primary tumor|This study will be performed using the SPAARC IBSI (International Biomarker Standardization Initiative) compliant software implemented in the MatLab environment (MathWorks, Boston, USA) through several steps: (a) CT imaging retrieval, (b) image segmentation and rendering, (c) feature extraction and (d) qualification/quantification. Approximately 200 radiomics characteristics will be extracted, such as: Morphology, Statistical, Intensity Histogram, Gray Level Co-occurrence Matrix 3D_average, Gray Level Co-occurrence Matrix 3D_combined, Gray Level Run Length 3D_average, Gray Level Run Length 3D_combined, Gray Level Size Zone Matrix 3D, Neighbor Gray Tone Difference Matrix 3D, Gray Level Distance Zone Matrix 3D.
45638794|NCT02377531|Other|Early glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 12 to 18 weeks of pregnancy instead of standard 24 to 28 weeks of pregnancy
45638795|NCT02377531|Other|Standard glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 24 to 28 weeks of pregnancy
45638796|NCT03101189|Drug|ACT-541468|Capsule
45638797|NCT03101189|Drug|placebo|Matching placebo capsule
45777072|NCT05847933|Device|rTMS (low frequency)|"rTMS using Low frequency protocol with the following characteristics:~Frequency: 1 Hz~Intensity: 110% of rMT~Location: temporo-occipital cortex of dominant brain hemisphere (MNI left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~Duration: 30 minutes, continuously~Timing: Starting 10 minutes before and continuing during the picture viewing and valence rating of the pictures of the memory task (on-line)."
45638798|NCT02377687|Other|observational study|
45777073|NCT05844332|Other|LUTATHERA|There is no treatment allocation. Patients administered LUTATHERA by prescription can be enrolled.
45638799|NCT02369965|Drug|albuvirtide|albuvirtide 320mg administered intravenously once a week
45638800|NCT02369965|Drug|lopinavir-ritonavir|lopinavir-ritonavir 400/100mg administered orally twice daily
45638801|NCT02369965|Drug|tenofovir|tenofovir 300mg administered orally once daily
45638802|NCT02369965|Drug|lamivudine|lamivudine 300mg administered orally once daily
45638803|NCT02369809|Drug|Neovasculgen®|Treatment according to routine clinical practice at the discretion of the treating physician. Patients receive two local intramuscular injections of Neovasculgen® at a course dose of 2.4 mg according to the summary of product characteristics (SmPC).
45638804|NCT02640755|Drug|[14C]AZD2014|Radiolabelled dual TORC1/TORC2 inhibitor
45638805|NCT02640755|Drug|Multiple dose AZD2014|Dual TORC1/TORC2 inhibitor
45638806|NCT02640755|Drug|Fulvestrant|Hormonal Agent
45638807|NCT02640755|Drug|Paclitaxel|Taxane
45638808|NCT02375425|Other|no intervention|no intervention-specimen collection study only
45638809|NCT04400539|Device|intrapleural photodynamic therapy with videothoracoscopy|MPM patients will be first administrated 20 mg/kg of oral photosensitizer, 5-Aminolevulinic Acid (5-ALA) {Gliolan®}, 4 to 6 hours prior undergoing thoracoscopy (VATS). During VATS procedure, after a qualitative control of the fluorescence of tumor lesions and some guided pleural tumor biopsies, the pleural cavity will be illuminated using a flexible probe and laser source at a specific wavelength for 5-ALA (400-500 nm; 25 J/cm2) during 15 minutes (6 fractions of 2.5 minutes separated by 5 pauses of 2 minutes each to improve tissue oxygenation for the PDT reaction). An IPC device (but no talc) will be inserted and used for pleurodesis and may permit to collect further pleural effusion samples. As 5-ALA has a short half-life and thus does not need extensive precautions to avoid patient photosensitivity, the patient would not stay longer than a standard procedure (about 2-3 days in the hospital)
45777074|NCT05837000|Drug|Dexmedetomidine|Patient will receive 0.5 ml/kg bupivacaine 0.25% + 1μg/kg dexmedetomidine caudally
45777075|NCT05837000|Drug|Ketamine|Patient will receive 0.5ml/kg bupivacaine 0.25% + 0.5mg/kg ketamine caudally
45777076|NCT05837000|Drug|Magnesium sulphate|Patient will receive 0.5ml/kg bupivacaine 0.25% + 1ml volume containing 50mg of magnesium caudally.
45777077|NCT05835986|Drug|RO7507062|RO7507062 solution for injection will be administered SC as specified in each treatment arm.
45777078|NCT05835986|Drug|Tocilizumab|Tocilizumab solution for infusion will be administered intravenously at 8 milligram per kilogram (mg/kg) for participants >/= 30 kg or at 12 mg/kg for participants < 30 kg.
45754290|NCT05580146|Dietary Supplement|Zynamite® 15% 600mg|leaves of the mango food plant
45935661|NCT05561998|Other|Usual conversation method|The standard procedure during needs-assessment conversation and conversations planning the provision of home care services.
46070281|NCT04703257|Drug|Metamizole|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days patients will be instructed to take 1000 mg paracetamol orally four times a day for four days. .
46070282|NCT04703257|Drug|Placebo|Patients in the control group will be instructed to take a placebo tablet three times a day for four days and patients will be instructed to take 1000 mg paracetamol orally four times a day for four days.
46070283|NCT00808327|Drug|Bupivacaine|A single, 15mg, intrathecal dose of bupivacaine.
46070284|NCT00808327|Drug|Bupivacaine, fentanyl|A single, 12 mg, intrathecal dose of bupivacaine, plus 15 micrograms of fentanyl
46070285|NCT00814567|Radiation|radiation therapy|Patients undergo standard whole breast, reduced whole breast, or standard partial breast radiotherapy
45638810|NCT04400539|Drug|Nivolumab Injection|Seven to 10 days after VATS, patients will start to be treated by Nivolumab 240mg IV every 2 weeks till progression (CT-scan reassessment every 8 cycles), unacceptable toxicity, or maximum 2 years.
45638811|NCT02369497|Device|HRA|Humeral head resurfacing with the HRA device
45777079|NCT05835063|Behavioral|We Chatt communication tool|This arm involves the collaborative completion of a 2-page communication preferences document between a primary physician and an adolescent/young adult patient. Physicians will participate in a 1-hour training led by study principal investigator featuring didactic, multimedia, and experiential-based learning to support the facilitation of the WE CHATT intervention with patients.
45452502|NCT05158946|Behavioral|Future Oriented Group Training|This study's experimental condition consisted of a Future Oriented Group Training (FOGT), originally developed in 2008 by van Beek et al. (2009). Participants followed this training weekly, over a period of 9 weeks in groups of 6 to 10 participants. The sessions, which lasted one and a half hours each, were each led by one trainer.
45452503|NCT00890968|Drug|Triamcinolone Acetonide (TAC) DuraPeel|topical gel; once daily (nightly); total duration: 4 weeks
45777080|NCT05835063|Behavioral|Usual/standard care|Usual/standard care will be provided. Physicians randomized to the control arm will not receive training in the WE CHATT communication intervention.
45638812|NCT03099785|Drug|Rifamycin SV 600mg t.i.d.|Morning: one 600 mg tablet Afternoon: one 600 mg tablet Evening: one 600 mg tablet
45638813|NCT03099785|Drug|Rifamycin SV b.i.d. + Placebo|Morning. one 600 mg tablet Afternoon: one matching placebo tablet Evening: one 600 mg tablet
45638814|NCT03099785|Drug|Placebo t.i.d.|Morning. one matching placebo tablet Afternoon: one matching placebo tablet Evening: one matching placebo tablet
45638815|NCT02389075|Procedure|Pinch biopsies|Biopsies obtained during colonoscopy or flexible sigmoidoscopy.
45638816|NCT02389075|Procedure|Flexible sigmoidoscopy|Offered to subjects with ankylosing spondylitis who do not meet criteria for colonoscopy
45915664|NCT05679817|Other|Dose-graded aerobic exercises|The D-GAE group received a 12-week aerobic training, three times in addition to the traditional physical rehabilitation. The D-GAE program commenced with a training intensity corresponding to 50% of the maximum age-predicted heart rate for 25 minutes in the first two weeks, which progressed on a two-week basis, and ended up with a training intensity corresponding to 75% of the maximum age-predicted heart rate for 50 minutes in the last two weeks. The D-GAE program included a warm-up for 5 minutes and a cool-down for 5 minutes
45915665|NCT05679817|Other|Traditional physical rehabilitation|The control group received the traditional physical rehabilitation only, 45 minutes per session, three times a week for 12 consecutive weeks. The program consisted of flexibility exercises, strengthening exercises, balance training, and general conditioning exercises.
45638817|NCT02375503|Dietary Supplement|Calcium/Vitamin D|Daily, calcium and vitamin D fortified snack bar
45638818|NCT02375503|Dietary Supplement|Placebo|
45638819|NCT02375269|Device|RIPC with a tourniquet|
45638820|NCT00867191|Drug|Placebo|Placebo, 1 tablet daily, per os., 15 days
45638821|NCT00867191|Drug|Desloratadine|Desloratadine, one 5 mg tablet daily, per os, 15 days
45638822|NCT05066945|Other|Observation|observe the association of ctDNA with efficacy of treatment
45638823|NCT02640677|Biological|4CMenB|This study is strictly observational; Administration of BEXSERO, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
45777081|NCT05834673|Drug|Inclisiran Prefilled Syringe|Inclisiran, 284 mg, 1.5 ml Liquid in a single-use prefilled syringe (PFS) for s.c. administration and any standard medications to be used within registered indication and at the treating physician's discretion.
45777082|NCT05834036|Drug|Amoxicillin Oral Capsule|Amoxicillin 875mg every 12 hours for 7 days.
45777083|NCT05833139|Drug|BI 1810631|BI 1810631
45638824|NCT05067023|Diagnostic Test|MRI scan|All participants will undergo 1 DCE-MRI scan.
45638825|NCT00834119|Drug|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day for 28 days
45638826|NCT00834119|Drug|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day plus an oral antihistamine added at Day 28 (Visit 2) at the discretion of the physician
45638827|NCT02299141|Drug|Nintedanib|
45638828|NCT02643251|Drug|Clonidine Hydrochloride Topical Gel, 0.1%|Clonidine Gel is supplied as an aqueous gel formulation for topical use.
45777084|NCT05833139|Drug|Itraconazole|Itraconazole
45777085|NCT05832814|Behavioral|Integrated training|For rhythm-guided walking exercise, the home exercise intensity, that is, the walking speed can be prescribed based on the incremental shuttle walking(ISWT) result. A rhythm matching with the walking speed can be calculated. Then patients will be provided a group of melodies identified by the calculated rhythm, which are also popular with the elder. During exercise, the patients are required to walking on a fixed speed identical with the rhythm. For singing training, patients follow the audios and videos to take training at home, which are recorded by singing teachers and physiotherapists prior to the trial. Each session includes technical instructions in order to achieve better respiratory control during singing.
45915666|NCT05679739|Other|Individualized blood pressure strategy|An individualized blood pressure strategy targeting cerebral blood flow, serially guided by near-infrared spectroscopy and transcranial Doppler ultrasound. Assessments are performed on admission, and at 12, 24 and 48 hours post-ROSC.
45915667|NCT00006381|Biological|trastuzumab|
45915668|NCT00006381|Drug|celecoxib|
45935662|NCT05561920|Device|High - speed video endoscopy (HSV)|Describe anatomical and morphological characteristics o phonatory movement of PEM in laryngectomy patients
45935663|NCT05561920|Device|Acoustic voice analysis|acoustic program (lingWAVES - Voice and speech analyser) - measuring the values of acoustic parameters in voice recordings
45638829|NCT02643251|Drug|Clonidine Hydrochloride Gel Comparator|Clonidine Gel Comparator is supplied as an aqueous gel formulation for topical use.
45638830|NCT02375191|Drug|fentanyl|
45638831|NCT02375191|Drug|dexmedetomidine|
45638832|NCT02375191|Drug|Ropivacaine|
45754291|NCT05580146|Dietary Supplement|Placebo|Sunflower oil matched for appearance
45754292|NCT03021044|Other|physical activity intervention|30, 60, 90 and 120 days after hospital discharge a clinical visit and session of physical activity training and program
45638833|NCT04477187|Device|Dermal Handpiece|Radiofrequency (RF) will travel through the RF generator through the electrodes and into the dermal layer beneath the surface of the skin. The microneedles of the dermal cartridges coupled with the thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.
45638834|NCT02375035|Device|CAMPROBE|To assess patient's experience and complications of the CAMPROBE biopsy needle and compare the results with known published outcomes from standard transrectal biopsies
45638835|NCT03100877|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
45638836|NCT03100877|Drug|Cyclophosphamide|Given IV
45638837|NCT03100877|Biological|Filgrastim|Given SC or IV
45448435|NCT03547414|Other|Nephrocheck test|A fresh urine sample was collected on inclusion (maximum 6 hours after starting catecholamines) through the urine collecting tube and frozen at -80°C. At the end of the study, urine samples were thawed and centrifuged as recommended by the manufacturer and the urinary TIMP2*IGFBP7 concentration was determined using the Nephrocheck™ test. The Nephrocheck™ test simultaneously measures into the Astute 140™ meter (a bench top analyzer) the urinary concentrations of TIMP2 and IGFBP7 on 100 µl of urine mixed with 100 µl of buffer. The result is expressed as a single number corresponding to the product of TIMP2 and IGFBP7 concentrations.
45638838|NCT03100877|Other|Laboratory Biomarker Analysis|Correlative studies
45638839|NCT03100877|Drug|Lenalidomide|Given PO
46070286|NCT00814645|Drug|Sodium Nitrite Inhalation Solution|a single dose of AIR001 Inhalation Solution administered by inhalation following nebulization
45638840|NCT03100877|Procedure|pheresis|Undergo apheresis
45448436|NCT04870762|Other|Best Practice|Receive standard of care
45448437|NCT04870762|Other|Medical Device Usage and Evaluation|Wear 3D printed oral stent
45638841|NCT03100877|Drug|Melphalan|Given IV
45638842|NCT03100877|Biological|Palifermin|Given IV
45638843|NCT03100877|Radiation|Total Marrow Irradiation|Undergo TMI
45638844|NCT02374879|Device|Blood Glucose Monitoring Systems.|In vitro diagnostic medical device.
45638845|NCT02369419|Other|Frailty|CRT device is implanted in all patients selected for the study. Frailty is evaluated before implant and defined as <14/17 points using the ONCODAGE score
45638846|NCT02365441|Drug|Regorafenib|
45638847|NCT02365441|Drug|imatinib|
45638848|NCT03099551|Device|Group using manual toothbrush Curaprox 5460 Ultra Soft|Manual toothbrush usage with Bass technique twice a day during 2 minutes
45638849|NCT03099551|Device|Group using sonic toothbrush Edel White|Sonic toothbrush usage twice a day during 2 minutes
45638850|NCT03099473|Other|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
45777086|NCT05832814|Behavioral|Rhythm-guided exercise training|For rhythm-guided walking exercise, the home exercise intensity, that is, the walking speed can be prescribed based on the incremental shuttle walking test(ISWT) result. A rhythm matching with the walking speed can be calculated. Then patients will be provided a group of melodies identified by the calculated rhythm, which are also popular with the elder. During exercise, the patients are required to walking on a fixed speed identical with the rhythm.
45777087|NCT05828017|Device|Hearing Aid - Standard Curve|Our current hearing aids which will be programmed to our standard frequency response curve.
45448438|NCT05454202|Device|ANI|Pain measurement during care procedures in palliative care
45638851|NCT03099473|Other|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
45777088|NCT05828017|Device|Hearing Aid - Variation #1|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
45777089|NCT05821504|Behavioral|High-Intensity Interval Training|The training intervention is a popular exercise format that consist of alternating brief bouts of high-intensity efforts with bouts of light effort or complete rest.
45777090|NCT05821296|Device|Crystal Peel|3 applications performed by a dermatologist.
46070287|NCT00814645|Drug|Placebo and AIR001 Inhalation Solution (Expansion arm)|On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
45638852|NCT03099473|Other|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
45638853|NCT02369107|Other|Verum acupuncture and medicine|Participants will receive acupuncture therapy 1 hour prior to chemotherapy administration ，6 hours after chemotherapy administration，and once acupuncture therapy on the following day2,3,4,5. The stimulation points are RN12,LR13(bilaterally), RN6, ST25(bilaterally), PC6(bilaterally), ST36(bilaterally). The acupuncture needle in ST36 and auxiliary point will be connected to form a circuit containing a SDZ-V stimulator for 30 min with a frequency of 2/100 Hz. They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
45638854|NCT02369107|Other|Sham acupuncture and medicine|Participants will receive minimal acupuncture therapy at the same time as the intervention group .The stimulation points are not belong to traditional Chinese medicine.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
45638855|NCT00794495|Drug|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
45638856|NCT00794495|Drug|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
45638857|NCT02369029|Drug|BAY 1238097|Oral administration twice weekly. Starting dose will be 10 mg per week and dose will be escalated dependent on any dose limiting toxicities.
45638858|NCT03099317|Other|Sinew acupuncture|Sinew acupuncture: subject will sit on chair with knee joint flexion with a most comfortable angle nearest to 90 degrees. Acupoints (1-2cm away from the point of tenderness or pain) near the knee will be punctured through the skin by using sterile needles of size 0.30mm × 40mm at the angle of 0-10 degrees pointing along the pain direction and meridian sinew. Immediately, needles will be retreated back just under the skin and inserted 10mm-20mm forward smoothly with minimal pain sensation. Walking and stepping will be advised and governed during acupuncture. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject. The treatment will last 20 minutes for each session.
45448439|NCT05575180|Drug|Acetazolamide 250Mg Tab|Oral acetazolamide
45638859|NCT03099317|Other|Sham acupuncture|Sham acupuncture: subject will receive the same procedures as the sinew acupuncture without penetrating the skin. The needle will be used to puncture on the acupoint slightly without passing through the skin. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject.
45638860|NCT04529707|Behavioral|Transdiagnostic Behavioral Sleep Intervention|"The Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-CY) uses a comprehensive sleep health framework along with robust evidence for promoting healthy sleep patterns in youth. The TranS-CY incorporates best practices from numerous efficacious behavioral sleep interventions including 1) cognitive behavioral therapy, 2) interpersonal and social rhythm therapy, and 3) behavioral treatment of circadian rhythm sleep-wake disorders. The traditional TranS-CY is clinician-led and provides a robust sleep treatment framework for youth with a wide range of disorders and sleep health concerns. For this study, investigators are using the basic framework of the TranS-CY, but clinicians will train parents to incorporate the intervention into the home for their young child with DMD. Trained clinicians will work with parents to ensure the basic components of the TranS-CY are incorporated into the home-based intervention."
45638861|NCT03105973|Behavioral|Technology-Enabled CBT Treatment|CBT-based modules delivered via tablet over 4 weeks.
45638862|NCT04157075|Drug|Bupivacaine|Bupivicaine injection into uterosacral ligaments prior to colpotomy
45638863|NCT00763529|Drug|Mometasone|Mometasone furoate cream 0.1% applied once daily
45638864|NCT00763529|Drug|Fluticasone|Fluticasone propionate cream 0.05% applied twice daily
45638865|NCT03105505|Drug|Permethrin 5%|Facial skin application once a night for 3 months.
45638866|NCT03105505|Drug|Synthomycine 5%|Eye ointment, eyelids and eyelashes application (chloramphenicol), once a night for 3 months.
45777091|NCT05820321|Dietary Supplement|Beetroot juice rich in nitrate|The participant will intake beetroot juice rich in NO3 (400mg) during 8-days. On the eighth day of the intervention, 2 hours after intake the last bottle of juice, the participants will return to the laboratory for the performance tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
45777092|NCT05820321|Other|Beetroot juice NO3 depleted|The participant will intake beetroot juice depleted in NO3. On the eighth day of the intervention, 2 hours after intake the last bottle of juice, the participants will to the laboratory for the performance tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
45777093|NCT05819398|Drug|Spesolimab Formulation 1|Spesolimab Formulation 1
45777094|NCT05819398|Drug|Spesolimab Formulation 2|Spesolimab Formulation 2
45777095|NCT05819398|Drug|Placebo matching Spesolimab Formulation 1|Placebo matching Spesolimab Formulation 1
45777096|NCT05819398|Drug|Placebo matching Spesolimab Formulation 2|Placebo matching Spesolimab Formulation 2
45915669|NCT05679583|Radiation|Preoperative Stereotactic body radiation therapy (SBRT), Pancreatic resection, Adjuvant Chemotherapy|"Preoperative Stereotactic body radiation therapy (SBRT) For the gross pancreatic cancer lesion, 30 Gy/5 fx will be prescribed considering respiratory movement. And 20 Gy/5 fx will be prescribed to the triangle operation area including the common hepatic artery, celiac artery, and portal vein.~Pancreatic resection Surgical resection will be performed 2-4 weeks after the end of radiation therapy. The surgical method and resection range depend on the surgeon's judgment at the time of surgery.~Adjuvant Chemotherapy Adjuvant chemotherapy will be given under the judgment of the oncologist from 4 weeks after surgical resection, considering the pathological findings (R0 or R1 resection status, etc.) and the patient's medical condition. Adjuvant chemotherapy includes gemcitabine alone, gemcitabine plus capecitabine combination therapy, and mFOLFIRINOX."
45915670|NCT05679505|Device|Auricular transcutaneous vagus nerve stimulation|Transcutaneous vagus nerve stimulation (taVNS) was performed with an FDA-approved Vagustim stimulation device and an electrode-shaped earpiece. In the participants included in the study and randomized to two groups, i) left ear taVNS was applied to the first group and ii) double-ear taVNS was applied to the second group.
45935664|NCT05561920|Behavioral|Quality of life questionnaire|Filling out questionnaires
46070288|NCT00814723|Drug|fluvastatin|80 mg MR, 12 weeks
46070289|NCT00814723|Drug|Fluvastatin plus ezetimibe|fluvastatin 80 mg MR plus ezetimibe 10 mg
45448440|NCT05575180|Drug|Methazolamide Pill|Oral Methazolamide
45448441|NCT05575180|Drug|Placebo|Oral placebo
45448442|NCT04846114|Procedure|Dental implant surgery|
45448443|NCT05433688|Device|Robotic assisted gastric bypass surgery|The product under investigation and the conventional suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
45448444|NCT04814524|Device|Fitbit|Wear Fitbit
45638867|NCT03105505|Drug|Fusidic Acid 1% M/R Eye Drops|viscous eye drops application once a night for 3 months.
45638868|NCT03105193|Drug|IV Saline bolus and infusion|Intravenous bolus of normal saline at induction 3 day postoperative infusion of normal saline administered by ambit pump
45638869|NCT03105193|Drug|IP Saline bolus and infusion|Intraperitoneal bolus of normal saline down first port site. 3 day post operative intraperitoneal infusion of normal saline via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
45638870|NCT03105193|Drug|IV lignocaine bolus and infusion|Intravenous lignocaine bolus at induction. 3 day postoperative IV infusion of lignocaine administered by ambit pump
45915671|NCT05679466|Biological|randomized, double-blinded, placebo-controlled|Approximately 3300 participants will be enrolled, including an immunogenic subgroup of approximately 240. Approximately 10% to 15% of all subjects will be 60 years of age and older. Enrolled subjects will be stratified by age (18-59 years, 60 years and older), number of previous doses of COVID-19 vaccine (2 or 3 doses), and interval from the last previous dose (180-365 days, 366-540 days). Participants will be randomized in a 1:1 ratio to receive 1 dose of the ReCOV or placebo on Day 0.
45638871|NCT03105193|Drug|IP Lignocaine bolus and infusion|Intraperitoneal bolus of lignocaine down first port site. 3 day post operative intraperitoneal infusion of lignocaine via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
45638872|NCT05066633|Drug|Metoprolol Succinate|Metoprolol Succinate will be in the form of tablets and will be administered orally once daily. The dose will depend on the patient's weight category. Subject should take their treatment at a consistent time each day to promote compliance. IMP will be up titrated. Every two weeks the patients will be given the higher dose of metoprolol succinate or placebo accordingly to scheme.
45638873|NCT05066633|Drug|Placebo|Placebo will be in the form of identical tablets and will be administered orally once daily.
45638874|NCT02365129|Other|Exercise training based on recommendations for adults (WHO)|The length of the trial will be 6 months. the total time of aerobic exercise in both moderate-intensity and vigorous-intensity groups will be 150 minutes/week, whereas the time needed to complete the resistance training exercises will be ≈15-30 minutes for both groups.
45638875|NCT03100799|Procedure|Arthroscopy|Arthroscopy of the target knee
45638876|NCT03100799|Procedure|Arthrocentesis|Arthrocentesis of the target knee and contralateral knee (if patient consents)
45638877|NCT03100799|Diagnostic Test|MRI|MRI with and without a gadolinium-based contrast agent
46070290|NCT00810433|Procedure|GO-LIF - Guided Oblique Lumbar Interbody Fusion|"All patients will undergo single-level instrumented interbody spinal fusion surgery with instrumentation.~Upon induction of general anesthesia, the patient will be positioned prone on a radiolucent operating table and prepared according to standard hospital procedure. An interbody fusion will be performed according to standard procedure and as indicated by the surgeon. The interbody fusion portion of the surgery will be carried out using any current technique - such as PLIF, TLIF, PLF, PLLF, XLIF or ALIF. The fusion strategy can be performed in an open or minimally invasive manner, as indicated. The interbody device will be inserted after the screws trajectory will be drilled and a 4.5mm Trajectory holder is in place. This will assure the surgeon that no collision will occur between the interbody and the screws.~Upon completion of the fusion stage of the surgery, SpineAssist will be used to introduce the GO-LIF screws for fixation of the spinal levels to be fused."
45777097|NCT05813730|Other|urinary creatinine excretion measurement|Urine samples will be collected up to 6 times a day from birth until discharge from the maternity hospital, to analyze the kinetics of creatinuria.
45777098|NCT05812027|Diagnostic Test|Tumor and HLA Profiling|HLA genotyping and tumor tissue profiling for certain TAA and LOH.
45777099|NCT05810597|Drug|Tirzepatide|Administered SC
45777100|NCT05810597|Device|Test|Used to administer tirzepatide SC
45915672|NCT00006384|Biological|recombinant interferon alfa|
45915673|NCT00006384|Drug|semaxanib|
45915674|NCT00386815|Drug|pemetrexed|
46070291|NCT00969761|Drug|BI-6727|Low to high dose (administered every 3 weeks). Depending on the toxicities observed, intermediary dose levels may be added
46070292|NCT00969761|Drug|BI 6727|low to high dose
46070293|NCT00845871|Drug|deferasirox:|Participants were administered daily with deferasirox starting dose of 20 mg/kg orally to a maximum dose of 40 mg/kg/day.
46070294|NCT02864849|Drug|Oxaliplatin|
46070295|NCT02864849|Drug|Capecitabine|
45638878|NCT04439305|Drug|Dasatinib|Given PO
45638879|NCT05066867|Other|Smart sharps bin - collects data on compliance|collects compliance data
45638880|NCT02368951|Drug|BAY1187982|A dose of 0.1 mg BAY 1187982 per kilogram (kg) body weight (BW) was chosen as the starting dose based on toxicology data. The investigational drug will be administered as a 1-hour IV infusion once every 21 days at the trial site (Day 1 of each 21-day Cycle). The maximum possible dose escalation will be 2-fold and not more than 0.5 mg/kg BW until maximum tolerated dose is selected
45638881|NCT03100643|Other|mHealth N'Gage mobile application|To enhance HIV care engagement among couples using mobile technology.
45638882|NCT02364973|Other|PET-MRI|The study patients undergo positron emission tomography (PET) after informed consent is obtained
45777101|NCT05810597|Device|Reference|Used to administer tirzepatide SC
45777102|NCT05807139|Drug|Spironolactone|"Spironolactone and its matched placebo will be encapsulated into hard gelatin capsules, in same color, size and taste, to allow blinding.~Participants will receive 2x50 mg/day, 2x100 mg, and 2x200 mg/day in three sessions (Visits); these Visits always occur in ascending order of dosage. In the remaining session, participants receive the placebo.~Spironolactone is approved by the FDA, commercially available, and used in clinical practice for the treatment of hypertension, NYHA Class III-IV heart failure, edema in cirrhotic patients, and primary hyperaldosteronism. Comprehensive information about spironolactone, including its pharmacological properties, are provided in the Prescribing Information."
45777103|NCT05807139|Other|Placebo|Placebo
45777104|NCT05806359|Drug|Danicamtiv|Specified dose on specified days
45777105|NCT05806359|Drug|Placebo|Specified dose on specified days
45777106|NCT05804396|Device|Relivion®|Active stimulation device
45777107|NCT05801679|Drug|Sugammadex|Fifteen minutes after ICU arrival, subjects will be administered sugammadex (2 mg/kg assuming a twitch count of 2-4 of 4 or 4mg/kg assuming a twitch count less than 2 of 4) by the anesthesia provider. Five minutes after administration, a quantitative neuromuscular monitor (TetraGraph, Senzime, Uppsala, Sweden) will be applied and the TOF ratio will be recorded.
45777108|NCT05801679|Other|Placebo|Fifteen minutes after ICU arrival, subjects will be administered placebo (2 mg/kg assuming a twitch count of 2-4 of 4 or 4mg/kg assuming a twitch count less than 2 of 4) by the anesthesia provider. Five minutes after administration, a quantitative neuromuscular monitor (TetraGraph, Senzime, Uppsala, Sweden) will be applied and the TOF ratio will be recorded.
45915675|NCT00386815|Drug|cisplatin|
45915676|NCT05442619|Procedure|Venous blood collection|Venous blood will be drawn from newborns.
45915677|NCT00386854|Behavioral|physical training|
45638883|NCT03100721|Behavioral|PNE+Physiotherapy|Physiotherapy cover kinesitherapy and exercises techniques. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
45638884|NCT03100721|Procedure|Physiotherapy|Physiotherapy cover kinesitherapy and exercises techniques.
45638885|NCT02368873|Procedure|Application of IPOM mesh|
45638886|NCT02368795|Device|Pancreatic Stent|A 5-Fr, 4-cm-long stent (Endoflex) with a single duodenal pigtail is used for pancreatic duct stenting
45638887|NCT02368795|Drug|Indomethacin|Indomethacin 100 mg suppository ten minutes before ERCP
45638888|NCT02368795|Drug|Isosorbide Dinitrate|Sublingual Isosorbide dinitrate 5 mg before ERCP
45638889|NCT02368795|Drug|Ringer's lactate|IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.
45638890|NCT05066243|Other|questionnaire|this study is to develop a questionnaire for vulval conditions
45638891|NCT00650663|Drug|Ezetimibe + Simvastatin|oral tablets; ezetimibe 10 mg and simvastatin 20 mg once daily for 12 weeks
45638892|NCT00650663|Drug|Simvastatin|oral tablet; simvastatin 20 mg once daily for 12 weeks
45638893|NCT02374723|Device|NuCornea|Deep anterior lamellar corneal transplantation where the NuCornea is substituting a donor cornea
45638894|NCT02374723|Device|donated human corneas|Deep anterior lamellar corneal transplantation with a donated cornea as graft material.
45638895|NCT05065853|Diagnostic Test|urine self-sampling group|collection of urine and vaginal samples
45638896|NCT05065853|Diagnostic Test|clinician-collected cervical sample group|A clinician takes a smear from cervix according to standard routine
45638897|NCT02368717|Drug|Mesalazine Enema|
45638898|NCT02368717|Drug|Placebo Enema|
45777109|NCT05798247|Other|Characteristics description|Caregivers who follow the patients of the study group will be contacted to collect these patients clinical and epidemiological characteristics
45448445|NCT04814524|Other|Questionnaire Administration|Ancillary studies
45638899|NCT04231565|Drug|Tenofovir alafenamide Fumarate|Patients would receive treatment of oral Tenofovir alafenamide Fumarate（TAF）once per day.
45638900|NCT02364817|Behavioral|cognitive and psychiatric assessment|"Administered at baseline:~Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar)~hyperactivity : Adult ADHD Self-Report Scale (ASRS), Wenders-Utah Rating Scale (WURS), Diagnostic Interview for Adult ADHD 2nd edition (DIVA 2.0)~psychiatric history : Mini International Neuropsychiatric Interview 5th edition (MINI 5.0), Personality Disorder Questionnaire for the DSM-IV (PDQ-4)~cognitive functions : Frontal Assessment Battery (FAB), Montreal Cognitive Assessment (MoCA)~impulsivity : Barratt's Impulsiveness scale 11th edition (BIS-11)~alcohol consumption: alcohol - timeline follow-back (A-TLFB) ,administered at baseline (month before hospitalization), week 4 visit, week 6 visit, and week 12 visit.~administered at week 12: ASRS"
45638901|NCT05065931|Other|Auxiliary diagnostic system by AI-CDSS|Helping clinicians to make diagnoses by using CDSS based-on AI
45638902|NCT02374801|Device|"SonR automatic optimization feature turned ON (AV+VV)."|
45638903|NCT05065385|Diagnostic Test|INTER-NDA|Neurodevelopmental Screening Test at age 2 years.
45777110|NCT05797610|Drug|RO7434656|RO7434656 will be administered subcutaneously per schedule as specified.
45777111|NCT05797610|Drug|Placebo|Matching placebo will be administered subcutaneously per schedule as specified.
45915678|NCT00006387|Biological|QS21|
46070296|NCT02864849|Radiation|Intensity modulated radiotherapy|
45638904|NCT02375113|Dietary Supplement|soy supplementation|"Isoflavones will be in the form of capsule (80 mg /capsule). Placebo capsule will be filled with cellulose. These capsules will be identical in size and color. Soy protein will be prepared in the form of powder, containing 25 g of soy protein per package. Placebo powder will contain 25 g whole milk protein. Both powders will be available in vanilla and chocolate flavors, and look and taste similar. They could be mixed with water, milk and other beverages. Subjects will be asked to consume 2 capsules and 1 powder packet daily, preferably at breakfast for 6 months.~Subjects failing to show up at the monthly visit for refilling supplement will be contacted by research staff via email or phone."
45754293|NCT03021044|Other|standard of care|30, 60, 90 and 120 days after hospital discharge a clinical visit with correct style life recommendation
45754294|NCT01797679|Other|Strength Training|
45754295|NCT01797679|Other|Aerobic Exercise|
45754296|NCT03587324|Drug|Whole blood aggregometry before and after vascular treatment (ASA/ Clopidogrel).|"To identify possible risk factors demographic data, concomitant medication, laboratory parameters, co-morbidities, severity of the condition and the type of procedure performed are documented.~Other Name: ASA (aspirin), Clopidogrel (Plavix)"
45915679|NCT00006387|Biological|ras peptide cancer vaccine|
46070297|NCT02864849|Procedure|Total mesorectal excision|
45638905|NCT05065229|Device|Oxygen saturation probe Mindray 520 N and Mindray 521 N|"Two oxygen saturation probes will be used in this study:~Mindray 520 N is a disposable oxygen saturation sensor for neonates and adults. It is a disposable, single-use sensor that is wrapped around the infant's arm or foot. Its ends stick together giving a firm, close contact with the skin.~Mindray 521 N is another disposable oxygen saturation sensor for neonates and adults that is used on the neonatal unit in routine practice. As Mindray 520 N and 521 N are CE marked and used within their intended purposes we do not require a letter of no objection from the MHRA for that usage. The Mindray probes will be used without modification and there are no safety issues to the patient. Therefore, a letter of no objection from the MHRA is not required and this is not a medical device study under the Medical Devices Directive."
45638906|NCT02364895|Other|Males control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
45638907|NCT02364895|Other|Males Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
45638908|NCT02364895|Other|Males Group 2: New letter with neutral gender content|Unisex letter
45638909|NCT02364895|Other|Males Group 3: New letter with male-specific content|New letter tailored for men
45638910|NCT02364895|Other|Females control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
45638911|NCT02364895|Other|Females Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
46070298|NCT00915278|Drug|PF-04605412|PF-04605412 will be administered as 2 hr IV infusion every 4 or 2 weeks. Start dose is 7.5 mg. Multiple doses are foreseen. Treatment will continue until intolerable toxicity, progression of disease or patient's refusal
45638912|NCT02364895|Other|Females Group 2: New letter with neutral gender content|Unisex letter
45638913|NCT03100565|Drug|local lidocaine spray|The lidocaine spray will be introduced to the cervix just before the biopsy procedure
45638914|NCT03100565|Other|forced coughing|The patients will be asked to forced coughing during the biopsy procedure
45638915|NCT03113227|Diagnostic Test|Transvaginal ultrasound|Transvaginal ultrasound will be made for assessment of posterior cervical angle and cervical length
45638916|NCT03113227|Diagnostic Test|Vaginal examination|Vaginal examination will be done for assessment of Bishop score
45638917|NCT05035277|Drug|Acetylsalicylic acid|Acetylsalicylic acid 75 mg once daily is the current standard-of-care in TAVI patients without other indications for anticoagulation therapy.
45638918|NCT05035277|Drug|Apixaban|Standard dose apixaban will be one of the options for the patients in the experimental arm.
45638919|NCT05035277|Drug|Rivaroxaban|Standard dose rivaroxaban will be one of the options for the patients in the experimental arm.
45638920|NCT05035277|Drug|Edoxaban|Standard dose edoxaban will be one of the options for the patients in the experimental arm.
45638921|NCT02374645|Drug|Volitinib|600mg or 800mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
45638922|NCT02374645|Drug|gefitinib|250mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
45638923|NCT02368483|Other|Neuromuscular training|Neuromuscular training for the hip and lower limb muscles.The training program is divided into 3 phases, and includes specific exercises for improving the hip range of motion, muscle strength of the hip and lower limb muscles, as well as the trunk stability and coordination. The intervention lasts 12 weeks. Patients will train 2 times/week with a physical therapist and 2 times/weeks alone at home.
45638924|NCT05030207|Diagnostic Test|Real-time Gated 4DCT|Real-time gated four-dimensional cone beam computed tomography (4DCT) will be conducted at the simulation session. The Real-Time Gated 4DCT will be conducted while the patient moves through the rotating X-ray imager. This method detects and then pauses the CT beam during irregular breathing events.
45638925|NCT05030207|Diagnostic Test|Conventional 4DCT|Four-dimensional computed tomography (4DCT), the standard of care for modern high-precision stereotactic ablative body radiotherapy (SABR), will be conducted at the simulation session. It will run continuously while the patient moves through the rotating X-ray imager.
45915680|NCT05679388|Drug|Relugolix Pill|A medication used to treat prostate cancer. Relugolix comes as a tablet to take by mouth. It is usually taken with or without food once daily.
45915681|NCT05679388|Drug|Ritonavir|HIV antiviral It can treat HIV infection, which causes AIDS. It does not cure HIV or AIDS, but combinations of drugs may slow the progress of the disease and prolong life.
45638926|NCT02368327|Biological|Fluad|
45638927|NCT02368327|Biological|Fendrix|
45638928|NCT02368327|Biological|Placebo|
45638929|NCT04147247|Drug|BI 905681|Infusion
45638930|NCT05001347|Drug|TJ004309|Antibody to CD73
45638931|NCT02368561|Drug|"Injection of Hyaluronic Acid - SYNVISC (hylan G-F 20)"|US guided weekly injection of sodium hyaluronate administered for 3 week in adult subjects with insertional achilles tendinopathy
45638932|NCT04095845|Device|CO THA|Replacement of arthritic hip with artificial implant using CT-based navigation and conventional technique
45915682|NCT05679388|Drug|Itraconazole|A drug used to treat fungal infections.
45638933|NCT04095845|Device|Mako THA|Replacement of arthritic hip with artificial implant using mako robotic-arm assist
45638934|NCT02368639|Device|Fisher & Paykel Healthcare PAP Device|The device is a modified version of the Fisher & Paykel Icon continuous positive airway pressure (CPAP) device, which is a fully released product in New Zealand.
45638935|NCT02374489|Drug|LDK378|LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle.
45638936|NCT04989725|Other|Standard arm|Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.
45777112|NCT05796505|Behavioral|ADVANCE Steering Committee interventions|Interventions will be selected by the ADVANCE Steering Committee and will be rapidly deployed without additional effort on the part of front-line staff at four distinct levels: patient, provider, practice and prison level. Interventions will be tested one at a time in an iterative process. A participatory, assets-based framework will be used to identify acceptable and feasible strategies to improve vaccine acceptance. Each round of testing will include 1 month of preparation by the steering committee,12-week intervention period, and 2 months for analysis and rapid dissemination.
45777113|NCT05795816|Drug|Testofen|Twice daily dose of 1 capsule (300mg per capsule Testofen)
45777114|NCT05795816|Drug|Microcrystalline cellulose|Twice daily dose of 1 capsule
45777115|NCT05794880|Device|Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)|Participants in this study will receive a blood stem cell transplant, which will use an investigational device called the CliniMACs device to remove alpha/beta T cells and B cells from the blood cells collected from the donor. This is called T cell depletion and B cell depletion.
45777116|NCT05792722|Procedure|Prostate capsule-sparing radical cystectomy|Patients randomized to this arm will receive the prostate capsule-sparing surgery performed in the form of standard simple prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
45638937|NCT04989725|Radiation|Experimental arm|SABR to all oligoprogressive lesions + continuation of current systemic therapy
45777117|NCT05792722|Procedure|Nerve sparing radical cystectomy|Patients randomized to this arm will receive the nerve-sparing surgery will be performed in the form of the standard nerve-sparing radical prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
45777118|NCT05786547|Drug|Varenicline|Per package dosing, tablet taken orally
45777119|NCT05786547|Behavioral|Positively Smoke Free Mobile (PSF-M)|Behavioral tobacco cessation intervention for people living with HIV, delivered via mobile phone
45777120|NCT05786547|Behavioral|Standard Care|Brief cessation advice plus referral to local tobacco quitline
45777121|NCT05786287|Biological|Conditioned Medium (CM)|Conditioned Medium (CM) injected by peribulbar
45777122|NCT05786287|Biological|Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar
45638938|NCT02374567|Drug|Phenobarbital|
45638939|NCT02374567|Drug|Phenytoin|
45638940|NCT02374567|Drug|Carbamazepine|
45638941|NCT02374567|Drug|Oxcarbazepine|
45638942|NCT02374567|Drug|Valproic Acid|
45638943|NCT02374567|Drug|Lamotrigine|
45638944|NCT02374567|Drug|Topiramate|
45638945|NCT02374567|Drug|Gabapentin|
45638946|NCT02374567|Drug|Levetiracetam|
45777123|NCT05785767|Drug|fianlimab|Every three weeks (Q3W) as intravenous (IV) co-infusion
45777124|NCT05785767|Drug|cemiplimab|Q3W as IV co-infusion
45777125|NCT05785767|Drug|Placebo|Q3W as IV co-infusion
45777126|NCT05783323|Drug|Larotrectinib monotherapy|Patients will receive larotrectinib monotherapy for 6 months at the FDA-approved dose.
45777127|NCT05783323|Radiation|131I therapy|Patients will receive 131I therapy after 6 months of larotrectinib.
45777128|NCT05780450|Device|Transcranial Direct Current Therapy (tDCS)|"Transcranial direct therapy (tDCS) is a non-invasive neuromodulation therapy of the cerebral cortex, which consists of the application of electrical microcurrents, of approximately 2mA, through surface electrodes placed on the scalp. Transcranial therapy (tDCS) produces immediate effects on the ability of neurons to change their electrical potential.~Each session lasts between 20 and 30 minutes, and approximately 10 consecutive sessions should be performed. It will be applied through two surface electrodes of 25 to 35 cm2 at 2 mA.~The equipment has a European health certificate (CE), so it is an approved equipment that complies with all the safety measures for the application of the treatment."
45777129|NCT05779306|Device|IOL Master 700|Biometry using the IOL Master 700
45777130|NCT05779306|Device|Casia-2|Anterior segment-OCT to evaluate lens tilt
45777131|NCT05779306|Device|MS-39|Corneal Topography using the MS-39
45777132|NCT05779306|Device|OSIRIS|Abberometry using the OSIRIS-Abberometer
45777133|NCT05779306|Device|Autorefractor|Evaluation of Refraction using an Autorefractor
45777134|NCT05779306|Diagnostic Test|Subjective Refraction|Refraction performed by experienced staff
45777135|NCT05775289|Drug|Tobemstomig|Participants will receive intravenous (IV) tobemstomig for four 21-day cycles
45777136|NCT05775289|Drug|Pembrolizumab|Participants will receive IV pembrolizumab four 21-day cycles
45777137|NCT05775289|Drug|Paclitaxel|Participants will receive IV paclitaxel Q3W for four 21-day cycles
45638947|NCT02374567|Drug|Pregabalin|
45638948|NCT02374567|Drug|Lacosamide|
45638949|NCT02374567|Drug|Clonazepam|
45638950|NCT02374567|Drug|Biperiden|
45638951|NCT02374567|Drug|Levomepromazine|
45638952|NCT02374567|Drug|Fluphenazine|
45638953|NCT02374567|Drug|Perphenazine|
45638954|NCT02374567|Drug|Perazine|
45638955|NCT02374567|Drug|Thioridazine|
45638956|NCT02374567|Drug|Haloperidol|
45638957|NCT02374567|Drug|Melperone|
45638958|NCT02374567|Drug|Pipamperone|
45638959|NCT02374567|Drug|Bromperidol|
45638960|NCT02374567|Drug|Benperidol|
45638961|NCT02374567|Drug|Sertindole|
45777138|NCT05775289|Drug|Pemetrexed|Participants will receive IV pemetrexed Q3W until disease progression or unacceptable toxicity
45777139|NCT05775289|Drug|Carboplatin|Participants will receive IV carboplatin Q3W for four 21-day cycles
45638962|NCT02374567|Drug|Ziprasidone|
45638963|NCT02374567|Drug|Flupentixol|
45638964|NCT02374567|Drug|Chlorprothixene|
45638965|NCT02374567|Drug|Zuclopenthixol|
45777140|NCT05774288|Device|Cera™ patent foramen ovale occluders|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Cera™ patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
45638966|NCT02374567|Drug|Fluspirilene|
45638967|NCT02374567|Drug|Pimozide|
45638968|NCT02374567|Drug|Clozapine|
45638969|NCT02374567|Drug|Olanzapine|
45638970|NCT02374567|Drug|Quetiapine|
45777141|NCT05774288|Device|Another patent foramen ovale occluders|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Another patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
45777142|NCT05771116|Procedure|ERECTOR SPINAE PLANE BLOCK and PARAVERTEBRAL BLOCK:|catheter will be placed for ERECTOR SPINAE PLANE BLOCK
45777143|NCT05771116|Procedure|PARAVERTEBRAL BLOCK:|catheter will be placed for PARAVERTEBRAL BLOCK
45777144|NCT05770856|Diagnostic Test|Metagenomic sequencing|Samples shall be submitted to high throughput sequencing using both illumine MiSeq and Oxford Nanopore Technologies.
45777145|NCT05763875|Drug|Inclisiran|284 mg (equivalent to 300 mg inclisiran sodium) subcutaneous injection given on Day 1 and Day 90
46070299|NCT00701961|Drug|Mefloquine-artesunate|Mefloquine-artesunate fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, developed by DNDi and manufactured by farmanguinhos (Brazil).
46070300|NCT04286711|Drug|Albumin-paclitaxel, Apatinib, Camrelizumab|Albumin-paclitaxel: ivgtt, 75 or 100 or 125mg /m2, d1, d8, Repeat the therapeutic schedule every 3 weeks; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day); Camrelizumab：ivgtt, 200mg, given on the first day, Q3W;
46070301|NCT04115709|Device|Beacon Caresystem device with advice|Beacon Caresystem device provides ventilator settings advice to Doctors
45638971|NCT02374567|Drug|Sulpiride|
46070302|NCT04115709|Device|Beacon Caresystem device without advice activated|Beacon Caresystem device does not give ventilator settings advice
46070303|NCT02863913|Biological|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
45638972|NCT02374567|Drug|Tiapride|
45638973|NCT02374567|Drug|Amisulpride|
45638974|NCT02374567|Drug|Prothipendyl|
45638975|NCT02374567|Drug|Risperidone|
45638976|NCT02374567|Drug|Aripiprazole|
45638977|NCT02374567|Drug|Paliperidone|
45638978|NCT02374567|Drug|Diazepam|
45638979|NCT02374567|Drug|Oxazepam|
45638980|NCT02374567|Drug|Lorazepam|
45638981|NCT02374567|Drug|Bromazepam|
45638982|NCT02374567|Drug|Clobazam|
45638983|NCT02374567|Drug|Alprazolam|
45638984|NCT02374567|Drug|Hydroxyzine|
45638985|NCT02374567|Drug|Buspirone|
45638986|NCT02374567|Drug|Chloral Hydrate|
45638987|NCT02374567|Drug|Flurazepam|
45777146|NCT05763875|Drug|Ezetimibe|10 mg over-encapsulated tablet taken once a day from Day 1 through Day 149
45777147|NCT05763875|Drug|Matching Placebo for Inclisiran|0mg placebo injection solution for subcutaneous injection on Day 1 and Day 90
45777148|NCT05763875|Drug|Matching Placebo for Ezetimibe|0mg over-encapsulated placebo tablet taken once a day from Day 1 through Day 149
45915683|NCT05678296|Diagnostic Test|Diagnosis|All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
45915684|NCT05678296|Drug|Analgesic|Analgesics are prescribed for the patients for all groups.
45915685|NCT05678296|Procedure|traditional osteotomies|In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
45638988|NCT02374567|Drug|Nitrazepam|
45638989|NCT02374567|Drug|Triazolam|
45638990|NCT02374567|Drug|Lormetazepam|
45638991|NCT02374567|Drug|Temazepam|
45638992|NCT02374567|Drug|Midazolam|
45638993|NCT02374567|Drug|Brotizolam|
45638994|NCT02374567|Drug|Zopiclone|
45638995|NCT02374567|Drug|Zolpidem|
45638996|NCT02374567|Drug|Zaleplon|
45638997|NCT02374567|Drug|Melatonin|
45638998|NCT02374567|Drug|Clomethiazole|
45638999|NCT02374567|Drug|Diphenhydramine|
45639000|NCT02374567|Drug|Promethazine|
45639001|NCT02374567|Drug|Imipramine|
45639002|NCT02374567|Drug|Clomipramine|
45639003|NCT02374567|Drug|Opipramol|
45639004|NCT02374567|Drug|Trimipramine|
45639005|NCT02374567|Drug|Amitriptyline|
45639006|NCT02374567|Drug|Nortriptyline|
45639007|NCT02374567|Drug|Doxepin|
45639008|NCT02374567|Drug|Maprotiline|
45639009|NCT02374567|Drug|Amitriptyline oxide|
45639010|NCT02374567|Drug|Fluoxetine|
45639011|NCT02374567|Drug|Citalopram|
45639012|NCT02374567|Drug|Paroxetine|
45639013|NCT02374567|Drug|Sertraline|
45639014|NCT02374567|Drug|Fluvoxamine|
45639015|NCT02374567|Drug|Escitalopram|
45639016|NCT02374567|Drug|Tranylcypromine|
45639017|NCT02374567|Drug|Moclobemide|
45639018|NCT02374567|Drug|Mianserin|
45639019|NCT02374567|Drug|Trazodone|
45639020|NCT02374567|Drug|Mirtazapine|
45639021|NCT02374567|Drug|Bupropion|
45639022|NCT02374567|Drug|Venlafaxine|
45639023|NCT02374567|Drug|Reboxetine|
45639024|NCT02374567|Drug|Duloxetine|
45639025|NCT02374567|Drug|Agomelatine|
45639026|NCT02374567|Drug|Pyritinol|
45639027|NCT02374567|Drug|Piracetam|
45639028|NCT02374567|Drug|Donepezil|
45639029|NCT02374567|Drug|Rivastigmine|
45639030|NCT02374567|Drug|Galantamine|
45639031|NCT02374567|Drug|Memantine|
45639032|NCT02374567|Drug|Nicergoline|
45639033|NCT02374567|Drug|Acamprosate|
45639034|NCT02374567|Drug|Lithium|
45639035|NCT04981535|Device|Head box during upper gastrointestinal endoscopy|"็Head box is an acrylic box over a patient's head who undergoing upper gastrointestinal endoscopy."
45777149|NCT05763849|Behavioral|Interoceptive Exposure Treatment (IE)|Interoceptive Exposure Therapy (IE) targets food avoidance in Anorexia Nervosa. Each session the therapist weighs the patient, checks-in, and reviews weekly homework. Sessions occur weekly for 20 weeks, with the first session lasting 1.5 hours and the remaining sessions one hour. Early sessions include using exposure to foods and counterconditioning to pair a positive stimulus with a food that would typically produce food avoidance. Parents are trained to model this at home. Sessions mid-way through address the use of non-judgmental description of appearance during mirror exposure. Sessions at the end of the 20 weeks are focused on recognizing change, planning for future obstacles, and developing a relapse prevention plan to continue practicing distress tolerance, counter-conditioning, and food/body exposure.
45777150|NCT05763849|Behavioral|Family-Based Treatment (FBT)|Family-Based Therapy (FBT) includes parent-enforced contingencies to increase value of eating and decrease the value of food avoidance. Each session the therapist weighs the patient, checks-in, and reviews weekly homework. Sessions occur weekly for 20 weeks, with the first session lasting 1.5 hours and the remaining sessions one hour. Sessions consist of checking in with the patient, discussion of the week's implementation of refeeding, and helping parents separate the illness from their child. In session 2, a family meal provides the therapist with an opportunity for direct observation of the familial interaction patterns around eating. The therapist makes careful and persistent requests for united parental action toward re-feeding and/or regulating eating habits, the primary concern at this point of the treatment, and the therapist tries to create and reinforce a strong parental alliance around efforts at feeding the child.
45777151|NCT05761561|Behavioral|Exercise and medical nutrition|"The study dietitian and exercise trainer will each conduct weekly counseling sessions via telephone or zoom throughout the course of chemotherapy (approximately 18 weeks) to assist the participants in achieving the diet and exercise study goals. Participants will be provided written informational material, exercise bands for strength training and a Fitbit to record activity.~Participant goals are to: 1) participate in 150 min/week of moderate-intensity physical activity 2) participate in two weekly strength training sessions; 3) eat a combination of 5 or more servings of vegetables and/or fruits per day 4) consume 25 grams or more of fiber/day; 5) consume adequate amounts of protein to prevent muscle wasting (1.2g/kg body weight)."
45777152|NCT05761509|Drug|Doravirine|The study treatments will used during 28 days according to the routine care of each investigator center.
45915686|NCT05678296|Biological|Platelet Rich Fibrin|Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
45915687|NCT05678296|Drug|Antibiotic|no systemic antibiotics are prescribed for the patients for all groups.
45915688|NCT05675293|Device|IONTOPHORESIS|The process of increasing the penetration of drugs into the skin by application of an electric current
45915689|NCT05675293|Drug|ORAL ANTIBIOTIC|Oral Antibiotic
45915690|NCT05675176|Drug|BCG|Intravesical Instillation
45915691|NCT05673304|Radiation|SBRT anticipated boost|24 Gy in 3 fractions to the tumour
45448446|NCT04814524|Device|Virtual Reality Device|Use VR
45639036|NCT04434989|Radiation|Stereotactic Body Radiation Therapy|SBRT for perivascular HCC
45639037|NCT04434989|Procedure|radiofrequency ablation|RFA for perivascular HCC
45639038|NCT05064215|Procedure|anatomical examination|After injection of dye, its distribution along lymphatic clearance paths was investigated
45639039|NCT03965741|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Follow clinical administration
45639040|NCT03965741|Drug|Apixaban(Eliquis)|Follow clinical administration
45639041|NCT03965741|Drug|Pradaxa (Dabigatran etexilate)|Follow clinical administration
45639042|NCT02364505|Behavioral|Telemedicine mindfulness-based intervention|Comparison of telemedicine mindfulness intervention with telemedicine psycho-education control group
45639043|NCT02364505|Behavioral|Psycho-education intervention|Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
45639044|NCT04478201|Other|back sleep positioning|sleeping on the back.
45639045|NCT04478201|Other|side sleep positioning|sleeping on the side
45639046|NCT02368171|Other|measure exhaled carbon monoxide and nitric oxide|
45639047|NCT04412447|Device|Functional Electrical Stimulation|Electrical stimulation of motor-nerves innervating the musculature of the lower limb.
45639048|NCT02364739|Other|Written information|Brochure
45639049|NCT02364739|Other|Written and oral information|Written information consists in a brochure with information about fertility, while oral information consists in a tailored oral explanation about the wrong answers to the pre-test (that is related to the brochure).
45639050|NCT05063513|Biological|Autologous Hematopoietic Stem Cell Transplantation|Experimental arm will undergo mobilisation with CY 4 g/m2 (in two divided doses), followed by Autologous Hematopoietic Stem Cell Transplantation using CY (200 mg/kg body weight given in 4 daily doses) plus ATG and unmanipulated autologous graft and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
45777153|NCT05758753|Device|Quantitative Sensory Test|Quantitative Sensory Test (Medoc Ltd, Israel), QST is a non-invasive neurophysiological method that refers to a group of procedures that assess the perceptual responses to systematically applied and quantifiable sensory stimuli (modalities including heat, cold and vibration) for the purpose of characterizing somatosensory function or dysfunction. For this test, subjects will be seated comfortably on a chair in a quiet room, or laying supine in a horizontal examination chair, with ambient temperature of 24-25◦ C. Medial upper eyelid; just below the supraorbital notch, nasolacrimal sac area; 4-5 mm medial to nasal cantus, and non-dominant forearm will be used as test sites. Patients will be instructed in detail of the nature of the test and the need to react attentively and promptly to change in temperatures.
45639051|NCT05063513|Drug|Rituximab|Control arm will receive 4 successive weekly infusions of rituximab (antiCD20) 375 mg/m2 body surface area for four weeks and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
45639052|NCT02374333|Biological|huCART19|
45639053|NCT05063669|Behavioral|Cognitive Occupational Therapy|In the sessions, activities aimed at reasoning and empathy skills, problem solving, evaluating emotional cues, evaluating events from different perspectives, providing personal control, delaying reactions, motor planning, visual perception and prolonging attention span were applied. The interventions were varied according to the personal characteristics of the individuals. In group interventions with three or four participants, group games in the form of cooperation or competition were planned to develop motor planning and cognitive strategy and it was aimed to improve children's rapid decision making and adaptation skills.
45639054|NCT02364583|Drug|Primaquine|Primaquine treatment given in a step-wise manner; (a) 0.5 mg/kg total dose daily for 14 days (n=40), (b) 1.0 mg/kg total dose daily for 7 days (n=40), (c) 1.0 mg/kg twice daily for 3.5 days (n=40)
45639055|NCT03100409|Other|Dietary modification|"Dietary intervention will consist on a low residue diet: 20% kcal from fat, 5g lactose/day, 20g fiber/day (5g from insoluble fiber).~Dietary intervention will be adapted to the patient's individual requirements, according to the presence of comorbidities or renal deterioration.~No comorbidities. Energy: 20-30 kcal/kg of body weight/day. Protein: 1.3 g/kg of body weight/day.~Comorbidities (diabetes, hypertension), or geriatric patient. Energy: 25-30 kcal/kg of body weight/day. Protein: 1.5 g/kg of body weight/day.~Renal deterioration. Energy: 30-35 kcal/kg of body weight/day. Protein: 1 g/kg of body weight/day. Sodium: 2000-2300 mg/day. Potassium: 1900-2730 mg/day. Phosphorus: 800-1000 mg/day."
45639056|NCT02368015|Other|Peripheral intravenous cannula (IVC)|Blood samples will be withdrawn prior, during and after the procedure using an additional peripheral intravenous cannula (IVC).
45777154|NCT05756465|Device|Smartphone-based virtual reality relaxation (SVR)|SVR is virtual relaxation and distraction therapy through a smartphone-based VR device (head-mounted display) that is attached to the head of a cancer patient undergoing chemotherapy, displaying a virtual environment of natural panoramas in 360-degree video and combined with traditional and classic musical instruments. SVR device is paired with smartphone using operating system either Android (minimum generation 11, Android 4.4 KitKat) or OS version 12, minimum screen size of 5.5-inch and maximum of 6.0-inch, screen resolution of at least 1080 x 1920 pixels, can connect to WIFI/ internet and provides a YouTube app to access 360-degree videos. SVR content uses original 360o videos produced by researchers using a video editor software for ± 10 minutes duration.
45935665|NCT05561725|Drug|Dexamethasone postoperative|"Patients randomized to the dexamethasone cohort will be administered 8 mg of dexamethasone with 3 additional (8mg doses) administered at 8-hour intervals following surgery for a total of 4 doses.~All patients will undergo a standardized post-operative pathway in the hospital following surgery that has been utilized for all AIS patients at our center since 2014."
45935666|NCT05561725|Drug|Standard of Care|"Patients in the control group will receive one 8mg dose of dexamethasone intraoperatively as per standard of care anesthesia protocols. No sham medication will be utilized for control subjects.~All patients will undergo a standardized post-operative pathway in the hospital following surgery that has been utilized for all AIS patients at our center since 2014."
46070304|NCT02863913|Drug|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
46070305|NCT02863913|Drug|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/day (if tolerant).
46070306|NCT02612649|Drug|Ramosetron|Oral
46070307|NCT02612415|Device|Treatment strategy: Non-invasive respiratory support delivered via high flow nasal cannula|A heated, humidified, HFNC device will be used to deliver a gas flow rate of 2 L/kg/min for the duration that the patient needs non-invasive respiratory support
46070308|NCT02612415|Device|Treatment strategy: Non-invasive respiratory support delivered via continuous positive airway pressure|CPAP will be provided using a set expiratory pressure of 6-8 cm water (H2O) pressure for the duration that the infant needs non-invasive respiratory support
45639057|NCT02368015|Drug|cefazolin|
45639058|NCT02364661|Behavioral|Over night starvation (fasting)|HBV viral load will be analyzed after over-night starvation versus following a morning meal
45639059|NCT02364427|Device|Arterial stiffness - Vicorder to measure pulse wave velocity|Pulse wave velocity (PWV)measures the stiffness of the arteries. This provides a simple and quick noninvasive method of obtaining the PWV for an arterial segment.
45639060|NCT02373943|Other|β-carotene biofortified maize|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene fortified maize
45639061|NCT02373943|Other|β-carotene supplemented maize|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene supplemented maize
45639062|NCT02373943|Other|Normal (non biofortified) maize without added β-carotene|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of normal maize
45639063|NCT05062499|Device|Active TENS|electrical stimulation
46070309|NCT04908800|Drug|KRP-A218|KRP-A218 tablet
45639064|NCT05062499|Device|Sham TENS|no stimulation
45639065|NCT02364193|Device|MRI|"Cardiac MRI for LVEF and segmentation.~Phase-contrast MRI for CO in aorta and each pulmonary vein.~DCE-MRI for bolus kinetic parameter analysis."
45639066|NCT02364193|Drug|Gd-CA|Bolus kinetic parameter analysis, different doses of Gd-CA (Dotarem by Guerbet) ranging between 0.1 and 0.5 mmol will be injected intravenously after dilution in 5 milliliter saline by an injector at a speed of 5 ml/s.
45639067|NCT02364193|Device|BIS ImpediMed™ SFB7|"BIS will be measured by Bio-impedance spectroscopy will be performed using ImpediMed™ SFB7 (ImpediMed Limited 2008).~Impedance will be measured continuously during the fluid challenge and for maximum 600 seconds before and after the fluid challenge.~Currents of different frequencies will be applied; the resulting voltage will be recorded, with a time resolution for the complete frequency span not lower than 2 seconds."
45639068|NCT02364193|Device|Autotransfusion Lympamat Digital Gradient system|Lympamat Digital Gradient system (Bosl, Aachen) inflatable leg compression trousers will induce an autotransfusion by compressing the legs with a maximum of 90 mmHg for a maximum of 300 seconds
45639069|NCT03100175|Behavioral|physiotherapy|strength training for upper and lower limbs fitness and balance work out
45639070|NCT04632433|Drug|Cemiplimab|350 mg every 3 weeks
45639071|NCT05231161|Diagnostic Test|Index of Microvascular Resistance|The invasive diagnostic procedure will be performed in at least one coronary artery. The left anterior descending coronary artery will be the preferred target vessel; however, if technical factors precluded guidewire-based assessment of this artery (e.g., tortuous anatomy), then the left circumflex or right coronary artery can be selected. In the case of multiple measurements per patient, the lowest FFR or highest IMR will be used for analysis. A coronary wire with a pressure and temperature sensor (PressureWire X, Abbott Vascular, Santa Clara, CA, USA) will be advanced to the mid to distal segment of the coronary artery. Bolus thermodilution technique with three 3-cc saline injections in rest and hyperemia will be used.
45639072|NCT03100097|Device|Aspen Horizon 627 LSO|
45639073|NCT02368249|Drug|Terlipressin|Patients are receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
45639074|NCT02368249|Drug|Placebo|Patients are receiving a post-operative intravenous Ringer's lactate solution
45639075|NCT04473443|Other|FEops HEARTguideTM|A patient-specific computer simulation that aims to improve the outcomes after TAVI by suggesting THV platform, THV size and implantation depth with the use of the pre-procedural CT-scan.
45448447|NCT01560754|Drug|nicotine transdermal patch|Transdermal patches containing 7 or 14 mg nicotine or placebo with subjects titrating up until reaching their highest tolerated dose of 7 to 28mg/day.
45777155|NCT05747924|Drug|AOC 1020|AOC 1020 will be administered via intravenous (IV) infusion
45777156|NCT05747924|Drug|Placebo|Placebo will be administered via intravenous (IV) infusion
45639076|NCT02367937|Drug|PRC-4016 (icosabutate)|"Midazolam, omeprazole, flurbiprofen and simvastatin interaction with PRC-4016. Detailed description under Study description"
45915692|NCT05669404|Behavioral|Salt Restriction Group (SRG)|Patients assigned to the SRG continued to consume their usual diet, but they had to restrict their sodium intake to 2,000 mg/ day. They were given a detailed booklet containing information about table salt, foods rich in sodium, and practical ways to decrease salt consumption. During each 45-min individual session, they received intensive counselling and training to increase adherence to salt restriction. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
45448448|NCT03547336|Device|Theranova 400 Dialyzer|Dialysis performed in HD mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.
45777157|NCT05747430|Drug|IRX-101|IRX-101 is a novel ocular anti-septic
45777158|NCT05747430|Drug|Providone-Iodine|5% Providone-Iodine
45777159|NCT05747339|Biological|tumor treatment vaccine injection|Patients will receive tumor treatment vaccine(TTV), which would be given deep subcutaneously in the arm or near the tumor.The initial dose is 1ml / week, if the reaction isn't obvious, the dose can be appropriately increased to 2.5-4.0ml / week.The interval between injections can be shortened or extended depending on the patient's condition and response.The duration of treatment should be extended as long as possible, at least 6-12 months.
45915693|NCT05669404|Behavioral|DASH Diet combined with salt restriction Group (DDG)|Patients assigned to the DDG received a more extensive booklet, which which in addition to the information regarding salt restriction, contained detailed information about the DASH diet, and practical advice about how to start and stay on the assigned dietary pattern. In addition to the booklet, each patient received an individualized eating plan with six sample daily menus, incorporating the goals of the DASH diet. During the 45-min individual sessions, patients were intensively counselled and trained to increase adherence to salt restriction and the assigned dietary pattern. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
45448449|NCT03547336|Device|FX800 Dialyzer|Dialysis performed in HDF mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.
45448450|NCT03547804|Drug|Apatinib|500 mg qd/250mg
45448451|NCT03547804|Drug|chemotherapy|Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
45448452|NCT01076465|Other|Disease management program|1. Educational intervention on management of heart failure and comorbidity to improve patient's knowledge of his/her disease and self-care 2) Monitoring of clinical status 3) Monitoring and improvement of therapeutic adherence.
45639077|NCT02364349|Drug|Bee Venom (BV)|Raw Bee Venom
45639078|NCT02364349|Drug|Essential Bee Venom (e-BV)|Bee venom without Hyaluronidase, Lysophospholipase, α-D-glucosidase, PLA2, Adolapin
45639079|NCT05011487|Drug|Osimertinib|80mg/qd oral for 60 days
45639080|NCT05011487|Drug|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.
45639081|NCT05011487|Drug|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin on Day 1 of every 3-week cycle for 2 cycles
45639082|NCT02373787|Device|creos xenoprotect|Implant placement with simultaneous bone augmentation
45935667|NCT00078195|Biological|omalizumab|A minimum equivalent dose of 0.016 mg/kg/IgE (IU/mL) every 4 weeks will be administered. Omalizumab is administered in two separate phases. In the pre-treatment period omalizumab will be administered to condition the participants to an immune tolerance state. Omalizumab will be also administered after RIT and during the maintenance immunotherapy phase.
46070310|NCT04908800|Drug|Placebo|Placebo tablet
45639083|NCT02373787|Device|Bio-Gide|resorbable collagen membrane
45639084|NCT05062187|Other|Proprioseption in hemiparetics|Proprioception on balance and gait functions in hemiparetic individuals
45639085|NCT02364115|Radiation|Stereotactic Body Radiotherapy|
45639086|NCT02367547|Drug|Hexylaminolevulinate cream|The cream is mixed up by the Pharmacy Yliopiston Apteekki for the study and every set is analysed by mass spectrometry.
45777160|NCT05741853|Behavioral|Video-Implemented Script Training for Aphasia (VISTA)|Participants with nonfluent/agrammatic variant primary progressive aphasia (PPA) or a predominantly nonfluent profile work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes two (one hour each) teletherapy sessions per week with a clinician targeting clear and accurate script production, script memorization, and conversational usage of scripts. The participant completes 30 minutes of independent, computer-based practice 5-7 times per week, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts.
45777161|NCT05741853|Behavioral|Lexical Retrieval Training (LRT)|Participants with logopenic variant PPA, participants with semantic variant PPA, and participants with a predominantly anomic profile will work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) teletherapy sessions per week with a clinician plus 30 minutes of additional independent, computer-based practice exercises 5-7 times per week.
45448453|NCT01076465|Behavioral|Usual care|Usual care
45639087|NCT02367547|Drug|Aminolevulinic Acid Nano Emulsion|In the study we use Ameluz.
45777162|NCT05741788|Device|Various Stimulation Patterns|Participants will undergo a structured optimization evaluating existing types of stimulation (tonic, burst, and multistim). Each participant will try out all types of available stimulation but be blinded to the type. Over the course of four months, each participant will evaluate each type of stimulation by reporting daily pain scores. Participants will follow up routinely to collect laboratory, behavioral, and survey responses to test for the feasibility of obtaining data explaining pain phenotype.
45777163|NCT05740839|Behavioral|HIIT Exercise Program|Exercise program with stationary bike via the Zoom platform.
45777164|NCT05740839|Behavioral|Control Group|Usual Activities
45777165|NCT05740475|Drug|9MW3811 injection|Single dose intravenously infused on day 1
45777166|NCT05740475|Drug|Placebo|Single dose of matching placebo intravenously infused on day 1
46070311|NCT04908800|Drug|itraconazole|10 mg/mL oral solution
45448454|NCT01064037|Drug|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h.
45448455|NCT01064037|Drug|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
45448456|NCT01064037|Drug|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
45448457|NCT01064037|Drug|Placebo|Infusion during 48h
45448458|NCT04728334|Drug|AK117|An intravenous (IV) infusion of AK117 as monotherapy. All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal
45448459|NCT03547648|Procedure|peak airway pressure|Patients' peak airway pressures will be raised to observe intraoperative bleeding in thyroidectomy surgery. Aim is to prevent postoperative bleeding.
45448460|NCT03735225|Drug|Dasiglucagon|Dasiglucagon injection
45448461|NCT03735225|Drug|Placebo|Placebo for Dasiglucagon injection
45639088|NCT02367547|Drug|Methylaminolevulinate cream|In the study we use Metvix.
45639089|NCT05061641|Drug|Progesterone|The delivery outcomes of the three groups were compared, including the rate of premature delivery (<37 weeks of gestation), the rate of early premature delivery (<32 weeks of gestation), and the need for anti-tocolysis treatment. Rates of premature rupture of membranes (<37 weeks), neonatal perinatal mortality and morbidity.
45639090|NCT02367625|Device|CryoPop|The new CryoPop device will be compared to standard cryotherapy
45639091|NCT02367625|Device|MedGyn MGC 200|Standard cryotherapy
45639092|NCT03055403|Drug|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
45639093|NCT03055403|Drug|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
45639094|NCT02367703|Procedure|laparoscopic hysterectomy|
45639095|NCT05060861|Other|ChAdOx1 nCoV-19 vaccine|covid-19 vaccine
45639096|NCT03100019|Dietary Supplement|Resveratrol|
45639097|NCT03100019|Drug|Placebo|
45639098|NCT02363725|Drug|Colchimax®|
45639099|NCT02363725|Drug|Conventional treatment|
45639100|NCT05060393|Behavioral|Mindfulness-based cognitive therapy|Mobile application, mindfulness-based therapy
45639101|NCT02367235|Procedure|Traditional vaginal positioning device|A vaginally placed endo-anal sizer will be used to position the vagina during surgery.
45639102|NCT02367235|Procedure|Colpassist vaginal positioning device|A vaginally placed Colpassist will be used to position the vagina during surgery.
45639103|NCT02373631|Other|Dry Needling, Conventional PT|Dry needling to the knee and conventional physical therapy (stretching, ROM, strengthening), 1-2 treatments per week X6 weeks (up to 10 sessions total)
45639104|NCT02373631|Other|Conventional PT|Conventional physical therapy to include knee stretching, range of motion, and strengthening exercises,1-2 treatments per week X6 weeks (up to 10 sessions total)
45777167|NCT05736861|Drug|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
45935668|NCT00078195|Biological|Placebo omalizumab|The placebo for omalizumab will contain the excipients and diluents of the omalizumab.
45935669|NCT00078195|Biological|Ragweed rush immunotherapy (RIT)|RIT will consist of a series of injections containing ragweed extract. The series of injections will have progressively greater amounts of ragweed extract: starting from the 1:1000 dilution of the maintenance vial and progressing to the 0.3 mL of 1:10 dilution of the maintenance vial or the maximally tolerated amount.
45639105|NCT02363413|Other|IniVAH|Initiation of the NIV during a 3 days hospitalization as usual.
45639106|NCT02363413|Other|IniVAD|Initiation of the NIV at home. The first day, the kinesiologist and the technician start-up the NIV at home with the patient. The investigator will validate the adjustment settings proposed by the kinesiologist. No procedure during the second day as described by the HAS. The third day, the kinesiologist and the technician come back to the patient home so as to adjust the settings if needed and if validated by the investigator.
45448462|NCT05373238|Procedure|Early discharge|Early discharge
45777168|NCT05736861|Other|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
45777169|NCT05732285|Behavioral|CRT|"Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
45777170|NCT05732285|Behavioral|CBT|"Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
45777171|NCT05732285|Behavioral|Modifiable lifestyle factors|The therapy sessions are coupled with homework and requires some lifestyle modifications such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
45777172|NCT05732285|Behavioral|Usual care Psychoeducation|"Participants will receive 15 minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
45777173|NCT05731128|Drug|Dupilumab|injection solution subcutaneous
45777174|NCT05731128|Drug|Placebo|injection solution subcutaneous
45777175|NCT05728372|Drug|Copper Cu 64-DOTA-pembrolizumab|Given IV
45777176|NCT05728372|Procedure|Positron Emission Tomography|Undergo PET scan
45777177|NCT05728372|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45777178|NCT05710965|Device|FRx-001|Wearable digital therapy
45448463|NCT02217267|Drug|Lidocaine|Lidocaine 3 mg/kg dilute in Normal Saline to 50 ml intravenous infusion in 1 hour
45777179|NCT05710965|Device|FRx-003|Wearable digital therapy
45935670|NCT00078195|Biological|Placebo rush immunotherapy (RIT)|The placebo for rush immunotherapy will contain the diluents and histamine.
45639107|NCT03099239|Biological|hCT-MSC infusion|hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked.
45639108|NCT02373475|Other|Conventional ventilation|Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia
45639109|NCT02373475|Other|Protective lung ventilation|Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
45639110|NCT05059613|Other|probiotics|one times a day during the whole treatment
45639111|NCT02373553|Other|EXERCISES|The postural reeducation in a sitting position, in ventral and dorsal recumbency, including manual techniques, stretching the sternocleidomastoid and scalene muscles. Exercises for pelvic girdle positioning and stretching the hamstrings muscles tibial and sural triceps are associated with respiratory exercise. Twice a week during 3 months
45639112|NCT02373553|Other|HEALTH EDUCATION|Booklet contain many pictures demonstrating some exercises and an importance to do it.
45639113|NCT03098849|Other|Buteyko Breathing Technique|Patients are trained in various exercises aiming at breath reduction and breath control as introduced by Dr. K. Buteyko
45777180|NCT05710965|Device|FRx-004|Wearable digital therapy
45777181|NCT05708833|Device|Intraosseous venous access|Immediate placement of humeral intra-osseous venous access (after a first failed attempt of peripheral venous access)
45777182|NCT05708833|Device|Peripheral venous access|Looking for peripheral venous access, changing the site of puncture, the caliber of the catheter and/or the operator and/or assistance tools (ultrasound, infra-red guidance...) and/or using another route (oral, rectal, subcutaneous, intramuscular route and central venous access)
45777183|NCT05708599|Diagnostic Test|Liquid biopsy|Liquid biopsy
45777184|NCT05707273|Drug|Autologous Anti-CD19 CAR-expressing T Lymphocytes|Given IV
45777185|NCT05707273|Procedure|Biospecimen Collection|Undergo blood sample collection
45777186|NCT05707273|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspirate
45935671|NCT00078195|Biological|Ragweed immunotherapy (IT)|Participants will receive weekly maintenance IT dosing for a total of 12 weeks.
45935672|NCT00078195|Biological|Placebo immunotherapy (IT)|The placebo for immunotherapy will contain the diluents and histamine.
45448464|NCT02217267|Drug|Placebo|
45448465|NCT05338372|Behavioral|Two days forest therapy|Participants attend two days (with a break day in between) of two-hour forest therapy at the Friedrichsruh, Barntrup or Wernigerode sites, led by an INFTA-certified forest therapy guide.
45448466|NCT05338372|Behavioral|Three days forest therapy|Participants attend three days of two-hour forest therapy at the Friedrichsruh, Barntrup or Wernigerode sites, led by an INFTA-certified forest therapy guide.
45452504|NCT00890968|Drug|Placebo DuraPeel|topical gel; once daily (nightly); total duration: 4 weeks
45777187|NCT05707273|Drug|Cyclophosphamide|Given IV
45777188|NCT05707273|Drug|Fludarabine|Given IV
45777189|NCT05707273|Procedure|Leukapheresis|Undergo T-cell leukapheresis
45777190|NCT05707273|Other|Questionnaire Administration|Complete questionnaires
45777191|NCT05706649|Behavioral|Plant-based diet|21 day diet that excludes any form of meat and other animal products, including dairy products.
45777192|NCT05705856|Drug|Ustekinumab|Patients will receive an intravenous induction (adjusted 6 mg/kg dose) followed by subcutaneous 90 mg every 12 or 8 weeks, and will receive dose escalation when response is not effective enough.
45777193|NCT05702385|Other|Educational Materials for a new diagnostic test|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
45777194|NCT05699668|Device|OCT Angiography|"2 views per eye (one centered on the fovea, one centered on the optic nerve), in 6x6 mm, using the OCT-A Plexelite®.~Acquisition time per image: about 10 seconds."
45777195|NCT05698654|Behavioral|Fasting-mimicking diet (FMD)|"The subjects will be instructed to follow their usual diet plan, except for 5 days when they eat the foods in the FMD box.The fasting-mimicking diet consists of a blend of 100% plant based nutrients generally regarded as safe. The formulation of these products is based on studies carried out at the Longevity Institute of the University of Southern California and his collaborators over several decades of studies.~This food plan provides for the replacement of the normal diet with the organic plant products contained in the fasting-mimicking diet for five consecutive days."
45639114|NCT02373397|Device|Cacicol20|Investigational device, regenerating agent, single-use doses, topical eye drops. Indicated for corneal wound healing.
45639115|NCT02373397|Device|Placebo|Vehicle only in identical packaging, with identical dosage and administration route.
45639116|NCT05059847|Other|Training|Training routine assigned by randomized chart
45639117|NCT03098927|Behavioral|Motor imagery training|Motor imagery training
45639118|NCT05060159|Other|Hemofiltration|Postdilutional Hemofiltration
45639119|NCT03098771|Procedure|the cell transplantation group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
45639120|NCT03098771|Drug|the control group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
45777196|NCT05698654|Behavioral|Longevity Diet (LD) + Fasting-mimicking Diet (FMD)|"The subjects will be instructed to follow their longevity diet plan, except for 5 days when they eat the foods in the FMD box, based on the following guidelines:~vegan based diet with the addition of low mercuryfish 2-3 times a week; protein content should be 0.7-0.8 grams per kilogram of ideal weight per day (most of the protein coming from whole cereals,vegetables, legumes and tree nuts only part from fish); monounsaturated and polyunsaturated fats are predominant and very low amounts of saturated and trans-fats are allowed; complex Carbohydrates from vegetables, whole grains and legumes; addition of vitamins, minerals and Omega3 fats; food selected between the traditional food consumed by ancestry; time-restricted feeding: all food must be consumed within 12 hours each day. for those who are overweight or are nearly overweight (BMI >25 kg/m2), either lunch or dinner will be substituted with a low calorie, low sugar snack (approximately 100 kcal: salad, nuts, fruit, etc.)."
45639121|NCT05047055|Drug|Isoniazid|Intensive Phase for 2 months and Continuation phase for 2 months dose: 75 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for >75 Kg) as a fixed-dose combination.
45777197|NCT05695417|Drug|OTX-TKI|Injection of OTX-TKI
45777198|NCT05695417|Drug|Sham|Sham Injection of OTX-TKI
45777199|NCT05694546|Behavioral|Community Health Worker Post-Discharge Intervention|Clients will be offered a community-based follow-up from a community health worker after hospital discharge.
45777200|NCT05690685|Device|Silver I Alginate Non-Woven Dressing (Hydro-Alginate)|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with Silver I Non-Woven dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change up-to six-week follow-up period."
45639122|NCT05047055|Drug|Rifampicin|Intensive Phase for 2 months and Continuation phase for 2 months dose: 150 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for >75 Kg) as a fixed-dose combination.
45639123|NCT05047055|Drug|Pyrazinamide|Intensive Phase for 2 months only dose: 400 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for >75 Kg) as a fixed-dose combination.
45639124|NCT05047055|Drug|Ethambutol|Intensive Phase for 2 months and Continuation phase for 2 months dose: 275 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for >75 Kg) as a fixed-dose combination.
45639125|NCT05047055|Drug|Moxifloxacin|Intensive Phase for 2 months and Continuation phase for 2 months dose: 400 mg for 30 to 64 yrs AND 600 mg for 65 and above years of age.
45639126|NCT03098537|Drug|enteral nutrition + proton pump inhibitor|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive enteral nutrition and proton pump inhibitor
45639127|NCT03098537|Other|enteral nutrition only|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive only enteral nutrition.
45639128|NCT05046665|Drug|89Zr-Girentuximab|Administration of 89Zr-girentuximab as per protocol.
45777201|NCT05689125|Device|Railroaded bougie|Residents expose the glottis by a video laryngoscope and place the tip of bougie through the vocal cords. Then, an assistant loads an endotracheal tube on the free end of the bougie. Residents advance the endotracheal tube over the bougie and withdraw the bougie.
46070312|NCT00702039|Other|No Music|No music will be played in patients in arm 2 of the study.
45639129|NCT05046041|Drug|Mifepristone + Misoprostol|A single 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed approximately 24 - 48 hours later with administration of 400 mcg misoprostol. Repeat doses of 400 mcg (two tablets) of misoprostol will be administered buccally (buccal) every three hours until the abortion is achieved.
45639130|NCT01970878|Drug|GFF MDI (PT 003)|GFF MDI administered as two puffs BID
45639131|NCT01970878|Drug|GP MDI (PT001)|GP MDI administered as two puffs BID
45639132|NCT01970878|Drug|FF MDI (PT005)|FF MDI administered as two puffs BID
45639133|NCT01970878|Drug|Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 μg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
45639134|NCT05045651|Procedure|Gender Solution®posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA and standard posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA|gender specific knee prosthesis:design for female to restore Q-angle, reduce anteroposterior (AP)/mediolateral(ML) ratio for reducing overhang of femoral component, increase valgus angle of trochlea groove, and reduce thickness of anterior part of prosthesis for prevention overstuff with patella. The standard TKA or unisex knee prosthesis was design for female and male.
45639135|NCT05045417|Diagnostic Test|Serum level of IL-17|"Measurement of serum level of IL-17 :~To explore the role of IL-17 in systemic lupus erythematosus~To determine the relation between IL-17 and lupus disease activity~To analyze the correlation between IL-17 and internal organ affection (lupus nephritis , interstitial lung disease)"
45639136|NCT05045339|Procedure|Ball Exercises|Different ball exercises which include stability ball roll, stability ball hug, catching, throwing was performed. Along with these exercises, ball tapping exercise was also performed. Exercises were performed with 55 and 65 inch gym ball and a small regular plastic ball.
45639137|NCT05059145|Drug|Chlorhexidine Gluconate|Vaginal cream 1%
45639138|NCT05059145|Drug|Fluconazole|150 mg oral capsule
45639139|NCT05058989|Diagnostic Test|Advanced ultrasound measurements (Duplex ultrasound (DUS) and Vector flow imaging (VFI)|PPG is a non-invasive method used to evaluates the severity venous reflux by measuring the venous refiling time (VRT).The principal of PPG works by using a small light source and a photoelectric cell attached to the skin in the medial supramalleolar area of the leg (the distal lower medial area of the leg).
45639140|NCT05058989|Other|Clinical interventions and procedures|"First trimester (0-13 weeks):~Consent~Clinical data collection~Blood samples (genomic+ hormonal)~Duplex ultrasound~Vector flow imaging (advanced ultrasound software)~Truncated cone tool (measuring leg circumference using a tape measure)~PPG~AVVQ (Aberdeen varicose veins questionaire)~Second trimester (14-26 weeks):~Clinical data collection~Blood sample (hormonal only)~DUS~VFI~Truncated cone tool~PPG~AVVQ~Third trimester (27-40 weeks):~Same as second trimester~Three months after giving birth:~Same as second trimester"
45639141|NCT05045105|Other|Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication|Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication and complications related to the maneuver between the two cohorts will be evaluated and compared.
45639142|NCT05059067|Device|Direct laryngoscopy for endotracheal intubation|Patients in operative room, intensive care unit and emergency department requiring direct laryngoscopy for endotracheal intubation
45639143|NCT05058677|Drug|aerosolized 2% lidocaine (20mg/ml)|The aerosolized solution to be used is 2% lidocaine (20 mg/ml) at a dose of 1.5 mg/kg with a maximum volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The aerosolized solution will be administered with an Aerogen ultrasonic nebulizer, which is standard of care for administering aerosolized solutions in our pediatric intensive care unit (PICU).After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
45639144|NCT05058677|Drug|instilled 0.9% sodium chloride (NS)|The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
45639145|NCT05058677|Drug|instilled 2% lidocaine solution|The instilled 2 % lidocaine solution used will be 1.5 mg/kg, with a max volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
45639146|NCT05058677|Procedure|Endotracheal Suctioning (ETS)|ETS will be performed in a single pass using a closed-system suctioning. Suction will be applied only on withdrawal of the catheter and fraction of inspired oxygen (FIO2) will remain at 100% for 60 seconds following suctioning and then returned to the preprocedural level (baseline).
45639147|NCT05058599|Diagnostic Test|DM|A new technology based on 3D reconstruction and deep learning algorithm to irreversibly erase the biometric attributes whilst retaining the clinical attributes needed for diagnosis and management
45639148|NCT01970488|Biological|Adalimumab|Administered by subcutaneous injection
45639149|NCT01970488|Biological|ABP 501|Administered by subcutaneous injection
45639150|NCT03097835|Drug|Hyper-Diluted Botox|"0.1ml of hyper-diluted Botox® Cosmetic will be administered in the superficial dermis using a 1ml luer lock syringe coupled with a 33g ½ needle"
45639151|NCT03097835|Drug|Topical anesthesia|Topical anesthesia will be bilaterally applied to the mid-face region for 20 minutes
45639152|NCT03097835|Other|0.9% saline solution|0.1ml of 0.9% saline solution will be administered to the side of the face
45639153|NCT03097601|Diagnostic Test|ELR+CXCL cytokines levels are of sunitinib response|Demonstrate on independent cohorts of patients that ELR+CXCL cytokines levels are of sunitinib response
45639154|NCT05058755|Drug|tislelizumab, azacytidine, lenalidomide|"tislelizumab, 200mg, iv, day 1, every 21 days.~azacytidine, 75mg/m2, ih, days 1-7, every 21 days.~lenalidomide, 25mg, po, days 1-14, every 21 days."
45639155|NCT05058755|Drug|tislelizumab, etoposide, pegaspargase|"tislelizumab, 200mg, iv, day 1, every 21 days.~etoposide, 100mg, iv, days 1-3, every 21 days.~pegaspargase, 2000U/m2, day 1, every 21 days"
45639156|NCT05044247|Procedure|ESP blocks|ultrasound and fluoroscopy to identify the spread of drug
45639157|NCT05044169|Drug|Broncho-Vaxom|administration for 6 months after remmission
46070313|NCT00702039|Other|Music Therapy|Classical music being played during intravitreal injection.
45777202|NCT05689125|Device|Preloaded bougie|Residents expose the glottis by a video laryngoscope and perform the endotracheal intubation using a bougie with a preloaded endotracheal tube while an assistant secures the free end of the bougie. Residents withdraw the bougie when the endotracheal tube reaches an appropriate depth.
45777203|NCT05689125|Device|Stylet|Residents expose the glottis by a video laryngoscope and perform the endotracheal intubation with the assistance of a stylet. An assistant withdraws the stylet when the tip of the endotracheal tube passes through the vocal cords. Then residents place the endotracheal tube to an appropriate depth.
45639158|NCT05058365|Behavioral|dots Curriculum|"dots is a mindfulness curriculum developed by Mindfulness in Schools Project (MiSP) for children aged 3-6 in pre-school settings. The program consists of 15-minute twice weekly lessons that span for fifteen weeks. dots has various suggestions for Have A Go after each session - both in the classroom and at home."
45639159|NCT05044559|Other|Continuous Positive Air Way Group|CPAP between 10 and 12 cmH2O
45777204|NCT05686551|Drug|Tominersen 60 mg|60 mg tominersen administered intrathecally every 16 weeks
45777205|NCT05686551|Drug|Placebo|Matching placebo administered intrathecally every 16 weeks
45777206|NCT05686551|Drug|Tominersen 100 mg|100 mg tominersen administered intrathecally every 16 weeks
45777207|NCT05684939|Behavioral|Questionnaire (patient reported outcome)|Online self-administered questionnaire exploring substance use, pain, chemotherapy-induced peripheral neuropathy, health-related quality of life, anxiety, depression, social and material deprivation, patients and oncological charactericitcs, and intercurrent pathologies
45777208|NCT05682937|Device|HFOV-sigh|HFOV-sigh setting both SLE6000 and Drager Babylog VN500: setting (Hz, MAP, delta pressure) same as HFOV, set sigh RR 3 breath/min, Sigh Ti = 1 sec, Sigh PIP = (MAP+5, maximum 30) cm H2O, Slope sigh 0.5. No change in Hz, MAP, delta pressure, and increased FiO2 less than 0.1 occurred between intervention
45777209|NCT05674942|Other|Patients with urinary tract infection and chronic kidney disease|The data that will be collected from the electronic patient records at the clinics through a google form will include sociodemographic (age, sex, weight and occupation), comorbidities (e.g., HTN, DM), medications used, renal functions (serum creatinine, and CKD stage calculated by 2021 CKD-EPI creatinine equation), and in case of positive urine culture (type of microorganism and antibiogram).
45777210|NCT05672173|Procedure|Biopsy|Undergo tumor biopsy
45777211|NCT05672173|Procedure|Biospecimen Collection|Undergo blood specimen collection
45448467|NCT05334628|Procedure|Preoperative Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position.
45448468|NCT05334628|Procedure|Postperative Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, after the surgical operation, under general anesthesia, and when the patient is placed in the lateral decubitus position.
45448469|NCT03670641|Drug|Glargine|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
45452505|NCT05218850|Drug|Butyrate|Butyrate enemas will be administered once a day for 12 weeks
45777212|NCT05672173|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy and/or aspiration
45777213|NCT05672173|Procedure|Computed Tomography|Undergo PET/CT
45777214|NCT05672173|Drug|Cyclophosphamide|Given IV
45777215|NCT05672173|Drug|Fludarabine|Given IV
45777216|NCT05672173|Drug|Ibrutinib|Given PO
45777217|NCT05672173|Biological|Lisocabtagene Maraleucel|Given IV
45777218|NCT05672173|Biological|Nivolumab|Given IV
45777219|NCT05672173|Procedure|Pheresis|Undergo apheresis
45777220|NCT05672173|Procedure|Positron Emission Tomography|Undergo PET/CT
46070314|NCT04253522|Behavioral|Cognitive training|Rehabilitation program in standard ergotherapy and cognitive training with Covirtua Software and Transcranial random noise stimulation
46070315|NCT04987112|Drug|CAN1012|CAN1012 IT injection (once every 4 weeks)
45777221|NCT05665634|Device|Concurrent transcranial magnetic stimulation and electroencephalogram|Single and paired-pulse TMS will be applied to 5 different brain regions during simultaneous recording of EEG. Paired-pulse stimulations will have either 3 ms or 11 ms between pulses, to stimulate cortical inhibition and excitation respectively. Stimulation intensity for single-pulse stimulation blocks will be 120% of the resting motor threshold (RMT). For paired-pulse blocks, the conditioning (first) pulse will be delivered at a stimulation intensity of 80% RMT, and the test (second) pulse will be delivered at 120% RMT. Each test block will consist of 60 TMS trials and will last for 5 minutes. Order of test blocks will be pseudo-randomized across participants. Out of 5 stimulation sites, 3 will be determined based on individual's own brain anatomy and resting state connectivity. These 3 regions will be stimulated using all 3 TMS protocols. The other two regions will be determined based on the literature and only be targeted using the single pulse TMS protocol.
45777222|NCT05661643|Drug|Temozolomide capsule|Temozolomide 200 mg/m2 is administered orally for 1-5 days of each cycle, and then canceled for 23 days (a total of 28 days is 1 cycle)
45777223|NCT05661344|Drug|BI 1015550|BI 1015550
45777224|NCT05660941|Drug|Lispro|Ultra rapid Lispro
45777225|NCT05660941|Drug|Lispro|Conventional Lispro
45777226|NCT05660096|Device|Cionic Neural Sleeve NS-100|Sleeve applies neuromuscular stimulation as patients walk to help contract appropriate muscles at appropriate times.
45777227|NCT05659056|Drug|Pyrotinib, trastuzumab, paclitaxel-albumin|pyrotinib: 400mg orally daily; trastuzumab: 8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles; paclitaxel-albumin: 260mg/m2, every 3 week, a total of 6 cycles
45777228|NCT05658107|Drug|BI 765423|BI 765423
45777229|NCT05658107|Drug|Placebo|Placebo
45777230|NCT05654649|Drug|0.9%sodium chloride|Patients received 5 ml of IV normal saline as a placebo just before spinal anesthesia
45777231|NCT05654649|Drug|Dexamethasone|Patients received IV dexamethasone 8 mg in 5ml normal saline 0,9%, just before spinal anesthesia.
45639160|NCT05044559|Other|Control Group|"Day 1: Bed mobility chest physiotherapy, active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise and vital was record after exercise.~Day 2: Active range of motion exercise progress with 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time will increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days."
45639161|NCT05058053|Other|Cold application|Cold application was applied a total of 12 times on the infused PVC with cold gel packs for 15 minutes at 2-hour intervals.
45639162|NCT03097679|Device|Pulsar Stent|Percutane transluminal stent angioplasty with a Pulsar Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
45639163|NCT03097679|Device|LifeStent Flexstar Vascular Stent|Percutane transluminal stent angioplasty with a LifeStent Flexstar Vascular Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
45639164|NCT05058209|Drug|Triamcinolone acetonide extended-release injectable suspension|Zilretta (Triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee OA. The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis (2%), cough (2%), contusions (2%) and joint swelling (3%). For additional details, please see Package Insert (http://www.zilrettalabel.com/PI.pdf). The website for Zilretta additionally lists: joint pain, headache, back pain, sore throat and runny nose, and bruising as common side effects of receiving a Zilretta injection.
45639165|NCT05058209|Drug|Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension|Celestone (betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL) is indicated as an intra-articular injection for the management of chronic or long-term inflammation associated with multiple conditions including severe allergies, dermatological diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system disorders, ophthalmologic diseases, renal diseases, respiratory diseases and rheumatic disorders, and others that may not be listed. Celestone Soluspan is available in generic form. The most commonly reported adverse reactions include acne, increased hunger, and weight gain.
45639166|NCT05057663|Drug|Bleomycin and 5-fluorouracil|"In the bleomycin-treated group, bleomycin vial will be diluted first with 5 ml distilled water At time of treatment session 2 ml of lidocaine 2% and 1 ml of the bleomycin stock solution will be taken in 100-unite insulin syringe. Thus, the working bleomycin solution will be used in treatment 1 mg/ml. The bleomycin solution will be injected intralesional till blanching of the wart will be occurred. The amount of injection ranging from 0.2, 0.5, 1 ml according to size of warts; (5 mm, 10 mm, >10 mm) maximum for 1 ml in single wart and 2ml in treatment session. Treatment session will be done every two weeks maximum four sessions.~In 5-fluorouracil treated group, 5-fluorouracil vial ( 1 ml of 50 mg/ml 5-FU will be mixed with 0.25 ml of lidcaine 2% Every wart will be injected with 0.1 ml of the previous mixture into it base using an insulin syringe till blanching of the warts maximum 2ml of 5-FU per session. Treatment session will be done every two week for maximum 6 sessions"
45639167|NCT03097445|Drug|Nicotine patch|mailed 5-week course of Habitrol® transdermal nicotine patches
45639168|NCT03097367|Diagnostic Test|bladder neck level on cystography|All patients had investigated by retrograde cystography after LRP and were grouped according their bladder neck position: Level 0: bladder neck at or above the superior margin of the symphysis pubis (SMSP), Level -1: bladder neck at <2 cm below SMSP, and Level -2: bladder neck at >2 cm below SMSP.
45639169|NCT05057351|Other|Isopentenyltheophylline 0.44% + Glycerin 4.56%|Application of topical cream twice a day on the area affected by Atopic Dermatitis
45639170|NCT05057351|Other|Glycerin 4.56%|Application of topical cream twice a day on the area affected by Atopic Dermatitis
45639171|NCT03097523|Device|Custom Thigh Cuff|The aim is to achieve positive and near normal forward arterial vascular blood flow to the lower extremities. Milder cuff pressures up to 65 mmHg will be used to limit venous return to the upper body.
45639172|NCT03097211|Drug|Placebo|Placebo capsules. Orally, with 240 mL of potable water.
45639173|NCT03097211|Drug|BIA 6-512|The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 75 mg, 100 mg. Orally, with 240 mL of potable water.
45777232|NCT05654324|Other|pelvic floor muscle exercises|Before the pelvic floor exercises are taught to all women participating in the study, a brief informational training about the function and structure of the pelvic floor and pelvis will be given using visuals. The application protocol will be given by experienced specialist physiotherapists who have received special training on pelvic floor muscle training. In this study, the training protocol described by Mørkved et al and Bø et al will be used. An exercise series will consist of slow and fast muscle contractions of the pelvic floor muscles. The exercise series will include 10 reps of maximum pelvic floor muscle contraction held for 6 seconds followed by three rapid muscle contractions. A 10-second rest period will be given between each exercise series. A total of 5 minutes, 4 repetitions of pelvic floor muscle contraction series will be applied, including the rest period.
45777233|NCT05653206|Procedure|Nonsurgical treatment|Cervical collar, Halo ring, Halo vest, cervical braces, skeletal skull traction, MAP, steroids, observation or bedrest
45777234|NCT05653206|Procedure|Surgical treatment|Anterior discectomy and instrumented fusion (single level), Anterior discectomy and instrumented fusion (multi-level), Posterior decompression-laminectomy, Posterior decompression-laminoplasty, Posterior decompression and instrumented fusion, Combined anterior and posterior decompression and instrumented fusion
45777235|NCT05650567|Drug|M5049 high dose|Participants will receive film-coated tablets of M5049 at a high dose orally, twice daily up to 24 weeks.
45777236|NCT05650567|Drug|Placebo|Participants will receive placebo matched to M5049 orally, twice daily up to 24 weeks.
45777237|NCT05649748|Drug|Treprostinil Palmitil|Administered by oral inhalation, using a Plastiape capsule-based dry powder inhaler.
45777238|NCT05649748|Drug|Placebo|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
45639174|NCT03097211|Drug|Madopar® 250|Levodopa/benserazide immediate release tablets 200mg/50mg. Orally, with 240 mL of potable water.
45777239|NCT05645042|Behavioral|Transcendental Meditation (TM)|During the first week, each participant randomized to undergo TM will meet with a TM instructor on four consecutive days for 60 minutes, for an introductory training. Next, participants will meet for twelve 60-minute sessions over the course of three months and then once monthly for booster sessions for 6 months. All sessions will be recorded and reviewed for adherence to the TM protocol.
45777240|NCT05645042|Behavioral|Present Centered Therapy (PCT)|PCT treatments will be delivered by trained clinicians at master's or doctoral-level. Study therapists will be supervised by a a licensed psychologist. Participants assigned to this treatment will meet with a PCT therapist once a week for twelve 60-minute sessions over the course of 3 months and then monthly for months four through nine. Sessions will focus on current life problems as manifestations of PTSD. All sessions will be recorded and reviewed for adherence to the treatment protocol.
45777241|NCT05640648|Behavioral|User-Centered Implementation Strategy|"4 participant-facing components: 1a) TB education pamphlet helps index TB persons disclose the need for household screening to contacts. 1b) Contact identification algorithm helps CHWs and index TB persons accurately enumerate contacts. 1c) Sputum collection video instructs contacts to expectorate good-quality sputum. 1d) Community Health Riders transport CHWs, index persons with TB, and contacts by motorcycle taxi, and collect and transport sputum.~3 community health-worker-facing components: a) Weekly CHW meetings create communities of practice (CoP), professionals organized for peer support and systematic learning. Meetings involve problem solving, review of audit and feedback reports, and didactics on TB care, among other activities. 2b) Audit and feedback reports on contact investigation performance indicators weekly (individual CHW) and monthly (health facility). 2c) A group-chat application facilitates peer support among CHWs."
45777242|NCT05640648|Behavioral|Standard Implementation Strategy|Once an eligible TB patient agrees to participate, CHWs will visit the patient to assess the eligibility of close contacts to participate. For eligible contacts who agree to participate, the CHW will perform TB symptom screening and arrange subsequent microbiologic, clinical, and/or radiographic evaluation. Those screening TB symptom-positive will be asked to expectorate a sputum sample, unless under age 5. If under age 5 or unable to produce sputum, contacts will be referred to the health centre for evaluation. A CHW will transport sputum samples to the health-centre laboratory for microbiologic evaluation and later report the test results back to the contact. During the standard implementation strategy period, CHWs at all sites will receive the standard TB program training on TB contact investigation and supportive supervision from the on-site National TB Program focal person.
45777243|NCT05634811|Biological|VLA15|6-valent OspA-based Lyme disease vaccine
45639175|NCT03097211|Drug|Nebicapone|Nebicapone 150 mg tablets. Orally, with 240 mL of potable water.
45639176|NCT05056961|Other|Multiparametric mesurements|Multiparametric assessments will necessitate the use of a plastic belt to record electro-impedancemetry tomography data; and a nano-gatsric tube fitted with esophageal and gastric low pressure balloons
45639177|NCT05044403|Procedure|Extracorporeal support with haemoperfusion|Use of extracorporeal support with haemoperfusion
45639178|NCT05044403|Procedure|Conventional treatment|Conventional treatment
45639179|NCT05044481|Procedure|third molar surgical removal|ambulatory surgical intervention of the maxilla and / or mandible for third molar removal
45639180|NCT04434443|Other|trunk exercise on unstable exercise|Participants would receive exercises on unstable surface. Started from supine position, participants had abdominal drawer-in maneuver with soft foam under the pelvic. Lower trunk rotation, bridging and abdominal muscles isometric contraction exercises were also used in this exercise during supine position, with different unstable surfaces used. Including soft foam under the feet, then progressed to BOSU ball under the feet, then progressed to the a BOSU ball under the feet combined with pelvic on soft foam. During sitting, BOSU ball and Swiss ball were used as unstable surface. Pelvic anterior-posterior tilt, lateral tilting, rotation, lifting, and stepping with arm swing were used in this position.
45639181|NCT04434443|Other|Upper limb range of motion exercise|Upper limb range of motion exercise with trunk fully supported
45639182|NCT05043935|Procedure|L-PRF with antimicrobial photodynamic therapy|Application of L-PRF with antimicrobial photodynamic therapy in the defect
45639183|NCT05043935|Procedure|antimicrobial photodynamic therapy without L-PRF|application of antimicrobial photodynamic therapy without L-PRF in the defect
45639184|NCT05056571|Behavioral|Progressive muscle relaxation|Progressive muscle relaxation exercise is a type of exercise in which tense muscles in your body gradually relax and relax. It is an application that allows you to forcefully stretch every muscle group in your body, hold it tight for 5 seconds, and then relax it. Visualize your tense muscles throughout this exercise and imagine that the feeling of relaxation spreads to all your muscles in the form of a wave and the tension is relieved. Keep breathing throughout the entire exercise.
45639185|NCT03096977|Diagnostic Test|Scale for the assessment and rating of ataxia (SARA)|Clinical evaluation of the manual dexterity through the SARA scale.
45777244|NCT05634811|Other|Normal Saline|0.9% sodium chloride solution for injection
45777245|NCT05629234|Drug|Osimertinib|Osimertinib (dose range of 40 mg to 240 mg orally, once daily)
45448470|NCT03670641|Drug|Lispro|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
45639186|NCT03096977|Device|JAMAR hand dynamometer|"Clinical evaluation of the prehension force using a JAMAR Dynamometer.~The prehension effort is made with the arm along the body, forearm horizontal, elbow flexed at 90 degrees, wrist in neutral position. The handle of the dynamometer is set to the second notch. The effort required is maximum effort.~Verbal encouragement is given during four successive tentative: the last three are averaged.~Each effort will be separated by a rest period of one minute. Interval: 1 min - Repeat: 3 times per hand"
45639187|NCT03096977|Device|Vibratory sensibility testing|"Test carried out using a tuned fork applied to the styloid radial process.~Position of the evaluated: elbow to the body with forearms horizontal and the wrist in neutral position. Stimulate the tuning fork and apply it to the styloid process of the radius. Ask the patient to say when he no longer feels the vibration.~Repeat 3 times for each hand."
45639188|NCT03096977|Device|Sermes and Weinstein test|"Instrumental, quantitative method of tactile pressure sensation (dermal contact at constant pressure) using monofilaments. The monofilaments bend when a threshold force is applied to them.There is a kit of 5 monofilaments, each one corresponding to a different functional level.~Familiarize the patient with the test, eyes open, on a normal healthy side. Determine the level of perception of the healthy side, eyes closed. Start with the finest monofilament. If the answer is negative, go to the next monofilament.~The monofilaments applications are randomly made in the Wynn Parry areas, 3 times / area for blue and green filaments, then 1 time / zone for others.~The monofilament must be applied in 1.5 sec, held 1.5 sec, removed in 1.5 sec. The patient must give a verbal response yes when he perceives the contact and the response time must be less than 3 sec."
45639189|NCT03096977|Device|Weber test|"Evaluate the discrimination of 2 motionless points. The tactile discrimination threshold is the smallest distance separating 2 simultaneous stimulations that are located and perceived separately.~The pressure stops at the whitening of the skin. The patient should specify if he feels one or two spikes.~To determine the discrimination threshold:~Perform 10 stimulations of the same spacing in the same area. The smallest interval for which 7 correct answers are obtained is retained as threshold value.~Perform the test 3 times."
45639190|NCT05056181|Other|Physical Activity|Physical activity
45777246|NCT05623345|Drug|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
45777247|NCT05623345|Drug|Placebo to izokibep|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
45777248|NCT05621096|Radiation|Bridging radiation therapy|Days -20 to -7: Patients will receive 2 fractions of 2 gray (Gy) for a total of 4 Gy received.
45777249|NCT05621096|Biological|Liso-cel|"Day 0: Patients will receive an infusion of liso-cel CAR T-cell product.~Prior to the liso-cell infusion (Days -5 to -3), patients will receive lymphodepleting chemotherapy using fludarabine 30mg/m2 and cyclophosphamide 300mg/m2 per institutional standard procedures."
45777250|NCT05621096|Radiation|Post-infusion radiation|Days 30 to 80: Patients eligible for post-infusion radiation will receive a total dose of up to 32 Gy.
45777251|NCT05614895|Drug|RO7223280|Participants will receive RO7223280, 600 mg, IV infusion for 1 hour on Day 1.
45777252|NCT05614739|Drug|LOXO-435|Oral
45777253|NCT05614739|Drug|Pembrolizumab|IV
45777254|NCT05613036|Drug|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1)|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1)
45777255|NCT05613036|Drug|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2)|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2)
45448471|NCT03670641|Device|Dexcom G6|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
45448472|NCT05298124|Device|Transcatheter edge-to-edge repair|Transcatheter edge-to-edge repair
45448473|NCT05298124|Other|Medical therapy|Medical treatment in an intensive care unit
45448474|NCT03621111|Behavioral|Patient-counseling|After one month from the hospital discharge, the pharmacist will give to the patient general advices and suggestions regarding disease, therapy and drugs.
45777256|NCT05613036|Drug|BI 907828|BI 907828
45777257|NCT05610579|Other|Remedial exercise|Remedial exercise program will be taught by qualified physiotherapist and given the initial session of exercise prescription and training. Patients will be practiced to the exercise 3 sets of 15 repetitions. Patients will be monitored telephonically in the evening at home.
45777258|NCT05610579|Other|Compression bandage|Multi-layered short stretch bandaging will be applied for 23 hour. Patients will be practiced to the exercise 3 sets of 15 repetitions. Patients will be monitored telephonically in the evening at home. The bandage will be removed at the same time the next day.
45777259|NCT05610319|Drug|Faricimab|Faricimab will be administered via intravitreal injection.
45777260|NCT05608759|Behavioral|Multimodal prehabilitation|4 weeks of an supervised, pre-operative exercise prescription augmented by a wearable fitness device.
45777261|NCT05606406|Other|Nocturnal Oxygen|Nocturnal oxygen will be increased hourly for a period of four hours up to 4 liters per minute (LPM). If the oxygen saturation (SpO2) falls below 70% the oxygen rate will be increased until patients achieve the threshold of 70% and then will proceed with titrations of 1 liter per minute LPM per hour.
45777262|NCT05599061|Other|FFR>0.80+ OCT with findings indicative of vulnerable plaque|Patients received OPTIMAL MEDICAL TREATMENT (OMT)+PCI
45777263|NCT05599061|Other|FFR>0.80+ OCT with findings indicative of vulnerable plaque|OPTIMAL MEDICAL TREATMENT (OMT)
45777264|NCT05591820|Behavioral|Brief behavioral parent training with optional booster sessions|A brief and individually-tailored behavioral parent training program that combines stimulus control and contingency management techniques to treat children's disruptive behaviors in three (bi)weekly sessions and optional booster sessions.
45777265|NCT05591820|Behavioral|Care as usual|The care that is usually provided by the clinical institutions to treat children's disruptive behaviors. There will be no restrictions regarding type or duration of CAU (only the brief parent training will not be allowed) which may for example include psychoeducation, (long) parent training, child treatment (e.g., pharmacotherapy, cognitive behavioral therapy) or family therapy.
45777266|NCT05589337|Behavioral|Baduanjin|The Baduanjin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
45639191|NCT05056337|Drug|Lenvatinib 4 MG Oral Capsule [Lenvima]|patients will be treated with lenvatinib in combination with toripalimab and TACE (on demand)
45639192|NCT05056337|Drug|Toripalimab|patients will be treated with lenvatinib in combination with toripalimab and TACE (on demand)
45639193|NCT05056337|Procedure|TACE|Hepatic arterial chemoembolization
45639194|NCT05056025|Dietary Supplement|Postbotics and Vitamins|2 capsule 3 times a day, before meals
45639195|NCT05056025|Dietary Supplement|Vitamins|2 capsule 3 times a day, before meals
45639196|NCT03097055|Procedure|Traditional Acupuncture|"widely ongoing traditional acupoints in scalp and limbs with traditional deqi manipulation, for stroke patient"
45639197|NCT03097055|Procedure|Minimal Acupuncture|non-traditional acupoints in scalp and limbs, with minimal manipulation
45639198|NCT02661217|Drug|LCZ696|"LCZ696 film-coated tables were supplied to the investigators. Tablets were taken with a glass of water, and were administered with or without food.~The target dose of LCZ696 was 200 mg twice daily. Starting dose of LCZ696 was either 50 or 100 mg, twice daily. The dose of LCZ696 should be doubled every 2-4 weeks to achieve the target dose of 200 mg twice daily, as tolerated by the patient."
45639199|NCT05044091|Drug|PARP inhibitor|Ovarian/fallopian tube/primary peritoneal cancer patients with PARP inhibitors according to the NCCN guideline and their instructions
45639200|NCT01952080|Drug|teduglutide|Open label intervention. Each subject will be assigned to receive 0.0125, 0.025, or 0.05 mg/kg/day for the duration of the study
45777267|NCT05589337|Behavioral|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
45777268|NCT05588063|Device|Transcutaneous auricular vagus nerve stimulation|The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.
45935673|NCT05561686|Drug|Pyrotinib|This study adopted a prospective, multicenter, observational design. From October 1, 2022, 100 patients with HER2-positive breast cancer scheduled to receive neoadjuvant therapy with pyrotinib were enrolled. The treatment regimen was determined according to the patient 's condition, physician' s treatment experience, evidence-based evidence and other factors to assess the clinical benefit (pCR, ORR) and safety of different neoadjuvant therapy modalities containing pyrotinib. Exploratory analysis was performed to investigate the correlation between the level of TMB and the pCR rate of neoadjuvant therapy in HER2-positive breast cancer patients, and the effect of pyrotinib on intestinal flora.
45448475|NCT03621111|Behavioral|Patient self-administered questionnaire|The pharmacist will submit the questionnaire to the patient for the evaluation of drug adherence, life style, feelings and approach to therapies, at 30 days, 3, 6, 9 and 12 months from the enrollment. This self-questionnaire of 13 questions contains the 8 multiple choice questions of the Morisky medication adherence scale (MMAS-8-Item, Italian version).
45448476|NCT03621111|Behavioral|Pills counts|At the time of the monthly drug re-supply at the community pharmacy, the patient will bring the boxes of the drugs taken in the previous month (empty or not), for the pill counts. The pharmacist will verify the correct assumption of the pharmacological therapies.
45639201|NCT05043779|Procedure|Awake Airway Nasoendoscopy|Preoperative Awake Airway Nasoendoscopy of upper airway
45639202|NCT05055791|Drug|SYHX1903|SYHX1903 tablets, orally, qd
45639203|NCT01951378|Device|Hudson RCI® nebulizer|After the first hour of treatment, patients in the standard arm will receive a repeat assessment, including all of the measurements collected at baseline as well as reported side effects. Those patients who score PAS 0-2 will then be discharged home, after an optional observation period, as per the pathway. Those who score PAS > 2 will receive a second treatment. At the end of the second treatment patients will again be re-assessed, and repeat measurements obtained. At that time, depending on the patient's PAS score, he/she will be dispositioned to home, the floor, the pulmonary high acuity unit (PHAU), or the pediatric intensive care unit (PICU).
45639204|NCT01951378|Device|NebuTech® HDN® nebulizer|All treatments in the NebuTech® arm will be given at a standard dilution of 5 ml (diluted with normal saline to a total volume of 5 ml as per the manufacturer's recommendation). Patients in this arm will receive up to four treatments with parameters measured after each treatment, similar to the control arm. Patients who complete four treatments will then be dispositioned based on PAS score, similar to the control arm. Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
45639205|NCT01951378|Drug|Albuterol|Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
45639206|NCT05055635|Radiation|Pencil beam proton therapy|Neo-adjuvant or definitive pencil beam proton therapy: 55 Gy(RBE)/44fx - 65 Gy(RBE)/52 fx (1.25 Gy per fraction), two fractions a day
45639207|NCT01944670|Device|Internal Joint Stabilizer - Elbow (IJS-E)|Device designed for internal stabilization of the elbow
45639208|NCT05043467|Drug|Duvie(Lobeglitazone) tab 0.5mg|patients with type 2 diabetes who received lobeglitazone 0.5mg for more than one year between February 1, 2014 and December 20, 2018
45639209|NCT04661176|Diagnostic Test|miR Sentinel™ PCC4 Assay|This study is a prospective clinical utility study. Urine samples will be collected from participants for the miR Sentinel™ PCC4 Assay, which interrogates the expression profile of 442 small non-coding RNAs to classify disease status as having no molecular evidence of prostate cancer (NMEPC) or molecular evidence of low-, intermediate- or high-risk prostate cancer.
45935674|NCT00044291|Drug|atamestane|
45639211|NCT03096899|Other|Observational|Best Supportive Care
45639212|NCT03096821|Drug|ngFDS selected treatment|Treatment based on next-generation functional drug screening (ngFDS). Treatment with commercially available treatments (per package insert instructions) selected by functional drug screening. For drug screening tumor cells from bone marrow aspirates, peripheral blood, pleural effusion, or excised lymph node samples are purified over Ficoll gradient (bone marrow, peripheral blood, pleural effusion) (GE healthcare) or homogenized and filtered (lymph tissue).
45639213|NCT02363179|Behavioral|Live preferential music|Live preferential music will be performed for patients in the emergency department.
45639214|NCT05055245|Other|cycles|Patients are grouped according to the number of IVF/ICSI cycles.
45639215|NCT03096587|Device|XP Endo Finisher|a flexible single use NiTi file with small diameter and no taper, changes from straight M-phase to A-phase in body temperature
45639216|NCT03096587|Device|ultrasonic activated irrigation|by Satelec,Acteon, France
45639217|NCT03096665|Diagnostic Test|blood test|Point of care blood analysis obtained from skin puncture
45448477|NCT02253706|Device|High flow nasal oxygen supplementation|High-flow nasal ventilation: This will be carried out using the Precision Flow device (Opti-Flow, Auckland, New Zealand). This device is intended to add warm moisture to breathing gases from an external source. Flow rate via the nasal cannula will be kept at 50 Liters/min and fractional inspired oxygen concentration will be set at 0.35.
45639218|NCT02373319|Behavioral|CV-screening-1 plus personalized|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
45639219|NCT02373319|Behavioral|CV-screening-2 plus personalized|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
45639220|NCT02373319|Behavioral|CV-screening-1 plus standard|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Standard communication of the health exam results
45639221|NCT02373319|Behavioral|CV-screening-2 plus standard|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Standard communication of the health exam results
45639222|NCT05055167|Drug|Envafolimab|single agent, 300mg Q3W IH until disease progressed
45639223|NCT05043233|Drug|Methimazole(MMI)|Methimazole is a widely used antithyroid drug and is often used in the treatment of Graves' disease hyperthyroidism
45639224|NCT02372929|Procedure|Endoscopic Ultrasound|Esophageal cancer patients will be staged by endoscopic ultrasound. All patients will undergo upper endoscopy prior to endoscopic ultrasound.
45639225|NCT03258853|Device|Bionic Pancreas|Bionic pancreas system: The bionic pancreas is an autonomous, self-learning system that requires only the subject's weight for initialization, and then autonomously adapts insulin dosing to maintain glycemic control. The bionic pancreas uses continuous glucose monitoring as input to the controller. The bionic pancreas can be used in a bi-hormonal configuration, administering both insulin and glucagon as well as an insulin only setting.
45639226|NCT03258853|Other|Usual Care|Subjects will remain on home insulin regimen (either insulin pump or injectable insulin). Subjects in usual care will wear a study CGM even if in typical care does not include CGM use.
45639227|NCT05054855|Behavioral|: Cognitive Support Technology (CST)|"Cognitive Support Technology (CST) products and strategies are used to help people with disabilities compensate for or accommodate cognitive limitations (including those related to interpersonal communication and social cognition) that present difficulties for them in the performance of desired social roles, especially education and employment.~CSTs may be mainstream everyday technologies such as tablet computers or they may be specialized devices designed for specific goals such as step-by-step instruction in the performance of a particular task (Scherer, 2012)."
45639228|NCT05054933|Other|ultrasound capsule endoscopy|Healthy volunteers or patients with suspected esophageal disease will be enrolled to take ultrasound capsule endoscopy examination followed by conventional endoscopic ultrasound examination within 2 weeks.
45639229|NCT03199651|Other|Best Practice|Receive usual care
45935675|NCT00044291|Drug|toremifene|
45935676|NCT00044291|Drug|letrozole|
45935677|NCT00044291|Drug|aromatase inhibition|
45448478|NCT02253706|Device|low flow nasal oxygen supplementation|Low-flow nasal ventilation: This will be carried out using a regular nasal cannula fed with oxygen at flow rates from 2 to 6 liters/minute.
45639230|NCT03199651|Procedure|Biospecimen Collection|Undergo collection of tumor tissue and blood sample for repository
45639231|NCT03199651|Procedure|Biospecimen Collection|Undergo tumor tissue and blood sample for AGIT/DS
45639232|NCT03199651|Other|Laboratory Biomarker Analysis|Correlative studies
45639233|NCT03199651|Other|Medical Chart Review|Undergo medical record abstraction
45639234|NCT03199651|Other|Quality-of-Life Assessment|Ancillary studies
45639235|NCT03199651|Other|Questionnaire Administration|Ancillary studies
45639236|NCT03199651|Behavioral|Smoking Cessation Intervention|Undergo usual care or NCCN-driven CTC/DS
45777269|NCT05588063|Device|Sham device|The device will appear to function but no electrical stimulation will be delivered.
45777270|NCT05579366|Drug|PRO1184|Intravenous infusion of PRO1184
45935678|NCT00044291|Procedure|hormone therapy|
45639237|NCT05054777|Procedure|oncoplastic breast-conserving surgery|The patients received oncoplastic breast-conserving surgery, including volume displacement or volume replacement techniques
45639238|NCT05054777|Procedure|conventional breast-conserving surgery|conventional breast-conserving surgery without any oncoplastic operations
45777271|NCT05574426|Behavioral|Movement Breaks|Participants will be asked to perform 30-60 second movement breaks 3-4 times per day on at least 3 days per week.
45777272|NCT05570825|Procedure|Biopsy|Undergo biopsy
45777273|NCT05570825|Procedure|Biospecimen Collection|Undergo collection of blood samples
45935679|NCT00044291|Procedure|endocrine therapy|
45935680|NCT00044291|Procedure|antiestrogen therapy|
45935681|NCT02965872|Other|No intervention|
45935682|NCT05561569|Procedure|Pars plana vitrectomy|23 gauge pars plana vitrectomy for managing primary retinal detachment.
45639239|NCT03112915|Procedure|quadratus lumborum block|QLB: Quadratus lumborum block : 20 mL of 0.25% bupivacaine will be administered between the quadratus lumborum and the psoas major muscle bilaterally in the lateral decubitus position
45639240|NCT03112915|Procedure|Transversus abdominis plan block|TAP: transversus abdominis plan block: 20 mL of 0.25% bupivacaine will be administered between the internal oblique muscle and the transversus abdominis muscle bilaterally in the supine position
45639241|NCT02367079|Device|Diathermy|Sham diathermy vs switched on diathermy effect on pain where assessed
45639242|NCT05054465|Drug|Navitoclax|P.O 50mg QD Q28 days for 2 cycles pre-transplant Up to 50mg QD Q28 days maintnance post-transplant based on MTD
45639243|NCT05054465|Drug|Venetoclax|P.O 400mg QD Q28 days for 2 cycles pre-transplant Up to 400mg QD Q28 days maintnance post-transplant based on MTD
45639244|NCT02367001|Other|Normal invitation|No modification and signed by the coordinating doctor as usual
45777274|NCT05570825|Procedure|Computed Tomography|Undergo PET/CT or CT
45777275|NCT05570825|Drug|CXCR1/2 Inhibitor SX-682|Given PO
45777276|NCT05570825|Procedure|Magnetic Resonance Imaging|Undergo MRI
45448479|NCT04029519|Device|PN40082|PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
45639245|NCT02367001|Other|revised invitation signed by the coordinating doctor|Invitation with revised text and layout and signed by the coordinating doctor as usual
45639246|NCT02367001|Other|Revised invitation signed by the attending physician|signature typed or typed + handwritten
45639247|NCT05054699|Device|Magnetic Seizure Therapy|Subjects will receive a train of magnetic pulses (between 600 and 1400 pulses) at 100Hz under general anaesthesia using a Magventure device with a Twin Coil
45777277|NCT05570825|Biological|Pembrolizumab|Given IV
45777278|NCT05570825|Procedure|Positron Emission Tomography|Undergo PET/CT
45777279|NCT05567315|Drug|local anaesthetic injection|Infiltration of 40 to 80 ml of a non-adrenalized 0.5% lidocaine solution into the vaginal wall at the level of the vaginal pouches, under ultrasound guidance. (within the limit of the toxic doses, i.e. 5mg/kg)
45448480|NCT03546400|Drug|methylphenidate HCl ERCT|methylphenidate HCl ERCT
45448481|NCT05666583|Other|Art therapy|The intervention group is the group in which art therapy is applied. They receive chemotherapy.
45448482|NCT03547258|Genetic|Clinical and Molecular data collection|Clinical and Molecular data collection at diagnosis, during treatment and at each relapse
45639248|NCT05054699|Device|Electroconvulsive Therapy|Subjects will receive a brief-pulse electrical stimulus (between 25 and 1008mC) under general anaesthesia using a ECT device
45639249|NCT02367157|Procedure|Kenzo Kase Method|
45639250|NCT02367157|Device|Kinesio Taping|
45639251|NCT05043389|Other|myofunctional therapy program|Exercise oral cavity muscle
45639252|NCT04059835|Other|OptiBra study|compare two different bra after breast cancer surgery
45639253|NCT04472195|Other|Simulation Airway Coaching|Airway coaching on laryngoscopy technique for intubation of neonates/infants within 1 hour of case utilizing RCDP simulation technique.
45639254|NCT02366455|Procedure|Measurement of the length of the right main stem bronchus|Measurement of the length of the right main stem bronchus on CT-Scan
45639255|NCT02366455|Procedure|Measurement of the right upper lobe bronchus antero-posterior angulation|Measurement of the right upper lobe bronchus antero-posterior angulation on CT-Scan
45639256|NCT04472117|Other|usual care|Interviews will be conducted in person or by telephone by an MD on the research team who does not have an ongoing treatment relationship with the patient, and has been trained by the qualitative methods specialist. Interviews will take place over the phone or in person and are anticipated to last approximately 20-30 minutes.
45639257|NCT04472117|Other|Educational video|Watch an educational video created by the research team and.will also complete the post-video survey,
45639258|NCT03860233|Drug|Oxytocin|40 IU administered intranasal, within 1 hour prior to sleeping for 14 days
45639259|NCT03860233|Drug|Placebo|Intranasal spray to mimic Oxytocin intranasal spray
45777280|NCT05567315|Device|hypnosis with Virtual reality mask|A 20-minute virtual reality hypnosis session is performed from the time the patient is placed on the surgical table until the end of the oocyte poncture
45777281|NCT05567237|Other|Microcurrent treatment with resistance exercise programme|This intervention will allow us to explore the effects of microcurrent added to resistance exercise.
45777282|NCT05567237|Other|Resistance exercise programme|This intervention works as a control group for the participants undergoing the exercise programme.
45777283|NCT05567237|Other|Microcurrent treatment|This intervention will allow us to explore the effects of microcurrent alone.
45777284|NCT05567237|Other|No treatment|This intervention works as a control group for the participants who are not taking part into the exercise programme.
45777285|NCT05563649|Behavioral|Online Guided Self-Help-Family-based Treatment|GSH-FBT consists of 10 20-minute sessions for parents only over 9 months. Sessions follow an online curriculum of 65 short videos: 62 with an expert clinician instructing parents on the principles of FBT, and 3 reflections from an adolescent who recovered from AN and completed FBT. Each lecture series contains an introduction orienting the viewer to the videos, 5-9 short videos (< 7 minutes each), and assigned reading from the parent education manual Help Your Teenager Beat an Eating Disorder. Three lectures include additional resources for parents (e.g., Academy of Eating Disorder (AED) Medical Management Guidelines). Homework assignments are included with some lectures (e.g., strategies to help the child eat during meals, practice making calorically dense meals). In line with GSH approaches, coach-therapists direct parents, to watch or re-watch specific video content contained in the online learning material related to their questions rather than direct behavioral change.
45639260|NCT04154189|Drug|Lenvatinib|"Lenvatinib 14 milligrams per square meter (mg/m^2) capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until disease progression (PD), development of unacceptable toxicity, participant request, withdrawal of consent, or discontinuation of study by the sponsor.~An extemporaneous suspension of lenvatinib capsules may be used for participants unable to swallow capsules."
45777286|NCT05563649|Behavioral|FBT via Videoconferencing|15 60-minute sessions of 3-phase manualized FBT modified for videoconferencing will be delivered to participants randomized to this treatment by therapists trained in FBT. The first phase encourages parental management of weight restoration (approximately 8 weekly sessions); the second phase promotes a developmentally appropriate transition back to adolescent management of weight restoration and maintenance under parental supervision (approximately 4 bi-weekly sessions), and the third phase focuses on adolescent development (approximately 3 monthly sessions). Each session consists of 10 minutes with the adolescent individually to discuss progress and the adolescent's perspective on treatment, followed by 50 minutes with the entire family.
45777287|NCT05563272|Drug|89Zr-DFO-girentuximab|Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
45777288|NCT05560100|Other|Nominal Group Technique - 2 to 3 hour virtual meeting|Participants will be invited to a 2-3 online virtual online meeting with the goal of constructing and defining elements for producing a risk statement for dry needling that can be used for informed consent.
45777289|NCT05559580|Drug|BI 685509|BI 685509
45777290|NCT05559580|Drug|Placebo|Placebo
45777291|NCT05556681|Device|BD™ Sirolimus Drug Coated Balloon Catheter angioplasty|The study will enroll patients presenting with clinical evidence of an angiographically significant lesion (Lesion ≥ 70% stenosis by visual estimate) in the femoropopliteal arteries. After pre-dilatation, patients will undergo angioplasty with the investigational BD™ Sirolimus Drug Coated Balloon Catheter.
45777292|NCT05556655|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a noninvasive method for stimulating neurons (axons not cell bodies) in the brain.
45777293|NCT05547386|Procedure|Computed Tomography|Undergo PET/CT scan
45777294|NCT05547386|Drug|Gallium Ga 68 Gozetotide|Given IV
45777295|NCT05547386|Procedure|Positron Emission Tomography|Undergo PET/CT scan
45777296|NCT05543616|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose|Injection in the muscle
45777297|NCT05543616|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose|Injection in the muscle
45777298|NCT05543616|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose|Injection in the muscle
45915694|NCT05669404|Behavioral|Mediterranean Diet combined with salt restriction Group (MDG)|Patients assigned to the MDG received a more extensive booklet, which which in addition to the information regarding salt restriction, contained detailed information about the MedDiet, and practical advice about how to start and stay on the assigned dietary pattern. In addition to the booklet, each patient received an individualized eating plan with six sample daily menus, incorporating the goals of the MedDiet diet. During the 45-min individual sessions, patients were intensively counselled and trained to increase adherence to salt restriction and the assigned dietary pattern. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
45915695|NCT00006396|Drug|Nevirapine|
45448483|NCT03735147|Biological|Live attenuated influenza vaccine (LAIV)|Single dose of LAIV
45448484|NCT05283538|Diagnostic Test|Coronary Artery Calcification Realization|Coronary Artery Calcification Realization
45448485|NCT03669861|Drug|Abatacept|Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)
45639261|NCT04154189|Drug|Ifosfamide|Ifosfamide 3000 milligrams per square meter per day (mg/m^2/day) intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
45639262|NCT04154189|Drug|Etoposide|Etoposide 100 mg/m^2/day intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
45639263|NCT04154189|Drug|Lenvatinib|Lenvatinib 14 mg/m^2 capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until the next PD (per response evaluation criteria in solid tumors [RECIST] 1.1 as assessed by investigator), development of unacceptable toxicity, participant request, or withdrawal of consent, whichever occurs first.
45777299|NCT05543616|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) Substudy A Ph 2/3 Selected Dose|Injection in the muscle
45777300|NCT05543616|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) Substudy C Ph 2/3 Selected Dose|Injection in the muscle
45777301|NCT05531656|Drug|CT1812|Study Drug
45777302|NCT05531656|Drug|Placebo|Non-active study drug
45777303|NCT05526560|Device|MITRIS RESILIA Mitral Valve, Model 11400M|Replacement of mitral valve with MITRIS RESLIA Mitral Valve
45777304|NCT05525806|Other|Education Materials for MyProstateScore|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
45777305|NCT05519111|Drug|Dronabinol|Dronabinol, an FDA approval oral agent containing synthetic tetrahydrocannabinol (THC)
45777306|NCT05519111|Drug|Placebo|placebo equivalent
45777307|NCT05519085|Drug|CC-92480|Specified dose on specified days
45777308|NCT05519085|Drug|Pomalidomide|Specified dose on specified days
45777309|NCT05519085|Drug|Bortezomib|Specified dose on specified days
45777310|NCT05519085|Drug|Dexamethasone|Specified dose on specified days
45915696|NCT00006396|Drug|Zidovudine|
45915697|NCT03996148|Drug|Remifentanil, Propofol, and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Propofol - titratable; initial starting dose 75 mcg/kg/min Desflurane 0.5 MAC
45915698|NCT03996148|Drug|Remifentanil, Dexmedetomidine, and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Dexmedetomidine - titratable; initial starting dose 0.5 mcg/kg/hr Desflurane 0.5 MAC
45915699|NCT03996148|Drug|Remifentanil and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Desflurane - titratable
45915700|NCT00006399|Drug|Donepezil|
45915701|NCT00006399|Drug|Estrogen|
45915702|NCT00006399|Drug|Progesterone|
45639264|NCT02373007|Procedure|Scopinaro Surgery|Classic Scopinaro Technique is a bariactric surgery that proposes the stomach will be divide in two parts: a proximal part and a distal part for performing horizontal gastrectomy. Differently what will happen in the Modified Scopinaro Surgery that will divide the stomach in two parts: a proximal part and a distal part for performing gastroplasty.
45639265|NCT02373085|Other|Antibiotic adjusted to antibiogram|A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria during the first 2 years after transplantation.
45639266|NCT02372851|Device|Pureit As+ Filter|The Pureit As+ water filter has been developed to effectively remove arsenic (both arsenite and arsenate) from over 300 µg/L to less than 10 µg/L in addition to removing microbial contamination (Institution of Public Health Engineers, 2011). It has an end-of-life indicator and consumables that do not re-contaminate the environment when disposed (Institution of Public Health Engineers, 2011). The technology requires no electricity, but only the replacement of the battery after 1000 L of water filtered (approximately 100 days based on a family of five drinking 2 L/day).
45639267|NCT01361009|Drug|pramipexole|as prescibed by the investigator
45915703|NCT05660200|Dietary Supplement|IBSA Iron ODF|IBSA Iron ODF is a food supplement based on ferric pyrophosphate and folic acid in orodispersible film. IBSA Iron ODF appears as a yellow, opaque, homogeneous film, without visible particles. Once taken, it dissolves on the tongue and can be swallowed without adding water.
45915704|NCT05660200|Dietary Supplement|SiderAL® FORTE|Sideral® r.m. contained in SiderAL® FORTE is an iron protected with Sucrosomial® Technology which passes through the gastric environment intact and is absorbed in the intestine, thus preventing any irritation and discomfort to the stomach. The presence of Vitamin C facilitates the absorption of iron.
45777311|NCT05517941|Other|active cycle breathing|The active cycle breathing technique will involve three steps: breathing control, thoracic expansion exercise, and forced expiration technique, In breathing control, the patient will sit comfortably in a chair and breathe at a normal rate and depth using the lower chest. In the thoracic expansion exercise, the physical therapist rested his/her hands on the patient's epigastrium and guided the patient's breathing so that they breathed at a slow and deep rate using the lower chest, then held their breath for 2 s and fully exhaled; this was repeated two or three times, then the patient returned to breathing control. For the forced expiration technique, the physical therapist asked the patient to inhale deeply while simultaneously contracting the abdominal muscle and keeping the mouth and throat open. They then held their breath for 2 s, followed by vigorous exhalation
45777312|NCT05517941|Other|incentive spirometer|Incentive spirometry is accomplished by using a device that provides feedback when the patient inhales at a predetermined flow and sustains the inflation for at least 5 seconds. The patient is instructed to hold the spirometer in an upright position, exhale normally, and then place the lips tightly around the mouthpiece. The next step is a slow inhalation to raise the ball (flow-oriented) or the piston/ plate (volume-oriented) in the chamber to the set target. At maximum inhalation, the mouthpiece is removed, followed by a breath-hold and normal exhalation.
45639268|NCT02373163|Drug|Hydrochlorothiazide|Arm: Active Comparator: Diuretic Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Calcium-channel blocker Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Angiotensin Receptor Blocker Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
45639269|NCT02373163|Drug|Amlodipine|Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
45915705|NCT05656183|Diagnostic Test|TruGenome Cardiovascular Disease test|The TruGenome Cardiovascular Disease (CVD) test which consists of an in-silico 200 gene cardiovascular disease panel, a further 4 genes with cardiovascular disease risk alleles, 10 pharmacogenomic genes, 35 non-cardiovascular ACMG secondary finding genes and a polygenic risk score (PRS) for coronary artery disease (CAD) will be utilized in this study.
45915706|NCT05656027|Drug|Aceclidine + Brimonidine|LNZ101 (Aceclidine/Brimonidine) ophthalmic solution
45777313|NCT05512377|Drug|BI 907828|BI 907828
45915707|NCT05656027|Drug|Aceclidine|LNZ100 Aceclidine ophthalmic solution
45639270|NCT02373163|Drug|Telmisartan|Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
45777314|NCT05509777|Drug|Mirikizumab|Administered IV or SC
45915708|NCT05656027|Drug|Brimonidine|Brimonidine ophthalmic solution
45935683|NCT05561296|Procedure|Femtosecond laser assisted cataract surgery with astigmatism management|The alignment would be guided by preoperatively obtained iris registration using Cassini Ambient. Patients will undergo femtosecond laser-assisted cataract surgery with Catalys femtosecond laser.
45935684|NCT05561140|Drug|Voxelotor Oral Tablet|Synthetic small molecule supplied as 500 mg tablets, administered Orally
45935685|NCT05561140|Other|Placebo|Placebo
45448486|NCT05572918|Diagnostic Test|Urodynamics aka filling cystometry|Participants will be undergoing a routine diagnostic test to characterise bladder function and volume
45639271|NCT02372539|Other|Diabetes|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
45639272|NCT02372539|Other|Control Group|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
45639273|NCT02366377|Drug|SHR3824|
45639274|NCT02366377|Drug|Placebo|
45639275|NCT02366377|Drug|Metformin|
45639276|NCT02362867|Device|Balanced Knee System|A multi-compartmental total knee replacement providing a system of components for primary posterior cruciate ligament substituting procedures. The system consists of femoral, tibial, and patellar components that allow the surgeon to select the most appropriate component combination to meet specific patient needs.
45639277|NCT05053685|Diagnostic Test|Measurement of Urine and plasma metanephrines|Measurement of Urine and plasma metanephrines
45639278|NCT02366299|Drug|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
45639279|NCT02366299|Drug|Propofol|Treatment of delirium by Propofol i.v. infusion
45915709|NCT05634070|Device|PCL Pectus scaffold implantation and autologous fat grafting|A suitable incision will be made using a scalpel and diathermy following standard surgical procedures.The implant pocket shall be rinsed with saline. The PCL Pectus Scaffold shall be inserted into the pocket following the Instruction for Use and fixed to the thoracic wall using 2 to 4 sutures. The device shall not be modified for any patient in any manner. The incision shall be closed using 2-0 Vicryl or Monocryl and 3-0 Monocryl sutures, if applicable. Number of layers to be sutured will be decided by the PI for each patient. Sterile bandaging as well as Steri-Strips shall be applied on the sutures. A prophylactic antibiotic such as Cefazolin 1g (3 shots per day x 2 days) shall be administered to the patient. In case the patient has Cefazolin allergy, Clindamycin 600 mg shall be prescribed. Autologous Fat Grafting procedure shall be performed immediately after implantation. The patients shall be hospitalized for the necessary number of days under clinical observation.
45915710|NCT03986203|Device|Spry Belt|The Spry Belt delivers energy to the user that may help prevent bone loss. Participants will wear the device for 30 minutes a day, 5 days a week for one year. The active and sham devices are identical except for the specific energy that is delivered to the user.
45639280|NCT05042297|Procedure|Combined posterior and anterior ring fixation: Active comparator. Isolated posterior ring fixation: Experimental intervention|Reduction of the posterior ring was either closed reduction in SI joint dislocations & fracture-dislocations and sacral fractures or open reduction in iliac wing fractures through the lateral window of the ilioinguinal approach. Anterior pelvic ring reduction and fixation in the combined APR fixation group was done via the classic Pfannenstiel approach or extension more lateral & completing the anterior intrapelvic approach. Fixation was via pubic rami plating.
45639281|NCT05053919|Device|Schumann resonance sleep device|"A Schumann resonance sleep device would stably output the composite frequency of a the Schumann resonance frequency (7.83 Hz) wave, theta wave, and delta wave.~The subjects were asked to use the device (place it next to the bed facing the subject's head, turn it on about one hour before going to bed every night, and turn it off after getting up the next day) every night for four weeks."
45639282|NCT05053919|Device|Placebo sleep device|"A Placebo sleep device is an instrument with the same appearance and operation as the Schumann resonance sleep device, but does not output any frequency wave.~The subjects were asked to use the device (place it next to the bed facing the subject's head, turn it on about one hour before going to bed every night, and turn it off after getting up the next day) every night for four weeks."
45639283|NCT02997553|Drug|Indocyanine green|Each patient receive injection of indocyanine green just before surgery Specify total dose : 2.5 mg/ml (Intravenous use)
45639284|NCT02997553|Drug|Technetium99|"Each patient receives injection of Technetium 99 ( injected in subcutaneously) before surgery.~Lymphoscintigraphy is performed to identify the sentinel node"
45639285|NCT02997553|Device|Optonuclear probe|The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery.
45639286|NCT02997553|Device|Quest Camera|The detection of sentinel lymph node will be conducted by a camera able to determine imagery of fluorescence during surgery.
45639287|NCT05041985|Drug|Diazepam Tablets|Diazepam 5 mg tablet once per day (bedtime) for 7 days
45639288|NCT02372695|Drug|Paricalcitol|
45639289|NCT05053841|Drug|Metformin|
45639290|NCT02372461|Drug|Placebo|This is an non inferiority trial, the intervention is a placebo
45639291|NCT02372461|Drug|Amoxicillin|Amoxicillin Liquid
45639292|NCT05053529|Other|Mirror therapy|Session consist of total 1hour,20 min of passive mobilization, 30 minutes for Movement mirror therapy,10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
45639293|NCT05053529|Other|CIMT group|Session consist of total 1hour ,20 min of passive mobilization, 30 min session to CIMT and 10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
45639294|NCT03096431|Behavioral|Physical Activity|"Self-exercise: number of steps per day, per fitness tracker; self-report of daily activity.~One-to-one intervention: 30 minute sessions with licensed therapist to include warm-up, generalized strengthening, stretching."
45639295|NCT03096431|Behavioral|Cognitive rehabilitation|One-to-one intervention: 45 minutes sessions with licensed therapist to include graded cognitive tasks designed to improve executive functioning with focus on both restorative and compensatory approaches.
45639296|NCT02372617|Procedure|periacetabular osteotomy|
45639297|NCT05053373|Device|Electroacupuncture group|
45639298|NCT05053373|Device|Sham electroacupuncture group|
45639299|NCT05053373|Behavioral|Pelvic floor muscle training|
45639300|NCT02859337|Drug|UPA-ECx1|Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 30mg of UPA-based EC
45639301|NCT02859337|Drug|UPA-ECx2|Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 60mg of UPA-based EC
45639302|NCT05053061|Behavioral|Application program for pulmonary rehabilitation|Exercise videos for pulmonary rehabilitation
45639303|NCT04499131|Drug|Progesterone|Subjects will undergo an artificial cycle with hormone replacement therapy (HRT) with the aim of comparing the endometrial gene expression profile in the different types of exogenous progesterone with different doses and routes of administration.
45639304|NCT04499131|Other|Artificial Cycle (no intervention)|Control group of 15 subjects in the context of a natural cycle with only endogenous progesterone present
45639305|NCT03096119|Other|home blood pressure measurement|We ask participants to measure their home blood pressure 7 days or more.
45639306|NCT03096197|Device|Exoskeleton-Assisted Walking|Exoskeleton-Assisted Walking (EAW) is an activity based therapy. Each group will receive 60 minutes of robotic intervention training per session, for a total of 80 sessions.
45639307|NCT03096197|Device|Transcutaneous Lumbosacral Stimulation (TLS)|EAW+TLS. This group will receive 60 minutes of exoskeleton assisted overground walking with simultaneous Transcutaneous Lumbosacral Stimulation (TLS) followed by 15 minutes of overground training without exoskeleton.
45639308|NCT02805595|Drug|23.4% Hypertonic saline|Saline Injections
45448487|NCT00127127|Drug|vorinostat|vorinostat 100 mg, 200 mg, 400 mg, or 500 mg single oral dose; once-daily or twice-daily administration
45639309|NCT05053295|Drug|autologous activated T lymphocyte|"Drug: Immuncell-LC IV~Drug: Nivolumab (Opdivo®) IV"
45915711|NCT05580718|Behavioral|MI-CBT|"Education Common reactions following MI and general lifestyle advice on e.g., physical activity. The role of cardiac anxiety and avoidance behavior on quality of life and physical health. Brief training in self-observation.~Goal setting Identifying life areas impaired by MI-related disability or symptom fear. Set health behavioral goals i.e., increased physical activity and gradually take steps towards them.~Exposure therapy Exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms. Gradual exposure to avoided situations, activities and increase in physical activity.~Relapse prevention Prevention of relapse into avoidance behaviors by identifying risk situations and conduct a plan forward on maintaining a healthy physically and active lifestyle."
45639310|NCT02372227|Drug|VS-5584 and VS-6063|Starting dose of VS-5584 will be 20mg taken once daily, 3x/week of each 21 day cycle. All subjects will also receive 2x/day treatment with 400mg VS-6063 in 21 day cycles. Number of Cycles: until progression or unacceptable toxicity develops.
45639311|NCT03095963|Other|a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®)|Patients assigned to the study group took the probiotic supplement VSL#3® for two months, in addition to levothyroxine
45639312|NCT03095963|Drug|levothyroxin|replacement therapy for hypothyroidism
45777315|NCT05503407|Procedure|Baseline V-RESOLVE score-guided PCI|"Jailed wire technique (JWT): Both main vessel (MV) and side branch (SB) are wired. The MV is stented with wire protection in SB. If suboptimal results exist, the SB would be rewired and a kissing balloon inflation (KBI) is undertaken.~Jailed balloon technique: A monorail balloon is advanced into the SB. If there is TIMI flow grade decrease in the SB after MV stenting, the SB balloon is inflated to simulate attempt to reopen the SB.~Provisional two-stent strategy: Lesion preparation and MV stenting are consistent with JWT. Provisional SB stenting could be undertaken when suboptimal results occur after SB rewiring and a KBI is undertaken.~Elective two-stent strategy: Patients in this subgroup would undergo crush procedure or any other elective two-stent strategy which usually stenting SB before MV stenting."
45777316|NCT05503407|Procedure|Angiography-guided PCI|The choice of interventional strategy was left to the discretion of experienced interventionists based on the coronary angiogram.
45777317|NCT05497284|Drug|LTP001|LTP001 will be administered once daily in the morning
45777318|NCT05497284|Drug|Placebo|Placebo to LTP001 will be administered once daily in the morning
45777319|NCT05497284|Drug|Standard of Care (SoC)|nintedanib, pirfenidone, or neither
45777320|NCT05492994|Diagnostic Test|Spirometry|Pulmonary function test
45777321|NCT05492994|Diagnostic Test|Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)|Pulmonary function test
45777322|NCT05492994|Diagnostic Test|Magnetic Resonance Imaging|Magnetic Resonance Imaging
45777323|NCT05492994|Diagnostic Test|Chest Computer Tomography|Chest Computer Tomography
45777324|NCT05492994|Diagnostic Test|Blood biomarker analysis|Blood biomarker analysis
45915712|NCT05552404|Other|conservative therapy|bed rest, fluids, abdominal binder, oral paracetamol, and caffeine
45915713|NCT05552404|Drug|Aminophylline|conservative therapy plus Aminophylline (250mg of Aminophylline dissolved in 100ml normal saline for intravenous infusion over 30 minutes)
45448488|NCT04708210|Drug|IBI319|Iv infusion day 1 of every 14 or 21 days in Phase Ia until disease progression or loss of clinical benefit.
45777325|NCT05492331|Other|Music Therapy|Patient preferred artist or music genre to be playing from an iPad
45777326|NCT05481710|Diagnostic Test|Nociplastic Pain Criteria|All participants will be assessed with the specific nociplastic pain criteria
45777327|NCT05471856|Drug|BI 1703880|BI 1703880
45915714|NCT05552404|Procedure|trans nasal sphenopalatine ganglion block|conservative therapy plus sphenopalatine ganglion block SPGB using hollow cotton swab and lidocaine 2%
45915715|NCT05546320|Drug|Aspirin 100mg|Anticoagulation or anti-platelet or migraine medication therapy will be provided for different groups.
45915716|NCT05546320|Drug|Metoprolol 25 Mg Oral Tablet|Metoprolol 25mg will be provided for the participants twice a day.
45639313|NCT05653687|Device|Intraoperative fluoroscopy|Fluoroscopy is a medical procedure that makes a real-time video of the movements inside a part of the body by passing x-rays through the body over a period of time.
45639314|NCT05053217|Procedure|transforaminal epidural steroid injection|In the transforaminal approach, a small amount of drug is injected into the epidural space, and in previous studies, reduction in pain and improvement in functionality were found in patients with lumbar radicular pain in the short and medium term.
45639315|NCT02366065|Drug|Acetaminophen|Before treatment, study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
45777328|NCT05471856|Drug|Ezabenlimab|Ezabenlimab
45777329|NCT05465525|Procedure|Quadratus Lumborum Block Type III|Patients will receive ultrasound-guided quadratus lumborum block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
45777330|NCT05465525|Procedure|Erector Spinae Plane Block|Patients will receive ultrasound-guided erector spinae plane block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
45777331|NCT05465525|Other|No Block|The patients will receive general anesthesia.
45777332|NCT05463237|Diagnostic Test|oral glucose tolerance test|oral glucose tolerance test (OGTT) used for the diagnosis of gestational diabetes mellitus between 24-28 weeks of gestation
45777333|NCT05463237|Diagnostic Test|Blood sample|Measurement of blood Visfatin, Vaspin and Omentin levels in pregnant women with diabetes
45777334|NCT05463133|Drug|Sirolimus|Post transplant drug - Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.
45777335|NCT05463133|Drug|Cyclophosphamide|Post transplant drug - cyclophosphamide give to prevent graft versus host disease. This is a well studied drug and s not under an IND.
45777336|NCT05463133|Drug|Alemtuzumab|Transplant Conditioning Drug - Monoclonal antibody that targets recipient and donor T-cells to prevent graft versus host disease. Not an IND. This is a well-studied drug, and is not under an IND.
45777337|NCT05463133|Drug|Busulfan|Transplant Conditioning Drug - Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under IND.
45639316|NCT05052593|Other|compressive myofascial release|Patients in this group will receive treatment through CMR that includes shaking the muscle belly of vastus lateralis for 30 seconds. Then the hip is fully extended on treatment table and CMR is applied on Vastus lateralis muscle for 1 minute. Treatment consists of broad strokes applied with clinicians knuckles to release superficial restrictions, followed by more specific strokes applied with clinicians' thumb on tight muscle. Strokes are applied at a contact point of 45 degree. With pressure directed from distal to proximal.
45639317|NCT05052593|Other|conventional treatment group|Patients in this group will receive treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)
45639318|NCT02362945|Drug|Intervention group:|Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl 0.9% solution IV).
45639319|NCT02365909|Drug|0.5% bupivacaine|This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
45639320|NCT02365909|Drug|normal saline|This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
45639321|NCT05052515|Dietary Supplement|Choline - Vitamin C, E and Ampelopsis Grossedentata natural extracts|Patients with NAFLD will be randomly allocated to receive Choline - Vitamin C, E and Ampelopsis Grossedentata natural extracts supplementation
45639322|NCT05052515|Other|Placebo|Patients with NAFLD will be randomly allocated to receive placebo
45639323|NCT05041595|Diagnostic Test|Lyme diagnostic assay|Serological and immunoresponse assay
45639324|NCT02365675|Device|Cotton gauze with petrolatum|
45639325|NCT02365675|Device|Cellulose acetate with petrolatum|
45639326|NCT02365675|Device|Nanocrystalline silver (Acticoat)|
45639327|NCT02365675|Device|Carboxymethylcellulose with ionic silver (Aquacel Ag)|
45639328|NCT05052437|Drug|Utidelone Injection; capecitabine|8 patients will be assigned to utidelone plus capecitabine arm receiving utidelone plus capecitabine. Utidelone injection 30mg/m2/day, intravenously administered once a day for 5 consecutive days; capecitabine tablets, 1000mg/m2, orally, 2 times a day for 14 consecutive days. 21 days is a cycle
45639329|NCT05052437|Drug|Utidelone|8 patients will be assigned to utidelone arm and receive utidelone injection 30 mg/m2/day intravenously, once a day for 5 consecutive days in a 21-day cycle.
45639330|NCT02365753|Device|SofPulse|Pulsed Electomagnetic Field Therapy Device placed over incision and turned on and kept in place with tape.
45639331|NCT05052359|Diagnostic Test|Lectin-histochemistry retrospectively performed|Lectin-histochemistry was performed on 37 archival paraffin wax-embedded specimens of various follicular thyroid tumours (10 follicular adenomas (FA), 10 minimally invasive follicular carcinomas (miFTC), 13 widely invasive follicular cancers (wiFTC) and 4 metastatic follicular thyroid cancers (metFTC)).
45639332|NCT02365831|Other|Observation of treatment management|Group/cohort
45639333|NCT05041517|Behavioral|BOLT + PTC|BOLT is a Brief Online Training (BOLT) for Measurement-Based Care (MBC). Participants in the BOLT condition were subsequently randomized into varying amounts of post-training consultation (PTC).
45639334|NCT02365987|Dietary Supplement|Interesterified blend of palm kernal and plam stearin|50g fat provided as interesterified palm kernal and palm sterin blend in a single meal
45639335|NCT02365987|Dietary Supplement|Un-interesterified blend of palm kernal and plam stearin|50g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal
45639336|NCT03095573|Device|Lateral-viewing CapsoCam device|Small bowel capsule endoscopy examination with the Lateral-viewing CapsoCam device
45639337|NCT03095573|Device|Axial-viewing capsule|Small bowel capsule endoscopy examination with the Axial-viewing capsule device
45639338|NCT05051423|Diagnostic Test|Endoscopic ultrasound|"Imaging tests:~All patients will be evaluated by EUS and CEH-EUS, using radial EUS instruments. Prior to the investigation the stomach has to be empty for at least 8 hours. During the examination biopsies will be taken from normal and tumor tissue for gene expression analysis.~CEH-EUS procedure:~A two panel image with the usual conventional gray-scale B-mode EUS image on the right side and with the contrast harmonic image on the left side will be used, according to pre-established presets. The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 2,4 mL), with the whole movie (T0-T120s) recorded on the embedded HDD of the ultrasound system for later analysis~Molecular tests:~Blood analysis. Whole blood (1ml) will be collected before imaging procedures in an Eppendorf tube on EDTA solution.~Biopsy samples of normal and GC tissue. Gene expression will be analyzed using qPCR with Taqman®- labeled probes."
45639339|NCT02359201|Drug|V0018|Oromucosal - Single dose
45639340|NCT02359201|Drug|Placebo|Oromucosal - Single dose
45639341|NCT05041283|Other|Chatbot|A artificial-intelligence based chatbot is provided 3 days before colonoscopy to answer questions concerning bowel preparation and colonoscopy conduct.
45639342|NCT05041283|Other|Phone call|A phone call is performed every day starting at 3 days before colonoscopy to support bowel preparation.
45639343|NCT02363023|Procedure|Collect tracheal and pulmonary secretions|Collect tracheal and pulmonary secretions (endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage)
45639344|NCT05041205|Dietary Supplement|Beauty drink powder|Beauty drink powder is designed as a oral beauty product to provide benefits to skin
45639345|NCT05041205|Device|Cosmetic apparatus|This device is designed to let participants to experience brighter, softer, smoother skin and an energizing facial massage. A synergestic effect when combine with beauty drink powder is expected.
45639346|NCT02362711|Drug|NPC-16 Standard Dosing Regimen Group|
45639347|NCT02362711|Drug|NPC-16 Continuous Dosing Regimen Group|
45639348|NCT02362711|Drug|Placebo Group|
45639349|NCT05041439|Behavioral|Community Health Worker|Participants will receive 5 one-on-one sessions with a CHW over 6 months.
45639350|NCT04434677|Radiation|Hypofractionation|3D conformal Radiotherapy whole breast irradiation +- Supraclavicular fossa using Linear Machine (6-15 MV energy) 40.05 Gray (2.67 Gy/ fx) over 15 fractions with or without boost over 3 weeks
45639351|NCT04434677|Radiation|ultraHypofractionation|3D conformal Radiotherapy whole breast irradiation +- Supraclavicular fossa using Linear Machine (6-15 MV energy) 26 Gray (5.2 Gy/fx) over 5 fractions over 1.5 weeks
45639352|NCT01944046|Drug|Double blind phase Placebo Nasal Spray|This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except oxytocin will NOT be added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.
45639353|NCT01944046|Drug|double Blind Oxytocin Nasal Spray|Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.
45915717|NCT05546320|Drug|Clopidogrel 75mg|Clopidogrel 75mg will be provided for the participant once a day.
45915718|NCT05546320|Drug|Rivaroxaban 20mg|Rivaroxaban 20mg will be provided for the participant once a day.
45639354|NCT01944046|Drug|Open Label intranasal oxytocin|All participants who completed the 24 week double blind phase were eligible to join a 24 week open label phase in which all participants received intranasal oxytocin
45639355|NCT03112681|Drug|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
45639356|NCT03112681|Drug|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
45915719|NCT05535595|Drug|genotyping and selection of renin-angiotensin system blocker|"One of perindopril or candesartan was chosen based on genotyping results on two NELL1 variants.~perindopril 4 mg/d after genotyping~candesartan 8 mg/d after genotyping"
45915720|NCT05535595|Drug|Perindopril|perindopril 4 mg/d without genotyping
45915721|NCT00006405|Behavioral|Exercise|
45639357|NCT03112681|Drug|Placebo Oral Tablet|Placebo once daily in the morning before breakfast without food, for a period of 16 weeks.
45639358|NCT05040737|Device|PS membrane versus PMMA membrane,|Patients will be dialysed according to the usual dialysis schedule of three weekly sessions. The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.
45639359|NCT02087891|Behavioral|Web-based Stress Management Program (WSM)|The intervention, developed by the Cleveland Clinic, is an 8-week online, interactive, educational program based on mindfulness meditation. Briefly, each week subjects are introduced to the (1) weekly audio introduction to the mindfulness theme or particular meditation technique of the week, (2) weekly audio meditation techniques for relaxation, (3) daily articles providing scientific evidence and merits of meditation, and (4) bi-weekly email reminders. The introductory talks and meditation exercises were also provided on compact discs (CD) in mp3 format.
45639360|NCT02087891|Behavioral|Group Support (WSMg1)|Subjects will meet once per week for 1 hour during the 8-week duration and practice 2-minutes of deep breathing exercises, listen to 10-minutes audio recording of the weekly lesson and practice 20-30 minutes guided meditation exercise. The remainder of the time will be used to foster sharing experiences and answering specific questions related to the weekly lesson.
45639361|NCT02087891|Behavioral|Clinical Expert Support (WSMg2)|A clinical psychologist will replace the non-expert facilitator during 4 group support sessions.
45915722|NCT05524402|Behavioral|TOR-C 1|TOR-C 1 is an active intervention, adapted from the original Toolkit for Optimal Recovery program, adjusted for patients with mTBI and anxiety. The TOR-C 1 sessions address mind-body skills, including eliciting the relaxation response (eg, body scan, deep breathing, mindfulness), cognitive-behavioral strategies (eg, reframing), acceptance and commitment skills (eg, acceptance), and skills for returning to activity (eg, goal setting, activity pacing). The format is a 4-week program with weekly sessions and home practice.
45598072|NCT02365623|Drug|TMC207 (bedaquiline)|TMC207 (bedaquiline): Participants will receive TMC207 (bedaquiline) 400 milligram (mg) as 4*100 mg tablets once daily 2 weeks (14 days) followed by 200 mg (2 tablets) 3 times a week up to Week 24 along with background regimen (BR). Based on the discussion with the Pharmaceuticals and Medical Devices Agency (PMDA), the extension of 24-week TMC207 treatment with BR drugs may occur up to Week 48, under certain circumstances, such that many BR drugs which are susceptible at the beginning of the Treatment Phase show resistance during the Treatment Phase.
45598073|NCT02365623|Drug|Background Regimen (BR)|Participants will receive anti-bacterial tuberculosis drugs (pyrazinamide [PZA], ethambutol [EB, EMB], streptomycin [SM], kanamycin [KM, KAN], enviomycin [EVM], ethionamide [TH], cycloserine [CS], para-aminosalicylic acid [PAS], amikacin [AMK], levofloxacin [LVFX] and other fluoroquinolone. Other drugs are used less commonly, such as amoxicillin-clavulanate, linezolid and clofazimine based on Investigator's decision twice a week from Day 1 up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
45598074|NCT05262647|Diagnostic Test|18F-FAPI|Patients with chronic liver disease underwent 18F-FAPI-04 PET/CT and percutaneous liver biopsy.
45598075|NCT02361957|Dietary Supplement|Ecologic 825|Multispecies probiotic product, 2.5 x10E9 colony forming units per gram, 6 grams a day
45598076|NCT02361957|Dietary Supplement|Placebo|Placebo
45598077|NCT02221115|Device|Google Glass|The device is a wearable, voice-controlled Android device that resembles a pair of eyeglasses and displays information directly in the user's field of vision
45777338|NCT05463133|Biological|Pheripheral blood stem cells|Donor peripheral blood stem cells either matched unrelated donors or matched related relative to replace the patient's immune cells with functional immune cells. The peripheral blood stem cells are not regulated by the FDA.
45777339|NCT05463133|Drug|Emapalumab-Izsg|Transplant conditioning drug for High Risk Group only - An interferon gamma blocking antibody used to prevent inflammation/engraftment syndrome post HSC transplant.
45777340|NCT05463133|Drug|Tociluzumab|Transplant Conditioning Drug - An interleukin-6 (IL-6) receptor antagonist used to decrease Chronic Granulomatous Disease (CGD) inflammation during the HSC transplant process.
45639362|NCT00773695|Drug|Aromatase Inhibitor|Participants will receive aromatase inhibitor therapy, at a dose per investigator discretion, once daily for 24 weeks.
45639363|NCT00773695|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg as IV infusion every 3 weeks (or 10 mg/kg every other week in participants receiving weekly paclitaxel), for 24 weeks.
45639364|NCT00773695|Drug|Epirubicine|Participants will receive epirubicine at a dose of 100 mg/m^2 as IV infusion every 3 weeks for 12 weeks.
45639365|NCT00773695|Drug|5-Fluorouracil (5FU)|Participants will receive 5FU at a dose of 600 mg/m^2 as IV infusion every 3 weeks for 12 weeks.
45639366|NCT00773695|Drug|Cyclophosphamide|Participants will receive cyclophosphamide at a dose of 600 mg/m^2 as IV infusion every 3 weeks for 12 weeks.
45639367|NCT00773695|Drug|Paclitaxel|Participants will receive paclitaxel at a dose of 80 mg/m^2 as IV infusion every week for 12 weeks.
45777341|NCT05463133|Drug|Total Body Irradiation|Transplant Conditioning - Total Body Irradiation (300 cGy in fractionated doses) to create space n the subject's bone marrow so that the donor peripheral blood stem cells can repopulate in the subject's bone marrow.
45639368|NCT00773695|Drug|Docetaxel|Participants will receive docetaxel at a dose of 100 mg/m^2 as IV infusion every 3 weeks for 12 weeks.
45639369|NCT02362633|Device|real tDCS|For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
45639370|NCT02362633|Device|sham tDCS|Sham tDCS will be delivered for 20 minutes. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
45639371|NCT03112525|Diagnostic Test|CYP3A4/5 and P-gp phenotyping|Phenotyping using a simplified version of the Geneva cocktail
45639372|NCT03112525|Genetic|CYP3A4/5 and P-gp genotyping|Selected CYP3A4, CYP3A5, CYP3A7 and ABCB1 single nucleotide polymorphism (SNP) determination
45777342|NCT05460676|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp.
45777343|NCT05460676|Other|Mindfulness|Participants will follow an audio track for guided mindfulness during the stimulation.
45777344|NCT05460676|Other|Sham - Transcranial Direct Current Stimulation (tDCS)|The tDCS device is programmed to mimic active tDCS.
45915723|NCT05524402|Behavioral|TOR-C 2|TOR-C 2 is an active intervention that will be dose, attention and time matched to the TOR-C 1 program. TOR-C 2 is an adaptation of the Health Enhancement Program, developed by Dr. Vranceanu and colleagues from Stony Brook, with adjustments for patients with mTBI and anxiety. The TOR-C 2 sessions provide educational information on the relationship between anxiety and mTBI, return to activity, the role of nutrition and sleep, and healthcare self-management. The format is a 4-week program delivered over live video.
45639373|NCT05040425|Drug|Zi-Yin-Liang-Ge-San|Zi-Yin-Liang-Ge-San is composed of five herb ingredients, namely Rx. Scutellariae (Huang Qin), Rx. Glycyrrhizae (Gan Cao), Hb. Dendrobii (Shi Hu), Rx. Ophiopogonis (Mai Men Dong), and Hb. Menthae Haplocalycis (Bo He). It is orally administrated trice daily from the first day to the end of RT in the treatment group, aiming to prevent and manage the OM. ZYLGS is manufactured as a concentrated herbal extract, constituted 4 g per packet, and origin from pharmaceutical companies in Taiwan with good manufacturing practice (GMP).
45639374|NCT03112837|Other|Lactobacillus, Bifidobacterium and Enterococcus|3 pills two times a day during the whole treatment
45639375|NCT01969084|Drug|Linagliptin|
45639376|NCT01969084|Drug|Placebo|
45639377|NCT01969084|Other|Microcirculation testing|The endothelial function of the micro-circulation will be assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.
45777345|NCT05460299|Combination Product|Telko plus conventional physical therapy (CPT)|All patients underwent about 15-minute CPT sessions 3 days a week for 4 weeks. The CPT intervention program consisted of closed kinetic chain exercises (squatting, hip bridge, lunge, and toe standing), 3 sets, 10 repetitions each and gait training (walking forward, backward, sidewalk, and between obstacles). Short breaks (1-5 minutes) were provided, depending on the patient tolerance. Before treatment, the skilled physical therapist was instructed about the duration, frequency, and content of therapy. The patients in the experimental group received additional lower extremities closed kinetic chain training using the Telko device. The participants train on Telko for 15 minutes using moderate resistance, 3 days a week for 4 weeks.
45777346|NCT05451810|Drug|Epcoritamab|Subcutaneous Injection (SC)
45777347|NCT05446129|Drug|Ezabenlimab|Ezabenlimab
45777348|NCT05446129|Drug|BI 765063|BI 765063
45777349|NCT05446129|Drug|Pembrolizumab|Pembrolizumab
45639378|NCT01969084|Other|Macrocirculation testing|Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasodilation).
45448489|NCT05571904|Procedure|thick STSG; thin STSG|"For all the patients, thick STSGs (at a depth of 0.7 mm) were harvested from the upper lateral thighs to repair skin defects at functional sites or joint sites. For patients in the thick STSG group, the surgeons harvested a larger size of thick STSGs than the size of recipient sites. The size of the donor site was 150% - 200% of the size of the recipient site. Part of the thick STSG was grafted onto the recipient site. Subsequently, the leftover skin was punctured (in 1.5:1 mesh ratio) and stretched to obtain expansion. The donor site was covered by the leftover skin completely. In other words, the donor site was reconstructed by resurfacing the large sheet of thick STSG in situ.~For patients in the thin STSG group, the surgeons harvested thick STSGs of the size of recipient sites. Their donor sites were covered with a large sheet of thin STSGs (at a depth of 0.4 mm) which were harvested from other parts of the patients."
45448490|NCT03669549|Drug|Nevanimibe hydrochloride|During the 16-week treatment period, all subjects will begin dosing with nevanimibe HCl 500 mg BID and be dose titrated to 1000 mg BID, 1500 mg BID, and 2000 mg BID as needed based on serum 17-OHP assessments every 4 weeks.
45639379|NCT01969084|Other|MRI Scans|Phosphorus-31 MRI data will be obtained during an exercise protocol. Muscle oxygenation will be measured using the blood oxygenation level-dependent magnetic resonance imaging (BOLD MRI) technique after induced hyperemia.
45639380|NCT05040347|Other|test NETs markers|NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3) and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits.
45639381|NCT02359123|Other|Cannabics capsules|Cannabis extract in an oil formulation
45639382|NCT05040503|Biological|Blood sampling at inclusion|"Sampling of 2 tubes of 3 ml:~patient: H0: 0-6h post-admission~healthy volunteer: at inclusion"
45639383|NCT05040503|Biological|Blood sampling at 24 hours|Collection of 2 tubes of 3 ml (H24: 24-30h post-admission)
45777350|NCT05440799|Drug|BI 1819479|BI 1819479
45915724|NCT05470816|Drug|Tranexamic Acid 100Mg/ml Inj Vial 10ml|Intervention is from the Tranexamic acid to Reduce Infection after Gastrointestinal Surgery: the TRIGS Trial. A multicentre, pragmatic, double-blind, randomised clinical trial will compare the incidence of surgical site infection and red cell transfusion requirements after IV tranexamic acid and placebo in patients undergoing gastrointestinal surgery
45915725|NCT05470816|Drug|Placebo|Normal saline
45448491|NCT05668767|Drug|Surufatinib Durvalizumab EP/EC|Etoposide: total 100 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w Cisplatin: total 75 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w; or Carboplatin: AUC 5-6, intravenous infusion, administered on day 1 of each treatment cycle, q3w
45639384|NCT05040503|Other|Data collection|clinical and biological medical data for patients and general health data for healthy volunteers
45639385|NCT02362477|Behavioral|Cognitive Processing Therapy in-person|Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, in-person.
45639386|NCT02362477|Behavioral|Cognitive Processing Therapy through videoteleconference|Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, through videoteleconference.
45639387|NCT04641286|Other|Body motion categorisation|All patients will receive passive motion categorisation monitoring
45639388|NCT05040191|Other|Traditional Education(control)|The application was made on the model that allows nasogastric tube application and the anatomical structure in the nasogastric region is seen. The student can experience the skill of applying a nasogastric tube to the nasogastric or orgastric region on this model. In the nursing skills laboratory, students were given a demonstration of nasogastric tube application on a model.
45777351|NCT05440799|Drug|BI matching placebo|BI matching placebo
45777352|NCT05440344|Drug|Imlunestrant|Administered orally.
45777353|NCT05438602|Drug|Nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir every 12 hours
45777354|NCT05438602|Drug|Ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
45915726|NCT00386893|Procedure|simultaneous EEG/fMRI|fMRI/EEG recordings
45915727|NCT00386893|Device|fMRI|
45915728|NCT00386971|Dietary Supplement|L-carnitine|3 grams daily in liquid form by mouth
45915729|NCT00386971|Other|placebo|1 oz sweet tasting liquid daily by mouth
45915730|NCT00387049|Behavioral|Anxiety Sensitivity Program for Smoking Cessation|
45915731|NCT05431543|Drug|Aceclidine+Brimonidine combination ophthalmic solution|LNZ101-combination ophthalmic solution
45448492|NCT05570032|Device|Virtual Reality Training|In intervention the participants took part in the VR training. The X-BOX 360 (Augmented virtual reality) device was used. The participants were guided about the virtual reality training including Kinect sports gamming (Trail 1. badminton, beach volley ball, Soccer goal keeping). Each training was performed for 15 minutes with 5 minutes break time. The whole training was performed for 8 weeks. After eight weeks final assessment was done through outcome measuring tools (TUG test, MAS scale, forward stepping test and Functional reach test).
45639389|NCT05040191|Other|Haptic interactive virtual reality simulation training|Haptic interactive virtual reality simulation technology; It functions by using haptic gloves that are interactive, visually enhanced, containing three-dimensional video and animation, wearable by students. This program has been developed by a software developer who is an expert in the field of information technologies, using the unreal program with a nine-generation computer with a game engine. All the necessary steps in the NGT application have been in simulation.
45777355|NCT05438602|Drug|Placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
45777356|NCT05438602|Drug|Placebo for ritonavir|Participants will receive 1 capsule of placebo for ritonavir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
45777357|NCT05438407|Drug|Leniolisib|The doses selected range from 20 to 70 mg BID (resulting in total daily doses ranging from 40 to 140 mg per day) based on weight. The doses will be administered as (a combination of) 10 mg and 30 mg tablets
45915732|NCT05431543|Drug|Aceclidine ophthalmic solution|Aceclidine alone + vehicle
45915733|NCT05431543|Drug|Vehicle proprietary ophthalmic solution|Proprietary vehicle ophthalmic solution
45915734|NCT00006417|Procedure|Stem cell transplantation|
45915735|NCT05401786|Drug|Ipilimumab|Anti-CTLA-4
45915736|NCT05401786|Drug|Cemiplimab|PD-1 inhibition
45639390|NCT05040191|Other|Haptic interactive computer-based simulation training|"Clinical tvr (tactile simulator) produced by a foreign commercial company used in nursing education was used. Clinical tvr simulation applications can be accessed online or downloaded to a computer. This simulator; It functions by using an interactive, visually enhanced 2D, animated, haptic arm that can be held by students like a pen. It includes applications such as nasogastric tube placement, urinary bladder catheter placement, heart massage. These applications can be realized through both mouse and haptic arm computer input devices. clinical tvr; It is a simulator that incorporates the enhanced benefits of haptic feedback through the use of haptic technology. This simulator provides a near-realistic sensory experience where the learner can practice a skill as it actually is. Computer-based simulation with haptic interaction was used in this study with the haptic arm in NGT application skill."
45639391|NCT02358577|Device|In-bed cycling|In-bed cycling will be applied using a cycle ergometer (RT300 Supine Cycle Ergometer) for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first). This cycle ergometer is specifically designed for pediatric use, and can be applied to facilitate lower or upper limb cycling. The intervention will be applied by a trained physiotherapist and/or clinician. Pre-defined Safety Criteria for interrupting or aborting the intervention will be observed. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
45639392|NCT02358577|Other|Usual Care|Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
45639393|NCT04636840|Device|Space From Body and Eating Concerns- Teen|Mobile application with coaching component
45639394|NCT05040035|Diagnostic Test|ACT measurement|Measurement of active clotting time (ACT)
45639395|NCT02353039|Drug|GC6101A 37.5mg|Administer 12.5mg of GC6101A t.i.d for 2 weeks.
45639396|NCT02353039|Drug|GC6101A 75mg|Administer 25mg of GC6101A t.i.d for 2 weeks.
45639397|NCT02353039|Drug|GC6101A 150mg|Administer 50mg of GC6101A t.i.d for 2 weeks.
45639398|NCT02353039|Drug|Placebo|Administer placebo t.i.d for 2 weeks
45639399|NCT05039957|Other|joint preparation|fixation of fracture with joint preparation
45639400|NCT05039957|Other|without joint preparation|fixation of fracture without joint preparation
45639401|NCT01942486|Device|Investigational Coating|
45639402|NCT03095729|Other|Neuropsychological tests|A battery of tests to evaluate the overall cognitive performance of the subjects (memory, executive, attentional or instrumental functions)
45639403|NCT04660084|Diagnostic Test|Ultra-rapid molecular point-of-care testing|"Ultra-rapid molecular testing (UR-MT) comprises automated detection using the new BioFire® FilmArray® Pneumonia plus platform (Biomérieux). The total turn-around time is <2 hrs.~The UR-MT is combined with standard of care, comprising:~Microbiological processing per current standard of care entails culture of respiratory tract samples according to national protocols to detect respiratory bacteria, identified using biochemical methods and/or matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF MS). Respiratory viruses are identified using real-time PCR (for metapneumovirus, rhinovirus, influenza A, influenza B, parainfluenza 1-3, RSV and SARS-CoV-2). The total turn-around time is up to 48 hrs."
45639404|NCT02352805|Device|ECLS/ECC|Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery
45639405|NCT02362399|Drug|sildenafil citrate|single oral dose of 50 mg
45915737|NCT05401786|Radiation|SBRT|Stereotactic Body Radiotherapy
45915738|NCT05397028|Dietary Supplement|Meal replacement system|Participants will replace meals with a meal replacement system to assess the efficacy of weight loss leading to remission of diabetes (optimal A1C levels).
45448493|NCT00126659|Procedure|therapeutic conventional surgery|Undergo cytoreductive nephrectomy
45639406|NCT02362399|Other|placebo|single oral dose of placebo tablet
45639407|NCT04410887|Drug|PIPAC+SOX+OLAPARIB|SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily) Repeated every 21st day OLAPARIB Day 1-14: Olaparib 300mg BID PO
45639408|NCT02362555|Other|no intervention was used in this observational study|
45915739|NCT05397028|Behavioral|Intensive lifestyle Intervention|Participants will sign up with a virtual health program which they will interact with.
45915740|NCT05391763|Procedure|Fascia pectoralis preservation|A total mastectomy will be performed in the control breast: a procedure which includes removal of the breast glandular tissue including the PF and subcutaneously excision of the nipple-areolar complex, while the pectoralis muscle will be spared. As much of the healthy skin envelope will be preserved to enable the performance of an effective breast reconstruction afterwards. When a nipple-sparing mastectomy is performed, the skin envelope together with the nipple-areolar complex will be spared. The investigational part of the operation is preservation of the PF. Dissection of cutaneous flaps and the breast with or without the PF will be performed with electrocautery.
45915741|NCT05388682|Device|Percutaneous transluminal pulmonary angioplasty|Percutaneous transluminal pulmonary angioplasty
45639409|NCT05050331|Procedure|Muscle Energy Technique|Muscle energy technique (MET) is an active manipulative technique that requires patient active muscle contraction of a respective muscle from a specific position in a specific direction with 10-20 percent force exerted by the patient which is resisted by the therapist in an attempt to relax and lengthen the muscle.
45777358|NCT05436418|Drug|Melphalan|Matched HCT: 100 mg/m^2 IV on day -2 over 30 minutes. Haplo HCT: 100 mg/m^2 IV on day -6 over 30 minutes.
45448494|NCT00126659|Drug|sorafenib tosylate|Given orally
45448495|NCT00126659|Other|laboratory biomarker analysis|Correlative studies
45777359|NCT05436418|Drug|Sirolimus|Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, max initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +80 with no taper. Doses should be modified as appropriate for drug interactions.
45777360|NCT05436418|Radiation|Total Body Irradiation (TBI)|Haplo HCT only: A dose of 200 cGy will be administered on day -1.
45639410|NCT05050331|Procedure|Trigger Point Release|In trigger point release, a vertical downward pressure toward the trigger point for 90 seconds is applied with the therapist's thumb. Three repetitions needed to be done with 30 seconds relaxation time. After that, 3 longitudinal strokes in caudal to cranial direction are given by therapist's thumb over the taut band.
45639411|NCT05050331|Procedure|Self-Stretching of Calf and Plantar Fascia|Self-stretching will be done 5 times twice a day with 20 seconds of intermittent stretch and 20 seconds relaxation time.
45639412|NCT02352961|Other|Exclusive Intervention Strategy|"The Exclusive Intervention Strategy aimed at men aged 25 - 49 years and Active Follow-up strategy"
45639413|NCT05039333|Device|RUS(TM) software : surgical navigation|This clinical trial is a sponsor-led clinical trial, and it is intended to confirm that RUS™, a surgical navigation system certified for level 2 endoscopic imaging treatment planning software, can be applied to real people as a clinical study by using preoperative CT and to confirm the safety of surgery. In addition, the secondary research objective was to examine the accuracy of the intra-abdominal surgical navigation system provided by RUS™ including: 1) the accuracy of the undulation prediction model, 2) the accuracy of the trocar insertion position, 3) the adequacy of 3D reconstruction of the main vessels, 4) the accuracy of the major vessel branching distances, 5) the intraoperative bleeding volume and operating time, and 6) the postoperative hospitalization period and complication rate were compared with the past control group.
45777361|NCT05436418|Drug|Cyclophosphamide|based on dose level being tested (50, 35, 25, or 15 mg/kg) IV once daily over 2 hours on days +3 and +4. Cyclophosphamide will be dosed according to ideal body weight. Cyclophosphamide infusion on days +3 should be started between 70-74 hours after the start of the PBSC infusion. Cyclophosphamide infusion on day +4 should be started between 94-98 hours after the start of the bone marrow infusion.
45639414|NCT01941940|Drug|Tocilizumab|Tocilizumab at a fixed dose of 162 mg as SC injection will be administered once every week.
45639415|NCT01941940|Drug|DMARDs|Non-biologic DMARDs according to standard of care, at a stable dose that was initiated at least 4 weeks prior to baseline.
45639416|NCT02358733|Procedure|Intra-cytoplasmic Sperm Injection|Selection of sperm at 400x for sperm injection
45639417|NCT02358733|Procedure|Intra-cytoplasmic Morphologically-selected Sperm Injection|Selection of sperm at 6000x for sperm injection
45639418|NCT02358499|Drug|Posaconazole|Posaconazole will be given as a one time intravenous (IV) dose. The dose will take ninety (90) minutes to be infused and will be based on weight at the time of the visit.
45639419|NCT04434755|Other|health care professionals' exposure to bioethical issues|health care professionals were differentiated considering the work context and the type of patients cured
45639420|NCT02362087|Other|Quality of life and brief pain inventory|blood collection and quality of life questionnaires and a pain medication diary
45639421|NCT03095807|Drug|NNC9204-1706 A|Administered subcutaneously (s.c., under the skin) Up to 7 dose cohorts will be investigated.
45639422|NCT03095807|Drug|Placebo|Administered subcutaneously (s.c., under the skin)
45777362|NCT05436418|Drug|Mycophenolate Mofeti|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. Dosing will be according to actual body weight.
45448496|NCT03757546|Other|observational|The aim of the study is to describe extra-pulmonary complications due to influenza virus and RSV in hospitalized patients from November 2018 to April 2019 and November 2019 to April 2020 in a French university hospital.
45639423|NCT02358655|Other|Retrospective review of OAC prescription|
45639424|NCT02358655|Other|Prescription of OAC in ED|
45639425|NCT02358655|Other|Community AF clinic|
45639426|NCT02358265|Drug|10 mg Rupatadine on demand|Group A1 (dose administered: 10 mg rupatadine on demand): one tablet of placebo once daily- one on-demand tablet of rupatadine 10 mg intake only if needed.
45777363|NCT05436418|Drug|Fludarabine|Matched HCT: 25 mg/m^2/day infused IV over 60 minutes from day -7 to day -3. Haplo HCT: 30 mg/m^2/day infused IV over 60 minutes from day -5 to day -2
45777364|NCT05436418|Procedure|Allogeneic HSCT|Stem cell transplant
45639427|NCT02358265|Drug|10 mg Rupatadine|Group B1 (dose administered: 10 mg rupatadine continuously): one tablet of rupatadine 10 mg once daily, one on-demand tablet of placebo, intake only if needed.
45639428|NCT02358265|Drug|20 mg Rupatadine|Group B2 (dose administered: 10 mg rupatadine continuously): two tablets of rupatadine 10 mg daily- one on-demand tablet of placebo , intake only if needed.
45639429|NCT02358265|Drug|10 mg Rupatadine on demand (sham updosing to 20 mg)|Group A2 (dose administered: 10 mg rupatadine on demand): two tablets of placebo daily- one on-demand tablet of rupatadine 10 mg ,intake only if needed.
45639430|NCT05038397|Device|Theraspere|Prior to the administration of TheraSphere, the patient should undergo hepatic arterial catheterization using balloon catheterization or other appropriate angiographic techniques to prevent extrahepatic shunting. Following the placement of the hepatic catheter, 75 MBq to 150 MBq (2 mCi to 4 mCi) of Tc-99m MAA is administered into the hepatic artery to determine the extent of A-V shunting to the lungs and to confirm the absence of gastric and duodenal flow. When the possibility of extrahepatic shunting has been evaluated and the patient deemed acceptable for treatment, TheraSphere may be administered.
45639431|NCT03112213|Drug|Tocilizumab|Tocilizumab (SC or IV) will be prescribed according to local clinical practice and the SPC.
45639432|NCT03112213|Drug|NSAIDs|Participants may receive NSAIDs, as prescribed by the treating physician or by self medication. Study protocol does not enforce any particular NSAID.
45639433|NCT01968694|Drug|IV Lidocaine|
45639434|NCT01968694|Drug|IV diphenhydramine|
45639435|NCT03097913|Device|video-stylet|recording each video-stylet endotracheal tube assembly advanced through the selected nasal cavity
45777365|NCT05435482|Behavioral|Education|Participants will receive two small group meetings and two follow-up calls
45777366|NCT05435482|Other|COVID-19 testing kits|Participants will receive two COVID-19 at-home antigen test kits.
45777367|NCT05435482|Other|Instruction|Participants will receive a written guide and a video clip guide to the test kit.
45777368|NCT05428202|Drug|GN037|GN-037 cream containing urea, salicylic acid, retinoic acid and clobetasol 17-propionate and matching placebo
45777369|NCT05428202|Drug|Placebo|Placebo cream containing base without active ingredients
45639436|NCT05049941|Diagnostic Test|lactat and blood gases|observational
45639437|NCT02362243|Other|Experimental Intervention|Participants will perform the back and core exercises that were tested in our previous firefighter study (Mayer, 2015), in addition to their usual physical fitness routine. All participants at a given fire station will receive the same intervention and all interventions will be completed at the fire station. Participants will perform 2 exercise sessions each week (each time they are on duty) throughout the study's 12-month duration. The back and core exercise program consists of 1 set of 5 exercises - 4 core exercises on a floor mat and 1 back extension exercise on a variable angle Roman chair - which will take approximately 10 minutes to complete for each session (Mayer, 2015).
45777370|NCT05427474|Drug|Propranolol , gabapentin|The combined therapy of propranolol and gabapentine can prevent the occurrence of paroxysmal sympathetic hyperactivity in traumatic brain injury patients and improve the clinical outcomes in emergency ICU.
45777371|NCT05424211|Device|Music Therapy Mobile Application|The authorities determined by taking consultancy from TÜMATA (Turkish Music Research and Promotion Group) will be uploaded to the mobile application developed by the software specialist. The maqams (Rast, Nihavent and Neva) to be used in the application will be played to the patients 3 times in half an hour at different times of the day via the mobile application. Rast tonality will be played in the morning, nihavent tune will be played at noon and neva tune will be played in the afternoon.
45777372|NCT05421598|Drug|Amlitelimab|Injection solution Subcutaneous injection
45777373|NCT05421598|Drug|Placebo|Injection solution Subcutaneous injection
45777374|NCT05418647|Other|high dialysate Na|high dialysate sodium (Na = 141 mmol/L) for 8 weeks
45777375|NCT05418647|Other|low dialysate Na|low dialysate sodium (Na = 136 mmol/L) for 8 weeks
45777376|NCT05415215|Drug|Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)|PH FDC SC is administered subcutaneously (SC) as a fixed non-weight-based dose. A loading dose of 1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase (rHuPH20) is given in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20 are administered once every 3 weeks (Q3W).
45777377|NCT05415215|Drug|Pertuzumab IV|Pertuzumab is given as a fixed dose of 840 mg intravenous (IV) loading dose and then 420 mg IV for subsequent maintenance doses once every 3 weeks.
45777378|NCT05415215|Drug|Trastuzumab IV|Trastuzumab is given as an 8 milligram per kilogram (mg/kg) intravenous (IV) loading dose and then 6 mg/kg IV for subsequent maintenance doses once every 3 weeks.
45777379|NCT05415215|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be given at a dose of 3.6 mg/kg by intravenous (IV) infusion, once every 3 weeks.
45777380|NCT05415215|Drug|Investigator's Choice of Chemotherapy|Option 1: Docetaxel and carboplatin once every 3 weeks for 6 cycles; Option 2: Doxorubicin plus cyclophosphamide once every 3 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles); Option 3: Dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles).
45777381|NCT05415215|Procedure|Surgery|After completing their neoadjuvant therapy, participants will undergo surgical resection for early or locally advanced HER2+ breast cancer (if eligible for surgery). Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice. The surgery cannot be performed ≤2 weeks from the last systemic neoadjuvant therapy and must be performed ≤6 weeks after the last systemic neoadjuvant therapy.
45777382|NCT05415215|Radiation|Radiotherapy|After surgery, radiotherapy is to be given as clinically indicated and as per local practice or institutional standards. The selected radiotherapy regimen should be initiated within 4 weeks after surgery.
45777383|NCT05415137|Drug|Efzofitimod 3 mg/kg|EfzofitimodIV infusion every 4 weeks for a total of 12 doses
45777384|NCT05415137|Drug|Efzofitimod 5 mg/kg|EfzofitimodIV infusion every 4 weeks for a total of 12 doses
45915742|NCT05382169|Other|Determine the presence of mast cell activation syndrome|"Mast cell activation syndrome will be confirmed if the following three conditions are met (according to Valent et al, 2012) :~At least two clinical signs compatible with MAS before the first consultation (V1)~Improvement of symptoms on antihistamines within 2 months of initiation of treatment~Significant increase in tryptase during crisis~Mast cell activation syndrome will be possible if :~At least two clinical signs consistent with MAS before the first consultation (V1)~Improvement of symptoms with antihistamines within 2 months of initiation of treatment~No significant increase in tryptase during crisis In all other cases, mast cell activation syndrome is unlikely."
45915743|NCT00006426|Procedure|Achilles tendon-lengthening surgery|
45915744|NCT03957733|Drug|Chemotherapy|Long course CRT is followed by 4 cycles of combination chemotherapy of modified FOLFOX6 or 3 cycles of XELOX (capecitabine and oxaliplatin) and then surgery
45915745|NCT00006429|Procedure|body weight-supported treadmill training|
45915746|NCT05350150|Device|Auricular Vagal Nerve Stimulation|The Parasym device will be placed on the patient's left tragus to provide transcutaneous electrical stimulation to the auricular branch of the vagus nerve.
45777385|NCT05415137|Drug|Placebo|Placebo IV infusion every 4 weeks for a total of 12 doses
45777386|NCT05414396|Behavioral|Behavioral Intervention|Attend EML program sessions
45777387|NCT05414396|Other|Questionnaire Administration|Ancillary studies
45777388|NCT05413850|Drug|177Lu-rhPSMA-10.1 injection|Therapeutic cycles of 177Lu-rhPSMA-10.1
45777389|NCT05413850|Diagnostic Test|18F-rhPSMA-7.3 injection|18F-rhPSMA-7.3 at an administered activity of 296 MBq (8 mCi) for PET/CT scan to ascertain whether the subject has PSMA-positive disease.
45777390|NCT05408507|Behavioral|ABC123 Framework|This care planning framework aims to implement existing tools in geriatric medicine, palliative medicine, and medical oncology to aid in cancer care planning for older adults with newly diagnosed incurable advanced bladder cancer, and to test the delivery of goal-concordant care. This patient centered intervention is the ABC123 care planning framework in parallel with usual care that includes a physical function assessment, chemotherapy toxicity estimate calculation and a guided goals of care discussion.
45639438|NCT02362243|Other|Placebo Comparator|Participants will receive a 45-60 minute, one-time educational session, which will be delivered to delivered by an exercise specialist in a 1-on-1 format while the participant is on-duty at the fire station, in addition to their usual physical fitness routine. Content for the educational session on evidence-based guidelines for exercise, physical fitness, and general physical activity will be derived from the American College of Sports Medicine (ACSM) Position Stand - Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory, Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults: Guidance for Prescribing Exercise (Garber, 2011).
45639439|NCT05038007|Drug|Liposomal bupivacaine|As prior described
45639440|NCT05038007|Drug|Bupivacaine Hydrochloride|As prior described
45777391|NCT05396833|Drug|M1774|M1774 will be administered orally once daily over a defined period of time in Part A1 and Part B1 until disease progression, death, discontinuation, or end of study.
45639441|NCT04639102|Other|PATH Intervention|"Patients will receive an enhanced level of care and service:~Discharge planning- PATH clinicians will develop an individualized treatment plan at time of ED discharge. Each patient will receive next-day phone call to monitor status. There will be additional patient and family education, triage of new or worsening symptoms, and additional telephone contact as determined in treatment plan. There will be communication with home health teams as needed.~Care coordination- PATH clinicians will arrange necessary primary medical doctor and specialty appointments. They will also communicate treatment plan to outpatient provider and arrange transportation for patients.~Home monitoring/ Home Health Services- If patients are eligible and consent to home health services, they will be enrolled in Penn Medicine Home Health (PMHH). This will include virtual home monitoring, skilled nurse care, home physical and occupational therapists, social work services, and wound care."
45639442|NCT04479007|Device|Probe based optical techniques|During the intervention of inspecting the airways, different segments of the alveolar compartment will be imaged by two different probe based (CLE and OCT).
45639443|NCT01968226|Drug|[F-18] RDG-K5|Up to fifteen (15) subjects with carotid stenosis >50% who are undergoing planned carotid endarterectomy will be imaged under PET with [F-18] RDG-K5
45639444|NCT02358109|Behavioral|exercise|The exercise intervention will be performed in groups of 20 participants which will train 3 days/week (60 min per session) for a 16-week period. Sessions will be designed and carefully supervised by exercise monitors, including a 15 minute warm-up period followed by 35 minute focused on aerobic exercises, developed progressively at intensity sufficient to achieve 50% (at the beginning of the intervention) and 80% (the last month of the intervention) of predicted maximum heart rate (209-0.73 × age) and resistance strength training.Monday sessions will involve resistance strength exercises. Wednesday sessions will include balance oriented activities and dancing aerobic exercises. Fridays will include aerobic, resistance strength and coordination using a circuit of different exercises.Sessions finish with a 10 minute cool-down period of stretching and relaxation exercises.
45639445|NCT05038319|Procedure|EUS|The procedures would be performed by a therapeutic endoscope with the through the scope method. The endoscope would be used to reach the site of Varices.
45639446|NCT05049629|Device|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
45639447|NCT05049629|Device|Hylo-Vision|Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine)
45777392|NCT05396833|Drug|M4076|M4076 will be administered orally once daily over a defined period of time in Part A1 until disease progression, death, discontinuation, or end of study.
45639448|NCT02362165|Drug|Cyclophosphamide|500mg/d,once-weekly,per oral.
45639449|NCT02362165|Drug|Bortezomib|1.3mg/㎡,once-weekly,subcutaneous injection
45639450|NCT02362165|Drug|Dexamethasone|40mg/d,once-weekly,per oral
45639451|NCT02362165|Drug|Doxorubicin|9mg/㎡,d1-4
45639452|NCT02352571|Biological|GC1118|"For Part A, GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in the dose escalation cohorts, starting 0.3mg/kg until Maximum Tolerated Dose is defined.~For Part B, the defined MTD/RP2D of GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in patients with stage IV of gastric cancer, colorectal cancer or other cancers.~For Part C, GC1118 will be administered by IV infusion once every 2 weeks for 4 weeks (28-day cycles) in patients with all stage IV advanced solid cancers.~Part A, Part B and Part C participants who qualify for subsequent cycles will receive continued GC1118 until evidence of progression of disease."
45639453|NCT03095495|Device|Heated Humidified High Flow Nasal Cannula|HHHFNC therapy is a simple to use system that delivers warm and moist air/oxygen mixture at high flow rates that generate positive airway pressure
45639454|NCT03095495|Device|Standard Therapy (Low Flow Nasal Cannula)|will be used only if the patient needs oxygenation and Rescue HHHFNC will be used if the patient needs PICU
45639455|NCT02352649|Drug|Neovasculgen|
45777393|NCT05396833|Drug|Avelumab|Avelumab will be administered by intravenous infusion once a day over a defined period of time in Part B1 until disease progression, death, discontinuation, or end of study.
45777394|NCT05392855|Other|Symptom driven performance of airway clearance|Perform symptom driven/intermittent airway clearance therapy with frequency based off of patient's daily symptoms including mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
45915747|NCT05314309|Diagnostic Test|Comparison of two tests (FIT and mtFIT) in the same bowel movement|Invitees for the Dutch National CRC screening program will be randomly selected by the Screening Organization and invited to participate in this study, where next to the current FIT, participants will also perform the mtFIT in one bowel movement. Both tests will be analysed and if one of the two test results is positive, the individual will be referred for colonoscopy.
45915748|NCT00006432|Procedure|very low fat diet|
45915749|NCT00387205|Drug|Pazopanib|Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications
45915750|NCT05285683|Drug|Methylphenidate|0.5 mg/kg
45915751|NCT05285683|Drug|carbidopa-levodopa|25 mg/100 mg
45915752|NCT05285683|Drug|Placebo|oral pill
45915753|NCT05247970|Drug|S-309309|Capsule administered orally
45915754|NCT05247970|Drug|Midazolam|Syrup administered orally
45639456|NCT05037773|Behavioral|Intervention targeting parental reminiscing style|8-session intervention (i.e., 1 session/week) targeting 3 main aspects of parental reminiscing: the promotion of child participation, the structure of discussions about the past and the content addressed during these discussions. Different learning techniques are used: psychoeducation, modeling and supervised practice.
45639457|NCT02357953|Other|Measurement of cardiac index|
45777395|NCT05392855|Other|Continuous daily performance of airway clearance|Continue run-in protocol of twice daily airway clearance using twice daily mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
45777396|NCT05389189|Behavioral|Intervention Arm|"The MITIG.RA program incorporates the following key topics during the 8 weeks of intervention (1st phase):~(i) Psychoeducation on RA, sleep hygiene, exercise, and general nutritional recommendations (promote behavioural change and self-care, boost the sense of self-worth and self-efficacy) (ii) Activity engagement and pacing (iii) The functioning of the mind and its problematic patterns (iv) Focusing on the 'here and now' (mindfulness) (v) Learning new ways of self-relating - self-compassion (vi) Making room for suffering (acceptance); and (vii) Moving towards what matters (identification of valued life directions and promotion of consistent values and goals-directed behaviour)."
45777397|NCT05383352|Drug|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase) and from cycle 2 onwards on Day 1 and Day 15 of every 28-day cycle (Extension Phase)
45915755|NCT05247970|Drug|Placebo|Matching capsule to S-309309 administered orally
45915756|NCT00006438|Device|Shoes with Rocker Soles|
45448497|NCT04022733|Drug|Moderate neuromuscular block|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
45448498|NCT04022733|Drug|Deep neuromuscular block|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 4 mg/kg based on actual body weight
45639458|NCT05049239|Behavioral|Physical training|Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks, consisting of fitness, strength and mobility exercises with a target level of 60-90% of maximum heart rate. Two sessions per week take place in a group led by a physiotherapist and once a week the training consists of self-chosen training individually or in group.
45639459|NCT05049239|Behavioral|Physical training combined with cognitive support.|"Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks, consisting of fitness, strength and mobility exercises with a target level of 60-90% of maximum heart rate. Two sessions per week take place in a group led by a physiotherapist and once a week the training consists of self-chosen training individually or in group.~The cognitive support consists of person centred individual occupational therapy with focus on daily time management skills and planning and organisation in daily life, i.e. make time for physical exercise. The number of session during the intervention period depend on the participants needs and is estimated to 4-6 sessions."
45639460|NCT05049473|Drug|Rituximab|Rituximab 375 mg/m² IV. Day 1. Cycles: A1/A1*, B1/B1*, C1/A2*, A2/B2*, B2/A3*, C2/B3*. Two additional doses after 6 cycles in case of localized stage patients without CR after four cycles or advanced stage patients.
45639461|NCT05049473|Drug|Methotrexate|Methotrexate 1500 mg/m² IV 24h-infusion. Day 2. Cycles: A1, B1, C1 (1000 mg/m² if patient in CR) , A2 (1000 mg/m² if patient in CR), B2 (1000 mg/m² if patient in CR) , C2 (1000 mg/m² if patient in CR) Methotrexate 500 mg/m² IV 24h-infusion. Day 2. Cycles: A1*, B1*, A2*, B2*, A3*, B3*
45639462|NCT05049473|Drug|Dexamethasone|Dexamethasone 10 mg/m² PO or IV bolus. Days: 2 to 6. Cycles: A1/A1*, B1/B1*, C1/A2*, A2/B2*, B2/A3*, C2/B3*.
45448499|NCT05568784|Other|Straight Leg Raise exercise|Patient lying supine will lift leg to the height of the contralateral knee flexed to 90 degrees with the ankle positioned and tested in all three positions (dorsiflexion, neutral, and plantarflexion)
45448500|NCT03735069|Procedure|IPT (Indirect pulp treatment)|Indirect pulp treatment involves complete caries excavation from the dentin-enamel junction using a round bur. Caries near the pulp is removed with caution using spoon excavator until the remaining dentine shows increased resistance to manual instrumentation. A layer of resin-modified glass ionomer (RMGI) dressing material is placed, followed by resin-modified glass ionomer (RMGI) build-up material, and the final restoration; a preformed Stainless Steel Crown (SSC).
45639463|NCT05049473|Drug|Iphosphamid|"Iphosphamid 800 mg/m² IV in 1 hour. Days: 2 to 6. Cycles: A1, A2 (500 mg/m² if patient in CR).~Iphosphamid 400 mg/m² IV in 1 hour. Days: 2 to 6. Cycles: A1*."
45639464|NCT05049473|Drug|Vincristine|Vincristine 2 mg IV bolus. Day 2. Cycles: A1, B1, A2, B2 Vincristine 1 mg IV bolus. Day 2. Cycles: B1*, B2*, B3*
45639465|NCT05049473|Drug|Etoposide|Etoposide (VP16) 100 mg/m² IV in 1 hour. Days: 5, 6. Cycle: A1, A2. Etoposide (VP16) 250 mg/m² IV in 1 hour. Days: 5, 6. Cycle: C1, C2. Etoposide (VP16) 60 mg/m² IV in 1 hour. Days: 5, 6. Cycle: A1*, A2*, A3*.
45639466|NCT05049473|Drug|Cytarabine|Cytarabine 150 mg/m² IV in 1 hour every 12 hours. Days: 5, 6. Cycles: A1, A2 Cytarabine 2 g/m² IV in 3 hours every 12 hours. Day: 6. Cycle: C1 (1.5 g/m² if patient in CR), C2 (1.5 g/m² if patient in CR) Cytarabine 60 mg/m² IV in 1 hour every 12 hours. Days: 5, 6. Cycles: A1*, A2*, A3*
45639467|NCT05049473|Drug|Cyclophosphamide|Cyclophosphamide 200 mg/m² IV in 1 hour. Days 1 to 5. Pre-phase. Cyclophosphamide 200 mg/m² IV in 1 hour. Days 2 to 6. Cycles: B1, B2, B1*, B2*, B3*
45639468|NCT05049473|Drug|Doxorubicin|Doxorubicin 25 mg/m² IV in 15 min. Days 5 and 6. Cycles: B1/B1*, B2, B2*, B3*
45639469|NCT05049473|Drug|Vindesine|Vindesine 3 mg/m2 (max 5 mg) IV bolus. Day 2. Cycles: C1, C2
45639470|NCT05049473|Drug|Cytarabine|Cytarabine 30 mg IT. Days 2 and 6. Cycles A1, B1, A2, B2
45777398|NCT05383352|Drug|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase)
45777399|NCT05383352|Drug|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 1 (Crossover Phase)
45915757|NCT05180656|Behavioral|Yoga Intervention|The yoga intervention will consist of two 60-minute yoga classes each week, taught by a certified yoga instructor and delivered remotely through videoconferencing. Participants will be asked to participate in the intervention for 8 weeks.
45915758|NCT00006441|Drug|Lamivudine/Zidovudine|300/150 mg respectively twice daily for 104 weeks. Patients who develop intolerence to AZT may use Stavudine (d4T) at a dose of 40 mg daily.
45915759|NCT00006441|Drug|Nelfinavir mesylate|1250 mg twice daily for 104 weeks.
45639471|NCT05049473|Drug|Methotrexate|Methotrexate 12 mg IT. Day 1. Pre-phase Methotrexate 12 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2 Methotrexate 15 mg IT. Day 2. Cycles: A1*, B1*, A2*, B2*, A3*, B3*
45639472|NCT05049473|Drug|Hydrocortisone|Hydrocortisone 20 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2
45639473|NCT05049473|Drug|Prednisone|Prednisone 60 mg/m2 PO or IV bolus. Days 1 to 5. Pre-phase.
45639474|NCT02357797|Drug|Vortioxetine|
45639475|NCT02357797|Other|Placebo|
45639476|NCT02361931|Drug|A hydrogel containing erythropoietin|Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. RMD-G1 applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
45777400|NCT05383352|Drug|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase) and from cycle 2 onwards on Day 1 and Day 15 of every 28-day cycle (Extension Phase)
45777401|NCT05383352|Drug|Folinic Acid|LV 400 mg/m2 intravenously over 30 minutes, on day 1 and day 15 of every 28-day cycle
45639477|NCT02361931|Drug|Hydrogel (as a part of SOC)|Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. Hydrogel applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
45639478|NCT02361853|Other|Exposure: abundance of Immature Myeloid Cells counts in blood samples|
45777402|NCT05383352|Drug|5-Fluorouracil|5-FU 2,400 mg/m2 intravenously over 46 hours, on day 1 and day 15 every 28-day cycle
45915760|NCT00006441|Drug|Aldesleukin|7.5 million units twice daily. Treatment will last until conclusion of study.
45777403|NCT05378373|Behavioral|Garmin, Pattern Health App|Wearable sensors will deliver individualized feedback to participants according to their assigned intervention
45777404|NCT05377736|Genetic|Molecular analyses|Collect thyroid tissue for molecular analysis from the histological specimen collected by routine surgery
45639479|NCT02361853|Other|Exposure: abundance of Immature Dentritic Cells counts in blood samples|
45639480|NCT02361853|Other|Exposure: abundance of Immature monocytes counts in blood samples|
45639481|NCT02361853|Other|Exposure: abundance of Immature neutrophils counts in blood samples|
45639482|NCT05037695|Drug|empagliflozin 25 MG|empagliflozin 25mg - daily
45598078|NCT03974061|Behavioral|Brief Acceptance and Commitment Therapy|Acceptance and Commitment Therapy utilizes mindfulness skills and values-guided behavioral action plans to decrease experiential avoidance and impact a broad array of psychological symptoms.
45639483|NCT02361697|Other|DTI-MRI|MRI of the brain with special DTI-sequences are performed in each child with multiple sclerosis or clinically isolated syndrome at timepoint of first manifestation and every 6 months in a longterm follow-up of 3 years
45777405|NCT05376800|Drug|BI 907828|BI 907828
45777406|NCT05376579|Other|siponimod|Prospective observational cohort study. There is no treatment allocation. Patients will be invited to participate in the study after the independent decision by physician and patient to start siponimod treatment as routine clinical care.
45915761|NCT02972671|Device|MiStent (MT005) Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
45915762|NCT02972671|Device|Xience Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
45915763|NCT05159791|Diagnostic Test|Invasive coronary blood flow assessment and simulations and fluid dynamic patient specific simulation|The coronary blood flow and its distribution between the anomalous and normal artery will be measured by invasive coronary catheterization. Coronary artery flow will be calculated based on intravascular ultrasound (IVUS) and pressure difference measurements. After the IVUS assessment, a pressure transducer (FFR/iFR probe) will be inserted in the coronary artery for pressure measurements. The measurements will be done in the anomalous and normal coronary arteries in each patient to determine coronary flow distribution. Patient's specific heart parameters will be retrieve from CT, MRI and other diagnostic tests and integrated in the simulation module.
45915764|NCT05147233|Drug|Dexamethasone|Dexamethasone
45915765|NCT05147233|Drug|Vehicle Placebo|Placebo comparator
45598079|NCT03974061|Behavioral|Brief Alcohol Intervention|The Brief Alcohol Intervention is a standard intervention that will be adapted for men and women living with HIV. The intervention will be matched in frequency and length to the brief ACT intervention.
45777407|NCT05371808|Other|EQ-5D-5L Instrument|This instrument is a measure of health status for use in evaluating health and healthcare.
45777408|NCT05371808|Other|Work Productivity and Daily Activity Impairment (WPAI) survey|The questionnaire includes three open-ended questions that determines: 1) hours absent from work due to health problems; 2) hours absent from work due to other reasons; and (3) hours actually worked over the past 30 days. Additional questions ask about the impact of health problems on work productivity and daily activities and are scored along a vertical visual analog scale. The WPAI provides estimates on absenteeism, presenteeism, global measures of lost productivity (absenteeism+presenteeism) and daily activity impairment (impaired ability to perform non-work activities including work around the house, child care, exercise, studying, and leisure activities)
45777409|NCT05371808|Other|Resource Utilization Form (SMRC)|Resource utilization data collection will be supplemented by a self-administered resource utilization form (Stanford SMRC) to document non-protocol specified utilization. This will include hospitalizations (including days in hospital), emergency room visits, and non-protocol specified ambulatory visits.
45915766|NCT00006447|Procedure|Social Support|
45639484|NCT05049395|Device|High Flow Nasal Cannula oxygen (HFNO)|The AIRVO2 is set at 30L/min, FiO2 100%, and 37℃ before anesthesia induction，and then 60L/min until the end of the procedure of sedated hysteroscopy.
45639485|NCT05049395|Device|Regular oxygen|The patients are administered oxygen of 3L-6L/min until the end of the hysteroscopy operation.
45639486|NCT02357641|Other|retrospective echographic myocardial strain analysis refering to acute coronary syndrome|retrospective evaluation for cut off value of circumferential and radial echographic strain parameters corresponding to acute coronary disease
45639487|NCT05048771|Other|Questionnaire|Patients will be surveyed through self-administered questionnaires and semidirected interviews with a psychologist
45777410|NCT05369975|Drug|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
45777411|NCT05369975|Other|Normal Transplantation Routine|Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
45777412|NCT05364021|Drug|LP352|LP352 administered three times daily, orally or through G-tube
45777413|NCT05364021|Drug|Placebo|Matching placebo for LP352 administered three times daily, orally or through G-tube
45777414|NCT05363345|Device|bile duct stone removal|Common bile duct stones (≧ 10 mm) are removed by using Vortic Catch V basket catheter or ordinary basket catheter following endoscopic papillary large balloon dilation.
45777415|NCT05355792|Device|OmniTaper EV implants|Partially edentulous subjects in need of one implant in the maxilla or mandible (2nd and 3rd molars excluded) will receive an OmniTaper EV implant system. The study will be done in accordance with standard dental practice using a one- or two-stage surgical protocol and immediate or delayed placement and/or loading.
45777416|NCT05349955|Other|Intensive guideline algorithm implementation|Diabetes guideline pharmacological algorithm will be implemented by primary care physicians in community. In brief, SGLT2i or GLP-1RA will be recommended to control blood glucose in priority when subjects at very high/high CV risk and meet the target HbA1C<7%, control blood pressure <130/80mmHg， LDL-c<1.8mmol/L at very high CV risk patients or <2.6mmol/L at high CV risk patients, and antiplatelet as secondary prevention of ASCVD.
45777417|NCT05349955|Other|Conventional guideline algorithm implementation|The guideline intervention is based the guidance which the local physicians followed through self learning and education. The management of diabetes paitients will be decided by local physicians.
45639488|NCT02352181|Procedure|Conventional coagulation profile Analysis|"Transfusional protocol for Standard group Red Blood cells concentrate if Hemoglobin <9 gram per liter Fibrinogen 3 gram, if fibrinogen <1gram per liter~Platelet concentrate :~if platelets <50gram per liter before transfusion, at anhepatic phase, or in case of bleeding.~if platelets <30gram per liter at vascular unclamping time at the end of intervention or without bleeding 2 Fresh frozen plasma if :~if prothrombin<40% before transfusion at anhepatic phase or in case of bleeding.~if prothrombin<30% at vascular unclamping time at the end of intervention or without bleeding Bolus Tranexamic acid 1g and 3g every 24 hours in case of fibrin degradation products.~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose.~Analyses in S Group only: coagulation profile (PT, APTT, INR, fibrinogen, platelet count, soluble complexes, PDF)."
45639489|NCT02352181|Procedure|Rotem analysis|"Transfusional protocol for Rotem group. Red Blood cells concentrate if Hemoglobin <9 gram per liter Fibrinogen 3 gram, if A10 FIBTEM <8 mm~Platelet concentrate :~If MCF EXTEM <40mm or A10<35 mm and MCF or A10 FIBTEM >8mm.~If platelets <30gram per liter at vascular unclamping time at the end of intervention or without bleeding.~2 Fresh frozen plasma if CT EXTEM >100s.~Bolus Tranexamic acid 1g and 3g every 24 hours :~if fibrinolysis in EXTEM~Reduction of 15 % of clotting time or clot formation time and increase of maximum clot firmness in APTEM compared to EXTEM, or maximal lysis at 60 minutes >15%.~Analyses in R group only: blood sampling on citrated tube for ROTEM analysis (EXTEM, INTEM, FIBTEM, APTEM +/- HEPTEM), coagulation profile (same as that of the S Group, for emergency procedure).~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose."
45777418|NCT05348681|Drug|RIST4721|RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
45639490|NCT02357563|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later for two courses, with an interval between the courses of 1 month
45639491|NCT02357563|Drug|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24) and repeated 3 months later
45639492|NCT04478929|Diagnostic Test|Gastroscopy|Routine gastroscopy
45639493|NCT02361541|Procedure|HCV screening|HCV antibody screening, liver function tests, full blood count and HbsAg will performed. Additional blood samples will be taken for further HCV diagnostic work-out (polymerase chain reaction (PCR) and genotyping). For patients with current HCV infection, liver ultrasound, transient elastography - Firbroscan and further lab analysis will be performed.
45777419|NCT05348681|Drug|Placebo|Matching placebo
45777420|NCT05340673|Drug|Agent Affecting Integumentary System|Apply Miaderm
45777421|NCT05340673|Other|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Apply to skin
45777422|NCT05340673|Other|Quality-of-Life Assessment|Ancillary studies
45777423|NCT05340673|Other|Questionnaire Administration|Ancillary studies
45915767|NCT05088109|Diagnostic Test|early mortality prediction using septic shock indices|The Shock Index (SI) is the ratio of pulse rate to systolic blood pressure calculated by dividing pulse rate (beat/min) by systolic blood pressure (mm Hg). The adjusted shock index (ASI) is SI calculated after adjusting the heart rate according to body temperature that 10 beats will be added to the heart rate for every 1.0 °C rise in the body temperature above 37.0 °C. The modified shock index (MSI) is a ratio of heart rate to mean blood pressure (MAP). The DSI is a ratio of heart rate to diastolic blood pressure (DAP).
45777424|NCT05327946|Drug|BI 770371|BI 770371
45777425|NCT05327946|Drug|ezabenlimab|ezabenlimab
45777426|NCT05322837|Other|Clinical and technological-aided assessments and questionnaires|Assessments and questionnaires related to upper limb function and quality of life will be used
45777427|NCT05321082|Drug|BI 1015550|BI 1015550
45777428|NCT05321082|Drug|Placebo|Placebo
45777429|NCT05321069|Drug|BI 1015550|BI 1015550
45777430|NCT05321069|Drug|Placebo|Placebo
45777431|NCT05320406|Radiation|Radiation therapy|Undergo radiation therapy
45777432|NCT05320406|Drug|Leuprolide|Given IM or SC
45777433|NCT05320406|Drug|Relugolix|Given PO
45639494|NCT03160105|Drug|Switch to DTG + FTC|Switch from standard cART to DTG + FTC dual maintenance therapy.
45639495|NCT03160105|Other|Patient-centered monitoring|Immunological and safety blood examinations performed only once per year at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
45639496|NCT02640053|Procedure|Cryotherapy|Applied topically
45639497|NCT02640053|Drug|Paclitaxel|Given IV
45639498|NCT02640053|Other|Quality-of-Life Assessment|Ancillary studies
45639499|NCT02640053|Other|Questionnaire Administration|Ancillary studies
45639500|NCT03160261|Drug|Exenatide Injection|Single injection of Exenatide 10μg subcutaneously
45639501|NCT05036837|Drug|OZOPROMAF_SEQ1|"OZOPROMAF protocol consists of: local superficial anesthesia by EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (mixture by 26Gx 1⁄2 - 0.45x13mm needle into the mucosal margin surrounding the bone exposure or around the situs already evidenced by CT scan. It is applied on 7-15 days, depending on the patient compliance, until the formation of sequestrum and clinical healing (T1).~Pain intensity is assessed by means of a questionnaire for pain and/or other symptoms evaluation before and after the protocol, based on numerical rating scale (NRS).~After resolution (T1), follow-up visits are scheduled to confirm the healing of MRONJ at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5).~Radiographic evaluations of bone healing are scheduled at T3 and T4.~Positive outcomes for the OZOPROMAF protocol are evaluated at T1 as no clinical signs of acute phlogosis and no symptoms compatible with MRONJ; at T5 as clinical healing and no radiological signs of MRONJ."
45639502|NCT02361775|Device|Paravertebral catheter|A catheter is placed ultrasound guided at the T5 paravertebral level
45639503|NCT02361775|Device|opioid iv pca|opioid pca consisting of hydromorphone
45639504|NCT02361775|Drug|Ropivacaine|0.2% ropivacaine infused through paravertebral catheter
45639505|NCT02361775|Device|Elastomeric Pump|Elastomeric pump connected to paravertebral catheter
45639506|NCT05036759|Drug|68Ga-FAPI|intravenously injected with 68Ga-FAPI
45639507|NCT02361619|Drug|Caffeine|probe
45639508|NCT02361619|Drug|Diclofenac|probe
45448501|NCT03735069|Procedure|Cvek/partial pulpotomy|Cvek/partial pulpotomy involves removal of inflamed pulp tissue to depth until healthy pulp tissue is reached (depth of 2-4 mm), as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 2-5 minutes and repeated for two times if required. Gray MTA will be placed in the pulp chamber in 2-3 mm thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with IRM, the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGIC and stainless steel crown will be placed , and a post-operative radiograph will be taken.
45777434|NCT05319184|Other|Myofascial Release Technique and Kinesiology Taping|"Myofascial release is a manual release technique that increases the elasticity and glide between soft tissue layers, reduces this increased muscle activity and pain intensity. Myofascial release is usually characterized by prolonged mechanical forces exerted directly or indirectly on the limited fascial layers with low load. Following the direction of the fascial restraint, the therapist's hands slowly maintain the stretch and allow the fascia to relax on its own.~Kinesio Taping is a non-invasive, painless and less time consuming method with fewer side effects. It is an elastic-cotton adhesive tape that is latex-free and can be used on any joint or muscle. It can stretch significantly (130-140% of its original length), which reduces mechanical movement limitations and mimics skin in thickness and elasticity. It is used in the treatment of LBP to reduce muscle tone and stiffness as a rehabilitative taping technique designed to support the body's natural healing process."
45777435|NCT05314218|Device|Electrophysiology catheters and cables|"The Xtrem electrophysiology catheter was developed for diagnosis of cardiac arrhythmias. Their function is to collect by contact, electrical signals generated by the heart muscle.~Xtrem are inserted via femoral vena cava or via artery and can be used in two occasions:~Exploration procedures for diagnosis alone~Diagnosis before ablation procedure An extension cable is used to connect the catheter to a stimulation/ recording device."
45448502|NCT03735069|Procedure|Cervical pulpotomy|Cervical pulpotomy involves removal of inflamed pulp tissue from all pulp chamber as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 6 minutes and repeated for two times if required. Gray MTA will be placed in the pulp chamber (2-3mm) thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with IRM, the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGIC and stainless steel crown will be placed , and a post-operative radiograph will be taken.
45448503|NCT03966599|Diagnostic Test|Pain|Patient's pain in order to VAS
45448504|NCT03966599|Diagnostic Test|Hemodynamic changes|changes in hemodynamic states
45639509|NCT02361619|Drug|Esomeprazole|probe
45639510|NCT02361619|Drug|Metoprolol|probe
45639511|NCT02361619|Drug|Midazolam|probe
45448505|NCT03547570|Other|Progressive heavy shoulder resistance training|The training programme includes five exercises identified in literature to target scapular and rotator cuff muscles.
45639512|NCT02361619|Drug|Dabigatran|probe
45915768|NCT05079139|Procedure|surgical technique of Musset|"The one-stage rectovaginal fistula cure according to Musset is an intervention indicated in the treatment of simple post-obstetrical or simple post-surgical rectovaginal fistulas.~The procedure consists in performing a perineal section to the perineal section to the fistula pathway in order to perform local excision followed by a repair plane by plane with rectal and anal closure, then of the external sphincter of the anus, and interposition of the deep and superficial transverse elevator and perineal muscles before closing the vagina and perineum."
45639513|NCT02361619|Drug|Clarithromycin|perpetrator
45639514|NCT05036369|Device|Vibrant capsule|The Vibrant Capsule is designed to mechanically induce a peristaltic wave in the large intestine, thus aiding in relieving constipated subjects. Constipation relief is achieved by the capsule's vibrations impinging on the gastrointestinal wall, consequently inducing peristaltic activity which promotes transit and facilitates defecation
45639515|NCT02361463|Device|3D vision|Laparoscopic simulator training to proficiency under 3D conditions
45639516|NCT02361463|Device|2D vision|Laparoscopic simulator training to proficiency under 2D conditions
45777436|NCT05312151|Drug|Psilocybin|Open label
45915769|NCT05058274|Device|Implant of the AT-TORBI 709 lens|Implant of the AT-TORBI 709 lens
45777437|NCT05307198|Drug|Oxaliplatin|"Drug: Oxaliplatin Oxaliplatin 130mg/m2 for inducing chemotherapy in Day 1 every 3 weeks and repeat for two cycles.~The dose of oxaliplatin used for rectal artery infusion was uncertain because there were no previous study. We design this study with Oxaliplatin 85mg/㎡for rectal artery infusion chemotherapy in Day 1 every 3 weeks and repeat for 2 cycles, based on intravenous chemotherapy regimens recommended by NCCN（mFolfox6）.If there were severe side effects caused by oxaliplatin observed within first 6 patients, we would decreasing the dose of oxaliplatin depending on the multidisciplinary discussion of researchers.~We acknowledged that our study did not determine the most appropriate dosage of oxaliplatin used for artery infusion, but rather performed a novel therapeutic method for microsatellite stable locally advanced rectal cancer."
45777438|NCT05307198|Procedure|Rectectomy|Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).
45777439|NCT05307198|Drug|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy in Day 1 to Day 14 every 3 weeks and repeat for 4 cycles.
45777440|NCT05307198|Drug|Anti-PD-1 monoclonal antibody|Anti-PD1 antibody 200mg/m2 in Day 2 after Rectal Artery Infusion Chemotherapy. Repeat every 3 weeks for 2 cycles.
45777441|NCT05306353|Drug|Placebo for VIB4920|26 participants will receive VIB4920 placebo administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including tumor necrosis factor alpha inhibitor (TNFi) (double-blinded)
45777442|NCT05306353|Drug|VIB4920 with TNFi|52 participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including Tumor necrosis factor alpha inhibitor (TNFi) (double blinded)
45777443|NCT05306353|Drug|VIB4920 without TNFi|Participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 but discontinue necrosis factor alpha inhibitor (TNFi) while continuing all other background rheumatoid arthritis (RA) therapy (evaluator-blinded)
45777444|NCT05300815|Other|Delphi Questionaire|"This study involves the use of questionnaires across 3 rounds as follows:~The objectives of round 1 are to collect participant demographic information and generate a list of adverse events. Round 1 will be open for 3 weeks with email reminders being provided at weeks 1 and 2.~The objectives of round 2 will be to share a list of adverse events generated from round 1 (with the addition of adverse events identified in literature if not generated in round 1) and allow participants to rate from 1-4 how important each item is for inclusion on informed consent. As per round 1, the round 2 questionnaire will remain active for 3 weeks with email reminders sent at weeks 1 and 2.~The objective of round 3 is to further gain consensus on adverse events from the results of round 2 where agreement was not reached. Round 3 remains active for 3 weeks with email reminders sent at weeks 1 and 2."
45639517|NCT05048303|Procedure|Arthroscopic modified individualized flexible Latarjet procedure|The modifications were as follows: (1)the coracoid graft and conjoint tendon were prepared using a mini-open technique with an incision of 2.5 cm and coracoacromial ligament were preserved. A total of 2 bone tunnels were drilled. (2)The anterior (including part of the incision used for obtaining the graft), standard antelateral, and posterior portals were set. (3) The glenoid was marked at the 4-o'clock position, and then the subscapularis muscle was split. (4)The glenoid tunnel was drilled where the suture linked to the graft was passed, and the graft was pulled to the glenohumeral joint via the sutures. A knotless suture anchor for antirotation (PushLock; Arthrex) was fixed to the glenoid to prevent rotation of the graft.
45639518|NCT02352025|Drug|S-equol|S-equol should be administered orally, twice daily (12 hours apart), preferably on an empty stomach with a glass of water. Tablets should be swallowed whole.
45639519|NCT01950364|Drug|brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
45639520|NCT01950364|Drug|Brentuximab vedotin and rifampicin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
45639521|NCT05047991|Drug|Irinotecan Liposome Injection|Irinotecan Liposome Injection, intravenously, over 90 min on day 1and day 15 of every 28-day cycle
45639522|NCT05047991|Drug|Fluorouracil|5-Fluorouracil (5-Fu), intravenously, over 46 h on day 1 and day 15 of every 28-day cycle
45639523|NCT05047991|Drug|Leucovorin|Leucovorin (LV), intravenously, over 30 min on day 1 and day 15 of every 28-day cycle
45639524|NCT05047991|Drug|Oxaliplatin|Oxaliplatin, intravenously, over 2 h on day 1 and day 15 of every 28-day cycle
45777445|NCT05299073|Drug|MB09 (denosumab biosimilar)|Single dose of 35mg SC administered
45777446|NCT05299073|Drug|US-sourced Xgeva|Single dose of 35mg SC administered
45777447|NCT05299073|Drug|EU-sourced Xgeva|Single dose of 35mg SC administered
45777448|NCT05298709|Other|MRI study session|The MRI study sessions will be approximately 1 to 1.5 hours duration. Resting state fMRI will be performed using either eyes open or eyes closed condition while relaxing as much as possible without moving and thinking of anything. Task-based fMRI will be performed using specific study defined tasks. Subjects will also be asked to complete hyperventilation and CO2 breathing tasks based on instruction from the study investigators.
45777449|NCT05296733|Drug|BI 456906|BI 456906
45915770|NCT05054647|Other|psychometric questionnaires|Perceived Stress Scale (PSS-10); Trier-Inventory on Chronic Stress; State/Trait Anxiety Inventory (STAI); AVEM-Work-related behaviour and experience pattern; Maslach Burn-out Inventory - Human Services Survey (MBI - HSS) health-related anxiety: Whiteley Index (WI)
45639525|NCT05047991|Drug|Nab paclitaxel|Paclitaxel (albumin bound), intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
45639526|NCT05047991|Drug|Gemcitabine|Gemcitabine, intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
45639527|NCT00014443|Drug|thalidomide|
45639528|NCT00014443|Drug|topotecan hydrochloride|
45639529|NCT05035979|Drug|BaidI Quzhi granule|Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
45639530|NCT05035979|Drug|Ju Yin cream|Take JY cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
45639531|NCT05035979|Drug|Baidi Quzhi placebo granule|Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
45639532|NCT05035979|Drug|Ju Yin placebo cream|Take JY placebo cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
45639533|NCT05047367|Behavioral|cross-sectional survey study|Beck Depression Scale, Beck Anxiety Scale for psychological evaluation, Visual Analogue Scale and PainDETECT Questionnaire for pain, Pittsburgh Sleep Quality Scale and Epworth Sleepiness Scale for sleep quality
45639534|NCT05036057|Other|Questionnaire|"Patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD), the COPD Assesment Test (CAT), the Saint George Respiratory Disease Questionnaire (SGRQ), the Charlson Comorbidity Index, and will rate the disease and general knowledge level on a numerical scale.~Proxies of patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD) and will rate the disease and general knowledge level on a numerical scale."
45777450|NCT05288764|Device|Bispectral Index|Comparing Bispectral index values (usually adopted during general anaesthesia monitoring) to Ketamine concenetration at the effector site calculated with Domino model pump (usually adopted for Ketamine infusion during general anaesthesia)
45639535|NCT02351635|Other|fecal calprotectin level|Stool sample collected by the subject, sent study laboratories where fecal calprotectin levels are quantified.
45639536|NCT05047133|Drug|Tranexamic acid|TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups
45639537|NCT02357251|Other|Enhanced recovery protocol|
45639538|NCT05035355|Procedure|a weaning protocol|a weaning protocol that is combined spontaneous breathing trial (SBT) with the high-flow nasal cannula (HFNC)
45639539|NCT04334863|Drug|WP1066|"WP1066 is an analogue of caffeic acid that is a potent inhibitor of p-STAT3.~It will be taken by mouth 2 times per day on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle."
45639540|NCT02357407|Drug|Patients in intensive care : infection treated with ciprofloxacin IV|8-10 samples per patients on day-4 of their treatment
45777451|NCT05285982|Drug|Nintedanib (Ofev®)|Nintedanib (Ofev®) soft capsules
45777452|NCT05282641|Dietary Supplement|10 g of collagen hydrolysate|Before breakfast, participants consume 1 sachet every day for 4 weeks. The sachet contains 10-gram collagen protein hydrolysates + 5-gram erythritol and it has to be dissolved in 250 ml of water.
45777453|NCT05282641|Dietary Supplement|Placebo|Before breakfast, participants consume 1 sachet every day for 4 weeks. The sachet contains 5-gram erythritol (placebo) and has to be dissolved in 250 ml of water.
45639541|NCT02357407|Drug|Osteoarticular infected patients : infection treated with oral ofloxacin|8-10 samples per patients on day-4 of their treatment
45777454|NCT05282121|Drug|BI 685509|BI 685509
45777455|NCT05282121|Drug|Empagliflozin|Empagliflozin
45639542|NCT05035433|Procedure|First lithotripsy and then EPBD|After successful selective bile duct intubation, contrast agent was injected to measure the thickness of the bile duct and the size of bile duct stones under fluoroscopy. For those meeting the inclusion criteria, sphincterotomy was performed first.Papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken line to suitable size after the switch to expanding balloon EPBD and further kidney stones, papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken balloon to suitable size after the switch to expansion, expansion size 10-12 mm, according to the lower bile duct diameter, expansion time of 30 seconds.Then, the stones were removed with a net basket or balloon, and the nasobiliary duct was placed to end the operation.
45777456|NCT05264194|Other|Suturing technique|The technique (subcuticular or transcutaneous) that will be used to close skin post-surgery.
45777457|NCT05255536|Procedure|Serratus Anterior Plan Block with 20 ml|Superficial serratus anterior plane block with 20 ml will be applied to the patients under real-time ultrasound guidance.
45777458|NCT05255536|Procedure|Serratus Anterior Plan Block with 30 ml|Superficial serratus anterior plane block with 30 ml will be applied to the patients under real-time ultrasound guidance.
45777459|NCT05249426|Drug|BI 765063|BI 765063 (anti-Signal Regulatory Protein Alpha (SIRPα) Monoclonal Antibody (mAb))
45777460|NCT05249426|Drug|Ezabenlimab|Ezabenlimab (anti-Programmed cell death protein 1 (PD-1) Monoclonal Antibody (mAb))
45777461|NCT05249426|Drug|BI 836880|BI 836880 (anti-Vascular Endothelial Growth Factor (VEGF) / Angiopoetin 2 (Ang2))
45915771|NCT03926845|Other|Isobutylamido-thiazolyl-resorcinol Cream 0.2%|Each bottle contains Isobutylamido-thiazolyl-resorcinol cream 0.2% to be applied on the entire face twice daily for 12 weeks.
45777462|NCT05249426|Drug|Cetuximab|Cetuximab
45777463|NCT05249426|Other|Investigator´s Choice Chemotherapy|Allowable chemotherapies include: paclitaxel, docetaxel, capecitabine, 5-fluorouracil, methotrexate or combinations thereof
45777464|NCT05247918|Behavioral|Digital-physical care|Patients will get access to a digital communication platform. Two in person session and two digital contacts per year with possibility to chat with caregivers in between.
45777465|NCT05247918|Behavioral|Treatment as usual|Four in person session at the center in a year.
45777466|NCT05247346|Device|SENSITIVE system|probe-based integrated Raman spectroscopy and scattering measurements of Barrett's and colorectal tissue during GI endoscopy
45777467|NCT05243290|Dietary Supplement|Nicotinamide Riboside|The product under investigation, Nicotinamide riboside (NR), is a naturally occurring NAD+ precursor and a member of the vitamin B3 family.
45777468|NCT05243290|Dietary Supplement|Placebo|Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured NR capsules, with the exception of any NR compound.
45777469|NCT05242822|Drug|KIN-3248|KIN-3248 will be administered orally once daily in 28-day cycles
45777470|NCT05242146|Drug|GB5121|Capsule containing GB5121
45777471|NCT05238675|Drug|BI 1291583|BI 1291583
45777472|NCT05238675|Drug|Placebo|Placebo
45915772|NCT03926845|Other|Vehicle|Each bottle contains vehicle cream to be applied on the entire face twice daily for 12 weeks.
45915773|NCT05048836|Other|Food Subsidy, 6 months|Food subsidy for 6 months
45639543|NCT05035433|Procedure|First EPBD and then lithotripsy|After puncture of the papillary sphincter, the guide wire was indwelled in the bile duct, and the columnar dilating balloon was inserted in exchange. The dilation size was 10-12mm, and the dilation time was 30 seconds according to the diameter of the lower end of the bile duct.At the end of the expansion, the stones were broken to a suitable size using a one-piece gravel net basket.The calculi were removed by using a stone net basket or balloon, and the nasobiliary duct was placed to end the operation.
45639544|NCT02038699|Drug|ONC201|ONC201 capsules will be administered orally once every three weeks with flat dosing. Dosage will be given according to a modified Fibonacci sequence with the anticipated starting dose being 125 mg.
45639545|NCT05046743|Other|Colonic gas load|Colonic infusion of gas via an anal cannula
45777473|NCT05236023|Behavioral|Zero separation and couplet care|"The essence of the intervention is that treatment-requiring mother-infant dyads are admitted together and receives couplet care provided by neonatal nurses.~The nurses will be educated for the intervention by participating in a two-day course about postpartum observations, treatment and care; and participate in education about family-centred care and family-focused nursing."
45777474|NCT05228964|Device|Focused ultrasound|Focused ultrasound at a 10 Hz pulse repetition frequency, 5% duty cycle, and 720 mw/cm squared de-rated spatial peak temporal average intensity, delivered over 10 min.
45639546|NCT05046743|Other|Sham load|Sham infusion of gas via an anal cannula
45639547|NCT03160651|Drug|Methylprednisolone or placebo|Patients will receive 28 days of methylprednisolone 32 mg/day
45777475|NCT05227209|Drug|SEP-4199 CR|SEP-4199 CR either 200 mg (one 200 mg tablet) or 400 mg (two 200 mg tablets) once daily
45777476|NCT05227001|Biological|PF-07852352 Influenza saRNA 1|Intramuscular injection
45777477|NCT05227001|Biological|PF-07836391 Influenza saRNA|Intramuscular injection
45777478|NCT05227001|Biological|PF-07836394 Influenza saRNA|Intramuscular injection
45777479|NCT05227001|Biological|PF-07836395 Influenza saRNA|Intramuscular injection
45777480|NCT05227001|Biological|PF-07836396 Influenza saRNA|Intramuscular injection
45777481|NCT05227001|Biological|PF-07867246 Influenza saRNA|Intramuscular injection
45915774|NCT05048836|Other|Food Subsidy, 12 months|Food subsidy for 12 months
45448506|NCT03669081|Drug|Ketorolac|Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
45639548|NCT05046977|Procedure|Single osteotomy|Single tibial osteotomy
45639549|NCT05046977|Procedure|Double Osteotomy|Double Tibial Osteotomy
45639550|NCT02357095|Procedure|monitoring|uterine artery chemo-embolization combined with suction curettage under different monitoring methods,such as hysteroscopic monitoring,ultrasonography monitoring and no monitoring
45639551|NCT05026307|Procedure|Excision of pterygium|Simple surgical excision of pterygium with bare sclera
45915775|NCT05048836|Behavioral|Lifestyle Support, 6 months|lifestyle support intervention delivered by community health workers for 6 months
45915776|NCT05048836|Behavioral|Lifestyle Support, 12 months|lifestyle support intervention delivered by community health workers for 6 months
45915777|NCT05048836|Other|Food Delivery, 6 months|Twice monthly delivery of healthy food for 6 months
45915778|NCT05048836|Other|Food Delivery, 12 months|Twice monthly delivery of healthy food for 12 months
45448507|NCT03669081|Drug|Pregabalin|Pregabalin was administered orally: 75 mg 30 minutes prior to operation.
45639552|NCT02351713|Other|Exercise|Continuous aerobic exercise prescribed according to two exercise intensity methods: threshold based method (i.e., ventilatory threshold) and relative percent method (i.e., heart rate reserve).
45639553|NCT05034965|Drug|hyaluronic acid filler injection|quantitative surface electromyography before injection(baseline) and one week after injection
45639554|NCT03160339|Biological|PXVX0047 Vaccine|PXVX0047 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in PXVX 0047 are unattenuated strains propagated in A549 human adenocarcinomic alveolar basal epithelial cells.
45777482|NCT05227001|Biological|Placebo|Intramuscular injection
45777483|NCT05227001|Biological|Quadrivalent influenza vaccine (QIV)|Intramuscular injection
45777484|NCT05227001|Biological|PF-07871987 Influenza saRNA|Intramuscular injection
45777485|NCT05227001|Biological|PF-07914705 Influenza saRNA|Intramuscular injection
45777486|NCT05227001|Biological|PF-07915048 Influenza saRNA|Intramuscular injection
45777487|NCT05226871|Drug|Palbociclib|oral
45777488|NCT05226871|Drug|Cetuximab|Intravenous (IV) infusion
45777489|NCT05226871|Drug|Fulvestrant|Intramuscular (IM)
45777490|NCT05226871|Drug|Letrozole|oral
45777491|NCT05221398|Drug|Immune Checkpoint Inhibitors Based Adjuvant therapy|Patients in this group will recieve immune checkpoint inhibitors based adjuvant therapy
45777492|NCT05213221|Drug|Envafolimab|300mg, subcutaneous injection, q3w
45777493|NCT05213221|Procedure|TACE|The first TACE will be started on d1, and the subsequent TACE will be performed on demand.
45915779|NCT05042908|Drug|LBL-003Injection|LBL-003 was given every two weeks for treatment
45915780|NCT05025241|Drug|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
45915781|NCT05018728|Drug|Voxelotor|Voxelotor is taken orally once a day. Participants 12 years or older will take 1500 mg/day. Participants younger than 12 years of age will receive a dose based on their body weight to provide exposure corresponding to the adult dose of 1500 mg/day.
45915782|NCT00006450|Drug|Phenylbutyrate|
45915783|NCT05000515|Other|High-resistance inspiratory muscle strength training|Participants will perform inspiratory muscle strength training.
45639555|NCT03160339|Biological|Teva Ad4/Ad7 Vaccine|Teva Ad4/Ad7 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in Teva Ad4/Ad7 are unattenuated strains propagated in WI-38 human diploid fibroblast cells.
45639556|NCT03094091|Other|News items with spin|Interpretation of news items with spin
45777494|NCT05213221|Drug|Lenvatinib|8mg,QD (body weight <60kg); 12mg, QD (body weight ≥ 60kg)
45777495|NCT05213208|Drug|Propofol|Using > 200 mg of propofol sedation colonoscopy is performed. After colonoscopy subjects go home. Within 1day patients will be asked about their condition and satisfaction for colonoscopy.
45777496|NCT05212337|Drug|Denosumab|Subcutaneous injection with 60 mg Denosumab once
45777497|NCT05212337|Drug|Sodium chloride|Subcutaneous injection with NaCl once
45777498|NCT05212168|Biological|VXA-G1.1-NN|Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant
45777499|NCT05212168|Other|Placebo Tablets|Oral tablets similar in appearance and number to active vaccine tablets
45777500|NCT05212168|Biological|Norovirus GI.1 Norwalk Virus Inoculum|Norwalk Virus Inoculum Lot 01-09NV
45777501|NCT05201469|Drug|VIB4920|Participants will receive 1500 mg of VIB4920 at Weeks 10, 12, 14, 18, 22, 26, 30, and 34, while continuing on MMF and prednisone
45777502|NCT05201469|Drug|Placebo for VIB4920|Participants will receive placebo for VIB4920 at Weeks 10, 12, 14, 18, 22, 26, 30, and 34, while continuing on MMF and prednisone
45777503|NCT05198349|Drug|M1069|Participants will receive escalated oral dose of M1069, twice daily (BID) until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from study intervention.
45777504|NCT05192382|Drug|Paltusotine|Paltusotine, tablets, once daily by mouth
45777505|NCT05192382|Drug|Placebo|Placebo, tablets, once daily by mouth
45777506|NCT05189223|Behavioral|Brief, values based intervention for early buprenorphine treatment|The initial intervention structure consists of four weekly sessions. Session one focuses on values clarification using an empirically validated clinical exercise. The second session will include a discussion of the connection between values, addiction treatment engagement, and the challenges associated with discomfort (i.e., withdrawal and cravings) in early treatment. The third session will focus on barriers and goal setting to enhance self-efficacy for committed action. The final session will review progress made and focus on the Veterans' recovery plan moving forward. The initial study intervention will be refined iteratively using Phase 1 stakeholder and Phase 2 open trial participant feedback.
45915784|NCT05000515|Other|Aerobic exercise|Participants will perform brisk walking.
45915785|NCT00006453|Drug|carboplatin|
45448508|NCT03669081|Drug|Placebo oral capsule|Placebo oral capsule was administered orally 30 minutes prior to operation.
45448509|NCT03669081|Drug|Saline|Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.
45915786|NCT00006453|Drug|gemcitabine hydrochloride|
45915787|NCT04986202|Drug|AZD4831|AZD4831
45915788|NCT04986202|Other|Placebo|Placebo
45915789|NCT00006456|Radiation|stereotactic radiosurgery|
45448510|NCT05266612|Drug|VG2025|"1.0×108PFU Day 1 and 15~2.0×108PFU Day 1 and 15~3.0×108PFU Day 1 and 15~4.0×108PFU Day 1 and 15"
45915790|NCT00387283|Drug|AVI-4020 Injection|
45915791|NCT00387322|Drug|erlotinib hydrochloride|Given orally
45448511|NCT05264350|Device|Sialic acid nasal spray|The nasal spray will be self administered twice daily for 8 weeks.
45448512|NCT05264350|Device|Isotonic Saline Nasal Spray|The nasal spray will be self administered twice daily for 8 weeks.
45448513|NCT03734913|Drug|ZSP1602|ZSP1602 capsules for oral administration
45639557|NCT03094091|Other|News items without spin|Interpretation of news items without spin
45639558|NCT02351791|Other|Patch 1, Center|
45639559|NCT02351791|Other|Patch 1, Leakage pocket|
45639560|NCT02351791|Other|Patch 1, Adhesive|
45639561|NCT02351791|Other|Patch 2, Center|
45639562|NCT02351791|Other|Patch 2, Leakage pocket|
45639563|NCT02351791|Other|Patch 2, Adhesive|
45639564|NCT02351791|Other|Patch 3, Center|
45639565|NCT02351791|Other|Patch 3, Leakage pocket|
45639566|NCT02351791|Other|Patch 3, Adhesive|
45639567|NCT02351791|Other|Patch 4, Center|
45639568|NCT02351791|Other|Patch 4, Leakage pocket|
45639569|NCT02351791|Other|Patch 4, Adhesive|
45639570|NCT02351791|Other|Patch 5, Center|
45639571|NCT02351791|Other|Patch 5, Leakage pocket|
45639572|NCT02351791|Other|Patch 5, Adhesive|
45639573|NCT02351791|Other|Patch 6, Center|
45639574|NCT02351791|Other|Patch 6, Leakage pocket|
45639575|NCT02351791|Other|Patch 6, Adhesive|
45639576|NCT05025839|Other|No Intervention|No Intervention takes place, Patients are being observed and classified according to disease severity
45777507|NCT05189223|Behavioral|Treatment as Usual|Veterans will be recruited from an intensive treatment phase where all Veterans receive case management and regular group therapy in addition to appointments with their buprenorphine prescriber. After the first two weeks, they have the option to continue with a less intensive group schedule and case management support through an Aftercare program.
45777508|NCT05186753|Drug|Bezuclastinib Tablets (Formulation A)|Bezuclastinib will be administered orally, once daily continuously for 28-day cycles
45777509|NCT05186753|Drug|Bezuclastinib Tablets (Formulation B)|Bezuclastinib will be administered orally, once daily continuously for 28-day cycles
45777510|NCT05186753|Drug|Placebo Tablets|Placebo will be administered orally, once daily continuously for 28-day cycles
45777511|NCT05181540|Biological|AB-205|Allogeneic genetically engineered human umbilical vein endothelial cells
45777512|NCT05181540|Other|Placebo|Placebo
45915792|NCT00387322|Drug|pemetrexed disodium|Given IV
45915793|NCT00387361|Procedure|Osteopathic Manipulative Treatment|20 minute post-operative osteopathic manipulation as described in the protocol
45915794|NCT00006459|Drug|gemcitabine hydrochloride|
45915795|NCT00006459|Drug|paclitaxel|
45915796|NCT02972437|Other|sample taking|throat culture and oral cavity sample
45915797|NCT00387400|Drug|everolimus|150 mg/m2/day PO Daily x 5, q 4 weeks
45915798|NCT00387400|Drug|temozolomide|2.5 mg PO Daily, beginning day 2 of cycle 1, q 4 weeks
45639577|NCT05034887|Drug|Trastuzumab Deruxtecan (T-DXd)|T-DXd will be administered at a dose of 6.4 mg/kg (decimal) by intravenous infusion every 21 days (3 weeks) for subsequent three cycles.
45639578|NCT05035121|Dietary Supplement|milk supplement|Intervention groups provided 200 mL long life milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
45639579|NCT05035121|Dietary Supplement|soy milk supplement|Intervention groups provided 200 mL long life soy milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
45639580|NCT05035121|Behavioral|resistance exercise|The participants joined the resistance exercise training program, three times per week (30 min/time)
45777513|NCT05181228|Behavioral|Web-Based Education Based on Family-Centered Empowerment Model|Parents in the intervention group will receive care for ten weeks using the family-centered empowerment model (FCEM). The first step (two weeks) is to increase knowledge. For this purpose, they will receive web-based training on cancer. The second step (four weeks) is to develop parents' self-efficacy and problem-solving skills. A web-based training and group meeting will be held to share information and experiences on the evaluation and control of the side effects of the treatment and to increase their self-efficacy in care. The third step (three week) was to increase self-esteem through participation in the training. At this stage, each participant will be asked to teach one of the family members responsible for the child's care what they have learned in the last two sessions. In the fourth step (one week), all participants in the intervention group will be evaluated by asking questions about the topics discussed in the second and third sessions and the overall content taught.
45777514|NCT05177536|Drug|Iberdomide|Iberdomide is a novel potent cereblon E3 ligase modulator
45777515|NCT05166889|Drug|Tozorakimab|Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.
45777516|NCT05166889|Drug|Tozorakimab|Administered subcutaneously tozorakimab Dose 2 through Week 52.
45777517|NCT05166889|Drug|Placebo|Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
45777518|NCT05165927|Device|BFR|BFR cuffs will be used at home during specified exercises in addition to SOC for post hip scope PT.
45777519|NCT05162404|Behavioral|Video Education Program|"The following topics are addressed in each module of the videos:~Understanding cancer and cancer treatment - including an understanding of stage, site of origin, metastases, treatment options, toxicities and anticipated outcomes.~Care coordination basics (CC: Communication) - including navigating care related to appointments, how to handle issues after-hours, and the expected roles of other healthcare providers (e.g., PCPs).~How to be a self-advocate (CC: Navigation and Operational) - including how to ask questions, being empowered to talk to your doctor, when a second opinion is needed, when to explore clinical trials, and how to best incorporate a caregiver into your treatment."
45777520|NCT05161481|Drug|BI 685509|BI 685509
45777521|NCT05161481|Drug|Placebo matching BI 685509|Placebo matching BI 685509
45777522|NCT05158387|Drug|Tozorakimab|Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.
45777523|NCT05158387|Drug|Tozorakimab|Administered subcutaneously tozorakimab Dose 2 through Week 52.
45777524|NCT05158387|Drug|Placebo|Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
45777525|NCT05157178|Biological|Covid-19 (recombinante) vaccine|Administration of the Covid-19 (recombinante) vaccine
45777526|NCT05155332|Drug|BI 1831169|BI 1831169; Intratumoral (i.t.) and/or Intravenous (i.v.)
45777527|NCT05155332|Drug|ezabenlimab|ezabenlimab; Intravenous (i.v.)
45777528|NCT05151653|Drug|BI 765250|BI 765250
45777529|NCT05151653|Drug|Placebo|Placebo
45777530|NCT05145062|Drug|BIVV003|Solution for intravenous administration
45639581|NCT05034653|Other|Intermittent Fasting|During fasting day, no food or drink allowed from dawn to dusk
45639582|NCT05034653|Other|Healthy Plate|Quarter-quarter-half meal concept
45639583|NCT02357017|Dietary Supplement|NaCl tablets|
45639584|NCT05025917|Dietary Supplement|Shatavari|Shatavari root powder
45639585|NCT05025917|Dietary Supplement|Magnesium stearate|Magnesium stearate powder
45639586|NCT02039011|Drug|Indacaterol|Participants receive indacaterol for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
45639587|NCT02039011|Drug|Indacaterol and tiotropium|Participants receive indacaterol and tiotropium for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
45639588|NCT04449055|Device|Transcranial Magnetic Stimulation|Participants will undergo 16 treatments consisting of intermittent theta burst stimulation targeting the dorsolateral prefrontal cortex and continuous theta burst stimulation targeting the medial prefrontal cortex, over a 4-week period that coincides with psychosocial treatment for methamphetamine use disorder.
45639589|NCT05025215|Behavioral|Precise Aerosol Inhalation Nursing Program|The precise aerosol inhalation nursing program was based on the traditional oxygen aerosol inhalation treatment, including precise body position care, time control, observation and treatment, evaluation, etc.
45639590|NCT05025215|Behavioral|Traditional Aerosol Inhalation Nursing Method|The traditional aerosol inhalation nursing method is carried out according to the operation of aerosol inhalation.
45639591|NCT02361385|Other|this is not an interventional study|this is not an interventional study; this is a pilot feasibility study to see whether or not 11CPR28 will be taken up in joints of those known to have active arthritis clinically
45639592|NCT03093857|Diagnostic Test|Determination of biomarker|Liquor, blood, and urine samples will be drawn and measured at different time points.
45639593|NCT02356627|Other|The Cancer Home Life Intervention|Adaptive interventions aiming at compensating for functional limitations.
45777531|NCT05145062|Drug|ST-400|Solution for intravenous administration
45777532|NCT05136053|Drug|Lu AG22515|sterile solution for infusion
45777533|NCT05136053|Drug|Placebo|sterile solution for infusion
45777534|NCT05136053|Drug|Immune System Activator|sterile powder for injection
45639594|NCT05025137|Other|Flexi-Bar Exercise|"In the experimental group, the Flexi-Bar was adopted as the tool for active vibration exercises. Featuring light weight and ease of operation, it weighs only 460 grams and has a vibration frequency of 4-5 Hz. With diversified functions, the Flexi-Bar can improve posture, burn fat, strengthen connective tissue, enhance body shape, and increase muscle strength.~The 12-week Flexi-Bar exercise course in this study was created by two assistant professors specializing in rehabilitation (one with an occupational therapy certificate and the other with a physical therapy certificate). The course, composed of one 60-minute class per week for a total of 12 weeks, progressed gradually from basic activities (e.g., standing with both feet) to advanced activities (e.g., standing with one foot)."
45639595|NCT05025137|Other|Multi-Component exercise|Alternatively, in the control group, the Multi-Component exercise was adopted, which included aerobic, resistance, flexibility, and balance exercises. The course was composed of one 60-minute class per week for a total of 12 weeks. The design was based on the ACSM's recommendations for the multiple-component exercise of the elderly (Chodzko-Zajko et al., 2009) and videos of the National Health Exercises for the Elderly formulated by the Ministry of Health and Welfare (Ministry of Health and Welfare, 2017). The course was created and led by a physical therapist to gradually progress from sitting postures to standing and walking postures. Additionally, the intensity of the exercises was adjusted according to the participants' physical conditions; fitness equipment was introduced when appropriate.
45639596|NCT02351479|Behavioral|Hula|
45639597|NCT05024669|Combination Product|Gluma desensitiser|Gluma desensitiser was used before restoration.
45639598|NCT05024669|Combination Product|Sheildforce Plus desensitiser|Sheildforce Plus desensitiser was used before restoration.
45639599|NCT05024669|Combination Product|Telio CS desensitiser|Telio CS desensitiser was used before restoration.
45639600|NCT02039167|Device|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
45639601|NCT05024825|Drug|Gabapentin|Patients in the gabapentin arm may at any point call the Pediatric ENT clinic if pain is not adequately controlled. Patients will be prescribed hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14 yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain. Patients will be informed to stop taking gabapentin.
45639602|NCT05024825|Drug|hydrocodone, acetaminophen and ibuprofen|Patients in the hydrocodone group will receive scheduled doses of hydrocodone, acetaminophen and ibuprofen at scheduled doses. Acetaminophen 15mg/kg (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain.
45639603|NCT02361151|Behavioral|TECH|Weekly newsletter with health information, mobile apps, and self-monitoring materials
45639604|NCT02361151|Behavioral|TECH+|Weekly newsletter with health information, mobile apps, and self-monitoring materials along with theory-based mobile web intervention
45915799|NCT00387400|Genetic|microarray analysis|Tissue sections will be stained by immunohisto-chemistry using the following antibodies: EGFRvIII, PTEN, phospho-specific PKB/Akt Ser473; phosphor-mTORSer2448, p70S6K Thr389; S6 ribosomal protein Ser235/236. These antibodies are selected on the basis of providing a readout of upstream and downstream signaling through mTOR, and availability of antibodies that reliably stain paraffinembedded tissue.
45639605|NCT05033795|Dietary Supplement|Water A|2 L of water A per day
45639606|NCT05033795|Dietary Supplement|Water B|2 L of water B per day
45639607|NCT03149965|Other|transperineal ultrasound|transperineal ultrasound was used by placing a vaginal ultrasound probe towards the vaginal distal wall pointing to the anus, measuring the anovaginal distance.
45915800|NCT00387400|Other|immunohistochemistry staining method|Tissue sections will be stained by immunohisto-chemistry using the following antibodies: EGFRvIII, PTEN, phospho-specific PKB/Akt Ser473; phosphor-mTORSer2448, p70S6K Thr389; S6 ribosomal protein Ser235/236. These antibodies are selected on the basis of providing a readout of upstream and downstream signaling through mTOR, and availability of antibodies that reliably stain paraffinembedded tissue.
45915801|NCT03923296|Device|Blood measurement and monitoring|Blood from a single fingerprick will be used to used to measure and monitor patients blood parameters.
45639608|NCT05024591|Device|Lunit INSIGHT MMG CADe/x for medical imaging|• A software that detects areas suspected of breast cancer using mammographic images, marks areas suspected of malignant lesions, and displays the probability of malignant lesions to assist with the interpreting physician's diagnosis
45639609|NCT02356549|Behavioral|EMR Tailoring|Electronic Medical Records (EMR) data alone will be entered into the Michigan Tailoring System (MTS system) and their brochures will be prepared.
45639610|NCT02356549|Behavioral|Survey Tailoring|Survey that will use standardized, psycho-metrically sound measures to gather information about patients, including their levels of trust in medical research and preferences for information and decision involvement. The survey augmented by their EMR data will be used to develop a level of tailored messages.
45639611|NCT02356549|Behavioral|Physician Involvement|Prior to the consultation, physicians of patients will receive a summary of patients' tailored message brochure from the Research Assistant (RA) and included in the patient's notes. At the conclusion of the consultation, the RA will ask the oncologist whether or not a clinical trial was discussed and whether or not they read the patients brochure.
45915802|NCT03923296|Behavioral|Interviews|Focus group interviews
45777535|NCT05135351|Dietary Supplement|Resistant Starch|A prebiotic nutritional supplement available at commercial grocery and health food stores. Specifically, we will be using Bob's Red Mill® potato starch.
45777536|NCT05135351|Dietary Supplement|Maltodextrin|A starch commonly used as a placebo in prebiotic trials that is digested in the stomach and rapidly absorbed
45777537|NCT05131425|Behavioral|Facing Your Fears: ASD/ID|This cognitive behavioral therapy, entitled Facing Your Fears for Adolescents with Autism and Intellectual Disability, is focused on somatic management, helpful cognitive mantras, emotion regulation, and graduated exposure adapted for the cognitive and linguistic needs of an Intellectual Disability population.
45777538|NCT05131425|Other|Treatment as Usual|The treatment as usual condition is being used in this study as a control condition. The investigators will track what medication and intervention services families are currently receiving.
45777539|NCT05123040|Drug|Ruxolitinib 10 MG Oral Tablet|By mouth twice daily through day 56, then tapered
45639612|NCT05024435|Device|Surfactant Administration|Laryngoscopy, intratracheal catheter placement and surfactant administration
45777540|NCT05123040|Drug|hCG|2,000 units/m2 SQ every other day x 3 doses, followed by twice weekly x 14 doses
45777541|NCT05123040|Drug|Corticosteroids|"Dose level 1 (starting dose) = 1 mg/kg~Dose level 2 = 0.5 mg/kg~Dose level 3 = 0.25 mg/kg~Dose level 4 = 0.1 mg/kg~Dose level 5 = 0 mg/kg~• If dose level 1 is determined to be below the Recommended Phase 2 Dose (RP2D), the dose will be escalated:~Dose level -1 = 1.5 mg/kg~Dose level -2 = 2 mg/kg"
45777542|NCT05113069|Drug|SHR-A1912|SHR-A1912, dose escalation and expansion.
45777543|NCT05106569|Diagnostic Test|Spirometry|All study participants will undergo pulmonary function testing using conventional spirometry in clinic and portable spirometry in clinic and at home. In-clinic conventional laboratory spirometry is compared with portable spirometry and Slow vital capacity is obtained in upright and supine positions.
45777544|NCT05096754|Device|OCS Liver|Transplant with an OCS preserved liver.
45777545|NCT05096702|Drug|Tafenoquine|Tafenoquine 300 mg (2x150mg tablets)
45639613|NCT02360917|Other|Emerging from the Haze|A 6 week psycho-educational class
45639614|NCT03093467|Behavioral|ASCENSO|Internet-based program: an adjunct support and monitoring system for the treatment of depression.
45639615|NCT03093467|Drug|Antidepressants or in combination with anxiolytics, neuroleptics or mood stabilizers.|Usual psychiatric treatment which may include drugs: antidepressant monotherapy or antidepressants in combination with anxiolytics, neuroleptics or mood stabilizers as needed, according to the psychiatric evaluation. Monthly controls during 5 months in average.
45639616|NCT03093467|Behavioral|Psychotherapy|Usual treatment: brief psychotherapy. One session per week, a total of 9 sessions in average.
45639617|NCT02356237|Other|No episiotomy|Avoidance of episiotomy
45639618|NCT03095261|Behavioral|Web-based exercise diary|All participants will have access to a web-based exercise tracking tool called ExTracker. Individuals will be asked to submit their exercise diaries daily for 52 weeks, using the ExTracker program. Upon entering exercise information, participants will receive individual (e.g., You've completed 50% of your exercise sessions this week!) and group-level (e.g., You and the other people in this study are walking across Canada! Next stop - Toronto!) feedback. Should participants cease to use the platform for one week, they will receive an email reminder to re-engage with the platform. Three such emails will be sent to lapsing participants.
45777546|NCT05096702|Drug|Primaquine|Daily primaquine adjusted by weight (0.5 mg/kg/day for 7 days)
45777547|NCT05096702|Drug|Primaquine|Weekly primaquine adjusted by weight (0.75mg/kg/week for 8 weeks)
45777548|NCT05081128|Device|programmable CSF shunt valve|Brain shunt surgery using a programmable CSF shunt valve
45777549|NCT05075824|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 kg and 100 kg) or 1500 mg IV (for participants with body weight >= 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, crovalimab will be administered at a dose of 680 mg SC (for participants with body weight between 40 kg and 100 kg) or 1020 mg SC (for participants with body weight >= 100 kg). Dosing schedule will be as per Arm Description.
45777550|NCT05075824|Drug|Placebo|Matching Placebo will be administered with the same dosing schedule and equivalent IV and SC volume as weight-based Crovalimab.
45777551|NCT05070533|Behavioral|Individual treatment|Participants will receive 7 home visits to implement the program.
45777552|NCT05070533|Behavioral|Groupal treatment|Subjects will participate in groups of about 8 - 12 to implement the program.
45915803|NCT03918343|Other|Blood sample|blood samples (4 times; 14ml per visit)
45639619|NCT03095261|Device|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, and track the steps per day and bout minutes of MVPA per day measured by the device. Additionally, participants will be mailed an accelerometer (and asked to return their used ones) at study weeks 26 and 52 in order for the researcher to confirm the data inputted into the ExTracker from the device.
45639620|NCT03095261|Behavioral|Virtual Reward|"Participants will earn 'virtual rewards' (i.e. a heart badge) each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'financial incentive' therapy, for six months."
45639621|NCT03095261|Behavioral|Financial Incentive|"Participants will earn financial incentives each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'virtual rewards' therapy, for six months."
45777553|NCT05068102|Drug|BI 765063|BI 765063
45777554|NCT05068102|Drug|Ezabenlimab|Ezabenlimab
45777555|NCT05068102|Drug|[89Zr]Zr- BI 765063|[89Zr]Zr- BI 765063, specifically radiolabelled for immune-Positron Emission Tomography (PET)
45777556|NCT05068102|Drug|BI 770371|BI 770371
45777557|NCT05068102|Drug|[89Zr]Zr- BI 770371|[89Zr]Zr- BI 770371, specifically radiolabelled for immune-PET
45915804|NCT00387972|Drug|denagliptin (GW823093)|
45777558|NCT05067543|Device|Tornier Perform Humeral - Stem|The PERFORM Humeral System - Stem is a non-constrained prosthesis intended for the total or partial replacement of the glenohumeral articulation.
45777559|NCT05066724|Drug|Centanafadine|400 mg total daily dose Centanafadine Sustained Release, oral tablets
45777560|NCT05048667|Device|Shock Wave therapy (SWT)|Each SWT will administer 720 shocks in the treatment arm. Total of 3600 shocks are given over 5 weeks treatment period.
45777561|NCT05048667|Drug|Platelet Rich Plasma (PRP)|5 mL PRP will be administered via intracavernous injection
45777562|NCT05048667|Other|Sham SWT|Sham Shockwave Therapy will be administered in the sham arm.
45777563|NCT05048667|Other|Placebo Saline|5 mL Placebo saline will be administered via intracavernous injection in the sham arm.
45777564|NCT05043103|Combination Product|Lecigon® based on European Medicines Agency (EMA) SmPC|There might be different brand names in other countries
45777565|NCT05041855|Behavioral|The Healthy Living Program/La Vida Saludable|A whole-family group childhood obesity intervention delivered at community recreation centers
45777566|NCT05041855|Behavioral|Recommended Treatment of Obesity in Primary Care|A healthy lifestyle counseling protocol that enhances usual primary care
45777567|NCT05040204|Dietary Supplement|Monosaccharide Powder|Monosaccharide powder dissolved in water.
45915805|NCT03906604|Procedure|Carpal Tunnel Procedure (open)|Patients with bilateral CTS will have one side released with incisionless thread carpal tunnel release and the contralateral side released with the mini-open carpal tunnel release.
45777568|NCT05040204|Dietary Supplement|Placebo Comparator|Placebo (glucose powder)
45777569|NCT05039840|Drug|SAR441344 IV|Pharmaceutical form: solution Route of administration: Intravenous infusion
45639622|NCT03149653|Drug|ClinOleic (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
45639623|NCT03149653|Drug|ClinOleic + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
45777570|NCT05039840|Drug|SAR441344 SC|Pharmaceutical form: solution Route of administration: subcutaneous injection
45777571|NCT05039840|Drug|Placebo IV|Pharmaceutical form: solution Route of administration: Intravenous infusion
45777572|NCT05039840|Drug|Placebo SC|Pharmaceutical form: solution Route of administration: subcutaneous injection
45639624|NCT03149653|Drug|Lipoplus (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
45639625|NCT03149653|Drug|Lipoplus + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
45639626|NCT03149653|Drug|SMOFlipid (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
45639627|NCT03149653|Drug|SMOFlipid + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
45777573|NCT05029284|Behavioral|teleABLE|Participants will be guided to self-monitor their daily activities, schedule personally meaningful non-sedentary activities, collaboratively problem solve to overcome barriers to the activity, and self-assess their progress. Participants may be asked to self-monitor their activity levels and complete planned activities between sessions.
45777574|NCT05027802|Drug|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day.
45639628|NCT03093545|Biological|Equine Rabies Immunoglobulin|40 IU per kg of body weight of ERIG at Day 0
45639629|NCT03093545|Biological|Purified chick-embryo cell rabies vaccine|1 ml of PCEC Rabies vaccine on days 0, 3, 7, 14 and 28.
45639630|NCT02351401|Behavioral|Education using ultrasonography as feedback tool|Education using ultrasonography as feedback tool
45777575|NCT05017454|Drug|the optimized sodium valproate-loaded nanospanlastic dispersion|participants will apply the optimized sodium valproate-loaded nanospanlastic dispersion twice daily, on the affected areas of the scalp for 3 months
45777576|NCT05017454|Drug|mometasone furoate lotion|participants will apply marketed mometasone furoate lotion twice daily on the affected areas of the scalp for 3 months
45915806|NCT03876106|Drug|LUT014|Topical
45915807|NCT00388011|Drug|Intranasal Morphine (MNS075) 3.75 mg|Intranasal Morphine (MNS075) 3.75 mg
45639631|NCT03093623|Behavioral|Physical activity|In physical activity experimental group, trained study nurses will interview with patients,give health education,teach how to use and record the Activity meter.Professionals will calculate Metabolic Equivalent of Task(MET) with formula weekly.MET = (intensity level 9 points * time of each exercise (hours) * Number of times per week + moderate level 5 points * time per activity (hours) * number of times per week + low level 3 points * time per activity (hours) * number of times per week),investigators hope patients in the first month MET can reach (3.75-7.49 MET-h/ week), and reach moderate or more than moderate activity (>= 7.5-16.49 MET-h/ week) at the starting of second month for at least one year.
45639632|NCT02360761|Procedure|VATS|Patients undergo lobectomy,wedge resection, or anatomical segmentectomy by thoracoscopic surgery or video assisted thoracoscopic surgery.
45777577|NCT05013424|Drug|OnabotulinumtoxinA|Intramuscular Injection
45777578|NCT05009381|Device|Stylage XXL at enrollment|Injection in the chin at enrollment
45777579|NCT05009381|Device|Stylage XXL at Month 6|Injection in the chin 6 months after randomization
45777580|NCT05001737|Drug|Emapalumab|Emapalumab iv infusion
45777581|NCT04999215|Drug|F-choline intravenous injection|Participants will receive one injection of F-choline before undergoing hybrid PET/CT imaging per standard procedures. F-choline PET examinations may be repeated, if this judged to be in the patient's best interest by his referring physician and the study staff, up to a maximum 4 examinations per year.
45777582|NCT04997265|Other|Low intensity anticoagulation|Participants assigned to the low intensity anticoagulation strategy will receive anticoagulation at doses used for DVT prophylaxis in critically ill patients. The choice of agent (e.g. heparin or enoxaparin) and specific dosing will be at the discretion of the treating clinicians and will be prospectively recorded.
45915808|NCT00388011|Drug|Intravenous Morphine 7.5 mg|Intravenous Morphine 7.5 mg
45915809|NCT00388011|Drug|Intranasal morphine (MNS075) 7.5 mg|Intranasal morphine (MNS075) 7.5 mg
45915810|NCT00388011|Drug|Intranasal morphine (MNS075) 15 mg|Intranasal morphine (MNS075) 15 mg
45777583|NCT04997265|Other|Moderate Intensity Anticoagulation|"Patients assigned to the moderate intensity anticoagulation strategy will receive anticoagulation targeting a PTT goal of 40-60 seconds or anti-Xa level of 0.2 to 0.3 IU/mL. Choice of anticoagulant and monitoring strategy (PTT or anti-Xa level) will be at the discretion of the treating clinicians and will be prospectively recorded. Anticoagulant drips will be titrated according to institutional protocols. For patients who survive to decannulation, the infusion will be stopped one hour prior to decannulation.~This approach to anticoagulation reflects the current approach for patients receiving V-V ECMO at Vanderbilt University Medical Center and is similar to protocols widely adopted for patients receiving V-V ECMO at other centers."
45777584|NCT04991467|Behavioral|CARE Program and Valera Application with care manager functionality|Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials as well as the ability to connect to their child's treatment team via care manager.
45639633|NCT02360761|Procedure|Thoracotomy|Patients undergo lobectomy, wedge resection, or anatomic segmentectomy by thoracotomy.
45639634|NCT05024357|Drug|Dasatinib|Take Dasatinib orally for 1 year or 6 months post-HSCT.
45639635|NCT03095183|Device|Grape flavored Puritan Junior tongue depressor|
45639636|NCT03095183|Device|Traditional unflavored Puritan Regular Tongue Depressor|
45777585|NCT04991467|Behavioral|Valera Application with care manager functionality|Participant will receive the Valera health application which will provide parent education materials and the ability to connect to their child's treatment team via care manger.
45777586|NCT04991467|Behavioral|CARE Program|Participant will take part in 12 week CARE program.
45777587|NCT04991467|Behavioral|Valera Application|Participant will receive the Valera health application which will provide parent education materials.
45777588|NCT04991467|Behavioral|CARE Program and Valera Application|Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials.
45777589|NCT04991025|Drug|Cisplatin|Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle. Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.
45777590|NCT04991025|Drug|Pemetrexed|Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle
45777591|NCT04991025|Drug|Gemcitabine|Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.
45777592|NCT04991025|Drug|Carboplatin|Participants not eligible for cisplatin (per treating physician discretion) may receive carboplatin at AUC = 5 instead of cisplatin.
45777593|NCT04991025|Drug|Certolizumab|Certolizumab 400mg subq will be administered in clinic within 1 hour before the start of chemotherapy on day 1 of a 21 day cycle.
45915811|NCT00388011|Drug|Intranasal morphine (MNS075) 30 mg|Intranasal morphine (MNS075) 30 mg
45915812|NCT00388011|Drug|Intranasal placebo|Intranasal placebo
45915813|NCT04961242|Device|Together for Wellness digital mental health website|The intervention is a digital mental health resources website that includes multiple, free resources for broad public use. Different categories of resources include information on COVID-19 from CDC, multi-language versions of the UCLA Mindfulness App and other meditation programs, resources for families and social connection, including addressing discrimination or equity, and resource links.
45639637|NCT02356315|Other|Functional Magnetic Resonance Imaging|Functional magnetic resonance imaging will be performed to measure brain, brainstem, and spinal cord activity.
45639638|NCT03095339|Other|Educational package|The educational package was offered to 30 villages post randomization. The field team completed the SARAR PHAST with community members for 2-3 days in each intervention village. The movie was projected every night for 2-3 days in each intervention village.
45639639|NCT03149731|Device|NIRS|The recent technological advancement of tissue NIRS enables continuous, real time and bedside monitoring of hemoglobin oxygen saturation in mixed arterial, venous, and primarily capillary blood in the tissue bed being probed.
45639640|NCT03095105|Drug|200 mg BIA 6-512|capsules containing BIA 6-512 200 mg was administered orally, with 240 mL of mineral water without gas at room tempera¬ture
45639641|NCT02351323|Drug|Glutamine (Pharmacological doses)|30 grams/day of glutamine for 12-14 months
45777594|NCT04991025|Drug|Nivolumab|Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 + nivolumab 360mg intravenously on day 1 of a 21 day cycle Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of 21 day cycle + nivolumab 360mg IV on day 1 of 21 day cycle.
45777595|NCT04989686|Other|Microsampling|Volumetric absorptive microsampling (VAMS) with Tasso-M20 devices allows for the accurate and precise collection of a fixed small volume of blood from a capillary needle without the need for phlebotomy.
45777596|NCT04985487|Other|brolucizumab|Prospective observational study. There is no treatment allocation. Patients administered brolucizumab, that have started before inclusion of the patient into the study will be enrolled.
45915814|NCT04918381|Device|CellFX System|Nano-Pulse Stimulation (NPS)
45915815|NCT00388050|Behavioral|Diabetes Medication Choice decision aid|The decision aid covers five commonly prescribed anti-hyperglycemic medications and their attributes.
45915816|NCT00388050|Behavioral|Usual Care|Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.
45639642|NCT02351323|Behavioral|Lifestyle change|Lifestyle change as recommended by Registered Dietitian
45777597|NCT04979130|Drug|Semaglutide|Semaglutide 1.34 mg/mL solution for injection in 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.
45777598|NCT04979130|Drug|Placebo|Semaglutide placebo, solution for injection, 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.
45777599|NCT04978506|Drug|BI 1569912|BI 1569912
45777600|NCT04978506|Drug|Placebo|Placebo
45777601|NCT04973163|Drug|BI 1823911|BI 1823911
45777602|NCT04973163|Drug|BI 1701963|BI 1701963
45915817|NCT04852978|Drug|casirivimab+imdevimab|Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration
45915818|NCT04852978|Biological|Moderna mRNA-1273 vaccine|Single intramuscular (IM) injection
45915819|NCT04849975|Other|Pelvimetric measurements|The patients in this group are pregnant women after failure of external manual version (EMV) in case of breech fetal presentation. The participants will successively perform MRI pelvimetry (conventional management) and EOS imaging.
45915820|NCT00388089|Drug|bortezomib|Dose level A: 1 mg/m2; Dose level B: 1.3 mg/m2; Dose level C: 1.6 mg/m2; Dose level D: 1.6 mg/m2
45639643|NCT05024123|Dietary Supplement|Placebo|"Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 ~ 180 min to measure 1) nitrate and 2) cGMP content."
45639644|NCT05024123|Dietary Supplement|AstraGin|"Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 ~ 180 min to measure 1) nitrate and 2) cGMP content."
45639645|NCT02360449|Behavioral|Social Initiation Motivation Intervention|The SIMI approach under investigation uses behavioral strategies based in Applied Behavior Analysis and Pivotal Response Treatment to motivate children with ASD to initiate to peers. The adult arranges the play environment in order to promote cooperation and facilitates frequent prompting and reinforcement from peers, thereby enhancing the reward value of peer interactions.
45915821|NCT00388089|Drug|topotecan hydrochloride|Dose level A: 3 mg/m2; Dose level B: 3 mg/m2; Dose level C: 3 mg/m2; Dose level D: 4 mg/m2
45639646|NCT05033951|Other|Standard care|Both groups: standard care+ questionnaires
45639647|NCT01968070|Drug|LY3127760|Administered orally
45639648|NCT01968070|Drug|Celecoxib|Administered orally
45639649|NCT01968070|Drug|Placebo|Administered orally
45448514|NCT03547492|Behavioral|Teaching Talking|Written packet including 8 lessons: What's My Corrected Age, Watch Me Learn (language milestones in the 1st year of life), Reading Aloud, Sing-a-long: Sleepy Songs, Sing-a-long: Alert Songs, Copying First Sounds, Playing Games, Talk to Your Baby.
45448515|NCT03547492|Behavioral|LENA recordings-language|LENA a special recording device. It records for 16 hours inside a specially designed infant vest. The recording is analyzed by a computer that generates an output of total number of adult words, infant vocalizations and conversational turns during the recording period. 4 LENA recordings are obtained: baseline, after reviewing Teaching Talking and linguistic feedback of first recording, 4 and 12 months of age. Participants are mailed feedback of their 2nd, 4 and 12 month recordings.
45448516|NCT03547492|Behavioral|LENA recordings-motor|LENA a special recording device. It records for 16 hours inside a specially designed infant vest. The recording is analyzed by a computer that generates an output of total number of adult words, infant vocalizations and conversational turns during the recording period. 4 LENA recordings are obtained: baseline, 2nd, 4 and 12 months of age. Participants are mailed feedback on recordings after completing study.
45448517|NCT03547492|Behavioral|Mastering Movement|A written curriculum containing 5 lessons adopted from Beautiful Beginnings: What's My Corrected Age, Watch Me Move! (review of motor milestones in 1st year), Gentle Stretching and Exercise, Tummy Time, Help Me Learn to...
45448518|NCT03547492|Behavioral|Language text messages|12 weekly text messages. Each is 1-2 sentences to review concepts of Teaching Talking
45639650|NCT02351089|Dietary Supplement|Capsules placebo|Capsules
45915822|NCT00388089|Other|flow cytometry|No description
45915823|NCT00388089|Other|immunoenzyme technique|No description
45915824|NCT00388089|Other|immunohistochemistry staining method|No description
45915825|NCT00388089|Other|laboratory biomarker analysis|No description
45915826|NCT04802824|Other|PET/CT|18F-fluoropivalate PET/CT scan.
45915827|NCT04775485|Drug|DAY101|DAY101 is an oral pan-RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL).
45915828|NCT04759456|Other|Remotely-supervised rehabilitation program|Include nutrition, health-related lifestyle and behavioral changes recommendations, and at least 5 times a week 30 minutes of moderate-intensity aerobic training, 10 minutes of inspiratory and expiratory muscle training with breathing device and 10 minutes of oropharyngeal exercise along with individually titrated CPAP therapy
45915829|NCT04742023|Device|Continuous Glucose Monitor Application|The Guardian™ Sensor glucose sensor is part of the Medtronic Continuous Glucose Monitoring (CGM) system. The system then uses these signals to provide sensor glucose values. Patients post-renal transplantation will have CGMs applied and values interpreted by nursing.
45915830|NCT04742023|Diagnostic Test|Finger Stick Glucose Measurement|Patients post-renal transplant will have finger-stick glucose measurements checked prior to meals.
45448519|NCT03547492|Behavioral|Motor text messages|4 text messages sent every 4 weeks. Each is 1-2 sentences reviewing concepts of Mastering Movement
45448520|NCT02253940|Drug|BILR 355 - Treatment A (current tablet formulation)|
45448521|NCT02253940|Drug|BILR 355 - Treatment B (new tablet formulation)|
45448522|NCT02253940|Drug|BILR 355 - Treatment C (new capsule formulation)|
45448523|NCT02253940|Drug|BILR 355 - Treatment D (current tablet formulation)|
45448524|NCT02253940|Drug|BILR 355 - Treatment E (new capsule formulation)|
45448525|NCT02253940|Drug|Ritonavir|
45448526|NCT04617964|Other|Ultrasound|Assessment the intra and interoperator reproducibility of the measurement of the right portal vein diameter at the routine third trimester ultrasound
45639651|NCT02351089|Dietary Supplement|Capsules probiotic powder and corn starch|
45448527|NCT05567380|Other|Observation|Observation of Rheumatoid arthritis disease response to JAK inhibitors and TNF inhibitors after definite timepoints from the initialization of treatment in comparison to the current standard of care of therapy with conventional DMARDs.
45777603|NCT04973163|Drug|Midazolam|Midazolam - only administered in Part B (dose confirmation) of the Monotherapy Arm
45448528|NCT02253472|Device|Deep Brain Stimulation|
45639652|NCT03093311|Other|NIRS based protocol|Each desaturation episode will be managed according to a standardized protocol - correction of extreme head position will be followed by optimisation of mean arterial pressure (MAP), arterial hemoglobin oxygen saturation, end tidal carbon dioxide concentration and a level of hemoglobine concentration.
45639653|NCT02351245|Other|observation|
45639654|NCT05033405|Behavioral|NEURO-LINGUISTIC PROGRAMMING (NLP)|● One session (20-minute long) of NLP application was performed. The NLP techniques that were employed were representational systems and submodality. In this technique, the sensory, auditory, and kinesthetic feelings of the individual are learned. These emotions are modified by imagining. The NLP application was carried out by a researcher who has a certificate in this field
45639655|NCT02351011|Biological|1 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
45639656|NCT02351011|Biological|10 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
45639657|NCT02351011|Biological|50 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
45639658|NCT03093233|Other|no intervention|only descriptive data analysis
45639659|NCT01949662|Drug|Lorazepam|3 mg by vein one time only.
45639660|NCT01949662|Drug|Placebo|Placebo consisting of preservative free 0.9% normal saline given one time by vein.
45639661|NCT01949662|Drug|Haloperidol decanoate|8 mg/day by vein.
45639662|NCT01949662|Behavioral|Questionnaires|Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete.
45639663|NCT02350855|Dietary Supplement|Improved Atta|Improved Atta is a multi macro- micronutrient bread mix. Patients were given 100 grams of Improved Atta (in the from of unleavened bread) everyday for consumption for six months.
45777604|NCT04968847|Device|FemaSeed Localized Directional Insemination|Subjects undergoing FemaSeed Artificial Insemination
45915831|NCT04742023|Drug|Insulin|Insulin will be administered.
45639664|NCT02350855|Other|Nutritional counseling|Dietary counseling for 30 minutes was imparted to all patients on every hospital visits by the researcher. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) was encouraged in their daily diets.
45639665|NCT02350855|Behavioral|Physical activity counseling|Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), was encouraged daily during counseling sessions.
45639666|NCT03093389|Drug|BIA 6-512|The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 100 mg and 150 mg. Products were administered orally, with approximately 240 mL of water in case of Doses 1 and 13, and at least 150 mL of water in case of Doses 2 to 12. First dose (Dose 1) and last dose (Dose 13) were administered in fasting of at least 8 hours and subject remained fasted until to 2.5 h post-dose. Meals were not served within 1 hour prior and 1 hour after investigational product administration in Doses 2 to 12
45639667|NCT03093389|Drug|Placebo|Matching placebo capsules
45777605|NCT04963153|Procedure|Biospecimen Collection|Undergo blood sample collection
45777606|NCT04963153|Procedure|Computed Tomography|Undergo CT
45777607|NCT04963153|Drug|Enfortumab Vedotin|Given IV
45639668|NCT05033249|Diagnostic Test|Immature granulocyte count|Automatically calculated immature granulocyte count in white blood cell count
45639669|NCT05033249|Diagnostic Test|Immature granulocyte percentage|Automatically calculated immature granulocyte percentage in white blood cell count
45777608|NCT04963153|Drug|Erdafitinib|Given PO
45777609|NCT04958239|Drug|BI 765179|BI 765179
45777610|NCT04958239|Drug|Ezabenlimab|Ezabenlimab
45777611|NCT04957290|Drug|NOX66|NOX66 800 mg daily (400 mg suppository twice daily [BID]).
45448529|NCT02253550|Drug|Simeprevir|Simeprevir is a Hepatitis C Virus (HCV) NS3/4A protease inhibitor approved in the United States, Canada and Japan for the treatment of chronic HCV infection.
45448530|NCT02253550|Drug|Sofosbuvir|Sofosbuvir is a nucleotide NS5B polymerase inhibitor developed by Gilead Sciences Inc. and approved for the treatment of chronic HCV infection.
45777612|NCT04957290|Drug|NOX66|NOX66 1200 mg daily (600 mg suppository BID).
45777613|NCT04957290|Drug|NOX66|NOX66 1600 mg daily (800 mg suppository BID).
45777614|NCT04957290|Drug|NOX66|NOX66 2400 mg daily (1200 mg suppository BID).
45777615|NCT04957290|Drug|NOX66|NOX66 RP2D
45777616|NCT04957290|Radiation|EBRT|The dose levels of EBRT will be either 8 Gy as a single fraction, or 20/25 Gy as 5 fractions given over 5 to 10 days.
45777617|NCT04956952|Device|EECP|1 hour of treatment with EECP
45777618|NCT04955626|Biological|BNT162b2|Intramuscular Injection
45777619|NCT04955626|Other|Placebo|Intramuscular Injection
45777620|NCT04955626|Biological|BNT162b2 OMI|Intramuscular Injection
45777621|NCT04955626|Biological|Combination BNT162b2 and BNT162b2 OMI|"30-µg (15-µg each) or 60-µg (30-µg each)~Site prepared dosing suspension from 1 vial each of diluted BNT162b2 and BNT162b2 OMI~Intramuscular Injection"
45777622|NCT04955626|Biological|Combination (Bivalent) BNT162b2 and BNT162b2 OMI|"30-µg (15-µg each) or 60-µg (30-µg each)~Preformulated bivalent mixture (no dilution required) presented in a single vial~Intramuscular Injection"
45639670|NCT02356081|Other|ASyMS intervention Group|ASyMS is a mobile phone-based remote-monitoring system that enables the 'real-time' monitoring of patients' symptoms through use of a patient-reported outcome measure (PROM)
45639671|NCT01918774|Behavioral|Cognitive behavior therapy for work success (CBTw)|The CBTw program includes 12 sessions that are delivered in a weekly one-hour group format. Sessions focused on identifying and modifying maladaptive thoughts related to work, enhancing self efficacy and beliefs in one's ability to succeed at work, identifying and addressing personal barriers to work, and increasing beneficial coping strategies that can be applied across employment settings, including during the job search phase and working on the job. The intervention is tailored toward both employed and unemployed persons seeking community work. Session content includes the following modules: Introduction-Work goals and work story; CBT model and work; Thinking about work; Barriers to work; Coping with stress and anxiety; Coping with anger and difficult emotions; Communication at work; Dealing effectively with people at work; Managing work success; Personal work success plan.
45639672|NCT02355925|Drug|intrauterine injection of uhCG|40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
45639673|NCT02355925|Drug|Placebo|only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
45777623|NCT04946721|Diagnostic Test|The standard care exam and biological specimens' collection|During each visit, in addition to standard of care exams, certain biological specimens ( ocular surface wash, mucocellular material, corneal filaments or impression cytology of conjunctiva, blood or serum) will be collected.
45777624|NCT04937829|Drug|BI 1569912|BI 1569912
45777625|NCT04937829|Drug|Placebo|Placebo
45777626|NCT04936542|Biological|AboBoNT-A|AbobotulinumtoxinA for injection: 500 Unit vial. Dose: 900 Units (3.6 mL)
45777627|NCT04936542|Biological|OnaBoNT-A|OnabotulinumtoxinA for injection: 200 Unit vial. Dose: 360 Units (3.6 mL)
45777628|NCT04935658|Device|Hypnotic relaxation induced by virtual reality (device)|A virtual reality device will be install on the patient 3-5 minutes before the beginning of the oocyte retrieval. The device will be wearing by the patient during the entire intervention and 2 minutes after the end of the ponction.
45777629|NCT04935658|Drug|local anesthesia|standard anesthesic procedure
45777630|NCT04930315|Drug|Apatinib Mesylate|250mg, po, qd, q2w in neoadjuvant and adjuvant group, before surgery
45777631|NCT04930315|Drug|Camrelizumab|200mg, iv, d1, q2w, both in two groups
45777632|NCT04927494|Behavioral|Health is Wealth: A Cervical Health Program|Health is Wealth: A Cervical Health Program will be introduced in a one-time 2-hour educational session, participants will be given HPV self-sampling kits, and instructional sheet that visually depicts the steps for self-sampling. The program will be culturally tailored to increase self-efficacy and knowledge while simultaneously addressing perceived health beliefs associated with cervical cancer and barriers associated with cervical cancer screening and HPV self-sampling. Content will be delivered in a group format (about 10-15 participants) by lecture, demonstration, and interactive exercises.
45777633|NCT04919499|Drug|BI 765128|BI 765128
45777634|NCT04919499|Other|Sham comparator|Sham comparator
45777635|NCT04915729|Drug|tenecteplase|tenecteplase
45777636|NCT04915729|Drug|alteplase|alteplase
45639674|NCT02355925|Other|control|the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
45639675|NCT03092999|Drug|Vilaprisan (BAY1002670)|2 mg tablet, single dose, oral administration
45639676|NCT02355847|Other|Lectures|Lectures
45777637|NCT04896801|Radiation|MR-guided RT|The dose to the planning target volume (PTV) is 36 Gy (5 x 7.2 Gy) prescribed on the 90% isodose line. The clinical target volume (CTV) is receiving 40 Gy (5 x 8 Gy = 100%). A simultaneous integrated boost (SIB) up to a total dose of 42 Gy (5 x 8.4 Gy = 105%) is delivered to the gross tumor volume (GTV), if present. In addition, relative sparing of the urethra will be applied by avoiding hotspots (V40 Gy < 1cc) in the urethra. Baseline and adapted treatment plans are generated using intensity-modulated RT
45777638|NCT04894929|Other|multi component exercise in the clinic|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform:~3 days of empowerment work, 4 days of flexibility work, and daily walking aerobic work and balance work."
45777639|NCT04894929|Other|vestibular exercise in the clinic|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform. sessions of about 20 minutes with 5 weekly sessions (Monday to Friday) consisting of 5 repetitions without fatigue of:~to. Head and eye movements while sitting. b. Head and body movements while sitting. c. Exercises standing. d. Combined exercises of modifications in steps, unstable surfaces and in progress.~and. Along with push up 30sec and squat 30sec"
45777640|NCT04894929|Other|vestibular exercise at home telerehabilitation|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform with the help of a video. sessions of about 20 minutes with 5 weekly sessions (Monday to Friday) consisting of 5 repetitions without fatigue of:~to. Head and eye movements while sitting. b. Head and body movements while sitting. c. Exercises standing. d. Combined exercises of modifications in steps, unstable surfaces and in progress.~and. Along with push up 30sec and squat 30sec"
45777641|NCT04894929|Other|multi component exercise at home telerehabilitation|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform with the help of a video:~3 days of empowerment work, 4 days of flexibility work, and daily walking aerobic work and balance work."
45777642|NCT04888507|Drug|Pozelimab|Intravenous (IV) loading dose (once) followed after 30 minutes by sub-cutaneous (SC) administration
45777643|NCT04888507|Drug|Cemdisiran|SC administration
45639677|NCT03093077|Device|DePuy ATTUNE total knee arthroplasty system|A standard midvastus approach will be used for both alignment technique groups. This is a standard approach for exposing the knee joint for TKA.
45639678|NCT02350933|Procedure|Endoscopy|A rigid endoscopy of the larynx and the trachea until the carina is performed using a rigid 0° endoscope.
45639679|NCT03092921|Device|F&P Mask Seal|Investigative Mask Seal to be used for OSA therapy
45639680|NCT03092921|Device|F&P Mask|Investigative Mask to be used for OSA therapy
45639681|NCT05024201|Behavioral|THERAPEUTİC TOUCH FOR HEMODİALYSİS PATİENTS|Therapeutic touch was applied to hemodialysis patients for 3 days every other day.
45777644|NCT04887857|Drug|CC-486|Specified dose on specified days
45777645|NCT04887857|Drug|Venetoclax|Specified dose on specified days
45777646|NCT04886999|Behavioral|Exploratory study on patient's perception of Asthma symptoms|To assess the perception of symptoms and the psychopharmacological aspects in patients with moderate to severe asthma comparing two inhalers of CHF1535 100/6 µg pMDI
45777647|NCT04880473|Device|PrevisEA device|The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. Under normal conditions, transformations of the data are visualized on the display. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants.
45777648|NCT04879329|Drug|disitamab vedotin|Given into the vein (IV; intravenous) every 2 weeks.
45777649|NCT04879329|Drug|pembrolizumab|Given by IV on Day 1 of each 6-week cycle.
45777650|NCT04876391|Drug|Spesolimab|Spesolimab
45639682|NCT04408183|Drug|GLS-1200|GLS-1200 is given as a nasal spray using an atomizer
45777651|NCT04860830|Drug|Iclepertin|Iclepertin
45777652|NCT04860830|Drug|Placebo|Placebo
45777653|NCT04855266|Drug|Sucrose|5 mg/kg of intravenous iron sucrose (maximum dose of 200 mg). Iron sucrose will be diluted
45639683|NCT04408183|Drug|Placebo|Placebo is given as a nasal spray using an atomizer
45639684|NCT03094793|Other|abnormal EEGs|"This study consists in a scalp EEG to detect, in real time, based on measurements of reaction time and accuracy of responses (recorded every two seconds), the level of attention given by the participant in a repetitive task of constant difficulty and correlate the behavioral results to AIC identified on the EEG recording. A computer equipped for the realization of the STABILO test is already available, its connection / synchronization with standard acquisition systems EEG data is already effective through an RS232 serial port.~Included patients will see their EEG extended for fifteen minutes, during which they will carry out a computerized attentional task to evaluate the stability of the attention."
45777654|NCT04855266|Drug|Placebo|Normal saline (NaCl 0.9%) 5 mL/kg (maximum volume 210 mL)
45777655|NCT04855266|Diagnostic Test|Tilt Table Test|A table that adjusts the body position from horizontal to vertical to simulate standing up. Heart rate and blood pressure are monitored throughout the test.
45777656|NCT04854499|Drug|Magrolimab|Administered intravenously
45777657|NCT04854499|Drug|Pembrolizumab|Administered intravenously
45777658|NCT04854499|Drug|Docetaxel|Administered intravenously
45777659|NCT04854499|Drug|5-FU|Administered intravenously
45777660|NCT04854499|Drug|Cisplatin|Administered intravenously
45777661|NCT04854499|Drug|Carboplatin|Administered intravenously
45777662|NCT04854499|Drug|Zimberelimab|Administered intravenously
45777663|NCT04852302|Behavioral|CALM Therapy|The CALM intervention is a brief, individualized psychotherapeutic intervention established to meet an unmet need to address psychological distress and promote well-being in advanced cancer patients.
45777664|NCT04846881|Drug|Iclepertin|Iclepertin
45777665|NCT04846881|Drug|Placebo|Placebo
45777666|NCT04846868|Drug|Iclepertin|Iclepertin
45777667|NCT04846868|Drug|Placebo|Placebo
45777668|NCT04844203|Diagnostic Test|Polygraphy with surface electrodes|Patients referred for ENMG to the Clinical Physiology Department and complaining of postural unsteadiness will undergo a polygraphy recording using surface electrodes (Natus Medical Incorporated), performed at the end of ENMG
45777669|NCT04832399|Drug|Natalizumab|As described in the treatment arm.
45777670|NCT04827394|Device|Neonatal warming mattress|Babies will be warmed with a standard neonatal transport warming mattress immediately after birth.
45777671|NCT04827394|Device|Sterile polyethylene wrap|Babies will be wrapped in a sterile polyethylene wrap prior to arrival at the warmer.
45777672|NCT04826939|Device|PFDx device and leva device|Participants will use the leva device, PFDx device and undergo ultrasound measurements during pelvic floor motion to compare the three measurements.
45777673|NCT04824066|Device|Device: Wearable Device|A Wearable Device will be placed on the wrist of the patient ~30 days prior to the patient's scheduled surgery, removed during the operation, and replaced for ~180 days post-operatively. The device will record activity in terms of steps, sleep quality, heart rate, etc.
45777674|NCT04822584|Drug|Baricitinib Oral Product|Baricitinib 4 mg/day orally for 36 weeks
45777675|NCT04822584|Drug|Placebo|Placebo once a day orally for 36 weeks
45777676|NCT04822194|Behavioral|Cognitive Emotion Regulation Training|Cognitive emotion regulation training via cognitive reappraisal involves the ability to modify the trajectory of an emotional response by thinking about and appraising emotional information in an alternative, more adaptive way. Reappraisal to down-regulate negative emotion can be operationalized via two tactics: psychological distancing and reinterpretation. The current study will randomly assign participants to receive a brief course of reappraisal training using either psychological distancing or reinterpretation.
45777677|NCT04821310|Drug|Full dose Pantoprazole plus matching placebo|Full healing dose of pantoprazole plus matching placebo
45639685|NCT05023889|Drug|patisiran|"Patients will receive 0.3 mg/kg patisiran once every 21 days administered as an IV infusion over 70 minutes (approximately 1 mL/minute for the first 15 minutes followed by approximately 3 mL/minute for the remainder of the infusion) by a controlled infusion device.~All patients in this study will be premedicated prior to dosing with patisiran. Study drug supplied for this study must not be used for any purpose other than the present study and must not be administered to any person not enrolled in the study.~The first dose of study drug (week 1) will be administered under the supervision of site personnel. After the first dose of patisiran, patients should return to the site for patisiran dosing once every 21 days or receive the patisiran infusions at a local infusion center by a healthcare professional trained on the Protocol, administration of premedication, and patisiran infusion. Patient must receive a dose of interventional drug within the dosing window (±3 days)."
45639686|NCT01949116|Drug|LDMTX|"LDMTX 5 mg: one 5-mg capsule by mouth once weekly~LDMTX 10 mg: two 5-mg capsules by mouth once weekly~LDMTX 15 mg: three 5-mg capsules by mouth once weekly"
45777678|NCT04821310|Drug|Half Dose Pantoprazole plus matching placebo|Half healing dose of pantoprazole plus matching placebo
45777679|NCT04806503|Drug|UNR844|Ophthalmic solution for topical ocular administration
45777680|NCT04806503|Drug|Placebo|Placebo
45777681|NCT04795245|Drug|afatinib|afatinib
46070316|NCT05237102|Procedure|Cerebrospinal fluid shunt|"The procedure is designed to reduce the amount of cerebrospinal fluid in a patient's brain by draining it through a shunt tube:~①V-P shunt is suitable for most types of hydrocephalus; ②L-P shunt is suitable for traffic hydrocephalus and positive pressure hydrocephalus, and patients with lower cerebellar tonsil hernia are contraindications; ③ Common terms of ventriculoatrial (V-A) shunt are not suitable for V-P shunt (abdominal infection, serious respiratory and circulatory diseases are contraindications); ④ The third ventriculostomy is suitable for patients with non-traffic and partial traffic hydrocephalus （infants and patients with severe ventricular enlargement should be cautious, and patients with shunt tube cannot be placed due to ventricular conditions）; ⑤Other shunt methods include septum pellucidum fistula and Torshunt （ventriculo-occipital cistern shunt after tumor resection）"
45639687|NCT01949116|Drug|Placebo|"Placebo 5 mg: one 5-mg capsule by mouth once weekly~Placebo 10 mg: two 5-mg capsules by mouth once weekly~Placebo 15 mg: three 5-mg capsules by mouth once weekly"
46070317|NCT00844857|Drug|Olanzapine Fluoxetine Combination (OFC)|OFC doses are capsules of 3 milligrams (mg) olanzapine and 25 mg fluoxetine (3/25), 6/25, 12/25, 6/50, or 12/50 mg to be taken orally once daily in the evening for 8 weeks.
45639688|NCT01949116|Dietary Supplement|Folic acid|1-mg tablet of folic acid by mouth once a day
45777682|NCT04786847|Biological|177Lu-DOTA-TLX591|TLX591, a monoclonal antibody HuX591 conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-TLX591)
45777683|NCT04774926|Drug|Brolucizumab|120 mg/ml solution for intravitreal injection
45777684|NCT04772209|Drug|Sodium bicarbonate|Dialysis catheter lumen will be filled (locked) by sodium bicarbonate solution. The amount of solution depends on the diameter and length and will be in accordance with the manufacturer's specifications.
45639689|NCT01673009|Drug|Gleevec|Gleevec® will be dosed orally 440 mg/m^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.
45639690|NCT02355535|Drug|PAC-1|PAC-1 is taken orally on days 1-21 of a 28-day cycle.
45639691|NCT05033015|Procedure|Mouth rinse|To test a novel mouth rinse containing enzymes to prevent development of WSL with a control
45639692|NCT02350387|Procedure|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
45639693|NCT02350387|Procedure|Low intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
45639694|NCT05023499|Drug|SYMPT-X Glutamine, Oral Powder for Reconstitution|erioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.
45777685|NCT04772209|Drug|Heparin|Dialysis catheter lumen will be filled (locked) by classic heparin. The amount of pure heparin depends on the diameter and length and will be in accordance with the manufacturer's specifications.
45777686|NCT04771273|Drug|BI 456906|BI 456906
45777687|NCT04771273|Drug|Placebo|Placebo
45777688|NCT04764188|Drug|Alectinib|Participants will receive alectinib in accordance with local clinical practice and local labeling.
45639695|NCT02350621|Procedure|ACDF|
45639696|NCT02350621|Procedure|minimal invasive Posterior Cervical Foraminotomy|
45639697|NCT05023421|Other|no intervention|no intervention
45639698|NCT02350543|Drug|Aspirin|
45639699|NCT05033093|Drug|Root Canal Sealants|it is planned to conduct the research described below, on the effect of calcium silicate-based (iRoot SP), silicone-based (GuttaFlow Bioseal) and rezin-based (AH Plus) sealer on postoperative pain
45777689|NCT04763447|Other|Attempt to withdrawal OMA treatment|Patients will be told to stop abruptly (no progressive decrease of the dose) their Omalizumab treatment and they will not be prescribed new OMA. In case of loss of control, pulmonologist can adapt asthma treatment, as in usual care. In that case, OMA can be prescribed for a second line
45777690|NCT04763447|Drug|Continuation of OMA treatment|"Patients will be prescribed the same dosage of Omalizumab than they received before randomization, according to their weight and total circulating IgE levels.~In case of safety concerns or loss of control, pulmonologist can modify the patient treatment regimen of OMA or other co-medications, as in usual care."
45777691|NCT04762368|Device|Active anodal tDCS|a weak electric current is applied to the head through electrodes to affect the cortical excitability of the targeted cells in the brain.
45639700|NCT02359747|Genetic|Polymerase Chain Reaction and Whole Genome Amplification|Polymerase Chain Reaction and Whole Genome Amplification
45777692|NCT04762368|Device|Sham anodal tDCS|The tDCS machine will be used as in active stimulation, except the electrical current will not be applied.
45777693|NCT04757662|Drug|Tadalafil|Tadalafil is commercially available and will be purchased by the Siteman Cancer Center and distributed to participants free of charge.
45777694|NCT04756050|Drug|Bupivacaine HCl 0.5% Injectable Solution|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
45777695|NCT04756050|Drug|Prilocaine HCl % 2 injectable solution|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
45639701|NCT05023577|Drug|Rabeprazole|20mg bid
45639702|NCT05023577|Drug|Bismuth potassium citrate|0.6g bid
45777696|NCT04756050|Drug|adrenaline amp 0.5mg|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
45777697|NCT04756050|Procedure|Ultrasound Guided Supraclavicular Block Corner pocket approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance. Local anesthetic mixture will be given to the corner pocket - where the artery and the first rib intersect in the sonoanatomical image.
45777698|NCT04756050|Procedure|Ultrasound Guided Supraclavicular Block Corner pocket + intracluster approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance .10 ml of the local anesthetic mixture will be given to the described corner pack and the remaining 10 ml into the largest nerve cluster (Intracluster injection).
45777699|NCT04756050|Procedure|Ultrasound Guided Supraclavicular Block multi approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance Local anesthetic mixture will be administered by multi injection method between the nerve groups seen in the sonoanatomical image.
45777700|NCT04756050|Procedure|diagraphma muscle evaluation with ultrasound|"All patients will be evaluated with USG in a head-up position facing the side to be operated before and 30 minutes after the block is performed.~The probe will be placed perpendicular to the chest wall, in the eighth or ninth intercostal space, between the anterior axillary and midaxillary lines, 0.5 to 2 cm below the costophrenic sinus."
45777701|NCT04752774|Biological|IPN10200|Powder and solvent for solution for injection
45777702|NCT04752774|Drug|Placebo|Powder and solvent for solution for injection
45777703|NCT04752774|Biological|Dysport|Powder for solution for injection
45777704|NCT04752332|Drug|Abemaciclib|Administered orally.
46070318|NCT00844857|Drug|Placebo|Orally, once daily in the evening for 8 weeks.
45639703|NCT05023577|Drug|Metronidazole|0.4g qid
45639704|NCT05023577|Drug|Clarithromycin|0.5g bid
45639705|NCT05023577|Drug|Levofloxacin|0.5g qd
45639706|NCT03149497|Procedure|anterior approach only in cervical spine trauma|evaluation of efficacy of single approach
45777705|NCT04752332|Drug|Standard Adjuvant ET|Administered according to label instructions.
45777706|NCT04752332|Drug|Placebo|Administered orally.
45639707|NCT05032625|Procedure|Surgery|Patients who undergo surgery for NSTI will be followed in hospital and for 1- year in the office. We will asses the quality of life and there functionality. This will help us in determining the predictors of poor outcome.
45639708|NCT03149419|Drug|Paroxetine|
45639709|NCT03149419|Drug|Placebo oral capsule|
45639710|NCT03092765|Drug|E6011|Intravenous administration
45639711|NCT03092765|Drug|Placebo|Intravenous administration
45639712|NCT02355223|Other|FAST|See information in arm description
45639713|NCT05032391|Biological|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Three times orally in a volume of 2.5 ml (1 dose)
45639714|NCT05032391|Drug|Placebo|Three times orally in a volume of 2.5 ml (1 dose)
45639715|NCT02359981|Behavioral|MyBehavior|The intervention automatically provides personalized suggestions based on users behavior and user context. Suggestions relates to users life and how often they have done them in the past. Since the suggestions relate to users' lives, they are easy to follow.
45777707|NCT04751487|Drug|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
45777708|NCT04751487|Drug|Placebo|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
46070319|NCT05158088|Device|Borescope|Endotracheal intubation using borescope
46070320|NCT05158088|Device|Video laryngoscope|Endotracheal intubation using video laryngoscope
45639716|NCT02359981|Behavioral|Generic suggestions|A nutritionist and an exercise trainer jointly created 45 food and exercise suggestions based on guidelines posted by the NIH. These suggestions ask users to walk for 30 minutes or eat healthier foods. These suggestions however doesn't personalize to users daily behavior into account.
45777709|NCT04748107|Diagnostic Test|Impendence Cardiography|ICG is a noninvasive method of determining the amount of blood flow using the Non-Invasive Cardiac System - Cardiac Surveyor (NICaS) system, which provides an assessment of the cardiovascular system, respiratory system, and fluid retention.
45639717|NCT02359981|Device|Smartphone|An Android Smartphone with operating system version higher than 2.2
45639718|NCT01939366|Drug|Cebranopadol 100 µg|Participants randomized to 100 μg cebranopadol will start with 100 μg per day and will remain on 100 µg per day.
45639719|NCT01939366|Drug|Cebranopadol 300 µg|Participants randomized to 300 μg cebranopadol will start with 100 μg per day and increase to 300 µg per day on day 4 and will remain on 300 µg per day.
45639720|NCT01939366|Drug|Cebranopadol 600 µg|Participants randomized to 600 μg cebranopadol will start with 200 μg per day and increase to 400 µg per day on day 4 and to 600 µg on day 7, thereafter they will remain on 600 µg per day.
45777710|NCT04736628|Drug|BI 685509|BI 685509
45777711|NCT04736628|Drug|Placebo|Placebo
45777712|NCT04735536|Drug|CT1812|Active Treatment- CT1812 at a dose of 300mg
45777713|NCT04735536|Other|Placebo|Placebo Comparator
45639721|NCT01939366|Drug|Pregabalin|Stepwise titration from 75 mg twice a day to 300 mg twice a day over 2 weeks.
45639722|NCT01939366|Drug|Matching Placebo|Placebo will be matched to pregabalin and cebranopadol.
45639723|NCT04434365|Drug|Berberine|Berberine 100 mg twice daily for 4±1 weeks (Stage 1); then, 200 mg twice daily for 4±1 weeks (Stage 2); then, 300 mg twice daily for 4 weeks (Stage 3).
45639724|NCT04434365|Drug|Aspirin|Aspirin 100 mg once daily for 12±1 weeks.
45639725|NCT04434365|Drug|Clopidogrel|Clopidogrel 75 mg once daily for 12±1 weeks.
45777714|NCT04732143|Other|Inspiratory muscle training|At least 2 weeks prior to surgery, participants will be given a Vyaire incentive spirometer device and provided with formal training on proper inspiratory muscle breathing exercise using the device. They will be instructed to perform 4 sets of these exercises per day for 14 days prior to surgery.
45777715|NCT04731103|Drug|Abacavir (ABC)|Tablets or oral solution
45639726|NCT04434365|Drug|Statin|Statins once daily for 12±1 weeks.
45639727|NCT02359669|Behavioral|StimuLearn Intervention|"StimuLearn apps~Cognitive questionnaires"
45639728|NCT02359669|Behavioral|Without StimuLearn intervention|Cognitive Questionnaires
45639729|NCT02359591|Other|text-based or multimedia|subjects fills in a questionnaire regarding whether the child meets the developmental milestones for his/her developmental age.
45639730|NCT05032469|Other|Reflexology|Reflexology is a method that creates nervous, hormonal and energetic effects in the body using pressure, rubbing and stretching applied with special hand and finger techniques to reflex points corresponding to all parts, organs and systems of the body in the ears, hands and feet
45639731|NCT02350075|Procedure|Dental implants installation|Dental implants installation is a procedure to insert dental implants into alveolar bone.
45777716|NCT04731103|Drug|Lamivudine (3TC)|Tablet or oral solution
45777717|NCT04731103|Drug|Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)|Tablet or oral solution
45777718|NCT04716712|Drug|Azithromycin|Azithromycin is a macrolide-type antibiotic that is used to treat various types of infections. Previous studies in Niger have demonstrated a nearly 18% reduction in all-cause child mortality following biannual mass administration to children 1-59 months.
45777719|NCT04716712|Drug|Placebo|Matching identical placebo in packaging, appearance, and taste.
45777720|NCT04713046|Biological|CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16|Patients will receive CD8+ T cell-depleted peripheral blood cells at one of three dose levels following cyclophosphamide: 1) 10^6 CD4+ cells/kg; 2) 5 x 10^6 CD4+ cells/kg; or 3) 10^7 CD4+ cells/kg of recipient ideal body weight.
45777721|NCT04713046|Biological|Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16|Standard dosing for bone marrow graft (target dose of 4 x 10^8 nucleated cells/kg) and if progression at Day 90, will receive dose level 1 for the CD8-depleted DLI (106 CD4+ cell/kg).
45639732|NCT02350075|Device|Osteotome Sinus floor elevation|Osteotomes with different diameters are specially-designed device to vertically increase the bone volume in atrophic maxilla.
45639733|NCT05032235|Drug|Fluzoparib|Normal Renal Function:A single oral dose of Fluzoparib will be administered.
45639734|NCT05032235|Drug|Fluzoparib|Mild Renal Impairment:A single oral dose of Fluzoparib will be administered.
45639735|NCT05032235|Drug|Fluzoparib|Moderate Renal Impairment:A single oral dose of Fluzoparib will be administered.
45639736|NCT02359279|Device|Sodium iodide|Comparison of control radiographs made before application of sodium iodide and test radiograph after application.
45639737|NCT02359357|Drug|FDL169|
45639738|NCT02359357|Drug|Placebo|
45639739|NCT05023265|Radiation|Stereotactic body radiotherapy|SBRT is a non-invasive treatment approach that delivers precise and highly conformal radiotherapy to the tumour with steep dose gradients that minimize exposure to the surrounding normal tissues.
45639740|NCT05031923|Procedure|SMV and antimicrobial photodynamic therapy|Application of SMV and antimicrobial photodynamic therapy in intrabony defects
45639741|NCT05031923|Procedure|SMV application|Application of SMV without antimicrobial photodynamic therapy in intrabony defects
45639742|NCT02354755|Device|Psychomotor vigilance test (PVT|The Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurements. The device measures the speed with which subject responds to visual stimulus (by pressing a response button).
45777722|NCT04710420|Device|Endovascular therapy|Endovascular treatment for critical limb threatening Ischemia
45777723|NCT04709562|Device|High Velocity Nasal Insufflation (HVNI)|The purpose of this intervention is to evaluate the efficacy of HVNI in clinically stabilizing patients presenting with hypercapnic respiratory distress.
45777724|NCT04709562|Device|Noninvasive Positive Pressure Ventilation (NIPPV)|The purpose of this intervention is to evaluate the efficacy of NIPPV in clinically stabilizing patients presenting with hypercapnic respiratory distress.
45639743|NCT04468919|Behavioral|BCI-FIT multi-modal access|Adding a personalized multi-modal access protocol to customize a BCI-FIT access method configuration for each individual end user, based on a combination of user characteristics, clinical expertise, user feedback, and system performance data in the software.
45639744|NCT04468919|Behavioral|BCI-FIT adaptive signal modeling|Adding a BCI-FIT adaptive signal modeling that employs transfer learning and on-line model adaptation techniques with noisy labels in the software of this brain-computer interface to eliminate the need for data collection exclusively for model calibration, as well as to address model drift issues associated with drowsiness, fatigue, and other human and environmental factors.
45639745|NCT04468919|Behavioral|BCI-FIT active querying|Adding BCI-FIT active querying techniques which are software-based optimal action control policies in the brain-computer interface developed with active and reinforcement learning techniques in order to perform efficient user intent inference to improve the entire speed-accuracy trade-off curve for alternative communication.
45639746|NCT04468919|Behavioral|BCI-FIT language modeling|Adding vocabulary and location information (called partner and environmental input) to the language models in the brain-computer interface from a user's communication partner.
45639747|NCT02354989|Device|Rate Response on first (VVI biventricular pacing)|Rate Response function is turned on in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned off and the patient performs a second 6 minute walking test.
45639748|NCT02354989|Device|Rate Response off first (VVI biventricular pacing)|Rate Response function is turned off in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned on and the patient performs a second 6 minute walking test.
45639749|NCT02354911|Biological|Immunoregulatory Dendritic Cells|Autologous dendritic cells harvested by leukapheresis and engineered ex vivo via incubation with antisense DNA oligonucleotides targeting the primary transcripts of CD40, CD80 and CD86. The ex vivo engineered product is then administered via blinded intradermal injection in the peri-umbilical region of the abdomen given as 4 separate injections at 2-week intervals (~10 million cells/injection).
45639750|NCT02354911|Other|Placebo Comparator: Placebo Control|Blinded intradermal injections in the peri-umbical region of the abdomen given as 4 separate injections at 2-week intervals
45639751|NCT04467749|Other|Suspension Wheel|Participants will be given a pair of Spinergy or Loopwheels to use during the 12-week intervention period. The Spinergy wheels consist of a lightweight carbon fiber material with natural shock absorbing properties. Loopwheels offer a rigid rim, a mid-wheel shock absorbing hub and three in-wheel loops that work as a self-correcting system when encountering uneven ground.
45639752|NCT03149575|Drug|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion at a dose 40 mg/m2 IV on days 1, 2, and 3 of a 21-day treatment-cycle, for up to 12, 21-day treatment cycles
45639753|NCT03149575|Drug|Physician's Choice of Salvage Therapy - temozolomide|"The product label for temozolomide (Temodar®) provides the following dosing information.~Newly Diagnosed GBM: 75 mg/m2 for 42 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m2 once daily for Days 1-5 of a 28-day cycle of Temodar® for 6 cycles.~Refractory Anaplastic Astrocytoma: Initial dose 150 mg/m2 once daily for 5 consecutive days per 28-day treatment cycle."
45639754|NCT03149575|Drug|Physician's Choice of Salvage Therapy - lomustine|"The product label for lomustine (CeeNu; lomustine; CCNU) provides the following dosing information.~The recommended dose of lomustine in adult and pediatric patients as a single agent in previously untreated patients is 130 mg/m2 as a single oral dose every 6 weeks In individuals with compromised bone marrow function, the dose should be reduced to 100 mg/m2 every 6 weeks."
45639755|NCT03149575|Drug|Physician's Choice of Salvage Therapy - carboplatin|"The product label for (Paraplatin) carboplatin Injection provides the following dosing information.~As a single agent at a dosage of 360mg/m2 IV on day 1 every 28 days Alternatively, the carboplatin dose may be calculated by the Calvert formula below Calvert formula for carboplatin dosing: Total Dose (mg) = (target AUC) x (GFR + 25), where AUC = area under the curve and GFR = glomerular filtration rate."
45639756|NCT05023187|Behavioral|SCOT|"A 8-week social and cognitive online training to improve both cognitive and social functioning, which includes 2 sessions (~45 minutes each) of individual cognitive training through the BrainHQ© program 2020 (BrainHQ© Posit Science) and a psycho-educational group session for each week (24 sessions in total).~In the experimental intervention, all activities are focused on enhancing executive functions (working memory, processing speed, inhibitory control etc.) and social cognition abilities (identifying/recognizing facial expressions, styles attribution, drawing conclusions etc.)."
45639757|NCT05023187|Behavioral|CON|"A 8-week active control intervention consisting of 2 sessions (~45 minutes each) of cognitive stimulation exercises and a group session for each week (24 sessions in total) during which the various cognitive domains are deepened and the exercises carried out during the week are reviewed all together.~The online control intervention has been specifically designed to increase the cognitive involvement of the subjects and to replicate the condition of exposure to social dynamics."
45639758|NCT05032001|Drug|Biguanide, DPP4 inhibitors, SGLT2 inhibitors|Oral antidiabetic treatment during twelve weeks
45639759|NCT05022875|Device|Healthcare CEO app- for experimental app intervention|The app content was designed based on the results of previous qualitative and Delphi studies (Chiang et al., 2021; Chiang et al., 2020) and consists of 11 interfaces: CEO's profile, Health Tracking, CEO Knowledge Base, Barrier-free Communication, See Here: Diet and Exercise, Help Me, Detective!, CEO Chatroom, CEO's Secretary, Who's the Best CEO, SOS Calls, and Q&A
45639760|NCT05022875|Device|Healthcare CEO app-for control app intervention|consists of 2 interfaces: CEO's profile, Health Tracking.
45639761|NCT03149263|Behavioral|distraction|Children will all benefit toxin injections with the same protocol. Only the distraction will be different during the session: either the children will have a distraction realized by the team of clowns / or children will benefit a classic distraction (TV, music, ...)
45639762|NCT05032079|Procedure|cryoablation|single probe ultrasound guided cryoablation
45639763|NCT03149341|Other|Magnetic Resonance Imaging|All subjects will undergo or have already undergone Magnetic Resonance Imaging. Normal volunteers will be used for comparison with subjects. To minimize risk, normal volunteers will NOT undergo anesthesia, sedation or receive intravenous contrast during procedure.
45639764|NCT04963517|Behavioral|Exercise therapy|8 weeks personalized, multi-modal exercise with focus on lower extremity
45777725|NCT04701983|Drug|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
45777726|NCT04701983|Drug|Placebo|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
46070321|NCT04712240|Device|Respiration rate monitor|A portable continuously monitoring respiration rate monitor will be fitted to each participant. The respiration rate monitor is housed within a comfortable chest strap that be secured to the participant for the duration of the surgical procedure
45777727|NCT04700553|Device|Localized muscle vibration|All patients in both experimental and control groups received CPT protocol consisted of 30 minutes of manual resistance exercise (3 sets/10 repetitions each for knee extensors and flexors) and 30 minutes of treadmill training, short breaks (1-5 minutes) were allowed, depending on the patient tolerance. The training was conducted for 3 days per week for 8 weeks. The patients in CPT+LMV experimental group received localized muscle vibration at the end of each CPT session. The LMV was applied for 5 minutes perpendicularly along quadriceps muscle fibers. The frequency set at 30 Hz, amplitude of 2 mm.
45777728|NCT04700553|Other|Conventional physiotherapy intervention|All patients in both experimental and control groups received CPT protocol consisted of 30 minutes of manual resistance exercise (3 sets/10 repetitions each for knee extensors and flexors) and 30 minutes of treadmill training, short breaks (1-5 minutes) were allowed, depending on the patient tolerance. The training was conducted for 3 days per week for 8 weeks. The patients in CPT+LMV experimental group received localized muscle vibration at the end of each CPT session. The LMV was applied for 5 minutes perpendicularly along quadriceps muscle fibers. The frequency set at 30 Hz, amplitude of 2 mm.
45639765|NCT04963517|Other|Information|"Initial consultation with recommendations for general physical activity~Brochure with exercise recommendations."
45639766|NCT03159715|Behavioral|Internet-based Global Protocol|Internet-based Global Protocol is an Internet-based treatment which includes therapeutic components of evidence-based treatments for depression: Motivation, Psychoeducation, Cognitive Therapy, and Relapse Prevention. Furthermore, it incorporates a Behavioural Activation component (BA). The whole protocol stresses the importance and benefits of being active and remaining involved in life, values and goals. The program also includes a component of Positive Psychology (PP). It allows the individual to learn and practice adaptive ways to cope with depressive and anxiety symptoms and confront daily problems. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
45639767|NCT03159715|Behavioral|Internet-based Behavioral Activation Protocol|Internet-based Behavioral Activation Protocol is an Internet-based treatment based on Behavioral Activation. It stresses the importance and benefits of being active and remaining involved in life, values and goals . It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
45639768|NCT03159715|Behavioral|Internet-based Positive Psychology Protocol|Internet-based Positive Psychology Protocol is an Internet-based treatment based on Positive Psychology, offering strategies to promote and enhance positive mood. It is an Internet-based treatment based on Positive Psychology. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
45639769|NCT05031689|Biological|SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract|Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
45639770|NCT05031689|Biological|SPF 30 sunscreen and pharmaceutical formulation containing green banana peel extract|Study Group In addition to the SPF 30 sunscreen, a pharmaceutical formulation containing green banana peel extract will be used.
45639771|NCT03147469|Procedure|Flexion|After changing the position of head and neck of subjects to flexion, the variables were measured.
45777729|NCT04699539|Radiation|SBRT|SBRT: in 5-6fractions with Cyberknife.
45777730|NCT04699539|Drug|Chemotherapy|Gemcitabine (1000mg/m2，d1, 8) + albumin-bound paclitaxel (125mg/m2，d1, 8) or single-agent oral S-1 (60-120 mg/ daily, d1-14) , repeat every 3 weeks.
45777731|NCT04697849|Behavioral|Cognitive Rehabilitation and Exposure/Sorting Therapy|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) provides training in compensatory cognitive strategies to address the executive dysfunction typical of individuals with HD, then helps reduce the distress associated with discarding items via exposure therapy.
45777732|NCT04697849|Behavioral|Case Management|Case Management (CM). CM is the most widely available and utilized intervention for HD and is considered standard of care. This form of treatment involves managing the functional, housing, and legal ramifications of HD. Additionally, CM often involves assistance with economic, health, and social resources while providing support for the client.
46070322|NCT00702117|Drug|flecainide|2 mg/kg iv in 10 minutes
45639772|NCT03147469|Procedure|Extension|After changing the position of head and neck of subjects to extension, the variables were measured.
45639773|NCT03147469|Procedure|Right rotation|After changing the position of head and neck of subjects to right flexion, the variables were measured.
45639774|NCT05022953|Other|Education, dijital storytelling|Digital story
45639775|NCT03159013|Other|Exposure|"Oral exposure: 0,025 mg/kg bw dissolved in oil, on day 1, with blood withdrawn on days 2,3,4.~Dermal exposure: 145 µl of commercial formulation (0,25 mg/kg bw) on 40 cm2 of forearm skin for 6 hours, on day 28, with blood withdrawn on days 29,30,31."
45639776|NCT05031377|Behavioral|HE programme|Participants will receive a 12-week integrated exercise and cardiovascular health education programme (HE programme) which is constructed based on self-efficacy theory. A booster intervention in the form of SMS messaging will be given from Week 1 to Week 12.
46070323|NCT00702117|Drug|ajmaline|1 mg/kg iv in 10 minutes
46070324|NCT00702117|Drug|procainamide|10 mg/kg iv in 10 minutes
46070325|NCT00702429|Other|Blood sampling|Analysis of the PNN, analysis of the monocytes
46070326|NCT00702429|Other|Blood sampling|Analysis of the PNN, analysis of the monocytes
45777733|NCT04690777|Procedure|Experimental: VESTIBULAR EXERCISE|OCULAR AND MOVEMENT EXERCISES
45777734|NCT04690777|Procedure|MULTICOMPONENT EXERCISE|exercises includes strengthening, cardiovascular training, flexibility and balance
45639777|NCT05031377|Behavioral|Usual care|Participants will receive usual care which primarily includes an education talk on basic health issues. Governmental health education leaflets will be provided for reference.
45639778|NCT02350231|Drug|The progesterone vaginal pessary|Those patients will receive progesterone vaginal pessary for prevention of preterm delivery in twins pregnancy
45777735|NCT04686305|Drug|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
45777736|NCT04686305|Biological|Durvalumab|Durvalumab: administered as an IV infusion
45777737|NCT04686305|Drug|Cisplatin|Cisplatin: administered as an IV infusion
45777738|NCT04686305|Drug|Carboplatin|Carboplatin: administered as an IV infusion
45639779|NCT02350231|Drug|Tonics group|Those patients will receive only tonics
45777739|NCT04686305|Drug|Pemetrexed|Pemetrexed: administered as an IV infusion
45777740|NCT04683640|Dietary Supplement|GABA|Daily oral GABA for 4 weeks
45777741|NCT04683640|Drug|Placebo|Daily oral Placebo for 4 weeks
45777742|NCT04680221|Drug|Liposomal bupivacaine|Deposition of liposomal bupivacaine
45639780|NCT03092141|Other|Physical training|
45639781|NCT05031299|Behavioral|Standard care|Participants will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors.
45777743|NCT04680221|Procedure|TAP block|Transversus abdominis plane block performed to deposit anesthetic
45777744|NCT04680221|Drug|Deposition of saline|Deposition of saline
45777745|NCT04676607|Drug|SHR7390|SHR7390
45777746|NCT04676152|Device|Masimo Noninvasive Blood Pressure Device|All enrolled subjects will have blood pressure measurements done using the Masimo NIBP device.
45777747|NCT04673370|Behavioral|Ba Duan Jin|Ba Duan Jin, a traditional Chinese health-preserving technique, combines techniques regulating body, breath and spirit. According to traditional Chinese theory, every movement of Ba Duan Jin has unique effect to different Zang-fu organs.
45777748|NCT04673370|Behavioral|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
45639782|NCT05031299|Behavioral|Health-promotion application for self-management|Participants will be provided with a health-promotion application for self-management for 3 months, additionally to the standard care.
45639783|NCT05031299|Device|Wearables and devices|Participants will be provided with wearables and devices, including a weighing scale (assessing also body composition) device and a smartwatch/wristband to assess physical activity but also sleep pattern, for 3 months, additionally to the standard care and the Health-promotion application.
45639784|NCT03147391|Device|LAA closure with LAmbre|Percutaneous Left Atrial Appendage Closure Using the LAmbre Device in Patients With Atrial Fibrillation
45639785|NCT03147547|Other|Promotional Brochure|Promotional brochure with information about the Triple P Positive Parenting Program and an enrollment form.
45639786|NCT03147547|Other|Family Testimonial Flyer|Flyer that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare.
45639787|NCT03147547|Other|Teacher Endorsement|Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended the parent attend.
45639788|NCT03147547|Other|Provider Engagement Call|This was a manualized, 20-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent problem solve barriers to attendance and develop an action plan to handle common barriers (e.g., scheduling conflicts) as well as set session reminders.
45777749|NCT04668144|Drug|Cangrelor|Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The total infusion will last 2 hours.
45777750|NCT04668144|Drug|Prasugrel|Prasugrel will be used in line with FDA recommendations using a 60mg LD followed by a 10mg daily maintenance dose started 24 hours after LD administration
45777751|NCT04667078|Drug|Cangrelor|administration of cangrolor by iv befor thrombectomy
45777752|NCT04667078|Other|best medical management|used yhe best medical management
45777753|NCT04663997|Drug|177Lu-PSMA-617|IA of 7.4GBq (± 10%) IV every 6 weeks; maximum 6 cycles
45777754|NCT04663997|Drug|Docetaxel|75mg/m2 IV every 3 weeks maximum 12 cycles
45777755|NCT04662060|Drug|Acebilustat|100 mg capsule administered orally once daily
45777756|NCT04662060|Drug|Placebo|Placebo to match acebilustat administered orally once daily
45777757|NCT04650581|Drug|Ipatasertib|400 mg PO QD days 1-21 every 28 days
45777758|NCT04650581|Drug|Fulvestrant|500 mg IM cycle 1 days 1 and 15 followed by 500 mg IM day 1 q 28 days subsequent cycles
45777759|NCT04650581|Other|Placebo|PO QD days 1-21 every 28 days
45777760|NCT04649190|Device|TAVI|Coronary access for PCI after TAVI
45777761|NCT04644796|Drug|saline 0.9%|Patients included in the placebo group will have their incisional site infused, targeting the paraspinal muscles with sterile saline at the end of their surgery.
45777762|NCT04644796|Drug|Liposomal bupivacaine|Patients included in the treatment group will have their incisional site infused, targeting the paraspinal muscles with liposomal bupivacaine at the end of their surgery.
45777763|NCT04643340|Other|real-time fMRI|Brain regions can be trained, i.e. fMRI activity can be actively modulated online by humans, using rt-fMRI (Bruhl, Scherpiet et al. 2014, Bruhl 2015, Emmert, Kopel et al. 2016).
45639789|NCT01918306|Drug|cisplatin|"In Arm I patients receive cisplatin IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may crossover to Arm II upon disease progression.~In Arm II patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 orally (PO) one time a day (QD) on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~--------------------------------------------------------------------------------"
45639790|NCT01918306|Other|laboratory biomarker analysis|correlative studies
45639791|NCT01918306|Other|pharmacological study|correlative studies
45639792|NCT01918306|Procedure|dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI|correlative studies
45639793|NCT01918306|Drug|GDC -0941|Patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 PO QD on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
45639794|NCT05031611|Behavioral|Intuitive Eating Treatment|"Participants received a brief web-based intervention for disordered eating which focused on a style of eating behavior called intuitive eating. Please see arm description for more details."
45639795|NCT05031533|Radiation|Dose-Painting Radiation|"Radiation therapy:~Delineation of target area:~The primary tumor is delineated into different target areas according to the anatomical position of the tumor, including the central area tumor GTV-Tcentral and GTV-Tperipheral.~Exposure dose:~1) GTV-Tcentral: 2.0～2.5Gy/f, bid, 10-13d, physical dose 40-65Gy 2) GTV-Tperipheral: 3.0～4.0Gy/f, bid, 10-13d, physical dose 60-104Gy 3) GTV-N (mediastinal lymph node): 2.0Gy/f, bid, 10-13d, physical dose 40-52Gy"
45639796|NCT02348515|Procedure|Heart failure or coronary disease|Small samples collected from the apex core in the heart. In addition, blood samples will be taken.
45639797|NCT02348515|Procedure|Heart transplant patients|Heart samples collected including, excess myocardial biopsy samples. In addition, blood samples will be taken.
45639798|NCT02348515|Procedure|Orthotopic Heart Transplant Patients|Myocardial tissue samples collected from the diseased heart. In addition, blood samples will be taken.
45639799|NCT02348515|Procedure|Heart Surgery Patients|Heart samples will be collected from the left atrial appendages. In addition, blood samples will be taken.
45639800|NCT02348515|Procedure|Blood Draw|All subjects will have 20 ml of blood drawn for further analysis.
45639801|NCT05022797|Drug|Glucarpidase 1000 UNT [Voraxaze]|2 vials of 1000 units per vial
45639802|NCT01917526|Device|oxygen mask|
45639803|NCT01917526|Device|oxygen cannula|
45639804|NCT05031143|Drug|Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease|Suprachoroidal steroid injection for management of serous retinal detachment in VKH disease
45639805|NCT01948258|Device|Clearblue Advanced Fertility Monitor|Clearblue Advanced Fertility Monitor used for one menstrual cycle in a home setting
45639806|NCT02354677|Other|In vitro experiments on bronchial epithelial cells|
45639807|NCT02354521|Other|NO INTERVENTIONS|
45639808|NCT02348437|Procedure|Repair|An on-going suture technique with minimum four stitches.
45639809|NCT02348437|Procedure|Non-repair|The PQ muscle will be placed so it covers the volar plate. No suture.
45639810|NCT01916980|Drug|Desloratadine 5 mg|Desloratadine 5 mg/day: one 5-mg tablet taken orally once daily in the evening for up to 12 weeks (Desloratadine 10 mg/day: two 5-mg tablets taken orally once daily in the evening for up to 8 weeks)
45639811|NCT05021627|Procedure|Cardiac autonomic nerve modification|Patients with sinus bradycardia undergoing cardiac autonomic ganglion ablation. Specific anatomic ablation of the 4 major left atrial GP and aorta-superior vena cava (Ao-SVC) GP was performed. Briefly, catheter ablation was performed under the guidance of an electroanatomic mapping system (CARTO,BiosenseWebster,DiamondBar,California). After completed the electroanatomic mapping of the left atrium was complete and pulmonary vein (PV) ostia identified, presumed GP clusters were ablated 1 to 2cm outside the PV-left atrium junctions at the following sites: the left superolateral area (leftsuperior GP[LSGP]), the leftinfer oposterior area(left inferior GP[LIGP]), the right superoanterior area (rightanterior GP[RAGP]), the right inferoposterior area(right inferior GP[RIGP]), and the Ao-SVC fat pad (Ao-SVCGP), and in that sequence.
45639812|NCT05021627|Procedure|Pacemaker implantation|Patients with sinus bradycardia received pacemaker implantation. The patient lay flat on the bed, puncture the subclavian vein and insert two guide wires. Cut the skin under the guide wire to make a skin bag, and stop bleeding accurately to avoid continuous bleeding of the skin bag. The pacemaker electrode is inserted into the heart cavity by guiding the guide wire, one is placed in the ventricle and the other in the atrium, and the corresponding parameters of the electrode, such as pacing threshold, impedance, etc., are measured at the same time. If the parameters are good, fix the electrode, connect the electrode with the pacemaker, place the pacemaker in the skin bag, fix the pacemaker and electrode, suture the skin layer by layer, and the operation is completed.
45639813|NCT02348281|Drug|Bicalutamide|150mg, po, qd, d1-28
45915832|NCT04742023|Device|Continuous Glucose Monitor Placebo Applied|The Guardian™ Sensor glucose sensor is part of the Medtronic Continuous Glucose Monitoring (CGM) system. The system then uses these signals to provide sensor glucose values. Patients post-renal transplantation will have CGMs applied however values will not be interpreted.
45915833|NCT00388128|Drug|Caffeine 6mg/kg|Capsules of caffeine 6 mg/kg, taken orally at each test. Before and after treadmill testing
45915834|NCT04740775|Device|LiquiBand Exceed|Cyanoacrylate glue for closure of surgical wounds
45915835|NCT04740775|Device|LiquiBand Rapid|Cyanoacrylate glue for closure of surgical wounds
45915836|NCT04703179|Other|Genetic test evaluation|Patients with rare and undiagnosed disease and their family members may be evaluated on a case by case basis. The research study may perform multi-omics testing to provide a diagnosis or to provide biomarker discovery.
45915837|NCT04689646|Behavioral|Mind Body Intervention 1|Mind body techniques for Intervention 1 will be taught in lectures and group discussion sessions.
45915838|NCT04689646|Behavioral|Mind body intervention 2|Mind body techniques for Intervention 2 will be taught in lectures and group and/or individual sessions.
45639814|NCT05021783|Diagnostic Test|Pressure pain threshold|The sacroiliac PPT scores will be obtained bilaterally from four measurement points; the first point is located 1 cm medially and caudally from spina iliaca posterior superior (SIPS) and 3 more laterally, medially and cranially.The left trapezius muscle will be used to evaluate distant control point .The 1 cm2 algometer probe will be placed vertically in the each selected point and pressure will be increased with 0.1 kg/sc until the participant reporting pressure became painful. The pressure value at which the pain is first felt will be accepted as the PPT of that point.
45639815|NCT05021783|Diagnostic Test|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
45639816|NCT05021783|Other|Spondyloarthritis Research Consortium of Canada scoring system|SPARCC scoring consists of two subcomponents to detect sacroiliitis activation and structural damage. In the short tau inversion recovery (STIR) sequence, 6 consecutive coronal sections will be examined and the signal increase will be scored as 0 = normal signal and 1 = increased signal. In this way, the maximum score can be 12 in a single coronal section. Evaluations Total maximum score of 72 in 6 consecutive coronal sections. In structural scoring, similar to sacroiliitis scoring, the SI joint is divided into four quadrants to evaluate whether there is fatty change, erosion, backfill and ankylosis. Each lesion is scored as 0=absent or 1=present. In this way, fatty change and erosion can be scored between 0-40 and backfill and ankylosis can be scored between 0-20 in 5 consecutive sections in total scoring.
45639817|NCT05021783|Diagnostic Test|Temporal Summation|TS will be evaluated over the trapezius muscle and sacroiliac joints with manuel algometer. In the evaluation of TS, a pressure as much the PPT value of each point will be applied with pain pressure algometer ten times with a 1-second interstimulus interval. Patients will be asked to rate their pain using on a 0 to 10 visual analogue scale (VAS) at 0, 5, and 10 seconds. TS will be calculated by subtracting the rating at 0 seconds from the rating at 10 seconds. The point that is located 1 cm medially and caudally from SIPS was used for SI joint TS measurement on both sides.
45639818|NCT05021783|Diagnostic Test|Conditioned pain modulation|First stimulus will be applied to trapezius with the pressure that induced a pain intensity of 4 point on a 10 point VAS as called a test stimulus. After that the right hand of the patient will be immersed in 7 Celsius water for 20 seconds to create a conditioning stimulus. Second test stimulus with the same intensity of first one will be applied to trapezius after the conditioning stimulus and patients will be asked to rate their pain. If the patients cannot hold their hand in the water for 20 seconds, the test stimulus will be applied immediately after the patients removed their hands out of water. The ratio between the first and second VAS values multiplied by 100 will be defined as CPM score
45777764|NCT04639414|Drug|Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector|Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d compared to matching placebo after 48-week treatment.
45777765|NCT04639414|Drug|Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide|Measurement of the effect of empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
45639819|NCT03147313|Device|MTS Medical UG Orthogold 100|300 or 500 pulses, frequency 3Hz, energy 1 (0,1mJ/mm2)
45639820|NCT03147313|Device|Sham|Extracorporeal shock wave treatment will be faked.
45639821|NCT04638400|Drug|Simvastatin 40mg|Simvastatin administered daily for 6 weeks
45639822|NCT04638400|Drug|Ezetimibe 10mg|Ezetimibe administered daily for 6 weeks
45777766|NCT04639414|Drug|Placebo matching empagliflozin and placebo pen injector matching semaglutide|Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d OR empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
45915839|NCT00006462|Drug|gemcitabine hydrochloride|
45915840|NCT04604197|Other|Angiography and Clinical Follow up|Angiography and Clinical Follow up
45915841|NCT04604197|Other|Clinical Follow up|Clinical Follow up
45777767|NCT04630158|Other|SAF312 Placebo|Topical ocular, suspension eye drops,
45915842|NCT00006465|Drug|capecitabine|Patients receive oral capecitabine twice daily on days 1-5 weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose(MTD).
46070327|NCT00913107|Drug|Lamictal®|"The regime of prescription for Lamictal® during the clinical trials was as follows:~50 mg twice daily for 10days, followed by,~100 mg twice daily for the next 10days, followed by,~100 mg thrice daily for the next10 days, followed by,~100 mg four times daily for the final 10 days."
45777768|NCT04630158|Drug|SAF312|Topical ocular, suspension eye drops
45777769|NCT04629716|Drug|Medical Cannabis|Medical marijuana is defined by Florida state statue 381.986 as all parts of any plant of the genus Cannabis, whether growing or not; the seeds thereof; the resin extracted from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant or its seeds or resin, including low-THC cannabis, which are dispensed from a medical marijuana treatment center for medical use by a qualified patient.
45777770|NCT04625270|Drug|avutometinib (VS-6766)|avutometinib (VS-6766) monotherapy
45777771|NCT04625270|Drug|avutometinib (VS-6766) and defactinib|avutometinib (VS-6766) and defactinib combination
45777772|NCT04623541|Biological|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days (except Cycle 1 for high-dose cohorts = 35 days).
45777773|NCT04623541|Biological|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 21 days (Cycle 1-6) and 28 days for Cycle 7 and beyond.
45777774|NCT04623541|Drug|rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone|R-CHOP will be administered intravenously in cycles of 21 days for the first 6 cycles.
45777775|NCT04623541|Drug|Venetoclax|Venetoclax tablets will be administered orally once daily during the 5-week ramp up period and during Cycle 1-26 of 28 or 35 days each.
45777776|NCT04623541|Biological|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days.
45777777|NCT04623541|Drug|Lenalidomide|Lenalidomide capsules will be administered once daily for 21 days in each cycle of 28 days up to 12 cycles.
45777778|NCT04621929|Drug|Phentermine / Topiramate Oral Product|All participants in the experimental group will receive oral generic tablet phentermine (18.75 or 37.5 mg dose) and topiramate (daily 100 mg or 150 mg dose)
45777779|NCT04621929|Combination Product|Citrate Salts, Allopurinol, Diet|Control participants will complete initial visit requirements and study enrollment and will be maintained on their current therapy.
45777780|NCT04614441|Drug|OFEV®|nintedanib
45777781|NCT04612491|Behavioral|Pre-operative Consultation|Pre-operative consultation will be given before Mohs surgery
45639823|NCT02354287|Procedure|Cold forceps polypectomy with pre lift|"Polyps ≤7mm will be included in the study if deemed appropriate by the colonoscopist..~These polyps will be resected with cold forceps after pre injection into the submucosa with a few millilitres of pre injection solution (19 ml gelofusine, 1ml 1:10000 adrenaline and 1ml indigo carmine). Polyps are grasped with the cold forceps and pulled away from the rest of the colonic mucosa. Attempt will be made to remove polyps with single attempt with the forceps however several grasps may be required for complete visual resection of the polyp.~The polypectomy site and a 5mm rim of normal appearing tissue will then be resected with endomucosal resection (EMR) using conventional snare method. This is to ascertain if there is any residual polyp tissue."
45639824|NCT03094949|Procedure|Partial Nephrectomy|The renal capsule is cut in a monopolar fashion around the tumor. After the renal artery is clamped with a bulldog clamp, cold cutting by scissors into the renal parenchymal boundary of the tumor is performed with an optimal surgical margin (a few millimeters). After retrograde injection of diluted indigo carmine, continuous suturing of the opened collecting system and transection of the major vessels is performed with intracorporeal knot-tying. Parenchymal suturing is performed in a continuous fashion. The 20-30 cm length of thread is used, and a knot is made at the end of the thread. A large Hem-o-lok polymer clip (Weck Closure System, Research Triangle Park, NC) is attached on the proximal side of the knot. Before the thread is tightened or cinched, the parenchyma is sutured in a running fashion with three or four stitches without any bolster so that the renal bed is kept in its natural position during the suturing.
45639825|NCT03094949|Procedure|microwave ablation|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
45777782|NCT04611022|Behavioral|HPV Educational Intervention|The videos are 8-minute narrative films created using an entertainment-education (E-E) approach that embeds an educational narrative message into an entertainment format such as media. E-E narratives have demonstrated a significant effect (r = .12, p < .001) on health behavior change. Evidence-based small media interventions that Dr. Borrayo has produced include videos that are highly verbal, visual, and entertaining (e.g., acted fictional stories). The aims of the video will be to model uptake of the HPV vaccine, but also to reinforce self-efficacy, subjective norms, and behavioral intentions, all significant precursors to behavior change.
45777783|NCT04596553|Dietary Supplement|Essential Amino Acid|Immediately following the exercise intervention participants will consume their assigned essential amino acid supplement
45777784|NCT04596553|Dietary Supplement|Collagen Peptide|Immediately following the exercise intervention participants will consume their assigned collagen peptide supplement
45777785|NCT04596553|Dietary Supplement|Maltodextrin Placebo|Immediately following the exercise intervention participants will consume their assigned maltodextrin supplement
45777786|NCT04593927|Drug|Mayzent|There is no treatment allocation. Patients administered Mayzent by prescription that have started before inclusion of the patient into the study will be enrolled.
45639826|NCT02349919|Drug|Procaterol|Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
45639827|NCT02349919|Drug|Placebo|Placebo twice daily for 4 weeks
45639828|NCT03091985|Device|PersonalFit - Breast shield|Subjects are to pump 15 min with the comparator device
45639829|NCT03091985|Device|Brownie - Breast shield|Subjects are to pump 15 min with the investigational device
45777787|NCT04582279|Diagnostic Test|Lung ultrasound|The lung ultrasound will be performed by a trained pulmonologist by gently pressing a probe to various areas of your chest. This is a non-invasive procedure and you should not feel any pain. The ultrasound will take less than 10 minutes.
45777788|NCT04573023|Drug|JR-141|IV infusion, 2.0 mg/kg/week
45777789|NCT04573023|Drug|Idursulfase|IV infusion
45777790|NCT04573023|Drug|JR-141 or Idursulfase|"The subjects who have achieved the pre-specified criteria* are able to change the drug.~*If a subject in Idursulfase group shows decline in their neurocognitive outcome, idursulfase can be switched to JR-141.~If a subject in JR-141 group shows decline in their peripheral outcome, JR-141 will be switched to idursulfase."
45777791|NCT04572763|Drug|Copanlisib|Intravenous infusion
45777792|NCT04572763|Drug|Venetoclax|Tablet taken orally
45777793|NCT04568161|Procedure|Physical Characteristics|Body weight, height and waist circumference
45777794|NCT04568161|Procedure|Muscular Sympathetic Nervous Activity|Microneurography technique.
45777795|NCT04568161|Diagnostic Test|Cardiac Function|Echocardiography.
45777796|NCT04568161|Diagnostic Test|Heart rate|Electrocardiography
46070328|NCT00913107|Drug|Tegretol®|"The regime of prescription for Tegretol® during the clinical trials was as follows:~150 mg twice daily for 10days, followed by,~200 mg thrice daily for the next 10days, followed by,~300 mg thrice daily for the next 10 days, followed by,~300 mg four times daily for the final 10 days."
45777797|NCT04568161|Diagnostic Test|Blood pressure|Non-invasive photoplethysmography.
46070329|NCT00569803|Drug|belatacept|single dose, 116 days
46070330|NCT00569803|Drug|Placebo|Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)
46070331|NCT00913185|Drug|Acne Free, Proactiv|
46070332|NCT00920426|Drug|GSK1265744 30mg|GSK1265744 30 mg
46070333|NCT00920426|Drug|Placebo|Placebo to match GSK1265744
46070334|NCT00920426|Drug|GSK1265744 5mg|GSK1265744 5mg
46070335|NCT04046185|Drug|PD-1 inhibitor combined progesterone|Toripalimab combine with progesterone
46070336|NCT04046185|Drug|progesterone|progesterone
46070337|NCT00810589|Drug|Levemir|0,4 IE per kg bodyweight
46070338|NCT00810589|Drug|Humalog NPL Insulin|0,4 IE per kg bodyweight
46070339|NCT00810667|Drug|Lu AE58054|twice daily oral dose (60 mg BID: total dose 120 mg/day)
45777798|NCT04568161|Diagnostic Test|Blood Assessments|Serum and Plasma will be extracted by centrifugation. Endothelial microparticles by flow cytometry Interleukin-6 and tumor necrosis factor α by ELISA, High-sensitive reactive serum C-reactive protein by immunoturbidimetric assay, NT- ProBNP According to Central Laboratory, Hospital das Clinicas, HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo. Endothelin-1 by immunoenzymatic method Nitric oxide by gas chemiluminescence Lipoperoxidation by fluorimetry Carbonyl by spectrophotometer, and Superoxide Dismutase (SOD) by colorimetry.
45777799|NCT04568161|Diagnostic Test|Muscle blood flow|Venous occlusion plethysmography
45777800|NCT04568161|Diagnostic Test|Endothelium-dependent vascular function|Brachial ultrasound
45777801|NCT04568161|Diagnostic Test|Vascular intima-media thickness|Carotid ultrasound
45777802|NCT04568161|Diagnostic Test|Physical Capacity|Cardiopulmonary exercise test
45639830|NCT03147235|Behavioral|vitrectomy with music listening|Those randomized to music listening will be exposed to a standardized playlist of previously validated relaxation music.
45777803|NCT04568161|Drug|Anthracycline & Cyclophosphamide treatment scheme|Four session of intravenous (in bolus) infusion of doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 with an interval of 21 days between sessions.
45639831|NCT04972721|Other|No treatment given|The study is non-interventional with no study-specific treatment during the study and the patients will be treated as per Treating Physician's and patient's own discretion.
45639832|NCT02349763|Drug|Intravenous Dexamethasone|Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
45639833|NCT02349763|Drug|Oral Dexamethasone|Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
45777804|NCT04559581|Drug|Nintedanib|Capsules
45777805|NCT04556981|Biological|M72/AS01E Mycobacterium tuberculosis vaccine|Participants will receive an intramuscular dose of M72 (10 micrograms of recombinant fusion protein) reconstituted with AS01E (an adjuvant system), on Day 1 and Day 29
45777806|NCT04556981|Biological|Placebo|Participants will receive an intramuscular dose of saline (0.9% NaCl), on Day 1 and Day 29
45777807|NCT04556370|Drug|Normal saline|Normal saline infusion simultaneous with subarachnoid block
45777808|NCT04556370|Drug|Norepinephrine|Different infusion dose of norepinephrine simultaneous with subarachnoid block
45777809|NCT04553692|Drug|IGM-8444|DR5 Agonist Investigational Drug
45777810|NCT04553692|Drug|FOLFIRI|Chemotherapy Regimen
45777811|NCT04553692|Drug|Bevacizumab (and approved biosimilars)|Targeted Therapy
45777812|NCT04553692|Drug|Birinapant|SMAC-mimetic Investigational Drug
45777813|NCT04553692|Drug|Venetoclax|Targeted Therapy
45777814|NCT04553692|Drug|Gemcitabine|Chemotherapy
45777815|NCT04553692|Drug|Docetaxel|Chemotherapy
45777816|NCT04553692|Drug|Azacitidine|Chemotherapy
45777817|NCT04539938|Drug|tucatinib|300 mg orally twice daily
45777818|NCT04539938|Drug|trastuzumab deruxtecan|5.4 mg/kg via intravenous (into the vein; IV) infusion on Day 1 of each of 21-day cycle
45448531|NCT03759418|Device|exclusion of the left atrial appendage|A trans esophageal echocardiogram will be performed to assess the Atriclip device in the closure of the left atrial appendage in patients that had surgery at least 12 months ago.
45639834|NCT02349841|Drug|Meropenem|To administer 2g daily 8 hourly for 14 days
45639835|NCT02349841|Drug|Faropenem|To adminster 600mg 8 hourly daily for 14 days
45639836|NCT02349841|Drug|Amoxycillin/clavulanic acid|To administer 625mg 8 hourly daily for 14 days together with the faropenem and meropenem
45639837|NCT02349841|Drug|Rifafour e275|To be taken as per the National TB treatment programme for 14 days
45639838|NCT02349997|Other|no interventions|This is an observational study and no intervention applied.
45639839|NCT05020925|Drug|SHR-1701|Intravenous (IV) on Day 1 of each cycle
45639840|NCT05020925|Drug|Famitinib|Famitinib, po, qd
45639841|NCT02349373|Behavioral|An 8 week preconditioning period|Receipt of a weekly running schedule through an online training diary.
45639842|NCT02349373|Behavioral|16 week training period|Receipt of a weekly running schedule through an online training diary.
45639843|NCT05029583|Other|routine screening|routine screening for advanced NASH
45639844|NCT05029583|Other|physician-driven screening|physician-driven screening for advanced NASH
45639845|NCT02349529|Behavioral|Psychosocial Intervention Group|6 group sessions
45777819|NCT04535882|Diagnostic Test|serum leucine-rich alpha-2 glycoprotein (LRG) levels|Patients who were diagnosed with possible UC or Crohn disease according to endoscopic, radiological, histological, and clinical criteria were enrolled. Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy were performed within 7 days.
45777820|NCT04535687|Drug|Fluzoparib|Fluzoparib
45777821|NCT04527887|Drug|Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg)|Intracanalicular dexamethasone insert contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for up to 30 days for the reduction of postsurgical inflammation and pain associated with ocular surgery.
45777822|NCT04527887|Other|ProLong™ collagen plugs|The long term synthetic punctal plug is composed of an absorbable copolymer material and measures 0.4mm in diameter and 2.0mm in length.
45777823|NCT04526145|Behavioral|Stress and emotion management|Group intervention led by a nurse and dietitian to address stress, emotion management and healthy lifestyle for African American women with hypertension. The weekly sessions will include:how to manage stress during Covid-19, taking blood pressure, interpersonal relationships skills, mindful awareness, restful sleep, physical activity, and healthy eating.
45777824|NCT04521478|Drug|BI 1358894|BI 1358894
45777825|NCT04521478|Drug|Placebo|Placebo
45777826|NCT04521478|Drug|Quetiapine|quetiapine
45777827|NCT04484285|Device|Transcutaneous Vagal Nerve Stimulation (tVNS)|vagal nerve stimulation
45777828|NCT04480099|Drug|CHOP|Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses
45639846|NCT02349529|Other|Waiting list control|Treatment as usual
45777829|NCT04480099|Drug|CHOP+X|X: X(i.e. targeted drug) will decided by NGS results as following. Decitabine 10mg/m2 ivgtt D-5 to-1 if with TP53 gene muation. Azacitadine 100mg/day ivgtt D-7 to -1 if with TET2/KMT2D gene mutation. Chidamide 20mg/day po D1,4,8,11 if with CREBBP/EP300 gene mutation. Lenalidomide 25mg/day po D1-10 if without gene mutation above. X will be added from the second cycle CHOP:Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses
45777830|NCT04474847|Drug|Abatacept|Participants randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
45777831|NCT04474847|Drug|Placebo|Participants randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
45777832|NCT04458831|Drug|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45639847|NCT05021159|Other|MTX, (but the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression)|the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression
45777833|NCT04458831|Drug|Pomalidomide|Pharmaceutical form: oral
45777834|NCT04458831|Drug|Dexamethasone|Pharmaceutical form: oral
45777835|NCT04458831|Drug|Carfilzomib|Pharmaceutical form: solution for infusion
45777836|NCT04458259|Drug|PF-07265807|Given 2 weeks on/1 week off
45777837|NCT04458259|Drug|Sasanlimab|Given SC Q3W
45777838|NCT04458259|Drug|Axitinib|Dosed per package label starting with 5 mg PO BID
45777839|NCT04438460|Biological|Blood test|"For patient group, blood tests will be performed at day 1-2, day 3-5 and day 60.~For control group, blood test will be performed the day of elective surgery."
45777840|NCT04436926|Behavioral|opioid approach bias modification|The investigators will use a training version of the Approach-Avoidance Task (AAT), in which patients are asked to respond to the format of presented pictures, irrespective of the pictures' content. Pushing a presented picture away will decrease picture size, whereas pulling a picture closer will increase size. There are 2 categories of pictures; 20 different opioid and 20 different non-medication alternative pain managing activities. Training effect is achieved by presenting opioid pictures in push format only and non-opioid pictures in pull format only. Two hundred training trials are presented per session.
45777841|NCT04436926|Behavioral|sham training|Sham training is identical to opioid approach bias training, except pictures are presented randomly in both formats.
45777842|NCT04423757|Drug|BI 1358894|125 milligram (mg) BI 1358894 taken orally as three film-coated tablets (1x 25mg and 2x 50mg) once a day in the morning for six weeks.
45777843|NCT04423757|Drug|Placebo|Placebo matching BI 1358894 taken orally as three film-coated tablets once a day in the morning for six weeks.
45777844|NCT04423055|Drug|Etonogestrel contraceptive implant|Place etonogestrel contraceptive implant.
45777845|NCT04418401|Drug|Donafenib and anti-PD-1 antibody|Donafenib was taken orally twice daily, and anti-PD-1 antibody was applied biweekly.
45777846|NCT04410523|Drug|CSJ117|"CSJ117 (0.5 mg, 1mg, 2mg, 4 mg and 8 mg) inhaled once daily for 12 weeks. Delivered via Concept1 device.~CSJ117 = inhaled monoclonal antibody fragment"
45777847|NCT04410523|Drug|Placebo|Placebo inhaled once daily for 16 weeks. Delivered via Concept1 device
45777848|NCT04408820|Drug|Roxadustat|Oral
45777849|NCT04407754|Dietary Supplement|Inositol supplement|Inositol supplements given to inositol arm
45639848|NCT02353975|Drug|SHR3824|SHR3824 tablet,10mg, fasting conditions and high fat, high calorie breakfast.
45639849|NCT05020613|Procedure|Procedure: Early removal group|Participants assigned this arm will have their urethral catheters removed at 2 days after low anterior resection of the rectum
45639850|NCT05020613|Procedure|Procedure: Late removal group|Participants assigned this arm will have their urethral catheters removed after 48.th hours after Low anterior resection of the rectum
45639851|NCT03159247|Behavioral|eyeGuide|The eyeGuide, a web-based tool to facilitate a personalized behavior change program for non-adherent glaucoma patients.
45777850|NCT04407754|Dietary Supplement|Placebo supplement|Placebo supplement given to placebo arm
45777851|NCT04404400|Drug|Investigational products administration|"Investigational products include:~Hydrocortisone hemisuccinate 50 mg: one intravenous injection every 6 hours, and~9 alpha fludrocortisone 50 μg: one tablet per day via a nasogastric tube.~All treatments will be stopped after 7 days or until the patient has left the intensive care unit (whichever occurs first) without tapering off."
45777852|NCT04404400|Drug|Placebo administration|Placebos for hydrocortisone and for fludrocortisone, administered in same manner as the active drugs in the interventional arm, for 7 days.
45777853|NCT04404283|Drug|Brentuximab vedotin|1.2 mg/kg administered into the vein (IV; intravenously) infusion every 3 weeks
45777854|NCT04404283|Drug|Rituximab|375 mg/m^2 administered via intravenous infusion on Cycle 1 Day 1. 1400 mg injected under the skin (subcutaneous) permitted every 3 weeks from Cycle 2 Day 1 through end of treatment.
45777855|NCT04404283|Drug|Lenalidomide|20 mg given by mouth (orally) daily
45777856|NCT04404283|Other|Placebo|Administered via intravenous infusion every 3 weeks
45777857|NCT04385602|Drug|Intratracheal dexmedetomidine|Thirty minutes before the end of the surgery, Dex (0.5μg/kg diluted and mixed in 1ml saline in a medical spray bottle) will be sprayed down the intratracheal tube
45777858|NCT04385602|Drug|Saline Solution|Thirty minutes before the end of the surgery, 1ml saline in a medical spray bottle will be sprayed down the intratracheal tube
45777859|NCT04379713|Biological|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
45777860|NCT04379713|Biological|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
46070340|NCT00810667|Drug|Placebo|twice daily oral dose
45639852|NCT03094559|Device|FlowMet|The FlowMet device will be placed on the index finger of the right hand. Signal fidelity will be assured by confirming the presence of a pulse waveform if one is expected and by assuring that an appropriate amount of light is be detected by the FlowMet device. Following placement of the FlowMet device, a period of 10 seconds will be allowed to elapse to allow transient changes in perfusion due to device placement to diminish. FlowMet blood flow data will be recorded for 20 seconds using the FlowMet data acquisition software. These steps will be repeated for digits 1 and 2 on the limb with diagnosed or suspected CLI, or on both limbs if both are diagnosed or suspected of having CLI.
45639853|NCT02354053|Drug|Switch to Triumeq|
45639854|NCT02354053|Behavioral|Adherence support + current ART|
45639855|NCT05029037|Drug|High doses of intravenous vitamin C|Two (2) High doses of intravenous vitamin C for seven (7) days.
45777861|NCT04379687|Other|Virtual reality|Use of virtual reality glasses for balance work
45777862|NCT04379687|Other|Control group|Balance treatment with according to Bayouk physiotherapy
45639856|NCT05029037|Drug|Dextrose 500 mL|"Application of a vial of LEV in 100 mL of water for injection, which is diluted in 400mL of 5% Dextrose for a final volume of 500mL of intravenous fluids, to be applied to the chosen patient, in a drip of 0.5 grams of the placebo solution per minute, for a total of 60 minutes.~Twice a day for seven days."
45639857|NCT05028959|Other|Multidisciplinary monitoring of healthy women|Multidisciplinary monitoring
45639858|NCT02353741|Drug|EGFR-TKIs|Beginning on day 2 of treatment, receive oral erlotinib 150mg per day.
45639859|NCT02353741|Radiation|thoracic radiotherapy|From the beginning of EGFR-TKIs, within 2 weeks, receive concurrent thoracic radiotherapy, pGTV54～60Gy/27～30f/5.5～6w.
45639860|NCT03092063|Behavioral|Tomando Control-Nurse|Tomando Control de su Diabetes-Nurse is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained Registered Nurses. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
45777863|NCT04359108|Device|Navigation System for Users of a Visual Prosthesis|We use common psychophysical judgments such as the following: discriminating between two alternatives by saying which is present in the field of view, touching a tablet computer to indicate the apparent location of a target in the frontal plane, and looking for targets by rotating the head and pointing when one is found. We will compare user performance using the Basic system with user performance using the Augmented and Augmented + Modal systems where contextual information associated with the task is conveyed to users via enhanced visual, auditory, and haptic modalities.
45777864|NCT04346615|Drug|Zavegepant (BHV-3500)|10 mg intranasal (IN) for 14 days
45777865|NCT04346615|Drug|Placebo|Placebo Q8h for 14 days
45777866|NCT04325217|Drug|Nintedanib|Capsules
45777867|NCT04323397|Device|Non-invasive ventilation|Intervention nasal high frequency oscillatory ventilation (nHFOV) and nasal synchronized intermittent positive pressure ventilation (nSIPPV) were generated by neonatal ventilators (SLE6000 infant ventilators, United Kingdom) using bi-nasal prongs (RAM cannula, NEOTECH®, USA) or the nasal mask of the same type for both ventilation modes. The size of the prongs was determined by the infant's weight. The largest possible prongs were used, with a snug fit to avoid leakage. Pacifier for preterm and term neonate (Jollypop™, USA) was taken to avoid leakage from the mouth. The disposable ventilator circuit (Fisher & Paykel RT268™, Evaqua Dual Limb Infant Breathing Circuit Kit with Evaqua 2 Technology and Pressure Line, Flow > 4L/min, New Zealand) was used. The initial NIV setting was (7) described in arm description. (above)
45777868|NCT04323280|Drug|Dexamethasone therapy|Dexamethasone 20MG once daily for 4 days with additional colchicine therapy for 3 months
45777869|NCT04323280|Drug|NSAID therapy|NSAIDS (Ibuprofen or Aspirin) or Glucocorticoid (Prednisone) therapy for 3 weeks with addional colchicine therapy for 3 months
45777870|NCT04317937|Other|Jaw opening-closing movements|"Jaw opening-closing movements Patient seated on a normal standard comfortable chair with proper back support and feet placed on the floor with no head support.~Active jaw movements The patient will then perform maximal Jaw opening-closing movements at a pace convenient for his/her for 15 times. Three sets with two minutes rest in between will be ensured.~Active neck exercises While performing the above movements of jaws, the patient will actively perform active neck exercise (head-neck movements in sagittal plane- Extension- Flexion).~Head-Neck extension on jaw opening (Mandible moves vertically downward); and then from Head-Neck extension to natural flexion movement on jaw closing (Mandible moves vertically upward)."
45915843|NCT00006465|Drug|irinotecan hydrochloride|Patients receive irinotecan IV over 30 minutes once weekly for 4 weeks (one hour after oxaliplatin). Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose(MTD).
45915844|NCT00006465|Drug|oxaliplatin|Patients receive oxaliplatin IV over 2 hours. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
45915845|NCT03863509|Behavioral|Cigarettes|smokes daily
46070341|NCT00810745|Procedure|starr|stapled transanal rectal resection
46070342|NCT04240340|Other|semi-structured interview|Semi-structured, face-to-face interviews will be carried out with participants.
46070343|NCT02552485|Other|No intervention was applied, because it is an observational study|
46070344|NCT04253132|Drug|Tolfenamic Acid|Tolfenamic acid is an NSAID closely resembling mefenamic and flufenamic acid.
46070345|NCT04253132|Drug|Placebos|oral placebo
46070346|NCT00814957|Drug|GSK618334|D3 receptor antagonist
45639861|NCT03092063|Behavioral|Tomando Control-Promotora|Tomando Control de su Diabetes-Promotora is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained promotoras. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
45639862|NCT03092063|Behavioral|Enhanced engagement|The Tomando Control clinician (either a promotora or a Registered Nurse, depending on the original group assignment), will conduct up to three home visits that are designed to explain the purpose of the TC intervention to a key relative so as to re-engage the family member in the group process
45639863|NCT03092063|Behavioral|Multifamily Group|"The multifamily group consists of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
45639864|NCT02353663|Other|Echocardiography|Echocardiography examination
45639865|NCT02347969|Dietary Supplement|X34|Dietary supplement named X34
45777871|NCT04317937|Other|Specific Active exercises|"Active neck exercises:~Patient seated on a normal standard comfortable chair with proper back support and feet placed on the floor with no head support.~Note: For Active neck exercise (flexion and extension movements of neck), firstly the patient will perform maximal Jaw opening-closing movements at a pace convenient for his/her for 5 times in order to observe (eyeball observation) the neck extension and flexion as reference point for each individual.~Using this reference points, the patient will ask perform below mentioned active neck exercise.~Active neck exercises: The patient will then perform active neck exercise (flexion and extension of neck) at a pace convenient for his/her for 15 times. Three sets with two minutes rest in between will be ensured.~Active jaw movement: While performing the above movements of neck, the patient will not perform any jaws movements."
45639866|NCT05028803|Drug|sodium phenylbutyrate|same as arm/group
45639867|NCT03146923|Other|Current Low Phosphorus Diet Prescription|"Routine / Standard Care: Routine dietary intervention is currently provided by one-to-one counselling to the subject and his/her relevant family members or carers, by a state registered dietitian regarding a diet which provides <15mg Phosphorus /g Protein (over the day). This is equivalent to approximately 1000mg P / day. This is based on the 'Eating Well with Kidney Disease' dietsheet produced by the Renal Interest Group (RIG) of the Irish Nutrition & Dietetic Institute (INDI) in 2010 and includes following main components:~Restricting protein intake to requirements (1-1.2g/kg Ideal Body Weight)~Restricting dairy intake (1-1.5 portions per day)~Avoiding foods high in phosphate~Avoiding foods with phosphate additives"
45639868|NCT03146923|Other|Modified Low Phosphorus Diet Prescription|"Modified Low Phosphorus Diet Prescription: The new prescription recommends five changes to current management~Introduction of some plant protein in the form of pulses and nuts where the phosphorus is largely bound by phytate~Increased focus on avoiding additives~Introduction of more whole grains e.g. wholemeal sliced pan/ pasta/rice .~Avoiding over-prescription of protein which carries an obligatory phosphorus load.~Focus on high protein foods with a low phosphorus to protein ratio"
45639869|NCT05020223|Other|Vital pulp therapy|Vital pulp therapy different modalities for management of deep carious lesion in primary teeth
45639870|NCT03147001|Other|Protein ingestion|A protein drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
45639871|NCT03147001|Other|Non-caloric placebo ingestion|A placebo drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
45639872|NCT03094481|Procedure|SCPB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Superficial Cervical Plexus Block at C4 or C5.
45639873|NCT03094481|Procedure|ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Interscalene Brachial Plexus Block at C5 or C6.
45777872|NCT04317937|Other|Exercise Therapy|"Isometric strengthening exercises For flexion the starting position will be upright head and neck. The patient will be asked to hold this position.~For extension the starting position will be upright head and neck. The patient will be asked to hold this position.~For rotation the starting position will be upright head and neck. The patient will be asked to hold this position.~• In all above movements ( flexion, extension & rotation) following method will be followed: Manual resistance will then be applied by the investigator by placing the hand on the patient's forehead, posterior part of the head and lateral part of the head with 6 second hold. 15 repetitions of this exercise will be performed. Three sets with one minute rest in between will be ensured."
45915846|NCT03863509|Behavioral|E-Cigarettes|E-cigarette usage >/= 5 days/week
45639874|NCT03094481|Procedure|SCPB + ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided SCPB at C4 or C5 + 10ml injected for ISB at C5 or C6.
45639875|NCT03094481|Drug|Bupivacaine hydrogen chloride , epinephrine|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine
45639876|NCT04438837|Drug|Hydroxychloroquine|Hydroxychloroquine post exposure prohylaxis
45915847|NCT04575181|Drug|NNC0268-0965|For subcutaneous (s.c., under the skin) injection once daily for 26 weeks
45639877|NCT05020067|Radiation|superficial parotid lobe-sparing intensity-modulated radiotherapy|The superficial parotid lobe was contoured as an OAR, and V26 (the percentage volume receiving 26 Gy or more) in the superficial parotid lobe was constrained to be less than 30%.
45639878|NCT02348125|Drug|Mitochondrial Cocktail|
45639879|NCT05019911|Device|Polysomnography|In the cross-sectional part, the group of patients with COPD alone and the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by traditional sleep monitoring equipment (polysomnography) for vital signs in order to diagnose COPD combined with sleep apnea hypopnea syndrome.
45915848|NCT04575181|Drug|Insulin glargine|For s.c. injection once daily for 26 weeks
45915849|NCT04575181|Drug|Placebo (NNC0268-0965)|For s.c. injection once daily for 26 weeks
45915850|NCT04575181|Drug|Placebo (insulin glargine)|For s.c. injection once daily for 26 weeks
45915851|NCT00006468|Drug|FOLFOX regimen|
45915852|NCT00006468|Drug|fluorouracil|
45915853|NCT00006468|Drug|leucovorin calcium|
45915854|NCT00006468|Drug|oxaliplatin|
45915855|NCT00387439|Behavioral|standard medical treatment + anoperineal physiotherapy.|
45639880|NCT05019911|Device|Millimeter wave radar equipment|In the cross-sectional part, the group of patients with COPD alone and the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by millimeter wave radar equipment for vital signs in order to diagnose COPD combined with sleep apnea hypopnea syndrome. In the cohort part, both groups of patients will be continuously monitored by millimeter wave radar equipment for vital signs for months in order to establish a model to predict acute exacerbations of COPD combined with sleep apnea hypopnea syndrome.
45639881|NCT03149185|Behavioral|Technology based cognitive behavioral stress management|Intervention is delivered through Telecare (web based technology) in a group for 60-90 minutes/session. During each session, participants are taught/discuss a new anxiety/arousal reduction technique and focus on stress management. Efficacy of available treatments, disease course, symptom burden, communication with intimate partner and/or family members and health care provider, impact of stress on physical and mental health and symptoms, and management of APC and HT symptoms are used for educational purposes and as catalysts for discussing TCBSM techniques. We allow participants to describe psychosocial stressors with an emphasis on symptoms and disruption, HRQOL and their coping responses for in-session role-plays. Participants are able to access the system at any time to retrieve relaxation and stress management didactics, and contact community resources and other participants in their group.
45639882|NCT03149185|Behavioral|Technology based health promotion group-based attention matched control condition|Sessions include content from relevant NCI, ACS and other resources developed to address the needs of advanced cancer populations into each topic session. All sessions address APC-specific issues. While men receiving treatment for APC remain interested in general health issues and as they become increasingly aware of the end-of-life issues raised by facing advanced disease, they seem to be interested in making life changes in areas in which they do exercise control (e.g., nutrition), and as such have been integrated into the T-HP modules in addition to general recommendations from sources such as American Heart Association, the NIA and the ACS. T-HP participants are scheduled for weekly group-based health information and promotion sessions (60-90 mins.), which are delivered via our videophones by our T-HP facilitators.
45915856|NCT00387439|Behavioral|Standard medical treatment|
45639883|NCT02353273|Drug|WH-1 ointment|Each subject will be applied the one dose of WH-1 ointment on Day 1, and twice a day of WH-1 application from Day 2 to Day 13, then one dose for Day 14.
45639884|NCT05028335|Other|Carbamide Peroxide (PC) 22%) + placebo gel|Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them. The volunteers were instructed to apply a small amount of placebo gel, without active ingredient, with color, texture and odor similar to 1.5% oxalate gel (Painless, BM4, SC, Brazil) in the spaces related to the vestibular portions of the teeth trays, which were used for 10 minutes.
45639885|NCT05028335|Other|Carbamide Peroxide (PC) 22%) + Potassium Oxalate gel 1.5%|Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them with absorbent paper. The volunteers applied a small amount of 1.5% potassium oxalate gel (Painless, BM4, SC, Brazil) in the spaces relative to the vestibular portions of the tray's teeth, which were used for 10 minutes.
45639886|NCT02353351|Device|atrial septal occluder|Single arm atrial septal defect closure with the AMPLATZER Septal Occluder
45639887|NCT04434053|Device|MIETHKE M.blue®|The programmable shunt will be adjusted through the MIETHKE M.blue® valve.
45639888|NCT04434053|Device|MIETHKE proGAV 2.0® (with SA 2.0®)|The programmable shunt will be adjusted through the MIETHKE proGAV 2.0® valve that will be implanted together with a shunt-assistant SA 2.0®.
45639889|NCT02348047|Device|Hamilton T1|
45639890|NCT03094403|Drug|Azelaic Acid 15% topical gel|Gel
45639891|NCT03094403|Drug|Finacea® (azelaic acid) Gel, 15%|Gel
45639892|NCT03094403|Drug|Placebo|Gel
45639893|NCT03148873|Device|RespiraSense patient respiratory monitor system|Subjects will have their respiratory rate monitored for two hours using three different methods for capturing it
45639894|NCT02347891|Drug|Belimumab|Randomized phase: Week 0 - Week 36
45639895|NCT02347891|Drug|Placebo|Randomized phase: Week 0 - Week 36
45639896|NCT04467671|Combination Product|Tissue Engineered Vascular Grafts|Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance imaging (MRI)
45639897|NCT02347735|Other|No interventions, only data collection|Only data is collected from the subjects in both groups.
45639898|NCT03091517|Behavioral|GlycoLeap|"GlycoLeap is a 24-week programme includes the following features:~Interactive Education Lessons: Beginning week 1, the participant will be presented with a diabetes self-management education curriculum. These lessons are divided into 6 phases, and each lesson is fully accessible online from a computer or mobile phone, and takes approximately 10 - 15 minutes to complete.~The Glyco Mobile Application: During the 24 week intervention period, the participant will use the Glyco mobile application that allows them to track their weight (measured on the wireless weighing scale), self-tested glucose readings (measured using the glucometer kit), and log their foods and meals by taking photos using their phone. A health coach will review the participant's data regularly, provide personalised feedback."
45639899|NCT03147157|Other|tacrolimus regimen guided by HLA matching rate|required low,middle and high tacrolimus concentration in high,middle and low MR group respectively
45653057|NCT05126199|Other|Time restricted eating|"Following a 3 day baseline dietary assessment using the Nutritics 'app', patients will immediately commence time-restricted eating on a 18:6 basis (18 hours fasting, 6 hours eating window) for 12 weeks.~Participants will consume all their meals within a daily 6-hour period of their choosing, and this may change according to patient's lifestyle and preference to reflect a real-world situation. Participants may eat ad libitum / according to appetite during the eating period. Participants will fast for 18 hours per day, consuming only plain water, unflavoured/unsweetened sparkling water, black breakfast tea or black coffee. Alcohol must not be consumed during fasting periods~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12)."
46070347|NCT05136404|Drug|Selpercatinib|Administered orally
45639900|NCT05028023|Biological|Apneic oxygenation - supplemental high flow oxygen administration by an apneic way|In pediatric patients undergoing tracheal balloon dilatation, oxygenation maintenance is essential, while induction in anesthesia, cessation of spontaneous ventilation by neuromuscular relaxant and pediatric i-gel placement are necessary for access to trachea. After i-Gel placement controlled ventilation with 100% oxygen is initiated. Pediatric bronchoscope and balloon dilatation catheter are advanced into trachea to the stenotic area. Overall dilatation duration is 2,5-3minutes, while the balloon is inflated for 60sec. Every dilatation cession consists of three dilatations. First dilatation is performed without oxygen enrichment. During second and third dilatation, a nelaton catheter, connected with high oxygen flow, is advanced into i-Gel canal, together with bronchoscope and balloon catheter. Effects of no oxygenation and apneic oxygenation in regional cerebral oxygen saturation rSO2, pulse oximetry SpO2, arterial blood gases and haemodynamics are recorded and compared.
45639901|NCT03146767|Device|Tetanus stabilization of baseline|Administering a Tetanic stimulus before baseline stabilization shortens the stabilization period of baseline of a neuromuscular block monitor. This acts on the baseline value
45639902|NCT02347501|Drug|Sitagliptin (Januvia)|Sitagliptin 100mg tablet once daily (or 50mg once daily for participants with moderate kidney disease) for twenty four weeks in patients due to undergo NBUVB light therapy.
45639903|NCT05020301|Device|external meditation guided audio|Examining DMN connectivity and CSF flow in external meditation state by External Meditation Instruction Audio.
45448532|NCT03547180|Behavioral|Cognitive Therapy|The training included four components: (a) educating patients about exacerbating panic symptoms through catastrophic thoughts (vicious cycle), (b) identifying negative cognitions associated with physical sensation triggers of recent panic attacks, (c) practicing replacement of maladaptive cognitions with non catastrophic explanations, and (d) instructing patients in between session exercises during Phase I.
45777873|NCT04317937|Other|Supportive Treatment|"Postural Advice and Home Exercise Program with Dairy Postural advice and home exercise program. Postural Advise Maintain upright posture while sitting.~Avoid prolonged neck bending.~Avoid twisting movement of the neck.~Use a suitable pillow to maintain cervical spine.~Adjust computer screen at eye level.~Avoid constant use of mobile or similar device to prevent excessive strain over neck joints and muscles.~Carry light and even weight in both hands while shopping and other chores.•Stay hydrated.~Home Exercise Program (unsupervised) (3 times a day)~Forward flexion (Self Resisted), 6 sec hold, number of repetitions 15~Right side flexion (Self Resisted ), 6 sec hold, number of repetitions 15~Left side flexion (Self Resisted) x 6 sec hold,number of repetitions 15~Backward flexion (Self Resisted) x 6 sec hold, number of repetitions 15~Home Dairy A home dairy will be provided to maintain home exercise program record."
45777874|NCT04305769|Drug|Alanyl-glutamine|The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.
45777875|NCT04300998|Behavioral|Activities of Daily Living/ADLs|7 activities: bathing, dressing, grooming, feeding, walking inside the home, walking outside the home, and bladder and bowel control. Participants get 2 points for each activity that is not limited at all, 1 point for limited a little, and 0 points for limited a lot. Total ADL score ranges from 0 to 14
45777876|NCT04300998|Behavioral|Instrumental Activity of Daily Living|8 activities: telephone use, doing laundry, shopping, preparing meals, doing housework, handling own medications, handling money and finances, and transportation to visit one's doctor. Participants get 2 points for each activity that can be done without help, 1 point for needing some help, and 0 point for being unable to do. Total iADL score ranges from 0 to16.
45777877|NCT04300998|Behavioral|Timed Up and Go|Participants are asked to get up from the chair, walk 10 feet, turn, and walk back to the char (<10 seconds, 10-20 seconds, >20 seconds)
45777878|NCT04300998|Behavioral|Cognition|Mini-Cognition test: CDT and 3-word recall
45777879|NCT04300998|Behavioral|Geriatric Depression Scale|Four yes/no questions regarding patient's psychological status. Score ranges from 0 to 4, and a score of >/=1 is usually indicative of depression.
45777880|NCT04300998|Behavioral|Social Support|Four 5-point Likert scale questions addressing 4 domains of social support: emotional/ informational, tangible, affectionate, and positive social interaction. Score for each item ranges from 1 to 5, and total score ranges from 4 to 20. A higher score means better social support.
45777881|NCT04300998|Behavioral|Brief Test of Attention|assess selective auditory attention.
45915857|NCT03832309|Behavioral|Do we speak to them in a way that convinces them to have the dream|During induction, and depending on what group they are randomized to, the physician will speak to them about having a dream while on the drug
45915858|NCT03832309|Behavioral|Speaking to them as a regualar person|During induction, if the patient is in group 1, the resident performing procedural sedation will remind the patient about what the patient wanted to dream and ask them to focus on that as the ketamine is being administered. If the patient is in group 2, the resident performing procedural sedation will give no specific instruction to the patient at this point.
46070348|NCT05054816|Device|Investigational adaptive directional microphone strategy|A receiver-in-canal hearing aid developed by the Study Sponsor used with the investigational adaptive directional microphone strategy that is expected to improve sound quality of speech in a car.
46070349|NCT05054816|Device|Comparator omnidirectional microphone strategy|A receiver-in-canal hearing aid developed by the Study Sponsor used with the comparator omnidirectional microphone strategy that is used with the default settings as specified in the manufacturer's fitting software.
45448533|NCT03547180|Behavioral|Capnometry-Assisted Respiratory Training|The training included four components: (a) educating patients about the exacerbation of panic symptoms through hypocapnia; (b) directing patients' attention to potentially detrimental respiratory patterns; (c) teaching patients techniques to control their respiration, in particular end-tidal PCO2; and (d) instructing patients in between-session exercises. Between-session exercises using a portable capnometer were to be performed twice a day for 17 min at home or elsewhere during Phase I.
45777882|NCT04300998|Behavioral|Trail Making Test|Assesses visual scanning, graphomotor speed, and set shifting.
45777883|NCT04300998|Behavioral|Controlled Oral Word Association Test|A timed test of verbal fluency
45777884|NCT04300998|Behavioral|Hopkins Verbal Learning Test-Revised|The HVLT-R is a test of verbal learning and recall. Scores obtained are the total number of words: 1) recalled over three trials; 2)recalled after a delay; 3) correctly recognized.
45639904|NCT05020301|Device|internal meditation guided audio|Examining DMN connectivity and CSF flow in external meditation state by Internal Meditation Instruction Audio.
45639905|NCT03155581|Behavioral|User intervention|To make participants aware of the lack of participation in screening programs and its consequences, and help to manage obstacles to participation
45639906|NCT03155581|Behavioral|Health professional intervention|To provide information on the low attendance of migrants to cervical cancer screening and tools to improve the situation
45777885|NCT04300998|Other|Blood draw|collection of blood tests
45777886|NCT04293146|Procedure|pre-pectoral IBBR|The breast is reconstructed by positioning a breast implant above (pre-pectoral) the pectoralis major muscle.
45777887|NCT04293146|Procedure|sub-pectoral IBBR|The breast is reconstructed by positioning a breast implant below (sub-pectoral) the pectoralis major muscle.
45777888|NCT04292288|Diagnostic Test|Biochemical observational|no intervention - observational
45777889|NCT04278417|Biological|Brolucizumab 6 mg|3 x q6w loading injections, followed by q12w maintenance through Week 90
45777890|NCT04278417|Procedure|Panretinal photocoagulation laser|initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed
45777891|NCT04270942|Biological|teplizumab|anti-CD3 humanized monoclonal antibody
45777892|NCT04264819|Drug|RTH258/Brolucizumab|Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients will be treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by Treat-to-Control regimen up to Week 44/46.
45777893|NCT04253015|Other|Data-collection|Data will be collected on dose, total cumulative amount of dinutuximab beta per course, dose interruptions, dose discontinuations, prophylactic treatment, use of all concomitant analgesia, assessments of pain, and occurrence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions and other AEs.
45777894|NCT04234399|Diagnostic Test|Fluciclovine PET/CT using a digital PET/CT|Fluciclovine is a radiotracer that will be used in conjunction with the high resolution digital Vereos PET/CT scanner.
45777895|NCT04222322|Device|Epitomee Capsule|Arm treatment: Epitomee Capsule combined with moderate intensity lifestyle counseling.
45777896|NCT04222322|Other|Control-Placebo|Arm treatment: Visually matching placebo capsule combined with moderate intensity lifestyle counseling.
45777897|NCT04222231|Other|Blood-flow restriction resistance training|Training program: After 10 minutes of warm-up the participant performs three exercises with BFRT for the lower extremities. The intensity is about 15-30% of 1-RM.
45777898|NCT04222231|Other|Classical resistance training|Training program: After warm-up the participant performs three exercises for lower body. The intensity is about 60-80% of 1-RM.
46070350|NCT05054816|Device|Comparator fixed directional microphone strategy|A receiver-in-canal hearing aid developed by the Study Sponsor used with the comparator fixed directional microphone strategy that is used with the default settings as specified in the manufacturer's fitting software.
45639907|NCT04130165|Other|Matched donor human milk|Milk from donor mothers will be sorted according to their secretor status. This milk will be provided to infants in the intervention (experimental) arm.
45915859|NCT00006471|Drug|Fenretinide|1800 mg/m2 per day for seven consecutive days, in two divided doses of 900 mg/m2 12 hours apart, repeated every 3 weeks.
45915860|NCT04428619|Device|Peripheral Electrical Nerve Field Stimulation (PENFS) Device|Patients will complete daily worst abdominal pain and bowel habit questionnaires for 1 week prior to initial PENFS device placement to provide a baseline. At visit 1, patients will complete the Bowel Symptom Questionnaire, IBS Symptom Severity Scale (IBS-SSS), PROMIS Belly Pain Scale, Gas and Bloating, Constipation, and Diarrhea Scales, Hospital Anxiety and Depression Scale, and Visceral Sensitivity Index, heart rate variability will be measured, and they will have the initial PENFS device placed. Patients will complete daily worst abdominal pain (scale 0-10) questionnaires throughout the duration of the study. They will return every 7 days for a total of 4 visits for device replacement and additional questionnaires, including the IBS-SSS. Four devices will be placed in total (start of weeks 1, 2, 3, and 4). Stimulation time is 5 days/week during each of the 4 consecutive weeks. Additional questionnaires will be completed at the end of week 4 and at extended follow-up (8 weeks).
45639908|NCT03148717|Drug|Misoprostol|Cytotec
45639909|NCT03148717|Other|Placebo|Placebo tablet similar in shape, odour and consistency to misoprostol tablet.
45639910|NCT02349607|Drug|PF-05089771 300mg|PF-05089771 300 mg
45639911|NCT02349607|Drug|PF-05089771 300 mg + pregabalin 300 mg|PF-05089771 300 mg + pregabalin 300 mg
45639912|NCT02349607|Drug|Placebo|Placeco
45639913|NCT02349607|Drug|pregabalin 300 mg|pregabalin 300 mg
45639914|NCT02349607|Drug|ibuprofen 600 mg|ibuprofen 600 mg
45639915|NCT05019755|Drug|IN-A002(IN-115314) capsule|Oral Administration of IN-A002(IN-115314), single dose
45639916|NCT05019755|Drug|IN-A002(IN-115314) capsule|Oral Administration of IN-A002(IN-115314), single dose
45639917|NCT04478461|Drug|PD-1 monoclonal antibody|"The enrollment mainly depends on 3+3 principle. A total of 3 or 4 dose groups will be evaluated during the dose escalation period: 1, 3, 10 mg/kg, and maybe an additional fixed dose (e.g., to evaluate 200 mg or other fixed dose as RP2D). The drug is scheduled to be administrated Q3W"
45639918|NCT04115501|Other|Fraction of Inspired Oxygen|Fraction of Inspired Oxygen during cardiac surgery, including cardiopulmonary bypass
45777899|NCT04218773|Drug|Phenylephrine|Patients will receive intravenous phenylephrine at a rate of 60 µg/min. The infusion rate will be adjusted at 30 µg/min increments (maximum 180 µg/min) at 3-minute intervals to maintain an increase in SBP to the target SBP of 160 - 220 mmHg or a 20% increase above baseline SBP values.
45777900|NCT04218773|Drug|Norepinephrine|As an alternative to intravenous phenylephrine, intravenous norepinephrine can be used with an initial infusion rate of 3 mcg/min. The initial infusion rate of norepinephrine will be adjusted at 1 mcg/min increments at 3-minute intervals to achieve and maintain the target blood pressure. Maximum dose is 25 mcg/min. Combination therapy with both agents (phenylephrine and norepinephrine) to achieve and maintain blood pressure targets is not permitted.
45777901|NCT04217447|Drug|OAC + Aspirin 100mg od|Patients will receive full-dose of OAC + Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)
45777902|NCT04217447|Drug|OAC + placebo of Aspirin 100mg od|Patients will receive full-dose of OAC + placebo of Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)
45777903|NCT04216329|Drug|Selinexor|Selinexor will be administered orally at an initial dose of 80 mg. The first dose will be given on day 2 of radiation and will thereafter be administered weekly on the second day of weekly radiation on weeks 1, 2, 4, and 5. If this dose level is tolerated, the dose will be escalated to 60 mg twice a week (days 1 and 4) on weeks 1,2,4,5. The third and final dose level will also be 60mg administered twice weekly for 6 weeks starting on days 1 and 4 radiation.
45777904|NCT04216329|Drug|Temozolomide|Temozolomide will begin on the first day or evening prior of radiation and be administered orally daily at a dose of 75 mg/m2 during the radiation treatment. Temozolomide will continue until the completion of radiation and then will be stopped. Beginning 1-month post-RT, the adjuvant temozolomide will be given per standard of care.
45639919|NCT04108481|Drug|Durvalumab|Immunotherapy
45777905|NCT04216329|Radiation|Generic Radiation therapy (RT)|Radiation therapy (RT) will be administered daily (Monday to Friday)
45639920|NCT04108481|Radiation|Yttrium-90 RadioEmbolization|Microscopic radioactive particles (TheraSphere®) will be used for radioembolization to deliver the Y90 drug to the liver
45777906|NCT04214184|Behavioral|Increased sleep duration|Participants will increase their nightly time in bed by 2 hours per night for 4 weeks to target the recommended 7 hours of sleep per night.
45777907|NCT04207892|Procedure|Conservative (non-surgical) treatment|Cast Sling Splint Collar
45777908|NCT04207892|Procedure|Surgical treatment|Elastic Stable Intramedullary Nailing (ESIN) K-Wire External fixation
45639921|NCT02039089|Drug|E2006 2.5 mg|
45639922|NCT02039089|Drug|E2006 10 mg|
45777909|NCT04206787|Drug|Afatinib|drug
45777910|NCT04194944|Drug|Selpercatinib|Administered orally
45777911|NCT04194944|Drug|Carboplatin|Administered IV
45639923|NCT02039089|Drug|E2006 25 mg|
45639924|NCT02039089|Drug|Placebo|
45777912|NCT04194944|Drug|Cisplatin|Administered IV
45777913|NCT04194944|Drug|Pemetrexed|Administered IV
45777914|NCT04194944|Drug|Pembrolizumab|Administered IV
46070351|NCT00644995|Behavioral|Step Up Wellness Program|Participants in the Step Up Wellness program will receive weekly phone calls from a study health coach. During these calls, the coach will discuss ways to improve and manage mood, increase physical activity, and prepare to quit smoking.
45639925|NCT02353507|Device|Opticell Ag+|
45639926|NCT02353507|Device|Aquacel Ag+|
45639927|NCT03148561|Drug|Misoprostol|received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose vaginally
45639928|NCT05027555|Other|Multisensory training|Multisensory training included marching on the foam with visual deprivation and treadmill training with visual deprivation
45639929|NCT05027555|Other|Conventional training|Conventional training included strengthening, balance training and gait training
45639930|NCT05231005|Biological|BNT162b2 vaccine|fourth dose of the BNT162b2 vaccine (30 microgram) adminstered IM
45639931|NCT05027321|Behavioral|Preparation in Self-Hypnosis by anchoring|Preparation in Self-Hypnosis by anchoring just before examination
45639932|NCT05027321|Behavioral|Conversational Hypnosis|Conversational Hypnosis during examination
45639933|NCT05027321|Behavioral|Preparation in Self-Hypnosis by anchoring + Conversational Hypnosis|Preparation in Self-Hypnosis by anchoring just before examination combied with Conversational Hypnosis during examination
45639934|NCT02348983|Behavioral|Health Coaching via Telephone|Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
45639935|NCT05027711|Radiation|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)
45639936|NCT05027711|Radiation|MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)|MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)
45639937|NCT02353429|Drug|Toremifene|Patients will receive 60 mg daily and then 180 daily in case of progression
45777915|NCT04191499|Drug|Inavolisib|Participants will receive oral inavolisib on Days 1-28 of each 28-day cycle.
45777916|NCT04191499|Drug|Placebo|Participants will receive oral placebo on Days 1-28 of each 28-day cycle.
45777917|NCT04191499|Drug|Palbociclib|Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.
45777918|NCT04191499|Drug|Fulvestrant|Participants will receive intramuscular (IM) fulvestrant approximately every 4 weeks.
45777919|NCT04186221|Device|OCS Liver System|OCS Liver System for preserving and assessing donor livers for transplantation
45777920|NCT04175431|Procedure|Positron Emission Tomography|Undergo fluciclovine PET/CT
45777921|NCT04175431|Procedure|Lymphadenectomy|Undergo lymphadenectomy
45777922|NCT04175431|Radiation|Radiation Therapy|Undergo radiation therapy
45777923|NCT04175431|Drug|Abiraterone Acetate|Given PO
45777924|NCT04175431|Drug|Prednisone|Given PO
45777925|NCT04175431|Procedure|Computed Tomography|Undergo fluciclovine PET/CT
45777926|NCT04175431|Drug|Abiraterone|Given PO
45777927|NCT04175431|Procedure|PSMA PET Scan|Undergo PSMA PET scan
45777928|NCT04175340|Device|BL-300-PFM04|Preservative Free Lubricating and Rewetting Drops for use during contact lens wear
45777929|NCT04175340|Device|OPTI-FREE|Replenish Rewetting Drops
46070352|NCT00644995|Behavioral|Usual care|Participants will receive referral usual care treatment for depression and smoking cessation, plus self-help physical activity intervention.
45777930|NCT04175119|Device|Visual attention/perception tasks in healthy participants|The participants complete visual attention and perception tasks while fMRI, EEG, and MEG record brain signals. The tasks acquire responses with a visual saccade or button presses which are coupled to brain responses. These responses are then analyzed to identify patterns of communication between brain areas (within-subject). The flickering stimuli (experiment 1) may alter oscillations in the brain, while participants complete visual attention and perception tasks, leading to a secondary outcome measure distinct from the button presses. The procedure concerning the flickers will be the same for participants. The tACS (experiment 2, 3) delivers input in addition to gathering output while participants complete visual attention and perception tasks. A sinusoidal current at a chosen frequency interacts with the brain's natural oscillations and alters responses. Participants will have sham sessions of tACS as well (there is no group division), The sham will be compared with the stimulation
45777931|NCT04172532|Procedure|Biopsy|Undergo tissue collection
45639938|NCT05019989|Behavioral|Intervention group on diet and physical activity|"The intervention wanted to increase physical activity, controlling weight, promoting healthy diet.~Physical activity: achieve and maintain regular participation in a moderate intensity physical activity program of 210 minutes/week (30 min on average per day) over at least 3 days /week; decrease sedentary behaviors by 30 minutes/day on at least 5 days/week~Weight control: reducing energy intake relative to expenditure is the primary dietary focus for promoting weight loss in overweight or obese participants, and maintaining a healthy energy balance is the primary focus for normal weight participants. Participants will be encouraged to include whole grains and high-fiber vegetables~Healthy diet: reducing calorie intake, through the preferred consumptions of unrefined cereals, pulses and vegetables, reducing high glycemic index food and high insulinemic foods, such as sugar and milk; reducing sources of saturated fat and animal protein (except fish)"
45639939|NCT05019989|Behavioral|Control group: only public recommendation an lifestyle|"Invitation leaflet, explaining the rationale of the study and including basic life-style recommendations, based on the 1997 World Cancer Research Fund recommendations (to be updated in 2007) and the Italian National Institute of Nutrition food pyramid.~Dissemination of the information on the study by media~Yearly follow-up questionnaire on breast events and dietary and physical activity chang"
45639940|NCT04478305|Drug|Duavive 0.45Mg-20Mg Tablet|Duavee, marketed as Duavive in Canada.
45639941|NCT05027243|Procedure|bilateral temporomandibular joint arthroscopy|The TMJ arthroscopy was performed with a 1.9-mm arthroscope including a video system, with a 2.8-mm outer protective cannula. Briefly, for TMJ arthroscopy level 1, the authors used the classic puncture with an entry point 10 mm anterior and 2 mm below the Holmlund-Hellsing (H-H) line. A second puncture with a 21-G needle was performed 30 mm anterior and 7 mm below the H-H line to wash the joint with 250-300 ml Ringer solution. After washing the joint, 1.5-2 cc of hyaluronic acid was injected into it. For level 2 TMJ arthroscopy, the second puncture was substituted by a 2.8-mm outer protective cannula with a sharp trocar until the joint was reached. The 2.8-mm cannula was used for (1) intra-articular coblation and/or (2) intrasynovial medication. Antibiotic and non-steroidal anti-inflammatory drugs were routinely prescribed. Patients were instructed to follow a soft diet for 3 days after surgery and 5 physiotherapy and 3 speech therapy exercise sessions after intervention.
45639942|NCT05027243|Drug|Xeomin® (Merz)|For tenderness grade 2, 155U of Incobotulinum toxin A was injected in the masticatory muscles and for tenderness grade 3 195U of Incobotulinum toxin A was injected. The authors used Xeomin® (Merz) in all patients.
45639943|NCT03147079|Behavioral|Lifestyle intervention|
45639944|NCT03148639|Behavioral|Avatar therapy|Patients will receive 6 sessions of avatar therapy consisting of 45 minute (1 session per week). The therapy will consist in prompting patients to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the character of the avatar will progressively become under patients' control. More precisely, the avatar's speech and tone will gradually be changed by the therapist to echo patients' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce patients' feeling of empowerment over their voices.
45639945|NCT03148639|Other|Treatment-as-usual|Treatment as usual will consist of typical or atypical antipsychotic medication and regulars appointments with psychiatrists and others care team members for a period of 6 weeks.
45639946|NCT05019599|Other|low protein diet|Low protein diet (<0.8g/kg/BW/day)
45639947|NCT03112135|Drug|Tranexamic Acid|TXA of 10-15 mg i.v over 30 min. followed by infusion in adose of 1 mg / kg /hr
45639948|NCT03112135|Drug|Tranexamic Acid|Topical TXA 1 gm diluted in 200 ml saline
45639949|NCT03112135|Drug|Adrenalin|Topical adrenaline 1 mg diluted on 200 ml saline
45639950|NCT03090893|Drug|ATryn continuous infusion|replenish serum thrombin levels
45777932|NCT04172532|Procedure|Biospecimen Collection|Undergo blood sample collection
45777933|NCT04172532|Procedure|Computed Tomography|Undergo CT
45777934|NCT04172532|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
45777935|NCT04172532|Procedure|Magnetic Resonance Imaging|Undergo MRI
46070353|NCT04045327|Drug|Normal saline + Standard Treatment|Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
45777936|NCT04172532|Drug|Peposertib|Given PO
45777937|NCT04172532|Other|Placebo Administration|Given PO
45777938|NCT04147234|Drug|BI 1387446|intratumoral injection
45777939|NCT04147234|Drug|BI 754091|intravenous infusion
45777940|NCT04138823|Drug|BI 891065|Tablets
45777941|NCT04138823|Drug|BI 754091|Solution for infusion
45777942|NCT04126031|Drug|Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3|Single intravenous infusion of ceftazidime-avibactam over 2 hours
45777943|NCT04126031|Drug|Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3|Multiple intravenous infusions of ceftazidime-avibactam over 2 hours, repeated every 8 hours up to 14 days
45777944|NCT04111458|Drug|BI 1701963|Tablet
45777945|NCT04111458|Drug|Trametinib|Tablet
45777946|NCT04100824|Procedure|stellate ganglion block by transcranial doppler|stellate ganglion block is a block of sympathetic ganglion
45777947|NCT04100824|Drug|Nimodipine|Nimodipine 60mg every 4h
45639951|NCT03112759|Behavioral|Cognitive Behavioral Therapy|Cognitive behavioral therapy (CBT) uses pain coping skills as a method of managing symptoms associated with chronic pain.Cognitive behavioral therapy teaches patients to identify and modify negative thoughts and behaviors that increase pain intensity, distress, and pain-related disability
45777948|NCT04088851|Drug|Metformin|Type 2 Diabetics with prescribed Metformin therapy (1 g / day) will pause the medication for 2 weeks and then continue the anti-diabetic treatment again. Aim is to measure the gluconeogenic precursor fluxes with and without metformin therapy.
45639952|NCT05019287|Biological|Allogeneic human menstrual blood stem cells secretome|This COVID-19 Study intervention consists of Intravenous Allogeneic human menstrual blood stem cell (MenSC) secretome injection in addition to standard care. The MenSC were characterized as CD90+, CD73+, CD105+, and CD45-based on multiparameter flow cytometry.
45777949|NCT04085328|Device|LID015385 soft contact lenses|Investigational silicone hydrogel contact lenses for up to 6 nights/7 days of continuous wear
45639953|NCT05019287|Other|Intravenous saline injection|Intravenous saline injection in addition to standard care
45639954|NCT03154255|Behavioral|Mediterranean-Style Diet Educational Training|"The intervention consists in a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose."
46070354|NCT04045327|Drug|Centhaquine + Standard Treatment|Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
46070355|NCT00914966|Biological|C1 inhibitor (human) [C1 INH]|
45639955|NCT03094169|Drug|AVID100 IV|AVID100 is administered once every 3 weeks
45777950|NCT04085328|Device|Comfilcon A soft contact lenses|Silicone hydrogel contact lenses for up to 6 nights/7 days of continuous wear
45777951|NCT04082611|Behavioral|Data-Driven Clinical Recommendations|Data-driven clinical recommendations. Participants will receive routine care with data-driven, personalized, multi-modal clinical recommendations by a study physician based on study assessments and clinical lab values and be monitored and re-assessed for a period of 12 months.
45777952|NCT04082611|Behavioral|Coached Data-Driven Clinical Recommendations|Data-driven multi-modal lifestyle intervention with coaching. Participants will receive coached routine care with data-driven, personalized, multimodal recommendations. MMIC participants will receive an intensive multi-modal intervention with health coaching, support and resources to carry out these recommendations. This additional intervention services include: 13 personal, data-driven brain health coaching sessions (with an RDN), 7 personal dietary counseling sessions (with an RDN), 33 group-based cognitive and physical exercise classes (CogFit) with a certified personal trainer and a computer-based neurocognitive program at home and be monitored and re-assessed for a period of 12 months.
45777953|NCT04074265|Drug|Ropivacaine injection|Injection containing a mix of the above medications will be performed while the patient is still under general anesthesia, following wound closure, and will be injected evenly between the deep and superficial tissues in an extra-articular pattern (no injection of the synovium or capsule).
45777954|NCT04074265|Drug|normal saline|Injection containing normal saline will be performed while the patient is still under general anesthesia, following wound closure, and will be injected evenly between the deep and superficial tissues in an extra-articular pattern (no injection of the synovium or capsule).
45777955|NCT04074252|Device|Lofstrand Crutches|Device: Set of Lofstrand Crutches
45777956|NCT04074252|Device|Axillary Crutches|Device: Set of Axillary Crutches
45777957|NCT04073498|Drug|SerpinPC|Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.
45777958|NCT04073498|Drug|Placebo|Matching placebo administered by SC injection according to cohort dosing instructions.
45777959|NCT04070144|Device|IQ-Tip(tm) system|Physician performs therapeutic or diagnostic lumbar puncture using Injeq IQ-Tip(tm) system
45639956|NCT04477993|Drug|Janus Kinase Inhibitor (ruxolitinib)|5 mg P.O. b.i.d. for 14 days. Dose reduction will occur if neutrophils < 500/mm3 or platelets <50,000/mm3.
45639957|NCT04477993|Other|Placebo|Placebo tablets P.O. b.i.d. for 14 days.
45639958|NCT03094013|Other|Assessment|Assessment
45639959|NCT03112447|Procedure|absorbable cartilage nail|The experiment group patients were fixed with absorbable cartilage nails
45639960|NCT03112447|Procedure|traditional Kirschner wires|The control group were fixed with traditional Kirschner wires
45639961|NCT05019443|Device|Wedge Scoring Balloon|Scoring balloon
45639962|NCT05019443|Device|Conventional Balloon|Conventional balloon
45639963|NCT03146533|Drug|Fludarabine|Fludarabine 30 mg/m2/day IV for 3 days.
45639964|NCT03146533|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8g/m2/day IV for 2 days.
45777960|NCT04058067|Drug|Brolucizumab|5 x every 6 weeks loading then every 12 weeks or every 8 weeks maintenance
45777961|NCT04058067|Drug|Aflibercept|5 x every 4 weeks loading then every 8 weeks maintenance
45639965|NCT03146533|Biological|CD19 CART|CD19 CART cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
45639966|NCT03093935|Device|StimRouter Neuromodulation System|The StimRouter Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.
45777962|NCT04015167|Device|T2 Alpha Tibia Nailing System|The T2 Alpha Tibia Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
45777963|NCT04015154|Device|Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System|The T2 Alpha Femur Antegrade GT / PF Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
45777964|NCT04015128|Device|Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System|The T2 Alpha Femur Antegrade GT / PF Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
45639967|NCT03148483|Other|Early PT|Women will receive conventional non-surgical periodontal therapy (PT), consisting of prophylactic dental polishing to remove the sticky bacterial film that forms on the teeth over time, scaling and root planing, as necessary throughout pregnancy, up to delivery
45639968|NCT03148483|Other|Delayed PT|Women will receive conventional non-surgical PT delayed until after delivery.
45639969|NCT03148483|Dietary Supplement|Fortified Milk|participants will be advised to take two servings of a powdered milk-based drink enriched with calcium and vitamin D daily during breakfast and afternoon snack or supper to avoid concomitant intake of the prenatal iron supplements routinely prescribed for consumption with hot main meals (e.g. lunch or dinner). Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with 500 IU of vitamin D3 and 1,2 g of a calcium supplement from milk extract (300 mg of calcium) twice a day.
45639970|NCT03148483|Dietary Supplement|Plain Milk|Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with flour (placebo).
45639971|NCT02353117|Behavioral|Congenital Syphilis Intervention Group|
45639972|NCT03093779|Other|Health Information Assessment|Assess how hearing loss and health literacy alters the ability to access and comprehend online health information
45639973|NCT02353195|Other|Radiofrequency|The equipment used, 35-mm diameter CAP and 30-mm diameter RES movable electrode was used on the affected site, and a planar electrode was used as a return electrode on the abdomen. The electricity was administered in the following manner: cream was applied to the site with the severest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient.
45639974|NCT03090971|Drug|Diclofenac Sodium|Following microporation, treatment neurofibromas will receive treatment with topical diclofenac
45639975|NCT03090971|Drug|Saline Solution|Following microporation, control neurofibromas will receive treatment with topical saline
45639976|NCT03154177|Behavioral|Group ANC/PNC|The primary intervention is group antenatal and postnatal care wherein women receive their care in a group with other women with similar due dates. After an initial individual visit all care is given in groups although the majority of the time is dedicated to facilitated discussion and women can come for additional acute care if needed. Group antenatal care will be three group visits between 20 and 40 weeks gestation and group postnatal care will be one group visit and approximately 6 weeks post delivery.
45639977|NCT03154177|Procedure|Ultrasound+Pregnancy Testing|"Half of all study sites will receive early pregnancy testing, conducted by community health workers at community level and ultrasound for gestational age dating and early screening at the health center.~The primary analysis will not assess the effectiveness of this intervention."
45639978|NCT05018741|Procedure|liver transplantation|liver transplantation for chronic liver disease or acute liver failure
45777965|NCT04007744|Biological|Pembrolizumab|Given IV
45777966|NCT04007744|Drug|Sonidegib|Given PO
45777967|NCT03998735|Drug|Herbal Snuff (Smokeless Tobacco)|4 levels of [D4]nornicotine in herbal snuff
45639979|NCT03146689|Drug|Topical NSAID|Applied four times daily
45639980|NCT03146689|Drug|Topical Capsaicin|Applied four times daily
46070356|NCT02551471|Other|Blinded inter-country reading of pelvic MRI (Magnetic Resonance Imaging)|"This experiment will consist of an inter-country reading of patients' pelvic MRIs, blind to the other country's decision. The MRI shared will be the one based on which the treatment decision will be made. In case of medical contraindication to perform pelvic MRI, the scan will be used to assess the care-decision concordance between both countries."
45639981|NCT02347267|Behavioral|Caloric and non-caloric SSBS reduction|Isocaloric individualized diet and sweetened caloric and non-caloric beverages restriction
46070357|NCT02551471|Other|MDT (Multidisciplinary team) meeting observation|"3 per centre with real patient cases and theoretical patient cases (blinded pelvic MRI re-reading)."
45639982|NCT02347267|Behavioral|Caloric SSBS reduction|Isocaloric individualized diet and caloric SSBS restriction
45639983|NCT05025995|Behavioral|Serious health game|Serious health game
45639984|NCT05255575|Drug|Ertapenem|Patients will receive ertapenem therapy.
45639985|NCT05026229|Drug|dasatinib plus consolidation chemotherapy with vincristine and prednisone|After induction therapy, the patients in the 'Dasatinib, Vincristine and Prednisone' group will receive dasatinib and consolidation chemotherapy with vincristine and prednisone.
45639986|NCT05026229|Drug|dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine|After induction therapy, the patients in the 'Dasatinib, Methotrexate and Cytarabine' group will receive dasatinib and consolidation chemotherapy with high-dose methotrexate and cytarabine.
45777968|NCT03993327|Biological|Iodine I 124 Monoclonal Antibody M5A|Given IV
45777969|NCT03993327|Procedure|Positron Emission Tomography|Undergo PET scan
45777970|NCT03983057|Drug|Anti-PD-1 monoclonal antibody|Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly.
45777971|NCT03964233|Drug|BI 907828|Film-coated tablets
45777972|NCT03964233|Drug|ezabenlimab|Solution for infusion
45777973|NCT03964233|Drug|BI 754111|Solution for infusion
45777974|NCT03960619|Behavioral|coping skills training|We aim to test a combined coping skills training and activity coaching protocol that: first, is feasible and acceptable, and second, improves physical disability, as well as pain, fatigue, distress, and physical activity in HCT patients. We propose a novel intervention protocol that uses a hybrid in-person and mHealth intervention delivery model.
45777975|NCT03953300|Biological|Benralizumab|Benralizumab: 30 mg/mL solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
45777976|NCT03953300|Biological|Placebo|Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
45777977|NCT03947437|Biological|LEP-F1 + GLA-SE|Leprosy antigen formulated with an adjuvant.
45777978|NCT03947437|Biological|Placebo|Sterile normal saline for injection.
45639987|NCT02343679|Drug|ceritinib|Ceritinib will be administered to ALK + hematologic malignancies orally at the 750mg/day dose that has been calculated as the maximum tolerated dose in prior phase I trials in lung cancer patients. Intra patient dose reductions will be allowed for toxicities. Subjects with stable disease or better will be allowed to continue study drug until disease progression or until intolerable adverse events or patient or physician choice.
45777979|NCT03933215|Drug|Cladribine Tablets|No intervention will be administered as a part of this study. Participants will receive cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
45777980|NCT03932643|Drug|ONC201|"ONC201 Capsules, 125 mg~Oral ONC 201 at various dose levels will be given at weekly intervals for up to 13 cycles (52 weeks); 4-week therapy will be considered 1 cycle."
45777981|NCT03915574|Device|25G Dural Puncture Epidural|Dural puncture created with a 25 gauge spinal needle
45777982|NCT03915574|Device|Standard Epidural|Control group - standard epidural (no dural puncture)
45777983|NCT03898310|Dietary Supplement|Cranberry extract capsules|Participants in the treatment arm will receive cranberry extract capsules.
45777984|NCT03898310|Dietary Supplement|Placebo capsule|Participants in the placebo arm will receive placebo capsules.
45777985|NCT03886246|Drug|Spesolimab|Solution for infusion
45777986|NCT03886246|Drug|Spesolimab|Solution for injection
45777987|NCT03879434|Device|Ostenil® Mini|Ostenil® Mini is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 1.0 % sodium hyaluronate from fermentation
45777988|NCT03879135|Biological|rVWF|Recombinant von Willebrand factor
45777989|NCT03879135|Biological|rFVIII|Recombinant Factor VIII
45777990|NCT03852030|Behavioral|Text or email message|Text or email messages sent to research participants
45777991|NCT03833154|Drug|Durvalumab|Durvalumab 1500 mg every 4 weeks [q4w] intravenously [iv] for up to 24 months or until progression or other discontinuation criteria are met.
45777992|NCT03833154|Other|Placebo|Matching placebo for infusion every 4 weeks iv for up to 24 months or until progression or other discontinuation criteria are met.
45777993|NCT03833154|Drug|Osimertinib (single-arm, open-label)|Osimertinib 80 mg every day [qd] orally for up to 36 months or until progression or other discontinuation criteria are met. Osimertinib treatment should start from 7 to 14 days after completion of SBRT
45448534|NCT03547180|Behavioral|In-vivo exposure|In this two-phase intervention, patients were randomized (within each site) to first receive five individual, weekly, 1-hr sessions of respiratory skill training (CART) or cognitive skill training (CT; Phase I, Skill Acquisition Training), followed by three weekly sessions of in-vivo exposure (Phase II, Application Training) plus a fourth session at 2-month follow-up.
45639988|NCT03148249|Other|interview|control group: interview, study group: explanation and exploration
45777994|NCT03822468|Drug|Ribociclib|Ribociclib will be supplied as 200 mg tablets as individual patient supply packaged bottles taken by mouth.
45777995|NCT03822468|Drug|Letrozole or Anastrozole|Letrozole 2.5 mg by mouth QD continuously or anastrozole 1 mg by mouth QD continuously (investigator choice)
45777996|NCT03822468|Drug|Goserelin|Goserelin 3.6 mg subcutaneously once every 4 weeks (pre-menopausal women only)
45777997|NCT03809962|Device|Ostenil® Plus|Ostenil® Plus is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 2.0 % Sodium hyaluronate from fermentation
45777998|NCT03802799|Drug|ZYN002 - Cannabidiol Transdermal Gel|Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)
45777999|NCT03789110|Drug|Nivolumab|Nivolumab is called an anti- PD-1 or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
45778000|NCT03789110|Drug|Ipilimumab|Ipilimumab is called an anti-CTLA-4 and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
45778001|NCT03778229|Drug|osimertinib|osimertinib (80 mg oral OD).
45778002|NCT03778229|Drug|savolitinib|savolitinib (300 mg oral OD or 300 mg oral BID or 600 mg oral OD)
45778003|NCT03778229|Drug|placebo|placebo to osimertinib (oral OD)
45778004|NCT03775915|Other|Neurofeedback|A visual representation of the participants brain activity during movement of their affected hand in the MRI scanner.
45778005|NCT03775915|Other|Sham Neurofeedback|A visual representation of brain activity pre-recorded from a previous participant
45778006|NCT03775759|Procedure|Tricuspid valve repair or replacement|Available rings used at Duke include the Tri-Ad™ Adams Tricuspid Ring by Medtronic, the TAILOR™ FLEXIBLE ANNULOPLASTY RING by St. Jude Medical/Abbott, and the Carpentier-Edwards Physio II Ring by Edwards LifeSciences. Available valves used at Duke include the Mosaic™ Mitral Orbutrator by Medtronic, the Carpentier-Edwardes PERIMOUNT Magna Mitral Ease Pericardial Bioprosthesis by Edwards LifeSciences, the On-X Mitral Valve, by CryoLife, the Carbomedics Prosthetic Heart Valve by LivaNova, and the St. Jude Medical™ Mechanical Heart Valve by St. Jude Medical/Abbott.
45778007|NCT03775759|Other|Medical management of tricuspid regurgitation|The medical therapy involved includes inotropic medications and diuretic medications, which are standard of care for patients in this population.
45778008|NCT03759028|Drug|Ibuprofen|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
45778009|NCT03759028|Drug|Oxycodone|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
45778010|NCT03759028|Drug|Acetaminophen|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
45778011|NCT03735121|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in arm or cohort.
45778012|NCT03735121|Drug|rHuPH20|rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.
45778013|NCT03734315|Device|Ostenil®|Ostenil® is a CE-certified viscoelastic solution for injection into the joint cavity, containing 1.0 % sodium hyaluronate from fermentation.
45778014|NCT03716921|Other|Short antibiotics treatment|Patients randomized in this arm will pursue antibiotic administration until visit 3 weeks after D0
45778015|NCT03706365|Drug|Abemaciclib|Administered orally.
45639989|NCT05026073|Behavioral|Information about clinical risk factors for endometrial cancer and endometrial hyperplasia|age, race, parity, body mass index, last menstrual period, menstrual cycle type, hypertension, type II diabetes, anovulation, polycystic ovary syndrome, indication for hysterectomy and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.
45639990|NCT05026073|Procedure|Blood and endometrial tissue sampling|"All women will undergo planned hysterectomy.~Venous blood sample will be collected prior to surgery.~Endometrial sampling via Pipelle device will be performed immediately prior to hysterectomy~Endometrial biopsy from the hysterectomy specimen will be obtained under direct vision~The plasma and serum obtained from the blood samples will be analysed with ATR-FTIR and Raman spectroscopes. Spectra from both wet and dry specimens will be recorded.~All tissue samples retrieved will be placed in Phosphate Buffered Solution for transfer to the histopathology laboratory. Spectra will be collected from the fresh samples with ATR-FTIR and Raman spectroscopes. Spectral analyses will subsequently be repeated on dry samples post fixation and processing.~All tissue samples will undergo haematoxylin and eosin staining after spectral analysis for standard histopathological confirmation."
45778016|NCT03706365|Drug|Abiraterone Acetate|Administered orally.
45778017|NCT03706365|Drug|Prednisone|Administered orally.
45778018|NCT03706365|Drug|Placebo|Administered orally.
45778019|NCT03702920|Biological|SMT + PE-A 5%|Plasma exchange treatment (PE-A 5%) will be performed using 5% albumin solution (Albutein 5%). Fresh frozen plasma will be given to prevent coagulopathy. IVIGs will be administered intravenously to prevent the development of hypogammaglobulinemia and infection.
45778020|NCT03702920|Other|Standard Medical Treatment|Standard medical treatment according to the institution's standard practice
45778021|NCT03697304|Drug|BI 754091|Solution for infusion
45778022|NCT03697304|Drug|BI 754111|Solution for infusion
45915861|NCT04428619|Device|Sham Device|Patients will complete daily worst abdominal pain and bowel habit questionnaires for 1 week prior to initial sham device placement to provide a baseline. At visit 1, patients will complete the Bowel Symptom Questionnaire, IBS Symptom Severity Scale (IBS-SSS), PROMIS Belly Pain Scale, Gas and Bloating, Constipation, and Diarrhea Scales, Hospital Anxiety and Depression Scale, and Visceral Sensitivity Index, heart rate variability will be measured, and they will have the initial sham device placed. Patients will complete daily worst abdominal pain (scale 0-10) questionnaires throughout the duration of the study. They will return every 7 days for a total of 4 visits for device replacement and additional questionnaires, including the IBS-SSS. Four devices will be placed in total (start of weeks 1, 2, 3, and 4). Stimulation time is 5 days/week during each of the 4 consecutive weeks. Additional questionnaires will be completed at the end of week 4 and at extended follow-up (8 weeks).
45915862|NCT04371172|Other|cognitive research battery, MRI, laboratory values|cognitive research battery, MRI, laboratory values
45639991|NCT05026073|Procedure|Lymph node sampling|"Lymph nodes will be excised if recommended as part of the standard treatment for endometrial cancer.~Each node will be cut in half or in quarters, depending on size, to expose the core. Wet and dry spectral analysis will be performed, followed by staining for histopathological confirmation."
45639992|NCT03148171|Other|WERK Supportive Contact|Provide emotional support and practical support. Support friend/family by helping him to stay engaged in PrEP Care.
45639993|NCT04478149|Device|SafelyYou|technology to detect and prevent falls
45915863|NCT00006474|Drug|O6-benzylguanine|
45915864|NCT00006474|Drug|temozolomide|
45915865|NCT00006474|Procedure|conventional surgery|
45915866|NCT04370119|Diagnostic Test|Nasal swab|SARS-CoV-2 PCR
45915867|NCT04370119|Diagnostic Test|Serum testing|Anti-SARS-CoV2 S protein IgG ELISA, serological changes after SARS-CoV-2 vaccination
45915868|NCT04369573|Combination Product|Early intra-aortic balloon pump (IABP) implantation|IABP implantation within 6 hours since cardiogenic shock symptoms onset
45778023|NCT03697304|Drug|BI 836880|Solution for infusion
45778024|NCT03693560|Drug|Vildagliptin 50 mg Oral Tablet|Patients who the endocrinologist prescribed them Vildagliptin 50 mg Oral Tablet plus their Metformin 1000 mg Oral Tablet to control their blood sugar level.
45778025|NCT03693560|Drug|Metformin 1000 mg Oral Tablet|Patients with Coronary artery diseases.and uncontrolled Diabetes Mellitus type 2 who's taking Metformin 1000 mg Oral Tablet only will be enrolled from endocrinology clinic.
45778026|NCT03693560|Drug|Glimepiride upto 4 mg Oral Tablet|Patients who the endocrinologist prescribed them Glimepiride 4 mg oral tablet plus their Metformin 1000 mg Oral Tablet
45778027|NCT03675893|Drug|Letrozole|Letrozole is a hormonal therapy that works by lowering the production of estrogen in the body.
45778028|NCT03675893|Drug|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor.
45778029|NCT03675893|Drug|LY3023414|LY3023414 is a potent selective inhibitor of the class I PI3K isoforms, mTOR, and DNA-PK.
45778030|NCT03675893|Drug|Metformin|Metformin inhibits mitochondrial adenosine-5'-triphosphate (ATP) synthesis, resulting in activation of the AMPK (5' AMP-activated protein kinase) pathway through LKB1, eventually causing inhibition of the mTOR pathway and subsequent reduction in protein synthesis and cellular proliferation.
45915869|NCT04369573|Other|Standard of care as vasoactive agent|Any agent (inotropes and vasopressors) will be allowed. However, the following guide is provided to increase uniformity: 1) vasopressors allowed will be either epinephrine or norepinephrine; 2) as inotropic agent milrinone or dobutamine or levosimendan could be used; 3) dopamine will be allowed in association with milrinone or dobutamine or levosimendan; 4) the maximum inotropic score allowed will be 20.
45915870|NCT04359121|Other|Questionnaires for specific phobia|Questionnaires will be used.
45915871|NCT03815851|Device|prophylactic drainage|place prophylactic drainage after surgery
45915872|NCT03815851|Device|no prophylactic drainage|Not place prophylactic drainage after surgery
45915873|NCT04271488|Drug|Tasurgratinib|Tasurgratinib oral tablet.
45915874|NCT04271488|Drug|Tasurgratinib|Tasurgratinib oral capsule.
45448535|NCT05225272|Other|Enhanced Recovery Program for on-pump cardiac surgery|Implementation of a Enhanced Recovery Program for on-pump cardiac surgery patients
45915875|NCT04232293|Diagnostic Test|Blood tests|eLift and FibroMeter
45915876|NCT04205149|Other|ERAS post-operative pathway|ERAS Pathway
45915877|NCT04201834|Drug|Risperidone|capsule or tablet, 0.5 mg
45639994|NCT04478149|Other|Control|technology present but not activated
45778031|NCT03664791|Procedure|Vanguard Rocc|Patient operated with the Vanguard Rocc knee prosthesis
45778032|NCT03660670|Behavioral|ONCORAL therapeutic education|Multidisciplinary program that includes informative cessions with a hospital pharmacist about the anticancer drug: information is given to the patients on adverse events and their managements, optimizing drug dosage plans. Moreover, information is shared with town partners: doctor, pharmacists, and nurses.
45448536|NCT05203432|Device|Red Light Intervention|Repeated Low-Level Red-Light Therapy
45778033|NCT03660670|Behavioral|Standard of care|In the group of standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessments.
45448537|NCT05203432|Drug|Atropine|0.01% atropine
45778034|NCT03631199|Drug|canakinumab|canakinumab every 3 weeks (squamous and non-squamous)
45778035|NCT03631199|Drug|canakinumab matching placebo|canakinumab placebo every 3 weeks (squamous and non-squamous)
45778036|NCT03631199|Drug|pembrolizumab|200 mg every 3 weeks (squamous and non-squamous)
45778037|NCT03631199|Drug|carboplatin|Area Under the Curve (AUC) 5 mg/mL*min every 3 weeks (non-squamous) or AUC 6 mg/mL*min (squamous)
45639995|NCT02347423|Biological|Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI|
45778038|NCT03631199|Drug|cisplatin|75 mg/m2 every 3 weeks (non-squamous)
45778039|NCT03631199|Drug|paclitaxel|200 mg/m2 every 3 weeks (squamous)
45448538|NCT03546244|Behavioral|musical treadmill|Patients will undergo a 4-week, 2 daily, incremental session of training with musical treadmill
45778040|NCT03631199|Drug|nab-paclitaxel|100 mg/m2 every 3 weeks (squamous)
45778041|NCT03631199|Drug|pemetrexed|500 mg/m2 every 3 weeks (non-squamous)
45778042|NCT03627988|Other|Patients with invasive breast cancer will receive:|"Mastectomy with Immediate prosthetic breast reconstruction~Adjuvant therapy by TomoTherapy (radiation therapy alone or preceded by chemotherapy)."
45778043|NCT03627026|Other|Blood samples will be collected at different time points:|"Baseline~Week 6 Day 1~Week 12 Day 1~If feasible, an optional tumor biopsy specimen will be collected during baseline visit for a maximum of 30 patients included in IUCT-O center."
45448539|NCT03546244|Behavioral|Traditional treadmill|Patients will undergo a 4-week, 2 daily, incremental session of training with traditional treadmill
45448540|NCT02253628|Other|Cold espresso|Volunteers consumed cold espresso with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
45448541|NCT02253628|Other|Hot instant coffee|Volunteers consumed hot instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
45448542|NCT02253628|Other|Cold instant coffee|Volunteers consumed cold instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
45448543|NCT02253628|Other|Hot filter coffee|Volunteers consumed hot filter coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
45448544|NCT03667053|Drug|dasiglucagon|glucagon analog
45448545|NCT03667053|Drug|placebo|placebo for dasiglucagon
45448546|NCT03667053|Drug|GlucaGen HypoKit|native glucagon
45448547|NCT04589728|Drug|Venetoclax plus HMA|patients with AML, ineligible for intensive chemotherapy, treated with the combination of HMA plus venetoclax under the Italian Law N. 648/96.
45448548|NCT05557240|Drug|NeoPep Vaccine1 plus Poly-ICLC|"NPVAC1： NPVAC1 drug products are composed of 5 peptides from the HCMV warehouse， NPVAC1 vaccine will be applied before maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 14 before the first maintenance TMZ cycle, patients will receive 7 vaccinations with NPVAC1 drug products during 6 weeks. 400 μg per peptide per vial are used.~Poly-ICLC:~Poly-ICLC（500ug）will be used as immunomodulator with all vaccinations."
45639996|NCT02347423|Biological|IPV Vaccine SSI|
45639997|NCT05018429|Procedure|nerve sparing|When resect the bladder and prostate, the neurovascular bundles around the prostate will be preserved.
45639998|NCT03146611|Diagnostic Test|nCD64|neutrophil CD64
45639999|NCT03146611|Diagnostic Test|Neutrophil/Lymphocyte Ratio|Neutrophil/ lymphocyte ratio
45640000|NCT03146299|Procedure|TLH vs LAVH|"TLH: The subjects undergoing laparoscopic hysterectomy with a giant uterus of 500 g or more~LAVH: The subjects undergoing Laparoscopic Assisted Vaginal Hysterectomy with a giant uterus of 500 g or more"
45640001|NCT05009693|Other|White Light Application|White Light Therapy
45640002|NCT02343601|Device|Photoplethysmography|Use Photoplethysmography for hemodynamic optimization during colorectal perioperative period
45640003|NCT03090815|Genetic|Sequencing of ctDNA in plasma|Sequencing of ctDNA in plasma
45778044|NCT03624062|Drug|MAS-1 adjuvanted Insulin B-chain|MER3101 (MAS-1 adjuvanted insulin B chain (IBC)), is a white, free-flowing 30:70 (w/w) water-in-oil (W/O) emulsion. MER3101 contains in the aqueous (disperse) phase 33, 109, or 327 µg per 0.25 mL dose of IBC (Drug Substance) and the oil (continuous) phase is comprised of MAS-1 oil vehicle.
45778045|NCT03610724|Biological|Tisagenlecleucel|Single intravenous infusion
45778046|NCT03610724|Drug|lymphodepleting chemotherapy|Prior to tisagenlecleucel infusion, each subject should undergo lymphodepletion with recommended Fludarabine and cyclophosphamide (unless contra-indicated for subject)
45778047|NCT03610724|Drug|Bridging Therapy|Pre-study treatment phase may also include bridging therapy of investigator's choice
45778048|NCT03594760|Diagnostic Test|18F-DCFPyL IV injection|Patient will receive one injection of 18F-DCFPyL and undergo PET-CT imaging
45778049|NCT03574090|Drug|Amoxicillin Clavulanate|To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
45778050|NCT03574090|Drug|Physiological Saline|To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
45778051|NCT03554473|Drug|M7824|Arm A &amp; B: 2400mg IV over up to 120 minutes every 3 weeks on a 3-week cycle. Arm C: 1200 mg IV over 1 hour every 2 weeks on a 4-week cycle.
45640004|NCT03147937|Other|Cognitive Testing|Computerized CogState Brief Battery (CBB), Cognigram, assesses changes in four cognitive domains including psychomotor function, attention, learning and memory, and working memory. The CBB is a computerized test based on card games that can be administered online
45778052|NCT03554473|Drug|Topotecan|Arm B: 1 mg/m2 IV over 30 minutes days 1-5 on a 3-week cycle.
45778053|NCT03554473|Drug|Temozolomide|Arm C and progressive disease patients on Arm A: 200 mg/m2 PO days 1-5 on a 4-week cycle
45778054|NCT03533283|Drug|Glofitamab|Glofitamab will be administered through IV infusion every 3 weeks (Q3W) beginning Cycle 1, Day 1, for up to 17 cycles (Cycle = 21 days). Step-up dosing, in which an initial lower dose will be followed by a higher dose 1 week later, will be considered for the initial treatment phase and for Cycle 9 of the re-treatment phase.
45778055|NCT03533283|Drug|Atezolizumab|Atezolizumab will be administered in combination with Glofitamab through IV infusion Q3W from Cycle 2, Day 1, for up to 16 cycles (Cycle = 21 days).
45778056|NCT03533283|Drug|Obinutuzumab|Obinutuzumab will be administered once, through IV infusion, at a fixed dose 7 days before the first dose of Glofitamab.
45778057|NCT03533283|Drug|Tocilizumab|Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
45778058|NCT03533283|Drug|Polatuzumab Vedotin|Polatuzumab vedotin will be administered in combination with Glofitamab (on different days) Q3W from Cycle 1, Day 2, for up to 12 cycles (Cycle = 21 days).
45778059|NCT03533283|Drug|89Zr-Df-IAB22M2C|Participants will receive 89Zr-Df-IAB22M2C (Cycle 1 only) prior to obinutuzumab pre-treatment and again on Day 10 after dosing with glofitamab, followed by PET/CT.
45778060|NCT03522246|Drug|Rucaparib|Oral rucaparib will be administered twice daily
45778061|NCT03522246|Drug|Nivolumab|IV nivolumab will be administered once every 4 weeks
45778062|NCT03522246|Drug|Placebo Oral Tablet|Placebo tablets will be administered twice daily
45778063|NCT03522246|Drug|Placebo IV Infusion|IV placebo will be administered once every 4 weeks
45778064|NCT03510117|Behavioral|Mindfulness|Mindfulness
45778065|NCT03507790|Drug|CT1812|Active Study Drug
45778066|NCT03507790|Drug|Placebo|Non-active study drug
45778067|NCT03504397|Drug|zolbetuximab|Zolbetuximab will be administered as a minimum 2-hour IV infusion.
45778068|NCT03504397|Drug|placebo|Placebo will be administered as a minimum 2-hour IV infusion.
45778069|NCT03504397|Drug|oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion
45778070|NCT03504397|Drug|folinic acid|Folinic acid will be administered as a 2-hour IV infusion.
45778071|NCT03504397|Drug|fluorouracil|Fluorouracil will be administered as IV bolus over 5-15 minutes and continuous IV infusion over 46-48 hours.
45778072|NCT03498716|Drug|Atezolizumab|"Atezolizumab will be administered by IV, 840 mg every 2 weeks, for 10 doses.~Atezolizumab maintenance will be administered by IV, 1200 mg every 3 weeks to complete 1 year"
45778073|NCT03498716|Drug|Paclitaxel|Paclitaxel will be administered by IV, 80 mg/m^2 every week for 12 weeks.
45778074|NCT03498716|Drug|Dose-dense Doxorubicin or dose-dense Epirubicin|"Dose-dense doxorubicin will be administered by IV, 60 mg/m^2 every 2 weeks for a total of 4 doses.~Or~Dose-dense epirubicin will be administered by IV, (90 mg/m^2) every 2 weeks for a total of 4 doses"
45778075|NCT03498716|Drug|Cyclophosphamide|Cyclophosphamide will be administered by IV, 600 mg/m^2 every 2 weeks for 4 doses
45778076|NCT03449381|Drug|BI 907828|Film-coated tablet
45778077|NCT03433898|Drug|BI 754091|Solution for infusion
45640005|NCT04954781|Drug|Tislelizumab|Tislelizumab will be initiated on day 14 after the first TACE session. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
45640006|NCT04954781|Combination Product|TACE|TACE is performed by using drug-eluting beads. TACE treatment starts on day 0. The second TACE will be repeated on day 28 (± 5 days) if necessary per Investigator's decision.
45640007|NCT02348905|Drug|ACTHAR Gel 40 units twice weekly|ACTHAR Gel (adrenocorticotropic hormone) 40 units twice weekly between Baseline and week 12.
45640008|NCT02348905|Drug|ACTHAR Gel 80 units twice weekly.|ACTHAR Gel (adrenocorticotropic hormone) 80 units twice weekly between Baseline and week 12.
45778078|NCT03433898|Drug|BI 754111|Solution for infusion
45778079|NCT03429543|Drug|Linagliptin|Film Coated Tablet
45778080|NCT03429543|Drug|Empagliflozin|Film Coated Tablet
45778081|NCT03429543|Drug|Placebo|Film Coated Tablet
45778082|NCT03427047|Device|MyKnee with single use Efficiency Instrument|Total Knee Arthroplasty utilizing a CT scan for customization of cutting blocks with single use instrumentation
45778083|NCT03427047|Device|Stryker Navigational with conventional metal instruments|Total Knee Arthroplasty without customization of cutting blocks using conventional metal instruments.
45778084|NCT03417544|Drug|ATEZOLIZUMAB|(IV) every 3 weeks
45778085|NCT03417544|Drug|PERTUZUMAB|Loading dose, followed every 3 weeks thereafter by a predetermined dose in the protocol via IV
45778086|NCT03417544|Drug|TRASTUZUMAB|Predetermined dose per protocol via IV, weekly for 24 weeks and after every 3 weeks
45778087|NCT03399500|Behavioral|In-Person Case Management at Homeless Recovery Program|In-Person Case Management at Homeless Recovery Program
45778088|NCT03399500|Behavioral|Unlimited Smartphone|Smartphone with unlimited calls, texts, and data plan
45778089|NCT03399500|Behavioral|Smartphone Based Case Management (SPCM) app|Smartphone Based Case Management app
45778090|NCT03388619|Radiation|Dose to prostate bed with integrated boost|Radiation will be delivered at an escalated dose to areas of recurrent prostate cancer identified on imaging and a reduced dose will be delivered to the entire prostate bed
45778091|NCT03388619|Radiation|Dose to prostate bed irradiation only|Radiation will be delivered to the prostate bed only
45778092|NCT03363464|Drug|Empagliflozin|Empagliflozin
45778093|NCT03363464|Drug|DPP-4 inhibitor|dipeptidyl peptidase-4 inhibitor
45778094|NCT03363464|Drug|GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonist
45778095|NCT03317405|Drug|Endoxifen hydrochloride gel 10 mg daily in Cohorts 1 and 3|Apply to each breast daily for total dose of 10 mg daily
45778096|NCT03317405|Other|Placebo daily in Cohorts 1 and 2|Apply to each breast daily
45778097|NCT03317405|Drug|Endoxifen hydrochloride gel 20 mg daily in Cohort 2|Apply to each breast daily for total dose of 20 mg daily
45778098|NCT03314714|Procedure|Acute bout of endurance exercise|Individuals will undergo an acute bout of endurance exercise for 90 min at 75% of maximal oxygen uptake.
45778099|NCT03314454|Drug|Beer|Common brands beer with similar calorie (125-150) and alcohol level (approximately 4.5% ABV)
45778100|NCT03314454|Device|Videotaped drinking session|Video-assisted alcohol topography to explore its utility as an indicator of alcohol use disorder
45778101|NCT03309878|Biological|Mogamulizumab|Given IV
45778102|NCT03309878|Biological|Pembrolizumab|Given IV
45640009|NCT04954157|Diagnostic Test|Phase-1: Breath Holding Test|In this phase of the study, each subject will be asked to hold their breath for up to 60 seconds or until they can longer hold it. While they are holding their breath, subjects will be hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
45640010|NCT04954157|Diagnostic Test|Phase 2: 6-Minute Walk Test (6MWT)|In this phase of the study, each subject will be asked to walk for 6 minutes in their hospital room or hallway. Their rate of perceived exertion will be measured while also hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
45778103|NCT03297606|Drug|Olaparib|300mg taken twice daily
45778104|NCT03297606|Drug|Dasatinib|100mg administered orally once daily
45778105|NCT03297606|Drug|Nivolumab plus Ipilimumab|"Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase.~Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks."
45778106|NCT03297606|Drug|Axitinib|5mg orally twice daily
45778107|NCT03297606|Drug|Bosutinib|500mg orally once daily
45778108|NCT03297606|Drug|Crizotinib|250mg orally twice daily
45778109|NCT03297606|Drug|Palbociclib|125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days
45778110|NCT03297606|Drug|Sunitinib|50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off
45653058|NCT05126199|Other|Normal ad libitum diet|"Following a 3-day baseline dietary assessment using the Nutritics 'app', participants with be directed to continue with their usual dietary intake without any time-related restrictions for 12 weeks. There will be no defined eating window and fasting or restrictions regarding types of food or drink consumed.~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12)."
45778111|NCT03297606|Drug|Temsirolimus|25mg infused over a 30-60 minute period once a week
45778112|NCT03297606|Drug|Erlotinib|150mg orally, once daily
45778113|NCT03297606|Drug|Trastuzumab plus Pertuzumab|"Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion.~Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes."
45778114|NCT03297606|Drug|Vemurafenib plus Cobimetinib|"Vemurafenib = 960 mg orally every 12 hours.~Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest"
45778115|NCT03297606|Drug|Vismodegib|150mg taken orally, once daily
45778116|NCT03297606|Drug|Tucatinib|300mg taken orally, twice daily
45778117|NCT03294863|Device|Embrace Scar Therapy Device|16x5-cm silicone elastomeric dressing that adheres to the skin using a pressure-sensitive silicone adhesive.
45778118|NCT03294863|Other|Standard of Care|Without the embrace Scar Therapy Device
45778119|NCT03275584|Drug|N-13 ammonia intravenous injection|"Participants will receive two injections of N-13 ammonia, once at rest and once at stress before undergoing positron emission tomography myocardial perfusion imaging"
45778120|NCT03253744|Drug|18F-DCFPyL|Subjects will receive 18F-DCFPyL at baseline and 6 months after radiation. The maximum amount of injected active drug will be less than 4.02 micrograms. The target administered activity will be 6-6.5 mCi.
45778121|NCT03253744|Radiation|Tumor Irradiation|SBRT will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy
45778122|NCT03253744|Radiation|Prostate + tumor irradiation|SBRT will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate
45778123|NCT03241459|Device|Surmodics SurVeil DCB|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
45778124|NCT03241459|Device|Medtronic IN.PACT Admiral DCB|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
45778125|NCT03233204|Drug|Olaparib|Given PO
45778126|NCT03229863|Other|Sweet Potatos|Plum Organics, Just Sweet Potato
45778127|NCT03229863|Other|Pears|Earth's Best, First Pears
45778128|NCT03194893|Drug|Alectinib|Alectinib capsules 600 mg twice a day (BID) orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
45778129|NCT03194893|Drug|Crizotinib|Crizotinib capsules 250 mg BID orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
45778130|NCT03179930|Drug|Entinostat|All patients will receive entinostat 5-7 mg PO as per the dosing regimen at the on D1, D8, and D15
45778131|NCT03179930|Drug|Pembrolizumab|pembrolizumab 200 mg IV on D1
45778132|NCT03113851|Radiation|Radiotherapy|One lesion received radiotherapy for 35 Gy in 10 fractions and rested for one week; then another metastatic lesion were treated with radiotherapy for 35 Gy in 10 fractions.
45778133|NCT03113851|Drug|rhGM-CSF|Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy
45778134|NCT03104517|Biological|AMDC-USR (iltamiocel)|Autologous Muscle Derived Cells for Urinary Sphincter Repair (generic name: iltamiocel)
45778135|NCT03104517|Other|Placebo|Placebo control is the vehicle solution used for the study product.
45778136|NCT03101891|Procedure|Serial amnioinfusions with isotonic fluid|Amnioinfusions will be performed by an expert in fetal procedures with a 20 or 22 gauge needle using sterile technique and ultrasound guidance. Local anesthetic will be employed. The fluid will consist of warmed isotonic fluid. Infusions may take up to 1 hour.
45640011|NCT02347033|Drug|Sertraline|"Sertraline will be prescribed by the patients' GP, starting at 25mg daily for 1-2 weeks and increasing to 50mg daily if tolerated. The GP should review the patient within the first 2 weeks, checking for acceptability, concordance and any side-effects, with further reviews at 6 and 12 weeks. We expect the usual treatment dose to be 50 to 100mg daily, although some may require 150mg.~We will suggest that the GPs use their usual procedures to review the patient's progress, asking about and noting functional change as well as clinical improvement. Minimal improvement after 12 weeks at a maximal tolerated dose should prompt consideration of change of treatment. If there has been an adequate therapeutic benefit there should be further review at 26 and 52 weeks."
45778137|NCT03101891|Device|Spinal needle|A 20 or 22 gauge spinal needle will be used with sterile technique to access the uterus under ultrasound guidance and to infuse isotonic fluid.
45778138|NCT03101891|Drug|Isotonic fluid|Isotonic fluids, including normal saline or lactated ringers solution, will be infused into the uterus through a spinal needle under ultrasound guidance using sterile technique. This fluid will act as replacement amniotic fluid.
45778139|NCT03074474|Device|OviTex 1S Permanent|OviTex 1S Permanent is a reinforced tissue matrix consisting of layers of extra-cellular matrix derived from sheep stomachs. The layers are embroidered together with a monofilament polypropylene. One side of the mesh has blue polypropylene stitching, which provides a surface conducive to native tissue growth. The other side of the mesh is a smooth surface intended to minimize tissue attachment (adhesions).
45778140|NCT03064503|Biological|Blood sampling|Blood sampling will be performed at inclusion to investigate some biological eligibility criteria, and the day of MRI in order to analyse fibrosis biomarkers and collagen synthesis biomarkers
45778141|NCT03064503|Device|MRI|MRI will be performed to measure interstitial fibrosis
45778142|NCT03064503|Biological|Skin auto-fluorescence|Skin auto-fluorescence measures will be performed to measure advanced glycation end-products (AGE) produced by collagen degradation
45778143|NCT03043313|Drug|Trastuzumab|Given intravenously (into the vein; IV)
45778144|NCT03043313|Drug|Tucatinib|Given orally
45778145|NCT03017118|Dietary Supplement|Turmeric|Subjects will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.
45778146|NCT03017118|Other|Placebo|Subjects in the control group will receive a placebo 3 times per day for 6 weeks.
45778147|NCT02990299|Behavioral|mHealth for Diabetes Adherence Support|Participants will be paired with a health coach who will provide ongoing support and resources in medication and lifestyle adherence and diabetes self-management. The health coach will perform regular home visits, telephone support and tailored text-messages based on the participant's preferences and needs. They will help assess barriers to adherence and use motivational interviewing to help patients set goals and create action plans. They will also facilitate videoconferences with an assigned clinical pharmacist who will provide consultation on medication use, reconciliation and adherence, identify therapeutic goals and formulate an approved plan of care.
45778148|NCT02972840|Drug|Acalabrutinib|Administered orally (PO)
45778149|NCT02972840|Drug|Bendamustine|Administered intravenously (IV)
45778150|NCT02972840|Drug|Rituximab|Administered intravenously (IV)
45778151|NCT02972840|Drug|Placebo|Placebo comparator
45653059|NCT04789265|Other|instrumented- assisted soft tissue mobilization (IASTM)|IASTM is a new, non-invasive, conservative therapeutic approach. Instead of the therapist's hands and fingers in treatment, these devices are used to provide contact mobilization power. AYDM intervention, such as friction, rubbing massage treatments, requires the therapist to apply a significant amount of pressure. The main purpose of IASTM is to eliminate scar tissue and to restore the normal function of the tissue following soft tissue regeneration.
45778152|NCT02968732|Procedure|Radical Cystectomy|
45778153|NCT02963558|Device|cycle ergometry|The cycler will provide 3 different possible modes of cycling-passive, active-assisted, and active. The subject will start with passive cycling and may progress to active-assisted and active cycling.
45778154|NCT02952248|Drug|BI 754091|
45778155|NCT02903381|Drug|Nivolumab|Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and
45778156|NCT02903381|Drug|Lenalidomide|Oral, predetermined dosage, Days 1-21 of cycle 1-12
45778157|NCT02903381|Drug|Dexamethasone|Oral, Days 1, 8, 15 of cycle 1-6
45778158|NCT02850991|Radiation|High-dose|Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
45778159|NCT02850991|Radiation|Standard-dose|Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
45778160|NCT02830724|Drug|Cyclophosphamide|"For Phase I, Days -7 and -6:~Dose Level 1: 15 mg/kg/day x 2 days IV Dose Level 2: 15 mg/kg/day x 2 days IV Dose Level 3: 15 mg/kg/day x 2 days IV Dose Level 4: 15 mg/kg/day x 2 days IV Dose Level 5: 30 mg/kg/day x 2 days IV Dose Level 6: 60 mg/kg/day x 2 days IV~For Phase II, Days -7 and -6:~60 mg/kg/day x 2 days IV"
45778161|NCT02830724|Drug|Fludarabine|"For Phase I, Days -7 to -5:~Dose Level 1: 25 mg/m(2)/day x 3 days IVPB Dose Level 2: 25 mg/m(2)/day x 3 days IVPB Dose Level 3: 25 mg/m(2)/day x 3 days IVPB Dose Level 4: 25 mg/m(2)/day x 3 days IVPB Dose Level 5: 25 mg/m(2)/day x 5 days IVPB Dose Level 6: 25 mg/m(2)/day x 5 days IVPB~For Phase II, Days -7 to -3:~25 mg/m(2)/day x 5 days IVPB"
45778162|NCT02830724|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
45778163|NCT02830724|Biological|Anti-hCD70 CAR transduced PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-5 days after the last dose of fludarabine).
45778164|NCT02811133|Drug|Inositol|Subjects will receive inositol
45778165|NCT02744391|Drug|Levodopa|
45915878|NCT04201834|Device|BioStamp nPoint device|MC10 has developed the BioStamp nPointTM, a FDA 510(k) cleared medical device. This multimodal, reusable and rechargeable biosensor uses flexible and stretchable electronics to enable unobtrusive wear on the body and monitoring in the home. The sensors have accelerometry, gyroscopy, and ECG/EMG capabilities. A docking station enables wireless recharging and data collection.
45915879|NCT04192435|Drug|Tranexamic Acid|100mg/ml
45915880|NCT04192435|Drug|Placebos|Placebo will be 5ml vials calculated to equivalent to the 100mg/ml of active drug.
45915881|NCT04185454|Dietary Supplement|Jarlsberg cheese|Daily intake of Jarlsberg cheese
45915882|NCT04130269|Other|No intervention|Questionnaires, lab-run
45640012|NCT02347033|Behavioral|Cognitive Behavioural Therapy|"CBT will consist of 14 (+ / - 2) weekly 50-minute sessions and will cover 6 treatment modules: psychoeducation and worry awareness training; re-evaluation of the usefulness of worry; uncertainty recognition and behavioural exposure; problem-solving training; written exposure; and relapse prevention.~Sessions will be digitally recorded and a random 10% assessed for quality (fidelity to the manual and therapist competence) by an independent external assessor according to pre-specified criteria. Patient consent for this will be obtained as part of obtaining informed consent."
45640013|NCT04949633|Drug|Prostaglandins|Second cervical ripening lasting a maximum of 24 hours
45915883|NCT04128670|Device|Kinesiotape|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. It is recommended that the application of the tape for lymphatic correction be applied for 24-72 hours. The tape will be applied with a tension of 10-20%.
45448549|NCT05557240|Drug|NeoPep Vaccine2 plus Poly-ICLC|"NPVAC2： NPVAC2 will be ready for use 2 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. NPVAC2 drug products are composed 20 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with NPVAC2 drug products beginning on day 33 of the 6 maintenance TMZ cycle.Patients will receive 9 vaccinations within 12 weeks. 400 μg per peptide per vial are used.~Poly-ICLC:~Poly-ICLC（500ug）will be used as immunomodulator with all vaccinations."
45640014|NCT04949633|Drug|Oxytocin|Induction of labor with oxytocin.
45640015|NCT02343367|Behavioral|behavioral counseling|Pediatrician trained in motivational interviewing techniques provides brief lifestyle behavioral counseling to child and parent using a Healthy Lifestyle Prescription
45640016|NCT02343367|Other|Education Materials|Health education materials about healthy eating and physical activity and a community resource guide
45640017|NCT02343367|Behavioral|Face to face counseling session|30 minute face-to-face family-centered behavioral counseling session delivered by a health educator
45640018|NCT02343367|Behavioral|Text messages|regularly scheduled cell phone text messages for 12 months
45640019|NCT02343367|Behavioral|Telephone Counseling|14 telephone counseling sessions delivered by a health educator using motivational interviewing techniques. Two sessions per month for the first two months followed by one session per month for 10 months
45640020|NCT02343367|Behavioral|Newsletters|12 monthly newsletters mailed to participant homes
45640021|NCT03146377|Drug|Capecitabine|1250 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
45640022|NCT03146377|Drug|Oxaliplatin|85 mg/m2 IV on day 1 of a 2-week cycle
45640023|NCT03146377|Drug|Irinotecan|165 mg/m2 IV on day 1 of a 2-week cycle
45640024|NCT05018195|Procedure|Excise adipose tissue|Perform partial omentectomy to obtain one 5*5 cm omental fat and excise one 3*3 cm subcutaneous adipose tissue( 2 finger width above the pubic symphysis) during surgery
45640025|NCT02343055|Other|Case Management and Self-Management Education|A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
45640026|NCT05009615|Dietary Supplement|Green coffee extract|150 mg polyphenols from green coffee, twice daily
45640027|NCT05009615|Dietary Supplement|Beta glucan|2.5 g BG twice daily
45640028|NCT05009615|Dietary Supplement|Green coffee + beta-glucan|150 mg polyphenols from green coffee + 2.5 g BG, twice daily
45640029|NCT02343133|Biological|HemaMax|
45640030|NCT02343133|Drug|Placebo|
45640031|NCT02349139|Drug|ASN001: Escalating dose Part A|Androgen inhibitor
45640032|NCT02348827|Behavioral|Family psychoeducation|
45640033|NCT02348827|Behavioral|Social support group|
45640034|NCT03090581|Procedure|Biopsies CP|Transbronchial biopsies will be obtained with a flexible bronchoscope, using a cryoprobe.
45640035|NCT03090581|Procedure|Biopsies FC|Transbronchial biopsies will be obtained with a flexible bronchoscope, using a forceps.
45640036|NCT02348671|Other|shear- force|19 Newton shear- force and 3,9 kPa pressure for half an hour
46070358|NCT02551471|Other|Semi-structured exploratory interviews and focus group with MDT health professional attendees|Will identify care management systems for PRC-bTME and LRRC patients, explore social representations that direct the formulation of a therapeutic decisions and identify cultural, medical and personal factors
45640037|NCT03079583|Dietary Supplement|Intervention-group|Biofortified Rice is grown by foliar Zn application
45640038|NCT03079583|Dietary Supplement|Control-group|Control Rice with normal zinc levels
45640039|NCT02346955|Biological|CM-24 (MK-6018)|humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion
45640040|NCT02346955|Biological|Pembrolizumab (MK-3475)|200 mg of Pembrolizumab by IV infusion
45640041|NCT03079505|Drug|Dasatinib 100 MG [Sprycel]|Dasatinib (Sprycel) 100 milligram, once-daily (QD) will be given to 25 patients orally
45448550|NCT03734835|Dietary Supplement|hesperidin|1000 mg hesperidin as two capsules
45640042|NCT03079505|Drug|Nilotinib 150mg oral capsule [Tasigna]|Nilotinib (Tasigna) 300 milligram, twice-daily (BID) will be given to 25 patients orally
45640043|NCT02343211|Drug|Immunoglobulin|
45640044|NCT03090503|Drug|Aripiprazole|Initial dose: 10 mg.
45640045|NCT03090503|Drug|Risperidone|Initial dose: 2 mg.
45640046|NCT02343289|Drug|Esketamine|28 mg of esketamine as a single, 40-minute, intravenous infusion on Day 1 of Period 1, 84 mg of esketamine solution as a single, oral dose on Day 1 of Period 2, 84 mg of intranasal esketamine on Day 1 of Period 3 and on Day 1 of Period 4.
45640047|NCT02343289|Drug|Clarithromycin|500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4.
45640048|NCT05008523|Behavioral|Opioids and Police Safety Occupational Risk Reduction Training (OPS)|Potential participants are provided with a flyer with directions to enroll online. Groups are randomized by zip code (all participants with the same zip code receive the same training to avoid contamination by precinct) Both the experimental and control groups first take the online GetNaloxoneNow.org First Responder training; then the experimental group takes the online OPS training and the control group takes the online COVID training. Both groups take a pre-survey prior to both trainings and a post-survey after they complete both trainings. Both groups also receive (via email) a resource list with information that was provided in their respective trainings plus additional resources re: occupational risk reduction appropriate to each training. Every quarter for one year, participants are emailed a reminder to get back online to take the survey again.
45640049|NCT05008523|Behavioral|Opioids and Police Safety Occupational Risk Reduction Training (COVID)|Potential participants are provided with a flyer with directions to enroll online. Groups are randomized by zip code (all participants with the same zip code receive the same training to avoid contamination by precinct) Both the experimental and control groups first take the online GetNaloxoneNow.org First Responder training; then the experimental group takes the online OPS training and the control group takes the online COVID training. Both groups take a pre-survey prior to both trainings and a post-survey after they complete both trainings. Both groups also receive (via email) a resource list with information that was provided in their respective trainings plus additional resources re: occupational risk reduction appropriate to each training. Every quarter for one year, participants are emailed a reminder to get back online to take the survey again.
45640050|NCT03090113|Drug|Shuxuetong Injection|intravenous drip
45640051|NCT03090113|Drug|Placebo Injection|intravenous drip
45640052|NCT02346799|Behavioral|Workout Window Reminders|Participants will receive emails at prespecified times reminding them to exercise, either during a specific two hour window or at any time during the day.
45640053|NCT02346799|Behavioral|Individual Workout Incentive Payment|Participants will be paid $3 or $7 for each workout completed during the appropriate times.
45640054|NCT02346799|Behavioral|Lump Incentive Payments|Participants will receive $20 payments for completing post treatment survey.
45640055|NCT02346799|Behavioral|Partner Assignment|"Participants will be required to have same workout window as partners."
45640056|NCT03146221|Other|To look for serum microRNA profiles associated with restenosis|To look for serum microRNA profiles associated with restenosis
45640057|NCT03090269|Drug|Methylphenidate Pill|3-month follow-up to study the effective dose as a treatment for cocaine dependence in toxicity and reduction in cocaine use
45640058|NCT02342899|Device|Outpatient NIV Set Up using AVAPS AE (Manufactured by Philips-Respironics)|Intervention set ups will follow a standard protocol for the automated device (A40 AVAPS-AE machine;Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) and patients will be discharged with the machine and a full face mask or nasal interface. Patients will then undergo a 1-2 night home oximetry study to ensure adequate control of overnight oxygenation. Patients will be reviewed clinically as an outpatient at 6 weeks and adherence to non-invasive ventilation will be evaluated and an arterial blood gas measurement will be undertaken. A full clinical review and optimisation of NIV and interface will be performed at this visit. Patients will be reviewed at 3 months as an inpatient where overnight transcutaneous carbon dioxide level and SpO2 studies will be performed. All other patient-centred, physician-centred and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
45653060|NCT05493787|Behavioral|Reminder|Patient portal, SMS, email, and/or another modality
45653061|NCT05613569|Drug|KLS-2031|KLS-2031 administered by transforaminal epidural injection
45653062|NCT05180955|Other|Digital drainage system|In the intervention group; chest tube removal will be determined by air flow criteria as indicated by the digital drainage system data, the tube will not be clamped.
46070359|NCT00815269|Drug|Halothane|Induction: 2-4% halothane pluses 3-5 L/min oxygen Maintenance: different doses from 0.5% to 3% with 1-2 L/min oxygen
45448551|NCT03734835|Dietary Supplement|hesperidin and flaxseed|1000 mg hesperidin as two capsules and 30 grams flaxseed
45778166|NCT02709226|Radiation|Radiation|Radiation therapy will be administered daily Monday-Friday at NCI, ROB unless the treatment schedule requires amendment in the event of inclement weather or federal holidays. Radiation therapy dose will be administered as per on consecutive treatment days, 5 fractions per week via a linear accelerator using 6 MV photons or greater. Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned re-irradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD ( provided no DLT) with a maximum of 21 evaluable patients enrolled.
45778167|NCT02634710|Radiation|Hypofractionated Radiation Therapy|Treatments will have a minimum of a 48-hour interfraction interval. Treatments will be completed over 20 days maximum.
45778168|NCT02634645|Procedure|Endoscopic eradication therapies (EET)|Endoscopic eradication therapies (EET) includes endoscopic mucosal resection (EMR), which describes the process by which the area most likely to harbor highest grade of dysplasia/neoplasia is removed; radiofrequency ablation (RFA), which describes the process by which Barrett's segments are removed via burning/ablation; and cryotherapy.
45640059|NCT02342899|Device|Inpatient NIV Set Up using spontaneous/timed (S/T) mode pressure support ventilation (Manufactured by Philips-Respironics)|The patient will follow a specialist nurse-led protocolised set up of spontaneous/timed (S/T) mode pressure support ventilation (A40 AVAPS-AE machine; Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) using limited respiratory polygraphy, including overnight TcCO2 (Trascutaneous Carbon Dioxide) and SpO2 (Oxygen Saturation) studies. Following the inpatient set-up, patients will be reviewed as an outpatient at 6 weeks and adherence with non-invasive ventilation will be evaluated and arterial blood gas measurements will be performed. Patients will then be reviewed at 3 months as an inpatient where overnight respiratory polygraphy, TcCO2 and SpO2 studies will be repeated. All other patient-centred, physician-centred measurements and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
45640060|NCT05008679|Drug|Oseltamivir|at a dose of 75 mg twice daily
45778169|NCT02634645|Procedure|Esophagectomy|The esophagus is surgically removed
45778170|NCT02634645|Drug|Chemotherapy|Chemical substances are used to treat cancer
45778171|NCT02634645|Radiation|Radiation|Cancer cells are destroyed by radiation therapy.
45778172|NCT02618577|Drug|Edoxaban|"Edoxaban will be applied at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:~Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein p inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole."
45778173|NCT02618577|Drug|ASA|ASA 100 mg tablets or Placebo
45778174|NCT02607722|Drug|Nintedanib|
45778175|NCT02600156|Procedure|Focal laser ablation of the prostate|MR guided laser ablation of the focal prostatic lesion which has been identified by MRI and biopsy prior to ablation.
45778176|NCT02594813|Procedure|Biopsy or cold snare polypectomy|
45778177|NCT02555072|Biological|yellow fever vaccine|yellow fever vaccination in naive individuals who leaves in a state where this type of vaccination is not recommendated
45778178|NCT02462837|Drug|Mirabegron|
45778179|NCT02462837|Drug|Placebo|
45778180|NCT02437500|Biological|SER-109|SER-109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors
45778181|NCT02436707|Drug|Ibrutinib|
45640061|NCT03090035|Drug|Pegylated Interferon α2|Peg-INF was given in a dose of 180 μg/week
45640062|NCT03090035|Drug|Ribavirin|ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 & 3
45640063|NCT03147781|Device|True AT with magnetic pellets|Magnetic pellets are affixed onto pre-selected auricular acupoints with tape.The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
45640064|NCT03147781|Device|Sham AT with Medulla Junci|Medulla Junci segments are crumbled into ball-shape and then attached to the pre-selected auricular acupoints with tape. The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
45778182|NCT02436707|Drug|Rituximab|
45778183|NCT02436707|Drug|Gemcitabine|
45778184|NCT02436707|Drug|Dexamethasone|
45778185|NCT02436707|Drug|Cisplatin|
45778186|NCT02436707|Drug|Mesna|
45778187|NCT02436707|Drug|Cyclophosphamide|
45778188|NCT02436707|Drug|Etoposide|
45915884|NCT04121728|Drug|Ginkgo biloba extract|Symfona® commercial standardized Ginkgo biloba extracts are used in this study, at a rate of 2 capsules of 120 mg per day for 170 days.
45448552|NCT03734835|Dietary Supplement|flaxseed|30 grams flaxseed
45778189|NCT02436707|Drug|G-CSF|
45778190|NCT02436707|Drug|Selinexor|
45778191|NCT02420977|Drug|Pelvic DCFPyL PET-MRI fusion or PET/MRI|"Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT~Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months"
45778192|NCT02392455|Drug|treatment|Docetaxel plus nintedanib until progression or intolerability
45778193|NCT02366221|Other|60-minute visit to the outpatient clinic|An interview, an injury-specific physical exam and/or a set of xrays.
45778194|NCT02366221|Other|Phone Interview|If subject cannot return to office in Boston, researcher may conduct interview over the phone.
45778195|NCT02346201|Drug|Methylphenidate|Two 5mg methylphenidate over-encapsulated drug taken twice a day for 6 months (total of 20 mg methylphenidate per day), and psychosocial intervention
45778196|NCT02346201|Drug|Placebo|Two over-encapsulated placebo taken twice a day for 6 months and psychosocial intervention
45778197|NCT02331134|Drug|Filgrastim|Patients will receive 10 μg/kg/day of filgrastim subcutaneously in a 4-day mobilization schedule
45778198|NCT02326207|Device|Infant Ventilator Circuit Dual Heated with Autofeed Chamber|
45778199|NCT02318732|Behavioral|APPS intervention|Contact with and recovery of firearms from individuals who are prohibited from possessing them
45778200|NCT02310321|Drug|gilteritinib|Once-daily oral administration on 14 consecutive days in every cycle in each period.
45640065|NCT03147703|Behavioral|Food Timing|the timing of the main meal of the day (lunch in Spain) is changed from early (14:00) to late (17:30) and viceversa in a randomized and crossover way
45778201|NCT02310321|Drug|Idarubicin|Induction period: Once-daily intravenous injection of 12 mg/m^2 idarubicin on 3 consecutive days.
45778202|NCT02310321|Drug|Cytarabine|"Induction period: Once-daily intravenous injection of 100 mg/m^2 cytarabine on 7 consecutive days.~Consolidation period: Twice-daily intravenous injection of 1.5 g/m^2 cytarabine on Days 1, 3, and 5."
45640066|NCT03079349|Other|Medical Education|All candidates in the Active Comparator: Traditional Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in the Active Comparator: Traditional Classroom will take a post course test.
45640067|NCT03079349|Other|Medical Intervention|All candidates in the Experimental: Online Synchronous Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in theExperimental: Online Synchronous Classroom will take a post course test.
45640068|NCT03147625|Behavioral|SHAPE Intervention|SHAPE seeks to identify, equip and strengthen resources in elderly residing in elderly-only households. The content will be further developed according to the findings of an existing descriptive qualitative study, literature review and a multi-disciplinary expert panel review. The home visit will involve assessment, observation and evaluation of elderly' health status, lifestyle and home environment, followed by guidance on health-promoting behaviour and emphasis on strengthening inner health resources. This provides an individualized approach to enhance personal health skills. Group-based activity sessions are directed to facilitate group interaction among peers as well as equipping and enhancing external resources.
45640069|NCT05017961|Device|Autograft|An autograft bone will be harvested from proximal tibia or posterior superior iliac crest. First the bony landmarks of the posterior iliac crest or proximal tibia are palpated. The skin is then injected down to and including the periosteum with 1% lidocaine without epinephrine. After 1 cm skin incision and gentle dissection of subcutaneous soft tissue, the bone harvesting device inserted through the skin and subcutaneous tissues until it reaches the cortical bone. Then, manual pressure is used to position the bone harvesting device against the dense cortical bone. A battery-powered power instrument is then will be used to drill the harvesting device into the medullary cavity. After the harvesting device insertion the cancellous strips of bone will be harvested and applied to the fracture site gap.At the conclusion of autograft bone harvesting procedure, the wound will be closed with 3-0 Nylon and a sterile dressing will be applied to the harvest site.
45640070|NCT05017961|Device|Allograft only|The jar containing allograft tissue and cryopreservation solution will be placed in a sterile basin containing a warm (35°C to 39°C; 95°F to 102.2°F) sterile irrigant (Normal saline or 5% Dextrose in Lactated Ringer's Solution). The jar containing the allograft will remain in this solution until the contents of the jar flows freely upon inversion. The jar will be removed from the warm solution once free-flowing. Sterile gauze or the optional strainer will be used to decant the cryopreservation solution into a waste container. 5% Dextrose in Lactated Ringer's Solution will be added to the indicated fill line to immerse the allograft tissue. The cap will be replaced and inverted twice to suspend tissue until ready for use. 5% Dextrose will be decanted in Lactated Ringer's Solution prior to use. Implant will be used within 2 hours of thawing.
45640071|NCT05017961|Device|Allograft combined with BMAC|A bone marrow aspiration kit will be used for bone marrow aspiration. First the bony landmarks of the posterior iliac crest and sacroiliac joint are palpated. The skin is then injected down to and including the periosteum with 1% lidocaine without epinephrine. Then, the bone marrow aspiration trochar and needle are percutaneously inserted through the skin and subcutaneous tis- sues until it reaches the posterior iliac crest. The trajectory of the needle will be parallel to the iliac crest, or perpendicular to the Anterior Superior Iliac Spine (ASIS) or Posterior Superior Iliac Spine (PSIS), depending on the harvest site used. After the trochar is inserted into the posterior iliac crest but prior to aspiration, 1 mL of heparin (1,000 U/mL) will be preloaded into the syringe. Approximately 60 mL of bone marrow will be aspirated, which requires the use of two 30-mL syringes. At the conclusion of BMAC harvesting, a sterile dressing will be applied to the harvest site.
45640072|NCT05008367|Drug|Dexamethasone|24 mg intravenous Dexamethasone (6 ml)
45640073|NCT05008367|Drug|Isotonic saline|6 ml of isotonic saline
45640074|NCT02346175|Drug|SHR3824|
45640075|NCT02346175|Drug|Placebo|
45640076|NCT05008211|Other|Information-Motivation-Behavioral skills (IMB) model-based intervention|A six-week programme
45640077|NCT05008211|Other|Control - usual care|he nurse will provide an one-hour face-to-face session to introduce the choices of domiciliary NIV and teach the patient or his/her family on how to operate and maintain the ventilator, interface and accessories, and also how to handle the common problems
45640078|NCT02342587|Drug|Lapatinib|Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
45640079|NCT02346331|Other|WHO algorithm of fluid boluses guided by physical examination|
45640080|NCT02346331|Other|Frequent patient monitoring|Vital signs and physical exam every 30-60 minutes
45640081|NCT02346331|Other|Early administration of empiric antibiotics|Clinician will be prompted to administer antibiotics within 60 minutes
45640082|NCT02346331|Other|Oxygen delivery|
45640083|NCT02346331|Other|Correction of hypoglycemia|If blood glucose is less than 3.0 mmol/L, IV dextrose will be administered
45640084|NCT02346331|Other|Correction of severe anemia|If hemoglobin is less than 7 mg/dL, clinician will be prompted to offer blood transfusion
45640085|NCT05017259|Dietary Supplement|calorie restriction diet|The 7-day low-calorie diet contained 15.8 ± 0.4 kcal/kg/d in both trials, divided into three meals a day.
45640086|NCT02342509|Drug|Desflurane|Group A: Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
45640087|NCT02342509|Drug|Sevoflurane|Group B: Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
45640088|NCT02342509|Drug|Isoflurane|Group C: Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
45778203|NCT02204072|Drug|BI 836845|
45778204|NCT02204072|Drug|Enzalutamide|
45778205|NCT02204072|Drug|Enzalutamide|
45778206|NCT02145741|Drug|Xentuzumab, low dose, every week (qw)|Patient to receive low dose of Xentuzumab IV
45448553|NCT03734835|Other|control|no supplementation
45640089|NCT02342431|Device|Forced air warming compressible|Warming with a compressible forced air mattress
45640090|NCT02342431|Device|Forced air non-compressible|Warming with a non-compressible forced air mattress
45640091|NCT03079271|Drug|Lacrisert, 5 Mg Ophthalmic Insert|
45778207|NCT02145741|Drug|Xentuzumab, middle dose, qw|Patient to receive middle dose of Xentuzumab IV
45778208|NCT02145741|Drug|Xentuzumab, high dose, qw|Patient to receive high dose of Xentuzumab IV
45640092|NCT02342353|Drug|Pacritinib|
45640093|NCT02342353|Drug|Erlotinib|
45640094|NCT02337127|Drug|Lamivudine|Lamivudine, 100mg/day, per os
45640095|NCT02336971|Behavioral|CBCT for PTSD|CBCT consists of three phases of treatment: Phase 1: treatment orientation and education about PTSD and its related intimate relationship problems Phase 2: behavioral communication skills training Phase 3: cognitive interventions based on Cognitive Processing Therapy (CPT)
45640096|NCT02336971|Behavioral|Prolonged Exposure|PE consists of: psychoeducation and some limited distress management training, but emphasizes the role of imaginal and in vivo exposure in treating PTSD.
45640097|NCT02337205|Drug|KX2-391 Ointment|KX2-391 Ointment will be applied at a predetermined concentration to the treatment area for a predetermined time period.
45640098|NCT05007587|Drug|Lenvatinib|8mg lenvatinib (weight<60kg) or 12mg lenvatinib (weight>60kg) QD
45640099|NCT05007587|Drug|mFOLFOX regimen|HAIC was performed every 3 weeks. The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil , 400mg/m2 , bolus at hour 3 ; and 2400mg/m2 over 46 hours on days 1 and 2.3mg/m2 , from hour 4 to 5 on day 1.
45640100|NCT05007587|Drug|ROX regimen|HAIC was performed every 3 weeks. The ROX regimen was administered via hepatic artery: oxaliplatin , 100mg/m2 , from hour 0 to 4 on day1 ;raltitrexed , 3mg/m2 , from hour 4 to 5 on day 1.
45640101|NCT05016557|Dietary Supplement|Protein ingestion|Bolus ingestion of 25g protein
45778209|NCT02137850|Drug|turoctocog alfa pegol|For intravenous (i.v.) injection. Frequency and dosage (20-75 U/kg) dependent on whether given as treatment for bleeding episode or as prophylaxis
45640102|NCT03078959|Other|immunohistochemistry|Samples will be stained using the SP263 antibody clone against PD-L1
45448554|NCT05549362|Other|Dial Health Research Study|To evaluate the feasibility and efficacy of dietary intervention approaches to slow mechanisms of aging.
45640103|NCT05015933|Procedure|Pump refill procedure at home|Implantable pump refill is performed at home
45640104|NCT03146143|Procedure|ultrafiltration|ultrafiltration after cardiopulmonary bypass
45778210|NCT02078427|Biological|ADVATE|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
45640105|NCT05016011|Biological|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|Human umbilical cord-derived mesenchymal stem cells
45640106|NCT05016011|Procedure|Marrow cellution|Patients will undergo marrow cellution surgical procedure.
45640107|NCT05015465|Diagnostic Test|Anterior Segment OCT|AS-OCT for juvenile SLE patients and compare them with normal subjects
45640108|NCT03945643|Drug|Sildenafil|50mg administration of sildenafil, one time, one hour prior to measurements.
45640109|NCT03945643|Other|Placebo|50mg administration in gel-encapsulated microcrystalline cellulose one time, one hour prior to measurements.
45640110|NCT05015777|Other|Emil Jaques-Dalcroze's Eurhythimcs Exercise Program|"Training sessions took place twice a week for 45 minutes each over a period of 12 weeks. Each training included rhythmic exercises using the Jaques-Dalcroze Eurhythmics (JDE) method with piano accompaniment and electronically played music. Training sessions were conducted by a JDE specialist.~Exercises with the use of this method consist mainly in the repetition of preset musical sequences using body movements. In addition to the physical layer, the cognitive layer was equally important: while performing a given movement exercise, participants often had to focus in order to react appropriately to additional tasks, such as changes in sound pitch and rhythm of the piece."
45640111|NCT02039323|Drug|Tenofovir|
45640112|NCT02039323|Drug|Maraviroc|
45778211|NCT02078427|Biological|ADYNOVI|Antihemophilic Factor (Recombinant) Pegylated
45778212|NCT02042378|Drug|Rucaparib|All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
45778213|NCT02019706|Radiation|DOTATATE PET-CT|68Ga-DOTATATE PET/CT
45778214|NCT02019706|Radiation|F-DOPA PET CT|68Ga-DOTATATE PET/CT
45778215|NCT02019706|Radiation|CT scan|routine CT scan
45778216|NCT02019706|Diagnostic Test|Routine MRI scan|routine 1.5 or 3T MRI scan
45778217|NCT02019706|Diagnostic Test|Gated MRI scan|Cardiac gated MRI scan
45778218|NCT02019706|Drug|68Ga-DOTATATE|68Ga-DOTATATE radioligand
45778219|NCT02019706|Drug|18F-DOPA|18F-DOPA radioligand
45640113|NCT05015699|Device|HT Supreme|HT Supreme ( R&D by Sinomed, Tianjin, China)
45640114|NCT04958161|Other|Exercise Therapy|Each exercise session will involve 5 to10 minutes of stretching and slow walking followed by a 30 minute stimulus phase of aerobic exercise. Exercise intensity during the stimulus phase will be prescribed based on the graded exercise test results and will be gradually increased with the goal of the participant exercising continuously for 30 minutes at 50% to 85% of symptom-limited maximum heart rate, or maintained at a level below that which causes symptomatic or silent ischemia. Following the aerobic phase of exercise, participants will complete one set of 8 to 12 repetitions of muscle-strengthening activities for all major muscle groups (legs, hips, back, abdomen, chest, shoulders, and arms). Participants will be provided with a home based aerobic exercise program. They will be encouraged to perform this home-based program twice a week on days when they are not attending the center-based program.
45640115|NCT02342119|Other|Talking About Living Kidney Donation|TALK participants receive a culturally sensitive educational booklet and video. A study interventionist encourages participants to share the materials with their family members or friends. Materials provide information to encourage patient and families shared and informed consideration of LDKT, including: 1) information about eligibility for LDKT, 2) the clinical evaluation required for LDKT, 3) the donor selection process, 4) surgical procedures for transplantation and donation, 5), and concerns brought forth about these factors, identified through structured group interviews.
45640116|NCT02342119|Other|Kidney Transplant Fast Track|KTFT is a one-day streamlined transplant evaluation process. Every patient who is evaluated at the University of Pittsburgh Starzl Transplant Center receives the KTFT. This approach involves completion of most or all testing on the same day that patients arrive for their first pre-transplant clinic appointment, rather than providing them with a list of tests they complete on their own with their referring physician. If patients are unable to be scheduled the same day, the transplant clinic scheduler secures appointment times and preparatory material for all testing to be completed within a 2 week period.
45640117|NCT03079115|Drug|High-dose Atorvastatin|high-dose Atorvastatin (80 mg QD from 3 days before to 3 days after CAS, and thereafter 20mg QD until 30 days after CAS)
45640118|NCT03079115|Drug|Conventional-dose Atorvastatin|conventional-dose Atorvastatin(20 mg QD from 3 days before to 30 days after CAS).
45640119|NCT02342041|Drug|SUVN-G3031|
45640120|NCT02342041|Drug|Placebo|
45640121|NCT05014997|Other|no intervention|this study was designed as retrospective observational study
45778220|NCT01956942|Device|Micropulse Laser Trabeculoplasty|
45778221|NCT01956942|Device|Selective Laser Trabeculoplasty|
45778222|NCT01866930|Biological|Pegylated Interferon Lambda-1a|
45915885|NCT04121728|Drug|Placebo|The placebo is presented in the form of capsules of identical mass, color and shape to those of the study product. It is composed of lactose, the excipients present in Symfona® 120 mg and colorants. The dosage is identical to that of the investigational product.
45640122|NCT05255185|Procedure|domino therapy|The investigators evaluated routine blood test results, C-reactive protein level, the erythrocyte sedimentation rate, and other indicators. X-rays and CT scans of the surgical site were obtained and the Musculoskeletal Tumor Society (MSTS) score was calculated. Treatment involved debridement and lavage of the prosthesis, and systemic and local antibiotics.
45640123|NCT05015075|Behavioral|cardiac rehabilitation|cardiac rehabilitation after pacemaker implantation
45640124|NCT04919863|Drug|NTP42:KVA4|Single ascending dose (SAD) or multiple ascending dose (MAD) of NTP42:KVA4 administered to healthy volunteers as an oral suspension.
45640125|NCT04919863|Drug|Placebo|Placebo, matched to corresponding doses of NTP42:KVA4 administered to healthy volunteers as an oral solution.
45640126|NCT05015231|Diagnostic Test|Echocardiography and MRI|Echocardiography and renal MRI before and after fistula closure
45640127|NCT04909177|Other|Smartphone application (app) in combination with headset|The intervention oVRcome is self-help VRET for specific phobia, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
45640128|NCT05917483|Diagnostic Test|Ultrasonography|Collect shoulder rotator cuff tendon ultrasound image during isotonic motion
45653063|NCT05180955|Other|Digital drainage system + clamping trial|In the control group removal will be determined by the same criteria of the digital drainage system but before removal, a chest tube clamping test will be performed.
45778223|NCT01866930|Drug|Daclatasvir (DCV)|
45778224|NCT01866930|Drug|Ribasphere (RBV)|
45778225|NCT01856478|Drug|methotrexate|intravenous bolus injection, once weekly
45778226|NCT01856478|Drug|afatinib|oral intake, once daily
45778227|NCT01853826|Drug|afatinib|Patients will receive afatinib once daily
45778228|NCT01807819|Other|Heart Failure|Patients will undergo echocardiogram and exercise testing. Two year phone follow-up.
45778229|NCT01693094|Behavioral|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
45778230|NCT01682187|Drug|LY2157299|Administered orally
45778231|NCT01682187|Drug|Lomustine|Administered orally
45915886|NCT03886519|Procedure|BRAP (Bevel/rotate/advance procedure)|Trichiasis surgery using the BRAP procedure
45915887|NCT03886519|Procedure|Trabut|Trichiasis surgery using the Trabut procedure
46070360|NCT00815269|Drug|Isoflurane|Induction: 2-5% isoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
45778232|NCT01621568|Drug|Sunitinib|50mg/day for 4 weeks daily, by mouth with 2 weeks off (6 week cycle)
45640129|NCT05917470|Drug|ONCT-534|ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) with a novel mechanism of action that includes inhibition of AR function and degradation of the AR protein mediated by interaction with the N-terminal domain (NTD) of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR ligand binding domain (LBD), and splice variants with loss of the AR LBD.
45778233|NCT01621568|Drug|Sunitinib|50mg/day for 2 weeks daily, by mouth with 1 week off (3 week cycle)
45640130|NCT05917457|Other|balance coordination and strengthening training|"The 25 individuals who met the inclusion criteria were divided into 2 groups, including 13 in the study group and 12 in the control group.~Study group: Low vision children were given balance, coordination training and general strengthening training with sandbags for 70 minutes 3 days a week (5-minute warm-up phase, 20-minute balance training, 20-minute coordination training, 20-minute strengthening training and 5-minute cooling phase) for 8 weeks."
45640131|NCT05917431|Combination Product|SBRT plus tislelizumab and regorafenib|Participants will receive SBRT plus tislelizumab and regorafenib concurrently
45640132|NCT05917418|Dietary Supplement|nutritional support|nutritional support
45640133|NCT05917405|Drug|Fludarabine|30 mg/m2/day IV fludarabine for 5 days (day-6 to day-2)
45778234|NCT01574170|Other|Construction of a prognostic score (non-drug intervention types)|Record of clinical, histological and biological data and questionnaires data in patients starting a third line metastatic until progression
45778235|NCT01511393|Other|No treatment given|None. Non-interventional study.
45778236|NCT01472328|Procedure|HBO therapy|Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
45778237|NCT01472328|Procedure|Hyperbaric room air|Effect of 2 hrs hyperbaric room air on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
45640134|NCT05917405|Drug|Busulfan|130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
45640135|NCT05917405|Drug|ATG|Thymoglobuline®: 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1)
45640136|NCT05917405|Drug|Clofarabine|30 mg/m2/day IV clofarabine for 5 days (day-6 to day-2)
45778238|NCT01452269|Behavioral|Deaf Weight Wise program|"Groups will consist of approximately 13 subjects who meet for 2 hours a week for 16 weeks. Group sessions will be offered at a variety of times and days of the week. A trained, deaf, ASL-fluent counselor will lead the sessions.~Subjects will be asked to complete a food and physical activity diary. Each intervention session will include a weigh-in, group sharing/problem solving, discussion of a weight management topic, and goal setting/action planning for the next week. Periodically, each subject will receive a Personal Feedback Report. Subjects will be able to earn points for complying with various aspects of the program. Points can be redeemed for small prizes (i.e. water bottles).~The maintenance phase consists of two meetings at the beginning of the 6-month maintenance period and three months later. This will consist of a weigh-in, review of self-monitored diet and physical activity, problem solving and goal setting/action planning for their long-term program."
45640137|NCT05917392|Dietary Supplement|Fermented Vegetables (Kimchi) supplementation|Fermented Vegetables (Kimchi) supplementation with 50 gm daily for two months and effects of DNA methylation, serum proteome and microbiota
45778239|NCT01366612|Drug|Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1"
45778240|NCT01366612|Drug|Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1 TBI 200cGY (as randomized) on day -1"
45640138|NCT05917392|Dietary Supplement|probiotic|Supplementation with Kimchi plus LGG 50 grams daily for two months
45640139|NCT05917392|Dietary Supplement|polyphenol|Supplementation with Kimchi plus polyphenol 50 grams daily for two months
45640140|NCT05917379|Biological|fecal microbiota|FMT utilizing stool from healthy donor
45640141|NCT05917366|Other|Exercises|Stretching exercise for the piriformis and iliopsoas muscles. strengthening exercises for pelvic floor muscles
45915888|NCT03771157|Drug|Shingrix vaccine|On day one, patients will receive the first of two doses of the Shingrix vaccine will be administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose.
45640142|NCT05917366|Other|Coccyx Manipulation|Application of manipulation to relax the levetor ani muscle
45640143|NCT05917353|Dietary Supplement|Hinex Jelly|"Name: Hinex Jelly~Dosage form: Semi-solid jelly/ A-114001297-00000-2~Dose(s): 300g/pack (per serving)~Dosing schedule: one pack (serving) per day~Mechanism of action: Nutritional supplement semi-solid food (content 61-91g/100g, protein 4.0-6.0/100g, saturated fatty acid 0.72-1.08g/100g, carbohydrate 12.56-18.84g/100g, dietary fiber 1.0-1.4g/100g), It is used as a nutritional supplement food."
45640144|NCT05917340|Drug|High dose rifampicin (25mg/kg)|Given for 2 months
45640145|NCT05917340|Drug|Moxifloxacin 400mg|Given for 2 months
45640146|NCT05917340|Drug|Aspirin 150 mg|Given for 2 months
45915889|NCT03765229|Drug|Entinostat|Oral drug 5 mg taken once weekly for up to nine 3-week (21 day) cycles. Take on an empty stomach i.e., at least 2 hours after a meal and at least 1 hour before the next meal. On days when entinostat is administered on the same day as pembrolizumab, entinostat should be taken before the pembrolizumab infusion.
45640147|NCT05917340|Drug|Isoniazid|Given for 6 months
45778241|NCT01196390|Drug|Carboplatin|Given IV
45915890|NCT03765229|Drug|Pembrolizumab|200 mg IV starting on Day 22 (cycle 2, Day 1) given every 3 weeks for up to 8 cycles.
45640148|NCT05917340|Drug|Pyrazinamide|Given for 6 months
45640149|NCT05917340|Drug|Steroid|Tapering dose of dexamethasone or prednisolone upto 8 weeks
45640150|NCT05917340|Drug|Rifampicin|Standard dose for 4 months after the initial treatment with high dose
45640151|NCT05917340|Drug|HRZE|2 months
45640152|NCT05917340|Drug|HRE|7-10 months as per TB program guidelines
45778242|NCT01196390|Other|Laboratory Biomarker Analysis|Correlative studies
45448555|NCT05533996|Diagnostic Test|ultrasound|Sonographic examination to measure the maternal pre-peritoneal fat thickness and subcutaneous fat thickness and calculate body fat index
45778243|NCT01196390|Drug|Paclitaxel|Given IV
45778244|NCT01196390|Other|Quality-of-Life Assessment|Ancillary studies
45778245|NCT01196390|Radiation|Radiation Therapy|Undergo radiation therapy
45640153|NCT05917327|Device|Low-volume continuous veno-venous haemodialysis|MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in low-volume continuous veno-venous hemodialysis. One treatment will last 4 hours. For non-hospitalized patients, the treatment is performed on an outpatient basis.
45640154|NCT05917314|Other|Slimbiotic Probiotic|"SlimBiotics Probiotic formula contains three probiotic strains of L. fermentum:~Limosilactobacillus fermentum K7-Lb1~Limosilactobacillus fermentum K8-Lb1~Limosilactobacillus fermentum K11-Lb3 The product also contains Microcrystalline cellulose."
45640155|NCT05917314|Other|Placebo|The placebo capsule contains microcrystalline cellulose.
45640156|NCT05917301|Radiation|hypofractionation|This study is being done to see if hypofractionation in treating sarcoma, will also provide patients with a faster and safer treatment outcome.
45640157|NCT05917288|Biological|Belimumab|Belimumab will be administered
45778246|NCT01196390|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45778247|NCT01196390|Biological|Trastuzumab|Given IV
45778248|NCT01042015|Combination Product|Emergency preservation and resuscitation|This involves the induction of profound hypothermia using a flush of ice-cold saline into the aorta. Once hypothermia is achieved, the subject would undergo rapid operative interventions to control bleeding followed by resuscitation/rewarming with cardiopulmonary bypass.
45448556|NCT04064008|Device|PROFEMUR® Z Revision Femoral Stem|Total Hip Total Hip Arthroscopy
45915891|NCT03746587|Drug|Arimoclomol|Arimoclomol in 3 different dosages
45640158|NCT05917288|Drug|Standard of care|Standard of care will be administered
45640159|NCT05917275|Drug|Amlodipine|4 weeks of Amlodipine
45640160|NCT05917275|Drug|Olmesartan|4 weeks of Olmesartan
45640161|NCT05917275|Drug|Hydrochlorothiazide|4 weeks of Hydrochlorothiazide
45640162|NCT05917275|Drug|Amlodipine/Olmesartan|4 weeks of Amlodipine/Olmesartan
45640163|NCT05917262|Behavioral|Mindfulness-based breathing|The 20-minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experiences in a non-judgmental fashion.
45640164|NCT05917262|Behavioral|HRV biofeedback|The 20-minute HRV biofeedback is based on the resonant frequency breathing with an external pacemaker. Generally, the breath rhythm is between 4.5 and 6.5 times per min.
45640165|NCT05917262|Behavioral|cognitive-behavioral pain psychoeducation|The 20-minute psychoeducation session is a supportive session where behavioral coping strategies for pain management are discussed.
45640166|NCT05917249|Device|Capacitive-Resistive Noninvasive Radiofrequency|The two passive plates were under the back of the patient. The active capacitive plates of the machine (CAPENGERY, C200, Spain) will be applied initially for 20 minutes over the sole of both feet, with the machine adjusted on the A-thermal mode (37 oC). During the remaining 20 minutes, active capacitive plates are relocated over femoral vessels at the femoral triangle with the machine adjusted on the frank thermal mode (41 oC).
45778249|NCT01042015|Other|Standard resuscitation|Standard resuscitation includes an emergency department thoracotomy, open cardiac massage, and fluid resuscitation.
45778250|NCT00903110|Drug|Increlex®|Increlex® (mecasermin [rDNA origin] injection), 10 mg/ml solution for injection, 40-120mcg/kg BID or 0,04 to 0,12 mg/kg BID, as prescribed by physician
45778251|NCT00813293|Drug|Sorafenib|
45778252|NCT00813293|Procedure|radiofrequency ablation|
45778253|NCT00777036|Drug|Dasatinib|
45778254|NCT00481091|Drug|ABT-263|Tablet; Oral
45448557|NCT05172388|Other|Air purifier|Real purification and sham purification would be conducted in the dormintory rooms (about 25 in total) of the study subjects for 4 days, following a randomized crossover design, which means a real air purifier and a sham purifier would be placed in the same dormintory room with a wash-out interval (15 days).
45640167|NCT05917236|Procedure|hepato-portoentostomy|the retro-colic Roux-en-Y limb of the jejunum, and finally hepato-portoentostomy (Kasai operation)
45640168|NCT05917223|Dietary Supplement|Milk protein ingestion|It's just an acute intervention, so the participant assigned to the Milk protein ingestion group will consume 20 g of milk protein during infusion protocol.
45778255|NCT00085982|Drug|Metreleptin|Administered SC twice/day to achieve physiological concentrations that will be effective in improving the severe state of insulin resistance seen in patients with genetic defects on their insulin receptor mutation
45778256|NCT00075946|Biological|rituximab|Given IV
45778257|NCT00067821|Drug|2-Flourodeoxyglucose|
45778258|NCT00003641|Biological|interferon alfa-2b|Given IV
45778259|NCT00003641|Other|observation|Patients undergo observation for 4 weeks.
45778260|NCT05327400|Other|Pathological|The pancreatic cancer cohort and the healthy cancer-free patient cohort were divided according to pathology reports
45778261|NCT05326542|Procedure|ESWL and ERCP|First, ESWL will be used for lithotripsy, and then ERCP will be performed to clear the stones after lithotripsy.
45778262|NCT05326542|Procedure|LL and ERCP|After establishing the working channel under ERCP, the stone will be crushed with a laser lithotripter, and then ERCP will clear the stones after lithotripsy.
45778263|NCT05363904|Other|Observation|Questionnaires, Clinical Scores, Biomaterial Sampling
45778264|NCT00392834|Biological|filgrastim|given subcutaneously
45778265|NCT00392834|Biological|pegfilgrastim|given subcutaneously
45778266|NCT00392834|Biological|rituximab|given IV
45778267|NCT00392834|Drug|cyclophosphamide|given IV
45778268|NCT00392834|Drug|cytarabine|given intrathecally
45778269|NCT00392834|Drug|doxorubicin hydrochloride|given IV
45778270|NCT00392834|Drug|etoposide|given IV
45778271|NCT00392834|Drug|ifosfamide|given IV
45778272|NCT00392834|Drug|leucovorin calcium|given IV
45778273|NCT00392834|Drug|liposomal cytarabine|given intrathecally
45778274|NCT00392834|Drug|methotrexate|given intrathecally
45640169|NCT05917223|Dietary Supplement|Cron protein ingestion|It's just an acute intervention, so the participant assigned to the Corn protein ingestion group will consume 20 g of corn protein isolation during infusion protocol.
45448558|NCT05158270|Procedure|Ultrasound Guided Erector spinae plane block|Patient will be placed in lateral decubitus position. By palpation of spinous processes starting from C7 downward, T7 spinous process will be located. Under complete aseptic precautions, linear probe of US machine will be placed in a transverse orientation at this level to identify tip of T7 transverse process (TP). By probe rotation into a longitudinal orientation, a parasagittal view will visualize skin and subcutaneous tissue, trapezius, and erector spinae (ES) muscle layers superficial to TPs. After local anesthetic (LA) infiltration, a 20 gauge spinal needle will be inserted in-plane and directed cranio-caudally until it contacts T7 TP. Target site for injection will be fascial plane deep to ES muscle. 1 mL saline will be injected to confirm correct needle-tip position by visualization of lifting of ES muscle off TP without distending the muscle and spreading cranio-caudally. 20 - 30 mL of 0.25% bupivacaine will be injected. Procedure will be performed bilaterally.
45640170|NCT05917223|Dietary Supplement|Corn+Pea protein ingestion|It's just an acute intervention, so the participant assigned to the Corn+Pea protein ingestion group will consume 20 g of Corn+Pea protein isolation during infusion protocol.
45640171|NCT05917223|Dietary Supplement|Non-protein, low energy|It's just an acute intervention, so the participant assigned to the Non-protein, low energy group will consume 20 g of carbohydrate during infusion protocol.
45640172|NCT05917210|Behavioral|Standard TB-EC|Standard TB-EC by healthcare workers
45640173|NCT05917210|Behavioral|Peer navigation strategy for TB-EC|multi-component, peer-navigation strategy for TB-EC
45640174|NCT05917197|Other|survey based information|Only survey based information collected
45640175|NCT05917184|Other|Telehealth|Two video telehealth visits will be conducted and recorded within 3 days of one another (+/- 1 day)
45640176|NCT05917171|Behavioral|painTRAINER|painTRAINER is an 8 week online behavioral pain coping skills training program derived from cognitive behavioral therapy approaches, which includes 45 minute behavioral coping sessions to be completed over 8 weeks. Weekly sessions are guided by an automated coach that teaches skills for coping with pain.
45640177|NCT05917158|Drug|RC48-ADC and JS001|Patients in group will receive 6 x 2 week cycles of JS001 (Toripalimab) 3mg/kg in combination with RC48-ADC (Disitamab Vedotin) 2mg/kg intravenously.
45640178|NCT05917145|Drug|WSD0628|A non-toxic compound and inhibits the DNA damage response associated with radiation therapy. • WSD-0628 radio sensitizes Glioblastoma cells.
45640179|NCT05917132|Other|Nutritionnal intervention|Participants will be provided with meals corresponding to each diet during the week. Participants will be required to eat only the meals provided.
45640180|NCT05917119|Other|BLT|Bright light therapy delivered via glasses
45640181|NCT05917119|Other|s-BLT|sham delivered with bright light therapy glasses to which a neutral density filter has been applied
45640182|NCT05917080|Other|Manual Therapy|"Manual Therapy: Manual therapy is the use of hands-on techniques to evaluate, treat, and improve the status of Neuro-musculoskeletal conditions.~Augmented Low-Dye Taping: Augmented Low-Dye taping is designed to off-load the plantar fascia & applied below the ankle and is hypothesised to generate a supinating force that controls the amount of pronation at the subtalar joint.~Neuromuscular Exercises: Neuromuscular training could be defined as training enhancing unconscious motor responses by stimulating both afferent signals and central mechanisms responsible for dynamic joint control.~Strengthening Exercises:The strengthening of the muscles promotes better overall functioning of the foot and thereby can help to take some of the tension out of the fascia.~Stretching exercises:Static stretching is defined as passively stretching a given muscle-tendon unit by slowly placing it maximal position of stretch and sustaining it there for an extended period of time."
45640183|NCT05917067|Diagnostic Test|Fluorescence imaging of the parathyroid glands of children|Patients that participate in this study will always receive standard care. For the purpose of this study, the camera settings (i.e. camera distance to the operating field, switching of OR-lights, and angle of the camera on the operating field) and ICG-protocol (i.e. dose, injection speed) will be standardized among the participating centers in order to generate an homogeneous data set for quantification of the fluorescence signal intensity.
45640184|NCT05917054|Other|use of bipolar vascular sealing method on the renal allograft at the back-table stage|Ligation of small vessels and lymphatics of the renal graft at the back-table stage prior to transplantation to the recipient is a routine practice in kidney transplantation. Bipolar vascular sealing method will be used for this purpose in Group 1, while the conventional silk-tie method will be used in Group 2.
45640185|NCT05917041|Device|SAT-001(Software as Medical Device)|Using SAT-001 application for 48 weeks and wearing glasses or not
45640186|NCT05917028|Device|Transcatheter Arterial Micro-Embolization|Participants will undergo TAME with Nexsphere-F.
45778275|NCT00392834|Drug|therapeutic hydrocortisone|given intrathecally
45778276|NCT00392834|Drug|vincristine sulfate|given IV
45778277|NCT05363670|Drug|ARS-1|ARS-1
45778278|NCT05363670|Drug|Albuterol MDI|180 mcg
45778279|NCT05363670|Drug|Placebo|Placebo
45778280|NCT02982980|Procedure|Physiotherapy Guidance|Pre and postoperative assessment and orientation, guidelines for lymphedema prevention and self drainage, follow-up for rehabilitation or maintenance of joint amplitude of shoulder movements and functional return.
45778281|NCT02982980|Procedure|Physiotherapy Muscle strengthening|The exercises performed were active-free, with the aid of a stick or resistance by elastic bands and dumbbells for flexion, extension, adduction, abduction, external and internal rotation of the shoulder, and elbow flexion and extension, besides activities to enable movements Functional. The mode of execution of the exercises was isotonic, done slowly and within the joint amplitude reached by the patient, using resistance according to the muscular capacity of each patient.
45915892|NCT03746587|Drug|Placebo oral capsule|Matching placebo capsule
45915893|NCT03651076|Device|Traxi panniculus retraction (Clinical Innovations, LLC)|class I, FDA-exempt, commercially available for use in panniculus retraction during cesarean delivery or other laparotomy
45915894|NCT03624517|Drug|Octreotide|Octreotide infusion for 24-hours in patients with bleeding esophageal varices.
45915895|NCT03609385|Diagnostic Test|Coronary angiography|In patients eligible for participation in the study coronary angiography, echocardiography and EKG will be performed systematically.
45640187|NCT05917015|Dietary Supplement|Treatment|Participants will receive daily 2 tablets of Proglucamune for a duration of 6 weeks. Each tablet contains ~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
45640188|NCT05917015|Other|Placebo|Participants will receive daily 2 placebo tablets containing microcrystalline cellulose. The size, shape and appearance of the placebo tablet is identical to the treatment tablet.
45640189|NCT05917002|Device|Real TBS to mPFC|This will be delivered with the Magventure MagPro System; (double blinded using the integrated active sham system).
45640190|NCT05917002|Device|Sham TBS to mPFC|This will be delivered with the Magventure MagPro System; (double blinded using the integrated active sham system). The Magventure MagPro system has an integrated active sham that passes current through two surface electrodes placed on the scalp. The electrodes are placed on the left frontalis muscle under the coil for both the real and sham stimulation sessions.
45640191|NCT05916976|Diagnostic Test|cardiac MRI|Multiparametric MRI of the heart
45640192|NCT05916963|Drug|Furosemide 40 mg|Injection of 40 mg of Furosemide during 10 minutes after the end of the flexible ureteroscopy for destruction of kidney stones with laser.
45915896|NCT03558958|Drug|P-188 NF|Poloxamer administered daily via sc injection at 5 mg/Kg
45448559|NCT05158270|Procedure|Ultrasound Guided Anterior Quadratus Lumborum Block|"Patient will be placed in lateral decubitus position. Under complete aseptic precautions, curved US probe will be placed in midaxillary line immediately above the iliac crest to identify anterior abdominal wall muscles. Probe will be then moved dorsally until visualization of transversus abdominis muscle becoming aponeurotic, then visualization of shamrock sign with psoas major muscle anteriorly, erector spinae muscle posteriorly and quadratus lumborum (QL) muscle adherent to the apex of L4 transverse process. After LA infiltration, a 20 gauge spinal needle will be inserted in-plane from posterior to anterior, and needle tip will be advanced through QL muscle, penetrating the ventral proper fascia of QL muscle. Target site for injection will be fascial plane between QL and psoas major muscles. 1 mL saline will be injected to confirm correct needle-tip position, followed by injection of 20 - 30 mL of 0.25% bupivacaine. Procedure will be performed bilaterally."
45915897|NCT03542773|Drug|18F-DCFPyL Injection|18F-DCFPyL with whole body PET/CT scan
45640194|NCT05916937|Drug|omalizumab 300 mg every four weeks|"Continue standard treatment with omalizumab 300 mg every four weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."
45640195|NCT05916937|Drug|omalizumab 300 mg every six weeks|"Treatment in an extended interval of omalizumab 300 mg every six weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."
45640196|NCT05916924|Other|Collection of clinical data including manual muscle test (MMT), range of motion (ROM), Fugl-Meyer assessment (FMA), berg balance scale (BBS) and kinetic data via video shooting|Collection of clinical data including manual muscle test (MMT), range of motion (ROM), Fugl-Meyer assessment (FMA), berg balance scale (BBS) and kinetic data via video shooting
45915898|NCT03427918|Behavioral|Mindfulness-Based Sex Therapy|Mindfulness-Based Sex Therapy in an integration of psychoeducation, sex therapy, and mindfulness-based skills.
45915899|NCT00423397|Biological|PEG-interferon alfa-2a|
45640199|NCT05916898|Device|PCI with support of Shockwave Intravascular Lithotripsy|Coronary artery angioplasty of the primary lesion or optimization of the previously implanted stent with the support of Shockwave Intravascular Lithotripsy device
45640200|NCT02342977|Drug|Placebo|Patients will randomly receive placebo
45640201|NCT02342977|Drug|Lacosamide|Patients will randomly receive lacosamide
45640202|NCT05916885|Other|short-intensity modified CIMT and conventional therapy|an experimental group receiving short-intensity modified CIMT and conventional therapy
45640203|NCT05916885|Other|conventional therapy alone|a control group receiving conventional therapy alone.
45640204|NCT05916872|Other|experimental group|Patients will receive Proprioceptive Neuromuscular Facilitation (contract-relax) technique with EMS
45640205|NCT05916872|Other|control group|Patients will receive conventional therapy.
45640206|NCT05916859|Other|Group 2 PDT (10 s)|- Conventional endodontic treatment associated with PDT (10 s)
45640207|NCT05916859|Other|Group 3 PDT 20 s|Conventional endodontic treatment associated with PDAT (20 s)
45640208|NCT05916859|Other|Group 1. Placebo|Conventional endodontic treatment
45640209|NCT05916846|Procedure|EUS-guided radiofrequency ablation of pancreatic cyst|EUS-RFA is performed with an 19 Gauge RFA needle (STARMed/TaeWoong Medical USA) applying up to 30 Watt (W) current with Continuance Mode setting. RFA confirmation is confirmed endoscopically via EUS (white bubbles on EUS imaging) and impedance monitoring on the VIVA™ Combo System. Impedance has a maximum value up 800 Ohms. Sequential doses of electrical energy at 10W-30W are applied to ablate the PCN.
45915900|NCT00423397|Drug|gefitinib|
45915901|NCT03407794|Other|Fermented vegetable|The intervention is to consume 1/2 cup fermented vegetables every day for 6 weeks
45915902|NCT03407794|Other|Non-fermented vegetable|The intervention is to consume 1/2 cup of non-fermented vegetables every day for 6 weeks
45915903|NCT03352765|Drug|rituximab|rituximab 375 mg/m2 on days -11 and -4, The second dose of rituximab (day -4) is administered 7 days after the first dose (day -11), +/- 1 day. Rituximab may be administered by a local oncologist. If the participant has a CD20 negative tumor, rituximab can be omitted from the conditioning regimen.
45915904|NCT03352765|Drug|bendamustine|bendamustine 160 mg/m2 intravenously on days -3 and -2
45915905|NCT03352765|Drug|melphalan|melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0.
45915906|NCT03352765|Procedure|Autologous Stem Cell Transplantation (ASCT)|reinfusion of autologous stem cells on day 0.
45915907|NCT03292198|Other|20-30 mmHg compression sleeve and gauntlet|"Compression garments are Juzo Soft, circular knit. Most will be off-the-shelf sizing, but custom when necessary.~Garment fittings will be performed by Certified Lymphedema Therapists."
45935686|NCT00078234|Drug|Oblimersen-rituximab-fludarabine|28-day cycles; Cycle 1: oblimersen by continuous IV infusion 1.5 mg/kg/d for 7 consecutive days, completing on Day 8; rituximab by IV infusion on Day 4 (125 mg/m2) and Day 6 (250 mg/m2); fludarabine 25 mg/m2 by IV infusion for 3 days, starting on Day 6. Subsequent cycles: oblimersen 3 mg/kg/d, completing on Day 8; rituximab 375 mg/m2 on Day 5; fludarabine 25 mg/m2 for 3 days starting the same day as rituximab
45935687|NCT00044369|Procedure|Varicocele repair|
45778282|NCT05362890|Device|DEVICE OPERATING UNDER THE CONTINOUS POSITIVE AIRWAY PRESSURE|The principle of operation is to prevent the closure and the narrowing of the structures of the upper respiratory tract by applying positive pressure. The device consists of a mask that protects the nose and/or mouth, a tube that connects the mask to the monitor and a monitor that blows air into the tube. A pressure in the range of 4 to 20 cm water is applied, depending on the individual needs of the patient to keep the airway open. The use is considered to be effective when the patient uses it continuously for at least 4 hours at bedtime. Today's modern devices have memory cards for storing data on the regularity and time of use of the device during the night and the efficiency of the device itself. For therapy to be considered effective, the number of apneas and hypopneas must be less than 5 per hour of sleep.
45778283|NCT00393380|Drug|Parathyroid Hormone (teriparatide)|Day +1: PTH 40 mcg, Day +2: PTH 60 mcg, Day +3: PTH 80 mcg, Day +4 to Day +29 or until ANC>2000/microL: PTH 100 mcg
45778284|NCT05362422|Device|long-term paired associative stimulation|Paired associative stimulation (PAS) administered 3-5 times per week for 4 weeks to upper limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
45778285|NCT05362422|Device|sham long-term paired associative stimulation|Sham transcranial magnetic stimulation and sham peripheral nerve stimulation.
45778286|NCT05361642|Drug|Bupivacaine HCl 0.5% Injectable Solution|using nasal block including sphenopalatine ganglion block with general anesthesia to optimize surgical field
45778287|NCT05361642|Drug|Dexmedetomidine|using dexmedetomidine with induction of general anesthesia to optimize surgical field
45778288|NCT05359770|Device|Active HD-tDCS|Experimental group: 10-sessions of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session). It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
45778289|NCT05359770|Device|Control group|Sham Control: 10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity. The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
45640210|NCT05916846|Device|FDA-cleared device (EUS-RFA probe)|FDA-cleared device (EUS-RFA probe).
45640211|NCT05916833|Other|hypopressive breathing|Hot pack for 10min.Hypopressive breathing in sitting, lying and standing position. Hypopressive breathing 2 times/weekly, 5sec hold, 2-3reps, 1-2sets for 12 weeks. Session will be weekly progress.
45640212|NCT05916833|Other|noble technique|Hot pack for 10min. Noble technique in relaxed supine position 2time/weekly, 3-5sec hold, 10-15reps, 2-3sets for 12 weeks. Session will be weekly progress.
45640213|NCT05916820|Other|Tanzberger Exercises|It consists of patients who will receive Tanzberger exercise 3 sessions per week for 4 weeks. e.g. Rolling on the ball forward, Back to back sitting.
45778290|NCT04422834|Other|Questionnaire|A group of students who studying at the Faculty of Health Sciences will be asked to fill the Turkish version of JSE-HPS and ETS. JSE-HPS will be asked to re-fill after seven days for retest analysis.
45640214|NCT05916820|Other|Pelvic floor muscle training|It consists of patients who will pelvic floor muscles exercise 3 sessions per week for 4 weeks. e.g. Assisted heel drop, Bridge, Dead Bug, Bird DOG
45640215|NCT05916807|Other|Stabilization Exercises|It consists of 26 patients who will receive stabilization exercises which will be divided in three components in lying posture, sitting, standing, rolling and kneeling positions to treat posterior, inferior muscles of scapula for 35-45 min for 3 days a week for 4 weeks.
45778291|NCT05356884|Behavioral|Diabetes Intervention|A 12-session group-based intervention that will target diabetes knowledge and leadership and communication skills through facilitated discussion and experiential learning.
46070361|NCT00815269|Drug|Sevoflurane|Induction: 3-8% sevoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
45640216|NCT05916807|Other|Posture Training|It consists of 26 patients who will receive postural training and breast-feeding patterns for the mother and child for 35-45 min in 3 days a week for 4 weeks.
45640217|NCT05916794|Other|Modified Cervical Retraction Exercises (MCRE)|Group A includes Modified cervical retraction exercise The patient is in sitting OR standing position and faces the physical therapist. The MCRE program consisted of alternating head position( neutral, side bending and rotation) while pushing their chin backward patients maintained an upright posture and tried to pull back their shoulders while maintaining this retracted position patient side bend OR rotate their head respectively hold the position for 20 sec.subject performed 5 sets of 10 repetition for 3-4 days per week. Rest intervals of 30 seconds were provided after the completion of 10 repetitions for each pattern and between sets, respectively. The total duration of MCRE will be of approximately 15-20 minutes
45640218|NCT05916794|Other|Motor Control therapeutic exercise(MCTE)|Motor control therapeutic exercises will be guided for the retraining of cervical muscles.it include craniocervical flexor exercise,craniocervical extensor exercise, co-contraction of flexors and extensor, a synergy exercise for retraining the strength of the deep neck flexors. Each of these four exercises will be performed for 3 sets of 8 to 10 repetitions, taking an approximate total duration of 15-20 minutes for, 3 days a week
45448560|NCT05158270|Other|Intravenous Multimodal Analgesia|Postoperative pain in the post-anesthesia care unit (PACU) and on the ward will be treated with a combination of IV multimodal analgesia in the form of Acetaminophen (15 mg/kg 4/day) and Ketorolac (0.5 mg/kg 3/day) using a fixed scheme. In addition, Morphine, as 3 mg IV bolus at each dose, will be given when VAS equals or above 3. VAS will be assessed 5 - 10 min. after each opioid dose to assess the need for additional opioid doses.
45640219|NCT05916781|Drug|Mycophenolate Mofetil|During the first 18 months, participants will take MMF+TAC. After 18 months, participants without lupus flare will randomly stop MMF or TAC.
45640220|NCT05916781|Drug|Tacrolimus|During the first 18 months, participants will take MMF+TAC. After 18 months, participants without lupus flare will randomly stop MMF or TAC.
45640221|NCT05916781|Drug|Glucocorticoid|Participants in steroid tapering group will stop taking glucocorticoid after the first 6 months. Participants in steroid maintenance group will consistently take glucocorticoid.
46070362|NCT00815269|Drug|Desflurane|Induction: 2-8% desflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
45640222|NCT05916768|Other|Pelargonium sidoides extract EPs® 7630|Kaloba® solution, a standardized alcoholic extract obtained from the roots of Pelargonium sidoides (EPs® 7630).
45448561|NCT05156008|Other|Ultrasound-guided vascular access|Patients in this arm will have peripheral venous cannula inserted under realtime ultrasound guidance. Out of plane technique (in plane technique if too deep when tip of the needle is on vessel wall) used by experienced physicians in UGVA. Out of plane technique strictly used in step by step manner. That means moving probe with the tip of the needle to always locate its exact position, all the way into the vein. All performed insertions are carried out by skilled operators in UGVA with out of plane technique. Just before surgery in block room.
45448562|NCT05152732|Genetic|VGB-R04|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant
45448563|NCT03631407|Drug|Vicriviroc|Vicriviroc tablets administered orally, QD at dose level 1 or 2.
45448564|NCT03631407|Biological|Pembrolizumab|Pembrolizumab administered by IV infusion at 200 mg every 3 weeks (Q3W), given on cycle day 1.
45640223|NCT05916768|Other|usual care|symptomatic treatments
45640224|NCT05916755|Diagnostic Test|Whole Genome Sequencing|Whole genome sequencing (WGS) will be performed in tumor tissue from baseline and from residual disease after neoadjuvant chemotherapy (NACT), if present.
45640225|NCT05916755|Diagnostic Test|RNA-Sequencing|RNA-Sequencing will be performed in tumor tissue from baseline and from residual disease after NACT (if present).
45640226|NCT05916755|Diagnostic Test|Microbiome analysis|Microbiome analysis will be performed in stools and saliva before, during NACT and at the end of adjuvant systemic therapy if adjuvant systemic therapy is clinically indicated.
45640227|NCT05916755|Diagnostic Test|ctDNA analysis|ctDNA analysis will be performed in plasma before and during NACT.
45640228|NCT05916755|Diagnostic Test|TCR-β repertoire sequencing|TCR-β repertoire sequencing will be performed in plasma before and during NACT.
45640229|NCT05916755|Diagnostic Test|PBMCs phenotyping|PBMCs phenotyping will be performed in plasma before and during NACT.
45640230|NCT05916755|Drug|Pembrolizumab|Pembrolizumab will be given in combination with standard NACT.
45448565|NCT03547102|Dietary Supplement|Cherry concentrate|
45448566|NCT03547102|Dietary Supplement|Placebo concentrate|
45640231|NCT05916755|Drug|Chemotherapy|Standard NACT will be given.
45640232|NCT05916742|Procedure|CAF|Periodontal surgical technique to treat gingival recessions
45640233|NCT05916742|Procedure|i-PRF|Blood-derived biomaterial. Two sterile plastic tubes (Process for PRF, Nice, France) with a volume of 10 ml will be used to generate fluid blood concentrate. After blood collection, the tubes will be centrifuged using a Duo centrifuge (Process for PRF, Nice, France) (fixed angle rotor with a radius of 110 mm) following the protocol proposed by Choukroun et al. (2018) (600 rpm; 8 min).
45640234|NCT05916742|Device|VCMX|Porcine derived collagen matrix.
45640235|NCT05916742|Drug|Sodium dipyrone|All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.
45640236|NCT05916742|Drug|Chlorhexidine rinse|All participants will be instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
45640237|NCT05916742|Drug|Amoxicillin 500mg|Participants enrolled in the CAF+VCMX and CAF+VCMX will be instructed to take amoxicillin 500mg (8 hours/8 hours, during 7 days) after the surgical procedures.
45640238|NCT05916729|Drug|Miconazole|Protocol for active control groups includes use of Miconazole Oral gel for 14 days with frequency of four time per day.
45640239|NCT05916729|Dietary Supplement|CandBerrol® lozenges|Protocol for experimental groups includes use of Miconazole Oral gel and CandBerrol® lozenges for 14 days with frequency of four time per day
45640240|NCT05916716|Procedure|Restorative procedure|Under local anesthesia, a rubber dam isolation will be placed at the site and a coronal bevel will be performed at the incisal margin of the NCCL allowing a correct tooth emergence profile. In sequence, acid etching with 35% phosphoric acid will be applied to the area and washed for 30 seconds with a water-air jet. The lesion will be dried with sterile cotton pellets to prevent dehydration. Active application of the adhesive will be performed for 20 seconds, followed by light curing for 30 seconds. The apical margin of the restoration will be placed 1 mm beyond the estimated position of the cementoenamel junction(CEJ) in order to rebuild only the anatomical part of the crown destroyed by the NCCL and 1 mm of the root surface to give the appropriate emergence profile. After rubber dam removal, the restoration will be finished with ultrafine-grained burs, and 48 hours after the restoration procedure, polishing will be completed with diamond paste and felt discs.
45640241|NCT05916716|Procedure|Coronally Advanced Flap (CAF).|Two horizontal incisions will be performed at the papilla base united by an intrasulcular incision around the tooth. In sequence, releasing incisions will be designed and a split-full-split flap will be raised beyond the mucogingival junction. Then, sling sutures will be placed to stabilize the flap margin 2 mm coronal to CEJ, followed by interrupted sutures to close the releasing incisions.
45640242|NCT05916716|Device|Volume-stable collagen matrix (VCMX)|VCMX will be cut according to the recession defect and moistened with saline solution. The biomaterial will be placed at the cementoenamel junction (CEJ) level and stabilized in the adjacent surgical papillae by interrupted sutures.
45640243|NCT05916716|Drug|Amoxicillin 500mg|Participants enrolled in the PR +CAF+VCMX will be instructed to take amoxicillin 500mg (8 hours/8 hours, during 7 days) after the surgical procedures.
45640244|NCT05916716|Drug|Sodium dipyrone|All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.
45778292|NCT05356884|Behavioral|Leadership & Life Skills|A 12-session group based intervention that will teach leadership and life skills (planning strategies, leadership values, emotional awareness, effective reasoning skills)
45778293|NCT00395876|Drug|placebo|2 mL of placebo instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of placebo). Patients weighing < 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
45778294|NCT00395876|Drug|tenecteplase|2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of tenecteplase). Patients weighing < 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
45778295|NCT05324982|Drug|Oral Placebo|Placebo will be orally self-administered by study participants.
45778296|NCT05324982|Drug|Oral CBG Cannabis|CBG cannabis oil will be orally self-administered by study participants.
45778297|NCT05324514|Procedure|Split-thickness skin grafting|Harvesting for split-thickness skin grafting will be performed at the specified donor site using a pneumatically powered dermatome with a setting of 10 /1000th inch and meshed 2:1.
45778298|NCT05324514|Device|High density microscopic skin tissue column grafting|MSTC harvest will be conducted using the ART system (Medline Industries) in accordance with the manufacturer's instructions and distributed at high density (300-360 columns/50cm2).
45778299|NCT05324514|Device|Low density microscopic skin tissue column grafting|MSTC harvest will be conducted using the ART system (Medline Industries) in accordance with the manufacturer's instructions and distributed at low density (150-180 columns/50cm2).
45778300|NCT05323578|Other|Survey|Prevalence of safe caffeine consumption among anesthetists
45778301|NCT02662634|Biological|AGS-003-LNG|autologous dendritic cell immunotherapy
45778302|NCT02662634|Drug|Carboplatin|"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
45778303|NCT02662634|Drug|Abraxane|Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.
45778304|NCT02662634|Drug|Alimta|By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell
45778305|NCT02662634|Drug|Cisplatin|Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis
45778306|NCT02662634|Drug|Taxol|Mechanism of action involves interference with the normal breakdown of microtubules during cell division.
45778307|NCT02662634|Radiation|Radiation Therapy|Causes DNA strand breaks.
45778308|NCT02524158|Behavioral|Yoga Therapy for CLBP|Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
45778309|NCT05323500|Other|Senobi breathing exercises|The study participants will be screened first, then trained to perform SBE (1-minute maneuver). Participants will be instructed to stand upright and tighten their gluteal muscle and then ask them to put one foot in front of their body and placing most of their body weight on back foot. Then, ask them to breath in for three seconds simultaneously, by raising their hands in the air above their heads. After this, instruct them to exhale by using their whole body for pushing air out of the lungs. Participants will also guided to tighten all their body muscles while pushing air out. Exhale should last for seven seconds.
45778310|NCT00396032|Drug|placebo|For the initial treatment, 2 mL of placebo instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
45778311|NCT00396032|Drug|tenecteplase|For the initial treatment, 2 mL of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
45778312|NCT02277782|Drug|Hydromorphone|
45448567|NCT03547024|Drug|JNJ-55308942 High Dose|Participants will receive high dose of JNJ-55308942 orally once daily.
45778313|NCT02277782|Drug|Hyperbaric bupivacaine|
46070363|NCT00815269|Drug|Enflurane|Induction: 2-5% enflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
45448568|NCT03547024|Drug|JNJ-55308942 Low Dose|Participants will receive low dose of JNJ-55308942 orally once daily.
45448569|NCT03547024|Drug|Levonorgestrel/Ethinyl Estradiol Fixed Dose combination (FDC)|Participants will receive 0.150 milligram (mg) levonorgestrel and 0.030 mg ethinyl estradiol FDC tablet orally.
45448570|NCT03547024|Drug|Drug Cocktail:Midazolam (2mg)/Omeprazole (20mg)/Dextromethorphan (30mg)|Participants will receive single dose of drug cocktail consisting of midazolam (2 mg), dextromethorphan (30mg) and omeprazole (20 mg) orally.
45448571|NCT03639909|Procedure|sweating function|Sweating dysfunction by Sudoscan
45448572|NCT03639909|Procedure|Cardiovascular function|Cardiovascular (CV) tests
45448573|NCT05115994|Device|Continous positive airway pressure|
45448574|NCT03734757|Procedure|imaging in trimodality|PET-CT and MRI
45448575|NCT03739125|Drug|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
45640245|NCT05916703|Diagnostic Test|SOLUS examination|"The examination of each subject will include: i) B-mode US, ii), color Doppler US, iii) shear wave elastography, and iv) SOLUS multimodal imaging.~For each subject various ultrasound images (modalities i-iii) will be taken and these images will determine the location for the SOLUS measurements (iv).~All measurements (i-iv) will be taken at the lesion location, in the normal breast tissue around the lesion, and in the mirror location of the contralateral breast.~Optically derived data (blood volume, blood oxygen saturation, water, lipid and collagen concentrations, tissue scattering parameters) will be obtained. Every subject included in the study will be evaluated separately by 3 radiologists, with different level of experience in breast imaging."
45640246|NCT05916690|Drug|Electrochemotherapy with bleomycin or cisplatin|Combination of drug delivery platform (electroporation) and drug (bleomycin)
45778314|NCT02277782|Drug|Fentanyl|
45448576|NCT03739125|Drug|Placebo|orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
45448577|NCT04019704|Drug|AXS-05|Oral AXS-05 tablets, taken daily for 6 weeks.
45448578|NCT04019704|Drug|Placebo|Placebo to match oral AXS-05 tablets, taken daily for 6 weeks.
45448579|NCT01310049|Drug|LEO 32731|"Part 1 and 2: Oral single dose of oral solution or capsule~Part 3: Twice daily dose of oral solution or capsule for 7 days"
45640247|NCT05916677|Other|Virtual Reality-training in Theory of Mind|"Two social scenarios will be used in a virtual environement. Experimenter and subject participate in the scenario as friends of the main character, Nicolas. During the training session, experimenter asks structured questions about participant's awareness of a mental state. In the case of a wrong answer, a feedback-correction is provided via the avatar's thought bubbles. The participant has access to all avatars thought bubbles. In this way, he is able to compare the desires, beliefs or false beliefs of each story character.~Participants included in this condition will also have an eye-tracking assessment before and after the training procedure."
45640248|NCT05916677|Other|Traditional training in Theory of Mind|The same two social scenarios are presented to the participant in a story-telling form. Participant has access to thought bubbles via an illustrated book. These trainings will take place in the same number of sessions and took place for a duration equivalent to those used in low immersion Virtual Reality mode. Each training session (EFB, BE, SOFB, ERA, FP, EFP) will be illustrated via visual aids taken from screenshots of the two virtual environments and the target protagonists.
45640249|NCT05916664|Behavioral|Kinto Care Coaching|Describe the basics of the intervention
45448580|NCT03739047|Behavioral|Desensitization with flipped spoon|Both groups will begin with a baseline phase: escape extinction (non-removal of an upright small maroon spoon) plus continuous access to reinforcement. The baseline phase will take place for 3, 5-bite sessions or until the data become stable. The baseline phase will be followed by desensitization. Desensitization will be conducted for 3, 45-minute treatment meals. Puree will be presented on a flipped EZ spoon after the desensitization sessions are completed. Bite size will be gradually increased. Acceptance of an upright EZ spoon and eventually an upright maroon spoon will be probed based on stability of the data.
45640250|NCT05916651|Behavioral|Learning to Offset Stress (LOS) (in Dutch: Leren Omgaan met Stress) training|The investigational treatment is the LOS training, which is an adaptation of two previously validated mindfulness-based programs: Mindfulness-Based Cognitive Therapy (MBCT) developed by Segal, Williams, and Teasdale (2002) and the Mindful2Work (M2W) program developed by de Bruin, Formsma, and Bögels (2018). The M2W program combines mindful physical activity, yoga, and mindfulness meditation to target stress symptoms and burn-out in adults. The LOS training was adapted from these programs to meet the needs of youth with internalizing problems. The training consists of 8 weekly 2-hour sessions that each comprise three elements: mindful physical activity (15-20 minutes), yoga (15-20 minutes), and mindfulness meditation exercises (80-90 minutes). In addition to attending group sessions, participants are invited to practice at home on a daily basis. Home practice consists of daily mindfulness practices comprising mindfulness exercises, yoga and mindful physical activity.
45640251|NCT05916651|Behavioral|Care as usual|"Youth who seek help for internalizing problems from a primary mental health practitioner, including student psychologists or mental health nurse practioners, but do not (yet) meet criteria for (major) mental illness are typically offered supportive counselling, aimed primarily at helping people feel understood and supported. Supportive counselling may also include instructions on behavioral activation, particularly when individuals report reduced activity and behavioral avoidance including social withdrawal. In addition, mental health practitioners commonly employ a watchful waiting policy for people with symptoms in the milder range, where they check-in with clients on a regular basis and refer for more intensive treatment if and when symptoms worsen."
45640252|NCT05916638|Other|blood sample|blood sample collection
45640253|NCT05916625|Other|neuropsychological assessment|a consultation to assess cognitive and psycho-behavioral functions with questionnaires
45640254|NCT05916625|Other|biological sample|10 mL intravenous whole blood collection in EDTA tube
45640255|NCT05916625|Procedure|medical imagery|Pet scan with the specific radioligand [11C]SB207145 and MRI
45640256|NCT05916599|Device|ultrasound|a device which is used in intensive care units,
45640257|NCT05916586|Drug|Prednisone|Prednisone 40 mg orally once a day for 7 days
45640258|NCT05916573|Drug|HSK16149|single oral adminiatration, 20mg
45640259|NCT05916560|Drug|LY3437943|Administered SC.
45915908|NCT03292198|Other|Manual Lymphatic Drainage|"Manual Lymphatic Drainage (MLD) is a gentle skin-stretch massage that stimulates the lymphatic system and assists in creating collateral drainage pathways out of non-intact (damaged) lymphatic territories. MLD is a critical part of Complete Decongestive Therapy (CDT), which is accepted as the international standard of care in the treatment of lymphedema.~The MLD sessions will be performed by 2 Certified Lymphedema Therapists, Megan Klote and Sarah Stolker, both trained through the Norton School of Lymphatic Therapy. The therapists have completed reliability meetings regarding MLD sequencing and techniques."
45640261|NCT05916521|Drug|0.454% stannous fluoride|Brush two times daily
45640262|NCT05916521|Drug|0.76% sodium monofluorophosphate|Brush two times daily
45640263|NCT05916521|Drug|0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM|Brush two times daily
45640264|NCT05916508|Drug|0.454% stannous fluoride|Brush two times daily
45640265|NCT05916508|Drug|0.76% sodium monofluorophosphate|Brush two times daily
45640266|NCT05916508|Drug|0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM|Brush two times daily
45640267|NCT05916495|Other|Hybrid care arm|Patients will be evaluated at 3 months via a remote review. This will review the patients-recorded spirometry and a questionnaire developed for this study which asses the patients' symptom burden and medication adherence. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry).
45640268|NCT05916495|Other|Standard of care arm|Patients will be reviewed in clinic at 3 months per the standard of care. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry).
45640269|NCT05916469|Drug|Levonorgestrel Intrauterine System|52 mg levonorgestrel intrauterine system
45640270|NCT05916469|Drug|Norethindrone Acetate|norethindrone acetate 5 mg daily
45778315|NCT05287100|Drug|Midodrine Oral Tablet|Midodrine starting at 0.25mg/kg/day in 2-3 divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by >10% ; Midodrine dosage will be decreased by 25% in case of arterial hypertension (>95th centile BP for the age). Also Standard medical therapy as per departmental protocol will be continued
45640271|NCT05916456|Diagnostic Test|The Hand10 Questionnaire|The Hand10 Questionnaire is a questionnaire consisting of 10 short questions used in the evaluation of upper extremity diseases. These questions are easy to understand and illustrated questions. Unlike other questionnaires, thanks to these features, it can be used in adults as well as in the elderly and children. Tore et al. In their study, the internal consistency of Hand10 was evaluated with Cronbach's alpha value according to statistical results and found it to be 0.919. According to these results, it has been determined that Hand10 is a reliable and valid assessment tool for patients with upper extremity disorders in the Turkish population.
45640272|NCT05916456|Diagnostic Test|DASH Questionnaire|DASH Questionnaire is one of the widely used questionnaires consisting of 30 items. There are five options for each answer. While getting answers ranging from 1 to 5; 1 means no symptoms and 5 means very severe symptoms. The total DASH score ranges from 0 to 100; 0 means no injury and 100 means serious injury. Contrary to the Hand10 questionnaire, DASH was not suitable for assessing upper extremity disorders in patients over 65 years of age.
45640273|NCT05916456|Diagnostic Test|Boston carpal tunnel syndrome questionnaire|Boston carpal tunnel syndrome questionnaire (BKTSA) will be used to evaluate the functionality level and symptom severity of the patients. In this questionnaire, which consists of 2 parts: symptom severity and functional capacity, the average score for each part will be calculated by dividing the total score obtained by the number of questions. An increased score indicates decreased functional capacity and increased symptom severity.
45640274|NCT05916430|Diagnostic Test|EarliPoint Investigational Device|Infants will complete eye-tracking data collection at the age of 9 months on the EarliPoint Investigational Device. Eye-tracking video cameras will safely measure the movements of the child's eyes while they watch age-appropriate video scenes of other children playing together. Parents/Caregivers will complete screening forms and questionnaires about their baby's health and development. Parents/caregivers will complete surveys about their child's development. The surveys will be emailed, to be completed when the child is approximately 9, 12, 15, 18, 21, and 24 months old. If the child shows signs of developmental delay, the child will be asked to participate in a comprehensive developmental and diagnostic assessment.
45640275|NCT05916404|Other|Upper extremity high-intensity interval aerobic exercise training|"High-intensity interval aerobic exercise training will be given to the training group on an arm ergometer 3 days in a week and 30-45 minutes a day for 6 weeks with the assistance of a physiotherapist. The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate. The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate.~In case of desaturation (<90%) during the training in the patients in the training group, O2 support with a nasal cannula will be given to the patient."
45640276|NCT05916404|Other|Control Group|The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
45640277|NCT05916391|Genetic|FT-003|Administration via intraocular injection
45640278|NCT05916365|Biological|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously
45640279|NCT05916352|Dietary Supplement|Caffeine Supplement|Caffeine tablet
45640280|NCT05916339|Drug|Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication|"Amphetamine (AMP) medication names: Adderall, Adderall XR, Adzenys ER, Adzenys XR-ODT, Dayanavel XR, Dexedrine (spansule), Dexedrine (tablet), Mydayis, Procentra liquid~Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid), Ritalin, Ritalin LA, Quillichew ER, Quillivant XR (liquid)"
45640281|NCT05916339|Drug|Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.|"If first line stimulant therapy (Amphetamine/Methylphenidate) is deemed not effective or tolerable, re-randomization to the alternate stimulant or alpha-2 agonist will occur. If participant is satisfied with first line stimulant treatment, first-line stimulant therapy will continue.~Catapres, Clonidine, Guanfacine, Intuniv, Kapvay, Tenex"
45640282|NCT05916326|Biological|Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)|Intramuscular injection of Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha) in the deltoid muscle of the upper arm
45640283|NCT05916326|Biological|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
45640284|NCT05916313|Drug|BI 764532|BI 764532
45640285|NCT05916300|Other|Diagnostic ultrasonography-guided physiotherapy group|"All participants will complete free 10 outpatient 30-minute sessions. The therapy will be focused on increasing the range of motion and muscle strength, optimizing the function of the lower limbs, reducing possible complications of post-traumatic conditions in the ankle area.~The physiotherapy procedures of the intervention group will be modified based on the control diagnostic ultrasonography performed at the fifth therapeutic intervention."
45640286|NCT05916287|Biological|Blood and urine samples|Blood and urine samples
45640287|NCT05916287|Genetic|Blood samples|Blood samples
45640288|NCT05916287|Other|Cardiovascular assessment|Echocardiography, Lung ultrasound, pulse wave velocity, carotid stiffness and thickness, Central and peripheral blood pressure, carotid pulse pressure, abdominal aorta ultrasound, jugular vein ultrasound, liver elastography (Optional).
45640289|NCT05916287|Behavioral|Dietary intake|Food frequency questionnaires, ''Dutch eating behaviour questionnaire'' and dietary supplement questionnaire
45640290|NCT05916287|Other|Anthropometric parameters|Measurement of height, weight, abdominal circumference, hip circumference, arm circumference
45640291|NCT05916287|Other|Hemodynamic parameters|Systolic pressure index measurement
45640292|NCT05916287|Other|Hemodynamic parameters|Heart rate measurements, blood pressure measurements, orthostatic BP measurements
45640293|NCT05916287|Other|Hemodynamic parameters|"Blood pressure measurements by unattended BP monitor over 5 min"
45640294|NCT05916287|Other|Hemodynamic parameters|Electrocardiogram
45640295|NCT05916287|Behavioral|Assessment of compliance with antihypertensive treatments for treated participants|EVALOBS scale and compliance questionnaire
45640296|NCT05916287|Other|Ambulatory 24 hours measurment of blood pressure|For the first 100 patients willing to participate
45640297|NCT05916287|Biological|24 hours urinary collection|For the first 100 patients willing to participate. For biobank constitution and measurement of microalbuminuria, creatininuria, osmolarity, natriuresis, kaliuresis, urea, proteinuria and urine dipstick
45448581|NCT03739047|Behavioral|flipped spoon|Both groups will begin with a baseline phase: escape extinction (non-removal of an upright small maroon spoon) plus continuous access to reinforcement. The baseline phase will take place for 3, 5-bite sessions or until the data become stable. The baseline phase will be followed by puree being presented from a flipped EZ spoon. Bite size will be gradually increased. Acceptance of an upright EZ spoon and eventually an upright maroon spoon will be probed based on stability of the data.
45640298|NCT05916287|Other|General questionnaires|Collection of socio-demographic data such as age, level of education, profession, household income, smoking status, physical activity, perception of health, prematurity, height and weight at birth, family and personal history especially cardiovascular (history of stroke, myocardial infarction, heart failure, current pathologies, drugs, tobacco...)
45640299|NCT05916287|Other|Women specific questionnaire|Women specific questionnaire
45640300|NCT05916287|Behavioral|Women specific questionnaire|Women specific questionnaire
45640301|NCT05916287|Diagnostic Test|NYHA dyspnea questionnaire|Determination of NYHA class.
45640302|NCT05916287|Behavioral|Anxiety questionnaire|Assessment of anxiety
45640303|NCT05916287|Behavioral|Epworth Sleepiness Scale|sleep quality assessment
45640304|NCT05916287|Other|"A questionnaire on the perception of the management of cardiovascular risk factors"|Patient's evaluation of cardiovascular risk factors by the health system
45640305|NCT05916287|Behavioral|A questionnaire on eating behaviors|Assessment of eating behaviors
45640306|NCT05916287|Behavioral|A questionnaire on eating habits to determine consumer profiles|Assessement of eating habit to create a consumer profile
45640307|NCT05916287|Dietary Supplement|A questionnaire on food supplements use|Evaluation od food supplements intake
45640308|NCT05916287|Other|SARS-CoV-2 Infection Questionnaire|SARS-CoV-2 Infection Questionnaire
45640309|NCT05916287|Other|Instantaneous expired air analysis|Carbon monoxyde analysis in expired air
45640310|NCT05916287|Biological|Capillary sampling|Capillary sampling for pollutant analysis (Optional)
45640311|NCT05916274|Biological|Blood and fecal samples|Blood and fecal samples will be performed
45640312|NCT05916274|Procedure|Coolonic biopsies|colonic biopsies will be analysed
45640313|NCT05916261|Biological|Personalized neoantigen tumor vaccine|neoantigen tumor vaccine with or without Pembrolizumab In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with Pembrolizumab
45640314|NCT05916248|Biological|Personalized neoantigen tumor vaccine|Neoantigen tumor vaccine with or without Pembrolizumab In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with Pembrolizumab
45640315|NCT05916235|Device|THOR® laser system|We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.
45640316|NCT05916222|Behavioral|Dynamic Temporal and Tactile Cueing (DTTC)|DTTC is a motor-based intervention where the client watches, listens to and imitates the clinician (Strand, 2020). Treatment follows a temporal hierarchy where children receive multisensory cueing to establish accurate movements. First, the child imitates the clinician's production. If inaccurate, the child simultaneously produces the target with the clinician while cueing is provided. Upon achieving accuracy within simultaneous productions, the target is practiced within direct imitation while the clinician adds/fades cues based on the child's productions. When the child accurately produces the target in direct imitation, the target is practiced with varied prosody. Next, the target is practiced within delayed imitation where a child produces a word following a 2-3 second delay after the clinician's production. Upon accurately producing the target at all levels, the word is practiced within spontaneous productions.
45640317|NCT05916209|Procedure|Peripheral nerve blocks|Peripheral nerve blocks provide intense, site-specific analgesia administring local anesthetics near the nerves.
45640318|NCT05916196|Drug|18F-Fluoroestradiol|18F-FES PET/CT
45640319|NCT05916183|Behavioral|Fluid loss and consumption|Upon 5% body mass loss, rehydration of fluid lost to sweating throughout a 2 hour recovery period
45915909|NCT03265405|Drug|Low dose prednisolone|An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
46070364|NCT00914810|Dietary Supplement|Vitamin D (cholecalciferol)|2000 I.U. daily for 6 weeks
45915910|NCT03265405|Drug|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
45778316|NCT05287100|Other|Standard Medical Treatment|"Albumin infusion 1g/kg/day - maximum 20gm/day and repeat till serum albumin reaches 2.8g/dl If serum albumin is < 2.8g/dl SBP - Day 1 and Day 3~For Ascites :~Restriction of sodium to < 2meq/kg/day A combination of a distal-acting diuretic (spironolactone, 3-6 mg/ kg/day) and loop-acting diuretic (furosemide,0.5- 2 mg/kg per day) was given with dose escalation by one step at a time if there is no decrease in weight (by ≥ 0.5 %/day) after 5-7 days Therapeutic paracentesis (>50ml/kg) with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~For Spontaneous Bacterial Peritonitis :~IV antibiotics for 7 days Albumin Infusion on Day 1 and Day 3"
45778317|NCT02525094|Biological|MEDI9929|Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
45778318|NCT02525094|Biological|Placebo|Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
45778319|NCT04255914|Procedure|Periodontal plastic surgery procedure and orthodontic treatment|subepithelial connective tissue graft and orthodontic tooth levelling and alignment
45778320|NCT04255914|Procedure|Periodontal plastic surgery procedure|subepithelial connective tissue graft procedure
45778321|NCT05610462|Behavioral|Guided Exercise Training Program|The guided exercise program training consists of: a video demonstration, an exercise training session or group session, a follow up home visit, and virtual check-ins. The exercises include treadmill, wall sits, straight leg raise, bicep curls, hand grips with dynamometer at 40% maximal voluntary contraction (MVC), and Stationary cycling at moderate intensity (100 Watts).
45778322|NCT05610462|Behavioral|Usual Care|Usual care consists of routine clinic visits and standardized counseling about exercise, including an exercise pamphlet that is given to all thoracic aortic dissection (TAD) patients.
45778323|NCT02271230|Drug|Vitamin D and fish oil|2000 IU vitamin D and 1g/d fish oil
45778324|NCT02271230|Dietary Supplement|Fish oil (EPA/DHA) alone|1 g/d fish oil
45778325|NCT02271230|Drug|Vitamin D alone|2000 IU vitamin D
45778326|NCT02271230|Other|Placebo|Vitamin D placebo and fish oil placebo
45778327|NCT04254666|Behavioral|Physical Literacy & Food Literacy Intervention.|A 12-week intervention designed to expose adolescents with ID to a variety of sports skills and healthy eating concepts to equip them with skills and confidence to participate in sports and make healthy food choices. The program will follow a protocol adapted to meet the needs of a diverse group of children with ID. Sessions will be held 1 time/week for 75 minutes virtually; 35 minutes will focus on sport skills activities with 35 minutes devoted to healthy eating.
45778328|NCT05321706|Drug|Dapagliflozin 10 mg|Participants will be randomized in a 1:1 fashion to receive 10 mg of oral dapagliflozin
45778329|NCT05321706|Drug|Placebo|Participants will be randomized in a 1:1 fashion to receive a matching placebo once daily for one year.
45778330|NCT05514990|Drug|Bortezomib|Given SC or IV
45778331|NCT05514990|Drug|Dexamethasone|Given PO, IV, or IM
45778332|NCT05514990|Biological|Pelareorep|Given IV
45778333|NCT05514990|Biological|Pembrolizumab|Given IV
45448582|NCT04587856|Other|bone marrow withdrawal|bone marrow samples evaluation
45448583|NCT03738969|Procedure|Laparotomic radical hysterectomy|Radical hysterectomy applied by laparotomy
45448584|NCT03738969|Procedure|Laparoscopic radical hysterectomy|Radical hysterectomy applied by laparoscopic
45915911|NCT03808480|Drug|CA and Nivolumab|Cyclophosphamide 500mg/m2 IV on D1 (C1-4), 1cycle=21days) Doxorubicin 50mg/m2 IV on D1 (C1~4, 1cycle=21days) Nivolumab 360 mg/IV C2~4 D1 (1cycle=21days) Nivolumab 400mg/IV on D1 from Cycle 5 every 4 weeks.
46070365|NCT00914810|Dietary Supplement|Placebo|Placebo (sugar pill) daily for 6 weeks
45640323|NCT05916131|Behavioral|Basic Education|2-week text message intervention for providing knowledge about hypoglycemia management and prevention.
45640324|NCT05916131|Behavioral|Hypoglycemia Symptom Detection Training|10-week text message intervention for providing training on skills of detecting hypoglycemia symptoms.
45640325|NCT05916131|Behavioral|Education Plus|10-week text message intervention for helping people consider how they think of hypoglycemia.
45640326|NCT05916118|Other|Aerobic Exercise|Patients will be asked to engage in aerobic exercise using a pedal machine to move their arms and legs while in a seated position. Patients will be asked to exercise for a total of 30 minutes, which may be divided in up to three, ten-minute bouts of exercise.
45640327|NCT05916105|Drug|Ciprofloxacin Tablets|Ciprofloxacin antibiotic
45640328|NCT05916092|Device|TransLoc 3D|TransLoc 3D SI Joint Fusion System
45640329|NCT05916066|Dietary Supplement|Nicotinamide|Tabletts of 500mg Nicotinamide (B3-vitamin)
45640330|NCT05916053|Dietary Supplement|Vitamin D supplementation|50.000 IU of vitamin D supplementation was prescribed for deficient/insufficient participants for a 3 month period.
45640331|NCT05916040|Device|Radiotherapy with MRIdian with simultaneous integrated boost|radiotherapy during 5 days given in 5 weekdays with simultaneous integrated boost
45778334|NCT05354856|Drug|Indocyanine green|A bolus of ICG (0.2 mg/kg body weight) will be injected intravenously and flushed with 5 mL of saline. Gastric perfusion will subsequently be assessed along specific regions of interest (ROI) with q-ICG (quantitative perfusion assessments with ICG) to obtain baseline perfusion values.
45778335|NCT05354778|Drug|Hydrocortisone|Corticosteroid
45778336|NCT05354778|Drug|Placebo|Normal saline only
45640332|NCT05916040|Other|Questionnaires before, during and after radiotherapy|"Questionnaires consisting of 3 quality of life scales and 1 mental state scale:~EORTC QLQ-C30~EORTC QLQ-CR29~Low Anterior Resection Syndrome Score (LARS) questionnaire~Hospital Anxiety and Depression Scale (HADS) questionnaire"
45448585|NCT05668689|Other|Preliminary testing|The pilot test will be administered by local investigators via a computer-based application to 35-50 trainees and consultants. The cohorts will include an equal number of trainees and consultants of varying experience, based on the new RCOA curriculum and the extent of their regional experience (stage 1 (CT1-3); stage 2 (ST4-5); stage 3 (ST6-7); stage 3 + regional fellowship trained; consultant; consultant with special interest in regional; consultant + regional fellowship trained). The pilot test will contain short video clips and images of ultrasound guided regional anaesthesia with questions in a constructed response question (CRQ) format to identify relevant structures, anatomy and clinical knowledge.
45640333|NCT05916027|Behavioral|The 15-Method|The 15-Method is a Screening and Brief Intervention method for identifying and treating alcohol problems in primary care. The method combines evidence-based approaches from specialized addiction treatment with screening and readily available treatment options in general practice to help identify and treat alcohol problems. The 15-method is based on Motivational Interviewing, Cognitive Behavioral Therapy and utilizes the Alcohol Use Disorder Identification Test (AUDIT) as a screening tool. The 15-Method contains three flexible steps: Identification of clinical problem related to alcohol; feedback and clinical work-up as needed; treatment. Treatment includes structured consultations (maximum of four) with patient home-work assignments, and can be combined with pharmacological treatment for alcohol problems.
45640334|NCT05916014|Diagnostic Test|Diagnostic Test: The diagnosis of Artificial Intelligence and endosopists|Endosopists and AI will assess the Kimura-Takemoto classification independently when the patients is eligible.
45640335|NCT05916001|Other|Placebo|A Placebo will be administered per os 3 times per day for 10 days before colorectal surgery
45640336|NCT05916001|Dietary Supplement|Oral Impact Nestle|Oral Impact Nestle will be administered per os 3 times per day for 10 days before colorectal surgery
45640337|NCT05916001|Procedure|Colorectal surgery|Colorectal surgery will include right colectomy, left colectomy, transverse colectomy, anterior rectal resection. All procedures will be performed according to the standard clinical practice.
45640338|NCT05915988|Device|UNEEG EpiSight solution|Implantation subcutis under local anesthetics
45640339|NCT05915975|Behavioral|Behavioral Care Coordinated with Medical Care Intervention|Participants will be meeting with a behavioral health provider during their clinic visit. Subsequent visits can be held either via telehealth or in-person. Participants should expect weekly visits during the first two months and less frequent visits (biweekly or monthly) for the last two months. Some sessions that are provided via telehealth might be video recorded and later reviewed to ensure that the program is being delivered as intended.
46070366|NCT00922285|Other|psychosocial support for caregiver|6 weekly 60 minute sessions
45640340|NCT05915975|Behavioral|Behavioral Care Not Coordinated with Medical Care Intervention|Participants will meet with a study team member during their in-person visit and will receive a list of clinics that are panelled with their insurance. The participants will be responsible for calling the clinics to set up their appointments. Services might be provided in person or via telehealth based on the participant's preference and the clinics' availability.
45640341|NCT05915962|Procedure|collecting a Nanofat-type microfat autograft|"Collecting and preparing a Nanofat autograft.~The protocol provides for the fat sample to be taken in a doctor's office during a consultation. The preparation will then be carried out at the MEARY center for cell and gene therapy of the AP-HP, at the Saint Louis hospital in Paris."
45640342|NCT05915949|Drug|Dapagliflozin 10mg Tab|Forxiga 10mg Tab once daily will be given to participants for 24 weeks.
46070367|NCT00922285|Other|questionnaire administration|Evaluated at baseline, week 1 and week 6 of art therapy
45640343|NCT05915949|Drug|Lobeglitazone 0.5 mg|Duvie 0.5mg Tab once daily will be given to participants for 24 weeks.
45640344|NCT05915949|Drug|Dapagliflozin + Lobeglitazone|Duvie 0.5mg Tab once daily will be given to participants for 24 weeks.
46070368|NCT00922285|Procedure|quality-of-life assessment|Evaluated at baseline, week 1 and week 6 of art therapy
45640345|NCT05915936|Procedure|LVMR|laoparoscopic ventral mesh rectopexy
45640346|NCT05915936|Procedure|PSR|perineal stapler resection
45640347|NCT05915923|Procedure|1 Hz Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 1Hz)
45640348|NCT05915923|Procedure|10 Hz Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 10Hz)
45640349|NCT05915923|Procedure|Sham Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received sham-rTMS once a day with the same parameters as the 10 Hz rTMS group, but the coil rotated 90° away from the scalp
45640350|NCT05915897|Diagnostic Test|Specimen Donation|blood donation
46070369|NCT00922285|Procedure|stress management therapy|6 weekly 60 minute sessions
45778337|NCT00396266|Drug|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
45640351|NCT05915884|Other|SGLT-2 inhibitors|This study is an observational study. It is not planned to do an interventional activity.
45640352|NCT05915871|Drug|Tegoprazan|Tablet for oral administration
45778338|NCT04271384|Combination Product|nivolumab|Combined neoadjuvant therapy consisting of nivolumab + SABR
45778339|NCT05319444|Device|Off-brand Waterpik®|"Study staff will use the Waterpik® device and brush for approximately two to five minutes on the participant's scalp until all scale and other debris appears to be resolved. Their scalp will then be rinsed and gently dried with a towel.~The off-label design utilizes the Waterpik® device, but with adjustments optimized for scalp health. The device settings are adjustable during the treatment, ranging from settings of 2-10. Study staff plan to utilize the setting of 10 unless the participant indicates discomfort. Investigators attached a small Losophy brush in replacement of the Waterpik® toothbrush. The small Losophy brush was connected to the device via PVC heat shrink and a hole was drilled on the brush in order to deliver water while simultaneously utilizing the brush on the scalp."
45778340|NCT05381142|Drug|Elinzanetant (BAY3427080)|Elinzanetant will be administered as a single dose on Study Day 1 and a multiple dose once daily for another 6 consecutive days on Study Day 8 to Study Day 13.
45778341|NCT05381142|Drug|Placebo|Matching placebo will be administered the same as Elinzanetant (BAY3427080)
45778342|NCT05610384|Drug|Ketorolac Injectable Solution|ketorolac 30 mg (diluted in 200 mL normal saline) intravenously over 5 minutes before induction of anesthesia then every 8 hours postoperatively
45778343|NCT05610384|Drug|Ibuprofen 800 mg|ibuprofen 800 mg intravenously (Diluted in 200 mL of normal saline) over 5 minutes before induction of anesthesia then every 8 hours postoperatively.
45778344|NCT05353296|Behavioral|Digital cognitive behavioral therapy for insomnia (CBT-I) program|A self-guided digital program of CBT-I (Somryst) that has been culturally adapted for Spanish-language speakers. Somryst is an interactive and tailored mobile-based program modeled on the primary tenets of face-to-face CBT-I. Patients will be asked to complete six cores (main intervention content) during the 9-week intervention period. The cores provide key content across six domains including behavioral (sleep restriction, stimulus control), cognitive (cognitive restricting), educational (sleep hygiene), overview, and consolidation/relapse prevention.
46070370|NCT00808561|Other|Group 1: Alternative Fistula|Performing other autogenous AV fistulas which include various options such as brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of other strategies to maintain a primary access. The advantage would be to maintain an autogenous all venous access with less risk of infection and thrombosis.
45778345|NCT05353296|Behavioral|Minimally Enhanced Usual Care (mEUC)|A minimally enhanced usual care, which will include usual care by patients' Primary Care Provider and a sleep hygiene brochure.
45778346|NCT05353296|Device|Somryst (culturally adapted)|FDA-authorized digital cognitive behavioral therapy for insomnia (CBT-I) trains your brain for better sleep.
45778347|NCT03570632|Drug|Metformin|Participants randomized to metformin will receive metformin in addition to standard treatment of diabetes during pregnancy
45778348|NCT05286944|Other|Mobile phone alarm reminder|Patients are reminded to take their INCS using a mobile phone alarm set to ring daily
45778349|NCT05319132|Other|Adult subjects with ROSAH syndrome|The main objective is to evaluate the ex vivo inhibitory potential of DF-003 on alpha-1 kinase activity.
45778350|NCT00397904|Biological|cetuximab|
45778351|NCT00397904|Drug|cisplatin|
45778352|NCT00397904|Drug|irinotecan hydrochloride|
45778353|NCT00397904|Other|immunohistochemistry staining method|
45778354|NCT00397904|Other|laboratory biomarker analysis|
45778355|NCT00397904|Procedure|biopsy|
45778356|NCT05610228|Other|NO intervention|No intervention
45778357|NCT05610150|Device|Myobrace Functional Appliance|An Appliance for treating growing Class II patients with mandibular deficiency
45778358|NCT05610150|Device|Twin Block|An Appliance for treating growing Class II patients with mandibular deficiency
45778359|NCT00398918|Drug|zonisamide|zonisamide (100 mg)one time
45778360|NCT00398918|Drug|Placebo|Placebo Comparator
45778361|NCT05380752|Drug|TPOXX IV (Tecovirimat Injection, 10 mg/mL)|IV solution (10 mg/mL) must be diluted with 2 parts 0.9% normal saline or 5% dextrose solution prior to dosing. Once diluted, the drug product should be stored at 2-8°C (36-46°F) and used as soon as possible (i.e., not more than 24 hours after dilution). Given via an IV infusion pump over a 6 hour period, twice daily, and for up to 7 days, or until the physician determines oral TPOXX may be given
45778362|NCT05352048|Device|Triggered Electromyography|Triggered electromyography will be used during surgery to detect nerve impingement by pedicle screws used for spinal fusion. Threshold stimulation data from the device will be recorded.
45778363|NCT05352048|Device|Mechanomyography|SENTIO MMG ball tip probe will be used during surgery to detect nerve impingement by pedicle screws used for spinal fusion. Threshold stimulation data from the device will be recorded, and the accuracy compared to the data from the triggered electromyography.
45778364|NCT00399308|Device|Celaderm (Frozen Cultured Epidermal Allograft)|Four biweekly applications of Celaderm plus compression therapy
45778365|NCT00399308|Device|Celaderm (Frozen Cultured Epidermal Allograft)|Four weekly applications of Celaderm plus compression therapy
45640353|NCT05915871|Drug|Bismuth|Capsule for oral administration
45640354|NCT05915871|Drug|Amoxicilli|Capsule for oral administration
45640355|NCT05915871|Drug|Clarithromycin|Tablet for oral administration
45778366|NCT00399308|Device|Control (compression bandaging)|Multi-layer compression bandaging
45640356|NCT05915858|Other|muscle energy technique|"Group 1: Group 2:~Muscle energy technique (Reciprocal inhibition) Stretching exercises Static stretching 2 weeks (twelve treatment session) patient supine, the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra-lateral knee (the leg on the side to be treated is crossed over the other, straight leg).~The angle of hip flexion should not exceed 60 degree.~The practitioner places one hand on the contra-lateral ASIS to prevent pelvis motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis for 7-10 seconds."
45915912|NCT03185728|Other|iLook Out for Child Abuse|"Online, interactive educational intervention that uses a video-based story-line and gamification to teach childcare providers about child abuse and mandated reporting."
45640357|NCT05915858|Other|stretching exercise|"Following the contraction the practitioner eases the treated side leg into adduction until a sense of resistance is noted; this is held for 10-30 seconds. 2 week (twelve treatment session) practitioner manual stretches the piriformis:~The patient lies in supine position the affected leg is placed into flexion at hip and knee so that the foot rests on the table lateral to the contra-lateral knee.~The practitioner places one hand over the contra-lateral ASIS to stabilize the pelvis during the exercise and passively abducts and internally rotates the hip medially till the pain is bearable.~The process is repeated 3-5 times with a 30"
45778367|NCT05599776|Other|Smart ring assisted physiotherapeutic intervention|the effect of a smart ring (Oura), a wearable activity tracker assisted physiotherapeutic intervention on the risk of poor outcome measured on patient reported post-operative outcome (Oxford Knee Score) 12 months after a primary total knee replacement.
45778368|NCT05286476|Combination Product|Whole Body Vibration|vibration was administered for 1min, with a rest interval of 1min between each vibration set repeating 10 vibrations, with a frequency of 30 Hz and an amplitude of 0-2 mm and a speed of 50 m /s,18 and these sessions lasted for 6 weeks 3 days a week. whole-body vibration was induced by a noninvasive oscillation platform
45778369|NCT05286476|Other|pelvic floor exercises and static abdominal exercises in addition to diet instructions|"During the low abdominal hollowing with instructed pelvic floor co-contraction test subjects were instructed with the standard command: 'Breathing normally, and keeping your back still, gently lift and tighten your pelvic floor. Now gently draw in your low tummy as well and hold it'. Pelvic floor facilitates transversus abdominis thickness.~subject in supine lying with her arms crossed over the diastasis for support. And subject has to draw or pull the abdomen inwards so that there elicits an isometric contraction of abdominal muscles and repeated this for 5-7 times."
45778370|NCT05351580|Device|DiSCERN|Smart watch Monitoring
45778371|NCT05599074|Device|extrusion arch|A stainless steel pre-formed arch wire custom made by placing V-bends 3-5 mm mesial to the molar tubes, placed into the auxiliary molar tubes after leveling phase and tied over the main arch wire distal to the lateral incisors
45778372|NCT00401102|Behavioral|Interpersonal Psychotherapy for Depressed Adolescents|Open clinical trial of IPT-ASI for depressed and self-injuring adolescents, 12-18 years. Goal is to assess feasibility of using IPT-A protocol for teens with co-morbid depression and self-injury. All eligible participants receive 12 weeks of individual IPT-ASI with optional monthly booster sessions. IPT-ASI is a psychosocial intervention that focuses on the importance of interpersonal relationships in relation to psychological functioning. The first phase (4 weeks) includes a review of depression and self-injury symptoms, psycho-education about depression and self-injury, and a detailed assessment of the patient's important interpersonal relationships. The middle phase (weeks 5-9) involves interpersonal skill building, including communication skills, affect identification and expression, problem solving. The final phase ( weeks 10-12) involves review of skills, generalization of skills to other relationships, termination.
45778373|NCT05350722|Radiation|Single dose ablative radiotherapy|Patients will receive a single dose of 20Gy/15Gy on the gross tumor volume and clinical tumor volume respectively, in the context of pre-operative partial breast irradiation
45778374|NCT04750694|Behavioral|Resistance training|A full-training programme with high intensity followed by back squat exercise with blood flow restriction. Inflatable cuffs will be placed proximally on both thighs. The cuff pressure will be 50% of individual arterial occlusion pressure and will be maintained during the rest intervals. Participants will perform 30, 15, 15 and 15 repetitions of 30% of 1 Repetition Maximum. Totally 75 repetitions will be performed. 45 seconds rest interval between sets will be given.
45778375|NCT05317104|Other|Aerobic exercise|For 6 weeks, 3 times a week, aerobic exercise will be performed with a treadmill at 55-74% of the maximal heart rate.
45778376|NCT01794884|Drug|Glutamine|20% N(2)-L-alanyl-L-glutamine 0.4g/kg(2ml/kg) mixed with compound amino acid (10ml/kg).Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h
45778377|NCT01794884|Drug|Ringer's solution|Ringer's solution 12ml/kg. Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h.
45778378|NCT05315934|Other|Upper body aerobic exercise|Participants will perform 30 minutes of continuous exercise on the arm-crank ergometer.
45778379|NCT05315934|Other|Lower body aerobic exercise|Participants will perform 30 minutes of continuous exercise on the cycle ergometer.
45640358|NCT05915845|Other|Laura Mitchell's Relaxation technique|This technique was used to eliminate muscular tension. Patients were taught to contract muscles opposite to the strained muscle groups, eventually to 'cease' shrunken them, and then to roster the position adaptation of the body structure. Patient was comfortably positioned.
45778380|NCT00401414|Drug|Warfarin|2 mg tablets take as directed by study staff (based on INR)
45778381|NCT05513196|Procedure|Erector spinae plane block (ESPB)|Bilateral erector spinae plane block will be performed with 20 mL, 0.25% bupivacaine at T9 level preoperatively.
45915913|NCT03116347|Biological|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
45915914|NCT03116347|Biological|KIOVIG|100 mg/ml solution for Immune Globulin Intravenous Infusion
45915915|NCT03116347|Biological|Cuvitru|200 mg/ml solution for Immune Globulin Subcutaneous Injection
45915916|NCT03102151|Other|Community Campaign La CLAVE|A community campaign to teach community residents and professional networks the signs and symptoms of psychosis using social media, community talks, and advertising.
45915917|NCT00387478|Biological|Tree MATA MPL or Tree MATA|"4 injections of increasing dose strength for Tree MATA MPL or Tree MATA:~600 SU/0.5 ml~1600 SU/0.5 ml~4000 SU/0.5 ml~4000 SU/0.6 ml~4 injections of 0.5 mL of 2% w/v L-tyrosine for Placebo"
45778382|NCT00370838|Drug|Levetiracetam|The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic suppression. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
45448586|NCT05668689|Other|Psychometric main study testing (Phase 5)|The main study assessment tool will be administered to trainees of all levels and consultants, aiming to recruit an equal number across different stages of the RCoA curriculum and of varying regional anaesthesia experience (stage 1; stage 2; stage 3; stage 3 + regional fellowship trained; consultant; consultant with special interest in regional; consultant + regional fellowship trained). The exam will consist of constructed response questions (CRQs), which will require the participant to write free-text responses to questions, in line with RCoA examinations.
45778383|NCT00370838|Drug|Clonidine|The initial dose of clonidine was 0.05 mg, twice daily. If needed for tic suppression, the dose was increased weekly by 0.05-0.1 mg, with a maximum dose of 0.4 mg per day. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
45640359|NCT05915845|Other|Papworth exercise|"The Papworth Method integrates five components, the principal one being specific breathing training:~• Breathing training, including teaching of appropriate minute and tidal volume and the development of a pattern of breathing suitable to current metabolic activity.~Elimination of dysfunctional breathing, including hyperinflation and hyperventilation patterns is discussed. A specific Papworth method diaphragmatic breathing technique is taught to replace the use of inappropriate accessory muscles of respiration. When relaxed, is placed on calm slow nasal expiration. Patients are encouraged to nose-breathe rather than mouth-breathe and eradication or reduction of habits such as yawning, sighing, etc. is taught and practiced."
45778384|NCT05512806|Drug|AZD5462|Participants will receive AZD5462 orally.
45778385|NCT00370994|Procedure|Caudal epidural injection|Caudal epidural injection with catheterization
45915918|NCT03078361|Other|Immunochemical Fecal Occult Blood Test (I-FOBT) Kit|Both intervention groups will receive an I-FOBT kit (by study coordinator) with verbal and written instructions in Spanish on how to complete the stool sampling at home within 1 week, and mail the completed kit in the pre-addressed, postage paid mailer. Patients with abnormal results will receive a call explaining the meaning of an abnormal I-FOBT and encouraging them to take specific next steps.
45915919|NCT03078361|Behavioral|LATINOS CARES Toolkit|DVD + photonovella booklet), about colorectal cancer screening (CRCS) targeted for a Latino medically underserved population.
45915920|NCT03078361|Behavioral|Standard Intervention|Standard intervention (CDC brochure) on colorectal cancer screening in community health clinics.
45915921|NCT03003325|Drug|AOP2014|AOP2014 will be supplied to the patients as pre-filled auto-injection pens, containing 250 µg of active drug (0.5 ml solution for injection). One pen may be used twice within a time period of 4 weeks. Hence investigators will provide one prefilled pen at every monthly visit. AOP2014 will be self-injected subcutaneously by patients once every 14 days at the single doses of 100 µg (0.2 ml).
45448587|NCT03546166|Drug|Picato 0.05% Topical Gel|apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days. In case of treatment failure after 3 months, apply again on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days.
45448588|NCT03738891|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
45448589|NCT04012996|Device|prodisc C SK and/or Vivo|Subjects will be randomized in a 2:1 ratio either to the two-level prodisc C SK or prodisc C Vivo device (investigational group) or to the two-level Mobi-C device (control group).
45448590|NCT04012996|Device|Mobi-C Cervical Disc|Subjects will be randomized in a 2:1 ratio either to the two-level prodisc C SK or prodisc C Vivo device (investigational group) or to the two-level Mobi-C device (control group).
45778386|NCT00370994|Procedure|Percutaneous adhesiolysis|Percutaneous adhesiolysis with hypertonic saline neurolysis
45778387|NCT04136652|Procedure|CO2 laser- treatment (DEKA SmartXide2 Laser System, MonaLisa Touch|women will receive a series of three treatments using a fractional (pulsed) CO2 laser system (SmartXide2 MonaLisa Touch, DEKA M.E.L.A Srl, Florence, Italy), each performed in an outpatient setting without analgesia. A tubular laser-probe is inserted in the vaginal canal until reaching the vaginal vault. A burst of laser pulses is transmitted through the probe and deflected at 90degrees in four directions towards the vaginal wall, then rotated 45degree for a second burst of pulses. Guided by markings on the probe, it is withdrawn 4mm and the procedure is repeated until reaching the introitus. Treatment parameters include power 30W, dwell time 1000us, 1000um spacing, using normal scan mode, with Smartstack setting for 1 at first application and 3 for the next two applications.
45778388|NCT05307666|Other|Medication minimization|During the medication minimization visit, and any necessary follow-up visits, patients and providers work together to gradually minimize medication dosages (e.g. reducing 1/4 or 1/2 dose at a time) using the following approach: 1) Medications Treating Symptoms: Find the minimum dose that controls the symptom, 2) Drugs that Lower Blood Pressure: Reduce dosages until systolic BP is in the upper 10mmHg of the target range (e.g. target 130 - 140 mmHg), 3) Drugs That Lower Blood Sugar: Reduce dosages until HbA1c is in the upper 5% of the target range (e.g. target 7.5 - 8.0%).
45778389|NCT01795430|Drug|etoposide|Given IV
45778390|NCT01795430|Drug|ifosfamide|Given IV
45778391|NCT01795430|Radiation|intensity-modulated radiation therapy|Undergo WB-MRI-guided IMRT
45778392|NCT01795430|Drug|topotecan hydrochloride|Given IV
45915922|NCT03003325|Procedure|Phlebotomies|According to current common clinical practice the regimen must be selected accordingly to maintain the recommended level of HCT< 45%. Once normalization of the hematocrit has been achieved, blood counts at regular intervals (every 4 weeks) will establish the frequency of future phlebotomies. Sufficient blood should be removed to maintain the hematocrit below 45%.
45778393|NCT01795430|Drug|busulfan|Given IV
45778394|NCT01795430|Drug|melphalan|Given IV
45640360|NCT05915832|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
45778395|NCT01795430|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell or bone marrow transplant
45778396|NCT01795430|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
45778397|NCT01795430|Procedure|autologous bone marrow transplantation|Undergo autologous bone marrow transplant
45640361|NCT05915832|Procedure|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
45778398|NCT05556876|Dietary Supplement|Fortifit|An oral supplement with a high content of protein
45778399|NCT04750382|Drug|HX008+Cisplatin+Gemcitabine|Participants will receive HX008 3mg/kg, Day 1,Q3W for up to 2 years + Cisplatin 75mg/m^2, Day 1, Q3W for up to 6 cycles +Gemcitabine 1250mg/m^2, Day 1, Day 8, Q3W for up to 6 cycles
45778400|NCT04271150|Device|Self-etch|Universal adhesive with self-etch mode
45778401|NCT04271150|Device|Total-etch|Universal adhesive with total-etch mode
45640362|NCT05915819|Other|Plyometric Training|Exercise prescription according to weeks, sets and repetition. Weeks 1 and 2 1-2 sets / 10 repetitions Double leg jump Medicine ball(MB) stuffer flutter MB overhead throw MB single leg dip, Arrow cone drill Figure 8 drill Weeks 3 and 4 1-2 sets / 8 repetitions Ankle jumps Lateral cone hops Zigzag jump drill MB chest pass Jump & turn 90° High-5 drill MB split squat Power skipping Clock drill T-drill Weeks 5 and 6 1-2 sets / 6 repetitions Dot drill Single leg cone hops Long jump and sprint Single leg zigzag drill MB lunge chest pass Jump and turn 180° Split squat jump Alternate bounding X-drill Shuttle drill
45778402|NCT05313438|Device|CPNS Therapy|Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
45778403|NCT00401882|Drug|Epinephrine|Epinephrine (1 mg) IV additional doses
45778404|NCT00401882|Drug|Metoprolol|Metoprolol 5 mg IV (up to two times only) instead of epinephrine additional doses
45915923|NCT03003325|Drug|ASA|100 mg/daily of ASA is recommended (when there are not contraindications) according with current guidelines for this risk class of patients
45448591|NCT03732417|Other|Secondary prevention of cardiovascular risk factors|Intervention group (n=35) Control group (n=35)
45448592|NCT03630393|Other|Pneumoperitoneum Pressure 6 mmHg|A pneumoperitoneum insufflation pressure of 6 mmHg will be used during robotic assisted laparoscopic prostatectomy (RALP).
45640363|NCT05915819|Other|Eccentric Training|The eccentric training will be Pull-ups 3-5 sets X 6-8 reps Glute-ham raise 3-5 sets x 10rep Manual glute-ham raise 3-5 sets x 10rep single-leg Romanian dead lift or good morning(barbell or dumbbell) 3-5 sets x 10rep Glute-bridge and hip thrust (can also perform single leg movement) 3-5 sets x 10rep Half-kneel-bottom-up press-eccentric only. 3-5 sets x 8rep The eccentric exercise technique will be 2/1 technique, Two-movement technique, Slow/super slow, Negative (supramax)
45448593|NCT03630393|Other|Pneumoperitoneum Pressure 15 mmHg|A pneumoperitoneum insufflation pressure of 15 mmHg will be used during robotic assisted laparoscopic prostatectomy (RALP).
45448594|NCT02253784|Drug|Dexamethasone|
45448595|NCT02253784|Drug|Bupivacaine|
45778405|NCT05313204|Other|Moderate-intensity cardiovascular exercise|The participant will be instructed to first rest quietly for 10 minutes wearing a heart rate monitor. The participant will then be instructed to exercise at an intensity of 60-70% heart rate reserve (HRR) for 20 minutes. The participant may choose any kind of cardiovascular exercise modality they prefer, as long as the exercise will meet the prescribed intensity. Following exercise, participants will rest quietly for 10 minutes wearing the heart rate monitor.
45778406|NCT01794962|Other|Cognitive functional therapy|The intervention is directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder.
45778407|NCT01794962|Other|manual therapy and exercises|Patients in this group will be treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and is designed to be consistent with best current manual therapy practice.
45448596|NCT03734445|Dietary Supplement|Vitamin Supplement|Subjects will be randomly allocated to a supplementation of vitamin C 1000mg, vitamin D 400 IU and zinc 10 mg or an identical placebo. Subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding
45778408|NCT00371540|Other|Home visit by community care coordinators|Decrease in patient visits to the clinic from the standard of once per month to every 3 months with home visits monthly.
45778409|NCT04248738|Behavioral|NEEDS|NEEDS intervention includes assessing patients' social needs and resources (SocNSuppR) and communicating those SocNSuppR to discharge teams
45778410|NCT05345886|Behavioral|Hippotherapy|Hippotherapy is a rehabilitation method entrusted to a paramedic or medical practitioner who uses the horse in his/her program treatment, in addition to conventional medical care.
45778411|NCT05555394|Other|Basic Body Awareness Therapy|The intervention will be twice a week during 12 weeks. It lasts 90 min of movements of daily life, massage and self-reflections.
45778412|NCT05555394|Other|Stretching Exercise|It consists in stretching movements of whole body
45778413|NCT00373334|Drug|nizatidine (axid)|nizatidine (axid)
45778414|NCT00373334|Drug|nizatidine (axid)|nizatidine (axid)
45778415|NCT00373334|Drug|placebo|placebo
45778416|NCT05507346|Device|Cross over Device (PCD or Dayspring - alternate to first group)|Cross over after three month of use and a month of washout period
45778417|NCT04749914|Drug|Lasmiditan|Administered orally.
45778418|NCT04749914|Drug|Dabigatran Etexilate|Administered orally.
45778419|NCT04749914|Drug|Rosuvastatin|Administered orally.
45778420|NCT00402194|Drug|Losartan|Tablet, 100mg, once per day for 3 months
45915924|NCT03001414|Biological|Placebo followed by Autologous EPCs transfected with human eNOS|4 doses of placebo in first 6 months followed by 4 doses of autologous EPCs transfected with eNOS in second 6 months
45915925|NCT03001414|Biological|Autologous EPCs transfected with human eNOS followed by Placebo|4 doses of autologous EPCs transfected with eNOS in first 6 months followed by 4 doses of placebo in second 6 months
45915926|NCT03001414|Biological|Autologous EPCs transfected with human eNOS|4 doses of autologous EPCs transfected with eNOS in first 6 months which is repeated in second 6 months
45640364|NCT05915806|Dietary Supplement|High-dose DHA|Direct enteral DHA supplementation at a dose of at least 40 mg/kg/day or DHA supplementation of breast milk or formula aiming for at least 0.4% of total fatty acids.
45640365|NCT05915806|Dietary Supplement|Control|Control with no or low-dose DHA.
45640366|NCT05915793|Other|Diaphragm strengthening and accessory muscles stretchings|Diaphragm strengthening and accessory muscles stretchings
45640367|NCT05915793|Other|Diaphragm strengthening|Diaphragm strengthening
45640368|NCT05915780|Device|Cycling|The experimental group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 8-week period
45640369|NCT05915780|Device|Balance Board|Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises (if required);
45640370|NCT05915767|Dietary Supplement|Olive leaf tea|Fresh olive leaves will be procured from Chakwal, Pakistan. The leaves will be rinsed to remove dust and debris and dried at 40℃ in the oven. The leaves will be ground into powder form and then incorporated in tea bags containing 1.8 g leave powder/tea bag. Participants in treatment group will be instructed to dip the tea bag in 200-250 ml boiling water for 3-5 minutes.
45640371|NCT05915754|Other|Hip abductors stretching and strengthening exercises|Treatment consist of four stretches for the ITB including: ITB stretch with trunk side bend, ITB stretch with trunk side bend and upward lateral reach, trunk side bend with downward lateral reach and side lying leg adduction and Strengthening exercise plan involving the gluteal muscle groups. These exercises include clams, side-lying abduction, reverse clams and supine bridge
45640372|NCT05915754|Other|Posterior oblique sling strengthening exercises|Treatment consists of treatment A plus the intervention program of POSS consisted of four different exercises utilizing activation of the POSS. The intervention program focuses on one specific exercise each week that will progress in difficulty over the 4 weeks. The equipment used in the exercise progression included a blue, latex-free, medium-resistance theraband (TB), and the final exercise of the progression will include the use of a step stool. The TB will be used to increase the activation of the latissimus dorsi while simultaneously performing lower-extremity exercise to increase gluteal muscle involvement. The exercises are to be used in the 4-week progression.
45640373|NCT05915728|Drug|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
45640374|NCT05915728|Drug|Gadobutrol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
45640375|NCT05915728|Drug|Gadoterate meglumine|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
45640376|NCT05915728|Drug|Gadoteridol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
45640377|NCT05915715|Other|McGill stabilization exercise|"McGill Curl Up Lie down on your back.~The Side Bridge Lie on your side.~The Bird Dog."
45640378|NCT05915715|Other|Proprioceptive neuromuscular facilitation technique|. The patient is in sitting position and faces the physical therapist. The RST program consisted of alternating (trunk flexion-extension) isometric contractions against resistance for 10 seconds, with no motion intended. Subjects performed 3 sets of 15 repetitions at maximal resistance provided by the same physical therapist. Rest intervals of 30 seconds and 60 seconds were provided after the completion of 15 repetitions for each pattern and between sets, respectively.
45640379|NCT05915702|Drug|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
45640380|NCT05915702|Drug|Gadobutrol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
45640381|NCT05915702|Drug|Gadoterate meglumine|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
45640382|NCT05915702|Drug|Gadoteridol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
45640383|NCT05915689|Other|Myofascial arm pull technique|patient in supine position move the arm passively in abduction to the restricted barrier and pull the arm only enough traction was used to counterbalance the weight of the patient's arm. Stretch was hold until the fibers were released, and then, stretch was given again by increasing traction. This sequence was repeated until an end feel was reached. same procedure for flexion and scapular protraction and Horizontal-adduction. Repetition will be 4-5 reps. per set, 3 times per week for 18 sessions.
45915927|NCT00387517|Drug|Aliskiren/HCTZ|
45915928|NCT02966548|Drug|Relatlimab|Specified dose on specified days
45778421|NCT05286086|Behavioral|prehabilitation|Control of the physical, nutritional and psychological preparation of the patient who will undergo rectal cancer surgery
45778422|NCT05305404|Drug|Dexamethasone Oral|1.5mg oral dexamethasone to be administered once at 11:00PM
45778423|NCT05305404|Drug|Placebo|oral placebo to be administered once at 11:00PM
45448597|NCT03734445|Other|Placebo|Subjects will be randomly allocated to a supplementation of an identical placebo. Subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding
45778424|NCT00402896|Drug|ZD6474|300 mg/day orally for 10 weeks.
45778425|NCT05268120|Drug|doxycycline 200 mg q.d. - rifampicin 600mg b.i.d.|Both first choice treatments in Dutch guideline for MRSA decolonization
45778426|NCT05268120|Drug|trimethoprim 200mg b.i.d. - rifampicin 600mg b.i.d.|Both first choice treatments in Dutch guideline for MRSA decolonization
45778427|NCT05303610|Other|Observational|This is a cross sectional study. The aim of the study is to evaluate the myofascial chain lines in addition to the general evaluation parameters in patients with patellofemoral pain syndrome (PFPS) and to determine whether deviations from normal in the myofascial structure have an effect on the development of PFPS.
45778428|NCT00405704|Drug|Trimethoprim-Sulfamethoxazole|Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
45915929|NCT02966548|Drug|Nivolumab|Specified dose on specified days
45915930|NCT02890069|Biological|PDR001|anti-PD1 antibody
45915931|NCT02890069|Drug|LCL161|
45915932|NCT02890069|Drug|Everolimus|
45915933|NCT02890069|Drug|Panobinostat|
45915934|NCT02890069|Drug|QBM076|
45915935|NCT02890069|Drug|HDM201|
45448598|NCT04554472|Diagnostic Test|Intraoperative ultrasound|During the surgery, the standard AP and lateral x-rays will be performed. Additional projections (lateral 30 degrees tilt, and dorsal tangential view) will also be registered. Finally an intraoperative ultrasound of the wrist extensor tendons will be taken, checking the compartments individually in order to detect invasion of the dorsal cortex by the screws. In case of no protrusion, the patient will be registered as a correct fixation. Otherwise, it will be specified which position of the plate and which compartment the screw/s protrude. A screw with a correct measurement will then be replaced and implanted and recorded as a measurement error.
45448599|NCT01310205|Drug|SCV-07|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
45448600|NCT03546946|Behavioral|Gaze-Contingent Music Reward Training|Participants will hear their selected music track playing, dependent on their gaze location, when viewing a grid on neutral and negative faces.
45915936|NCT02425501|Drug|Aflibercept (Eylea, BAY86-5321)|Administration by intravitreal injection
45448601|NCT03546946|Behavioral|Control Training|Participants will hear their selected music track playing, regardless of their gaze location, when viewing a grid on neutral and negative faces.
45448602|NCT05668611|Other|Primary Training Phase|A four-day training program taken over the course of two weekends will include materials on RHD and RHD echocardiographic screening using focused artificial intelligence navigational guided echocardiographic acquisition to identify patients who are screen positive or screen negative for RHD. The echo protocol will be limited to the parasternal long axis-view (2D and color Doppler) focusing on mitral and aortic valve morphology and function and a single 2D apical 4 chamber view for auto EF. The curriculum package will include online modules, instructor delivered PowerPoint presentations, and hands on practice on volunteers with and without RHD.
45778429|NCT00405704|Drug|Placebo|Cherry flavored liquid suspension matched to active comparator.
45778430|NCT01657266|Drug|PRO-155|Pre-medication (before surgery) and maintenance treatment.
45778431|NCT01657266|Drug|Nevanac|Pre-medication (before surgery) and maintenance treatment.
45778432|NCT00375830|Procedure|Bone scan|Scan to diagnose a number of bone conditions including cancer or metastasis
45778433|NCT00375830|Drug|99mTc-methyl diphosphonate|Radiolabel for bone scan procedures
45778434|NCT00375830|Procedure|Positron Emission Tomography (PET) scan|Scan to detect gamma rays emitted by a positron-emitting radioligand such as 18F
45778435|NCT00375830|Drug|18F-Fludeoxyglucose (18F-FDG)|Radiolabel for positron emission tomography scan procedures
45778436|NCT00375830|Procedure|Computed Tomography (CT) scan|Scan to detect & analyze X-rays
45778437|NCT00375830|Drug|18F-Sodium Fluoride (18F-NaF)|Radiolabel for CT and PET scans, & as a contrast agent for MRI scans.
45778438|NCT00375830|Procedure|Whole Body Magnetic Resonance Imaging (WB-MRI) scan|Whole Body Magnetic Resonance Imaging (WB-MRI) scan: Scan that uses strong magnetic fields & radio waves to generate images of the organs in the body.
45778439|NCT00375830|Drug|Gadopentetate dimeglumine|A gadolinium-based contrast agent for MRI
45915937|NCT02409238|Drug|Metformin|Metformin dosage schedule: 250 mg thrice a day titrated from 250 mg once a day. Patients will first be started on Metformin 250 mg once a day with meals, and the dose increased to 250 mg twice a day at Day 8, to 250 mg three times a day at Day 15, subject to reports of poor tolerance of gastrointestinal symptoms or other side effects.
45935688|NCT05561023|Drug|Hawthorn red pigment|"For patients with refractory cancer pain who meet the enrollment conditions, on the basis of the clinician's normal adjustment of the analgesic regimen (the initial adjustment is the first day), the dose ramp up study of Hawthorn red pigment was started on the third day. The Hawthorn red dose group includes 10 tablets → 15 tablets → 20 tablets / time, orally, twice a day.~3 + 3 dose escalation scheme"
45778440|NCT00375830|Drug|Gadofosveset|A gadolinium-based contrast agent for MRI
45778441|NCT00375830|Drug|Gadobutrol|A gadolinium-based contrast agent for MRI
45778442|NCT05217264|Other|Assesment|This is a single-center, prospective, observational study. The assessment and reporting will be followed the Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) checklist.
45778443|NCT05479734|Behavioral|mHealth Intervention|A smartphone app (mHealth app) will deliver daily tailored messages with tips on monitoring and promoting child development and positive parenting tips.
45778444|NCT05302440|Device|remote real-time health monitoring system with ring-like sensor|The remote monitoring system will constantly record the temperature, pulse and SpO2 of the residents wearing the equipment. When the staff find abnormal vital signs, they will provide further medical assistance. All care staff who manage the system will be complete a very brief survey (1-minute) after each work shift for 14 days.
45778445|NCT05286008|Drug|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
45778446|NCT05286008|Drug|Ropivacaine at high concentration|Before the induction of anesthesia,0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
45640384|NCT05915689|Other|post isometric relaxation technique|The therapist stood in front of the patient, then placed one hand over the top of the subject's involved shoulder. The therapist cups the gleno humeral joint to palpate for motion and the subjects are directed to press the elbow towards therapist hand for shoulder abduction, internal rotation and external rotation. Muscle energy technique was applied for five repetitions per set, five sets per session, one session per day, three days a week for six weeks with each repetition maintained for the duration of 7-10 second
45640385|NCT05915676|Diagnostic Test|Leukocyte Immunoglobulin-like receptors A3|Leucocyte immunoglobulin-like receptor A3 (LILRA3) belongs to a family of leucocyte receptors produced as a soluble molecule by monocytes and macrophages. (3) The function of LILRA3 remains obscure, but LILRA3 could bind to HLA class I molecules HLA-G and HLA- C (4) and may act as an antagonist on other LILRs or a soluble ligand to other receptors(5) Growing evidence shows that (LILRA3) is associated with many autoimmune disorders.(6) (7) The functional LILRA3 is a susceptibility factor for AS and axial psoriatic arthritis (axPsA) has not been investigated.
45778447|NCT05286008|Drug|Ropivacaine and dexamethasone|Before the induction of anesthesia, 0.375% Ropivacaine and 5.0mg dexamethasone are used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
45778448|NCT05215314|Behavioral|mHealth Meditation|Participants will receive access to the 4-week Healthy Minds Program (HMP) Foundations module. The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). The full HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose. At post-treatment, participants will be given access to additional HMP content to support their continued practice.
45778449|NCT05302284|Drug|RC48-ADC|2.0 mg/kg IV every 2 weeks
45778450|NCT05302284|Drug|Toripalimab|3.0 mg/kg IV every 2 weeks
45778451|NCT05302284|Drug|Gemcitabine|1000mg/m2 IV infusion on Days 1 and 8 of every 3 week cycle
45778452|NCT05302284|Drug|Cisplatin|70mg/m2 IV infusion on Day 1 of every 3 week cycle
45778453|NCT05302284|Drug|Carboplatin|AUC=4.5, IV infusion on Day 1 of every 3 week cycle
45915938|NCT02409238|Behavioral|Intensive Lifestyle Intervention|"The intensive lifestyle interventions for the Active Intervention groups will be done at the Lifestyle Intervention Centres. The aim would to achieve and maintain a weight reduction of at least 7 percent of initial body weight through a healthy reduced-calorie, low-fat diet and engagement in physical activity of moderate intensity for at least 150 minutes per week.~This will be accomplished through a programme of individualized fitness assessment and exercise prescription for cardiovascular, strength and functional training that is standardized across study sites and facilities. The programme comprises an initial 32 sessions (2 times weekly) for supervised gym workout over 16 weeks, followed by maintenance programme of regular unsupervised exercises."
45778454|NCT05301036|Device|Diadem prototype|Diadem prototype device delivers personalized low-intensity transcranial focused ultrasound stimulation
45778455|NCT05263284|Drug|8-Chloroadenosine|Given IV
45778456|NCT05263284|Drug|Venetoclax|Given PO
45778457|NCT05214144|Other|PRO Instruments assessment questionnaire|"Patient Reported Outcome (PRO) questionnaire consisting of:~PRO-CTCAE (approximately 11 questions plus free text)~Patient-Reported Outcomes Measurement Information System (PROMIS) physical function short form (version 8c) (8 questions)~PRO ECOG question (1 question)~EORTC Quality of Life questionnaire (QLQ)-F17 questions (17 questions)~Functional Assessment of Cancer Therapy-General version, rated on a 5-point Likert scale, (FACT-GP5) (single item global side effect bother question) (1 question)~The Patient Global Impression (PGI)-C and PGI-S items (anchors for physical function) (2 questions)"
45778458|NCT05214144|Other|Baseline Survey Clinician- reported (ClinRO) ECOG|Baseline Survey completed prior to initiation of chemotherapy
45778459|NCT05214144|Device|Fitbit|wearable device
45778460|NCT05214144|Other|"Hugo Health (Hugo)"|an electronic platform that aggregates real world EHR data with patient's wearable and PRO data
45778461|NCT05214144|Other|6 Minute Walk Test (6MWT)|A comprehensive performance measure of exercise capacity, encompassing components of mobility, endurance, and functional capacity measure (PerfO)
45448603|NCT05668611|Other|Primary Assessment Phase|A pre- and post-training test on RHD knowledge and diagnosis will be administered. A rapid competency assessment, including obtaining imaging on volunteers with or without RHD and an online test with pre-recorded cases of RHD, LV dysfunction and Pericardial effusions, will be utilized at the end of the 4-day training sessions. Trainees will be monitored by trained study personnel and at the end of the practicum training, the expert users will blindly review and assess the quality of each study using the standardized scale and competency scorecard provided below. Additionally, they will be asked to pass the knowledge quiz (80% or better). If competency is not achieved, an additional weekend of training can be added.
45915939|NCT02409238|Behavioral|Standard LIfestyle Recommendation|The standard lifestyle recommendations for the Control groups are in the form of standard diabetic education pamphlets and a 20-to-30-minute individual session that emphasizes the importance of a healthy lifestyle to reduce their weight and to increase their physical activity. Activity will be monitored using a pedometer.
45640386|NCT05915663|Other|nasogastric tube and orogastric tube|nasogastric tube in period 1 and orogastric tube in period 2
45640387|NCT05915663|Other|orogastric tube and nasogastric tube|orogastric tube in period 1 and nasogastric tube in period 2
45640388|NCT05915650|Behavioral|Pain Neuroscience Education|Carry out pain neuroscience education intervention for TKA patients
45640389|NCT05915650|Behavioral|Routine Education|Carry out routine education intervention for TKA patients
45640390|NCT05915624|Other|telephone counseiling|One day before the operation, information was given about the operation process via tele-nursing and counseling was provided.
45640391|NCT05915611|Other|Combined physical and psychological intervention|"Physical therapy components will include splinting, tendon and nerve gliding exercises.~Psychological components will include cognitive-behavioral therapy (CBT), delivered in individual sessions, targeting pain catastrophizing and fear of movement.~Participants will attend 2 physical therapy sessions and one CBT session per week. for a period of 12 weeks"
45640392|NCT05915611|Other|Standard care|Participants will be asked to wear a prefabricated wrist splint during the night and during strenuous activity. Also, they will receive tendon and nerve gliding exercises
45640393|NCT05915598|Other|Right/left discrimination training|"Participants will use recognize app by Neuro-orthopedic institute (NOI) for daily right/left discrimination training.~The training will include visual and auditory stimuli, with tasks such as identifying the laterality of images and sounds.~Participants will engage in training for 20 minutes per day, 5 days per week, over a six-week period.~Weekly monitoring and feedback will be provided by the research team"
45640394|NCT05915598|Other|usual care|"Usual care: Participants will continue their usual care management for fibromyalgia, including any prescribed medications and physician consultations. No specific right/left discrimination training will be provided to the control group.~Follow-up assessments: Participants in the control group will undergo the same follow-up assessments as the intervention group to evaluate changes in pain perception, functional disability, and cognitive function."
45640395|NCT05915585|Device|High-Intensity Laser Therapy|"The patient will receive HILT using the Mectronic Exand MY high-intensity laser system with the following parameters:~Wavelength: 1064 nm (near-infrared) Power: 12 W Energy density: 8 J/cm² Pulse duration: 200 µs Treatment duration: 10 minutes Frequency: 3 sessions per week for 4 weeks Total energy delivered: 96 J per treatment session"
45640396|NCT05915559|Procedure|Tonsillectomy|Tonsillectomy
45640397|NCT05915559|Other|daily follow-up|daily follow-up of clinical parameters (pain, feeding) and analgesia adapted to the pain
45640398|NCT05915546|Drug|Emraclidine|Tablets
45640399|NCT05915533|Other|Dance therapy|Before/after study to measure the effects of the dance therapy activity on the quality of life of the disabled adults housed in the establishments of UNIVI group.
45640400|NCT05915520|Behavioral|baduinjuin activities|in this 20-geriatric group will receive 5-session per-week 40-minute baduinjuin for 8 weeks plus the daily dose of pantoprazole (40 mg orally administered tablet drug)
45640401|NCT05915520|Other|pantoprazole|in this 20-geriatric group will receive the daily dose of pantoprazole (40 mg orally administered tablet drug for 8 weeks .
45640402|NCT05915507|Other|pranayama plus acupoint stimulation by laser|"This group will receive 3-session per-week laser stimulation (for eight weeks) to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for eight weeks) composed from (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama )"
45640403|NCT05915507|Other|acupoint stimulation by laser|This group will receive 3-session per-week laser stimulation (for eight weeks) to some selected acupoints, the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
45640404|NCT05915481|Drug|Cadonilimab|Participants will receive SBRT combined with Cadonilimab. Cadonilimab will be administered, 6mg/kg, twice a week, intravenous until disease progression or intolerable toxicities or death. The first cycle of Cadonilimab was started within 3 days before and after the first fraction of SBRT treatment.
45640405|NCT05915481|Radiation|Stereotactic body radiotherapy|Participants will receive SBRT to one lesion or more lesions.
45640406|NCT05915442|Drug|Quemliclustat|100mg IV once every two weeks
45640407|NCT05915442|Drug|Etrumadenant|150 mg orally (PO) once a day (QD)
45640408|NCT05915442|Drug|Zimberelimab|240 mg IV once every two weeks starting within 1 week of completing metastasis-directed SBRT
45640409|NCT05915442|Radiation|Stereotactic Body Radiation Therapy|Standard of care metastasis-directed hypofractionated radiotherapy treatment starting 4 weeks (+/- 1 week) of starting Etrumadenant and Quemliclustat
45915940|NCT00006477|Dietary Supplement|mistletoe extract|
45915941|NCT00006480|Biological|aldesleukin|
45915942|NCT00006480|Biological|therapeutic autologous lymphocytes|
45448604|NCT05668611|Other|Primary Screening Phase|"Following certification, the certified MOH nurses will integrate echocardiographic screening into the routine workflow at the 4 HCIII/IV clinics with each nurse carrying out screening at the assigned HC on patients (aged 5-40) presenting to the health center for routine care.~Screening will be done daily over a period of one month. A minimum total of 400 participants will be screened during this period; each nurse will screen as many patients as they can, with a minimum of 100 participants (at least 5 participants per day). At the end of each screen, the trainees will interpret the screen as screen negative or screen positive. They will go ahead to refer participants identified as screen positives to the district hospital (LRRH) for a confirmatory echo.~At the end of each screening day, all images will be uploaded to a cloud server for a confirmatory review by a cardiology fellow or cardiology attending physician, within in 1 - 2 weeks."
45778462|NCT05213442|Diagnostic Test|To estimate the prevalence rates of liver disease in psychiatric inpatients and to explore factors associated with the existence of liver disease.|"Patients will receive the usual clinical and paraclinical examinations as part of their hospitalization diagnostic workup. For the biological analyses, a blood sample will be taken following inclusion as well as a Fibroscan examination.~Data will be collected from the patient, or if necessary from the health care team, using the medical record (interview and/or self-questionnaires)."
45448605|NCT05668611|Other|Secondary Training Phase|Each Primary Trained MOH Nurse will train 3 other nurses from their Health Center using pre-recorded PowerPoints.
45448606|NCT05668611|Other|Secondary Assessment Phase|The secondarily trained nurses will be assessed and certified by the nurse trainer.
45640410|NCT05915416|Behavioral|Child Abuse and Neglect Prevention Program|The Child Abuse and Neglect Prevention Program was then revised in line with the opinions and suggestions of the experts. Power-point presentations and training booklet prepared for the final form of this program have been prepared in such a way that the content is exactly the same. Training booklet was distributed to the experiment group after the pre-test and to the control group after the re-test. This booklet is designed as a resource that participants can refer to whenever they need it. Trainings were provided online through the Google Meet application, in a total of four sessions with an average of 30 minutes per session. The contents of the trainings are child neglect, physical abuse, emotional abuse and sexual abuse, respectively. Four different power-point presentations, addressing these sub-dimensions, were prepared for training purposes.
45640411|NCT05915403|Diagnostic Test|Fibromyalgia Impact Questionnaire|diagnostic tests
45778463|NCT05300802|Drug|Placebo|50 ml of Ringer acetate will be added to the priming solution and followed by a continuous 50 ml infusion of Ringer acetate running at 25 ml/hour.
45778464|NCT05300802|Drug|Dexmedetomidine Hcl 100 Mcg/mL Inj|1 mcg/kg diluted DEX will be added to the priming solution and followed by a continuous infusion of 50 ml Ringer acetate running at 25 ml/hour.
45778465|NCT05300802|Drug|Dexmedetomidine Hcl 100 Mcg/mL Inj|0.5 mcg/kg DEX will be added to the priming solution and followed by a continuous infusion of 0.25 mcg/kg/hour DEX diluted in 50 ml of ringer acetate running at 25 ml/hour.
45778466|NCT05299476|Drug|CAPOX combined with bevacizumab and Tislelizumab|"Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 4-8 cycles; Capecitabine: oral administration, 2g/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Bevacizumab was administered intravenously (without prophylaxis) at 7.5mg/kg. The first infusion was 90min, the second infusion was 60min, and each infusion was 30 min. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years.~Tislelizumab is administered intravenously (without prophylaxis) at a fixed dose of 200mg. Each infusion was 30 min (no less than 20 min, no more than 60 min), and the drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years."
45778467|NCT00405938|Drug|Bevacizumab|Bevacizumab 10mg/kg IV every 2 weeks
45778468|NCT00405938|Drug|Anastrozole|anastrozole (1 mg orally daily)
45778469|NCT00405938|Drug|Fulvestrant|fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant).
45915943|NCT00006480|Drug|chemotherapy|
45915944|NCT00006480|Drug|ganciclovir|
45915945|NCT00006483|Biological|sargramostim|
45915946|NCT00006486|Drug|carboxyamidotriazole|Given orally
45915947|NCT00006486|Other|placebo|Given orally
45915948|NCT00006495|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
45915949|NCT00006495|Biological|HIV-1 Immunogen|
45915950|NCT00006501|Procedure|ECG|A diagnostic tool that is routinely used to assess the electrical and muscular functions of the heart (non-experimental).
45915951|NCT00006507|Behavioral|Occupational Therapy|
45915952|NCT00006516|Behavioral|Infant stimulation|
45915953|NCT00006519|Drug|Capravirine|
45598080|NCT02221193|Other|traditional mouth rinsing and site-specific mouth rinsing (crossover)|blinded prospective, descriptive correlational crossover cross-section clinical trial conduct during the month of Ramadan in the lunar Hajri year 1434 AH (10 July 2013-8 August 2013) in Albaha province in Saudi Arabia involving the application of Listerine® Cool Mint® mouth rinse by either the traditional panoral rinsing method or a site-specific disinfection method targeting the subgingival and supragingival plaque and the posterior third of the tongue dorsum while avoiding the remaining locations within the oral cavity
45598081|NCT03927261|Drug|PRGN-3006 T Cells|Participants will receive up to 2 intravenous (IV) administrations of PRGN-3006 T Cells with or without lymphodepletion and will be monitored for safety, efficacy, and correlative endpoints for up to 12 months following infusion.
45598082|NCT02209493|Behavioral|Food supplementation: nopales|Consumption of 2 cups/day of test food: nopales
45778470|NCT04239534|Device|Convergence Of Epicardial And Endocardial RF Ablation|The epicardial lesion pattern will be created using the EPi-Sense®-AF Guided Coagulation System with VisiTrax®. Epicardial linear lesions will be created endoscopically using the EPi-Sense-AF Guided Coagulation System with VisiTrax throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. An endocardial ablation catheter will be used to ablate endocardially to connect lesions at the reflections, complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter. Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi- Sense-AF Guided Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation.
45778471|NCT05299398|Drug|Trazodone|Trazodone capsule once daily
45778472|NCT05299398|Drug|Placebo|Placebo capsule once daily
45778473|NCT01793480|Drug|Methadone|
45448607|NCT05668611|Other|Secondary Screening Phase|"Following certification, the certified MOH nurses will integrate echocardiographic screening into the routine workflow at the 4 HCIII/IV clinics with each nurse carrying out screening at the assigned HC on patients (aged 5-40) presenting to the health center for routine care.~Screening will be done daily over a period of two months. A minimum total of 1200 participants will be screened during this period; each nurse will screen as many patients as they can, with a minimum of 100 participants. At the end of each screen, the trainees will interpret the study as screen negative or screen positive. They will go ahead to refer participants identified as screen positives to the district hospital (LRRH) for a confirmatory echo.~At the end of each screening day, all images will be uploaded to a cloud server for a confirmatory review by a cardiology fellow or cardiology attending physician, within in 1 - 2 weeks."
45448608|NCT03758560|Other|Pre-operative Nepali version of pain catastrophizing scale (PCS) questionnaire|Patients will be asked to complete the scores based Nepali version of pain catastrophizing scale (PCS) questionnaire preoperatively
45640412|NCT05915390|Dietary Supplement|walnuts|walnuts will provide 15% of the total energy
45640413|NCT05915390|Dietary Supplement|Habitual diet|continue with habitual diet and abstain from walnuts
45640414|NCT05915325|Procedure|Physical training|"Supervised Physical Training in SeniorGym for 12 weeks: 1) Aerobic exercise: Patient-tailored intensity-modulated ergometer training for the limbs; 2) Resistance exercise: Patient-tailored resistance exercise by Theraband for the limbs~Nutrition intervention for 24 weeks: Dietitian consultation, education and intervention for 24 weeks"
45640415|NCT05915299|Device|OCS Heart|"The TransMedics® OCS Heart System is a portable system available for ex-vivo maintenance of a donor heart in a metabolically active and beating state.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation."
45778474|NCT05299086|Drug|Intranasal Drug (INCS = Fluticasone furoate nasal spray, Placebo = Normal saline nasal spray)|The investigators want to compare the efficacy of intranasal corticosteroid between daily versus as needed use in children with perennial allergic rhinitis which had not been studied before.
45778475|NCT05285930|Combination Product|Bee venom phonophoresis|phonophoresis with Bee Venom gel in form of a noncontact low-frequency pulsed ultrasound delivered through Bee Venom gel as a topical treatment at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care. The performance of the ultrasound applicator was tested regularly before and after each patient exposure; each test included all relevant acoustic field parameters (pressure amplitude, frequency) and uniformity of the field distribution. This type of test of the acoustic output of the applicators was important to eliminate the possibility of any malfunctioning of the devices.
45778476|NCT05285930|Device|low intensity ultrasound|a noncontact low-frequency pulsed ultrasound delivered through plain gel only at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care.
45778477|NCT00407420|Device|Mandometer|A computerised device, Mandometer, providing real time feedback to participants during meals to slow down speed of eating and reduce total intake; standard lifestyle modification therapy.
45778478|NCT00407420|Behavioral|Lifestyle|Typical dietary and activity advice as normally provided in clinic (control).
45778479|NCT05299008|Drug|Bethanechol|Infants whom will be treated with bethanechol for tracheobronchomalacia in level IV center Neonatal Intensive Care Unit.
45778480|NCT05258526|Other|Home based exercise training|The intervention will be based on a remote approach, lasting 12 weeks. The training routine will consist of aerobic (walking), muscle strengthening and stretching exercises, with a frequency of three days per week. The contents related to the exercise prescription will be made available by phone call, text messages and short videos for exercise demonstration.
45778481|NCT05258292|Device|Continuous glucose monitoring|Glucose levels will be measured using continuous glucose monitoring
45778482|NCT05258292|Drug|Insulin|Insulin doses will be retrieved from insulin pump reports (for insulin pump users) or journals for (for multiple daily injections users)
45778483|NCT05258292|Other|Premenstrual symptoms|Premenstrual symptoms will be assessed using the Premenstrual symptoms screening tool
45778484|NCT05258292|Other|Ovulation kits|Ovulation testing will be done using ovulation kits
45778485|NCT05258292|Device|Fitbit Inspire 2|Physical activity will be assessed using the Fitbit Inspire 2
45778486|NCT05258292|Other|Keenoa|Food intake will be assessed using the Keenoa phone application
45778487|NCT05258292|Other|Menstrual cycle|The application My Calendar will be used to record information on the menstrual cycle
45778488|NCT00378326|Drug|Tacrolimus|Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone
45778489|NCT05256264|Drug|Ketamine|Ketamine infusion at different dose to observe EEG DSA changes
45448609|NCT03546868|Drug|[18F]FSPG|Patients will receive 200 MBq of [18F]FSPG and undergo PET/CT for assessing disease activity in inflammatory bowel disease
45448610|NCT03738813|Device|Gloreha Aria|Device offers specific programs that help patients to move arm, wrist and fingers
45448611|NCT03738813|Other|Usual care|Conventional occupational therapy
45915954|NCT00006591|Drug|Ritonavir|
45640416|NCT05915286|Drug|Furosemide|Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
45640417|NCT05915286|Drug|Chlorthalidone|Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
45640418|NCT05915273|Other|Computer Aided Design/ Computer Aided Manufacturing Retainers|Custom-bent fixed retainer wires from an in-office CAD/CAM system with FixR software and the BenderI machine (YOAT Corporation, Lynwood, WA). Dentaflex wires- round, 0.5mm in diameter, three-stranded Stainless Steel (Dentaurum GmbH & Co., Ispringen, Germany)- were used for the CAD/CAM group
45640419|NCT05915273|Other|Lab-based Retainers|The lab group used the same type of wire as the CAD/CAM group but was manually bent by a lab technician
45640420|NCT05915273|Other|Chairside Retainers|The chairside group used three-stranded Stainless Steel, 0.974mm x 0.402 mm, flexible Ortho-FlexTech wires (Reliance, Itasca, IL)
45640421|NCT05915260|Diagnostic Test|All subjects will undergo cardiac magnetic resonance imaging with gadolinium contrast and with adenosine myocardial perfusion|This is a observational follow up study accordingly all subjects will undergo the same examinations
45778490|NCT00379574|Drug|Bortezomib|"Bortezomib:~For phase I, 3 dose levels (1.0, 1.3 or 1.6 mg/m2), days 1 and 4, every 2 weeks.~For phase II, suggested dose of Bortezomib through phase I, days 1 and 4, every 2 weeks."
45778491|NCT00379574|Drug|Cyclophosphamide|cyclophosphamide 750mg/m2 day 1, every 2 weeks
45778492|NCT00379574|Drug|Doxorubicin|doxorubicin 50 mg/m2 day 1, every 2 weeks
45640422|NCT05915247|Drug|HER-096|Administered as a single dose via s.c. injection
45640423|NCT05915247|Drug|Placebo|Administered as a single dose via s.c. injection
45640424|NCT05915234|Device|Crushed ice|Each participant will receive two active devices and one sham comparator in a crossover design.The cryotherapy device used consists of an opaque bag with a plastic outer cover and an aluminum interior filled with 80 grams of crushed ice. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed to reduce skin temperature in ranges that decrease nerve conduction velocity and increase pain threshold.
45640425|NCT05915234|Device|Frozen peas|Each participant will receive two active devices and one sham comparator in a crossover design. The cryotherapy device used consists of an opaque bag with a plastic outer cover and an aluminum interior filled with 80 grams of frozen peas. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed to reduce skin temperature in ranges that decrease nerve conduction velocity and increase pain threshold.
45778493|NCT00379574|Drug|Vincristine|vincristine 1.4 mg/m2 (max. 2 mg) day 1, every 2 weeks
45778494|NCT00379574|Drug|Prednisolone|prednisolone 100 mg days 1-5, every 2 weeks
45778495|NCT00379574|Drug|Lenograstim|Lenograstim 5 microgram/kg subcutaneously days 4-13 every 2 weeks
45778496|NCT05256108|Drug|Oxycodone 40 mg|Participants will be administered a single dose of 6 capsules containing oxycodone and placebo in a randomized crossover manner
45778497|NCT05256108|Drug|Tramadol 600 mg|Participants will be administered a single dose of 6 capsules containing tramadol in a randomized crossover manner
45778498|NCT05256108|Drug|Placebo|Participants will be administered a single dose of 6 capsules containing placebo in a randomized crossover manner
45915955|NCT00006591|Drug|Amprenavir|
45915956|NCT00006630|Drug|Vaccinia Immune Globulin (Human)|
45640426|NCT05915234|Device|Room temperature gel|Each participant will receive two active devices and one sham comparator in a crossover design. The sham comparator device used consists of an opaque bag with an external plastic cover and an aluminum interior filled with 80 grams of ultrasound gel at room temperature. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed.
45640427|NCT05915221|Procedure|SMS|Receive SMS
45778499|NCT05256108|Drug|Cebranopadol 600 µg|Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
45778500|NCT05256108|Drug|Cebranopadol 1000 µg|Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
45778501|NCT05209776|Biological|Peripheral immunological assessment on venous blood|Peripheral immunological assessment carried out as part of the research, on venous blood at the puncture point necessary for the electrophysiological examination: 1 heparin tube and 1 EDTA tube
45778502|NCT05209776|Biological|Immunological assessment carried out on intracardiac material|Immunological assessment carried out as part of the research, on intracardiac material taken during the electrophysiological examination: 1 EDTA tube
45778503|NCT00407654|Drug|aflibercept|Given intravenously
45915957|NCT00006669|Biological|rituximab|
45915958|NCT00006669|Biological|sargramostim|
45915959|NCT00006669|Drug|EPOCH regimen|
45915960|NCT00006669|Drug|cyclophosphamide|
45778504|NCT05484492|Biological|demineralized and mineralized combination putty bone allograft|Subjects in this group will receive an intrasocket demineralized and mineralized combination putty bone allograft following tooth extraction
45778505|NCT05484492|Biological|calcium phosphosilicate putty alloplast graft|Subjects in this group will receive an intrasocket synthetic resorbable calcium phosphosilicate putty alloplast graft following tooth extraction
45915961|NCT00006669|Drug|doxorubicin hydrochloride|
45915962|NCT00006669|Drug|etoposide|
45915963|NCT00006669|Drug|prednisone|
45915964|NCT00006669|Drug|vincristine sulfate|
45915965|NCT00006708|Biological|filgrastim|5 μg/kg/day subcutaneous injection on Days 5-12 every 21 days for 3 cycles.
45915966|NCT00006708|Biological|rituximab|
45915967|NCT00006708|Drug|carboplatin|
45915968|NCT00006708|Drug|etoposide|
45915969|NCT00006708|Drug|ifosfamide|
45915970|NCT00006747|Drug|carmustine|IV
45915971|NCT00006747|Drug|melphalan|IV
45915972|NCT00006747|Drug|etoposide|IV
45915973|NCT00006747|Drug|cytarabine|IV
45640428|NCT05915195|Other|Postural and Kinesthetic Awarness|Firstly, patient performed therapeutic activities/exercise to achieve balance in sitting position using chair with arm rest and with planted feet then progressed to sitting on chair without arm rest with proper feet placement. Once the patient achieved balance in sitting on chair then shifted to sitting on the stool and later standing in parallel bar that leads to balance training in independent standing.
45640429|NCT05915195|Other|Routine Physical Therapy|Range of motion exercises (Active assisted), stretching exercises, strengthening and positioning.
45640430|NCT05915182|Combination Product|Budesonide Glycopyrronium bromide Formoterol fumarate pressurized Metered Dose Inhaler|Participants with moderate to severe Chronic Obstructive Pulmonary Disease
45640431|NCT05915169|Other|Topical haemoglobin wound care spray|It is a wound care spray used in the care of chronic wounds.
45640432|NCT05915156|Other|Post-acute home physiotherapy program|This health services research assessed the effects of a post-acute home physiotherapy program that was designed to provide physical rehabilitation services to older adults recently discharged from acute or post-acute care. Under this program, every patient was attended by a physiotherapy technologist within 48 hours of being discharged and received home physiotherapy for a minimum of three days per week for a maximum of eight weeks.
45640433|NCT05915130|Behavioral|Gait training|They will negotiate (natural or virtual) obstacles such as avoiding a rock or crossing over a tree root, thus improving their gait adaptability capacities.
45640434|NCT05915117|Dietary Supplement|Polyphenols of pomegranate fruit peel extract (PoPex)|PoPex in form of capsule will be orally administered in total daily dose of 500/mg in subjects with metabolic syndrome and obesity over 8 weeks.
45640435|NCT05915117|Drug|Placebo|Placebo in form of capsule will be orally administered in subjects with metabolic syndrome and obesity over 8 weeks.
45640436|NCT05915104|Drug|Budesonide MMX®|9 mg delayed and extended-release tablet once daily
45640437|NCT05915104|Drug|Budesonide controlled ileal release (CR) capsules|three 3 mg capsules daily oral administration for 8 weeks
45640438|NCT05915091|Diagnostic Test|Dry Needling|Dry needling is a treatment that healthcare providers use for pain and movement issues associated with myofascial trigger points. With this technique, a provider inserts thin needles into or near your trigger points. The needles stimulate your muscles, which causes them to contract or twitch
45640439|NCT05915091|Other|Cross Friction Massage|Cross friction massage breaks down scar tissue and remodels the tissue into more flexible, pliable, and functional, healthy soft tissue. Also known as transverse friction massage, this technique is a deep tissue massage technique performed at the site of injury
45640440|NCT05915078|Combination Product|Iontophoresis and tube placement|Iontophoretic delivery of TYMBION™ otic anesthetic using the Tula Iontophoresis System and tube insertion using the Tula Tube Delivery System
45640441|NCT05915065|Device|Coapt Phantom Limb Pain Management System|The PLP-MS consists of (1) an expandable arm/leg cuff with electrode sensors to collect EMG signals from residual limb muscles, (2) an integrated hardware module (the Coapt Complete Control Gen2.5 system) that translates users' EMG signals into game commands, (3) game software for mobile applications, and (4) a secure, HIPAA-compliant cloud-based data storage system for storing and retrieving user data remotely.
45640442|NCT05915052|Procedure|B-type suture ileostomy|Type B suture stoma group：2-0 stitched sutures were placed in the center of the incision, from the anterior rectus sheath on the left side of the incision → the posterior rectus sheath on the left side of the incision → through the avascular area below the vascular arch at the mesenteric border of the ileum to the contralateral side → the posterior rectus sheath on the right side of the incision → the anterior rectus sheath on the right side of the incision→ the posterior rectus sheath on the right side of the incision → through the avascular area below the vascular arch at the mesenteric border of the ileum to the contralateral side → the posterior rectus sheath on the left side of the incision →the anterior rectus sheath on the left side of the incision sutures were sewn through in the sequence, tightened and knotted .
45640443|NCT05915052|Procedure|the traditional ileostomy|Then take the right lower abdominal incision to cut a circular incision of 3 cm in diameter, round excision of subcutaneous fat, cross incision of rectus sheath and peritoneum, enter the abdomen, raise the marked ileum out of the body, interrupt suture of ileum with peritoneum and posterior sheath of rectus abdominis for one week, then interrupt suture of ileum with anterior sheath of rectus abdominis for one week, transverse incision of 2 cm in diameter, interrupted with 3-0 absorbable thread, The ileocecal incision and the skin of the right lower abdominal circular incision were sutured for one week to complete the double-lumen stoma at the end of the ileum.
45640444|NCT05915026|Drug|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
45640445|NCT05915013|Drug|Ketamine|Intravenous ketamine
45640446|NCT05915013|Drug|Perampanel|Oral perampanel (6 mg)
45640447|NCT05915013|Drug|Placebo|Oral placebo
45640448|NCT05915000|Diagnostic Test|Lumbar CSF protein marker determination|The cerebrospinal fluid levels of the Aβ1-42 amyloid, h-tau and phospho-tau proteins will be assessed. The response of patients to the possible implantation of a ventricular peritoneal shunt will be assessed through neuropsychological, gait and ventricular size studies assessed through cerebral magnetic resonance studies.
45640449|NCT05914987|Other|Targeted Therapy|Approved interventions based on the subject's genomic profile will be provided to investigators for consideration for ant-tumor therapy.
45640450|NCT05914948|Device|Medtronic 8-contact Vectris subcompact or compact electrode.|Subjects meeting study eligibility criteria will be implanted with a Medtronic 8-contact Vectris subcompact or compact electrode.
45640451|NCT05914935|Drug|Recombinant L-IFN adenovirus injection|The Ommaya reservoir was surgically implanted, and multiple intracapsular injections were given medicine. On the second day after Ommaya reservoir implantation, CT examination confirmed that the implantation was successful, and the experimental drug injection was started.
45915974|NCT00006747|Drug|tacrolimus|IV
45915975|NCT00006747|Drug|methotrexate|IV
45598083|NCT02209493|Behavioral|Food supplementation: cucumber|Consumption of 2 cups/day of test food: cucumber
45598084|NCT02365779|Procedure|bilateral laparoscopic salpingectomy|Use of the confocal laser endomicroscopy Cellvizio® system during laparoscopy salpingectomy
45598085|NCT02365779|Device|endomicroscopy Cellvizio® system|
45598086|NCT02221271|Drug|NPB-01|
45598087|NCT02205671|Behavioral|Building Better Caregivers Small-group Workshop|
45640452|NCT05914922|Other|Educational Tool|20 MSK short case simulations were developed based on authentic patient experiences. Strategies to optimize learning of MSK conditions to prepare learners for real-world clinical encounters would be important for family medicine resident learners. To address this need, 20 case simulations of 15 minute duration were developed. This study will determine if an online educational tool may be impactful for determining competency of family medicine resident learners in developing skills and knowledge of 20 MSK conditions while also determining if the tool impacts patient care and satisfaction.
45640453|NCT05914909|Biological|AD-214|AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.
45448612|NCT03993106|Drug|sEphB4-HSA|sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
45640454|NCT05914909|Other|Placebo|Placebo
45448613|NCT03738735|Drug|Hypertonic saline|For the intervention group, the surgical staff will add 120 mL of 23.4% saline to the 3L bags of lactated Ringer's solution, and this new solution will be used for arthroscopic irrigation purposes throughout the rotator cuff repair surgery.
45640455|NCT05914896|Drug|HighOsmo|This group received a priming solution with high osmolality
45640456|NCT05914883|Diagnostic Test|Long-term continuous ECG monitoring|Long-term continuous ECG monitoring with ECG247 Smart Heart Sensor
45640457|NCT05914870|Other|Multi-component training|"The multicomponent training group will perform 60 minutes of training per session:~10 minutes of joint mobility exercises and dynamic stretching.~20 minutes of strength work with 2 exercises; the first, bench press, at an intensity of 50% of your 1RM. The number of repetitions will be individualised for each subject by testing the loss of speed in the series with respect to the first repetition (15% loss); the second, the squat, at an intensity of 60% of your 1RM. The number of repetitions shall be individualised for each subject by means of the loss of speed test in the series with respect to the first repetition (10% loss). The rest between sets will be 3 minutes.~20 minutes of continuous cardiovascular work. The intensity will be increased every 4 weeks, from week 1 to 4 between 55%-65%FCR or VO2peak, from week 5 to 8 between 65%-%75%FCR or VO2peak and from week 9 to 12 between 75%-%85%FCR or VO2peak.~10 minutes of cool down and static stretching."
45640458|NCT05914870|Other|Continuous Cardiovascular Training|"The Continuous Cardiovascular Training group will perform 60 minutes of training per session distributed as follows:~Preparatory Phase: 10 minutes of standardised warm-up with joint mobility exercises and dynamic stretching.~Main Training Phase:~In this phase we will work 40 minutes of continuous aerobic exercise, maintaining the same intensity range throughout the session. We will increase the intensity every 4 weeks, from 1 to 4 you will work between 55%-65%FCR or VO2peak, from 5 to 8 between 65%-%75%FCR or VO2peak and from 9 to 12 between 75%-%85%FCR or VO2peak.~Post-training phase: 10' cool down and static stretching."
45640459|NCT05914857|Drug|Dapagliflozin 10mg Tab|Dapagliflozin Tablets, Oral, 10mg, Once daily
45640460|NCT05914857|Behavioral|lifestyle interventions|Consisting of 30 minutes of moderate-intensity exercise every day and a reduction of 300 calories in the total diet
45640461|NCT05914831|Radiation|Ultra-fractionated radiation therapy|An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the whole breast or the part of the breast where the tumor was located.
45640462|NCT05914818|Device|EXPLORER V2|4 sessions of use of the exoskeleton, 1 in a laboratory of gait analysis and 3 in the home and the community of the participants
45640463|NCT05914805|Drug|Clascoterone 5% solution|Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)
45640464|NCT05914805|Drug|Vehicle solution|Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)
45640465|NCT05914779|Other|No use of antibiotics|Subjects will be randomized into antibiotics and no antibiotics groups based on inclusion and exclusion criteria
45640466|NCT05914779|Other|with antibiotics treatment|with antibiotics treatment
45640467|NCT05914753|Drug|Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; Xihuang Pill：3g po bid，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W；Xihuang Pill：3g po bid，4 cycles
45640468|NCT05914753|Drug|Epirubicin, Cyclophosphamide, Docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W，4 cycles
45640469|NCT05914740|Procedure|Ultrasound guided functional remodeling of lower extremity superficial vein valve|Preoperative ultrasound was used to re-evaluate and confirm the valve function, disinfect the tissue, inject hyaluronic acid around the great saphenous vein valve to reshape the valve about 1-2ml, monitor the whole process under ultrasound, pump back for protection during injection, and inject multiple times at different points.
45640470|NCT05914727|Diagnostic Test|eNose|Collection of breath profile with eNose
45640471|NCT05914727|Diagnostic Test|Volatile exhaled breath sample|Collection of exhaled breath in Tedlar bag
45640472|NCT05914727|Diagnostic Test|Condensate sample|Collection of exhaled breath condensate with EcoScreen
45640473|NCT05914714|Drug|Ruxolitinib 5 MG BID Oral Tablet|ruxolitinib 5mgBID will be administrated at the beginning of the conditioning regimen until 3 months post-transplantation.
45640474|NCT05914701|Drug|Letermovir for secondary prophylaxis|For enrolled patients, Letermovir would be administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). The regimen duration of dosing was approximately 120 days or 16 weeks. Or physicians could adjust regimen duration according to the CMV infection risk factors.
45640475|NCT05914688|Drug|LY3209590 (Formulation 1)|Administered SC.
45640476|NCT05914688|Drug|LY3209590 (Formulation 2)|Administered SC.
45448614|NCT03734367|Behavioral|Emotional abilities training program|A randomized controlled trial that evaluates the effectiveness of a program of emotional skills on metabolic control to be assessed through the glycosylated hemoglobin (HbA1c), healthy lifestyle habits and wellbeing in adolescents with type 1, Diabetes Mellitus
45448615|NCT03734133|Other|Foot insoles|Different foot insoles of different hardness
45640477|NCT05914675|Drug|Letermovir|For enrolled patients, Letermovir would be administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). The regimen would start between +7~+14d after transplantation. The total duration of dosing was approximately 100 days or 14 weeks.
45915976|NCT00006747|Drug|sargramostim|IV
45915977|NCT00006747|Procedure|transplant|
45915978|NCT00006786|Biological|bevacizumab|
45778506|NCT05261048|Other|Pelvic Proprioceptive neuromuscular facilitation in addition to Conventional Physical Therapy|"The experimental group received both conventional and Pelvic PNF for 30 minutes each, once in a day, 4 days per week. The experimental group will be given anterior elevation-Posterior depression pattern with the techniques of Rhythmic initiation, Slow reversal and Stabilizing reversal. These techniques will be given on affected side for total 30 minutes with 15 minutes of pelvic PNF in one session with rest periods in between. Participants will be positioned into side lying with both hip flexion 1000 and knee flexion 450, neck supported by a pillow with flexion of 300. Hand placement for anterior elevation over the crest of the ilium one hand overlaps other for posterior depression heel of the one hand hold with other hand on the ischial tuberosity.~Pull up and Push down command will be given along with the techniques of rhythmic initiation, slow reversal and stabilizing reversal."
45778507|NCT05261048|Other|Conventional Physical Therapy|"Conventional physiotherapy will be asked to perform truncal exercises in spine and sitting position for total 30 minutes including rest periods in between, once in a day for 4 days per week.~Exercises in supine position included (pelvic bridging, unilateral pelvic bridging, upper trunk rotation (clasped hand), lower trunk rotation (crook lying) with 3 repetitions for each exercise.~In sitting position, exercises included flexion and extension of lower trunk, rotation of upper and lower trunk, forward and lateral reach with 3 repetitions for each exercise."
45778508|NCT05260580|Other|No Intervention: Routine care|
45778509|NCT00407888|Drug|doxorubicin hydrochloride|Given IV
45778510|NCT00407888|Drug|cyclophosphamide|Given orally
45778511|NCT00407888|Biological|filgrastim|Given SC
45640478|NCT05914662|Drug|Zanubrutinib, Bendamustine and Rituximab|Zanubrutinib, 160mg orally, twice a day; Bendamustine 70 mg/m2 on days 1 and 2 of each cycle; Rituximab (375 mg/m2 intravenously on day 0 of each cycle. ZBR was administered every 4 weeks for a total of 6 cycles, followed by maintenance therapy with zanubrutinib monotherapy for another 6 months.
45640479|NCT05914623|Procedure|Repetitive transcranial magnetic stimulation|After enrollment, the patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).
45640480|NCT05914623|Procedure|Sham repetitive transcranial magnetic stimulation|After enrollment, the patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.
45640481|NCT05914610|Drug|Envolimab|Envolizumab 300mg, D1, ih, Q3W 4-6cycles
45640482|NCT05914610|Drug|Fuquinitinib|Fuquinitinib 3mg/d, QD, PO, D1-D14, Q3W 4-6cycles
45778512|NCT00407888|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
45778513|NCT00407888|Biological|trastuzumab|Given IV
45778514|NCT00407888|Other|laboratory biomarker analysis|Correlative studies
45778515|NCT00407888|Procedure|quality-of-life assessment|Ancillary studies
45778516|NCT05208684|Other|Breast stimulation|Breast stimulation by the Elvie Pump to trigger prolactin release.
45778517|NCT05208606|Behavioral|Wawokiya Health Advocate|"Study visits 1 and 2 will follow the same broad procedures. Subsequent visits will be structured around needs. WHAs will cover multiple domains of assessment utilizing a visit guide.~Visit 1: Specific topics covered in this visit will include; 1) an explanation of palliative care, study, and WHA role and 2) mapping of providers/family/caregivers The WHA will arrange dates and times for future visits.~Visit 2: Occurs 1 week after the first visit. WHAs will begin to assess patient needs utilizing a needs assessment tool. Specific topics covered will include: 1) Documentation of disease history 2) Needs assessment screen~Following Visits: After visit 2, activities will be based on needs assessed. Activities may entail: 1) Review of palliative care and WHA role, 2) Assessment of needs, 3) Addressing needs 3) Exploring goals of care.~We anticipate patients will receive an average of 2-3 WHA visits per month. Investigators will hold regular supervisory meetings with the WHA."
45448616|NCT03738657|Other|Olfactory screening|Therefore prior to gustatory testing, patients will be screened and assessed as having either normal or abnormal olfactory function using the Sniffin' Sticks (Burghart; Wedel, Germany). The test consists of 12 odour pens which represent every-day odours (peppermint, fish, coffee, banana, orange, rose, lemon, pineapple, cinnamon, cloves, leather and liquorice). Patients are presented with an odour and select the perceived smell using a multiple-forced-choice method.
45448617|NCT03738657|Other|Quantative Gustatory Testing using Taste Strips|"Following screening for olfactory function, whole mouth gustatory function will be assessed using validated taste strips (Burghart; Wedel, Germany). Filter paper test strips are impregnated at one end with 2cm2 of either sweet, sour, salty or bitter taste solutions in four concentrations. In a pseudo-randomised sequence, individual strips will be placed on the tongue and patients will be asked to close their mouth in order to assess whole mouth function. Through a forced-choice procedure patients will be asked to identify the taste stimuli. Scores for individual taste qualities will range from 0-4 and an overall taste score will range from 0-16.~Patients will rinse their mouth with tap water prior the application of each taste strip."
45915979|NCT00006786|Drug|fluorouracil|
45448618|NCT03983980|Drug|Tapinarof|Tapinarof cream, 1%, applied once daily
45448619|NCT03983980|Drug|Vehicle Cream|Vehicle cream applied once daily
45915980|NCT00006786|Drug|irinotecan hydrochloride|
45915981|NCT00006786|Drug|leucovorin calcium|
45640483|NCT05914610|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2, ivgtt 0-2h, D1, Q3W 4-6cycles
45640484|NCT05914610|Drug|Tegafur|Tegafur was calculated according to body surface area , P.O., bid, d1-d14#And the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time Q3W 4-6cycles
45640485|NCT05914597|Other|Setting up home delivery of Colon capsule endoscopy|Feasibility study of home delivery of CCE
45640486|NCT05914584|Drug|Baricitinib 4 MG|Reference drug
45778518|NCT00407966|Drug|alvocidib|Given IV
45778519|NCT00407966|Drug|cytarabine|Given IV
45778520|NCT00407966|Drug|mitoxantrone hydrochloride|Given IV
45915982|NCT00006825|Biological|trastuzumab|
45915983|NCT00006825|Drug|pegylated liposomal doxorubicin hydrochloride|
45915984|NCT00006864|Biological|aldesleukin|
45915985|NCT00006942|Drug|bryostatin 1|Given IV
45915986|NCT00006942|Drug|cisplatin|Given IV
45915987|NCT00006942|Other|laboratory biomarker analysis|Correlative studies
45640487|NCT05914558|Diagnostic Test|Clinical appointment|One clinical interview and examination to confirm the diagnosis of trigeminal neuralgia and temporomandibular disorder.
45778521|NCT00408200|Drug|propafenone; flecainide; sotalol; dofetilide|Above drugs prescribed per established guidelines for treatment of AF
45640488|NCT05914545|Drug|FZ-AD004|"Dose Escalation：Subjects will receive an intravenous infusion of FZ-AD004 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.~Dose Expansion：Subject will receive a single dose of FZ-AD004 at 1-2 dose level on Day1 of each cycles."
45640489|NCT05914532|Other|lab testing|Complete blood count and erythrocyte sedimentation rate and C-reactive protein values of the participants were analyzed by laboratory test.
45640490|NCT05914519|Procedure|Ejaculatory Preserving Transurethral resection of prostate|Transurethral resection of prostate with preservation of 1cm safety area above verumontanum and without paracollicular digging
45640491|NCT05914519|Procedure|Standard Transurethral Resection of prostate|Transurethral resection of prostate including whole adenoma till the capsule.
45778522|NCT00408200|Device|Radiofrequency catheter ablation|A special catheter that delivers radiofrequency (heat) energy is advanced into the heart and used to destroy small areas of heart tissue responsible for causing atrial fibrillation. All catheters / devices used in the study are FDA approved for human use and currently being used to perform the AF ablation procedure in the United Sates.
45778523|NCT05255406|Drug|Furmonertinib (160mg)|160mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (80mg).
45778524|NCT05255328|Dietary Supplement|Glutamine oral supplement|12-18 g /day of glutamine supplementation
45778525|NCT05250050|Drug|Esomeprazole|20mg bid
45778526|NCT05250050|Drug|Bismuth potassium citrate|0.6g bid
45778527|NCT05250050|Drug|Metronidazole|0.4g qid
45778528|NCT05250050|Drug|Clarithromycin|0.5g bid
45778529|NCT05250050|Drug|Levofloxacin|0.5g qd
45778530|NCT05250050|Drug|Amoxicillin|1g bid
45778531|NCT05250050|Drug|Tetracycline|0.5g qid
45778532|NCT05500248|Behavioral|Leave In Situ|"Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.~This behaviour is recommended by guidelines if the endoscopist is expert in optical diagnosis. In this case the endoscopists will be experts and they will also be helped by the CADx system that has shown to exceed the thresholds requested for use in clinical practice in previous trials."
45778533|NCT05500248|Behavioral|Standard|All identified polyps will be removed and sent to pathology.
45915988|NCT02972580|Genetic|Genetic characterization|Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts
45778534|NCT05499390|Drug|AK112|Subjects receive AK112 intravenously.
45640492|NCT05914493|Other|The effect of posture on cognitive function in early adolescence athletes|"Posture evaluation:~The form of Corbin et al. will be applied.~Evaluation of cognitive functions:~Basically, the Stroop test will be used, which evaluates the concentration and maintenance of attention depending on time and the task given."
45640493|NCT05914467|Drug|Teicoplanin|Dose will be adjusted in the study arm using MIPD guided TDM- dosing
45640494|NCT05914454|Drug|Anakinra 100Mg/0.67Ml Inj Syringe|anakinra 100 mg per day for 14 days
45640495|NCT05914441|Other|Standard clinical practice|The study will be carried out in the context of the usual clinical practice conditions, not imposing restrictions on the participating physician or influencing their normal clinical practice.
45778535|NCT05499390|Drug|Pembrolizumab|Subjects receive Pembrolizumab intravenously.
45778536|NCT05294328|Drug|Aceclidine+Brimonidine combination ophthalmic solution|Ophthalmic Solution
45778537|NCT05294328|Drug|Aceclidine ophthalmic solution|Ophthalmic Solution
45778538|NCT05294328|Drug|Vehicle Proprietary Ophthalmic Solution|Ophthalmic Solution
45778539|NCT05204238|Diagnostic Test|Transthoracic Echocardiography|LV dimensions, LV mass and indices of LV function LA area and volume Indices of diastolic function (E/A ratio, E/e' ratio) Heart valve assessment according to GL RV dimensions and indices of RV function PAPs (RV-RA gradient and vena cava dimensions and collapsibility) B-lines at lung ultrasounds (comet lung score) Speckle Tracking analysis of LV (GLS), LA (PALS) and RV (LS of free wall) Optional 3D analysis of left and right ventricle
45778540|NCT01657032|Dietary Supplement|Smectite|Eligible children received smectite (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
45778541|NCT01657032|Dietary Supplement|Placebo|Eligible children received placebo: glucose (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
45778542|NCT01657032|Dietary Supplement|Lactobacillus GG|All children received LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days with placebo or smectite
45778543|NCT05254236|Biological|COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose)|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
45778544|NCT05254236|Biological|COVID-19 Vaccine (Vero Cell), Inactivated (High-dose)|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
45778545|NCT05202912|Drug|IDX-1197(After a meal)|randomized, open-label, single-dose, 2-period, 2-sequence crossover study in healthy male Korean and Caucasian volunteers
45778546|NCT05202912|Drug|IDX-1197(fasting)|open-label, single-dose study in Chinese male volunteers
45778547|NCT05292690|Device|Powered Wheelchair Obstacle Alerting System|Evaluation of an Obstacle Alerting System
45778548|NCT00408590|Biological|carcinoembryonic antigen-expressing measles virus|
45640496|NCT05914428|Other|ALDH2 rs671 mutation|We selected blood samples from sepsis patients from the biological bank of Qilu hospital and tested their genotypes. The intervention group was ALDH2 rs671 mutation patients
45778549|NCT00408590|Biological|oncolytic measles virus encoding thyroidal sodium iodide symporter|
45915989|NCT00006981|Biological|SS1(dsFv)-PE38 immunotoxin|
45915990|NCT00007059|Drug|mycophenolate mofetil|
45778550|NCT00408590|Genetic|reverse transcriptase-polymerase chain reaction|
45778551|NCT00408590|Other|laboratory biomarker analysis|
45778552|NCT05250960|Device|SCD|Patient will receive 1L of LR and have SCDs applied 15 minutes before epidural placement and will be removed 1 hour after epidural placement
45778553|NCT05292222|Device|Intermittent theta burst stimulation|MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
45778554|NCT05250648|Drug|complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes|In the arm with HIPEC, this will be performed with Mytomicin C, at a dose of 35 mg/m2 in peritoneal dialysis solution (2 liter/m2) for 90 minutes, with dose fractionation: 50% min 0, 25% min 30, 25% min 60
45778555|NCT05250648|Procedure|complete cytoreductive surgery without HIPEC|in the arm without HIPEC, only complete cytoreductive surgery will be performed
45778556|NCT00382148|Drug|omalizumab|SC repeating dose
45778557|NCT02111252|Drug|TAK-850|TAK-850 injection
45778558|NCT05292066|Drug|Duloxetine Tablets,|"Duloxetine is an FDA-approved medication used to treat the major depressive disorder, generalized anxiety disorder, fibromyalgia, and neuropathic pain. It is taken by mouth. It is a serotonin-norepinephrine reuptake inhibitor.~Pregabalin is an FDA approved, sold under the brand name Lyrica. it is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome,"
45778559|NCT05292066|Drug|Pregabalin Tablets|Pregabalin is an FDA approved, it is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome,
45778560|NCT05199948|Other|Soybean Oil Foods|Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day
45778561|NCT05199948|Other|Palm Oil Foods|Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
45778562|NCT04270994|Drug|Misoprostol|
45778563|NCT05249868|Other|Exposure SARS-CoV-2 Infection|"The exposure variable is confirmed SARS-CoV-2 infection with diagnosis after 11 May 2020.~Positive confirmatory test on nucleic acid amplification (rRT-PCR) or having had symptoms for <5 days is positive on a PRAg test."
45778564|NCT05495490|Procedure|Osseodensification Internal Sinus Lift|"The osteotomy for the Osseodensification internal sinus lift begins with the advancement of a twist drill at 800 rpm and saline irrigation to within 1-2 mm of the sinus floor. The osteotomy is then widened by employing a series of osteotomy drills rotating at 800 rpm. Infracture of the sinus has occurred when the final osteotomy drill is advanced with gentle pressure at 100 rpm counterclockwise without irrigation until a bouncing sensation (haptic feedback) occurs. After infracture, the graft material will be injected into the osteotomy site. Using the final osteotomy drill, the graft is guided apically. This procedure is repeated incrementally to raise the membrane. Once sufficient space has been created beneath the antral membrane, the implant will be inserted followed by suturing."
45778565|NCT05495490|Procedure|Osteotome Internal Sinus Lift|"The osteotomy for the Osteotome internal sinus lift will begin with standard drills and saline irrigation to prepare the implant socket with a working length that is 1-2 mm shorter than the residual bone height as determined by radiographic examination. After preparation, a series of osteotomes of varying diameters will be sequentially utilized to widen the osteotomy and elevate the Schneiderian membrane by vertical tapping to create a greenstick fracture. The Valsalva maneuver (nasal blowing test) will be performed to determine the integrity of the Schneiderian membrane. During the osteotomy, the graft material will be injected and slowly placed into the elevated space using osteotomes until the desired depth is reached. Implant placement and suturing will conclude the procedure."
45915991|NCT02972541|Device|Stenting with neoadjuvant chemotherapy|After clinical success of colonic stenting, patients will be given neoadjuvant chemotherapy. Surgery is performed after 3 cycles of mFOLFOX6 or 2 cycles of CapeOx. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 5-9 cycles of mFOLFOX6 or 4-6 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
45640497|NCT05914415|Other|Supportive care and education before surgery|we will give supportive and informative education before surgery in order to increase patient' recovery rates
45640498|NCT05914402|Procedure|axillary surgery de-escalation after NAT|the process of axillary surgical evaluation will be spared after NAT using the prediction model if the probability is more than 90%.
45915992|NCT02972541|Device|Stenting with immediate Surgery|After clinical success of colonic stenting, patients will undergo surgery 7-14 days later. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 8-12 cycles of mFOLFOX6 or 6-8 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
45915993|NCT02109523|Behavioral|Motivational Interviewing (MI|Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.
45640499|NCT05914389|Drug|Oxaliplatin|Oxaliplatin 130mg/m2 for inducing chemotherapy on Day 1 every 3 weeks and repeat for 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.
45778566|NCT05291832|Other|Brain.fm Music|Experimental arm
45778567|NCT05291832|Other|Spectrally-matched Noise|Active control arm
45778568|NCT02111798|Drug|Placebo|Participants will be randomly assigned to receive placebo powder in twice-daily capsules at the end of week 2.
45778569|NCT02111798|Drug|Bupropion XL|Participants will be randomly assigned to receive bupropion XL 150mg/day in twice-daily capsules at the end of week 2.
45778570|NCT02111798|Behavioral|Abstinence Initiation|Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who do not provide 3 urine samples that test negative for cocaine by the end of week 6 will be assigned to an Abstinence Incentive condition.
45640500|NCT05914389|Drug|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.
45640501|NCT05914389|Drug|Anti-PD-L1 Monoclonal Antibody|The incidence of adverse events with Anti-PD-L1 Monoclonal Antibodies is relatively low. Based on phase I clinical trial data of Envafolimab, a dose reduction design was conducted to minimize the incidence of adverse events while ensuring therapeutic efficacy. In the two cohorts of the efficacy-enhancing design, a reduced dose of 100mg/0.5ml IH QW will be used for 6 weeks. The PD-L1 monoclonal antibody (Envafolimab) dose adjustment was implemented according to the prescribing information.
45640502|NCT05914389|Drug|Clostridium butyricum|Clostridium butyricum is treated with Miyarisan 588 powder, 160mg/day (4 packets/day) taken orally for a total of 6 weeks.There have been no reports of adverse reactions for Lactobacillus. There is no predetermined reduction plan.
45640503|NCT05914389|Procedure|Colectomy|The specific surgical approach, whether it be laparoscopic or open surgery, is determined by the surgeon. The tumor blood supply is ligated and cut at the root of the mesentery, and the margin of resection should be no less than 10cm. Complete resection of the mesocolon (CME) is performed in conjunction.
45640504|NCT05914376|Biological|Recombinant human IL-21 oncolytic vaccinia virus injection|hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.
45640505|NCT05914363|Other|Sealed washable floor plus behaviour change|Replacement of rudimentary floors with a cement stabilised floor in all rooms in the dwelling, combined with support for behaviour change through 'floor clubs'.
45640506|NCT05914350|Procedure|ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis|ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis
45640507|NCT05914350|Drug|methylprednisolone acetate and lidocaine|40 mg methylprednisolone acetate and 1 mL lidocaine
45640508|NCT05914350|Drug|PRP and lidocaine|3 mL PRP and 1 mL lidocaine
45778571|NCT02111798|Behavioral|Relapse Prevention|Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who provide 3 urine samples that test negative for cocaine will be promptly assigned to a Relapse Prevention incentive condition.
45915994|NCT02109523|Behavioral|volitional intervention|Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.
45915995|NCT02109523|Behavioral|Routine discharge counseling|
45915996|NCT01955356|Procedure|Scratching|Endometrial biopsy
45915997|NCT00387556|Drug|Ondansetron|ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
45640509|NCT05914350|Drug|medical ozone|10 ml of medical ozone
45640510|NCT05914337|Behavioral|exercise|A program consisting of strengthening and stretching exercises 2 days a week was applied to the study group for 8 weeks. One day a week, 30 minutes of mild moderate walking was requested.
45640511|NCT05914337|Biological|gene expressions of miRNA|In the samples taken, gene expressions of miRNA-146a, miRNA-155, miRNA-16, miRNA-145 were determined by real-time polymerase chain reaction method.
45915998|NCT03780790|Drug|Bupivacaine|% 0,25
45915999|NCT04712227|Other|intubation|intubation
45916000|NCT04712227|Other|mask ventilation|mask ventilation
45916001|NCT01742143|Behavioral|The Integrated Cancer Care Access Network (ICCAN)|"Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.~Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance."
45640512|NCT05914324|Device|Phefumla device|The Phefumla device uses the Motorola Moto G Power mobile phone. The device utilizes an Android 10 operating system and has 64 gigabyte memory with 4 gigabyte random access memory (RAM). The battery is a 5000 milliampere lithium polymer rechargeable battery, which should last at least 24 hours with minimal phone use. Data can be stored on the device and integration with information systems is planned. The reflectance sensor works on a variety of body parts including the finger, toe, and forehead.
45640513|NCT05914324|Device|LB-01 device|The LB-01 probe uses transmissive oximetry with the light-emitting diode (LED) and photodetector (PD) positioned opposed to one another when placed on body tissues like fingers, and is used with the Acare pulse oximeter device. The LB-01 probe is an elongated clip sensor with an offset optics location near the hinge, permitting stable positioning on the child's big toe. By incorporating softer hollow silicone pads this design grasps the foot while placing the optics over the toe, to minimize movement artifact, an important issue for child measurements. The soft pads allow comfortable use across the smaller foot of neonates, and the design remains similar enough to a conventional finger sensor that it can be used on adult fingers as well.
45640514|NCT05914311|Device|Suture|secures SCS trial leads with a suture
45640515|NCT05914311|Device|Dermabond|secures SCS trial leads with dermabond
45640516|NCT05914298|Diagnostic Test|blood and buccal swab genetic test|blood samples and buccal swabs will be obtained from patients with HME in order to analyze the genotype (EXT1 or EXT2 mutations) and correlate the genotypic pattern with the phenotypic presentation
45640517|NCT05914298|Diagnostic Test|PUL|measurement of ulnar length with anthropometer and patient's height
45640518|NCT05914298|Diagnostic Test|Range of motion|measurement of range of motion of elbow, forearm and wrist
45778572|NCT05145140|Drug|Standardized Western Medicine Treatment|Standardized Western Medicine Treatment includes hypoglycemic, debridement and anti infection treatments.
45778573|NCT05145140|Drug|Tangningtongluo tablet and cream|Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.There are two dosage forms: tablet and cream.
45778574|NCT05145140|Drug|Tangningtongluo tablet|Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.The participants in this arm use tablet.
45778575|NCT05145140|Drug|Tangningtongluo cream|Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.The participants in this arm use cream.
45778576|NCT05290662|Drug|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
45778577|NCT05290662|Drug|Cyclophosphamide/Fludarabine (Cy/Flu)|Lymphodepleting conditioning regimen
45778578|NCT05143502|Drug|Montelukast|"Montelukast is a leukotrienes antagonist which has proven efficacious in chronic inflammatory conditions of the airways, including allergic rhinitis, asthma, and aspirin-exacerbated respiratory disease (AERD), all diseases that often coexist with CRSwNP.~We will use oral Montelukast (montelukast 10 mg, once a day) for 3 monthes"
45778579|NCT05143502|Drug|Prednisolone|Oral Prednisolone 40 mg/day for two weeks.
45640519|NCT05914285|Drug|5ml of inhaled normal saline|After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
45640520|NCT05914285|Drug|2.5mg (2.5ml) of inhaled salbutamol and 2.5ml of inhaled normal saline|After the initiation of OLV, mixture of salbutamol 2.5mg and normal saline 2.5ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
45640521|NCT05914272|Drug|Osmotic drugs|Patients had used osmotic drugs within 72 hours of admission.
45640522|NCT05914259|Other|No Intervention|Following the manner of observational study, no intervention will be provided in the study.
45640523|NCT05914246|Device|VIOLA proximal seal|VIOLA proximal seal system for maintenance of hemostasis when suturing the aortic anastomoses
45640524|NCT05914233|Device|Non-invasive ultrasound retinal stimulation Device|Record user feelings during the device is working
45640525|NCT05914220|Device|AI Insights Application|Predictive AI Model Risk score
45640526|NCT05914207|Behavioral|Lifestyle modifications|Written suggestions on lifestyle modifications including duration of sleep, meal frequency, reduce screen time, exercise duration, food to avoid.
45640527|NCT05914207|Other|Vestibular rehabilitation exercise|Each participant will be taught simple home-based vestibular rehabilitation exercise, which needs to be repeated
45778580|NCT05143502|Drug|Fluticasone Furoate|fluticasone furoate nasal: (50 micrograms /spray ) 100 micrograms (2 sprays) in each nostril twice daily
45778581|NCT05247840|Diagnostic Test|uroflowmetry|Uroflowmetry will be performed using a uroflow-cystometer (UroDoc Frytech) which determines Qmax, Qave and TQmax. Voided volume (in mL), voiding time (in sec), average and maximum urinary flow rate (Qave and Qmax in mL/sec), and time to maximum urinary flow (TQmax in sec) will be measured; urine flow acceleration (Qacc in mL/sec2) will be calculated. Qmax and Qave are defined according to the International Children's Continence Society. Voided volume will be measured by the uroflow-cystometer device; boys void in a standing, girls in a sitting position. Postvoid bladder diameter (mm) will be measured by ultrasonography and converted to bladder residual volume (mL). The device will be calibrated according to the prescribed instructions for use by a skilled technician. The examinations will take approximately 10 minutes.
45778582|NCT05247840|Diagnostic Test|Cardiovascular autonomic dysfunction test proposed by Ewing et al.|CAD will be assessed by five reproducible and standardized cardiovascular reflex tests described by Ewing et al. Three of the five tests assess parasympathetic function: heart rate response to deep breathing, to standing, and the Valsalva maneuver. Two tests evaluate sympathetic function which are blood pressure responses from lying to standing and at sustained handgrip. Each of these five tests is assigned a score of 0 for normal, 0.5 for borderline, and 1 for abnormal results. The sum of these 5 scores - which is the Ewing score - is used to assess severity of CAD. Patients having Ewing score ≥ 2 form the CAD + group, and patients who have less than 2 form the CAD - group.
45640528|NCT05914194|Drug|NLS-2|Participants will receive NLS-2 tablets orally.
45640529|NCT05914194|Drug|Placebo|Participants will receive NLS-2 matching placebo tablets orally.
45778583|NCT05247840|Diagnostic Test|peripheral nerve conduction test|Peripheral neuropathy will be evaluated by nerve conduction test. The device measures motor conduction in the lower extremities. It operates at two dedicated frequencies in order to perform a thick myelin sheath cordless fibre (5Hz) and thin myelinated nerve fibre (2000Hz) examination. The device will be calibrated according to the prescribed instructions for use by a skilled technician.
45778584|NCT00382928|Device|Defibrillation of pulseless VT/VF by AECD|In case of cardiac arrest caused by shockable rhythms the automatic external cardioverter defibrillator (AECD) will automatically deliver defibrillation. Automated External Cardioverter Defibrillator (AECD; The PowerHeart CRM, Cardiac Science Inc., Seattle, WA) is a device attached to the chest wall by pads, monitors the electrocardiogram, and is capable of automatically delivering electric countershock to appropriate rhythms without operator intervention. The device will deliver only one shock of 150 Joules for pulseless ventricular tachycardia and ventricular fibrillation.
45916002|NCT01742143|Behavioral|Usual and Customary Group (U&C)|"Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.~Chart review at 3 mo, 6 mo and 1 year, and as needed."
45916003|NCT00388167|Drug|Caspofungin|The patients are treated with 70 mg IV of caspofungin on day 1, followed by 50 mg/day IV during the rest of treatment
45916004|NCT00388245|Procedure|Percutaneous Coronary Intervention|
45640530|NCT05914168|Device|Breast Tomosynthesis|Three dimensional mammography
45640531|NCT05914155|Drug|Rituximab (genetical recombination)|Administer 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses in double-blind phase.
45640532|NCT05914155|Drug|Placebo|Administer placebo IV infusion every two weeks for two doses in double-blind phase.
45640533|NCT05914155|Drug|Rituximab (genetical recombination)|Patients who remain to be ICR II (Incomplete Remission Type II) or NR (No Response) until Week 26 in the double-blind phase, if the patients wish to move to the open-label phase and the investigator or a subinvestigator considers the move necessary, the patient will move to the open-label phase and receive 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses after the readministration criteria are confirmed to be met.
45640534|NCT05914142|Device|Proton radiation therapy|Radiation: Proton Therapy System (ProBeam)
45778585|NCT05290116|Drug|HAIC Combined with Tislelizumab and Apatinib|"Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Tislelizumab and Apatinib treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Tislelizumab 200 mg, ivdrip, Q3W; Apatinib 250 mg, po, QD."
45640535|NCT05914129|Other|Diaphragm, Stomach and Liver techniques|"Diaphragm Stretching:~The participant is seating down and the researcher will be behind, placing their hands on the inferior costal border. Cephalic traction is performed during inhalation, remaining during exhalation. Procedure is repeated 2 times, for 10 respiratory cycles, with 1-minute intervals.~Inferior Mobilization of the Stomach:~The participant is seating down with slight flexion of the torso, while the investigator stands behind them, placing the thumbs on the epigastric region. The volunteer will extend their body while the researcher performs a caudal traction. This procedure lasts 5 minutes.~Liver Pump:~Participant is laying on their back, and the investigator is standing on the participants side. The researcher places one hand on the right side inferior costal border posteriorly and the other one bellow the costal border anteriorly. Researcher compresses during exhalation and releases their hands abruptly during inhalation. This procedure lasts 5 minutes."
45640536|NCT05914129|Other|Stomach and Liver techniques|In this group, techniques are the exact same as described previously but only liver and stomach ones will be performed.
45640537|NCT05914129|Other|Sham technique|In the sham group, manual contact without any therapeutic intention will be performed in the same regions as the experimental groups. This contact will be maintained during the same amount of time as for the experimental group A.
45640538|NCT05915494|Other|intermittent pneumatic compression, physiotherapy, and walking|intermittent pneumatic compression group (n = 20 inhalation injury children). in this children group, intermittent pneumatic compression will be used to resist diaphragm muscle during 10-set-training session which will be done five session per the week, for 12 weeks. besides this training, traditional physical therapy program will be handled). In other inhalation group, n =20, traditional physical therapy program will be handled only). Also, free walking for 30 minutes daily will be performed by children.
46070371|NCT00808561|Other|Group 2: Forearm AV Graft|a) ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal forearm to the radial or brachial artery and to an antecubital vein. The advantages include a quick maturation of 2-3 weeks, excellent flow rates and high technical success rates. Although secondary patency rates approach 80% at one year postoperatively, disadvantages include a more involved surgical procedure, a lower primary patency than a well functioning AV fistula, and higher revision and infection rates.4, 5
46070372|NCT00808717|Drug|Atorvastatin|Atorvastatin 10 mg vs. 80 mg before intervention
45640539|NCT05915494|Other|physiotherapy and walking|in this children group, n = 20, for 12 weeks, traditional physical therapy program (chest physical therapy, flexibility exercises, range of motion exercises) will be handled. Also, free walking for 30 minutes daily will be performed by children.
45640540|NCT05914116|Drug|DB-1311|Administered I.V.
45640541|NCT05914103|Procedure|ERAS|The primary endpoint is the rate of composite outcomes. The composite outcomes include the major adverse cardiac events (MACE), major postoperative pulmonary complication (PPCs), and acute kidney injury (AKI)
45640542|NCT05914090|Procedure|ERAS|Among adults, patients undergoing elective extracorporeal circulation for cardiac surgery are included in the ERAS strategy intervention plan, which mainly includes preoperative education, preoperative oral intake of multidimensional carbohydrate beverages, multimodal analgesia, blood protection strategies, correction of perioperative hypoalbuminemia, early removal of tracheal intubation, maintenance of blood sugar at reasonable levels, and targeted liquid therapy.
45640543|NCT05914077|Drug|Secretin|Secretin will be administered intravenous during 1 minute at a dose of 0,2 μg/Kg previous to the endoscopic procedure.
45640544|NCT05914077|Procedure|Endoscopic aspiration|Endoscopic aspiration of duodenopancreatic juice after secretin stimulation
45640545|NCT05914077|Procedure|Endoscopic ultrasound-guided fine needle aspiration|Endoscopic ultrasound-guided fine needle aspiration of intraductal papillary mucinous intraductal neoplasia (IPMN).
45778586|NCT05289024|Behavioral|Mindful Awareness in Body-Oriented Therapy|Up to 8 individually delivered clinical sessions
45778587|NCT00409292|Drug|RAD001|Taken orally daily for as long as the participant continues to receive a benefit.
45778588|NCT05246046|Drug|Tiotropium Bromide Monohydrate|In each period, subjects receive single dose of tiotropium consisting of 2 inhaled doses via Easyhaler or 2 Spiriva capsules inhaled via HandiHaler
45778589|NCT00383942|Drug|Misoprostol|Misoprostol,25 micrograms every 4 hours.
46070373|NCT00644917|Drug|Xenaderm|20mg under Finn chambers
46070374|NCT00644917|Drug|Placebo|20mg under Finn chambers
46070375|NCT00914732|Biological|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered by subcutaneous (SC) route at 1x10^8 TCID50 per 0.5 mL dose on Days 0 and 28.
45640546|NCT05914064|Device|Gravitas FT and Gravitas FT Monitor guidance|FT placed with guidance from the Gravitas FT system
45640547|NCT05914064|Device|Gravitas FT System without placement guidance|SOC placement
45778590|NCT00383942|Device|Catheter|A catheter with extra amniotic saline infusion (EASI) is placed in the uterus and applies pressure to the cervix to cause it to ripen
45778591|NCT05482308|Drug|Tafamidis free acid tablet (Test)|Variant 12.2 mg tafamidis free acid tablet (Test)
45778592|NCT05482308|Drug|Tafamidis free acid tablet (Reference)|Proposed commercial 12.2 mg tafamidis free acid tablet (Reference)
45778593|NCT05196672|Behavioral|Virtual reality and eye mask|Adults will receive a virtual reality program 30 min before bedtime and then be placed on an eye mask during their sleep for consecutive 2 nights of ICU stay.
46070376|NCT00914732|Biological|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered at lower dose [2x10^7 tissue culture infectious dose 50 (TCID50) per 0.1 mL dose] by intradermal (ID) route on Days 0 and 28.
46070377|NCT00914732|Biological|MVA Smallpox Vaccine|Vaccinia vaccine lyophilized formulation delivered by subcutaneous (SC) route at 1x10^8 TCID50 per 0.5 mL dose on Days 0 and 28.
45778594|NCT05288400|Combination Product|Amlodipine 5mg + bisoprolol fumarate 5mg + perindopril arginine 5mg|1 capsule/day Oral administration
45778595|NCT05288400|Drug|Norvasc 5mg tablet|Norvasc (amlodipine) 5mg, 1 tablet/day
45640548|NCT05914051|Other|Colloid preload|250 cc of colloid preload solution will be infused in the intervention group
45640549|NCT05914038|Device|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex.
45640550|NCT05914025|Behavioral|Behavioral Activation|Individuals will be provided with information about maladaptive patterns of behavior and how to correct these cycles with activity scheduling to elicit more positive emotional experiences. Participants will be provided with categories/lists of activities and a downloadable calendar after receiving the psychoeducation.
45640551|NCT05914012|Other|Telerehabilitation based on Otago Exercise Program|It took a total of 21 sessions, 7 days a week for 3 weeks. The sessions lasted 30 minutes. It is recommended to do exercises with comfortable shoes at least 1 hour after a meal. Each of his exercises will be videotaped and numbered and delivered to the intervention group via social networks and the Internet or by memory. In each exercise session, the physiotherapist followed the exercise sessions through social networks and answered questions from the older adults.
45640552|NCT05913986|Dietary Supplement|LUDLEV®300 mg/46.2 mg|LUDLEV®300 mg/46.2 mg once day
45778596|NCT05288400|Drug|Concor 5mg tablet|Concor (bisoprolol fumarate) 5mg, 1 tablet/day
45778597|NCT05288400|Drug|Coversyl 5mg tablet|Coversyl (perindopril arginine) 5mg, 1 tablet/day
45778598|NCT05193864|Device|Device: JVPHome and ultrasound|Remote clinician assessment of JVP height using the JVPHome, and ultrasound based assessment of JVP height in the same patients.
45778599|NCT00454532|Drug|BZL101|Freeze dried powder mixed with liquid. Administered as a daily dose. Dosage to be determined in Phase 1 portion.
45778600|NCT05193630|Dietary Supplement|Milnutri Sure™|"Milnutri Sure™, a commercially available oral nutritional support (ONS) product in powder format, for children of 1 y of age and above (1.0 kcal /ml).~For children between 1 and 3 years of age, the recommendation is to use 2 servings per day, and for children from 4 to 6 years of age, the recommendation is to give 3 servings per day. One serving contains of 45 grams of product and 180 ml water."
45916005|NCT00388245|Procedure|Coronary Artery Bypass Grafting|
45448620|NCT04538092|Other|Enhanced Recovery After Surgery Protocol|The investigators have developed an Enhanced Recovery After Surgery protocol for complex spine surgery at UNC. This study will help elucidate the effects of multiple interventions tailored to help patients recover from complex surgery.
45448621|NCT03628599|Device|Delefilcon A contact lenses|Water Gradient silicon hydrogel daily disposable contact lenses
45448622|NCT03628599|Device|Senofilcon A contact lenses|Silicon hydrogel daily disposable contact lenses with HydraLuxe™ Technology
45448623|NCT03545776|Other|Critical Care EEG Course|"Medical and nursing staff will be given a 10-points EEG face-to-face initial training course followed by an online teaching and educational quizzes at day-1, day-15 and day-30 after initial training. A final evaluation will be performed at day-90 after beginning of the training course.~10-points EEG educational objectives : physiological rhythms, reactivity, symmetry, effects of sedation, burst suppression, paroxysmal activities, periodic / pseudoperiodic activities, rhythmic activities, artifacts, null EEG"
45448624|NCT03733821|Device|Repetitive Transcranial Magnetic Stimulation|Non-invasive brain stimulation tool
45448625|NCT03546790|Drug|Marijuana|Marijuana smoked via blunts with different cigar wrappers
45640553|NCT05913986|Other|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
45640554|NCT05913960|Device|sham stimulation|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
45640555|NCT05913960|Device|accelerated intermittent theta burst stimulation|"Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
45640556|NCT05913960|Device|high frequency stimulation|"Participants in the active stimulation group will receive the high frequnency stimulation to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
45778601|NCT01796600|Device|The patients will have a conventional scanner, a reference examination, and a cone-beam scanner Newtom 5G just after the conventional scanner|
45778602|NCT05474040|Drug|Morphine versus multimodal analgesia for post elective craniotomy pain|To compare the effectiveness of opioid- sparing multimodal analgesia and opioid analgesia in the treatment of post-craniotomy pain
45778603|NCT05245422|Other|Infant Formula - Partially hydrolyzed protein|Partially hydrolyzed cow's milk protein
45778604|NCT05245422|Other|Infant Formula - Intact protein|Intact cow's milk protein
45778605|NCT00410150|Drug|Helium-oxygen-driven albuterol nebulizer|Subjects will be treated with continuous albuterol nebs with Heliox
45778606|NCT00410150|Drug|Oxygen|Subjects will be treated with continuous albuterol nebs in oxygen
45778607|NCT01796678|Drug|Arginine|
45778608|NCT01796678|Drug|Placebo|Saline or Sugar pill was given as placebo
45916006|NCT00388284|Device|Arterial Sealing|
45916007|NCT01541839|Device|Septal Stapler|This device is a stapler designed to place resorbable implants into the nasal septum. Each device contains 8 staples.
45916008|NCT00388323|Other|blood and biopsies|blood and biopsies
45778609|NCT05288322|Procedure|Mostafa Maged maneuver|"The Mostafa Maged maneuveur has been applied to those all female patients to prevent or control post-partum bleeding in normal delivery . The Mostafa Maged technique is applied by :- (Description of the new Mostafa Maged technique) :-~First , placing our right hand to the posterior fornix of vaginal canal trying to cuddle the lower part of uterus compressing the anterior and posterior walls of the uterus .~Second , placing our left hand over the fundus of the uterus and the posterior wall of uterus from the abdominal part.~Third , by our two hands , trying to grasp the whole uterus by our two hands abdominally and vaginally against the symphysis pubis as if the uterus is cuddling the symphysis pubis bone and in this way , we try to get the anterior and posterior walls against each other and reducing the intra-cavitary space so we prevent the expansion of the uterus ."
45778610|NCT01796756|Other|Handover program|
45778611|NCT05288088|Diagnostic Test|No intervention|This is an observational study
45778612|NCT00385268|Drug|acamprosate|1998 mg/dau fpr 8 weeks
45640557|NCT05913947|Drug|Lithium|The starting dose (day one) of lithium citrate is 12 mmol (one tablet of lithium citrate contains 6 mmol lithium) given once a day before bedtime. On day three the dose is increased to 18 mmol. Dose adjustments are permitted after 7 days in a flexible manner to result in a 12-hour se-lithium between 0.6 and 0.8 mmol/l, aiming for the upper limit at the treating physician's discretion.
45640558|NCT05913947|Drug|Cariprazine|The starting dose for cariprazine is 1.5 mg daily in a single dose, and subsequently, after a minimum of two weeks, the dose can be increased to 3 mg and decreased again to 1.5 mg daily at the treating physician's discretion.
45640559|NCT05913934|Behavioral|Gait analysis|Walk over 25 meters in a gym (GaitUp) Walk over 6 meters with footscan v9 in the office
45640560|NCT05913921|Drug|Amphotericin B liposome for injection|IV infusion, 2.0 mg/kg
45640561|NCT05913921|Drug|AmBisome|IV infusion, 2.0 mg/kg
45778613|NCT00385268|Drug|placebo|placebo pills
45640562|NCT05913895|Other|hydrogen water|To investigate whether the intervention of hydrogen water adjuvant therapy can improve oral mucositis, oral frailty, pain and Quality of Life with head and neck cancer who have received radiation therapy or combined chemotherapy.
45640563|NCT05913882|Device|Respiratory Muscle Strength Training (LVR+EMST)|Combined respiratory muscle strength training regimen that will be completed daily for 5 weeks.
45640564|NCT05913869|Behavioral|Online Mindfulness Based Stress Reduction|Based on the UMASS curriculum developed by Dr. Jon Kabat-Zinn, it is an 8-week mindfulness stress reduction program. It is a skill-based psychoeducational program that meets 2 hours for 8 weeks to discuss stress, cognition and health. The weekly intervention includes didactic presentations, class dialogue and inquiry, formal (e.g., body scan, walking meditation) and informal (e.g., awareness of pleasant and unpleasant events, interpersonal communications, etc.) mindfulness practice.
45778614|NCT05287932|Behavioral|Brief physical activity intervention|See arm/group descriptions
45448626|NCT03546088|Device|fiberoptic naso-tracheal intubation|The trachea will be intubated under direct fiberoptic view after a fiberoptic upper airway examination. The flexible nasolaryngoscope will be armed with an intubating tube and passed inside tracheal lumen trough one of the nostrils.
45448627|NCT03546088|Drug|Topical anaesthesia|Topical anaesthesia with lidocaine will be provided through nebulisation and instillation. The intubating tube will be lubricated with a gel containing lidocaine.
45448628|NCT03546088|Drug|Light sedation|The patient will be sedated with a combination of midazolam, fentanyl administered intravenously in small boluses until the desired level of sedation is achieved as expressed of The Observer's Assessment of Alertness/Sedation Scale (OAA/S) of 4 or 5.
45448629|NCT04531618|Behavioral|Family Nurture Intervention (FNI)|FNI is a family based intervention that facilitates and strengthens the mother-infant emotional connection through a structured guided interaction by a Nurture Specialist. The mother is asked to sit with her baby in her arms so that they are face-to-face, and when the baby becomes restless, the physician will coach the mom to bring the baby back to a calm state. The mother will also be encouraged to verbalize her feelings to her baby. Mother-infant emotional connection is known to affect various developmental processes and improve overall health. FNI was previously shown to be efficacious in improving several long-term health outcomes in preterm infants in the neonatal intensive care unit (NICU).
45640565|NCT05913856|Other|Normal saline|Normal saline will be applied to irregate the oral cavity after the swabing of the surface of patients' teeth and oral cavity by a sponge swab by the primary care nurse in the MICU.
45640566|NCT05913856|Other|Chlorhexidine|15ml of 0.12% chlorhexidine will be applied to irregate the oral cavity after the swabing of the surface of patients' teeth and oral cavity by a sponge swab by the primary care nurse in the MICU.
45640567|NCT05913843|Device|Take photo|We will use the camera to take 2 front and side images of the participant, and select one of the better images to upload to the facial analysis system (GestaltMatcher Database) for analysis.
45640568|NCT05913830|Other|Auricular pressure|The seeds of blancia blanc were fixed on the acupoints with patches. The intervention measure in the experimental group was auricular point sticking. The two groups received four measurements before the intervention and 2 weeks, 4 weeks, and 6 weeks after the start; while the control group received no Auricular pressure.
45778615|NCT05287464|Drug|pembrolizumab plus axitinib|collect global experiences with the use of immuno-combinations in patients with metastatic RCC
45778616|NCT01657500|Other|Corneal donor storage in Optisol GS media solution|Donor tissue is preserved in the Optisol media until ready for implantation
45778617|NCT01657500|Other|Life 4°C solution for cornea storage|Donor cornea is stored in the Life 4°C media prior to implantation.
45916009|NCT00786760|Other|Cohort: 3000 men examined every 6 months for 4 years.|Prospectively assess HPV infection in a large cohort of men in the US , Mexico, and Brazil representing countries of low and high risk.
45916010|NCT00786760|Other|Pilot study: 150 men examined every 6 months for 4 years.|Prospectively assess HPV infection in a large cohort of men in the US , Mexico, and Brazil representing countries of low and high risk.
45916011|NCT00006043|Drug|temozolomide|
45916012|NCT00006049|Drug|carboplatin|
45778618|NCT05242848|Behavioral|Exercise intervention|The intervention is a supervised group-based exercise intervention for 16 weeks, including two outdoor sessions per week. The workout consists of two parts, endurance and a strength training segment. Every workout follows the same structure and lasts approximately 45 minutes. The exercise starts with roughly 15 minutes of endurance warm-up. After the warm-up follows the interval with eight repetitions of 30 seconds uphill, and the participants can freely choose between walking or running. The desired intensity of the intervals is >13 on Borg-score 20. The session will end with four specific exercises focusing on strength training of large muscle groups, including mm. pectoralis major, rectus abdominis, quadriceps femoris, gluteus maximus and latissimus dorsi. The strength training program follows the same structure as the intervals. Clinical staff, research staff, and people with user experience will supervise the exercise sessions.
45778619|NCT00411086|Biological|Rituximab|375 mg/m^2 By Vein Weekly on Days 1, 8, 15, and 22.
45640569|NCT05913804|Biological|YTS104 Cells injection|YTS104 Cell injection is a new STAR-T cell transfected by lentivirus.The study required that lymphocytes were collected from the subjects and cultured for 2-3 weeks to obtain YTS104 cell injection. Subjects were treated with fludarabine and cyclophosphamide chemotherapy prior to reinfusion, followed by a 2-day rest period before cell infusion.
45640570|NCT05913791|Dietary Supplement|Nutrients-fortified egg|Consumption of 2 cooked nutrients fortified eggs (half-boiled, hard-boiled, or steamed)
45640571|NCT05913791|Other|Regular egg|Consumption of 2 regular eggs, prepared in the same manner as nutrients-fortified egg, which serves as a placebo comparison.
45640572|NCT05913778|Device|Enhanced external counterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive therapy for the treatment of patients with coronary artery disease.The systolic deflation/diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner in coronary artery and in others organ arteries.
45640573|NCT05913765|Device|Air cleaner|Austin Air Healthmate air cleaner with or without standard filter
45640574|NCT05913752|Drug|CMND-100|The investigational product CMND-100 consists of gelatin capsules, each containing the active ingredient (either 20 or 60 mg) 5-methoxy-2-aminoindane (MEAI) and excipients (stabilizers). MEAI is a psychoactive compound of the aminoindane class
45640575|NCT05913739|Other|Oxygen Therapy|Nocturnal oxygen therapy minimum 6 hours
45640576|NCT05913713|Behavioral|12-week Intervention Period|Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period.
45778620|NCT00411086|Biological|Sargramostim (GM-CSF)|250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.
45778621|NCT05191524|Other|Constrained induced movement|Practice in two sessions per day (supervised) for 3 days per week, for six consecutive weeks. The unaffected limb will be constraint using a knee immobilizer only during practice sessions. We will perform the interventions under the supervision of a trained physiotherapist.
45778622|NCT05191524|Other|Proprioceptive Neuromuscular facilitation|Group B will receive PNF intervention given for 30 minutes to the lower limb 3 times a week for 6 weeks
45640577|NCT05913713|Behavioral|12-week Observation Period|After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises.
45640578|NCT05913687|Diagnostic Test|AIDP|Machine learning algorithm of imaging data
45778623|NCT05190900|Other|neural mobilization|neural mobilisation of the posterior tibial, deep peroneal and lateral, intermediate and medial dorsocutaneous nerves.
45778624|NCT05190354|Device|Xtremity Polymer Prosthetic Socket|Subjects with transtibial unilateral or bilateral amputation who have experience using a standard carbon fiber or high temperature thermoplastic prosthetic socket will be evaluated and fitted with a below knee prosthesis socket
45916013|NCT00006049|Drug|gefitinib|
45916014|NCT00006049|Drug|paclitaxel|
45640579|NCT05913674|Drug|Modified early post-operative intraperitoneal chemotherapy (mEPIC)|"On post-operative days 1 and 2, an abdominal reservoir is obtained by administering 1000 mL of plasmalyte with 50 mEq NaHCO3 via a Tenckhoff catheter. Participants will then receive an intraperitoneal fluorouracil bolus of 400 mg/m2 administered over 1 to 2 minutes followed by a continuous intraperitoneal fluorouracil infusion of 1200 mg/m2 over the next 24 hours. During the continuous intraperitoneal infusion of fluorouracil, 50 mg of folinic acid is administered intravenously.~After completion of mEPIC day 1, the perfusate is drained out before starting mEPIC day 2."
45448630|NCT04524832|Drug|Oral semaglutide|Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 16 weeks
45448631|NCT05070052|Behavioral|cognitive behavioral therapy|9 sessions of CBT weekly treatment in group setting
45448632|NCT05070052|Behavioral|mindfulness-based cognitive therapy|9 sessions of MBCT weekly treatment in group setting
45448633|NCT04506814|Device|Endocardial PVI|Catheter based PVI
45640580|NCT05913661|Drug|Pemigatinib|Pemigatinib is scheduled to be administered at a dose of 13.5 mg quaque die according to a 2-week dosing and 1-week discontinuation regimen.
45640581|NCT05913661|Drug|PD-1 Inhibitors|The dosing regimen is 200 mg IV Q3W
45916015|NCT00006052|Drug|imatinib mesylate|
45916016|NCT00007254|Drug|Pain relief for pressure ulcers|
45916017|NCT00006055|Drug|anti-thymocyte globulin|
45916018|NCT00006055|Drug|cyclophosphamide|
45916019|NCT00006055|Drug|cyclosporine|
45916020|NCT00006055|Drug|filgrastim|
45916021|NCT00006055|Drug|methylprednisolone|
45916022|NCT00006055|Drug|prednisone|
45916023|NCT00006055|Procedure|Autologous Peripheral Blood Stem Cell Transplantation|
45448634|NCT04506814|Device|Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI|Minimally invasive PVI with posterior wall RF ablation + LAA clip + endocardial PVI
45448635|NCT05063812|Other|Observational|All these patients have been enrolled in the COVID-19 remote patient monitoring program
45916024|NCT00006061|Drug|phosphatidylcholine|
45916025|NCT00007293|Device|UV-B Lightsource and Fiber Optic Comb|
45916026|NCT00006070|Drug|etanercept (Enbrel)|
45916027|NCT00007332|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
45916028|NCT00007332|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
45640582|NCT05913648|Other|Tool Translation|The Data Collection procedure will be done in two phases. The first phase will revolve around the translation of the instrument. Firstly the tool will be translated into Urdu with the help of two professional translators and then it will be back-translated into English to cross-check the clarity of the text. The translation will focus more on the context and understanding of the text rather than literal word-to-word meanings. The translation will be done according to the WHO guidelines. The Urdu version of MENQOL will be used to assess content validity on menopausal women.
45640583|NCT05913635|Behavioral|Consumption of lunch and dinner, with no breakfast|The day before intervention day, all participants will be provided with 3 nutritionally balanced meals which are designed by the investigators. On the no-breakfast intervention day, participants are instructed to fast and only be allowed to consume water until 1.00 p.m. and consume the above-designed lunch and dinner at 1.00 p.m. and 8.00 p.m. Additionally, all participants are informed that they are only allowed to consume water between meals and before receiving breakfast at 7.30 a.m. the following day.
45778625|NCT05190198|Other|Proprioceptive neuromuscular facilitation|"Weight shifting in each direction (anteriorly, posteriorly, and lateral side) combined with side-to-side head movements (5 times for each direction).~One-legged stance with slight knee flexion of another leg for 15 seconds (5 times for each leg).~One-legged stance with increasing knee flexion of the other leg for 15 seconds (5 times for each leg).~Standing on a balance pad with shifting weight (anteriorly, posteriorly, and lateral side) 10 times in each direction.~In standing position, moving the weight left and right maximally.~In standing position, moving the weight forward and backward maximally.~In standing position, moving both heels of feet up and down.~In standing position, bending and stretching both knees by squatting as much as possible."
45778626|NCT05190198|Other|conventional therapy|"(Dorsiflexion, planter flexion, eversion and inversion) 10 repetitions for each movement.~(A) Sit to stand (5 times). (B) Standing with shifting Weight anteriorly, posteriorly, and sideway (5 times for each direction). (C) Functional reach sideway and anterior for touching targets set by the therapist (5 times for each direction). (D) Standing on heels for 20 seconds (5 times). (E) Standing on toes for 20 seconds (5 times).~(A) Spot marching (2 min). (B) Walking over the heels, toes, lateral border of feet with the preferred speed (6 min). (C) Tandem walking in a straight line (2 min)."
45778627|NCT01658904|Drug|Carfilzomib|
45778628|NCT01658904|Drug|Melphalan|
45778629|NCT01658904|Drug|Filgrastim|
45640584|NCT05913635|Behavioral|Consumption of breakfast and lunch, with no dinner|The day before intervention day, all participants will be provided with 3 nutritionally balanced meals which are designed by the investigators. On the no-dinner intervention day, participants are instructed to consume the above-designed breakfast and lunch at 7.30 a.m. and 1.00 p.m., and no dinner. Additionally, all participants are informed that they are only allowed to consume water between meals and before receiving breakfast at 7.30 a.m. on the following day.
45640585|NCT05913622|Device|Intra-aortic balloon pump|An IABP is placed percutaneously into the thoracic aorta and supports the heart through synchronized inflation and deflation of a balloon.
45778630|NCT04235400|Diagnostic Test|No Dye BreakUp Time|Measurement without dye of the tear meniscus height (TMH) which give an rapid hint on the quantity of tears present on the ocular surface, the measure in real time of the tear osmolarity and, at last, the analysis of the thickness of the tear's layer by interferometry (measurement of the light fringes reflected by the tears when illuminated with polarized light, whereby the complete layer or the lipid layer alone can be evaluated separately depending on the machines used) and of the assessment of the quality of the Meibomian glands (non-contact imaging by infrared illumination).
45778631|NCT05238948|Drug|Midazolam|Substrate of CYP3A4
45778632|NCT05238948|Drug|CKD-506|Perpetrator of CYP3A4
45778633|NCT05188872|Diagnostic Test|68Ga-Pentixafor|Each patient receive a single intravenous injection of 68Ga-Pentixafor, and undergo PET/CT scan within specified time.
45778634|NCT05284578|Other|Self-compassionate writing intervention|Participants assigned to this intervention were asked to engage in one brief online self-compassionate writing session, where they were asked to write about and experience their feelings from the perspective of an inner compassionate observer.
45778635|NCT05284578|Other|Expressive writing intervention|Participants assigned to this intervention were asked to engage in one brief online expressive writing session, where they were asked to explore their deepest thoughts and emotions surrounding an upsetting situation through writing.
45778636|NCT05284578|Other|Control writing task|Participants assigned to this condition were asked to engage in a neutral time management writing task.
45778637|NCT00385580|Drug|dasatinib|Tablets, Oral, 100 mg or 70 mg, twice daily, treatment may continue until disease progression
45778638|NCT00385580|Drug|dasatinib|Tablets, Oral, 100 mg, once daily (QD) treatment may continue until disease progression
45778639|NCT05489640|Other|No Intervention|No Intervention will be administered in this study.
45778640|NCT05185674|Other|Exposure: Coronavirus disease 2019 (COVID-19)|Having presented Coronavirus disease 2019 (COVID-19) and stay in the Intensive Care Unit
45778641|NCT05184504|Other|Renal cell carcinoma|Clinical-pathological characterization and outcomes of renal cell carcinoma in Latin America
45778642|NCT05236530|Drug|Midazolam|Midazolam 2 mg (1 mL of 2 mg/mL oral solution) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
45778643|NCT05236530|Drug|Repaglinide|Repaglinide 0.5 mg (1 x 0.5 mg tablet) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
45640586|NCT05913609|Device|Yaari Extractor|The Yaari Extractor device is a single-use prescription device for neonatal extraction in deliveries that are complicated by shoulder dystocia. The Study Device consists of two curved, rigid plastic-coated metal Arms with Handles which are used for control of the device outside the body, and an elastic Engagement Element which conforms to the maternal and neonatal anatomy, and which is used for direct contact with the entrapped neonate within the birth canal.
45640587|NCT05913596|Drug|Daratumumab|After successful enrollment, the patient will receive daratumumab of 16mg/kg once every two weeks (0-22 weeks) for a total of 12 times. Peripheral blood samples were collected from 0 to 24 weeks (weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24) for routine blood tests, liver and kidney function electrolytes, tacrolimus or cyclosporine trough concentrations, HLA antibody quantification (weeks 0, 4, 8, 12, 16, 20, and 24), infection indicators (weeks 0, 8, and 24), immune status assessments (weeks 0, 4, 8, 12, 16, 20, and 24), and biopsy of transplanted kidneys was performed at 24 weeks to assess pathological changes.
45778644|NCT05236530|Drug|Dextromethorphan|Dextromethorphan 15 mg (10 mL of 7.5 mg/5 mL syrup) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
45640588|NCT05913583|Drug|Immune checkpoint inhibitor|"Immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the off signal from being sent, allowing the T cells to kill cancer cells.One such drug acts against a checkpoint protein called CTLA-4. Other immune checkpoint inhibitors act against a checkpoint protein called PD-1 or its partner protein PD-L1."
45778645|NCT05236530|Drug|Metformin|Metformin 500 mg (1 x 500 mg tablet) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
45778646|NCT05236530|Drug|Ganaplacide|Ganaplacide 400 mg (4 x 100 mg tablets) administered q.d. in Period 2 on Days 1 - 3, with the 4-probe cocktail co administered on the morning of Day 3.
45640589|NCT05913570|Drug|Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody|10mg/kg, Q3W for 4 cycles
45778647|NCT05236530|Combination Product|Lumefantrine|Lumefantrine 960 mg (4 x 240 mg sachets) administered q.d. on Days 1 - 3, with the 4-probe cocktail (as a single dose) co administered on the morning of Day 3.
45778648|NCT05236530|Drug|Rosuvastatin|Rosuvastatin 5 mg (1 x 5 mg tablet) administered as a single dose in a 2-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
45778649|NCT05236530|Drug|Dolutegravir|Dolutegravir 50 mg (1 x 50 mg tablet) administered as a single dose in a 2-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
45778650|NCT05236530|Drug|Ganaplacide|Ganaplacide 400 mg (4 x 100 mg tablets) administered q.d. in Period 2 on Days 1 - 3, with the 2-probe cocktail co administered on the morning of Day 3.
45778651|NCT05236530|Combination Product|Lumefantrine|Lumefantrine 960 mg (4 x 240 mg sachets) administered q.d. on Days 1 - 3, with the 4-probe cocktail (as a single dose) co administered on the morning of Day 3.
45778652|NCT00455702|Drug|d-cycloserine|50mg dose d-cycloserine v placebo
45778653|NCT04388306|Other|Shoulder Performance Test- Functional Impairment Test-Head and Neck, Shoulder, Arm (FIT-HaNSA)|Participants were evaluated with all tests, respectively. To eliminate the fatigue factor, 5 minutes breaks were given after each test.
45778654|NCT00456014|Drug|Escitalopram|Escitalopram will be administered at a dose of 10 mg daily for 4 weeks. If participants have not achieved response (greater than 50 % improvement in Hamilton Depression Rating Scale) by 4 weeks, the dose will be increased to 20 mg. Remission status is determined after an 8-week trial.
45778655|NCT00456014|Drug|Desipramine|Subsequent to escitalopram trial, non-remitters will be offered pharmacotherapy with desipramine. Desipramine will be initiated at a dose of 50 mg and titrated according to a treatment manual, with monitoring of therapeutic blood levels. Remission status is determined after an 8-week trial.
45778656|NCT05279664|Other|Remote ischemic conditioning (RIC) + Standard of Care for NEC|RIC will consist of 4 cycles of limb ischemia (4 min) followed by reperfusion (4 min) and a 5 minute-gap before the next cycle of ischemia, repeated on two consecutive days. An appropriately sized blood pressure cuff (covering 2/3 of the distance between the shoulder and the elbow) will be applied by a trained research fellow or nurse to an arm (or leg if the arm is not available because of medical reasons such as central line insertion). The systolic blood pressure will be measured before the first RIC cycle using a different cuff of same size connected to a monitor. During ischemia time, the cuff will be inflated to a pressure of 15 mmHg above the child's systolic pressure. Neonates in this arm will continue to receive standard of care for NEC.
45778657|NCT05279664|Other|Standard of Care for NEC|Neonates in this arm (i.e. the control arm) will receive standard of care for NEC.
45778658|NCT05235516|Drug|AK104|q3w iv
45778659|NCT05235516|Radiation|EBRT|45-50.4Gy
45640590|NCT05913557|Behavioral|Radically Open Dialectical Behavior Therapy (RO DBT)|Radically Open Dialectical Behavior therapy (RO DBT) is a type of cognitive behavioral therapy developed by Dr. Thomas Lynch for disorders of emotional overcontrol. RO DBT is a treatment indicated for patients across multiple psychiatric disorders, including diagnoses of chronic depression, treatment resistant anxiety disorders, anorexia nervosa, autism spectrum disorders, and avoidant, paranoid, and obsessive-compulsive personality disorders.
45778660|NCT05235516|Radiation|BT|≥80Gy
45778661|NCT05235516|Drug|cisplatin|qw iv
45778662|NCT05235516|Drug|Placebo|q3w iv
45778663|NCT00411398|Drug|Namenda/Memantine|5mg tablets, 1-4 tabs by mouth per day
45778664|NCT05234268|Other|Manual Cervical Traction|"Time: 20 minutes Duration: thrice a week for 4 weeks.~Position:~The patient is in supine lying. The head and neck of patient are held in the hands of the practitioner, and then a gentle traction of a pulling force is applied. Intermittent periods of traction can be applied, holding each position for about 10 seconds. Traction is usually applied at about 20-30 degrees of neck flexion."
45778665|NCT05234268|Other|Passive Accessory Intervertebral Movements|"Time: 20 minutes Duration: thrice a week for 4 weeks~Position:~Patient lying in prone. Therapist stands to side of patient placing their pisiform/ulnar surface of hand over the selected spinous process (SP) with their wrist in full extension.~Other hand placed on top of hand to reinforce. Therapist's shoulders should be directly above the SP with elbows slightly bent. Therapist uses their body weight to apply a PA force to the selected SP by leaning their body over their arms and performing rocking movements to provide oscillatory movements of the vertebra."
45916029|NCT00006079|Drug|Eflornithine|Arm I-II: Patients receive one of two different doses of oral eflornithine daily for 28 days.
45640591|NCT05913544|Other|SINTYA|10-week psychotherapy program consisting of a weekly 1h30 hour group therapy session plus 1 hour individual therapy session
45640592|NCT05913518|Device|Neurofeedback active|Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Active neurofeedback group aims at enhancing the sensorimotor rhythm (12-15 Hz).
45640593|NCT05913518|Device|Neurofeedback placebo|Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Placebo feedback group (PFT) : patients enhance random frequency bands
45640594|NCT05913505|Behavioral|OSC+|The first session of the HRVB intervention will focus on introducing the client to HRVB and calculating the participant's resonance frequency which typically range from 4.5-7 breaths per minute. Participants will first complete a five-minute baseline breathing condition. Following the breathing condition, the participants will complete five conditions for five minutes each. Specifically, each condition will have the person breath at 6, 6.5, 5.5, 5, and 4.5 breaths per minute with a minute break between. Session two will focus on practicing resonance frequency breathing and solidifying the correct resonance frequency for the participant. Additionally, this session will introduce the technique of breathing through pursed lips and abdominal breathing. For sessions three through five, participants will practice resonance frequency breathing and review previous strategies.
45640595|NCT05913505|Behavioral|OSC-|During the first week, the baseline will be assessed and resonance frequency. Specifically, during their first intervention session the participants will be told that the goal of the sessions includes decreasing heart rate variability and avoiding slow and steady breathing. The participants will then be asked to choose five strategies to lower their heart rate oscillations. Participants will be told to avoid slow breathing as it causes large heart rate oscillations. For the second session, the therapist will check in with the participant and discuss how the practice went. Participants will then select three strategies that they will practice for three five-minute conditions following a five-minute baseline. Sessions three, four, and five will include three conditions: a five-minute baseline and two strategies of their choice. For each session, the best strategy will be calculated and written on the assignment sheets to be used during the week for their four homework sessions.
45640596|NCT05913492|Behavioral|Simulation training|"Each volunteer went through two simulation scenarios of difficult airway management: 1) cannot intubate, can ventilate (CI), 2) cannot intubate, cannot ventilate (CICV) with the assistance of the training centre operator. Following the first simulation round, volunteers were trained on the same day in difficult airway management according to DAS guidelines, using the same equipment as during the simulation. The participants repeated the simulation scenarios immediately after the training and six months later."
45640597|NCT05913479|Device|Mucogyne Gel|At inclusion visit (V0), the Investigator will ask the subject to apply MUCOGYNE® Gel as described in the Instructions For Use, i.e., internally, one application 2 to 3 times a week until symptoms improve during 5 weeks (D35 +/- 3)
45640598|NCT05913466|Drug|Tranexamic Acid group|Patients in this group will receive 1 gm of Tranexamic Acid (Cyklokapron) that will be dissolved in 50 ml of injectable 0.9% saline
45778666|NCT05234268|Other|Active Strength Training|"Time: 20 minutes Duration: thrice a week for 4 weeks. The progression of exercises will be done using different colors of Thera-band indicating varied resistance. (A) Resistive lateral flexion of uninvolved side.~Position:~The patient is in sitting position. By the help of thera-band patient will actively flex the neck against resistance on the uninvolved side."
45778667|NCT05231694|Drug|Nerver growth factor (NGF) injection|The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.
45778668|NCT05231694|Drug|Placebo injection|The patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
45640599|NCT05913466|Drug|Distilled water group|This group will receive 10 mL of distilled water (placebo) in 1 L of irrigation solution sterile wash (glycine).
45640600|NCT05913427|Drug|Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG|"EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days.~Megestrol acetate will be prepared and packaged by the authorized external contract development and manufacturing organization (CDMO) Doppel Farmaceutici s.r.l. (Cortemaggiore, PC), that, according to the GMP and applicable law (FU XII ed) will also prepare the related placebo, in accordance with GMP (annex 13) and applicable law (FU XII ed.)."
45640601|NCT05913427|Drug|Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo|EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Placebo 160 mg tablets will be developed by the CDMO to have the same appearance and taste as the tablet containing the active drug.
45640602|NCT05913414|Drug|Iron Isomaltoside 1000|Patients receive Iron isomaltoside after IC and CCRT
45640603|NCT05913414|Drug|Polysaccharide Iron Complex Pill|Patients receive Polysaccharide Iron Complex Pill after IC and CCRT
45640604|NCT05913414|Radiation|Intensity-modulated radiotherapy|All patients received intensity-modulated radiotherapy before enrolled.
45640605|NCT05913401|Behavioral|Aerobic Exercise|20 minutes of supervised aerobic exercise on a treadmill prior to each TMS session
45640606|NCT05913401|Behavioral|Video Watching|20 minutes of watching documentaries or educational videos prior to each TMS session
45640607|NCT05913388|Drug|GB1211|Administered orally twice daily at 400mg.
45640608|NCT05913388|Drug|Pembrolizumab|Administered at a fixed dose of 200 mg every 3 weeks intravenously.
45916030|NCT00006079|Other|Placebo|Patients receive oral placebo daily for 28 days.
45916031|NCT00006082|Drug|rubitecan|
45916032|NCT00006085|Drug|CP-609,754|
45916033|NCT00006088|Drug|vinorelbine tartrate|
45916034|NCT00006091|Drug|arsenic trioxide|
45916035|NCT00006094|Drug|oxaliplatin|Given IV
45916036|NCT00006094|Drug|fluorouracil|Given IV
45916037|NCT00006094|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
45778669|NCT05231694|Device|EA intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day."
45778670|NCT05231694|Device|sham EA intervention|The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.
45640609|NCT05913388|Drug|Placebo|Administered orally twice daily at 400mg.
45778671|NCT00457730|Drug|Duloxetine|Patients will be randomly assigned to Duloxetine 30mg/d for 1 week, 60mg/d for 5 weeks and 30mg/d for 1 week or placebo for 7 weeks under double-blind conditions.
45778672|NCT00457730|Drug|Placebo|Subjects are randomized to either Duloxetine or Placebo
45778673|NCT05183802|Drug|Setmelanotide, administered subcutaneously [SC], once daily.|Dosing based on age, and titrated from starting dose to target dose.
45640610|NCT05913375|Radiation|Stereotactic Body Radiotherapy|Non-invasive delivery of ablative radiotherapy dose to the arrhythmia substrate defined with electroanatomical mapping (EAM)
45640611|NCT05913362|Behavioral|IVUS based ultralow contrast PCI|IVUS based ultralow contrast PCI
45778674|NCT01965470|Other|Combination Prevention|
45640612|NCT05913349|Behavioral|Group Cognitive Behavioral Therapy (GCBT)|Group cognitive behavioral therapy can achieve its therapeutic effect by enhancing emotion regulation and cognitive control, and by improving the activation patterns of the brain's internal networks to promote self-regulation. This can help individuals better manage emotional fluctuations in daily life, resulting in further improvement of depressive and anxious symptoms.
45640613|NCT05913336|Drug|Remimazolam Tosilate|Loading dose: 0.08mg/kg , Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1-0.2mg/kg/h
45778675|NCT01965470|Other|Enhanced Care|
45778676|NCT05182554|Behavioral|Doctor Videos|Receive ads on Facebook or through our website with videos in which health professionals tell people to get the Covid-19 vaccine. The health professionals answer common questions about the Covid-19 vaccine, such as how mRNA vaccines work, and what types of side effects to expect.
45778677|NCT05182554|Behavioral|Sharing Videos|Receive ads on Facebook with videos in which health professionals tell people to encourage their unvaccinated friends to get the Covid-19 vaccine.
45778678|NCT05182554|Behavioral|Sharing Videos (Influencers)|Receive ads on Facebook with videos in which health professionals tell people to get their most influential friends to encourage their unvaccinated friends to get the Covid-19 vaccine.
45778679|NCT05182554|Behavioral|Vaccine Ambassador|"Adults in participating geographic areas can sign up to be a vaccine ambassador on a website that the study team has built. The study team will send updates to vaccine ambassadors when new content has been posted to the website (e.g. a new video) and/or to remind the vaccine ambassadors to encourage their friends to get vaccinated. The study team will incentivize vaccine ambassadors by entering participating ambassadors into a lottery for a prize."
45778680|NCT05182554|Behavioral|Video framing|"The same videos will be displayed using two different frames: a myth frame and a fact frame. Visitors to the vaccine content website will randomly receive one framing of each video."
45778681|NCT05182554|Behavioral|Video order|The order in which videos appear on the vaccine content website will be randomized.
45778682|NCT05182008|Other|Decision aid|Online interactive decision aid on method of early abortion
45778683|NCT05182008|Other|Usual care|Patients will be directed to the abortion clinic website
45916038|NCT00006097|Drug|CC-1088|
45916039|NCT00006100|Biological|aldesleukin|
45916040|NCT00006100|Biological|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
45778684|NCT05181384|Other|isolated pelvic floor muscles training|isolated pelvic floor muscles training was emphasized, consisting of both quick and sustained contractions.
45778685|NCT05181384|Other|comprehensive stabilization exercise program|incorporated the contraction of PFMs with other spinal or extremity muscles
45916041|NCT00006100|Drug|fludarabine phosphate|
45916042|NCT00006100|Procedure|peripheral blood stem cell transplantation|
45640614|NCT05913323|Device|Rapid Expiratory Occlusion Monitor (REOM)|Device for which Health Canada approval (ITA Authorization) has been obtained for use in the present study.
45640615|NCT05913323|Diagnostic Test|Standard oscillometry|tremoflo device-100, Thorasys Thoracic Medical Systems Inc., Montreal, Canada
45640616|NCT05913323|Diagnostic Test|Standard pulmonary function test|Standard-of-care respiratory test.
45640617|NCT05913310|Drug|Kui-Yuan Chewable Tablets|Kui-Yuan chewable tablets are the optimal ingredients found in sunflower dish that can reduce uric acid and anti-gout, including flavonoids, Coumarin (including scopolamine) and phenolic acids.
45640618|NCT05913310|Drug|Placedo of Kui-Yuan Chewable Tablets|Placedo of Kui-Yuan Chewable Tablets are composed of L-arabinose, food starch and a few auxiliary materials.
45916043|NCT00006103|Drug|fluorouracil|
45916044|NCT00006103|Drug|irinotecan hydrochloride|
45916045|NCT00006103|Drug|leucovorin calcium|
45916046|NCT00006106|Drug|cisplatin|
45916047|NCT00006106|Drug|fluorouracil|
45916048|NCT00006106|Drug|ONYX-015|
45916049|NCT00006112|Drug|chemotherapy|
45916050|NCT00006112|Drug|fluorouracil|
45916051|NCT00006112|Drug|leucovorin calcium|
45916052|NCT00006112|Drug|mitomycin C|
45916053|NCT00006115|Drug|FOLFIRI regimen|
45916054|NCT00006115|Drug|FOLFOX regimen|
45916055|NCT00006115|Drug|fluorouracil|
45640619|NCT05913297|Diagnostic Test|Magnetic Resonance|Magnetic Resonance
45640620|NCT05913297|Diagnostic Test|Polysomnographic evaluation|Polysomnographic evaluation
45640621|NCT05913284|Drug|Methadone|The drug will be prepared by study investigator and then handover to the anaesthesiologist which is blinded to the study. The syringe will be labelled as study drug and given on induction of anaesthesia as intravenous infusion over 30 minutes
45640622|NCT05913284|Drug|Morphine|The drug will be prepared by study investigator and then handover to the anaesthesiologist which is blinded to the study. The syringe will be labelled as study drug and given on induction of anaesthesia as intravenous infusion over 30 minutes
45640623|NCT05913258|Device|Er:YAG laser system (Doctor smile, Pluser, Italy)|The Er:YAG laser offers a virtually painless alternative to conventional methods of caries removal, and its adoption in clinical practice could greatly reduce children's fear of going to the dentist. Caries removal is one of the leading reasons for dentist visits among children, and many children become fearful at the mere thought of a drill touching their teeth, before they even hear the sound. Laser caries removal could go a long way toward eliminating children's fear of going to the dentist; it is virtually painless, and most children are able to get through the entire procedure without needing local anesthesia.
45640624|NCT05913258|Device|Master Torque high/low-speed air rotor handpiece (KaVo Dental, Charlotte, North Carolina, USA)|Mechanical removal of carious lesions with a rotating handpiece and bur instruments is the most often used approach for treating dental caries because it is cost-effective, timesaving, and simple. However, these procedures have many drawbacks, including the potential for removing healthy tooth structures, vibration and noise, which can cause the patient anxiety and pain, thus necessitating local anesthesia.
45778686|NCT05181384|Other|education of pelvic girdle|educational session includes pelvic anatomy, mechanism of and risk factors for PPGP, and proper posture or body mechanism
45778687|NCT00458822|Drug|bortezomib|Given IV
45778688|NCT00458822|Drug|dexamethasone|Given orally
45778689|NCT05229744|Device|sequence MRI 3D FLAIR|"Participation in this research entails the addition of an MRI sequence and an injection of contrast product (Gadovist®):~- 3D FLAIR MRI sequence dedicated to the exploration of the inner ear, lasting 6min30s, performed 4 hours after the initial injection of contrast product"
45640625|NCT05913245|Dietary Supplement|Maltodextrin 12.5%|Preoperative Maltodextrin 12.5%
45640626|NCT05913245|Other|Water|Preoperative water
45778690|NCT00459368|Behavioral|Feedback of patient adherence information|Patient inhaled corticosteroid adherence information is being provided to physicians at clinic sites randomized to the intervention arm. Adherence information is available via electronic prescribing software, and so is available to physicians when writing, renewing, or viewing medications. Physicians at intervention sites also receive standard training in how to interpret adherence metrics and how to intervene on poor adherence.
45778691|NCT00459368|Behavioral|Active control group|Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
45778692|NCT05229588|Drug|Lurbinectedin 4 MG Injection [Zepzelca]|"Lurbinectedin will be administered with a minimum total volume of 100 mL of solution for infusion (either on 5% glucose or 0.9% sodium chloride).~Lurbinectedin will be administered intravenously through peripheral or central lines at a dose of 3.2 mg/m2 at a fixed infusion rate."
45778693|NCT01795040|Dietary Supplement|omega-3/omega-6 fatty acids (PUFAs)|Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid
45778694|NCT05278572|Behavioral|Stress Management and Relaxation Training/Expressive Supportive Therapy (SMART/EST)|Cognitive-behavioral stress management/expressive supportive therapy (CBSM+) group targeting depression
45778695|NCT00413582|Drug|Epidural Analgesia|Upon arrival to the operating room, patients will have a thoracic epidural (T 6-9) placed while in the sitting position. All epidural catheters will be inserted 3-5 cm within the epidural space and will be placed by attending anesthesiologists. Patients will receive midazolam 0.025 - 0.05 mg/kg IV (max 5mg) and/or fentanyl 0.5 - 2 mcg/kg IV for comfort during the procedure. Once the epidural is placed, the patient will be positioned for surgery. The epidural catheter will be initially bolused with 0.3ml/kg of ropivacaine 0.10% (max 10 ml), fentanyl 1 - 1.2 mcg/kg and clonidine 1.8 - 2mcg/kg. An infusion of ropivacaine 0.10%, fentanyl 2mcg/ml and clonidine 1.5mcg/ml will be initiated immediately at the rate of 0.3ml/kg/hr (max 10ml/hr). Intraoperatively, patients will receive intravenous fentanyl if indicated.
45778696|NCT00413582|Drug|Patient-Controlled IV Analgesia|In the PCA arm, patients will receive fentanyl (3-6 mcg/kg) at anesthesia induction. Additional fentanyl may be administered intraoperatively as indicated. Patients who are > 35 Kg. (in keeping with current FDA approved labeling) will receive a clonidine 0.1 mg/day transdermal patch to the deltoid immediately after induction of anesthesia. Subjects in the epidural arm also receive clonidine. Upon arrival to the post anesthesia care unit, patients will be placed on a patient controlled analgesic (PCA) pump (hydromorphone: loading dose if needed; 5-6 mcg/kg continuous infusion; 5-6 mcg/kg six minute demand dose). An additional hydromorphone dose (8mcg/kg) will be available every 2 hours for pain scores of > 4/10 throughout the duration of PCA use.
45778697|NCT00389168|Drug|Irbesartan|Titrated to 300 mg od, 48 weeks.
45640627|NCT05913232|Drug|H-1337 0.6%|ophthalmic solution
45640628|NCT05913232|Drug|H-1337 1.0%|ophthalmic solution
45640629|NCT05913232|Drug|H-1337 Placebo|ophthalmic solution
45640630|NCT05913232|Drug|Timolol 0.5%|ophthalmic solution
45640631|NCT05913206|Behavioral|Ambiguity|The intervention is a novel communication approach to communicate ambiguity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.
45640632|NCT05913206|Behavioral|Complexity|The intervention is a novel communication approach to communicate complexity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.
45640633|NCT05913206|Behavioral|Normalizing language|The intervention is a novel communication approach to normalize and explain the inherent uncertainty faced by parents of children with medical complexity during clinical decision making.
45640634|NCT05913206|Behavioral|Narrative|Parent and caregiver narratives about their decision making experiences for the care of their child with medical complexity.
45640635|NCT05913193|Other|Oral Nutritional Supplement (ONS)|Diabetes specific oral nutritional supplement
45778698|NCT00389168|Drug|Atenolol|Titrated to 100 mg od, 48 weeks.
45778699|NCT05179122|Procedure|Surgical drain|In this arm a surgical drain will be inserted prior to surgical wound closure
45916056|NCT00006115|Drug|irinotecan hydrochloride|
45916057|NCT00006115|Drug|leucovorin calcium|
45916058|NCT00006115|Drug|oxaliplatin|
45916059|NCT00006118|Drug|cisplatin|
45916060|NCT00006118|Drug|gemcitabine hydrochloride|
45640636|NCT05913180|Drug|Ascorbic Acid 1000 MG|1000mg Ascorbic acid orally daily started on the day of elective gynecological surgery for 10 days
45640637|NCT05913180|Drug|Placebo|Placebo tablet daily starting day of elective gynecological surgery for 10 days
45640638|NCT05913167|Procedure|laparoscopic nephrectomy|laparoscopic nephrectomy
45640639|NCT05913141|Other|Drug screen with PDO/PDO-TIL/PDOTS|Drug screen with patient-derived organoids, patient-derived organoids-tumor-infiltrating lymphocyte coculture system, or patient-derived organotypic tissue spheroids.
45778700|NCT05179044|Device|Guardian Sport Rehabilitator knee brace|The Guardian Sport Rehabilitator knee brace has pneumatic condyles that can be used to support and control the knee joint as well as an extension swing assist design which automatically assists in extending the knee when the patient themselves may guard against it. The Guardian Rehabilitator Knee Brace is considered by the FDA as a Class I external medical device. It is used on label and therefore exempt from IDE requirements.The Guardian Brace FDA registration to manufacturer external limb devices is attached for reference.
45778701|NCT00462020|Drug|5 days of IV antibiotics (ceftriaxone and metronidazole)|5 days of IV antibiotics (ceftriaxone and metronidazole once a day dosing)
45778702|NCT00462020|Drug|Home with oral antibiotics when eating (ampicillin/clavulanic acid)|Augmentin 40mg/kg BID when tolerating POs to complete 7 days total
45778703|NCT05277012|Drug|Etrumadenant|Etrumadenant capsule and tablet formulations
45778704|NCT05275374|Drug|XP-102|XP-102 will be administered orally once or twice daily in a continuous regimen.
45778705|NCT05275374|Drug|Trametinib|Trametinib will be administered 2mg orally once a day.
45778706|NCT05178576|Drug|Gevokizumab|120mg IV on day 1 of every 28-day cycle for 1 year (maximum of 13 cycles)
45778707|NCT05178576|Diagnostic Test|Signatera test|ctDNA monitoring at weeks 8, 12, 24, 36, 48, 60 and 72 unless disease recurrence is documented.
45778708|NCT05177718|Drug|Natalizumab 300 MG in 15 ML Injection|Disease modifying agent
45778709|NCT05177250|Device|HPLC|taking urine samples from participants and analyze these samples to detect bisphenol A and paraben
45778710|NCT05226390|Biological|MVA-SARS-2-ST|In this trial MVA-SARS-2-ST will be used. Each vial contains 1 x 107 IU/dose MVA-SARS-2-ST in 0.5 mL as active ingredient. The solution will be used for nebulization and direct administration to the respiratory tract.
45778711|NCT00414206|Drug|Mecamylamine|
45778712|NCT00414206|Drug|Placebo|
45778713|NCT05480046|Drug|Risperidone ISM|Risperidone ISM is administered every 4 weeks
45778714|NCT04241874|Other|Mechanical Ventilation|Respiratory support through mechanical ventilator
45778715|NCT04241640|Drug|Nefopam 20 MG/ML|Nefopam group nefopam 20 mg during surgery and follow by 80 mg in 24 hours postoperative
45778716|NCT04241640|Drug|Placebo|Placebo
45640640|NCT05913128|Procedure|Glandular Urethral Disassembly technique|For Primary Distal Hypospadius Repair
45640641|NCT05913115|Drug|FPA144|FPA144 will be administered intravenously Q2W.
45640642|NCT05913102|Drug|PDLLA|Administer PDLLA/saline every 2 weeks for 2.5 months
45916061|NCT00006118|Drug|paclitaxel|
45916062|NCT00006121|Drug|oxaliplatin|
45640645|NCT05913076|Device|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for first group|"The study involved the fabrication of occlusal-coverage bonded type RME devices utilizing Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy). Each patient in Group 1 (classical RME method) was instructed to open Hyrax screw twice a day for a week. At the end of the respective periods (1 week), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
45640646|NCT05913076|Device|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for second group|"The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 2. Each patient in Group 2 (3-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. At the end of the respective periods (3 weeks), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
45916063|NCT00006124|Drug|celecoxib|Given orally
45778717|NCT00462332|Drug|Fludarabine|Induction therapy
45778718|NCT00462332|Drug|Campath|Induction therapy
45778719|NCT00462332|Procedure|Transplant|Post-induction therapy
45778720|NCT00462332|Drug|Campath|Post-induction therapy
45778721|NCT00462332|Drug|Fludarabine|Induction therapy
45778722|NCT00462332|Drug|Campath|Induction therapy
45778723|NCT00462332|Drug|Campath|Post-induction therapy
45778724|NCT04241094|Behavioral|Loved one assisted treatment|The investigators propose to bring a loved one into PE, one of the most researched and efficacious treatments for PTSD, to increase support for PE adherence. The intervention is a 13-session cognitive-behavioral, intimate partner-assisted treatment for PTSD that draws from PE, ICBT, and PE2.
45778725|NCT05226312|Other|Local Warm Compress|The warm application will be made by the researcher for 15 minutes three times a day according to the local warm application process steps.
45778726|NCT00462644|Drug|RSI sedation with etomidate/succinylcholine|etomidate 0.3 mg/kg IV plus succinylcholine 1 mg/kg IV
45778727|NCT00462644|Drug|RSI sedation with fentanyl/midazolam/succinylcholine|100 micrograms fentanyl IV, plus 5 mg midazolam IV, plus 1 mg/kg succinylcholine IV
45778728|NCT05176704|Device|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
45916064|NCT00006124|Drug|placebo|Given orally
45916065|NCT00006127|Drug|amifostine|
45916066|NCT00006130|Procedure|Core decompression|
45916067|NCT00006133|Drug|estradiol|
45916068|NCT00006133|Drug|ethinyl estradiol|
45916069|NCT00006133|Drug|medroxyprogesterone|
45916070|NCT00006133|Drug|norethindrone|
45916071|NCT00006136|Drug|arginine butyrate|
45640647|NCT05913076|Device|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for third group|"The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 3. Each patient in Group 3 (5-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. The aforementioned screw open-close procedure was implemented over a period of five weeks. At the end of the respective periods (5 weeks), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
45640648|NCT05913063|Device|Structured Light Imaging Microscopy|Conducting the psychophysical task on the perception of OAM-coupled polarized light created using the experimental setup - Structured Light Imaging Microscopy (SLIM). Four types of vortex orbital angular momentum, differing by the number of fringes l=5;10; 15;20, will be presented for 0.5s per trial during which an azimuthally varying entoptic profile rotated clockwise or counterclockwise. A circular mask with a varying radius will be placed at fixation, thus the task will be performed at varying eccentricities. Circular obstruction of the area will be achieved due to the high refresh-rate structured light modulator. The threshold mask size will be changed by a 2up/1down staircase method (71% accuracy for the estimation of mask size).
45640649|NCT05913050|Other|Therapeutic resistance exercise|Therapeutic exercise program based on individualized progressive resistance exercises performed during 3 months at home, with a frequency of 1-3 sessions per week at the hospital.
45640650|NCT05913050|Other|Education|Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
45640651|NCT05913037|Drug|Test group (Group A): FCN-159 8 mg, orally, once daily;|After completing all screening visit items, qualified patients will be randomly assigned to the test group (Group A) or control group (Group B) in a 2:1 ratio, and receive FCN-159 or placebo within 3 days after randomization.
45640652|NCT05913037|Drug|Control group (Group B): Placebo, orally, once daily;|After completing all screening visit items, qualified patients will be randomly assigned to the test group (Group A) or control group (Group B) in a 2:1 ratio, and receive FCN-159 or placebo within 3 days after randomization.
45778729|NCT00462722|Drug|Ibuprofen|400 mg with each exercise session (up to 5 days per week) for 9 months
45916072|NCT00006136|Drug|epoetin alfa|
45448636|NCT05056480|Other|Surveys|Parent/caregivers participants will complete multiple repeating surveys to gather family-reported perspectives on the impact of the PCCI care management program. Clinical staff participants will complete multiple repeating surveys that gather clinician perspectives on the impact of the PCCI care management program. Parent/caregiver and clinical staff participants will also be invited to participated in one-on-one semi-structured interviews with the study team.
45640653|NCT05913024|Biological|Enterovirus Type 71 Vcacine|Participants received two doses of the vaccine, 28 days apart
45640654|NCT05912998|Procedure|cartilage regeneration technique|autologous adipose tissue graft with hyaline cartilage graft mixed with fiberinglu
45640655|NCT05912985|Other|different oxygenation methods|Different oxygenation methods are used in bronchoscopy procedures under sedation.
45640656|NCT05912972|Other|Patient registry|Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
45640657|NCT05912959|Other|photo biostimulation|the intervention is a type of wavelength around 820 nm. this method of treatment is totally safe. yet, it has many therapeutic effects on the cellular level as well as tissue and organ level. during treatment with laser, the patient does not feel any specific sensation.
45640658|NCT05912946|Drug|Interferon|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. Interferon solution was configured according to the ratio of 3 million IU interferon +49ml normal saline. The urinary tube was clamped and the interferon solution was injected through the water inlet tube and retained for 30 minutes.
45640659|NCT05912946|Drug|Sodium Hyaluronate|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sterile sodium hyaluronate solution was injected through the water inlet tube and retained for 30 minutes.
45640660|NCT05912946|Drug|Sodium Chloride Injection|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sodium chloride injection was injected through the water inlet tube and retained for 30 minutes.
45778730|NCT00462722|Drug|Placebo|with each exercise session (up to 5 days per week) for 9 months
45778731|NCT00462722|Behavioral|musculoskeletal-loading exercise|Exercise training program designed to increase bone and muscle mass, including weight lifting and weight-bearing exercises such as jumping in place and treadmill walking up to 5 days per week for 9 months
45778732|NCT05176392|Device|Active rTMS|Active rTMS will be given at the left dorsolateral prefrontal cortex with a double blind TMS coil.
45778733|NCT05176392|Behavioral|Headache Management Therapy|Therapy will be provided on headache management.
45916073|NCT00006142|Behavioral|phenylalanine restricted diet|
45916074|NCT00006145|Drug|Valganciclovir|
45916075|NCT00006154|Drug|Indinavir sulfate|400 mg tablets equaling 1600 mg daily
45916076|NCT00006154|Drug|Ritonavir|100 mg liquid capsules equaling 400 mg daily
45916077|NCT00006154|Drug|Abacavir sulfate|300 mg capsules equaling 600 mg daily. Administration based on individual results after 16 weeks.
45916078|NCT00006154|Drug|Efavirenz|200 mg capsules equaling 600 mg daily
45916079|NCT00006154|Drug|Stavudine|30-40 mg capsules equaling 60 or 80 mg daily
45448637|NCT03875950|Behavioral|Clinician training intervention|This intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care workers delivering PrEP to adolescent girls and young women to prevent HIV in Kenya.
45448638|NCT04472572|Biological|Convalescent Plasma|Fresh or frozen plasma will be infused one time to patients with COVID-19 infection
45916080|NCT00006154|Drug|Didanosine|250-400 mg E.coated tablets equaling 250 or 400 mg daily
45640661|NCT05912920|Procedure|gastric band|gastric band
45778734|NCT05176392|Device|Sham rTMS|Sham rTMS will be given at the left dorsolateral prefrontal cortex. All parameters of the treatment will appear identical to the active treatment, with only the rTMS coil used to administer the treatment flipped 180 degrees to prevent stimulation.
45778735|NCT05176392|Behavioral|Headache Education Control|In the control, educational sessions on headaches will be provided.
45640662|NCT05912907|Other|potassium nitrate in polycarboxilate cement|5% potassium nitrate in polycarboxylate; pre-weighed 95 mg zinc oxide powder and 5mg of KNO3 will be placed on a glass slab followed by mixing by polyacrylic acid (liquid) in a 1:1 P/L ratio
45640663|NCT05912894|Procedure|Videolaparoscopic cholecystectomy|Evaluation of Rouvière's Sulcus Anatomical Variation.
45640664|NCT05912881|Other|Olfactory training|Participants perform olfactory training using sticks filled with scented essential oils.
45640665|NCT05912881|Other|Placebo training|Participants perform olfactory training using sticks filled with unscented medium chain triglycerides.
45640666|NCT05912868|Device|Endoscopic Mini/Less Open Sublay Repair|The traditional techniques are open sublay or transabdominal intraperitoneal onlay mesh (IPOM) repair. In order to avoid the risks -large trauma to the abdominal wall with pain and infection, lesion of intraabdominal organs - a new hybrid technique - small skin incision, wide endoscopic dissection of the retrorectus space with implantation of a large mesh - was developed (EMILOS -Endoscopic Mini/Less Open Sublay).
45640667|NCT05912855|Device|qNOX|Non
45640668|NCT05912842|Behavioral|Organizational Partnerships for Healthy Living|Component 1 is a comprehensive training for all MLP care providers delivered to clinical, social and behavioral, and legal staff together to establish a collaborative environment. Component 2 consists of the screening tool and screening protocol that is designed to identify health-harming legal needs of PLWH patients. Component 3 includes the provision of legal support through partnership with the Legal Clinic for the Disabled.
45640669|NCT05912842|Behavioral|Standard of Care|Comparison arm health organization will only receive the HIV standard of care (U.S. CDC HIV standard of care) and referral to legal aid.
45640670|NCT05912829|Device|IOL Master 700|Biometry using the IOL Master 700
45640671|NCT05912829|Device|Casia-2|Anterior segment-OCT to evaluate lens tilt
45640672|NCT05912829|Device|MS-39|Corneal Topography using the MS-39
45640673|NCT05912829|Device|OSIRIS|Abberometry using the OSIRIS-Abberometer
45640674|NCT05912829|Device|Autorefractor|Evaluation of Refraction using an Autorefractor
45778736|NCT05224830|Other|Nijmegen questionnaire score|We collected the Nijmegen Questionnaire in order to diagnosis of Hyperventilation Syndrome
45916081|NCT00006154|Drug|Aldesleukin|Subcutaneous injection equaling 15 x 10^6 IU daily dose. Administration based on individual results after 16 weeks and randomization.
45640675|NCT05912829|Diagnostic Test|Subjective Refraction|Refraction performed by experienced staff
45640676|NCT05912829|Diagnostic Test|Biomicroscopy|Slit Lamp Examination
45640677|NCT05912816|Drug|RC48 Combined With Tislelizumab|"In this trial, RC48 was scheduled to be administered at a dose of 2.0 mg/kg every 3 weeks, with the first dose on day 1 of the first cycle.~Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle. The drug is diluted with normal saline and administered by intravenous drip for one hour."
45640678|NCT05912803|Device|Simulated Equestrian Therapy|"The treatment group will receive Simulated Equestrian Therapy for 12 weeks thrice per week using 2 horse simulators (wooden and mechanical) in two phases.~Phase I The child will be instructed to ride the mechanical simulator in a pre-defined area measuring 10 yards and complete a total of 4 rounds of this area. Rest periods in between and after will be provided to the child when required. Major muscles of the body will be targeted here to strengthen the core.~Phase II The child will be instructed to ride the wooden simulator and a combination of goal directed activates will be performed."
45640679|NCT05912803|Other|Neuro-Motor Therapy|This group will perform overall stability and body balancing exercises to strengthen the core and develop the coordination and balance required for task performance. Each activity will be performed in a set of 2-3, considering the activity level of the child, with 8-12 repetitions attaining the available ROM and flexibility of the child. The participants will undergo warm-up before the exercise and cool-down afterwards.
45640680|NCT05912790|Device|eyeTube|Implantation of a drainage device in the eye, in combination with the eyeWatch implant
45778737|NCT05272254|Drug|10% povidone iodine + FV|applied to children's teeth
45778738|NCT05272254|Other|Placebo +FV|applied to children's teeth
45778739|NCT00528398|Drug|cytarabine|
45778740|NCT00528398|Drug|idarubicin|
45778741|NCT05223348|Other|Meditation practice|Our intervention will involve two meditation exercises. 1) the experimental condition (body scan meditation). 2) the active comparator condition (listening task)
45778742|NCT00528788|Drug|doxercalciferol|
45916082|NCT00006157|Drug|Desipramine|
45916083|NCT00006157|Behavioral|Cognitive Behavioral Treatment|
45916084|NCT00006160|Behavioral|home based worker|
45916085|NCT00006163|Behavioral|Personalized Self-management|
45916086|NCT00006163|Behavioral|Community Resources|
45916087|NCT00006166|Procedure|Transjugular intrahepatic portasystemic shunts (TIPS)|
45916088|NCT00006166|Procedure|Total paracentecis (TP)|
45778743|NCT05174520|Other|Routine Physical Therapy|Routine physical therapy will be provided to group A for 25 minutes thrice a week for 4 weeks.
45640681|NCT05912751|Other|Exercise Then Foam Roll|Participants in AB will perform the experimental (exercise) intervention first and the control (foam rolling) intervention second.
45640682|NCT05912751|Other|Foam Roll Then Exercise|Participants in BA will perform the control (foam rolling) intervention first and the experimental (exercise) intervention second.
45640683|NCT05912725|Procedure|Implant placement|"4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar~4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar"
45778744|NCT05174520|Other|Muscle Energy Technique|Muscle Energy technique along with Routine physical therapy will be provided to group B for40 minutes thrice a week for 4 weeks.
45778745|NCT05173974|Device|Super Poligrip Free|A single application of 1 gram of Super Poligrip Free will be applied topically to oral tissues via the upper denture.
45778746|NCT05173974|Device|Experimental Denture Adhesive 1|A single application of 1 gram of Experimental Denture Adhesive 1 will be applied topically to oral tissues via the upper denture.
45778747|NCT05173974|Device|Experimental Denture Adhesive 2|A single application of 1 gram of Experimental Denture Adhesive 2 will be applied topically to oral tissues via the upper denture.
45778748|NCT00414518|Drug|Tenofovir disoproxil fumarate/Emtricitabine|300 mg Tenofovir disoproxil fumarate/ 200 mg emtricitabine tablet taken orally once daily
45640684|NCT05912712|Other|Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum Treatment|10 mL PRP and thrombin coagulum gel was administered every night for seven consecutive days by the same IBD specialist. Before the intervention, the patients had to defecate. The prepared PRP gel was injected into the external opening of the rectum using the same syringe, and the patient was kept in the Trendelenburg position to ensure that the therapeutic drug remained in place under gravity. The normal supine position was returned after 15 minutes to minimize PRP leakage. The outflow was observed, and the amount of outflow was recorded.
45640685|NCT05912712|Other|Autologous Platelet-poor Plasma (PPP) and Thrombin Coagulum Treatment|10 mL PPP and thrombin coagulum gel was administered every night for seven consecutive days by the same IBD specialist. Before the intervention, the patients had to defecate. The prepared PPP gel was injected into the external opening of the rectum using the same syringe, and the patient was kept in the Trendelenburg position to ensure that the therapeutic drug remained in place under gravity. The normal supine position was returned after 15 minutes to minimize PPP leakage. The outflow was observed, and the amount of outflow was recorded.
45640686|NCT05912712|Drug|Mesalazine Suppository Treatment|For patients receiving mesalazine suppositories, the intervention was inserted through the anus with a disposable sanitary finger to the point of slight loss of resistance. To facilitate intervention, moisturize with water or cream. If the drug drains within 10 minutes, it should be re-inserted. The swelling at the local injection site on each group's intervention day was recorded.
45640687|NCT05912712|Biological|Infliximab Treatment|Patients, in every arm, all receive infliximab (300 mg iv at 0, 2, 6 weeks, and then every eight weeks).
45640688|NCT05912699|Other|Slimbiotics Postbiotic|"SlimBiotics postbiotic formula contains the following ingredients:~Heat-inactivated L. fermentum K8 Postbiotic.~Microcrystalline cellulose."
45640689|NCT05912699|Other|Placebo|The placebo capsules contain microcrystalline cellulose only.
45640690|NCT05912686|Drug|Atorvastatin 80mg|The test group will undergo high-dose atorvastatin treatment (80mg/day) for the first 3 days after the procedure, transitioning to a standard dose (20mg/day) of atorvastatin thereafter.
45640691|NCT05912686|Drug|Atorvastatin 20mg|The control group will receive a consistent standard dose (20mg/day) of atorvastatin.
45640692|NCT05912673|Device|renal doppler|Toshiba Aplio ultrasound machine and renal resistive index will be measured (peak systolic velocity- end diastolic velocity/ peak systolic velocity
45640693|NCT05912660|Device|Aortic Valve Replacement|Aortic Valve Replacement (surgically or TAVI)
45778749|NCT00414518|Drug|Lopinavir/Ritonavir|Three 400 mg lopinavir/ 100 mg ritonavir soft gel capsules taken orally twice daily
45778750|NCT01795664|Radiation|Functional Respiratory Imaging|CT-scan of thorax, at visit 2 pre and postdose and at visit 3 pre and postdose
45778751|NCT01795664|Drug|Salmeterol xinafoate and Fluticasone propionate HFA pMDI|"Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)"
45778752|NCT01795664|Drug|Seretide Evohaler|"Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)"
45778753|NCT01795664|Drug|Placebo of Test product|"Single dose of 2 puffs~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
45778754|NCT01795664|Drug|Placebo of Reference product|"Single dose of 2 puffs~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
45778755|NCT05271084|Drug|Citalopram (tablet) 20 mg + Pentoxifylline (tablet) 400Mg|Selective serotonin reuptake inhibitor (SSRI) + phosphodiesterase inhibitor with anti-inflammatory properties
45778756|NCT05271084|Drug|Citalopram (tablet) 20 mg + Placebo (tablet)|Selective serotonin reuptake inhibitor (SSRI) + placebo
45778757|NCT00531518|Drug|aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine|Oral, daily, generally at lower than manufacturer's recommendations
45778758|NCT00531518|Behavioral|Psychoeducational multifamily group treatment|Families and patients are educated on psychobiology of psychosis and trained in coping skills to avoid psychosis by reducing stress and optimizing social environment at home, school, work
45778759|NCT00531518|Behavioral|Supported employment and education|Participants are provided direct assistance, guidance and ongoing support to gain employment and succeed in their educational goals.
45778760|NCT01658514|Drug|Met DR|metformin delayed-release tablets
45640694|NCT05912647|Behavioral|MTM|Participants will receive added medicine management support from a pharmacist. This will involve one 60-minute session with the pharmacist either in-person or over the phone and at least four 30-minute follow-up sessions with the pharmacist over the phone.
45778761|NCT01658514|Drug|Met XR|metformin extended-release tablets
45778762|NCT01658514|Drug|Placebo|
45778763|NCT00533546|Drug|Activated Protein C|Intravenous APC (10, 15, 22, 33, 50, and 75 mcg/kg) administered to patients with acute ischemic stroke within 0 - 9 hours of symptom onset
45640695|NCT05912647|Behavioral|CHW|Participants will receive support from a Community Health Worker (CHW) to address life challenges that might be affecting their health and diabetes and to discuss diabetes beliefs and concerns. This will involve one ~30-minute phone call with the CHW to discuss needs and a 2-hour session with the CHW in-person for a comprehensive assessment. Participants will also receive ~10, 15 to 30-minute calls from the CHW to discuss diabetes beliefs and concerns.
45640696|NCT05912634|Procedure|Conservative TAAD-R|Cardiac arrest will be ensured using antegrade potassium-rich cardioplegia solution delivered directly into the coronary ostium or after coronary sinus cannula insertion, in patients with aortic regurgitation aorta will be resected down to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion could be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget over each commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients revealing normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferred.
45640697|NCT05912634|Procedure|Extensive TAAD- R|Patients who experienced dilatation of the sinuses of Valsalva >4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will undergoing replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure.Total arch replacement procedures (TARP) will fulfilled with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total arch)
45640698|NCT05912621|Drug|Tirzepatide|Tirzepatide dose is titrated up by 2.5 mg every four weeks as per below, starting with 2.5 mg weekly and maxing out at 15 mg.
45640699|NCT05912608|Procedure|Conservative TAAAD-R|Cardiac arrest will be ensured using antegrade potassium-rich cardioplegia solution delivered directly into the coronary ostium or after coronary sinus cannula insertion, in patients with aortic regurgitation aorta will be resected down to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion could be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget over each commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients revealing normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferred.
45778764|NCT00534794|Drug|Elestat|Elestat BID for 2 days
45778765|NCT00534794|Drug|Pataday|Pataday QD for 2 days
45778766|NCT01658436|Drug|BEZ235 (Stage 1)|The investigational study drug used in this trial was BEZ235, which was supplied as 50mg, 200mg, 300mg, and 400mg solid dispersion sachets. Supply as 200mg and 50mg were provided for dose reduction. Patients were instructed to take the contents of one sachet of BEZ235 twice a day in the morning within 30 minutes after a light meal (breakfast).
45778767|NCT04244604|Other|Acute Salt (sodium chloride)|Varied amounts of salt (sodium chloride) will be added to a very low sodium soup to determine the effects of a single high sodium meal on measures of vascular function and autonomic regulation of blood pressure
45778768|NCT05170776|Other|Pilates and postural correction exercise|"ten exercises will be performed:~Hip Twist Level 1~Double leg stretch Level 1~Double leg stretch Level 2~One leg stretch Level 1~Clam Level 1~Scissors Level 1~Arm openings Level 1~Breast stroke prep Level 1t~Hip Twist Level 1.~Breast stroke prep Level 2 as for level 1 postural correction exercise~1-Strengthening deep cervical flexors 2-Stretching cervical extensors 3- Strengthen shoulder retractors 4-Unilateral and bilateral pectoralis stretch"
45778769|NCT05170776|Other|Pilates exercises|"ten exercises will be performed:~Hip Twist Level 1~Double leg stretch Level 1~Double leg stretch Level 2~One leg stretch Level 1~Clam Level 1~Scissors Level 1~Arm openings Level 1~Breast stroke prep Level 1t~Hip Twist Level 1.~Breast stroke prep Level 2 as for level 1"
45778770|NCT05170776|Other|postural correction exercises|"postural correction exercise in the form of :~Strengthening deep cervical flexors through chin tucks,~Stretching cervical extensors through a chin drop~Strengthen shoulder retractors~Unilateral and bilateral pectoralis stretch alternating each two-week period."
45778771|NCT05219838|Drug|Lu AG06466|Lu AG06466 will be administered per dose and schedule specified in the arm description.
45778772|NCT05168280|Drug|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively.
45778773|NCT05168280|Drug|0.9% saline|The 0.9% saline is administered with the same volume at the same speed as the other group.
45778774|NCT05219370|Drug|Cannabis oil|administration of different cannabis oil types as compared with placebo
45778775|NCT05170308|Device|CO2 fractional laser|The study subjects' body will be divided into two equal halves along sagittal midline section with one side receiving treatment with fractional CO2 laser (experimental) to treat dyspigmentation in lichen planus pigmentosus
45778776|NCT05170152|Procedure|ultrasonography-guided injection|ultrasonography-guided injection
45778777|NCT05170152|Procedure|pullae A1 release|ultrasonography-guided pullae A1 release
45916089|NCT00006169|Behavioral|Behavioral Treatment|
45916090|NCT00006172|Device|Bright light box|60-min light therapy shortly after awakening
45916091|NCT00006172|Device|High-output negative ion generator|60-min high-density ion exposure shortly after awakening
45916092|NCT00006172|Device|Low-output negative ion generator|60-min low-density ion exposure shortly after awakening
45916093|NCT00006181|Behavioral|Team-based intervention|
45916094|NCT00006181|Behavioral|One-on-one intervention|
45640700|NCT05912608|Procedure|Extensive TAAAD-R|Patients who experienced dilatation of the sinuses of Valsalva >4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will undergoing replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure.Total arch replacement procedures (TARP) will fulfilled with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total hemiarch) or reimplantation of the innominate trunk only (partial hemiarch).
45916095|NCT00006187|Drug|Investigational drug|
45916096|NCT00006190|Drug|Nelfinavir mesylate|
45778778|NCT05165160|Diagnostic Test|Blood sample|Pre- and postoperative blood sample
45778779|NCT05168514|Other|Massage|"Patient Identification Form, Pittsburgh Sleep Quality Index and McGill Pain Scale Short Form will be applied to patients with written and verbal consent. Scales and massage application will be done before the pharmacological agent is administered to the patients.~Back massage will be applied to the experimental group for 10 minutes every day for 10 days. Routine treatment and care practices in the clinic will continue. Pittsburgh Sleep Quality Index, McGill Pain Scale Short Form will be applied to the experimental group before and after each massage and scores will be recorded for 10 days.~The control group will not be interfered with, and the routine treatment and care practices in the clinic will continue. Pittsburgh Sleep Quality Index, McGill Pain Scale Short Form will be applied to the control group simultaneously with the experimental group and scores will be recorded for 10 days."
45778780|NCT05053854|Drug|Talazoparib|During dose escalation, doses of talazoparib that can be administered are 0.1mg, 0.25mg, 0.5mg or 1mg oral daily. Talazoparib will be given on days 2-6 of each cycle of 177Lu-DOTA-Octreotate for cycles 2-4, every 8 weeks
45778781|NCT05108376|Device|Visensia Safety Index (VSI)|Enrolled patients will undergo continuous vital sign monitoring, to be used by the Visensia Safety Index (VSI) to identify early deterioration. If early deterioration is identified, the VSI will produce an alert to notify the RACE team.
45778782|NCT00464204|Drug|"6 % Hydroxyethylstarch 130/0.4 = Voluven®"|Voluven® was administered intravenously. Voluven® rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day on the second to fourth days, according to patient needs.
45778783|NCT00464204|Drug|0.9 % NaCl|NaCl 0.9 % was administered intravenously. NaCl 0.9% rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day from the second to the fourth day, according to patient needs.
45778784|NCT05107206|Device|Mechanical Thrombectomy using the Envi™-SR Thrombectomy device|Clot removal using the Envi™-SR Thrombectomy device
45778785|NCT05107206|Device|Mechanical Thrombectomy using the Solitaire or Trevo Revascularization Device|Clot removal using the Solitaire or Trevo Revascularization Device
45916097|NCT00006190|Drug|Stavudine|
45916098|NCT00006190|Drug|Lamivudine|
45640701|NCT05912595|Device|EXOPULSE Mollii Suit Stimulation|"We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of tissue oxygenation and frequent MS symptoms following a single session of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for one month (3 sessions per week) on tissue oxygenation and MS related symptoms."
45640702|NCT05912582|Radiation|Intensity modulated radiation therapy (IMRT) combined with chemotherapy|Intensity modulated radiation therapy (IMRT) combined with chemotherapy
45640703|NCT05912569|Procedure|Delay sentinel node biopsy|In the case of a patient undergoing breast-conserving surgery for intraductal carcinoma, the sentinel lymph node is not excised during the primary surgery but only marked for identification. I
45640704|NCT05912556|Device|Digital Program 1|2/3 of randomized subjects use digital program 1 for 12 weeks to provide mental stimulation
45778786|NCT05164458|Drug|IBI 308 injection|IBI308 IV 200mg Q3W Day1
45916099|NCT00006190|Drug|Efavirenz|
46070378|NCT00844545|Drug|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange
45640705|NCT05912556|Device|Digital Program 2|1/3 of randomized subjects use digital program 2 for 12 weeks to provide mental stimulation
45640706|NCT05912543|Procedure|Titration of FiO2|The inhaled oxygen concentration after one-lung ventilation will be treated by the group.
45640707|NCT05912530|Other|no intervention|there is no intervention will done
45916100|NCT00006193|Behavioral|diet|
45916101|NCT00006196|Drug|Vitamin D|
45916102|NCT00006199|Drug|R115777 (farnesyl transferase inhibitor)|
45916103|NCT00006199|Drug|Topotecan|
45916104|NCT00006202|Drug|Lutein|
45916105|NCT00006205|Drug|ondansetron + cognitive behavioral therapy|ondansetron (4 mcg/kg b.i.d)
45916106|NCT00006205|Drug|topiramate + cognitive behavioral therapy|topiramate (up to 300 mg/day)
45916107|NCT00006205|Drug|Placebo + cognitive behavioral therapy|placebo
45916108|NCT00006205|Drug|ondansetron + topiramate + cognitive behavioral therapy|ondansetron (4 mcg/kg b.i.d) + topiramate (up to 300 mg/day)
45916109|NCT00006208|Drug|Efavirenz|
45916110|NCT00006208|Drug|Emtricitabine|
45916111|NCT00006208|Drug|Stavudine|
45916112|NCT00006208|Drug|Didanosine|
45916113|NCT00006211|Drug|Capravirine|
45916114|NCT00006211|Drug|Nelfinavir mesylate|
45916115|NCT00006214|Drug|flutamide|
45916116|NCT00006214|Other|placebo|
45916117|NCT00006220|Drug|arsenic trioxide|
45916118|NCT00006220|Drug|tretinoin|
45916119|NCT00006223|Biological|recombinant flt3 ligand|
45916120|NCT03761953|Drug|Oritavancin Injection|single 1200mg infusion of IV oritavancin.
45916121|NCT00387634|Biological|TBE vaccine for adults|Serology blood draw.
45916122|NCT00006226|Drug|thalidomide|Given PO
45640710|NCT05912504|Other|Phoen survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
45640711|NCT05912491|Diagnostic Test|Transperineal ultrasonography|Transperineal ultrasound (TPU) with a Voluson E6 (GE Medical systems, Milwaukee, WI, USA). The probe was oriented to coaxially visualise the pubic symphysis on one side and the anus and rectum on the other side of the 2D image. Next, 3D/4D ultrasound was performed to obtain an image in the coronal plane at the level of the arms of the levator ani muscle, showing the pubic symphysis and the anus. All measurements were performed in three states: during pelvic muscle relaxation, during Valsalva manoeuvre, and during perineal squeezing.
45640712|NCT05912478|Other|Videogame-Based Therapy|The Nintendo Switch (Version 2) will be used to play video games. Within the scope of the study, Nintendo Switch games were analyzed with respect to their technical and fictional characteristics, required and optional movement patterns, difficulty levels, transitions between difficulty levels, and compatibility with priority problems. The selected activities will prioritize the activation of the scapular muscles. Throughout the activities, the participant will be required to mimic the on-screen avatar's movements. The player will receive a higher score if his or her movements in the game resemble the avatar's in terms of angular, velocity, and fluidity.
45778787|NCT05164458|Drug|IBI 389 Injection|IBI 389 IV Q2~Q3W Day 1
45778788|NCT05106816|Other|skin surface vibration|This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones.
45640713|NCT05912478|Other|Waiting list|The participants who were placed on a waiting list for eight weeks and constituted the control group will be asked to carry on with their normal activities. Participants in the control group will be contacted by phone in the fourth week to inquire about their status and to remind them that the exercise program will begin in the coming weeks. At the end of the 8-week study, the participants from the control group will participate in the exercise program.
45640714|NCT05912465|Other|Stress Reduction Training|A subgroup of patients from Vienna will undergo an additional PET/CT scan after the first follow-up PET/CT, which takes place one month after stress reduction training. The stress reduction training involves performing a breathing technique.
45640715|NCT05912452|Other|Percussion Massage Therapy|Individuals who receive percussion massage therapy will be treated with a 5-minute medium-frequency percussion massage on the deltoid muscle group every other day. Percussion massage therapy will be applied in a total of 10 sessions and will be completed in 20 days.
45640716|NCT05912452|Other|Kinesiotaping|the Kinesiotape group; Kinesiotape banding will be done with 25% tension by applying a Y band to the deltoid muscle group. After the application, the Kinesio band will stay on the participant for 2 days. The next day, the participant will rest. This cycle will be repeated for 20 days.
45640717|NCT05912452|Other|Dynamic stretching|Dynamic stretching exercises will be applied to the shoulder flexor and abductor muscle groups in the Dynamic Stretching Group with 10 repetitions. As in percussion massage therapy, these exercises will be performed under the supervision of a physiotherapist every other day. The application will continue for 20 days.
45640718|NCT05912439|Behavioral|SidekickHealth|Usage of mobile application called SidekickHealth.
45640719|NCT05912426|Behavioral|Reduced-sodium potassium-enriched salt|Supply and use of a reduced-sodium, potassium-enriched iodised salt (66% potassium chloride, 34% sodium chloride).
45640720|NCT05912413|Other|there is no intervention|there is no intervention
45640721|NCT05912400|Diagnostic Test|Blood draw|• An additional 10 mL of blood will then be drawn for mitochondrial testing purposes.
45778789|NCT05106816|Other|light skin surface vibration- SHAM|This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones. Worn at the lowest frequency will simulate the active arms with no potential change in symptoms.
45778790|NCT00464438|Drug|gatifloxacin|Day 1-6 = 1 drop of study medication three times a day
45640722|NCT05912400|Other|FACIT-F and Pain Scales|• Questionnaires regarding pain and fatigue will be provided for the subject to review and answer.
45640723|NCT05912387|Drug|Rosuvastatin|Rosuvastatin 20 mg tablet once daily by mouth
45640724|NCT05912374|Behavioral|standard Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)|CHRP-BB is an evidence-informed behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. CHRP-BB consists of 4 weekly 50- minute sessions.
45640725|NCT05912374|Behavioral|enhanced Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)|The enhanced version of CHRP-BB is an adapted behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. This intervention consists of 4 weekly 50- minute sessions that include cognitive dysfunction accommodation strategies.
45778791|NCT00464438|Drug|moxifloxacin 0.5% eye drops|Day 1-6 = 1 drop of study medication three times a day
45778792|NCT05053308|Drug|Intravenous Infusion|IV PCA(fentanyl) Fentanyl bolus = MME * 15%
45778793|NCT05053308|Drug|Sublingual Tablet|subligual fentanyl(Narco®) Fentanyl 100mcg/200mcg/300mcg according to the around-the-clock opioid requirement.
45778794|NCT05161728|Diagnostic Test|PSMA-PET/CT|PSMA-PET/CT
45778795|NCT00465530|Drug|Saline|Intranasal Saline
45778796|NCT00465530|Drug|Gentamycin|Intranasal irrigation
45916123|NCT00006226|Other|laboratory biomarker analysis|Correlative studies
45916124|NCT00006232|Drug|dexamethasone|
45916125|NCT00006232|Drug|doxorubicin hydrochloride|
45916126|NCT00006232|Drug|idarubicin|
45916127|NCT00006232|Drug|vincristine sulfate|
45916128|NCT00006235|Drug|carboplatin|
45916129|NCT00006235|Drug|pegylated liposomal doxorubicin hydrochloride|
45916130|NCT00006241|Biological|filgrastim|
45916131|NCT00006241|Drug|chemotherapy|
45916132|NCT00006241|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45640726|NCT05912361|Behavioral|receiving a one hour theoretical and hands on training session before using an AI-based platform|The students at the experimental group will receive a one-hour hands-on training session before logging in to the online platform. The session will be presented by a dentist with AI experience and this session will present basic aspects of AI in radiology, deep learning (DL) applications for cariology and endodontics, as well as basics of excavation therapy and pulp exposure. the theoretical part will be followed by a hands on session on which each participant will check 11 cases of teeth with deep caries and will find the closest line between caries and pulp. their performance will be supervised by the training session presenter and the correct line will be shown them in case of making wrong line.
45640727|NCT05912348|Behavioral|Obesogenic Lifestyle Group|Young men will transition into a sedentary lifestyle for 10 days and consume added sugar-sweetened beverages. The intervention group will be compared to two control groups. One of the control groups will undergo a sedentary intervention.
45640728|NCT05912348|Behavioral|Sedentary Control|Young men will transition into a sedentary lifestyle for 10 days.
45640729|NCT05912335|Drug|Topical anesthetic|The topical anesthetic, or topical formulation, was applied to the palatal mucosa for 2 minutes.
45640730|NCT05912322|Dietary Supplement|Black chokeberry juice|100ml black chokeberry juice/day
45640731|NCT05912309|Behavioral|Time Restricted Eating (TRE)|Participants will be required to reduce their eating time window to ≤ 8 hours/day. Women can choose when to begin eating, but the last meal should be completed before or at 20:00 hours (concentrating the eating window towards the active phase confers higher cardiometabolic health benefits). Our preliminary results suggest that this eating window is feasible and safe. Participants will receive dietary advice regarding the daily amount of high quality protein and meal-specific protein quantities. All the participants will attend a lifestyle education program based on Mediterranean diet and WHO physical activity recommendations every two weeks.
45640732|NCT05912309|Behavioral|Exercise|Sport sciences specialists will design, supervise and monitor the concurrent exercise intervention following the 2020 WHO recommendations. The program will be tailored to the participant's ability and health, and will be focused on a gradual increase to levels that are safe. Resistance training: 3 times/week designed to manage, attenuate and even prevent the loss of skeletal muscle tissue and function. Endurance training: 2 times/week, performed as high intensity interval training which is time-efficient, safe and effective reducing visceral adipose tissue in postmenopausal women. The exercise sessions will be scheduled within or immediately after their eating window in order to maximize muscular muscle protein synthesis. Morning and afternoon training schedules will be offered to participants.
45640733|NCT05912309|Behavioral|Caloric Restriction|Individualised intensive behavioural intervention weight loss program including CR, exercise training and lifestyle education designed according to the current guidelines. CR will be tailored to participants (objectively assessed). Diet will provide 600 kcal/day less than the individual energy requirements based on measured resting energy expenditure (indirect calorimetry) and multiplied by an activity factor obtained by accelerometry. Experienced nutritionists will design personalized and balanced CR diet, and will train the participants through the food exchange system to follow the treatment. In those cases in which the CR compromised a protein intake of at least 1.2 g/kg/day, the macronutrient percentage distribution will be modified prioritizing achieving this minimum protein intake.
45640734|NCT05912296|Drug|RBD7022|Subcutaneously Administered RBD7022 in Healthy Subjects.
45640735|NCT05912296|Drug|RBD7022|Subcutaneously Administered RBD7022 in Healthy Subjects.
45640736|NCT05912296|Drug|Placebo|Subcutaneously Administered Placebo in Healthys Subject.
45640737|NCT05912296|Drug|Placebo|Subcutaneously Administered Placebo in Healthys Subject.
45640738|NCT05912283|Device|Synthetic Nitrile Condoms (53mm)|53mm width synthetic nitrile condoms
45640739|NCT05912283|Device|Synthetic Nitrile Condoms (56mm)|56mm width synthetic nitrile condoms
45640740|NCT05912283|Device|Control Latex Condom|Commercial natural rubber latex condom
45640741|NCT05912270|Behavioral|Orchestra in Class|See arm/group descriptions
45778797|NCT04421430|Other|Distraction cards|The distraction cards contain various hidden pictures and patterns which are visible only when looked at carefully. During a procedure, the child is expected to focus on the cards and answer the questions asked about what they see in them. Just before the venipuncture, the researcher showed the distraction cards participants the distraction cards and asked them to check them and then asked them questions about what they saw on the cards and kept asking questions until the end of the venipuncture. The distraction cards intervention and venipuncture were terminated at the same time.
45916133|NCT00006241|Procedure|peripheral blood stem cell transplantation|
46070379|NCT00815503|Drug|Ropivacaine|Approved by the Danish Medicines Agency
45640742|NCT05912257|Behavioral|Structured perioperative nutrition and exercise|Nutrition counseling by a RD and prescribed a eucaloric diet with protein intake of 1.5 g/kg/d and at least 30 g high quality protein per meal. They will be provided 30 grams of high quality protein twice a day, Hydroxymethylbutyrate, and vitamin D3 and multi-vitamin. Participants will attend nutrition and exercise group classes 6-8 weeks. Following following discharge home, participants will be instructed to resume group classes and protein, HMB, vitamin-D and MVS regimen, and exercise classes will resume when cleared by surgical team.
45778798|NCT04421430|Other|Virtual reality|The virtual reality participants put on the virtual reality glasses and headsets about two minutes before the venipuncture and watched the 3D Dinosaur Animation movie throughout the procedure. The virtual reality intervention and venipuncture were terminated at the same time.
45916134|NCT00006241|Radiation|radiation therapy|
45916135|NCT00006247|Drug|semaxanib|
45916136|NCT00006250|Drug|chlorambucil|
45916137|NCT00006250|Drug|dexamethasone|
45916138|NCT00006250|Drug|fludarabine phosphate|
45916139|NCT00006250|Drug|mitoxantrone hydrochloride|
45916140|NCT00007449|Drug|DPC 083|
45916141|NCT00006253|Behavioral|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
46070380|NCT00815503|Drug|Placebo|Saline
46070381|NCT02552407|Device|Manual Aspiration Thrombectomy|Thrombus aspiration
45640743|NCT05912257|Behavioral|Nutrition and Exercise Counseling|nutrition counseling by study Registered Dietitian (RD) and prescribed a eucaloric diet with protein intake of 1.0 g/kg/d and a one a day multivitamin/multimineral supplement. They will be counseled on exercising three times per week and given access to exercise videos. Following following discharge home, participants will be instructed to resume protein recommendations and MVS, and exercise recommendations will resume when cleared by surgical team.
45778799|NCT04421430|Other|Buzzy|Buzzy® applies high frequency vibration and concentrated cold at injection site for procedural pain management and distraction before the shot in children and adults. Buzzy® was placed on the injection site (antecubital fossa) of the Buzzy® participants, and cold application and vibration was turned on 60 seconds before the procedure. After the 60 seconds, the nurse moved Buzzy® about 3 cm above the injection site and applied a tourniquet and performed the procedure. Buzzy® was on throughout the procedure. The Buzzy® intervention and venipuncture were terminated at the same time.
45778800|NCT05052762|Other|Group A: Elastic resisted training for Gluteus Maximus strength|"Subjects attended physical therapy two times per week for a total of 10 visits. In the first five sessions, subjects performed the following exercises to strengthen the gluteus maximus: bilateral bridge, unilateral bridge, and non-weight-bearing hip extension in prone with the knee flexed at 90 degrees. In the next five sessions, abduction and external rotation in a quadruped (fire hydrant exercise) and weight-bearing hip extension (known as deadlift exercise) are added. Each exercise was performed for 10 repetitions. Elastic resistance was Added to the fire hydrant, hip extension in prone and deadlift exercises to allow each subject to perform at a 10-repetition maximum. The resistance for each subject was adjusted weekly as needed. The exercise program was performed under direct supervision only during the physical therapy sessions."
45778801|NCT05052762|Other|Group B: Weight resisted training for Gluteus Maximus strength|Subjects attended p two times per week for a total of 10 visits. The participants performed PHEKF in 90° knee flexion with 30° hip abduction and 10° hip extension to increase the muscle activity of the gluteus maximus. In the prone position, the participant performed 10° hip extension until the posterior knee reached the horizontal bar. The participants maintained 90° knee flexion with 30° hip abduction and 10° hip extension in the prone position against the resistance. Sandbags (3 kg) will be used to provide resistance on the ankle through a rope and pulley. Each subject performed three sets with three repetitions of five seconds each. 1-minute break is allowed between each set.
45778802|NCT00466310|Drug|Aripiprazole|Aripiprazole for 4 weeks
45778803|NCT00466310|Drug|Risperidone|Subjects will be randomized to risperidone for 4 weeks
45778804|NCT00466310|Other|Healthy volunteers|Healthy volunteers
45778805|NCT05106270|Diagnostic Test|Atrial pressure measurement using transseptal puncture sheath|both left and right atrial pressure was measured using transseptal puncture sheath before and after combined procedure
45778806|NCT02116322|Procedure|EUS-FNA with Corkscrew technique|
45778807|NCT02116322|Device|Expect 19 G Flex needle|
45640744|NCT05912231|Radiation|Accelerated Proton Beam Radiation Therapy (PBT)|per protocol
45640745|NCT05912231|Radiation|Accelerated Photon Radiation Therapy (XRT)|per protocol
45640746|NCT05912218|Biological|MEI6570|Saline Control
45778808|NCT05106036|Other|Clinical Support Decision Tool|Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the Clinical Decision Support (CDS) tool to assist their physicians with their blood pressure management. Home BP data will be averaged each month via Omron Connect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health. We have designed CDS to present treatment choices of antihypertensive medication regimen based on medications patients are currently taking. For example, patients who are currently taking an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), our CDS algorithm will recommend addition of a calcium channel blocker as the first tier of recommendation and thiazide diuretics as second tier of recommendation. Laboratory data and home BP in the past month will be presented in a clear and simple manner for the clinicians to activate and use to optimize BP control.
45778809|NCT03463460|Other|Laboratory Biomarker Analysis|Correlative studies
45778810|NCT03463460|Biological|Pembrolizumab|Given IV
45778811|NCT03463460|Drug|Sunitinib Malate|Given PO
45778812|NCT00535652|Drug|Ertapenem|powder for infusion, 1 gram I.V., single dose over 30 min.
45916142|NCT00006253|Behavioral|Non-nurse coach|Receives 6 telephone calls over 8 weeks from a non-nurse coach to assist with symptom management
45916143|NCT00006259|Radiation|stereotactic radiosurgery|Patients undergo stereotactic head frame placement, followed by stereotactic radiosurgery using Gamma Knife, on day 1.
45448639|NCT05123248|Device|Blinded Group|Participants in the blinded group will be wearing the sensor for 14 days without a reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. After 14 days, participants are required to scan the sensor themselves or with the assistance of a CRC to a designated blinded-reader.
45778813|NCT05103384|Other|Virtual Reality Environment|Participants complete various tasks in a virtual home and grocery store environment.
45778814|NCT05160636|Other|ARI symptom and Positive RT-PCR for COVID-19|Subjects with a self reported ARI and a positive COVID-19 nasopharyngeal swab collected for SOC will be approached to participate to assess impact on COVID-19 infection on quality of life.
45916144|NCT00006265|Drug|ara-C|3 g/sq m IV infusion over 3 hours Days 1-5
45916145|NCT00006265|Biological|gemtuzumab ozogamicin|9 mg/sq m IV infusion over 2 hrs D 1 (Cohort I); D 7 (Cohorts II, IA, & IV); & D 14 (Cohort IV) 4.5 mg/sq m IV infusion over 2 hrs D 8 (Cohort I) & D 14 (Cohort II)
45640747|NCT05912205|Drug|Disitamab Vedotin|Four cycles of neoadjuvant therapy with Vidiximab (2.0mg/kg) were administered first, followed by bladder sparing therapy using maximized TURBT combined with radiotherapy and chemotherapy. The patient will receive vidiximab combined with local radiotherapy after maximizing TURBT surgery. The subjects received treatment with Vidixitol every two weeks for six consecutive treatment cycles, and simultaneously received 1 month of radiation therapy (SBRT, total dose of bladder irradiation field greater than 50 Gy)
45640748|NCT05912205|Radiation|radiotherapy|radiotherapy
45640749|NCT05912192|Drug|Elonide Nasal Spray|50mcg/dose One puff for each nostrils twice daily
45640750|NCT05912192|Drug|Nasonex Nasal Spray|50mcg/dose One puff for each nostrils twice daily
45916146|NCT00006268|Biological|cintredekin besudotox|
45640751|NCT05912192|Drug|Normal saline|50mcg/dose of 0.9% sodium chloride One puff for each nostrils twice daily
45640752|NCT05912179|Diagnostic Test|Liver biopsy - percutaneous|liver biopsy obtained using percutaneous ultrasound guided technique
45640753|NCT05912179|Diagnostic Test|Liver biopsy - transjugular|liver biopsy obtained using an interventional transjugular approach
45640754|NCT05912179|Diagnostic Test|liver biopsy - EUS guided|liver biopsy obtained during endoscopic ultrasound
45640755|NCT05912166|Behavioral|Wakeful Spanish|"Wakeful Spanish is the Spanish-language version of Wakeful, a self-directed 9-week digital mindfulness course closely aligned with traditional 8-week Mindfulness-based Stress Reduction (MBSR) programs. Wakeful makes one new class available to users each week for 9 weeks. Users receive weekly email notifications from Wakeful informing them when a new class is available. Estimated class duration is 1-1.5 hours.~With Wakeful, users can -~Write what they observed during meditations.~Be guided by videos/audios through breathing exercises and gentle stretching.~See what others experienced and their tips for overcoming challenges.~Access videos/audios that explain how mindfulness benefits the body and mind.~Receive suggestions on meditations to do during the week~Set an intention for the week based on class content."
45640756|NCT05912153|Diagnostic Test|SPECT/CT|SPECT/CT of the foot and ankle
45640757|NCT05912153|Diagnostic Test|MRI|MRI of the foot and ankle
45640758|NCT05912140|Other|TRACE 2|"The first version of TRACE2 will be retrospectively verified through its application by experts on 150 photos of scoliosis patients who agreed to use the material produced for clinical use for retrospective research. Both intra-operator and inter-operator repeatability will be evaluated and a first Rasch analysis will be performed.~The new version of TRACE2 (TRACE2.2) obtained following the retrospective validation on the photos will be verified prospectively through its application by the experts on 150 patients in specialist medical examination. Both intra-operator and inter-operator repeatability will be evaluated and further Rasch analysis will follow. On the basis of the results obtained from the analysis, the new TRACE2 scale (TRACE2.3) will then be applied to a further 150 patients, its intra- and inter-operator repeatability will be calculated and a final Rasch analysis will be performed to arrive at the final version of the scale (TRACE2.4)."
45640759|NCT05912127|Device|implant supported fixed full arch prosthesis|the patients will receive screw-retained cast metal-ceramic fixed prostheses that replace lost gingival tissues with pink porcelain.
45778815|NCT05050266|Behavioral|EBQI|"EBQI is a systematic quality improvement method for engaging frontline practices in improvement that introduces best science and evidence in the service of operational goals. EBQI has been tested in several VA implementation trials. Sites randomized to EBQI will meet monthly with the implementation support team (i.e., high-intensity)."
45778816|NCT05050266|Behavioral|REP|The REP framework consists of 4 phases: pre-conditions, pre-implementation, implementation and maintenance/evolution. REP has a strong evidence-base and application in VHA health services research in promoting uptake of EBPs. Sites randomized to REP will meet quarterly with the implementation support team (i.e., low-intensity).
45778817|NCT00418028|Drug|Capecitabine|
45778818|NCT05050110|Other|Fruits and Vegetable increase|Increase fruits and vegetable consumption in chronic Kidney Patients to maintain Normokalemia
45640760|NCT05912114|Drug|Mannitol|Mannitol, as an osmotic laxative, increases the colloid osmotic pressure in the intestinal lumen, which results in a hyperosmolar state in the intestine, thus allowing easy elimination of stools.
45640761|NCT05912114|Drug|Polyethylene glycol electrolyte|Polyethylene glycol electrolyte is an inert polymer that cannot be absorbed by the body itself. Due to its high permeability, it retains water in the intestinal tract, increasing the amount of fluid retained in the intestine and softening the stool, thus acting as a diuretic.
45778819|NCT05160246|Other|kinesiology tape|The tape will be fixed without any tension 10 cm below the origin of the rectus femoris muscle. Then 35-50% tension will be applied to the band and descended to the patella. After this point, the Y-shaped band will be terminated to wrap the patella medially and laterally without any tension.
45778820|NCT05160246|Other|Placebo tape|The tape will attach to the rectus femoris without any tension.
45778821|NCT05049954|Other|Calorie-Restricted Healthy Ketogenic Diet|Participants in the experimental group will be advised on a Calorie-restricted Healthy Ketogenic Diet via 7 workshops. Participants will also be advised to monitor their urinary ketones to track compliance.
45778822|NCT05049954|Other|Calorie-Restricted Low Fat Diet|Participants will be advised on Calorie-restricted Low Fat diet via 7 workshops.
45778823|NCT00537290|Drug|Rituximab|Rituximab 1000mg IV on Days 0 and 15
45778824|NCT05049720|Device|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
45916147|NCT00006268|Drug|isolated perfusion|
45916148|NCT00006268|Procedure|conventional surgery|
45916149|NCT00007527|Drug|naloxone|
45916150|NCT00007527|Drug|buprenorphine|
45916151|NCT00006280|Drug|Tobramycin for Inhalation|
45916152|NCT00006286|Drug|Fluoxetine|
45916153|NCT00006286|Behavioral|Psychotherapy|
45916154|NCT00007605|Drug|Amiodarone|Patients assigned will receive 400 mg bid for 14 days, 400 mg QAM and 200 mg QHS for 14 days, 300 mg qd for 48 weeks, then 200 mg qd.
45916155|NCT00007605|Drug|Sotalol|Patients assigned will receive 80 mg bid for 7 days and 160 mg bid thereafter.
45916156|NCT00006292|Drug|Infliximab|
45916157|NCT03709888|Drug|Memantine XR-pregabalin combination therapy|Pregabalin and memantine XR work in different pathways and are approved by the U.S. Food and Drug Administration for various indications. Both medications have an established safety profile and have demonstrated improvement on neuropathy-related symptoms.
45778825|NCT00537680|Drug|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 450 mg/day; Patients > 45 kg/99 lbs: idebenone 900 mg/day
46070382|NCT04708262|Other|Cognitive Analytic Therapy for Containing Self-Harm in Young People|The intervention will run over five sessions, each lasting around 30 - 40 minutes. Researchers will follow the CATCH-Y manualised treatment guide. CATCH-Y is a brief, five session psychological intervention based upon CAT principles and designed to help young people who have self-injured.
46070383|NCT04848896|Device|CORI Robotics|Total knee arthroplasty (TKA) treated with CORI Robotics System.
45640762|NCT05912101|Procedure|Pericapsular Nerve Group Block|A convex USG Probe (1-5 mHz) is placed transversely on the SIAS (Spina Iliaca Anterior Superior). The probe is then rotated 45 degrees and aligned with the pubic ramus. In this position, the iliopubic eminence, ilipsoas muscle-tendon, femoral artery and pectineus muscle are observed. A 100 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is inserted in-plane from lateral to medial to the musculofascial plane with the psoas tendon in front and the pubic ramus behind and the injection is performed.
45640763|NCT05912101|Procedure|Suprainguinal Fascia Compartment Block|A linear USG probe (7-13 mHz) is placed parasagittal to obtain an image of the SIAS. The probe is then shifted medially to identify the fascia iliaca, iliac muscle, internal oblique muscle and deep circumflex iliac artery. A 50 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is advanced in-plane from caudal to cephalic and injected between the fascia iliaca and iliac muscle.
45640764|NCT05912101|Procedure|3-1 Block|A linear USG probe (7-13 mHz) is placed at the level of the femoral fold and the femoral vein-arterial-nerve is visualized. The femoral nerve is located below the fascia iliaca. At this point, a 50 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is inserted in-plane from lateral to medial and injected lateral to the femoral nerve. After injection, pressure is applied distal to the needle entry site to spread the local anesthetic proximally in the nerve sheath.
45778826|NCT00537680|Drug|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients > 45 kg/99 lbs: idebenone 2250 mg/day
45640765|NCT05912088|Behavioral|Intervention Group|Subjects will participate in groups of about 14 to implement the program.
45640766|NCT05912088|Behavioral|Control Group|Subjects will receive the usual care advice
45640767|NCT05912075|Drug|mFOLFIRINOX|prior to tolinapant (ASTX660) for 6 cycles over 12 weeks
45640768|NCT05912075|Radiation|Pelvic radiotherapy LCRT|50-Gy total dose in 25 daily fractions of 2 Gy (5 days per week from Monday to Friday) for 5 weeks
45640769|NCT05912075|Drug|Capecitabine|800 mg/m2 bid for 5 days per week (From Monday to Friday) for 25 days will be given concomitantly during the 5 weeks of radiotherapy
45640770|NCT05912075|Drug|TOLINAPANT (ASTX660)|starting from 14 days before the first dose of radiotherapy, for 10 weeks.
45640771|NCT05912075|Radiation|Pelvic radiotherapy SCRT|total dose of 25 Gy, in 5 daily fractions of 5 Gy for 1 week (5 days from Monday-Friday)
45640772|NCT05912075|Drug|FOLFOX4|given every 2 weeks for 9 cycles, starting 10 days after the last session of short course radiotherapy
45640773|NCT05912075|Drug|CAPOX|every 3 weeks for 6 cycles, starting 10 days after the last session of short course radiotherapy.
45640774|NCT05912062|Drug|Trastuzumab (neoadjuvant)|Trastuzumab loading dose at 8mg/kg at day 1 followed by Trastuzumab at 6mg/kg in a 21-day cycle for six cycles
45640775|NCT05912062|Drug|Pertuzumab (neoadjuvant)|Pertuzumab loading dose at 840mg at day 1 followed by Pertuzumab at 420mg in a 21-day cycle for six cycles
45640776|NCT05912062|Drug|Paclitaxel (neoadjuvant)|Paclitaxel starting at day 8 at 80mg/m2, days 1, 8, and 15 of a 21-day cycle for up to fifteen weeks
45778827|NCT00537680|Drug|Placebo|Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.
45778828|NCT05158842|Device|Adult bubble CPAP oxygen therapy device|"In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the patient. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the patient. Oxygen is delivered by a successfully tested, silicon-based, ergonomically designed adaptive version of nasal canula (nasal seal) inserted into the nostril of a patient.~The components are:~Adaptive version of nasal canula (nasal seal)~A nasal canula with connecting circuit system~Water-filled bottle with marking water pressure from10 to15 L/min.~Oxygen cylinder, central distribution through pipelines or by oxygen concentrator will be used as an oxygen source."
46070384|NCT04848896|Procedure|Conventional Procedure|Total knee arthroplasty (TKA) treated with conventional approach with conventional manual instrumentation.
46070385|NCT00702819|Drug|Bevacizumab|Dosage of 0.75mg/0.03ml injectable, one time only.
45640777|NCT05912049|Drug|9MW3811 Injection|Single dose intravenously infused on day 1
45640778|NCT05912049|Drug|Placebo|Single dose of matching placebo intravenously infused on day 1
45778829|NCT00538304|Drug|bimatoprost eye drops|1 drop in each eye daily for 1 month
45778830|NCT00538304|Drug|placebo|1 drop in each eye daily for 1 month
45916158|NCT03682744|Biological|anti-CEA CAR-T cells|Intraperitoneal delivery of anti-CEA CAR-T cells
45916159|NCT00007683|Drug|Warfarin titrated to an INR of 2.5-3.0|anticoagulation (administered without blinding) titrated to a target INR of 2.5 to 3.0, monitored by measurements at 6 week intervals after initial titration and stabilization.
45916160|NCT00007683|Drug|Aspirin|an antiplatelet agent whose mechanism is inhibition of thromboxane, a platelet activator) administered in a double blind manner.
45916161|NCT00007683|Drug|Clopidogrel 75|(an antiplatelet agent whose mechanism is ADP inhibition) administered in a double blind manner)
46070386|NCT00651157|Biological|wild-type reovirus|Given IV: Administered at a dose of 3 x 10^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle.
46070387|NCT02691182|Drug|SPN-810|
46070388|NCT00843843|Device|Bright light box|Bright light of about 5000 lux, administered while sitting at a desk.
46070389|NCT00650845|Drug|Dotarem®-enhanced MRI|Single IV administration before MRI exam
46070390|NCT00650845|Other|non-enhanced MRI|non injected MRI
46070391|NCT00842985|Drug|drug condition|Dronabinol (15mg) or Modafinil (400mg) or Dronabinol + Modafanil or placebo
45640779|NCT05912036|Behavioral|CRT|CA-CRT treatment will entail exercises aimed to improve cognitive strategies, encourage subjects' reflection on their way of thinking, and explore the possibility of implementing new schemas in everyday life. The CA-CRT program will employ a range of cognitive exercises and tasks to address cognitive inflexibility and weak central coherence. The treatment will consist of 10 individual CA-CRT sessions, 2 times per week for 5 weeks, for a duration of 40 minutes per session with 15 individual CA-CRT sessions, 3 times a week for 5 weeks, with a duration of 30 minutes per session
45640780|NCT05912010|Diagnostic Test|NP/OP swab|NP/OP (nasopharyngeal/oropharyngeal) swabs will be collected from all cases at enrollment for respiratory pathogen multiplex PCR or pneumococcus culture.
45640781|NCT05911997|Drug|MTC 01|Slurry to be administered via colonoscopy
45778831|NCT05048862|Diagnostic Test|Neuromuscular ultrasound|Ultrasound will be performed with the Affiniti 70 (Philips Medical Instruments, Bothell, WA). all patients following standardized methods of our hospital. All the patient would be checked the skin surface temperature before the ultrasound examination. The image would be exported from the echo machine as DICOM format.
45778832|NCT05048862|Diagnostic Test|Muscle MRI|Muscle MRI will be performed on a 3-T MR machine (Trio; Siemens, Erlangen, Germany). Each subject will lie in a supine position comfortably, supplied with ear plugs. A high resolution T1 weighted scan and Short-T1 Inversion Recovery series (STIR) of the four limbs muscle were obtained in axial and coronal plane. MR spectroscopy in interested muscle was also sampled to evaluate the composition of fat, water, lactate, and other studied molecules.
45778833|NCT05048862|Diagnostic Test|Nerve conduction studies and autonomic function tests|Nerve conduction study will be performed with a Nicolet Viking IV Electromyographer (Madison, WI) in all patients following standardized methods recommended by the Consensus Development Conference on Standardized Measures in Diabetic Neuropathy. Studied nerves include sural, peroneal, tibial, median and ulnar (motor and sensory) nerves.Autonomic functions will be assessed by the SSR and RRIV with established protocol by using Nicolet Viking IV Electromyographer (Madison, WI).
45778834|NCT05048862|Diagnostic Test|Quantitative sensory test|Quantative sensory test will be performed with a Thermal Sensory Analyzer and Vibratory Sensory Analyzer (Medoc Advanced Medical System, Minneapolis, MN). The procedure is the same as previously described 25. Briefly, the machine delivers to the patient a stimulus of constant intensity which is pre-set by the algorithm. By adjusting the intensity of stimulus (increase or decrease the intensity by a fixed ratio) according to the response of the subject (i.e. whether the subject perceives the stimulus or not), sensory thresholds of the warm, cold and vibratory modalities will be measured.
45778835|NCT05048862|Diagnostic Test|Skin biopsy|A skin specimen of 3 mm in diameter will be taken with a biopsy punch from the lateral side of the distal leg under 2% lidocaine local anaesthesia 26. No suturing is required, and the wounds are covered with a piece of gauze. Wound healing takes 7~10 days, similar to a typical abrasion wound. Informed consent will be obtained from each patient before the skin biopsy. The intraepidermal nerve fiber density and sweat gland nerve innervation will be examined.
45778836|NCT05048862|Diagnostic Test|Muscle and nerve biopsy|Two muscle specimens with 5 x 5 x 5 mm were collected in an open muscle biopsy or needle biopsy at studied muscles under 2% lidocaine local anaesthesia. The wound was about 2-3 cm long, and suture was required. Would healing usually takes 10-14 days. First specimen was undergoing snap freezing fixation in a longitudinal axis perpendicular to the cork with the liquid nitrogen and isopentane. The second specimen was divided into two equiponderous tissues, and one was freezed in liquid nitrogen for DNA and protein analysis. The another one was treated with RNAlater solution in 4°C overnight for RNA analysis. Sural nerve biopsies or superficial peroneal nerve were obtained from a standard site posterior to the lateral malleolus under local anesthesia. The nerves were then fixed in 5% glutaraldehyde in 0.1 M phosphate buffer (PB) at 4 °C overnight. All samples were stored in the -80°C refrigerator for further analysis.
45778837|NCT05048862|Diagnostic Test|Genomics, transcriptome, and proteomics|The DNA, RNA, and protein of the tissues (blood, muscle, nerve and skin) were retrieved and stored in the -80°C refrigerator. The next generation sequencing (whole exon sequencing or whole genome sequencing) and RNA-seq would be performed by NGS & Microarray Core lab in National Taiwan University or another professional team. The protein analysis would be performed by the Proteomics & Protein Function Core Lab in National Taiwan University.
45778838|NCT05048862|Diagnostic Test|Laboratory of blood chemical substances, metals and endocrine profiles|The methods of the measurement will follow the standards set by Department of Laboratory Medicine of National Taiwan University Hospital.
45778839|NCT05048862|Diagnostic Test|Contact heat evoked potentials|A contact heat evoked potential stimulator (Medoc, Ramat Yishai, Israel) will be used for delivering heat stimulation. Stimuli will be delivered repeatedly to the same stimulation site and the inter-stimulus interval will be randomly set to around 18~22 s. CHEP will be recorded using a Nicolet Bravo evoked potential system (Nicolet Biomedical, Madison, WI). The recording electrode was placed at the Cz and P3 of international 10-20 system. The impendence of all recording electrodes was kept below 3 kΩ. The evoked potentials were filtered with a bandpass filter at 0.1~30 Hz. Recording was triggered by the onset of each stimulus, and the sweep time was 1500 ms.
45778840|NCT05048862|Diagnostic Test|Nerve excitability study|Nerve excitability studies will be undertaken on the median, tibial, peroneal and sural nerves as per previously detailed protocols. Skin temperature will be monitored at the site of stimulation and was maintained at >32°C. Stimulation and recording will be controlled by automated computerized system (QTRAC; Institute of Neurology, London, U.K.) and the stimulus current will be administered using an isolated linear bipolar constant-current stimulator (DS5; Digitimer, Welwyn Garden City, U.K.). Responses will be amplified (ICP511 AC amplifier, Grass Technologies, West Warwick, USA) with electronic noise removed (Hum Bug 50/60 Hz Noise Eliminator, Quest Scientific Instruments, North Vancouver, Canada).
45778841|NCT05048862|Diagnostic Test|Transcranial magnetic stimulation (TMS)|In simple rTMS protocols, individual stimuli are spaced apart by identical interstimulus intervals (ISI). The stimulation protocol was in accordance with published safety recommendations. The patterned rTMS protocols included (1) Theta burst stimulation, (2) Repetitive paired-pulse TMS. All the above stimulation protocols or paradigms will follow the international guideline of the use of TMS in clinical practice and research (Rossi et al., 2009; Fitzgerald and Daskalakis, 2012; Groppa et al., 2012; Steeves et al., 2012).
45640782|NCT05911997|Drug|Fecal Microbiota Transplantation (FMT)|Stool from a healthy donor is blended with salt water and made into a liquid solution rich in bacteria. This solution is sprayed into the recipient's colon during a colonoscopy
45778842|NCT05048862|Diagnostic Test|fMRI acquisition and image analysis|fMRI will be performed on a 3-T MR machine (Trio; Siemens, Erlangen, Germany). Each subject's head will be positioned comfortably inside a receive-only 8-channel birdcage head coil, supplied with ear plugs, heavily padded and secured with a strap across the forehead in order to minimize head motion. All data will be processed using SPM2 (Wellcome Department of Cognitive Neurology, London UK) 36 implemented on MATLAB (Mathworks Inc. Sherborn, MA).
45640783|NCT05911984|Drug|9MW3811 Injection|Intravenous injection
45640784|NCT05911971|Other|Experimental|specific reeducation (not detailed to maintain blinding of participants)
45640785|NCT05911971|Other|Sham comparator|sham reeducation (not detailed to maintain blinding of participants)
45640786|NCT05911958|Drug|SHR-A1811 for injection|SHR-A1811 for injection
45640787|NCT05911945|Procedure|Flexible Ureterorenoscopy|A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, a 26 cm, 4.8 Fr JJ stent was placed under fluoroscopy and the procedure was terminated. Patients underwent a second f-URS session, 4 - 6 weeks later. After the JJ stent was removed, an 11 - 13 Fr UAS was placed in the ureter. Digital flexible ureterorenoscope was used as the flexible ureteroscope. Stone fragmentation was performed in dusting mode using a Ho:YAG laser with a 272 µ probe. After fragmentation, a 26 cm 4.8 Fr JJ stent was inserted into the ureter. The JJ stent was removed at 4 - 6 weeks postoperatively.
45640788|NCT05911945|Procedure|Mini Percutaneous Nephrolithotomy|A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, patients were positioned in prone position and access was performed to the appropriate calyx with an 18-gauge percutaneous access needle using the triangulation technique accompanied by fluoroscopy, in the same session. After the guidewire was introduced into the pelvicalyceal system, sequential dilatation was applied with Amplatz dilatators, and a 21 Fr metallic sheath was placed. Stones were fragmented with a yttrium-aluminum-garnet (Ho:YAG) Laser lithotripter. At the end of the procedure, a 14 Fr nephrostomy catheter was placed in according to the residual stone, hemorrhage, and perforation status. In other cases, the procedure was concluded as totally tubeless.
45640789|NCT05911932|Other|Biosample collection.|Blood draw.
45778843|NCT00538616|Drug|Dexmedetomidine|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
45778844|NCT00538616|Drug|Propofol|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
45640790|NCT05911919|Device|brainQuant module of brainTale-care platform|brainQuant is a software module of brainTale-care medical device (a medical device software as a service (web platform) ) for the automatic processing of brain diffusion Magnetic resonance images and the provision of the diffusion regional standardised parameters.
45640791|NCT05911906|Drug|Remdesivir|To be confirmed.
45640792|NCT05911893|Dietary Supplement|high caloric oral nutritional supplements|High caloric oral nutritional supplements (which can supplement 30% of the energy requirement) is given daily, and the recommended amount of energy and protein is referred to the 2013 Chinese Dietary Nutrient Reference Intake Table. At 6 months of enrollment, participants will be asked to evaluate whether to continue feeding according to the experimental group protocol or to stop to ensure proper nutritional intake.
45778845|NCT00469274|Drug|Antibiotic PEP|Azithromycin 1000mg po x 1, then 500mg po Q day for 4 days; TMP-SMX DS one BID for 14 days
45778846|NCT00469274|Drug|Antibiotic PEP|TMP-SMX DS po BID for 14 days
45778847|NCT04232670|Procedure|EUS + SHAM|Endoscopic Ultrasound
45778848|NCT04232670|Procedure|EUS + Pancreatic Endotherapy|Pancreatic endotherapy may include any or all of the following maneuvers: pancreatic endoscopic sphincterotomy, stricture dilation using a bougie or hydrostatic balloon catheter, pancreatic stone extraction with or without mechanical or electrohydraulic lithotripsy, extracorporeal shock wave lithotripsy, and stent placement.
45778849|NCT05158296|Drug|Ultevursen|RNA antisense oligonucleotide for intravitreal injection
45778850|NCT05158296|Other|Sham-procedure|Sham-procedure (no experimental drug administered)
45640793|NCT05911893|Behavioral|nutritional education|After enrollment,health education information is pushed approximately every 4 weeks through the WeChat platform or/and short text messages to parents.
45640794|NCT05911893|Behavioral|dietary guidance|At follow-up visits at 0, 1, 2, 3, 6,and 12 months after enrollment, a professionally trained pediatrician give the participant's guardian dietary instructions appropriate to the age stage and physical condition of the child. Each session lasts approximately 10 minutes.
45778851|NCT05048394|Device|Semi-autonomous myoelectric control algorithm|The semi-autonomous myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
45778852|NCT05048394|Device|Standard-of-care myoelectric control algorithm|The standard of care myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
45778853|NCT05099094|Genetic|BD311|Integration-deficient lentiviral vector (IDLV) expressing VEGFA antibody
45916162|NCT00006325|Drug|Peginterferon alfa-2b|
45916163|NCT00006331|Procedure|renal transplant|
45916164|NCT00007761|Behavioral|Bipolar Disorder Program|
45916165|NCT00007761|Behavioral|Usual (psychiatric) Care|
45640795|NCT05911880|Behavioral|Plant-based diet for 14 days in patients with rheumatoid arthritis.|Patients with low to moderate disease activity of rheumatoid arthritis (2.6-5.1 DAS28-CRP) underwent a dietary intervention consisting of an individualized, isocaloric, and plant-based diet with 57% carbohydrates, 25% lipids, and 18% proteins (80% of plant origin) for 14 days, without any modification of their medication regimen and with restricted consumption of processed foods.
45640796|NCT05911867|Other|combination of mobilization with movement and muscle energy techniques|"The examiner passively abducts the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.~Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position. The passive gliding is maintained in the anterosuperior direction along the facet joint line while flexing or extending the neck throughout the range."
45640797|NCT05911867|Other|muscle energy techniques Interventions:|The examiner passively abduct the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. This passive stretch will be held for three seconds. The examiner then instruct the participant to attempt to horizontally adduct the test arm at 25% of their maximal effort while the examiner applied manual resistance at the distal humerus to create an isometric contraction lasting five seconds. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.
45640798|NCT05911867|Other|mobilization with movement|Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position. The passive gliding is maintained in the anterosuperior direction along the facet joint line while flexing or extending the neck throughout the range.
45640799|NCT05911854|Device|Multi-waved Locked System Laser|The M6 therapy laser is a robotized multi-target device designed to treat patients suffering pathologies affecting a wide area, and to perform automatic applications.
45640800|NCT05911854|Device|Cold Compression therapy|The BioCryo Cold Compression System is a cold therapy pneumatic compression device that safely administers sequential, gradient pneumatic compression and CryoTherapy combined.
45640801|NCT05911854|Other|complete decongestive therapy|"Complete decongestive therapy consists of:~Meticulous skin care with the use of emollients~Using short stretch bandages or continuous wearing of a pressure garment~Manual lymphatic drainage therapy~Remedial exercises (e.g., aerobic exercise, strength training, and stretching exercises)"
45778854|NCT05099016|Other|Joint Effort|The Joint Effort intervention is available in the form of an iPhone mobile application (running on iOS 13 and 14) in French language. It aims to support young adults in school who have used cannabis in the past month into taking action on their cannabis use.
45640802|NCT05911841|Drug|LY3454738|Administered SC
45640803|NCT05911841|Drug|Placebo|Administered SC
45640804|NCT05911828|Drug|ZY19489 + Ferroquine (FQ)|ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
45778855|NCT05099016|Other|Brief normative feedback and standard information|The brief normative feedback is based on the frequency of cannabis use use. Participants will also be offered basic reliable non personalized information on lower-risk cannabis use in the form of official public websites.
45640805|NCT05911828|Drug|Placebo|ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
45640806|NCT05911815|Radiation|hysterosalpingography|hysterosalpingogram (HSG) is an X-ray visualization of the lumen of the uterus and fallopian tubes, which can detect abnormalities including blockage, polyps, and salinities
45640807|NCT05911789|Radiation|Online adaptive radiation therapy|A dose of 45Gy will be delivered to planning target volume (PTV)
45640808|NCT05911776|Drug|Nasal packing Dexmedetomidine|patients will receive nasal packing Dexmedetomidine (1.5 mg/kg intranasal dexmedetomidine diluted with saline) and Intravenous infusion saline.
45778856|NCT05157126|Drug|Gentamicin|Liquid gentamicin administered at the open fracture site
45778857|NCT05157126|Drug|normal Saline|Normal saline administered at the open fracture site
45778858|NCT05097222|Device|BioFlex Dualport System|The device consists of a laptop computer preprogrammed with the Bioflex® Practitioner+ Software, the Bioflex® DUO 180+ array pad that has 180 bicolour Light Emitting Diodes (LED) that emit red and near infrared light, and two laser probes, the LD-R 100 that emits red light, and the LD-I 200 that emits near infrared light.
45778859|NCT05097222|Device|Sham device|Control
45916166|NCT00006337|Drug|KW-6002|
45778860|NCT00469508|Drug|Modafinil|400mg pills taken orally daily for 12 wks.
45778861|NCT00469508|Drug|Placebo|400mg pills taken orally daily for 12 wks
45778862|NCT05097144|Device|Lens A (Test)|Test toric lens A
45778863|NCT05097144|Device|Lens B (control)|Control toric lens B
45916167|NCT00006337|Drug|IV Levodopa|
45916168|NCT00006340|Drug|arginine butyrate|
45916169|NCT00006340|Drug|ganciclovir|
45916170|NCT03677011|Diagnostic Test|Andrositol® Test|The intervention consists in the addiction of myo-inositol directly to the semen identifying the quality of sperm prior ICSI procedure
45916171|NCT00007800|Behavioral|Behavioral Group Weight Loss Intervention|
45916172|NCT00007800|Behavioral|Motivational Interviewing|
45916173|NCT00006229|Drug|carboplatin|
45916174|NCT00006229|Drug|paclitaxel|
45916175|NCT00006229|Drug|rebimastat|
45916176|NCT00006343|Biological|recombinant interferon alfa|
45916177|NCT00006343|Drug|cytarabine|
45916178|NCT00006343|Drug|imatinib mesylate|
45916179|NCT00006346|Procedure|psychosocial assessment and care|
45916180|NCT00006346|Procedure|quality-of-life assessment|
45916181|NCT00387868|Drug|cisplatin and etoposide|Cisplatin: 50mg/m2 - administered on days 1,8,29&36 Etoposide: 50 mg/m2 - administered on days 1-5 & 29-33
45640809|NCT05911776|Drug|Intravenous Dexmedetomidine|patients will receive 0.5 mg/kg bolus over 10 min then 0.1- 0.4 mg/kg Intravenous infusion Dexmedetomidine and nasal packing with saline.
45640810|NCT05911763|Drug|Efanesoctocog Alfa BIVV001|Given per investigator's discretion
45640811|NCT05911750|Diagnostic Test|Anal pap smear and oral swab for cytology and HPV testing|Anal and oral swab sampling for HPV detection (polymerase chain reaction) and cytology
45778864|NCT05096832|Biological|Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|"Appearance: Creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5 mL) /vial Vaccination route: Intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg (0.5 mL) Immunization schedule: 1 dose on Day 0, which should be 3-6 months after the second dose of 2-dose regimen of inactive vaccine (BBIBP-CorV or CoronaVac).~Storage condition: Store at 2-8 °C protected from light Expiry date: 24 months temporarily"
45640812|NCT05911737|Behavioral|Short video and Questionnaire|A 10-minute video in a foreign language (not English or Greek) with greek subtitles will be presented and a questionnaire will follow to assess the level of concentration during the video
45640813|NCT05911724|Other|Group I|Healthy Subjects
45640814|NCT05911724|Other|Group II|Stable Angina Patients
45640815|NCT05911724|Other|Group III|Heart Failure Patients
45640816|NCT05911711|Other|Prognostic factor|normal person (no sepsis group)
45640817|NCT05911698|Device|Fractional co2 laser|"The development of fractional resurfacing has led to improvements to melasma treatment with decreased incidence of post-inflammatory hyperpigmentation; these improvements are due to the enhanced healing times and decreased inflammation as a result of the formation of microscopic columns of tissue destruction.~These microscopic columns of damaged tissue are surrounded by areas of normal tissue, allowing for shorter migratory paths for the healing keratinocytes."
45640818|NCT05911685|Device|SeaLA™ left atrial appendage occluder|"Guided by esophageal ultrasound (TEE) and angiography, the diameter of the left atrial appendage anchoring zone and the longest depth of the left atrial appendage were measured to determine the appropriate size of the left atrial appendage occluder.~Maintain Activated Clotting Time (ACT) greater than 250 seconds after atrial septal puncture to the completion of the entire procedure.~Before the plugging device is released, confirm whether there is a residual peri-device leak, and if there is a residual peri-device leak, consider retracting the occluder to reposition the release or retract the occluder to choose a larger size occluder to re-occlusion. If ultrasound confirms residual peri-device leak greater than 5 mm, do not release and implant the left atrial appendage occluder.~Before and after release, confirm the position and stability of the occluder under ultrasound (TEE), and confirm that the occluder completely occludes the left atrial appendage."
45640819|NCT05911672|Device|PRICE|Working closely with 51 cancer patients, medical and paramedical personnel, we co-designed an intelligent personalized mobile application to first collect ecologically momentary assessment data on symptoms like pain and fatigue and Health-Related Quality of Life and subsequently enhance symptom management of cancer patients at home. The full description is available here: https://dl.acm.org/doi/abs/10.1145/3491101.3503562?casa_token=tC5fSN8-k5EAAAAA:56_TMf6HitVQXZypY2j9FCCcroIFZW9kxxzCEt0yJNFJmNrv79m9W7htznSzMWqGLwE4eimBU0vkLA
45640820|NCT05911659|Drug|Ticagrelor|Patients with acute coronary syndromes undergo primary PCI and administered 180 mg loading dose ticagrelor before PCI
46070392|NCT04017091|Diagnostic Test|Virtual Reality Cognitive Training|Bimodal VR-Stroop (ClinicaVR: Apartment Stroop) Patient find themselves seated with a virtual apartment, where they see a living room, in front of a flat-screen TV set, a kitchen and a window. This intervention consisted of two Stroop conditions across all 8 sessions. In Condition 1 (Inhibition), Patients indicated when the color named (audio stimulus) matched the color shown (visual stimulus). Participants were to withhold their response in mismatched trials. In Condition 2 (Interference), Participants clicked the mouse when the color heard was the same as the ink color; not the word printed.
46070393|NCT00808795|Drug|N-acetylcysteine|NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
45640821|NCT05911646|Other|OSA-18 Survey|"OSA 18 is an 18-item questionnaire that uses a Likert-type scoring system to collect information about 5 subscales that are considered to be elements in quality of life: sleep disturbance, physical symptoms, emotional symptoms, daytime function, and caregiver concerns. On the basis of this information, a summary score is calculated and scores are divided into three categories:~Mild (40-60), moderate (61-80) and severe >81."
45640822|NCT05911646|Other|Decisional Conflict (DCS)|The DCS is a 16-item survey in which participants are asked to respond to statements related to their decision on a five-point ordinal Likert scale: 0) strongly agree, 1) agree, 2) neither agree nor disagree, 3) disagree, and 4) strongly disagree. Scores are summed, divided by 16, and multiplied by 25. Scores range from 0, signifying that the respondent has complete certainty about the best choice, to 100, which signifies that the respondent feels extremely uncertain about the best choice.
45778865|NCT05096832|Biological|Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.
45778866|NCT05047302|Device|BlueLeaf Procedure|The device is intended to form autogenous tissue leaflets from vein walls without the use of a permanent vascular implant.
46070394|NCT00808795|Drug|Placebo|Placebo of NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
45640823|NCT05911633|Device|BioPearl™|TACE
45640824|NCT05911620|Device|Magnetic resonance elastography (MRE)|Magnetic Resonance Imaging (MRI) imaging with low-frequency vibrations to create a visual map (elastogram) that shows stiffness of body tissues
45640825|NCT05911607|Procedure|Low power laser|Phototherapy for extraction sockets using two different lasers.
46070395|NCT00815581|Device|photorefraction,cycloautorefraction,cycloretinoscopy|
46070396|NCT00808873|Other|socio-educational intervention|brief mental health education and 6 follow-up visits
46070397|NCT00811213|Device|SleepStyle 200 Auto Series with SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
46070398|NCT00811213|Device|SleepStyle 200 Auto Series with out SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
45778867|NCT00470600|Drug|Caldolor|800 milligrams intravenous
45778868|NCT00470600|Other|Normal Saline|Placebo comparator
45448640|NCT05123248|Device|Unblinded group|Participants in the non-blinded group are required to wear the CGM sensor for 14 days with an open reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. The participant will be required to upload their glucose readings no longer than 8 hours by scanning the reader provided.
45640826|NCT05911594|Drug|Solifenacin group|Patients in this group will receive medical treatment (Solifenacin 5 mg once or twice daily) without any second line of treatment
45778869|NCT04221594|Procedure|Invasive Cardiac Catheterization (ICA)|Invasive functional measurements will be performed to assess the functional significance of specific lesions by means of FFR and CFR, and to test the presence of microvascular disease by means of IMR in all vessels for which the procedures are feasible. In summary, a 5- to 7-F guide catheter without side holes is used to engage the coronary artery and a pressure-temperature sensor-tipped guidewire introduced. The pressure sensor is positioned at the distal segment of a target vessel, and intracoronary nitroglycerine (100-200 mg) administered before each measurement. The best systolic and diastolic phase (located between 30-50%, and 60-75% of the cardiac cycle) will be selected for successive processing as it allows a relative motion free visualization of the main vessels and the myocardium.
45778870|NCT04221594|Procedure|Coronary Computed Tomographic Angiogram (CCTA)|Fasting patients will undergo a test for coronary calcium by CT; calcium scoring analysis will be done post image data acquisition using the manufacturer's software. Nitroglycerine will be administered in all patients (sublingual administration prior to CCTA initiation). CT acquisitions will be prospectively ECG-gated (30-80% of the cardiac cycle). The acquisition begins with a scout scan to identify the borders of the heart to minimize the field of view and exposure to the patient. A bolus of 60 mL nonionic contrast agent is then injected followed by 60 mL of saline at a rate of 4 mL/s to enhance signal from coronary arteries and blood chambers. In case of irregular heart rate, beta-blockers can be provided to keep optimal heart rate ~65-70 bpm. Trans-axial images are reconstructed by means of a filtered back-projection algorithm.
45778871|NCT04221594|Procedure|Dynamic Cardiac Positron Emission Tomography (dPET)|Patients will be asked to fast for 24 hours prior to the test. Before the resting perfusion phase, a single low-dose CT-based transmission scan is acquired for attenuation correction (AC) of all subsequent acquisitions. AC-CT images are automatically registered to the perfusion images, visually verified and manually corrected if necessary. Resting perfusion imaging started with the intravenous injection of a single bolus of 82Rb. Pharmacological stress imaging is obtained after adenosine infusion (140 μg/kg/min) through a peripheral vein, followed by a second dose of 82Rb. Image reconstruction is achieved by means of ordered subset expectation maximization (OSEM) iterative method. The hemodynamic responses to rest/stress tests are collected in terms of mean heart rate, mean blood systolic pressures and diastolic at rest and stress. Dynamic, gated and ungated trans-axial reconstructions are saved in DICOM format for further analysis and processing.
45778872|NCT00471068|Drug|Travatan|Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
45778873|NCT00471068|Drug|Cosopt|treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)
45778874|NCT00471068|Drug|Placebo (Timolol Vehicle)|Travatan group: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
45778875|NCT04231110|Biological|Fecal microbiota transplantation|Use of fecal microbiota transplantation enemas once weekly in patients who are initiating vedolizumab treatment
45778876|NCT00471380|Drug|travoprost 0.004% and brinzolamide 1%|Group A = concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.)
45778877|NCT00471380|Drug|fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle|group B = fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.).
45778878|NCT00471848|Drug|rabbit antithymocyte globulin|1.5 vials/10kg daily for 5 days
45916182|NCT00387868|Procedure|Surgical Resection|Resection will take place 4-8 weeks after completion of radiotherapy.
45916183|NCT00387868|Radiation|Concurrent Radiotherapy|Preoperative External Beam Radiotherapy
45916184|NCT00007839|Drug|beta alethine|
45916185|NCT03616717|Drug|Modafinil|"Drug: modafinil Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.~Other Names:~Provigil Alertec Modavigil"
46070399|NCT00808951|Drug|Artesunate-amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
45640827|NCT05911594|Procedure|Percutaneous tibial nerve stimulation group|Patients in this group will receive Percutaneous tibial nerve stimulation after failure of medical therapy
45640828|NCT05911594|Drug|Intradetrusor BOTOX group|Patients in this group will receive Intradetrusor BOTOX after failure of medical
45448641|NCT05046028|Dietary Supplement|Oral nutritional supplements (ONS) with a cooling effect + ONS without a sensor component and taste + standard diet|ONS with a cooling effect and Red Fruits taste. 3 bottles (х 200 ml) per day X 14 days (at severe mucositis period) in addition to a standard diet and other ONS without a sensor component and taste according to protein and energy requirements based on ESPEN guidelines (protein 1.5 g/kg/day and Energy -25 and 30 kcal/kg/day)
45640829|NCT05911594|Combination Product|Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation group|Patients in this group will receive Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation after failure of medical
45778879|NCT00538850|Drug|Fentanyl sublingual spray|In the open-label titration period of the study, participants started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 21±5 days was reached. In the double-blind period of the study, participants received fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, or 1600 µg determined in the open-label titration period of the study.
45778880|NCT00538850|Drug|Placebo|Matching placebo to fentanyl sublingual spray.
45778881|NCT00418262|Drug|Atomoxetine|Titrating with oral administration of 0.25 mg/kg, 0.50 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with food.
45778882|NCT00418574|Biological|Abagovomab|2 mg/ml SC (subcutaneously)
45778883|NCT00418574|Biological|Placebo|2 mg/ml SC (subcutaneously)
45778884|NCT00473642|Drug|Ranibizumab|intravitreal administered ranibizumab 0.5 mg in 0.05 mL
45778885|NCT00473642|Drug|Verteporfin|Verteporfin with 50% fluence photodynamic therapy (25 J/cm2)
45778886|NCT00473642|Drug|Verteporfin|Verteporfin with standard fluence photodynamic therapy (50 J/cm2)
45778887|NCT00418964|Procedure|Single bundle hamstring|Single bundle hamstring
45778888|NCT00418964|Procedure|Double bundle hamstring|Double bundle hamstring
45778889|NCT00418964|Procedure|Bone patellar tendon bone|Bone patellar tendon bone
45640830|NCT05911581|Other|intra-arterial flushing|"The catheter will be flushed to prevent occlusion after radial artery catheterization.~intra-arterial flushing with heparinized fluid kept in room air"
45640831|NCT05911581|Other|intra-arterial flushing|Intra-arterial flushing with heparinized fluid at patient body temperature
45640832|NCT05911568|Procedure|Endovascular Stroke Treatment|Patients who receive endovascular stroke treatment when they are admitted into the hospital, as determined by their clinical care team. Endovascular stroke treatment consist of catheter-based treatment for the blood clot causing the acute ischemic stroke
45778890|NCT01796834|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|An 8-9 week MBSR course led by an experienced instructor in a group format. Participants learn mindfulness meditation techniques and simple yoga exercises. Subjects receive four phone support calls.
45778891|NCT00539942|Drug|Arixtra (fondaparinux sodium)|Treatment will consist of daily injections of pharmacy prepared syringes of Arixtra (fondaparinux sodium) 2.5mg. Treatment will continue for 21 consecutive days to end on post-operative day 22.
45778892|NCT00539942|Device|Intermittent compression devices (ICD)|All patients will receive intermittent compression devices (ICD's) during the patient's entire hospitalization after the operative procedure. Patients randomized to the standard of care management will receive ICD's only. This represents the current standard of care at our institution at the time of initiation of the trial.
45778893|NCT00419666|Drug|Calcitriol 3mcg/g|Calcitriol 3mcg/g ointment applied twice daily for 56 weeks.
45778894|NCT00540722|Drug|R-(-)-gossypol acetic acid|Given PO
46070400|NCT00808951|Drug|Artemether-lumefantrine|Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing > 35 kg.
46070401|NCT00815737|Drug|rhubarb|14 days of rhubarb
46070402|NCT00815737|Drug|Placebo|14 days of Placebo
46070403|NCT00809029|Other|GIP (glucose dependent insulinotropic peptide) infusion|an intravenous infusion of GIP (glucose dependent insulinotropic peptide)or placebo will be administered at a rate of 2 pmol/kg/min and maintained for 240 minutes.
45778895|NCT00540722|Other|laboratory biomarker analysis|Correlative studies
45778896|NCT00541190|Other|Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA|Subjects perform a single nuclear medicine scan after inhaling an aerosol containing Technetium 99m sulfur colloid and Indium 111 DTPA.
45778897|NCT00542750|Drug|N-Acetylcysteine|N-Acetylcysteine 1200 mg twice daily for four weeks
45778898|NCT00475904|Drug|EpiCept-NP-1 Cream|ketamine 4% amitriptyline 2% cream, twice daily for 4 weeks
45778899|NCT00475904|Drug|Gabapentin Capsules|1800mg/day capsules for 4 weeks
45778900|NCT00475904|Drug|placebo|placebo cream and caps
45778901|NCT00420992|Drug|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)|capsules, up to 80 mg bid
45778902|NCT00420992|Drug|Placebo|capsules, bid
45778903|NCT00423878|Drug|Risperidone|Continued treatment with the medication risperidone for schizophrenia for up to 6 months in study
45778904|NCT00423878|Drug|Olanzapine|Continued treatment with the medication olanzapine for schizophrenia for up to 6 months in study
45778905|NCT00423878|Drug|Quetiapine|Continued treatment with the medication quetiapine for schizophrenia for up to 6 months in study
45778906|NCT00423878|Drug|Aripiprazole|Switching medication to aripiprazole for schizophrenia for up to 6 months in study
45778907|NCT00478556|Drug|Omnipaque|Oral CT contrast
45778908|NCT00478556|Drug|Gastroview|Oral CT contrast
45778909|NCT00480740|Drug|Dexmedetomidine|Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization
45778910|NCT00424268|Drug|Roflumilast|500 µg, once daily, oral administration in the morning
45778911|NCT00424268|Drug|Placebo|once daily
45778912|NCT00424502|Drug|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
45778913|NCT00424502|Drug|Methotrexate|10-25mg po/week
45778914|NCT00425672|Biological|ONTAK|Given IV
45778915|NCT00425672|Other|flow cytometry|Correlative studies
45778916|NCT00425672|Other|immunohistochemistry staining method|Correlative studies
45778917|NCT00425672|Other|enzyme-linked immunosorbent assay|Correlative studies
45778918|NCT00425672|Other|laboratory biomarker analysis|Correlative studies
45778919|NCT00425672|Genetic|protein expression analysis|Correlative studies
45778920|NCT00543764|Other|pathway|Comparison of pre and post pathway
45778921|NCT00544076|Drug|sildenafil citrate|Given orally
45778922|NCT00544076|Drug|alprostadil|Given intraurethrally
45778923|NCT00544076|Procedure|robotic-assisted laparoscopic surgery|Undergo prostatectomy
45778924|NCT00544076|Procedure|quality-of-life assessment|Ancillary studies
45778925|NCT00544076|Other|questionnaire administration|Ancillary studies
45640833|NCT05911568|Other|Medical Management|Patients who receive MMM when they are admitted into the hospital, as determined by their clinical care team. MMM may involve any combination of the following: intravenous thrombolysis, antiplatelets, anti-hypertensives, cholesterol-lowering medications, and rehabilitative care. Specifically, this treatment does not involve endovascular stroke treatment.
45778926|NCT00544778|Biological|filgrastim|
45778927|NCT00544778|Drug|dexrazoxane hydrochloride|
45640834|NCT05911542|Behavioral|Survey|Participants complete survey about pain management practices
45778928|NCT00544778|Drug|doxorubicin hydrochloride|
45778929|NCT00544778|Drug|ifosfamide|
45778930|NCT00544778|Drug|irinotecan hydrochloride|
45916186|NCT03616717|Drug|placebo|Drug: Placebo Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.
45916187|NCT00006349|Dietary Supplement|vitamin E|
45916188|NCT00006349|Drug|donepezil hydrochloride|
46070404|NCT04045483|Other|Virtual reality based cognitive training|The VR-based cognitive training consists of a three-dimensional simulation of home, a mart, bus stop, and street. It provides an integrative cognitive training experience where participants are required to accomplish some common ADL's in three frequently visited places: home, a supermarket, and bus stop.
45916189|NCT00006349|Other|placebo|
45916190|NCT00006352|Biological|BCG vaccine|
45916191|NCT00006352|Biological|monoclonal antibody BEC2|
45916192|NCT00007878|Drug|bortezomib|Given IV
45916193|NCT00007878|Drug|fluorouracil|Given IV
45640835|NCT05911529|Behavioral|Motivational Interviewing|In our study intervention, patients should receive four session of motivational interviewing (MI). Throughout the MI sessions, interviewers use common MI techniques including open-ended questions, affirmations, reflections, summaries, asking permission, expressing empathy, supporting self-efficacy, etc. Interviewers are clinical psychologists who received MI training immediately prior to the study.
45778931|NCT00544778|Genetic|protein expression analysis|
45778932|NCT00544778|Other|immunoenzyme technique|
45916194|NCT00007878|Drug|leucovorin calcium|Given IV
45916195|NCT00007878|Other|pharmacological study|Correlative studies
45916196|NCT00007878|Other|laboratory biomarker analysis|Correlative studies
45448642|NCT05046028|Dietary Supplement|ONS without a sensor component and taste + standard diet|Nutritional support + ONS without a sensor component and taste (cooling effect) in addition to a standard diet according to protein and energy requirements based on ESPEN guidelines (protein 1.5 g/kg/day and Energy -25 and 30 kcal/kg/day)
45448643|NCT05046028|Dietary Supplement|Standard diet|Without appropriate nutritional support - not in accordance with current ESPEN guidelines (protein and Energy intake less than 1.5 g/kg/day and 25 and 30 kcal/kg/day). (Historical retrospective control).
45448644|NCT04427722|Device|MPS-Flex Total Knee Joint Prostheses|Patients who have received MPS-Flex Total Knee Joint Prostheses for their primary TKA and meet the Patient Selection Criteria outlined in the study protocol.
45448645|NCT03866980|Biological|AK105|IV infusion
45778933|NCT00544778|Procedure|adjuvant therapy|
45778934|NCT00544778|Procedure|conventional surgery|
45778935|NCT00544778|Procedure|neoadjuvant therapy|
45778936|NCT00544778|Radiation|radiation therapy|
45778937|NCT02122796|Other|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin at certain points in the body.
45778938|NCT00484874|Drug|I-131 Tositumomab therapeutic regimen|Tositumomab and I-131 tositumomab are given intravenously. A test dose is given followed by a larger treatment dose.
45778939|NCT01795742|Device|Human-Powered Nebulizer|
45778940|NCT00486824|Drug|Indomethacin|One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.
45778941|NCT00486824|Drug|Nifedipine|Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.
45778942|NCT00489086|Drug|tazarotene|Tazarotene is a member of the acetylenic class of retinoids.
45778943|NCT02119442|Device|Transcather Valve Implantation|Transcather Valve Implantation
45778944|NCT00489866|Drug|Aripiprazole|Aripiprazole: 5 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-10 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-15 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-20 mg taken once a day orally for 2 weeks
45778945|NCT00489866|Drug|Placebo|Same as active drug.
45778946|NCT00546104|Drug|Dasatinib|An initial dose of 50 mg PO BID; following 4 weeks of treatment, dose adjustment will be based on inhibition of phosphorylation of FAK and paxillin per biopsy assessment, as well as toxicity assessment.
45778947|NCT00546728|Drug|Exenatide|exenatide 10 mcg twice daily
45778948|NCT00546728|Drug|Metformin|metformin 500 twice daily
45916197|NCT00006355|Drug|pyrazoloacridine|
45916198|NCT00006355|Procedure|adjuvant therapy|
45916199|NCT00006355|Radiation|radiation therapy|
45916200|NCT00006358|Drug|temozolomide|
45916201|NCT00006358|Drug|thalidomide|
45916202|NCT00006361|Drug|semaxanib|
45916203|NCT00006364|Drug|omacetaxine mepesuccinate|Given IV or SC
45916204|NCT00006364|Other|pharmacological study|Correlative studies
45916205|NCT00006364|Other|laboratory biomarker analysis|Correlative studies
46070405|NCT02551393|Behavioral|Home Blood Presssure Monitoring, Education|Doctors and Nurses in intervention clinic will receive 1 hour briefing + education on the background, scientific basis and detail of the program during lunch time. People from intervention clinics will be invited to attend 2 x 2 hours education group (15-30 subjects / group) ran by clinic nurses and doctors. You will be educated on basic knowledge, management and drug for hypertension in the first session. In the 2nd session, a certified valid Home BP device will be loaned to you for 6-9 months and you will be taught to perform home BP monitoring, record and response to the BP reading accordingly. Upon completion of session 2, you will be arranged for nurse individual follow up after 4-8 weeks to see their progress and monitoring
46070406|NCT00842829|Drug|Fentanyl Buccal Tablet (FBT)|FBTs were self-administered by participants via the oral mucosa. During the open-label dose titration period, participants used 1 to 4 tablets of the 100 mcg or 200 mcg strength to individually titrate upwards to an effective dose through the range of available strengths (i.e. 100, 200, 400, 600, or 800 mcg). For the open-label treatment and continuation periods, single dose tablets at the effective dose identified during the titration period were used. The maximum dose allowed per breakthrough pain (BTP) episode was 800 mcg. On any single day, participants were not to use FBT for more than 4 BTP episodes.
46070407|NCT04045249|Dietary Supplement|Home based food|Home based food is compare able to RUTF
46070408|NCT04045093|Drug|Dabigatran etexilate|Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.
46070409|NCT04045093|Drug|Warfarin|Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.
46070410|NCT00811291|Dietary Supplement|Vitamine-B and Folic Acid Complex, calcium|90 days of intake, will be given in drink (e.g. tea, milk, juice). Dosage within official recommendations for kindergarten kids
45778949|NCT00546884|Behavioral|MI condition|Individuals randomized to this condition will be provided with written end of life educational materials an advance directive form, along with instructions to complete it.
45778950|NCT00546884|Behavioral|GI|The GI condition will expose participants to education, guidance and counseling, and an advance directive tool.
45778951|NCT00547586|Drug|N-methylnaltrexone bromide (MOA-728)|Oral
45778952|NCT00547586|Other|placebo|placebo
45778953|NCT00547898|Drug|Crofelemer 125 mg|Crofelemer 125 mg
45778954|NCT00547898|Drug|Crofelemer 250 mg|Crofelemer 250 mg
45778955|NCT00547898|Drug|Crofelemer 500 mg|Crofelemer 500 mg
45778956|NCT00547898|Drug|Placebo|Placebo
45916206|NCT00007917|Drug|alvocidib|
45916207|NCT00007917|Drug|gemcitabine hydrochloride|
46070411|NCT00811291|Dietary Supplement|calcium|according to protocol
46070412|NCT00811369|Drug|Fulvestrant + ZACTIMA|ZACTIMA 100 mg tablets. Dose = 1 tablet daily until disease progression or intolerance
46070413|NCT00811369|Drug|Fulvestrant + Placebo|ZACTIMA Placebo 100 mg tablets. Dose = 1 tablet daily for duration of study.
46070414|NCT00842361|Drug|insulin degludec/insulin aspart|The insulin NN5401 (insulin degludec/insulin aspart) injected subcutaneously immediately before breakfast and dinner.
45640836|NCT05911529|Behavioral|Supportive conversations|"In the control intervention patients should also be given four sessions, in which no MI techniques take place. They will be carried out in the sense of supportive conversations (i. e. conver-sations that do not follow a specific psychotherapy concept).~Since we want to check whether the patients really benefit from the specific intervention and not from getting more speaking time, the patient in the control group will also be given four conver-sations. It is known that supportive conversations can have a certain effect on the well-being and recovery process of patients, as the therapeutic relationship, i.e. appreciation, attention and/or attention, is an important efficacy factor (e. g. Grawe, 1995)."
45640837|NCT05911516|Dietary Supplement|Pennisetum purpureum|300mg Participants received 900mg of Pennisetum purpureum orally daily for 12 weeks
45640838|NCT05911516|Dietary Supplement|Placebo|Placebo
45778957|NCT00548132|Device|Chlorhexidine-impregnated foam dressing|Patients in the treatment arm will have the Biopatch incorporated into their catheter care protocol. ICU nurses were instructed on the proper use of this novel dressing/sponge. Catheter dressing changes will only be done every 7 days unless there is visible blood, soiling underneath the dressing, or if the dressing comes off.
45778958|NCT00490100|Drug|Increlex|
45778959|NCT00490256|Procedure|Modified Selective Cerebral Perfusion|Modified Selective perfusion is a cardiopulmonary bypass circuit that has been modified to allow blood flow to the lower body as well as the upper body while the surgery is being performed.
45778960|NCT00490802|Drug|Oxytocin|Intranasal Oxytocin
45778961|NCT00490802|Drug|Placebo|Placebo Comparator
45778962|NCT00550394|Drug|quetiapine and placebo|"Dosing Schedule and Titration of Quetiapine: open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1~Dosing Schedule and Titration of Topiramate:~All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.~Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4."
45778963|NCT00550394|Drug|Quetiapine and Topiramate|"Dosing Schedule and Titration of Quetiapine:~open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1~Dosing Schedule and Titration of Topiramate:~All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.~Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4."
45778964|NCT00550862|Drug|INT-747|Once a day (QD) by mouth (PO)
45778965|NCT00550862|Drug|Ursodeoxycholic Acid (URSO)|Stable dose for at least 6 months prior to screening. Dose as prescribed by physician.
45778966|NCT00550862|Drug|Placebo|Placebo
45916208|NCT00006367|Biological|filgrastim|
45916209|NCT00006367|Drug|busulfan|
45916210|NCT00006367|Drug|cytarabine|
45916211|NCT00006367|Drug|idarubicin|
45916212|NCT00006367|Procedure|peripheral blood stem cell transplantation|
45916213|NCT00006370|Radiation|yttrium Y 90-edotreotide|
45916214|NCT00007956|Biological|monoclonal antibody mono-dgA-RFB4|
45916215|NCT00006373|Drug|etoposide|Etoposide IV 500 mg/m2/day over 24 hours Days -5, -4, -3
45916216|NCT00006373|Drug|ifosfamide|Ifosfamide 3,333 mg/m2/day IV over 2 hours (total dose 10,000 mg/m2)Days -8, -7, -6
45778967|NCT00551174|Drug|ibandronate [Bonviva/Boniva]|3 mg IV every 3 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
45778968|NCT00551174|Drug|ibandronate [Bonviva/Boniva]|2 mg IV every 2 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
45778969|NCT03430076|Procedure|revascularization|open revascularization for below-knee popliteal in the absence of an suitable autologous vein with PTFE.
45640839|NCT05911503|Drug|2% Ganciclovir Eye Drops|Administration method and dosage adjustment: 2% ganciclovir eye drops, 10 times/day for two weeks, 8 times/day for two weeks, 6 times/day for two weeks, 4 times/day for more than 6 weeks
45778970|NCT03430076|Device|Propaten®|Propaten®
45778971|NCT03430076|Device|Crude PTFE|Crude PTFE
45778972|NCT00492206|Drug|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. Subjects will receive cetuximab from week 0 through week 26.
45778973|NCT00431132|Drug|estradiol, 10 mcg|Tablets, administered intravaginally twice weekly
45778974|NCT00493064|Drug|Nicotinic acid|topical eye drops
45778975|NCT00493064|Drug|Prednisolone acetate|topical eye drops
45778976|NCT00552422|Drug|domperidone|10mg orally four times per day
45778977|NCT00552812|Device|Stent therapy of aortic coarctation|Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.
45778978|NCT00432458|Drug|Thalidomide|200 mg orally on days 1-28 of 28 day cycle
45778979|NCT00432458|Drug|zoledronic acid|4 mg^2 by IV on day 1 every 84 days for 1 year and once per year thereafter
45448646|NCT03866980|Drug|carboplatin|IV infusion
46070415|NCT00842361|Drug|biphasic insulin aspart 30|The insulin (biphasic insulin aspart 30) injected subcutaneously immediately before breakfast and dinner.
46070416|NCT00811447|Drug|5-fluorouracil|600 mg/m²/day intravenous
46070417|NCT00811447|Drug|Cisplatin|60 mg/m² or 75 mg/m² intravenous
45640840|NCT05911490|Behavioral|Prolonged sitting|In the laboratory, after consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min. After data collection was completed in the laboratory, participants were asked to keep wearing the same pedometer and to record any food and liquid consumption for the rest of the day (until midnight) under free-living conditions.
45778980|NCT01656408|Drug|MK-8150|
45778981|NCT01656408|Drug|Placebo for MK-8150|
45778982|NCT05046600|Device|Products listed in cohort description|Depending on approved indication per product
45778983|NCT05155956|Other|transcranial Doppler ultrasonography (TCD)|"Transcranial Doppler (TCD) is a non-invasive ultrasound-based technique that facilitates insonation of the cerebral arteries. TCD probe design enables continuous monitoring of cerebral blood flow velocity (CBFv). TCD has a variety of clinical applications, including intraoperative monitoring for detection of microemboli. The TCD probe can be comfortably secured to the patient's head by a headframe in order to maintain continuous vessel insonation. Microembolic signals (MES) can be reliably detected based on standard criteria:~Brief in duration (<300msec)~High intensity (amplitude >3 dB above background)~Unidirectional~Audible chirp or snap~Further, CBFv monitoring during may inform flow perturbations that occur during cardiac or vascular manipulations."
45778984|NCT05045196|Behavioral|Health promoting conversations|The Health-promoting conversations intervention is a conversation model between the patient, family members, and a trained nurse. Patients and families included in the study will, after submitting base-line-data, be randomized to
46070418|NCT00811447|Drug|Docetaxel|60 mg/m² intravenous
45778985|NCT05095272|Biological|HMPBS02-Pv|The blood-stage P. vivax master cell bank HMPBS02-Pv was also produced using blood collected from a consenting patient with naturally acquired malaria infection. The malaria infection was confirmed to be P. vivax by species-specific PCR at Pathology Queensland (accredited by the Australian National Association of Testing Authorities) and further confirmed by deep sequencing at the Sanger Institute. The clinical response to antimalarial chemotherapy was also demonstrated with this donor, who was successfully cured with artemether/lumefantrine.
45778986|NCT00433550|Drug|capecitabine|given orally
45778987|NCT00433550|Drug|irinotecan hydrochloride|given IV
45778988|NCT00433550|Drug|oxaliplatin|given IV
45778989|NCT02208037|Drug|Tacrolimus (ARM with Methotrexate)|Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels. The dose should be adjusted accordingly to maintain a suggested level of 5-15 ng/mL. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
45916217|NCT00006373|Drug|topotecan hydrochloride|Topotecan 21.3 mg/m2/day (total dose 64 mg/m2 ) IV over 30 minutes Days -8, -7, -6
45916218|NCT00006373|Procedure|autologous bone marrow transplantation|
45916219|NCT00006373|Drug|Mesna|Mesna 1,111 mg/m2/dose IV over 30 minutes; 30 minutes before and 4 and 8 hours after ifosfamide (total dose 10,000 mg/m2) Days -8, -7, -6
45916220|NCT00006376|Drug|chemotherapy|
45448647|NCT03866980|Drug|pemetrexed|IV infusion
45448648|NCT03866980|Drug|placebo|IV infusion
45448649|NCT03866980|Drug|Anlotinib|PO
45448650|NCT02253862|Drug|Tadalafil|administered days 1, 8 and 16
45640841|NCT05911490|Behavioral|Breaking prolonged sitting|In the laboratory, after consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min. After data collection was completed in the laboratory, participants were asked to keep wearing the same pedometer and to record any food and liquid consumption for the rest of the day (until midnight) under free-living conditions.
45640842|NCT05911477|Drug|RhBMP-2|1mg RhBMP-2 for one fusion-level
45640843|NCT05911464|Drug|HS-10386|Starting dose 10 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of HS-10386, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined
45640844|NCT05911451|Procedure|Arteriovenous fistula creation|It is recommended to create the arteriovenous fistula 3 to 6 months before the expected start of hemodialysis treatment using locoregional anesthesia. It is recommended to use minimal venous and arterial diameters of 2mm for radiocephalic fistulas and 3mm for brachiocephalic and brachiobasilic fistulas. It is recommended to avoid creating an arteriovenous fistula at the same side as a pacemaker, central venous catheter, or arterial stenosis. It is recommended to use the following order of preference for arteriovenous fistula creation: radiocephalic fistula as first choice, brachiocephalic fistula as second choice, and brachiobasilic fistula as third choice.
45778990|NCT02208037|Drug|Tacrolimus (ARM with MMF and Cyclophosphamide)|Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day +5. Serum levels of tacrolimus will be measured at Day 7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
45640845|NCT05911451|Procedure|Arteriovenous graft placement|It is recommended to implant the arteriovenous graft 2 weeks before the expected start of hemodialysis treatment under antibiotic prophylaxis. Implantation of an early-cannulation graft is recommended for patients who require more urgent start of hemodialysis to avoid the use of a temporary central venous catheter. It is recommended to use minimal arterial and venous diameters of 3mm and 4mm, respectively. It is recommended to avoid placing an arteriovenous graft at the same side as a pacemaker, central venous catheter, or arterial stenosis.
45448651|NCT02253862|Drug|Tipranavir|administered days 8-18
45778991|NCT02208037|Drug|Methotrexate (ARM with Maraviroc)|Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of maraviroc. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
45640846|NCT05911451|Procedure|Central venous catheter placement|It is recommended to place a tunneled central venous catheter just before the start of hemodialysis treatment under local anesthesia, with conscious sedation if preferred by the patient. The catheter should preferably be placed in the right internal jugular vein with ultrasound-guided puncture and fluoroscopy control under sterile conditions. According to usual practice at the trial center, catheters may be implanted by surgeons, interventional radiologists, or nephrologists.
45640847|NCT05911438|Drug|Ferric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection (EPIAO)|Ferric Derisomaltose Injection (Monoferric): 1000 mg, intravenous infusion 6±2 days before surgery; Human Erythropoietin Injection (EPIAO): 36000 IU, subcutaneous injection 6±2 days before surgery and 3±1 days after surgery.
45778992|NCT02208037|Drug|Methotrexate (ARM with Bortezomib)|Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of bortezomib. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
45778993|NCT02208037|Drug|Maraviroc|Maraviroc will be dosed at 300 mg orally twice a day and will start on Day -3 prior to hematopoietic stem cell infusion, and continue until Day 30 post HSCT. If the patient requires a two-day stem cell infusion, maraviroc treatment will end 30 days after the first infusion day.
46070419|NCT00702975|Drug|Paclitaxel, Carboplatin and Bevacizumab,Erlotinib|4 cycles (or less in case of progression) with carboplatin AUC 6 -paclitaxel 200mg/m2 -bevacizumab 15 mg/kg i.v. At (early) progress Bevacizumab 15 mg/kg i.v. q 21 days plus Erlotinib 150 mg/day orally
46070420|NCT02552251|Biological|Hormonal balance measurements|
45448652|NCT02253862|Drug|Ritonavir|administered days 8-18
45448653|NCT03546010|Behavioral|Neuropsychological tests|WISC test, BRIEF test, NEPSY-2 test, TAP2.3 test, Teach test
45448654|NCT03546010|Behavioral|Oculometric tests|When the subject see a peripheric target, he should take a look not at the target but in the controlateral half-field, at a mirror position. This is called an anti-saccade task.
45640848|NCT05911438|Other|Basic Treatment|Daily energy intake of 20-30 kcal/kg, with fat accounting for 20-30% of total energy; Iron: ≥15 mg/d, protein intake of 1.2-1.5 g/kg/d; Simultaneously enhance functional exercises.
45640849|NCT05911425|Drug|envolizumab , sovalteinib|Envolizumab 300mg, Q2W, day 1, subcutaneous injection Soventinib 200mg, Q2W, once daily, orally Every 2 weeks as a cycle.
45916221|NCT00006376|Drug|tipifarnib|
46070421|NCT02552251|Biological|metabolic balance measurements|
46070422|NCT02552251|Biological|bone balance measurements|
46070423|NCT02552251|Behavioral|quality of life assessment|
45448655|NCT03627195|Drug|DSP-1349M|DSP-1349M injectable
45448656|NCT03627195|Drug|placebo|placebo injection
45448657|NCT04375072|Device|active tDCS paired with active MBM|Active tDCS with a constant current intensity of 2 milli ampere( mA)will be applied for 20 minutes per session daily for 2 weeks via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session daily for 2 weeks by a recorded meditation.
45778994|NCT02208037|Drug|Bortezomib|Bortezomib will be administered at the dose of 1.3 mg/m2 based upon actual body weight (ABW) as an approximately 3-5 second IV push on Days +1, +4, and +7 after hematopoietic stem cell infusion. There must be at least 72 hours between each dose of bortezomib. Subcutaneous administration of bortezomib is not allowed on this protocol.
45778995|NCT02208037|Drug|Mycophenolate mofetil|MMF will be given at a dose of 15 mg/kg three times a day (TID) based upon ABW with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day 5 and discontinue after the last dose on Day 35, or may be continued if active GVHD is present.
45778996|NCT02208037|Drug|Cyclophosphamide|"Hydration prior to cyclophosphamide may be given according to institutional standards.~Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide [50 mg/kg ideal body weight (IBW); if ABW < IBW, use ABW] will be given on Day 3 post-transplant (between 60 and 72 hours after the start of the HSCT) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
45640850|NCT05911412|Behavioral|Mindfulness-based cognitive therapy using neuroscience (NMBCT)|Mindfulness-based cognitive therapy using neuroscience (NMBCT) is a standardized 8-week course taught by trained instructors. The NMBCT is a group therapy that takes place once a week for about 90 minutes per session. The program consists of mental education for each session, 2-3 mindfulness meditation practice, mindfulness practice in daily life, and about 30 minutes of daily home mindfulness meditation task. While participating in the program, the subjects will receive psychoeducation and various mindfulness meditation techniques (eating meditation, breathing meditation, sedentary meditation, viewing meditation, and listening meditation, etc.).
45778997|NCT05043402|Drug|navicixizumab|navicixizumab IV
45640851|NCT05911399|Drug|Tiratricol|Tiratricol (3,3',5-triiodothyroacetic acid) is available as 350 µg tablets for oral administration (suspended in water and, if needed, mixed with food) or by percutaneous endoscopic gastrostomy (PEG), nasogastric or jejunal tube.
45640852|NCT05911386|Other|study of biological samples and echocardiographic data and link with need of hemodynamic support|observational study : there is no intervention
45640853|NCT05911373|Other|group serratus plan block|preoperativelly, Superficial Serratus Block performed with 30 ml %0.25 Bupivacaine and Parasternal Block performed with 10 ml saline
45640854|NCT05911373|Other|group serratus and parasternal plan block|preoperativelly, Superficial Serratus Block performed with 30 ml %0.25 Bupivacaine and Parasternal Block performed with 10 ml %0.25 Bupivacaine
45778998|NCT05043402|Device|Xerna™ TME Panel|RNA-seq-based biomarker platform that classifies any given patient tumor sample into phenotypes based on the dominant biology of the tumor microenvironment (TME).
45640855|NCT05911360|Drug|DTG/3TC|DTG/3TC FDC will be administered once daily.
45778999|NCT03008161|Drug|NPT088|IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
45779000|NCT03008161|Drug|Placebo|Placebo
45779001|NCT00496262|Biological|Human Fibrinogen Concentrate|Single intravenous infusion of 70 mg/kg body weight
45779002|NCT05043246|Biological|SARS-COV-2 VACCINE|the antibody titer and adverse reactions were observed.
45779003|NCT03007927|Drug|Bupivacaine-Dexamethasone|Bupivacaine 1,5 mg/kg-Dexamethasone 2ml 8 mg
46070424|NCT05603403|Drug|Probiatop|1 sachet orally, 2 times a day, for 42 days
45640856|NCT05911347|Dietary Supplement|Psyllium|15g psyllium added to inulin solution to form a gel
45640857|NCT05911347|Dietary Supplement|Methylcellulose|15 g methylcellulose added to inulin solution to form a gel
45640858|NCT05911347|Dietary Supplement|Maltodextrin|15g maltodextrin added to inulin solution to form a gel
45640859|NCT05911334|Behavioral|ROADE Program|Outpatient Behavioral Intervention for Eating Disorder
45640860|NCT05911321|Drug|Isatuximab|Pharmaceutical form: Solution for infusion. Route of administration: Intravenous 10 mg/kg will be administered intravenously once weekly during cycle 1 and every other week during each subsequent cycle.
45640861|NCT05911321|Drug|Pomalidomide|Pharmaceutical form: Pill for oral use. Route of administration: 3 mg Pomalidomide 3 mg pill will be taken by mouth once daily on days 1-21 of each 28-day cycle.
45640862|NCT05911321|Drug|Dexamethasone|Pharmaceutical form: Tablet for oral use Route of administration: Pill for oral use. Dexamethasone 20 mg tablet will be taken by mouth once per week.
45640863|NCT05911308|Drug|Durvalumab|1,500 mg Durvalumab IV infusion will be given on day 1 of each cycle for 3 cycles.
45640864|NCT05911308|Drug|Carboplatin|Carboplatin IV infusion will be given on day 1 of each cycle for 3 cycles. The dose will be AUC 5.
45640865|NCT05911308|Drug|Abequolixron|100 or 120 mg Abequolixron will be administered by mouth twice a day for 5 days followed by 2 days off throughout your treatment (5 days a week for up to 9 weeks).
45640866|NCT05911308|Drug|Abraxane|100 mg/m2 Abraxane will be given by IV infusion on days 1, 8, and 15 of each cycle for 3 cycles.
45640867|NCT05911308|Drug|Pemetrexed|500 mg/m2 pemetrexed will be given by IV infusion on day 1 of each cycle for 3 cycles.
45779004|NCT03007927|Drug|Bupivacaine- physiological solution|Bupivacaine 1,5 mg/kg- physiological solution
45779005|NCT05151900|Behavioral|Support Group for Caregivers|"Engage parents in the community via this support group, so they can be supported by other parents who know the system, can advise them on how to proceed, and empower them to help their children. Parents will learn psychoeducation about eating disorders and how to support their children."
46070425|NCT05603403|Other|Placebo|1 sachet orally, 2 times a day, for 42 days
46070426|NCT00815815|Behavioral|Structured Behavioral Treatment|Daily therapy sessions and a weight gain protocol involving set meals and exercise levels
46070427|NCT00809107|Drug|HCG|5000IU
45779006|NCT01483807|Behavioral|Sound Production Treatment - Blocked|Sound Production Treatment is a treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Blocked entailed practicing all treatment targets blocked by target. SPT-Random entailed practicing all treatment targets in a non predictable, random order.
45640868|NCT05911295|Drug|disitamab vedotin|Given into the vein (IV; intravenous) every 2 weeks
45779007|NCT01483807|Behavioral|Sound Production Treatment - Random|A treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Random entailed practicing treatment targets in a non predictable order. SPT-Blocked entailed practicing treatment targets blocked by target.
45779008|NCT05042076|Drug|BK-specific T cells from Donor Lymphocytes|"Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis, enriched for BK-specific CD4+ and CD8+ T cells~Suspension of BK-specific T cells in approximately 7 mL (5-10 mL range for volume of IMP) of 0.9% NaCl with 2.5% HSA at a cell dose of: ≥ 300 and ≤ 5,000 BK virus-specific CD3+ T cells/kg body weight (BW).~IV bolus injection; IV push of IMP over approximately 2-4 minutes, resulting in an infusion rate of approximately 3 mL/min."
45779009|NCT05041998|Device|Trans-femoral prosthetic socket|"Unmodified) A custom-made check socket serving as the interface between residual limb and prosthesis~Soft socket (Socket made from softer material than unmodified original)~Stiff socket (Socket made from stiffer material than unmodified original)~moderately lower brim height (Brim of the socket is lowered by 10% of socket length compared to unmodified original)~slightly lower brim height (Brim of the socket is lowered by 5% of socket length compared to unmodified original)~Oversized socket (The socket volume is 6% larger than the unmodified original)~Undersized socket (The socket volume is 6% smaller than the unmodified original)~CAT-CAM influenced geometry (The cross sectional geometry of the socket is modelled following the contoured adducted trochanteric-controlled alignment method (CAT-CAM))~MAS influenced geometry (The cross sectional geometry of the socket is modelled following the Marlo Anatomic Socket (MAS) template)"
45448658|NCT04375072|Device|sham tDCS paired with active MBM|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2(milli ampere) mA current for 30 seconds. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session daily for 2 weeks by a recorded meditation.
45779010|NCT05041842|Drug|Tucatinib|300 mg orally twice daily
45779011|NCT05041842|Drug|Pertuzumab|Initial loading: 840 mg Maintenance: 420 mg, 3-weekly
45779012|NCT05041842|Drug|Trastuzumab|"Intravenous formulation :~Initial loading: 8 mg/kg Maintenance: 6 mg/kg, 3-weekly~Subcutaneous formulation:~600 mg (fixed dose regardless of patient's body weight), 3-weekly"
45779013|NCT05041842|Drug|Hormone therapy|Anastrozole (1 mg/day) or letrozole (2.5 mg/day) or fulvestrant (2x250 mg at day 1 and day 15 then every 4 weeks after the first injection)
45640869|NCT05911295|Drug|pembrolizumab|400mg given by IV every 6 weeks
45640870|NCT05911295|Drug|gemcitabine|1000 mg/m^2 given by IV on days 1 and 8 of every 3-week cycle
45640871|NCT05911295|Drug|cisplatin|70 mg^2 given by IV on day 1 of every 3-week cycle
45448659|NCT04375072|Device|active tDCS paired with sham MBM|Active tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
45640872|NCT05911295|Drug|carboplatin|Area under the plasma concentration-time curve (AUC) 4.5 or 5 given by IV on day 1 of every 3-week cycle
45640873|NCT05911282|Drug|N Acetylcysteine|"The study began at 7 pm, when the volunteers in NAC group drank the contents of a numbered cup with NAC (1.2 g of NAC). At 9 pm, they were given the second cup with 1.2 g of NAC corresponding to their randomized number.~The cups with pure substance NAC were prepared and numbered by the physician not attending the drinking just before the study."
45640874|NCT05911282|Other|Lemon juice|"The study began at 7 pm, when the volunteers in placebo group drank the contents of a numbered cup with lemon juice. At 9 pm, they were given the second cup with lemon juice corresponding to their randomized number.~The cups with lemon juice were prepared and numbered by the physician not attending the drinking just before the study."
45640875|NCT05911230|Diagnostic Test|Advanced diffusion-weighted MRI (ADW-MRI)|An advanced diffusion weighted MRI-sequence will be performed in addition to the routine MRI-diagnostics. This will require the patient to be scanned for additional 30 minutes in a separate MRI-scanner. This technique offers the opportunity of higher sensitivity towards subtle tissue changes associated with increased specificity relating to damage of different tissue components of the CNS. In the case of surgical resection, the histopathological findings will be correlated to the findings of the ADW-MRI.
45640876|NCT05911165|Other|No surgical coaching|During the twelve-month study period, all participants will have access to an instructional video related to laparoscopic vaginal cuff suturing and the laparoscopic vaginal cuff trainer in order to practice laparoscopic suturing as desired. All participants will keep a log of voluntary practice time on the vaginal cuff trainer. These resources will constitute the control arm of the study
45779014|NCT05041842|Drug|Pertuzumab/ Trastuzumab|"Initial loading:~1200 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight)~Maintenance:~600 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight), 3-weekly"
45779015|NCT00434018|Behavioral|Wheelchair Skills Training|Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs.
45779016|NCT00434018|Behavioral|Basic Health Education|Five sessions are held with subjects to provide them with educational information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
45779017|NCT05150496|Biological|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
45779018|NCT05150496|Biological|High-dose COVID-19 Vaccine(Vero Cell),Inactivated|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
45779019|NCT04421586|Behavioral|VISTA|VISTA will be an educational intervention.
45916222|NCT00006379|Biological|anti-thymocyte globulin|anti-thymocyte globulin IV over at least 4 hours on days -2 and -1
45916223|NCT00006379|Biological|graft-versus-tumor induction therapy|Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
45779020|NCT05090514|Behavioral|Reading and Growth Mindset|Parents and students receive a packet of age-appropriate books and educational materials (flyer/handouts, link to educational video) on how to read together/promote reading with their child using growth mindset strategies and where to find other reading materials. Parents also receive 2 weekly text messages with tips and reminders to read with their child daily for 20 minutes over the course of 8 weeks. The messages contain a link to a secure Redcap survey to log days and time spent reading the prior week.
45779021|NCT05090514|Behavioral|Wait-list Control|Parents and students receive a packet of age-appropriate books at the same time as the intervention group, but do not receive specialized instruction or reminders to read or any information on growth mindset and reading.
45779022|NCT00496340|Drug|Pentostatin|"Pre-conditioning therapy:~All participants will receive pentostatin 4 mg/m^2 on day -28. Patients may receive additional doses on days -21 & -14 depending on cell counts.~Participant will receive pentostatin at a dose of 4 mg/m^2 by intravenous infusion over 1-2 hours on days -4, -3."
45640877|NCT05911165|Other|Surgical coaching|Surgical coaching sessions will include 30-60 minute meetings in which the coach-coachee pair reviews recorded laparoscopic suturing practice sessions to examine different aspects of surgical performance.
45640878|NCT05911100|Diagnostic Test|Spirography and assessment of pulmonary diffusion capacity|Using the Master Screen Body device you will be asked to take two series of breaths through a special tube for 2-3 minutes. Usually the procedure does not cause any discomfort
45779023|NCT00496340|Drug|Busulfan|"Pre-conditioning therapy:~Intravenous Busulfan (1st dose) at a dose of 200mg/m^2 on day -4.~Intravenous Busulfan (2nd dose) will be administered on day (-2) to target a total AUC of 16,000 +/- 1600."
45640879|NCT05911100|Diagnostic Test|Cardiopulmonary stress test|The exercise test is performed on a bicycle ergometer Oxycon Pro. Prior to the test, special sensors for recording the electrocardiogram, a sensor to determine blood saturation, and a cuff to measure blood pressure will be glued on the body. Breathing during the test takes place through a face mask with a built-in gas analyzer sensor. The stress test is conducted up to an individual maximum (according to the age, sex, height and weight of the patient), followed by a recovery period. There is some temporary discomfort associated with performing physical activity. Dyspnea, leg fatigue, and dizziness may occur. Observation continues until full recovery of hemodynamic and gas exchange parameters, in case of appearance of unfavorable symptoms - until their disappearance.
45779024|NCT00496340|Drug|Rituximab|"Pre-conditioning therapy:~Patients with CD20+ expressing malignancies will be treated with rituximab at a dose of 375 mg/m^2 according to prescribing and institutional guidelines."
45779025|NCT00496340|Procedure|Allogeneic Hematopoietic Cell Transplant|Hematopoietic progenitor cells to be infused at least 36 hours after last dose of Busulfan.
45779026|NCT05090358|Dietary Supplement|Ketogenic Diet|Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
45779027|NCT05090358|Dietary Supplement|Low Carbohydrate Diet|Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
45779028|NCT05090358|Drug|Alpelisib|The recommended dose of PIQRAY is 300 mg (two 150 mg film-coated tablets) taken orally, once daily, with food. Patients should take their dose of PIQRAY at approximately the same time each day.
45779029|NCT05090358|Drug|Fulvestrant|"The recommended dose is 500 mg to be administered intramuscularly into the buttocks slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on days~1, 15, 29 and once monthly thereafter."
45779030|NCT05090358|Drug|Canagliflozin|Canagliflozin is an inhibitor of SGLT2, the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. For the first week of canagliflozin dosing, the dose will be 100 mg. Starting week 2 and onward the dose will be 300 mg and supplied by the site.
45779031|NCT00496808|Drug|Herceptin (Trastuzumab)|8 mg/kg IV Over 90 Minutes
45779032|NCT05089812|Procedure|Third-molar extraction using platelet-rich fibrin as a filling of the alveolus|see above
45779033|NCT05040672|Behavioral|questionare online application|questionare online application
45779034|NCT04220970|Other|BIA-ALCL|Observational : no intervention
45779035|NCT05039268|Drug|3K3A-APC Protein|3K3A-APC with intravenous dosing of five doses of either 15mg or 30mg at 12 hourly interval. The first 8 patients will receive 15mg dose, and the next 8 patients will receive 30mg dose.
45779036|NCT05148078|Other|Compare general anesthesia treatment|The percentage of pediatric patients age 3-7 who require daily general anesthesia for all treatments, compared to historical control.
45779037|NCT05038878|Drug|Elagolix|Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months
45640880|NCT05911100|Diagnostic Test|Computed tomography of the chest organs|"CT is a method of examination based on X-rays, but unlike conventional X-rays, it gives the most complete picture of the body structure, with less radiation.~Tomography usually does not cause any unpleasant feelings and is performed in a specialized department."
45640881|NCT05911100|Diagnostic Test|Heart echocardiography|It's a specific method of ultrasound examination, which consists in examining the heart in real time and usually does not cause any unpleasant feelings
45640882|NCT05911100|Other|SF-36 Quality of Life Questionnaire|https://clinmedjournals.org/articles/jmdt/jmdt-2-023-figure-1.pdf
45640883|NCT05911100|Diagnostic Test|Demographic and antropometric measures|Age, sex, height. weight, body mass index (BMI)
45640884|NCT05911100|Other|Indicators characterizing the severity of the underlying disease|"Severity of underlying disease (mMRC, BODE, SMRT-CO Respiratory Support Need Scale), and comorbidities (cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease)~Medications taken."
45916224|NCT00006379|Drug|cyclophosphamide|cyclophosphamide IV over 2 hours on days -3 to -2
45640885|NCT05911022|Drug|Colchicine 0.5 MG|three times per day for three days and subsequently twice per day for four days
45640886|NCT05911022|Dietary Supplement|Probiotic Formula|oral sachets once daily for two weeks
45779038|NCT05038566|Device|Pointdexter|i-Digits partial hand prosthesis modified with the investigational pointdexter finger in place of the usual index finger.
45779039|NCT00554372|Genetic|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|Patients will be randomized 1:1 to one of two total doses (1e8 or 1e9 pfu)and injected intratumorally in 1-5 intrahepatic tumors on Days 1, 15, and 29.
45779040|NCT04225884|Other|DTx for pain software|Software with active intervention
45779041|NCT04225884|Other|Control software|Software without active intervention
45779042|NCT04225884|Other|Standard care|Pain medication
45640887|NCT05911022|Other|Standard protocol|the Egyptian Supreme Council of University Hospitals (Vitamin C 500 mg twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75 mg once daily for two weeks
45640888|NCT05910983|Procedure|Thulium Laser Enucleation of the Prostate (ThuLEP)|Thulium Laser Enucleation of the Prostate
45779043|NCT04225806|Device|BlueLeaf® Endovenous Valve Formation System (BlueLeaf System)|The BlueLeaf System is a single-use, disposable device designed to modify the vein wall to form one or more functional autogenous valves to improve the hemodynamics of the deep venous system treated.
45640889|NCT05910983|Drug|Intravesical Botox injection|Intravesical botox injection given only in experimental group.100 units of Botox will be used and diluted in 10 mL of normal saline. 0.5 cc injections will be administered in 20 injection sites (trigone sparing).
45640890|NCT05910970|Drug|Adjuvant tislelizumab plus lenvatinib|Patients at high-risk of hepatocellular carcinoma recurrence after curative resection or ablation will receive adjuvant tislelizumab plus lenvatinib treatment for six months, HCC recurrence, or unacceptable adverse events.
45640891|NCT05910970|Drug|Adjuvant tislelizumab|Patients at high-risk of hepatocellular carcinoma recurrence after curative resection or ablation will receive adjuvant tislelizumab treatment for six months, HCC recurrence, or unacceptable adverse events.
45640892|NCT05910944|Procedure|Shunt surgery|Shunt surgery according to each local centers routine
45640893|NCT05910931|Drug|ICG angiography|"A first injection with the patient asleep before starting the intervention to visualize the vascular anatomy of each patient and assess the pedicles and incisions.~A second bolus after breast resection to assess the viability of skin flaps and glandular pedicles.~A third injection to obtain an angiography after implant placement and wound closure.~For angiography, the SPY System with the SPY-Q software will be used."
46070428|NCT00811525|Device|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|"The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement. CPG was available in sizes 120 cc-775 cc and 5 styles with various projection and height options.~With approval of MemoryShape™ (CPG 321) Breast Implants, the study converted to a post approval study for this style."
45640894|NCT05910918|Behavioral|Intensive Care Nurses' Training Package|For the study group, the researcher will explain the method of the training package program application to critical care nurses as follows; firstly, the researchers will assess the nurses' roster, then the researchers will classify the subjects into groups in order to conduct the training package for a group of them while the other subjects taking care of the patients in the intensive care units and repeat the same session to the others in the same manner.
45779044|NCT01795820|Drug|loading with Ticagrelor|Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2
45779045|NCT01795820|Drug|no loading with Ticagrelor|"Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2.~In other words, patients randomized to this group (group 1) will not receive a loading dose of ticagrelor during the passage from clopidogrel to ticagrelor."
45779046|NCT00554996|Device|E. coli 83972 coated urinary catheter|E. coli 83972 coated urinary catheter
46070429|NCT02612181|Drug|Dexmedetomidine for dexmedetomidine group|The effect of dex and placebo for sedation on microcirculation
45779047|NCT05037318|Behavioral|Stress arousal reappraisal|Participants will watch a video explaining that stress arousal is not harmful but rather functional and adaptive for performance in stressful situations.
45779048|NCT05037318|Behavioral|Worked examples|The worked example will be in form of brief video sequences showing a physician (played by an actor) delivering the bad diagnosis of lung cancer to an SP following the SPIKES protocol.
45779049|NCT05148000|Biological|QM1114-DP|QM1114-DP
45779050|NCT05087238|Behavioral|CBT|Cognitive Behavior Therapy for PVC-specific anxiety education, in-vivo exposure, interoceptive exposure, behavioral activation, relapse prevention
45779051|NCT05085990|Biological|TARA-002|Phase 1b, Dose Expansion Phase: All subjects will receive 6 weekly doses of TARA-002 at the recommended Phase 2 dose (R2PD)
45779052|NCT01483963|Biological|AA4500 0.29 mg/1 mL|treatment of adhesive capsulitis
45779053|NCT01483963|Biological|AA4500 0.58 mg/2 mL|treatment of adhesive capsulitis
45779054|NCT01483963|Biological|AA4500 0.58 mg/1 mL|treatment of adhesive capsulitis
45779055|NCT01483963|Biological|AA4500 0.58 mg/0.5 mL|treatment of adhesive capsulitis
45779056|NCT01483963|Other|Shoulder exercises|Home shoulder exercises, minimum of 3 times per day
45779057|NCT05145660|Radiation|intensity-modulated radiotherapy (IMRT) with reduced-volume|PGTVnx: 69.9Gy/2.12Gy/33f GTVrpn: 69.9Gy/2.12Gy/33f GTVnd: 69.9Gy/2.12Gy/33f GTVnd-suspicious: 60.06Gy/1.82Gy/33f PTV1: 60.06Gy/1.82Gy/33f PTV2: 50.96Gy/1.82Gy/28f
45779058|NCT05145660|Drug|Chemotherapy|Concurrent cisplatin (100 mg/m², d1-3, Q3w, maximum to three cycles); The application of induction chemotherapy and consolidation chemotherapy is dependent on the physician's discretion.
45640895|NCT05910905|Procedure|Prefabricated pediatric zirconia crown group|Zirconia crown application: After preparing the molars, the crown was cemented by passive seating with modified glass ionomer cement (GC FujiCEM Evolve, GC America, Alsip, USA).
45640896|NCT05910905|Procedure|Prefabricated stainless steel crown group|Stainless steel crown application: After preparing the molars, the crown was filled with type-1 glass ionomer cement (Aqua Meron, Voco, Cuxhaven, Germany) and cemented.
45640897|NCT05910892|Drug|Aromatherapy packet|5 deep breaths from packet prior to treatment
45640898|NCT05910892|Drug|Placebo packet|5 deep breaths from packet prior to treatment
45640899|NCT05910879|Behavioral|Self-Affirmation Implementation Intentions (SAII) Intervention|"In an brief exercise, participants are asked to provide a personal story and positive experience during the challenging and sometimes stressful COVID19 pandemic, …a time when you felt successful and proud of yourself. …You can also tell us about a time that you did something to help someone in need. The self-affirmation is designed to offset effects of threats to self. In the next section participants are asked to formulate an if-then plan with one preferred self-affirmation-inducing cognition: If I feel sad, threatened, or discriminated against, then I will… a)…think about things I value about myself, b)…remember things that I have succeeded in, c) …think about what I stand for, or d)…think about things that are important to me. After selecting response, participants read the full If-Then plan out loud and are provided with a paper copy of their exercise to take home."
45779059|NCT05085132|Behavioral|MindFi app: Standard content|Digital wellness training in this study will be delivered via the MindFi app, designed by Jaedye Labs. Content includes learning, assesesment, and practice tracks A core component of the exercises in this app is mindfulness training; however, the app also incorporates other exercises drawn from positive psychology such as journaling and diaphragmatic breathing. The app goes beyond traditional guided meditation through content that reinforces the principles and attitudes taught during in-person training, and also seeks to maximize user experience by using interactive tasks and progress charts.
45640900|NCT05910879|Behavioral|Promotores de Salud (Health Education)|The Promotores de Salud intervention includes: (1) a culturally tailored health education to increase knowledge about COVID-19 and the benefits of testing; (2) motivational interviewing (MI) strategies to explore personal, social, and behavioral barriers to testing and to discuss available resources to resolve these barriers; (3) emotional support to address testing-related concerns and anxieties that may dissuade Latinx individuals from getting tested; and (4) service navigation. When promotores (community health advocates) are on-site at Mexican Consulate events, they will provide information about COVID-19 and preventive behaviors using in-person instruction on effective mask wearing, hand washing, and physical distancing, as well as the importance of repeated testing and vaccines.
45779060|NCT05085132|Behavioral|Mindfi app: Standard content without practice|In this condition, participants will receive a version of the MindFi app that does NOT contain the practice tracks, only the learning and assessment tracks.
45779061|NCT05034900|Other|Chest physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, postural drainage and coughing techniques.
45779062|NCT05034900|Device|Oscillatory Positive Expiratory Pressure (OPEP) device|Shaker® device will be used.
46070430|NCT02612259|Dietary Supplement|TRYPTOPHAN|at the dose of 3,5 m/kg/ day divided in two capsules
45640901|NCT05910866|Device|Left bundle branch area pacing (LBBAP)|Pacing of the conduction system of the heart to obtain physiological activation
45640902|NCT05910866|Device|Right ventricular pacing (RVP)|Conventional ventricular pacing
45779063|NCT01484041|Drug|Dovitinib|Dovitinib at the recommended Phase 2 dose for 5 consecutive days followed by a 2-day rest
45779064|NCT01484041|Drug|Aromatase Inhibitors|Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily
45779065|NCT00555152|Other|Laboratory Biomarker Analysis|Correlative studies
45779066|NCT00555152|Drug|Lapatinib Ditosylate|Given PO
45779067|NCT00555152|Other|Placebo|Given PO
45779068|NCT05034822|Drug|Ruxolitinib cream|Ruxolitinib 1.5% cream applied twice daily.
45779069|NCT01461499|Drug|Aliskiren|The patient will start taking one a daily 150 mg/day of aliskiren. In case blood pressure doesn't reach the target (SBP/DBP < 130/80 mmHg), higher dose of aliskiren will be given.In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
45779070|NCT01461499|Drug|any angiotensin receptor blockers|The patient will start taking one a standard dose of an ARB in Japan. In case blood pressure doesn't reach the target (SBP/DBP < 130/80 mmHg), higher dose of the ARB will be given. In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (DRI, another ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
45779071|NCT00555464|Drug|Vincristine|Vincristine (0.05 mg/kg/dose) will be administered into a vein (PICC line) every week for 12 weeks. If assigned to receive Vincristine, a PICC line will be placed by a doctor who is a specialist in this procedure, an interventional radiologist. This will require sedation and when possible, will be coordinated with sedation for the MRI.
45779072|NCT00555464|Drug|Prednisone|Prednisolone given at 3 mg/kg/day by mouth for 12 week
45779073|NCT05082948|Other|Suture fixation of stent|Esophageal stent will be placed in the standard of care fashion by the endoscopists using standard gastroscopes. Covered self-expanding metal stent will be placed as per endoscopist preference. After esophageal stent placement, endoscopic suturing will be performed in cases of patients randomized to suture fixation.
45779074|NCT05082948|Other|Non suture|Standard placement of stent without suture fixation
45779075|NCT01795976|Genetic|NY-ESO-1 T cells|
45779076|NCT01795976|Drug|cyclophosphamide|cyclophosphamide 60mg/kg/day day -7 and day -6
45779077|NCT01795976|Drug|Fludarabine|Fludarabine given 25mg/m2 day -5 to day -1
45779078|NCT01795976|Biological|Interleukin 2|Interleukin 2 (IL2) immunotherapy given day 0 to day 6
45916225|NCT00006379|Drug|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
46070431|NCT02612259|Other|PLACEBO|at the dose of 3,5 m/kg/ day divided in two capsules
46070432|NCT00841035|Drug|erlotinib|Preoperative dosing of 150 mg oral erlotinib for 7 days before surgery. followed by erlotinib 100 mg daily 6 month/6 chemotherapy cycles. Gemcitabine 1000 m2 weekly after surgery for 6 cycles.
45640903|NCT05910853|Diagnostic Test|Specimen Donation|Blood donation
45640904|NCT05910840|Other|Support-t|Support-t plus usual diabetes care for 18 months
45640905|NCT05910827|Drug|HMBD-001|HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly
45640906|NCT05910827|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV once every 3 weeks
45640907|NCT05910827|Drug|Cetuximab|Cetuximab 400 mg/m^2 IV loading dose, followed by 250 mg/m^2 weekly
45640908|NCT05910814|Behavioral|Sleep Deprivation (SD)|Participants in the sleep deprivation group will spend a night awake, under the supervision of an investigator, at Croix-Rousse Hospital. The investigator will provide a list of activities to maintain the participant awake.
45640909|NCT05910814|Behavioral|Normal Night (Night)|Participants in the normal night group will spend one night sleeping in their own home.
45640910|NCT05910814|Behavioral|Physical Exercise (HIIE)|"Participants in the physical exercise group (i.e. IM+HIIE, PP+HIIE, SD+PP+HIIE) will start with a 2-minute warm-up on an ergometer cycle.~After the warm-up, they will perform 3 minutes of exercise at a workload customized to their maximal aerobic power (MAP) corresponding to 80 % their MAP and then rest actively for 2 minutes at 40 % of MAP. This cycle of 5 minutes will be repeated 3 times in row, resulting in a total of 17 minutes of physical exercise including the warm-up."
45640911|NCT05910814|Behavioral|Rest control|Participants will watch a documentary during an equivalent time as the physical exercise (i.e. 17 minutes).
45640912|NCT05910814|Behavioral|Motor imagery|On the bimanual finger tapping task composed of 8 elements, the participant will be required to repeat the motor sequence mentally using MI (mental rehearsal of movement) during twelve blocks of 30 seconds. Participant will imagine performing the sequence as fast and accurately as possible without overt movement.
45779079|NCT01461655|Drug|marketed topical retinoid|once daily application, 4 weeks
46070433|NCT00703131|Device|Anal Fistula Plug (SurgiSIS AFP)|Anal Fistula Plug
45640913|NCT05910814|Behavioral|Physical Practice (PP)|Participants will practice a bimanual sequential finger tapping task composed of 8 movements. Participant will be required to perform the sequence as fast and as accurately as possible during blocs of 30 s (i.e. twelve blocs during training).
45640914|NCT05910801|Procedure|Biopsy|Undergo biopsy
45640915|NCT05910801|Procedure|Biospecimen Collection|Undergo blood sample collection
45640916|NCT05910801|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
45640917|NCT05910801|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
45640918|NCT05910801|Procedure|Computed Tomography|Undergo CT scan
45640919|NCT05910801|Drug|Lenalidomide|Given PO
45640920|NCT05910801|Procedure|Lumbar Puncture|Undergo lumbar puncture
45640921|NCT05910801|Procedure|Magnetic Resonance Imaging|Undergo MRI
45640922|NCT05910801|Procedure|Positron Emission Tomography|Undergo PET/CT scan
45640923|NCT05910801|Biological|Tafasitamab|Given IV
45640924|NCT05910801|Drug|Venetoclax|Given PO
45640925|NCT05910788|Device|high flow nasal cannula|"The purpose of this intervention is clarify the benefit with the perioperative use of HFNC, in thoracic surgeries, from intubation to the postoperative period, evaluating mortality and in-hospital complications.~is to clarify whether there is benefit from the perioperative use of HFNC, in thoracic surgeries, from intubation to the postoperative period, evaluating mortality and in-hospital complications."
45779080|NCT01461655|Drug|marketed topical NSAID|once daily application, 4 weeks
46070434|NCT00703209|Procedure|Nerve Decompression|"Nerve decompression on a randomized leg, with similar skin incisions on the opposite leg so that the patient is blinded to which leg received the decompression."
45640926|NCT05910775|Behavioral|Pre and Post Treatment Presentations|A short presentation provided to the participants within 72 hours prior to the first treatment of the acute course. The presentation will emphasize the effectiveness of the treatment, and provide notable encouragement and reassurance. The intervention group will additionally receive a follow up session within 24 hours after the first treatment to provide encouragement and reassurance
45779081|NCT01461655|Drug|vehicle gel|once daily application, 4 weeks
46070435|NCT00642811|Drug|Ticagrelor|Tablets, Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily for 2 weeks
45640927|NCT05910762|Behavioral|Associative inference|Participants will engage in an associative inference paradigm. Memory will be assessed behaviorally and neural representations will be assessed using functional magnetic resonance imaging.
45640928|NCT05910762|Behavioral|Category learning|Participants will engage in a category learning paradigm. Memory will be assessed behaviorally (Arms 2 and 3), and neural representations will be assessed using functional magnetic resonance imaging (Arm 2).
45640929|NCT05910762|Behavioral|Sleep|Participants will sleep after engaging in a category learning paradigm while electroencephalography data are collected, and memory will be assessed behaviorally after sleep.
45640930|NCT05910749|Device|QEEG-Guided sLoreta Neurofeedback Training|The team will produce a neurofeedback (NFB) protocol based on QEEG sLORETA Brodmann Voxel evaluation of brain deviated/dysregulated areas. Subsequent 12 to15 sessions of individualized NFB protocol will be conducted using BrainAvatar software to normalize these regions. The NFB session will display the cortical surface and subsurface networks being trained in a live fashion. Patients will be seated on a comfortable chair in a dimly lit room and, wearing a 19-channel EEG-cap connected to an EEG amplifier, they will receive auditory and visual feedback when they meet Brodmann Voxels Z-Scores inside of +/-1.5 standard deviations (SD) on each electrode training site. Thresholds for the feedback will be first set a +/-2 SD and brought down to +/-1.5 SD throughout the sessions (subject performance dependent). Patients are encouraged to relax, hear the sounds, and watch a feedback game.
45640931|NCT05910736|Behavioral|Medicare AWV Practice Redesign Toolkit|Electronic health record-based tools coupled with practice redesign strategies and approaches
45640932|NCT05910710|Genetic|Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)|Visium : Spatial transcriptomics WGS/WTS : detection of somatic mutation
45779082|NCT01461655|Drug|marketed topical retinoid|once daily application, 4 weeks
45779083|NCT05144334|Drug|BTX-1188|One 28 day cycle of treatment will consist of 4 weeks of treatment with BTX-1188 administered orally per dosing schedule.
45779084|NCT01461733|Drug|amiodarone|standard dose amiodarone
45779085|NCT01461733|Drug|Placebo|placebo delivered blinded
45640933|NCT05910697|Diagnostic Test|MyProstateScore 2.0 Results|A diagnostic test for the likelihood of finding clinically significant cancer from a prostate biopsy.
45640934|NCT05910684|Diagnostic Test|Aegis CDM Test and Educational Materials|The Aegis CDM diagnostic test will be given to intervention participants to use on their patients. The participants will receive the results of the test through a web portal. Investigators will analyze the differences in quality of care between the control arm and the intervention arm.
45640935|NCT05910671|Behavioral|Physical Activity|This intervention encouraged parents to model physical activity behaviors and co-participate in physical activity with their young child. Each week behavioral strategies for promoting physical activity change will be discussed to help parents work towards meeting their activity goals. The behavioral strategies will be discussed weekly for 30 minutes via telephone.
45640936|NCT05910671|Behavioral|Physical Activity Notebook with Newsletters|As part of the physical activity intervention parents will receive a physical activity notebook that has newsletters, suggested activities that can be done with their child, and other material that will help the parent and child be active active together. The information presented in the physical activity notebook will be discussed weekly during the 30 minute phone calls.
45640937|NCT05910658|Behavioral|Competence in Romance and Understanding Sexual Health (CRUSH)|Manualized curriculum targeting sexual health and behavior in intimate relationships designed to meet the specific needs of autistic adults
45640938|NCT05910632|Behavioral|Eccentrically strengthened resistance exercise|For each resistance exercise session, 6 to 7 generic exercises will be performed, involving small and large muscle groups (leg extension, leg curl, biceps curl, triceps extension, seated row, shoulder flexion, and shoulder raise). They will perform with 4 sets of 8 repetitions, with a break between exercises of 1 minute and between sets of 2 minutes. They perform those exercises with high intensity (ever 10 on the OMNI-RES Scale).
45640939|NCT05910632|Behavioral|Traditional resistance training|For each resistance exercise session, 6 to 7 generic exercises will be performed, involving small and large muscle groups (leg extension, leg curl, biceps curl, triceps extension, seated row, shoulder flexion, and shoulder raise). They will perform with 4 sets of 8-12 repetitions, with a break between exercises of 1 minute and between sets of 2 minutes. They perform those exercises with moderate and high intensities (6 to 10 on the OMNI-RES scale).
45640940|NCT05910619|Device|Neurolith Transcranial Pulse Stimulation Active|5hz (200-300 milliseconds) stimulation pulses transcranial pulse stimulation (TPS) will be applied to each of the following five regions twice per session in sequential order with the specified stimulation parameters: left dorsolateral prefrontal cortex and inferior frontal cortex extending to Broca's area (2x800 pulses), right dorsolateral prefrontal cortex and inferior frontal cortex extending to Broca's area (2x800 pulses; ROI volume ~136/164 cms), the left lateral parietal cortex extending to Wernicke's area (2x400 pulses; ROI volume ~122/147 cms), the right lateral parietal cortex extending to Wernicke's area (2x400 pulses; ROI volume ~122/147 cms), and the extended precuneus cortex (2x600 pulses; ROI volume 66/92 cms). With a repetition time of 5hz (0.00333 seconds) per pulse at a total of 6,000 pulses per participant, the duration of stimulation is about 20 minutes, not including transition time between ROI localization.
45640941|NCT05910619|Device|Neurolith Transcranial Pulse Stimulation Sham|The intervention procedure described in the Active condition above will also be repeated in participants randomized to the Sham procedure, with the exception of the insertion of a lens over the device by the interventionist to prevent stimulation from reaching the brain.
45640942|NCT05910606|Behavioral|Digital Exercise|Fall Prevention Program: Our fall- risk reduction program overs digitally delivered exercise with real time feedback from expert instructors.
45640943|NCT05910593|Diagnostic Test|Dexterity Assessment Tool|Measures finger dexterity using pressure sensor pads.
45779086|NCT01462279|Drug|Thiamine|200mg of intravenous thiamine in 50ml of D5W will be infused over 30 minutes once
45779087|NCT03839472|Procedure|CBI|CBI with 5 liters normal saline in 1 liter increments up to 2 hours after TURBT procedure.
45779088|NCT02207803|Behavioral|Transition Assistance Program|
45779089|NCT00435812|Biological|HEPLISAV and/or Placebo|Intramuscular (IM) injections on Week 0, Week 4; placebo (saline) injection at Week 24
45640944|NCT05910580|Behavioral|Screening, Brief Intervention, and Referral to Treatment (SBIRT)|See SBIRT arm description.
45640945|NCT05910398|Drug|pyrotinib|an irreversible anti-HER2 tyrosine kinase inhibitor
45779090|NCT00435812|Biological|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4, and Week 24
45779091|NCT05081466|Other|Dietary pattern|(regular meat-eater, occasional meat-eater, fish-eater, vegetarian, and vegan)
45779092|NCT05081466|Other|Fruit and vegetable intake|Intake of fruits, vegetables, fruits and vegetables combined from food frequency questionnaire
45779093|NCT05081466|Other|Meat intake|Red meat, poultry, processed meat from food frequency questionnaire
45779094|NCT05081466|Other|Fish intake|Intake of fish from food frequency questionnaire
45779095|NCT05081466|Other|Egg intake|Intake of eggs from food frequency questionnaire
45779096|NCT05081466|Other|Dairy intake|Intake of dairy products from food frequency questionnaire
45779097|NCT05081466|Other|Tea intake|Intake of tea (drink) from food frequency questionnaire
45779098|NCT05081466|Other|Coffee intake|Intake of coffee (caffeinated or decaffeinated) from food frequency questionnaire
45779099|NCT05081466|Other|Tea and coffee intake|Combined intake of tea and coffee from food frequency questionnaire
45779100|NCT05081466|Other|Protein intake|Estimated intake of protein, derived from food frequency questionnaire
45779101|NCT05081466|Other|Calcium intake|Estimated intake of calcium, derived from food frequency questionnaire
45779102|NCT05081466|Other|Vitamin D intake|Estimated intake of vitamin D, derived from food frequency questionnaire and any recorded supplemental intake
45779103|NCT01464229|Drug|Iloperidone|Iloperidone 1-8 mg for 4 weeks
45779104|NCT01464229|Drug|Placebo|Placebo
45779105|NCT05030688|Other|Postoperative analgesia management|Intravenous 0.5 mg/kg tramodol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
45916226|NCT00006379|Procedure|peripheral blood stem cell transplantation|Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
45779106|NCT00556478|Drug|PSD502, contains a mixture of lidocaine and prilocaine|"PSD502 spray contains a mixture of lidocaine and prilocaine with Norflurane (HFA-134a) is used as both propellant and solvent. A single dose consists of 3 sprays applied to the glans penis.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period."
45779107|NCT00556478|Drug|Placebo|"The placebo is a metered dose aerosol spray that is identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing.~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period."
45779108|NCT01467037|Other|No intervention done|Not applicable because no intervention was done.
45779109|NCT05080998|Diagnostic Test|CxBladder Monitor|CxBladder Monitor (CxbM) is a high sensitivity and negative predictive value (NPV) urinary biomarker test to rule-out subjects at low risk of bladder cancer monitoring for recurrence of disease.
45779110|NCT01912040|Drug|Administration of 123Iodine MIBG|Patients will be administered the locally produced 123 Iodine MIBG
45640946|NCT05910164|Device|PELGRAZ prefilled syringe or PELGRAZ prefilled pen|PELGRAZ prefilled syringe or PELGRAZ prefilled pen https://www.ema.europa.eu/en/medicines/human/EPAR/pelgraz
45640947|NCT05910138|Diagnostic Test|Serum Interlukin-15|Evaluate its serum level and detect its relation to the activity and severity of Alopecia Areata.
45779111|NCT05141526|Other|Non-restrictive satiating intervention|Diet group containing satiating foods
45779112|NCT05141526|Other|Conventional restrictive intervention + non-restrictive satiating intervention|Diet group with a calorie deficit during the first phase followed by a diet containing satiating foods in the second phase
45640948|NCT05910138|Diagnostic Test|Serum Interlukin-21|Evaluate its serum level and detect its relation to the activity and severity of Alopecia Areata.
45779113|NCT05141526|Other|Control group|This group will receive minimal healthy guidelines
45640949|NCT05910073|Device|Lamina curved plate|Use of a Lamina Curved plate (Osteobiol® Laboratory) in the treatment of OAC
45640950|NCT05910008|Procedure|Stereotactic imaging|Prior to electrode implantation , stereotactic imaging (Magnetic Resonance Imaging )
45640951|NCT05909722|Diagnostic Test|Gastrointestinal Dysfunction Score will be calculated|We collect routine daily data on GI signs and symptoms and calculate the score (GIDS). We collect serum phosphate values as measured in routine practice of participating sites.
45640952|NCT05909657|Other|questionnaires (surveys)|Mixed-methods study. Both the qualitative interview guides and the questionnaire surveys are adapted from the Sickle Cell Disease Implementation Consortium (SCDIC) project which is a multicentre study occurring in the United States.
45779114|NCT01468675|Other|Intervention|risk assessment survey; decision support for providers for prevention based on risk
45779115|NCT00500240|Drug|Insulin Glargine|Use of human insulin glargine for slow decrease of blood sugar level over 24 hours.
45779116|NCT00500240|Drug|Insulin Aspart|Use of human insulin aspart for rapid lowering of the blood glucose level over 24 hours.
45779117|NCT01469767|Drug|Fluocinonide cream|Fluocinonide cream 0.1% applied twice daily for 5 days.
45640953|NCT05909644|Drug|Omaveloxolone|Omaveloxolone Capsules, 150 mg, administered orally
45640954|NCT05909644|Drug|Efavirenz|Efavirenz Tablet, 600 mg, administered orally once daily
45640955|NCT05909553|Drug|Venetoclax|Oral; Tablet
45640956|NCT05909527|Biological|CD7 CAR-T|A single infusion of autologous CD7 CAR-T cells administered intravenously
45640957|NCT05909306|Other|Education Group|Two online meetings were planned with the education group. In the first meeting, an average of 35-minute-long live lecturing was performed on filling out the data forms and using the partograph e-learning tool through e-learning tool created in the first interview. The researcher held the second interview one week after the first one. In the second interview, a live lecture lasting 30 minutes was given to talk about and solve the problems that students experienced with the partograph e-learning tool and answer the questions. The partograph e-learning tool was kept open for one month for the students in the education group. At the end of the one-month education, the students were asked to fill out the post-test (Academic Achievement Test) defined in the system. After the post-test was completed, the system was closed to the access of the students in the education group and made available to the students in the control group.
45779118|NCT05029596|Drug|Normal Saline Group|A 10cc NS flush will be administered intravenously through the peripherally inserted central line catheter after administration of medication, blood products, and blood draws. In addition the peripherally inserted central line catheter will be flushed intravenously with 10cc Normal Saline every 24 hours.
45779119|NCT05029596|Drug|Heparin Group|All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws.
45779120|NCT03246620|Drug|Olanzapine oro-dispersible 5Mg Tab|Patient allocated to this arm will be given 5 mg olanzapine oro-dispersible tablet and an encapsulated placebo tablet
45779121|NCT03246620|Drug|Haloperidol 2Mg encapsulated Tab|Patient allocated to this arm will be given 2 mg encapsulated haloperidol tablet and an oro-dispersible placebo tablet
45779122|NCT03246620|Drug|Diazepam 2Mg encapsulated Tab|Patient allocated to this arm will be given 2 mg encapsulated diazepam tablet and an oro-dispersible placebo tablet
45779123|NCT05141058|Biological|Coronavirus-specific T cell (CST)|Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and <4 months after hematopoietic stem cell transplantation (HSCT).
45916227|NCT00006382|Procedure|bronchoscopic and lung imaging studies|
45916228|NCT00006382|Procedure|comparison of screening methods|
45916229|NCT00006382|Procedure|computed tomography|
45916230|NCT00006382|Procedure|radiography|
45779124|NCT01470781|Behavioral|BrainWorks|"13 programs targeting cognition in 4 separate domains: Auditory processing, visual processing, social cognition, and executive functioning. Games are imbedded in a format that is engaging and interactive. Animated characters serve as directors for each program, explaining the tasks in both verbal and written formats and providing feedback on each trial and overall after each activity. Users move systematically through the programs and can track their progress as the go. Each session includes activities from several different games to maintain interest and train a variety of skills; however, games are presented in the order of domains listed above (i.e. auditory, then visual, then social, and finally executive) to avoid stimulus interference during the training."
45779125|NCT01470781|Behavioral|Computer Control|"Sessions will involve generic computer games administered via the game interface Sporcle. Sporcle is a game site that offers a collection of quiz-type activities available on line. The activities include typing, basic timed arithmetic (e.g. simple addition); picture identification (e.g. name the corporate logo; name the sitcom), and subject-based quizzes in areas like history (e.g. name the US presidents), geography (e.g. name the state capitals), and literature (e.g. book title fill-in-the-blank). An administrator can track the activity of subjects including when they logged in, which games they played and for how long, and what their accuracy was on each game. We will use a pre-developed game schedule that includes a mix of each type of game in each session, and ensures that subjects are playing the same games in the same order. This format was developed to mirror the treatment condition, as subjects are given a variety of specific games to play at each session."
45779126|NCT05080218|Drug|Upadacitinib|Hold UPA x 2 weeks at time of COVID booster
45779127|NCT05080218|Drug|Abatacept|Hold SQ ABA x 2 weeks at time of COVID booster
45779128|NCT05080218|Drug|Secukinumab|Hold SEC x 2 weeks at time of COVID booster
45779129|NCT05080218|Drug|Tofacitinib|Hold TOF x 2 weeks at time of COVID booster
45779130|NCT05080218|Drug|TNF Inhibitor|Hold SQ TNFi x 2 weeks at time of COVID booster
46070436|NCT00642811|Drug|Clopidogrel|(over encapsulated) capsule, Oral, 75 mg; 600 mg loading dose followed by 75 mg once daily for 2 weeks
45640958|NCT05909241|Drug|BA1202|"BA1202 will be administered intravenously (IV) once every 3 weeks (Q3W) until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the duration of administration was no more than 2 years.~Part A: Patients will receive one of the following dosages of BA1202: 0.016mg, 0.08mg, 0.4mg, 1.6mg, 6.4mg, 19mg, 38mg, 56mg.~Part B: Based on the data of part A, one or two dose levels will be discussed for further evaluation in part B."
45916231|NCT00006382|Procedure|study of high risk factors|
45916232|NCT00006385|Biological|MART-1 antigen|
45640961|NCT05909150|Drug|Sodium chloride solution 3,5%|Patients will receive 150 mL HSS 3,5% intravenous twice daily for 3 days after heart transplantation.
45640962|NCT05909150|Drug|Sodium chloride solution 0,9%|Patients will receive 150 mL NS 0,9% intravenous twice daily for 3 days after heart transplantation.
45779131|NCT05080218|Drug|Canakinumab Injection|Hold CAN TNFi x 2 weeks at time of COVID booster
45640963|NCT05909098|Combination Product|autologous NK cell|autologous NK cell
45640964|NCT05908825|Drug|Vitamin C with AHA Exfoliative Serum|Catalyst is a novel skincare product comprised of low concentrations of multiple hydroxy acids and will be randomly assigned as Product A or Product B to be applied to one side of the face.
45640965|NCT05908825|Drug|Placebo serum|Placebo serum will be randomly assigned as Product A or Product B to be applied to one side of the face.
45640966|NCT05908760|Device|CO2 ReHaler|The ReHaler captures expired CO2, which is then re-inhaled. The net effect is a transient increase in CO2.
45640967|NCT05908578|Other|High Frequency Exercise Training|Two sessions per week of high-intensity interval training (30 min each) and two sessions per week of continuous endurance exercise (30 min each). All exercise sessions will be performed on a stationary bike under supervision by an investigator.
45640968|NCT05908578|Other|Low Frequency Exercise Training|One session per week of high-intensity interval training (60 min) and one session per week of continuous endurance exercise (60 min). All exercise sessions will be performed on a stationary bike under supervision by an investigator.
45640969|NCT05908409|Drug|IDP-121|IDP-121 is a new chemical entity specifically designed to directly target cMyc protein that has demonstrated activity in multiple liquid and solid tumor cell lines and preclinical animal models
45640970|NCT05908136|Other|restorative materials|two types of composite with strip crown in primary molars
45779132|NCT05080218|Drug|Baricitinib|Hold BAR x 2 weeks at time of COVID booster
45779133|NCT05080218|Drug|Ixekizumab|Hold IXE x 2 weeks at time of COVID booster
45779134|NCT05079984|Behavioral|Graded exposure treatment (GET)|Graded-exposure is a theory driven, individually tailored, and evidenced based behavioral intervention for individuals with chronic pain targeting pain-related impairment by exposing patients to previously feared and avoided activities.
45779135|NCT01470859|Drug|pramipexole|tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.
45779136|NCT01470859|Drug|Sinemet CR|tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year
45779137|NCT00436046|Biological|Trivalent inactivated influenza virus vaccine (2006-2007 formulation)|Commercially available trivalent inactivated influenza virus vaccine without or with 1 of 2 dosages of commercially available type 1 interferon administered once by nasal instillation. Dosages: 0.6 ml of IVV or 0.7 ml of IVV.
45779138|NCT00436046|Biological|Type 1 interferon|Commercially available lyophilized IFN; dosages 1 M unit (Mu) of IFN; 10 M units (Mu) of IFN.
45779139|NCT01471639|Drug|intranasal ketorolac|15 mg
45779140|NCT05622656|Drug|Dexmedetomidine|Dexmedetomidine 0.0005%
45779141|NCT05622656|Drug|Placebo|0.9% Sodium Chloride Solution
45779142|NCT05079282|Drug|ONO-4685|ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed
45779143|NCT05079126|Drug|Trans Sodium Crocetinate|Single IV Bolus
45779144|NCT05079126|Drug|Placebo|Single IV Bolus
45779145|NCT05149872|Other|Muscle relaxation|Rocuronium will be used to induce partial paralysis
45916233|NCT00006385|Biological|gp100 antigen|
45640971|NCT05908123|Behavioral|The Blank Center CARE Model(TM) for Individuals who Stutter|The over-arching goal of the Blank Center CARE Model is to ensure individuals who stutter communicate effectively, advocate for themselves in a manner that maintains agency, and ensure their quality of life does not depend on producing, or attempting to control, stuttered speech.
45640972|NCT05908071|Drug|SHEN26 capsule|Capsule administered orally after meals.
45640973|NCT05908071|Drug|SHEN26 placebo|Capsule administered orally after meals.
45779146|NCT05149872|Other|Reversal|Sugamamdex will be used to reverse muscle relaxation
45779147|NCT05140278|Drug|Argesun 60mg (1 step parenteral artesunate)|Each vial of powder contains 60mg artesunate. Each ampoule of 6 ml solvent contains: sodium bicarbonate 8.4mg/ml; arginine 20mg/ml.
45779148|NCT05140278|Drug|Artesun 60mg (2-step parenteral artesunate)|Each vial of powder contains 60 mg artesunate. Each ampoule of 1 ml solvent contains 50 mg sodium bicarbonate. Each ampoule of 5 ml diluent contains 45 mg sodium chloride.
45779149|NCT00436904|Drug|Alemtuzumab|30 mg Monday, Wednesday, and Friday x 5 weeks
45779150|NCT00436904|Drug|Rituximab|375mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)
45779151|NCT05139654|Other|Arm elevation in the scapular plane|Lift the arm up in the scapular plane
45640974|NCT05907876|Other|Functional Test|UULEX uses a table of horizontal parallel lines with 8 levels. Each level is 84 cm wide and 8 cm high. The distance between the levels is 15 cm. The subject is seated on a straight chair with his/her feet on the floor facing the wall with the UULEX table. He/she holds a bar weighing 0.2 kg and lifts the bar at hip level. Keeping his/her arms shoulder-width apart, he/she raises the bar to different levels of the chart. As a warm-up, he/she is instructed to raise the bar to the first level and hold this position for 2 minutes. Then the bar is moved to each level and the levels are increased for 1 minute. The starting and ending point of each level is the hip joint. As the exercise progresses each minute, the weight of the bar is increased by 0.5 kg up to a maximum of 2 kg. During the test, a subject can move up to a maximum of a 2kg bar in a maximum of 12 minutes. The subject is instructed to continue the test until limited by the occurrence of symptoms.
45779152|NCT05139654|Other|Pull up with gymbar|Grasp the gymbar with both hands and pull up as high as the subject can
45779153|NCT05139654|Other|Pull up with fingerboard|The width of the fingerboar is 20 mm. Pull up with fingers on the fingerboard.
45779154|NCT05028504|Drug|Penpulimab|Penpulimab is a humanized monoclonal antibody targeting programmed cell death-1 (PD-1), which prevents PD-1 from binding to PD-L1 and PD-L2 receptors on tumor cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
45779155|NCT05028504|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
45779156|NCT00438854|Drug|Dasatinib|Taken orally once daily. Participants may continue on study treatment as long as there is no disease progression or serious side effects.
45779157|NCT01485055|Drug|Infliximab and Basiliximab|"Participants in this research study will receive combination therapy (2 drugs: Infliximab and Basiliximab)once a week for four weeks. Both drugs will be given through the participant's broviac, port or through a vein in the arm. It will take about 4-5 hours to complete the 2-drug combination therapy each week. Participants will be given pre-medications to help prevent reactions to the study drugs.~Infliximab will be given at a dose of 10mg per Kg per dose. Basiliximab will be given in 10mg doses to patients who weigh less than 35kg. Patients who weigh weigh more than 35kg will receive 20mg doses. Patients will receive both drugs weekly on days 1,8,15 and 22. Each drug will be given 4 times."
45779158|NCT05028348|Drug|Selinexor|Selinexor will be given as an oral dose 40 mg (2 20 mg tablets) QW on Days 1, 8, 15, and 22 of each 28-day cycle.
45779159|NCT05028348|Drug|Elotuzumab|Elotuzumab will be given IV 10 mg/kg on Days 1, 8, 15, and 22 of cycle 1 and 2 then 20 mg/kg on Day 1 of cycles ≥3 of each 28-day cycle.
45779160|NCT05028348|Drug|Pomalidomide|Pomalidomide will be given as an oral 4 mg dose QD on Days 1 to 21 of each 28-day cycle.
45640975|NCT05907785|Behavioral|Educational intervention|The intervention will consist of recommendations to improve physical activity (PA) and dietary habits. It is based on the PAIDO Programme (www.programapaido.es), an outpatient family-based multidisciplinary programme that combines PA, education on nutrition, and behavioural therapy. It will last 6 months and improvement of metabolic health and body weight loss is expected, particularly in the groups with overweight and obesity. The dietary intervention will be focused on the promotion of the Mediterranean diet, with follow-up and advice from a dietitian-nutritionist. Participants will be encouraged in reducing sedentary behaviour (watching television, playing computer games, playing board games). Performance of aerobic and strength physical exercises will be scheduled, progressively increasing the intensity. Volunteers and their parents will participate in monthly sessions to follow-up on adherence to the PA and dietary recommendations and give personalized advice.
45640976|NCT05907655|Drug|Nitroglycerin 0.3 MG|Sublingual nitroglycerin will be used to provoke spontaneous-like migraine attacks in migraine patients. A dose of 0.9 mg of sublingual nitroglycerin will be used. The same dose will be administrated to controls.
45779161|NCT05028348|Drug|Dexamethasone Oral|Dexamethasone will be given as an oral 40 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Preferred dosing of dexamethasone is 40 mg QW for patients who are ≤75 years of age (20 mg QW for >75-year-old patients at the Investigator's discretion) before QW dosing of selinexor, however, it may be divided over 2 days at the Investigator's discretion.
45779162|NCT05622578|Other|QST, CPM and Paisudoscan|Quantified pain tests
45779163|NCT01486615|Drug|meloset (melatonin)|3 mg melatonin tablet 1-2 hour prior surgery
45779164|NCT01486615|Drug|stresnil ( melatonin and alprazolam)|3 mg melatonin and 0.5 mg alprazolam 1-2 hr before anesthesia
45779165|NCT01486615|Drug|(alprax) alprazolam|0.5 mg alprazolam
45779166|NCT01486615|Drug|placebo|similar looking placebo tablet
45779167|NCT05027880|Other|Web-based single-session growth mindset intervention for adolescent anxiety|This proposed study will use a three-arm, parallel group, randomized control trial design to evaluate the efficacy of SIGMA compared to both a web-based growth mindset SSI (SSI-GP) and an active web-based control programme. The concurrent parallel group structure assures that the different groups take part in their respective intervention at the same time.
45916234|NCT00006385|Biological|incomplete Freund's adjuvant|
45916235|NCT00006385|Biological|recombinant interferon alfa|
45779168|NCT01797068|Behavioral|Patient Navigator|Patients in the intervention group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH), a local non-profit organization that coordinates the provision of donated medical care and services to underserved patients through a network of participating hospitals and volunteer physicians.
46070437|NCT00642811|Drug|Aspirin|Tablets, Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study
45640977|NCT05907655|Diagnostic Test|MRI|The following brain MRI sequences will be acquired before and after nitroglycerin administration: fluid attenuated inversion recovery (FLAIR), 3D T1-weighted inversion recovery prepared gradient echo, diffusion weighted sequence and 3D susceptibility weighted images.
45640978|NCT05907655|Diagnostic Test|Blood sampling|Plasma levels of neuropeptides involed in migraine will be measured using commercially available enzyme-linked immune-sorbent assay (ELISA) kits. All ELISA will be performed by the same experienced technician who will be blinded for the clinical diagnosis.
45640979|NCT05907655|Device|Sleep profiler|Sleep architecture will be investigated using the Sleep Profiler. Sleep Profiler is medical device with CE mark which is produced by Advanced Brain Monitoring and distributed throughout Italy exclusively by Medigas. Sleep staging will be automatically performed for 30-second epochs throughout a dedicated software and a standardized and validated procedure. Frontopolar EEG signal waveforms will be visually inspected to confirm the accuracy of the auto-staging.
45640980|NCT05907551|Other|Questionnaires|25-items questionnaire
45640981|NCT05907525|Drug|Remimazolam|"To induce anesthesia, remimazolam is continuously infused in a dose of 6mg/kg/hr with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). Maintenance dose of remimazolam is 1mg/kg/hr, up to 2mg/kg/hr, and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg."
45640982|NCT05907525|Drug|1% propofol|"To induce anesthesia, 1% propofol 1.5-2.5mg/kg is used with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). After patient loses consciousness, anesthesia is maintained through the inhalation of sevoflurane between 1-2 minimum alveolar concentrations (MAC), and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg."
45640983|NCT05907512|Drug|Endostar|The dose of 210 mg (14 vials) is administered by intravenous pump from Day 1 to Day 3 of each course, every 4 weeks as a cycle, until disease recurrence, metastasis or intolerable toxicity, and up to 6 courses of administration.
45640984|NCT05907512|Drug|Toripalimab|3 mg/kg by intravenous drip every 2 weeks (Day 1 and Day 15 of each cycle) in a 4-week cycle until disease recurrence, metastasis, or intolerable toxicity for up to 1 year (about 13 cycles).
45640985|NCT05907460|Device|transesophageal echocardiography examination during cardiopulmonary resuscitation|Perform transesophageal echocardiography in patients with out-of-hospital cardiac arrest during cardiopulmonary resuscitation and adjust the chest compression site to compress the left ventricle and avoid left ventricular outflow tract.
45640986|NCT05907434|Diagnostic Test|Nephrocheck (AKI score)|Early biomarker of AKI
45640987|NCT05907421|Behavioral|Acceptance mindset|Brief training of acceptance versus emotional reactivity as emotion regulation strategy.
45640988|NCT05907356|Other|sciatic nerve slider technique in supine lying position|The patient will be in a supine position. The therapist will hold the patient's limb passively and then move the hip into flexion with the ankle in plantar flexion and the knee in extension, stretching the nerve at the hip and relaxing at the ankle, Then reversing the movement with the hip into extension, maintaining the knee in extension and the ankle in dorsiflexion, relaxing the nerve at the hip and stretching at the ankle. Provide five sets in every session; the first: 10 repetitions, the second: 15 repetitions, the third: 20 repetitions, the fourth: 25 repetitions, and the fifth: 30 repetitions. The end position is held for 5 seconds, and the rest between sets is 1-2 minutes.
45640989|NCT05907356|Other|sciatic nerve slider technique in slump position|The patient will be sitting at the edge of the couch with the posterior aspect of the knee at the edge, the thighs parallel to each other, and flexion at the thoracic and lumbar spines (slouch position). The therapist will be standing at the bedside of the patient with a proximal arm over the patient's shoulder and one hand guiding the neck movements of the patient and the other hand guiding the knee movements, passively performing cervical neck flexion with knee flexion (stretching the nerve proximally and relaxing at the distal end) and then moving into cervical extension with knee extension. Provide five sets in every session: the first: 10 repetitions, the second: 15 repetitions, the third: 20 repetitions, the fourth: 25 repetitions; and the fifth: 30 repetitions. The end position is held for 5 seconds, and the rest between sets is 1-2 minutes.
45640990|NCT05907356|Other|Conventional physiotherapy|The patient will receive conventional physiotherapy, which includes: a moist hot pack, TENS, and back strengthening exercises (as a home program).
45640991|NCT05907304|Drug|Naporafinib|Naporafenib (ERAS-254) 200 mg twice daily (BID) of an experimental Pan-Raf inhibitor
45640992|NCT05907304|Drug|Trametinib|Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
45779169|NCT01797068|Other|Standard of Care|Patients in the standard of care group will experience the usual intake process in the ED setting.
45779170|NCT00503750|Drug|Pre operativeTrastuzumab|"Trastuzumab one-time loading dose of 4 mg/kg as 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as 30 minute infusion.~As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52."
45916236|NCT00006385|Biological|sargramostim|
45640993|NCT05907200|Other|combination ultrasound therapy and manual therapy|The proposed manual therapy lasted 90 minutes and involved a combination of three different techniques: McMennel manipulation, connective tissue massage and mobilization technique of pumping. Patients in the treatment group also received a treatment with US (I-Tech medical device certified UT2 CE0476) in combination with manual therapy. Dipping technique was applied with a frequency of 1 MHz, intensity of 1W/cm2, duty cycle of 60% and a duration of 15 minutes per session.
45640994|NCT05907200|Other|manual therapy|manual treatment lasting 90 minutes which involved a combination of three different techniques: McMennel manipulation, connective tissue massage and pumping mobilization technique.
45640995|NCT05906875|Other|Lateral Stepping Exercise 1|1. Standing hip abduction: Performed without and with resistance bands and/or support. The participant will raise one leg out to the side and return. If using a resistance band, one end of the band will be secured to a stable surface and the other end placed around one of the participants' ankles. The banded leg will be raised to the side. Three sets of 8-12 repetitions will be performed per side.
45448660|NCT04375072|Device|sham tDCS paired with sham MBM|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
45640996|NCT05906875|Other|Active Control Group Exercise 1|1. Seated ankle movements (dorsi-/plantarflexion)hree sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
45640997|NCT05906875|Other|Active Control Group Exercise 2|2. Knee extension Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
45640998|NCT05906875|Other|Active Control Group Exercise 3|3. Hip flexion Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
45640999|NCT05906875|Other|Active Control Group Exercise 4|4. Hip abduction Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
45779171|NCT00503750|Drug|ABI-007 (Abraxane)|ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8).
45779172|NCT00503750|Drug|Vinorelbine|Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20).
45779173|NCT05078112|Device|Sleep sensor technology|Infants will sleep on a novel device with built-in sensor technology that tracks sleep patterns and provides output based on historical sleep data.
45916237|NCT00006385|Biological|tyrosinase peptide|
45916238|NCT00007995|Biological|filgrastim|
45916239|NCT00007995|Biological|recombinant interferon alfa|
45916240|NCT00007995|Biological|sargramostim|
45448661|NCT03738345|Other|HFNC flow|HFNC flow will be titrated based on the hospital's policy or protocol for hypoxemic patients and research protocol for healthy volunteers
45448662|NCT01063803|Drug|ATN-103|A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
45641000|NCT05906875|Other|Lateral Stepping Exercise 2|2. Lateral stepping: Performed without and with resistance bands. The participant will perform a series of steps to the side. If using a resistance band, the band will be placed around both ankles in a 'loop' and the participant will perform the lateral stepping. Three sets of 8-12 repetitions will be performed per side per subject.
45641001|NCT05906875|Other|Lateral Stepping Exercise 3|3. Single leg stance: The participant will stand on one leg with support as needed. The contralateral knee will be held at 45 degrees throughout the exercise. The instructor will observe to ensure the bent leg does not contact the ground. Three repetitions of static stance per side will be performed with a goal of 30 seconds, and a maximum time of 60 seconds, per repetition.
45779174|NCT00438932|Drug|Lanthanum Carbonate|Lanthanum carbonate 1000mg 3x/day
45779175|NCT00438932|Dietary Supplement|Low Phosphorus Diet|Low phosphorus diet will consist of 800 mg of phosphorus per day.
45779176|NCT00438932|Dietary Supplement|Unrestricted Phosphorus Diet|Unrestricted diet will contain 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.
45779177|NCT00438932|Drug|Placebo|Lanthanum Carbonate placebo given three times a day with meals.
45779178|NCT05077332|Drug|Famotidine|80 mg tablet, QID for 14 days
45779179|NCT05077332|Drug|Celecoxib|400 mg (initial dose) then 200 mg capsule, BID for 5 days
45779180|NCT05077332|Other|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
45448663|NCT01063803|Drug|ATN-103|A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
45448664|NCT04982458|Diagnostic Test|68Ga-FAPI|68Ga-FAPI injection is a radiopharmaceutical used for positron emission tomography (PET) diagnosis. This product is used for PET, qualitative and localized diagnosis and evaluation of abnormal expression of fibroblast-activated protein in focus-associated fibroblasts.
45448665|NCT05144776|Diagnostic Test|GeneXpert HBV DNA Viral Load Assay|The Xpert venous blood HBV DNA viral load assay will be adapted to operate using fingerstick capillary blood samples.
45779181|NCT05076006|Drug|PF-06700841|Active study drug
45779182|NCT05076006|Drug|Placebo|placebo comparator
45779183|NCT04421274|Biological|Bone marrow mesenchymal stem cells transfer|Inject the BM-MSCs into the infarct-related arterial hypertension through the central cavity of the guide wire balloon catheter under the complete blockage of the target blood vessel. Each time the balloon continues to fill for 2 minutes to block blood flow, then resume perfusion for 2 minutes. The above process is repeated 6 ~ 8 times
45779184|NCT04421274|Drug|Best medical treatment|Refer to the latest medication guidelines and give the best medication to the patients
45779185|NCT04421274|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention
45916241|NCT00007995|Drug|busulfan|
45916242|NCT00007995|Drug|cyclophosphamide|
45916243|NCT00007995|Drug|melphalan|
45916244|NCT00007995|Procedure|autologous bone marrow transplantation|
45916245|NCT00007995|Procedure|bone marrow ablation with stem cell support|
45916246|NCT00007995|Procedure|peripheral blood stem cell transplantation|
45779186|NCT00439946|Drug|treprostinil|rapid switch from intravenous epoprostenol on the CADD ambulatory pump to intravenous Remodulin on the Crono Five ambulatory pump
45779187|NCT00439946|Device|Crono Five ambulatory pump|Used for administration of IV Remodulin (treprostinil)
45641002|NCT05906875|Other|Lateral Stepping Exercise 4|4. Half-pelvic drop: The participant stands on both legs with one knee straight and the other knee bent to approximately 45 degrees. Participants will be instructed to drop their pelvis (hip) on the side with the bent knee, then raise it as high as possible. Support is used as needed. This exercise will be performed for 3 sets with each set stopping when an RPE of 5-7 is reported.
46070438|NCT00838929|Drug|Vorinostat|"All doses given for 3 weeks~Dose level -2 - 50 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level -1 - 100 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level I - 200 mg PO qd (initial starting dose) Dose level II - 300 mg PO qd Dose level III - 400 mg PO qd"
45641003|NCT05906875|Other|Lateral Stepping Exercise 5|5. Lateral Reactive Postural Control: The participant will lean into the researcher's hand to shift their center of mass outside of their base of support. Hand placement will be at the glenohumeral joint and the pelvis. The researcher will withdraw support and guard the participant as the participant regains their balance. This is item 6 on the Mini-BESTest assessment that will be incorporated as an intervention. To be performed 3x per side.
45779188|NCT05022498|Behavioral|Exercise|60 min treadmill exercise performed at 60% of maximum oxygen uptake.
45641004|NCT05906446|Other|Multicomponent (Exercise + Protein Supplementation)|"Exercises selected from a pre-specified list, reassessed weekly~Participants will receive individualized exercise sessions, (e.g. 15-30 minutes per session, one session per day, offered five times a week)~Participants will also be offered a protein supplement within 30 min of exercise.~Sessions will be supervised"
45641005|NCT05906407|Other|Genomic Profiling / Sequencing|Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) in high-risk early breast cancer patients pre- and post neoadjuvant therapy
45641006|NCT05906303|Drug|Caffeine and Sodium Benzoate Injection|Provide caffeine to shorten second stage of labor and augment pushing efforts
45779189|NCT00506714|Device|single point cane|Adjustable single point cane with SureGrip handle
45779190|NCT04228380|Other|No intervention|No intervention
45779191|NCT04227678|Drug|Heparin|an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours, starting 15 minutes before ingestion of liquid meal
45779192|NCT04227678|Dietary Supplement|liquid meal|low fat meal: (500 mL, 898 Kcal, 13% fat, 20.3% protein and 62.3% carbohydrates) will be ingested over 20 minutes
45779193|NCT00508118|Drug|Nicardipine|on bypass
45779194|NCT00508118|Drug|0.9% saline|on bypass
45779195|NCT04222764|Diagnostic Test|Real-time three-dimensional echocardiography|"The initial hemodynamic assessment and monitoring using echocardiography will be performed within 12h following ICU admission. TTE will be performed systematically as first-line examination and TEE will be performed only on ventilated and sedated patients for whom additional information is required for their management, according to the standards of care of the participating centers. In that case, TEE will be performed immediately after TTE.~3D echocardiographic measurements will be performed after the examination by two independent intensivists expert in critical care echocardiography who will be blinded from the usual parameters of RV systolic functions; these parameters will be measured during the examination to guide the management of patients, according to the standard of care of the participating centers."
45779196|NCT00508196|Other|RVP-min|DDD pacing with long AV delay
45448666|NCT05144776|Diagnostic Test|Dried Blood Spot HBV DNA test|HBV DNA viral load will be measured from a fingerstick capillary dried blood spot sample using a gold standard HBV DNA viral load assay
45448667|NCT03738111|Drug|TG02 Citrate|TG02 citrate capsules
45448668|NCT03738033|Other|educational platform|The platform would be opened before they entered the study.
45779197|NCT00508196|Other|RVP-max|DDD pacing with short AV delay
45779198|NCT04227054|Device|IMPEDE-FX Embolization Plug|Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft
45779199|NCT05622266|Procedure|Pulpotomy|The patients who are randomly assigned to the experimental group receive pulpotomy.
45448669|NCT03776656|Drug|Allopurinol|Daily oral administration
45448670|NCT03733743|Other|Standardized living protocol|Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
45641007|NCT05906303|Drug|Normal Saline|Provide normal saline to serve as a placebo
45641008|NCT05906082|Behavioral|E-cigarette cessation text-messaging intervention|This is the intervention for e-cigarette cessation using text messages targeting young adults in rural areas.
45641009|NCT05906082|Behavioral|Standard care control using standard national resources|This is the standard care with national resources from smokefree.gov.
45779200|NCT05622266|Procedure|Root Canal Therapy|The patients who are randomly assigned to the Active Comparator group receive root canal therapy.
45779201|NCT05139030|Drug|bupivacaine liposome injectable suspension|Adductor canal block with EXPAREL
45779202|NCT05139030|Drug|Bupivacaine Hydrochloride|Adductor Canal Block with bupivacaine HCl
45779203|NCT00440180|Drug|Anastrozole|1 mg qd for 4 months
45779204|NCT00440180|Drug|Placebo|Placebo Comparator
45779205|NCT05021484|Drug|Felzartamab|Intravenous infusion in regular intervals over 6 months
45779206|NCT05021484|Drug|Placebo|Intravenous infusion in regular intervals over 6 months
45779207|NCT05021094|Drug|Kuntai Capsule|The instructions is pointed that each Kuntai capsule is 0.5g and the usage of Kuntai capsule is oral taking 4 capsules each time, 3 times a day, and 4 weeks is a course of treatment. The patients will taking 3 courses of treatment in this study.
45916247|NCT00006388|Drug|tamoxifen citrate|
45916248|NCT00006388|Radiation|radiation therapy|
45916249|NCT00008034|Drug|capecitabine|
45916250|NCT00008034|Drug|cyclophosphamide|
45916251|NCT00008034|Drug|epirubicin hydrochloride|
45916252|NCT00006391|Drug|oxaliplatin|
45916253|NCT00006391|Drug|topotecan hydrochloride|
45779208|NCT05021094|Drug|Femoston|The estrogen and progesterone sequential regimen was adopted. The Femoston was contain estradiol tablets and estradiol didroxyprogesterone tablets. Red tablets (estradiol, 2 mg/d) were taken in the first 14 days, and gray tablets (estradiol, 2 mg/d, dydrogesterone,10 mg/d) were taken in the last 14 days. 28 days was a course of treatment, and three courses of treatment were taken. The patients will taking 3 courses of treatment in this study.
45641010|NCT05906056|Device|Continuous Passive Motion (CPM)|CPM uses machines to move a joint passively i.e. without the patient exerting any effort. A motorized device moves the joint repetitively to a set of degrees and movement speed, determined by the caregiver either a medical doctor (physiatrist or orthopedic surgeon) or a physiotherapist. Its action preserves the joint's range of motion (ROM)
45641011|NCT05906056|Other|Conventional physiotherapy (PT)|Daily passive range of motion exercises (ROM) performed by the physiotherapist of the intensive care unit (ICU)
45641012|NCT05906056|Drug|Zoledronic Acid Injection|one dose of intravenous zoledronic acid will be administered
45641013|NCT05906043|Behavioral|Exercise Intervention|Exercise intervention
45641014|NCT05906043|Behavioral|Acceptance and Commitment Therapy|ACT will be used for patients with psychological disability as well as for those with sleep disturbance
45641015|NCT05906043|Dietary Supplement|Probiotic|Use of a probiotic
45641016|NCT05905783|Drug|Placebo|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
45641017|NCT05905783|Drug|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
45641018|NCT05905770|Drug|Alemtuzumab Injection [Campath]|Alemtuzumab 1mg/kg
45641019|NCT05905627|Behavioral|exercise|intervention group
45641020|NCT05905510|Drug|Lumbar Erector spinae plane block (L-ESPB)|The fourth lumbar vertebral level will be determined using the conventional method (the imaginary line between two crista iliacas). The convex transducer will be placed at the mid-vertebral line in the sagittal plane. The transducer will be shifted from the midline, 3.5-4 cm laterally, to the side of the surgery to visualize the erector spinae muscle and transverse process. Using the out-of-plane technique, a 22G/80-mm block needle will be advanced until it reached the transverse process. 0.5-1 ml of the prepared local anesthesia solution (30 ml bupivacaine 0.25%) will be administered, leading to hydro dissection to confirm the correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurred when administering local anesthesia. All local anesthesia will be administered to this location between the transverse process and the erector spinae muscle
45641021|NCT05905510|Drug|Fascia iliaca compartment block (FICB)|The transducer will be placed laterally to the femoral nerve. It then rotated 90 degrees to the sagittal plane, under ultrasound guidance, a regional block needle (22 G, 80 mm) will be introduced in the cranial direction. Once good needle alignment with the ultrasound beam is achieved, the needle will be inserted deep into the tissues until an optimal position of the needle tip is obtained. Needle location will be additionally verified by injecting 0.5-1 ml of the prepared local anesthesia solution and observing the solution spread within the tissues. Once the correct position of the needle tip is confirmed, the local anesthetic will be deposited under the iliac fascia to force its flow towards the lumbar plexus. 30 ml of bupivacaine 0.25% solution will be used for the block. local anesthesia will be administered as 5 mL boluses with a 20 second interval.
45779209|NCT02114216|Procedure|endoscopic mucosal biopsy|endoscopic mucosal biopsy was undertaken for every participant.
45779210|NCT02982746|Other|gPCC (Gothenburg Person Centred Care)|
45779211|NCT01364298|Drug|Gabapentin/B-complex|Gabapentin/B-complex (Gavindo®) tablet will be administered orally at an initial dose of 300 milligram per day (mg/day) on Day 1, followed by 600 mg/day (one 300 milligram [mg] tablet every 12-hour) on Day 2, then 900 mg/day (one 300 mg tablet every 8-hour) on Day 7, then 1800 mg/day (two 300 mg tablets every 8-hour) on Day 21, then 2700 mg/day (three 300 mg tablets every 8-hour) on Day 35, and finally 3600 mg/day (four 300 mg tablets every 8-hour) on Days 56 and 84. Maximum dose allowed will be 3600 mg/day. The total duration of treatment will be 84 days (12 weeks).
46070439|NCT00838929|Radiation|Radiation Therapy|Patients will take Vorinostat daily during radiation therapy, they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation.
45448671|NCT03733665|Other|Patients admitted to hospital|Data is captured in HES for all patient interactions with the NHS (each episode) in England. All patients admitted for heart failure have data captured in the National Heart Failure Audit.
45641022|NCT05905510|Drug|spinal anesthesia plane block|Patients will receive spinal anesthesia alone
45641023|NCT05905432|Drug|Vaccine AnAPN1|AnAPN1 is a recombinant protein expressed in Escherichia coli. It consists of the UF6b construct, derived from the sequence of the Anopheles gambiae alanyl aminopeptidase N (XM_318000.4) and will be formulated with or without Synthetic Glucopyranosyl Lipid A (GLA)- LSQ adjuvant. Route of administration is intramuscular.
45779212|NCT01364298|Drug|Pregabalin|Pregabalin (Lyrica®) capsule will be administered orally at an initial dose of 150 mg/day (one 75 mg capsule every 12-hour) from Day 1 to 7, followed by 300 mg/day (one 150 mg capsule every 12-hour) on Day 7, then 600 mg/day (two 150 mg capsule every 12-hour) on Days 21, 35, 56 and 84. Maximum dose allowed will be 600 mg/day. The total duration of treatment will be 84 days (12 weeks).
45779213|NCT04421742|Drug|Beclomethasone Dipropionate/Formoterol Fumarate|BDP/FF NEXThaler® 100/6 μg b.i.d.
45779214|NCT00441350|Drug|OM 40|Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/12.5 mg and responders remained on the previous therapy for further 8 weeks.
45779215|NCT00441350|Drug|OM/HCTZ 40/12.5|Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/25 mg and responders remained on the previous therapy for further 8 weeks.
45916254|NCT00006394|Drug|growth hormone|
46070440|NCT02612025|Behavioral|Exercise Training|Exercise training during intensive medical treatment. Training mainly composed of endurance and resistance exercises. 3 to 5 times per week for six weeks.
46070441|NCT00811603|Drug|Cefazolin (Timing of Antibiotic Prophylaxis)|Patients scheduled for a cesarean delivery will be randomly assigned to receive Cefazolin (antibiotic prophylaxis) either prior to skin incision or after the clamping of the umbilical cord
45641024|NCT05905081|Other|aerobic exercise|30-minutes aerobic exercise intervention on the bicycle ergometer. The exercise protocol includes 5 minutes of warm-up, 20 minutes of loading and 5 minutes of cool-down. The intensity of the exercise will be adjusted to be between 46% and 63% of the VO2max calculated according to the exercise programming guide published by the American College of Sports Medicine (ACSM), and the perceived effort level on the Borg scale will be 12-13. Warm-up and cool-down periods will be set to 46% of VO2max and Borg perceived exertion level below 9.
45641025|NCT05904964|Drug|Disitamab vedotin|Disitamab Vedotin 2mg/kg was injected every 2 weeks,
45641026|NCT05904964|Other|Endocrine therapy|Doctors choose endocrine therapy independently
45641027|NCT05904730|Drug|Axitinib|The starting dose of axitinib is 5 mg twice daily by mouth with meals. (reception is desirable at the same time every day)
45448672|NCT03545698|Other|Avizia Telehealth Platform|Avizia will be utilized as a communication tool between home-based caregivers (family members, formal caregivers, or informal caregivers) and the House Calls care management team.
45641028|NCT05904483|Other|PFA|PFA
45641029|NCT05904418|Other|Robot-assisted US Scan of the vertebra L1 to S1|A standardized robot-assisted US-Scan of the vertebra L1 to the S1 is executed. The two probe trajectories are generated automatically by an optical camera or RedGreenBlue-Depth (RGB-D) camera. Then the robot will scan at two mm/s, automatically following the trajectory. A 6 degrees of freedom (DoF) force sensor (Nano25, Ati Industrial Automation Inc.) was assembled at the US probe. During the scanning, it measures the interaction force and torque between the US probe and volunteers' skin to ensure volunteer safety. The US images and corresponding robot poses are recorded for the reconstruction. A previously developed algorithm is used to obtain a preliminary 3D reconstruction that will be used to adapt the scanning pattern in case of incomplete scanning.
45641030|NCT05904418|Other|Handheld US scan of the vertebra L1 to S1|A handheld US-Scan of the vertebra L1 to S1 is executed. An optical marker for an Atracsys Camera is mounted to the US probe to track its position. Simultaneously, the optical tracking allows for standardization of the US-Scan through navigation. The acquired US images and corresponding poses are used to reconstruct the lumbar spines and compared to the ground truth (CT scan). Handheld US scanning will be performed at around two mm/s in two scanning trajectories. The US probe orientation will be adjusted during the scanning by comparing the optical marker orientation with the initial probe orientation. This combination leads to different scanning patterns. For each pattern, the scanning procedure will be repeated three times. At least once per volunteer, each handheld scanning pattern will be performed with a higher manual speed to assess the reconstruction quality with faster scanning. A graphical user interface (GUI) will synchronize and store the data during the scanning.
45641031|NCT05904418|Radiation|ULD CT scan of the vertebra L1 to S1|A ULD CT scan (CT, Siemens Naeotom Alpha: A-207883-62) of the lumbar spine (L1-S1) is performed at the Swiss Center for Musculoskeletal Imaging (SCMI) at Balgrist Campus, Zurich. The total duration estimate for the CT examination is 30 minutes, whereas the scan takes 15 minutes. The volunteers lie on their abdomen during this procedure to simulate the spine's position during the subsequent US examination. The vertebrae (L1-S1) in the CT Scans are manually segmented with global thresholding and the region growing tool in a standard segmentation software (Materialise Mimics, Leuven, Belgium). The 3D surface models are then exported as Standard Triangle Language (STL) files.
45641032|NCT05904353|Procedure|Ambulant nurse-assisted administration of zoledronic acid|Patients from the intervention regions will be followed by the protocol of ambulant nurse-assisted administration of zoledronic acid.
45641033|NCT05904353|Procedure|Usual care|General practitioners are requested to take care of the follow-up, through the patients and the discharge summary, with annual infusions of zoledronic acid.
45641034|NCT05903950|Device|Air cleaners with HEPA filter|PM 2.5 exposure reduction using in home portable air cleaners fitted with HEPA filters
45779216|NCT05072652|Other|Neuromuscular Electrical Stimulation|Participants in this group will perform twice daily neuromuscular electrical stimulation training sessions of the quadriceps muscles (specifically, the vastus lateralis and rectus femoris) or the immobilized left leg.
45641035|NCT05903950|Device|Air cleaners without HEPA filter|Simulation of PM 2.5 exposure reduction using in home portable air cleaners without HEPA filters.
45641036|NCT05903625|Dietary Supplement|Control Group - Standard White Bread|Participants consume commercially available standard white bread, serving as the control intervention.
45641037|NCT05903625|Dietary Supplement|Lysine Group - Lysine-Fortified Bread|Participants consume bread fortified with lysine, an essential amino acid, in a specified dosage, frequency, and duration.
45641038|NCT05903625|Dietary Supplement|Phosphorus Group - Phosphorus-Fortified Bread|Participants consume bread fortified with phosphorus, an essential mineral, in a specified dosage, frequency, and duration
45779217|NCT05072652|Other|Action Observation + Mental Imagery|Participants in this group will perform daily action observation + mental imagery training via video and audio recordings.
45779218|NCT01488019|Drug|Perforomist-Placebo|Placebo vehicle, 2mL, twice daily for 52 weeks
45779219|NCT01488019|Drug|Perforomist, nebulization, COPD|Perforomist, 20 mcg/2 mL, twice daily for 52 weeks
45779220|NCT05138796|Drug|TP-05 (lotilaner oral capsules)|TP-05 (lotilaner oral capsules)
45916255|NCT00008073|Drug|doxorubicin hydrochloride|
45779221|NCT05138796|Drug|Placebo|Placebo to match TP-05 (lotilaner oral capsules)
45916256|NCT00008073|Drug|octreotide acetate|
45916257|NCT00006397|Drug|Indinavir sulfate|
45916258|NCT00006397|Drug|Ritonavir|
45916259|NCT00006397|Drug|Stavudine|
45916260|NCT00006397|Drug|Didanosine|
45598088|NCT03112707|Drug|Aspirin|After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
45779222|NCT04351321|Procedure|Totally Laparoscopic Total Gastrectomy|Totally laparoscopic total gastrectomy will be performed in patients with gastric or esophagogastric junction adenocarcinoma of preoperative clinical stage I (T1N0M0, T1N1M0, T2N0M0) with D1+/D2 lymph node dissection.
45779223|NCT04351321|Procedure|Laparoscopy-Assisted Total Gastrectomy|Laparoscopy-Assisted Total Gastrectomy will be performed in patients with gastric or esophagogastric junction adenocarcinoma of preoperative clinical stage I (T1N0M0, T1N1M0, T2N0M0) with D1+/D2 lymph node dissection.
45779224|NCT05071248|Device|VEMO (Reactive Robotics GmbH)|The robot used for early mobilization is able to verticalize the patients in their bed without transfer and to generate a movement of the legs that measures and supports the patients' own movement. The device meets the requirements for mobilizing critically ill patients in an intensive care unit, maintaining hygiene standards and providing the best possible support for the patient's own movement.
45779225|NCT01797146|Procedure|Catheter Reminder and Evaluation Program|"This intervention will be implemented by ward nurses and responsible physicians. The details of intervention are shown below.~Nurse: Every morning, a ward nurse will check if any patient has a urinary catheter or a central venous catheter in place. An order sheet will be marked with a CARE-rubber stamp and the following information will be added by hand-writing.~Type and duration of urinary catheter use.~Indication of urinary catheter _________~Type and duration of central venous catheter use~Indication of urinary catheter _________~Responsible physician: During a morning round, a physician needs to fill the indication of catheter use. If a given physician does not fill the indication of urinary catheter use, the catheter will be automatically removed. If a given physician does not fill the indication of central venous catheter, the CARE team will be notified."
45779226|NCT01488409|Drug|Acipimox|250 mg by mouth (PO) three times daily
45779227|NCT01488409|Drug|Placebo|0 mg by mouth (PO) three times daily
45779228|NCT05070546|Biological|Ad26.RSV.preF-based Vaccine|Participants will receive a single IM injection of an RSV vaccine.
45779229|NCT05070546|Other|Placebo|Participants will receive a single IM injection of matching placebo.
45779230|NCT01488877|Drug|PF-03882845|3 mg tablet once daily
45641039|NCT05903625|Dietary Supplement|Lysine and Phosphorus Group - Double Fortified Bread|Double Fortified Bread: Participants consume bread fortified with both lysine and phosphorus in specified dosages, frequencies, and durations.
45641040|NCT05903469|Other|Implicit Attitude Test|The IAT (Implicit Attitude Test) is a method of indirectly measuring the relative strength of associations between different concepts stored in memory based on reaction times on computer. The general idea behind this measure is that an individual will be much faster to categorize an object into a predetermined category, if this categorization is consistent with their own way of processing information.
45779231|NCT01488877|Drug|PF-03882845|up to 10 mg tablet once daily
45779232|NCT01488877|Drug|PF-03882845|up to 30 mg once daily
45779233|NCT01488877|Drug|Spironolactone|spironolactone 25 mg once daily
45598089|NCT03112707|Drug|P2Y12 inhibitor|After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
45779234|NCT01488877|Other|placebo|placebo once daily
45779235|NCT01364922|Drug|hydrocodone/acetaminophen extended release|
45779236|NCT01364922|Drug|Placebo|
45779237|NCT01489579|Behavioral|Telephone Counseling for Tobacco Cessation|"The patients in the Brief, Structured, Telephone (BST) counseling group will receive tobacco cessation counseling by a trained CPCRS pharmacist as part of their routine CPCRS care. The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C). These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting. A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources (Ready to quit patient handout)"
45779238|NCT01489579|Behavioral|Usual Care|Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices. These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications. Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
45779239|NCT05019612|Procedure|Laparoscopy: A minimal invasive surgery|A low-risk minimal invasive surgery performed in the pelvis using small incisions. With the aid of a laparoscope, the operator views the affected area in real-time. Beyond that, the camera sends images to a video monitor. The operator obtains endometriosis and biopsy samples with small surgical instruments. Before laparoscopy, individuals are provided with a general anaesthetic to relax muscles and prevent pain during surgery.
45779240|NCT01489969|Drug|Neu-P11|1 tablet daily 1-2 before bed time for 28 days of double blind treatment
45779241|NCT00509288|Biological|autologous anti-MART-1 F5 T-cell receptor|"Autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes.~A minimum of approximately 5 X 10^8 cells will be given up to 3x10^11 anti-MART-1 F5 TCR engineered TIL or PBL."
45779242|NCT00509288|Drug|Cyclophosphamide|Day -7 to -5: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
45779243|NCT00509288|Drug|Fludarabine|Day -5 to 1: Fludarabine 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days
45916261|NCT03586479|Behavioral|Interactive storybook reading|Children will be taught 30 words prior to, during, and after reading a commercially available storybook by an adult.
45916262|NCT00006412|Drug|Pravastatin sodium|
45916263|NCT00006412|Drug|Fenofibrate|
45779244|NCT00509288|Biological|Aldesleukin|Day 0: Cells will be infused intravenously (i.v.). Patients will receive up to 3x10e^11 (with a minimum of 5x10e^8 cells) anti-MART-1 F5 TCR engineered TIL or PBL Aldesleukin (based on total body weight) 720,000 IU/kg intravenous (IV) over 15 minute every eight hours beginning within 24 hours of cell infusion
45779245|NCT00509288|Biological|autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes|
45779246|NCT01490359|Behavioral|Men Making a Difference HIV/STD Risk Reduction Intervention|Developed based on social cognitive theory and extensive formative research, Men Together Making a Difference HIV/STD risk-reduction intervention consists of 6 75-minute modules designed to increase beliefs that support condom use; skill and self-efficacy to use condoms; and HIV/STD risk-reduction knowledge. Two modules are implemented in each of 3 weekly sessions. It is highly structured and implemented in small groups of 9 to 15 men led by a male, isiXhosa-speaking facilitators using standardized intervention manuals. It includes interactive exercises, games, brainstorming, role-playing, take-home assignments, group discussions, and videos, produced specifically for the interventions, shot in authentic township settings, including a shebeen (i.e., an informal alcohol outlet).
45779247|NCT01490359|Behavioral|Health Promotion Control|The health-promotion intervention was designed to control for non-specific features including group interaction and special attention. It was structurally similar to the HIV/STD risk-reduction intervention in that it contained activities similar to the HIV/STD risk-reduction intervention but focused on behaviors linked to the risk of heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among South Africans. It also consisted of 6 75-minute modules implemented 2 modules per week during 3 weekly sessions led by isiXhosa speaking male facilitators. It was designed to increase fruit and vegetable consumption and physical activity and decrease excessive alcohol consumption.
45779248|NCT00442364|Drug|Polidocanol (1%) Microfoam (Varisolve)|Varisolve polidocanol 1% microfoam, maximum of 20ml injected into affected great saphenous vein.
45598090|NCT02209571|Other|Venous blood markers|Routine venous blood sampling
45779249|NCT00442364|Procedure|Endovenous Microfoam Occlusion|Varisolve® polidocanol microfoam injection under duplex guidance to fill proximal and distal great saphenous vein and varicose tributaries.
45779250|NCT01492309|Device|Active Transcranial Magnetic Simulation|Subjects will be given active TMS 5 days per week for 4 weeks for a total of 20 sessions. Each session will last approximately 10 minutes.
45779251|NCT01492309|Device|Sham Transcranial Magnetic Stimulation|Subjects will be given sham TMS 5 days per week for 4 weeks for a total of 20 sessions. The sham coil contains a shielding mechanism which diverts the magnetic field away from the patient. The sham treatment will last approximately 10 minutes.
45779252|NCT05018598|Drug|Administration via pressurized metered dose inhaler (pMDI)|Either CHF5993 or CHF1535
45641041|NCT05903417|Drug|Intrapleural fibrinolytic with alteplase 5mg and pulmozyme 5 mg|The number of installation of intrapleural t-PA/DNase depends on the discretion of the treating physician (at least 6 hours apart between each dose). 5mg of Alteplase (t-PA) and 5mg DNase are diluted in each 50ml of 0.9% sodium chloride solution. t-PA and DNase are not mixed together in one syringe. In brief , both medication are administered sequentially which t-PA is first instilled intrapleurally and the chest tube is then clamped for 45 minutes, then unclamped to allow free drainage for 45 minutes. The same procedure is then repeated for DNase. Selection of the timing of treatment and removal of chest tube are depending on the chest physician's judgement.
45779253|NCT00444080|Procedure|Trabeculectomy|"Standard trabeculectomy procedure~Creation of a fornix or limbal based conjunctival flap in upper quadrants~Creation of a limbal-based scleral flap extending into clear cornea~Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)~Creation of fistula 1mm x 2mm in size~Iridectomy~Suturing the scleral flap~Repositioning of conjunctiva with sutures After procedure, antibiotics & steroids are administered topically; eye is covered with a pad - patient is discharged."
45641042|NCT05903417|Other|Saline irrigation with 250 mls normal saline (over 1 hour)|subjects were administered 250 ml of 0.9% sodium chloride via chest tube a three way tap from a drip stand which were allowed drainage freely over 1 hour. Pleural irrigation will be performed minimum of 3 installations and maximum of 9 installation (3 times per day).
45641043|NCT05903274|Drug|JSP191|Subjects will receive intravenous JSP191
45641044|NCT05903014|Drug|n-acetylcysteine|we give 3600 mg n-acetylcysteine divided twice a day, for 12 weeks
45779254|NCT00444080|Device|Ex-PRESS mini shunt|"Ex-PRESS implantation procedure:~Creation of a fornix or limbal based conjunctival flap in upper quadrants~Creation of limbal-based scleral flap extending into clear cornea~Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)~Penetration into anterior chamber using 23-25G needle, halfway between the white sclera and clear cornea (in the center of the grey zone);creation of track incision at limbus~Prior to implantation, a thorough mobility check should be performed~Implantation of Ex-PRESS implant loaded on its introducer, through that pre-incision~Withdrawal of introducer~Tucking plate under the scleral flap, and verification of its position~Suturing scleral flap After implantation procedure, antibiotics & steroids administered topically; eye is covered with a pad - patient is discharged."
45779255|NCT01493167|Other|limb casting/splinting|ankle and arm cast
45779256|NCT05136300|Behavioral|Pulmonary rehabilitation|"Patients in the intervention group will receive physical therapy, scheduled pain monitoring and coaching by a social worker.~The intensity of the rehabilitation training program will be determined separately for each patient by a steepramp and 1-repetition test within 3 weeks post-operative. The intervention group will be trained and educated in 2 sessions of 2 hours per week, for a period of 3 months."
45641045|NCT05903014|Behavioral|Motivational Enhancement Therapy|Motivational enhancement therapy with individual and/or group session to maintain and increase subject's motivation to quit smoking
45779257|NCT00510224|Drug|Sandostatin|Sandostatin 30mg intramuscular every 28 days
45916264|NCT00008112|Drug|cisplatin|
45916265|NCT00008112|Procedure|hyperthermia treatment|
45598091|NCT03912207|Biological|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
45598092|NCT03912207|Other|Saline placebo|Saline is a routinely used placebo.
45598093|NCT05262413|Drug|QL1706 Plus Lenvatinib|QL1706 5mg/kg administered intravenously (IV), every 3 weeks, plus Lenvatinib 20 mg or 14mg administered orally, once daily.
45779258|NCT05070156|Biological|Biological/Vaccine: Low-dose group|1.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
45779259|NCT05070156|Biological|Biological/Vaccine: Mid-dose group|2.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
45779260|NCT05070156|Biological|Biological/Vaccine: High-dose group|3.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
45779261|NCT05069610|Biological|AD17002|A recombinant protein
45641046|NCT05902325|Drug|Mepolizumab 100 MG Injection|Patients will receive Mepolizumab 100mg SC once every 4 weeks for 48 weeks (twelve injections, no placebo) at the hospital. The IMP will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction. Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas) or the upper arms. Background therapy will be assured with mometasone furoate nasal spray (200µg BID) daily throughout the study.
45641047|NCT05901831|Drug|Finerenone|Dose A, Dose B, oral
45779262|NCT05069610|Biological|Placebo (Formulation buffer)|Formulation buffer
45779263|NCT00511706|Drug|dexamethasone|Intravitreal injection of dexamethasone 700 µg at Day 1.
45641048|NCT05901831|Other|Placebo|Oral
45779264|NCT00511706|Biological|ranibizumab|Ranibizumab 500 µg at day -30 and Day 7-14.
45916266|NCT00008112|Radiation|brachytherapy|
45779265|NCT00511706|Other|sham|Sham needle-less injection administered in the study eye at Day 1.
45779266|NCT05068674|Drug|Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells|50 million (M) cells delivered in a dose of 5M cells per injection over 10 injections.
45779267|NCT05068674|Drug|Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells|150M cells delivered in a dose of 15M cells per injection over 10 injections
45779268|NCT05068674|Drug|Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells|300M cells delivered in a dose of 30M per injection over 10 injections
45779269|NCT05015244|Procedure|3T (Tesla) Magnetic Resonance Imaging (MRI)|Neurological evaluation using MRI and neuropsychological tests
45779270|NCT00511862|Device|Yttrium 90 glass microspheres|120 Gy unilobar or bilobar infusion with the second infusion occurring 3-7 weeks following treatment of the first lobe
45916267|NCT00008112|Radiation|radiation therapy|
45916268|NCT00006418|Procedure|DNA collection|
45916269|NCT00006427|Drug|Amitriptyline|
45916270|NCT00006430|Biological|Autologous dendritic cells transfected with amplified tumor RNA|
45779271|NCT05067894|Biological|SARS-CoV-2 Protein Subunit Recombinant Vaccine|intramuscular injection
45779272|NCT05067894|Biological|SARS-CoV-2 Inactivated Vaccine|intramuscular injection
45779273|NCT05621954|Procedure|Telehealth Monitoring|Connected devices and smartphone apps to measure symptoms and observations at home, with centralisation of results to a staffed hub
45779274|NCT05621798|Other|Hearing Aid Manufacturer's Software|"When using hearing aid manufacturer's software (s.c. first-fit or initial fit) the fitting will follow the guided fitting procedure in the fitting software."
45779275|NCT05621798|Other|REM (Real Ear Measurements)|Participants' hearing aids are fitted by using REM. In this method REM measurement tube is placed inside participant's ear canal near the tympanic membrane and the Real Ear Unaided Gain (REUG) is measured. REUG is used to measure the ear canal without any hearing device and shows the patients ear acoustics. Next the hearing aid is placed on the patients ear together with the REM measurement tube. In REM measurements the Real-Ear Occluded Gain (REOG) is measured with the hearing aid off. REOG allows consideration of the attenuation caused by the earpiece and its obstructing effect of external sounds. Next Real Ear Aided Response (REAR) is measured with the hearing device on. REAR allows measurement of the hearing device's amplification effect within the patients' ear and includes the effect of the patient's ear acoustics.
45779276|NCT01493947|Drug|Ivermectin 1% cream|Ivermectin 1% cream applied once daily on the face during 16-week plus 36-week extension period.
45779277|NCT01493947|Drug|Metronidazole 0.75% cream|Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.
45779278|NCT05067348|Drug|Tocilizumab Injectable Product|Participants will receive IV tocilizumab
45916271|NCT00006433|Drug|Doxil|
45916272|NCT00006433|Procedure|heat treatment|
45916273|NCT00008151|Drug|cyclosporine|
45916274|NCT00008151|Drug|fludarabine phosphate|
45916275|NCT00008151|Drug|gemtuzumab ozogamicin|
45916276|NCT00008151|Drug|methotrexate|
45916277|NCT00008151|Drug|mycophenolate mofetil|
45916278|NCT00008151|Procedure|allogeneic bone marrow transplantation|
45916279|NCT00008151|Procedure|peripheral blood stem cell transplantation|
45916280|NCT00008151|Radiation|radiation therapy|
45916281|NCT00006439|Behavioral|Counseling in the home|
45916282|NCT00006445|Procedure|Ultrasound|
45916283|NCT00006445|Procedure|Serum screen|
45916284|NCT00006448|Behavioral|cognitive therapy|
45916285|NCT00006448|Procedure|Physical Therapy|
45916286|NCT00006448|Drug|Methadone|
45916287|NCT00008190|Biological|aldesleukin|
45916288|NCT00008190|Biological|filgrastim|
45916289|NCT00008190|Drug|busulfan|
45916290|NCT00008190|Drug|cyclophosphamide|
45916291|NCT00008190|Drug|etoposide|
45916292|NCT00008190|Drug|melphalan|
45916293|NCT00008190|Procedure|peripheral blood stem cell transplantation|
45916294|NCT00006451|Drug|anti-thymocyte globulin|
45916295|NCT00006451|Drug|cyclophosphamide|
45916296|NCT00006451|Drug|cyclosporine|
45916297|NCT00006451|Drug|methotrexate|
45916298|NCT00006451|Drug|methylprednisolone|
45916299|NCT00006451|Procedure|allogeneic bone marrow transplantation|
45916300|NCT00006451|Procedure|in vitro-treated bone marrow transplantation|
45916301|NCT00006451|Procedure|radiation therapy|
45779279|NCT05621720|Other|Case management|On enrolment, the nurse case manager will perform the initial comprehensive assessment based on the Omaha domains of environment, psychosocial, physiological and health-related behavior. The nurse case manager will execute the intervention scheme of teaching, guidance & counseling, treatments & procedure, case management, and/or surveillance, with the mutual goal set with clients to promote health and self-efficacy. Home visits and telephone calls will be employed. The referral network to health and social service will be activated as appropriate.
45779280|NCT05621720|Other|Social control call and usual are|Subjects in the control group will receive usual community service. in addition, a monthly social control call from trained community workers will be given to rule out the possible social effects of the intervention. These social calls will not be related the participants' health condition nor delivery of any health information.
45779281|NCT05013372|Drug|CD147- CAR T cells|CAR T cells targeting CD147
45779282|NCT05132556|Other|Acute Beetroot Juice|Participants will ingest a beetroot juice supplement with and without inorganic nitrate to determine the effects of acute dietary nitrate ingestion on blood pressure and arterial stiffness
45779283|NCT00445484|Biological|pneumococcal polyvalent vaccine|Given intramuscularly
45916302|NCT00006454|Drug|carboplatin|
45916303|NCT00006454|Drug|paclitaxel|
45916304|NCT00006454|Drug|topotecan hydrochloride|
45916305|NCT00008229|Biological|filgrastim|
45916306|NCT00008229|Drug|melphalan|
45916307|NCT00008229|Procedure|peripheral blood stem cell transplantation|
45641049|NCT05901818|Drug|Autologous induced neural stem cell-derived DA precursor cells|The autologous induced neural stem cell-derived DA precursor cells will be stereotactically implanted into the striatum of PD patients.
45641050|NCT05900973|Drug|Darolutamide Oral Tablet [Nubeqa]|Oral use of Darolutamide as an Inducer of Increased Expression of Prostate-specific membrane antigen (PSMA) in patients with Localized prostate cancer
45641051|NCT05899816|Drug|Rocatinlimab|Subcutaneous (SC) injection
45641052|NCT05899816|Drug|Placebo|SC injection
45779284|NCT00445484|Drug|lenalidomide|Given orally
45779285|NCT05130996|Device|dental prothesis|5 ranges of implants can be used : IDAll, IDBio, IDCam, IDMax, ID3
45779286|NCT01495585|Drug|Lonafarnib|Commercially approved products used to test the research hypothesis
45779287|NCT01495585|Other|Placebo|Placebo control
45779288|NCT04421976|Procedure|PEEP|"Driving pressure (DP) is calculated as plateau pressure - PEEP. 10min after position adjustment, PEEP is increased from 2 to 10 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively."
45641053|NCT05898607|Other|continuous Thoracic paravertebral block|continuous infusion U/S-Guided TPVB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure intraoperative.
45641054|NCT05898607|Other|continuous Erector spinae plane block|continuous U/S-Guided ESPB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure
45641055|NCT05897593|Device|GlenXRose Augmented Reality Acquired Brian Injury Therapies|Rehabilitation therapies for ABI have been developed for augmented reality implementation. These include various games to interact within an augmented environment while conducting rehabilitation therapy.
45641056|NCT05897554|Drug|intra-arterial alteplase|For patients in the successful MT plus intra-arterial alteplase group, after successful recanalization, neurointerventionalists administered intra-arterial thrombolysis with alteplase according to protocol. The angiographic scores will be assessed immediately after intra-arterial thrombolysis.
45779289|NCT00446264|Procedure|islet transplantation|Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
45779290|NCT00446264|Drug|daclizumab - sirolimus - tacrolimus|Immunosuppressive consisted of Tacrolimus, target through level at 3-6 ng/ml, Sirolimus, target through level at 12-15 ng/ml for three months and at 7-10 ng/ml thereafter. A five-dose induction course of Daclizumab 1mg/Kg was administered biweekly beginning one hour prior to the first infusion
45916308|NCT00008229|Radiation|holmium Ho 166 DOTMP|
45916309|NCT00006457|Drug|oltipraz|
45916310|NCT00387946|Drug|SSR591813L (dianicline)|
45916311|NCT00387985|Drug|MOA-728|
45916312|NCT00008268|Biological|filgrastim|
45779291|NCT01495819|Drug|Saline|5cc's of saline give at least once.
45779292|NCT01495819|Drug|Nicotine|(0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg).
45916313|NCT00008268|Drug|melphalan|
45916314|NCT00388063|Drug|Atiprimod|oral, 14 days on / 14 days off; 30mg capsules
45916315|NCT00006460|Drug|hyperbaric oxygen|
45916316|NCT00006460|Radiation|radiation therapy|
45916317|NCT00006463|Drug|ECTEINASCIDIN 743|
45916318|NCT00008307|Biological|anti-thymocyte globulin|
45916319|NCT00008307|Drug|cyclosporine|
45916320|NCT00008307|Drug|fludarabine phosphate|
45916321|NCT00008307|Drug|melphalan|
45916322|NCT00008307|Drug|methylprednisolone|
45916323|NCT00008307|Drug|mycophenolate mofetil|
45916324|NCT00008307|Procedure|allogeneic bone marrow transplantation|
45641057|NCT05897320|Drug|Eptinezumab|Solution for infusion
45641058|NCT05897320|Drug|Placebo|Solution for infusion
45641059|NCT05896566|Drug|Giredestrant|Giredestrant: 30 mg daily, PO from day 1 until the day of re-biopsy/surgery.
45641060|NCT05896566|Drug|Triptorelin|Triptorelin: 3.75 mg IM on day 1. Note: If re-biopsy/surgery cannot be done on day 29 (±3 days) from the first injection, then a second dose of triptorelin should be given on day 29 (±3 days).
45641061|NCT05896566|Drug|Anastrozole|Anastrozole: 1 mg daily, PO from day 1 until the day of re-biopsy/surgery.
45641062|NCT05896514|Device|ultrasound-guided carotid artery flow time measurement|Ultrasound-guided corrected carotid artery flow time will be measured before anestesia induction.
45641063|NCT05896098|Other|Ultrasound|Measurement of the airway by ultrasound in obese patients.
45641064|NCT05895786|Drug|PF-06823859|anti-interferon beta therapy
45779293|NCT04214886|Drug|Fludarabine|Fludarabine is an anti-cancer drug acting as an antimetabolite that is used to treat leukemia and lymphoma cancers.
45641065|NCT05895786|Drug|Placebo|Placebo for PF-06823859
45641066|NCT05895578|Dietary Supplement|Probiotic|1 capsule of probiotic (Lactobacillus CECT 9422 + Bifidobacterium CECT 30257) every 12 hours for 6-months.
45641067|NCT05895578|Dietary Supplement|Probiotic + placebo|1 capsule of probiotic + 1 capsule of placebo per day for 6-months.
45641068|NCT05895578|Dietary Supplement|Placebo|1 capsule of placebo every 12 hours for 6-months.
45641069|NCT05895500|Drug|Injection for SC administration (120mg/syringe)|Injection
45779294|NCT04214886|Drug|Cyclophosphamide|Cyclophosphamide is is an anti-cancer drug acting as an alkylating agent that is used to treat leukemia and lymphoma cancers.
45779295|NCT04214886|Biological|CD19-CD34 CAR transduced T cells|CD19-CD34 CAR transduced T cells are the subject's own immune cells that target B cell markers on cancer cells.
45779296|NCT05621642|Other|Breathing exercises|In the sitting position, the patient does 15 diaphragm breathing and 15 huffing exercises.
45779297|NCT05621642|Other|Core stabilization exercises|This intervention includes bridging exercise and abdominal exercises.
45779298|NCT05621642|Other|Balance and strengthening exercises|It includes sitting and standing on the chair 15 times and turning around the chair.
45779299|NCT00512876|Drug|Bevacizumab (Avastin)|Bevacizumab 10mg/mL 1 drop BID x 3 weeks
45779300|NCT05128422|Other|Normobaric oxygen therapy|it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours.This therapy should begin in the emergency room as early as possible when patients meet the inclusion criteria and are randomized to the experimental group
45779301|NCT00513344|Dietary Supplement|Dark Chocolate|1 portion
45779302|NCT00513344|Dietary Supplement|Milk Chocolate|1 portion
45779303|NCT00513344|Dietary Supplement|"Control (polyphenol-free) Chocolate"|one portion
45779304|NCT00514592|Other|New Guidelines|New practical guidelines after half of the study aimed at reducing the delay and increasing the patient safety.
45641070|NCT05895500|Drug|Tablet (50mg/tablet), oral|Tablet
45641071|NCT05895344|Radiation|Proton-therapy|Proton pencil-beam-scanning irradiation (50,4 Gy (RBE) in 28 fractions)
45916325|NCT00008307|Procedure|peripheral blood stem cell transplantation|
45779305|NCT04422054|Procedure|Open Surgery|We will retrospectively review patients with abdominal aortic aneurysms that underwent open surgical repair.
45779306|NCT04422054|Procedure|Endovascular Surgery|We will retrospectively review patients with abdominal aortic aneurysms that underwent endovascular repair.
45779307|NCT05127876|Drug|Ondansetron 4 MG|Ondansetron 4mg was given over 1 min, 5 min before spinal anesthesia
45779308|NCT05127876|Drug|Ondansetron 8mg|Ondansetron 8mg was given over 1 min, 5 min before spinal anesthesia
45916326|NCT00008307|Procedure|syngeneic bone marrow transplantation|
45641072|NCT05895344|Radiation|Photon radiotherapy|Intensity modulated radiotherapy with or without stereotactic positioning (50,4 Gy in 28 fractions)
45641073|NCT05894421|Drug|TQB2223 injection+ Penpulimab Injection|TQB2223 is an anti lymphocyte activation gene-3 (LAG-3) antibody. Penpulimab Injection is an anti-PD-1 antibody.
45641074|NCT05894239|Drug|Inavolisib|Participants will receive an inavolisib tablet to be taken orally (PO), once a day (QD), on Days 1-21 of each 21-day cycle, beginning on Day (D) 1 of Cycle (C) 1 of maintenance treatment.
45641075|NCT05894239|Drug|Phesgo|Phesgo will be administered to participants subcutaneously every 3 weeks (Q3W) on D1 of each 21-day cycle.
45641076|NCT05894239|Drug|Placebo|Inavolisib-matching tablet taken PO QD on Days 1-21 of each 21-day cycle, beginning on D1 C1 of maintenance treatment.
45641077|NCT05894239|Drug|Taxane-based Chemotherapy|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy will be administered after Phesgo.
45641078|NCT05894239|Drug|Optional Endocrine Therapy of Investigator's Choice|Optional endocrine therapy (ET) is allowed at the discretion of the investigator, based on the standard of care. Allowed ETs are tamoxifen, or one of the specified third-generation aromatase inhibitor (AI [anastrozole, letrozole, or exemestane]), or fulvestrant. The investigator will determine and supply the appropriate luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
45641079|NCT05893823|Diagnostic Test|Pelvis CT scan|Post-THA hip pelvis CT scan execution for pain, noise or THA planning for the controlateral hip, with identification of acetabular cup protrusion. Comparation of cases and controls to identify radiological factors that could potentially lead to symptomatic psoas impingement prediction.
45779309|NCT05127876|Drug|EPHEDrine 10 Mg/mL-NaCl 0.9% Intravenous Solution|Ephedrine 10mg was given over 1 min, 5 min before spinal anesthesia
45779310|NCT05127876|Other|10 mL normal saline|10 mL normal salinwe 0.9% was given over 1 min, 5 min before spinal anesthesia
45779311|NCT05010174|Drug|MDR product|Observation of patients previously receiving MDR product(s)
45779312|NCT02522286|Behavioral|Ask 3 Questions|"Participants were asked to bring an Ask 3 questions flyer into their appointment to use if they needed to make a choice about their health care during their appointment. These 3 questions have been shown to help patients make more informed decisions about their healthcare."
45916327|NCT00006466|Drug|beta alethine|
45916328|NCT00006469|Drug|carboplatin|
45916329|NCT00006469|Drug|paclitaxel|
45916330|NCT00006469|Procedure|conventional surgery|
45641080|NCT05893680|Other|Group to play online games|Playing games in children is one of the non-pharmacological pain relief methods. In this study, the effect of playing an online game on pain level in children who underwent orthopedic surgery for pain management after the surgery was measured.
45779313|NCT02522286|Behavioral|Open Communication|"Open Communication includes a combination of interventions. 1) Participants used a Visit Companion Booklet to write out issues they would like to discuss with their physician during their appointment before showing up. They were also asked to write out any next steps decided on during their appointment and to repeat back to their doctor what they wrote before leaving.~2) Patients watched a short, informational cartoon video to better understand the Visit Companion Booklet.~3) Participating physicians received a training through the use of a Standardized Patient Instructor as a means of providing convenient, individualized training on communication techniques. Dyads (physicians and their medical assistants) were trained on how to incorporate the Visit Companion Booklet into workflow."
45641081|NCT05893680|Other|Group that received cold application|Previous studies have demonstrated that cold application has anti-inflammatory, muscle spasm reducing, and pain relieving properties. In this study, the effect of cold application on pain level in children who underwent orthopedic surgery was investigated.
45641082|NCT05893680|Drug|Group that received placebo (PHYSIOLOGICAL SALINE ISOTONIC 9 mg/ml AMPULE)|The placebo effect has been demonstrated in various studies today. Some of these studies describe placebo analgesia. In this study, the placebo analgesic effect was investigated, and the child and parent were told that an analgesic was applied, but instead 2 cc of PF 0.9% ISOTONIC SODIUM CHLORIDE solution was intravenously administered.
45641083|NCT05893680|Other|Group that played an online game and received cold application at the same time|To investigate the combined effect of online gaming and cold application as two separate non-pharmacological interventions, both interventions were applied together in this group
45641084|NCT05893160|Drug|JAN101 SR|The dosage form of JAN101 to be used in clinical investigations is a sustained release (SR) tablet containing Sodium Nitrite drug substance.
45641085|NCT05893160|Other|Placebo|Inert placebo formulation
45916331|NCT00006469|Procedure|neoadjuvant therapy|
45641086|NCT05893121|Other|Cardiac coherence session|A cardiac coherence session consists of an exercise of six breaths per minute during five minutes.
45641087|NCT05893121|Other|Information note about MRI|explanatory note about MRI examination
45641088|NCT05890404|Behavioral|LGBTQ-Affirmative CBT Training: Materials Only|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment."
45641089|NCT05890404|Behavioral|LGBTQ-Affirmative CBT Training: Direct Training|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers."
45641090|NCT05890404|Behavioral|LGBTQ-Affirmative CBT Training: Local Supervision|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers. This arm will also receive one year of ongoing (at least monthly) supervision in LGBTQ-affirmative CBT from an expert supervisor at your center."
45641091|NCT05889572|Drug|MaaT033|MaaT033 is a Microbiome Ecosystem Therapy (MET), composed of allogeneic, full-ecosystem pooled biotherapeutic gut microbiota.
45641092|NCT05888870|Drug|SCT800 and Daratumumab|SCT800 50IU/kg TIW alone or treated with Daratumumab 8mg/kg 4-8 times
45916332|NCT00006469|Radiation|radiation therapy|
45916333|NCT00006472|Drug|carboplatin|Carboplatin AUC 6 days 1 and 22
45916334|NCT00006472|Drug|fluorouracil|5FU 225mg/m2 continuous infusion on days 1-42 during radiation
45641093|NCT05888870|Drug|SCT800|SCT800 50IU/kg TIW alone
45916335|NCT00006472|Drug|paclitaxel|taxol
45916336|NCT00006472|Procedure|conventional surgery|
45916337|NCT00006472|Radiation|radiation therapy|The initial fields should be treated AP:PA when possible to a dose of 4500 cGy in 180 cGy fractions
45916338|NCT00008346|Diagnostic Test|Full Field Digital Mammography|Radiologic test to screen women for Breast cancer using digital detectors
45916339|NCT00008346|Diagnostic Test|Screen Film Mammography|Radiologic test to screen women for Breast cancer using plain film detectors a resolution screen
45641094|NCT05888753|Procedure|Adrenalectomy|Scheduled adrenal surgery
45641095|NCT05888532|Drug|Copper-64 labeled Granzyme B (64Cu-GRIP B)|Given IV prior to imaging
45641096|NCT05888532|Procedure|Positron Emission Tomography (PET)|Imaging procedure
45641097|NCT05888389|Procedure|Nerve Block Anesthesia Combined With Sedative Anesthesia|Patients will firstly receive cranial nerve blocks (ipsilateral auriculotemporal, greater occipital nerve, and lesser occipital nerve block) with 1.5ml~2.0ml 0.5% ropivacaine and 1% lidocaine at each site under standard monitoring. At the same time, intravenous dexmedetomidine infusion will be initiated for sedation at a rate of 2-4ug/kg for 10 minutes, followed by a continuous infusion of 0.5 to 1ug/kg/h until the end of the operation. The responsible anesthesiologist could adjust the rate of infusion according to the patient's physical condition. The bispectral index value will be maintained around 60 to 70 via adjusting the infusion of dexmedetomidine.
45916340|NCT00006475|Drug|imatinib mesylate|
45916341|NCT00006481|Drug|Biafine cream|
45916342|NCT00006481|Procedure|quality-of-life assessment|
45916343|NCT00006481|Radiation|radiation therapy|
45916344|NCT00008424|Drug|irinotecan hydrochloride|
45916345|NCT00006484|Drug|carboplatin|
45916346|NCT00006484|Drug|paclitaxel|
45916347|NCT00006484|Drug|tirapazamine|
45916348|NCT00006487|Drug|cisplatin|"During induction: 50 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~During consolidation: 60 mg/m2, IV on Day 1 only at approximately Week 11, Week 14. 1 hour infusion."
45916349|NCT00006487|Drug|etoposide|"During induction: 50 mg/m2/day, IV on Days 1 - 5, 29 - 33. 1 hour infusion~During consolidation: 120 mg/m2, IV on Days 1, 2 and 3 at approximately Week 11, Week 14. 1 hour infusion."
45641098|NCT05888389|Procedure|General Anesthesia|General anesthesia patients are preoxygenated for 6 min, and standardized anesthesia induction is initiated with propofol 1-2mg/kg or etomidate 0.15mg/kg-0.4mg/ kg, sufentanil 0.2-0.3ug/kg, rocuronium 0.6mg/kg or cisatracuronium 0.2mg/kg for induction. Anesthesia is maintained by total intravenous anesthesia, and intraoperative bispectral index monitoring is maintained between 40 and 60. H3 receptor blocker is given before the end of surgery to prevent nausea and vomiting.
45641099|NCT05888389|Procedure|Burr hole craniostomy|A single 1.5 cm burr hole is drilled over the maximum width of the hematoma cavity. After coagulating with bipolar diathermy, dura mater is opened with a cruciate incision. A soft catheter is placed carefully in all directions of the hematoma cavity for irrigating subdural collections with 1,000 mL warm Ringer's lactate saline until clarification. The drainage catheter is inserted ½ length of the maximum diameter of the hematoma cavity toward the frontal region. After the skin is closed, the catheter is connected to a soft collection bag that is placed under the head for passive drainage. During the drainage period, participants stay in bed until the drain is removed.
45779314|NCT01496131|Radiation|Radiation therapy|Radiation therapy will be administered at a daily dose of 180 centigrays (cGy) 5 days a week for approximately 6 to 8 weeks.
45641100|NCT05888337|Device|Contoura LASIK with Phorcides planning strategy|Bilateral treatment with topography guided LASIK
45641101|NCT05888337|Device|Contoura LASIK with manifest refraction planning strategy|Bilateral treatment with topography guided LASIK
45641102|NCT05887739|Diagnostic Test|Inertial gait analysis|All groups will be evaluated with inertial gait analysis
45779315|NCT01496131|Drug|Goserelin|ADT (Goserelin) will be administered at a dose of 10.8 milligrams (mg) subcutaneously every 3 months for 24 months for the high risk group and for 6 months in the intermediate risk group, starting 2-3 months prior to radiation therapy.
45641103|NCT05886777|Biological|Combination [RSVpreF+BNTb162b2]|Combination of RSVpreF and Bivalent BNT162b2 given as a single intramuscular injection
45641104|NCT05886777|Biological|Bivalent BNT162b2 (original/Omi BA.4/BA.5)|Bivalent BNT162b2 given as an intramuscular injection
45641105|NCT05886777|Biological|RSVpreF|RSVpreF given as an intramuscular injection
45641106|NCT05886777|Biological|QIV|Licensed QIV given as an intramuscular injection
45641107|NCT05886777|Biological|Normal Saline Placebo|Normal saline (0.9% sodium chloride solution for injection)
45641108|NCT05884528|Biological|CC BoNT/A|Complex-containing BotulinumtoxinA (BoNT/A) formulations
45779316|NCT01496131|Drug|Cyclophosphamide|Cyclophosphamide will be administered at a single dose of 300 milligrams per square meter (mg/m^2) to a maximum of 600 mg, as an intravenous injection 3 days prior to the first administration of tecemotide (L-BLP25).
45641109|NCT05884528|Biological|CF BoNT/A|Complex-free BotulinumtoxinA (BoNT/A) formulation
45641110|NCT05884528|Biological|CF to CC BoNT/A|Switch from complex-free to complex-containing BoNT/A formulations
45641111|NCT05884528|Biological|CC to CF BoNT/A|Switch from complex-containing to complex-free BoNT/A formulations
45641112|NCT05882318|Device|eCoin Peripheral Neurostimulator System|The eCoin device is a leadless, coin-sized tibial neurostimulator for treatment of urgency urinary incontinence. It emits a dome-shaped electrical field to deliver low-duty cycle stimulation to the tibial nerve. The device is to be implanted under local anesthetic in the lower leg, and once activated delivers automatic 30-minute treatment sessions without the need for patient management.
45779317|NCT01496131|Drug|Tecemotide (L-BLP25)|Tecemotide (L-BLP25) will be administered at a dose of 918 microgram (mcg) as subcutaneous injection every 2 weeks for 5 doses followed by every 6 weeks for an additional 4 doses, starting 2-3 months prior to radiation therapy and on the same day that ADT began.
45779318|NCT02520726|Drug|Sertraline|< 65years: sertraline 50mg PO qday increasing by 50mg per day per week until 200mg for one week, then stop.
45779319|NCT02520726|Drug|Placebo oral capsule|Matched encapsulated placebo from 1-4 capsules daily
45641113|NCT05881837|Drug|HRS9531 injection|HRS9531 injection: dose level 1
45779320|NCT05062434|Other|Academic detailing and audit and feedback intervention|An academic detailing and audit and feedback intervention will be presented to VA cardiac electrophysiologists, and will include quantitative data about the individual physician's facilities cardiovascular implantable electronic device lead implants and national data on lead implants over the past year.
45779321|NCT01497613|Behavioral|PRISM C: Computer Condition|A specialized computer system designed to support social connectivity and access to resources; knowledge and prospective memory
45916350|NCT00006487|Drug|tirapazamine|"During induction:~Phase I low dose: 260 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~Phase II high dose: 330 mg/m2/day, IV on Days 1, 8, 29, 36 1 hour infusion~During consolidation:~330 mg/ m2, IV Day 1 only at approximately Week 11, Week 14. 1 hour infusion."
46070442|NCT00811681|Drug|pioglitazone|administered orally once a day after the first visit and for a total of 2 years. Initially, Pioglitazone will be started at 15mg /day. Dosage will then increase by 15mg /d/ week up to the maximal dose of 45mg /day
45641114|NCT05881837|Drug|HRS9531 injection|HRS9531 injection: dose level 2
45779322|NCT01497613|Behavioral|PRISM B: Notebook Condition|Telephone check-in calls and a notebook that contains information about community resources, games; topics of interests to seniors; a calendar and contact list.
45779323|NCT05126550|Biological|SARS-CoV-2 vaccine (Vero cell) inactivated|"Two doses of 0.5 mL intramuscular injection containing 4 mcg (6.5 Unit) antigens with an interval of 21-28 days in accordance with Vaksinasi Gotong Royong (mutual cooperation vaccination program)"
46070443|NCT00811681|Drug|Placebo|a placebo administered orally once a day after the first visit and for a total of 2 years.
46070444|NCT00811759|Drug|sorafenib tosylate|
46070445|NCT00811759|Drug|temozolomide|
45641115|NCT05881837|Drug|HRS9531 injection|HRS9531 injection: dose level 3
45641116|NCT05881837|Drug|HRS9531 injection|HRS9531 injection: dose level 4
45641117|NCT05881837|Drug|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 1
45641118|NCT05881837|Drug|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 2
45641119|NCT05881837|Drug|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 3
45641120|NCT05881837|Drug|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 4
45641121|NCT05881603|Other|" VExUS score  (Venous Excess Ultrasound Score)"|" VExUS score  (Venous Excess Ultrasound Score)"
45641122|NCT05880940|Device|Boost - Moveable Wheelchair Armrest|"The movable wheelchair arm rest device is a novel wheelchair armrest that quickly clicks into a manual wheelchair frame just like a conventional armrest. However, unlike a conventional armrest, the movable wheelchair arm rest device allows users to activate arm muscles in a way that is appropriate for the early stages of stroke recovery and consistent with the Feys et al. rocking chair approach: with biomechanical support of the shoulder, without high cognitive demand, and focusing on the out-of-synergy movement pattern that requires elbow extension. For the study, the investigators ask participants to exercise using Boost for a 30-minute period per day for 5 times a week in addition to their regular therapy until their discharge from the unit."
45779324|NCT02115542|Drug|Regorafenib|Four 40 mg regorafenib tables should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (<30% fat) breakfast.
45916351|NCT00006487|Radiation|radiation therapy|Radiotherapy should begin within 1 - 3 hours after completion of TPZ infusion on Day 1 of Cycle 1 of induction chemotherapy as outlined above. Computed tomography based treatment planning is strongly recommended.The primary tumor, adjacent mediastinum and other targeted lymph nodes shall receive 4,500 cGy in 25 fractions, five days/week at 180 cGy daily. A 1,600 cGy boost to areas of gross disease will be delivered through reduced off-spinal cord fields in eight fractions, five days/week at 200 cGy daily.
45916352|NCT05448261|Behavioral|Emotion-centered problem-solving intervention (EPi)|"The EPi is built upon the model of relational/problem-solving model of stress and is aimed at supporting caregivers in (1) revisiting stressful caregiving and associated problem from a psychological distanced perspective; (2) adopting problem orientation toward one's experience in the present moments with curiosity, openness and acceptance; and (3) applying the problem-solving skills learned for the enhancement of their psychosocial wellbeing in the stressful caregiving context. To reduce the incongruence between caregivers and stroke survivors in problem-solving, we will adopt a shared problem, shared action plan approach for the family caregivers and stroke survivors."
45916353|NCT05448261|Other|stroke education|Information is related to stroke and recurrent stroke and strategies for assisting stroke survivors in day-to-day activities.
45641123|NCT05880940|Behavioral|Electronic Arm and Hand Exercise Program|These exercises will be assigned to the participants electronically using a commercial home exercise program platform commonly used by hospital systems (i.e.: Medbridge). They will be encouraged to exercise for 30 min/day in addition to the regular rehabilitation therapy at ARU. These exercises will be monitored and supervised by therapists who have been trained in the study protocol. Once participants are discharged from the unit, they will be allowed to keep the electronic exercise program until their 3-month post stroke follow up visit, the last visit of the study. For this study, the investigators ask participants to exercise following this customized arm and hand exercise program for a 30-minute period per day for 5 times a week in addition to their regular therapy until their discharge from the unit.
45641124|NCT05880914|Other|Patients are mainteined to their clinically indicated treatment plan|All patients will be followed on their clinically indicated treatments for changes in bone turnover.
45779325|NCT01540513|Drug|NM404|"injection of 5.0mCi I-124 NM404 Arms: I124-NM404 brain metastases or GBM imaging~Other Names:~PET imaging with I-124 NM404"
45779326|NCT01540513|Drug|NM404|injection of an experimental imaging agent, 5mCi I-124NM404
45779327|NCT05061576|Behavioral|Standard of Care advice on physical activity|Oral advice on exercise from a physician.
45779328|NCT05061576|Behavioral|Structured advice on physical activity|A leaflet with instructions and images on different forms of physical activities as well as clear recommendations on when to perform these.
45916354|NCT00006493|Drug|Rosiglitazone|
45641125|NCT05880771|Other|Immediate Implant Placement|Tooth extraction followed by immediate implant placement. One group will have Allograft graft in the buccal gap, the other will have Xenograft graft.
45641126|NCT05879718|Drug|Placebo|Placebo (intravenous infusion)
45916355|NCT00008463|Drug|Ribavirin|
45916356|NCT00008463|Drug|Interferon alfa-2a|
45641127|NCT05879718|Drug|PF-06823859|PF-06823859 (intravenous infusion)
45779329|NCT05621486|Biological|B4T2-001 Autologous CAR T cells|Each subject will receive infusion with B4T2-001 autologous CAR T Cells
45779330|NCT02519712|Drug|Induction Chemotherapy|Patients with newly diagnosed AML will receive standard induction chemotherapy with daunorubicin and cytarabine (7+3 scheme). Patients who achieve CR may undergo consolidation chemotherapy at the discretion of the treating leukemia physician.
45779331|NCT02519712|Procedure|G-PBSC Infusion|G-CSF-mobilized peripheral blood cells will be collected from the donors in the Donor Room according to standard MSKCC BMT guidelines. Patients will be infused by infusion of unmanipulated G-PBSC from a haploidentical related donor.
45779332|NCT00450242|Drug|5% topical lidocaine ointment|Lidocaine 5% in hydrophilic petrolatum, dime-sized amount, applied nightly.
45916357|NCT00008463|Drug|Peginterferon alfa-2a|
45779333|NCT00450242|Drug|Placebo cream|hydrophilic petrolatum, dime-sized amount, applied nightly.
45779334|NCT05009238|Other|lumbar stabilization exercises|selected exercises will taught to participant and practiced 3 times per week for 6 weeks
45779335|NCT05124132|Behavioral|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction
45779336|NCT05124132|Behavioral|Exercise|Exercise
45779337|NCT05124132|Behavioral|Mindfulness-Based Stress Reduction + Exercise|Mindfulness-Based Stress Reduction + Exercise
45779338|NCT05124132|Behavioral|Health Education|Health Education
45779339|NCT05621252|Drug|PLN-74809|160 mg PLN-74809
45779340|NCT05621252|Drug|Placebo|Matching placebo
45779341|NCT00515528|Biological|4-peptide melanoma vaccine|Experimental cancer vaccine given as a shot under the skin once every two weeks
45779342|NCT00515528|Drug|Ontak|A single dose of Ontak given as an intravenous infusion over 30 minutes, 4 days before the first vaccine is given.
45916358|NCT00006505|Drug|Islet Transplantation|Islet cell transplantation. This study will test whether a new islet transplant procedure will enable patients with type 1 diabetes mellitus to stop insulin therapy
45916359|NCT00006508|Procedure|Controlled hypoglycemia using insulin|
45916360|NCT00006508|Procedure|formula meal|
45916361|NCT03612154|Drug|Lorlatinib|Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
45916362|NCT00006517|Device|bright light box|10,000 lux bright light therapy
46070446|NCT00811759|Genetic|gene expression analysis|
45779343|NCT05007444|Drug|P2Et (Caesalpinia spinosa extract)|Patients who meet inclusion criteria will begin taking 4000mg daily, distributed in 2 doses with meals of 2000mg of P2Et extract during neoadjuvant treatment. In case of presenting toxicity, it will be lowered to the next dose level, that is, 2000 mg under the same dosage schedule and 1000 mg following the same principle. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard neoadjuvant therapy and will restart 3 days after having passed the cycle. That is, in the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days after the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
45641128|NCT05879666|Behavioral|Online educational phthalate course|This is an online course focused on phthalates for reproductive health professionals. It consists of videos from patient, scientist, and OBGYN perspectives describing how phthalates relate to reproductive health. There is also an interactive module and worksheet to facilitate conversations about phthalates with pregnant individuals.
45779344|NCT05007444|Drug|Placebo|After determining the optimal biological dose (OBD), the patients will be divided into the placebo arm or the treatment arm. In the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking according to the asignation as stated in the drug intervention.
45779345|NCT00517010|Drug|Proton beam irradiation and ranibizumab|ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.
45641129|NCT05879250|Drug|WP1066|Orally administered as an outpatient
45641130|NCT05879224|Combination Product|Revised case management package|"Point-of-care quantitative G6PD testing using G6PDSTANDARD (SD Biosensor) prior to use of primaquine (Day 0)~Prescription of short course primaquine (7 mg/kg total)(Day 0):~PQ7 (1 mg/kg/day for 7 days) if G6PD activity greater than 70 percent~PQ14 (0.5 mg/kg/day for 14 days) if G6PDactivity is 30-70 percent~PQ8w (0.75 mg/kg/week for 8 weeks) if G6DPactivity less than 30 percent~Participant counselling at the health facility (Day 0):~Supervision of first dose of primaquine~Education regarding the importance and risks of primaquine therapy and necessity to take primaquine with food~Community based clinical review on Day 3 (and Day 7 for the first 300 participants) to detect and manage gastrointestinal or haemolytic adverse effects of treatment and encourage adherence to full treatment regime~Improved malariometric surveillance and pharmacovigilance to support wider scale use of the revised case management"
45641131|NCT05877963|Biological|Ublituximab|Administered as an IV infusion.
45641132|NCT05877716|Device|Cognitive and Social Cognitive Training|"The Cognitive Training Module is designed to improve the speed and accuracy of auditory information processing while engaging working memory and cognitive control under conditions of close attention and reward. The goal is to increase the effectiveness by which salient stimuli engage and drive plastic changes in brain systems that in individuals with psychosis exhibit relatively poor temporal response.~The Social Cognition Training Module consists of exercises designed to ameliorate core deficits in social cognition expressed in schizophrenia and Autism Spectrum Disorders. The exercises apply principles of implicit learning to restore the brain's capacity to process and utilize socially-relevant information, and include training to improve affect perception, social cue perception, theory of mind, self-referential style, and emotion labeling and working memory."
45779346|NCT05006430|Biological|Fecal Microbiota Transplantation|It's an intestinal microbial suspension prepared form stool obtained from carefully and thoroughly screened healthy human donors.
45779347|NCT05006430|Other|Placebo|Placebo will be identical to the investigational product but will not contain fecal material.
45779348|NCT00517556|Drug|CCOCP|(CCOCP) continuous treatment with Monophasic oral gestodene/ethinyl estradiol
45779349|NCT00517556|Drug|Traditional OCP|(traditional OCP) (21 active days/7 inactive days) treatment regimen
45916363|NCT00006517|Device|dawn simulator|gradual rise in bedroom illumination prior to wake-up
45916364|NCT00006517|Device|high-output negative ion generator|automated air ion delivery in bedroom prior to wake-up
45916365|NCT00006517|Device|low-output negative ion generator|automated air ion delivery in bedroom prior to wake-up
45916366|NCT00006517|Device|dawn light pulse|rectangular light pulse matched for lux.time of dawn simulation delivered prior towake-up
45916367|NCT00006565|Device|HEPA Air Cleaner|Placement of two active HEPA air cleaners in the homes of children
45916368|NCT00006565|Device|Placebo Filtration Unit|Placement of inactive filtration unit in the homes
45916369|NCT00006682|Drug|docetaxel|Docetaxel 70mg/m2 on day 1 of every 21-day cycle
45916370|NCT00006682|Drug|vinorelbine ditartrate|Navelbine 20mg/m2 on Day 1 and D8 of a 21-day cycle
45916371|NCT00008697|Drug|arsenic trioxide|
45916372|NCT00388141|Behavioral|NIDCAP|Systematic care, where the mother and the nurses organize the caring on behalf of the preterm infants' ressources and developmental capacity such as the infant avoid over stimulation and distress
45916373|NCT00006760|Biological|filgrastim|subcutaneously or IV over 15-30 minutes beginning 24-36 hours after completion of vinorelbine and continuing daily until blood counts recover.
45916374|NCT00006760|Drug|ifosfamide|V over 24 hours on days 1-4
45916375|NCT00006760|Drug|vinorelbine tartrate|IV over 6-10 minutes on days 1 and 5.
45916376|NCT00008736|Drug|metoclopramide|
45916377|NCT00006799|Drug|megestrol acetate|
45916378|NCT00006799|Procedure|quality-of-life assessment|
45641133|NCT05877716|Behavioral|Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App|The PRIME smartphone-based app is designed to be used for 12 weeks to enhance motivation in people with early psychosis. Participants work towards self-identified goals with the support of the virtual community of age-matched peers, as well as with motivation coaches. Participants discuss their interests and aspirations with each other and with their coach, and the coach sends daily individualized motivational messages. Coaches also provide tailored interventions to enhance motivation, and post daily discussion topics to the PRIME community to encourage interaction between members. Coaches will maintain close communication and feedback on progress with each individual's clinical team.
45641134|NCT05877716|Other|Early Psychosis Coordinated Specialty Care|Participants will continue to engage in treatment as usual at their early psychosis coordinated specialty care clinic. These clinics may follow the NAVIGATE model, as an example.
45641135|NCT05877625|Procedure|Expectoration care|"Endotracheal aspiration: from discarded samples after expectoration care~BALF (bronchoalveolar lavage fluid): if patients with fiber bronchoscope examination, take the rest of the BALF after examination~Oropharyngeal swabs"
45641136|NCT05877560|Device|Anodal-Transcranial Direct Current Stimulation|Non-invasive brain stimulation will involve the use of anodal transcranial direct current stimulation to apply a 2 milliamp current over the left frontal eye field for approximately 30 minutes with a ramp up to the maximum programmed current and ramp down of 10 seconds.
45641137|NCT05877560|Behavioral|Office-Based Vergence/Accommodative Therapy|Office-based vergence accommodative therapy involves weekly in-office appointments with the therapist lasting approximately 60 minutes per visit during which time in-office procedures will be performed, and home therapy procedures will be demonstrated. Participants will be prescribed 15 minutes of home reinforcement therapy procedures to be completed 5 days per week. Therapy will consist of two phases adapted from the Convergence Insufficiency Treatment Trial (CITT). Therapy procedures will include gross convergence, accommodation. non-computer based vergence, and computer-based vergence.
45641138|NCT05877560|Device|Sham Transcranial Direct Current Stimulation|Sham transcranial direct current stimulation will be applied over the left frontal eye field with the current ramping up for 20 seconds before ramping down for 20 seconds. The 2 milliamp current stimulation will occur for only a few seconds at the start and at the end of the 30 minutes.
45641139|NCT05876923|Procedure|Biospecimen Collection|Undergo collection of blood
45641140|NCT05876923|Other|Cardiopulmonary Exercise Testing|Undergo CPET
45641141|NCT05876923|Procedure|Dual X-ray Absorptiometry|Undergo DEXA scan
45641142|NCT05876923|Other|Electronic Health Record Review|Ancillary studies
45641143|NCT05876923|Other|Exercise Intervention|Undergo aerobic based training program
45641144|NCT05876923|Procedure|Physical Examination|Undergo measurement of height/weight and vital signs
45641145|NCT05876923|Other|Quality-of-Life Assessment|Ancillary studies
45641146|NCT05876923|Other|Questionnaire Administration|Ancillary studies
45641147|NCT05876923|Procedure|Spirometry|Undergo spirometry
45641148|NCT05875857|Behavioral|Opioid destruction education|Intervention group will receive a specialized handout and patient education on the safe storage of opioid medications, importance of opioid destruction, opioid destruction options and medication destruction (Deterra) bag before discharge.
45641149|NCT05875727|Biological|20-valent pneumococcal conjugate vaccine|One dose of 20vPnC will be administered intramuscularly.
46070447|NCT00811759|Genetic|mutation analysis|
45448673|NCT03737877|Other|Diet modification|"The parents will have four group sessions with a nutritional therapist, where in depth advice and information about the diet will be provided. Ongoing support will also be provided throughout the study by use of a closed Facebook or WhatsApp group (whichever the parents choose as most appropriate). The diet is based on five main principles:~Eat at least seven portions of different varieties of fruit and vegetables each day.~Have a 12 hour overnight break from food (water only during this time).~Drink a Kefir drink each day - provided free of charge.~Eat a microbiome friendly, protein rich, breakfast from our menu.~Reduce sugar and artificial sweeteners."
45916379|NCT00006877|Drug|temozolomide|
45916380|NCT00006994|Dietary Supplement|glutamine|20 cc three times daily for 60 days
45448674|NCT03750838|Behavioral|Text Messaging Intervention|The content for the TM Intervention will be designed to be non-confrontational in tone, seek to increase motivation to drink lightly or not at all, and based both on general information about light and non-drinking as well as information provided during the baseline assessment.
45641150|NCT05874492|Other|Thermal cure with a primary dermatological indication|The thermal treatment combines baths which have a sedative, muscle-relaxing effect and encourage joint mobilisation, sprays which have a decongestant effect and, above all, thread-like showers which are carried out by jets of thermal water under high pressure for several minutes plus educational workshops (relaxation, sophrology, hygiene...)
45916381|NCT00006994|Radiation|radiation therapy|Per institutional standard; minimum of 6,000 cGy with a daily dose of 180-200 cGy.
45916382|NCT00006994|Drug|l-glutamine placebo|20 cc three times daily for 60 days
46070448|NCT00811759|Other|laboratory biomarker analysis|
46070449|NCT00811759|Other|pharmacological study|
46070450|NCT00811759|Procedure|biopsy|
46070451|NCT00815893|Drug|dexmedetomidine|dexmedetomidine 1.0 mcg/kg infusion for 10minutes
46070452|NCT00815893|Drug|Normal Saline 0.9%|0.9% Normal Saline 0.25ml/kg infusion for 10minues
46070453|NCT00815893|Drug|propofol 1%|"Propofol: The initial target = 3 μg/ml. The TCI is adjusted by 0.5μg/ml according to patient comfort during the procedure.~The Orchestra® Base Primea(Fresenius, Brezins, France) offers a Target Controlled Infusion (TCI) target controlled infusion."
45779350|NCT05058456|Device|Shockwave Medical Mini S Peripheral IVL Catheter|The Shockwave Medical Mini S Peripheral IVL Catheter is intended for lithotripsy-enhanced catheter dilatation of lesions, including calcified lesions found in the peripheral vasculature, such as the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. The Mini S IVL Catheter is not for use in the coronary or cerebral vasculature.
45779351|NCT05057988|Behavioral|Empowered Relief class|The participants will attend the Empowered Relief class online via Zoom. The class includes pain neuroscience education, as well as cognition, emotion, and physiologic self-regulation for people with chronic pain. Class participants will learn self-management skills and develop a personalized plan to use the skills every day. Participants will receive an audio file (Relaxation Response) post-class. The class provides patients rapid access to actionable skills for symptom management and pain relief.
45641151|NCT05873361|Other|Questionnaire|The questionnaire is about hypocalcemia, dysphonia and anxiety. It will be carried out by phone call for 10 minutes
45641152|NCT05872854|Drug|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment
45779352|NCT00519584|Drug|Ropivacaine|30 ml 0.5%
45779353|NCT00519584|Drug|dex|8 mg (2 ml)
45779354|NCT00519584|Drug|Bupivacaine|30 ml 0.5%
45779355|NCT00519584|Drug|Saline|0.9% saline; systemic and local
45779356|NCT05057910|Diagnostic Test|SARS-CoV-2 IgG II Quant|3ml of blood samples are collected, contained in heparin-free tubes, and centrifuged. Blood serum samples are collected and stored at the -80 Celcius degree. SARS-CoV-2 IgG antibodies in human serum and plasma are detected using chemiluminescent microparticle immunoassay (CMIA) technology on the ARCHITECT I 1000r System. Quality Control procedures will take place once daily, with three levels: one negative control and two positive controls. Sample, SARS-CoV-2 antigen-coated paramagnetic microparticles, and assay diluent are combined and incubated. The SARS-CoV-2 IgG antibodies present in the sample bind to the antigen-coated microparticles. The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the titres of IgG antibodies to SARS-CoV-2 in the sample and the RLU detected by the system optics. Interpretation of Results: < 50.0 AU/mL, Negative, ≥ 50.0 AU/mL, Positive
45779357|NCT05122884|Drug|Milrinone|Prepare milrinone 20 mg with NSS 100 ml then starts dose 0.5 mg/kg/min for up to 12 hours.
45779358|NCT00520286|Drug|Modafinil|200 mg or 400 mg /daily
45779359|NCT00520286|Drug|Placebo|Placebo / daily
45779360|NCT01540825|Drug|BI 113608|Low dose powder for oral solution
45779361|NCT01540825|Drug|BI 113608|High dose powder for oral solution
45779362|NCT01540825|Drug|BI 113608|Medium dose powder for oral solution
45779363|NCT01540825|Drug|BI 113608|Low dose powder for oral solution
45916383|NCT00008775|Device|Pressure support ventilation|
46070454|NCT00816049|Drug|6MPindividualized|Oral 6-mercaptopurine with a starting dose of 25 mg/m2 and upward adjusted in steps of 25 mg/m2 (i.e. 50 or 75 mg/m2) if unacceptable bone-marrox toxicity is not encountered
45641153|NCT05872854|Other|Visible Light|After application of HyBryte (0.25% hypericin ointment), participants will be placed in a light booth containing fluorescent light bulbs to activate the HyBryte.
45641154|NCT05872347|Drug|SPH4336 Tablets|SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion; Exemestane：Administered by oral.
45641155|NCT05872321|Other|Complication|whether or not complications occur
45641156|NCT05871840|Other|Repeated Low-Level Red-Light (RLRL) Therapy|This treatment device was made by Eyerising SuzhouXuanjia Optoelectronics Technology, which has been on the market and used widely for amblyopia treatment for the past decade in China. This device is certified as a class IIa device by the China National Medical Products Administration. It consists of semiconductor laser diodes, which deliver low-level red light with a wavelength of 650 ±10 nm at an illuminance level of approximately 1600 lux through the pupil to the fundus. Based on calculations completed by an independent lab, the light power going through a 4-mm pupil is 0.29 mW and is classified as class 1 under the International Electrotechnical Commission 60825-1:2014 standard, which is at a level considered safe for direct ocular exposure that would not create retinal thermal hazard.
45641157|NCT05870891|Other|Food|Food
45641158|NCT05869422|Dietary Supplement|Iron|90 days of daily oral iron supplementation.
45779364|NCT01540825|Drug|Placebo|Powder for oral solution
45779365|NCT01540825|Drug|BI 113608|Low dose powder for oral solution
45779366|NCT01540825|Drug|BI 113608|High dose powder for oral solution
45779367|NCT01540825|Drug|BI 113608|High dose powder for oral solution
45779368|NCT01540825|Drug|BI 113608|Medium dose powder for oral solution
45779369|NCT01540825|Drug|BI 113608|Medium dose powder for oral solution
45779370|NCT01540825|Drug|BI 113608|Low dose powder for oral solution
45779371|NCT05122416|Device|FibroScan examination (S)|A FibroScan examination with the Exploratory S probe.
45779372|NCT05122416|Device|FibroScan examination (M)|A FibroScan examination with the Optimized M probe.
45779373|NCT05122416|Device|FibroScan examination (XL)|A FibroScan examination with the Exploratory XL probe.
45779374|NCT05122416|Device|FibroScan examination (Standard M)|A FibroScan examination with the Standard M probe.
45779375|NCT01796288|Radiation|simultaneous radiotherapy|
45779376|NCT01796288|Drug|Erlotinib|
45779377|NCT01395043|Procedure|Placing bilateral TAP-catheters preoperatively|Place bilateral TAP-catheters preoperatively and give repeated boluses of local analgetics in order to treat postoperative pain after colon-surgery.
45779378|NCT01395043|Drug|Bupivacain 2.5 mg/ml with epinephrine bolus in TAP-catheters|Intermittent boluses of Bupivacain 2.5 mg/ml with epinephrine, 20 ml in each catheter every 12 hours for the first 2 postoperative days.
45916384|NCT00007033|Drug|magnesium gluconate|
46070455|NCT00816049|Drug|6MPfixed|Oral 6-mercaptopurine at a fixed dose of 25 mg/m2 treatment days 30-85
46070456|NCT02550925|Behavioral|Acceptance and Commitment Therapy (ACT) Group|A 7-session Acceptance and Commitment Therapy (ACT) group intervention
46070457|NCT02550925|Behavioral|Usual Care|Check in with clinical social worker at oncology care site and obtain list of supportive resources
46070458|NCT04648891|Drug|Lidocaine|Subcutaneous lidocaine injection prior to laryngeal injection
46070459|NCT04648891|Device|Vibrating wand|Concomitant use of vibrating wand during laryngeal injection
45641159|NCT05869422|Other|Placebo|90 days of daily oral placebo intake.
45779379|NCT05573750|Behavioral|Singing group|Intervention involves singing groups with person with dementia and carer. Please see earlier descriptions.
45779380|NCT01542229|Behavioral|Prolonged Exposure for PTSD (PE) + Treatment as Usual (TAU)|12 weekly sessions of Prolonged Exposure in addition to Treatment As Usual
45779381|NCT01542229|Behavioral|Treatment As Usual (TAU)|Treatment as usual (TAU) will receive support services through the VA potentially inclusive of case management, psychotropic medication management, and/or supportive counseling
45641160|NCT05869149|Behavioral|Multilevel restaurant intervention to improve the food environment|FRESH is a restaurant-based intervention in low-income neighborhoods in Baltimore, MD and the Washington, District of Columbia metro area that aims to improve the healthy prepared-food environment for consumers, informed by community members and other stakeholders. FRESH intervention components include food preparation, food access and procurement, and consumer nutrition environment. Activities will take place over 16 months, and include training restaurant chefs to use healthier cooking methods, partnering with restaurant suppliers to offer healthier ingredients, and offering point-of-purchase promotions to educate customers on the healthier promoted food options. Intervention staff will form strong relationships with restaurant owners and chefs via in-person visits at least twice a month. Data from the intervention trial will inform the development of a system dynamics simulation model that will allow stakeholders to test new policy ideas prior to implementation.
45779382|NCT00520910|Drug|Polypodium leucotomos|Subject is given a 7.5 mg/kg oral dose of Polypodium leucotomos during Baseline visit, and again at 8 hours and 2 hours before the Follow-up visit #2.
45641161|NCT05868785|Dietary Supplement|Parenteral nutrition|Parenteral nutrition will be administered starting at 8 pm
45916385|NCT00007033|Drug|magnesium sulfate|
45641162|NCT05868785|Dietary Supplement|Parenteral nutrition|Parenteral nutrition will be administered starting at 8 am
45641163|NCT05868382|Biological|mRNA-1010|Sterile liquid for injection
45916386|NCT00388401|Drug|Alvimopan|
45916387|NCT00388180|Drug|GW501516|
45641164|NCT05868382|Biological|mRNA-1010.4|Sterile liquid for injection
45641165|NCT05868382|Biological|mRNA-1010.6|Sterile liquid for injection
45641166|NCT05868057|Drug|SHR7280 tablets|SHR7280 tablets 1 time
46070460|NCT04648891|Other|Control|Laryngeal injection without additional anesthesia
45641167|NCT05868057|Drug|SHR7280 dry suspension|SHR7280 dry suspension 1 time
45641168|NCT05867329|Drug|Cyclosporine Injection (IV)|"Drug be administered as weight-based continuous infusion (2mg/kg/day) during the second stage of treatment (if applicable).~Cyclosporine monitoring will take place approximately 18-24 hours stage of treatment (Day 4 at the earliest). The goal is to achieve whole blood levels of 300 (range 200-400) ng/ml with adjustments according to the table in the protocol. The intravenous cyclosporine dosage is rarely raised above 4 mg/kg/day, in rare patients that are fast metabolizers."
45641169|NCT05867329|Drug|Cyclosporine Oral Product|"Once participants meet discharge criteria, participant's that received IV Cyclosporine (stage 2) will be transitioned to oral Cyclosporine.~The oral dose is calculated to be approximately twice the daily intravenous dose or approximately 5 mg/kg, rounded to nearest 25 mg, and is administered every 12 hours (h). Oral cyclosporine solution will be administered as Sandimmune capsules available in 25mg 100mg capsules size.~After the intervention period (during hospitalization after IV cyclosporine is complete) and during the follow-up period any cyclosporine adjustments are permissible under the current study protocol according to the discretion of the treating physician."
45641170|NCT05867329|Drug|Upadacitinib Extended Release Oral Tablet|"This will be administered orally once daily as 45mg (stage one) or twice daily as a 30mg oral tablet (first stage and second stage) of treatment (if applicable).~Upon discharge a patient will be switched from Upadacitinib 30mg twice daily to 45mg daily for 8 weeks followed by 30mg or 15mg subsequently if Upadacitinib is to be continued after discharge. The choice of induction/maintenance agent initiated after discharge will be determined by inpatient treatment team and in consultation with the outpatient gastroenterologist. No patient will continue Upadacitinib 30mg twice daily after discharge from the hospital."
45779383|NCT00521456|Drug|ketorolac eye drops|"1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day~Placebo"
45779384|NCT01542307|Biological|Oxygen|Oxygen is inhaled for 30 minutes during migraine attack
45779385|NCT01542307|Biological|Room air|Placebo
45779386|NCT01796366|Drug|insulin 338 (GIPET I)|Each subject will be allocated to one of three dosing periods only. The subject will receive oral insulin 338 and placebo, administered subcutaneously (s.c., under the skin) once daily for 10 days at fixed dose levels.
45779387|NCT01796366|Drug|placebo|S.c placebo administered in combination with insulin 338
45779388|NCT01796366|Drug|insulin glargine|Each subject will be allocated to one of three dosing periods only. The subject will receive insulin glargine for s.c. administration and oral placebo once daily for 10 days at fixed dose levels.
45779389|NCT01796366|Drug|placebo|Oral placebo administered in combination with s.c. insulin glargine
45916388|NCT00388180|Drug|GW590735|
45916389|NCT00007189|Drug|Naproxen Sodium (Aleve)|
45916390|NCT00007189|Drug|Celecoxib (Celebrex)|
46070461|NCT04045015|Dietary Supplement|Liqourice|Liqourice corresponding to 1.5, 3.0 or 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
45916391|NCT00388219|Drug|Transtec (R) PRO (buprenorphine)|
45916392|NCT00388258|Drug|Alvimopan|
45916393|NCT00388336|Drug|Epoetin Alfa|
45916394|NCT00388375|Procedure|Ultrasound|limited ultrasound examination to evaluate the following areas: Examination of the subclavian and internal jugular veins to assess proper catheter placement PTX detection, using lung sliding and comet-tail artifact Visualization of the heart (right atrium and ventricle) and the inferior vena cava through the subcostal window
45916395|NCT05636046|Procedure|transseptal catheterization|puncture of interatrial septum at the level of fossa ovalis, using transseptal needle.
45916396|NCT00007267|Behavioral|Cognitive behavioral therapy|
45916397|NCT00007267|Behavioral|Disease/health education|
45916398|NCT00007267|Behavioral|Self-help cognitive behavioral intervention facilitated by a psychologist|
46070462|NCT00811837|Drug|Midazolam|Intravenous infusion
46070463|NCT00811837|Drug|Remifentanil|Intravenous infusion
46070464|NCT00817609|Drug|Angongniuhuang Pill|7 days of Angongniuhuang Pill
45779390|NCT05120544|Behavioral|EXTEND Plus|The EXTEND Plus approach builds patient self-management capacity by focusing on knowledge, self-efficacy, and goal setting (using an RN-delivered, module-based approach). All material is at an 8th grade reading level. Module topics include, but are not limited to, use of self-monitoring of blood glucose (SMBG), BP monitoring, developing a diet plan, medication adherence, hypoglycemia and hypotension self-management, and self-managing insulin. In addition, this intervention component addresses diet and activity self-management during each encounter.
45779391|NCT05120544|Behavioral|EXTEND|EXTEND patients self-manage using data they collect during the study, and continue to receive standard behavioral counseling from primary providers.
45779392|NCT03326180|Drug|Liposomal bupivacaine|266mg/20ml vial of EXPAREL
45779393|NCT03326180|Drug|Bupivacaine hydrochloride|100mg/20ml 0.5% bupivacaine hydrochloride. Branded or generic, must be plain (cannot contain adrenaline/epinephrine)
45641171|NCT05867329|Drug|Intravenous Methylprednisolone|Drug will be administered as 30mg twice daily during the first stage of treatment (if applicable) and through the second stage of treatment (if applicable). Prior to discharge a patient will be switched from IV Methylprednisolone to prednisone 40-60mg with plans to taper by 5mg/week (dose subject to adjustment by treating inpatient team and in consultation with the outpatient gastroenterologist).
45779394|NCT01498549|Drug|Atomoxetine|Atomoxetine 40mg and 80mg compared to the sugar pill
45779395|NCT01498549|Drug|Sugar Pill|Sugar pill compared to Atomoxetine 40mg and 80mg.
45779396|NCT05055570|Other|No intervention|No intervention
45641172|NCT05867329|Drug|Prednisone Oral Product|Patients that received IV Methylprednisolone will be switched prior to discharge from IV Methylprednisolone to prednisone 40-60mg with plans to taper by 5mg/week (dose subject to adjustment by treating inpatient team and in consultation with the outpatient gastroenterologist).
45641173|NCT05866913|Procedure|Sciatic nerve slippage.|Sciatic nerve slippage.
45641174|NCT05866913|Procedure|Passive stretching of the hamstring muscles.|Passive stretching of the hamstring muscles.
46070465|NCT00817609|Drug|placebo|7 days of placebo
45779397|NCT05549102|Behavioral|Cognitive Behavioural Therapy|In the Cognitive Behavioural Therapy group (N=87), patients will undergo CBT as part of their routine care in Step 3 of the IAPT programme. This will be administered by suitably trained clinicians. The specification of CBT is as recommended by the National Institute for Health and Care Excellence (NICE) guidelines (CG113 - Generalised anxiety disorder and panic disorder in adults: management). In these guidelines, patients are offered on average, 12-15 hourly, weekly sessions of CBT with a trained and competent practitioners. Therapy sessions involve discussions that identify patterns in thinking or behaviours which may be problematic, and therapists and patients work to set goals to reduce these using cognitive techniques. The principle is to teach the patient how to use CBT techniques in their day-to-day life to promote a lasting effect on mental health. We will test patients before (T1) and after (T2) a course of treatment.
45779398|NCT05549102|Other|Waiting List|In the control group (N=87), we will test patients who are currently seeking (but not undergoing) treatment before (T1) and after a wait (T2) of equivalent time (i.e. waiting list controls)
45779399|NCT05119920|Drug|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
45779400|NCT05119920|Drug|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
45779401|NCT05119920|Drug|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
45779402|NCT05119920|Drug|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
45779403|NCT01499173|Behavioral|Stroke Preparedness Intervention|A faith-based, scientific theory-driven, peer-led behavioral intervention performed in a group setting in African American churches.
45779404|NCT01796444|Procedure|Sentinel Lymph Node Biopsy|Sentinel lymph nodes are identified with the combining use of intraoperative gamma detector and/or blue dye.
45916399|NCT00007306|Drug|Parathyroid hormone ointment|
46070466|NCT00811915|Drug|Sirolimus|"Sirolimus introduction and tacrolimus withdrawal~Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14. Sirolimus daily dose according to CYP3A5 genotype CYP3A5*1/*1 or *1/*3: 4 mg/d CYPY3A5*3/*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml"
45641175|NCT05866913|Procedure|passive shoulder mobilization.|passive shoulder mobilization.
45641176|NCT05866770|Device|U8|The U8 Research System
45641177|NCT05866770|Device|N8 sound processor|Nucleus 8 sound processor
45641178|NCT05865171|Drug|IXP|Tablets for oral administration.
46070467|NCT00816127|Drug|Desmopressin|intranasal desmopressin (300μg)
46070468|NCT00816127|Biological|blood transfusion|fresh frozen plasma 10ml/kg and/or 1 unit of single donor platelets
46070469|NCT00916058|Drug|Bendamustine|30 mg/m^2 given on day 2 of melphalan
46070470|NCT00916058|Drug|Melphalan|100 mg/m^2 for 2 days (70 mg/m^2 for patients with Creatinine Clearance <70 ml/min)
46070471|NCT00916058|Drug|Bendamustine|60 mg/m^2 given on the 2nd day of melphalan
46070472|NCT00916058|Drug|Bendamustine|90 mg/m^2 given on the 2nd day of melphalan
45779405|NCT01796444|Procedure|Intraoperative Pathological Examination|touch imprint cytology and/or frozen section and/or OSNA
45641179|NCT05864456|Device|Prizvalve Pro™ transcatheter aortic valve system|Transcatheter Aortic Valve Replacement
45641180|NCT05864326|Device|Warm group|The operator will introduce a 14Fr or 18Fr Balloon catheter through the cervical canal, up above the internal orifice using a long Pean clamp and inflate the internal balloon with 30 to 80ml of Heated saline water (NaCl 0.9%) at 40°C - according to the mechanic resistance with a graduated syringe.
45641181|NCT05864326|Device|Room temperature group|The operator will introduce a 14Fr or 18Fr Balloon catheter through the cervical canal, up above the internal orifice using a long Pean clamp and inflate the internal balloon with 30 to 80ml of unheated saline water (NaCl 0.9%) - according to the mechanic resistance with a graduated syringe.
45641182|NCT05863130|Drug|BI 764198 (C-14) (approach 1)|BI 764198 (C-14) (approach 1)
45641183|NCT05863130|Drug|BI 764198 (C-14) (approach 2)|BI 764198 (C-14) (approach 2)
45779406|NCT01796444|Procedure|Axillary Lymph Node Dissection|Axillary lymph node dissection involving removal of at least level I and II nodes.
45641184|NCT05862909|Other|CHD-specific web-based emotion regulation intervention|CHD-specific web-based emotion regulation intervention with ten video-based sessions covering emotional challenges of CHD and effective emotion regulation strategies (i.e., reappraisal, acceptance, problem solving, distraction, rumination, avoidance, suppression). To integrate the intervention into emotional experiences occurring in the daily life of patients with CHD, the sessions are supported by everyday emotion regulation exercises using an ecological momentary intervention.
45641185|NCT05862909|Other|General web-based emotion regulation intervention|General web-based emotion regulation intervention with ten video-based sessions covering topics related to emotional awareness and effective emotion regulation strategies (i.e., reappraisal, acceptance, problem solving, distraction, rumination, avoidance, suppression). To integrate the intervention into emotional experiences occurring in daily life, the sessions are supported by everyday emotion regulation exercises using an ecological momentary intervention.
45641186|NCT05861999|Drug|risdiplam|Participants will receive risdiplam orally at the currently approved dose. The dose should be adapted for weight and age.
45641187|NCT05861986|Drug|risdiplam|Participants will receive risdiplam orally at the currently approved dose. The dose should be adapted for weight and age.
45641188|NCT05861856|Other|Manual therapy|Mobilization for the spine, mobilization and relaxation methods for the soft tissues around the spine will be performed.
45641189|NCT05861856|Other|Virtual reality|Virtual reality supported core stabilization exercises will be performed.
45641190|NCT05860972|Device|Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.|After subjects meet the eligibility criteria, they will be randomized with a 1:1 ratio to one of two treatment groups: Active or Sham. Subjects will receive two active or sham treatments, one month apart, with the InMode RF Pro System with the Morpheus8 Applicator and 24 pins tip and will return for three follow up visits: 4 weeks 12 weeks and 24 weeks post the second treatment
45641191|NCT05860881|Drug|Sirolimus Topical Cream|The intervention topical cream consists of sirolimus 1% in a vehicle. Patients randomised to the intervention will be required to apply the sirolimus topical cream to their face for 6 months
45641192|NCT05860881|Other|Placebo|Cream containing only the base, or vehicle.
45641193|NCT05860660|Behavioral|survey|questionnaires
45641194|NCT05860465|Drug|SPH4336 Tablets|SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
45641195|NCT05860465|Drug|SPH4336 Tablets Placebo|SPH4336 Tablets Placebo ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
45641196|NCT05860400|Behavioral|Healthy life style|Healthy diet, regular exercise, and quitting smoking
45641197|NCT05860400|Drug|Secondary prevention for atherosclerotic coronary artery disease|Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose
45641198|NCT05860400|Drug|Immunosuppressive therapy|Glucocorticoids and/or immunosuppressive agents
45641199|NCT05860400|Procedure|Coronary revascularization|Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).
45641200|NCT05860400|Drug|Supportive therapies|Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.
45779407|NCT01796444|Procedure|Pathological Evaluation|H&E and IHC
45779408|NCT01796444|Drug|Adjuvant Systemic Therapy|Adjuvant systemic therapy was determined by the treating physician according to the recently NCCN.
46070473|NCT00916058|Drug|Bendamustine|60 mg/m^2 given on the 1st and 2nd day of melphalan
45641201|NCT05860270|Drug|Cholecalciferol|Patients in the intervention group will receive oral cholecalciferol 4000U per day.
45641202|NCT05860270|Drug|Placebo|Patients in the control group will receive placebo 2 capsules per day.
45641203|NCT05860140|Other|Education video|Six minutes long education video focusing on protein and energy meals
45641204|NCT05859464|Drug|ZL-1218|ZL-1218 dose escalation
45641205|NCT05859464|Drug|Pembrolizumab|Combination treatment with ZL-1218
45779409|NCT01796444|Radiation|Radiation Therapy|Whole-breast opposing tangential-field radiation therapy.
45641206|NCT05859295|Device|Red Low-Level Light Therapy|Visible red light (633nm) projected onto the face using an light emitting diode (LED) mask
45779410|NCT04226508|Other|Physical exercise|"The patients can choose between three modality of EX:~Autonomous supervised training : a personalized activity is proposed. People choosing this modality have a written material, in which all the exercise, the activity, the frequency, the duration, the intensity are specifically described and reported, to perform the training at home. A training diary and 7 meetings (face to face, or skype or other modality) are proposed for monitoring the intervention.~Personal training program: a personalized activity is proposed. Patients are followed individually in a gym contest by a qualified kinesiologist.~Group training program: the training is performed in a small group, supervised and monitored by a qualified kinesiologist. The instructor-user ratio is 1:4 - 1:8, depending on the functional conditions and the heterogeneity of the participants."
45779411|NCT01542541|Drug|Rifaximin|550mg BID for 2 days
45641207|NCT05858996|Behavioral|Pain-CPG-EIT|"Following randomization champions and stakeholder team members from the communities will be identified. The investigators will recommend the following individuals to be members of the stakeholder team: a nurse in a leadership position (e.g., director of nursing); the designated champion(s); nursing home administrator; physician/medical director, nurse practitioner and/or physician assistant; unit nurse; nursing assistant; activity staff; social worker; pharmacist; and rehabilitation therapists.~Following the first stakeholder team meeting, treatment communities will be provided with a research nurse facilitator to work 8 hours weekly during months one and two and then for four hours weekly starting in month three for a total of 12 months to provide the four components of the PAIN-CPG-EIT."
46070474|NCT00916058|Drug|Bendamustine|90 mg/m^2 given on the 1st day of melphalan and 60 mg/m^2 given on the 2nd day of melphalan
45641208|NCT05858996|Other|Pain-CPG-Education Only|The Pain-CPG-Education only group will be provided with the same education as used in Component II of the Pain-CPG-EIT intervention. The education will be provided based on the preferences of the community (this may be face-to-face; online; or via handouts).
45641209|NCT05858268|Genetic|Whole-genome sequencing|Whole-genome sequencing
45641210|NCT05857644|Drug|PF-07923568|One time dose of 4 capsules taken orally.
45641211|NCT05856656|Behavioral|Music therapy|Music therapy is a technique of care, accompaniment and support, which aims to improve health and well-being.
45641212|NCT05856331|Drug|INBRX-101|A1PI, Recombinant, Bivalent Fc Fusion Protein
45641213|NCT05856331|Drug|Zemaira|Alpha1-Proteinase Inhibitor (Human)
45641214|NCT05856305|Drug|Chlorophyllin, Sodium Copper Complex|Additional Chlorophyllin tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose
45641215|NCT05856305|Drug|Placebo|Additional Placebo tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose
45641216|NCT05856227|Drug|Ceftobiprole medocaril|Ceftobiprole medocaril: 7.5 mg/kg every 12 hours to 15 mg/kg every 8 hours, administered IV as a 2-hour infusion.
45641217|NCT05856058|Drug|SHR0302|SHR0302 oral solution 1 time, SHR0302 tablets 1 time
45641218|NCT05855421|Device|Auricular Acupuncture|Aplication of semi-permanents needls in the ear by an experient and specialized professional using tradicional chinese maps and a specific device to find acupuncture points. There is a gap of one day minimum between sessions and two non-consecutive absences are allowed.
45641219|NCT05854069|Behavioral|FAMS-T1D|"FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled.~Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly."
45641220|NCT05854069|Behavioral|Digital resources for diabetes|Quality digital resources about diabetes management provided upon enrollment and during the study.
45641221|NCT05853835|Drug|LPX-TI641|LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).
45916400|NCT00007423|Biological|ALVAC-HIV MN120TMG (vCP205)|
45916401|NCT00007423|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
45641224|NCT05851625|Device|Press needle acupuncture|Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
45641225|NCT05851625|Device|Plesterin|The plaster used is a round plaster that resembles the shape of an acupuncture press needle.
45641226|NCT05851443|Drug|povorcitinib|povorcitinib
45641227|NCT05851443|Other|placebo|placebo
45641228|NCT05851443|Drug|ICS-LABA|Background Therapy
45641229|NCT05851430|Device|PEF ablation|Pulsed Electric Field (PEF) Ablation per institutional standard of care
45641230|NCT05849337|Behavioral|Brief imagery-competing task|Two digital self-guided sessions of a brief digital imagery-competing task. A memory cue followed by playing a computer game with mental rotation instructions.
45641231|NCT05849337|Behavioral|Brief psychoeducation and signposting task|Two digital self-guided sessions and access to psychoeducation and signposting regarding resources for psychological trauma in Iceland.
46070475|NCT00916058|Drug|Bendamustine|125 mg/m^2 given on the 1st day of melphalan and 100mg/m^2 given on the 2nd day of melphalan
46070476|NCT05228678|Diagnostic Test|cardiopulmonary exercise tests|"Spirometry~forced expiratory volume in 1 second (FEV1) % predicted,~forced vital capacity (FVC)% predicted,~forced expiratory volume in 1 second /forced vital capacity FEV1 /FVC"
45641232|NCT05849337|Other|Treatment as usual (TAU)|Routine care that participants would otherwise receive if having intrusive memories of traumatic events
45641233|NCT05848739|Drug|ST316|IV
45641234|NCT05848700|Drug|SEP-363856|SEP-363856 Tablet
45641235|NCT05848700|Drug|Placebo|Placebo Tablet
45641236|NCT05848375|Procedure|Arthroscopic rotator cuff repair|The operation involves systematic acromioplasty during the supra +/- infraspinatus repair and sometimes requires a tenotomy of the long biceps if it is pathological.
45641237|NCT05848375|Drug|naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA associated to GA)|Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance associated to General Anesthesia performed by injection of diprivan and ultiva.
45641238|NCT05848375|Drug|naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA)|Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance
45641239|NCT05847608|Dietary Supplement|Omega-3|Daily consumption of 500 mg DHA and 750 mg EPA in liquid form
45779412|NCT05054946|Procedure|Laparoscopic cystectomy|All surgeries will be performed under general anesthesia by laparoscopically.
45916402|NCT00007501|Biological|Varicella-zoster vaccine|Immunization with 0.5 ml, live, attenuated (Oka/Merck) varicella-zoster vaccine.
45916403|NCT00007501|Biological|Placebo|Placebo vaccine
45916404|NCT00007657|Procedure|Intensive medical therapy|
45916405|NCT00007657|Procedure|Percutaneous Coronary Intervention (PCI) plus intensive medical therapy|
45916406|NCT00007735|Drug|Doxycycline (200mg/day) or Placebo|
45641240|NCT05847608|Dietary Supplement|Placebo|Oleic Acid, Linoleic Acid
45641241|NCT05847387|Diagnostic Test|V-Check|Preoperative analysis of endothelial tissue staining with vital dye (Trypan Blue 0.05%) and image analysis to identify the percentage of Trypan Blue Positive Areas, corresponding to dead endothelial cells and/or denuded areas of endothelium, in tissues destined to keratoplasty
45641242|NCT05847153|Behavioral|MASC|"The intervention arm will be comprised of:~Six Virtual Group Sessions. The sessions will teach mindfulness, self-compassion and behavioral management skills.~At Home Practice. After each group session, participants will have the opportunity to integrate the practices learned into their everyday life."
45779413|NCT00524264|Drug|ketorolac|"Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.~Placebo"
45779414|NCT05119218|Other|No Intervention|No Intervention
45779415|NCT05505110|Procedure|Vaginal Seeding|Following delivery by C-section, participating infants randomized to the intervention group will have their nasal cavity swabbed with maternal vaginal secretions.
45779416|NCT05505110|Procedure|Sterile Swab|Following delivery by C-section, participating infants randomized to the control group will have their nasal cavity swabbed with a sterile swab.
45779417|NCT01395277|Dietary Supplement|High Flavanol first then Low Flavanol|The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
45779418|NCT01395277|Dietary Supplement|Low Flavanol first then High Flavanol|The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
45779419|NCT00452426|Device|Computer-Assisted Personalized Sedation (CAPS) Device (SEDASYS® System)|propofol sedation per device instructions for use
45779420|NCT00452426|Other|benzodiazepines and opioid sedation|per site's current standard of care
45779421|NCT01396837|Device|RedDress Wound Care System (RD1)|Weekly application. A blood based wound care treatment
45779422|NCT04999488|Drug|BPM31510|A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
45779423|NCT04999488|Other|Placebo|A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
45448675|NCT03750838|Behavioral|Active Control|Participants will receive a series of TM based on nutritional data on the same schedule as those in the TM intervention and will complete a 6 week post-intervention assessment as well as all follow-ups.
45448676|NCT03733587|Drug|GX-I7|GX-I7 25mg/ml/vial
45448677|NCT03733587|Drug|Cyclophosphamide|Cyclophosphamide 500mg/vial
45641243|NCT05847114|Other|Stres ball|Stress ball compression for 15 minutes during surgery
45779424|NCT05117814|Drug|Zanubrutinib|as long as 24 months or consolidated with ASCT or WBRT after achieving PR or CR
45779425|NCT04999254|Other|Medical treatment|"Medical treatment will be based on functional treatment and the doctor will prescribe the RICE protocol. For this, the patient will have to :~place an ice pack on the sprain~apply sports rest for three weeks~compress the sprain with a compression stocking when standing in order to prevent phlebitis. In addition, to avoid this complication, the doctor will prescribe an anticoagulant.~raise the foot with crutches during the day~elevate the foot at night or when doing an activity in a sitting position, using a cushion for example.~In addition, the doctor will prescribe anti-inflammatory drugs to ease the pain and physiotherapy to establish proprioception, muscle strength, joint range and dynamic postural balance of the sprain."
45779426|NCT04999254|Other|osteopathic treatment|Each patient will be treated as a whole and within a time limit of 45 minutes. The consultation will start with a medical history followed by medical tests. Then, the osteopath will perform osteopathic tests and manual treatment.
45779427|NCT00524342|Drug|Oprelvekin, Interleukin 11, IL-11|25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
45779428|NCT01545193|Other|Age and incidence of residual neuromuscular blockade|An older cohort is anticipated to have a higher incidence of residual neuromuscular blockade
45448678|NCT04364074|Dietary Supplement|Goodbelly|Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This will be followed by an observation period for 6 weeks during which the subjects will not consume Goodbelly.
45779429|NCT05117658|Drug|HA121-28 tablet|HA121-28 tablet, 450 mg, po, QD×21 days, every 4 weeks (28 days)
45779430|NCT00524576|Biological|Engerix™-B|One dose (10µg Hepatitis B surface antigen (HBsAg))
45779431|NCT04950660|Drug|Caffeine Tablet|Caffeine is approved by the FDA as a stimulant. A stimulant approved by the United States Food and Drug Administration (FDA) for the treatment to increase mental alertness and in combination with painkiller to treat migraine headaches. It is approved in the form of pill or tablet.
45779432|NCT04950660|Drug|Placebo|Placebo, empty opaque dark blue blank capsule, taken twice daily. This will be an adjuvant to their standard pain control.
45779433|NCT02516202|Drug|Vagifem|One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.
45779434|NCT02516202|Device|Replens|2.5 gm to be applied vaginally every 3 days over 12 weeks.
45779435|NCT02516202|Other|Placebo tablet|Dispensed in visually identical bottle and tablet form to Vagifem.
45779436|NCT02516202|Other|Placebo gel|Dispensed in visually identical tube and gel form to Replens.
45779437|NCT00526058|Device|Secura then Futura|Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.
45916407|NCT00007774|Drug|Haloperidol|
45641244|NCT05846776|Device|DigiPrehab system|Using an Artificial Intelligence-Machine Learning (AI-ML) DSS platform, which analyzes a large collection of data (screening and local data) from different sources, the DigiPrehab system will allow to predict the risk of falling in the elderly subjects. Once the screening will be completed, to carry out the prevention of falls, the system will assign to the participants a personalised exercise program that the patient will carry out at home for 12 weeks. The exercises will be chosen from the following: squat at door, squat on chair, squat with knee-lift, squat with heel-raise, stand-no support, toe-raise with support, toe-raise, one leg balance, weight-shift with support, weight-shift without support, lunge with support, lunge, step on book, step over book, step onto box or stair, step forward-sideways, step forward-sideways-backwards, knee to elbow, timed up and go.
45641245|NCT05845749|Drug|Vosoritide Injection [Voxzogo]|Vosoritide will be given via a once daily subcutaneous injection at a dose of 15 ug/kg/day, at approximately the same time each day when feasible. Vosoritide will be supplied to the subject as 0.4 mg vial, 0.56 mg vial or 1.2 mg vials to be reconstituted with sterile water up to 0.8 mg/mL or 2 mg/mL concentrations for injection. The volume to be administered (injection volume) will be based on the subject's body weight and the concentration of vosoritide. All supplies will be provided to the subject for home based administration after training at the study site.
45641246|NCT05845450|Drug|Trastuzumab deruxtecan|trastuzumab deruxtecan 5.4 mg/kg IV on day 1
45641247|NCT05845450|Drug|Durvalumab|durvalumab 1500 mg IV on day 1
46070477|NCT04253288|Other|Morbidity Mortality Review (MMR)|"Standardization of Morbidity Mortality Review (MMR) in radiotherapy centers~National database from MMR board meetings which include clinical , radiation technique and biological parameters of intrinsic radiosensitivity of patients"
45641248|NCT05845450|Drug|Panitumumab|panitumumab 6 mg/kg IV on days 1 and 15
45641249|NCT05845450|Drug|Botensilimab|botensilimab 1 mg/kg on day 1
45641250|NCT05845450|Drug|Balstilimab|balstilimab 3 mg/Kg on days 1 and 15
45779438|NCT00526058|Device|Futura then Secura|Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.
45779439|NCT04950504|Drug|CNP-201|CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of ~5 μg of PPE per mg of PLGA.
45779440|NCT04950504|Drug|Placebo|CNP-201 Placebo
45779441|NCT00526292|Biological|natural killer cell therapy|The patient must be admitted by Day -8 to the Bone Marrow Transplant Service. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor and will be monitored for hematopoietic recovery.
45779442|NCT00526292|Drug|cyclophosphamide|Day -6 cyclophosphamide 60mg/kg infused over 1 hour (dose adjusted for body weight) for 2 days
45779443|NCT00526292|Drug|fludarabine|Day -5 fludarabine 25mg/m2 CIV for 5 days
45779444|NCT05115396|Other|Mirror therapy|The patient shall be seated in a chair with a table in front of him/her. On the table there is a mirror in the sagittal plane between the two upper extremities. The affected hand will be behind the mirror, without visibility, while the hand without symptoms will be reflected laterally in the mirror. Thus, the mirror will reflect the movements of the unaffected side as if these movements were executed with the affected side. During the procedure, patients will be instructed to concentrate on the hand reflected in the mirror.
45779445|NCT05115396|Other|Cross-education treatment|Participants will perform the same exercise protocol with the unaffected hand and without the use of a mirror.
45779446|NCT04949490|Biological|BNT162b2s01|intramuscular (IM) injection
45779447|NCT04949490|Biological|BNT162b2|IM injection
45779448|NCT02121860|Drug|IDN-6556|
45779449|NCT04203810|Device|Ectoin® Mouth and Throat Spray Althaea Honey (ERS09)|4 puffs to be administered as needed several times a day for patients aged ≥ 12 years. A maximum of 10 applications per day should not be exceeded.
45779450|NCT04203810|Device|EMSER® Hals-und Rachenspray (throat spray)|1 to 3 puffs to be administered several times a day
45779451|NCT02122406|Other|Hospital Anxiety and Depression Scale (HADS) questionnaire|Patients filled in the Hospital Anxiety and Depression Scale (HADS) questionnaire
45779452|NCT03184454|Device|Medtronic Percept Deep Brain Stimulation|"Deep Brain stimulation involves bilateral stereotactic placement of stimulating leads into specific brain structures. Leads are attached to permanent subcutaneous wires and battery-powered implantable neurostimulators (INSs). Noninvasive INS programming can achieve a balance between maximal benefit (reduction in disabling OCD symptoms), while minimizing adverse effects (eg sensorimotor effects such as dysarthria or paresthesias; as well as behavioral side effects, e.g., hypomania, insomnia, or increased anxiety)."
45779453|NCT05113446|Diagnostic Test|Delirium assessment using S-CAM|Twice a day, the rounds of nurses in shifts, 8:00 am - 10:00 am, 4:00 pm - 6:00 pm Trained research assistants assessed delirium using S-CAM
45779454|NCT04521140|Drug|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
45779455|NCT04521140|Drug|Prednisolone Acetate 1% Oph Susp|Prednisolone Acetate 1% is a corticosteroid used as a topical drop after corneal transplant to decrease inflammation and prevent graft rejection
45779456|NCT04420806|Other|HIT-exercise|13 months of high intensity endurance and resistance exercise, 3x 45 min/week - 3 months of COVID-19 induced exercise break
45779457|NCT04420806|Other|Sham intervention|Types of exercise (flexibility, relaxation) that did not affect the present outcomes
45779458|NCT04211766|Dietary Supplement|Dietary Fiber|Given fiber supplement
45779459|NCT04211766|Dietary Supplement|Fish Oil|Given fish oil supplement
45641251|NCT05845138|Drug|SHR-A1811 for injection ; capecitabine|SHR-A1811 for injection; Capecitabine tablets
45779460|NCT04211766|Other|Placebo|Given fiber supplement placebo
45779461|NCT04211766|Other|Placebo|Given fish oil supplement placebo (corn oil)
45916408|NCT00007774|Drug|Olanzapine|
45779462|NCT05298332|Drug|ATI-2173 50 mg|ATI-2173 is a phosphoramidate prodrug of the oral, non-chain terminating nucleoside analog clevudine being developed by Antios Therapeutics, Inc. for treatment of men and women with chronic hepatitis B (CHB)
45779463|NCT04211610|Diagnostic Test|Blood and urine sampling|"Blood tests - hs-cTnT, hs-cTnI, complete metabolic panel including urea, creatinine, albumin and myoglobin~Urine tests - hs-cTnT, hs-cTnI, urea, creatinine, albumin, total protein, β2-microglobulin."
45779464|NCT04211220|Other|A decision support software|Insulin pump Continuous glucose monitoring
45779465|NCT01545583|Drug|LY3016859 intravenous|Administered intravenously
45779466|NCT01545583|Drug|Placebo intravenous|Administered intravenously
45779467|NCT01545583|Drug|LY3016859 subcutaneous|Administered subcutaneously
45779468|NCT01545583|Drug|Placebo subcutaneous|Administered subcutaneously
45641252|NCT05844176|Other|Routine clinical treatment|Routine clinical treatment is based on the latest international and local guidelines
45779469|NCT04210362|Behavioral|Workshops on responsive caregiving|Caregivers will receive monthly workshops about several dimensions of nurturing care, responsive caregiving and early child development. Workshops will be reinforced through home visits.
45779470|NCT02124044|Drug|Asunaprevir and Daclatasvir|Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients
45779471|NCT02124044|Drug|Asunaprevir and Daclatasvir with BMS-791325|Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients
45779472|NCT01502761|Drug|Magnesium Sulfate|Intra-arterial
45779473|NCT05112276|Other|Diet|A review has been undertaken to both identify specific bacteria associated with cardiometabolic risk factors and food items that have been shown to affect such bacteria in a beneficial direction. The intervention diet will include a variety of food items e.g. vegetables, fermented vegetables, fermented dairy products and cereal products. The control diet is based on a Swedish Average Diet
45779474|NCT02124122|Biological|Lactobacillus reuteri|Probiotic
45779475|NCT02124122|Biological|Placebo|Placebo
45779476|NCT01504477|Drug|Panitumumab and bortezomib|"Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.~Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle."
45916409|NCT00007813|Biological|filgrastim|
45779477|NCT02124512|Drug|Rifaximin SSD|Study Drug dosing will be 80 mg SSD once daily
45779478|NCT02124512|Other|Placebo|80 mg placebo once daily
45779479|NCT05111886|Behavioral|Communication Skills Training|The training will focus on communication skills based on key constructs in the Health Belief Model and motivation/resistance research (described in section A3), the training will focus on: (1) conveying the benefits of parenting programs, (2) knowledge of and responses to common perceived barriers to attending parenting programs, and (3) skills and strategies to effectively motivate and refer parents in ways that are least likely to elicit resistance. The in-person training will last 60-90 minutes. It will include a theoretical background and experiential learning; each step of the referral process will be demonstrated and role-played. The investigators will work to ensure that personnel receive continuing education credits for the training.
45779480|NCT05111886|Behavioral|eHealth GenPMTO|The GenPMTO is delivered over the phone (not online). This version is up to 6 sessions in length. This brief eHealth version of GenPMTO will be delivered through community therapists. The program will be delivered one-on-one (i.e., between a therapist and a parent or couple).
45779481|NCT05111886|Behavioral|Written Referral Process|"A written summary and process map of the referral process, modeled on the Institute for Healthcare Improvement (IHI) 9-step process for closing the loop on referrals."
45779482|NCT05111886|Behavioral|One Session Education about Resources|"One online or phone conversation with the therapist in which the therapist guides the parent to the following resources: (a) a book, Raising Cooperative Kids, by GenPMTO co-developer Marion Forgatch; (b) a website, behaviorchecker.org, which includes behavioral prescriptions for common behavior issues; and (c) information about Early Childhood and Family Education classes, which are provided for free in Minnesota through public schools."
45779483|NCT05111886|Diagnostic Test|Survey of Experience|Satisfaction with referral process
45779484|NCT01504711|Drug|fosaprepitant dimeglumine|Given IV
45779485|NCT05148260|Behavioral|Learning Through Play plus (LTP+)|Group-1: Experimental (n=40 participants) will receive the LTP+ which consist of a total of 12-group integrated treatment sessions lasting approximately 60-90 minutes per session every fortnight with 10 mother/child pair per sub-group.
45916410|NCT00007813|Drug|carboplatin|
45779486|NCT05148260|Behavioral|Psychoeducation|Group-2: Controlled (n=40 participants) will receive 'psychoeducation' which consist of a total of 12-group sessions lasting approximately 60-90 minutes per session every fortnight with 10 mother-child pair per sub-group.
45779487|NCT05131880|Other|GAIT RE-EDUCATION PROGRAM ON A SEQUENTIAL MAT IN SUBJECTS WITH PARKINSON'S DISEASE|"Randomized controlled study that will include participants diagnosed with Parkinson's disease in mild or moderate stage with altered gait pattern who will be randomized following a simple randomization procedure in which one group will perform an intervention based on a gait re-education program called TAPIZ FISIOR- motor control and learning added to a conventional physiotherapy program; and the other group will perform only a conventional physiotherapy program. The evaluators will be unaware of the patient's treatment condition."
45779488|NCT04993950|Other|sustained natural apophyseal glides|SNAGS will be applied in flexion, extension and rotation for a few seconds with 3 repetitions on the first day and 10 repetitions from the next visit.
45916411|NCT00007813|Drug|cyclophosphamide|
45916412|NCT00007813|Drug|etoposide|
45916413|NCT00007813|Procedure|autologous bone marrow transplantation|
45916414|NCT00007813|Procedure|peripheral blood stem cell transplantation|
45641253|NCT05843773|Procedure|Low Load Strength Training under Blood Flow Restriction|"The first training includes one initiation/warm up set and two sets of normal training. Every set lasts 60 seconds and the patient is asked to bend and stretch the knee with a standard speed of 20°/s.~From the second to the ninth training, the patient will have one warm up set plus three trainings sets. The speed of execution will be increased every training.~The 20-40% range of the 1RM will be applied according to the values of the theoretical maximal strength.~If no strength progression is observed in the three last training sessions, the speed of execution will automatically be increased by 15°/s.~In order to keep the training intensity low and to not overload the knee, participants will be instructed to control the intensity with the Borg CR10. The volunteers will have to keep their efforts between 2/10 and 4/10. They will also be asked to stay in the range defined thanks to the theoretical maximal strength shown by the screen."
45641254|NCT05842239|Device|Hyperbaric oxygen therapy|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
45779489|NCT04993950|Other|SNAGS with thoracic postural correction techniques|thoracic extension in sitting, Wall angle stretch and Corner stretch, while the therapist-facilitated stretches will be seated mid-thoracic stretch and prone mid thoracic stretch. Stretches will be maintained for 15-20 seconds with 10 repetitions of each stretch per session
45779490|NCT02208349|Device|King Video Laryngoscope|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
45448679|NCT04364074|Dietary Supplement|Placebo|To prepare the placebo, the dietitian will first heat a water bath to 80 degrees Celsius. This removes the lactobacillus plantarum 299v from the probiotic drink
45779491|NCT02208349|Device|traditional direct laryngoscopy (DL)|
45779492|NCT04993716|Other|observational|Collect from a bank of biological samples, identification of prognostic factors associated with survival without serious neurological heavy sequelae
45779493|NCT04842266|Device|IlluminOss Pelvic Implant for the Treatment of Impending and Actual Pathological Fractures in the Pelvis from Metastatic Bone Disease|The study design is prospective and single center with the purpose of evaluating the performance of the IlluminOss Pelvic Implant in the treatment of pain due to impending or actual non-displaced or minimally displaced pathologic fractures of the pelvis secondary to metastatic malignancy in skeletally mature adults.
45779494|NCT04842266|Device|IlluminOss Pelvic Implant for the Treatment of Geriatric Pelvic Fractures|The study design is prospective and single center with the purpose of evaluating the performance of the IlluminOss Pelvic Implant in the treatment of pain due to geriatric pelvic fractures.
45779495|NCT02209519|Drug|Metronidazole (male partner)|500 mg PO BID for 7 days
45779496|NCT02209519|Other|Placeob (male partner)|matching placebo capsules PO BID for 7 days
45779497|NCT01546285|Device|Blood Pressure Readings on B40 Patient Monitor|Simultaneous blood pressure reading on the Investigational B40 patient monitor and DINAMAP PRO1000 patient monitor
45779498|NCT01397071|Other|Avocado|Fresh Avocado
45779499|NCT01546675|Other|Skeletal Stabilization|Upper Limb Prosthetic Socket hypothesized to increase skeletal stabilization
45779500|NCT01397617|Device|NobelActive Internal implant|Dental implant
45916415|NCT00007852|Biological|rituximab|Rituximab at 375 mg/m2 administered approximately one week apart prior to collection of the hematopoietic stem cells. Rituxan at a dose of 375 mg/m2 IV will be given either on the days prior to initiation of the BCNU (days -10 to -7) or on the same day that the BCNU is administered for the BEAM chemotherapy regimen (Day -6). A fourth infusion of Rituxan 375 mg/m2 will be given at 30 day (+/- 20 days) post-transplant. At approximately 6 months post-transplant, if the patients have not had progressive lymphoma, they will receive four weekly doses of Rituxan 375 mg/m2 IV.
45916416|NCT00007852|Drug|carmustine|BCNU 300 mg/M2 IV day -6
45448680|NCT00126581|Drug|Carboplatin|Given IV
45779501|NCT01397617|Device|NobelActive External implant|Dental implant
45779502|NCT01397617|Device|NobelReplace Tapered Groovy implant|Dental implant
45779503|NCT01397851|Device|Insecticide-treated net (BASF Incerceptor)|One per farmer, once during the 2010-2011 season
45779504|NCT02518620|Biological|ALX-0061|Subjects received ALX-0061 150 mg s.c. injections, beginning at Week 0 and q2w thereafter, up to and including Week 102. Subjects from the preceding study ALX0061-C201 also continued their MTX treatment.
45779505|NCT02129660|Drug|Dose 1 of glycopyrrolate, 2.0% QD|Dose 1 of glycopyrrolate Topical Wipes
45779506|NCT02129660|Drug|Dose 2 of glycopyrrolate, 3.0% QD|Dose 2 of glycopyrrolate Topical Wipes
45779507|NCT02129660|Drug|Dose 1 of glycopyrronium, 2.5% QD|Dose 1 of glycopyrronium Topical Wipes
45779508|NCT02129660|Drug|Dose 2 of glycopyrronium, 3.75% QD|Dose 2 of glycopyrronium Topical Wipes
45779509|NCT02129660|Other|Vehicle|Vehicle Topical Wipes
45448681|NCT00126581|Drug|Erlotinib|Given PO
45448682|NCT00126581|Drug|Erlotinib Hydrochloride|Given PO
45448683|NCT00126581|Drug|Paclitaxel|Given IV
45641255|NCT05840666|Other|Mulligan Sustained Natural Apophyseal Glide (SNAG)|Application of the MWM technique developed by Brian R. Mulligan. The clinical researcher will perform and holds sustained passive segmental glide at the target joint maintaining the slack whereas the patient will actively move in the direction of pain or stiffness. These MWM techniques when applied to spinal segments or joint is called sustained natural apophyseal glide (SNAG).
45779510|NCT04797650|Drug|CTP-543, 8 mg BID|8 mg twice-daily (BID)
45779511|NCT04797650|Drug|CTP-543, 12 mg BID|12 mg twice-daily (BID)
45779512|NCT04797650|Drug|Placebo, BID|Placebo, twice-daily (BID)
45779513|NCT01398475|Drug|LY3009104|Administered orally
45779514|NCT04946370|Drug|225Ac-J591|Alpha-emitter Actinium-225 conjugated to the anti-PSMA antibody J591.
45779515|NCT04946370|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously, 400mg every 6 weeks. Patients may receive maximum 18 cycles of therapy, approximately 2 years.
45916417|NCT00007852|Drug|cytarabine|100 mg/m2 on days -5 through -2
45916418|NCT00007852|Drug|etoposide|100mg/M2 BID on days -5 through -2
45779516|NCT04946370|Drug|Androgen receptor pathway inhibitor|Patients will receive an oral androgen receptor pathway inhibitor (ARPI). Examples include enzalutamide and apalutamide. Dosing will be the standard dosing, as described by the package insert.
45641256|NCT05840666|Other|McKenzie Method|An active therapy technique involving repeated movements or sustained positions along with an educational component prescribed to the patient for of minimizing the pain and disability and increase the spinal range of motion. The method will involve the assessment of symptomatic and mechanical responses to repeated movements and sustained positions in the direction of preference. The method will be used for assessment and treatment of patients and with derangement syndrome.
45641257|NCT05840666|Other|Conventional Physical Therapy|It includes usual physical therapy care such as Therapeutic Ultrasound, Moist Heat-pack, TENS and standard exercises.
45641258|NCT05839730|Device|Pacemaker PLR + TRT ON|RAMware modified implantable pulse generator (IPG) with personalized lower rate (PLR) and tachycardia remodeling therapy (TRT) on
45916419|NCT00007852|Drug|melphalan|140 mg/m2 IV on day -1
45916420|NCT00007852|Procedure|autologous hematopoietic stem cell transplantation|Following the chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
45641259|NCT05839730|Device|Pacemaker PLR ON|RAMware modified implantable pulse generator (IPG) with personalized lower rate (PLR) on
45641260|NCT05839184|Device|therapeutic toy|Neonates in the therapeutic toy group will be given an octopus-shaped therapeutic toy that they can hold in their hands throughout the procedure and IV catheter will be inserted and their comfort levels and vital signs will be monitored.
45641261|NCT05839041|Drug|AVD-104|Intravitreal injection
45916421|NCT00007891|Biological|filgrastim|
45641262|NCT05839041|Procedure|Sham injection|A sham injection with no scleral penetration
45641263|NCT05838664|Drug|No OAC|AF Patient who were not exposed to oral anticoagulation
45641264|NCT05838664|Drug|VKA|AF patients who received VKA
45641265|NCT05838664|Drug|apixaban|AF patients who received apixaban
45641266|NCT05838664|Drug|rivaroxaban|AF patients who received rivaroxaban
45916422|NCT00007891|Procedure|autologous bone marrow transplantation|
45448684|NCT03704584|Drug|Treatment Group: Corticosteroid injection|Subjects will receive a corticosteroid injection that is 40 mg/mL injection of Methylprednisolone or 40mg/mL injection of methylacetate injectable suspension or 40 mg/mL triamcinolone.
45448685|NCT03704584|Drug|Control Group (corticosteroid alone)|Control Group (corticosteroid alone) subjects will receive (40 mg/mL injection of Methylprednisolone acetate injectable suspension or 40 mg/mL triamcinolone) .
45641267|NCT05838664|Drug|dabigatran|AF patients who received dabigatran
45641268|NCT05836792|Other|Cycle Ergometer|Patients will attend cycle ergometer exercise. Volunteers will monitor their pedaling forces as right and left force. They will try to make these forces equal while they are pedaling.
45641269|NCT05836792|Device|Transcutaneous electrical nerve stimulation|Transcutaneous electrical nerve stimulation will be used for the reduction of pain. TENS will be used 5 times in a week for 3 weeks. Each procedure will take 20 minutes.
45779517|NCT04946370|Diagnostic Test|68Ga-PSMA-11|[185 ±74 MBq or 5 ±2 mCi] intravenous during screening and 12 weeks. Imaging agent for PSMA PET/CT.
45779518|NCT04946136|Other|Gait modification|Individualized gait modifications guided by real-time visual feedback of knee load
45916423|NCT00007891|Procedure|peripheral blood stem cell transplantation|
45916424|NCT00007891|Radiation|indium In 111 monoclonal antibody BrE-3|
45916425|NCT00007891|Radiation|yttrium Y 90 monoclonal antibody BrE-3|
45916426|NCT00007930|Procedure|conventional surgery|
45916427|NCT00007930|Procedure|laparoscopic surgery|
45916428|NCT00007969|Biological|Detox-B adjuvant|
45916429|NCT00007969|Drug|verteporfin|
45448686|NCT03704584|Drug|Treatment Group: Lidocaine|Subjects will receive an injection of lidocaine (1% lidocaine HCl).
45641270|NCT05836792|Device|Ultrasound|Ultrasound will be used for increase the permeability of cells to treat pain and inflammation. US will be used 5 times in a week for 3 weeks. Each procedure will take 5 minutes
45641271|NCT05836792|Other|Isometric exercises|The aim of the isometric exercises is increasing muscle strength. Each session patients will do quadriceps isometric exercises 5 times in a week for 3 weeks
45779519|NCT04235582|Behavioral|App + Inputs Contingency Management|The app has programmed contingencies whereby incentives can be earned for behaviors that are inputs to abstaining from drug use (e.g., attending psychotherapy or taking SUD psychopharmacology).
45916430|NCT00008008|Biological|filgrastim|
45916431|NCT00008008|Biological|sargramostim|
45916432|NCT00008008|Drug|cyclophosphamide|
45916433|NCT00008008|Drug|thiotepa|
45916434|NCT00008008|Procedure|autologous bone marrow transplantation|
45916435|NCT00008008|Procedure|bone marrow ablation with stem cell support|
45916436|NCT00008008|Procedure|peripheral blood stem cell transplantation|
45916437|NCT00008047|Drug|fluorouracil|
45916438|NCT00008047|Drug|hydroxyurea|
45916439|NCT00008047|Drug|paclitaxel|
45916440|NCT00008047|Procedure|conventional surgery|
45916441|NCT00008047|Radiation|radiation therapy|
45779520|NCT04235582|Behavioral|App + Outcomes Contingency Management|The app has programmed contingencies whereby incentives can be earned for outcomes of abstaining from drug use (e.g., drug-negative saliva samples on saliva opioid tests).
45779521|NCT01549405|Other|İntercostal nerve block|Nerve block group was administered two levels intercostal block (11 and 12th ribs) with 0.5% bupivacaine with epinephrine before surgery.
45779522|NCT04945044|Device|Computed adenoma detection system (CADe)|This is a computed system that helps the endoscopist to increase the detection of colorectal polyps
45779523|NCT04945044|Behavioral|Control group (regular colonoscopy)|It is exclusively the endoscopist in charge of the detection of the polyps (usual practice)
45916442|NCT05636397|Dietary Supplement|L-Citrulline|Citrulline is a nonessential amino acid made in the small intestine, occurs naturally in the body, and is believed to help reduce inflammation.L-CIT is a part of the urea cycle, produced as a by-product along with nitric oxide (NO).
45916443|NCT00008086|Dietary Supplement|calcitriol|
45641272|NCT05836779|Drug|CBL-514 injection|CBL-514 will be administered at the raised area of cellulite.
45641273|NCT05836220|Drug|PLS240|Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.
45641274|NCT05836220|Drug|Placebo|Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.
45641275|NCT05836220|Drug|Open-Label Extension PLS240|Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.
45641276|NCT05835895|Genetic|GNSC-001|intra-articular injection
45779524|NCT01797770|Drug|polyethylene glycol|mechanical bowel preparation with polyethylene glycol one day prior to surgery
45779525|NCT01797770|Other|No Preparation|No laxatives or bowel preparation
45916444|NCT00008086|Drug|carboplatin|
45916445|NCT00008125|Biological|filgrastim|
45916446|NCT00008125|Drug|carboplatin|
45916447|NCT00008125|Drug|docetaxel|
45641277|NCT05835895|Drug|transient immune-modulation|oral
45641278|NCT05835895|Drug|Placebo|intra-articular injection
45641279|NCT05834426|Diagnostic Test|Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)|For metabolomic analysis, different portions of the blood (plasma and lymphocytes) will be subjected to metabolite extraction by the extraction method defined by Glasgow Polyomics. With protein precipitation, 200 microliters (uL) of the fluid with the metabolites is transferred to a new microtube and must be maintained at -80 °C until the time of metabolomic analysis.
45641280|NCT05832931|Drug|PLS240|Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.
45641281|NCT05832931|Drug|Placebo|Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.
45779526|NCT05109780|Device|My EMI, Emotional Well-being + self-applied online transdiagnostic treatment|The intervention will consist in a self-applied online transdiagnostic intervention for emotional problems together with an app-based EMI. In terms of monitoring, the My EMI, Emotional Well-being is a mobile app whose contents have been adapted to conduct ecological momentary assessments in different health conditions. The app assesses important psychological variables, namely anxiety, depressive symptoms,etc. Participants respond daily to the questions in the app. In terms of the online self-applied intervention, the Unified Protocol is a transdiagnostic extension of CBT which works on regulate emotions in a more adaptive way through 5 core treatment modules: present-focused emotional awareness, cognitive flexibility, identification and prevention of emotional avoidance patterns, increasing awareness and tolerance to emotion-elicited physical sensations, and graded (interoceptive and situational) exposure procedures.
45779527|NCT01505179|Drug|Ranolazine|Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
45916448|NCT00008125|Drug|gemcitabine hydrochloride|
45916449|NCT00008164|Procedure|umbilical cord blood transplantation|
45916450|NCT00008203|Biological|aldesleukin|
45916451|NCT00008203|Biological|recombinant interferon gamma|
45916452|NCT00008203|Drug|carboplatin|
45916453|NCT00008203|Drug|cyclophosphamide|
45916454|NCT00008203|Drug|cyclosporine|
45916455|NCT00008203|Drug|thiotepa|
45916456|NCT00008203|Procedure|autologous bone marrow transplantation|
45916457|NCT00008203|Procedure|peripheral blood stem cell transplantation|
45916458|NCT00008242|Drug|dexamethasone|
45916459|NCT00008242|Drug|doxorubicin hydrochloride|
45916460|NCT00008242|Drug|thalidomide|
45916461|NCT00008281|Drug|FOLFOX regimen|
45916462|NCT00008281|Drug|fluorouracil|
45448687|NCT03662997|Device|Bordered Five-Layer Foam Dressing|Bordered, five-layer, flexible foam dressing with soft silicone adhesive technology
45448688|NCT03662997|Device|Hydropolymer Foam Dressing|Hydropolymer, adhesive foam island dressing
45448689|NCT03662997|Device|Hydrocellular Multi-Layer Foam Dressing|Multi-layered, hydrocellular foam dressing with silicone adhesive
45641282|NCT05832931|Drug|Open-Label Extension PLS240|Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.
45916463|NCT00008281|Drug|leucovorin calcium|
45916464|NCT00008281|Drug|oxaliplatin|
45916465|NCT00008320|Drug|ceramide|
45916466|NCT00008359|Drug|caspofungin acetate|
45916467|NCT00008359|Drug|liposomal amphotericin B|
45916468|NCT00008398|Biological|sargramostim|
45916469|NCT00008398|Procedure|quality-of-life assessment|
45916470|NCT00008398|Radiation|radiation therapy|
45916471|NCT00008437|Device|high-intensity focused ultrasound ablation|
45916472|NCT00008476|Drug|Capsaicin|
45916473|NCT00008515|Drug|Fluocinolone|
45916474|NCT00008554|Drug|Abacavir sulfate|
45779528|NCT01505179|Drug|Placebo|Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
45779529|NCT01797848|Drug|Peginterferon alfa 2a|
45779530|NCT01797848|Drug|Ribavirin|
45779531|NCT01797848|Drug|Placebo matching Daclatasvir|
45779532|NCT01797848|Drug|Daclatasvir|
45779533|NCT04944576|Device|Total Ankle Prosthesis, EasyMove®|Patients who will be implanted with a total ankle prosthesis, EasyMove.
45779534|NCT04740632|Behavioral|Personalized Nutritional Counseling by a multidisciplinary team|Active diet therapy, instructions on reading labels, cross-contamination, allergen-free, foods recipes
45779535|NCT04580810|Behavioral|CBT4CBT in the Black Church|Use of Computer Based Treatment for Cognitive Behavioral Therapy for alcohol use disorder offered in a Black church setting
45641283|NCT05832411|Device|Endoangle|there is additional information presented to endoscopists:（1）the virtual stomach model monitoring；（2）time;（3）scoring.
45779536|NCT01398943|Drug|Tetrahydrobiopterin (BH4)|single dose = 5 mg/kg
45779537|NCT01398943|Dietary Supplement|Antioxidant Cocktail|1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid
45779538|NCT04118660|Other|Tissue Banking|Blood, tissue, and fluid collection
45779539|NCT04372862|Procedure|Plane block|Two different plane blocks to control post-mastectomy pain
45641284|NCT05832008|Behavioral|Patient Nudge|Framed Messaging - brief persuasive messaging to increase awareness about the risks and benefits of lung cancer screening and completion of recommended follow-up sent to patients via text message.
45641285|NCT05832008|Behavioral|Clinician Nudge|EHR-based Prompts - an EHR-based prompt that alerts a clinician if a patient is due for screening or diagnostic follow-up.
45641286|NCT05831904|Device|whole-body vibration|After attaching the surface electromyography(EMG) to bilateral hip girdle muscles, participants will walk and jump at their comfortable speed. After investigator record the muscle activation values, participants will be asked to stand on the vibration device. While the whole-body vibration is applied, the hip girdle muscles activation values will be recorded accordingly via sEMG.
45779540|NCT01550341|Drug|Buprenorphine/naloxone|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
45779541|NCT01550341|Drug|Placebo Oral Tablet|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
45916475|NCT00008554|Drug|Nelfinavir mesylate|
45641287|NCT05831540|Other|Discussion|Participate in focus group
45641288|NCT05831540|Other|Educational Activity|Undergo training to use CDS tool
45641289|NCT05831540|Behavioral|Healthcare Activity|Utilize CDS tool
45641290|NCT05831540|Other|Survey Administration|Complete survey
45641291|NCT05831228|Dietary Supplement|Ketogenic food products|Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
45641292|NCT05831228|Dietary Supplement|Control: Placebo|Participants will be given a dietary supplement comparator prior to the hyperbaric oxygen exposure.
45641293|NCT05831124|Other|Low dose multivalent pneumococcal conjugate vaccine formulation A|Biological
45779542|NCT02125292|Drug|Mesalamine|
45779543|NCT01401517|Drug|sodium nitrite|0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.
45779544|NCT05079698|Drug|177Lu-PSMA-617|Intravenous (IV) infusion of 177Lu-PSMA-617 on Day 1 of treatment Cycles 1 and 2. PSMA PET utilizing either the 68Ga-PSMA-11 or 18F-DCFPyL tracer is acceptable. Patients should be restaged using the same tracer which was utilized to establish initial eligibility for the trial.
45779545|NCT05079698|Procedure|Stereotactic Body Radiotherapy (SBRT)|No later than 5 weeks (+/- 7 days) after the 2nd cycle of 177Lu-PSMA-617, patients will then undergo SBRT (900 cGy x 3 fractions).
45779546|NCT05038436|Device|Polyglucosamine L112|Two tablets once daily per os
45779547|NCT02214277|Device|Cerebral Protection System-The SENTINEL System with TAVR|Claret Medical Sentinel Cerebral Protection System is intended for use as an embolic protection system to contain and remove embolic material (thrombus/debris) that may enter the carotid arteries.
45779548|NCT02214277|Device|TAVR|
45779549|NCT02126306|Drug|Beta Glucosylceramide|Beta Glucosylceramide
45779550|NCT02126306|Drug|Placebo|normal saline
45779551|NCT01550731|Behavioral|PREPARE website|Advance care planning website and materials plus an advance directive.
45779552|NCT01550731|Behavioral|Advance directive|The control group will only receive an advance directive.
45779553|NCT02127632|Device|Endotracheal Tube|ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
45779554|NCT02127632|Device|Laryngeal Mask Airway-Supreme|"Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based K-YTM gel (Johnson & Johnson Ltd. Maidenhead, UK) without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.~Other Names:~LM-S (The Laryngeal Mask Company Limited, Singapore) serial number: 175030 lot: hmabw7"
45779555|NCT01550809|Other|iBolus|Insulin bolus calculated from data obtained through CGM
45779556|NCT01550809|Other|tBolus (traditional bolus)|Insulin bolus dose calculated using the standard procedure based on the insulin-to-carbohydrate ratio
45916476|NCT00008554|Drug|Lamivudine|
45916477|NCT00008554|Drug|GW433908|
45916478|NCT00008827|Behavioral|Behavioral weight loss|
45641294|NCT05831124|Other|Low dose multivalent pneumococcal conjugate vaccine formulation B|Biological
45779557|NCT01551199|Behavioral|Multiple Channel Exposure Therapy- Veterans|Individual therapy design completed over a 12-week period. The treatment will include psychoeducation about panic attacks and trauma and behavioral and cognitive exposure exercises.
45779558|NCT03905876|Other|Questionnaire|Questionnaire to evaluate psychological experience
45779559|NCT01653912|Drug|GSK2110183 in combination with carboplatin and paclitaxel|Phase I is a dose escalation evaluation of increasing doses of GSK2110183 administered on a continuous daily schedule in combination with carboplatin AUC 5 and paclitaxel 175mg/m2 given every three weeks for a maximum 6 cycles. The dosing regimen identified in Phase I will then be evaluated in Phase II, a single arm study focused on clinical efficacy. Treatment with the three drug regimen will continue for a maximum of 6 x 21 day cycles followed by continuous GSK2110183 at the single agent MTD. Subjects may continue on study drug until progression, death or unacceptable toxicity.
45779560|NCT01551979|Device|Repetitive Transcranial Magnetic Stimulation|"intermittent Theta Burst (iTBS) pattern (20 trains of 10 bursts given with 8s intervals) will be applied at 80% of active motor threshold. Each participant will receive 600 pulses per session.~Sham participants will undergo the same procedures as those in the active rTMS group."
45779561|NCT03833258|Behavioral|Rehabilitation with no precautions|Patients will recover from total hip replacement surgery being guided by pain only and not by the precautions imposed upon them by clinicians.
45779562|NCT04132388|Other|Electronic Reporting|"The electronic reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter.~Subjects will return for evaluation at 12 & 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit."
45779563|NCT04132388|Drug|Adalimumab|Subjects will be instructed to take Humira according to the labelled dosing regimen. Treatment will be for 26 weeks
45779564|NCT04944030|Procedure|Metastasis biopsy|Metastasis biopsy will be performed for multi-omic analysis Biological/Vaccine: Biomarkers blood, urine and microbiota samples Biomarkers blood, urine and microbiota samples for multi-omic analysis Behavioral: Patient Reported Outcome (PRO) Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.
45779565|NCT01552213|Other|Minimum intervention control group|A single visit with a dietician or health educator to discuss general health risks, good eating habits, and appropriate weight gain. This will be followed by routine prenatal care per provider.
45779566|NCT01552213|Other|Treatment for glucose intolerance|Diet, exercise glucose monitoring, insulin if necessary
45779567|NCT02982824|Dietary Supplement|Magnesium|Oral magnesium
45779568|NCT02982824|Drug|Placebo - Concentrate|Placebo will be given
45641295|NCT05831124|Biological|Low dose of multivalent pneumococcal conjugate vaccine control|low dose multivalent pneumococcal conjugate vaccine
45779569|NCT04991688|Drug|BOTOX-A|10 injections of 20 U of toxin will be made into the rectum 5, 10 and 15 cm above the pectinate line. At each level, 3 injections of 20 U will be performed in the submucosa, circumferentially.The last injection is made 20 cm above the pectinate line. Total does not exceed 200U of Botox-A
45779570|NCT03693014|Radiation|Stereotactic Body Radiotherapy|(27 Gy over 3 fractions)
45779571|NCT03693014|Biological|Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab|The checkpoint inhibitor that the patient was already receiving should be continued according to the standard schedule and dose of administration as determined by the treating physician. Immune Checkpoint Inhibitors include Ipilimumab (Melanoma) Nivolumab (Melanoma, Renal, NSCLC), Pembrolizumab (Melanoma, NSCLC), Atezolizumab (Bladder)
45779572|NCT02483520|Behavioral|FamTechCare|Caregiver submitted videos of challenging care situations are uploaded to a HIPAA secure site and reviewed by dementia care experts who provide feedback for improving care.
45779573|NCT01797692|Other|geriatric assessment|A single geriatric assessment with a geriatrician was proposed to patients and to control population.
45779574|NCT04989738|Behavioral|THRIVE intervention|Parents learn responsive parenting skills, such as a) recognizing infant hunger and satiety cues and using feeding more selectively in response to hunger only, b) recognizing other reasons for crying or fussy behavior and using alternative soothing strategies when these other reasons apply, c) learning to lay the foundation for healthy infant sleep and respond to nighttime awakenings to promote self-soothing, and d) learning to introduce complimentary foods at 6 months, provide repeated exposure to a variety of healthy foods using positive role modeling, and allow infants to determine the amount consumed.
45779575|NCT04989738|Behavioral|Active Control|Parents learn about development, safety, and positive parenting without a specific emphasis on feeding, sleep, and soothing.
45641296|NCT05831124|Biological|Standard dose multivalent pneumococcal conjugate vaccine control|multivalent pneumococcal conjugate vaccine
45641297|NCT05830968|Device|Morpheus8 Applicator Radiofrequency device|Eligible subjects will receive 2 treatments with the Morpheus8 according to the study protocol. All participants will return for 2 follow up visits: 4 weeks (1M FU) and 12 weeks (3M FU) after the 2nd treatment. Total expected study duration is ~6 months, depending on subject recruitment rate.
45653064|NCT04830163|Combination Product|Brain state-dependent paired corticomotoneuronal stimulation (PCMS)|Paired corticomotoneuronal stimulation (PCMS) involves delivering precisely timed pairs of transcranial magnetic stimulation (TMS) and peripheral nerve stimulation (PNS) so that the neuronal activity evoked by such stimulation arrives synchronously at corticospinal-motoneuronal synapses. This synchronous arrival is postulated to cause long-term potentiation via spike timing-dependent plasticity, which then improves corticospinal transmission and hand function. In this study, paired corticomotoneuronal stimulation (PCMS) will be applied during specific brain states that reflect increased recruitment of motoneurons via the corticospinal tract. This increased recruitment is expected to enhance the beneficial effects of PCMS on human hand function after stroke.
45653065|NCT04788719|Other|Gait analysis|Gait analysis
45779576|NCT01798160|Procedure|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
45779577|NCT01798160|Procedure|SIRT|Selective Internal Radiation Therapy once at the beginning of the study. Follow up until endpoint.
45779578|NCT02514174|Drug|Afatinib|afatinib starting at 30 mg daily dose
45779579|NCT02132468|Drug|fosbretabulin tromethamine|60 mg/m2, IV on Day 1, 8 and 15 of a 3-week cycle; 3 cycles or until progression or unacceptable toxicity
45779580|NCT03509558|Device|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of spinal cord over the skin combined with physical therapy to improve walking and standing functions
45779581|NCT03509558|Other|Physical Therapy|physical therapy to improve walking and standing functions
45779582|NCT01507987|Device|Implanted with one or more of the following SJM leads: Riata leads, RiataST leads, Durata leads, and QuickSite/QuickFlex leads|"Riata leads implanted between 2002-2009 Riata ST leads implanted between 2006-2009 Quicksite or QuickFlex leads implanted between 2006-2010 Durata leads implanted between 2008-2010~Subjects were followed for three years and cinefluoroscopy imaging was done annually to determine prevalence of externalized conductors or other visual lead anomalies"
45779583|NCT03906578|Dietary Supplement|Vivomixx®|Microbiotic food supplement with L. paracasei, L. plantarum, L. acidophilus, L. delbrueckii, B. longum, B. infantis, B. breve, S. thermophilus
45779584|NCT03906578|Other|Placebo|Placebo with similar appearance to probiotic
45779585|NCT03265808|Drug|allogeneic human mesenchymal stem cells (allo-hMSCs)|Single administration of allogeneic hMSCs: 100 x 106 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
45779586|NCT03265808|Drug|Placebo|Placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
45779587|NCT03195764|Drug|T-1101 (Tosylate)|T-1101 (Tosylate) powder in bottle
45779588|NCT01508455|Drug|Dexmedetomidine|
45779589|NCT01508455|Drug|Midazolam|
45779590|NCT01508455|Drug|Fentanyl|
45779591|NCT01508455|Drug|Morphine|
45779592|NCT03127982|Behavioral|Unified Protocol|The Unified Protocol (UP) is a trans-diagnostic cognitive-behavioral therapy (tCBT) for individuals diagnosed with anxiety disorders, depression and related disorders (which we refer to as emotional disorders).
45448690|NCT03677284|Other|Time assistive products|The decision on the specific time assistive product to be prescribed will be decided based on current knowledge and the personal goal of the PwD.
45779593|NCT03114254|Drug|Cabazitaxel|"Six cycles of chemotherapy comprising:~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days."
45779594|NCT03095612|Drug|Selinexor|Selinexor once weekly oral or twice weekly oral
45779595|NCT03095612|Drug|Docetaxel|Docetaxel once every 3 weeks (75 mg/m2 IV)
45779596|NCT01509625|Drug|Fulvestrant|It is an observacional retrospective study to asses the results of the administration of fulvestrant in the routine clinical practice.
45779597|NCT04081922|Procedure|Erector spinae plane block|Using ultrasound, place the needle in the erector spinae fascia plane at T7-8 level. Then, 0.25% ropivacaine 0.5 ml is injected to confirm the needle location. After checking the location, 0.25% ropivacaine 0.5 ml/kg is administered. This procedure is repeated at contralateral side.
45448691|NCT03677284|Other|Information brochure|The information brochure will provide information frequent problems about daily time management and suggest strategies to manage them.
45754297|NCT04233385|Other|Myofascial Massage|The myofascial protocol outlines techniques, areas of the body, as well as time to be spent for each technique for a total of 25 minutes. The remaining 5 minutes of the massage are for the massage therapist to tailor myofascial massage to the needs and circumstances of each participant. In order to provide some level of customization, the therapist will determine the impact of massage on the participant's pre-existing pain and/or mobility limitations. Second, the therapist will assess the soft tissues around the affected breast, chest, and shoulder to determine the locations of pain, tissue firmness, and restricted mobility. Third, the therapist will use effleurage and petrissage techniques to gently massage the identified locations to soften and release the tissues. Techniques used will include deep friction of muscles, sustained compression, and fascial stretch.
45779598|NCT02482428|Drug|Investigational Treatment|Applied twice daily for up to 12 weeks
45779599|NCT02482428|Drug|Aldara|Applied 3 times a week for 16 weeks
45779600|NCT04054076|Device|Prefabricated insoles|The participants received prefabricated insoles
45779601|NCT04054076|Device|Soft custom-made insoles|The participants received soft custom-made insoles
45779602|NCT04054076|Device|Hard custom-made insoles|The participants received hard custom-made insoles
45779603|NCT03796754|Behavioral|YoBEKA|The teachers and students of the YoBEKA study arm receive a guided YoBEKA practice from an experienced YoBEKA trainer during the regular 4 month intervention period. The YoBEKA program is based on a combination of different, easy to perform exercises appropriate to the school situation, consisting of postures, verses for speech, song and movement, affirmations in movement to promote balance and coordination, and various rest and silence exercises to promote body awareness and relaxation techniques. The teaching is ideologically neutral and without religious background. The participating teachers receive an initial two-hour YoBEKA introductory course. Every 2 weeks there is a one to two-hour training course. The pedagogical specialists are supported once a week by an experienced YoBEKA trainer. The teachers are encouraged to integrate the learned exercises independently and regularly into their everyday school life.
45779604|NCT02319824|Biological|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
45779605|NCT02319824|Other|Laboratory Biomarker Analysis|Correlative studies
45779606|NCT02319824|Radiation|Palliative Radiation Therapy|Undergo palliative radiation therapy
45779607|NCT01510327|Device|PROMUS Element Everolimus-Eluting Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
45779608|NCT01510327|Drug|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
45779609|NCT01510327|Drug|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
45779610|NCT04019522|Other|Acute Intermittent Hypoxia (AIH)|An oxygen monitor will continuously measure and record the fraction of inspired oxygen delivered to the subject. Inspired fraction of oxygen (FiO2) of the gas mixture will be individually adjusted using the valve settings to reach the targeted SpO2. The gas mixtures administered during the four sessions will be 21% O2 (target SpO2 = 95%), 17% O2 (target SpO2 = 92%), 13% O2 (target SpO2 = 87%) and 9% O2 (target SpO2 = 82%).
45779611|NCT04011800|Procedure|Catheter ablation|Pulmonary vein isolation, or additional left or right-sided atrial lesions.
45779612|NCT04011800|Combination Product|Risk Factor Modification|dietary restriction, physical exercise, reduced alcohol intake with antiarrhythmic drugs
45779613|NCT01401595|Drug|escitalopram oxalate|The purpose of this study is to determine the effectiveness of the anti-depressant Lexapro in the treatment of the Night Eating Syndrome. An ADAM SPECT-CT study of SERT binding will be conducted which will compare SERT binding in 31 night eaters with that of 10 control subjects. The first procedure will be to assess SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls. Medication will be administered starting at 10 mg daily, with increase up to 20 mg, as indicated and tolerated, for up to three months. Visits will occur at baseline and weeks 1, 2, 4, 6, 8, 10, and 12.
45779614|NCT03971630|Other|Telemedicine|Patients will be followed up using the MyVENT System and APP
45641298|NCT05830877|Other|the tiaoshen acupuncture|"The primary choice is to puncture GB20 with a quick puncture, which means regulate the mind and open the way. ①Scalp acupuncture: Du 20(Baihui), EX-HN 3(Yintang), EX-HNl(Sishencong); ②Select acupoints from six acupoints for mind-regulating, ear points (both sides): heart, lung, and Shenmen; body points (both sides): LI20(Yingxiang), EXTRA 12(Anmian), ST36(Zusanli) as the main hole. ③Sleeping three needles(both sides): HT7(Shenmen), PC6(Neiguan), SP6(Sanyinjiao); ④Opening four gates: LI4(Hegu) , LR3(Taichong) ⑤Abdominal four needles:ST25(Tianshu), CV12(Zhongwan), CV4(Guanyuan). For body acupuncture, a 0.3 mm×40 mm needle was used to insert directly for 0.5-1.0 cun, and twisting to gain the qi; for auricular points, a 0.25 mm×40 mm needle was used for 2-3 minutes without manipulating the needle. The acupuncture points were retained for 30 min, and the treatment was performed once every other day, three times a week, and the curative effect was evaluated after 4 weeks of treatment."
45779615|NCT01511809|Drug|Atazanavir/ritonavir monotherapy|Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.
45779616|NCT01401907|Other|early palliative care|patient assigned to the intervention will receive early palliative care along with standard oncology care.
45779617|NCT02480712|Drug|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet administered orally once daily
45779618|NCT02678156|Device|Lyoplant Onlay|
45779619|NCT01512667|Drug|MK-0822|A single oral dose (50 mg tablet) of MK-0822 will be administered on Day 1 after an overnight fast.
45779620|NCT04988022|Drug|Dupilumab|300 mg prefilled syringe
45779621|NCT04988022|Drug|Placebo|Matching placebo
45779622|NCT03916094|Drug|HLX22|Humanized Anti-Human Epidermal Growth Factor Receptor-2 Monoclonal Antibody
45779623|NCT04987476|Biological|analyzes in singles cells|genome expression analyzes in single cells
45779624|NCT04986852|Drug|Olinvacimab|Treatment with Olinvacimab and Pembrolizumab is to be continued until disease progression, the development of unacceptable toxicity or patient's withdrawal of consent. Maximum duration of treatment will be 35 cycles (approximately 2 years).
45779625|NCT03628976|Other|tVNS|Intervention
46070478|NCT04559906|Other|Spray and Stretch technique (Ethyl chloride)|"Group A receive spray and stretch technique (Ethyl chloride) with conventional treatment.~The upper trapezius muscle stretches on the basis of the Technique originally described by Simons. The subject is seated in a relaxed position on their homolateral hand for anchoring the distal end of the studied muscle. Initially, 3 to 5 parallel sweeps of ethyl chloride spray is applied covering the Upper trapezius muscle. Then, the muscle are positioned in a maximal but tolerable stretch and lengthened until the Physical Therapist felt the muscle tension barrier. This procedure repeated 2 or 3 times."
45448692|NCT03666676|Other|Signal processing to improve intelligibility|Signal processing will be used to manipulate frequency and amplitude fluctuations in complex sounds.
45448693|NCT03648879|Device|Endoscope+Cellvizio(R) 100 microscope|Patients will undergo white-light, upper endoscopy. In addition, during this endoscopy patients will undergo Confocal Endoscopic Microscopy (CEM) using the Cellvizio probe (Mauna Kea Technologies) to scan the same anatomic zones.
45779626|NCT03628976|Other|Motor training|Same finger training for both arms
45779627|NCT00115700|Drug|Cyclophosphamide|1000 mg/m2 I.V. on day 1
45779628|NCT00115700|Radiation|Radiotherapy|The prescribed dose to the target volume will be 30 Gy. Daily fractions of 1.5-2.0 Gy will be employed.
45779629|NCT00115700|Drug|Vincristine|1.4 mg/m2 (maximum single dose of 2 mg) I.V. on day 1
45779630|NCT00115700|Drug|Prednisolone|50 mg/m2 orally daily for days 1 - 5
45779631|NCT00115700|Drug|Rituximab|375 mg/m2 IV Infusion day 1
45779632|NCT01553539|Drug|therapeutic angiotensin-(1-7)|Given SC
45779633|NCT01553539|Other|laboratory biomarker analysis|Correlative study
45779634|NCT05566171|Dietary Supplement|Activia Probiotic Yogurt|Activia probiotic Yogurt will be consumed by participants in this group
45779635|NCT00557882|Device|synthetic polypropylene mesh|Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.
45448694|NCT03643510|Drug|Fulvestrant|Fulvestrant will be dosed 500mg intramuscularly (IM) on days 1 and 15 during cycle 1 and then on Day 1 during subsequent cycles.
45448695|NCT03643510|Drug|Abemaciclib|Abemaciclib 150 milligrams mg orally once every 12 hours on days 1-28.
45779636|NCT03848000|Other|Exercise Programme|Two sessions per week for 12 consecutive weeks. 30 minute education talks covering topics regarding the physical and mental health benefits of exercise and behaviour change. The following 30-60 minute exercise sessions will utilise pad-boxing, football, body-weight training and circuit training.
45779637|NCT03848000|Behavioral|NHS Standard Care|Weekly one-to-one cognitive-behavioral counselling alcohol addiction support session lasting 1 hour. Drug therapy will be offered if indicated in line with standard therapy.
45779638|NCT01555567|Device|Electrical Stimulation|Electrical stimulation will be delivered 2 times per week
45779639|NCT01555567|Other|Eccentric Exercise|Eccentric Exercise will be delivered 2 times per week
45641299|NCT05830877|Other|the common acupuncture|"According to the Insomnia section in the textbook Acupuncture and Moxibustion (New Century Fifth Edition), the acupoints are selected as follows: GV20(Baihui), HT7(Shenmen), SP6(Sanyinjiao), KI6(Zhaohai), BL62(Shenmai), EX-HN22(Anmian), using a 0.3 mm×40 mm needle straight insert in skin with depth of 0.5-1.0 cun. After twisting to get qi, the researcher will manipulate the needle, and keep the needle in acupoints for 30 minutes."
45641300|NCT05830669|Procedure|Remote ischemic preconditioning (RIPC)|3 cycles of 5 min inflation of a blood-pressure cuff to 200 millimetres of mercury (mmHG) (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed.
45779640|NCT01555957|Drug|intravenous lipid|intravenous given daily for 6 weeks
45641301|NCT05830669|Procedure|Sham RIPC|3 cycles of 5 min inflation of a blood-pressure cuff to 20 mmHG to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed
45641302|NCT05830409|Behavioral|Multisensorial Stimulation|Strategies such as touching, calling, making sense of smell, entering the eye area, and activating the sense of taste will be applied to activate the five senses of the newborn.
45641303|NCT05829135|Device|Acuvue Oasys with Transitions|soft contact lenses with darkening technology
45641304|NCT05828069|Procedure|Biospecimen Collection|Undergo collection of blood samples
45641305|NCT05828069|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
45641306|NCT05828069|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
45641307|NCT05828069|Procedure|Computed Tomography|Undergo CT
45641308|NCT05828069|Procedure|Echocardiography|Undergo ECHO
45779641|NCT03243890|Dietary Supplement|Menaquinone-7 720 µg/day including the recommended daily dose of vitamin D (25 µg/day).|Half of the patients are randomized to supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day).
45779642|NCT03243890|Dietary Supplement|Placebo|Half of the patients are randomized to placebo treatment (no active treatment).
45779643|NCT03750500|Device|Biofeedback device|12-week exercise program performed through the device
45779644|NCT03750500|Behavioral|Education on falls risk|Education on falls risk factors and how to minimize them
45641309|NCT05828069|Procedure|FDG-Positron Emission Tomography and Computed Tomography Scan|Undergo FDG-PET imaging
45641310|NCT05828069|Procedure|Lumbar Puncture|Undergo lumbar puncture
45641311|NCT05828069|Procedure|Multigated Acquisition Scan|Undergo MUGA
45641312|NCT05828069|Drug|Tovorafenib|Given PO
45779645|NCT03750500|Other|Medication review|Medication will be reviewed to reduce sedative drugs and minimize interactions
45779646|NCT03750500|Diagnostic Test|Visual and auditory screening|Patients will go through visual and auditory screening as part of their regular care
45779647|NCT00560612|Drug|Paroxetine|Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
45779648|NCT00560612|Drug|Placebo|Placebo: same as paroxetine (active comparator)
45779649|NCT01556347|Drug|Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis|
45779650|NCT00561002|Biological|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
45779651|NCT00561002|Biological|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
45779652|NCT03236792|Drug|Ixazomib|3 mg or 4mg of Ixazomib will be taken orally on days 1, 8, and 15 of a 28-day cycle
45779653|NCT03236792|Drug|Cyclophosphamide|300, 400, or 500 mg of oral Cyclophosphamide on days 1, 8, and 15 of a 28-day cycle
45779654|NCT03236792|Drug|Dexamethasone|20 mg of oral Dexamethasone on days 1, 8, 15, 22 in a 28-day cycle
45779655|NCT03725384|Drug|Ferrous Sulfate 300Mg Tablet|oral dose of Ferrous Sulfate (300 mg) every day versus every other day along with vitamin C
45779656|NCT03725384|Drug|Vitamin C 500Mg tablet|Vitamin C 500 Mg tablet every day versus every other day along with ferrous sulfate
45641313|NCT05828043|Behavioral|Multi-domain intervention|Each session comprises of 45 minutes physical fitness activities targeting on muscle strength, balance, and flexibility; 1-hour cognitive training primarily on reasoning and memory exercises; and 15-minute for nutritional advices based on national diet guidelines for older adults
45641314|NCT05825651|Other|no interventions|This is an observational study without any intervention.
45641315|NCT05825222|Dietary Supplement|E-PR-01 (Low dose)|One Capsule to be consumed twice a day
45641316|NCT05825222|Dietary Supplement|E-PR-01 (High Dose)|One Capsule to be consumed twice a day
45641317|NCT05825222|Dietary Supplement|Placebo|One Capsule to be consumed twice a day
45641318|NCT05824884|Behavioral|Visual Feedback|Visual progress feedback and words of positive affirmation will be presented triggered by checkpoints set in the VR-height-exposure.
45779657|NCT01556425|Drug|Vivitrol|Participants receiving this intervention will receive the FDA-approved dose, route, and schedule of administration of VIVITROL. The dose of VIVITROL of 380 mg will be delivered intramuscularly every 4 weeks.
45779658|NCT01556425|Behavioral|Employment-based opiate abstinence reinforcement|This intervention will require participants to provide opiate-negative urine samples on Monday, Wednesday and Friday to maintain their maximum pay. If a participant provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.
45641319|NCT05824884|Behavioral|Self-efficacy enhancement:|specific instructions regarding the retrieval of mastery experiences during exposure will be given (modified version of the procedure used in Raeder et al. 2019).
45779659|NCT01556425|Other|Usual Care Control|Participants receiving this intervention will be invited to attend the workplace and outpatient drug abuse counseling.
45779660|NCT01798628|Drug|Treatment A: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal
45779661|NCT01798628|Drug|Treatment B: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal
45779662|NCT01798628|Drug|Treatment C: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
45779663|NCT03143270|Drug|Drug Eluting Bead Transarterial Chemoembolization|Hepatic embolization will occur on Day 0 of the study for all cohorts. On the day of the procedure, baseline angiography including celiac and superior mesenteric angiography will be performed to delineate arterial anatomy and blood supply to the tumor. After the entire dose has been used, the embolized vessels will be re-catheterized and embolized to stasis with Bead Block beginning with 100-300 micron spheres and using a maximum of 10 cc of any given size per vessel before moving to the next size microsphere.
45779664|NCT03143270|Drug|Nivolumab|All participants will receive at a flat dose of 240 mg IV q 12 weeks for up to one year. In cohort 1, participants will begin nivolumab two weeks (+/- 5 days) after deb-TACE every two weeks. In cohort 2, participants will begin nivolumab every 2 weeks for 1 year and undergo deb-TACE 4 weeks after the initiation of nivolumab (+/- 5 day). Nivolumab will not be dosed on the day of embolization in this cohort. In cohort 3, nivolumab will be dosed every two weeks starting 4 weeks (+/- 5 days) prior to deb-TACE and continue every 2 weeks for up to one year. Nivolumab will be dosed on the day of embolization in this cohort. It will be administered before the deb-TACE procedure.
45779665|NCT01513447|Drug|Intracutaneous injections|Four intracutaneous injections: two sites lateral to the lumbosacral spine and two sites 2-3 centimeters below and 1- 2 centimeters medial to the original two injections sites. 0.1 millimeters of the study drug is injected between the dermal layers at each of the four sites. The injections are administered sequentially, with the series of four injections, performed two at a time, completed in 20-30 seconds.
45779666|NCT00562328|Biological|Alemtuzumab|"Week 1 (dose escalation):~Day 3: 3mg subcutaneously; Day 4: 10mg subcutaneously; Day 5 30mg subcutaneously~Weeks 2-5:~30mg subcutaneously three times a week."
45779667|NCT00562328|Biological|Rituximab|"Weeks 2-5:~375 mg/m^2 by IV once weekly"
45779668|NCT00562328|Biological|Sargramostim|"Week 1-6:~250 mcg subcutaneously three time as week"
45779669|NCT01514149|Drug|CJC-1134-PC Injection|CJC-1134-PC administered weekly by subcutaneous injection
45779670|NCT01514149|Drug|Weekly placebo for CJC-1134-PC Injection|Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection
45779671|NCT03131492|Diagnostic Test|Blood test|C-reactive protein and PCT measured preoperatively, and on the second, fourth and sixth postoperative days.
45779672|NCT01514383|Device|Cyanoacrylate (Octylseal )|surgical adhesive
45779673|NCT01556581|Procedure|Usual Care (UC)|Initial management for all patients will include an activity-limiting profile for up to 30 days and a 10-day supply of medications if needed (NSAIDs and muscle relaxers). All patients will then receive advice and education about the favorable natural history of LBP and the advantages of remaining as active as possible. All patients will be recommended to follow-up with their primary care provider using normal procedures if they are not satisfied with their progress.
45779674|NCT01556581|Procedure|Early Physical Therapy (PT)|Patients in the early PT group will receive the same treatment as the usual care group, but will then be referred to physical therapy within 3 days. The physical therapy treatment will be based on the Treatment Based Classification system (an approach that places patients into either an extension-oriented, core strength/stabilization, or a spinal manipulation treatment group based on signs and symptoms).
45779675|NCT05566093|Procedure|EUS-guided ethanol ablation|After puncturing with the needle, 95% ethanol under the guidance of EUS was injected into the tumor. The injection volume of ethanol was estimated according to the following principles: (1) The injection volume was not larger than the tumor spherical volume. (2) Injection volume was reduced when the tumor was adjacent to the pancreatic duct or vessel. (3) Injection volume for the lesions with repeated EUS-FNI was reduced.
45779676|NCT05566093|Procedure|EUS-guided lauromacrogol ablation|After puncturing with the needle, lauromacrogol under the guidance of EUS was injected into the tumor. The injection volume of lauromacrogol was estimated according to the following principles: (1) The injection volume was not larger than the tumor spherical volume. (2) Injection volume was reduced when the tumor was adjacent to the pancreatic duct or vessel. (3) Injection volume for the lesions with repeated EUS-FNI was reduced.
45779677|NCT05565859|Behavioral|Planetary Health Plate signage|A Planetary Health Plate graphic was developed based on the healthy reference diet proposed by the Eat Lancet Commission. The graphic was designed to capture the food groups and proportions of food groups promoted by the Planetary Health diet.
45641320|NCT05824884|Behavioral|placebo intervention|specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (modified version of the procedure used in Raeder et al. 2019).
45641321|NCT05824884|Behavioral|No visual feedback|Participants can not trigger any checkpoints during VR and therefore not receive any progress feedback or positive affirmation.
45641322|NCT05824702|Behavioral|Peer education & communications|The intervention trains peer educators to promote medication-assisted drug treatment among peer who inject drugs and are living with HIV.
45641323|NCT05824702|Behavioral|Standard of care educational|This is an educational equal attention control group
45779678|NCT01557595|Device|Polarized glasses designed to filter out blue light|"Participants will be given polarized glasses (yellow sun- glasses) which filter out blue light to wear only from sundown until bedtime for two weeks. They will be instructed to turn off fluorescent lights and only use household lamps for evening activities. They will be instructed not to drive while wearing the glasses. In addition to the oral instructions, they will also be given a written Instruction Sheet. Any oral insomnia agent will be held throughout the study, otherwise they are to follow their usual evening routines. This is an alternative treatment already in use in Dr. Fargason's practice for those patients who don't want to take sleep medications. This research focuses on the effectiveness of this treatment and involves questionnaires to do so."
45448696|NCT03737721|Combination Product|Avelumab and Radical radiotherapy|A single-arm, interventional study combining Avelumab with radical radiotherapy. Avelumab will be delivered on a 14-day cycle, with the first cycle administered 14 days in advance of the radiation therapy start date; 63-66 Gy radiation will be delivered over 30 daily fractions concurrent with an additional 4 cycles of Avelumab
45779679|NCT02127710|Drug|AZD6094|AZD6094 is a potent and selective small molecule mesenchymal epithelial transition (c-MET) kinase inhibitor.
45779680|NCT01558063|Drug|Ketamine|Single dose of 0.1, 0.2, 0.3, 0.4 or 0.5 mg/kg of ketamine given intravenously over 40 minutes.
45641324|NCT05824546|Procedure|Intervention Arm (uSINE-PAMS technique):|Patients will be lying in a lateral recumbent position and in a fetal position with the neck, back and limbs held in flexion. L3-L4 inter-vertebral space will be identified by palpation of external landmarks of the patients' iliac crests and spinous process of lumbar vertebrae L3, L4 and L5 and confirmed using uSINE-integrated ultrasound. The angle of needle during needle advancement will also be determined using the uSINE-integrated ultrasound. Markings on the patients' skin surface will be made using PAMS (non-sterile component) to enable relocation of the site and angle of the needle entry. Patients' back will be cleaned and draped using aseptic technique. Next, local anaesthesia is infiltrated into the previously identified needle entry site before the LP needle is inserted with location and angulation according to PAMS (sterile component) guidance.
45641325|NCT05824546|Procedure|Control Arm (traditional landmark-based technique):|Patients will be lying in a lateral recumbent position and in a fetal position with the neck, back and limbs held in flexion. L3-L4 inter-vertebral space will be similarly identified by palpation of external landmarks of iliac crests and spinous process of lumbar vertebrae L3, L4 and L5. Markings on the patients' skin surface will be made with a washable marker or any other methods according to the operator's preference to enable relocation of the site of the needle entry. Patients' back will be cleaned and draped using aseptic technique. Next, local anaesthesia is infiltrated into the previously identified needle entry site before the LP needle is inserted into marked entry site.
45448697|NCT04973410|Diagnostic Test|Coronary Physiology|Invasive coronary physiology measurements during diagnostic CAG with thermodilution method with the CoroFlow® (Coroventis, Uppsala, Sweden)
45641326|NCT05823896|Drug|Nirmatrelvir/ritonavir|300/100 mg tablet twice daily (q12h) administered orally for 15 days
45641327|NCT05823896|Drug|Placebo/ritonavir|100mg tablet twice daily (q12h) administered orally for 15 days
45641328|NCT05822154|Other|comprehensive geriatric assessment|The clinical, biological and functional characteristics will be collected in elderly subjects attending the hospitals of participating centers.
45779681|NCT01558063|Drug|Saline|Single infusion of saline given intravenously over 40 minutes.
45779682|NCT01558063|Procedure|Magnetic Resonance Imaging (MRI)|90-minute scan during the 40-minute infusion.
45779683|NCT01515943|Other|Active home-based computer vergence/accommodative therapy|At enrollment, subjects will be prescribed 15 minutes/day of active home-based computer therapy for 5 days/week during the 12 week treatment phase. Active home-based computer therapy will be provided the Home Therapy System (HTS) computer software and will include both fusional vergence and accommodative therapy. Subjects will perform the computer therapy while wearing red/blue glasses and accommodative therapy will be performed using the HTS accommodative flippers. Please refer to the procedures manual for further details.
45779684|NCT01515943|Procedure|Near target push-ups|At enrollment, subjects will be prescribed 15 minutes/day (3 sessions of 5 minutes each) of near target push-ups (NTP) for 5 days/week during the 12-week treatment phase. An alphabet pencil will be used as the target and an index card placed in the background will provide physiological diplopia control. With the pencil positioned at arm's length directly between the subject's eyes, the subject will slowly bring the pencil toward his/her nose while focusing on the small letter on the pencil. When the subject is no longer able to maintain a single image of the pencil, he/she will slowly move the target away from the nose until the pencil becomes single again. This procedure will be repeated several times. Please refer to the procedures manual for further details.
45779685|NCT01515943|Other|Placebo home-based computer vergence/accommodative therapy|At enrollment, subjects will be prescribed either 5 minutes/day (NTP group) or 15 minutes/day (Placebo group) of placebo home-based computer therapy for 5 days/week during the 12 week treatment phase. Placebo computer-based therapy will be provided by the Home Therapy System (HTS) computer software. The vergence procedures are similar to the active version, however, the tasks will be modified to ensure no demand on the vergence system and no accommodative therapy is included in the placebo version. Please refer to the procedures manual for further details.
45779686|NCT01515943|Procedure|Placebo yoked prism flippers|"Subjects will be prescribed 5 minutes/day of placebo yoked prism flipper therapy for 5 days/week during the 12 week treatment phase. This procedure utilizes a 4 pd base right/4 pd base left prism flipper and Accommodative Hopping Cards. Subjects view the text on the card through the prisms at 40 cm, perform the appropriate task and then flip the prism flipper to the other side after each word before proceeding to the next line. Please refer to the procedures manual for further details. The task remains constant, but the nature of the procedure changes with time:~Weeks 1-4: View the target through prism flippers~Weeks 5-8: Wear red-blue filter glasses while viewing the text through prism flippers~Weeks 9-12: Wear polaroid glasses while viewing the text through prism flippers"
45779687|NCT03670784|Other|No intervention|No intervention, epidemiological investigation
45779688|NCT01798238|Drug|MP-513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
45779689|NCT01798238|Drug|Placebo|Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day
45779690|NCT02857400|Other|current standard of care|connection documentation faxed to GP (General practitioner) on the day of patient's discharge
45779691|NCT02857400|Other|CREDO standard of care|"organized consultation return home between patient, GP DESC (diploma of complementary specialized study) and patient's referent GP"
45641329|NCT05821413|Behavioral|Data to care|Participants meet with a case manager who asks about health, basic needs such as housing and finances, and relationships and support systems. A score is assigned that reflects how much support is needed. A care plan is developed to address areas of need. The case manager meets regularly with participants to determine if needs are being met and identify strategies for meeting those needs. Participants with higher scores will receive more intensive contact with case managers, typically every month, until their level of need goes down. All participants will have their level and types of needs reassessed to determine if they need additional support or are moving toward self-management. Participants work with case managers for 6 months.
45641330|NCT05821413|Behavioral|Standard of Care|Participants can use standard case management and other services offered by the clinic.
45641331|NCT05821088|Procedure|Biopsy|Undergo tissue biopsy
45779692|NCT05565781|Device|ECG smartwatch|Testing ECG smartwatch
45779693|NCT05565781|Device|Insertable Cardiac Monitor (ICM)|Gold-standard cardiac monitor for comparison of testing device (ECG smartwatch)
45779694|NCT05565781|Device|External ECG Monitoring|Regular cardiac monitor for diagnosis of atrial fibrillation
45779695|NCT03641846|Other|DornierAries2 LiST device + 5 mg Tadalafil|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks
45779696|NCT03641846|Other|DornierAries2 LiST device + Placebo Pill|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Placebo pills. Total treatment period = 4 weeks.
45779697|NCT05560802|Other|WHOs Labour care guide|Guidelines for monitoring labor progress, the WHOs LCG
45779698|NCT05560724|Device|Transcranial direct current stimulation (tDCS)|Anodal stimulation or sham
45779699|NCT02490722|Other|Patient education|Four times two hours group based patient education
45779700|NCT02241980|Other|Patient survey|
45779701|NCT02241980|Other|Physician survey|
45779702|NCT02118662|Other|Energy Expenditure during seated in an office chair|You will first rest motionless in a chair for 20 minutes. You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
45779703|NCT02118662|Other|Energy Expenditure during seated and typing|You will complete this working conditions for 15 minutes. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
45779704|NCT02118662|Other|Energy Expenditure during Treadmill walking work condition|You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
45779705|NCT02118662|Other|Energy Expenditure during cycling work condition|You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
45779706|NCT03545282|Behavioral|Amigas Latinas Motivando el Alma (ALMA)|"In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed.~Due to COVID-19 pandemic, the intervention was changed to online synchronous delivery via Zoom over 6 weekly sessions."
45779707|NCT05560334|Drug|Pemigatinib Pill|13.5mg, po, 2 weeks on/1 week off, Q3W
45779708|NCT05560256|Other|Diary/Journal|Participants will be given a diary to record their blood glucose measurements, and other pertinent information (diet and activities).
45916479|NCT05636137|Other|Survey application|Researchers will go to the designated high schools and meet face-to-face with the responsible/guidance teachers at the school. The research will be explained to the students by going to the classrooms with the teachers, and they will be asked to fill in the consent forms of the parents and themselves. Students will be given 5 days to explain the work to their families and bring their signed consent forms. Students who bring consent forms, meet the criteria for participation in the study, and volunteer will be included in the study. Evaluation forms and questionnaires will be explained to the students included in the study by a designated researcher and they will be asked to fill them in under the supervision of the researcher. The completed evaluation form and questionnaires will be collected by a researcher in a sealed envelope.
45916480|NCT00423462|Behavioral|Brief dynamic psychotherapy|
45448698|NCT04973410|Diagnostic Test|15O-H2O-PET scan|Myocardial blood flow (MBF) measured with oxygen-15 (O-15) labelled water used as a tracer molecule with positron emission tomography (PET)
45448699|NCT03733431|Device|Gammacore device|Transcutaneous stimulation of vagus nerve with the device positioned below the mandibular angle, medial to the sternocleidomastoid muscle and lateral to the larynx.
45448700|NCT03733431|Device|Gammacore sham device|Sham device which does not deliver electrical stimulation, but instead, produces a buzzing sound will be placed along the lateral border of the sternocleidomastoid muscle in order to avoid mechanical stimulation of the vagus nerve in the carotid triangle.
45641332|NCT05821088|Procedure|Biospecimen Collection|Undergo blood sample collection
45641333|NCT05821088|Drug|Carboplatin|Given IV
45641334|NCT05821088|Procedure|Computed Tomography|Undergo CT
45641335|NCT05821088|Drug|Etoposide|Given IV
45779709|NCT05560178|Other|SEXUAL HEALTH EDUCATION|Women in the intervention group will be given sexual health education once a week for 4 weeks
45779710|NCT03474458|Drug|Doxycycline|Doxycycline
45779711|NCT03474458|Drug|Standard of care therapy|Standard of care therapy
45779712|NCT01516957|Drug|AMG 827 140|140 mg AMG 827 SC (subcutaneous)
45779713|NCT01516957|Drug|Placebo|Placebo SC (subcutaneous)
45779714|NCT01516957|Drug|AMG 827 280|280 mg AMG 827 SC (subcutaneous)
45779715|NCT01516957|Drug|AMG 827 210|210 mg AMG 827 SC (subcutaneous)
45779716|NCT03448250|Behavioral|Optimune|Optimune is a web-based psychological intervention developed for women with breast cancer.
45779717|NCT03448250|Other|Care-As-Usual|Participants are free to continue to engage with any treatment they require (i.e., CAU).
45779718|NCT01519063|Drug|Naltrexone and memantine first|Naltrexone 50mg memantine 20mg
45779719|NCT01519063|Drug|Naltrexone and Placebo first|Naltrexone 50 mg Placebo
45779720|NCT01559857|Drug|Pioglitazone|30mg once daily for 12 weeks
45779721|NCT01559857|Drug|Sugar Pill|Placebo
45779722|NCT01814540|Dietary Supplement|Bovine Milk Oligosaccharide|The BMO powder will be isolated from whey streams by Hilmar Ingredients (Hilmar, California 95324). Hilmar Ingredients employs the same membrane filtration, and centrifugation processes used to purify whey protein in their commercial practice to extract and purify BMO from whey permeate. Furthermore, the same sterilization processes used on the equipment to purify whey products will be used to purify BMO. This method uses a novel high-throughput food-grade isolation protocol that leads to purification of specific BMOs with bifidogenic activity as prebiotic oligosaccharides that mimic the activities observed for Human Milk Oligosaccharides (HMO). This strategy of developing methods for their large scale fractionation allows us to obtain a final product that mimics the naturally beneficial oligosaccharides present in human milk.
45779723|NCT01814540|Dietary Supplement|Placebo Glucose Polymer|
45779724|NCT05565625|Other|Sunscreen A|Participants will topically apply Sunscreen A at Visit 1.
45641336|NCT05821088|Drug|Ifosfamide|Given IV
45641337|NCT05821088|Drug|Lenalidomide|Given PO
45779725|NCT05565625|Other|Sunscreen B|Participants will apply Sunscreen B at Visit 1.
45779726|NCT05565625|Other|Sunscreen C|Participants will apply Sunscreen C at Visit 1.
45779727|NCT05565625|Other|Sunscreen D|Participants will apply Sunscreen D at Visit 1.
45641338|NCT05821088|Procedure|Positron Emission Tomography|Undergo PET
45779728|NCT05565625|Other|Sunscreen E|Participants will apply Sunscreen E at Visit 1.
45779729|NCT05565625|Other|Sunscreen F|Participants will apply Sunscreen F at Visit 1.
45779730|NCT00754208|Drug|methylphenidate|Starting dose: methylphenidate (immediate-release pill) or Methylin (immediate-release chewable tablet for those unable to swallow pills) 2.5mg Q AM and Q noon. Target dose of 1mg/kg/day. Titration will occur as follows: 5mg Q AM and Q noon, then 7.5mg Q AM and Q noon, then 10mg Q AM and Q noon, as tolerated, not to exceed 30mg per day. Once each child arrives at a stable dose with a good response and good tolerability, they will be converted to the closest Ritalin LA dose, with a target dose of 1mg/kg/day.
45779731|NCT01562041|Drug|Ranolazine 500 mg|Ranolazine 500 mg, oral tablet, b.i.d.
45779732|NCT01519453|Behavioral|Home Based Asthma Education|4 home based and 3 phone based sessions with community asthma outreach worker to provide families with asthma education
45779733|NCT02210065|Biological|Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)|CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.
45779734|NCT05565547|Device|META|The META device is used for a comprehensive ophthalmic examination.
45779735|NCT05565547|Device|Commercial devices|Commercial devices (including near and far eye charts, refractometer, optical biometry, slit lamp microscopy, fundus camera and OCT) are used for a comprehensive ophthalmic examination.
45779736|NCT00634166|Drug|Sulfamylon® For 5 % Topical Solution|Sulfamylon® For 5% Topical Solution is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.
45779737|NCT00634166|Drug|Topical Antimicrobial/Antifungal Medications|'Topical Antimicrobial/Antifungal Medications' Various topical antimicrobials and antifungals include: Bacitracin; Amphotericin B; Silver Sulfadiazine; Cefazolin; Vancomycin; Nystatin; Fluconazole; Piperacillin Sodium with Tazobactam.
45779738|NCT02981251|Behavioral|Health education with support by trained female health volunteer|Along with usual care four sessions of interactive health education will be provided to the participants by medical officer and/or registered nurse based on a syllabus for six months. Trained female female health volunteer will motivate the participants through their home visit twice a month where they will monitor blood pressure and counsel the family members to support the patient.
45779739|NCT05559944|Behavioral|Expressive Writing|Participants will be asked to write about the biggest body image or eating-related stressor they have experienced as a member of the LGBTQ+ community.
45779740|NCT05559944|Behavioral|Self-Affirmation|Participants will receive one new vignette per day describing a SM young adult experiencing severe body image stress in Alabama. Participants will be asked to write to this person and provide advice based on their own experience as a SM young adult. Vignettes will be identical across participants; however, they will be matched to participants' sexual identity, gender identity, and race/ethnicity.
45916481|NCT05636254|Diagnostic Test|MRI Brain and spine|"MRI Brain~Ax T2 TSE~3D Sag T1~Ax DWI~3D Sag Flair~Ax SWI~Post-gad 3D Sag T1~3D TOF Circle-of-Willis~MRI Spine~Sag T2 whole spine (2 stations)~Post-gad Sag T1 whole spine (2 stations)"
45641339|NCT05821088|Biological|Tafasitamab|Given IV
45641340|NCT05819619|Drug|Prophylactic use of ibuprofen and ondansetron post misoprostol administration|Prophylactic use of ibuprofen and ondansetron post misoprostol administration
45641341|NCT05819619|Drug|Use of ibuprofen and ondansetron at symptom onset post misoprostol administration|Administration of ibuprofen or ondansetron only when experiencing pain or nausea respectively post misoprostol administration.
45779741|NCT05559944|Behavioral|Control|Consistent with prior research participants will write about their routine daily activities since waking up for 20 minutes each day, sans emotional content.
45779742|NCT00565370|Drug|Capecitabine, Cisplatin, Sorafenib|Capecitabine ( ) mg/m2 bid D1-D15 Cisplatin 80 mg/m2 D1 Sorafenib ( ) mg bid PO daily every 3 weeks
45779743|NCT05559632|Procedure|osteotomy for implant placement|preparing the bone for implant placement
45641343|NCT05816473|Other|LLM|Use of a Large Language Model (LLM) chatbot interface to Interact with the Machine Learning Algorithm and interpretability dashboard.
45641344|NCT05813834|Procedure|Genicular Nerves Block|US guided genicular nerves block
45641345|NCT05813288|Drug|Dexpramipexole Dihydrochloride|Oral administration of dexpramipexole tablet
45641346|NCT05813288|Drug|Placebo|Oral administration of placebo tablet
45641347|NCT05808764|Drug|Risdiplam|Participants will receive 0.15 mg/kg risdiplam orally once daily for 28 days.
45641348|NCT05807867|Behavioral|WMM-based intersectional stigma intervention|"Intervention components consist of:~psychoeducation: facilitating the achievement of good womanhood by adhering to psychiatric medications and ART post-discharge~cognitive restructuring to challenge stereotypes: involves reframing psychiatric and ART adherence postdischarge as enacting 'good womanhood' by countering stereotypes of being unable to care for the family or be a suitable marriage partner~Coping skills for discrimination: promoting safe disclosure of SMI and/or HIV status to facilitate psychiatric and ART adherence post-discharge.~Note: enhancing skills for discrimination sessions for women and family members are provided when female participants transition to outpatient care, thus enabling practice of skills in community-based situations. Intervention closes with a ceremony intended to convey WMM by bestowal of ceremonial shawls. The family member version will follow the same format, but each component will be covered in one session (3 sessions total)."
45779744|NCT03315182|Biological|rAAV9.CMV.hNAGLU|Adeno-associated virus serotype 9 carrying the human NAGLU gene under the control of a CMV enhancer/promoter (rAAV9.CMV.hNAGLU) will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
45641349|NCT05807867|Behavioral|Attention placebo control|To isolate intervention effects, our attention control is designed to mimic all salient features of the WMM-based intervention (i.e., group format, co-leaders, duration, inpatient followed by community location) except for the WMM stigma content.
45641350|NCT05807750|Other|Post-discharge income supplement|$300 income supplement
45779745|NCT03303950|Drug|Busulfan|Given IV
45779746|NCT03303950|Drug|Cyclophosphamide|Given IV
45779747|NCT03303950|Drug|Fludarabine|Given IV
45779748|NCT03303950|Procedure|Hematopoietic Cell Transplantation|Undergo HSCT
45779749|NCT03303950|Other|Laboratory Biomarker Analysis|Correlative studies
45448701|NCT04964986|Drug|Apraglutide|Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
45641351|NCT05807750|Other|Enhanced care planning|Enhanced care planning provided by a nurse care manager
45641352|NCT05807529|Drug|2ccPA|"2-carba-cyclic phosphatidic acid (2ccPA) is a first-in-class phospholipase autotaxin (ATX) inhibitor that may act as a disease-modifying drug and may relieve OA associated symptoms.~Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29"
45641353|NCT05807529|Drug|Placebo|"Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29"
45641354|NCT05806801|Behavioral|MICT Exercise|Subjects randomized into this group will complete a moderate intensity continuous exercise 4 days/week.
45641355|NCT05806801|Behavioral|No Exercise (Control)|Subjects randomized into this group will remain sedentary throughout the duration of the study.
45779750|NCT01563055|Drug|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
45779751|NCT01563055|Drug|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
45779752|NCT00565916|Drug|Estrogen|"Estrogen only plus placebo: estradiol topical patch 0.3 mg placed on the lower abdomen for 3 days plus an oral placebo.~Other procedures: heart metabolism tests which includes a positron-emission tomography (PET) scan, an electrocardiogram (ECG), and an echocardiogram (ECHO)."
45779753|NCT00565916|Drug|Progesterone|Estrogen plus progesterone: estradiol with oral progesterone (Prometrium, 200 mg/day) for 3 days, instead of placebo. Progesterone therapy involves taking a daily oral pill of 200 mg Prometrium for the same 3 days that the estradiol is taken.
45779754|NCT00565916|Drug|Placebo|Placebo progesterone therapy involves taking a daily placebo pill for the same 3 days that the estradiol is taken.
45448702|NCT03546712|Other|Tactile Localization|tactile localization is help to assess touch sensation
45641356|NCT05806788|Behavioral|Binge Eating Syndrome Treatment (BESTOW)|The BESTOW program involves discussions as well as written and behavioral activities. Participants will also be asked to complete activities, or 'homework,' in between sessions that will help to stop binge eating and to improve eating habits.
45641357|NCT05805735|Other|Face care product (Eye cream)|The test material(s) will be cosmetic products to be applied around the eye region on both sides of the face daily. The test product will be applied twice daily in the morning and in the evening by the subjects
45779755|NCT03258320|Drug|Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin|As preoperative neoadjuvant chemotherapy, drugss including Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) will be administered as a single agent performed 45 days before surgery：Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.
45779756|NCT05565469|Other|Adjustment of neurostimulator settings|"This is an interventional prospective study. After obtaining informed consent, only necessary information will be extracted through the electronic patient record. Through post-operative imaging, a level determination of the neurostimulator tip will be done. During general consultations, patients will be asked if they experienced abdominal wall stimulation after the procedure and when (YES/NO, NRS). This will include looking at the settings of the neurostimulator. And its adjustments. Furthermore, general epidemiological characteristics such as age, gender, height, weight will be extracted from the electronic patient record.~At the consultation, another active programming will take place (in accordance with clinical programming) on the tip of the electrode to check whether it provokes abdominal wall stimulation. This will also be scored YES/NO + NRS. Then the settings will be returned as they were pre-consultation."
45779757|NCT05559554|Drug|AK104 (before the change)|Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.
45779758|NCT05559554|Drug|AK104 (after the change)|Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.
45641358|NCT05805709|Other|Study Physician/Advance Practice Provider|The nephrologist and/or nephrology-associated advanced practice provider (APP) at each site will lead the intervention team for the duration of the study. The study physicians will fulfil two main roles: (a) Provide supervision to the rest of the study team and (b) conduct a discharge assessment to triage and make recommendations for follow-up care.
45641359|NCT05805709|Other|Nurse Navigator|The nurse navigator will be the primary contact for the participants assigned to the intervention group for the study. The navigator will obtain contact information, information about the patient's usual care providers and pharmacy, review medications, show the participant how to use the home blood pressure machine and scales and arrange for follow-up visits. The role of the nurse navigator will be to monitor the participant's medical condition; facilitate scheduling of needed medical follow-up including both routine (pre-scheduled) and ad hoc (urgent or emergency); enhance adherence with prescribed medical care and follow-up appointments; and serve as a resource to the patient to answer questions about their AKI-related management, facilitate medical and associated care and provide enhanced psychosocial support.
45641360|NCT05805709|Other|Pharmacist|The pharmacist will complete the medication reconciliation and medication regimen review per the predetermined checklist, via telemedicine if agreeable to the patient. The goal of the patient/caregiver-pharmacist interaction is to cover the following: avoidance of nephrotoxins when possible and appropriate, appropriate dosing of renally cleared drugs, review for drug-drug interactions, monitoring appropriate use of chronic medications, medication adherence, monitor for adverse drug reactions, evaluation of non-prescription medication use, medication/disease education and social support.
45641361|NCT05805709|Other|Patient Education|Written information about kidney disease, nephrotoxins to be avoided and importance/need for follow up with a physician will be provided.
45641362|NCT05802966|Behavioral|Mindfulness-Based Cognitive Therapy|MBCT will be offered according to the MBCT manual developed for relapse prevention in MDD (Zindel V. Segal, Williams, & Teasdale, 2002). Thus, MBCT will consist of 8-weekly sessions of 2,5 hours, a 6-hour silent day, and daily home practice (± 45min). MBCT will be taught by a certified MBCT teacher meeting the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders (Belgium) which are in concordance with the Good Practice guidelines of the UK Network of Mindfulness-Based Teacher Trainers (Crane et al., 2012).
45641363|NCT05802654|Radiation|SBRT|The participants enrolled will receive single fraction of ultra-high dose SBRT(30Gy/1F).
45641364|NCT05800444|Drug|BAY3283142|Oral administration as tablet.
45641365|NCT05800444|Other|Placebo|Oral administration as tablet.
45779759|NCT01797926|Drug|Reference Treatment: 5 mg amlodipine + 50 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 50 mg losartan tablet administered orally in fasted state as a single dose
45779760|NCT01797926|Drug|Reference Treatment:5 mg amlodipine + 100 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 100 mg losartan tablet administered orally in fasted state as a single dose
45779761|NCT01797926|Drug|FDC 5/50 amlodipine/ losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 50 mg losartan in fasted state
45779762|NCT01797926|Drug|FDC 5/100 amlodipine /losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 100 mg losartan in fasted state
45779763|NCT03008083|Drug|3 months DAPT|Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 90 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
45779764|NCT03008083|Drug|12 months DAPT|Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
45779765|NCT05559398|Drug|Glenzocimab|"Glenzocimab (ACT-017, Acticor Biotech) is formulated for IV administration as a sterile product with 20 mM sodium citrate and 130 mM sodium chloride buffer at pH of 5.0.~It is supplied for clinical trial use in vials containing 50 mL of the drug product at a concentration of 10 mg/mL.~Each vial contains 500 mg of glenzocimab. Two vials (2x500 mg) of glenzocimab should be administered concomitantly for eligible patients for a total daily dose of 1g.~Glenzocimab is intended to be administered as an IV infusion over 6 hrs, with 1/4 of the dose administered by a 15-minute bolus and 3/4 of the dose administered by 5h45min-slow infusion."
45779766|NCT05559398|Drug|Placebo|Placebo of glenzocimab is 0.9%NaCl (Acticor Biotech) for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo of glenzocimab should be administered concomitantly for eligible patients.
45779767|NCT04388462|Other|Finite element analysis|Biomechanical study to describe micromotion
45448703|NCT03647709|Other|opioids|dosage frequency and duration
45779768|NCT01521871|Procedure|Skin wound closure by tissue glue|The glue is used both as closure device and as wound dressing.
45779769|NCT01521871|Procedure|Skin wound closure by conventional suture + dressing|Suture: Intracutaneous skin closure, by running, absorbable suture (Caprosyn 4-0) Dressing: Conventional textile dressing (Mepor)
45779770|NCT00566150|Drug|Levetiracetam|Flexible dose up to 2500mg per day, for 6 weeks.
45779771|NCT00566150|Drug|Placebo|Flexible dose up to 2500mg per day, for 6 weeks.
45641366|NCT05800431|Device|Non-invasive neuromodulation through the Nesa device|patients receive non-invasive neurostimulation through the Nesa device
45641367|NCT05795699|Drug|Ripasudil|K-321 ophthalmic solution
45779772|NCT05565157|Procedure|Zygomatic implants|A robotic assisted new strategy for positioning zygomatic implants will be performed and its efficacy and accuracy will be assess
45779773|NCT01521949|Drug|Acai Juice Product|2 ounces of Acai Juice Product twice daily.
45779774|NCT05559242|Drug|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor
45779775|NCT01522339|Device|GE OPTIMA MR430s with HDX/GE Electronics|MRI scan(s) for no longer than 60 minutes
45779776|NCT00566540|Drug|Cisplatin|Patients will receive Cisplatin (30 mg/m2 i.v.) daily x 3 days in week 1.
45779777|NCT00566540|Drug|Paclitaxel|Patients will receive Paclitaxel (45 mg/m2i.v.) infusion over 3 hours during weeks 7,8,9,10
45779778|NCT00566540|Radiation|Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation|Patients will receive Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation to tumor and involved regional nodes 20Gy over 10 daily (M-F) treatments (2 Gy Fractions with 6 millivolts photons)week 1 and 2.
45779779|NCT00566540|Procedure|Triple endoscopy and biopsy|Resection of the primary tumor: Patients must have surgery performed according to the following surgical guidelines. The extent of the surgical resection will be dictated by the extent of the tumor at the time of initial evaluation. The primary lesion must be widely excised using accepted criteria for adequate excision depending on the region involved. All patients will undergo percutaneous endoscopic gastrostomy tube placement at the time of endoscopy and biopsies.
45779780|NCT00566930|Other|spinal manipulation|Monthly cervical spinal manipulation
45779781|NCT00566930|Other|Spinal manipulation + exercises|Monthly cervical spine manipulation and daily home exercises
45641368|NCT05795699|Drug|Placebo|Placebo ophthalmic solution
45641369|NCT05795686|Other|"Evaluation of program AVanCer"|Evaluation of program AVanCer with quantitative and qualitative approaches
45641370|NCT05795465|Drug|GEn-1124|Intravenous infusion
45641371|NCT05795465|Drug|Placebo|Intravenous infusion
45641372|NCT05795439|Behavioral|Low-fat, vegan diet|The intervention diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Participants will also be guided to favor foods with a low glycemic index. Animal products and added oils will be excluded. The diet is designed to derive approximately 10% of energy from fat, approximately 10-15% of energy from protein, and the remainder from mostly complex carbohydrates. The diet will also provide approximately 40 g of fiber per day.
45779782|NCT00567008|Drug|varenicline|1.0 mg BID for 8 weeks
45641373|NCT05794672|Drug|Elarekibep|Subjects will receive single or multiple inhaled doses A, B or C, or single IV dose D of elarekibep.
45641374|NCT05794672|Drug|Placebo|Subjects will receive single or multiple inhaled doses A, B or C.
45779783|NCT00567008|Drug|placebo|placebo BID for 8 weeks
45779784|NCT00567242|Behavioral|Word-finding with intention component|Word-finding trials (picture-naming) with intention manipulation (initiating word-finding trials with a complex left-hand movement). 8 (or more) baseline sessions over 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
45779785|NCT00567242|Behavioral|Word-finding with no intention component|Word-finding trials with no intention manipulation. 8 (or more) baseline sessions in 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
45779786|NCT00567320|Drug|Varenicline|Varenicline up to 2 mg a day
45779787|NCT00567320|Drug|Sugar pill or Placebo|Placebo
45779788|NCT01522417|Drug|Short Tirofiban|25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.
45779789|NCT01522417|Drug|Eptifibatide|180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.
45779790|NCT01522417|Drug|Long Tirofiban|25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI.
45779791|NCT00568022|Drug|Ixabepilone|Ixabepilone: Intravenous (IV) Solution, IV, 32(40)mg/m^2, once every 3 weeks, up to 6 cycles
45779792|NCT00568022|Drug|Capecitabine|Capecitabine: Tablets, Oral, 1650(2000)mg/m^2, twice daily for 2 weeks, one week off, up to 6 cycles
45779793|NCT05554562|Other|Adductor strength assessment|Adductor strength will be evaluated with HHD (handheld dynamometer) and forceplates (Forceframe), both injured leg and healthy will be assess in order to compare both limbs
45779794|NCT01522963|Drug|Nicotine lozenge|A single dose of nicotine lozenge will be given at various timepoints relative to completion of a somewhat stressful task
45779795|NCT03094286|Drug|Durvalumab|Durvalumab monotherapy of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients until progression significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled
45779796|NCT03071666|Dietary Supplement|cobalamin|Vitamin supplment tablet containing 50µg cobalamin
45779797|NCT03071666|Dietary Supplement|placebo|A tablet identical to the vitamin supplement but containing no vitamin B12
45641375|NCT05794581|Drug|CT-868|CT-868
45641376|NCT05794581|Drug|Placebo|Placebo as SC Injection
45641377|NCT05794581|Drug|Victoza|Victoza as active comparator as SC Injection
45779798|NCT01865162|Other|ketogenic diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
45779799|NCT05363306|Procedure|implant insertion|"4% articaine solution, a mid-crestal incision along the center of the edentulous bone ridge was performed. A full-thickness flap was elevated. The sites were prepared to permit insertion of transmucosal, external hex, implants (I-smart, I-RES, Lugano, Switzerland) at three different crestal levels, based upon vertical mucosa thickness measured at implant placement.~Owing to width crest, all implants were 3.75 mm in diameter and operators selected appropriate implant lengths (8, 10 mm) according to available bone crest height. All implants were not submerged and flaps were sutured around the transmucosal component."
45779800|NCT05363228|Behavioral|Therapy by Dance and Movement|Therapy by dance and movement is based on the principals of movement-analysis by Rudolf Laban and Irmgard Bartenieff. Participants will attend sessions twice a week (90 minutes each) for the duration of three months.
45779801|NCT05363228|Behavioral|Tai Chi|Tai Chi is based on somatic approach. Participants will attend sessions twice a week (90 minutes each) for the duration of three months.
45779802|NCT05547620|Device|LIFUS Online Real|Stimulation using NeuroFUS device while standing
45779803|NCT05547620|Device|LIFUS Online Sham|Stimulation using NeuroFUS device while standing
45779804|NCT05547620|Device|LIFUS Offline|Stimulation using NeuroFUS device prior to standing
45779805|NCT05533580|Drug|Remimazolam|The experimental group was sedated with remimazolam.
45779806|NCT05533580|Drug|Propofol|The control group was sedated with propofol.
45779807|NCT05529914|Other|Myofascial release|It is a type of physical therapy often used to treat myofascial pain syndrome with pressure.
45779808|NCT05529914|Other|Neuromuscular exercises|Exercises commonly utilized in neuromuscular training programs to improve strength, balance , speed and agility. It will comprised of Warm-up, Lunges, Sideways exercises, Wall squats, Weight transfer exercise, Step up & down, Cool-down
45779809|NCT05529914|Other|Cold pack|Application of cold pack around the patient's body, and covered with dry towel
45641378|NCT05794555|Behavioral|Enhanced Usual Care|Patients will be provided and counseled on two methods which will enhance care. The first is a handout on nutrition recommendations and protein supplementation. This will include the recommendation of both high protein snacks during the daytime (e.g., protein bars) and a high-protein night-time snack (e.g., peanut butter and crackers). The second will be to counsel participants on falls prevention methods that can be enacted in day-to-day life. All participants will be provided with a standard hand-out of Centers for Disease Control and Prevention (CDC)-endorsed fall-risk reduction measures.
45779810|NCT02998892|Behavioral|Traditional Exercise Training|Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 4 weeks. This intervention corresponds to the current recommendations.
45779811|NCT02998892|Behavioral|Daily Microbursts of Activity|Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 10 hours, 5 days/week, by brisk walking for 4 weeks.
45779812|NCT05362604|Procedure|scheduled delivery at a tertiary center|Neonatal units in French hospitals are classified in three levels. The intention is for infants requiring high level care to receive it in a tertiary neonatal unit within the same network when appropriate. In case of known fetal gastro-intestinal artesia, the prenatal care includes obstetric consultation and level 3 ultrasound scheduled every four weeks at our unit until the end of the pregnancy, antenatal consultations with a specialized multidisciplinary team, and an antenatal visit of the birth center to reduce the parental anxiety.
45779813|NCT05473286|Drug|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
46070479|NCT04559906|Other|Sustain pressure release|"Group B receive sustain pressure release with conventional treatment. Progressive pressure release are considered in two stages. The initial step is to recognize and find the trigger in upper fiber of trapezius, utilizing trigger point palpation. Trigger point felt as firm and restricted hyperirritable knots with in gut of the muscle.~The second step is to applying pressure release ranging from eight to twelve second for each pressure, then it increases gradually for maximum of twenty seconds. The total duration of pressure is five minutes or more until the discharge is felt by the fingers."
45598094|NCT02704429|Drug|PRN1008|"Part A dosing was initiated administering 400 mg BID. Intrapatient dose adjustments (reductions and increases) were permitted based upon tolerability and clinical response with the maximum dose allowed up to 600 mg BID for 12 weeks.~Part B initial dosing was 400 mg QD for 2 weeks with dose escalation to 400 mg BID at the discretion of the Investigator for the purposes of investigating dose response and identifying the minimal efficacious dose of rilzabrutinib for 24 weeks."
45598095|NCT02209649|Drug|Lacidipine and Telmisartan fixed dose combination (FDC) tablet|
45779814|NCT02129426|Drug|Ketamine|Sedation medication
45779815|NCT02129426|Drug|Midazolam|Sedation medication
45779816|NCT02129426|Drug|Dexmedetomidine|Sedation medication
45598096|NCT02209649|Drug|Lacidipine|
45598097|NCT02209649|Drug|Telmisartan|
45598098|NCT02361567|Drug|Tramacet|Pain medication commonly used post-operatively
45779817|NCT01523821|Drug|Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]|Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia] at various levels over different days
45779818|NCT01523899|Device|Xpert MRSA/SA SSTI|Use of Xpert MRSA/SA SSTI assay
45779819|NCT01523899|Diagnostic Test|Standard culture|
45641379|NCT05794555|Drug|Lactulose|"Patients will be prescribed lactulose and will also receive enhanced usual care. Lactulose will be taken on a specific schedule based on the average number of bowel movements on average per day. It will be started at 15 milliliter (mL) dose and will be instructed to slowly increase the lactulose dose over the course of the first week of Stage 1 participation. The prescribed maximum dose will be 30 mL (20g) twice daily. The dose will slowly increase toward the maximum or until participants reach 2-3 soft bowel movements daily.~Participants that receive Lactulose during stage 1 will continue this in stage 2 (if re-randomized)."
45641380|NCT05794555|Behavioral|Investigator recommended exercise|Participants randomized to enhanced usual care will be reminded of standard fall precautions outlined in the Fall Prevention Primer that were provided in Stage 1 and will receive exercise recommendations.
45641381|NCT05794555|Behavioral|TeleTai-Chi (virtual)|TeleTai-Chi will be taught remotely via live Zoom classes of up to 15 patients by a certified TeleTai-Chi instructor three times per week (for approximately 12 weeks). Classes will be conducted via a HIPAA-compliant Zoom server through the University of Michigan. Participants will be instructed to use Zoom by smartphone, tablet, or computer. High-Definition Multimedia Interface (HDMI) cables to connect devices to televisions will be provided.
45641382|NCT05794516|Drug|ZB004|ZB004 single doses administered subcutaneously as solution
45641383|NCT05794516|Drug|Placebo|Placebo single doses administered subcutaneously as solution
45641384|NCT05794438|Behavioral|Static Approach Bias Modification|In the static approach bias modification, users were instructed to swipe upward when they see portrait format images and swipe downward when they see landscape format images. A shrinking animation comes after swiping upward to simulate the visual effect of moving away (approach), and a growing animation comes after swiping downward to simulate the visual effect of moving towards (avoidance). Two types of images, namely drug-related and non-drug-related, were used in the training. The drug-related images were related to methamphetamine (methamphetamine crystals, powders, and paraphernalia), and the non-drug-related images were related to healthy lifestyles (wealth, sports, gourmet, family activities, etc).
45779820|NCT05409716|Procedure|Compressive Elastic dressing for hemostasis in cardiac procedure using radial approach|Following cardiac procedure using radial approach, compressive elastic dressing, standardized as 13 threads gauze overlapped, opened, longitudinally pleated once and wrapped, making a 5-cm long cylinder, 1-cm in height, fixed with elastic crepe bandage was used to achieve hemostasis.
45779821|NCT05409716|Procedure|Wristband TR band for hemostasis in cardiac procedure using radial approach|Following cardiac procedure using radial approach, hemostatic wristband TR BandR (Terumo Corporation, Tokyo, Japan) was utilized was used to achieve hemostasis.
45779822|NCT01565551|Other|N/A (Observational Study)|No Interventions: Observational Study
45779823|NCT05356598|Other|Authority-delivered Health promotion video|A video delivered by a US Army Lieutenant Colonel (authority figure) encouraging participants to seek help for musculoskeletal injuries experienced while in ROTC.
45779824|NCT05356598|Other|Peer-delivered Health Promotion Video|A video delivered by a US Army ROTC cadet (peer) encouraging participants to seek help for musculoskeletal injuries experienced while in ROTC.
45779825|NCT05356598|Other|Control Group Video|Video of a US Army First Lieutenant squatting, bench pressing, and deadlifting with voiceover. No mention of musculoskeletal injuries or help-seeking behavior.
45779826|NCT05395910|Drug|Paclitaxel|This is a prospective, two armed phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC/ePIPAC using paclitaxel in patients with peritoneal carcinomatosis.
45779827|NCT01566331|Device|Baby-guardTM|Baby-guardTM system, through its ergonomic, three chamber, inflatable abdominal belt, engineered after studies of biomechanics and biophysics, that follows obstetric semiotics, that applies fundal pressure during the second stage of labor in the direction of the pelvic outlet, may be of maternal and fetus aid for a safe natural childbirth for their better outcomes
45779828|NCT05389046|Drug|Escitalopram|Escitalopram
45598099|NCT02361567|Drug|Percocet|Pain medication commonly used post-operatively
45779829|NCT05389046|Drug|Escitalopram+Aripiprazole|Escitalopram+Aripiprazole
45779830|NCT05389046|Drug|Escitalopram+omega-3 PUFAs|Escitalopram+omega-3 PUFAs
45779831|NCT05389046|Drug|Escitalopram+Aripiprazole+omega-3 PUFAs|Escitalopram+Aripiprazole+omega-3 PUFAs
45779832|NCT01566409|Drug|Polyethylene glycol 3350|Powder for solution. Each sachet contains 13.125 g of macrogol 3350. Disimpaction dosage consists of 1,5 g/kg, maintenance treatment are adjusted according til the Bristol stool chart. The drug can be taken at anytime of the day and can also be divided. Treatment duration up to ½ year.
45779833|NCT01566409|Other|Placebo|Placebo will be manufactured and packaged as a powder to make it identical to the bags with the PEG 3350. The powder will comprise of a non-active substance, like a mild rehydration solution, which is a composition consisting of salt and sugar.
45598100|NCT02205749|Behavioral|Study-specific consent model|• Review plain language brochure describing consent to a biobank based on the study-specific model of consent
45598101|NCT02205749|Behavioral|Broad consent model|• Review plain language brochure describing consent to a biobank based on the broad model of consent
45598102|NCT02205749|Behavioral|Notice consent model|• Review plain language brochure describing consent to a biobank based on the notice model of consent
45641385|NCT05794438|Behavioral|Adaptive Approach Bias Modification|In the adaptive approach bias modification, users were instructed to swipe upward when they see portrait format images and swipe downward when they see landscape format images. A shrinking animation comes after swiping upward to simulate the visual effect of moving away (approach), and a growing animation comes after swiping downward to simulate the visual effect of moving towards (avoidance). Two types of images, namely drug-related and non-drug-related, were used in the training. The drug-related images were related to methamphetamine (methamphetamine crystals, powders, and paraphernalia), and the non-drug-related images were related to healthy lifestyles (wealth, sports, gourmet, family activities, etc). An algorithm continuously monitors the performance of the user and adjusts the ratio of congruent and incongruent trials accordingly to attain a desired difficulty curve.
45641386|NCT05794412|Other|No intervention|No intervention
45641387|NCT05793684|Drug|Period A|Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo
45641388|NCT05793684|Drug|Period B|Week 1: AD816 low dose; Week 2: AD816 high dose
45641389|NCT05793684|Drug|Period C|Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
45641390|NCT05792956|Behavioral|Using mobile app|Women with OAB in this group will be informed about mobile application usage. The group using the mobile application will add the times they have consumed fluid and urine leakage to the bladder diary section of the mobile application. During the day, the application will remind participants to consume fluids and urinate. There will also be a question and answer section in the mobile application. Women will be able to direct their questions about OAB to the researcher. After the first meeting, the scales sent through the mobile application will be applied in the 3rd and 6th months.
45641391|NCT05791318|Drug|VYD222|Monoclonal antibody
45641392|NCT05791318|Other|Placebo|Matching Placebo
45641393|NCT05790915|Combination Product|Standardized interventions|Standardized interventions according organ dysfunction
45641394|NCT05790304|Drug|Camizestrant|Camizestrant 75 mg tablets. Experimental drug.
45641395|NCT05789394|Biological|Allogeneic Adipose-derived Mesenchymal Stem Cells|Receive IT
45641396|NCT05789394|Procedure|Biospecimen Collection|Undergo blood sample collection
45641397|NCT05789394|Procedure|Craniotomy|Undergo craniotomy
45641398|NCT05789394|Procedure|Magnetic Resonance Imaging|Undergo MRI
45641399|NCT05789394|Procedure|Ommaya Reservoir Tap|Undergo Ommaya reservoir placement for collection of CSF
45641400|NCT05789082|Drug|GDC-6036|Participants will receive one of two doses of GDC-6036 orally (PO), QD on days 1-21 of each 21-day cycle.
45641401|NCT05789082|Drug|Pembrolizumab|Participants will receive a 200 mg IV infusion of pembrolizumab Q3W on Day 1 of each 21-day cycle.
45598103|NCT03112785|Device|Total hip arthroplasty (Fitmore or CLS uncemented femoral stem made by Zimmer-Biomet, Warshaw, USA)|The most symptomatic side is randomised to one of the two stem types studied. If the patient has equal amount of symptoms on both sides, the one with most pronounced degenerative Changes on plain radiographs will be randomised. On the second side the type of stem not used on the first one will be inserted. All patients and allhip will receive the same type and design of cup.
45598104|NCT02205827|Other|Single-arm|collection of blood for assessment of whole blood clotting time
45641402|NCT05788692|Device|electric tootbrush|Participants will brush twice per day with an electric toothbrush
45641403|NCT05788692|Device|manual toothbrush|Participants will brush twice per day with a manual toothbrush
45641404|NCT05788692|Device|toothbrushing assisting application|Participants will brush twice per day with toothbrushing assisting application
45641405|NCT05786118|Other|No intervention|There is no intervention in this study
45641406|NCT05785949|Procedure|Microfracture|Use of standard tool kit to drill vertically from the periphery to the center with a hole spacing of 3~4 mm with care to prevent penetrating adjacent holes. The hole depth should be 3~5 mm and fat droplets or blood oozing is seen after loosening the tourniquet. However, no blood oozing is observed in some holes and in such case, the hole depth should be deepened to 5~7 mm.
45641407|NCT05785949|Device|Chondro-Gide bilayer collagen membrane|After the Microfracture, the porous layer of the bilayer collagen membrane faces the bone surface. The already trimmed, cut and wetted membrane is insert into the defect and fixed symmetrically with absorbable surgical suture with needle. Knots are put on the pinhole of collagen membrane to avoid tearing of surrounding cartilage or collagen membrane during knotting.
45779834|NCT04388696|Behavioral|Sisterhood 2.0|The Sisterhood 2.0 curriculum was adapted from Program M, created in 2006 by Promundo to address health and empowerment of young women aged 15-24. The curriculum engages young women in questioning rigid and non-equitable stereotypes about masculinity and femininity and how they affect both women's and men's health and well-being.
45779835|NCT02184416|Other|observational|The study is non interventional. All drugs will be prescribed
45779836|NCT04387838|Diagnostic Test|Anti-SARS-CoV2 Serology|A blood sample is collected by venipuncture at Day 0, Day 30 and Day 60. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France.
46070480|NCT04633694|Dietary Supplement|insect, pea or whey protein|The protein powder is dissolved in 400 mL water and given relative to lean body mass, 0.25 g protein pr kg lean body mass.
45598105|NCT02361879|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later
45598106|NCT02361879|Drug|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
45598107|NCT03133429|Device|MER|carotid artery stenting
45598108|NCT05262335|Drug|Anlotinib + Oxaliplatin + Capecitabine|"Before 6 cycles, Anlotinib 12mg, po.qd, d1-14; Capecitabine 850 mg/m2, po. bid, d1-14; Oxaliplatin 130 mg/m2, iv (D1). The above schemes are repeated every three weeks.~After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
45598109|NCT05262335|Drug|Anlotinib + Cisplatin + Paclitaxel/ Docetaxel|"Anlotinib 12mg, po.qd, d1-14; Cisplatin 60-75mg/m2, iv, d1/d1-d3; Paclitaxel 135mg/m2, iv (D1). or Docetaxel 75mg/m2, iv (D1). The above schemes are repeated every three weeks.~After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
45641408|NCT05785806|Behavioral|Skin to skin contact and co-parenting theory course|On the day before delivery, pregnant women and their husbands attend a course on the theory of skin contact and co-parenting to explain the role and importance of skin contact ; to understand the knowledge of co-parenting and parenting care ; to learn the communication method and future parenting plan based on the theory of co-parenting, and to learn the operation of skin contact with newborns after delivery.
45641409|NCT05785806|Behavioral|Skin to skin contact instruction manual and co-parenting theory brochure|According to reading and analyzing the literature on skin contact, summarize the content of skin contact operation guidance ; read and analyze the relevant literature of co-parenting theory, and summarize the theoretical knowledge and practical operation methods of co-parenting. Pregnant women and their spouses can check in time.
45641410|NCT05785806|Behavioral|Daily face-to-face skin to skin contact guidance during hospitalization|After delivery, face-to-face skin-to-skin contact guidance and co-parenting communication and practice were given to the parturient and her husband on a daily basis during hospitalization. Establish a daily fixed skin contact duration target, and the specific operation is freely allocated by both parents.
45641411|NCT05785806|Behavioral|Online punching skin to skin contact|Share common parenting related knowledge, daily skin contact reminders, emphasize mutual recognition and mutual support of parents, and conduct WeChat follow-up every two weeks to understand the physical and mental status of both parties and the growth of infants.
45641412|NCT05785806|Behavioral|Routine obstetric care|Routine prenatal training and postpartum education, including basic breastfeeding guidelines, touching, etc.
45641413|NCT05785741|Drug|DB-1310|Administered I.V.
45779837|NCT04387838|Other|Questionnaire|"Data concerning personal exposure factors are collected in a questionnaire:~Socio-demographic factors: sex, age~Professional factors: Employment (type, pace, reception, service, care practices), wearing of personal protective equipment (type of equipment, frequency of use) and type of hospital~Non-professional factors: Contact with infected individuals, carrying of professional equipment and compliance with barrier measures"
45641414|NCT05785390|Drug|NP-101|NP-101 is an organically derived, GMP manufactured product covered under IND #152687.
45641415|NCT05785390|Other|Placebo|Identical placebo
45779838|NCT01567891|Biological|NYESO-1c259 T cells|Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells. Patients will receive at least 1x10⁹ transduced cells, however the target dose for this protocol is for patients to receive 5x10⁹ transduced cells with a maximum possible dose of 6x10⁹ administered as a single intravenous (IV) infusion.
45641416|NCT05784012|Drug|Dostarlimab|Dostarlimab 500 mg IV every 21 days in neoadjuvant and adjuvant stage.
45641417|NCT05784012|Drug|Niraparib|Niraparib 200 or 300mg orally administered QD in neoadjuvant, concurrent with radiotherapy and adjuvant stage until completing week 48.
45779839|NCT05354336|Drug|SHR6390(100mg)|SHR6390 at a single oral dose of 100 mg.
45779840|NCT05354336|Drug|SHR6390(125mg)|SHR6390 at a single oral dose of 125 mg.
45779841|NCT05354336|Drug|SHR6390(150mg)|SHR6390 at a single oral dose of 150 mg.
45779842|NCT05564923|Drug|there is no intervention|there is no intervention
45779843|NCT05349110|Device|Computer-aided diagnosis (CADx) systems|"AI4CRP (artificial intelligence for colorectal polyps), a CNN based computer-aided diagnosis system for diagnosis of colorectal polyps (COMET-OPTICAL research group);~CAD EYE, a computer-aided diagnosis system for diagnosis of colorectal polyps (Fujifilm® Corporation, Tokyo, Japan)."
45779844|NCT01568827|Dietary Supplement|Blackraspberry Slurry|Blackraspberry slurry is 45 g blackraspberry powder mixed in 8oz. water. This is equivalent to 450 g fresh black raspberries.
45779845|NCT05245370|Behavioral|Control video|Control group 1 will see a control video consisting of basic information about the different types of psychotherapy that are covered by insurance in Germany and the process of applying for psychotherapy with the insurance. The control video is matched in duration (10 minutes), set-up and the overall topic (psychotherapy) to the intervention video testimonials.
45779846|NCT05245370|Behavioral|Rationale video|The active control group 2 will see a short rationale and the control video. The rationale is a 2:45 minute-long animated video (designed via the visual communication platform powtoon, https://powtoon.com/) explaining some of the underlying mechanisms of depression.
45779847|NCT05245370|Behavioral|Clinician testimonial|This group will see the rationale video first, followed by testimonial of a professional clinician/psychotherapist.
45779848|NCT05245370|Behavioral|Patient testimonial|This group will see the rationale video first, followed by testimonial of a patient who is being treated for depression with psychotherapy.
45779849|NCT01568905|Other|Low level nicotine cigarette|smoke the study cigarette exclusively for one week
45779850|NCT01568905|Other|Intermediate nicotine level cigarette|smoke the study cigarette exclusively for one week
45779851|NCT01568905|Other|High level nicotine cigarette|smoke the study cigarette exclusively for one week
45779852|NCT05322980|Diagnostic Test|Microcephaly|Those with a z score of birth head circumference < -2 (primary microcephaly) are classified into the Microcephaly group.
45779853|NCT01569451|Drug|Rituximab|intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
45641418|NCT05784012|Drug|cisplatin plus radiotherapy|In the concurrent phase
45641419|NCT05784012|Drug|Niraparib|Niraparib 200 or 300mg orally administered QD (Neoadjuvant and Maintenance stages).
45641420|NCT05783505|Other|Multicomponent intervention program|Non-pharmacological interventions combined with goal directed sedation using dexmedetomidine if needed
45641421|NCT05782218|Dietary Supplement|Almonds|Participants will receive 2.2 oz (62 g) of almonds to ingest within 15 minutes.
45641422|NCT05782218|Dietary Supplement|Coconut|Participants will receive 1 oz (30 g) of a coconut-chocolate bar and 1.4 oz (40 g) of 100% dried coconut chips to ingest within 15 minutes.
45641423|NCT05780710|Other|Aktiia Optical Blood Pressure Monitoring (OBPM) device and antihypertensive drugs|"The device under test is Aktiia Optical Blood Pressure Monitoring (OBPM) device and the comparator is the Aktiia cuff.~The 3 drug treatments are the following ones:~Perindopril Arginine 5 mg (Angiotensin Converting Enzyme (ACE) inhibitors)~Indapamide 1.5 mg (Diuretics)~Amlodipine 5 mg (Calcium channel blockers)"
45641424|NCT05777993|Drug|Mitapivat|Tablets
45779854|NCT01569451|Drug|Glatiramer Acetate|20 mg injected subcutaneously daily
46070481|NCT04624334|Other|Elektro-Entero-Graphy procedure|Fasting, after which pre- and postprandial EEnG measurements are performed.
45641425|NCT05776524|Drug|Nab paclitaxel|125 mg/m2 weekly, on days 1,8, and 15 or on days 1 and 15 as a 30-40 minute infusion administered first
45779855|NCT01569451|Other|Placebo|Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab or placebo (normal saline) on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
45779856|NCT01569529|Behavioral|Online advertisement|Internet advertisement with messages tailored for young adult smoker's motivated to quit
45779857|NCT01569607|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Training sessions for 5 days in a row
45779858|NCT01569607|Device|Sham stimulation|Sham stimulation
45779859|NCT05564845|Diagnostic Test|MR scan of the brain|Subjects will undergo MRI of the head, blood sampling and neurological examination on the same day or spread over 2 days. On a separate day from blood sampling and undergoing an MRI scan, the neuropsychological assessment will take place. The interval between the MRI scan and the neuropsychological assessment will be a maximum of 2 months. These measurements will be performed a total of 3 times with an interval of 2 years.
45779860|NCT05564845|Diagnostic Test|Blood work|Lab work for current lab values and biobanking
45641426|NCT05776524|Drug|Gemcitabine|1000 mg/m2 weekly, on day 1,8 and 15 or 1000 mg/m2 weekly, on day 1 and 15 over 30 minutes after nab- paclitaxel infusion
45641427|NCT05776524|Device|TheraBionic|This treatment consists of delivering low levels of radio waves into the body with a spoon-shaped antenna placed in the mouth, three times a day, for an hour each time.
45779861|NCT05564845|Diagnostic Test|Neurological examination|Classical neurological examination
45779862|NCT05564845|Diagnostic Test|Neuropsychological assessment|"Overview of standard neurocognitive assessment tools in BRICK study Children and adolescents (Young) Adults~Wechsler Intelligence Test for Children- Fifth edition (WISC-V) (6-16 YOA) Wechsler Adult Intelligence Scale- Fourth edition WAIS-IV (16-24 YOA)~A Developmental NEuroPSYchological Assessment, Second Edition (NEPSY-II)~Narrative memory~Word fluency~Route finding NEPSY-II~World Fluency~Additional Questionnaires (6-18 years):~Child Behavior Checklist (CBCL)~Teacher Report Form (TRF)~Youth Self Report (YSR)~Behavior Rating Inventory of Executive Function (BRIEF), parent- and teacher-report)~Conners-3® • Additional Questionnaires (18+ years):~Adult Self-Report (ASR) / Adult Behavior Checklist (ABCL) (in case of IQ<70)~Behavior Rating Inventory of Executive Function Adult version (BRIEF-A), self-report / informant-report (in case of IQ<70)~Conners' Adult ADHD Rating Scales (CAARS)~Emma toolbox"
45779863|NCT02132936|Drug|LEO 90100 aerosol foam|
45779864|NCT02132936|Drug|Aerosol foam vehicle|
45779865|NCT02132936|Drug|Calcipotriol BDP gel|
45641428|NCT05776498|Procedure|immediate implant placement with particulate bone graft using the dual zone technique.|Tooth extraction and immediate implant placement as mentioned, then particulate bone graft will be packed in the gap between the implant and the buccal plate of bone and the tissue (dual zone), then will be covered by a customized healing abutment.
46070482|NCT04624334|Other|EEnG Questionnaire|Filling out questionnaire about EEnG procedure.
45641429|NCT05776498|Procedure|immediate implant placement with connective tissue grafting|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supraperiosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
45641430|NCT05775068|Radiation|Radiotherapy|Radiotherapy
45641431|NCT05770609|Drug|SPH3127 Tablets with Dose A|See Arm description
45641432|NCT05770609|Drug|SPH3127 Tablets with Dose B|See Arm description
45641433|NCT05770609|Drug|SPH3127 Tablets placebo|See Arm description
45641434|NCT05770518|Behavioral|Biofeedback|Biofeedback is a strategy used in the treatment of PVFM, which involves allowing patients to directly visualize their breathing patterns during laryngoscopy.
45641435|NCT05770518|Behavioral|Laryngeal control therapy (LCT)|This treatment typically involves 2 guided therapy sessions that include patient education, relaxation techniques, and training in specific breathing techniques.
45641436|NCT05769959|Drug|RO7515629|RO7515629 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.
45641437|NCT05769959|Drug|tocilizumab|Tocilizumab will be used as rescue medication only. Tocilizumab will be administered as required for the management of cytokine release syndrome (CRS).
45779866|NCT02132936|Drug|Gel vehicle|
45779867|NCT05300516|Procedure|vagus nerve-guided group|The vagus nerve-guided procedure was performed in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, blunt dissect the left lateral surface of the distal esophagus using Bipolar Forceps, and find posterior vagal trunk; (3) along posterior vagal trunk towards left lateral esoph-agogastric junction, find and protect gastric and celiac branches; (4) enter the lesser omental sac from the right crural diaphragm using Bipolar Forceps; (5) transect the left gastric artery and vein together using a linear vascular stapler; (6) blunt dissect the anterior surface of the distal esophagus using Bipolar Forceps, and find anterior vagal trunk; (7) along anterior vagal trunk towards right lateral esoph-agogastric junction, find and protect gastric and hepatic branches; and (8) blunt dissect the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved.
45779868|NCT01528891|Drug|Dexmedetomidine|0.5 micrograms/Kilogram one time bolus 5 minutes prior to the end of surgery
45779869|NCT01528891|Other|Placebo|
45779870|NCT05230628|Device|Active TENS|Active TENS stimulation will occur daily for 10 minutes, 3-4 times a day, 30 minutes before the main meals. The duration will be 6 months for each patient.
45779871|NCT05230628|Device|Sham TENS|Sham TENS stimulation will occur daily for 10 minutes, 3-4 times a day, 30 minutes before the main meals. The duration will be 6 months for each patient.
46070483|NCT04624334|Other|Gold Standard Questionnaire|Filling out questionnaire about Gold Standard diagnostic used to diagnose colonic motility disorder.
46070484|NCT04619498|Device|PediAppRREST|PediAppRREST is a new audiovisual interactive app for tablets developed to support the management of pediatric cardiac arrest. It sequentially displays directions on recommended management interventions. It was specifically designed to guide the team leader to perform resuscitation interventions in the sequence/timing and modality reported by the American Heart Association Pediatric Advanced Life Support (AHA-PALS) guidelines.
45641438|NCT05769517|Diagnostic Test|Germinal BRCA|We will conduct a multicenter prospective observational study aimed at automatically implementing the predictive model and collecting US images of healthy ovaries from patients tested for germline BRCA pathogenetic variants according to current indications.
45641439|NCT05769153|Drug|AR-14034 SR implant lower dose|AR-14034 SR administered as an intravitreal implant
45641440|NCT05769153|Drug|Aflibercept Injection|Aflibercept administered as a 2 milligram (mg) intravitreal injection
45641441|NCT05769153|Drug|Sham procedure|Needleless syringe used to simulate an intravitreal injection
45641442|NCT05769153|Drug|AR-14034 SR implant higher dose|AR-14034 SR administered as an intravitreal implant
45641443|NCT05768854|Drug|Bisphosphonate|Administered per investigator discretion via intravenous (IV) infusion
45641444|NCT05768854|Biological|Setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
45641445|NCT05768360|Drug|Savolitinib|The subjects will receive single dose of oral film-coated tablet of Savolitinib A dose on Day 1 of Period 2 within 25 minutes [+ 5 minutes] from the start of meal.
45641446|NCT05768360|Drug|Digoxin|The subjects will receive single dose of oral uncoated tablet of Digoxin Dose B on Day 1 of Period 1 and Period 2 within 25 minutes [+ 5 minutes] from the start of meal.
45641447|NCT05768360|Drug|Metformin Hydrochloride|The subjects will receive single dose of oral film-coated tablet of Metformin Hydrochloride Dose D on Day 1 of Period 1 and Period 2 within 25 minutes [+ 5 minutes] from the start of meal.
45779872|NCT05198102|Biological|Recombinant novel coronavirus vaccine (CHO cells)|At 12 months after the basic immunization (window period ± 3 months), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
45779873|NCT05289596|Behavioral|Sleep Healthy Using the Internet (SHUT-i)|SHUTi is a six session, 6-8 week cognitive behavioral therapy for insomnia program over the internet. The online, self-paced program offers illustrations, graphics, videos and built-in algorithms offering brief sleep diaries, personalized sleep window recommendations, education from sleep experts, peer stories about insomnia, and skills to help participants relearn proper sleep dynamics and increase sleep efficiency.
45916482|NCT05636254|Diagnostic Test|Reference standard diagnostic criteria|"Diagnostic criteria-TBM~Microbiologic evidence of TB in CSF~Microbiologic evidence of TB from pulmonary or extrapulmonary sites~Reasonable clinical certainty OR allied investigations such as CXR/CECT chest/abdomen/PET CT as per clinical indication suggestive of tuberculosis~Other relevant investigations like CSF analysis not suggestive of alternative diagnosis such as neurocysticercosis/cryptococcal/other fungal infections/other causes of chronic meningitis such as brucella/ nocardia/ syphilis/recurrent viral meningitis/ carcinomatous/ lymphomatous meningitis or non infective causes such as sarcoidoisis/sub-arachnoid hemorrhage etc.~Reasonable clinical certainty OR allied investigations such as CXR/CECT chest/abdomen/PET CT as per clinical indication ruling out competing diagnoses~Patients who develop features or test results suggestive of alternative diagnosis with will be considered to be not due to tubercular meningitis"
45916483|NCT05636332|Diagnostic Test|12 lead Electrocardiogram|12 lead Electrocardiogram
45641448|NCT05768360|Drug|Rosuvastatin|The subjects will receive single dose of oral film-coated tablet of Rosuvastatin Dose E on Day 1 of Period 1 and Period 2 within 25 minutes [+ 5 minutes] from the start of meal.
45916484|NCT05636410|Diagnostic Test|Larynx and trachea ultrasound|After meeting enrolment criteria the larynx and trachea ultrasound will be performed at 32 and 42 weeks of gestation.
45916485|NCT05636488|Other|No intervention|There is no intervention group in this study
45916486|NCT05636553|Other|Massage|Individualised treatment using massage techniques such as longitudinal gliding, transverse gliding, digital ischemic pressure, transverse frictions, and transverse gliding.
45641449|NCT05768360|Drug|Furosemide|The subjects will receive single dose of oral solution of Furosemide Dose C on Day 1 of Period 1 and Period 2 within 25 minutes [+ 5 minutes] from the start of meal.
45916487|NCT05636566|Drug|Sevoflurane|inhalational anaesthesia for maintenance
45916488|NCT05636566|Drug|Propofol infusion for maintance|propofol infusion after induction for maintenance of anaesthesia
45916489|NCT05636566|Drug|Dexmedetomidine|0.5 mic /kg dexmedetomedine is injected after induction of anaesthesia
45641450|NCT05767944|Other|local anaesthesia infiltration|Infiltration of 150 mg of lidocaine solution per ray at site of surgical incision for flexor tendon repair in the palm, the 2 proximal & distal phalanges
45641451|NCT05767944|Other|brachial plexus block|ultrasound-guided infiltration of local aesthetics around brachial plexus trunks & divisions
45641452|NCT05766787|Device|Serafilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
45641453|NCT05766787|Device|Senofilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
45641454|NCT05766787|Device|CLEAR CARE|Hydrogen peroxide based contact lens cleaning and disinfecting solution
45641455|NCT05765253|Device|Scorpion Portal Vein Access Kit|Portal Vein Access with Scorpion or Scorpion X set
45641456|NCT05765253|Device|Cook Transjugular Liver Access Set|Portal Vein Access with Ring or Rosch-Uchida set
45779874|NCT01529203|Drug|Botulinum Toxin Type A (Azzalure)|Powder for solution for injection
45779875|NCT01529203|Device|Restylane ranges|Hyaluronic acid (HA) 20 mg/mL + Lidocaine 0.3% (Restylane® Lidocaine, Restylane® Perlane™ Lidocaine, Restylane® SubQ Lidocaine, Restylane® Lip Volume, Restylane® Lip Refresh)
45779876|NCT01529827|Drug|fludarabine phosphate|Given IV
45779877|NCT01529827|Drug|melphalan|Given IV
45779878|NCT01529827|Radiation|total-body irradiation|Undergo TBI
45779879|NCT01529827|Drug|tacrolimus|Given IV or PO
45779880|NCT01529827|Drug|mycophenolate mofetil|Given IV or PO
45779881|NCT01529827|Drug|methotrexate|Given IV
45779882|NCT01529827|Other|laboratory biomarker analysis|Correlative studies
45779883|NCT01529827|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
45779884|NCT01529827|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
45779885|NCT00569192|Drug|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
45641457|NCT05765253|Procedure|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Transjugular Intrahepatic Portosystemic Shunt (TIPS)
45779886|NCT00569192|Drug|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
45779887|NCT00569192|Drug|Placebo|Placebo delivered by nebulization twice daily for 12 weeks
45779888|NCT05289206|Other|Vaccine - ChAdOx1-S/nCoV-19 [recombinant]|ChAdOx1-S/nCoV-19 [recombinant] - 0.5 mL single dose, intramuscular in deltoid, with an interval of 180 days (+/- 30 days) from the 2nd dose of the initial vaccination schedule with CoronaVac
45779889|NCT01571557|Drug|dexamethasone 700 ug intravitreal implant|dexamethasone 700 ug intravitreal implant administered according to standard of care.
45641458|NCT05764135|Behavioral|SCI-Lynx Mobile Application|. The SCI-Lynx application will enable people to find others with the same chronic condition who have similar exercise interests and goals. Individuals can make social connections, set, and track their exercise goals and support one another in their physical activities. It provides content customized for each condition to encourage participant's belief in the benefits of exercise and improve their self-efficacy for exercise through tracking of their own progress. An additional feature of SCI-Lynx is the ability to direct messages to other individuals or create subgroups within their network providing a further social support for individuals with SCI.
45779890|NCT00569660|Drug|Azacitidine|75 mg/m^2 subcutaneous daily for 7 days (every 4 week cycle)
45779891|NCT05129228|Device|OCT-guided saphenous vein CABG|OCT examination of harvested saphenous vein conduits will indicate pathology. Under the surgeon's discretion the conduit segments with pathology will not be grafted.
45779892|NCT01573273|Drug|Oxytocin|intranasal administration, 40 IUs
45779893|NCT01573273|Drug|Saline|intranasal administration, 40 IUs
45779894|NCT00572234|Drug|bupropion SR|12 week course of bupropion SR 150 mg, BID
45779895|NCT01574287|Drug|FACBC|Drug is give intravenously over 2 minutes at time of scan
45641459|NCT05763576|Drug|RO7565020|RO7565020 will be administered by subcutaneous injection or intravenous infusion.
45779896|NCT00572468|Drug|Simvastatin|40 mg of simvastatin
45779897|NCT00572468|Other|Placebo|placebo
45779898|NCT02339246|Drug|Prograf vs Envarsus XR vs Astagraf XL|prograf vs Envarsus XR vs Astagraf XL
45779899|NCT02339246|Drug|Prograf vs Astagraf XL vs Envarsus XR|Prograf vs Astagraf XL vs Envarsus XR
45916490|NCT05636644|Drug|Taxol|All patients received TAC regimen: both groups received AC (epirubicin 75 mg/m ² and cyclophosphamide 500mg/m ²)， Group A was treated with docetaxel for 6 cycles every 3 weeks (75 mg/m on the first day ²)； Group B received six cycles of nab paclitaxel (125 mg/m ²)， every 3 weeks is a course of treatment.
45916491|NCT05636722|Behavioral|Unguided web-based intervention|An online unguided intervention based on Cognitive Behavioural Therapy and elements of Dialectical Behaviour Therapy, Problem Solving Therapy, and Mindfulness Based Cognitive Therapy. The intervention consists of 6 modules with each a theoretical part, a weekly assignment and (optional and mandatory) exercises. Participants are advised to complete one module weekly. The original intervention was adapted to students (language, addition of podcasts, examples that were more suited to their lives).
45916492|NCT05447143|Other|Fatigue Severity Scale|Evaluation for severity of fatigue
45916493|NCT05447143|Other|Berg Balance Test|Evaluation of balance
45916494|NCT05447143|Other|Time up and go- 25 steps walking test|Evaluation for walking
45916495|NCT05447143|Other|Multiple Sclerosis Quality of Life|Evaluation of quality of life
45916496|NCT05447143|Other|Brief International Cognitive Assessment for MS (BICAMS)|Evaluation of cognitive functions
45916497|NCT05447143|Other|Beck Depression and Anxiety Scale|Evaluation of depression and anxiety
45916498|NCT05636631|Device|Chest ultrasound|chest ultrasound as a non invasive, low cost & bedside device for differentiation & follow up of lung congestion & pneumonia
45641460|NCT05763576|Other|Placebo|Matching placebo will be administered by subcutaneous injection or intravenous infusion.
45641461|NCT05763576|Drug|Nucleos(t)ide analogue (NUC) treatment|NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.
45916499|NCT05636761|Diagnostic Test|Heart rate variability|Collection and Analysis of Heart Rate Variability
45641462|NCT05763121|Drug|Dexpramipexole Dihydrochloride|oral administration of dexpramipexole tablet
45916500|NCT05636839|Radiation|UVB treatment|UVB treatment 3 times per week for 10 weeks
45916501|NCT05636956|Other|Education and Counseling Program|Researches created an education and counseling program. In this context, patients receive an one hour education. Education program consist of face-to-face informing and teach-back method. At the end of the face-to-face informing, researchers give a comicbook about instructions of living with CIEDs as a written material. After discharge, researches follow-up patients with phone calls. In the context of phone calls researches continue to informing patients, remind related instructions for that time and answer questions of patients. Patients are allowed to reach reserarches any time if they have any concern or question. This program lasts for six months.
45916502|NCT05636995|Diagnostic Test|Aldosterone/Renin Ratio|Blood sample collected to measure the aldosterone/renin ratio for the primary hyperaldosteronism screening.
45916503|NCT05637034|Diagnostic Test|68Ga-DOTA-F2 PET/CT and 18F-FDG|Each subject receive a single intravenous injection of 68Ga-DOTA-F2 and 18F-FDG, and undergo PET/CT imaging within the specified time.
45779900|NCT00572936|Drug|Latanoprost|prostaglandin
45779901|NCT00572936|Drug|Dorzolamide|carbonic anhydrase inhibitor
45779902|NCT00572936|Drug|Timolol|beta blocker
45779903|NCT05085626|Drug|fluzoparib+chidamide|Arms A will be treated with fluzoparib in combination with cedaramide
45779904|NCT05085626|Drug|fluzoparib+camrelizumab|Arms B will be treated with fluzoparib in combination with camrelizumab
45779905|NCT05041946|Drug|Methylphenidate|Given PO
45779906|NCT05041946|Other|Placebo (Sugar Pill)|Given PO
45779907|NCT00573872|Radiation|Radiosurgery|"Phase I: 20-25 Gy in 5 fractions~Phase II: 9-24 GY in 1 fraction"
45779908|NCT05092412|Radiation|Low-dose radiotherapy|The LDRT deals with primary tumour in a 15 Gy of 5fractions over five days, starting from Day 1 in the first cycle.
45779909|NCT05092412|Drug|Durvalumab|Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy.
45779910|NCT05092412|Drug|Etoposide, and cisplatin/carboplatin|Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide [80 to 100mg/m2] via intravenous infusion and carboplatin [ The area under the curve (AUC) is 5-6] by intravenous infusion or cisplatin [75-80 mg/m2] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator.
45779911|NCT00574340|Other|Hyperinsulinemic Hypoglycemic Clamp|all participants received (2) hyperinsulinemic glucose clamp studies separated by 8 weeks
45641463|NCT05763121|Drug|Placebo|oral administration of placebo tablet
45641464|NCT05760300|Drug|Bulevirtide (BLV)|Administered via subcutaneous (SC) injections
45641465|NCT05759078|Drug|Ferinject|The first dose of FCM will be administered during the first visit on the day of randomisation (V1). Then, the participants will be reassessed at 4 and 8 months (visits V2, V3) for: haemoglobin, serum ferritin and TSAT. They will receive an additional dose of 1000 mg of FCM during these visits if ferritin <100 ng/mL or/and TSAT <20% (ferritin cannot exceed 400 ng/dL, TSAT cannot exceed 40%, haemoglobin cannot exceed 15 g/dL). If these criteria are not fulfilled, a patient in the active study arm will receive i.v. NaCl 0.9% during the particular visit.
45641466|NCT05759078|Drug|Sodium Chloride 0.9% Inj|The first dose of placebo will be administered during the first visit on the day of randomisation (V1). During visits V2 i V3 (at 4 and 8 months) they will receive next dose of placebo.
45641467|NCT05758727|Other|Exercise intervention|The exercise programme is progressive and has three levels. Each bout of exercise and Tai-chi snacking consists of 5 exercises. Each exercise is performed for one minute with one minute rest in between. For exercise snacking movements (including leg exercise, shoulder exercise, single leg exercise, arm exercise, and ankle exercise), participants are encouraged to complete as many repetitions as possible of that exercise in that minute. For Tai-chi snacking movements (including single leg squat, trunk rotation, single leg stand, hip and knee exercise, and ankle mobility exercise), participants are encouraged to complete repetitions of each exercise at a self-selected pace that is comfortable for them to maintain for the full minute, with the aim being to complete the movements as accurately and smoothly as possible (based on correct posture and proper alignment).
45779912|NCT05004896|Drug|Ketamine Hydrochloride|50 patients will receive ketamine hydrochloride, over four infusions, flexibly dosed between 0.5 mg/kg to 0.75 mg/kg
45779913|NCT05004896|Drug|Midazolam Hydrochloride|50 patients will receive midazolam hydrochloride, over four infusions, flexibly dosed between 0.02 mg/kg to 0.03 mg/kg
45779914|NCT05005754|Dietary Supplement|Probiotics|During the study period, subjects are instructed to take one capsule of probiotics daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
45916504|NCT05636709|Device|Adacolumn|Non interventional study
45641468|NCT05757908|Drug|Long-Acting Beta Agonist|The Investigator will prescribe standard of care LABA to eligible study participants. Participants will self-administer LABA once or twice daily at the maximum feasible standard of care dosage, per the time points specified in the study Schedule of Assessments. LABA should be taken within 1 to 3 hours prior to morning and evening at-home mobile Spirometry testing.
45779915|NCT05005754|Dietary Supplement|Placebo control|During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
45779916|NCT01798082|Other|Pelvic organ prolapse decision aid|
45779917|NCT01771718|Device|MPTflex-multiphoton microscopy-based tomograph.|non-invasive optical biopsy
45779918|NCT00576680|Drug|RAD001|Given orally once a day
45779919|NCT00576680|Drug|Temozolomide|Taken orally once a day for one week followed by a one-week break period
45779920|NCT04866602|Drug|Atoguanil|Atovaquone + Proguanil free base:125 mg: 87 mg, 4 tablets
45779921|NCT04866602|Drug|Malarone|Atovaquone + Proguanil HCl: 250 mg: 100 mg, 4 tablets
45641469|NCT05755906|Drug|BFF MDI 160/9.6 μg BID (320/19.2μg/day)|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg BID (320/19.2μg/day)
45641470|NCT05755906|Drug|BD MDI 160 μg BID (320 μg/day)|Budesonide (BD) metered-dose inhaler (MDI), 160 μg BID (320 μg/day)
45641471|NCT05755347|Other|General health survey questionnaires|Patient-reported outcome survey will be offered at baseline.
45779922|NCT04945538|Other|Scatter radiation exposure measurement|Scatter radiation exposure of the operator and sterile assistant is recorded with digital live dosimeters at 3 locations of the operator (frontal head at eye level, left lateral head, below the left shoulder) and at 2 locations of the sterile assistant (left neck and below the left shoulder)
45779923|NCT04730648|Drug|PCSK9 inhibitor|For newly diagnosed ACS patients with diabetes, multivessel occlusion, or recurrent ACS attack, who are willing to accept PCSK9 inhibitor injection.
45779924|NCT05246540|Other|Data collection|Data collection
45916505|NCT05637073|Drug|Dienogest|Some women in the cohort will be treated with dienogest for one year after consensus with the physician
46070485|NCT04619498|Other|AHA-PALS pocket reference card|It is a 10 cm x 16.5 cm, full-color, 2-sided, 6-panel card that shows the American Heart Association Pediatric Advanced Life Support (AHA-PALS) treatment algorithms. By providing a quick reference tool, it serves as a cognitive aid for healthcare providers who either direct or participate in the management of pediatric respiratory and/or cardiovascular emergencies, including cardiac arrest.
46070486|NCT04422314|Diagnostic Test|T-Detect Lyme|T-Detect Lyme is an investigational use test that uses multiplex PCR and NGS to assess rearranged T-cell receptor beta (TRB) gene sequences from genomic DNA isolated from human peripheral blood.
46070487|NCT04599920|Dietary Supplement|Partial replacement of red meat with legume-based foods|560 g of cooked and boneless red meat is replaced with legume-based foods providing the equal amount of protein.
45641472|NCT05755347|Other|PROMIS Cancer Function Brief 3D profile questionnaires|Patient-reported outcome survey will be offered at baseline.
45641473|NCT05755347|Other|FACT-G questionnaires|Patient-reported outcome survey will be offered at baseline.
45641474|NCT05755347|Other|Godin Leisure-Time Exercise Questionnaire|Patient-reported outcome survey will be offered at baseline.
45641475|NCT05755347|Other|REAP-S questionnaires|Patient-reported outcome survey will be offered at baseline.
45641476|NCT05754190|Device|SOMA pain manager smartphone application|SOMA is a smartphone application developed for acute and chronic pain patients to track daily mood and pain symptoms and overall activity.
45779925|NCT05246462|Other|Logotherapy|In this study, the experimental group received seven-session logotherapy-based interviews on making sense of life, while the control group received only routine nursing care. In this study, Personal Meaning Oriented Psychotherapy (PMOP) was used to structure interviews on making sense of life based on Logotherapy and enhance the sense of meaning in cancer patients, share their concerns, experiences, and feelings about diagnosis-treatment, have their difficulties defined, maintain, and develop their sense of purpose and responsibility.
45779926|NCT00578552|Drug|Placebo|Placebo pill - non active sugar pill designed to look alike to the gabapentin medication
45779927|NCT00578552|Drug|Gabapentin - 1800 mg/day|gabapentin - 1800 mg/day for 12 weeks.
45779928|NCT00578552|Drug|Gabapentin - 2700 mg/day|gabapentin - 2700 mg/day for 12 weeks.
45779929|NCT01532089|Biological|Bevacizumab|Given IV
45779930|NCT01532089|Drug|Erlotinib|Given PO
45779931|NCT01532089|Drug|Erlotinib Hydrochloride|Given PO
45779932|NCT01532089|Other|Laboratory Biomarker Analysis|Correlative studies
45779933|NCT04640792|Procedure|Screening or Surveillance Conventionall colonoscopy|Patients in Group A (CC) will undergo Screening or Surveillance Conventual Colonoscopy, Patients in Group B (MEAC) will undergo Screening or Surveillance Colonoscopy with ME-ADPS Device
45779934|NCT05563987|Behavioral|ACT-DE|The acceptance and commitment therapy is a psychological component to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the hexagonal model of ACT, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.
45779935|NCT05563987|Behavioral|DE|DE
45916506|NCT05637073|Procedure|Laparoscopic cystectomy|Some women in the cohort will be treated with laparoscopic cystectomy after consensus with the physician
45779936|NCT00579878|Drug|Leflunomide|A loading dose of 100 mg (or placebo) for three (3) days will be given. Following that three-day period, a dose of 20 mg/day will be maintained throughout the remainder of the study. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur (e.g., diarrhea, liver enzyme elevations
45779937|NCT00579878|Drug|Methotrexate-Sulfasalazine-Hydroxychloroquine|"Methotrexate:~dosing starts at 10mg/week (4 tabs/wk). If total remission (according to ACR criteria found in Appendix II) has not been achieved and the labs are acceptable at the 8-week evaluation, the dose increased to 15 mg/week (6 tabs/wk);at the 16-week evaluation, the dose increased to 20 mg/week (8 tabs/wk). This dose will remain stable until the end of the study.~Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable,dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day)."
45598110|NCT05262335|Drug|Anlotinib + Standard first-line chemotherapy|"Anlotinib 12mg, po.qd, d1-14; Standard first-line chemotherapy determined by the researchers. The above schemes are repeated every three weeks.~After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
45916507|NCT05637073|Other|Control with ultrasound without other type of intervention|Some women in the cohort will be followed with ultrasound control, without other intervention, after consensus with the physician
45641478|NCT05753930|Drug|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
45641479|NCT05753839|Procedure|Cytoreductive nephrectomy±metastasectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.
45779938|NCT00579878|Drug|Leflunomide-Sulfasalazine-Hydroxychloroquine|Leflunomide: dose of 100 mg (or placebo) for three (3) days. Followed by a dose of 20 mg/day will be maintained throughout the remainder of the study. dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable, dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day).
45779939|NCT05563285|Behavioral|Exercise and Mindfulness-Based Intervention|"1.Exercise Intervention~1st-2nd week: 15 min for Brisk walking. Intensity: HRmax (60%-65%); CR10 (5-6). 3rd-4th week: 20 min for Brisk walking. Intensity:HRmax (65%-70%); CR10 (6-7). 5th-6th week: 25 min for Brisk walking. BW: Intensity: HRmax(70%-75%); CR10 (6-7). 7th -8th week:30 min for Brisk walking.~Exercise Intervention basic content:~(1) Gradually increase the walking speed; (2) Slowly reduce the speed; (3) Rest for 5 min.~2. Mindfulness-Based Intervention~1st-2nd week: 30 min for mindfulness training. 3rd-4th week: 35 min for mindfulness training. 5th-6th week: 40 min for mindfulness training. 7th-8th week: 45 min for mindfulness training.~Mindfulness-Based Intervention basic content:~(1) Yoga; (2) Mindful breathing; (3) Mindfulness meditation; (4) Body scan; (5) Mindfulness awareness; (6) RAIN technique; (7) Mindful Stretching; (8) Mindful walking; (9) Mindful running"
45779940|NCT05563285|Behavioral|Control Group|The control group maintained their classes as usual, usual physical education sessions, and usual daily life.
45779941|NCT01746056|Device|Occlusive Heat Patch|The heat patch will be applied for 2 hours every day for a period of 12 weeks.
45779942|NCT05246228|Other|Peripheral blood sampling in order to evaluate changes in the circulating immune population|Eveluation: circulating T cells CD3+CD8+ and CD3+CD4+, absolute lymphocyte count (ALC) and neutrophil counts (ANC) and neutrophil/lymphocyte ratio (NLR), Treg lymphocytes, Naïve/Memory T lymphocytes CD4+ and CD8+,myeloid-derived suppressor cells, Plasmacytoid Dendritic Cells NK cells dimension and bright, NKT cells, Myeloid Dendritic cells, Monocytes subsets, B lymphocytes ,Analysis of plasma cytokines (TNFalpha, TGFbeta, IL-6, IL-10) by ELISA,FN signature: real-time PCR on mRNA from peripheral blood mononuclear cells (PBMCs)
45916508|NCT05637268|Drug|Camrelizumab|Camrelizumab 200mg iv q2w
45916509|NCT05637268|Drug|Paclitaxel|150mg/m² iv d1 q2w
45916510|NCT05637268|Drug|Cisplatin|50 mg/m² iv d2 q2w
45916511|NCT05637385|Behavioral|Training of perception and oculo-motor control|Behavioral training of eye movements and perception
45916512|NCT05637463|Other|No intervention|no intervention was made
45916513|NCT05637580|Drug|Timing of drug administration|The effect of drug administration timing on tumor and lymph node responses was observed.
46070488|NCT04443842|Behavioral|Financial and social incentives|"Participants will be credited with HK$1000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, participants will lose HK$40 for each subsequent week that they do not meet their personal weekly step target.~The social incentives are peer comparison and social support. Participants receive feedback of their physical activity performance by assessing whether they met or exceeded their step count target, followed by positive messages for encouragement. Nominated supporters will be informed of participants' performance for social support."
46070489|NCT00912782|Drug|Vitamin D3|Vitamin D3 200,000 IU once a week for 3 weeks
46070490|NCT00912782|Drug|Placebo|Placebo one time per week for 3 weeks
46070491|NCT00632060|Procedure|Manual / Manipulative Therapy (M/MT)|Subjects will receive M/MT twice a week for 4 weeks
45598111|NCT02361645|Drug|Ketorolac 0.5% eyedrops|
45598112|NCT02361645|Drug|Indomethacin 0.5% eyedrops|
45598113|NCT02361645|Drug|Bromfenac 0.09% eyedrops|
45598114|NCT02361645|Drug|Nepafenac 0.1% eyedrops|
45598115|NCT03525769|Diagnostic Test|FibroTouch|"FibroTouch is a non-invasive image-guided integrated detection system, providing an integrated detection and comprehensive evaluation program for hepatic fibrosis and hepatic steatosis.~The FibroTouch is a completely non-invasive liver testing device that can obtain the following results: 1. Liver Fibrosis: quantitative results of hepatic fibrosis; 2. Fatness: quantitative result of hepatic steatosis; 3. Liver tissue morphology: detected by ultrasound imaging."
45641480|NCT05753839|Procedure|Cytoreductive nephrectomy±metastasectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.
45641481|NCT05753839|Other|Human-derived materials sampling|Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, after induction therapy, and after 3 months of maintenance therapy.
45779943|NCT01533259|Drug|Stribild|Elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen (STR) administered orally once daily with food
45779944|NCT05246072|Drug|Ivermectin + colchicine|In addition to the local standard of care for COVID 19 patients, the patient will receive Ivermectin + colchicine
45641482|NCT05753761|Behavioral|Behaviour- & Imaging-Guided Stepping Training Early Post-Stroke (BIG STEPS) intervention|Using baseline accelerometry data, personalized goals of replacing sedentary time with stepping time will be developed.
45641483|NCT05753501|Drug|ABBV-101|Oral:Tablet
45641484|NCT05753436|Dietary Supplement|Puritans Pride Turmeric curcumin® 500 mg|Turmeric curcumin 500 mg per oral capsule of Puritans Pride company supplement composed of Turmeric (curcuma longa) root 450mg and Turmeric extract (curcuma longa root 50mg ) standardized to contain 95%curcuminoids.It is added because of its possibility to reduce the risk of ASCVD by lowering blood pressure, lipid profile, blood glucose, inflammation, and oxidative stress.
45641485|NCT05753384|Drug|treatment of TKI in CML|continued treatment with TKI at randomization a then stopped treatment 12 months after randomization
45779945|NCT05246072|Drug|Colchicine|In addition to the local standard of care for COVID 19 patients, the patient will receive colchicine
45779946|NCT02135432|Drug|Ivacaftor|
45779947|NCT02135432|Drug|Placebo|
45779948|NCT01576003|Drug|Glutamine|0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 days (6 months)
45779949|NCT01576003|Dietary Supplement|L-alanine|0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 day (6 months)
45779950|NCT05245994|Drug|Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib|Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy. Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide [80 to 100mg/m2] via intravenous infusion and carboplatin [ The area under the curve (AUC) is 5-6] by intravenous infusion or cisplatin [75-80 mg/m2] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator. The initial dose of olaparib is 300mg twice daily. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food.
45779951|NCT05547529|Procedure|Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.|Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.
45779952|NCT05547529|Procedure|Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy|Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
45779953|NCT05245604|Drug|TJO-087|Cyclosporine ophthalmic nano-emulsion 0.08%, 1 drop once daily
45779954|NCT05245604|Drug|Cyclosporine ophthalmic solution 0.05%|Cyclosporine ophthalmic solution 0.05%, 1 drop twice/day
45779955|NCT01576471|Biological|Trichuris suis ova (TSO)|TSO 7500: 7500 embryonated, viable TSO every 2 weeks X 10 weeks (up to 6 total doses)
45779956|NCT01576471|Biological|Placebo|Placebo: dose every 2 weeks X 10 weeks (up to 6 total doses)
45779957|NCT05245448|Drug|Tetrandrine|Administered orally
45779958|NCT05245448|Drug|Placebo|Administered orally
45779959|NCT00580502|Device|LAP-BAND® Adjustable Gastric Band (LAGB®)|Bariatric surgery for patient whose BMI is between 30 and 40 kg/m^2
45779960|NCT01576939|Radiation|Intensity Modulated Radiation Therapy|"We are using thermoluminescent dosimeter (TLD) to measure the mucosal dose adjacent to the dental fillings in a standard, non-filling optimized IMRT (intensity modulated radiotherapy treatment) plan that is normally delivered in the clinic. If the measured mucosal dose exceeds 35 Gy, we will generate a filling optimized IMRT plan to reduce it to < 35 Gy. The new plan will be deemed acceptable and implemented only if it does not (1) compromise the tumor coverage, (2) increase the dose to either the remaining oral cavity or the spared parotid gland(s)."
45779961|NCT00581048|Drug|Natural source d-α-tocopheryl acetate|1500 units daily for 16 weeks
45779962|NCT01577329|Behavioral|Mindfulness meditation|Group class on mindfulness meditation. One hour weekly class led by nurse expert on meditation that includes mindfulness skills, body awareness skills and emotional awareness skills. Homework is assigned.
45779963|NCT04391504|Procedure|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
45779964|NCT05233280|Other|Oral liquids and soft food 2 hours postoperative|Early versus delayed oral liquid feeding after ceasarean section
46070492|NCT03520712|Biological|Valoctocogene Roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
45779965|NCT05222360|Other|Education|3 educational sessions about body image and nutrition
45779966|NCT01578031|Device|Positive Airway Pressure During Sleep (ResMed S9 Elite)|Positive airway pressure during sleep (ResMed S9 Elite).
45779967|NCT01578031|Other|Usual Care|Usual care.
45779968|NCT01798472|Procedure|cemented hemiarthroplasty|Patients aged 80 years and older operated with an cemented hemiarthroplasty. Fixation of the wedge-shaped, polished ChromCobalt steel femoral stem to host bone by use of PolyMetylMetAcrylat bone cement. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel.
45641486|NCT05753085|Device|Conavi Medical Novasight Hybrid System intervention|Patients for a coronary angiogram who meet the inclusion criteria and none of the exclusion criteria are enrolled. Participants are prepared for angiography and PCI procedure in the usual way. Radial or femoral artery cannulation is done under local anaesthetic and the angiogram performed as per standard practice. IVUS-OCT imaging of the culprit vessel using the Novasight Hybrid system is then performed. If image quality of the IVUS-OCT is suboptimal it will be repeated. If the IVUS-OCT catheter cannot cross the lesion, pre-dilatation is performed. The acquired IVUS-OCT images can be used to optimise PCI. Following PCI, angiography is repeated and if the findings are optimal, IVUS-OCT imaging is repeated. If the PCI results are suboptimal further stent optimisation is performed and IVUS-OCT imaging repeated; The procedure is then completed as clinically indicated. The participant will then receive conventional post PCI care
45779969|NCT01798472|Procedure|reverse hybrid total hip arthroplasty|Patients aged 65 to 79 years operated with an uncemented femoral component combined with cemented acetabular cup. The femoral stem is fixed to the host bone by press-fit technique. We use a tapered, proximally hydroxyapatite coated, titanium stem. The acetabular cup is fixed to the host bone with bone cement. We use an all-polyethylene design. Bone cement consists of PolyMetylMetAcrylat.
45779970|NCT01798472|Procedure|cemented total hip arthroplasty|Patients aged 65 to 79 years operated with a cemented femoral stem combined with a cemented acetabular cup. Femoral and acetabular component are fixed to the host bone by use of bone cement. The femoral stem is a polished, wedge-shaped design made of ChromCobalt steel. The acetabular cup is fixed to the host bone with bone cement.The acetabular cup an all-polyethylene design. Bone cement consists of PolyMetAcrylat.
45779971|NCT01798472|Procedure|uncemented hemiarthroplasty|"Patients aged 80 years and older are randomized to uncemented hemiarthroplasty. Fixation of the tapered, proximally hydroxyapatite coated, titanium stem to the host bone by press-fit-technique. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel."
45779972|NCT04378166|Device|Smart glass|Practitioner wears smart glasses connected to ultrasound machine during central venous catheterization
45779973|NCT01578577|Behavioral|EHMI|The EHMI intervention consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
45779974|NCT01578577|Behavioral|Nurse Educator + EHMI|This intervention is a combination of the use of a nurse educator and the EHMI tools described in the EHMI intervention arm. A nurse educator perform the following: 1) perform medication and medical record review 2)assess adherence and medication problems 3) provide counseling to promote safe and effective medication use 4) follow-up with patients after their visit to confirm they have filled all prescriptions, and can accurately teach back their medicine regimen, 5) communicate with prescribing physician when problems are identified.
45779975|NCT04361396|Other|Collection of samples|Only in enrolled patient : different samples will be taken at different times of the surgery (3 samples of pneumoperitoneum, 1 sample of peritoneal effusion or peritoneal lavage fluid and 1 sample of bile, in case of cholecystectomy.
45779976|NCT04333082|Other|Data collection|"collection of patient data~Data collection (demographics, prehospital management, duration of ICU and hospital stay, destination at discharge, date(s) of seizure(s), electroencephalographic (EEG) data, seizure history and etiology, number and duration of SE episodes, medication, types of SE according to the current guidelines from the International League of Epilepsy (ILAE), neuroimaging features, comorbidities, laboratory parameters, complications during and after SE , laboratory testing, vital signs, fluid balance) will be performed from the digital medical records, the electroencephalographic and microbiologic database of patients"
45779977|NCT01579045|Device|senofilcon A|bilateral daily use soft contact lens
45779978|NCT01579045|Device|etafilcon A|bilateral daily use soft contact lens
45779979|NCT01579045|Device|nelfilcon A|bilateral daily use soft contact lens
45779980|NCT01579045|Device|Filcon II 3|bilateral daily use soft contact lens
45779981|NCT01579045|Device|Filcon II 3|bilateral daily use soft contact lenses
45779982|NCT00582998|Procedure|Standard Wound Dressing|Following repair of fracture of calcaneus, pilon or tibial plateau, a standard wound dressing is applied in the OR. Dressing is taken down post-op day 1 to evaluate draining, and if necessary, replaced. Dressing will be monitored for drainage every 48 hours until wound is clean, dry and intact.
45779983|NCT00582998|Device|Vacuum Assisted Closure Device|Following repair of fracture of calcaneus, pilon or tibial plateau, a Vacuum Assisted Closure (VAC) device is applied in the OR. VAC cannister is evaluated for drainage, and if necessary, replaced. VAC sponge will be monitored for drainage every 48 hours, replaced if needed, until wound is clean, dry and intact.
45779984|NCT05208476|Procedure|Osteopathic manipulative medicine|A set of hands-on techniques used by osteopathic physicians to help diagnose, treat and prevent illness or disease.
45779985|NCT01579513|Drug|Methylprednisolone|Methylprednisolone at a dose of 30 mg/kg body weight and a concentration of 62.5 mg/cc. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
46070493|NCT04205396|Behavioral|Written emotional disclosure|Participants will write five stories (days 8, 11, 14, 17 and 20) about an assigned topic relating to their experiences as a caregiver of someone with advanced liver disease. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
45641487|NCT05751265|Drug|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks . Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
45641488|NCT05751265|Drug|5Fu|Participants will receive 5-FU, 2.4 g/m2，bid，d1-d14，q3w
45641489|NCT05751265|Drug|Paclitaxel injection|Participants will receive paclitaxel 135 mg/m2 ivgtt q2w or 175mg/m2 q3w
45641490|NCT05748600|Drug|Dexpramipexole Dihydrochloride|administration of dexpramipexole tablet
45641491|NCT05748600|Drug|Placebo|administration of placebo tablet
45779986|NCT01579513|Drug|Placebo|Normal saline will be drawn up in an identical volume to that needed for active study drug. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
45779987|NCT04266392|Drug|[18F]-DCFPyl Ligand|To assess the performance of [18F]-DCFPyl PET with whole-body MRI and multiparametric pelvic/prostate MRI for PCa detection in men with recurrence as determined by biochemical PSA level or evidence on CIM. Results of tracer uptake and MRI image features on whole body PET/MRI and dedicated pelvic/prostate PET/MRI, alone and together, will be correlated and compared to detection of lesions on CIM that usually includes bone scan (BS) and CT scan of the abdomen and pelvis, or PET imaging with F-18 Fluciclovine.In addition, in patients who undergo biopsy when performed as standard of care, we will correlate image features directly with histopathological findings on lesion biopsy to directly demonstrate that 'radiotracer and/or MRI positive' lesions contain tumor cells.
45779988|NCT01534897|Drug|GSK2118436|150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)
45779989|NCT05121350|Drug|Anlotinib hydrochloride capsule|Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor.
45779990|NCT05121350|Drug|Epirubicin|Epirubicin can inhibit the synthesis of DNA and RNA.
45779991|NCT05121350|Drug|Arotinib hydrochloride capsule placebo|Placebo of Anlotinib hydrochloride capsule
45779992|NCT01534975|Diagnostic Test|contrast agent|we are randomizing patients to different contrast agents.
45779993|NCT00583622|Drug|Bevacizumab|5 mg/kg by vein daily over 90 minutes for 2 Days
45779994|NCT00583622|Drug|Carboplatin|333 mg/m^2 by vein over 2 hours for 3 Days
45779995|NCT00583622|Drug|Docetaxel|300 mg/m^2 by vein over 2 hours for 1 Day
45779996|NCT00583622|Drug|Gemcitabine|1,800 mg/m2 by vein over 3 hours for 4 Days
45779997|NCT00583622|Drug|Melphalan|50 mg/m^2 by vein over 15 minutes for 3 Days
46070494|NCT04205396|Behavioral|Resilience training|Participants will write three things that went well at the end of their day (before going to sleep), and what was their role in bringing them. These will be done about every three days (days 8, 11, 14, 17 and 20) for 2 weeks at home. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
45641492|NCT05746988|Other|Mouthwash gargling|15 - 20 ml of mouthwash to be gargled vigorously for 30 to 60 seconds daily (morning and night) as an adjunct to regular toothbrushing, and before and/or immediately after sexual activities.
45641493|NCT05744687|Drug|SPH4336 Tablets 400mg|"SPH4336 Tablets ：Orally, 400mg once a day; 28 days/cycle~Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle"
45641494|NCT05744687|Drug|SPH4336 Tablets Placebo|"SPH4336 Tablets Placebo：Orally,28 days/cycle~Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle"
45641495|NCT05743413|Procedure|Armeo Spring physiotherapy|Study subjects will undergo physiotherapy sessions using the Armeo Spring device.
45779998|NCT00583622|Procedure|Stem Cell Transplant|"Stem Cell Removal via apheresis through a central venous catheter (CVC), usually in chest~Stem Cell Replacement through CVC over about 30-60 minutes, Day 7 of treatment, following study drug regimen"
45779999|NCT01535365|Other|Heat|Application of heat pack to the back or neck sprain.
45641496|NCT05743413|Procedure|Standard physiotherapy|Study subjects will undergo standard physiotherapy sessions.
45641497|NCT05742711|Device|Primary Relief|Continuous neurostimulation with a set of pre-assigned stimulation parameters.
45780000|NCT01535365|Other|Cold|Application of ice pack to the back or neck sprain.
45780001|NCT00583700|Drug|Pentoxifylline|Pentoxifylline 400 mg, 3 times daily for 7 months, beginning immediately after radiation therapy.
45780002|NCT00583700|Drug|Vitamin E|Vitamin E (Over-the-counter) 400 I.U. once daily
45780003|NCT05540743|Drug|biologic DMARDs|follow up the clinical response in Egyptian population to the drug
45780004|NCT00584402|Drug|perflutren lipid microspheres|perflutren lipid microspheres IV in 0.1 cc doses, as needed, to enhance lesion conspicuity
45641498|NCT05742711|Device|Primary Relief - Sham Device|Standard treatment with the application of sham device shall be followed with additional analgesics available if necessary.
45641499|NCT05742139|Other|Non intervention|Non intervention
45641500|NCT05740722|Dietary Supplement|Nicotinamid riboside|500 mg x 2 po
45641501|NCT05740722|Dietary Supplement|Placebo|Placebo tablets
45780005|NCT01537315|Drug|Hydroxychloroquine|200 mg capsule daily for 10 +/- 4 days, then 200 mg twice daily till end of study (duration approximately 6 months)
45780006|NCT01537315|Other|Matching Placebo|matching placebo capsule 200 mg daily for 10 +/- 4 days and thereafter 200 mg twice a day for duration of study, approximately 6 months
46070495|NCT04205396|Other|No treatment|Participants will complete baseline and outcome assessments and no intervention will be conducted.
46070496|NCT04730804|Drug|ALXN1830|ALXN1830 will be administered as SC infusion(s).
46070497|NCT04730804|Drug|Placebo|Placebo will be administered as SC infusion(s).
46070498|NCT04363112|Behavioral|Mini Kid II|Mini Kid II (Mini International Neuropsychiatric Interview ) is a standardised, hetero mental health questionary for children, according to DSM IV. Mini Kid II will be administered to children between day 3 and 7 during the study.
45780007|NCT05094986|Behavioral|Initial Medication Adherence (IMA) Intervention|The IMA intervention promotes health literacy and patient participation in the decision-making process during the recommendation and prescription of a new drug for the management of cardiovascular disease and diabetes. The IMA intervention has four main components: 1. Training for healthcare professionals (GPs, nurses, and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; 2. Intervention support tools; decision aids (leaflets and website) and implementation tools (dispensing alert in community pharmacies when dispensing insulins and antiplatelet drugs); 3. Shared decision-making process during the GP's consultation; and 4. Information support provided by the nurses and community pharmacists that use the intervention decision aids to explore the patients' doubts and standardise the discourse between primary healthcare professionals.
45780008|NCT05094986|Other|Usual Care|Patients received the usual care when being prescribed a new prescription for treatments of cardiovascular disease or diabetes. Nurses and community pharmacists were asked to also provide usual care to those patients. Community pharmacists from the control group had the dispensing alert available when dispensing insulins and antiplatelet drugs.
45780009|NCT04257188|Procedure|minimally invasive vitrectomy under subtenon anaesthesia|The safety and feasibility in terms of tolerance and pain sensation during the surgery as well as the possible perception of light and colour sensations in minimally invasive vitrectomy under sub-tenon anesthesia shall be investigated.
45780010|NCT01579669|Behavioral|Use of toolkit|Patient participants will be given access to the toolkit and will create a customized report for their provider. Team will send report to providers and ask them to schedule appointment with patient to discuss.
45780011|NCT05039996|Behavioral|education and relaxation program|randomized controlled trial
45780012|NCT04224428|Drug|Fexofenadine Pill|fexofenadine tablets 60 mg once daily will be taken for six months
45780013|NCT04224428|Drug|Placebo oral tablet|lactose oral tablet
45780014|NCT01579747|Procedure|Ultrasound|Using ultrasound for nerve localization when performing a sciatic nerve block via the lateral popliteal approach
45780015|NCT01579747|Procedure|Nerve stimulation|Using nerve stimulation for nerve localization in sciatic nerve blocks via the lateral popliteal approach
45780016|NCT00584480|Other|Hyperbaric Oxygen Treatment (HBOT)|1.5 ATA at 100% Oxygen of HBOT
45780017|NCT05534581|Device|PVI using the Arctic Front Cryoballoon (Medtronic)|Patients randomized to the Arctic Front cryoballoon group will undergo PVI using the Arctic Front Cryoballoon (Medtronic). At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring.
45780018|NCT05534581|Device|PVI using FARAPULSE Pulsed Field Ablation (Boston Scientific)|Patients randomized to the Pulsed Field Ablation group will undergo PVI using the FARAPULSE PFA system (Boston Scientific). At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring.
46070499|NCT04202978|Drug|Camrelizumab|Camrelizumab ：200mg intravenous injection d1 q3w
46070500|NCT04202978|Drug|Apatinib Mesylate|Apatinib：250mg/d P.O ,qd ,3weeks
46070501|NCT04202978|Drug|Capecitabine|capecitabine:850mg/m2 P.O ,bid ,d1-d14
46070502|NCT04202978|Drug|Oxaliplatin|oxaliplatin:130mg/m2 intravenous injection d1 q3w
45641502|NCT05740007|Drug|IW-3300 rectal foam|IW-3300 rectal foam administered daily for 12 weeks
45448704|NCT04945876|Behavioral|Digital follow-up|"Participants will receive:~One session of individual exercise and diet guidance focusing on goals and motivation.~An activity tracker and instructions on how to use it both for motivation, daily activity tracking, logging of specific exercise and using the wristbands heart rate monitor to control intensity level during exercise.~Monthly digital follow-up to provide support and address questions and goals regarding nutrition, daily energy expenditure and exercise.~Opportunity to send sms with questions regarding nutrition and exercise. Participants who are malnourished, or at risk of malnutrition will be offered a total of two hours of additional individualized, digital guidance on nutrition as needed."
45641503|NCT05740007|Drug|Placebo|Placebo rectal foam administered daily for 12 weeks
45641504|NCT05738252|Diagnostic Test|Clinical Frailty Scale|A way to summarize the overall level of fitness or frailty of an older adult after they had been evaluated by an experienced clinician
45641505|NCT05738252|Diagnostic Test|Frailty Phenotype|Defined by the presence of three from the following five clinical features: weakness, slow walking speed, unintentional weight loss, exhaustion, and low physical activity
45780019|NCT03007693|Drug|JNJ-61393215|Participants will receive JNJ-61393215 for 7 days.
45780020|NCT03007693|Drug|Placebo|Participants will receive JNJ- 61393215 matching placebo for 7 days.
45780021|NCT00584558|Procedure|Catheter Ablation|Catheter Ablation of arrhythmias
45780022|NCT04224194|Combination Product|Adalimumab|Combined product as Drug is delivered through an autoinjector pen on which real-life patient handling experience is assessed.
45780023|NCT02215369|Device|VenaCure EVLT 400 µm fiber Procedure Kit|The study intervention will be conducted according to the DFU included with the VenaCure EVLT 400 µm fiber Procedure Kit.
45780024|NCT04986176|Drug|HC-1119|oral
45780025|NCT04986176|Drug|Placebo|oral
45780026|NCT00584948|Drug|Memantine|Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
46070503|NCT04202978|Radiation|radiofrequency ablation|radiofrequency ablation:between first cycle and second cycle percutaneous
46070504|NCT04186442|Drug|Botulinum toxin type A injection|Experimental
46070505|NCT04186442|Drug|Botulinum Toxin Type A Injection [Botox]|Active Comparator
46070506|NCT00631982|Procedure|in vitro matuartion of oocytes|in vitro maturation of (immature) oocytes
46070507|NCT04203368|Drug|adenosine|patients received IV adenosine 6 mg bolus then wait 2 minutes, if it failed to return to sinus rhythm then another 12 mg IV bolus of adenosine was administered, if supraventricular tachycardia persisted then the patient was shifted to verapamil.
45448705|NCT03546634|Biological|Sabin IPV|We select one Sabin IPV product, produced by China National Biotec Group, which is available for China's National Immunization Program in the selected study sites.
45448706|NCT02254096|Drug|BIRT 1696 BS|
45780027|NCT00584948|Drug|Placebo|Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
45780028|NCT00605072|Drug|candesartan|orally 8 mg increased to 16 mg then 32 mg to achieve target blood pressure of 140/90, then daily for 12 months
45780029|NCT00605072|Drug|lisinopril|orally 10 mg increased to 20 mg then 40 mg to achieve target blood pressure of 140/90, then daily for 12 months
45780030|NCT00605072|Drug|hydrochlorothiazide|orally 12.5 mg increased to 25 mg to achieve target blood pressure of 140/90, then daily for 12 months
45780031|NCT00605072|Drug|nifedipine, long acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 30 mg increased to 60 mg and 90 mg in 2 week increments
45780032|NCT00605072|Drug|metoprolol, long-acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 12.5 mg increased to 25 mg and 50 mg
45780033|NCT00585104|Drug|levosimendan|10-minute infusion
45780034|NCT00585182|Drug|Enoxaparin 0.5 mg/kg once daily|Enoxaparin 0.5 mg/kg (kg= actual body weight) subcutaneous once daily for 2 doses.
45448707|NCT02254096|Drug|Placebo|
45448708|NCT02254096|Other|Grapefruit juice (GFJ)|
45448709|NCT02254096|Other|High fat meal (HFM)|
45448710|NCT03661983|Drug|Aripiprazole|Participants received aripiprazole tablets, orally as per the regimen specified in the arm description.
45641506|NCT05738239|Device|Laser therapy|Biological effects of low-level LASER therapy have been studied for various clinical indications, including musculoskeletal conditions and some acute pain conditions. PBMT includes low level LASER (works on pain) and light-emitting diodes (LED) (works on wound healing).
45448711|NCT03661983|Drug|Placebo|Participants received aripiprazole matching-placebo tablets, orally as per the regimen specified in the arm description.
45448712|NCT02783170|Biological|Tetanus, Diphtheria, and Pertussis Vaccine|
45641507|NCT05737823|Behavioral|Carers-ID online support programme|The Carers-ID online programme, which consists of ten modules which cover topics including: promoting resilience, reducing anxiety, managing stress, accessing local supports, managing family conflict and information for siblings who are carers.
45641508|NCT05737823|Behavioral|Carers-ID online support programme - Wait-list control|The same programme as above delivered to the wait-list control after the T2 follow-up data has been collected.
45641509|NCT05735730|Other|Blood draw|The study intervention consists of a blood draw for genetic analysis.
45641510|NCT05733845|Other|Samples|The intervention is to collect blood; urine; saliva and stool samples but also mucosal biopsies at each protocol visits (baseline and follow up visits).
45641511|NCT05733767|Other|Enhanced Usual Care (EUC)|Patients randomized to arm 1, enhanced care (EC), will receive the following intervention: 1) referral to the state quitline, 1-800-QUIT-NOW, 2) primary care physician notification of an ongoing quit attempt, and 3) enrolled in an assessment-only text message system. This text message system will assess medication use and self-reported smoking cessation outcomes, but will not provide any counseling, advice, or feedback. Participants in arm 1 will receive a text message at discharge, and then they will receive 1 text assessment at the following time points: day 7, month 1, and month 3.
45641512|NCT05733767|Other|Nurse Practitioner Tobacco Treatment Team (NPT3)|Patients randomized to arm 2, personalized care (PC), will receive a multi-component, multi-disciplinary smoking cessation intervention in addition to usual care. This intervention will include three main interventions. First, a nurse practitioner will assess all patients and then prescribe tailored medications for smoking cessation based on patient preferences. Patients will also then receive a sample ad-lib nicotine replacement therapy (NRT) packet for use as needed to their prescribed medications. Second, a Tobacco Treatment Counselor (TTC) will provide personalized advice, education, and coaching to the patient and encourage medication adherence. Third, patients will be enrolled in a smoking cessation text messaging program designed to maintain motivation, encourage medication adherence, and allow communication with the team. The text message program will last for 6 months and will include assessment at the following time points: day 7, month 1, and month 3.
45641513|NCT05733611|Biological|RP2|Genetically modified herpes simplex type 1 virus
45641514|NCT05733611|Biological|RP3|Genetically modified herpes simplex type 1 virus
45641515|NCT05733611|Biological|atezolizumab|anti-PD-L1 monoclonal antibody
45641516|NCT05733611|Biological|bevacizumab|anti-VEGF therapy
45780035|NCT00585650|Biological|Etanercept|Subcutaneous injections 50 mg Etanercept will occur twice weekly over a 12-week treatment period.
45780036|NCT00585650|Other|Placebo injections|Placebo injections twice weekly for 12 weeks.
45780037|NCT04856228|Diagnostic Test|diagnostic posterior interosseous nerve lidocaine injection|ultrasound guided posterior interosseous nerve and lateral epicondyle 1 ml 2% lidocaine injection
45780038|NCT04817696|Other|Patients without chronic pain symptoms|Verbal score < 3 at 3 months
45780039|NCT04817696|Other|Patients with chronic pain symptoms|Verbal score ≥ 3 at 3 months
45780040|NCT03830528|Drug|KW-6356 Low Dose|KW-6356 will be administered as single doses.
45780041|NCT03830528|Drug|KW-6356 Middle Dose|KW-6356 will be administered as single doses.
45780042|NCT03830528|Drug|KW-6356 High Dose|KW-6356 will be administered as single doses.
45780043|NCT03830528|Drug|KW-6356 X Dose|KW-6356 will be administered as multiple doses.
45780044|NCT03830528|Drug|KW-6356 Y Dose|KW-6356 will be administered for Japanese healthy men as multiple doses.
45780045|NCT03830528|Drug|Placebo|All study cohorts (except Part C) are placebo controlled.
45780046|NCT00605384|Drug|Entecavir + Tenofovir|Tablets, Oral Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks
45780047|NCT00605384|Drug|Adefovir + continuing Lamivudine|Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks
45448713|NCT02783170|Biological|2016-2017 Quadrivalent Inactivated Influenza Vaccine|
45448714|NCT02783170|Biological|2017-2018 Quadrivalent Inactivated Influenza Vaccine|
45448715|NCT05144620|Diagnostic Test|3D Mapping|3D model will be made from diagnostic imaging for pre-surgical planning
45780048|NCT00586196|Drug|donepezil|5 mg each day for 30 days
45780049|NCT00586196|Drug|Placebo|Encapsulated cornstarch One capsule daily for 30 days
45780050|NCT00605696|Drug|Insulin|Participants will receive intravenous insulin to target tight glycemic control (80 to 110 mg/dL) for up to 48 hours after ICU admission.
45780051|NCT04745312|Device|Visible light|Ambient room lighting will be supplemented with additional light from a task lamp.
45780052|NCT00606554|Device|Computer-assisted weaning program|Closed-loop, knowledge-based, computer-assisted wean program initiated at the start of ventilator weaning.
45780053|NCT00606554|Behavioral|Standard of Care weaning|Evidence-based standard of care weaning process.
45780054|NCT00587132|Drug|Synthetic Human Secretin|0.2mcg/kg one time dose.
45780055|NCT00606944|Behavioral|fast-track rehabilitation|fast-track rehabilitation with early ambulation and diet after elective colorectal resection
45780056|NCT00587678|Drug|Simvastatin|40mg each night
45780057|NCT00587678|Drug|Ezetimibe|10mg daily
45641517|NCT05733520|Behavioral|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by informal caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
45780058|NCT00587678|Drug|Simvastatin/Ezetimibe|40mg/10mg each night
45780059|NCT02138006|Drug|Intensive insulin treatment|Mealtime insulin (Actrapid) Basal insulin (Monotard)
45780060|NCT02138006|Drug|Standard insulin treatment|Insulin Mixtard
46070508|NCT04203368|Drug|verapamil|patients received IV verapamil 5mg bolus slowly over 2 minutes followed by a second IV bolus dose of 5 mg ,10 minutes after the initial dose in case of persistence of supraventricular tachycardia (SVT). If SVT persisted, the patient was shifted to adenosine
45641518|NCT05733520|Behavioral|Dementia Guide Expert|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
45641519|NCT05732896|Device|Nociception Leve Indeks|During TIVA-TCI, propofol (Schnider) effect site concentration (Ce) was titrated to BIS score between 40-60 and remifentanil (Minto) Ce to standard hemodynamic parameters in the control group and NOL index value between 10-25 in the study group.
46070509|NCT04159220|Procedure|Clamping of the ventilator endotracheal tube|The transport will be released in accordance with SFAR SRLF guideline. Before each disconnection from ventilator endotracheal tube will be clamped.
46070510|NCT03444038|Drug|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
46070511|NCT04133948|Drug|Domatinostat|"Patients in arm B and C will receive domatinostat 200 mg BID, days 1-14 q3weeks.~Patients in arm D will start with once daily (OD) dosing scheme of domatinostat 200mg, d1-14 q3wks. Based on safety data of the first 5 patients in this arm, the next patients will be treated with either a higher dosing scheme (200mg BID, d1-14, q3wks), a lower dosing scheme (100mg OD, d1-14, q3wks) or the same dosing scheme (200mg OD, d1-14, q3wks)."
46070512|NCT04133948|Drug|Nivolumab|2 courses nivolumab 240 mg q3weeks
46070513|NCT04133948|Drug|Ipilimumab|2 courses ipilimumab 80 mg q3weeks
45641520|NCT05731817|Other|Observational study|N/A - observational study.
45780061|NCT00587834|Device|Gintuit|Application of Gintuit at Day 0 to the gingival bed
45780062|NCT00587834|Other|Autologous palatal tissue|Tissue will be harvested from the subject's palate and placed on the gingival bed
45780063|NCT05247476|Drug|L-T4|Patients with refractory hypothyroidism continued to receive L-T4 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.
45780064|NCT05247476|Drug|L-T4+T3 (thyroid tablet)|Patients with refractory hypothyroidism changed to receive L-T4 +T3 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.
45780065|NCT04565210|Other|Music exposure|Participants will be offered individual sessions of music. They will be exposed for 10 minutes per day, 3 days per week for a period of 2 weeks using a headphone.
45780066|NCT04565210|Other|Silence|Participants in this group will be offered individual silence session for 10 minutes per day, 3 days per week for a period of 2 weeks using a headphone.
45780067|NCT04545008|Drug|Famotidine|Oral Famotidine
45780068|NCT04545008|Drug|N-Acetyl cysteine|Oral N-Acetyl Cysteine
45780069|NCT04527770|Drug|Dexamethasone|Ultrasound guided median nerve hydrodiseection using dexamethasone or midazolam
45780070|NCT04527770|Drug|Midazolam injection|intracarpal injection of midazolam and bupivacaine 0.5%
45780071|NCT02138240|Behavioral|Social network intervention|The intervention combined a social network approach with strategies that address public housing residents' challenges related to the built environment to improve dietary habits. Given the frequent intake of sugar-sweetened beverages (SSB) in this population, the intervention focused on reducing added sugar intake through the reduced consumption of SSB.
46070514|NCT00911534|Drug|rabeprazole sodium|One rabeprazole extended release (ER) 50 mg capsule daily; rescue medication will be provided to subjects to take as needed.
45641521|NCT05730725|Drug|BMS-986322|Specified dose on specified days
45780072|NCT05247086|Device|Negative pressure therapy|After surgical wound closure we will apply negative pressure therapy
45780073|NCT05247008|Other|Thyme honey|"Thyme honey will topically be applied to the oral mucosa as oral rinse based on the Biswal et al. (2003) administration protocol.~Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day."
45780074|NCT02139176|Behavioral|contract referral|A female partner signs a contract saying it is permissible for a community worker to trace a male sex partner in the community.
45780075|NCT02139176|Behavioral|patient referral|A patient agrees to recruit their partner using the invitation.
45780076|NCT01798784|Behavioral|Sweepstake Incentive 1|Daily sweepstake conditional on daily medication adherence
45780077|NCT01798784|Behavioral|Sweepstake Incentive 2|Daily sweepstake conditional on daily medication adherence
45780078|NCT01798784|Behavioral|Sweepstake Incentive 3|Daily sweepstake conditional on daily medication adherence
45780079|NCT04492436|Drug|thrombomodulin alfa|Weight based dose of reconstituted treatment administered through intravenous drip infusion on Day1 of each chemotherapy cycle
45780080|NCT04492436|Drug|Placebo|Weight based dose of reconstituted treatment administered through intravenous drip infusion on Day1 of each chemotherapy cycle
45641522|NCT05730725|Other|Placebo|Specified dose on specified days
45780081|NCT01798940|Drug|Torrent's Pioglitazone|
45780082|NCT00609128|Drug|olopatadine|olopatadine one drop in one eye for one week
45448716|NCT03646305|Behavioral|Cognitive Defusion|Cognitive defusion aims to change one's relationship to their thoughts - as opposed to changing the content, form, or frequency - by reframing internal experiences as less threatening (Hayes, Luoma, Bond, Masuda, & Lillis, 2006). It is the process of detaching the link between one's thoughts and perceptions of reality and acknowledging the role one's thoughts play in their internal events. A number of techniques have been developed to remove the literal quality of such thoughts, including repeating the thought, and, more recently, singing the thought.
45780083|NCT04409054|Other|Cough and Valsalva effort|Three increasingly cough effort and three Valsalva type effort at four different volumes of rectal distension (empty rectum, volume for a first sensation of filling, volume for desire to defecate and maximal tolerable volume) while recording the external anal sphincter activity
46070515|NCT00911534|Drug|Placebo|One rabeprazole placebo capsule daily; rescue medication will be provided to subjects to take as needed.
45780084|NCT00668564|Procedure|Stem Cell Transplantation|The purpose of hematopoietic stem cell transplantation is to introduce blood producing cells from a normal donor. These cells can either provide what is missing in the body to the other cells, or can change the body's immune response to the substances that have accumulated in the body. These normal hematopoietic stem cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut). The new donor cells repopulate the blood and bone marrow system and enter the organs of the body, including the brain. Wherever these cells go, they will produce the needed enzyme.
45780085|NCT00668564|Drug|Cyclophosphamide|"Days before Transplant Drug Frequency~4 Cyclophosphamide Once, given over 2 hours~3 Cyclophosphamide Once, given over 2 hours~2 Cyclophosphamide Once, given over 2 hours~1 Cyclophosphamide Once, given over 2 hours"
45780086|NCT00668564|Drug|Campath-1H|"Days before Transplant Drug Frequency~12 Campath-1H Once, given over 2 hours~11 Campath-1H Once, given over 2 hours~10 Campath-1H Once, given over 2 hours"
45448717|NCT04307134|Drug|Inotuzumab ozogamicin|R/R ALL who treated with Inotuzumab ozogamicin
45780087|NCT00668564|Drug|Busulfan|"Days before Transplant Drug Frequency~9 Busulfan Four times per day~8 Busulfan Four times per day~7 Busulfan Four times per day~6 Busulfan Four times per day"
45780088|NCT00610688|Drug|Prenatal Vitamin|Once daily, prenatal vitamin containing 400IU of Vitamin D, until delivery
45780089|NCT00610688|Drug|Cholecalciferol (Vitamin D3)|Once daily, 1600IU dose of Vitamin D from 12 weeks gestation to delivery
45780090|NCT00610688|Drug|Cholecalciferol (Vitamin D3)|Once daily, 3600IU dose of Vitamin D, from 12 weeks until delivery
45780091|NCT00669578|Drug|CC-4047|CC-4047: taken orally each day in a 28 day cycle.
45448718|NCT04913272|Drug|US-APR2020|US-APR2020 capsules 45 billion CFUs of the LBT.
45780092|NCT02135900|Drug|Heliox|From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.
45780093|NCT02137382|Drug|Creon®|active comparator
45780094|NCT02137382|Drug|Creon N|experimental drug
45780095|NCT00611468|Drug|Topotecan|All subjects receive treatment with intravenous topotecan and oral erlotinib.
45780096|NCT00611468|Drug|Erlotinib|All subjects receive treatment with intravenous topotecan and oral erlotinib.
45780097|NCT00670202|Drug|Fasudil Hydrochloride|Fasudil 40 mg three times a day x 14 days
45780098|NCT00670202|Drug|Placebo Oral Tablet|Placebo oral tablet manufactured to mimic fasudil three times a day x 14 days
45780099|NCT00670982|Drug|bevacizumab|Given intravenously every 2 weeks
45780100|NCT00670982|Drug|vinorelbine|Given intravenously once a week
45780101|NCT00670982|Drug|trastuzumab|Given intravenously once a week
45780102|NCT00611624|Radiation|Mammosite brachytherapy radiation|Treatment using MammoSite will begin within five days of placement of the catheter. Only high dose rate (HDR) with Ir-192 treatment is allowed. The balloon will remain inflated throughout the treatment course. A total of 34 Gy will be prescribed to an approximate 1 cm radial distance from the balloon surface. Two fractions per day, each of 3.4 Gy, separated by at least 6 hours, given on 5 treatment days (over a period of 5 to 10 days), will sum to 10 fractions and 34 Gy.
45780103|NCT00612560|Drug|Anastrozole|1 mg per day
45780104|NCT00612560|Dietary Supplement|flaxseed|25 g per day ground
45780105|NCT00612560|Drug|Placebo|Placebo pill 1 per day
45916514|NCT05637736|Behavioral|Mindfulness-based Stress Reduction by Therapeutic VR|Therapeutic VR+MBT was provided using a head-mounted display which designed to enclose eyes and block external stimuli almost entirely. Patients can see immersive natural scenes through VR devices and hear stereo sounds through headphones. We uploaded a programme, which was designed to induce recordings of guided meditations (The same as the MBT), musics for meditation and consists of meditation-videos of 40 minutes. We will guide patients to choose their favorite meditation videos, such as forest, seaside, lake, snow mountain, field and so on.
46070516|NCT04319042|Procedure|Immediate Loading|The implant receives an artificial tooth the same day as it is placed.
46070517|NCT04319042|Procedure|Early Loading|The implant receives an artificial tooth 4 weeks after placement.
46070518|NCT00632138|Behavioral|exercise intervention|
46070519|NCT00632138|Other|questionnaire administration|
45641523|NCT05727436|Dietary Supplement|Dentoblis|Dissolve the tablets in the mouth once a day for 4 weeks
45641524|NCT05727436|Dietary Supplement|Placebo|Dissolve the tablets in the mouth once a day for 4 weeks
46070520|NCT00632138|Procedure|biofeedback|
45641526|NCT05724472|Drug|rVSV∆G-SEBOV-GP Vaccine or Placebo|rVSV∆G-SEBOV-GP Vaccine or Placebo
45641527|NCT05723289|Device|MI-E Telemonitoring|Daily telemonitoring using a ad-hoc communicating device
45641528|NCT05722938|Drug|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days
45641529|NCT05722938|Drug|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days
46070521|NCT00632138|Procedure|management of therapy complications|
45780106|NCT00671918|Drug|Lymphoseek|Breast Cancer: Intradermal admin of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site OR periareolar administration of Lymphoseek: Inject 0.2-.04 mL in multiple divided doses at the margin of the areola OR subareolar administration of Lymphoseek: Inject 0.2-0.4 in multiple divided injections or a single injection in subareolar area as a subcutaneous injection OR peritumor administration of Lymphoseek: Inject 2.0-4.0 mL in multiple divided injections, intraparenchemally surrounding the tumor or biopsy cavity. For melanoma pts intradermal administration of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site.
45641530|NCT05722418|Biological|CB-011|CB-011 allogeneic CAR T cell therapy targeting BCMA Cyclophosphamide Chemotherapy for lymphodepletion Fludarabine Chemotherapy for lymphodepletion
45641531|NCT05722015|Biological|Pembrolizumab coformulated with hyaluronidase|MK3475A SC will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
45780107|NCT00612716|Drug|busulfan|For those not eligible for total body irradiation: busulfan 4 mg/kg/day orally (1 mg/kg orally every 6 hrs) on Days -9 through -6.
45780108|NCT00612716|Drug|cyclophosphamide|Cyclophosphamide 60 mg/kg/day on days -7 and -6. For patients not eligible for total body irradiation: cytoxan 50 mg/kg intravenously (IV) on days -5 through -2.
45780109|NCT00612716|Biological|Stem cell infusion|Infused on Day 0
46070522|NCT00632138|Procedure|psychosocial assessment and care|
46070523|NCT00632138|Procedure|quality-of-life assessment|
45641532|NCT05722015|Drug|Pemetrexed|Pemetrexed 500 mg/m² by IV Infusion will be administered for nonsquamous NSCLC as per the schedule specified in arm.
45641533|NCT05722015|Drug|Cisplatin|Cisplatin 75 mg/m² by IV Infusion will be administered for nonsquamous and squamous NSCLC as per the schedule specified in arm.
45780110|NCT00612716|Radiation|Total body irradiation|165 cGy morning and evening on days -4 through -1.
45641534|NCT05722015|Drug|Carboplatin|Carboplatin AUC 5 mg/mL/min in nonsquamous and AUC 6 mg/mL/min in squamous NSCLC will be administered as per the schedule specified in arm.
45780111|NCT04242602|Device|Transcranial Doppler|Record flow velocity tracing of middle cerebral artery using a transcranial doppler.
45780112|NCT04220684|Drug|Cytarabine Hydrochloride|Given IV
45641535|NCT05722015|Drug|Paclitaxel|Paclitaxel 200 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
45780113|NCT04220684|Drug|Fludarabine|Given IV
45780114|NCT04220684|Biological|Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells|Given via infusion
45780115|NCT00613028|Drug|Temo + Avastin|Patients have progressed/had gr3/> toxicity related to etoposide, with no had progression/gr 3/> toxicity related to temozolomide, will only be considered for bevacizumab and temozolomide. Bevacizumab intravenously at dose 10mg/kg every other wk. For patients on bevacizumab and temozolomide, temozolomide administered on continuous dosing schedule at 50mg/m2/day.
45780116|NCT00613028|Drug|VP-16 + Avastin|Patients have progressed/had gr3/> toxicity related to temozolomide, but have not progressed/gr3/> toxicity related to etoposide,considered only for bevacizumab and etoposide. Bevacizumab intravenously at dose 10mg/kg every other wk. Patients on bevacizumab and etoposide, etoposide once daily at 50mg/m2/day first 21 days of each 28-day cycle.
45780117|NCT01799798|Drug|Denosumab|Denosumab will be given subcutaneously in a dosage of 1mg/kg body weight every 12 weeks. 4 interventions are planned until trial week 36. There is no control group planned.
45780118|NCT00614198|Other|Gluten- and casein-free diet|Removal of foods containing gluten (cereal produce) and casein (dairy produce)
45780119|NCT00616772|Drug|ABT-335|Capsule
46070524|NCT04571840|Diagnostic Test|Multiparametric MRI +/- prostate biopsy|MRI with T2-weighted, diffusion weighted and dynamic contrast enhanced sequences followed by prostate biopsy if indicated on MRI and clinical findings
46070525|NCT04571840|Diagnostic Test|Biparametric MRI +/- prostate biopsy|MRI with T2-weighted and diffusion weighted sequences followed by prostate biopsy if indicated on MRI and clinical findings
46070526|NCT04302974|Procedure|Different structures and processes of primary care management strategies|Different structures and processes of primary care management strategies includes: Multi-morbidity, continuity-of-care, different service delivery models and management strategies (i.e. investigation frequency and specific drug regimens)
46070527|NCT04302974|Procedure|Multi-disciplinary Risk Factor Assessment and Management Programmes for diabetes (RAMP-DM)|Under the Multi-disciplinary Risk Factor Assessment and Management Programmes (RAMP) for diabetes (RAMP-DM), multi-disciplinary teams of health care professionals (doctors, nurses, dietitians, pharmacists, opticians etc) were established at designated GOPCs. All DM patients are eligible to enrol into the DM RAMP programmes. Each patient in the RAMP receives a comprehensive risk factor and complication screening to determine his/her overall cardiovascular risk and presence of modifiable risk factors, and according to their risk level and need, the patient may receive additional interventions such as additional counselling by the nurse or additional consultations with a senior doctor.
45641536|NCT05722015|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
45780120|NCT00616772|Drug|Placebo|Capsule
45780121|NCT00616772|Other|Atorvastatin|Capsule
45916515|NCT05637736|Behavioral|Mindfulness-based Stress Reduction|39 participates randomized and allocated to this group. MBT was conducted as an 8-week group intervention. Sessions typically began with formal mindfulness meditations that include breathing exercises, prolonged expiratory relaxation, body scan, and meditation. MBT was delivered by the first author, who has specialized training in mindfulness meditation.
45641537|NCT05722015|Biological|Pembrolizumab|Pembrolizumab by IV Infusion will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
45641538|NCT05721222|Drug|PRO1160|Intravenous infusion of PRO1160
45448719|NCT04913272|Drug|Placebo|Placebo
45641539|NCT05720117|Drug|PYX-201|Intravenous (IV) infusion
45641542|NCT05718700|Drug|Bulevirtide|Administered via subcutaneous (SC) injections
45780122|NCT00672854|Drug|ClinOleic 20% Intravenous Emulsion|ClinOleic 20% is a lipid emulsion containing a mixture of refined olive oil (approximately 80%) and refined soybean oil (approximately 20%) corresponding to an essential fatty acid intake of approximately 20% of the total fatty acids intake.
45780123|NCT00672854|Drug|Intralipid, 20% Intravenous Emulsion|It is made up of 20% Soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection
45780124|NCT00672932|Drug|raltegravir|400 mg two times daily for three months
45780125|NCT02513550|Drug|Ixekizumab|Administered SQ
45448720|NCT04300426|Drug|"ACHIM as solute (10^9 intestinal microbes/ml)"|Culture of intesinal microbiota originally derived from a healthy subject are administered to a person with presumed dysbiotic intestinal symptoms with an objective to treat these symptoms.
45641543|NCT05716854|Drug|Clarithromycin|"Subjects receive the Clarithromycin intervention orally according to the following schedule:~Day 1: 1 Clarithromycin 500 mg immediate release (IR) tablet twice (Clarithromycin 500 mg BID).~Day 2: 2 Clarithromycin 500 mg immediate release (IR) tablets twice (Clarithromycin 1000 mg BID).~Day 3: 2 Clarithromycin 500 mg immediate release (IR) tablets once (Clarithromycin 1000 mg QD)."
45641544|NCT05716854|Drug|Pimozide|"Subjects receive the Pimozide intervention orally according to the following schedule:~Days 1-3: Pimozide 6 mg immediate release (IR) once per day."
45641545|NCT05716854|Drug|Placebo (Part 1)|Subjects receive matching placebo for treatments.
45641546|NCT05716854|Drug|Moxifloxacin|Subjects receive Moxifloxacin 800 mg orally once on day 1.
45641547|NCT05716854|Drug|Cobicistat|Subjects receive Cobicistat 450 mg orally once on day 1.
45641548|NCT05716854|Drug|Moxifloxacin and Cobicistat|Subjects receive Moxifloxacin 800 mg and Cobicistat 450 mg orally once on day 1.
45641549|NCT05716854|Drug|Placebo (Part 2)|Subjects receive matching placebo for treatments.
45780126|NCT02513550|Drug|Placebo|Administered SQ
45780127|NCT00673400|Procedure|Stapled transanal rectum resection|Contour Transtar-STR5G (Ethicon EndoSurgery Inc., Cincinnati, OH).The circular anal dilator is fixed to perianal skin.Rectal intussusception is evidenced with a swab.The first stitch is placed superficial on top of the intussusception. The procedure is performed 5to6 times counterclockwise.A final stitch for first radial cut at 3 o'clock.The device is introduced into the rectum. This cut opens the prolapse. Check with a finger the vagina. The device is then closed and fired. After replacing the cartridge, the device is introduced in the rectum, placed parallel to the circular anal dilator and moved counter clockwise with 4to6firings to complete the resection. Additional stitches across the staple line to assure haemostasis.
45780128|NCT00673712|Device|Continuous Sternal Block|Elastomeric Pump for Continuous Infusion of Local Anesthetic
45641550|NCT05714553|Drug|Fosifloxuridine Nafalbenamide|Intravenous infusion
45641551|NCT05714553|Drug|Leucovorin|Intravenous infusion
45641552|NCT05714553|Drug|Pembrolizumab|Intravenous infusion
45780129|NCT00673712|Drug|Opioid based analgesia|"Opioid Analgesic agents delivered by:~PCA on demand mode IV injections PRN IM injections PRN Oral PRN"
45780130|NCT04062032|Drug|Aspirin 81 mg|ASA 81mg taken daily
45448721|NCT02782780|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBTi)|CBTi is a multicomponent treatment that seeks to teach patients about sleep and the factors that affect sleep (e.g., homeostatic regulation, circadian rhythm, age, social and work schedule) and to work with the patients toward minimizing unwanted arousal at bedtime and altering sleep habits to increase sleep propensity and regularity. The intervention is 8-weeks long.
45448722|NCT02254018|Drug|bivatuzumab mertansine|
45641553|NCT05714553|Drug|Docetaxel|Intravenous infusion
45641554|NCT05713760|Drug|Tirbanibulin Ointment 1%|Klisyri® ointment is a microtubule inhibitor for topical use and is currently on the market for the treatment of actinic keratosis of the face or scalp. The chemical name of tirbanibulin is N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl) acetamide. Tirbanibulin ointment 1% contains 10 mg tirbanibulin per gram of white to off-white ointment containing mono- and di-glycerides and propylene glycol and is supplied in packets containing 250 mg of tirbanibulin ointment 1%. Each packet includes single-dose packets (2.5 mg tirbanibulin in 250 mg) to be applied to evenly cover up to 25 cm² of the treatment field once daily for 5 consecutive days using 1 single-dose packet per application.
45641555|NCT05713630|Drug|GD-Tranexamic Acid 500 MG Oral Tablet|Tranexamic acid film-coated oral tablet.
45641556|NCT05713630|Drug|Sandoz-Tranexamic Acid 100 MG/ML|Sandoz-Tranexamic acid 100 milligram/millilitre (mg/mL) via nasogastric tube.
45641557|NCT05713630|Drug|Sandoz-Tranexamic Acid 100 Mg/mL Solution for Injection|Sandoz-Tranexamic acid 100 mg/mL solution for injection via intravenous (IV).
45780131|NCT04062032|Drug|Aspirin 325mg|ASA 325mg taken daily
45780132|NCT03981380|Drug|11C-PIB|Participants will be injected with an intravenous bolus of up to 5-15mCi (370 MBq) (+/-10%) of [11C]PiB (over 5-10 seconds).
45780133|NCT00617396|Drug|Quetiapine (50 mg/day-100mg/day)|Subject begin with a dose quetiapine of 50mg for 2 weeks, increasing to 100mgs for the remainder of the study. (8 weeks total)
45780134|NCT03722966|Drug|Varenicline|All participants will be offered a 13-week course of varenicline (including a 1 week titration period). Dosage and administration per manufacturer: 0.5mg once daily for days 1-3 and 0.5mg twice daily for days 4-7 encompass the titration period, then 1mg twice daily for 12 weeks. An additional 12 weeks of treatment is recommended for long-term abstinence.
45780135|NCT03722966|Drug|Oral Nicotine Replacement Therapy (NRT)|Half of study participants will be randomly assigned to receive oral nicotine replacement therapy (4mg gum or 4mg lozenge, depending on preference; to be used every 1-2 hours as urges occur) in addition to varenicline.
45780136|NCT03722966|Behavioral|Medication Reminders|Half of study participants will be randomly assigned to receive automated medication reminders via their smartphones.
45780137|NCT03722966|Behavioral|Tobacco Cessation Counseling|All participants will be offered 6 weekly tobacco cessation counseling sessions with a Tobacco Treatment Specialist.
45780138|NCT01581541|Drug|PU-H71|PU-H71 is a synthetic HSP90 inhibitor which can bind both open and closed conformations of HSP90. It demonstrates extended tumor retention and client protein degradation, while being rapidly cleared from normal tissues. It has shown complete tumor responses and retained sensitivity to retreatment in vivo.
45641558|NCT05713630|Drug|Placebo|The placebo 500 mg will consist of an identical capsule to over-encapsulated tranexamic acid oral tablet entirely filled with microcrystalline cellulose, and sealed. Placebo 100 MG/ML via nasogastric tube and placebo 100 Mg/mL solution for injection via intravenous (IV). The solution form of the placebo will consist of 0.9% sodium chloride (saline).
45780139|NCT02142608|Drug|BR55|Ultrasound contrast agent
45780140|NCT02143310|Device|EVP|
45780141|NCT01582477|Drug|EXPAREL 20 mL|EXPAREL 266 mg (undiluted)
45780142|NCT01582477|Drug|EXPAREL 40 mL|EXPAREL 266 mg diluted with preservative-free 0.9% normal saline to 40 mL.
45780143|NCT03001687|Dietary Supplement|enteral supplementation with vitamin D|"Patients allocated to the vitamin D + group receive enteral supplementation with high-dose vitamin D (250.000UI)"
45780144|NCT03001687|Other|blood collection 3mL|all patients will have hepcidin levels measured in the first 24 hours after admission and one week after
45780145|NCT03001765|Other|"Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac Monitoring System."|Intensive monitoring strategy of discharge from Emergency Department with 30 day SEEQ external monitor, followed by implantable cardiac Reveal LINQ monitor if negative 30 day result.
45780146|NCT03007771|Device|Magnetic Resonance-guided High-Intensity Focused Ultrasound|-Heating will not be performed in two areas of the body near each other (for example, not heating in two different places of the same thigh) to minimize the risk of overheating any one part of the subject's body. Heating a second target site is not mandatory, even if time allows, and the participant may refuse.
45916516|NCT05637775|Other|EEG-based BCI system for (hands) Motor Imagery training|For the purposes of this study we adapted an available BCI-supported motor imagery (MI) training station, equipped with a computer, a commercial wireless Electroencephalography (EEG)/ Electromyography (EMG) system, a screen for therapist feedback and a screen for the real-time ecological feedback to patient - a custom software program that provides a for (personalized) visual representation of the patient's own hands. This software allows the therapists to create an artificial reproduction of patient's hands/forearms by adjusting a digitally created image in shape, size, skin colour and orientation to match as much as possible the real patient hands/forearms. Training consists of the MI tasks of both hands, grasping or finger extension in separate runs. The trial length will include a constant baseline period of 4 sec and a task period of maximally 10 sec for BCI intervention group. Each training session will consist of 4 runs (20 trials each).
45916517|NCT05637775|Other|Control - MI intervention|Training consists of MI tasks of both hands, grasping or finger extension in separate runs. MI training will be delivered with a dose/setting regimen equivalent to EXP intervention. The trial length will include a constant baseline period of 4 sec and a task period of maximally 4 sec. Each training session will consist of 4 runs (20 trials each).
46070528|NCT04302974|Procedure|Multi-disciplinary Risk Factor Assessment and Management Programmes for hypertension (RAMP-HT)|Under the Multi-disciplinary Risk Factor Assessment and Management Programmes (RAMP) for hypertension (RAMP-HT), multi-disciplinary teams of health care professionals (doctors, nurses, dietitians, pharmacists, opticians etc) were established at designated GOPCs. All HT patients are eligible to enrol into the HT RAMP programmes. Each patient in the RAMP receives a comprehensive risk factor and complication screening to determine his/her overall cardiovascular risk and presence of modifiable risk factors, and according to their risk level and need, the patient may receive additional interventions such as additional counselling by the nurse or additional consultations with a senior doctor.
45641559|NCT05712876|Drug|CK-0045|Interleukin-22 agonist
45641560|NCT05712876|Drug|Placebo|Matching placebo
45780147|NCT01583101|Other|Receiving Highlighted Prompts|Prompts received by physicians were highlighted.
45780148|NCT01583101|Other|Receiving Non-highlighted Prompts|Prompts received by physicians were not highlighted.
45780149|NCT03001609|Drug|AC0010|Oral dose of 14C-labeled AC0010 suspension including 200 mg/83μCi[14C]
45780150|NCT03007381|Drug|Ketorolac Tromethamine|Intravenous analgesic
45780151|NCT03007381|Drug|Normal Saline|Sham comparator
45916518|NCT05637216|Drug|Losartan 12.5milligram capsule|The drug losartan will be used as a 12.5 milligram capsule taken by mouth twice daily. Losartan or its identical placebo will be randomized separately each to all breast conservation participants and to all mastectomy participants.
45916519|NCT05637216|Drug|Placebo|The placebo will be a 12.5 milligram capsule identical in appearance to the interventional drug losartan.
45916520|NCT05637931|Diagnostic Test|plexinD1|evaluation of the serum level of plexinD1
45641561|NCT05712356|Drug|LSTA1|LSTA1 3.2 mg/kg given as a slow IV push over 1 minute when standard treatment(s) are given
45641562|NCT05712356|Drug|Paclitaxel|paclitaxel 175 mg/m^2 IV administered over 3 hours every 21 days
45780152|NCT03001921|Other|No intervention|Registration of all HD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospital which have signed the contract in China.
45780153|NCT01585129|Drug|Postpartum Antibiotics|Patients randomized into this arm will receive one additional dose of gentamicin (1.5 mg/kg) and clindamycin (900mg) in the postpartum setting.
45780154|NCT01585129|Drug|No postpartum antibiotics|Patients randomized into this arm will not receive any postpartum antibiotics after delivery. They will be managed identically to the other arm in terms of chorioamnionitis (fever pre-delivery). The groups will be managed identically if endometritis (post-partum fever) develops.
45780155|NCT01585207|Drug|vigabatrin|3 tablets, bid for 8 weeks
45641563|NCT05712356|Drug|Docetaxel|docetaxel 75 mg/m^2 IV administered over 1 hour every 21 days
45780156|NCT03007303|Drug|Atypical Antipsychotic|Olanzapine: tablet ,5-20mg, Po q.d. Risperidone: tablet ,1-3 mg, Po q.d. Quetiapine: tablet ,100-400mg, Po b.i.d. ziprasidone : tablet ,40 -80mg, Po b.i.d.
45780157|NCT03007303|Other|atypical antipsychotic combined with MECT|The schizophrenia who matches the indications such as severe negativism, refused to eating or stupor may be treated with antipsychotic combined with MECT, the frequency and times of MECT depend on the state of illness
45780158|NCT01585441|Drug|Finasteride|Finasteride is available as white, round 5 mg tablets. During the masked period, the tablets are re-formulated in capsules with inactive ingredients. The re-formulated finasteride capsules are indistinguishable from the placebo capsules.
45780159|NCT01585441|Drug|Placebo|Capsule with no active ingredients to mimic finasteride
45780160|NCT04345315|Other|serological test|serological test assessing IgM and IgG directed against SARS-CoV-2
45780161|NCT04345315|Other|Rapid molecular test|Molecular test to detect SARS-CoV-2 in oro/rhinopharyngeal swab
45780162|NCT04345315|Genetic|Next generation Sequencing (NGS) analysis|analysis of genetic variability of virus and host
45780163|NCT04345315|Other|serum chemistry analysis|Analysis of serum chemistry factors and coagulation panel in blood samples
45780164|NCT03007459|Other|Psychological health|Observing and measuring baseline, and changes in, psychological health through a fitness contest preparation period
45780165|NCT03007459|Other|Physiological health|Observing and measuring baseline, and changes in, physiological health through a fitness contest preparation period
45780166|NCT02980861|Procedure|Laparoscopic total gastrectomy|When the participants with advanced proximal gastric cancer are randomized in the laparoscopic totalgastrectomy (LATG) group, they will received LTG with spleen-preserving splenic hilum lymph nodes dissection.
45780167|NCT02980861|Procedure|Open total gastrectomy|When the participants with advanced proximal gastric cancer are randomized in the open total gastrectomy(OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
45780168|NCT03007615|Other|Intimate Lubricant Gel|
45780169|NCT03006913|Behavioral|In-person|At all sites, patients randomized to/preferring in-person counseling will meet with a counselor.
45780170|NCT03006913|Behavioral|By phone|Patients in the phone arm will receive a scheduled call at their home.
45780171|NCT03006913|Behavioral|By video|Because low income patients are not likely to have video conference capability at home, this service will be offered at all three hospitals, and patients will have scheduled appointments to come to the hospital to receive counseling delivered through a computer.
45780172|NCT04345237|Dietary Supplement|dietary supplement consumption|"Consumption of the product under study for 3 months, milk placebo or experimental product (leucine milk).~In addition, 5 of the arms perform physical activity training"
45780173|NCT03001531|Device|HydroSun|a skin area of the lower limb will be treated three times with ultraviolet light emitted by a halogen lamp
45780174|NCT03001531|Device|Hilotherm|a skin area of the lower limb will be treated three times with heat applied by a sleeve
45780175|NCT00617942|Drug|Cohort 1 neo-adjuvant|"Cohort 1 : Trastuzumab 6 mg/kg IV over 60 minutes day -14~Trastuzumab 2 mg/kg IV over 60 minutes weekly then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16"
45780176|NCT00617942|Drug|Cohort 2 neo-adjuvant|Cohort 2 :Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Trastuzumab 2 mg/kg IV over 60 minutes weekly (4 mg/kg week 1) then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16
45780177|NCT00617942|Drug|Cohort 1 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
45780178|NCT00617942|Drug|Cohort 2 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
45916521|NCT05638048|Behavioral|Precision grip training|First determine patients for holding the ball movement should reach the effective blood flow velocity and best duration - relaxation, and USES the electronic grips and color doppler ultrasonic diagnostic apparatus, for individual patients to choose the best grip the efforts and training, to form the best grip the training plan, and observe the scheme for Peripheral central venous catheter-associated thrombosis prevention effect.
45916522|NCT05638048|Behavioral|Use maximum strength grip training|Patients were routinely implanted with PICC, and on the basis of health education in the control group, the best continuous-relaxation time, frequency and maximum grip strength of patients were used for grip strength training.
45641564|NCT05712356|Drug|Durvalumab|1500 mg of durvalumab IV administered over 1 hour every 21 days for 8 cycles then every 28 days for additional cycles
45641565|NCT05712356|Drug|Cisplatin|cisplatin 25 mg/m^2 IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
45641566|NCT05712356|Drug|Gemcitabine|gemcitabine 1000 mg/m^2 IV administered over 30 minutes on day 1 and day 8 every 21 days up to 8 cycles
45780179|NCT03001375|Procedure|Laparoscopic high anterior resection splenic flexure mobilization|
45780180|NCT03001375|Procedure|Laparoscopic high anterior resection without splenic flexure mobilization|
45641567|NCT05712356|Drug|Placebo|Placebo given as a slow IV push over 1 minute when standard treatment(s) are given
45641568|NCT05711394|Drug|Atogepant|Oral Tablet
45641569|NCT05711394|Drug|Placebo-Matching Atogepant|Oral Tablet
45641570|NCT05710848|Drug|STM-416|STM-416 monotherapy
45641571|NCT05710783|Biological|AVX-COVID/12|Single dose IM administration of a Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
45641572|NCT05710783|Biological|ChAdOx-1-S[recombinant]|Single dose IM administration of ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine
45641573|NCT05709873|Behavioral|Imagery rehearsal therapy|Therapy to reduce nightmares, delivered via videoconference sessions
45641574|NCT05709873|Behavioral|Targeted dream control|Therapy to reduce nightmares, delivered in videoconference sessions and lab session. Lab session will involve a sleep study during a daytime nap.
45641575|NCT05708105|Diagnostic Test|Cerebral near-infrared spectroscopy|Continuous cerebral NIRS will be monitored using the INVOS 5100C Cerebral Oximeter (Medtronic, Minneapolis, MN, USA), initiated as early as feasible after birth or postnatal consent and continued until 48 hours of age. Neonatal sensors applied over a light-permeable barrier will be placed on the right or left side of forehead, like the methods used in our pilot study and in line with our clinical protocol. The continuous parameters recorded for this study using cerebral NIRS will include CrSO2 and COIx.
45641576|NCT05708105|Diagnostic Test|Functional echocardiography|"The first echocardiogram will be completed as soon as possible after consent and < 24 hours of age in all cases. This will be to capture markers of early low systemic blood flow and document patent ductus arteriosus and its size, as known to be associated with IVH.~The second scan will be performed at the end of the monitoring period, between 48-60 hours of age. This scan is planned to record the change in LVO from baseline (re-perfusion), which has been postulated to relate to development of IVH."
45641577|NCT05708105|Diagnostic Test|Head Ultrasound|HUS will be paired with both echocardiograms. The first HUS will document baseline IVH status (paired with the first ECHO). The final HUS will be performed between days 4-7 of age, as per the standard clinical practice by site radiology service and will be used to confirm the final IVH status.
45780181|NCT03001297|Biological|Placebo|Participants will receive single dose of placebo matched MEDI5884 injection SC on Day 1
45780182|NCT03001297|Biological|MEDI5884 Dose 1|Participants will receive single dose MEDI5884 Dose 1 injection SC on Day 1.
45780183|NCT03001297|Biological|MEDI5884 Dose 2|Participants will receive single dose MEDI5884 Dose 2 injection SC on Day 1
45780184|NCT03001297|Biological|MEDI5884 Dose 3|Participants will receive single dose MEDI5884 Dose 3 injection SC on Day 1
45780185|NCT03001297|Biological|MEDI5884 Dose 4|Participants will receive single dose MEDI5884 Dose 4 injection SC on Day 1
45780186|NCT03000985|Behavioral|Psychoeducation|6 session psychoeducation program with the family caregiver of schizophrenics patients.
45780187|NCT00618332|Drug|mometasone furoate nasal spray|2 puffs in each nostril once a day for 2 weeks
45780188|NCT00618332|Drug|placebo|2 puffs in each nostril once a day for 2 weeks
45641578|NCT05706766|Behavioral|PARE|Aerobic and resistance exercise program via Zoom platform.
45780189|NCT03001141|Other|Observational|Device: MultiPoint Pacing will be enabled in enrolled patients at the discretion of the physician.
45780190|NCT03000907|Other|Intervention|Diet and physical exercises
45780191|NCT01585597|Device|Zoll- Coolgaurd 3000|Goal temperature of 33 degrees Centigrade for a duration of 12 hours and then actively rewarmed by 0.2 degrees Centigrade per hour.
45780192|NCT01588561|Drug|Intravenous Nicotine|Subjects received a single infusion of nicotine, 1.5 mg/70kg (New England Compounding Center, Framingham, MA), administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
45780193|NCT01588561|Other|Saline - placebo|Subjects received a single infusion of saline, administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
45641579|NCT05706766|Behavioral|Waitlist Control Group|Normal Activities.
45641580|NCT05705271|Drug|Finerenone (Kerendia, BAY94-8862)|Film-coated tablet, oral administration, once daily (OD), dosage based on the eGFR and serum potassium thresholds
45641581|NCT05704205|Device|NB-UVB phototherapy|Narrowband ultraviolet B irradiation 3 times a week
45641582|NCT05704205|Combination Product|Optimal topical therapy|A combination of detailed instructions about the disease and treatments by trained nurses, bathing and washing advices, adequate emollients use, avoidance of triggers (including possible and proven contact allergens), fingertip unit explanation for active topical therapy, and personalized topical therapy with different potency topical steroids, calcineurin inhibitors and tar ointments
45641583|NCT05703880|Drug|Finerenone (Kerendia, BAY948862)|Retrospective cohort analysis using United States Optum EHR data and OM1 RWDC databases.
45641584|NCT05702853|Drug|Cyclophosphamide injection|500 mg/m2 IV over 30-60 minutes +/- 10 minutes before Fludarabine Days -5, -4, - 3
45641585|NCT05702853|Drug|Fludarabine Injection|30 mg/m2 IV over 30-60 minutes +/- 10 minutes after cyclo- phosphamide infusion Days -5, 4, -3
45641586|NCT05702853|Biological|CD19-CD34t metabolically programmed CAR transduced T-cells|Cells are to be infused intravenously (IV) over 30 minutes or less via nonfiltered tubing either by gravity or a peristaltic pump, gently agitating the bag during infusion to prevent cell clumping
45780194|NCT00619190|Drug|aripiprazole|aripiprazole, open label, flexibly dosed from 1mg to 30mg, provided for up to 12 months
45780195|NCT01589263|Drug|onaBoNT-A + placebo|"200 U prostate injection once~Arms: ARM 1: onaBoNT-A + placebo"
45780196|NCT01589263|Drug|Tamsulosin + placebo|0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin
45780197|NCT01590979|Drug|Ranolazine|1000mg, two times a day, 12 hour intervals
45780198|NCT01590979|Drug|Placebo|two times a day, 12 hour intervals
45780199|NCT00619970|Procedure|Lactulose Breath Test|Healthy controls will receive one lactulose breath test to assess for SIBO
45780200|NCT00619970|Drug|xifaxan|xifaxan 550mg TID x10days
45780201|NCT00619970|Drug|placebo|placebo TID x 10days
45780202|NCT00619970|Procedure|Lactulose Breath Test|Children with CAP will receive one lactulose breath test to assess for SIBO and one after receiving either Rifaximin or Placebo
45780203|NCT01591837|Biological|CSL Influenza Vaccine|The study vaccine (CSL Influenza Vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2012/2013 influenza season). The vaccine will be administered by intramuscular or subcutaneous injection.
45780204|NCT01592071|Other|Replace reactive foods with non-reactive foods|Subjects were provided with the test results and an individualized dietary plan based on replacing reactive foods with non-reactive foods as replacements per the Immuno Bloodprint results.
45780205|NCT03531788|Device|Armon Ayura (Kinova)|Actively assisted mechanical arm support (electric powered to balance arm)
45780206|NCT03531788|Device|JAECO Wrex|Passive mechanical arm support (elastic bands to balance arm)
45916523|NCT05638048|Behavioral|Health education on routine grip strength training|Patients were routinely implanted with PICC and received routine health education. The content of health education included face-to-face language explanation of the whole process of catheter knowledge, issuing catheter maintenance manual, issuing ordinary grip ball and telling how to use it, and follow-up.
45916524|NCT05638087|Drug|Dexamethasone|Dexamethasone Oral Suspension
45780207|NCT03445130|Other|Lavandula Angustifolia oil (LO)|two drops on the inside of an oxygen face mask for 15 minutes.
45780208|NCT03445130|Other|Michelia Alba Leaf oil (MA)|two drops on the inside of an oxygen face mask for 15 minutes.
45780209|NCT03445130|Other|Almond oil (AO)|two drops on the inside of an oxygen face mask for 15 minutes.
45780210|NCT03445130|Other|Water|two drops on the inside of an oxygen face mask for 15 minutes.
45780211|NCT03006991|Other|therapeutic drug monitoring|dose of methotrexate can be adjusted by therapeutic drug monitoring.
45780212|NCT01592851|Drug|Stannous Fluoride|dentifrice containing stannous fluoride
45780213|NCT01592851|Drug|Sodium Monofluorophosphate|dentifrice containing Sodium Monofluorophosphate
45780214|NCT00675584|Drug|Budesonide|Participants in Arm 1 will receive 0.5 mg of budesonide once a day. Participants in Arm 2 will receive 1 mg of budesonide twice a day for 7 days at the onset of respiratory tract illnesses.
45780215|NCT00675584|Drug|Placebo Budesonide|Participants in Arm 1 will receive placebo budesonide each morning during respiratory tract illnesses for 7 days. Participants in Arm 2 will receive placebo budesonide once a day for the entire study, other than when they have a respiratory tract illness.
45780216|NCT03007069|Other|Mineralized plasmatic matrix (MPM).|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM, for 10 minutes , Which will result if sticky bone graft consistency after mixing.
45780217|NCT03007069|Other|Autogenous bone graft (gold standard).|Exposed implant threads are to be covered with autogenous bone and collagen membrane.
45916525|NCT05638087|Drug|Placebo Control|Placebo Oral Mix
45916526|NCT00388531|Drug|Depocyte®|Depocyte® is a cytostatic drug
45780218|NCT00620126|Other|UC Home Automated Telemanagement|Weekly assessment with UC Home Automated Telemanagement
45916527|NCT05638126|Drug|HRS-1780 table or placebo|HRS-1780 table or placebo single dose
45916528|NCT05638126|Drug|HRS-1780 table or placebo|HRS-1780 table or placebo single dose with food effect
45916529|NCT05638126|Drug|HRS-1780 table or placebo|HRS-1780 table or placebo multiple dose
45780219|NCT00620126|Other|Best Available Care|Routine follow up visits and as needed telephone calls and clinic visits, written action plans, educational fact sheets from the CCFA
45780220|NCT03376646|Device|Cohort A: Dissolve™|Dissolve™ are to be used in the trial
45780221|NCT03376646|Device|Cohort A: Resolute™ Integrity|Resolute™ Integrity are to be used in the trial
45780222|NCT03376646|Device|Cohort B: Dissolve™-2.00mm|Dissolve™ are to be used in the trial
45780223|NCT00620828|Other|Placebo saline injection|20 cc of sterile, injectable saline
45780224|NCT00620828|Drug|Ropivicaine 0.5%|Ropivicaine
45780225|NCT01596283|Procedure|Standard fluid management|The patient will receive standard fluid management
45780226|NCT01596283|Device|Goal directed fluid therapy with the Edwards EV1000 system|This arm will have fluid therapy guided by the Edwards EV1000 system.
45780227|NCT00676364|Drug|4% lidocaine topical anesthetic cream|A dollop of 4% lidocaine cream was applied under occlusive dressing for 15 mins prior to venipuncture
45780228|NCT00676364|Drug|Placebo cream|A dollop of matching placebo cream was applied under occlusive dressing for 15 mins prior to venipuncture
45780229|NCT00676676|Drug|Testosterone|Testosterone atch delivering 300mcg daily for 8-weeks
45916530|NCT05637372|Radiation|CBCT|CBCT scan
45916531|NCT05638321|Device|MIMS|sterile surgical device made of stainless steel and plastic, which is coupled to a rotating system. The surgical device consists of stainless steel micro trephine, covered by a small needle and rotating mechanism behind it. Mechanical rotation of the surgical device is achieved by the rotating system which is comprised of a 1) Controller which dictates the activation pulse duration and RPM, 2) a Motor, and 3) Footswitch.
45916532|NCT05638438|Procedure|transarterial therapies|transarterial therapies combine with donafenib and Anti-PD-1 Antibody
45916533|NCT05638477|Behavioral|Free-viewing eye tracking|Participants will watch 20 minutes of video clips while their eye movements, pupil size and blink rate are recorded
45916534|NCT05637411|Other|Predictive model|We will define and validate predictive models of risk of exacerbations in asthmatic patients
45780230|NCT00677690|Other|neuromuscular electrical stimulation (NMES)|NMES was applied by means of a commercially available four channel electrostimulator which generated a symmetrical biphasic pulsed current. Each session lasted 30 minutes and was performed 5 days/week for 5 weeks.
45780231|NCT00677690|Other|Sham electrical stimulation|Sham stimulation was performed with the same modality and time, but the stimulus was set up at 5 Hz.
45916535|NCT05638633|Drug|Prednisolone 20 mg/ 5 mg|Administration of prednisolone 20 mg for 5 days, followed by prednisolone 5 mg for 23 days.
45916536|NCT05638633|Drug|Vitamin B compound (100mg B1, 50 mg B6, 500 µg B12)|Administration of vitamin B compound for 28 days.
45780232|NCT00677924|Drug|Zalutumumab|Solution for infusion
45641592|NCT05701488|Drug|Durvalumab|Intravenous infusion
45641593|NCT05701488|Drug|Tremelimumab|Intravenous infusion
45641594|NCT05701488|Device|SIRT|SIR (Selective Internal Radiation) Sphere resin microspheres, radioactive particles delivered via injection into an artery.
45641595|NCT05700461|Combination Product|Implantable Microdevice (IMD)|"Small, implantable device with 20 microreservoirs for drug and drug combinations, via needle, percutaneously, and guided by interventional radiologic techniques.~Drugs include all or a subset of the following: Cabozantinib, Pazopanib, Lenvatinib, Axitinib, Ipilimumab, Nivolumab, Pembrolizumab, Carboplatin, Paclitaxel, Abemaciclib, Gemcitabine, Everolimus, Belzutifan, Cabozantinib + nivolumab, Cabozantinib + belzutifan, Ipilimumab + nivolumab, Lenvatinib + pembrolizumab, Lenvatinib + everolimus, Abemaciclib + belzutifan, and Tivozanib."
45780233|NCT03177122|Drug|Myo-inositol|Patients belonging to this group will receive 1 gram of Myo-Inositol, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) starting 6 weeks prior to stimulation and extending until final oocyte maturation, combined with 400 µg of folic acid supplemented daily.
45780234|NCT00621530|Drug|ketorolac tromethamine opthalmic solution|ketorolac 2 mg will be added to the patient's routine spinal anesthetic for surgery
45780235|NCT00621530|Drug|placebo|placebo will be added to the patient's routine spinal anesthetic for surgery
45780236|NCT02513472|Drug|Eribulin Mesylate|Eribulin Mesylate will be administered as a 1.4 milligram per square meter (mg/m^2) IV (intravenous) infusion on Day 1 and Day 8 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent.
45780237|NCT02513472|Drug|Pembrolizumab|Pembrolizumab will be administered as a 200 milligram (mg) IV infusion on Day 1 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent.
45780238|NCT03109028|Behavioral|Peer-to-Peer-Groupintervention|"Target group: Adult participants with mild to moderate depressive symptoms who prefer therapists with the same cultural background.~Therapists: Recruitment of psychosocial counselors within refugee community who have sufficient German or English language knowledge. Counselors will be trained for a time period of two months.~Content: Vulnerability and resilience factors; Self-efficacy strategies; Causes and consequences of stress; Possibilities on accelerating the integration process; Strategies preventing violence and radicalization Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two psychosocial counselors."
45780239|NCT03109028|Behavioral|Smartphone-based-Intervention|"Target group: Participants with moderate depressive symptoms who prefer an internet-based intervention.~Content: Five modules with 20 exercises elaborating on psycho-education, treatment options, self-management and diagnostics.~Form of therapy: Participants receive regular emails and sms to encourage steady participation via the internet-based smartphone-application. Weekly questionnaires ascertain the degree of participants symptomatology."
45916537|NCT05638633|Drug|Placebo for Vitamin B compound|Administration of placebo for vitamin B compound placebo for 28 days.
45916538|NCT05638633|Drug|Placebo for Prednisolon|Administration of placebo for prednisolone 20 mg for 5 days, followed by placebo for prednisolone 5 mg for 23 days.
45916539|NCT05637450|Dietary Supplement|Blue Whiting Protein Hydrolysate|25g Blue Whiting Protein Hydrolysates mixed with an everyday food / drink product daily for 6 weeks
45916540|NCT05637450|Dietary Supplement|Placebo|Isocalorific maltodextrin citrus flavoured powder mixed with an everyday food / drink product for 6 weeks
45916541|NCT05638711|Device|Built-in calculator to calculate Filtration fraction|A calculator built in electronic CVVH prescription system to calculate Filtration fraction
45916542|NCT05638789|Procedure|endoscopic sphincterotomy (EST) versus EST plus endoscopic papillary large balloon dilatation (EPLBD)|EST alone vs EST plus EPLBD in removing common bile duct stone
45916543|NCT05637489|Behavioral|PING|Brief survey of goals and preferences
45916544|NCT05638828|Drug|RD14-01 Cell injection|RD14-01 Cell injection
45916545|NCT05638906|Device|MINT|Mechanical rotation of the Surgical Device is achieved by the rotating system (i.e., Activation Device), which is comprised of: (1) Controller which dictates the activation pulse duration, the rotations per minute (RPM) and the forwards and backwards movement of the micro trephine; (2) Motor; and (3) Footswitch.
45916546|NCT05638984|Drug|Decitabine Injection|Injection site citabine, 10 mg/ bottle, 10 mg/d, Q3W, D1-D5 intravenous infusion; Tirelizumab injection 200mg D5 intravenous infusion
45641596|NCT05700279|Procedure|Stellate Ganglion Block|Stellate Ganglion Block (SGB) procedure involves an injection of a local anesthetic (0.5% ropivacaine) around the stellate ganglion (a bundle of nerves located at the base of the neck) to block the transmission of pain signals. The SGB injection is administered by an anesthesiologist.
45916547|NCT05638984|Drug|tirelizumab|10ml: 100mg / 1 bottle, 200mg, Q3W, D1 i. v. infusion.
45916548|NCT05637528|Diagnostic Test|MRI|Patients will undergo an MRI and mammography one year after MagTrace injections
45916549|NCT05639023|Other|Manipulation Techniques|Subjects will received 12 times orthopedic manipulation. Three times of treatment per months, and less than twice a week.
45780240|NCT03109028|Behavioral|Gendersensitive-Groupintervention|"Target group: Vulnerable group of adult women while taking cultural characteristics into account Therapists: Recruitment of psychosocial counselors (similar to Peer-to-Peer-Intervention); Training and supervision of gender-specific aspects.~Content: Focus on psycho-education which consider women specific topics such as gender-differences in symptoms and prevalence in psychic stress related and trauma disorders; physical, psychic and psychosocial consequences of traumatic and violent experiences; gender-specific risk and safety factors; stress and emotional self-regulation Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two female psychosocial counselors."
45780241|NCT03109028|Behavioral|Empowerment-Groupintervention|"Target group: Gender-sensitive group with mild to moderate depressive symptoms. Therapists: Psychologists and doctors in psychotherapeutic advanced training; The therapist-training lasts for three months with continued supervision during the intervention.~Content: Low-threshold intervention based on the treatment of depression; psycho-education about psychic burdens, trauma, stress and grief as well as vulnerability and resilience factors; Problem solving and self-actualization strategies.~Form of therapy: Group-based intervention for a time period of two months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants;"
45780242|NCT03109028|Behavioral|Adolescent-Groupintervention|"Target group: Adolescent participants with moderate depressive symptoms. Therapists: Two child and adolescent psychiatrists with translators or two native speaking child and adolescent psychotherapists.~Content: Elements which are based on the START-Manual13 teaching emotion recognition and emotion regulation; Foundations are based on Dialetical behavior therapy; Specific focus lies on the use of mindfulness; Additionally the social network of the participants will receive psycho-education; Professional helpers in facilities will acquire E-learning elements of the SHELTER-program (Safety and Help for Early Adverse Life events and Traumatic Experiences in minor refugees)"
45780243|NCT03109028|Other|Treatment as Ususal|Participants will receive the currently conducted routine and standard psychiatric health care. This involves ambulatory and stationary treatment by board certificated psychiatrists and psychotherapists.
45780244|NCT00621686|Biological|bevacizumab|
45780245|NCT00621686|Drug|sorafenib tosylate|
45780246|NCT02924714|Other|Discontinuation of imatinib|
46070529|NCT04302974|Procedure|Patient Support Call Centre (PSCC)|RAMP Patients can also be referred to the Patient Empowerment Programme(PEP) - a structured self-care education programme delivered by non-governmental organisations(NGOs). If the DM control is suboptimal but the patient is unable to attend the PEP, they may be referred to the Patient Support Call Centre(PSCC) service. PSCC provides individualized telephone counselling by trained nurses. PSCC empowers high-risk DM patients to engage in self-care behaviours by providing regular protocol-led telephone support to advise and reinforce healthy behaviours. Targeted self-care behaviours include self-monitoring, medication management, balanced diet, exercise, risk factor reduction, problem solving and healthy coping. Enrolled patients receive weekly to bi-weekly calls in the first 3 months and additional calls as required for a maximum of 9 months. Subsequent follow-up calls are undertaken to assess self-care behaviours related to the selected goals and to develop a care plan with the patient.
46070530|NCT00911300|Drug|fondaparinux|Comparison of different drugs
45916550|NCT05639023|Other|Physiotherapy Scoliosis-Specific Exercise|Subjects will receive 14 supervise training, 5 times of intensive supervise training for first two weeks and then 1-2 trainings per month for the rest. Subjects are encouraged to perform home exercise everyday on their own throughout the study.
45916551|NCT05637346|Procedure|Intra-operative ultrasound measurement|A patient-specific 3D model will be created using an available pre-operative CT scan. Anatomical target points are selected on this virtual model before the start of the surgery. Prior to surgery, a patient-reference electromagnetic (EM) sensor will be placed between the patient and the matrass on the operating table to account for patient movement during acquisition. Intra-operatively, an initial point registration of the 3D model with the electromagnetic tracking system (EMTS) will be performed based on ultrasound (US) imaging of the arterial bifurcations by the surgeon. Then, the surgeon will acquire multiple US sweeps of the pelvic arteries (abdominal aorta and left and right iliac arteries). For validation purposes, the pre-operatively defined anatomical target points will be visualized on US imaging and by pinpointing the EM tracked pointer. All tracking and US data will be recorded and stored for post-operative analysis.
45641597|NCT05700279|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a form of trauma-based talk therapy that will be conducted by clinical therapists. CPT can help people identify and challenge unhelpful trauma-related beliefs about themselves, others, and the world.
45641598|NCT05698433|Other|No intervention|No intervention
45641599|NCT05695521|Biological|CK0803|CK0803 (cryopreserved, allogeneic, cord blood derived T regulatory cells that express neurotropic homing markers) will be administered intravenously
45641600|NCT05695521|Other|Excipient|Excipient
45916552|NCT05639062|Behavioral|Narrative-based card game|This intervention aims to evaluate the preliminary effects of narrative-based card game intervention on spiritual well-being, hope, anxiety, depressive symptoms, and QoL of childhood cancer patients at postintervention and at 1-, and 3-month follow-up postintervention.
45641601|NCT05695261|Biological|Microbial Transplantation Therapy|Subjects randomized to the MTT/antibiotic arm will be administered oral MTT capsules over the course of 28 days.
45641602|NCT05695261|Drug|Antibiotic|Subjects randomized to the MTT/antibiotic arm will receive oral antibiotics for 7 days prior to the MTT administration visit.
45641603|NCT05695261|Other|Placebo (in place of MTT)|Subjects randomized to the placebo arm will be administered oral placebo capsules in place of MTT over the course of 28 days.
45641604|NCT05695261|Other|Placebo (in place of antibiotics)|Subjects randomized to the placebo arm will receive oral placebo in place of antibiotics for 7 days prior to the MTT administration visit.
45641605|NCT05694013|Device|Roche DPM Module|Participants will be trained in the use of the Roche DPM Module, which they will use alongside local SOC support
45641606|NCT05694013|Drug|Atezolizumab SC|Participants will receive atezolizumab SC for 16 cycles (cycle length = 21 days)
46070531|NCT00911300|Drug|unfractionated heparin|Comparison of different drugs
46070532|NCT00911300|Drug|Vitamin-K-Antagonist|Comparison of different drugs
46070533|NCT00632294|Procedure|Tissue Sample|A leftover sample of the removed allograft bone will be collected.
45780247|NCT00678470|Drug|Intralesional Alefacept|Patients enrolled in this study will receive intralesional alefacept injections to a single psoriatic plaque at week 0. After a two week observation period, patients will receive 15 mg intramuscular alefacept for 12 weeks.
45780248|NCT00679952|Procedure|closed suction drainage of pancreatic duct|A Fr 5-8 silastic polyethylene pediatric feeding tube with multiple side-holes is inserted 2 cm into the pancreatic duct. The catheter exited via a small enterotomy in the jejunal loop of the distal portion of the hepaticojejunostomy. Totally externalized pancreatic stents were connected to the aspiration bag of a Jackson-Pratt drain to generate negative pressure or to a bile bag for natural drainage.
45780249|NCT00679952|Procedure|natural drainage of pancreatic duct|Natural drainage group
45780250|NCT00623012|Drug|Rapamycin|Rapamycin will be initiated 24 weeks post SCT, while the patient is on Tacrolimus. The initial dose of rapamycin is 12 mg of loading dose, followed by 4 mg daily. The dose will be adjusted to keep trough level at 3-12 ng/dl. Rapamycin will be continued at the therapeutic dose for 4 additional weeks after Tacrolimus is stopped. Rapamycin will then be tapered off over 2 weeks. The patients will be on 50% of steady state dose for one week and 25% of the steady state dose for the last week.
45780251|NCT00623012|Drug|Tacrolimus|Tacrolimus target level is 5-10 ng/dl. Tacrolimus taper will start at 26 weeks post SCT. Tacrolimus will be tapered off over 4-8 weeks. The rate of taper will be 25% every to weeks for patients on 4 mg or more tacrolimus daily. For the patients on 3 mg or less of tacrolimus, the dose will be reduced 1 mg every two weeks, and the last dose will be 1 mg every other day for two weeks.
45641607|NCT05694013|Other|Local SOC support|Participants will receive local SOC support
45780252|NCT02699060|Procedure|Upper gastrointestinal endoscopy with biopsy and collection of refluxate|we analyzed esophageal mucosa, expression of inflammatory changes, location, size, number of mucosal defects, as well as the appearance of the gastric and duodenal mucosa.
45780253|NCT02699060|Procedure|Esophageal high-resolution manometry and 24-h esophageal pH-impedance monitoring|we analyzed following HRM parameters: the distal contractile integral (DCI), the lower esophageal sphincter resting pressure (LES RP) and standard measuring parameters were be collected: percentage of total time when pH was <4, longest reflux event, number of reflux events longer than 5 minutes, and number of reflux episodes in 24 hours.
45916553|NCT05639101|Other|Clinical Decission support system management & mobile App Intervention Group|"The clinicians treating the patients will use a clinical decision support system that includes predictive models associated with the level of risk of exacerbation. This models have been obtained in asthmatic patients by applying data mining techniques and multilevel analysis in the study of the influence of clinical characteristics and the environment of each subject.~The patients will use a mobile app to help manage their symptoms."
46070534|NCT04202822|Other|Oral soft tissues biopsies|Oral soft tissues biopsies (alveolar mucosa, buccal gingiva, and palatal tissue) will be harvested by the examiner at the time of the surgery (immediately before to start the surgical procedure -T0) and 24 hours after surgery (T24) at the level of the vertical released incisions (VRIs) with a biopsy punch with plunger of 2.0 mm diameter.
45780254|NCT02592356|Procedure|Computed Tomography|Correlative studies
45780255|NCT02592356|Procedure|Dual X-ray Absorptiometry|Correlative studies
45916554|NCT05639140|Other|Data collection|Neuropsychological assessment, FM-1OO, brain MRI, electroencephalogram and biomarker datas will be collected
45780256|NCT02592356|Procedure|Physical Examination|Correlative studies
45641608|NCT05692973|Behavioral|Role of Knowledge Retrieval|Students will learn a new knowledge base to perfect mastery. Following the attainment of mastery students will read passages on the topic and answer questions that prompt the literal recall of key facts and the formation of inferences.
45780257|NCT02592356|Other|Quality-of-Life Assessment|Ancillary studies
45780258|NCT02592356|Other|Questionnaire Administration|Ancillary studies
45780259|NCT02592356|Drug|Cabozantinib|
45780260|NCT02592356|Drug|Lenvatinib|
45780261|NCT00623636|Drug|MAP0004|MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks. Placebo treated patients will receive MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks only.
45780262|NCT00623636|Drug|Placebo|Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks.
45780263|NCT02549222|Other|Standard of Care|
45780264|NCT02446964|Procedure|Bone Marrow Transplantation|Undergo bone marrow transplant
45780265|NCT02446964|Drug|Cyclophosphamide|Given IV
45916555|NCT05637684|Device|low intensity pulsed ultrasound|mechanical sound waves
46070535|NCT00911144|Biological|GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A)|Intramuscular injection, administered as a single dose
45780266|NCT02446964|Drug|Fludarabine Phosphate|Given IV
45780267|NCT02446964|Other|Laboratory Biomarker Analysis|Correlative studies
45780268|NCT02446964|Drug|Mycophenolate Mofetil|Given PO or IV
45641609|NCT05692973|Behavioral|Inference Intervention|The intervention will pre-teach students a set of 20 essential facts about Egypt. Students will interact with expository and narrative texts. Students will practice using a text clue strategy to activate and integrate prior knowledge, will make in-text connections, connections across the 3 intervention texts, and connections between text and knowledge, and will make inferences about character motives and author intent. The tutor will ask students to justify connections and evaluate how these connections enhance understanding. Students will answer inference questions that require using text and background knowledge. A simple graphic organizer will support and scaffold inferencing. Throughout the intervention, students will practice retrieving the 20 essential facts about Egypt from memory using flash cards, completed in pairs with students providing each other feedback.
45780269|NCT02446964|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
45780270|NCT02446964|Drug|Tacrolimus|Given IV and PO
45780271|NCT02446964|Radiation|Total Marrow Irradiation|Undergo TMLI
45780272|NCT01799876|Procedure|Autologous Cell|
45780273|NCT01799876|Procedure|Standard microfracture arthroscopic surgery|
45780274|NCT01799954|Biological|DNA-HIV-PT123|4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered intramuscularly (IM)
45780275|NCT01799954|Biological|NYVAC-HIV-PT1|(along with NYVAC-HIV-PT4); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
45780276|NCT01799954|Biological|NYVAC-HIV-PT4|(along with NYVAC-HIV-PT1); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
45780277|NCT01799954|Biological|AIDSVAX® B/E|300mcg of subtype B (MN) HIV gp120 glycoprotein and 300mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600mcg of aluminum hydroxide gel adjuvant, administered IM.
46070536|NCT00911144|Biological|Wyeth-Lederle's Prevenar™|Intramuscular injection, administered as a single dose
45780278|NCT01799954|Biological|Placebo for DNA/NYVAC|Sodium Chloride for injection, 0.9% administered IM
45780279|NCT01799954|Biological|Placebo for AIDSVAX(R) B/E|600 mcg of aluminum hydroxide adjuvant, administered IM
45780280|NCT00623714|Drug|Comparator: fluticasone|Two puffs, of 250 µg each, will be administered to each patient to obtain a 500-µg dose at each prespecified time point. A total of five (5) doses (500 µg) each of inhaled fluticasone will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
45780281|NCT00623714|Drug|Placebo|Two puffs, of placebo, will be administered to each patient at each prespecified time point. A total of five (5) doses of placebo will be administered during the single blind run-in phase. and matching placebo will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
46070537|NCT00911144|Biological|GSK Biologicals' Hiberix™|Intramuscular injection, administered as a single dose
45780282|NCT02174822|Drug|AVP-786|
45780283|NCT02174822|Drug|Paroxetine|
45780284|NCT02174822|Drug|Duloxetine|
45780285|NCT02139800|Procedure|Sustained Inflation|The first sustained inflation will use inflation pressure of 20 cm H20 for 15 seconds
45780286|NCT02139800|Procedure|Standard of Care|Newborn Resuscitation Program (NRP) Guidelines using a standard PEEP/CPAP of 5-7 cm H2O as compared to the Sustained Inflation intervention
45780287|NCT02139878|Other|Wild blueberry juice|
45780288|NCT02139878|Other|Placebo wild blueberry juice|
45780289|NCT00624416|Drug|Prednisolone synthetic cortisone and Isoproterenol together|Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.
45780290|NCT01894646|Radiation|Positron Emission Tomography (PET) Imaging|
45780291|NCT01872260|Drug|LEE011|LEE011 - 28 day cycles (21 days followed by a 7 day break) for Arms 1, 3. LEE011 28 days cycles (continuous) Arm 4.
45780292|NCT01872260|Drug|Letrozole|Letrozole 2.5 mg/day
45780293|NCT01872260|Drug|BYL719|BYL719 - 28 days cycle (continuous) for Arm 2; 3 and 4
45780294|NCT00682838|Behavioral|Self-management|Self-management
45916556|NCT05639218|Drug|Inclisiran|Patients are receiving PCSK9 inhibitors or inclisiran in the context of optimal hypolipidemic pharmacotherapy
45780295|NCT00682838|Behavioral|Telemonitored care|Telemonitored care
45780296|NCT00624806|Behavioral|Daily telephone calls|Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers.
45780297|NCT00624806|Behavioral|Weekly telephone calls|Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
45780298|NCT00626210|Drug|modafinil|100-400 mg daily for 4 weeks
45916557|NCT05639257|Drug|Lamotrigine|Lamotrigine tablets increasing dosis to maximal 300 mg daily
45916558|NCT05639257|Drug|Namuscla|Namuscla tablets increasing dosis to maximal 501 mg daily
45916559|NCT05639608|Procedure|SCALING|SCALING WILL BE DONE AT BASELINE IN TEST GROUP.
45916560|NCT05639725|Procedure|maxillary Ist premolar extraction|Procedure/Surgery: Patients will undergo bilateral maxillary 1st premolars extraction before bonding followed by leveling & alignment.
45916561|NCT05639725|Procedure|SURGICAL|Surgery:After leveling and alignment,placement of zygomatic miniplates in bilaterally
45916562|NCT05639764|Device|Oculus Quest 2|A specific immersive virtual reality software designed to address chronic shoulder pain on the Oculus Quest 2 device.
45916563|NCT05639764|Device|Oculus Quest 2|"a VRi placebo intervention with the game Tsuro, which consists of a puzzle-based strategy game where the patient will have to solve a maze by placing pieces."
45780299|NCT01653080|Procedure|dynamic contrast-enhanced MRI|Studies will be performed on standard clinical MR Systems which are available on Campus. With the proposed imaging technique, we are able to acquire a 3D volume covering the orbit with a temporal resolution of approximately 15s. The affected eye will be immobilized to reduce motion artifacts. A routinely used MR contrast agent will be administered in a dose of 0.1mmol/kg bodyweight.
45780300|NCT00626366|Radiation|Sinus CT Scan|Subjects will undergo a Xoran miniCAT scan of their sinuses
45780301|NCT00626366|Drug|Omnipaque 240 Contrast Solution|Subjects will spray 2-4 drops of half-strength Omnipaque 240 mgI/mL into each nare. Each spray is approximately 0.1 ml.
45780302|NCT00626366|Drug|Omnipaque 240 mg I/mL|Subjects will place two drops of half-strength Omnipaque 240 mg I/mL intranasally to each nose. Each drop is approximately 1 ml.
45780303|NCT00653276|Drug|ezetimibe|ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through Day 7.
45780304|NCT00653276|Drug|Comparator: cyclosporine|single oral dose of cyclosporine 100 mg capsules on Day 1 or Day 7.
45780305|NCT00683852|Drug|Aripiprazole 5mg|Tablet dose of aripiprazole will be 2 mg/day during the first phase (30 days) of the study, and 5 mg/day in the second phase (30 days)
45780306|NCT00683852|Drug|Aripiprazole 2mg|For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study (30 days)
45780307|NCT00683852|Drug|Placebo|for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study (60 days)
45641610|NCT05690334|Drug|Crystalloid - 0 ml/kg|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
45780308|NCT01596751|Drug|PLX3397|Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration
45780309|NCT01596751|Drug|Eribulin|Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days
45780310|NCT03000751|Other|Simple Audit Report|The simple audit provides comparison and feedback on radiation doses.
45780311|NCT03000751|Other|Multi-Component Intervention|The multi-component intervention gives tailored feedback on needed changes plus guidance using quality improvement methods that facilitate organizational change. Provides access to experts, detailed audit, collaborative calls, and site visits (as needed).
45780312|NCT03000751|Other|In-Person Meeting|Collaborator meeting with an emphasis on quality improvement.
45780313|NCT03000595|Drug|SAN007 Cream|A cream containing 5% East Indian sandalwood oil (EISO).
45780314|NCT03000595|Drug|Placebo|The vehicle cream
45780315|NCT03006835|Drug|Clopidogrel|
45780316|NCT03006757|Other|titanium dioxide denture base|
45916564|NCT05639803|Drug|PEGIFNα1b|100μg/vial
45641611|NCT05690334|Drug|Crystalloid - 5 ml/kg|5 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
45780317|NCT02247271|Behavioral|Diabetes health coach support|Receives support from a trained peer health coach for a six month period
45780318|NCT05566405|Procedure|General Anaesthesia|All patients in the general anaesthesia group will be premedicated with intravenously administered (iv) midazolam (2mg) and fentanyl (100 mcg). Induction will be performed using intravenous propofol (2.5-3mg/kg) and lidocaine (40mg); dexamethasone 8mg, metoclopramide 10mg and omeprazole 40mg will also be administered. After successful tracheal intubation, total intravenous anaesthesia will be maintained by administering propofol (0.05 mg/kg/sec iv) and remifentanil (0.2 mcg/kg/sec iv). Pain management will be achieved by paracetamol (1g iv) and tramadol (100mg iv) whereas muscle relaxation by vecuronium (0.6 mg/kg iv).
45780319|NCT05566405|Procedure|Combined (Epidural and Spinal) Anaesthesia|Combined (epidural and spinal) anaesthesia will be performed using an epidural 18G needle and a spinal 27G needle, in the L2-L3 or L3-L4 interspace. Induction will be carried out by spinal intrathecal administration of levobupivacaine (2.6-3ml of 0.5%) and mild sedation by midazolam (5mg iv in bolus). All patients will be administered dexamethasone 8mg, metoclopramide 10mg and omeprazole 40mg iv. Maintenance will be performed 75 minutes after induction and obtained using an epidural administration of levobupivacaine (4-5ml of 0.5%).
45780320|NCT05566405|Procedure|Open Retropubic Radical Prostatectomy|All patients will undergo a nerve-sparing open retropubic radical prostatectomy
45780321|NCT03000361|Procedure|Motorized Spiral Colonoscopy|For any pathological finding during colonoscopy standard endoscopic techniques, e.g. forceps biopsy, injection, endoscopic mucosal resection, argon plasma coagulation
45780322|NCT03000127|Drug|AndroGel 1 % Topical Gel|testosterone gel
45916565|NCT05639803|Drug|Placebo|0.5ml/vial
45916566|NCT05639842|Other|Pain in competitive athletes with physical disabilities. Techniques for its management, support received and perceived difficulties.|A total of 413 athletes with physical disabilities participated in the study, 157 Spanish athletes and 260 Latin American athletes. The athletes were contacted through different sports federations, Paralympic Committees and sports teams of people with disabilities.For the distribution of the questionnaire, the researcher made an initial telephone contact with the Spanish Paralympic Committee and the Spanish Sports Federation for People with Physical Disabilities, to explain the objectives of the study and ask for their collaboration in the dissemination. Subsequently, the information was officially sent to them by email.
45916567|NCT00000115|Drug|Acetazolamide|
45916568|NCT00000121|Device|Prisms in Eyeglasses|
45916569|NCT00000133|Procedure|Trans-scleral Cryotherapy|
45916570|NCT00000136|Drug|Foscarnet|60 mg/kg every 8 hours, 90 mg/kg/day
45780323|NCT03000127|Drug|Placebos|Placebo gel
46070538|NCT04561622|Behavioral|Emotional Stroop Task|"Classic Stroop task The subject names one of the 3 colors of the crosses on a sheet.Then, the subject must read the words written on the sheet for 45 seconds.These are the words: RED, BLUE and GREEN, written in black color. The subject must name the color of the word.~Emotional Stroop task This is a computed task in which the patient is asked to answer both as accurately and as quickly as possible.~The target stimulus is an emotional face of joy or anger, surmounted by the word joy or anger.The subject must respond using the arrow corresponding to the face he sees.~A training phase is offered to the subject.~3 / Categorization task For each trial the participant will visualize a short emotional film or not. Then, the participant will have to choose, the emotion corresponding to what he just saw. A training period is offered too."
45641612|NCT05690334|Drug|Crystalloid - 10 ml/kg|10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
45641613|NCT05690061|Dietary Supplement|Grain-Fed Beef Hamburger|Bowl of grain-fed beef hamburger cooked without seasonings. 250 grams of uncooked hamburger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
45780324|NCT03000049|Other|bedside blood culture|
45780325|NCT02999815|Procedure|Human tetanus immunoglobulin|Adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin. Second, participants will be randomized to receive the addition of 500 IU intrathecal human antitoxin.
45780326|NCT02999815|Procedure|Intramuscular antitoxin|First, adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin including a 0.05ml test dose (ie 75 units equine antitoxin or 12.5 IU human antitoxin). Second, participants will be randomized with sham procedure
45780327|NCT02999659|Device|Pupilometer|Device to measure change in pupil diameter due to a defined light stimulus.
45780328|NCT03006523|Procedure|Intrauterine insemination|IUI will be performed with a Wallace® insemination 2 Catheter (Cooper Surgical, Trumbull, CT, USA) depositing 0.2 or 0.5 ml of the sperm sample at the uterine fundus. All IUIs will be performed between 12 p.m. and 4 p.m. After the procedure, 10 min of bed rest will be prescribed. Inseminations will be performed every day of the week, including weekends.
45916571|NCT00000136|Drug|Ganciclovir|5 mg/kg every 12 hours, 5 mg/kg every 24 hours
45916572|NCT00000139|Behavioral|Stress|
45916573|NCT00000139|Drug|Acyclovir|
45916574|NCT00388570|Device|The Aerocrine NIOX MINO® Airway Inflammation Monitor|
45916575|NCT00388648|Drug|mixture of amino and keto acids|
45780329|NCT05134363|Drug|Dexmedetomidine Hydrochloride 0.5 mic/kg bolus|comparison between two bolus doses of dexmedetomidine with a placebo group
45916576|NCT00388687|Drug|18F Fluoroazomycin Arabinoside (FAZA)|
45916577|NCT00000142|Drug|Cidofovir|"Three groups:~the deferral group, treatment deferred until retinitis progressed~Low-dose cidofovir group, 5 mg/kg of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks.~High-dose cidofovir group, 5mg/kg once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks."
45916578|NCT00000145|Dietary Supplement|Antioxidants|500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene
45916579|NCT00000145|Dietary Supplement|Zinc|80 milligrams zinc oxide; 2 milligrams of cupric oxide
45780330|NCT05134363|Drug|Dexmedetomidine Hydrochloride 0.75 mic/kg bolus|comparison between two bolus doses of dexmedetomidine with a conventional group receiving ondansetron.
45780331|NCT05134363|Drug|Placebo|equal volume of normal saline
45780332|NCT02247817|Device|Hybrid CRT-D/P implantation|
45780333|NCT05096299|Device|OCS Heart|Transplanted with OCS preserved heart.
45780334|NCT03006679|Drug|Meropenem-Vaborbactam|meropenem 2 g and vaborbactam 2 g
45780335|NCT03006679|Drug|Piperacillin/Tazobactam|piperacillin 4 g and tazobactam 0.5 g
45916580|NCT00000145|Dietary Supplement|Antioxidants and zinc|500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene; 80 milligrams zinc oxide; 2 milligrams of cupric oxide
45916581|NCT00000148|Procedure|Argon Laser Trabeculoplasty|
45916582|NCT00000148|Procedure|Trabeculectomy|
45916583|NCT00000151|Drug|Aspirin|
45916584|NCT00000151|Procedure|Argon Laser Photocoagulation|
45916585|NCT00000154|Procedure|Vitrectomy|
45916586|NCT00000157|Drug|Aspirin|
45916587|NCT00000172|Drug|Galantamine|
45916588|NCT00000175|Drug|Estrogen|
45916589|NCT00000175|Drug|Testosterone|
45916590|NCT00000187|Drug|Ritanserin|
45916591|NCT00000205|Drug|Buprenorphine|
45916592|NCT00000214|Drug|Buprenorphine|
45916593|NCT00000220|Drug|Buprenorphine|
45916594|NCT00000256|Drug|20% N2O|
45916595|NCT00000256|Drug|40% N2O|
45916596|NCT00000256|Drug|60% N2O|
45916597|NCT00000256|Drug|80% N2O|
45916598|NCT03582085|Biological|Bacillus Calmette Guerin Vaccine|Experimental
45916599|NCT03582085|Biological|Saline Injection|Placebo
45916600|NCT03573739|Procedure|low-calorie low-protein|In the low-calorie low-protein (Low) group, the calorie target will be 6 kcal/kg/day and the protein target 0.2-0.4 g/kg/d during the acute phase, i.e. from D0 to D7. On D8, the calorie target will be 30 kcal/kg/d and the protein target 1.2-2.0 g/kg/d.
45641614|NCT05690061|Dietary Supplement|Grass-Fed Beef Hamburger|Bowl of grass-fed, grass-finished beef hamburger cooked without seasonings. 250 grams of uncooked hamburger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
45641615|NCT05690061|Dietary Supplement|Impossible BurgerTM|Bowl of plant-based Impossible burger cooked without seasonings. 250 grams of uncooked Impossible burger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
45780336|NCT05069155|Behavioral|Gamification|Each participant signs a pre-commitment contract agreeing to try their best to achieve their daily step goal. Each week over the 12 week intervention period, participants are endowed 70 points (10/day). Participants are informed they will lose 10 points for each day the step goal is not met. Points are replenished at the start of the week. At the end of the week, if the participant has 40 points or more, he/she will advance one level, or drop one level if they have less than 40 points. The levels include: blue (lowest), bronze, silver, gold, platinum (highest). Each participant begins in the middle (silver). Each participant will also select a spouse, family member, or friend that they see often to serve as a supportive sponsor that receives a weekly email participants progress including points, game level, and average step countThis supportive sponsor will help to enhance social incentives to motivate the individual towards his or her goal.
45780337|NCT02998333|Procedure|Surgical stabilization|Surgical stabilization of the ankle joint, performed as an open or arthroscopic procedure.
45780338|NCT03006601|Other|Office-based accommodative/vergence therapy|Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 12 weeks) and home reinforcement (15 minutes each time, five times per week, 12 weeks)
45780339|NCT03006445|Drug|FYU-981|
45780340|NCT02247895|Device|Sham Treatment|Subjects will undergo the same protocol as the treatment group except no electrical stimulation will be applied.
45780341|NCT02247895|Device|Electrical stimulation|Two thirty minute sessions of neuromuscular electrical stimulation applied to both quadriceps for seven days for a total of 14 treatments
45916601|NCT03573739|Procedure|standard-calorie/standard-protein|In the standard-calorie/standard-protein (Standard) group, the first-line calorie target calculated based on body weight is 25 kcal/kg/day and the protein target 1.0-1.3 g/kg/d during the acute phase, i.e. from D0 to D7. On D8, the calorie target will be 30 kcal/kg/d and the protein target 1.2-2.0 g/kg/d.
45916602|NCT05637762|Other|- EEG video recording or extension of an EEG video recording planned as part of the care - Wearing a connected heart rate and motion recording patch|The study consists of creating a database to develop an algorithm using machine learning methods.
45916603|NCT05637957|Device|active transcranial direct current stimulation|Device: 20 minutes of up to 2.0 mA active anodal tDCS (anode positioned at C3/4, cathode positioned at Fp1/2 as per 10-20 electrode placement guidelines) Behavioral: Physiotherapy motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
45916604|NCT05637957|Device|sham transcranial direct current stimulation|Device: 1 minute of 1.0 mA anodal tDCS (anode positioned at C3/4, cathode positioned at Fp1/2 as per 10-20 electrode placement guidelines) and 19 minutes with unit turned off and electrodes remaining in place Behavioral: Physiotherapy motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
45916605|NCT03562156|Drug|Oteseconazole (VT-1161)|Oteseconazole (VT-1161) 150mg capsule
45916606|NCT03562156|Drug|Placebo|matching placebo capsule
45916607|NCT03545386|Other|Fecal microbiota transplantation|Stool from healthy donor administered via enema
45916608|NCT03545386|Other|Placebos|Saline with food coloring administered via enema
45916609|NCT00000388|Behavioral|Psychosocial treatment|
45916610|NCT00000388|Drug|Anti-ADHD medication|
45916611|NCT00000388|Behavioral|Assessment-and-Referral|
45916612|NCT00000397|Behavioral|Behavioral insomnia therapy|
45916613|NCT05638035|Diagnostic Test|Ultrasonografi, Sarcopenia measurement, Zebris|"The rectus femoris muscle thickness of the participants will be performed in B mode via USG (Mindray-UMT 200,USA) with a multifrequency (7-15 MHz) linear probe and the measurement will be reported.~TANITA for sarcopenia, hand grip strength and walking speed will be evaluated.~Gait time-distance parameters and Static balance COP parameters (COP speed (cm/s) and COP length (cm)) will be recorded using Zebris™ FDM-2."
45916614|NCT00000409|Procedure|Decompressive laminectomy|Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis
45916615|NCT00000409|Other|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated. Any non-operative therapies other than these are accepted and collected as data.
45448723|NCT03545620|Device|rescue technique|which rescue technique will be preferred while established/predicted difficult airway/intubation occurs in the operation room after failed direct laryngoscopy
45641616|NCT05689411|Device|Musical Toy|The child and his parents in the experimental group were distracted by playing with the xylophone, a musical toy, 5 minutes before the peripheral vascular access procedure. The xylophone is a percussion wooden toy. There are two wooden bars on the xylophone that make melodious sounds when the metal plates are struck. The xylophone toy was introduced to the child and the parent, and they were given the opportunity to examine it. Before the procedure, one of the wooden sticks of the toy was given to the child and the other to the parent. Before, during and after the procedure, the child and his parents played together by making a melodic sound from the musical toy xylophone. While the child and his parents were playing with the toy, the researcher attached a tourniquet to the appropriate extremity of the child and determined the vein to which the vascular access would be performed.
45641617|NCT05689021|Drug|Abiraterone Acetate/Niraparib|Given PO
45641618|NCT05689021|Procedure|Biospecimen Collection|Undergo blood specimen collection
45641619|NCT05689021|Procedure|Bone Scan|Undergo technetium-99m bone scan
45641620|NCT05689021|Procedure|Computed Tomography|Undergo CT scan
45780342|NCT05007847|Device|Apple Watch-based heart rhythm monitoring|"For the duration of the study, participants in the active arm will be asked to make ECG recordings in three circumstances:~Routinely once per day from the day of randomisation till the 12-month visit after AF Catheter Ablation (they will be encouraged to do so at the same time each day with the option to set a reminder on the watch).~If the AW requests them to do so (the automatic AF-notification algorithm will be active throughout the study period and if AF is suspected based on the tachogram, it will trigger notification for the participant to make an ECG recording). This will be till the 12-month time point.~If the patient has symptoms of palpitations, pre-syncope or syncope. This will be till the 12-month time point. Monitoring should continue even if AF has been diagnosed to characterise arrhythmia burden and profile. Participants will be given the contact details of a dedicated email inbox to which to send ECGs recorded through the AW."
45780343|NCT05237479|Procedure|Suprainguinal fascia ilica block|Patients who have been randomized to Group B Intervention will receive a preoperative S-FICB using 35ml of 0.5% ropivacaine under ultrasound guidance by the regional anesthesia block team once patient has been marked by surgeon. Sensory & motor distribution of the LFCN, FN, & ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery. Patients who received a S-FICB in preop, approximately 15 minutes after the block, sensory & motor distribution of LFCN, FN, & ON will be assessed by the regional anesthesia block team prior to going to the operating room. All patients, regardless of group allocation, will be followed by the acute pain service team on postoperative day one to assess sensory & motor distribution of LFCN, FN, & ON & adjustment of pain medication regimens. All patients will receive a call from a research assistant blinded to group allocation 24 hours post-discharge for a patient satisfaction survey.
45780344|NCT05237479|Other|Placebo|The sensory and motor distribution of the LFCN, FN, and ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery.
45780345|NCT03006367|Drug|NFC-1 100 mg|
45641621|NCT05689021|Procedure|Magnetic Resonance Imaging|Undergo MRI
45780346|NCT03006367|Drug|NFC-1 200 mg|
45780347|NCT03006367|Drug|NFC-1 400 mg|
45780348|NCT03006367|Drug|NFC-1 800 mg|
45780349|NCT02980939|Other|iv fluid infusion|Intravenous isotonic saline infusion
45780350|NCT04987723|Other|Holter monitoring|Assessment of HRV shall be performed in all enrolled patients. Ventricular HRV will be derived from a continuous 24-hour period of a 48-hour ambulatory Holter recording during AF. Participants will be requested to avoid alcohol and caffeine from 24-hours prior to fitting and any activity more strenuous than walking for the recording duration. After initial fitting, a 20-minute high-resolution ECG recording will be performed lying supine at rest.
45780351|NCT04987723|Other|stress echocardiography|Echocardiography will be performed using a GE Vivid 9 echocardiography machine (Vingmed-General Electric, Horten, Norway) equipped with a phased-array 3.5 MHz transducer. All measurements will be made according to the guidelines set by the British Society of Echocardiography.
45780352|NCT04987723|Other|Cardiac MRI|Contraindications to MRI will be excluded using the appropriate departmental screening forms. A trained scanner operator or radiographer will co-ordinate and supervise the scan. Cardiac MRI will be performed at 1.5T (Aera, Siemens Healthineers, Erlangen, Germany) with a protocol consisting of cine imaging, stress and rest perfusion, and late gadolinium enhancement (LGE).
45780353|NCT04987723|Other|Patient questionnaires|Two validated Health Related Quality of Life (HRQoL) surveys designed for patients with AF will be used; the AF Effect on Quality of Life (AFEQT) and Barts AF Patient reported objective measure (PROM).
45780354|NCT04906369|Procedure|Biospecimen Collection|Undergo collection of blood samples
45780355|NCT05164471|Genetic|verbrinacogene setparvovec|FLT180a is a gene therapy intended to increase endogenous FIX production in adults with Hemophilia B
45780356|NCT05160961|Procedure|Serratus anterior plane block|Serratus anterior plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
45780357|NCT05160961|Procedure|Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
45780358|NCT05673031|Diagnostic Test|68Ga-HA-DOTATATE PET/CT imaging|"Each patient will receive an IV injection 68Ga-HA-DOTATATE. Imaging will be conducted beginning 45-90 minutes after an injection of between 100-250 MBq 68Ga-HA-DOTATATE in patients.~After the 68Ga-HA-DOTATATE acquisition is complete, a CT scan will be performed for attenuation correction and localization in the same in line gantry without patient movement between the two scans.~The results of the 68Ga-HA-DOTATATE PET/CT will be compared to any prior imaging and pathologic results."
45780359|NCT05672875|Diagnostic Test|Anthrax LF Dx System|Lateral flow immunoassay for the detection of the LF biomarker in whole blood samples.
45916616|NCT00000409|Procedure|Fusion--Instrumented|In addition to decompressive laminectomy, additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
45448724|NCT04249882|Drug|Placebo|Matched to active medication
45641622|NCT05689021|Drug|Prednisone|Given PO
45641623|NCT05688592|Procedure|PET-CT|"This is a before-and-after study (not a clinical trial)~in the case of fungemia, 2 weeks after the initial staging 18F-FDG PET-CT.~in the case of focal IFIs, 2-4 and 12 weeks after the initial staging 18F-FDG PET-CT"
45641624|NCT05687188|Other|Blood Sample Collection|Participants will have 40 mL of blood drawn at baseline/pre-treatment. The study team will aim to have this blood collected at the time of standard of care blood draw if possible.
45641625|NCT05687188|Other|Tissue Sample Collection|At the time of tissue biopsy or surgical resection (if applicable) pancreatic tumor tissue, fat, tissue from site of metastasis, and cyst fluid (if applicable) will be collected.
45641626|NCT05687188|Other|Data Collection|Participants will complete a study questionnaire at baseline that includes medical history, lifestyle, and family history information.
45780360|NCT03006211|Other|Nitrogen protoxide|
45780361|NCT03006211|Other|Oxygen|
45780362|NCT05672797|Other|Wellth app|The Wellth app will be provided to treatment groups 1 and 2 for free and it is available for download through all common mobile app stores for both iOS and Android phones. The Wellth App is a private company that serves over five million clients that range from patients of healthcare providers and beneficiaries of various health insurance companies to employees of large corporations, where the Wellth App is offered as a behavioral tool for increasing meditation adherence among individuals who are managing chronic conditions through daily meditations, e.g. chronic obstructive pulmonary disease, asthma, high blood pressure, coronary artery disease, and HIV. The Wellth App has already been offered to some members of Arizona Complete Health, so both Wellth and Arizona Complete Health are familiar with implementing this program among this target population.
45780363|NCT05672797|Behavioral|Habit training|"Participants in treatment groups 1 and 2 will be asked to identify an existing routine behavior that will act as a cue for their daily pill-taking behavior to. However, only participants in treatment group 2 will have to submit visual evidence of their cue to the Wellth app in addition to photos of their medication in order to receive credit for the medication check-in (i.e., financial incentives conditional on using their cue)."
45780364|NCT05672719|Diagnostic Test|Right Heart Catheterization|Procedure
45780365|NCT02248051|Drug|CXA-10|CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
45780366|NCT05672641|Other|Inertial training|Inertial training group performed their training three times a week (Monday, Wednesday, and Friday) between between 7:00 a.m. and 8:30 a.m. for 6 weeks. Participants performed inertial training using Cyklotren (Inerion, Poland). Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
45780367|NCT05672641|Other|Body building training|Body building group performed body building training three times a week (Monday, Wednesday, and Friday) between 7:00 a.m. and 8:30 a.m. for 6 weeks using free weights. Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
45780368|NCT05672563|Drug|Saline infusion sonography for evaluation of cesarean scar|The intervention included the usage of balloon-less GIS catheter with a soft tapered tip inserted into the endocervical canal, with no use of a tenaculum or a cervical dilatator. Normal saline is slowly introduced into the uterine cavity via the catheter until achieving satisfactory distension and visualization of the uterine cavity using trans-vaginal ultra-sonographic imaging.
45780369|NCT03005821|Other|Chinese pediatric massage therapy + usual care|
45641627|NCT05687188|Other|Medical Image Collection|Medical images that are obtained during routine care such as computed tomography (CT) scans, magnetic resonance imaging (MRIs) and ultrasounds will be reviewed by the study team throughout the participant's medical care.
45780370|NCT03005821|Other|Sham massage therapy + usual care|
45780371|NCT02247505|Drug|Harnal-D Cap. 0.2mg|
45780372|NCT02247505|Drug|Cialis Tab. 5mg|
45780373|NCT02996929|Device|LC System|Subjects will undergo CIED lead extraction with the LC system
45780374|NCT04707625|Drug|Aflibercept Ophthalmic|Anti-vascular endothelial growth factor intraocular injection
45780375|NCT02248129|Drug|Telmisartan and hydrochlorothiazide|
45780376|NCT04627675|Drug|CORVax|DNA-encodable coronaviral vaccine
45780377|NCT04627675|Drug|IL-12 plasmid|cytokine
45780378|NCT04627675|Device|Cliniporator|electroporation system
45780379|NCT02248207|Drug|Pramipexole|
45780380|NCT03006055|Device|Circulating tumor cells|
45780381|NCT03005743|Radiation|Magnetic Resonance Image based Brachytherapy|MRI based BT prescription will be in accordance to the GEC-ESTRO guidelines [Intention will be to treat the whole cervix and the remaining residual tumour tissue at the primary site at the time of BT (high risk-clinical target volume) to a dose level analogue to the dose level previously prescribed for point-A]
45780382|NCT03005743|Radiation|Conventional Radiograph based Brachytherapy|The standard conventional radiography based prescription will be according to Manchester system Point A and bladder & rectum ICRU point dose constraints
45780383|NCT00683930|Drug|Mycophenolate Mofetil 2 g/Day|Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
45780384|NCT00683930|Drug|Mycophenolate Mofetil (MMF) 3 g/Day|Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
45916617|NCT00000409|Procedure|Fusion-Non-instrumented|additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
45916618|NCT00000418|Procedure|Psychosocial intervention|
45641628|NCT05686642|Drug|LT3001 Drug:high dose|Administered by intravenous infusion.
45448725|NCT04249882|Drug|Naltrexone|50 mg once a day
45448726|NCT04249882|Drug|Varenicline|1 mg twice a day
45641629|NCT05686642|Drug|Placebo|Administered by intravenous infusion.
45641630|NCT05686642|Drug|LT3001 Drug:low dose|Administered by intravenous infusion.
45641631|NCT05686044|Drug|Buntanetap|HPMC (vegetarian source) capsule shells
45641632|NCT05686044|Drug|Placebo|HPMC (vegetarian source) capsule shells
45641633|NCT05685407|Drug|Caffeine|300mg caffeine will be administered orally via capsules to participants with female sexual arousal disorder.
45641634|NCT05685407|Other|Placebo|A placebo pill that matches in size, shape, and color will be administered to participants with female sexual arousal disorder.
45641635|NCT05684276|Drug|Carboplatin|"Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, sodium chloride and glucose 5% solution solution or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of ech center."
45641636|NCT05684276|Drug|Paclitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexa-hydroxy-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines on Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
45780385|NCT00683930|Drug|Placebo|Placebo for MMF 2 g/day group: 4 tablets orally twice daily for 52 weeks; placebo for MMF 3 g/day group: 6 tablets orally twice daily for 52 weeks
45641637|NCT05684276|Drug|Nivolumab|"Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains. Route of administration: Intravenous infusion. Product Description: Nivolumab (BMS-936558-01) Injection drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated in 10 mg/ml.~Storage Conditions: It must be stored at 2 to 8 degrees Cº and protected from light and freezing.~Guidelines: The administration of nivolumab infusion must be completed within 24 hours of preparation.The dose of Nivolumab for the adjuvant treatment is 360 mg administered as an intravenous infusion over 30 minutes every 3 weeks (+/-3 days) for 3 cycles.~For the maintenance adjuvant treatment the dose is nivolumab 480 mg Q4W (+/-3 days) over 30 minutes for 6 months (6 cycles).~Subjects should be carefully monitored during nivolumab administration to follow infusion reactions. Doses of nivolumab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment."
45641638|NCT05683691|Device|Vanquish System|Water vapor ablation delivered transurethrally in patients with intermediate risk, localized prostate cancer.
45780386|NCT02248363|Other|Multimodal rehabilitation|Multimodal rehabilitation (MMR) distinguishes itself as an interdisciplinary-coordinated (e.g., physician, occupational therapist, physiotherapist, and psychologist) intervention using a bio-psycho-social view of chronic pain. The MMR continues over a lengthy period with a common goal and generally includes patient education, supervised physical activity, simulated work training, and cognitive behavioural therapy (CBT). The exact composition of these MMR components depends on initial evaluations of the patients health status and furhter follow-up testing. The MMR interventional components can act independently and interdependently, resulting in combined effects due to known and unknown mechanisms; the effects are intended to be greater than the sum of its components.
45780387|NCT03005509|Other|TQIM checklist|"The intervention phase will include an intense training period covering:~Conduct of Trauma Quality Improvement Meeting (TQIM) (and Trauma Quality Improvement program in general). The training will be delivered using the World Health Organization (WHO) Trauma Quality Improvement Programmes short course and online resources.~Implementation of Trauma Quality Improvement Meeting (TQIM) Checklist."
45780388|NCT00684242|Drug|Lenalidomide|10 mg by mouth daily
45780389|NCT00684320|Behavioral|Attention Disengagement Training (ADT)|Those assigned to ADT condition will receive a computer delivered attention retraining protocol designed to enhance attention disengagement from socially threatening stimuli. The ADT protocol includes eight 30-min sessions delivered over a 6-week period (i.e., bi-weekly sessions). During each session, participants will see 320 trials that consist of the various combinations of probe type (E or F) probe position (top or bottom), and emotion type (Neutral, Disgust, Anger). 256 trials will include one neutral face and one disgust face or one angry face: 2 (probe type) X 2 (probe position) X 16 (person) X 4 (repetitions). On trials where participants see one neutral face and one disgust or angry face (i.e., 80% of the trials), the probe will always follow the neutral face.
46070539|NCT04395248|Procedure|Exploring potential risk factors of difficult intubation using ultrasound|Before surgery, ultrasound will be used to assess pretracheal soft tissue depth and height and width of tongue base. The distance from the skin to the anterior aspect of the trachea will be measured at three levels: vocal cords, thyroid isthmus, and suprasternal notch. With the patient in a seated position, the convex transducer of a portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be introduced to the skin of the neck in the submental region coronally, immediately cephalad to the body of the hyoid bone, and then in the area between the hyoid bone and the symphysis of the mandible. Maximal width of tongue base, tongue base height, and maximal height of mid-tongue will be measured. The laryngoscopy intubation will be performed using a size-3 or -4 Macintosh (Rüsch Inc., Duluth, GA, USA) blade and a styletted endotracheal tube. The laryngoscopic view will be graded according to Cormack and Lehane's classification with external laryngeal pressure applied.
45780390|NCT00684320|Behavioral|Placebo Condition|The placebo condition (PC) will be identical to the AMP condition except that during the presentation of the trials where a threat picture is present, the probe will appear with equal frequency in the position of threat and neutral pictures. Thus, neither threat nor neutral pictures have signal value with regard to the position of the probe.
45780391|NCT00651560|Drug|ezetimibe (+) simvastatin|ezetimibe 10mg (+) simvastatin 20 mg once daily for 4 weeks of treatment.
45641639|NCT05683262|Procedure|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection|Ultrasound guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position with a pillow under the abdomen to flatten the lumbar curvature. Lower extremities should be internally rotated while feet are inverted to help flatten the gluteal region. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. Ultrasonography gel was applied on the probe and the probe was wrapped with a transparent thin sheath and cleaned with povidone iodine. Sterile gel is applied on the skin. The sacrococcygeal ligament, the sacrococcygeal and intercoccygeal joints were visualized. The sacrococcygeal and/or intercoccygeal joints were entered using the in-plane technique with a 23 gauge 6 cm long needle. When it was seen that the needle tip was inside the joint, 3 cc of 2% lidocaine + 1 cc betamethasone solution was injected.
45641640|NCT05683262|Procedure|Ultrasound-guided coccygeal nerve block|Patients are placed in the prone position with a pillow under the abdomen. Lower extremities are internally rotated while feet are inverted. Injection site and the probe are cleaned thrice with povidone iodine %10 solution. Sterile gel is applied. The prob was placed on coccygeal cornu and the coccygeal nerve was visualized superomedial to the CC in the subcutaneous tissue layer. Hydrodissection was made by administering 5 ml of 5% dextrose + 1 ml of 2% lidocaine via an in-plane approach with a 23 gauge 6 cm long needle, targeting the short axes of the bilateral coccygeal nerves.
45641641|NCT05683262|Procedure|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection after coccygeal nerve block|After the coccygeal nerve block, when the pain with palpation of the coccygeal region was reduced by at least 50%, the sacrococcygeal ligament, sacrococcygeal and intercoccygeal joints were visualized.The sacrococcygeal and/or intercoccygeal joints were entered using the in-plane technique with a 23 gauge 6 cm long needle. When the needle tip was inside the joint, 3 cc of 2% lidocaine + 1 cc betamethasone solution was injected.
45780392|NCT04492111|Procedure|post-extraction dental implant|Insertion of a dental implant immediately after tooth extraction.
45780393|NCT00684554|Drug|Buprenorphine|Dose is determined according to the participants' individual need.
45780394|NCT04490395|Behavioral|Engage PA|Engage PA will consist of a 2-session intervention delivered to participants at the medical center or virtual visit by their study therapist, and includes a wearable personal fitness monitor for tracking their daily activity levels throughout.
45780395|NCT04490395|Other|Treatment as Usual plus (TAU+)|The comparison condition will receive treatment as usual throughout the study, and are given a wearable personal fitness monitor for tracking their daily activity levels throughout the study.
45780396|NCT00626912|Procedure|endovascular coil embolization|standard endovascular coil embolization with or without adjunct techniques
45780397|NCT02248441|Other|Daily ischemic conditioning treatment|RIC stimulus will be conducted as 4 x 5 minutes upper arm ischemia achieved by inflation of a blood pressure cuff to 200 mmHg and 5 minutes reperfusion between inflations. The procedure will be performed using the AutoRICTM (CellAegis Devices Inc., Toronto, Ontario, Canada).
45780398|NCT00551876|Drug|MK0653, ezetimibe / Duration of Treatment: 30 Weeks|
45780399|NCT00551876|Drug|Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks|
45916619|NCT05638074|Procedure|Interlaminar Epidural Steroid Injection|"The patient will be placed in the prone position and cutaneous anesthesia is performed with 3 mL of 2% prilocaine using the sterile technique. After imaging the C7-T1 space with fluoroscopy, it will be entered from the right/left paramedian part of the C7-T1 space with an 18G Touhy needle, and the C-arm will be set in the contralateral oblique position for depth determination.~Under intermittent fluoroscopic imaging, the needle will be advanced, and access to the epidural space wiil be confirmed by the loss of resistance technique. Afterwards, the epidural spread will be controlled with a contrast agent, and a mixture of 10 mg dexamethasone, 1 mL 2% lidocaine hydrochloride, and 1 mL 0.9% saline will be applied to the epidural space. The patient will be discharged with recommendations after being kept under observation for 2 hours post-procedure. All injections will be performed by the same pain medicine specialist who has at least 5 years of experience."
45916620|NCT00000421|Drug|Prednisone|
45916621|NCT00000421|Drug|Placebo|
45916622|NCT00000424|Procedure|Tidal lavage vs. sham lavage of the knee|
45916623|NCT00388440|Biological|MMR vaccine (Priorix)|
45780400|NCT04451863|Drug|Low THC|Vaporized THC (5 mg)
45780401|NCT04451863|Drug|High THC|Vaporized THC (15 mg)
45780402|NCT04451863|Drug|Low Myrcene|Vaporized Myrcene (0.5 mg)
45780403|NCT04451863|Drug|High Myrcene|Vaporized Myrcene (12.0 mg)
45780404|NCT04451863|Drug|Low Beta-Caryophyllene|Vaporized Beta-Caryophyllene (0.5 mg)
45780405|NCT04451863|Drug|High Beta-Caryophyllene|Vaporized Beta-Caryophyllene (7.5 mg)
45780406|NCT04451863|Drug|Placebo|Vaporized Placebo
45916624|NCT00000427|Drug|Parathyroid hormone|
45916625|NCT00000427|Drug|Alendronate|
45916626|NCT00000433|Drug|Anti-Tumor Necrosis Factor|
45916627|NCT00000457|Drug|bupropion (Wellbutrin)|"1 pill in the am of 150 mg of Bupropion~1 pill (150 mg) in the AM and one in the PM for a total of 300 mg per day for subsequent 44 weeks."
45641642|NCT05681078|Behavioral|A Matter of Balance: Managing Concerns about Falls|A Matter of Balance is an evidence-based program targeting physical activity and fall prevention for adults 60 years of age and older. This program incorporates active learning discussions and activities along with exercise training to reduce the fear of falling, improve fall efficacy and management, and increase physical activity levels in older adults.
45641643|NCT05679726|Behavioral|massage|reflexology foot massage
45641644|NCT05679427|Radiation|radiosurgery and stereotactic ablative radiotherapy with simultaneous integrated boost, respectively|Two protocols of stereotactic ablative radiotherapy, in one vs five fractions ( the later with SIB) are compared
45641645|NCT05676385|Dietary Supplement|First concept product (containing 50 grams of carbohydrates)|Fasted intake of First concept product (randomised)
45641646|NCT05676385|Dietary Supplement|Second concept product (containing 50 grams of carbohydrates)|Fasted intake Second concept product (randomised)
45641647|NCT05676385|Dietary Supplement|Reference product (containing 50 grams of carbohydrates)|Fasted intake of Reference product (randomised)
45780407|NCT00628394|Drug|Atomoxetine|40mg 2po qam
45780408|NCT00628394|Drug|Placebo|40mg 2po qam
45780409|NCT04449835|Procedure|Intracept Procedure|radio frequency ablation of the basivertebral nerve for the relief of chronic vertebrogenic low back pain
45780410|NCT00251576|Drug|A-Phase: tirofiban; Z-Phase simvastatin|
45780411|NCT00251576|Drug|Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years|
45780412|NCT00251576|Drug|Comparator: A-Phase: low molecular weight heparin, unfractionated heparin|
45780413|NCT00251576|Drug|Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours|
45780414|NCT00251576|Drug|Duration of Treatment: Z-Phase, 2 years.|
45780415|NCT02996617|Drug|rhG-CSF regimen|Patients weren't preventive use of rhG-CSF.If their WBC≤1×10^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10^ 9/L.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
45780416|NCT02996617|Drug|Pegylated rhG-CSF regimen|Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
45780417|NCT04387604|Drug|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|"PRN regimen. Treatment Schedule Repeat injections at every 4-week visit if eye improves or worsens (defined as ≥5 letter change from last injection or ≥10% CST change on OCT from last injection or CSF>300 μm at any timepoint).~Defer injections if either BCVA of 85 letters and OCT CSF normal (CSF≤300 μm and non-existent intra- or sub-retinal fluid); or OCT CSF normal (CSF≤300 μm) and stable BCVA (defined as < 5 letters change from last injection) after two consecutive injections during the first 24 weeks, or after one injection if the initial stability period has already been achieved (OCT CSF normal and stable BCVA).~Resume injections if BCVA or OCT worsens."
45641648|NCT05676112|Drug|nintedanib|nintedanib
45780418|NCT03005665|Drug|Acetazolamide|
45780419|NCT03005665|Drug|Normal Saline|
45780420|NCT04429945|Device|Virtual Reality|Virtual Reality Headset with Virtual Reality Applications
45780421|NCT00684788|Combination Product|employment-based reinforcement|"Participants in the Work Plus Naltrexone Contingency condition were required to take scheduled doses of depot naltrexone to work and earn wages."
45780422|NCT04351165|Drug|IMP4297|IMP4297 10mg/capsule; IMP4297 20mg/capsule;
45780423|NCT00628628|Drug|As Needed Rasburicase|.15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.
45780424|NCT00628628|Drug|Fixed Dose Rasburicase|.15 mg/kg IV Over 30 Minutes Daily
45916628|NCT00000457|Drug|Placebo|placebo pill to match (look alike) the 150 mg pill of the bupropion given in the am for 3 days and then two pills (one in the morning and one at night) for the subsequent 44 mg.
45641649|NCT05676112|Drug|pirfenidone|pirfenidone
45916629|NCT00000460|Behavioral|Low intensity exercise|
45916630|NCT00000460|Behavioral|High intensity exercise|
45916631|NCT00388479|Drug|Alvimopan|
45916632|NCT00000463|Drug|lovastatin|
45916633|NCT00000463|Drug|cholestyramine|
45916634|NCT00000463|Drug|warfarin|
45916635|NCT00000466|Drug|estrogens, conjugated|
45916636|NCT00000466|Drug|medroxyprogesterone|
45916637|NCT00000466|Drug|progesterone|
45780425|NCT04386811|Drug|Calcitriol|A total of 24 otherwise medically healthy individuals with ADHD will be studied as outpatients. All subjects will undergo neurocognitive assessments of attention/vigilance, spatial working memory, and reversal learning both before and after subjects' daily dosing with their currently prescribed stimulant medication on both calcitriol and placebo pretreatment days using a randomized, double-blind, placebo controlled, within-subject, two-day study design.
45780426|NCT04386811|Other|Placebo|A total of 24 otherwise medically healthy individuals with ADHD will be studied as outpatients. All subjects will undergo neurocognitive assessments of attention/vigilance, spatial working memory, and reversal learning both before and after subjects' daily dosing with their currently prescribed stimulant medication on both calcitriol and placebo pretreatment days using a randomized, double-blind, placebo controlled, within-subject, two-day study design.
45916638|NCT00000466|Drug|estrogen replacement therapy|
45916639|NCT00000472|Drug|tissue plasminogen activator|
45916640|NCT00000472|Drug|heparin|
45916641|NCT00000475|Behavioral|health education|
45780427|NCT04366999|Procedure|LSG|The operation was started by replacing the 12-mm bladed trocar, and two additional trocars were inserted. LigaSure was used to dissect the omental pieces of the great curvature and any adhesions of the pancreas and stomach. A 36-French orogastric tube was then placed in the stomach. Gastric transection was started at a distance of approximately 4cm from the pylorus using a stapler (EndoGIA™; Covidien). All stapling was performed with yellow/green/black/blue cartridges. The staple line was reinforced with continuous barbed prolene sutures, and any sites of bleeding were closed with the LigaSure device. The portion of the stomach that had been transected from the pylorus was extracted through the 12-mm trocar site.
45780428|NCT04366999|Procedure|LRYGB|LRYGB is performed as described as standard. In brief, smaller stomach pouch of 10 to 20 ml or larger stomach pouch of 25 to 35 ml were created according to the metabolic status of the patients. The jejunum at approximately 150 cm distal site was dragged up and connected (anastomosed) to the remnant stomach.
45780429|NCT04366999|Procedure|OAGB-MGB|"Four ports are placed generally. Thepaddleretractor is used to retract the liver. The GIA stapler divides the stomach at the junction of the body and antrum, at a location where the jejunal loop can be brought up comfortably. With 4-6 lines of staples that seal the gastric pouch. The division of the stomach is parallel to the lesser curvature and up to the angle of His. A point is selected on the small bowel about 150 cm distal to the ligament of Treitz. The jejunal loop is brought up antecolic, and the Endo-GIA stapler is used to anastomose the stomach and the small bowel at this point. The distal end of the gastric tube is anastomosed to the side of the small bowel. The inside of the anastomosis is inspected for bleeding before final closure. The stapler then closes the anatomosis."
45780430|NCT00629018|Biological|CD34+ autologous stem cell transplantation|Peripheral blood stem cells will be mobilized by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labeled with technetium. Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment and the collected CD34+ cells will be injected intracoronary in the artery supplying the segments of reduced tracer accumulation
45780431|NCT00629018|Drug|Bone Marrow Stimulation|Patients will undergo filgrastim stimulation and viability assessment using the same protocol as in Arm 1. However, in this group, no intracoronary stem cell delivery will be performed; the patients will receive placebo (saline).
45780432|NCT00629018|Biological|SC therapy|In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect
45780433|NCT04357873|Drug|pembrolizumab; vorinostat|"Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations~Vorinostat: 400 mg once daily, until progression"
45780434|NCT04343209|Diagnostic Test|Myocardial Perfusion Imaging Study|Evaluation of myocardial perfusion via PET imaging agent
45780435|NCT04343209|Drug|AMMONIA N-13 37.5 mCi in 1 mL INTRAVENOUS INJECTION [Ammonia N 13]|Cardiac PET imaging agent
45780436|NCT00199238|Drug|Rupatadine Fumarate|
45780437|NCT05671081|Drug|Dexmedetomidine|patients will receive combined general anesthesia and bilateral bilevel at T5 &T10 Erector spinae plane block with 20mL of bupivacaine 0.125 %. plus 0.5 μg/kgof Dexmedetomidine for each injection
45780438|NCT05671081|Drug|Magnesium sulfate|patients will receive combined general anesthesia and bilateral bilevel at T5 &T10 Erector spinae plane block with 20mL of bupivacaine 0.125 %. plus 2 mg/kg Magnesium sulfate for each injection
45780439|NCT05671081|Drug|Narcotic Analgesics|patients will receive general anesthesia and conventional intraoperative and postoperative analgesia
45780440|NCT05670067|Procedure|maxillary tuberosity bone graft (autogenous graft)|the usage of maxillary tuberosity as source of autogenous graft supplying the needed cells for bone regeneration
45780441|NCT05670067|Procedure|Bone graft (xenograft)|xenograft is bone graft material that is obtained from porcine, bovine or equine source
45780442|NCT00630734|Drug|Pravastatin|Pravastatin 40 mg by mouth daily on days 1-4
45916642|NCT00000478|Drug|atenolol|
45916643|NCT00000478|Drug|nifedipine|
45916644|NCT00000478|Drug|diltiazem|
45916645|NCT00000478|Drug|isosorbide dinitrate|
45916646|NCT00000478|Procedure|coronary artery bypass coronary artery bypass|
45916647|NCT00000478|Procedure|angioplasty, transluminal, percutaneous coronary|
45916648|NCT00000481|Behavioral|diet, fat-restricted|
45916649|NCT00388882|Drug|tiotropium|
45916650|NCT00388882|Drug|ipratropium bromide / albuterol|
45916651|NCT00388999|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
45916652|NCT00388999|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
45916653|NCT00388999|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
45916654|NCT00000487|Drug|antihypertensive agents|
45916655|NCT00000487|Behavioral|smoking cessation|
45916656|NCT00000487|Behavioral|diet, fat-restricted|
45641670|NCT05673876|Drug|GDC-8264|GDC-8264 tablets will be administered as per the schedule specified in the respective arms.
45641671|NCT05673187|Drug|Adagrasib|Adagrasib is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.
45780443|NCT00630734|Drug|Darunavir|Darunavir 600mg by mouth twice daily on days 12-18
45780444|NCT00630734|Drug|Ritonavir|Ritonavir 100mg by mouth twice daily on days 12-18
45780445|NCT00630734|Drug|Pravastatin|Pravastatin 40 mg by mouth daily on days 15-18
45780446|NCT00630734|Other|Washout|Washout (no medication) on days 5-11.
45780447|NCT05666323|Behavioral|Single Text Messaging (TM1)|Receives single text message
45780448|NCT05666323|Behavioral|Patient Navigation (PN)|Receive phone calls from trained MAPS counselors
45780449|NCT05666323|Behavioral|Multiple Text Messaging (TM+)|Receives multiple scheduled text messages
45780450|NCT05665933|Behavioral|ACCEPTANCE AND COMMITMENT THERAPY-BASED PSYCOEDUCATION|Total Duration: 6 Weeks Session Duration: 90 min Frequency: 1 day per week Number of People: 30
45780451|NCT01799096|Dietary Supplement|Sucrose|Sucrose in carbonated soft drinks (4 x250ml total1800 kJ per day)
45780452|NCT01799096|Dietary Supplement|Aspartame|Intensely sweetened soft drink (no energy content)
45780453|NCT03005431|Behavioral|Parent training and support|Parents will be given access to participate in an on-line support forum and a set of on-line parent training modules.
45641672|NCT05672459|Drug|Single Injection of IVS-3001- Anti - HLA-G CAR-T cells|Given by IV (vein)
45641673|NCT05672459|Drug|Fludarabine phosphate|Given by IV (vein)
45641674|NCT05672459|Drug|Cyclophosphamide|Given by IV (vein)
45641675|NCT05672459|Procedure|leukapheresis|Given by IV (vein)
45641676|NCT05672342|Drug|Cannabidiol|Given PO
45780454|NCT05516017|Device|Vestibular Electrical Stimulator and Pinhole Glasses|"It is applied with a vestibular electrical stimulation device for 20 msec with 2 Hz, 1-4 mA, 1 mA increments. Very high frequencies can cause auditory perceptions such as 0.5 - 20 kHz, should be avoided.~The pinhole glasses are made of 2 pieces of opaque black plastic material with a total of 113 holes on each side. The opaque black plastic is 1.7 mm thick, 4.5 cm wide, and 5.5 cm long.~The holes in the opaque black material are arranged horizontally in 11 rows from top to bottom. The diameter of each hole is 1.1 mm, the horizontal distance of the holes from each other is 4.5 mm, and the vertical distance is 3.5 mm."
45780455|NCT05516017|Device|Vestibular Electrical Stimulator|It is applied with a vestibular electrical stimulation device for 20 msec with 2 Hz, 1-4 mA, 1 mA increments. Very high frequencies can cause auditory perceptions such as 0.5 - 20 kHz, should be avoided.
45780456|NCT01799174|Procedure|UVA-1 Phototherapy|
45641677|NCT05672342|Drug|Delta-8-Tetrahydrocannabinol|Given PO
45641678|NCT05672342|Drug|Placebo Administration|Given PO
45641679|NCT05672342|Other|Questionnaire Administration|Ancillary studies
45641680|NCT05672095|Procedure|Biopsy|Undergo needle or core biopsy
45641681|NCT05672095|Procedure|Biospecimen Collection|Undergo blood sample collection
45641682|NCT05672095|Drug|Niraparib|Given PO
45641683|NCT05672095|Other|Questionnaire Administration|Ancillary studies
45641684|NCT05672095|Dietary Supplement|Selenium|Given IV
45641685|NCT05669989|Drug|Isatuximab (SAR650984)|Pharmaceutical form: Vial Route of administration: IV infusion
45641686|NCT05669989|Drug|Cemiplimab (SAR439684)|Pharmaceutical form: Vial Route of administration: IV infusion
45641687|NCT05669989|Drug|Dexamethasone|Pharmaceutical form: Tablets Route of administration: Oral
45780457|NCT01799174|Procedure|Placebo|
45780458|NCT05644249|Drug|Combined Doxorubicin and Cisplatin Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic FOLFOX chemotherapy|Each course of combined treatment will start with PIPAC (a pressurized aerosol containing cisplatin 10.5 mg/m2 and doxorubicin 2.1 mg/m2 diluted in NaCl 0.9% applied through the nebulizer inside the abdominal cavity during laparoscopy). Fourteen days afterward 2 cycles of systemic FOLFOX chemotherapy will be applied within 28 days. The interval between combined treatment courses will be 14 days.
45780459|NCT00686582|Biological|IMVAMUNE|1x 10E8_TCID50
45780460|NCT00686582|Biological|IMVAMUNE|1x 10E8_TCID50
45641688|NCT05669989|Drug|Lenalidomide|Pharmaceutical form: Capsules Route of administration: Oral
45641689|NCT05669989|Drug|Pomalidomide|Pharmaceutical form: Hard capsules Route of administration: Oral
45641690|NCT05669820|Dietary Supplement|Salovum|Salovum is an eggyolkpowder derived from hens fed with SPC (specially processed cereals) and contains increased amounts of the endogenous protein antisecretory factor.
45641691|NCT05669820|Dietary Supplement|Placebo egg yolk powder|Egg yolk powder derived from hen fed with normal feed.
45641692|NCT05668754|Drug|Serdexmethylphenidate|Participants randomized to active drug will receive their optimized dose according to a dosing regimen set by randomization at the start of the OLTP. The 4 possible oral SDX doses are 80, 160, 240, or 320 mg/day. The optimal SDX dose will be determined during the 5-week OLTP preceding the 2-week DBWP.
45641693|NCT05668754|Other|Placebo|Participants randomized to placebo will receive matching placebo capsules to the optimized dose established at the end of the OLTP, according to a dosing regimen set by randomization at the start of the OLTP.
45780461|NCT00686582|Procedure|Blood Draw Only|
45780462|NCT02223637|Biological|Meningococcal quadrivalent CRM-197 conjugate vaccine|This pregnancy registry is strictly observational. Decisions of vaccination are made by health care providers.
45780463|NCT00631358|Drug|Maxidex|Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily
45780464|NCT00631358|Other|No treatment|Healthy normal control group receiving no treatment
45916657|NCT00000487|Drug|diuretics|
45641694|NCT05667116|Drug|EVUSHELD|EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
45780465|NCT02248753|Drug|Pharmacological cardioversion - Flecainide|
45780466|NCT02248753|Procedure|Electrical cardioversion|
45780467|NCT02248753|Drug|Metoprolol|
45780468|NCT02248753|Drug|Verapamil|
45780469|NCT02248753|Drug|Digoxin|
45780470|NCT02248753|Drug|Pharmacological cardioversion - Amiodarone|
45780471|NCT00687674|Drug|dexamethasone|20 mg orally Days 1, 8, 15, 22 of 28 day cycle
45780472|NCT00687674|Drug|sorafenib tosylate|Phase I - dose escalating: 200mg once daily dose level -2, 200mg once daily dose level -1, 200mg once daily dose level 0, 200mg twice daily dose level 1, 200mg twice daily dose level 2, 400mg AM & 200mg PM daily dose level 2a, 400mg twice daily dose level 3 orally days 1-28 every 28 days until progression
45780473|NCT00687674|Drug|Lenalidomide|Phase I - dose escalating: 5mg level -2, 10mg level -1, 15mg level 0, 15mg level 1, 25mg level 2, 25mg level 2a, 25mg level 3 orally days 1-21 every 28 days until progression
45641695|NCT05666518|Drug|Vericiguat (Verquvo, BAY1021189)|Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
45641696|NCT05666518|Drug|Standard of care|Dosage at the discretion of the treating physician
45641697|NCT05665543|Behavioral|GLAm app|Game-based Learning Avatar-navigated mobile (app) provides information on HPV infection susceptibility, risk of HPV-associated cancers, screening methods, and ways to overcome screening barriers. Users navigate the app using an avatar, and earn points for game components completed. The app prompts screening using text message reminders based on patient-entered information, and links to schedule cervical cancer screening. Completing cervical cancer screening earns an electronic badge visible to other users via an anonymous screen name and avatar.
45641698|NCT05665322|Procedure|Thermoablation with standard CT guidance|Guidance with small volume breathing and high frequency. The contrast product will be venously injected in the elbow.
45641699|NCT05665322|Procedure|Thermoablation with porto-scanner guidance with Angio-CT|Real time guidance, small volume and high frequency respiration. Contrast medium will be directly injected into the superior mesenteric artery (SMA) after puncture of the femoral artery at the inguinal fold and catheterization of the SMA.
45641700|NCT05664698|Behavioral|SKILLS-ER|The intervention (SKILLS-ER) has been developed by the research group, and aims to increase a participant's emotion regulation capacity by targeting different stages of the emotion regulation process proposed by the extended process model of emotion, i.e. identification, selection, implementation and monitoring (Sheppes, Suri & Gross, 2015). SKILLS-ER will comprise of eight sessions and include identification and differentiation of emotions, tolerance/acceptance of emotions, education of different regulatory skills, as well as on how to select, implement and monitor strategies. Sessions will take place at the Uppsala child- and adolescent psychiatry outpatient unit and consist of activating and experiential exercises administered by a clinical psychologist. Participants will gain access to internet-delivered material, such as homework assignments in-between sessions. SKILLS-ER will be delivered individually to the participants, where their parents will be involved in some sessions.
45641701|NCT05663203|Other|Internet-Based Intervention|Attend CRCWeb intervention
45641702|NCT05663203|Other|Interview|Complete interview
45641703|NCT05663203|Other|Survey Administration|Complete survey
45641704|NCT05663203|Other|Electronic Health Record Review|Medical records are reviewed
45641705|NCT05662540|Device|Positron Emission Tomography/Magnetic Resonance (PET/MR)|18F-FDG PET/MR imaging (manufacturer: Siemens, model: Biography mMR). Research devices are marketed products.
45641706|NCT05662033|Drug|AZD6793|AZD6793 will be administered orally
45780474|NCT03005197|Device|Laser Doppler Flowmetry|
45780475|NCT00687830|Drug|Polyethylene Glycol afternoon|Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Evening prep, between 5PM and 9PM
45780476|NCT00687830|Drug|Polyethylene Glycol morning|Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Morning prep, between 6AM and 10AM
45780477|NCT02248831|Device|Recording Doppler ultrasound signals noninvasively|Using ultrasound noninvasively and recording Doppler signals from the right chest wall
45780478|NCT00687908|Drug|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel|Topical Gel to the face, once daily in the evening for 24 weeks.
45780479|NCT00687908|Drug|Vehicle Gel|Topical Gel to the face, once daily in the evening for 24 weeks.
45780480|NCT04028011|Diagnostic Test|Novel Wearable device|patient will wear novel wearable device overnight along with normal standard of care
45780481|NCT04002583|Diagnostic Test|Computer assisted ambulatory electroencephalogram|A portable 16 channel CAA-EEG is used to detect epileptiform abnormalities in a 48 hour ambulatory electroencephalogram (EEG)
45780482|NCT05626231|Behavioral|Gender-Affirming Psychotherapy (GAP) Training|"The GAP training is a modular online asynchronous training intervention designed to increase mental health providers' use of gender-affirming practices with GMY (ages 12-25). It was developed using community-engaged and human-centered design methods with key stakeholders (GMY, their caregivers, mental health providers). In this open trial, GAP training will be offered to mental health providers at a multisite mental health clinic in the U.S. (referred to as pilot site herein)."
45641707|NCT05662033|Drug|Placebo|Placebo will be administered orally
45780483|NCT00689078|Drug|Prednisolone Acetate 1%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
45780484|NCT00689078|Drug|Prednisolone Acetate 0.12%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
45780485|NCT00689078|Drug|Loteprednol Etabonate 0.2%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
45780486|NCT00689078|Drug|Placebo|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
45780487|NCT05590819|Device|repetitive transcranial magnetic stimulation(rTMS)|5 hertz(Hz), 1000 pulses, 90% RMT stimulation; 15 minutes per session; for a total of 10 sessions
45780488|NCT05590819|Device|Intermittent Theta-burst Stimulation(iTBS)|3 pulses of stimulation delivered at 50 Hz and repeated at 5 Hz; 2s train of TBS with repetitive interval of every 10s, 70% RMT; 600 pulses in total; 15 minutes per session; for a total of 10 sessions
45641708|NCT05661916|Drug|ALN-TTRSC04|ALN-TTRSC04 will be administered by subcutaneous (SC) injection.
45641709|NCT05661916|Drug|Placebo|Placebo will be administered by SC injection.
45641710|NCT05661006|Dietary Supplement|Use of food supplement|"On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute).~In the following days: continuation of consumption of test product once per day until end of the intervention. Subjects are recording daily consumption of the product. Intervention diet recording during last week of intervention (days 49-56): 3x24h dietary records (two days during weekday, one weekend day).~Intervention end on day 56 ±3 (fasted condition):~Measuring S-25-OH-VitD, S-VitB12, S-protein, S-albumin, S-CRP Measuring body weight & height Collecting data regarding the palatability of the product"
45641711|NCT05661006|Dietary Supplement|Use of placebo food supplement|On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute). In the following days: continuation of consumption of test product once per day until end
45641712|NCT05660980|Drug|Once daily CAB tablet + RPV tablet|Tablet
45641713|NCT05660980|Drug|Long acting CAB injectable + long acting RPV injectable|Injectable
45780489|NCT05590819|Device|Sham stimulation|Set-up the coil without true stimulation; 15 minutes per session; for a total of 10 sessions
45780490|NCT01795508|Behavioral|PMTO|Parent Management Training, Oregon
45780491|NCT01795508|Behavioral|TAU|Other kinds of family training
45780492|NCT05568979|Biological|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
45780493|NCT05568979|Biological|High-Dose Quadrivalent Influenza Vaccine|Intramuscular administration
45780494|NCT00588380|Drug|GLP-1|GLP-1 infused at 0.75 pmol/kg/min from 121-180 minutes, GLP-1 infused at 1.55 pmol/kg/min from 181-240 minutes,
45916658|NCT05638230|Diagnostic Test|Left atrial reservoir strain|"LA strain measurements can be obtained by two dimensional (2D) speckle tracking echocardiography (STE). Longitudinal strain and strain rate curves are generated for each of six atrial segments, obtained from the apical four and two chamber views.~In the reservoir phase, as the LA fills and stretches, there is positive atrial strain that reaches its peak in systole at the end of LA filling, prior to opening of the mitral valve. Following this, passive LA emptying ensues with opening of the mitral valve resulting in decreased atrial strain with negative deflection of the strain curve up to a plateau period which is analogous to diastasis. LA reservoir strain (LARS), or peak atrial longitudinal strain or LA systolic strain, is measured at the end of the reservoir phase."
45916659|NCT00000490|Procedure|jejunoileal bypass|
45916660|NCT00000490|Behavioral|diet, fat-restricted|
45641714|NCT05660980|Drug|Long acting CAB injectable + long acting RPV injectable|Injectable
45780495|NCT03991429|Diagnostic Test|Simultaneous functional MRI and urodynamic studies|"Double lumen 7 Fr MRI-compatible catheters will be placed in the bladder and rectum. A Phillips Ingenia 3.0T full body MRI scanner with standard 12 channel head coil will be used. Instructions to communicate using right hand signals representing full urge and voiding or attempt of voiding will be given. Signs will be shown to the patient when filling of the bladder is begun and when filling is stopped. Also, in order to keep our noise-to-signal ratio low, all stimulators including any extra visual stimuli and the UDS machine will be removed from the MRI scanner room. The filling and voiding cycle will be repeated up to 4 times in each patient. Bladder will be aspirated after each voiding. This algorithm will be performed before, and, 3 and 6 months following BOO procedure."
45780496|NCT03991429|Behavioral|Questionnaires|Each patient will provide a detailed history and undergo a complete physical examination. Each patient will have the following assessments: IPSS and Incontinence Severity Index (ISI), Patient Global impression of severity (PGI-S) and improvement (PGI-I), International Index of Erectile Function (IIEF-5), MRI Safety Screening Questionnaire.
45780497|NCT03991429|Other|Post Void Residual (PVR), Uroflow and Bladder Diary|Follow-up assessments: Uroflow and PVR assessment, bladder diary, and all questionnaires will be repeated in all patients at one, three, and six months.
45780498|NCT03991429|Diagnostic Test|Urinalysis|Urine sample
45780499|NCT03005353|Drug|Cumin seed extract|patients will receive the drug in suppository form
45780500|NCT03005353|Drug|clotrimazole|patients will receive the drug in suppository form
45780501|NCT00588536|Drug|Methotrexate|MTX 30mg/m2 (or 1mg/kg for infants) orally, given in three equally divided doses at 0,8, and 16hrs
45780502|NCT00588536|Drug|6-Thioguanine|6-TG 300mg/m2 (or 10mg/kg for infants) orally, given in one dose.
45780503|NCT00588536|Drug|Leucovorin Calcium|5mg orally at 36,48, and 60hrs (or 12 hrs after the dose of 6-TG and then every 12 hrs for a total of 3 doses)
45780504|NCT03977233|Drug|Oxaliplatin|85 mg/m2 in 250 cc Dextrose solution given by IV on Day 1 of each 14-day cycle
45780505|NCT03977233|Drug|Leucovorin|400 mg/m2 in 100 cc dextrose solution given with irinotecan by IV on Day 1 of each 14-day cycle
46070540|NCT04395248|Procedure|Radial artery catheterization using ultrasound guidance or blind palpation|For all patients, the wrist will be extended and taped to a board to maintain wrist extension. All patients will receive local skin anesthesia at the anticipated puncture site. All radial artery catheterizations will be performed by anesthesiology residents with similar levels of experience in both blind-palpation and ultrasound-guided radial arterial catheterization. In the ultrasound group, a linear vascular probe of portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be applied to the skin to localize the radial artery and a 20-gauge catheter will be inserted distal to the transducer and directed according to the ultrasound image. In the palpation group, the radial artery will be identified by palpation, and the cannula will be directed by continuous or intermittent palpation of arterial pulsation. An attempt is defined as a new penetration of the skin with the needle, followed by an unlimited number of subcutaneous needle redirections.
46070541|NCT04395248|Device|Comparing the effectiveness of preoxygenation between high-flow nasal cannula and facemask|In the HFNC group, preoxygenation will be performed using HFNC (Optiflow™, Fisher & Paykel Healthcare, Auckland, NZ), nasal prongs set at 30 L/min flow of heated and humidified 100% oxygen. In the facemask group, patients will breath spontaneously with an anesthetic facemask and 100% oxygen 15 L/min. Gas flow for HFNC or facemask can be adjusted depending on patients' tolerance. During laryngoscopy intubation, HFNC will be left in place with the nasal flow escalated to 50 L/min of 100% oxygen in order to achieve apneic oxygenation. In the facemask group, the facemask will be removed when apnea occurs. After tracheal intubation, correct placement of the endotracheal tube will be confirmed by capnography and the nasal prongs of the HFNC group will be removed.
46070542|NCT04395248|Drug|Type of volatile anesthetics and M-Entropy guidance of anesthesia depth|"At the operating room, a M-Entropy™ sensor and S/5™ module (GE Healthcare, Helsinki, Finland) will be applied to all patients' forehead before induction of anesthesia according to the manufacturer's recommendations. Patients will be randomized to Sevoflurane or Desflurane as the single volatile anesthetics for general anesthesia.~Besides, patients will be randomized to M-Entropy group or controls. In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the Response and State Entropy value between 40 and 60 from the start of anesthesia to the end of surgery. In the usual care group, dosage of volatile anesthetics will be titrated according to clinical judgment. M-Entropy monitoring will be continued in the usual care group, but the Entropy number and EEG waveform will be concealed from the anesthetist in charge."
45780506|NCT03977233|Drug|Irinotecan Hydrochloride|180 mg/m2 in 500cc dextrose solution given with leucovorin by IV on Day 1 of each 14-day cycle
45780507|NCT03977233|Drug|5-FU|400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion on Day 1 of each 14-day cycle
45780508|NCT03951649|Drug|Occipital Nerve Block|This is an open label randomized controlled trial evaluating response to bupivacaine occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients seeking care of headache.
45916661|NCT00000493|Drug|propranolol|
45641715|NCT05660772|Device|Microfragmented Adipose Tissue|Microfragmented Adipose Tissue derived using Lipogems® Kit
45448731|NCT03461536|Behavioral|Ultrasound-first Clinical Decision Support tool|"Intervention: The intervention is the CDS tool, which consists of 4 components:~Four questions which assess the appropriateness of ultrasound for this patient~A link to the evidence~Buttons to remove CT scan and order ultrasound~If the CT scan order is kept, reasons why ultrasonography is not appropriate The CDS tool will be placed or integrated into EPIC, at the point of order entry. The tool will be triggered by an order for CT scan for kidney stone.~Appropriateness criteria for ultrasound:~Adults aged >18 and < 76~Non-obese (men < 285lbs, women < 250lbs)~Low risk of Stone Emergency (Obstructing stone and any of the following: urosepsis, renal deterioration, post kidney transplant, solitary kidney, intractable symptoms)~Low risk of clinically significant alternative diagnosis (e.g. appendicitis, cholecystitis, AAA, ovarian torsion) If all responses are affirmative, then the subject should receive US, and US order is provided."
45448732|NCT03396952|Drug|Aspirin|Given PO
45448733|NCT03396952|Biological|Ipilimumab|Given IV
45448734|NCT03396952|Other|Laboratory Biomarker Analysis|Correlative studies
45448735|NCT03396952|Biological|Pembrolizumab|Given IV
45448736|NCT03378934|Drug|Berberine|Berberine 200 mg twice daily for 4±1 weeks (Stage 1); then, 300 mg twice daily for 4±1 weeks (Stage 2); then, 400 mg twice daily for 4 weeks (Stage 3).
45448737|NCT03378934|Drug|Standard treatment|Standard treatment for 12±1 weeks.
45780509|NCT00590018|Drug|Hydrocortisone|Hydrocortisone taper (100mg/m2/day --> 25mg/m2/day) over 5 days intravenously.
45780510|NCT00590018|Drug|Placebo|Placebo for 5 days intravenously.
45780511|NCT02219503|Drug|Ombitasvir/Paritaprevir/Ritonavir|Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
45641716|NCT05660772|Drug|Corticosteroid|intra-articular knee injection of corticosteroid
45916662|NCT00000493|Drug|hyaluronidase|
45448738|NCT03378934|Drug|Aspirin|Aspirin 100 mg once daily for 12±1 weeks.
45448739|NCT03378934|Drug|Clopidogrel|Clopidogrel 75 mg once daily for 12±1 weeks.
45641717|NCT05659797|Device|BPET/DBT imaging|Imaging of the breast with a novel device combining dedicated Breast Positron Emission Tomography (BPET) and Digital Breast Tomosynthesis (DBT) following intravenous injection of [18F]-Fluoroestradiol (FES).
45641718|NCT05659797|Drug|18F-FES|Radiolabelled fluoroestradiol for PET imaging
45641719|NCT05659173|Diagnostic Test|Blood taking|Blood test for vitamin D level and DNA extraction for VDR gene polymorphism
45780512|NCT02219503|Drug|Dasabuvir|Tablet
45780513|NCT02219815|Behavioral|Prehab Intervention|Pre-operative, structured exercise intervention.
45916663|NCT05638308|Diagnostic Test|FAZA PET/MRI scan|FAZA PET/MRI scan before the standard of care biopsy for case group
45916664|NCT00000499|Drug|chlorthalidone|
45916665|NCT00000499|Drug|reserpine|
45916666|NCT00000499|Drug|hydralazine|
45641720|NCT05658952|Other|Microcatheter-derived FFR|FFR pullback trace is obtained through the manual retrieval performed after the positioning of the microcatheter FFR in the distal portion of the vessel. The pullback speed should be steady and the overall duration would be between 20 and 40 seconds. Then, the Interventional Cardiologist has to decide the procedural plan according to the pullback trace aiming to obtain an optimal post-PCI result in terms of physiology. FFR with pullback can be repeated after stenting to check and correct the result if needed.
45641721|NCT05658952|Other|Angiography-derived FFR|FFR pullback trace is automatically obtained after the 3-Dimensional reconstruction of the vessel through angiography derived FFR. Then, Interventional Cardiologist has to decide the procedural plan according to the pullback result aiming to obtain an optimal post-PCI result in terms of physiology. Angiography-derived FFR can be repeated after stenting to check and correct the result if needed.
45641722|NCT05658952|Other|Angiography-guided PCI|Interventional Cardiologist will perform PCI plan according to his/her the evaluation of angiography.
45641723|NCT05658484|Drug|Dimethyl fumarate|Administered as specified in the treatment arm.
45641724|NCT05655182|Biological|PIV5-vectored RSV Vaccine (BLB-201) Low Dose|BLB201 10^6 PFU
45641725|NCT05655182|Biological|PIV5-vectored RSV Vaccine (BLB-201) High Dose|BLB201 10^7 PFU
45448740|NCT04894240|Drug|Monepantel|Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals
45916667|NCT00000499|Drug|metoprolol|
45448741|NCT00126503|Biological|Bevacizumab|Given IV
45448742|NCT00126503|Drug|Sorafenib Tosylate|Given PO
45448743|NCT00126503|Other|Pharmacological Study|Correlative studies
45641726|NCT05655182|Drug|Placebo|The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10^6 PFU).
45641727|NCT05654623|Drug|ARV-471|orally, once daily on a 28-day continuous dosing schedule
45641728|NCT05654623|Drug|Fulvestrant|intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from C2D1 (28-day cycle)
45641729|NCT05651841|Drug|Tezepelumab|"Tezepelumab is supplied as a sterile, single-use, preservation-free, clear, colourless to slightly yellow liquid for subcutaneous administration in accessorized pre-filled syringes (APFS).~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram."
45641730|NCT05651841|Other|placebo|"APFS containing analogous placebo identical in appearance:~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram."
45641731|NCT05651295|Behavioral|Checking the Facts|Checking the Facts is a form of cognitive reappraisal in which participants identify negatively-valenced automatic thoughts and both generate and consider evidence that challenges the validity of those thoughts.
45641732|NCT05651295|Behavioral|Opposite to Emotion Action|Opposite to Emotion Action teaches participants to identify their momentary emotion(s), identify the associated behavioral urge(s), and implement a behavior inconsistent with that urge (e.g., approaching a feared stimulus instead of avoiding it).
45641733|NCT05651295|Behavioral|Mindfulness of Current Emotions|Mindfulness of Current Emotions teaches participants to nonjudgmentally observe the experience of their emotions, including physiological and cognitive responses to those emotions.
45641734|NCT05650333|Drug|Ritlecitinib 20 mg|orally administered, Ritlecitinib 20 mg once daily (QD)
45641735|NCT05644977|Drug|Emraclidine|Oral tablets
45448744|NCT00126503|Other|Laboratory Biomarker Analysis|Correlative studies
45641736|NCT05644977|Drug|Placebo|Oral tablets
45780514|NCT00592124|Drug|Tenofovir disoproxil fumarate|300 mg tablet daily
45780515|NCT00592124|Drug|Tenofovir gel|1 gm/100 ml of 1% gel vaginally daily
45916668|NCT00000502|Procedure|cardiopulmonary resuscitation|
45916669|NCT00000514|Drug|chlorthalidone|
45916670|NCT00000514|Drug|atenolol|
45448745|NCT03546478|Biological|99mTc-ABH2|99mTc-ABH2 were injected into the patients before the SPECT/CT scans
45448746|NCT03545932|Other|exercise program hydrogymnastics|4 months of practice hydrogymnastics
45448747|NCT05134636|Other|Text triage|The e-triage will consist of 16 questions, modified from the validated NCI Pro-CTCAETM, which will be sent to patients via WaytoHealth©'s two-way texting system 96 hours prior to their scheduled immunotherapy infusion. Questions will pertain to common or emergent immune related adverse events as defined by the NCCN guidelines and two senior disease experts. Patients will be prompted via text to measure the presence and severity of symptoms over the week prior. A final question will be included to capture any additional symptoms patients wish to disclose.
45448748|NCT00126425|Drug|123I-mIBG (meta-iodobenzylguanidine)|Single dose
45780516|NCT03005119|Drug|PTL201|Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg THC and 5 mg CBD
45780517|NCT03005119|Drug|Placebo Oral Capsule|Placebo seamless gelatin matrix green beads containing excipients only
45780518|NCT00593372|Behavioral|Spaced Retrieval Training|Increasing time to remember important information.
45916671|NCT00000514|Drug|reserpine|
45916672|NCT05638425|Radiation|Radiotherapy combined with PD-1 inhibitors|Radiotherapy should be carried out within 4 weeks after the first dose of PD-1 inhibitor; the radiotherapy method should be determined according to the patient's condition; PD-1 inhibitor and chemotherapy should refer to the actual product instructions
45916673|NCT00000517|Drug|warfarin|
45916674|NCT00000520|Drug|immunoglobulins, intravenous|
45916675|NCT00000520|Drug|aspirin|
45641737|NCT05644600|Drug|Nintedanib|The subjects will be administered Nintedanib soft capsules single oral dose in the morning of Day 1 in fasted state.
45448749|NCT03545854|Procedure|Erector Spinae Plane Block|Ultrasound guided injection of coloring solution (methylene blue diluted in water) with a 18G echogenic tuohy needle deep to the plane of the erector spinae muscles.
45448750|NCT00126191|Drug|Rituximab|Low Risk: Intravenously on Day 3 of the first cycle (One cycle is 14 days) then day 1 for next 2 cycles (Regimen A) High Risk: Regimen A followed by a 5-day cycle where rituximan is given on day 1
45916676|NCT00000526|Drug|encainide|
45641738|NCT05644600|Drug|AZD5055|The subjects will be administered as single oral dose on Day 1 in the fasted state.
45916677|NCT00000526|Drug|flecainide|
45641739|NCT05643755|Other|Preoperative image-based education|Intervention group: education handout containing pictographic and written education material on wound appearance following primary closure after Mohs Micrographic Surgery (MMS) or Wide Local Excision (WLE)
45641740|NCT05642325|Drug|RO7200220|Participants will receive RO7200220 IVT injection
45916678|NCT00000526|Drug|moricizine|
45780519|NCT02221219|Drug|Indomethacin|indomethacin at standard dose for prevention of intraventricular hemorrhage in preterm infants
45448751|NCT00126191|Drug|Cyclophosphamide|Low Risk/High Risk: Intravenously on day 1 and day 2 of a 14-day cycle for 3 cycles (regimen A)
45448752|NCT00126191|Drug|Doxorubicin|Low Risk/High Risk: Given on day 1 of a 14-day cycle for 3 cycles (regimen A)
45780520|NCT02221219|Procedure|delay in umbilical cord clamp at birth|provision of a ~45 second delay of umbilical cord clamping at birth in preterm infants (recorded in delivery note)
45780521|NCT02221219|Drug|placebo infusion|saline infusion to match input of indomethacin treatment group (and serve as drug-dosing 'blinding' for bedside staff)
45780522|NCT02221219|Procedure|immediate cord clamp at birth|no delay in umbilical cord clamp; <10sec (recorded in delivery note)
45916679|NCT05638464|Device|multisite HD-tDCS|5-8 sintered Ag/AgCl ring electrodes will be placed based on the neuroimaging and computation modelling. The electrodes will be placed inside plastic electrode holders which will be filled with gel to have good contact with the scalp.
45916680|NCT05638464|Device|Conventional tDCS|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
45916681|NCT05638464|Device|multisite HD-tDCS EMG-driven robot hand|Multisite HD-tDCS will individual stimulation montages with robot hand training will be applied on chronic stroke survivors. In the multisite HD-tDCS group, 5-8 sintered Ag/AgCl ring electrodes will be placed based on the neuroimaging and computation modelling. The location of the electrodes will be identified by the individual brain activity in the primary motor cortex derived from tasked-based fMRI. The Finite Element Model (FEM) will be used to simulate the electric field distribution on individual brain. Optimization of stimulation montages will be based on the derived activation pattern of the brain. After 20-minute multisite HD-tDCS, EMG-driven robot hand training will be conducted.
45448753|NCT00126191|Drug|Vincristine|Low Risk/High Risk: Given intravenously on day 1 and day 10 of a 14-day cycle for 3 cycles (regimen A)
45916682|NCT05638464|Device|Sham HD-tDCS EMG-driven robot hand|"Sham stimulation with robot hand training will be applied on chronic stroke survivors.~A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands. After the sham stimulation, EMG-driven robot hand training will be conducted."
45916683|NCT00000529|Drug|tamoxifen|
45916684|NCT00000532|Behavioral|diet, fat-restricted|
45916685|NCT00000535|Behavioral|diet, reducing|
45916686|NCT00000535|Behavioral|diet, sodium-restricted|
45916687|NCT00000538|Behavioral|diet, fat-restricted|
45916688|NCT05638503|Other|Left ventricular hypertrophy|Hypertension with normal left ventricular geometry and left ventricular concentric remodeling
45448754|NCT00126191|Drug|Methotrexate|Low Risk: Given on day 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: Regimen A followed by methotrexate on day 3 and day 5 of a 5-day cycle
45448755|NCT00126191|Drug|Leucovorin|Low Risk/High Risk: Given on days 11, 12 and 13 of a 14-day cycle for 3 cycles (regimen A)
45448756|NCT00126191|Drug|Ifosfamide|High Risk: After Regimen A, Ifosomide given on days 1-5 of a 5 day cycle
45448757|NCT00126191|Drug|Etoposide|High Risk: After Regimen A, etoposide given days 1-5 of a 5-day cycle
45448758|NCT00126191|Drug|Cytarabine|Low Risk: Given on days 1, 3, 5 and 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: After regimen A, cytarabine given on days 1 and 2 of a 5-day cycle
45641741|NCT05642325|Other|Sham|Participants will receive a sham procedure that mimics an IVT injection.
45641742|NCT05641051|Drug|Metoclopramide|Cases will receive 10 mg intravenous metoclopramide every 6 hours.
45641743|NCT05641051|Drug|Placebo|Cases will receive the same volume of IV placebo / 6 hours.
45641744|NCT05639400|Device|Thoraflex Hybrid|Thoraflex Hybrid is designed for the open surgical repair of aneurysms and/or dissections in the aortic arch and descending aorta with or without involvement of the ascending aorta. There are two types of Thoraflex Hybrid implants, namely the Plexus 4 and the Ante-Flo versions. Each patient receives one Thoraflex Hybrid device (either the Plexus 4 or Ante-Flo).
45780523|NCT03005275|Other|IVM|"FSH injection: Day 9, 10 and 11 (can be adjusted 1-3 days before or after to avoid Ultrasound and OPU on holidays). Dose: normally 100 IU/day (maybe 75 - 150 IU/day).~Follicle and endometrium can be evaluated: on the day of final injection or one day later.~hCG 10.000 IU: one day after the final FSH injection, at 9 p.m. Can be adjusted HCG injection day (± 1-2 days) to avoid Ultrasound and OPU on vacation.~OPU: 1,5 day after hCG injection (normally 36-42 hours later). Sperm collection: on OPU day (if mature follicle presents) or 1 day after OPU day.~Embryo transfer: 3 days after OPU. Luteal support: progesterone gel (90 mg once daily) intra-vaginally and estradiol (4 mg/day PO, twice daily) initiated on the day of OPU or the day thereafter."
45916689|NCT05638503|Other|Left ventricular non-hypertrophy|Hypertension with left ventricular concentric hypertrophy and left ventricular eccentric hypertrophy
45916690|NCT00000550|Behavioral|health education|
45916691|NCT00000553|Drug|simvastatin|
45916692|NCT00000553|Drug|niacin|
45916693|NCT00000553|Drug|antioxidants|
45916694|NCT00000556|Drug|amiodarone|
45916695|NCT00000556|Drug|sotalol|
45916696|NCT00000556|Drug|propafenone|
45916697|NCT00000556|Drug|flecainide|
45916698|NCT00000556|Drug|quinidine|
45641745|NCT05639400|Device|RelayPro NBS|The RelayPro NBS Thoracic Stent-Graft System is an endovascular device intended for treatment of thoracic aortic pathologies such as aneurysms, pseudoaneurysms, dissections, penetrating ulcers and intramural hematoma.
45641746|NCT05638334|Drug|89Zr-S095012 tracer and S095012 will be administered via an IV infusion|"Imaging period 1 (Part A and Part B): The tracer will be administered with S095012 at non-therapeutic mass dose. The optimal mass dose of S095012 will be investigated in part A, and used in part B.~Treatment period (Part A to C): S095012 will be administered with multiple 28 days- cycles in a Q2W schedule.~Imaging period 2 (Part C): A second tracer dose will be administered at 1st treatment dose of S095012 in part C."
45641747|NCT05638282|Drug|Cendakimab|Specified dose on specified days
45641748|NCT05638282|Drug|Placebo|Specified dose on specified days
45641749|NCT05638139|Biological|SygeLIX-F + SygeLIX-G|SygeLIX-F (plug) is inserted through the internal orifice while cryptoglandular space is filled by SygeLIX-G (gel).
45641750|NCT05634499|Drug|Giredestrant|Participants will receive giredestrant 30 milligrams (mg) taken orally (PO) once a day (QD) on Days 1 to 28 of each 28-day cycle for 6 cycles. After completion of 6 cycles, the participant and investigator can choose to continue study therapy or discontinue study therapy and receive investigator-determined care. After 6 months, participants can discontinue study treatment and undergo surgery or continue to receive study treatment for up to 18 additional cycles, per shared decision-making by the participant and physician.
45641751|NCT05633615|Biological|Axicabtagene Ciloleucel|Given IV
45641752|NCT05633615|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
45641753|NCT05633615|Procedure|Computed Tomography|Undergo PET-CT or CT
45641754|NCT05633615|Drug|Cyclophosphamide|Given IV
45641755|NCT05633615|Drug|Fludarabine|Given IV
45641756|NCT05633615|Biological|Lisocabtagene Maraleucel|Given IV
45780524|NCT03005275|Other|ICSI|"Daily SC injections with rFSH (minimum starting dose is around 150 IUI) are started on On day 2 or day 3 of the menstrual cycle (Stimulation Day 1) and continue up to and including Stimulation Day 7.~From Stimulation Day 8 onwards, subjects from ICSI treatment groups will continue with a daily SC dose of rFSH up to the day before GnRH agonist day. The maximum rFSH dose to continue treatment after the first 7 days is 300 IU but the dose could be adjusted when desired.~As soon as three follicles of 17mm are observed by USS at least, a GnRH agonist (Triptorelin 0.2 mg) will be used for final oocyte maturation at the same day. About 34-36 h thereafter, OPU followed by ICSI is performed. Two days after oocyte pick-up 2 fresh embryos will be transferred"
45448759|NCT00126191|Drug|Mesna|High Risk: After regimen A, mesna is given on days 1-5 of a 5-day cycle
45641757|NCT05633615|Biological|Mosunetuzumab|Given IV
45641758|NCT05633615|Other|Patient Observation|Undergo observation
45641759|NCT05633615|Drug|Polatuzumab Vedotin|Given IV
45641760|NCT05633615|Procedure|Positron Emission Tomography|Undergo PET-CT
45641761|NCT05633615|Biological|Tisagenlecleucel|Given IV
45916699|NCT00000556|Drug|moricizine|
45641763|NCT05633329|Procedure|single level|injection of 40 ml bupivacaine 0.25 at T8 (20 ml on each side)
45641764|NCT05633329|Procedure|dual level|injection of 40 ml of bupivacaine 0.25 at two level T7 and T9 (10 ml on each level of both side)
45641765|NCT05632926|Drug|40 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
45641766|NCT05632926|Drug|60 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
45780525|NCT05556733|Procedure|Faecal Microbiota Transplantation|FMT at baseline, week 2, week 4, week 8
45641767|NCT05632926|Drug|80 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
45641768|NCT05631626|Drug|CTx-1301 - Dexmethylphenidate 25mg|25mg CTx-1301 (Dexmethylphenidate tablet)
45780526|NCT00593450|Drug|ranibizumab|• 0.5 mg (0.05 mL)intravitreal injection
45641769|NCT05631626|Drug|CTx-1301 - Dexmethylphenidate 37.5mg|37.5mg CTx-1301 (Dexmethylphenidate tablet)
45641770|NCT05631626|Drug|CTx-1301 - Dexmethylphenidate 50mg|50mg CTx-1301 (Dexmethylphenidate tablet)
45641771|NCT05631626|Drug|Placebo|Placebo
45641772|NCT05630937|Drug|NMS-01940153E|Route of administration: intravenous (IV) solution
45641773|NCT05630885|Drug|CVC 150 mg|Administered as one 150-mg tablet by mouth once a day with food.
45641774|NCT05630885|Drug|CVC 300 mg|Administered as two 150-mg tablets by mouth once a day with food.
45641775|NCT05630885|Other|Placebo for CVC 150 mg|Administered as one 150-mg matching placebo tablets by mouth once a day with food.
45641776|NCT05630885|Other|Placebo for CVC 300 mg|Administered as two 150-mg matching placebo tablets by mouth once a day with food.
45641777|NCT05630040|Device|Non-invasive vagus nerve stimulation|Participants will take the VNS device home and asked to perform a daily VNS protocol designed to down regulate sympathetic nervous system activity for 6 weeks.
45641778|NCT05630040|Device|Sham Intervention|Participants will take a placebo device home for 6 weeks and use daily.
45641779|NCT05629052|Procedure|Pulmonary endarterectomy|Surgical removal of a chronic clot from the pulmonary artery
45641780|NCT05629052|Procedure|Balloon pulmonary angioplasty|Catheter-based intervention to dilate occluded pulmonary vessels through the insertion and inflation of a small balloon
45641781|NCT05629052|Drug|Pulmonary hypertension (PH)-specific medication|Treatment with any PH-specific medication, i.e. endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, drugs acting on the prostanoid pathway and prostaglandin I2 receptor agonists
45780527|NCT00593450|Drug|bevacizumab|• 1.25 mg (0.05 mL)intravitreal injection
45780528|NCT00631670|Radiation|Stereotactic Body Radiation Therapy|15 Gy in one treatment
45780529|NCT00631670|Radiation|Stereotactic Body Radiation Therapy|Dose: 70 Gy at 2.8 Gy/treatment
45916700|NCT00000556|Drug|disopyramide|
45916701|NCT00000556|Drug|procainamide|
45916702|NCT00000556|Drug|adrenergic beta antagonists|
45916703|NCT00000556|Drug|verapamil|
45916704|NCT00000556|Drug|diltiazem|
45780530|NCT00631748|Drug|quetiapine fumarate|At baseline, subjects in the experimental group will initially be administered 50 mg/day of Seroquel XR™ (extended release formulation of quetiapine fumarate), to be titrated up to 400 mg/day of Seroquel XR™ by the end of the second week. By the end of week 2, subjects will be stabilized on a dose of 400 mg/day or alternatively 300, 200, 100, or 50 mg/day of study drug, as tolerated. If a subject is unable to tolerate the 50 mg/day dose, he or she will be discontinued from the drug portion of the study.
45780531|NCT00631748|Drug|Matched Placebo|Subjects randomized to the placebo comparator group will follow the same titration and dosing procedures as the experimental group, but will receive matched placebo tablets.
45780532|NCT00631748|Behavioral|Cognitive-behavioral Therapy|During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
45780533|NCT04387682|Dietary Supplement|β-glucan|β-glucan, a biological response regulator, derived from yeast has been known for more than 45 years, and has anti-infective and anti-tumor activities. β-glucan is a molecule with a β-1,3-linked D-glucose backbone and β-1,6-linked side chains. Thus far, at least 4 receptors for β-glucan have been discovered in humans, which are surface antigens associated with macrophages or myeloid precursor cells as complement receptor 3 (CR3; CD11b/CD18, Mac-1, αMβ2 integrin) (Vetvicka et al. 1996; Xia et al. 1999), lactosylceramide (Zimmerman et al. 1998), scavenger receptor (Rice et al. 2002) and dectin-1 (Brown et al. 2003; Taylor et al. 2007; Saijo et al. 2007).
45780534|NCT00594230|Drug|Panobinostat|Panobinostat(20 mg or 30 mg PO) will be administered three times a week on Monday, Wednesday and Friday. Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28 days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will be determined every 2 treatment cycles (8 weeks). Patients will be allowed to continue on treatment for a maximum of eight four week treatment cycles. Treatment will be discontinued if there is evidence of disease progression, unacceptable toxicity and/or at the discretion of the investigator.
45780535|NCT00594308|Drug|Cyclophosphamide|60mg/kg/day for two consecutive days (-7,-6).
45780536|NCT00594308|Drug|Fludarabine|25mg/m2/day for 5 consecutive days
45780537|NCT00594308|Drug|Cyclosporine|3mg/kg/day will be given by continuous intravenous infusion beginning on Day -1.
45448760|NCT03283540|Procedure|TaTME|Low anterior resection of the rectum entails a sharp dissection circumferentially around the mesorectum in an avascular plane between the visceral and parietal layers of the endopelvic fascia in what is known as Total Mesorectal Excision. This dissection can be achieved transanally starting down in the pelvis and going up in what is known as Transanal Total Mesorectal Excision
45641782|NCT05628181|Behavioral|Educational nudge intervention|This project will adapt the EMPOWER educational brochure for PLWD receiving CNS polyRx. The educational brochure will be mailed to intervention participants identified through EHR at Michigan Medicine and Henry Ford Health System. The brochure will describe what CNS polyRx is, present information about the associated risks, and suggest that participants speak with the prescribing clinician or pharmacist about ways to potentially simplify the medication regimen. The tool will be adapted through three successive rounds of focus groups (AIM one of this project) of PLWD.
45641783|NCT05627128|Other|DAIN|Participants in the experimental arm will have access to the newly created DAIN curriculum including menus, recipes, and recorded 'how to' recipes. Participants in the experimental arm will also have once-per-week dietary counseling with DAIN-trained nutritionists and monthly cooking classes with a DAIN-trained chef.
45780538|NCT00594308|Drug|Mycophenolate mofetil|1000 mg will be administered through day +60 and then discontinued if there is no GVHD.
45641784|NCT05626855|Drug|Apitegromab|Apitegromab (SRK-015) is an investigational, fully human immunoglobulin G4 monoclonal antibody that specifically binds to human proforms (i.e., inactive precursor forms) of myostatin, pro- and latent- myostatin, with high affinity, inhibiting activation of myostatin, a negative regulator of muscle growth and strength.
45916705|NCT00000556|Drug|digoxin|
45641785|NCT05626673|Behavioral|Prayer app|Participants will be given the Pray.com app and directed to use it daily.
45641786|NCT05626218|Other|stress ball|The woman is usually laid in the last side position during the procedure. A stress ball will be given to the right hand of the participants during the NST procedure (average 15-20 minutes). This stress ball will be squeezed for 2-3 seconds, and then the hand and arm will be told to relax. This process will be repeated throughout the NST. Hospital protocol will also be applied to these participants.
45780539|NCT00594308|Drug|Basiliximab|20mg , will be given by intravenous infusion (without an in-line filter) over at least 15 minutes beginning 3 days after engraftment.
45916706|NCT00000556|Procedure|catheter ablation|
45916707|NCT00000556|Device|pacemaker, artificial|
45916708|NCT00000559|Drug|estrogen replacement therapy|
45916709|NCT00000559|Drug|hormone replacement therapy|
45916710|NCT00000559|Drug|estradiol|
45916711|NCT00000559|Drug|medroxyprogesterone|
45916712|NCT00000568|Behavioral|smoking cessation|
45916713|NCT00000568|Drug|ipratropium|
45916714|NCT05638659|Behavioral|Computerized dual-task balance and home program|Portable force plate with aluminum top plate for measuring ground reaction forces, moments and the center of pressure in biomechanics. Through software to collect data from the force plates, converts the trials into useful information and plots the results. The force plates and charge amplifiers are fully remote controlled by software thus making the system extremely flexible and easy to use.
45916715|NCT05638659|Behavioral|Medical consultation and traditional balance training|Participants were assigned to read the health education flier and were assessed directly.
45916716|NCT00000571|Device|ventilators, negative pressure|
45916717|NCT00000586|Drug|hydroxyurea|
45916718|NCT00000589|Procedure|platelet transfusion|
45916719|NCT00000592|Procedure|blood transfusion|
45916720|NCT00000595|Drug|deferoxamine|
45916721|NCT00000598|Behavioral|diet, fat-restricted|
45916722|NCT00000598|Behavioral|exercise|
45916723|NCT00000601|Drug|estrogen replacement therapy|
45916724|NCT00000601|Drug|estrogens|
45916725|NCT00000601|Drug|progesterone|
45641787|NCT05626114|Biological|OpRegen|OpRegen dose up to approximately 200,000 cells will be delivered into the subretinal space
45641788|NCT05625932|Drug|Tinzaparin|Patients < 80 kg will receive a fixed dose of 4500 IU daily. Patients between 80-100 kg will receive a fixed dose of 6000 IU daily. Patients > 100 kg will receive a fixed dose of 8000 IU daily.
45780540|NCT00595088|Biological|BC-819/PEI|Papillary tumors will be resected with the exception of one marker tumor that will remain to examine the effects of the treatment on the remaining tumor. Study treatments will consist of an induction course of six weekly instillations of 20 mg of DTA-H19/PEI into the urinary bladder. Intravesical therapy will be delivered through a Foley catheter. Patients will be instructed to hold the dose in the bladder for two hours after administration. If the patient has a complete response, then she/he will be eligible to receive three additional courses of 3 weekly intravesical administrations of the same dose of investigational product every 12 weeks.
45780541|NCT02137538|Drug|Letrozole|
45641789|NCT05625594|Procedure|Aspiration|Undergo CSF aspiration
45780542|NCT02137538|Drug|Anastrozole|
45780543|NCT01799330|Procedure|Transcutaneous Electrical Muscle Stimulation (TCEMS)|
45780544|NCT01799330|Other|Sham TCEMS|Patients randomized to Group 2 (Sham TCEMS) will receive the identical set-up for active TCEMS except they will receive a minimal electrical stimulus that does not produce a motor response
45641790|NCT05625594|Procedure|Biospecimen Collection|Undergo blood sample collection
45641791|NCT05625594|Procedure|Catheterization|Undergo catheterization
45641792|NCT05625594|Biological|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes|Given ICV
45641793|NCT05625594|Procedure|Computed Tomography|Undergo CT
45641794|NCT05625594|Drug|Cyclophosphamide|Given IV
45641795|NCT05625594|Drug|Fludarabine|Given IV
45641796|NCT05625594|Procedure|Leukapheresis|Undergo leukapheresis
45641797|NCT05625594|Procedure|Lumbar Puncture|Undergo lumbar puncture
45641798|NCT05625594|Procedure|Magnetic Resonance Imaging|Undergo MRI
45780545|NCT00595556|Drug|zonisamide|flexible dosages of 100-500mg/day
45780546|NCT00595556|Drug|Placebo|Placebo
45780547|NCT00595790|Biological|IC51|
45780548|NCT00595946|Drug|Lubiprostone|24 mcg capsules twice daily (BID)
45916726|NCT00000601|Drug|hormone replacement therapy|
45916727|NCT00000604|Procedure|cardiopulmonary bypass|
45916728|NCT00000604|Procedure|heart arrest, induced|
45916729|NCT00000607|Device|Left ventricular assist device|A type of implantable heart pump
45641799|NCT05625594|Procedure|Positron Emission Tomography|Undergo PET
45641800|NCT05625412|Drug|BMS-986360|Specified dose on specified days
45641801|NCT05625412|Drug|Docetaxel|Specified dose on specified days
45641802|NCT05625412|Drug|Nivolumab|Specified dose on specified days
45641803|NCT05625412|Drug|Capecitabine|Specified dose on specified days
45641804|NCT05624996|Drug|Carboplatin|Given IV
45641805|NCT05624996|Drug|Cisplatin|Given IV
45641806|NCT05624996|Procedure|Computed Tomography|Undergo CT and/or PET/CT
45641807|NCT05624996|Biological|Durvalumab|Given IV
45641808|NCT05624996|Drug|Etoposide|Given IV
45641809|NCT05624996|Radiation|Image Guided Radiation Therapy|Undergo IGRT
45641810|NCT05624996|Drug|Paclitaxel|Given IV
45641811|NCT05624996|Drug|Pemetrexed|Given IV
45641812|NCT05624996|Procedure|Positron Emission Tomography|Undergo PET/CT
45641813|NCT05624996|Other|Quality-of-Life Assessment|Ancillary studies
45641814|NCT05624996|Other|Questionnaire Administration|Ancillary studies
45641815|NCT05624996|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45780549|NCT00595946|Drug|Placebo|0 mcg capsules twice daily (BID)
45780550|NCT00596102|Biological|Japanese Encephalitis purified inactivated vaccine|Japanese Encephalitis purified inactivated vaccine
45780551|NCT00638924|Other|Shuttle walk test|the test requires patients to walk at a gradually increasing speed, up and down a 10 m course identified by two marker cones, until they reach a symptom limited maximum. The walking speed was externally paced and controlled by a series of beeps played on a compact disk.
45780552|NCT00597038|Drug|Dasatinib and Dacarbazine (DTIC)|"Arm A/ Phase I Potential Dose Levels.~Dose Level -1: Dasatinib 40 mg; DTIC 600 mg/m^2. Dose Level 1: Dasatinib 50 mg; DTIC 800 mg/m^2. Dose Level 2: Dasatinib 70 mg; DTIC 800 mg/m^2. Dose Level 3: Dasatinib 70 mg; DTIC 1000 mg/m^2.~Arm B/Phase II Potential Dose Levels.~MTD1: Dasatinib 70 mg; DTIC 1000 mg/m^2. MTD2: Dasatinib 70 mg; DTIC 800 mg/m^2. MTD3: Dasatinib 100 mg: DTIC 1000 mg/m^2."
45780553|NCT00597272|Biological|KLH conjugates with GD2L and GD3L|6 vaccinations (on weeks 1, 2, 3, 8, 20 and 32) which will contain the same KLH conjugates with GD2L and GD3L. All vaccines contain KLH conjugates containing 30mcg of GD2L and 30mcg of GD3L and QS-DG or OPT-821. The initial 8 patients will receive the same QS-DG or OPT-821 vaccine dose in all of their vaccines. This dose will be 50 mcg for the first patient, 75 mcg for the second patient and 100 mcg for the third through eighth patients. In all subsequent patients the 1st, 4th and 5th vaccinations will include 150 mcg of OPT-821. The 2nd and 3rd vaccinations will contain 100 mcg of OPT-821 and the 6th vaccination will contain 200 mcg of OPT-821.
45780554|NCT00597428|Drug|Lubiprostone|24 mcg capsules twice daily (BID)
45780555|NCT00597428|Drug|Placebo|0 mcg capsules twice daily (BID)
45780556|NCT00597818|Drug|Cobiprostone|18 mcg cobiprostone capsules for oral administration
45780557|NCT00597818|Drug|Placebo|Matching placebo capsules for oral administration
45916730|NCT00000607|Device|Optimal medical therapy|(non-experimental) One possibility in handling Heart failure effectively is optimal medicine therapy. The most popular treatment medications at present are ACE Inhibitors and Beta Blockers. The result is the heart being able to pump more effectively and allowing blood to circulate freely.
45916731|NCT00000610|Drug|magnesium|
45916732|NCT00000625|Drug|Zidovudine|
45916733|NCT00000625|Drug|Zalcitabine|
45916734|NCT00000625|Drug|Didanosine|
45641816|NCT05624788|Other|No Intervention|Participants who self-identify as American Indian or Alaska Native with any indication requiring referral to a specialist after a primary care provider standard of care visit will be observed to collect data, using several surveys at 6 and 12 months. No additional specialty care visits will be added for the purpose of this study given the intent to observe medical care received following primary care provider referral. Referral to a specialist will be based on local clinical practice.
45916735|NCT00000631|Biological|HIVAC-1e|
45780558|NCT00597818|Drug|Non-steroidal anti-inflammatory drug|Any marketed non-steroidal anti-inflammatory drug used by the participants as standard care.
45780559|NCT00597896|Drug|pramipexole|po pramipexole versus matching placebo minimum 0.125 mg bid and maximum 0.75 mg bid
45916736|NCT00000631|Biological|gp160 Vaccine (MicroGeneSys)|
45916737|NCT00000637|Drug|Zidovudine|
45916738|NCT00000637|Drug|Didanosine|
45916739|NCT00000640|Drug|Primaquine|
45916740|NCT00000640|Drug|Sulfamethoxazole-Trimethoprim|
45916741|NCT00000640|Drug|Dapsone|
45916742|NCT00000640|Drug|Clindamycin|
45916743|NCT00000646|Drug|Pentoxifylline|
45916744|NCT00389038|Behavioral|Coping Skills Training|Behavioral Treatment 1 (coping skills training)--Behavioral Treatment session 1 and 2: Doses are one session a week for 8 weeks, followed by one session a month for 2 months, followed by 1 session every three months for 1 year.
45916745|NCT00389038|Behavioral|Headache Education|Behavioral Treatment 2 (headache education)
45916746|NCT00389038|Drug|Amitriptyline|Amitriptyline: up to 1 mg/kg capsule taken once daily at bedtime. Taken up to Week 20. After Week 20 medications and doses may change with standard care.
45641825|NCT05623488|Drug|huCART-meso cells|Autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor M5 scFv fused to the 4-1BB and CD3ζ signaling domains
45641826|NCT05623488|Device|Mesothelin Expression Testing|Laboratory Developed Test
45641827|NCT05621967|Behavioral|Tonation Breathing Techniques|Tonation and Breathing Techniques (TBT): consist of a combination of organic inhalation and controlled exhalation with tonation. This will be guided by a trained facilitator, and the entire exercise will take 20 minutes. This will include guided relaxed breathing, mindful breathing, patterned tonation, nasal tonation, and pursed lip tonation.
45641828|NCT05621967|Behavioral|Music Driven Vocal Exercises|Music Driven Vocal Exercises (MDVE): A Music Therapy procedure will be implemented by a trained facilitator, utilizing an accompanying instrument (ie, guitar or Autoharp) and moving stepwise up and down within a scale of 8 whole steps. The total length of the procedure is 20-25 minutes. This will include vocal exercises, and melodic exercises alternating with speaking,
45641829|NCT05621967|Behavioral|Silent Breathing|Patient will sit in a quiet room and focus on silent breathing x 20 min.
45641830|NCT05620342|Biological|iC9.GD2.CAR.IL-15 T Infusion|iC9-GD2.CAR.IL-15 T-cells product will be administered via intravenous injection over 5 - 10 minutes.
45641831|NCT05619991|Other|Group watching video|The video will include preparation for the surgery, the operating room environment and the post-operative process.
45780560|NCT00600080|Device|etafilcon A|contact lens worn daily for one week (first or second week depending on arm)
45916747|NCT00389116|Drug|gastrograffin|ingestion
45448761|NCT03283540|Procedure|TME|Low anterior resection of the rectum entails a sharp dissection circumferentially around the mesorectum in an avascular plane between the visceral and parietal layers of the endopelvic fascia in what is known as Total Mesorectal Excision. This surgery can also be done via an up-to-down approach beginning high in the abdomen and going low in the pelvis to achieve dissection around the mesorectum.
45448762|NCT03250078|Diagnostic Test|MRI/MRCP|An MRI/MRCP plus IV gadolinium contrast with high resolution imaging of the pancreas will be performed annually
45641832|NCT05619991|Other|Scheduled training group|The scheduled training will include preparation for the surgery, the operating room environment and the post-operative process.
45641833|NCT05618808|Drug|REGN9933|Participants will receive a single dose of REGN9933 by IV infusion
45916748|NCT00389116|Drug|water|oral water ingestion
45780561|NCT00600080|Device|nelfilcon A|Contact lens worn daily for one week (first or second week depending on arm)
45780562|NCT00600704|Procedure|Fluid Restriction Policy|Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary bypass
45780563|NCT00600704|Procedure|Free fluid infusion|Free fluid infusion unless Hb< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
45780564|NCT01790282|Drug|estradiol plus progesterone 100 mg IM injection|estradile valaerate 2mg plus progesterone 100 mg/day support arm :E2 valerate 2mg three times /day are given to the arm cases plus P4 100 IM/day for 14 days starting on day of ovum pickup and single IM injection of 0.1 mg decapeptyl on day of ET
45780565|NCT01790282|Drug|Progesterone IM of 100 mg|Starting on day of ovum pickup ICSI cases are given prontogest 100 mg IM /day plus single dose dose of treptorline 0.1mg is given sc on day of embryo transfer
45916749|NCT00000652|Drug|Zidovudine|
45916750|NCT00000652|Drug|Didanosine|
45916751|NCT00000676|Drug|Clotrimazole|
45916752|NCT00000676|Drug|Fluconazole|
45916753|NCT00000679|Drug|Zidovudine|
45916754|NCT00000679|Drug|Zalcitabine|
45916755|NCT00000682|Drug|Zidovudine|
45916756|NCT00000682|Drug|Zalcitabine|
45916757|NCT00000688|Drug|Ganciclovir|
45916758|NCT00000712|Drug|Zidovudine|
45916759|NCT00000712|Drug|Acyclovir|
45916760|NCT00000715|Drug|Pentamidine isethionate|
45916761|NCT00000715|Drug|Sulfamethoxazole-Trimethoprim|
45916762|NCT00000718|Drug|Zidovudine|
45916763|NCT00000718|Drug|Zalcitabine|
45916764|NCT00000739|Drug|Dapsone|
45916765|NCT03503695|Device|Sterile acupuncture semi-permanent (ASP) gold needles|
45916766|NCT00000742|Drug|Atevirdine mesylate|
45916767|NCT00000742|Drug|Zidovudine|
45916768|NCT00000742|Drug|Didanosine|
45916769|NCT00000745|Biological|Hepatitis B Vaccine (Recombinant)|
45916770|NCT00000745|Biological|gp160 Vaccine (MicroGeneSys)|
45916771|NCT00000748|Drug|Sulfamethoxazole-Trimethoprim|
45916772|NCT00000751|Drug|Anti-HIV Immune Serum Globulin (Human)|
45641834|NCT05618808|Drug|Enoxaparin|Participants will receive enoxaparin by SC administration daily through the time of venography (or day 12, whichever is earlier)
45641835|NCT05618808|Drug|Apixiban|Participants will receive apixaban orally twice a day through the time of venography (or day 12, whichever is earlier)
45641836|NCT05618444|Behavioral|Automated Management (AM)|A tele-management intervention that will deliver two-way messages to participants via a bot - a computer program that simulates human activity. Programmed AM messages will address evidence based intervention components for positive airway pressure (PAP) adherence, including PAP use awareness (tele-monitoring), support and troubleshooting, education, and brief motivational messaging.
45641837|NCT05618366|Drug|Venetoclax|Participants will receive oral venetoclax taken once per day. The dose will be between 200 and 800 mg daily, with the exact dose determined by the protocol.
45641838|NCT05618366|Drug|Tazemetostat|Tazemetostat 800mg taken orally, twice daily.
45641839|NCT05617820|Drug|Estradiol|Vaginal Insert, 4 mcg tablet
45641840|NCT05617820|Drug|Imvexxy|Estradiol 4 mcg Vaginal Insert
45641841|NCT05617820|Drug|Placebo|Vehicle Vaginal Insert
45641842|NCT05617040|Biological|ChAdOx1-PCAQ|Recombinant nonreplicating chimpanzee adenovirus Oxford 1 (ChAdOx1) vector encoding 4 prostate cancer antigens: prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), six-transmembrane epithelial antigen of prostate 1 (STEAP1), and an oncofoetal antigen (5T4).
45780566|NCT00691808|Drug|LX6171 High Dose|A high dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
45641843|NCT05617040|Biological|MVA-PCAQ|Replication-deficient recombinant Modified Vaccinia virus Ankara (MVA) vector encoding the same prostate cancer antigens as ChAdOx1-PCAQ (prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), six-transmembrane epithelial antigen of prostate 1 (STEAP1), and an oncofoetal antigen (5T4))
45780567|NCT00691808|Drug|LX6171 Low Dose|A low dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
45641844|NCT05615389|Drug|Medicinal Cannabis - C12T12|"Participants randomised to receive C12T12 Ruby Balanced Oil will commence with 0.008ml/kg/day (0.1 mg/kg/day THC) in two divided doses, and titrate up in four steps (increase by 0.008ml/kg/day every four days) over 16 days up to a maintenance dose of 0.04ml/kg/day (0.5mg/kg/day THC) in two divided doses, with a ceiling dose of 2ml/day (25mg/day THC) for participants weighing 50kg or more. The maintenance dose will then be continued from day 17 until day 42.~Down-titration will occur for 16 days after the end of study visit, in the reverse of the up-titration period."
45641845|NCT05615389|Drug|Medicinal Cannabis - C20T5|Participants randomised to the C20T5 Ruby CBD Oil will receive a matched volume to the C12T12 arm during the up-titration, maintenance, and down-titration phases.
45641846|NCT05610683|Device|Hemodialysis sessions using SHFVE dialyzer (VieX™) or the MCO (Theranova 500™) dialyzer|Patients will receive thrice weekly 4 hours hemodialysis sessions during 3 months
45641847|NCT05609968|Biological|Sacituzumab Govitecan|IV infusion
45641848|NCT05609968|Biological|Pembrolizumab|IV infusion
45641849|NCT05609864|Other|Quantification of injectable drugs wastage|Drugs are prescribed at discretion of physicians. For each patient who have anesthesia in the operating room, all labelled syringes having contained drugs (name + dilution) are collected and analyzed.
45641850|NCT05605678|Other|No Intervention|This is a non-interventional study.
45641851|NCT05603143|Drug|Obeldesivir|Tablets administered orally without regard to food.
45641852|NCT05603143|Drug|Obeldesivir Placebo|Placebo tablets administered orally without regard to food.
45780568|NCT00691808|Drug|Placebo|Matching placebo dosing with daily oral intake for 28 days in the morning at approximately the same time.
45916773|NCT00000751|Drug|Globulin, Immune|
45916774|NCT00000751|Drug|Zidovudine|
45916775|NCT00000754|Drug|Interferon alfa-2a|
45916776|NCT00000754|Drug|Zidovudine|
45916777|NCT00000754|Drug|Zalcitabine|
45916778|NCT00000760|Drug|Ro 24-7429|
45916779|NCT00000760|Drug|Zidovudine|
45916780|NCT00000760|Drug|Didanosine|
45448763|NCT03545542|Diagnostic Test|Initial fecal microbiome|Stool sampling for fecal microbiome analysis by 16S rDNA pyrosequencing. Neuroblastoma group and Control group.
45641853|NCT05601726|Drug|ABD-3001|Each patient will receive a single and fixed 4 hours-intravenous infusion dose of ABD-3001. The first dose of the first cohort will receive an estimated infusion dose of 18 mg/m² at Day 1. Subsequent cohorts will be given the following doses: 54 mg/m², 135 mg/m², 270 mg/m², 405 mg/m², 540 mg/m².
45641854|NCT05601726|Drug|ABD-3001|"Based on PK data gathered during the SAD, a dose regimen optimization will be done using population Pharmacokinetic modelling in order to set the optimal frequency of infusion per week to achieve sustained exposition throughout treatment period. Based on this analysis, the Sponsor will, in accordance with the Safety review Committee, define the occurrence of infusion to 1, 2 or 3 times per week, during 4 weeks (28 days ± 3 days).~Number of infusions given per week and dose increase between each dose will be set so that, whatever the initial dose used in the MAD part, total dose increase will never get above the MTD determined in the SAD part or a dose defined by the SRC, if no MTD is determined during the SAD part."
45641855|NCT05600985|Procedure|FS-LASIK|Laser-assisted in situ keratomileusis, commonly referred to laser eye surgery or laser vision correction, is a type of refractive surgery for the correction of myopia, hypermetropia, and astigmatism.
45780569|NCT03843541|Drug|N-acetylcysteine (NAC) 600 mg|NAC will be administered twice a day, morning and evening, during treatment period.
45780570|NCT03843541|Drug|Ambroxol hydrochloride 30 mg|Ambroxol hydrochloride will be administered twice a day, morning and evening, during treatment period.
45916781|NCT00000790|Drug|Thalidomide|
45916782|NCT00000793|Drug|Mexiletine hydrochloride|
45916783|NCT00000793|Drug|Benztropine mesylate|
45916784|NCT00000793|Drug|Amitriptyline hydrochloride|
45916785|NCT00000799|Drug|Cidofovir|
45916786|NCT00000799|Drug|Probenecid|
45916787|NCT00000817|Drug|Amitriptyline hydrochloride|75 mg oral tablet taken daily
45916788|NCT00000817|Drug|Amitriptyline hydrochloride placebo|Oral placebo tablet taken daily
45916789|NCT00000817|Procedure|Point acupuncture|Standardized or alternate acupuncture procedure
45916790|NCT00000820|Drug|Aldesleukin|
45916791|NCT00000826|Drug|Clarithromycin|
45916792|NCT00000826|Drug|Rifabutin|
45641856|NCT05599399|Dietary Supplement|Gum acacia|25 grams of gum acacia powder is administered on daily-basis
45641857|NCT05599373|Device|Bilateral Active Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) over bilateral dorsolateral prefrontal cortex (DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of each side resting motor threshold (MT). The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
45641858|NCT05599373|Device|Left Active Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex(DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of left resting motor threshold (MT). Sham rTMS stimulation was delivered over right dorsolateral prefrontal cortex(DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
45641859|NCT05599373|Device|Sham rTMS over bilateral dorsolateral prefrontal cortex|Sham rTMS stimulation was delivered over bilateral dorsolateral prefrontal cortex (DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
45916793|NCT00000826|Drug|Sulfamethoxazole-Trimethoprim|
45641861|NCT05593874|Diagnostic Test|Histones H3.1 blood levels|Measure of blood concentrations of histone subtype H3.1
45641862|NCT05593432|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
45641863|NCT05593432|Drug|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
45641864|NCT05592990|Drug|NGI226|NGI226 MP
45641865|NCT05592990|Drug|Placebo|Placebo MP
45641866|NCT05591898|Behavioral|Progressive relaxation exercises|Training booklet and CD as a guide on the implementation of Progressive Relaxation Exercises prepared by the Turkish Psychological Association; muscle relaxation exercises, rhythmic breathing and music recital. In the first 10 minutes of this three-part CD, the definition and purpose of deep relaxation and the practices to be considered during exercise are explained. In the second part of 30 minutes; relaxation exercises are explained with the sound of the stream and verbal instructions. The third part, consisting of 30 minutes; it contains only relaxation music without instructions.
45641867|NCT05590377|Drug|Modakafusp Alfa|Modakafusp alfa intravenous infusion
45641868|NCT05590377|Drug|Daratumumab|Daratumumab SC injection
45780571|NCT03843541|Other|placebo|Placebo will be administered twice a day, morning and evening, during treatment period.
45780572|NCT00692198|Drug|Supplemental oxygen therapy|Oxygen dose at rest and during sleep will be 2 L/min via nasal cannula. The oxygen dose used while walking will be individually prescribed and will be sufficient to maintain oxygen saturation at 90% or above for at least 2 minutes while walking. Participants who have low blood oxygen levels at rest will be instructed to use oxygen 24 hours per day. Participants who have normal resting blood oxygen levels, but low or very low blood oxygen levels during exercise, will be instructed to use oxygen during physical activity and sleep.
45916794|NCT00000826|Drug|Dapsone|
45916795|NCT00000826|Drug|Fluconazole|
45641869|NCT05589831|Device|Non-invasive Neurally Adjusted Ventilatory Assist|Neurally Adjusted Ventilatory Assist (NAVA) is a new non-invasive ventilation mode that uses the electrical activity of the diaphragm (EAdi) to offer ventilatory assistance in synchrony with patient effort, thus potentially reducing stress and discomfort. It uses electrodes placed on a modified nasogastric feeding tube to detect the electrical activity of the diaphragm (EAdi), such that both the initiation and termination of a breath during each respiratory cycle is in synchrony with the infant's effort
45641870|NCT05589740|Behavioral|Culturally tailored healthy eating advice|Culturally-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
45641871|NCT05589740|Behavioral|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips for general dietary recommendations from USDA My Plate
45641872|NCT05588739|Behavioral|Cognitive Behavioral Therapy|The manualized CBT protocol is five session that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
45641873|NCT05587998|Drug|AZD4041 and morphine|Participants will receive 2 doses of morphine (IV administration) and multiple doses of AZD4041 (Oral solution)
45641874|NCT05587998|Other|Placebo and morphine|Participants will receive 2 doses of morphine (IV administration) and multiple doses of Placebo (Oral solution)
45641875|NCT05585398|Drug|IncobotulinumtoxinA|Intradermal injections using different delivery methods (conventional needle and microneedles)
45641876|NCT05582551|Other|Highlighting Patients at Risk for Sensory Screening (HPARSS)|Collaborators in the Informatics Research branch of the Institute of Informatics at the Washington University School of Medicine will identify CCS at risk for sensory deficits based upon their therapy exposure to generate the HPARSS document.
45641877|NCT05581589|Procedure|Lymphadenectomy|Undergo pelvic lymph node dissection
45641878|NCT05581589|Procedure|Radical Cystectomy|Undergo radical cystectomy
45641879|NCT05581589|Biological|Sacituzumab Govitecan|Given IV
45916796|NCT00000859|Drug|Indinavir sulfate|
45916797|NCT00000859|Drug|Ritonavir|
45916798|NCT00000859|Drug|Nelfinavir mesylate|
45916799|NCT00000871|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
45916800|NCT00000871|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
45916801|NCT00000871|Biological|ALVAC-HIV MN120TMG (vCP205)|
45916802|NCT00000871|Biological|rgp120/HIV-1 SF-2|
45916803|NCT00000877|Drug|Indinavir sulfate|
45916804|NCT00000877|Drug|Rifabutin|
45641880|NCT05579860|Drug|Olezarsen|Olezarsen will be administered by SC injection.
46070543|NCT04247048|Other|infusion of tracer [5,5,5-2H3] -L-leucine|A bolus of 6ml of [5,5,5-2H3] -L-leucine tracers will be performed followed by an infusion of 90 ml of [5,5,5-2H3] -L-leucine infused over 14 hours. This tracer participates in protein synthesis and especially in the synthesis of all apolipoproteins and PCSK9. Blood samples will be taken at T0, T2min, T5min, T10 minutes, T30 minutes and then every hour until 14 hours (a total of 240 ml of blood will be collected) to measure the stable tracer enrichment in the proteins of interest.
45780573|NCT03795493|Behavioral|Short-term diet and exercise intervention|Participants assigned to the intervention group will perform both the diet and acute exercise interventions. The interventions will be applied prior to up to six chemotherapy cycles of a consistent protocol. The total number of treatments of a given protocol received prior to treatment conclusion is dependent on patient condition and oncologic care preferences.
45780574|NCT00639158|Drug|ABT-335|135 mg capsule, daily, 12 weeks
45916805|NCT00000883|Drug|Azithromycin|
45916806|NCT00000892|Drug|Ritonavir|
45916807|NCT00000892|Drug|Nelfinavir mesylate|
46070544|NCT00632216|Drug|Risedronate Sodium|
45916808|NCT00000892|Drug|Levocarnitine|
45916809|NCT00000892|Drug|Adefovir dipivoxil|
45916810|NCT00000892|Drug|Saquinavir|
45916811|NCT00000892|Drug|Delavirdine mesylate|
46070545|NCT04276298|Drug|Metronidazole cream|10% metronidazole applied rectally
46070546|NCT04276298|Drug|Metronidazole and Diltiazem cream|Combination Metronidazole and Diltiazem applied rectally
45916812|NCT00000895|Drug|Nelfinavir mesylate|
45641887|NCT05576077|Biological|TBio-4101|TBio-4101 is an autologous selected and expanded tumor infiltrating lymphocyte (TIL) product generated following ex vivo expansion of tumor reactive TIL population found in tumor harvest. After preparation with non-myeloablative lymphodepletion chemotherapy (cyclophosphamide and fludarabine) followed by low dose radiation,TBio-4101, and IL-2.
45641888|NCT05576077|Drug|Pembrolizumab|Pembrolizumab will be administered after TIL infusion and continue every 3-6 weeks for up to 2 years.
45641889|NCT05574335|Drug|Siplizumab|Weekly siplizumab doses for a total of 12 weeks
45641890|NCT05574114|Radiation|Bridging radiotherapy (BRT)|RT Part I. The target will be to complete the 9th fraction of radiotherapy (i.e., total of 27Gy) between days -12 and -8 Day -2: BRT Part II (intervention is one fraction 3 Gy to receive a total dose of 3 Gy).
45641891|NCT05574114|Drug|Conditioning chemotherapy|Day -5 to -3: Patients will receive standard of care lymphodepleting chemotherapy
45641892|NCT05574114|Biological|CAR T-cell product|Day 0: Subject will receive standard of care infusion of a manufactured commercial CAR T-cell product.
45641893|NCT05573555|Drug|ARV-471|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
45641894|NCT05573555|Drug|Ribociclib|Daily oral dosages of ribociclib consecutively for 21 days followed by 7 days off treatment, cycles lasting 28 days
45641895|NCT05573334|Device|BioNourish|"BioNourish is a 510k-cleared class II medical device that has been on the market for over two years. It is a vaginal moisturizing gel that is designed with pH, osmolality, and lactic acid levels that match those observed in healthy vaginas. It does not have an active ingredient, but only provides moisture in a formula that is matched for physicochemical characteristics to healthy vaginal fluid."
45641896|NCT05572177|Device|Asthma SMART|The intervention is a smartphone application to improve self-management of asthma designed to appeal to adolescents. The app integrates four components to facilitate asthma self-management: 1) self-monitoring of peak-flow and symptoms; 2) graphical health user interfaces with avatars, infographics, and rewards; 3) interactive educational materials; and 4) patient-provider interactions.
45641897|NCT05571735|Biological|Pfizer-BioNTech COVID-19 vaccine|Pfizer-BioNTech COVID-19 vaccine, Messenger RNA (mRNA) based vaccine encoding the viral spike glycoprotein (S) Formulation: Frozen concentrate before dilution with 0.9% sodium chloride solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.3 mL per dose) (at least 3 weeks apart)
45780575|NCT00639158|Drug|placebo|placebo capsule, daily, 12 weeks
45780576|NCT00639158|Drug|atorvastatin|40 mg, tablet, daily, 12 weeks
45780577|NCT00639158|Drug|ezetimibe|10 mg capsule, daily, 12 weeks
45780578|NCT03004885|Device|PrismaLung|Low flow Extracorporeal CO2 removal using a 0.32 m² membrane oxygenator
45780579|NCT03728335|Drug|Enasidenib Mesylate|Given PO
45780580|NCT02994589|Other|Tegaderm™(Absorbant, 3M)|3M™ Tegaderm™ Dressing helps provide the natural moisture balance conducive to wound healing.
45780581|NCT02994589|Device|OASIS® wound matrix|OASIS® Matrix is indicated for the management of wounds including: partial- and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, trauma wounds (abrasions, lacerations, second-degree burns, skin tears), draining wounds, surgical wounds (donor sites/grafts, post-Mohs' surgery, post-laser surgery, podiatric, wound dehiscence).
45916813|NCT00000895|Drug|Nevirapine|
45916814|NCT00000895|Drug|Azithromycin|
45916815|NCT00000898|Drug|Ritonavir|
45916816|NCT00000898|Drug|Nelfinavir mesylate|
45916817|NCT00000898|Drug|Saquinavir|
45916818|NCT00389194|Drug|continuing AZT+3TC or switching AZT+3TC to TDF+ FTC|
45916819|NCT00389233|Drug|Macrogol3350 NA sulphate NACl KCl ascorbic acid NA ascorbate|"1 pack will consist of 2L NRL 994 - 4 (2 x PEG + E/P + 2 x Vitamin C/C) sachets for the 2L of 2 sachets (1 x P plus 1 x C) will be dissolved in 1L of water. Each litre will be drunk within 1 hour followed by at least 500ml of any additional clear fluid."
45916820|NCT00389233|Drug|Macrogol3350 Na sulphate Na bicarbonate NaCl KCl|"1 pack will consist of 4L PEG + E - contains 4 sachets for the 4L of PEG + E/P/E. Each sachet will be dissolved in 1L of water. Each litre will be drunk within 1 hour."
46070547|NCT04276298|Drug|Metronidazole and Lidocaine cream|Combination metronidazole and lignocaine applied rectally
46070548|NCT04276298|Drug|Metronidazole, Diltiazem and Lidocaine cream|Combination of all active agents tested applied rectally
46070549|NCT04273880|Drug|Methylphenidate|10mg of MPH taken an hour and a half before one of the testing sessions.
46070550|NCT04273880|Drug|Vitamin C|90 mg of Vitamin C taken an hour and a half before the other testing session
45780582|NCT02994589|Other|Xeroform™|Xeroform™ consists of a fine-mesh gauze impregnated with bismuth tribromophenate.
45641898|NCT05571735|Biological|AstraZeneca vaccine|AstraZeneca vaccine, a replication-deficient simian adenoviral vector expressing the spike (S) protein of SARS-CoV-2 Formulation: Aqueous solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.5 mL per dose) (at least 12 weeks apart)
45641899|NCT05571735|Biological|Janssen Ad26.COV2.S COVID-19 vaccine|"Janssen Ad26.COV2.S COVID-19 vaccine, recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein.~Formulation: Suspension for injection Route of Administration: Intramuscular (IM) Dosing regimen single dose (0.5 mL)"
45641900|NCT05570812|Drug|Placebo|(4-week ramp, 4-week steady dosing)
45780583|NCT03498859|Other|Physiotherapist-supervised training|The intervention is physiotherapist-supervised training once per week during 10 weeks.
45780584|NCT03498859|Other|Home-based training|The intervention is home-based training during 10 weeks
45780585|NCT05484661|Dietary Supplement|BCAA|Participants will participate in high-volume, moderate-intensity exercise 3x/week and consume either a placebo or BCAA (~7-10 g of BCAAs (100 mg/kg) daily for eight weeks.
45780586|NCT05424133|Other|High frequency chest wall oscillation|High frequency chest wall oscillations at 13-15Hz oscillating frequency for 20 minutes twice a day for 4 weeks.
45780587|NCT05424133|Other|Active cycle of breathing|Active cycle of breathing technique and it will performed twice a day for 4 week intervention period for 20 minutes
46070551|NCT03316742|Combination Product|Intervention 1|Intervention 1 includes providing participants with a high fiber food product, protein source, high intensity sweetener and adult multivitamin.
45780588|NCT05411653|Other|Virtual reality training with motor imagery|comprised of 30 minutes, VRT (15 minutes) and MI (15 minutes) daily for 3 days respectively. Five Xbox Kinect gaming will be selected and explained to the patients for the virtual training session and additional 15 minutes will be given to them for practice. The games consists of 20,000 water leaks, river rush, reflex ridge, soccer and football for the patients.
45780589|NCT05411653|Other|Conventional physical therapy|range of motion exercises, muscle strengthening, functional training, balance training, and gait training. The specific tasks will be selected by the therapist based on the requirement of each patient. It will be performed for 30 minutes for 3 days a week for 6 weeks
45916821|NCT00000904|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
45916822|NCT00000904|Biological|gp160 MN/LAI-2|
45916823|NCT00000904|Biological|ALVAC(1)120(B,MN)GNP (vCP1433)|
45916824|NCT00000904|Biological|ALVAC-HIV MN120TMG (vCP205)|
45916825|NCT00000904|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
45641901|NCT05570812|Drug|Pregnenolone|(4-week ramp, 4-week steady dosing)
45641902|NCT05569512|Drug|Uproleselan|Administered by intravenous infusion
45641903|NCT05569512|Drug|Fludarabine|Administered by intravenous infusion
45641904|NCT05569512|Drug|Clofarabine|Administered by intravenous infusion
45641905|NCT05569512|Drug|Busulfan|Administered by intravenous infusion
45641906|NCT05569005|Other|THS use|Subjects who are not willing to quit smoking during the study duration will switch from cigarettes to using THS
45641907|NCT05569005|Other|Cigarette|Subjects who are not willing to quit smoking during the study duration will continue smoking their own preferred brand of commercially available cigarettes.
45641908|NCT05569005|Other|Smoking Abstinence|Subjects who are willing to quit smoking may be prescribed an NRT to support them in remaining abstinent from use of any tobacco and nicotine containing products during the study. (Behavioral support will be provided to subjects to aid with abstinence.)
45641909|NCT05568095|Drug|Domvanalimab|Intravenous (IV) Aqueous Solution
45641910|NCT05568095|Drug|Zimberelimab|IV Aqueous Solution
45641911|NCT05568095|Drug|Capecitabine|Oral Tablets
45641912|NCT05568095|Drug|Fluorouracil|IV Aqueous Solution
45641913|NCT05568095|Drug|Leucovorin|IV Aqueous Solution
45641914|NCT05568095|Drug|Oxaliplatin|IV Aqueous Solution
45641915|NCT05568095|Drug|Nivolumab|IV Aqueous Solution
45641916|NCT05567172|Device|Left atrial appendage closure device WM FLX Pro|Left atrial appendage closure
45641917|NCT05565768|Drug|HZN-457|HZN-457 will be given in one subcutaneous administration
45641918|NCT05565768|Drug|Placebo|Placebo will be given in one subcutaneous administration
45641919|NCT05561491|Biological|ONCOS-102|Oncolytic virus
45780590|NCT00692276|Device|Superion™ Interspinous Spacer|Implantation of interspinous process spacer to treat lumbar spinal stenosis
45780591|NCT00692276|Device|X-STOP® IPD® Device|Implantation of interspinous process spacer to treat lumbar spinal stenosis
45780592|NCT02248987|Other|patients treated with antipsychotics|
45780593|NCT03004963|Device|Body composition monitor|Both body composition monitor (BCM) is used to evaluate the volume status of patients.
45780594|NCT03004963|Device|clinical indexes|The investigators evaluate the volume status of patients according to clinical indexes.
45780595|NCT00639860|Device|OSSIX-Plus|resorbable collagen membrane
45780596|NCT05392309|Other|Manual ankle rocking training|Group will receive manual ankle rocking training with lower limb exercise and core strengthening of trunk
45916826|NCT00000919|Drug|Indinavir sulfate|
45916827|NCT00000919|Drug|Lamivudine/Zidovudine|
45916828|NCT00000919|Drug|Ritonavir|
45916829|NCT00000919|Drug|Hydroxyurea|
45916830|NCT00000919|Drug|Abacavir sulfate|
45916831|NCT00000919|Drug|Amprenavir|
45916832|NCT00000919|Drug|Nelfinavir mesylate|
45916833|NCT00000919|Drug|Efavirenz|
45916834|NCT00000919|Drug|Lamivudine|
45916835|NCT00000919|Drug|Stavudine|
45916836|NCT00000919|Drug|Zidovudine|
45916837|NCT00000919|Drug|Didanosine|
45916838|NCT00000922|Drug|Indinavir sulfate|
45916839|NCT00000922|Drug|Abacavir sulfate|
45641920|NCT05561491|Biological|Balstilimab|Anti PD-1
45641921|NCT05561387|Drug|Bortezomib|Given SC
45780597|NCT05392309|Other|Conventional|Group will receive lower limb exercises and core strengthening of trunk. Sessions will be 4 days in a week
45916840|NCT00000922|Drug|Nelfinavir mesylate|
45641922|NCT05561387|Drug|Daratumumab and Hyaluronidase-fihj|Given SC
45641923|NCT05561387|Drug|Dexamethasone|Given PO
45641924|NCT05561387|Drug|Lenalidomide|Given PO
45641925|NCT05561387|Other|Quality-of-Life Assessment|Ancillary studies
45641926|NCT05561387|Other|Questionnaire Administration|Ancillary studies
45641927|NCT05559671|Biological|Herpes Zoster Subunit (HZ/su) Vaccine|Manufactured by GSK Biologicals SA. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.
45641928|NCT05559671|Biological|Placebo|Saline injection. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.
45641929|NCT05559021|Other|Myofascial Therapy Treatments|"• Myofascial approach: After the bibliographic review of myofascial therapy treatments in fibromyalgia patients based on the articles by CastroSánchez AM et al., and an expert consensus, the following approach was decided: patients would have 4 sessions in total with 1 session per week of 30 minutes each.~Transverse planes in the thoracolumbar fascia (TCL) and abdomen: Performing a myofascial induction as described by Pilat.~Transverse planes at C7-D3 and sternum: Performing a myofascial induction as described by Pilat.~Suboccipital inhibition: Performing a myofascial induction as described by Pilat"
45641930|NCT05559021|Other|Passive Mobilizations Approach|"• Approach with passive mobilizations: After the literature review of manual therapy treatments in fibromyalgia patients and a consensus of experts in Manual Therapy with more than 15 years of experience, the following approach was agreed upon by the expert: patients would have 4 sessions in total with 1 session per week of 30 minutes each.~Postero-anterior cervical sliding~Postero-anterior lumbar slippage~Postero anterior dorsal slippage"
45641931|NCT05558995|Other|ketogenic diet|All the subjects will be instructed by a nutrition professional to have at least 3 meals per day consisting of 20 g to 30 g of carbohydrate in the form of green vegetables and salad, and 80 g to 100 g of protein in the form of meat, fish, fowl, eggs, shellfish and cheese for 12 weeks. Polyunsaturated and monounsaturated fats will also be included in the diet. Micronutrients (vitamins and minerals) will be given to each subject in the form of one capsule per day. The adherence to diet will be confirmed weekly through a food log and urinary ketones assessment using dipstick to ensure that all individuals remain in a ketotic state.
45916841|NCT00000922|Drug|Efavirenz|
45916842|NCT00000922|Drug|Nevirapine|
45641932|NCT05558982|Drug|BXCL701|BXCL701 0.3 mg, orally, twice a day on days 1-14 every 21 days
45641933|NCT05558982|Drug|Pembrolizumab|Pembrolizumab 200 mg intravenous (IV) on day 1 every 21 days.
45641934|NCT05558527|Behavioral|social support|social support is provided in the form of social touch (hand holding)
45641935|NCT05557513|Device|STANDARD Q COVID-19 Ag Test|"Device Name: STANDARD Q COVID-19 Ag Test Manufactured by SD Biosensor, Inc., Korea~Purpose: To detect COVID-19 (Its manufacture specification sensitivity was at 84.97% and specificity 98.4%)"
45641936|NCT05556616|Drug|Modakafusp alfa|Modakafusp alfa intravenous infusion.
45641937|NCT05556616|Drug|Lenalidomide|Lenalidomide capsules orally.
45641938|NCT05556616|Drug|Bortezomib|Bortezomib injection subcutaneously.
45641939|NCT05556616|Drug|Carfilzomib|Carfilzomib intravenous infusion.
45641940|NCT05556616|Drug|Daratumumab|Daratumumab injection subcutaneously.
45641941|NCT05556616|Drug|Pomalidomide|Pomalidomide capsules orally.
45641942|NCT05556252|Other|Hydrogenated water consumption|Participants will start consuming hydrogenated water on the 16th day of the menstrual cycle and will continue to apply it until the 2nd day of the next cycle. Within the scope of the study, they will be asked to drink of 300-400 ml hydrogenated water each morning before breakfast; 300-400 ml an hour before lunch; 300-400 ml two hours after lunch; 300-400 ml an hour before dinner; 300-400 ml half an hour before going to bed. Participants will be asked to consume a minimum of 1500 ml (1.5 L) and a maximum of 2000 ml (2.0 L) hydrogenated water in total. In this way, participants will be provided with hydrogenated water for three cycles.
45780598|NCT00692978|Drug|Fluticasone Propionate_1.5|Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 1.5 micros, inhaled
45780599|NCT00692978|Drug|Fluticasone Propionate_3|Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 3.0 microns, inhaled
45780600|NCT00692978|Drug|Fluticasone Propionate_6|Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 6.0 microns, inhaled
45780601|NCT00692978|Drug|FP From Active 250 ug MDI Inhaler|Monodisperse aerosols inhaled of Fluticasone Propionate at 250micrograms dose with active MDI inhaler
45780602|NCT03004807|Dietary Supplement|Centrum Silver Mens' Formula|Multivitamin/Multimineral dietary supplement produced for Pfizer for use in older men.
45780603|NCT03004807|Other|Control|A matching tablet to the dietary supplement, but without any active ingredients
45916843|NCT00000922|Drug|Lamivudine|
45916844|NCT00000922|Drug|Stavudine|
45916845|NCT00000922|Drug|Didanosine|
45916846|NCT00000931|Behavioral|Behavioral intervention|
45916847|NCT00000931|Behavioral|Risk-reduction counseling|
45916848|NCT00000940|Drug|Ritonavir|
45916849|NCT00000940|Drug|Abacavir sulfate|
45916850|NCT00000940|Drug|Amprenavir|
45916851|NCT00000940|Drug|Lamivudine|
45916852|NCT00000940|Drug|Stavudine|
45916853|NCT00000943|Biological|Tetanus Toxoid Vaccine|
45916854|NCT00000943|Biological|Hepatitis A Vaccine (Inactivated)|
45916855|NCT00000943|Biological|HIV-1 Immunogen|
45916856|NCT00000943|Biological|Hepatitis B Vaccine (Recombinant)|
45916857|NCT00000952|Drug|Ritonavir|
45916858|NCT00000952|Drug|Lamivudine|
45916859|NCT00000952|Drug|Zidovudine|
46070552|NCT03316742|Combination Product|Intervention 2|Intervention 2 includes providing participants with an alternative dietary fiber source, milk protein, high intensitysweetener and adult multivitamin.
46070553|NCT03969992|Drug|AeroFact|Aerosolized SF-RI 1
46070554|NCT03969992|Other|nCPAP|nCPAP (nasal continuous positive airway pressure) alone
45780604|NCT03286699|Behavioral|Dietary Intervention|The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address eating behaviors. Subjects will also participate in phone calls with the interventionist (~10 minutes). Depending on the week, subjects will have between 10 and 45 minutes of total intervention contact.
45780605|NCT03286699|Behavioral|Physical Activity Intervention|The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address physical activity behaviors. Subjects will also participate in phone calls with the interventionist (~10 minutes). Depending on the week, subjects will have 10 to 45 minutes of total intervention contact.
45641943|NCT05556252|Other|Drinking water consumption|Participants will start consuming drinking water on the 16th day of the menstrual cycle and will continue to apply it until the 2nd day of the next cycle. Within the scope of the study, they will be asked to drink of 300-400 ml drinking water each morning before breakfast; 300-400 ml an hour before lunch; 300-400 ml two hours after lunch; 300-400 ml an hour before dinner; 300-400 ml half an hour before going to bed. Participants will be asked to consume a minimum of 1500 ml (1.5 L) and a maximum of 2000 ml (2.0 L) drinking water in total. In this way, participants will be provided with drinking water for three cycles.
45641944|NCT05556096|Combination Product|ALXN1720|Combination product consisting of syringe prefilled with ALXN1720.
45641945|NCT05556096|Combination Product|Placebo|Combination product consisting of syringe prefilled with placebo.
45780606|NCT00601718|Drug|vorinostat|Given PO
45780607|NCT00601718|Biological|rituximab|Given IV
45641946|NCT05554354|Drug|Binimetinib|Given PO
45780608|NCT00601718|Drug|ifosfamide|Given IV
45641947|NCT05554354|Procedure|Biopsy|Undergo tumor biopsy
45641948|NCT05554354|Procedure|Bone Scan|Undergo bone scan
45641949|NCT05554354|Procedure|Computed Tomography|Undergo CT scan
45641950|NCT05554354|Drug|Fulvestrant|Given IM
45641951|NCT05554354|Procedure|Magnetic Resonance Imaging|Undergo MRI
45641952|NCT05554237|Drug|Placebo|Placebo
45641953|NCT05554237|Drug|PF-07612577|PF-07612577
45641954|NCT05554237|Drug|PF-06264006|PF-06264006
45641955|NCT05553054|Other|Quantification of IV drugs wastage|"Drugs are prescribed depending on physician discretion.~Specific collection bins are provided to ICU. Healthcare teams discard syringes labelled with name and dilution which have been used to prepare drugs into these bins. After 24 hours of collection, bins are analyzed by investigators."
45641956|NCT05552976|Drug|CC-92480|Specified dose on specified days
45641957|NCT05552976|Drug|Carfilzomib|Specified dose on specified days
45780609|NCT00601718|Drug|carboplatin|Given IV
45780610|NCT00601718|Drug|etoposide|Given IV
45916860|NCT05638971|Device|ivWatch|The second half sample size PIVC will be enrolled into an alarming group. ivWatch will monitor the PIVC insertion site collecting data and sending visual and auditory notifications of any infiltration. The goals of the study on the alarming group are: a) to estimate the notification rate (the number of detected infiltration in the studied period; b) to evaluate the extension and severity of the detected infiltration at the time of the notification, so to gather if ivWatch is helpful in early diagnosis
45641958|NCT05552976|Drug|Dexamethasone|Specified dose on specified days
45641959|NCT05552664|Genetic|GIFT|GIFT features a web-based intervention that offers access to an online family communication program containing key facts about genetics, cancer risk, and the role of genetic testing and helps patients share health information with their first-and second-degree relatives, whom they can invite to join the study to receive education/support and access to low-cost genetic testing.
45916861|NCT00000958|Biological|MTP-PE/MF59|
45916862|NCT00000958|Biological|Env 2-3|
45641960|NCT05550870|Dietary Supplement|Raw fenugreek seed powder|It will be given to group 1
45641961|NCT05550870|Dietary Supplement|Roasted fenugreek seed powder|It will be given to group 2
45641962|NCT05549323|Drug|PF-07054894|Oral
45641963|NCT05549323|Drug|Placebo|Placebo
45641964|NCT05548296|Drug|ACR-368|ACR-368 is an experimental drug
45641965|NCT05548296|Drug|Gemcitabine|Gemcitabine is a standard of care given at ultralow dose in combination with the experimental drug ACR-368
45641966|NCT05548296|Diagnostic Test|OncoSignature|Biomarker profile based on prediction of drug sensitivity performed on biopsy tissue
45641967|NCT05547880|Drug|[11C]ER176|Brain PET with [11C]ER176. [11C]ER176 is a PET ligand that images TSPO.
45641968|NCT05547464|Biological|BNT164a1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
45641969|NCT05547464|Biological|BNT614b1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
45641970|NCT05547464|Other|Placebo|Placebo
45641971|NCT05546151|Drug|BMS-986322|Specified dose on specified days
45641972|NCT05546151|Other|Placebo for BMS-986322|Specified dose on specified days
45780611|NCT00601718|Other|pharmacological study|Correlative studies
45780612|NCT00601718|Other|laboratory biomarker analysis|Correlative studies
45780613|NCT00601718|Genetic|gene expression analysis|Correlative studies
45780614|NCT03004729|Other|CoMiSS questionnaire|
45780615|NCT03275779|Behavioral|Low Frequency Condition|Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.
45916863|NCT00000643|Drug|Pyrimethamine|
45916864|NCT00000643|Drug|Leucovorin calcium|
45916865|NCT00000970|Drug|Foscarnet sodium|
45641973|NCT05544695|Device|intravesical sodium hyaluronate (Cystistat®)|Cystistat will be instilled into the bladder according to the instructions for use and in line with the routine clinical practice.
45641974|NCT05543278|Drug|Amiodarone|Patients randomized to the Amiodarone Arm will receive a 5-day course of amiodarone after surgery.
45780616|NCT03275779|Behavioral|High Frequency Condition|Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.
45780617|NCT03004651|Other|Power Doppler ultrasound|Mesure of synovitis (≥ grade 1 synovitis on a semi-quantitative scale)
45780618|NCT03004651|Other|Clinical evaluation|swollen joint count (SJC) as componant of SDAI
45780619|NCT03004573|Other|Neuropsychological detailed tests with focus on social cognition|MATTIS, MOCA, BREF, Light points test, PDQ39
45780620|NCT00640250|Biological|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Disperse blue 106 in PVP, 0.15 mg/cm2 Disperse blue 106 in PVP, 0.050 mg/cm2 Disperse blue 106 in PVP, 0.017 mg/cm2 PVP Negative Control Bronopol in PVP, 0.75 mg/cm2 Bronopol in PVP, 0.50 mg/cm2 Bronopol in PVP, 0.25 mg/cm2 Bronopol in PVP, 0.125 mg/cm2~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
45780621|NCT03050671|Device|Intermittent Pneumatic Compression, Rapid|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a sharp and rapid way
45780622|NCT03050671|Device|Intermittent Pneumatic Compression, Slow|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a smooth, slow and progressive way
45780623|NCT00601796|Biological|Vaccine Treatment|We created a vaccine in which irradiated allogeneic lung adenocarcinoma cells are combined with a bystander K562 cell line transfected with hCD40L and hGM-CSF. By recruiting and activating dendritic cells, we hypothesized the vaccine would induce tumor regression in metastatic lung adenocarcinoma. Intradermal vaccine was given every 14 days x3, followed by monthly x3.
45780624|NCT00601796|Drug|Cyclophosphamide|Cyclophosphamide (300 mg/m^2 IV) was administered before 1st and 4th vaccines to deplete regulatory T-cells.
45780625|NCT00601796|Drug|All-trans retinoic acid (ATRA)|All-trans retinoic acid was given (150/mg/m^2/day) after 1st and 4th vaccines to enhance dendritic differentiation.
45916866|NCT00000970|Drug|Ganciclovir|
45641975|NCT05538663|Drug|Gemcitabine|Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
45641976|NCT05538663|Drug|Docetaxel|Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
45641977|NCT05538663|Drug|Bacillus Calmette Guerin|intravesical once a week for 6 consecutive weeks during induction followed by weekly instillations for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 months
45641978|NCT05538312|Drug|ARV-471|Participants will receive a single dose of ARV-471 by mouth in Period 1 and Period 2, with a washout period of at least 10 days between doses of ARV-471
45916867|NCT00000973|Drug|Pyrimethamine|
45916868|NCT00000973|Drug|Leucovorin calcium|
45641979|NCT05538312|Drug|Itraconazole|Participants will receive itraconazole by mouth once a day for 11 days in Period 2.
45641980|NCT05537519|Biological|Phage Therapy|3-phage cocktail comprised of HP3, HP3.1 and ES19
45916869|NCT00000973|Drug|Zidovudine|
45916870|NCT05639049|Device|Enova GF3|Enova GF3, monofocal IOL
45916871|NCT05639049|Device|Tecnis 1-piece ZCB00|Tecnis 1-piece ZCB00, monofocal IOL
45916872|NCT00000985|Drug|Vidarabine|
45916873|NCT00000985|Drug|Acyclovir|
45916874|NCT00000985|Drug|Foscarnet sodium|
45916875|NCT00001000|Drug|Ampligen|
45916876|NCT00001003|Drug|Pentamidine isethionate|
45916877|NCT00001003|Drug|Zidovudine|
45641981|NCT05534984|Drug|Tecovirimat Oral Capsule|"Drug: Tecovirimat Oral capsules~Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg every 12 hours for 14 days~Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days"
45641982|NCT05534984|Drug|Placebo|"Drug: Placebo Oral capsules~Participants weighing 25 kg to less than 40 kg - Placebo for Tecovirimat 400 mg every 12 hours for 14 days~Participants weighing 40 kg to less than 120 kg - Placebo for Tecovirimat 600 mg every 12 hours for 14 days~Participants weighing 120 kg and over - Placebo for Tecovirimat 600 mg every 8 hours for 14 days"
45916878|NCT00001021|Biological|rgp120/HIV-1IIIB|
45916879|NCT00001021|Biological|rgp120/HIV-1MN|
45916880|NCT05639088|Behavioral|Transition preparation program|"AYA will participate in virtual or in-person sessions with a transition coach and receive bi-weekly messages that encourage self-management.~Caregivers will attend a virtual or in-person session with a transition coach."
45916881|NCT05639088|Other|Educational materials|AYA and caregivers will receive educational materials regarding healthcare transition and diabetes management monthly for 6 months
45916882|NCT03474445|Procedure|Volar Plate Osteosynthesis Aptus 2.5|Volar plating of distal radius fracture. Device: Aptus 2.5
45916883|NCT03474445|Procedure|Volar Plate Osteosynthesis Inteos 2.5|Volar plating of distal radius fracture. Device: Inteos 2.5
45916884|NCT00001030|Drug|Clarithromycin|
45916885|NCT00001030|Drug|Rifabutin|
45916886|NCT05639127|Drug|Prednisolone|Nebulization of prednisolone
45916887|NCT00001033|Drug|Ethambutol hydrochloride|
45916888|NCT00001033|Drug|Isoniazid|
45916889|NCT00001033|Drug|Pyrazinamide|
45916890|NCT00001033|Drug|Pyridoxine hydrochloride|
45916891|NCT00001033|Drug|Levofloxacin|
45916892|NCT00001033|Drug|Rifampin|
45916893|NCT00001036|Drug|Thymalfasin|
45916894|NCT00001036|Drug|Interleukin-2, Polyethylene Glycolated|
45916895|NCT00001036|Drug|Zidovudine|
45916896|NCT00001045|Drug|Nevirapine|
45916897|NCT00001045|Drug|Zidovudine|
45916898|NCT00001045|Drug|Didanosine|
45916899|NCT05639244|Behavioral|Time restricted eating (TRE)|Participants have to consume their regular food intake during a 6 hour period per day for 2 weeks.
45641983|NCT05534984|Drug|Tecovirimat Oral Capsule (Open Label)|"Participants weighing 4 to <6kg and >7 days old - Tecovirimat 50mg every 12 hours for 14 days~Participants weighing 2.5 to <4kg and >7 days to <4 weeks old - Tecovirimat 20 mg every 12 hours for 14 days~Participants weighing 4 to <6kg and ≤7 days old - Tecovirimat 50mg every 24 hours for 14 days~Participants weighing 2.5 to <4 kg and ≤7 days old - Tecovirimat 20mg every 24 hours for 14 days~Participants weighing 6 kg to less than 13 kg - Tecovirimat 100 mg every 12 hours for 14 days~Participants weighing 13 kg to less than 25 kg - Tecovirimat 200 mg every 12 hours for 14 days~Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg (2 capsules) every 12 hours for 14 days~Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days"
45641984|NCT05533775|Drug|Obinutuzumab|Participants will receive intravenous (IV) obinutuzumab pretreatment on Days 1 and 2 of Cycle 1 (Cycle length = 21 days)
45780626|NCT00601952|Behavioral|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
45780627|NCT00601952|Behavioral|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
45641985|NCT05533775|Drug|Glofitamab|"Arm A: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of Cycles 2 and 3~Arm B: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of each cycle thereafter~(Cycle length = 21 days)"
45780628|NCT00693992|Other|Laboratory Biomarker Analysis|Correlative studies
45780629|NCT00693992|Other|Placebo|Given PO
45780630|NCT00693992|Other|Quality-of-Life Assessment|Ancillary studies
45780631|NCT00693992|Drug|Sunitinib Malate|Given PO
45780632|NCT00645710|Drug|gemcitabine hydrochloride|Given IV
45780633|NCT00645710|Drug|floxuridine|Given via hepatic arterial infusion
45916900|NCT05639244|Behavioral|Regular diet|Participants have to consume their regular diet within an unrestricted time period for 2 weeks
45916901|NCT00001048|Drug|Filgrastim|
45916902|NCT00001048|Drug|Cytarabine|
45916903|NCT00001048|Drug|Zidovudine|
45916904|NCT00001048|Drug|Zalcitabine|
45641986|NCT05533775|Drug|Rituximab|Participants will receive IV rituximab on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
45916905|NCT00001048|Drug|Didanosine|
45641987|NCT05533775|Drug|Ifosfamide|Participants will receive IV ifosfamide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
45641988|NCT05533775|Drug|Carboplatin|Participants will receive IV carboplatin on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
45641989|NCT05533775|Drug|Etoposide|Participants will receive IV etoposide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
45780634|NCT00645710|Genetic|proteomic profiling|Correlative studies
45780635|NCT00645710|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
45780636|NCT00645710|Other|liquid chromatography|Correlative studies
45780637|NCT00645710|Radiation|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Given IV
45780638|NCT00645710|Other|laboratory biomarker analysis|Correlative studies
45780639|NCT00645710|Other|mass spectrometry|Correlative studies
45780640|NCT00645710|Other|pharmacological study|Correlative studies
45780641|NCT00603044|Drug|fluticasone furoate|treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy
45780642|NCT00603902|Drug|Lorcaserin 10 mg once daily (QD)|Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
45780643|NCT00603902|Drug|Lorcaserin 10 mg twice a day (BID)|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
45780644|NCT00603902|Drug|Matching Placebo|Matching placebo tablet each morning and evening for a duration of 52 weeks.
45780645|NCT00646646|Drug|propofol|sedative
45780646|NCT00646646|Drug|dexmedetomidine|Sedative
45916906|NCT00001066|Drug|Lamivudine|
45916907|NCT00001066|Drug|Zidovudine|
45916908|NCT00001066|Drug|Didanosine|
45916909|NCT00001075|Drug|Ritonavir|
45780647|NCT00646646|Drug|Midazolam|sedative
45780648|NCT00646646|Drug|saline placebo|saline placebo
45780649|NCT02998658|Device|Vaginal cuff closure using barbed sutures|Vaginal cuff will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA )
45916910|NCT00001075|Drug|Lamivudine|
45916911|NCT00001075|Drug|Zidovudine|
45916912|NCT00001084|Drug|Indinavir sulfate|
45916913|NCT00001084|Drug|Lamivudine|
45916914|NCT00001084|Drug|Stavudine|
45916915|NCT00001084|Drug|Zidovudine|
45916916|NCT00001087|Drug|Ritonavir|
45916917|NCT00001087|Drug|Nelfinavir mesylate|
45916918|NCT00001087|Drug|Efavirenz|
45916919|NCT00001087|Drug|Levocarnitine|
45916920|NCT00001087|Drug|Adefovir dipivoxil|
45916921|NCT00001087|Drug|Saquinavir|
45916922|NCT00001087|Drug|Lamivudine|
45916923|NCT00001087|Drug|Stavudine|
45916924|NCT00001087|Drug|Zidovudine|
45916925|NCT00001087|Drug|Zalcitabine|
45916926|NCT00001087|Drug|Didanosine|
45916927|NCT00001105|Drug|F105 Monoclonal Antibody (Human)|
45780650|NCT02998658|Device|Vaginal cuff closure using conventional sutures|Vaginal cuff will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
45780651|NCT02998424|Drug|Propofol|Continuous infusion
45780652|NCT02998424|Device|Pupillary diameter measurement|Instantaneous measure
45780653|NCT00696488|Drug|Fluorouracil 0.5%|Subjects will apply the smallest amount of study medication possible that is just sufficient to cover all of the affected areas daily to AK lesions
45641990|NCT05533775|Drug|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
45780654|NCT00648908|Drug|Fampridine-SR|Tablets, 10 mg, BID
45780655|NCT00697190|Device|senofilcon A toric|silicone hydrogel contact lens for patients with astigmatism
45641991|NCT05531526|Drug|AR1001|AR1001 Active Oral Tablet
46070555|NCT04099628|Diagnostic Test|Rapid diagnostic test (RDT); Serological and molecular tests on DBS|"The population of low to zero prevalence HAT foci will be actively screened for HAT by taking a blood sample for performing 3 rapid diagnostic tests (RDT) and for preparing dried blood spots to perform 4 serological and molecular high throughput reference tests. If at least one of the RDTs, serological or molecular reference tests is positive, parasitological examination is performed twice. The combined results of parasitological examinations serve as reference standard.~Other Names:~rHAT Sero-Strip (Coris Bioconcept, Belgium) SD Bioline HAT 1.0 (Standard Diagnostics Korea) HAT Sero-K-Set (Coris Bioconcept, Belgium) Immune trypanolysis: presence of antibodies ELISA: on native LiTat 1.3 + LiTat 1.5 variant surface glycoprotein (VSG) LAMP T. brucei Detection Kit (Eiken) RT-PCR: Trypanozoon 18S, Tbg Trypanosoma gambiense specific glycoprotein (TgsGP)"
45780656|NCT00697190|Device|galyfilcon A toric|silicone hydrogel contact lens for patients with astigmatism
45780657|NCT02998112|Drug|fecal microbiota transplantation|Fecal microbiota which was purified from fresh stool defecated by a healthy donor
45780658|NCT02998112|Drug|Saline|
45780659|NCT00650078|Drug|MR prednisone|1 x 5 mg daily
46070556|NCT04385108|Biological|Blood collection on admission and longitudinally|33 mL of blood collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)
45641992|NCT05531526|Drug|Placebo|Placebo Oral Tablet
45641993|NCT05529862|Genetic|Pre-treatment biopsy|Pre-treatment fragments will be collected during the biopsy visit organised as part of routine medical practice, prior to the start of treatment with ribociclib + ET
45641994|NCT05529862|Genetic|Post treatment biopsy|Post-treatment fragments will be collected during a biopsy visit specifically planned for Trans-RosaLEE study.
45780660|NCT00650078|Drug|Placebo|1x daily
45780661|NCT00699140|Biological|IGIV3I Grifols|Immune Globulin Intravenous (Human)
45641995|NCT05529862|Genetic|Pre treatment blood sampling|Sampling of 4 EDTA Tubes (4ml) and 2 Streck tubes (10ml)
45641996|NCT05529862|Genetic|Post treatment blood sampling|Sampling of 2 Streck tubes (10ml)
45641997|NCT05529277|Other|Dementia Care Management|Comprehensive assessment of health care needs of person with cognitive impairment and caregiver followed by algorithm-/ and person-based support in health care planning, implementing and monitoring
45780662|NCT01799486|Drug|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
45780663|NCT01799486|Drug|Enecavir|0.5 mg monotherapy supplied in tablets.
45780664|NCT01799486|Drug|Adefovir|10 mg monotherapy supplied in tablets.
45780665|NCT02320838|Device|5 KHz|5 KHz transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
45780666|NCT02320838|Device|TENS|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
45780667|NCT02320838|Device|Sham stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
45780668|NCT00650546|Drug|Exenatide|5 mcg twice a day titrated to 10 mcg twice a day
45916928|NCT00001111|Drug|Nevirapine|
46070557|NCT04385108|Biological|Blood collection on their first consultation and 10 to 14 days later|33 mL of blood collected on their first consultation and 10 to 14 days later
46070558|NCT00910988|Drug|Olanzapine|olanzapine/Zyprexa
46070559|NCT00910988|Drug|Ziprasidone|ziprasidone/Geodon
45641998|NCT05529043|Behavioral|MINISTOP app|The MINISTOP app is a behavioural change program aiming to promote healthier diet and physical activity behaviours in pre-school children. The program consists of features such as information, monitoring and feedback (dietary variables, physical activity, and screen time) and it is built around 13 themes. The participants will have access to the app for 12-months.
45780669|NCT02998190|Drug|Single Ascending Doses of EB8018|
45780670|NCT02998190|Drug|Single Ascending Doses of placebo|
45780671|NCT02998190|Drug|Multiple Ascending Doses of EB8018|
45780672|NCT02998190|Drug|Multiple Ascending Doses of placebo|
45780673|NCT00699218|Device|Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.|High frequency repetitive TMS given daily on weekdays for 3 weeks
45780674|NCT01386710|Drug|Bevacizumab and Carboplatin|"Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier~Day 28: Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until progression on MRI scan.~Repeat Cycle"
45780675|NCT01386710|Drug|Bevacizumab and Carboplatin|"Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier~Day 28: No biweekly IV Bevacizumab plus Carboplatin treatment~If MRI shows progression then repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression Repeat Cycle"
45780676|NCT00650858|Drug|tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)|0.3 mg and 1.0 mg of rt-PA (Cathflo) were administered every 12 hours (dose finding) and every 8 hours (dose frequency) via the intraventricular catheter to treat intraventricular hemorrhage.
45780677|NCT00650936|Device|AMPLATZER Septal Occluder|AMPLATZER Septal Occluder
45780678|NCT00651482|Drug|Everolimus|
45916929|NCT00001111|Drug|Zidovudine|
45780679|NCT00651482|Drug|Bevacizumab|
45641999|NCT05529043|Behavioral|MINISTOP Plus Program|Consists of the MINISTOP app and the Community Group Mini. The Community Group Mini consists of group activities to promote physical activity for both children and parents. The Community Group Mini will meet once per week in different playgrounds and nature reserves and will be organized by a trained group leader.
45780680|NCT02998034|Device|Uncemented Furlong Hemiarthroplasty|A furlong uncemeneted hyroxyapatite coated prosthesis.The hydroxyapatite stimulates bone ingrowth around the prosthesis and is this is thought to reduce loosening of the implant, residual pain and the long-term revision rate.
45780681|NCT02998034|Device|Cemented tapered stem hemiarthroplasty|A cemented double tapered stem hemiarthroplasty
45780682|NCT00651794|Behavioral|Teamwork training|Crew Resource Management (CRM) is an aviation training program mandated for all crew members that teaches human factors concepts, communication skills, and teamwork behaviors that can prevent and manage error. Over the last six years the study team has translated these behaviors to neonatal resuscitation and demonstrated that they can be reliably measured. Adding teamwork instruction to the existing NRP, based upon CRM, may be a method to improve communication, teamwork, and the overall quality of neonatal resuscitation.
45780683|NCT00651794|Behavioral|Standard NRP curriculum|The existing NRP course, taught to most caregivers in the United States who care for newborns, focuses on teaching the technical aspects of neonatal resuscitation with little attention paid to communication and teamwork.
45780684|NCT00651794|Behavioral|Skills practice with low-fidelity mannequin|
45780685|NCT00651794|Behavioral|Skills practice with high-fidelity mannequin|SimBaby mannequins (Laerdal Medical Corp, Stavanger, Norway) were used in the high-fidelity skills stations. These mannequins have simulated heart tones, breath sounds, pulses, and cries.
45642000|NCT05527015|Device|Bifocal Spectacles|Bifocals with a +3.00 Diopter flat top 35
45642001|NCT05527015|Device|Single Vision Lenses|Single vision lens as prescribed by provider
45642002|NCT05521919|Behavioral|Sympathetic Nervous System Activation|Participants will complete a task that increases sympathetic nervous system activation.
45642003|NCT05521919|Behavioral|No-stress|Participants will complete a task that will not affect their sympathetic nervous system activity.
45642004|NCT05521191|Drug|RGLS8429|Solution for subcutaneous injection
45780686|NCT01560182|Genetic|OTL-200 Gene Therapy|Autologous hematopoietic stem/progenitor cells collected from the bone marrow and transduced ex vivo with a Lentiviral vector encoding the human ARSA cDNA
45780687|NCT02997956|Drug|Tocilizumab|Participants will receive Tocilizumab (ACTEMRA®) at 4, 6, or 8 mg/kg IV dose escalation on days 1, 29 and 57.
45780688|NCT02997956|Procedure|Transcatheter Arterial Chemoembolization|Minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
45780689|NCT00654836|Biological|bevacizumab|Participants will receive bevacizumab 15 mg/kg on days 1,22, and 43.
45780690|NCT00654836|Drug|Carboplatin|Participants will receive a standard carboplatin dose according to their area under the plasma drug concentration-time curve (AUC-6) on days 1, 22, and 43.
45780691|NCT00654836|Drug|ABI-007|Participants will receive ABI-007 (Abraxane) 100mg/m2 on days 1,8, 15, 22, 29, 36,43,and 50.
45642005|NCT05521191|Drug|Placebo|Solution for subcutaneous injection
45780692|NCT02997800|Drug|Esmolol|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of esmolol 30 mg IV (30 mg in 5 ml of normal saline). An intravenous esmolol infusion will be initiated at 5mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5mcg/kg/min each time HR or MAP >20% of baseline. An intravenous bolus of placebo (normal saline 1 ml) will be administered whenever a change to the infusion rate is made.
45780693|NCT02997800|Drug|Labetalol|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of labetalol 10 mg IV (10 mg in 5 ml of normal saline). Any further increases in HR or MAP >20% of baseline will be treated with intravenous boluses of labetalol 5 mg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
45916930|NCT00001114|Drug|Interferon alfa-2b|
45448764|NCT03545542|Diagnostic Test|Initial fecal volatile organic compounds|Volatile organic compound analysis of stool samples by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
45642006|NCT05520593|Dietary Supplement|Complex Carbohydrate Drink|Patients will drink a complex carbohydrate drink 3 hours before surgery. Drink to be given at the preoperative holding area.
45642007|NCT05518708|Drug|BI 3032950|BI 3032950
45642008|NCT05518708|Drug|Placebo|Placebo
45642009|NCT05517902|Biological|StrataGraft|StrataGraft® Construct
45642010|NCT05516498|Drug|Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
45642011|NCT05516498|Drug|Part A: zibotentan (dose B) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
45642012|NCT05516498|Drug|Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
45642013|NCT05516498|Drug|Part B: placebo (matching zibotentan capsule) + dapagliflozin|"placebo capsule (matching zibotentan capsule)~dapagliflozin tablet"
45642014|NCT05516498|Drug|Part B: zibotentan (dose A) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
45916931|NCT00001114|Drug|Didanosine|
45916932|NCT00001144|Drug|Modified bone marrow stem cell transplantation|
45642015|NCT05516498|Drug|Part B: zibotentan (dose B) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
45642016|NCT05516498|Drug|Part B: zibotentan (dose C) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
45642017|NCT05516316|Drug|EP395|Capsule for oral use
45642018|NCT05516316|Drug|Placebo|Capsule for oral use
45916933|NCT00001165|Drug|combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin|
46070560|NCT00644059|Biological|Adjuvanted trivalent inactivated subunit influenza vaccine|Either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
45916934|NCT05639439|Device|"Ventilation using the Fastrach intubating laryngeal mask airway and glottic view using fibrescope - Group A"|"Insertion of the intubating laryngeal airway device Fastrach, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
45780694|NCT02997800|Drug|Fentanyl|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of fentanyl 50 mcg IV (50 mcg in 5 ml of normal saline). Any further increases in HR or MAP >20% of baseline will be treated with intravenous boluses of fentanyl 25 mcg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
45780695|NCT02997800|Other|saline infusion|An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus drug dose (fentanyl or labetalol depending upon randomization) and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
45780696|NCT02997800|Other|1 ml saline infusion|Every time the infusion rate of esmolol is changed, 1 ml of normal saline will be infused.
45780697|NCT02997644|Behavioral|Video Education|"The content of the education focuses on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage.~The consent, enrollment, and video education will take about 20-30 minutes for patients in this group, and occur at the end of their preoperative visit. The patient will watch the video on a portable Tablet computer."
45780698|NCT02997644|Behavioral|Usual Care Group|Patients that are randomized to usual care will only receive the regular instructions about opioid usage they typically receive from their surgeon.
45642019|NCT05515393|Drug|XY03-EA|The sample size was 420 patients, and 140 patients were treated with XY03-EA 300 mg, 600 mg and placebo respectively. The 300-mg group took two tablets of placebo and two tablets of XY03-EA once, three times a day. The 600-mg group took four tablets of XY03-EA once, three times a day. The placebo group took four tablets of placebo once ,three times a day.
45642020|NCT05515393|Drug|XY03-EA Placebo|XY03-EA Placebo
45642021|NCT05514340|Drug|Normal Saline along with standard treatment|Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm normal saline along with standard treatment will be given for active comparison.
45780699|NCT00701636|Drug|daptomycin|Subjects enrolled in the intervention group will receive a single intravenous administration of daptomycin 8 mg/kg 30-60 minutes prior to surgery (incision). The 500 mg vial will be reconstituted with 10 mL of 0.9% normal saline (NS) and further diluted in 50 mL of 0.9% NS to be given over a 30 minute infusion.
45780700|NCT00701714|Drug|HX575 recombinant human erythropoietin alfa|Solution for injection (s.c.)
45642022|NCT05514340|Drug|Sovateltide along with standard treatment|Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm sovateltide along with standard treatment will be given for active comparison.
45780701|NCT00701714|Drug|ERYPO|Solution for injection (s.c.)
45780702|NCT00655538|Drug|Placebo|po daily for 36 weeks
45780703|NCT00655538|Drug|dalcetrapib|600mg po daily for 36 weeks
45780704|NCT00656630|Drug|Acamprosate|Two 333mg capsules, 3 times daily (Total dose, 1998 mg daily), 1 week duration
46070561|NCT00644059|Biological|Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine|For both vaccines, either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
46070562|NCT00644059|Biological|Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine|"Meningococcal vaccine: two IM injections~Tick-borne encephalitis vaccine: two IM injections"
45642023|NCT05512819|Biological|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
45642024|NCT05512819|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
45780705|NCT00656630|Drug|Naltrexone|50mg capsule, Once daily, 1 week duration
45642025|NCT05511038|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Injection, 2mg (equivalent to 50 µL solution for injection)
45780706|NCT00656630|Drug|Placebo|Matched placebo capsule, 1 week duration
45780707|NCT02994914|Other|Onco Geriatric Evaluation|"Seven tests will be performed by an onco geriatrician : Activities of Daily Living, Instrumental Activities Of Daily Living, Mini Mental State Examination, mini Geriatric Depression Scale, Mini Nutritional Assessment, Cumulative Illness Rating Scale-Geriatric, and  timed get up and go  tests. Those tests lead to a score, and this score will determine the scheme of patients radiotherapy."
45642026|NCT05509049|Other|Precision nudging|Precision nudging (i.e., the application of behavioral science and reinforcement learning to create individualized, tailored health messaging at scale that matches the right message to the right person at the right time)
45642027|NCT05509049|Other|Standard of care|Standard of care communication (e.g., personalized letters and patient portal notices)
45642028|NCT05507515|Drug|ONO-2020|ONO-2020 tablets
45780708|NCT01362998|Drug|Preservative free morphine|3mg given epidurally during the Cesarean section.
46070563|NCT00817687|Drug|mycophenolate mofetil [CellCept]|As prescribed; + early biopsy
46070564|NCT00817687|Drug|mycophenolate mofetil [CellCept]|As prescribed; + standard treatment
46070565|NCT00811993|Drug|RG1507|Starting dose of >=3mg/kg iv escalating to a maximum dose of <=16mg/kg iv, depending on dosing schedule in each combination treatment arm
46070566|NCT00811993|Drug|RO1507|27mg/kg iv, monotherapy
46070567|NCT00811993|Drug|bevacizumab [Avastin]|as prescribed
46070568|NCT00811993|Drug|capecitabine [Xeloda]|as prescribed
46070569|NCT00811993|Drug|carboplatin|as prescribed
46070570|NCT00811993|Drug|cetuximab|as prescribed
46070571|NCT00811993|Drug|docetaxel|as prescribed
46070572|NCT00811993|Drug|erlotinib [Tarceva]|as prescribed
45642029|NCT05507515|Drug|Placebo|Placebo tablets matching ONO-2020 tablets
45780709|NCT01362998|Drug|Fentanyl|An infusion of epidural fentanyl started during the Cesarean section. It will be given on a patient controlled analgesia basis, with a basal rate of 60 micrograms, a demand dose of 16 micrograms, and a lockout of 15 mins.
45780710|NCT04387526|Drug|(SOF and DCV)|
45642030|NCT05507476|Drug|Desmopressin Acetate Nasal, 10 μg/0.1 ml per spray|The patient will receive two puffs of desmopressin acetate 10 µg/puff in the side of the nasal cavity ipsilateral to the obstructed lacrimal duct (20 μg totally) 60 minutes before surgery.
45780711|NCT04387526|Drug|(SOF, DCV, and RBV)|
45780712|NCT02997566|Other|Autonomic evaluation|
45780713|NCT02997488|Device|Pentax Airwayscope|intubation using Pentax Airwayscope
45780714|NCT02997488|Device|McGrath Videolaryngoscope|intubation using McGrath Videolaryngoscope
45780715|NCT00658112|Drug|Benzoyl Peroxide|Benzoyl peroxide 5% gel. Applied once daily to face, minimum amount usable to cover area. Every day for six weeks.
45780716|NCT02997332|Drug|Durvalumab|Durvalumab will be administered every 3 weeks for 3 injections at week 1, 4, 7. Dose levels: the durvalumab first dose level is 1120 mg Q3W, and the dose level -1 is 750 mg Q3W.
45780717|NCT02997332|Drug|Docetaxel|Docetaxel 75mg/m² on D2, IV in 1 hour
45780718|NCT02997332|Drug|Cisplatin|Cisplatin 75mg/m² on D2, IV in 3 hours
45780719|NCT02997332|Drug|5 Fluorouracil|5 Fluorouracil 750mg/m²/day on D2, D3, D4, D5, D6 IV in 24 hours
45780720|NCT04345094|Other|Hexylresourcinol|Emulsion containing hexylresorcinol as an active
45780721|NCT04345094|Other|Hydroquinone|Emulsions containing hydroquinone as an active
45780722|NCT00702884|Drug|sunitinib malate|Sunitinib 37.5 mg daily for a 4 week cycle
45916935|NCT05639439|Device|"Ventilation using the Proseal laryngeal mask airway and glottic view using fibrescope- Group B"|"Insertion of the laryngeal airway device Proseal, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
45916936|NCT05639439|Device|"Ventilation using the I-gel supraglottic airway device and glottic view using fibrescope- Group C"|"Insertion of the supraglottic airway device I-gel, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
45642031|NCT05507476|Drug|Epinephrine topical 1:100,000 Nasal Packs|The patient will receive topical 1:100,000 epinephrine in the side of the nasal cavity ipsilateral to the obstructed lacrimal gland via 3 soaked packs placed in the middle meatus for 5 minutes immediately before the start of surgery.
45642032|NCT05507450|Biological|V181 High-Potency Level|0.5 mL SC dose of V181 High-Potency vaccine
45642033|NCT05507450|Biological|V181 Mid-Potency Level|0.5 mL SC dose of V181 Mid-Potency vaccine
45642034|NCT05507450|Biological|V181 Low-Potency Level|0.5 mL SC dose of V181 Low-Potency vaccine
45642035|NCT05507450|Biological|Placebo|0.5 mL SC dose of placebo
45780723|NCT00703508|Drug|Metformin 500 mg tablet|Metformin 500 mg tablets; two tablets every 12 hours for 9 months
45780724|NCT01284335|Drug|Gemcitabine|1000 mg/m2 administered intravenously on Days 1 and 15 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
45642036|NCT05507138|Device|AKL-T01|AKL-T01 is an iPad-based video game designed to improve executive dysfunction and depression symptoms by targeting executive skills (multitasking) and ECN abnormalities.
45642037|NCT05507138|Behavioral|Metacognitive Strategy Training|Metacognitive Strategy Training involves working with a clinician (neuropsychologist or occupational therapist) to learn strategies to manage cognitive difficulties
45642038|NCT05505838|Drug|Patisiran|Patisiran administered by intravenous (IV) infusion
45780725|NCT01284335|Drug|Docetaxel|60 mg/m2 administered intravenously over 60 minutes on Day 1 of the 28-day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
45642039|NCT05503797|Drug|FORE8394|Oral tablets
45642040|NCT05503797|Drug|Cobicistat|Oral tablets
45642041|NCT05502757|Other|Fruit and vegetable provision|Fresh fruits and vegetables are provided to families at no cost
45780726|NCT01284335|Drug|Temozolomide|200 mg/m2 administered orally on days 1-5 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
45780727|NCT01284335|Drug|Cisplatin|75 mg/m2 administered intravenously on Day 1 of the 28-day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
45780728|NCT01284335|Drug|Erlotinib|150 mg administered orally days 1-28 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
45780729|NCT01284335|Drug|LY573636|Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.
45780730|NCT01230125|Drug|Mapracorat|Instill study medication into study eye per dosing instructions for 14 days
45780731|NCT01230125|Drug|Vehicle|Instill study medication into the study eye per dosing instructions for 14 days
45780732|NCT01194479|Drug|Formoterol|Formoterol inhaler, 12mcg capsules, 4 capsules for one administration
45780733|NCT01194479|Other|Placebo|Participants in both arms received placebo on 1 of the 2 visits.
45916937|NCT05639439|Device|"Ventilation using the Protector laryngeal airway device and glottic view using fibrescope- Group D"|"Insertion of the laryngeal airway device Protector, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
45916938|NCT00001180|Drug|Ovine Corticotropin-Releasing Hormone (oCRH)|
45916939|NCT00389272|Drug|Ibuprofen, acetaminophen|
45916940|NCT00389311|Drug|Normosol-R|
45916941|NCT00389311|Drug|Nonoxynol-9|
45916942|NCT00389311|Procedure|Gastrointestinal instrumentation|
45916943|NCT00389350|Drug|Extract of Green and Black Tea|
45916944|NCT00001213|Drug|Cysteamine|
45916945|NCT00001234|Genetic|human glucocerebrosidase cDNA|
45916946|NCT00000114|Drug|Vitamin E|
45916947|NCT00000114|Drug|Vitamin A|
45916948|NCT00001255|Drug|ADA PBSC|
45916949|NCT00001255|Drug|ADA Umbilical Cord Blood Cells|
45780734|NCT01230593|Drug|Hot Compress plus Tobramycin Drops and Ointment|In addition to hot compress, Tobramycin drops will be given to the affected eye 3x/day, and Tobramycin ointment will be given at night before bed.
45780735|NCT01230593|Drug|Hot compress plus Tobramycin/Dexamethasone Drops and Ointment|In addition to hot compress, Tobramycin/Dexamethasone drops will be given to the affected eye 3x/day, and Tobramycin/Dexamethasone ointment will be given at night before bed.
45780736|NCT01230593|Other|Hot Compresses|Hot compresses 3x/day to eyelids
45642042|NCT05501873|Device|FARAPULSE Pulsed Field Ablation system|Any subject who has signed the informed consent and for whom the FARAPULSE Pulsed Field Ablation system has been inserted into the body, and pulsed field ablation treatment has been received, are assigned to the treatment group.
45780737|NCT01195025|Drug|acetated Ringers|Infusion of Ringer acetate 20 ml/kg over 30 min
45780738|NCT01195025|Drug|colloid|Infusion of starch 10 ml/kg over 30 min
45780739|NCT01195025|Drug|colloid+acetated Ringer|Infusion of combined colloid+acetated Ringer; 10 ml/kg of starch was infused between 0 and 30 min, followed by 20 ml/kg of Ringers acetate between 105 and 135 min.
45448765|NCT03545542|Diagnostic Test|Initial breath volatile organic compounds|Breath sampling for organic compound analysis by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
45780740|NCT01195025|Device|Non-invasive hemoglobin with pulse-oximeter (SpHb)|Non-invasive hemoglobin with pulse-oximeter (SpHb) was measured in all subjects, during all infusions.
45780741|NCT03009695|Device|High frequency repetitive dTMS|Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically high-frequency rTMS (18 Hz) enhances cortical excitability.
45780742|NCT03009695|Device|Low frequency repetitive dTMS|Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically low-frequency rTMS (1 Hz) inhibits cortical excitability.
45916950|NCT00001255|Drug|Transduced Lymphocytes|
45916951|NCT00001261|Drug|Gamma Globulin|
45916952|NCT00001267|Drug|zidovudine|
45448766|NCT03545542|Diagnostic Test|Microbiome under chemotherapy|Stool sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to Société Internationale d´Onclogie Pediatrique Neuroblastoma Group (SIOPEN) guidelines
45448767|NCT03545542|Diagnostic Test|Fecal volatile organic compounds under chemotherapy|"Stool sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group"
45448768|NCT03545542|Diagnostic Test|Breath volatile organic compounds under chemotherapy|"Breath sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group"
45916953|NCT00001267|Drug|2',3'-dideoxyinosine|
45916954|NCT00001303|Drug|Reference Endotoxin|
45916955|NCT00001303|Drug|Inhaled Nitric Oxide|
45916956|NCT00000120|Drug|Erythromycin Ointment|
45916957|NCT00000120|Drug|Silver Nitrate Drops|
45916958|NCT00001333|Drug|topotecan|
45916959|NCT00000129|Procedure|Radial Keratotomy|
45916960|NCT03444727|Other|Ice Pre-treatment|Topical application of ice prior to local anesthetic injection.
45916961|NCT03444727|Other|Room Temperature Water Pre-treatment|Topical application of room-temperature water prior to local anesthetic injection.
45916962|NCT00000135|Drug|MSL-109|60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
45916963|NCT00000135|Other|Placebo|60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
45916964|NCT00001378|Drug|fenretinide|
45916965|NCT00001387|Drug|paclitaxel|
45916966|NCT00001396|Device|Paragon Pacemaker|
46070573|NCT00811993|Drug|etoposide|as prescribed
45448769|NCT03545542|Diagnostic Test|Final microbiome|Stool sampling 3 weeks after completion of chemotherapy Neuroblastoma group
45642043|NCT05501756|Drug|Alemtuzumab|Alemtuzumab (Campath®) is a recombinant DNA-derived humanized monoclonal antibody directed against CD52. Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Neomycin is not detectable in the final product. Alemtuzumab is a sterile, clear, colorless, isotonic pH 6.8-7.4 solution for injection. Alemtuzumab is supplied in single-use clear glass ampules containing 30 mg of Alemtuzumab in 3 mL of solution. A single use vial of alemtuzumab contains 30 mg alemtuzumab, 8 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate.
45916967|NCT00388557|Drug|vinflunine + ketaconazole|vinflunine solution for injection, ketaconazole tablets, vinflunine IV, ketaconazole oral, vinflunine 80 to 320mg/m2 + ketaconazole 400 mg, vinflunine every 3 wks, ketaconazole C1 only, variable duration
45916968|NCT00001399|Drug|Transduced CD34+ Cells|
45916969|NCT00001402|Device|PET scan|
45916970|NCT00388596|Drug|SB-751689|
45916971|NCT00388635|Drug|Velcade|Phase I: Velcade, 1.0mg/m2-1.3mg/m2 in escalating doses every 6 weeks for 4 cycles Pase II: Velcade at optimal doses, twice a week (days 1, 4, 8, 11, 22, 25, 28 and 32) follow a rest period for 10 days (days 33 to 42)
45916972|NCT00388635|Drug|Melphalan|Melfalán 9mg/m2 days 1 to 4, V.O, follow by a rest period of 38 days in phse I and II
46070574|NCT00811993|Drug|gemcitabine|as prescribed
45780743|NCT03009695|Device|Sham|Sham stimulation will be performed by an H-sham-coil. The H-sham-coil is designed to mimic the auditory artifacts and the scalp sensation evoked by the real coil, without stimulating the brain itself. As in the other groups, in each patient the rMT will be determined before each repetitive dTMS session. The sham stimulation will be performed either at high frequency (50% of subjects) or at low-frequency (50% of subjects), according to the previously described methodologies. All obese people in this group will be submitted at the sight of food preferred (cue).
45780744|NCT03009851|Behavioral|OBCHI|Occupation-based cultural heritage intervention emphasizing the cultural background of residents in LTC settings.
45780745|NCT01286441|Drug|10% EISO|During the Treatment Period, subjects will apply study medication (10% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
45780746|NCT01286441|Drug|Placebo|During the Treatment Period, subjects will apply placebo to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
45780747|NCT01286441|Drug|20% EISO|During the Treatment Period, subjects will apply study medication (20% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
45780748|NCT01286441|Drug|30% EISO|During the Treatment Period, subjects will apply study medication (30% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
45780749|NCT01195883|Drug|Crystalloid|For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.
45780750|NCT01195883|Drug|Colloid|For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.
45780751|NCT01196117|Device|14 days of placebo therapy|14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
45780752|NCT01196117|Device|14 days of CPAP therapy|14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
46070575|NCT00811993|Drug|irinotecan|as prescribed
45448770|NCT03545542|Diagnostic Test|Final fecal volatile organic compounds|Stool sampling 3 weeks after completion of chemotherapy Neuroblastoma group
45642044|NCT05501366|Dietary Supplement|Ketone Supplement|Four different exogenous ketone products at two serving sizes or a non-ketogenic placebo (one study product per test day). 1) Monoester of BHB (R)-1,3 butanediol (BHB Mono-ester), 2) diester of hexanoic acid (a ketogenic medium chain fatty acid) and (R)-1,3 butanediol (C6 Di-ester) 3) diester of AcAc and (R,S)-1,3 butanediol (AcAc Di-ester) & 4) (R) -1,3 butanediol only (BDO). All products will be delivered in 2 different dosages 180mg/kg and 360mg/kg on separate testing days.
45780753|NCT00703664|Drug|Bortezomib|Bortezomib: 1.3 mg/m^2/d IV days 1, 4, 8, and 11.
45780754|NCT00703664|Other|Laboratory Biomarker Analysis|Correlative studies
45780755|NCT00703664|Drug|Vorinostat|Vorinostat: 400 mg (total daily dose as a single dose) days 1-5 and 8-12.
45780756|NCT03009929|Other|Observational study|No intervention, observational only
45780757|NCT00658736|Drug|Triamcinolone|Injection of bupivacaine and triamcinolone
45780758|NCT00658736|Drug|Bupivicaine alone|Injection of bupivacaine
45780759|NCT01196819|Device|Firehawk|Implantation of Firehawk drug eluting stent
45780760|NCT01196819|Device|Xience V|Implantation of Xience V drug eluting stent
45780761|NCT04387058|Device|TIPS|TIPS (Transjugular Intrahepatic Portosystemic Shunt) is an interventional radiology method that creates an anastomosis between the portal venous network and the hepatic venous network.
45780762|NCT01799564|Procedure|Micropulse|Between 1 and 3 sessions of micropulse laser will be applied in the inferior hemiretina of the randomly selected eye
45780763|NCT00659360|Drug|saracatinib|Given orally
45780764|NCT01197833|Drug|endovenous ablation+polidocanol injectable microfoam 0.125%|All components except API
45642045|NCT05501366|Behavioral|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale will be administered at beginning and end of testing day to tests palatability of supplement
45780765|NCT01197833|Drug|Endovenous ablation+polidocanol injectable microfoam 1.0%|endovenous ablation to target vein, followed by injection of polidocanol injectable foam 1.0%
45780766|NCT01197833|Drug|Endovenous ablation+polidocanol injectable foam 2.0%|Endovenous ablation to target vein followed by injection of polidocanol injectable foam 2.0%
46070576|NCT00811993|Drug|mFOLFOX6|as prescribed
46070577|NCT00811993|Drug|paclitaxel|as prescribed
46070578|NCT00811993|Drug|pemetrexel|as prescribed
46070579|NCT00811993|Drug|sorafenib|as prescribed
46070580|NCT00811993|Drug|temozolomide|as prescribed
46070581|NCT00811993|Drug|trastuzumab [Herceptin]|as prescribed
46070582|NCT00817765|Drug|Posaconazole|Posaconazole oral solution 40mg/mL; 400mg BID treatment for 10 days, including dose escalation
46070583|NCT00817765|Drug|Fosamprenavir|fosamprenavir tablet 700mg; 1 tablet BID for 10 days
46070584|NCT00817765|Drug|Ritonavir|Ritonavir 100mg capsule; 1 capsule BID for 10 days
45780767|NCT04270448|Behavioral|Motor Sequence Task|"Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear."
45780768|NCT04270370|Drug|LY3478045|Administered orally.
45780769|NCT04270370|Drug|Placebo|Administered orally.
45642046|NCT05501366|Biological|Blood Draw|IV cannula will be inserted at the start of each Test Day, and removed at the end of each Test Day, Blood samples will be collected according to the schedule in Figure 1. Cannula will be flushed with a small volume of saline after each sample to maintain patency. We will draw 504 mL of blood, which is about 2.1 cups throughout the 4-week intervention
45642047|NCT05501366|Other|Breath Reading|Participants will breathe into a commercially available handheld breath acetone analyzer according to the schedule. Participants will wear a fitted face mask attached to a metabolic cart for a 10-minute period every 60 minutes
45780770|NCT04270370|Drug|Atorvastatin|Administered orally.
45780771|NCT01288781|Drug|Acetazolamide|During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
45780772|NCT01288781|Drug|Lactose monohydrate|During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
45780773|NCT02990078|Drug|Sildenafil citrate|Sildenafil is a potent and specific PDE5 inhibitor, which was initially developed for the treatment of hypertension and angina. Its effectiveness as a treatment for male erectile dysfunction became apparent during Phase I clinical trials, and the focus of drug development shifted to this indication. In patients with cerebrovascular dysfunction, a few preliminary studies have used sildenafil to increase CVR. Participants in the pilot study had CVR tested in response to hypercapnia measured twice, at baseline and then 1 hour after administration of sildenafil citrate, 50 mg by mouth. The investigators have an IND exemption for the uses in this study.
45780774|NCT02990078|Device|Functional Near Infared Spectroscopy|Functional near-infrared spectroscopy (fNIRS) will be used to measure regional cerebral blood flow and cerebrovascular reactivity. are connected to the scalp and surrounding detectors a few cm away detect the light as it scatters through the underlying tissues. The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes.
45780775|NCT02990078|Other|Hypercapnia Challenge|The study device is a Douglas Bag that traditionally is designed to measure respiratory exchange. It consists of large bag attached to a mouthpiece utilized to hold either expired air from the subject or filled with different concentrations of air to be aspired. For the purposes of this study, the Douglas Bag will be utilized to induce hypercapnia in the subject. The bag is equipped with a switch that allows rapid shifting from room air to 5% CO2 each minute over 7 minutes.
45916973|NCT00388635|Drug|Prednisone|Prednisone 60mg/m2 v.o days 1 to 4 follows by a rest period of 38 days (phase I and II)
45642048|NCT05501366|Other|Heart Rate Variability|Participants will wear a Bluetooth heart rate monitor chest strap throughout the test day.
45642049|NCT05501366|Other|CGM/CKM|Continuous Ketone Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at ~2- week intervals during the study. The sensor will be removed at the end of the final test day
45642050|NCT05501366|Radiation|DXA|Lean Body Mass will be assessed once via DXA
45642051|NCT05501366|Other|Urine Analysis|Prior to consumption of the Study Product, participants will be asked to completely void bladder. And hydration status will be determined via urine specific gravity (USG) reporting <1.025. Urine passed after the ingestion of the study product will be collected in a plastic container; participants will be asked to void their bladder and collect urine at the end of the test day. The volume produced will be recorded at the end of the study and aliquots will be frozen and stored for future analysis
45916974|NCT00001474|Drug|Interleukin-2|
45642052|NCT05500417|Drug|ALFQ|ALFQ (Army Liposome Formulation containing QS-21) is composed of ALF55 (cGMP-manufactured Army Liposome Formulation), QS-21 (purified extracted saponin), and Sorensen's Phosphate Buffer. Full dose of AFLQ compromised of 200 microgram 3D-PHAD and 100 microgram QS-21, co-administered with main intervention.
45448771|NCT03545542|Diagnostic Test|Final breath volatile organic compounds|Breath sampling 3 weeks after completion of chemotherapy Neuroblastoma group
45448772|NCT03754426|Device|Fluorescence Imaging Device|Hand-held, real-time fluorescence imaging device
45916975|NCT00001483|Drug|buproprion (Wellbutrin)|
45916976|NCT00001483|Drug|sertraline (Zoloft)|
46070585|NCT02552329|Other|Tai Chi exercise|The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down, The 10 forms Tai Chi will be used.
46070586|NCT00812071|Biological|RiVax|vaccine
45916977|NCT00001483|Drug|venlafaxine (Effexor)|
45916978|NCT00388713|Procedure|carotid intima-media thickening ultrasound|
45916979|NCT00001495|Drug|irinotecan (CPT-11)|
45916980|NCT00001507|Drug|Monoclonal Antibody 3A1|
45916981|NCT00001507|Drug|Monoclonal Antibody 95-5-49|
45916982|NCT00001507|Drug|Monoclonal Antibody 95-6-22|
45916983|NCT00001507|Device|Baxter Isolex 3001 Stem Cell Selection System|
46070587|NCT00816205|Drug|Coated Nifedipine Suppositories|"Subjects will take rectally a total of 3 Coated Suppositories per study. 90 minutes after each coated suppository insertion this suppository will be removed and a amnometric study will be performed:~The first dose will contain 4 mg of Nifedipine and the manomentric measurement performed afterwards will be used to determine baseline anal pressures.~The second dose will contain 12 mg of Nifedipine. The third dose will contain 24 mg of Nifedipine."
45916984|NCT00001507|Device|Ceprate SC|
45916985|NCT00388752|Procedure|Acupuncture|
45916986|NCT00000144|Procedure|Argon Laser Treatment|
45916987|NCT00001564|Drug|EF-1 Peptide|
45916988|NCT00001564|Drug|EF-2 Peptide|
45916989|NCT00001564|Drug|PXFK Peptide|
45916990|NCT00001564|Drug|E7 Peptide|
45916991|NCT00001564|Drug|IL-2|
45916992|NCT00001564|Drug|IL-4|
45916993|NCT00001564|Drug|GM-CSF|
45780776|NCT02995850|Drug|CRS+HIPEC|"Ib~Dose-escalation of intraperitoneal paclitaxel will follow a modified 3 + 3 dose escalation procedure.~II~① CRS If PCI <12, CRS will be performed by gastrectomy with D2-lymphadenectomy and resection of any involved adjacent structures.~If PCI≥12, instead of CRS, 3 times of IP paclitaxel +cisplatin and oral S-1 chemotherapy every 3 weeks, and then PCI <12, CRS will be done.~② Extensiveintraperitoneal lavage Peritoneal lavage after CRS will be done with 10 L before HIPEC.~③ HIPEC Following surgery HIPEC will be performed using CDDP (60 mg/m2) and PTX (P2RD mg/m2). IP chemotherapy will be performed.~④ Post-operative intraperitoneal chemotherapy Postoperative chemotherapy will be done 8 cycles of IP paclitaxel+ cisplatin and oral S-1 after 4 weeks."
45780777|NCT01288859|Other|free curcumin|free curcumin in bread, dosage 1g/100g, 200g/day per 1 day
45780778|NCT01288859|Other|encapsulated curcumin|encapsulated curcumin-enriched bread, 1g/100g bread, 200g bread/day
45780779|NCT01288859|Other|encapsulated curcumin + PQG|bread enriched with encapsulated curcumin plus piperine, quercetin and genistein, 1g/100g bread, 200g bread/day
45448773|NCT03207958|Drug|Belimumab|-Given over 1 hour
45642053|NCT05500417|Biological|CJCV2|Vaccine comprised of C. jejuni capsule conjugated to Cross-Reactive Material 197 (CRM197), a non-toxic mutant protein of diphtheria toxin. CJCV2 will be reconstituted in 1 mL of sterile water for injection (SWI). The resuspended CJCV2 product will be diluted with sterile 0.9% Sodium Chloride for Injection. 3 dosages for administration: 1 microgram, 3 micrograms, and 10 micrograms.
45642054|NCT05500326|Drug|Ivermectin Tablets|All participants will receive one dose of oral ivermectin 3mg on day 0 and have two blood samples taken to determine the serum ivermectin concentrations after the dose. Timing of blood samples will vary depending on the allocated group.
45780780|NCT01288859|Other|free cocoa polyphenol|nut cream enriched with free cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day
45780781|NCT01288859|Other|encapsulated cocoa polyphenols|nut cream enriched with encapsulated cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day
45642055|NCT05495997|Behavioral|Mental Imagery Training|Participants will practice mental imagery of everyday tasks daily for 6 weeks.
45642056|NCT05495997|Behavioral|Psychoeducation|Participants will receive psychoeducation on cognition and brain health.
45780782|NCT01288859|Other|control nut cream|nut cream, cocoa polyphenols 0g/100g cream, 100 g/day per 1 day
45780783|NCT02994134|Behavioral|Moderate intensity exercise.|Moderate intensity aerobic exercise intervention (delivered at 55-64% age-predicted maximal heart rate), 4 times per week for 4 weeks.
45780784|NCT02994134|Behavioral|High intensity exercise.|High intensity aerobic exercise intervention (delivered at 65-90% age-predicted maximal heart rate), 4 times per week for 4 weeks.
45780785|NCT00659828|Drug|Recombinant methionyl human leptin|Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
45780786|NCT01235195|Drug|sertraline hydrochloride|50 mg capsule, single-dose
46070588|NCT00816283|Drug|dasatinib|50 mg orally 2 times per day or 140 mg orally one time per day
45448774|NCT00124943|Drug|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, administered via intracoronary catheter.
45448775|NCT00124709|Drug|Pimecrolimus|Pimecrolimus cream 1 %
45448776|NCT00124709|Drug|Corticosteroid|conventional corticosteroid-based treatment
45448777|NCT01078181|Procedure|gastric bypass|laparoscopic gastric bypass with circular stapled 21mm gastrojejunostomy
45448778|NCT01076699|Drug|0.075 mg RVX-100|This group is taking the lowest dose of RVX-100
45448779|NCT01076699|Drug|0.125 mg RVX-100|This group is taking an average dose of RVX-100
45448780|NCT01076699|Drug|0.250 mg RVX-100|This group is taking the highest dose of RVX-100
45642057|NCT05495282|Other|Microvideo|Asynchronous 10-minute micro-video on the topic for which no face-to-face interaction with faculty will be conducted.
45642058|NCT05494125|Other|Ropivacaine|Patients will receive a continuous infusion of ropivacaine through bilateral ESP catheters
45780787|NCT01235195|Drug|sertraline hydrochloride|50 mg tablet, single-dose
45448781|NCT01076699|Drug|placebo|This group is taking a placebo
45780788|NCT04387214|Other|survey|online survey
45780789|NCT01198691|Device|Insorb absorbable staples|Patients will be randomized to receive either the standard metallic staples or the Insorb absorbable staples
45642059|NCT05494125|Other|Placebo|Patients will receive a continuous infusion of saline solution through bilateral ESP catheters
45642060|NCT05492422|Device|Central Executive Training (CET)|Central Executive Training (CET)
45642061|NCT05492422|Behavioral|Behavioral Parent Training (BPT)|Behavioral Parent Training (BPT)
45916994|NCT00001564|Drug|CD40 Ligand|
45916995|NCT00001567|Drug|Roferon-A|
45916996|NCT00001573|Drug|SU101|
45916997|NCT00001576|Drug|Melphalan|
45916998|NCT00001576|Drug|Floxuridine|
45916999|NCT00001576|Drug|Leucovorin|
46070589|NCT00816283|Drug|vorinostat|100 mg orally 2 times per day
46070590|NCT00816283|Genetic|cytogenetic analysis|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
45448782|NCT01078337|Procedure|bone marrow aspiration|
45448783|NCT01078337|Procedure|peripheral blood sampling|
45448784|NCT01076777|Behavioral|Physical exercise|Manualised Exercise performed in groups (5-8 participants per group). 3 sessions (á 60 minutes) per week for 12 consecutive weeks
45448785|NCT01076777|Behavioral|Cognitive-behavioral therapy|Cognitive-behavioral therapy conducted in groups (5-8 participants per group). 1 session (á 2-2.25 hours depending on group size) per week for 12 consecutive weeks
45448786|NCT01078415|Device|Ablation with the NanoKnife Low Energy Direct Current (LEDC) System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
45448787|NCT01076933|Procedure|repetitive Transcranial Stimulation Magnetic (rTMS)|The motor threshold was determined in each subject once, before treatment. This was defined as the lowest stimulation intensity capable of inducing a visible movement at least five times out of 10 stimulations. The position of the right dorsolateral prefrontal cortex was defined as 5 cm anterior (in a parasagittal line) to the motor cortex. The stimulus intensity was 80% of the patient's motor threshold intensity. Treatments were given for 20 minutes per day over 10 working days.
45448788|NCT01076933|Procedure|sham rTMS|sham rTMS
45780790|NCT01198691|Device|Insorb|Patients will be randomized to receive either standard metallic staples or Insorb absorbable staples
45642062|NCT05492006|Behavioral|Indirect contact with nature|The participants will watch a video with validated images of nature from e-Nature Positive Emotions Photography Database (e-NatPOEM). Four fifteen-minute sessions will be held on four consecutive days, totaling 1 hour.
45642063|NCT05492006|Behavioral|Intentional contact with nature|The participants will take a light walk in a park with green spaces guided by research team in a single 1-hour session, with an emphasis on sense-directed appreciation.
45642064|NCT05491447|Drug|BMX-010|Ointment
45448789|NCT01078493|Device|MyCells® (injection of platelet rich plasma)|PRP contains at least 1,000,000 platelets per mm3 or 2-6 times the native concentration of whole blood at a pH of 6.5 to 6.7
45780791|NCT00660530|Drug|Lanthanum Carbonate Chewable Product|Lanthanum carbonate 1 g to be chewed, three times daily with meals
45780792|NCT00660530|Drug|Lanthanum carbonate crushed powder|Lanthanum carbonate (Fosrenol) 1 g crushed into a fine powder, three times daily with meal
45780793|NCT01198769|Biological|Rotarix TM|Oral, 2 doses
45780794|NCT02996942|Biological|Factor VIII replacement|Patients receive their usual treatment
45448790|NCT04166656|Biological|Trumenba®|Trumenba® (Pfizer): Suspension for intramuscular injection in 0.5 mL single-dose prefilled.
45448791|NCT04166656|Biological|Bexsero®|Bexsero® (GSK): available as a suspension for intramuscular injection in a prefilled syringe
45448792|NCT04139434|Drug|LP-108|For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD.
45448793|NCT04139434|Drug|LP-108 and azacitidine|For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD, with azacitidine at the standard dose of 75 mg/m2 on Day 1 - Day 7 of each 28-day cycle (weekly schedule) or on Days 1-5, 8, 9 of each 28-day cycle (5-2-2 schedule), according to institutional guidelines.
45642065|NCT05491447|Drug|Placebo|Ointment
45642066|NCT05485961|Drug|CSL300|Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
45780795|NCT02998580|Device|LFR followed by HFL|Magventure Cool B70 Coil with RX100 Stimulator
45780796|NCT02998580|Device|cTBS followed by iTBS|Magventure Cool B70 Coil with RX100 Stimulator
45780797|NCT01199237|Drug|Sevoflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
45780798|NCT01199237|Drug|Desflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
45780799|NCT01199237|Drug|Rocuronium|
45780800|NCT01199237|Drug|Neostigmine|
45780801|NCT01199237|Drug|Glycopyrrolate|
45448794|NCT04135300|Genetic|Single dose intravenous injection of BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of the human factor IX (hFIX) transgene in liver. The dose of BBM-H901 will be 5x10'12 vg/Kg.
45448795|NCT04133038|Other|Questionnaire|Parent(s) answering questionnaires about his child's phobic and selective eating behaviour.
45642067|NCT05485961|Drug|Placebo|0.9% w/v NaCl
45642068|NCT05485961|Drug|Placebo|Part 2 (Phase 3): Matching the excipient content and concentration of the CSL300 product, minus the active ingredient
45642069|NCT05484401|Drug|Ibuprofen 200Mg Oral Cap|2 x 200mg Liquid Capsules once in 12 hours
45642070|NCT05484401|Drug|Ibuprofen 200Mg Oral Tablet|2 x 200mg Tablets once in 12 hours
45642071|NCT05484401|Other|Placebo Liquid Capsule|2 x Liquid Capsules once in 12 hours
45642072|NCT05484401|Other|Placebo Tablets|2 x Tablets once in 12 hours
45642073|NCT05482919|Behavioral|Baseline Survey|The baseline survey, initial PHQ-9 and GAD-7, could be collected prior to surgery after consent, or on the day of surgery, for participants who are undergoing elective surgery or urgent procedures and did not attend pre-operative clinic. Demographic information such as race and ethnicity, pain medications and pain history and baseline self-reported health information will be collected. It will take about 15 minutes to complete.
45780802|NCT01235897|Drug|MK-2206|Different dose levels of MK-2206 will studied, and co-administered with paclitaxel and trastuzumab. MK-2206 will be given orally with a starting dose of 135 mg weekly
45780803|NCT01235897|Drug|Paclitaxel|80 mg/m2 weekly - paclitaxel
45780804|NCT01235897|Drug|Trastuzumab|2 mg/kg weekly after a 1-time loading dose of 4 mg/kg - trastuzumab
45780805|NCT01236053|Drug|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulry codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to two years prior to the index date (the exposure window). A two year lagged exposure is incorporated to account for latency between cancer onset and GPRD diagnosis, and for protopathic bias (gabapentin prescription for initial pain symptoms of undiagnosed cancer). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose.
45780806|NCT00703976|Drug|Bevacizumab|Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.
45780807|NCT00703976|Drug|Cetuximab|Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
45780808|NCT00703976|Drug|Pemetrexed|Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
45780809|NCT00703976|Radiation|Radiation therapy|Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks
45780810|NCT02320214|Device|Miami w/ frag Personal lubricant|
45780811|NCT02994368|Other|Observation|
45780812|NCT00661544|Drug|Arsenic Trioxide|Dose Level 1: None; Dose Level 2: 0.15 mg/kg days Intravenous (IV) Days -9 to -3; Dose Level 3: 0.25 mg/kg days IV Days -9 to -3.
45780813|NCT00661544|Drug|Melphalan|Dose Levels 1, 2, & 3: 100 mg/m2 IV Days -4, -3.
45448796|NCT04130464|Drug|Ropivacaine Infusion from ON-Q Pump|Infusion of 0.2% ropivacaine at 8 mL/hour for 72 hours
45448797|NCT04130464|Drug|Ropivacaine + Ketorolac Infusion from ON-Q Pump|Infusion of 0.2% ropivacaine + 30 mg ketorolac at 8 mL/hour for 72 hours
45642074|NCT05482919|Behavioral|Post Operative Surveys|Post operative surveys will be collected at one week, two weeks, one month, then monthly up to 6 months after surgery with total of 7 post-op surveys. Refer to Table 1 for visit windows. The study survey could be collected by phone, REDCap texting or email per the subject's preference. Survey content will also include: daily average and maximum self-reported pain scores on a 0-10 Numeric Rating Scale (NRS) pain scale, average hours of sleep, anxiety and depression screens using the PHQ-9 and GAD-7 questionnaires (Months 1, 3, and 5), pain location and quality, percentage of day spent in pain, satisfaction with recovery using a five-point Likert scale, and type, quantity and timing of any medications used for pain (including opioid alternatives).
45448798|NCT04130464|Drug|Normal Saline Infusion from ON-Q Pump|Infusion of 0.9% normal saline at 8 mL/hour for 72 hours
45642075|NCT05482919|Behavioral|Qualitative Interviews|Using sampling to identify adolescents who exhibit higher pain scores or prolonged opioid use compared to peers after completion of the first three surveys (pre-operative, Week 1, Week 2), the study will also select a representative sample of adolescents who are recovering as anticipated. Examples of delayed recovery include a higher proportion of moderate to severe pain scores, dissatisfaction with recovery and prolonged opioid use compared to peers. As a balancing measure, the upper limit of adolescents who are perceived to exhibit delayed recovery that are approached for interviews will be capped at a 3:1 ratio compared to those who are recovering as anticipated, and Investigators will prioritize an equal demographic distribution among the two groups. Interviews will take place over the phone or through a CHOP approved vendor at 1 and 3 months after surgery; audio will be recorded with participant consent.
45642076|NCT05481086|Other|No Interventions|There is no interventions in this study
45642077|NCT05481034|Device|SMA bolus option|SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit.
45642078|NCT05481034|Device|Exactly estimated carbohydrate content bolus option|The carbohydrate content of meals is estimated in grams of carbohydrates prior to a meal bolus
45642079|NCT05477576|Drug|RYZ101|RP3D as determined in Phase 1b
45642080|NCT05477576|Drug|Everolimus 10 mg|Everolimus 10 mg daily by mouth
45448799|NCT02143258|Procedure|Stenting of the venous sinus|Patients with medically refractory idiopathic intracranial hypertension who meet the eligibility criteria will be offered stenting of their venous sinus in effort to reduce their intracranial pressure and improve their visual capabilities.
45448800|NCT03058354|Drug|Propofol|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using intraoperative TIVA with propofol.
45448801|NCT03058354|Procedure|general anaesthesia|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using general anaesthesia methods other than intraoperative TIVA with propofol.
45448802|NCT02933242|Radiation|Stereotactic Ablative Body Radiotherapy|The total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks
45448803|NCT02911792|Drug|Dapagliflozin|SGLT2 inhibitor
45448804|NCT02911792|Drug|Metformin|Oral diabetes medicine that helps control blood sugar levels.
45642081|NCT05477576|Drug|Sunitinib 37.5 MG|Sunitinib 37.5 mg daily by mouth
45642082|NCT05477576|Drug|Octreotide LAR 60 MG Injection|High-dose octreotide LAR 60 mg Q4W by i.m. injection
45642083|NCT05477576|Drug|Lanreotide 120Mg Sa Susp Inj Syringe|High dose frequency lanreotide 120 mg Q2W by deep s.c. injection
45642084|NCT05474651|Other|Questionnaires set|Participants will be asked to respond to the demographic information sheet, characteristics of smoking sheet, the Fagerstrom Test of Nicotine Dependence,Smoking Self-efficacy Questionnaire, Cigarette Withdrawal Scale, smoking hazard questionnaire, motivation to quit smoking sheet, ability to quit smoking sheet, alcohol consumption, International Physical Activity Questionnaire.
45642085|NCT05473117|Diagnostic Test|Coronary Magnetic Resonance Angiography (CMRA)|A highly optimised CMRA protocol integrating advanced, automated software for detection of coronary artery stenosis
45780814|NCT00661544|Drug|Ascorbic Acid|Dose Levels 1, 2, & 3: 1000 mg IV Days -9 to -3.
45917000|NCT00000147|Drug|Methylprednisolone|
45448805|NCT02911792|Drug|Glipizide 5 MG|Oral diabetes medicine that helps control blood sugar levels.
45780815|NCT02996552|Procedure|M & T Repair Group|After the mitral valve repair a device for tricuspid annuloplasty will be implanted.
45780816|NCT02996552|Procedure|Mitral-Only Group|Mitral valve repair alone; after the mitral valve repair no device for tricuspid annuloplasty will be implanted.
45780817|NCT00706394|Device|Endologix Powerlink 34 mm stent graft cuff|Endovascular abdominal aortic aneurysm repair
45780818|NCT00706550|Biological|(PV) 23-valent pneumococcal polysaccharide vaccine|Currently commercially available pneumococcal polysaccharide vaccine
45780819|NCT00706550|Biological|Placebo|Placebo
45780820|NCT02997878|Biological|Orbcel-C|Selected Mesenchymal Stromal Cells derived from human umbilical cord
45917001|NCT00000147|Drug|Prednisone|
45917002|NCT00000150|Procedure|Subfoveal Choroidal Neovascularization Removal|
45448806|NCT02143336|Procedure|subcuticular suture|
45448807|NCT02143336|Procedure|Skin staples|
45448808|NCT01375114|Drug|Panax Ginseng|400 mg by mouth twice daily from Day 1-29.
45448809|NCT01375114|Dietary Supplement|Placebo|Placebo by mouth twice daily for 4 weeks.
45448810|NCT01375114|Behavioral|Questionnaires|Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
45780821|NCT02979392|Drug|TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel)|TENPA IV once every 3 weeks (Phase I starting dose 75 mg/m2)
45780822|NCT01237301|Device|CGM Group|Using CGM unblinded for 16 weeks versus fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes.
45780823|NCT01237301|Device|SMBG Group|Fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes. Used CGM blinded once every four weeks.
45780824|NCT02999906|Drug|Oral Treprostinil|Sustained release oral tablets for three times daily administration
45642086|NCT05472142|Other|UP FOR IT - practice facilitation|"Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The practice facilitation collaborative trains and supports clinical teams to use the Model for Improvement to make breakthrough improvements in diabetes care and DSMES utilization by recognizing barriers and changing clinical systems and care practices."
45780825|NCT02999906|Drug|Placebo|Placebo (sugar pill) for three times daily oral administration
45642087|NCT05472142|Other|UP FOR IT - health information technology|Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The health information technology component provides the scaffolding for quality improvement efforts by automating patient identification and enabling bi-directional referral communication between providers and diabetes self-management education and services (DSMES) programs.
45780826|NCT01200875|Procedure|Ultrasound-guided platelet-rich-plasma (PRP) injection|One ultrasound-guided intratendinous or intramuscular PRP injection
45780827|NCT01200875|Procedure|Platelet-Rich Plasma (PRP)|One ultrasound-guided PRP injection
45780828|NCT02999750|Other|individual therapy|Patient will be treated with individual therapy.
45780829|NCT01238471|Drug|propranolol|2 mg per kg per day divided in 3 doses for 2-4 weeks
45448811|NCT03545152|Behavioral|Exercise|"Prescription exercise: frequency, intensity, type, time, and progression (FITT-PRO).~150 min/week (the intensity will be moderate). exercise routine: warming up, resistance training and aerobic exercise training(range of motion and flexibility exercises)"
45780830|NCT01238471|Drug|sucrose 5%|2 ml per Kg per day divided in 3 doses for 2-4 weeks
45642088|NCT05470491|Drug|RIC|e-ATG 40 mg/kg/day IV on days -14 and -13. Prednisone tapering doses given orally daily: -days -14 through -12: 1mg/kg/day -days -11 and -10: 0.75 mg/kg/day -days -9 and -9: 050 mg/kg/day -day -7: 0.25 mg/kg/day Pentostatin 4 mg/m2/day IV on days -11 and -7. Cyclophosphamide 5 mg/kg orally or IV daily on days -11 through -4. Busulfan IV AUC targeted dose of 14.8-23.0 mg*h/L, on days -3 and -2.
45642089|NCT05470491|Drug|GVHD prophylaxis|Cyclophosphamide 50 mg/kg IV daily Bortezomib 1.3 mg/m2 IV +6 hours and +72 hours after graft infusion Mesna 50 mg/kg IV concomitant with cyclophosphamide
45780831|NCT00706784|Drug|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System
45780832|NCT02996786|Dietary Supplement|Danggui Buxue Tang|Danggui Buxue Tang purchased from Kaiser Pharmaceutical
45780833|NCT02996786|Other|Placebo|Consisting of corn starch and carboxymethyl cellulose
45448812|NCT03545152|Behavioral|Cognitive training|Cognitive training intervention consisted of 12 weekly sessions, lasting 60-90 minutes in groups of 5-8 participants, and 3 monthly boost sessions (to review the strategies and practice solving problems as well). The main strategy was to use cognitive rehabilitation strategies to promote generalization in this process to improve memory and behavior.
45642090|NCT05470491|Procedure|allo HCT|bone marrow transplant
45642091|NCT05470491|Drug|Plerixafor|In phase 1 dose level 3 and phase 2 only: Plerixafor 240 (Micro)g/kg subcutaneously every other day, starting day +1 through day +21
45642092|NCT05470491|Drug|Maraviroc|Phase 1 dose level 2: 300 mg orally twice daily starting day-3 through day day+30
45780834|NCT00664430|Drug|Calcitriol|Initial doses determined according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) guideline (Am J Kidney Dis 2003;42(4)Suppl 3:S1-S201). During therapy, calcitriol dose may be modified by 0.5 - 1 mcg at 2- to 4-week intervals.
45780835|NCT00664430|Drug|Paricalcitol|Dose calculated by 0.04 to 0.1 microgram per kilogram (mcg/kg). Paricalcitol will be administered intravenously after the participants' dialysis. The paricalcitol dose will be titrated every 2 weeks until iPTH presents a reduction or up to 4 months, after which it will be adjusted monthly based on serum PTH, calcium, phosphorus and albumin measurements. Dosing may be modified by 2-4 mcg increments at 2- to 4-week intervals.
45780836|NCT02996162|Device|Massimo Root Monitoring System|The Masimo Root system is a patient monitoring and connectivity platform; Root displays patient monitoring information from the connected modules. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
45780837|NCT02996162|Device|ISA-Infrared Sidestream Gas Analyzer|The ISA-Infrared Sidestream Gas Analyzer displays end-tidal carbon dioxide waveforms and measurements and trends of end tidal CO2. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
45780838|NCT01292135|Drug|PCI-32765|420 mg daily
45448813|NCT03545152|Behavioral|New life-style|Combination of exercise and cognitive interventions
45448814|NCT02885428|Device|echography|
45448815|NCT02860702|Other|Human Milk Derived Fortifier|Human milk derived fortifier will be utilized to increase caloric intake in infants assigned to the exclusive human milk arm
45780839|NCT01241435|Drug|LY2216684|Administered orally
45780840|NCT01292447|Drug|2% lidocaine gel|120mg lidocaine x 1
45780841|NCT01292447|Drug|Placebo gel|Inert gel x 1
45780842|NCT00704912|Drug|Orlistat/Meal Replacement/Lifestyle Modification|Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.
45917003|NCT00001624|Drug|Insulin|
46070591|NCT00816283|Genetic|gene expression analysis|Bone marrow aspirate obtained pre-treatment, at first scheduled bone marrow assay and at relapse. Peripheral blood drawn pre-therapy, day +14 of first treatment cycle and at relapse.
45780843|NCT00704912|Drug|Loestrin 1/20|Patients will be started on a low dose containing OCP for a continuous 4 month period.
45642093|NCT05470218|Other|Meal|Liquid mixed meal with different amounts of protein and leucine
45780844|NCT00704912|Drug|Combination of treatments|Medications will be administered as described for the other 2 arms.
45780845|NCT02195921|Other|single point Zhongwan(CV12) plus antiemetic drug|"All participants were supine in the hospital bed. A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1 cm above the CV12 acupoints of the stimulation point, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle."
45780846|NCT02195921|Other|single point Zusanli(ST36) plus antiemetic drug|"A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1cm below ST36 acupoints of the stimulation point, respectively, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle."
45780847|NCT02195921|Other|Zusanli(ST36)and Zhongwan(CV12) plus antiemetic drug|Stimulating both Zusanli(ST36)and Zhongwan(CV12)
45780848|NCT02195921|Drug|only antiemetic drug|received routine antiemetic treatment
45780849|NCT04387292|Procedure|Ophthalmologic exam|"Visual acuity (ETDRS exam)~Slit lamp examination : fluorescein test, Oxford score, break up time, Schirmer II test~Lipiview~Eye pressure measurement (air tonometer)~Wide field retinophotography~Multicolor and auto-fluorescence retinophotography~Indocyanine green retinal angiography~Optical coherence tomography (OCT) B posterior pole scan~OCT Angiography (OCT-A) of the optic nerve and posterior pole~Adaptive optics~Visual field (Humphrey)"
45780850|NCT02189213|Drug|Sertraline|Sertraline will be administered to treat anxiety disorders in children and adolescents.
45780851|NCT02999828|Biological|inactivated EV71 vaccine (KMB-17)|3.0EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
45780852|NCT01241513|Drug|NAC|NAC provided to determine if beneficial at altitude
45780853|NCT01241513|Drug|Placebo|Placebo
45780854|NCT00665132|Device|StimRouter System|Implanted with StimRouter System receive 6 hours (or less if not tolerated by the Subject)of electrical therapeutic stimulation each day for a total of 5 days (from start of successful programming)
45780855|NCT01241903|Drug|rosuvastatin|Patients (n = 54) presenting acute coronary syndrome/non-ST elevation myocardial infarction who present within 8 hours of symptom-onset will be randomized to two groups to receive rosuvastatin (40 mg oral dose) or placebo at the time of presentation, in addition to standard of care (aspirin, clopidogrel, low molecular weight heparin). Blood will be collected at baseline (time of enrollment, immediately prior to drug or placebo), at 6 - 8 hours, at 18 - 24 hours, and at 30 days for analysis of platelet - leukocyte co-aggregate formation, biomarkers of platelet - leukocyte interactions, and biomarkers of myocardial necrosis. Additional samples may be collected just after revascularization, in patients undergoing PCI. The group of patients treated with rosuvastatin will be maintained on rosuvastatin 20 mg daily and the group randomized to placebo will be given rosuvastatin (20 mg oral once daily) within 48 hoursof enrollment and after planned PCI, but before hospital discharge.
45780856|NCT01241903|Drug|placebo|frequency and duration
45780857|NCT00666848|Drug|Placebo|Enalapril 0mg after 5 days of placebo versus after 5 days sitagliptin 100mg/d
45642094|NCT05469737|Drug|Oral Azacitidine|Specified dose on specified days
45448816|NCT02860702|Other|Human/Bovine Milk|Bovine milk derived fortification
45642095|NCT05469737|Drug|Placebo for Oral Azacitidine|Specified dose on specified days
45642096|NCT05468814|Procedure|Z-plasty|It is a surgical technique in which a Z-shaped section of the transverse carpal ligament is performed, to later join both ends with a resorbable stitch.
45642097|NCT05468814|Procedure|Conventional|It is a surgical technique in which a complete section of the transverse carpal ligament is performed, without subsequent closure.
45642098|NCT05468697|Drug|Belzutifan|40 mg tablet administered orally at a dose of 120 mg.
45780858|NCT00666848|Drug|Enalapril 5mg|Enalapril 5 mg after 5 days placebo versus after 5 days sitagliptin 100mg/d
45780859|NCT00666848|Drug|Enalapril 10mg|Enalapril 10mg after 5 days placebo versus after 5 days sitagliptin 100 mg/d
45780860|NCT00666848|Drug|Sitagliptin|Sitagliptin 100mg/day for 5 days crossed over to placebo daily for 5 days prior to arms.
45642099|NCT05468697|Drug|Palbociclib|75, 100, or 125 mg tablet administered orally according to randomized dose for 21 days consecutive days followed by 7 days off.
45642100|NCT05466955|Device|Free eye glasses for un or under-corrected myopia|All participants randomised to the intervention group will be provided with free eye glasses
45642101|NCT05465083|Device|Lungpacer AeroPace Protect System|AeroPace Catheter will be placed percutaneously into the left internal jugular vein or left subclavian vein and stimulating electrodes mapped for therapy.
45642102|NCT05463952|Drug|ARV-471|ARV-471 will be administered orally QD with food, in continuous dosing over 28-day cycles.
45642103|NCT05462145|Device|Globe Pulsed Field System|Ablation and atrial mapping with the Globe Pulsed Field System
45642104|NCT05461547|Diagnostic Test|Lung Ultrasound|LUS will be performed and interpreted in real-time to guide acute management.
45642105|NCT05461547|Other|Usual Care|Usual care to decide diagnosis and treatment
45642106|NCT05459961|Dietary Supplement|oral spermidine|oral supplement
45642107|NCT05459688|Drug|CIN-107|2 mg of CIN-107, once a day for 52 weeks
45780861|NCT01287377|Behavioral|Telephone Counseling|Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling. The follow-up call schedule includes a reminder call if the quit date is more than one week out, a call within 24 hours of the quit attempt, another call 4-7 days after the quit date, and another call 10-14 days after the quit date.
45780862|NCT01287377|Drug|Nicotine Patches|"Subjects are randomized into one of these pharmacotherapy interventions: direct mailing of active patches with a message to start using it on their quit date, direct mailing of active patches with a message to start using it right away, or usual care patches in which no patches are sent directly (although clients may still get them through their usual channels).~For those in the usual care condition, patches will not be mailed directly to them; however, we will facilitate their use by providing a certificate that can be used by the State Medicaid program and some other insurance companies to obtain free patches. For those in the active condition, we will mail 2 weeks of patches directly to their home. All subjects will receive a 2 week starter kit with fourteen 21mg patches."
45917004|NCT00001651|Other|[6,6-2H2]-glucose|[6,6-2H2]-glucose will be administered as a continuous IV infusion for one to five days.
45642108|NCT05459545|Device|Use of Eko CORE and Eko DUO electronic stethoscope|Auscultation of heart sounds using electronic stethoscopes
45642109|NCT05457439|Behavioral|Sustainable diet promotion through behavioral change intervention|15 weeks digital intervention to promote sustainable diets through workshops, and behavioral change techniques in a mobile application, to decrease environmental impact of diets and improve health.
45642110|NCT05457101|Other|AI-based biliopancreatic EUS navigation system|The endoscopists in the experimental group will be assisted by EndoAngel, which can in real-time prompt standard stations and anatomical structures during EUS. The system is an non-invasive AI system .
45448817|NCT03545074|Behavioral|Mindful Awareness Practices- English|The 6-week intervention aimed at teaching mindfulness-based strategies to participants (in English)
45642111|NCT05457010|Biological|SPRX002|"SPRX002 is a soluble protein with a TAG region to which ARC-T cells bind and a binding region targeting CD123"
45780863|NCT01511042|Drug|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
45780864|NCT01511042|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
45917005|NCT00000153|Procedure|Blue-Green Argon Laser Treatment|
45917006|NCT00000153|Procedure|Red Krypton Laser Treatment|
45917007|NCT00001663|Device|Magstim Super Rapid Stimulator|
45917008|NCT00001666|Device|Cadwell High-Speed Magnetoelectric Stimulator|
45917009|NCT00001666|Device|Magpro High-Speed Magnetoelectric Stimulator|
45917010|NCT00000156|Device|Goggles|
45917011|NCT00000156|Procedure|Ambient Light Reduction|
45917012|NCT00001669|Drug|rhIGF-1 (CEP-151)|
45917013|NCT00001693|Drug|Celecoxib (SC-58635)|
45917014|NCT00001696|Drug|Genistein|
45917015|NCT00389389|Drug|AZD4877|intravenous infusion
45917016|NCT00389428|Drug|CPX-351 (Cytarabine:Daunorubicin) Liposome Injection|
45917017|NCT00001720|Drug|Alendronate|
45917018|NCT00001723|Drug|Orlistat|Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
45642112|NCT05457010|Biological|ARC-T Cells|"ARC-T Cells is a genetically modified autologous T-cell product. The T cell has a binding domain chimeric antigen receptor (CAR), which specifically binds to the TAG protein of the soluble protein antigen-receptor x-linker (sparX; specifically, SPRX002). When ARC-T cells bind to a TAG and the SPRX protein is bound to its target (in this case CD123), ARC-T cells are capable of activation, expansion, and killing (based on preclinical experiments)."
45917019|NCT00001723|Drug|Placebo|Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
45917020|NCT00001729|Drug|Ribavirin|
45917021|NCT00001735|Procedure|Gene therapy|
45917022|NCT00001741|Drug|Losartan|
45917023|NCT00001750|Drug|Stemgen|
45917024|NCT00001777|Drug|Sertraline|
45917025|NCT00001783|Drug|0-15 Water|
45448818|NCT03545074|Behavioral|Mindful Awareness Practices- Spanish|The 6-week intervention aimed at teaching mindfulness-based strategies to participants (in Spanish)
45448819|NCT03545074|Behavioral|Health Education - English|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general (in English)
45448820|NCT03545074|Behavioral|Health Education - Spanish|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general (in Spanish)
45917026|NCT00001789|Drug|BG9588|
45917027|NCT00000171|Drug|Melatonin|
45917028|NCT05641636|Diagnostic Test|12-lead ECG, hormone and lipid blood tests, echocardiography (Echo-CG), cardiopulmonary exercise testing (CPET) and pulse wave analysis|Echocardiography - standart protocol. Pulse wave characteristics were obtained using finger photopletysmography (PPG) (Angioscan-01, AngioScan-Electronics) from an infrared light sensor. Endothelial function was also evaluated using occlusion index and shear rate during post-occlusive reactive hyperemia (PORH). CPET was conducted on a treadmill (Intertrack 8100, Schiller, Switzerland) with a breath-by-breath algorithm of gas exchange analysis (Cardiovit CS-200 Ergo-Spiro, Schiller, Switzerland), using Bruce, modified Bruce or Naughton protocols depending on the level of physical tolerance.
45917029|NCT05641597|Other|Actimetric measurement|"Evaluation during 7 days in real life condition Carried out during the pre-operative evaluation (M0), the post-operative evaluation (M1) and the post-operative evaluation (M6)"
45917030|NCT05641597|Other|Evaluation of plantar flexion, dorsal flexion and ankle eversion forces|Performed at the preoperative (M0), postoperative (M1) and postoperative (M6) assessments
45917031|NCT05641597|Other|Assessment of static and dynamic balance and quality of life|Performed at the preoperative (M0), postoperative (M1) and postoperative (M6) assessments
45642113|NCT05456139|Behavioral|Treatment as Usual|"Families in the Treatment as Usual (TAU) condition will receive usual care and EI services in their community, which will be tracked with the BSRC Intervention History Form. Because all families join My Baby Navigator and will be screened by the SoCo CheckUp, families in both conditions will have access to the Seamless Path for Families which includes online tools about social communication developmental milestones. Families will also have access to Autism Navigator About Autism in Toddlers, the ASD Video Glossary, and the Autism Navigator How-to Guide for Families, a self-guided online course."
45780865|NCT01511042|Drug|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
45780866|NCT02996240|Dietary Supplement|Omega-3 FFA|Omega-3 Free Fatty Acid will be given as a fish oil in a capsule.
45780867|NCT02996006|Procedure|stepwise vascular control|"Before liver parenchymal resection, we performed total hepatic vascular preparation for occlusion with portal triad (PT), infra-hepatic inferior vena cava (IIVC), and supra-hepatic inferior vena cava (SIVC) preparation in order. Then we performed step-by-step vascular occlusion according to the individual bleeding situation."
45780868|NCT01242527|Drug|placebo|4 capsules (1g) daily for 12 weeks
45780869|NCT01242527|Drug|omefas|2 capsules (1g) + 2 placebo daily for 12 weeks
45780870|NCT01242527|Drug|omefas|3 capsules (1g) + 1 placebo daily for 12 weeks
46070592|NCT00816283|Genetic|mutation analysis|Performed at baseline and at every bone marrow analysis on peripheral blood
45780871|NCT01242527|Drug|omefas|4 capsules (1g)daily for 12 weeks
45780872|NCT00667004|Drug|ecabet ophthalmic solution|sterile ophthalmic solution
45780873|NCT00667004|Drug|placebo|sterile ophthalmic solution
45780874|NCT02991014|Behavioral|researcher-selected frequency-modulated music|Music pieces have been selected in advance by the researchers. Furthermore, musical frequencies have been artificially modulated.
46070593|NCT00816283|Genetic|reverse transcriptase-polymerase chain reaction|Peripheral blood drawn prior to starting Vorinostat on Day 1 and on Day 14 of treatment
46070594|NCT00816283|Other|flow cytometry|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
45448821|NCT02143570|Drug|Darifenacin|Darifenacin will be prescribed in a starting dose of 7.5mg, once daily. This dose may be increased to 15mg a day in cases with refractory symptoms.
45780875|NCT02991014|Behavioral|researcher-selected non-modulated music|The same music pieces as in the active comparator arm have been selected in advance by the researchers, but no artificial frequency modulation.
45780876|NCT02991014|Behavioral|participant-selected non-modulated music|Participants bring their own choice of personally preferred music pieces and listen to them during the intervention sessions. There is no frequency modulation in this condition.
45780877|NCT02995616|Device|Regular therapy settings|Patients will walk in the Lokomat according to their regular therapy settings for a minimum of 20 minutes (i.e. minimum tolerable guidance force (GF), minimal tolerable body weight support (BWS) and maximum tolerable walking speed)
45780878|NCT02995616|Device|100% guidance force|Patients will walk in the Lokomat with 100% GF for a minimum of 20 minutes (same amount of body weight support and walking speed as in the first session)
45780879|NCT02995616|Device|60% guidance force|Patients will walk in the Lokomat with 60% GF for a minimum of 20 minutes (same amount of body weight support and walking speed as in the first session)
45780880|NCT01204853|Drug|Sitaxentan|sitaxentan sodium 100 mg
45780881|NCT01028846|Drug|Diazoxide|1-2 mg/kg total dose given intravenously
45917032|NCT05641597|Other|Functional gait assessment (TM6)|Performed at the preoperative (M0), postoperative (M1) and postoperative (M6) assessments
45917033|NCT05641558|Drug|611 150mg|subcutaneous injection, 150 mg (single dose treatment period) + 300mg (loading dose, week 0) + 150mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
45917034|NCT05641558|Drug|611 300mg|subcutaneous injection, 300 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 1 to Week 15, 8 cycles)
45917035|NCT05641558|Drug|611 600mg|subcutaneous injection, 600 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
45917036|NCT05641558|Other|Placebo|During the study, placebos shall be filled timely according to the administration of the test drug to ensure the consistency of the times of administration in each group, so as to maintain the blind state.
45917037|NCT05641441|Radiation|Stereotactic radiosurgery|Stereotactic radiosurgery
45642114|NCT05456139|Behavioral|Early Social Interaction Mobile Coaching (ESI-MC)|The ESI-MC coach will offer 24 weekly sessions for the 6-month ESI-MC condition. The parent will be the focus of training. Each session includes: setting the stage to develop that session's agenda; intervention implementation with these coaching steps: a) review the target, b) use guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to support caregiver reflection and independence in the activity, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and summarize plans for deliberate practice between sessions. Families will be invited to participate in the online Autism Navigator How-To Guide, a self-guided online course and companion to the online group education meetings to engage families in the content of the online course and provide support through interaction with other families. Families will also participate in TAU usual care and EI services in their community.
46070595|NCT00816283|Other|laboratory biomarker analysis|Performed pre-treatment and day +14 of treatment
46070596|NCT00643279|Device|Chronicle Implantable Hemodynamic Monitor|Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead. The implantable hemodynamic monitoring device captures intracardiac hemodynamic information about the patient including trended right ventricular (RV) and estimated pulmonary arterial (PA) pressures, heart rate and activity data. The IHM device does not provide therapy, but rather provides intracardiac diagnostic information about the patient which the physician can utilize to manage the patient and the patients heart failure.
45780882|NCT01028846|Drug|Placebo|Intravenous normal saline
45780883|NCT02998814|Other|acid-etch|acid-etch
45780884|NCT02998814|Other|self-etch adhesive|Self etch (7th generation ) bonding agent
45780885|NCT02998814|Other|etch-and-rinse adhesive|Total etch bonding agent (5th generation)
46070597|NCT00643279|Other|Standard of Care|Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead, but physician and patient access to the intracardiac information provided by the device is restricted until the end of the randomized period of the study, at 6 months. Patients and patients heart failure are managed conventionally per standard of care.
46070598|NCT00910910|Drug|Lenalidomide|"For patients with normal renal function (defined as CrCl ≥ 60 mL/min), 5 mg once daily on Days 1 through 28 of the first 28-day cycle, 10 mg once daily on Days 1 through 28 starting at the second cycle, 15 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first.~For patients with moderate renal impairment (defined as CrCl ≥ 30 to < 60 mL/min), 2.5 mg once daily on Days 1 through 28 of the first 28-day cycle, 5 mg once daily on Days 1 through 28 starting at the second cycle, 7.5 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first."
46070599|NCT00910910|Drug|Chlorambucil|Patients assigned to the chlorambucil arm will receive oral chlorambucil tablets at 0.8 mg/kg on Days 1 and 15 of each 28-day cycle for a total duration of 12 months (approximately 13 cycles).
46070600|NCT04267172|Behavioral|Surgical simulation training in primary Total Hip Arthroplasty|The simulation-based and cognitive learning package will be delivered to a randomised sub-group of 50% of the Surgical Residents recruited into this study. This will be delivered in a supervised non-clinical setting within a dedicated University-owned simulation laboratory over a 4-week period for between 1 to 2 hours per week, over 3 to 4 consecutive but separate six-month placements.
45448822|NCT02143570|Procedure|Physiotherapy|All patients will received a tailored pelvic floor exercise programme as part of the standard of care of overactive bladder at the study centre. This intervention will be mainly comprised of biofeedback stimulation techniques.
45917038|NCT00000177|Drug|Estrogen|
45780886|NCT02998814|Other|self-etch adhesive after acid-etch|acid etch + self-etch adhesive Self etch (7th generation ) bonding agent
45780887|NCT00714272|Device|Treatment with a Granulocyte Adsorber, Medica Adsorber 1.1|6 treatments. One per week during the first six consecutive weeks.
45780888|NCT00714272|Device|Treatment with a sham device, EXcorLab box 1.2|6 sham treatments. One treatment per week during the first six consecutive weeks.
45780889|NCT04386122|Drug|FABALOFEN 60|Dosage: Single dose of one tablet of test product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of test product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
45780890|NCT04386122|Drug|JAPROLOX TABLET|Dosage: Single dose of one tablet of reference product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of reference product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
45917039|NCT03444376|Drug|GX-188E|GX-188E (1.0mg/0.5ml/vial), Intramuscular administration using electroporator, Ichor TDS-IM device
45642119|NCT05454241|Drug|Anti-CD7 CAR-T|Universal CAR-T cells targeting CD7
45642120|NCT05453578|Other|Placebo|0.9 percent sodium chloride
45642121|NCT05453578|Biological|WRAIR-PAM-CF1|Bacteriophage combination composed of the following phages: PaWRA01Phi11, PaWRA01Phi39, PaWRA02Phi83, and PaWRA02Phi87.
45642122|NCT05453396|Biological|Loncastuximab Tesirine|Given IV
45642123|NCT05453175|Other|Interrupting sitting with Physical activity|Participants will engage in three minutes of walking, five sit to stands and five calf raises every thirty minutes
45642124|NCT05452590|Procedure|Ultrasound-guided wire-in-needle technique for central venous catheter placement|The guidewire will be connected to the needle. The IJV will be punctured in a long-axis in-plane approach. When the needle tip enters the IJV, the guidewire will be advanced through the needle into the IJV under continuous ultrasound visualization. The needle will then be removed. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view. Afterwards, the second guidewire will be placed in the same IJV approximately 1-2 centimeters distal to the fist guidewire using the same technique. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view again.
45780891|NCT03009461|Procedure|HAIC|Intra-arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. For each cycle, leucovorin calcium 200 mg/m2 was intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.
45780892|NCT03009461|Drug|Sorafenib|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.
45780893|NCT02995460|Behavioral|interval training|4x4 high intensity interval training
45780894|NCT02990702|Other|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block for forearm or hand surgery
45780895|NCT02990702|Other|Ultrasound guided coracoid infraclavicular block|Ultrasound guided infraclavicular block for forearm or hand surgery
45780896|NCT02990702|Drug|Bupivacaine|
45780897|NCT02990702|Device|Ultrasound|
45780898|NCT01243619|Drug|3'-deoxy-3'-(18) F-fluorothymidine|Radio-tracer for tumor imaging
45780899|NCT02995304|Drug|Morphine premedication|30 children will 0.1 mg/kg morphine as a premedication 20 to 30 min before surgical incision.
45780900|NCT02995304|Drug|Midazolam premedication|All children who will receive 0.025 mg/kg midazolam IV as a premedication 20 to 30 min before surgical incision.
45780901|NCT02995304|Drug|Saline premedication (placebo)|30 children in midazolam only group will receive saline after midazolam
45780902|NCT02990858|Drug|PRO 140 SC injections|
45780903|NCT02995148|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z43-104)
45917040|NCT03444376|Drug|Keytruda|pembrolizumab(100mg/4mL/vial), Intravenous administration
45917041|NCT00000180|Drug|AIT-082|
45917042|NCT03422224|Diagnostic Test|Mixed lymphocyte reaction|Assessment of alloreactive T cell repertoire
45917043|NCT00000216|Drug|Buprenorphine|
45917044|NCT05641168|Other|Adhesive material|Newly developed adhesive material
45917045|NCT05641168|Other|Standard adhesive material|Standard adhesive material
45754298|NCT04233385|Other|Light Touch|Participants randomized to this group will receive 30 minutes of light touch to their affected breast, chest, and shoulder areas twice a week for 2 months. Therapists will follow a detailed light touch protocol for each of the 16 sessions. In addition, the therapist will inquire about the participant's response to the previous light touch treatment. Second, the therapist will assess the soft tissues around the affected breast, chest, and shoulder to determine the locations of pain, tissue firmness, and restricted mobility. Third, the therapist will place both hands on the participant for 3 minutes at each identified location. Pressure will be very light and consistent, with no side-to-side movement.
45780904|NCT02995148|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
45780905|NCT00725504|Drug|Intravenous lidocaine|Intravenous lidocaine administered up to 5 µg/ml.
45780906|NCT02990624|Radiation|PUVA|36 sessions of psoralen-ultraviolet A, divided as 3 sessions weekly
45780907|NCT01275872|Other|Guided Imagery and Progressive Muscle Relaxation|4 supervised sessions per patient for 4 weeks additional to daily unsupervised sessions
45780908|NCT01275950|Behavioral|Health Education|"Implementing the intervention programme designed for creating awareness about harmful effect of tobacco (smoked and smokeless forms) and the current regulation to the shop-owners.~Administering the questionnaire to objectively asses the impact of direct/ surrogate tobacco advertisements influencing student behavior and perception about tobacco and tobacco products.~Implementing the intervention programme designed for creating awareness about harmful effect of tobacco (smoked and smokeless forms) and the current regulation to the students through interactive sessions with students in their respective educational institute."
45780909|NCT02995226|Other|Clinical and biological examination, Saliva (or blood) test Glycemia, thermal test, cognitive and bike tests, questionnaires|Clinical and biological examination, Saliva (or blood) test, glycemia, thermal test, cognitive and bike tests, questionnaires
45780910|NCT02995226|Other|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires
45780911|NCT02995070|Procedure|CTG|Periodontal plastic surgery for root coverage by the trapezoidal flap plus connective tissue graft
45780912|NCT02995070|Device|LLLT|Low Level Laser Therapy on the buccal recipient site of connective tissue graft.
45917046|NCT05641090|Other|Nordic walking in water|Nordic walking in water will be based on nordic walking in water at temperature 34◦C. Nordic walking in water will be conducted at moderate intensity (40-60% heart rate reserve). The program was exercised 60 minutes include warm-up and cool down. At first 6 weeks, The exercise intensity was 40-50% heart rate reserve and it will be increased 50-60% heart rate reserve. The training program will be performed 3 times per week for 12 weeks.
45448823|NCT02780284|Behavioral|Physical activity intervention|150 minutes per week of moderate intensity cardiovascular exercise. The exercise sessions will include a minimum of 30 minutes of exercise each day, 3 to 5 times per week for a total of 150 minutes of exercise per week.
45917047|NCT05641090|Other|No exercise intervention|This group wasn't receive intervention program. The participants in this group will do following a physician who treat them. They can exercise according to the physician recommend.
45917048|NCT00000252|Drug|0% N2O|
45917049|NCT00000252|Drug|10% N2O|
45917050|NCT00000252|Drug|20% N2O|
45917051|NCT00000252|Drug|30% N2O|
46070601|NCT04267172|Other|No intervention: Surgical Resident Control Group|Control Group
46070602|NCT04267172|Other|No Intervention: Consultant and Fellow Comparator Group|Comparator Group
45448824|NCT05084482|Other|Prediction models|The prediction scores are validated by the CAM-ICU scores up to 14 days after ICU admission.
45448825|NCT00108862|Other|Strategy: Immediate ART|The intervention is the strategy of initiating antiretroviral therapy (ART) after approximately 2 weeks of rifampin (RIF)- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is efavirenz (EFV) 600 mg (1 tablet orally), emtricitabine (FTC) 200 mg (1 capsule orally), and tenofovir disoproxil fumarate (TDF) 300 mg (1 tablet orally) daily. Substitutions with other locally available U.S. Food and Drug Administration (FDA)-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
45780913|NCT02995070|Device|SHAM|Simulation of GaAlAs laser to irradiation on connective tissue graft recipient site.
45780914|NCT01276028|Procedure|Acupuncture|"For the Acupuncture group: Women will be eligible to receive from 1 to 20 treatments over a six month period. These women will receive an initial evaluation by a acupuncturist and will be given a Traditional Chinese Medicine (TCM) diagnosis as well as a recommended treatment schedule which they can then negotiate.~Women in the waitlist group will not receive any acupuncture for 6 months. At the end of the 6 month period the participants will be allowed to begin the acupuncture treatments."
45780915|NCT03830684|Drug|Baicalein Tablets 400mg|4 Baicalein Tablets and 2 placebo per time, three times a day
45780916|NCT03830684|Drug|Baicalein Tablets 600mg|6 Baicalein Tablets per time, three times a day
45780917|NCT03830684|Drug|blank control 0mg|6 placebo per time, three times a day
45917052|NCT00000252|Drug|40% N2O|
45917053|NCT05641012|Other|data collection|helioderma evaluation
45917054|NCT05640973|Other|Evaluation|Evaluation of ease of use
45917055|NCT05640856|Procedure|intubation|Endotracheal tube placement
45917056|NCT05640817|Drug|Pentoxifylline 400 mg SR tablets|a nonspecific phosphodiesterase inhibitor, was first considered in the treatment of peripheral vascular diseases
45917057|NCT05640817|Drug|cisplatin with standard hydration with normal saline|chemotherapy
45917058|NCT00000255|Drug|Nitrous oxide|
45917059|NCT05640739|Behavioral|Demonstration method for the use of the Metered Dose Inhaler|The effectiveness of the training given by the demonstration method for the use of the Metered Dose Inhaler (MDI)
46070603|NCT04232462|Diagnostic Test|Endoscopists refer to AI for diagnosis|The AI will provide a clinical diagnosis during endoscopy.
46070604|NCT04522544|Drug|Tremelimumab|300 mg Tremelimumab C1D1
46070605|NCT04522544|Drug|Durvalumab|1500 mg Durvalumab C1D1 + Q4W (max. 13 cycles)
46070606|NCT04522544|Procedure|Y-90 SIRT|Locoregional therapy will be performed as a standard-of-care procedure
45780918|NCT02990546|Drug|midodrine|Midodrine will be given to treatment arm as enteral medication
45780919|NCT02990546|Other|Standard of Care|Patients in the control arm will receive standard of care for septic shock
45448826|NCT00108862|Other|Strategy: Deferred ART|The intervention is the strategy of initiating ART either after 8-12 weeks of RIF- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is EFV 600 mg (1 tablet orally), FTC 200 mg (1 capsule orally), and TDF 300 mg (1 tablet orally) daily. Initiation outside of these windows, on a case by case basis, is permitted at the discretion of the site investigator. Substitutions with other locally available U.S. FDA-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
45642125|NCT05448196|Other|Coordinated Financial Navigation Program|Patients randomized to the intervention arm will be enrolled in a four-month coordinated financial navigation program. This program will take a more proactive, coordinated, and systematic approach and includes concrete action plans, and frequent and standardized follow-ups. All patients randomized to the intervention arm will meet with the nurse navigator (NN) for an intake. The NN will introduce navigation services and navigator's NN role and describe the financial navigation program (e.g., goals and expectations of the financial advocacy and social work programs). Next, the navigator will elicit from the patient their potential and current barriers to completing the diagnostic test or treatment. The navigator will then perform proactive outreach to these resources and coordinate an action plan with the patient.
45642126|NCT05447676|Drug|Dalfampridine|The study drug (4-AP) will be administered as a 10 mg dose.
45780920|NCT00727064|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
45780921|NCT00727064|Drug|Venlafaxine Extended Release (VEN ER)|
45780922|NCT01294163|Drug|Xenon|Inhaled xenon, maximal inspired concentration of 65%.
45642127|NCT05447676|Other|Placebo drug|The pharmacy will also provide a placebo drug that looks identical to 4-AP to verify participants and therapists do not know who is receiving the drug and who is receiving the placebo.
45642128|NCT05447676|Other|STDP stimulation|Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
45917060|NCT05640739|Behavioral|Video watching method for the use of the Metered Dose Inhaler|The effectiveness of the training given by video watching method for the use of the Metered Dose Inhaler (MDI)
45448827|NCT02143804|Biological|oncolytic adenovirus expressing GMCSF|Treatment once weekly by intravesical route. Use of DDM to first remove the GAG layer of the bladder and to improve virus transduction. Installation of 100 ml. of CG0070 at 10e12 viral particles for 45 minutes inside bladder.
45642129|NCT05447676|Behavioral|Exercise training|Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.
45642130|NCT05444465|Device|Isolated Bioinductive Repair|Isolated Bioinductive repair with REGENETEN™ Bioinductive Implant
45917061|NCT05640622|Other|Gait Outcomes Assessment List (GOAL)|Gait Outcomes Assessment List (GOAL) is a scale developed to contribute to the determination of treatment goals. This questionnaire includes the priorities, expectations, and goals of children with CP who can walk and reveals their walking characteristics.
45917062|NCT00000258|Drug|Nitrous oxide 10% & placebo|
45917063|NCT00000258|Drug|Nitrous oxide 20% & placebo|
45917064|NCT00000258|Drug|Nitrous oxide 30% & placebo|
45917065|NCT00000258|Drug|Nitrous oxide 40% and placebo|
45917066|NCT00389506|Biological|LMB-2 immunotoxin|
45642131|NCT05444465|Procedure|Completion and Repair|Standard surgical repair using the 'Completion and Repair' technique.
45642132|NCT05444244|Other|Relational Research Recruitment and Engagement Intervention|"Specified recruiter/point of contact~Flexibility in study time, place, method of recruitment (preferred participant email, phone), and follow-up (in registry, if participant calls back at all restart 3 failed phone contacts)~Resource matching (financial, transportation constraints)"
45642133|NCT05443555|Drug|Gabapentin|Dosing will be titrated up over 3 weeks, starting with a daily dose of 300mg (1 capsule/day) in week 1, followed by a daily dose of 900mg (3 capsules/day) in week 2, up to a target daily dose of 1800mg (6 capsules/day) in week 3. The target dose of 1800mg per day will be sustained from weeks 3 through day 4 of week 12. Then, dose will be tapered down to 900mg in days 5-7 of week 12, and medication will be discontinued at the end of week 12.
45780923|NCT01294163|Drug|Sevoflurane|Inhaled sevoflurane, maximal inspired concentration of 1.8%.
45780924|NCT01294163|Drug|Propofol|Hourly dose of 2-4 mg/kg
45780925|NCT01294241|Drug|Oleogel-S10|1 cm or 125 µL or 115 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
45780926|NCT01294241|Device|Mepilex® soft silicone faced polyurethane foam dressing|Mepilex® soft silicone faced polyurethane foam dressing was changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
45780927|NCT01244243|Device|Hand & Wrist Assisting Robotic Device|Treatment occurs in 2 hour sessions, 4 times a week over 3 weeks. In each treatment session, you will sit in a chair and have your weak hand attached to a mechanical device (the robot), which will help you open and close your hand. During the treatment, different types of objects (with varying shapes, sizes, and weight) will be placed into your hand. You will be given a variety of instructions related to the grasping, feeling, or identifying of the object in your hand. Sometimes these instructions will be given from the investigator and sometimes from the computer. You will often be asked to grasp, or release, each of these objects as best you can. You will also be asked to concentrate on the object in your hand. An example of what you may be asked to do is to name the object. During other times, you will play games, using the robot to control game parts on the computer screen. At other times, you will move your hand so that the robot can measure your hand function.
45780928|NCT01294319|Drug|Mifepristone|
45780929|NCT01294319|Drug|Placebo|
45917067|NCT00389506|Drug|cyclophosphamide|
45917068|NCT00389506|Drug|fludarabine phosphate|
45780930|NCT01294319|Drug|Spironolactone|
45780931|NCT01294319|Drug|Combined|
45642134|NCT05443555|Drug|Placebo|Participants randomized to this group will receive a placebo medication for 3 months and will be instructed to follow the same pill regimen as the intervention arm.
45642135|NCT05442580|Drug|3x10(6) CART-38 cellls|3x10(6) CART-38 cells via intravenous infusion
45780932|NCT01294319|Drug|Dexamethasone|
45780933|NCT00727298|Biological|Infliximab|Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
45917069|NCT00389506|Other|pharmacological study|
45917070|NCT00389545|Procedure|Intracoronary infusion of autologous bone-marrow derived stem cells|
45917071|NCT00389584|Drug|irinotecan hydrochloride|
45917072|NCT00389584|Procedure|cognitive assessment|
45917073|NCT00389584|Procedure|management of therapy complications|
45917074|NCT00389584|Radiation|radiation therapy|
45917075|NCT00389662|Device|"Wearing the Nike Free shoe"|
45917076|NCT05640544|Other|Sound and light stimulation in Gamma band|"We expect to screen out the efficacy of Gamma band in the prognosis and treatment of disorders of consciousness by various frequencies of stimulation.~Optical stimulation:~A computer program is used to control the flashing frequency of LED lights for stimulation. The serial port can convert the parallel data characters of the computer CPU into a continuous serial data stream. According to the frequency designed by experiment (10Hz, 20hz, 40hz, 80hz), we modulate the flicker frequency of LED lamp. LED lamp uses T8 lamp, diameter 25.4 mm, length 620 mm, and power 20W.~Acoustic stimulation:~We use Adobe Audition CC 2022 to modulate the tones. The tones modulated to 10Hz, 20Hz, 40Hz and 80Hz are play by noise-canceling headphones to the patients."
46070607|NCT04522544|Procedure|TACE|Locoregional therapy will be performed as a standard-of-care procedure
46070608|NCT04384562|Drug|Methylphenidate|A 20 mg methylphenidate (Ritalin®) is administered only once for the dopamine reuptake inhibitor group.
45642136|NCT05442580|Drug|7x10(5) CART-38 cells|7x10(5) CART-38 cells via intravenous infusion
45642137|NCT05442580|Drug|7x10(6) CART-38 cells|7x10(6) CART-38 cells via intravenous infusion
45642138|NCT05442580|Drug|3x10(7) CART-38 cells|3x10(7) CART-38 cells via intravenous infusion
45642139|NCT05442580|Drug|Cyclophosphamide|Lymphodepleting chemotherapy administered at physician discretion
45917077|NCT00000324|Drug|Tryptophan|
45917078|NCT05640505|Behavioral|School based Gratitude Interventions|Three gratitude interventions including Count your blessings, Gratitude Letter and Loving Kindness Meditation were applied with modification focusing on school related experiences. For example, writing a gratitude letter to a teacher, mentor or coach who played a significant role in one's life then imagining on the same person during LKM exercise of imagery. There were 9 sessions with 3-4 exercises in each session.
45917079|NCT05640427|Drug|Dexmedetomidine|Groups D1 received general anesthesia with intravenous pump of 0. 2μg/kg/h dexmedetomidine to 30min before the end of the operation.Groups D2 received general anesthesia with intravenous pump of 0. 5μg/kg/h dexmedetomidine to 30min before the end of the operation.
46070609|NCT04384562|Drug|Reboxetine|A 4 mg reboxetine (Edronax®) is administered only once for the noradrenaline reuptake inhibitor group.
46070610|NCT04384562|Drug|Nicotine gum|A 2 mg nicotine (Nicorette®) gum is administered only once for the cholinergic receptor agonist group.
46070611|NCT04384562|Drug|Placebo pill|A placebo pill is administered only once.
46070612|NCT04384562|Drug|Placebo gum|A placebo gum is administered only once.
46070613|NCT04519892|Other|PDRC|Personalized depression risk communication.
46070614|NCT04519892|Other|Coach guidance|Coaching service to guide the understanding of PDRC and answer questions.
46070615|NCT04243304|Other|11C-UCB-J PET-CT|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
46070616|NCT04243304|Other|18F-PE2I PET-MR|Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I, and brain MRI performed simultaneously.
46070617|NCT04515134|Diagnostic Test|assessment of follicular level of coenzyme Q10 in the ovaries in females undergoing ICSI|human coenzyme Q10 (CoQ10) ELISA kit
46070618|NCT04238390|Drug|Ceftolozane-Tazobactam|Ceftolozane-tazobactam 3 grams (comprising ceftolozane 2 grams and tazobactam 1 gram) administered, every 8 hours, three times a day, intravenously over 60 mins. Dose adjusted for renal function.
45642140|NCT05442580|Drug|Fludarabine|Lymphodepleting chemotherapy administered at physician discretion
45780934|NCT02994992|Drug|BAY 987516|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z46-100)
45780935|NCT02994992|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
45780936|NCT02990312|Drug|Sirolimus + Maraviroc|Patients will be placed on the combination of Sirolimus and Maraviroc starting on Day 0 and followed for 96 weeks during which they will have regular monitoring of both clinical safety labs, Sirolimus levels, and research labs to look at the HIV reservoir, CCR5 density, and immune activation
45780937|NCT01244477|Behavioral|Group CPT-C|Participants will be randomly assigned to participate in CPT-C or a 12 week waitlist control group. Waitlist control subjects will participate in CPT-C after the 12 weeks.
45780938|NCT02994524|Procedure|Rerouting technique for transsphincteric perianal fistula|
45780939|NCT01294709|Drug|telcagepant|
45780940|NCT01294709|Drug|Placebo to telcagepant|
45780941|NCT01295879|Drug|Ergocalciferol|Ergocalciferol 50,000 IU's orally per week, for 8 weeks
45780942|NCT01244633|Drug|Ecopipam|50 or 100 mg tablets given once per day for eight weeks
45780943|NCT01296191|Drug|Moxifloxacin|One drop 4 times daily for 3 days and one drop the day of sample collection
45780944|NCT01296191|Drug|besifloxacin|One drop 4 times daily for 3 days and one drop on day of sample collection
45780945|NCT01244711|Drug|quetiapine|Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
45780946|NCT01245413|Device|SenSura|Adhesive to stoma bag
45780947|NCT01245413|Device|Athena|Adhesive to stoma bag
45780948|NCT01210079|Drug|Gabapentin;|Gabapentin titrated to daily dose of 2400mg PO over 1 week with established dose taken daily for 5 weeks.
45780949|NCT01210079|Drug|Placebo|Placebo titrated over 1 week with established dose taken daily for 5 weeks.
45642141|NCT05441462|Procedure|Silastic Joint Replacement|Participants who have had silastic joint replacement surgery for degenerative or inflammatory arthritis within the last three years
45642142|NCT05440643|Biological|Peanut SLIT-tablet|Peanut extract
45642143|NCT05439616|Drug|Cariprazine|Oral Capsules or Oral Solution
45642144|NCT05439616|Drug|Placebo|Oral capsules or Oral Solution
45642145|NCT05439603|Drug|ANC-501|Five 10 mg capsules per day
45642146|NCT05438719|Device|BalancedBack Total Joint Replacement|The BalancedBack Total Joint Replacement is indicated for the biomechanical reconstruction and stabilization of a spinal motion segment following decompression at one lumbar level from L1/L2 to L5/S1 for skeletally mature patients due to symptomatic lumbar degeneration with or without foraminal or recess spinal stenosis confirmed by radiographic imaging (CT, MRI, X-rays), with no more than a Grade 1 spondylolisthesis at the involved level.
45642147|NCT05438212|Procedure|Brain Surgery|Undergo surgery per standard of care
45780950|NCT01245647|Drug|Naltrexone, 50mg, once per day for 4 months|Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
45780951|NCT01245647|Other|Sugar pill, 50mg, once per day for 4 months|Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
45780952|NCT00708110|Drug|GSK1349572|GSK1349572 is an experimental drug being developed for the treatment of HIV. It is in the class of integrase inhibitors.
46070619|NCT04238390|Drug|Meropenem|Meropenem 1 gram, every 8 hours, three times a day, intravenously over 30 mins. Dose adjusted for renal function.
46070620|NCT04237220|Diagnostic Test|stomach biopsies|To determine the diagnostic performance in the detection of Helicobacter pylori in biopsies taken only from the gastric antrum for the determination of the positive predictive value, the negative predictive value, and sensitivity and specificity.
45780953|NCT00708110|Drug|Placebo|Placebo is a tablet with no drug in it.
45780954|NCT01296815|Drug|Bevacizumab|Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3
45780955|NCT01246349|Behavioral|Motivational Interviewing (Treatment Group)|Motivational interviewing (MI) can be defined as a client-centered, directive method of therapy for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller and Rollnick, 2002). MI manifests through specific strategies, such as reflective listening, summarization, shared decision making, and agenda setting.
45780956|NCT01246349|Behavioral|Social Skills Training (Control Group)|Within the social skills training framework, advice is given to clients and sessions are focused on assigning goals for clients to work towards without specific regard for their readiness to change. The intervention is aimed at finding appropriate ways to navigate typical social situations (e.g., how to negotiate with parents).
45780957|NCT01276262|Drug|fostamatinib|Oral tablets, repeated doses for 21 days (2 x 50mg BID)
45780958|NCT01276262|Drug|Microgynon® 30 (Oral contraceptive)|Oral tablets, repeated doses
45780959|NCT01276262|Drug|Placebo|Oral tablets BID, repeated doses for 21 days
45780960|NCT01276340|Device|KEAT stimulator|electrical stimulation with KEAT stimulator : 4 times per week during 2 months
45780961|NCT01276418|Device|CO2 laser|Ablation and coagulation of soft tissue
45780962|NCT01297283|Other|LECG first|Measurement of the pacing threshold with the support of a leadless ECG
45780963|NCT01297283|Other|Programmer ECG first|Pacing threshold measurements are done with the support of the programmer ECG
45780964|NCT02995382|Procedure|Anterior Intramuscular Transposition|Anterior intramuscular transposition technique to decompress the ulnar nerve at the level of the elbow
45780965|NCT02998502|Device|Freespira Breathing System|Over an 8-week period the efficacy of the FBS system in youth will be tested, with those in the randomized active device group. The control group will not receive the device until completion of the 8 week baseline.
46070621|NCT04236830|Drug|Silver diamine fluoride/ potassium iodide|Thirty six first permanent molars will receive 38% SDF/KI as an indirect pulp capping material.
46070622|NCT04236830|Drug|Silver diamine fluoride|Thirty six first permanent molars will receive 38% SDF as an indirect pulp capping material.
46070623|NCT04236830|Drug|Resin modified glass ionomer cement|Thirty six first permanent molars will receive RMGIC as an indirect pulp capping material.
45448828|NCT03544996|Combination Product|TD Insulin|Human Insulin USP formulated in a solution capable of transdermal delivery.
45448829|NCT00564850|Drug|Triptorelin pamoate 11.25mg (Decapeptyl® SR)|One intra muscular injection at day 1 and month 3.
45642148|NCT05438212|Other|Quality-of-Life Assessment|Ancillary studies
45642149|NCT05438212|Other|Questionnaire Administration|Ancillary studies
45780966|NCT04351997|Procedure|Cord clamping|Umbilical cord clamping after delivery.
45780967|NCT01276496|Drug|Cilengitide|Given IV
45642150|NCT05438212|Radiation|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
45642151|NCT05437640|Behavioral|Protein Redistribution Diet|PD participants will be instructed by a Registered Dietitian to consume 10 grams or less of protein until their evening meal. They will then consume a high protein evening meal to meet their protein needs. They will receive one-on-one education and supportive materials to follow diet plan.
45642152|NCT05437640|Behavioral|Protein Consistent Diet|PD participants will be instructed by a Registered Dietitian to consume 20-30 grams of protein per meal. They will receive one-on-one education and supportive materials to follow diet plan.
45780968|NCT01276496|Other|Laboratory Biomarker Analysis|Correlative studies
45780969|NCT01276496|Drug|Paclitaxel|Given IV
45780970|NCT01276496|Other|Pharmacological Study|Correlative studies
45780971|NCT01297595|Drug|crizotinib|Each subject will receive 250 mg single oral doses of oral liquid formulation and formulated capsule of crizotinib separated by at least 14 days.
45917080|NCT05640427|Drug|normal saline|The same capacity of 0.9% normal saline was used in group C
45917081|NCT00000363|Drug|Antihistamine|
45917082|NCT00000363|Drug|Corticosteroid|
45917083|NCT03312868|Radiation|SBRT|Stereotactic Body Radiotherapy
45653066|NCT05125263|Other|kinesiotaping group|"Kinesio-taping with conventional therapy 24, 48 and 72 hours standardized therapeutic KT application along with conventional therapy (hot pack, strengthening and stretching exercises). The patient laid supine.To maintain proprioceptive stimulation in the quadriceps (from origin towards insertion) and to alleviate the tension of hamstring muscle, a 'Y'-shaped kinesiotaping will be applied. Afterward, 2 pieces of 'I'-shaped tapes were stretched by 75% through the mechanical correction technique and will be applied around the patellar circumference in the way that it would allow the patella to move naturally in the femoral cavity while the knee was in 45 flexion~CONVENTIONAL THERAPY:~Stretching of hamstrings 10 reps 10 sec hold. Straight leg raise 3 sets* 10 reps, 1 min interval. Strengthening of Quadriceps (quads isometric) and VMO with 10 reps and 3 sets, 1 min interval) Squatting (10 reps* 3 sets, 1 min interval)"
45780972|NCT01297985|Behavioral|BRIDGES Peer-Led Education|The BRIDGES program is a 10-week, manualized education course designed to provide basic education about the etiology and treatment of mental illness, self-help skills, and recovery principles in order to empower participants to return to valued social roles within their communities. BRIDGES is a peer-led program and all instructors are adults with mental illnesses. For this intervention study, the BRIDGES curriculum was modified from a week course to an 8-week course, meeting for 2 1/2 hours once a week.
45780973|NCT02992418|Biological|CYD Dengue Vaccine|0.5 milliliter (mL), Subcutaneous at Month 1, 7 and Month 13, respectively
45780974|NCT02992418|Biological|Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed|0.5 mL, intramuscularly (IM) at Month 1.
45780975|NCT02992418|Biological|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly at Day 0.
45780976|NCT01276730|Drug|Interferon, Retinoic Acid and radiation|Interferon-α2b will be administered 3 times a week for four weeks at a dose of 3 x 106 IU subcutaneously concomitant with radiotherapy. The first dose will be administered on the day the subject starts radiotherapy; 13-cis-retinoic acid will be administered orally at a dose of 40 mg/day for 1 month starting from day 1 of radiotherapy; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions to both the study group and the control group. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
45780977|NCT01276730|Drug|Cisplatin and radiation|Weekly cisplatin will be administered concurrent with external beam radiation at a dose of 40mg/m2/week for 5 weeks; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
45780978|NCT02994212|Dietary Supplement|Monthly distribution of RUTF|115 children eligible for the outpatient treatment of SAM were provided a monthly ration of RUTF.
45780979|NCT01298063|Drug|Afatinib|1 tablet, once qd in the morning
45780980|NCT01298063|Drug|Afatinib|1 tablet, once qd in the morning
45780981|NCT01298063|Drug|Afatinib|1 tablet, once qd in the morning
45780982|NCT04386356|Device|Orotracheal intubation with either Macintosh laryngoscope versus Airtraq video laryngoscope|Tracheal intubation will be performed by first year anaesthesia trainee using either Macintosh laryngoscope or Airtraq video laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.
45780983|NCT02999594|Drug|Tramadol Hydrochloride|50mg intramuscularly
45780984|NCT02999594|Drug|Distilled Water|2ml intramuscularly
45780985|NCT01298219|Drug|Lubiprostone|24 mcg administered orally twice daily (BID)
45780986|NCT01298219|Drug|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
45780987|NCT01276808|Procedure|Magnetic navigation PCI|Magnetically navigated angioplasty wire technique
45780988|NCT01276808|Procedure|Conventional PCI|Conventional manual angioplasty wire percutaneous coronary intervention
45780989|NCT01276886|Drug|antibiotic|
45780990|NCT01276886|Procedure|Colonic resection with or without stoma|
45780991|NCT02322242|Drug|Systemic Dexamethasone|Intravenous infusion of dexamethasone (4mg)
45917084|NCT05640388|Other|RV3278A - ET0943 cosmetic product|RV3278A - ET0943 study product is applied twice a day on the face during the whole study.
45917085|NCT05640388|Other|RV4632A - RY1845 cosmetic product|RV4632A - RY1845 study product must be applied only in case of sensation of skin discomfort
45917086|NCT05640349|Biological|Positive blood culture|Positive blood culture recorded at the microbiology laboratory of University Hospital of Nic
45917087|NCT00000369|Behavioral|Individual psychotherapy|
45917088|NCT00000369|Drug|Lithium carbonate|
45917089|NCT05640154|Behavioral|educational program|The nursing educational program will be implemented in small groups from (5-7) in outpatient clinics. It includes nutrition, exercise, control hypertension , engage in weight control measures, smoking cessation, stress management, breathing exercise, appropriate treatment of diseases, control of diabetes, control of cholesterol in blood and routine follow up).
45917090|NCT00000375|Drug|Nortriptyline-lithium (NOR-Li)|
45917091|NCT00000375|Procedure|Bilateral electroconvulsive therapy (ECT)|
45917092|NCT00000375|Drug|Continuation therapy|
45917093|NCT00000375|Behavioral|Continuation ECT|
45917094|NCT03295747|Drug|Peppermint oil|Three doses of peppermint oil will be investigated: 180, 360, 540 mg; i.e. three arms.
45917095|NCT05639998|Biological|COVAXIN(BBV152)|COVAXIN® on day 0 and on day 28 via the intramuscular route in GROUP 1. COVAXIN® (Intramuscular) on day 0 and BBV154 (Intranasal) day 28:GROUP 2
46070624|NCT04203212|Drug|Goserelin Acetate|Goserelin the a GnRH analog that will be administered to achieve menstrual cessation for 6 months
45448830|NCT02143882|Drug|Fluenz|Live attenuated influenza vaccine
45917096|NCT05639998|Biological|BBV154 Intranasal Vaccine|BBV154 (Intranasal) on day 0 and COVAXIN® (Intramuscular) on day 28: GROUP 3 BBV154 on day 0 and on day 28 via the intranasal route: GROUP 4
45917097|NCT05639959|Drug|Mometasone Nasal 50 Mcg/Inh Nasal Spray|Mometasone furoate nasal spray effectively reduced total and individual symptoms scores in patients with allergic rhinitis.
45917098|NCT05639959|Device|Nasal spray|device can work properly for actuation during trials
46070625|NCT04187066|Behavioral|mindset induction|induction of a health mindset to measure changes in cue-dependent and goal-directed behavior
45780992|NCT02322242|Drug|Perineural dexamethasone|Perinerual administration of dexamethasone (4mg)
45780993|NCT02993666|Device|Bair Hugger|forced air warming with Bair Hugger air warmer
45917099|NCT05639920|Combination Product|Scoreing|Validation of Emergency surgery score in predicting mortality and mortality in Egyptian patients undergoing Emergency laparotomy
46070626|NCT04163042|Behavioral|12-week videoconferencing behavioural support intervention to promote physical activity behaviour|Participants in Group A will receive six real-time, 1-on-1 60-minute sessions led by a physical activity counsellor over a 12-week period. Sessions will be delivered via videoconferencing and will aim to provide young adult cancer survivors with support as well as the knowledge, skills, and confidence to identify and overcome challenges to engaging in physical activity in order to increase physical activity behaviour and enhance patient-reported outcomes.
45780994|NCT02993354|Device|The EUM300 (electrical uterine myography)|External monitor intended for the evaluation of electrical signals originating in the uterus, thus providing a tool for measuring uterine activity as well as fetal heart rate.
45780995|NCT01211873|Drug|Dotarem (gadoterate meglumine)|0.1 mmol/kg by body weight, single IV injection
45780996|NCT01211873|Drug|Magnevist (gadopentetate dimeglumine)|0.1 mmol/kg by body weight, single IV injection
45780997|NCT02993588|Drug|Melatonin|Melatonin 6 mg tablet once daily
45754299|NCT03919292|Drug|Neratinib|Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study.
45780998|NCT02993588|Other|Placebo|one tablet once daily
46070627|NCT04789538|Other|monofocal lens|not applicable as patients are already implanted with the monofocal intraocular lens
46070628|NCT04484168|Procedure|Terminal Interruption of the Reflux Source|Foam Sclerotherapy of veins in the immediate vicinity of the venous ulcer
46070629|NCT04484168|Procedure|Axial Ablation|Endovenous ablation of venous reflux in the main superficial veins of the leg
46070630|NCT00637910|Drug|Erlotinib|Erlotinib 150 mg/day per os until disease progression or unacceptable toxicity develops
45780999|NCT02991092|Procedure|fluid administration|"After surgery, patients in the experiment group were provided with intravenous fluid administration at 1.0ml/Kg/h and encouraged to take food and drink water early after surgery, and the intravenous fluid administration was stopped immediately when the oral intake was more than 1500ml/h; patients in the control group strictly followed the fasting and were provided with the intravenous fluid administration according to Total amount of fluid = physiological requirement + additional loss (fever + gastrointestinal decompression) + amount lost until their intestinal function completely recovered."
46070631|NCT00637910|Drug|Docetaxel|Docetaxel 75 mg/mq on day 1, every 21 days (3-weekly schedule) or Docetaxel 35 mg/mq 0n day 1,8 and 15 every 28 days (weekly schedule). _Until disease progression or unacceptable toxicity develops
45781000|NCT01270022|Other|Implementation|
45917100|NCT03575208|Biological|hepatitis B immune globulin (HBIg)|HBIg 20,000 U/L iv. Dosing interval will depend on anti-HBs levels.
45917101|NCT03575208|Drug|Pegylated interferon alfa (pegIFN)|peginterferon alfa-2a 180 mcg weekly for 24 weeks
45917102|NCT03295552|Drug|Decitabine|decitabine 7mg/m2, d1-d5, q3w
45917103|NCT03295552|Drug|Carboplatin|carboplatin AUC = 6, d6, q3w
45917104|NCT05637541|Drug|GST-HG141|The trial consisted of a low-dose group and a high-dose group, each of which was 50mg bid and 100mg bid for 12 or 24 weeks of treatment
45917105|NCT05635591|Biological|(Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell line lysate|Patients will receive approximately （5-10）x10^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times.
45917106|NCT05634187|Device|Functional endoscopy|Transnasal endoscopy by an ultrathin video endoscope
46070632|NCT03408236|Drug|Botulinum toxin type A|Experimental
46070633|NCT03408236|Drug|Botulinum toxin type A|Active Comparator
45754300|NCT03919292|Drug|Divalproex Sodium|Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion).
45754301|NCT00604045|Behavioral|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
45781001|NCT01270022|Other|dissemination|
45754302|NCT00604045|Behavioral|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
45781002|NCT01277276|Device|Diffuse optical spectroscopy and Near infrared spectroscopy|Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
45781003|NCT04386824|Other|Erectil dysfunction|A complete ophthalmological examination including best-corrected visual acuity using the decimal system (BCVA), measurement of intraocular pressure (IOP) and axial length (AL), slit-lamp examination and dilated fundus examination
45781004|NCT01270100|Behavioral|Recovery management|
45781005|NCT01277432|Other|Psychiatrist Interview|"Patients will receive a face-to-face interview by a trained clinician or psychiatrist using the following instruments:~MINI~SSI-28 (somatization)"
46070634|NCT04155320|Behavioral|IMPART|Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell), 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together), or 3) have their partner(s) notified confidentially by a disease notifier (anonymous provider referral), who will locate partners, notify them of potential HIV exposure, and offer them HIV testing. Partners with an initial reactive HIV screening test will be referred to care and treatment services.
45781006|NCT01277432|Other|Depression screening - control|"All study participants will undergo;~a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal~a detailed psychological and behavioral assessments using validated questionnaires~several specialist questionnaires on depression, self care and quality of life"
45781007|NCT01270178|Drug|Entecavir|film coated tablets / 0.5mg / once daily / 3 years
45781008|NCT02993276|Device|Neurocap®|NEUROCAP®, a bioresorbable nerve capping device based upon the NEUROLAC® nerve guide, is indicated to protect a peripheral nerve end and to separate the nerve from surrounding environment to reduce the development of a symptomatic neuroma.
45642153|NCT05436028|Device|Transcatheter Tricuspid Valve Intervention|Due to unsustainable effect of medical therapy and high risks of surgical treatment, transcatheter tricuspid valve intervention (TTVI) has been a major field of study in the world in the last 10 years. TTVI could potentially reduce TR with lower periprocedural risk and improve the patient's clinical status and prognosis. Per the ESC guidelines for surgical and interventional treatment of tricuspid regurgitation (2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease), Transcatheter intervention for symptomatic secondary severe TR may be considered in inoperable patients at a Heart Valve Centre with expertise in the treatment of tricuspid valve disease (Class IIb). 20 Transcatheter tricuspid treatment options can be divided into categories based on their mechanism of action: coaptation enhancement (edge-to-edge repair and spacer device), annuloplasty devices, caval valve implantation and valve replacement.
45642154|NCT05435573|Drug|1000 mL of ringer's acetate solution|1000 mL of ringer's acetate solution
45642155|NCT05435573|Drug|250 mL 6% hydroxyethyl starch (Voluven) then 500 mL of ringer's acetate solution then 250 mL of 6% hydroxyethyl starch (Voluven)|500 mL 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride plus 500 mL of ringer's acetate solution
45642156|NCT05435235|Drug|Dapagliflozin 10mg Tab|One tablet daily starting 48h prior to PCI and continuing for 48h post-PCI.
45781009|NCT02993042|Device|Robot-assisted gait training|Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.5km / h (0.42m / s) and can be increased gradually to 3.0km / h (0.83m / s) by increasing to 0.2km / h (0.06m / s) per session. The therapist provides appropriate visual and auditory instructions to allow the patient to participate as fully as possible in the walking cycle provided by the walking robot. The treatment time per session is 30 minutes except for the time of wearing and releasing.
45781010|NCT01270334|Other|PH meassurment|meassuring ph USING PROBE
45781011|NCT01277900|Procedure|Laparoscopic Roux en Y gastric Bypass|Laparoscopic Roux-en-Y gastric bypass will be used as a standard procedure to treat type 2 diabetes mellitus
45781012|NCT02992730|Behavioral|No Intervention|No Intervention
45642157|NCT05435235|Drug|Placebo|Microcrystalline cellulose
45781013|NCT01270412|Biological|Platelet Rich Plasma (Preparation Rich in Growth Factors)|intra articular injection 6ml
45781014|NCT01270412|Drug|Hyaluronic acid|Intra articular injections: 20 mg / 2 ml
45781015|NCT02992496|Drug|Ketamine|1mg/kg, 6 applications over 2 weeks
45781016|NCT02992496|Drug|Midazolam Hydrochloride|0.03mg/kg, 6 applications over 2 weeks
45781017|NCT00729482|Drug|RAD001|RAD001 (everolimus) 10mg daily administration orally until disease progression and/or intolerability
45917107|NCT03572634|Drug|TP-0903|"Monotherapy: PHASE 1: TP-0903 will be a 25 mg flat dose. The study drug will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period).~Patients may continue to receive TP-0903 in 28-day cycles at the same dose given during Cycle 1 until they experience unacceptable toxicity or unequivocal disease progression. No intrapatient escalation of the TP-0903 dose is permitted.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. TP 0903 will be administered orally at a fixed dose once daily for 28 days (each cycle is 28 days; no drug-free period) with repeated cycles permitted until a patient experiences unacceptable toxicity or unequivocal disease progression."
45917108|NCT03572634|Combination Product|TP-0903 and ibrutinib combination therapy|"Combination therapy: PHASE 1: TP-0903 and ibrutinib combination therapy: The starting dose of TP-0903 will be a 20 mg flat dose. TP-0903 will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period). Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment.~Patients should continue with the combination of ibrutinib and TP-0903 for at least 3 months after study start.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment. Both TP 0903 and ibrutinib will be administered orally at fixed doses once daily for 28 days (each cycle is 28 days; no drug-free period)."
45917109|NCT03283930|Behavioral|Active Attention Bias Modification Training|Computer-based attention bias modification training administered at weekly CBT session aimed at re-training attentional biases
45917110|NCT03283930|Behavioral|Placebo Attention Bias Modification Training|Placebo version of a computer-based attention bias modification training administered at weekly CBT session thought to not influence attentional biases
45917111|NCT05632744|Device|CG-100 Intraluminal Bypass Device|Subjects will be treated with the CG-100 Intraluminal Bypass Device
45917112|NCT03562221|Other|Gluten free diet|Controlled gluten free diet
45917113|NCT03562221|Dietary Supplement|Probiotics|Capsules
45917114|NCT03562221|Dietary Supplement|Placebo|Capsules
45781018|NCT01270490|Drug|Interferon-gamma, Recombinant|Interferon 50 mcg/m2 to be administered three times per week during two weeks
45642158|NCT05433493|Behavioral|Cognitive stimulation|"The intervention program will have 24 sessions (base scheme of 4 series of 6 sessions), lasting approximately 45 min and will be developed according to the following structure: - welcoming (greeting to the participant) (5 min); - orientation to reality (10 min); - main cognitive stimulation activity (25 min); - return to calm and evaluation of the session (5 min).~The CS sessions will have an individual format and will be conducted by a professional with experience in CS and previously trained in this intervention. The intervention sessions will include several activities based on the CS principles, with evidence suggesting positive participant effects. The CS sessions will be carried out using material, developed by the principal investigator, in digital format (power point presentations). There will be no repetition of activities, and throughout the base CS program, the degree of difficulty of the exercises will be adjusted based on the dementia stage of the participant."
45781019|NCT01278056|Drug|Exjade|Two dose escalating cohorts of oral administration in Phase I. Phase II: oral administration of the maximum tolerated dose.
45781020|NCT02992652|Drug|Allopurinol|600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)
45781021|NCT01270646|Device|Invasive mapping with CARTO3 system and Non-Invasive mapping with CardioInsight Atlas EC Mapping system|"Day 1: CRT device is implanted under general anesthesia in a conventional fashion. The coronary sinus leads will be implanted guided by the acute hemodynamic response (+(dP/dt)max) using a RADI guide wire. After device implantation, a steerable mapping catheter will be inserted in the Left Ventricle (LV) cavity to build a tridimensional activation map of the LV. This map will be obtained with and without CRT. From these maps different parameters describing LV activation will be measured and compared between patients with and without CRT.~Day 5±2: A non-invasive map of the LV will be recorded with the CardioInsight ® system with and without CRT. The same parameters will be measured and compared with those obtained with invasive mapping."
45781022|NCT01270724|Drug|Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).|Two to four cycles of induction therapy with GemPOx followed by consolidation and ASCT.
45642159|NCT05432635|Biological|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
45642160|NCT05432635|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autoHSCT
45642161|NCT05432635|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
45781023|NCT00709826|Drug|gemcitabine|Gemcitabine: per package insert.
45781024|NCT00709826|Drug|placebo|placebo: 100 mg tablets, 400 mg/day
45781025|NCT00709826|Drug|Erlotinib|Erlotinib - per package insert.
45781026|NCT00709826|Drug|apricoxib|apricoxib: 100mg tablets, given orally
45917115|NCT05631379|Other|Measurement of body composition with computed tomography (CT)|The cross section of the third lumbar vertebrae in the CT scan images of the patients will be analyzed for assessment of body composition parameters including skeletal muscle area (SMA), muscle radiation attenuation (MRA), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT)
45917116|NCT05631379|Diagnostic Test|GLIM malnutrition criteria|GLIM criteria (Global Leadership Initiative on Malnutrition) will be applied to assess malnutrition
45642162|NCT05432635|Procedure|Myeloablative Conditioning|Given standard conditioning regimen
45642163|NCT05432388|Drug|remibrutinib|oral tablets
45917117|NCT05631379|Diagnostic Test|EWGSOP2 sarcopenia criteria|EWGSOP2 criteria (Writing Group for the European Working Group on Sarcopenia in Older People 2) will be followed to determine the diagnosis of sarcopenia
45917118|NCT05631379|Diagnostic Test|ESPEN-EASO criteria for sarcopenic obesity|The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) consensus criteria from 2018 will be applied to assess sarcopenic obesity
45917119|NCT05631379|Diagnostic Test|Prognostic Nutritional Index (PNI)|Prognostic Nutritional Index is diagnostic test based on serum albumin level and total lymphocyte count
45917120|NCT05631379|Diagnostic Test|The high-sensitivity modified Glasgow prognostic score|The high-sensitivity modified Glasgow prognostic score (Hs-mGPS) is an inflammation-based score consisted of C-reactive protein level and serum albumin
45917121|NCT05630248|Diagnostic Test|Recurrent Neural Network|it is to classify pulse types by using specialized pulse measuring instruments.
45917122|NCT05629468|Drug|Azithromycin|antibiotic
45917123|NCT05629468|Drug|Probiotic Formula|probiotics
45917124|NCT05629468|Drug|Benzoyl Peroxide 4 % Topical Cream|topical cream
45642164|NCT05432388|Drug|placebo|oral tablets
45781027|NCT01271114|Drug|Hypertonic Saline and Terlipressin|Hypertonic saline 3% 7mL/Kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation more than 10%; Terlipressin infusion (dilution 1mg in 100mL) triggered by MAP below 70 mmHg for a goal MAP above 70 mmHg
45781028|NCT01271114|Drug|Normal saline and norepinephrine|Normal saline IV bolus 7mL/kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation above 10%; Norepinephrine drip (80 micrograms/mL) to keep MAP at least 70 mmHg
45917125|NCT00000378|Drug|Sertraline|12 week trial dose up to 200mgs
45917126|NCT00000378|Drug|Nortriptyline|12 week trial dose adjusted to therapeutic level
45642165|NCT05428969|Drug|Bexmarilimab|Intravenous
45642166|NCT05428969|Drug|Azacitidine|As per label, subcutaneous
45642167|NCT05428969|Drug|Venetoclax|Oral
45642168|NCT05428891|Procedure|Abrams' needle pleural biopsy (IG-ANPB) versus medical thoracoscopy in the diagnosis of pleural diseases.|We compare the diagnostic efficacy and safety of imaging-guided Abrams needle biopsy with medical thoracoscopy.
45642169|NCT05426863|Behavioral|DeVI|A multi-component intervention is devised from the components of PM+ developed by WHO incorporating the components of violence prevention. The intervention is anticipated to provide behavioral skills to the participants in the intervention arm which will enhance their coping skills with past experiences of violence, stress management skills, problem-solving skills and safety planning skills. Further, they will be shared the best practices and lessons learned which will aid in danger assessments and prevention of future violence. The intervention will be given to intervention arm in 5 different sessions, one in each week. The 1st session of the intervention is about understanding the multi-component intervention. The 2nd session is identifying and managing problem, 3rd session is about stress management, followed by development of safety plan in 4th session and last session is about promotion of social support.
45642170|NCT05426629|Device|Venus Glow|"The Venus Glow hydradermabrasion device is a class 1 device trimodality dermal system consisting of vacuum, 360 degrees rotating tip and two jet streams of saline.~Adjustable vacuum deep cleanses the pores by pulling up daily dirt and debris, dry and dead skin cells, and excess sebum from the stratum corneum. It helps increase the microcirculation.~The 360-degree rotation helps in spreading the saline evenly, which is expelled from two ultra-fine jet streams. This micro massaging helps in faster release of nutrients from the skin. The jet stream is smaller than the average pore size measuring 50- 70 microns each, enabling the jet stream to deep clean each pore."
45642171|NCT05425901|Other|biopsy|endoscopy biopsies (6)
45781029|NCT00710840|Procedure|Minimally Invasive Total Knee Arthroplasty [TKA Min]|TKA Min is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee. TKA Min, as opposed to TKA Traditional, employs smaller skin incisions and smaller instrumentation and avoids turning the knee cap out and dislocating the knee. This procedure also avoids disrupting the knee extensor mechanism and the suprapatellar pouch and minimizes extreme knee flexion during surgery.
45642172|NCT05424120|Procedure|Manual aspiration|One option from standard of care
45642173|NCT05424120|Procedure|Wall suction|One option from standard of care
45917127|NCT05626621|Drug|Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray|Participants will follow this medication regimen for 6 months.
45917128|NCT05626621|Drug|Mometasone Nasal Irrigation (1 mg capsule)|Participants will follow this medication regimen for 6 months.
45917129|NCT05626621|Drug|Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation|Participants will follow this medication regimen for 6 months.
45917130|NCT05625256|Device|SentiCor-300|Continuous blood pressure measurement with the SentiCor-300.
45917131|NCT00000381|Drug|Fluoxetine|
45642174|NCT05424120|Procedure|Vacuum bottle drainage|One option from standard of care
45642175|NCT05423340|Other|E-cigarette Flavor|Participants use an electronic nicotine delivery system with an assigned tobacco-flavored e-liquid
45917132|NCT05619172|Drug|SOT101|Subcutaneous (SC) injection
45917133|NCT05619172|Drug|Cetuximab|Intravenous (IV) infusion via peripheral or central venous line
45642176|NCT05423340|Other|Tobacco Free Nicotine Pouch|participants will use tobacco free oral nicotine pouches
45642177|NCT05422690|Drug|Induction Chemotherapy Triplet Therapy|Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2, Nab-paclitaxel 125 mg/m2 given on days 1 and 8 of a 21-day cycle for two cycles.
45642178|NCT05422690|Radiation|Concurrent Y-90 treatment|One or two cycles (depending on whether or not one or two sessions of yttrium-90 are indicated as per the treating interventional radiologist) of gemcitabine 300 mg/m2 and cisplatin, 25 mg/m2 given on day 1 and 8 of a 21-day cycle. Y-90 will be administered on day 3-7 or day 10-21 of the cycle.
45917134|NCT05618041|Biological|CAR-T Autologous T cell injection|Biological: CAR-T; Drug: Cyclophosphamide,Fludarabine；Procedure: Leukapheresis
45917135|NCT05631925|Drug|propofol bolus|Propofol will be added in bolus doses of 0.5mg/kg.
45917136|NCT05631925|Drug|propofol infusion|Propofol will be administered as 10mg/kg/hour infusion.
45917137|NCT00000405|Procedure|Exercise intervention|
45642179|NCT05422690|Drug|Consolidation Doublet Therapy:|Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 given on days 1 and 8 of a 21-day cycle for 4-5 additional cycles. For the cycle directly after Y-90, gemcitabine will be kept at a dose of 300 mg/m2 to minimize risk of toxicity.
45642180|NCT05419505|Drug|CCH-aaes|Administered by subcutaneous injection.
45642181|NCT05419505|Drug|Antifibrinolytic Agent|Self-administered by participants enrolled in Cohort 7.
45642182|NCT05418673|Drug|BIIB122|Administered as specified in the treatment arm.
45642183|NCT05418673|Drug|BIIB122-Matching Placebo|Administered as specified in the treatment arm.
45642184|NCT05418582|Drug|DZD9008 and intraconazole|All subjects will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with itraconazole after the wash-out period.
45642185|NCT05418582|Drug|DZD9008 and carbamazepine|All subjects will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with carbamazepine after the wash-out period.
45781030|NCT00710840|Procedure|Total Knee Arthroplasty (TKA) Traditional|TKA is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee.
45781031|NCT02992340|Drug|Varlitinib|Per oral (PO) Varlitinib BID (starting dose at 200 mg BID)
45917138|NCT00389701|Drug|bortezomib|
45917139|NCT00389701|Drug|dexamethasone|
45917140|NCT05606926|Other|physical therapy program|Flexibility exercises to restore joint mobility of soft tissues, Static and dynamic balance exercises, Functional gait training , Functional strengthening exercises will be conducted three times a week, for three consecutive months.
45917141|NCT05606926|Other|whole body vibration (without extra weight vest)|9 minutes of three sets of 3-min semi-squats on the vibration platform. three times a week, for three consecutive months.
45781032|NCT02992340|Drug|Cisplatin|On D1 and D8, every 3 weeks. Cisplatin (25 mg per square meter of body surface area) in 1 litre of 0.9% saline with 20 mmol of potassium chloride and 8 mmol of magnesium sulfate intravenous (IV) infusion for 2 hours, followed by 500 mL of 0.9% saline over 30 minutes before the administration of Gemcitabine
45642186|NCT05417425|Combination Product|Omeza collagen matrix, Omeza lidocaine lavage, Omeza skin protectant|The three omeza products were designed to be used in combination for the treatment of chronic wounds
45781033|NCT02992340|Drug|Gemcitabine|On D1 and D8, every 3 weeks. Gemcitabine (1000 mg per square meter of body surface area) as a 30-minute infusion.
45642187|NCT05414955|Device|Neuromodulation|Neuromodulation
45642188|NCT05414617|Device|Intra-articular single injection|"Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injection will be performed at Day 1."
45781034|NCT00711464|Drug|modafinil (M1, M2, M4)|modafinil 100, 200, and 400 mg oral dose
45781035|NCT01278290|Diagnostic Test|Triptorelin acetate and Gonadorelin acetate|Triptorelin acetate test, using aqueous 0.1 mg/m2 subcutaneous. Gonadorelin test using 100 ug intravenous.
45642189|NCT05414617|Device|Intra-articular three injections|"Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injections will be performed at Days 1, 8 and 15."
45642190|NCT05414526|Other|InterCARE package|"The InterCARE package includes:~Healthcare Provider HTN/CVD Curriculum A new HTN curriculum will be developed in collaboration with local stakeholders using KITSO Master trainer program documents (Healthcare provider HIV curriculum), Primary Care Guidelines, HTN/CVD curriculum/protocols trialled in Kweneng District and the CDC Prevention Hypertension Management Curriculum.~Adaptation of HIV care EHR for HTN/CVD care EHR modifications will be done to enhance data collection around HTN/CVD care, with input from MoH.~Patient and treatment partner sessions Clinic staff will provide in-clinic education and counselling on HTN/CVD to all PLWHIV with a diagnosis of hypertension during their routine HIV clinic visit. All patients will be provided a take-home easy-to-read pamphlet on HTN/CVD risk factor management. All PLWHIV will be asked to bring a treatment partner from their social network at the 2nd study visit so that they can practice role-plays with each other."
45781036|NCT01278290|Diagnostic Test|Gonadorelin acetate and Triptorelin acetate|Gonadorelin acetate intravenous 100 ug. Triptorelin acetate 100 ug/m2.
45781037|NCT00575432|Radiation|diffusion MRI|diffusion MRI
45642191|NCT05414123|Device|CNSide|The Cerebro-Spinal Fluid (CSF) of subjects enrolled into each cohort will be used for Standard of Care diagnostic assessments used for subjects with either confirmed or suspicious LM (Cytology, protein and glucose) in combination with CNSide analysis.
45642192|NCT05413915|Drug|Asciminib|Tyrosine kinase inhibitor
45642193|NCT05413915|Drug|Imatinib|Tyrosine kinase inhibitor
45642194|NCT05413668|Drug|RVP-001|Intravenous administration of RVP-001
45642195|NCT05413668|Drug|Placebo|Intravenous administration of saline placebo
45781038|NCT00575432|Radiation|BOLD MRI|BOLD MRI
45781039|NCT00575432|Other|Clinical Outcome|Clinical outcome
45781040|NCT01278368|Procedure|Pancreatic resection after preoperative chemotherapy|Pancreatic resection after preoperative chemotherapy
45781041|NCT01278368|Procedure|Pancreatic resection|Pancreatic resection
45781042|NCT01278446|Other|Extensively hydrolyzed, whey protein infant formula|New hydrolyzed formula
45781043|NCT01278446|Other|Extensively hydrolyzed, casein protein infant formula|Commercially available hydrolyzed infant formula
45781044|NCT01271192|Procedure|surgical resection and adjuvant therapy|"Postoperative:~Drug: fluorouracil Given IV continuously, Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks"
45781045|NCT01271192|Procedure|Neoadjuvant followed by operation|"Preoperative:~Drug: fluorouracil Given IV continuously,Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks~Postoperative:~Drug: fluorouracil Given IV continuously,Irinotecan Given IV"
45781046|NCT02339558|Other|Laboratory Biomarker Analysis|Correlative studies
45781047|NCT02339558|Biological|Nivolumab|Given IV
45781048|NCT01271270|Drug|Palomid 529|
45781049|NCT00730730|Device|Complete SE Iliac Stent|Iliac stenting
45781050|NCT00730730|Device|Complete SE Iliac Stent|Self-expanding stent
45781051|NCT00730964|Drug|Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)|"The recommended dose of Optison is 0.5mL injected into a peripheral vein. This may be repeated for further contrast enhancement as needed.~The injection rate should not exceed 1mL per second. Follow the Optison injection with a flush of 0.9% sodium chloride injection, USP or 5% dextrose in water injection, United States Pharmacopeia (USP) .~The maximum total dose should not exceed 5.0mL in any 10 minutes period. The maximum total dose should not exceed 8.7mL in any one patient study."
45781052|NCT00731198|Drug|Drotaverine hydrochloride|Drotaverine hydrochloride 40mg was administered intravenously 15 minutes before ERCP
45781053|NCT00731198|Drug|Hyoscine-N-butylbromide|Hyoscine-N-butylbromide 20mg was administered intravenously 15 minutes before ERCP.
45781054|NCT01278602|Drug|R-ESHAP|Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
45781055|NCT00712244|Device|DisCoVisc|Use of DisCoVisc Ophthalmic Viscosurgical Device (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery.
45781056|NCT00712244|Device|DuoVisc|Use of DuoVisc viscoelastic system consisting of Viscoat (3% sodium hyaluronate, 4% chondroitin sulfate)and Provisc(1% sodium hyaluronate) during cataract surgery.
45781057|NCT00712244|Device|Healon5|Use of Healon5 ophthalmic viscosurgical device (2.3% Sodium Hyaluronate) during cataract surgery.
45781058|NCT00712244|Device|Amvisc Plus|Use of Amvisc Plus ophthalmic viscosurgical device (1.6% Sodium Hyaluronate) during cataract surgery.
45917142|NCT05606926|Other|whole body vibration (with weight vest)|The extra-weight applied in the vest will be calculated as 10% of the child body weight. The vest is designed to allow small bags of sand with different weights that are distributed equally on anterior-posterior and mediolateral plans.
45917143|NCT05606809|Diagnostic Test|Calculation of early prognosis score|Early prognosis score will be calculated at intensive care unit admission for each patient based on clinical and biological values as required
45642196|NCT05412628|Diagnostic Test|Oral swab test|In this study, we will perform tissue biopsy at esophageal tumor site in esophageal cancer patients and perform random biopsy at middle esophagus in patients without esophageal cancer. Besides, we will take oral swab in all participants.
45781059|NCT02992106|Other|Parental questionnaires|"We will provide parents with questionnaires depending on the age of their children:~Children aged 0-6 years old:~Questionnaire on socio-demographic characteristics~Dutch Eating Behaviour Questionnaire~Food Frequency Questionnaire~Ages and Stages Questionnaire~Strengths and Difficulties Questionnaire~Questionnaire on developmental milestones~Questionnaire on behaviour~Children older than 6 years:~Questionnaire on socio-demographic characteristics~Dutch Eating Behaviour Questionnaire~Food Frequency Questionnaire~Pediatric Quality of Life Questionnaire~Children's Behaviour Questionnaire in Dutch~Questionnaire on developmental milestones~Developmental Coordination Disorder Questionnaire~Strengths and Difficulties Questionnaire"
45781060|NCT02992106|Other|Blood sample|We will determine the following biochemical parameters: glucose, insulin, total cholesterol, LDL, HDL, triglycerides, uric acid, IGF-1, adiponectin, leptin, hs-CRP, IL-6, TNF-α and ICAM-1.
45781061|NCT02992106|Other|Urine sample|We will take a urine sample to evaluate the albumin to creatinin ratio.
45781062|NCT02992106|Other|Anthropometric measurements|We will measure weight, Height, hip, waist and neck circumference, blood pressure, 4-site skinfold measurements and BIA.
45781063|NCT02992106|Other|Ultrasound|We will do an abdominal ultrasound to measure the abdominal fat accumulation
45781064|NCT02992106|Other|EndoPAT|We will use the EndoPAT device to measure endothelial function, which is a non-invasive and innovative technique (peripheral pulse wave amplitude measurement).
45781065|NCT02992106|Other|Faces Pain Scale|After performing the measurements with the EndoPAT device, Harpender kalliper and ultrasound, the children will be asked to fill out a Faces Pain Scale, validated for children aged 4-16 years old and obtained for use from the International Association for the Study of Pain
46070635|NCT04155320|Behavioral|Standard Care|Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects are responsible for contacting and notifying their partner(s) on their own. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell) or 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together). Subjects may decide which partners to notify and may choose the same or a different method for each partner.
45781066|NCT02991950|Drug|Parnaparin Sodium|Parnaparin sodium ( Fluxum 4250 anti-Xa IU /0.4 mL or Fluxum 6400 anti-Xa IU /0.6mL; Alfa Wassermann S.p.A.) was administered at a dose of 100 IU/kg/day from the day before the beginning of the stimulation phase of the cycle until the result of the procedure was confirmed by pregnancy and, in the case of evolutive pregnancy, until delivery or the end of pregnancy
45781067|NCT02991872|Procedure|Blood draw|Subjects aged from ≥6 to ≤17 years at the time of enrolment in the parent clinical trial (following the CFDA post-marketing commitment requirement) and who received the full PEP rabies regimen as an intramuscular injection according to the vaccine group to which they were assigned in the V49_24 (NCT01680016) study will be invited to take part in this study. Single blood draw from subjects at Day-1/Visit-1. Subjects will be observed for 15 minutes after the blood draw.
45917144|NCT05601778|Drug|HSK31858|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 24-week treatment period in patients with non-cystic fibrosis bronchiectasis
45917145|NCT05601778|Drug|placebo|the placebo comparator of study
45917146|NCT00000408|Procedure|Patient education evaluation|
45917147|NCT05593900|Behavioral|Nurse-to-Family Video Chat|A Nurse-To-Family Video Chat will be offered to parents/guardians to virtually connect with their post-transfer nurse; this intervention is changing the behavior of how providers deliver healthcare and how parents/guardians engage in their child's care.
46070636|NCT04202744|Other|Shoulder and core evaluations|Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated.
46070637|NCT04202510|Procedure|Glaucoma and Cataract Surgery|Patients requiring combined cataract and glaucoma surgery will be randomized to either iStent, iStent Inject or Hydrus (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
46070638|NCT04202666|Device|convex skin barrier|Total 300 patients and grouping in 1:1 ratio.(1)peristomy skin complication (30 mins) (2)life quality stomy care (3-5 mins) (3)stomy appliance satisfaction (3-5 mins)
45781068|NCT02992262|Device|Point of care ocular ultrasound|
45917148|NCT00000411|Procedure|Decompressive laminectomy|Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis.
45917149|NCT00000411|Other|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
45642197|NCT05409066|Drug|Epcoritamab|Subcutaneous Injection
45642198|NCT05409066|Drug|Rituximab|Intravenous Infusion
45642199|NCT05409066|Drug|Lenalidomide|Oral Capsules
45642200|NCT05408845|Drug|Docetaxel|Given IV
45642201|NCT05408845|Other|Questionnaire Administration|Ancillary studies
45642202|NCT05408845|Biological|Trastuzumab|Given IV
45642203|NCT05408845|Biological|Trastuzumab Emtansine|Given IV
45781069|NCT01271582|Drug|Irinotecan, 5FU, leucovorin|FOLFIRI regimen every 2 weeks [irinotecan 150mg/m2 or 180mg/m2, leucovorin 20(200)mg/m2, 5FU 400 mg/m2 (bolus) or 2400 mg/m2 (46hour infusion)]
45781070|NCT02991638|Drug|Ibrutinib|Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression
46070639|NCT04473014|Behavioral|Heat Pain Paradigm|A standardized heat pain paradigm will be applied. Pain threshold will be determined with the self-controlled search method starting at 32°C, with a mouse-click-induced increase of 0.1°C per click. Pain tolerance is defined as the time in seconds elapsed from the onset of the pain stimulus to a participant's withdrawal from the stimulus. Participants will be instructed to continue with the task for as long as they can and to press a button if it becomes too uncomfortable or painful. Temperature will then return to baseline. To avoid physical injury, the measurement will stop automatically at a maximum temperature of 50°C.
46070640|NCT04031690|Other|Caregiver Quality of Life Questionnaires|Measurement of quality of life at D0, M6 and M12 via SF-36, CarGOQoL and the one-dimensional Zarit score
46070641|NCT04031690|Other|Patient Quality of Life Questionnaires|Quality of life measurement at D0, M6 and M12 via the SF-36
46070642|NCT04364828|Genetic|Whole Genome Analysis|Whole Genome Analysis with whole transcriptome analysis and deoxyribonucleic acid (DNA) methylation analysis using Methylation beadchip (EPIC) arrays
46070643|NCT04364828|Genetic|T-cell receptor (TCR) repertoire|Longitudinal analysis of TCR repertoire of Cluster of Differentiation 4+ (CD4+) and CD8+ T cells from blood samples (Peripheral Blood Mononuclear Cells, PBMCs) from clinically characterized patients
46070644|NCT04364828|Genetic|SARS-CoV-2 viral composition|Determined by Next Generation sequencing
45642204|NCT05408130|Device|Remote Ischemic Conditioning with Novel Optical Sensor Feedback Device|All patients randomized to intervention arm will receive 5 cycles of ischemia/reperfusion in non-paralysed upper limb or if no upper limb paralysis non-dominant arm. They will receive it once daily for a period of 7 days or during hospital stay whichever is shorter.
45642205|NCT05408130|Device|Sham Remote Ischemic Conditioning with Novel Optical Sensor Feedback Device|In the sham group subjects will receive pressure sensation by keeping the pressure at 30 mmHg for 3 min in both arms All patients in sham and intervention group will receive standard of care management for ischemic stroke
45642206|NCT05407675|Drug|BMS-986408|Specified dose on specified days
45917150|NCT05582746|Behavioral|Tri-City COVID Attitudes Study|We propose a two-year study to rapidly assess (Aim 1), build and push (Aim 2), evaluate and disseminate (Aim 3) an mHealth intervention to boost COVID-19 testing and vaccine literacy, access, and uptake among women with CLSI in three cities
45917151|NCT05573113|Diagnostic Test|Bowel Ultrasound|Bowel Ultrasound
45642207|NCT05407675|Biological|Nivolumab|Specified dose on specified days
45642208|NCT05407675|Biological|Ipilimumab|Specified dose on specified days
45917152|NCT05573113|Diagnostic Test|Abdominal radiograph|Abdominal radiograph
45917153|NCT05568706|Drug|EDP-938|Subjects will take EDP-938 once daily for 5 days
45917154|NCT05568706|Drug|Placebo|Subjects will take matching placebo, once daily for 5 days
46070645|NCT04354220|Diagnostic Test|capnography monitoring|routinely used capnography monitoring
46070646|NCT04354220|Diagnostic Test|arterial blood gas|Routinely taken arterial blood gas values
46070647|NCT04449536|Drug|Mesna|Administration of a single oral dose, using film-coated tablets of either 400 mg or 600 mg or a combination of maximum 3 tablets up to a maximum of 1600 mg
46070648|NCT03960554|Drug|Denosumab Inj 60 mg/ml|Treatment will be administered by study personnel as a subcutaneous injection every 6-months for one year.
46070649|NCT03960554|Other|Placebo|Placebo will be administered by study personnel as a subcutaneous injection every 6-months for one year.
46070650|NCT00911768|Dietary Supplement|Korean Red Ginseng Powder Capsule|Generic name: Korean Red Ginseng Powder Capsule Original herb name: Panax ginseng Form and contents: Capsule with powder of steamed root of 6-year Panax ginseng Dosage and frequency: 6 g per day (twice a day), Oral administration Administration duration: 56 days in the study
46070651|NCT00911768|Dietary Supplement|Corn-starch powder with ginseng flavor|"There is no specific name because this intervention is placebo. This placebo has the same form, color and flavor as Korean Red Ginseng Powder Capsule.~The dosage form, dosage, frequency and duration is also same as experimental intervention (Korean Red Ginseng Powder Capsule).~Main contents: corn-starch with Panax ginseng flavor"
45642209|NCT05407441|Drug|Tazemetostat|oral, twice daily, dosage per protocol
45642210|NCT05407441|Drug|Nivolumab|IV, dosage and schedule per protocol
45642211|NCT05407441|Drug|Ipilimumab|IV, dosage and schedule per protocol
45642212|NCT05406401|Biological|Zilovertamab Vedotin|IV infusion
45642213|NCT05406401|Drug|Cyclophosphamide|IV infusion
45642214|NCT05406401|Drug|Doxorubicin|IV infusion
45642215|NCT05406401|Biological|Rituximab|IV infusion
45642216|NCT05406401|Biological|Rituximab Biosimilar|IV infusion
45642217|NCT05406401|Drug|Prednisone|IV or oral administration (per local guidelines)
45642218|NCT05406401|Drug|Prednisolone|IV or oral administration (per local guidelines)
45642219|NCT05404542|Drug|Tavapadon|Oral tablets
45781071|NCT01271660|Drug|Pregabalin|"drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering"
45917155|NCT00000414|Behavioral|Arthritis Self-Management Program|
45917156|NCT00000414|Behavioral|SMART Program|
45917157|NCT00000420|Drug|Ortho-Novum 777|
45917158|NCT05563792|Behavioral|Options for Pain Management using Non-medication Strategies|The purpose of this study is to help Veterans learn about different ways they can manage chronic pain that do not involve medications. Veterans will work with a coach to explore their values and goals and how different non-medication approaches may fit into these values and goals.
45917159|NCT00000426|Drug|Calcium supplement|
45917160|NCT05555758|Drug|Aom0319|Multiple Dose for intravenous drip infusion
45917161|NCT05551858|Drug|Proglumide|(CAS: 6620-60-6.)
45917162|NCT05551858|Drug|Placebo|Avicel fiber filled capsule taken by mouth three times daily
45642220|NCT05402657|Procedure|Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy|UBRUL-FP involves ultrabrief right unilateral ECT delivered using a novel frontoparietal montage, where the anterior electrode is shifted frontally to a position above the midpoint of the right eye to avoid temporal lobe stimulation (and reduce memory side effects). UBRUL-FP will be delivered using standard ECT devices.
45917163|NCT00000432|Behavioral|Education about disease prevention|
45917164|NCT05539534|Behavioral|Training on suicide prevention|Suicide prevention training in Flanders is organised by the Centre for the Prevention of Suicide and the suicide prevention workers of the Centra for Mental Health Care. These trainings are announced via the website zelfmoord1813.be/vormingen or are organized on demand. When a participant registers, they will be invited to participate in the study one week before the training.
46070652|NCT04131374|Behavioral|Reminiscence Therapy|Virtual reality scenarios will be used to delivered reminiscence therapy with each caregiving dyad (i.e. person living with dementia; family member).
45642221|NCT05402657|Procedure|Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy|UBRUL-TP is the standard form of ultrabrief right unilateral ECT, using the conventional temporoparietal (d'Elia) electrode placement, where the anterior electrode is placed over the right temporal lobe. UBRUL-TP will be delivered using standard ECT devices.
45781072|NCT01271660|Drug|Placebo|"drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering"
45917165|NCT05530174|Other|Antibiotic dosage practice|"Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years.~All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered.~In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines."
45917166|NCT00000456|Drug|naltrexone (Revia)|
45917167|NCT00000456|Behavioral|cognitive behavior therapy|
45917168|NCT00000456|Behavioral|motivational enhancement therapy|
45917169|NCT05529628|Diagnostic Test|Cytokine levels|Preoperative cytokine levels of the patients
45917170|NCT00000459|Behavioral|diet, fat-restricted|
45917171|NCT05519683|Device|TEA|The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.
45917172|NCT05519683|Drug|Lexapro|This arm will receive treatment with the chemical neuromodulator escitalopram (Lexapro) at 10 mg once per day for 8 weeks. Lexapro is often used as a standard treatment for IBS.
46070653|NCT04117334|Other|Bracing|
46070654|NCT02377622|Device|THERANOVA 400 dialyzer prototype AA|
46070655|NCT02377622|Device|THERANOVA 400 dialyzer prototype BB|
46070656|NCT02377622|Device|FX CorDiax 80 Dialyzer|
46070657|NCT02377622|Device|FX CorDiax 800 Dialyzer|
45642222|NCT05394675|Drug|DS-9606a|Intravenous infusion
45642223|NCT05394103|Drug|Q901|The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter
45642224|NCT05394103|Drug|Pembrolizumab|Pembrolizumab will be administered Q6W
46070658|NCT03038984|Behavioral|At Home Screening procedure On demand|Home monitoring is a supportive treatment. Patients are randomized to screen themselves on demand
46070659|NCT03038984|Behavioral|At Home Screening procedure every 3 months|Home monitoring is a supportive treatment. Patients are randomized to screen themselves every 3 months
46070660|NCT03753932|Device|Fixed prosthodontics|The intervention takes place six months after finishing radiotherapy.
46070661|NCT04084106|Drug|Phenoxymethylpenicillin|Oral administration
46070662|NCT04084106|Drug|Amoxicillin|Oral administration
46070663|NCT04084106|Drug|Amoxicillin-clavulanic acid|Oral administration
45781073|NCT02991794|Device|EinsteinVision 3D visualization system|Elective laparoscopic radical prostatectomy due to histologically proven prostate cancer using EinsteinVision® 3D visualization system.
45781074|NCT02991560|Other|Strengthening exercises|The exercises consisted of 3 sets with 20 repetitions of wrist and elbow flexion; 2 sets with 10 repetitions of wrist extension strengthening starting with 50% of the maximum strength and density increasing the resistance each week; and finally, 2 sets with 10 repetitions of the wrist flexor and extensor muscle groups comprising 20 sec of stretching and 10 sec of relaxing using the healthy hand.
46070664|NCT04229654|Other|Questionnaire|A written questionnaire was used to capture demographic data, obstetric history, knowledge, expectations, and perception of anomaly scans.
46070665|NCT04227080|Drug|BH4|oral administration of 20 mg/kg KUVAN (BH4)
46070666|NCT03750110|Other|Intervention|"In addition to usual care, personalised feedback from the participants screening appointment will be provided;~For participants with emphysema, an image of their own emphysematous lung compared to a library image of normal lung, or a section of their own non-emphysematous lung. Where emphysema is not present, library pictures showing normal and emphysematous lung will be used.~For participants with coronary artery calcification, a cross sectional segment from their chest scan (either horizontal or vertical) showing the calcium compared to a library image of coronary arteries without calcification and/or a healthy section of the participant's own heart scan. Where coronary artery calcification is not present, library pictures showing normal and calcified coronary arteries will be provided."
46070667|NCT03750110|Other|Usual Care|Smoking cessation support in line with NICE PH48 guidelines
46070668|NCT03746210|Diagnostic Test|Standard diagnostic procedures|B-Mode ultrasound, Duplex sonography, contrast-enhanced ultrasound, elastography, CT, MRI, anthropometrics
46070669|NCT02977052|Drug|Ipilimumab|
46070670|NCT02977052|Drug|Nivolumab|
45642225|NCT05389618|Other|Diagnostic Tests|Assessment of socio-demographic parameters, anthropometric and body composition parameters, food intake (dietary recalls, food propensity questionnaire) and nutritional status (blood biomarkers)
45642226|NCT05389293|Drug|Mosunetuzumab|During Cycle 1, mosunetuzumab will be administered SC in a step-up dosing schedule at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15). Beginning with Cycle 2, mosunetuzumab will be administered SC at the dose of 45 mg on Day 1. Each Cycle lasts 3 weeks. After the first 8 cycles (approximately 6 months) of therapy, subjects who achieved CR will discontinue therapy, those who attained a PR will receive up to 17 doses (approximately 12 months). Subjects who achieve stable disease (SD) or who experience progressive disease (PD) will be taken off study and subsequent management will be left at the discretion of the investigator.
45642227|NCT05388851|Other|Educational Intervention|Complete educational training module
45642228|NCT05388851|Other|Questionnaire Administration|Complete questionnaire
45642229|NCT05388474|Other|No ibalizumab or Pre-ibalizumab treatment|Patient registry
45642230|NCT05388474|Biological|On ibalizumab treatment|Patient registry
45781075|NCT02991560|Other|Intensive Physioytherapy|The treatment consisted of a cold pack (enclosed in a moist towel for 12 minutes around the elbow joint), TENS (in an asymmetrical biphasic wave form and burst modulation, current width 150 mms, pulse frequency 5 Hz), and deep transverse friction massage (2 minutes of application to the locally sensitive areas determined through palpation on anterolateral surface of lateral epicondyle) followed by home exercises.
45781076|NCT02991560|Device|Kinesio taping|Kinesio tape has been implemented on forearm of the patients for the treatment of lateral epicondylitis
45781077|NCT02991560|Device|Athletic taping|By athletic taping, similar effects with Kinesio taping were aimed to gain. Considering the McConnel principles
46070671|NCT02977052|Procedure|Surgery|Surgery will be done at 6 weeks
45781078|NCT00731588|Biological|Transfused Biotin RBCs - Adults Phase I|A 3 mL venous blood sample is obtained. 250 mL of blood will be drawn to a blood collection bag containing the anticoagulant CPD. Separate equal volumes of RBCs are labeled with up to five different densities of biotin. The biotinylated RBCs are resuspended in autologous plasma to achieve a 60 to 70% hematocrit. An IV is inserted for the reinfusion of the biotinylated RBCs. Three mL aliquots of blood are sampled at 5, 10, 20, and 60 minutes after infusion. The subject returns ~24 hours and 3 days after the RBC infusion to obtain a 3 mL venous blood sample. Subjects return for weekly 3 mL blood sampling.
45781079|NCT00731588|Biological|Transfused Biotin RBCs - Infants Phase II|After the infant's clinical care team decides that a RBC transfusion is needed, a 15mL/kilogram of body weight is ordered. Transfusion will be given in 2 parts: 1) approximately 80% of the total transfusion to be transfused over 3-4 hours and 2) approximately 20% of the total transfusion will be marked with biotin to be transfused upon completion of the first part. The bedside nurse maintains constant observation of the infant as appropriate for the infant's condition, assessing for signs and symptoms of a transfusion reaction.
45781080|NCT00731588|Biological|Transfused Biotin RBCs - Infants Phase III|Phase III (infants) to be determined upon completion of Phase II (infants).
45781081|NCT01271738|Procedure|Remove tumor only|No additional margins (tissue) removed at the initial surgery
45781082|NCT01271738|Procedure|Removal of tumor and tissue|5 additional margins (tissue) removed at the time of surgery
45917173|NCT05516563|Other|EDucation and eXercise intervention|"The exercise programme includes 3 key streams:~Low-load isometric abduction~Functional loading~Abductor loading: Graduated abductor loading, designed to improve load tolerance by applying progressively higher loads across the abductor muscles. Daily exercise will be completed three days a week at a 'hard' to 'very hard' level, alternating with three 'light' days and one rest day. The clinic day will constitute one of the 'hard' days.~Education will be delivered via a 20 minute video which focusses on understanding and managing lateral hip pain ( ie pain associated with gluteal tendinopathy). Education will also be tailored to each patient on attendance with the physiotherapist at the 6 clinic visits"
45642231|NCT05386550|Drug|Xevinapant (Debio 1143)|Participants will receive 3 cycles of oral solution of Xevinapant (Debio 1143) at a dose of 200 milligrams per day (mg/day) once daily from Day 1 to 14, per 3-week cycle in combination with radiotherapy followed by 3 cycles of monotherapy of Xevinapant (Debio 1143) at a dose of 200 mg/day from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).
45642232|NCT05386550|Radiation|IMRT|Participants will receive 66 Gy of intensity modulated radiation therapy (IMRT) in 33 fractions, 2 Gy/fraction, 5 days/week.
45642233|NCT05386550|Drug|Placebo|Participants will receive 3 cycles of oral solution of placebo matched to Xevinapant (Debio 1143) once daily from Day 1 to 14 per 3-week cycle in combination with radiotherapy followed by 3 cycles of monotherapy of placebo matched to Xevinapant (Debio 1143) from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).
45642234|NCT05384769|Procedure|Liquid Biopsy|Undergo liquid biopsy
45642235|NCT05384769|Procedure|Low Dose Computed Tomography of the Chest|Undergo low dose CT
45642236|NCT05384769|Other|Survey Administration|Ancillary studies
45642237|NCT05383976|Other|Machine Learning Algorithm with Existing Penn Medicine CRC Patient Navigation Program|This intervention will utilize the existing Penn Medicine CRC patient navigation program. There will be a monthly list of patients with unfilled coloscopies provided, that are risk-stratified according to the machine learning algorithm and select high-risk criteria. The navigation team will prioritize timely outreach and navigation to high-risk patients according to a script that communicates risk.
46070672|NCT02977052|Procedure|Blood for PBMCs|Blood will be taken for translational research on PBMCs
46070673|NCT02977052|Procedure|Biopsies|Biopsies will be taken during screening and at relapse.
45642238|NCT05383378|Drug|si-544|Subcutaneous injection in the abdomen
45642239|NCT05383378|Drug|Placebo|Subcutaneous injection in the abdomen
45642240|NCT05382559|Drug|ASP3082|Intravenous Infusion
45642241|NCT05382559|Drug|Cetuximab|Intravenous Infusion
45642242|NCT05379699|Other|TOR-BSST© eLearning Training|An online self-directed training program for TOR-BSST© dysphagia screeners.
45642243|NCT05379699|Other|Standard TOR-BSST© Training|Standard 4-hour in-person TOR-BSST© screener training conducted by a Speech-Language Pathologist.
45642244|NCT05379439|Other|Structured Family Deliberation|Intervention families will be guided through the six modules included in the web-based decisional aid using a Structured Family Deliberation Tool. Parents will view narrated videos corresponding to each module and will be asked a series of questions related to their own lives and values. The process will continue until all modules are reviewed and all questions are completed.
45642245|NCT05375955|Drug|PF-07038124 ointment 0.01%|Atopic Dermatitis and Plaque Psoriasis
45642246|NCT05375955|Drug|Vehicle ointment|Atopic Dermatitis and Plaque Psoriasis
45642247|NCT05375955|Drug|PF-07038124 ointment 0.03%|Atopic Dermatitis and Plaque Psoriasis
45642248|NCT05375955|Drug|PF-07038124 ointment 0.06%|PF-07038124 ointment 0.06% (Plaque Psoriasis only)
45642249|NCT05375162|Behavioral|Core Intervention|"All participants will receive a low-resource self-monitoring intervention consisting of the Fitbit Alta HR (or similar) and the Opt2Move self-monitoring app.~Participants will be provided with the Fitbit Alta HR. They will be asked to download the Fitbit app and wear the Fitbit 24/7 throughout the 24-week study period. The Fitbit measures PA intensity, steps, and heart rate, and it syncs directly with the Ftibit app on the smartphone which will ill automatically sync with the Opt2Move study app and provide Fitbit data to the study team in real-time.~The core Opt2Move study app will support YACS to increase their MVPA. The app will also contain educational information on MVPA and effective behavior change strategies for building self-efficacy, overcoming barriers, enhancing facilitators, setting realistic outcome expectations, and self-regulatory skill-building (i.e., reviewing progress, goal setting, action-planning and coping with disruptions)."
45642250|NCT05375162|Behavioral|E-Coach|Participants assigned to this condition will receive a weekly scheduled text message from their coach. Text messages will focus on building self-efficacy and self-regulation skills, setting realistic outcome expectations, overcoming barriers, and problem-solving and will directly support the participant's engagement in the intervention. The coach will provide a brief overview of the participant's recent progress and goals, ask if they are having any barriers and help them troubleshoot and set specific goals for the next week. Text message protocols will be informed by the investigators' previous experience using telephone coaching to promote MVPA in cancer survivors. In addition to the scheduled messaging, participants will also be instructed to reach out to their coach with any questions or for additional assistance.
45642251|NCT05375162|Behavioral|General Mindfulness Training|Participants assigned to this condition will be instructed to watch 1 (1-2 mins), mindfulness education videos each week which lay the foundation for what mindfulness is and how it can be an important health behavior. Each week participants will also be asked to listen to general guided mindfulness audio files ≥5 days/ week. The length of recordings will gradually increase each week from 3-5 to 25-30 minutes. All videos and recording will be available via the Opt2Move app.
45781083|NCT01278680|Behavioral|Incentives for walkstation usage|The investigators are testing the effect of two different incentive schemes on people's usage of walkstations at work: either a personal incentive (in which people receive personal financial benefit for using the walkstations) vs. a charitable incentive (in which others receive financial benefit if a given individual uses the walkstation).
45781084|NCT01271894|Drug|Efavirenz|600 mg once daily; given as 3 x 200 mg once
45781085|NCT01271894|Drug|Efavirenz|400 mg once daily; given as 2 x 200 mg + 1 x placebo
45781086|NCT01271972|Drug|nesvacumab (REGN910/ SAR307746)|
45781087|NCT01278758|Drug|ASA404, DMXAA or DXAA|
45781088|NCT02991716|Other|recorded patients|No intervention applied, only recording of cutaneous ECG signal from specific points on the torsi
45917174|NCT05510635|Other|interactive bibliotherapy|The researcher selected two picture books whose central issues are about the common emotional distress of adolescents with cancer, that is, negative emotion coping, and self-worth. The researcher will read the story to the participant and then use the interview guideline to discuss it with him or her one by one. The interview guideline for interactive bibliotherapy is listed according to the mechanism of bibliotherapy, including identification, catharsis, and insight, and additional questions leading a reader to think deeply.
45781089|NCT00717626|Drug|Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS|Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is < 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.
45917175|NCT05510635|Other|reading bibliotherapy|The researcher selected two picture books whose central issues are about the common emotional distress of adolescents with cancer, that is, negative emotion coping, and self-worth. The participant can take 20 to 25 minutes to read the story. No one can bother the participant during the intervention.
45781090|NCT04386668|Other|Let It Out (LIO)-C|Participants complete three online 20-minute writing sessions in response to prompts asking them to write about their experiences during the COVID19 pandemic from a self-compassionate perspective
45917176|NCT00000462|Procedure|angioplasty, transluminal, percutaneous coronary|
45917177|NCT00000462|Procedure|coronary artery bypass|
45917178|NCT05507944|Diagnostic Test|FeNO measurement|Diurnal measurements before work and at 3 hours after work start.
45917179|NCT05486611|Device|W-GenZD Mobile Application|"W-GenZD is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need."
45642252|NCT05375162|Behavioral|MVPA-Specific Mindfulness Training|Participants assigned to the MVPA-specific mindfulness training component will be instructed to watch 1-2 brief (1-2 minute), mindfulness education videos each week which lay the foundation for what mindfulness is and the importance of linking mindful awareness with MVPA. Each week participants will be provided access to MVPA-specific guided mindfulness audio files (e.g., 10-minute treadmill walking meditation, 20-minute bicycling meditation) that they will be asked to listen to during ≥3 MVPA sessions/week. The length and intensity of these audio files will correspond to their progression in the program. All videos and recordings will be accessed via the Opt2Move app.
45642253|NCT05375162|Behavioral|Buddy|Participants assigned to this condition will select a buddy of their choice (i.e. friend, co-worker, caregiver or family member) that is ≥ 18 years of age and willing to share their Fitbit data with the study team. The buddy will be mailed a Fitbit, share their Fitbit data with the study team, and be provided with access to, and instructions for, all of the Opt2Move app modules the participant has access to for their assigned condition. The Opt2Move app will include a buddy module where the buddy and participant can view each other's progress. The buddy will be expected to attend a 15-30 minute group orientation call and listen to four 10-15 minute podcasts (one every 3 weeks) during the first 12 weeks of the intervention. Each podcast will provide social support training and peer discussion of challenges and successes in providing YACS with MVPA support.
45642254|NCT05374044|Diagnostic Test|pelvic MRI for establishing new mrTRG method|they will received two pelvic MR examinations before and after neoadjvant therapy. The MRI before neoadjvant therapy is considered as baseline MRI, which is usually taken within 3 weeks before NAT. The MRI after neoadjvant therapy is considered as preoperative MRI, which is usually taken within 3-8 weeks before NAT.
45642255|NCT05372744|Other|Active Placebo labelled as antidepressant|Participants receive an active nasal spray that is in fact a placebo with a specific framing in regards to its affect-regulatory characteristics, respectively.
45642256|NCT05372328|Other|Position of arm while taking blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which their arm position changes prior to each set of measurements.
45781091|NCT04386668|Other|Neutral writing control|Participants complete three online 20-minute writing sessions in response to neutral writing prompts
45781092|NCT00718094|Drug|Polyphenon E®|Oral capsules
45781093|NCT00718094|Drug|Placebo Oral Tablet|Oral tablet: placebo
45917180|NCT05486611|Device|Digital Education Application (W-EdZD)|"Digital Education will be available to the participant via the 'Quest GenZ' smartphone application but will be devoid of active elements included in WB002. We will source this material from kidshealth.org, which is supported by Nemours Children's Health. We have received permission to use their content.~The materials are written at an 8th grade reading level and will include general health (e.g., food plate guide, caffeine, online safety, study skills) articles. A new article will be provided to the participant at a rate of once per week across the 4 weeks (4 articles total) and they will receive a weekly notification when a new article is available. Each article will be available for one week from release date."
45917181|NCT05486455|Diagnostic Test|Low-dose chest CT scan|baseline, 1-year, 3-year and 5-year low-dose CT scan
45917182|NCT05481658|Drug|Diphencyprone (DPCP)|topical immunomodulator
45917183|NCT05455060|Drug|Chinese herbal formula (CHF)|Each CHF capsule, weighing 500mg, is composed of Xiao-Feng-San 200mg, Zhen-Ren-Huo-Ming-Yin 200mg, Dictamnus dasycarpus 50mg and Houttuynia cordata 50mg. Patients will take the medicine 2 times a day (6gm BID for BW≥40kg), for 12 weeks, and the dosage will be modified according to patients' body weight. (3gm BID for 20kg≦BW<40kg; 1.5gm BID for BW<20kg)
45917184|NCT05455060|Drug|Placebo|The patients in control group will take the placebo capsules, which has the similar look, smell, and taste. The dosage, frequency, and duration are the same as CHF group.
45781094|NCT01272128|Drug|Interferon beta-1a|Interferon beta-1a will not be provided as a part of this study. Participants will receive Interferon beta-1a as prescribed by their treating physician prior to enrollment.
45781095|NCT02991326|Other|Osteopathic Manipulative Treatment|"The Osteopathic manipulative treatment will follow the approach bellow (using latex gloves for intra oral techniques):~Compression of the fourth ventricle;~inhibitory intra-oral pressure technique (IPT) of the temporal muscle;~inhibition of the inferior head of the lateral pterygoid muscle;~intra-oral inhibition of the masseter muscle;~Balanced ligamentous tension (BLT) of the accessory ligaments - sphenopalatine;~BLT of the accessory ligaments - pterygomandibular raphe;~sphenopalatine ganglion technique;~Craniosacral rebalancing;"
45781096|NCT02991326|Other|Sham intervention|The sham intervention will be made in the same examination table and the same position, with the use of the latex gloves, to simulate the Osteopathic Manipulative Treatment, only doing simple touches without therapeutic effect intention.
45642257|NCT05372172|Other|none, observational study|none, observational study
45642258|NCT05372159|Other|none, observational study|none, observational study
45642259|NCT05371587|Other|Autonomy and Perceptions Approach to Resistance Training (APART)|Alternative resistance training prescription based on trainees' autonomy and perceptions.
45642260|NCT05371587|Other|Standard prescription|Standard resistance training prescription, based on international organization's guidelines.
45642261|NCT05371093|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
45642262|NCT05371093|Drug|Cyclophosphamide|Administered intravenously
45642263|NCT05371093|Drug|Fludarabine|Administered intravenously
45642264|NCT05371093|Drug|Lenalidomide|Administered orally
45642265|NCT05371093|Drug|Rituximab|Administered intravenously
45781097|NCT02991170|Procedure|unipolar or bipolar radiofrequency ablation+CABG|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing unipolar or bipolar radiofrequency ablation and Coronary Artery Bypass Grafts at the same time
45781098|NCT02991170|Procedure|CABG|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing Coronary Artery Bypass Grafts
45781099|NCT01278836|Procedure|fasciocutaneous flap|flaps which include skin, subcutaneous tissue, and the underlying fascia.
45781100|NCT00719186|Drug|Clomiphene citrate|Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
45781101|NCT00719186|Drug|Letrozole|Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
45781102|NCT02991404|Procedure|Multimodal Peripheral Nerve Block Injection|After successful placement of the adductor canal catheter placed in standard fashion , the patient will receive a one-time 20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine followed by a continuous infusion of 0.125% bupivacaine set at 10ml/hour.
45917185|NCT05442268|Procedure|Acetaminophen group|patients will receive intravenous 500 mg acetaminophen(every 6 hours postoperatively
45917186|NCT05442268|Procedure|Duloxetine group|Patients will receive duloxetine 30 mg every 12 hours for 3 days before surgery, 30 mg 2 hours preoperatively and 30 mg 12 hours postoperatively and intravenous 500 mg acetaminophen every 6 hours postoperatively
45917187|NCT05451355|Behavioral|Family Safety Check-In|Prototype decision aid to support within-family communication and decision making about firearm storage.
45642266|NCT05371093|Drug|Doxorubicin|Administered intravenously
45642267|NCT05371093|Drug|Vincristine|Administered intravenously
45642268|NCT05371093|Drug|Prednisone|Administered orally
45642269|NCT05371093|Drug|Bendamustine|Administered intravenously
45642270|NCT05371028|Other|Non-interventional Study|This is non-interventional study.
45642271|NCT05368883|Other|Exercise- One-Legged|"One-legged cycling ergometer training will consist of 5 minutes of warm-up, 10 minutes for each leg in the first 2 weeks, 15 minutes of cycling training in the following weeks (5-10 minutes of rest while switching from one leg to the other leg) and a 5 minutes cool-down period. In the one-legged cycling ergometer training, it will be determined randomly that the patients start the exercise with the dominant or non-dominant leg.~One-legged and two-legged exercise training will be maintained at moderate intensity (64-76%) according to maximum heart rate.~Both groups will be given walking on flat ground once a week, with an exercise intensity of 11-13 according to the Borg scale, as home exercise."
45642272|NCT05368883|Other|Exercise-Two-Legged|"Two-legged cycling ergometer training will consist of 5 minutes of warm-up, 20 minutes for the first 2 weeks, 30 minutes of cycling training in the following weeks, and a 5 minutes cool-down period.~One-legged and two-legged exercise training will be maintained at moderate intensity (64-76%) according to maximum heart rate.~Both groups will be given walking on flat ground once a week, with an exercise intensity of 11-13 according to the Borg scale, as home exercise."
45642273|NCT05363540|Procedure|pre-incisional parasternal intercostal block|LA will be administrated by the anesthesiologist under ultrasound guidance and before surgical incision On either side of thorax, 2 cm lateral to sternal edge from 2nd to 6th intercostal space, A volume of (4 mL) of 0.25% bupivacaine will be used
45642274|NCT05363540|Procedure|post-incisional parasternal intercostal block|LA will be administered by the cardiac surgeon before the sternal closure. injection will introduced 2 cm lateral to sternal edge from 2nd to 6th intercostal space and volume (4 mL) of 0.25% bupivacaine will be used.
45642275|NCT05362318|Drug|Nicotine patch and lozenges|Participants will receive nicotine patch and lozenges. The regimen will be based on the participant's self-reported smoking rate. At the time of enrollment, a research staff member will determine the proper dose. Participants who smoke >10 cigarettes/day will receive 8 weeks of 21 mg. patches, 2 weeks of 14 mg. patches, 2 weeks of 7 mg. patches, and 12 weeks of 2 mg. lozenges. Those who smoke <10 cigarettes/day will receive 8 weeks of 14 mg. patches, 4 weeks of 7 mg patches, and 12 weeks of 2 mg. lozenges
45642276|NCT05362318|Behavioral|Telephone counseling sessions|Participants will be offered 6 Motivation and Problem Solving (MAPS)-based counseling sessions by phone over a 6-month period.
45642277|NCT05362318|Behavioral|Access to a web-based video|"Participants will be given web-based access to the relapse prevention video Surviving Smokefree."
45448831|NCT02143960|Device|VelaShape III|Subjects will receive one treatment to their entire waist / love-handle/ flanks area in a split-waist fashion, so that one side is treated with one device and the other side is treated with the other device. The treatment session will include: one side (right or left) treated with the VelaShape III device and the other side (left or right, respectively) with the CoolSculpt device. The subject will be randomized to one of 2 treatment groups, one will receive treatment to the left side with the VelaShape II and the right side will receive treatment with the CoolSculpt. The other group will receive treatment to right side with the VelaShape II and the left side will receive treatment with the CoolSculpt.
45448832|NCT02143960|Device|CoolSculpt|Noninvasive Cryolipolysis
45781103|NCT02991404|Procedure|Single Shot Adductor Canal Block|A total of 20 ml of solution containing a combination of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, 150 micrograms of buprenorphine, 2 mg of dexamethasone, and 1:400,000 epinephrine will be administered underneath the Sartorius muscle. A sham catheter will then be placed subcutaneously into the Sartorius muscle, secured in typical fashion, and connected to a pump containing saline to provide similar shape and weight with an opaque bag covering the pump. The pump will be run at the lowest possible ml/hour rate, which is currently 0.1 ml/hour with the current pump used in our hospital.
45781104|NCT02991404|Drug|Initial Bolus|20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine
45917188|NCT05451355|Behavioral|AAP Firearm Storage Web Page|Educational web page that discusses safe firearm storage practices.
45448833|NCT00561340|Dietary Supplement|Pediasure|50% will be randomized to pediasure with nutritional counseling
45642278|NCT05362318|Behavioral|Florida Tobacco Quitline|Participants will receive an offer of enrollment to the Florida Tobacco Quitline which enables participant to speak with a Quit Coach who will assess nicotine addiction and help create a quit plan.
45642279|NCT05361967|Device|The Tack Endovascular System|The Tack Endovascular System is designed to treat vascular dissections with Tack implant(s) following angioplasty.
45448834|NCT00561340|Behavioral|Nutritional counseling|50% randomized to nutritional counseling only
45448835|NCT02144038|Drug|LGH447|pan-PIM inhibitor
45642280|NCT05360069|Device|Linear stapler|Linear stapler is adopted in esophagojejunostomy
45642281|NCT05360069|Device|Circular stapler|Circular stapler is adopted in esophagojejunostomy
45642282|NCT05359367|Diagnostic Test|Observational|Laboratory movement analysis, navigated transcranial magnetic stimulation and clinical aspects of gait function and walking.
45642283|NCT05359068|Drug|SPH3127 tablet|50 mg tablet
45642284|NCT05359068|Drug|SPH3127 tablet|100 mg tablet
45642285|NCT05359068|Drug|SPH3127 tablet|200 mg tablet
45642286|NCT05359068|Drug|Valsartan|Valsartan 80mg
45642287|NCT05359068|Drug|SPH3127 tablet|100 mg tablet
45642288|NCT05359068|Drug|Valsartan|Valsartan 80mg
45642289|NCT05358886|Drug|BPN14770/ zatolmilast|25mg BID BPN14770
45781105|NCT02991404|Drug|Continuous infusion|Continuous infusion of 0.125% bupivacaine
45781106|NCT00719576|Biological|autologous cultured chondrocytes on porcine collagen membrane|Implantation via mini-arthrotomy
45781107|NCT00719576|Procedure|Microfracture|Microfracture performed by arthroscopic surgery
45781108|NCT00721136|Drug|continue warfarin through the procedure|The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.
45781109|NCT00721136|Drug|Hold warfarin|For moderate risk patients, warfarin will be held for 4-5 days prior to the procedure.
45642290|NCT05358886|Drug|Placebo|Placebo
45642291|NCT05357794|Drug|Brentuximab vedotin|Given by Vein (IV)
45642292|NCT05352815|Drug|IcoSema|Participants will receive once weekly IcoSema subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
45642293|NCT05352815|Drug|Insulin icodec|Participants will receive once weekly Insulin icodec subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
45642294|NCT05352672|Drug|Fianlimab|Intravenous (IV) infusion
45642295|NCT05352672|Drug|Cemiplimab|IV infusion
45642296|NCT05352672|Drug|Pembrolizumab|IV infusion
45642297|NCT05352672|Drug|Placebo|IV infusion
45642298|NCT05348603|Other|Traditional Letter|Patients receive a traditional letter.
45781110|NCT00721136|Drug|Warfarin held with heparin transition.|For high risk patients, warfarin is held for 4-5 days prior to the procedure and heparin is given to provide anticoagulation while the INR is subtherapeutic.
45917189|NCT05448820|Drug|YH001|Anti-CTLA4 antibody
45917190|NCT05448820|Drug|Envafolimab|Anti-PD-L1 antibody
45917191|NCT05448820|Drug|Doxorubicin|Anthracycline
45917192|NCT00000465|Procedure|angioplasty, transluminal, percutaneous coronary|
45917193|NCT00000465|Procedure|coronary artery bypass|
46070674|NCT05580302|Other|Transcranial Magnetic Stimulation (TMS)|An anatomical T1 magnetic resonance image (MRI) with high resolution will be acquired on a separate day before the TMS experiment. The image will be imported into the neuronavigation system (Nexstim, Helsinki, Finland) to guide the localization of the primary motor cortex (M1) for laryngeal muscle representation. Prior to M1 mapping for laryngeal muscle representation, mapping of the representation for hand muscle representation will be performed. Hand region excitability (abductor pollicis brevis, APB) will be evaluated by using surface electrodes attached to the right-hand APB muscle. The cSP threshold is defined as the lowest TMS intensity that elicits a cSP in 5 out of 10 consecutive trials. Single-pulse cortical stimulations will be performed during the vocalization of sustained /i/ sound.
46070675|NCT02973542|Drug|Ethosuximide|The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
45781111|NCT01278992|Dietary Supplement|Rhodiola rosea|1 capsule = 182 mg Rhodiola rosea extract standardized to 2.8% total rosavins. Take 2 capsules at start of wakeful period each day. Participants will self-determine need for second dose, of 1 capsule, within 4 hours of the initial dose.
45642299|NCT05348603|Other|Direct to Patient Message|Patients receive a direct to patient message via the portal.
45642300|NCT05348603|Other|Chatbot|Patients are contacted by a chatbot via the portal.
45642301|NCT05348603|Other|Banner|Patients are exposed to a banner ad via the portal.
45642302|NCT05348356|Drug|Nirogacestat|nirogacestat oral tablet
45642303|NCT05347771|Drug|Dupilumab|Dupilumab is a recombinant DNA-derived humanized IgG4ĸ monoclonal antibody that selectively binds to anti IL-4R monoclonal antibody (mAb).
45642304|NCT05347771|Drug|Placebo|The composition of the placebo for dupilumab is the same as the active study drug without the dupilumab.
45642305|NCT05346484|Biological|CF33-hNIS|CF33-hNIS is a chimeric orthopoxvirus (oncolytic virus) engineered to express the human sodium iodide symporter (hNIS)
45781112|NCT00736580|Other|Blunt tipped needle|The Cesarean delivery is performed using blunt tipped needles.
45917194|NCT05446012|Diagnostic Test|thyroid function tests|blood sample for thyroid function tests (TSH,T3,T3,Anti peroxidase antibody, anti thyroglobulin antibody)
45917195|NCT05444023|Procedure|Pubocervical fascia reconstruction|Suturing type techniques on pubocervical fascia reconstruction at anterior compartment defects.
45642306|NCT05346484|Biological|Pembrolizumab|Pembrolizumab 200mg administrated IV every 3 weeks (Q3W).
45642307|NCT05344170|Drug|30 mg Cannabinol (CBN)|Participants will receive a 2 mL oral dose of 'ECS 310' (1.5%), an oral formulation of CBN (15 mg/mL) suspended in medium chain triglycerides (MCT) oil.
45642308|NCT05344170|Drug|300 mg Cannabinol (CBN)|Participants will receive a 2 mL oral dose of 'ECS 310' (15%), an oral formulation of CBN (150 mg/mL) suspended in medium chain triglycerides (MCT) oil.
45642309|NCT05344170|Drug|Placebo|Participants will receive a 2 mL oral dose of placebo. Placebo contains the same excipient, medium chain triglycerides (MCT) oil, as the investigational products but does not contain cannabinoids.
45642310|NCT05343611|Behavioral|Combination of High Protein Diet and Physical Exercise protocol|"A high Protein Diet (HPro) will be provided to maintain individual caloric endpoint and to adjust protein intake to 0.9-1.0 g/Kg ideal body weight. Each participant will receive a tailored diet (taking into account personal preference) which will follow common general guidelines. Servings of food high in polyphenols will be limited to one per day.~Physical exercise will be undertaken three times each week for about 50 minutes per session. The intervention will consist of both aerobic and strength training exercises. Aerobic exercise will consist of walking on a treadmill with 4 x 4 minutes at (85-95% of HRmax), interrupted by 3-minute active recovery periods (60-70% of HRmax). Strength exercise consists of maximal strength training, using a seated leg press with 4 sets of 4 repetitions at ~90% of maximal strength (1RM). Rest periods between the sets will be 3-4 min."
45642311|NCT05343611|Dietary Supplement|HPP Choko|Participants add to their diet with 30 g/day of 85% dark chocolate high in polyphenols
45642312|NCT05343611|Dietary Supplement|HPP/VE Choko|Participants add to their diet 30 grams of 85% dark chocolate high in polyphenols, functionalized with 100 mg of Vitamin E per day.
45642313|NCT05342844|Drug|Dexmedetomidine 0.5 mcg|0.5 mcg/kg
45642314|NCT05342844|Drug|Dexmedetomidine 1 mcg|1 mcg/kg
45781113|NCT00736580|Other|Sharp needles|The cesarean is performed using standard sharp surgical suture needles.
45781114|NCT01272206|Drug|NNC 0128-0000-2011|Administered as one single i.v. (intravenous) injection, 100 mcg/kg
45781115|NCT01272206|Drug|NNC 0128-0000-2021|Administered as one single i.v. (intravenous) injection, 100 mcg/kg
45781116|NCT00737204|Drug|Armodafinil|Participants will receive 50 mg of armodafinil per day, increasing to 250 mg per day as clinically indicated.
45781117|NCT00737204|Drug|Placebo|Participants will receive placebo pills matched to the active armodafinil and according to the same dosing strategy
45781118|NCT04385810|Procedure|Ophthalmologic exam|Direct exam and Slit lamp exam Shirmer test Retinophotography At inclusion, day 7, day 14 and discharge from hospital
45917196|NCT00000468|Drug|tissue plasminogen activator|
45917197|NCT02972476|Drug|Budesonide & formoterol fumarate and Aclidinium bromide|
45917198|NCT02972476|Drug|Fluticasone 500 & salmeterol and Aclidinium bromide|
45917199|NCT02972476|Drug|Fluticasone 250 & salmeterol and Aclidinium bromide|
45917200|NCT02972476|Drug|Aclidinium bromide & formoterol fumarate|
45917201|NCT00000471|Behavioral|diet, vegetarianism|
45917202|NCT00000471|Behavioral|diet, fat-restricted|
45917203|NCT00000471|Behavioral|exercise|
45917204|NCT00000471|Behavioral|smoking cessation|
45917205|NCT05418868|Drug|Cabotegravir 200 mg/mL|CAB 200 mg/mL will be administered.
45917206|NCT05418868|Drug|Cabotegravir 400 mg/mL|CAB 400 mg/mL will be administered.
45917207|NCT05418868|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|rHuPH20 will be administered.
45642315|NCT05339087|Drug|Riociguat Oral Tablet|Riociguat Oral Tablet (1 mg, 1.5 mg, 2.0 mg or 2.5 mg three times daily) Titration phase: dose will be individually adjusted in accordance with the in-label titration regimen. Dose adjustment will be performed every two weeks by phone taking the systemic blood pressure of the patient, the subjects and physicians' subjective estimation and occurrence of adverse reactions into account. At week 8 the maintenance dose will be established and continued for the rest of the study
45781119|NCT00722072|Drug|fulvestrant|Loading dose for cycle 1: 500 mg intramuscular(IM) on Day 1;250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or until unacceptable toxicity occurs requiring discontinuation of study therapy
45917208|NCT05409079|Device|Abilitech Assist|The Abilitech™ Assist is an externally worn device supported by a body frame, which is designed to support and assist the arms in activities of daily living (ADL's). The Abilitech Assist is comprised of three parts: a modular body vest that adjusts to accommodate different body sizes, a single arm orthosis that attaches to the body vest, and an external power pack and controller for tensioning the arm's internal springs to adjust the arm's level of assist. The device augments a user's native arm function to provide lift assistance. Software customizes the spring tension for the level of assist required. The user can turn the system ON/OFF and toggle and adjust the level of assist (e.g., low, medium or high assist) using a pushbutton controller.
45781120|NCT00722072|Drug|sorafenib tosylate|Subjects will take sorafenib 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy
45781121|NCT04385186|Drug|Inactivated convalescent plasma|"Day 0: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma, Start of support treatment selected by medical staff according to each institutional protocol~Day 1: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma"
45917209|NCT00000474|Behavioral|behavior therapy|
45917210|NCT05398003|Device|Implantation of the WAVEWRITER ALPHA ™ device|"The 12 patients will be implanted by the WAVEWRITER ALPHA ™ device. Then, the order of the three stimulation modes will be randomly selected and will be composed of 5 modalities:~tonic stimulation LF: In tonic mode, the electrical stimulation of the sensory fibres of the posterior cords of the spinal cord induces local paresthesias~high frequency stimulation (1000 Hz) High Frequency.~stimulation in bursts (or Burst)"
46070676|NCT02973542|Other|Placebo|The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
45781122|NCT04385186|Drug|Support treatment|Day 0: Start of support treatment selected by medical staff according to each each institutional protocol
45781123|NCT04385420|Drug|ATR-002 MEK Inhibitor|Drug ATR-002 administered as film-coated tablet via oral route
45917211|NCT02972320|Drug|temozolomide|temozolomide maintain therapeutic
45917212|NCT00000480|Procedure|electrophysiology|
45917213|NCT00000480|Drug|anti-arrhythmia agents|
46070677|NCT04228874|Device|coronary artery stents|"Coronary angiography was done for all the patients according to the Judkins technique. All images were evaluated by an experienced operator, significant coronary artery disease was defined as > 70 % luminar diameter stenos. The following data was obtained:~Site of stent implantation within LAD. The first Diagonal branch serves as the boundary between the proximal and mid portion of the LAD. Thus, the portion of the artery prior to the origin of the 1st diagonal is known as the proximal LAD, while the segment just below the1st diagonal branch is the mid LAD. The distal segment of the LAD is the terminal third of the artery (Cao et al., 2017).~Length, diameter and number of stents.~TIMI flow after stent deployment."
46070678|NCT02973386|Drug|IMRT combine with cisplatin concurrent chemotherapy|Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT.
46070679|NCT02973386|Drug|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy|Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles at 4 weeks later after RT.
46070680|NCT04228718|Behavioral|Zarit Burden Interview Scale|It is a questionnaire consisting of 22 items. A minimum score of 0 and a maximum score of 88 can be obtained. The higher the scale score, the higher the difficulty experienced.
45781124|NCT04385420|Drug|Placebo oral tablet|Placebo film-coated tablet administered via oral route
45781125|NCT00737360|Drug|TAS-106|6.5 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
45781126|NCT00795080|Procedure|Dynamic cervical MRI scans|Serial MRI examination with the neck in flexion and extension to document changes in the cord compression and cerebral spinal fluid (CSF)
45781127|NCT01279226|Device|Auralevée device|Single treatment with Auralevée device.
45781128|NCT01276106|Drug|AC-201, 25mg|Capsule, 25mg BID
45781129|NCT01276106|Drug|AC-201, 50mg|Capsule, 50mg BID
45781130|NCT01276106|Drug|AC-201, 75mg|Capsule, 75mg BID
45781131|NCT01276106|Drug|Placebo|Placebo BID
45448836|NCT02144038|Drug|BYL719|PI3K-alpha inhibitor
45781132|NCT01275170|Drug|MK-7655|125 mg intravenous (IV) over 30 minutes as a single dose
45781133|NCT01275170|Drug|Imipenem + Cilastatin|250 mg IV over 30 minutes as a single dose
45448837|NCT00108628|Behavioral|Imagery Rehearsal|IR is a manual-based CBT predicated on the idea that waking mental activity influences nighttime dreams. Veterans examine the content of a recurrent nightmare, use imagery to alter disturbing aspects of the nightmare to promote mastery and control, and rehearse the new dream nightly, before bedtime.
45642316|NCT05339087|Other|Placebo|Sham titration and adjustment to maintenance dose will be performed according to individual tolerability as in the experimental arm.
45917214|NCT00000480|Device|defibrillators, implantable|
45917215|NCT05383417|Device|EndoClip|Clip attached to mid portion of the endotracheal tube.
45917216|NCT05374915|Combination Product|REM-001 photodynamic therapy|Infusion of REM-001 (iv) followed by light treatment to treatment field 24 hrs after infusion of REM-001
45917217|NCT05349838|Drug|Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy|Daily oral tablet
45917218|NCT00388791|Drug|Systane Free|
46070681|NCT04228718|Behavioral|Family Needs Survey (FNS)|It is a questionnaire consisting of 35 items prepared to determine the requirements. In the FNS survey; The points given to the items can be directly collected and the amount of family needs can be determined over the total score. The lowest score that can be obtained from FNS is 29 and the highest score is 87. As the scores obtained from the scale and subscales increase, it can be said that the families' level of necessity increases.
46070682|NCT04228718|Other|Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)|CHOP-INTEND uses a scale of 0-64 points. Higher scores indicate better motor function. It is used to reliably measure natural motor function decline in infants with SMA Type 1.
45642317|NCT05337982|Other|Downhill Eccentric Treadmill Training with Electrical Stimulation|Participants will walk on a treadmill with a downward incline with support from a harness and assistance from trainers as needed. Participants will also simultaneously receive stimulation to their muscles including their trunk and legs. Each session will include 20 minutes of walking divided into 5 minute bouts with 5 minute rest breaks in between for 3 sessions per week for 12 weeks.
46070683|NCT04228718|Other|Hammersmith Functional Motor Scale Expanded (HMFSE)|It is an extended version of the 20-item HFMS. Based on another scale known as GMFM, 13 items were added and expanded HFMS to include these elements. Therefore, HFMSE is a scale used to evaluate motor functions in types 2 and 3 SMA. It contains 33 items with a total score of 66 on a scale of 0, 1, 2.
45642318|NCT05334329|Biological|Antineoplastic Immune Cell|Given COH06 IV
45642319|NCT05334329|Biological|Atezolizumab|Given IV
45642320|NCT05334329|Procedure|Biospecimen Collection|Correlative studies
45642321|NCT05334329|Drug|Cyclophosphamide|Given IV
45642322|NCT05334329|Drug|Fludarabine|Given IV
45642323|NCT05333133|Dietary Supplement|high calorie formula (oral nutritional supplement/ONS)|"every subject is given 400 ml (equal with 400 kcal) high calorie formula for 90 days. before (day 0) and after (day 91) the intervention was enrolled, blood samples was taken to investigate IGF-1 and total lymphocyte counts.~The body weight and body height will be measured at day-0, day-14, day-30, day 60 and 90."
45642324|NCT05332509|Device|C-BRACE|The C-BRACE is a custom made Knee-Ankle-Foot-Orthosis with a microprocessor-controlled hydraulic knee-joint articulation. The C-BRACE technology offers to a patient with knee locking deficiencies the following advantages: approximation of the physiological gait pattern, stability while standing and walking, adaptation to various surfaces, inclines, gait situations and walking speeds.
45642325|NCT05332509|Device|SCO|The SCO is a custom made Knee-Ankle-Foot-Orthosis with a knee-joint locked during stance phase and released during swing phase.
45642326|NCT05329792|Drug|L19IL2/L19TNF|Patients will be treated with a mixture of L19IL2 and L19TNF once weekly for 4 consecutive weeks
45642327|NCT05329220|Biological|ABNCoV2|ABNCoV2 100μg single dose
45642328|NCT05329220|Biological|Comirnaty|Comirnaty
45642329|NCT05328908|Drug|Nivolumab-relatlimab FDC|Specified dose on specified days
45642330|NCT05328908|Drug|Regorafenib|Specified dose on specified days
45642331|NCT05328908|Drug|TAS-102|Specified dose on specified days
45642332|NCT05328752|Drug|XXB750|XXB750
45781134|NCT01275170|Drug|Caffeine|Caffeine caplet, single 200 mg dose, orally
45781135|NCT01275170|Drug|Midazolam|Midazolam hcl syrup single 2.0 mg dose by mouth.
45781136|NCT01275170|Drug|Omeprazole|Omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally
45781137|NCT04385654|Drug|Toripalimab|Toripalimab (240 mg,ivgtt,q3w) was administered to patients for 6 weeks and underwent surgery within 2-4 weeks
45642333|NCT05328752|Drug|Placebo|Placebo
45642334|NCT05327803|Drug|Epetraborole|500 mg taken orally QD
45642335|NCT05327803|Drug|Placebo|Placebo taken orally QD
45642336|NCT05327686|Biological|Avelumab|Given IV
45642337|NCT05327686|Drug|Axitinib|Given PO
45642338|NCT05327686|Drug|Cabozantinib|Given PO
45642339|NCT05327686|Biological|Ipilimumab|Given IV
45642340|NCT05327686|Drug|Lenvatinib|Given PO
45642341|NCT05327686|Biological|Nivolumab|Given IV
45642342|NCT05327686|Biological|Pembrolizumab|Given IV
45642343|NCT05327686|Radiation|Stereotactic Ablative Radiotherapy|42 Gy in 3 fractions
45917219|NCT05346289|Procedure|Elective surgery for intact AAA|Elective surgery including the following modalities: open repair, endovascular repair (EVAR), fenestrated end-vascular repair (FEVAR).
45642345|NCT05324371|Device|Watchman FLX Device|Left atrial appendage closure using the Watchman FLX device
45642346|NCT05323656|Drug|Setanaxib|Oral tablets, 400 mg per tablet
45642347|NCT05323656|Biological|Pembrolizumab|200 mg IV infusion
45642348|NCT05323656|Drug|Placebo|Oral tablets
45642349|NCT05323617|Drug|Romiplostim|Administered as a subcutaneous injection.
45642350|NCT05323617|Drug|Antithymocyte Globulin|Horse or rabbit antithymocyte globulin administered as an intravenous infusion.
45642351|NCT05323617|Drug|Cyclosporine A|Administered orally.
45781138|NCT04385654|Drug|Axitinib|Axitinib (5 mg,po,qd) was administered to patients for 6 weeks and underwent surgery within 2-4 weeks
45781139|NCT01272674|Other|exercise training|4 weeks supervised physical exercise training
45781140|NCT00400634|Drug|CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])|CERE-120 5.4 x 10^11 vg
45781141|NCT00400634|Procedure|Sham Surgery|Bilateral partial thickness burr holes placed, no intraparenchymal injections
45781142|NCT01273064|Drug|CTS-1027|Supplied in 30mg, 10mg, or 5mg tablets (depending on dose arm) taken twice daily for up to 48 weeks.
45781143|NCT01273064|Drug|pegylated interferon|180 micrograms in 0.5 ml of solution subcutaneously (SQ), delivered in single use syringes administered once per week, for up to 48 weeks.
45917220|NCT05314816|Diagnostic Test|Blood culture identification panel|multiplex PCR panel to be performed on positive blood cultures
46070684|NCT04228328|Diagnostic Test|The 6-minutes Walk Test|To walk for 6 minutes
45642352|NCT05322161|Behavioral|yoga classes|"There will be 6 total yoga classes (one introduced per week for a 6 week period). Each yoga session will be divided into three components, which will vary in duration based on a curriculum designed specifically with the post-partum state of mothers in mind:~Yoga postures (Asana) = low impact gentle postures meant to be done individually~Breathing techniques (Pranayama) = deliberate modifications of breath such as rapid diaphragmatic breathing, slow/deep breathing, alternate nostril breathing, breath holding~Meditation (Dhyana) = guided meditation"
46070685|NCT05576714|Other|delineate its prognostic biomarker, host genetic factors, immunopathogenesis and viral pathogenesis|We will delineate the clinical and laboratory characteristics of COVID-19 associated encephalopathy and encephalitis, the role of immune, virology, genetics mechanism in pathophysiology, and will optimize the treatment algorithm based on the result of this study. We also expect that the important biomarkers and risk factors associated with clinical outcome and severity, the immunopathogenesis of MIS-C, host genetic factors and the viral pathogenesis and microbiota associated with MIS-C will be found.
45781144|NCT01273064|Drug|Ribavirin|200 mg capsules of ribavirn taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg
45781145|NCT01273064|Drug|Placebo|"Tablets identical in appearance to CTS-1027 containing inactive ingredients.~Placebo arm patients: Two tablets taken twice daily, for a total daily dose of four tablets.~30 mg CTS-1027 patients: One tablet taken twice daily, for a total daily dose of two tablets. One bottle of placebo is added to the 30mg kits in order to maintain the study blind (all patients recieve two-bottle kits of CTS-1027 and/or placebo)."
45781146|NCT01279382|Behavioral|Hypnotherapy (HYP)|Hypnotherapy was given to a subgroup of patients as intervention in IBS treatment
45781147|NCT01279382|Behavioral|Relaxation training (RT)|RT was given to a subgroup of patients as intervention in IBS treatment
45781148|NCT01279382|Other|Care as usual (CON)|CON was given to a subgroup of patients as control intervention in IBS treatment
45781149|NCT01272986|Device|ALOA IgG-Elisa|measurement of IgG Level in blood
46070686|NCT00632528|Drug|MEOPA|Administration of MEOPA gaz during postoperative physical therapy
46070687|NCT00632528|Drug|Medicinal air|Administration of medical air during postoperative physical therapy
46070688|NCT04019132|Diagnostic Test|Muscle function test|Body measurements, power and strength tests of the knee extensor muscle, handgrip strength, functional capacity tests, objective measurement of physical activity (subgroup of older adults, n=50)
46070689|NCT00632372|Device|Cardiac Resynchronization Therapy|Pacing of the left ventricle to resynchronize ventricular contraction.
46070690|NCT00632372|Device|HeartPOD™ System|Left atrial pressure monitoring.
46070691|NCT00909428|Drug|Solifenacin Succinate|Participants take 10mg daily solifenacin succinate for 30 days
46070692|NCT03718130|Combination Product|Hantann virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The HTNV vaccine will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
46070693|NCT03718130|Combination Product|Hantann virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)|The HTNV vaccine will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
45642353|NCT05318105|Device|Aquadex Smartflow® System|ultrafiltration
45642354|NCT05318105|Drug|IV Loop Diuretics|diuretics
45642355|NCT05316012|Device|Smart diapers|"Residents receive standard continence care while using the smart diaper (without the alerting system) - fase 1~Diapers are changed as usual, e.g., after morning care, visual soiling, unpleasant odor, saturation, leakage.~Residents receive continence care while using the smart diaper with the alerting system - fase 2"
45642356|NCT05315297|Device|PEMF device|PEMF device wear overnight daily for four weeks
45781150|NCT01272986|Device|ALOA IgG-AtheroAbzyme|measurement of IgG in blood
45781151|NCT01272908|Drug|rituximab|1000 mg intravenously on Days 1 and 15
45781152|NCT01271504|Drug|Sorafenib|Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib
45781153|NCT01271504|Drug|Sorafenib|"E7050 given orally at 200, 300 or 400 mg once daily.~Sorafenib given orally, 400 mg twice daily."
45781154|NCT02144714|Biological|SB5|
45781155|NCT02144714|Biological|EU sourced Humira®|
46070694|NCT03718130|Combination Product|Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The PUUV vaccine will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
46070695|NCT03718130|Combination Product|Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)|The PUUV DNA vaccine will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
46070696|NCT03718130|Combination Product|Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The HTNV and PUUV vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
45781156|NCT02144714|Biological|US sourced Humira®|
45781157|NCT01279538|Drug|bleselumab|Intravenous (IV) infusion
45781158|NCT01279538|Drug|Placebo|Intravenous (IV) infusion
45781159|NCT00741026|Drug|Olanzapine 10 mg po qhs for 3 days|(1) 10 mg tablets administered orally before bed for three consecutive evenings (Total Dose = 30 mg, 3 tablets)
45781160|NCT00741026|Drug|Placebo|(1) placebo tablets administered orally before bed for three consecutive evenings (Total Dose = 3 tablets)
45781161|NCT00741104|Drug|Infliximab|Treatment of RA with Infliximab according to and under normal routine clinical practice.
45781162|NCT01273298|Drug|Bisoprolol|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
45781163|NCT01273298|Drug|Placebo|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
45781164|NCT01273376|Drug|RX-10100|Extended-release tablet, taken twice daily for 8 weeks
45781165|NCT01270958|Drug|Avamys aqueous nasal spray 110mcg|"At the visit 1, subjects who fulfill the inclusion criteria are eligible to be included in the group to self-administer intranasal treatment of fluticasone furoate aqueous nasal spray 110 mcg once daily for 6 week. The subjects are instructed to administer two sprays from the device into each nostril once daily every morning. Administration of the dose will be performed by alternately spraying one spray to each nostril followed by a second spray to each nostril. Subjects will not be permitted to take any anti-allergy or rhinitis medication during the screening or treatment period.~Throughout the study, subjects will document their study drug administration/compliance, any medical conditions experienced, and any concomitant medications taken."
45781166|NCT01270880|Drug|Hsp90 inhibitor STA-9090|Given IV
45917221|NCT05313763|Other|conventional physical therapy|A hotpack will be applied to the neck area for 15 minutes in the prone position of the patients. Conventional type Tens with a frequency of 50 Hz and a pulse duration of <150 microseconds will be applied for 20 minutes, taking the painful area to the center. Ultrasound will be applied to the patients for 5 minutes with a dosage of 1-1.5 watts/cm2. Cervical joint range of motion exercises, stretching exercises for trapezius, scalenia, rhomboid, levator scapulae, pectoral and suboccipital muscles will be applied, then cervical isometric strengthening exercises and stabilization exercises will be carried out in a controlled manner. Conventional physical therapy will be applied by the same physiotherapist 5 days a week for 3 weeks.
45917222|NCT05313763|Other|Active Kinesiotaping|For kinesio-tape application, a 20 cm long Y strip and a 15 cm long I strip tape will be prepared. The patient will flex his neck, and the application will be started from the midline of the upper thoracic vertebrae. Initially, 4-5 cm stretching will be applied, and the arms of the Y strip will be adhered to the cervical paravertebral muscles without stretching. I strip will be applied to the painful area with the area correction technique, with maximum stretching in the middle and without stretching the ends. The applications will be made by the same physiatrist with 7 years of clinical experience.
46070697|NCT03718130|Combination Product|Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM)|The HTNV and PUUV vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
45642357|NCT05315297|Device|Sham PEMF device|Sham PEMF device wear overnight daily for four weeks. Sham PEMF devices do not emit a radiofrequency electromagnetic field but are otherwise identical in appearance to the PEMF device
45642358|NCT05313165|Device|LimFlow Stent Graft System|Creation of an arteriovenous fistula in the desired limb location
45642359|NCT05312879|Drug|VX-147|Tablets for oral administration.
45642360|NCT05312879|Drug|Placebo|Tablets for oral administration.
45642361|NCT05310877|Behavioral|Values-Affirmation|Participants will engage in a brief values-affirmation exercise to target personal motivation and openness to medication adherence. The interventionist will then review tailored medication education and individual skills training recommendations. Following the intervention session, participants will receive electronic pill box(es) that are labeled with the participants' most important core value(s) and will be asked to use these pill box(es) to take their HF medications for 4 weeks.
45781167|NCT01270880|Other|laboratory biomarker analysis|Correlative studies
45781168|NCT01270880|Genetic|polymerase chain reaction|Correlative studies
45781169|NCT01270880|Other|enzyme-linked immunosorbent assay|Correlative studies
45781170|NCT01270880|Genetic|RNA analysis|Correlative studies
45781171|NCT01270880|Other|spectrophotometry|Correlative studies
45781172|NCT01270880|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
45781173|NCT01270880|Genetic|gene expression analysis|Correlative studies
45781174|NCT01270802|Drug|Tenofovir/emtricitabine|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
45781175|NCT01270802|Drug|Tenofovir/emtricitabine/efavirenz|Continued therapy with tenofovir/emtricitabine/efavirenz
45781176|NCT01270802|Drug|Raltegravir|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
45642365|NCT05307952|Diagnostic Test|Tone Audiometry|Evaluation of the participants' audiometrical thresholds
45642366|NCT05307952|Diagnostic Test|Spectrotemporal Assessment|Evaluation of the participants' promptness in detecting a modulation of a harmonic complex
45781177|NCT01273454|Drug|OROS Hydromorphone|8,16, 32 mg once a day for 4 weeks
45781178|NCT01270256|Drug|Budesonide|Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
45781179|NCT01270256|Drug|Placebo|Placebo delivered intranasally via NasoNeb nebulizer once daily
45781180|NCT01279694|Drug|Carfilzomib|There are 9 cycle of 20mg/m²,Intravenous for J1, J2, J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the first cohort; or 20mg/m²,Intravenous for J1, J2, and 27 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the second cohort for the last, third cohort 20mg/m²,Intravenous for J1, J2, and 36 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle)and the fourth cohort 20mg/m²,Intravenous for J1, J2, and 45 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle). .
45781181|NCT01279694|Drug|Melphalan|from 9 cycle: 9 mg/m²/day PO from day 1-4
45781182|NCT01279694|Drug|Prednisone|from 9 cycle: 60 mg/m²/day PO from day 1-4
45781183|NCT01273532|Drug|tapentadol (CG5503) ER 100-mg TRF|100mg TRF single oral dose
45642367|NCT05307952|Diagnostic Test|Phoneme and Speech Perception|Evaluation of the participants' understanding of phonemes and short words, both in quiet and in noise
45781184|NCT01273532|Drug|tapentadol (CG5503) ER 50-mg TRF|100 mg TRF single oral dose
45781185|NCT04386434|Behavioral|Active for Life: Assisted Living|"Each intervention session will take place within the assisted living facility twice a week for 12 weeks.~Sessions will begin with 5-10 minutes of walking in the hallway. Participants will be encouraged to walk at their own pace and allowed to take breaks if needed.~Next, behavioral strategies based on the construct of self-efficacy from social cognitive theory and education about physical activity will be delivered. This component is scheduled between the walking and circuit training, lasts 15-20 minutes, and serves as a rest period.~Circuit training will focus on strength and balance. Approximately 8 exercise stations will be set up, and the exercises performed at each station will be changed approximately every 4 weeks. The circuit training will last ~30-40 minutes, with participants moving from one station to the next at their own pace and taking breaks in between."
45781186|NCT00744380|Drug|Midazolam|Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
45781187|NCT00744380|Drug|Dexmedetomidine|Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
46070698|NCT04756856|Other|Muscle-target oral nutritional supplementation|Patients will receive daily for 12 weeks two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, and 800 IU vitamin D. Patients will be also followed for 12 weeks after the suspension of supplementation.
45781188|NCT00744692|Biological|Unrelated Umbilical Cord Blood Transplant|Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
45781189|NCT00744692|Drug|Reduced Intensity Conditioning|
45781190|NCT00744848|Drug|Bupivacaine HCl|100 mg Bupivacaine HCl
45781191|NCT00744848|Drug|SKY0402|Single administration 300 mg SKY0402 in a 40-mL injection volume
45781192|NCT00745940|Behavioral|MBCT for TBI|Subjects will participate in a 10-week Mindfulness-Based Cognitive Therapy Program led by two trained facilitators. Weekly one-and-a-half hour group sessions will guide subjects through exercises such as meditation, awareness, and breathing techniques aimed at developing skills to help with tension, stress, anxiety and depression. Subjects will be encouraged to practice skills at home and in daily life.
45781193|NCT03830606|Drug|Nab-paclitaxel,S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area < 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area >1.5 m2; D1-14, q3w)
45781194|NCT04385342|Drug|FSH|Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
45781195|NCT04385342|Drug|HP-hMG|Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
45917223|NCT05313763|Other|Sham Kinesiotaping|For Sham kinesio-tape application, a 20 cm long Y strip and a 15 cm long I strip tape will be prepared. The patient will flex his neck, the application will be started from the midline of the upper thoracic vertebrae, and the Y and I bands will be applied without stretching. The applications will be made by the same physiatrist with 7 years of clinical experience.
45642368|NCT05307952|Diagnostic Test|Digit Triplet Test|Evaluation of the participants' ability to discern speech in noise
46070699|NCT04756076|Diagnostic Test|Metal level measurements|Measure multiple metal levels
45781196|NCT01272752|Dietary Supplement|IHBG-10|500 mg IHBG-10
45781197|NCT01272752|Dietary Supplement|Placebo|Placebo taken 15 minutes prior to the three main meals of the day
45781198|NCT00751634|Device|Gaymar Rapr-Round (external cooling blanket)|Application of the device per its approved labeling
45781199|NCT01278134|Drug|Copegus placebo|1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
45781200|NCT01278134|Drug|RO5024048|1000 mg bid orally, up to 24 weeks
45781201|NCT01278134|Drug|danoprevir|100 mg bid orally, up to 24 weeks
45781202|NCT01278134|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
46070700|NCT05579834|Procedure|posterior correction surgery|Cases of hemothorax developing after posterior correction surgery for spinal deformities
45642369|NCT05307952|Other|Personalized fitting|Adjustment of the parameters of the participants' cochlear implants aimed at improving their speech perception
45642370|NCT05307952|Behavioral|Personalized training|Self-administered training exercises focused on the speech components the participants are experiencing difficulties into
45642371|NCT05306964|Procedure|Restrictive UFnet Rate Strategy|In the restrictive group, the UFnet rate will be titrated between 0.5-1.5 mL/kg/h and maintained throughout fluid removal.
45642372|NCT05306964|Procedure|Liberal UFnet Rate Strategy|In the liberal group, the UFnet rate will be titrated between 2.0-5.0 mL/kg/h and maintained throughout fluid removal.
45781203|NCT01278134|Drug|ribavirin [Copegus]|1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
45781204|NCT01278134|Drug|ritonavir|100 mg bid orally, up to 24 weeks
45781205|NCT01273844|Drug|Bortezomib|Bortezomib
45781206|NCT01270568|Other|Positive Psychology|Weekly exercises focused on optimism, gratitude, altruism, and other positive affective states
45917224|NCT03164980|Drug|Trabectidin (Yondelis)|To compare QoL in patients treated with trabectedin/PLD vs. other standard combination therapy of carboplatin/ PLD, carboplatin/ gemcitabine, or carboplatin/ paclitaxel
45917225|NCT00388830|Procedure|Ultrasound|
45917226|NCT05305456|Drug|Tanreqing capsule|3 capsules per time, 3 times a day
45917227|NCT05305456|Drug|Tanreqing capsule simulator|3 capsules per time, 3 times a day
45781207|NCT01270568|Behavioral|Relaxation Response|Daily practice of relaxation response, reviewed on a weekly basis
45781208|NCT01270568|Behavioral|Recollection|Subjects record daily events on a weekly basis for 8 weeks
45642373|NCT05306873|Drug|Mycophenolate Mofetil|"Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily~Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening~Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily"
45781209|NCT01271348|Drug|Etoricoxib|Etoricoxib film tablet, 90 mg, q.d.
46070701|NCT02801084|Behavioral|Reduced environmental stimulation|"Participants will complete one arm involving four sequential float sessions. Float 1: chair float. Participants will first float in a comfortable chair in the supine position, for up to 90 minutes. The chair is in a room with sound and light attenuation. Orthostatic blood pressure (BP) will be measured before and after each float. Anxiety and body image will be measured afterwards.~Float 2: open pool float. Participants will float for up to 90 minutes in an open pool (8 foot diameter, no enclosure). Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Floats 3 & 4: domed pool float. Participants will float for up to 90 minutes in a domed pool the same size as the open pool, with an enclosure wall and 8 foot tall ceiling. Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Each float will occur approximately 1 to 7 days apart."
46070702|NCT05333276|Drug|TQB3602 Capsule + AK105 Injection|TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-PD-1 antibody.
45781210|NCT01271348|Drug|placebo|Placebo tablet, q.d.
45781211|NCT04385264|Drug|Hydroxychloroquine|Day 0: 800mg PO OD (4 capsules) Days 1-5: 400mg PO OD (2 capsules daily)
45781212|NCT04385264|Drug|Mannitol|Day 0: 4 capsules PO OD Days 1-5: 2 capsules daily PO OD
46070703|NCT00908960|Drug|Enoxaparin|
45642374|NCT05306873|Drug|Placebo for Mycophenolate Mofetil|"Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily"
45642375|NCT05306873|Drug|Voclosporin|Weeks 1-24: 23.7 mg Voclosporin (3 x 7.9 capsules) twice daily
45781213|NCT00746954|Drug|Acetazolamide|Cabonic Anhydrase inhibitor
45781214|NCT00746954|Drug|Buspirone|Agonist of a 5-HT1a receptor with some D2 agonist properties.
45917228|NCT05278234|Behavioral|STEPS|Participants will initially meet with a community health worker (CHW) for a 1-hour orientation at the participant's home, a Henry Ford Health System site or the University of Michigan Detroit Center, or virtual. The CHW will show participants how to use the web modules. Participants will be given (or mailed) a wearable activity tracker to use throughout the course of the 7-week program. Each week participants will watch a brief video on the STEPS website; they may also be asked to complete handouts in the workbook. They will have a weekly 30-minute telephone session with the CHW. CHWs will review the weekly topic, help participants practice new skills, and set a related goal. CHWs will screen for social needs and make appropriate community referrals. Participants will set walking goals each week, using step-count data from the physical activity tracker. Participants will track daily step counts.
45917229|NCT05260918|Other|Float-REST|Participants will utilize sensory deprivation tanks.
46070704|NCT03933020|Device|VR active video game intervention|The Microsoft VR active game program will consist of 3 weekly sessions of 45 minutes each combining 3 different types of exercise
45642376|NCT05306873|Drug|Placebo for Voclosporin|Weeks 1-24: 23.7 mg Placebo for Voclosporin (3 x 7.9 capsules) twice daily
45642377|NCT05306873|Drug|Mycophenolate Mofetil|"Stage 3 Dosing:~Participants who received placebo MMF in Stage 2:~Week 1: Participants will receive 500mg MMF plus matching placebo for MMF (to appear like a 1000mg dose) twice daily~Week 2: Participants will receive 500mg plus matching placebo for MMF (to appear like a 1000mg dose) and 1000mg in divided doses~Weeks 3-24: 1000mg MMF twice daily~Participants who received MMF in Stage 2~• Week 1-24: 1000mg MMF twice daily"
45781215|NCT00752102|Drug|Calcitriol (Rocaltrol®)|Subjects taking calcitriol will be started at 0.25 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then calcitriol will be increased to 0.5 mcg 3x/week.
45781216|NCT00752102|Drug|Paricalcitol|Subjects taking paricalcitol will be started at 2 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then paricalcitol will be increased to 4 mcg 3x/week.
45781217|NCT01273922|Biological|NDV-3 investigational vaccine|Two doses of vaccine 6 months apart or placebo(only one dose at Time 0) administered intramuscularly
45781218|NCT01279928|Procedure|Video Nailfold Capillaroscopy|Single session of video Nailfold Capillaroscopy wit KKK technology
45781219|NCT01279928|Device|Ambulatory 24 hr Blood Pressure Monitoring|24 hr upper arm cuff measurement of Blood Pressure
45781220|NCT01279928|Procedure|Fundoscopy of eyes|examination of microvascular health of eye with the use of opthalmoscope
45781221|NCT01279928|Procedure|Laser Doppler Flowmetry|Examination of vascular flow
45781222|NCT00723632|Biological|peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling, ie, 1.5 μg/kg weekly SC for 48 weeks for participants with hepatitis C virus (HCV) genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
45781223|NCT00723632|Drug|ribavirin|Ribavirin administered in accordance with approved labeling, ie, 800 mg/day for participants <65 kg, 1000 mg/day for participants >65 to <85 kg, and 1200 mg/day for participants >=85 kg, administered orally for 48 weeks for participants with HCV genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
45781224|NCT00723788|Device|MRI of the abdomen|Multiple MRI pulse sequences of the abdomen
45781225|NCT01279304|Radiation|radiation - no radiation see intervention description|after MRM in group 1 (low risk): no radiotherapy after BCT in group 1 (low risk): radiation treatment of the breast with boost (optional)
45781226|NCT01279304|Radiation|radiation: see intervention description|after BCT in group 2 (intermediate risk): radiation treatment of the breast with boost (optional) after MRM in group 2 (intermediate risk): radiation treatment of the thoracic wall If no full ALND is performed in group 2 (intermediate risk) add radiation treatment of level 1 and 2 of the axilla.
45781227|NCT01279304|Radiation|radiation: see intervention description|after MRM in group 3 (high risk): radiation treatment of the thoracic wall and supraclavicular nodes after BCT in group 3 (high risk): radiation treatment of the breast with boost (optional) and supraclavicular nodes If no full ALND is performed group 3 (high risk) add radiation treatment of level 1 and 2 of the axilla.
45781228|NCT01279616|Drug|Fludarabine monophosphate|180 mg/m2 over 6 days.
45642378|NCT05305547|Drug|S-217622|Administered as a round tablet.
45642379|NCT05305547|Drug|Placebo|Administered as a round tablet.
45642380|NCT05304962|Drug|RGT-419B|oral capsules
45642381|NCT05304962|Drug|RGT-419B in combination with hormonal therapy|RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)
45642382|NCT05302765|Other|Normal Saline Intravenous Fluids|Administration of normal saline intravenous fluids (20 milliliters/kilogram).
45642383|NCT05300724|Other|No intervention|No intervention will be administered in this study.
45642384|NCT05300568|Other|No Intervention|This is a non-product related survey.
45642385|NCT05294016|Device|BRA CONNECT device|skin thermal analysis for the detection of breast abnormalities
45642386|NCT05293431|Other|Transcranial Alternate Current Stimulation|tACS utilizes low-amplitude alternating currents to modulate brain activity and entrain specific brain oscillations depending on the applied stimulation frequency
45781229|NCT01279616|Drug|Rituximab|375 mg/m2 on day -13 and day -3
45781230|NCT01279616|Drug|Busulfan|AUC 1000-1200 microM.mt
45642387|NCT05293431|Other|Sham stimulation|Sham stimulation will simulated the real tACS stimulation
45642388|NCT05292508|Diagnostic Test|C-reactive Protein Rapid Diagnostic Test|In the intervention arm in addition to Usual Standard of Care, CRP Testing will be performed. In this test, health worker at health post will prick the finger of the patient using a lancet device following aseptic precautions. A very small drop (10 microliters) of whole blood will be obtained. This will be added to specimen dilution buffer. Then the sample will be mixed by inverting the tube upside down 10-15 times. Then the yellow dip area of the dipstick will be placed into the diluted sample. It will be held there until the liquid rises to the result area by capillary action. The the dipstick is removed from the solution and placed in a horizontal position. The timer will be started and result will be interpreted in 5 minutes. Treatment decision making regarding the use of antimicrobials will be conducted with the help of CRP test results and other clinical features.
45781231|NCT01279616|Drug|ATG|2.5 mg/kg for 3 days
45642389|NCT05291169|Device|Omeza® Collagen Matrix|"Omeza® Collagen Matrix is a wound care matrix comprised of hydrolyzed fish collagen infused with cod liver oil, which acts as an anhydrous skin protectant. When applied to a wound surface, the matrix is naturally incorporated into the wound over time. Omeza® Collagen Matrix is designed for intimate contact with both regular and irregular wound beds, to provide a conducive environment for the patient's natural wound healing process.~Contains: Fish collagen, cod liver oil, medium chain triglyceride oil, coconut oil, hemp seed oil, triethyl citrate, ethyl linoleate, caprylic acid, red palm concentrate, monolaurin, cetyl esters NF, beeswax, ascorbyl palmitate, sea salt Omeza® Collagen Matrix is supplied in a sterile single use vial."
45642390|NCT05290766|Procedure|placement of four dental implants|"placement of four dental implants according to the  All on four concept"
45781232|NCT01279616|Drug|Cyclophosphamide|50 mg/kg on day +3
45781233|NCT01279616|Drug|Mycophenolate mofetil|15 mg/kg q 8 hours
45781234|NCT01279616|Drug|Tacrolimus|0.03 mg/kg /d
45781235|NCT01275638|Drug|Prednisolone|Soon after the presumptive diagnosis of severe sepsis, initial laboratory specimens were obtained within 2 hours, and the patients were randomized to treatment with prednisolone or placebo groups. The treatment groups were determined by a computer-generated randomization procedure (in a 1:1 ratio). The steroid group received prednisolone at a moderate-dose (20 mg/day). Prednisolone was given intravenously at 06.00 (10 mg) 14.00 (5 mg) and 22.00 (5 mg) for 10 days. The standard therapy group received a placebo infusion containing physiological saline solution in an identical manner. Patients and their primary physicians were blinded as to which therapy was administered.
45642391|NCT05290766|Procedure|placement of two dental implants|"placement of two dental implants according to  All on two concepts"
45642392|NCT05290766|Device|mandibular full arch prosthesis|loading of the mandibular fixed full-arch screw-retained metal acrylic prosthesis
45642393|NCT05290610|Other|Functional mapping|Intracranial EEG data acquisition, observation and behavioral testing, and intracranial electrical stimulation
45642394|NCT05289687|Drug|Daratumumab / Hyaluronidase Injection|Daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 1, 8, 15, and 22
45642395|NCT05289687|Drug|Daratumumab / Hyaluronidase Injection|Patients that are MRD Negative on Day 29 will receive daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57.
45781236|NCT00724568|Drug|Lenalidomide|Patients will be treated with Revlimid on days 1-14 in 3-week cycles for 4-8 cycles.
45781237|NCT00724568|Drug|Bortezomib|Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11
45781238|NCT00724568|Drug|Dexamethasone|Patients will be treated with Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels.
45781239|NCT00724568|Drug|Doxil|Patients will be treated with Doxil on day 4.
45781240|NCT01279070|Behavioral|Repyflec cognitive remediation training|Comparison of 32 Repyflec group sessions among 32 leisure group sessions where we stimulated non-specific cognitive perform.
45781241|NCT01274000|Drug|YM060|oral
45781242|NCT01274000|Drug|placebo|oral
45781243|NCT04270526|Drug|Bicarbonate protocol|Intradetrussor treatment with 50 mL 1% lidocaine + 45ml of 0.9% normal saline + 5 mL 8.4% sodium bicarbonate
45781244|NCT04270526|Drug|Standard protocol|Intradetrussor treatment with 50 mL 1% lidocaine + 50ml of 0.9% normal saline
45781245|NCT04274426|Drug|Carboplatin|Carboplatin will administered by intravenous route
45781246|NCT04274426|Drug|Pegylated liposomal doxorubicin (PLD)|PLD will be administered by intravenous route
45781247|NCT04274426|Drug|Gemcitabine|Gemcitabine will be administered by intravenous route
45781248|NCT04274426|Drug|Paclitaxel|Paclitaxel will be administered by intravenous route
45781249|NCT04274426|Drug|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine will be administered by intravenous route
45781250|NCT04274738|Drug|Mavorixafor|Mavorixafor capsules will be administered per dose and schedule specified in the arm.
45781251|NCT04274738|Drug|Ibrutinib|Ibrutinib capsules will be administered per dose and schedule specified in the arm.
45781252|NCT04272320|Drug|Bupivacaine Hydrochloride|Ultrasound-guided Transversalis Fascia Plane Block with 0.5 ml/kg %0.25 bupivacaine
45781253|NCT01274078|Biological|Blueberries|150 grams of frozen blueberries on the same day as exercise
45781254|NCT01277744|Procedure|Hyperthermic Peritoneal Perfusion (HIPEC)|HIPEC, technique for combining hyperthermia and chemotherapeutic agents delivered intraoperatively to the peritoneal and retroperitoneal surface via a recirculating perfusion circuit, performed after cytoreductive surgery and lysis of adhesions.
45642396|NCT05289687|Drug|Daratumumab / Hyaluronidase Injection|"Patients that remain MRD positive on Day 29 will receive a combination of daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57 and chemotherapy selected from the combinations listed below:~Cytarabine 3000 mg/m2, IV, Every 12 hours for 4 doses on Days 37 and 38~Methotrexate 1000 mg/m2, IV, Over 24 hours on Day 36~OR~Methotrexate, Starting dose 100 mg/m2, IV, Days 36, 46, 56~Vincristine, 1.5 mg/m2 (2 mg cap), IV, Days 36, 46, 56~Pegaspargase, 2000 IU/m2 (Capped at 3750 IU), IV Days 37, 57~Methotrexate 15 mg, IT, Days 36, 56"
45642397|NCT05289687|Drug|Daratumumab / Hyaluronidase Injection|All patients with MRD negative response after completion of previous course are eligible for daratumumab-hyaluronidase 1800mg/ 30,000 units every 2 weeks on Days 1,15, 29, 43, 57, 71, 85, and 99 for 8 doses.
45642398|NCT05289037|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
45781255|NCT01277744|Drug|Cisplatin|100 mg/M2 per perfusion catheter. The perfusion is continued for 90 minutes after adding the cisplatin.
45781256|NCT04386200|Other|web-based thecnologies|"Integration of traditional face-to-face educational approach with web-based technologies."
45781257|NCT04386200|Behavioral|traditional approach|"traditional face-to-face educational approach"
45781258|NCT01274156|Device|"MEDISPEC treatment probe"|300 shocks in 5 different anatomical locations of the penis.
45781259|NCT01274156|Device|"MEDISPEC Sham Probe"|Sham probe applied same as treatment probe without energy
45781260|NCT01274156|Device|"MEDISPEC Low intensity shock waves"|Treatment parameters will be as follows: Intensity: 0.09 mj/mm2 ,300 shocks per site, on 5 penile anatomical sites. Total number of shock waves: 1500/ session Frequency of 120/min
45781261|NCT01274156|Device|Sham|Probe does not deliver energy but creates same noise and sensation of active probe
45781262|NCT01274234|Device|COMBO Stent (OrbusNeich Medical, Fort Lauderdale, Florida)|The COMBO Stent is a hybrid version of the GENOUS Stent. Upon implantation to the coronary artery, the stent will deliver a drug (sirolimus) to the wall of the treated segment to suppress neointimal growth, in addition to the anti-CD34 antibody coating which will in theory attract circulatory endothelial progenitor cells to hasten endothelialization and promote healing of the stented segment, and thereby may reduce late stent thrombosis.
45781263|NCT04385576|Device|Aerosol Box|Usage of an Intubation Box to minimize intubator and environment contamination during intubation and extubation. Time taken for first-pass success if also expected to be reduced with the usage of the Intubation Box.
45448838|NCT00108628|Behavioral|Sleep and Nightmare Management|This comparison condition involved psychoeducation about PTSD, sleep and nightmares, progressive muscle relaxation and standard CBT for insomnia. This latter part included education about sleep hygiene (e.g., avoidance of caffeine and alcohol close to bedtime, benefit of regular bed time routines), stimulus control and sleep restriction (i.e., reestablishing a conditioned association between the bed/bedroom and sleep by reducing time spent tossing and turning in bed). Therapists worked with patients to identify problem areas in their sleep habits and to problem-solve about possible treatment targets
45642399|NCT05289037|Biological|BNT162b2|A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2.
45642400|NCT05289037|Biological|BNT162b2 (B.1.1.529)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
45642401|NCT05289037|Biological|BNT162b2 (B.1.351)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.351 (Beta) variant SARS-CoV-2 strain.
45642402|NCT05289037|Biological|BNT162b2 bivalent (wildtype and Omicron BA.1)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer. Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.1 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.
45781264|NCT04385576|Device|Intubation Box|Usage of an Intubation Box to minimize intubator and environment contamination during intubation and extubation. Time taken for first-pass success if also expected to be reduced with the usage of the Intubation Box.
45781265|NCT01274312|Procedure|Xiao procedure|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
45781266|NCT01277822|Drug|Losartan (+) amlodipine|One tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks.
45781267|NCT01277822|Drug|Placebo to match losartan/amlodipine tablets|One tablet containing placebo, orally, once daily, for 8 weeks.
45781268|NCT01277822|Drug|Amlodipine camsylate|2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks.
45781269|NCT01277822|Drug|Placebo to match amlodipine|2 tablets containing placebo, orally, once daily, for 8 weeks.
46070705|NCT03933020|Behavioral|Educational session|This consists of two education discussion sessions on the benefits of exercise for people with MS. The investigator MS specialists will conduct these sessions either by phone or at the time of a clinic visit and will also discuss difficulties encountered by participants with adherence.
45642403|NCT05289037|Biological|BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer. Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.4/BA.5 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.
45642404|NCT05289037|Biological|CoV2 preS dTM [B.1.351]|Is a liquid formulation made of recombinant protein placed in a formulation buffer that contains the spike protein sequence of the B.1.351 (Beta) variant SARS-CoV-2 strain.
45642405|NCT05289037|Biological|CoV2 preS dTM/D614|Is a liquid formulation made of recombinant protein placed in a formulation buffer. The antigen solution contains the spike protein sequence of the ancestral strain of SARS-CoV-2.
46070706|NCT03933020|Behavioral|Standard Management of Physical Activity|Routine discussion of lifestyle factors including physical activity during clinic visits
45642406|NCT05289037|Biological|CoV2 preS dTM/D614+B.1.351|Is a liquid formulation made of recombinant protein placed in a formulation buffer contains the spike protein sequences of the ancestral and B.1.351 (Beta) variant SARS-CoV-2 strains
45642407|NCT05289037|Biological|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV).
45642408|NCT05289037|Biological|mRNA-1273.351|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike (S) protein of the B.1.351 variant SARS-CoV-2 strain.
45642409|NCT05289037|Biological|mRNA-1273.529|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
45781270|NCT01277666|Drug|GSK1605786A|500 mg twice daily, administered orally for 12 weeks
45781271|NCT01277666|Drug|GSK1605786A|500 mg once daily, administered orally for 12 weeks
45781272|NCT01277666|Drug|Placebo|Placebo capsules, administered orally for 12 weeks
45781273|NCT00249002|Drug|ABI-007|
45781274|NCT04386278|Device|Intervention 1|Side one: No treatment Side two: OrthoPulse Gen 2 (2RP) for one minute
45781275|NCT04386278|Device|Intervention 2|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for one minute
45781276|NCT04386278|Device|Intervention 3|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for 5 minutes
45781277|NCT04386278|Device|Intervention 4|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RCW) for five minutes
45781278|NCT04386278|Device|Intervention 5|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
45781279|NCT04386278|Device|Intervention 6|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes
45917230|NCT05260918|Other|Nappod|Participants will utilize nappod.
45917231|NCT05254795|Other|Molecular tumor board assisted care|Participants in this group will obtain recommendations for care from the molecular tumor board.
46070707|NCT03682796|Drug|TRPH-222|administered by IV, 21-day Cycle
45642410|NCT05289037|Biological|mRNA-1273.617.2|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.617.2 (Delta) variant SARS-CoV-2 strain.
45642411|NCT05289037|Other|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
45642412|NCT05288855|Drug|Voclosporin|calcineurin inhibitor
45642413|NCT05288855|Drug|Placebo Oral Capsule|matching placebo capsule
45781280|NCT04386278|Device|Intervention 7|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
45781281|NCT04386278|Device|Intervention 8|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RBP) for five minutes
45781282|NCT01277042|Biological|GSK580299 (CervarixTM)|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
45781283|NCT01277042|Biological|Engerix-BTM|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
45781284|NCT01274546|Device|cruciate-retaining Foundation Knee system|subjects who received the cruciate-retaining Foundation Knee system greater than or equal to 10 years ago and still maintain the original device in their knee.
45781285|NCT00748826|Biological|Infliximab|"Patients with active rheumatoid arthritis (RA) confirmed with American College of Rheumatology (ACR) criteria could take part in the project if they did not respond sufficiently to disease-modifying products, including methotrexate, received Infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of~Infliximab therapy with additional infusions of 5 mg/kg at week 2"
45781286|NCT00754130|Drug|Placebo|Placebo tablets before every meal (q.a.c) Treatment period is 5 days.
45917232|NCT05247658|Other|Therapeutic lens alone|Therapeutic lens will be apposed on patient's dominant eye after bilateral PRK. Therapeutic lens will be maintained without interruption until the first postoperative visit when it will be removed by the surgeon.
45917233|NCT05247658|Other|Therapeutic lens + amniotic membrane (Visio-AMTRIX)|Amniotic membrane (Visio-AMTRIX) will be apposed under therapeutic lens on patient's non-dominant eye after bilateral PRK. Amniotic membrane and therapeutic lens will be maintained without interruption until the first postoperative visit when it will be removed by the surgeon.
45917234|NCT05241379|Device|Amber UI System|The implantable components of the Amber UI system consist of an implantable pulse generator (Picostim Amber IPG), 2 electrode leads with anchoring system
45917235|NCT00388986|Drug|GK Activator (2)|100mg po bid
45448839|NCT02144116|Other|Dance-movement therapy|The dance-movement was practised in groups. Dance-movement therapy derived from dance education. The goals of dance-movement therapy included assessing patient needs, communicating emotions, improving self-control, organizing thoughts and actions, developing interpersonal skills, integrating physical and emotional selves, promoting body awareness, and supporting healing.
45642414|NCT05286762|Drug|CTx-1301-Dexmethylphenidate 12.5 mg (titration only)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg
45642415|NCT05286762|Drug|CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg
45642416|NCT05286762|Drug|CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg
45917236|NCT00388986|Drug|Glyburide|10-20mg po daily
45642417|NCT05286762|Drug|CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg, then week 3 to 37.5 mg
45642418|NCT05286762|Drug|Placebo|Subjects will be randomized at Visit 2 to Placebo
45917237|NCT05234203|Dietary Supplement|HTB Rejuvenate|90 days of BID dosing of 2 capsules of HTB Rejuvenate
45917238|NCT05233696|Drug|Nab-paclitaxel|All patients are encouraged to receive nab-paclitaxel 100 mg/m2 IV D1 and D8 every 21 days (in combination with pembrolizumab) for at least 4-6 cycles per institutional standards and treating physicians' recommendations.
45448840|NCT02144116|Other|Control group|Standardized educational information in the form of a leaflet about balance disorders and quality of life in fibromyalgia.
45448841|NCT02715856|Other|Monitoring Device|Undergo surgical wound and physical activity monitoring
45448842|NCT02715856|Other|Physical Activity Measurement|Undergo physical activity measurement
45448843|NCT02715856|Other|Quality-of-Life Assessment|Ancillary studies
45642419|NCT05282823|Device|Boston Scientific Cardiac Cryoablation System|is indicated for cryoablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of AF as per current and future guidelines and system IFU/ Tenpubunsyo.
45642420|NCT05281510|Drug|Vesatolimod|Administered orally
45642421|NCT05281510|Biological|VRC07523LS|Administered intravenously
45642422|NCT05281510|Biological|CAP256V2LS|Administered intravenously
45642423|NCT05384249|Drug|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
45642424|NCT05384249|Drug|Placebo|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
45642425|NCT05278533|Dietary Supplement|BioPlete™ Advanced Formula|2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
45642426|NCT05278533|Dietary Supplement|Placebo|2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
45642427|NCT05277571|Biological|UCB1381|UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B
45642428|NCT05277571|Drug|Placebo|Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.
45642429|NCT05276674|Device|ZNN Bactiguard Retrograde Femoral Nail|Femoral fracture internal fixation.
45642430|NCT05275699|Drug|68Ga-FAPI|Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of keloid by PET/CT.
45642431|NCT05272852|Device|FARAPULSE™ Pulsed Field Ablation System Plus|Ablation using FARAPULSE™ Pulsed Field Ablation System Plus
45642432|NCT05272384|Procedure|Biospecimen Collection|Undergo collection of blood samples
45642433|NCT05272384|Procedure|Computed Tomography|Undergo PET/CT
45448844|NCT02715856|Other|Questionnaire Administration|Ancillary studies
45448845|NCT02715856|Procedure|Standard Follow-Up Care|Undergo standard follow-up care
45448846|NCT02715856|Other|Survey Administration|Ancillary studies
45448847|NCT02688166|Other|Complete Cardiac Magnetic Resonance Imaging (MRI)|Complete Cardiac Magnetic Resonance Imaging (MRI) prior to treatment and then at approximately 1 year after completion of radiation therapy
45642434|NCT05272384|Drug|Decitabine and Cedazuridine|Given PO
45642435|NCT05272384|Biological|Nivolumab|Given IV
45642436|NCT05272384|Procedure|Positron Emission Tomography|Undergo PET/CT
45642437|NCT05267613|Drug|Nexium 20mg|Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.
45917239|NCT05233696|Drug|Paclitaxel|Paclitaxel can be substituted for nab-paclitaxel at the discretion of the treating physician 80 mg/m2 IV D1 and D8 every 21 days.
45917240|NCT05233696|Radiation|Radiation Therapy|The treating radiation oncologist will select 1-4 sites of metastatic disease to target with radiation. All sites of disease may be targeted with radiation. Sites of metastatic disease planned to be biopsied should not be radiated.
45642438|NCT05267613|Drug|Nexium 10mg|Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.
45642439|NCT05267535|Drug|Piromelatine 20 mg|Tablets
45642440|NCT05267535|Drug|Placebo|Tablets
45642441|NCT05263674|Drug|Rapid sedation|High-dose Propofol (bolus 3-5 g / kg, maintenance dose 5-10 mg / kg / hour) to - 5 on the Richmond agitation sedation scale (RASS) for 20 hours, and a single anti-epileptic drug should be added as adjunctive therapy. Addition of low-dose Midazolam (max. 0.1 mg / kg / h) is permitted if deep sedation (defined clinically by RASS -5) is not possible with Propofol alone.
45642442|NCT05262530|Biological|BNT142|Intravenous bolus/infusion
45642443|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
45642444|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
45642445|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
45642446|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
45642447|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
45642448|NCT05262400|Drug|PF-07104091 + PF-07220060 + fulvestrant dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant
45642449|NCT05262400|Drug|PF-07104091 + PF-07220060 + fulvestrant dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant
45642450|NCT05262400|Drug|PF-07104091 + PF-07220060 + letrozole dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with letrozole
45917241|NCT05233696|Drug|Pembrolizumab|Patients will receive pembrolizumab 200 mg D1 every 21 days.
46070708|NCT03984422|Other|Smartphone application|use of smartphone application during 2 weeks to 3 months to collect frequency and duration of crises, RCS, photography of finger.
45642451|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
45781287|NCT00754130|Drug|MK-0941|MK-0941 5 mg tablets q.a.c.; 10 mg tablets q.a.c.; 20 mg tablets q.a.c.; or 40 mg tablets q.a.c. Treatment period is 5 days.
45781288|NCT00246740|Drug|Periostat|In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
45781289|NCT00246740|Drug|Placebo Oral Tablet|In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
45781290|NCT01274624|Biological|REOLYSIN®|1 hour intravenous infusion administered on Days 1, 2, 3, 4, and 5 every 4 weeks.
45781291|NCT01274624|Drug|Irinotecan|90-minute intravenous infusion on Day 1 every 2 weeks. Dose levels of 125 mg/m2, 150 mg/m2, 150 mg/m2, 180 mg/m2.
45781292|NCT01274624|Drug|Leucovorin|2-hour infusion of 400 mg/m2 on Day 1 every 2 weeks.
45781293|NCT01274624|Drug|Fluorouracil (5-FU)|400 mg/m2 intravenous bolus followed by 2400 mg/m2 as a continuous intravenous infusion over 46 hours administered on Day 1 every 2 weeks.
45781294|NCT01274624|Drug|Bevacizumab|30, 60 or 90 minute infusion on Day 1 every 2 weeks. Dose level 5 mg/kg.
45781295|NCT00748982|Drug|AZD1305|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
45781296|NCT00748982|Drug|Placebo|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
45917242|NCT05223673|Biological|Futuximab/modotuximab|Concentrate for solution for infusion, futuximab/modotuximab will be administered via IV route, once weekly of each cycle at 9 mg/kg/dose at Cycle 1 Day 1 and then at 6 mg/kg/dose. Each cycle is up to 28 days.
45917243|NCT05223673|Drug|Trifluridine/Tipiracil|Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally before futuximab/ modotuximab administration, twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
45917244|NCT05223673|Drug|Trifluridine/Tipiracil|Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
45781297|NCT00749606|Behavioral|Individual telephone intervention|"Individually administered telephone-based weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff."
45781298|NCT00749606|Behavioral|Group telephone intervention|"Group education conference calls administered weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff."
45781299|NCT01274936|Drug|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
45642452|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
45642453|NCT05262400|Drug|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
45642454|NCT05259774|Device|Relizema cram|Relizema cream is a CE marked, Class IIa medical device, dermatological cream for topical use indicated for symptomatic treatment of dermatitis and erythema. Relizema cream is indicated for the treatment of itching and flushing associated with different types of dermatitis, including atopic dermatitis.
45642455|NCT05259085|Drug|ALXN2050|ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
45642456|NCT05259033|Drug|IcoSema|"IcoSema once weekly subcutaneously (s.c., under the skin) using a needle and a pen.~For about 1 year and 1 month."
45642457|NCT05259033|Drug|Semaglutide 1 mg|Semaglutide once weekly subcutaneously (s.c., under the skin). Dose titrated to 1mg over 8 weeks (0.25 mg for 4 weeks, 0.5 mg for 4 weeks). For about 1 year and 1 month.
45642458|NCT05257668|Other|High Intensity Interval Exercise Training|High Intensity Interval Training Group
45642459|NCT05257668|Other|Moderate Intensity Exercise Training|Moderate Intensity Training Group
45781300|NCT01274936|Drug|Qishe Placebo|Pill, 3.75 g, twice per day, four weeks
45917245|NCT00000489|Procedure|coronary artery bypass|
45917246|NCT05213299|Procedure|AURICULAR ACUPUNCTURE|Auricular acupuncture is a method for diagnosing and treating physical and psychosomatic dysfunctions by stimulating a specific point in the ear. To conducting this intervention, the investigators use press tack needles to perform auricular acupuncture.
45781301|NCT00761930|Drug|Fluoride|Brush twice daily
45781302|NCT00761930|Drug|Triclosan and fluoride|Brush twice daily
45781303|NCT00761930|Drug|Herbal Ingredient and fluoride|Brush twice daily
45781304|NCT00245102|Drug|sorafenib tosylate|Given orally
45781305|NCT01275014|Drug|Dexamethasone|1 ml of 20mg/ml solution was applied once, following the arthrocentesis procedure of the TMJ
45781306|NCT01275014|Drug|Isotonic saline|1 ml of isotonic saline was applied once, following the arthrocentesis procedure of the TMJ
45781307|NCT00754832|Drug|American ginseng extract HT-1001|Ginseng HT-1001 was dosed at 100 mg orally per day initially, increased after one week to 200 mg per day, then further increased the next week to 400 mg per day as tolerated. Subjects were then maintained on 400 mg per day or the maximum tolerated dose for the remainder of the 6 week treatment period.
45781308|NCT00754832|Drug|placebo|Placebo capsules were identical to the study drug and were dose escalated to match the study drug. Subjects were maintained on placebo capsules for the remainder of the 6 week treatment period.
45781309|NCT01275248|Drug|Ondansetron|Oral tablets in 0.5mg or 0.75mg strength
45781310|NCT01275248|Drug|Placebo|Oral tablet to match the experimental interventions
45781311|NCT00756236|Drug|Metoprolol|60ml syringes of 0.9% NaCl, 5ml syringes of metoprolol at 1mg/ml concentration
45448848|NCT00006256|Drug|paclitaxel|Patients receive paclitaxel IV over 3 hours every 21 days for 4 courses beginning 3 weeks after completion of the last doxorubicin and cyclophosphamide adjuvant regimen.
45448849|NCT00006256|Procedure|adjuvant therapy|doxorubicin and cyclophosphamide adjuvant regimen
45642460|NCT05251363|Device|Solia S lead|The Solia S pacing lead will be implanted in the LBB area for patients who meet all inclusion/exclusion criteria and give written informed consent.
45642461|NCT05251233|Drug|Placebo|Placebo capsules contain pharmaceutical-grade lactose monohydrate NF, a naturally occurring disaccharide of galactose bound to glucose.
45642462|NCT05251233|Drug|Pantoprazole|The study will use commercial supply.
45781312|NCT00756236|Drug|Esmolol|60ml syringes of esmolol at 10 mg/ml concentration, 5ml syringes of 0.9% of NaCl
45781313|NCT00756236|Drug|P-Group|0.9%NaCl dispensed in 60ml & 5ml syringes
45781314|NCT00762320|Drug|Low dose Kaletra tablets|Lopinavir/Ritonavir tablets 100mg/25mg
45781315|NCT03807830|Procedure|Electrocochlography|Intra-operative ECochG recording via the implant, post operative ECochG measurements. Impedances measured over time.
45781316|NCT03807752|Dietary Supplement|MPH_active|One daily intake at breakfast of supplementary marine protein hydrolysate (MPH), a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water. Random sequence of arms.
45917247|NCT05213299|Other|PLACEBO|For this intervention, instead of needles, the investigators use four pieces of tape.
45917248|NCT05212363|Device|Lower extremity compression garments|Compression garments are used to exert external pressure on the lower extremities to reduce vascular wall tension and prevent gravity form pooling blood in the lower extremities which will improve venous return and lymphatic output. Following the resting measurements, subjects will be instructed to wear the garments and moved to the seated gaming position for 2 hours.
45917249|NCT05212363|Behavioral|Active break|"An active break is currently considered gold standard for increasing blood flow after prolonged sitting. The 6-minute walk will be conducted indoors next to the esport lab in the Wisser library at NYIT, Old Westbury. Participants will be asked to walk for 6 minutes on a flat surface back and forth following one hour of game play."
45781317|NCT03807752|Dietary Supplement|MPH_placebo|One daily intake at breakfast of supplementary placebo, a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water.
45781318|NCT03807674|Procedure|Coronal pulpotomy|Coronal pulpotomy was performed with a sterile high-speed round bur under water coolant. Pulp vitality was confirmed by the presence of bleeding pulp tissue from all of the canal orifices. Hemostasis was achieved through the application of a pellet moistened with 2.5% NaOCl for two minutes and was repeated as needed. Calcium-silicate based material was prepared ac-cording to the manufacturer's instructions and gently placed over the pulp to fill the entire cavity.
45781319|NCT01275404|Behavioral|Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls|"Baseline Assessment which is 90-minute patient focus group interviews. SMRP, provided to all participating patients, consists of the following steps: 1) An introductory visit with SMRP Director, Dr. Mulhall, to orient the patient to post-surgery erectile rehabilitation and assess the patients success with PDE-5 inhibitors; 2) Penile injection training provided by a NP over two visits, with follow-up calls as necessary until injection method and dose are deemed correct; 3) Follow-up visits with Dr. Mulhall every 4 months to monitor progress with rehabilitation. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2)."
45781320|NCT01275404|Behavioral|Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction|Baseline Assessment which is 90-minute patient focus group interviews. SMRP+ACT-ED will receive four individual ACT-ED counseling sessions (60 minutes each) over a period of approximately four months, and will also be followed up with questionnaires 4 and 8 months post baseline These sessions focus on the four core elements of ACT: values, acceptance, exposure, and commitment. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2).
45781321|NCT03807206|Behavioral|Questionnaire|Patient questionnaire
45448850|NCT00006256|Radiation|radiation therapy|Patients also undergo concurrent radiotherapy 5 days a week for approximately 6-7 weeks.
45642463|NCT05251181|Drug|Normal Saline|Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
45642464|NCT05251181|Drug|Centhaquine|Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
45642465|NCT05249465|Behavioral|Core behavioral weight loss intervention|"All participants will receive a 6-month core behavioral obesity treatment consisting of goal setting, behavioral lessons, action plans, and tailored feedback - all of which will be delivered remotely."
45642466|NCT05249465|Behavioral|Self-monitoring diet|Participants randomized to receive this component will be instructed to self-monitor their dietary intake daily via the Fitbit mobile app. Participants will receive a daily calorie goal.
45917250|NCT05199805|Behavioral|Mindfulness-based pain management|The structured program will include mindfulness exercises, meditation, a gentle body exercise series, and body awareness exercises, as well as information about pain, mindfulness-based pain management, and pain regulation methods suitable for everyday life. During the 8 weeks, treatment as usual is allowed.
45917251|NCT00000492|Drug|propranolol|
46070709|NCT03680066|Other|Oral food challenge to foods with traces|"Subjects will undergo an open food challenge to 3 processed foods labeled with may contain traces. The following foods (similar for all patients) will be given in one dose in the size of a regular serving:~cookies, max 30 g;~chocolate, max 30 g;~breakfast cereals, max 50 g.~Each meal will be administered with a 1 hour observation period in between and at the end."
45448851|NCT02144194|Drug|Vinorelbine-Docetaxel|Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks x 6 cycles
45448852|NCT02144194|Drug|Vinorelbine|Oral Vinorelbine 60mg/m2 or 80mg/m2 D1, D8 every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue (dose schedule is at investigator's discretion)
45917252|NCT05192590|Other|Educational Materials and Chronic Disease Management Test (CDMT)|"Intervention-1- and Intervention-2-arm participants will receive educational materials duplicating what physicians would receive in the real-world market as they adopt the CDMT technology. These materials are comprised of a PowerPoint presentation.~Intervention 1 participants only will receive the CDMT test results whether they select it or not, and Intervention 2 participants will receive the CDMT test results only if they select it during the second round of case simulations."
45642467|NCT05249465|Behavioral|Self-monitoring weight|Participants randomized to receive this component will be instructed to self-monitor their body weight daily via a wireless e-scale (e.g., the Fitbit Aria Scale).
45642468|NCT05249465|Behavioral|Self-monitoring steps|Participants randomized to receive this component will be instructed to self-monitor their step count daily via a wrist-worn Fitbit activity monitor. A daily step goal will be given that will adapt based on progress.
45781322|NCT00244712|Drug|emtricitabine/tenofovir|The intervention is an active comparator regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.
45781323|NCT00244712|Drug|abacavir/lamivudine|The experimental intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo + lopinavir/ritonavir.
45781324|NCT00725270|Drug|Mifepristone|600 mg of mifepristone
45781325|NCT00725270|Drug|Placebo Oral Tablet|Placebo comparator
45781326|NCT00243932|Drug|coenzyme Q10|antioxidant and mitochondrial cofactor, given in capsules three times daily
45781327|NCT00243932|Drug|Placebo|Placebo capsules, indistinguishable from CoQ10 capsules, given three times daily
45781328|NCT01275482|Procedure|Transverse friction massage (TFM)|The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue. During the massage, we can caused isolated contractions from the fiber muscles containing the latent trigger points.
45781329|NCT01275482|Procedure|Transverse friction massage (TFM)|The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue.
45781330|NCT00243386|Drug|Antihemophilic factor, recombinant, manufactured protein-free|Standard prophylaxis: 20-40 IU/kg every 48+/-6 hours, actual dose determined by investigator
45781331|NCT00243386|Drug|Antihemophilic factor, recombinant, manufactured protein-free|PK-driven prophylaxis: 20-80 IU/kg every 72+/-6 hours, actual dose determined by Baxter using an algorithm and the patient´s pharmacokinetic data
45781332|NCT03807284|Behavioral|A group psychosocial course|A 2 hour, weekly group psychosocial therapy RCAS course that aims to improve confidence and help adjustment after a stroke.
45781333|NCT03807362|Drug|CC-11050|CC-11050 is a novel anti-inflammatory compound with potential to treat a variety of chronic inflammatory conditions.
45781334|NCT01275560|Drug|Metronidazole|Metronidazole,per os,500mg, 3 per day during 10 days
45781335|NCT01275560|Drug|CArbosylane|
45781336|NCT00762710|Drug|Prazosin medication|"Form: Prazosin will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
45781337|NCT00762710|Drug|Placebo medication|"Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
45781338|NCT03807518|Behavioral|Standard Exercise Program|Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing neo adjuvant therapy and for a six week period when deemed fit post surgery.
45781339|NCT04384640|Other|Change of posture after Intra Tympanic injection|Seating position after Intra Tympanic injection
45781340|NCT03807128|Other|No interventional study|No interventional study
45781341|NCT03807050|Dietary Supplement|Astaxanthin|Capsules containing astaxanthin derived from the yeast Phaffia rhodozyma .
45781342|NCT00756548|Drug|BLI850|multi-dose preparation for oral administration prior to colonoscopy
45781343|NCT00756548|Drug|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
45781344|NCT00243230|Drug|Vicriviroc 30 mg|Three tablets of vicriviroc 10 mg once daily for 48 weeks (Double-blind Period) or for up to 45 months (Open Label Period).
45781345|NCT00243230|Drug|Vicriviroc 20 mg|Two tablets of vicriviroc 10 mg once daily for 48 weeks.
45781346|NCT00243230|Drug|Placebo|Three tablets of placebo once daily for 48 weeks.
45642469|NCT05248009|Device|Semi-Permanent Tattoo Ink|Subjects will receive semi-permanent tattoo ink in place of the permanent ink utilized in the standard of care. Subjects will be monitored during their treatment course and for 15 months following treatment completion.
45642470|NCT05247034|Dietary Supplement|Cocoa|Each capsule of cocoa powder contains 12.5 mg of flavonoids, providing a total of 50 mg per day.
45642471|NCT05247034|Other|Placebo|Each capsule contains 500 mg of methylcellulose
45642472|NCT05242510|Procedure|Patching|The subject will occlude the non-dominant eye for 24 hours.
45781347|NCT00243230|Drug|Placebo|Two tablets of placebo once daily for 48 weeks.
45781348|NCT00243230|Drug|Background ART Regimen|"An open-label ritonavir-boosted optimized background ART regimen containing ≥3 drugs (including a protease inhibitor [PI]) selected for each individual study participant by the investigator. The optimized regimens most commonly include new nucleoside analogs (NRTIs) and a PI, usually boosted with concomitant ritonavir."
45781349|NCT00243074|Drug|cediranib maleate|Given orally
45781350|NCT00243074|Other|laboratory biomarker analysis|Correlative studies
45781351|NCT00241358|Drug|AMD3100|
45781352|NCT00241358|Procedure|Stem Cell Transplant|
45781353|NCT00241280|Device|etafilcon A|
45781354|NCT00241280|Device|galyfilcon A|
45781355|NCT00240500|Biological|Engerix™-B|In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.
45781356|NCT00778310|Drug|methylphenidate-OROS|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of Concerta that are made to appear similar to placebo capsules. The subject will be administered their usual dose of Concerta the morning of the scan.
45781357|NCT00778310|Drug|Placebo|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of placebo that are made to appear similar to Concerta capsules. The subject will be administered placebo the morning of the scan.
45642473|NCT05242510|Procedure|Prism Adaptation|The subject will undergo prism adaptation targeting the pre-occlusion distance angle for 1-2 weeks. • Fresnel prism(s) will be applied to the patient's spectacles equaling the distance angle between the two eyes. At the examiner's discretion depending on the size of the deviation, the prism(s) can be placed solely over the non-dominant eye, or split between the 2 eyes in some combination which results in equalization of the distance exotropia. If the distance angle calls for an amount of prism that cannot be exactly replicated with Fresnel prisms (e.g., 32 PD), the amount of prism used will be determined by rounding down to the nearest practical amount at examiner discretion.
45642474|NCT05239728|Drug|Belzutifan|Three 40 mg tablets given as a single oral 120 mg dose.
45642475|NCT05239728|Biological|Pembrolizumab|400 mg via IV infusion
45917253|NCT05183152|Device|NMES-BCI|Electroenceauphalography (EEG) signals will be recorded from subjects as they perform cued tasks for flexing/extending their non-dominant hand. The signals will be processed and classified in real-time using machine learning algorithms to trigger electrical stimulation on the flexors/extensors of the targeted arm contingent to the detection of a subject-specific flexion/extension EEG patterns.
45917254|NCT05183152|Device|Visual-BCI|Electroenceauphalography (EEG) signals will be recorded from subjects as they perform cued tasks for flexing/extending their non-dominant hand. The signals will be processed and classified in real-time using machine learning algorithms to control the right/left movement of a bar on a computer screen. The bar feedback is contingent to the detection of a subject-specific flexion/extension EEG patterns.
45917255|NCT00000495|Behavioral|diet, reducing|
45917256|NCT00000495|Behavioral|diet, sodium-restricted|
45917257|NCT00000495|Behavioral|alcohol restriction|
45917258|NCT00000495|Behavioral|exercise|
45917259|NCT05174299|Device|magnetic stimulation|For Experimental Arm, active magnetic stimulation on motor cortex followed by active magnetic stimulation on spinal cord, patients underwent ten sessions of double active magnetic stimulation with low frequency repetitive transcranial magnetic stimulation (rTMS) over the bilateral primary motor cortex of the lower leg followed by low frequency repetitive magnetic stimulation over the spinal cord. For Active Comparator Arm, active magnetic stimulation on motor cortex followed by sham magnetic stimulation on spinal cord. For Sham Comparator Arm, sham magnetic stimulation on motor cortex followed by sham magnetic stimulation on spinal cord.
45917260|NCT00000498|Behavioral|diet, sodium-restricted|
45917261|NCT00000498|Behavioral|diet, reducing|
45642476|NCT05239728|Drug|Placebo|Oral tablet
46070710|NCT03449732|Device|PDR measurement|"PDR measurement at two standardized times perioperatively:~Anesthetized subject by sevoflurane sedation until a minimum alveolar concentration (MAC) of at least 1,5 is reached~Administration of fentanyl 2µg/kg, in the absence of adjustments in sedation depth"
45781358|NCT03806426|Drug|Eicosapentaenoic acid free fatty acid (EPA-FFA)|500mg capsule, two 500mg capsules to be taken twice daily for 24 months
45781359|NCT03806426|Drug|Placebo|500mg capsule, two 500mg capsules to be taken twice daily for 24 months
45917262|NCT00000498|Behavioral|alcohol restriction|
45917263|NCT00000498|Drug|antihypertensive agents|
45917264|NCT03129139|Drug|Minnelide™Capsules|Minnelide™ is a water soluble disodium salt variant of triptolide an heat shock protein (HSP) inhibitor.
45917265|NCT00000501|Behavioral|diet, sodium-restricted|
45917266|NCT00000501|Behavioral|diet, reducing|
45781360|NCT03805646|Other|Mobile Phone-based Triage Tool|The proposed intervention is a mobile phone-administered survey. Participants that have been admitted to participating hospitals for treatment of injury will be contacted by mobile phone approximately two weeks after discharge. A seven-question survey will be administered over the phone to each participant. Cross-validation with a separately administered in-person physical exam will be performed to assess the survey tool's prediction of who needs further care for treatment of their injury.
45781361|NCT03809390|Procedure|Vaginal seeding|The same as that stated in arm descriptions.
45781362|NCT01212107|Drug|FGF Receptor|LY2874455 administered orally.
45781363|NCT01212107|Drug|Phosphate Binders|
45781364|NCT03801278|Drug|FPA144|Bemarituzumab administration every two weeks
45917267|NCT00000501|Drug|potassium|
45917268|NCT05157607|Behavioral|Family Connections Protocol for Relatives of Patients with SBD.|Family Connections is a Dialectical Behavioral Therapy. All the modules include practice exercises, video viewing, and homework assignments. In addition, throughout the program, with the aim of increasing social support, the FC-SBD program provides a forum where participants can stay in touch and share common problems and solutions.
45917269|NCT05157607|Behavioral|Treatment as Usual Optimized Protocol (TAU-O)|Participants will receive the usual treatment in their mental health service and will also receive a psychoeducation session of approximately 3 hours where the predictive and protective factors of suicidal behavior will be explained.
45917270|NCT05148013|Other|Pilates exercise|All participants will be given a basic introduction to the Pilates-based exercises and will be taught how to activate the core muscles, which entails isometric contraction of the transverses abdominis, pelvic floor, and multifidus muscles while exhaling during diaphragmatic breathing, before beginning the exercise program. The Pilates exercise program will consist of floor exercises on a mat, including the following exercises: one-leg kick, single leg stretch, shoulder bridge, the hundred, one leg circle, and swimming. All exercises progressed at three degrees of difficulty: basic, intermediate, and advanced. Depending on the patient's tolerance, each exercise will be done for 8-10 repetitions. The treatment plan included a five-minute warm-up, twenty minutes of exercise, and a five-minute cool-down.
46070711|NCT03407768|Behavioral|Individualized interventions|"A participant will be able to select one or more (or no intervention) based on her preferences.~Individualized exercise program Yoga and mindfulness Massage therapy Acupuncture Others: Women who are not interested in any above intervention but like to explore other interventions will be offered material pertinent to their choice of complimentary techniques."
46070712|NCT05332106|Drug|Estradiol Valerate and Dienogest 2 mg/ 2 mg Test Drug tablet|Investigational Medicinal Product
46070713|NCT05332106|Drug|Estradiol Valerate and Dienogest 2 mg/ 2 mg Reference Product tablet|Climodien (Bayer plc.)
46070714|NCT05333198|Other|Traditional physical therapy using Epley's maneuver|Epley's maneuver was performed once a week for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes.
45781365|NCT03808064|Behavioral|FCHV home visit|Behavioral: FCHV visit Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages Other Name: FCHV Home Visit
45781366|NCT03801356|Drug|Selective Nerve Root Block|Prior to single level foraminotomy for lumbar foraminal stenosis, patients will undergo SNRB of the suspected nerve root. Patients will undergo surgery despite the response to injection. Patients will complete an ambulation assessment immediately before and after the injection. Distance and time will be noted. Patients will be called within 48 hours of injection to determine response to injection, and recorded as Pre-and Post-injection VAS leg as well as duration of the response. Patients will be seen at 6 weeks, 3,6, and 12 months post-surgery and outcome measured by VAS-leg, ODI, PDQ and EQ-5D scores. Data will be used to determine the ideal improvement in leg pain and duration of improvement, predicting a statistical and meaningful improvement in leg pain following foramintomy.
45781367|NCT04271306|Biological|Pfs25-IMX313 (10ug)/Matrix-M (50ug)|3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(10µg)/Matrix-M (50µg)
45917271|NCT05148013|Other|PNF exercise|The PNF techniques utilized in the PNF exercise group will include a combination of isotonics, rhythmic stabilization, and repeated stretch. The exercises which will be performed are; (1) Trunk rotation in sitting position (1a) Chopping to the left and right and (1b) Lifting to the left and right, (2) Rolling activity (2a) Resistance to pelvic anterior patterns 2(b) Resistance to posterior patterns, 2(c) Combination of scapula and pelvis, 2(d) Combination of scapula and pelvis (i.e. asymmetrical exercise for trunk extension: the scapula moves in posterior elevation, the pelvis in posterior depression) and (3) Bridging activity (3a) Stabilize the pelvis in its neutral position, 3(b) Bridging lower trunk rotation and, 3(c) Bridging on two legs in the supine position.
45781368|NCT04271306|Biological|Pfs25-IMX313 (50ug)/Matrix-M (50ug)|3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg)
45781369|NCT04271306|Biological|Pfs25-IMX313 (50ug)/Matrix-M (50ug) & Pfs25-IMX313 (10ug)/Matrix-M (50ug)|2 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg) followed by one at Pfs25-IMX313(10µg)/Matrix-M (50µg)
45781370|NCT01246895|Device|Microfracture with BST-CarGel|
45781371|NCT01246895|Device|Microfracture without BST-CarGel|
45781372|NCT03800420|Drug|BBT-401-1S first and then Placebo|Total 16 week treatment period: The subject takes BBT-401-1S, QD for the first 12 weeks, then placebo for the last 4 weeks.
45781373|NCT03800420|Drug|Placebo first and then BBT-401-1S|Total 16 week treatment period: The subject takes the placebo, QD for the first 8 weeks, then BBT-401-1S for the last 8 weeks.
45917272|NCT00000504|Drug|encainide|
45642477|NCT05236348|Device|Aktiia.product-us|The study will collect data from subjects by means of the device under test and collect data from subjects by means of double-auscultation, pulse oximetry and volume-clamp BP reading while subjects wear the devices at different body positions and induce BP changes, during eight visits that will be held over the span of seven days, and generate performance reports.
45642478|NCT05233098|Device|Technetium-99m macroaggregated albumin (Tc-99m MAA)|Patients who are being evaluated for TheraSphere administration.
45781374|NCT03802760|Device|Transcranial Doppler (TCD) ultrasound measurement|Non-invasive measurement of cerebral embolic load and blood flow using TCD
45781375|NCT04345484|Behavioral|Goal-management training|9-week goal-management program
45781376|NCT04345484|Behavioral|Control|Healthy Lifestyle Program
45781377|NCT01247285|Drug|Fluoxetine Hydrochloride|90 mg Capsules
45781378|NCT01247285|Drug|PROZAC WEEKLY®|90 mg Capsules
45781379|NCT03806582|Drug|Norepinephrine|intervention with norepinephrine to reach a MAP of 85 mmHg
45781380|NCT00779558|Drug|Heparin sulfate infusion at 10 units/kg/hour|Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery
45781381|NCT00779558|Drug|Placebo infusion|Infusion of normal saline
45917273|NCT00000504|Drug|moricizine|
45917274|NCT00000504|Drug|flecainide|
45917275|NCT00000504|Drug|imipramine|
45917276|NCT05146219|Drug|TY-9591 Tablets|TY-9591 Tablets 160mg/d
45917277|NCT00389935|Drug|Thalidomide|Thalidomide 50 - 200 mg once at nightime
46070715|NCT05333198|Other|Oculomotor and Vestibular Ocular Reflex (VOR) exercises|oculomotor and VOR exercises after Epley's maneuver. The exercises were performed for approximately 5 minutes daily or 1 to 2 minutes, 3 to 4 times a day, in sitting position. The exercises were continued for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes. Saccadic exercises were performed by moving eyes between two stationary targets. Smooth pursuit exercises were performed by tracking a moving target while keeping head still and VOR exercises were performed by moving head left to right while maintaining eyes on stationary target
45448853|NCT02140684|Device|eNO monitoring|Patient undergoing review with eNO monitored using either NIOX MINO® and NIOX Flex®
45642479|NCT05232929|Drug|Risdiplam|Participants will receive risdiplam orally.
45642480|NCT05232864|Drug|Secukinumab|STUDY DRUG
45642481|NCT05231837|Behavioral|Experimental: Fee Waiver|Fees are waived for youth sports programs at the park and recreation center
45781382|NCT01300559|Device|Tissuelink device|Tissuelink device plus Unipolar electrocautery
45781383|NCT03806894|Diagnostic Test|Quantification of platelet aggregation|Platelet aggregation will be determined by vasodilator-stimulated phosphoprotein (VASP) assay
45781384|NCT00758342|Drug|Travoprost 0.004% + Brinzolamide 1.0%|Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
45781385|NCT00758342|Drug|Travoprost 0.004% + Tears Natural|Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
45781386|NCT01300949|Diagnostic Test|Spaeth/Richman Contrast Sensitivity Test|internet based computerized contrast sensitivity test measuring central and peripheral vision using black and white stripes that decrease in contrast by fading to a white background.
45781387|NCT01300949|Diagnostic Test|Pelli-Robson Contrast Sensitivity Chart|wall chart contrast sensitivity test measuring central vision using black letters that decrease in contrast by fading to a white background.
45642482|NCT05231837|Behavioral|Fee Waiver Plus Intensive Outreach|Fees are waived for youth sports programs at the park and recreation center and intensive outreach is conducted in the neighborhood through community advisory boards and partner engagement.
45448854|NCT02140840|Drug|Trametinib|2 mg of Trametinib daily by mouth in 28 day cycles
45448855|NCT02140918|Drug|Fludrocortisone 100 μg|Fludrocortisone 100 μg/day
45781388|NCT01301183|Drug|RhIGF-1 with transdermal 17-beta estradiol|"RhIGF-1 will be started at a dose of 30mcg/k/dose twice daily, and will be titrated up or down in 25% dose increments to maintain IGF-1 levels in the upper half of the normal range.~Estradiol will be delivered transdermally using a 100 mcg patch (Vivelle Dot) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D."
45781389|NCT01301183|Drug|Placebo and transdermal 17-beta estradiol|Placebo injections will be administered twice daily. Estradiol will be delivered transdermally using a patch (100 mcg) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D.
45781390|NCT00758420|Drug|Varisolve (Polidocanol Endovenous Microfoam)|1% polidocanol, up to 15 mL, one treatment session (initially up to 30 ml, reduced to up to 15 ml in Amendment #2)
45781391|NCT00758420|Drug|Agitated Saline|10 u/mL normal heparinized saline solution, up to 20 mL, one treatment session
45781392|NCT00779870|Other|bronchoscopy|bronchoscopy under local anaesthetic and sedation to obtain endobronchial biopsies
45781393|NCT01213043|Biological|Prolastin-C, 60 mg/kg|60 mg/kg weekly infusion of Prolastin-C for 8 weeks
45781394|NCT01213043|Biological|Prolastin-C, 120 mg/kg|120 mg/kg weekly infusion of Prolastin-C for 8 weeks
45781395|NCT00758576|Device|ACRYSOF Multifocal Single-piece Intraocular Lens (IOL) Model SN6AD1|Implantation with the AcrySof ReSTOR Intraocular Lens (IOL) Model SN6AD1 following cataract removal.
45781396|NCT01213199|Drug|Adapalene|Adapalene Gel 0.3%
45781397|NCT03809702|Drug|Pregabalin|Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
45781398|NCT03809702|Drug|Placebo|Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
45781399|NCT03806036|Drug|Vitamin D|300.000 I.U single dose of VIT D IM injection
45781400|NCT03806036|Drug|Clomiphene Citrate|100mg daily for 5 days starting from third day of menstruation
45781401|NCT03806504|Other|PEEP|performing 35 cm/H2O PEEP and 2-3 ml/kg tidal volume
45781402|NCT03806504|Other|control group|performing 6 cm/H2O PEEP and 6-8 ml/kg tidal volume
45781403|NCT01213823|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
45781404|NCT01213823|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
45781405|NCT00780026|Drug|insulin|bolus or infusion 80 to 110 mg/dl
45781406|NCT01214057|Drug|Propofol and Remifentanyl|Anesthesia will be induced with lidocaine 0.5 mg kg, propofol infusion at 250 mcg/kg/min (to reduce visual bias of propofol infusion) and total volume infused will be adjusted for an induction dose of 2-3 mg/kg before bolus of muscle relaxant, rocuronium 0.5 mg kg in both SR and PR groups. Remifentanil infusion will be started at a rate of 0.4 mcg/kg/min 1-2 minutes before the propofol infusion and a 100 ml 0.9% normal saline bag will be used to blind surgeons in the sevoflurane group. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the propofol concentration within their range (100-150 mg ml for propofol) according to the anaesthesiologist's judgement and by surgeon request. If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.
45781407|NCT01214057|Drug|Sevoflurane and Remifentanyl|Sevoflurane 1-3% will be administered in group SR, and the infusion of propofol will be stopped. After intubation remifentanil infusion will be changed to 0.2 mcg/kg/min. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the sevoflurane concentration within their range (between 1-3 vol% for sevoflurane) according to the anaesthesiologist's judgement and by surgeon request.If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.In order to limit the amount of fluids remifentanil wil be diluted at a concentration of 4 mg in 100 ml.
45781408|NCT03009149|Other|Aerobic exercise|Aerobic exercise will perform 3 days per week
45781409|NCT00780338|Other|Assets Getting To Outcomes|Face to Face Training Assets Getting To Outcomes Manuals Technical Assistance
45781410|NCT03805958|Procedure|realtime ultrasonography|Applying realtime ultrasound during the combined anesthesia
45448856|NCT02140918|Drug|Fludrocortisone 200 μg|Fludrocortisone 200 μg/day
45448857|NCT02140918|Drug|Fludrocortisone 400 μg|Fludrocortisone 400 μg/day
45448858|NCT02140918|Drug|Placebo|
45448859|NCT00108160|Drug|Mupirocin Ointment [Treatment]|The impact of the treatment arm versus placebo arm on development of new (recurrent) S. aureus infection will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
45448860|NCT00108160|Drug|Polyethylene Glycol Ointment [Placebo]|The impact of the treatment arm versus placebo arm on development of S. aureus re-infections will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
45448861|NCT02140996|Drug|Ad-sig-hMUC-1/ecdCD40L vector vaccine|
45642483|NCT05231629|Drug|Dara-VRd intensification, Dara-R maintenance|"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance"
45781411|NCT03805958|Procedure|prescan ultrasonography|Applying realtime ultrasound before the combined anesthesia
45781412|NCT03809546|Drug|Dronabinol|THC (Marinol® [dronabinol]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users (Ménétrey et al., 2005; Issa et al. 2016).
45781413|NCT03809546|Drug|dextrose|We are administering dextrose to health volunteers for our placebo group
45642484|NCT05231629|Drug|AHCT intensification, Dara-R maintenance|"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance"
45781414|NCT03809312|Drug|Amoxicillin / Clavulanic acid 875mg / 125mg|Amoxicillin / Clavulanic acid 875 mg / 125 mg BID x 10 days
45781415|NCT03809312|Drug|Placebos|Placebos BID x 10 days
45781416|NCT03807986|Procedure|Nanofat grafting|Nanofat grafting will be applied once every three months for 2 times.
45781417|NCT03807986|Procedure|Microfat grafting|Microfat grafting will be applied once every three months for 2 times.
45642485|NCT05231629|Drug|AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance|Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
45448862|NCT03544528|Procedure|Regeneration|Apical bleeding will be induced by passing a hand instrument beyond the apical foramen to allow blood filling in the canal. Mineral trioxide aggregate will be placed directly over the coagulated blood clot.
45642486|NCT05231629|Drug|AHCT intensification, Dara-R consolidation, Dara-R maintenance|Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
45781418|NCT03807986|Procedure|Platelet-rich plasma (PRP) Injection|PRP Injection will be applied once a month for 6 times.
45781419|NCT03805802|Other|active product|Once daily consumption over the period of the study
45642487|NCT05231629|Drug|Dara-VRd induction|Patients undergo induction therapy with 6 cycles of daratumumab, bortezomib, lenalidomide and dexamethasone
45781420|NCT03805802|Other|reference product|Once daily consumption over the period of the study
45781421|NCT01247363|Drug|LY2608204|Administered orally.
45781422|NCT00780494|Drug|bevacizumab|Intravenous 15 mg/kg
46070716|NCT05332028|Drug|bupivacaine|Block applications
45781423|NCT00780494|Drug|carboplatin|AUC 6, Intravenously Day 1 every 21 days
45781424|NCT00780494|Drug|capecitabine|850mg/m2, Orally twice daily days 1-14 every 21 days.
45781425|NCT03806348|Procedure|Resuturing|Early reconstruction of the perineal body after wound dehiscence within two weeks of delivery.
45781426|NCT00763412|Drug|placebo|CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
45781427|NCT00763412|Drug|repaglinide|CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
45781428|NCT01302743|Drug|Group 1: Metformin|Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days
45781429|NCT01302743|Dietary Supplement|Group 2: Cinnamon Bark|Group 2: Will receive Cinnamon Bark 1000 mg once a day for 90 days
45781430|NCT01302743|Dietary Supplement|Group 3: Cinnulin PF|Group 3: Will receive Cinnulin PF 500 mg once a day for 90 days.
45781431|NCT01248221|Drug|[13C]-Spirulina platensis and 99mTc sulfur colloid|The subject will consume the test meal containing 13C-Spirulina and 99mTc sulfur colloid in no more than 10 minutes. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
45781432|NCT00763490|Procedure|Full intensity, double umbilical cord, stem cell transplant|stem cell transplant using two umbilical cord blood units, combined with a Flu/Bu4 conditioning regimen prior to transplantation
45781433|NCT00763490|Drug|Flu/Bu4 conditioning regimen|"Fludarabine: 40 mg/m² daily on days -5, -4, -3, -2~Busulfan: 3.2 mg/kg IV daily on days -5, -4, -3, -2"
45781434|NCT00763490|Radiation|Total Lymphoid Irradiation (TLI)|one dose, 400 cGy,on day -1 or day 0, prior to cord blood infusion
45781435|NCT00763490|Drug|Graft versus Host Disease prevention (GVHD prophylaxis)|Tacrolimus for GVHD (Graft Versus Host Disease Prevention) Tacrolimus - will begin on day -3 (IV or oral) for at least 180 days. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant.
46070717|NCT05332028|Device|22 gauge 100 mm needle|Block applications
45448863|NCT03750370|Device|Doppler ultrasound|Colored Doppler Sonography is well established to illustrate microvascularity and therefore perfusion of the testis. The arterial flow velocities (peak systolic velocity [PSV] and end diastolic velocity [EDV]) and the resistance indices against this flow (resistive index [RI] and pulsatility index [PI]) in the testis can be measured with this technique.
46070718|NCT05332028|Drug|Propofol|Routine general anesthesia protocol
46070719|NCT05332028|Drug|fentanyl|patient-controlled analgesia
46070720|NCT00650767|Drug|ARRY-438162, MEK inhibitor; oral|multiple dose, single schedule
46070721|NCT00650767|Drug|Placebo; oral|matching placebo
46070722|NCT02552095|Device|Triathlon PKR|
46070723|NCT02552173|Radiation|The Relationship Between Operative and Radiologic Stem Version|intraopertive surgeon's estimation and postoperative CT scan
46070724|NCT00818077|Other|Continuous Glucose Monitoring of Carbohydrate Intake|Subjects eat standard breakfast and lunch and keep food records.
45642488|NCT05230030|Behavioral|Improvisation Workshop|Each improvisation workshop will involve a series of exercises derived from an improvisation game book previously developed by study investigators, followed by a reflective debrief of the experience.
45642489|NCT05229965|Drug|Paracetamol|21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
45642490|NCT05229965|Drug|Paracetamol Codeine|14 pills will be provided with a preconised dose of 1 pill 2 times per day over 7 days period
45781436|NCT00763490|Drug|Mycophenolate Mofetil|"Mycophenolate Mofetil (MMF) for GVHD prophylaxis. MMF - will be given at a dose of 10mg/kg IV q 8 hours if the patient weight is more than 50 kg, or 15 mg/kg IV q 8 hours if less than 50 kg, beginning the morning of day -3. (If renal failure and Glomerular Filtration Rate (GFR) < 25 mL/min, the dose should not exceed 1 gm every 8 hours. (No dose adjustment for liver disease is required.) MMF should be given via IV until oral medications are tolerated.~MMF will be stopped at Day +28 if no acute GVHD is seen by that time. If there is not any donor cell engraftment, MMF will be continued as directed by the attending physician. If the patient has active acute GVHD requiring systemic therapy, MMF may be continued."
45781437|NCT01214759|Drug|Truvada|Tenofovir 200mg/emtricitabine 300mg once a day
45781438|NCT01214759|Drug|Raltegravir|Raltegravir 400mg twice a day
45781439|NCT03805724|Other|Plaque Samples|After carefully drying of the selected site and isolation by cotton roll, plaque samples will be collected by sweeping movement of the probe at gingival crevices of the tooth aspect with pervious inclusion criteria for obtaining of the plaque sample. Samples will be immediately dipped in sterile Eppendorf tubes containing PVA.
45781440|NCT03806192|Behavioral|Telephone-Based Intervention|Attend psychoeducational counseling sessions via telephone
45781441|NCT03806192|Other|Behavioral, Psychological or Informational Intervention|Attend psychoeducational counseling sessions via video teleconference
45781442|NCT03806192|Other|Questionnaire Administration|Ancillary studies
45781443|NCT01249625|Device|N95 Respirator|Participants in this arm will be asked to wear an N95 respirator for the extent of the 12 week study period.
45781444|NCT01249625|Device|Medical/surgical mask|Participants in this arm will be asked to wear a medical/surgical mask for the extent of the 12 week study period.
45781445|NCT03809468|Other|phone call follow up|instead of a clinic visit, patients will be randomized to a phone call
45781446|NCT00759668|Device|Acrysof Natural ReSTOR SN60D3|Bilateral implantation with the AcrySof Natural ReSTOR Intraocular Lens (IOL) SN60D3 following cataract removal.
45781447|NCT00759668|Device|Acrysof Natural Monofocal SN60AT|Bilateral implantation with the AcrySof Natural Intraocular Lens (IOL) Model SN60AT following cataract removal.
45781448|NCT00780572|Behavioral|ADE alert assistant|A note in CPRS alerting providers that patients are at risk for an adverse event based on prescription and lab value histories.
45781449|NCT00780962|Drug|N-Acetylcysteine (NAC)|"Experimental:~Before CT: 3 g NAC IV in 500 cc of 0.9% Sodium-chloride~After CT: 200 mg NAC/hour in 0.9% Sodium-chloride at 67 cc/hour for up to 24 hours."
45781450|NCT00780962|Drug|0.9% Sodium-chloride|"Placebo:~Before CT: 500 cc 0.9% Sodium-chloride~After CT: NS at 67 cc/hour for up to 24 hours."
45781451|NCT04384874|Other|Exercise therapy|A 12 week multi-stage exercise rehabilitation program
45781452|NCT00764738|Device|OCT, Multifocal ERG, Microperimetry|"OCT performed monthly. Fluorescein Angiography performed at baseline, month 3, month 5, month 8 and month 12.~Microperimetry performed at baseline, month 3, month 5, month 8, and month 12 for monthly ranibizumab and at baseline, month 3, month 5 through month 12 for as needed ranibizumab.~Multifocal ERG done at the same monthly visits as the microperimetry."
45781453|NCT00764738|Drug|Ranibizumab Ophthalmic|0.5 mg ranibizumab vs 2.0 mg ranibizumab
45781454|NCT00781508|Drug|sildenafil|Changes in left ventricular filling pressure 1 hour after the administration of a single oral dose of sildenafil 50 mg.
45642491|NCT05229965|Drug|Paracetamol caféine|21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
45642492|NCT05229120|Behavioral|Episodic Future Thinking|The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.
45642493|NCT05227391|Procedure|Oral Letrozole|Oral Letrozole at a dose of 2.5mg daily will be started on days 3-5 of the menstrual cycle and will be continued for 5 days.
45642494|NCT05227391|Procedure|Oral estradiol valerate|Oral estradiol valerate at a dose of 3mg twice daily will be started on days 3-5 of the menstrual cycle.
45642495|NCT05225415|Drug|CT1812|Orally administered CT1812
45642496|NCT05224141|Biological|Pembrolizumab/Vibostolimab Co-Formulation|Pembrolizumab 200 mg plus vibostolimab 200 mg fixed dose coformulation administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.
45642497|NCT05224141|Drug|Saline placebo|Saline solution administered via IV infusion on Cycle 1 (and Q3W as needed beyond Cycle 1)
45642498|NCT05224141|Drug|Etoposide|Etoposide 100 mg/m^2 administered via IV infusion Q3W on Days 1 2, 3 of each cycle for up to 4 cycles
45642499|NCT05224141|Drug|Cisplatin|Cisplatin 75 mg/m^2 administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
45642500|NCT05224141|Biological|Atezolizumab|Atezolizumab 1200 mg administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.
45781455|NCT00781508|Other|Placebo|Changes in left ventricular filling pressure 1 hour after oral administration of placebo
45781456|NCT03805568|Drug|dexmedetomidine infusion group|dexmedetomidine as anaesthetic adjuvant
45781457|NCT03805568|Drug|remifentanil infusion group|remifentanil as anaesthetic adjuvant
45781458|NCT00781898|Drug|Depot naltrexone|Vivitrol® extended release naltrexone 380 mg per month delivered in monthly intramuscular injections.
45781459|NCT00781898|Other|Treatment as Usual (TAU)|Treatment as Usual (TAU) community treatment provided to the participant
45781460|NCT03800732|Other|With Meal during night work|Two nights of work with a meal during the shift and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
45781461|NCT03800732|Other|Without Meal during night work|Two nights of work without a meal during the shift and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
45448864|NCT02254174|Drug|Tiotropium/Salmeterol|Fixed dose combination of tiotropium 7.5 μg and salmeterol 25 μg inhalation powder, PE capsule via HandiHaler®
45642501|NCT05224141|Drug|Carboplatin|Carboplatin AUC 5 mg/mL/min administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
45642502|NCT05220631|Behavioral|Technology intervention|Older Adult Technology Services (OATS) 5-week technology intervention
45642503|NCT05220631|Behavioral|Digital Nutrition Intervention|15-week nutrition intervention delivered completely online
45642504|NCT05215600|Device|Anaverse Shoulder System|Reverse Shoulder Arthroplasty
45642505|NCT05214287|Drug|Hypoxic Gas Mixture|Using a commercially available hypoxicator, varying gas mixtures as described will be administered via a tight-fitting oxygen mask. In the circuitry, a three-way valve is placed that allows for the intermittent administration of hypoxia: the valve either passes the hypoxic mixture from the hypoxicator or room air.
45642506|NCT05211986|Drug|IMM01-STEM|IMMUNA (IMM01-STEM) is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules.
45642507|NCT05210998|Other|Gradual Aerobic exercise training AND Respiratory muscle training|Combined Exercise Group
45781462|NCT03800732|Other|Sleep night|Two sleep nights and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
45781463|NCT00765128|Drug|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
45917278|NCT05129527|Device|InspirerMundi app|"Patients in the experimental group, in addition to usual care, will be invited to use the InspirerMundi app for 4 months to support adherence to preventive inhaled medication and their asthma self-management. The purpose of the InspirerMundi app is to transform the adherence process into a positive experience through immediate and pleasant rewards. The InspirerMundi app integrates 3 main components: monitoring (symptoms, control, adherence), gaming and social/peer support.~Participants will be able to include their action plan in the app. Within the action plan, the application can lead to changes in the medication effectively taken, which means that the therapeutic level can be adjusted according to the action plan.~Participants in the experimental arm will be able to share with their physician, through the app, their medication adherence and asthma control data in the 3 months visit, and whenever patients wish during the study period."
45642508|NCT05210998|Other|Gradual Aerobic exercise training|Aerobic exercise Group
45642509|NCT05209880|Behavioral|ED GOAL|The emergency department clinician-led, behavioral intervention (ED GOAL) is designed to engage seriously ill yet clinically stable older adults in the emergency department to address their values and preferences towards end-of-life care with their outpatient clinicians. The intervention consists of an interview to discuss participants' values and preferences for end-of-life care. The participants will receive coaching on how to initiate/re-introduce discussions about end-of-life wishes with their loved ones and outpatient clinicians. The participants' outpatient clinicians will also receive a summary of what participants disclosed via email or mailed letter.
45642510|NCT05208047|Drug|CGT9486 plus sunitinib|Participants will receive both CGT9486 and sunitinib orally until study stopping rules are met.
45642511|NCT05208047|Drug|CGT9486|Participants will receive CGT9486 until steady state then both CGT9486 and sunitinib orally until study stopping rules are met.
45642512|NCT05208047|Drug|Sunitinib|Participants will receive sunitinib until steady state then both sunitinib and CGT9486 orally until study stopping rules are met.
45642513|NCT05208047|Drug|Sunitinib|Participants will receive sunitinib orally until study stopping rules are met.
45642514|NCT05207709|Drug|Ribociclib + Letrozole OR Fulvestrant|Endocrine Therapy will be selected by the investigator. For premenopausal women and men: LHRH agonist once every 4 weeks
45642515|NCT05207709|Drug|Palbociclib + Letrozole OR Fulvestrant|Endocrine Therapy will be selected by the investigator. For premenopausal women and men: LHRH agonist once every 4 weeks
45642516|NCT05207709|Drug|Paclitaxel +/- Tislelizumab|Patients in this arm could receive as the first line of therapy
45642517|NCT05207033|Other|Regulated ad condition|This intervention will determine if restriction of appealing features in e-cigarette ads deter young adults from trying the product.
45642518|NCT05207033|Other|Unregulated ad condition|This intervention will determine if unrestricted appealing features in e-cigarette ads deter young adults from trying the product.
45642519|NCT05205161|Drug|AZD0466|All patients will receive treatment with the investigational product AZD0466 via intravenous infusion.
45642520|NCT05203731|Behavioral|Exercise|Moderate intensity exercise (typically a brisk walk or light run) will occur for 20 minutes after the emotional learning procedures on Day 1.
45917279|NCT05129527|Other|Usual care|Usual care will consist of pharmacological treatment and medical monitoring through routine medical visits.
45642521|NCT05203731|Behavioral|Sitting|Sitting will occur for 20 minutes after the emotional learning procedures on Day 1.
45781464|NCT00765128|Drug|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
45781465|NCT00765206|Drug|Omeprazole/sodium bicarbonate|Single dose of omeprazole/sodium bicarbonate per day for either 1 or 7 days.
45781466|NCT00765206|Drug|omeprazole magnesium (20 mg equivalent)|Single dose of omeprazole magnesium per day for either 1 or 7 days.
45448865|NCT02254174|Drug|Serevent® Diskus®|
45448866|NCT02254174|Drug|Spiriva®|
45448867|NCT03545308|Drug|Rocuronium|Dose: 1 mg/kg
45448868|NCT02144272|Drug|LY3114062 SC|LY3114062 administered SC.
45448869|NCT02144272|Drug|Placebo|Placebo administered SC.
45448870|NCT02144272|Drug|LY3114062 IV|LY3114062 administered IV.
45642522|NCT05203315|Drug|Duobrii 0.01 % / 0.045 % Topical Lotion|Duobrii® lotion (halobetasol propionate [HP] and tazarotene [Taz] 0.01%/0.045%) is currently on the market for the treatment of moderate to severe stable plaque psoriasis, and is classified as a high potency (Class II) corticosteroid.
45642523|NCT05203315|Drug|CeraVe, Topical Cream|CeraVe cream will be used twice daily (in the morning and again in the evening) by the study participant in conjunction with Duobrii and Hydrocortisone cream.
45781467|NCT05316896|Other|Internal Perturbation|"Raising and lowering arms 90 degrees forward and sideways with eyes open and closed.~In tandem stance with eyes open and closed, arms are raised and lowered 90 degrees forward and to the side.~While standing on one leg with eyes open and closed, arms are raised and lowered 90 degrees forward and to the side.~Step forward and backward with right and left foot alternately~Take a step back and step back alternately with right and left foot~Put the right foot on the step and take it back, then do the same with the left foot and ask the patient to do it quickly.~First step on the step with the right foot and put the left foot next to it, then step down with the right foot and take the left foot with it, repeat the same with the left foot and ask the patient to do this. rapidly.~Normal gait, sideways gait, tandem gait, backward gait, raising and lowering the arms forward and sideways 90 degrees, respectively, during back-to-back tandem gait."
45781468|NCT05316896|Other|Eksternal Perturbation|"Front, side, and rear loading and release, pushing and pulling while standing with eyes open and closed~Front, side and rear loading and release, pushing and pulling while standing in tandem with eyes open and closed~Loading and releasing from the front, sides and back, pushing and pulling while turning the head left and right while standing~Front, side and rear loading and release, pushing and pulling while standing up and down with eyes open and closed~Front, side, and rear loading and release, pushing and pulling while standing on one leg with eyes open and closed~Holding the ball thrown by physiotherapist~Kicking a ball thrown by physiotherapist~Holding the ball thrown by the physiotherapist while standing in tandem, walking, walking sideways, walking in tandem, walking backwards."
45781469|NCT03809156|Drug|Riociguat Oral Product|Dual therapy of Riociguat and Ambrisentan at initiation of treatment.
45781470|NCT03808844|Drug|HSK3486|Initial dose of 0.4 mg/kg followed by 0.2 mg/kg if needed.
45781471|NCT03808844|Drug|Propofol|Initial dose of 2.0 mg/kg followed by 1.0 mg/kg if needed
45781472|NCT03809078|Drug|68Ga RM2|PET radiopharmaceutical
45781473|NCT03809078|Drug|68Ga-PSMA-11|PET radiopharmaceutical
45781474|NCT03809078|Device|Investigational PET scanner coils and software|GE Healthcare non-approved PET scanner coils and software
45781475|NCT05316428|Drug|TPN171H tablet plus alcohol|10 mg TPN171H tablet QD plus 0.5 g/kg alcohol
45781476|NCT05316428|Other|alcohol|0.5 g/kg alcohol
45781477|NCT05316428|Drug|TPN171H tablet|10 mg TPN171H tablet QD
45781478|NCT05316506|Other|Anticipated Discomfort Language|This language involves pain descriptors provided from physician to patient during procedure.
45781479|NCT05316506|Other|Objective Descriptive Language|This language involves neutral/objective descriptors provided from physician to patients during procedure.
45642524|NCT05203276|Drug|Envafolimab|300mg，SC，Q3W，d1
45642525|NCT05203276|Drug|Endostar|210mg，CIV，Q3W，d1-3
45642526|NCT05202353|Drug|BI 456906|BI 456906
45642527|NCT05202353|Drug|Semaglutide|Semaglutide
45781480|NCT03805178|Drug|Belatacept|"Initial phase: 10 mg/kg on days 0 and 4, and again at weeks 2 and 4. Maintenance phase: 10 mg/kg every month beginning 4 weeks after completion of the initial phase.~No dosage adjustments required for renal or hepatic impairment. No known drug interactions for usual post-transplant medication regimen."
45781481|NCT03805178|Drug|Carfilzomib|20mg/m2 Plasmapheresis
45781482|NCT05318378|Diagnostic Test|BIXAM|Series two consisted of inverted and conventional X-rays of the same subject (BIXAM) shown together
45781483|NCT01303835|Drug|LDN|Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
45781484|NCT01303835|Drug|Placebo|Randomized patients received placebo to be taken every night before bed.
45781485|NCT03805334|Other|Touchpoints|Touchpoints are worn on either the wrists or ankles. They deliver a low level vibration in an alternating fashion to the skin.
45781486|NCT01250717|Drug|Docetaxel|Given by an IV infusion over 1 hour on day 2 of a three-week cycle
45781487|NCT01250717|Drug|Dexamethasone|Orally 12 hours and 1 hour before docetaxel and again 12 hours after docetaxel
45781488|NCT01250717|Drug|Estramustine|Taken orally three times a day for 5 days for the first part of every three week cycle
45781489|NCT01250717|Drug|Zoladex|Given subcutaneously for 4 doses every three months
45781490|NCT01250717|Drug|Casodex|Taken orally once a day for 6 months
45781491|NCT01250717|Procedure|Radical Prostatectomy|after the chemo and hormonal therapy all patients have a radiacal prostatectomy
45781492|NCT03808532|Other|Cura+ Moisturizing Cream|Parents of at-risk infants in the intervention arm will be instructed to apply moisturizer to the infant's entire body once daily for six months.
45781493|NCT03808376|Device|Continuous Glucose Monitoring System|The Eversense® 180 CGM System
45642528|NCT05201547|Drug|Carboplatin-Paclitaxel|Chemotherapy will be administered by intravenous infusion. Carboplatin AUC 5-6 + Pacltaxel 175 mg/m² every 3 weeks. Total duration of treatment: 6 cycles
45642529|NCT05201547|Drug|Dostarlimab|Dostarlimab will be administered through a 30-minute infusion at a dose of 500 mg Q3W from Cycle 1 through Cycle 4 and at a dose of 1,000 mg Q6W thereafter, beginning at Cycle 5 Day 1 up to a maximum of 2 years.
45642530|NCT05201066|Drug|decitabine|Solution for intravenous infusion
45642531|NCT05201066|Drug|Spartalizumab|Solution for intravenous infusion
45642532|NCT05201066|Drug|Sabatolimab|Solution for intravenous infusion
45642533|NCT05201066|Drug|Azacitidine|Solution for subcutaneous injection or intravenous infusion
45642534|NCT05201066|Drug|Venetoclax|Tablet for oral administration
45642535|NCT05201066|Drug|INQOVI (oral decitabine)|Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral)
45642536|NCT05199090|Drug|MBL949|subcutaneous injections administered for 14 weeks
45642537|NCT05199090|Drug|Placebo|Placebo Comparator to MLB949
45781494|NCT03009305|Other|Lower body negative pressure|Model of hypovolemia: Lower body negative pressure down to -80 mmHg (maximum).
45781495|NCT03009305|Device|Continuous positive airway pressure|CPAP of 0, 5 and 10 cm water (H2O).
45781496|NCT03009305|Device|Positive expiratory pressure|PEP of 0, 5 and 10 cm H2O.
45448871|NCT01366846|Other|Avoidance of peanut|All participants will be assigned to peanut avoidance as per United Kingdom (UK) public health recommendations and will avoid exposure to peanut protein during the study until the last study visit when they will receive the Oral Food Challenge.
45642538|NCT05198674|Device|Renal Denervation (Symplicity Spyral™)|Device: Symplicity Spyral™ multi-electrode renal denervation system. After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
45642539|NCT05194540|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin-13 (IL-13) and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration
45781497|NCT05744258|Device|Bio-electrical impedance analysis|"Bio-electrical Impedance Analysis will be performed by trained personnel. BIA will be performed after fasting for at least 6 hours. Subjects should refrain from intensive physical activity the day be-fore the measurement. For women, measurements will be performed outside menstruating periods. Subjects will lay down on an examination couch with bare feet. Any jewelry will be removed.~Reactance and resistance will be obtained. Phase angle will be calculated according to the formula:~PhA (°) = (reactance/ resistance° x (180°/π). Body composition, including muscle mass and percentage body fat will be calculated."
45781498|NCT02189915|Drug|Creatine monohydrate|
45781499|NCT04385030|Device|TRANSCRANIAL DIRECT CURRENT STIMULATION AND MIRROR THERAPY|The study will consist of 12 sessions, carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
45781500|NCT03804866|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
45781501|NCT03804866|Drug|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
45781502|NCT03804866|Drug|Doxorubicin|60 mg/m² iv every 3 weeks for a maximum of 8 cycles
45781503|NCT01251575|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
45781504|NCT01251575|Drug|Cyclosporine|Given PO or IV
45781505|NCT01251575|Drug|Fludarabine Phosphate|Given IV
45781506|NCT01251575|Other|Laboratory Biomarker Analysis|Correlative studies
45781507|NCT01251575|Drug|Mycophenolate Mofetil|Given PO
45642540|NCT05192941|Drug|Inclisiran Sodium|Subcutaneously injected on Day 1, Day 90, and Day 270
45781508|NCT01251575|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
45781509|NCT01251575|Drug|Sirolimus|Given PO
45781510|NCT01251575|Radiation|Total-Body Irradiation|Undergo total-body irradiation
45781511|NCT00782756|Other|radiotherapy (RT) in combination with temozolomide and bevacizumab|"Bevacizumab10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (Cycle defined as 28 days). Temozolomide 75mg/m2 daily beginning on day 1 through completion of radiotherapy. Hypofractionated dose painting IMRT will start on day 1 and will be delivered on a Monday, Wednesday, Friday schedule for a total of 6 fractions.~Post RT therapy: Bevacizumab 10mg/kg IV every two weeks. Temozolomide 150-200mg/m2 daily for 5 consecutive days will be given on 28 day cycles.~Follow up: CBC weekly, comprehensive panel and urinalysis monthly, blood pressure every other week. Neurological/physical examination monthly. Gd-enhanced MRI with perfusion every 2 cycles. Neurocognitive testing (approximately 4months post RT, 1 year after diagnosis and then annually in long term survivors). Blood sample for correlative studies monthly."
45642541|NCT05192941|Drug|Placebo|Placebo to inclisiran 300 mg subcutaneously
45642542|NCT05192200|Drug|Anti-Beta Interferon (PF-06823859)|IV infusion
45642543|NCT05187013|Behavioral|mHealth for Hypertension in Homeless Persons|SMS text messages sent to participants' mobile phones
45642544|NCT05186714|Behavioral|Tai Chi versus wellness education|12 weeks of Tai Chi (2x/week) or a wellness education (2x/week)
45781512|NCT01215695|Device|aScope (Ambu Inc. 6740 Baymeadow Drive Glen Burnie, MD)|The aScope is a flexible, disposable plastic tracheoscope that incorporates a high-resolution video camera with an LED light at its flexible tip and has attached monitor.
45781513|NCT01215695|Device|Control|pre-formed stylet provided by the manufacturer of the GlideScope® video laryngoscope
45781514|NCT05744102|Diagnostic Test|MRI Image|MRI sequences
45448872|NCT02144350|Procedure|Hyperbaric oxygen|patients will be placed in a monoplane chamber and pressurized to 2.4 atmospheres with 100% oxygen for 90 minutes per session.
45642545|NCT05185037|Device|Philips IntelliVue X3 patient monitor with investigational NIBP measurement algorithm (measured once per 3 minutes)|The purpose of this study is to compare measurements of NIBP taken by the study device and measurements taken by the current FDA-approved algorithm included in Rev. N.0 software for the IntelliVue patient monitors during motion artifact in patients undergoing caesarian section deliveries under epidural anesthesia
45642546|NCT05180240|Drug|CardiolRx|Eligible patients will be randomized to receive CardiolRx or placebo. Intervention will be administered orally (via syringe) with food twice daily.
45781515|NCT03808142|Other|myBETAapp|Patients choosing to use the myBETAapp were required to insert the Mixject number from their prescribed Betaferon box, which serves as an opening key for the app. Obtaining a new Betaferon box and obtaining a new Mixject number was not interfere with the process of continuously allocating data to a single patient; each patient had a unique personal identifier in the database. All data recorded in the myBETAapp including demographic and injection-related data were stored in the database once the mobile device was connected to the internet.
45781516|NCT03808142|Other|PEAK|Peak is an application that aims at helping its users to challenge their brains and keep them sharp.
45781517|NCT03808142|Drug|Betaferon, BAY86-5046|Injection
45781518|NCT03808142|Device|BETACONNECT|BETACONNECT automatically records and stores injection-related details including injection time, speed, and depth upon every injection.
45781519|NCT00760526|Device|Continuous glucose monitor|Daily use of a continuous glucose monitor
45781520|NCT00760526|Device|Home blood glucose monitor|Home monitoring 3 or more times a day
45781521|NCT01306175|Drug|Digoxin plus BI 10773|Digoxin 0.5 mg as single dose, BI 10773 medium dose once daily
45642547|NCT05180045|Behavioral|LINKED-BP Program|The intervention arm will include training on HBPM, Sphygmo BP telemonitoring app, and CHW visits for education and counseling on lifestyle modification. Patients will be trained to measure their BP in the morning and evening for 7 days. Patients enter data using Bluetooth device transmission or manual entry. Guidance is provided on accurate BP measurement. The app stores and securely relays data to the cloud. The primary care provider and CHW will be able to visualize the remotely transmitted data via the clinician portal. Other components of usual care at the practices may include dietary counseling, on-site clinical pharmacists, social workers, case managers as needed for BP follow up, and assistance with medications and appointments as needed. The intervention period for each study participant is 12 months.
45917280|NCT05119777|Device|HArmonyCa Injectable Gel|Subdermal or deep dermal injection
45917281|NCT05116930|Drug|Neostigmine|IV infusion 20 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses
45448873|NCT02144350|Procedure|Sham Hyperbaric Air|Patients will undergo a brief compression to 1.34 atmospheres with room air and then they will be brought back to 1.1 atmospheres to complete a 90 minute session.
45448874|NCT03545230|Procedure|":Four Not Techniques"|":Four Not Techniques~Not enter posteriorly~Not too much dissection the muscle around the lateral condyle during surgery~Not perfect anatomical reduction~Not using bone graft."
45642548|NCT05178589|Device|One Unit TENS|TENS was administered by the participant at home. Application was limited to the abdominal area and instructed to be placed at the location of pain. Single unit TENS was administered via 2 channels. Participants chose an intensity of comfort and continued the treatment for 30-90 minutes per session with unlimited sessions allowed per day.
45448875|NCT02141230|Drug|Alli® 60 mg|Participants purchasing Alli®
45448876|NCT02141386|Other|PACR (Plasticity-based, Adaptive, Computerized Cognitive Remediation)|
45448877|NCT02314702|Device|PROFEMUR® L Revision Femoral Stem|Revision Total Hip Arthroplasty
45448878|NCT02144506|Other|T&E|
45642549|NCT05178589|Device|Two Unit TENS|TENS was administered by the participant at home. Application was limited to the abdominal area and instructed to be placed at the location of pain. Double unit TENS was administered via 4 channels. Participants chose an intensity of comfort and continued the treatment for 30-90 minutes per session with unlimited sessions allowed per day.
45642550|NCT05176366|Biological|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
45642551|NCT05175105|Drug|Mitapivat|Tablets or granules
45642552|NCT05175105|Drug|Mitapivat-matching placebo|Tablets or granules
45642553|NCT05173987|Biological|pembrolizumab|Intravenous (IV) infusion
45642554|NCT05173987|Drug|carboplatin|IV infusion
45642555|NCT05173987|Drug|paclitaxel|IV infusion
45642556|NCT05173987|Drug|docetaxel|IV infusion
45642557|NCT05173987|Drug|cisplatin|IV infusion
45642558|NCT05172973|Device|SAPIEN X4 THV|Implantation of the SAPIEN X4 valve
45642559|NCT05172960|Device|SAPIEN X4 THV|Implantation of the SAPIEN X4 valve
45642560|NCT05171855|Drug|Lonapegsomatropin|Study participants are individually dosed with subcutaneous injection of Lonapegsomatropin once-weekly for 52 weeks
45642561|NCT05171348|Drug|CM326|a humanized monoclonal antibody
45642562|NCT05171348|Drug|Placebo|Placebo
45642563|NCT05170178|Behavioral|inclusion and familiarization|"presentation of the study purpose and the protocol to the volunteer~clinical examination to check inclusion and exclusion criteria~Familiarization with the crying of one assigned baby, by listening to several bath cries from this baby"
45642564|NCT05170178|Behavioral|fMRI acquisition and closure|"Second phase of familiarization, listening again to bath cries of their assigned baby. These cries will be different from those listened during the first familiarization phase.~MRI acquisition: after acquisition of the anatomical images (5 min), the subjects will listen to 64 cries divided into 4 functional MRI sessions of 10 minutes each. The cries will be those of their baby or of unknown babies, evoked in a painful (vaccination) or a non-painful (bath) situation, presented in a pseudo-random order. Participants will be asked to assess whether they recognize their baby (yes/no) and whether they recognize a pain cry (yes/no).~debriefing~Protocol ending"
45642565|NCT05169437|Drug|Niraparib|Eligible participants will receive daily dosing of Niraparib.
45642566|NCT05168423|Drug|CART-EGFR-IL13Ra2 Cells|autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR epitope 806 and a humanized scFv targeting IL13Ra2
45781522|NCT01306175|Drug|Digoxin|Digoxin 0.5 mg as single dose
45781523|NCT03804476|Drug|AER-271|AER-271, the test article for this study.
45781524|NCT03804476|Drug|Placebo|Placebo control for this study.
45781525|NCT01215929|Drug|Dextroamphetamine|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral d-amphetamine at a dose of 30 mg twice daily for 2 weeks.
45781526|NCT01215929|Drug|Placebo|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility in this 4-week, double-blind, placebo-controlled, clinical trial and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral placebo tablets twice daily for 2 week.
45917282|NCT05116930|Drug|Atropine|IV infusion 10 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses
46070725|NCT00812227|Behavioral|Psychodynamic Psychotherapy|Screened and eligible patients will receive 16 individual sessions of psychodynamic psychotherapy, each lasting 45-50 minutes.
45448879|NCT02144506|Other|OTAGO|
45448880|NCT02165410|Procedure|ASL-MRI|ASL MRI is a non-invasive technique without injection to measure rCBF at rest marking the intravascular water molecules and use it as an endogenous tracer. Premedication, if required, will concern autistic and mentally retarded subjects only.
45642567|NCT05167695|Behavioral|Habit-based Sleep Health Intervention|A novel low-cost approach derived by leveraging the science of habit formation
45642568|NCT05167695|Behavioral|Text messaging intervention|In addition to the Habit-based Sleep Health Intervention, the participants will also receive the text messaging intervention.
45781527|NCT03804398|Device|compliance guided an optimal Positive End-Expiratory Pressure|The study groups received an alveolar recruitment maneuver(increase inspiratory pressure to 30cmH2O for 10s) at the 10min after one-lung ventilation. After the alveolar recruitment maneuver,the study group titrate PEEP from 4cmH2O,increased in 2cmH2O steps and hold at each step for 1min,and the static pulmonary compliance(Cst) would be record.Optimal PEEP was determined until the maximal static pulmonary compliance was obtained.
45781528|NCT03804398|Device|PEEP level of 5 cmH2O|In the control group at PEEP level of 5 cmH2O was established and maintained during the study period
45448881|NCT02165410|Procedure|Diffusion tensor imaging (diffusion MRI)|Diffusion MRI enables the mapping of the diffusion process of water molecules, which allows visualizing anatomical connections between different parts of the brain, noninvasively and on an individual basis. The sequence is acquired following clinical MRI sequences, while the child is still inside the MRI machine, with no further intervention applied.
45642569|NCT05167487|Drug|Cisplatin|Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
45642570|NCT05167487|Drug|Carboplatin|Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
45642571|NCT05164341|Drug|metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
45642572|NCT05164341|Drug|Placebo|Placebo
45781529|NCT05744024|Device|Virtual Reality system|The intervention group 1 will be wearing the 'SyncVR' Virtual Reality system during the wound care moment in addition to the standard procedure. The VR system consists of Virtual Reality glasses, a controller, and a headphone. The SyncVR Relax & Distract Application (SyncVR R&D) will be used.
45642573|NCT05163808|Drug|zatolmilast|Subjects will receive a low dose, high dose of zatolmilast (BPN14770) or placebo
45642574|NCT05163808|Drug|Placebo|Placebo
45642575|NCT05162976|Biological|Nivolumab|Given IV
45642576|NCT05162976|Drug|Oral Azacitidine|Given PO
45642577|NCT05162638|Procedure|thoracic duct cannulation|"Contrast is injected into lymph nodes until lymphatics visualized at about level of L3 lumbar spine. After target lymphatic vessel is identified, needle is passed transabdominally into the vessel. Guidewire is advanced through the needle into the lymph vessel & advanced into thoracic duct. Microcatheter is then advanced into thoracic duct over the wire.~IN & OUT-up to 100mL collected via catheter over 30-min at 2 levels within thoracic duct, then catheter removed.~INDWELLING-As described above, then guidewire placed through original catheter & advanced into subclavian vein. Vascular sheath is placed into vein in the upper arm under ultrasound/fluoroscopy guidance. Wire in the subclavian vein then snared through venous access sheath & pulled out. Catheter then threaded & advanced over the wire until tip is in thoracic duct. Catheter from thoracic duct removed, leaving catheter extending from arm into thoracic duct. Catheter left in place up to 21 days for sampling."
45781530|NCT05744024|Other|Headphones|Headphones with audio. The patients will be hearing their preferred audio, chosen by patient to relaxing and to offer distraction, through headphones during wound care.
45781531|NCT01252277|Drug|Lovaza™|4 capsules daily for 6 months
45781532|NCT00767624|Drug|Antidepressant|Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
45781533|NCT00767624|Behavioral|Desensitization Therapy for Insomnia|
45781534|NCT00767624|Behavioral|Cognitive Behavioral Therapy for Insomnia|
45781535|NCT01216241|Drug|Daptomycin|8 MG/KG IV
45781536|NCT01216241|Other|Saline Placebo|50 ml normal saline once daily
45781537|NCT01216241|Drug|Daptomycin|8 mg/kg once daily
46070726|NCT00816517|Biological|injection of botulinum toxin type A.|35 to 100 units injected around a skin lesion (plaque) one time.
45448882|NCT02165410|Procedure|Resting state MRI|This sequence is based on the synchronization of fluctuations in the blood-oxygen level dependent (BOLD) signal of different brain regions that work as a network. Therefore this sequence allows for the establishing of maps of funcitonal connectivity.
45642578|NCT05159778|Biological|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
45781538|NCT03807908|Other|Tape|"The patient will be placed into maximal flexion of the lumbar spine prior to the tape being applied. The vertical strips will be applied on either side of spine, on the erector muscle group; from the lower PSIS with and end around the twelfth rib. The third strip of tape will be applied horizontally to superior to the posterior superior iliac spines (PSIS) and extend over the 2 vertical strips of tape. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index)."
45781539|NCT03807908|Other|Sham Tape|"One strip of tape will be applied horizontally to the thoracolumbar junction (at the level of the lower rib cage over the T12-L1 spinous processes) with no tape-tension. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index)."
45642579|NCT05159778|Biological|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
45781540|NCT01216397|Drug|Linagliptin/Metformin (standard batch)|Fixed dose combination tablet
45781541|NCT01216397|Drug|Linagliptin/Metformin (side batch)|Fixed dose combination tablet
45781542|NCT04345406|Drug|ACEIs|Captopril or enalapril
45781543|NCT04345406|Drug|Conventional treatment|alexoquine
45781544|NCT05621174|Drug|Dexamfetamine|Magisterial Dexamfetamine
45781545|NCT05621174|Drug|Dexamfetamine|Tentin
46070727|NCT00973349|Biological|MF59-eH1N1_f|8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant
46070728|NCT00629603|Genetic|cytokine|polymorphisms of fibrosis-relating cytokine were measured to validate the effectiveness of fibrosis in HCV-related chronic liver disease
45781546|NCT01216943|Drug|bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
45781547|NCT00783614|Drug|Aspirin 325mg|Patients randomized to Aspirin 325mg po daily versus placebo pill daily
45781548|NCT00783614|Drug|Antiretroviral therapy (ART)|Patients randomized to start ART immediately or defer use for 1 month
45781549|NCT01252745|Drug|10.0 mg of Testosterone, 4.0% TID|
45781550|NCT01252745|Drug|13.5 mg of Testosterone, 4.5% B.I.D|
45642580|NCT05159050|Drug|Paclitaxel-loaded tumor penetrating microparticles|"Paclitaxel-loaded TPM, suspended in 0.5 L of 0.1% (w/v) polysorbate 80 in 0.9% sodium chloride is instilled into the peritoneal cavity over 3 to 5 minutes. Mixing of TPM is achieved by putting patient in 5 different positions for about 80 minutes.~Dose escalation, the starting dose of TPM is 50 mg/m^2 paclitaxel-equivalents. Dose escalation will follow the Accelerated Titration Design. The dose levels to which patients will be assigned in sequential cohorts are listed below.~Dose escalation schedule of TPM, Dose Level 1*: 50 mg/m^2; Dose Level 2: 100 mg/m^2; Dose Level 3: 135 mg/m^2; Dose Level 4: 175 mg/m^2; Dose Level 5: 200 mg/m^2~*Starting Dose"
45642581|NCT05153915|Drug|Tacrolimus granules|Oral
45642582|NCT05152966|Device|Ablation|Ablation using the FARAPULSE™ Cardiac Ablation System Plus
45781551|NCT01252745|Drug|11.25 mg of Testosterone, 4.5% T.I.D|
45781552|NCT05743868|Behavioral|Standardized Dinner|De novo lipogenesis (DNL) will be assessed in all participants with a standardized dinner
45781553|NCT05743868|Behavioral|Premeal exercise|DNL will be assessed in all participants with short bouts of premeal exercise with a standardized dinner
45781554|NCT04278872|Drug|SJX-653|administered orally once daily
45781555|NCT04278872|Drug|Placebo|administered orally once daily
45781556|NCT03807596|Procedure|Periodontal treatment with Hyaluronic acid associated with SRP|In addition to SRP, patients in the test group received adjunct subgingival application of hyaluronic acid in all selected periodontal pockets.
45781557|NCT03807596|Procedure|Scaling & root planning alone|Patients received full-mouth supra- & sub-gingival SRP with the use of ultrasonic device & periodontal universal & Gracey curettes under local anesthesia.
45781558|NCT02147522|Behavioral|Self-care management|AHH behavioral intervention is provided by promotoras
45781559|NCT01217411|Drug|Gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
45781560|NCT01217411|Radiation|Whole-brain radiation therapy (WBRT)|Undergo WBRT
45781561|NCT01217411|Radiation|Stereotactic radiosurgery (SRS)|Undergo SRS
45781562|NCT01217411|Procedure|Cognitive assessment|Ancillary studies
45781563|NCT01217411|Other|Laboratory biomarker analysis|Correlative studies
45781564|NCT05623046|Behavioral|Treatment|8 one-on-one teletherapy training sessions to enhance emotional skills. Teletherapy sessions will last approximately 60-90 minutes
45781565|NCT05595356|Device|transcranial direct current stimulation|"Session description: An electric current of 2mA will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. The anode will be placed over the left dorsolateral prefrontal cortex and the cathode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.~Session duration: 20 minutes~Frequency of sessions: Daily sessions, from monday to friday, skipping weekends, during 6 weeks.~Number of sessions: 30 sessions~The first randomized session will be delivered in the third assessment visit, two weeks after the run-in sham session."
45781566|NCT05595356|Device|sham transcranial direct current stimulation|"Session description: Three ramps of 30 seconds of current will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.~Session duration: 20 minutes~Frequency of sessions: Daily sessions, from monday to friday, skipping weekends, during 6 weeks.~Number of sessions: 30 sessions~The first randomized session will be delivered in the third assessment visit, two weeks after the run-in sham session."
45781567|NCT05595356|Device|run-in sham transcranial direct current stimulation|In the second assessment visit, one run-in 20-minute session of sham stimulation, consisting of three ramps of 30 seconds of current, will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.
45781568|NCT05595356|Behavioral|Psychoeducation video|Watching a video, produced by the research team, containing a brief explanation of what depression is and how it's treated.
45781569|NCT05595356|Behavioral|Tutorial video|Watching a video, produced by the research team, containing instructions on how to operate de tDCS devices.
46070729|NCT00629603|Genetic|cytokine polymorphisms|Fibrosis-relating cytokine polymorphisms in hepatitis C virus-related chronic liver disease were measured to validate the degree of fibrosis
46070730|NCT00629603|Genetic|cytokine polymorphism|fibrosis-relating cytokine polymorphism
45642583|NCT05152888|Drug|Evolocumab|Evolocumab is a human monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9). Evolocumab was FDA approved in 2015 for the treatment of hyperlipidemia and subsequently approved in 2017 for the prevention of stroke and heart attack. 140mg single use SureClick autoinjector that is administered subcutaneously once every 2 weeks.
45642584|NCT05152628|Drug|Tacrolimus granules|Oral
45642585|NCT05151731|Drug|RO7200220|RO7200220 will be administered by IVT injection as specified in each treatment arm.
45448883|NCT02165410|Procedure|Eye-tracking|Eye tracking is a non-invasive method that allows objectifying gaze parameters during presentation of stimuli on a computer screen. Children will be presented with a series of social and no social stimuli and are required to watch it, with no further intervention applied.
45642586|NCT05151731|Drug|Ranibizumab|Ranibizumab 0.5 mg will be administered to the participants by IVT injection, as specified in the treatment arm.
45642587|NCT05151731|Other|Sham Procedure|Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Sham procedure will be administered to participants in the Q8W arms at applicable visits to maintain masking between treatment arms.
45781570|NCT03804086|Procedure|Advanced PRF (A-PRF) + nano-crystalline hydroxyapatite bone substitute combined with open flap debridement|"will treated with OFD +A- PRF+ nano-crystalline hydroxyapatite bone substitute,10 mL of blood will be drawn from only patient assigned to the intervention group by vein puncture of the antecubital vein and is collected in sterile glass test tube, without any anticoagulant.~The blood will be quickly collected, and the tube will immediately centrifuge at 1500 rpm for14 min at room temperature.~After centrifugation, the A-PRF clot will be removed from the tube using sterile tweezers and placed on sterile woven gauze. Membrane will prepared by compressing clots between two pieces of woven gauze."
45781571|NCT03804086|Procedure|Open flap debridement|a periodontal access flap will be initiated by intrasulcular incisions on the buccal and lingual aspects. The incisions will be carried as far interproximally as possible to preserve the entire Interdental papillae and to achieve primary wound closure.
45781572|NCT03804242|Behavioral|Black Youth M.A.T.T.E.R.: Molding Young Advocates While Transforming the School to Prison Pipeline Through Psychological Services Education and Resilience|This is a group psychoeducational and positive youth development intervention for students who have been expelled from school and are now enrolled in a specialized school at Youth Justice Coalition.
45781573|NCT01253525|Biological|Ramucirumab (IMC-1121B )|8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle
45781574|NCT01253525|Drug|Paclitaxel|80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle
45781575|NCT05743712|Other|SMART-Wrap|This intervention, SMS (short message system)-based augmentation, seeks to improve the impact and approach of the Wraparound service model by utilizing SMS, which has been shown to increase treatment adherence and sustained engagement. This intervention will facilitate regular, repeated evaluation of intermediate outcomes through self-report assessments.
45781576|NCT01247675|Drug|ACP-001 (TransCon hGH)|s.c., weekly injection
45781577|NCT01247675|Drug|ACP-001 (TransCon hGH)|s.c., weekly injection
45781578|NCT01247675|Drug|ACP-001 (TransCon hGH)|s.c., weekly injection
45781579|NCT01247675|Drug|Omnitrope|s.c., daily injection
45781580|NCT05310968|Drug|Tirofiban hydrochloride sodium chloride injection|Day 1: Tirofiban will be given by bolus injection at 0.4ug/kg/min for the first 30 minutes, followed by a continuous infusion at 0.1ug/kg/min for the next 24 hours.
45781581|NCT05310968|Drug|Tirofiban hydrochloride sodium chloride injection placebo|Day 1: Tirofiban placebo will be injected at the same rate with experimental group.
45781582|NCT05310968|Drug|Aspirin|Day 1: Aspirin 100-300mg per day Day 2-90: Aspirin 100mg per day
45781583|NCT03804164|Other|Educational Intervention|Attend Emerging from the Haze psychoeducational sessions
45781584|NCT03804164|Other|Quality-of-Life Assessment|Ancillary studies
45781585|NCT03804164|Other|Survey Administration|Ancillary studies
46070731|NCT04288739|Diagnostic Test|flow cytometric immunophenotyping|Flow cytometric (FCM) immunophenotypic analysis of peripheral blood or bone marrow aspiration samples will be performed using a panel of monoclonal antibodies (HLA DR, CD34, CD117, Cyto MPO, CD13, CD33, CD3, CD4, CD8, CD10, CD19, CD5, CD14, CD64, CD36, CD235a, cyto CD41, cyto CD61).
45781586|NCT01254851|Behavioral|goal-augmented post-operative care|Patients in the goal-augmented post-operative care group will be given a goal number of steps to take on each post-operative day following in-patient gynecologic surgery.
45781587|NCT00768716|Drug|Acetaminophen|2 x 500 mg by mouth once
45781588|NCT05743634|Biological|YY001|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
45781589|NCT05743634|Biological|OnabotulinumtoxinA|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
45781590|NCT05743634|Biological|Placebo|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
45781591|NCT05743478|Behavioral|Forging Hopeful Futures|Forging Hopeful Futures is a 12 session curriculum for youth ages 14-19 that uses strengths-based and healing-centered approaches to critically examine structural forces that perpetuate racial and gender injustice, develop leadership skills in promoting gender equitable relationship norms, non-violent practices, and upstander skills, and enhance economic justice through job skills and employment opportunities. Through 12 sessions (3 hours/session) over a 6 to 12 week period, Forging Hopeful Futures combines racial, gender, and economic justice content with leadership development and workforce development opportunities.
45781592|NCT05743478|Behavioral|Wellness Check-ins|Individual wellness checks will occur through a strengths-based telephone conversation focused on wellness resources. Youth will be provided with tailored resources based on needs identified during the call. Youth will be offered the option for additional phone check-ins to coordinate access to community resources and connection to individualized behavioral health supports if desired.
45642588|NCT05151484|Drug|Teriparatide|Participants will receive 20 μg teriparatide per day via subcutaneous injections. Participants, and if needed a caregiver, will be trained in the subcutaneous administration of teriparatide according to the manufacturer's guidelines. The investigators will measure serum calcium, BSAP and TRAP-5b levels via blood draws at quarterly monitoring visits. If BSAP or TRAP-5b do not increase compared to baseline or decrease after any quarter, participants will be contacted and correct administration will be reviewed. Serum calcium is measured for safety to avoid hypo- and hypercalcemia. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.
45781593|NCT05583188|Device|Aliya Pulsed Electric Fields (PEF) ablation|Patients will undergo PEF ablation
45781594|NCT05583188|Drug|Nivolumab plus Platinum Doublet Chemotherapy|If EGFR/ALK mutation negative, patients will receive standard of care dosing of three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) post-PEF ablation followed by resection.
45781595|NCT05583188|Drug|Standard of care neoadjuvant therapy|Patients not eligible for neoadjuvant nivolumab plus chemotherapy will receive standard of care systemic therapy post-PEF ablation followed by resection.
45781596|NCT05583188|Other|Surgical Resection|Patients not eligible for systemic therapy will receive definitive surgery without neoadjuvant therapy as per institutional standard of care post-PEF ablation.
45781597|NCT05743322|Device|Left atrial appendage closure|Left atrial appendage will be occluded using commercially available device
45781598|NCT01218971|Drug|Medisorb naltrexone 190 mg|naltrexone for extended-release injectable suspension
45781599|NCT01218971|Drug|Medisorb naltrexone 380 mg|naltrexone for extended-release injectable suspension
45781600|NCT05743244|Drug|Abrocitinib 200 MG Oral Tablet|Abrocitinib
45781601|NCT05743244|Drug|Ritlecitinib|Ritlecitinib
45781602|NCT05743244|Drug|Placebo|Placebo for Abrocitinib or Ritlecitinib
45781603|NCT01337687|Drug|Intranasal Oxytocin|Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.
45781604|NCT01337687|Drug|Placebo|Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.
45781605|NCT04351919|Drug|Hydroxychloroquine|400mg per day during 10 days
45781606|NCT04351919|Drug|Azithromycin|500 mg per day during 5 days
45781607|NCT05743088|Behavioral|questionnaire|The questionnaire consists of the following parts: socio-demographic data of participants, student perception and attitude towards the COVID-19 pandemic and its consequences, as well as practices of preventive measures in the community.
45781608|NCT00769808|Device|Bausch & Lomb 217z Excimer Laser|LASIK correction of myopia and myopic astigmatism
45781609|NCT00769886|Drug|Ketotifen/naphazoline|One drop of ketotifen/naphazoline in study eye at visit 3 and visit 4.
46070732|NCT04288739|Genetic|Xist gene by fluorescence insitu hybridization|"Fluorescence in situ hybridization (FISH) is a kind of cytogenetic technique that allows the visualization of defined nucleic acid sequences in particular cellular or chromosomal sites by hybridization of complementary fluorescently labeled probe sequences within intact metaphase or interphase cells.~The fluorescent probes are nucleic acid labeled with fluorescent groups and can bind to specific DNA/RNA sequences. Fluorescence microscopy can be used to find out where the fluorescent probe is bound to the chromosomes."
45448884|NCT02165410|Procedure|Cognitive profile|Children will be asked to perform certain tasks, adapted for their age.
45448885|NCT00108082|Drug|carvedilol MR|Study drug
45448886|NCT00108082|Drug|atenolol|Comparator
45448887|NCT00108082|Drug|lisinopril|Comparator
45448888|NCT02144662|Drug|Ranibizumab|0.5mg ranibizumab intravitreal injection
45448889|NCT02141698|Drug|TAK-438|TAK-438 tablets
45448890|NCT02141698|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets
45448891|NCT02141698|Drug|Esomeprazole|Esomeprazole tablets
45448892|NCT02144740|Dietary Supplement|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
45781610|NCT00769886|Drug|Ketotifen|One drop of Ketotifen in study eye at visit 3 and visit 4.
45781611|NCT00769886|Drug|Naphazoline|One drop of naphazoline in study eye at vist 3 and visit 4.
45781612|NCT00769886|Drug|Vehicle|One drop of vehicle in study eye at visit 3 and visit 4.
45781613|NCT00794144|Drug|Olopatadine Hydrochloride Nasal Spray 0.6%|one spray in each nostril twice daily for 2 weeks
45781614|NCT00794144|Drug|Olopatadine Hydrochloride Nasal Spray Vehicle|one spray in each nostril twice daily for 2 weeks
45781615|NCT05743010|Drug|APL-1401|APL-1401 capsules orally once daily
45781616|NCT05743010|Drug|Placebo|Placebo capsules orally once daily
45781617|NCT01309451|Drug|Bevacizumab|intravitreal, 1.25mg., monthly
45781618|NCT01309451|Drug|dexamethasone intravitreal implant|0.7mg, intravitreal every 4 months
45781619|NCT04351841|Other|arabinogalactan|A beverage will be prepared by thoroughly mixing the 15 g of arabinogalactan with water and Crystal Light flavoring
45781620|NCT04351841|Other|maltodextrin|A beverage will be prepared by thoroughly mixing the 15 g of maltodextrin with water and Crystal Light flavoring
45781621|NCT05621018|Device|Maze Out|Play for 15 weeks, at list once a week the serious game: Maze Out
45781622|NCT05492162|Other|well-being promotion intervention|"The intervention will be organized on both conferences and workshops.~Four themes will be covered :~Well-being (Workshops)~Smoking prevention (Conference)~Balanced diet (Workshop)~Optimal organization for daily healthy living (Conference)"
45781623|NCT04383704|Other|New Dietary pattern ( Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND))|A new brain-protection pattern that has been designed after the Mediterranean and DASH diet to improve some of their dietary factors to have the highest impact on brain health and cognitive performance.
45781624|NCT03803384|Other|Oxygen therapy|Oxygen supply during ESWT, once with the prescribed constant oxygen flow and once using an auto-regulated oxygen flow system setting the SpO2 target at 92%.
45781625|NCT03803306|Combination Product|Vedic Medical Astrology|Individualised astrological based interventions were given including vedic counselling, diet, colors, gems, mantras and the worship deities as an adjuvent to ongoing conventional treatments
45781626|NCT03803306|Other|Placebo vedic medical astrology (PMA)|Conventional treatments were followed with counselling and diet suggestions. astrological interventions were not incorporated during the study phase.
45917283|NCT05112484|Diagnostic Test|Measurement of concentrations of orally-used DMDs|"For effectiveness - the measured concentrations of orally used DMDs will be correlated with the clinical condition of patients with MS (usual clinical examinations such as physical assessment of clinical condition, evaluation of EDSS scale, MSQOL-54 quality of life questionnaire, and routine magnetic resonance imaging of the brain once a year). At the same time, the relationship between the measured concentrations of orally used DMDs and the concentrations of other biomarkers of MS, such as signs of axonal (so-called plasma neurofilament light chain - pNfL) and glial (so-called chitinase 3-like 1 - CHI3L1) damage, will be analyzed. concentrations of selected cytokines, concentrations of CD4 + and CD8 + T-lymphocytes, and the results of a genetic examination of drug transporters, again with an effect on the clinical condition of the patient."
45917284|NCT05112484|Diagnostic Test|Genetic testing|One blood tube will be taken for genetic testing for the duration of the study, again with standard and routine single injections before taking the drug.
45917285|NCT05112484|Diagnostic Test|Parameters for routine use of DMDs|"For safety - the usual parameters for routine use of DMDs will be monitored (blood count, liver tests, renal function, etc. according to the specifics of individual drugs)."
45917286|NCT05112484|Other|Side effects of orally used DMDs|"For tolerability - possible side effects of orally used DMDs will be monitored and the effect of genetic testing of drug transporters will be analyzed."
45917287|NCT05100316|Other|Screening Platform|Eligible participants who qualify as per this screening protocol may be referred to evaluate adoptive cell therapy in participants with various malignancies, on a separate treatment trial. No study treatment will be administered in this screening study.
45917288|NCT05094388|Other|Admitted to intensive care units|Admitted to intensive care units
45642589|NCT05151484|Drug|Alendronate|Participants will receive 70 mg alendronate p.o. once per week. Participants will be carefully instructed to follow the manufacturer's recommendations for administration. Compliance will be assessed by measurement of the bone turnover markers BSAP and TRAP-5b from blood drawn at quarterly monitoring visits. These markers have been shown to be useful for assessment of turnover changes with treatment. If these markers do not decrease compared to baseline or rise after any quarter, participants will be contacted and correct administration will be reviewed. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.
45448893|NCT02144740|Dietary Supplement|Placebo|A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
45642590|NCT05151380|Device|CO2 laser MonaLisa Touch ®|"3 sessions of SmartXide fractional CO2 laser via the MonaLisa Touch® device, spaced 4 weeks apart, will be performed. An additional comfort session will be performed at 1 year if needed.~The handpiece of the MonaLisa Touch® device is applied to the vaginal walls with a 360° scan, between 800 and 1100µs, to the vaginal orifice"
45917289|NCT05090800|Drug|Definity contrast during ultrasound|Participants will undergo an ultrasound contrast evaluation of both kidneys. This will include placement of an intravenous (IV) catheter in a vein and the delivery of Definity ultrasound contrast agent through the IV. Imaging will be completed for each kidney. The proposed total dose for adult patients will not exceed 20 microliters/kilograms (kg). Each individual dose not to exceed 10 microliters/kg. At initiation of patient studies, the dose will start at 10 microliters/kg for the first injection and a second 10 microliters/kg dose to evaluate the contralateral kidney. However, if ultrasound findings in patient studies demonstrate a dose that is too high (unable to make accurate ultrasound assessment), the dose will be reduced.
45917290|NCT00423475|Drug|goserelin acetate|
45917291|NCT00423475|Procedure|adjuvant therapy|
45917292|NCT00423475|Radiation|radiation therapy|
45781627|NCT00771056|Drug|Hydroxychloroquine|400mg by mouth daily x 1 year
45598198|NCT02224859|Device|HCP will place the Invictus Cranial Support Device (CSD) on the patient|"There is no active therapeutic treatment (e.g., medication, stimulation, etc.) associated with this device or study. All supplies for this study will be supplied by the sponsor and returned to them upon completion of the trial.~The device used in this study is a soft gel based bonnet referred to as a Cranial Support Device (CSD). In this study, after obtaining written informed consent from the patient's parent(s) or guardian(s) and confirming that the patient meets all inclusion and no exclusion criteria, the study HCP will place the CSD on the selected patient."
45781628|NCT00795002|Drug|alvocidib|Given IV
45781629|NCT00795002|Drug|mitoxantrone hydrochloride|Given IV
45781630|NCT00795002|Drug|cytarabine|Given IV
45781631|NCT00795002|Other|pharmacological study|Correlative studies
45781632|NCT00795002|Other|laboratory biomarker analysis|Correlative studies
45781633|NCT05742698|Drug|Nabilone|Nabilone is a synthetic cannabinoid that has shown benefit for agitation in Alzheimer's disease. Nabilone further has potentially beneficial properties on oxidative stress and inflammation in neurodegenerative diseases, mechanisms that have been linked to the pathophysiology of frontotemporal dementia.
45781634|NCT05742698|Drug|Placebo|The placebo is a capsule identical to the nabilone capsules that will be used in this clinical trial.
45781635|NCT03802838|Device|acupuncture|Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks. These patients were combined with acupuncture. Acupuncture points include:'Yintang', 'Shenting', 'Taiyang', 'Jingming', 'Zanzhu', 'Yuyao', 'Jiaosun', 'Baihui', 'Fengchi', 'Anmian'.
45781636|NCT03802838|Drug|Amisulpride|Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks.
45917293|NCT00000516|Drug|enalapril|
45917294|NCT05061940|Diagnostic Test|Tumor Profiling|Testing TAA and HPV expression. HLA typing.
45917295|NCT05054608|Other|No intervention|Observational study. No intervention.
45917296|NCT05049616|Drug|ACE Inhibitors and Diuretics|Hctz/Lisinopril (brand name: Zestoretic)
45917297|NCT05049616|Drug|NIFEdipine ER|Extended release nifedipine
45917298|NCT00000519|Behavioral|diet, reducing|
45917299|NCT00000519|Behavioral|exercise|
45917300|NCT00000519|Behavioral|diet, fat-restricted|
45781637|NCT03802682|Drug|Apalutamide|Participants will receive apalutamide 240 mg as a whole tablets administered orally (Treatment A) or as a dispersed mixture in applesauce (Treatment B) under fasted condition.
45781638|NCT00772304|Drug|Olopatadine 0.6% / Azelastine 137 mcg|single dose; 2 sprays per nostril
45781639|NCT01310231|Drug|Metformin|"metformin 850 mg bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).~Number of cycles: Until progression or unacceptable toxicity develops."
45781640|NCT01310231|Drug|Placebo|"Placebo bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).~Number of cycles: until progression or unacceptable toxicity develops."
45917301|NCT05041699|Combination Product|IPM Ring-105|DPV-LNG Ring containing xx mg of dapivirine + xx mg of levonorgestrel
45917302|NCT05041699|Combination Product|IPM Ring-106|DPV-LNG Ring containing xx mg of dapivirine + xx mg of levonorgestrel
45642591|NCT05147324|Behavioral|"MyPlan - Individualized Eating Pattern"|Sessions involve a structured behavior change counseling module derived from FLEX (NCT01286350), DASH-4-Teens (NCT00585832), and a Social Cognitive Theory and Transtheoretical Model informed conceptual framework, which uses education, motivation and self-efficacy enhancement, goal setting, and problem-solving skills training to initiate and sustain eating plan adherence. Sessions support incremental progress towards meeting all five eating behavior goals by helping youth develop action plans, troubleshoot barriers to adherence, and refine action plans to improve adherence. Youth log in MyFitnessPal three days per week. Logs are used to assess and troubleshoot adherence, support youth in developing and refining action plans, and reward youth with points. Incentives are allocated using a point scheme designed to promote logging and goal achievement. Formal adjustment of eating plan at three months is based on weight status, adherence according to logs, and youth/guardian acceptability.
45781641|NCT00789074|Drug|Varenicline|Varenicline 1mg twice daily
45781642|NCT00789074|Drug|Placebo|Placebo 1mg BD
45781643|NCT01338857|Drug|Sorafenib (Nexavar)|"Sorafenib (in tablet form) will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.~Children/adolescents (< 18 years of age, non-NF1): 200 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 400 mg PO twice daily~Adults (greater than or equal to 18 years of age, non-NF1): 400 mg PO twice daily~NF1 patients (regardless of age): 80 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 150 mg PO twice daily"
45781644|NCT05742620|Drug|anlotinib+CAPEOX/SOX|"Patients with colorectal cancer use the anlotinib+CAPEOX protocol, and patients with gastric cancer use the anlotinib+SOX protocol.~Anlotinib: 12mg, administered once a day on day 1-14, taken about half an hour before breakfast (the time of daily administration should be the same as much as possible), delivered with warm water, repeated once every three weeks;~CAPEOX: capecitabine 1000mg/m2 each time, oral, twice a day, 1-14 days; Oxaliplatin: 130mg/m2 iv drip d1.~SOX: Tegio: 100mg/day, continuous medication for 2 weeks, stop for 1 week; Oxaliplatin: 130mg/m2 iv drip d1."
45917303|NCT05039359|Drug|Placebo|Vehicle-matched inhalation solution
45917304|NCT00000522|Behavioral|diet, sodium-restricted|
45917305|NCT00000522|Behavioral|diet, reducing|
45917306|NCT00000522|Behavioral|exercise|
45917307|NCT00000522|Behavioral|alcohol restriction|
45917308|NCT00000522|Drug|chlorthalidone|
45917309|NCT00000522|Drug|acebutolol|
45917310|NCT00000522|Drug|doxazosin|
45917311|NCT00000522|Drug|amlodipine|
45917312|NCT00000522|Drug|enalapril|
45917313|NCT03126799|Drug|Erlotinib plus Bevacizumab|Erlotinib 150mg, po, daily, q 3weeks plus Bevacizumab 15mg/kg, IV, on D1 Q 3 weeks
45917314|NCT03126799|Drug|Erlotinib|Erlotinib 150mg, po, daily, Q weeks
45917315|NCT00000525|Drug|hydrochlorothiazide|
45917316|NCT00000525|Behavioral|diet, potassium supplementation|
45917317|NCT00000525|Behavioral|diet, magnesium supplementation|
45917318|NCT00000525|Drug|triamterene|
45917319|NCT00000525|Drug|chlorthalidone|
45917320|NCT05020483|Drug|FEIBA|Administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously. Three small doses, 5 mg/kg each, will be available.
45917321|NCT05020483|Drug|Placebo|Contains no active ingredient and administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously.
45917322|NCT00000528|Behavioral|diet, sodium-restricted (Phase III) diet, sodium-restricted|
45917323|NCT00000528|Behavioral|diet, reducing (Phase III)|
45642592|NCT05145010|Drug|Infigratinib|Infigratinib minitablets to be administered by mouth. In subjects that completed a prior study with infigratinib, the starting dose will be the same as the last dose received in the prior interventional study with infigratinib. Infigratinib dose may be adjusted to the dose identified from the dose escalation portion of the Phase 2 study (PROPEL 2).
45642593|NCT05145010|Drug|Infigratinib|Infigratinib minitablets to be administered by mouth. Starting dose for the subjects naive to infigratinib will be the one identified during QBGJ398-201 (PROPEL 2).
45642594|NCT05144841|Biological|MK-2140 (zilovertamab vedotin)|IV infusion of 2.5 mg/kg
45642595|NCT05144841|Biological|MK-2140 (zilovertamab vedotin)|IV infusion of 2.25 mg/kg
45642596|NCT05144256|Drug|Mitapivat|Tablets or granules
45642597|NCT05144256|Drug|Mitapivat-matching placebo|Tablets or granules
45642598|NCT05144009|Drug|Loncastuximab Tesirine|Intravenous (IV) Infusion
45642599|NCT05144009|Drug|Rituximab|Cycle 1 - Intravenous (IV) Infusion. Cycle 2+ - Intravenous (IV) Infusion or Subcutaneous (SC) Administration.
45642600|NCT05143840|Drug|Asciminib|Potent tyrosine kinase inhibitor that displays anti-tumor activity by specifically targeting the ABL myristate-binding pocket (STAMP).
45642601|NCT05143840|Drug|Ascimininb + Nilotinib|For subjects that do not achieve MR4.5 (molecular response) after 24 months of single-agent asciminib will be offered the addition of nilotinib 300mg, twice daily, with the goal of attaining MR4.5.
45642602|NCT05142189|Biological|BNT116|intravenous injection
45642603|NCT05142189|Biological|Cemiplimab|intravenous infusion
45642604|NCT05142189|Drug|Docetaxel|intravenous infusion
45642605|NCT05139017|Biological|Zilovertamab vedotin|Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg
45642606|NCT05139017|Biological|Rituximab|IV Infusion 375 mg/m^2
45642607|NCT05139017|Drug|Gemcitabine|IV Infusion 1000 mg/m^2
45642608|NCT05139017|Drug|Oxaliplatin|IV Infusion 100 mg/m^2
45642609|NCT05139017|Drug|Bendamustine|IV Infusion 90 mg/m^2
45642610|NCT05138458|Biological|MT-101|CD5 ATAK cells
45642611|NCT05138458|Other|MT-101 + Conditioning (Lymphodepleting) Chemotherapy|IV administration of fludarabine and cyclophosphamide
45642612|NCT05138133|Drug|Anifrolumab|Anifrolumab intravenous infusion (IV)
45642613|NCT05138133|Drug|Placebo|Placebo intravenous infusion (IV)
45642614|NCT05132322|Behavioral|Educational Outreach|Educational outreach includes staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for pulse oximetry use in bronchiolitis.
45642615|NCT05132322|Behavioral|Audit & Feedback (unit level)|Weekly unit-level feedback of each hospital's guideline-concordant practice will be distributed to sites in the form of a visual dashboard that includes comparisons over time and between hospitals. The dashboard will then be shared locally on a weekly basis with clinicians in person and electronically.
45642616|NCT05132322|Behavioral|Audit & Feedback (real time, individual-level)|Real-time feedback will occur at the individual clinician level. When collecting data on an individual patient, data collectors encountering guideline-discordant continuous monitoring are empowered to briefly ask any available clinician responsible for that patient's care, in a nonjudgmental way, about indications for monitoring that patient. The clinician is ultimately responsible for deciding if any changes are indicated.
45642617|NCT05132322|Behavioral|Clinical Pathway Integrated into Electronic Health Record|Clinical pathways guide clinicians step-by-step through evidence-based care. Based on the existing guidelines for physiologic monitoring in bronchiolitis, the pathway will clearly specify (a) situations when it is appropriate to initiate intermittent SpO2 measurement instead of continuous SpO2 monitoring, and (b) when it is appropriate to discontinue continuous SpO2 monitoring altogether, and transition to intermittent SpO2 measurement. In order to be visible to clinicians as they perform patient care, the pathway will be integrated into the electronic health record at sites randomized to this intervention.
45642618|NCT05131828|Drug|Metformin and clemastine in combination|"Metformin hydrochloride 500 mg prolonged release (SR) tablet for oral administration.~Clemastine hydrogen fumarate 1.34 mg tablet for oral administration."
45642619|NCT05131828|Drug|Placebo|Placebo tablets to match both metformin and clemastine tablets.
45642620|NCT05131022|Drug|NX-5948|Oral NX-5948
45642621|NCT05130983|Biological|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
45642622|NCT05130268|Drug|Dronedarone|Dronedarone 400 mg twice daily in addition to usual care
45642623|NCT05128227|Behavioral|Pharm-SAVES|A 30 minute long online module with videos and didactic content that covers the following topics: warning signs of suicide, how to ask a patient if they are contemplating suicide, and how to refer a patient to the Crisis Line. Three videos model patient scenarios of suicidal behavior in pharmacy settings including the pharmacy drive through, over the phone, and in person. Participants will receive continuing education credits (CEUs) (0.1 CEUs) for completing the course.
45642624|NCT05128227|Behavioral|Interactive video cases|Two video interactive cases (approximately 10-minutes combined total) ask participants to complete open and close-ended questions about patients who exhibit suicidal behavior at the pharmacy. Participants will receive continuing education credits (0.1 CEUs) for completing the course.
45642625|NCT05127824|Biological|Autologous alpha-DC1/TBVA vaccine|"Dendritic cells (DC) are derived from autologous (the subject's own) mononuclear cells in the peripheral blood obtained from the PRBC. In this case, biologic product and biologic substance are the same. The vaccine will be manufactured in the HCC-IMPCL, under cGMP conditions."
45642626|NCT05127824|Drug|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
45781645|NCT03802448|Combination Product|Study group|"Each pregnant woman in the study group received myofascial release technique, 3 sessions/week for 4 weeks. a myofascial release in addition to wearing a natural wrist splint during sleeping for 4 weeks.~Myofascial wrist retinaculum (Transverse carpal ligament) release.~• Second part; Interosseous membrane and forearm muscles myofascial release (Bilateral thumb pressure technique)."
45781646|NCT03802448|Device|Control group|A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping.
45781647|NCT01339013|Device|Anesthetic Conserving Device (AnaConDa )|Standard HME was replaced by AnaConDa. AnaConDa has charcoal filter, HME does not.
45781648|NCT01339091|Drug|Dalbavancin|IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
45781649|NCT01339091|Drug|Vancomycin / Linezolid|IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.
45781650|NCT01257347|Behavioral|Disclosure of adherence report to clinician|During clinical visits with patients with uncontrolled hypertension, clinicians will be provided with a quantitative summary of their patients' electronically-monitored adherence to antihypertensive medications. The summary will be in the form of a report that fits onto one page and lists the percent of days patients correctly adhered to each of the monitored BP medications and the mean adherence to the whole regimen. Adherence data will be provided for the 7-days and 1-month prior to the clinic visit. The report will also show the number of days patients exceeded the recommended number of pill container openings. Clinicians in the intervention arm will get a brief training (<10 minutes) in the interpretation and use of the report at the time of enrollment.
45781651|NCT01257347|Device|MedSignals pillbox|(Non-experimental) Patients will be given an electronic pillbox. The device records the date and time when each compartment is opened. Adherence to each BP medication was calculated as the percent of doses taken as prescribed. Patients are informed that their adherence was recorded by the electronic pillbox and might be shared with their clinician depending on randomization.
45781652|NCT05742542|Other|Exercise training|Two weeks of high intensity interval training with high or low time spent near VO2max.
45781653|NCT03837314|Device|"Bioinduction Picostim Deep Brain Stimulation system"|Neurostimulation of the subthalamic nucleus region.
45781654|NCT04383236|Other|Probiotics|Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For test subgroups, probiotic lozenges were consecutively administered twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
45781655|NCT04383236|Drug|Oracure oral gel|Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For control subgroups, oracure gel were consecutively applied twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
45781656|NCT01339247|Drug|Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico|Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
45642627|NCT05124574|Other|Samples concern SARS-COV-2 + pregnant women at the time of childbirth|"nasopharyngeal PCR in the mother (performed systematically in this epidemic context),~Blood samples: 1 EthyleneDiamineTetraacetic Acid (EDTA) tube (immunohistochemistry), 1 yellow tube (COVID + RT-qPCR serology).~Sampling of amniotic fluid in case of cesarean section~Sampling of the placenta for histological and virological study."
45642628|NCT05124574|Other|Samples concern newborns of SARS-COV-2 + mothers at birth|"In the birth room:~Collection of gastric fluid (PCR SARS-COV-2),~Cord blood: 1 EDTA tube (immunohistochemistry), 1 yellow tube (SARS-COV-2 + RT-qPCR serology).~In the newborn at D3 of life:~- 1 yellow tube (SARS-COV-2 + RT-qPCR serology) at the same time as the DNN.~In symptomatic newborns:~1 yellow tube (SARS-COV-2 + RT-qPCR serology).~nasopharyngeal PCR,"
45642629|NCT05122975|Drug|S48168 (ARM210)|Ryanodine Receptor modulator
45642630|NCT05122975|Drug|Matching Placebo|Placebo of same size and consistency as S48168 (ARM210)
45642631|NCT05122650|Drug|JZP385|JZP385 capsules will be administered orally (PO) once daily in the morning on an empty stomach for 12 weeks.
45781657|NCT01339247|Drug|Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada|Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
45781658|NCT00772772|Drug|Vitamin D3|2 single oral dose of Vitamin D3 30,000 international units and 8 weeks supply of Vitamin D3 (10,000 IU tablets, 3 pills to be taken by mouth as one dose weekly)
45781659|NCT01339403|Other|non-interventional trial|No study specific intervention, non-interventional trial
45781660|NCT01339403|Other|non-interventional trial|No study specific intervention, non-interventional trial
45781661|NCT05742464|Behavioral|RUBI|"RUBI teaches caregivers a range of skills to support the building of a behavioral management toolbox. The intervention emphasizes: 1) tailoring the intervention to the child; 2) identifying behavioral function instead of topography as a means to inform behavioral strategy choice (i.e., targeting what is driving the behavior, instead of the behavior itself); 3) decreasing behavioral excess as well as increasing appropriate behaviors; and 4) using positive behavioral supports, such as antecedent management (e.g. use of visual supports), reinforcement, and functional communication strategies as the means to modify behaviors. RUBI uses a behavioral skills training approach, which includes direct instruction, modeling, role-play and practice with feedback in order to train caregivers in the various RUBI skills. Sessions also have accompanying video vignettes that are used to illustrate skills or test parental understanding of session materials."
45781662|NCT03802526|Drug|NVP-1805-R1|1 tablet, multiple oral dosing
45781663|NCT03802526|Drug|NVP-1805-R2|1 tablet, multiple oral dosing
45781664|NCT03802526|Drug|NVP-1805-R1 and NVP-1805-R2|NVP-1805-R1,1 tablet and NVP-1805-R2, 1 tablet, co-administration, multiple oral dosing
45781665|NCT02197481|Procedure|Clamp-Crushing technique|Liver transection during hepatectomy by monopole electronicknife and blood vessel forceps, but without BiClamp forceps
45781666|NCT02197481|Device|BiClamp forceps|liver transection during hepatectomy by BiClamp forceps
45781667|NCT00773474|Drug|Lonafarnib|All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
45781668|NCT01310855|Drug|cediranib maleate|
45781669|NCT01310855|Drug|gefitinib|
45781670|NCT01310855|Drug|Placebo|
46070733|NCT04286945|Procedure|LATERAL RECTUS MUSCLE AUGMENTED RECESSION BY ELONGATION OF THE TENDON WITH AUTOGRAFT FROM RESECTED MEDIAL RECTUS MUSCLE|After resection of the medial rectus muscle, the resected segment is sutured to the lateral rectus muscle after dissection and marking to elongate and slaken the muscle then the elongated muscle is sutured to the sclera at the desired amount of conventional recession.
45642632|NCT05122650|Other|Placebo|Placebo capsules will be administered orally (PO) once daily in the morning on an empty stomach for 12 weeks.
45781671|NCT00773786|Drug|Arformoterol (Brovana)|twice daily via nebulizer added to maintenance daily tiotropium
45781672|NCT00773786|Drug|Placebo|Placebo twice daily for 1 week (added to maintenance tiotropium)
45781673|NCT03802370|Procedure|connective tissue grafting by Dome Technique|The dome technique addresses the placement of the CT, as it is layered over the implant and takes the shape of an inverted dome
45781674|NCT01312181|Behavioral|HealthCall and Motivational Interviewing|Patients access HealthCall by calling a toll-free number and putting a four-digit Personal Identification Number (PIN). The HealthCall system will then ask a short script of pre-recorded questions in English or Spanish, on substance use and other variables (e.g., medication adherence, unprotected sex, feeling of physical well-being, stress, etc). The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
45781675|NCT01312181|Behavioral|Motivational Interviewing (MI)|The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
45781676|NCT01312181|Behavioral|HIV/AIDS health education|The purpose of this condition is to control for clinical attention associated with Motivational Interviewing (MI)participation, and to provide an analogue of standard care, i.e. brief advice but no other intervention.
45781677|NCT03802292|Biological|YQ23|Single dose of YQ23 delivered via intravenous route. Ascending dose levels will be evaluated
45781678|NCT03802292|Biological|Matching Placebo|Single dose of the matching placebo delivered via intravenous route.
45781679|NCT01258049|Drug|Artemether Sublingual Spray|Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints
45781680|NCT01258049|Drug|Quinine|Quinine administered intravenously, 20 mg/kg loading dose followed by 10 mg/kg every eight hours
45781681|NCT03802214|Drug|Vedolizumab|standard vedolizumab induction (300mg IV at week 0, 2, 6)
45781682|NCT04384016|Biological|Skyvaricella Injection|"The main target is evaluating the safety of SKYVaricella injection in healthy Vietnamese children from 12 months to 12 years, with a single injection.~The secondary target is to Assess the immunogenicity of SKYVaricella inj. in a small group of healthy Vietnamese children from 12 months to 12 years, with a single injection."
45781683|NCT03801980|Drug|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
45781684|NCT03801980|Drug|Placebo|Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
45781685|NCT03801746|Drug|vadadustat|Oral dose 300 mg
45781686|NCT03801746|Drug|Rifampin|IV Rifampin
45642633|NCT05122546|Drug|Cabozantinib S-malate|Given PO
45642634|NCT05122546|Drug|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
45642635|NCT05122546|Biological|Nivolumab|Given IV
45642636|NCT05121831|Drug|DGX-001Dose 1|Dose level 1 of DGX-001
45642637|NCT05121831|Drug|DGX-001 Dose 2|Dose level 2 of DGX-001
45642638|NCT05121831|Drug|DGX-001 Dose 3|Dose level 3 of DGX-001
45642639|NCT05121831|Drug|DGX-001 Dose 4|Dose level 4 of DGX-001
45642640|NCT05121831|Drug|MAD dose panel of DGX-001|Dose levels confirmed through SAD and MAD
45781687|NCT03801746|Drug|Probenecid|Oral Probenecid
45781688|NCT03801746|Drug|Cyclosporins|Oral Cyclosporine
45781689|NCT03801668|Drug|Albumin-bound Paclitaxel plus S-1|Albumin-bound Paclitaxel 260mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
46070734|NCT00643201|Drug|Enoxaparin|solution, subcutaneous, 1 mg/kg Q12h until International normalized ratio (INR) ≥2.
46070735|NCT00643201|Drug|warfarin|tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
46070736|NCT00643201|Drug|Placebo for apixaban|tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months
45452506|NCT01098383|Drug|Acetyl-Choline Esterase Inhibitors and Choline supplements|"Donepezil will be used at initial dose of 2.5 mg/day (during the first two weeks), and an increased dose of 5 mg/day (from the 3rd week and on), according to the treatment protocol listed below. The tablets will be taken during breakfast.~AChE inhibitors are considered as potent agents for clinical use in Alzheimer's and Parkinson's dementias (Wevers & Schroder, 1999) and treatment with these agents was proven to be well-tolerated, safe and effective in these populations. Cholinergic side effects are generally transient, mild and dose-related, and primarily include diarrhea, nausea, and vomiting.~Choline tablets will be taken at daily doses of 250 mg (in children with up to 40 kg body weight) and 500 mg (in children with more than 40 kg body weight), based on half of the adult daily dose."
45642641|NCT05121558|Other|Yoga|Participants will have instructional yoga classes twice each week over the course of 8 weeks. Each yoga class will be 60 minutes, and it will be taught by an experienced yoga instructor. Participants in the yoga group will also have the option to participate in a recorded final check-in session after they have completed their 16 yoga classes. The discussion facilitator will follow the Semi-Structured Interview Guide to further understand participants' experiences in the yoga group.
45642642|NCT05121558|Other|Education control|Participants will have educational sessions over 8 weeks. The sessions will be on the causes and impact of Chemotherapy-Induced Peripheral Neuropathy (CIPN) , how yoga may help with CIPN, and how different therapies may help with CIPN.
45642643|NCT05121558|Other|Usual care|Participants in the usual care control group will complete the same assessments as the other two arms. To encourage participation and adherence, patients in the UC group will receive a voucher for sixteen free yoga sessions after completing the study. Patients in the UC group will be asked to not go for their own yoga classes locally until their participation in the study is completed.
45642644|NCT05120895|Drug|Mevalotin|Oral tablets (starting dose 5 mg)
45642645|NCT05118932|Behavioral|Mindful Movement Intervention|"There are five components that together make-up the Mindful Movement Intervention: Biomechanical Warm-ups, Yoga postures, modified Tai Chi sequence, Imaginative Play, and Reflection. During the year, participants will learn a Simplified Form of a classic Tai Chi sequence. Yoga movements will be used to prepare participants for the nuanced movements of Tai Chi practice, with both Yoga and Tai Chi providing a physical framework in which participants can track their own progress and begin to understand how to better regulate their attention, behavior and emotional responses. Imaginative Play and Reflection Activities are used to stimulate a deeper curiosity in participants about the everyday use and employment of mindfulness practice and to engage participants."
45642646|NCT05118009|Other|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
45642647|NCT05117476|Drug|CLN-619|Anti-MICA/MICB monoclonal antibody
45642648|NCT05117476|Drug|Pembrolizumab|Keytruda
45642649|NCT05116202|Drug|Nivolumab|Nivolumab will be administered at a dose of 3 mg/kg IV on Day 1 of each 21 day cycle.
45642650|NCT05116202|Drug|Ipilimumab|Ipilimumab will be administered at a dose of 1 mg/kg by IV on Day 1 of each 21 day cycle.
45642651|NCT05116202|Drug|RO7247669|RO7247669 will be administered at a dose of 2100 mg by IV infusion on Day 1 of each 21 day cycle.
45642652|NCT05116202|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg IV on Day 1 of each 21 day cycle.
45642653|NCT05116202|Drug|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21 day cycle.
45642654|NCT05114746|Radiation|177Lu-PSMA-617|administered intravenously at a dose of 7.4 GBq (+/- 10%). A 7.4 GBq dose is equivalent to 200 mCi or 7400 MBq.
45642655|NCT05114746|Radiation|68Ga-PSMA-11|68Ga-PSMA-11 is manufactured by radiolabeling of PSMA-11 precursor with 68Ga directly at clinical trial sites immediately prior to administration into participants. The 68Ga used for radiolabeling will be eluted from the 68Ge/68Ga generator. 68Ga-PSMA-11 will be prepared as a sterile solution and administered intravenously at a dose of 111 - 185 MBq (3 - 5 mCi).
45642656|NCT05114746|Other|Best supportive/best standard of care|Best supportive/best standard of care as defined by the local investigator (Post taxane population only)
45642657|NCT05113537|Drug|Abemaciclib|Given Orally
45642658|NCT05113537|Drug|Lutetium Lu 177-PSMA-617|Given IV
45642659|NCT05113303|Device|Navigated Revision Total Knee Arthroplasty|Patients in the case group receive a Columbus® Revision knee prosthesis, implanted with computer assisted surgery
45642660|NCT05113303|Device|Manual Revision Total Knee Arthroplasty|Patients in the control group will correspond to a historical cohort of patients in which manual jig-assisted knee revision was done.
45642661|NCT05111613|Device|Catheter-Directed Thrombolysis|Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system)
45781690|NCT03801668|Drug|Oxaliplatin plus S-1|Oxaliplatin 130mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
45781691|NCT05414006|Drug|S-ketamine|S-ketamine or placebo were given to the fetus after delivery Patient-controlled intravenous analgesia or patient-controlled epidural analgesia were administered postoperatively
45781692|NCT02199041|Drug|Cyclophosphamide|Given by intravenous infusion as part of the preparative regimen.
45781693|NCT02199041|Drug|Thiotepa|Given by intravenous infusion as part of the preparative regimen.
45642662|NCT05111613|Device|FlowTriever System|Mechanical thrombectomy for pulmonary embolism
45642663|NCT05110300|Device|Body weight support system control group|Participants will complete the physical therapy exercises as described previously, without experiencing, therapist induced, balance perturbations.
45781694|NCT02199041|Drug|Fludarabine|Given by intravenous infusion as part of the preparative regimen.
45781695|NCT02199041|Drug|Melphalan|Given by intravenous infusion as part of the preparative regimen.
45781696|NCT02199041|Drug|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
46070737|NCT00643201|Drug|Placebo for enoxaparin|solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2.
45642664|NCT05110300|Device|Body weight support system with balance perturbations|Participants will complete the physical therapy exercises as described previously, while experiencing intermittent, therapist induced, balance perturbations aimed at training the participant's balance-control and balance-reactions. With the ZeroG BWSS integrated TRiP module, therapist's are able to induce safe lateral, anterior, or posterior perturbations via a Wi-Fi-enabled handheld device. The force, or level, of perturbation can be adjusted from 1 (least amount of force) up to 10 (highest amount of force) using the same handheld device,
45642665|NCT05109442|Drug|AFM24|intravenous infusion
45448894|NCT03544450|Behavioral|Psychosocial counselling|"Individuals with psychological distress receive psychosocial counselling and enhanced usual care. The psychosocial the counselling process consists of: (i) introduction, explanation and rapport building; (ii) assessment of and understanding of the problem (including looking for positive assets); (iii) goal setting (asking the client what outcomes are preferred); (iv) problem management (exploring and identifying solutions, brainstorming, working with existing coping strategies, using social and cultural resources, and additional techniques such as relaxation and psycho-education); (v) implementation (making a plan of action and transition); and, finally, (vi) termination of counselling (including closing and follow-up). Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support)."
45917324|NCT04997434|Behavioral|Art-therapy in the emergency department|"The intervention will begin with a 5-10 minute interview with the patient to define his or her tastes and contraindications to certain techniques. Since the art-therapeutic intervention that will be proposed seeks to generate pleasant feelings, it will be important to rely on the patient's tastes. At the end of the interview, modern art therapy will be presented to the patient and several artistic activities will be proposed (origami, drawing, creative writing).~Once the activity has been chosen, the patient will have 15 to 20 minutes to carry it out, accompanied by the art therapist according to his/her needs. During the activity, verbal exchanges will continue. After the 15 to 20 minutes of the session, 5 minutes will be devoted to the patient's self-evaluation of the past moment, of his level of anxiety, of the intensity of his pain and of his feelings in relation to his passage in the Emergency Department and the art therapy session."
45917325|NCT00000531|Device|defibrillators, implantable|
45917326|NCT00000531|Drug|amiodarone amiodarone|
45917327|NCT00000531|Drug|sotalol|
45917328|NCT04997044|Other|Concomitant physical rehabilitation|Children of this group will receive a regular exercise rehabilitation program including starching exercises, functional strength training and static and dynamic balance exercises.The program will be conducted by six licensed pediatric physical therapists for one hour/session, 3 times/week, and six successive months.
45917329|NCT04997044|Other|Standard Orthotic Management|A custom-made articulating ankle foot orthosis was prescribed with a hinge at the level of the medial malleolus extends distally to the tip of the toes and proximally on the posterior surface of the leg to about 5 cm below the knee and secured straps. It is fabricated to permit free ankle dorsiflexion and lock the plantar flexion at 0 dorsiflexion. The splinting schedule started gradually for 2 h/day in the first month, 4 h/day in the second month to the entire wake-up time of the day.
45917330|NCT04997044|Other|selective dorsal rhizotomy|The surgical procedures were tailored to each child according to preoperative assessment plan. All SDRs were performed by a single neurosurgeon through an osteoplastic laminotomy from L2 to L5 that left the facet joints intact.
45917331|NCT00000534|Drug|calcium|
45642666|NCT05109442|Drug|Atezolizumab 840 MG in 14 ML Injection|intravenous infusion
45642667|NCT05109091|Drug|ATH434 dose level 1|ATH434 taken BID
45642668|NCT05109091|Drug|ATH434 dose level 2|ATH434 taken BID
45642669|NCT05109091|Drug|Placebo|Placebo taken BID
45781697|NCT02199041|Biological|G-CSF|Given either by intravenous infusion or subcutaneously daily until absolute neutrophil count (ANC) >2000 for 3 consecutive days.
45781698|NCT02199041|Drug|Mycophenolate mofetil|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
45781699|NCT02199041|Drug|Tacrolimus|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
45781700|NCT02199041|Drug|Methylprednisolone|Given either intravenously or orally, if needed to treat graft-versus-host-disease (GVHD).
45781701|NCT02199041|Radiation|Total lymphoid irradiation|TLI will be administered in divided fractions given at a minimum of 6 hours apart.
45917332|NCT00000534|Behavioral|dietary supplements|
45917333|NCT03067636|Behavioral|Physical Exercise|Physical exercise: Amount of time exercising gradually titrated from 90-minutes in week one to 180-minutes in week eight. Intensity titrated concurrently from 40 - 60% VO2 max in week one to 40 - 90% VO2 max in week eight. Eight week gym membership provided to all participants to facilitate engagement in exercise.
45917334|NCT03067636|Behavioral|Stress management training A|Stress management training A: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
45917335|NCT03067636|Behavioral|Stress management training B|Stress management training B: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
45917336|NCT00000537|Behavioral|meditation|
45917337|NCT00000537|Behavioral|relaxation|
45917338|NCT04935814|Drug|Vasopressin, Arginine|Once vasopressin infusion started, patients positions will be randomized: Trendelenburg (-30°), anti Trendelenburg (+30°) and supine position (0°).
45917339|NCT00000540|Device|defibrillators, implantable|
45781702|NCT02199041|Biological|Lymphocyte infusions|Donors will undergo haploidentical mobilization with G-CSF. Cells will be collected by leukapheresis over two days, then processed using the investigational CliniMACS device and CD34 Microbead reagent as directed by the manufacturer.
45642670|NCT05108298|Other|Questionnaires|Patients will complete questionnaires online through EASEE-PRO. There will be a set of fixed questionnaires at each timepoint for both arms. The patients will be asked to rank the 15 types of PROs according to their importance. The participants randomized to the choice arm will be asked to choose 5 of the 15 PROs to complete. The participants randomized to the fixed arm will be given a fixed 5 of the 15 PROs at each time point.
45642671|NCT05107544|Other|HIGH INTENSITY INTERVAL TRAINING|Will be prescribed HIIT through online modality to a group of adolescents with type 1 diabetes 3 times a week for 3 months. The training is going to have 2 phases, the initial phase and improvement phase, which are going to be differentiated according to work intensity following the recommendations of the American College of Sports Medicine. During the initial phase (first 4 weeks) the intensity is going to be 60-75% of the VO2 max. During the improvement phase the intensity is going to increase to a 75-85% of the VO2 max for 8 week.
45781703|NCT02199041|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
45781704|NCT00789776|Procedure|Allogeneic Bone Marrow Transplantation|Undergo donor bone marrow transplantation
45781705|NCT00789776|Drug|Cyclophosphamide|Given IV
45781706|NCT00789776|Drug|Fludarabine Phosphate|Given IV
45448895|NCT03544450|Other|Enhanced Usual Care|Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support).
45642672|NCT05104554|Dietary Supplement|Iron and folic acid (IFA)|IFA: Weekly regimen of one tablet containing iron (60 mg) and folic acid (2800 μg)
45642673|NCT05104554|Dietary Supplement|Multiple Micronutrient Supplement (MMS)|MMS: Daily regimen of one multiple micronutrient tablet containing fifteen micronutrients in the United Nations International Multiple Micronutrient Preparation (UNIMMAP) preparation. Composition includes vitamin A (800 ug), vitamin D (5 ug), vitamin E (10 mg), vitamin C (70 mg), vitamin B1 (1.4 mg), vitamin B2 (1.4 mg), niacin (18 mg), vitamin B6 (1.9 mg), vitamin B12 (2.6 ug), folic acid (400 ug), iron (30 mg), zinc (15 mg), copper (2 mg), selenium (65 ug), and iodine (150 ug).
45642674|NCT05103696|Drug|Remimazolam Besylate|Remazolam 7mg for the first time (push time 1min), 2.5mg can be added after 2min according to MOAA/S score, no more than 4 times within 15min
45642675|NCT05103696|Drug|etomidate combined with propofol|Etomidate 0.1mg/kg+1% propofol 0.5mg/kg for the first time ,etomidate0.05mg/kg+ 1% propofol 0.25 mg/kg can be added according to MOAA/S score
45781707|NCT00789776|Other|Laboratory Biomarker Analysis|Correlative studies
45781708|NCT00789776|Drug|Mycophenolate Mofetil|Given PO
45781709|NCT00789776|Biological|Natural Killer Cell Therapy|Given IV
45781710|NCT00789776|Drug|Tacrolimus|Given IV or PO
45781711|NCT00789776|Radiation|Total-Body Irradiation|Undergo total-body irradiation
45781712|NCT04384094|Device|Esthesiometer measurement|Measuring the corneal sensitivity using rebound technology.
45781713|NCT03801590|Device|Crosslinking with Riboflavin and UV-A|the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea.
45781714|NCT03801512|Other|Steroid|Triamcinolone 1pc + lidocaine 1% 1cc inject at neuritis nerve roots
45781715|NCT03801512|Other|Acupuncture|1.5 inch acupuncture needles insert at acupoints BL23, BL24, BL25 and BL26
45781716|NCT03801512|Other|Platelet Rich Plasma|Inject investigators Platelet Rich Plasma at neuritis nerve roots
45781717|NCT03800966|Other|Leaflet|Leaflets for both groups will be printed in colour. Leaflet in each group contains 8 pictures and 8 statement, whose sequences will be scrambled. Primary school students need to do the matching, to ensure they read the statements.
45448896|NCT02141776|Device|Transcranial direct current stimulation (t-DCS)|The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
45781718|NCT05734820|Diagnostic Test|HD- colonoscopy|HD-colonoscopy performed by an expert or non-expert endoscopist. All lesions will be recorded, assessed, and removed for histological analysis.
45781719|NCT05734820|Diagnostic Test|HD-colonoscopy assisted by AI|HD-colonoscopy with AI-assisted polyp detector. New polyps detected by AI will be recorded, removed, and studied.
45781720|NCT00775658|Drug|olopatadine|olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day
45781721|NCT00775658|Drug|placebo|placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day
45781722|NCT02199197|Drug|Radium Ra 223 Dichloride|Radium Ra 223 Dichloride, 55 kilobecquerel (kBq)/kg body weight, administered as a bolus intravenous (IV) injection (up to 1 minute) on Day 1 of each cycle for 6 cycles.
45781723|NCT02199197|Drug|Enzalutamide|Enzalutamide 160 mg administered orally once a day (continuously) for 6 cycles.
45781724|NCT05721950|Drug|Brigatinib|Brigatinib Tablets
45781725|NCT01258985|Behavioral|Tai Chi|12 weeks of Tai Chi
45781726|NCT01258985|Behavioral|Physical Therapy|6 weeks of individualized Physical Therapy followed by 6 weeks of supervised Home Exercise
45781727|NCT00799604|Drug|clevidipine|Clevidipine (0.5mg/mL in 20% lipid emulsion) was administered as an IV bolus (<5 sec) by rapid injection for Bolus 1 and for Bolus 2, if second bolus dose was administered, directly into a peripheral venous catheter followed by a normal saline flush (10mL).
45781728|NCT03009383|Device|A bedside portable endoscopy|
45917340|NCT04914403|Biological|UMC119-06-05|Cohort 1: Low does of UMC119-06-05 Cohort 2: High does of UMC119-06-05
45917341|NCT00000552|Procedure|angioplasty, transluminal, percutaneous coronary|
45642676|NCT05103345|Drug|SGN1|SGN1,will be administered intratumorally,which dosage is 0.9-2.0×109 cfu /vial.
45642677|NCT05101551|Drug|Talazoparib|"Talazoparib will be administered in escalating doses based on current dose level.~Dose Level 1: 400 µg/m2/dose once daily~Dose Level 2: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~Dose Level 3: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~Dose Level 4: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~Dose Level 5: 600 ug/m2/dose BID on Day 1, then daily on Days 2 to 5 and 15 to19"
45448897|NCT02141776|Other|Sham Controlled Arm|The subjects randomized to this group will not receive stimulation daily for four weeks.
45642678|NCT05101551|Drug|Topotecan|"Administered IV route on Days 1 to 5~Dose Level -2: 1 mg/m2/dose once daily by IV days 1 to 5~Dose Level -1: 2 mg/m2/dose once daily by IV days 1 to 5~Dose Level 1: 2 mg/m2/dose once daily by IV days 1 to 5~Dose Level 2: 2 mg/m2/dose once daily by IV days 1 to 5~Dose Level 3: 3 mg/m2/dose once daily by IV days 1 to 5~Dose Level 4: 4 mg/m2/dose once daily by IV days 1 to 5~Dose Level 5: 4 mg/m2/dose once daily by IV days 1 to 5"
45642679|NCT05101551|Drug|Gemcitabine|"Single dose (IV) of gemcitabine on Day 1 of each 28 day cycle for 1 cycle.~Dose Level -2: 600 mg/m2/dose once daily by IV days 1~Dose Level -1: 600 mg/m2/dose once daily by IV days 1~Dose Level 1: 1200 mg/m2/dose once daily by IV days 1~Dose Level 2: 1200 mg/m2/dose once daily by IV days 1~Dose Level 3: 1200 mg/m2/dose once daily by IV days 1~Dose Level 4: 1200 mg/m2/dose once daily by IV days 1~Dose Level 5: 1200 mg/m2/dose once daily by IV days 1"
45642680|NCT05099770|Biological|Renal Autologous Cell Therapy (REACT)|Participants will receive either 2 REACT injections or 2 Sham REACT injections into biopsied and non-biopsied contralateral kidneys 3 months apart.
45642681|NCT05099679|Behavioral|Cognitive behavioral therapy (supportive counseling)|Patients will complete a psychosocial intake that generally takes up to 2 hours, but the time required for the intake varies per patient. Subsequently they will be offered up to 7 optional counseling sessions with a clinical social worker
45642682|NCT05099679|Behavioral|Virtual Cardiac Rehabilitation|If eligible, patients will be referred to Movn Health Virtual Cardiac Rehabilitation to provide approximately 3 exercise sessions per week, with approximately eight coaching sessions over a 12 week period
45642683|NCT05099003|Procedure|Biopsy|Undergo a biopsy
45642684|NCT05099003|Procedure|Magnetic Resonance Imaging|Undergo a MRI
45642685|NCT05099003|Radiation|Radiation Therapy|Undergo radiation therapy
45642686|NCT05099003|Drug|Selinexor|Given orally
45642687|NCT05095727|Drug|mRNA-3745|Sterile frozen liquid dispersion for injection
45642688|NCT05095376|Drug|Lomustine|Given PO
45642689|NCT05095376|Radiation|Photon Beam Radiation Therapy|Undergo radiation therapy
45642690|NCT05095376|Other|Quality-of-Life Assessment|Ancillary studies
45642691|NCT05095376|Other|Questionnaire Administration|Ancillary studies
45642692|NCT05095376|Drug|Temozolomide|Given PO
45642693|NCT05092958|Drug|Avelumab|Given IV
45642694|NCT05092958|Drug|Cabozantinib S-malate|Given PO
45642695|NCT05092958|Other|Quality-of-Life Assessment|Ancillary studies
45642696|NCT05092958|Other|Questionnaire Administration|Ancillary studies
45642697|NCT05092542|Behavioral|Refugee and Immigrant Well-being Project (RIWP)|6-month mental health intervention that pairs university students with newcomers to engage in mutual learning, resource mobilization, and social change efforts
45642698|NCT05092490|Procedure|Combined serratus anterior plane block and transversus thoracis plane block|The study group will receive a combined plane block by a dedicated anesthesia team prior to their procedure. 20 mL of local anesthetic (0.25% bupivacaine) will be injected for the Serratus anterior plane block and another 20 mL of local anesthetic (0.25% bupivacaine) will be injected in transversus thoracis plane block
45642699|NCT05092490|Procedure|Standard local infiltration technique|Local anesthetic infiltration of the incision sites will be performed by the cardiologist prior to, and as, necessary during the procedure. The amount of local anesthetic used will be determined intraoperatively by the cardiologist according to the patients' requirements.
45642700|NCT05091567|Drug|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 4 cycles in the induction phase. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle in the maintenance phase.
45642701|NCT05091567|Drug|Lurbinectedin|Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 of each 21-day cycle in the maintenance phase.
45642702|NCT05091567|Drug|Carboplatin|Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.
45642703|NCT05091567|Drug|Etoposide|Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.
45642704|NCT05088252|Drug|Desflurane|After induction, anesthesia will be maintained with 0.7-1.0 MAC desflurane and 0.05-0.3 μg/kg/min remifentanil.
45642705|NCT05088252|Drug|Propofol|After induction, anesthesia will be maintained with 4-6mg/kg/h propofol and 0.05- 0.3 μg/kg/min remifentanil.
45642706|NCT05086744|Drug|Iptacopan|Iptacopan 200 mg BID
45642707|NCT05083364|Drug|ARO-C3|ARO-C3 for sc injection
45642708|NCT05083364|Drug|Placebo|sterile normal saline (0.9% NaCl) for sc injection
45642709|NCT05077904|Drug|Staccato alprazolam|"Route of administration: Inhalation~Participants will receive one dose of Staccato alprazolam during the Treatment Period."
45642710|NCT05077904|Other|Placebo|"Route of administration: Inhalation~Participants will receive one dose of placebo during the Treatment Period."
45642711|NCT05076617|Drug|Staccato alprazolam|"Pharmaceutical form: Inhalation powder~Route of administration: Inhalation~Participants will receive Staccato alprazolam during the Treatment Period."
45642712|NCT05076175|Drug|Ozanimod|Specified dose on specified days
45642713|NCT05073575|Procedure|Hyaluronic acid|"After local anesthesia, an access flap will be prepared. Scaling and root planning will be performed combining the use of metal curettes and power-driven instrumentation by means of ultrasonic scaler.~Hyaluronic acid gel will be applied to exposed roots surface, followed by a tension-free primary closure of the surgery wound by means of 5-0 monofilament (polypropylene) non-resorbable suturing material."
45917342|NCT00000552|Procedure|coronary artery bypass|
45917343|NCT00000552|Drug|thrombolytic therapy|
46070738|NCT00643201|Drug|Placebo for warfarin|tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
45642714|NCT05073575|Procedure|No-hyaluronic acid|"An access flap will be prepared in order to perform scaling and root planning therapy with the use of metal curettes.~After intervention, a tension-free primary closure of the interdental papillae and of the mucoperiosteal flaps by means of 5-0 monofilament (polypropylene) non-resorbable suturing materia will be performed"
45448898|NCT02147860|Device|Diabetes Assistant (DiAs) with USS Virginia|DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
45642715|NCT05073133|Genetic|OAV101|Gene Therapy IV infusion
45917344|NCT04910074|Device|Low-level laser therapy|The proposed LLLT protocol will use the Biolase Epic X, an InGaAsP diode laser (940nm) using the pain relief handpiece, a device which has received FDA approval (GUDID 00647529002537) for the treatment of pain, muscle relaxation and healing via increased local circulation. The LLLT will be administered to the experimental group at 30 j/cm2. The laser will be applied extraorally, on the skin overlying the mandible. Application will be for 40 seconds per side, with 10 seconds administered in four places along the jawline, 1 cm apart starting from the gonial angle.
45642716|NCT05073003|Drug|altSonflex Placebo|2 doses of altSonflex Placebo, administered intramuscularly, in the non-dominant arm, either at Day 1 and Day 85 or at Day 1 and Day 169 (depending on the vaccination schedule) to adults in the ST1_Adults_Placebo_GR1 and ST1_Adults_Placebo_GR2 groups in Stage 1 (Europe).
45781729|NCT05721638|Diagnostic Test|Neutrophil gelatinase-associated lipocalin|Neutrophil gelatinase-associated lipocalin (NGAL) is a 25 KDa, neutrophil-derived molecule from the lipocalin family. It is also secreted in small amounts from kidney, prostate, and respiratory tract epithelial cells. After ischemic and nephrotoxic acute tubular necrosis, NGAL levels peak at the 3rd hour and remain elevated for approximately 24 hours. In patients who do not progress to AKI, NGAL levels begin to decrease as of the 1st hour after injury.
45781730|NCT05721482|Behavioral|Caregiver Training|"A trained MIM provider and dietitian will deliver the MIM DASH group intervention in eight weekly 1-hour sessions via telehealth. Participants will receive session materials so they can follow along. Each MIM session consists of material related to mindfulness-the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Group interaction centers on sharing ideas toward effective practice and practical daily challenges to being mindful. Each class begins with a prompt for participant contemplation during the next hour that reference a unique weekly theme which will be reiterated in the session materials.~The DASH portion, led by the Registered Dietitian, focuses on education to increase vegetables, fruits, whole grains and decrease intakes of fat and sodium, sugar sweetened beverages and sweets. Education includes adapting traditional Soul food dishes to meet the DASH dietary guidelines."
45781731|NCT00791102|Drug|ASP-1001 nasal spray|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
45781732|NCT00791102|Drug|Placebo for ASP-1001|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
46070739|NCT00643201|Drug|apixaban|tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
45917345|NCT04910074|Device|Dummy LLLT|The Biolase Epic X with pain relief handpiece will be applied with no power extraorally, on the skin overlying the mandible. Application will be for 40 seconds per side, with 10 seconds administered in four places along the jawline, 1 cm apart starting from the gonial angle.
45448899|NCT02147860|Other|Sensor Augmented Pump Therapy|Subjects randomized to this placebo group will wear a continuous glucose monitoring system (CGM) to measure sensor glucose and a physiological monitor to measure heart rate and 3-axis accelerometer for 24-72 hours.
45448900|NCT02144818|Drug|Ovitrel|Triggering of ovulation with Ovitrel
45917346|NCT00000555|Drug|estrogen replacement therapy|
45917347|NCT00000555|Drug|estrogens, conjugated|
45917348|NCT00000555|Drug|progesterone|
46070740|NCT00643123|Drug|Allopurinol|300-600 mg/day over a 6 week period
46070741|NCT00643123|Other|Placebo|Inactive substance
46070742|NCT00816673|Drug|placebo Circadin|Placebo tabs of Prolonged release melatonin
46070743|NCT00816673|Drug|Circadin|prolonged release melatonin 2 mg taken daily 2 hours before bed-time for 3 weeks
46070744|NCT00818155|Drug|desvenlafaxine succinate SR|desvenlafaxine succinate SR
46070745|NCT00818155|Other|Placebo|
46070746|NCT00968981|Drug|GDC-0449|Daily oral repeating dose
46070747|NCT00968981|Drug|GDC-0449|Three times weekly oral repeating dose
45448901|NCT02144818|Drug|Decapeptyl|Triggering with GnRH agonist
45448902|NCT02147938|Drug|Tacrolimus|oral
45448903|NCT03544060|Drug|Volanesorsen|Volanesorsen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
45452507|NCT01098383|Drug|Indistinguishable placebo tablets, matching both donepezil and choline|Indistinguishable placebo tablets, matching both donepezil and choline, will be given in the same amounts and schedules
45452508|NCT00890890|Drug|Avagacestat|Capsules, Oral, 50 mg, once daily, 104 - 220 Weeks
46070748|NCT00968981|Drug|GDC-0449|Once weekly oral repeating dose
46070749|NCT04288817|Biological|Tuberculin purified protein derivative|Intralesional injection of tuberculin PPD in treatment of multiple common warts
46070750|NCT02863133|Device|Liquid Embolic|The Easyx liquid embolic, manufactured by Antia AG, is intended to occlude hypervascular lesions in the brain such as tumors, arteriovenous malformations (a tangle of abnormal and poorly formed blood vessels) and dural arteriovenous fistulas (abnormal connection of blood vessels).
46070751|NCT00641719|Drug|Duloxetine hydrochloride|Duloxetine 40 mg QD, PO, 1 year
46070752|NCT00641719|Drug|Duloxetine hydrochloride|Duloxetine 60 mg QD, PO, 1 year
46070753|NCT02863367|Drug|Apatinib|Apatinib：500 mg，po，qd, d1-14, every 3 week
46070754|NCT02863367|Drug|Gemcitabine|Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week
46070755|NCT00922363|Biological|50 µg Ag85B-ESAT-6 alone|0.5 mL solution for injection x 2 (2 months interval)
46070756|NCT00922363|Biological|50 µg Ag85B-ESAT-6 + 125/25 µg CAF01|0,5 mL suspension for injection x 2 (2 months interval)
46070757|NCT00922363|Biological|50 µg Ag85B-ESAT-6 + 313/63 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
45448904|NCT02148016|Procedure|LSCs and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following removal of scar tissue due to chemical injury or pterygium. The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
45448905|NCT02148016|Procedure|Amniotic membrane only (Traditional Technique)|Amniotic membrane alone will be used to cover the corneal surface, after removal of scar tissue from a chemical injury or pterygium.
45781733|NCT01259063|Drug|Everolimus and Intravesical Gemcitabine|Phase I: Everolimus will be adm as follows: Dose level 1: 5 mg every other day, Dose level 2: 5 mg daily, Dose level 3: 10 mg daily Phase II: Everolimus will be adm at 10 mg daily the dose determined in Phase I. Pts will receive a dose of 2000 mg of intravesical gemcitabine twice a week (72-96 +8 hours between doses) for 3 weeks for a total of 6 treatments in course 1. After 1 week of rest from intravesical gemcitabine, course 2 will be administered, provided the treating physician notes acceptable pt tolerance. The total number of intravesical instillations will be 12. There will be no dose modifications to gemcitabine; however, pts will be allowed to skip gemcitabine doses if needed, per the treating physician's discretion. Missed or skipped doses of gemcitabine will not be repeated. The pt will receive as many instillations as tolerable up to the maximum of 12 instillations.
45781734|NCT05317052|Behavioral|Massage group|Massage and music therapy
45781735|NCT01312805|Other|CHICA Asthma Module|This module was added to CHICA to help diagnose and manage asthma
45781736|NCT01312805|Other|CHICA Control|This is CHICA without the asthma module, and was used as a control
45781737|NCT04383548|Other|hyper immunoglobulins containing anti-Corona VS2 immunoglobulin|Prospective randomized clinical study for efficacy of anti-SARS-CoV-2 hyper immunoglobulins prepared from COVID19 convalescent plasma using VIPS Mini-Pool IVIG medical device
45781738|NCT04383392|Device|Rate adaptive pacing|Rate-adaptive pacing is a function of permanent pacemaker to accelerate patients' heart rate when they are walking, stair climbing, running or carrying on intensive physical activity. Appropriately, the function is similar to human's electrophysiology of sinus node but it may be difficult to replace sinus node's function totally. For example, the acceleration or deceleration slope when exercise beginning or cessation is not always the same or consistent in different patients and different time.
45781739|NCT01313507|Biological|NewGam|The initial dose and dosing interval for each participant was the dose and dosing interval the participant received at the end of the NGAM-01 study. The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as the minimum trough level of serum immunoglobulin G (IgG) was above 5 g/L. If the serum IgG trough level dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
45781740|NCT01313897|Drug|Bortezomib|bortezomib to be given days -9, -6, and -2 at 1.0mg/m2, i.v.
45781741|NCT01341977|Device|Alcon MPDS|Multi-Purpose Solution intended for use with silicone hydrogel and soft contact lenses
45781742|NCT01341977|Device|ReNu Fresh MPS|ReNu Fresh MPS is a marketed product indicated for cleaning, removing protein deposits, rinsing, disinfecting and storage of soft contact lenses.
45642717|NCT05073003|Biological|altSonflex1-2-3 Dose C|2 doses of altSonflex1-2-3 Dose C administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to adults in the ST1_Adults_Dose C_GR1 and ST2_Adults_Dose C groups in Stage 1 and 2 (Europe and Africa) and children in the ST2_Children_Dose C group in Stage 2 (Africa), and at Day 1 and Day 169 to adults in the ST1_Adults_Dose C_GR2 group in Stage 1 (Europe); 3 doses of altSonflex1-2-3 Dose C administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2_Infants_Dose C_Safety and ST2_Infants_Dose C_Dose find groups in Stage 2 (Africa).
45781743|NCT02192879|Device|thoracic epidural|Thoracic Epidural catheters will be placed between T8-12 interspaces preoperatively. Epidural hydromorphone (200-600mcg) will be given preoperatively. TEA will be dosed intraoperatively with a continuous infusion of 0.25% bupivacaine at 3-6ml per hour. At the end of surgery, infusion will be changed to 0.125% bupivacaine + 10mcg/ml hydromorphone at 4-6ml/hour. In PACU, a PCEA button will given to the patient for bolus dosing of 1-2ml and a lockout of 30 minutes. Changes to the epidural infusion solution, rate, and PCEA bolus dosing will be made clinically as required by the Acute Pain Service (APS).
45781744|NCT02192879|Device|continuous paravertebral catheter|Bilateral PVB catheters will be placed between the T8-12 interspaces preoperatively. 10ml of 0.5% ropivacaine will be injected into the paravertebral space, then catheter placed. The same procedure will be used for the placement of the PVB catheter on the opposite side. The catheter may be bolused with 5ml 0.5% ropivacaine hourly intraoperatively if needed. In PACU, PVB catheters will be infused continuously with 0.2% ropivacaine at 8-12ml/hr. Subjects will also be given a hydromorphone PCA button to deliver additional IV opioid medication to the patient as needed.
45781745|NCT02192879|Drug|Patient-Controlled Analgesia|Intravenous hydromorphone PCA will be initiated postoperatively with dosing prescriptions made by the primary surgical team.
45781746|NCT04351763|Drug|Amiodarone|Ion channel blocker
45781747|NCT04351763|Drug|Verapamil|Ion channel blocker
45452509|NCT00890890|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 104 - 220 Weeks
45781748|NCT00801398|Drug|Oxymorphone IR|Open-label, 2 part, ascending dose, single and multiple dose q4-6 hrs up to 48 hrs
45781749|NCT01342523|Other|CIS - telephone cessation quitline counseling|Up to 5 total tobacco cessation counseling calls
45781750|NCT01342523|Other|Lozenge - nicotine mini-lozenges|2-week starter pack of nicotine mini-lozenges
45781751|NCT01342523|Other|Emails - Brief smoking prevention messages|Brief email messages that could be accessed by any computer or mobile device that allowed email receipt
45781752|NCT01342523|Other|Full website - standard smokefree.gov website content|Over 50 web pages of resources for quitting smoking, including interactive features and referral links
45781753|NCT01342523|Other|Lite website - lite version of smokefree.gov|Reduced version of the smokefree.gov website developed for the research; reduced number of web pages and external links (considered a placebo intervention)
45917349|NCT00000555|Drug|hormone replacement therapy|
45917350|NCT00000555|Drug|supplementation, food|
45917351|NCT00000555|Drug|ascorbic acid|
45917352|NCT00000555|Drug|vitamin e|
45642718|NCT05073003|Biological|altSonflex1-2-3 Dose B|2 doses of altSonflex1-2-3 Dose B administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to children in the ST2_Children_Dose B group in Stage 2 (Africa); 3 doses of altSonflex1-2-3 Dose B administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2_Infants_Dose B_Safety and ST2_Infants_Dose B_Dose find groups in Stage 2 (Africa).
45642719|NCT05073003|Biological|altSonflex1-2-3 Dose A|3 doses of altSonflex1-2-3 Dose A administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2_Infants_Dose A_Safety and ST2_Infants_Dose A_Dose find groups in Stage 2 (Africa).
46070758|NCT00922363|Biological|50 µg Ag85B-ESAT-6 + 625/125 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
46070759|NCT00648895|Drug|Nebivolol|nebivolol 10mg, 20mg, 40mg daily dosage, oral administration
46070760|NCT00648895|Drug|Metoprolol ER (TM)|Metoprolol ER 100mg, 200mg, 400mg, daily dosage, oral administration
46070761|NCT00812539|Other|"Subject/Provider Portal Diabetes Connected Health tool - Deluxe"|"Subjects enrolled into the Deluxeintervention will use a glucometer, a modem to upload the blood glucose readings to a secure, web-based portal (Diabetes Connected Health tool) where they can view detailed graphical representation of their blood glucose levels over time, educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to their subjects' information on the web portal and contact them by an embedded messaging system). Subjects with new high or low readings will be flagged. Providers can initiate messages to subjects regarding symptoms or medications. A medication summary and log of all readings uploaded with date/time will be displayed on the website as well as a graphical display of all uploaded glucose readings over time and will allow subjects to enter comments regarding each critical reading."
45448906|NCT02148016|Procedure|PRK, LSCs, and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following photo-refractive keratectomy (PRK). The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
45642720|NCT05073003|Biological|GSK's Meningococcal A, C, Y and W-135 conjugate vaccine|1 dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly, in the non-dominant arm, at Day 1 to adults in the ST2_Adults_Control C group and children in the ST2_Children_Control B and ST2_Children_Control C groups in Stage 2 (Africa); 2 doses of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to infants in the ST2_Infants_Control A_Safety, ST2_Infants_Control B_Safety, ST2_Infants_Control C_Safety and ST2_Infants_Control_Dose find groups in Stage 2 (Africa).
45642721|NCT05073003|Combination Product|GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered intramuscularly, in the non-dominant arm, at Day 85 to adults in the ST2_Adults_Control C group in Stage 2 (Africa).
45642722|NCT05073003|Combination Product|GSK's Diphtheria, tetanus and pertussis vaccine|1 dose of GSK's Diphtheria, tetanus and pertussis vaccine administered intramuscularly, in the non-dominant arm, at Day 253 to infants in the ST2_Infants_Control A_Safety, ST2_Infants_Control B_Safety, ST2_Infants_Control C_Safety and ST2_Infants_Control_Dose find groups in Stage 2 (Africa).
45642723|NCT05073003|Combination Product|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, in the non-dominant arm, at Day 85 to children in the ST2_Children_Control B and ST2_Children_Control C groups in Stage 2 (Africa).
45642724|NCT05073003|Biological|Serum Institute of India's Measles and rubella vaccine|2 doses of Serum Institute of India's Measles and rubella vaccine administered subcutaneously, in the non-dominant arm, at Day 29 and Day 281 to infants in the safety groups, and at Day 1 and Day 253 to infants in the dose-finding groups, in Stage 2 (Africa).
45642725|NCT05070845|Biological|PF-06835375|CXCR5 inhibitor
45642726|NCT05069298|Dietary Supplement|Silibinin A|The compound will be administered following a 300 mg / 3 day schedule, before each main meal.
45642727|NCT05069259|Other|Stool sample collection|collection for measuring calprotectin levels
45642728|NCT05068258|Procedure|Lymphovenous bypass, including lymphaticovenular anastomosis/implantation|Lymphovenous bypass (LVB) is a supermicrosurgical technique by diverting lymphatic drainage into venous system. Simultaneously, we performed LVB at ipsilateral foot dorsum and debride the VLUs and resurface the wound primarily or by skin graft depending on defect size.
45642729|NCT05065632|Diagnostic Test|Wantai kit Elisa|to mesure antibodies against SARSCov-2 recombinant antigen
45642730|NCT05064709|Device|Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System|The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed ON for the first 18 months (blinded phase). CCM therapy will be programmed to deliver 7 one-hour phases of CCM therapy that are distributed equally over every 24-hour period. CCM will remain on following completion of the 18-month visit.
45642731|NCT05064709|Device|OPTIMIZER™ Smart Mini System|The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed OFF for the first 18 months (blinded phase). CCM will be turned on following completion of the 18-month visit.
45642732|NCT05062759|Drug|Tezepelumab|210 mg SC injection Q4W.
45642733|NCT05062759|Drug|Placebo|SC injection Q4W.
45642734|NCT05062044|Dietary Supplement|Multivitamins (Elevit, BAY987808)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
45642735|NCT05062044|Dietary Supplement|Multivitamins (Elevit, BAY2906300)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
45642736|NCT05062044|Drug|Multivitamins (Elevit, BAY987386)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
45781754|NCT01342523|Other|Full mailed booklet - NCI's detailed 36-page quit guide|NCI's Clearing the Air brochure for preparing to quit, quitting and preventing relapse
45642737|NCT05062044|Dietary Supplement|Folic acid|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
45781755|NCT01342523|Other|brief mailed booklet - smaller version of NCI's booklet|12-page booklet developed by the investigators for the research (considered to be placebo intervention)
45781756|NCT01261559|Device|Chrysalis breast displacement device|Chrysalis is a cloth device secured with velcro and buckles around the upper abdomen and chest following manual cephalad breast displacement.
46070762|NCT00812539|Other|"Subject only Portal Diabetes Connected Health Tool Basic"|"Patients enrolled in the Diabetes Connect Basic intervention will use a glucometer, a modem which will upload the blood glucose readings to a secure, web-based portal (the Diabetes Connected Health tool) where they can view their readings in a less detailed/journal fashion. No detailed graphical representation of their blood glucose levels over time is available to this group, nor is any educational material regarding diabetes management. Their physicians will not have access to these subjects' information on the web portal and will not have the ability to contact them by an embedded messaging system."
46070763|NCT00818233|Device|Dynamic contour tonometry|Observe variability of measurements by dynamic contour tonometry
45448907|NCT02148016|Procedure|PRK only (Traditional Technique)|PRK alone will be performed.
45448908|NCT02148016|Drug|Levofloxacin|
45448909|NCT02148016|Drug|Betamethasone|
45448910|NCT02148016|Drug|Limbal stem cells (LSCs)|
45781757|NCT01342757|Drug|vorinostat|Given orally
45917353|NCT00390052|Drug|triapine|Given IV and orally
45642738|NCT05061862|Device|cardiac implantable electronic devices (CIEDs)|Subjects will be implanted with various cardiac implantable electronic devices and followed according to their standard of care. Medical imaging will be collected at various stages of the implant procedure
45642739|NCT05059522|Drug|Avelumab|oral
45642740|NCT05059522|Drug|Lorlatanib|oral
45642741|NCT05059522|Drug|Talazoparib|oral
45642742|NCT05059522|Drug|Pemetrexed|IV (intravenous) infusion
45781758|NCT01342757|Drug|temozolomide|Given orally
45781759|NCT01342757|Procedure|magnetic resonance spectroscopic imaging|Undergo MRI
45781760|NCT01342757|Other|survey administration|Ancillary studies
45917354|NCT00390052|Other|pharmacological study|correlative study
45917355|NCT00390052|Procedure|laboratory biomarker analysis|Correlative study
45917356|NCT04888858|Drug|Epidural analgesia (0.125% bupivacaine/2mcg fentanyl solution)|As part of standard protocol for all patients who receive a labor epidural, the epidural will then be tested using 3ml of 1.5% lidocaine and 1:200,000 epinephrine test solution, and the epidural catheter will then be loaded with 10ml of 0.125% bupivacaine solution. The epidural catheter will then be connected to a programmed intermittent epidural bolus pump which will administer 5ml of a 0.125% bupivacaine/2mcg fentanyl solution every 30minutes. The first dose will be given following 30minutes after the loading dose. 30 minutes after loading the loading dose and after the first pump dose has been given, we will assess the VAS pain scores and the level of the analgesic based on decreased sensation to ice.
45917357|NCT04870957|Behavioral|PainGuide|A 4-week, online, self-management program for pain known as PainGuide (online or smart phone). Participants will use this during the run-in period as well as after the run-in period.
45917358|NCT04870957|Behavioral|MBSR|"In this group (mindfulness-based stress reduction) participants will take part in 9 group sessions.~The groups sessions will be divided into 8 weekly 2-hour groups sessions and one 6-hour retreat. During the sessions participants will practice mindfulness exercises directed by the a MBSR therapist. Additionally, participants will also be asked to practice daily formal mindfulness at home using audio recordings of 30-45 minute guided meditation exercises. These audio recordings can be accessed online. The sessions may take place in-person or virtually."
46070764|NCT00812617|Dietary Supplement|Mineral water (Hita, Oita, Japan)|
46070765|NCT00812617|Dietary Supplement|Mineral water (Aso-gun, Kumamoto, Japan)|
46070766|NCT00975221|Drug|Cinacalcet|Administered orally at a starting dose of 30 mg twice a day (BID). Participants will be eligible for a dose titration once every 3 weeks during the placebo-controlled dose titration phase based on corrected total serum calcium concentration and safety assessments obtained the previous week. Doses may be sequentially increased to 60 mg BID, 90 mg BID, and 90 mg 3 times a day (TID).
46070767|NCT00975221|Drug|Placebo|Administered orally following the same tiitration regimen as the experimental arm.
45448911|NCT03543982|Dietary Supplement|Oral probiotic product|Once per day (QD), 28 days
45642743|NCT05059522|Drug|Axitinib|oral
45642744|NCT05059522|Drug|CMP 001|IT (intratumoral) or SC (subcutaneous)
45642745|NCT05059522|Drug|Utomilumab|IV infusion
45642746|NCT05059522|Drug|PF04518600|IV infusion
45642747|NCT05058651|Biological|Atezolizumab|Given IV
45642748|NCT05058651|Procedure|Biospecimen Collection|Undergo blood sample collection
45642749|NCT05058651|Drug|Carboplatin|Given IV
45642750|NCT05058651|Drug|Cisplatin|Given IV
45642751|NCT05058651|Procedure|Computed Tomography|Undergo CT scan
45781761|NCT02199743|Drug|Lurasidone|Compare to haloperidol and perphenazine
45781762|NCT02199743|Drug|Haloperidol|Compare to lurasidone
45642752|NCT05058651|Drug|Etoposide|Given IV
45642753|NCT05058651|Procedure|Magnetic Resonance Imaging|Undergo MRI
45642754|NCT05058651|Other|Patient Observation|Undergo observation
45642755|NCT05057715|Biological|VCN-01|Intravenous administration of VCN-01
45642756|NCT05057715|Biological|huCART-meso Cells|Intravenous administration of huCART-meso cells
45781763|NCT02199743|Drug|Perphenazine|Compare to lurasidone
45781764|NCT01315145|Procedure|Percutaneous Lumbar Decompression|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
45781765|NCT01315145|Drug|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
45781766|NCT01316315|Drug|Active|A 5 mg single dose given intravenously via syringe pump over 1 minute.
45642757|NCT05057494|Drug|Acalabrutinib|Dose formulation: Capsule
45642758|NCT05057494|Drug|Venetoclax|Dose formulation: Tablet
45642759|NCT05057494|Drug|Obinutuzumab|Dose formulation: Injection
45642760|NCT05056454|Behavioral|Online therapy with coaching|"Participants with moderate depressive symptoms on the CAT-MH (and no current suicidality) will meet with a trained coach, and receive access to online course materials from one of 2 lesson platforms - ThisWayUp's MUMentum course or Rainfrog's ParentMood course. Lesson content is presented as illustrated stories about characters who are anxious and depressed then gain mastery over their problems using CBT techniques. The efficacy of each online course will be compared for equivalency.~Following each lesson, participants are provided a document that summarizes key lesson information and practical homework exercises that reinforce the content of the lesson. Participants are encouraged to practice their lesson homework for at least one week before meeting with their coach and starting the next lesson."
45642761|NCT05056454|Behavioral|Clinical care|Participants with severe depressive symptoms or significant suicidality on the CAT-MH will be allocated to access clinical care, which entails weekly psychotherapy sessions and psychiatric care, when needed or appropriate. While clinical care will be available for the entire 6-month duration of the treatment component of the study, participants will be informed that on average therapy is completed within 13 sessions. The schedule of psychiatric care will be determined by the provider and will be comparable to that provided in the TAU arm.
45781767|NCT01316315|Drug|Placebo|Same as active
45781768|NCT00776594|Drug|Androgen Deprivation Therapy|leuprolide: 22.5mg given IM every 3 months for a total of 6 months or, goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months
45781769|NCT00776594|Drug|bicalutamide|50mg orally daily for 6 months
45781770|NCT00776594|Drug|bevacizumab|15mg/ks given IV every three weeks for a total of 8 infusions over 6 months
45781771|NCT01262105|Device|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the site.
46070768|NCT02864693|Device|Kinnex|The Kinnex is a microprocessor controlled hydraulic ankle foot device (Freedom Innovations, Irvine, CA).
46070769|NCT02864693|Device|Pacifica LP|The Pacifica LP is a carbon-fiber ankle foot device (Freedom Innovations, Irvine, CA)
46070770|NCT04204421|Other|Experience Sampling Method (ESM)|Experience Sampling Method (ESM) is a method for real time complaints assessment where people are asked to fill out a questionnaire 10 times per day at random moments. This will be done via a mobile phone application.
45642762|NCT05053867|Drug|tranexamic acid|Inhaled
45642763|NCT05053867|Other|Usual Care|Standard of Care
45642764|NCT05053152|Drug|Placebo Administration|Given PO
46070771|NCT02863679|Drug|Tetracaine hydrochloride gel|Tetracaine hydrochloride gel contains 1% tetracaine hydrochloride, and a fair dose of fungicide, lubricants, remove foam agent, as the long-term local anesthetics.
46070772|NCT00972179|Drug|Placebo|Administered by subcutaneous or intravenous injection.
46070773|NCT00972179|Drug|Tezepelumab|Administered by subcutaneous or intravenous injection
45642765|NCT05053152|Other|Quality-of-Life Assessment|Ancillary studies
45642766|NCT05053152|Drug|Relugolix|Given PO
45642767|NCT05053152|Radiation|Stereotactic Body Radiation Therapy|Undergo SABR
45642768|NCT05052996|Drug|ISL|Capsules administered orally without regard to food
45642769|NCT05052996|Drug|LEN|Tablets administered orally without regard to food
45642770|NCT05052996|Drug|B/F/TAF|Tablets administered orally without regard to food
45781772|NCT00777062|Drug|VIVITROL (Naltrexone extended-release injectable suspension)|VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6.
45781773|NCT00777062|Drug|Placebo|Placebo injection at the start of weeks 2 and 6.
45781774|NCT01264601|Biological|Trivalent Influenza Vaccine|Age appropriate dose of seasonal Trivalent Influenza Vaccine (TIV), either 0.25mL under age 3 or 0.5mL over the age of 3.
45781775|NCT01317095|Device|Sternalock Rigid Fixation|Patients will have their sternum closed by rigid fixation using Sternalock plates.
45781776|NCT01345721|Biological|MenACWY-CRM|
45781777|NCT01346267|Procedure|Real Acupressure Band|Acupressure wristband
45781778|NCT01346267|Procedure|Placebo Acupressure Band|Sham wristband
45781779|NCT02193347|Biological|PEPIDH1M vaccine|PEPIDH1M vaccine is made up of 500 µg of 25 amino acid peptide administered with 150 µg of GM-CSF mixed 1:1 with Montanide ISA 51 administered intradermally. The peptide vaccine is administered in the groin area approximately 10 cm below the inguinal ligament.
45781780|NCT02193347|Biological|Tetanus-Diphtheria Toxoid (Td)|After consent has been signed, all subjects will undergo standard of care vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly (I.M.) into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Within 48 hours of leukapheresis, subjects will receive a vaccine site pre-conditioning as a single dose of Td toxoid (1 flocculation unit, Lf, in a total volume of 0.4 mLs saline) administered intradermally to the right side of the groin one day prior to receiving the first PEPIDH1M vaccine.
45781781|NCT02193347|Drug|Temozolomide|Subjects are treated with temozolomide (TMZ) at a targeted dose of 50-100mg/m2/d for 21 days every 28 days for up to 12 cycles. Subjects that have transitioned to a higher grade brain tumor at time of surgery will receive TMZ and radiation therapy per standard of care before starting TMZ cycles.
45781782|NCT01318577|Device|Investigational Cleaning & Disinfecting Solution|Contact lenses will be cleaned and stored daily in the cleaning, disinfecting and storage solution
45781783|NCT01318577|Device|Clear Care Solution|Contact lenses will be cleaned and stored daily in the cleaning, disinfecting and storage solution
45781784|NCT01318733|Drug|CD07805/47 gel 0.5%|In this open-label study, all subjects will receive treatment with CD07805/47 gel 0.5% applied once daily, for up to 12 months.
46070774|NCT04288505|Diagnostic Test|VIRTUAL REALITY application|application on virtual reality headset
45781785|NCT01318967|Drug|Furosemide|Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.
45781786|NCT01318967|Other|Placebo|
45781787|NCT01319045|Drug|Iloprost|Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months
45781788|NCT01267019|Behavioral|social cognitive training with in vivo augmentation|24 sessions of social cognitive training plus 6 sessions of in vivo exercises
45781789|NCT01267019|Behavioral|social cognitive training|30 sessions of social cognitive training without in vivo exercises
45781790|NCT01267019|Behavioral|non-social skills training|30 sessions of skills training that has no specific social content
45781791|NCT01348607|Drug|methylphenidate hydrochloride|Given orally
45781792|NCT01348607|Drug|modafinil|Given orally
45781793|NCT01348607|Drug|placebo|Given orally
45781794|NCT01268111|Drug|Ergocalciferols|ERgocaclciferol 50,000 units weekly for 8 weeks
45781795|NCT01268111|Drug|Placebo|matching placebo
45781796|NCT01349231|Drug|ketamine|Ketamine (a single 0.5mg intravenously over 40 minutes).
45781797|NCT01349933|Drug|Akt inhibitor MK2206|Given PO
45781798|NCT01350245|Radiation|Total Body Irradiation (TBI)|Total body irradiation is given in 8 fractions over 4 days (total dose of 12 Gy).
45642771|NCT05052983|Drug|Nemolizumab|Participants will receive either 1 [30 milligram (mg)] or 2 (2×30 mg) subcutaneous injection(s) of nemolizumab every 4 weeks (Q4W) for a period of 24 weeks (with last injection at Week 20). Participants will receive the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by interactive response technology (IRT).
45781799|NCT01350245|Biological|Donor Lymphocyte Infusion (DLI)|After TBI, the patients will receive a dose of 2 x 10e8 of their donor's T cells. After this infusion, the patients will have 2 rest days.
45781800|NCT01350245|Drug|Cyclophosphamide|Cyclophosphamide is administered 2 days after the DLI to help tolerize the donor T cells. It is given at a dose of 60 mg/kg/d for 2 days
45781801|NCT01350245|Drug|Mycophenolate Mofetil (MMF)|Started the day before the transplant to prevent graft versus host disease (GVHD)
46070775|NCT00906698|Drug|BIBW 2992 low (20mg) dosage|Patients will receive 20mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
45781802|NCT01350245|Drug|Tacrolimus|Started the day before the transplant to prevent graft-versus-host disease (GVHD)
45781803|NCT01350245|Device|Hematopoietic stem cell transplantation (HSCT)|"One day after the cyclophosphamide is finished, the patients will receive a CD34 selected-donor stem cell product. This is the day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
45781804|NCT01350401|Genetic|Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T|Cytoreductive chemotherapy followed by infusion of NY-ESO-1ᶜ²⁵⁹T
45781805|NCT01320137|Procedure|Blood withdrawal|Blood sampling
45781806|NCT01321151|Drug|Resveratrol|The dose of resveratrol is 500 mg. The route of administration is oral, once-a-day for 30 days after injury.
45781807|NCT01321151|Drug|Placebo|The placebo is a sugar pill. The route of administration is oral, once-a-day for 30 days after injury.
45781808|NCT01350947|Drug|5-Azacitidine|"Administered on Days 1-7 of each Cycle.~Subcutaneous administration:~To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration.~The 5-azacitidine suspension is administered subcutaneously.~Intravenous Administration:~5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes."
45781809|NCT01268189|Device|Oxygen diffusing dressing|Oxygen diffusing dressing applied to study wound
45452514|NCT00964990|Drug|JNJ-42160443|Type=exact number, unit=mg, number= 1, 3, or 10, form=solution for injection, route=Subcutaneous use. One injection of 1, 3, or 10 mg of JNJ-42160443 every 28 days for up to 52 wks and then every 4, 8, or 12 weeks for up to an additional 52 weeks
45642772|NCT05052983|Drug|Placebo|Participants will receive either 1 (30 mg) or 2 (2x30 mg) subcutaneous injection(s) of placebo every 4 weeks for a period of 24 weeks (with last injection at Week 20). Participants will receive the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by IRT.
45781810|NCT01268189|Device|Standard of care dressing|Xeroform control dressing applied to control wound
45781811|NCT01269047|Drug|Pramlintide|Start at 15 mcg capped at 60 mcg before breakfast and supper subcutaneously for 4 months
45781812|NCT01269047|Drug|Exenatide|Start at 1.25 mcg, capped at 5 mcg, subcutaneously, before breakfast and supper for 4 months
45781813|NCT01269047|Drug|Insulin|Rapid acting and long acting, subcutaneously, according to their regimen for the entire duration of the study.
45781814|NCT01351337|Procedure|diffusion tensor tractography neuronavigation and intraoperative subcortical stimulation|All of the patients underwent tumor resection assisted with combined use of Diffusion tensor tractography-integrated functional neuronavigation and intraoperative subcortical stimulation
45781815|NCT02147990|Drug|Rociletinib|Rociletinib will be administered to patients orally
45781816|NCT02148302|Device|Harvesting Device (CelluTome©)|Subjects who continue to meet eligibility criteria will be randomized to one of two groups: (1) Up to 3 applications of Epidermal grafting harvested utilizing the CelluTome® system at day zero, week 4 and week 8, visits plus standard of care (multi-layer compression) (2) Multilayer compression alone.
45781817|NCT03800498|Other|DASH Education|DASH health education about general knowledge of DASH diet Plan and lifestyle modification
45781818|NCT03800186|Other|Proximal type A|Patients with fracture of proximal type A
45781819|NCT03800186|Other|Proximal type B|Patients with fracture of proximal type B
45781820|NCT03800186|Other|Proximal type C|Patients with fracture of proximal type C
45781821|NCT03800186|Other|femoral shaft|Patients with fracture of femoral shaft
45781822|NCT03800186|Other|distal femur|Patients with fracture of distal femur
45781823|NCT04383860|Procedure|5-0 suture|5-0 suture administration during surgery
45781824|NCT04383860|Procedure|4-0 suture|4-0 suture administration during surgery
45781825|NCT03800264|Drug|Bisoprolol|PREVENTIVE DOUBLE BLINDED
46070776|NCT00906698|Drug|BIBW 2992 medium (40mg) dosage|Patients will receive 40mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
45781826|NCT03800342|Other|Aerobic Exercise Training|see arm/group description
45781827|NCT05287724|Drug|N-acetyl cysteine|1,500 mg twice daily for seven days
45781828|NCT05287724|Drug|Placebo|Placebo taken twice daily for seven days
45781829|NCT01321541|Drug|Pixantrone + Rituximab|Pixantrone + Rituximab: Rituximab 375 mg/m2 IV on day 1 and pixantrone 50 mg/m2 (equivalent to 85mg/m2 pixantrone dimaleate)IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
45781830|NCT01321541|Drug|Gemcitabine + Rituximab|Gemcitabine + Rituximab: Rituximab 375 mg/m2 IV on day 1 and gemcitabine 1000 mg/m2 IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
45781831|NCT05286242|Biological|COVID19 vaccine|All participants receive one or more FDA-authorized COVID19 vaccinations according to standard of care and current medical recommendations. The intervention is not specifically administered as part of the study.
45781832|NCT05282186|Behavioral|Cognitive Enhancement Therapy|CET's group-based exercises are delivered for 1.5 hours each week in a group of 6-8 participants led by a clinician and an assistant, for one year. During each of three modules (basic concepts, social cognition, CET applications), the groups focus on acquisition of adult social milestones in perspective-taking, social context appraisal, and other aspects of social cognition, with psychoeducational lectures, homework assignments, and in-group exercises. Weekly supervision sessions for the clinician trainers will include review of how patients respond to the different demands of computer-based training and group-based exercises and guidance about improving engagement in both.
45781833|NCT05282186|Behavioral|Social Skills Training|"The psychosocial component involves weekly skills training classes delivered over one year, with modules including Communicating Effectively, Making and Keeping Friends, Making the Most of Leisure Time, Healthy Living, Using Medications Effectively, and Making the Most of a Health Care Visit (Pratt et al., 2008). Participants attend two sessions each week (normally morning and afternoon of the same day): a 90-minute session focused on a specific skill and a 60-minute session in which the specific skill is used in role-play exercises."
45642773|NCT05050240|Other|Cooling Vest Procedure|"A cold vest will be placed on the participant (consisting of a water-perfused CFA wearable vest, size S-M or M-L with adjustable straps Polar Products, Stow, OH; attached to a small 'cooler' reservoir to circulate cold water between the vest and the cooler; Product link: https://www.polarproducts.com/polarshop/pc/CoolOR-13-Quart-System-with-Arctic-Chiller-p24757.htm This product is safe and recommended by experimental guidelines and BARCIST criteria for human BAT studies. Note, the cooling vest will be cleaned between participants according to the manufacturer's guidelines found here: https://www.polarproducts.com/polarshop/pc/catalog/pdf/Polar_CoolFlow_Manual.pdf.~Briefly, the vest will be hand washed with a mild detergent and warm soapy water and air-dried. The vest will then be stored in a clean, dry environment with ventilation."
45781834|NCT01270529|Other|Increasing Physical activity|The subjects (CKD Stages 1-4, ESRD on Hemodialysis or Peritoneal Dialysis) will continue to wear the pedometer for 12 weeks during which time he or she will be asked to gradually increase steps walked per day above baseline physical activity. The patient will be called once a week in order to monitor progress, set new weekly step goals (usually 500-1000 steps/day greater than the previous week), and also to motivate the participant.
45781835|NCT05254262|Procedure|Elderly surgical patients|Patients who needs elective or emergency surgery for any reason
45642774|NCT05050240|Other|Fasting overnight|Participants will be requested to refrain from food and caloric drinks overnight (starting at 10pm) prior to the hospital visit. Blood will then be drawn the following morning (between 8 and 9am) and 3hrs later (between 11am and noon). Participants will be sat in a room with ambient temperature (room temperature w/o cooling) between the two blood draws.
45917359|NCT04870957|Behavioral|PT and exercise|"Participants will take part in 10 physical therapy visits over the course of 8 weeks. Participants will meet with the physical therapist twice a week for a 1-hour session for weeks 1 and 2 and then weekly for the remaining 6 weeks. The physical therapist will tailor a program to the participant's needs according to recommended PT practice guidelines that will include in-person treatment, home exercise prescription, and encouragement of progressive, low-intensity, submaximal fitness and endurance activities, such as walking.~Participants will be given a home program of exercises to be done daily and asked to engage in daily walking with a set goal based on the individual's capacity and current fitness level. Walking was selected as the aerobic exercise of focus for this treatment because it is recommended for patients with all levels of pain severity, is highly feasible to complete, and has shown effects on outcomes such as pain and disability."
45917360|NCT04870957|Device|Self -administered acupressure|"A device called the AcuWand will be used to administer the self-acupressure intervention for approximately 30 minutes daily for 8 weeks. Participants will use a mobile application (app) called MeTime that will have daily instructions on how to use the AcuWand. Research staff will show participants how to use the AcuWand and MeTime app. In addition, participants will keep a daily log to track at-home acupressure sessions."
46070777|NCT00906698|Drug|BIBW 2992 high (50mg) dosage|Patients will receive 50mg dosage of BIBW 2992 plus standard dosage of vinorelbine.
45452515|NCT00964990|Drug|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 52 wks
45642775|NCT05050162|Drug|Cisplatin|Given high-dose cisplatin IV
45781836|NCT04351607|Dietary Supplement|Oleovital® Eisen Forte|60 mg daily oral Supplementation for 3 to 6 weeks
45781837|NCT03801434|Drug|Ruxolitinib|Given PO
45781838|NCT01322633|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
45781839|NCT01322633|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
45917361|NCT04870957|Drug|Duloxetine|For days 1-7, patients will take 30mg of duloxetine once a day, in the morning. Starting day 8, participants tolerating the medication will be escalated to 60mg once a day. They will also have the option of staying at 30mg, once a day or stopping the medication. At the end of the 8-week intervention period, participants will have the option to continue the medication commercially (non-study medication) under the care of their physician or taper off the medication. During the entire 8-week intervention, patients will be asked to keep a daily log of medication dosage, any missed doses, and any side-effects they may have experienced.
45642776|NCT05050162|Drug|Cisplatin|Given low-dose cisplatin IV
45917362|NCT04870957|Device|Pro-Diary monitor|"Participants will wear during 5 separate 7-day home monitoring periods to assess physical activity (objectively measured via accelerometry), and ecological momentary assessment (EMA) of mental and physical symptoms. EMA will be collected during Weeks 1, 6, 15, 24 and 36."
45917363|NCT00000558|Drug|angiotensin-converting enzyme inhibitors|
45452516|NCT03175172|Biological|CRS-207|Administered by IV infusion over approximately 1 hour.
45917364|NCT00000561|Device|pacemaker, artificial|
45917365|NCT04846504|Behavioral|MMBFM program with clinician coach support|Clinician-delivered telephonic coaching to support participants in the Mindful Mood Balance for Moms online course for prevention of depression relapse/recurrence among perinatal women who have had prior episodes of depression but are not currently depressed.
45642777|NCT05050162|Other|Quality-of-Life Assessment|Ancillary studies
45642778|NCT05050162|Other|Questionnaire Administration|Ancillary studies
45642779|NCT05050162|Radiation|Radiation Therapy|Undergo radiation therapy
45642780|NCT05050084|Drug|Bicalutamide|Anti-androgen
45642781|NCT05050084|Drug|Buserelin|GnRH agonist
45642782|NCT05050084|Drug|Darolutamide|Anti-androgen
45642783|NCT05050084|Drug|Degarelix|GnRH antagonist
45642784|NCT05050084|Drug|Flutamide|Anti-androgen
45642785|NCT05050084|Drug|Goserelin|GnRH agonist
45642786|NCT05050084|Drug|Histrelin|GnRH agonist
45642787|NCT05050084|Drug|Leuprolide|GnRH agonist
45642788|NCT05050084|Radiation|Radiation Therapy|Undergo RT
45642789|NCT05050084|Drug|Relugolix|GnRH antagonist
45642790|NCT05050084|Drug|Triptorelin|GnRH agonist
45642791|NCT05047640|Biological|BNT162b2 vaccine|Single dose of 0.3 mL BNT162b2 vaccine administered intramuscularly in the deltoid muscle
45642792|NCT05047640|Biological|JNJ-78436735 Vaccine|Single dose JNJ-78436735 Vaccine administered intramuscularly in the deltoid muscle
45642793|NCT05047263|Drug|Finerenone (BAY94-8862)|Tablet, 10 mg or 20 mg, once daily (OD), oral
45452517|NCT03175172|Biological|Pembrolizumab|Administered by IV infusion over approximately 30 minutes.
45452518|NCT01093547|Procedure|Blood samples|Samples taken monthly
45642794|NCT05047263|Drug|Placebo|Tablet, once daily, oral
45642795|NCT05047250|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by investigators.
45642796|NCT05047224|Behavioral|Tele-assessment + in-person assessment|Participants will complete a tele-assessment using the TAP. They will complete a traditional, in-person autism spectrum disorder assessment approximately two weeks later.
45642797|NCT05047224|Behavioral|Tele-assessment only|Participants will complete a tele-assessment using the TAP. They will complete a second, shorter tele-assessment approximately two weeks later.
45642798|NCT05046314|Biological|TK216+Vincristin|TK216 was continuously administered for 14 days，then rest for 14 days. Vincristin is given before TK216 only in the first day of each cycle, the first cycle of VCR is 0.75mg/m^2 and 1.5mg/m^2 from the second cycle，every 28 days is a study cycle.
45642799|NCT05043714|Biological|NG-641 in combination with Nivolumab|"NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.~Nivolumab is a human monoclonal antibody that targets the PD-1 cluster of differentiation 279 cell surface membrane receptor."
45642800|NCT05039073|Drug|Brentuximab Vedotin|Given IV
45642801|NCT05039073|Procedure|Hematopoietic Cell Transplantation|Undergo HSCT
45642802|NCT05039073|Biological|Nivolumab|Given IV
45642803|NCT05039073|Other|Quality-of-Life Assessment|Ancillary studies
45642804|NCT05039073|Other|Questionnaire Administration|Ancillary studies
45642805|NCT05038228|Drug|Apixaban|Anticoagulant
45642806|NCT05038228|Drug|Rivaroxaban|Anticoagulant
45642807|NCT05038228|Drug|Dabigatran|Anticoagulant
45642808|NCT05038228|Drug|Vitamin K antagonist (VKA)|Anticoagulant
45642809|NCT05037669|Biological|PACE CART19|PACE CART19 cells are allogeneic T cells transduced with a lentiviral vector to express an anti-CD19 scFv TCRz:41BB and electroporated to temporarily express the CRISPR/Cas9 RNA system resulting in beta-2 microglobulin (B2M), Class II Major Histocompatibility Complex Transactivator (CIITA) and TCR-α chain (TRAC) targeted disruption. PACE CART19 cells will be administered by IV infusion.
45642810|NCT05033262|Other|Our Memory Care Wishes|Our Memory Care Wishes is a web-based advance care planning platform designed for persons living with dementia in nursing homes to discuss and document healthcare and daily life preferences with the help of shared decision-makers. Penn researchers meet via Zoom with PLWD and their SDMS and nursing home staff to facilitate website completion.
45642811|NCT05031780|Drug|Mitapivat|Mitapivat tablets
45642812|NCT05031780|Other|Mitapivat-matching placebo|Placebo to match 50 mg or 100 mg tablets
45642813|NCT05031780|Other|Mitapivat-matching placebo|Placebo to match selected Phase 3 dose tablets
45642814|NCT05030584|Drug|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
45642815|NCT05030584|Drug|Placebo|Matching placebo orally once daily.
45642816|NCT05029999|Drug|PLD Chemotherapy|PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle.
45642817|NCT05029999|Drug|CDX-1140|CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle.
45642818|NCT05029999|Drug|CDX-301|CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 doses per cycle for 2 cycles.
45781840|NCT03804008|Drug|Ultrasound-guided corticosteroid injection|A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid 20mg/ml + 1 ml Lidocain 10 mg7ml. The skin is cleansed with Chlorhexidine alcohol 0.5 %. The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness. Participants are asked to start performing the exercise as soon as they feel ready but not before 24 hours after the injection. Furthermore, they are asked not to progress the method used to achieve 8RM when they start to do the exercise after the injection until Week 3 of the exercise programme. If standing on both feet was sufficient to achieve 8RM at baseline, the participant must not perform the exercise single-legged or to wear a backpack with weights after the injection regardless of any pain reduction afforded by the injection.
45781841|NCT03804008|Other|Heavy-slow resistance training|Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. Participants are instructed in performing the exercise with a load as heavy as possible but no higher than 8RM and for as many sets as possible every other day.
45642819|NCT05027958|Drug|Tuberculin Purified Protein Derivative|PPD administered through the airways to elicit the development of alveolar inflammation challenge dose of 0.5 TU
45781842|NCT03804008|Other|Fundamental advice and a silicone heel cup|Participants receive brief information about pathology, risk factors and advice on how to decrease activities that lead to symptom flares and slowly increase their activity level based on their symptoms. They also receive a leaflet that includes the same information as the research assistants will deliver orally after inclusion and a silicone heel cup.
45781843|NCT01271543|Device|Endotracheal Intubation|General anesthesia will be induced with fentanyl 1-2 mcg/kg, 2-3 mg/kg propofol and maintained with 50% air /50% oxygen and isoflurane. Neuromuscular blockade will be obtained with rocuronium 0.5 mg/kg. Laryngoscopy will be performed with Shikani optical stylet (SOS) (one size) or MacIntosh laryngoscope blade size 3 for women and size 4 for men. Endotracheal intubation will be performed with an endotracheal tube of internal diameter of 7.0 mm l for female patients and 8 mm for male in both groups. Noninvasive blood pressure and heart rate will be recorded preinduction, preintubation, and every min for the first 5 min after successful intubation. The patients will be questioned post-operatively about symptoms of a sore throat, hoarseness, dysphonia or dysphagia in the Post Anesthesia Care Unit and again 24 hours after surgery.
45781844|NCT05655572|Other|Action Observation Theraoy|After initial baseline assessment patients allocated in AOT group will undergo treatment protocol of 6 weeks having 4 stages of duration 1.5 weeks each performed 3 days per week. . Assessment will be perform at baseline after 2, 4 and 6 weeks
45781845|NCT05655572|Other|Functional Training|after baseline assessment participants including in this group will perform the tasks for 6 weeks (3 days per week) s and after that again assessment will be made for examining the improvements.Assessment will be perform at baseline after 2 ,4 and 6 weeks
45781846|NCT01323959|Biological|BoostrixTM Polio|Single dose, intramuscular administration.
45917366|NCT04846504|Behavioral|MMBFM program with peer coach support|Peer-delivered telephonic coaching to support participants in the Mindful Mood Balance for Moms online course for prevention of depression relapse/recurrence among perinatal women who have had prior episodes of depression but are not currently depressed. Peers will be women with lived experience of perinatal depression who are trained on the coaching protocol.
45642820|NCT05025956|Drug|Fisetin|Oral Fisetin 20 mg/kg taken for 8 days total.
45642821|NCT05025956|Drug|Placebo|Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 8 days total.
45642822|NCT05024292|Procedure|in situ ischemic postconditioning (ISIPC)|with 5 circules of balloon inflations in the ipsilateral internal carotid artery, each circulation includes inflation lasting 15 seconds followed by 15 seconds of deflation
45642823|NCT05023967|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
45642824|NCT05023967|Drug|Extended Release Metformin Hydrochloride|Given PO
45642825|NCT05023967|Other|Monitoring|Use continuous glucose monitoring system
45781847|NCT05652608|Behavioral|Immune Strength|Multi-week wellness program provided by the Cleveland Clinic
45781848|NCT00792428|Device|Real Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
45781849|NCT00792428|Device|Sham Transcranial Direct Current Stimulation|A sham current runs between two electrode positions and might affect the underlying brain tissue.
45917367|NCT04846504|Behavioral|Patient facing strategy intervention arm|Direct outreach and recruitment of participants into Mindful Mood Balance for Moms study by study teams. Participants will be women receiving prenatal care at the 4 study sites: Kaiser Permanente Colorado, Southern California, and Georgia, and HealthPartners.
45917368|NCT04846504|Behavioral|Patient facing plus clinic facing strategy intervention arm|Direct outreach and recruitment of participants into Mindful Mood Balance for Moms study by study teams, plus recommendation of / referral to the Mindful Mood Balance for Moms study by OB clinicians at the 4 study sites. OB clinicians will choose from printed materials (e.g., flyers, posters in exam rooms and waiting rooms, prescription pads) and electronic medical record prompts (e.g., smart lists, dot phrases) to facilitate engagement in the Mindful Mood Balance for Moms course. Participants will be women receiving prenatal care at the 4 study sites: Kaiser Permanente Colorado, Southern California, and Georgia, and HealthPartners.
45917369|NCT00000564|Procedure|oxygen inhalation therapy|
45917370|NCT04842253|Device|High flow nasal cannula|HFNC during deep sedation undergoing radiofrequency ablation for atrial fibrillation.
45917371|NCT04841629|Other|PreBioGyn Gel|Cellulose-based prebiotic gel developed to optimize vaginal health and reduce the risk of cervical cancer in women.
45642826|NCT05023967|Other|Nutritional Assessment|Receive nutritional counseling
45642827|NCT05023967|Other|Short-Term Fasting|Perform intermittent fasting
45642828|NCT05022264|Diagnostic Test|RIA-VS|Measuring vital signs with a new contactless camera technique
45642829|NCT05022004|Drug|Brinzolamide ophthalmic suspension|dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
45781850|NCT05201612|Drug|Olaparib|Olaparib 300 mg, orally (po), twice a day (BID) continuously
45781851|NCT05201612|Drug|Pembrolizumab|Pembrolizumab 200 mg, intravenously (IV), every 21 days. Max 2 years (i.e. 35 cycles)
45781852|NCT01271855|Drug|Belladonna and opioid suppository|Belladonna and opioid suppository 16.2mg/30mg per rectum every 8 hours for 24 hours following delivery
45781853|NCT01271855|Drug|Glycerin Suppository|A vegetable oil suppository (placebo) per rectum every 8 hours for the first 24 hours following delivery.
45642830|NCT05022004|Drug|Azopt®|dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
45781854|NCT03803852|Device|Intraocular Lens Implantation|"Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impressinto the capsular bag using an injector, after removing of the human cristalline lens.~Implantation of the Alcon Clareon toric IOL on the axis according to the steep meridian of the cornea"
45781855|NCT00777764|Drug|Cohort I|"In sterile water for injection (SWFI), full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:1000, 1:100 and 1:10 were followed by 20 minutes of observation. For the skin prick test, participants were tested initially with positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~Dilutions of omalizumab and its excipients were in SWFI."
45781856|NCT00777764|Drug|Cohort 2|"In a saline solution, full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:100,000 and 1:10,000 were followed by 20 minutes of observation.~For the skin prick test, participants were tested initially by positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~Dilutions of omalizumab and its excipients were made in saline."
45781857|NCT00808340|Device|balafilcon A|multifocal contact lens
45781858|NCT00808340|Device|senofilcon A production|multifocal contact lens
45781859|NCT00808340|Device|senofilcon A test|multifocal contact lens
45781860|NCT04865978|Drug|Apixaban|Patients randomized to apixaban will be started on a dose of 5 mg BID.
45781861|NCT04865978|Drug|Warfarin|Patients randomized to warfarin will be started on a dose per institutional protocol and titrated to an INR goal of 2.0 - 2.5.
45781862|NCT04865978|Device|LVAD implant|Subjects will undergo HeartMate 3 LVAD implant prior to randomization
45448912|NCT02148094|Drug|Truvada|The demonstration project will use a prospective cohort design, enrolling individuals and following them up at multiple intervals over the course of 16 months. Study participants will be asked to take one tablet of Truvada daily, as HIV Pre-Exposure Prophylaxis, over this period. They will be asked to attend 7 regular visits at the project sites over the course of the project. In between visits, they will receive peer educator home visits every other day, as part of regular DMSC (Kolkata) and Ashodaya (Mysore/Mandya) outreach prevention activities. We plan to enroll 2000 female sex workers equally split between the two sites.
45448913|NCT02148172|Procedure|Standard Plyometric Training|Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises.
45642831|NCT05014672|Drug|Setanaxib|Oral tablets, 400mg per tablet
45781863|NCT01354145|Drug|Chondroitin sulfate|Chondroitin sulphate 1200 mg/day, 24 months treatment period
45781864|NCT01354145|Drug|Celecoxib|Celecoxib 200 mg/day, 24 months treatment period
45917372|NCT04841629|Other|Trimosan Gel|Carbomer-based gel
45917373|NCT04841629|Other|RepHresh Gel|Carbomer-based gel
45917374|NCT04833283|Device|ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT)|Perform 4 trainings daily of intermittent hypoxic hyperoxic trainings before surgery, using 40 min trainings periods, the patient will receive air with reduced oxygen content (12 %) through a mask under constant monitoring of heart rate (HR) and SpO2. As a safety measure, minimal SpO2 was set at 82 % and maximal accepted increase of heart rate was set to + 50 % of the initial HR. When these values would be reached, the supply of oxygen automatically switched to a hyperoxic gas mixture (35% - 40% O2), inhaling of which would be continued until SpO2 reached 100% (even if SpO2 would be lower before the procedure), which, depending on the rate of saturation reduction, will takes 1 to 3 min (mean 1 min and 50 s).
45448914|NCT02148172|Procedure|Plyometric Training with BWS|Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises while their body weight is supported via adjustable harness.
46070778|NCT00906698|Drug|Vinorelbine per os 60 mg/m²|Patients will receive 60 mg/m² Vinorelbine per os at J1 J8 and J15
45642832|NCT05014672|Drug|Placebo|Oral tablets
45642833|NCT05013229|Drug|IcoSema|Participants will receive a once weekly subcutanous (s.c.) injection of IcoSema, on the same day every week for 52 weeks.
45642834|NCT05013229|Drug|Insulin glargine|Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
45642835|NCT05013229|Drug|insulin aspart|Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
45781865|NCT05168462|Drug|Reduced noradrenaline use|Reduced noradrenaline by using a lower MAP target
45781866|NCT04383782|Behavioral|Expectancy Challenge|Expectancy challenge intervention (see description in study arms).
45781867|NCT04383782|Behavioral|Expectancy Challenge + Behavioral Activation|Expectancy challenge + behavioral activation interventions (see description in study arms)
45781868|NCT04383782|Behavioral|Control|Neutral reading condition (see description in study arms).
45781869|NCT02196857|Drug|Azacytidine|75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) on Days 1 - 7 for a 28 day cycle.
45781870|NCT02196857|Drug|Sorafenib|400 mg by mouth twice daily about 12 hours apart, every day for a 28 day cycle.
45781871|NCT01272245|Drug|Omacetaxine|1.25 mg/m2 subcutaneously (SQ) every 12 hours (+/- 3 hours) for 3 days (Days 1-3). Each cycle will be 4-7 weeks.
45781872|NCT01272245|Drug|Cytarabine|20 mg subcutaneously every 12 hours (+/- 3 hours) for 7 days (Days 1-7). Each cycle will be 4-7 weeks.
45781873|NCT00802100|Drug|Olanzapine|Daily tablets of 10 to 30 mg
45781874|NCT00802100|Drug|Perphenazine|Daily tablets of 8 to 24 mg
45781875|NCT00802100|Drug|Aripiprazole|Daily tablets of 10 to 30 mg
45642836|NCT05012254|Drug|Ipilimumab|"Patients will receive Ipilimumab 1mg/Kg administered by IV infusion every 42 days (Q6W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: is a fully human monoclonal antibody with two heavy chains and two kappa light chains linked together by way of disulfide bonds. The molecular weight is approximately 148 kDa and it exists in solution at a physiologic pH of 7.0.~Route of administration: Intravenous infusion."
45642837|NCT05012254|Drug|Nivolumab|"Patients will receive Nivolumab 360 mg administered by IV infusion every 21 days (Q3W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~Route of administration: Intravenous infusion."
45781876|NCT00802100|Drug|Metformin|Daily tablets of 850 to 2550 mg
45448916|NCT03543904|Procedure|Pre-operative physiotherapy education|"Pre-operative education regarding post-operative physiotherapy intervention in children with abdominal surgery which includes,~Deep breathing exercises~Pursed lip breathing exercises~Diaphragmatic breathing exercises~Leg ROM (active hip and knee flexion, extension and abduction exercises)~Ankle toe movements exercises"
45448917|NCT03543904|Procedure|Post-operative physiotherapy intervention|"Post-operative physiotherapy intervention which includes,~Deep breathing exercises~Pursed lip breathing exercises~Diaphragmatic breathing exercises~Leg ROM (active hip and knee flexion, extension and abduction exercises)~Ankle toe movements exercises"
45642838|NCT05012254|Drug|Carboplatin|"Patients will receive Carboplatin AUC 5 or 6 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosa or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center."
45642839|NCT05012254|Drug|Cisplatin|"Patients will receive Cisplatin 75mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: (CAS No. 15663-27-1, MF-Cl2H6N2Pt; NCF-119875), cisplatinum, also called cis-diamminedichloroplatinum(II), is a metallic (platinum) coordination compound with a square planar geometry. It is a white or deep yellow to yellow-orange crystalline powder at room temperature.~Stability: Do not store above 25°C. Do not refrigerate or freeze. Keep container in the outer carton to protect from light. Following dilution in 0.9% sodium chloride injection, chemical and physical in-use stability has been demonstrated for up to 14 days at 20°C.~Route of administration: Intravenous infusion. Guidelines of Cisplatin administration: According to the standard of each center."
45781877|NCT00802100|Drug|Simvastatin|Daily tablets of 20 to 40 mg
45781878|NCT00802100|Drug|Benztropine|Daily tablets of 1 to 2 mg
45781879|NCT01354691|Drug|ladostigil hemitartrate|Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.
45781880|NCT00809276|Drug|Busulfan, Fludarabine, Cytoxan|"Busulfan once a day for 4 days~Fludarabine once a day for 4 days~Bone marrow transplant~Cytoxan two doses"
45781881|NCT03009617|Behavioral|the educational program and counseling|to examine the effectiveness of web-based health education and consultation on health promotion behaviors of adolescents, their e-health literacy, and their information levels.
45781882|NCT04024670|Other|Arts Intervention|If selected for the arts activity, an artist in residence will visit you 3 times a week for a total of 3 weeks during your hospital stay. Two visits will focus on the arts activity and one visit will be the administration of the questionnaire. Each visit will be approximately 25 minutes at a time.
45781883|NCT01355471|Drug|CD07805/47 Gel|applied topically once daily
45781884|NCT01355471|Drug|Placebo|applied topically once daily
45448918|NCT02148328|Biological|Trivalent virosomal influenza vaccine|Trivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
45781885|NCT00802412|Drug|Topiramate|Topiramate will be titrated over 5 weeks to a maximum dosage of 200 mg according to the following schedule: 25mg daily for days 1-7, 50mg daily for days 8-14, 75mg daily for days 15-21, 100mg daily for days 22-28, 150mg daily for days 29-35, 200mg daily for days 36-42. Maximum dosage will be maintained for 6 weeks, followed by a one-week taper-off period (100mg daily for 4 days and 50mg daily for 3 days).
45781886|NCT00802412|Drug|Placebo|Placebo/study medication will be administered in opaque capsules in an identical fashion to maintain the double-blind study design.
45781887|NCT01355705|Drug|Amrubicin|40, 60, or 80 mg/m2 intravenous (IV)
45781888|NCT01355705|Drug|Lenalidomide|15 mg daily by mouth
45781889|NCT01355705|Drug|Dexamethasone|40 mg weekly by mouth
45781890|NCT01355705|Drug|Aspirin|81 or 325 mg daily by mouth
45781891|NCT01355705|Drug|Pegfilgrastim|6 mg subcutaneous on Day 2
45781892|NCT05136092|Dietary Supplement|Cohort 1: HFCS (fructose) fed|"Day Before Surgery Subjects will prepare the sugar solutions (Fructose-containing solution: 250 mL of water containing 41.25 g of D-Fructose and 33.75 g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between 09:00 pm and 10:00 pm.~Samples collected before surgery:~Blood sample of 5 ml~Urine Samples 5 ml~Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed~Blood sample of 5 ml blood will be obtained from the IV line~Tissue samples~2 Tumor tissue samples 5mmx5mmx5mm,~2 Intestinal /colon tissue samples 5mmx5mmx5mm~2 tissue samples from mesentery tissue 5mmx5mmx5mm~Liver Biopsy - a 3-5 mm liver tissue will be obtained for research.~Urine Samples 5 ml"
46070779|NCT00906698|Drug|Vinorelbine per os 80 mg/m²|Patients will receive 80 mg/m² Vinorelbine per os at J22
46070780|NCT00906698|Drug|Vinorelbine i.v. 25 mg/m²|Patients will receive 25 mg/m² of Vinorelbine i.v.
45781893|NCT05136092|Dietary Supplement|Cohort 2: D-Xylose (xylose-fed)|"Day Before Surgery~Subjects will prepare the sugar solutions (Xylose-containing solution: 250 mL of water containing 41.25 g of D-Xylose and 33.75g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between 09:00 pm and 10:00 pm.~Samples collected before surgery:~Blood sample of 5 ml~Urine Samples 5 ml~Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed~Blood sample of 5 ml blood will be obtained from the IV line~Tissue samples~2 Tumor tissue samples 5mmx5mmx5mm,~2 Intestinal /colon tissue samples 5mmx5mmx5mm~2 tissue samples from mesentery tissue 5mmx5mmx5mm~Liver Biopsy - a 3-5 mm liver tissue will be obtained for research.~Urine Samples 5 ml"
46070781|NCT00972023|Drug|DHEA|DHEA administration will begin approxiately 14 days prior to surgery.
45448919|NCT02148328|Biological|Commercial vaccine 1|Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
45781894|NCT03009071|Procedure|Doin (conduction exercise)|Doin (conduction exercise) will be combined with acupuncture as active and passive movement to the aim of effective treatment of pain and functional disability. Doin (conduction exercise) sessions will be conducted 2 times a week for 5 weeks.
45781895|NCT03009071|Device|Acupuncture|Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks.
45781896|NCT01274585|Device|Posterior tibial nerve stimulation (PTNS)|Stimulation using PTNS device for 30 minutes weekly for 12 weeks
45781897|NCT01274585|Device|Posterior tibial nerve stimulation|Sham needle placement without active PTNS device for 30 minutes weekly for 12 weeks
45781898|NCT01327157|Procedure|occlusal adjustment.|It prompted the patient to perform the act of swallowing for 3 times to reach a terminal axis of rotation of the jaw and from this to start. Will be held palpation of the muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth. After starts the adjustment following the rules of Guichet with a cylindrical drill with a thin cut . basic principles 1 Occlusive stress maximum distribution in centric relation 2 The occlusive strengths should by the teeth's major axis.3 When the contact is surface to surface, it must be exchanged to another surface point. 4 Once the stability to the centric relation is achieved, it should be kept. The rules to guide the occlusal adjustment selective grinding .
45781899|NCT01327157|Behavioral|Visual analog scale.|"Visual analog scale-Graduation was held on the visual analogue scale in the first and last query to measure discomfort chewing.Graduation was held on the visual analogue scale .in the first and last query to measure discomfort chewing. After graduating dental cleaning was performed, with the purpose of blinding the study, Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient.~Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient."
45781900|NCT00802880|Drug|Dacarbazine|
45781901|NCT04814186|Drug|Tafamidis|61 mg, once daily, oral administration, for 12 months.
45781902|NCT04382378|Device|neuromuscular electrical stimulation|application of an electric current through electrodes placed on the skin over the targeted musclesto induce skeletal muscle contractions
45917375|NCT04833283|Device|ReOxy Cardio device|Perform 4 trainings daily of intermittent hypoxic-hyperoxic trainings before surgery, using 40 min trainings periods, whereas moistened air will be delivered through a mask under constant monitoring of heart rate (HR) and SpO2.
45917376|NCT04826068|Behavioral|Emotional Processing|Processing Emotions of others based on photographs of faces
45917377|NCT00000567|Procedure|high-frequency ventilation|
45917378|NCT04820335|Behavioral|Structured External Memory Aid Treatment (SEMAT)|"During the 7 weeks of treatment, the interventionist will teach 3 categories of external memory aids (calendars, timers, notes) following an already-developed detailed treatment manual (described here briefly).~Week 1: Introduction of External Memory Aid Treatment and Person-Centered Goal Setting. Weeks 2-7. In the next six weeks, three categories of external memory aids will be taught: calendars, timers, and notes. The focus of the first session will be how to use the strategies, and the second session will build awareness of when to use these strategies during everyday tasks. Within each category, three types of strategies will be taught to participants. Within each session, learning phases will follow training stages from compensatory learning theory: 1) acquisition phase, 2) application phase, and 3) an adaptation phase."
45917379|NCT04806685|Behavioral|Sleep education|Medical nutrition therapy plus behavior-based sleep education intervention
45917380|NCT04806685|Behavioral|Diet only|No sleep education
45917381|NCT04802746|Drug|Alprazolam|Study participants will receive Staccato alprazolam Dose 1 and Staccato alprazolam Dose 2 at pre-specified time points in Part A. Study participants will receive single dose of Staccato alprazolam at pre-specified time points in Part B.
45917382|NCT04802746|Other|Placebo|Study participants will receive Staccato placebo at pre-specified time points in Part A and Part B matching the pre-specified Staccato alprazolam dosing.
45781903|NCT04932824|Biological|SCB-2019|a Recombinant SARS-CoV-2 Trimeric S-Protein Subunit Vaccine for COVID-19.
46070782|NCT00972023|Procedure|Surgical resection|Surgical procedure of the invasive breast cancer
46070783|NCT04223414|Device|Analgesia Nociception Index (ANI)|"ANI will be used to analyse the autonomic nervous system's response to volume expansion.~ANI will be assessed during surgery, before during and after the volume expansion"
45448920|NCT02148328|Biological|Quadrivalent virosomal influenza vaccine|Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
45448921|NCT02148328|Biological|Commercial vaccine 2|Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
45642840|NCT05012254|Drug|Paclitaxel|"Patients will receive Paclitaxel 200mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
46070784|NCT03396926|Biological|Bevacizumab|Given IV
45781904|NCT05118854|Drug|AMG 510|Given by IV
45781905|NCT05118854|Drug|Cisplatin|Given by IV
45781906|NCT05118854|Drug|Carboplatin|Given by IV
45781907|NCT05118854|Drug|Pemetrexed|Given by IV
45781908|NCT03839888|Drug|0.125% Atropine|patients used 0.125% atropine eyedrop per night before sleep for 7 days.
45781909|NCT03839966|Behavioral|Interpretation Bias Modification for Loneliness|Participants will receive eight treatment sessions. They will be presented with ambiguous training scenarios on a computer screen. Scenarios will be presented in two discrete formats: a word-sentence relatedness task (adapted from Beard & Amir, 2008 and Beard, Weisberg, & Amir, 2011), and a sentence completion and comprehension task (adapted from paradigms used by Mathews and Mackintosh (2000), Steinman and Teachman (2010), and Beard and Amir (2008)). Both of these formats have been used to reduce maladaptive threat interpretations and increase benign interpretations.
45781910|NCT03839966|Behavioral|Healthy Habits Psychoeducation and Relaxation|Participants will receive eight computerized sessions consisting of psychoeducation on healthy behaviors as well as relaxing video clips with pleasant music (e.g., videos of rainforests, wildlife, and space). These sessions will be matched for time with the active condition, lasting approximately 25-30 minutes each. Psychoeducation will cover the topics of exercise, diet, hygiene, social support, healthy activities, and sleep. The relaxing videos will be presented after the psycho-education in each session. At the conclusion of the study, participants will be provided with the active IBM treatment free of charge if they wish to receive it.
45781911|NCT04000880|Behavioral|Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health|AMPLIFI will provide participants with a secure website where they receive and participate in educational sessions tailored to their assigned topics for the intervention arm. The website will provide a resource library for static documents, tips of the day, tracking of health behaviors, and goal-setting.
45781912|NCT04000880|Other|Diet-Exercise|Diet-Exercise
45781913|NCT04000880|Other|Exercise-Diet|Exercise-Diet
45781914|NCT04000880|Other|Combined Diet and Exercise|Combined Diet and Exercise
45781915|NCT03839654|Device|continuous positive airway pressure|The CPAP treatment group received both baseline medicine and CPAP treatment for 7 days preoperatively.
45781916|NCT04768868|Drug|IMP7068|To evaluate the safety tolerability, pharmacokinetics, and anti-tumor activity of the WEE1 inhibitor IMP7068 monotherapy in patients with advanced solid tumors
45781917|NCT04754048|Device|Avance Solo NPWT System|Wound treatment with Avance Solo NPWT System for up to 28 days.
46070785|NCT03396926|Drug|Capecitabine|Given PO
45448922|NCT03749668|Other|non applicable|no intervention in this observational study
45452519|NCT01093547|Procedure|Measure of peritoneal ultrafiltrates|Measured by the investigators intermittently and by the patients themselves on a monthly basis
45781918|NCT05089526|Drug|ketamine-lidocaine-dexmedetomidine|"In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving~1mL/10kg/h of the aforementioned solution."
45781919|NCT05089526|Drug|fentanyl|In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
45781920|NCT04645550|Drug|Apixaban|From postoperative day 3, patients will receive oral Apixaban 2.5mg bid for six months.
45781921|NCT04645550|Drug|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for six months.
45781922|NCT04645550|Drug|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for six months.
45781923|NCT04645550|Drug|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
45781924|NCT04645550|Drug|Low molecular weight heparin|From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
45781925|NCT05046080|Other|Electronic Health Record Review|Medical records reviewed
45781926|NCT05046080|Other|Laboratory Biomarker Analysis|Correlative studies
45781927|NCT05040776|Drug|EP-7041 Injection|EP-7041 infusion
45917383|NCT00000573|Procedure|enteral nutrition|
45917384|NCT00000576|Drug|beclomethasone|
46070786|NCT03396926|Other|Laboratory Biomarker Analysis|Correlative studies
46070787|NCT03396926|Biological|Pembrolizumab|Given IV
46070788|NCT00971945|Drug|Paclitaxel|Solution, I.V., 100 mg/m2, Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
45781928|NCT00804596|Device|Apollo Blood Glucose Monitoring System|Subjects with diabetes were rated for success in performing tasks with a new blood glucose monitoring system (BGMS). Also, subjects and healthcare professionals (HCPs) used the new blood glucose monitoring system with subject capillary blood. All blood glucose results were compared to a laboratory glucose method - Yellow Springs Instrument(YSI) Analyzer.
45781929|NCT01327313|Biological|EMD525797|Subjects will receive 250 milligram (mg) of EMD525797 intravenously every 2 weeks, until progressive disease (PD), unacceptable toxicity or withdrawal of consent.
45781930|NCT01327313|Biological|EMD525797|Subjects will receive 500 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity or withdrawal of consent.
45781931|NCT01327313|Biological|EMD525797|Subjects will receive 1000 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity or withdrawal of consent.
45781932|NCT01327313|Biological|EMD525797|Subjects will receive 1500 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity, or withdrawal of consent.
45781933|NCT04382846|Drug|Nitazoxanide|Nitazoxanide
45781934|NCT04641260|Drug|Fezolinetant|Oral
45781935|NCT02200055|Device|Bodystat Quadscan 4000|"Each patient involved in the study will be evaluated with a bioimpedance monitor to assess total body water, estimated body water, and intravascular body water volume preoperatively, postoperatively, and daily during the postoperative recovery period.~Bioimpedance Assessment"
45781936|NCT05032820|Drug|Lenalidomide and bb2121|Patients complete apheresis and proceed to lymphodepleting chemotherapy with cyclophosphamide 300mg/m2 and fludarabine 30mg/m2 for 3 consecutive days followed by the infusion of BCMA CAR T-cells at a target dose of 450 x106 cells. Maintenance lenalidomide, starting at 10mg a day for 21 days of a 28-day cycle will be initiated at a minimum of at least 30 days, but no later than 180 days after the CAR T-cell infusion and will continue until the patient reaches 12 months post CAR T-cell infusion and continue free of progression.
45781937|NCT02200523|Device|SARA electrode|
45781938|NCT02200523|Device|Gold cup|
45642841|NCT05012254|Drug|Pemetrexed|"Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrol [2,3 d]-pyrimidine based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center"
45781939|NCT01328405|Device|Laryngeal Mask Airway (LMA)|Comparison of airway seal pressure, airway morbidity bronchoscopic view obtained between two different laryngeal mask airways.
45781940|NCT05021510|Other|Simultaneous Cervical Traction & Neural Mobilization|Simultaneously Mechanical Cervical traction with Neural Mobilization of the upper limb for 3 times a week, 45 minutes per day for 4 weeks
45781941|NCT05021510|Other|consecutive Cervical Traction & Neural Mobilization|consecutive Mechanical Cervical traction with Neural Mobilization of the upper limb for 3 times a week, 45 minutes per day for 4 weeks
45781942|NCT04639622|Diagnostic Test|Investigation procedures|All participants will be assessed longitudinally with a set of clinical evaluation, neuropsychiatric and cognitive assessments, imaging (MRI and PET scans) and biosample (CSF, blood samples)
45781943|NCT01274897|Biological|Novartis MenACWY-CRM|All subjects had blood drawn at Day 1 and Day 29.
45781944|NCT01274897|Biological|Saline Placebo|All subjects had blood drawn at Day 1 and Day 29.
45781945|NCT04693130|Behavioral|Mindfulness-based prenatal education|Mindfulness-based prenatal education involves mindfulness breathing and other skills with mindfulness meditations.
45781946|NCT04693130|Behavioral|Hospital-based antenatal care|Hospital-based antenatal care involves all aspects of pregnancy, childbirth and postpartum.
45781947|NCT03947840|Behavioral|Physical activity|Se their physical activity level
45781948|NCT02323217|Radiation|[11C]BU99008|Baseline Scan, Test-ReTest or Dosimetry
45781949|NCT02323217|Drug|Idazoxan|Idazoxan block of [11C]BU99008
45917385|NCT04782505|Drug|DWJ1248|Camostat mesylate Tablet from Daewoong
45448923|NCT03544840|Other|Physical Therapy Home Program|On the first day of the intervention phase (B), the PI will deliver the dynamic standing home program device (Upsee) to the parent and child. The PI will provide training and education to the parent on the device and home program. At the weekly visit to score outcome measures, the PI will check the fit of the devices, ensure compliance, and answer any questions about the home program. Parents will be encouraged to use the device with their child 5 days per week, 30 minutes per day. Parents will keep a daily log sheet to record duration of device use, activities performed, and subjective observations of the child during the intervention (Appendix K). The PI will collect these log sheets each week. The baseline phases (A1 and A2) will last 4 weeks and the intervention phase (B) will last 6 weeks. Part 2 of the study is expected to last 14 weeks.
45642842|NCT05012241|Diagnostic Test|Nine Hole Peg Test|At first, each patient will be asked to fill in the questionnaire. Then he/she will be tested by the Nine Hole Peg Test according to the new Czech version of extended manual for this test. Audio recording of verbal instructions will be used.
45781950|NCT02323217|Drug|Isocarboxazid|Isocarboxazid block of [11C]BU99008
45781951|NCT05002322|Other|Systems Analysis and Improvement Approach|"Intensive phase: district MOH supervisors receive a one-week training on SAIA-HTN. The first year of implementation will be mentored by INS study personnel who will accompany and support district MOH supervisors as they implement at the facility level. Over the first week of each iterative cycle, facility teams populate and interpret the HCAT, develop process maps, define one to two micro-interventions and indicators to monitor these modifications. Facility teams receive bi-weekly mentorship visits by district supervisors and study personnel for the first two months, followed by monthly visits throughout intensive implementation.~Sustainment phase (7, 14 or 21 months, depending on implementation wave allocation): district supervisors will independently lead implementation, with financial support for travel to clinics and to hold meetings, but without intensive support from study personnel."
45781952|NCT01275053|Drug|leptin|0.01mg/kg
45781953|NCT02324075|Behavioral|Behavior change|Non governmental organization delivers communication intervention with facilitating hardware, a waste bin and bucket
45781954|NCT04979234|Device|Endomina- Endoscopic Sleeve Gastroplasty|Endoscopic gastric reduction
45917386|NCT03036007|Other|Prescribed Physical Activity|General physical activity prescribed by a physiotherapist
45917387|NCT03036007|Other|Exercises with Internet support|Neck-specific exercise with Internet support
45917388|NCT00000579|Procedure|Low Tidal Volume Ventilation|
45781955|NCT04979234|Behavioral|Diet|Multidisciplinary follow up
45781956|NCT04382768|Drug|Inhaled Hypertonic ibuprofen|Standard of care plus lipid ibuprofen 50mg tid
45781957|NCT03932162|Drug|Insulin-Like Growth Factor 1|Growth factor protein
45781958|NCT03932162|Other|No Insulin-Lie Growth Factor 1|No Insulin-Like Growth Factor 1 will be given.
45781959|NCT04617548|Combination Product|tDCS and CO-OP Group|Transcranial direct current stimulation modulates the excitability of targeted brain regions, and is thought to facilitate or inhibit neuroplasticity. Participants will receive anodal tDCS (1.5 mA) to the dorsolateral prefrontal cortex (dlPFC) for 20 minutes at the beginning of each session. CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the Goal-Plan-Do-Check process.The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
45781960|NCT04595474|Device|Transient Elastography|Transient elastography is a noninvasive imaging modality used to assess NAFLD and advanced fibrosis
45781961|NCT03839108|Other|Paraffin wax|Paraffin group patients will be told to take of jewellery and dip their hands into the bath of melted wax (52 ºC) with hands open and hand wrist in neutral position for 10 times .In paraffin wax group, patients will be treated 5 days a week for 2 weeks period. Paraffin wax bath will be applied for 20 minutes in every physical therapy session.
45781962|NCT03839108|Drug|Prolotherapy|. Prolotherapy is a nonsurgical regenerative injection technique that introduces small amounts of an irritant solution to the site of painful and degenerated tendon insertions (entheses), joints, ligaments, and in adjacent joint spaces during several treatment sessions to promote growth of normal cells and tissues.Hypertonic dextrose solution is most common used agent. In prolotheraphy group, %15 dextrose solution will be applied to medial and lateral aspect of proximal interphalangeal joints (PIJ), distal interphalangeal joints and carpometacarpal joint of thumb for 3 sessions once a week period
45781963|NCT04553744|Other|Survey Administration|Complete survey
45781964|NCT00811382|Device|Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, with Home Monitoring feature)|Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, where the physician receives relevant daily data from the implant via Home Monitoring
45781965|NCT00811382|Device|Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, without Home Monitoring)|Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, without daily data transmission from the implant via Home Monitoring (except for the safety data on device integrity)
45642843|NCT05009121|Diagnostic Test|Box and Block Test|"At first, each person will be asked basic questions about present feelings according to their condition using a questionnaire. Than he/she will be tested by the Box and Block Test according to the Czech version of extended manual for this test in only one session. Audio recording of verbal instructions will be used.~The results will be used only for establishing of the variability and inter-rater reliability of the Box and Block Test, not for patients' other interventions."
45781966|NCT04155164|Drug|Metformin|Participants will receive Metformin at 1000mg for 12 months.
45781967|NCT04155164|Drug|Placebos|Placebo group will take Placebo at 1000mg for 12 months.
45781968|NCT00806078|Drug|quinine sulfate|2 x 324 mg capsules (648 mg)
45448924|NCT03544762|Drug|18F-FES PET|18F-FES PET will be performed for each patient. All patients will receive intravenously injection of 5-8 mCi (185-296 MBq) of 18F-FES. PET imaging will be performed on PET/CT system. The 1-frame dynamic data acquisition of thoracic region including the primary tumor will be started immediately after tracer injection. Whole-body PET acquisition from skull base to upper thigh will be started 60 minutes after tracre injection.
45448925|NCT02142010|Drug|paclitaxel liposome injection plus cisplatin|Paclitaxel liposome injection 80 mg/m2, given on days 1, 8,15 and 22 of a 28-day cycle. Cisplatin 25 mg/m2, given on days 1, 8 and 15 of a 28-day cycle, for 4 cycles(4 months)
45448926|NCT02142088|Device|GlySure Intravascular Continuous glucose monitoring sensor|Comparator device is an iSTAT device from Abbott Diagnostics
45781969|NCT00806078|Drug|quinine sulfate|2 x 324 mg capsules (648 mg)
45781970|NCT00806234|Drug|Aripiprazole or Perphenazine|Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.
45781971|NCT00806234|Drug|Metformin|Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.
45781972|NCT00806234|Drug|Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine|Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated
45917389|NCT00000579|Procedure|Positive End-Expiratory Pressure|
45917390|NCT00000579|Drug|Lysofylline|
45917391|NCT00000579|Drug|Methylprednisolone|
45917392|NCT00000579|Drug|Ketoconazole|
45917393|NCT00000579|Procedure|Fluid Management|
45781973|NCT00807560|Behavioral|FBT-PO|The goal of FBT-PO is to resolve the eating disorder and return the patient to healthy psychosocial and physiological developmental trajectories through active family involvement across three treatment phases.
45781974|NCT00807560|Behavioral|NEC|Families assigned to NEC will receive a minimal nutrition and physical activity education curriculum across 16 sessions over 24 weeks.
45781975|NCT04497428|Behavioral|Adaptation|Sensorimotor adaptation in speech
45781976|NCT04497428|Other|cTBS|continuous theta-burst stimulation
45781977|NCT03735680|Drug|ONM-100|A polymer micelle covalently conjugated to indocyanine green, an FDA-approved fluorophore
45781978|NCT04494074|Other|External Cooling|External Cooling
45781979|NCT04493138|Drug|Azacitidine|Given SC or IV
45781980|NCT04493138|Drug|Quizartinib|Given PO
45781981|NCT01275365|Drug|Testosterone enanthate|Testosterone enanthate 100 mg intramuscularly weekly
45781982|NCT01275365|Drug|Testosterone enanthate|Testosterone enanthate 100 mg intramuscularly weekly
45781983|NCT00811850|Drug|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
46070789|NCT03672500|Drug|Bupivacaine 0.5%+Epinephrine 50mc|Local infiltration of the perineum with Bupivacaine 0.5%+Epinephrine 50mc
45781984|NCT00811850|Drug|fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
45781985|NCT03678506|Drug|Apixaban|Apixaban 2.5 mg x 2 will be administered to patients with positive D-dimer results
45781986|NCT01328873|Other|Microbiological analysis|Bronchoalveolar lavage (BAL) with subsequent testing for pathogens
45781987|NCT00844298|Drug|Nilotinib+mVPD|"Induction:~Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3)~Vincristine 2 mg iv push (d1, 8, 15, 22)~Prednisolone 60 mg/m2/day po (d1-28)~Nilotinib 400mg bid/d (d8-)~Consolidation A (cycle1)~Daunorubicin 45 mg/m2/day by continuous iv (d1, 2)~Vincristine 2 mg iv (d1, 8)~Prednisolone 60 mg/m2/day po (d1-14)~Nilotinib 400mg bid/d~Consolidation B (cycles 2&4)~Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)~Etoposide 150 mg/m2/day iv over 3 hours (d1-4)~Nilotinib 400mg bid/d~Consolidation C (cycles 3&5)~Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)~Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,~Nilotinib 400mg bid/d~Maintenance~◦Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT)~Consider alloHCT"
45781988|NCT01329185|Drug|Valganciclovir|Valganciclovir 450mg twice a day for 14 days prior to transplant date
45781989|NCT01329185|Drug|Placebo|1 capsule twice a day for 14 days prior to transplant date
45781990|NCT01276301|Drug|Verapamil|single dose verapamil
45781991|NCT01276301|Drug|BI 10773|single dose BI 10773
45781992|NCT01276301|Drug|BI 10773|single dose BI 10773
45781993|NCT00845000|Drug|SCH 420814 10 mg|one 10-mg capsule, orally, at hour 0 of treatment period
45781994|NCT00845000|Drug|SCH 420814 100 mg|single oral dose of four SCH 420814 25-mg capsules at hour 0 of treatment period
46070790|NCT03672500|Other|Sham injection|Sham injection of the perineum
46070791|NCT00971867|Drug|Paclitaxel|Solution, I.V., 100 mg/m2 Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
45781995|NCT00845000|Drug|Placebo|Placebo capsule, oral, at hour 0 of treatment period
45781996|NCT00845000|Drug|Levodopa|levodopa intravenous (IV) infusion (1 mg/kg body weight) was beginning 1 hour after study drug administration and continued for 2 hours
45781997|NCT00845000|Drug|Carbidopa|one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period
45781998|NCT01330043|Drug|Bupropion|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
45781999|NCT01330043|Drug|Nicotine patch|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
45782000|NCT01330043|Drug|Varenicline|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
45782001|NCT01330355|Drug|Besivance|Besifloxacin hydrochloride 0.6% ophthalmic suspension, one drop instilled into infected eye, three times daily (TID) for 7 days
45917394|NCT00000579|Procedure|Pulmonary Artery Catheter|
45448927|NCT02142166|Procedure|Biomarker in serum, liquor, micro-dialysate|Daily (21 days) analysis of biomarker in serum, in liquor and in micro-dialysate
45642844|NCT05009108|Diagnostic Test|Purdue Pegboard Test|"At first, each person will be asked to fill in the informed agreement and answer short questionnaire. Than he/she will be tested by the Purdue Pegboard Test according to the Czech version of extended manuals for those tests in only one session. Audio recording of verbal instructions will be used and whole testing process will be video recorded which is necessary for establishing the internal variability and variability of results of the Purdue Pegboard Test.~The results will be used only for establishing of the variability and inter-rater reliability of the Purdue Pegboard Test, not for patients' other interventions."
45642845|NCT05009069|Radiation|Radiotherapy|Weeks 1-5: 45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.
45642846|NCT05009069|Drug|Capecitabine|Weeks 1-5: Capecitabine 825 mg/m^2 orally twice daily (bid) 5 days/week during radiotherapy.
45642847|NCT05009069|Drug|Fluorouracil|Weeks 1-5: fluorouracil (5-FU) 225 mg/m^2 intravenously (IV) over 24 hours 5 days/week during radiotherapy.
45642848|NCT05009069|Drug|Atezolizumab|Weeks 8, 11 and 14: Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle for 3 cycles.
45642849|NCT05009069|Drug|Tiragolumab|Weeks 8, 11 and 14: Tiragolumab 600 mg IV on Day 1 of each 21-day cycle for 3 cycles.
45642850|NCT05006404|Device|Pulmonary Valve Replacement Surgery|Pulmonary valve replacement surgery with the Autus Valve
45642851|NCT05005429|Drug|Bintrafusp alfa|"Bintrafusp alfa (M7824) is a bifunctional fusion protein composed of the extracellular domain of the transforming growth factor β (TGF-β) receptor II (a TGF-β trap) fused to a human immunoglobulin G1 antibody blocking programmed death-ligand 1 (PD-L1).~Day 1 of week 1 of treatment will start within 1-5 days from enrollment. Cycles will be administered every 2 weeks (±3 days) until progression or other reason to discontinue. If a pseudoprogression is suspected patient is allowed to continue treatment until loss of clinical benefit as judged by principal investigator and after the permission from the trial chair is granted.~On Day 1 of each cycle (QW2), all eligible patients will receive:~Bintrafusp alfa (M7824): 1200mg, IV infusion over 60 minutes Current experience revealed that IRRs to bintrafusp alfa occur seldomly and are generally mild to moderate in severity. Therefore, administration of a premedication is generally not required."
45642852|NCT05005052|Drug|Vessel|Sulodexide has protective effect on the endothelium, antithrombotic, fibrinolytic and anti-inflammatory effects. In the last 20 years, it has been well established in the common practice and its efficacy and safety have been demonstrated notably in the treatment of venous diseases such as post-thrombotic syndrome of the lower extremities, secondary prevention of deep and superficial venous thrombosis, supportive treatment of leg venous ulceration, ischemic disease of the lower limbs; symptomatic therapy of intermittent claudication, treatment of diabetic ulcers and microcirculation disorders of various aetiology. Patients with CVD were shown to respond quickly to sulodexide therapy in single arm observational studies. Sulodexide seems to provide both symptomatic and causal therapy.
45642853|NCT05005052|Drug|Placebo|Placebo and no compression or venopharmaceutical regimen
45642854|NCT05004311|Drug|Cenerimod|A single oral dose of 0.5 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions
45642855|NCT05002998|Drug|Teprotumumab|"Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20-mL glass vials as a freeze-dried powder containing, in addition to the drug substance, 20 mmol/L histidine-histidine chloride, 250 mmol/L trehalose and 0.01% polysorbate 20 (w/w).~Prior to administration, each vial containing 500 mg teprotumumab freeze-dried powder will be reconstituted with 10 mL of sterile water for injection. The resulting solution will have a concentration of 47.6 mg/mL teprotumumab-trbw antibody. The reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration"
45642856|NCT05002998|Drug|Placebo|Placebo will consist of a normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as appropriate, per weight-based dosing volumes.
45642857|NCT05002569|Biological|Nivolumab|Specified dose on specified days
45642858|NCT05002569|Biological|Nivolumab + Relatlimab Fixed Dose Combination|Specified dose on specified days
45642859|NCT05001139|Device|Relizema ecofoam|DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration
45642860|NCT04995978|Drug|Pioglitazone 30 mg|"Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily."
45642861|NCT04995978|Drug|placebo tablet|Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
45642862|NCT04995952|Behavioral|Gross motor training|Gross motor training activity (1 hour session, 3 times a week for 3 months). Pre ad post assessments will be taken. The Gross motor training activity will include: sit to stand, step-ups and walking. The sit to stand will be performed for 20 minutes involving 20 repetitions. We will progress from high seat sit to stand to low seat sit to stand. The step up will progress initially from a bench having low height to high height and then to stepping of stairs for 20 minutes involving 30 repetitions. The walking will occur from 3m walk and then increasing the distance
45754303|NCT05582954|Behavioral|EsteemUp|EsteemUp is a guided e-health application based on cognitive-behavioural therapy (CBT). It consists of four modules that take approximately 30 to 45 minutes to complete. Each module includes evidence-based psycho-education, reflection questions, interactive exercises, and homework assignments. The content is delivered both textually and visually, including the use of pictures, infographics and videos. Every week trained e-coaches (trained clinical psychology master students) will provide asynchronous written personalized feedback to each participant on the progress of the program and the exercises via the program platform.
45782002|NCT01330355|Drug|Gatifloxacin|Gatifloxacin 0.3% ophthalmic solution one drop instilled into infected eye, TID for 7 days
45448928|NCT02142166|Procedure|Biomarker in serum and in liquor|Single analysis of biomarker in serum and liquor
45448929|NCT02144896|Other|Ankle splinting|Ankle dorsiflexion splinting will be performed 30 minutes per day, 5 days per week for 4 weeks.
45448930|NCT02148406|Behavioral|Yoga Skills Training (YST)|Undergo YST
45448931|NCT02148406|Other|questionnaire administration|Ancillary studies
45448932|NCT02148406|Other|fatigue and depressive symptom assessment and management|Ancillary studies
45448933|NCT02148406|Other|psychological stress assessment|Ancillary studies
45782003|NCT01359371|Behavioral|Peer telephone cessation counseling|For Veterans who received the inpatient Tobacco Tactics intervention, trained volunteers initiated follow-up telephone cessation counseling at 2, 14, 21 and 60 days after in-patient discharge; three attempts were made per time point.
45782004|NCT01276535|Device|Erchonia MLS + Erchonia THL|"The Erchonia® MLS is administered weekly for 6 continuous weeks at the test site by the study investigator.~The Erchonia THL is administered twice daily for 6 continuous weeks (42 days) at home by the subject.~Administration of the MLS and the THL occur simultaneously over the 6-week administration phase.~The intent is to evaluate the effectiveness of Erchonia MLS & Erchonia THL when administered together, and not to compare Erchonia MLS vs. Erchonia THL"
45782005|NCT01360229|Procedure|Acupuncture|Subjects will be randomized in a 1:1 ratio to receive real acupuncture. Acupuncture is a procedure in which specific body areas are pierced with fine needles for therapeutic purposes
45782006|NCT01360229|Other|Acupuncture to treat fatigue in Parkinson disease|Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
45782007|NCT02193815|Drug|PF06263276|4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD
45782008|NCT02193815|Other|Vehicle|Active ingredient-free vehicle to 4% solution
45782009|NCT02193815|Drug|2%Tofacitinib Ointment|Daily Dosage: approximately 4 mg tofacitinib
45782010|NCT02193815|Other|Vehicle|Active ingredient-free vehicle to 2% Ointment
45782011|NCT02193815|Drug|Daivonex|Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
45782012|NCT02193815|Drug|Daivonex Ointment|Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
45917395|NCT04770142|Device|TIRA catheter|treat hypertrophic obstructive cardiomyopathy
45448934|NCT02148406|Other|laboratory biomarker analysis|Correlative studies
45448935|NCT02148406|Other|Attention Control|
45448936|NCT05054140|Drug|IMU-838|IMU-838 tablets
45448937|NCT05054140|Drug|Placebo matching IMU-838|Placebo matching IMU-838 tablets
45642863|NCT04995952|Behavioral|Trunk targeted training|"Trunk targeted training (1hour session, 3 times a week for 3 months). Pre and Post assessment will be evaluated. The trunk targeted training will include: weight supported treadmill walk, specific trunk exercises with vibration therapy and reaching forward to the limits of stability.~Specific trunk exercises will involve stride sitting to standing, sitting on a roll and moving the roll in diagonal and forward backward directions along with giving vibrational therapy on wobble board, side sitting. This activity will be performed for 30 minutes with 30 repetitions. Reaching forward to the limits of stability exercises will be performed. Asking the children to hold objects from right hand while reaching for an object on left side and vice versa. This will be performed for 20 minutes having 20 repetitions."
45642864|NCT04995523|Drug|AZD2936|Anti-TIGIT/Anti-PD-1 Bispecific Antibody
45642865|NCT04994509|Drug|Oral Lenacapavir (LEN)|Tablets administered orally without regard to food
45782013|NCT01277081|Drug|Paracetamol hot drink|Hot drink containing paracetamol
45782014|NCT01277081|Drug|Paracetamol tablets|Paracetamol tablets
45782015|NCT01361633|Drug|d-cycloserine|single oral administration of 250 mg d-cycloserine
45782016|NCT01361633|Drug|Sugar Pill|Single oral administration 250 mg Sugar Pill
45448938|NCT02142244|Procedure|Near infra red sentinel node biopsy|Explicated in the protocol arm
45448939|NCT02142244|Drug|Indocyanine green|Explicated in the protocol arm
45448940|NCT02142244|Device|Intraoperative Near-Infrared Imaging System|Explicated in the protocol arm
45448941|NCT02145052|Other|Continuous suture|A continuous suture is considered standard of care.
45448942|NCT02145052|Other|Interrupted suture|Interrupted sutures are considered standard of care.
45782017|NCT01331213|Drug|Pregabalin|FDA approved medication (capsules) at 200mg dose.
45782018|NCT01331213|Drug|Placebo|Placebo capsules
45782019|NCT01332071|Drug|Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg|Avandamet reference product
45782020|NCT01332071|Drug|Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg|Avandamet test product
45782021|NCT01277159|Drug|A. Control Nerve Block. IV Dexamethasone (4 mg).|A. Control Nerve Block. IV Dexamethasone (4 mg).
45782022|NCT01277159|Drug|B. Nerve Block with Dexamethasone (4 mg). IV saline.|B. Nerve Block with Dexamethasone (4 mg). IV saline.
45782023|NCT01277159|Drug|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
45782024|NCT01277159|Drug|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
45782025|NCT01277159|Drug|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
45782026|NCT01361867|Device|Robot-induced perturbations|A robotic system is used to generate mechanical perturbations and study how subjects generate motor adaptations in response to the mechanical perturbations.
45782027|NCT01277783|Device|Endocardial Left Ventricular pacing|Subjects receive an endocardial LV lead placement via superior approach using Medtronic Model 3830 lead and Medtronic Model 6227ATS deflectable delivery catheter and Medtronic Model 6248HS, 6248JL, or 6248JS delivery catheter, using trans esophageal echo (TEE) or intra-cardiac echo (ICE) to guide the procedure.
45782028|NCT01278485|Drug|Sulphonylurea|SU administered according to usual practice.
45782029|NCT01278485|Drug|Metformn|Metformin administered according to usual practice.
45782030|NCT01362959|Drug|Transdermal nicotine patch|The test product is a transdermal nicotine patch. The dosage of the test product depends on the amount of cigarettes used by a specific patient (21 or more or less than 21) delivering 21 or 14 mg nicotine/24 hrs. During the study period of thirty (30) days a patch will be applicated daily.
45782031|NCT01362959|Other|Cutaneous patch, containing no active substances|During the study period of thirty (30) days, the control product will be applicated daily.
45782032|NCT01278953|Device|Catheter ablation to treat paroxysmal atrial fibrillation|A pulmonary vein isolation procedure will be performed using radiofrequency ablation.
45782033|NCT01332461|Drug|fluticasone propionate/salmeterol xinafoate combination|Patients filling a prescription for fluticasone/salmeterol combination as index drug
45782034|NCT01332461|Drug|Other maintenance Treatments (OMT)|OMT group includes tiotropium, ipratropium alone or in combination with albuterol, inhaled steroids, long acting beta agonists
45782035|NCT01279109|Behavioral|Social network building intervention|Group support and 12 weekly health education/skills building sessions during pregnancy
45782036|NCT01279109|Behavioral|Home visit|Three home visits during pregnancy focused on providing education on infant injury prevention
45782037|NCT01279187|Drug|Teriparatide|20ug per day,via subcutaneous injection, for 7 weeks
45782038|NCT01279187|Drug|Placebo|20ug per day, self administered injection, for 7 weeks
45782039|NCT01279265|Dietary Supplement|Nutramigen with Enflora|Hypoallergenic formula with probiotic - Lactobacillus GG
45782040|NCT01279265|Dietary Supplement|Nutramigen A+|Hypoallergenic formula without lactobacillus
45782041|NCT00848510|Biological|EMD 525797|Abituzumab will be administered as an intravenous infusion for an hour at a dose of 250 milligram (mg) to 1500 mg at Weeks 1, 3 and 5. In case of clinical benefit (stable disease [SD], complete response [CR], or partial response [PR]) that will be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0) during initial 6 Weeks, subjects will be allowed to continue treatment at the start of Week 7 at the given dose (250 mg or 500 mg or 1000 mg or 1500 mg) every second week until intolerance to treatment, withdrawal of consent, or the subject is no longer benefiting from treatment in the opinion of the Investigator.
45782042|NCT00848744|Drug|Formulation A|Formulation A will be applied to the randomly-assigned single (left or right) side of the face twice daily.
45782043|NCT00848744|Drug|Formulation B|Formulation B will be applied to the randomly-assigned single (left or right) side of the face twice daily.
45782044|NCT03717974|Other|Telemedecine follow-up after an intervention at home of the mobile team|"After a first visit of the mobile team at home, patients are followed by telemedicine. Moreover, in case of pain, a specialized consultation by an algologist of La Sagesse will be realized."
45782045|NCT03717974|Other|Mobile team follow-up after an intervention at home of the mobile team|"After a first visit of the mobile team at home, patients are followed by mobile team. Moreover, in case of pain, a specialized consultation by an algologist of La Sagesse will be realized."
45782046|NCT03698708|Behavioral|CARES Intervention|A group-based telemedicine intervention to treat depression in parents/caregivers of children with T1D using a cognitive-behavioral approach.
45642866|NCT04994509|Drug|Subcutaneous (SC) Lenacapavir (LEN)|Administered via SC injections
45642867|NCT04994509|Drug|F/TAF|Tablets administered orally
45642868|NCT04994509|Drug|F/TDF|Tablets administered orally
45642869|NCT04994509|Drug|Placebo SC LEN|Administered via SC injections
45782047|NCT01280123|Drug|Pioglitazone|"Oral capsules of Pioglitazone (15 mg capsules) either 15 mg/qd or 45 mg/qd~Subjects will titrate in a blinded fashion to 30 mg/day after 2 weeks and to 45 mg per day) 2 weeks later as tolerated."
45782048|NCT01280123|Drug|placebo|Placebo will contain microcrystalline cellulose. An over-encapsulation process will be conducted in accordance with Clinical Good Manufacturing Procedures (cGMP) regulations to create a dosage form for the active study drug that will be indistinguishable from the comparator (Placebo) capsule.
45782049|NCT04345640|Other|no intervention|no intervention
45782050|NCT01280201|Drug|Pazopanib|Single arm of pazopanib 800 mg (2x400mg) given once daily as a single agent.
45782051|NCT00851006|Drug|Creatine Monohydrate|Creapure brand of creatine monohydrate
45782052|NCT01364207|Other|Caffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
45917396|NCT04762225|Biological|RPTR-168|Escalating doses of RPTR-168 as a monotherapy
45642870|NCT04994509|Drug|PTM Oral LEN|Tablets administered orally
45642871|NCT04994509|Drug|PTM F/TAF|Tablets administered orally
45642872|NCT04994509|Drug|PTM F/TDF|Tablets administered orally
45642873|NCT04994483|Drug|Simufilam|Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 52 weeks at a dose of 100 mg.
45642874|NCT04994483|Drug|Placebo|Matching placebo given b.i.d. for 52 weeks.
45782053|NCT01364207|Other|Decaffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
45782054|NCT03608696|Drug|Buprenorphine|buprenorphine 0.075 mg/ml solution
45782055|NCT02247089|Other|Massage Therapy|Intervention consists of administering a 30-minute-long upper body massage by a registered massage therapist following a massage protocol developed by Vancouver College of Massage Therapy (VCMT).
45782056|NCT02247089|Other|Journal reading (No massage therapy)|Intervention consists of journal reading in the same sitting position as the massage therapy session for approximately 30 minutes.
45448943|NCT02142322|Drug|MODIFIED FOLFOX6|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
45642875|NCT04993781|Behavioral|eSTEPS CDS|Primary care clinics at Brigham and Women's Hospital will be randomized to receive the eSTEPS CDS or usual care. The University of Texas Medical Branch (UTMB) will be the replication site, with all participating primary care practices receiving the eSTEPS CDS.
45642876|NCT04993157|Drug|FIA586|FIA586 capsule
45782057|NCT04382690|Behavioral|All participants will be asked to respond to the same survey questions|All participants will be asked to respond to the same survey questions
45782058|NCT01334723|Drug|Adherent with 5-alpha-reductase inhibitor (5ARI) therapy|Patient with BPH who are adherent to 5ARI therapy (Adherence will be calculated using a medication possession ratio (MPR); 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
45782059|NCT01334723|Drug|Non-adherent to 5ARI therapy|Patients with BPH non-adherent to 5ARI therapy (Adherence will be calculated using a MPR; 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
45782060|NCT04311710|Drug|ipilimumab|Specified Dose on Specified Days
45782061|NCT04311710|Drug|nivolumab|Specified Dose on Specified Days
45782062|NCT04311710|Drug|ENHANZE (rHuPH20)|Specified Dose on Specified Days
45782063|NCT04311710|Drug|nivolumab|Specified Dose on Specified Days
45782064|NCT01334957|Drug|Intravenous ibuprofen|800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
45782065|NCT01402427|Drug|Verapamil|Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.
45782066|NCT01402427|Drug|Placebo|Intraarterial administration of 10 mL saline.
45782067|NCT00813176|Device|Double Lumen Endotracheal Tube|
45448944|NCT02142400|Drug|DS-1093|DS-1093 in capsules with 2.5mg or 25mg per capsule
45448945|NCT02142400|Drug|placebo|matching placebo capsules to DS-1093 capsules
45642877|NCT04991935|Drug|CC-93538|CC-93538
45642878|NCT04990102|Drug|CPX-351|Daunorubicin 8.8mg/m2 + cytarabine 20mg/m2
45642879|NCT04988867|Drug|Trofinetide|Trofinetide solution of 10-30 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
45642880|NCT04987294|Drug|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
45642881|NCT04987294|Drug|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
45642882|NCT04987242|Drug|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
45642883|NCT04987242|Drug|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
45782068|NCT00813176|Device|Arndt Bronchial Blocker|
45782069|NCT03637400|Drug|TMP-SMX|TMP-SMX will be administered over a period of 7 days.
45782070|NCT03637400|Drug|DOXY|DOXY will be administered over a period of 7 days.
45782071|NCT01335191|Biological|TUTI-16 (1.0 mg)|Two subcutaneous injections of TUTI-16 (1.0 mg) at Day 0 and Week 3.
45782072|NCT01335191|Other|Placebo|Two subcutaneous injections of Placebo at Day 0 and Week 3.
45782073|NCT03170258|Device|Neurofeedback (from fMRI and/or EEG)|During part of the task, a feedback display (e.g., thermometer stimulus) will be used to display the average brain activity for each participant. This signal will be acquired ~ every 1 second during the neurofeedback session and will dynamically update to reflect ongoing changes in brain activity. This continuously updated display is the primary feedback mechanism provided to the participant.
45782074|NCT01365611|Drug|Ketorolac tromethamine|A single intranasal dose of 30 mg ketorolac tromethamine was administered to all subjects on Days 1 and 6.
45782075|NCT01365611|Drug|Fluticasone Propionate|Daily intranasal dose of 200 ug fluticasone propionate on Days 2-6
45782076|NCT01403441|Device|Radiosurgical Neuromodulation using the Cyberknife|our team has selected 60 Gray (Gy) as the dose to the target margin to be used for radiosurgical neuromodulation in patients with intractable bipolar disorder; the target being the anterior cingulate (Cg) that correlates with Brodmann area 25 (Cg25).
45782077|NCT01404611|Drug|DF289|Ear drops
45782078|NCT01404611|Drug|DF277|Ear drops
45782079|NCT01404611|Drug|DF289 plus DF277|Ear drops
45782080|NCT01365845|Radiation|Photon|50.4 Gy to the breast/chest wall and peripheral lymph nodes at 1.8 Gy per fraction
45782081|NCT01365845|Radiation|3D-Proton/Conventional plan or 3D-proton only|50.4 Cobalt Gray Equivalent/Gray to the breast/chest wall and peripheral lymph nodes at 1.8 Cobalt Gray Equivalent/Gray per fraction
45917397|NCT03011593|Other|Nutrition Support Product|Nutrition support product contains macronutrients, micronutrients, glutamine, and prebiotics. Product is in powder form (41 grams per serving) and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
45917398|NCT04758988|Other|DermLoop Learn|DermLoop Learn is our AI augmented digital online educational system with case training on a library of 10,000+ benign and malignant skin lesion as well as written learning modules for the most common skin lesion diagnosis.
45917399|NCT00000588|Drug|Chelation therapy|After an initial 21 day balance study to demonstrate that a selected dose of PIH produced sufficient iron excretion, patients were begun on chronic therapy. PIH or placebo were given on days 4 to 9 and days 13 to 18 in a randomized, double-blind, cross-over design.
46070792|NCT03383354|Other|Sleep-related disturbances (exposure)|Sleep-related disturbances such as sleep-disordered breathing (e.g. sleep apnea), sleep fragmentation, abnormal sleep architecture, and periodic limb movements (PLMs)
46070793|NCT04744376|Other|QoR15|Quality of Recovery 15 questionnaire (QoR-15) is a measurement tool that evaluates the recovery quality of patients after surgery and anesthesia by the patient himself.
45642884|NCT04985916|Biological|Vehicle|topical liniment without investigational product
45642885|NCT04985916|Biological|botulinum toxin, Type A|ET-01 topical liniment
45642886|NCT04984005|Behavioral|Low intensity exercise training|The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a low-intensity exercise training.
45642887|NCT04984005|Behavioral|Moderate intensity exercise training|The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a moderate-intensity exercise training.
45642888|NCT04984005|Behavioral|Intermittent high intensity exercise training|The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a high-intensity exercise training.
45642889|NCT04978129|Behavioral|Online and Text Messaging Intervention|The online and TM intervention, and its delivery, will be designed and adapted based on the results of the formative focus groups and cognitive interviews and is meant to be non-confrontational in tone, seeks to increase motivation to increase the quality use of PBS and decrease motivations for non-use of PBS.
45642890|NCT04977050|Diagnostic Test|Quidel quickvue antigen test for COVID-19|rapid antigen test on nasal swab specimen for COVID-19
45782082|NCT03008681|Device|Andresen functional removable orthodontic appliance|Included patients were treated for 24 months with a Functional removable orthodontic appliance, the Andresen activator. The initial checks were performed after 6 weeks with subsequent checks being carried out every 8th week, with the final follow-up at 24 months. The patient underwent functional treatment using the activator described in the protocol with midlines coincidence.
45917400|NCT00000588|Other|Placebo|Placebo given at same time points as the Intervetnion for each clinical condition.
45917401|NCT04749238|Device|NucleoCapture device|Device: 100 ml NucleoCapture selective DNA adsorber. Treatment with NucleoCapture in one arm
45917402|NCT00000591|Procedure|lymphocyte depletion|
45642891|NCT04976192|Combination Product|TEV-45779|TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe
45642892|NCT04976192|Combination Product|XOLAIR® Injection|XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.
45642893|NCT04975997|Drug|Dexamethasone|Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle
45642894|NCT04975997|Drug|Daratumumab|Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7 of a 28-day cycle
45917403|NCT04713514|Drug|OSE2101|subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.
45642895|NCT04975997|Drug|Bortezomib|Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.
45642896|NCT04975997|Drug|Iberdomide|Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle
45642897|NCT04975997|Drug|Iberdomide|Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle
45917404|NCT04713514|Drug|Pembrolizumab 25 MG/ML [Keytruda]|400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.
45917405|NCT04709419|Device|Celliant Diabetic Medical Socks|"Celliant® Diabetic Medical Socks (Celliant Socks) are intended to provide infrared radiation (IR) to increase tissue oxygen thereby increasing blood flow and circulation in the affected area leading to an effect on wound closure outcomes and possible pain reduction."
45642898|NCT04975997|Drug|Iberdomide|Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle
45642899|NCT04975399|Drug|CC-92328|CC-92328
45642900|NCT04974528|Biological|Afrezza|"Pharmaceutical form: powder~Route of administration: inhalation"
45642901|NCT04974528|Biological|Rapid-acting Insulin Analog|"Pharmaceutical form: clear and colorless solution for injection~Route of administration: subcutaneous"
45782083|NCT01472549|Drug|Iodine-alcohol|Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.
45782084|NCT01472549|Drug|Chlorhexidine-alcohol|Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation
45782085|NCT00852644|Procedure|computed tomography|Standard CT scans
45782086|NCT00852644|Radiation|fludeoxyglucose F 18|standard doses with CT scans
45782087|NCT00852644|Radiation|hypofractionated radiation therapy|4 doses over 2 weeks
45782088|NCT00852644|Radiation|stereotactic radiosurgery|CyberKnife radiosurgery
45782089|NCT01404923|Drug|anti spasmodic agents|best standard of care prescriptions
45782090|NCT01404923|Drug|alverine citrate, simeticone|on-demand therapy
45782091|NCT00854594|Behavioral|Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT)|The intervention is designed to educate the clinicians at intervention CBOCs by modeling interprofessional team practices during SMAs for diabetes mellitus (DM) patients from each CBOC primary care provider's (PCP) patient panel. We hypothesize that this education at intervention CBOCs will improve interprofessional practices and overall quality care delivered to veterans.
45782092|NCT01368263|Drug|goserelin acetate|Given SC
45782093|NCT01368263|Drug|letrozole|Given PO
45782094|NCT01368263|Drug|anastrozole|Given PO
45782095|NCT01368263|Drug|chemotherapy|Standard chemotherapy
45782096|NCT01368263|Procedure|Surgery|
45782097|NCT03032276|Other|Safe motherhood and newborn health promotion package|The intervention package consists of three components: facility, community and linkages between the community and health facilities. Facility based interventions will serve both the comparison and intervention arms. However, other two interventions will serve the intervention arm only. Specific interventions and approaches for the three components will be implemented within the MOH&FW service delivery system to improve MNH practices in families and communities and to increase the use of MNH services from appropriate facilities/providers. The intervention package has been developed based on the experiences from SMPP in Narsingdi district and on the basis of consultations with the International Advisory Body (IAB) that included GoB, JICA, ICDDR,B, other experts and stakeholders.
45782098|NCT01405313|Device|Modified Adaptive Servoventilation Device|The modified ASV has a greater adaptive response to meet a target ventilation level that is constantly being assessed.
45782099|NCT01405313|Device|Conventional Adaptive Servoventilation device|Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed.
45782100|NCT00814970|Device|Complete SE Vascular Stent System|Complete SE Vascular Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or the Proximal Popliteal Artery (PPA) in subjects with symptomatic Peripheral Artery Disease (PAD).
45782101|NCT00815360|Drug|intravitreal injection of ranibizumab|intravitreal injection of 0.5 mg ranibizumab
45448946|NCT02142478|Behavioral|Adapted Exercise for Health (EFH) scheme|"12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week. In February 2012, Centre A introduced some changes to the EFH scheme as follows:~Pre-scheme meeting with a health trainer to help the patient decide if EFH is for them.~Participants offered specially tailored group classes (exclusive to EFH participants, e.g. low-impact circuits, Zumba) as well as access to the main gym.~Opportunities to attend daily.~Although subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members) is also available, this option is not openly advertised on the adapted scheme."
45642902|NCT04974528|Biological|Basal Insulin|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
45642903|NCT04973553|Other|upper limb rehabilitation|the intervention consisting of two components: a) Upper limb training protocol; b) Technology-assist training.
45642904|NCT04971785|Drug|Semaglutide (SEMA)|Administered as subcutaneous (SC) injection
45642905|NCT04971785|Drug|Cilofexor (CILO)/Firsocostat (FIR)|Tablets administered orally
45642906|NCT04971785|Drug|PTM SEMA|Administered as SC injection
45642907|NCT04971785|Drug|PTM CILO/FIR|Tablets administered orally
45642908|NCT04970290|Device|Definisse threads free floating and definisse threads double needle|Definisse threads are two class III medical devices, for evaluate the performance of the reshaping effect of the face at day 30
45642909|NCT04967677|Diagnostic Test|Nine Hole Peg Test, Purdue Pegboard Test, Box and Block Test|At first, each person will be asked to fill in the questionnaire. Than he/she will be tested by the Nine Hole Peg Test, Purdue Pegboard Test and the Box and Block Test according to the Czech version of extended manuals for those tests. Audio recording of verbal instructions will be used.
45642910|NCT04965688|Drug|Drug determined by treating oncologist based on recommendation from systems biology analysis.|All patients will have a biopsy at the beginning of the trial. The biopsy will be sent for DNA sequencing through FoundationOne(clinical test) and RNA profiling at Fulgent(research test) for determination of activation of various oncogenic pathways and phenotypes. The results will be analyzed and a treatment recommendation will be made to the treating physician based on an algorithm.
45754304|NCT05582954|Behavioral|EsteemUp-G|The gamification elements added to this arm include (1) Badges - digital rewards upon completing important milestones within the programme EsteemUp. (2) Unlockable content - downloadable worksheets of the exercises that they have done in the module, (3) A certification of completion at the end of the program, (4) Goal setting (5) Gamification terminology - All homework assignments will be framed as a 'challenge' that needs to be completed, (6) a progress bar that will indicate how far along the participant is in the program
45754305|NCT05246683|Other|observational|registry
45782102|NCT00815360|Procedure|peripheral laser|ultra-widefield fluorescein angiography guided peripheral laser
45782103|NCT00815360|Drug|intravitreal injection of triamcinolone acetonide|intravitreal injection of 4.0 mg triamcinolone acetonide
45782104|NCT00815360|Procedure|macular laser|macular laser to areas of retinal thickening or leakage
45782105|NCT00855842|Device|osmotic dilator insertion|osmotic dilators are placed in the cervix to cause cervical dilation
45782106|NCT00856232|Biological|Medical Air|Compressed medical air
45782107|NCT00856232|Biological|Oxygen|Medical Oxygen
45782108|NCT01474109|Drug|macitentan 3mg|macitentan 3mg tablet once daily
45782109|NCT01474109|Drug|macitentan 10mg|macitentan 10mg tablet once daily
45782110|NCT01474109|Drug|placebo|matching placebo once daily
45782111|NCT01405469|Other|Peroral Endoscopic Myotomy|A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. An electric generator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips
45782112|NCT01405937|Drug|vaniprevir|vaniprevir capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
45642911|NCT04965285|Behavioral|quality assesment|"For each time-out procedure observed, the investigators will record compliance for each element of the time-out. Elements that are clearly verbalized by the member of the operating room team performing the time-out were considered compliant.~As each step of the time-out is verbalized by a team member, the operating room team members are expected to respond. The observations will be conducted by trained study staff using a standardized Checklist/ Proforma to assess surgical team compliance with the time-out protocol and to record general observations of the operating room environment. Any non-routine events that occurred during the time-out process will be recorded.~In each phase, the Checklist coordinator must be permitted to confirm that the team has completed its tasks before it proceeds onward."
45642912|NCT04963062|Device|Holmium laser with Moses lasers|The holmium laser with Moses is FDA approved. It emits two separate laser pulses with a short time interval between them. The first pulse divides the water between the laser fiber tip and the stone and the second pulse hits the stone unobstructed. The goal is to increase stone ablative volume and decrease retropulsion of the stone.
45782113|NCT01405937|Biological|peg-IFN|peg-IFN 1.5 µg/kg once per week, subcutaneously (SC) for 24 weeks
45782114|NCT01405937|Drug|ribavirin|Capsules containing 200 mg ribavirin, orally, 3 to 5 capsules, dosage based on participant weight (600 mg/day to 1000 mg/day), for 24 weeks
45782115|NCT01368653|Behavioral|Standard treatment|Standard treatment includes a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling sessions to help smokers quit smoking
45782116|NCT01368653|Behavioral|Standard treatment+practice quitting|This intervention includes standard treatment (a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling session) and an experimental treatment that involves practice quitting 7 times prior to a target quit date (for 4-12 hours per day) and returning to smoking by puffing smoke without inhaling
45448947|NCT02142478|Behavioral|Standard Exercise for Health (EFH) scheme|"12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week.~The scheme includes exclusive EFH gym sessions (i.e. includes EFH participants only) on two to three days of the week, plus subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members)."
45448948|NCT02148484|Behavioral|Prolonged Exposure for Adolescents|
45448949|NCT02148484|Behavioral|Client Centered Therapy|
45448950|NCT03543826|Combination Product|Protocol for rocuronium neuromuscular block|The protocol includes specified appropriate rocuronium dosing and a valid pre-reversal assessment of the adductor pollicis response guides optimal neostigmine vs. sugammadex reversal.
45448951|NCT03543748|Device|Transcranial Magnetic Stimulation|A total of 2000 trains will be delivered successively. The pulses will be delivered at 80% of motor thresholds.
45642913|NCT04963062|Device|Holmium laser with thulium lasers|The holmium laser with thulium laser is FDA approved. It has a different wavelength then the holmium laser with Moses and thus has slightly different energy properties. It has also been shown to increase ablative volume and decrease retropulsion without any safety concerns
45782117|NCT01368653|Drug|Very low nicotine cigarettes|This intervention will be offered to a subset of smokers from both of the other study arms. To be eligible for this intervention, participants must be smoking at the follow-up interview conducted four weeks after a target quit day in the two arms listed above. Tobacco cigarettes containing very low levels of nicotine (.016-.019 mg in smoke from the cigarettes). These are to be smoked no more often than a smoker normally smokes regular cigarettes and for no longer than 6 weeks.
45782118|NCT01407107|Drug|Nitroglycerin 0.2 MG/HR|0.2mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr).
45782119|NCT01407107|Drug|Nitroglycerin 0.4 MG/HR|0.4mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr) if this is well tolerated a higher dose patch (0.4mg/hr) will be used for the next 3 patients.
45782120|NCT01407107|Drug|Nitroglycerin 0.6 MG/HR|0.6mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr) if this is well tolerated a higher dose patch (0.4mg/hr) will be used for the next 3 patients and if this is well tolerated an even higher dose patch (0.6mg/hr) will be used.
45782121|NCT01368809|Drug|Saline|2 ml at induction 1-2 ml boluses as needed
45782122|NCT01368809|Drug|Fentanyl|Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
45782123|NCT01369745|Drug|Prednisolone|Prednisolone 2.7 mg daily
45782124|NCT01369745|Drug|dipyridamole|dipyridamole 360 mg daily
45782125|NCT01369745|Drug|Prednisone|Prednisone 5 mg daily
45782126|NCT01369745|Drug|Z102|Prednisolone 2.7 mg plus dipyridamole 360 mg daily
45782127|NCT01369745|Other|placebo|
45782128|NCT01475513|Drug|Ortho Cyclen®|Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) will be taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.
45782129|NCT01407575|Drug|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)
45782130|NCT01407575|Drug|Placebo|matched placebo
45782131|NCT01476449|Drug|Ranibizumab|Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
45782132|NCT01476449|Drug|Ranibizumab|Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
45642914|NCT04961996|Drug|Giredestrant|Giredestrant 30 milligrams (mg) will be administered orally once a day (QD) on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
45782133|NCT01370369|Drug|Testosterone gel (FE 99903)|
45642915|NCT04961996|Drug|Endocrine Therapy of Physician's Choice|The endocrine therapy of physician's choice (TPC) is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane. Participants will receive TPC daily on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first). Continuing TPC after 5 years is at the discretion of the investigator and per local standard of care. Dose administration of TPC should be performed in accordance with the local prescribing information for the respective product.
45782134|NCT01370837|Other|Intracutaneous injection of Candida albicans antigen.|Intracutaneous injection of 0.05 ml of four different concentrations of Candida albicans antigen on both the arm and foot.
45782135|NCT01370837|Other|Temperature measurement.|Temperature measurement at the site of injection of the highest concentration of Candida albicans antigen on the foot and the same location on the contralateral foot using an infrared thermometer.
45782136|NCT01477463|Drug|Vitamin D3|4,000 IU oral vitamin D3
45782137|NCT01477463|Drug|placebo and vitamin D|
45448952|NCT03543748|Device|Sham Transcranial Magnetic Stimulation|The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field.
45782138|NCT01410773|Device|Ninja 2 Investigational Blood Glucose Monitoring System|The Ninja 2 meter is a Bayer investigational meter that uses an investigational sensor.
45782139|NCT01478009|Dietary Supplement|Korean red ginseng|Korean red ginseng(3.0g/day) for 12 weeks
45782140|NCT01478009|Dietary Supplement|Placebo|Placebo (3.0g/day) for 12 weeks
45782141|NCT01373489|Behavioral|Technology-Assisted Case Management|The TACM intervention uses the FORA 2-in-1 Telehealth System for diabetes to link a case manager to poorly controlled diabetics in real time. Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse case manager will have access to a secure server to which the uploaded measurements are stored in real time. Medications are titrated under supervision of a primary care and endocrinology physicians
45782142|NCT02203565|Drug|Dakin's solution|Applied topically
45782143|NCT02203565|Radiation|radiation therapy|Undergo radiation therapy
45782144|NCT02203565|Other|questionnaire administration|Ancillary studies
45782145|NCT02203565|Other|laboratory biomarker analysis|Optional correlative studies
45754306|NCT03587246|Diagnostic Test|3DTVUS : Uterine peristaltic frequencies|Perform three-dimensional transvaginal ultrasonography To observe uterine peristaltic frequencies in embryo transfer cycles
45782146|NCT01375127|Drug|Tofacitinib|Subjects who previously took 15 mg BID or 30 mg BID
45448953|NCT02148640|Drug|Innovator infliximab|
45754307|NCT01798459|Drug|Methylphenidate|
45782147|NCT01375127|Drug|Tofacitinib|Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID
45782148|NCT02960204|Drug|Emricasan|
45448954|NCT02148640|Drug|Biosimilar infliximab|
45782149|NCT02960204|Drug|Placebo|
45782150|NCT02152826|Device|Potassium oxalate|Professional application
45782151|NCT00857714|Drug|lapatinib|1500 mg lapatinib for 14-21 days
45782152|NCT02839148|Dietary Supplement|Food supplementation|"Arm 1 will be given food supplementation (FS), psychosocial stimulation (PS) and routine clinical care will be given and arm will be provided only with routine clinical care.~The control children will receive routine clinical care but no FS or PS."
45782153|NCT00858494|Drug|Hyland's Cold 'n Cough 4 Kids|Liquid homeopathic cold remedy, 5 ml by mouth every 4 hours as needed for relief of cold symptoms for up to 10 days
45782154|NCT00858962|Drug|Raltegravir|400 mg of raltegravir orally twice daily together with normally prescribed stable dose of buprenorphine for a minimum of 4 days and up to 14 days.
45782155|NCT03839810|Other|stochastic resonance electrical stimulation|"stochastic resonance electrical stimulation is applied in the upper extremity during motor functional training.~Sham comparator group uses sham stimulation - same electrode location, but no electrical current is applied during motor functional training"
45782156|NCT01376297|Drug|Netupitant and Palonosetron|
45782157|NCT01376297|Drug|Aprepitant|
45782158|NCT01376297|Drug|Palonosetron|
45782159|NCT01376297|Drug|Dexamethasone|
45782160|NCT00859040|Drug|SOM230C|Injection in the buttocks every 28 days
45782161|NCT02669186|Drug|Bupivacaine + Fentanyl|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
45782162|NCT02669186|Drug|Bupivacaine|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control
45782163|NCT00859508|Device|SyntheCel|Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
45782164|NCT00859508|Device|Other FDA cleared dura replacements|Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
45782165|NCT01377467|Drug|Denosumab (Prolia)|60 mg s.c. injection at baseline and after 6 months
45782166|NCT02348762|Dietary Supplement|Cysteine (as n-acetylcysteine) and Glycine|Older subjects will be studied before and after receiving cysteine and glycine
45782167|NCT00859976|Device|BoneMaster coated acetabular shell.|Bonemaster coated Exceed Acetabular Shell
45782168|NCT00859976|Device|Plasma Coated Acetabular Shell|Plasma HA coated Exceed Acetabular Shell
45782169|NCT01377623|Drug|Dexmedetomidine group|Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
45782170|NCT01377623|Drug|Placebo group|Fifty six subjects (28 in each arm) will be enrolled. Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
45782171|NCT01479725|Procedure|HBOT|HBOT
45782172|NCT01481129|Drug|Akt Inhibitor MK2206|Given PO
45642916|NCT04961996|Drug|LHRH Agonist|A luteinizing hormone-releasing hormone (LHRH) agonist will be administered to male participants and premenopausal/perimenopausal participants according to local prescribing information. The investigator may determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
45782173|NCT01481129|Other|Laboratory Biomarker Analysis|Correlative studies
45917406|NCT04709419|Device|Control (placebo) Medical Socks|The Control Sock will be visually identical to the Active Celliant® Sock. The sock will be made of identical materials without the Celliant® components. The Control sock will be 82% standard polyester, 13% Nylon, and 5% Spandex.
45917407|NCT04709224|Drug|Lumateperone Long-Acting Injectable|Lumateperone Long-Acting Injectable
46070794|NCT04744376|Other|ACS risk calculator|American College of Surgeons risk calculator is a risk prediction tool for abdominal surgery. It calculates the risk of possible postoperative complications according to the type of surgery, ASA score, and patients' preoperative co-morbidities.
46070795|NCT04744376|Other|Clavien - Dindo classification|It is a classification for postoperative complications.
45642917|NCT04961567|Drug|BIIB059 (litifilimab)|Administered as specified in the treatment arm.
45642918|NCT04961567|Drug|Placebo|Administered as specified in the treatment arm.
45642919|NCT04958551|Other|No intervention|No intervention
45642920|NCT04958486|Drug|5-Azacytidine and trastuzumab infusion|Patients will receive once weekly 10 mg intraventricular 5-Azacytidine infusions for six consecutive weeks followed by observation in the infusion suite for a minimum of 30 minutes and once weekly 21 mg intraventricular trastuzumab infusions for six consecutive weeks followed by observation for a minimum of 2 hour after each infusion for the first 2 infusions. During this monitoring period, temperature, blood pressure, heart rate, and oxygen saturation will be measured. Patients will also have a neurological examination performed to observe for neurological changes. All patients will undergo an MRI of the brain and total spine with and without gadolinium within 7 days after the final 5-AZA and trastuzumab infusion to determine treatment response and to assess for any signal changes in the brain or spine caused by the infusions and they will have a 30 day and a 90 day follow-up assessment by telephone or in person for assessment of outcome measures and safety
45754308|NCT03587090|Diagnostic Test|echocardiography|echocardiography by subcostal and transhepatic views
45754309|NCT04143308|Other|Simultaneous training of walking and cognitive group|"Device:~SWATCH system (App & controller)~Wearable technology Fitness wristband & APP"
45782174|NCT01481129|Other|Pharmacological Study|Correlative studies
45782175|NCT03008447|Drug|LEM5|Single dose of lemborexant 5 mg administered within 5 minutes before bedtime.
45782176|NCT03008447|Drug|LEM10|Single dose of lemborexant 10 mg administered within 5 minutes before bedtime.
45782177|NCT03008447|Drug|ZOL|Single dose of zolpidem 6.25 mg administered within 5 minutes before bedtime.
45782178|NCT03008447|Drug|PBO|Single dose of placebo administered within 5 minutes before bedtime.
45782179|NCT01486043|Drug|Metformin|All subjects will be started on metformin 500 mg orally twice daily. The dose will be increased by 500 mg weekly as tolerated until subjects' blood glucoses are well controlled or until the patient reaches metformin 1000 mg PO BID.
45782180|NCT03007901|Behavioral|Mindful Climate Action|Educational and Behavioral Training Curriculum: An article describing our proposed program was recently published in Sustainability (1) and is summarized here. Experienced instructors from the UW Integrative Medicine Mindfulness Program will teach the 8-week program. Classes will meet weekly for 2½ hours, with a 6 hour weekend retreat. Twenty to 45 minutes of daily home practice will be guided by audio recordings leading participants through body scan, sitting meditations, breath awareness, and mindful movement. Each of the 2½ hour weekly classes includes topics (~30 min) relating to climate change, energy use, and carbon footprint.
45782181|NCT03008525|Biological|subcutaneous and visceral adipose tissue biopsies|
45782182|NCT03008525|Biological|blood samples analysis|
45782183|NCT01490723|Drug|Rituximab|250 mg/m2 by vein preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively on Days -22 and -14.
46070796|NCT04202432|Diagnostic Test|Mean systemic filling pressure|"Peri- and postoperative measurement of continuous cardiac output with thermodilution derived pulse contour calculated device (PiCCO).~Estimation of mean systemic filling pressure using a computerized algorithm and by creating venous return curves with inspiratory hold maneuvers, thereby extrapolating the VR-curve until mean systemic filling pressure is calculated."
45782184|NCT01490723|Drug|111In Ibritumomab|(5.0 mCi +/- 10% of 111In) by vein immediately following the infusion of rituximab on Day -22.
45782185|NCT01490723|Procedure|Planar Scintigraphy Imaging|Day -22, -21 to -16: Planar scintigraphy whole-body imaging started on Day -22 post 111In Ibritumomab infusion prior to voiding, and repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Whole-body planar scintigraphy imaging will be repeated between 22-26 hours, then between 70-74 hours, and later between 142-146 hours post 111In Ibritumomab injection.
45642921|NCT04958265|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 mg intravenously (IV) (for participants weighing 40 to <100 kg) or 1500 mg IV (for participants weighing >=100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants weighing 40 to <100 kg) or 1020 mg SC (for participants weighing >=100 kg). Enrollment of participants weighing <40 kg will be staggered using two weight-based dose confirmation groups (Group 1 participants weighing >=20 kg to <40 kg, followed by Group 2 participants weighing >=5 kg to <20 kg). All participants will receive an initial IV loading dose, which will be followed by SC dosing at either Q2W or Q4W intervals (depending on body weight), until study completion.
45782186|NCT01490723|Drug|90Y IbritumomabTiuxetan|Calculated to deliver not below 10 Gy to normal organs (liver, lungs, kidneys) by vein post rituximab on Day -14.
45782187|NCT01490723|Drug|Fludarabine|30 mg/m2 intravenously on Days -5, -4, and -3.
45448955|NCT02142556|Drug|Administration of quetiapine XR|The treatment was initiated with a 7-day cross-titration period. Previous antipsychotic medication was maintained at the original dose from day 1 to day 3; then reduced to 50% of the original dose from day 4 to day 7 and discontinued on day 8. Meanwhile, the patients started quetiapine XR with daily dose at 300 mg on day 1, 600 mg on day 2 and up to 800 mg after day 2. From day 8 until the end of the study, the dose of quetiapine XR was adjusted within 400-800 mg per day, depending on the clinical response and tolerability of the patients.
45782188|NCT01490723|Drug|Bendamustine|130 mg/m2 intravenously on D-5, -4 and -3.
45782189|NCT01490723|Drug|Thymoglobulin|1 mg/kg (based on actual body weight) on Days -2 and -1 will be administrated to patients receiving a cord blood (CB) and a matched unrelated donor (MUD).
45782190|NCT01490723|Drug|Tacrolimus|"Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after day +90 if no Graft versus Host Disease (GVHD) is present.~For patients receiving cord blood (CB) graft, the Graft versus Host Disease (GvHD) prophylaxis will be with Tacrolimus. Tacrolimus will start on D-2 administrated at starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on D -2 and will be tapered around Day +180 if no GvHD is present."
45448956|NCT02145130|Biological|denovoDerm|Transplantation of an autologous tissue-engineered dermal substitute, covered with autologous split-thickness skin
45782191|NCT01490723|Drug|Methotrexate|5 mg/m2 by vein on Day +1, +3 and +6. Patients receiving an unrelated graft will also be given methotrexate on Day +11 after the transplant.
45782192|NCT01490723|Drug|Mycophenolate|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth administered from Days -3 to +45 and then tapered to end by day 100 if there is no Graft versus Host Disease (GVHD).
45782193|NCT01490723|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning Day +7 for patients receiving related and matched unrelated donor (MUD) grafts and on Day 0 for patients receiving a cord blood (CB). G-CSF will continue until the absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
45782194|NCT01490723|Procedure|Stem Cell Transplantation|Stem Cell Transplantation on Day 0
45782195|NCT04351217|Behavioral|Music|Raga Ahir Bhairav and Bhairavi were used, played primarily on flute, without lyrics.
45917408|NCT04688242|Other|Anal dilatation per anus|Digital anal dilatation through anastomosis, with concomitant administration of probiotics per anus
45782196|NCT04351217|Behavioral|Progressive Muscle Relaxation|The instructions were recorded in both English and the local language, Kannada
45782197|NCT01491113|Drug|Levetiracetam 250 mg|Tablet containing Levetiracetam 250 mg
45782198|NCT01491113|Drug|Levetiracetam 500 mg|Tablet containing Levetiracetam 500 mg
45782199|NCT00816062|Device|Talent Abdominal Stent Graft|The Talent Abdominal Stent Graft is indicated for the endovascular treatment of abdominal aortic aneurysms with or without iliac involvement.
45782200|NCT01415453|Procedure|Ultrasound Stimulus|Short pulses of focused ultrasound will be directed at spots on the retinal surface.
45917409|NCT04688242|Drug|administration of probiotics (Clostridium butyricum TO-A; Bacillus mesentericus TO-A; Streptococcus faecalisT-110) per anus|Digital anal dilatation through anastomosis, with concomitant administration of probiotics per anus
45917410|NCT04677400|Other|More than Body Appearance (MBA) Intervention|"The MBA intervention is a structured 2-weeks psychological intervention. Participants will receive psychoeducational online materials pertaining body image (1st week) and will be required to produce writing assignments pertaining body image in terms of body functionality (2nd week).~During the first week of intervention participants receive psychoeducational online materials pertaining to: positive and negative body image; body image disorders; risk and protective factors for body image; relationship and influences between body image and physical activity, including reasons for exercise; what is body functionality and why it is important.~During the second week participants produce 3 structured writing assessment pertaining to body functionality and why it is important."
45917411|NCT04663828|Other|Structured counseling|Structured patient education and counselling is considered as providing information to patients in order to empower them to better manage their disorder
45917412|NCT04663828|Device|Hearing aids|Hearing aids are considered medical devices and are recommended to patients with a certain degree of hearing loss. Hearing aids amplify environmental sounds.
45448957|NCT02145130|Biological|denovoSkin|Transplantation of autologous tissue-engineered dermo-epidermal skin substitute, no additional coverage needed
45448958|NCT02145286|Radiation|Stereotactic Body Radiation Therapy|SBRT is a high dose and highly conformal radiation dose treatment with the goal of rapid tumor killing and/or ablation of tumors
45448959|NCT02142634|Drug|Budesonide granules 9 mg|per day
45448960|NCT02142634|Drug|Placebo granules|per day
45782201|NCT03839498|Drug|Axitinib|"Axitinib (AG-013736) is an oral, potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3.~Starting dose level 1: 5 mg every morning; 5 mg every evening. Dose level 2: 7 mg every morning; 7 mg every evening. Dose level 3: 10 mg every morning; 10 mg every evening. Dose level -1: 3 mg every morning; 3 every evening. Dose level -2: 2 mg every morning; 2 mg every evening.~Axitinib is supplied as 1 and 5-mg tablets and is administered orally twice a day with or without food, each morning and evening (i.e., every 12 hours). Axitinib will be given as self-administered."
46070797|NCT03336164|Behavioral|Front-of-pack labelling Nutri-Score|Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the university restaurant
45782202|NCT02252432|Drug|Ketamine|A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min)
45782203|NCT02252432|Drug|Methadone|A single dose of IV methadone (0.2 mg/kg) preinduction.
45782204|NCT02252432|Drug|Ketamine + methadone|Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
45782205|NCT01492673|Drug|Cyclophosphamide, Topotecan, and Bevacizumab|The treatment schedule for this study will consist of a 21-day cycle. Dose modification will only occur with administration of the investigational agent, bevacizumab. The schedule of administration is summarized as follows. Administration of bevacizumab will precede the administration of the cyclophosphamide and topotecan by 3 days (Day - 3) to allow for vascular stabilization prior to initiation of chemotherapy. The chemotherapy backbone will consist of cyclophosphamide and topotecan administered as follows: cyclophosphamide 250 mg/m2/day IV over 30 minutes ± 5 minutes on Days 0-4 followed by topotecan 0.75 mg/m2/day IV over 30 minutes ± 5 minutes on Day 0-4 of every cycle. The dosing of cyclophosphamide and topotecan will be fixed.
45917413|NCT04663828|Other|Cognitive behavioral therapy|This is a structured intervention and consists of a several week program both with noise exposure and structured interviews and expert-patient as well as patient-patient interaction in groups
45917414|NCT04663828|Other|Sound therapy|Several sounds and music are used for tinnitus disorder
45917415|NCT00000594|Drug|cholestyramine|
45917416|NCT00390091|Drug|abetimus sodium (LJP 394)|
45917417|NCT00390130|Drug|Pentacel (DPTaP+Hib)|
45917418|NCT00390130|Drug|Prevnar (conjugated pneumococcal vaccine)|
45917419|NCT00390169|Behavioral|Mindfulness Meditation-Based Stress Reduction|
46070798|NCT05331872|Biological|Human umbilical cord-derived mesenchymal stem cell infusion|Human umbilical cord-derived mesenchymal stem cell infusion in the management of adult liver cirrhosis
45642922|NCT04957719|Combination Product|Selatogrel|"Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.~Participants will self-administer 16 mg of selatogrel subcutaneously with the autoinjector upon occurrence of symptoms suggestive of an acute myocardial infarction. Self-administration encompasses the use of the autoinjector by another person (e.g., partner, close relative, friend, caregiver) who may be called for help during the emergency situation of a suspected AMI."
45642923|NCT04957719|Combination Product|Placebo|"Placebo will be administered as a liquid formulation in a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.~Participants will self-administer placebo subcutaneously with the autoinjector upon occurrence of symptoms suggestive of an acute myocardial infarction. Self-administration encompasses the use of the autoinjector by another person (e.g., partner, close relative, friend, caregiver) who may be called for help during the emergency situation of a suspected AMI."
45642924|NCT04952961|Behavioral|Training in Vulval Self-Examination|Face-to-face training in vulval self-examination Supplemented with use of aids ( hand mirror, mobile phone with selfie-stick), patient information leaflet, reminders to self-examine
45754310|NCT04143308|Other|Cognitive training group|"Device:~SWATCH system (App)~Wearable technology Fitness wristband & APP"
45917420|NCT00390169|Behavioral|Supportive-Expressive Group Therapy|
46070799|NCT05422508|Biological|MG1111 (BARICELA)|0.5ml, single dose, subcutaneous injection
45782206|NCT01494545|Device|Delefilcon A contact lens|Silicone hydrogel contact lens CE-marked for single use, daily disposable wear
45782207|NCT00818324|Drug|OPC-12759 Ophthalmic suspension|Instillation,4times/day,for 52weeks
45782208|NCT01419275|Drug|Xenon contrast agent|
45782209|NCT01419275|Device|Magnetic Resonance Imaging|Arterial spin label sequence for the purpose of measuring collateral flow
45782210|NCT02155010|Drug|Dexmedetomidine|Dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
45782211|NCT02155010|Drug|Dexmedetomidine with heavy bupivacaine|Dexmedetomidine infusion after IT of heavy bupivacaine
45782212|NCT01495481|Drug|Dexmedetomidine|Dexmedetomidine 2 mcg/kg, Intravenous push
45782213|NCT01495481|Drug|Adenosine|Stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful
45782214|NCT01954550|Behavioral|Cycling exercise|An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.
45782215|NCT01954550|Behavioral|Range of motion/stretching exercise|An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
45917421|NCT00000603|Procedure|stem cell transplantation|
45917422|NCT02978755|Drug|GM102|GM102 escalating doses (phase1)
45917423|NCT02978755|Drug|GM102 escalating doses|GM102 escalating doses combined with paclitaxel and carboplatin
45917424|NCT02978755|Drug|GM102|GM102 single agent at recommended dose in 3 parallel cohorts (sex cord, epithelial ovarian, cervix cancers)
45782216|NCT00861146|Behavioral|behavioral counseling plus contingency management|Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum
45782217|NCT00819182|Behavioral|Paced respiration|Breathing exercise
45782218|NCT00819182|Behavioral|Sham comparator: fast shallow breathing|sham breathing exercise
45782219|NCT01497665|Drug|GRN1005|650 mg/m2 IV every 3 weeks
45782220|NCT00819260|Device|Harmonic Scalpel|harmonic scalpel used to reduce breast on this side
45782221|NCT00819260|Device|Electrocautery|Electrocautery used to reduce breast on this side
45782222|NCT01379183|Drug|Erythromycin|200 mg suspension
45782223|NCT01379183|Drug|Placebo|200 mg suspension
45782224|NCT01379183|Procedure|Magnetic Resonance Imaging|An MR enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel.
45782225|NCT01379183|Other|Barium Sulfate Solution|Participants will be given a low concentration of barium sulfate solution (1350 mL) prior to the MRI procedure. Barium sulfate is a radiopaque agent. Radiopaque agents are used to help diagnose certain medical problems. Since radiopaque agents are opaque to (block) x-rays, the areas of the body in which they are localized will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.
45782226|NCT01333436|Other|Test Meal|During Visit 2, a test meal will be supplied by the Sponsor of approximately 944 kcal (57% fat, 31% carbohydrate, and 12% protein), and postprandial blood draws will be done at 1, 2, 3, 4, and 6 hours after the meal.
45782227|NCT04382456|Dietary Supplement|acacia gum|Two sachets (à 5 g) in the morning and two sachets in the evening, reconstituted in 120 ml water and stirred until fully dissolved to be taken 10 minutes before meals.
45782228|NCT01379651|Other|Specific oral tolerance induction|Specific oral tolerance induction consisted in the administration of increasing amounts of raw emulsion egg
45782229|NCT01380197|Drug|Morphine|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
45782230|NCT01380197|Drug|Nubain|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
45642925|NCT04950010|Behavioral|High-Intensity Interval Training|HIIT is a type of training in which short periods of high-intensity anaerobic exercise (1-4 minutes at 80-95% of VO2peak) are alternated with less intense aerobic recovery periods (1-3 minutes at 50-60% VO2peak). Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise (i.e., number and intensity of intervals) increases across weeks. Intervals will progress from a heart rate corresponding with 75% VO2peak in Week 1 to 90-95% VO2peak in Weeks 5-8. Sessions will be ~30 minutes in length. Indoor cycling is the primary mode of exercise.
45782231|NCT00862784|Biological|IMC-1121B (ramucirumab)|8 milligrams/kilogram (mg/kg) IMC-1121B (ramucirumab) infusions every 2 weeks
45782232|NCT00862784|Drug|Oxaliplatin|85 milligrams/square meter (mg/m²) intravenous infusion over 2 hours on Day 1
45782233|NCT00862784|Drug|Folinic acid|400 mg/m² intravenous infusion over 2 hours on Day 1
45782234|NCT00862784|Drug|5-FU|400 mg/m² intravenous bolus injection over 2-4 minutes, immediately following folinic acid infusion
45782235|NCT00862784|Drug|5-FU|2400 mg/m² intravenous continuous infusion over 46 hours immediately following bolus 5-FU on Days 1 and 2
45642926|NCT04950010|Behavioral|Moderate-Intensity Exercise|Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise increases across weeks. Indoor cycling is the primary mode of exercise. Sessions will include moderate-intensity cycling that progresses from a heart rate corresponding with 55-60% VO2peak for 30 minutes in Week 1 to 65-70% VO2peak for 45-50 minutes in Weeks 5-8.
45642927|NCT04949165|Dietary Supplement|Iron Supplementation|low dose ferrous sulphate (65mg elemental iron) supplements
45782236|NCT00246116|Procedure|Functional Imaging of Treatment Effects|PET & VQ Scans
45782237|NCT03532100|Device|Torsionally adaptive prosthesis with 0:1 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 0:1 means there will be no coupling between the transverse- and sagittal-plane motion. That is, regardless of any motion in the sagittal plane, there will be zero motion in the transverse plane.
45642928|NCT04948554|Biological|MK-2225|Administered Subcutaneously (SC)
45642929|NCT04948554|Biological|Placebo|Administered SC
45642930|NCT04948099|Drug|VIB1116|VIB1116
45642931|NCT04948099|Drug|Placebo|Placebo
45782238|NCT03532100|Device|Torsionally adaptive prosthesis with 1:6 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:6 means there will be one degree of motion in the transverse plane for every six degrees of motion in the sagittal plane.
45782239|NCT03532100|Device|Torsionally adaptive prosthesis with 1:4 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:4 means there will be one degree of motion in the transverse plane for every four degrees of motion in the sagittal plane.
45782240|NCT03532100|Device|Torsionally adaptive prosthesis with 1:3 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:3 means there will be one degree of motion in the transverse plane for every three degrees of motion in the sagittal plane.
45782241|NCT03532100|Device|Torsionally adaptive prosthesis with 1:2 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:2 means there will be one degree of motion in the transverse plane for every two degrees of motion in the sagittal plane.
45782242|NCT00864032|Drug|Sorafenib|400mg twice daily
45642932|NCT04944979|Biological|Kedrion IVIG 10%|Kedrion intravenous immunoglobulin (IVIg) 10%
45642933|NCT04942210|Biological|Yellow fever vaccine (produced on serum-free Vero cells)|Powder and diluent for suspension for injection Subcutaneous injection
45642934|NCT04942210|Biological|Yellow fever vaccine|Powder and diluent for suspension for injection Subcutaneous injection
45782243|NCT00820664|Drug|Comparator: Estrace 0.5 mg|0.5 mg tablet taken once daily for 28 days
45782244|NCT00820664|Drug|Comparator: Estrace 2 mg|2 mg tablets taken once daily for 28 days.
45782245|NCT00820664|Drug|Comparator: Placebo|Placebo 0 mg capsule taken once daily for 28 days
45782246|NCT01380743|Drug|duvoglustat|Single oral dose
45782247|NCT01380743|Drug|rhGAA|Single intravenous infusion
45782248|NCT01380899|Procedure|Biopsy of skin|Under local anesthesia with 1% xylocaine, 4-mm punch biopsies with 3-mm depth, including the dermis and subcutaneous fat tissue, will undergone from two regions, neck and lower back.
45782249|NCT01498601|Other|Enhanced oral care protocol|"Changing mouth suction equipment every 24 hours~Mouth assessment every 2-4 hours~Cleansing mouth with toothbrush every 12 hours~Cleansing oral mucosa with oral rinse solution every 2-4 hours~Moisturize mouth/lips with swab and standard mouth moisturizer every 4 hours~Suction mouth and throat as needed~Head of the bed elevated to a minimum of 30° during oral care"
45782250|NCT01419977|Drug|Placebo|Normal saline solution, administered by nursing staff once daily
45782251|NCT01419977|Drug|Dalteparin|Low molecular weight heparin (LMWH), 5000 unites subcutaneously, administered by nursing staff once daily, Other Name: Fragmin
45782252|NCT01420289|Device|High pressure intermittent pneumatic compression (HPIPC)|Apply therapy for 45 minutes twice daily
45642935|NCT04940767|Drug|Isotretinoin|Isotretinoin is a retinoic acid analogue (13-cis-retinoic acid) supplied as oral capsules. and was approved in the US for the treatment of severe acne vulgaris in 1982 under the brand name Accutane®.
45782253|NCT01420289|Behavioral|Excercise|Treadmill walking 45 minutes once daily
45782254|NCT01499147|Drug|fludarabine/busulfan|All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 <40%, DLCO<50%, LVEF<40, Serum bilirubin >1.5 mg% or serum transaminases > 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.
45782255|NCT01499147|Drug|fludarabine/ melphalan|All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 <40%, DLCO<50%, LVEF<40, Serum bilirubin >1.5 mg% or serum transaminases > 2x nl).
45782256|NCT01499147|Drug|ATG|Patients receiving a transplant from a matched unrelated or mismatched related/unrelated donor would receive ATG in the conditioning regimen.
45782257|NCT00823082|Drug|Antithrombin III|Single dose of antithrombin III sufficient to achieve a preoperative level of 120%
45782258|NCT01382303|Drug|Pentoxifylline|Pentoxifylline 400mg three times a day
45782259|NCT01382303|Drug|Placebo|placebo tablet three times a day
45782260|NCT03008993|Behavioral|HQIS implementation|
45782261|NCT05236634|Drug|Phosphodiesterase 5 Inhibitors|A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
45782262|NCT05236634|Drug|Alpha Blockers|A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
45782263|NCT05236634|Drug|Combined Alpha Blockers and Phosphodiesterase 5 Inhibitors|A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
45642936|NCT04940767|Drug|Amzeeq 4% Topical Foam|AMZEEQ® is a topical lipophilic foam containing 4% minocycline that was approved in the US for the treatment of acne vulgaris in 2019
45642937|NCT04931654|Drug|AZD7789|anti-PD-1 and anti-TIM-3 bispecific antibody
45642938|NCT04929223|Drug|Inavolisib|Inavolisib will be administered orally as per schedule specified in the respective arms.
45642939|NCT04929223|Drug|Bevacizumab|Bevacizumab IV will be administered as per schedule specified in the respective arm.
45642940|NCT04929223|Drug|Cetuximab|Cetuximab IV will be administered as per schedule specified in the respective arm.
45642941|NCT04929223|Drug|Atezolizumab|Atezolizumab IV infusion will be administered as per schedule specified in the respective arm.
45782264|NCT05236322|Device|soft tissue laser|Surgical laser used in excision purpose
45782265|NCT01422161|Drug|Botulinum Toxin commonly known as BOTOX®|"A total dose between 200-300 units of Botulinum toxin will be administered across 12 muscles of the affected hand.~There will be 1 treatment cycle during the 9 week study."
45642942|NCT04929223|Drug|Tiragolumab|Tiragolumab IV infusion will be administered as per schedule specified in the respective arm.
45642943|NCT04929223|Drug|SY-5609|SY-5609 will be administered by mouth as per schedule specified in the respective arm.
45642944|NCT04929223|Drug|Divarasib|Divarasib will be administered orally as per schedule specified in the respective arms.
45754311|NCT04143308|Other|Treatment as usual group|Keep treatment as usual
45782266|NCT01422161|Drug|Placebo|The control group will receive a placebo injection.
45782267|NCT05236166|Drug|Rapid withdrawal of antiepileptic|"Reduction by about 20 % of initial dosage every 15 days until complete discontinuation (total withdrawal time: 60 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide"
45917425|NCT04650880|Dietary Supplement|Vitamin D|Vitamin D supplementation
45782268|NCT05236166|Drug|Slow withdrawal of antiepileptic|"Slow withdrawal: reduction by about 20 % of initial dosage every 40 days, until complete discontinuation (total withdrawal time: 160 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide"
45782269|NCT03495128|Other|Bed Rest|3 days of head down tilt (-6 degrees) bed rest
45782270|NCT03495128|Other|Reconditioning|daily resistance training (for 3 days) on one leg
45782271|NCT01502813|Drug|Citicoline, Omega-3 Fatty Acids and Creatine|Citicoline: 500 mg/day for 28 days Omega-3 Fatty Acids: 2 g/day for 28 days Creatine: 5 g/day for 28 days
45782272|NCT00865202|Drug|L-tryptophan supplementation|L-tryptophan 1 gram enterally TID for a maximum of nine doses or to be discontinued at the time of discharge from the ICU (whichever occurs first)
45782273|NCT00865202|Drug|placebo|Similar appearing placebo administered post-operatively (1 enterally TID) for a total of nine doses or discharge from ICU (whichever occurs first)
45782274|NCT01424033|Drug|N-Acetylcysteine|600mg by mouth, three times daily for 12 months
45782275|NCT01503749|Drug|G-colony stimulating factor|G-colony stimulating factor (5ug/kg/day)will be administered subcutaneously to three patients with liver cirrhosis of this arm.
45782276|NCT01503749|Other|Infusion of the mobilized monocyte cells|G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance.
45782277|NCT00867932|Drug|Eculizumab|5 mg/mL solution in 5% Dextrose
45782278|NCT05236088|Device|Neuromuscular electrical stimulation application|It was applied with INNOVO brand (Atlantic Therapeutics, Galway, Ireland) device. It was applied for 30 minutes 3 days a week during 4 weeks
45782279|NCT05236088|Device|Sham neuromuscular electrical stimulation application|Sham group will be applied from the same device, again 3 days a week for 30 minutes during 4 weeks, but no current will be given from the device.
45782280|NCT02209259|Other|PROMIS Upper Extremity Function|
45782281|NCT02209259|Other|Pain intensity|
45782282|NCT02209259|Other|PROMIS depression|
45448961|NCT02145442|Dietary Supplement|Obex|Obex® will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during three months. Participants will be not trained about changes of lifestyle on their diets, or physical activity.
45642945|NCT04929223|Drug|FOLFOX|FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) IV will be administered as per schedule specified in the respective arm.
45642946|NCT04929223|Drug|FOLFIRI|FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) IV will be administered as per schedule specified in the respective arm.
45642947|NCT04927702|Device|Synthetic Hybrid-Scale Fiber Matrix|A synthetic absorbable skin substitute indicated for use in the local management of wounds. It is made of small synthetic fibers that are designed to be similar to the structure of human skin.
45782283|NCT02209259|Other|Positive affect negative affect scale (PANAS)|
45782284|NCT02209259|Other|standard PCS|
45782285|NCT02209259|Other|positively-adjusted version of the PCS|
45782286|NCT00825266|Drug|bosentan|Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.
45782287|NCT00825266|Drug|Pioglitazone|Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.
45782288|NCT05235932|Procedure|Robotic radical total gastrectomy with D2 lymphadenectomy|Most surgical procedures are performed using the robot system.
45782289|NCT05235932|Procedure|Laparoscopic radical total gastrectomy with D2 lymphadenectomy|Without the robot system, Most surgical procedures are performed using laparoscopic equipment.
45782290|NCT01385189|Biological|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
45782291|NCT01385189|Biological|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
45782292|NCT01385189|Biological|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
46070800|NCT05422508|Biological|VARIVAX|0.5ml, single dose, subcutaneous injection
45642948|NCT04927702|Device|Standard of Care|To ensure off-loading, each patient will be fitted with an off-loading device based on the investigator's decision, e.g. a boot for forefoot and a heel protector for hindfoot. Patients is instructed on how to care for the surgical site, utilize an off-loading device, and keep the surgical site moist and clean. If the wound is dry, a hydrogel category dressing type should be used. If the wound has exudate, an alginate or foam dressing is recommended.
45754312|NCT01980355|Drug|Tranexamic Acid|
45754313|NCT01980355|Other|Placebo|
45782293|NCT01385189|Biological|10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)|3 doses 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
45782294|NCT01385189|Biological|30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)|3 doses of 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
45782295|NCT01385189|Biological|30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
45782296|NCT01385189|Biological|100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
45782297|NCT05235776|Other|observation|observation
45782298|NCT05235620|Other|PatientToc use in pharmacies|PatientToc has been adapted for use in pharmacies. Patients first complete a self-guided medication reconciliation and then patients using specific medications will be prompted to complete questionnaires about their self-reported adherence.
45782299|NCT01385579|Other|Care manager outreach|Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit. Patients who do not respond to the mail outreach received up to 3 attempts at telephone outreach by the care manager.
45782300|NCT01386983|Drug|5ARI|Dutasteride or Finasteride
45782301|NCT01386983|Drug|5ARI + AB|5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
45782302|NCT01387139|Drug|Ketamine|1.0 milligrams/kilogram (mg/kg) ketamine with additional doses of 0.5 mg/kg ketamine as needed (maximum single dose based on 100 kilogram (kg) person)
45642949|NCT04927702|Device|Living Cellular Skin Substitute|An absorbable skin substitute comprised of human and bovine (cow) tissues indicated for use in the local management of wounds.
45642950|NCT04926636|Behavioral|Health and Wellness Coaching|An enhanced mobile application that allows for participation in health coaching features. Participants will be assigned to a health coach and will have coaching sessions scheduled.
45642951|NCT04926623|Device|FreeStyle Libre|FreeStyle Libre flash sensor-based glucose monitoring system (FSGM; Abbott Diabetes Care, Witney, Oxon, UK)
45642952|NCT04926623|Other|SMBG|Self-Monitoring of Blood Glucose
45642953|NCT04925986|Drug|Sitravatinib|Groups 1A and 2A receive Sitravatinib 100mg orally (PO) daily starting on cycle 1 day 1 (C1D1). Groups 1B and 2B) receive Sitravatinib 100mg orally (PO) daily starting on Cycle 2 Day 1 (C2D1).
45642954|NCT04925986|Drug|Pembrolizumab|All groups (1A, 1B, 2A, 2B) receive Pembrolizumab 200mg intravenous every three weeks (IV Q3w) on cycle 1 day 1 (C1D1).
45642955|NCT04923334|Behavioral|Brief Pain Teleconsult|The Brief Pain Teleconsult intervention includes 2 sessions provided by a licensed physical therapist over about 1 week. The sessions focus on pain education from a biopsychosocial perspective that is designed to address negative pain appraisals and catastrophizing thoughts, providing advice to be active and engage in exercise and physical activity, and reassurance that activity is beneficial and safe.
45642956|NCT04923334|Behavioral|Telehealth Physical Therapy|The Telehealth Physical Therapy intervention involves weekly telehealth sessions provided over 10 weeks. Telehealth Physical Therapy is provided by a licensed physical therapist. Key components of the intervention include reinforcing biopsychosocial education messages and developing an exercise and physical activity program using cognitive behavioral principles such as goal setting and positive reinforcement. Pain coping strategies including mindful breathing and progressive relaxation techniques will be included.
45642957|NCT04922229|Procedure|RCT|This is the standard of care for this diagnosis
45642958|NCT04922229|Procedure|Pulpotomy|For cases with normal apical tissues, pulpotomy using tricalcium silicates has been shown to have high clinical success. Either partial or complete pulpotomy will be performed depending on the size of pulp exposure.
45642959|NCT04916470|Drug|Semaglutide|Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly for 52 weeks. Dose will be gradually increased to 2.4 mg: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 52.
45642960|NCT04916470|Drug|Placebo (Semaglutide)|Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly for 52 weeks.
45642961|NCT04914117|Drug|RC118 for injection|RC118 will be administered intravenously (IV) on Day 1 of every 14-day cycle.
45642962|NCT04913805|Drug|Potassium Nitrate|Potassium Nitrate is the active intervention that may increase blood flow to exercising muscle
45642963|NCT04913805|Drug|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside will be used as a combination intervention to both increase blood flow (KNO3) and mitochondrial function (PLC + NR)
45642964|NCT04913805|Other|Potassium Chloride|Active control
45642965|NCT04912869|Drug|Crovalimab|Crovalimab will be administered as a single dose of 1000 milligrams (mg) IV (for participants with a body weight between 40 kilograms (kg) and 100 kg) or 1500 mg IV (for participants with a body weight >=100 kg).
45642966|NCT04912869|Drug|Placebo|Placebo will be administered as a single IV infusion, with an equal volume and over the same duration as weight- based crovalimab
45642967|NCT04912713|Other|Stress group|This group will perform the MAST stress protocol
45642968|NCT04912713|Other|Control group|This group will perform the MAST control protocol
45642969|NCT04907968|Drug|XMT-1536 (Upifitamab Rilsodotin)|"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~XMT-1536~UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."
45642970|NCT04907968|Drug|Carboplatin|"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~XMT-1536~UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."
45642971|NCT04902794|Device|Light Emitting Diode|Blue light-emitting diode applied to the female genital region for eight minutes, for five sessions, one per week
45642972|NCT04902794|Device|Sham Light Emitting Diode|Sham Blue light-emitting diode turned off applied to the female genital region for eight minutes, for five sessions, one per week
45642973|NCT04901377|Combination Product|Estradiol valerate/ Dienogest|Combined hormonal contraceptive (combined oral contraceptives, COCs)
45782303|NCT01387139|Drug|Ketamine Co-administered with Propofol|0.5 mg/kg ketamine and 0.5 mg/kg propofol with additional doses of 0.25 mg/kg ketamine and 0.25 mg/kg propofol as needed (maximum single dose based on 100 kg person)
45782304|NCT00870896|Drug|Tiotropium|Each subject will then receive Spiriva 18 ug/day for a total of 4 weeks. Each subject will be instructed by the PI on the proper use of the Spiriva inhaler and demonstrate the ability to properly perform the inhalation technique prior to leaving the laboratory. The patient will receive their first dose in the laboratory under the direct supervision of one of the investigators. In addition, subjects will be requested to take their Spiriva inhalation treatment the same time each day.
45642974|NCT04901195|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
45642975|NCT04900220|Drug|Betamethasone|The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of betamethasone (6 mg)
45642976|NCT04900220|Drug|Methylprednisolone|The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of methylprednisolone (40 mg)
45782305|NCT03008135|Other|Elderly Mobility Scale|The Elderly Mobility Scale was devised to assess the mobility of fragile elderly people, and contains seven items considered as essential for performing the basic activities of the daily routine: Lying down to sitting, sitting to lying down, sitting to standing, standing, Gait/ work on body posture, timed walk (6 meters) and work on Functional Reach/movements?
45917426|NCT04650880|Other|Placebo|Placebo tablets with the same external appearance
45782306|NCT03008135|Other|Frailty scale|"6 questions are asked to the person about his or her living conditions to determine the level of frailty. The scale is produced by the board High Health Authority"
45782307|NCT00825344|Drug|Etanercept|50 mg subcutaenous preoperatively
45782308|NCT00825344|Drug|Saline|Given subcutaneously preoperatively
45782309|NCT00871286|Procedure|Pre-treatment Sinus CT Scan|Pre-treatment Sinus CT Scan
45782310|NCT00871286|Procedure|Post-treatment Sinus CT Scan|Post-treatment Sinus CT Scan
45782311|NCT01426763|Biological|CINRYZE with rHuPH20|
45782312|NCT00825500|Drug|Inhaled Placebo|Inhaled Staccato placebo (0 mg)
45642977|NCT04899245|Diagnostic Test|BinaxNOW Rapid Antigen System|"BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes.~The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more."
45642978|NCT04897217|Drug|Megestrol Acetate|The control arm will consist of oral progesterone therapy (megestrol acetate 160mg po daily). The intervention will be administered on an outpatient basis.
45782313|NCT00825500|Drug|Inhaled Loxapine 1.25 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
45782314|NCT00825500|Drug|Inhaled Loxapine 2.5 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
45782315|NCT01504997|Device|Robot assisted distal gastrectomy (DaVinci)|patients who received robot assisted distal gastrectomy
45782316|NCT03489434|Behavioral|Intervention|Preliminary prevention program component content is based on evidence-based prevention programs and will integrate prevention content for substance use, sexual assault, and sexual risk behaviors.
45782317|NCT01505933|Drug|Dexmedetomidine|"Administer dexmedetomidine at 1mcg/kg over 10min followed by an infusion of dexmedetomidine at 1mcg/kg/hr and image the upper airway.~After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of dexmedetomidine 2mcg/kg followed by increase in the infusion rate to 3mcg/kg/hr. Upper airway images will be repeated 5mins after increasing infusion Image acquisitions will be repeated approximately 5 min after the increase in infusion rate."
45782318|NCT01505933|Drug|propofol|"Administer propofol bolus at 2mg/kg,followed by an infusion of propofol at 100 mcg/kg/min. Upper airway images will be obtained 5 mins after the patient is stable on this infusion.~After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of 1mg/kg propofol and infusion increased to 240mcg/kg/min.~Image acquisitions will be repeated approximately 5 min after the increase in infusion rate."
45917427|NCT04601077|Drug|Nitric Oxide lozenges, 30 mg|Nitric Oxide lozenge, 30 mg twice a day for 30 days
45917428|NCT04601077|Drug|Placebo|Placebo for Nitric Oxide lozenge, 30 mg twice a day for 30 days
45917429|NCT00000606|Procedure|Lung volume reduction surgery|
46070801|NCT05422508|Biological|Suduvax|0.5ml, single dose, subcutaneous injection
46070802|NCT00971321|Biological|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections
46070803|NCT03295682|Device|Endovascular thoracoabdominal aneurysm repair|Endovascular treatment of patients with thoracoabdominal aneurysm using a multibranch stent graft tailored to the patient´s anatomy in combination with peripheral covered stents to bridge the visceral arteries
45642979|NCT04897217|Drug|Levonorgestrel Drug Implant|Participants in the comparison arm will have a levonorgestrel intrauterine device placed in the office or in the operating room if the office procedure not tolerated or if they have not had a prior dilation and curettage.
45642980|NCT04896684|Biological|blood and intestinal biopsy sampling|24 mL of blood and 10 intestinal biopsies will be sampled
45642981|NCT04896320|Drug|Tucatinib|Tucatinib is a highly selective, oral, reversibly Her2 small molecule tyrosine kinase inhibitor (TKI).
45782319|NCT03484130|Dietary Supplement|Sodium loaded diet|At baseline, and annually, participants will undergo aldosterone dynamic testing after ~5 days of a sodium loaded diet. The diet will consist of >180 mmol/day of sodium, ~50 mmol/day of potassium, and 600mg/d of calcium.
45782320|NCT03484130|Dietary Supplement|Restricted sodium diet|At baseline, and annually, participants will undergo aldosterone dynamic testing after ~5 days of a sodium restricted diet. The diet will consist of <40 mmol/day of sodium, ~50 mmol/day of potassium, and 600mg/d of calcium.
45782321|NCT00825734|Drug|Sorafenib|Dose Level 1 - Sorafenib PO BID (200mg) Dose Level -1 - Sorafenib PO BID (200mg) Dose Level 1a - Sorafenib PO BID (400mg)
45782322|NCT00825734|Drug|Ixabepilone|Dose Level 1 - Ixabepilone IV every 21 days (40mg/m^2) Dose Level -1 - Ixabepilone IV every 21 days (32mg/m^2) Dose Level 1a - Ixabepilone IV every 21 days (32mg/m^2)
45782323|NCT00826202|Drug|D-serine|60 mg/kg/day
45782324|NCT00826202|Other|Placebo|Inert Placebo
45782325|NCT02153528|Drug|double rimfampicin|Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained
45782326|NCT02153528|Drug|Standard TB treatment|Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
45782327|NCT00872534|Drug|acetylsalicylic acid|325mg once a day for 7 days
45782328|NCT00873782|Other|Retrograde high pressure transvenous perfusion with normal saline|Dose escalation of saline volume, infusion rate, and tourniquet pressure, as determined in a stepwise manner and by careful monitoring
45782329|NCT02513160|Drug|Beclomethasone Dipropionate 640|Beclomethasone Dipropionate 640 mcg BAI
45782330|NCT02513160|Drug|Placebo|"Placebo, taken in the morning and evening each day, was provided in matching BAI and MDI devices.~The placebo devices were identical to the devices used to deliver active drug."
45782331|NCT02513160|Drug|Beclomethasone dipropionate via 320 mcg BAI|Beclomethasone dipropionate treatment administered via breath-actuated inhaler (BAI) (320 mcg/day).
45917430|NCT02972281|Biological|Immunological diagnosis tests|(Non exhaustive list): hemogram, IgG, A, M, IgG subclasses, complement, vaccinal response to protein and polysaccharide antigens, ...
45917431|NCT00000609|Drug|amiodarone|
45782332|NCT02513160|Drug|albuterol/salbutamol|Each patient's current rescue medication was replaced with study-supplied albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent during the run-in and double-blind study periods.
45782333|NCT02513160|Drug|Beclomethasone dipropionate via 320 mcg MDI|Beclomethasone dipropionate treatment administered via metered-dose inhaler (MDI) (320 mcg/day).
45782334|NCT00874094|Biological|Platelet rich fibrin matrix|0-2 cc of autologous platelet rich fibrin matrix injected intra and subdermally to effect nasolabial fold.
45782335|NCT01507103|Biological|Tecemotide (L-BLP25)|Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8, which will be administered concomitantly with the chemoradiotherapy, followed by a 9th subcutaneous injection 7 to 11 days prior to surgery.
45782336|NCT01507103|Drug|cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of CPA will be given 3 days before the first tecemotide (L-BLP25) administration.
45782337|NCT01507103|Other|Chemoradiotherapy|Radiotherapy of 45-52 grays (Gy) will be applied 5 times per week, over a minimum period of 5 weeks. Capecitabine at a dose of 825 mg/m^2, twice daily or equivalent dose of 5-fluorouracil (5-FU) will be given orally, starting at the first day of radiotherapy and given 5 to 7 days per week during the time of radiotherapy.
45782338|NCT00874250|Device|GORE CTAG Device|Endovascular aortic stent-graft
45782339|NCT02480010|Drug|Pertuzumab|Participants will receive pertuzumab on Day 1 of each 3-week cycle. In Cohort A, an 840-mg loading dose will be administered prior to the 420-mg IV infusion. In Cohort B, the 1050-mg IV infusion will be administered with no loading dose.
45782340|NCT01388777|Device|Visica 2™ Treatment System|The Visica 2™ Treatment System uses a closed system to circulate liquid nitrogen within the probe tip creating sub-freezing temperatures that result in precision cryoablation of the intended target tissue.
45782341|NCT01388777|Procedure|Cryoablation|Cryoablation procedure uses a hollow, thin tube called a cryoprobe to freeze and destroy cancer tissue. The cryoprobe needle insertion is done using ultrasound guide to reach target, procedure lasts about 20 minutes.
45782342|NCT01388777|Procedure|Surgical Resection|Complete surgical resection of the primary tumor following cryoablation therapy.
45782343|NCT00875342|Drug|DCS|1. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)
45782344|NCT00875342|Other|Placebo|2. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)
45782345|NCT00876200|Drug|Minoxidil|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
45642982|NCT04895696|Drug|Afimetoran|Specified dose on specified days
45782346|NCT00876200|Drug|Placebo|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
45782347|NCT02512302|Drug|SUN-101 via eFlow nebulizer|50 mcg glycopyrrolate via Electronic Nebulizer
45782348|NCT02512302|Drug|SUN-101 via eFlow nebulizer with activated charcoal|50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
45782349|NCT02512302|Drug|Seebri® Breezhaler®|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
45782350|NCT02512302|Drug|Seebri® Breezhaler® with activated charcoal|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
45782351|NCT02512302|Drug|Glycopyrrolate Injection|50 mcg glycopyrrolate via IV
45782352|NCT01507181|Drug|Ketamine|single dose IV ketamine, .5mg/kg infused over 40 minutes
45782353|NCT01507181|Drug|Midazolam|single dose IV midazolam, .45mg/kg infused over 40 minutes
45642983|NCT04895696|Other|Placebo|Specified dose on specified days
45917432|NCT00000609|Device|defibrillators, implantable|
46070804|NCT05403944|Behavioral|Standard of Care Rehabilitation (SOC)|6 weeks of standard of care rehabilitation will be given designed to target the core, hip, and quadriceps muscles. Each participant will be expected to complete 3 supervised telehealth sessions per week.
45642986|NCT04895358|Biological|pembrolizumab|Intravenous (IV) infusion
45642987|NCT04895358|Drug|paclitaxel|IV infusion
45782354|NCT00877058|Behavioral|preventive home visit|
45782355|NCT00877058|Behavioral|senior meetings|
45782356|NCT01428245|Drug|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
45782357|NCT01428245|Drug|Estrace (estrogen)|oral estrace, 0.5-1 mg once a day for seven days
45782358|NCT00877370|Drug|ertapenem|One gram ertapenem will be infused intravenously in subjects receiving continuous hemodialysis (CVVHD). Pharmacokinetic sampling in this study will occur with the first dose of ertapenem. While on CVVHD, enrolled subjects will receive ertapenem 1 g intravenously administered over 30 minutes. Two blood samples (5 mL each) will be collected from the arterial (pre-diafilter) port of the CVVHD tubing at time 0 (baseline), ½ hour (end of infusion), 1, 1½, 2, 3, 6, 12, and 24 hours. Effluent (5 mL) will also be collected at these predefined time points from the effluent port of the CVVHD tubing. If ertapenem is discontinued after the first dose then additional samples will be collected at 36 and 48 hours, otherwise ertapenem will be administered as soon as the 24 hour sample is obtained.
45782359|NCT02210039|Device|SECM Probe|Imaging of the esophagus using SECM probe and system.
45782360|NCT00877604|Drug|tauroursodeoxycholic acid (TUDCA)|Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year
45642988|NCT04895358|Drug|nab-paclitaxel|IV infusion
45642989|NCT04895358|Drug|liposomal doxorubicin|IV infusion
45642990|NCT04895358|Drug|capecitabine|oral administration
45642991|NCT04895358|Drug|normal saline|IV infusion
45642992|NCT04895358|Drug|dextrose|IV infusion
45754314|NCT00555321|Drug|Tacrolimus|Capsules, Oral, dosed to achieve 12 hour trough level of 6-12 ng/mL, twice daily, 52 weeks (Short Term [ST]), in accordance with local practice and the package insert, 4 years (Long-Term Extension [LTE])
45754315|NCT00555321|Drug|Basiliximab|Intravenous (IV), 20 mg, Day1 and Day 5
45782361|NCT00877604|Drug|Placebo|identical placebo by oral route at the same dosing schedule
45782362|NCT01508117|Drug|Axitinib|5 mg twice daily starting 21 days after resection and continuing until progression or unacceptable toxicity
45782363|NCT01508117|Radiation|Radiation Therapy|45 Gy in 15 fractions starting after 28 days of Axitinib monotherapy
45642993|NCT04895085|Diagnostic Test|BinaxNOW Rapid Antigen System|"BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes.~The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more."
45642994|NCT04893564|Biological|bone marrow sample|8 to 13 ml bone marrow sample for frozen storage within one of the 5 certified biobank of the canceropole area.
45448962|NCT02254798|Other|no intervention|this is a non interventional study
45448963|NCT02142790|Drug|paclitaxel liposome injection|
45642995|NCT04893564|Biological|blood sample|20 ml blood sample for frozen storage within one of the 5 certified biobank of the canceropole area.
45448964|NCT02142868|Drug|Palbociclib|Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1)
45448965|NCT02142868|Drug|Letrozole|Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
45642996|NCT04889924|Radiation|Axillary Radiotherapy|Axillary radiotherapy without lymphadenectomy (level I and II) + level III and supraclavicular +/- internal mammary chain
45642997|NCT04889924|Procedure|Lymphadenectomy|Axillary Lymph node dissection
45642998|NCT04889209|Biological|Ad26.COV2.S|Formulated to contain 5x10 virus particles of the Ad26 vector encoding the S glycoprotein of SARS-CoV-2. Each dose of the Ad26.COV2.S vaccine also includes sodium chloride, citric acid monohydrate, trisodium citrate dihydrate, polysorbate-80, 2-hydroxypropyl-ß-cyclodextrin, and ethanol. Ad26.COV2.S will be used undiluted to obtain the specified vp content in 0.5 mL doses. Each dose is 0.5 mL.
45642999|NCT04889209|Biological|BNT162b2|A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2. Each vial contains up to six doses. BNT162b2 (250 mcg/0.5 mL) will be administered in diluted 0.3 mL doses (30 mcg/0.3 mL).
45643000|NCT04889209|Biological|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV).
45643001|NCT04889209|Biological|mRNA-1273.211|Lipid nanoparticle (LNP) dispersion containing 1:1 mix of mRNAs that encodes for the prefusion stabilized S protein of the B.1.351 variant SARS-CoV-2 strain and the prefusion stabilized S protein of the Wuhan-Hu-1 strain used in mRNA-1273. mRNA-1273.211 (0.2 mg/mL) will be administered in 0.5 mL doses (100 mcg/0.5 mL).
45643002|NCT04889209|Biological|mRNA-1273.222|Formulated in the same way as the mRNA-1273 vaccine but contains 1:1 mix of mRNAs that encodes for the prefusion stabilized S protein of the Omicron BA.4/BA.5 variant SARS-CoV-2 strain and the prefusion stabilized S protein of the Wuhan-Hu-1 strain used in mRNA-1273.
45643003|NCT04889209|Biological|SARS-CoV-2 rS/M1|SARS-CoV-2 rS Drug Substance containing the prototype Wuhan is formulated with saponin-based Matrix-M adjuvant in a buffer of 25 mM sodium phosphate (pH 7.2), 300 mM sodium chloride, and 0.01% (weight per volume [w/v]) polysorbate 80. NVX-Co-V2373 will be administered in 0.5 mL dose (5 mcg Prototype SARS-CoV-2 rS with 50 mcg Matrix-M adjuvant)
45643004|NCT04887259|Biological|LAVA-051|In part 1 and part 2, LAVA-051 will be administered via intravenous (IV) infusion
45643005|NCT04887259|Biological|Interleukin 2|In Part 1 and Part 2, a low dose of interleukin 2 will be given via subcutaneous injection with LAVA-051 in a selected group of patients
45643006|NCT04886804|Drug|BI 1810631|BI 1810631
45782364|NCT00878228|Drug|Ondansetron|The study group will receive 4 mg of IV ondansetron perioperatively and also postoperative oral ondansetron tablets (8 mg each day for two days). The tablets will be concealed in generic capsules prepared by the pharmacy at the Hospital for Special Surgery to make the ondansetron tablets indistinguishable from the placebos.
45782365|NCT00878228|Drug|Placebo|The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days). These placebo tablets will contain lactose and be indistinguishable from the study medication.
45782366|NCT01390259|Device|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
45782367|NCT01390259|Device|Closed-Loop|In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This system uses two DexComTM Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer based algorithm used CGM values to make recommendations of insulin treatment. The study included a challenge to the insulin management system with meals and mild exercise, so as to demonstrate its capacity to avoid large glucose excursion with changing metabolic state.
45782368|NCT04091516|Behavioral|Low-fat plant-based diet|Participants will follow a diet that consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. Except for light refreshments and tastings at the group sessions, no meals will be provided. Participants will handle their own food preparation and purchases, with guidance from the education team, with no restriction on energy intake.
45782369|NCT05235386|Device|Automated oxygen titration|Automated oxygen administration to maintain the SpO2 target at a predefined value during emergency length of stay
45782370|NCT01391273|Drug|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
45917433|NCT04557124|Behavioral|USS|social cognitive training
45782371|NCT01391273|Drug|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
45782372|NCT05235230|Drug|Test product (T) 25 mg Film Coated Tablets|Film Coated Tablets products containing 25 mg Quetiapine
45782373|NCT05235230|Drug|Reference product (R) 25 mg Film Coated Tablets|Reference product (R) 25 mg Film Coated Tablets
45782374|NCT01429259|Drug|meropenem|meropenem 40mg/kg total body weight will be administered every 8 hours. Each infusion will be infused as a 3 hour infusion.
45782375|NCT05177198|Procedure|M-MIST + Clindamycin augmented PRF|modified minimally invasive surgical technique with Clindamycin (at concentration of 150 mg/ml) augmented platelet-rich fibrin.
45782376|NCT05177198|Procedure|M-MIST + PRF|modified minimally invasive surgical technique with platelet-rich fibrin alone.
45782377|NCT01392053|Other|Lumbosacral Massage|Massage Group (GM) will receive lumbosacral massage for 30 minutes, during uterine contractions between 4-5 cm of cervical dilation.
45782378|NCT02512068|Drug|Trelagliptin 25 mg|Trelagliptin 25 mg Tablets
45782379|NCT02512068|Drug|Placebo|Placebo Tablets
45782380|NCT02979821|Drug|Poziotinib|A cycle of study treatment is defined as 28 days.
45782381|NCT02204657|Device|Continuous Glucose Monitoring System|Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) at weeks 28, 32 and 36 and have the CGMS reviewed at weeks 29, 33 and 37 and management adjusted based on the CGMS readings
45782382|NCT03008603|Device|XACT Robotic System|The XACT device is a real-time, CT image guided, 3-dimensional robotic system. The XACT device is intended for use as an image guided positioning and steering system for insertion of clinical tools, such as biopsy needles, ablation needles, etc., during minimally invasive percutaneous procedures. The system is defined to guide (i.e., position and steer) the tool according to a predefined trajectory following a registration process between the device's coordinate system and real-time CT images.
45782383|NCT02511678|Device|Cryoablation|The application of repeated freeze and thaw cycles to the identified tissues.
45782384|NCT01392989|Drug|CIK cells|Standard of care
45782385|NCT01392989|Drug|Cyclosporine|5 mg/kg, po
45782386|NCT01392989|Drug|Mycophenolate Mofetil|15 mg/kg, oral
45917434|NCT04557124|Behavioral|MovingForward|problem solving training
45917435|NCT04547530|Dietary Supplement|Vitamin D|as above
46070805|NCT05403944|Behavioral|Strength Training Rehabilitation Incorporating Power Exercises (STRIPE)|6 weeks of STRIPE rehabilitation will be given designed to target the core, hip, and quadriceps muscles. Each participant will be expected to complete 3 supervised telehealth sessions per week.
45448966|NCT02145520|Drug|Magnesium Sulfate|The use of magnesium sulfate intravenous in patient with bronchiolitis in pediatric emergency; follow Broncholitis severity score and length of stay
45448967|NCT02145520|Other|placebo|use of placebo with standard therapy
45782387|NCT01392989|Drug|Thymoglobulin|7.5 mg/kg, IV
45448968|NCT03544372|Other|Assessment of Concussion History using NIH Concussion History Tool|NIH concussion tool
45782388|NCT01392989|Radiation|Total Lymphoid Irradiation (TLI)|
45643007|NCT04884815|Genetic|UX701|Nonreplicating, recombinant gene transfer vector
45643008|NCT04884815|Other|Placebo|Normal saline
45643009|NCT04877613|Drug|single dose of CART-GFRa4 cells|Intravenous infusion of lentiviral transduced autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity towards GFRa4 with fludarabine and cyclophosphamide.
45782389|NCT02511444|Other|GBS culture and real time PCR|patients with signs and symptoms of threatened preterm labor, or indications for preterm delivery will have GBS colonization screened by culture and real time PCR.
45782390|NCT01393457|Drug|levodopa/carbidopa|800/200 mg/d
45782391|NCT01393457|Drug|Ropinirole 2 mg/d|2 mg/d
45782392|NCT01393457|Drug|Placebo|sugar pill
45782393|NCT01393457|Drug|Ropinirole 4 mg/d|4 mg/d
45782394|NCT02518464|Drug|Ticagrelor 90 mg twice per day|Patients will be loaded with 180 mg of Ticagrelor during the enrollment office visit and provided with a 28 day supply of Ticagrelor, 90 mg twice per day. P2Y12 reactivity unit (PRU) testing will be conducted at 7-14 days. If the patient has a positive response, they will have the option of continued access of Ticagrelor 180 mg for another 2 months. Participants will be reminded via text message daily to complete a headache survey on line in order to track their headaches.
45782395|NCT02479230|Biological|tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine|Given ID
45643010|NCT04877613|Drug|Fludarabine|Lyphodepletion
45643011|NCT04877613|Drug|Cyclophosphamide|Lyphodepletion
45643012|NCT04875195|Biological|Pembrolizumab|Pembrolizumab, 400 mg, Q6W, intravenous (IV) infusion.
45782396|NCT02479230|Drug|gemcitabine hydrochloride|Given IV
45782397|NCT04985136|Drug|camrelizumab；Rivoceranib|Camrelizumab at 200 mg via intravenous administration (IV), once every 2 weeks (Q2W), in combination with 250 mg of rivoceranib mesylate, oral administration, once a day (QD)
45782398|NCT04985136|Drug|Rivoceranib|Rivoceranib mesylate (750 mg, QD, po)
45782399|NCT04985136|Drug|Sorafenib|Sorafenib tosylate (400 mg, twice a day (BID), po)
45917436|NCT04547530|Dietary Supplement|Placebo|as above
45643013|NCT04871607|Biological|Basiliximab|Given IV
45643014|NCT04871607|Drug|Carmustine|Given IV
45643015|NCT04871607|Drug|Cytarabine|Given IV
45643016|NCT04871607|Drug|Etoposide|Given IV
45643017|NCT04871607|Biological|Genetically Engineered Hematopoietic Stem Progenitor Cells|Given via infusion
45643018|NCT04871607|Biological|Recombinant Granulocyte Colony-Stimulating Factor|Given SC or IV
45643019|NCT04871607|Biological|Yttrium Y 90 Basiliximab|Given IV
45643020|NCT04869917|Behavioral|Decision Aid intervention|"Displays information about the benefits and risks of ILI and metformin~Asks open-ended questions: What am I willing to do to prevent T2D? and What do I need to prevent T2D?~Prompts patients to commit to immediate next steps~Health educator schedules interested patients for first ILI session or sends message to provider about patients' interest in starting metformin, if chosen"
45643021|NCT04869917|Behavioral|Text Messaging intervention|"Defines prediabetes and includes individualized A1c values~Present benefits and risks of intensive lifestyle intervention and metformin~States that other prediabetic Erie patients are adopting intensive lifestyle intervention and metformin~Encourages initiating intensive lifestyle intervention or discussing metformin with provider~Include selected behavioral content from diabetes prevention program~Initial message with automatic opt-in, allows opt-out for messages~Subsequent messages include: information about T2D risk and treatments; prompts to directly schedule intensive lifestyle intervention or office visit to discuss metformin; selected behavioral content from diabetes prevention programming"
45643022|NCT04869917|Behavioral|Usual Care|Patients receiving care at non-intervention clinic sites will not be exposed to treatment intervention.
45643023|NCT04869397|Biological|Allogeneic Wharton's jelly-MSCs (WJ-MSC)|"The product is provided cryopreserved by NextCell Pharma. The cells are frozen in cryobags at a concentration of 2 × 107 cells/ml in 5% Human Serum Albumin (HSA) and 10% dimethylsulfoxide (DMSO). One cryobag contains one dose. The bags are frozen in a controlled rate freezer and directly transferred to -190 ºC for storage until the time of infusion.~Cryobags are thawed at bedside and diluted in 100 ml of saline prior to administration. Cells will be delivered at a rate of 5 million cells per minute over a total of 20 minutes."
45643024|NCT04869397|Other|Placebo|Sodium chloride buffer supplemented with 5% HSA and 10% DMSO same volume and mode of administration as treatment group
45782400|NCT04985136|Drug|Regorafenib|Regorafenib (160 mg, administer for 21 days then stop for 7 days, po)
45782401|NCT02510820|Device|comfilcon A|soft contact lens
45782402|NCT02510820|Device|Synergi|Multipurpose solution
45782403|NCT02510820|Device|Biotrue|Multipurpose solution
45448969|NCT02145598|Drug|Lenalidomide|after 6 cycles VMP Patients will receive Lenalidomide given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
45643025|NCT04865042|Drug|Gabapentin 300mg|"The patient will receive in addition to the usual analgesic treatment, the treatment under study: Gabapentin.~During the first 3 days of his hospitalization, an evaluation of the pain and the tolerance to the treatment will be performed.~The patient will have to take the treatment as follows:~Day 1 (1st day of hospitalization): 1 capsule/day~Day 2: 2 capsules/day~Day 3: 3 capsules/day 72 hours after the first treatment, a blood test will be performed."
45782404|NCT02510820|Other|stenfilcon A|daily disposable contact lenses for washout period
45643026|NCT04865042|Drug|PLACEBO|"The patient will receive in addition to the usual analgesic treatment, the Placebo During the first 3 days of his hospitalization, an evaluation of the pain and the tolerance to the treatment will be made.~The patient will have to take the treatment as follows:~Day 1 (1st day of hospitalization): 1 capsule/day~Day 2: 2 capsules/day~Day 3: 3 capsules/day 72 hours after the first treatment, a blood test will be performed."
45782405|NCT02510664|Behavioral|Diabetes Strengths Study|"The intervention consists of: (A) assessing youth and family diabetes strengths and adherence prior to each visit, and (B) training diabetes care providers to tailor their clinical encounters around reinforcing each patient and family's unique diabetes strengths profile generated from the strengths and adherence assessments."
45782406|NCT01509677|Drug|Roflumilast|500 μg tablet, once daily, oral administration in the morning after breakfast
45782407|NCT01509677|Drug|Placebo|tablet, once daily, oral administration in the morning after breakfast
45782408|NCT02510040|Device|Prism|Ground-in or Fresnel prism
45782409|NCT02510040|Other|Orthoptic Exercises|Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy
45782410|NCT02510040|Procedure|Eye Muscle Surgery|"Bilateral medial rectus muscle resection surgery~Single medial rectus muscle resection surgery~Recess lateral rectus muscle resection medial rectus muscle surgery~Bilateral lateral rectus muscle recession surgery~Single lateral rectus muscle recession surgery~Bilateral lateral rectus muscle resection surgery~Single lateral rectus muscle resection surgery~Recess medial rectus muscle resection lateral rectus muscle surgery~Bilateral medial rectus muscle recession surgery~Single medial rectus muscle recession surgery~Vertical rectus muscle recession surgery~Vertical rectus muscle mini-tenotomy (snip) surgery"
45782411|NCT02510040|Procedure|Botox Injection|Botulinum toxin injection
45782412|NCT05460936|Other|Lower Extremity Functional Training|motor learning, skill progression, and resistance training to target the balance, strength, and coordination impairments of the lower extremities. Motor learning will be based on strength and balance training using tandem walks, balance boards, and one-leg standing. Skill progression will be used to challenge the LIFT and the strength training will be achieved by performing sit-to-stand, sit-ups, stair climbs, and vertical jumps
45448970|NCT02145598|Drug|Placebo|after 6 cycles VMP Patients will receive Placebo given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
45782413|NCT05460936|Other|conventional physical therapy|Resistive Exercises Stretching exercise of quadriceps , hamstring adductors and abductors.
45782414|NCT04411446|Drug|Vitamin D|5 capsules of 100.000 UI Vitamin D orally given all at once. One dose.
45782415|NCT04411446|Drug|Placebo|5 capsules of containing placebo orally given all at once. One dose.
46070806|NCT03200054|Other|Adherence Clubs|Women will be referred to the ACs at their postpartum ART clinic visit at the midwife obstetric unit (MOU) at the Gugulethu community health centre (CHC). AC visits occur 2-4 monthly at a community hall near the CHC. At routine visits, which last ~1 hour, community health workers provide health education, weigh participants, ask about symptoms, and dispense pre-packed ART. Symptomatic participants are referred back to the main ART facility at the CHC for assessment by a nurse. A nurse performs routine phlebotomy at an annual club visit, and does a clinical assessment and reviews blood results at the subsequent visit. Participants requiring more regular follow-up and those with raised viral loads are referred back to the ART clinic at the CHC by the nurse.
45448971|NCT02145832|Drug|Fluconazole|
45448972|NCT02145832|Drug|Micafungin|
45448973|NCT03749122|Procedure|Waiting time for hip fracture surgery|Time from hospital admission to start of hip fracture surgery
45448974|NCT02149030|Other|Cytological screening in A1 and A3|Cytological screening.
45782416|NCT01510379|Device|Reletex|Neurostimulation device for prevention/treatment of post-operative nausea and vomiting, Reletex arm.
45782417|NCT01510379|Drug|IV ondansetron 4 mg q 6 hours for a total of 4 doses|
45643027|NCT04861441|Device|Aircast Cryo Cuff (Shoulder) and Aircast Cryo Cuff I/C Motorized Cooler|Patient will wear the continuous cryo cuff for a designated period of time and will record their pain and narcotic use post operatively.
45643028|NCT04861441|Device|Icepacks|Standard of care icepacks will be used postoperatively for designated amount of times and patients will record pain and narcotic use post operatively.
45643029|NCT04861259|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight >=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. On Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight >=100kg).
45643030|NCT04858334|Procedure|Biospecimen Collection|Undergo collection of blood
45643031|NCT04858334|Procedure|Computed Tomography|Undergo CT
45643032|NCT04858334|Procedure|Magnetic Resonance Imaging|Undergo MRI
45782418|NCT01510379|Drug|IV promethazine 25 mg q 6 hours prn|
45782419|NCT01510379|Drug|Elixir promethazine 25 mg q 6 hours prn after discharge|
45782420|NCT03784716|Other|Ketogenic Diet|Ketogenic diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 70% fat, 25% protein, and 5% carbohydrate for the ketogenic diet.
45782421|NCT03784716|Other|Standard Weight Loss Diet|Standard weight loss diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 30% fat, 20% protein, and 50% carbohydrate for the standard weight loss diet.
45782422|NCT01363986|Drug|trastuzumab [Herceptin]|Initial loading dose of 4 mg/kg i.v. infusion, followed by weekly doses of 2 mg/kg for up to 18 weeks.
45782423|NCT01510457|Drug|Milnacipran|Total target dose of 200 mg/day. Subjects will titrate-up according to the following schedule: 25 mg/d (2 pills, 2 days), 50mg mg/d (4 pills, 2 days), 100mg/d (2 pills, 3 days), 150 mg/d (3 pills, 4 days), and steady state is reached once the study participant ingests 200 mg/d(4 pills). The steady state is maintained for 44 days (approx. 6 weeks). If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 100 mg/day at the discretion of the PI. Subjects unable to tolerate 100 mg/day will be discontinued from the study. A 2-week down-titration will be used.
45782424|NCT01510457|Drug|Placebo|Subjects will receive identical placebo pills and dosing schedule as that of participants receiving active study medication.
45782425|NCT04983966|Drug|Desﬂurane|"General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.~Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5"
45782426|NCT04983966|Drug|Remimazolam|"General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.~Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5"
45782427|NCT01430741|Behavioral|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
45782428|NCT01430741|Other|Getting To Outcomes|"GTO strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. GTO consists of a series of steps practitioners should follow in order to obtain positive results and then provides them with the guidance necessary to complete those steps with quality. According to GTO, carrying out an evidence based program includes a series of steps corresponding to three general areas: (1) planning - e.g., developing goals and performance targets, ensuring staff are trained in the evidence based program; (2) implementation - e.g., monitoring program activities, maintaining adherence to an evidence based program model, supervision; and (3) self-evaluation - e.g., tracking patient outcomes, using data to improve program operations."
45782429|NCT01430741|Behavioral|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
46070807|NCT00648739|Drug|Samalizumab|Samalizumab is a humanized anti-CD200 monoclonal antibody.
46070808|NCT00812695|Device|CPAP|Gold standard treatment for Obstructive sleep apnea
46070809|NCT00812773|Drug|GSK2190915|Investigational Product
45448975|NCT02149186|Device|iCTuS-L|
45448976|NCT00104728|Drug|ZD1839|
45643033|NCT04858334|Drug|Olaparib|Given PO
45643034|NCT04858334|Drug|Placebo Administration|Given PO
45643035|NCT04857138|Drug|RO7300490|Participants will receive RO7300490, as described in the Arm Descriptions.
45643036|NCT04857138|Drug|Atezolizumab|Participants will receive Atezolizumab, as described in the Arm Descriptions.
45643037|NCT04854005|Procedure|Breast surgery|Patients will undergo SLNB with single or dual-tracer lymphatic with technetium-99m sulfur colloid either lymphazurin or methylene blue dye, per institution standard, in accordance with routine clinical practice.
45643038|NCT04853368|Drug|ABBV-576|Oral capsules
45643039|NCT04853368|Drug|Galicaftor|Oral capsules
45643040|NCT04853368|Drug|Placebo|Oral capsules
45643041|NCT04853368|Drug|Navocaftor|Oral capsules
45643042|NCT04853368|Drug|ABBV-119|Oral capsules
45643043|NCT04851964|Biological|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
45782430|NCT01430741|Other|Getting To Outcomes|"GTO strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. GTO consists of a series of steps practitioners should follow in order to obtain positive results and then provides them with the guidance necessary to complete those steps with quality. According to GTO, carrying out an evidence based program includes a series of steps corresponding to three general areas: (1) planning - e.g., developing goals and performance targets, ensuring staff are trained in the evidence based program; (2) implementation - e.g., monitoring program activities, maintaining adherence to an evidence based program model, supervision; and (3) self-evaluation - e.g., tracking patient outcomes, using data to improve program operations."
45782431|NCT01430741|Behavioral|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
45782432|NCT02478372|Drug|Patient Controlled Epidural (PCEA)|Following the operation, 4ml of 0.25% levobupivacaine was administered and the catheter was connected to a PCEA. Self-medication with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes until the following morning (post-operative day one) when it was stopped.
45643044|NCT04851964|Other|Placebo|Placebo subcutaneous injection
45782433|NCT02478372|Drug|Local Infiltration Analgesia (LIA)|Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine.
45643045|NCT04838925|Device|Mobile Neurofeedback App|Neurofeedback intervention delivered via mobile app. Participants wear an EEG headset which is connected to a mobile app that delivers feedback about brainwave data indicating whether they are in a calm, relaxed state. Participants hear a lower/simple sound when they are below a target level and higher/richer sound when they approach or achieve their target.
45643046|NCT04838626|Drug|[18F]CTT1057|PET/CT imaging with [18F]CTT1057
45643047|NCT04838106|Other|Not applicable as observational study|Not applicable as observational study.
45782434|NCT01511315|Drug|Ustekinumab|Biologic agent: sub-cutaneous injection at Weeks 0, 4, and then every 12 weeks thereafter.
45643048|NCT04837365|Other|Three dimensional gait analysis with eyetracking|An emotional impregnation and eye pursuit assessment are specific to the study. Emotional impregnation involves making the patient look at images from the International Affective Picture System (IAPS) on a screen before initiating walking. The equipment will be identical to that of the patient during walking tasks. Eye movement analysis is performed using a pair of eyetracking glasses.
45782435|NCT01654536|Drug|ciclesonide nasal aerosol|ciclesonide nasal aerosol 74 mcg (given as 1 actuation per nostril of 37 mcg ciclesonide nasal aerosol)
45782436|NCT01654536|Drug|ciclesonide nasal spray|ciclesonide nasal spray 200 mcg (given as 2 actuations per nostril of 50 mcg ciclesonide nasal spray)
45782437|NCT01654380|Drug|LY2605541|LY2605541 is a solution. The concentration of LY2605541 is 100 units/milliliter (U/mL).
45643049|NCT04833790|Behavioral|Free distribution of ORS|Provides will receive 3 months supply of ORS at the beginning of the study to dispense to their patients. They will be asked to dispense the ORS at the market rate and not to give it away to other providers.
45643050|NCT04833790|Behavioral|Standardized patient with ORS preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who requests ORS to treat their child's diarrhea.
45643051|NCT04833790|Behavioral|Standardized patient with Antibiotic preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who requests Antibiotics to treat their child's diarrhea.
45643052|NCT04833790|Behavioral|Standardized patient with no preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who does not request anything specific to treat their child's diarrhea.
45782438|NCT01654380|Other|Insulin glargine|Insulin glargine is a 100 U/mL solution in 10 milliliter (mL) glass vial.
45782439|NCT02477670|Drug|AVP-786|
45782440|NCT02477670|Drug|Placebo|
45782441|NCT04943562|Diagnostic Test|ACT+EEG|Combination of ACT+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
45782442|NCT02509026|Biological|Etanercept|50 mg subcutaneous, once weekly, 24 weeks
45782443|NCT03439280|Drug|Mezagitamab|Mezagitamab subcutaneously.
45782444|NCT03439280|Drug|Pomalidomide|Pomalidomide orally.
45782445|NCT03439280|Drug|Dexamethasone|Dexamethasone orally.
45782446|NCT03438032|Diagnostic Test|Bronchoscopy with lavage|During an elective bronchoscopy procedure, the bronchoscope will be wedged into an affected lung segment guided by CT scanning. When involved an anterior segment will be used to maximize return. After wedging the bronchoscope, 120ml of sterile 0.09% normal saline will be instilled. Up to 40-60 mL of BAL fluid will be obtained for analysis during each sampling.
45782447|NCT04982562|Other|7T MRI|Seven tesla brain MRI (7T MRI) at day 7 in patients suffering from post concussionnal symptoms after mild traumatic brain injury admitted to emergency departement of Poitiers CHU (University Hospital
45782448|NCT00828074|Drug|sorafenib tosylate|Dose level 1 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 2 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 3 = 200 mg by mouth in the am and 400 mg by mouth in the pm on days 1-28 of a 28 day cycle. Dose level 4 = 400 mg by mouth two times a day on days 1-28 of a 28 day cycle.
45782449|NCT00828074|Drug|vinorelbine ditartrate|Dose level 1 = 20 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 2 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 3 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 4 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle.
45782450|NCT01394003|Drug|LY2584702|administered orally
45643053|NCT04833790|Behavioral|Standardized patient with no preference + no financial incentive|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who does not request anything specific to treat their child's diarrhea. In addition they will inform the provider that they are not going to purchase anything from the provider because they have an uncle with a drug shop where they can get a discount.
45643054|NCT04832854|Drug|Atezolizumab|Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of each 21-day cycle.
45643055|NCT04832854|Drug|Tiragolumab|Tiragolumab 600 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
45782451|NCT03434444|Drug|Oxytocin|Oxytocin in solution, ranging from 10 -12M to 10 -5M
45782452|NCT03434444|Drug|Propranolol|Propranolol in solution, 10-6M
45782453|NCT04382300|Drug|pyrotinib combined with thalidomide|Single Group Assignment
45782454|NCT01394081|Other|Enhanced Engagement and Enrollment (EEE)|Consists of motivational interviewing, educational outreach, and patient navigation.
45782455|NCT01394081|Other|Administrative Outreach (AO)|Consists of giving information about enrolling for VA medical care or scheduling an appointment
45782456|NCT04382534|Combination Product|Respiratory rehabilitation|Health education and energy saving techniques, chest activity training, local lung dilation techniques, breathing training, airway clearance training, aerobic exercise, resistance training
45643056|NCT04832854|Drug|Carboplatin|Carboplatin at initial target area under the concentration curve (AUC) of 5 or 6 mg/mL/min will be administered by IV infusion on Day 1 of each 21-day cycle.
45782457|NCT00880022|Device|Flexitouch System|( 10 to 30 treatments depending on group assignment)
45782458|NCT01430819|Biological|Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation|0.5 mL, Intramuscular
45782459|NCT01430819|Biological|Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation|0.5 mL, Intramuscular
46070810|NCT02552017|Device|Endocuff Vision|Endocuff Vision is a new device made of soft plastic material with a unique dynamic shape. It is manufactured by ARC Medical Design Limited and Diagmed in the United Kingdom. It has European Conformity in United Kingdom. The core is made of polypropylene and the 'finger like' projections are made of a thermoplastic elastomer. It comes in four colour coded sizes (purple, blue, green and orange) to fit a range of paediatric and adult colonoscopes. Endocuff Vision is the more updated version of device that has only one proximal row of more rounded finger-like projections. It is mounted at the tip of the colonoscope and held on by friction (pull-off force is a minimum of 10 Newtons).
45448977|NCT02145910|Drug|Vemurafenib|Given PO
45448978|NCT02145910|Radiation|Whole-brain radiation therapy (WBRT)|Undergo WBRT
45448979|NCT02145910|Radiation|Radiosurgery (SRS)|Undergo SRS
45643057|NCT04832854|Drug|Cisplatin|Cisplatin at 75 mg/m^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
45643058|NCT04832854|Drug|Pemetrexed|Pemetrexed at 500 mg/m^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
45643059|NCT04832854|Drug|Gemcitabine|Gemcitabine at 1000 or 1250 mg/m^2 will be administered by IV infusion on Days 1 and 8 of each 21-day cycle.
45643060|NCT04832854|Drug|Paclitaxel|Paclitaxel at 175 or 200 mg/m^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
45643061|NCT04830592|Biological|NG-641|Patients receive three doses of NG-641 by intravenous infusion. NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.
45643062|NCT04830592|Biological|Pembrolizumab|Patients receive three doses of NG-641 by intravenous infusion and a single dose of Pembrolizumab by intravenous infusion.
45643063|NCT04827849|Other|Structured education and follow-up|"The women in the intervention groups will administer a seven-session intervention program in addition to the routine care they will receive.~The training including preparation practices for the transition with the mother, which is planned to last for 7 weeks encompassed providing the women with an educational programme that were created to increasing women's adaptation to motherhood and perceptions of newborn baby~Nursing-recommended follow-up and physical examination of the pregnant woman will be performed at 28th and 34th week of pregnancy. In addition, postpartum and newborn follow-up, and mother-newborn physical examinations will be performed at the postpartum period."
45782460|NCT00828542|Drug|etonogestrel implant|Etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate postpartum period (from 24 to 48 hours postpartum)
45782461|NCT00828542|Drug|depot medroxyprogesterone acetate|150 mg medroxyprogesterone administered I.M. every three months starting 6 weeks after delivery
45782462|NCT01394159|Procedure|22G ProCore biopsy needle|Tissue will be acquired with the 22G Procore biopsy needle and the sample will be compared to the sample obtained with the 22G standard FNA needle.
45782463|NCT01394159|Procedure|22G standard FNA needle|Tissue will be acquired with the 22G standard FNA biopsy needle and the sample will be compared to the sample obtained with the 22G ProCore biopsy needle.
45782464|NCT03008759|Other|Dentifrice 100% Nano-F|Use of few of dentifrice 100% Nanoencapsulated Fluoride on brushing for one week, twice day.
45782465|NCT03008759|Other|Dentifrice 50% Nano-F|Use of few of dentifrice 50% Nanoencapsulated Fluoride on brushing for one week, twice day.
45782466|NCT03008759|Other|Dentifrice standard|Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluorid
45782467|NCT01394705|Device|BodyMedia|Accelerometer
45782468|NCT01395329|Drug|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
45782469|NCT01395329|Drug|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
45782470|NCT01395329|Drug|Placebo|gelatin capsule to be taken by mouth once per day for 12 weeks
45782471|NCT01395329|Other|Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)|The forearm blood flow response to the endothelin (ET) -1 A receptor blocker BQ-123 (100 nmol/min) for 60 minutes at baseline and at 12 weeks.
45782472|NCT01395329|Other|FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)|The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
45782473|NCT01395329|Other|FBF response to Acetylcholine|The FBF response to the endothelium-dependent vasodilator ACh (4, 8 and 16 ug/100 mL tissue/min) at baseline and at 12 weeks.
45782474|NCT01395329|Other|FBF response to Sodium Nitroprusside|The FBF response to the endothelium independent vasodilator NTP (1,2 and 4 ug/100 mL tissue/min) at baseline and at 12 weeks.
45782475|NCT01395329|Other|FBF response to BQ-123+BQ-788+ACh|The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
45782476|NCT00882206|Drug|cytarabine|"At baseline when peripheral blood draw and bone marrow aspirate performed.~*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg."
45782477|NCT00882206|Drug|decitabine|Days 1-4, 15 mg/m^2 intravenously (IV) over 1 hour
45782478|NCT00882206|Drug|doxorubicin hydrochloride|Day 5, 60 mg/m^2 intravenously (IV) over 15 minutes
45782479|NCT00882206|Drug|imatinib mesylate|340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age <18 years and 400 mg orally every day for >18 years on Days 5-33.
45782480|NCT00882206|Drug|methotrexate|**Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
45782481|NCT00882206|Drug|pegaspargase|2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)
45782482|NCT00882206|Drug|prednisone|40mg/m2/day divided BID (days 5 - 33)
45782483|NCT00882206|Drug|vincristine sulfate|1.5mg/m2 (max 2 mg) iv push q week (days 5, 12, 19, 26)
45782484|NCT00882206|Drug|vorinostat|Days 1-4, (230 mg/m2)orally divided twice a day (max dose 400 mg daily)
45782485|NCT00831272|Drug|naltrexone|50mg/day
45782486|NCT00831272|Drug|Placebo|Placebo
45782487|NCT00831428|Other|no intervention|this is a screening study, not an interventional study
45782488|NCT00832130|Device|Manual Mini System|In-office device treatment for meibomian gland dysfunction by a physician
45782489|NCT00832130|Device|iHeat Portable Warm Compress Therapy|At-home daily warm compress therapy
45917437|NCT04544683|Drug|Cervical Transforaminal Epidural Injection with dexamethasone sodium phosphate|Transforaminal epidural steroid injection: Injection of 1 to 2 mL of 1% lidocaine to the skin and subcutaneous tissues, a 25-gauge spinal needle will be placed at the level and side of radicular pathology, based on clinical correlation of symptoms/signs and magnetic resonance imaging findings. Advancement to the appropriate target position in the neuroforamen will be performed under fluoroscopic guidance. Satisfactory target position achieved and confirmed in both anterior-posterior and oblique views, 0.5 to 1 mL of contrast will be injected under live fluoroscopic observation with or without digital subtraction angiography depending on suggestion of vascular uptake. Upon confirmation of a satisfactory epidural contrast pattern without vascular uptake, the injectate will be delivered: dexamethasone sodium phosphate 1mL (10mg/mL) and 0.5 ml of 1% preservative-free lidocaine (total volume 1.5 mL).
45448980|NCT02145988|Drug|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
45643064|NCT04827680|Device|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.
45643065|NCT04827576|Drug|Magrolimab|Administered intravenously
45643066|NCT04827576|Drug|Docetaxel|Administered intravenously, 75 mg/m^2 on Day 1 of each cycle
45643067|NCT04826640|Other|Observational|Observational
45643068|NCT04826224|Biological|Concentrated bone marrow aspirate administration after Comprehensive Arthroscopic Management (CAM) surgical procedure.|Bone marrow aspirate concentrate contains a median nucleated cell count of 121,700/uL, and platelets of 384,000/uL. This leads to a cellular dose of approximately 400 million cells.
45643069|NCT04824794|Biological|GEN3014|GEN3014 is administered by intravenous (IV) infusion.
45643070|NCT04824794|Drug|Daratumumab|Daratumumab is administered by subcutaneous (SC) injections.
45917438|NCT00000612|Drug|estrogens, conjugated|
45917439|NCT00000612|Behavioral|diet, soy proteins|
45448981|NCT02145988|Drug|Placebo|Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
45643071|NCT04824131|Drug|Oral cabotegravir (CAB)|30 mg tablets
45643072|NCT04824131|Drug|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
45643073|NCT04824131|Drug|Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)|300 mg/200 mg fixed-dose combination tablets
45782490|NCT00885092|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses.
45782491|NCT00885092|Device|RepleniSH Multi-Purpose Disinfecting Solution (MPDS) (OPTI-FREE® RepleniSH®)|Commercially marketed solution intended for use as a cleaning, conditioning, rinsing, disinfecting, and storage solution for all silicone hydrogel and soft (hydrophilic) contact lenses.
45782492|NCT00885092|Device|Senofilcon A contact lens (ACUVUE® Oasys™)|Commercially marketed silicone hydrogel contact lens for daily wear use
45782493|NCT00885092|Device|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
45782494|NCT01512251|Drug|BKM120 Combined with Vemurafenib (PLX4032)|"Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)~Dose Level -1: BKM120 60 mg daily, Vemurafenib 480 mg bid~Dose Level 1: BKM120 60 mg daily, Vemurafenib 720 mg bid~Dose Level 2: BKM120 80 mg daiy, Vemurafenib 720 mg bid~Dose Level 3: BKM120 100 mg daiy, Vemurafenib 720 mg bid~Dose Level 4: BKM120 100 mg daiy, Vemurafenib 960 mg bid~Phase II is a single-stage, single arm prospective trial: patients will receive BKM120 and vemurafenib at the RP2D"
45917440|NCT00000612|Behavioral|dietary supplements|
45917441|NCT00000639|Drug|Itraconazole|
45917442|NCT00000639|Drug|Flucytosine|
45782495|NCT00885638|Drug|Sitagliptin|100 mg sitagliptin before ingestion of macronutrient
45782496|NCT00885638|Drug|placebo|A placebo tablet is given before ingestion of macronutrients
45917443|NCT00000639|Drug|Fluconazole|
45917444|NCT00000639|Drug|Amphotericin B|
45917445|NCT04531696|Procedure|Blood draw|Blood draw at inclusion
45782497|NCT01512797|Drug|Sitagliptin phosphate|100 mg/day orally
45782498|NCT01512797|Other|Placebo|1 Placebo Pill per day
45917446|NCT04531696|Procedure|Post-mortem tissue collection|Sample collection (both liquids, tumour tissue and non-tumour tissue) during post-mortem research autopsy
45917447|NCT00000642|Drug|CD4-IgG|
45917448|NCT04511494|Dietary Supplement|Peanut (bamba)|OIT peanut with slow-updosing for 40-60 weeks followed by maintenance. 3 years treatment.
45917449|NCT00000645|Drug|Hypericin|
45917450|NCT04495504|Drug|Ropivacaine|Administration of a bolus dose of 10 ml of ropivacaine 7, 5 mg/mL in each catheter Continuous infusion of ropivacaine 2 mg/ml in a rate of 3 mL/h during the first 48 hours postoperatively.
45448982|NCT02781844|Drug|25mcg rhPTH(1-84)|Participants will receive rhPTH(1-84) as twice-daily regimen (12 hours apart) of two 25mcg doses without calcium in cohort 1 and with calcium in cohort 3.
45448983|NCT02781844|Drug|50mcg rhPTH(1-84)|Participants will receive rhPTH(1-84) as twice daily regimen (12 hours apart) of two 50mcg doses without calcium in cohort 2 and with calcium in cohort 4
45917451|NCT00390208|Drug|ranibizumab, dexamethasone and verteporfin|One 500 microgram dose (0.05cc) intravitreal dexamethasone (10 mg/ml vial) in combination with Visudyne Photodynamic Therapy and 0.5 mg intravitreal Ranibizumab injection on the same day.
45917452|NCT00390208|Drug|Ranibizumab|One 0.5 mg intravitreal Ranibizumab injection
45917453|NCT00389025|Drug|Olopatadine (generic name)|
45917454|NCT04466956|Device|Virtual reality|Virtual reality headset worn with short relaxing video played during MVA procedure
45917455|NCT00389103|Biological|MVA (smallpox vaccine)|0.5ml of MVA3000 Smallpox vaccine, administered twice separated by 28 days, subcutaneous injections
45448984|NCT02781844|Drug|100mcg rhPTH(1-84)|Participants will receive rhPTH(1-84) as once-daily regimen of one 100 mcg dose without calcium in cohort 1 and 2 and with calcium in cohort 3 and 4 in the morning.
45643074|NCT04823689|Procedure|reductions|"Two reduction techniques are compared: dorsal decubitus and ventral decubitus reduction. The dorsal decubitus reduction consists in placing the patient in the dorsal position and achieving reduction by traction maneuvers on the luxated upper limb. This maneuver generally requires procedural sedation. A mild traction of the traumatized limb in the axis is performed, with slight external rotation and progressive abduction. In the absence of reduction at this stage, this gesture is completed by a flexion adduction of the limb. A counterweight is then made by a rolled sheet and passed under the armpit of the patient.~The ventral decubitus reduction consists in placing the patient in the ventral position. The luxated limb is positioned in pendulum and the line of contact with the stretcher must pass through the mid-clavicular line. The humeral head is brought to the scapula."
45643075|NCT04823377|Other|Usual care|Patients receiving systemic anticancer treatment in their last days of life
45448985|NCT03544684|Behavioral|Effects of the type of exercise on blood glucose concentrations|glucose concentrations were assessed over the 24 hour periods following no exercise, a single bout of high intensity interval training and a single bout of moderate intensity continuous training
45448986|NCT03544294|Device|Xience alpine, ultimaster, resolute onyx, synergy|PCI will be performed
45448987|NCT02146066|Biological|DCVax-L|Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen
45448988|NCT03747172|Dietary Supplement|complementary and alternative therapy|complementary and alternative therapies were grouped into five main categories: (1) biologically based therapies , (2) mind/body therapies, (3) manipulative and body-based therapies, (4) Energy therapies and (5) alternative medical systems.
45448989|NCT02146222|Drug|VEGFR/PDGFR dual kinase inhibitor X-82|Given PO
45643076|NCT04823377|Other|Optimization of the medical decision|Impact of the use of an optimization device of the decision of cancer treatment on aggressiveness of end of life care
45643077|NCT04815707|Procedure|Occcult hernia repair|The occult hernia will be repaired during the same inguinal hernia repair
45643078|NCT04812028|Drug|Magnesium sulfate|Magnesium sulfate (MgSO4) will be administered intravenously at induction of anesthesia as a 30-minute bolus dose of 50 mg/kg (maximum 2 grams) in the OR, followed by a 15 mg/kg/hr IV infusion for 48 hours or once the patient has transferred out of the PICU, whichever comes first.
45917456|NCT04438447|Dietary Supplement|parenteral feeding|A 3-bag compartment peripheral parenteral solution (mOsm < 800) containing carbohydrate, lipids and proteins will be infused to deliver 20/25 total Kcal/kg for a total of 5 days after the operation
45782499|NCT03838952|Drug|Herbal medicine|Each pack: Jia Wei Xiao Yao San granule(5 gm), Gou Teng granule (1.1 gm),and Ba Ji Tian (1.1 gm), 2 times per day for 12 weeks.
45782500|NCT05620940|Drug|Vivitrol Injectable Product|Naltrexone Long-Acting Injection
45917457|NCT00390247|Drug|thalidomide|
45917458|NCT00000651|Drug|Zidovudine|
45917459|NCT00000651|Drug|Zalcitabine|
45782501|NCT05620940|Drug|IVL3004|Naltrexone Long-Acting Injection
45782502|NCT01395797|Drug|PIO|0, 15, and 45 mg per day.
45782503|NCT01395797|Drug|Placebo|Placebo
45782504|NCT05124704|Drug|5-8ml 0.375% ropivacaine|5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction in experimental group. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.
45782505|NCT05124704|Other|5-8ml normal saline|5-8ml of normal saline depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.
45782506|NCT00834236|Other|normal subject|biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
45917460|NCT04396288|Device|ultrasound imaging at the forearm and at the tibia|ultrasound imaging will be performed at the radius bone (forearm) and at the tibia, before, during, and after a change of intraosseous blood flow
45643079|NCT04810975|Device|Muscle Strength Training|Strength training occurring specific exercise regimens using Exercise Equipment A or B
45643080|NCT04808843|Drug|Dienogest (BAY86-5258, Visanne)|Following the physicians' decision.
45782507|NCT00834236|Other|gastric cancer|biomarker in gastric juice, e.g., alpha 1-antitrypsin
45782508|NCT01431131|Procedure|Intrasocket graft|Intrasocket mineralized cancellous allograft
45782509|NCT01431131|Procedure|Intrasocket plus facial overlay graft|Intrasocket mineralized cancellous allograft plus a facial overlay graft of bovine xenograft
45643081|NCT04807439|Device|SYNERGY XLV (Megatron) Coronary Stent System|The SYNERGY MEGATRON Everolimus-Eluting Platinum Chromium Coronary Stent System is indicated for improving luminal diameter in patients, including those at high risk for bleeding, with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST elevation MI or documented silent ischemia due to atherosclerotic lesions in native coronary arteries >3.50 mm to <5.00 mm in diameter in lesions <28 mm in length.
45782510|NCT05102318|Procedure|Direct Pulp Capping|Direct Pulp Capping
45782511|NCT05102318|Procedure|Partial Pulpotomy|Partial Pulpotomy
45782512|NCT05102318|Procedure|Pulpotomy|Pulpotomy
45782513|NCT02203019|Drug|Propofol|Propofol will be administered for sedation in mechanically ventilated patients with sepsis.
45782514|NCT02203019|Drug|Dexmedetomidine|Dexmedetomidine will be administered for sedation in mechanically ventilated patients with sepsis.
45782515|NCT02203019|Drug|Fentanyl|"Fentanyl will be administered for analgesia in mechanically ventilated patients with sepsis. The use of Fentanyl is not an intervention of interest."
45782516|NCT05015504|Behavioral|Time restricted feeding|In Phase II the study subjects will be placed on time-restricted fasting (feeding between 4 AM - 4 PM, fasting in the rest of the day) for one week.
45782517|NCT05000450|Genetic|ALLO-605|ALLO-605 is an anti-BCMA, TRAC/CD52 allogeneic edited, intracellular cytokine signaling containing, CAR T cell product
45782518|NCT05000450|Biological|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
45782519|NCT05000450|Drug|Fludarabine|Chemotherapy for lymphodepletion
45782520|NCT05000450|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
45782521|NCT00886262|Drug|Vasopressin|Patients randomly assigned to the experimental arm of the study will receive vasopressin 0.5U/hr IV (20 U vasopressin in 250mL of 0.9% NaCL to infuse at a rate of 6.25mL/hr) via internal jugular catheter. Vasopressin infusion is started at the time of incision and is stopped at the time abdominal closure is completed
45782522|NCT00886262|Drug|Normal saline placebo|Patients randomly assigned to the placebo arm of the study will receive placebo (0.9% NaCl to infuse at a rate of 6.25 mL/hr) via internal jugular catheter
45782523|NCT00887510|Drug|Hydrochlorothiazide|"25 mg tablet once daily for 6 weeks~Other Names:~HCTZ"
45782524|NCT00887510|Drug|Trandolapril|4 mg tablet once daily for 6 weeks
45782525|NCT00834626|Procedure|Ileal Interposition with Sleeve Gastrectomy|Transposition of a segment of Ileum proximally coupled with limited /complete sleeve gastrectomy.
45782526|NCT03313778|Biological|mRNA-4157|Personalized cancer vaccine, IM injection
45782527|NCT03313778|Biological|Pembrolizumab|Intravenous infusion
45448990|NCT02146222|Drug|docetaxel|Given IV
45782528|NCT01431209|Other|Laboratory Biomarker Analysis|Correlative studies
45643082|NCT04804644|Drug|Memantine Hydrochloride|Given PO
45782529|NCT01431209|Drug|Ruxolitinib Phosphate|Given PO
45448991|NCT02146222|Other|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
45448992|NCT02146222|Procedure|positron emission tomography/computed tomography|Undergo FLT PET/CT
45448993|NCT02146222|Other|pharmacological study|Correlative studies
45448994|NCT02146222|Other|laboratory biomarker analysis|Correlative studies
45448995|NCT02146300|Biological|1. session birch pollen nasal exposure 2. session xylometazoline nasal exposure|Aquagen SQ 10 000 SQ/ml nasal exposure Xylometazoline 1 mg/ml nasal exposure
45782530|NCT01431989|Drug|Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL|Test formulation
45782531|NCT01431989|Drug|Amoxil® 500mg/5mL powder for oral suspension|Reference formulation
45782532|NCT03247088|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT IV
45782533|NCT03247088|Drug|Busulfan|Given IV
45782534|NCT03247088|Drug|Cyclophosphamide|Given IV
45782535|NCT03247088|Biological|Filgrastim|Given SC
45782536|NCT03247088|Drug|Fludarabine|Given IV
45782537|NCT03247088|Drug|Mycophenolate Mofetil|Given PO
45782538|NCT03247088|Drug|Sorafenib|Given PO
45782539|NCT03247088|Drug|Tacrolimus|Given PO
45782540|NCT01397591|Biological|Ofatumumab|Given intravenously
45782541|NCT01397591|Drug|Bortezomib|Given intravenously
45782542|NCT01398059|Other|Sedentary|In this condition, participants will engage in 8 hours of uninterrupted sedentary behaviour.
45782543|NCT01398059|Other|Sedentary With Breaks|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak.
45782544|NCT01398059|Other|Sedentary With Breaks and Physical Activity|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak. Participants will also engage in 20 minutes of structured physical activity at an intensity of 60% of VO2peak in both the morning and afternoon.
45782545|NCT03855332|Drug|Sildenafil|See above
45782546|NCT03855332|Drug|Cilostazol|See above
45782547|NCT03855332|Drug|Placebo|Overencapsulated placebo
45782548|NCT02335580|Drug|Somatostatin and its analogs|Somatostatin and/or octreotide will be intravenously infused.
45782549|NCT02335580|Procedure|Endoscopic sclerotherapy, endoscopic variceal ligation, endoscopic tissue glue injection|Endoscopic sclerotherapy, endoscopic variceal ligation, and/or endoscopic tissue glue injection will be performed based on the endoscopists' choice.
45782550|NCT01514279|Behavioral|HealthyCHANGE|"Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls."
45782551|NCT01514279|Behavioral|SystemCHANGE|"Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines regarding eating, activity and sleep.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls."
45643083|NCT04804644|Other|Neurocognitive Assessment|Ancillary studies
45782552|NCT03226730|Behavioral|Household Visits|Household visits will be conducted to build trust in the health system, educate regarding different forms of modern contraception, (how administered, how they work, availability), dispel related myths (i.e., those regarding infertility), promote the health advantages of birth spacing, and create related dialogue among adolescent wives and other household members present during these visits. The relais will provide and resupply oral contraceptive pills and condoms to interested participants and will accompany the married adolescent to the nearest health facility for other forms of contraception, if requested to do so. To complement the household visits to married female adolescents, male relais will conduct home visits to discuss healthy timing and spacing of pregnancy with husbands of adolescent females, provide education on different forms of contraception, and discuss concerns husbands may have regarding use of contraception.
45782553|NCT03226730|Behavioral|Small Groups|In the wife-only groups, adolescent wives will be convened by trained adult female community members to learn and discuss a broad range of gender and health-related topics, with a focus on modern contraception, and cultivate self-efficacy, social support and life skills. The small groups will be led by trained female small group mentors who are trained peers and will follow a designated curriculum consisting of different topics each week developed by Pathfinder International and derived from Population Council/UNFPA's Safe Spaces curriculum. The husband groups will follow a curriculum adapted from Promundo's Program P6 and supplemented by the tools and activities developed by Pathfinder International. These groups of husbands will focus on fostering reflection and dialogue to contribute to more equitable gender norms, support for contraception use for HTSP, positive health seeking behavior for them and their families, and increased couples communication and joint SRH decision-making.
45643084|NCT04804644|Radiation|Stereotactic Radiosurgery|Undergo SRS
45643085|NCT04804644|Radiation|Whole-Brain Radiotherapy|Undergo HA-WBRT
45782554|NCT02476968|Drug|Olaparib|"Olaparib Capsule - 50 mg. Olaparib capsules will be packed in high-density polyethylene (HDPE) bottles with child-resistant closures. Each bottle will contain 120 capsules and 4 bottles will be dispensed for a 4 weekly visit, with a 2 day overage.~Patients will be administered olaparib capsules orally at a dose of 400 mg twice daily.~Eight 50 mg olaparib capsules should be taken at the same time each day approximately 12 hours apart with approximately 240 mL of water."
45782555|NCT03201068|Dietary Supplement|Probiotic supplement|Probiotic supplement capsule
45782556|NCT03201068|Dietary Supplement|Placebo|Placebo capsule
45782557|NCT01514513|Drug|Licefreee Spray|Liquid applied to hair and left on for at least one hour once on day 1 and once on day 8 if live lice are present.
45782558|NCT01514513|Drug|1% permethrin creme rinse|Creme rinse applied to hair and rinsed off after 10 minutes once on day 1 and once on day 8 if live lice are present.
45782559|NCT04981860|Drug|Betadine|One drop of 5% Betadine will be administered to the inferior conjunctiva of the eye
45782560|NCT04981860|Drug|Avenova|One drop of 0.01% Avenova will be administered to the inferior conjunctiva of the left eye
45643086|NCT04803851|Drug|Anlotinib plus AK105|Anlotinib： a multi-kinase inhibitor AK105： an anti-PD-1 antibody
45643087|NCT04802759|Drug|Giredestrant|30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
45448996|NCT02146456|Drug|Tranexamic Acid|
45448997|NCT02151760|Drug|18F-DCFPyL|
45643088|NCT04802759|Drug|Abemaciclib|150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
45643089|NCT04802759|Drug|Ipatasertib|400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
45643090|NCT04802759|Drug|Inavolisib|9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
45643091|NCT04802759|Drug|Ribociclib|600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
45643092|NCT04802759|Drug|Everolimus|10 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
45643093|NCT04802759|Drug|Samuraciclib|360 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
45782561|NCT02476578|Other|Email|Automated Email to the primary doctor and nurse, with the details of the patient, the condition found and the relevant measures to consider.
45782562|NCT01432145|Drug|6-Mercaptopurine|6-Mercaptopurine (6MP) 55mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given continuously until disease progression.
45782563|NCT01432145|Drug|Methotrexate|Methotrexate (MTX) 15 mg/m2 taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.
45782564|NCT04979520|Drug|Brodalumab|Subcutaneously Brodalumab/Siliq, 210mg/1.5ml once a week
45643094|NCT04802759|Drug|PH FDC SC|On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.
45643095|NCT04802759|Drug|Palbociclib|125 mg orally once a day on Days 1-21 during each 28-day cycle until unacceptable toxicity or disease progression
45782565|NCT00889928|Device|NOTES GEN 1 Toolbox|"Articulating Hook Knife~Articulating Snare~Articulating Needle Knife~Articulating Graspers~Articulating Biopsy Forceps~Steerable Flex Trocar with Rotary Access Needle~Flexible Bipolar Hemostasis Forceps~Flexible Maryland Dissector"
45782566|NCT01432379|Biological|botulinum toxin Type A|155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
45782567|NCT02504892|Drug|Everolimus|Everolimus is a commercial agent and is supplied by Novartis.
45782568|NCT02504502|Other|enhanced genomic report|a patient-centered version of a genomic results report delivered to patient through the electronic record portal
45782569|NCT01432535|Drug|PegIFN-2b (Sylatron®)|Single 4.5 μg/kg dose
45782570|NCT00890162|Drug|Epinephrine|
45782571|NCT00890162|Drug|Omalizumab (Xolair)|
45782572|NCT00890162|Drug|Placebos|
45782573|NCT02504424|Device|AeroForm Tissue Expander|The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
45782574|NCT01433081|Drug|Placebo infusion of .9 normal saline|administration of .9 normal saline
45782575|NCT01433081|Drug|administration of magnesium sulfate|administration of magnesium sulfate
45643096|NCT04802759|Drug|Atezolizumab|840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.
45782576|NCT00890396|Drug|Hydroxyurea|Parents and child's doctor may plan to use or not to use hydroxyurea.
45782577|NCT03798782|Procedure|Ross procedure|The patient will undergo the Ross procedure where the surgeon will replace the aortic valve using a pulmonary autograft (Ross procedure) with pulmonary homograft replacement of the pulmonary root. Identified Ross experts will perform all Ross procedures.
45782578|NCT03798782|Procedure|Conventional aortic valve replacement|The patient will undergo Conventional aortic valve replacement where the surgeon will replace the aortic valve with another prosthesis which can include a mechanical prosthesis, a stented biological prosthesis, a stentless biological valve or root, or a catheter valve.
45782579|NCT01434641|Other|low-dose stress MPI SPECT|novel low-dose rest/high-dose Tc-99m sestamibi SPECT protocol with wide beam reconstruction SPECT processing
45448998|NCT02146534|Drug|extended release fampridine|pts will receive Fampyra 10 mg BID PO for the duration of the study
45448999|NCT02146534|Drug|Placebo|placebo will be taken PO BID
45643097|NCT04800822|Drug|PF-07284892|PF-07284892
45643098|NCT04800822|Drug|lorlatinib|lorlatinib
45643099|NCT04800822|Drug|binimetinib|binimetinib
45643100|NCT04800822|Biological|cetuximab|cetuximab
45643101|NCT04800822|Drug|encorafenib|encorafenib
45643102|NCT04798274|Device|Continuous Theta Burst Stimulation|Continuous theta burst stimulation (cTBS) will be applied using a MagPro X100 (MagVenture, Inc. Alpharetta, GA). The cTBS protocol consists of bursts of three pulses of 50 Hz stimulation repeated at 200 ms intervals (5 times per second) for 40 seconds (for a total of 600 pulses). Stimulation will be applied at an intensity of 80% of active motor threshold (AMT). Brainsight (Rogue Research) frameless neuronavigation system will be used to target the specific structural MRI-defined region of stimulation.
45782580|NCT01400477|Drug|DMXB-A-SR|Experimental Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR)
45782581|NCT01400477|Other|Placebo|Placebo Comparator
45782582|NCT01401023|Drug|Tigecycline|: Standard treatment doses of oral antibiotics (vancomycin or metronidazole) for CDAD along with IV tigecycline (100 milligram loading dose followed by 50 milligrams every 12 hours) will be given to patients during their hospitalization (usually 7-14 days). Patients well enough to go home will receive only oral therapy.
45782583|NCT01401101|Other|PCM|Care Manager (CM) intervention
45782584|NCT01401101|Other|MEU|The MEU condition consists of only the clinician education and patient screening without written feedback.
45782585|NCT01515995|Drug|Nebulized magnesium sulfate|"15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour~Versus~15 mg albuterol in 22 ml of normal saline via nebulizer over one hour"
45782586|NCT01436045|Drug|Insulin glulisine|Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)
45782587|NCT01436045|Drug|Saline|Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)
45782588|NCT01519271|Drug|Exelon Patch (rivastigmine transdermal system)|"The Exelon Patch (rivastigmine transdermal system) is a Cholinesterase Inhibitor approved by the FDA to treat Alzheimer's and Parkinson's Disease Dementia.~5-10cm2 (4.6-9.5 mg of rivastigmine/24 hours )"
45782589|NCT01519271|Drug|Placebo Patches|The placebo patches will appear identical to the medication patches however they will be inactive (they will not contain rivastigmine).
45782590|NCT01401257|Drug|PXT3003 Low dose|Liquid,5 ml, twice a day, 12-month treatment
45782591|NCT01401257|Drug|PXT3003 Intermediate Dose|Liquid,5 ml, twice a day, 12-month treatment
45782592|NCT01401257|Drug|PXT3003 High Dose|Liquid,5 ml, twice a day, 12-month treatment
45643103|NCT04783207|Dietary Supplement|Mitopure|Softgel containing 250 mg of Urolithin A (Mitopure) with excipients. 4 soft-gels to be taken daily
45643104|NCT04783207|Dietary Supplement|Placebo|Softgel containing only excipients. 4 soft-gels to be taken daily
45782593|NCT01401257|Other|Placebo|Liquid,5 ml, twice a day, 12-month treatment
45643105|NCT04781296|Device|CT with a photon-counting detector|Enrolled subjects will complete an exam using the photon-counting CT, with or without IV contract as indicated. Images will then be compared with the previously acquired CT conducted as standard of care.
45782594|NCT01402115|Dietary Supplement|Polycan|polycan 150 mg/d for 12 weeks
45782595|NCT01402115|Dietary Supplement|Placebo|Placebo 150mg/d for 12 weeks
45782596|NCT01436279|Drug|Mifepristone|200 mg po 20-24 hours prior to the procedure
45782597|NCT01436279|Device|osmotic dilators|osmotic dilators placed in the cervix 20-24 hours prior to the procedure
45782598|NCT02210195|Drug|aprepitant|125 mg daily for 8 weeks.
45782599|NCT02210195|Drug|Placebo|Placebo daily for 8 weeks.
45782600|NCT02210195|Behavioral|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
45782601|NCT01436435|Device|Jetstream Atherectomy System|Atherectomy
45782602|NCT01437449|Drug|Docetaxel|30 mg/m² by intravenous (IV) administration
45782603|NCT01437449|Drug|Cisplatin|30 mg/m² by intravenous (IV) administration
45782604|NCT01437449|Drug|Cetuximab|400 mg/m² by intravenous (IV) administration, thereafter 250 IV
45782605|NCT01437449|Drug|Carboplatin|Area under the free carboplatin plasma concentration versus time curve (AUC)=2 by intravenous (IV) administration
45782606|NCT00836888|Biological|ONO-4538|1mg/kg, 3mg/kg, 10mg/kg and 20mg/kg ONO-4538 infusion cohorts
45782607|NCT02262026|Drug|125 mg AZD0530|Randomized to receive 125 mg of AZD0530
45782608|NCT02262026|Drug|50 mg AZD0530|Randomized to receive 50 mg of AZD0530
45782609|NCT02262026|Drug|Placebo|Placebo
45917461|NCT04384003|Device|Shear Wave Ultrasound Elastography|"Scanned protocols of sonographic imaging will be used in this study to measure extrinsic (FDL, FHL and PER) and intrinsic (AbdH, FDB and FHB) muscle CSA and thickness, and plantar fascia thickness (at heel, mid and forefoot sites).~The muscle stiffness will be calculated from the program provided by the US machine as shown real time elastography (RTE, unit: KPa)."
45917462|NCT04384003|Device|The 3-D Motion Analysis|The 3-D Motion Analysis, Forceplates and EMG acquisition system and full body kinematic model (Bonita, VICON Corp, UK) in the Biomechanics and Motor Control Laboratory (BMCL).
45449000|NCT02151916|Other|Dental care, AG, MI & fluoride varnish|Dental care during pregnancy, or soon thereafter, will comprise of a screening oral examination, extractions, restorations, scaling and prophylaxis, if needed, and will take as many dental visits as required to achieve a non-diseased mouth. Fluoride varnish application to the teeth of children in the immediate intervention group will occur when children are aged 6 to 10 months (time of tooth eruption), 12 and 18 months, as well as at 24 months. Oral health anticipatory guidance and motivational interviewing for the caregivers/mothers in the immediate intervention group will occur during pregnancy and when the children are aged 6-10 months (time of tooth eruption), 12 and 18 months.
45643106|NCT04776447|Drug|Carboplatin|"Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosamine or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center.~Other Name: ATC code: L01XA02"
45754316|NCT00555321|Drug|Belatacept More Intensive (MI)|"Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24.~After 6 months (24 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term [ST]), 5 mg/kg, every 4 weeks, 4 years (Long-term extension [LTE])"
45782610|NCT03839030|Other|MBHP-Educa|This intervention is a meditative practice which the individuals will practice in their daily life following the MBHP-educa protocol
45782611|NCT03145688|Behavioral|Family Physical Activity Planning|"Families will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include a skill training content workbook on how to plan for family physical activity. The material includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past, as well as activities that they would find enjoyable to do as a family. We will provide this material as prompts/suggestions. Families will be instructed to plan for when, where, how, and what physical activity will be performed & then track their physical activity. These aspects will be re-introduced and discussed at week 6 and week 12 in booster sessions"
45782612|NCT03145688|Behavioral|Family Physical Activity Habit Formation|Families will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms. The importance of creating cues for parental support of child physical activity is then outlined. Cues will also be considered factors that a) can precede the support activity but b) not be present very often when the activity is not to be performed. We will suggest that cues that have repeated exposure during times when family physical activity is not present Parents will then be asked to brainstorm and create a plan of consistency and cues with the workbooks provided. These aspects will be re-introduced and discussed at week 6 and week 12 in booster sessions.
45782613|NCT00889226|Drug|Pitavastatin|Drug: Pitavastatin 2mg daily for 8wks after initial visit. After assessment of LDL-C <100mg/dL at 8wks → Dose adjustment Yes → 2mg daily for second 8wks No → 4mg daily for second 8wks
45782614|NCT00889226|Drug|Atorvastatin|Drug: Atorvastatin 10mg daily for 8wks after initial visit. After assessment of LDL-C <100mg/dL at 8wks → Dose adjustment Yes → 10mg daily for second 8wks No → 20mg daily for second 8wks
45782615|NCT00837200|Drug|Oncaspar, Doxil, Decadron|Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
45782616|NCT00837512|Device|Microneedle|Microneedle used to deliver insulin at a depth less than 900 micrometers
45449001|NCT02151916|Other|Delayed intervention|Delayed intervention controlled design; all participants ultimately receive the benefits of the interventions. The intervention group receives the interventions when the mother is pregnant until the child is two years old. The delayed intervention group receives the interventions when the child is two years old until the child is three years old.
45782617|NCT00837512|Device|Subcutaneous insulin catheter|Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
45782618|NCT03125720|Other|Image fusion of SPECT MPI and fluoroscopy venography|In this study, MPI-Fluoro Fusion tool is used to help the implanting physicians to precisely implant LV lead to the optimal/suboptimal venous segments in the guided group.
45782619|NCT00837590|Drug|Chronic salsalate|Subjects will receive 2 months of treatment with 4 gram/day of oral salsalate divided into 3 doses.
45782620|NCT00837590|Drug|Acute Salsalate|Subjects will receive a single oral dose of 2 gram of oral salsalate
45449002|NCT02146612|Other|Amino Acid Supplement Group|Group receiving nutritional supplement
45782621|NCT00837824|Biological|Fabrazyme (agalsidase beta)|1.0 mg/kg every 2 weeks
45782622|NCT00837824|Biological|Fabrazyme (agalsidase beta)|3.0 mg/kg every 2 weeks
45782623|NCT03048188|Other|wound dressing|Manuka honey wound dressing
45782624|NCT01540409|Drug|AVI-4658 (Eteplirsen)|Eteplirsen will be administered once weekly via an IV infusion. There are two treatment groups, 30 mg/kg and 50 mg/kg.
45782625|NCT00891176|Biological|MenitorixTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
45782626|NCT00891176|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
45782627|NCT00891176|Biological|PrevenarTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
45782628|NCT00891176|Biological|MeningitecTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
45782629|NCT00891176|Biological|NeisVac-CTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
45782630|NCT00891176|Biological|InfanrixTM hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
45782631|NCT00891176|Biological|InfanrixTM penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
45782632|NCT00891176|Biological|InfanrixTM IPV/Hib|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
45643107|NCT04776447|Drug|Placlitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more than 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
45643108|NCT04776447|Drug|Atezolizumab|"Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. Atezolizumab targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.~Patients will receive 1200 mg of atezolizumab administered by IV infusion every 21 days (+/- 3 days) in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions."
45782633|NCT00891176|Biological|InfanrixTM IPV|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
45782634|NCT00839540|Drug|micafungin|100 mg qd by slow IV infusion for 24 h
45782635|NCT00839540|Drug|Micafungin|200 mg qd by slow IV infusion for 24 h
45782636|NCT00839540|Drug|Caspofungin|70 mg LD followed by 50 mg qd by slow IV infusion for 24 h
45449003|NCT02146690|Other|osteopathic manipulative treatment|
45782637|NCT02966912|Dietary Supplement|400 mg of Magnesium Oxide twice daily for 24 weeks|
45782638|NCT02966912|Other|Open label (none)|
45782639|NCT02964182|Drug|Cigarette|Smoke usual brand of cigarettes
45782640|NCT02964182|Drug|Nicotine Replacement|Received NRT (Electronic Cigarette - ECIG-Hi)
45782641|NCT02964182|Drug|Nicotine Replacement|Received NRT (Electronic Cigarette - ECIG-Hi)
45782642|NCT02964182|Other|Questionnaire Administration|Ancillary studies
45782643|NCT02964182|Other|Survey Administration|Ancillary studies
45782644|NCT02964182|Drug|Very Low Nicotine Content Cigarette|Smoke very low nicotine content cigarette
45782645|NCT02964182|Device|ECIG-Hi|Patients smoke ECIG-Hi for 3 weeks and then ECIG-Lo for 3 weeks.
45782646|NCT02964182|Device|ECIG-Lo|Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks
45782647|NCT01437605|Drug|MAGE-A3 ASCI injections without Poly IC:LC|MAGE-A3 ASCI injections without Poly IC:LC as outlined in Detailed Description
45782648|NCT01437605|Drug|MAGE-A3 ASCI injections with Poly IC:LC|MAGE-A3 ASCI injections with Poly IC:LC as outlined in Detailed Description
45782649|NCT00841412|Behavioral|Immediate Intervention Group|Unit staff received weekly training and feedback for 12-weeks to improve daily nutritional care processes.
45643109|NCT04776317|Biological|ChAdV68-S|Chimpanzee Adenovirus serotype 68 - Spike (ChAdV68-S) is a replication-defective, E1, E3 E4Orf2-4 deleted adenoviral vector based on chimpanzee adenovirus 68 (C68, 68/SAdV-25, originally designated as Pan 9), which belongs to the sub-group E adenovirus family. A single 0.5 mL intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
45782650|NCT00841412|Behavioral|Delayed Intervention Group|Research staff monitored this group under usual care conditions, then these units crossed over into intervention.
45782651|NCT02873468|Drug|Florence 30 μg/mL|10 mL, oral, twice a day.
45782652|NCT02873468|Drug|Florence 60 μg/mL|10 mL, oral, twice a day.
45782653|NCT02873468|Drug|Florence 90 μg/mL|10 mL, oral, twice a day.
45782654|NCT02873468|Other|Placebo|10 mL, oral, twice a day.
45782655|NCT02154386|Device|Ridge preservation using DFDBA|tooth extraction followed by ridge preservation grafting using DFDBA
45782656|NCT01438229|Device|St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)|Catheter-based RF ablation in renal artery
45782657|NCT02684006|Drug|Avelumab (MSB0010718C)|IV treatment Avelumab administered at 10 mg/kg IV every two weeks
45782658|NCT02684006|Drug|Axitinib (AG-013736)|Oral treatment Axitinib given 5 mg PO BID
45782659|NCT02684006|Drug|Sunitinib|Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2
45782660|NCT01541735|Drug|Pantoprazole|The pantoprazole will be administered in capsules of 40mg. The dose will be 1 capsule per day during 45 days.
45782661|NCT01541735|Drug|placebo|Placebo 40 mg dose.
45782662|NCT01541891|Drug|PRO-148 Ophthalmic Solution|PRO-148 Ophthalmic Solution applied four times per day (c/6 hours) during 60 days.
45782663|NCT01541891|Drug|Active Comparator: SYSTANE ® Ophthalmic Solution|Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.
45782664|NCT01520207|Drug|Mannitol (20%)|0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session)
45782665|NCT01520207|Drug|0.9% saline|1.25mL/kg/hour; maximum 125mLs/hour; maximum total volume 375mLs per treatment
45782666|NCT01203722|Drug|Fludarabine|Fludarabine 30 mg/m2/day
45917463|NCT04384003|Device|Electromyographic|Electromyographic activity (EMG) of AbdH, TA, PL, SO, gluteus medius (Glut Med) and gluteus maximus (Glut Max) will be recorded bilaterally using pairs of surface electrodes. Motor coordination of these muscles will be evaluated through assessment of temporal and spatial parameters of EMG during functional tasks such as kicking in one leg standing. The primary outcome measure will be percentage of EMG relative to maximal voluntary contraction (MVC) on the same side. In order to remove the potential for investigator bias, all data will be presented individually without identification of the muscle, order of trials or whether the trials precede or follow the intervention.
45449004|NCT02146690|Other|sham therapy|
45449005|NCT02146690|Other|usual care|
45449006|NCT02152072|Other|Using Simulation-Based Training to Incorporate Lung Ultrasound into Physical Examination|
45449007|NCT02146846|Drug|Imatinib|Patients with chronic myeloid leukemia who receive Imatinib as treatment
45449008|NCT02152150|Other|Iron bio-fortified pearl millet|Pearl millet variety ICTP8203-Fe (82 mg/kg iron content) prepared as a traditional flatbread (bhakri)
45449009|NCT02152150|Other|Control pearl millet|Conventional pearl millet: variety DG9444 (22 mg/kg iron content) and JKBH778 (52 mg/kg iron content), prepared as a traditional flatbread (bhakri)
45643110|NCT04776317|Biological|ChAdV68-S-TCE|Chimpanzee Adenovirus 68 - Spike plus additional SARS-CoV-2 T cell epitopes (ChAdV68-S-TCE) is a replication-defective, E1, E3 E4Orf2-4 deleted adenoviral vector based on chimpanzee adenovirus 68 (C68, 68/SAdV-25, originally designated as Pan 9), which belongs to the sub-group E adenovirus family. A single 0.5- or 1.0-mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
45643111|NCT04776317|Biological|SAM-LNP-S|Self-Amplifying mRNA - Lipid Nanoparticles - Spike (SAM-LNP-S) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 mL or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
45782667|NCT01203722|Drug|Cytoxan|Pre-BMT: Cytoxan 14.5 mg/kg/day administered IV; Post-Transplantation: High-dose Cytoxan 50mg/kg/day
45782668|NCT01203722|Radiation|Total Body Irradiation|400 cGy TBI administered in a single fraction
45782669|NCT01203722|Procedure|Allogeneic Blood or Marrow Transplant|
45782670|NCT01203722|Procedure|Peripheral Blood Stem Cell Transplant|
45782671|NCT01203722|Drug|Mycophenolate Mofetil|15mg/kg by mouth three times daily
45782672|NCT01203722|Drug|Sirolimus|Loading Dose: Sirolimus 6mg by mouth once; Maintenance dose: Sirolimus 2mg by mouth daily
45782673|NCT01203722|Drug|Tacrolimus|Tacrolimus 1mg intravenously, daily
45782674|NCT01520519|Drug|Rituximab|375 mg/m2 intravenously on Day 1, Day 8, Day 15, and Day 22, then continued once every 4 weeks only on Days 1 during cycles 2 - 6.
45782675|NCT01520519|Drug|PCI-32765|420 mg (3 * 140-mg capsules) orally started on Day 2 of cycle 1 once daily and will be continued daily.
45782676|NCT00185744|Radiation|Intra-Operative Radiotherapy (IORT)|single dose in the operating room after lumpectomy
45782677|NCT00185744|Procedure|Lumpectomy|
45782678|NCT00185744|Radiation|Whole Breast Radiotherapy|six and a half week treatment
45782679|NCT00185744|Radiation|Intracavitary Brachytherapy|5 day treatment
45782680|NCT00185744|Radiation|Accelerated External Beam 3-D Conformal Radiotherapy|5 day treatment
45782681|NCT00185744|Radiation|Stereotactic APBI|4 day treatment
45782682|NCT03008057|Dietary Supplement|vitamin D|vitamin D supplement, 4000 IU tablet daily , one time a day, for 3 months
45782683|NCT03008057|Dietary Supplement|vitamin D placebo|vitamin D placebo tablet (Containing starch powder), one time a day, for 3 months
45782684|NCT03692312|Drug|Tideglusib|Tideglusib for oral suspension, weight-adjusted at 400mg, 600mg or 1000 mg dose levels, once daily
45782685|NCT03692312|Drug|Placebo|Matching placebo formulation
45782686|NCT01542125|Drug|Liposomal Lidocaine|4% Liposomal Lidocaine
45782687|NCT01542125|Drug|Placebo|Tubes were visually identical to the Liposomal Lidocaine tubes.
45643112|NCT04776317|Biological|SAM-LNP-S-TCE|Self-Amplifying mRNA - Lipid Nanoparticles -Spike plus additional SARS-CoV-2 T cell epitopes (SAM-S-TCE) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
45782688|NCT03216668|Drug|TONKA|Administered orally twice a day, 2 tablets each time, for 6 weeks.
45782689|NCT03216668|Drug|LEGALON|Administered orally three times a day, two tablets each time, for 6 weeks
45782690|NCT01439087|Device|MGH Optical Frequency Domain Imaging (OFDI) System|Imaging of Colonic Polyps with OFDI system
45782691|NCT05314478|Device|Continuous laryngoscopy during exercise test using the HALOS headgear|"The participant will undergo the CLE test following standard clinical practice.~The order of events of the aspects of the investigation related to the headgear will be:~The headgear is prepared for use.~The headgear is fitted onto the participant's head.~The endoscope is inserted into the participant.~The endoscope is fitted onto the headgear.~The CLE test is carried out.~The endoscope is removed from the headgear.~The endoscope is removed from the participant.~The headgear is removed from the participant.~The headgear is cleaned and stored."
45782692|NCT01439633|Device|MGH OFDI marking|Imaging of esophagus with OFDI system
45782693|NCT02548832|Drug|Berberine|"Berberine 1500 mg, each 24 h for 90 days~1 Berberine capsule 500 mg for breakfast.~1 Berberine capsule 500 mg for lunch.~1 Berberine capsule 500 mg for dinner."
45782694|NCT02548832|Drug|Bezafibrate|"Bezafibrate capsule 400 mg each 24 h for 90 days.~1 Bezafibrate capsule 200 mg for breakfast.~1 Bezafibrate capsule 200 mg for dinner."
45782695|NCT02548832|Drug|Berberine plus Bezafibrate|"Berberine 1500 mg each 24 h for 90 days~1 Berberine capsule 500 mg for breakfast.~1 Berberine capsule 500 mg for lunch.~1 Berberine capsule 500 mg for dinner.~Bezafibrate 400 mg each 24 h for 90 days.~1 Bezafibrate capsule 200 mg for breakfast.~1 Bezafibrate capsule 200 mg for dinner."
45782696|NCT01440959|Drug|dovitinib|TKI258 at 500 mg/day on a 5 days on/2 days off dosing schedule
45782697|NCT03216278|Drug|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
45782698|NCT03216278|Drug|Dapagliflozin/metformin XR 5/500 mg|Tablets for oral administration, once daily, once per treatment period
45449010|NCT02152228|Drug|EnteraBio's Oral Parathyroid Hormone (1-34)|Oral administration
45598199|NCT02224859|Other|human intervention|This study is designed to evaluate the safety of the Invictus Cranial Support Device (CSD) when worn by medically stable infants within a neonatal intensive care unit (NICU), to evaluate the form, fit, and ease of use/application of the CSD device (i.e., utility), as well as initial impressions of safety, by health care providers (HCPs) after placing the current CSD on infants for approximately six (6) hours in a NICU
45598200|NCT03160677|Other|Systolic blood pressure target < 130 mm Hg|Adaptation of antihypertensive treatments to reach the Systolic blood pressure target < 130 mm Hg
45598201|NCT03160677|Other|Systolic blood pressure target < 185 mm Hg|Adaptation of antihypertensive treatments to reach the Systolic blood pressure target < 185 mm Hg
45643113|NCT04776317|Other|Sodium Chloride, 0.9%|The diluent used for this study will be 0.9% Sodium Chloride Injection, USP, and is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each milliliter (mL) contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. 0.308 mOsmol/mL (calc.). 0.9% Sodium Chloride Injection, USP contains no preservatives.
45643114|NCT04775953|Drug|Cefazolin|Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. Cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks)
45643115|NCT04775953|Drug|Dalbavancin|A second-generation lipoglycopeptide antibiotic synthesized from a fermentation product of Nonomuraea species
45643116|NCT04775953|Drug|Daptomycin|Daptomycin (USA) or Cubicin (Spain) is a cyclic lipopeptide antibiotic that inhibits gram-positive bacteria. Daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks
45643117|NCT04775953|Drug|Nafcillin|Nafcillin is a semi-synthetic antibiotic related to penicillin. Nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks)
45782699|NCT03216278|Drug|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
45782700|NCT03216278|Drug|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
45782701|NCT03216278|Drug|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
45782702|NCT03216278|Drug|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
45782703|NCT03216278|Drug|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
45782704|NCT03216278|Drug|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
45782705|NCT01543607|Device|Radiofrequency ablation catheter (Habib EndoHBP)|Catheter placement into bile duct
45782706|NCT03216590|Device|Compressive draping using adhesive incise drape|In the intervention group the shoulder will be drape with compressive draping using adhesive incise drape (Ioban™2 Antimicrobial Incise Drape, 3M Inc.,USA).
45782707|NCT04381754|Device|Passeo-18 Lux|Patients with significant inflow or outflow stenosis between the anastomosis to the axillary-subclavian vein junction, as defined by the insertion of the cephalic vein, who had undergone fistuloplasty with Passeo-18 Lux
45782708|NCT01521845|Drug|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
45782709|NCT05310344|Combination Product|Albumin-bound paclitaxel and bevacizumab|Patients will receive albumin-bound paclitaxel (260 mg/m2) and bevacizumab (7.5mg/kg) intravenously every 21 days. The total treatment periods are no more than 6 cycles.
45782710|NCT04381676|Other|Flipped Classroom Approach|In the Flipped Classroom, participants form groups of 2-3 and are instructed to work together through clinical cases of the in-class case based activity, committing to group answers to the clinical questions before advancing to the next case. At the end of class, the faculty instructor facilitated a short interactive group discussion.
45782711|NCT03216434|Diagnostic Test|MRI using DaTscan|"A standard, non-contrast-enhanced structural/anatomic brain MRI will be performed. It will be used to exclude potential subjects and controls with significant and potentially confounding structural/anatomic findings. It will also be used as an anatomic overlay with the functional DaTscan image to aid in anatomic/physiologic correlation. At the same imaging session, a brief functional MRI (not requiring the subject to perform any tasks) will also be performed."
45782712|NCT01522391|Drug|DPK-060 1% ointment|DPK-060 1% ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
45782713|NCT01522391|Drug|Placebo for DPK-060 ointment|Placebo for DPK-060 ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
45782714|NCT04381520|Other|Heat-sensitive moxibustion plus antihypertensive drugs|In this arm, patients will administer heat-sensitive moxibustion by themselves or by the help of their family after professional training. Patients will maintain their original antihypertensive drugs. The periods of treatment and follow-up will be one year.
45782715|NCT04381520|Drug|Antihypertensive drugs|In this arm, patients will maintain their original antihypertensive drugs. The periods of treatment and follow-up will be one year.
45782716|NCT00837902|Drug|Atenolol (β-blocker)|25 mg tablet
45643118|NCT04775953|Drug|Oxacillin|Oxacillin is an antibiotic used in resistant staphylococci infections. Oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks
45598202|NCT02221895|Other|Postpartum follow up appointment 2-3 weeks after delivery|experimental arm
45598203|NCT02221895|Other|Postpartum follow up 6-8wk after delivery|control arm
45598204|NCT03395197|Drug|Talazoparib with enzalutamide|Talazoparib 0.5 mg/day plus enzalutamide 160mg/day
45643119|NCT04775953|Drug|Vancomycin|Vancomycin is a glycopeptide antibiotic product of the organism Amycolatopsis orientalis. Vancomycin (dose per local standard of care × 4-6 weeks)
45643120|NCT04774718|Drug|Alectinib|Participants will receive twice-daily alectinib capsules on Days 1-28 of each 28-day cycle
45598205|NCT03395197|Drug|Placebo with enzalutamide|Placebo plus enzalutamide 160 mg/day
45598206|NCT02358915|Device|FastStart neuromuscular electrical stimulator|
45598207|NCT02221973|Dietary Supplement|sterols and hawthorn powder|there are two dose level of sterols (1.2g/d; 1/8g/d)
45643121|NCT04770896|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
45643122|NCT04770896|Drug|Lenvatinib|Lenvatinib will be administered once daily by mouth each day of every 21-day study treatment cycle. Participants with a baseline body weight of < 60 kg will receive a daily dose of 8 mg. Participants with a baseline body weight of ≥ 60 kg will receive a daily dose of 12 mg.
45643123|NCT04770896|Drug|Sorafenib|Sorafenib will be administered at a dose of 800 mg per day, i.e. two tablets of 200 mg swallowed by mouth twice daily (equivalent to a total daily dose of 800 mg) each day of every 21-day study treatment cycle.
45782717|NCT01830452|Procedure|Self-fixating Parietex Progrip Mesh|Lichtenstein hernioplasty using a self fixating Parietex Progrip mesh not needing any fixating devices
45782718|NCT04381598|Drug|stevia rebaudiana bertoni|Stevia has an anti-plaque effect because of its ability in decreasing the formation of bacterial insoluble polymers.It significantly decreases the production of TNF-R and IL-1a and slightly decreases the production of NO in stimulated cells with LPS and THP-1 showing its anti-inflammatory properties.These characteristics in combination with anti-diabetic properties could results in the effective treatment of periodontal diseases.
45782719|NCT04381598|Other|placebo|A placebo without the active drug will be placed in the control sites.
45782720|NCT04382144|Drug|Liposomal bupivacaine|Patient will receive a single injection of a local anesthetic into the common extensor origin.
45782721|NCT03215888|Procedure|bariatric surgery|Obese patients will undergo brain imaging, neurocognitive function testing and measurement of insulin resistance and inflammatory markers pre- and post bariatric surgery
45782722|NCT05319938|Procedure|CAF only|After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.
45782723|NCT05319938|Procedure|CAF+CGF|"After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.~Blood samples were collected into 10 ml glass-coated plastic tubes without anticoagulant solutions. These tubes were placed into CGF centrifuge machine and centrifuged immediately . CGF membrane were placed over the defect. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture."
45782724|NCT05319938|Procedure|CAF+A-PRF|"After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.~Blood samples were collected into 10 ml glass-coated plastic tubes without anticoagulant solutions. These tubes were placed into A-PRF centrifuge machine and centrifuged immediately. A-PRF membrane were placed over the defect. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture."
45782725|NCT01522703|Drug|Broccoli Sprouts|100g of either broccoli or alfalfa sprouts will be eaten daily in a sandwich or wrap form.
45643124|NCT04770779|Drug|Placebo Matching Mitapivat|Tablets
45643125|NCT04770779|Drug|Mitapivat|Tablets
45643126|NCT04770753|Drug|Placebo Matching Mitapivat|Tablets
45782726|NCT01522703|Drug|Placebo|Alfalfa Sprouts
45782727|NCT03215732|Diagnostic Test|HBV testing with dried blood spots (DBS) technique|Survey participants will be tested at home for chronic HBV infection using the DBS technique (collection of drops of whole blood dried onto filter paper).
45782728|NCT01830686|Other|Sugarcane bagasse|One brownie containing 10 g of sugarcane bagasse and 2 cookies containing 3 g of sugarcane bagasse (total of 13 g of sugarcane bagasse per day)
45782729|NCT01830686|Other|Non-caloric, non-fermentable fiber|One brownie containing 10 g of fiber and 2 cookies containing 3 g of fiber (total of 13 g of non-caloric, non-fermentable fiber per day)
45782730|NCT01830686|Other|Minimal fiber|One brownie containing 3g of fiber and two cookies containing 1g of fiber (total of 4 g of dietary fiber per day)
45782731|NCT03215654|Other|"EspaiJove.net mental health literacy program"|"The EspaiJove.net: a space for mental health (EspaiJove.net) project is a MHL program which aims the promotion of mental health, the prevention of mental disorders, the facilitation of help-seeking behaviors and the eradication of stigma among secoundary students into the Spanish context."
45782732|NCT01830764|Drug|Red Light (PDT)|LTS, 0.3% applied topically followed by red light dose (75 J/cm2 or 150 J/cm2)
45782733|NCT05313698|Diagnostic Test|No intervention|cross-sectional study/psychometric study
45782734|NCT03215966|Combination Product|Macitentan / tadalafil FDC|Tablets for oral administration containing 10 mg of macitentan and 40 mg of tadalafil
45782735|NCT03215966|Drug|Macitentan (Opsumit®)|Film-coated tablets for oral administration formulated at a strength of 10 mg
45782736|NCT03215966|Drug|Tadalafil (Adcirca®)|Film-coated tablets for oral administration formulated at a strength of 20 mg
45782737|NCT01522937|Radiation|individualized Stereotactic Body Radiation Therapy (SBRT)|The individualized SBRT involves two treatment phases. The first phase of treatment involves receiving three fractions of SBRT, followed by a 1-month break and assessment of liver function with a blood test - Indocyanine Green (IC-Green). The second phase of treatment involves receiving two more fractions of SBRT, whose doses are adjusted to account for tolerance of the first phase of treatment.
45782738|NCT05316662|Drug|Semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
45782739|NCT03215498|Drug|Faster-acting insulin aspart|In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
45643127|NCT04770753|Drug|Mitapivat|Tablets
45643128|NCT04770337|Device|STARSTIM device|Cathodal Transcranial Direct Current Stimulation (tDCS). Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
45643129|NCT04770337|Device|Sham Device|Intervention which uses enough currents to generate a sensory feedback similar to that of active stimulation via electrodes on the scalp
45643130|NCT04768556|Other|EEG experimental sessions 1|An EEG experimentation session on the stop-signal task of inhibiting a prepared discrete graphic action.
45643131|NCT04768556|Other|EEG experimental sessions 2|An EEG experimentation session on the stop-signal task of inhibiting an ongoing rhythmic action
45643132|NCT04768504|Drug|Tofacitinib 10 mg|Tofacitinib 10 mg PO BID for 30 days
45782740|NCT03215498|Drug|Insulin aspart|In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
45782741|NCT03215108|Device|Endoscopic Retrograde CholangioPancreatography(ERCP)|This study is prospective randomized multicenter study by using Endoscopic Retrograde CholangioPancreatography(ERCP). Comparison between Novel flower-type covered stent and Conventional covered stent in malignant extrahepatic biliary obstruction will be conducted after stent insertion by using Endoscopic Retrograde CholangioPancreatography(ERCP).
45782742|NCT01441037|Drug|Danazol|Danazol, 800 mg daily by mouth for 2 years
45782743|NCT00891878|Drug|capecitabine|Given orally
45643133|NCT04766723|Drug|NT 201|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
45782744|NCT00891878|Drug|sunitinib malate|Given orally
45782745|NCT01442129|Biological|MPC Intramyocardial injection|Intramyocardial injection of 25 million mesenchymal precursor cells at the time of LVAD implantation
45782746|NCT01442129|Biological|Control Solution|Injection of control solution during the LVAD implantation.
45782747|NCT01445873|Drug|Sitaxentan sodium|Sitaxentan sodium 100 mg / day
45643134|NCT04766723|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
45643135|NCT04765202|Procedure|AG Tx|The control treatment is meshed autograft applied to a FT burn area
45782748|NCT03838328|Drug|Tranexamic Acid|Tranexamic acid will be delivered by loading dose plus maintenance infusion until the end of the operation.
45782749|NCT03838406|Genetic|BRCA 1|The investigators evaluated the incidence of BRCA loss in patients with advanced gastric cancer and observed the treatment outcome and prognosis.
45782750|NCT03838406|Drug|Chemotherapy|"FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
45643136|NCT04765202|Biological|SOMA Tx|The experimental treatment is meshed autograft applied to a FT burn area and covered with SOMA
45643137|NCT04764656|Drug|Brolucizumab|There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
45782751|NCT01525667|Biological|150M PLX-PAD|Single course, multiple IM injections
45782752|NCT01525667|Biological|300M PLX-PAD|Single course, multiple IM injections
45782753|NCT01525667|Biological|Placebo|Single course, multiple IM injections
45782754|NCT01831310|Dietary Supplement|Standard (Kabiven)|Parenteral nutrition provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
45782755|NCT01831310|Dietary Supplement|Standard-Glutamine|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. it was 0.3-0.4 g/kg/day for glutamine dipeptide (Dipeptiven) supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
45782756|NCT01831310|Dietary Supplement|Standard-Omega 3 fatty acid|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven)supplementation was 0.1-0.2 g/kg /day. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
45782757|NCT01831310|Dietary Supplement|Standard-glutamine-omega 3|Parenteral nutrition (kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven) supplementation was 0.1-0.2 g/kg /day and it was 0.3-0.4 g/kg/day for glutamine dipeptide (dipeptiven)supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
45782758|NCT01526213|Drug|Fexofenadine|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice, or furanocoumarin-free grapefruit juice.
45782759|NCT01548833|Device|Delefilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
45782760|NCT01548833|Device|Narafilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
45782761|NCT01548833|Device|Filcon II 3 contact lens|Silicone hydrogel contact lens for single use, daily disposable wear
45449011|NCT02147002|Dietary Supplement|Gold omega 3|At the beginning and at the end of the observation period, besides the clinical test, some other tests will be carried out: echocardiography, pulse wave velocity (PWV), ambulatory blood pressure monitoring (ABPM). Blood will be collected for laboratory tests such as: lipid profile, uric acid, CRP, BUN, creatinine, morphology, Ca, P, Ca x P, ionogram, xanthine oxidase, MPC1,Omega-3 acids, resolvin and protectins - the metabolites of Omega-3 acids, creatinine excretion, MPC1 excretion and excretion of uric acid.The patients will be treated with Omega-3 acids as a Gold Omega 3 preparation (2x1 capsule where 1 capsule = 1000 mg) for 6 months.
45782762|NCT01549223|Drug|Oxytocin Infusion|500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request.
45782763|NCT01549223|Drug|Oxytocin Bolus|3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).
45643138|NCT04763967|Device|PedSCath Pediatric Urinary Catheter|PedSCath Pediatric Sampling Catheter is a pediatric sampling catheter. The product is supplied as a catheter and syringe. PedSCath Pediatric Sampling Catheter is manufactured by Medical Murray Inc. for Big Blue Biotech. The device consists of a blend of LDPE/Elvax/Crodamide.
45643139|NCT04763967|Device|Standard of Care|Current Standard of Care for pediatric patients
45754317|NCT00555321|Drug|Belatacept Less Intensive (LI)|"Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 8 and 12.~After 3 months (12 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term [ST]), 5 mg/kg, every 4 weeks, 4 years (Long-Term Extension(LTE)"
45754318|NCT00555321|Drug|Mycophenolate Mofetil (MMF)|Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term [ST]), ≤ 1 g/day, 4 years (Long-term extension [LTE])
45782764|NCT01549925|Other|Standard Surgical resection|standard surgical resection using clamps and surgical ligatures
45782765|NCT01549925|Device|LIGASURE|resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
45782766|NCT00895934|Drug|vorinostat|Given orally
45782767|NCT00895934|Drug|gemtuzumab ozogamicin|Given intravenously (IV)
45782768|NCT00895934|Drug|azacitidine|Given IV or subcutaneously (SC)
45782769|NCT01447121|Device|Tatsu/Tradewind Investigational BG Monitoring System|Tradewind is a Bayer investigational meter that used an investigational sensor.
45782770|NCT01831388|Other|breathing techniques|"During all practice sessions, patients are seated in a chair, where they are guided through a set routine of various breathing techniques (detailed in Appendix A). No yoga poses are involved. There is no demand on the patient's physical condition and no risk of injury. The breath training program, with patients seated throughout, includes:~- an initial teaching session (approximately 30-minute) at main campus by an MSKCC Integrative Medicine Service yoga-breathing instructor; - twice daily,breathing exercises (each approximately 15-minute) for 6 weeks practiced by patients at home with supplied recorded audio instructions; - and weekly follow-up phone calls by research staff (+/- 3 days from day 7 of each week) to identify and manage problems and to determine compliance."
45782771|NCT01831388|Behavioral|Self-Administered Baseline and Transition Dyspnea Indexes|Patients are asked to complete baseline SAC-BDI/TDI questionnaires at the pulmonary clinic. Patients will return to the pulmonary clinic at about week 6 for SAC-BDI/TDI and tests, and to return the diary recording their home exercises. Resting and post-6MWT pulse oximetry, and Hospital Anxiety and Depression Scale (HADS) will be evaluated as well.
45782772|NCT05315102|Other|Sham intervention|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust
45782773|NCT05315102|Other|Chiropractic Care|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
45782774|NCT05315102|Other|Physical therapy intervention|The standardized treatment protocol will be provided according to the guidelines, which will include various modalities and treatment approaches, including stretching exercises; massage; strengthening exercises of weak muscles, weight-bearing, balance (static and dynamic) and gait training; electrical stimulation; treadmill use; and endurance training for the improvement of gait, motor function, strength and functional mobility in Cerebral Palsy children, where Conventional Therapy will be provided according to the respective needs of the individual patient.
45643140|NCT04762342|Other|Power training|"First a brief warm up on a stationary bike and uni-lateral knee raises is completed.~Power training: Involves exercises performed with fast/explosive muscle contraction during the concentric phase, and slow/controlled (approximately 2-3 s) muscle contraction during the eccentric phase.~Functional- and balance exercises are included from week 9-24.~Progression:~Week 1-4: 3 sets of 12 repetitions at a load of 14 repetitions maximum (RM) with focus on introducing resistance exercise and familiarizing participants with exercises.~Week 5-8: 3 sets of 12 repetitions at a load of 14 RM the power training component.~Week 9-16: 3 sets of 10 repetitions at a load of 12 RM. Week 17-24: 3 sets of 8 repetitions at a load of 10 RM~Strengthening exercises:~Bilateral leg-press~Bilateral plantar flexion~Bilateral knee extension~Unilateral banded dorsal flexion~Bilateral lying leg curl~Back extension~Shoulder press~Seated row~Chest press~Lat pull-down"
45449012|NCT02152306|Drug|Fimasartan and Amlodipine|
46070811|NCT00816985|Procedure|Liposuction|Liposuction is a procedure that involves the removal of fat from deposits beneath the skin using a hollow stainless steel tube with the assistance of a powerful vacuum. Liposuction can be accomplished either with the use of local or general anesthesia.
45449013|NCT02152306|Drug|Fimasartan|
45449014|NCT02261116|Drug|Telmisartan|
45643141|NCT04757402|Other|Counselling with NSQIP Surgical risk calculator|Use of NSQIP surgical risk calculator to check for patient satisfaction regarding pre operative counseling.
45782775|NCT01550471|Drug|Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo|Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
45449015|NCT02261116|Drug|Candesartan|
45449016|NCT02261116|Drug|Placebo|
45449017|NCT02254720|Drug|BEA 2180 BR solution for infusion|
45449018|NCT02254720|Drug|Placebo|Intravenous infusion
45449019|NCT02254720|Drug|BEA 2180 BR solution for inhalation|
45449020|NCT02254720|Device|Respimat®|
45782776|NCT01550471|Drug|Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase|Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
45782777|NCT01550471|Drug|QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo|QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
45782778|NCT01550471|Drug|QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris|QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
45782779|NCT01550471|Drug|Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase|Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
45782780|NCT01550471|Drug|Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris|Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
45782781|NCT01528319|Device|MG-1|Being embedded in the area of glenohumeral instability by arthroscopic Bankart repair method.
45643142|NCT04756037|Drug|Relugolix Combination Therapy|Participants will receive orally 1 fixed-dose combination tablet (relugolix 40 mg/E2 1 mg/NETA 0.5 mg) once daily.
45782782|NCT00896012|Procedure|Kidney Biopsy|Skin over the kidney will be cleansed and disinfected. The skin and deeper tissue will be numbed with novocaine like solution. A special needle will be inserted guided by ultrasound into the kidney for an instant to withdraw the small specimen.
45782783|NCT00896012|Drug|Rapamune (sirolimus/rapamycin)|Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
45782784|NCT00896012|Drug|Tacrolimus|Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months).
45782785|NCT03215264|Drug|hydroxychloroquine|160mg daily
45643143|NCT04755452|Procedure|Low intra-abdominal pressure|7 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
45643144|NCT04755452|Procedure|High (standard) intra-abdominal pressure|12 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
45643145|NCT04751773|Behavioral|Exercise training|Perioperative exercise training
45782786|NCT03215264|Drug|entinostat|2-5mg weekly
45782787|NCT03215264|Drug|regorafenib|400-1200mg daily
45782788|NCT05312528|Procedure|endometriosis surgery|Laparoscopy was performed in the follicular phase of the woman's menstrual cycle and all recognizable endometriotic lesions were treated by bipolar coagulation, resection of endometriotic nodules and ovarian cystectomy.
45782789|NCT05312528|Procedure|other benign condition surgeries|ovarian cystectomy, bilateral tubal ligation, myomectomy etc.
45782790|NCT01447511|Drug|Control - Warfarin only|A single 10 mg warfarin dose taken at the start of the study period. No other medications taken during this study period.
45643146|NCT04750928|Drug|Abemaciclib|Abemaciclib is to be administered orally on Days 1 through 28 of each 28-day cycle
45782791|NCT01447511|Drug|Fluconazole - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
45782792|NCT01447511|Drug|Rifampin - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
45643147|NCT04748172|Biological|SARS-CoV-2 virus vaccines|mRNA SARS-CoV-2 virus vaccines ( By Pfizer or Moderna)
45643148|NCT04748172|Diagnostic Test|AMH sampling|Blood sample for AMH on recruitment and after three months
45643149|NCT04748172|Diagnostic Test|anti Covid-19 antibody levels (Serology)|Blood sample for IgG against S1 protein after three months
45782793|NCT01831622|Drug|Ritalin|On one of the two test-dates the patient participant is administered methylphenidate, in the dose prescribed by the patients doctor.
45643150|NCT04747041|Combination Product|CYSCONTROL/PHYTOCYST Herbal tea|Alternating every month from Day1 to Day15 cyscontrol and phytocyst herbal tea to prevent episode of cystitis
45643151|NCT04745871|Diagnostic Test|PSMA PET/CT|The PSMA PET/CT will be performed on an outpatient in the nuclear medicine department of the Brest University Hospital (CHRU). For this exam, the administration of 2-4 MBq/kg of 68Ga-HBED-CC-PSMA will be performed to patient by a single intravenous injection.
45643152|NCT04741646|Drug|Ferric Citrate|Auryxia® 210 mg ferric iron tablets equivalent to 1 g of FC and matching placebo will be supplied as 200 tablets in 400cc high-density polyethylene bottles.
45643153|NCT04741646|Drug|Placebo|Placebo to match Ferric Citrate tablets
45643154|NCT04739059|Biological|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody
45643155|NCT04736823|Drug|AK112|IV infusion
45643156|NCT04736823|Drug|Pemetrexed|IV infusion
45643157|NCT04736823|Drug|Paclitaxel|IV infusion
45782794|NCT01831622|Drug|Placebo|On one of the test-dates the patient participants are administered a sugar pill, matching their prescribes medical dose.
45782795|NCT03215420|Diagnostic Test|MRI 3T|
45782796|NCT01550549|Drug|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in in Study A05(NCT00702143) and A07(NCT00857415) will be read
45782797|NCT04380818|Radiation|Low-dose radiotherapy|Bilateral low-dose lung irradiation: 0.5 Gy in a single fraction. Optionally, additional 0.5 Gy fraction 48h later
45782798|NCT04380818|Drug|Hydroxychloroquine Sulfate|200 mg/12h for 5 days
45782799|NCT04380818|Drug|Ritonavir/lopinavir|400/100 mg/12h for 7-10 days
45782800|NCT04380818|Drug|Tocilizumab Injection [Actemra]|600 mg/day for 1-2 doses
45782801|NCT04380818|Drug|Azithromycin|500 mg/24h for 3 days
45782802|NCT04380818|Drug|Corticosteroid|Corticosteroids (methylprednisolone/dexamethasone/prednisone)
45643158|NCT04736823|Drug|Carboplatin|IV infusion
45782803|NCT04380818|Drug|Low molecular weight heparin|low molecular weight heparin (LMWH) in prophylaxis of venous thromboembolism
45782804|NCT04380818|Device|Oxygen supply|Oxygen
45782805|NCT01448447|Device|Mammosite ML|34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days
45782806|NCT01448447|Device|Mammosite ML|5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)
45782807|NCT05312294|Biological|Flu-M [inactivated split influenza vaccine] without preservative|Solution for intramuscular injection, 0.5 ml
45782808|NCT05312294|Biological|Flu-M [inactivated split influenza vaccine] with preservative|Solution for intramuscular injection, 0.5 ml
45782809|NCT05311982|Device|DLPFC-R (F4) TDCS|direct current brain stimulation- The study was developed through a triple-blind, crossover, randomized, placebo-controlled clinical trial (dummy tDCS). Participants were randomized into three groups receiving unilateral tDCS in DLPFC-L F3 (Block A), combined tDCS in DLPFC-L (F3) and DLPFC-R (F4) simultaneously (Block B) or sham-tDCS (Block C) with equal electrode configuration guaranteed blindness. After the procedures, each participant received the following intervention in the order ABC, BCA or CAB with a period of 1 week between each one. Each block took 3 weeks, organized into: 1) Assessment; 2) Application of stimulation; 3) Reassessment and washout week. Adding 1 more week of final evaluation, the study totaled the period of 10 weeks. During this period, patients were instructed to continue their behavioral/educational treatment and medication routines.
45782810|NCT05311982|Device|DLPFC-L (F3) and DLPFC-R (F4) TDCS|DLPFC-L (F3) and DLPFC-R (F4) (Bock B)
45782811|NCT05311982|Device|sham-tDCS|sham-tDCS (Block C) with equal electrode configuration guaranteed blindness
45782812|NCT02214017|Device|A videotelephone, TandBerg E20,|
45643159|NCT04736823|Drug|Docetaxel|IV infusion
45643160|NCT04736706|Biological|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
45643161|NCT04736706|Drug|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
45643162|NCT04736706|Biological|Pembrolizumab/Quavonlimab|Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion
45782813|NCT02214017|Behavioral|Behavioral motivation|Optimization of medical care in diabetes
45782814|NCT05311904|Other|Survey|1 initial questionnaire and 1 monthly follow-up questionnaire for 11 months
45782815|NCT05311748|Diagnostic Test|Ultrasound and doppler|Penile echocolour doppler ultrasound
45782816|NCT01550705|Drug|Isoniazid|Isoniazid 5 mg/Kg up to 300 mg per day. Oral tablets. 2 months.
45782817|NCT01831700|Drug|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
45782818|NCT01831700|Drug|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
45782819|NCT01531439|Drug|Naloxone|Naloxone infusion 0.5 mcg/kg/hr
45782820|NCT01531439|Drug|Naloxone|Naloxone infusion 2.5 mcg/kg/hr
45782821|NCT01832012|Other|Multimedia|AHA specific BLS refresher video, 7 minutes in length.
45449021|NCT02152462|Other|Exergaming|The participants in the Wii Fit exergaming group will be encouraged to meet and then maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. Goals per individual will be based on their baseline data. Exercise duration will increase gradually from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, women will maintain >150 min/wk of moderate-intensity physical activity. The training will consist of 3 days/wk of supervised physical activity using Nintendo Wii Fit active videogames.
45643163|NCT04736706|Drug|Lenvatinib|Lenvatinib 20 mg administered QD via oral capsule
45643164|NCT04732676|Other|Smartphone application|"Ecological Momentary Assessment (EMA)~: ambulatory assessment of behaviors/symptoms in real-time on smartphones"
45782822|NCT01832012|Other|Hands-on practice|Hands-on BLS CPR practice on a Laerdal BLS manikin.
45782823|NCT03214874|Drug|Demadex 20mg Tablet|Immediate Release (IR) Torsemide
45782824|NCT03214874|Drug|ER Torsemide 20mg Tablet|Extended Release Torsemide 20 mg tablet given once daily
45782825|NCT02504268|Drug|Abatacept|
45782826|NCT02504268|Drug|Methotrexate|
45782827|NCT02504268|Other|Abatacept Placebo|
45782828|NCT02504268|Other|Methotrexate Placebo|
45782829|NCT01832168|Procedure|Robotic Assisted Laparoscopic Prostatectomy|Robotic Assisted Laparoscopic Prostatectomy with nerve-sparing technique
45643165|NCT04732273|Other|Physical examination, diagnostic tests, laboratory tests|Physical examination, diagnostic tests depending on examined organ system (e.g. lung function test, echocardiography, audiometry), and laboratory tests (e.g. kidney parameter, hormonal levels).
45643166|NCT04732273|Other|Personal history, questionnaire|Personal history and focused questionnaires per organ system including symptoms, medication use, physical activity, and general wellbeing.
45643167|NCT04731571|Radiation|CBCT-guided Adaptive Radiotherapy|The aim is to deliver adaptive radiotherapy using a CBCT-based radiotherapy delivery system.
45643168|NCT04729946|Device|Pure-Vu Cleansing Device|The Pure-Vu device attaches to the colonoscope and provides colonic cleansing during urgent colonoscopy without the need for a bowel preparation
45643169|NCT04729621|Combination Product|TVB-009|TVB-009 Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
45782830|NCT01832168|Other|Application of Absorbable Hemostat|Application of Surgicel® SNoW Absorbable Hemostat by Johnson and Johnson on the neurovascular bundle after removal of the cancerous prostate.
45782831|NCT01832168|Other|Application of dehydrated human amniotic membrane|Application of dehydrated human amniotic membrane (DHAM) on the neurovascular bundle after removal of the cancerous prostate.
45782832|NCT00904826|Drug|Eculizumab|"The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks.~The first infusion will be given at Mayo Clinic site; subsequent infusions will be administered in the subject's home by a company which will send a nurse to administer the infusion. Subjects will receive therapy for a total of 12 months."
45782833|NCT01532453|Device|MD-3511356|Every morning MD-3511356 should be applied liberally to those skin areas exposed to direct sunlight before exposing to the sun.
45782834|NCT01532453|Other|Standard Sun Protection Measures|Self-provided commercially available sunscreen products, corresponding to the dosage recommendations on the product.
45782835|NCT05311514|Biological|Allogeneic platelet lysate eye drops|Eye drops
45782836|NCT01448525|Drug|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
45782837|NCT01448525|Drug|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
45782838|NCT01654302|Drug|Synera|70 mg lidocaine/ 70 mg tetracaine topical patch applied once for 12 hours
45782839|NCT01654302|Drug|Inactive patch|placebo patch applied once for 12 hours
45782840|NCT03215186|Other|observational study|
45782841|NCT01832558|Drug|Eplerenone|
45782842|NCT01832558|Drug|Placebo|
45782843|NCT01551095|Device|PEGJ tube|The self-propelled PEGJ feeding tube
45782844|NCT01832636|Dietary Supplement|Alanyl-Glutamine|Alanyl-Glutamine and Glycine doses will be prepared immediately prior to administration by dissolving in formula, milk, or fruit juice. Administration of each dose will be directly observed by a study nurse or health agent.
45782845|NCT01449305|Device|Nanoone Woman Underwear|Chen Yi Enterprise, Co., Ltd. design a kind of negative ion materials can supply delocalized electron, and add fiber inside, make clothes to wear in the body, no external power or battery, only depend on infrared body photon hit of thermoelectric effect or heart compression pulse, blood flow of piezoelectric, therefore can sustained sufficient amount of effective negative ion, to eliminate positive ions in vivo, or make oxygen free radical to obtain the lack electrons. Decrease active free radical and get non toxic effect in short time.
45643170|NCT04729621|Combination Product|Prolia®|Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
45643171|NCT04726514|Device|SleepFlex|SleepFlex Program
45782846|NCT02476422|Drug|Diclofenac potassium|Single dose of diclofenac 50 mg soft gelatin capsule
45782847|NCT02476422|Drug|Ibuprofen|Single dose of ibuprofen 400 mg tablet
45782848|NCT02476422|Drug|Placebo to ibuprofen|Single dose of placebo to ibuprofen 400 mg tablet
45643172|NCT04725383|Drug|amitriptyline|Amitriptyline is a tricyclic antidepressant being studied off-label here for repetitive behaviors in autism spectrum disorders.
45782849|NCT02476422|Drug|Placebo to diclofenac potassium|Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule
45782850|NCT01832792|Other|Face-to-face self-help|Participants in this arm will receive face-to-face self-help; that is, self-help with the support of a therapist, attending the clinic in person.
45782851|NCT01832792|Other|E-mail self-help|Participants in this arm will receive e-mail self-help; that is, self-help with the support of a therapist, provided via e-mail.
45782852|NCT01832792|Other|Waiting List|Waiting list condition - participants assigned to a waiting list (no intervention) condition
45782853|NCT03214484|Other|By comparing the evolution of the visual acuity curves.|By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.
45782854|NCT03214484|Other|By comparing the evolution of the curves.|By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.
45782855|NCT01450319|Drug|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m^2) every 2 weeks until disease progression, death, or consent withdrawal.
45782856|NCT02475954|Behavioral|TH-CBT|The TH-CBT group will receive the study intervention and standard care. The study treatment has been previously manualized and modified for remote administration, as described in the introduction to the revised application.12 PD Veterans will receive 10 weekly individual sessions (60 minutes each) of CBT, delivered via Video-to-Home (V2H).
45782857|NCT02475954|Other|Standard Care|Standard Care is defined as medical and psychiatric treatment provided by patients' personal doctors (e.g., neurologists, psychiatrists, therapists). Veterans will continue to receive routine clinical care and will remain on all depression treatments that they were receiving prior to their study (e.g., stable anti-depressant medications, established psychotherapy, clinical monitoring).
45643173|NCT04722003|Biological|Meningococcal Group B Vaccine|A combination vaccine consisting of recombinant proteins Neisserial adhesin A (NadA), Neisserial Heparin Binding Antigen (NHBA), and factor H binding protein (fHbp), Outer Membrane Vesicles (OMV), aluminum hydroxide, sodium chloride, histidine, and sucrose.
45643174|NCT04722003|Other|Placebo|0.9% Sodium Chloride, USP injection.
45917464|NCT04384003|Diagnostic Test|Foot intrinsic muscle assessment and training device|The main concept for this design is to provide the quantitative assessment of the foot intrinsic muscles and facilitation of intrinsic muscles of the fool during functional sporting activities such single-leg-standing.
45917465|NCT00000666|Drug|Pyrimethamine|
45917466|NCT04362748|Drug|AMG 256|AMG 256 administered as an intravenous (IV) infusion.
45782858|NCT05310812|Diagnostic Test|Biochemical evaluation.|Blood will be taken for biochemical evaluation-ELISA.
45917467|NCT04350073|Device|Q-NRG Metobolic Cart Device|COVID-19 ICU patients will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
46070812|NCT00816985|Other|Quality of Life Questionnaires|Ratings of 0 to 4, with 0 being Not at ll and 4 being Very Much, regarding how true each statement has been. Statements are in the following categories: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Additional Concerns.
45917468|NCT04350073|Device|MuscleSound Ultrasound|COVID-19 ICU patients will have muscle mass, muscle glycogen, and muscle quality measured at rectus femoris (leg), intercostal, and temporal muscle. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
45782859|NCT05310656|Behavioral|Mindfulness Based Empowerment Programme|Mindfulness Based Strengthening Program consists of 8 sessions, once a week. Each session has specific goals and objectives, and each session also has a separate theme along with its subject. The subject of the program sessions is as follows: 1st session; Getting to know, explaining the operation plan of the program, defining violence against women and its causes, 2nd session; Emotions and Perceptions, session 3; Being in the Body and Developing Self-Esteem; Session 4, Stress and Meeting Stress with Conscious Awareness; Session 5, The Case of Violence and the Meanings We Ascribe; Session 6, Aware Communication and Conflict Resolution; Session 7, Self-Care and Self-Compassion; Session 8 is Ending the Empowerment Program, Farewell, and a New Beginning. Each session is planned to last an average of 90-120 minutes. Mindfulness teachings and practices will be applied in the content of the program.
45782860|NCT01552343|Drug|Desmopressin|Desmopressin orally disintegrating tablets. Female participants took a 25 μg tablet and male participants took a 75 μg tablet one hour prior to bedtime for one month.
45782861|NCT01552343|Drug|Placebo|Placebo to match the 25 μg tablet of active drug taken by female participants or the 75 μg tablet taken by males. One placebo tablet taken one hour prior to bedtime for one month.
45782862|NCT02475564|Drug|Placebo|40mg of starch
45782863|NCT02475564|Drug|Resveratrol|40mg of resveratrol (powder)
45782864|NCT05310578|Procedure|Posterior cervical foraminotomy (with our without laminectomy)|The aim of surgery is to decrease the compression of the affected nerve. In posterior cervical foraminotomy, the foramina is expanded to create more space and with posterior cervical laminectomy the lamina is removed to create space mainly for the spinal cord.
45782865|NCT04381442|Radiation|Low Level Laser Therapy|
45782866|NCT00893984|Drug|Nebivolol|Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.
45782867|NCT01552889|Behavioral|Collaborative Care|No direct treatment will be offered. We will make treatment recommendations to the patient, PCP and cardiologist. Referral to mental health specialist is also possible, depending on need. The nurse case manager will monitor treatment progress and patient status for duration of the intervention period.
45782868|NCT03214328|Diagnostic Test|Determination of causes of fetal death|Determination of causes of fetal death using systematic protocol testing
45782869|NCT01832870|Drug|sipuleucel-T|
45782870|NCT01832870|Drug|ipilimumab|
45917469|NCT04350073|Device|Multifrequency Bioimpedance Spectroscopy|COVID-19 ICU patients will have body composition and phase angle measured using Multifrequency Bioimpedance Spectroscopy. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
45917470|NCT00000672|Drug|Didanosine|
45782871|NCT01553201|Drug|Botulinum toxin (BoNT)|OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration
45917471|NCT04331353|Behavioral|Comparator 1 (tailored approach)|Tailored to a child's sensitization status. Components include, education, cockroach baiting, mattress and bed covers, high efficiency particulate air (HEPA) vacuum cleaner, air purifier.
45917472|NCT04331353|Behavioral|Comparator 2 (insecticidal bait)|Cockroach bait
45917473|NCT04321954|Drug|LENVATINIB|Orally
45917474|NCT00000675|Drug|CD4-IgG|
45643179|NCT04712721|Drug|68Ga-FF58|Single intravenous radiolabeled gallium FF58 injection determined by body weight (3 Megabecquerel (MBq)/Kg (+/- 10%)). Administered dose must not be lower than 150 MBq or higher than 250 MBq.
45782872|NCT01553201|Drug|Placebo|Saline, 4cc, one time intramuscular administration
45782873|NCT05313542|Behavioral|Physical Activity|Physical Activity in the format of Self-defence Training
45782874|NCT03214172|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15/20 mg
45643180|NCT04708782|Drug|Placebo|Placebo administered QID
45643181|NCT04708782|Drug|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
45643182|NCT04708782|Device|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
45782875|NCT05318300|Dietary Supplement|tested formula with fiber|formula containing fibers
45754319|NCT05583500|Other|Experimental: Single group: excentric exercise protocol|Excentric exercise protocol will be performed for all subjets, consisted of 10 sets of 20 repetitions of squats, jumping from a height of 50 cm
45754320|NCT01911013|Procedure|anterior cervical discectomy and fusion|anterior cervical discectomy and fusion with anterior plating or not
45782876|NCT05318300|Dietary Supplement|Control|formula without fiber
45782877|NCT01832948|Drug|Endostar|
45782878|NCT01832948|Drug|Oxaliplatin|
45782879|NCT01832948|Drug|Folinic acid|
45782880|NCT01832948|Drug|5-FU|
45782881|NCT03214016|Other|Aerobic Exercise|1 hour of aerobic training on a treadmill, 3 times a week, during 8 weeks.
45917475|NCT04312672|Biological|AAV-RPGR|Genetic
45917476|NCT04540159|Diagnostic Test|Flow-cytometric analysis|Measuring the level of sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9 in the intraabdominal ascites
45917477|NCT00000678|Drug|Zidovudine|
45917478|NCT00000678|Drug|Zalcitabine|
45917479|NCT00390403|Drug|R-(-)-gossypol acetic acid|
45917480|NCT00390403|Drug|temozolomide|
45917481|NCT00390403|Genetic|gene expression analysis|
45917482|NCT00390403|Genetic|mutation analysis|
45917483|NCT00390403|Genetic|protein expression analysis|
45917484|NCT00390403|Other|laboratory biomarker analysis|
45917485|NCT00390403|Other|pharmacological study|
45917486|NCT00390403|Procedure|adjuvant therapy|
45917487|NCT00390403|Radiation|radiation therapy|
45917488|NCT00390442|Device|continuous positive airway pressure|
45917489|NCT00000681|Drug|Bleomycin sulfate|
45917490|NCT00000681|Drug|Vincristine sulfate|
45917491|NCT00000681|Drug|Doxorubicin hydrochloride|
45917492|NCT00000681|Drug|Zidovudine|
45917493|NCT00000681|Drug|Sargramostim|
45782882|NCT03214016|Other|Pilates|1 hour of Mat Pilates, 2 times a week, during 8 weeks.
45782883|NCT01833182|Other|Tailored home intervention|The occupational therapist (OT) interventionist will develop a set of environmental modification choices to improve performance in problematic activities identified during the clinical evaluation. A plan for resolving the barriers identified during clinical assessment will be developed. The participant will review the barrier removal options and will make an informed choice resulting in a final treatment plan. Modification installation which will be provided, at no cost to the participant, by a contractor trained by the study PI. The tailored intervention includes training in the use of the new equipment or architectural changes. Photographs of identified barriers, study measures, and intervention plans will be reviewed by the principal investigator during team meetings to ensure treatment fidelity.
45782884|NCT01833182|Other|Sham intervention|We have developed a kit containing 12 standard adaptive equipment (AD) items (e.g., jar opener). The AD kit has been specifically designed to address fine motor function and will not influence fall outcomes. Two pieces of AD will be provided during each session, and the individual will be instructed to use each AD by the OT interventionist
45782885|NCT01833260|Behavioral|Music|
45782886|NCT01533077|Drug|BIA 9-1067|50 mg of BIA 9-1067 (single-dose)
45782887|NCT01533077|Drug|Sinemet® 100/25 mg|immediate-release levodopa/carbidopa 100/25 (single-dose).
45782888|NCT05312684|Procedure|cardiac surgery|cardiovascular surgery including valve repair/replacement or CABG or combined procedures
45782889|NCT05313464|Other|parent-pushed enteral feeding|skin-to-skin enteral nutrition pushed by the parent
45782890|NCT05313464|Other|syringe-push enteral feeding|skin to skin nutrition with syringe pump
45643183|NCT04707885|Device|Electrocochleography|"The use of ECochG monitoring will be employed. This will be conducted intraoperatively during the entire portion of the CI electrode insertion component.~For the purposes of this clinical trial, the stimulus will consist of a 500 Hz tone burst presented at ~105-110 dB SPL. This was chosen due to the time and resource limitations in the operating room. Hence, the surgical team can only utilize a very limited dataset for intraoperative decision making and previous studies have demonstrated that 500 Hz stimulation offers the most robust, reliable, and useful ECochG signal during electrode insertions."
45643184|NCT04702425|Drug|VOB560|Powder for concentrate for solution for infusion
45782891|NCT05310500|Diagnostic Test|Finishing files of ProTaper Gold (F2) without effect to NaOCL|Finishing files of ProTaper Gold (F2) without effect to NaOCL
45917494|NCT00390481|Procedure|EC-IC Bypass in the COSS study|EC-IC Bypass surgery involves taking an artery from the scalp outside the skull, making a small hole in the skull, and then connecting the scalp artery to a brain artery inside the skull. In this way, the blockage of the carotid artery in the neck is bypassed and more blood can flow to the brain.
45643185|NCT04702425|Drug|MIK665|Concentrate for solution for infusion
45917495|NCT00000684|Drug|Dextran sulfate|
45643186|NCT04700124|Biological|Pembrolizumab|200 mg of Pembrolizumab IV infusion, on Day 1 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 Q3W for 13 cycles in postoperative phase (up to approximately 9 months). The total duration of treatment is up to approximately 1 year.
45643187|NCT04700124|Biological|Enfortumab vedotin (EV)|1.25 mg/kg of EV IV infusion, on Day 1 and Day 8 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 and Day 8 Q3W for 5 cycles (each cycle length = 21 days) in postoperative phase (up to approximately 4 months). The total duration of treatment is up to approximately 7 months.
45643188|NCT04700124|Procedure|RC + PLND|Curative intent RC + PLND surgery will be administered to all participants randomized to Arm A and B after completion of preoperative systemic treatment (RC + PLND to be done approximately at 15 weeks from randomization).
45782892|NCT05310500|Diagnostic Test|Finishing files of ProTaper Gold (F2) with effect to NaOCL|Finishing files of ProTaper Gold (F2) with effect to NaOCL
45782893|NCT05310500|Diagnostic Test|Finishing files of Dia-X ProTaper (D4) without effect to NaOCL|Finishing files of Dia-X ProTaper (D4) without effect to NaOCL
45782894|NCT05310500|Diagnostic Test|Finishing files of Dia-X ProTaper (D4) with effect to NaOCL|Finishing files of Dia-X ProTaper (D4) without effect to NaOCL
45782895|NCT03213860|Other|Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China|The experimental group will receive protective devices Single use eye masks during nocturnal sleep (Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China). The caregiver will explain to them that they should wear eye masks during their stay in ICU to ensure rest and instructed patients to use them properly. During the ICU stay, ICU nurses will assist patients with wearing eye masks from 9:00 pm to 7:00 am the next morning.
45782896|NCT01534013|Device|The Imperial College Closed-Loop Insulin Delivery System|The Imperial College closed-loop insulin delivery system comprises 3 main components: the glucose sensor, the control algorithm and the insulin delivery system.
45917496|NCT00000687|Drug|Interferon alfa-2a|
45917497|NCT00000687|Drug|Zidovudine|
45917498|NCT01350115|Drug|LDE225|supplied as 100 mg capsules
45917499|NCT01350115|Drug|Placebo|supplied in capsules
45917500|NCT00000690|Drug|Dextran sulfate|
45917501|NCT04286269|Other|Music Based Intervention|Participants assigned to MBI will receive a total of 1.5 hours of music intervention 5-6 sessions per week. Music will be alternating: 30 minutes on and 30 minutes off and will be played when the subject is awake to cue pacification and initiate the sleep process. Music will be delivered through headphones using an MP3 player.
45643189|NCT04700124|Drug|Gemcitabine|1000 mg/m^2 of Gemcitabine IV infusion, Day 1 and Day 8 Q3W for 4 cycles in preoperative phase (up to approximately 3 months)
45782897|NCT01534013|Device|Open loop|glucose sensor and pump
45782898|NCT03216122|Procedure|Conventional/Delayed Loading|
45782899|NCT03216122|Procedure|Immediate Loading|
45917502|NCT04286269|Other|Sham Treatment|Participants assigned to the control group will have the same treatment as the MBI group, but with no sound played through the headphones.
45917503|NCT04286191|Combination Product|Operant Conditioning|This is a training intervention in which the brain-spinal cord-muscle pathways are strengthened in individuals with incomplete spinal cord injury. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the tibialis anterior (TA), the muscle that lifts your toes and foot.
45782900|NCT03211988|Drug|Entinostat|Dose is 5 mg orally every week (days 1, 8, 15, and 22) of a 28 day treatment cycle. Study drug should be taken in the morning and on an empty stomach, at least 2 hours after a meal and at least 1 hour before the next meal. Tablets should be taken whole and not crushed.
45782901|NCT01450397|Biological|XIAFLEX|One Injection of 0.58 mg of Xiaflex into the affected area of the hand.
45643190|NCT04700124|Drug|Cisplatin|70 mg/m^2 of Cisplatin IV infusion, Day 1, Q3W for 4 cycles in preoperative phase (up to approximately 3 months)
45643191|NCT04695028|Other|Data collection|"The following data will be collected by the physician: sociodemographic profile, clinical manifestations, comorbidities, laboratory tests,etc.~Diagnostic performance of different imagery techniques, performance of crystal deposit quantification in ultrasound and Dual-energy computed tomography (DECT), link between co-morbidities and volume of baseline crystal deposits then during monitoring, link between co-morbidities (including cardiovascular events and new diagnoses of co-morbidity) and vascular baseline crystal deposits and during follow-up, link between microcrystalline rheumatism activity and the quantity of crystal deposits in baseline imaging and during follow-up, link between co-morbidities and the evolution of microcrystalline baseline rheumatism and then during follow-up, link between co-morbidities and the evolution of crystal deposition volumes, the concordance of the evaluation of uratic stocks and their evolution between the imagery means."
45643192|NCT04694534|Diagnostic Test|Serious game|"The serious game is accessible via an online platform, on a tablet: 4 20-minutes activities sessions per week must be carried out.~The program format in the serious game form makes possible to simultaneously understand a large number of cognitive functions."
45643193|NCT04694534|Diagnostic Test|Usual HAS care|The control group patients will follow the care they need, according to the HAS recommendations. Non-specific cognitive activities notebooks will be provided to them. They will be instructed to perform the 4 20-minutes sessions per week for 4 months.
45782902|NCT03218072|Drug|HLX01|a potential rituximab biosimilar
45782903|NCT01833338|Device|Imaging|All patients undergo non-invasive (MSCT) and invasive (IVUS, OCT) imaging
45782904|NCT01833572|Drug|Gefitinib|Eligible participants will be given orally gefitinib 250mg daily before surgery for 42 days or until disease progression or unacceptable toxicity. Best supportive care is allowed in this period.
45782905|NCT01833650|Dietary Supplement|thymus honey mouthwash|
45782906|NCT03213470|Other|magnetic resonance imaging|
45782907|NCT01833728|Drug|nefopam-propacetamol combination|"Patients in both groups will receive intravenous patient-controlled analgesia (PCA) using fentanyl.~In nefopam-propacetamol combination group, patients will receive nefopam(20mg mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours."
45782908|NCT01833728|Drug|propacetamol alone|In propacetamol alone group, patients will receive placebo (normal saline 2 ml mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours.
45782909|NCT01833884|Other|Collection of blood specimen|Collection of blood specimen for Cytokines dosing scheduled before , during and after treatment of Hodgkin's lymphoma (last collection date about 90 days after the end of treatment)
45782910|NCT03217682|Other|Music Therapy|Music therapy sessions
45782911|NCT03217682|Other|Massage Therapy|Massage therapy sessions
45782912|NCT03838250|Biological|Cellgram™ (Bone marrow-derived MSCs)|Approximately 15 to 30 mL of bone marrow is aspirated from the posterior iliac crest of patients under local anesthesia. Approximately 30 days (±7 days) after BM aspiration, the participant will return to the study center for admission and for the infusion Cellgram™ (Bone marrow-derived MSCs).
45782913|NCT03838172|Other|Family impact scale|The family Impact Scale (FIS) will be completed by the parents
45782914|NCT03213392|Drug|Anesthetic Agents|four different anesthetic agents will be used during the surgical clipping or coiling of the aneurysm for the maintenance of anesthesia.
45782915|NCT03219788|Drug|Normal Saline|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline will be given
45782916|NCT03219788|Drug|Remifentanil 0.1 ug/kg|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.1 ug/kg Remifentanil will be given
45782917|NCT03219788|Drug|Remifentanil 0.2 ug/kg|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.2 ug/kg Remifentanil will be given
45782918|NCT01834040|Other|Intralesional/ Intravenous of Autologous Stem cells.|Intralesional/ Intravenous of Autologous MNCs per dose
45782919|NCT03213314|Diagnostic Test|Multiparameter magnetic resonance imaging|LiverMultiScan before and after surgery to assess liver health prior to liver resection and in the regenerative phase.
45782920|NCT01834118|Procedure|Renal Denervation|Sympathetic nerve ablation via transcatheter renal denervation
45782921|NCT01834196|Device|Swept-Source Optical Coherence Tomography|Noninvasive imaging of the retinal vasculature in patient with existing microvascular disease.
45782922|NCT03219944|Procedure|Platelet Rich Fibrin|: Platelet Rich Fibrin for soft tissue augmentation around implant in the aesthetic zone
45782923|NCT03219944|Procedure|sub epithelial connective tissue graft|sub epithelial connective tissue graft for soft tissue augmentation around implant in the aesthetic zone
45782924|NCT03219710|Drug|Ondansetron|Ondansetron will be given at a dosage of 0.15mg/kg IV/PO q8h.
45917504|NCT04286191|Combination Product|Control Group|This is the control intervention, or the non-conditioning group. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the tibialis anterior (TA), the muscle that lifts your toes and foot.
45917505|NCT00000696|Drug|Interferon alfa-2a|
45917506|NCT00000696|Drug|Zidovudine|
45917507|NCT04260256|Drug|[18F]F-AraG|[18F]F AraG injection and PET Scan Two tumor biopsies of single lesion
45782925|NCT03219710|Drug|Dexamethasone|Dexamethasone will be given as 3mg/m2 IV/PO q8h.
45782926|NCT03219710|Drug|Aprepitant|Aprepitant will be given as per the weight. weight (15-40kg) - Day1 to Day 3 - 80 mg PO weight (>40 kg) - Day 1 -125mg , Day 2 & Day 3 - 80 mg PO
45782927|NCT03219710|Drug|Olanzapine|olanzapine will be given as 0.14mg/kg PO (rounded off to nearest 2.5 mg )
45782928|NCT01532141|Drug|BIA 9-1067|50 mg BIA 9-1067 (single-dose)
45782929|NCT01532141|Drug|Rasagiline|1 mg rasagiline (single-dose)
45643194|NCT04684836|Other|Exposure to telemedicine, after the onset of the pandemic|Telemedicine exposure will be defined based on the proportion of all visits at a given clinic that are delivered via telemedicine in each month.
45782930|NCT03213080|Device|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD) procedure.
45782931|NCT04380194|Diagnostic Test|nano-composite screening|Recovery of the bottoms of the victims' blood and urine tubes at H+4. Blood and urine samples from the victims at two years of age. Single blood and urine samples from the witnesses
45782932|NCT00899600|Drug|Ketamine|Peripheral provision of 0.5mg/kg of ketamine on induction followed by a 10mcg/kg/min infusion until surgical wound closure
45643195|NCT04684121|Drug|Granexin® gel (200 μM)|Granexin® gel (200 μM) will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
45782933|NCT00899600|Other|Normal saline|Normal saline at same rate as the previously described ketamine infusion (10mcg/kg/min), same amount of ketamine/placebo syringe on induction (0.5mg/kg).
45782934|NCT04379882|Device|Digital Sedation (Silva)|Use of Digital Sedation (virtual reality associated with psychological interventions) for preoperative anxiety management
45782935|NCT03219554|Drug|Palbociclib|oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
45782936|NCT03213236|Diagnostic Test|Homemonitoring diagnostic system|"In addition to the standard full-night diagnostic polysomnography, patients will be evaluated during the same night with a homemonitoring diagnostic system that consists out of a pulse oximeter, accelerometer, smartphone for audio recording and a mattress that measures the ballistocardiogram."
45782937|NCT03837782|Procedure|minimally invasive surgery|Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery. No individual surgeons performed only the open approach or only the minimally invasive approach. The committee members reviewed the patients' outcomes and the videos to ensure the adequacy of the surgeon's technique.
45782938|NCT01554371|Drug|Eribulin|"Given intravenously (IV)~Phase II: Eribulin mesylate (mg/m2) + Cyclophosphamide (mg/ m2) for advanced breast cancer participants only"
45782939|NCT01554371|Drug|Cyclophosphamide|Given IV
45782940|NCT03219398|Procedure|Pneumoperitoneum pressure|Subjects were set to 8- 10 mmHg pressure during laparoscopic surgery; Subjects were set to 12-14 mmHg pressure during laparoscopic surgery
45782941|NCT01834352|Drug|Walnut Protein Flour|Daily ingestion of gradually increasing amounts of walnut protein flour in order to induce desensitization to walnut and an unrelated tree nut.
45643196|NCT04684121|Drug|Vehicle gel|Vehicle gel will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
45782942|NCT01834352|Drug|Oat flour|Oat flour that is administered as a placebo in identical increasing doses as the active walnut flour treatment.
45782943|NCT01451411|Drug|Conivaptan hydrochloride|Intravenous
45782944|NCT01451411|Drug|Placebo|Intravenous
45643197|NCT04682639|Drug|Etrasimod|Participants will receive etrasimod tablet by mouth, once daily during the 24-week Double-Blind and 28-week Extension Treatment Periods.
45782945|NCT01834430|Dietary Supplement|enteral nutrition|
45643198|NCT04682639|Drug|Placebo|Participants will receive etrasimod matching placebo tablet by mouth, once daily during the 24-week Double-Blind Treatment Period.
45643199|NCT04682639|Drug|Etrasimod|Participants will receive etrasimod tablet by mouth, once daily during the 28-week Extension Treatment Period.
45643200|NCT04673266|Drug|Romiplostim|All patients will begin weekly (+/- 2 days) romiplostim at 3 mcg/kg subcutaneously. The romiplostim dose will be titrated, based on weekly CBC/platelet counts.
45643201|NCT04672369|Biological|IBI939|IBI939 injection
45643202|NCT04672369|Biological|Sintilimab|Sintilimab injection
45782946|NCT03837938|Drug|Levopront® syrup 30 mg/5 ml|The first study drug administration will be performed at the clinical site on the day of randomization; the last study drug administration will be performed in the evening before Day 8 (±1).
45782947|NCT03837938|Drug|Libexin®|The first study drug administration will be performed at the clinical site on the day of randomization; the last study drug administration will be performed in the evening before Day 8 (±1).
45782948|NCT01554683|Drug|Low/High/Placebo Dose Keppra (Levetiracetam)|Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)
45782949|NCT04380584|Diagnostic Test|plasma Apelin level|blood sample for detection of plasma Apelin level
45643203|NCT04672356|Biological|IBI939|IBI939 injection
45643204|NCT04672356|Biological|Sintilimab|Sintilimab injection
45782950|NCT01452191|Behavioral|Injury Prevention Briefing Plus facilitation|Injury Prevention Briefing (IPB) to provide best evidence on what works to reduce house fire injuries, and activities to get the evidence into practice. This arm will receive facilitation to support the implementation of the information in the IPB
45782951|NCT01452191|Behavioral|Injury Prevention Briefing|Children's centres will receive the Injury Prevention Briefing only.
45782952|NCT00905060|Biological|HSPPC-96|Autologous tumor-derived heat shock protein peptide-complex (HSPPC-96) administered at 25 μg per dose injected intradermally once weekly for 4 consecutive weeks and monthly following standard treatment with radiation and temozolomide.
45782953|NCT00905060|Drug|Temozolomide|Maintenance temozolomide treatment is given 2 weeks after administration of the fourth vaccine at an initial dose of 150 mg per square meter (mg/m2) for 5 consecutive days in a 28-day cycle. The dose was increased to 200 mg/m2 for 5 days in subsequent cycles.
45917508|NCT02903212|Biological|Autologous apoptotic cells injection|cells injection
46070813|NCT00817141|Other|Observational study, no intervention|Observation of the complications seen without urinary catheter (which is the habitual protocol in our institution)
45643205|NCT04668170|Biological|Blood collection on admission and longitudinally|Samples already collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)
45643206|NCT04668170|Biological|Blood collection on their first consultation and 10 to 14 days later|Samples already collected on consultation (D0) and 14 days later
45782954|NCT00905060|Procedure|Standard Surgical Resection|Patients will undergo standard surgical resection of intracranial tumor
45782955|NCT01535573|Drug|Citalopram|20 mg once per day for 9 weeks
45782956|NCT01535573|Drug|Citalopram|40 mg per day for 9 weeks
45782957|NCT01535573|Drug|Placebo|0 mg per day for 9 weeks
45782958|NCT01452425|Device|Tourniquet|Inflation of a tourniquet (pressure equal to the mean arterial pressure) obtaining a model of slight venous congestion and arterial hypoperfusion
45782959|NCT01452425|Device|INVOS assessment|Near Infraread spectroscopy, non invasive
45782960|NCT01452425|Device|EMG assessment|Electromyography, non invasive
45782961|NCT00905450|Drug|BOL-303242-X|Medication instilled into the study eye, subjects randomized to various drug concentrations and dose schedules.
45782962|NCT00905450|Drug|Vehicle for BOL-303242-X|Medication instilled into the study eye, subjects randomized to various drug dose schedules.
45782963|NCT01536197|Procedure|Gastric bypass|Roux-en-Y gastric bypass
45782964|NCT01536197|Procedure|Gastric banding|Laparoscopic adjustable gastric banding
45782965|NCT01536197|Procedure|Sleeve gastrectomy|Sleeve gastrectomy surgery
45782966|NCT01834508|Drug|oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks|
45782967|NCT01537367|Behavioral|Enhanced contact plus behavioral skills|The enhanced contact plus behavioral skills arm is the longer experimental arm.
45782968|NCT01537367|Behavioral|Enhanced contact only|The enhanced contact only arm is the shorter experimental arm.
45782969|NCT01537367|Behavioral|Standard of Care|The standard of care arm is the comparison group arm that receives only standard clinical services.
45782970|NCT04380662|Other|Risk factors|"The studied potential risk factors will be the following:~Socio-demographic: age, sex, place of residence, CSP and income.~Comorbidities or aggravation: COPD, asthma, immunosuppression, or heart failure, diabetes imbalance, etc.~Clinical signs: asthenia, dyspnea (kinetics), blood sugar, nutritional status, weight gain…~Drugs other than those related to the infection and potential self-medication (anti-inflammatory, CEI, ARA…)"
45782971|NCT01537835|Other|Antimicrobial Scrubs|Participants will be randomized to one of three types of scrubs. There will be a control (standard scrubs without antimicrobial properties) and two scrubs with reported antimicrobial properties.
45782972|NCT00906074|Procedure|Elective or emergency abdominal surgery|Clinical record review.
45782973|NCT00906074|Procedure|Elective or emergency abdominal surgery|Clinical record review
45782974|NCT01538615|Behavioral|HOME Plus intervention|The HOME Plus program families will participate in monthly, two-hour group sessions for ten months at local community centers. Each session offers new ideas focusing on family meals, healthy eating, and reducing sedentary behavior. At each session, families prepare and eat a meal together and participate in small group discussions and activities for both parent and child groups to promote healthy behaviors in the home. Topics include planning healthy meals and snacks with your family, having meals with your family more often, and improving the healthfulness of the food available at home. Families also receive periodic supportive phone calls throughout the year using motivational interviewing techniques to promote healthy behaviors to prevent and reduce childhood obesity.
45782975|NCT04380428|Other|No Intervention. Observational study.|No Intervention. Observational study.
45782976|NCT03219242|Device|Caiman® device|Using CAIMAN device in primary surgery for ovarian cancer. Analyze potential time-sparing and the incidence of post-surgical complications.
45782977|NCT04380506|Procedure|Surgical Drains Management|The Role of Amylase Drain Level in the Management of Surgical Drains after Pancreratoduodenectomy
45782978|NCT03213002|Drug|Capecitabine|Capecitabine at 1500 mg/m2
45782979|NCT03213002|Drug|Temozolomide|Temozolomide at 150 mg/m2 - 200 mg/m2
45782980|NCT01556633|Drug|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers on dialysis
45782981|NCT01556633|Drug|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers with creatinine clearance from 10 to 30 mL/min
45782982|NCT03218696|Device|Cough Syrup for adults and children|The intervention product is a medical device in Europe due to its non-pharmacological mode of action, which makes the product compliant to the medical device definition. It is made of specific extracts of plants (plantago and thymus) which provide the product with protective characteristics of the oropharynx. These protective features enable the syrup to reduce the irritative cough promoting stimuli on the throat, which decrease urge to cough threshhold. In addition to these extract, honey completes the formula. The product does not contain any artificial component and no preservatives.
45782983|NCT03218696|Device|Placebo|The placebo intervention is a syrup of same taste and colour without the natural protective components but with the necessary synthetic preservatives and other co-sweeteners to guarantee quality and safety. The placebo has, in fact, all the features of a cough syrup since true placebo syrup is not possible in cough. The lack of specific natural protective components is weighed against the presence of other necessary substances which may still have an effect on cough, but this effect is not envisaged to be a specific protective effect.
45782984|NCT03218774|Behavioral|Home Exercise Group|The Home group will meet with an exercise professional once and be given a home exercise program to complete 3 to 5 times per weeks at home.
45782985|NCT03218774|Behavioral|Fitness Center Group|The Center group will be given an exercise program, a membership to a community fitness gym where they will be asked to exercise 3-5 times per week, and will be provided with 6 individual personal training sessions.
45782986|NCT03218852|Drug|prednisone and cyclophosphamide|Prednisone and cyclophosphamide are both administered to participants in this group.
45782987|NCT03218852|Drug|prednisone alone|Prednisone is administered to participants in this group.
45782988|NCT01834664|Biological|stem cell (MNCs )|Intra thecal transplantation of autologous stem cell [MNCs ]Per dose at the interval
45782989|NCT01834742|Drug|NER1006|Single evening dose of 750mL solution containing 100g PEG3350 plus 6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
45782990|NCT01834742|Drug|NER1006|Single evening dose of 750mL solution containing 100g PEG3350 plus 9g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
45782991|NCT01834742|Drug|NER1006|Single evening dose of 750mL solution containing 75g PEG3350 plus 5.6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
45782992|NCT01834742|Drug|Moviprep|Reconstituted and administered in accordance with recommended split dose intake: one litre in the evening, one litre the following morning.
45782993|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350 and 56.6g sodium ascorbate.
45643207|NCT04665869|Behavioral|Combined balance and brisk walking training|6-months of combined balance and brisk walking training
45782994|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate and 21.4g magnesium ascorbate.
45782995|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 6g sodium sulphate and 33.9g sodium ascorbate.
45782996|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 29g PEG3350 and 4.8g sulphate and 23.3g ascorbic acid.
45782997|NCT03836690|Biological|CD62L- Tem|Donor memory T cells that have been depleted of CD62L+
45643208|NCT04665869|Behavioral|Flexibility and strengthening exercise|6-months of flexibility and strengthening exercise
45782998|NCT03212768|Procedure|Trans-syndesmotic fixation|antromedial approach for medial malleolus fractures, posterolateral or direct lateral approach for fibula fractures, direct fixation of third malleolus by posterior approach, Trans-syndesmotic fixation ,cement augmentation and Tibiotalocalcaneal fusion
45782999|NCT01834898|Drug|Controlled-release oxycodone|Controlled-release oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
45783000|NCT03218462|Behavioral|Sensory Adapted Dental Environment (SADE)|No fluorescent room lights, solar projector on ceiling, regular dental x-ray apron laying on patient, quiet music playing in background
45917509|NCT04251949|Procedure|LED photobiomodulation|1 PLED session before each radiotherapy session, until the end of the radio or radio-chemotherapy treatment. Each session will last 7 minutes. The light delivered will be preset on the lamp which will deliver a red light of a wavelength of 630nm, at a fluence of 37J/cm².
45917510|NCT00000705|Drug|Zidovudine|
45917511|NCT04227106|Biological|EB-101|autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7
45917512|NCT04206007|Biological|UMC119-06|Cohort 1: Low does of UMC119-06 Cohort 2: Medium does of UMC119- 06 Cohort 3: High does of UMC119-06
45917513|NCT00000708|Drug|Flucytosine|
45917514|NCT00000708|Drug|Fluconazole|
45917515|NCT00000708|Drug|Amphotericin B|
46070814|NCT00818311|Device|LED GentleWaves®|primary spectral radiance with a dominant 590 nm wavelength (yellow visible light), irradiance power level of 4mW/cm2, Light pulsed with sequential period on/off for a total duration of 35 seconds per cycle.
45643209|NCT04665739|Drug|Everolimus|Given PO
45643210|NCT04665739|Drug|Lutetium Lu 177 Dotatate|Given IV
45783001|NCT03212378|Other|percutaneous coronary interventions|Percutaneous coronary intervention.
45783002|NCT03218228|Procedure|implants in periodontitis|it targets immediate implant placement in patients suffering from aggressive periodontitis
45783003|NCT03212300|Behavioral|Aerobic Exercise Training (AET)|20 sessions of AET over a 4 week period just prior to surgery
45783004|NCT03218306|Device|Surgical Pleth Index|Effector site concentration of remifentanil based on SPI
45643211|NCT04664023|Procedure|Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection.|40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
45643212|NCT04664023|Procedure|Blood collection at 1st injection of vaccine against COVID-19, at at second injection of vaccine, at Month 1, Month 2, Month 6 and Month 12 after second injection of vaccine for volunteers|40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
45643213|NCT04660201|Biological|AV7909|AV7909 (Liquid Formulation) is an investigational vaccine that is a preformulated, sterile, milky-white suspension for IM injection. It consists of the Anthrax Vaccine Adsorbed (AVA) bulk drug substance and CPG 7909 adjuvant
45783005|NCT03218306|Other|Clinical guidance|Effector site concentration of remifentanil based on hemodynamic data
45783006|NCT01557959|Drug|cisplatin|Given IV
45783007|NCT01557959|Biological|pegfilgrastim|Given SC
45783008|NCT01557959|Drug|erlotinib hydrochloride|Given PO
45783009|NCT01557959|Other|laboratory biomarker analysis|Optional correlative study
45783010|NCT01557959|Genetic|polymorphism analysis|Correlative study
45917516|NCT00000711|Drug|Zidovudine|
45917517|NCT00000711|Drug|Sargramostim|
45643214|NCT04660201|Biological|AV7909|AV7909 (Lyophilized Formulation) is a thermostable, lyophilized version of the liquid AV7909 formulation. Sterile, milky-white suspension for intramuscular injection. It consists of polysorbate 80, CPG7909 adjuvant and AVA bulk drug substance
45643215|NCT04658186|Drug|UCB0599|Drug: UCB0599 Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive UCB0599 in a pre-specified sequence during the Treatment Period.
45643216|NCT04658186|Drug|Placebo|Drug: Placebo Pharmaceutical form: Capsules Route of administration: Oral use Participants will receive Placebo in a pre-specified sequence during the Treatment Period.
45783011|NCT01557959|Other|pharmacogenomic studies|Correlative study
45783012|NCT01557959|Genetic|genetic linkage analysis|Correlative study
45783013|NCT01557959|Drug|docetaxel|Given IV
45783014|NCT03212456|Drug|opioid-free group|We'll study if the opioid-free anesthesia can reduce the biochemical recurrence of prostate cancer.
45917518|NCT00000717|Drug|Primaquine|
45917519|NCT00000717|Drug|Clindamycin|
45917520|NCT04185415|Drug|bepranemab|"bepranemab will be administered in a predefined dosage.~Pharmaceutical Form: Solution for infusion~Route of Administration: Intravenous"
45917521|NCT04185415|Drug|Placebo|"Pharmaceutical Form: Solution for infusion~Concentration: 0.9% w/v sodium chloride aqueous solution~Route of Administration: Intravenous"
46070815|NCT00812851|Drug|Dronabinol|
45643217|NCT04655755|Drug|Decitabine and Cedazuridine|Given PO
45643218|NCT04655755|Drug|Venetoclax|Given PO
45783015|NCT03212456|Drug|Opioid Group|This group will receive fentanyl in the induction of anesthesia.
45783016|NCT03212456|Procedure|transversus abdominal plane block with ropivacaine|The opioid-free group will receive transversus abdominal plane block with ropivacaine 0,375% 20 ml each side
45783017|NCT03212456|Procedure|transversus abdominal plane block with placebo|the non-opioid free group will receive transversus abdominal plane block with physiological solution 0,9% 20 ml each side
45783018|NCT04380272|Diagnostic Test|The ROC analysis|The Brodsky clinical stage and ultrasonographic data of the participants will be matched, and the diagnostic value of the submental US in the classification of tonsil hypertrophy as non-obstructive and obstructive will be evaluated. A ROC analysis will be used to determine the optimal cut-off value.
45783019|NCT03212612|Diagnostic Test|samples obtained by laparoscopy or punch biopsy for analysis by ELISA|Endometrial samples(1-2 gram) will be separated from each women during proliferative phase(days 5-15) by laparoscopy or punch biopsy and washed several times with 0.9% sterile saline solution to remove any blood from the tissues. The tissue samples will homogenized by tissue homogenizer at 40,000rpm. The supernatant extracts will be collected in Ependorf tubes and frozen at -80°C till analysis by ELISA
45783020|NCT03218150|Procedure|cranioplasty|". The margins of the craniectomy defects exposed, and the bone flaps fixed in their original positions using wires or titanium plates with screws. As prophylaxis, all patients intravenously administered with pre- and postoperative antibiotics.~In cases of artificial substitutes , The polymethyemethacrylate implant fixed to the defective region with titanium plates and self-tapping screws."
45783021|NCT02503332|Drug|Pegcetacoplan|
45783022|NCT02503332|Other|Sham Procedure|
45783023|NCT03217838|Drug|AZD2811|AZD2811 will be administered by IV infusion with the specified dose level as reported in arms in 28-day cycles.
45783024|NCT03217838|Drug|Azacitidine|Azacitidine is supplied in vials of 25 mg/mL powder for suspension for injection. After reconstitution, each vial contains a maximum of 100 mg. Participants should be pre-medicated for nausea and vomiting according to institutional standards before receiving azacitidine. Participants will receive 75 mg/m² on Days 1 through 7 or for 5 consecutive weekdays with rest on the 2 weekend days, and azacitidine dosing the first 2 weekdays of the next week of each 28-day cycle.
45783025|NCT03217838|Drug|Venetoclax|Venetoclax (VENCLEXTA®) is approved by the FDA for use in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed AML in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Venetoclax is planned to be given at a dose of 100 mg orally (PO) on Day 1 and 200 mg (PO) on Days 2- 28 of each 28-day cycle or 100 mg orally (PO) on Day 1, 200 mg PO on Day 2, and 400 mg PO from Days 3 to 28 of each 28-day cycle. The third participant in Group 3 Arm A will only be enrolled after the first 2 participants will receive ≥2 weeks of treatment and have shown no evidence of toxicity observed to be compatible with a DLT.
45917522|NCT04169347|Drug|Oxaliplatin|2 week cycles
45917523|NCT00000720|Drug|Globulin, Immune|
45917524|NCT00000720|Drug|Zidovudine|
45917525|NCT04142983|Biological|Adacel|0.5 mL, Intramuscular
45917526|NCT00000726|Drug|Foscarnet sodium|
45917527|NCT03509181|Behavioral|I-Change|smartphone delivered word-sentence association task that encourages a healthier interpretive style
45917528|NCT03509181|Behavioral|Symptom Tracking|smartphone delivered self-monitoring of anxiety and depression symptoms
45917529|NCT04112914|Behavioral|Post-concussion education for families|An educational resource for families will be developed based on the CDC guidelines for returning to daily activities, school, and sports, adapted with stakeholder feedback to meet the learning needs of low health literacy parents. An implementation toolkit will be developed, adapting the AHRQ RED Toolkit, to support communication about the educational resource and other best-practices for communication with families, including low health literacy families.
45917530|NCT04104139|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
45917531|NCT04104139|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45917532|NCT04104139|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
45643219|NCT04650854|Drug|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
45643220|NCT04647253|Device|AGENT DCB|Drug coated PTCA balloon catheter
45643221|NCT04647253|Device|PTCA balloon catheter|PTCA balloon catheter
45643222|NCT04643457|Drug|UCB9741|- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
45643223|NCT04643457|Drug|Intravenous Placebo|- Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.
46070816|NCT00818467|Other|Tanning spray|using 3% DHA twice a week for the 1st week and then once a week for 4 weeks and receiving 40mJ UV-B phototherapy three times a week for four weeks
46070817|NCT00818467|Other|UVB|receiving 40mJ UV-B phototherapy three times a week for four weeks
45643224|NCT04643457|Drug|Subcutaneous Placebo|Pharmaceutical form: Solution Participants will receive subcutaneous Placebo to maintain the blinding during the Treatment Period.
45643225|NCT04642781|Diagnostic Test|reading of a text|Reading of 2 IRest Texts presented on a laptop in randomized order while eye movements are recorded with a tracking bar.
45643226|NCT04636177|Behavioral|Pain Rehabilitation Virtual Reality (PRVR)|Participants will receive approximately 8, 1-hour physiotherapy sessions delivered over the course of 6-12 weeks. Adequate dose: 75% (6 of 8 sessions).
45643227|NCT04635995|Biological|LVGN7409|IV infusion once every 3 weeks (Q3W).
45783026|NCT01558661|Drug|AG-013736 (AXITINIB)|All eligible patients will receive a starting axitinib dose of 5 mg twice daily (BID) taken orally in 4-week (28-day) cycles. Patients who tolerate axitinib with no adverse events related to study drug above CTCAE v. 4.0 Grade 2 for a consecutive 2-week period may have their dose increased by one dose level according to the discretion of the treating physician (NOT allowed for patients with blood pressure (BP) > 150/90 mm Hg or who are receiving antihypertensive medication). This dose escalation is not mandatory. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity.
45783027|NCT01835288|Drug|arsenic trioxide|Given IV
45783028|NCT01835288|Other|laboratory biomarker analysis|Correlative studies
45783029|NCT03212534|Other|Patient mortality prediction|Healthcare provider is notified of patient mortality prediction.
45783030|NCT03212222|Other|Peek Acuity|Cell phone application for visual acuity screening
45783031|NCT03212222|Other|Standard Visual Screening|Visual screening exam conducted in Duke University Eye Center
45783032|NCT02502864|Drug|Standard of Care: Docetaxel|Pharmacokinetic(PK)-guided docetaxel. Cycle 1: 75 mg/m^2, intravenously (IV) on Day 1 for 60 minutes. Beginning with cycle 2, the docetaxel dose will be individually adjusted before each cycle.
45783033|NCT02502864|Drug|Standard of Care: Cyclophosphamide|Cycle 1: 600 mg/m^2, via IV on Day 1 for 30 minutes. The cyclophosphamide dose will not be changed unless dictated by toxicity.
45783034|NCT02502864|Other|Function Assessment of Cancer Therapy (FACT) Surveys|Participants will complete the FACT-Taxane and FACT-Breast quality of life assessment written surveys at baseline, during each chemotherapy cycle, and 3-5 weeks following the last cycle in which PK monitoring was performed.
45783035|NCT03211598|Procedure|TACE with Surefire|Subjects that consent to the study will receive their TACE procedure through the Surefire Infusion System
45783036|NCT01835600|Other|PEEP|PEEP means that when mechanical ventilation is suspended, the value of expiratory valve in the anesthesia machine is set at 10 cmH2O with 1 L/min 100% oxygen.
45783037|NCT01835834|Procedure|zirconia bridge restoration|
45783038|NCT03217760|Procedure|Endodontic treatment|Endodontic treatment or root canal therapy is a sequence of treatment for the infected pulp of a tooth which results in the elimination of infection and the protection of the decontaminated tooth from future microbial invasion.
45783039|NCT03217760|Other|VAS of stress|The VAS is a 10-cm scale without graduation on which subjects are asked to score the specific level of stress experienced from 0 (not stressed at all) to 10 (worst stress imaginable)
45783040|NCT03217760|Other|CORAH scale|At the beginning of the treatment (T1), the patient is asked to complete a French version of the Corah Dental Anxiety scale (DAS).
45783041|NCT03217760|Other|HAD Scale|At the beginning of the treatment (T1), patients and students are asked to complete the Hospital Anxiety and Depression Scale (HAD Scale) which is presented as a reliable instrument for assessing clinically significant anxiety and depression.
45917533|NCT04084795|Behavioral|Eye Movement Desensitization and Reprocessing therapy|"EMDR is a psychotherapeutic approach using a standardized 8-phase protocol to alleviate the distress associated with traumatic memories, facilitating the access to and processing of traumatic memories. Patients will receive 20 individual EMDR sessions of 60 minutes each using the standard protocol, as well as a specific pain protocol and the fibromyalgia protocol. EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements).~The current standard protocol includes eight phases:~Patient history. Patient preparation. Patient assessment. Memory desensitization. Installing the positive cognition. Body scan. Closure. Reevaluation."
46070818|NCT00648037|Drug|Rituximab|Rituximab 375 mg/m^2 starting approximately 1 month post transplant (no later than day 45), and continuing monthly until the CD4 cell count is > 200 cells/ul or a maximum of 6 doses have been given.
46070819|NCT00813007|Behavioral|Questionnaires|5 Questionnaires at differing times before and after surgery.
45783042|NCT03217760|Other|Cardiovascular Parameters|For each subject, the physiological indicators of stress (ie, heart rate [HR], systolic blood pressure [SBP], and diastolic blood pressure [DBP]) are monitored during each of the 6 steps.
45783043|NCT03217760|Other|Cortisol Measurements|Salivary samples are collected during each of the 6 steps of endodontic treatment which are then stored at -20° before being sent to the laboratory to test cortisol levels .
45783044|NCT03217760|Other|Discomfort and Pain Experienced During Treatment|Patients were asked to report the levels of discomfort and pain experienced during the 6 steps using the VAS and at the next visit for the final restoration.
45783045|NCT03217760|Other|Patient's preferences.|After the completion of each treatment patients will have to report whether they thought that they would have experienced as much pain, stress, or discomfort if they had received premedication before treatment.
45449022|NCT02147080|Behavioral|UV4me|Tailored website includes: personalized responses to quizzes, information on skin type and burn risk, UV damage photo of similar individual, avatar activity, age progression images, personal risk calculator, SPF (sun protection factor) calculator
45449023|NCT02147080|Behavioral|Skin Cancer Foundation website|Current best practice website for skin cancer and prevention. Includes information, images, news, and opportunities for advocacy.
45643228|NCT04634435|Combination Product|CIML NK Cells plus KP1237 and low dose IL-2|Single dose infusion of CIML NK Cells plus KP1237 followed by low dose IL-2
45643229|NCT04633889|Drug|Deferoxamine|Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours
45643230|NCT04633889|Drug|Normal saline|Normal saline (240mL) intravenous infusion over 12 hours
45643231|NCT04631016|Biological|MEDI3506|Dose 1
45643232|NCT04631016|Other|Placebo|Dose 1
45643233|NCT04630886|Drug|Tranexamic acid injection|subcutaneous injection of 50mg/ml TXA
45783046|NCT03217760|Other|student preferences.|"When the treatment is complete the students are asked to report:~his/her level of satisfaction with the course of treatment,~whether he/she felt awkward faced with the patient's manifestations of stress, discomfort, or pain during the session~whether he/she would have preferred that the patient had received sedative medication before the endodontic treatment."
45643234|NCT04630886|Drug|Lidocaine Epinephrine|subcutaneous injection of 1% lidocaine mixed with 1:200,000 epinephrine
45783047|NCT03211910|Device|SacralSaver|Sacral Savers is a combination of a strong bubble wrap sheet with a fold at the head end and a nylon sham with a pocket into which the bubble wrap sheet is inserted. This combination is then placed under the fitted sheet on the patient's mid back and the pressure exerted by the lower back of the patient is markedly reduced or nearly eliminated (tested and proven using computer models), thereby preventing the onset of pressure ulcers in the sacro-coccygeal area.
45783048|NCT03211910|Other|Standard Care of Treatment|Standard Care of Treatment
45783049|NCT01457417|Drug|DKN-01|DKN-01 will be administered intravenously (IV) once a week over 30 minutes (min) and 2 hours (max) for 75, 150 and 300 mg. At 600 mg, DKN-01 will be administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: 3 participants will be treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation will occur sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching maximum tolerated dose (MTD) are met (or highest planned dose study group is completed). Cycle 1 will define the dose limiting toxicity (DLT) that governs dose escalation. PART B - Dose Confirmation: Once the MTD is established (or the highest planned dose level), 300 mg of DKN-01 will be administered IV on days 1 and 15 of every 28 day cycle.
45783050|NCT03217292|Procedure|Serratus Anterior Plane Block|
45783051|NCT03217292|Drug|IV patient-controlled analgesia (PCA) tramadol|
45783052|NCT03217448|Drug|Dabigatran etexilate|Subjects should take Dabigatran etexilate 150mg twice a day for 6 months after randomization.
45783053|NCT03217448|Drug|Warfarin|Subjects should take Warfarin for 6 months after randomization and the dose will be changed according to investigator's judgment.
45783054|NCT03217370|Other|education of guidelines|"Guidelines will be updated and education will be given to haematologists in several ways.~ICT implementations: a) last result of haemoglobin and platelet count will be shown on the electronic blood order; b) an electronical clinical decision support system will be implemented to order blood components"
45449024|NCT03542968|Procedure|magnetic resonance imaging|Acquisition 4D Flow magnetic resonance Imaging-8 minutes
45783055|NCT03211754|Dietary Supplement|walnuts and almonds|The subjects consumed 15g of walnuts and 15g of almonds/day for 8 weeks
45783056|NCT01457573|Drug|Tamsulosin|Alpha blocker used to in the treatment of urinary difficulties related to enlarged prostate or symptomatic benign prostatic hypertrophy. All men will receive Tamsulosin (Flomax®) 0.4 mg, 1 tab, per morning with Solifenacin (Vesicare®).
45783057|NCT01457573|Drug|Solifenacin|Antispasmodic/anticholinergic used to treat overactive bladder. All men will receive Solifenacin (Vesicare®) 5 mg, 1 tab, per morning with Tamsulosin.
45783058|NCT03217526|Other|Gait Training|Gait Training: Training will be applied by a physiotherapist on a treadmill or on an overgorund.
45783059|NCT02474082|Biological|Secukinumab|Secukinumab 150 mg, 1 ml liquid formulation in a pre-filled pen for s.c. injection
45783060|NCT02474082|Drug|Fumaric acid|Fumaric acid initial therapy (tablet contains 30 mg dimethylfumarate, 67 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt) and Fumaric acid maintenance therapy (tablet contains 120 mg dimethylfumarate, 87 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt)
45783061|NCT01836146|Device|EnligHTN™ Renal Artery Ablation Catheter|
45783062|NCT01560143|Drug|Tigecycline|100 mg IV as a single infusion over 30 minutes
45783063|NCT03212066|Behavioral|Master Mind|Master Mind is a 25-lesson elementary school mindfulness education substance abuse prevention program. Each lesson takes approximately 15 minutes and is designed to be taught by trained teachers every day for 5 weeks.
45783064|NCT01836224|Drug|Terlipressin|Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure) >65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
45783065|NCT01836224|Drug|Noradrenaline|Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65
45783066|NCT01560377|Device|PINPOINT Endoscopic Fluorescence Imaging System|The PINPOINT system will be used to provide real-time endoscopic visible and endoscopic NIR fluorescence imaging. PINPOINT enables surgeons to perform routine visible light endoscopic procedures as well as further visually assess vessels, blood flow and related tissue perfusion with near infra-red imaging during minimally invasive surgery
45449025|NCT02147236|Behavioral|Social Skills Training|
45449026|NCT02152618|Other|Parent Management Training - Oregon Model (PMTO)|Evidence-based, behavioral parent management training model, Parent Management Training - Oregon Model (PMTO) tailored to address permanency barriers of parents of children with SED.
45643235|NCT04628780|Biological|PF-07209960|PD-1 targeted IL-15 mutein
45643236|NCT04628767|Procedure|Biopsy|Undergo tissue biopsy
45449027|NCT02147392|Drug|[11C]ER-176|
45643237|NCT04628767|Procedure|Biospecimen Collection|Undergo blood sample collection
45643238|NCT04628767|Drug|Cisplatin|Given IV
45643239|NCT04628767|Procedure|Computed Tomography|Undergo CT
45643240|NCT04628767|Drug|Doxorubicin Hydrochloride|Given Iv
45643241|NCT04628767|Biological|Durvalumab|Given IV
45643242|NCT04628767|Drug|Gemcitabine Hydrochloride|Given IV
45643243|NCT04628767|Procedure|Magnetic Resonance Imaging|Undergo MRI
45643244|NCT04628767|Drug|Methotrexate|Given IV
45643245|NCT04628767|Biological|Pegfilgrastim|Given via injection
45643246|NCT04628767|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45643247|NCT04628767|Drug|Vinblastine Sulfate|Given Iv
45643248|NCT04628494|Biological|Epcoritamab|Following mandatory pre-medication subject will be administered epcoritamab as a subcutaneous injection.
45783067|NCT03211676|Device|Theranova-500 dialyzer|hemodialysis with Theranova-500 dialyzer.
45783068|NCT03211676|Device|Elisio-21H|hemodialysis with Elisio-21H dialyzer
45783069|NCT03217214|Diagnostic Test|Thermography|Passive thermography for Phase I subjects and Active Thermography for Phase II subjects
45783070|NCT03211442|Radiation|Radiotherapy|Breast cancer patients treated with radiotherapy
45783071|NCT01836302|Other|Observation|
45449028|NCT02147470|Drug|Definity ultrasound contrast agent|All subjects will undergo CEUS of the kidney at baseline to measure renal blood flow. This procedure will be repeated after volume expansion and if indicated, once again after treatment with albumin, midodrine and octreotide.
45783072|NCT01836380|Behavioral|Exercise Training|
45783073|NCT03211364|Other|Glenohumeral mobilization|Comparing the effect of angular mobilization in frontal or scapular plane and of providing soft tissue techniques on hemiplegic shoulder range of motion and pain.
45783074|NCT03211364|Other|Scapular mobilization|
45783075|NCT01836536|Drug|Bevacizumab standard of care|Standard treatment associated with circulating leucocytes (blood samplings)
45783076|NCT03216980|Dietary Supplement|PTSD/GAD Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
45783077|NCT03216980|Dietary Supplement|PTSD/GAD Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
45783078|NCT03216980|Dietary Supplement|Healthy Control Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
45783079|NCT03216980|Dietary Supplement|Healthy Control Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
45783080|NCT00895232|Drug|Cohort I|
45783081|NCT00895232|Drug|Cohort II|
45783082|NCT00895232|Drug|Cohort III|
45783083|NCT03211130|Behavioral|SystemCHANGE™|During the intervention phase, the PI will visit both groups of participants at home at baseline and telephone them three times (day 3 ±2 days and months 1 and 2). Refer to tables 1 and 2 for intervention details. Treatment participants will implement SystemCHANGE™ activities related to medication taking with the assistance of the PI while attention-control participants will receive patient education materials on stroke. Perceived health data will be collected during the intervention phase. A 1-month maintenance phase follows the intervention phase. Electronic medication monitoring continues, but no intervention is delivered to either group.
45783084|NCT03211130|Behavioral|Attention-Control|An experienced stroke nurse will deliver the attention control intervention. Table 3.2 shows the 2-month attention-control intervention. The stroke materials were developed by the Saint Luke's Marion Bloch Neuroscience Institute and are given to every stroke patient prior to dismissal. The PI will call participants at day 3 ±2 days, and months 1 and 2 to review chapter(s) from the book and answer questions about it. Interval, frequency, and setting are all exactly the same for the intervention and control groups. If the control participant raises questions about medications or medication-taking, PI will refer them to their Neurologist.
45783085|NCT04380974|Procedure|OCTA plus OCT guided 3+PRN regimen|"For the OCTA plus OCT guided 3+PRN regimen, we recorded patients' data after retreatment by 3 monthly intravitreal injections of anti-VEGF drug. Subsequent reinjections were given as needed according to the changes in patients' visual acuity, activity of PCV lesions shown by OCTA and/or the exudation shown by OCT. Four weeks after the third and last injection, all patients in this group underwent an examination, including ETDRS visual acuity, fundus photography, OCTA and OCT.~In case of BVN increased or polypoidal lesion progressed on OCTA scans, persistent subfoveal or perifoveal fluid, macular intraretinal edema on OCT scans, or visual loss of >5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later."
45783086|NCT04380974|Procedure|OCT guided 3+PRN regimen|"For the OCT guided 3+PRN group, we recorded patients'data after retreatment by 3 monthly intravitreal injections of Anti-VEGF drugs. Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four weeks after the third and last injection, all patients in this group underwent an examination, including ETDRS visual acuity, fundus photography, and OCT.~In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of >5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later."
45783087|NCT04380974|Drug|Anti-VEGF drug|Conbercept or other anti-VEGF drugs
45783088|NCT01836692|Radiation|Intensity Modulated Radiotherapy treatment|Intensity Modulated Radiotherapy treatment
45783089|NCT03211052|Drug|TAK-700 and LHRH agonist|TAK-700 for 6 months 300mg BD with Leuprorelin Acetate Injections prior to planned prostatectomy
45783090|NCT03211052|Procedure|prostatectomy|SURGICAL REMOVAL OF THE PROSTATE
45783091|NCT01560923|Biological|Indoximod|Given twice daily (1200 mg total) by mouth for 6 months.
45449029|NCT02152774|Drug|Rho-Kinase Inhibitor|
45449030|NCT02147548|Drug|etifoxine|
45783092|NCT01560923|Biological|Sipuleucel-T|Sipuleucel-T will be administered as standard of care. Given by infusion over 60 minutes at Week 0, 2 and 4. Patients will undergo leukapheresis at weeks 0, 2, and 4 with sipuleucel-T infused 3 days later (i.e. Monday/Thursday; Tuesday/Friday).
46070820|NCT00817297|Device|noninvasive ventilator|Experimental V60 Mask noninvasive Ventilator for treating patients with COPD, then Comparator Conventional Mask noninvasive Ventilator for treating patients with COPD in crossover study design
45449031|NCT02147548|Drug|lorazepam|
45449032|NCT02147548|Drug|Placebo|
45598208|NCT02359071|Other|handover duration, handover rate|To better analyze independent variables, we dichotomized the data. First, we dichotomized handover duration into two groups according to the median handoff time of 20 minutes. Second, we divided handover rates into two groups using the median rate of handovers per shift, which was 3.87%.
45598209|NCT02358759|Procedure|Correction of abnormally fertilized oocytes|Removing of extra developed nucleus from fertilized oocyte.
45598210|NCT05092841|Drug|PXT3003|Patients will be administered PXT3003 twice daily (bid) at 10mL.
45783093|NCT01560923|Other|Placebo|Given in same manner as Indoximod; 1200 mg per day by mouth.
45783094|NCT03837548|Other|Training with Neurofeedback|Neurofeedback the brain activities by Magnetoencephalography
45783095|NCT03837548|Other|The other Training with Neurofeedback|Neurofeedback the brain activities by Magnetoencephalography
45643249|NCT04628494|Drug|Investigator's Choice Chemotherapy|Following mandatory pre-medication subject will be administered intravenously either BR or R-GemOx.
45783096|NCT01836848|Procedure|measuring cerebral perfusion by NIRS with ICG|application of a bolus of 5mg indocyanine green (ICG) in 3ml saline 0,9% i.v. in 1 second and measuring the ICG turnover with the near-infrared-spectroscopy (NIRS)
45783097|NCT03836924|Drug|Perampanel|Perampanel tablets.
45783098|NCT03837002|Other|foot care protocol|foot assesment, foot care, foot care education
45783099|NCT03837080|Other|Nutrition Education|Every patient will receive one individual and two group counselings on specific nutrition-related recommendations for chronic pain patients.
45783100|NCT03836456|Behavioral|Mindfulness-based Stress Resilience Training|Mindfulness is a form of cognitive training that cultivates self-regulative ability and enhances resilience
45783101|NCT03836456|Behavioral|Health Enhancement Program|This is a validated active control developed to serve as a control for mindfulness-based studies.
45783102|NCT01839032|Drug|Vinorelbine cisplatin radiotherapy|"During the induction period, patients received chemotherapy for two 3-week cycles. Bolus intravenous vinorelbine 25 mg/m², was administered on day 1, then cisplatin 80 mg/m² was administered over 1-hour infusion. Vinorelbine 60 mg/m² was also administered on day 8.~Patients with objective response (OR) or no change (NC) continued the concomitant period (CP) including two additional 3-week cycles of radio chemotherapy (vinorelvine 20 mg D1 D3 D5 Cisplatin 80 mg/m² 66 Gy)."
45783103|NCT00906776|Device|Emdogain PLUS|Emdogain treatment followed by Straumann Bone Ceramic application during periodontal surgery
45783104|NCT00906776|Device|Autogenous bone|Autogenous bone application during periodontal surgery
45783105|NCT01457885|Drug|Clofarabine/Busulfan x 4|"Clofarabine IV dose level: 40 mg/m2/day x 5 days~Busulfan IV dose level: 3.2 mg/kg daily x 4 days"
45783106|NCT01457885|Procedure|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
45783107|NCT03830138|Genetic|Oxidized-LDL gene polymorphism|Oxidized-LDL gene polymorphism will be measured by RFLP. In addition, Oxidized-LDL will be measured in the plasma by ELISA
45783108|NCT05565989|Behavioral|MBM and II|An initiation to MBM practice (including 4 exercices) and 2 intention implementation exercices are proposed to participants
45783109|NCT05565989|Behavioral|MI|A motivational Interview will be conducted with participant.
45783110|NCT03210818|Device|Extra-corporeal membrane oxygenation life support|Adjustment of blood flow of extra-corporeal membrane oxygenation life support
45783111|NCT01460225|Drug|lubiprostone|24 micrograms twice daily for 1 week
45783112|NCT01836926|Procedure|Open intersphincteric resection|"laparotomy arm: surgical Instruments for open approach operation: Abdominal anterior resection combined with peranal intersphincteric resection of the rectum~Abdominal step a high ligation of the inferior mesenteric artery is performed together with a full mobilization of the left colon. A circular incision of the anal canal is performed 1 cm below the tumour. Both the mucosa and the muscular layer are incised to transect the internal anal sphincter. A coloanal anastomosis, transverse coloplasty or colonic J-pouch and a diverting loop ileostomy are associated with the hand-sewn coloanal anastomosis.~laparoscopic approach group: instruments used: laparoscopic instruments mentioned at the arm description~intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach"
45783113|NCT01836926|Device|transanal minimally invasive intersphincteric resection|minimally invasive approach group: instruments used: laparoscopic instruments mentioned at the arm description instruments: laparoscopic instruments mentioned in the laparoscopic rectal resection arm intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach
45783114|NCT05565911|Other|no intervention|this is an observational study, there is no intervention.
45783115|NCT01837004|Behavioral|CORTEX|2-hour sessions for a period of four weeks prior to the initial exercise program start. One hour will be devoted to computerized training (stationary dual-task & cognitive control training, self-priming, certainty training) whereas the other hour will be devoted to exergaming involving non-stationary, dual-task training.
45783116|NCT01561469|Drug|Linezolid|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with linezolid according to routine medical care.
45783117|NCT01561469|Drug|Vancomycin|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with vancomycin according to routine medical care.
45783118|NCT01837082|Drug|ferric carboxymaltose|
45598211|NCT05092841|Drug|PXT3003 placebo|Patients will be administered PXT3003 placebo twice daily (bid) at 10mL.
45598212|NCT02358525|Behavioral|multi-modality rehabilitation program for heart failure|rehabilitation consists of supervised exercise training, both endurance and strength, as well as gymnastics, diet and psychosocial education around living with heart failure
45598213|NCT02358447|Procedure|TKR|non-navigated versus computer-navigated total knee replacement
45643250|NCT04626349|Other|FOCUS+ (face-to-face nurse-led intervention)|"Home-based psycho-educational intervention consisting of two 90-minute home visits and one 30-minute video-conferencing session, conducted by a trained intervention nurse over a period of 12 weeks (4 weeks between each session).~The intervention is comprehensively manualized and there is a protocol to guide delivery of the intervention for each home visit and video call. The content of the sessions is always tailored to the needs of the dyads, so certain topics can be discussed more in-depth and specific information can be shared. The nurses who will deliver the FOCUS+ intervention will receive an extensive online training and additional continuous follow-up training to provide them with the knowledge and skills required to successfully implement the intervention. A FOCUS+ core booklet is provided as a supporting guide for the dyads that they can refer to at their own discretion and reinforces key intervention messages linked to the core components of the intervention."
45598214|NCT02224937|Drug|Melatonin|
45598215|NCT02224937|Drug|Placebo|
45598216|NCT03160131|Device|Neuro Vision Technology|Training using Neuro Vision Technology
45598217|NCT02210429|Procedure|Elbow Fracture Fixation|
45783119|NCT01837082|Drug|Placebo|
45783120|NCT01837160|Procedure|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
45783121|NCT01837160|Radiation|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
45783122|NCT01837160|Procedure|Echocardiogram|Echocardiography.
45783123|NCT01837160|Radiation|CT-coronary angiogram scan|CT-coronary angiogram following CT-PET scan. Standard protocol.
45783124|NCT01837160|Procedure|Aortic Valve Replacement|For AVR (already scheduled prior to enrollment)
45643251|NCT04626349|Other|iFOCUS (web-based intervention)|"Self-managed psycho-educational intervention that is completed autonomously by the patient-caregiver dyads together. It encompasses four sessions (with three weeks between each session) over a period of 12 weeks.~The sessions are completed simultaneously by the patient and the family caregiver, sitting side by side at a computer. Patient-caregiver dyads have flexibility as to when they want to complete the intervention session. Based on the information patients and caregivers provided at enrollment and during the web-based sessions, they receive tailored individual and dyadic messages. An online personal workbook is provided containing the results of the interactive exercises that are provided to the dyads during the web-sessions. Any information brochures, leaflets and information sheets that the dyad indicated as 'of interest to them' during the web-sessions will be included as a hyperlink in their personal workbook."
45783125|NCT01561703|Drug|Antibiotic|One of seven antibiotics (amoxicillin; amoxicillin/clavulanate potassium; azithromycin; cefaclor; cephalexin; cefdinir; or clindamycin) will be given at standard dosage that may be used for 7-10 days following surgery .
45783126|NCT01837238|Dietary Supplement|HMB|Following this initial round of testing,participant will be assigned to daily HMB supplementation for 6 months. You will be asked to consume a 1000mg HMB capsule 3 times per day, 7 days per week, for 6 months.
45783127|NCT01837238|Dietary Supplement|placebo|The placebo group will consume non-nutritive placebo pills daily for 6 months.
45783128|NCT01460303|Device|Bladder catheter: OPTION-vf patient controlled catheter vs. indwelling transurethral catheter with leg bag|"OPTION-vf patient controlled catheter (transurethral catheter with external drainage valve to provide on-demand drainage of urine stored directly from the bladder), worn maximum of 30 days post-op until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter)."
45783129|NCT01460303|Device|Transurethral catheter with leg bag|"Transurethral catheter w/leg bag urine storage, worn maximum of 30 days post-up until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter)."
45783130|NCT01837316|Drug|FF/VI 100/25 mcg|First strip: Fluticasone furoate inhalation powder blended with lactose, 100 mcg per blister
45783131|NCT01837316|Drug|Placebo|First strip: Inhalation powder of lactose
45783132|NCT01839422|Behavioral|Memory assessment|Cognitive assessment : Neuropsycological tests, learning sessions of new stimuli.
45783133|NCT01839422|Other|Brain imaging examination MRI|Brain imaging examination : Structural and functional MRI to compare differences between each sample.
45783134|NCT01460927|Device|TriActive+ RF|"Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts."
45783135|NCT01839500|Drug|Trastuzumab|Trastuzumab administered in accordance with routine care practice.
45783136|NCT05565755|Other|Motivational interview|Motivational interview Training
45783137|NCT05565677|Device|micro-computed tomography scanning of lung tissue specimens|Micro-computed tomography will be utilized to scan surgically resected lung tissue specimens.
45783138|NCT04379726|Behavioral|therapeutic optimization|patients with diagnosis of CFRD will undergo the gold standard treatment for the disease (insulin therapy)
45783139|NCT03210662|Radiation|External Beam Radiation Therapy|Undergo EBRT
45783140|NCT03210662|Biological|Pembrolizumab|Given IV
45783141|NCT01461473|Device|Positive Airway Pressure (PAP)|Participants randomized to the Positive Airway Pressure treatment group received adequate Positive Airway Pressure (PAP) pressure therapy by a PAP titration study and used the device for 6 months.
45783142|NCT01461473|Device|Oral Appliance (OA)|Participants randomized to the Oral Appliance treatment group received a dental evaluation to determine the optimal setting for the Oral Appliance (OA), and used the appliance for 6 months.
45783143|NCT00901316|Procedure|Routine Measures Group|"Cultures will be obtained from the anterior nares of the nose, the throat and the groin using separate culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. All patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding routine measures."
45783144|NCT00901316|Procedure|Bleach Bath Group (Bleach plus routine measures)|"Cultures will be obtained from the anterior nares of the nose, the throat and the groin using culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. Patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Patients will be given further oral and written instructions regarding clorox baths. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding instructions for bleach baths."
45783145|NCT02501928|Drug|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 28 or 40 weeks
45783146|NCT02501928|Drug|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 28 or 40 weeks
45783147|NCT02501928|Drug|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 28 weeks
45783148|NCT02501928|Drug|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 28 weeks
45783149|NCT01839734|Drug|Lubiprostone|Lubiprostone 24 mcg by mouth (PO) once-daily
45783150|NCT01461863|Dietary Supplement|Porridge protein calorie supplement|250 gm of fortified flour to make porridge containing 1062 kcal and 42 gm protein
45783151|NCT01461863|Dietary Supplement|multivitamin|Standard multivitamin
45783152|NCT00907088|Other|Healthy milk intake|In addition to the standard nutrition counselling, the intervention group will receive specific information regarding healthy milk intake (2 cups per day, maximum 16 ounces) and the potential negative health effects of prolonged bottle use and excessive milk intake including anemia, iron depletion, and dental carries.
45783153|NCT00907088|Other|Standard nutrition counselling|Parents of children will receive nutrition counselling via trained study personnel, including recommendations for iron containing food choices and timing of cow's milk introduction. This group will also receive a colourful nutrition book.
45643252|NCT04622228|Drug|Atezolizumab|Atezolizumab will be administered by intravenous infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.
45643253|NCT04622228|Drug|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m^2) after completion of atezolizumab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
45783154|NCT04379804|Procedure|Lateral approach|Following the ligation of upper pole vessels, the thyroid lobe was pulled anteromedially and the RLN was dissected within the carotid triangle at the level of inferior thyroid artery (ITA).
45783155|NCT04379804|Procedure|Cranio-caudal approach|Following the ligation of upper pole vessels, the upper pole was retracted antero-medially to expose crico-pharyngeal muscle. The RLN was identified at the point of entry both visually and with hand held stimulation probe
45783156|NCT01462253|Drug|Clofarabine, Cyclophosphamide|The proposed treatment schedule consists of a combination of Clofarabine plus Cyclophosphamide administered over 5 consecutive days (Treatment scheme).
45783157|NCT01837394|Procedure|Block of the SN and ONP|7.5 ml of Ropivacaine 7.5 mg/ml injected at each site
45783158|NCT01837394|Procedure|Placebo block|7.5 ml of isotonic saline solution 154 mmol/l injected at each site
45783159|NCT01837394|Drug|Paracetamol|
45783160|NCT01837394|Drug|Morphine|5 mg as needed
45783161|NCT01837394|Drug|Ondansetron|4 mg i.v. as needed in the PACU
45783162|NCT01837394|Drug|Metoclopramide|10 mg tablet as needed in the postoperative period after discharge from the PACU
45783163|NCT00902018|Drug|Eltrombopag|The 10 subjects will be treated with eltrombopag 75 mg once daily. Patients will be monitored 3 times, weekly, for the first 2 weeks, and then monitored as clinically indicated as they continue eltrombopag dosing for 3-4 months.
45783164|NCT00902018|Drug|Romiplostim|three of the patients treated with eltrombopag will be treated with weekly romiplostim at a dose of 10 micrograms/kg weekly for 2 weeks with testing at weekly intervals for 3 times
45783165|NCT00902018|Other|healthy controls|single blood draw for all measures included in the intervention arms
45598218|NCT02373111|Dietary Supplement|Isoflavone|
45598219|NCT02373111|Dietary Supplement|Astaxanthin|
45598220|NCT02373111|Dietary Supplement|Placebo|
45598221|NCT02225015|Behavioral|Follow-up Telephone Genetic Counselling|Individualized theoretical genetic counselling among women with BRCA mutations to assess the impact it has on the uptake of cancer prevention strategies.
45643254|NCT04622228|Drug|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
45643255|NCT04622228|Drug|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
45754321|NCT01911013|Device|Cage and Plate|anterior cervical discectomy and fusion is performed using cervical cage and plate
45783166|NCT04974762|Procedure|Wound infiltration|Surgical wound infiltration by proceduralist
45783167|NCT04974762|Procedure|Truncal blocks|Truncal blocks provided by anesthesiology team for device placement
45783168|NCT01462565|Drug|current marketed FLOLAN (epoprostenol sodium)|continuous intravenous infusion
45783169|NCT01462565|Drug|new thermo stable formulation of epoprostenol sodium|continuous intravenous infusion
45783170|NCT03210896|Dietary Supplement|Orange juice|Sub group I will drink Orange juice and have repeat measures.
45783171|NCT02473614|Device|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimum of 3 hours per week.
45783172|NCT02473614|Other|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimum of 3 hours per week.
45783173|NCT01837628|Drug|Lidocaine Gel|
45783174|NCT01837628|Drug|Paraffin Oil|
45783175|NCT05565443|Device|Blood Brain Barrier Disruption - Functional|Delivery of GCase across the BBB to form a disease modifying strategy for patients with Parkinson's Disease
45783176|NCT05565365|Procedure|Transversalis fascia plane (TFP) block|Patients will receive unilateral US-TFP block with 0.3 mL/kg bupivacaine 0.25% 15 minutes before skin incision
45783177|NCT05565365|Procedure|Erector Spinae Plane (ESP) Block|Patients will receive unilateral US-ESP block with 0.3 mL/kg bupivacaine 0.25% 15 minutes before skin incision
45783178|NCT00908882|Behavioral|Motivation Interviewing Counseling|Stage-based smoking cessation information written in the spirit of motivational interviewing in addition to weekly telephonic motivational interviewing counseling sessions
45783179|NCT01462877|Drug|fenofibrate|Fenofibrate Capsule 200mg qd orally
45783180|NCT04972656|Drug|Ambrisentan|"Titration:~Monotherapy using ambrisentan will be initialized at a beginning dose of 5 mg (once daily). Drug intake is scheduled at the morning. After 4 weeks monitoring, the dose of ambrisentan will be uptitrated to 10 mg once daily. Otherwise, if intolerability is indicated, a dose of 5 mg (once daily) will be maintained through the study duration.~Maximum dose allowed: not to exceed 10 mg/day.~Administration:~Ambrisentan will be administered orally with or without food intake."
45783181|NCT04972656|Drug|Placebo|"Placebo tablet (one to two tablets corresponding to one to two verum tablets).~Administration:~Placebo will be administrated orally with or without food intake in the morning."
45783182|NCT03210506|Drug|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
45783183|NCT03210272|Drug|Placebo|Tablet
45783184|NCT03210272|Drug|BI 1358894|Tablet
45643256|NCT04622228|Radiation|Thoracic radiation therapy (TRT)|Participants will receive concurrent thoracic radiation therapy (TRT) treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle.
45643257|NCT04619316|Drug|Trametinib 2 MG [Mekinist]|Monotherapy with Trametinib is given in patients with BRAF wildtype.
45783185|NCT03210272|Drug|BI 1358894 (Test)|Fasting state
45783186|NCT03210272|Drug|BI 1358894 (Reference)|Fed state
45783187|NCT02500758|Procedure|Preparatory handwash|Preparatory handwash follows the UNE-EN 12791 standard using a diluted soft soap, 200g/1000g, made in community pharmacy service and sterilize in autoclave. Washing hands were prepared without use of a brush for 1 minute with 10 ml of soft soap. After being rinsed with running tap water, they are thoroughly dried with paper towels.
45783188|NCT02500758|Procedure|Preoperative surgical scrubbing using 3% PCMX|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
45783189|NCT02500758|Procedure|Preoperative surgical scrubbing using 4% CHG|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
45783190|NCT05565209|Other|SA brief descriptive name used to refer to the intervention(s) studied|Details that can be made public about the intervention
45783191|NCT01839812|Drug|Cosyntropin|A cosyntropin stimulation test is administered to each patient at 3 time points during the study to evaluate adrenal response.
45783192|NCT01565369|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
45783193|NCT02500056|Device|Optilene LP mesh|Lichtenstein hernioplasty
45783194|NCT02500056|Device|Ultrapro mesh|Lichtenstein hernioplasty
45783195|NCT03210350|Diagnostic Test|Optic nerve sheath diameter|Optic nerve sheath diameter measurement using ultrasound
45783196|NCT01463267|Device|iPhone or pillbox|People will be reminded to take their medications by a device that alerts the patient to the need to take a medication.
45783197|NCT01463267|Behavioral|Non-reminding|As a comparison, the devices will collect medication taking information without providing reminders.
45783198|NCT04379648|Other|self-assessment and hetero-assessment|Self assessment for the passing of the following rating scales CTQ-SF36-ITQ-PCL5-DES Hetero-assessment for the pasing of the following rating scales DDIS FR and medical interview
45783199|NCT04939272|Drug|Copanlisib Hydrochloride|"Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 for each cycle.~Copanlisib will be given at 30mg, 45mg, or 60 mg depending on the assigned dose level."
46070821|NCT00817375|Drug|SSRI treated group|Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
45783200|NCT04939272|Drug|Venetoclax|Patients receive venetoclax PO QD on days 1-28 for each cycle. Venetoclax will have a weekly dose ramp up in cycle one from 20mg, 50mg, 100mg, 200mg, and then 400mg daily thereafter starting from cycle 2.
45783201|NCT01839890|Device|Bare metal Stent plus Paclitaxel Balloon|After the permeabilization of the clinical event responsible artery with conventional therapy (including the insertion of a conventional metal stent and once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
45783202|NCT01839890|Device|Bare metal Stent|After the permeabilization of the clinical event responsible artery with conventional therapy a conventional metal stent will be inserted. Once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
45783203|NCT04969770|Other|Ultrasound elastography (USE)|"Visualization of the vertebral disc and the para-vertebral muscles.~Intra and inter observer reproducibility analysis carried out for each of the measurements made, by two operators.~Patients with instrumented neuromuscular scoliosis: 5 elastographies : preoperatively, then during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Patients with neuromuscular pathologies without instrumented scoliosis: 4 elastographies during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Healthy control patients without neuromuscular pathology or scoliosis :~1 elastography during an usual consultation."
45783204|NCT02205983|Drug|2 mg hydromorphone|We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
45783205|NCT02205983|Drug|1000 mg Acetaminophen|We are administering sublingual buprenorphine to healthy volunteers to measure its effects on the performance of a verbal task.
45643258|NCT04619316|Drug|Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]|Combination therapy is given in patients with BRAF V600E mutation.
45643259|NCT04618484|Other|Biomodulation (non-pharmacological)|cryo-, photo- and electro-biomodulation
46070822|NCT00817375|Drug|non-SSRI treated group|Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
46070823|NCT00818545|Drug|ER4017 (hydroxypropyltetrahydropyrantriol)|Cream, 10%, each day during 3 months
45643260|NCT04618211|Drug|Deucrictibant|deucrictibant soft capsules for oral use
45643261|NCT04618211|Drug|Placebo|Matching placebo capsules for oral use
45643262|NCT04612244|Device|FARAPULSE Pulsed Field Ablation System|Ablation using the FARAPULSE Pulsed Field Ablation System
46070824|NCT00818545|Drug|placebo|
45783206|NCT02205983|Drug|4 mg hydromorphone|We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
45783207|NCT02205983|Drug|dextrose|We are administering dextrose to healthy volunteers for our placebo group.
45783208|NCT01839968|Other|Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma|
45783209|NCT04969692|Procedure|warming to increase local skin (puncture site) temperature|According to the group of participants, investigator applies the warmer to the hands and wrists of the participants, makes a local temperature of 40℃ gradually, and maintains it for about 10 minutes in warming group (which is divided in to warming-palpation (WP) and warming-US (WU) group).
45783210|NCT01838096|Device|THA using 4th generation CoC|
45783211|NCT05565053|Procedure|Bilateral thoracal erector spinae plane block|Bilateral upper thoracal erector spinae plane block with ultrasound
45783212|NCT05565053|Procedure|Trapezius muscle trigger point injection|Trapezius muscle trigger point injection
45783213|NCT04201548|Other|Endurance Training|"These patients will perform an aerobic exercise with a moderate intensity cycle ergometer. The exercise session on an exercise bike will last 33 minutes at a constant load, starting from an intensity equal to the load of 60% of the maximum load (max watt) achieved at the incremental test.~Working volume = 60 X 33 = 1980"
45783214|NCT04201548|Other|Long High Intensity Interval Training|"The patients assigned to the Long-HIIT group will perform a 32-minute interval work with 4x4 protocol (active phase x passive phase) performing 4 minutes at an intensity of 80-85% of the Max Watt (active phase) spaced from 4 minutes to 40% of the Max Watt (passive phase). The goal of high intensity work will be to bring the heart rate to a level close to 85-90% of the maximum cardiac frequency achieved in the incremental exercise test. If this target is not reached within the session, the load of the next one will be increased in the following session with 10 watt steps.~Working volume = 16 X 85 + 16 x 40 = 2000"
45783215|NCT04201548|Other|Short High Intensity Interval Training|"The patients assigned to the Short-HIIT group will perform an interval work with initial intensity equal to 100% of the Max Watt highlighted in the incremental exercise stress test in the phase (30 seconds) followed by a passive phase of 30 seconds at 50% of the Max Watt for a period of 26 minutes a day. The intensity will be gradually increased during the sessions with symptom-based progression, according to the protocol of Maltais et al. with steps of 10 watts each increment.~Working volume = 13 X 100 + 13 x 50 = 2050"
45783216|NCT01837784|Other|Optimization of blood pressure according to guidelines|There is no specific recommendation for the intervention. The goal of the intervention is an optimization of blood pressure control. The intervention is at the discretion of the physician, but should adhere to guidelines. The intervention may therefore embrace measures such as drug prescriptions or lifestyle interventions.
45783217|NCT02206217|Device|Multiple-Segment spectacle lens|A multifocal spectacle lens that corrects distance refraction and provides myopic defocus images simultaneously. The myopic defocus aims at slowing down myopia progression.
45783218|NCT03210038|Drug|Lidocaine|Pad soaked with lidocaine gel (Esracaine) left on the introitus for 5 minutes
45783219|NCT03210038|Drug|Water|Water based non-anesthetic lubricant gel left on the introitus for 5 minutes.
45783220|NCT02472756|Drug|Chemotherapy|The choice of the chemotherapy regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
45783221|NCT02472756|Drug|Rituximab|The choice of the rituximab regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
45783222|NCT01837940|Dietary Supplement|Placebo|Galactooligosaccharide (GOS) and rhamnose in a powder formulation
45783223|NCT01837940|Dietary Supplement|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM17938, Galactooligosaccharide (GOS), rhamnose in a powder formulation
45783224|NCT01464359|Drug|Allopurinol|On Day 8 pre-transplant, start hydration with allopurinol per standard of care.
45783225|NCT01464359|Drug|Fludarabine|On Days 7, 6 and 5 pre-transplant, 25 mg/m^2 intravenously over 1 hour.
45783226|NCT01464359|Radiation|Total body irradiation|On Days 5, 4, 3, and 2 pre-transplant, 165 cGy times 2 (330 cGy daily, 1320 total dose) according to the University Of Minnesota Blood and Marrow Transplant Program total body irradiation (TBI) guidelines.
45783227|NCT01464359|Drug|Cyclophosphamide|"On Days 7 and 6 pre-transplant, 60 mg/kg intravenously (IV) over 2 hours with a high volume fluid flush and mesna per institutional guidelines.~Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 5, 4, 3 and 2 pre-transplant; 50 mg/kg/day IV over 2 hours."
45783228|NCT01464359|Drug|Levetiracetam|Alternate Preparative Therapy for Patients Not Able to Receive Total Body Irradiation (TBI): Hydration therapy on Day 10 pre-transplant.
46070825|NCT00818701|Drug|low dose Nesiritide|Nesiritide infusion 0.005ug/kg/min
46070826|NCT00818701|Drug|nesiritide, Sildenafil|Nesiritide 0.005ug/kg/min Sildenafil 50 mg
46070827|NCT04574635|Procedure|Biospecimen Collection|Undergo collection of blood samples
46070828|NCT00813085|Other|Electronic disease management decision support|A Diabetes Tracker embedded in a Core Data Set (DT/CDS) supported by an automated telephone reminder system (ATRS)
45643263|NCT04612244|Device|RadioFrequency and Cryoballoon Ablation|Contact Force Enabled RF and Cryoballoon ablation catheters indicated for Paroxysmal Atrial Fibrillation
45643264|NCT04610528|Drug|U3 1402|6.4 mg/kg dose
45643265|NCT04610528|Drug|U3 1402|5.6 mg/kg dose
45643266|NCT04609111|Drug|No aspirin|1-month prasugrel monotherapy followed by clopidogrel monotherapy
45643267|NCT04609111|Drug|1-month DAPT|1-month dual antiplatelet therapy comprising of aspirin and prasugrel followed by aspirin monotherapy
45643268|NCT04607421|Drug|Encorafenib|75 mg capsules
45643269|NCT04607421|Drug|Cetuximab|Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial
45643270|NCT04607421|Drug|Oxaliplatin|Powder for solution for intravenous use 50 mg/vial, 100 mg/vial, or 200 mg/vial
45643271|NCT04607421|Drug|Irinotecan|Solution for intravenous infusion 40 mg/vial, 100 mg/vial, or 300 mg/vial
45643272|NCT04607421|Drug|Leucovorin|Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
45643273|NCT04607421|Drug|5-FU|Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial
45643274|NCT04607421|Drug|Capecitabine|150 mg or 500 mg Tablet
45783229|NCT01464359|Drug|Busulfan|Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 9, 8, 7 and 6 pre-transplant; 0.8 mg/kg (1.1 mg/kg if <12 kg) intravenously every 6 hours
45783230|NCT01464359|Biological|Umbilical Cord Blood Transplantation|Day 0: Two UCB units will compose the graft. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. The UCB unit without IL-2 activation will be infused first, followed by the IL-2 activated unit. Both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending.
45783231|NCT01464359|Biological|Interleukin-2|"First Course of IL-2 (begin day +3) post-transplant: For patients ≥ 45 kg, IL-2 will be given at 9 million units every other day for a total of 6 doses subcutaneously. Patients weighing less than 45 kilograms, the IL-2 will be dosed at 5 million units/m^2 every other day for a total of 6 doses.~Second Course of IL-2 (day +60):~Patients will receive a second course of IL-2 beginning on Day +60 post transplant to expand and educate the NK cells derived from the UCB graft source."
45783232|NCT04969224|Drug|ELX/TEZ/IVA|FDC tablet for oral administration.
45783233|NCT04969224|Drug|IVA|Tablet for oral administration.
45643275|NCT04607421|Drug|Bevacizumab|Optional Injection for intravenous use 100 mg/vial or 400 mg/vial
45643276|NCT04605458|Combination Product|Contingency Management|Participants will receive 3-6 counseling sessions, nicotine patches & lozenges, and monetary payment delivered contingent on abstinence verified by CO breath test.
45643277|NCT04605458|Combination Product|Standard Care|Participants will receive 3-6 counseling sessions, nicotine patches & lozenges, and CO breath test monitoring.
45643278|NCT04604210|Procedure|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive FDA-approved technique that is commonly used as a treatment for depression. It has been shown to focally activate specific brain regions that are believed to be underactive in patients suffering from depression. In this study, TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications.
45643279|NCT04599062|Drug|Talimogene Laherparepvec|Talimogene Laherparepvec
45643280|NCT04599062|Radiation|Radiotherapy|Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
45643281|NCT04597359|Drug|Placebo Administration|Given PO
45643282|NCT04597359|Other|Quality-of-Life Assessment|Ancillary studies
45643283|NCT04597359|Other|Questionnaire Administration|Ancillary studies
45643284|NCT04597359|Drug|Sinecatechins|Given PO
45643285|NCT04597125|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants will receive Radium-223 (BAY88-8223) every 4 weeks for a total of 6 administrations via intravenous (IV) injection
45643286|NCT04597125|Drug|NAH therapy|Participants will receive continuous NAH (either Abiraterone acetate plus prednisone/prednisolone [AAP] or enzalutamide) by mouth (per os) daily
45917534|NCT04084795|Other|Multifocal transcranial Current Stimulation|MtCS represents a promising intervention option, given its capacity to modulate cerebral excitability in a simple, safe manner. F3 anodal; AF3, FC1, FC3, FC5, F5, return montage will be used with the anode over the left DLPFC. Half of the patients will receive active stimulation and the other half sham stimulation. Active stimulation will consist of 1mA MtDCS for 20 minutes applied immediately before EMDR sessions. The same protocol and montage will be used for sham stimulation.
45917535|NCT00000741|Drug|Methylprednisolone|
45643287|NCT04596631|Drug|Oral semaglutide|Oral semaglutide treatment for 52 weeks. All participants will be dose-escalated to an individual maximum tolerated dose.
45643288|NCT04596631|Drug|Placebo (semaglutide)|Placebo treatment for 52 weeks.
45643289|NCT04590196|Drug|Longvida curcumin|longvida curcumin verdure sciences formulation
45643290|NCT04590196|Other|placebo|"Composition of Placebo :~95.66% Maltodextrin 0.34% Sunset Yellow Color 0.06% Tartrazine Food Color 3.91% Silicon Dioxide"
45643291|NCT04589208|Drug|Ketamine Hydrochloride|We will assign ketamine doses in successive 10 subject cohorts. The ketamine dose for the 1st cohort will start at 0.08 mg/kg. For subsequent cohorts, the bolus will be successively reduced or increased by 0.02 mg/kg (n=10/dose) to determine the lowest dose of ketamine that still produces a robust phBOLD response
45643292|NCT04588246|Drug|Memantine|Given PO
45643293|NCT04588246|Other|Quality-of-Life Assessment|Ancillary studies
45643294|NCT04588246|Other|Questionnaire Administration|Ancillary studies
45643295|NCT04588246|Radiation|Stereotactic Radiosurgery|Undergo salvage SRS
45643296|NCT04588246|Radiation|Whole-Brain Radiotherapy|Undergo HA-WBRT
45643297|NCT04587427|Drug|Radium 223 dichloride (Xofigo, BAY88-8223)|Prescribed by physicians.
45643298|NCT04585815|Drug|Sasanlimab Prefilled syringe|prefilled syringe
45783234|NCT03210740|Drug|AM001 Cream, 7.5%|Active Cream
45783235|NCT03210740|Drug|Vehicle Cream|Placeo
45783236|NCT05564897|Drug|H101, Camrelizumab|Patients receive a combination therapy of Camrelizumab 200 mg i.v. every 3 weeks with intravesical H101 with a dose of 5×10*11 Vp weekly for 6 weeks for both induction and maintenance treatments up to 1 years.
45917536|NCT04069897|Drug|Botulinum toxin type A|Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.
45917537|NCT04069897|Drug|placebo|0.5 ml Sodium Chloride (NaCl) 0.9% Braun. Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.
45643299|NCT04585815|Drug|Encorafenib|capsules
45643300|NCT04585815|Drug|Binimetinib|tablets
45643301|NCT04585815|Drug|Sasanlimab|solution supplied in vials
45643302|NCT04585815|Drug|Axitinib|tablets
45643303|NCT04585815|Drug|SEA-TGT|solution in vials
45643304|NCT04582864|Drug|Flotetuzumab|Will be provided by MacroGenics Inc.
45643305|NCT04582864|Procedure|Donor lymphocyte infusion|DLI represents a non-specific form of adoptive cell therapy which involves infusion of a pool of allogeneic immune cells, including CD4+ T cells, CD8+ T cells, regulatory T cells (T Regs), natural killer (NK) cells and professional antigen presenting cells.
45643306|NCT04582227|Device|Ambu aura-i LMA|The ETT or the LMA will be inserted with the patient's head position is aided either by pins or head rest, and either the head will be in neutral position or tilted as long as the airway device is successfully placed.
45783237|NCT01838252|Procedure|Hyaluronic acid|Hyaluronic acid filler will be injected in to the lower lid, elevating it to a more anatomic position
45783238|NCT01838252|Procedure|Saline|Saline will be injected in to the lower lid, elevating it to a more anatomic position
45783239|NCT01838330|Dietary Supplement|psyllium|15 grams/day for 1 week, followed by 30 grams/day for 4 months
45643307|NCT04580914|Device|Treatment with IntellaNav StablePoint Ablation Catheter|Patients will be treated with an ablation catheter
45643308|NCT04580524|Procedure|Repair of ventral hernia using biologic mesh|Ventral hernia will be repaired using biologic mesh
45783240|NCT02498652|Drug|RDEA3170 2.5 mg|"Cohort 1: RDEA3170 2.5 mg, 7.5 mg (2.5 mg × 3 tablets), and 15 mg (2.5 mg × 6 tablets).~Cohort 2: RDEA3170 5 mg (2.5 mg × 2 tablets), 10 mg (2.5 mg × 4 tablets), and 20 mg (2.5 mg × 8 tablets)."
45783241|NCT02498652|Drug|allopurinol 300 mg|allopurinol 300 mg, allopurinol 600 mg (300 mg x 2 tablets)
45783242|NCT01838408|Other|Ez2go Complete|EZ2Go Complete
45783243|NCT01838408|Other|LoSo Prep|LoSo Prep ™ Magnesium Citrate plus Bisacodyl Kit Study Arm
45783244|NCT01835990|Device|geko|The geko is a neuromuscular stimulation device that stimulates the common peroneal nerve resulting in contraction of the leg muscles and increased venous and arterial flow. It is Health Canada approved for prevention of deep venous thrombosis.
45783245|NCT01835990|Device|IPCs|devices that pneumatically compress the leg, resulting in increased venous blood flow.
45783246|NCT01838486|Procedure|Bladder Thermal Distention|Bladder Thermal Distention (BTD) is an approved procedure in Europe and Israel. Continuous irrigation of the bladder with warm saline with the PelvixTT system. The procedure will be performed on an outpatients basis. The procedure lasts 1 hour.
45783247|NCT03213158|Drug|Ixazomib Oral Capsule|Highly sensitized kidney transplant candidates on the waitlist for more than 24 months will receive ixazomib 3 mg (and dexamethasone 20 mg) on days 1, 8, and 15 of a 28 cycle. Patients will take ixazomib and dexamethasone for twelve (12) 28-day cycles.
45783248|NCT02498418|Drug|Rifaximin|Tablets, generic formulation of the brand product.
45643309|NCT04580524|Procedure|Repair of ventral hernia using suture repair or synthetic mesh|Ventral hernia will be repaired using the current treatment methods
45783249|NCT02498418|Drug|Xifaxan®|Tablets, brand product.
45917538|NCT00000744|Drug|Fluconazole|
45783250|NCT02498418|Drug|Placebo Tablet|Placebo tablets in the same image of the generic rifaximin. Has no active ingredient.
45783251|NCT03219476|Drug|Anastrozole|1 mg once daily.
45783252|NCT03219476|Drug|Letrozole|2.5mg once daily.
45783253|NCT03219476|Drug|Exemestane|25 mg once daily.
45783254|NCT03219476|Drug|Tamoxifen|20 mg once daily.
45917539|NCT04039204|Drug|Elagolix|This orally active, reversible GnRH antagonist will be used to suppress endometriosis by lowering estrogen levels for 2 months prior to FET
45917540|NCT04039204|Drug|Oral Contraceptive|Oral contraceptive prescribed by physician.
45917541|NCT04038346|Drug|Naproxen|Patients will be randomized to an NSAID (naproxen)
45917542|NCT04038346|Drug|Acetaminophen|Patients will be randomized to acetaminophen
45917543|NCT04020172|Drug|Dobutamine|intraoperative fluid administration will be guided by cardiac output monitoring
46070829|NCT00813241|Drug|celecoxib reference formulation|200 mg single oral dose of celecoxib tablets
45917544|NCT04016896|Behavioral|WIdowed Elders' LIfestyle after Loss (WELL)|Digital monitoring; motivational health coaching; personalized feedback
45917545|NCT04016896|Other|Enhanced Usual Care|psychoeducation plus study assessments controlling for time and attention
45917546|NCT00000747|Drug|Nevirapine|
45643316|NCT04573192|Drug|L19TNF|Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
45643317|NCT04573192|Drug|Lomustine|Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
45783255|NCT02472366|Drug|ILUVIEN|
45783256|NCT01724606|Radiation|Whole Brain Radiotherapy (WBRT)|WBRT (30 Gy) will be delivered in 10 fractions. Standard opposed lateral fields with multileaf collimation blocking will be used. Treatment will be administered on business days and delivered over an approximate 2 week period. Dexamethasone may be given at the discretion of the treating physician but the dose cannot exceed greater than 16mg daily as it is a strong CYP3A4 inducer. Patients will also receive a proton pump inhibitor with dexamethasone.
45783257|NCT01724606|Drug|Sorafenib|The proposed three dose levels of sorafenib during dose escalation are 200 mg, 400mg, and 600 mg administered daily orally. Patients will be enrolled in cohorts of 3.The first three subjects will take sorafenib 200 mg daily within a few hours after the first RT fraction. Sorafenib will be continued concurrently with WBRT (1 fraction /day x 10 fractions) without breaks and then continued after WBRTfor a total of 21 days. If no dose limiting toxicity (DLT) is observed in a cohort of 3 patients until two weeks after completion of WBRT, the next dose level will be evaluated.
45783258|NCT04201704|Other|Balanced crystalloid solution volume administration|Maintenance and bolus fluid volumes of balanced isotonic crystalloid solution administered based on arm.
45783259|NCT04201704|Other|Packed Erythrocytes Units, Blood Product Unit volume|For patients designated as Bleeding, where hemoglobin <7 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
45783260|NCT04201704|Other|Plasma volume|For patients designated as Bleeding, where International Normalized Ratio (INR) > 1.5 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
46070830|NCT00813241|Drug|celecoxib test formulation A1|150 mg single oral dose of celecoxib A1 formulation tablets
46070831|NCT00813241|Drug|celecoxib test formulation B2|150 mg single oral dose of celecoxib B2 formulation tablets
46070832|NCT00813241|Drug|celecoxib test formulation C1|150 mg single oral dose of celecoxib Cl formulation tablets
46070833|NCT00818857|Behavioral|Early Intervention|At the point of randomization the early group will receive increasingly intensive reminders to complete specific cancer screening tests.
46070834|NCT00818857|Behavioral|Delayed intervention|One year from the point of randomization patients will begin to receive increasingly intensive reminders to complete specific cancer screening tests.
46070835|NCT00813397|Device|Sepraspray|Max. 10g of Sepraspray
45643318|NCT04570709|Other|Palliative And supportive Care inTervention (PACT)|Using the Adaptive Leadership Framework for Chronic Illness as a guide. The nurse, occupational and physical therapists will meet with the patient and caregiver after the baseline assessment to discuss their Specific, Measurable, Achievable, Relevant, and Time-Bound (SMART) goals. Additionally, the occupational and physical therapists will provide the patient a PACT intervention binder. Regular phone calls or visits from a registered nurse, occupational therapists, and physical therapists for patients and caregivers in the intervention.
45643319|NCT04566393|Drug|Ulixertinib (BVD-523)|Ulixertinib (BVD-523) is an oral, first-in-class ERK1/2 inhibitor
45643320|NCT04566328|Drug|Bortezomib|Given SC
45643321|NCT04566328|Biological|Daratumumab and Hyaluronidase-fihj|Given SC
45643322|NCT04566328|Drug|Dexamethasone|Given PO
45783261|NCT04201704|Other|Platelets volume|For patients designated as Bleeding, where platelets < 50,000 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
45783262|NCT01720004|Other|Repeated hands-and-knees positioning during labour|Details are in the Arm Description.
45783263|NCT03836534|Behavioral|adherence to treatment of patients coming out of emergencies|Phone contact of patients within 48 hours of the consultation
45783264|NCT04968990|Device|Proton Beam Radiation (PBRT)|The treatment approach with radiation therapy prescribed in this trial is designed to deliver highly conformal radiation therapy (proton beam radiation or intensity modulated photon radiation) to target volumes that are based on the burden of disease.
45643323|NCT04566328|Drug|Lenalidomide|Given PO
45783265|NCT04968990|Drug|DD-4A Chemotherapy Regimen|Patients will receive standard of care chemotherapy based on diagnosis and stage.
45783266|NCT04968990|Procedure|Complete Surgical Resection|Participants will undergo complete surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy
45783267|NCT04968990|Procedure|Surgical Resection|Participants will undergo surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy.
45783268|NCT04968990|Procedure|Partial Nephrectomy|Participants will undergo partial nephrectomy after 6-12 weeks of induction chemotherapy.
45783269|NCT04967742|Biological|UB-612|UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
45643324|NCT04566328|Other|Quality-of-Life Assessment|Ancillary studies
45643325|NCT04565795|Device|Uriprene® Degradable Temporary Ureteral Stent|Assess adequate intervention-free drainage during use and the time to complete degradation or the passage of stent fragments/segments from the urinary system by radiological assessment.
45643326|NCT04565236|Biological|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1|"25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day according to individual requirements for 6 months.~The dose decisions are at the discretion of the investigator."
45783270|NCT03753750|Device|Noninvasive spinal cord stimulation|Noninvasive spinal cord stimulation is a transcutaneous technique used to modulate the activity of the spinal cord. Subjects will undergo sham or actual stimulation 3-4 times a week for one hour at a time.
45783271|NCT01720082|Procedure|Single incision laparoscopic appendectomy|A multiport device will be introducted through a 2-2.5 transumbilical incision. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
45783272|NCT01720082|Procedure|Multiport laparoscopic appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
45643327|NCT04565236|Biological|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2|"12 year-old: 25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day for 6 months.~>12 year-old: 20 to 40 IU of Kovaltry per kg of body weight given via intravenous (IV) infusion two or three times per week for 6 months.~The dose decisions are at the discretion of the investigator."
45643328|NCT04565236|Biological|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3|"15 to 50 IU of Kovaltry per kg body weight (minimum dose: 250 IU) given via intravenous (IV) infusions at least once a week.~The dose decisions are at the discretion of the investigator."
45643329|NCT04563520|Drug|aPCC-emicizumab|Personalized dose of aPCC-emicizumab will be administered to participants. The max dose allowed for aPCC will be 25 U/kg/dose every 8 hours, for no more than 72 hours without further discussion with the PI.
45643330|NCT04563520|Drug|FEIBA|"FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia patients with inhibitors for: control and prevention of bleeding episodes, perioperative management, routine prophylaxis to prevent or reduce the frequency of bleeding episodes. If there is less than a good' response in bleed event at 48 hours or less than moderate for surgical event control, the local PI can consider the use of thrombin generation guided rFVIIa with a max dose of no more than 90 µg/kg/dose every 8 hours for 72 hours, with wean to occur for no more than 7 total days."
45643331|NCT04563520|Drug|rFVIIa|rFVIIa is a coagulation factor VIIa concentrate indicated for the treatment and control of bleeding episodes occurring in adults and adolescents with hemophilia with inhibitors.
45783273|NCT01838720|Procedure|zero ischemia laparoscopic RFA assisted TE|
45783274|NCT01838720|Procedure|ischemia|conventional laparoscopic partial nephrectomy
45783275|NCT01838798|Other|Baseline activities|Initial consent procedures and baseline data collection.
45783276|NCT01838798|Other|Clinical interview with a psychologist|"Clinical interview with a psychologist.~This interview with a psychologist will take place after patient consent procedures, and at least 2 days after discontinuation of sedation, and before leaving the ICU. This interview will include:~An inventory of peritraumatic distress symptoms~A questionnaire on peritraumatic dissociative experiences~An assessment of related, potential impacts~The HADS questionnaire"
45783277|NCT01838798|Other|Telephone interview 2 months after ICU discharge|"At 2 months after leaving the ICU, a psychologist will contact the patient with questions regarding his/her representation of hospitalization. This implies the following:~Questionnaires assessing memories and stressors (Questionnaires ICUMT, and ICU-SEQ~An assessment of psychological trauma~An assessment of potential impacts"
45643332|NCT04563013|Device|Transcutaneous vagus nerve stimulation|the transcutaneous vagus nerve stimulation was conducted by ear clip with cathode and anode placed at the tragus for 30 min.
45643333|NCT04559724|Device|Indego Therapy|Indego Therapy consists of 15 + 2 sessions of Indego - Therapy, each lasting 30 minutes for a maximum of 6 weeks. All the device parameters such as step height (knee and hip), step length, step cycle speed, single and bilateral assistance are customizable. The use of aids during Idego-Therapy is allowed if needed. The Indego specialist should initially be positioned behind the patient, checking the exoskeleton and patient's gait pattern. The supervision of an assistant placed on the patient's healthy side is recommended in the first sessions in order to ensure greater safety to the patient. Constant supervision should be provided by Indego specialist during the whole treatment.
45643334|NCT04559139|Drug|Cisplatin|Given IV
45643335|NCT04559139|Drug|Gemcitabine Hydrochloride|Given IV
45783278|NCT01838798|Other|Clinical interview with a psychologist|"At 4 months after ICU discharge, the patient has a clinical interview during which a psychologist will:~assess cognitive functions~evaluate clinical symptoms of depression~assess quality of life~assess symptoms of post traumatic stress"
45783279|NCT03219164|Drug|AZLI|Administered via the PARI Altera® Nebulizer System. Participants < 2 years will receive via the SmartMask® Baby, 2 to < 6 years via the SmartMask Kids® and > 6 years via the nebulizer mouthpiece.
45783280|NCT03219164|Drug|Placebo|Administered via the PARI Altera® Nebulizer System. Participants < 2 years will receive via the SmartMask® Baby, 2 to < 6 years via the SmartMask Kids® and > 6 years via the nebulizer mouthpiece.
45783281|NCT01838954|Device|Short-wave diathermy|Device operating at a frequency of 27.12 MHz in continuous mode with an effective nominal output of 400 W in the patient circuit.
45783282|NCT01566461|Device|Drug-Coated Balloon (DCB)|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
45783283|NCT01566461|Device|PTA Balloon: Balloon Angioplasty|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
45783284|NCT01830062|Other|NIRS|Near infrared spectroscopy of at least 2 major epicardial vessels
45783285|NCT01830062|Other|CACS|Coronary artery calcium score assessed by multi-slice computed tomography
45917547|NCT04011202|Behavioral|Virtual reality gaming program (VR-gaming program)|Participants in the VR-gaming program will receive three 20-30 minutes sessions of VR-gaming per week for the duration of their inpatient stay. Participants will select VR games/program in categories of: Relaxation; Leisure sport and activities; or Action/adventure. The VR-gaming program will be implemented one-on-one, face-to-face by a clinician using the commercially-available Oculus Go system.
45783286|NCT01725698|Drug|Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant|
45783287|NCT01720238|Drug|Entecavir|0.5mg qd
45783288|NCT01720238|Drug|Lamivudine plus Adefovir Dipivoxil|Lamivudine:100mg qd Adefovir Dipivoxil:10mg qd
45783289|NCT02981225|Dietary Supplement|Phytostandard® Rhodiola-Saffron|
45917548|NCT00000753|Drug|Atevirdine mesylate|
45917549|NCT00000753|Drug|Zidovudine|
45643336|NCT04559139|Procedure|Lymphadenectomy|Undergo portal lymphadenectomy
45643337|NCT04559139|Procedure|Partial Hepatectomy|Undergo partial hepatectomy
45643338|NCT04557449|Drug|PF-07220060|CDK4 inhibitor
45643339|NCT04557449|Combination Product|Letrozole|Endocrine Therapy
45643340|NCT04557449|Combination Product|Fulvestrant|Endocrine Therapy
45643341|NCT04557449|Drug|Midazolam|Benzodiazepine used for DDI
45643342|NCT04557449|Combination Product|Enzalutamide|Androgen Receptor inhibitor
45783290|NCT03836222|Drug|PCS499|MR tablet
45783291|NCT03836222|Drug|Trental|comparator tablet
45783292|NCT02471586|Procedure|Coronary PCI guided by IVUS|Imaging type
45783293|NCT02471586|Procedure|Coronary PCI guided by OCT|Imaging type
45783294|NCT02471586|Procedure|Coronary PCI guided by Angiography|Imaging type
45783295|NCT03835988|Device|Geniculate Artery Embolization|Embolization is a procedure completed by an Interventional Radiologist in which abnormal blood vessels are blocked for treatment purposes. In the case of geniculate artery embolization, abnormal blood vessels which supply your knee joint are blocked in an effort to reduce inflammation and subsequently and reduce pain and improve joint function.
45783296|NCT01830218|Procedure|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
45783297|NCT00910208|Device|Patient-controlled analgesia|Intravenous morphine delivered via Curlin painsmart PCA device
45783298|NCT00910208|Drug|morphine|Intravenous morphine
45783299|NCT01566539|Drug|Intranasal Oxytocin (OT) 24 IU|Participants will self-administer a single dose of 24 international units (IU) oxytocin. Five puffs per nostril, each with 2.4 IU oxytocin. Ten puffs total.
45783300|NCT01566539|Drug|Intranasal Vasopressin (AVP)|Participants will self-administer a 1 ml solution containing 20 units of AVP. Five puffs per nostril, each with 2 International Units (IU) AVP. Ten puffs total).
45917550|NCT00000753|Drug|Zalcitabine|
45917551|NCT00000753|Drug|Didanosine|
45917552|NCT03991741|Biological|Autologous Tumor Infiltrating Lymphocytes|Autologous TILs
45917553|NCT03991741|Biological|High-Dose Interleukin 2|720,000 IU/kg every 8 hours for up to 15 doses
45917554|NCT03978793|Device|MyTPill, a digital pill|MyTPill is a digital pill containing an approved medication
45917555|NCT00000762|Biological|rgp120/HIV-1MN|
45917556|NCT00000762|Biological|rgp120/HIV-1 SF-2|
45783301|NCT01566539|Drug|Intranasal Placebo|Participants will receive placebo sprays that are pH adjusted to comparable levels of the drugs given. Five puffs per nostril; ten puffs total.
45783302|NCT01566539|Drug|Intranasal Vasopressin (AVP) 40 IU|Participants will self-administer a 0.5 ml solution containing 40 international units (IU) of AVP. 5 puffs in total, each with 4 International Units (IU) AVP.
45783303|NCT01566539|Drug|Lorazepam|Subjects will take 1.0 mg of lorazepam orally 60 minutes prior to fMRI scan.
45643343|NCT04556773|Drug|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
45783304|NCT04967664|Drug|Qutenza (capsaicin) 8% topical system|High concentration capsaicin
45783305|NCT04967664|Drug|capsaicin 0.04% topical system|Low-dose capsaicin control
45643344|NCT04556773|Drug|Durvalumab|Durvalumab: administered as an IV infusion
45643345|NCT04556773|Drug|Paclitaxel|Paclitaxel: administered as an IV infusion
45783306|NCT01725776|Drug|Inhaled milrinone 5 mg|Inhaled milrinone 5 mg (as for the injectable solution)
45643346|NCT04556773|Drug|Capivasertib|Capivasertib: administered orally
45643347|NCT04556773|Drug|Anastrozole|Anastrozole: administered orally
45643348|NCT04556773|Drug|Fulvestrant|Fulvestrant: administered as an IM injection
45643349|NCT04556773|Drug|Capecitabine|Capecitabine: administered orally
45917557|NCT00000762|Biological|gp160 Vaccine (MicroGeneSys)|
45917558|NCT03967522|Drug|Cabozantinib|All participants will be treated by 60 mg of cabozantinib once daily. Temporary or permanent discontinuation and/or dose reduction of cabozantinib therapy may be required for the management of some adverse reactions. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
45917559|NCT03962374|Device|Frova|Frova will be used to facilitate the endotracheal intubation. The success rate of first attempt of intubation will be assessed.
45917560|NCT03962374|Device|Stylet|Stylet will be used to facilitate the endotracheal intubation. The success rate of first attempt of intubation will be assessed.
45643350|NCT04556045|Behavioral|Exercise therapy|The exercise therapy intervention will last 4 weeks. Each participant assigned to this intervention will receive a personalized ET regimen, including in-person, supervised exercise sessions; other activities to be followed at home. Participants will exercise between one and seven times per week depending on their tolerance to the treatment and exercise program.
45643351|NCT04551222|Drug|probenecid|1 gr. orally of probenecid twice daily for 180 days
45643352|NCT04551222|Drug|Placebo|identical tablets to probenecid
45643353|NCT04548752|Procedure|Biopsy|Undergo tumor biopsy
45643354|NCT04548752|Procedure|Biospecimen Collection|Undergo blood sample collection
45643355|NCT04548752|Procedure|Computed Tomography|Undergo CT scan
45917561|NCT00000768|Drug|Glutamic acid hydrochloride|
45917562|NCT00000768|Drug|Ganciclovir|
45917563|NCT00000789|Drug|Stavudine|
45917564|NCT00000789|Drug|Zidovudine|
45643356|NCT04548752|Procedure|Magnetic Resonance Elastography|Undergo MRI
45643357|NCT04548752|Drug|Olaparib|Given PO
45643358|NCT04548752|Biological|Pembrolizumab|Given IV
45643359|NCT04543617|Drug|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
45643360|NCT04543617|Drug|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
45643361|NCT04543617|Drug|Tiragolumab Matching Placebo|Tiragolumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
45643362|NCT04543617|Drug|Atezolizumab Matching Placebo|Atezolizumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
45643363|NCT04542148|Drug|Sliding Scale Insulin|After antenatal corticosteroid administration, women will continue to receive long- and short-acting subcutaneous insulin injections as prescribed at home. In addition, they will receive supplemental short-acting insulin using a sliding scale based on postprandial glucose values. Capillary blood glucose values will be measured with fingersticks 4 times daily (fasting and 1-hour postprandial).
45643364|NCT04542148|Drug|Up-Titration of Home Insulin|After antenatal corticosteroid administration, women will receive long- and short-acting subcutaneous insulin injections at increased dosages compared to that prescribed at home. Insulin will be increased by 30% on the day that they receive their 1st dose of antenatal corticosteroids (day 1), 50% on day 2, 50% on day 3, 30% on day 4, and 15% increase on day 5. On day 6 they will return to their home insulin regimen. Capillary blood glucose values will be measured with fingersticks 4 times daily (fasting and 1-hour postprandial).
45643365|NCT04542148|Drug|Continuous Insulin Infusion|After antenatal corticosteroid administration, women will discontinue their home insulin regimen and be placed on a continuous insulin infusion with insulin boluses and titration of infusion rate per institutional L&D protocol. Capillary blood glucose values will be measured with fingersticks every hour.
45643366|NCT04542148|Device|Dexcom G6 Professional Continuous Glucose Monitor|Masked Dexcom G6 Pro devices will be worn for 10 days.
45783307|NCT01830296|Drug|Remifentanil+morphine|Morphine, Remifentanil+Morphine
45783308|NCT05564819|Drug|Acetaminophen|When the infants woke up after surgery and were transported back to the ward, they were randomly divided into two groups immediately. The intervention group was given oral acetaminophen, once every 6 hours, for a total of 4 times.
45917565|NCT00000792|Drug|Hypericin|
45917566|NCT00000795|Biological|HIV-1 Peptide Immunogen, Multivalent|
45783309|NCT05564819|Drug|Sterilized water|When the infants woke up after surgery and were transported back to the ward, they were randomly divided into two groups immediately. The control group was given sterilized water, once every 6 hours, for a total of 4 times.
45783310|NCT01725854|Behavioral|Relaxation Response training|Behavioral Relaxation Response Training (Benson-Henry Institute Relaxation Response Training) Participants randomized to the intervention group will participate in the six weekly RR sessions. Examples of in-group skill building exercises are mini relaxations, diaphragmatic breathing, introduction to imagery, and eliciting RR through Yoga. Presentations topics include Introduction to Mind/Body Medicine, Introduction to the RR, Experiential RR Sessions, and Introduction to Cognitive Restructuring. Home skill building assignments include relaxation focus practice, an appreciation journal, self-monitoring with Biodots (biosensor technology that helps participants to monitor and regulate their psycho-emotional state), physical activity, balanced nutrition, and progress notes.
45783311|NCT04967274|Procedure|Startling acoustic stimulus|StartReact: involuntary triggering of a planed movement by a loud acoustic stimulus.
45783312|NCT03409952|Device|LaseMD and DUAL 1927nm Laser|Laser treatment of benign pigmented lesion based on photothermolysis whereby the target molecule, the chromophore, absorbs a delivered wavelength of light over a period of time to damage the target while limiting collateral damage to adjacent structures, leading to pigmentary clearance.
45783313|NCT03409952|Device|LaseMD|Laser treatment of benign pigmented lesion using optimized treatment settings.
45783314|NCT01567943|Behavioral|Contingency Management|Behavioral reinforcement for alcohol abstinence
45783315|NCT04378322|Behavioral|Nutrition and food purchasing tool + telenutrition|Participants will be asked to use a meal planning and food purchasing feature regularly (at least once every two weeks) and schedule appointments with a registered dietitian.
45783316|NCT04378322|Behavioral|Nutrition and food purchasing tool|Participants will be asked to use a meal planning and food purchasing feature regularly (at least once every two weeks).
45783317|NCT04378322|Behavioral|Nutrition education tool|Participants will be asked to review nutrition education materials online.
45783318|NCT01467557|Device|narafilcon B daily disposable soft contact lenses|daily disposable soft contact lenses
45783319|NCT01467557|Device|etafilcon A daily disposable soft contact lenses|daily disposable soft contact lenses
45783320|NCT01725932|Behavioral|Culturally adapted CBT based Self Help|Intervention was based on our initial work using mixed methods, using mixed methods,in Pakistan. It focused on psycho-education, symptoms management, changing negative thinking, behavioral activation, problem solving, improving relationships and communication skills. One person from the family was involved in all cases. The intervention consists of 7 chapters. Manual can be used by the patient's or carers with at least 5 years of education. A member of the research team called them once every week to remind them of the next chapter and also to discuss any issues o problems that emerged during the previous week. This manual can be downloaded from PACT website (http://www.pactorganization.com/)
45783321|NCT01720394|Device|Cervical Ripening Balloon, Cook Medical Inc.|Application of the cervical ripening double-balloon (filled with 2x 80ml) on day 1.
46070836|NCT00627523|Drug|Genotropin (PN-180,307) Somatropin|Injectable Genotropin
45643367|NCT04541056|Behavioral|Goal Management Training (GMT)|The manual comprises an introduction to GMT for the survivors of ALL, and a detailed session structure incorporating cognitive and behavioral tasks. The GMT program involves teaching the participants about goals, attention slips and how to manage these, how to review and prioritize goals (e.g., Stop, Think, Organize, Plan), and how to keep goals in mind (e.g., using analogies such as the mental blackboard). Each session will follow the same general format; namely, facility-delivered presentations, flipchart discussions, group activities and homework.
45783322|NCT01720394|Drug|Dinoprostone|Application of Propess-vaginal-insert, (Dinoprostone 10mg - Ferring Arzneimittel Ges.m.b.H., 1100 Vienna, Austria) for labor induction on day 1-3 in therapy arm 2.
45783323|NCT01467947|Biological|Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection|Individual treatment duration per subject is 9 months, irrespective of the number of treated attacks. Each attack that occurs in this time frame will be treated with 20 IU Berinert/kg body weight.
45783324|NCT01568021|Other|No Intervention|No intervention was administered in this study.
45783325|NCT00910520|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
45917567|NCT03937609|Drug|Infliximab|infliximab iv 5mg/kg
45917568|NCT00000798|Biological|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
45643368|NCT04541056|Behavioral|Brain Health Workshop (BHW)|BHW is a psycho-educative control condition, and is typically part of psycho-educative Acquired Brain Injury (ABI) rehabilitation programs, but adjusted for the ALL group of participants. The psycho-educative control condition BHW will be matched GMT for amount of training and therapist contact. Homework assignment and in-session tasks included readings, brain games, puzzles, and practical exercises such as logging sleep.
45643369|NCT04537208|Biological|CoV2 preS dTM-AF03 (low-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
45783326|NCT00910520|Drug|normal saline|Normal saline (placebo) injected into the detrusor at Day 1.
45783327|NCT01568255|Drug|Ergocalciferol|Ergocalciferol therapy at 50,000IU for 8 weeks
45783328|NCT01568255|Drug|Placebo|placebo at 50,000IU for 8 weeks
45783329|NCT01720472|Genetic|Biomarker studies|
45783330|NCT01720628|Other|serum levels of angiogenin, bFGF, VEGF|Behçet's patients
45783331|NCT01569191|Other|Artificial Tear Supplement|artificial tear supplement (Hypromellose)
45917569|NCT03906175|Device|Whole-body hyperthermia|Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization). The hyperthermia will be applied using Heckel-HT3000 MPIIb.
45917570|NCT02858284|Device|TUG|Therapeutic Ultrasound for Glaucoma
46070837|NCT00627523|Drug|Control-no treatment|Control-no treatment
46070838|NCT00640393|Drug|Etanercept|Etanercept 50 mg, subcutaneous (SC) injection.
46070839|NCT00640393|Device|nbUVB|
46070840|NCT00821353|Procedure|RF catheter ablation|RF catheter ablation
45783332|NCT01569191|Device|Cold compress|Cold compress bag fill with temperature retention gel placed over closed eyes Sold by http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
45783333|NCT01569191|Drug|Anti-allergic Medication|1 drop on single occasion after exposure to grass pollen
45783334|NCT03409874|Other|Dry Needling|Dry needling to the muscle of mastication and temporomandibular joint capsule. 1-2 treatment sessions per week for up to 4 weeks
45783335|NCT03409874|Other|Spinal manipulation|Spinal manipulation, targeting the upper cervical spine (C1-C2, C2-C3 or OA). 1-2 treatments per week for up to 4 weeks.
45783336|NCT03409874|Other|Interocclusal Appliance|Interocclusal appliance worn every nights for 4 weeks.
45783337|NCT03409874|Drug|NSAIDs|diclofenac (Voltaren) 3 X 50mg per day for 4 weeks. If the patient's TMJ pain improves, the dosage may be reduced to 2 X 50mg per day.
45783338|NCT03409874|Other|TMJ Mobs|Temporomandibular joint mobilization targeting the temporomandibular joint capsule. 1-2 treatments per week for up to 4 weeks.
45783339|NCT01726010|Device|22-G Procore Needle|
45783340|NCT01726088|Drug|Modafinil|we will compare the effect of modafinil and matching placebo on clinical and objective measures detailed above.
45783341|NCT01468337|Drug|Interferon gamma-1b|"Participant 1: 2 drops of topical interferon gamma-1b three times daily in the study eye for a daily dose of 42 μg~Participant 2: 3 drops 3 times daily in the study eye for a daily dose of 63 μg, if the 1st participant's dose is deemed well-tolerated by the investigator at Weeks 1, 2 and 4.~Participant 3: 3 drops 4 times daily in the study eye for a daily dose of 84 μg, if the 2nd tolerates the daily dose of 63 μg at Weeks 1, 2 and 4.~Participants 4 and 5: 4 drops 4 times daily in the study eye for a daily dose of 112 μg, if the 3rd tolerates the daily dose of 84 μg at Weeks 1, 2 and 4.~If the 63, 84 or 112 μg doses are not well-tolerated, subsequent participants will be enrolled at the prior dose level (42, 63 or 84 μg). Well-tolerated is defined as no corneal irritation (e.g., punctuate epithelial keratitis), no coexisting conjunctival erythema and edema, and no signs of more serious toxicities (e.g., intraocular inflammation or lens changes)."
45783342|NCT01726166|Procedure|Suprapubic Aspiration|Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
45783343|NCT01726166|Procedure|Urinary Catheterization|Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
45783344|NCT01720706|Device|RFA Loosely wound thermal coil|"This new device uses radiofrequency energy to destroy kidney or liver tumours. It is called radiofrequency ablation.~This type of energy is simply an alternating current that passes from a coil (electrode) into the tissue causing heating of the tissue in the vicinity of the electrode."
45643370|NCT04537208|Biological|CoV2 preS dTM-AF03 (high-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
45643371|NCT04537208|Biological|CoV2 preS dTM-AS03 (low-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
45783345|NCT00911612|Drug|Colesevelam|Welchol (Colesevelam HCL) 1.875 gram twice daily for 12-14 days
45643372|NCT04537208|Biological|CoV2 preS dTM-AS03 (high-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
45783346|NCT00911612|Drug|Placebo|Inert capsule matching the study drug, given twice daily
45783347|NCT01469039|Drug|ALKS 9072|Intramuscular (IM) injection, 441 mg or 882 mg given monthly
45783348|NCT01469039|Drug|Placebo|Placebo for IM injection, given monthly
45783349|NCT01720784|Dietary Supplement|Alginate dietary fiber|
45783350|NCT01720784|Dietary Supplement|Placebo|
45783351|NCT01726244|Behavioral|Multidisciplinary Intervention|Health education sessions consisting in controlling disease and stress asociated to it, and modifying eating habits
45783352|NCT01569737|Drug|ella|ella, single intake, tablet 30mg
45783353|NCT03409484|Other|Concord Grape Juice|Concord Grape Juice
45643373|NCT04537208|Biological|CoV2 preS dTM (high-dose) without adjuvant|Pharmaceutical form: liquid; route of administration: intramuscular injection
45643374|NCT04537208|Biological|Placebo (0.9% normal saline)|Pharmaceutical form: liquid; route of administration: intramuscular injection
45643375|NCT04535011|Behavioral|PPKAY (brief intervention)|PPKAY is a nurse-administered, one-on-one, 15-minute brief intervention (BI) for alcohol use using FRAMES motivational interviewing techniques. The BI is a four-step discussion: 1) Raise the Subject of Alcohol, 2) Provide Feedback, 3) Enhance Motivation 4) Negotiate and Advice.
45643376|NCT04535011|Behavioral|Standard Booster|After discharge from the hospital, a standard motivational text message will be sent to their cell phone twice monthly for the duration of the study. In a rotating fashion, one of four standard motivational texts translated into Swahili will be sent to their cell phones.
45754322|NCT01911013|Device|Cage alone|anterior cervical discectomy and fusion is performed using cage alone with plate.
45754323|NCT03587012|Other|Brain fitness app|Daily tutored sessions of brain exercises on an iPAD (in-person or remote)
45783354|NCT03409484|Other|Low flavoniod low essence beverage|Low flavoniod low essence beverage
45783355|NCT03409484|Other|Low flavonoid beverage|Low flavonoid beverage
45917571|NCT02858284|Device|Sham|
45917572|NCT00390520|Drug|Vildagliptin|
45917573|NCT00000813|Biological|ALVAC-HIV gp160MN (vCP125)|
45783356|NCT05562089|Device|A Paclitaxel Drug-Coated Balloon|Size: 2.0mm-4.0mm x 15-30mm Coated drug: Prevail TM
45783357|NCT01726478|Drug|2.5 units Oxytocin|Administration of 2.5 units of oxytocin after clamping of umbilical cord
45783358|NCT01726478|Drug|10 units Oxytocin|Administration of 10 units of oxytocin after clamping of umbilical cord
45783359|NCT04379492|Drug|Hydroxychloroquine|Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.
45783360|NCT04379492|Other|Placebo|Participants will receive masked placebo given as 2 tablets orally q12h for 2 doses on day 1, followed by 1 tablet orally q12h for days 2-5.
45783361|NCT02470806|Device|PICO System|Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
45783362|NCT02470806|Device|tNPWT System|NPWT from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
45783363|NCT00912002|Drug|MK-0941|A single dose of 40 mg of [14C]MK-0941 (160 µCi), taken orally as eight 5-mg capsules
45783364|NCT01726556|Device|Rigid thoracoscope (Richard Wolf GmbH, Knittlingen, Germany)|Pleuroscopy using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany
45783365|NCT01726556|Device|Semirigid thoracoscope (model LTF-160Y1, Olympus, Japan)|Pleuroscopy using a semirigid thoracoscope model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan
45783366|NCT03409250|Drug|Ranibizumab, Lucentis|Intravitreal injection with Lucentis (Ranibizumab)
45783367|NCT01569815|Drug|LCZ696|LCZ696 400 mg once daily
45783368|NCT01726634|Other|Elastic Tapping|
45783369|NCT01726712|Other|Supportive Care|Provide emotional support. Provide practical support. Support friend/family by helping him find information or help for those with HIV in the community
45783370|NCT01469585|Drug|Doxycycline|40 mg orally at the start of cycle 3 (study day 57) for 28 days.
45783371|NCT01720940|Drug|continuous vancomycin infusion|24-hour continuous infusion of vancomycin
45783372|NCT01720940|Drug|intermittent vancomycin infusion|
45783373|NCT03409172|Other|CTR|no counseling or nutritional therapy and no exercise
45783374|NCT03409172|Other|MICT|no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based moderate continuous intensity training (MICT).
45449033|NCT02152852|Behavioral|Community Health Worker Intervention|For the intervention group, a trained Community Health Worker (CHW) will provide education, support and service coordination through in-home visits. The CHW will first make an in-home assessment visit. At the assessment visit, the participant has the opportunity to ask questions and sign written consent. During this visit, the CHW assesses the participant's history with diabetes, medication adherence, self-management activities, healthcare utilization and will administer a finger stick blood test for HbA1c and a full lipid panel. After enrollment, the participant receives up to five follow-up educational visits 0.5, 1.5, 3.5, 7 and 10 months later. In addition to scheduled visits, the CHWs work with their participants on an as-needed basis via telephone, or additional home visits.
45783375|NCT03409172|Other|HIIT|no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based high intensity interval training (HIIT)
45783376|NCT01721018|Biological|HSV1716 Intra-pleural delivery|
45783377|NCT01721174|Procedure|SEMS only|The SEMS (Niti-S biliary uncovered metallic stent; Taewoong Medical, Korea) would be placed.
45449034|NCT02152930|Drug|Omega-3 fatty acids|1000 mg of omega-3 fatty acid ethylesters, 2 times daily, for 4 weeks, followed by 12 weeks of supervised exercise therapy in combination with 2 times daily omega-3 fatty acid supplementation.
45449035|NCT02147704|Dietary Supplement|High-sodium diet|"One of high- or low sodium intake for 7 days during each period~High sodium intake: 50 mmol/day by diet + 250 mmol/day by salt tablets"
45783378|NCT01721174|Procedure|EBRFA and SEMS|The radiofrequency ablation (RFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter is a bipolar RFA probe that is 8F (2.6 mm), 1.8 m long, compatible with standard (3.2-mm working channel) side-viewing endoscopes, and passes over 0.035-inch guidewires. The catheter has 2 ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5-cm length. Depending on the length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after 2 sessions of EBRFA.
45783379|NCT01726868|Device|Liposorber LA-15 System|Six sessions of blood purification treatment with Liposorber LA-15 System.
45783380|NCT03408938|Device|of Masimo Radical-7¿ Pulse CO-Oximeter|"The Masimo pulse oximetry model:~The pulse oximetry model which Masimo developed accounts for saturation values contributed by the true arterial signal, and by one or more motion or noise signals. lt is assumed that under conditions of motion, the detected IR and RD signals comprise both the true arterial saturation signal and a venous (or non-arterial) motion noise signal. Masimo uses a highly sophisticated adaptive filter with, Discrete saturation transform (DST) four other parallel engines, to leverage each algorithm's unique strengths to ensure accurate readings through all patient conditions. Masimo SET's most powerful algorithm is Signal extraction technology (SET). All algorithms depend upon assumptions. The more assumptions, the weaker the algorithm. DST makes only one assumption -that arterial blood has a higher oxygenation than venous - making it the most powerful pulse oximetry algorithm"
45783381|NCT01363908|Drug|SPD602|
45783382|NCT00915590|Drug|Placebo|Custom eye drop eye three times a day in both eyes for a period of 6 weeks
45783383|NCT00915590|Drug|IL-1Ra|5% custom made topical IL-1Ra 3 times a day in both eyes for a period of 6 weeks
45783384|NCT03408782|Procedure|Insertion of drainage|
45783385|NCT01570829|Drug|Dietressa|Oral administration.
45783386|NCT01570829|Drug|Placebo|Oral administration.
45783387|NCT01721642|Device|Apica Cardiovascular ASC Access, Stability and Closure Device|Access, stabilisation and closure of trans-apical approach for TAVI
45917574|NCT00000813|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
45917575|NCT00000813|Biological|rgp120/HIV-1 SF-2|
46070841|NCT00821353|Drug|Antiarrhythmic drugs|One of AA drugs (preferably Amiodarone) and cardioversion in cases of chronic AF
45643377|NCT04535011|Behavioral|Personalized Booster|After discharge from the hospital, a personalized motivational text message will be sent to participant cell phones twice monthly for the duration of the study. In a rotating fashion, one of four personalized motivational texts will be sent to their cell phones. Personalized texts will be created with the content obtained from the motivational interview sessions. At each session, the research nurse conducting the intervention will record four messages based on the content of the session to be sent as the Personalized Booster.
45783388|NCT03408626|Drug|Papain-based Chemo-mechanical caries removal agent|Birx 3000 and the exclusive Encapsulating Buffer Emulsifier (EBE) technology claim it has effective and selective proteolytic action to remove collagen fiber in the carious tissue. It has an antibacterial and antifungal power, thus it has an antiseptic power at the tissue level .furthermore, this gel does not contain chloramines in its formula, which enhances its toxicological safety feature.
45783389|NCT03408626|Device|conventional rotary|traditional rotary method
45783390|NCT01721798|Device|Mirena levonorgestrel IUD|Intrauterine contraception system
45783391|NCT01721798|Device|Copper T-380a IUD|intrauterine contraception system
45783392|NCT01471457|Drug|Trimo-San gel|Pessary wearers are instructed to apply one fingertip (approx 1 tablespoon) of Trimo-San gel inside the vagina or to the pessary (for women removing and cleaning pessary before reinsertion after cleaning) once nightly
45783393|NCT03408548|Procedure|Scaling root planning|Periodontal treatment
45783394|NCT03408548|Dietary Supplement|Probiotic|two lozenge per day containing Bifidobacterium animalis lactis HN019
45783395|NCT03408548|Other|Placebo|two lozenge per day not containing Bifidobacterium animalis lactis HN019
45783396|NCT02497404|Drug|5-Azacytidine|"Patients will be given a five day course of subcutaneous 5-azacytidine followed by a reduced intensity conditioning regimen of fludarabine and melphalan with or without total body irradiation prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor. 5-Azacytidine 75 mg/m2 subcutaneously daily at the same time on days -11, -10, -9,~-8 and -7. This will be administered on an outpatient basis if possible."
45783397|NCT02497404|Drug|Fludarabine|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Fludarabine will be given at 40 mg/m2 intravenously daily at the same time over 30 minutes on days -6,-5,-4,-3.
45783398|NCT02497404|Drug|Melphalan|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Melphalan will be given at 140 mg/m2 IV on day -3.
45783399|NCT02497404|Drug|Alemtuzumab|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Alemtuzumab will be given at 30 mg subcutaneously on Days -4 and -2 for unrelated donors, and Day -2 for related donors.
45783400|NCT02497404|Radiation|Total Body Irradiation|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Total Body Irradiation (TBI) will be given at 2 doses of 200 cGy each on one day of the conditioning regimen (between days -6 and -3).
45783401|NCT03408470|Drug|TD-1473 oral capsule|(Intervention description included in arm description)
45783402|NCT03408470|Drug|[14C]-TD-1473 IV bolus|(Intervention description included in arm description)
45783403|NCT03408470|Drug|[14C]-TD-1473 Oral Capsule|(Intervention description included in arm description)
45783404|NCT01573169|Drug|Enoxaparin|enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke
45783405|NCT01573169|Other|Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization|placebo standard therapy
45783406|NCT01727492|Drug|Antioxidantia|
45783407|NCT04938492|Behavioral|Cognitive Behavioral Therapy for loneliness (CBT-L)|6 sessions focused on addressing thoughts, emotions, and behaviors that maintain feeling alone as a way to reduce loneliness and substance use.
45783408|NCT04938492|Behavioral|Physical Health Education Training (PHET)|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
45783409|NCT05522309|Drug|ET0111|Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with ET0111 administered, once daily (QD).
45783410|NCT01727570|Dietary Supplement|Whey Protein (Immunocal®)|The amount of Immunocal® whey protein the patient is required to take daily will be determined on an individual basis by the nutritionist according to the assessed protein deficit in the patient's diet.
45783411|NCT03001895|Drug|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT
45783412|NCT01727648|Behavioral|RT in sequential combination with dCIT|The participants will received 2 weeks of RT therapy using the ArmeoSpring and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.
45783413|NCT01727648|Behavioral|Distributed Constraint-Induced Therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
45783414|NCT01727648|Behavioral|Robot-Assisted Therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring (Hocoma AG, Switzerland) will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.
45917576|NCT03877549|Drug|Dexamethasone|Additional of two different doses of dexamethasone via the epidural catheter during surgical closure after cesarean section
45917577|NCT00390598|Drug|PEG (solution given 4 L)|
45917578|NCT00390598|Drug|senna glycoside 36 mg and PEG (solution given 2 L)|
45643378|NCT04533750|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45643379|NCT04533750|Drug|Peposertib|Given PO
45643380|NCT04528082|Drug|Apremilast|Participants will receive apremilast orally.
45783415|NCT01727648|Behavioral|Dose-matched control therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
45783416|NCT04205994|Drug|Tolcapone 200 MG|Tolcapone is a brain penetrant catechol-O-methyltransferase (COMT) inhibitor. It will be administered in randomized, double-blind, counterbalanced fashion with a placebo.
45783417|NCT04205994|Other|Functional Magnetic Resonance Imaging (fMRI)|FMRI provides an indirect and noninvasive measure of brain activity.
45783418|NCT03007745|Device|autoadjusting continuous positive airway pressure|Participants in both arms who are diagnosed with obstructive sleep apnea will be treated with autoadjusting continuous positive airway pressure
45783419|NCT01727804|Other|Laser in caries prevention|
45783420|NCT01727882|Behavioral|Brief feedback|A brief feedback was given on the results of the daily assessments, including a recommendation to the paroled offender and a email report was sent to the probation officer.
45783421|NCT01727882|Behavioral|Daily assessments|Daily assessment of stress, mental symptoms, alcohol and substance use during 30 consecutive days after parole.
45783422|NCT04937868|Other|There are no interventions associated with this study|This study is purely observational, there will be no interventions or changes in care related to patient inclusion in this study.
45783423|NCT02218307|Drug|Mupirocin|
45783424|NCT02218307|Drug|Placebo|
45783425|NCT01727960|Behavioral|Education and posture correction|a lecture concerning the fine posture for health and exercises
45917579|NCT03872479|Drug|EDIT-101|Participants will receive a single dose of EDIT-101 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study.
45917580|NCT00000816|Drug|Sulfamethoxazole-Trimethoprim|
45449036|NCT02147704|Dietary Supplement|low-sodium diet|"One of high- or low sodium intake for 7 days during each period~Low sodium intake : 50 mmol/day by diet"
45643381|NCT04528082|Drug|Placebo|Participants will receive the matching placebo orally.
45449037|NCT02775916|Drug|CDZ173|
45449038|NCT02775916|Drug|Placebo|
45449039|NCT04931056|Device|Titanium Facial Plates|The Facial Plating System provides a comprehensive titanium fixation solution for maxillofacial surgery procedures. More than twenty-five different plating options in two systems, the 1.5 mm and 2.0 mm with a variety of instruments, and high torque screws, including meshes, are part of this system. Plates and screws are made of commercially pure titanium per ASTM F-67, Titanium 6Al 4V Alloy per ASTM F-136.
45449040|NCT04931056|Device|Titanium Mandibular Plates|"The Mandibular Plating System provides a comprehensive titanium fixation solution for mandibular surgical procedures. Several plating options, a variety of instruments, and high torque screws with various plate shapes are part of this system.~Plates in the Mandibular Plating System have profiles of various thicknesses. Screws are available in self-tapping, locking and non-locking varieties, and in various sizes between 2.0 mm and 2.3 mm in diameter, and 5 mm to 18 mm in length."
45643382|NCT04527991|Biological|Sacituzumab Govitecan-hziy|Administered intravenously
45643383|NCT04527991|Drug|Paclitaxel|Administered intravenously
45643384|NCT04527991|Drug|Docetaxel|Administered intravenously
45643385|NCT04527991|Drug|Vinflunine|Administered intravenously
45643386|NCT04527549|Drug|Dabrafenib Mesylate|Given PO
45643387|NCT04527549|Drug|Hydroxychloroquine Sulfate|Given PO
45643388|NCT04527549|Drug|Placebo Administration|Given PO
45643389|NCT04527549|Drug|Trametinib Dimethyl Sulfoxide|Given PO
45643390|NCT04524273|Drug|inebilizumab|Participants will receive IV inebilizumab
45643391|NCT04524273|Drug|IV Placebo|Participants will receive IV placebo matched to inebilizumab
45643392|NCT04522414|Other|cries longitudinally registered|Their cries will be longitudinally registered from the age of birth to the return home using an automatic record device: Song Meter SM4.
45643393|NCT04521361|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Drug will be administered as aqueous solution intravenously at a dose of 55 kBq/kg body weight every 4 weeks for 6 cycles (cycle length = 4 weeks).
45643394|NCT04514783|Device|Debridement with Debritom+ micro water jet device|"Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~Removal of old dressing~Woundworks® 3D imaging~Applying analgesic if necessary~Applying a soaked gaze with Sodium chloride (NaCl) 0.9% solution on the wound (5 minutes)~Debridement using Debritom+ micro water jet technology~Wound cleansing with NaCl 0.9% solution~Woundworks® 3D imaging~Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~Removal of old dressing~Woundworks® 3D imaging~Wound cleansing with NaCl 0.9% solution~Application of new dressing (according to the wound healing phases, medical prescription)"
45754324|NCT03587012|Other|Brain fitness app with tACS|Daily tutored sessions of brain exercises on an iPAD with simultaneous transcranial alternating current stimulation (tACS)
45754325|NCT03904316|Biological|Biodesign Otologic graft|Acellular matrix derived from porcine small intestine submucosa
45783426|NCT03007433|Other|400ml of Liquid Nutrient Drink|12MBq Technetium-99m-DTPA will be added as a non-absorbable marker incorporated into liquid nutrient drink Fortisip Vanilla (Nutricia Clinical)
45783427|NCT01728038|Behavioral|Cessation Counseling|Parental Smokers will be given brief cessation counseling, nicotine replacement therapy and Quitline connection.
45783428|NCT04937400|Other|Daily screening for delirium|Each child will be screened twice daily for delirium throughout the transplant hospitalization
45783429|NCT01722032|Other|Childhood Obesity|
45783430|NCT01722110|Drug|Indomethacin Extended-Release Capsules USP 75 mg|75 mg tablet once a day
45783431|NCT01722110|Drug|Indomethacin Extended Release Capsules USP 75 mg|75 mg tablet once a day
45783432|NCT01573949|Drug|Metformin|Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month for a duration of 3 months.
45783433|NCT02496702|Device|Training on Interactive Modulare Tiles|Training with the Interactive Modulare Tiles
45783434|NCT01574183|Drug|Vilazodone|up to 40 mg capsule daily
45783435|NCT01574183|Drug|Placebo|up to 40 mg capsule daily
45783436|NCT01574807|Drug|mepivacaine + lidocaine followed by lidocaine +lidocaine|1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
45643395|NCT04514783|Other|Debridement with|"Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~Removal of old dressing~Woundworks® 3D imaging~Applying analgesic if necessary~Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes)~Debridement using scalpel and curette~Wound cleansing with NaCl 0.9% solution~Woundworks® 3D imaging~Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~Removal of old dressing~Woundworks® 3D imaging~Wound cleansing with NaCl 0.9% solution~Application of new dressing (according to the wound healing phases, medical prescription)"
45783437|NCT01574807|Drug|lidocaine + lidocaine followed by mepivacaine + lidocaine|1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
45917581|NCT03842137|Device|tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
45917582|NCT03842137|Device|sham tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
45917583|NCT03836053|Drug|AMG 420|28 day continuous Intravenous infusion of either 400 mcg/d or 600 mcg/d followed by 2 treatment free weeks
46070842|NCT02550847|Device|The imaging biomarkers determined by MR-PET|The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.
45643396|NCT04513717|Drug|Apalutamide|Nonsteroidal Antiandrogen
45643397|NCT04513717|Drug|Bicalutamide|Antiandrogen
45643398|NCT04513717|Drug|Buserelin|Luteinizing hormone-releasing hormone (LHRH) agonist
46070843|NCT02550535|Genetic|Autologous WT1 TCR transduced T cells|Gene therapy: Autologous WT1 TCR transduced T cells administered by intravenous infusion
45449041|NCT04931056|Device|Add-on Condyle|The Add-On Condyle is intended to be implanted in the human jaw to replace the mandibular condyle to functionally reconstruct the temporomandibular joint on a temporary basis for patients undergoing ablative tumor surgery requiring the removal of the native mandibular condyle. This device is not for permanent implantation, traumatic injuries, or for treatment of temporomandibular joint disease.
45643399|NCT04513717|Drug|Degarelix|Gonadotropin-releasing hormone (GnRH) antagonist
45643400|NCT04513717|Drug|Flutamide|Antiandrogen
45643401|NCT04513717|Drug|Goserelin|Gonadotropin-releasing hormone (GnRH) agonist
45643402|NCT04513717|Drug|Histrelin|Gonadotropin-releasing hormone (GnRH) agonist
45643403|NCT04513717|Drug|Leuprolide|Gonadotropin-releasing hormone (GnRH) agonist
45643404|NCT04513717|Other|Quality-of-Life Assessment|Ancillary studies
45643405|NCT04513717|Other|Questionnaire Administration|Ancillary studies
45643406|NCT04513717|Radiation|Radiation Therapy|Undergo radiation therapy
45643407|NCT04513717|Drug|Triptorelin|Gonadotropin-releasing hormone (GnRH) agonist
45643408|NCT04512950|Drug|Ringer's lactate|Half of the hospitals will be randomized to Ringer's Lactate for a 12 week study period; after a 2 week run-out, the study fluid will be switched to 0.9% saline for another 12 week study period, followed by a 2 week run-out.
45643409|NCT04512950|Drug|0.9% saline|Half of the hospitals will be randomized to 0.9% saline for a 12 week study period; after a 2 week run-out, the study fluid will be switched to Ringer's Lactate for another 12 week study period, followed by a 2 week run-out.
45643410|NCT04512430|Drug|Atezolizumab|"Patients will receive 1200 mg of Atezolizumab every 21 days (QW3) (+/- 3 days) during neoadjuvant phase and every 28 days (QW4) (+/- 3 days) at adjuvant phase in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.~First Infusion~No premedication administered for atezolizumab specifically is permitted~Infuse atezolizumab (1200 mg in a 250 mL 0.9% NaCl IV bag) over 60 (+/- 15) minutes.~Subsequent Infusions:~If patient experienced infusion-related reaction during any previous infusion, premedication with antihistamines may be administered for Cycles > 2 at the discretion of the treating physician.~If the patient tolerated the first infusion well without infusion-associated adverse events, the successive infusion may be delivered over 30 (+/- 10) minutes."
45754326|NCT03904316|Other|Autologous temporalis fascia|An autologous graft for tympanic membrane repair
45783438|NCT01575275|Drug|aminolevulinic acid|Given PO
45783439|NCT01575275|Procedure|therapeutic conventional surgery|Undergo surgery
45783440|NCT03408158|Procedure|same type infusion of main HPA antigen|Compare the differences of platelet count between participants with same type infusion of main HPA antigen and not
45783441|NCT03001973|Other|No Intervention|Registration of all LN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
45783442|NCT01728272|Drug|blood concentration of metoprolol|measure blood concentration of metoprolol
45783443|NCT03007823|Biological|High-activity natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
45783444|NCT01728350|Behavioral|HOPE - Helping Others through Purpose and Engagement|
45783445|NCT01728506|Behavioral|Weight Loss and Exercise|Internet delivered, behaviorally based weight loss and exercise intervention
45783446|NCT03408002|Behavioral|Psychological intervention|"The intervention aims to increase self-efficacy perception in managing pre-operative anxiety. The intervention is based on one single psychological consultation adopting the Four elements technique elaborated by Shapiro"
45783447|NCT04378088|Other|Validation of CEBuS|Validation of a new score for bubbles in the colon.
45783448|NCT03407924|Other|Aerobic Exercise (AER)|Aerobic exercise will be performed with a treadmill or stationary tandem bike 3 times per week. Each exercise session will take about 30 minutes plus 5 to 10 min of warm-up and cool-down. Participants will wear a safety harness.
45643411|NCT04512430|Drug|Bevacizumab|Patients will receive 15mg/Kg of Avastin® (bevacizumab) administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase, in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.
45783449|NCT03407924|Other|Rehabilitation|Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
45783450|NCT03835286|Drug|Vitamin C|6 grams of Vitamin C in 250 ml of 0.9% saline in continuous infusion for 24 hours, 3 doses.
45783451|NCT03835286|Drug|Placebos|Placebos: 250 ml of 0.9% saline in continuous infusion for 24 hours, 3 doses.
45783452|NCT04377386|Dietary Supplement|1000 IU D vitamin|Participants in the intervention group will receive 105 DV doses of 1000 IU. The supplementation will be given by the Farma de Colombia laboratory, known commercially as Farma D, whose presentation is in soft gelatin capsules. It is recommended to take one dose per day at the same time and participants should record the daily intake time of the supplement for 15 weeks on a calendar.
45783453|NCT04377386|Dietary Supplement|200 IU D vitamin|Participants in the control group will receive 105 DV doses of 200 IU. The supplementation will be given by the same laboratory; it will have the same characteristics and recommendations for the intake as for the intervention group.
45783454|NCT03834896|Other|AYMES MADRID|AYMES MADRID is a gum-based commercial thickener, that can be utilised to modify fluid consistencies to Stage 1, 2 or 3 (as per the National Descriptors for Texture Modification) to enhance the safety of fluids in those with dysphagia.
45783455|NCT03835208|Behavioral|High/low carbohydrate distribution|A total of 2x3 days, were the patient follow a detailed diet plan. For 3 days they follow a diet plan where the majority of the carbohydrates are located on either the first part of the day(HMK) or the last part of the day(LMK). 4 days of washout are placed between the two interventions. They will not receive food but will be guided by a trained dietitian and the use of a meal plan.
46070844|NCT00907478|Biological|romiplostim|Romiplostim administered by subcutaneous injection
45643412|NCT04512430|Drug|Carboplatin|"Structure: The cis-diamino (cyclobutan-1, 1 dicarboxilate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion Patients will receive Carboplatin AUC6 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.~Guidelines of Carboplatin administration: According to the standard of each center"
45783456|NCT04377230|Procedure|biliopancreatic limb length of 60cm.|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 60cm.
45783457|NCT04377230|Procedure|biliopancreatic limb length of 100cm.|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 100cm.
45783458|NCT03407846|Procedure|Hystrectomy|Total laparscopic hystrectomy versus total abdominal hystrectomy
45783459|NCT01728662|Procedure|ELVR Procedure|Lung Volume Reduction Procedure
46070845|NCT05315024|Drug|Fluarix Tetra|Fluarix Tetra
46070846|NCT05315024|Drug|Imiquimod cream|Imiquimod cream
46070847|NCT00627445|Drug|biphasic insulin aspart 30|Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before dinner
46070848|NCT00627445|Drug|metformin|Tablets, 500 - 2000 mg, once, twice or three times daily
46070849|NCT00627445|Drug|biphasic insulin aspart 50|Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before breakfast and lunch
45783460|NCT01728740|Drug|Acarbose/Metformin FDC (BAY81-9783)|Acarbose/Metformin FDC (BAY81-9783)50mg/500mg, oral, single dose
45783461|NCT01728740|Drug|Acarbose (Glucobay, BAYG5421)|Acarbose (Glucobay, BAYG5421) 50mg, oral, single dose
46070850|NCT00905840|Device|Titanium Zircon implant|"The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.~The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing."
46070851|NCT00905840|Device|Titanium Grade IV implant|"The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.~The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing."
45783462|NCT01728740|Drug|Metformin|Metformin 500mg, oral, single dose
45783463|NCT01728818|Drug|Gemcitabine|1000 mg/m² d1,8,15 q4weeks
45783464|NCT01728818|Drug|Afatinib|40mg flat dose, po, once daily
45783465|NCT01728818|Drug|Gemcitabine|1000 mg/m², d1,8,15 q4weeks
45783466|NCT04377542|Procedure|LIFT|Ligation of the fistula tract in the intersphincteric plane
45783467|NCT04377542|Procedure|Parks|Modified Parks fistulotomy with complete internal anal sphincterotomy
45783468|NCT04377542|Procedure|Seton|Excision of the superficial part of fistula tract and tying loose seton around the remaining part and anal sphincter muscles
45783469|NCT01728896|Other|Patient-controlled oral refeeding|
45783470|NCT03407690|Other|nasal swab|collection of nasal swab to allow carriage of pneumococci to be assessed
45783471|NCT03835832|Other|The participants do not receive any intervention for this study|The participants do not receive any intervention for this study
45783472|NCT03407456|Other|Gastroesophageal reflux symptoms questionnaire|Reflux Symptom Questionnaire, 7-day recall (RESQ-7).
45643413|NCT04512430|Drug|Pemetrexed|"Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.~Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrolo[2,3 d]pyrimidine-based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center"
45783473|NCT03835520|Drug|Immunotherapeutic Agent|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.
45783474|NCT03835520|Drug|Molecular Target|Targeted agents will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.
45783475|NCT01576055|Device|TIGRIS Vascular Stent|Implant
45643414|NCT04504734|Drug|Bucillamine|100mg tablets
45783476|NCT01576055|Device|BARD LifeStent|Implant
45783477|NCT01728974|Other|Pharyngeal topical anesthesia|Pharyngeal topical anesthesia will be performed using 4% lidocaine spray
45783478|NCT01729052|Device|Acupuncture|
45783479|NCT01729130|Procedure|Adipose tissue biopsy|Adipose tissue biopsy is done at time of transplant surgery. There is a second needle biopsy done between 3-12 months post transplant surgery.
45643415|NCT04504734|Drug|Placebo|100mg tablets
45917584|NCT03801031|Drug|Lidocaine Topical|Many women treated for gynecologic cancer complain of sexual dysfunction and discomfort. It is thought that topical lidocaine application prior to sexual encounters may have reduced discomfort and improved overall quality of life during and following cancer treatment. The use of the lidocaine solution/placebo is the intervention.
45783480|NCT03407378|Drug|IPT803|Administration of IPT803 three times a day for 12 weeks as add-on therapy to patient regular PD medication(s) or as a new therapy for drug naïve patients.
45783481|NCT03407378|Genetic|Optional pharmacogenetic assessment|Blood sample of 3 milliliters for genotyping assessment (according to patient consent).
45783482|NCT03407378|Other|Questionnaires|Personality, Health and Disease questionnaires completion during the study (Visits 1, 2, 3 and 4)
45783483|NCT03407378|Other|Optional Blood-Oxygen-level Dependent functionalMRI|BOLD fMRI performed in a sub-group of patients, depending of randomization (exploratory)
45917585|NCT03801031|Drug|Placebo|Placebo solution intervention used to validate the effects of the lidocaine solution usage.
45643416|NCT04504734|Drug|Bucillamine|200mg tablets
45643417|NCT04504669|Drug|AZD8701|FOXP3 antisense oligonucleotide
45643418|NCT04504669|Biological|Durvalumab|anti PDL-1 monoclonal antibody
45643419|NCT04502433|Drug|CUROSURF® (poractant alfa)|"Three administrations with a 24 hours dosing interval.~Each endotracheal (ET) administration 1, 2, and 3 consisted of poractant alfa bolus:~30mg /kg (Lean Body Weight-LBW) = 0.375ml /kg LBW, diluted with normal saline up to 2ml /kg LBW."
45783484|NCT03407378|Other|Motor Assessments before taking regular PD treatment|Regular PD treatment stopped 12 or 24 hours prior to Visits 2, 3 and 4 depending on the drug form (extended vs standard release). Motor assessments using UPDRS Part III are performed when patients are OFF regular PD treatment. Regular PD treatment is taken on site during the visit after the motor assessments are performed.
45783485|NCT03407378|Other|Motor Assessments on regular PD treatment|Regular PD treatment is not modified before the visits. The motor assessments using UPDRS Part III are performed while the patient is on regular PD treatment.
45783486|NCT03407300|Drug|Docetaxel|To evaluate the safety and efficacy of Docetaxel alone in stage III-IV NSCLC patients
45783487|NCT03407300|Drug|Chinese traditional medicine XH1|To evaluate the safety and efficacy of Docetaxel combined with Chinese tradition medicine XH1 in stage III-IV NSCLC patients
45783488|NCT01729286|Device|PriMatrix Moist Wound Therapy|sharp debridement, PriMatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
45783489|NCT01729286|Other|Standard of Care Moist Wound Therapy|sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
45783490|NCT01729364|Drug|crystalloid|
45783491|NCT01729364|Drug|colloid|
45783492|NCT01722968|Drug|Bevacizumab|15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly
45783493|NCT01722968|Drug|Paclitaxel|80mg/m2 iv weekly
45783494|NCT03407222|Other|Text messages|Text messages which encourage the increment of daily step count
45783495|NCT01723046|Device|Training with new upper limb robot assisted therapy device|During 8 weeks, 3 times a week, 1 hour therapy sessions with the device
45783496|NCT01729442|Other|Shear-wave ultrasound elastography (SWUE)|
45917586|NCT00000822|Drug|Ritonavir|
45643420|NCT04499339|Drug|SLAMF7 CAR-T|Single infusion of autologous SLAMF7 CAR-T cells
45643421|NCT04495348|Drug|Doravirine|Participants will be switched to doravirine and then switched back to INSTI-based therapy to determine the impact on energy balance.
45643422|NCT04488133|Drug|Nusinersen|Administered as specified in the treatment arm.
45917587|NCT00000822|Biological|gp160 Vaccine (Immuno-AG)|
45643424|NCT04485468|Other|Questionnaire|The patient answers the questionnaire directly following his consultation or teleconsultation or may arrange a telephone appointment with the clinical research associate a little later.
45643425|NCT04484818|Drug|Darolutamide|Given PO
45643426|NCT04484818|Drug|Goserelin Acetate|Given via injection
45643427|NCT04484818|Drug|Leuprolide Acetate|Given IV
45783497|NCT01729520|Other|Knee extension strength training|"Load experiment: Four knee extensions will be performed with the operated leg at 20, 14, and 8 RM loadings each, in a randomized order. Range of knee joint motion and time under tension for each repetition will be controlled for~Failure experiment: One strength training set of knee extensions will be performed with the operated leg at 10 RM loading until contraction failure. Range of knee joint motion and time under tension for each repetition will be controlled for"
45917588|NCT00000822|Drug|Stavudine|
45917589|NCT00000822|Drug|Didanosine|
45783498|NCT01729676|Drug|Degarelix or GnRH agonist|Degarelix or GnRH agonist for treatment of prostate cancer according to physicians current practice
45783499|NCT04379180|Drug|Bosentan Tablets|2mg/kg, bid
45783500|NCT04379180|Drug|Sildenafil Tablet|1mg/kg, q6h/q8h
45783501|NCT04379180|Drug|Tadalafil Tablets|1mg/kg, qd
45783502|NCT03406754|Behavioral|rehabilitation programs|an 8-week multidisciplinary inpatient rehabilitation program
45783503|NCT01576523|Biological|C1-esterase inhibitor - single intravenous dose|A single intravenous dose of C1-esterase inhibitor (Berinert) at 20 units per kg body weight will be administered to all subjects prior to receiving the first dose of subcutaneous C1-esterase inhibitor.
45783504|NCT01576523|Biological|C1-esterase inhibitor - subcutaneous low dose|A low dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
45783505|NCT01576523|Biological|C1-esterase inhibitor - subcutaneous medium dose|A medium dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
45783506|NCT01576523|Biological|C1-esterase inhibitor - subcutaneous high dose|A high dose of C1-esterase inhibitor will administered subcutaneously twice a week for four weeks.
45783507|NCT01723124|Procedure|Molecular Breast Imaging|Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
45783508|NCT03406676|Drug|Methylene Blue|2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.
45783509|NCT03406598|Other|Patients in shock|Analysis of sublingual microcirculation by nurses in ICU patients in shock to predict needs for fluid challenge, vasopressors or transfusion.
45643428|NCT04484818|Drug|Placebo Administration|Given PO
45783510|NCT03007355|Other|peripheral perfusion index measurement|
45783511|NCT04378946|Behavioral|Intensive physical rehabilitation type training|Multiple reaching tasks aiming at increasing voluntary elbow range of motion
45783512|NCT04378946|Device|Robotic system for supporting and monitoring arm motion|"Ergonomic double-joint horizontal manipulandum mounted on a rigid, movable arm (used to support UL movement during tasks).~An electromyogram (EMG) is used to monitor elbow extensor and flexor muscle activity.~A motion tracking device based on the Kinect II skeleton ( with Kalman filter to improve accuracy).~Simple Virtual Reality Reaching Game providing visual feedback with screen display of the subject's arm avatar and arm workspace for the VR training."
45783513|NCT04378946|Device|Actigraph Activity Monitor|Used during and outside training sessions, this device is worned on the affected wrist that records activity (movements metrics) as a measure of upper extremity as well as heart rate
45783514|NCT04378946|Diagnostic Test|Magnetic resonance imaging (MRI)|Done once before treatment (PRE)
45783515|NCT04378946|Diagnostic Test|Montreal Spasticity Measure (MSM)|Used to identify the actual spatial threshold (ST) prior to every training session
45783516|NCT03001739|Drug|Urapidil Hydrochloride Injection|Urapidil Hydrochloride Injection or other antihypertensive agents to decrease the BP to the target level.
45783517|NCT03001583|Behavioral|Education program with cooking lessons|Structured education program of mediterranean diet and lifestyle changes with cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
45783518|NCT03001583|Behavioral|Education program WITHOUT cooking lessons|Structured education program of mediterranean diet and lifestyle changes WITHOUT cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
45783519|NCT01729832|Procedure|breast reconstruction|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
45783520|NCT01729832|Procedure|intraoperative imaging|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
45783521|NCT03007277|Other|PANJO|PANJO consists on a 6 to 12 home visitation intervention aiming at supporting the parents, supporting their upcoming then relationship with their first newbord child and to help them reaching all services they may need.
45783522|NCT01729988|Procedure|Carotid body excision|"This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation."
45783523|NCT03002129|Other|fluid challenge|At two pre-defined time points during the procedure, enrolled patients will receive a fluid bolus of 5 ml/kg during 5 minutes
45783524|NCT03406364|Drug|MG005|"Phase I:~Eligible patients will receive different dosages of GW5074 in 1 of the 3 dose cohorts plus 200 mg of sorafenib. Dose cohorts will be escalated sequentially from Cohort 1 at 750 mg QD GW5074 plus 200 mg QD sorafenib to Cohort 2 at 1500 mg QD GW5074 plus 200 mg QD sorafenib, and Cohort 3 at 750 mg BID GW5074 plus 200 mg QD sorafenib. Owing to the fact that there is no previous human experience for GW5074, Cohort 1 will include a monotherapy stage with 750 mg QD GW5074 prior to administration of the GW5074 and sorafenib combination to initially assess the safety of GW5074 monotherapy."
45643429|NCT04484818|Other|Quality-of-Life Assessment|Ancillary studies
45643430|NCT04484818|Drug|Triptorelin|Given via injection
45643431|NCT04484012|Drug|Acalabrutinib|Given PO
45643432|NCT04484012|Biological|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
45643433|NCT04482855|Device|Low-level laser|Low-level laser therapy
45754327|NCT02133235|Procedure|conventional|insertion endobronchial blocker with the guidance of fiberoptic bronchoscopy
45754328|NCT02133235|Procedure|auscultation|insertion endobronchial blocker by auscultation, without the guidance of fiberoptic bronchoscopy
45754329|NCT05583266|Drug|Pentoxifylline sustained-release tablets|a dose of 1 tablet twice a day of Pentoxifylline sustained-release tablets
45754330|NCT05583266|Drug|Pentoxifylline sustained-release tablets placebo|Pentoxifylline sustained-release tablets placebo will be administrated at the same dosage and frequency as the experimental group
45783525|NCT03001661|Device|Dilapan-S|DILAPAN-S® is a non-pharmacological synthetic rod, which is inserted into the cervical canal and through the internal os, for cervical ripening prior to induction. Its mode of action consists in the hydrophilic properties of the device absorbing fluids from surrounding tissue structures, thus expanding the volume of DILAPAN-S® sticks, usually within a 12-hour period. Subsequently it exerts radial pressure on the surrounding structures (cervix) to dilate progressively. Endocervical pressure on the cervix results not only in its mechanical dilatation but the pressure on the endocervical structures also stimulates the production of endogenous PGs and promotes cervical ripening through its collagenolytic action.
45783526|NCT03001661|Drug|Dinoprostone|Dinoprostone slow release 10mg vaginal insert is currently the standard method used for induction of labour in the NHS, particularly in nulliparous woman.
45783527|NCT01723358|Device|Neuromuscular electrical stimulation (NMES)|The intervention will consist of a period of treatment with NMES. This treatment will involve 20-45 minute feeding therapy sessions during which NMES will be administered by an Occupational Therapist. Frequency of therapy sessions will be 4 times per week for the first 2 weeks (as in inpatient, if hospitalized) and then biweekly for 14 weeks for a total of 36 sessions (over 16 weeks). For patients who are discharged prior to the first 2 weeks of treatment, outpatient sessions will be biweekly.
45783528|NCT01723436|Other|Hypothetical scenarios and related decisions|Surrogates are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
45783529|NCT03006965|Drug|octocog alfa|Pharmacokinetic Characterization of the Hemophilia A Population in Spain using an standalone web-based software
45783530|NCT03006965|Drug|rurioctocog alfa pegol|Pharmacokinetic Characterization of the Hemophilia A Population in Spain using an standalone web-based software
45783531|NCT03406208|Behavioral|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
45783532|NCT03406208|Behavioral|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 (SMP2) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
45783533|NCT01577537|Drug|1% SPL7013 Gel|Vaginal gel, daily for 7 days
45783534|NCT01577537|Drug|Placebo|Vaginal gel, daily for 7 days
45449042|NCT04931056|Device|HTR-PEKK|The HTR-PEKK implants are fabricated from polyether-ketone-ketone (PEKK) via selective laser sintering (SLS), a 3D manufacturing technique. The laser sintering machine builds the implant in layers as dictated from a stereolithographic (STL) file of the approved implant. The HTR-PEKK implants are designed individually for each patient to replace bony voids in the facial anatomy using a patient's own CT imaging data. The implant is made to fill an existing or planned void (where appropriate) using computer-aided design technology for anatomy enhancement, correction of trauma injuries, and/or to correct congenital defects in the craniofacial bone.
45643434|NCT04478370|Biological|Mosquito bites|"Participants will be exposed to mosquito bites.~For the low-dose challenge, five 5 to 7-day-old nulliparous female imagoes (i.e. that have never blood fed before) will be introduced individual into 50 mL plastic tube covered with netting material.~For high-dose challenge, 47 mosquitoes will be split into four plastic cups of 10 cm in diameter covered with netting material (three cups with 12 mosquitoes and one cup with 11 mosquitoes), and 3 mosquitoes will be introduced individually into 50 mL plastic tubes.~Mosquito bites administered on participant's arm will be used to assess immediate and delayed skin reactions. Immediate and delayed skin reactions will be recorded respectively 20-30 min and 24-36 hours after the day 14 and day 21 challenges, requiring additional visits at day 15 and 22."
45643435|NCT04478227|Drug|Romiplostim|Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
45449043|NCT02155582|Drug|Copanlisib (BAY80-6946)|0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients;45 mg and 60 mg for the diabetic patients; Intravenous (IV) infusion over 1 hour. Dosing of copanlisib will be on Days 1, 8, and 15 of each 28 day treatment cycle.
45449044|NCT02155816|Dietary Supplement|Omega 7 + 3|Ingestion of omega 7 + 3 daily for 8 weeks.
45643436|NCT04477291|Drug|CG-806|CG-806 will be given orally in ascending doses starting at 450 mg PO BID until the maximum tolerated dose or candidate recommended Phase 2 dose is reached.
45643437|NCT04477200|Drug|Mycophenolate Mofetil|500-2000mg orally twice daily, one week prior to re-resection (2 participants at each of 4 dose levels: 500mg, 1000mg, 1500mg and 2000mg)
45643438|NCT04477200|Radiation|Radiation Therapy|40.5 Gy in 15 fractions
45643439|NCT04477200|Procedure|Re-resection (as part of standard of care)|Re-resection or biopsy of tumor as part of standard of care
45449045|NCT02155816|Dietary Supplement|Omega 3|Omega 3 daily for 8 weeks.
45643440|NCT04477200|Drug|Temozolomide|Temozolomide capsules are an approved oral chemotherapeutic drug for the treatment of adult patients with newly diagnosed GBM/GS concomitantly with radiotherapy and then as adjuvant treatment. The dosing and timing of temozolomide therapy will be determined as per standard-of-care for the individual patient by the treating oncologist.
45449046|NCT02155816|Dietary Supplement|Placebo|Medium chain triglycerides
45783535|NCT04379102|Other|with NT/TLA (NT or also referred to as therapy with local anesthetics (TLA) )|Patients who visited our family planning clinic and opted for IUD application for contraception purposes were also offered NT/TLA treatments simultaneously. 40 patients who matched the inclusion criteria and received IUDs and NT/TLA treatments were included in the study group and 41 patients who only received IUDs were included in the control group. All patients received copper IUDs and none of them were on additional hormonal treatment. Before the insertion of IUD, women in the therapy group received NT treatment with 6ml of 1% procaine injected transvaginal into the cervix at 5 and 7 o'clock localizations.
45643441|NCT04477200|Drug|Mycophenolate Mofetil|250-2000mg orally twice daily, one week prior to and concurrent with RT.
45783536|NCT02469246|Drug|F/TAF|200/10 mg FDC tablet (with boosted 3rd ARV agents) or 200/25 mg FDC tablet (with unboosted 3rd ARV agents) administered orally once daily
45783537|NCT02469246|Drug|ABC/3TC|600/300 mg FDC tablets administered orally once daily
45783538|NCT02469246|Drug|ABC/3TC Placebo|Tablets administered orally once daily
45783539|NCT02469246|Drug|F/TAF Placebo|Tablets administered orally once daily
45783540|NCT02469246|Drug|3rd ARV agent|An allowed 3rd ARV agent of the participant's pre-existing regimen may include one of the following boosted ARV agents: ritonavir boosted lopinavir (LPV/r), atazanavir (ATV) + ritonavir (RTV), ATV + cobicistat (COBI) or ATV/COBI FDC, darunavir (DRV) + RTV, DRV+COBI or DRV/COBI FDC; or, one of the following unboosted ARV agents: efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP).
45783541|NCT01720550|Drug|Astragalus Polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
45783542|NCT01720550|Drug|Astragalus Polysaccharides 250 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
45783543|NCT03001427|Behavioral|Structured center-based lifestyle intervention|
45783544|NCT03001427|Behavioral|Standard education and physician advice|
45783545|NCT01723202|Drug|dabrafenib|150 mg orally twice daily given orally
45783546|NCT01723202|Drug|trametinib|150 mg orally twice daily and GSK1120212 (MEKi) 2 mg orally once daily given orally
45783547|NCT01723202|Other|Correlative Studies|"Signaling inhibition studies in tumor biopsies (10 pts in each arm; 5 pts per center)~BRAF mutation studies in circulating plasma DNA (all study patients)~Mechanisms of drug resistance in tumor biopsies or tumor blocks (5 pts in each arm)~Assess predictors of response (Archival tumor block/unstained slides in all study patients)~Pharmacokinetic studies (First 10 pts enrolled on each arm)~Pharmacogenomics studies (All study patients)"
45783548|NCT01578317|Biological|H5N1 vaccine plus AS03 adjuvant|H5N1 influenza vaccine with AS03 at the 3.75 mcg dose level given 21 days apart.
45783549|NCT01578317|Biological|H5N1 vaccine without adjuvant|H5N1 influenza vaccine non- adjuvanted form at the 3.75 mcg dose level given 21 days apart.
45783550|NCT03406130|Procedure|Orthodontic Procedure|"Damon self-ligating systems (Ormco) were used for all patients. The patients were allowed to choose between clear and metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in. copper nickel-titanium Damon arch forms were placed. The subjects returned every 2 wk, and the archwires were changed only when full bracket engagement were achieved. The sequence of archwires was the following: 0.018-in., 0.014 × 0.025-in., and 0.018 × 0.025-in. copper nickel-titanium archwires were used for alignment, while 0.019 × 0.025-in. stainless-steel archwires were used for fine-tuning. Following the alignment steps, impressions were taken, and a blinded senior orthodontist validated appliance removal or provided advice regarding further adjustments.~Alginate impressions were taken after the removal of the appliances, and fixed and removable retainers were placed."
45783551|NCT03406130|Procedure|Piezocision surgery|The piezocision surgery was performed 1 week after orthodontic appliance placement. The surgical protocol was performed as described by Dibart and al. (Dibart et al. 2009). However, to avoid bias, hard and soft tissue augmentations were not considered. The patients received local anesthesia in both arches; vertical interproximal microincisions were created below each interdental papilla. In cases of root proximity (i.e., <2 mm of interdental bone), this procedure was not performed. These incisions were kept to a minimum (varying from 5 to 8 mm). Next, with a vertical piezoelectric device, 5-mm-long and 3-mm-deep corticotomies were made, and no subsequent sutures were required. The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intake for 1 wk. Anti-inflammatories were prohibited to avoid interference with the RAP.
45783552|NCT04965012|Behavioral|Online CBT with MET treatment|The CBT with MET treatment condition will begin with an MET-therapist guided introduction to the program and first module. After this guided introduction, they will have access to the remaining 7 treatment modules and have 6 weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to cannabis use, learn strategies to cope with cravings, triggers, and social pressures, and learn to how prevent relapse. Participants will work through modules sequentially.
45917590|NCT03797560|Other|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-health-care Qigong exercise that has been practiced by Chinese people for at least eight hundred years. It consists of eight sets of simple movements. By combining meditation with slow, graceful movements, deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear, previous clinical trials have demonstrated that Ba-Duan-Jin can improve sleep quality, physical health, and mental health in patients with various chronic diseases"
45917591|NCT03797560|Drug|Pregabalin capsule|Pregabalin is one of the three medications (pregabalin, duloxetine, and milnacipran) that have been approved by the Food and Drug Administration (FDA) to treat fibromyalgia in US, and the only medicine that has been approved in China.
45449047|NCT03542890|Device|Baska Mask|used in adult low risk females undergoing elective gynecological operations
45643442|NCT04477200|Drug|Mycophenolate Mofetil|250-2000mg orally twice daily, one week prior to and concurrent with RT and cyclic chemotherapy with temozolomide.
45643443|NCT04477200|Radiation|Radiation Therapy|60 Gy in 30 fractions
45643447|NCT04467021|Other|Best Practice|Receive usual blood pressure management
45783553|NCT04965012|Behavioral|CBT without MET treatment|The CBT without MET treatment condition will begin with a brief non-MET trained research assistant welcome to the program, and will not include working through the first module together. After this welcome, they will have access to the 8 treatment modules and have 6 weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to cannabis use, learn strategies to cope with cravings, triggers, and social pressures, and learn to how prevent relapse. Participants will work through modules sequentially.
45643448|NCT04467021|Other|Blood Pressure Measurement|Undergo blood pressure measurement
45783554|NCT03830216|Device|Connected insulin pen and smartphone app|The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is paired with a smartphone app with dose calculator.
45783555|NCT03830216|Device|Inactive connected insulin pen without smartphone app|The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is inactive and not paired with a smartphone app or dose calculator.
45783556|NCT01726946|Drug|VX-135|12 weeks of VX-135
45783557|NCT01726946|Drug|ribavirin|12 weeks of ribavirin
45643449|NCT04467021|Other|Clinical Management|Undergo intensive systolic BP management
45643450|NCT04467021|Other|Quality-of-Life Assessment|Ancillary studies
45643451|NCT04467021|Other|Questionnaire Administration|Ancillary studies
45643452|NCT04465721|Behavioral|TRE|The TRE intervention will be administered and monitored via the study app. It combines self-monitoring behavior, daily eating window reminders, positive reinforcement based on number of log entries or based on meeting eating widow target, and basic lifestyle text messages. It also allows research staff to monitor in real-time, via the backend cloud, adherence to self-monitoring, and to reducing the eating window.
45643453|NCT04465721|Behavioral|HABIT|The HABIT intervention will be administered and monitored via the study app. It combines self-monitoring behavior, positive reinforcement based on number of log entries, and basic lifestyle text messages. It also allows research staff to monitor in real-time, via the backend cloud, adherence to self-monitoring.
45783558|NCT02469168|Device|Recell|ReCell Treatment over wound pretreated with INTEGRA™ MBWM Wound Matrix
45783559|NCT02469168|Procedure|Control|Standard meshed split thickness skin graft over wound pretreated with INTEGRA™ MBWM Wound Matrix
45783560|NCT01723592|Dietary Supplement|Probiotics|Probiotics oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains,L.rhamnosus/ LbV96 (DSM 22560),L.jensenii /LbV 116 (DSM 22567),L.crispatus/ Lbv88 (DSM 22566),L.gasseri /LbV 150N (DSM 22583)
45783561|NCT01723592|Dietary Supplement|Oral lactose placebo|Placebo
45643454|NCT04464564|Drug|AVP-786|oral capsules
45643455|NCT04464564|Drug|Placebo|oral capsules
45643456|NCT04462770|Drug|EPX-100 (Clemizole HCl)|Daily dose of EPX100
45643457|NCT04462770|Drug|Placebo|Daily dose of Placebo
45643458|NCT04455802|Drug|Buprenorphine or Placebo|The double blind, double dummy design necessitates that both drugs be on an identical schedule. The 4-hour dosing allows for this pairing. If a patient is randomized to the buprenorphine arm, medication administration will follow an every 8-hour dosing but medication will be substituted with placebo during the intermediary time point.
45783562|NCT01723670|Drug|CHF 5074 1x|oral tablet, 1x, once a day for 24 months
45783563|NCT01723670|Drug|CHF 5074 2x|oral tablet, 2x, once a day for 24 months
45917592|NCT03495414|Other|Brain Imaging|"Structural MRI (T1 weighted)~Diffusion Tensor Imaging (DTI)~resting state functional MRI (rs-fMRI)~functional MRI (fMRI): Brain activity will be measured in response to sexual images (visually evoked sexual arousal; processing of sexual stimuli), and importantly during a phase when these stimuli are anticipated (neural correlates of wanting and desire; reward anticipation)."
45643459|NCT04455802|Drug|Morphine or Placebo|If a patient is randomized to the morphine arm, morphine will be given every 4 hours. Placebo will also be given at the same frequency as a faux drug.
45643460|NCT04454437|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
45643461|NCT04446052|Drug|GM-CSF priming|
45643462|NCT04446052|Drug|Placebo|Placebo
45643463|NCT04444921|Drug|Carboplatin|Given IV
45643464|NCT04444921|Biological|Nivolumab|Given IV
45643465|NCT04444921|Drug|Paclitaxel|Given IV
45643466|NCT04443088|Drug|INV-1120|INV-1120 is an investigational selective and potent small molecule indicated for the treatment of solid malignancies including, but not limited to colorectal, breast, pancreatic, lung and liver cancers.
45643467|NCT04443088|Combination Product|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg on Day 1 of each 3-week treatment cycle.
45643468|NCT04442503|Drug|SAGE-217|SAGE-217 oral capsules.
45643469|NCT04442503|Drug|Placebo|SAGE-217 matched-placebo oral capsules.
45643470|NCT04441905|Other|Placebo|One time 60-minute IV infusion of lyophilized placebo for SAR440894
45783564|NCT01723670|Drug|Placebo|oral tablet,once a day for 24 months
45783565|NCT01723748|Drug|genotropin|iii) intravenous exogenous bolus of GH (0.5 mg) followed by muscle and fat biopsies.
45783566|NCT01720160|Device|BAROSTIM NEO® System|Implant procedure
45783567|NCT01720160|Other|Standard of care medical managment therapy for heart failure|Standard of care medical management therapy for heart failure (AHA/ACC guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
45783568|NCT03405896|Other|Turning|start to walk with normal speed, and then turn to approach the terminal under different angle.
45783569|NCT02469090|Drug|APL-130277|"Use to treat up to 5 OFF episodes per day"
45783570|NCT02469090|Drug|Placebo|placebo
45783571|NCT02496000|Drug|ORMD-0801|Oral Insulin
45783572|NCT02496000|Drug|Placebo Comparator|Placebo
45783573|NCT02468934|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
45783574|NCT02517528|Drug|ABT-450/r/ABT-267|Tablet
45783575|NCT02517528|Drug|ABT-333|Tablet
45783576|NCT02517528|Drug|ribavirin|Tablet
45783577|NCT02495844|Drug|UCB0942|Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use
45783578|NCT02495844|Drug|UCB0942|Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use
45783579|NCT02495844|Drug|Placebo|Pharmaceutical form: Film-coated tablet Route of administration: Oral use
45783580|NCT02468778|Device|HeartMate PHP|The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is an acceptable therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.
45783581|NCT02468778|Device|Any Abiomed Impella® device approved for use in high-risk PCI|Any Abiomed Impella® device approved for use in high-risk PCI.
45783582|NCT04963842|Behavioral|Use of bio-plastic food packaging material and avoidance of plastic food packaging material|The bio-plastic food packaging material will be used by the study participants for 5 days and no plastic packaged food will be consumed.
45783583|NCT01727336|Drug|Dalantercept and axitinib|
45783584|NCT01727336|Drug|Placebo and axitinib|
45783585|NCT01578707|Drug|ofatumumab|"The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity.~Week 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)"
45783586|NCT01578707|Drug|ibrutinib|ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity
45783587|NCT03835442|Drug|Baclofen|baclofen 10mg tid for 4 weeks
45783588|NCT03835442|Other|Placebos|placebo tid for 4 weeks
45783589|NCT02466516|Drug|SEL|SEL tablet administered orally once daily
45783590|NCT02466516|Biological|SIM|Simtuzumab (SIM) 125 mg/mL single-dose vials administered subcutaneously once weekly
45783591|NCT04377464|Other|SF12, EQ-5D-5L and work status standardized quantitative assessments|Quality of life assessments
45643471|NCT04441905|Biological|SAR440894|One time 60-minute IV infusion of SAR440894 monoclonal antibody (IgG1) directed against the E2 envelope protein of chikungunya virus
45643472|NCT04438382|Biological|Infliximab|Given IV
45783592|NCT01722656|Drug|Aflibercept|
45783593|NCT04963764|Drug|Amoxicillin|Participants will be randomized to receive oral amoxicillin for a standard course (10 days)
45783594|NCT04963764|Drug|Placebo|Participants will be randomized to receive oral placebo for a standard course (10 days)
45783595|NCT03405584|Drug|Esomeprazole|Proton pump inhibitor
45643473|NCT04438382|Biological|Intravenous Immunoglobulin Therapy|Given IV
45783596|NCT03405584|Drug|Amoxicillin|Antibiotic for H. pylori eradication
45783597|NCT03405584|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
45783598|NCT03007043|Other|blood sample|
45643474|NCT04438382|Drug|Prednisone|Given IV or PO
45783599|NCT04935840|Dietary Supplement|FertyBiotic Pregnancy|DHA, folic acid, Iodine, iron, Lactobacillus rhamnosus, Lactobacillus reuterii, magnesium, zinc, vitamin D3, Vitamin C, Vitamin E, Group B vitamins and Biotin
45783600|NCT04935840|Other|Control|400 mcg of folic acid
45449048|NCT03542890|Device|I-gel|used in adult low risk females undergoing elective gynecological operations
45643475|NCT04438382|Other|Quality-of-Life Assessment|Ancillary studies
45643476|NCT04438382|Other|Questionnaire Administration|Ancillary studies
45643477|NCT04436640|Drug|Bimekizumab|Subjects will receive bimekizumab at prespecified time-points.
45643478|NCT04434040|Drug|Atezolizumab|Atezolizumab is a type of antibody and is administered intravenously.
45783601|NCT03834662|Drug|AVID200|A TGFβ receptor ectodomain-IgG Fc fusion protein inhibitor of TGFβ
45643479|NCT04434040|Drug|Sacituzumab govitecan|Sacituzumab govitecan is an antibody drug conjugate and is administered intravenously
45643480|NCT04431544|Device|AcQMap System|To evaluate procedural and long-term outcomes when using the diagnostic AcQMap System as an imaging and mapping system for ablation of arrhythmias in accordance with the Instructions for Use (IFU).
45783602|NCT03007121|Drug|Morphine intrathecal|Administration of intrathecal injection of 0.3 mg preservative-free morphine in 3 ml NS
45783603|NCT03007121|Drug|Bupivacaine + Sufentanil epidural|Continuous epidural infusion of a mixture containing in 1 ml bupivacaine 0,125% and sufentanil 0,4 mcg at 8 ml/h.
45783604|NCT03007121|Drug|Morphine intravenous|Patiernt-controlled i.v. analgesia with morphine
45783605|NCT04959864|Dietary Supplement|Isitol®|"1 sachet of Isitol® (2,1g) contains :~1000 mg of myo-inositol ;~300 mg of N-acetyl-cystein ;~48.5 mg of zinc citrate (equivalent zinc pure element : 15 mg) ;~35 mg of D-a-tocopherol (equivalent vitamin E pure element : 12 mg) ;~16 mg of vitamin B3 ;~1.8 mg of pyridoxin hydrochloride (equivalent vitamin B6 pure element : 1.4 mg) ;~1.4 mg of vitamin B2 ;~0.37 mg of (6S)-5-methyltetrahydrofolic acid, glucosamine salt (equivalent vitamin B9 pure element : 0.2 mg).~Sachets are packaged in box of 30."
45783606|NCT04959864|Other|Placebo|"1 sachet of placebo (2,1g) contains :~1765.1 of maltodextrin ;~300 mg of magnesium carbonate ;~40 mg of citric acid ;~5.3 mg of beta-carotene ;~2.16 mg of silicon dioxide ;~1.44 mg of sucralose.~Sachets are packaged in box of 30."
45783607|NCT01725152|Drug|Ganaxolone|oral suspension, given in 3 divided doses
45783608|NCT01725152|Drug|Placebo|oral suspension, given in 3 divided doses
45783609|NCT02980913|Device|Thealoz Duo eye drops and Thealoz Duo gel|Thealoz Duo eye drops during the day + Thealoz Duo gel at night (1 drop before going to bed) for 7 days
45783610|NCT02980913|Device|Thealoz Duo gel|Thealoz Duo gel during the day and at night for 7 days
45783611|NCT04959552|Device|FreeStyle Libre 2|The FreeStyle Libre 2 Flash Glucose Monitoring
45783612|NCT01723982|Drug|Barusiban (FE 200440)|
45783613|NCT01723982|Drug|Placebo Comparator|
45783614|NCT02981303|Biological|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
45783615|NCT02981303|Drug|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
45783616|NCT03834038|Drug|Lyophilized Fecal Microbiota Transplantation|Lyophilized FMT
45783617|NCT02981459|Drug|Mirabegron|daily mirabegron 25mg with the option to increase dose based on symptoms to 50mg daily after 4 weeks
45783618|NCT01724138|Drug|Deferasirox|Patients will start their deferasirox treatment with a dose of 20 mg/kg/day.
45783619|NCT02247167|Procedure|adenotonsillectomy|adenotonsillectomy in children with OSAS and adenotonsillar hypertrophy.
45643481|NCT04428658|Behavioral|Supplemental video visits|Receiving home-based video visits with a pediatric endocrinologist monthly as a supplement to regular diabetes clinic visits.
45643482|NCT04428658|Behavioral|Standard of Care|Usual quarterly visits with the UCD Pediatric Diabetes Clinic.
45783620|NCT03006809|Biological|Fecal Microbiota Transplantation (FMT), OpenBiome|Delivered by colonoscopy, enema or orally (as capsules)
45917593|NCT03495414|Other|Cognitive testing|"We will administer neuropsychological tests assessing objective measures for~intelligence (Ravens Matrices)~impulsivity and risk-taking behavior (Balloon Analogue Risk Task)~inhibitory control (Stop Signal Task)."
45917594|NCT03495414|Other|Psychometric|Administered questionnaires include anxiety and depression symptoms (MADRS, HADS, GAD), drug use (AUDIT, DUDIT), attention deficits (ASRS), impulsivity (BIS-11), reward seeking behavior (BIS/BAS), sexual orientation, (hyper)sexual behavior, desire and compulsivity aspects (HDSI, HBI, SCS, SDI, SIS/SES).
45917595|NCT03495414|Other|Blood test|Blood samples will be taken for routine health assessment, measurement of sex hormonal levels, HPA-axis function test (dexamethasone suppression), and potential DNA extraction and (epi)genetic profiling.
45917596|NCT03730948|Biological|DC vaccine|DC vaccine for colorectal cancer
45643483|NCT04428658|Behavioral|Supplemental remote monitoring|Receiving remote glucose monitoring with monthly outreach from a pediatric endocrinologist as a supplement to regular diabetes clinic visits.
45643484|NCT04427384|Device|GammaTile|Surgically Targeted Radiation Therapy
45643485|NCT04426890|Biological|CT-P39|Prefilled syringe (PFS) of 1 mL solution
45917597|NCT03729271|Drug|Rifaximin|Rifaximin will be given during weeks 2-4
45917598|NCT03729271|Device|Glucose and lactulose hydrogen breath testing|Subjects will undergo glucose and lactulose hydrogen breath tests for Small Intestinal Bacterial Overgrowth (SIBO) on consecutive days using a commercially available home base kits (Glucose Hydrogen Breath Test Collection Kit and Lactulose Hydrogen Breath Test Collection Kit for SIBO from Commonwealth Diagnostic International) prior to Rifaximin treatment and at week 13 of the study.
45643486|NCT04426890|Biological|EU-approved Xolair|Prefilled syringe (PFS) of 1 mL solution
45643487|NCT04423211|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
45643488|NCT04423211|Drug|Apalutamide|Given PO
45643489|NCT04423211|Procedure|Computed Tomography|Undergo PET/CT
45643490|NCT04423211|Radiation|External Beam Radiation Therapy|Undergo EBRT
45643491|NCT04423211|Radiation|Fluciclovine F18|Given IV
45783621|NCT03006809|Other|pretreatment antibiotics|5 day course (vancomycin PO 500mg bid, metronidazole PO 500mg bid, and neomycin PO 500mg bid) starting 6 days prior FMT
45783622|NCT01580423|Drug|aprepitant|125 mg capsule
45783623|NCT01580423|Drug|placebo|capsule identical to aprepitant
45783624|NCT01049984|Drug|Rasagiline|1mg tablet daily for 18 weeks
45917599|NCT00390637|Behavioral|High or low Glycemic Index and high or low Protein Diet|
45917600|NCT03646123|Drug|brentuximab vedotin|1.2 mg/kg by IV infusion
45917601|NCT03646123|Drug|doxorubicin|25 mg/m^2 by IV infusion
45917602|NCT03646123|Drug|vinblastine|6 mg/m^2 by IV infusion
45917603|NCT03646123|Drug|dacarbazine|375 mg/m^2 by IV infusion
45917604|NCT03646123|Drug|G-CSF|Granulocyte colony stimulating factor (G-CSF) primary prophylaxis administered 24-36 hours after each dose of A+AVD
45643492|NCT04423211|Drug|Goserelin Acetate|Given SC
45643493|NCT04423211|Procedure|Intensity-Modulated Proton Therapy|Undergo IMPT
45643494|NCT04423211|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45643495|NCT04423211|Drug|Leuprolide Acetate|Given IM
45643496|NCT04423211|Procedure|Positron Emission Tomography|Undergo PET/CT
45643497|NCT04423211|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45643498|NCT04423211|Radiation|Volume Modulated Arc Therapy|Undergo VMAT
45643499|NCT04422132|Radiation|5 days Radiation Therapy (32.5 Gy in 5 fractions)|Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
45643500|NCT04422132|Radiation|20 days Radiation therapy (55 Gy in 20 fractions)|Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
45783625|NCT01049984|Drug|Placebo|one tablet daily for 18 weeks
45783626|NCT03001271|Drug|Angiotensin 1-7|
45783627|NCT03001271|Other|Placebo|
45783628|NCT03001349|Procedure|Computed Tomography|Undergo PET/CT
45783629|NCT03001349|Drug|Gallium Ga 68-Edotreotide|Given IV
45783630|NCT03001349|Procedure|Positron Emission Tomography|Undergo PET/CT
45643501|NCT04417530|Drug|AU-011|AU-011 Via Suprachoroidal Administration with laser treatment
45643502|NCT04417530|Device|Suprachoroidal Microinjector|Suprachoroidal Injection Device
45643503|NCT04417530|Device|PDT Laser|Laser Administration
45783631|NCT04377152|Drug|68Gallium-PSMA-11|PSMA-11 Ga 68 Injection is a positron emitting radiopharmaceutical containing radioactive 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-11), which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET).
45783632|NCT04377152|Procedure|Positron Emission Tomography (PET)|A PET scan is an imaging test that helps reveal how your tissues and organs are functioning using a radioactive drug (tracer) to show this activity
45783633|NCT04378634|Behavioral|Exercise|Sub-maximal exercise test
45783634|NCT04378634|Other|Mental Stress Test|Computerised mental arithmetic challenges and social evaluative threat tasks
45783635|NCT03006575|Radiation|split-course radiotherapy|split-course chest radiation at 40-51 Gy/10-17f and 15-24 Gy/5-8f
45783636|NCT03006575|Drug|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
45783637|NCT03405506|Device|Quantitative Flow Ratio (QFR)|FFR measured by pressure wire, QFR computed by coronary angiographic images
45643504|NCT04417062|Drug|Olaparib|Olaparib is taken by mouth, twice daily through out the 28 day study cycle.
45643505|NCT04417062|Drug|Ceralasertib|Ceralasertib is taken by mouth, twice daily on days 1-14 of the study cycle.
45643506|NCT04416984|Genetic|ALLO-501A|ALLO-501A is an allogeneic CAR T cell therapy targeting CD19
45643507|NCT04416984|Biological|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
45783638|NCT03001193|Drug|DF 01|
45783639|NCT03001193|Drug|Oxytocin|
45783640|NCT03001193|Drug|Placebo|
45783641|NCT05517083|Diagnostic Test|Ultarthin bronchoscopy with intratumoral washing|Each subject with NSCLC will undergo bronchooscopic procedure. First, ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Then, intratumoral washing is performed. Subsequently, transbronchial lung biopsy is performed under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance.
45783642|NCT01049360|Drug|Aclidinium 400 μg / Formoterol 12 μg|Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
45783643|NCT01049360|Drug|Aclidinium 400 μg / Formoterol 6 μg|Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
45783644|NCT01049360|Drug|Aclidinium 400 μg|Aclidinium bromide 400 μg administered twice-daily (BID) for a 14 day period within four different treatment periods.
45783645|NCT01049360|Drug|Formoterol 12 μg|Formoterol fumarate 12 μg twice-daily for a 14 day period within four different treatment periods.
45783646|NCT01049360|Drug|Placebo|Placebo twice-daily delivered by inhalation for a 14 day period within four different treatment periods.
45783647|NCT02494596|Drug|Capecitabine|Participants will receive capecitabine on Days 1 to 14 of each 3-week cycle as 825, 1000, or 1250 mg/m^2 PO twice daily. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
45783648|NCT02494596|Drug|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 1050 mg via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
45783649|NCT03006653|Behavioral|Assessment only|Mobile ecological assessment only.
45783650|NCT01581437|Procedure|64 pole basket catheter|The 64 pole basket catheter expands into a small flexible balloon that conforms to the atrial anatomy.
45783651|NCT03405428|Other|Allen test|Before induction, with firm occlusive pressure held on both the radial and ulnar arteries, the patient is asked to clench his or her fist several times until the palmar skin is blanched. The patient is then instructed to unclench the fist, and then ulnar artery pressure is released while maintaining occlusion of the radial artery. Overextension of the hand and wide spreading of the fingers should be avoided because it can lead to falsely abnormal results. The time required for palmar capillary refill is noted. An abnormal Allen test result was defined as a recovery time of more than 10 seconds.
45783652|NCT03405428|Other|Radial artery diameter measurement by ultrasonography|Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the radial artery will be scanned. The diameter of the radial artery will be measured and recorded.
45783653|NCT03405428|Other|Ulnar artery doppler ultrasonography|Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the ulnar arter will be scanned. The blood fow of ulnar artery will be measured and recorded.
45917605|NCT03646123|Drug|nivolumab|240 mg by IV infusion
45917606|NCT03574402|Drug|Avitinib Maleate|300mg orally (PO) twice daily (BID) on day 1-28.
45917607|NCT03574402|Drug|Afatinib|40mg orally once a day, 28 days as one cycle.
45643508|NCT04416984|Drug|Fludarabine|Chemotherapy for lymphodepletion
45643509|NCT04416984|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
45643510|NCT04411914|Drug|Clavulanic Acid|Drug will be given in 250mg capsules.
45643511|NCT04411914|Other|Placebo|Placebo
45643512|NCT04411836|Drug|Tafenoquine|patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ).
45643513|NCT04411836|Drug|Primaquine|patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)
45643514|NCT04408755|Drug|AVP-786|oral capsules
45643515|NCT04408755|Drug|Placebo|oral capsules
45643516|NCT04401319|Device|Sham Stimulation for Crossover Study|Stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or the angular cortex (AG) using a sham coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.
45783654|NCT02494206|Drug|QBX258|Once patients are registered for the trial, they will be treated with QBX258 (VAK694 3mg/kg and QAX576 6mg/kg) delivered via peripheral intravenous injection once every 4 weeks (+ 1 week) for 4 treatments.
45783655|NCT01582139|Device|Heart rate informed SSM+HMM|The Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) of the Closed Loop is informed about heart rate during exercise. The goal is to demonstrate the feasibility of a modular insulin management system based on continuous glucose monitoring that additionally employs heart rate information to reduce exercise-related hypoglycemic episodes.
45917608|NCT03574402|Drug|Crizotinib|250mg PO QD on days 1-28. 28 days as one cycle.
45643517|NCT04401319|Device|DLPFC Stimulation for Crossover Study|Stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.
45917609|NCT03574402|Drug|X-396|225mg PO QD on days 1-28. 28 days as one cycle.
45917610|NCT03574402|Drug|Chidamide|30mg orally twice weekly, 28 days as one cycle.
45917611|NCT03574402|Drug|Pyrotinib Maleate|400mg PO QD on days 1-28. 28 days as one cycle.
45917612|NCT03574402|Drug|AZD3759|200mg PO BID on days 1-28. 28 days as one cycle.
45917613|NCT03574402|Drug|Pirotinib|60mg PO QD/40mg PO BID on days 1-28. 28 days as one cycle.
45917614|NCT03574402|Drug|Nimotuzumab|400mg, iv gtt. on day 1,8,15. 21 days as one cycle.
45917615|NCT03574402|Drug|Pemetrexed|500mg/m^2, iv gtt. Q3W. 21 days as one cycle.
45917616|NCT03574402|Drug|Cisplatin|75mg/m^2, iv gtt. Q3W on day1. 21 days as one cycle.
45917617|NCT03574402|Drug|Sintilimab|200mg iv gtt. Q3W on day1. 21 days as one cycle.
45917618|NCT03574402|Drug|Gemcitabine|1g/m^2 iv gtt. on day1,8. 21 days as one cycle.
45917619|NCT03574402|Drug|Gemcitabine|1.25g/m^2 iv gtt. on day1,8. 21 days as one cycle.
45917620|NCT03574402|Drug|Carboplatin|AUC5 iv gtt. Q3W on day1. 21 days as one cycle.
45917621|NCT03539302|Drug|Flecainide Acetate|Oral inhalation form using a nebulizer
45917622|NCT03524989|Device|Hyperbaric Oxygen Therapy|40 daily sessions, 60 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 2 months.
45917623|NCT03524989|Device|SHAM treatment|40 daily sessions, 60 minutes of 21% oxygen at pressure of 1.01 ATA each, five days a week for 2 months.
45917624|NCT03479203|Drug|Electronic Cigarette Aerosol|16 two-second-long puffs from a non-nicotinized electronic cigarette.
45917625|NCT03460483|Other|Genetic Counseling|Undergo genetic counseling
45643518|NCT04401319|Device|AG Stimulation for Crossover Study|Stimulation will be delivered on the left angular cortex (AG) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.
45783656|NCT01048502|Drug|Fenofibrate (Tricor) tablets|One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks
45783657|NCT01048502|Drug|Placebo|Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks
45643519|NCT04401319|Device|Sham Stimulation for Parallel Study|Stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or the angular cortex (AG) using a sham coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.
45917626|NCT03460483|Other|Genetic Testing|Undergo genetic testing
45917627|NCT03460483|Other|Laboratory Biomarker Analysis|Correlative studies
45917628|NCT03460483|Procedure|Mutation Carrier Screening|Undergo tumor screening via next-generation sequencing
45917629|NCT03458533|Procedure|Bariatric surgery|
45917630|NCT03458533|Behavioral|Diet and lifestyle changes|
45917631|NCT03423160|Other|None--observational|Observational study of behavior and electrical brain activity
45917632|NCT03404986|Procedure|ureteroscopy|The patients will be subjected to rigid ureteroscopy
45917633|NCT03404986|Radiation|Ultrasonography|The patients will be subjected to Ultrasonography
45917634|NCT00000831|Drug|Lamivudine|
45917635|NCT00000831|Drug|Stavudine|
45917636|NCT00000831|Drug|Zidovudine|
45917637|NCT00000831|Drug|Didanosine|
45917638|NCT03399136|Behavioral|Exercise training|Participants attended center-based exercise sessions three times per week at the research exercise training facility located at the Baltimore VA Medical Center. All exercise training was performed under the supervision of research exercise physiologists. Heart rate (HR) was measured continuously during each session using a Polar HR watch and chest strap allowing for assessment and maintenance of treatment fidelity. Exercise logs included details on exercise type, duration, time in target heart rate zone, blood pressure and perceived intensity during each training session.
45917639|NCT00000849|Drug|Aldesleukin|
45917640|NCT03357952|Drug|Daratumumab|Participants will receive daratumumab 16 milligram per kilogram (mg/kg) intravenously (IV) once every week for 8 weeks (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards).
45917641|NCT03357952|Drug|JNJ-63723283|Participants will receive JNJ-63723283 240 mg IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter.
45917642|NCT00000855|Drug|Zidovudine|
45917643|NCT03317392|Other|Laboratory Biomarker Analysis|Correlative studies
45917644|NCT03317392|Drug|Olaparib|Given PO
45783658|NCT01048502|Drug|Lovaza|900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.
45783659|NCT02465034|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim^2 paired pulse stimulator to measure transient cortical excitability. Single pulse transcranial magnetic stimulation applied at low frequencies (not greater than 0.25 hertz (Hz)) will be used. The may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
45783660|NCT02465034|Device|Traditional Paired Associative Stimulation|Paired associative stimulation (PAS) is a combination of transcranial magnetic stimulation (TMS) and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25 Hz for 12 minutes. Median nerve stimuli at 300% of the perceptual threshold will be applied 25ms prior to transcranial magnetic stimulation delivery over the ipsilesional (stroke) or non-dominant (control) cortex. Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This traditional paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
45783661|NCT02465034|Device|Median Nerve Stimulation|Stimulation of the median nerve will be performed using a bipolar bar electrode affixed to palmar aspect of the forearm proximal to the crease of the wrist bilaterally. Stimuli will be delivered 23ms prior to the transcranial magnetic stimulation (TMS) pulse with 0.1 milliseconds (ms) rectangular pulses at an intensity to evoke a 1 millivolt (mV) response in the abductor pollicis brevis (APB) muscle. This may may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
45783662|NCT02465034|Device|Corticocortical Paired Associative Stimulation|Cortico-cortical Paired Associative Stimulation (CC-PAS) is a combination of TMS and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25 Hz for 12 minutes. The interstimulus interval will range from 5-15 ms depending on site of stimulation.TMS will be performed using the Magstim BiStim^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This CC-PAS may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
45783663|NCT02465034|Device|Sham Paired Associative Stimulation|The sham PAS is a combination of TMS and electrical stimulation of the median nerve. The coil is rotated and separated from the head with a plastic spacer to ensure indirect contact with the head.180 paired stimuli are delivered at 0.25 Hz for 12 minutes. TMS will be performed using the Magstim BiStim^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This sham paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
45783664|NCT00918866|Drug|Definity|one bolus dose of Definity per intravenous injection, 30-60 second injection, dose value calculation = maximum of 10 microliter/kg patient weight
45783665|NCT02516982|Other|Whooley Questions|The Whooley questions are a case-finding instrument for depression in primary care. This 2-question instrument screens for depressed mood and anhedonia that have been present during the past month. Respondents are required to answer Yes or No to each of these questions. An affirmative answer to any of them should be followed by further assessment, including the use of a validated screening instrument or referral to a general practitioner or a mental health practitioner.
45783666|NCT02516982|Other|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-administered survey that screens for symptoms such as feelings of guilt, sleep disturbance, reduced energy levels, anhedonia and suicidal ideation that have been present during the 7 days preceding its administration. Each question is scored on a 4-point scale ranging from 0 to 3 points. Overall scores between 10 and 12 points suggest increased risk for depression; scores of 13 points or above indicate that the diagnostic criteria for major depression disorder have probably been met. In addition, item 10 deals with suicidal thoughts. The EPDS is a valid and reliable tool for identifying women at risk of depression, both during pregnancy and postpartum, and is sensitive to changes in the severity of depression over time.
45917645|NCT03317392|Other|Quality-of-Life Assessment|Ancillary studies
45917646|NCT03317392|Radiation|Radium Ra 223 Dichloride|Given IV
45917647|NCT03299179|Device|MRI scan|Several MRI scan modalities: MPRAGE (structural scan), arterial spin labeling (cerebral perfusion), resting state functional-MRI (fMRI, cerebral activity) and diffusion MRI (white matter diffusion and white matter tracts).
45917648|NCT03299179|Device|Physiological monitoring|During MRI: heart rate, end-tidal carbon dioxide (CO2), respiratory rate and skin conductance
45917649|NCT03299179|Biological|Blood sample|Blood sample after MRI-session: measurement of hematocrit, hemoglobin, estradiol, progesterone, follicle stimulation hormone and luteinizing hormone.
45917650|NCT03299179|Device|Blood pressure measurement|Measuring blood pressure before and after MRI-scan
45917651|NCT03299179|Device|Body temperature|Measuring body temperature before and after MRI-scan
45917652|NCT03299179|Other|Questionnaires|Questionnaires at the start of the study on lifestyle. Additionally, a questionnaire before each scan session on the actual state of the volunteer (e.g. mood, caffeine consumption, alcohol, medication, etc.)
45917653|NCT03299179|Diagnostic Test|Pregnancy test|Test for pregnancy using a pregnancy dipstick test
45643520|NCT04401319|Device|DLPFC Stimulation for Parallel Study|Stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.
45643521|NCT04401319|Device|AG Stimulation for Parallel Study|Stimulation will be delivered on the left angular cortex (AG) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.
45643522|NCT04396366|Drug|Active drug|QBW251 Capsule 300mg Oral use, one capsule twice daily.
45643523|NCT04396366|Drug|Placebo|Placebo Capsule 300mg Oral use, one capsule twice daily.
45783667|NCT02516982|Other|Momentary questions|These will consist of 5 questions on a 5-point pictorial scales, assessing participants' mood, sleep, energy, enjoyment and worry.
45783668|NCT02516982|Other|Contextual questions|Two questions asking for participants' location and activity at the time they were asked to complete the momentary questions.
45643524|NCT04395365|Drug|Co-Trimoxazole 960Mg Dispersible Tablet|Antibiotic prophylaxis of Spontaneous Bacterial Peritonitis
45783669|NCT01583543|Drug|Olaparib|400mg PO BID Continuous
45783670|NCT01724372|Drug|Antidepressant|
45783671|NCT01724372|Drug|Antipsychotic|
45643525|NCT04395365|Drug|Placebo oral tablet|Placebo
45783672|NCT00919100|Device|Buzzy|"Buzzy is a vibrating cold pack attached with Velcro strap or tourniquet 5-10cm proximal to the site of venipuncture. The vibration is activated and the device remains in place throughout the procedure. The distraction cards are offered to the parents to show the children, with questions on the back and pictures on the front."
45783673|NCT00919100|Other|vapocoolant|venipuncture with vapocoolant spray offered
45783674|NCT03405350|Procedure|Redon-sulfide baths|Encompassing whole body or isolated limbs - upper and/or lower limbs - temperature: 37-38 degrees Celsius, duration: 20 minutes.
45783675|NCT03405350|Procedure|Partial Mud Baths|duration: 20 minutes, temperature 40-42 degrees Celsius
45783676|NCT03405350|Procedure|Kinesiotherapy|It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min.
45783677|NCT03405350|Procedure|Terrain Therapy|walking, outdoors physical activities,
45783678|NCT03405350|Procedure|Dry Massage|Depending on the needs of each patient it involved cervical (CC), thoracic (TH), or lumbar spine (LS).
45783679|NCT03405350|Procedure|Laser Therapy|treatment parameters: sweeping, continuous, wavelength 808 nm, power 12 J, 400mV, duration 30s,
45783680|NCT03405350|Procedure|Low-frequency Magnetic Field|duration 20 minutes, impulse shape - rectangular, induction 5 mT, frequency 20-50Hz,
45643526|NCT04394858|Procedure|Biospecimen Collection|Undergo collection of blood samples
45643527|NCT04394858|Procedure|Computed Tomography with Contrast|Undergo CT with contrast
45643528|NCT04394858|Procedure|Magnetic Resonance Imaging|Undergo MRI
45643529|NCT04394858|Drug|Olaparib|Given PO
45643530|NCT04394858|Other|Quality-of-Life Assessment|Ancillary studies
45643531|NCT04394858|Drug|Temozolomide|Given PO
45643532|NCT04394546|Device|WATCHMAN FLX LAAC Device|WATCHMAN FLX LAAC Device Implantation
45643533|NCT04394546|Drug|Non-Vitamin K Oral Anticoagulant|Initiation or continuation of a NOAC drug
45643534|NCT04392635|Device|Trocar Placement Assist Device (TPAD)|The TPAD is an experimental device used to assist with placement of Veress needle and trocar during laparoscopic surgery.
45643535|NCT04389671|Drug|Lucinactant|Lucinactant administered as a liquid at a dose of 80 mg total phospholipids (TPL)/kg lean body weight delivered
45643536|NCT04389281|Combination Product|X-PACT|X-PACT is comprised of a phosphor device, the drug methoxsalen sterile solution and X-ray energy. The dose of methoxsalen sterile solution per injection will vary per patient and will remained fixed across injections within each patient as it is based on the applicable tumor volume at baseline. Immediately after each injection of the combination product, patients will be exposed to an X-ray beam delivered via a LINAC (and thus targeted at the tumor) at a fixed dose to activate the combination product.
45643537|NCT04388748|Behavioral|Stress Management and Resiliency Training for Depression (SMART-D) Therapy|6 SMART-D group therapy sessions over 8 weeks
45643538|NCT04386057|Drug|Hydroxychloroquine Sulfate|HCQ will be administered by mouth twice daily continuously throughout each treatment per 28 day cycle
45783681|NCT03405350|Procedure|Ultrasonotherapy|treatment parameters: 800kHz/6cm2 head, ultrasound impulse wave: 2ms - impulse, 9ms - break, dose 0.5-0.6 W/cm2 over 6 minutes,
45783682|NCT03405350|Procedure|Cryotherapy|ventilator, treatment duration 2-3 minutes, temperature - 80 to - 110 degrees Celsius,
45783683|NCT03405350|Procedure|Electrotherapy|Bernard's diadynamic currents - treatment parameters: DF1 CP4 LP4, Nemec interference currents (frequency range 0-100Hz), percutaneous electrostimulation (TENS) - rectangular impulse currents, impulse duration 0.2ms, frequency 40Hz, regulated current 0-100mA,
45783684|NCT03405350|Procedure|Light Therapy|blue filter Sollux lamp, radiation distance 30-40 cm, duration 15 minutes, Bioptron lamp - radiation distance 10 cm, duration 5-10 minutes
45783685|NCT02464410|Behavioral|Motivational intervention|The intervention session combines elements of motivational enhancement (ME) and cognitive behavioral therapy (CBT). Similar to other ME brief interventions, the intervention content will be covered in a single session. Participants are presented with a variety of risk reduction strategies and strategies for coping with pain that may reduce reliance on opioids for managing pain.
45783686|NCT02464410|Behavioral|Psycho-educational control|The educational control condition provides educational content related to the biology of pain response and an overview of pain conditions. The overall style is didactic.
45783687|NCT02464410|Other|Long-term opioid therapy informed consent|The Veterans Health Administration instituted a requirement that all patients receiving long-term opioid therapy receive an informed consent process that reviews the risks of opioid therapy. All individuals eligible for this study will meet this definition of long-term opioid therapy. The study therapists for both study arms will deliver the informed consent process during the sessions as part of treatment as usual.
45783688|NCT03006419|Drug|Basiliximab|Standard induction therapy
45783689|NCT03006419|Drug|Thymoglobulin|Induction therapy
45783690|NCT04956978|Other|Patient Decision Support Tool|Patient decision support tool is a web based educational material that informs a patient on the risk and benefits of oral anticoagulation. In addition, such a tool aims to assess patient values and preferences in the decision making process for oral anticoagulation for stroke reduction.
45783691|NCT03000881|Other|standard adhesive|This is a standard adhesive (hydrocolloid)
45783692|NCT03000881|Other|New adhesive strip|This is a newly developed adhesive strip
45783693|NCT01047332|Device|Partially Covered Wallstent|Partially covered wallstent
45783694|NCT01047332|Device|Uncovered Wallstent|Uncovered wallstent
45917654|NCT03285880|Behavioral|Napping|Children nap during the nap opportunity
45917655|NCT00000867|Drug|Memantine|
45783695|NCT03006497|Other|Exercise program based on motor learning principles|The exercise program will include simple activities exposing volunteers in various environmental conditions with a view to adjust their head posture in such conditions. The progressiveness of exercises will be based on the two-dimensional classification system of Gentile (1987). Furthermore, external attentional focus will be used.
45783696|NCT03405272|Biological|Recombinant Anti-EGFR Monoclonal Antibody（SCT200）|Experimental: recombinant anti-EGFR monoclonal antibody（SCT200） Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
45783697|NCT03006263|Procedure|Totally Laparoscopic Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Totally Laparoscopic Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
45783698|NCT03006263|Procedure|Laparoscopy Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Laparoscopy Assisted Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
45783699|NCT03000647|Procedure|Pelvic floor exercises guided by a physiotherapist|Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day and once a week they check it with a physiotherapist (this day only they do it twice at home)
45783700|NCT03000647|Procedure|Non guided pelvic floor exercises|Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day. They do not attend to meetings with a physiotherapist
45783701|NCT03405194|Drug|Elvitegravir, Cobicistat, TAF, FTC|Started on day of HIV diagnosis
45783702|NCT03405194|Drug|Efavirenz, TDF, and 3TC|Started on day of HIV diagnosis
45643539|NCT04386057|Drug|LY3214996|LY3214996-daily oral dosage per protocol per 28 day cycle
45783703|NCT03006107|Procedure|intraligamentary injection piroxicam|"intraligamentary injection Piroxicam is another NSAID that which has the ability for the treatment of pain, fever and inflammation in the body , has a half-life of 50h in the plasma , oral piroxicam reaches a peak concentration in the plasma within 2 to 4 hours .~The needle will be placed in the gingival sulcus at a 30- degree angle to the long axis of the tooth then apical pressure is applied until the needle wedged into the periodontal ligament between the tooth and the alveolar crest of the bone"
45783704|NCT03006107|Procedure|Intraligamentary mepevacaine|mepevacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to brain . It is also used as an anesthetic for dental procedures.
45783705|NCT01046396|Drug|adapalene cream 0.1% and adapalene lotion 0.1%|adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks
45783706|NCT01046396|Drug|adapalene lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
45783707|NCT01586039|Device|Visible light|We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime. We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
45643540|NCT04383457|Device|RIA-device (Remote Investigation and Assessment)|The investigated new system consists of a high-speed digital video camera, a digital radiometric infrared camera, LED lights and a computer for data recording. This system faces the subject at a distance of approximately one meter, capturing a 30 second recording of the subject's face.
45783708|NCT01046084|Drug|Lansoprazole|30 mg Delayed-Release Capsule
45783709|NCT01046084|Drug|Prevacid®|30 mg Delayed-Release Capsule
45783710|NCT01586741|Procedure|Quill suture application for repair or polypropylene mesh|The first arm may be insertion of the-mesh The second arm may double row- suture The third arm may be conservative -training
45783711|NCT01045694|Drug|Botulinum Toxin Type A|One-time injection of 50 units of Botulinum Toxin A suspended in 2 mL of normal saline, with approximately 1 mL injected or sufficient quantity to fill joint capsule
45783712|NCT01045694|Drug|Steroid - Triamcinolone Acetonide|Single injection of 1 - 3 mL of 40mg/mL Triamcinolone acetonide solution
45783713|NCT01045694|Drug|Lidocaine|Single injection of 1 - 3 mL of 2% Lidocaine
45783714|NCT01586897|Device|Medication Metronome|Providers allocated to intervention will see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.
45783715|NCT01586897|Other|Usual Care|
45783716|NCT04378712|Device|Hydrogen Oxygen Generator with Nebulizer|Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge.
45783717|NCT04378712|Other|Standard-of-care|Standard-of-care consisted of the supportive therapies (including oxygen therapy) recommended by the Chinese National Health Commission
45783718|NCT04378556|Behavioral|Nutritional coaching|Participants were provided with nutrition education and a per-meal protein prescription followed by 9 weeks of nutritional coaching.
45783719|NCT03404492|Other|Stress echocardiography|A stress echocardiography will be performed in addition to the traditional patient care
45643541|NCT04381494|Device|Multiparametric Mobile Technology|Using a spirometer, an armband, and a tablet to collect data.
45643542|NCT04380545|Drug|Fluorouracil|Given IV
45783720|NCT01586975|Drug|Clopidogrel|Clopidogrel 75 mg QD
45783721|NCT01586975|Drug|Aspirin 81 mg|Aspirin 81mg QD
45783722|NCT01586975|Drug|Aspirin >300 mg|Aspirin >300 mg QD
45643543|NCT04380545|Biological|Nivolumab|Given IV
45643544|NCT04380545|Biological|Recombinant Interferon Alpha 2b-like Protein|Given SC
45643545|NCT04368559|Drug|Rezafungin for Injection|Intravenous antifungal therapy
45643546|NCT04368559|Drug|Posaconazole|Oral antifungal therapy
45643547|NCT04368559|Drug|Fluconazole|Oral antifungal therapy
45783723|NCT01724840|Procedure|GraftJacket|Interposition with GraftJacket
45643548|NCT04368559|Drug|Trimethoprim-sulfamethoxazole (TMP/SMX)|Oral antibacterial therapy
45783724|NCT01724840|Procedure|Tendon Interposition|Tendon Interposition with the FCR tendon
45783725|NCT03000413|Drug|Ketamine|Active treatment
45783726|NCT03000413|Drug|Fentanyl|
45783727|NCT01724918|Drug|Lacosamide|
45783728|NCT03000725|Behavioral|Using Practice and Learning to Increase Favorable Thoughts|"Description of the UPLIFT program: Participants who choose to participate in UPLIFT will complete 8 weekly group sessions via telephone.~Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping & Relaxing Session 4: Attention & Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure & the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks"
45783729|NCT03000725|Behavioral|Usual Care|Participants randomized to the UC group will receive printed educational materials on management of epilepsy in English or Spanish as preferred.
45598222|NCT02358291|Procedure|open discectomy|The open discectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
45783730|NCT01724996|Other|Clinical examination: chest wall tenderness|The physical examination includes the testing of chest wall tenderness: Palpation of chest wall tenderness in lying 30° elevation of chest position. Flat index with standardized pressure where spontaneous maximum pain is reported (reproducible vs. not reproducible pain vs. no pain). Negative control (right side of chest mid-clavicle intercostal 6/7), reproducible vs. not reproducible pain vs. no pain.
45783731|NCT03000491|Other|No intervention|
45643549|NCT04368559|Drug|Intravenous Placebo|Normal saline
45643550|NCT04368559|Drug|Oral Placebo|Microcrystalline cellulose
45643551|NCT04365868|Drug|belapectin|intravenous
45643552|NCT04365868|Drug|Placebo|intravenous
45643553|NCT04364048|Drug|Induction Durvalumab|Induction durvalumab at 1500 mg intravenously (IV) will be given on Day 1 of a four week cycle for 1 cycle,
45783732|NCT01588457|Drug|Lithium|Therapeutic dosage as indicated by participants condition with blood levels. LI will be dosed to attain Li of ≥0.5mEq/L (milliequivalents per liter).
45783733|NCT01588457|Drug|Divalproex|DV will be dosed to attain DV levels of ≥45mg/L.
45783734|NCT01588457|Drug|Lamotrigine|LM will be incrementally dosed up to 400 mg/day, or, in combination with DV, 200 mg/day. Dosage may be reduced for adverse effects to one half of the target dose.
45783735|NCT01588457|Drug|Quetiapine|QT will be started at 50 mg/day and titrated up to 300 mg as tolerated. QT will be discontinued if not tolerated at 100mg/day and the patient will be treated according to guidelines.
45783736|NCT01589315|Device|focal ECT|FEAST, ECT, unidirectional stimulation
45783737|NCT04377776|Other|Practice details|Questionnaire
45598223|NCT02358291|Procedure|microendoscopic discectomy|Microendoscopic discectomy combines standard lumbar microsurgical techniques with endoscope, enabling surgeons to successfully address free-fragment disc pathologic factors and lateral recess stenosis.
45598224|NCT02358291|Procedure|transforaminal endoscopic lumbar discectomy|transforaminal endoscopic lumbar discectomy removes the intervertebral disc portion through the intervertebral foramen
45598225|NCT02290327|Drug|Pantoprazole|Proton pump inhibitor
45598226|NCT02290327|Drug|Placebo|50 ml of 0.9% normal saline
45598227|NCT02750813|Device|Delefilcon A contact lenses|
45598228|NCT02750813|Device|Senofilcon A contact lenses|
45643554|NCT04364048|Drug|Chemotherapy|Concurrent chemoradiation will be with platinum-based chemotherapy (cisplatin or carboplatin, with etoposide, taxane, or pemetrexed) selected at the treating physician's discretion. The chemotherapy regimen used should be administered per institutional standards following the prescribing guidelines for each drug
45754331|NCT04405856|Device|Intra Aortic Balloon Pump|Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle.
45783738|NCT03006029|Drug|TAB08|The initial dose of TAB08 will be 1 µg/kg TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.
45783739|NCT04377854|Other|Observation. No intervention per se.|Observation. No intervention (no collection of blood).
45783740|NCT04377854|Other|2) Observation and collection and of blood sample|All patients evaluated for adv HF (HTX/LVAD) will be offered to contribute to this database; Blood samples will be collected from all at baseline. Patients receiving LVAD will contribute on a yearly basis (or until withdrawal of consent). For other patients no further blood will be collected unless they receive an LVAD at a later point.
45783741|NCT04377698|Biological|Platelet Rich Fibrin|regeneration, restoration or reconstitution of the lost periapical tissues of the tooth by using regenerative therapies that utilize growth factors and barrier membranes.
45598229|NCT02358213|Procedure|Ultrasound|Ultrasound examinations are done 5 times
45598230|NCT02290561|Procedure|SmartTarget Therapy|MRI to Ultrasound fusion directed HIFU
45783742|NCT04377698|Biological|FDBA|regeneration, restoration or reconstitution of the lost periapical tissues of the tooth by using regenerative therapies that utilize growth factors and barrier membranes.
45783743|NCT03005873|Drug|TLC599 LD group|Single dose via intra-articular injection
45783744|NCT03005873|Drug|Normal Saline|Single dose via intra-articular injection
45783745|NCT03005873|Drug|TLC599 HD group|Single dose via intra-articular injection
45783746|NCT03005639|Drug|Vemurafenib and Cobimetinib|All participants will receive study treatment for up to 56 days (8 weeks). After completing treatment, they will undergo a lymph node removal surgery. After surgery, they will have follow-up visit 2-4 weeks after surgery.
45783747|NCT03005795|Device|Headphones|Music can be heard through headphones
45783748|NCT03005795|Other|No Headphones|No Headphones will be used.
45783749|NCT01044290|Other|Life Completion|Subjects discussed life review, issues of forgiveness and heritage and legacy.
45783750|NCT01044290|Other|Attention Control|Subjects listened to a non-guided relaxation CD
45783751|NCT01590875|Drug|Adenosine arm|In the adenosine arm, 25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose. In the observation arm, 25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation.
45783752|NCT03404414|Drug|18F-FDG|"Single-dose 18F-FDG were injected into the patients before the PET/MR or PET/CT scans.~patients before the PET/CT scans"
45783753|NCT01591655|Drug|Mapracorat|1 drop of study medication into the study eye four times daily (QID) for 14 days
45783754|NCT01591655|Drug|Vehicle|1 drop of vehicle into the study eye QID for 14 days.
45783755|NCT00916136|Procedure|Femoral Traction|Femoral Traction is a temporary intervention to realign the broken bone and help relieve pressure and muscle spasms until operative fixation.
45783756|NCT01725074|Behavioral|"Case Management CM CHD"|"Patients, who are randomized to the intervention group, will receive case management from a trained and experienced physician assistant. The case manager will carry out following tasks:~Biweekly/monthly telephone consultations or home visits~Identification of health or personal problems of the patient~Monitoring of medical parameters~Coordination of contact with health care providers if necessary~Support to the patient related to health status and environmental changes~Promote disease-self management through coaching~Counseling, that is focused on emotional support and active listening"
45783757|NCT01725074|Behavioral|Social Interaction|Identical as the CM CHD group, but with exclusion of medical control measures and the medical aspects.
45783758|NCT01725230|Drug|Fostamatinib|100-mg tablet
45783759|NCT01725230|Drug|Rosuvastatin|20-mg tablet
45783760|NCT01725230|Drug|Simvastatin|40-mg tablet
45783761|NCT01591733|Drug|FOLFIRINOX|Up to Eight-14 day cycles
45783762|NCT01591733|Drug|Capecitabine|Orally, for 10 days
45783763|NCT01591733|Radiation|Short Course Radiation|Five or ten days
45643555|NCT04364048|Radiation|Radiation|Treatment will be delivered using IMRT or 3DCRT using typically 6-10MV photons per institutional standards. 4D simulation and appropriate IGRT are encouraged. Radiation therapy must begin within one week of the first day of chemotherapy (or vice versa). Therapy will be 1.8-2 Gy per day; 5 days per week, excluding holidays per institutional standard as this is a standard of care regimen for this patient population. 54-66 Gy will be delivered.
45643556|NCT04364048|Drug|Consolidation durvalumab|Durvalumab at 1500 mg intravenously (IV) will be given on Day 1 of a four week cycle for 12 cycles
45643557|NCT04358458|Biological|GEN3009|GEN3009 will be administered by intravenous (IV) infusion in cycles of 28 days
45783764|NCT01591733|Procedure|Surgery|1-4 weeks after completion of capecitabine therapy
45783765|NCT03005561|Behavioral|Play Back Sessions|"100 participants that will be participating in two Play Back meetings. Playback define that improvisation as a theater facilitator asks the audience to share moments, feelings and stories of his daily life, and a group of actors improvise their stories in front of the stage as a kind of play-back. Unlike hobbies such as sports or singing, the method allows not only to unload the tensions but also communication and collaboration. It is very reminiscent of psychodrama, but unlike, is not considered a therapeutic tool."
45783766|NCT03005405|Procedure|Ionomer Restoration (control)|Restoration of moderate caries lesions after partial caries removal using high viscosity glass ionomer cements
45917656|NCT00390676|Drug|ADH -1 and carboplatin|
45917657|NCT00390676|Drug|ADH -1 and docetaxel|
45598231|NCT02290561|Device|MRI|
45598232|NCT02290561|Device|high intensity focused ultrasound (HIFU)|
45783767|NCT03005405|Procedure|Ionomer Sealant (test)|Sealing of moderate caries lesions without any caries removal or cavity opening.
45783768|NCT03005405|Procedure|Oral hygiene orientation and professional fluoride application|Oral hygiene orientation and professional fluoride application
45783769|NCT03005717|Drug|LIPO-202|
45783770|NCT03005717|Drug|Placebo for LIPO-202|Lyophile manufactured to mimic LIPO-202 lyophile.
45598233|NCT02373267|Biological|Technozyme|determination of ADAMTS13 activity
45598234|NCT02222051|Behavioral|Tai Chi|traditional chinese martial art meditative movement technique
45598235|NCT02222051|Behavioral|Neck exercises|group exercises for strengthening and stretching neck and back muslces to alleviate neck pain
45598236|NCT02372955|Drug|dapagliflozin|subjects will be randomly assigned to receive dapagliflozin 10 mg daily
45783771|NCT02999243|Behavioral|HIV self-testing|The intervention group will be offered HIV self-testing kits for testing HIV status
45783772|NCT02999243|Behavioral|Harm reduction education|Both arms will receive harm reduction education
45783773|NCT03005483|Drug|Gabapentin|Orthopedic Surgery was applied for the treatment of osseous disorders
45783774|NCT03005483|Other|Placebo|Orthopedic Surgery was applied for the treatment of osseous disorders
45783775|NCT01593215|Drug|Yohimbine|Yohimbine capsule
45917658|NCT00390676|Drug|ADH -1 and capecitabine|
45917659|NCT00390715|Drug|chemotherapy|
45917660|NCT00390754|Behavioral|Education for pregnancy planning|Provision of free home pregnancy tests to women at risk for unintended pregnancy
45917661|NCT00000870|Drug|Indinavir sulfate|
45598237|NCT02372955|Drug|glimpiride|subjects will be randomly assigned to receive glimpiride 4 mg daily
45598238|NCT02211053|Drug|Levothyroxine|20 mg IV bolus + 10 mg/h infusion
45783776|NCT05511155|Other|Oxygen therapy|Oxygen therapy will be given for 15 minutes with a non-rebreathing mask.
45783777|NCT05423483|Behavioral|Safe Home Text Message Reminders|Text messages sent 2x a week with reminders to keep lethal means restricted and surveys of lethal means practices that serve as a prompt to adhere to suggested restriction measures.
45783778|NCT05504681|Other|Observational study|It takes the patient on average 15 minutes to complete the Brainlab Cognition app.
45917662|NCT00000870|Drug|Lamivudine|
45917663|NCT00000870|Drug|Stavudine|
45917664|NCT00000870|Drug|Zidovudine|
45917665|NCT00000870|Drug|Didanosine|
45917666|NCT00000870|Drug|Aldesleukin|
45643558|NCT04358458|Biological|Epcoritamab|Epcoritamab will be administered by subcutaneous (SC) injections in cycles of 28 days
45643559|NCT04355819|Behavioral|Disclosure timing|When patients are told that a hernia was present on the CT scan
45783779|NCT05504135|Diagnostic Test|Pharmacogenomics Testing|To test if pharmacogenomics information (produced from testing) included by us in the Raffles' Electronic Health Records (EHR) will be used by physicians to personalize patients' prescriptions.
45783780|NCT01594385|Biological|Seprafilm|"Two sheets of the Seprafilm material will be applied at each reoperation. Each sheet will be cut into 1x1 inch squares and applied to the following anatomic areas:~Two Seprafilm pieces between the liver and the anterior abdominal wall~Four pieces over the exposed bowel surfaces anteriorly~Two slightly staggered pieces of Seprafilm in each colic gutter~Two pieces in the pelvic area.~If any of the above areas involve an anastomosis or bowel repair, then the Seprafilm should be placed at least 1 inch away from the anastomosis and/or bowel repair."
45449049|NCT02155894|Behavioral|Disease control, Telemedicine, doctor|"Control of disease activity by a telemedicine consultation carried out by a doctor.~The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.~Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.~During telephone consultation, updated clinical test results will be available through the electronic medical system."
45783781|NCT05404919|Drug|Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide|Anti-hepatitis B medications
45643560|NCT04350359|Device|Variable-dose TTNS Protocol 5 x week|Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
45783782|NCT03005249|Procedure|neural stem cells therapy group|The patients will be assigned to neural stem cells therapy group for cerebral palsy.
45783783|NCT03005249|Other|the control group|The patients will be assigned to the control group for cerebral palsy.
45783784|NCT03005327|Drug|X4P-001|Mavorixafor will be provided as either 25 mg or 100 mg capsules.
45783785|NCT05329961|Drug|Gardasil9|The Gardasil 9 vaccine is a recombinant L 1 VLP vaccine containing HPV types 6, 11,16,18, 31, 33, 45, 52 and 58 VLP. The vaccine is not currently licensed for children under 9 years of age but it is licensed in the USA for males and females ages 9 to 45 years old.
45783786|NCT02247323|Other|Risk of malignancy index|Calculation of RMI before sugery.
45783787|NCT03005015|Drug|Lenvatinib|
45783788|NCT03005015|Drug|Doxorubicin|
45783789|NCT03005171|Drug|Bupivacaine|Thoracic epidural bupivacaine infusion
45917667|NCT00390832|Drug|Erythropoietin|33.333 IU of recombinant human erythropoietin beta are given at 3 time points (immediately, 24 hours and 48 hours after percutaneous coronary intervention) providing a cumulative dose of 100.000 IU
45598239|NCT02211053|Drug|placebo|
45598240|NCT02358057|Drug|Dexmedetomidine|
45598241|NCT02358057|Drug|Alfentanil|
45598242|NCT02225093|Drug|Caffeine|Oral
45643561|NCT04350359|Device|Fixed-dose TTNS Protocol|Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes. This will continue at 5x weekly until 1-year post-injury.
45783790|NCT03005171|Drug|Lidocaine|Intravenous lidocaine infusion
45598243|NCT02225093|Drug|Dextromethorphan|Oral /.L
45598244|NCT02225093|Drug|Enzalutamide|Oral
45783791|NCT03005093|Other|CAREGIVERS|The Turkish Feeding/Swallowing Impact Survey will be completed by the caregivers
45783792|NCT03005093|Other|CHILDREN OF CAREGIVERS|Chewing performance with Karaduman Chewing Performance Scale, tongue control with Tongue Thrust Rating Scale, dysphagia symptom severity with the Pediatric version of the Eating Assessment Tool will be evaluated. These assessments will be done before and after swallowing rehabilitation program.
45783793|NCT05310617|Other|Survey|Survey on the parental project and its realisation
45917668|NCT00390832|Other|Placebo|Patients will receive placebo immediately, 24 hours and 48 hours after percutaneous coronary intervention.
45917669|NCT00390871|Drug|Fentanyl/Dexmedetomidine|
45917670|NCT00390871|Drug|Fentanyl/Propofol|
45598245|NCT02225093|Drug|Enzalutamide Placebo to Match (PTM)|Oral
45598246|NCT02212535|Drug|Plerixafor|0.24 mg / kg / day, by subcutaneous injection, 11h before the beginning of cytapheresis
45598247|NCT02372487|Drug|sildenafil citrate|sildenafil citrate 25 mg every 8 hours
45598248|NCT02372487|Dietary Supplement|fluid therapy|2 liters of fluid per day
45783794|NCT05566613|Radiation|Blood sample|Blood sample before and after radiotherapy and photography before radiotherapy
45783795|NCT05566535|Drug|Ruxolitinib|Ruxo will be administered to patients with PV in a real-world setting. Treatment with Ruxo is according to local approved label. Ruxo treatment should be administered according to drug official instruction and in compliance with clinical practice at the certain medical center.
45783796|NCT05566457|Drug|Huangqi Guizhi Wuwu decoction (HGWD) infusion packs|Patients in the HGWD group (n = 46) soaked and washed Immersion and Washing limbs with HGWD infusion packs, followed by smearing limbs with vitamin E and vitamin B12. The composition of HGWD infusion pack was: 60g Radix Astragali (Huangqi), 15g Ramulus Cinnamomi (Guizhi), 15g Paeonia lactiflora (Baishao), 15g Gentiana (Qinjiao), 6g Scorpio (Quan-Xie), 20g Rhizoma Zingiberis Recens (Shengjiang), 20 Jujubes (Dazao), 30g Geranium wilfordii (Laoguancao), 12g radix sileris (Fangfeng), 30g Spatholobus suberectus (Jixueteng), 15g Ligusticum (Chuanxiong), 15g Poria (Fuling), and 15g Radixcyathulae (Chuanniuxi). HGWD infusion pack was boiled in water and extraction was performed twice to obtain a total of 500 ml drug-containing water. The drug-containing water was maintained at 39 to 40℃ for soaking and washing limbs for 20min twice a day for consecutive 14 days
45917671|NCT00390871|Drug|Fentanyl|
45783797|NCT03004937|Other|Family Medicine Hearing Loss Best Practice Alert|A Best Practice Alert, or BPA, was created in the electronic medical record system, which fires when patients meet the inclusion criteria. It reminds providers to ask their patients if they think have a hearing loss and allows them to respond as needed (refer to audiology, add hearing loss to the problem summary list, or dismiss for one year).
45783798|NCT03004781|Behavioral|Parenting program|
45783799|NCT05147909|Dietary Supplement|Sodium Phosphate|Sodium Phosphate 2 capsules daily (containing a total of 500 mg of Pi, 372mg of sodium)
45783800|NCT05147909|Dietary Supplement|Sodium Chloride|Sodium Chloride 2 capsules daily (NaCl, containing a total of 372mg of sodium)
45783801|NCT01041638|Biological|Aldesleukin|Given IV
45783802|NCT01041638|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
45783803|NCT01041638|Biological|Dinutuximab|Given IV
45783804|NCT01041638|Drug|Isotretinoin|Given PO
45783805|NCT01041638|Biological|Sargramostim|Given IV or SC
45783806|NCT03004625|Drug|daclatasvir|to evaluate the treatment efficacy and safety of the drug in HCV patients
45783807|NCT03004625|Drug|asunaprevir|to evaluate the treatment efficacy and safety of the drug in HCV patients
45449050|NCT02155894|Behavioral|Disease control, Telemedicine, nurse|"Control of disease activity by a telemedicine consultation carried out by a nurse.~The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.~Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.~During telephone consultation, updated clinical test results will be available through the electronic medical system."
45643562|NCT04350359|Device|Variable-dose TTNS Protocol 2 x week|At the 4 month CMG, subjects initially randomized into the variable dose protocol of 2 x weekly will start doing so for the remainder of the study.
45643563|NCT04350138|Biological|Meningococcal Group B Vaccine|A combination vaccine consisting of rMenB and OMV NZ.
45643564|NCT04350138|Other|Placebo|150mM sodium chloride (0.9% saline solution).
45643565|NCT04338815|Other|Exoskeleton optimization|Participants will walk 10 times 1 minute while an optimization algorithm changes the assistance profile of an exoskeleton.
45643566|NCT04338815|Other|Endurance evaluation|Participants will walk 2 times at a speed of 1 meter per second until the participant indicates claudication or a maximum duration of 6 minutes.
45783808|NCT03004625|Drug|Ribavirin|to evaluate the treatment efficacy and safety of the drug in HCV patients
45783809|NCT03004703|Drug|Tocilizumab|Active drug: Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
45783810|NCT03004703|Drug|Sodium chloride 0.9%|Placebo: Sodium chloride 0.9%; 100 ml i.v. once.
45783811|NCT03404102|Device|Cu-IUD|Copper Intra-uterine device used as contraceptive method
45783812|NCT05566301|Drug|Clopidogrel|All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel
45783813|NCT05566301|Drug|Ticagrelor|All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel
45783814|NCT03404024|Biological|Stage 1-Low dose VM202RY|Day 0: 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY)
45783815|NCT03404024|Biological|Stage 1-Middle dose VM202RY|Day 0: 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY)
45783816|NCT03404024|Biological|Stage 1-High dose VM202RY|Day 0: 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY)
45449051|NCT02153320|Procedure|Blood Sampling|Single blood sample taken from subjects who had participated in the study 287615 (NCT00508833).
45643567|NCT04338269|Drug|Atezolizumab|Atezolizumab 1200 mg will be administered at a fixed dose on Day 1 of each 21-day cycle by IV infusion every 3 weeks.
45643568|NCT04338269|Drug|Cabozantinib|Cabozantinib 60 mg (three 20-mg tablets) administered orally once daily.
45643569|NCT04336098|Drug|SRF617|SRF617 prevents CD39 mediated conversion of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to adenosine monophosphate (AMP) and phosphate, leading to an increase in extracellular ATP and a reduction in adenosine levels within the tumor microenvironment (TME). There is an important role for extracellular ATP and adenosine in cancer maintenance and progression, and maintaining high levels of ATP (and low levels of adenosine) in the TME may have anticancer therapeutic activity.
45643570|NCT04336098|Drug|Gemcitabine|Gemcitabine as an intravenous (IV) infusion
45643571|NCT04336098|Drug|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel as an IV infusion
45643572|NCT04336098|Drug|Pembrolizumab|Pembrolizumab as an IV infusion .
45783817|NCT03404024|Drug|Stage 2-Placebo|Day 0: 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl)
45783818|NCT03404024|Biological|Stage 2-Low dose VM202RY|Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY)
45783819|NCT03404024|Biological|Stage 2-High dose VM202RY|Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
45783820|NCT03404024|Device|C-Cathez® Catheter|Day 0 (Stage 1-Low dose VM202RY): 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-Middle dose VM202RY): 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-High dose VM202RY): 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 2-Placebo): 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl) Day 0 (Stage 2-Low dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY) Day 0 (Stage 2-High dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
45783821|NCT05131919|Drug|Pembrolizumab|Treatment with pembrolizumab 200 mg intravenously on day 1 of each 3-week cycle. Treatment will be continued for a maximum duration of 2 years, or until the tumor becomes resectable.
45783822|NCT01725464|Device|oxygen cannular|Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
45783823|NCT01725542|Drug|Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a|
45917672|NCT03211741|Drug|Bevacizumab Injection [Avastin]|Bevacizumab 1.25mg/0.05 mL will be injected intravitreally using one 30-gauge x 1/2-inch injection needle vials are for single eye use only.
45917673|NCT03206203|Drug|Atezolizumab|Given by vein
45783824|NCT05672849|Device|Modified Surgical Instruments/Devices (Sheaths and Irrigator)|Patients who choose to undergo fetoscopic surgery will be offered participation in this study. All patients will undergo a fetoscopic repair of the fetal open neural tube defect with the use of the modified devices in this study.
45783825|NCT02247869|Drug|dose dense ABVD|"dose dense ABVD will be administered intravenously on day 1 and 8 every 21 days Chemotherapy regimen~Doxorubicin 25 mg/m2 i.v. day 1 and 8~Bleomycin 10 mg/m2 i.v. day 1 and 8~Vinblastine 6 mg/m2 i.v. day 1 and 8~Dacarbazine 375 mg/m2 i.v. day 1 and 8~Granulocyte colony-stimulating factor (G-CSF): days 9 to 14"
45783826|NCT05048459|Other|Standard surveillance|Participant coming to the clinic for in-person follow-up visits and having routine endoscopy and cancer imaging procedures as needed
45783827|NCT05048459|Other|Telemedicine surveillance (tele-surveillance)|The tele-surveillance visit occurs annually after completion of therapy and consists of a phone call with or without video conferencing between the patient and the treatment team (physician, nurse, and/ or nurse practitioner). The use of video conferencing is strongly encouraged. Clinic visits, endoscopies, and imaging studies can be performed at the discretion of the treatment team for concerning patient symptoms.
45783828|NCT05048459|Other|Questionnaires|EORTC QLQ-C30 and EORTC QLQ-HN43 at 12 and 24 months, FACE-Questionnaire Module, Telehealth Usability Questionnaire, Telehealth Usability Questionnaire, Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction -Patient Satisfaction inventory
45783829|NCT00914186|Drug|TS022|Lotion
45643573|NCT04333537|Procedure|Computed Tomography (CT)|Undergo SPECT/CT scan
45783830|NCT00914186|Drug|Vehicle|Lotion
45643574|NCT04333537|Drug|Imaging Agent|Receive imaging agent via injection
45643575|NCT04333537|Procedure|Neck Dissection|Undergo standard elective neck dissection
45783831|NCT05046353|Drug|D-serine|Auditory remediation +/-D-serine
45783832|NCT05046353|Other|Placebo|Auditory remediation +/-D-serine
45783833|NCT05672771|Behavioral|Different Mixed Condition (DM)|Participants engage in home-based training on two working memory tasks, both different from those in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.
45783834|NCT05672771|Behavioral|Different Single Condition (DS)|Participants engage in home-based training on a working memory task that is different from that in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.
45783835|NCT05672771|Behavioral|Same Task (ST) Practice Control|Participants engage in home-based training on the exact same working memory tasks as that in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.
45783836|NCT05672771|Behavioral|Non-WM Placebo Control (PC)|Participants engage in home-based training on speeded verbal decision, which unlike the target task training, has no memory component. Goal is 10 days of training, with 4 8-min blocks of training each day.
46070852|NCT04523779|Behavioral|Brief Cognitive Behavioral Therapy|The proposed bCBT treatment for anxiety was specifically designed for use within VA PCMHI settings and uses a patient-centered approach to increase engagement while addressing the mental health needs of anxious Veterans. Emphasis was placed on maximizing intervention potency and minimizing intensity and duration to improve implementation value and alignment with VA PCMHI requirements. The intervention directly addresses challenges to delivery of CBT providing 1) a brief, practical model of care to address multiple anxiety conditions consistent with the PCMHI model (e.g. 4-6 sessions; measurement-based care), and 2) a clinically potent intervention that includes exposure-based skills.
45449052|NCT00122681|Biological|Cervarix™|Intramuscular injection, 3 doses
45449053|NCT00122681|Biological|Havrix™-based investigational formulation|Intramuscular injection, 3 doses
45449054|NCT02774278|Drug|Erlotinib|Erlotinib will be administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death.
45643576|NCT04333537|Procedure|Planar Imaging|Undergo planar imaging
45643577|NCT04333537|Procedure|Sentinel Lymph Node Biopsy|Undergo SLN biopsy
45643578|NCT04333537|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT scan
45783837|NCT03403868|Diagnostic Test|conductance catheter|pressure volume loops are assessed via a special catheter (Conductance catheter)
45643579|NCT04328727|Drug|eltrombopag|Tablet 25mg and 12.5mg
45643580|NCT04328727|Drug|rabbit anti-thymocyte globulin (r-ATG)|r-ATG 25 mg sterile lyophilized powder in 10 mL vials for IV use
45643581|NCT04328727|Drug|cyclosporine A (CsA)|CsA 25mg Capsule or CsA 5.0g/50mL solution for oral use
45643582|NCT04324112|Drug|binimetinib|Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.
45783838|NCT01725620|Drug|LBEC0101 (Etanercept 25mg)|
45783839|NCT01725620|Drug|Enbrel (Etanercept 25mg)|
45917674|NCT03206203|Drug|Carboplatin|Given by vein
45917675|NCT03206203|Other|Laboratory Biomarker|Correlative study
46070853|NCT00821665|Dietary Supplement|Sucrose consumption|Sucrose
46070854|NCT00821665|Dietary Supplement|water consumption|water
45643583|NCT04324112|Drug|Encorafenib|Encorafenib will be given orally at a dose of 450mg QD continuously for 28-day cycles with no resting period between cycles.
45643584|NCT04321031|Drug|Placebo|Tablet
45643585|NCT04321031|Drug|PF-06865571|Tablet
45643586|NCT04321031|Drug|PF-05221304|Tablet
45643587|NCT04320888|Procedure|Computed Tomography|Undergo CT, PET/CT, and/or CT/MRI
45643588|NCT04320888|Procedure|Magnetic Resonance Imaging|Undergo MRI, PET/MRI, and/or CT/MRI
45643589|NCT04320888|Procedure|Positron Emission Tomography|Undergo PET, PET/CT, and/or PET/MRI
45643590|NCT04320888|Procedure|Radionuclide Imaging|Undergo scintigraphy
45643591|NCT04320888|Drug|Selpercatinib|Given PO
45643592|NCT04320888|Procedure|X-Ray Imaging|Undergo x-ray imaging
45783840|NCT03004157|Procedure|cardiopulmonary resuscitation|CPR for 10 minutes with a chest compression: ventilation ratio of 15:2 according to international CPR guidelines
45783841|NCT01045460|Biological|Activated marrow infiltrating lymphocytes|Administered on Days 3 and 4.
45917676|NCT03206203|Other|Quality-of-Life Assessment|Ancillary studies
45917677|NCT03155347|Drug|Tocilizumab|Participants will receive tocilizumab 162 mg given as 0.9 milliliter (mL) of a 180 mg/mL solution in a prefilled syringe, administered by SC injection Q2W.
45643593|NCT04319198|Drug|Sacituzumab Govitecan-hiy|Administered intravenously
45643594|NCT04316117|Procedure|Computed Tomography|Undergo PET/CT
45783842|NCT01045460|Biological|Allogeneic Myeloma Vaccine|Allogeneic granulocyte macrophage colony-stimulating factor (GM-CSF)-based myeloma cellular vaccine. Administered on Days 21, 60, 180, and 300.
45783843|NCT01045460|Drug|Cyclophosphamide|Administered at 2.5 g/m^2.
45783844|NCT01045460|Biological|Filgrastim|Administered post cyclophosphamide daily until leukapheresis.
45783845|NCT01045460|Procedure|Leukapheresis|Performed approximately 12 days post cyclophosphamide. Exact date depends on peripheral blood CD34+ cell counts.
45783846|NCT01045460|Drug|Melphalan|100 mg/m^2/day given on Days -2 and -1.
45783847|NCT01045460|Biological|Autologous stem cell transplant|Infused on Day 0.
45783848|NCT05672693|Other|Several Calculation Formulas of Intraocular Lens|Comparison of the accuracy of several intraocular lens calculation formulas
45783849|NCT03004313|Procedure|Pet Scan|Subjects will undergo Pet Scanning for 90 minutes
45783850|NCT03004313|Procedure|MRI scan|
45783851|NCT03004313|Procedure|Quantitative Sensory Testing (QST)|
45643595|NCT04316117|Other|Fludeoxyglucose F-18|Given IV
45783852|NCT03403790|Drug|Quetiapine|Oral (extended-release tablet)
45783853|NCT03404258|Other|Research Blood Sampling|Blood samples will be collected at specified time points and research assays will be performed.
45643596|NCT04316117|Procedure|Positron Emission Tomography|Undergo PET/CT
45643597|NCT04315064|Drug|Treatment with MTX110|"Patients will undergo surgery for maximum safe tumor resection with simultaneous placement of a ventricular access device (VAD) into the fourth ventricle or posterior fossa tumor resection cavity.The specific ventricular access device that will be placed is Medtronic Reference number 44102, Medtronic CSF-Ventricular Reservoir Side Inlet, 18 mm.If a patient already has a ventricular access device in place and additional tumor resection is not required, then that patient can proceed with intraventricular chemotherapy infusions after study enrollment. If the patient has metastatic disease in the brain and/or spine without resectable tumor in the posterior fossa, then only catheter and ventricular access device placement will be performed.Enrolled patients will receive 4 infusions per week of panobinostat (MTX110; 0.25 ml of 300 μM = 26.2 μg), per infusion into the ventricular access device for 6 consecutive weeks for a total of 24 infusions."
45783854|NCT05014919|Drug|Vortioxetine|Tablets
45783855|NCT05014919|Drug|Placebo|Tablets
45783856|NCT03403556|Drug|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe10mg qd for 24 weeks
45783857|NCT03403556|Drug|Monorova|Rosuvastatin 20mg qd for 24 weeks
45783858|NCT05010473|Behavioral|Speech and non-speech sound stimulation|Listening to repetitive and extended sound presentation induces specific neural and physiological activity that we will measure via electroencephalography and pupillometry
45449055|NCT02155972|Dietary Supplement|Bifidobacterium infantis|Probiotic supplement
45643598|NCT04313634|Drug|Dasatinib|Dasatinib will be supplied as 100 mg tablet white to off-white, biconvex, oval, film- coated
45783859|NCT05620862|Drug|Mitoxantrone Hydrochloride Liposome|Mitoxantrone hydrochloride liposome will be administered by an intravenous infusion at three doses of 16 mg/m2, 20 mg/m2 and 24 mg/m2 for up to 6 cycles (21 days per cycle).
45783860|NCT03004235|Device|Observational data collection|Observational data collection
45783861|NCT03406286|Drug|Tolvaptan|
45783862|NCT05672537|Drug|Durvalumab|1500mg intravenous injection for 21d cycle
45783863|NCT05672537|Procedure|Surgery|Surgery
45783864|NCT05672537|Drug|Gemcitabine|gemcitabine 1000mg/m2, D1&D8, 21d cycle.
45783865|NCT05672537|Drug|Cisplatin|cisplatin 25mg/m2, D1&D8, 21d cycle.
45783866|NCT03834428|Behavioral|Text Message Intervention|A text message will be sent once daily (between noon and 3p) to remind participants to ambulate at least 3 times each day while hospitalized.
45783867|NCT03834428|Behavioral|ICOUGH protocol|Education will be provided about the ICOUGH protocol which includes: Incentive spirometry (a breathing device that expands the lungs), Coughing and deep breathing, Oral hygiene (for example using a toothbrush), Understanding (patient and family education), Getting out of bed at least three times daily, and Head-of-bed elevation to prevent choking.
45783868|NCT03003845|Other|Questionnaires|QOL and pain questionnaires will be given to patients at 3, 6, and 12 months post surgery
45783869|NCT03003845|Other|Collection of Blood samples|Blood for PBLs will be collected at 3, 6, and 12 months post surgery
45783870|NCT03400670|Device|ventilator NCPAP|infants will be randomized into two different NCPAP groups
45783871|NCT03400592|Drug|Irinotecan|180 mg/m2 IV once every 2 weeks until radiographically documented tumour progression, unacceptable toxicity, or withdrawal of consent by the patient
45783872|NCT03400592|Drug|nimotuzumab|400mg IV once weekly until radiographically documented tumour progression, unacceptable toxicity, or withdrawal of consent by the patient
45783873|NCT02218463|Drug|Estradiol cream 0.01%|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
45783874|NCT02218463|Drug|Cetaphil|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
45783875|NCT03403478|Other|LICE|No specific exercise will be performed. The participant will walk into the pool accompanied with a researcher for 45 minutes.
45783876|NCT03403478|Other|MICE|"The following exercises will be carried out: a) jumping jacks (shoulder abduction and adduction); b) horizontal adduction and abduction of the shoulder; c) stationary running with knee elevation; d) pull and push horizontally with upper limbs; e) pull and push vertically with upper limbs.~Note: For exercises 'a' and 'b', the legs alternated in movements in the sagittal plane to provide greater stability to the participant's movement. For exercises 'd' and 'e', the legs simulates a stationary running."
45783877|NCT03403478|Other|HIIE|"The following exercises will be carried out: a) jumping jacks (shoulder abduction and adduction); b) horizontal adduction and abduction of the shoulder; c) stationary running with knee elevation; d) pull and push horizontally with upper limbs; e) pull and push vertically with upper limbs.~Note: For exercises 'a' and 'b', the legs alternated in movements in the sagittal plane to provide greater stability to the participant's movement. For exercises 'd' and 'e', the legs simulates a stationary running."
45917678|NCT03155347|Drug|MTX|Participants will receive MTX stable doses at 10 to 25 mg orally.
45917679|NCT03155347|Drug|Placebo Matched to MTX|Placebo matched to MTX.
45783878|NCT03403478|Other|Aquatic exercise training|"The sessions of the aquatic exercise training will be divided into 3 phases: warm-up (10 minutes), main part (40 minutes) and cool down.~In order to increase intensity to aquatic exercise, the training program will carried out as follows:~From week 1 to 4 the instructors will use a 128 bpm musics in both warm-up and cool down. In main part, will be used a 130 bmp musics.~From week 5 to 8 the instructors will use a 130 bpm musics in both warm-up and cool down. In main part, will be used a 132 bmp musics.~From week 9 to 12 the instructors will use a 132 bpm musics in both warm-up and cool down. In main part, will be used a 135 bmp musics."
45449056|NCT02155972|Other|Placebo|Placebo capsules
45643599|NCT04313634|Drug|Quercetin|Quercetin will be supplied as quercetin phytosome (sophora japonica concentrate (leaf) / phosphatidylcholine complex from Sunflower) 250 mg
45643600|NCT04313634|Drug|Fisetin|Fisetin will be supplied in 100 mg capsules to be administered orally
45643601|NCT04311580|Combination Product|intravesical electromotive administration of mitomycin|
45643602|NCT04310007|Procedure|Biospecimen Collection|Undergo blood collection
45643603|NCT04310007|Drug|Cabozantinib S-malate|Given PO
45643604|NCT04310007|Procedure|Computed Tomography|Undergo CT
45643605|NCT04310007|Drug|Docetaxel|Given IV
45643606|NCT04310007|Procedure|Echocardiography|Undergo ECHO
45643607|NCT04310007|Drug|Gemcitabine Hydrochloride|Given PO
45643608|NCT04310007|Drug|Nab-paclitaxel|Given IV
45643609|NCT04310007|Biological|Nivolumab|Given IV
45643610|NCT04310007|Drug|Paclitaxel|Given IV
45643611|NCT04310007|Biological|Ramucirumab|Given IV
45643612|NCT04303858|Drug|Eciskafusp Alfa|Participants will be administered eciskafusp alfa in different schedules.
45643613|NCT04303858|Drug|Atezolizumab|Participants will be administered 1200 mg of atezolizumab once every 3 weeks.
45643614|NCT04303182|Procedure|Standard 3 port TEP|3 port TEP inguinal hernia repair with 10mm. port under the umbilicus and two 5mm. port in line under the 10mm. port
45643615|NCT04303182|Procedure|LESS TEP|TEP inguinal hernia repair with one vertical skin incision under the umbilicus
45643616|NCT04301492|Drug|Vortioxetine|16 weeks for each participant. During the first visit a collection of medical and pharmacological history will be collected and ECG, laboratory tests and clinical assessment will be performed. After verifying the absence of significant abnormalities at the ECG and laboratory tests and after confirming all inclusion and exclusion criteria, subjects will perform the second visit to receive study drug (Brintellix drops 20 mg/ml). All subjects will be instructed to take Vortioxetine 1 drop every day after lunch, increasing of 1 drop per day arriving to 10 drops per day. After 5 days from the beginning of treatment, subject will be contacted by phone to check on tolerability and in absence of side effects, the dosage will be increased to 10 drops per day. At Week 4-8-12 patients will return to the site to perform all clinical evaluations required and to receive study drug.
45643617|NCT04301076|Drug|Cyclophosphamide|Given IV
45643618|NCT04301076|Drug|Doxorubicin Hydrochloride|Given IV
45643619|NCT04301076|Drug|Etoposide|Given IV
45643620|NCT04301076|Drug|Lenalidomide|Given PO
45643621|NCT04301076|Drug|Prednisone|Given PO
45643622|NCT04301076|Drug|Vincristine Sulfate|Given IV
45643623|NCT04300816|Behavioral|CBT for Uncertainty Tolerance|"Participants work one-on-one with an interventionist. Treatment sessions focus on understanding the difference between the controllable and uncontrollable aspects of MS, ability to tolerate not knowing exactly what the future will hold, setting personal goals for what accepting what MS will look like, and finding ways to live in conjunction with personal values despite the MS diagnosis."
45643624|NCT04300816|Behavioral|Traditional CBT|Participants work one-on-one with an interventionist. Treatment sessions focus on goal setting, positive activities, identifying and challenging unhelpful thoughts, and bolstering social support.
45643625|NCT04297787|Device|Thrombolysis in combination with endhole aspiration|The treatment protocol the study team will be following is as follows. First, a pulse spray tPA infusion with 20 cc of 8 mg tPA and saline will be administered to the thrombus with a 20-minute dwell time. Afterwards, an 8F curved sheath (Indigo 8 Torq Tip, ranges 85 to 115 cm) with CAT8 penumbra device will be used to aspirate the thrombus. If the operating physician deems necessary, they will have the option at that point to balloon plasty, stent, or use catheter-directed thrombolysis at this point. Clinical parameters such as areas of clinically-significant stenosis, extent of thrombus, (more parameters) will be tracked at the time of the procedure. The device is being used is FDA approved and being used according to FDA indications.
45643626|NCT04295473|Procedure|Reduced port laparoscopic gastrectomy|The ports were reduced in the surgery of intervention arm.
45643627|NCT04290039|Drug|Atropine Sulfate Ophthalmic Solution|Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP.
45643628|NCT04290039|Drug|Atropine Sulphate Injection|Atropine sulfate injection, USP, 8mg/20mL (0.4 mg per mL) is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; sodium chloride 9 mg; and may contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8).
45783879|NCT03834584|Drug|AG-636|AG-636 will be administered orally intermittently in 28-day cycles.
45917680|NCT03155347|Drug|Placebo Matched to Tocilizumab|Placebo matched to tocilizumab.
45917681|NCT00000879|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
45917682|NCT00000879|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
45917683|NCT00000879|Biological|ALVAC-HIV MN120TMG (vCP205)|
45643629|NCT04282850|Procedure|Pulmonary Vein Isolation|The intervention will involve standard of care electrophysiology ablation for rhythm management of atrial fibrillation with a procedure called a pulmonary vein isolation.
45643630|NCT04278339|Other|Evoked Related Potentials|Evoked Related Potentials are measured by means of electroencephalography. During this measure, 2 informatic task will be performed to evaluated evoked related potentials.
45917684|NCT03142204|Drug|[18F]F-AraG|Single dose IV injection of [18F]F-AraG for each imaging day.
45449057|NCT02153554|Behavioral|Training civil servants on attention to violence against women|The Secretary of Women of Medellin, through the ICONTEC, intends to conduct training to officials of the 22 family commissioners in Medellin. The objective of these trainings is to standardize procedures in order that women do not feel re-victimized and can forward complaints.
45917685|NCT03134833|Behavioral|Automated Messaging & Monitoring|"Youth will receive messages 1-5 messages per day for 24 months. Message banks of about 750 text messages (70-120/domain) will focus on the HIV Prevention Continuum, with messages dedicated to healthcare, wellness, sexual health, drug use and medication reminders (e.g., for PrEP) for MSM and non-MSM. Youth will be able to choose the time that they receive daily texts. Text timing and the frequency of texts (e.g., if the youth comes out) will be updated at 4-month intervals.~Youth will complete weekly monitoring surveys by text message. The survey will cover seven domains related to the HIV Prevention Continuum. In case of non-response, reminder messages will be sent to the youth. After three days of non-response, a follow-telephone call will occur."
45917686|NCT03134833|Behavioral|Peer Support|"Youth will be enrolled in online, private discussion groups.~Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.~Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content."
45783880|NCT03003689|Procedure|Scaling and Root Planing|Standard of care scaling and root planing using hand instruments and ultrasonic scaler
45783881|NCT03003689|Device|Er:YAG Laser|Er:YAG laser as an adjunct therapy to standard of care scaling and root planing using hand instruments and ultrasonic
45783882|NCT03830372|Device|VR Tier One|"10 sessions of 20 minutes virtual terapeutic game~Thanks to using VR googles and the phenomenon of total immersion VR Tier One terapy game allows to completely separate the patient from the hospital environment and provides an intense visual, auditory and kinesthetic stimulation. Depending on the stage of therapy it can have a calming and mood-improving effect or it can motivate and cognitively activate the patient. The additional aim of the game is to help the patients regain their emotional balance, let them recognize their resources in order to bring them to power in the rehabilitation process and trigger the natural recovery mechanisms."
45783883|NCT03830372|Other|Control|10 sessions of 20 minutes of Schultz Autogenic Training
45783884|NCT03003923|Behavioral|Taste exposure|Exposure to the same vegetable
45917687|NCT03134833|Behavioral|Coaching|Youth will have access to a dedicated Coach to assist with crisis support and problem-solving, linkage to HIV and related services (e.g., for substance use, mental health), and care coordination. Coaches will be accessible electronically (using social media, e-mail, text messaging) and by phone. In cases where virtual support has failed, Coaches will be available in-person (e.g., to accompany a participant to a doctor's appointment). We anticipate that Coaches will provide each youth with 10 hours of support, on average, per year.
45917688|NCT03129061|Drug|[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.|"Baseline: Blood sampling, tumor biopsy, [18F]F-AraG PET/CT scan within two weeks prior to standard of care anti-PD-1 therapeutic dose.~Anti PD-1 per standard of care~Blood sampling and tumor biopsy within 2-3 weeks after first anti-PD-1 SOC dose.~[18F]F-AraG PET/CT scan 6 - 12 weeks post first anti-PD-1 dose."
45917689|NCT03129061|Drug|[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.|"Baseline: Blood sampling, tumor biopsy, [18F]F-AraG PET/CT scan within two weeks prior to treatment.~Anti PD-1, single dose~Blood sampling, tumor biopsy and [18F}F-AraG PET/CT scan within 2-3 weeks after single dose of anti-PD-1 treatment. For patients having surgical resection, biopsy will be immediately prior to resection or from sample of resection."
45917690|NCT00000882|Drug|Indinavir sulfate|
45917691|NCT00000882|Drug|Delavirdine mesylate|
45917692|NCT00000882|Drug|Lamivudine|
45917693|NCT00000882|Drug|Stavudine|
45917694|NCT00000882|Drug|Zidovudine|
45917695|NCT03096886|Behavioral|Computer-Augmented Cognitive Behavioral Therapy|"The model of CCBT, Good Days Ahead (GDA) will be utilized, it has been found that it is not inferior to CBT in MDD treatment efficacy. CCBT participants will complete 9 modules of the GDA program, including 240 minutes of computer training; participants will also meet with a therapist on 6 occasions for a total of 180 minutes of clinician administered cognitive behavioral therapy."
45917696|NCT00000888|Drug|Ritonavir|
45449058|NCT05666349|Drug|Niraparib|100 mg, 200 mg, or 300mg oral niraparib once daily.
45917697|NCT00000888|Drug|Lamivudine|
45917698|NCT00000888|Drug|Zidovudine|
45783885|NCT03003923|Behavioral|Nutritional education|Eat Well and Strive for Five nutritional education
45917699|NCT03055858|Device|ADO II AS (PDA closure)|Closure of PDA using Amplatzer Duct Occluder II Additional Sizes (ADO II AS).
45917700|NCT00000891|Drug|Ritonavir|
45449059|NCT05666349|Radiation|Re-irradiation (re-RT)|Intensity modulated radiotherapy (IMRT)-based re-RT for a total dose of 35 Gy in 10 daily fractions.
45449060|NCT02156050|Device|two sessions of 4 hours Phototherapy treatment|two sessions of 4 hours Phototherapy treatment
45643638|NCT04268979|Behavioral|eSNAP|eSNAP is a web based tool that quickly collects and organizes social support information entered by Family Caregivers (FCGs) into visualizations of the size, quality, and function of support networks. Visualizations can help FCGs catalogue support resources and present them in a new way, which may make them more salient and remind FCGs of their availability.
45783886|NCT02248025|Other|Observational study: No special intervention will be made.|No special intervention will be made, only data will be collected before, and after a passive leg raising and a fluid challenge decided and performed by the attending physician.
45917701|NCT00000891|Drug|Saquinavir|
45917702|NCT00000891|Drug|Delavirdine mesylate|
45917703|NCT00000891|Drug|Lamivudine|
45917704|NCT00000891|Drug|Stavudine|
45643639|NCT04268979|Behavioral|Caregiver Navigator|The Caregiver Navigator will have social work training and will help Family Caregivers (FCGs) identify and leverage informal and formal social support, including enrolling or directing FCGs to services.
45917705|NCT00000891|Drug|Zidovudine|
45917706|NCT00000891|Drug|Didanosine|
45783887|NCT00919802|Drug|Oxytocin|A single dose of oxytocin 40 IU (20 IU to each nostril) will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of saline as an alternate agent on the second day if needed.
45783888|NCT00919802|Other|Saline as a nasal spray|A single dose of saline will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of oxytocin 40 IU as an alternate agent on the second day if needed.
45783889|NCT02222129|Drug|Bupivacaine|
45783890|NCT02222129|Drug|liposomal bupivacaine|
45783891|NCT03403322|Other|Kinesio taping|An experienced physiotherapist placed the base of the Kinesio taping strip, over rectus femoris muscle, 3cm bellow the anterior iliac spine, without tension. From this point, the Kinesio taping was placed up to the upper edge of the patella and stretched to 100% tension. It was, then, bi-sectioned, circled the patella and ended in the tuberosity of the femur, without tension. In order to avoid interference in the electromyography signals, a section was held at Kinesio taping at the point where the electrode was placed.
45783892|NCT03403322|Other|Without taping|Children performed functional activities without tape
45783893|NCT03400436|Other|No intervention in observational studies|No intervention in observational studies
45783894|NCT03003611|Procedure|hypnose sedation|Patient will be anesthetized with an hypnose sedation and a complement with light anesthesia
45783895|NCT03003611|Procedure|general anesthesia|Patient will be anesthetized with a classical general anesthesia
45783896|NCT03400358|Other|uterocervical angle|the angle between cervical canal and anterior uterine wall is measured sonographically.
45783897|NCT03003455|Procedure|Nasotracheal intubation over a bougie|Nasotracheal intubation over a bougie, placed with videolaryngoscopy assistance, via a nasopharyngeal airway with or without the aid of Magill forceps
45783898|NCT03003455|Procedure|Conventional Nasotracheal Intubation|Blind passage of an endotracheal tube via the nare followed by videolaryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
45783899|NCT03400280|Other|Best practice algorithm for postoperative care|See arm/group description
45449061|NCT03733275|Drug|Lidocaine|for experimental arm, lidocaine spray and lidocaine bupivacine mixture-soaked nasal packing vs. for placebo arm, normal saline spray and packing
45783900|NCT03401294|Drug|FOLFOXIRI and Bevacizumab|Every 2 week for a total of 12 cycles
45783901|NCT05672069|Procedure|Osteosynthesis|Foot pathologies
45449062|NCT02255188|Procedure|blood sampling procedure|30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent. Blood sampling is carried out from an arm vein. All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary
45783902|NCT03404726|Drug|BAY2402234|BAY2402234 is a potent and selective small molecule inhibitor of dihydroorotate dehydrogenase. A solution of BAY2402234 will be available to initiate the trial and there are plans to transition to a tablet form of BAY2402234 once it becomes available. Both liquid and tablet formulations of BAY2402234 will be continually administered once daily by mouth in 28 day cycles.
45783903|NCT03403166|Behavioral|DASH diet|Diet intervention
45783904|NCT03403166|Behavioral|Fruits and vegetables diet|Diet intervention
45783905|NCT03403166|Behavioral|Control diet|Diet intervention
45783906|NCT03400202|Device|Skin imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight Ox Optical Coherence Tomography (OCT).
45783907|NCT03400202|Other|Facial cleanser|Facial cleanser prior to procedures.
45449063|NCT03542422|Drug|Apatinib|Metastasis after primary treatment : Apatinib + yew + platinum. Local recurrence after previous surgery/radiotherapy: Apatinib alone or in combination with platinum-based chemotherapy.
45783908|NCT02981147|Drug|Phytus (Cisti, Thyme and Ivy Leaves)|Phytus is a medicinal herb containing Ivy leaves, Cisti and Thyme.
45783909|NCT03400124|Procedure|ISBCS|The intervention group will undergo cataract surgery in both eyes on the same day (ISBCS)
45783910|NCT03400124|Procedure|DSBCS|The usual care / control group will undergo cataract surgery in both eyes on separate days, with a time period of at least two weeks between surgeries.
45783911|NCT02980991|Drug|Pemetrexed|Two cycles of pemetrexed 500mg/m2 day 1, 21 days per cycle for patients before surgery
45783912|NCT02980991|Drug|Cisplatin|Two cycles of cisplatin 75mg/m2 day 1 (or 25mg/m2 day 1-3), 21 days per cycle for patients before surgery
45449064|NCT03621189|Device|intermittent theta burst stimulation|stimulatory protocol
45449065|NCT01077011|Other|Lubricant eye drop FID 115958D|1 drop in each eye, one time
45449066|NCT01077011|Other|GenTeal Gel|1 drop in each eye, one time
45449067|NCT02153866|Biological|rotavirus vaccine|3ml/dose, oral
45449068|NCT02153866|Biological|measles-rubella vaccine|0.5ml per dose, subcutaneous injection
45449069|NCT02153866|Biological|measles-mumps-rubella vaccine|0.5ml per dose, subcutaneous injection
46070855|NCT02030990|Drug|Mitomycin-C|0.01% applied to cornea with a sponge during PRK
46070856|NCT02030990|Drug|Fluorometholone 1% topical ocular steroid|topical steroid drops applied to the cornea after PRK
45643649|NCT04267211|Other|Illustrated handout at prenatal consult|Illustrated consult group will be given an illustration paper describing the majority of the issues discussed at the prenatal consult
45643650|NCT04267211|Other|Standard Prenatal Consult|Standard prenatal consult
45754332|NCT00607243|Biological|smallpox vaccine CJ-50300|Conventional dose group: 2.5 x 10 5 pfu/dose Diluted dose group:2.5 x 10 4 pfu/dose
45783913|NCT03403088|Device|Experimental: • Group LA|to apply Laser (780 nm and 70mW) at the cementum-enamel junction fat the teeth affected by sensitivity
45783914|NCT03403088|Device|Placebo Comparator: • Group LA-P|to apply Laser (780 nm and 70mW) at the cementum-enamel junction at the teeth affected by sensitivity with the laser device having no effective laser emission, only guided by light
45783915|NCT03403088|Other|Experimental: • Group DE|to brush teeth with a blinded dentifrice with 0,45% of stannous fluoride and a soft-bristled manual toothbrush (Johnson & Johnson®).
45783916|NCT03403088|Other|Placebo Comparator: • Group DE-P|to brush teeth with a blinded dentifrice with 1500 ppm of available fluoride and a soft-bristled manual toothbrush (Johnson & Johnson®).
45643651|NCT04266704|Behavioral|Sharing Intervention|intervention includes both analytic and socioemotional components related to self-management of hypertension and is specifically targeted to African American women. Along with providing education on lifestyle changes to lower blood pressure, DASH diet, exercise, and medication adherence (analytic components), the intervention is designed to promote social activities around blood pressure self-management, in particular, sharing blood pressure management information with peers (socioemotional components).
45643652|NCT04266249|Drug|Docetaxel|Given IV
45643653|NCT04266249|Procedure|Lumpectomy|Undergo lumpectomy
45643654|NCT04266249|Procedure|Mastectomy|Undergo mastectomy
45643655|NCT04266249|Drug|Nab-paclitaxel|Given IV
45643656|NCT04266249|Drug|Paclitaxel|Given IV
45643657|NCT04266249|Biological|Pertuzumab|Given IV
45643658|NCT04266249|Radiation|Radiation Therapy|Undergo radiation therapy
45643659|NCT04266249|Biological|Trastuzumab|Given IV
45643660|NCT04266249|Biological|Trastuzumab Emtansine|Given IV
45643661|NCT04260126|Combination Product|Pembrolizumab and PDS0101|IV infusion of pembrolizumab 200 mg + two 0.5mL sub-cutaneous injections of PDS0101 administered on Cycle 1, 2, 3, 4 and 12. IV infusion of Pembrolizumab 200 mg monotherapy will be administered Cycles 5 - 11 and 13 - 35.
45643662|NCT04248452|Drug|Capecitabine|Given PO
45643663|NCT04248452|Drug|Fluorouracil|Given IV
45643664|NCT04248452|Drug|Leucovorin|Given IV
45643665|NCT04248452|Drug|Leucovorin Calcium|Given IV
45643666|NCT04248452|Drug|Oxaliplatin|Given IV
45643667|NCT04248452|Radiation|Radiation Therapy|Undergo radiation therapy
45643668|NCT04247997|Procedure|disconnect pulmonary vague nerve branches|When the operation is in the right side, the Azygous vein bow is used as the marker, and in the left side, the aortic arch is used as the marker to identify the vagus nerve trunk.Then the surgeons dissect the vagus nerve trunk. This is used as a clue to find the vagus nerve pulmonary branch leading to the hilum. The position of the detachment is after the anterior and posterior pulmonary branches of the vagus nerve separating from the trunk and before the formation of the lung plexus.
45643669|NCT04247334|Device|Transcranial direct current stimulation|20 minutes of 2 milliamp transcranial direct current stimulation
45643670|NCT04246463|Device|Thoracic|Implant of a Relay stent graft system
45643671|NCT04246463|Device|Abdominal|Implant with an Anaconda or Treo Stent graft system
45643672|NCT04246463|Device|Custom Device|Implant of a Fenestrated device such as Fenestrated Anaconda or Fenestrated TREO, Relay Branch or other customised device
45643673|NCT04246463|Device|Illiac Artery|Implant with an Anaconda Iliac leg only
45643674|NCT04246333|Other|Mode of Delivery of Feeds|Eligible infants will be recruited and enrolled and randomized to either duodenal feeds (DF) or gastric feeds (GF), which will occur just prior to the infants advancing beyond 50mL/kg/day of enteral feeds. All enrolled infants will be fed per our institutional feeding protocol. Once infants advance past a volume of 50mL/kg/day of enteral feeds, at this point infants will be randomized to DF or GF groups.
45643675|NCT04242264|Other|Placebo|0.9% Sterile Normal Saline, USP
45643676|NCT04242264|Biological|Shigella sonnei strain 53G|1.5 x 10^3 Colony Forming Units (cfu) Shigella sonnei 53G, a virulent strain of wildtype Shigella sonnei
45643677|NCT04242264|Biological|WRSs2|10^6 Colony Forming Units (cfu) dose of an oral live-attenuated Shigella sonnei vaccine candidate derived from a virulent S. sonnei strain Moseley (WRSs2)-a live, attenuated vaccine that has been manufactured under cGMP conditions at the WRAIR PBF
45643678|NCT04241757|Diagnostic Test|ElectroCardioGram (ECG)|Collection of results ElectroCardioGram (ECG).
45643679|NCT04240054|Drug|Bortezomib|Bortezomib (1.5 mg/m^2) subcutaneous on days 1, 8 and 15
45643680|NCT04240054|Drug|Isatuximab|Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22
45783917|NCT03403088|Other|Experimental: • Group RGI|to apply a thin layer of resin based glass-ionomer product on the cervical surface of the affected teeth affected by sensitivity following the manufacturer instructions.
45783918|NCT03403088|Other|Experimental: Group RX|to apply Adper Single Bond Plus Adhesive in accordance with the manufacturer instructions, at the teeth affected by sensitivity product for 20 seconds.
45783919|NCT05441345|Other|questionnaires with collection of stool and urine|questionnaires will be completed (GPAQ, SarQoL, EQ-5D-3L, SF36), with collection of stool (for care and research) and urine
45643681|NCT04240054|Drug|Cyclophosphamide|Cyclophosphamide (250 mg/m^2) IV on days 1, 8 and 15
45643682|NCT04240054|Drug|Dexamethasone|Dexamethasone 20 mg PO or IV (10 mg if >75 years) on days 1, 2, 8, 9, 15, 16, 22 and 23
45643683|NCT04240002|Drug|gilteritinib|Administered orally.
45643684|NCT04240002|Drug|fludarabine|Administered by intravenous (IV) infusion
45643685|NCT04240002|Drug|cytarabine|Administered by intravenous (IV) infusion
45643686|NCT04240002|Drug|granulocyte colony-stimulating factor (G-CSF)|Administered by subcutaneous injection
45643687|NCT04239573|Procedure|Computed Tomography|Undergo CT
45643688|NCT04239573|Procedure|Endoscopic Ultrasound|Undergo EUS
45643689|NCT04239573|Procedure|Magnetic Resonance Imaging|Undergo MRI
45643690|NCT04239573|Other|Quality-of-Life Assessment|Ancillary studies
45643691|NCT04239573|Other|Questionnaire Administration|Ancillary studies
45643692|NCT04235374|Behavioral|FFC-AC-EIT|The two intervention arms will receive the same educational information. The education group will not be exposed to any other activities. The FFC-AC-EIT will focus strongly on motivation of staff and patients to get the patients engaged in functional and physical activities.
45643693|NCT04233866|Drug|Fluorouracil|Given IV
45643694|NCT04233866|Drug|Gemcitabine|Given IV
45643695|NCT04233866|Drug|Gemcitabine Hydrochloride|Given IV
45643696|NCT04233866|Drug|Leucovorin|Given IV
45643697|NCT04233866|Drug|Leucovorin Calcium|Given IV
45643698|NCT04233866|Drug|Liposomal Irinotecan|Given IV
45643699|NCT04233866|Drug|Nab-paclitaxel|Given IV
45643700|NCT04233866|Other|Quality-of-Life Assessment|Ancillary studies
45783920|NCT03400046|Drug|Nutritional Product Supplementation|Patients with chronic intestinal failure were administered nutritional support including enteral and parenteral nutrition.
45783921|NCT03403010|Other|Rehabilitation-specific gaming platform|The rehabilitation specific gaming software was developed as part of the ICT4rehab project with partners from the Vrije Universiteit Brussel and the University Libre de Bruxelles. The ICT4Rehab puts several ICT tools supporting 2/3D user interaction into place. The games can be controlled using a Kinect camera system (Microsoft(®) (Redmond, WA) Kinect™) or a Wii balance board (® NintendoTM, Japan), depending on the choice of the therapist and the needs of the child.
45783922|NCT03003377|Device|laryngeal mask supreme|Sevoflurane was administered by facial mask with concomitant remifentanil administration (at an effect-site of 4 ng/ml). The LMAS was inserted according to the manufacturer's recommendations with the patient's head in the neutral position. After equilibrium the LMAS was inserted and secured according to the manufacturer's recommendations, without using muscle relaxants. A single measurement will be obtained from each patient. If the patient reacted with movement, a 1-2 mg/kg dose of Propofol was administered.
45783923|NCT03003377|Device|laryngeal mask proseal|Sevoflurane was administered by facial mask with concomitant remifentanil administration (at an effect-site of 4 ng/ml).The LMAP was inserted according to the manufacturer's recommendations with the patient's head in the neutral position. After equilibrium the LMAP was inserted and secured according to the manufacturer's recommendations, without using muscle relaxants. A single measurement will be obtained from each patient. If the patient reacted with movement, a 1-2 mg/kg dose of Propofol was administered.
45783924|NCT04375436|Drug|NTRX-07-SDD|NTRX-07-SDD for oral administration
45783925|NCT03003221|Behavioral|AIR-P Dental Toolkit|The AIR-P Dental Toolkit is designed to provide caregivers with guidance and information related to dental care and support strategies for children with autism spectrum disorder.
45783926|NCT03003221|Behavioral|Parent Training|The parent-training intervention integrates strategies shown to be efficacious for: 1) improving adherence to dental care, 2) enhancing dental experiences for children with neurotypical development and high levels of dental fear, and 3) evidence-based behavioral techniques established for children with autism spectrum disorder.
45783927|NCT03402776|Drug|4th dose of hexavalent vaccine 1 month after the 3rd dose|4th dose of hexavalent vaccine 1 month after the 3rd dose
45783928|NCT04712669|Drug|rodatristat ethyl 300 mg tablet BID|rodatristat ethyl 300 mg tablet + matching placebo tablet twice daily on top of standard of care
45783929|NCT04712669|Drug|rodatristat ethyl 600 mg BID|2 rodatristat ethyl 300 mg tablets twice daily on top of standard of care
45643701|NCT04233866|Other|Questionnaire Administration|Ancillary studies
45643702|NCT04233112|Drug|Melatonin 5 mg|Capsules containing 5mg melatonin will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
45643703|NCT04233112|Device|Osteogenic loading|Osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform osteogenic loading once per week.
45643704|NCT04233112|Device|Mock for Osteogenic Loading|Mock osteogenic loading will occur using the osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform mock osteogenic loading once per week.
45643705|NCT04233112|Drug|Placebo (plant fiber) for melatonin|Capsules containing plant fiber will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
45643706|NCT04228172|Genetic|DNA/GeneticTesting|Subjects will be tested for GBA and LRRK2 mutation status at baseline.
45449070|NCT00122135|Other|Values Inventory (VI)|The Values Inventory was given to patients for self-administration while they were awaiting their clinic appointment. They were instructed to bring it to their physician's attention right at the beginning of their clinic visit.
45643707|NCT04228172|Radiation|FDG PET scan|18F-Fluoro-2-deoxy-glucose (FDG) PET scan is a nuclear medicine test that measures glucose metabolism (energy) in your brain at baseline and 18 months later.
45643708|NCT04228172|Other|MRI scan|Magnetic Resonance Imaging (MRI) is a noninvasive scan which produces detailed pictures of the brain using a magnetic field. In addition, a special type of MRI, called resting state functional MRI (rs-fMRI), will measure and map brain activity. Conducted at baseline and 18 months later.
45643709|NCT04228172|Other|Clinical and neuropsychological assessments|Investigator will evaluate subjects according to the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), the standard clinical tool used to measure the severity and progression of PD. Neuropsychological evaluation will assess how one's brain functions (via pencil and paper testing), which indirectly yields information about the structural and functional integrity of the brain. Conducted at baseline and 18 months later.
45783930|NCT04712669|Drug|Placebo|2 matching placebo tablets on top of standard of care
45783931|NCT03404570|Drug|Dexmecamylamine HCl|Investigational drug
45783932|NCT03404570|Other|Placebo|Oral tablet containing no active drug.
45783933|NCT03409796|Dietary Supplement|Gluten|Gluten powder.
45783934|NCT03408080|Drug|BHV-4157|BHV-4157 is a glutamate modulating drug that is being developed for eventual commercial use in the treatment of spinocerebellar ataxia (SCA). This is currently no approved medication indicated for SCA.
45783935|NCT03402698|Dietary Supplement|cholecalciferol|supplementation at a dose 1000 IU/d
45783936|NCT03406520|Device|Chlorhexidine-impregnated disk|The chlorhexidine-impregnated sponge, named biopatch, is a protective disk (2.5 cm x 0.7 cm), which is hydrophilic polyurethane absorptive foam with chlorhexidine gluconate, in average of 86.8mg per disk
45783937|NCT02248181|Drug|Pramipexole|
45643710|NCT04226755|Dietary Supplement|Sodium chloride|1 gram tid (with every meal)
45783938|NCT03002909|Device|epidural catheter|
45783939|NCT03002909|Device|preperitoneal catheter|
45783940|NCT04347590|Device|Unblinded - CGM (Medtronic Guardian)|Data from device will be readable and alarms on
45783941|NCT04347590|Device|Blinded - CGM (Medtronic Guardian)|Data from device will be blinded and alarms off
45917707|NCT02972203|Behavioral|Mindfulness Training for Primary Care|• MPTC is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements. MTPC is a referral-based, insurance-reimbursable 8-week group psychotherapy delivered primarily by Patient-Centered Medical Home-integrated behavioral clinicians. MTPC groups are 2 hours long for 8 weeks, with a 7-hour day of silent group practice on a weekend. MTPC also emphasizes psychoeducational skills for self-regulation including a collaborative primary care provider (PCP) action-planning appointment during week 6.
45917708|NCT02972203|Behavioral|Mindfulness Intro. +resources +waitlist|Control arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month waitlist for a Cambridge Health Alliance mindfulness-based intervention group. All participants are scheduled to meet with their primary care provider during week 6 for a collaborative action planning visit.
45917709|NCT02987335|Drug|Pancreatic Clamp|We are not performing any interventions; we are only characterizing participants using tests. The hormones that we are administering are not a treatment but are typically used in context of routine care.
45917710|NCT00000903|Drug|Indinavir sulfate|
45917711|NCT00000903|Drug|Lamivudine/Zidovudine|
45917712|NCT00000903|Drug|Nelfinavir mesylate|
45917713|NCT00000903|Drug|Efavirenz|
45917714|NCT02939365|Drug|Belatacept|The transition to belatacept monotherapy and possibly to q 8 weeks administration can be safely done by applying personalized (i.e. precision) medicine. This includes phenotypic analysis of lymphocyte subsets, a quiescent molecular profiling of blood and urine prior to drug withdrawal and immune monitoring with KSORT after stepwise withdrawal of steroids and antiproliferatives. Furthermore, trough PK of belatacept will be measured for conversion to q 8 week therapy for discovering research purposes.
45643719|NCT04223856|Drug|Enfortumab vedotin|Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle
45643720|NCT04223856|Drug|Pembrolizumab|IV infusion on Day 1 of every 3-week cycle
45643721|NCT04223856|Drug|Cisplatin|administered as IV infusion on Day 1 of each 3-week cycle
45643722|NCT04223856|Drug|Carboplatin|Dosed according to local guidelines and will be administered as IV infusion on Day 1 of each 3-week cycle
45643723|NCT04223856|Drug|Gemcitabine|IV infusion on Days 1 and 8 of every 3 week cycle
45643724|NCT04223596|Drug|Brigatinib|Brigatinib 90 mg for the first 7 days (D1-7 at cycle 1) and then 180 mg daily thereafter for QW4 cycles of duration (28 days+-3 days)
45643725|NCT04222387|Device|OCT-B scan|OCT-B scan (Optical coherence tomography)
45643726|NCT04221438|Drug|Binimetinib|Given PO
45643727|NCT04221438|Procedure|Computed Tomography|Undergo PET/CT
45643728|NCT04221438|Procedure|Conventional Surgery|Undergo surgery
45643729|NCT04221438|Drug|Encorafenib|Given PO
45783942|NCT03402620|Drug|Gonadotropins|Human menopausal gonadotropin 75 IU ampoules start at cycle day 2
45783943|NCT03003143|Drug|Vigabatrin 500 MG|
46070857|NCT00821743|Device|Deep brain stimulation electrode|The DBS electrodes (model 3389, Medtronic) will be stereotactically implanted bilaterally in the PPN, according to the technique usually used for STN-DBS, and connected to the subcutaneously implanted stimulator (Kinetra, Medtronic).
45449071|NCT02156128|Behavioral|Cogmed working memory training|
45449072|NCT02156128|Behavioral|Control group|
45643730|NCT04221438|Other|Fluorothymidine F-18|Given IV
45643731|NCT04221438|Procedure|Positron Emission Tomography|Undergo PET/CT
45783944|NCT04374968|Device|Blood flood restriction cuff|Blood flow restriction cuffs will be used as an augment to physical therapy
45783945|NCT03002987|Behavioral|Active Pregnancy policy|Education (3 hours) of leaders in how to implement Active pregnancy policy at their departments/work places
45783946|NCT03402542|Procedure|Cholecystectomy|Cholecystectomy
45449073|NCT03645057|Drug|Crisaborole|This topical ointment is FDA-approved to treat atopic dermatitis of moderate or less severity in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
45643732|NCT04217954|Drug|OXA, 5-FU and bevacizumab plus Toripalimab|"concomitant treatment: A. HAIC: oxaliplatin (40 mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for 22 hours) on days 1-3, and arterial bevacizumab 300mg for 2 hours on d1 before oxaliplatin through a percutaneously implanted port-catheter system.~B. Intravenous PD-1 inhibitor (Toripalimab) 240 mg for 30-60 minutes on d1 before the HAIC.~The concomitant treatment repeat every three week, up to 6 cycles.~Maintenance treatment: Bevacizumab (300mg) + PD-1 inhibitor (Toripalimab 240mg) will be given intravenously, every 3 weeks."
45643733|NCT04216316|Drug|Berzosertib|Given IV
45643734|NCT04216316|Procedure|Biospecimen Collection|Correlative studies
45643735|NCT04216316|Drug|Carboplatin|Given IV
45783947|NCT02462928|Drug|Abicipar Pegol|Abicipar pegol intravitreal injection.
45783948|NCT02462928|Drug|Ranibizumab|Ranibizumab intravitreal injection.
45643736|NCT04216316|Procedure|Computed Tomography|Undergo CT
45643737|NCT04216316|Drug|Gemcitabine Hydrochloride|Given IV
45643738|NCT04216316|Procedure|Magnetic Resonance Imaging|Undergo MRI
45643739|NCT04216316|Biological|Pembrolizumab|Given IV
45643740|NCT04214249|Procedure|Biospecimen Collection|Undergo collection of blood
45643741|NCT04214249|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
45643742|NCT04214249|Procedure|Computed Tomography|Undergo CT
45643743|NCT04214249|Drug|Cytarabine|Given via continuous IV infusion
45643744|NCT04214249|Drug|Daunorubicin Hydrochloride|Given IV
45643745|NCT04214249|Procedure|Echocardiography|Undergo ECHO
45643746|NCT04214249|Procedure|Hematopoietic Cell Transplantation|Undergo HSCT
45643747|NCT04214249|Drug|Idarubicin Hydrochloride|Given IV
45643748|NCT04214249|Procedure|Multigated Acquisition Scan|Undergo MUGA
45643749|NCT04214249|Biological|Pembrolizumab|Given IV
45783949|NCT02462928|Other|Sham Procedure|Sham injection.
45917715|NCT02795338|Procedure|brain mapping|pre-operative and intra-operative brain mapping to identify eloquent areas
46070858|NCT00821899|Biological|administration of autologous bone marrow blood|administration of autologous bone marrow blood through magna pancreatic artery after femoral catheterization once during 12-month study period
45783950|NCT03002831|Biological|Cytokine-induced Killer Cells|
45449074|NCT03645057|Drug|Tacrolimus 0.03% Ointment|This topical ointment is FDA-approved to treat atopic dermatitis in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
45449075|NCT04863430|Drug|Apatinib|500mg oral qd
45643750|NCT04214249|Procedure|Punch Biopsy|Undergo a skin punch biopsy
45643751|NCT04210986|Dietary Supplement|Fisetin|Fisetin will be administered orally at 20 mg/kg for two consecutive days, followed by 28 days off, then 2 more consecutive days.
45783951|NCT03002831|Drug|Tegafur-Gimeracil-Oteracil Potassium|
45783952|NCT04375046|Drug|Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2)|In this study, the experimental group will receive 0.4 mg/kg rbACE2 IV
45783953|NCT03402464|Drug|Icotinib combined dihydroaremisinin|Icotinib should be taken by the patients continuously until disease progressed or intolerable toxicity. On day 1-3, oral dihydroaremisinin was given at 20mg per day, the dose of dihydroaremisinin is increased to 40mg daily on day 4 to 6, and 80mg twice daily until disease progressed or intolerable toxicity.
45783954|NCT02248259|Drug|BI 409306|Oral single dose of BI 409306
45783955|NCT02248259|Drug|Itraconazole|Oral dose, twice daily on Day -3, once daily on Day -2 to Day 2 of Itraconazole
45783956|NCT02248259|Drug|BI 409306|Oral single dose
45643752|NCT04210986|Drug|Placebo oral capsule|Placebo will be administered orally for two consecutive days, followed by 28 days off, then 2 more consecutive days.
45643753|NCT04210427|Drug|Polyethylene Glycol 3350|All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily for total of 2 weeks.
45783957|NCT05667701|Drug|Soy isoflavone|Soy isoflavone supplement (Novasoy) that contains isoflavones (genistein, daidzein, glycetein) given at a dose of genistein aglycone equivalents to provide the genistein dosing of 22.6 mg/day for children aged 2-10 months, and 30.3 mg/day children aged 10-24 months
45783958|NCT05667701|Drug|matching placebo|A matching placebo also administered twice daily.
45783959|NCT04375280|Other|"Development of a screening algorithm designed to determine a dysmobility profile in patients with chronic illness."|"Firstly, volunteers will be invited to complete online questionnaires on a secure platform. The mobility assessment will be carried out initially (t1) and up to a maximum of 4 times (t1 to t4) as part of a day hospitalization. Questionnaires will be diverse (SF36, KOOS, HOOS, BROCKER, MNA, TAMPA, etc.) in order to assess several aspects that compose mobility.~Physical evaluations will include various validated tests (isokinetic strength measure, TUG, 6MWT, Berg Balance Scale, etc.)"
45783960|NCT02248337|Drug|Colon preparation for colonoscopy|Colon cleansing prior to perform colonoscopy
45783961|NCT03402308|Dietary Supplement|Schisandra chinensis extract|Schisandra chinensis extract 1,000 mg/day for 12 weeks
45783962|NCT03402308|Dietary Supplement|Placebo|Starch placebo 1,000 mg/day for 12 weeks
45783963|NCT04526951|Drug|Intravenous injection of Tenecteplase and one dose of placebo tablet|Drug: Tenecteplase Tenecteplase administered as an intravenous injection (0.25 mg/kg body weigh; maximum 25 mg)
45783964|NCT04526951|Drug|One tablet of Acetylsalicylic Acid and one dose of IV placebo|300 mg Acetylsalisylic acid
45783965|NCT04374890|Device|CP308|3 weeks of baseline followed by 2x3 weeks use of the test device
45643754|NCT04210427|Device|SmartPill Motility System & PillCam Patency Capsule|Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.
45783966|NCT04956744|Biological|IMS001|IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC).
45783967|NCT03408860|Other|Countering Emotional Behaviors Module from Unified Protocol|This is a 4-week behavioral treatment that teaches patients to counter problematic emotional avoidance by approaching behaviors and situations that may bring up strong emotions in the short-term, but prevent interfering emotional difficulties in the long-term.
45783968|NCT04956432|Drug|SHR4640|SHR4640 Dose 1 ,tablets, QD
45783969|NCT04956432|Drug|Allopurinol|Allopurinol 300mg, tablets, QD
45783970|NCT02248415|Other|No pump|In the no pump group blood cardioplegia was delivered using the arterial line pressure, created by the arterial centrifugal pump of the cardiopulmonary bypass system. Blood cardioplegia flow depended on the difference between arterial line pressure and aortic root pressure.
45783971|NCT02248415|Other|Pump|In the pump group blood cardioplegia was delivered using a roller pump. The blood cardioplegia flow was given at 200 mL/min.
45783972|NCT02248415|Other|Blood sample collection: after induction of anaesthesia (T0)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
45783973|NCT02248415|Other|Blood sample collection: after arrival at the ICU (T1)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
45783974|NCT02248415|Other|Blood sample collection: 4 hours in ICU (T2)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
45783975|NCT02248415|Other|Blood sample collection: the first postoperative day (T3)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
45643755|NCT04209114|Biological|Nivolumab|Specified dose on specified days
45643756|NCT04209114|Procedure|Radical cystectomy (RC)|Surgical removal of the bladder
45643757|NCT04209114|Biological|Bempegaldesleukin|Specified dose on specified days
45643758|NCT04201574|Drug|ALY688 0.1%|ALY688 0.1% Ophthalmic Solution
45783976|NCT03409406|Behavioral|Caregiver Intervention|This intervention is a 3-month (or 12 weeks) sequenced mobile health intervention provided to the parent/caregiver to use at home with the child. It supplements the 30 minute speech and language therapy session provided to the child at the hospital once a month
45783977|NCT03409406|Behavioral|ST Intervention|This intervention is the 30 minute speech and language therapy session provided to the child at the hospital once a month for three months.
45783978|NCT02248571|Drug|Bevacizumab|administered as combined therapy with Capecitabine
45783979|NCT02248571|Drug|Capecitabine|administered as combined therapy with Bevacizumab
45783980|NCT02248571|Drug|Everolimus|administered as combined therapy with Exemestane
45783981|NCT02248571|Drug|Exemestane|administered as combined therapy with Everolimus
45783982|NCT02248571|Other|Patient questionaires|Patients will fill out questionaires at four specific time points during study treatment to assess patient reported outcome and patients' preference
45783983|NCT04376840|Other|Blood sample and data record|Blood sample and data record
45783984|NCT00019604|Procedure|computed tomography|Scan to assess the effects of ablation.
45783985|NCT00019604|Procedure|magnetic resonance imaging|Imaging used to assess the effects of this ablative therapy on tumor vascular density.
45783986|NCT00019604|Procedure|positron emission tomography|Physiology based method of imaging disease based on uptake and metabolism of radiopharmaceutical by the tissues.
45783987|NCT00019604|Procedure|radiofrequency ablation|Radiofrequency ablation uses saline infusion into and out of needle/electrode through a closed system. More energy may be deposited without tissue-charring or gas vaporization.
45783988|NCT00019604|Procedure|radionuclide imaging|Imaging following injection of a radioactive material.
45783989|NCT00019604|Procedure|ultrasound imaging|An ultrasound (e.g. sound waves) is used to identify the lesion and needle placement.
45783990|NCT00019604|Radiation|fludeoxyglucose F 18 (FDG-PET)|FDG PET scans rely on metabolic changes to evaluate response to therapy.
45783991|NCT00019604|Radiation|gadopentetate dimeglumine|Food and Drug Administration approved contrast agent.
45783992|NCT03002675|Drug|Bydureon|exenatide (Bydureon) 2mg s.c. 1x/wk
45783993|NCT03002597|Device|BrainPort V200 Device|To see if the device can be used in a pediatric population by measuring the subjects' improvement over baseline in any of the following areas: light detection, light localization, movement perception, and standardized object recognition tasks after use of the BrainPort.
45783994|NCT03402074|Behavioral|Group hypnosis|5 session of group hypnosis, each 90 minutes, to reduce subjective stress and increase relaxation. Additional auditapes of hypnosis sessions as hoemwork
45783995|NCT03002441|Device|Same-Day Dilapan-S|Dilapan-S cervical dilators placed the same day as the D&E procedure
45783996|NCT03002441|Device|Overnight Dilapan-S|Dilapan-S cervical dilators placed the day prior to D&E procedure
45783997|NCT02246270|Drug|Intravesical Heparin|Heparin bladder instillation
45783998|NCT02246270|Other|Placebo|Intravesical saline
45783999|NCT03002363|Behavioral|Video Modeling Intervention|Prior to arrival of the audiological evaluation, the child and caregiver will be required to watch one of two videos created by the research personnel. One video, the intervention video, is a behavior modeling video walking through the entire audiological evaluation. It also includes tips for caregivers to practice with their child before the appointment. The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
45784000|NCT03002363|Behavioral|Placebo Video|The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
45784001|NCT04374344|Other|Qualitative analysis of PPG, single-lead ECG, and 12-lead ECG measurements|Participants are instructed to qualitatively analyse PPG, single-lead ECG, and 12-lead ECG heart rhythm traces.
45784002|NCT03002285|Behavioral|Cerebral Palsy group|Group with Cerebral Palsy that performed the Fitts law in a computer task
45784003|NCT03002285|Behavioral|Control group|Group with typical development that performed the Fitts law in a computer task
45784004|NCT04374422|Behavioral|fsfi survey|sexual behavior Questionaire
45784005|NCT03002051|Device|EUS-guided drainage|"Ultrasonographic evaluation of the lesion by linear echoendoscope and positioning for transenteric puncture in shortest distance between enteric wall and the target lumen for drainage.~EUS-guided transenteric puncture by using a 19-gauge needle followed by placement of a 0.035 or 0.025-inch guidewire into the target lumen.~After the needle is removed in remaining the guidewire, the tract is dilated over the guidewire by using bougie dilator or needle type cystotome (Endoflex, Voerde, Germany). And then, the tract may be more dilated by using balloon catheter (4-mm).~After dilation of the tract, stent delivery system is inserted over the guidewire into the target lumen.~After complete deployment of the distal flange under EUS and fluoroscopic guidance into the target lumen, proximal retraction of the delivery system until the blue mark on the handle of the introducer is seen. And then, the proximal flange is deployed slowly under endoscopic guidance."
45784006|NCT02247557|Drug|Liposome encapsulated BoNT-A|Liposome encapsulated BoNT-A ( mixed BOTOX 200U/10ml in Liposome 80mg/40ml) in single intravesical instillation
45784007|NCT02247557|Drug|BOTOX 200U in normal saline|BOTOX 200U in normal saline (BoNT-A/NS) 50ml in single intravesical instillation
45784008|NCT02247557|Drug|Normal saline|Normal saline (N/S) 50ml in single intravesical instillation
45784009|NCT03401996|Device|1 mA tDCS over bilateral SMA|"A 1mA direct current will be delivered through two 5cm x 5cm saline-soaked surface sponge electrodes by a battery-driven, constant-current stimulator (Neuroconn DC stimulator). First, the SMA will be identified based on the guidelines of the international 10-20 electrode system. The tDCS will then be applied using the following procedure:~The head of participants will be measured to find the 'vertex' (top) of the head. This point will be used as a landmark to locate the SMA. This region corresponds to the FCZ (e.g., Legon et al., 2013).~The return electrode will be placed over the mastoids. Once the electrodes are in position, cathodal tDCS will be applied at 1mA for 15 minutes, 2 times a day with a resting period of 20 minutes in between treatment periods, for 5 consecutive days."
45784010|NCT04374110|Other|Clinical data|Clinical characteristics from medical records
45784011|NCT02996045|Other|Clinical Decision Support (CDS)|"A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-6, and scans scored 7-8 for which an alternative scan scored 8-9 exists.~This screen will show the appropriateness score of the original scan order, and will display up to 7 alternative scans that are scored >4 and greater than or equal to the original score for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication."
45784012|NCT03401684|Behavioral|Resilient Minds|The program is designed: 1) to decrease the risk of developing a stress disorder or other mental illnesses due to workplace incidents and/or unhealthy stress; 2) to mitigate the negative impacts of mental illness and trauma through early recognition and early intervention; 3) to support the public while on the frontline; and 4) to improve the psychological health of fire staff while cultivating resilience and enhancing quality of life.
45784013|NCT02240264|Dietary Supplement|Krill oil capsules|1 year supplementation with Krill oil provided by Aker BioMarine Antarctic AS equalling almost the daily recommended amount of 450 mg of EPA/DHA intake per day.
45643759|NCT04201574|Drug|ALY688 0.4%|ALY688 0.4% Ophthalmic Solution
45643760|NCT04201574|Drug|Vehicle|Vehicle Ophthalmic Solution
45784014|NCT02240264|Dietary Supplement|Placebo|Capsules containing a fatty acid mixture that reflects the fatty acid composition of the average European diet.
45784015|NCT04373798|Diagnostic Test|C-reactive protein|Measurement of CRP value from blood sample taken at covid19 check point (baseline).
45784016|NCT02226965|Drug|PNT2258|
45784017|NCT04374188|Drug|Ciprofloxacin|drug adminstration to ameliorate sepsis incidence
45643761|NCT04200443|Drug|Cabozantinib|Given PO
45784018|NCT04374188|Drug|Levofloxacin|levofloxacin pill
45784019|NCT04374032|Drug|metenkefalin + tridecactide|ENKORTEN® 5 mg + 1 mg Lyophilisate for Solution for Injection
45784020|NCT04374032|Drug|The standard of care|The usual therapeutically established protocol, for the treatment of patients with moderate to severe COVID-19 infection prescribed by The Agency for medicinal products and medical devices of Bosnia and Herzegovina
45784021|NCT02227121|Device|Defibrillation following induction of VT/VF|Up to 10 VT/VF induction attempts followed by shock(s) delivered by an externally placed ICD and/or external defibrillator.
45784022|NCT04373876|Device|Subcutaneous Implantable Cardioverter Defibrillator|Patients implanted with a totally subcutaneous defibrillator system
45784023|NCT02492958|Biological|Staphylococcus aureus 4-antigen vaccine|a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
45784024|NCT02492958|Biological|Placebo|a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
45784025|NCT04373408|Procedure|ACL repair without anterolateral repair|Surgical repair of the ACL using semitendinous autograft
45784026|NCT04373408|Procedure|ACL repair with anterolateral repair|Surgical repair of the ACL using semitendinous autograft, and surgical repair of the ALL using an allograft (Arthrex, Extra-Articular Augmentation device)
45784027|NCT04906421|Drug|TVB-2640|Oral dose, tablet
45784028|NCT04906421|Other|Placebo|Oral dose, tablet
45784029|NCT02492880|Device|Precision Spectra™ SCS system programming features|Precision Spectra™ SCS system programming features using the CoverEdge surgical lead.
45784030|NCT03401606|Drug|remifentanil|remifentanil, 0.25 ng/mL, given intravenous, infusion, until surgery finished
45449076|NCT04863430|Drug|Oxaliplatin|130mg/m^2 administered as IV infusion on Days 1 of each 21-day cycle
45643762|NCT04200443|Other|Quality-of-Life Assessment|Ancillary studies
45643763|NCT04200443|Other|Questionnaire Administration|Ancillary studies
45643764|NCT04200443|Drug|Temozolomide|Given PO
45643765|NCT04199741|Drug|89Zr-DFO-SC16.56|Injection of 2 mCi of 89Zr-DFO-SC16.56 for Phase I participants. Dose for Phase II will be determined by results from Phase I.
45643766|NCT04199741|Drug|SC16.56, Phase I, Cohort 2|7.5mg
45784031|NCT03401606|Drug|Dexmedetomidine|dexmedetomidine, 0.125 mcg/kg/hour, given intravenous, infusion, until surgery finished
45784032|NCT04347668|Other|Virtual Reality|VR requires the user to use a multi-projected in their own room using BroomX to generate realistic images, sounds and other sensations that simulate a user's physical presence in a virtual or imaginary environment
45784033|NCT04347668|Other|Usual Care|meals, engagement in scheduled and non-scheduled programs such as exercise, and activities, groups. Residents are supported in their activities of daily living, and social engagement. Specific interventions based on resident needs are supported in a Dementia capable environment.
45784034|NCT03401528|Drug|AVB-S6-500|AVB-S6-500 is an investigational drug.
45784035|NCT03401528|Other|Placebo|Matching placebo
45784036|NCT05627687|Behavioral|Heart Rate Variability Biofeedback|Practice using the Inner Balance app and device, 10 minutes/day, 4-5 days per week
45784037|NCT05627687|Behavioral|Music Listening Control|Listening to music using the Coffeehouse playlist on either Pandora or Spotify app, 10 minutes/day, 4-5 days per week
45784038|NCT02516592|Drug|QVA149 110/50 micrograms|QVA149 110/50 micrograms o.d. capsules for inhalation, supplied in blisters via a single dose dry powder inhalater (SDDPI)
45784039|NCT02516592|Drug|Salmeterol/fluticasone 50/500 microgrammes|Salmeterol/fluticasone 50/500 microgrammes b.i.d.dry inhalation powder delivered via Accuhaler / Diskus device
45784040|NCT03401372|Drug|Doxycycline|Oral doxycycline 100mg twice daily
45784041|NCT03401372|Drug|Bortezomib|1.3mg/m2 of bortezomib on days 1, 8, 15 and 22 of a 35-day cycle
45784042|NCT03401372|Drug|Cyclophosphamide|300mg/m2 cyclophosphamide on days 1, 8, 15 and 22 of a 35-day cycle
45784043|NCT03401372|Drug|Dexamethasone|40mg of dexamethasone on days 1, 8, 15 and 22 of a 35-day cycle
45449077|NCT04863430|Drug|S1|According to body surface area,(<1.5m^2) 40mg or (≥1.5m^2)50mg bid oral on Day 1-14 of each 21-day cycle
45643767|NCT04199741|Drug|SC16.56, Phase I, Cohort 3|22.5mg
45643768|NCT04199741|Drug|SC16.56, Phase II|Dose for Phase II will be determined by results from Phase I.
45643769|NCT04194840|Other|physical therapy consult|Physical therapy consult to assess physical functioning on a separate office visit prior to attending the Transplant Wellness Clinic. Full evaluation that incorporates several tools to measure the risk of falling and to assess mobility and strength
45643770|NCT04194840|Other|Cognitive Assessment|Montreal cognitive assessment (MoCA) and the Blessed Orientation-Memory-Concentration Test (BOMC)
45643771|NCT04194840|Other|Cancer Aging Research Group (CARG) assessment|CARG assessment - utilized to capture information about a participant's medical history as well as functional, cognitive, and psychosocial status
45643772|NCT04194840|Other|Medication Review|Medication Review via Beers Assessment
45643773|NCT04194840|Other|Nutrition assessment|Nutrition assessment Via Mini Nutrition Assessment (MNA)
45643774|NCT04194840|Other|Laboratory studies|Laboratory studies including urine toxicology screen, C-reactive protein, albumin, pre-albumin, vitamin D
45643775|NCT04194840|Other|Patient satisfaction questionnaire|Patient satisfaction questionnaire
45643776|NCT04194840|Other|Physician Questionnaire|"Physician Questionnaire:~Questionnaire to learn about physician satisfaction with information received from reports and participant questionnaires."
45784044|NCT05606705|Dietary Supplement|Baked Milk|Participants to regularly eat a baked milk muffin for 6 weeks
45784045|NCT05597969|Behavioral|FoodCoach|The FoodCoach app displays transparent analysis and recommendations regarding participant's food purchases recorded on their loyalty cards. It tries to help participants understand why and how they should/can shop more healthily, motivating them to change their unhealthy food purchase behavior.
45643777|NCT04194840|Other|Patient follow-up questionnaire|"Patient follow-up questionnaire:~Questionnaire to learn more about participant opinions concerning the clinic and the quality of care received during visits with specialists"
45643778|NCT04194034|Biological|TG6002|"Phase I part: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU. Phase II part: Established recommended Phase II dose (RP2D).~Intrahepatic arterial (IHA) administration on Day 1 within a 14-day cycle of TG6002/5-FC combination treatment.~A second cycle of TG6002/5-FC combination starting with TG6002 (IHA) administration at the same dose on Day43 can be initiated if no progressive disease or Dose Limiting Toxicity event in between; maximum 2 cycles of TG6002/5-FC combination treatment for each patient."
45643779|NCT04194034|Drug|Flucytosine (5-FC)|"Oral administration 4 times per day at the total dose of 200 mg/kg/day for 10 consecutive days per 14-day cycle of TG6002/5-FC combination.~A second cycle of TG6002/5-FC combination will be initiated if no progressive disease or Dose Limiting Toxicity event in between."
45784046|NCT04373096|Device|current IPAC-UHN PPE|"Fit-tested N95 mask~Open face shield~Double extended-cuff"
45784047|NCT04373096|Device|modified IPAC-UHN PPE|"Fit-tested N95 mask~Hood~Double extended-cuff gloves"
45784048|NCT04763915|Other|Correlative Studies (Survey)|Administer surveys
45784049|NCT04763915|Other|Correlative Studies (Interview)|In-depth interviews among a subset of participants after the 12-month follow-up survey to either: 1) determine additional resources and tailored message that would be helpful; or 2) assess the adaptive intervention
45784050|NCT04763915|Behavioral|GeneSHARE|Access to GeneSHARE, a web-based toolkit which includes interactive and narrative components to enhance FC of genetic test results.
45784051|NCT04763915|Behavioral|LivingLabReport|Access to LivingLabReport, a website containing multiple resources including a summary of the patient's genetic test results, condition-specific information, recommended CRM, and information on accessing CRM services.
45784052|NCT04763915|Behavioral|Standard-of-care & Adaptive Intervention|Receive standard-of-care from their treating healthcare provider. A subset of individuals will also be asked to test and pilot the adaptive intervention, which will consist of tailored resources to promote CRM and FC, after the 12-month follow-up survey.
45784053|NCT04934904|Drug|Ropivacaine injection|On the first day of inclusion, performed T8 bilateral ultrasound-guided erector spinae plane block and indwelling tube will be left + 0.375% ropivacaine 20ml to both sides. Patients will be given injections every 12 h for 7 days.
45784054|NCT03401216|Device|SYNERGY 48 mm|Material: Platinum-Chromium alloy. Stent strut thickness: 0.0029-0.0032 inches. Polymer carrier composed of PLGA (poly(DL-lactide-co-glycolide)). Drug product: Everolimus, 1µg per 1 mm2. Stent diameters available: 2.25; 2.50; 2.75; 3.00; 3.50; 4.00 mm. Stent length: 48 mm. Nominal balloon pressure: 11 atm. (1117 kPa). Manufacturing company: Boston Scientific Corporation (USA)
45784055|NCT03401216|Procedure|PCI|Standard PCI procedure
45784056|NCT03401216|Procedure|3 month OCT follow-up|Optical coherence tomography imaging of target vessel within 3 month after PCI
45784057|NCT03401216|Procedure|6 month OCT follow-up|Optical coherence tomography imaging of target vessel within 5 month after PCI
45784058|NCT02219321|Drug|Lidocaine infusion|Lidocaine intravenous 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg /kg /hour for 4 hours
45784059|NCT02219321|Drug|Saline infusion|A continuous intravenous infusion of saline at the same volume with lidocaine infusion for 4 hours
45784060|NCT02241044|Device|Argon plasma coagulation|Argon plasma coagulation therapy was realized by an Olympus electrosurgical unit/APC unit (PSD-60/Endoplasma, Olympus Corporation, Tokyo, Japan), and its catheters were 2.3mm and 3.5 mm equipped with different endoscope channels.7 APC treatment used a coagulation mode at gas flow/power settings of 1.5L/min and 40 watt for duodenal ulcers and 40-60 watt for gastric ulcers.10 Operative distance between the probe and target bleeding ranged from 2 to 8 mm. Air warranted to be sucked frequently at endoscopy in an attempt at decrease of APC-induced smoke and gastric decompensation, with appropriate treatment of high-risk bleeding ulcers.
45784061|NCT02241044|Device|Distilled water|Distilled water was then applied in aliquots of 0.5-2.0 mL, at and around the site of target bleeding, up to 25.0 ml if necessary. Injection amount was determined by endoscopists according to ulcer or vessel size and its location.
45784062|NCT04955574|Other|SH-DS01 + Antibiotic Placebo|Participants will be instructed to take 2 capsules of SH-DS01 probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of SH-DS01 probiotic once daily (at lunch) and 1 capsule of placebo for antibiotic twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
45784063|NCT04955574|Drug|SH-DS01 + Metronidazole|Participants will be instructed to take 2 capsules of SH-DS01 probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of SH-DS01 probiotic once daily (at lunch) and 1 capsule of 500mg metronidazole twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
45643780|NCT04191187|Drug|Fludarabine|Fludarabine 30mg/m^2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2 for a total dose of 150 mg/m^2
45643781|NCT04191187|Drug|Melphalan|Melphalan 70 mg/m^2 over 45 minutes will be administered Day -6. Melphalan dose will be calculated based on Actual Body Weight.
45643782|NCT04191187|Radiation|Total Body Irradiation|Total Body Irradiation (TBI) will be delivered at a dose of 200 centigray units (cGy)
45643783|NCT04191135|Biological|Pembrolizumab|intravenous (IV) infusion
45643784|NCT04191135|Drug|Olaparib|oral tablets
45643785|NCT04191135|Drug|Carboplatin|IV infusion
45643786|NCT04191135|Drug|Gemcitabine|IV infusion
45643787|NCT04356170|Drug|Docetaxel|Docetaxel 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour
45643788|NCT04356170|Drug|Cisplatin|cisplatine 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour
45643789|NCT04356170|Drug|Fluoro Uracil|750 mg/m²/j administered continuously at D1 to D5 of each cure, every 3 weeks by intravenous infusion ( so 120 hours)
45643790|NCT04188418|Drug|Fentanyl Citrate Buccal Tablet|Given transmucosally
45643791|NCT04188418|Drug|Morphine|Given PO
45784064|NCT04955574|Other|Probiotic Placebo + Antibiotic Placebo|Participants will be instructed to take 2 capsules of placebo for probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of placebo for probiotic once daily (at lunch) and 1 capsule of placebo for antibiotic twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
45784065|NCT04751279|Other|Blood sample|Blood sample collection of 5 blood sample at the inclusion in the study the samle consite of 5 tubesEthylene Diamine Tetra Acetate (ADTA) of 7 ml
45784066|NCT02156258|Device|FFDM Mammography|Standard mammography image collection
45784067|NCT02156258|Device|DBT Mammography|Collection of breast images using DBT mammography
45784068|NCT02492100|Behavioral|Multi-modality sexual dysfunction intervention|
45784069|NCT04716335|Drug|DMT|DMT
45784070|NCT04716335|Drug|Harmine|Harmine
45784071|NCT04716335|Drug|Placebo (Harmine)|Placebo for Harmine
45784072|NCT04716335|Drug|Placebo (DMT)|Placebo for DMT
45784073|NCT00924482|Device|Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery|Measure cardiac output during perioperative period and compare to pulmonary artery thermodilution cardiac output measurements.
45784074|NCT04283669|Drug|Crizotinib|Oral
45784075|NCT04366934|Other|Nasal swab|Nasal swab
45784076|NCT04366934|Other|Taste and olfactory function evaluation|Taste and olfactory function evaluation
45784077|NCT02221349|Device|Potassium oxalate|Professionally applied (liquid) and self applied (gel)
45784078|NCT02221349|Drug|Sodium fluoride paste|Toothpaste used by subject
45784079|NCT02221349|Drug|Stannous fluoride paste|Toothpaste used by subject
45784080|NCT02461758|Biological|Standard dose Influenza vaccine (SDIV)|
45784081|NCT02461758|Biological|High dose influenza vaccine (HDIV)|
45643792|NCT04188418|Other|Physical Performance Testing|Complete shuttle walk test
45643793|NCT04188418|Other|Placebo Administration|Given PO
45643794|NCT04188418|Other|Quality-of-Life Assessment|Ancillary studies
45643795|NCT04188418|Other|Questionnaire Administration|Ancillary studies
45643796|NCT04181762|Drug|secukinumab|STUDY DRUG
45784082|NCT04372784|Device|Cryotherapy|Cryotherapy entails introducing a 9 French catheter via the endoscope's accessory port. The catheter is advanced until it is visualized on the endoscopy monitor. Under 4 psi pressure, liquid nitrogen is sprayed from the catheter for twenty seconds over each four-centimeter segment of stricture
45784083|NCT04372784|Procedure|Esophagogastroduodenoscopy with Balloon Dilatation|This procedure entails deploying a balloon via the accessory port of the esophagogastroduodenoscope under direct visualization and serially inflating the balloon. Balloon dilatation disrupts not only the muscular rings surrounding strictures but also the granulation tissue composing the strictures.
45784084|NCT04248023|Behavioral|Practice Facilitation|A practice facilitator will be assigned the each participating practice to assist with the development of a workflow, screening process, counseling resources, and referral resources for unhealthy alcohol use. Practices in control group will receive delayed intervention at 3 months after their matched cohort of practices.
45784085|NCT04376996|Diagnostic Test|NO intervention planned due to the observational study design - only a diagnostic testing|Only a diagnostic tests are planned: SARS-CoV-2 RNA in nasopharyngeal samples and anti-SARS-CoV-2 antibodies in blood
45784086|NCT04222673|Behavioral|Peer Specialist Suicide Prevention|The intervention will last 3-months, a time frame that overlaps with the typical duration of a VA suicide high risk flag. Meetings will be 30-45 minutes and occur primarily in the community, home, or by telephone. Session content will be rooted in Peer Specialists (PSs) offering nonjudgmental empathic support, active listening, and constructive disclosure and role modeling. A primary focus will be helping patients with flags to identify and strengthen connections with informal supports and participation in activities in their community that will enable them to feel more worthwhile as individuals and hopeful about their future.
45784087|NCT00921518|Drug|0.9% Sodium Chloride (Placebo)|0.9% Sodium Chloride (placebo) will infuse at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
46070859|NCT03861572|Other|Isokinetic eccentric training|Training sessions will be performed in the same isokinetic dynamometer used in previous evaluations, twice a week, with a minimum interval of 72 hours between sessions.
45643797|NCT04181060|Biological|Bevacizumab|Given IV
45643798|NCT04181060|Procedure|Biospecimen Collection|Undergo blood sample collection
45643799|NCT04181060|Procedure|Computed Tomography|Undergo CT
45643800|NCT04181060|Procedure|Echocardiography|Undergo ECHO
45643801|NCT04181060|Procedure|Magnetic Resonance Imaging|Undergo MRI
45643802|NCT04181060|Procedure|Multigated Acquisition Scan|Undergo MUGA
45643803|NCT04181060|Drug|Osimertinib|Given PO
45643804|NCT04176198|Drug|TP-3654|Oral PIM Inhibitor
45784088|NCT00921518|Drug|Sodium Bicarbonate|Group two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
45784089|NCT04221269|Behavioral|Enhanced Treatment as Usual|Routine community care plus assessment feedback reports to clinicians.
45784090|NCT04221269|Behavioral|Coping Long-term with Active Suicide Program for Schizophrenia|Adjunctive psychosocial intervention for suicide prevention involving in person, family, and phone sessions.
45784091|NCT02461290|Radiation|Chemotherapy|
45784092|NCT02461290|Drug|Rituximab|
45784093|NCT04376528|Drug|Cyclosporin A|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with cyclosporin A)
45784094|NCT04376528|Drug|Mycophenolate Mofetil|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with mycophenolate mofetil )
45784095|NCT04366466|Other|suicide attempt patient using PEPS Program|"The research protocol consists of two phases separated by randomization.~A Hospital Phase common to both groups:~Day zero is the day of the suicide attempt for which the patient came to the hospital.~A post-hospital phase including the P.E.P.S. program for the intervention group and telephone reminders for the usual treatment group."
45784096|NCT02461134|Drug|Ponesimod|Oral film-coated tablets at the doses of 2, 3, 4, 5, 6, 7, 8, 9, 10, and 20 mg. One tablet of ponesimod at any dose will be taken orally once daily.
45784097|NCT04373018|Procedure|Sodium hypochlorite|Sodium hypochlorite irrigant will be used during biomechanical preparation.
45784098|NCT04373018|Procedure|Chlorhexidine|Chlorhexidine irrigant will be used during biomechanical preparation.
45643805|NCT04176133|Drug|Entolimod|Intramuscular (IM) single dose administration. Entolimod is provided as a sterile, clear, colorless or slightly yellow liquid for IM injection.
45784099|NCT04373018|Procedure|Chlorhexidine + Hydrogen peroxide|Chlorhexidine + Hydrogen peroxide irrigant will be used during biomechanical preparation.
45784100|NCT04636307|Other|Biomarkers|To identify biomarkers obtained using non-invasive procedures that can predict disease progression and progression to sight-threatening stages of the disease and to characterize the retinal changes that occur in NPDR.
45784101|NCT04366154|Other|Questionnaire|delivery of questionnaires on perceived stress, post-traumatic stress, sleep disorders, quality of life, cognitive complaint
45643806|NCT04176133|Drug|Placebo|Intramuscular (IM) single dose administration, no active ingredient. A matching placebo is provided as a sterile, clear, colorless to slightly yellow liquid for IM injection in prefilled vials that are identical in appearance to the vials containing active drug.
45643807|NCT04176133|Drug|Influenza vaccine|Intramuscular (IM) single dose administration. Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur
45643808|NCT04175418|Other|Supervised Exercise Program|The exercise program in this group includes aerobic (walking) training and exercises to strengthen the upper and lower extremities and trunk muscles.
45643809|NCT04175418|Other|Online Education Program|The exercise program in this group includes aerobic (walking) training and home exercises to strengthen the upper and lower extremities and trunk muscles.
45784102|NCT04934748|Drug|Phenylephrine|Phenylephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
45784103|NCT04934748|Drug|Norepinephrine|Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
45784104|NCT04934748|Drug|Phenylephrine|Phenylephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
45784105|NCT04934748|Drug|Norepinephrine|Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
45784106|NCT04594733|Drug|minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo|minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo
45784107|NCT04594733|Drug|Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)|Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)
45784108|NCT02241122|Procedure|prostate biopsy|
45643810|NCT04174560|Biological|Norovirus GII.4 Challenge Pool|Subjects will be NPO (nothing by mouth) for at least 90 minutes followed by ingestion of 60 mL of a 2% sodium bicarbonate solution by mouth. 2 minutes later, subjects will be administered Norovirus GII.4 CIN-3. Five minutes following administration of the challenge dose, subjects will be administered a 60 mL volume of a 2% sodium bicarbonate solution and then remain NPO for at least the next 90 minutes. Subjects will be observed during the 60 minutes after receipt of the challenge by a study team member to detect and treat any immediate adverse reactions.
45643811|NCT04171908|Other|Conventional therapy|Conventional Physical therapy for the upper limb
45784109|NCT02223065|Drug|Saxagliptin|
45643812|NCT04171908|Other|semi-inversive tech|Conventional Physical therapy for the upper limb plus Semi-inversive tech
45784110|NCT02223065|Drug|Dapagliflozin|
45784111|NCT04366232|Drug|Anakinra alone (stages 2b/3)|Anakinra 300 mg 1/d Intravenous 5 days then dose tapering
45784112|NCT04366232|Drug|Anakinra and Ruxolitinib (overcome stage 3)|Anakinra 300 mg od Intravenous (maximum14 days) Ruxolitinib 5 mg bid per os (maximum 28 days)
45784113|NCT04366232|Other|Standard of care|Routine clinical care for Covid-19
45784114|NCT02241200|Drug|DA3880|
45784115|NCT02241200|Drug|Aranesp|
45784116|NCT02223455|Other|Hand Hygiene Signs|Hand hygiene signs will not be changed (control) or change weekly/monthly on wards/units randomized to each of these study arms. Signs will be posted by the hand hygiene sanitizer outside each patient room.
45784117|NCT02241278|Drug|Ketamine|In the operating room, the anesthesiologist administered 0.5 mg/kg of ketamine chlorhydrate in 50 mL of 0.9 % saline intravenously to patients in the ketamine group 30 minutes before surgical incision (a single dose).
45784118|NCT04347512|Drug|Hydroxychloroquine and azithromycin treatment arm.|"Patient allocated in this arm receive hydroxychloroquine and azithromycin for 5 days.~For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~For azithromycin, there is a loading dose of 500 mg per day at D1, followed by 250 mg per day D2-D5.~Every patient receive as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc)."
46070860|NCT03861572|Other|Traditional eccentric training|Training sessions will be performed at university gym, twice a week, with a minimum interval of 72 hours between sessions.
45643813|NCT04170621|Device|Ablation|Ablation using the FARAPULSE Endocardial Multi Ablation System
45643814|NCT04166409|Procedure|Biospecimen Collection|Correlative studies
45643815|NCT04166409|Drug|Carboplatin|Given IV
45643816|NCT04166409|Procedure|Magnetic Resonance Imaging|Undergo MRI
45643817|NCT04166409|Other|Quality-of-Life Assessment|Ancillary studies
45643818|NCT04166409|Other|Questionnaire Administration|Ancillary studies
45643819|NCT04166409|Drug|Selumetinib Sulfate|Given PO
45643820|NCT04166409|Drug|Vincristine Sulfate|Given IV
45643821|NCT04166318|Drug|Capecitabine|Given PO
45643822|NCT04166318|Drug|Fluorouracil|Given IV
45784119|NCT04347512|Drug|Hydroxychloroquine|"Patient allocated in this arm receive hydroxychloroquine for 5 days. For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~Every patient receives as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc)."
45784120|NCT04347512|Drug|Control arm|In this arm, no experimental treatment is prescribed. Patients receive IV antibiotics and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).
45643823|NCT04166318|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45643824|NCT04166318|Drug|Mitomycin|Given IV
46070861|NCT03859999|Diagnostic Test|Analysis of primary radiograph and available demographics|Multivariate analysis of the fracture x-ray features measured by computer, together with the database demographic and outcome data will be used to develop the best model /decision rule to predict likelihood of MUA success
45643825|NCT04166318|Other|Quality-of-Life Assessment|Ancillary studies
45784121|NCT04366076|Diagnostic Test|Fetal heart rate (FHR) monitoring through computerized cardiotocography (cCTG) analysis antepartum|The investigator conducted antepartum surveillance through computerized cardiotocography (cCTG) analysis antepartum. This is a non-invasive method to study fetal well being. For each patient, a cCTG was attended using a computerized cardiotocography machine. External cCTG was practised for no less than 20 min (max 60 min), two transducers were fixed on the maternal abdomen: one above the fetal heart level and the other at the uterine fundus
45784122|NCT04160429|Procedure|Biospecimen Collection|Undergo collection of sweat, saliva, and blood samples
45784123|NCT04160429|Other|Medical Chart Review|Review of medical chart
45784124|NCT04160429|Other|Questionnaire Administration|Complete questionnaire
45784125|NCT02460978|Drug|Dapagliflozin|Tablets
45784126|NCT02460978|Other|Placebo for dapagliflozin|Tablets
45784127|NCT04365842|Behavioral|Digital exercise group|"Hand Rehabilitation Program: Developed hand exercise smartphone app which include: Self-assessment, (b) self-monitoring (c) exercises types/frequency/ diary, (d) patient education, (e) behavioral change and encouragement (f) exercise adherence Sample exercises~Hand and finger movements: 6-8 repetitions, according to the diagnosis of the patient~Strengthening exercises of hand and finger muscles~Exercises to increase grip and pinch strength~Exercises to increase tendon swing and pull angle"
45784128|NCT04365842|Other|General Home Hand Therapy|"Hand rehabilitation home program will be given to the through the telephone messages with brochures.~Hand and finger movements: 6-8 repetitions, according to the diagnosis of the patient~Strengthening exercises of hand and finger muscles~Exercises to increase grip and pinch strength~Exercises to increase tendon swing and pull angle"
45784129|NCT04372316|Drug|methylcobalamin|methylcobamin injection 8 weeks or tablet 8 weeks， followed by 24 weeks methylcobamin tablet until 32 weeks
45784130|NCT02221739|Drug|Ipilimumab|
45784131|NCT02221739|Radiation|Radiotherapy (IMRT or 3-D CRT)|
45784132|NCT02241356|Device|bifocals|bifocal glasses with an addition of 2.5 Dioptres
45784133|NCT02241356|Device|single vision glasses|single vision glasses
45643826|NCT04166318|Other|Questionnaire Administration|Ancillary studies
45643827|NCT04165317|Drug|PF-06801591|A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
45643828|NCT04165317|Drug|Bacillus Calmette-Guerin|Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
45643829|NCT04165213|Behavioral|COPE online training|"The intervention being tested is PACE staff training in COPE - accomplished with the creation of self-paced online learning modules.~The modules will include rich multimedia content and interactive assessments to keep the learner engaged and will allow for easy packaging of the content into the latest interoperability standards for such content including the latest Shareable Content Object Reference Model (SCORM) specifications, which will allow for repurposing and sharing with other institutions and will be designed using a hyperlearning model with four dimensions. The self-paced modules will be highly interactive featuring integrated multimedia content, assessments, and learner evaluations to allow PACE staff to engage with the content at a high level and practice application in simulated scenarios. Each module will require approximately 45-60 minutes/module for the learner to complete.le for the learner to complete."
45643830|NCT04164082|Drug|Gemcitabine Hydrochloride|Given intravesically
45784134|NCT02241434|Biological|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
45784135|NCT04479761|Behavioral|Visual and Auditory Cues|Within each scene there will be 2 levels of visual input (static or dynamic) combined with 3 levels of sounds (static, none or dynamic). Postural responses to each combination will be evaluated in order to assess the role of generated and natural sounds in postural control and whether static sounds can improve balance within dynamic virtual environments.
45784136|NCT04365686|Drug|Ketofol as induction agent|Patients who received propofol (1mg/kg) plus ketamine (0.5mg/kg) at the induction of general anesthesia
45784137|NCT04365686|Drug|Propofol as induction agent|Patients who received propofol (2mg/kg) only at the induction of general anesthesia.
45784138|NCT02241590|Drug|Entecavir + Placebo|The subjects will be taking 1 Entecavir tablet per day and 4 Placebo tablets three times a day for 48 weeks.
45784139|NCT02241590|Drug|Entecavir + Fuzheng Huayu Tablet|The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 48 weeks.
45784140|NCT04083755|Drug|Ferric Carboxymaltose Injection [Injectafer]|1000mg intravenous
45784141|NCT04083755|Other|no treatment or oral iron supplementation|No treatment or treatment oral with iron supplementation if iron-deficiency anemia
45784142|NCT04372394|Drug|surufatinib|Surufatinib: 300 mg as a single dose on Days 1 and 8 with or without food
46070862|NCT00822055|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
46070863|NCT00822055|Drug|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
46070864|NCT00822055|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
45643831|NCT04164082|Biological|Pembrolizumab|Given IV
45643832|NCT04160221|Other|12 hours interval|Time interval between treatments
45643833|NCT04160221|Other|24 hours interval|Time interval between treatments
45784143|NCT04365608|Procedure|Direct laryngoscopy|standard laryngoscope with Macintosh blade
45754333|NCT04143074|Behavioral|multidisciplinary behavioral intervention|behavioral intervention - 4 visits with each of the specialist team (pediatrician, dietician, psychologist, physical activity specialist), (4 visits x 4 specialists). Each specialist ap. 30 min time. Wisits in 0-3m-6m-12m time frame. Visits focused on behavioral intervention - motivation for change and basic tools (dietician, physical activity specialist, psychologist) to implement change in nutrition and physical activity based on individual reediness for change (based on Prochaska model).
45784144|NCT04365608|Procedure|Vie Scope laryngoscopy|Vie Scope with dedicated bougie stylet
45784145|NCT05465603|Device|ETDNO (Elastic Tension digital neoprene orthosis)|A bespoke orthosis created from neoprene.
45784146|NCT04065971|Drug|2LHERP®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
45784147|NCT04065971|Drug|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
45784148|NCT04372550|Other|Exercise|Resistance and aerobic exercise in addition to standard of care rehabilitation
45784149|NCT04372550|Other|Standard of Care|Standard of care rehabilitation
45784150|NCT04372160|Other|Dietary assessment|24-hr dietary recall
45784151|NCT04040075|Drug|Biktarvy Tab|Antiretroviral drug
45784152|NCT04372004|Diagnostic Test|diagnostic tests for COVID-19 infection|Compare the efficacy of diagnostic tests for COVID-19 infection in detecting antibodies and viral-RNA
45784153|NCT02247635|Behavioral|Healthy lifestyle and adherence|"Behavioral intervention to improve adherence to treatment and 1) Maintain a caloric restriction of 500kcal in overweight adults, 2) Have a total fat intake <30% (including cholesterol and trans fat), 3) A total intake of complex carbohydrates for 50%, 3) 30g fiber, 4) Perform at least 30 minutes of moderate physical activity at least 5 days a week; 5) Maintain education and behavioral therapy changes in your lifestyle.~The model consists of monthly visits to the doctor, nutritionist and psychologist, for screening cardiometabolic risk factors, to know limitations on treatment adherence, to start intervention to evaluate reasons for success or failure, to evaluate and maintain motivation to adherence to diet, physical activity and medication and long-term care"
45784154|NCT04372082|Other|Standard of care (SOC)|SOC procedures including self-monitoring and medical follow-up of clinical signs and if necessary any other symptomatic treatment (paracetamol, antibiotics, steroids, oxygen…) during the whole study duration
45784155|NCT04372082|Drug|Hydroxychloroquine|200 mg x 3 per day during 10 days in addition to SOC
45784156|NCT04372082|Drug|Association of diltiazem and niclosamide|niclosamide 500 mg x 4 at J1 then 500 mg x 2 per day + diltiazem 60 mg x 3 per day during 10 days in addition to SOC
45784157|NCT02993393|Other|Teacher|The teachers' questionnaire based on table of specification of the learning contents, consisted of 4 parts: airway evaluation, patient preparation, strategic planning and follow up care.
45784158|NCT02993393|Other|Student|The students' questionnaire comprised 3 parts: learning content, process and evaluation.
45917716|NCT00389181|Procedure|Interventional therapy|All interventional procedures are standard of care for the treatment of AVMs. They are not experimental. A patient randomized to interventional therapy is expected to begin interventional therapy within 3 months following randomization. Interventional therapy consists of endovascular attempts at occlusion of the nidus and feeding vessels, coiling or microsurgery for feeding artery aneurysms, microsurgery for BAVM itself, and radiosurgery, these alone or in various combinations and timings.
45917717|NCT00389181|Other|Medical management|Patients participating in the trial will receive the best medical management possible for the disorder being tested in the trial and for any general medical illnesses they are demonstrated to have. One important consideration in the medical management of patients in this trial is stroke risk factor reduction.
45754334|NCT04142918|Other|Immunostaining|Immunostaining of oral mucosa/gingiva samples
45784159|NCT02241668|Procedure|PET Scan|FLT Pet Scan performed about 60 minutes after 3'-Deoxy-3'-18f-Fluorothymidine solution injected.
45784160|NCT02241668|Drug|3'-Deoxy-3'-18f-Fluorothymidine|3'-Deoxy-3'-18f-Fluorothymidine solution injected through a central venous catheter after MRI scan. After solution injected into a vein, PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. Entire procedure should last about 60-70 minutes.
45784161|NCT05363111|Biological|Actinium Ac 225-DOTA-Daratumumab|Given IV
45917718|NCT00389220|Device|Coronary stent placement|Coronary stent placement
45754335|NCT00607321|Device|Medtronic Bifurcation Stent System|Percutaneous Coronary Stenting
45784162|NCT05363111|Biological|Daratumumab|Given IV
45784163|NCT05363111|Biological|Indium In 111-DOTA-Daratumumab|Given IV
45784164|NCT02241746|Other|no intervention|
45784165|NCT04365296|Other|Experimental|The purpose of the study is to evaluate which is more effective aerobic or resistance exercises in reducing plasma liver enzymes level (AST and ALT) post burn. Subjects and Methods: Sixty burned patients with burned body surface area about 30% to 50% will participate in this study. Their ages will be ranged from 20-45 years. They will be selected from Orabi Hospital and will be divided randomly into two equal groups.
45784166|NCT04263077|Other|PLACEBO|The diamond shape technique, which is a kinesio tape technique, will be used in the lateral epicondyle region. The ends of the kinesiotapes will be applied tension-free without overlapping.
45784167|NCT04263077|Other|50% TENSION GROUP|Kinesiotape will be applied to the lateral epicondyle region with 50% tension.
45784168|NCT04263077|Other|75% TENSION GROUP|Kinesiotape will be applied to the lateral epicondyle region with 75% tension.
45784169|NCT04263077|Other|100% TENSION GROUP|Kinesiotape will be applied to the lateral epicondyle region with 100% tension.
45784170|NCT02241824|Device|In-elastic lumbar brace|
45784171|NCT02241824|Device|Elastic abdominal binder|
45917719|NCT02773849|Biological|ADSTILADRIN|
45643834|NCT04158921|Other|Control:Diabetes mobile app|The Control:Diabetes app will encourage patients to: a) predict their blood glucose level at a particular time point in the future (e.g. the next morning); then b) enter their actual blood glucose levels when that time (the next morning) comes; and c) enter reasons for the discrepancy between prediction and reality, if the prediction was significantly (e.g. > 20%) different from the actual measurement. We hypothesize that by repeatedly encouraging disassembly of blood glucose changes into individual reasons (cognitive task analysis) while providing an incentive in the form of being able to more accurately predict blood glucose levels (operant conditioning), the app will prompt the patient to learn how various internal and environmental factors affect their blood glucose. They will then be able to adjust their behavior and medications to improve their blood glucose control.
45643835|NCT04153864|Behavioral|Brief Behavioral Activation Treatment|A manualized 6-8 session BA treatment delivered individually to each participant.
45784172|NCT04224155|Device|enVista MX60EFH trifocal intraocular lenses (IOLs)|enVista MX60EFH trifocal intraocular lenses (IOLs) implanted bilaterally
45784173|NCT04224155|Device|enVista MX60E monofocal intraocular lenses (IOLs)|enVista MX60E monofocal intraocular lenses (IOLs) implanted bilaterally
45784174|NCT02489448|Drug|MEDI4736|"The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments."
45784175|NCT03850847|Other|Step 1: Semi-structured Interviews|"Cover SDMs' experience around:~withdrawal of life sustaining therapies~organ donation among those who were approached (including with the medical team and the organ donation organisation)~understanding of the situation~views on any gaps in the quantity or quality of information and discussion they received concerning their loved one's end-of-life care or donation process~Explore factors they perceived to influence their decision to consent to organ donation or not (or that would have influenced their decision for those not approached), and how such factors may have changed over the course of making this decision and since the decision (or since the event for those not approached)."
45784176|NCT03850847|Other|Step 2: National Telephone Survey|Explore SDM's beliefs and experiences around end of life and assess which beliefs are associated with the decision taken at the end of life, including decision to donate organs or not (and the strength of this association)
45784177|NCT00926588|Drug|Stepped care|Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are new tools developed for this study.
45784178|NCT05323331|Other|Circuit Training Exercise Program|The participants allocated to this group will perform Circuit Training Exercise Program
45643836|NCT04152421|Other|Software use|"The patient will connect to a computerized platform to access the program. The program consists of 5 modules (lessons), each lasting approximately 40 minutes. Each module or lesson includes pedagogical assessments and explanations of the problem(s) in question, illustrations, testimonies, tips, exercises and recommended activities."
45643837|NCT04152330|Other|Early stimulation protocol on neuropsychomotor development of children with congenital heart disease|A parenting guidance booklet will be prepared. It will contain a specific program of stimulation activities for each stage of development in simple language and with illustrations. Subdivided into 4 areas: Cognition, Language, Large Motor and Fine Motor. The duration will be 6 weeks. Parents will participate in 1 individual face-to-face meeting, where they will receive information and clarification on the application of the booklet and will have a mobile communication channel to answer questions throughout the process. Parents will be instructed on the capabilities and limitations of their babies according to the child's congenital heart disease, as well as what is expected within the typical development for this age group and the importance of early stimulation activities in each child in 4 areas of development.
45643838|NCT04152018|Drug|PF-06940434|PF-06940434 is given intravenously (IV) every 2 weeks in a 28 day cycle. Multiple dose levels will be evaluated
45784179|NCT05323331|Other|Aerobic Training Exercise Program|The participants allocated to this group will perform Circuit Training Exercise Program
45784180|NCT04371926|Drug|Hydroxychloroquine Sulfate|"Patients will receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.~Staff will receive HCQ sulfate 400mg/week for 4 weeks"
46070865|NCT00822055|Drug|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
45917720|NCT00000906|Drug|Ritonavir|
46070866|NCT00822133|Drug|lidocaine|lidocaine 5%
46070867|NCT00822133|Drug|ketamine|ketamine cream
46070868|NCT00822133|Drug|non-active drug cream|will be put on the skin
45643839|NCT04152018|Drug|PF-06801591|PF-06801591 will be administered subcutaneously on Day 1 of each 28 day cycle.
45643840|NCT04150614|Drug|Granisetron Transdermal Patch|Antiemetic
45643841|NCT04150614|Drug|Intravenous Dexamethasone|Antiemetic
45643842|NCT04150614|Drug|Ondansetron|ondansetron
45784181|NCT02248883|Drug|TPV low|
45784182|NCT02248883|Drug|Placebo|
45784183|NCT02248883|Drug|Moxifloxacin|
45784184|NCT02248883|Drug|TPV high|
45784185|NCT02248883|Drug|RTV|
45784186|NCT04365452|Device|Invia Motion|Invia Motion NPWT system at cesarean delivery
45784187|NCT04371692|Other|self-administered questionnaire|Every weeks during 2 months, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure
45917721|NCT00000906|Drug|Saquinavir|
45917722|NCT00000906|Drug|Methadone hydrochloride|
45917723|NCT02740816|Other|Comparative blood analysis|Collection of menstrual blood and systemic blood
45917724|NCT00000927|Drug|BufferGel|
46070869|NCT00822211|Drug|Vildagliptin 50 mg bid|
46070870|NCT00822211|Drug|Vildagliptin 50 mg qd|
46070871|NCT00822211|Drug|Placebo|
46070872|NCT03614858|Biological|CART-19/22|Split intravenous infusion of CART-19/22 cells of (Dose escalating infusion of 1 - 20 x10^6 CART-19/22 cells/kg).
46070873|NCT05493800|Drug|MIT-001|Corresponding dose of MIT-001 IV injection during 0.5~1hr
46070874|NCT05493800|Drug|normal saline|normal saline IV injection
45784188|NCT04371692|Diagnostic Test|SARS-Cov2 testing|Every weeks during 2 month, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure
45784189|NCT04364906|Other|Regional anesthesia|The effects of QLB 2, 3 interfascial plane blocks on post-operative analgesia after cesarean section surgery
45784190|NCT04134845|Drug|Dantrolene/Ryanodex|muscle relaxant
45784191|NCT04134845|Drug|Placebo|Controlled placebo of saline administered Intravenous; 1 mg/kg IV over 3 minutes, one time dose
45784192|NCT02488980|Drug|Tafenoquine|Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.
45643843|NCT04148911|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 of every 28-day cycle. Day 15: Atezolizumab may be administered on Days 15-18 of each cycle.
45784193|NCT02488980|Drug|Mefloquine|Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.
45784194|NCT02488980|Drug|Placebo|Placebo for three days followed by placebo once a week for 24 weeks
45784195|NCT04371302|Diagnostic Test|Questionnaire|Assessment of demographics, burnout, depression and self-perceived medical errors
45784196|NCT05244239|Drug|Lurbinectedin|Given IV
45784197|NCT05244239|Radiation|Palliative Radiation Therapy|Undergo RT
45784198|NCT04130321|Dietary Supplement|Camu camu|3 capsules of camu camu powder (500 mg / capsule) daily during 12 weeks
45784199|NCT04130321|Dietary Supplement|Placebo|3 capsules of placebo daily during 12 weeks
45784200|NCT02242058|Other|Quantitative sensory testing|
45598249|NCT02588885|Behavioral|Trauma-sensitive Care|"Psychological intervention~education~empowerment~desensitization~relaxation tools~Physical therapy intervention~techniques to address muscular tension~empowerment~comfort~encouragement of trauma-related coping skills"
45643844|NCT04148911|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered at the 100 mg/m2 dose via IV infusion on Days 1, 8, and 15 of every 28-day cycle. Day 8: Nab-paclitaxel may be administered on Days 8-11 of each cycle. Day 15: Nab-paclitaxel may be administered on Days 15-18 of each cycle, on the same day with the atezolizumab infusion.
45643845|NCT04145297|Drug|Ulixertinib|"Ulixertinib will be provided as 150 mg capsules and will be self-administered twice daily by mouth at the assigned dose level.~Ulixertinib Dose Level 0 300 mg PO BID, Dose Level 1 (starting dose) 450 mg PO BID, Dose Level 2 600 mg PO BID,~Medication will be administered in 28-day cycles"
45643846|NCT04145297|Drug|Hydroxychloroquine|Hydroxychloroquine will be provided as 200 mg tablets and will be self-administered by mouth twice daily. Fixed Dose 600mg POBID. Medication will be administered in 28-day cycles
45643847|NCT04138940|Behavioral|Script Training|Participant uses a computer program to practice scripts with a virtual therapist.
45643848|NCT04134260|Drug|Apalutamide|Given PO
45643849|NCT04134260|Drug|Hormone Therapy|Receive hormone therapy
45643850|NCT04134260|Other|Quality-of-Life Assessment|Ancillary studies
45784201|NCT04952064|Drug|Monosialoganglioside GM1|Monosialoganglioside GM1 diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
45784202|NCT04950816|Behavioral|tailored MBI (.b)|The session will include brief didactic presentations, videos, and mindfulness practice followed by inquiry. We anticipate that sessions will take place twice a week. Sessions will be held on site at the Covenant House Texas (CHT) shelter in a quiet, designated learning space to ease access to sessions for the participants and to assure access to shelter staff (e.g., social workers and case managers) and services (e.g., food and shelter). CHT has onsite, weekday clinical and mental health care and established protocols for accessing needed resources 24/7. Selection criteria for the interventionist include maintaining a personal mindfulness practice for at least two years, trained in .b, and prior experience working with high-risk youth. The interventionist will receive additional training in Trauma-Informed Care as well as study procedures.
45784203|NCT04950816|Behavioral|attention control condition|Participants will receive no training in MBI or meditation. Topics covered may include physical activity, nutrition, managing weight, understanding adolescence, personal care, avoiding tobacco, alcohol, and drugs though this will be finalized in YR-1 with the HYWG and advisory panel. The HT program will be led by a positive adult instructor with training in health education or a related field and experience working with YEH.
45784204|NCT02242136|Behavioral|FORNET|
45784205|NCT02227667|Drug|MEDI4736|Patients will be seen the day of administration of MEDI4736. A medical history, with particular reference to toxicities, including medication review, and physical examination will be conducted at each treatment visit.
45784206|NCT04365062|Device|Excimer laser and drug coated balloon|Excimer laser and drug coated balloon
45784207|NCT04365062|Device|Excimer laser and plain balloon|Excimer laser and plain balloon
45784208|NCT04365062|Device|plain balloon and drug coated balloon|plain balloon and drug coated balloon
45784209|NCT04926090|Behavioral|Emotional Support Plan - Clinician Guided (ESP-C)|The Emotional Support Plan (ESP) is designed to help prepare students to cope with stress experienced during postsecondary education. The ESP-C is delivered by a clinician in 2 sessions.
45784210|NCT04926090|Behavioral|Emotional Support Plan - Self Guided (ESP-S)|The Emotional Support Plan (ESP) is designed to help prepare students to cope with stress experienced during postsecondary education. The ESP-S is created by the participant on their own, with the support of self-guided materials.
45784211|NCT02242214|Drug|Misoprostol|
45643851|NCT04134260|Other|Questionnaire Administration|Ancillary studies
45643852|NCT04134260|Radiation|Radiation Therapy|Undergo pelvis and prostate bed radiation therapy
45784212|NCT04925700|Dietary Supplement|ProDentis Lozenge|1-2 ProDentis Lozenges per day
45784213|NCT04925700|Other|Placebo Lozenge|1-2 Placebo Lozenges per day
45784214|NCT04371068|Biological|Culture of removed prosthesis using DTT|No specific or supplementary intervention is performed among patients. The included patients have scheduled surgery consisting of prosthesis removal or change. Instead of being discarded, the prosthesis which was removed during the surgery was sent to the laboratory using the MicroDTTect system and bacterial culture was performed with the fluid obtained. Results will be then compared to classical culture of periprosthetic tissues (PPT).
45784215|NCT02245256|Drug|Precedex|infusion of 0.1mcg/kg/hr of precedex
45784216|NCT02245256|Drug|placebo control|placebo
45784217|NCT02460822|Device|MyChemoCare iPad application|
45784218|NCT05208983|Biological|mRNA Vaccines or Viral vector-based vaccines for COVID|Participants receiving an approved COVID vaccine
45643853|NCT04131712|Other|Massage|A custom-made cyclic compressive loading (CCL) device will be used to apply a mechanical load to the left thigh of the participants. Massage application using a 35 Newton load will be applied for 15 minutes every other day over the course of 7 days for a total of four massages.
45643854|NCT04130542|Biological|LVGN6051|IV infusion once every 3 weeks (Q3W).
45643855|NCT04126096|Diagnostic Test|Skin Testing beta-lactams|Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
45643856|NCT04125836|Drug|CAM2029 (octreotide subcutaneous depot)|Octreotide subcutaneous depot for monthly injections in acromegaly patients
45643857|NCT04125732|Biological|AdVEGFXC1|AdVEGFXC1 at one of 4 doses
45784219|NCT02242292|Drug|Hyoscine butylbromide|
45784220|NCT02242292|Drug|Placebo|
45784221|NCT02994329|Device|OraQuick® HIV Self-Test (Orasure Technologies, Thailand)|All individuals aged 16 and above who are approached by community health workers conducting door-to door HIV testing will be offered the choice to use an oral HIV self test kit or to have standard of care finger-prick rapid HIV testing
45784222|NCT02488824|Procedure|Warm Temperature|Subjects will be exposed to a routinely encountered warm temperature (95 F) for up to to 2 hours, depending on their vital signs (BP, HR, Tcore) and tolerance (comfort).
45643858|NCT04123795|Drug|Certolizumab pegol|"Certolizumab Pegol~Pharmaceutical Form: Solution for injection in pre-filled syringe~Route of Administration: Subcutaneous use~Other Names:~Cimzia~CDP870~CZP"
45784223|NCT04346966|Other|Study Group|Video Based Exercises 64 young adults aged 18-40, who are socially isolated due to coronavirus, will be included in this group. A video-based exercise protocol was created for individuals to participate in the study. Each exercise session is planned as 30 minutes 7 days a week for 6 weeks. The protocol was planned to start with warm-up exercises and end with cooling exercises. The exercise protocol has also been determined as a combination of aerobic exercises, strengthening and posture exercises. Individuals will be classified at 4 levels according to their physical activity levels and will be shared with volunteers according to their level of exercise. Volunteers will be evaluated before and after 6 weeks of exercise.
45643859|NCT04123795|Drug|Placebo|"Placebo~Pharmaceutical Form: Solution for injection in pre-filled syringe~Route of Administration: Subcutaneous use~Other Names:~-PBO"
45643860|NCT04121455|Drug|Olaptesed pegol|Olaptesed pegol continuous administration for 26 weeks
45643861|NCT04121455|Radiation|Radiotherapy|Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions
45643862|NCT04121455|Drug|Bevacizumab|Bevacizumab every 2 weeks i.v. for 26 weeks
45643863|NCT04121455|Drug|Pembrolizumab|Pembrolizumab every 3 weeks i.v. for 26 weeks
45643864|NCT04117958|Drug|AMG 199|AMG 199 is a BiTE® molecule designed to direct T cells towards MUC17-expressing cells.
45643865|NCT04117672|Dietary Supplement|Salovum|Active egg yolk powder
45643866|NCT04117672|Dietary Supplement|Placebo egg yolk powder|Normal egg yolk powder
45643867|NCT04115631|Drug|Acalabrutinib|Given PO
45643868|NCT04115631|Drug|Bendamustine|Given IV
45784224|NCT05204615|Other|Collection of clinical, psychometric and biometric data|Wearable devices and a mobile app will be used to collect real-time data for 4 weeks to detect physiological and psychological complications based on biometric and psychometric (patient-reported outcomes) information.
45784225|NCT02242370|Drug|Low dose of telmisartan|
45784226|NCT02242370|Drug|High dose of telmisartan|
45784227|NCT04371146|Drug|Methylphenidate|35 mg methylphenidate (Ritalin®) is administered once using a randomized placebo-controlled between subject's design
45784228|NCT04371146|Drug|Reboxetine|8 mg Reboxetine (Edronax®) is administered once using a randomized placebo-controlled between subject's design
45784229|NCT04371146|Drug|Placebos|A placebo pill is administered once using a randomized placebo-controlled between subject's design
45784230|NCT01623479|Drug|bimatoprost 0.03%|Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
45784231|NCT04347044|Other|Pulmonary Rehabilitation|Exercise training+ Optimal medication and clinical follow-up
45784232|NCT04347044|Other|Standart care|Optimal medication and clinical follow-up
45784233|NCT03399539|Drug|Dexamethasone|Given PO
45784234|NCT03399539|Drug|Ixazomib Citrate|Given PO
45784235|NCT03399539|Other|Laboratory Biomarker Analysis|Correlative studies
45784236|NCT03399539|Drug|Venetoclax|Given PO
45784237|NCT02242526|Device|Parietex™ Composite Hiatal Mesh, North Haven, CT|Parietex™ Composite Hiatal Mesh (North Haven, CT) designed for hiatal hernia repair.
45643869|NCT04115631|Drug|Bendamustine Hydrochloride|Given IV
45643870|NCT04115631|Drug|Cytarabine|Given IV
45643871|NCT04115631|Biological|Rituximab|Given IV
45643872|NCT04112667|Other|Normal Macular Health|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
45643873|NCT04112667|Other|Early Macular Degeneration|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
45643874|NCT04112667|Other|Young Normals|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
45754336|NCT04142840|Drug|Dexmedetomidine|a selective α-2 adrenoceptor agonist which is widely used as an adjuvant to general anesthesia
45784238|NCT02242526|Device|Biodesign™ Surgisis® Graft, Cook Medical, Bloomington|Biodesign™ Surgisis® Graft (Cook Medical, Bloomington) designed for hiatal hernia repair.
45643875|NCT04109482|Biological|MB-102|"The study drug, MB-102 consists of adoptively transferred T cells that are genetically modified using a self-inactivating (SIN) lentiviral vector to express a CD123-specific, CD28-costimulatory chimeric antigen receptor (CAR) as well as a truncated human epidermal growth factor receptor (EGFRt) (CD123.CD28.CD3ζ.EGFRt+T cells) derived from autologous leukapheresis which is administered after a lymphodepletion regimen.~Single dose of MB-102 up to 600 x 10 6 CART-T+ cells (Day 0) as defined by Phase 1 will be administered."
45643876|NCT04109482|Drug|Fludarabine|"Fludarabine 30 mg/m2/day IV (3 days) on days -5, -4, and -3~A 20% dose reduction (24 mg/m2/day IV (3 days) on days -5, -4, and -3) is required for patients with moderately impaired renal function (creatine clearance ≤ 70 mL/min)."
45784239|NCT04370912|Diagnostic Test|Bed side Ultrasound|Handgrip strength will be measured using a digital grip strength dynamometer (Sammons Preston, Nottinghamshire, UK). This measurement is carried out three times using the subject's dominant hand, and then averaged
45784240|NCT04347200|Drug|Antiplatelet Drug|single or dual antiplatelets, triple antithrombotic theraphy
45784241|NCT02242604|Other|Multidimensional Geriatric Assessment (MGA)|"The MGA contains the following tests:~Barthel Katz Index (activity of daily living, ADL)~Mini Mental State Test (MMST)~DemTec (dementia detection test)~Clock Test~Geriatric Depression Scale (GDS)~Tinetti Test~TUG (timed up-and-go Test)~Esslinger Transfer Scale (ETS)~Handgrip Test~Mini Nutritional Assessment (MNA)"
45784242|NCT04364516|Drug|Anticoagulation|Study of prognostic impact according to oral anticoagulation therapy (Vitamin K Antagonists or Direct Oral Anticoagulants)
45784243|NCT02242682|Other|Child passenger safety video|
45784244|NCT01623869|Other|Laboratory Biomarker Analysis|Correlative studies
45643877|NCT04109482|Drug|Cyclophosphamide|Cyclophosphamide 300 - 500 mg/m2/day IV (3 days) on days -5, -4, and -3
45784245|NCT01623869|Biological|Trebananib|Given IV
45784246|NCT04364594|Diagnostic Test|conjunctival swab|analysis of conjunctival cells (real time PCR) collected by conjunctival swabs in both eyes
45784247|NCT04370600|Drug|beta hydroxybutyrate (BHB) ester|Ketone supplementation given 3x/day (60mL per dose, or 22g BHB)
45784248|NCT04370600|Drug|Placebo|Denatonium benzoate + HVMN ketone placebo flavor mix + Stevia
45784249|NCT04364204|Other|Kangaroo Mother Care and BEMPU bracelet|Kangaroo mother care involves early, continuous and prolonged skin-to-skin contact between a mother and her newborn, frequent and exclusive breastfeeding and early discharge from hospital. The BEMPU bracelet, also known as the BEMPU Tempwatch, is a silicone band with a thermistor metal cup that emits an audio alarm and flashes an orange light when the body temperature drops below 36.5⁰C, signaling hypothermia and prompting caregiver to provide thermal care.
45784250|NCT04364204|Other|Kangaroo Mother Care|Kangaroo mother care involves early, continuous and prolonged skin-to-skin contact between a mother and her newborn, frequent and exclusive breastfeeding and early discharge from hospital. This is the current standard of care for low birthweight/preterm infants.
45784251|NCT01625507|Behavioral|PANDA intervention|Participants will follow a menu plan and receive training in how to manage their diet in type 2 diabetes, following the recommendations of the Canadian Diabetes Association, 2008
45784252|NCT02242838|Drug|Telmisartan|
45784253|NCT03207347|Drug|Niraparib|Patients will take 300 mg of niraparib orally once daily each day of a 28 day cycle.
45784254|NCT04364438|Device|Electric Muscle Stimulation|EMS is believed to produce some inhibition of the bladder, allowing the bladder to reach a greater volume. This is believed to occur because electrical stimulation also stimulates nerves in the pelvic floor. In most people, bladder voiding is inhibited when the skin of the pelvis is touched or otherwise manipulated. This inhibition is via a reflex in the spinal cord that may have evolved to inhibit voiding during sexual contact. The pelvic floor nerves are responsible for transmitting the sensation of touch from the pelvis to the spinal cord. Electrical stimulation of these nerves thus activates sensory fibers that cause inhibition of bladder voiding via a reflex mechanism in the spinal cord. This may explain EMS is an effective treatment for people with incontinence.
45643878|NCT04109196|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based treatment for PTSD that will be delivered intensively twice per day over the course of five days.
45917725|NCT02735083|Biological|UCART19 follow-up|UCART19 will not be administered during the study period. Patients who will be rolled-over from the parent study to this long term follow-up study, have previously received UCART19. The roll-over occurs at the end of the parent study, or at any time after UCART19 administration, in case of premature discontinuation from the parent study.
45784255|NCT04364438|Device|Transcutaneous Electric Nerve Stimulation|TENS is based on the gate control theory of abolishing the local micturition reflex arc. It is a non-pharmacological method of inhibiting the presynaptic afferent neurons carrying impulses from bladder by stimulating the nerves of peripheral segmental dermatome (gate control theory of electro modulation by stimulating the peripheral nerves corresponding to the visceral organ). It acts at the level of primitive voiding reflex coordinating the bladder, sphincter and the pelvic floor. Detrusor hyperreflexia can be inhibited by direct inhibition of impulses in the preganglionic afferent neuron or by inhibition of bladder preganglionic neurons of the efferent limb of micturition reflex.
45784256|NCT02242916|Radiation|Photon therapy versus proton therapy|
45784257|NCT02242916|Radiation|Photon therapy versus C-ion therapy|
45784258|NCT02243072|Behavioral|Fit Families plus Standard Medical Care|Adolescents will receive the Fit Families plus Standard Medical Care which consists of twice weekly home-based, family psychotherapy from a CHW for 6 months
46070875|NCT04614805|Behavioral|Mobilizing clinical leaders|Clinical leaders and clinical personnel will regularly receive feedback regarding performance of their own hospital as well as other providers in the regional health trust of North Norway.
45917726|NCT00390988|Procedure|blood sampling|
45917727|NCT02690545|Biological|ATLCAR.CD30 cells|For Phase Ib, in adults and separately in children, two doses will be investigated: 1x10^8 cells/m^2 and 2x10^8 cells/m^2. Phase II patients will receive the dose level decided upon in Phase I.
45917728|NCT02681302|Drug|Ipilimumab|1 mg/kg; 6 doses Weeks 1, 4, 7, 10, 16, 22
45784259|NCT04370210|Behavioral|Questionnaires|Child of both groups enrolled, and their parents, must complete online questionnaires
45784260|NCT02249039|Drug|intermittent IV CLON|Mechanically ventilated infants and children receive intravenous intermittent Clonidine instead of dexmedetomidine
45784261|NCT04363892|Other|Optical and infrared imaging|Acquiring images (photographs) of the skin
45784262|NCT03593057|Other|Manual therapy|Manual therapy protocol and self-care advice and body awareness.
45784263|NCT03593057|Other|Control group|Advice on self-care and body awareness.
45784264|NCT04369898|Other|Image analysis/ Central vein detection|Image analysis/ Central vein detection will be performed using a fully automated approach based on an ensemble of 3D convolutional neural Networks. The method is applied to T1w, T2w and T2*w data . Results will be manually reviewed by 2 experts in CVs detection. MRI data must have been collected at 3 Tesla (3T) between 1990 and 2020 and must include T1 w, T2 w, T2-star based sequence (CVs detection).
45784265|NCT04369898|Other|Image analysis/ Automatic cortical lesion detection|Image analysis/ Automatic cortical lesion detection will be performed by using a convolutional neural network-based method. MRI data must have been collected at 3T between 1990 and 2020 and must include Double inversion recovery (DIR)/Phase-Sensitive Inversion Recovery (PSIR)/Magnetization Prepared - 2- RApid Gradient Echo Gradient Echo (MP2RAGE) (eventually also high spatial resolution Magnetization Prepared - RApid Gradient Echo (MPRAGE)) for cortical lesion detection.
45643886|NCT04105010|Drug|AZD4205|AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions
45643887|NCT04100135|Device|Actual device PFO closure|Actual PFO closure with the GORE® CARDIOFORM Septal Occluder
45643888|NCT04100135|Drug|Thienopyridine (clopidogrel or prasugrel)|Thienopyridine tablets (clopidogrel or prasugrel) administered for 6 months following device procedure
45643889|NCT04100135|Device|Sham device PFO closure|Sham (simulated) device PFO closure with result of no device implantation and no PFO closure
45643890|NCT04098523|Diagnostic Test|Duplex ultrasound|A one-time carotis and abdominal aorta duplex ultrasound will be performed on-site by a skilled site staff to determine the prevalence of, and risk factors associated with, CAS and AAA. A diameter measurement will be performed of the abdominal aorta as well as a determination of the carotid arteries.
45784266|NCT03590249|Procedure|Osteopathic Manipulative Treatment|Osteopathic manipulation involves a number of different manual (hands-on) techniques. These include muscle inhibition (applying pressure to a muscle to induce relaxation); myofascial release (applying pressure to the fascia and moving it toward/away from a strain); muscle energy stretch (contraction of a stretching muscle); counterstrain (shortening a strained muscle); facilitated positional release (moving a vertebra into a restriction and applying a gentle compression); osteopathy in the cranial field (balancing the cranial tissue); balanced ligamentous tension/ligamentous articular strain (moving a joint into ease to release tension in the ligament); one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure. Treatment will last approximately 45 minutes.
45784267|NCT04370288|Drug|MCN (Methylene blue, vitamin C, N-acetyl cysteine)|A mixture of MCN will be injected to covid-19 patients.
45784268|NCT02993705|Drug|Trabectedin|Chemotherapy drug
45784269|NCT02245178|Procedure|Lung spirometry|measurement of pulmonary function pre- and post-bronchodilator
45784270|NCT02245178|Other|CT scan analysis|Analysis of existing year 25 thoracic CT scans for lung and intrathoracic vascular structure
45784271|NCT04369820|Other|draw blood|40 mL blood sample will be taken within the first three days of hospitalization, a second sample will be taken between the 5th and 10th day of hospitalization and a third sample will be taken on the 10th day of hospitalization or the day of discharge if earlier.
45784272|NCT02243150|Drug|G1T28-1 (CDK 4/6 Inhibitor)|
45784273|NCT02243150|Drug|Placebo|
45784274|NCT02243228|Drug|GM-CSF|
45643891|NCT04094584|Drug|Vivitrol (Extended Release Naltrexone)|Monthly Injections of 380mg Extended-Release Naltrexone, case management services as needed tailored to the individual participant
45917729|NCT02681302|Drug|Nivolumab|3 mg/kg; 12 doses Weeks 1, 4, 7, 10, 12, 14, 16, 18, 20, 22, 24, 26
45917730|NCT02650258|Behavioral|treadmill walking|all participants walking at increasing speeds on a treadmill
45917731|NCT00000951|Drug|Fluconazole|
45643898|NCT04091308|Other|Usual Care|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
45643899|NCT04091308|Other|Usual Care with Protein Supplementation|The intake of protein supplementation (ARLA PROTINO) will be consumed by participants in the form of protein-enriched yogurts for easy consumption two times daily, with each bottle containing 14 g of protein.
45643900|NCT04091308|Other|Individualized Physical Exercise Training with Protein Supplementation|Besides getting prescribed individualized physical exercise training programs, this group will consume protein supplementation (ARLA PROTINO) in form of protein enriched yogurts for easy consumption, two times daily, with each bottle containing 14 g of protein.
45643901|NCT04086264|Drug|Azacitidine|Commercially available formulation given subcutaneously (SC) or intravenous (IV)
45784275|NCT01628159|Device|Lutonix Drug Coated Balloon|balloon angioplasty with a drug coated balloon
45784276|NCT04363970|Other|removal of the urinary catheter|in group A, we will remove the catheter after 24 h. In group B, we will remove the catheter after 48 h.
45784277|NCT02243462|Device|Forced Air Warmer|"A forced air warmer device will be used to pre-warm patients for 10 minutes in holding bay before surgery. Air warming device is an electrically powered control unit, hose, and inflatable blanket. The control unit has an air filter and heater, which warms air entrained from the environment. The hose connects to a blanket."
45784278|NCT02243462|Other|No pre-op warming|No forced air warming of the patient prior to being taken in for surgery
45784279|NCT03506945|Behavioral|mPEP|Behavioral Activation Therapy
45784280|NCT03506945|Behavioral|Bibliotherapy|Provide educational material on coping strategies pertinent to caregivers
45784281|NCT02243618|Drug|Polaprezinc|Administration of pantoprazole 40 mg q.d. and polaprezinc 75 mg b.i.d. for 4 weeks after the ESD.
45784282|NCT02243618|Drug|Rebamipide|Administration of pantoprazole 40 mg q.d. and rebamipide 100 mg t.i.d. for 4 weeks after the ESD.
45784283|NCT03481751|Diagnostic Test|Diagnostic test: Ultrasound|Transabdominal ultrasound of the bowel for categorization of disease activity
45784284|NCT02243774|Behavioral|Core letter signed by Surgeon General|The core letter provides information about influenza and the risks associated with it, incorporating a number of behavioral insights. All four letters evaluated in this study will contain the same tops and bodies that are included in the core letter, but the signature and P.S. tag region will differ among the various intervention groups. In this intervention, the core letter is signed by and includes a picture of the Surgeon General. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.
45643902|NCT04086264|Drug|IMGN632|Study formulation given intravenously (IV)
45643903|NCT04086264|Drug|Venetoclax|Commercially available formulation administered orally
45784285|NCT02243774|Behavioral|Core letter signed by the Director of the National Vaccine Program|The core letter is signed by and includes a picture of the Director of the National Vaccine Program. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.
45784286|NCT02243774|Behavioral|Core letter signed by Surgeon General + implementation prompt|The core letter is signed by and includes a picture of the Surgeon General. Below the signature line of the core letter, an implementation intention prompt is provided in the P.S. tag region that invites the recipient to write in the day of week, month, day, and time at which he or she plans to get vaccinated.
45784287|NCT02243774|Behavioral|Core letter signed by SG + enhanced implementation prompt|"The core letter is signed by and includes a picture of the Surgeon General (SG). Below the signature line of the core letter, an enhanced implementation intention prompt is provided in the P.S. tag region that prompts recipients to decide now - by checking one of two boxes - indicating they will or will not get vaccinated. The options use language that highlights the losses incumbent in refusing to vaccinate. In addition, an implementation intention prompt is embedded into the checkbox for indicating a choice to be vaccinated."
45784288|NCT03170375|Behavioral|Performance of WHEELS-I in promoting DASH/SRD adoption|Participants will receive the WHEELS-I electronically-delivered tailored messaging intervention in addition to motivational interviewing-based counseling.
46070876|NCT00822367|Dietary Supplement|Glucerna; Ensure; SlimFast|Each participant will consume all three nutritional supplements randomly assigned by computer program to drink one of the three products in one week intervals. Each product will contain 50 grams of carbohydrate but differs in volume, fat, protein, and fiber composition. BG will be tested by finger sticks before (fasting) and at 15, 30, 60, 90, 120, 150 and 180 minutes after drinking the supplement. The participants will have 8 finger stick blood sugar measurements over about 3 hours on each of the 3 testing days.
46070877|NCT05295602|Radiation|CT scan|CT of lower leg
45643904|NCT04083599|Biological|GEN1042|Intravenous
45643905|NCT04083599|Drug|Pembrolizumab|Intravenous
45643906|NCT04083599|Drug|Cisplatin|Intravenous
45643907|NCT04083599|Drug|Carboplatin|Intravenous
45643908|NCT04083599|Drug|5-FU|Intravenous
45643909|NCT04083599|Drug|Gemcitabine|Intravenous
46070878|NCT01977560|Behavioral|Intensive Lifestyle Intervention|Participants will be instructed to consume ~500 kcal/day less than their calculated estimated total daily energy requirements. The supervised exercise program will include both endurance and resistance exercise training sessions. The doses of diabetes medications will be adjusted by study physicians every 1-2 weeks, as needed to avoid hypoglycemia.
45643910|NCT04083599|Drug|Nab paclitaxel|Intravenous
45643911|NCT04083599|Drug|Pemetrexed|Intravenous
45643912|NCT04083599|Drug|Paclitaxel|Intravenous
45784289|NCT03170375|Behavioral|Effects of a 2-week DASH/SRD intervention vs. control diet on HFpEF functional cardiovascular risk factors|Participants will be randomized to the sequence DASH/SRD-control diet or control diet-DASH/SRD, and consume the diets for 14 days each.
45784290|NCT02243852|Drug|Growth Hormone Replacement Therapy|An observational study of patients who are commencing GH replacement as part of their routine NHS clinical care to assess changes in serum FGF21 concentration and determine how these relate to changes in body composition.
45784291|NCT03150329|Other|Laboratory Biomarker Analysis|Correlative studies
45784292|NCT03150329|Biological|Pembrolizumab|Given IV
45784293|NCT03150329|Drug|Vorinostat|Given PO
45784294|NCT02243930|Device|Disposable distal attachment|
45784295|NCT02244008|Other|joint mobilization|The experimental group received joint mobilization (anteroposterior mobilization of the talus - Maitland grade III). During the mobilization cyclic movements were applied in an anteroposterior direction from the first tissue resistance barrier until the end of the accessory range of motion without any pain or discomfort. This mobilization maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
45784296|NCT02244008|Other|manual contact|The placebo group received only manual contact. This maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
45643913|NCT04082754|Biological|Human beta common receptor antagonist monoclonal antibody|Human beta common receptor antagonist monoclonal antibody
45643914|NCT04082754|Drug|Placebo|0.9% sodium chloride, same volume and same duration as CSL311
45643915|NCT04082338|Behavioral|VPN|"The intervention will be delivered through virtual patient navigation (VPN) toolkit system (a web/mobile application). The system includes education modules on HBV management, CHB patient success stories and virtual patient navigation clinical support for overcoming barriers.~In addition to the VPN, each participant will receive 5 text messages; one message once a week for 5 weeks on HBV management for every 6 months in the 18-month study period."
45643916|NCT04082338|Behavioral|TM|Receive TM on HBV management respectively once a week for 5 weeks for every 6 months in the 18-month study period.
45643917|NCT04077723|Drug|RO7227166|RO7227166 will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).
45643918|NCT04077723|Drug|Obinutuzumab|A fixed dose of obinutuzumab will be administered seven days prior to first does of RO7227166 and glofitamab and then Q3W in combination with RO7227166 in Part I
45643919|NCT04077723|Drug|Glofitamab|A fixed dose of glofitamab will be administered Q3W in combination with RO7227166 in Part II and Part III
45784297|NCT03102125|Drug|Regadenoson|For use in stress myocardial perfusion imaging.
45784298|NCT04347278|Drug|Patients with the treatment agains COVID19|"Data will be collected from patients who receive any of the treatments included in the Technical Document. Manejo clínico del COVID-19: tratamiento médico of the Ministry of Health, and Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2 of the AEMPS, either as antivirals or as treatment of the inflammatory process in patients with SARS, or others as they arise."
45784299|NCT04369586|Drug|meplazumab for injection|single dose: 6 dose level, multiple dose: 0.3mg/kg/dose
45643920|NCT04077723|Drug|Tocilizumab|Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).
45784300|NCT04369586|Drug|Placebo|placebo
45784301|NCT02231177|Drug|BI 1744 CL|
45784302|NCT02231177|Drug|BI 1744 CL/Tiotropium FDC|
45784303|NCT02231177|Drug|Tiotropium|
45784304|NCT02223689|Procedure|Skin Affix|
45784305|NCT04369118|Procedure|Conventional follow-up|Patients in this group benefit from conventional post-operative follow-up
45784306|NCT04369118|Device|Conventional follow-up+chest wall restriction belt|Patients in this group benefit from conventional post-operative follow-up. The patient wear the selective chest wall restriction belt from Day 2 (after surgery) until he ceases to need it.
45784307|NCT03283007|Drug|Nintedanib|Eligible LTx recipients with BOS receive Nintedanib treatment at a dose of 150 mg twice daily (bid) for 6 months
45784308|NCT03283007|Drug|Placebo|Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months
45784309|NCT04363190|Diagnostic Test|Cytogenetic analysis|"FISH study using the UroVysion kit in interphase peripheral lymphocytes, that allows the study of numerical aberrations for chromosomes 3, 7 and 17 and locus 9p21.~G banding study to analyse the whole karyotype study regarding both numerical and structural aberrations during metaphase.~Sister chromatid exchanges (SCE) analysis with bromodeoxyuridine (BrdU) staining for the whole karyotype during metaphase: analizing the proportion of SCE per metaphase (NSM)."
45784310|NCT03277469|Device|MRI|Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
45917732|NCT02638987|Procedure|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
45917733|NCT02627443|Drug|Berzosertib|Given IV
45643921|NCT04076059|Drug|Enzalutamide|Oral
45643922|NCT04076059|Drug|Placebo|Oral
45643923|NCT04076059|Drug|Androgen deprivation therapy (ADT)|All participants will be required to maintain ADT during study treatment, either using luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or having a history of bilateral orchiectomy.
45643924|NCT04075292|Drug|Acalabrutinib|acalabrutinib 100 mg twice daily orally
45643925|NCT04075292|Drug|Rituximab|Rituximab: 375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)
45643926|NCT04075292|Drug|Chlorambucil|Chlorambucil: 0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6
45784311|NCT03277469|Radiation|Brachytherapy|Radiation therapy that is delivered by inserting radioactive sources directly into a tumor
45917734|NCT02627443|Drug|Carboplatin|Given IV
45643927|NCT04074616|Device|High Dose|Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks,with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used.
45643928|NCT04074616|Device|Low dose|Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes
45643929|NCT04071236|Drug|Avelumab|Given IV
45643930|NCT04071236|Drug|Peposertib|Given PO
45784312|NCT03277469|Device|MRI Tracker|The MR tracking device consists of a series of radiofrequency (RF) microcoils that are embedded into brachytherapy catheter stylet. The RF microcoils allows for accurate spatial localization of an individual brachytherapy catheter.
45784313|NCT02706197|Device|OxyChip|The OxyChip is an investigational device to assess oxygen level in tissues, when measured with Electron Paramagnetic Resonance (EPR).
45784314|NCT00927992|Other|Epidemiological Non interventional|Epidemiological Non interventional
45784315|NCT02244086|Drug|bupivacaine|At the beginning of the work of effective labor maneuver randomly be allocated ( using sealed envelopes) and an outsider to the study prepared the dosage to bupivacaine 0.125% or 0.25% to be administered by epidural catheter for an anesthesiologist to disown the concentration employed. It is measured vital signs, and visual analogue scale dilatation in minutes 0,15,30,60 and 90 after being applied analgesia.
45784316|NCT01629797|Behavioral|Educational script on Acne|An educational script on Acne will be presented by investigator
45784317|NCT02249117|Drug|BIWH 3|
45784318|NCT02249117|Drug|Placebo|
45784319|NCT03234023|Behavioral|INTERVENTION GROUP|Offer recommendations of healthy living habits and control of pharmacy administration
45784320|NCT00928304|Drug|Florbetaben (BAY94-9172)|300 megabecquerels (MBq) as single IV injection of 2 to 10 mL
45784321|NCT03205709|Other|Computerized Cognitive Training|Computerized online cognitive training will be used to target specific cognitive abilities and neural networks to potentially improve cognitive functioning through neuroplasticity.
45917735|NCT02627443|Drug|Gemcitabine Hydrochloride|Given IV
45917736|NCT02627443|Other|Laboratory Biomarker Analysis|Correlative studies
45643931|NCT04071236|Other|Quality-of-Life Assessment|Ancillary studies
45643932|NCT04071236|Other|Questionnaire Administration|Ancillary studies
45784322|NCT03205709|Other|Crossword Puzzles|These are intended to mimic crossword puzzles in newspapers.
45784323|NCT04362020|Other|Distal radial access|Distal radial access and No anticoagulation
45784324|NCT04362020|Other|Distal radial access|Distal radial access and ACT-guided anticoagulation
45784325|NCT04368572|Behavioral|Hypnosis|"An interview assesses the patient's level of anxiety, interests and dissociative abilities. Hypnosis is done by following the steps:~First step: reception and installation of the patient Second step: induction phase Third step: hypnotic trance phase Fourth step: reorientation phase"
45784326|NCT01630109|Drug|Metoclopramide|A one time dose of either Metoclopramide 5 mg or 10 mg (or placebo) given orally 30 minutes prior to pill capsule endoscopy.
45784327|NCT01630109|Drug|Placebo|A placebo capsule made to look like the metoclopramide capsule.
45784328|NCT04368650|Drug|BMP-2|lyophilized Human Bone Morphogenetic Protein-2 was used as an active drug.
45784329|NCT04368650|Procedure|PRF|For the preparation of sticky bone, the patient's venous blood is collected and centrifuged at 2400rpm for 2min which leads to two different layers in the vacutainer the upper autologous fibrin glue (AFG) and the lower RBC portion, the upper AFG is mixed with a particulate bone graft (hydroxyapatite). Within 5-10 min fibrin meshwork was formed
45784330|NCT02663297|Drug|ATLCAR.CD30 cells|"Three dose levels will be evaluated:~Group One, 2x10^7 cells/m^2 (maximum dose 5x10^7 cells)~Group Two, 1x10^8 cells/m^2 (maximum dose 2.5x10^8 cells)~Group Three, 2x10^8 cells/m^2 (maximum dose 5x10^8 cells)"
45784331|NCT04367948|Diagnostic Test|18F-FDG and 68Ga-NOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
45643933|NCT04071236|Radiation|Radium Ra 223 Dichloride|Given IV
45643934|NCT04071223|Drug|Cabozantinib S-malate|Given PO
45784332|NCT04367948|Diagnostic Test|18F-FDG and 18F-NOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
45784333|NCT04368026|Other|No intervention (survey study for medical doctors).|No intervention
45784334|NCT04368182|Biological|Autologous C-TCR055|Autologous C-TCR055 administered by intravenous (IV) infusion
45784335|NCT01632215|Drug|Gabapentine|Gabapentine 600 mg 01 dose
45784336|NCT01632215|Other|Sugar pill|Sugar pill 01 dose
45784337|NCT02994095|Behavioral|Pilot Study|Trained community health agents used Motivational Interviewing-based counseling and action planning in monthly home visits with adults with diabetes
45784338|NCT02244242|Drug|Tamsulosin hydrochloride|
45784339|NCT03127631|Behavioral|Nutrition|Standardized advice on healthy diet practices.
45784340|NCT03127631|Behavioral|Exercise|Standardized advice on exercise including strength training and resistance training exercises.
45643935|NCT04071223|Other|Quality-of-Life Assessment|Ancillary studies
45643936|NCT04071223|Other|Questionnaire Administration|Ancillary studies
45643937|NCT04071223|Radiation|Radium Ra 223 Dichloride|Given IV
45643938|NCT04070560|Procedure|Intact cord (≥ 180 seconds) resuscitation|Resuscitation performed in near proximity to the mother with umbilical cord uncut
45643939|NCT04070560|Procedure|Early (≤ 60 seconds) cord clamping|Resuscitation performed at a designated area after umbilical cord is cut
45643940|NCT04069468|Device|TheraSphere|Participants will receive treatment with TheraSphere in accordance with Instructions for Use
45917737|NCT02627443|Other|Pharmacological Study|Correlative studies
45917738|NCT00389259|Drug|Placebo|IV placebo q4h
45643943|NCT04064359|Drug|OBT076, a CD205-directed antibody-drug conjugate|Intravenous (IV) infusion of OBT076 every 3 weeks.
45643944|NCT04061603|Device|Adagio AF Cryoablation System (iCLAS™)|Endovascular ablation of the left and right atrium
45754337|NCT04142840|Drug|Propofol|a short -acting medication that result in a decreased level of consciousness and lack of memory for events,widely used including the starting and maintenance of general anesthesia.
45784341|NCT03127631|Behavioral|Smoking cessation|Advice to quit smoking, if applicable, and on available aids to quit smoking,
45784342|NCT03127631|Drug|Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)|Prescription for a low to moderate dose statin, such as simvastatin 10-40mg daily, atorvastatin 10-40mg daily, rosuvastatin 5-20mg daily or pravastatin 10-40mg daily.
45784343|NCT03127631|Drug|ACE inhibitor|Prescription for an ACE-I (preferable) or an angiotensin receptor blocker for baseline systolic blood pressure greater >130mmHg, or other blood pressure lowering medication as applicable.
45784344|NCT02244320|Drug|Tamsulosin|
45784345|NCT04376450|Procedure|Experimental- Nonincised papillae surgical approach|"The basic principle of the technique is the placement of only one buccal horizontal or oblique incision in the mucosa, as apically as possible from the periodontal defect and the marginal tissues, and the raising of a mucoperiosteal flap coronally, which permits apical access to the defect but leaving the marginal tissues intact, acting as a dome for the protection of the clot."
45784346|NCT04376450|Procedure|Active comparator- Entire papilla preservation technique|The entire Papilla Preservation Technique is to preserve the whole integrity of the defect- associated papilla providing a tunnel-like undermining incision. The completely preserved interdental papilla provides an intact gingival chamber to stabilize the blood clot and improve the wound healing process. To provide adequate access for debridement, EPP requires a short buccal vertical releasing incision on the buccal side of the neighboring tooth extending just beyond the mucogingival line.
45784347|NCT04376294|Device|Extracorporeal Shockwave Therapy(ESWT)|Each session of Extracorporeal Shockwave Therapy(ESWT) consists of 2000 pulses with a pressure of 3 bars (equals an energy flux density of 0.1 mJ/mm²), and treatment frequency of 8 pulses/sec
45784348|NCT04376294|Other|Eccentric training of the calf muscle:|The patients were asked to stand with all their body weight on the injured leg on a wooden step. From an upright body position and standing with all body weight on the forefoot, with the ankle joint in plantar flexion. The calf muscle is loaded by having the patient lower the affected limb down by dorsiflexion the ankle until the plantar aspect of the heel lay below the level of the step, and the ankle is in maximum dorsiflexion.
45643945|NCT04053634|Biological|Benralizumab|Benralizumab solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
45784349|NCT04376294|Other|Gastrocnemius, soleus, and hamstring stretch|Stretching every muscle for 30 seconds. Each stretch was performed 3 times (holding for 30 seconds and rest for 30 seconds). All these stretches were performed directly after the eccentric exercises twice/day for 7 days/week for weeks
45784350|NCT02244632|Drug|Modufolin (arfolitixorin)|IV injection every second week for 8 weeks.
45784351|NCT02244632|Drug|Fluorouracil|IV injection every second week for 8 weeks.
45784352|NCT02244632|Drug|Oxaliplatin|IV infusion every second week for 8 weeks.
45784353|NCT02244632|Drug|Irinotecan|IV infusion every second week for 8 weeks.
45784354|NCT02244632|Drug|Bevacizumab|IV infusion every second week for 8 weeks.
45784355|NCT03060083|Other|Very low nicotine content (VLNC) cigarettes and nicotine replacement therapy (NRT)|Participants will switch to very low nicotine content (VLNC) cigarettes with the aid of nicotine replacement therapy (NRT)
45784356|NCT03060083|Other|Reduce cigarettes per day (CPD) with nicotine replacement therapy (NRT)|Participants will reduce cigarettes per day (CPD) with the aid of nicotine replacement therapy (NRT)
45784357|NCT02244710|Drug|Ticagrelor vs Clopidogrel|
45784358|NCT04362332|Drug|Chloroquine Sulfate|cluster randomized
45784359|NCT04362332|Drug|Hydroxychloroquine|cluster randomized
45643946|NCT04053634|Biological|Placebo|Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
45784360|NCT04362332|Other|Standard supportive care|cluster randomized
45784361|NCT02308241|Drug|Ribavirin|self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day)
45784362|NCT01632683|Device|C-MAC|C-MAC arm
45784363|NCT01632683|Device|Glidescope|Glidescope arm
45784364|NCT00932282|Drug|Peanut Oral Immunotherapy|Peanut flour taken by mouth, given every day. Dose ranges from 0.2mg of peanut flour to 8000mg of peanut flour during the maintenance phase.
45643947|NCT04053283|Biological|NG-641|NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.
45784365|NCT00932282|Drug|Omalizumab|Omalizumab (anti-IgE) will be given for 4 months prior to starting oral immunotherapy. The medication is given as a subcutaneous injection with dose based on total IgE levels and weight at the beginning of the study. This medication is given for a total of 10 months.
45784366|NCT02159495|Drug|cyclophosphamide|Given IV
45784367|NCT02159495|Biological|Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes|Given IV
45784368|NCT02159495|Other|laboratory biomarker analysis|Correlative studies
45784369|NCT02159495|Biological|Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes|Given IV
45643948|NCT04047628|Procedure|Autologous Hematopoietic Stem Cell Transplantation|"PBSC mobilization & collection regimen per protocol/ institutional standards includes: intravenous cyclophosphamide (Cytoxan®), 4 grams/m^2); intravenous mesna (Mesnex®),a total delivery of 4 grams/m^2); oral dexamethasone, 10 mg dose, four times daily); subcutaneous filgrastim,10 mcg/kg/day until leukapheresis goal is completed; and CD34+ peripheral blood stem cells collection by leukapheresis.~Conditioning per protocol& institutional standards:~6-day BEAM (e.g. Carmustine (BCNU), Etoposide (VP-16), Cytarbine (Ara-C), and Melphalan) chemotherapy protocol and,~rabbit anti-thymocyte globulin (rATG) 2.5 mg/kg/day x2~Autologous cryopreserved graft infusion: The target Cluster of Differentiation (CD)34+ cell dose for infusion is 5 x 10^6 CD34+ cells/kg (minimum 4 x 10^6 CD34+ cells/kg; maximum 7.5 x 10^6 CD34+ cells/kg).~For 1&2 above: Ideal body weight (IBW) versus Actual Body Weight (ABW) are applicable."
45643949|NCT04047628|Biological|Best Available Therapy (BAT)|"Disease-modifying therapy (DMT) selected by the Site Investigator from the below:~cladribine~natalizumab~alemtuzumab~ocrelizumab,~rituximab, or~ofatumumab"
45643950|NCT04047472|Drug|Brolucizumab 6mg|Subjects will receive Brolucizumab 3 x q4w up to Week 8 followed by q12w / q8w up to Week 40 or Week 44, depending on disease activity status.
45784370|NCT02159495|Drug|Fludarabine Phosphate|Given IV
45784371|NCT04367558|Procedure|Minimally invasive, in-office, RF reduction of the affected area|Usage of RF needle to treat one or more of the affected areas
45784372|NCT04346810|Other|Patient management suffering of coronavirus infection|Welle-being and stress of the caregivers
45784373|NCT01632995|Drug|FTC 200 mg/TDF 300 mg fixed-dose combination tablet|Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.
45784374|NCT04362098|Behavioral|Home visiting Program for Young Pregnant Women|The visitation program was elaborated based in the following theoretical principles: a) Albert Bandura's self-efficacy theory; b) Urie Brofenbrenner's bioecological theory, which recognizes the importance of the insertion of individuals in families in varied contexts of life in society; c) John Bowlby and Mary Ainsworth's attachment theory. The basic premises of the intervention are health care, environmental health, life course development, development of parenting ability, relationship with friends and family, and social service support.
45784375|NCT02245022|Drug|Dolutegravir 50mg od|Patients randomised to receive either Dolutegravir 50mg od or standard of care (Efavirenz 600mg od) plus Lamivudine 300mg od/ Tenofovir 300mg od
45784376|NCT02245022|Drug|Standard of Care|Patients are randomised 1:1 to receive either Dolutegravir 50mg once daily in combination with Lamivudine 300mg od and tenofovir 300mg od or standard of care (Efavirenz 600mg plus Lamivudine 300mg od and tenofovir 300mg od)
45784377|NCT02224313|Drug|oral estradiol 1.0 mg|one tablet of oral estradiol 1.0 mg once a day for 28 days
46070879|NCT01977560|Behavioral|Standard Care|After receiving dietary and physical activity instructions as recommended by the American Diabetes Association (ADA) guidelines participants will meet approximately every month for about 7 months with a study team member to record body weight, review diet and physical activity behaviors, and document medication use. Participants will continue their routine medical management, including regular clinic visits with their personal physician and/or diabetes educator during their participation in this study. Any changes medications will made by the participants' personal physician(s).
45784378|NCT02224313|Drug|oral progesterone 100 mg|one tablet of oral progesterone 100 mg once a day for 14 days
45784379|NCT04362410|Biological|Experimental: Tezepelumab|Tezepelumab single dose subcutaneously injection.
45784380|NCT04362410|Other|Placebo|Placebo single dose subcutaneously injection.
45784381|NCT02460198|Biological|Pembrolizumab|IV infusion
45784382|NCT01633853|Drug|Vitamin D2|Treatment with Vit D2.
45784383|NCT01633853|Drug|1,25(OH)2 Vit D3|Treatment with 1,25(OH)2 Vitamin D3(Rocaltrol).
45784384|NCT04367402|Other|BioMedomics COVID-19 IgM-IgG Rapid Test|Qualitative test to aid in the diagnosis of COVID-19 novel coronavirus
45784385|NCT04361552|Other|Best Practice|Receive standard of care
45784386|NCT04361552|Biological|Tocilizumab|Given IV
45784387|NCT02487810|Behavioral|Cognitive load|Patients in the intuition arm of the study will be asked to complete a memorization task while they are answering survey questions.
45784388|NCT02487810|Behavioral|Deliberative instructions|Patients in the deliberative arm will be given instructions to take their time and deliberate on their decisions
45784389|NCT04367324|Device|Low-level laser therapy|The low-level laser was applied to each patient in low-level laser therapy group.
45784390|NCT02862353|Biological|blood sample|15 ml of blood
45784391|NCT04361630|Drug|FGF 2|Following a standard surgical protocol, rhFGF-2 impregnated membranes will be placed in sites with gingival recession.
45784392|NCT02639897|Other|Direct Laryngoscopy|Tracheal intubation with direct laryngoscopy using Macintosh laryngoscope blade
45784393|NCT04376216|Drug|Prednisone|60 mg with dose tapering over 2 months
45784394|NCT02452320|Drug|intravenous acetaminophen|administration of 1000mg of intravenous acetaminophen or placebo every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
45784395|NCT02452320|Drug|Placebo|Subjects randomized to placebo will receive every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
45784396|NCT02459964|Drug|Fentanyl Nasal Spray|Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h)
45784397|NCT02459964|Drug|Hydromorphone Hydrochloride|Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).
45784398|NCT02459964|Behavioral|Phone Call|Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study. The phone call should last about 5 minutes.
45784399|NCT01635101|Drug|IV Acetaminophen|IV Acetaminophen given every 6 hours (q6h); 4 doses, in 24 hours
46070880|NCT00626821|Device|SenSura|Real life assessment of SenSura
46070881|NCT03847766|Behavioral|PRO-based follow-up|Diagnose specific questionnaires are used to screen patients in need of contact to the outpatient clinic
45784400|NCT01635101|Drug|IV Control|IV Control q6h; 4 doses, in 24 hours
45784401|NCT02138669|Device|Intacs|INTACS® prescription inserts are an ophthalmic medical device designed for the reduction or elimination of myopia and astigmatism in patients with keratoconus so that their functional vision may be restored and the need for a corneal transplant procedure can potentially be deferred.
45784402|NCT02087111|Drug|Telaprevir|375 mg film coated tablets
45784403|NCT02087111|Drug|40 Kd Pegylated interferon alfa 2a|180 µg in pre-filled syringe for sub-cutaneous injection
45784404|NCT02087111|Drug|Ribavirin|200 mg tablets
45784405|NCT02993939|Procedure|Interscalene block|Ultrasound guided single shot block above the clavicle
45784406|NCT02993939|Procedure|Infraclavicular-suprascapular block|Combined block of nerves far away from phrenic nerve
45784407|NCT00932438|Device|LC beads loaded with Irinotecan|Chemoembolization using LC beads loaded with 100mg Irinotecan
45784408|NCT00932438|Drug|Oxaliplatin|Oxaliplatin 85 mg/sqm, IV infusion every two weeks
45784409|NCT00932438|Drug|Leucovorin|Leucovorin 200 mg/sqm, IV infusion every two weeks
45784410|NCT00932438|Drug|5-Fluorouracil|5-Fluorouracil 2400 mg/sqm, IV infusion every 2 week
45784411|NCT00932438|Drug|Bevacizumab|Bevacizumab 5 mg/kg given at the discretion of the treating physician
45784412|NCT01635881|Device|Emerge™ 1.20 mm PTCA Dilatation Catheter|"The Emerge 1.20 mm device is the next-generation Boston Scientific PTCA dilatation catheter. It is a sterile, single-use, intravascular medical device used to improve lumen diameter.~The catheter consists of a shaft with a balloon near the distal tip. The balloon is designed to provide an inflatable segment of known diameter and length at recommended pressures."
45784413|NCT02100683|Device|PDA Coil|The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter < 4 mm.
45784414|NCT04375748|Diagnostic Test|Performing routine care (clinical and paraclinical tests)|ECG, standard biology and cardiology tests, and routine transthoracic echocardiography (TTE), MRI
45784415|NCT04375748|Diagnostic Test|Examinations for the research:|"Systematic research by polymerase chain reaction (PCR) for Covid-19 in the blood and in an oro-pharyngeal swab, in addition to the usual immunologic, bacteriological, viral and parasitic tests carried out as part of the routine care of all patients with suspected myocarditis.~A 30-days phone call follow-up (vital status) and a systematic 1-year follow-up will be realized (clinic, biology, ECG, TTE, +/- MRI)"
45784416|NCT01869413|Drug|Tranexamic Acid|Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours).
45784417|NCT01869413|Drug|Placebo|As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
45643951|NCT04047472|Drug|Aflibercept 2 mg|Subjects will receive Aflibercept 3 x q4w up to Week 8 followed by q8w up to Week 40.
45643952|NCT04047355|Drug|Propranolol|Propranolol is a beta-blocker used to treat high blood pressure, irregular heartbeats, and tremors. It is used after a heart attack and to prevent migraine headaches and chest pain. It is also used off-label for anxiety and PTSD.
45784418|NCT01636661|Device|tDCS|transcranial direct current stimulation- non-invasive brain stimulation
45784419|NCT04375592|Dietary Supplement|Phenylalanine-free protein substitute in tablet form (XPhe minis)|Intervention is a Phenylalanine-free protein substitute in tablet form. Subjects who currently take a concentrated second stage phenylalanine-free protein substitute will be recruited. Subjects will take the study product for 7 days and daily questionnaires will be completed. Subjects will replace some or all of their usual protein substitute with the new product. The amount of study product prescribed will be calculated to provide the same amount of protein as their usual protein substitute. Daily acceptability and tolerance questionnaires will record information on ease of preparation and administration; how it is taken; and any problems or gastrointestinal effects. Additional questions at the beginning and end of the study will record information on taste, appearance, smell, presentation and packaging of the product. Routine weekly finger prick blood spots will be collected and analysed for phenylalanine and tyrosine as usual.
45643953|NCT04045431|Device|PAAG-OA|Intra-articular injection of 6ml PAAG-OA in the target knee (incl. five (5) years follow-up) period.
45643954|NCT04045431|Device|Synvisc-One|Intra-articular injection of 6ml Synvisc-One in the target knee
45784420|NCT01637207|Other|Palpation|Group A: Palpation Group
45784421|NCT01637207|Other|Ultrasound|Group B: Ultrasound Group
45784422|NCT02245100|Other|Cytology specimen|Correlative studies
45784423|NCT02245100|Other|Laboratory biomarker analysis|Correlative studies
45643955|NCT04037254|Biological|Gonadotrophin Releasing Hormone|Receive standard of care GnRH agonist androgen suppression therapy
45784424|NCT02982512|Drug|Dexmedetomidine|Administration of dexmedetomidine a different concetrations
45784425|NCT01555697|Drug|Memantine|Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
45784426|NCT01555697|Drug|Placebo|Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
45643956|NCT04037254|Radiation|Intensity-Modulated Radiation Therapy|Undergo standard of care IMRT
45643957|NCT04037254|Drug|Niraparib|Given PO
45643958|NCT04036682|Drug|CLN-081|CLN-081 tablets
45643959|NCT04028973|Other|Single then dual task situation|Firstly, the participants have to perform the fatiguing task in simple task condition (control condition, i.e., muscle contraction alone). Secondly, few days later (between 3 and 7 days later), the participants have to perform the same fatiguing task with a concomitant memory cognitive task (i.e. dual-task condition).
45643960|NCT04028973|Other|Dual then single task situation|Firstly, the participants have to perform the fatiguing task in dual-task condition (i.e. muscle fatiguing contraction with a concomitant memory cognitive task). Secondly, few days later (between 3 and 7 days later), the participants have to perform the same muscle fatiguing task without a concomitant memory cognitive task (i.e. control condition).
45784427|NCT02982434|Drug|Pharmaceutical composition containing botulinum toxin|
45784428|NCT02982434|Drug|0.9% normal saline|
45784429|NCT02982434|Procedure|Coronary artery bypass grafting|
46070882|NCT03847766|Behavioral|PRO-based telephone consultation|diagnose-specific questionnaires are used to support communication between clinician and patient during a phone consultation
45643961|NCT04027426|Behavioral|FBT|FBT will receive a family-based, behavioral intervention for childhood obesity, consisting of group meetings once a week for months 1 to 4, twice a month for months 5 to 6, once a month for months 7 to 12, and once every two months for months 13 to 18 (29 sessions). For all meetings, the child and adult caregiver will be weighed and be provided with feedback, homework will be reviewed, and a behavioral lesson will be presented. At the 60-min meetings, the child and adult will attend separate 40 min group meetings, and then for the last 20 min of the meetings they will meet together with an individual therapist to address specific family-issues by developing behavioral action plans. No goals on variety in RED foods will be provided.
45643962|NCT04027426|Behavioral|FBT+Variety|This condition is FBT with a limited variety prescription. The limited variety prescription reduces the number of different RED foods consumed.
45917739|NCT02587897|Other|Academic Coursework|Didactic training provided by the university through coursework and laboratory training that meets requirements of the accreditation standards provided by the professional society associated with each professional degree granting program.
45917740|NCT02587897|Other|Work-Related Hand Activities|Exposure to intensive training in the use of dental scaling tools as part of laboratory courses, as well as fieldwork and residency training during the academic degree program.
45917741|NCT02491099|Drug|Afatinib|Afatinib, 40 mg orally once daily on a 21 day cycle for the first 12 weeks, then every 28 days for subsequent cycles until progression
45784430|NCT02451930|Drug|Necitumumab|Administered IV
45784431|NCT02451930|Drug|Pembrolizumab|Administered IV
45784432|NCT04358120|Device|Hyaluronic Acid Combined With Chondroitin Sulfate|"Subjects' participation in the study will last 26 weeks. The study includes 7 visits that consist of a Screening visit, three treatment visits and three follow-up visits.~Eligible subjects will undergo a Baseline visit (V1 at week 0) during which, after the confirmation of eligibility, assessments and ultrasound evaluation, the study subjects will be treated with the 1st injection of 2%Hyaluronic Acid and 2% chondroitin sulfate Subsequent treatments will be administered at weekly intervals during Visit 2 (V2 at week 1) and Visit 3 (Visit 3 at week 2) after the effectiveness assessments.~Study subjects will return for Follow-up visits 1 month (Visit 4 at week 6), 3 months (Visit 5 at week 14) and 6 months (Visit 6 at week 26) after the last injection"
46070883|NCT03609866|Procedure|rapid thoracic compression technique|in the expiratory time of the ventilation set, it will be applied a rapid thoracic compression
45784433|NCT01203839|Radiation|multiple beams utilizing either intensity-modulated or 3D-conformal techniques|A dose of 40 Gy will be delivered to the tumor bed plus 1.5-2 cm margin. Treatment will be delivered once daily, 5 days a week, for approximately 2 weeks. Radiation therapy will begin within a minimum of 4 weeks and a maximum of 3 months from definitive surgical procedure and 2-6 weeks after chemotherapy, if chemotherapy given first. Prior to radiation, patients will receive a lumpectomy with an assessment of axillary lymph node status (for invasive tumors only). Axillary assessment may be any combination of sentinel lymph node biopsy or axillary lymph node dissection.
45784434|NCT00932828|Drug|Peanut oral immunotherapy|Defatted peanut in flour form to be used as treatment for peanut allergy
45784435|NCT04932798|Diagnostic Test|Resting ECG (if first visit is done on site only)|"The standard 12-lead electrocardiogram is a representation of the heart's electrical activity recorded from electrodes on the body surface.~This test requires around 15 minutes of the participant's time."
45784436|NCT04932798|Diagnostic Test|24-hour ambulatory electrocardiographic monitoring (Holter) (if first visit done on site only)|The Holter monitor is a type of portable electrocardiogram (ECG) worn continuously for 24 hours.
45643967|NCT04023370|Device|Treatment of primary iliac artery stenosis and/or occlusive lesions|Stent implantation
45643968|NCT04022239|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplantation
45784437|NCT04932798|Diagnostic Test|3-month AF detection monitoring using the Apple Watch|Patients with irregular heart rates will be notified by the Apple Watch and instructed to confirm the rhythm by using the integrated ECG recording system. This simply requires touching the watch with a finger from the opposite hand and provides a 30 seconds one-lead ECG recording of diagnostic quality. These tracing will be transferred to the study team for analysis using a dedicated email.
45784438|NCT00928694|Drug|fenofibrate (U.S. formulation)|Single dose of 160 mg fenofibrate U.S. formulation (Tricor®) in one of two treatment periods.
45784439|NCT00928694|Drug|fenofibrate (UK formulation)|Single dose of 160 mg fenofibrate UK formulation (Supralip®) in one of two treatment periods.
45784440|NCT01639157|Drug|Buspirone|Subjects will be maintained on oral buspirone (10 mg administered 3 times daily) for 6 days each during the study in random order.
45784441|NCT01639157|Drug|Placebo|Subjects will be maintained on oral placebo (0 mg administered 3 times daily) for 6 days each during the study in random order.
45784442|NCT02451696|Drug|Everolimus|This study will measure if the drug called Everolimus effects mTOR signaling (an electrical activity signal in the brain) in patients with Tuberous Sclerosis Complex (TSC) and Focal Cortical Dysplasia (FCD) with treatment resistant epilepsy (TRE) who will be undergoing brain surgery. One group of patients will be treated with Everolimus, for 7-28 days prior to epilepsy surgery and another will not. We will determine if there is a difference in mTOR signaling between the patients who were treated with Everolimus and those who were not
45784443|NCT00928772|Device|CRANIAL ELECTROTHERAPY (Alpha Stim) + SHAM MIDAZOLAM|APPLYING OF ELECTRODES ON THE EAR LOBES AND TEMPLES WHICH ARE SENDING AN ACTIVE MICROCURRENT THROUGH THE MIDBRAIN PRODUCING SEDATION WITHOUT PHARMACOLOGICAL AGENTS AND GIVING NORMAL SALINE AS A SHAM DRUG SEDATION
45784444|NCT00928772|Drug|MIDAZOLAM + SHAM ELECTRODES SIMULATING CRANIAL ELECTROTHERAPY|CONVENTIONAL METHOD OF PERIOPERATIVE SEDATION
45784445|NCT00928772|Other|NO SEDATION WITH SHAM CRANIAL ELECTROSTIMULATION AND PLACEBO VERSED|NO ACTIVE SEDATION, ONLY SHAM ELECTRODES AND NORMAL SALINE SIMULATING MIDAZOLAM.
45643969|NCT04022239|Drug|Bendamustine|Given IV
45643970|NCT04022239|Drug|Cyclophosphamide|Given IV
45643971|NCT04022239|Biological|Filgrastim-sndz|Given SC
45784446|NCT04361084|Other|traditional simulated training|traditional simulation using actors as standardised patients playing out scenarios plus pre and post questionnaires and semi structured interviews
45784447|NCT04361084|Other|mixed reality simulation|using immersive technologies to create a virtual reality simulated training scenario's plus pre an post questionnaires and semi structured interview's
45784448|NCT02459418|Drug|Afolia|"During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27"
45784449|NCT02459418|Drug|US Gonal-f®|"During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27"
45784450|NCT04361318|Combination Product|Hydroxychloroquine plus Nitazoxanide|Both hydroxychloroquine & nitazoxanide will be administered orally to participating patients
45784451|NCT04361318|Other|Standard care|"Oxygen administered via ventilator. In addition, antipyretic paracetamol may be added if necessary"
45784452|NCT00695279|Procedure|Venipuncture|Blood draw
46070884|NCT03609866|Procedure|metatarsophalangeal joint passive mobilization|it will be performed a metatarsophalangeal joint passive mobilization technique on the patient
46070885|NCT05332886|Behavioral|MetaHealth Group|Three metaverse rooms will be created via metaverse technology that aims to develop healthy nutrition, physical activity, and psychological resilience skills to reduce the risk of of NCDs in youth.
45643972|NCT04022239|Drug|Fludarabine|Given IV
45643973|NCT04022239|Drug|Melphalan|Given IV
45643974|NCT04022239|Drug|Mycophenolate Mofetil|Given PO
45643975|NCT04022239|Biological|Rituximab|Given IV
45643976|NCT04022239|Drug|Tacrolimus|Given IV and PO
45643977|NCT04022239|Radiation|Total-Body Irradiation|Undergo TBI
45643978|NCT04021290|Drug|DTG/3TC FDC|DTG/3TC FDC will be available as white, oval, film-coated tablets at a unit dose strength of 50 mg/300 mg. Participants will take DTG/3TC once daily via oral route.
45754338|NCT04142762|Drug|ABI-H2158|ABI-H2158 tablets
45643979|NCT04021290|Drug|CAR|Participants who are randomized to the CAR arm will continue to take the current treatment until Week 52. CAR will include 2 NTRIs plus either an INI, NNRTI, or boosted PI or atazanavir unboosted.
45643980|NCT04020341|Drug|Gepotidacin|Gepotidacin will be available as tablets containing 750 mg gepotidacin. Each dose should be taken with water after consumption of food.
46070886|NCT05332886|Behavioral|MobileHealth Group|The intervention aims to develop healthy nutrition, physical activity, and psychological resilience skills using mobile application materials to reduce the risk of NCDs in youth.
45643981|NCT04020341|Drug|Placebo matching nitrofurantoin|Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Each dose should be taken with water after consumption of food.
45643982|NCT04020341|Drug|Nitrofurantoin|Nitrofurantoin will be available as over-encapsulated capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Each dose should be taken with water after consumption of food.
45643983|NCT04020341|Drug|Placebo matching gepotidacin|Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Each dose should be taken with water after consumption of food.
45784453|NCT04367012|Other|Abdominal Ultrasound|patient in supine position and external carotid artery was examined to meausre the intima using US .Machine GE logic FB inear probe10Mhz.and intimal media thickness mean =10mm
45784454|NCT04925076|Drug|Ethanol|A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
45917742|NCT02471053|Other|Moderate Intensity Exercise|Exercise sessions will be held twice-weekly and will begin with a group warm-up activity, followed by 45 minutes of aerobic activity and ending with a cool down. All aerobic exercise will be performed at a moderate intensity, defined as exercise that elicits a heart rate (HR) between 40-60% of heart rate reserve (HRR). Prior to the initial exercise session target heart rates will be calculated for each subject based on the maximum HR achieved during their baseline stress test.
45917743|NCT00000957|Biological|gp160 Vaccine (Immuno-AG)|
45643984|NCT04020276|Radiation|SBRT|Participants will receive 5 fractions of radiation, which will be delivered 2-3 times per week. SBRT should be complete in a 1.5 to 2 week time frame. There should be a minimum of 12 hours between treatments. Each fraction will be escalated or de-escalated to meet the overall constraints in phase IA or both previously identified constraints in phase IB
45917744|NCT00000966|Drug|Azithromycin|
45917745|NCT00000966|Drug|Pyrimethamine|
45643985|NCT04015141|Drug|Perampanel Oral Suspension|Perampanel oral suspension.
45643986|NCT04015141|Drug|Perampanel Tablet|Perampanel tablet.
45643987|NCT04014166|Other|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|This is a single-arm study to evaluate the safety and efficacy of hUC-MSCs to treat refractory immune thrombocytopenia. The dose of hUC-MSCs will be successively divided into three increasing dose(group A: hUC-MSCs 0.5×10^6/kg, weekly for 4 weeks, 3 patients; group B: hUC-MSCs 1.0×10^6/kg, weekly for 4 weeks, 3 patients; hUC-MSCs 2.0×10^6/kg, weekly for 4 weeks, 3 patients) with 3 patients in each group according to the dose. The principle of increasing dose will be carried out successively from low dose to high dose group. According to the results of the safety and efficacy data from these 9 patients, the investigator will determine one of the doses and expand the sample size to 6 cases.
45643988|NCT04012138|Drug|Salbutamol|10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air) 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period.
45754339|NCT04142762|Drug|Itraconazole|Itraconazole capsules
45754340|NCT04142762|Drug|Rifampin|Rifampin capsules
46070887|NCT03842930|Procedure|Endovascular embolization|Endovascular embolization of the Lumbar Arteries
46070888|NCT04018417|Drug|Amphotericin B|Drug concentration: 0.255 μg/mL
46070889|NCT03808220|Behavioral|postoperative pain intensity|estimate the postoperative pain intensity by using a scaling system via questionnaire
46070890|NCT03808220|Behavioral|preoperative pain frequency|estimate the preoperative pain intensity by using a scaling system via questionnaire
46070891|NCT03808220|Behavioral|Side effect|investigate the presence of any side effect
46070892|NCT00826345|Other|Acupuncture / Moxibustion|"Acupuncture/Moxibustion points will be administered per point prescription.~- Active"
46070893|NCT00826345|Other|Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion - Not active
45754341|NCT04142762|Drug|Midazolam|Midazolam syrup
45754342|NCT04142762|Drug|Ethinyl Estradiol / Levonorgestrel|Ethinyl Estradiol / Levonorgestrel tablets
45754343|NCT04142762|Drug|Esomeprazole|Esomeprazole capsules
45784455|NCT04925076|Other|Placebo|A beverage that does not meaningfully increase breath alcohol concentration.
45784456|NCT04366700|Procedure|Periapical surgery with autograft and collagen membrane|periapical surgery will be done and the defects will be filled with a mixture of autograft and prf and will be covered with a collagen membrane
45784457|NCT04366700|Procedure|Periapical surgery with collagen membrane|periapical surgery will be done and the defects will be filled with blood clot and covered with a collagen membrane
45784458|NCT01598207|Drug|Marinol|5mg BID, orally for 1 month
45784459|NCT01598207|Drug|Placebo|5mg BID, orally for 1 month
45784460|NCT01640171|Procedure|Xylocaine 2% Injectable Anesthetic|xylocaine 2% injection 0.1 cc
45784461|NCT01640171|Drug|Proparacaine Hydrochloride 0.5% Drop|Topical drop given first to the treated eye.
45784462|NCT01640171|Drug|Tetravisc 0.5% Gel|Gel applied to eye 3 times prior to treatment
45784463|NCT01640171|Drug|Acuvail|Anti-inflammatory drop given after treatment
45917746|NCT00000966|Drug|Leucovorin calcium|
45917747|NCT00000969|Drug|Zalcitabine|
45917748|NCT00000969|Drug|Didanosine|
45917749|NCT00000972|Biological|MTP-PE/MF59|
45917750|NCT00000972|Biological|Env 2-3|
45917751|NCT00000975|Drug|Itraconazole|
45917752|NCT00000978|Drug|Zidovudine|
45917753|NCT00000978|Drug|Zalcitabine|
46070894|NCT01791920|Drug|Botulinum toxin type A(Botulax®)|Single administration, Day 0, 20 units
46070895|NCT01791920|Drug|Botulinum toxin type A(Botox®)|Single administration, Day 0, 20units
45784464|NCT01640171|Drug|Intra-vitreal Anti-VEGF Drug|Intravitreal injection treating wet AMD or Diabetic Macular Edema or Retinal Vein Occlusion
45784465|NCT04361474|Drug|Budesonide Nasal|Nasal irrigation with budesonide and physiological saline morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.
45784466|NCT04361474|Other|Physiological serum|Nasal irrigation with physiological saline morning and evening, for 30 days, in addition to olfactory re-education twice a day.
45784467|NCT04357808|Drug|Sarilumab|Single dose treatment with sarilumab 2 x 200 mg subcutaneously
45784468|NCT04357808|Other|Standar of care|Usual clinical care
45784469|NCT04366622|Drug|Riociguat (Adempas, BAY 63-2521)|0.5 mg riociguat as an immediate-release (IR) tablet
45784470|NCT04366778|Diagnostic Test|TEM-tPA|325 patients with Covid-19 hospitalized in Lyon University Hospitals will have TEM-tPA measurements in parallel to D-dimers every 3 days during the hospitalization period. TEM-tPA of patients with and without thrombosis will be compared and their fibrinolysis (PAI-1, TAFI, tPA, thrombin) will be further explored.
45784471|NCT02245334|Drug|Povidone-Iodine|1 pill per biopsy
45449078|NCT02156206|Behavioral|123 women emergency phone line in Medellin, Colombia|"123 is the emergency number in Colombia. The 123- woman line consists of supplementary emergency services to meet the demands of urgency in relation to cases of VAW. This service is implemented by the mayor of Medellin, in collaboration with the national police who is the institution in charge of managing the 123 line.~When the police attends an emergency on VCM, the call is derived to the 123- woman line. There, a team consisting of a psychologist and a lawyer serves women in crisis, as emergency services provided by the police are developed in parallel. The team verifies that the rights of women are respected and that women are oriented to the relevant services. The 123- woman line operates from 7:00 am to 7:00 pm, Monday through Friday."
45784472|NCT04775810|Device|The device is an algorithm designed to enhance speech intelligibility of speech-in-noise signals|Normal-hearing and hearing-impaired subjects will listen to speech-in-noise audio files that are either unprocessed or processed in order to increase speech intelligibility.
45449079|NCT04859920|Other|Questionnaires|QLQ-C30, SF-12, HADS, SARASON, EPICES, socio-professional data
45449080|NCT04859920|Other|Collection of clinical data and treatments|clinical data and treatments
45449081|NCT00132041|Device|radiofrequency ablation|
45449082|NCT05665881|Drug|Ephedrine|vasopressor
45643989|NCT04012138|Drug|Insulin Aspart|"Patients in the experimental group will receive either:~10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR~10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol."
45643990|NCT04011280|Drug|Varenicline|The ten 30-minute sessions will target core processes in ACT such as acceptance and being present.
45449083|NCT05665881|Drug|Phenylephrine|vasopressor
45917754|NCT02393716|Device|Endurant Evo AAA Stent Graft System|
45917755|NCT02393716|Procedure|Endovascular aneurysm repair (EVAR)|
45917756|NCT00000999|Drug|Zidovudine|
45917757|NCT02312011|Drug|IONIS-DMPKRx|Drug
45784473|NCT04762160|Drug|Tazemetostat|Study Drug
45917758|NCT02312011|Drug|Placebo|Placebo
45917759|NCT02304913|Other|Hypoglossal acupuncture|
45917760|NCT02304913|Other|Sham acupuncture|
45917761|NCT02304913|Behavioral|Dietary recommendations|
45917762|NCT00001002|Drug|Zidovudine|
45449084|NCT05665881|Drug|Norepinephrine|vasopressor
45449085|NCT02154100|Dietary Supplement|Tart Cherry|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
45449086|NCT02154100|Dietary Supplement|Placebo|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
45449087|NCT03730077|Drug|18F-FMISO|18F-FMISO PET/CT
45917763|NCT00001002|Drug|Foscarnet sodium|
45917764|NCT02270359|Device|OCT|Optical coherence tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.
45917765|NCT02270359|Procedure|CMR|Cardiac magnetic resonance imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (smelling)
45917766|NCT02270359|Drug|contrast agent, Gadolinium|Gadolinium contrast will be administered during CMR
45643999|NCT04002934|Drug|Bazedoxifene Acetate|40 mg Bazedoxifene delivered orally in the form of 2x 20 mg blinded capsules
45644000|NCT04001829|Drug|Docetaxel|Given IV
45644001|NCT04001829|Drug|Paclitaxel|Given IV
45644002|NCT04001829|Other|Quality-of-Life Assessment|Ancillary studies
45784474|NCT04762160|Combination Product|Rituximab|Partner Drug
45784475|NCT04357340|Other|Pulmonary Physiotherapy Techniques|Participants will receive pulmonary physiotherapy techniques in six session during three days (twice daily). Four distinguished interventions will be provided for the patients: 1) Chest expansion exercises (for prevention and treatment of potential atelectasis); 2) Techniques to Mobilize or loosen the pulmonary secretions (Active cycle breathing, Coughing techniques, Vibration and Postural drainage); 3) Hold breathing exercise (3 sets, 10 repetition) and; 4) Walking training (based on patient's tolerance until 6 minute).
45784476|NCT02487498|Drug|QVA149|QVA149 capsules for inhalation, delivered via QVA149 SDDPI
45784477|NCT02487498|Drug|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
45784478|NCT02487498|Drug|Placebo (umeclidinium/vilanterol )|Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
45784479|NCT02487498|Drug|Placebo (QVA149)|Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
45784480|NCT04357418|Other|it is a survey|this interview can be carried out face to face or remotely.
45784481|NCT04357028|Drug|Measles-Mumps-Rubella Vaccine|Measles mumps Rubella vaccine is a weak attenuated life vaccine
45784482|NCT04357028|Drug|Placebos|0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm
46070896|NCT00826501|Procedure|Endoscopic cyst-gastrostomy|After passing a small camera into the stomach the pseudocyst will be punctured and drained into the stomach by stent placement.
45784483|NCT05620316|Drug|BOTOX® Injection|100 MU of botulinum toxin type A (BOTOX® - Allergan Inc. - Dublin - Ireland) were diluted in 2ml of saline. Patients were injected with 10 MU of BTXA per side at two sites into the masseter muscle bilaterally. The first site was the inferior prominent part of the masseter muscle observed when the subject was asked to clench, and the other site was 5 mm below the first point
45784484|NCT05620316|Other|Prick skin|patients were pricked twice at the inferior prominent part of the masseter muscle observed using the stinger pen used in the blood glucose meter; it is less painful and provides psychological benefits, instead of injecting the physiological saline into the muscle to avoid the severe pain without a benefit to the patient which would not conform to the ethical standards.
45784485|NCT04357106|Biological|Convalescent plasma|Convalescent plasma obtained by aphaeresis from recovered patients.
45784486|NCT04360304|Device|Echocardiographic exam|"An echocardiographic exam is realised after inclusion, measuring especially :~LVOT VTI~Respiratory variation of inferior veina cava diameter For theses two measurements, the manual method is first recorded, and then the automated one is done.~For patients that need fluid resuscitation of at least 250mL in less than 10minutes (indication at the discretion of the physician in charge of the patient), a second echocardiography is done according to the same protocol described before."
45784487|NCT04356872|Drug|Sintilimab|immune check point inhibitor, 200mg, iv, d1
45784488|NCT04356872|Drug|Doxorubicin Hydrochloride|ADM, 60mg/m2, iv, d1
45644003|NCT04001829|Other|Questionnaire Administration|Ancillary studies
45644004|NCT03999229|Drug|SNO|S-nitrosylating agent (SNO) Inhalation
45644005|NCT03999229|Drug|Normal Saline|Normal Saline transfusion
45784489|NCT04356872|Drug|Ifosfamide|IFO, 1.8 g/m2/d, d1-5
45784490|NCT02487108|Drug|TV-46763|TV-46763 will be administered per dose and schedule specified in the arm description.
45784491|NCT02487108|Drug|Placebo|Placebo matching to TV-46763 will be administered per schedule specified in the arm description.
45784492|NCT04746872|Device|Alinity m HR HPV|Alinity m HR HPV
45784493|NCT02982356|Procedure|Fetal Selective Reduction Technology|Fetal Selective Reduction Technology will be conducted according to different gestational weeks: before 16weeks, 16~24 weeks, 24~27+6 weeks,>28weeks
45784494|NCT02982356|Drug|Potassium Chloride|
45784495|NCT04360382|Other|ERACS|Pregnant women scheduled for cesarean section will be subjected to preoperative, intra-operative and postoperative nurse care aiming at early recovery.
45784496|NCT04360382|Other|Regular care|Usual care for all cases subjected to cesarean section at our hospital.
45784497|NCT02487030|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
45784498|NCT02487030|Drug|RBV|Tablets administered orally in a divided daily dose based on weight (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45784499|NCT04360148|Dietary Supplement|very-low-calorie-ketogenic-diet|VLCKD-group will undergone to VLCKD for 8 weeks. VLCKD is based on protein preparations of high biological value. Total daily energy intake is < 800 kcal.Daily carbohydrate intake is lower than 30 g/day, while daily protein intake is approximately 1.2-1.5 g/kg of ideal body weight. The following four weeks, carbohydrates are gradually reintroduced, starting from foods with the lowest glycemic index (fruit, dairy products), followed by foods with moderate and high glycemic index (bread, pasta and cereals). The goal is to achieve a hypocaloric balanced diet (HBD), as well as the controlled group. From the 12th week to the 24 th week, all subjects enrolled will continue follow-up with HBD.
46070897|NCT00826501|Procedure|Surgical cyst-gastrostomy|After making an incision in the abdomen the pseudocyst contents will be emptied and the pseudocyst will be sutured to the stomach.
45449088|NCT01582841|Procedure|MSI screening test|All individuals in the intervention arm who consent to participate in the HNPCC screening will have their tumors evaluated for MSI.
45644006|NCT03999229|Drug|Red Blood Cell|Blood transfusion (RBCs)
45644007|NCT03994367|Other|High animal protein isolate|Increased dietary protein content from animal protein isolates
45644008|NCT03994367|Other|High animal protein whole food|Increased dietary protein content from animal protein whole food
45644009|NCT03994367|Other|High plant protein isolate|Increased dietary protein content from plant protein isolates
45644010|NCT03994367|Other|High plant protein whole food|Increased dietary protein content from animal protein whole food
45644011|NCT03990428|Behavioral|online surveys|Survey data about supportive care needs, mood, and the experience of IC's finding meaning and purpose in the caregiving experience.
45644012|NCT03989271|Drug|Quercetin|Placebo
45644013|NCT03988621|Behavioral|ViCCY|Virtual Health Coaching for You
45644014|NCT03987711|Drug|Warfarin|Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.
45754344|NCT04142762|Drug|Placebo matching oral contraceptive|Placebo matching Ethinyl Estradiol / Levonorgestrel tablets
45784500|NCT04360148|Other|hypocaloric-balanced-diet|HBD-group will undergone to hypo caloric balanced diet for 24 weeks. Total daily average energy intake is 1500-1600 kcal/day. 30% of total daily energy is composed by lipids (10% MUFA, 10% PUFA, 10% SFA), 55% carbohydrates, while daily protein intake is approximately 0.8-1.5 g /kg of ideal body weight.
45784501|NCT02486952|Drug|Cyclophosphamide|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
45784502|NCT02486952|Drug|Hydroxydaunorubicin|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
45784503|NCT02486952|Drug|Oncovin|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
45784504|NCT02486952|Drug|Prednisone|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
45784505|NCT02486952|Drug|Rituximab|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
45784506|NCT02486796|Biological|Reishi mushroom extract|Reishi mushroom preparation produced water-ethanol extraction.
45784507|NCT02486796|Drug|Coenzyme Q10|Preparation of coenzyme Q10
45784508|NCT02486796|Drug|Melatonin|Preparation of melatonin
45784509|NCT02459262|Biological|GBS-NN vaccine|Three dose levels will be administered, with and without Alhydrogel®
45644015|NCT03987711|Drug|Apixaban|Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).
45644016|NCT03987711|Other|No oral anticoagulation|No oral anticoagulation
45644017|NCT03983967|Biological|Immuncell-LC|Activated T lymphocyte
45784510|NCT01598831|Drug|ART-123|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
45784511|NCT01598831|Drug|Placebo|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days.
45784512|NCT00841685|Device|Goldlock|Insertion of Goldlock marker
45644018|NCT03974113|Drug|Fitusiran|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
45784513|NCT00841685|Device|Visicoil smallest size|Insertion of Visicoil, smallest size, marker
45784514|NCT00841685|Device|Visicoil larger size|Insertion of Visicoil, larger size, marker
45784515|NCT00841685|Device|Bard goldmarker smallest size|Insertion of Bard goldmarker, smallest size
45784516|NCT00841685|Device|Bard goldmarker larger size|Insertion of Bard goldmarker, larger size
45784517|NCT00620477|Drug|injection in the knee joint with 20 ml of chirocaine 0.125%|injection in the knee joint with 20 ml of chirocaine 0.125%
45644019|NCT03970447|Drug|Temozolomide|Dosage Form: Capsule for oral administration Strengths: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg
45644020|NCT03970447|Drug|Lomustine|Dosage Form: Capsule for oral administration Strength: 5 mg, 10 mg, 40 mg, and 100 mg
45644021|NCT03970447|Drug|Regorafenib|Dosage Form: Tablet for oral administration Strength: 40 mg Standard Regimen: 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
45784518|NCT00620477|Drug|injection in the knee joint with 20 ml of physiological fluid|injection in the knee joint with 20 ml of physiological fluid
46070898|NCT00826579|Procedure|Sentinel lymph node procedure|After careful mobilization of the affected colon segment, isosulfan blue 1% is injected in vivo into the subserosa circumferentially around the tumor. Lymph nodes in the mesentery staining blue within the first minutes are marked as SLN. The procedure is followed by a resection of the affected colon segment with standard lymphadenectomy.
45644022|NCT03970447|Radiation|Radiation|60 Gy
45644023|NCT03970447|Drug|Paxalisib|Dosage Form: Tablet for oral administration Strength: 15 mg Standard Regimen: 45 mg orally (PO) every day for 28 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 28 days for all subsequent cycles
45784519|NCT01640327|Biological|Trivalent influenza virus vaccine (TIVf)|A single dose (0.5 mL) of vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm
45784520|NCT01641653|Other|Normal saline|Normal saline 2cc. one dose prior to OR
45784521|NCT01641653|Drug|Midazolam|1-2.5 mg
45784522|NCT05111093|Device|ARC-IM Investigational System implantation|Implantation of a stimulation lead on the low thoracic level of the spinal cord and implantation of a neurostimulator in the abdominal region.
45784523|NCT01600703|Drug|Sitagliptin|Sitagliptin, 100mg, oral, single dose
45644024|NCT03970447|Drug|VAL-083|Dosage Form: Infusion for intravenous administration Strength: 40 mg per vial Standard Regimen: 30 mg/m2 on Day 1, 2 and 3 of 21-day cycle. The drug is available in powder form. It is reconstituted with 5 mL of 0.9% Sodium Chloride for Injection, USP. This will produce a solution of 40 mg VAL-083 in 5 mL. The required volume of reconstituted VAL-083 for the patient is then calculated at the rate of 30 mg/m2. The corresponding volume is further diluted into 250 mL of 0.9% Sodium Chloride for Injection, USP, prior to intravenous administration.
45754345|NCT00607867|Other|LoBAG30 diet|A LoBAG30 diet consists of 30% of total energy intake as carbohydrate, 30% protein, and 40% fat.
45754346|NCT00607867|Other|Control Diet|A control diet consists of 55% of total energy intake as carbohydrate, 15% protein, 30% fat
45784524|NCT01600703|Drug|Placebo|Placebo, oral, single dose
45784525|NCT01643213|Device|Non Boston Scientific SCS Trial Therapy|No procedures will be attempted as part of this study. This intervention refers to connection and activation of a previously implanted and programmed FDA-approved non Boston Scientific SCS trial system for 30 minutes of SCS therapy for pain
45784526|NCT01643213|Device|BSC approved SCS Trial Therapy w/ OMG|No procedures will be attempted as part of this study. This intervention refers to connection and activation of all Boston Scientific commercially approved SCS trial systems for 30 minutes of SCS therapy for pain
45784527|NCT01644695|Procedure|Bony Anchoring Reinforcement System|Abdominal exposure was obtained via a lower horizontal incision, a vertical incision, or through a combination horizontal/vertical (ie fleur-di-lis) pattern. Exploratory laparotomy, lysis of intra-abdominal adhesions with hernia sac excision was performed prior to fascial closure. Primary closure of the abdominal fascia was performed with a combination of components separation and placement of biologic mesh over the fascial incision line in onlay fashion. Typically three bone anchors were used to secure the synthetic mesh at the pubic symphysis and two bone anchors to the ASIS bilaterally. The superior aspect of the marlex mesh was sutured to fascia avoiding any incorporation of the costal perichondrium. Quilting sutures were used to secure the mesh to the rest of the abdominal fascia.
45784528|NCT01602731|Device|Automated Medication Dispensing Device|All patients had a pre-filled medication dispensing machine set up at their homes, filled by home health nurses once a month. Safety phone call was made by the AMDD company if doses were missed.
45784529|NCT02450526|Biological|Botulinum toxin type A|
45754347|NCT03020264|Device|glycemic sensor FREESTYLE Libre Pro|Collection of hypoglycemia episodes with glycemic sensor FREESTYLE Libre Pro
45784530|NCT02450526|Biological|Botulinum toxin type A|
45784531|NCT02450526|Drug|Placebo|50 Units
45784532|NCT02450526|Drug|Placebo|20 Units
45784533|NCT02233517|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy provides patients with the skills to 1) identify and challenge maladaptive cognitions that are contributing to self-destructive behaviors; and 2) implement techniques such as relaxation training, communication skills, and relaxation training to address physiological and environmental barriers to effective functioning.
45784534|NCT02233517|Behavioral|Present Centered Therapy|"Present Centered Therapy utilizes interpersonal process, supportive techniques, identification of response options, encouragement of adaptive reactions, and focus on the here-and-now to support patients in their efforts to improve functioning."
45644025|NCT03970447|Drug|VT1021|"Dosage form: Infusion for intravenous administration Strength: 10 mg/mL Standard Regimen Newly Diagnosed: Dose as confirmed through the dose finding phase, administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri).~Standard Regimen Recurrent: 12 mg/kg administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri). The drug is available as a sterile solution of the acetate salt formulated with phosphate-buffered saline, mannitol, and 2.5% polysorbate 80. The required volume stock solution for the patient is calculated. The corresponding volume is diluted in 500 mL of either 0.9% saline or D5W, prior to intravenous administration."
45644026|NCT03970447|Drug|Troriluzole|Dosage from: Capsule for oral administration Strength: 100 mg Standard Regimen: Dose as confirmed through the dose finding phase orally BID.
45784535|NCT01605539|Drug|Cannabidiol 400|Subjects in Arm CBD 400 will receive 400mg of Cannabidiol in each of the three test sessions
45917767|NCT00005819|Drug|cisplatin|Patients receive cisplatin IV over 30 minutes on day 7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
46070899|NCT00826579|Procedure|Bone marrow aspiration|Prior to surgery, bone marrow is aspirated from both iliac crests. Bone marrow aspirates are analyzed for the presence of occult metastatic colon cancer cells.
45784536|NCT01605539|Drug|Cannabidiol 800|Subjects in Arm CBD 800 will receive 800mg of Cannabidiol in each of the three test sessions
45784537|NCT01605539|Drug|Control|Subjects will receive a harmless, inactive pill to compare and validate the results of the other arms of the study
45784538|NCT02458638|Drug|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|Atezolizumab will be given as IV infusion over 60 minutes on Day 1 of Cycle 1, then over 30 minutes (as tolerated) on Day 1 of each subsequent 3-week cycle.
45784539|NCT01607255|Drug|Indigo carmine|0.008% indigo carmine in water is used as a surface contrast agent to enhance visualization of diminutive polyps (adenoma) during screening colonoscopy
45784540|NCT01607255|Procedure|water (exchange) method|Residual pocket of air will be suctioned. Water is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions.
45784541|NCT01607255|Procedure|water (exchange) plus dye method|Residual pocket of air will be suctioned. Water with 0.008% indigocarmine is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions
45784542|NCT01607255|Procedure|air method|The colonoscope is inserted gently and advanced slowly using minimal air insufflation, if necessary, the assistant will provide abdominal compression or the patient's position will be changed to facilitate scope passage. The scope is inserted until the cecum is reached. Air is insufflated on scope withdrawal for visualization and water irrigation is used to remove any adherent feces covering the mucosa. Biopsy or polypectomy is performed where indicated.
45784543|NCT01607411|Drug|Fluoride|Fluoride Toothpaste
45784544|NCT01607411|Drug|Placebo|Fluoride free toothpaste
45449089|NCT03729921|Procedure|gastric variceal ligation|The highest point of the variceal vein was used as the primary ligation site. If the input vein was not obvious, the edge of the variceal vein was ligated. The variceal veins were ligated with a 6-ring ligation device, and more than 18 rings rubber bands could be applied in one session. GVL was performed regularly until varices were obliterated or reduced to residual small varices, which could not be ligated. The residual small varices was treated by cyanoacrylate injection.
45644027|NCT03970447|Drug|VT1021|Dosage form: Infusion for intravenous administration Strength: 10 mg/mL Standard Regimen Newly Diagnosed: Dose as confirmed through the dose finding phase, administered twice weekly Standard Regimen Recurrent: 12 mg/kg administered twice weekly.
45754348|NCT02137603|Other|Patients discharged home the same day following appendectomy|Patients are discharged to home on the same day following appendectomy with oral antibiotics.
45784545|NCT01691339|Biological|Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|0.5 mL, Intramuscular
45784546|NCT01691339|Biological|Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation|0.1 mL, Intradermal
45784547|NCT01691339|Biological|Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|0.5 mL, Intramuscular
45784548|NCT01691339|Biological|Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation|0.5 mL, Intramuscular
45784549|NCT01692743|Behavioral|Home Monitoring|Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
45784550|NCT01692743|Behavioral|Home Monitoring|Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
45917768|NCT00005819|Drug|fenretinide|Patients receive oral fenretinide twice daily for 7 days. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
45917769|NCT00005819|Drug|paclitaxel|Patients receive paclitaxel IV over 3 hours. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
46070900|NCT03014024|Other|Low-Level Laser Therapy|The laser is an infrared (invisible) 60 mW 904 nm, made by Irradia Midlaser
46070901|NCT03014024|Other|Placebo Low Level Laser therapy|This i laser is not giving any irradiation, but is identical to the infrared (invisible) 60 mW 904 nm Irradia Midlaser, made by Irradia.
46070902|NCT00826657|Dietary Supplement|Vitamin B12|500 microgram daily supplement of vitamin B12 1000 mg injection vitamin B12 given at the start of the study
46070903|NCT00826657|Dietary Supplement|placebo|placebo given as a daily supplement 1000 mg injection of vitamin B12 given at the end of the study
46070904|NCT02992964|Drug|Nivolumab|Nivolumab (also referred to as BMS-936558 or MDX1106) is a human monoclonal antibody (HuMAb; immunoglobulin G4 [IgG4]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor.
45784551|NCT02233751|Combination Product|Testosterone enanthate auto-injector|Randomization then administration of combination product study medication according to group assignment
45784552|NCT02233985|Drug|0.9% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 0.9% saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
45784553|NCT02233985|Drug|3% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
45784554|NCT01607645|Drug|decitabine|Given IV
45784555|NCT01607645|Drug|idarubicin|Given IV
45644028|NCT03969212|Drug|Baloxavir Marboxil|IPs less than 12 years old will receive either 2 mg/kg (if weight less than 20 kg) or 40 mg (if weight more than or equal to 20 kg) of Baloxavir Marboxil as oral suspension. IPs more than or equal to 12 years old will receive either 40 mg (if weight less than 80 kg) or 80 mg (if weight more than or equal to 80 kg) of Baloxavir Marboxil as tablets. HHCs of IPs will not receive study medication.
45644029|NCT03969212|Drug|Placebo|IPs less than 12 years old will receive placebo oral suspension and those above 12 years will receive placebo tablets. HHCs of IPs will not receive study medication.
45644030|NCT03962543|Drug|Mirdametinib (PD-0325901) oral capsule or dispersible tablet|Mirdametinib (PD-0325901) capsule or dispersible tablet
45644031|NCT03962348|Behavioral|Specialized Early Engagement Support Service|The Specialized Early Engagement Support Service (SEESS - a Social Worker and Peer Specialist) will link detainees with first-episode psychosis (FEP), using tenets of person-centered treatment and shared decision-making, and the Critical Time Intervention model, to community-based Coordinated Specialty Care (CSC).
45784556|NCT01607645|Drug|cytarabine|Given IV
45784557|NCT01647581|Device|Hemoclip Placement|Placement of hemoclip at polypectomy site for polyps at least 1cm in size
45784558|NCT01647581|Device|NO hemoclip placement|No hemoclip placement (placebo / sham)
45784559|NCT01608659|Drug|botulinum toxin Type A|Previous treatment with botulinum toxin Type A for treatment of facial lines
45784560|NCT01608815|Biological|Typhoid Vi polysaccharide|0.5 mL, Intramuscular
45784561|NCT01647737|Dietary Supplement|MighTeaFlow|4-6 times daily
45784562|NCT01647737|Dietary Supplement|Xylitol|4-6 times daily
45784563|NCT02458092|Biological|Plasmodium falciparum Malaria Protein 010 (FMP010)|Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
45784564|NCT02458092|Biological|Rabipur|Rabipur is a licensed rabies vaccine.
46070905|NCT03597776|Drug|Lidocaine|Bolus of lidocaine will be given over 5 minutes before skin incision
46070906|NCT03597776|Drug|Saline|Bolus of saline will be given over 5 minutes before skin incision
45784565|NCT01649609|Drug|Tacrolimus|Reduction of standard immunosuppression - The standard of care immunosuppression treatment commonly used for renal transplant patients
45784566|NCT01649609|Drug|Mycophenolate acid|Myfortic or CellCept - The standard of care immunosuppression treatment most commonly used for renal transplant patients
45784567|NCT01649609|Drug|Sirolimus|mTOR Substitution - Replacing tacrolimus (a calcineurin inhibitor) with sirolimus (an mTOR inhibitor) along with reduction of mycophenolic acid
45784568|NCT01610453|Procedure|ultrasound examination|transabdominal and transperineal ultrasound examinations
45784569|NCT02449902|Drug|Estradiol|1 10 µg capsule inserted vaginally for 14 days.
45784570|NCT02449902|Drug|placebo|1 placebo capsule inserted vaginally for 14 days.
45784571|NCT02449044|Drug|Tolvaptan|Once Daily
45784572|NCT04931394|Other|Adjuvant chemotherapy guided by organoid drug sensitivity test|Adjuvant chemotherapy guided by organoid will be given to pancreatic cancer patients.
46070907|NCT00625183|Dietary Supplement|selenomethionine|
46070908|NCT00625183|Drug|capecitabine|
46070909|NCT00625183|Drug|oxaliplatin|
46070910|NCT00625183|Other|laboratory biomarker analysis|
45784573|NCT04942938|Device|Neubie|The Neubie is a direct current neuromuscular electrical stimulation device. This system uses an exponential wave pattern to mimic the natural pattern neurologically to lengthen fibers of the sarcomere and engage force velocity of muscle with minimized protective co-contraction of nearby muscle groups. The golgi tendon and muscle spindles code for joint position and muscle/tendon stretch with 66% of fibers being intrafusal. Impacting these structures has direct impact on reticulospinal tract fibers and proprioceptive central fibers modulation of levels of spasticity. The Neubie direct current is designed to improve positioning of these stretch receptors.
45784574|NCT04942626|Drug|Kineret 100 MG in 0.67 ML Prefilled Syringe|Anakinra 100 mg s.c. (Kineret) will be administered from day -10 (i.e. 10 days before initiation of RT) to the last day of RT.
45784575|NCT04942626|Drug|Capecitabine|Capecitabine will be administered using a 3+3 dose escalation design (500 mg/m2 bid, 650 mg/m2 bid and 825 mg/m2 bid po, respectively) from day 1 to day 40 of RT including weekends.
45784576|NCT04942626|Radiation|Radiotherapy|PTV: 1.8 Gy to 45 Gy (#28 fractions) to the primary tumor and pelvic lymph nodes; followed by a sequential boost of 1.8 Gy to 9 Gy (#5 fractions) to the gross tumor volume
45784577|NCT04942626|Procedure|Watch and Wait (cCR) or TME surgery (non-cCR)|Restaging to evaluate tumor response will be conducted 10 weeks after completion of CRT. For patients achieving a clinical complete response (cCR), a Watch and Wait (W&W) option with close follow-up is scheduled. In case of non-cCR, immediate total mesorectal excision (TME) surgery is recommended. According to the current German S3-guidelines, adjuvant chemotherapy is optional.
45784578|NCT04942470|Other|Aloe vera and propolis applied|Suitable of sterile pads containing aloe vera and propolis to the area with pressure sores
45784579|NCT02228681|Drug|Everolimus|10mg daily by mouth
45784580|NCT02228681|Drug|Tamoxifen|20 mg daily by mouth on alternating weeks (even numbered) weeks
45644032|NCT03961893|Device|G-EYE first and standard colonoscope|Patients undergo two successive colonoscopies, first balloon-assisted colonoscopy (G-EYE device) and then standard colonoscopy
45784581|NCT02228681|Drug|Letrozole|2.5mg once a day by mouth
45784582|NCT02228681|Drug|Medroxyprogesterone Acetate|200 mg daily by mouth
45784583|NCT00942578|Drug|Bevacizumab|15 mg/kg cycle 1 day 1, repeated every 21 days
45784584|NCT00942578|Drug|Lenalidomide|Once daily days 1-14 of every 21
45784585|NCT00942578|Drug|Docetaxel|75 mg/m^2 intravenous (IV) over 60 minutes on cycle 1 day 1, repeated every 21 days (a 3-week cycle)
45784586|NCT00942578|Drug|Prednisone|10 mg orally every day
45784587|NCT02229461|Drug|Naproxen Sodium (Aleve, BAY117031)|Naproxen sodium 220 mg qd or bid
45784588|NCT02229461|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|ASA 81 mg qd
45784589|NCT04356482|Biological|convalescent plasma|"In phase 1, different amounts of convalescent plasma will be evaluated depending on the severity of the case.~In phase 2, both clinical, laboratory, imaging and viral presence (effectiveness) and safety will be evaluated."
45784590|NCT04641104|Drug|Thiamine 500 MG|A solution of 500 mg of Thiamine Hydrocloride in a solution of 100 ml of NaCl 0.9% will be administered post-cardiac surgery in patients with lactate levels ≥ 2 mmol / L in the first 6 hours post-ICU admission.
45644033|NCT03961893|Device|standard colonoscope first and G-EYE|Patients undergo two successive colonoscopies, first standard colonoscopy and then balloon-assisted colonoscopy (G-EYE device)
45644034|NCT03953898|Procedure|Biospecimen Collection|Undergo collection of blood
45644035|NCT03953898|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
45784591|NCT04641104|Drug|Placebo|100 ml of NaCl 0.9% will be administered in the placebo group.
45784592|NCT01695473|Drug|BKM120|Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy. Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14. No further drug will be administered after radical prostatectomy. For unforeseen delays in OR scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.
45784593|NCT04359680|Drug|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for six weeks
45784594|NCT04359680|Drug|Placebo|Placebo administered orally twice daily for six weeks
45644036|NCT03953898|Drug|Olaparib|Given PO
45784595|NCT04359680|Dietary Supplement|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
45784596|NCT02237417|Drug|Standard of Care Oral antipsychotics|A total of 15 to 20 subjects with schizophrenia will receive SOC oral antipsychotic medications (e.g., aripiprazole (Abilify®), risperidone (Risperdal®), lurasidone HCI (Latuda®), quetiapine fumarate (Seroquel®), olanzapine (Zyprexa®), and ziprasidone HCI(Geodon®)) or once monthly aripiprazole (Abilify®), PO daily, in accordance with their respective product labeling.
45644037|NCT03953417|Device|Bilateral accelerated intermittent theta-burst treatment|"All participants will receive bilateral accelerated intermittent theta-burst stimulation to the left and right DLPFC. Treatment will be targeted by utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to left and right-DLPFC using the MagPRo stimulator."
45644038|NCT03950739|Drug|Treprostinil Inhalation Powder|Treprostinil inhalation powder single-use cartridges containing either 32 or 48 micrograms of treprostinil per cartridge (QID)
45644039|NCT03945669|Procedure|Intramedullary Nailing|fracture fixation of the tibial shaft fracture with an intramedullary nail.
45784597|NCT02237417|Drug|IM aripiprazole once monthly|A total of 30 to 40 subjects with schizophrenia will receive aripiprazole (Abilify®) monthly, at a starting dose of 400 mg IM or an approved dose based on the investigator's judgment and in accordance with product labeling.
45784598|NCT02237417|Other|No Treatment|A total of 15 healthy controls will participate in the study and will not receive medication
45784599|NCT04603898|Dietary Supplement|Low Oxalate Diet|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 4 days
45784600|NCT04603898|Dietary Supplement|Carbon-13 Ascorbic Acid Oral Load|Subjects will be instructed to ingest 1mg/kg of carbon-13 ascorbic acid at breakfast, 2 days after initiating the low oxalate controlled diet.
45784601|NCT04580420|Drug|DCR-PHXC|Monthly dosing throughout study period
45784602|NCT04359836|Other|There is no intervention in this study|There is no intervention in this study
45644040|NCT03945669|Procedure|External Ring fixation|fracture fixation of the tibial shaft fracture with an external ring fixator.
45784603|NCT03833492|Behavioral|Underwater EMR|Polypectomy is performed under full water emersion without the use of submucosal injection.
45784604|NCT00942890|Device|NMES (EMPI 300PV stimulator) plus standard of care|In addition to the standard rehabilitation, the NMES treatment group will receive neuromuscular electrical stimulation to the quadriceps muscle of the residual and intact limb. The name of the NMES device is EMPI 300PV. NMES training will consist of performing 15 to 20 minute stimulation sessions with a 5-minute patient treatment log, 5 times per week for 12 weeks. During each training session, 15 NMES contractions per leg will be completed. Each contraction will be elicited by an electrical impulse (300PV) generated by a battery-operated device. This will be performed at home.
45784605|NCT00942890|Behavioral|TMARP standard of care|The usual care is 12 weeks of the Traditional Military Amputee Rehabilitation Program (TMARP). TMARP training starts 1week after surgical closure of the residual limb. Physical Therapy performs Pre-Prosthetic Training for about 6 weeks, preparing for the prosthetic. After pre-prosthetic training, patients are fitted with their prosthetic leg and began post-prosthetic training with PT. The training focus is lower limb prosthetic proficient in ambulation.
45784606|NCT02245490|Drug|Tamsulosin HCl controlled release capsules|
45784607|NCT02245490|Drug|Matching placebo capsule|
45784608|NCT04356092|Diagnostic Test|2D perfusion digital subtraction angiography of the foot.|2D perfusion digital subtraction angiography of the foot was performed after infrapopliteal angioplasty and Perfusion Blood Volume (PBV), Mean Transit Time (MTT), and Perfusion Blood Flow (PBF) maps were extracted by analyzing Time-Intensity Curves and signal intensity on the perfused vessel mask.
45784609|NCT04355936|Drug|Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.|Control arm will receive standard care.
45784610|NCT00934934|Other|Normal Saline|Normal Saline
45784611|NCT00934934|Drug|anidulafungin|TBA
45784612|NCT01651793|Other|Caffeinated cocoa|70 mg caffeine, 179 mg theobromine, 499 mg flavanols, and 1 packet of Truvia sweetener
45784613|NCT01651793|Other|Cocoa|21 mg caffeine, 179 mg theobromine, 499 mg flavanols, and 1 packet of Truvia sweetener
45784614|NCT01651793|Other|Caffeine|473 ml brewed water containing 66 mg caffeine, caramel coloring and one packet Truvia sweetener
45784615|NCT01651793|Other|Placebo|473 ml of brewed water, caramel coloring and one packet Truvia sweetener
45644041|NCT03940950|Biological|Autologous Adipose-Derived SVF (Stromal Vascular Fraction)|60 ml of fat is collected from subjects abdominal wall and SVF is removed from the fat. The SVF is injected into the knee through a needle.
45644042|NCT03940950|Drug|Placebo|Saline control that contains no active ingredient
45644043|NCT03939767|Drug|Aflibercept (Eylea, BAY86-5321)|As prescribed by the treating physician according to the local label. No IVT aflibercept will be provided due to a nature of observational study.
45644044|NCT03938688|Procedure|Mesh placement with Transfascial Sutures|Sutures that pass through the full thickness of the abdominal wall, which are used routinely for mesh fixation
45784616|NCT01611779|Device|Encore Tongue Suspension System|The primary components of the Encore Tongue Suspension System consist of a suture passer, suspension line and bone screw.
45784617|NCT01699373|Procedure|Ultrasound scan|Pre-procedural ultrasound scan was performed
45784618|NCT01652495|Drug|methylprednisolone acetate|Single intrabursal ultrasound guided injection of 40 mg (1 ml) of methylprednisolone acetate
45784619|NCT01652495|Drug|Triamcinolone Acetonide|Single intrabursal ultrasound guided injection of 40 mg (1 ml) of triamcinolone acetonide
45784620|NCT00935792|Drug|alemtuzumab|Given subcutaneously
45784621|NCT00935792|Drug|everolimus|Given orally
45784622|NCT01699607|Drug|Amphetamine|All subjects will receive amphetamine to induce elevated dopamine levels in the brain at 0.5mg/kg
45784623|NCT04355468|Drug|Opioid Anesthesia|Intraoperatively, fentanyl in fractional doses of 1-3 µg∙kg-1 were applied if the heart rate (HR; Heart Rate) or mean blood pressure (MBP; Mean Blood Pressure) increased by more than 20% above the baseline value obtained just before surgery commencement.
45784624|NCT04355468|Drug|Opioid Free Anaesthesia|"Before the induction of general anesthesia, a single-shot thoracic paravertebral block (ThPVB) was performed at the Th3-Th4 level. An insulated needle was used, connected to a peripheral nerve stimulator. 0.5% bupivacaine (0.3 ml∙kg-1) was then injected after a negative aspiration test. The efficacy of the blockade was checked after 20 min on both sides of the thorax with a plastic ampoule of saline. A difference in the sensation of cold between the sides of the thorax was assumed to indicate an effective block. Afterwards a continuous intravenous infusion of lidocaine and ketamine was started:~immediately after anesthesia induction, lidocaine was administered as an i.v. bolus at a dose of 1.5 mg∙kg-1 and ketamine in an i.v. bolus of 0.35 mg∙kg-1;~followed by an infusion of lidocaine 2.0 mg∙kg-1∙h-1 for 2 hours, continued at a dose of 1.2 mg∙kg-1∙h-1, and ketamine infusion 0.2 mg∙kg-1∙h-1 for 2 hours, continued at a dose of 0.12 mg∙kg-1∙h-1."
46070911|NCT00625183|Other|pharmacological study|
46070912|NCT00625183|Procedure|adjuvant therapy|
46070913|NCT00625183|Procedure|neoadjuvant therapy|
46070914|NCT00625183|Procedure|therapeutic conventional surgery|
46070915|NCT00625183|Radiation|radiation therapy|
45784625|NCT01699763|Device|Contour® NEXT LINK BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Contour® NEXT LINK BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
45784626|NCT01699763|Device|OneTouch® UltraLink® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® UltraLink® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
45784627|NCT01699763|Device|Nova Max Link® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Nova Max Link® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
45644045|NCT03938324|Behavioral|PiCASO Intervention Group|This mobile health intervention utilizes an established telephone/text based secure interface to allow AYAs access knowledge, experience, and instrumental/emotional support from a trained peer coach who has already developed independence an active self-manager. Peers with shared experiences provide instrumental (e.g., health maintenance skills) and emotional support that likely lead to improvements in quality of life. Involving peers in supporting AYAs with chronic conditions to promote self-management and patient activation disrupts the typical over-reliance on the parent and health care provider that often impedes developing independence.
45784628|NCT04355000|Procedure|Hall technique|SS Crown will be cemented on primary carious molar which satisfy the inclusion criterion without any carious removal, without any tooth preperation, without any local anaesthesia.
45784629|NCT04355000|Procedure|RMGIC restoration|Complete removal of caries and filling will be done with RMGIC material
45784630|NCT01612793|Device|AlphaCore Device|multiple stimulation treatments per day for duration of hospitalization
45644046|NCT03938324|Behavioral|Sham Comparator: Attention Control Group|Over 12 months the attention control group participants will receive a monthly electronic newsletter with educational content about childhood onset chronic condition management and the differences between pediatric and adult health care systems, as well as a monthly phone call from study staff to ensure receipt of the newsletter and to answer questions regarding content, and an opportunity to link them to other resources. If participants report health concerns they will be directed to contact their health care team.
45644047|NCT03937635|Biological|Daratumumab|Given IV
45784631|NCT01613339|Other|Balance training using Body awareness therapy|Once a week, 1 hour for 8 weeks.Body awareness training may be performed by physiotherapist. Exercises are performed in standing, sitting and lying. Example of exercises are weight-balancing in standing and relaxation exercises.
45784632|NCT01653509|Device|Acyclovir patch|Patch containing acyclovir
45644048|NCT03937635|Drug|Dexamethasone|Given PO
45784633|NCT01653509|Device|Placebo patch|Patch without acyclovir
45784634|NCT01614509|Procedure|intravitreal bevacizumab monotherapy|The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle.
45784635|NCT01614509|Procedure|combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab injection|The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
45784636|NCT01614743|Drug|IncobotulinumtoxinA|Experimental injection given at baseline and Week 16
45784637|NCT01614743|Drug|Bacteriostatic saline|Placebo at baseline, incobotulinumtoxinA at 16 weeks
45784638|NCT01701011|Behavioral|Coping intervention|Positive reappraisal coping intervention
45784639|NCT01653587|Device|Percutaneous coronary intervention|Both transradial and transfemoral coronary angiography will be performed by the Judkins technique using arterial introducers with 6 French diameter and pre-molded catheters for selective catheterization of left and right coronary arteries.Percutaneous coronary intervention will be indicated when a culprit lesion is identified, with stenosis diameter severity ≥ 70%, with high probability of angiographic success, being ideally performed immediately after coronary angiography and left ventriculography. Patients with multiarterial coronary disease will be submitted to percutaneous coronary intervention after agreement among cardiologist, interventional cardiologist and thoracic surgeon. Procedures will be performed according to recommendations and provisions of current guidelines.
45784640|NCT00943202|Biological|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine, 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm or in the anterolateral thigh muscle (1 injection in each arm or each thigh if receiving 2 doses).
45644049|NCT03937635|Drug|Lenalidomide|Given PO
45917770|NCT02225392|Procedure|Bronchial thermoplasty|Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated.
45917771|NCT02225392|Device|Alair system (Boston Scientific, USA)|The alair system consist of a controller and a bastket catheter.
45644050|NCT03937635|Other|Quality-of-Life Assessment|Ancillary studies
45644051|NCT03937635|Other|Questionnaire Administration|Ancillary studies
45644054|NCT03933176|Procedure|Restoration of carious lesions|Selective carious tissue removal followed by restoration of the cavity using composite resin.
45644055|NCT03930953|Drug|CC-99282|Specified dose on specified days
45644056|NCT03930953|Drug|Rituximab|Specified dose on specified days
45784641|NCT00943202|Biological|Trivalent Inactivated Influenza Vaccine|Licensed seasonal trivalent influenza vaccine (TIV) (2009-2010 season). For subjects greater than or equal to 6 - <36 months, licensed TIV will be administered as a single 0.25 mL intramuscular (IM) injection in the deltoid muscle of the arm or in the anterolateral thigh muscle. For subjects greater than or equal to 36 months - 17 years, licensed TIV will be administered as a single 0.5 mL IM injection in the deltoid muscle of the arm or in the anterolateral thigh muscle.
45784642|NCT00943436|Other|Exercise Session|"This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The Exercise Session will consist of the participant coming into the lab and completing 45 min bout of exercise on an exercise bike, followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum."
45784643|NCT00943436|Other|Rest Session|"This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The Rest Session will consist of the participant coming into the lab and completing a 45 min period of reading followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum."
45784644|NCT01614821|Drug|PCI-32765|Taken orally, once daily in the morning
45784645|NCT01654445|Drug|Tenecteplase|Tenecteplase will be given to the patient as an intravenous bolus over 1- 2 minutes within 90 minutes of the first slice of the CTA. This is an open-label trial, all patients will receive tenecteplase, either tier 1 or tier 2 dosage.
45784646|NCT01615367|Other|Nutrition, Exercise, and Wellness (NEW) psychotherapy|NEW Tx is a flexible modular treatment such that modules are selected based on the needs of the individual to increase its generalizability across patients, settings, and providers as well as its acceptability to patients.
45784647|NCT01615367|Drug|Typically consists of at least one FDA-approved mood stabilizer|Pharmacotherapy will be conducted by experts in BD treatment and will follow the empirically-supported treatment algorithm for BD that has been developed and recently revised. The foundation of TAU is to maintain treatment with at least one Food and Drug Administration approved mood stabilizer. For TAU, medication and dosage changes are allowed as needed as long as the change is recommended based on the guidelines and participants remain on a mood stabilizer.
45784648|NCT01702259|Device|Erchonia Scanner device (GLS)|The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
45917772|NCT00001005|Drug|Zidovudine|
45917773|NCT00001005|Drug|Aldesleukin|
46070916|NCT05562128|Behavioral|Active forest therapy|Participants take part in a two-hour active clinical forest therapy in Berlin-Wannsee on two days (with a break day in between). In this setting, a trained clinical forest therapist teaches exercises on the perception of nature and the connection between nature and health.
46070917|NCT05562128|Behavioral|Passive forest therapy|Participants take part in a two-hour passive clinical forest therapy in Berlin-Wannsee over two days (with a break day in between). In this setting, a trained clinical forest therapist will guide participants to various locations in the forest where participants can stay and let nature have its effect on them.
45449090|NCT03729921|Procedure|gastric variceal obturation|Gastric varices were uniformly treated via the sandwich technique, which starts with an injection of lauromacrogol, followed by N-butyl cyanoacrylate, then finished with flush of lauromacrogol. The number of injection sites and volume of lauromacrogol and cyanoacrylate used, directly correlated with the size of the varix. Multiple injection sites were chosen in attempt to obliterate the varix or varices in one session. Volume of lauromacrogol used ranged from 2-10ml, while that of cyanoacrylate ranged from 0.5-2ml, per injection site.
45644057|NCT03930953|Drug|Obinutuzumab|Specified dose on specified days
45644058|NCT03930953|Drug|Tafasitamab|Specified dose on specified days
45644059|NCT03930953|Drug|Tazemetostat|Specified dose on specified days
45644060|NCT03924778|Behavioral|DASH diet|brief description
45917774|NCT00391105|Drug|Remifentanil|
45917775|NCT00391144|Procedure|intravitreal triamcinolone injection of avastin (1.25 mg)|
45917776|NCT00005822|Drug|doxorubicin hydrochloride|Patients receive doxorubicin IV continuously over 72 hours on days 1-3 of course 1. For all subsequent courses, patients receive doxorubicin as in course 1. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
45917777|NCT00005822|Drug|semaxanib|For all subsequent courses, after course 1 patients SU5416 IV over 1 hour twice weekly (on days 1 and 4) beginning on week 2 of course 2. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
45917778|NCT00005822|Procedure|conventional surgery|Patients undergo a modified radical mastectomy.
45917779|NCT00005822|Radiation|radiation therapy|Patients undergo radiotherapy to the chest wall and regional lymph nodes.
45917780|NCT00005822|Drug|tamoxifen|Patients with estrogen or progesterone receptor positive disease receive oral tamoxifen for 5 years after radiotherapy.
45917781|NCT00391183|Procedure|Biliary stenting|ERCP and stenting
45644061|NCT03924778|Behavioral|standard American diet|describe
45644062|NCT03923582|Behavioral|Health Curriculum Training|"This is a randomized, controlled, single blinded, trial, stratified by health profession, of the intervention versus waitlist control assessing knowledge, attitude change and skill development. At the end of the intervention as compared with waitlist controls.~Participants will significantly increase knowledge about sexual health and sexual health care.~Participants will significantly improve attitudes about provision of sexual health services, sexual health communication skills, and comfort in addressing sexual health care in routine care.~Participants' sexual health communication, history taking, and counseling skills will be significantly improved as assessed by independent evaluators blinded to trial assignment."
45644063|NCT03922971|Other|Option 1: National comparison|Ability to view center's rate compared with all others.
45644064|NCT03922971|Other|Option 2: National comparison with benchmarking|Ability to view center's rate compared with the others with a similar patient comorbidity profile and in addition to viewing option 1.
45644065|NCT03922581|Behavioral|Mindfulness-Based Cognitive Therapy|The intervention consists of MBCT for the prevention of depression relapse with adaptations for discussing trauma and PTSD. Participants attend eight, weekly 90-minute group sessions involving skills training and in-class practice. Participants will return one month after the intervention has ended for a follow-up assessment.
45784649|NCT01702259|Device|Placebo device|Inactive Erchonia GLS.
45784650|NCT01703039|Drug|Riluzole|
45784651|NCT01703039|Drug|Sertraline|
45784652|NCT01703039|Other|placebo|
45784653|NCT01656629|Drug|Teriparatide|20 mcg subq daily for 3 months
45784654|NCT01656629|Drug|Alendronate|70 mg weekly for 3 months
45784655|NCT01656629|Dietary Supplement|calcium and vitamin D|
45784656|NCT01703507|Drug|Ipilimumab|Given IV
45784657|NCT01703507|Radiation|Whole-Brain Radiation Therapy (WBRT)|Undergo WBRT
45784658|NCT01703507|Radiation|Stereotactic Radiosurgery (SRS)|Undergo SRS
45784659|NCT02158520|Biological|Bevacizumab|Given IV
45784660|NCT02158520|Biological|Ipilimumab|Given IV
45784661|NCT02158520|Other|Laboratory Biomarker Analysis|Correlative studies
45784662|NCT02158520|Drug|Nab-paclitaxel|Given IV
45784663|NCT02158520|Other|Pharmacological Study|Correlative studies
45784664|NCT01703663|Device|EPAP|
45784665|NCT01704521|Drug|PegInterferon|
45784666|NCT01704521|Drug|Ribavirin|
45784667|NCT01704521|Drug|Telaprevir|
45644066|NCT03921554|Drug|Baricitinib|Baricitinib will be taken by mouth or via gastrostomy feeding tube or nasogastric tube as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will include 1 mg and 2 mg tablets and will be used without splitting. Dispersion will be permitted to aid in swallowing.
45644067|NCT03914326|Drug|Semaglutide|Increasing doses (3 mg/7 mg/14 mg) of semaglutide tablets to be taken with water at the same time every morning in a fasting state
45644068|NCT03914326|Drug|Placebo (semaglutide)|Placebo tablets to be taken with water at the same time every morning in a fasting state
45644069|NCT03911141|Behavioral|Gamification|"Participants have an 8-week ramp-up period where daily goals increase from baseline to the step target, and sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. Every 8 weeks, have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
45784668|NCT04154072|Drug|NLY01|exenatide and polyethylene glycol (PEG)
45784669|NCT04154072|Drug|Vehicle|Saline (Sodium Chloride)
45784670|NCT01617083|Drug|Azithromycin|Antibiotic used to treat infections
45784671|NCT01617083|Drug|Placebo|Thickening compound with sugar and flavoring
45784672|NCT04136132|Other|Biological collection|The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.
45784673|NCT04111172|Biological|Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE|Given as intramuscular injection
45784674|NCT04359524|Dietary Supplement|Vitamin D3 (1200 IU/30µg)|
45784675|NCT04359524|Dietary Supplement|Placebo|Placebo oil capsule
45784676|NCT00943904|Device|Interstim implant for SNS|stimulates third sacral nerve root
45784677|NCT01658657|Drug|Hydrochlorothiazide|
45784678|NCT01658657|Drug|Lisinopril|
45784679|NCT01658657|Drug|Amlodipine|
45784680|NCT01658657|Drug|metoprolol|
45784681|NCT01658657|Drug|lisinopril/hydrochlorothiazide|This is a combination pill
45784682|NCT04359212|Drug|thromboprophylaxis with low-molecular-weight heparin or fondaparinux|thromboprophylaxis with low-molecular-weight heparin or fondaparinux
45784683|NCT04359290|Drug|Ruxolitinib administration|Ruxolitinib will be administered p.o. or by gavage feeding starting with 2 x 10mg or 2 x 15mg bid dose at day 1 according to the investigator's decision and can be increased up to 2 x 15mg bid from day 2 to day 28 (max) (depending on platelet counts and renal function). Ruxolitinib will be administered in the morning and evening. Dosing will be adjusted according to toxicity and kidney function.If the patient is discharged before day 28, the therapy will be discontinued for discharge.
45784684|NCT01618955|Device|VIBEX MTX|Self-administration of Single Dose of SC MTX using Vibex MTX 10 mg, 15 mg, 20 mg or 25 mg Device
45784685|NCT04359368|Other|collection of patient data|Data collection (history, clinical presentation, medication, complications, laboratory testing) will be performed from patient records stored in the protected electronic patient system ISMed (Integrated System for Medical Diagnostic) of patients with HSRs to NDIPs.
45784686|NCT01620047|Drug|Fentanyl|Fentanyl 3 µg/ml continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU)through a femoral nerve sheath catheter.
45784687|NCT01620047|Drug|Ropivacaine|Ropivacaine 0.1% delivered through a femoral nerve sheath catheter continuously for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
45784688|NCT01620047|Drug|Fentanyl|0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
45784689|NCT00944450|Drug|Sitagliptin phosphate anhydrous formulation|Single dose sitagliptin 100 mg tablets (anhydrous form) in one of two treatment periods.
45784690|NCT00944450|Drug|Comparator: sitagliptin phosphate monohydrate form|Single dose sitagliptin 100 mg tablets [monohydrate Final Market Image (FMI) form] in one of two treatment periods.
45784691|NCT03875144|Procedure|PIPAC|Pressurized IntraPeritoneal Aerosol Chemotherapy of Cisplatin 10.5mg/m² + Doxorubicin 2.1 mg/m² every 6 weeks
45784692|NCT03875144|Drug|Cisplatin|standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
45784693|NCT03875144|Drug|Pemetrexed|standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
45917782|NCT00391261|Drug|Metformin|open-label, flexible dosing
45917783|NCT00001008|Drug|Methadone hydrochloride|
45917784|NCT00001008|Drug|Zidovudine|
45784694|NCT01706081|Procedure|Acupuncture|Each treatment will be 30 minutes in duration. Patients will receive two acupuncture treatments each week for six consecutive weeks. Patients will be advised to continue their standard lymphedema treatments such as exercise or use of compression garments if these were in use prior to clinical trial participation.
45784695|NCT01706081|Procedure|Wait-list|For participants in the wait-list control group, follow-up objective and subjective assessments of lymphedema will be performed after approximately 6 weeks on the wait-list, before onset of acupuncture treatment, following 6 weeks of acupuncture treatment and about 3 months after completion of treatment. BMI will be measured at the same timepoints.
45784696|NCT04358978|Procedure|laparoscopic sacral colpopexy with posterior mesh no attachment|pelvic organ prolapse correction with laparoscopic sacralcolpopexy with no attachement of posterior mesh
45784697|NCT04358978|Procedure|laparoscopic sacral colpopexy with posterior mesh attachment|pelvic organ prolapse correction with laparoscopic sacralcolpopexy with the attachement of posterior mesh to vagina
45784698|NCT04358666|Procedure|surgery and focal radiosurgery of the surgical bed|hypofractionned radiosurgery of the lesion
45784699|NCT02982044|Other|Suprasystolic (300 mmHg) cuff compressions|10 minutes of ECG-gated repeated suprasystolic (300 mmHg) cuff compressions, with inflation occurring every other heart cycle. These cuff compressions may be triggered 0 seconds, 0.2 seconds, or 0.4 seconds from the R spike (systole) on the ECG signal.
45784700|NCT02982044|Other|Handgrip exercise|10 minutes of ECG-gated rhythmic handgrip exercise at 30% maximal voluntary contraction, with contraction occurring every other heart cycle
45784701|NCT02982044|Other|Passive heat stress|10 minutes of passive heat stress at 42 degrees Celsius with a commercially available heating blanket
45784702|NCT01661621|Drug|Detrusitol 4 mg QD|Group 1
45784703|NCT01661621|Drug|Doxazosin 4 mg QD|Group 2
45784704|NCT04358822|Procedure|Delayed cord clamping|The umbilical cord will be clamped after specific time intervals
45784705|NCT04354844|Behavioral|questionnaire|questionnaire
45784706|NCT01707095|Other|Unbundling of cords|The active electrode and camera cords will be place off opposite sides of the table and will not run adjacent to or in parallel with one another
45784707|NCT01707095|Other|Bundling of cords|The cords from the camera/active electrode will be bundled together along their lengths during a laparoscopic cholecystectomy.
45784708|NCT04355078|Other|Neuromuscular Training|Muscular and neural training by complex exercises
45784709|NCT04355078|Other|Strength Training|Strength Training
45784710|NCT01620593|Drug|Placebo|All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of placebo after castration, blinded to the patient and the study team.
45784711|NCT01620593|Drug|Metformin|All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of metformin after castration, blinded to the patient and the study team.
45784712|NCT00939536|Drug|Zolpidem Tartrate Tablets 10 mg|
45784713|NCT02982122|Other|For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.|For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.
45784714|NCT02981810|Device|Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55*|The treatment was conducted using an Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55* for tonsillar tissue ablation at low temperatures with only one treatment. All the patients underwent tonsil channeling treatment with coblation, and 4-6 channels were done in each tonsil under local anesthesia, in the operating room. The patients were observed overnight.
45784715|NCT02981810|Procedure|tonsillectomy|
45784716|NCT04358354|Drug|Irinotecan|Irinotecan 150 mg/m2
45784717|NCT04358354|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2
45784718|NCT04358354|Drug|5-fluorouracil|5-fluorouracil 400 mg/m2 iv bolus and 2400 mg/m2 civ 46 hours
46070918|NCT05332808|Other|questionnare|collecting data about treatment and quality of life
45784719|NCT03531086|Drug|Ioflupane I 123|Ioflupane I 123 will be administered IV push prior to SPECT imaging
45784720|NCT03524378|Behavioral|Ergonomic and movement modifications|Introduction of basic ergonomic and self-management principles, participants will review video clips of the prioritized and revised solutions. Adjustments in work tasks, movement strategies or self-management techniques will be self selected by workers after an educational session using videotapes of work processes.
45784721|NCT03516968|Drug|Monthly bolus of cholecalciferol per os|Bolus therapy (100'000 - 200'000 IU/month depending on age: < or ≥ 9 years old) for 3 months
45784722|NCT03516968|Drug|Daily dose of cholecalciferol per os|Daily substitution (3'500 to 6'500 IU/day depending on age: < or ≥ 9 years old) for 3 months
45784723|NCT03516968|Other|Control|no cholecalciferol therapy
45784724|NCT04354766|Other|Blood sample|This study will require a blood sample (4 ACD tubes, 20 ml) at one time.
45784725|NCT04355156|Drug|Axitinib|"All patients randomised to this arm will receive 3mg BD, and increased at 2 weeks to 5mg BD~Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)~At 8 weeks, after tumour CT RECIST assessments, responders will continue monotherapy. In non-responders, those with disease progression, monotherapy can be continued if patient chooses to continue and if tolerated"
45784726|NCT04355156|Drug|Placebo|"All patients receiving placebo will receive tablets to take BD~Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)"
45784727|NCT04358510|Device|COViage|The COViage machine learning algorithm is designed to predict mortality in COVID-19, pneumonia and mechanically ventilated ICU patients.
46070919|NCT00826735|Behavioral|Guided imagery|A relaxation focused guided imagery intervention was used through the remainder of pregnancy plus a physiologic guided imagery intervention was used during the third stage of labor.
45784728|NCT03320018|Drug|Hydrogen|Hydrogen will be infused into bags of normal saline solution and administered intravenously, or hydrogen generating tablets will be dissolved into water for the patient to drink, as the patient's condition permits. This will be administered TID for 3 days.
45784729|NCT03320018|Drug|Minocycline|"Minocycline 200 mg will be mixed with normal saline and given by i.v. administration, or provided as capsules for the patient to swallow, q 24 hours for 5 days.~Once patients regain the ability to swallow capsules, minocycline will be given orally in capsule form (2 capsules of 100 mg each), administered once daily for the remainder of the 5 day period."
45784730|NCT03320018|Other|Placebo Hydrogen|"Normal saline solution will be administered intravenously, in place of hydrogen solution.~Placebo tablets will be dissolved into water for the patient to drink, as the patient's condition permits. This will be administered TID for 3 days."
45784731|NCT03320018|Other|Placebo Minocycline|Normal saline solution or placebo capsule will be administered i.v. or p.o. respectively, in place of minocycline.
45784732|NCT03032666|Drug|sofosbuvir/velpatasvir|treatment of hepatitis C genotype 1-6 in patients with transfusion-dependent thalassemia.
45784733|NCT03318380|Procedure|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo CEUS
45784734|NCT03199274|Procedure|Yttrium-90 Microsphere Radioembolization|Undergo standard of care Y-90 radioembolization
45784735|NCT03199274|Drug|Perflutren Protein-Type A Microspheres|Given IV.
45784736|NCT03199274|Procedure|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo CEUS
45784737|NCT04354610|Procedure|Biological samples specific to research|Blood samples, saliva collection, and urine collection to carry out biomarker assays and for the constitution of a biological collection.
45784738|NCT04354610|Procedure|Clinical examination|Clinical examination
45784739|NCT04354610|Procedure|Telephone follow-up|Telephone follow-up at 3 months after discharge from hospital
45784740|NCT04354376|Drug|Loop diuretics, thiazides, dihydropyridines|Loop diuretics, thiazides, or dihydropyridines dispensing claim is used as the reference
45784741|NCT04354376|Drug|Telmisartan|Telmisartan dispensing claim is used as the exposure
45784742|NCT03032588|Biological|sIPV|Participants will receive single dose (0.5 milliliter [mL]) of sIPV as a suspension for intramuscular injection on Day 1.
45784743|NCT03032588|Biological|cIPV|Participants will receive single dose (0.5 mL) of cIPV as a suspension for intramuscular injection on Day 1.
45784744|NCT03032432|Device|Dynamic Elastic Garment (DEG) brace|Improve function of the shoulder
45784745|NCT03032432|Drug|Corticosteroid injection|Injection to improve rotator cuff tendinosis pain and functional score
45784746|NCT02939924|Device|Kanshas DCB|The appropriate Kanshas DCB size is selected after review of the patient's baseline angiogram and determination of the reference vessel diameter and lesion length. The balloons is sized to ensure the full length of the lesion is treated. The initial inflation of the study device should be approximately 1 minute for optimal drug release. In order to optimize lesion dilatation, longer inflation times are possible at the discretion of the operator.
45784747|NCT03032354|Drug|Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12|Combination therapy of probiotics during 6 months
45449091|NCT02156284|Behavioral|Empathic behaviour by nurses|"Control group: patients without specific empathic behaviour~Intervention group: patients who received the empathic behaviour was performed by a trained nurse."
45784748|NCT03032354|Other|Placebo, (Placebo group)|Placebo during 6 months
45784749|NCT02777372|Drug|Sertraline|Sertraline will be provided at a dose of 50 mg daily for up to 3 weeks, depending on the length of a woman's luteal phase. Medication will be taken only during the luteal phase. Women will initiate sertraline treatment upon determining that they have ovulated (using a urine luteinizing hormone (LH) Kit) and remain on sertraline until onset of their next menstrual period at which time they will stop taking the medication.
45784750|NCT04354142|Device|iSpy|iSpy is a novel healthcare application that hopes to address an important clinical need by facilitating carbohydrate counting using pictures or voice recognition. Proprietary algorithms adjust for portion size and identify hidden carbohydrates (such as in ketchup or other condiments) and quantify the amount of carbohydrates in a meal.
45784751|NCT04354532|Procedure|Laparoscopic Banded Sleeve Gastrectomy|The investigators performed Laparoscopic Sleeve Gastrectomy adding a MiniMizer Ring (Bariatric Solutions), a radiopaque silicone ring with four closing positions. The ring has a blue colour and for this reason it can easily be found back in revision surgery. The pulling lid is left in place with all closing positions in order to be adjusted postoperatively without having to place a new ring. The ring is slightly elastic and the fixation loops provide an anchorpoint to fix the ring in place which prevents it from slipping
45784752|NCT01622543|Drug|Folfox plus Bevacizumab and reolysin|FOLFOX6/bevacizumab given every 14 days plus reolysin days 1-5 on cycles 1, 2, 4, 6, 8 and alternate cycles thereafter
45784753|NCT01622543|Drug|Folfox plus Bevacizumab|FOLFOX6/bevacizumab given every 14 days.
45784754|NCT04354298|Behavioral|Improvisational Dance Class|Hour long movement classes that meet weekly for 12 weeks.
45449092|NCT02154178|Other|Biomarker group|use of invasive fungal disease biomarkers (β-1,3-glucan, mannan/anti-mannan antibodies)
45449093|NCT01078649|Drug|Debio 1143 (AT-406)|Oral Debio 1143 (AT-406) will be administered in a dose escalation study to determine the maximally tolerated dose in humans. Patients will receive Debio 1143 (AT-406) on days 1-5, and 15-19 of a 28 day cycle, or days 1-5 of a 21 day cycle, repeated until progression or unacceptable toxicity occurs.
45449094|NCT02154256|Behavioral|Increasing incentives|Offer incentives that increase over time.
45449095|NCT02154256|Behavioral|Decreasing incentives|offer incentives that decrease over time
45784755|NCT03032042|Drug|Azithromycin|
45784756|NCT03032042|Drug|Albendazole|
45784757|NCT03032042|Drug|Delayed treatment|Albendazole+Azithromycin
45784758|NCT01622699|Device|Transcutaneous Bilirubinometer|If a baby is jaundiced, the ward-nurse will perform a transcutaneous bilirubin measurement. It takes about 5 seconds to perform the measurement at the forehead or sternum of the baby. The device is a validated measurement-tool, which provides us with an estimated serum bilirubin-concentration. This is not an invasive procedure: A light-reflection is used to measure transcutaneous bilirubin.
45784759|NCT01622699|Other|visual assessment of neonatal jaundice|To detect newborns with jaundice (who will possibly meet the criteria for phototherapy) there have been international guidelines formulated by the American Academy of Pediatrics. The standard of care at the neonatal- and maternity ward of our hospital to detect those newborns is visual assessment according to these guidelines.
45784760|NCT05620082|Dietary Supplement|Standard liquid-based oral nutritional supplement|An anonymous ready-made drink supplement: 125g, 306kcal, 18.3g protein.
45784761|NCT05620082|Dietary Supplement|Fortified porridge|Vital Daily High Protein Oats (Adams Vital Nutrition Ltd.): 157g, 230kcal, 15g protein.
45784762|NCT01623323|Drug|Fluticasone Propionate|Fluticasone Propionate 400 μg
45784763|NCT05620004|Drug|Bifidobacterium Bifidum Oral Product|experimental group use Bifidobacterium Bifidum Oral Product and control group without Bifidobacterium Bifidum Oral Product
45784764|NCT02018198|Diagnostic Test|FebriDx|Point of Care Host Immune Response Test
45784765|NCT01708967|Procedure|pretreatment method for transnasal endoscopy|"Catheter-free method : The patient then takes simethicone (10cc). After that, the nasal cavity is sprayed with epinephrine (1cc) and lidocaine HCL (4%, 4cc).~Catheter inesertion method: After preparation steps the same as in the 'catheter-free' method, a 14 Fr. flexible catheter is coated with 2% lidocaine HCL gel and 8% lidocaine HCL spray. After that, the catheter is inserted into the patient's nasal cavity, and maintained about 1 minute for anesthesia. A 16 Fr. catheter is prepared by the same method with as the 14Fr. catheter. After the 14 Fr. cathter has been removed from the patient's nasal cavity, the 16 Fr. catheter is inserted into the patient's nasal cavity."
45784766|NCT01911104|Behavioral|Exercise|10 weeks of aerobic exercise
45784767|NCT03032120|Dietary Supplement|Orange juice|Lean and obese subjects drank one single dose (5 mL/kg body weight) of fresh-squeezed orange juice (FOJ) and processed orange juice (POJ) followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
45784768|NCT03032120|Dietary Supplement|Control|Lean and obese subjects drank one single dose (5 mL/kg body weight) of an energy and sugars-matched orange-flavored drink (control), followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
45784769|NCT03031652|Device|Phacoemulsification|The device device used to provide and perform small profile entry for cataract extraction with or without option of insertion of a specified intraocular lens implant
45784770|NCT01709747|Drug|Hydromorphone Hydrochloride|Opioid for chronic pain
45784771|NCT01709747|Device|Programmable Implantable pump|"Device: Programmable Implantable pump~Programmable Implantable pump delivering intrathecal hydromorphone"
45784772|NCT05615324|Behavioral|Family Talk Preventive Intervention|This is a clinician facilitated, psychoeducational preventive intervention that includes on average 8 sessions designed to improve family communication and understanding of parental mental illness, improve interpersonal relationships, and promote child resilience and utilization of social support. An important tool throughout the intervention is the logbook which the clinician uses for taking notes with each family. The logbook prescribes the planned topics to be covered in each session and the contents of the sessions are noted in the logbook by the clinicians.
45784773|NCT03031808|Drug|Lidocaine spray (2%)|Spraying trachea from 2 cm above the vocal cords and 5 cm down with a straw with multiple side holes
45784774|NCT03031808|Drug|Muscle Relaxant (Rocuronium)|After induction of anesthesia, the participants are given 0,6 mg/kg bodyweight intravenously.
45784775|NCT03031808|Other|No Muscle relaxant, no Lidocaine|This group get general anesthesia without Rocuronium or Lidocaine
45784776|NCT03035474|Other|Digital Engagement|Patient engagement to improve self-management/medication adherence
45784777|NCT03035474|Other|Direct Engagement|Health system engagement to improve local QI programs
45784778|NCT01662791|Drug|Rifaximin|All individuals in the weight loss group (i.e., only the Case group) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO BID for 14 days. Treatment will not depend upon the results of the bacterial overgrowth breath test. Thus, both normal and abnormal breath test subjects received antibiotic treatment.
45784779|NCT03035240|Behavioral|Financial Education|Participants randomized to financial education will undergo a year long financial education. This involves 9 weeks of weekly classes followed by one on one coaching for a year.
45784780|NCT05711225|Behavioral|smoking cessation intervention given according to the web-based transtheoretic model during pregnancy on postpartum smoking relapse.|Smoking cessation videos prepared according to the Web-Based Transtheoretic model A module was created on the web, with 5 sections, prepared by the researcher according to the Web-Based Transtheoretic model, for quitting smoking or for pregnant women who quit smoking to maintain this behavior. The modules are prepared in the form of animated videos in which the researcher is educational. Each module is arranged for an average of 5-10 minutes. Theoretical information about the content has been added under each video.
45784781|NCT03035396|Device|Diassess Influenza A and B Test|
45784782|NCT03035162|Device|Transcranial direct current stimulation|Dual Active/sham tDCS will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 48 hours. The two experiments will be performed in random order for each subject.
45784783|NCT03031886|Other|low glycaemic index intervention|Low GI sweetener would be added to the treatment meals. 30 grams of isomaltulose to dinner and breakfast and 20 grams of isomaltulose to lunch and snack.
45784784|NCT03031886|Other|high glycaemic index intervention|High GI sweetener would be added to the treatment meals. 30 grams of sucrose to dinner and breakfast and 20 grams of sucrose to lunch and snack.
45784785|NCT03031574|Drug|SUVN-D4010|Tablets
45917785|NCT00391300|Procedure|bioelectric field imaging|
45917786|NCT00391300|Procedure|biopsy|
45917787|NCT00391300|Procedure|histopathologic examination|
46070920|NCT03569072|Radiation|Functionally adapted, dose escalated VMAT radiotherapy|Volumetric Modulated Arc Therapy planning and treatment delivery to treat primary and nodal planning target volume with 60 Gy in 30 fractions and a simultaneous integrated boost to the primary tumour to a total dose 69Gy in 30 fractions while avoiding organs at risk including functional lung, heart and oesophagus.
45449096|NCT02154256|Behavioral|stable incentives|offer incentives that are stable over time, but higher than usual care
45784786|NCT03031418|Diagnostic Test|ExoDx Prostate Intelliscore|ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
45784787|NCT03035084|Drug|Vitamin D3|Single oral dose of 50,000 IU of vitamin D3
45784788|NCT03035084|Drug|Vitamin D2|Single oral dose of 50,000 IU of vitamin D2
45784789|NCT03035084|Drug|Placebo oral capsule|Placebo oral capsule
45784790|NCT03034850|Procedure|CRS/HIPEC|The generic surgical approach involved peritonectomy procedures and visceral resections called CRS as described by Sugarbaker (1995). Peritoneal disease burden was assessed using the perito- neal cancer index (PCI), which scores 13 intra-abdominal sites on a scale of 0 (no disease) to 3 (lesion size > 5 cm), thus giving a range of possible scores from 0 to 39. The same team performed the surgical procedure of all included patients. Before connection to the patient, the circuit was filled with dextrose 5% (2 L/m2 body surface area) and warmed to 37°C.
45784791|NCT01663259|Drug|Cetuximab|Before Radiotherapy patients you will receive a single loading dose of cetuximab. Patients will also have two additional biopsies before and after cetuximab to determine how the tumor is affected. A Cetuximab infusion will also be delivered once a week during radiotherapy.Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week. In order to evaluate swallowing problems from radiotherapy, patients will undergo an evaluation of swallowing by videofluoroscopy (VF). Quality of Life questionnaires will be given before therapy and periodically up to 36 months after therapy. In order to assess if the tumor was completely eradicated, CT-PET scan will be performed 3 months after the completion of therapy.
45784792|NCT01663259|Radiation|Radiotherapy|Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week.
45784793|NCT05711069|Other|Core Stability Exercise Program|Core stability is an important component maximising efficient athletic function. Function is most often produced by the kinetic chain, the coordinate sequenced activation of body segments that places the distal segment in the optimum position at the optimum velocity with the optimum timing to produce the desired athletic task. Speed and power are critical performance factors in football. Football including jumping, kicking, tackling, turning, sprinting, changing pace, and sustaining forceful contractions to maintain balance and control of the ball against defensive pressure. İn the literature, no study has demonstrated the effectiveness of core stability exercise program in adolescent football players.
45784794|NCT05711069|Other|Routine Football Training Program|Core stability is an important component maximising efficient athletic function. Function is most often produced by the kinetic chain, the coordinate sequenced activation of body segments that places the distal segment in the optimum position at the optimum velocity with the optimum timing to produce the desired athletic task. Speed and power are critical performance factors in football. Football including jumping, kicking, tackling, turning, sprinting, changing pace, and sustaining forceful contractions to maintain balance and control of the ball against defensive pressure. İn the literatüre, no study has demonstrated the effectiveness of core stability exercise program in adolescent football players.
45784795|NCT05513846|Device|DREEM EEG Device|The DREEM EEG device will be used to measure brain age.
45784796|NCT05513846|Device|SleepImage Ring|The SleepImage ring uses plethysmography to analyze sleep architecture and cardiopulmonary coupling.
45784797|NCT02980328|Device|Low-level light therapy|we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating overactive bladder. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
45784798|NCT02980328|Device|Placebo|we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating overactive bladder. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
45784799|NCT03035006|Drug|Lipotecan|Lipotecan based concurrent chemoradiotherapy
45784800|NCT03034694|Other|teledermatology consult|teledermatology consult
45784801|NCT03034694|Other|Routine Care|The patient will undergo imaging but this report will not be put into the chart.
45784802|NCT05710991|Behavioral|Sleep Hygiene Workshop|Psychoeducation on the perinatal period and sleep difficulties including principles of sleep hygiene conducive environment for sleep, bedtime routine, food, beverage, and stimulant consumption, exercise
45784803|NCT05710991|Behavioral|Cognitive Behavioural Therapy for Insomnia Workshop|The CBT-I workshop group contains empirically supported strategies for insomnia modified to target the transitions and concerns faced by perinatal individuals. Content includes Sleep drive, stimulus control, sleep restriction, counter-arousal techniques, cognitive restructuring
45784804|NCT03031184|Drug|Mirtazapine|
45784805|NCT03031184|Other|Placebo|
45917788|NCT01889992|Radiation|Cardiac MRI|1 month post HTx, year 1 and year 2 annual post HTx eval. CMRIs completed using 1.5-Tesla Whole Body MRI system. Scout images will determine short & long-axis views of the heart. ECG-gated cine MR of 3 long axis and a contiguous short axis orientation will be obtained. T1-weighted delayed enhancement images will be obtained 10 minutes after injection of a gadolinium-based contrast agent. Measurements from each slice will be summed using the method of disks. Myocardial mass will be estimated by multiplying the myocardial wall volume at end diastole by the specific gravity of muscle (1.05gm/ml) and LV hypertrophy will be defined as LV mass indexed to height in meters 2.7 >/=35.8 g/m 2.7) (18). Delayed Gadolinium enhancement will be defined as any enhancement pattern greater than 0%.
45784806|NCT03034616|Device|OLIVA device|"OLIVA device is a laparoscopic device with a standard handle and a tip built of 5 parallel razor blades enclosed by protective cap opened by a separate button.~This device will enable to perform shallow slashes on the ovarian cortex following the grasping of the ovary without damaging other abdominal and pelvic organs"
45784807|NCT02238977|Drug|Fluoxetine|Antidepressant
45784808|NCT02238977|Drug|Bupropion|Antidepressant
45784809|NCT00945854|Other|Wholegrain cereal diet|Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on wholegrain cereals and foods with low glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
45784810|NCT00945854|Other|Refined cereal diet|Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on refined cereals and foods with high glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
45784811|NCT02239289|Other|Biofeedback|Idem as described in the arm section (above)
45784812|NCT05454488|Other|Focal Cryoablation|Participants will have the Focal cryoablation placed by the needles in such a way that the area of affected tissue is much smaller and focus just on the tumor tissue and surrounding area
45784813|NCT05454488|Other|Standard of Care|Participants will receive a prostate biopsy.
45784814|NCT05454488|Other|Quality-of-life Questionnaires|Participants will fill out questionnaires.
45784815|NCT03031028|Other|ketogenic diet|Ketogenic Diet is a high fat, low carbohydrate diet.
45784816|NCT03034382|Drug|Morphine|5 mg morphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block
45784817|NCT03034382|Drug|Nalbuphine|5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block
45784818|NCT03034382|Drug|Bupivacaine 0.5%|10 ml of 1% lidocaine +1:400,000 epinephrine and 5 ml of bupivacaine 0.5% injected perineurally in interscalene block
45644070|NCT03911141|Behavioral|Financial|"Participants are informed that each week money is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that some of the money was taken away. We will use an 8-week ramp-up period in which daily goals are increased gradually from baseline to targets.~During the follow-up period, participants in this arm will continue to receive a daily text message stating whether or not they achieved their step goal on the prior day."
45784819|NCT03034382|Drug|Lidocaine Hydrochloride 1% and epinephrine 1:400,000|10 ml of 1% lidocaine and 1:400,000 epinephrine were injected perineurally in interscalene block
45784820|NCT01664741|Drug|Nicotine patch - transdermal|21 mg patch
45784821|NCT01664741|Drug|placebo|
45784822|NCT02062346|Drug|BQ123|Intravenous infusion of BQ123 ( selective ETA antagonist )
45784823|NCT02062346|Drug|BQ123/788|or BQ123/788 (mixed ETA/B antagonists)
45784824|NCT02062346|Drug|Placebo|Intravenous infusion of saline
45784825|NCT03030950|Drug|Dexmedetomidine|to investigate the effect of dexmedetomidine on motor and sensory properties of adductor canal block
45784826|NCT03030950|Drug|Normal saline|to give normal saline to the other group as a placebo
45784827|NCT02022644|Drug|nanoliposomal irinotecan|The drug named here (nanoliposomal irinotecan) will be used in varying amounts, based on tumor volume.
45784828|NCT01664897|Drug|Erlotinib Hydrochloride|Given PO
45644071|NCT03910478|Device|DBS Self-Collection Kit|Kit for self-collection of Dried Blood Spot (DBS) samples
45644072|NCT03910478|Other|Standard Control Strategy|Standard of care with office-based testing.
45784829|NCT01664897|Other|Laboratory Biomarker Analysis|Correlative studies
45784830|NCT05417906|Other|Standard care|Oral prednisolone for 5 days
45784831|NCT05417906|Other|Eosinophil-directed care|Oral prednisolone for 5 days if eosinophil count is ≥ 0.300 x 10^3/µL, or 3 days if eosinophil is < 0.300 x 10^3/µL
45784832|NCT03034148|Diagnostic Test|Platelet Acetyl Coenzyme A Carboxylase analysis in CAD|
45784833|NCT01664975|Drug|GDPT regimen|GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
45784834|NCT01664975|Drug|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
45784835|NCT03030794|Device|Repetitive transcranial magnetic stimulation|A non-invasive method of brain stimulation that emits a magnetic pulse.
45784836|NCT03030794|Device|Repetitive transcranial magnetic stimulation (sham)|No brain stimulation will be administered.
45784837|NCT03034070|Diagnostic Test|Diagnostic performance 3D T1|"Although non-invasive, the prospective addition of a new MRI sequence to a routine MRI protocol is considered by our ethical committee as an interventional study."
45784838|NCT03033680|Drug|[F-18]PBR06|PET radiopharmaceutical
45784839|NCT05335850|Behavioral|Isha Kriya|Isha Kriya is a 15-minute guided meditation that incorporates the breath and the awareness to create mental clarity and health, to be practiced at least once (ideally twice) daily.
45644073|NCT03900689|Other|Part 1 Survey Group|At the first study visit, participants will answer a series of survey questions about their neighborhoods, educational levels, social activities, access to transportation and food, healthcare management and where participants find social and spiritual support. General information such as age, ethnicity and address will also be collected.
45784840|NCT05335850|Behavioral|Nadi Shuddhi|Nadi Shuddhi is a gentle 4-minute breathing practice for creating mental balance and relaxation, to be practiced for a minimum of 4 minutes daily.
45784841|NCT05335850|Behavioral|Nada Yoga|Nada Yoga is a 6-minute meditation that uses sound to create balance and stability in the body and mind.
45644074|NCT03900689|Other|Part 2 Focus Group|If participants from Part 1 agree to be contacted for Part 2, participants will be included in a focus group to explore unexpected findings and further investigate social determinants identified in Part 1.
45784842|NCT05335850|Other|Routine Daily Activity|"Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm.~Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm."
45784843|NCT00950612|Biological|GSK's investigational vaccine 692342|Intramuscular injection, 2 doses
45784844|NCT00950612|Biological|Placebo|Intramuscular injection, 2 doses
45917789|NCT01889992|Procedure|Coronary angiography with IVUS|"Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart."
45917790|NCT01889992|Other|Cardiac Allograft Remodeling|A surgical procedure in which a diseased heart is replaced with a healthy heart from a deceased person.
45917791|NCT01889992|Drug|M-TOR Immunosuppression|"Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B-cells by inhibiting their response to interleukin-2 (IL-2).~Sirolimus dosage based on blood levels."
45644075|NCT03897075|Drug|Tildrakizumab|PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
45644076|NCT03897075|Drug|Placebo|PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
45644077|NCT03896945|Drug|Placebo|oral capsules
45784845|NCT01665053|Device|PROMUS Element Plus|A drug eluting coronary stent system
45784846|NCT01665053|Device|SYNERGY|A drug eluting coronary stent system
45784847|NCT05292638|Drug|CKDB-501A|Intramuscular injection CKDB-501A
45917792|NCT01889992|Procedure|Cardiac Biopsy C4D stain|A long, thin tube called a biopsy catheter is inserted through a vein in your neck or grion and guided through your blood vessels to your heart.
45644078|NCT03896945|Drug|AVP-786|oral capsules
45644079|NCT03896750|Drug|PA-824|PA-824, a nitroimidazooxazine, used in prior studies of pretomanid is a novel TB treatment that is being investigated for use with other TB drugs to shorten and/or simplify regimens to treat either drug susceptible or resistant disease. After fasting for a minimum of 8 hours, subjects will receive one dose of 200 mg of pretomanid orally under direct supervision with 240 mL of water and a mouth check will be done.
45644080|NCT03893682|Drug|CG-806|CG-806 will be given orally in ascending doses starting at 150 mg PO BID until the maximum tolerated dose or recommended dose is reached.
45644081|NCT03893370|Device|RejuvenAir System|RejuvenAir Metered CryoSpray
45644082|NCT03893370|Device|Sham Control Procedure|Sham Control Procedure
45644083|NCT03893331|Device|AcQMap System|To evaluate procedural and long-term outcomes when using the diagnostic AcQMap System as an imaging and mapping system for ablation of arrhythmias in accordance with the Instructions for Use (IFU).
45784848|NCT05292638|Drug|Botox®|Intramuscular injection Botox®
45784849|NCT03030716|Dietary Supplement|95% condensed proanthocyanidins from grape seed extract|0.03, 0.25, and 1.5 g 95% condensed proanthocyanidins from grape seed extract consumed three times daily for 4 weeks each
45784850|NCT05281718|Drug|Factor IX|Factor IX is on of the substrates of emicizumab.
45784851|NCT05219864|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
45784852|NCT05219864|Drug|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
45784853|NCT05282615|Device|Emanate Tray|Emanate Tray, a personalized dental tray set (upper and lower) with PVA hydrogel containing 0.05% w/w chlorhexidine gluconate
45784854|NCT04353362|Drug|Ofloxacin|400 mg, 1 time per day for 5 days
45784855|NCT04353362|Drug|Amoxicillin|500 mg, 3 times per day for 7 days
45784856|NCT04353362|Drug|Metronidazole|500 mg, 3 times per day, for 7 days
45917793|NCT01889992|Genetic|Genetic Mechanism of M-TOR|To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.
45917794|NCT01889992|Other|Cardiopulmonary Exercise Test (CPET)|The Cardiopulmonary Exercise Test is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
45917795|NCT00005825|Drug|cisplatin|
45917796|NCT00005825|Drug|mitomycin C|
45917797|NCT00005825|Drug|tretinoin|
45917798|NCT00005825|Drug|vinorelbine tartrate|
45917799|NCT00001011|Drug|Zidovudine|
45917800|NCT00005828|Dietary Supplement|green tea extract|
45917801|NCT01804816|Procedure|Acupuncture|Standardized acupuncture administration for 10 sessions.
45917802|NCT01804816|Other|No Intervention|No intervention during this period. This was a control period. Each subject acted as their own control.
45784857|NCT00946478|Drug|Pimecrolimus|"20 AD patients will be given pimecrolimus 1% to apply twice daily for up to three weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.~Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit)."
45784858|NCT00946478|Other|Vehicle cream|"20 AD patients will be treated with vehicle cream twice daily for up to 3 weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.~Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit)."
45784859|NCT01667471|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
45784860|NCT03030482|Procedure|touch massage|Patients will have a touch massage session during 30 minutes the intervention will take place remotely (1 h) of all events that can generate anxiety
45784861|NCT03033524|Drug|TTAC-0001|Calculated amount of drug will be diluted with normal saline and administered intravenously.
45784862|NCT02249741|Drug|Treated with Ibandronic acid as per protocol|treated with Ibandronic acid at a dose of 150 mg once a month for six months
45784863|NCT03033836|Drug|ARV treatment|Dolutegravir 50 mg QD plus co-formulated emtricitabine 200 mg/tenofovir 300 mg QD.
45644084|NCT03892044|Drug|Duvelisib|Given PO
45644085|NCT03892044|Biological|Nivolumab|Given IV
45644086|NCT03891953|Drug|DKY709|Novel immunomodulatory agent
45784864|NCT05710757|Other|myofascial release|Myofascial release (MFR) is a technique that involves applying gentle sustained pressure into the myofascial connective tissue restrictions to eliminate pain and restore motion.
45784865|NCT05710757|Device|blood flow restriction|Blood flow restricted (BFR) exercise is the brief and non-continuous blockage of venous blood flow using a device that restricts the flow of blood while exercising. This technique is used to produce hypertrophy (muscle growth) and strength responses while exercising at a lighter load than traditionally required to produce a similar response.
45784866|NCT05710757|Other|myofascial release|Sham MFR.
45784867|NCT05135156|Behavioral|Investigator-designed lung transplant education resource (Research Intervention)|Participants will access the investigator-designed educational resource via their login to a secure website. After two weeks, participants will gain access to the publicly available website (attention control) and will have an additional two weeks of access to both of these resources.
45784868|NCT05135156|Behavioral|Publicly available transplant education resource (Attention Control)|Participants will access the publicly available education resource via their login to a secure website. After two weeks, participants will gain access to the investigator-designed educational resource (research intervention) and will have an additional two weeks of access to both of these resources.
45644087|NCT03891953|Drug|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2
45784869|NCT05710679|Biological|Blood sample|"The intervention consist in a blood sample that will be taken twice :~at the inclusion (before treatment)~3 months after the potentiated radiotherapy in case of incomplete response (PET-CT)"
45784870|NCT03030872|Device|Investigational software|The study evaluated retrospective de-identified cases that were processed after the imaging procedure had been completed (off-line) using a dedicated workstation.
45784871|NCT03033290|Drug|Bu-Zhong-Yi-Qi-Tang|Qi-tonifying regimen of traditional Chinese herbal medicine
45449097|NCT03965663|Device|Vibro-tactile Feedback|The device measures the force between the prosthetic food and the ground. With this signals, vibratators are triggered. The vibrators are housed by the prosthetic socket and stimulate the stump.
45644088|NCT03887780|Drug|Rivaroxaban (Xarelto,Bay 59-7939)|15 mg and 20 mg (OD)
45644089|NCT03886038|Biological|Shingrix|immunization with 2 doses of a subunit vaccine against herpes-zoster (Shingrix) administrated with at least 2 months apart
45644090|NCT03885037|Drug|Infliximab [infliximab biosimilar 3]|<Rheumatoid arthritis> The usual dose is 3 mg as Infliximab [Infliximab Biosimilar 3] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks. This drug should be given in combination with methotrexate.
45784872|NCT03033290|Drug|placebo|placebo control
45784873|NCT03030560|Drug|Lidocaine|patients (n = 20) will receive a loading dose of lidocaine 2 mg ̸ kg slowly IV just before induction of anesthesia, then the lidocaine infusion started at a rate of 3 mg ̸ kg/h, and continued until the end of the operation.
45784874|NCT03030560|Drug|0.9% Sodium-chloride|patients (n = 20) will receive an equal volume of 0.9% saline (both the loading and the infusion), the infusion will be initiated at the time of induction of anesthesia and continued until the end of the operation.
45784875|NCT03033212|Other|Therapist-Guided Rehabilitation|Rehabilitation consists of exercises guided by a certified physical therapist. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.
45784876|NCT03033212|Other|Self-Guided Rehabilitation|Rehabilitation consists of self-guided exercises with provided instructions. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.
45784877|NCT03033368|Drug|Rilpivirine|Rilpivirine 25 mg tablet
45784878|NCT03031262|Drug|Cytarabine|Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
45784879|NCT03031262|Drug|Chidamide|Chidamide at a dose of 20mg/d twice a week for 3 months.
45784880|NCT03030326|Behavioral|heart rate variability biofeedback|Patients learn to increase heart rate variability by breathing at the resonance frequency of the cardiovascular system, at approximately 6 breaths/min, varying among people.
45917803|NCT01776229|Behavioral|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing,child-friendly exposure to the trauma-nightmare, and rescription.
45917804|NCT00001014|Drug|Trimetrexate glucuronate|
45784881|NCT05089058|Behavioral|Brief, digitally delivered imagery-competing task intervention package, comprised of:|"Two sessions guided (remotely) by a researcher. Sessions comprised of:~(i) task procedure: a memory cue followed by playing imagery-competing computer game task with mental rotation instructions. Monitoring of intrusive memories to select hotspot cue, and which intrusion to target.~(ii) accompanying information, including rationale for the brief cognitive task.~(iii) option to use the brief cognitive task after the session (self-administered); option to engage in up to 6 guided booster sessions supported by a researcher."
45784882|NCT05089058|Behavioral|Brief, digitally delivered relaxation task intervention, comprised of:|"Brief, digitally delivered relaxation task intervention, comprised of:~Two sessions guided (remotely) by a researcher. Sessions comprised of:~(i) relaxation exercise task using instruction components from progressive muscle relaxation~(ii) accompanying information, including rationale for the brief relaxation exercise task.~(iii) option to use the brief relaxation exercise task after the session (self-administered); option to engage in up to 6 guided booster sessions supported by a researcher."
45784883|NCT05073458|Drug|parsaclisinib|parsaclisib will be administered QD orally
45784884|NCT05073458|Drug|placebo|placebo will be administered QD orally follwed by Parsaclisinib in the open label period
45784885|NCT03032978|Other|Calcium hydroxide|Pulp capping material
45644091|NCT03884439|Drug|Infliximab [infliximab biosimilar 3]|<Crohn's disease> The usual dose is 5 mg as Infliximab [Infliximab Biosimilar 3] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have reduced effects. At an increased dose, the dose may be adjusted to 10 mg for every kg of body weight. At a reduced dosing interval, the dose of 5 mg for every kg of body weight may be given at the minimum dosing interval of 4 weeks. <Ulcerative colitis> The usual dose is 5 mg as Infliximab [Infliximab Biosimilar 3] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter.
45784886|NCT03032978|Other|Calcium silicate|Pulp capping material
45784887|NCT03030092|Other|Maximal Strength Training|leg pres and abduction exercises
45784888|NCT02982278|Behavioral|Community-based Intervention under Nurse Guidance after Stroke|CINGS is a 12-week nurse coordinated, Community Health Worker intervention structure. Intervention home visits will be conducted by the CHW and will include home-based training in self-care and self-management strategies alongside strategies to address risk of negative stroke outcomes that will be determined once these risk factors are identified and community-engaged approaches to their resolution derived. CHW efforts will be guided via televideo interactions with nurse coordinator. During home-visits, self-reported assessments will be collected via RedCap as well as assessments collected by the CHW and research nurse (weight, blood pressure, medication adherence). After baseline, participants randomized to the intervention group will have home visits, once a week for the first month, and biweekly for the other two months, conducted by the CHW. Additionally, there will be post-intervention follow-up assessments at 3, 6, and 12-month time intervals.
45784889|NCT03030248|Drug|Vancomycin Oral Capsule|We have chosen oral vancomycin capsules as it is currently a standard of care for Clostridium difficile infections, is poorly absorbed by the intestines, and is easier to blind compared to oral vancomycin solution.
45784890|NCT03030248|Drug|Placebo Oral Capsule|A capsule containing gelatin, polyethylene glycol, titanium dioxide, iron oxide, and FD&C blue No. 2. Contains the inactive ingredients of the vancomycin oral capsule, as mixed by the Froedtert Health Research Pharmacy.
45784891|NCT03030014|Behavioral|educational programm|Oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
45784892|NCT03030014|Other|no educational program|without oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
45784893|NCT03032744|Other|Asthma Assessment & Management|Asthma Assessment & Management based on NAEPP-EPR3 guidelines
45784894|NCT03032744|Other|Asthma Education|Asthma education on medications
45644092|NCT03879629|Drug|Carvedilol|oral Carvedilol maximally tolerated doses 3.125 mg to 25 mg twice a day
45784895|NCT03032744|Other|Controller medication at school|Students will receive the morning dose of their daily preventive asthma medication at school on school days.
45784896|NCT03030170|Device|ENDO GIA X-tra Thick reload with Tri Staple Technology|Suture of the pancreas by normal stapling
45784897|NCT03030170|Device|ENDO GIA Articulating Reinforced Reload with Tri-Staple Technology|Suture of the pancreas by reinforced stapling
45784898|NCT03028532|Drug|Clomid|Participants will self-administer Clomid (50mg oral tablet) once daily for 30 consecutive days
45784899|NCT02245724|Biological|Stem Cell|Autologous bone marrow mononuclear cell transplantation
45784900|NCT03027206|Other|Vibration technique|Comparison of different technique
45784901|NCT03027206|Other|Acceleration of expiratory flow|Comparison of different technique
45784902|NCT04857476|Diagnostic Test|Ultrasound scan|"Psoriasis epidemiology screening tool (PEST) score for completion Brief questionnaire about current psoriasis symptoms, current treatment and if any features associated with psoriatic arthritis.~One-off musculo-skeletal ultrasound Questionnaire at 2 years"
45917805|NCT00001014|Drug|Sulfamethoxazole-Trimethoprim|
45449098|NCT02156362|Other|follow up visit|At least 1 follow up visit per year will be done and an additional visit if needed.
45449099|NCT03643575|Drug|Vicks Cough Syrup for Chesty Coughs|Vicks Cough Syrup for Chesty Coughs 15 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
45449100|NCT03643575|Drug|Robitussin Extra Strength Chest Congestion|Robitussin Extra Strength Chest Congestion 5 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
45784903|NCT03017768|Dietary Supplement|Acute tryptophan depletion|an amino-acid mixture will be administered without tryptophan (active comparator). After an incubation period of 5 hours esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of depleted tryptophan levels on esophageal sensitivity
45784904|NCT03017768|Dietary Supplement|Placebo|an amino-acid mixture with tryptophan (placebo mixture) will be administered. After an incubation period of 5 hours esophageal sensitivity will be assessed by multimodal stimulation
45784905|NCT03017768|Device|Multimodal stimulation probe|The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
45784906|NCT02981888|Radiation|X-Ray|X-ray of the abdomen will be performed to assess colonic transit
45784907|NCT02981732|Other|Liuwei Dihuang Pill|
45784908|NCT03017534|Procedure|Spinal Manual Therapy|Supine thoracic spine sham manipulation located between the levels of T4-7; identical procedure as an active treatment intervention but without the delivery of a high velocity low amplitude thrust
45784909|NCT03026660|Dietary Supplement|Moringa Oleifera|
45784910|NCT03026660|Dietary Supplement|Cabbage Placebo|
45784911|NCT02981576|Biological|Autologous Mesenchymal Stem Cells|Autologous Mesenchymal Stem Cells will be collected from patients, prepared in the lab and then injected intrathecally.
45784912|NCT01006538|Device|Epimacular Brachytherapy|Strontium-90. The device delivers 24 Gray of beta radiation to the choroidal neovascular membrane (CNV) lesion. Each device is calibrated for a set duration.
45784913|NCT01006538|Drug|Ranibizumab|intravitreal injection of Ranibizumab (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria
45784914|NCT03026114|Other|No intervention is planned in our study.|No intervention is planned in our study.
45784915|NCT03017222|Drug|Ondansetron|Ondansetron also has been reported as effective prophylactic and therapeutic 5-HT3 receptor antagonist for the treatment of PONV. Ramosetron has been shown to have a very strong effect for preventing PONV in previous meta-analyses, but in recent report, its clinical significance may be questioned to request for additional study.
45784916|NCT03017222|Drug|Ramosetron|Ramosetron is a newly developed selective 5-HT3 (5 hydroxytryptamine 3) receptor antagonist with longer duration of action up to 48hours and higher receptor affinity, than its previously developed congeners, including ondansetron.
45784917|NCT03026426|Behavioral|CONEMO|"Participants will be offered a behavioral activation-based intervention delivered by an application for smartphones (CONEMO) oriented to encourage them to be more active and to incorporate more activities in participants' everyday life.~Nurses will train participants to use CONEMO, make phone calls when participants are non-adherent, and provide technical support when necessary. Nurses will be supervised by clinical psychologists."
45784918|NCT03025724|Drug|Levulan Kerastick|Intervention group subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours.
45784919|NCT03025724|Device|blue light source|At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals).
45784920|NCT03025724|Other|participant satisfaction survey|Participants will be asked to fill out a satisfaction survey.
45784921|NCT03017378|Biological|TB/FLU-01L|TB / FLU-01L (intranasal application)
45644093|NCT03875651|Device|SYNERGY 4.50 mm and 5.0 mm Coronary Stent System|The SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System), manufactured by BSC, is a device/drug combination product comprised of two regulated components: a device (Coronary Stent System) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).
45644094|NCT03873389|Drug|Ocrelizumab|Patients who are beginning this medication based on patient's treating physician's recommendation will be enrolled in the study.
45644095|NCT03871257|Drug|Carboplatin|Given IV
45784922|NCT03017378|Biological|TB/FLU-01L|TB/FLU-01L (sublingual application)
45784923|NCT03024710|Behavioral|Intervention cluster|The mother- infant pairs (the infant who has completed his/her 6 month of age from the date of birth along with their mother) of intervention clusters will receive the CF practice counselling in groups as soon as enrolment is completed by CHRW at fixed site clinic and refreshers will be arranged 3 months apart from first training in groups at same place and by same person. However CHRWs will also counsel each participant during her bimonthly household visit.
45784924|NCT03017144|Other|Pit crew model education|A pit crew model for resuscitation is educated to all resuscitation team members.
45784925|NCT03017300|Device|Threshold IMT®|A device used to offer threshold load to inspiratory muscle
45449101|NCT03643575|Drug|Organ-I- NR tablet|Organ-I- NR tablet (containing 200 mg guaifenesin) with 240 mL of water
45644096|NCT03871257|Procedure|Magnetic Resonance Imaging|Undergo MRI
45644097|NCT03871257|Other|Quality-of-Life Assessment|Ancillary studies
45644098|NCT03871257|Other|Questionnaire Administration|Ancillary studies
45784926|NCT03017300|Device|PFLEX®|A device used to offer resisive to inspiratory muscle
45917806|NCT00001014|Drug|Leucovorin calcium|
45917807|NCT01776190|Device|UVA1 radiation treatment|
45917808|NCT00005831|Biological|trastuzumab|Given IV
45917809|NCT00005831|Drug|paclitaxel|Given IV
45917810|NCT00005831|Drug|carboplatin|Given IV
45784927|NCT00952718|Other|Inspiratory muscle training|A pressure threshold device (Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA) was used for the inspiratory muscle training program. The individualized training program was started at an intensity of 30% MIP, which was increased by 2 cmH2O each week, but the maximal intensity did not exceed 50% of MIP. Patients were encouraged to perform IMT for 30 minutes per day, at least 5 days a week for 8 weeks.
45784928|NCT01010282|Drug|Glycerin and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
45784929|NCT01010282|Drug|Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
45784930|NCT01010282|Drug|Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
45784931|NCT03016988|Drug|Bortezomib|Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11;
45644099|NCT03871257|Drug|Selumetinib Sulfate|Given PO
45784932|NCT03016988|Drug|Fludarabine|Fludarabine(F) 25mg/m2, intravenously day 1-3;
45784933|NCT03016988|Drug|Cytarabine|Cytarabine(A) 500mg/m2 for 3 days(day1-3)
45784934|NCT00953654|Other|Strength Training|6 weeks of strength training exercise sessions involving leg press, leg curl, and leg extension exercises twice weekly at an intensity progressing from 50% to 75% of predicted one-repetition maximum across the 6 weeks of the trial.
45784935|NCT00953654|Other|Endurance Training|Six weeks of lower-body dynamic cycling exercise completed on an electronically-braked cycle ergometer twice weekly. The intervention will be matched to the strength training intervention on total work completed, total time actively engaged in exercise, a focus on leg muscles, and load (intensity) progression across the 6 week training protocol.
45784936|NCT03017066|Device|Ultrasound|Ultrasound assessment of gastric volume is performed three times; before ingestion of infant formula or carbohydrate drink; 1 hour prior to the surgery; and before induction of general anesthesia.
45784937|NCT03017066|Other|General anesthesia|Scheduled operation under general anesthesia
45784938|NCT03016832|Drug|Placebo drug that simulates Irbesartan tablets|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing
45644100|NCT03871257|Drug|Vincristine Sulfate|Given IV or IV push
45644101|NCT03869749|Behavioral|Learning to BREATHE Plus|Activities include psycho-education about stress and emotion regulation, and practices of body scanning, non-aerobic yoga, and meditation, which are designed to cultivate and provide opportunities to practice present-focused, non-judgmental attention.
45644102|NCT03869749|Behavioral|Health and wellness|The Health Education Wellness Program (modeled after Hey Durham) (Bravender, 2005) will provide didactic information on substance use, nutrition/body image, stress management, exercise, and signs of depression/suicide.
45784939|NCT03016832|Drug|irbesartan tablets|irbesartan tablets 150mg /qd, oral dosing
45784940|NCT03016832|Drug|Placebo drug that simulates HuangKui capsule|Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing
45784941|NCT03016832|Drug|HuangKui Capsule|HuangKui Capsule 2.5g/tid, oral dosing.
45644103|NCT03869190|Drug|Atezolizumab|"For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle."
45644104|NCT03869190|Drug|Enfortumab Vedotin|Enfortumab vedotin will be administered at a dose of 1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle.
45644105|NCT03869190|Drug|Niraparib|Niraparib will be administered at a dose of 200 mg once daily (QD) by mouth.
45784942|NCT00955916|Drug|CLAG Regimen|The CLAG regimen consisted of: Cladribine, 5 mg/m^2 administered via 2 hour IV daily for 5 consecutive days starting on day 2; Cytarabine, 2 mg/m^2 administered through a 4 hour IV starting 2 hours after the ignition of Cladribine for 5 days starting on day 2; granulocyte colony-stimulating factor (G-CSF): 300 mcg subcutaneous (SC) for 6 days starting 12-24 hours (Day 1) before the first dose of Cladribine.
45784943|NCT00955916|Drug|Gleevec®|Imatinib mesylate 400 mg orally twice daily was administered on day 2 to day 15. Re-induction was allowed if participant had partial response (PR).
45784944|NCT01010906|Drug|Vaniprevir 300 mg|single dose administration of 300 mg oral tablet
45784945|NCT01010906|Drug|Vaniprevir 200 mg|single dose administration of 200 mg oral tablet
45784946|NCT01668017|Drug|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 30 mg twice a day (BID) in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
45784947|NCT01668017|Drug|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
45917811|NCT00005831|Drug|gemcitabine hydrochloride|Given IV
45784948|NCT01668017|Drug|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 60 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
45784949|NCT01668017|Drug|Pimasertib|Subjects with HCC will be administered with Pimasertib 30 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
45784950|NCT01668017|Drug|Pimasertib|Subjects with HCC will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
45784951|NCT01010984|Device|LC beads loaded with Doxorubicin|During each TACE, 2 vials (1 vial, 75mg Doxorubicin) of 100-300 micrometer size LC beads loaded with doxorubicin will be delivered to the liver tumor(s). Total Doxorubicin dose for each TACE is 150mg
45784952|NCT05710601|Procedure|Laparoscopy|Operative laparoscopies carried out according to the most recent national guidelines and following the good clinical practice of our operative unit.
45784953|NCT05710523|Behavioral|I-ACE training|"The I-ACE training encompasses a training on the non-pharmacological therapies' methodology and a training on awareness of body language which favors a passage from implicit to explicit knowledge. It allows the reading of the subjective relational experience of the care situation by the professional caregiver and a comparison of shared readings of the situation itself by the group of colleagues, and with the residents. Participants will follow:~Two sessions, each lasting 4 hours, on theoretical introduction to the non-pharmacological therapies' methodology; Ten monthly supervisions, each lasting one and half hours, on discussion of clinical cases and implementation of the non-pharmacological therapies with person with dementia.~Ten monthly supervisions, each lasting two hours, on theatrical exercises guided by an expert actor, with the help of a psychologist-psychotherapist who promotes understanding and awareness of self-reading in the relationship with the other."
45644106|NCT03869190|Drug|Magrolimab (Hu5F9-G4)|Participants will receive an 1-mg/kg priming dose IV on Day 1 followed by three weekly IV doses of 30 mg/kg on Days 8, 15, and 22. During Cycle 2, participants will receive weekly IV doses of 30 mg/kg on Days 1, 8, 15, and 22. For all subsequent cycles, participants will receive 30 mg/kg on Days 1 and 15. Cycle = 28 days.
45784954|NCT05710523|Other|Standard non-pharmacological therapies (NPT) training|"The standard NPT training encompasses a training on the non-pharmacological therapies' methodology. Participants will follow:~Two sessions, each lasting 4 hours, on theoretical introduction to the non-pharmacological therapies' methodology; Ten monthly supervisions, each lasting one and half hours, on discussion of clinical cases and implementation of the non-pharmacological therapies with person with dementia."
45784955|NCT05214599|Drug|Budesonide Gel|Twice daily regimen
45784956|NCT05207267|Device|driving pressure guided tidal volume|Volume control mode without spontaneous breathing, PEEP will be set according to best respiratory compliance method, and tidal volume (VT) will be set to reach three levels of driving pressure (High 14-15cmH2O, moderate 10-11 cmH2O, and low 7-8 cmH2O). Each level of VT was maintained 10 minutes in supine and/or prone position.
45784957|NCT01011218|Behavioral|BBT-I|Brief Behavioral Intervention for Insomnia (BBT-I): 2 sessions in person and additional brief sessions over the phone
45784958|NCT01011218|Behavioral|Control|Control behavioral intervention is a sleep hygiene handout completed by participant.
45784959|NCT01011218|Drug|Armodafinil|150 mg by mouth. Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil), containing only the (R)-(-)-enantiomer of the racemic modafinil.
45784960|NCT01670201|Device|Mepilex Transfer Ag|Silver dressing
45784961|NCT02245217|Device|PET/CT scan to assess treatment efficacy|
45784962|NCT03023228|Behavioral|diabetes self-management education|1-group, pre-test/post-test design feasibility and preliminary efficacy evaluation of diabetes survival skills self-management education delivered at the hospital bedside.
45644107|NCT03869190|Drug|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21-day cycle.
45784963|NCT03023306|Other|Antiemetics perioperatively|Preemptive group ondansetron 4 mg will be administered 1h before surgery Intraoperative group Ondansetron 4 mg will be administered intraoperatively
45784964|NCT05710367|Drug|Dapagliflozin 10mg Tab|Forxiga® as an add-on treatment in patients with renal and/or cardiac association FD in an exploratory framework.
45784965|NCT05710367|Drug|Placebo|matched oral drug. Placebo tablet will have the same color, taste, smell and package as the verum tablet
45784966|NCT05710289|Biological|Immune Responses|To compare the immune responses against the original strain and circulating strain prior to and post homologous dose of WHO EUA qualified COVID-19 vaccine in adults aged 18 years and older regardless of prior history of SARS-CoV-2 infection with immunogenicity profile of single heterologous dose by GBP510 vaccine acquired from GBP510_004 study.
45644108|NCT03869190|Drug|Sacituzumab Govitecan|Sacituzumab Govitecan will be administered at a dose of 10 mg/kg by IV on Day 1 and 8 of each 21-day cycle.
45644109|NCT03869190|Drug|Tocilizumab|Tocilizumab will be administered by IV infusion at a dose of 8 mg/kg every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
45644110|NCT03869190|Drug|Cisplatin|Cisplatin will be administered at a dose of 70mg/m^2 by IV on Day 1 of each cycle for Cycles 1-3 pre-surgery.
45644111|NCT03869190|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 1000mg/m^2 by IV on Days 1 and 8 of each cycle for Cycles 1-3 pre-surgery.
45784967|NCT01012388|Device|Radiesse® Injectable Dermal Filler|Calcium hydroxylapatite particles suspected in an aqueous based gel carrier
45784968|NCT01670825|Procedure|Pulsed radiofrequency|Local anesthetic injection and pulsed radiofrequency treatment x 6 minutes over each affected occipital nerve
45784969|NCT01670825|Drug|Corticosteroid injection|Corticosteroid and local anesthetic injection plus sham pulsed radiofrequency over each affected occipital nerve
45784970|NCT01670825|Drug|Local anethestic injection|
45917812|NCT00005831|Other|laboratory biomarker analysis|Correlative studies
45917813|NCT00001020|Biological|rgp120/HIV-1IIIB|
45917814|NCT00001020|Biological|rgp120/HIV-1MN|
45644112|NCT03868891|Device|EMST150|The EMST150 consists of a handheld plastic tube with a mouthpiece on one end and an adjustable valve on the other end. Your child will close his/her lips around the mouthpiece and breathe out against resistance. The EMST150 will be adjusted to the point where airflow stops. Each day, your child will blow into the EMST150 5 sets of 5 times with a 10-15 second rest between each use and a 1-2 minute rest between each set of 5. You will adjust the resistance of the device each week, take a picture of the device settings, and document exercise sets performed in an exercise diary. These exercises will be performed twice in each nostril 2 times a day until your child's next visit at the MEPL (at least 8 weeks). Each session should take approximately 10-15 minutes, for a total of 30 minutes per day.
45784971|NCT03016676|Other|Spinal Manipulation|High velocity low amplitude thrust (HVLA) to the lumbar region of the spine between L1 and L5 vertebrae. The exact level thrust will be at the discretion of the treating practitioner determined by the level with the greatest perceivable motion restriction. The HVLA thrust will be performed with the patient side lying in a neutral.They take part in 12 treatment visits, 10 to 20 minutes sessions of SM over 2 weeks. Light soft tissue techniques (i.e., active and passive muscle stretching, and ischemic compression of tender points) may be used as needed to facilitate the manual therapy.
45784972|NCT03016676|Other|Exercise therapy|Self education, supervised exercise visits, and home exercise. The overall objectives are to help patient's mange their LBP and prevent future LBP recurrences. Total number of visits 12.Each visit starts with 10 minutes of self-care education to help patients establish and monitor goals aligned with the exercise program and enhance their understanding of LBP. Participants will be taught the importance of movement and activity, pain management techniques, and methods for developing spinal posture awareness during activities of daily living (e.g., lifting, pushing, pulling, sitting, getting out of bed, and using a backpack).
45784973|NCT03022994|Other|Duodenum and rectum examination|All subjects will undergo upper gastrointestinal endoscopy and proctoscopy. In addition, it will be also evaluated duodenal and rectal biopsies.
45784974|NCT03022760|Behavioral|Work-related measures|After mapping the patient's psychosocial work situation using tools provided at the one-day training, the patient's employer will be contacted and involved in the rehabilitation planning.
45784975|NCT05710211|Biological|Clonal architecture determination|"Biological:~Determination of clonal architecture by sorting of circulating CD34 positive cells followed by cell culture and colony genotyping and/or single-cell DNA-sequencing~Secondary outcome: transcriptomic study by RNA-sequencing"
45784976|NCT00956540|Procedure|Deflating tracheal cuff|Deflating tracheal cuff during ventilatory disconnections along the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support.
45784977|NCT00956540|Procedure|Deflating tracheal cuff 2|Deflating tracheal cuff during ventilatory disconnections along the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate manage the airway.
45644113|NCT03867851|Drug|IBsolvMIR|Study drug IBsolvMIR
45784978|NCT05184101|Drug|Unfractionated Heparin|Heparin sodium will be administered as a nebulised aerosol dose of 25,000 IU heparin three times a day (TDS) via an Aerogen Solo (Aerogen, Ireland) vibrating mesh aerosol drug nebulizer.
45784979|NCT03022136|Other|cold sensation method|Complete sensory loss to ice will be evaluated form anterior median line to posterior median line at the end of surgery.
45784980|NCT01671293|Behavioral|Multicomponent remote care model|A remote intervention based on counseling (telephone-based) was implemented. This counseling intervention is the core of the multi-component model, which also includes counseling through text messages, the purveyance of educational material, and self-monitoring equipment (pedometer & waist circumference measuring tape). The phone counseling is made by health centers professionals who have been trained to apply theories on behavioral change and decision-making. Phone counseling is conducted at least once a month. Messages are sent weekly and are related to the topics referred to in phone counseling sessions. The educational material and equipment -respectively- seek to provide additional information and foster the habit of self-monitoring progress and/or reversions in the change process.
45784981|NCT01671293|Other|Usual care|Usual care from health centers consisting of medical indication of physical activity and healthy eating recommendations, as well as referral to Dietitian if appropriate, an invitation to participate in educational activities at health centers and periodic inspection appointments
45784982|NCT05710133|Other|food|alectinib-d6 will be administered with breakfast on day 1 to determine the food-effect
45784983|NCT05710133|Other|fast|alectinib-d6 will be administered after an overnight fast of minimal 10 hours on day 9 to determine the food-effect
45784984|NCT00957242|Drug|warfarin|Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.
45644114|NCT03867851|Drug|Heparin|Clinical praxis
45784985|NCT00957242|Drug|placebo|Oral placebo (1mg or 2.5mg)
45784986|NCT01671839|Device|Subcutaneous tissue release with the Cabochon System|Device: Subcutaneous tissue release
45917815|NCT00005834|Biological|filgrastim|Arms 1 and 2: 300 mcg (pts </= 60 kg) or 480 mcg (pts > 60 kg), SC beginning day 5
45644115|NCT03866382|Procedure|Bone Scan|Undergo bone scan
45644116|NCT03866382|Drug|Cabozantinib S-malate|Given PO
45644117|NCT03866382|Procedure|Computed Tomography|Undergo CT scan
45644118|NCT03866382|Biological|Ipilimumab|Given IV
45644119|NCT03866382|Procedure|Magnetic Resonance Imaging|Undergo MRI
45917816|NCT00005834|Drug|cisplatin|Arms 1 and 2: 15 mg/m2/d continuous IV days 1-4
45449102|NCT03965507|Other|Evaluation of the prevalence of sacroiliac joint dysfunction in lumbar disc herniation|
45644120|NCT03866382|Biological|Nivolumab|Given IV
45644121|NCT03866382|Procedure|Positron Emission Tomography|Undergo PET scan
45644122|NCT03861273|Biological|PF-06838435/ fidanacogene elaparvovec|Gene Therapy
45644123|NCT03860207|Biological|Humanized 3F8 Bispecific Antibody|Phase I Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle.Phase II Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle.
45644124|NCT03860207|Other|Blood draw|In cycle 1, blood is drawn for PK studies.
45784987|NCT02992379|Device|pivot splint|A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of selfcuring acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe.
45784988|NCT02992379|Device|stabilizing splint|A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. intervention: pivot splint
45784989|NCT01014728|Drug|propofol|100-200mcg/kg/min by infusion
45784990|NCT01014728|Drug|sevoflurane|1-3% of sevoflurane (expired)
45784991|NCT05164211|Other|Didgeridoo|the children will have 6 didgeridoo lessons given by a teacher spread over 3 months.
45784992|NCT02249351|Drug|Talsaclidine|
45784993|NCT02249351|Drug|Placebo|
45784994|NCT01015586|Drug|Lamotrigine|Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks
45784995|NCT01015586|Drug|Placebo|Placebo once daily for 12 weeks
45784996|NCT03021902|Drug|IV amino acids|IV amino acids delivered by continuous infusion, such that the total enteral and IV protein will be between 2.0-2.5 g/kg/day as a combination of amino acid infusion plus standard feeding.
45644125|NCT03857490|Behavioral|Lower leg heat therapy|Home-based 8 weeks of lower leg repeated heating.
45784997|NCT03021902|Device|In-bed cycle ergometry exercise|"In-bed cycle ergometry exercise delivered in 45-minute sessions once-daily 5 days per week according to a detailed specific protocol that includes a safety check in combination with vigorous verbal encouragement from trained research staff delivering the intervention to promote active cycling.~Cycling is protocolized to provide graduated increases in resistance during each session and between daily sessions. Cycling will continue through ICU discharge or 21 calendar days after randomization. The intervention will specifically occur during ICU stay."
45784998|NCT01676831|Drug|Topical resiquimod 0.06%|topical resiquimod 0.06% dosing frequency begins at 3 times per week and evaluated every two weeks. Will be applied for a total of 8 weeks followed by 4 weeks rest and then followed by another 8 weeks of application with another 4 weeks rest.
45784999|NCT01676831|Drug|topical resiquimod 0.03%|topical resiquimod 0.03% applied initially 5 times weekly for 8 weeks with adjustments up or down based upon tolerability followed by 4 weeks rest followed by another 8 weeks of treatment followed by another 4 week rest period.
45785000|NCT03021434|Other|Community and household water safety education sessions|Data collectors will give a short community presentation on water treatment, as well as safe water handling and storage. Then, data collectors will immediately visit households and review this information. Data collectors will return within 72 hours and review this information once more.
45785001|NCT03021434|Other|Household-specific water quality information|Household specific water quality data will be provided in two ways. In the Standard Testing Arm, water quality data will be analyzed in a laboratory by standard methods and results will be delivered to households. In the Test Kit arm, water quality data will be analyzed in households using provided water test kits.
45785002|NCT03021434|Other|Low-cost microbiological water test kits|Intervention component consists of low-cost, biodegradable that tests for the presence of E. coli in water samples. The test uses Aquatest broth medium with resorufin methyl ester chromogen. Presence of E. coli (positive test) imparts bright red color, making it easy to use/interpret at the household level with minimal training
45785003|NCT02246309|Device|Embryoscope Time Lapse System|The EmbryoScope® time-lapse system is a unique platform facilitating improved IVF treatment, flexible work routines and effective communication, through comprehensive documentation of embryo development and evolving improvements in selection.
45785004|NCT02246309|Device|Standard Embryo Culture|Standard embryo culture in a Standard water jacketed carbon dioxide/low oxygen incubator system.
45644126|NCT03851250|Drug|MRx-4DP0004|Participants randomised to receive MRx-4DP0004 will take it in addition to their regular asthma medication.
45644127|NCT03851250|Drug|Placebo|Participants randomised to receive placebo will take it in addition to their regular asthma medication.
45644128|NCT03850912|Other|eSyM App Usage|Patients (and/or proxy) will report their cancer-related symptoms and receive tailored feedback via eSyM
45644129|NCT03850912|Other|SASS Questionnaire|"A subset of eSyM+ and eSyM- patients will be asked to complete a research questionnaire called the SASS Questionnaire asking about their Self-efficacy, Attainment of information needs, Symptom burden, and Satisfaction with care (see PROMIS, CAHPS, IAM/AIM question banks - Appendices C through G). The questionnaire will stop being administered once 1800 total surveys have been received."
45785005|NCT01680653|Drug|Mini-glucagon|Mini dose glucagon given for glucose <70 mg/dl at a dose of 1unit/year of age
45785006|NCT01680653|Device|Remote monitoring|Provides real-time continuous glucose monitoring
45785007|NCT01680653|Dietary Supplement|Carbohydrates|16 grams of carbohydrate
45785008|NCT02448810|Biological|BAX69 + infusional 5-FU/LV|"Study Part 1: Safety Run-in~Administered weekly as part of a 4 week treatment cycle~Intravenous injection"
45785009|NCT02448810|Biological|BAX69 + panitumumab|"Study Part 1: Safety Run-in~Administered weekly as part of a 4 week treatment cycle~Intravenous injection"
45785010|NCT02448810|Biological|BAX69 + 5-FU/LV|"Study Part 2: Administered weekly as part of a 4 week treatment cycle~•Intravenous injection"
45785011|NCT02448810|Biological|BAX69 + panitumumab|"Study Part 2: Administered weekly as part of a 4 week treatment cycle~•Intravenous injection"
45785012|NCT02448810|Drug|Standard of Care|"Investigator's choice~Dose according to drug label"
45785013|NCT02448810|Biological|Standard of Care|"Investigator's choice~Dose according to drug label~Choice includes panitumumab in KRAS &NRAS wt group only"
45644130|NCT03850691|Drug|Aldesleukin: All Patients|"Cycle 1:~(600,000 U/kg/dose) given as a bolus infusion once every 8 to 12 hours over 5 days or until no longer tolerated (to a maximum of 10 doses). Administered as an inpatient.~Days 1-5 and Days 15-19 (all patients)"
45785014|NCT05035667|Other|Questionnaire Administration|Complete questionnaires
45785015|NCT05709587|Other|Virtual reality training|Virtual reality Training for 12 sessions, two to three times for one week, one training session last for 20 minutes
45785016|NCT00958334|Drug|Proellex®|25 mg daily (two 12.5 mg capsules)
45785017|NCT05709431|Other|Questionnaire CIQoL-35|The Cochlear Implant - Quality of Life (CIQoL) PROM is a quality-of-life assessment questionnaire for adults with cochlear implants (1-7). The CIQoL responds to an important need for a questionnaire that captures the benefits of cochlear implantation as perceived by patients and that can be used in clinical practice. The CIQoL is available in two lengths: 35 questions (CIQoL-35) and 10 questions (CIQoL-10). The CIQoL-35 has interesting measurement properties including good construct validity, convergent validity, and test-retest reliability.
45785018|NCT05031065|Radiation|Breast Cancer Radiotherapy|4000-4250 cGy in 15-16 daily fractions
45785019|NCT01015976|Procedure|bariatric surgery|Roux en Y bariatric surgery
45785020|NCT01015976|Other|control|No surgery
45785021|NCT03021200|Device|Green indocianine|Laser fluorescence using green indocianine guiding the surgical procedure.
45785022|NCT01680887|Drug|Varenicline|
45785023|NCT01680887|Drug|Placebo|
45785024|NCT01016678|Drug|Treximet|85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache. The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.
45785025|NCT01016678|Drug|Placebo|Dummy pill comparator
45785026|NCT02457546|Biological|EVICEL Fibrin Sealant|
45785027|NCT02457546|Device|Hydrogel sealant|
45785028|NCT01681121|Drug|ADX-N05|150 mg once a day for 4 weeks followed by 300 mg once a day for 8 weeks
45644131|NCT03850691|Drug|Nivolumab: Cohort 1 (Cutaneous)|"Cycle 1: 6 Week Duration Nivolumab 240 mg IV~Cycle 2: 6 Week Duration Nivolumab 240 mg IV on Day 1, 15 and 29~Cycle 3: 4 Week Duration Nivolumab 240 mg IV on Day 1 and 15~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study"
45644132|NCT03850691|Drug|Nivolumab: Cohort 2 (Ocular)|"Cycle 1: 6 Week Duration Nivolumab 3 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Nivolumab 1 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Nivolumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Nivolumab on Day 8 using the same dose regimen as used Cycle 1 Day 29.~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study"
45785029|NCT01681121|Drug|Placebo|One capsule placebo to match ADX-N05 to be taken for 4 weeks followed by 2 capsules placebo to match ADX-N05 to be taken for 8 weeks
45785030|NCT04930692|Diagnostic Test|Contrast-enhanced CT lymphography with the periareolar injection of iopamidol|"Patients who meet the inclusion/exclusion criteria will undergo the CT lymphography with periaoreolar injection of a mixture of 4 mL iopamidol and 2 mL of 1% lidocaine hydrochloride. Computed tomographic images will be obtained 1, 3, 5, and 10 minutes after administration of the iopamidol. Following enhancement of the lymphatic duct, the first lymph node to show enhancement will be defined as the SLN.~No later than 10 days after the CT lymphography patients will receive surgical treatment. During breast cancer surgery identification of the SLN using the ICG-fluorescence method with injection of 2 ml indocyanine green into the skin of the areola and the biopsy of identified SLN will be performed. The comparison of the results of CT lymphography and SLN biopsy will be administrated by the investigator."
45785031|NCT01016834|Device|Sumavel DosePro|Needle free delivery system containing 0.5 mL of solution of 6 mg sumatriptan, subcutaneous administration
45785032|NCT01016834|Drug|Sumatriptan|subcutaneous injection, 6 mg, per migraine attack, no more than two administrations within a 24 hr period
45785033|NCT05708651|Device|Investigational device [I-IV]|Intra-individual randomised paired crossover evaluation of airway patency with investigational device in volunteer study participants [I-II] and study patients [III-IV] at low, moderate and deep steady-state sedation [I-II] or procedural sedation according to SOC [III-IV].
45785034|NCT05708651|Device|Comparator [I-IV]|Intra-individual randomised paired crossover evaluation of airway patency with comparator (biteblock [I-II] or no device [II-IV]) in volunteer study participants [I-II] and study patients [III-IV] at low, moderate and deep levels of steady-state sedation [I-II], and during procedural sedation according to SOC for scheduled colonoscopy [III] or ureteral catheterization [IV].
45785035|NCT04924283|Behavioral|Tetris and Assessments|Participants will complete assessments on their phone to rate cravings for alcohol. Participants will complete a visual cognitive interference task (i.e., play Tetris on their phone) after endorsing a alcohol craving, and then re-rerate craving after the task.
45785036|NCT04924283|Other|Assessment Only|Participants will complete assessments on their phone to rate cravings for alcohol.
45785037|NCT02447952|Device|Faros Sensor (FS) and LifeInsight Hub|Each subject will be issued one FS and a MAT LifeInsight Hub for use during the study. At each clinic visit in the Pilot and Core Study Phases, the Faros sensor will be placed on the subject just prior to the defined reference tasks and will be worn on the subject's sternum during completion of the tasks. The morning after the clinic visit, the subject will re-attach the sensor and wear it for approximately 3 days. In between visits during the Core Study Phase the subject will wear the FS every month for approximately 3 days to enable data collection on a monthly basis over the 48 week study period. Movement/physical activity data will be collected by the FS throughout the study.
45785038|NCT02447952|Device|Fast Fix electrode patch|The Fast Fix electrode patch will be worn with the FS on the subject's sternum according to the same schedule as the FS. The Fast Fix electrode patch will be replaced by the subject on a daily basis during the 3 day monitoring period. Subjects will be provided instructions on how to operate and wear the Fast Fix electrode patch.
45785039|NCT02447952|Procedure|Quantitative Measure of Speech (Core Phase Only)|Subjects will follow simple prompts on a computer screen instructing them to say a series of vowels, words, and paragraphs which will be recorded using a high definition digital microphone and stored securely on a laptop. The speech waveform data will be sent via secure method to GSK/MAT for processing.
45785040|NCT00959660|Behavioral|Exercise|walking, treadmill and bicycle exercise
45785041|NCT00959660|Dietary Supplement|Dietary Intervention|Subjects will be provided meals and instructions for individual food selections.
45785042|NCT00959660|Behavioral|Diet and exercise|Subjects will be provided meals and instructions for individual food selections and will undergo walking, treadmill and bicycle exercise.
45785043|NCT00959660|Other|Attention Control|control group- continue their previously randomized life style
45785044|NCT03020732|Procedure|test groups|Coronally advanced flap procedure is a mucogingival surgery technique that was used to prepare recipient sites. Concentrated growth factor(CGF) membranes were placed over the exposed root surface. The flap was advanced 1 mm coronally from CEJ to completely cover.
45785045|NCT03020732|Procedure|control groups|Coronally advanced flap procedure is a mucogingival surgery technique that was used to prepare recipient sites. Subepithelial connective tissue graft was placed over the exposed root surface. The flap was advanced 1 mm coronally from CEJ to completely cover.
45785046|NCT03020186|Other|Physical activity|
45785047|NCT03020186|Other|Physical activity+ MED diet|
45785048|NCT03020186|Other|Physical activity+green MED diet|****Sub-study from all 3 main arms: Autologous fecal microbiota supplement intervention derived from the time of maximal weight loss: At the 6-month time period, the time of anticipated greatest weight reduction, participants's feces samples will be processed to capsulized inocula. Samples will be frozen within 2 hours and will be kept at -80c pending analysis. Participants will be randomized to receive either research capsules or identical placebo capsules between 8 and 14 months time period. Placebo capsules will consist of a combination of powdered cocoa and vegetable gelatin in normal saline/glycerol and will be identical in appearance to research capsules.
45785049|NCT04923594|Drug|mazindol extended release|Dosed orally, once daily for up to 3 weeks
45785050|NCT04923594|Drug|Placebo|Dosed orally, once daily for up to 4 weeks.
45785051|NCT00961532|Drug|DDAVP injection (desmopressin acetate)|0.4 mcg/kg in 250 mL NS intravenously once over 30 minutes
45785052|NCT00962000|Other|Dialysis Flow Rate Start 600mL/min|ABAB sequence where A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min and B represents three consecutive treatments with a dialysate flow rate of 800 mL/min.
45785053|NCT00962000|Other|Dialysis Flow Rate Start 800mL/min|BABA sequence where B represents three consecutive treatments with a dialysate flow rate of 800 mL/min and A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min.
45785054|NCT02447718|Biological|Prevnar®13|A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.
45644133|NCT03850691|Drug|Ipilimumab: Cohort 2 (Ocular)|"Cycle 1: 6 Week Duration Ipilimumab 1 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Ipilimumab 3 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Ipilimumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Ipilimumab on Day 8 using the same dose regimen as used Cycle 1 Day 29"
45785055|NCT02447718|Biological|Pneumovax® 23|A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13
45785056|NCT02447718|Biological|Pediacel®|A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.
45785057|NCT01017536|Biological|AERAS-402|AERAS-402 is a replication-deficient serotype 35 adenovirus containing DNA that expresses a fusion protein of three Mycobacterium tuberculosis (Mtb) antigens: 85A, 85B and TB10.4.
45785058|NCT01017536|Biological|Placebo|Placebo was the identical buffer solution in which AERAS-402 is formulated.
45785059|NCT03019874|Dietary Supplement|Cranberry Extract|3 x Cystorenal Cranberry plus daily for 6 months (contains 300 mg Cranberry-Extract, 100 mg Pumpkin seeds-Extract, 20 mg Vitamin C und 0,47 mg Riboflavin)
45644134|NCT03842228|Procedure|Biopsy|Undergo tumor biopsy
45644135|NCT03842228|Procedure|Biospecimen Collection|Undergo collection of blood samples
45785060|NCT00962078|Other|continuous endurance training|at 60 percent of peak Watt
45785061|NCT00962078|Other|interval training|at 100 percent of peak Watt
45785062|NCT03019952|Behavioral|Care Coordination Visit|This is a longitudinal study. Adolescents or young adults with autism will participate in this study. Participants will be required to complete a baseline of assessment measures at enrollment and then monthly assessments (described in the study procedures below) during the first (approximately) 10-15 minutes of each visit with the t-CARE coordinator. The remainder of the visit will focus on care coordination and clinical treatment goals.
45917817|NCT00005834|Drug|cyclophosphamide|Arms 1 and 2: 400 mg/m2/d continuous IV days 1-4
45917818|NCT00005834|Drug|dexamethasone|Arms 1 and 2: 40 mg/d PO days 1-4
45644136|NCT03842228|Procedure|Computed Tomography|Undergo CT
45644137|NCT03842228|Drug|Copanlisib Hydrochloride|Given IV
45644138|NCT03842228|Biological|Durvalumab|Given IV
45644139|NCT03842228|Procedure|Echocardiography|Undergo ECHO
45644140|NCT03842228|Procedure|Magnetic Resonance Imaging|Undergo MRI
45644141|NCT03842228|Drug|Olaparib|Given PO
45644142|NCT03842228|Procedure|X-Ray Imaging|Undergo x-ray
45644143|NCT03836040|Drug|Erenumab Dose 1|Subjects in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.
45785063|NCT00963482|Behavioral|Cognitive-behavioural smoking cessation program|It's a cognitive-behavioural intervention for smoking cessation. Originally based on a 6 week program designed for outpatients (Batra & Buchkremer 2004). This program was then specifically tailored for inpatient use with additional information addressing the interaction of smoking and drinking and its consequences.
45785064|NCT00963482|Behavioral|Autogenic training|Learning and exercising of autogenic training. There's evidence that autogenic training is not effective in smoking cessation.
45644144|NCT03836040|Drug|Erenumab Dose 2|Subjects in the low body-weight group at day 1 who are randomized to Dose Level 2 and subjects in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.
45785065|NCT05395988|Device|Digital hand washing instructions|Tablet displaying animated hand washing instructions
45785066|NCT05395988|Device|Digital hand washing reward|Tablet displaying animated hand washing instructions and animated animals as reward
45785067|NCT00963560|Device|ReSTOR +3|Bilateral implantation of the AcrySof ReSTOR Aspheric +3 Model SN6AD1 Intraocular lens (IOL) for the treatment of cataract.
45785068|NCT00963560|Device|Crystalens HD|Bilateral implantation of the Crystalens HD intraocular lens (IOL) for the treatment of cataract.
45785069|NCT00963560|Device|Crystalens AO|Bilateral implantation of the Crystalens AO intraocular lens (IOL) for the treatment of cataract.
45785070|NCT03019718|Other|GSA-Online plus|A 12-week online writing intervention based on the Core Conflictual Relationship Theme Method (CCRT) with feedback provided by online therapists.
45785071|NCT00963638|Dietary Supplement|MagTabSR|MagTabSR/placebo 168 mgs BID for 6 six weeks
45785072|NCT00963638|Dietary Supplement|Placebo|MagTabSR/placebo 168 mgs BID for 6 six weeks
45785073|NCT02246036|Device|APD probe|The probe will be placed in the patient with an endoscopic procedure by a gastroenterologist (standard procedure for post-pyloric tubes placement).
45785074|NCT03016442|Device|Cook Double Balloon Catheter|A double- balloon catheter (Cook Cervical Ripener Balloon,Cook OB/GYN,Spencer IN) is inserted into cervical canal under direct visualisation during a sterile speculum examination.İt is placed for 12 hours
45785075|NCT03016442|Drug|Dinoprostone|10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
45785076|NCT01682135|Biological|Ramucirumab|Administered IV.
45917819|NCT00005834|Drug|etoposide|Arms 1 and 2: 40 mg/m2/d continuous IV days 1-4
45644145|NCT03836040|Drug|Erenumab Dose 3|Subjects in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.
45644146|NCT03836040|Other|Placebo|Placebo matching dose for erenumab dose 1, 2 and 3.
45785077|NCT03019484|Behavioral|Breastfeeding support|Self-efficacy
45785078|NCT05395676|Device|Exergame home training programme|Each training programme (Xbox or Wii Fit) is aimed at improving the following issues: improper weight shifting and reduced dual tasking. The participants will be guided in the first sessions to familiarize themselves with the exercises. Then, they will be allowed to exercise independently at home. Allowing enough practice time before collecting data helps minimize practice effects. practice effects are confounding factors that can affect the results and make it difficult to identify whether the improvement in outcome is due to the training or not. The duration of the training programme will be approximately 30 minutes. Each game will be played three times (the duration for each game is approximately one minute).
45785079|NCT01684007|Device|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
45785080|NCT01684007|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1|Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
45785081|NCT05395520|Other|Retrospective chart review|Retrospective chart review to be conducted at Methodist Charlton Medical Center (MCMC) in Dallas, TX. Adult patients who received vancomycin while inpatient at MCMC with at least one corresponding vancomycin trough level taken at steady state will be included. All vancomycin orders by providers are entered as pharmacy to dose; thus dosing and routine monitoring is conducted by pharmacists.
45785082|NCT02249897|Drug|CHOLESTYRAMINE|CHOLESTYRAMINE CAPSULES, 6 G/DAY P.O. DURING 12 WEEKS
45644147|NCT03833726|Procedure|Experimental: LED group|5 Sessions of 8 minute 405 nm Blue Light Emitting Diode, LED, with a power of 1.66 W / m2, 7 days apart.
45644148|NCT03833726|Procedure|Sham Comparator: Control|5 Sessions of 8 minute with device off and heated gel, 7 days apart.
45644149|NCT03832920|Other|Analgesia Nociception Index|A monitor of nociception for patients under general anesthesia
45644150|NCT03827655|Drug|TAK-954 Placebo|TAK-954 placebo-matching intravenous infusion.
45785083|NCT05706545|Diagnostic Test|Acquisition of cardiovascular signals and microcirculation sidestream darkfield images|ECG, arterial pressure and peripheral flow velocity via a percutaneous laser doppler will be acquired together with images of the sublingual microcirculation detected with sidestream darkfield images microscope
45785084|NCT00963872|Drug|cyclophosphamide|50 mg/kg intravenously (IV) over 2 hours on Day -6.
45917820|NCT00005834|Drug|thalidomide|Arm 2: 800 mg/d (max dose) PO daily
45644151|NCT03827655|Drug|TAK-954|TAK-954 intravenous infusion.
45644152|NCT03822793|Drug|Placebo|Patient will receive a perfusion of NaCl (sodium chloride 9%; placebo) intravenous over 10 minutes just before surgery.
45785085|NCT00963872|Drug|fludarabine phosphate|40 mg/m^2 over 1 hour on Days -6 through -2.
45785086|NCT00963872|Radiation|Total body irradiation|200 cGy on Day -1
45917821|NCT00001029|Drug|Zidovudine|
45917822|NCT00001029|Drug|Zalcitabine|
45917823|NCT00001029|Drug|Didanosine|
45917824|NCT00001032|Drug|Zidovudine|
45917825|NCT00001032|Drug|Zalcitabine|
45917826|NCT00005837|Drug|oxaliplatin|
45917827|NCT00001038|Drug|Valacyclovir hydrochloride|
45917828|NCT00001038|Drug|Acyclovir|
45917829|NCT00005840|Drug|Paclitaxel|Given IV
45917830|NCT00005840|Drug|Cisplatin|Given IV
45917831|NCT00005840|Radiation|Radiation Therapy|Undergo whole abdominal radiation therapy
45917832|NCT00005843|Drug|tipifarnib|
45917833|NCT00001041|Biological|rgp120/HIV-1MN|
45917834|NCT00005849|Drug|bryostatin 1|
45917835|NCT00005849|Drug|paclitaxel|
45785087|NCT00963872|Biological|Umbilical cord blood unit with C3a fragment|On Day 0, the C3a primed UCB unit will be infused intravenously SECOND, within 30 minutes of the completion of the infusion of the unmanipulated UCB unit, through a central line without in-line filtration in a manner identical to the unmanipulated UCB unit.
45785088|NCT00963872|Biological|Unmanipulated UCB Unit|On Day 0, the unmanipulated UCB unit will be infused FIRST through a central line without in-line filtration per institutional guidelines.
45785089|NCT00964496|Drug|Thalidomide|Patients were randomly assigned to receive a four-month course of 25 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang-zhou, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
45785090|NCT00964496|Drug|Iron|Patients were randomly assigned to receive a four-month course of 100 mg of iron (Pharmaceutical Co., Ltd. of Nanjing, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
45785091|NCT02245880|Device|Glidescope|videolaryngoscope
45785092|NCT02245880|Device|ILMA|handling of the device till the optimal ventilation achieved
45785093|NCT02981654|Device|Alma Lasers Pixel carbon dioxide laser system|The vaginal handpiece sheath is lubricated with baby oil. Set the initial energy level (startup set up recommendations: High mode, 40 millijoule/pixel; according to the patient reaction you can increase up to 120 max. Pulse mode or Repeat mode). The handpiece is inserted as distally as possible, with the laser energy's window oriented to the 12:00 o'clock position. There are position markings on the handpiece. Trigger a laser pulse by pressing the footswitch. Shoot the laser and rotate the probe by one hour at a time. When you reach the 12:00 o'clock position again, withdrawal the headpiece back by one centimeter and repeat the rotational treatment process.
45785094|NCT01685021|Drug|MOR00208 (formerly Xmab5574)|
45644153|NCT03822793|Drug|Group 1: perfusion of 300 mg Exacyl|Patient will receive a perfusion of 300 mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
45785095|NCT05691101|Other|CISB with IV PCA group|"Ultrasonography guided interscalene brachial plexus block was done with a 5 cm block needle and catheter was inserted. (Stimuplex®A, B Braun Medical, Bethlehem, PA). 10 mL 0.375 % ropivacaine was injected through the catheter.~0.2 % ropivacaine 4 ml/hour was injected through the continuous brachial plexus block catheter. IV-PCA with fentanyl (basal flow 0 ml with patient selected bolus 14 mcg, lockout 10 minutes) was started."
45785096|NCT05691101|Other|CISB group|"Ultrasonography guided interscalene brachial plexus block was done with a 5 cm block needle and catheter was inserted. (Stimuplex®A, B Braun Medical, Bethlehem, PA). 10 mL 0.375 % ropivacaine was injected through the catheter.~0.2 % ropivacaine (4 ml/hour with patient selected bolus 5 ml, lockout 60 minutes) was injected through the continuous brachial plexus block catheter."
45785097|NCT04834193|Procedure|Endoscopic ultrasound-guided fine-needle biopsy|Solid lesions will be sampled under endoscopic ultrasound guidance using the two techniques (wet-suction and slow-pull)
45785098|NCT00966446|Drug|Unsupervised Decolonization|Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member.
45785099|NCT00966446|Drug|Supervised Decolonization|Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member. In addition, households are contacted by study stuff via phone or text messages to ensure compliance, to provide reminders to household members to perform the decolonization protocol as well as to answer any question/concerns household members may have.
45785100|NCT01685411|Drug|Allopurinol|Day -8 (prior to transplant): Per institutional guidelines
45917836|NCT00001047|Drug|Ethambutol hydrochloride|
45917837|NCT00001047|Drug|Clarithromycin|
45644154|NCT03822793|Drug|Group 2: perfusion of 500 mg Exacyl|Patient will receive a perfusion of 500 mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
45644155|NCT03822793|Drug|Group 3: perfusion of 1000 mg Exacyl|Patient will receive a perfusion of 1000 mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
45644156|NCT03822793|Drug|Group 4: perfusion of 3000 mg Exacyl|Patient will receive a perfusion of 3000 mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
45644157|NCT03816163|Drug|zolbetuximab|Administered as an intravenous infusion.
45644158|NCT03816163|Drug|nab-paclitaxel|Administered as an intravenous infusion
45644159|NCT03816163|Drug|gemcitabine|Administered as an intravenous infusion
45644160|NCT03815825|Drug|IONIS-FB-LRx|IONIS-FB-LRx at multiple ascending doses, administered subcutaneously every 4 weeks
45785101|NCT01685411|Drug|Keppra|Day -8 (prior to transplant): Per institutional guidelines
45785102|NCT01685411|Drug|Busulfan|Days -7 through -4 (prior to transplant): given intravenously (IV) infusion over 2 hours every 6 hours following dose, administration and pharmacokinetic monitoring per University of Minnesota institutional guidelines.
45785103|NCT01685411|Drug|Cyclophosphamide|Days -3 and -2 (prior to transplantation): given as a 2 hour intravenous infusion with a high volume fluid flush and mesna per institutional guidelines. Dosing is based on actual body weight.
45917838|NCT00001047|Drug|Clofazimine|
45917839|NCT00001047|Drug|Rifabutin|
45917840|NCT00005852|Biological|anti-thymocyte globulin|
45917841|NCT00005852|Biological|filgrastim|
45917842|NCT00005852|Biological|muromonab-CD3|
45785104|NCT01685411|Drug|Tacrolimus|All patients (regardless of allograft source) will receive tacrolimus therapy beginning on day -3. Dosing will be monitored and altered as clinically appropriate per institutional pharmacy guidelines. Dose adjustments will be made on the basis of toxicity and/or low tacrolimus levels. Taper at day +100 for matched sibling donor (MSD) recipients, and day +180 for non-MSD recipients. Taper to zero by 10% weekly dose reduction over approximately 10 weeks.
45785105|NCT01685411|Drug|Mycophenolate mofetil|Day -3 (prior to transplant): Recipients of umbilical cord blood will given a dose of 3 gm/day every 8 or 12 hours (> or = 40 kg) or 15 mg/kg 3 times per day (< 40 kg) for up to 30 days unless no engraftment.
45785106|NCT01685411|Biological|Allogeneic hematopoietic stem cell transplant|Day 0 (or Day+1/+2 to accommodate weekdays): Infusion of cells from related or unrelated donor bone marrow or single or double unrelated donor umbilical cord blood.
45644161|NCT03815825|Drug|Placebo|Placebo matching solution, administered subcutaneously every 4 weeks
45644162|NCT03811015|Drug|Cisplatin|Given IV
45644163|NCT03811015|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45644164|NCT03811015|Biological|Nivolumab|Given IV
45644165|NCT03811015|Other|Patient Observation|Undergo observation
45785107|NCT01685411|Biological|Filgrastim|Beginning Day +1: Intravenously (IV) 5 mcg/kg once daily and continuing until the absolute neutrophil count is >2500 x 10^9/L or per institutional guidelines.
45785108|NCT01685411|Biological|antithymocyte globulin|Administered per institutional guidelines for recipients of umbilical cord blood transplant.
45785109|NCT05395286|Behavioral|Innovation Lab|An Innovation Lab is a facilitated 5-day residential event designed to create novel, transdisciplinary and potentially transformative research ideas and proposals to address a specific grand challenge. Participants, along with a director, organizers, subject matter guides, and KI facilitators communally explore the problem space, generate a broad range of ideas, and form transdisciplinary teams to pursue research projects.
45785110|NCT05395208|Behavioral|Therapeutic touch group accompanied by white noise|During the intravenous catheter intervention, approximately 15-20 minutes of white noise was applied with therapeutic touch.
45785111|NCT02243813|Drug|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
45785112|NCT02991209|Drug|Testosterone|
45785113|NCT02991209|Drug|Placebos|
45785114|NCT00954356|Drug|XPF-001|Single oral administration of 500 mg XPF-001 capsules (5 x 100 mg capsules)
45785115|NCT00954356|Drug|placebo|Single oral administration of 5 x 100 mg Placebo capsules.
45785116|NCT00954824|Biological|Endotoxin (LPS)|Single administration low-dose (3 ng/kg) endotoxin (LPS).
45785117|NCT03019562|Drug|Oxycodone|4mg of oxycodone iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA)
45785118|NCT03019562|Drug|Fentanyl|50ug of fentanyl iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA),
45785119|NCT01685567|Device|MICHI NPS+f|Cerebral protection with carotid flow reversal
45785120|NCT05394584|Behavioral|Cognitive Stimulation Therapy|Cognitive stimulation therapy is a non-pharmacological intervention for people with dementia at mild to moderate stages. Group cognitive stimulation therapy is a 14-session intervention delivered twice every week for 7 weeks. In each session, mentally stimulating activities are conducted around a specific themed, such as current affairs, word association, categorising objects, and number game. Each group consists of eight people with similar levels of cognitive impairment, facilitated by two group leaders who lead the activities according to 18 key principles of the therapy, including new associations, opinions rather than facts, implicit learning, and person-centred.
45785121|NCT05394506|Procedure|Skin Biopsy|The skin biopsy is performed in the consultation outclinic room. A local anaesthetic (anaesthetic patch to be applied to the skin) is required for this procedure. The skin biopsy is usually performed on the front of the forearm (but can be performed on the arm, thigh or leg). After disinfection, a fragment of 3 to 4 mm in diameter is removed with a biopsy-punch (single-use device). If necessary, a suture can be placed. Otherwise, the wound is covered with Steristrip and a sterile dressing. The skin sample, intended for a fibroblast culture, will be placed in a flask to be kept at room temperature. It will be labelled with specific labels and sent to the local biological resource centre.
45785122|NCT05394506|Procedure|Muscle biopsy|The muscle biopsy is performed in a sterile room. A local anaesthetic is required for this procedure. After selecting the muscle from which the sample will be taken (usually from the deltoid muscle at the shoulder stump), placing a sterile field and disinfecting, a small incision is made in the skin until the selected muscle is exposed. A bundle of muscle fibres of approximately 1 cm x 0.5 cm is removed. The skin is then sutured and covered with a sterile dressing. The procedure takes about 30 minutes (including patient set-up). The muscle sample will be divided into 2 fragments, one for myoblast culture, the other for frozen tissue. The 2 vials will be labelled with specific labels and then sent to the local biological resource centre
45917843|NCT00005852|Drug|cyclophosphamide|
45917844|NCT00005852|Drug|cyclosporine|
45644166|NCT03810651|Other|Proton beam radiation using pencil beam scanning|Proton beam radiation using pencil beam scanning, characterized by Bragg peak dose deposition and high conformality of dose to target regions
45644167|NCT03809780|Drug|Lenalidomide|-high dose: [lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly] -Low dose: [lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly]
45644168|NCT03809780|Drug|Dexamethasone|-high dose: [lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly] -Low dose: [lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly]
45644169|NCT03808818|Other|Behavioral, Psychological or Informational Intervention|Receive information about tobacco cessation
45644170|NCT03808818|Drug|Nicotine Replacement|Given NRT patch or lozenge (or both)
45644171|NCT03808818|Other|Quality-of-Life Assessment|Ancillary studies
45644172|NCT03808818|Other|Survey Administration|Ancillary studies
45644173|NCT03808818|Other|Tobacco Cessation Counseling|Receive virtual tobacco cessation counseling
45644174|NCT03804788|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. A sixth week of treatment will be included - and scheduled for the same date as the post-treatment assessment - if the participant and research team agree that it would be beneficial (e.g., if a participant has difficulty grasping cognitive therapy concepts). Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, & Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
45785123|NCT01686503|Drug|IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose|Depending on study arm, participants will receive 0.2 mL intradermally, 0.1 mL intradermally, 0.5 mL intramuscularly, or 0.2 mL intramuscularly.
45785124|NCT00969878|Drug|TA-CD Vaccination|On Day 1, subjects will be randomized to receive vaccination. Day 1 to Week 16 (3 visits per week) Subsequent vaccinations will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between vaccinations. Three times per week visits will be scheduled during this period through Week 16. The assessments for the active phase will be scheduled. Therapy sessions will be provided by a qualified professional such as a master's level counselor.
45785125|NCT00969878|Other|Placebo Injection|On Day 1, subjects will be randomized to receive placebo injection. Day 1 to Week 16 (3 visits per week) Subsequent placebo injections will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between injections. Three times per week visits will be scheduled during this period through Week 16. The assessments for the efficacy and safety monitor will be scheduled.Therapy sessions will be provided by a qualified professional such as a master's level counselor.
45644175|NCT03804788|Behavioral|Sleep Hygeine|All participants will receive a one-page handout on sleep hygiene that includes personalized normative feedback on their alcohol use. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
45785126|NCT05677919|Procedure|Biospecimen Collection|Undergo collection of blood, tissue, stool, and saliva samples
45785127|NCT05677919|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
45785128|NCT05677919|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
45785129|NCT05677919|Procedure|Computed Tomography|Undergo CT scan
45917845|NCT00005852|Drug|methylprednisolone|
45644176|NCT03802604|Biological|Talimogene laherparepvec|Talimogene laherparepvec will be given via intra-tumoral injection at an initial dose of 10^6 PFU/mL. On week 3 (i.e. 21 days [± 2] days), a second talimogene laherparepvec injection will be administered at a dose of 10^8 PFU/mL. Third, fourth and fifth injections will be administered every 2 weeks (every 14 [± 2] days). The maximum volume for each injection will be 4.0 mL.
45644177|NCT03802604|Drug|Atezolizumab|Atezolizumab 840 mg will be administered by IV infusion on Day1 week 3, then every 2 weeks (every 14 [± 2] days), for a total of 4 treatment courses.
45644178|NCT03801876|Drug|Carboplatin|Given IV
45644179|NCT03801876|Procedure|Esophagectomy|Undergo esophagectomy
45644180|NCT03801876|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45644181|NCT03801876|Drug|Paclitaxel|Given IV
45644182|NCT03801876|Radiation|Proton Beam Radiation Therapy|Undergo PBT
45644183|NCT03801876|Other|Quality-of-Life Assessment|Ancillary studies
45644184|NCT03801876|Other|Questionnaire Administration|Ancillary studies
45785130|NCT05677919|Procedure|Magnetic Resonance Imaging|Undergo MRI scan
45785131|NCT05677919|Drug|Pirtobrutinib|Given PO
45785132|NCT05677919|Procedure|Positron Emission Tomography|Undergo PET scan
45785133|NCT05677919|Drug|Venetoclax|Given PO
45785134|NCT04810091|Drug|Placebo Administration|Given PO
45785135|NCT04810091|Other|Questionnaire Administration|Ancillary studies
45785136|NCT04810091|Drug|Telotristat Ethyl|Given PO
45785137|NCT00970814|Behavioral|BBCET|11 BBCET sessions
45785138|NCT00970814|Behavioral|BBCET|11 BBCET Sessions
45785139|NCT00970814|Drug|Levetiracetam XR|500mg - 2000mg Once per day 16 weeks
45785140|NCT00970814|Drug|Sugar Pill|500mg - 2000mg Once per day 16 weeks
45785141|NCT02486406|Drug|Ombitasvir/paritaprevir/ritonavir|Film-coated tablet for oral use
45785142|NCT02486406|Drug|Dasabuvir|Film-coated tablet for oral use
45785143|NCT02486406|Drug|Ribavirin|Film-coated tablet for oral use
45785144|NCT02486406|Drug|Ombitasvir mini tablet|Film-coated tablet for oral use
45917846|NCT00005852|Procedure|allogeneic bone marrow transplantation|
45917847|NCT00001071|Drug|Filgrastim|
45917848|NCT00005855|Drug|carmustine|
45917849|NCT00005855|Drug|efaproxiral|
45917850|NCT00001074|Drug|Hydroxyurea|
45917851|NCT00001074|Drug|Didanosine|
45917852|NCT00005858|Biological|LMB-9 immunotoxin|
45917853|NCT00001077|Dietary Supplement|Multivitamin and mineral supplements|Oral tablets taken daily
45917854|NCT00001077|Dietary Supplement|Peptamen|Solution received daily
45917855|NCT00001077|Dietary Supplement|NuBasics|Solution or dietary bar received daily
45917856|NCT00005861|Drug|pegylated liposomal doxorubicin hydrochloride|
45917857|NCT00001083|Drug|Indinavir sulfate|
45917858|NCT00001083|Drug|Ritonavir|
45917859|NCT00001083|Drug|Nevirapine|
45644185|NCT03801876|Drug|FOLFOX regimen|Folinic acid, flurouracil and oxaliplatin
45644186|NCT03801876|Drug|CAPOX regimen|Capecitabine combined with oxaliplatin
45785145|NCT02486406|Drug|Paritaprevir mini tablet|Film-coated tablet for oral use
45785146|NCT02486406|Drug|Ritonavir mini tablet|Film-coated tablet for oral use
45785147|NCT02486406|Drug|Dasabuvir mini tablet|Film-coated tablet for oral use
45785148|NCT02486406|Drug|Ribavirin solution|Oral solution
45785149|NCT00971282|Drug|adapalen 0.1%|"Intra-individual (split-face) comparison: Differin® 0.1% (whole face) will be applied once daily for 4 weeks.~Visits will be conducted weekly for a maximum of 5 visits."
45644187|NCT03801876|Drug|Docetaxel|Chemotherapy
45785150|NCT00971282|Other|Cetaphil®|"Intra-individual (split-face) comparison: Cetaphil® (only one side of the face) will be applied once daily for 4 weeks.~Visits will be conducted weekly for a maximum of 5 visits."
45644188|NCT03801876|Drug|5FU|Chemotherapy
45785151|NCT01688141|Other|Enhanced management|Specialist nurses providing enhanced CKD management using NICE guidelines and enhanced access to secondary care.
45785152|NCT03019250|Dietary Supplement|Colostrum|Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.
45785153|NCT03019250|Dietary Supplement|Maltodextrin|Maltodextrin mixed with water given via NG tube Q 4 hours.
45644189|NCT03801382|Device|IntelliSpace Cognition (ISC)|Philips ISC is a Class-II Medical Device in the US and provides objective data regarding cognition via scoring algorithms that HCPs can use to inform diagnostic decision making and treatment planning. It enables tracking cognition over time and offers the possibility of new outcome measures. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.
45644190|NCT03801382|Diagnostic Test|Paper-Pencil Tests|The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.
45644191|NCT03800680|Behavioral|Diabetes Management Package (DMP)|"M-POWER app: A one-stop portal to monitor diabetes self-management activities and progress. The app syncs and displays relevant data from study devices and apps.~GlycoLeap: A 24-week, digitally-delivered education and behavior change program for T2DM patients.~4 study devices with accompanying apps to aid in diabetes self-management: weighing scale, pedometer, glucometer, and pill tracker.~Recommended activities:~Complete all 24 GlycoLeap lessons and quizzes~Weight Monitoring: Weigh at least once a week.~Physical Activity: At least 150 minutes of moderate-to-vigorous activity per week, targeting at least 420 Fitbit active minutes per week.~Blood Glucose Monitoring: At least three post-meal measurements within 4.0-10.0 mmol/L per week, with each reading taken on different days.~Medication: Take medications as prescribed."
45644192|NCT03800680|Behavioral|M-POWER Rewards|A financial incentive program were participants can earn up to 516 M-Points (1 M-Point is equivalent to S$1) over the one-year study period for performing specific activities according to recommendations that are meant to improve glycemic control and for achieving HbA1c and weight loss goals. M-Points can be reimbursed in the form of financial rebates for approved non-inpatient healthcare-related expenses incurred during the study period.
45644193|NCT03795298|Device|WATCHMAN FLX Implant|Left atrial appendage closure with the WATCHMAN FLX device
45644194|NCT03795298|Drug|Market-approved OAC|Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
45644195|NCT03793361|Drug|Regorafenib|"Oral Drug in the form of 40 mg tablets - Regorafenib (120 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.~Provided by BAYER"
45785154|NCT03019172|Combination Product|Lactobacillus reuteri|Sachet one contains a total of 5*10^8 CFU of Lactobacillus reuteri DSM 16666 & Lactobacillus reuteri DSM 17938, mixed with maltodextrin for flowability during production. Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica. The products will be taken twice per day, morning and evening. The daily dose in the active group will be at least 5*10^8 CFU of L.reuteri DSM16666 and L. reuteri DSM17938), PAC-A and zinc
45785155|NCT03019172|Dietary Supplement|Sachet with cranberry + placebo|Sachet one contains placebo for probiotics (maltodextrin). Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica.
45785156|NCT02247245|Drug|Ivabradine|Ivabradine 7.5mg
45785157|NCT02247245|Other|Atrial fibrillation|Pacemaker base rate alteration
45785158|NCT02247245|Drug|Placebo|Placebo
45644196|NCT03793361|Drug|Placebo|"Oral tablets - Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression~Provided by BAYER"
45917860|NCT00001083|Drug|Lamivudine|
45785159|NCT02485704|Drug|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
45785160|NCT02485704|Other|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
45785161|NCT03019016|Procedure|Right Colectomy|Robotic-assisted or laparoscopic right colectomy with intracorporeal or extracorporeal anastomosis either on or proximal to midtransverse colon.
45785162|NCT01688609|Drug|lapatinib ditosylate|Given PO
45785163|NCT01688609|Drug|paclitaxel|Given IV
45785164|NCT01688609|Biological|trastuzumab|Given IV
45785165|NCT01688609|Procedure|therapeutic conventional surgery|Undergo lumpectomy or mastectomy
45785166|NCT01688609|Other|pharmacological study|Correlative studies
45785167|NCT01688609|Other|laboratory biomarker analysis|Correlative studies
45785168|NCT02485158|Drug|THC|This is a within-subjects, double-blind, placebo controlled design. We administered oral THC to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
45917861|NCT00001083|Drug|Stavudine|
45917862|NCT00001083|Drug|Zidovudine|
45917863|NCT00005864|Drug|chloroquinoxaline sulfonamide|
45917864|NCT00001086|Drug|Indinavir sulfate|
45917865|NCT00001086|Drug|Abacavir sulfate|
45785169|NCT02485158|Drug|AMP|This is a within-subjects, double-blind, placebo controlled design. We administered AMP to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
45785170|NCT02485158|Drug|ALC|This is a within-subjects, double-blind, placebo controlled design. We administered alcohol to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
45785171|NCT02485158|Drug|Placebo capsules|This is a within-subjects, double-blind, placebo controlled design. We administered size 00 gelatin capsules containing dextrose to healthy volunteers as a control for when they received either amphetamine or THC.
45785172|NCT02485158|Drug|Placebo beverage|This is a within-subjects, double-blind, placebo controlled design. We administered a drink containing cranberry juice plus 1% alcohol added as a taste mask.
45785173|NCT01688843|Device|INGEVITY lead|
45785174|NCT02455518|Drug|Oxycodone/acetaminophen|
45917866|NCT00001086|Drug|Efavirenz|
45785175|NCT02455518|Drug|Hydrocodone/acetaminophen|
45785176|NCT02455518|Drug|Codeine/acetaminophen|
45785177|NCT02455518|Drug|Ibuprofen/acetaminophen|
45785178|NCT05643911|Procedure|HFNC|In the HFNC group, patients will receive HFNC oxygen therapy for 20 minutes.
45785179|NCT05643911|Procedure|NIV|Patients will receive NIV for 20 minutes delivered with a naso-buccal or face mask according to the patient's tolerance.
45785180|NCT00972374|Drug|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
45785181|NCT00972374|Drug|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
45785182|NCT00972374|Other|Sham (no implant)|Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.
45785183|NCT01689155|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
45785184|NCT00972530|Behavioral|immobilisation in a triangular sling|"Intervention group: Immobilisation 48 hours in a triangular sling (mitella)~Control group: normal activity without restrictions"
45785185|NCT05394272|Other|Energy Therapy - Pranic Healing|Energy therapy - Non invasive non touch and non pharmacological - 100% natural complementary therapy
45917867|NCT00700258|Drug|Temsirolimus|Non-interventional study. Treatment decision already made before inclusion into the registry.
45785186|NCT01689701|Dietary Supplement|Hizikia Fusiformis extract|Hizikia Fusiformis extract(1.3g/d)
45917868|NCT00700258|Drug|Temsirolimus|Non-interventional study. Treatment decision already made before inclusion into the registry.
45917869|NCT00700258|Drug|Sunitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
45785187|NCT01689701|Dietary Supplement|Placebo|Placebo(1.3g/d)
45785188|NCT03019094|Device|The RENOVA tibial nerve stimulation system|Study participants will be implanted with the RENOVA tibial nerve stimulation system
45785189|NCT04675541|Biological|Afstyla®|Solution for injection
45785190|NCT03018626|Drug|Rituximab|rituximab (375 mg/m2) given intravenously (IV) on day 0
45785191|NCT03018626|Drug|Etoposide|Etoposide(50 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
45785192|NCT03018626|Drug|Doxorubicin|Doxorubicin(10 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
45785193|NCT03018626|Drug|Vincristine|Vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
45917870|NCT00700258|Drug|Sunitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
45917871|NCT00700258|Drug|Axitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
45644205|NCT03786406|Other|No treatment given|No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
45644206|NCT03785873|Drug|Nivolumab|Intravenous (IV) infusion
45644207|NCT03785873|Drug|Nanoliposomal-Irinotecan|Intravenous (IV) infusion
45644208|NCT03785873|Drug|5-Fluorouracil|Intravenous (IV) infusion
45644209|NCT03785873|Drug|Leucovorin|Intravenous (IV) infusion
45644210|NCT03784677|Drug|TRPV6 Calcium Channel Inhibitor SOR-C13|Given IV
45644211|NCT03783546|Device|Acupuncture|Acupuncture is a complementary therapy in which, hair-thin, sterile disposable needles are inserted into various spots on your skin, with the goal of affecting body's natural healing system
45785194|NCT03018626|Drug|Cyclophosphamide|Cyclophosphamide(750 mg/m2)/dayg IV on days 5
45785195|NCT03018626|Drug|Prednisone|prednisone (100 mg) given orally bid on days 1 through to 5.
45785196|NCT03018626|Drug|Doxorubicin|Doxorubicin (75 mg/m2) given intravenously (IV) on day 1,
45785197|NCT03018626|Drug|Cyclophosphamide|Cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1,
45785198|NCT03018626|Drug|Vindesine|Vindesine (2 mg/m2) given on days 1 and 5
45785199|NCT03018626|Drug|Bleomycin|Bleomycin (10 mg) given IV on days 1 and 5
45785200|NCT05394038|Other|None，observational study.|observational study
45785201|NCT01689779|Drug|100,000 IU cholecalciferol|active drug
45785202|NCT01689779|Drug|Placebo|comparator drug
45785203|NCT05388500|Drug|Paclitaxel + Trastuzumab|"Regarding neoadjuvant treatment :~- 9 to 12 weeks of neoadjuvant treatment Trastuzumab IV (8mg/kg loading dose followed by 6 mg/kg maintenance dose) or SubCutaneous (SC) (600mg fixed dose) every 3 weeks + weekly Paclitaxel IV : 80 to 90 mg/m2~Regarding adjuvant treatment patients will receive one of the following anti-HER2 therapy following the current standard to complete 1 year of anti-HER2 therapy in total :~in case of pCR : patient will receive trastuzumab~in case of non pCR : patients will receive trastuzumab emtansine (T-DM1)"
45785204|NCT05388500|Drug|Trastuzumab|"Regarding neoadjuvant treatment :~- 9 to 12 weeks of neoadjuvant treatment Trastuzumab IV (8mg/kg loading dose followed by 6 mg/kg maintenance dose) or SC (600mg fixed dose) every 3 weeks~Regarding adjuvant treatment patients will receive one of the following anti-HER2 therapy following the current standard to complete 1 year of anti-HER2 therapy in total :~in case of pCR : patient will receive trastuzumab~in case of non pCR : patients will receive trastuzumab emtansine (T-DM1)"
45917872|NCT00001113|Drug|Interferon alfa-2a|
45917873|NCT00001113|Drug|Zidovudine|
45785205|NCT05387174|Behavioral|: Nursing intervention in two risk factors of the Metabolic Syndrome, abdominal obesity and arterial hypertension and quality of life in the climacteric period.|Nursing intervention with technological support (Metamorphosis) in two risk factors of Metabolic Syndrome, abdominal obesity and hypertension and quality of life in the climacteric period, developed in 3 months, in the experimental group that includes individual nursing counseling, group education virtually and physical activity sessions for 12 weeks virtually.
45785206|NCT01691027|Behavioral|Visuo-motor training|Participants will undergo training on three developed software modules on Samsung Galaxy Note Pro tablets to see their effect on low vision rehabilitation
45785207|NCT05616533|Other|biopsy of tumor before treatment|samples obtained from biopsy will be used in the zebrafish PDX model
45785208|NCT02159768|Device|Airtraq visualization|Larynx visualization with Airtraq and attached handphone
45785209|NCT03212885|Device|Deep Brain Stimulation|Electrode that provides electrical stimulation to deep brain structures for relief of Parkinson's Disease symptoms.
45644212|NCT03783546|Other|Usual Care|the current standard of care with non-hormonal pharmacotherapy of western medicine
45644213|NCT03783507|Behavioral|Order 1|"Meal Order 1:~Meal Session 1 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 2 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 3 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 4 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED)"
45644214|NCT03783507|Behavioral|Order 2|"Meal Order 2:~Meal Session 1 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 2 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 3 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 4 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED)"
45644215|NCT03783507|Behavioral|Order 3|"Meal Order 3:~Meal Session 1 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 2 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 3 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 4 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED)"
45644216|NCT03783507|Behavioral|Order 4|"Meal Order 4:~Meal Session 1 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 2 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 3 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 4 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED)"
45785210|NCT00974246|Drug|Advair diskus|Advair diskus 50/250 1 inhalation bid for 16 weeks
45785211|NCT05572073|Other|Natural History Study|Natural History Study
45785212|NCT00974480|Other|Redermic|Cosmetic cream formulation 609637 43.
45785213|NCT00974480|Drug|Tretinoin (Rejuva-A)|Tretinoin 0.025% cream.
45785214|NCT04632641|Device|Perclose ProGlide Suture-Mediated Closure System (SMC) - LARGE-BORE PROCEDURES|The Perclose ProGlide Suture-Mediated Closure System (SMC) will be used to close the vein access site(s) at the completion of the large-bore procedure in order to achieve hemostasis.
45785215|NCT04632641|Other|Figure 8 Suture - LARGE-BORE PROCEDURES|A figure 8 suture will be done as a closure strategy in order to achieve hemostasis in large-bore procedures.
45785216|NCT04538261|Device|Fetal Pillow insertion|Inflation of balloon device used to elevate fetal buttocks prior to performing external cephalic version procedure
45785217|NCT02244983|Other|Patients History|History taking and drawing of a blood sample
45785218|NCT00975650|Drug|Nasobol®|Intra-nasal Testosterone (2 syringes), b.i.d.
45785219|NCT00975650|Drug|Androderm® (Positive Control)|QD administration
45917874|NCT00001113|Drug|Interferon alfa-n1|
45917875|NCT00005867|Biological|bleomycin sulfate|
45449103|NCT01078727|Device|A custom-made constant temperature thermal stimulation system (FIRSTEK, Model-B401L, B-300, local company, Taiwan).|The subjects meeting our criteria will be randomly assigned to either the experimental group or the control group. First stage (3 months after onset), the subjects in the experimental group will receive an upper extremity Thermal Stimulation (TS) protocol for 30 minutes (3 times a week for 8 weeks). The subjects in the control group will receive a lower extremity TS protocol.
45449104|NCT05665491|Behavioral|HabitWorks|Smartphone app-delivered interpretation bias intervention
45449105|NCT05665491|Behavioral|Self-Assessment|Self-assessment of parenting behaviors and anxiety symptoms
45644217|NCT03783195|Other|Sugar drink|A sugar drink made with 1.2 g/kg body weight of added sugar( 0.75g/kg body weight of fructose + 0.45g/kg body weight of glucose) and 24oz water
45785220|NCT02249429|Drug|bimiralisib|60 mg or 80 mg bimiralisib per oral (p.o.) once daily or intermittent dosing (120mg,140mg and 160mg) until unacceptable AE, disease progression, patient's request for withdrawal, investigator judgement or death - whichever comes first.
45785221|NCT02245958|Other|No Intervention|No treatment (intervention) was administered.
45785222|NCT02249507|Other|aerobic exercise|aerobic exercise (cycloergometer) at selected intensity (HRmax or equivalent)
45785223|NCT03032627|Procedure|Collection of discarded heart tissue|Discarded heart tissue will be collected from patients undergoing the aforementioned cardiac surgeries.
45785224|NCT04474379|Behavioral|Strategy Training (Time- and Event- Based)|In time-based training, strategic clock-checking behavior is taught by requiring participants to click a button to reveal the virtual time of day. Event-based training involves implementation intention methods.
45917876|NCT00005867|Drug|CHOP regimen|
45917877|NCT00005867|Drug|cyclophosphamide|
45917878|NCT00005867|Drug|doxorubicin hydrochloride|
45917879|NCT00005867|Drug|etoposide|
45917880|NCT00005867|Drug|mitoxantrone hydrochloride|
45917881|NCT00005867|Drug|prednisolone|
45917882|NCT00005867|Drug|vincristine sulfate|
45785225|NCT00976352|Drug|rAAV1-CMV-GAA (study agent) Administration|rAAV1-CMV-GAA via intramuscular injection into the diaphragm. Dose selection for cohort 1: 1.0 x 10e12 vector genomes Cohort 1 will have a total of 3 participants enrolled. Dose selection for cohort 2 and 3: 5.0 x 10e12 vector genomes rAAV1-CMV-GAA. Cohort 2 = 6 subjects.
45785226|NCT00976352|Other|RMST|After enrollment and screening visit, the subject will be given a RMST prescription and will complete RMST for a minimum of 4 weeks prior to study agent administration. RMST prescription will be adjusted as needed at Day 14, 90, 180, and 270.
45785227|NCT03018782|Other|Brief Pain Inventory Short Form|Brief Pain Inventory Short Form
45785228|NCT00976664|Device|Shoe orthotic|Shoe orthotics are devices worn in the shoe to modify the patient's stance and gait.
45785229|NCT00976664|Device|Shoe Orthotic Wait Group|This group receives the custom-made shoe orthotics at week 6 of the 12 week treatment program rather than week 1.
45785230|NCT05362448|Device|Frequency|First, we will calculate for each patient and each frequency the amplitude therapeutic window (difference between therapeutic and side effect threshold). We will determine an optimal amplitude for each frequency that we will apply in the second part of the study.
45785231|NCT03018470|Other|Analysis of data from NIV built-in software|Analysis of breathing pattern using data obtained from NIV built-in software
45785232|NCT05336552|Other|Validated questionnaire : Social Phobia Inventory ( SPIN ) questionnaire|Social Phobia Inventory ( SPIN ) questionnaire which is consisted of 17 items. . The answers of each item ranged from 0 ( Not at all ) to 4 ( Extremely ). The total score will be calculated to determine the severity of the problem .
45785233|NCT03018548|Other|blood draw|subjects will have blood drawn done. This blood will then be exposed to blasting with CO2 cartridge
45785234|NCT03018158|Device|denture wear.|MR Imaging was collected with or without denture wear.
45785235|NCT03830294|Other|different temperature-controlled breast prostheses|Two types of temperature-controlled breast prostheses were applied to patients in each group
45785236|NCT00979940|Drug|Atorvastatin|Atorvastatin 80mg po given one time before PCI in cath lab.
45785237|NCT04353518|Drug|Suspension of heat killed (autoclaved) Mycobacterium w|Subjects randomized to Test arm will receive intraderma Mw in divided doses at least 2 cm away from first injection site in the deltoid region.
45785238|NCT04353518|Other|Placebo|Subjects randomized to placebo arm will receive intraderma Placebo in divided doses at least 2 cm away from first injection site in the deltoid region.
45785239|NCT00980642|Device|Draeger double-sensor|The sensor will be attached to the patient's forehead with adhesive tape, and a small amount of contact gel will be applied between sensor and skin.
45785240|NCT00980642|Device|Esophageal stethoscope temperature sensor|Esophageal temperature is measured by sensors incorporated into an esophageal stethoscope during the surgery.
45785241|NCT00980642|Device|Foley catheter temperature sensor|Urinary bladder temperature is measured via a sensor incorporated into a Foley catheter during the surgery
45785242|NCT04353908|Procedure|Rehabilitation|The Kabat procedure consists of facilitating the voluntary response of an impaired muscle through a global pattern of an entire muscular section which undergoes resistance. This method considers that harmony, coordination and optimal strength of body movements mainly depend upon the fact that they are performed following diagonal lines with respect to the sagittal axis of the body, thus implying a 'rotational' effect. It will performed twice a week for 8 weeks
45917883|NCT00584233|Device|computed tomography|Computed tomography of both breasts. For all subjects, CT scanning will be performed before and after an I.V. iodinated contrast injection (100 mL).
46070921|NCT00826813|Device|Esophageal stent placement|The esophageal stent combined a self-expandable covered esophageal stent and 125I radioactive seeds. Sheathes were attached to the outer surface of the stent, containing 125I radioactive seeds of CIAE 6711. The seeds were loaded into the sheathes on the stent immediately before implantation of the stent. The numbers and dose of the radioactive stent seeds was determined by the treatment plan system based on the size of the individual tumor. To cover the entire lesion of the tumor by the sheaths containing 125I seeds, at least 2 cm exceeding the tumor margins was required. The distance between the two sheaths was 15mm. In the control group, conventional covered esophageal stents were used which provided by the same company as those attached with 125I seeds.
45644218|NCT03782337|Behavioral|multi-discipline disease management program|The multi-discipline disease management program consists of nursing lead education program, dietitian consultation, psychologist consultation and assessment, and cardiac rehabilitation program by physical therapist.The cardiovascular lead nurse will contact the patient by telephone within 3 days after discharge. An appointment at the outpatient clinic will be arranged within 1 to 2 weeks after discharge. The purposes of the telephone call are to reinforce self-management and recognition of HF symptoms and to screen post-discharge health status.
45644219|NCT03782064|Drug|Nivolumab|Nivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells.
45449106|NCT02768194|Device|Stannous fluoride|Dentifrice containing 0.454% stannous fluoride
45449107|NCT02768194|Other|Sodium monofluorophosphate|Dentifrice containing 0.76% sodium monofluorophosphate
45449108|NCT02768194|Other|Mineral water|Commercially available mineral water
45644220|NCT03782064|Biological|DC/myeloma fusions/GM-CSF|The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.
45917884|NCT00584233|Device|MRI|Breast MRI
45917885|NCT00001116|Drug|Tumor Necrosis Factor soluble receptor-immunoadhesin complex|
45917886|NCT00556972|Device|Fecal Incontinence Management System|The device is intended to remedy fecal incontinence.
45917887|NCT00005870|Drug|fluorouracil|
45917888|NCT00005870|Drug|gemcitabine hydrochloride|
45917889|NCT00005870|Drug|mitomycin C|
45917890|NCT00005870|Drug|rubitecan|
45917891|NCT00017407|Biological|ISIS 3521|
45917892|NCT00017407|Drug|carboplatin|
45917893|NCT00017407|Drug|paclitaxel|
45917894|NCT00008866|Biological|Tetanus Toxoid Vaccine|
45917895|NCT00008866|Drug|Hydroxyurea|
45917896|NCT00008866|Drug|Didanosine|
45785243|NCT04353908|Procedure|Collagen Injection|With an insulin-type syringe and 30-gauge needle, a bolus of about 0.4 cc per point of the collagen solution will be injected in the orbicularis oculi muscle 1 cm outside the orbital rim and 0.5 cm superior and inferior to the first injection point, respectively, and in the orbicularis oris muscle, where the 2 injection points are on the border between the pars peripheralis and pars marginalis, located about 5 mm above the superior and inferior vermilion, respectively
45785244|NCT03018314|Other|Blood sample|Serum analysis
45785245|NCT00981812|Procedure|PEM Breast Biopsy|Breast biopsy using PEM guidance and Stereo Navigator software
45785246|NCT05160038|Device|Embodied virtual reality|An immersive headmounted display visually depicts a relaxing woods scene, coupled with a virtual avatar that either shows bodily illusions or no bodily illusions
45785247|NCT05129618|Dietary Supplement|MHS 1031|prebiotic syrup in individual sachets containing 1g (1.4 ml) of panosyl-isomaltooligosaccharides
45785248|NCT05129618|Other|placebo|liquid combination formulation of Neotame 7.92 mcg/g, phosphoric acid, and sterile water, designed to have the same degree of sweetness as the test material, provided in individual sachets containing 1.4 ml.
45785249|NCT05127512|Other|Education Video|A 6.47-minute education video was created by the research group based on American Urogynecology Society (AUGS) and International Urogynecologic Association (IUGA) patient education pamphlets. Participants in the intervention group will be asked to watch this video after completing a baseline knowledge questionnaire of pelvic floor disorders.
45785250|NCT03016364|Device|APP software|A software used to by physicians to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain
45785251|NCT03018002|Other|iSTAR|"Each component of the iSTAR intervention targets a specific point along the HIV continuum: confidential, onsite integrated laboratory tests during baby showers targets HIV diagnosis (b) church-based Health Advisors (CHAs) trained in motivational interviewing and quality improvement skills as promotoras target linkage, engagement and adherence by providing counseling and other support to HIV-infected women and children (c) integrated network of community and clinic case management targets reduction in loss to follow-up.~CHAs will support participants during the study period by being available to accompany them to clinic visits, review laboratory results and medications after clinic visits. They will be available to speak with them at intervals to see how they are doing either by phone or through home visits as they prefer. At each follow-up study visit, the trained CHA will review and collect data on participants' clinic visits, treatment, and laboratory results."
45785252|NCT03018236|Drug|Alcohol N-acetylcysteine|1200 mg of NAC per day, taken in two doses, for subjects with alcohol use disorder
45785253|NCT03018236|Drug|Alcohol Placebo|Flour pills looking exactly the same as the active compound, for subjects with alcohol use disorder
45785254|NCT03018236|Drug|Cocaine N-acetylcysteine|1200 mg of NAC per day, taken in two doses, for subjects with cocaine use disorder
45785255|NCT03018236|Drug|Cocaine Placebo|Flour pills looking exactly the same as the active compound, for subjects with cocaine use disorder
45785256|NCT05096546|Other|No intervention|No intervention will be applied for the observational study.
45785257|NCT05084066|Other|Repeated remote ischemic preconditioning|"An automated device performs four 5-minute episodes of upper limb ischemia in which the cuff pressure in the experimental group remains at 200 mmHg for 5 minutes, causing and ensuring ischemia. Ischemic episodes alternate with 5-minute reperfusion. The intervention lasts a total of 35 minutes. The participant places the device on his upper arm and presses the Start button, starting the intervention. The intervention takes place at rest in the patient's home environment daily for 28 days. During the first visit to the research center, the research assistant teaches the participant how to use the device. The device measures the patient's blood pressure at the start of the intervention. If the patient's blood pressure is above 200 mmHg, the device will not perform the intervention."
45785258|NCT05084066|Other|Simulation of repeated remote ischemic preconditioning (sham)|The automated device simulates the intervention of the experimental group with the difference that the device does not apply pressure to the upper limb and, therefore, no ischemia occurs.
45785259|NCT05061602|Diagnostic Test|Evaluation of biomechanics and viscoelastic properties of plantar fascia|The biomechanical and viscoelastic properties of the plantar fascia will be measured with the MyotonPRO device.
45785260|NCT02873195|Drug|Atezolizumab|Given IV
45785261|NCT02873195|Biological|Bevacizumab|Given IV
45785262|NCT02873195|Drug|Capecitabine|Given PO
45449109|NCT01582919|Other|Neuroimaging|
45917897|NCT00001119|Biological|Tetanus Toxoid Vaccine|
45449110|NCT03732183|Behavioral|Podcast SMART-3RP|28 daily podcasts, each 15 minutes.
45644234|NCT03773471|Behavioral|Mobile Health App|ArthritisPower App
45644235|NCT03772522|Behavioral|dk Leadership|Participants will attend two full-day workshops and four half-day group coaching sessions over the course of six weeks. The workshops and coaching sessions will be supplemented by on-line (e.g., podcasts) and print (e.g., workbooks) material. The full-day workshops will focus on identity-enhancing topics such as self-understanding, creating a life of meaning and purpose, and strategic career development. The half-day group coaching sessions will focus on workshop debriefing and on exploring solutions to transition-related challenges faced by study participants. The program was designed and carried out by dk Leadership - an established leadership and executive coaching centre in Toronto, Canada.
45785263|NCT02873195|Other|Laboratory Biomarker Analysis|Correlative studies
45785264|NCT02873195|Other|Placebo|Given IV
45785265|NCT02248103|Procedure|Periosteal pedicle graft|Autogenous pedicle graft harvested from the periosteum
45785266|NCT02248103|Biological|Bioresorbable collagen membrane|Biocollagen is a thin equine Achilles tendon collagen barrier membrane used for guided tissue regeneration
45785267|NCT02242019|Device|Erchonia LUNULA|The Erchonia LUNULA is administered to the infected toes for 12 minutes per treatment for 4 treatments, each treatment one week apart.
45785268|NCT02817659|Drug|Glucagon|Glucagon infusion
45917898|NCT00001119|Drug|Indinavir sulfate|
45917899|NCT00001119|Drug|Lamivudine/Zidovudine|
45917900|NCT00001119|Drug|Ritonavir|
45917901|NCT00001119|Drug|Abacavir sulfate|
45917902|NCT00001119|Drug|Amprenavir|
45917903|NCT00001119|Drug|Efavirenz|
45917904|NCT00001119|Biological|Hepatitis B Vaccine (Recombinant)|
45917905|NCT00001119|Drug|Lamivudine|
45917906|NCT00001119|Drug|Zidovudine|
45785269|NCT04431323|Behavioral|ESPRIMO|"Participants will receive the intervention during Phase 2.~The intervention is based on the cognitive behavioral, the third-wave (mindfulness and acceptance and commitment therapy), and the positive psychology approach.~The frequency of the intervention and the specific content and aims of the psychological and physical intervention will be based on the results of the surveys and the focus group discussion (Pre-phase and Phase 1). In order to maximize the benefit of the integrated intervention, all the three components of the interventions (i.e., psychological, motor exercise and social components) will be administered in the same time period.~A preliminary theoretical framework of the intervention will be created prior to the survey phase according to the literature in the field. Specific aspects of this preliminary framework will be discussed during the co-creation phase and adapted after the analysis of the qualitative results."
45785270|NCT02659241|Drug|Adavosertib|Given PO
45785271|NCT02659241|Other|Laboratory Biomarker Analysis|Correlative studies
45785272|NCT04337177|Drug|VAL-413|a flavored preparation of orally administered irinotecan
45785273|NCT04337177|Drug|Temozolomide|alkylating oral chemotherapy agent used to treatment brain cancers
45785274|NCT05532683|Behavioral|Health Behaviors Group|The proposed intervention will include eight modules across nine weekly group sessions targeting psychoeducation of CHR-P symptoms, goal setting, physical activity, sleep, substance use, nutrition, and evidence-based strategies for stress management. Intervention facilitators will utilize motivational interviewing (MI; Miller & Rollnick, 2012) strategies to engage youth in goal setting to target change in health promotion behaviors. Caregivers will be invited to join at the end of each session for a 10-minute check-out where an outline of content covered and patient goals for the week will be shared.
45785275|NCT02563145|Behavioral|Real-time fMRI feedback|feedback about activation patterns in brain regions related with instrumental aggression
45785276|NCT02563145|Behavioral|Treatment as usual|Psychoeducation, general counselling
45785277|NCT00982592|Drug|oxaliplatin|Given IV
45785278|NCT00982592|Drug|leucovorin calcium|Given IV
45785279|NCT00982592|Drug|fluorouracil|Given IV
45785280|NCT00982592|Other|placebo|Given PO
45785281|NCT00982592|Drug|vismodegib|Given PO
45785282|NCT00982592|Other|laboratory biomarker analysis|Correlative studies
45785283|NCT00983216|Drug|Colchicine|A single dose of colchicine 0.6 mg administered alone at 7:30 a.m. on Day 1.
45917907|NCT00009061|Drug|Ritonavir|
45917908|NCT00009061|Drug|Abacavir sulfate|
45917909|NCT00009061|Drug|Nelfinavir mesylate|
45917910|NCT00009061|Drug|Lamivudine|
45644236|NCT03766126|Biological|CART123 cells; cyclophosphamide; fludarabine|"CART123 cells following lymphodepleting chemotherapy in patients with relapsed/refractory AML. Subjects will be treated with a split dosing approach of CART123 cells (10% Day 0; 30% Day 1; 60% Day 2) for Cohort 1a/1b or a single IV administration of CART123 cells for Cohort 2.~The total dose administered to each subject will be based on body weight obtained at the time of apheresis. Thus, the target total transduced dose, preceded by lymphodepleting chemotherapy, is 1-2x10^6 CART123 cells/kg for Cohort 1a, 5x10^6 CART123 cells/kg for Cohort 1b, or 2x10^6 CART-123 cells/kg for Cohort 2. The protocol-specified minimum acceptable dose for infusion is 1x10^5 CART123 cells/kg."
45644237|NCT03764488|Drug|Tofersen|Administered as specified in the treatment arm.
45644238|NCT03764488|Drug|99mTc-MAG3-BIIB067|Administered as specified in the treatment arm.
45785284|NCT00983216|Drug|Ketoconazole|one 200 mg Ketoconazole tablet administered twice daily at 7:15 a.m. and 7:15 p.m. on Days 15-18 without regard to meals, then along with colchicine at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 200 mg administered at 7:15 p.m. on Day 19
45785285|NCT00983216|Drug|Colchicine|A single dose of colchicine 0.6 mg administered along with ketoconazole at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours
45785286|NCT01788020|Drug|Dexamethasone, Rituximab, Cyclophosphamide|
45785287|NCT01788020|Drug|Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib|
45785288|NCT02435849|Biological|CTL019|Tisagenlecleucel was administered as a single iv infusion. Dose: 2.0 to 5.0x10^6 tisagenlecleucel per kg body weight (for patients ≤ 50 kg) or 1.0 to 2.5x10^8 tisagenlecleucel (for patients >50 kg).
45785289|NCT00984308|Procedure|CPAP Therapy for Newly Diagnosed Obstructive Sleep Apnea (OSA)|Continuous Positive Airway Pressure (CPAP) is provided for those patients who are diagnosed with OSA.
45785290|NCT02249585|Device|Standard abdominal pressure|Abdominal pressure maintained 12mmHg throughout laparoscopic colon surgery
45785291|NCT02249585|Device|Low abdominal pressure|Abdominal pressure maintained 8mmHg throughout laparoscopic colon surgery
45917911|NCT00009061|Drug|GW433908|
45917912|NCT00005873|Drug|rubitecan|
45917913|NCT00009178|Drug|Fluoxetine|
45917914|NCT00009178|Behavioral|Guided Self-Help|
45785292|NCT02249585|Drug|Conventional neuromuscular blockade|Anesthesia induction with rocuronium 0.4mg/kg and maintenance with rocuronium 0.15mg/kg to maintain TOF 1-2 twitch
45785293|NCT02249585|Drug|Deep neuromuscular blockade|Anesthesia induction with rocuronium 0.8mg/kg → maintenance with rocuronium 0.3mg/kg to maintain PTC 1-2 twitch
45785294|NCT00984698|Behavioral|Cognitive Behavioral Social Rhythm Group Therapy|12 weeks, 2h structured group therapy
45785295|NCT00984698|Behavioral|Present Centered Group Therapy|12 weeks, 2h relatively unstructured group therapy
45785296|NCT05478863|Drug|Oral Placebo|Placebo will be orally self-administered by study participants.
45917915|NCT00009217|Drug|Haloperidol-Haloperidol|Haloperidol open label flexible dose 1-5 mg daily for 20 weeks followed by haloperidol double-blind 1-5 mg for 24 weeks
45917916|NCT00009217|Drug|Haloperidol-Placebo|Haloperidol open-label flexible dose of 1-5 mg for 20 weeks followed by placebo double-blind for 24 weeks
45917917|NCT00005876|Drug|rubitecan|
45917918|NCT00001146|Drug|Ethyl Eicosapentaenoic Acid|
45917919|NCT00001146|Drug|OmegaBrite|
45917920|NCT00009646|Drug|indomethacin|Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa
45917921|NCT00009646|Drug|Indomethacin|0.1 mg per kilogram of body weight
45917922|NCT00009646|Drug|Placebo|0.1 mg per kilogram of body weight
45917923|NCT00009685|Drug|VRC4302|
45785297|NCT05478863|Drug|Oral THC|THC will be orally self-administered by study participants.
45785298|NCT05478863|Drug|Oral CBD|CBD will be orally self-administered by study participants.
45785299|NCT05478863|Drug|Oral Caffeine|Caffeine will be orally self-administered by study participants.
45785300|NCT03016520|Drug|DWJ1392|
45785301|NCT03016520|Drug|DWC20164|
45644239|NCT03764293|Drug|SHR-1210|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
45785302|NCT02240069|Behavioral|Education (Tx1)|Education on best burn practices
45785303|NCT02240069|Device|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (3M, St. Paul, MN) will be placed in the same room as the wood stove"
45917924|NCT00005888|Behavioral|Fortified Pasteurized Donor Human Milk supplement|
45917925|NCT00005888|Behavioral|Preterm Formula supplement|
45917926|NCT00009763|Biological|filgrastim|
45917927|NCT00009763|Biological|monoclonal antibody m170|
45917928|NCT00009763|Drug|cyclosporine|
45644240|NCT03764293|Drug|Apatinib|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet
45644241|NCT03764293|Drug|Sorafenib|Subjects receive Sorafenib orally, Dosage form: tablet, Strength: 0.2 g/tablet
45644242|NCT03763708|Device|Spinal Cord Stimulation|Programming
45644243|NCT03763643|Drug|Rituximab|Rituximab 375mg/m2 intravenous on day 0 or -1 prior to kidney transplant
45644244|NCT03763643|Procedure|Plasmapheresis|1.5 volume exchange plasmapheresis with fresh frozen plasma replacement
45644245|NCT03761160|Other|Mobile Health App|mobile health app aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habit
45644246|NCT03761160|Other|Usual care|Usual care per hospital guidelines
45785304|NCT02240069|Device|Placebo Intervention (Tx3)|"A 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
45917929|NCT00009763|Drug|paclitaxel|
45917930|NCT00009763|Procedure|peripheral blood stem cell transplantation|
45917931|NCT00009763|Radiation|yttrium Y 90 monoclonal antibody m170|
45917932|NCT00009802|Dietary Supplement|calcitriol|
45917933|NCT00009802|Drug|paclitaxel|
45644247|NCT03761095|Drug|Unesbulin|Unesbulin will be administered as per the dose and schedule specified in the arm.
45644248|NCT03761095|Drug|Dacarbazine|Dacarbazine will be administered as per the dose and schedule specified in the arm.
45785305|NCT04352972|Device|Tele-monitored home exercise program|Tele-monitoring home exercise program used in the home with monitoring by physiotherapists.
45785306|NCT04352972|Other|Hospital-based rehabilitation program|Participants will receive a maximum of 8 sessions over 10 weeks with the option of two additional sessions. Participants will receive exercises, patient education, manual therapy and other modalities that were prescribed and progressed at the project physiotherapist's discretion. Participants will also receive a set of home exercises and they will be instructed to exercise on days when not attending rehabilitation.
45785307|NCT01774487|Drug|Pentoxifylline|20 mg/kg/day divided in 3 doses, given orally for 90 days
45785308|NCT01023074|Behavioral|Auditory training|the study was originally set up so that half of the MS subjects would received auditory training. This intervention has since been discontinued.
45785309|NCT01023074|Other|MS: Control Activity|MS group not receiving auditory training, doing control activity
45644249|NCT03759379|Drug|Patisiran|Patisiran will be administered by IV infusion.
45644250|NCT03759379|Drug|Vutrisiran|Vutrisiran will be administered by SC injection.
45644251|NCT03755518|Drug|FEDRATINIB|A potent and selective inhibitor of JAK2 kinase activity
45644252|NCT03755414|Procedure|Stem cell transplantation|Standard of care
45644253|NCT03755414|Drug|Itacitinib|Itacitinib may be taken without regard to food.
45785310|NCT04409600|Behavioral|Supervised Gait Retraining|The participants allocated to this group will attend 8 sessions during the course of 6 weeks in the clinic with a trained medical professional to complete a supervised gait retraining program.
45785311|NCT04409600|Behavioral|Home Based Gait Retraining|The participants allocated to this group will have 1 session in the clinic with a trained medical professional and be given a gait retraining program to complete at home.
45785312|NCT04409600|Drug|Saline Injection|The participant will receive a saline injection to their painful lower leg compartment(s).
45785313|NCT04409600|Drug|Botulinum Toxin Injection|The participant will receive a botulinum toxin injection to their painful lower leg compartment(s).
45917934|NCT00009841|Biological|EGFR antisense DNA|
45917935|NCT00009841|Biological|growth factor antagonist therapy|
45917936|NCT00009841|Drug|DC-cholesterol liposome|
45917937|NCT00005891|Drug|cyclophosphamide|
45917938|NCT00005891|Procedure|Allogeneic Bone Marrow Transplantation|
45917939|NCT00009880|Biological|filgrastim|
45917940|NCT00009880|Drug|cisplatin|
45917941|NCT00009880|Drug|fluorouracil|
45917942|NCT00009880|Drug|paclitaxel|
45917943|NCT00009880|Radiation|radiation therapy|
45917944|NCT00009919|Drug|semaxanib|Given IV
45917945|NCT00009958|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given SC
45917946|NCT00009958|Biological|recombinant vaccinia-CEA(6D)-TRICOM vaccine|Given intradermally
45917947|NCT00009958|Biological|sargramostim|Given SC
45917948|NCT00009958|Other|laboratory biomarker analysis|Correlative studies
45917949|NCT00009997|Biological|trastuzumab|
45917950|NCT00009997|Drug|cyclophosphamide|
45917951|NCT00009997|Drug|doxorubicin hydrochloride|
45917952|NCT00009997|Drug|paclitaxel|
45917953|NCT00009997|Drug|tamoxifen citrate|
45917954|NCT00009997|Procedure|conventional surgery|
45917955|NCT00010036|Drug|carboplatin|
45917956|NCT00010036|Drug|irinotecan hydrochloride|
45917957|NCT00010036|Radiation|radiation therapy|
45917958|NCT00005903|Drug|GDNF & Synchro Med Infusion System|
45917959|NCT00010075|Drug|fluorouracil|
45917960|NCT00010075|Drug|leucovorin calcium|
45917961|NCT00010075|Drug|mitoxantrone hydrochloride|
45644254|NCT03755414|Other|Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT)|"Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~Screening, day 14, day 28, day 42, day 74, day 100, day 180, taper period, and follow-up period (expansion study)"
45785314|NCT04340492|Other|Education to Adapted Physical Activity|4 group sessions (5 patients) aiming at promoting physical activity, the first three focusing respectively on endurance, posture and balance and power re-enforcement at one-week interval. A fourth session, 3 months latter is a consolidating session aiming at identify and overcome obstacles to practice physical activity in everyday life.
45785315|NCT04340492|Other|Standard care|Standard care concerning Parkinson's disease and physical activity
45785316|NCT02161484|Procedure|Continuous Lumbar Plexus Block|Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
45785317|NCT02161484|Procedure|Parasacral Nerve Block|A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected.
45785318|NCT02161484|Drug|Ropivacine 0.2%|Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm.
45785319|NCT02161484|Drug|Bupivacaine 0.0625%|In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
45644255|NCT03755414|Other|Human Activity Profile|"Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~Screening, day 14, day 28, day 42, day 60, day 74, day 100, day 180, taper period, and follow-up period (expansion study)"
45785320|NCT00988832|Biological|Infliximab|Infliximab as prescribed by a physician in normal practice for Crohn's disease
45785321|NCT01023776|Biological|A/California/07/09 live monovalent H1N1 vaccine|0.1mL per nares intranasally, second identical dose given 28 days after first vaccine
45785322|NCT00989612|Biological|Influenza investigational vaccine GSK2340274A|Two intramuscular injections on Day 0 and Day 21, respectively
45785323|NCT00989768|Drug|Botulinum Toxin Type A (Dysport®)|"Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2,5:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~-Dysport®: 5 units will be injected in the left or right forehead side."
45785324|NCT00989768|Drug|Botulinum Toxin Type A/Botox®|2 units will be injected in the left or right forehead side.(opposite side of dysport injection)
45785325|NCT00989768|Drug|Botulinum Toxin Type A/Dysport®|"Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~-Dysport®: 4 units will be injected in the left or right forehead side, 2:1 ratio Dysport/Botox."
45785326|NCT00990236|Drug|Enoxaparin dose adjusted Lovenox based on TEG|Enoxaparin doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R < 1.0 min - increase dose by 10 mg BID; delta-R >/= 1.0 min and </= 2.0 min - no change; delta-R > 2.0 min - decrease dose by 10 mg BID.
45785327|NCT00990236|Drug|Enoxaparin 30 mg BID|Enoxaparin dose of 30 mg twice a day without any adjustments
45785328|NCT01024010|Drug|Cyclophosphamide|Given IV
45644256|NCT03754114|Other|ICP + PbtO2 guided management strategy|In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg and to avoid PbtO2 dropping below 20 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada for patients with severe TBI. The devices are used in standard care at hospitals participating in this research study. Doctors adjust their treatment choices to try to achieve these ICP and PbtO2 goals. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
45785329|NCT01024010|Other|Laboratory Biomarker Analysis|Correlative studies
45785330|NCT01024010|Biological|Ofatumumab|Given IV
45785331|NCT01024010|Drug|Pentostatin|Given IV
45917962|NCT00010153|Drug|fulvestrant|
45644257|NCT03754114|Other|ICP guided management strategy|In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull, but PbtO2 is not used to guide care. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada, and are routinely used in patients with severe TBI. Doctors adjust their treatment choices to try to achieve this ICP goal. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
45785332|NCT00990782|Diagnostic Test|PillCam ESO Capsule Endoscope|Utilization of the PillCam ESO capsule endoscope to evaluate the condition of a patient's esophagus before and after RFA therapy to treat atrial fibrillation.
45917963|NCT00010153|Procedure|conventional surgery|
45917964|NCT00010192|Biological|rituximab|Given IV
45644258|NCT03753490|Other|ABC score guided therapy|In the ABC arm, individual treatment recommendations based on the ABC-scores for stroke and bleeding including non-vitamin K oral anticoagulant or no anticoagulant treatment, and other drugs and interventions, to improve stroke free survival.
45785333|NCT02484690|Drug|Faricimab|Faricimab will be administered as per the regimen specified in the individual arm.
45785334|NCT02484690|Drug|Ranibizumab|Ranibizumab will be administered as per the regimen specified in the individual arm.
45917965|NCT00010192|Biological|aldesleukin|Given SC
45917966|NCT00010192|Other|laboratory biomarker analysis|Correlative studies
45917967|NCT00010192|Other|pharmacological study|Correlative studies
45917968|NCT00005912|Drug|Voriconazole|
45917969|NCT00391339|Drug|Bryophyllum p.|
45785335|NCT02484690|Drug|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in treatment arm D at applicable visits to maintain masking.
45785336|NCT01027598|Drug|Pazopanib|Pazopanib: 600 mg orally daily
45785337|NCT01027598|Drug|Erlotinib|Erlotinib: 150 mg orally daily
45785338|NCT01654224|Biological|High Dose Inactivated Influenza Vaccine|0.5 ml HDIV consisting of 180 mcg (60 mcg each strain) of influenza virus hemagglutinin
45785339|NCT01654224|Biological|Standard Dose Inactivated Influenza Vaccine|0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg each strain) of influenza virus hemagglutinin
45785340|NCT02447328|Drug|Fulvestrant|fulvestrant (Faslodex®) 500mg/month for about 6 months with an additional 500mg dose given 14 days after the initial dose injection.
45785341|NCT02447250|Drug|Varied albuterol dose response|Subjects will be evaluated in 3 sessions. The sessions will occur within a 7 day time span, beginning between 14 or more days from birth and at a corrected gestational age of 28w0d to 33w6d. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a sinlge dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
45785342|NCT00990938|Drug|IMO-2125|IMO 2125 is a synthetic DNA-based agonist of Toll-like receptor 9, which is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system.
45785343|NCT00990938|Drug|Saline|Subcutaneous injection once per week for four weeks
45785344|NCT00992264|Behavioral|Message Tone|All participants receive an tailored, online smoking cessation program. Participants in this intervention group either receive content written in a prescriptive tone or a motivational tone.
45785345|NCT00992264|Behavioral|Navigation|Persons in this arm either have their ability to navigate the site dictated for them based on their readiness to quit smoking or they are able to freely navigate through the website.
45785346|NCT00992264|Behavioral|Proactive Outreach|Persons receive periodic, proactively delivered email reminders to visit the intervention website.
45785347|NCT00992264|Behavioral|Testimonials|People receive a personally-tailored testimonial as part of their online smoking cessation program.
45785348|NCT00993200|Genetic|warfarin pharmacogenetic dosing|Warfarin pharmacogenetic dosing incorporated into a validated clinical algorithm displayed in a computer (PERMIT) management interface
45785349|NCT00993200|Drug|Warfarin|Usual care warfarin dosing
45785350|NCT00993824|Drug|colesevelam HCl|3.75 grams of colesevelam HCl (6 tablets)
45785351|NCT00993824|Drug|placebo|
45785352|NCT00994604|Drug|broccoli sprout extract|consumption of broccoli sprout extract for 2 weeks
45785353|NCT04084652|Dietary Supplement|Mycoprotein ingestion|The ingestion of mycoprotein
45785354|NCT04061876|Drug|Ruxolitinib|Participants began oral administration of ruxolitinib at 5 mg QD;Methylprednisolone: 1mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.
45785355|NCT04061876|Drug|Corticosteroid|Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 3 days, then taper according to the clinical response. 1mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.
45785356|NCT02447172|Drug|Gentamicin Collagen sponge|Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
45785357|NCT02447172|Other|Placebo|Matching placebo sponge
45785358|NCT02163824|Drug|KPI-121 0.25%|KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
45785359|NCT02163824|Drug|KPI-121 1.0%|KPI-121 drug product will be supplied as 1.0% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
45785360|NCT02163824|Drug|Vehicle of KPI-121 0.25%|Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
45785361|NCT02163824|Drug|Vehicle of KPI-121 1.0%|Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
45785362|NCT04200066|Drug|Temozolomide, Tamoxifen, Maprotiline|Subjects will receive a combination of temozolomide and tamoxifen for two weeks. After that, they will receive a combination of temozolomide, tamoxifen and maprotiline for the remainder of the study. All drugs are administered orally. Subjects will undergo visits at the beginning of week 3, week 5 and week 7 that will involve multiple blood draws and ECGs to evaluate for pharmacokinetics and drug interactions. Response will be assessed every two months with an MRI and patients will continue on study as long as their tumors are under control and they are tolerating the regimen.
45785363|NCT02165384|Device|Ear tube placement with the Hummingbird TTS|Using the Hummingbird TTS to make a myringotomy and deliver a tympanostomy tube across the tympanic membrane with one pass.
45785364|NCT02455050|Drug|Carboxymethylcellulose Sodium Based Eye Drops|1 to 2 drops of Carboxymethylcellulose Sodium Based Eye Drops [New Eye Drop Formula] in each eye.
45785365|NCT02455050|Drug|Systane® Gel Drops|1 to 2 drops of Systane® Gel Drops in each eye.
45917970|NCT00010231|Dietary Supplement|calcitriol|
45917971|NCT00010231|Drug|dexamethasone|
45917972|NCT02122354|Behavioral|"Hide and Seek videogame"|
45917973|NCT00389298|Drug|VCH-759 (BCH-27759)|
45917974|NCT00010270|Biological|LMB-9 immunotoxin|
45917975|NCT00010309|Biological|MART-1 antigen|
45917976|NCT00010309|Biological|gp100 antigen|
45917977|NCT00010387|Drug|cyclophosphamide|
45917978|NCT00010387|Drug|filgrastim|
45785366|NCT02455050|Drug|Genteal® Lubricant Gel Drops|1 to 2 drops of Genteal® Lubricant Gel Drops in each eye.
45785367|NCT04420650|Device|transcranial direct current stimulation|anodal or cathodal transcranial direct current stimulation
45785368|NCT04927962|Other|Questionnaires|For youth: self-reported questionnaires (on oral quality of life, bullying and cyberbullying, dental anxiety) and routine clinical examination for adolescents. For one parent: self-reported questionnaires (on perceived oral quality of life of their child and on their own dental anxiety).
45785369|NCT00994760|Drug|Instanyl (Intranasal Fentanyl)|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
46070922|NCT00826891|Drug|Cisplatin Combined With Topotecan|"Patients must have specific minimum neutrophil and platelet counts before administration of Hycamtin. The dose of Hycamtin is 0.75 mg/m2 by intravenous infusion over 30 minutes daily on days 1, 2, and 3; followed by cisplatin 50 mg/m2 by intravenous infusion on day 1 repeated every 21 days (a 21-day course).~Dosage adjustments for subsequent courses of Hycamtin in combination with cisplatin are specific for each drug.~Dose levels for cisplatin Initial dose 0 = 50 mg/m2 Dose reduction level -1 = 37.5 mg/m2 Dose reduction level -2 = 25 mg/m2~Dose levels for topotecan Initial dose 0 = 0.75 mg/m2 Dose reduction level -1 = 0.60 mg/m2 Dose reduction level -2 = 0.45 mg/m2"
46070923|NCT02549443|Dietary Supplement|Amino acids|AA (Travasol Baxter, Deerfield IL) during and after surgery in an amount equivalent to 20% and 35% of the patient's energy expenditure (EE)
45785370|NCT02418468|Drug|Indacaterol|Indacaterol 150µg capsules for inhalation daily
45785371|NCT02418468|Drug|Placebo|Matching placebo indacaterol capsules for inhalation daily
45785372|NCT04927572|Drug|FMX114|Active Comparator
45785373|NCT04927572|Other|Vehicle|Placebo Comparator
45785374|NCT02418156|Device|CorMatrix ECM for Vascular Repair|Standard femoral arterial interventional procedure using CorMatrix ECM for vascular repair.
45785375|NCT00995072|Drug|nebivolol and metoprolol succinate|Subjects randomized to treatment Arm A will receive nebivolol 5 mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm A will then receive metoprolol succinate 100 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
45785376|NCT00995072|Drug|metoprolol succinate and nebivolol|Subjects randomized to treatment Arm B will receive metoprolol succinate 100mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm B will then receive nebivolol 5 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
45785377|NCT01027910|Drug|PCI-24781|Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle
45449111|NCT05666271|Procedure|Radiofrequency ablation|Radiofrequency ablation will be performed by using the Octopus MP electrodes. It is a method of directly measuring the temperature near the surrounding tissue of the target tumor using the Octopus MP electrode, and stopping ablation when the temperature rises above 60 degrees to prevent adjacent organ (gallbladder, gastrointestinal tracts, diaphragm, and heart). If the shape of the tumor is elliptical or irregular rather than circular, using an adjustable tip that can change the length of the active tip of the electrode according to the size of the tumor has the advantage of tailoring the ablation zone.
45785378|NCT01027910|Drug|Doxorubicin|Administered intravenously on Day 4 of each 3 week cycle
45449112|NCT02254954|Drug|Macitentan in combination with RT and TMZ|Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.
45785379|NCT01027910|Drug|GCSF|Administered on Day 5 of each 3 weeks cycle in Arm 1 if determined to be clinically indicated, and in all patients enrolled into Arm 2
45785380|NCT01030406|Drug|40/0mg taken first|8x Oxycodone/Niacin 5/0mg tablets All arms taken with a 48 hour washout between doses
45785381|NCT01030406|Drug|80/0mg taken first|8x Oxycodone/Niacin 10/0mg tablets All arms taken with a 48 hour washout between doses
45785382|NCT01030406|Drug|40/240mg taken first|8x Oxycodone/Niacin 5/30mg tablets All arms taken with a 48 hour washout between doses
45785383|NCT01030406|Drug|80/480mg taken first|8x Oxycodone/Niacin 10/60mg tablets All arms taken with a 48 hour washout between doses
45785384|NCT01030406|Drug|0/0mg taken first|Placebo All arms taken with a 48 hour washout between doses
45785385|NCT00996164|Drug|Flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
45785386|NCT00996164|Drug|Placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
45785387|NCT03894098|Procedure|Nerve block|High ankle nerve block
45785388|NCT03873584|Other|Fatigue|Iron deficiency anemia with fatigue symptoms
45785389|NCT03868748|Dietary Supplement|Beta-arbutin|Beta-arbutin capsules
45785390|NCT03868748|Other|Placebo|Placebo capsules containing non-medicinal ingredients
45785391|NCT03809936|Device|real tDCS|Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7 3 5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
45785392|NCT03809936|Device|sham tDCS|For the sham condition(sham tDCS), the same electrode placement was used as in the stimulation condition, but the current was applied for only 5 seconds, and was then ramped down.
45785393|NCT03804554|Other|Non-Interventional|Non-Interventional
45785394|NCT01031420|Drug|single arm dose dense MVAC|standard doses of methotrexate, vinblastine, adriamycin, and cisplatin given every 14 days.
45917979|NCT00386438|Procedure|Honan balloon application|
45917980|NCT00010426|Drug|cysteamine hydrochloride|
45785395|NCT03707834|Behavioral|Antenatal Obesity Treatment (AO)|Participants in the treatment (AO) arm will receive a 4-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; and 4)WIC provider counseling Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
45785396|NCT01031498|Drug|Ondansetron|8 mg IV as bolus followed by 24 mg IV from 30 minutes before chemotherapy until 12 hours after chemotherapy ends.
45785397|NCT01031498|Drug|Palonosetron|"Palonosetron Group 1: 0.25 mg IV bolus over 30 seconds daily for 5 days, 30 minutes before cytarabine chemotherapy.~Palonosetron Group 2: 0.25 mg IV bolus over 30 seconds on Days 1, 3, and 5 of cytarabine chemotherapy, 30 minutes before chemotherapy."
45785398|NCT01031810|Drug|tranylcypromine|MAO-Inhibitor 60mg-120mg
45785399|NCT03426566|Other|retrospective observational study with no intervention|no intervention
45785400|NCT03425006|Drug|Itacitinib|a JAK 1 selective small molecule inhibitor
45785401|NCT03425006|Biological|Pembrolizumab|a highly selective humanized monoclonal antibody (mAb)
45785402|NCT03341858|Other|no intervention-strictly observational|
45785403|NCT03296150|Behavioral|PRESTAGE|PRESTAGE educational program targets the acquisition by the patients and their caregivers of competencies in (1) a better understanding of their disease and (2) their treatment, (3) a better drug management, including both anticancer and supportive treatments, (4) maintenance of a good nutritional status, (5) general health and psychological well being and (6) physical well being. After an individual educational diagnosis, each patient will be proposed an individualized educational program consisting in 1 to 6 of these workshops. An individualized final interview - entitled educational synthesis - will assess patient's skills and satisfaction.
45785404|NCT03208322|Other|Non-Interventional|Non-Interventional
45785405|NCT00998426|Procedure|glucose monitoring before and after HepaGam B administration|Glucose monitoring before and after HepaGam B administration. Prior to receiving the dose of HepaGam B HBIG, blood glucose will be monitored in 3 manners. These will include two finger stick tests, one with a glucose-specific monitoring device and one with a glucose non-specific monitoring device; a venous blood glucose level; and a urine glucose test. Patients will receive the HBIG infusion and then immediately after the dose will have the same blood glucose tests repeated (finger sticks, venous glucose and urine glucose). Then at 60 minutes and 120 minutes after the dose is given, patients will again have finger stick tests with the glucose specific and glucose non-specific monitoring devices.
45785406|NCT00998426|Biological|HepaGam B (Hepatitis B Immune Globulin (HBIG))|Subjects will be given 20,000 IU HepaGam B after the initial blood glucose monitoring, and prior to the post-infusion blood glucose monitoring.
45785407|NCT00998582|Drug|Tenofovir disoproxil|Participants taking an abacavir-based HIV treatment regimen will be randomized to switch to a tenofovir-based regimen or continue taking abacavir.
45785408|NCT00998660|Device|Activa RC|Patients receiving Activa RC as their first implantable neurostimulator or as a replacement implantable neurostimulator for deep brain stimulation
45785409|NCT00999830|Drug|IPH2101|One infusion of IPH2101 every 4 weeks
45785410|NCT01001078|Device|I-Gel supraglottic airway device|2 attempts to secure the airway will be tried. If they both fail, there will be a crossover with a Supreme LMA.
45785411|NCT01001078|Device|LMA Supreme supraglottic airway device|In the LMA Supreme group, the same interventions will be done as in the I-Gel group. The cuff of the LMA Supreme will be inflated with 25 mL of air and then by intervals of 5 mL until no leak is heard (max 45 mL). Leak pressure will also be measure at 45 mL. Once the leak test is done, the cuff will be deflated to initial volume necessary to avoid audible leaks.
45785412|NCT01001078|Device|Standard endotracheal tube|In case both supraglottic airway devices fail, a standard endotracheal tube will be inserted
45785413|NCT02418000|Drug|E6201|Single Group Assignment
45785414|NCT01001546|Behavioral|Internet-based|Veterans randomized to the QuitNet will immediately be given access to the Premium, lifetime membership services.
45785415|NCT01001546|Behavioral|Standard Clinic-Based|Veterans randomized to the control condition will have a consult placed to the Durham VA Medical Center (DVAMC) specialty Smoking Cessation Clinic placed on their behalf.
45785416|NCT04927104|Device|PEEK Knee Prosthesis|After subjects drop out of the study for any reason, the researchers can perform revision surgery using the prosthetic joint that is now routinely used.
45785417|NCT02168660|Drug|Vitamin D3|Vitamin D3, liquid formulation, 5000 IU/mL.
45785418|NCT01003106|Drug|Ranibizumab 0.5mg (monthly)|Branch retinal vein occlusion- Intravitreal injection of 0.5mg ranibizumab alone
45785419|NCT01003106|Drug|Ranibizumab 2.0mg (monthly)|
45785420|NCT01003106|Drug|Pro re nata (prn) ranibizumab|
45785421|NCT01003106|Procedure|Pro re nata (prn) Laser photocoagulation|
45785422|NCT01003418|Biological|GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine|Two doses; intramuscular administration
45785423|NCT01003418|Biological|Infanrix™-IPV/Hib|Routine infant immunisation vaccine, three doses administered intramuscularly
45917981|NCT00010465|Procedure|Craniosacral Osteopathic Manipulative Treatment|
45785424|NCT01003418|Biological|Prevenar|Routine infant immunisation vaccine, three doses administered intramuscularly
45449113|NCT00130793|Biological|Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation|1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Merck) refrigerated formulation at Day 1
45917982|NCT00010465|Drug|Botanicals|
45917983|NCT00010504|Procedure|Acupuncture|
45917984|NCT00010621|Procedure|Acupuncture|
45917985|NCT00010621|Procedure|chiropractic therapy|
45917986|NCT00010621|Procedure|bodywork therapy|
45917987|NCT00386516|Drug|GM-CT-01|GM-CT-01 at 280 mg/m2 given IV for 4 consecutive days in 28 days cycle until disease progression
45917988|NCT00386516|Drug|5-Fluorouracil|5-FU given IV by infusion for 30, at 600 mg/m2 in combination with GM-CT-01 for 4 consecutive days in 28 days cycle until disease progression
45917989|NCT00010699|Drug|Vitamin E|
45917990|NCT00010738|Procedure|Meditation|
45917991|NCT00010777|Procedure|Multiple Component Mind/Body therapy|
45917992|NCT00010816|Drug|Herbal remedies|
45917993|NCT00386555|Drug|docetaxel|
45917994|NCT00386555|Drug|CP-868,596 + docetaxel|
45785425|NCT02162576|Device|Propeller Health intervention|The Propeller intervention works through the provision of information to patients and their providers. With the Propeller sensor device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp and geographic location. Actuation data are then securely transmitted to Propeller Health where the information is also compiled into individual reports via mobile apps, online dashboards, email reports and text message reminders that are returned to the patient. This communication provides an ongoing assessment of their management based on the national guidelines, together with personalized information to help encourage and support self-management. Each participant was invited to share reports with his or her healthcare provider, but this was not required.
45785426|NCT01004042|Drug|Botulinum Toxin Type A|Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.
45785427|NCT01004354|Drug|Ergocalciferols|2000 international units by mouth daily for 8 weeks.
45785428|NCT02951546|Dietary Supplement|Mediterranean diet|In the Mediterranean diet fat intake will be equal to 35% of the total energy intake minus carbohydrate and protein energy carbohydrate as 65% of total calorie intake, dietary cholesterol <300 mg/day, dietary fiber 25 g/day.
45785429|NCT02951546|Dietary Supplement|Low fat diet|In the hypocaloric low fat diet, fat will represent less than 25% of the total energy intake. Branched and essential amino acids will be administered taking into account the total protein intake.
45644259|NCT03753490|Other|Standard care|In the standard care arm, management according to local practice, national and international guidelines, including the potential use of traditional clinical risk scores for stroke and/or bleeding, anticoagulant treatment and other treatments and interventions.
45785430|NCT02951546|Other|Aerobic exercise|"A personalized program of aerobic exercise will be prescribed to the participants of both arms, following the FITT principles (frequency, intensity, time and type)."
45785431|NCT02902874|Other|Blood sample|
45785432|NCT02808416|Biological|Personalized cellular vaccine|"Cancer patients with brain metastases will undergo tumor resection or biopsy, and receive tumor antigen mRNA pulsed cellular vaccines.~Other Names:~• Tumor antigen pulsed DC and PBMC, autologous tumor vaccine"
45785433|NCT02417064|Drug|Esketamine|Participants will self-administer either 84 mg or 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
45785434|NCT02417064|Drug|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
45785435|NCT02417064|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
45785436|NCT02417064|Drug|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated up to a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
45785437|NCT02417064|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
45785438|NCT02417064|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
45785439|NCT02165462|Other|Patients with haemophilia|Assessment of bilateral deficit phenomenon during dynamic plantar flexion task with a force platform (Kistler 9286 BA model, Kistler Instruments, Amherst, NY, USA)
45785440|NCT05593640|Other|biological samples|blood and synovial liquid will be sampled
45917995|NCT00386555|Drug|AG-013736 + docetaxel|
45644260|NCT03747042|Drug|Letrozole|Patients will receive a prescription for letrozole to be taken orally for 7-30 days to allow for variations in surgical scheduling. Patients are to undergo surgical resection of their tumor the day after the last dose of letrozole. Post-treatment tumor biopsies (a goal of 4-6 cores) will be obtained following 7-56 days of letrozole treatment on the day of surgery.
45785441|NCT02357654|Drug|GnRH|single shot of GnRH agonist
45785442|NCT02357654|Drug|placebo|placebo
45785443|NCT02349074|Procedure|Digestive endoscopy|Performed a systematic œsophago-gastro-duodenoscopy between 2 and 4 days after out-of-hospital cardiac arrest
45785444|NCT01653132|Drug|Incobotulinum Toxin A|Twenty units (0.2 ml) of incobotulinum toxin A were injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks
45785445|NCT01653132|Drug|Placebo|Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
45785446|NCT02300012|Procedure|Surgeons knowledge of pre-operative PBIs|Surgeon performing ACL repair will have prior knowledge of patients pre-operative PBIs to inform surgical practice
45917996|NCT00386555|Drug|CP-868,596 + AG-013736 + docetaxel|
45917997|NCT00010855|Behavioral|Self-hypnotic relaxation|
45917998|NCT00001191|Drug|Pantoprazole|
45917999|NCT00001191|Drug|Omeprazole|
45918000|NCT00010933|Drug|chamomile tea|
45918001|NCT00010933|Procedure|Relaxation/Guided Imagery|
45918002|NCT00010972|Procedure|Acupuncture|
45918003|NCT00011011|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
45918004|NCT00386594|Drug|852A|
45918005|NCT00011089|Drug|Tenofovir disoproxil fumarate|
45644261|NCT03745326|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
45918006|NCT00011128|Behavioral|Antiretroviral Treatment Interruption|
45918007|NCT00005921|Drug|L-743,872|
45785447|NCT02266628|Biological|RSV-F Vaccine|
45785448|NCT02266628|Biological|Saline Placebo|
45918008|NCT00011362|Drug|Dexamethasone Early|Tapering course of dexamethasone in doses given twice a day (0.25 mg per kilogram of body weight per dose for five days, then 0.15 mg, 0.07 mg, and 0.03 mg per kilogram per dose for three days each), followed by two weeks of saline.
45918009|NCT00011362|Drug|Dexamethasone Late|Saline for two weeks, followed by either the same tapering two-week course of dexamethasone given to the first group, if the respiratory-index score was >=2.4 on treatment day 14, or an additional two weeks of saline
45918010|NCT00001212|Drug|prednisone|
45918011|NCT00001212|Drug|cyclophosphamide|
45918012|NCT00001212|Drug|cyclosporin A|
45918013|NCT00011479|Drug|Abacavir sulfate|
45918014|NCT00011557|Device|Assistance in Voiding|
45918015|NCT00011596|Procedure|Gait Training|
45918016|NCT00011635|Drug|Silymarin (milk thistle)|
45644262|NCT03745326|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m^2/day IVPB daily over 30 minutes for 5 days.
45918017|NCT00011713|Other|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes online questionnaire on lifestyle and medical history. Diet questionnaire is completed at home and mailed back. Online questionnaire about personal care product use and medications is completed at each scheduled study visit.
45918018|NCT02972645|Drug|LY3305677|Administered SC
45918019|NCT02972645|Drug|Placebo|Administered SC
45918020|NCT00011752|Drug|FCWAY|
45918021|NCT00001221|Drug|Growth Hormone (Humatrope)|
45918022|NCT00391417|Drug|estradiol gel|
45918023|NCT00005939|Radiation|brachytherapy|
45918024|NCT00005939|Radiation|phosphorus P32|
45918025|NCT00011830|Drug|G-CSF|
45644263|NCT03745326|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
45644264|NCT03745326|Biological|anti-KRAS G12D mTCR PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
45785449|NCT02246192|Procedure|sinus pilonidal excision+ PRGF|open sinus pilonidal excision and plasma rich grow factor infiltration intra and postoperatively
45918026|NCT00011830|Procedure|Apheresis|
45785450|NCT02246192|Procedure|sinus pilonidal excision and standard cares|sinus pilonidal excision and postoperative standard care with povidone daily
45918027|NCT00011908|Drug|hLL2 (Epratuzumab)|
45918028|NCT00012025|Drug|fulvestrant|
45918029|NCT00005942|Drug|liposomal daunorubicin citrate|Given IV
45449114|NCT00130793|Biological|Comparator: zoster vaccine live (Oka/Merck) frozen formulation|1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Meck) frozen formulation at Day 1
45644265|NCT03740997|Drug|Optison|Optison is administered intravenously
45644266|NCT03739112|Biological|Quadrivalent VLP Vaccine|Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
45644267|NCT03739112|Biological|Fluarix Quadrivalent® Comparator Vaccine|Single dose of a 15 μg/strain of Fluarix Quadrivalent® Comparator Vaccine
45644268|NCT03738072|Diagnostic Test|StiMiC stimulation condition|This new condition of stimulation of electrical Brain Stimulation will be evaluate to determine if this stimulation is more efficient that standard stimulation condition
45785451|NCT01004744|Drug|Anastrozole|1mg PO daily for two weeks prior to scheduled surgery
45785452|NCT01005290|Drug|Combination pill|A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.
45918030|NCT00005942|Drug|semaxanib|Given IV
45918031|NCT00005942|Other|laboratory biomarker analysis|Correlative studies
45918032|NCT00012064|Biological|therapeutic autologous dendritic cells|Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
45918033|NCT00012103|Other|bronchoalveolar lavage|
45918034|NCT00012103|Other|screening questionnaire administration|
45918035|NCT00012103|Other|sputum cytology|
45918036|NCT00012103|Procedure|bronchoscopic and lung imaging studies|
45918037|NCT00012103|Procedure|bronchoscopy|
45918038|NCT00012103|Procedure|computed tomography|
45918039|NCT00012103|Procedure|study of high risk factors|
45918040|NCT00001251|Drug|Mafosfamide|
45918041|NCT00012142|Drug|temsirolimus|
45918042|NCT00012181|Drug|alvocidib|Given IV
45918043|NCT00012181|Other|pharmacological study|Correlative studies
45918044|NCT00005945|Drug|cyclophosphamide|Given IV
45918045|NCT00005945|Drug|cytarabine|Given IT
45918046|NCT00005945|Drug|daunorubicin hydrochloride|Given IV
45918047|NCT00005945|Drug|dexamethasone|Given PO
45918048|NCT00005945|Drug|doxorubicin hydrochloride|Dose 25 g/m² IV Days 0, 7, 14, given over a period of 15 minutes to 2 hours
45918049|NCT00005945|Drug|mercaptopurine|Given PO
45918050|NCT00005945|Drug|methotrexate|Given PO and IT
45918051|NCT00005945|Drug|pegaspargase|Given IM
45918052|NCT00005945|Drug|thioguanine|Given PO
45918053|NCT00005945|Drug|vincristine sulfate|Given IV
45918054|NCT00005945|Radiation|radiation therapy|Undergo radiation therapy
45918055|NCT01929811|Drug|Metformin|Metformin: 500mg tid, orally (500mg daily in first cycle) on day 1 to day 21 of each 21 day cycle
45918056|NCT01929811|Drug|Docetaxel|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
45918057|NCT01929811|Drug|Epirubicin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
45785453|NCT01005290|Drug|Ramipril|A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.
45785454|NCT05593484|Other|Standard Referral|Schools in the control condition will use standard referral, as determined by the school district. Standard referral is typically a letter home from the school to parents/caregivers of children who refer screening.
45785455|NCT05593484|Other|Specialty Telemedicine Access for Referrals (STAR)|The STAR intervention will include a lay-friendly smartphone or tablet that connects to tools necessary for an ear and hearing evaluation. If a child requires referral from hearing screening, a school nurse/teacher will complete the established protocol for the STAR intervention and send the information asynchronously to an audiologist for review.
45644269|NCT03734237|Biological|Egg based influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
45785456|NCT04494932|Procedure|Self-Locking Tenotomy|Self-locking Tenotomy describes the surgical procedure that will be performed to treat SLAP tears.
45785457|NCT04494932|Procedure|Biceps Tenodesis|Biceps tenodesis describes the surgical procedure that will be performed to treat SLAP tears.
45785458|NCT02453334|Drug|Injectafer|
45785459|NCT02453334|Other|Normal Saline|
45785460|NCT04488692|Other|Early intervention (Mobility functional training)|functional training focused on mobility (bed mobility, sitting balance, standing balance, and ambulation)
45785461|NCT04488692|Other|Sham intervention|friendly visit and education
45785462|NCT04481516|Other|Yoga|SKY Yoga
45785463|NCT04478474|Drug|Ganciclovir|Type of allogeneic transplant, HLA match, graft manipulation, use of ATG and/or Campath, CMV status (donor and recipient), maximal acute GVHD stage and grade, CMV viremia/disease through day +100, days received ganciclovir prophylaxis, adverse events related directly or secondary to ganciclovir prophylaxis.
45785464|NCT03015506|Other|Bread|
45785465|NCT01051310|Device|Medtronic CoreValve System|Transcatheter Aortic Valve
45785466|NCT05592860|Device|Mobile application|participants in intervention group will use smart phone application and update glucose level and investigator will adjust the insulin accordingly
45785467|NCT05592860|Behavioral|Daily Diary|participants will use daily diary to record glucose level
45785468|NCT01051778|Drug|enoxaparin 40mg plus low dose aspirin|Enoxaparin 40mg/day by subcutaneous injection ( Clexane 40 mg, Aventis international, Sanofi-aventis France ) is started when the serum pregnancy test become positive. Enoxaparin is stopped 2 days before planned induction of labor or cesarean section and twice-daily unfractionated heparin (UFH) is initiated. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop enoxaparin or UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID)) is started before conception and continued until 36 weeks gestation.
45785469|NCT01051778|Drug|Heparin calcium5,000 U twice daily plus low dose aspirin|Heparin Calcium 5,000 U twice daily (Cal-Heparine, Amoun Pharmaceutical Co, Egypt) by subcutaneous injection is started when the serum pregnancy test become positive. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID))is started before conception and continued until 36 weeks gestation .
45785470|NCT05592782|Behavioral|Virtual Reality Based Mindfulness meditation|Participants will undergo a guided VR meditation using a commercial VR application. The meditation will last approximately 15 minutes. Prior to starting and on upon completion of each VR meditation session, participants' state pain, anxiety, depression, and stress will be assessed. For each participant enrolled, baseline and monthly assessments using the DASS-21 and PPI-SFI3a will be performed for three consecutive months.
45785471|NCT01052948|Other|Retrospective study-|
45918058|NCT01929811|Drug|cyclophosphomide|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
45918059|NCT00012220|Drug|cisplatin|50 mg/sq m IV infusion over 30 min on Days 1 & 15 of ea cycle
45918060|NCT00012220|Drug|docetaxel|40 mg/sq m IV infusion over 60 min on Days 1 & 8 of ea treatment cycle
45918061|NCT00012220|Drug|gemcitabine hydrochloride|"Gemcitabine only arm: 1500 mg/sq m in 250 mL NS IV infusion over 150 min Days 1, 8, & 15 of ea cycle~cisplastin arm: 1000 mg/sq m 250 mL NS IV infusion over 30 min Days 1, 8, 15 of ea cycle~docetaxel and + irinotecan arms: 1000 mg/sq m in 250 mL NS IV infusion over 30 min Days 1 & 8 of ea cycle"
45785472|NCT01052948|Other|Retrospective study-|
45785473|NCT01052948|Other|Retrospective study-|
45785474|NCT01052948|Other|Retrospective study-|
45785475|NCT03015662|Other|Dry Needling Therapy|Dry needling procedures will be performed in the following pairs of muscles in the same intervention: occipital, splenius capitis, sternocleidomastoid (Clavicular branch TrPs 1, 2 and 3; sternal branch TrPs 1, 2, 3 and 4), scalene (anterior TrPs 1, and 2; medial TrP (Trigger Point) 1; posterior TrP 1), trapezius (upper TrPs 1, and 2; middle TrPs 5, 6 and 7; lower TrPs 3, and 4), supraspinatus (central point; myotendinous union; tendon insertion), infraspinatus (medial/superior; lateral/superior; lateral scapular side; medial scapular side), and multifidus (level C6).
45918062|NCT00012220|Drug|irinotecan hydrochloride|100 mg/q m in 500 mL D5W or D5NS IV infusion over 90 min Days 1 & 8 of ea cycle
45918063|NCT00012259|Drug|troxacitabine|
45918064|NCT00012337|Drug|gefitinib|
45918065|NCT00012376|Drug|bryostatin 1|Given IV
45644270|NCT03734237|Biological|Recombinant influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
45644271|NCT03734237|Biological|Cell-culture based influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
45918066|NCT00012376|Biological|sargramostim|Given subcutaneously
45918067|NCT00012376|Other|laboratory biomarker analysis|Correlative studies
45918068|NCT00012376|Other|pharmacological study|Correlative studies
45785476|NCT03015662|Other|Myofascial Release Therapy|Patients will develope a myofascial therapy protocol, administered in the following order in the same intervention: deep fascia release in temporal region, suboccipital release, compression-decompression of temporomandibular joint, global release of cervicodorsal fascia, release of pectoral region, diaphragm release (transverse slide), and transverse diaphragmatic plane.
45785477|NCT05592704|Device|Usage of a wearable heart rate monitor and a smartphone with the application for home-based exercises|Physical activity self-monitoring using a wearable heart rate monitor and a smartphone with specially designed application
45785478|NCT04400084|Other|Placenta perfusion|Placenta perfusion in double closed circuit, during 3 hours
45785479|NCT02169440|Drug|BIA 9-1067|BIA 9-1067 25 mg
45785480|NCT02169440|Drug|Warfarin|Warfarin 25 mg
45785481|NCT05592392|Device|Synchronized Diaphragmatic Stimulation|Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.
45785482|NCT03015350|Drug|Sevoflurane|Measurement of blood desflurane level during one lung ventilation
45785483|NCT03015350|Drug|Desflurane|Measurement of blood desflurane level during one lung ventilation
45785484|NCT03015428|Other|psychoeducation|Providing knowledge and skills development in family caregivers of people with dementia, through a structured psychoeducational programme
45785485|NCT03015272|Behavioral|Auditory-Motor Mapping Training|AMMT is a novel, intonation-based intervention that is accompanied by simultaneous tapping each spoken syllable on tuned drums, designed to help minimally verbal children between the ages of 5.5 and12.0 years develop and/or improve speech output. AMMT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in the method.
45785486|NCT03015272|Behavioral|Speech-Repetition Therapy|SRT is a novel, non-intonation-based intervention designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. SRT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention. SRT serves as a control intervention to AMMT.
45785487|NCT01054586|Drug|Intervention A Standard dose|HIV subjects with HBV or HCV co-infection but normal hepatic function, defined by receipt of FPV 700mg BID/RTV 100mg BID and a baseline AST-platelet ratio index (APRI) score of <2.0.
45785488|NCT01054586|Drug|Intervention B Reduced Dose|HIV subjects with mild hepatic impairment, defined by receipt of the recommended reduced FPV/RTV dose (700mg BID/100mg QD).
45785489|NCT01054586|Drug|Intervention C|HIV subjects with moderate hepatic impairment, defined by receipt of FPV 450mg BID/RTV 100mg QD.
45644272|NCT03724071|Biological|TG6002|"Phase I, Arm A: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU; Phase I, Arm B: Dose escalation from 1 x 10E9 PFU to 1 x 10E10 PFU; Phase II: Established recommended Phase II dose (RP2D)~Administration intravenously on Days 1, 8 and 15 (Phase I, Arm A) or on Days 1, 3 and 5 (Phase I, Arm B). Three intravenous infusions at the Dose Recommended for Phase 2 (RP2D) in Phase IIa.~An extension of the 28-day cycle of TG6002/5-FC combination can be repeated in case of evidence of patient benefit, defined as an objective radiological response or disease stabilization, and/or a clinically significant relief in patient's symptoms. Additional cycle(s) will start from 2 to 4 weeks following the last 5-FC intake."
45644273|NCT03724071|Drug|Flucytosine (5-FC, Ancotil)|"Administered orally at a dose of 200 mg/kg/day for a total of 10 days (Phase I, Arm B) or 16 days (Phase I, Arm A).~An extension of the cycle of TG6002/5-FC combination can be repeated in case of evidence of patient benefit, defined as an objective radiological response or disease stabilization, and/or a clinically significant relief in patient's symptoms."
45785490|NCT01054586|Drug|Intervention D|HIV subjects receiving the standard dose of FPV/RTV despite evidence of abnormal hepatic function according to APRI score: HIV subjects with HBV or HCV co-infection, receipt of FPV 700mg BID/RTV 100mg BID and a baseline APRI score of ≥2.0.
45785491|NCT01054586|Drug|Intervention E|HIV subjects coinfected with HBV or HCV who have initiated standard doses of LPV 400mg/RTV 100mg and enrolled in the same cohorts as the FPV/RTV exposed subjects.
45785492|NCT01054742|Drug|Standard of Care PegIntron|Commercially available PegIntron administered subcutaneously (SC) at 1.5 μg/kg weekly in accordance with the PegIntron Summary of Product Characteristics (SmPC).
45785493|NCT01054742|Drug|Standard of Care Ribavirin|Commercially available ribavirin administered orally at 800-1200 mg/day based on body weight in accordance with the ribavirin SmPC.
45785494|NCT01056302|Procedure|Surgical repair of mandibular fractures|Patients will undergo whatever needed surgical repair of maxillofacial trauma that is necessary. Records such as CT imaging and plaster models of the jaws will be utilized in the standard way to plan and carry out the surgery. The CT scan will also be used within the visuohaptic computational environment to develop and evaluate the user interface. The amount of time taken to work up and plan surgery using standard surgical practice and using the computational platform will be compared. Real surgical outcome will be compared to the simulated surgical outcome using the proposed software tool.
45644274|NCT03712605|Other|Best Practice|Receive standard of care observation
45644275|NCT03712605|Procedure|Biospecimen Collection|Correlative studies
45785495|NCT05591612|Other|MSG|MSG to be added to vegetables in diet
45785496|NCT05591612|Other|NaCl (sodium chloride/table salt)|NaCl (sodium chloride/table salt)
45785497|NCT05591612|Other|KCl (potassium chloride/salt substitute)|KCl (potassium chloride/salt substitute)
45785498|NCT04197596|Biological|BK CTL|"Patient with refractory BK infection and a HLA Matched Related Donors: BK specific CTLs (2.5 x 104 CD3/kg) infused intravenously on day 0 and may be additionally reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 12.5 x 104 CD3/kg).~Patients with refractory BK virus and a HLA Mismatched Related Donors: BK specific CTLs (0.5x104 CD3/kg) infused intravenously on day 0 and may additionally be reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg)."
45785499|NCT05591456|Radiation|adjuvant radiotherapy|Treatment schedule and delivery The patients who met the inclusion criteria were randomly divided into two groups, each group of 50 patients. The first group (arm A) will receive a dose of 27 Gy to the chest wall using 3D conformal radiotherapy (5.4 Gy per fraction) over one week, whilst, the second group (arm B) will receive a dose of 40 Gy to the chest wall (2.67 Gy per fraction) over three weeks.
45785500|NCT05590208|Procedure|sleeve gastrectomy+ cruroplasty+ omental rap|sleeve gastrectomy+ cruroplasty+ omental rap
45785501|NCT04171466|Other|Ciprofloxacin + Metronidazole|Participants will be instructed to take 1 capsule of Ciprofloxacin (500mg) twice daily for 7 days and 1 capsule of Metronidazole (500mg) thrice daily for 7 days. Antibiotics should be taken at least 2 hours before or 6 hours after mineral supplements containing magnesium or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc.
45785502|NCT04171466|Other|SH-DS01|SH-DS01 is a rationally defined microbial consortia consisting of 24 strains across 12 species, with polyphenolic and phenolic prebiotic bioactive compounds. Participants will be instructed to take 2 capsules daily for the duration of the trial.
45785503|NCT04171466|Other|Placebo|Placebo capsules for SH-DS01 will contain rice flour matched for color and texture in an identical outer capsule shell. Participants will be instructed to take 2 capsules daily for the duration of the trial.
45785504|NCT05587634|Behavioral|Virtual Peer Health Coaching|"Intervention arm: weekly sessions (~30 min each session) of physical activity counseling with an assigned peer health coach over the course of 12 weeks. The focus of the initial 2 calls is on rapport development and trust building with a focus around PA with discussion of physical activity goals and motives, where possible. The remainder of the call sessions follow a standardized format of a 30-minute call to 1) review the previous week, 2) integrate motivational strategies, and 3) develop action and support plans for the next week. The final call format includes a summary and evaluation of the intervention, discussion of short- and long-term goals, and relapse prevention strategies. Sessions guided by a call tracking form.~These participants receive an adaptive physical activity local guide including information on local adaptive sports opportunities, which the control group also receives."
45785505|NCT05577338|Behavioral|group psychotherapy|a semi-structured, multidomain, tailored group psychotherapy
45785506|NCT05577338|Behavioral|health education|disease-related health knowledge
45785507|NCT02246348|Radiation|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
45785508|NCT02443740|Drug|BIIB118|Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 3 mg, 30 mg, 200 mg, 800 mg and placebo
45785509|NCT02443740|Drug|BIIB118|Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 10 mg, 100 mg, 400 mg, and placebo
45785510|NCT02443740|Drug|BIIB118|Single dose (Maximum Tolerated Dose) of BIIB118 as extemporaneously prepared solution/suspension
45785511|NCT02170376|Drug|BIA 9-1067|BIA 9-1067 25 mg and 50 mg
45785512|NCT02170376|Drug|Entacapone|Entacapone (ENT), over-encapsulated tablet 200 mg
45785513|NCT02170376|Drug|Placebo|PLC, placebo
45785514|NCT02170376|Drug|Levodopa/carbidopa|Levodopa/carbidopa, tablet 100/25 mg
45785515|NCT05551988|Other|Retrospective observational study of diabetic foot ulcer|This is a retrospective observational study of antibiotic resistance and risk factors of amputation in diabetic foot ulcer patients
45785516|NCT02170532|Drug|levalbuterol|0.5 ml. levalbuterol
45785517|NCT02170532|Drug|saline|0.5ml saline
45785518|NCT02170532|Other|levalbuterol MDI|
45785519|NCT02170532|Device|breath actuated nebulizer|
45644276|NCT03712605|Procedure|Computed Tomography|Undergo PET-CT or CT
45644277|NCT03712605|Biological|Pembrolizumab|Given IV
45785520|NCT02170532|Device|aerochamber max|
45785521|NCT02170532|Drug|ipratroprium|
45785522|NCT05551832|Drug|Arm I (Placebo),|Placebo after Pylurus preserving Pancreaticoduodenctomy (PPPD) for 6 months
45785523|NCT05551832|Drug|Arm II (ESMESOL)|SMESOL 40 mg dose administrea daily at bedtime for 6 months after PPPD ,
45644278|NCT03712605|Procedure|Positron Emission Tomography|Undergo PET-CT
45644279|NCT03712605|Radiation|Radiation Therapy|Undergo radiation therapy
45785524|NCT04124120|Procedure|Single arterial graft|This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
45785525|NCT04124120|Procedure|Multiple arterial grafting|This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
45785526|NCT04099004|Other|Neural Imaging|During the acquisition of magnetic resonance (MR) images, the study participants will lie on the scanner table. For most portions of MR acquisition, the study participants will be instructed to lie still. For other parts of the acquisition, study participants will be asked to complete a combined knee and hip flexion/extension movement and a quadriceps contraction task in which they will be asked to 'squeeze' their quadriceps while keeping the rest of their body still. For the last 15 minutes of MR acquisition, the researcher will place one hand above the participants' knee and apply intermittent pressure to their quadriceps and medial aspect of the patella. Pain scales will be administered after every fMRI task to assess subjective perceptions of pain. Peripheral pulse oximetry and respiration waveforms will be collected for data analysis in order to minimize the potential confounding effect from the physiological changes.
45918069|NCT00012454|Drug|E-Selectin nasal spray|
45918070|NCT00001266|Drug|Suramin|
45918071|NCT00005948|Biological|aldesleukin|
45918072|NCT00005948|Biological|recombinant interferon alfa|
45918073|NCT00005948|Biological|sargramostim|
45918074|NCT00005948|Drug|busulfan|
45449115|NCT03732105|Radiation|Radiotherapy|Patients in radiotherapy group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50Gy/25fraction after randomization.
45644280|NCT03709680|Drug|Palbociclib|Phase 1: Administered (oral) at 55 mg/m2, 75 mg/m2, or 40 mg/m2, or 95 mg/m2 or 115 mg/m2 on days 1-14 of a 21-day cycle Phase 2 : Administered (oral) at 75 mg/m2 on days 1-14 of a 21-day cycle
45644281|NCT03709680|Drug|Temozolomide|Phase 1 and Phase 2: Administered at 100 mg/m2 (oral or intravenous), on days 1-5 of a 21-day cycle
45644282|NCT03709680|Drug|Irinotecan|Phase 1 and Phase 2: Administered at 50 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
45644283|NCT03709680|Drug|Topotecan|Phase 1 only : Administered at 0.75 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
45644284|NCT03709680|Drug|Cyclophosphamide|Phase 1 only: Administered at 250 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
45644285|NCT03709446|Drug|Leflunomide|Single agent leflunomide
45785527|NCT03014960|Other|Online Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I is a psychological treatment designed to break the patterns of maladaptive thinking and behavior that maintain insomnia. CBT-I includes a range of techniques including a behavioral component (stimulus control, sleep restriction, relaxation) combined with a cognitive component (managing sleep related worries, the racing mind and intrusive thoughts) and an educational (sleep hygiene) component.
45785528|NCT04098224|Device|smART+ System|Utilizing the smART+ System to provide feeding optimization to the patient
45785529|NCT05522426|Device|SyntrFuge System|Microsized Adipose Tissue
45785530|NCT04090268|Other|Sport Therapy|Children and adolescent with malignant hemopathies will attend a 3 days/weekly combined training
45785531|NCT04079582|Other|Dialysate magnesium formulation of 1.5 mEq/L (0.75 mmol/L).|(Dialysate magnesium concentration currently used in Canada and the United States)
45785532|NCT04079582|Other|Dialysate magnesium formulation of ≤1.0 mEq/L (≤0.5 mmol/L).|(Dialysate magnesium concentration currently used in Canada and the United States)
45785533|NCT04069520|Other|aNMT Biofeedback|"aNMT biofeedback is created by calculating kinematic and kinetic data in real-time from the athlete's own movements. These values determine realtime transformations of the stimulus shape the athlete views via augmented-reality (AR) glasses during movement performance. The athlete's task is to move so as to create (animate) a particular stimulus shape that corresponds to desired values of the biomechanical parameters targeted by the intervention. The aNMT biofeedback occurs during neuromuscular training sessions. The neuromuscular training is a 12-week, pre-season training program occurring over 6 weeks."
45785534|NCT04069520|Other|Sham Biofeedback|Sham biofeedback provides a similar phenomenological experience to aNMT biofeedback for athletes-both groups experience a shape that changes with their movements-but the sham biofeedback will not provide usable information to modify movement parameters during critical movement phases. The sham biofeedback occurs during neuromuscular training sessions. The neuromuscular training is a 12-week, pre-season training program occurring over 6 weeks.
45785535|NCT03990662|Other|Physiotherapy - Manual Therapy|Participants will receive four sessions of manual therapy applied to craniomandibular structures over four weeks. The application of manual therapy aims to decrease pain by treating masticatory muscle trigger points, muscle tightness, and restricted temporomandibular joint movements. Several techniques will be considered, including ventral and caudal anterior glide temporomandibular joint mobilisation, soft tissue interventions for the management of trigger points in masticatory muscles and myofascial induction therapy applied to craniomandibular structures. The structures targeted in the treatment sessions will be the temporomandibular joint, temporal muscles, masseter muscles, medial and lateral pterygoid muscles and suprahyoid muscles.
45785536|NCT03987854|Behavioral|diet and lifestyle program|Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep. They will also be taught taught about positive affect skills (such as gratitude, positive reappraisal, and personal strengths) and mindfulness (general mindfulness and mindful eating).
45785537|NCT05509634|Drug|HR20013 for injection；dexamethasone|"HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
45785538|NCT05509634|Drug|fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone|"fosaprepitant dimeglumine for injection: Drug for preventing nausea and vomiting caused by chemotherapy~palonosetron hydrochloride injection: Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
45785539|NCT02246504|Device|HIFU treatment|
45785540|NCT03937700|Device|CPWalker Robotic Exoskeleton|The CPWalker rehabilitation platform is a robotic device composed by an exoskeleton linked to a walker that provides support and balance to a child during overground training. The device is able to implement user's partial body weight support (PBWS) and allows the adaptation of exercises to the patient's capabilities by means of individual controllers for each joint, which increases the modularity of the system. Each joint of the CPWalker can operate in a range of modes with varied levels of robotic assistance or resistance
45785541|NCT03930056|Device|C-Brace II|"Participant will complete 3-6 orthoses sessions to complete clinical evaluations and fittings conducted by certified orthotists.~Participant will receive 10-20, one hour training sessions over 1-2 months in the lab. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention.~Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row.~Participant will take the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing."
45918075|NCT00005948|Procedure|peripheral blood stem cell transplantation|
45918076|NCT00012610|Procedure|Telepsychiatry|
45918077|NCT00012688|Drug|Doxycycline HCI 10mg po for 2 weeks|
45918078|NCT00012688|Procedure|Ultrasonic scaling with 0.12% chlorhexidine gluconate|
45918079|NCT00005951|Drug|irinotecan hydrochloride|
45644286|NCT03708965|Drug|JR-141|IV infusion (lyophilized powder)
45644287|NCT03708809|Device|Intrauterine system|13.5 mg levonorgestrel-releasing intrauterine system
45918080|NCT00005951|Drug|temozolomide|
45644288|NCT03708809|Other|Alternative contraception to intrauterine system|Alternative contraception including contraception pills, hormonal patches, hormonal vaginal , condomsring,
45785542|NCT03930056|Device|Traditional Care KAFO intervention|Participant will continue with use of their own KAFO. Participant will receive 10-20, one hour training sessions over 1-2 months in the lab, if Patient is not already receiving care in a therapy setting. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention. Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row. Participant will continue with the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing.
45785543|NCT02175212|Drug|Short term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~Bicalutamide 50 mg tablet every day for 2 months"
45785544|NCT02175212|Drug|Long term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~Bicalutamide 50 mg tablet every day for 2 months~Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy"
45785545|NCT02175212|Radiation|Short term androgen deprivation|Minimum dose of 76 Gy (range 76-82 Gy)
45785546|NCT02175212|Radiation|Long term androgen deprivation|Minimum dose of 76 Gy (range 76-82 Gy)
45785547|NCT05419856|Drug|4P-004|single intraarticular administration in the knee joint
45785548|NCT05419856|Drug|Placebo|single intraarticular administration in the knee joint
45785549|NCT01060592|Device|EndoFLIP device (FDA Device Listing Number : D091203)|The EndoFLIP balloon catheter will be introduced to the band and used to permit the band stoma size to be adjusted to 7mm.
45785550|NCT03014882|Drug|L-Carnitine and N-acetyl cysteine|
45785551|NCT02171234|Drug|Placebo|
45785552|NCT02171234|Drug|BIA 2-093|
45785553|NCT01061528|Drug|Transdermal Nicotine|Participants will use the full strength 21mg. patch for 4 weeks, will taper to the 14 mg. patch for the next 2 weeks, and then to the 7 mg. patch for the remaining 2 weeks of treatment.
45785554|NCT03016286|Other|vibration|Whole body vibration at 25Hz frequency
45785555|NCT05343182|Other|Modified Technique|This operation is performed using modified anesthesia care/deep sedation (MAC) for anesthesia. The vestibule is removed to the boundary of Harts line. The surgical flap for this procedure is the Hymen plus 1 cm of the vagina.
45785556|NCT05343182|Other|Traditional Technique|This operation is performed using an Laryngeal Mask Airway (LAM), (modified anesthesia care/deep sedation) for anesthesia. The vestibule is removed 0.5 to 1 cm beyond the boundary of the Hart's line. The Hymen plus 1 cm of the vagina is excised.
45785557|NCT01062230|Drug|Bortezomib (Velcade)|"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles.~Patients will undergo three 21-day cycles."
45785558|NCT01062308|Procedure|Taping and Sham Taping|"Taping shoulder with Hospiplast tape.~Taping the shoulder after acute stroke to prevent shoulder injury and pain.~Taping the shoulder after acute stroke and compare with sham taping group.~Treatments:~Positioning technique~Handling technique~Range of motion exercises~Taping technique"
45785559|NCT01062308|Procedure|Sham Taping|Shoulder Taping for 14 days which will be changed after every 3 days.
45785560|NCT01063712|Device|Nit-Occlud® PDA-R|"Transcatheter implantation of a PDA Device (Nitinol) The catheterism was done under sedation, using a protocol established by inserting a catheter through a femoral artery and/or vein directed to the heart and great vessels. Invasive measurements are obtained in the descending aorta and pulmonary artery. Once in ductal position, we inject iodinated contrast medium that allows us to observe via X-ray the ductal morphology; obtaining accurate measurements to choose the appropriate device. The device is then inserted via the catheter, closing the ductus.~The catheterism provides measures of aortic and pulmonary pressure, before, during and after the closure."
45785561|NCT01064882|Drug|bimatoprost ophthalmic solution 0.005%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
45785562|NCT01064882|Drug|bimatoprost ophthalmic solution 0.015%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
45785563|NCT01064882|Drug|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
45785564|NCT01065506|Behavioral|Cognitive Behavioral Treatment|Cognitive Behavioral Treatment
45785565|NCT01065506|Drug|Nicotine Patch|Nicotine Patch
45785566|NCT01065506|Behavioral|Wellness Program|Wellness Program
45785567|NCT01065506|Behavioral|Aerobic Exercise|Aerobic Exercise
45785568|NCT03014726|Device|Urotronic Drug Coated Balloon (DCB)|Urotronic Drug Coated Balloon (DCB) is a catheter with a tapered atraumatic tip. The distal end of the catheter has a semi-compliant inflatable balloon coated with a proprietary coating containing the drug and carriers.
45785569|NCT03817736|Procedure|TACE|Procedure of TACE will be standardized.
45785570|NCT03817736|Radiation|SBRT|SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.
45785571|NCT03817736|Drug|Immune Checkpoint Inhibitor|An immune checkpoint inhibitor may be administered up to 3 days before or after the scheduled day of administration of each cycle due to administrative reasons.
45918081|NCT00012727|Procedure|Matching Symptom Severity to Service Intensity|
45918082|NCT00012766|Behavioral|Integrated team care|
45918083|NCT00012805|Procedure|Telephone Monitoring|
45918084|NCT00001287|Drug|intravenous immunoglobulin (IVIg)|
45918085|NCT00005954|Drug|temozolomide|
45918086|NCT00012844|Device|Redesigning patient handling tasks using equip: Arjo Bianca Overhead Lift, Hill-Rom Resident Transfer Device, TranSit Chair, Total Care Bed|
45785572|NCT03811886|Drug|Natalizumab|"Natalizumab is an FDA approved monotherapy for treatment of relapsing forms of MS. It is also indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active CD who have had an inadequate response to, or intolerance of, conventional therapies and TNF-α inhibitors.~Traditional 3+3 escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed 300mg. If no subjects experience a dose limiting toxicity (DLT), 3 more subjects are enrolled at the next dose of 3mg/kg, not to exceed 300mg. If no subjects experience a DLT, 3 more subjects will be enrolled at the next and final dose of 4mg/kg, not to exceed 300mg.~Phase II will continue if the subject has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS, defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If subject has progressive disease after cycle 6, they will be removed from the study."
45785573|NCT03794726|Procedure|Orthodontic Molar Protraction and PAOO|Molar Protraction with Orthodontic Tooth Movement and Adjunctive Periodontally Accelerated Osteogenic Orthodontics (PAOO) Surgery was performed on all study sites in this arm in coordination with standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
45785574|NCT03794726|Procedure|Orthodontic Molar Protraction|Standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
45785575|NCT03761186|Behavioral|traditional diabetes diet|Diet with carbohydrate content 50-60% of total energy intake
45785576|NCT03761186|Behavioral|moderately low carbohydrate diet|Diet with carbohydrate content 30-40% of total energy intake
45785577|NCT03761186|Behavioral|strictly low carbohydrate diet|Diet with carbohydrate content 15-20% of total energy intake
45785578|NCT03733730|Device|ACRYSOF IQ RESTOR +3.0 Multifocal Toric IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
45785579|NCT03733730|Device|ACRYSOF IQ RESTOR +2.5 D Multifocal Toric IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
45785580|NCT03733730|Device|ACRYSOF IQ RESTOR +2.5 D Multifocal IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
45785581|NCT03733730|Procedure|Cataract Surgery|Routine small incision cataract surgery with IOL implantation
45785582|NCT01066364|Drug|Colesevelam Hcl|3.75 gm/day (six 675 mg tablets)
45785583|NCT01066520|Drug|Traumeel S ointment|2 g, 3 times daily topical during 14 days
45785584|NCT01066520|Drug|Traumeel S gel|2 g, 3 times daily topical during 14 days
45785585|NCT01066520|Drug|Diclofenac gel|2 g, 3 times daily topical during 14 days
45785586|NCT01067456|Radiation|Comprehensive Cardiothoracic CT arm|Subjects in this arm will receive the comprehensive cardiothoracic CT to rule out aortic dissection/pulmonary embolism/acute coronary syndrome in a single scan.
45918087|NCT00012844|Procedure|Redesigned patient handling tasks using work practice controls: setting bed height at correct level; applying anti-embolism stockings from foot of bed|
45918088|NCT00012883|Behavioral|Homewalking exercise program|
45918089|NCT00012922|Behavioral|Low Literacy Intervention for Colorectal Cancer Screening|
45918090|NCT00001302|Drug|PSC 833|
45918091|NCT00005960|Biological|filgrastim|
45918092|NCT00005960|Drug|cyclophosphamide|
45918093|NCT00005960|Drug|docetaxel|
45918094|NCT00005960|Drug|doxorubicin hydrochloride|
45918095|NCT00005960|Procedure|pain therapy|
45918096|NCT00013000|Behavioral|Test strategy for implementation guideline|
45918097|NCT00013039|Behavioral|Computer reminders|
45918098|NCT00013078|Procedure|Physical restoration intervention|
45918099|NCT00005963|Drug|carboplatin|
45918100|NCT00005963|Drug|docetaxel|
45918101|NCT00013117|Behavioral|Telephone specialist consultation|
45918102|NCT00013156|Procedure|Effectiveness of Lung Reduction Therapy|
45918103|NCT00013195|Behavioral|Telephone Care|
45918104|NCT00013234|Procedure|Teledermatology|
45785587|NCT01067768|Other|Daily review|"Daily nursing review of the urinary catheter´s indication. If the patient meets at least one of the entries to stay with bladder catheter, the nurse will record collection in the format but will not contact the health team. If there aren´t indication in the medical record, she contacts at the attending physician and said: Doctor, I didn´t find record in the history of the indication of the urinary catheter, can we withdraw?. If the physician reported the indication, will be recorded in the format without additional comments.~The attending physician decides withdraw or no withdraw the urinary catheter"
45918105|NCT00013273|Procedure|Physical Conditioning|
45644289|NCT03705910|Other|Perceptive Rehabilitation|"In each session, over one hundred cones will be placed on a rigid wooden base using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks.~The therapist will ask the patient firstly to breathe normally and feel the pressure. The patient will then perform breathing exercises and active exercises (including stretching, warming up, and cooling down) under supervision. During the session, the therapist will ask about the pressure of the cones and will correct the patient's posture. At the end of each session, the therapist will photograph the patient's back with the aim of documenting the pressure and hyperaemic areas."
45918106|NCT00391456|Behavioral|Animal-assisted Therapy|
45918107|NCT00013312|Procedure|Determine colonic tone|
45918108|NCT00013351|Procedure|Prevention of Falls|
45918109|NCT00013390|Procedure|Tinnitus Masking|"Tinnitus Masking is a widely-used method for providing relief of tinnitus. The central premise of Tinnitus Masking involves the use of wearable ear-level devices (hearing aids, maskers, or combination instruments) that deliver sound to a patient's ear(s). The primary purpose of the sound presentation is to produce a sense of relief from the annoyance caused by the tinnitus sound. The relief is accomplished by either obscuring, or covering up (masking) the tinnitus sound, or by changing the sound of the tinnitus in some way, usually by reducing its loudness (Vernon, Meikle)."
45785588|NCT01068548|Other|reminder|computer based reminder to change patients from IV to oral antibiotics based on evidence based clinical practice guidelines
45785589|NCT05239130|Device|Auralya|Auralya® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation. Auralya® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile glass syringe with a Luer adapter.
45918110|NCT00013390|Procedure|Tinnitus Retraining Therapy|"Tinnitus Retraining Therapy (TRT) was derived from a purely psychological approach for facilitating tinnitus habituation (Hallam et al). The current method is based on neurophysiological principles, and aims at retraining brain regions that are involved in processing the tinnitus signal, without attempting to suppress generation of the signal (Jastreboff). The retraining involves a systematic effort aimed at decreasing both the detectability of tinnitus and the transmission of the tinnitus signal to emotional centers of the brain. Habituation of tinnitus thus purportedly occurs at two levels: habituation of emotional reactions to the tinnitus and habituation of tinnitus perception. Habituation is achieved by utilizing directive counseling, along with the use of low-level broadband noise to reduce the detectability of tinnitus for patients with normal or near-normal hearing. When hearing loss is a significant problem to the patient, appropriate hearing aids are fitted."
45918111|NCT00013429|Procedure|Visual|
45918112|NCT00013468|Procedure|Tinnitus|
45918113|NCT00013507|Procedure|Falls|
45918114|NCT00391495|Procedure|Blood drawing|
45644290|NCT03705910|Other|Mobilisation Techniques|"A certified physiotherapist will perform mobilisation techniques. All participants in this group will receive treatment protocol according to the list on below. Treatments will be 2 times a week till 8 weeks.~For this treatment, the participant should lie on a bed and change their position according to the technique (supine, position or side-lying). Also, the therapist will be changing her position according to the technique. All technique will be on the range of motion limit. For releasing techniques the therapist will apply three-dimensional pressures till 3-5 minutes, with the feeling of relaxing therapist will change the limit for the next point."
45644291|NCT03705169|Biological|SAR441236|Administered by intravenous (IV) infusion or subcutaneous (SC) injection
45918115|NCT00013546|Drug|TMTDS|
45918116|NCT00013585|Drug|Selegiline hydrochloride|
45918117|NCT00013624|Drug|IV Levodopa|
45918118|NCT00013663|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
46070924|NCT00904982|Behavioral|Financial Incentive and Med-eMonitor|"Financial Incentives: Study participants are entered into a daily lottery. It includes a chance to win either $10 or $100 on any given day throughout the participant's duration in the study (6 months). Participants are assigned a number and each day a computer randomly draws a winning number. Participants whose number is drawn can only collect money if they have taken the medication correctly.~Med-eMonitor: The Med-eMonitor is a device used to measure medication compliance. The device has 5 drawers in which the participants' medication is placed. When a drawer opens, a message displays on the monitor, and asks the participant if he/she is taking his/her medication for the day. The device registers their answers and sends the compliance information via the participants' telephone line nightly to a central study server."
46070925|NCT00904982|Device|2Med-eMonitor|Med-eMonitor is a device that subjects will be given that will monitor an individual's warfarin adherence.
45918119|NCT00013663|Drug|Aldesleukin|
45918120|NCT00013702|Drug|Adefovir|
45918121|NCT00001305|Drug|Humatrope|Patients receive a subcutaneous injection.
45918122|NCT00013741|Behavioral|Tailored Education Messages|
45918123|NCT00005966|Biological|recombinant interferon alfa|
45918124|NCT00005966|Drug|thalidomide|
45918125|NCT00005969|Drug|Chemotherapy|
45918126|NCT00005969|Drug|Tretinoin Liposome|Liposome by vein (IV) over 30 minutes every other day for 28 days
45918127|NCT00014014|Drug|Lamivudine/Zidovudine|
45918128|NCT00014092|Biological|aldesleukin|
45918129|NCT00014092|Biological|recombinant interferon alfa|
45918130|NCT00014092|Biological|sargramostim|
45918131|NCT00014092|Drug|temozolomide|
46070926|NCT00826969|Drug|Ciclesonide|320µg Ciclesonide versus Placebo
46070927|NCT00826969|Drug|Placebo|Placebo
46070928|NCT04222166|Biological|CAM|Cryopreserved Amniotic Membrane
45785590|NCT05227898|Device|Device: Attune™|People enrolled in the study use the app to complete ten informational sessions, each approximately 60-minute in length. The app also include guided exercises and other interactive opportunities.
45785591|NCT05227898|Device|Device: Cerena™|People enrolled in the study use the app to complete ten informational sessions, each approximately 60-minute in length. The app also include guided exercises and other interactive opportunities.
45785592|NCT03014804|Biological|autologous dendritic cells pulsed with tumor lysate antigen Vaccine|Given ID
45644292|NCT03705169|Biological|Placebo|Administered by intravenous (IV) infusion or subcutaneous (SC) injection
45785593|NCT03014804|Other|Laboratory Biomarker Analysis|Correlative studies
45785594|NCT03014804|Biological|Nivolumab|Given IV
45785595|NCT03014804|Other|Quality-of-Life Assessment|Ancillary studies
45785596|NCT03014804|Other|Questionnaire Administration|Ancillary studies
45785597|NCT03583190|Other|Cervical-cranial dry needling|Segmental needling of the neck and needling in the patient's headache distribution. Peripherally sensitized areas of the neck may also be dry needled based on the findings of the clinical evaluation.
45644293|NCT03705169|Drug|Antiretroviral treatment|Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.
45785598|NCT03583190|Other|Orthopedic manual therapy|Orthopedic Manual Therapy (OMT) that includes either mobilization or manipulation to the cervical spine applied pragmatically to the most symptomatic level.
45785599|NCT03583190|Other|Thoracic Manipulation|Thoracic Manipulation (applied pragmatically) to the levels determined to be provocative or hypomobile.
45785600|NCT03583190|Other|Exercise|Clinicians select 1 active range of motion exercise for the cervical spine, deep cervical flexion endurance exercise, and 5 upper extremity exercises (from a set of 10). Additionally, patients will be assigned a headache management technique.
45785601|NCT03583190|Other|Patient Education|Patients will receive education regarding their headache condition, proper performance of their symptom management technique, posture.
45785602|NCT05224388|Drug|Enoxaparin|Use of enoxaparin in either prophylactic dose regimen or therapeutic dose regimen
45785603|NCT05224388|Drug|Heparin|Use of heparin in either prophylactic dose regimen or therapeutic dose regimen
45785604|NCT03558464|Dietary Supplement|Intervention (integrated package)|"During whole study (pregnant women and offspring):~Soap (for daily hand washing)~Chlorine solution (for daily drinking water treatment)~Life stage-appropriate (pregnancy, lactation, IYCF) monthly nutrition and WASH trainings~During pregnancy and up to when offspring turns 6 months old:~LNS (Enov' Mum, 20g sachet daily)~Anthelminthic treatment (single-dose mebendazole (500mg), once during second trimester of pregnancy)~Children 6-24 months of age~MNP (MixMe, 1g sachet every three days)~ORS + zinc~1 egg per day~All families in the intervention group will receive the same agriculture-focused package (see section 'control intervention' below) as those in the control group. All women will follow regular antenatal care as provided by the Kenyan government as part of their routine health system (e.g. intermittent preventive malaria treatment and iron-folic acid-supplements)."
45785605|NCT03558464|Other|Control|"Active control: The families living in the control clusters will receive the agriculture-focused package that is already in place in all participating clusters through the 1AF programme. This agriculture focused package consists of: - Agricultural training (every 2 weeks on average) for all - Free to enrol for the following products on credit: o Compost boosters~Cook stoves o Seeds (onions, maize, indigenous greens, beans) o Maize storage bags o Drying tarps~Trees o Solar lights o Fertilizer o Actellic dust (insecticide) o Re-usable sanitary pads"
45785606|NCT05205980|Behavioral|Perturbation training|Participants will experience repeated perturbations mixed with non-perturbed trials on the treadmill with the protection by a harness.
45785607|NCT03520790|Drug|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
45785608|NCT03520790|Drug|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
45785609|NCT03520790|Drug|Paricalcitol|Paricalcitol (IV or oral) is a man-made form of vitamin D. It is thought to work by blocking a signal in the cancer tumor cells that leads to growth and spreading of the tumor.
45644294|NCT03701646|Device|Measurement by Clearsight device|Clearsight Device is used to obtain non-invasive measurements to be correlated to standard invasive measurements.
45644295|NCT03701334|Drug|Ribociclib|Ribociclib orally taken at 400 mg on days 1 to 21 of a 28-day cycle
45644296|NCT03701334|Other|Endocrine Therapy|ET will be administered according to the local clinical guidelines and current local prescribing information
45644297|NCT03697148|Diagnostic Test|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
45644298|NCT03689296|Other|Questionnaires (Phase 3)|"CardioVascular Risk (CVR) questionnaire representation~SF12~Getting Better My Way~My recovery plan~Psycom~Partner In Health scale"
45785610|NCT03520790|Other|Placebo|Placebo
45785611|NCT03833336|Other|Placebo|The group assigned to placebo will receive an infusion of normal saline solution plus oral lactose capsules identical to oral medication.
45785612|NCT03833336|Drug|Ferric carboxymaltose|The group assigned to receive intravenous iron will receive intravenous ferric carboxymaltose ajusted by weight and Hb levels according to study protocol plus oral placebo
45785613|NCT03833336|Drug|Ferroglycine Sulfate|One group assigned to receive oral iron will receive two 100 mg oral capsule of ferroglycine sulfate plus intravenous placebo (normal saline solution)
46070929|NCT00822601|Device|rTMS|Arm 1 (experimental) : rTMS, 4 weeks of stimulation with RMT frequency 1Hz, intensity 100% of RMT for 20 minutes (1500 pulses), 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks.
45785614|NCT03833336|Drug|Sucrosomial Iron|One group assigned to receive oral iron will receive or two oral capsule containing 30 mg of pyrophosphate sucrosomial iron plus intravenous placebo (normal saline solution)
45918132|NCT00014131|Biological|Biological/Vaccine: therapeutic autologous dendritic cells.|Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
45918133|NCT00005972|Drug|gemcitabine hydrochloride|
45918134|NCT00005972|Drug|irinotecan hydrochloride|
45785615|NCT01069562|Other|Conventional control|The isoflurane administration to deliver anesthesia will be done conventionally through a Tec 7 vaporiser to maintain the bispectral index at 50.
45785616|NCT01069562|Other|Closed loop control|The isoflurane administration to maintain anesthesia will be by infusion to the anesthesia circuit using syringe pump (injection technique). The rate of delivery of isoflurane will be regulated by computer that uses a control algorithm.
45785617|NCT02416908|Drug|Selinexor|
45785618|NCT02416908|Drug|Cladribine|
45785619|NCT02416908|Drug|G-CSF|
45785620|NCT02416908|Drug|Cytarabine|
45785621|NCT02416908|Procedure|Bone marrow biopsy|
45785622|NCT01070810|Drug|D5W|Dextrose 5%
45785623|NCT01070810|Drug|Thiamine|Thiamine 200mg in 50ml D5W
45785624|NCT01071044|Drug|Lisdexamfetamine Dimesylate|Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
45785625|NCT01071044|Drug|"Placebo 30, 50 or 70 mg"|Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
45785626|NCT05150756|Drug|Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE]|At induction of anesthesia, patients will receive a loading dose of 1.5mg/kg lidocaine hydrochloride 2% slowly over 3 min followed by IV infusion of 2mg/kg/hr lidocaine hydrochloride 2% till the end of surgery
45785627|NCT05150756|Drug|morphine sulphate (10mg/ ml ampoule)|At induction of anesthesia, patients will receive a loading dose of IV 0.1mg/kg morphine sulphate slowly over 3 minutes followed by IV infusion of normal saline via infusion pump. The infusion will be continued till the end of surgery
45785628|NCT01071356|Behavioral|Intensive MI|Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
45785629|NCT01071356|Behavioral|Single session MI|Comparator arm that includes 1.5 hours of MI, 8 hours of nutrition classes and outpatient substance abuse treatment
45785630|NCT04352582|Other|Survey|Survey
45785631|NCT03364400|Drug|VT1021|Peptide
45785632|NCT03359252|Procedure|non-stent assisted coiling|non-stent assisted coiling of unruptured intracranial aneurysm
45785633|NCT03359252|Procedure|stent assisted coiling|stent assisted coiling of unruptured intracranial aneurysm
45644299|NCT03689296|Other|Focus groups (Phase 2)|Focus group interviews conducted by two health sociologists in 4 distinct categories: caregivers, patients, primary health care professionals and psychiatric professionals.
45785634|NCT03333356|Radiation|pelvic radiotherapy|adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).
45644300|NCT03689296|Other|semi-structured interviews (Phase 1)|Conduct of exploratory semi-directive interviews with users, caregivers, primary health care professionals and psychiatric professionals by a health sociologist
45644301|NCT03686007|Other|Informational Intervention|Receive MSM intervention handbook
45644302|NCT03686007|Other|Informational Intervention|Receive MSM intervention research nurse coaching
45644303|NCT03686007|Other|Informational Intervention|Receive ASCO print materials
45644304|NCT03686007|Other|Informational Intervention|Receive CRA assistance
45785635|NCT01072136|Other|Placebo|Capsule will be filled with lactose and be identical in appearance to the capsule with the active ingredient.
45785636|NCT01072136|Drug|Azithromycin|Single dose will consist of 2 over-encapsulated capsules (500 mg each) administered orally.
45785637|NCT01072136|Drug|Cefixime|Single dose will consist of 1 over-encapsulated capsule (400 mg) administered orally.
45785638|NCT05135858|Drug|Glucarpidase|Glucarpidase (CPG2) Dose: 2000 U (2 vials of 1000 U per dose) 5 minutes-intravenous administration 24 hours after each Methotrexate infusion (i.e. 6 times in the whole protocol)
45785639|NCT05135858|Drug|Methotrexate (MTX)|MTX will be administred 6 times during the protocol, at a variable interval of 8, 6 or 5 days. It will be administrated in a 2 to 3-hour IV infusion, at the dose of 3.5 g/m2 (body surface area capped at 2 m2). Each MTX administration will be preceded by a prehydration and will be followed by a posthydration
45785640|NCT05116904|Other|Assessment|Pupil reflex and melatonin profile, circadian profile assessment
45644305|NCT03686007|Other|Media Intervention|View the MSM intervention videos
45644306|NCT03686007|Other|Media Intervention|View ASCO Cancer.net videos
45644307|NCT03686007|Other|Quality-of-Life Assessment|Ancillary studies
45785641|NCT05073926|Other|No intervention is part of the study protocol|No intervention is part of the study protocol. The choice of treatment for latent tuberculosis is is made by the treating physician.
45785642|NCT01074164|Other|Standard-of-care treatment for AD|Subjects will receive standard of care treatment for atopic dermatitis, including moisturizers and topical corticosteroids, per their dermatologist.
45785643|NCT01074164|Device|Accu-patch pellet|The accu-patch pellets will be applied to the LI11 pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times a week for 1 month.
45918135|NCT00014170|Drug|gefitinib|Given orally
45644308|NCT03686007|Other|Questionnaire Administration|Ancillary studies
45644309|NCT03683186|Drug|Ralinepag|Active
45785644|NCT03130244|Device|Magnet Anastomosis System|The MAS will be placed using an endoscope in the duodenum and and laparoscopically into ileum. A compression anastomosis will be created in each of the patients and the diversion of enteral flow from the duodenum to ileum treats Type 2 diabetes.
45785645|NCT03130244|Drug|Best Medical Management|The best medical management for the patients in this arm will be decided by the endocrinologist based on protocol parameters.
45785646|NCT05070650|Drug|Acetylcysteine|200 mg/500 mg/10 mg granules for oral solution: one sachet three times per day
45785647|NCT05070650|Drug|Paracetamol|500 mg/10 mg granules for oral solution: one sachet three times per day
45785648|NCT05070650|Drug|Phenylephrine|500 mg/10 mg granules for oral solution
45785649|NCT03014102|Drug|Recombinant Human Thrombopoietin|Recombinant human Thrombopoietin is a full length glycosylated molecule identical to endogenous Thrombopoietin.
45785650|NCT03041324|Biological|SB-913|Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor
45785651|NCT05017532|Behavioral|The program Remédiation Cognitive de la Cognition Sociale en Schizophrénie (RC2S+)|The program Remédiation Cognitive de la Cognition Sociale en Schizophrénie (RC2S+) is a personalized CR treatment targeting social cognition (e.g. theory of mind, emotion recognition) using virtual reality to emulate daily social interactions
45785652|NCT03012230|Other|Laboratory Biomarker Analysis|Correlative studies
45785653|NCT03012230|Biological|Pembrolizumab|Given IV
45785654|NCT03012230|Drug|Ruxolitinib Phosphate|Given PO
45785655|NCT03005444|Drug|Rivaroxaban|10mg/day, for 2 years
45785656|NCT01076270|Drug|plerixafor|Given SC
45785657|NCT01076270|Biological|filgrastim|Given SC
45785658|NCT01076270|Procedure|peripheral blood stem cell transplantation|Infusion of peripheral blood stem cells
45785659|NCT01076270|Procedure|allogeneic hematopoietic stem cell transplantation|Infusion of hematopoietic stem cells
45785660|NCT04937192|Other|No intervention|No intervention
45785661|NCT01076504|Drug|Amrubicin|30 mg/m2 IV on Days 1-3 of each 3-week treatment cycle
45785662|NCT01076504|Drug|Carboplatin|AUC=5 IV, Day 1 of each 3-week treatment cycle
45785663|NCT01076504|Drug|Pegfilgrastim|6 mg SQ on Day 4 of each 3 week treatment cycle
45785664|NCT02453256|Drug|Placebo|Participants will receive matching placebo subcutaneous (SC) injections once weekly for 48 weeks of double-blind treatment.
45785665|NCT02453256|Drug|Tocilizumab|Participants will receive 162 mg SC tocilizumab once weekly for 48 weeks of double-blind treatment. The same regimen will be given to all eligible participants for 48 weeks of open-label treatment.
45785666|NCT04912050|Device|Tablo Hemodialysis System|Renal Replacement Therapy between 12< to ≤ 24 hours.
45785667|NCT02442804|Dietary Supplement|POMx|Pomegranate supplement (1g) by mouth twice per day for 7 days
45785668|NCT02442804|Other|Placebo|Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
45785669|NCT05458128|Drug|pitolisant|"Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. The 4.45 mg strength tablet may be marked with S on one side and is plain on the other side. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. The 17.8 mg strength tablet may be marked with H on one side and is plain on the other side. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant."
45785670|NCT01076972|Drug|Lopinavir/ritonavir (Kaletra)|Lopinavir/ritonavir evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
45785671|NCT02174198|Device|BioOss Collagen at the time of implant placement|Experimental: placement of BioOss Collagen No intervention: no BioOss Collagen
45785672|NCT02174432|Drug|nalbuphine HCl ER|nalbuphine HCl ER BID for up to 50 weeks
45785673|NCT02176382|Drug|denosumab|denosumab subcutaneous injection
45785674|NCT02176382|Drug|teriparatide|teriparatide daily subcutaneous injection
45785675|NCT02176382|Drug|Zoledronic acid|zoledronic acid infusion
45785676|NCT01077596|Drug|Regular bupropion use|Regular use of bupropion is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
45785677|NCT01077596|Drug|Regular SSRI (Selective serotonin reuptake inhibitors) use|Regular use of SSRI is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
45785678|NCT01077596|Drug|Regular TCA (Tricyclic antidepressants) use|Regular use of TCA is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
45785679|NCT01077596|Drug|Regular use of any other antidepressant|"Regular use of any other antidepressants is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date. An other antidepressant would be any antidepressant other than bupropion, a SSRI or a TCA."
45785680|NCT03013712|Biological|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen.
45785681|NCT02765672|Behavioral|Driving Behavior Interview|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
45785682|NCT02765672|Other|Clinical Driving Assessment|Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Mini-Mental State Examination (MMSE) and Strength tests. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
45785683|NCT02765672|Behavioral|Propensity for Angry Driving Scale|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
45785684|NCT02765672|Behavioral|Community Integration Questionnaire|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
45785685|NCT02765672|Behavioral|Satisfaction with Life|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1
45785686|NCT02765672|Behavioral|Fitness-to-Drive Screening Measure (FTDS)|Fitness-to-Drive-Screening Measure will be completed twice, at baseline and at end of study
45785687|NCT02765672|Procedure|Simulated Driving Evaluation|This involves driving a simulator fitted simulated drives engineered to to address Veteran's driving concerns such as reactions to other drivers and road conditions(e.g. debris). The simulator is used at baseline and at post-test1 and 2. The intervention and traffic safety education session 3 also occurs using the driving simulator.
45644310|NCT03679338|Device|Ablation Therapy|Ablation Therapy With Bipolar Radio frequency
45785688|NCT02765672|Procedure|Driving Safety Education|This involves the following: Session1: general traffic safety discussion; Session 2: Rules of the road and acknowledgement of the road discussion and Session 3: driving the simulator without any feedback from traffic safety professional
45785689|NCT02765672|Procedure|Occupational Therapy Driving Intervention (OT-DI)|This has three sessions: 1. Driving evaluator reviews explicit driving errors with Combat Veteran; 2. driving evaluator provide tailored strategies to mitigate errors; Combat Veteran drives simulator with targeted feedback from driving evaluator.
45785690|NCT02765672|Procedure|On-road driving test|This involves and on-road driving test supervised by Driving Rehabilitation Specialist. To be completed at baseline and at month 5
45785691|NCT02765672|Procedure|Driving triggers evaluation|The simulator-drives evaluation group will evaluate the current simulator-triggers prior to baseline testing
45785692|NCT02740868|Drug|Xenon-129|Xenon gas to be inhaled by research participants
45785693|NCT02740868|Device|Magnetic Resonance Imaging|Lung imaging will be performed for participants using MRI for all 3 arms
45785694|NCT02740868|Device|Lung Clearance Index|Lung clearance index (measure of lung health) will be performed for all participants of all 3 arms
45785695|NCT04352894|Diagnostic Test|Fluorescence guided peritoneal exploration|Intravenous injection of ICG
45785696|NCT02414958|Drug|Empagliflozin|
45785697|NCT02414958|Drug|Empagliflozin|
45785698|NCT02414958|Drug|Placebo|
45785699|NCT03016208|Drug|Misoprostol vaginal insert|
45785700|NCT03013790|Drug|Melatonin|Patients will receive Melatonin at 2 different doses or a placebo
45785701|NCT01078376|Drug|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 80 mg, tablets, orally, one day only
45785702|NCT01078376|Drug|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
45785703|NCT01078376|Drug|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
45785704|NCT01078376|Drug|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
45644311|NCT03678883|Drug|9-ING-41|Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.
45644312|NCT03678883|Drug|Gemcitabine - 21 day cycle|Gemcitabine 1250 mg/m2 as a 30-minute intravenous infusion on Days 1 and 8 of a 21-day cycle
45644313|NCT03678883|Drug|Doxorubicin.|Doxorubicin 75 mg/m2, intravenous bolus on Day 1 of a 21-day cycle up to a maximum lifetime dose of 550 mg/m2.
45644314|NCT03678883|Drug|Lomustine|Lomustine 30 mg/m² orally as a single dose, weekly for twelve weeks.
45644315|NCT03678883|Drug|Carboplatin.|Carboplatin AUC 6 IV over 1 hour on Day 1 of a 21-day cycle.
45644316|NCT03678883|Drug|Nab paclitaxel.|Nab-paclitaxel 125 mg/m2 intravenously on Days 1, 8 and 15 of a 28-day cycle
45644317|NCT03678883|Drug|Paclitaxel.|Paclitaxel 175 mg/m2 intravenously over 3 hours on Day 1 of a 21-day cycle.
45644318|NCT03678883|Drug|Gemcitabine - 28 day cycle|Gemcitabine 1000 mg/m2 intravenously over 30-minutes on Days 1, 8 and 15 of a 28-day cycle
45644319|NCT03678883|Drug|Irinotecan|Irinotecan 350 mg/m2 intravenously over 90-minutes on Day 1 of a 21-day cycle
45785705|NCT02485184|Procedure|Transjugular intrahepatic portosystemic shunt|Transjugular intrahepatic portosystemic shunt refers to an interventional radiological procedure by placing a stent between portal vein and hepatic vein. No specific device was used in the Interventional field.
45785706|NCT02485184|Drug|Non-selective beta blockers|Non-selective beta blockers are the drugs for reducing the portal pressure.
45785707|NCT02485184|Procedure|Endoscopic therapy|Endoscopic therapy includes the endoscopic variceal band ligation
45785708|NCT02485184|Drug|Anticoagulation|Anticoagulation therapy includes heparin and warfarin.
45785709|NCT03015818|Other|18F-Fluoride PET-CT ; CT calcium scoring ; 18F-FDG PET-CT|18F-Fluoride PET-CT CT calcium scoring 18F-FDG PET-CT
45785710|NCT01079390|Device|acupuncture|patient will receive high dose, low dose or sham acupuncture treatment.
45785711|NCT01080248|Drug|Gemcitabine|
45785712|NCT01080248|Drug|Pazopanib|
45785713|NCT01080794|Device|Repetitive transcranial magnetic stimulation (rTMS)|"DLPFC Active rTMS: Each treatment will consist of 2000 stimuli (50 X 4-second trains of 40 stimuli at 10 Hz, administered every 30 seconds for 25 minutes). Stimulus intensity for the first and second trains will be 80 and 90 percent of motor evoked potential (MEP), respectively. If no adverse effects are observed following each of the first two trains, then the subsequent trains will be given at MEP threshold.~M1 Active rTMS: Stimulation will be applied one side at a time, to the motor cortex site at 90 percent of each subject's motor threshold intensity, and at a frequency of 10 Hz with 1000 stimuli per side (25 X 8-second trains of 40 stimuli).~Sham rTMS: Patients from all four centers randomized to receive sham treatment will undergo the same procedures used in patients receiving active rTMS."
45785714|NCT04802876|Drug|Spartalizumab|Spartalizumab (PDR001) 400mg will be given intravenously every 28 days
45785715|NCT02452476|Drug|CHF5633|Rescue treatment (if needed)
45785716|NCT02452476|Drug|Poractant alfa|Rescue treatment (if needed)
45785717|NCT01082588|Drug|Pravastatin|pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
45785718|NCT01082588|Drug|Placebo|pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
45785719|NCT02442336|Behavioral|My Journey AHead|The intervention program will contain information and interactive activities around swallowing concerns, proper oral care, healthy eating and nutrition, speech issues, stress and coping with cancer, and pain management.
45785720|NCT02119988|Procedure|TIPS|TIPS will be performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.
45785721|NCT02119988|Procedure|Variceal Embolization|Embolization of gastroesophageal collaterals will be conducted via the same jugular vein before TIPS implantation. The major procedures includ (a) angiography of gastroesophageal collaterals after successful intrahepatic puncture of a branch of the portal vein and (b) embolization of gastroesophageal collaterals with coils of varying diameters, which result in the gastroesophageal collaterals disappearing at postembolization angiography.
45785722|NCT03016052|Behavioral|ABMT|Participants will be trained with a dot-probe task including angry-neutral faces. The task will be adapted for the oddball paradigm, such that in 80% of trials the probe will appear in place of the neutral face, and in 20% of trials in place of the angry face.
45785723|NCT02452398|Device|Treatment group|The intense pulsed light (IPL) applicator with a wavelength of 690 nm and spot size (treatment area) of 30 mm by 10 mm will be used to deliver the energy to the treatment area.
45785724|NCT02452398|Other|No intervention|Subject will act as their own control where the baseline hair count will be used as a comparator to the hair count after treatment.
45785725|NCT02413398|Drug|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks. Randomization will be stratified by pre-enrolment anti-hyperglycemic therapy
45785726|NCT02413398|Drug|Matching Placebo for Dapagliflozin|Matching Placebo for Dapagliflozin tablets administered orally once daily for 24 weeks
45785727|NCT04926168|Other|Delay of TMZ|Delay of TMZ to analyze the current standard of care practice of prescribing TMZ post combination (RT and TMZ).
45785728|NCT04926168|Other|Standard of Care (SOC) Adjuvant TMZ (no intervention|SOC in Adjuvant Setting no intervention
45785729|NCT02441946|Drug|Abemaciclib|Administered orally
45785730|NCT02441946|Drug|Loperamide|Administered orally
45785731|NCT02441946|Drug|Anastrozole|Administered orally
45785732|NCT01083368|Drug|temsirolimus|Given IV
45785733|NCT01083368|Biological|bevacizumab|Given IV
45918136|NCT00014170|Other|pharmacological study|Correlative studies
45918137|NCT00014170|Other|laboratory biomarker analysis|Correlative studies
45644320|NCT03678753|Drug|Cenobamate|12.5 mg tablet, 25 mg tablet, 50 mg tablet, 100 mg tablets, 150 mg tablets, 200 mg tablets. The adolescent subjects will follow the same regimen in an oral suspension adolescent equivalent dose based on weight.
45918138|NCT00014170|Other|questionnaire administration|Ancillary studies
45644321|NCT03678753|Drug|Placebo|Matching Placebo
45918139|NCT00014170|Procedure|quality-of-life assessment|Ancillary studies
45918140|NCT00014209|Drug|cisplatin|
45918141|NCT00014209|Drug|dexamethasone|
45644322|NCT03678350|Device|Light Dosimetry for Intranoperative Therapy|Undergo IO-PDT
45918142|NCT00014209|Drug|gemcitabine hydrochloride|
45918143|NCT00014248|Drug|adenosine triphosphate|
45918144|NCT00014248|Procedure|quality-of-life assessment|
45644323|NCT03678350|Procedure|Photodynamic Therapy|Undergo IO-PDT
45644324|NCT03678350|Drug|Porfimer Sodium|Given IV
45644325|NCT03671590|Drug|TG-1701|Oral daily dose
45644326|NCT03671590|Drug|Umbralisib|Oral Daily Dose
45644327|NCT03671590|Biological|Ublituximab|IV infusion
45644328|NCT03671525|Drug|Nimodipine|Subject will receive two 30mg capsules of nimodipine during study visit.
45785734|NCT01083368|Genetic|polymorphism analysis|Correlative studies
45785735|NCT01083368|Other|laboratory biomarker analysis|Correlative studies
45785736|NCT01083758|Drug|LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)|Topical suspension applied once daily for up to 8 weeks
45785737|NCT02387580|Drug|OZ439 + TPGS|
45785738|NCT02387580|Drug|OZ439 Prototype 1|
45785739|NCT02387580|Drug|OZ439 Prototype 3|
45785740|NCT02387580|Drug|PQP|
45785741|NCT02440854|Drug|afatinib|Patients were treated as per the routine medical practice in terms of visit frequency, types of assessments performed and with adherence to the local prescribing requirements for afatinib.
45785742|NCT01084148|Drug|V0034CR01B|
45785743|NCT01084148|Drug|V0034CR01B vehicle|
45785744|NCT01085006|Drug|Tranexamic acid|Tranexamic acid in cases, normal saline in controls
45785745|NCT01085006|Drug|Normal saline|Tranexamic acid in cases, normal saline in controls
45785746|NCT01085318|Drug|Rebif|44 mcg tiw
45785747|NCT01085786|Drug|14-day sequential treatment|"14-day sequential therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days~14-day hybrid therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days"
45785748|NCT01085786|Drug|14-day hybrid treatment|esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
45918145|NCT02972164|Behavioral|Weight loss program for school children|"The intervention involves developing social and emotional competences, promotion of healthy lifestyle, use of activity monitoring devices to promote increased activity and enlisting family to maintain weight loss in the long term.~The intervention group receives all program components: 1. Parent information sessions and orientation, 2. Two week intensive weight loss and lifestyle education camp, 3. after school clubs for consolidation (including physical activity and lifestyle education), and 4. wearable sensors and social media modules with parental involvement. Assessed outcomes include pre- and post-measurement at each phase included: weight, height, BMI, waist circumference, blood pressure, physical activity, dietary intakes, self-esteem, and subjective well-being."
45918146|NCT00005975|Drug|Megestrol Acetate 20mg/day|Double blinded Megestrol Acetate 20 mg/day
45785749|NCT04670822|Behavioral|Breastfeeding promotion|The intervention group will receive multicomponent interventions consisting of 7 half-hour postnatal visits for lactation counseling, family/peer/employer support, contingent financial incentives, and early limited formula milk via syringe (optional for at-risk infants).
45785750|NCT04670822|Behavioral|Attention placebo control|The attention placebo control group will complete the same frequency and duration of study visits as the intervention group but focus on general infant care counseling and support.
45785751|NCT01035788|Behavioral|Mindfulness Based Cognitive Behavioral Conjoint Therapy|This intervention combines Cognitive Behavioral Conjoint Therapy for PTSD and mindfulness skills. Cognitive Behavioral Conjoint Therapy for PTSD includes PTSD psychoeducation, communication skills training and cognitive restructuring. Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses.
45785752|NCT01035788|Behavioral|CBCT for PTSD - Communication Skills|This control intervention will provide psychoeducation including the communication skills content from sessions 1-7 of Cognitive Behavioral Conjoint Therapy for PTSD.
45785753|NCT02412852|Drug|Sodium nitrite|Sustained release formulation of sodium nitrite
45785754|NCT02412852|Drug|Placebo|Placebo tablets containing same excipients and coatings used in the active tablets, without sodium nitrite being added.
45785755|NCT02170220|Drug|Vortioxetine|Vortioxetine tablets
45785756|NCT01036490|Other|Exercise|Exercise training for 12 weeks followed by home exercise for 40 weeks
45785757|NCT01036802|Drug|Warfarin|Patients on the active treatment arm will receive warfarin to achieve a target international normalized ratio of between 2 and 3
45785758|NCT01036802|Drug|Placebo|
45785759|NCT01037192|Drug|vancomycin|vancomycin 30 mg/kg intravenous administered once daily
45644329|NCT03671525|Drug|Placebo oral capsule|Two coconut oil capsules that mimic the size and color of the nimodipine capsules
45918147|NCT00005975|Drug|Megestrol Acetate 40 mg/day|Double blinded Megestrol Acetate 40 mg/day
45918148|NCT00005975|Drug|Megestrol Acetate Placebo 20 mg/day|Megestrol Acetate Placebo 20 mg/day
45918149|NCT00005975|Drug|Megestrol Acetate Placebo 40 mg/day|Megestrol Acetate Placebo 40 mg/day
45918150|NCT00014287|Drug|gemcitabine hydrochloride|
45918151|NCT00014326|Radiation|radiation therapy|
45644335|NCT03656380|Drug|Mepolizumab 300 mg|Mepolizumab 300 mg subcutaneous injection
45644336|NCT03656380|Drug|Mepolizumab 100 mg|Mepolizumab 100 mg subcutaneous injection
45785760|NCT01037192|Drug|vancomycin|vancomycin 15 mg/kg intravenous administered twice daily (standard dosing)
45785761|NCT03014258|Biological|NF54 P. falciparum malaria challenge|Aseptically-raised A. stephensi female mosquitoes infected with aseptically-raised P. falciparum parasites of the NF54 strain.
45785762|NCT01088672|Procedure|Mechanical Thrombectomy|The Trevo device is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke.
45785763|NCT02386098|Drug|BMS-955176|HIV Maturation Inhibitor
45785764|NCT02386098|Drug|Atazanavir (ATV)|Atazanavir
45785765|NCT02386098|Drug|Ritonavir (RTV)|Ritonavir
45918152|NCT00014365|Drug|MKC-1|
45918153|NCT02971930|Biological|BAY94-9027|Intravenous infusion of BAY94-9027
45918154|NCT00005978|Biological|filgrastim|
45918155|NCT00005978|Drug|carboplatin|
45918156|NCT00005978|Drug|etoposide|
45644337|NCT03656380|Other|Placebo|Saline subcutaneous injection
45644338|NCT03654716|Drug|ALRN-6924|ALRN-6924 is a drug that blocks certain proteins in tumor cells called MDM2 and MDMX. These proteins may be important in the growth of some cancers. Laboratory experiments and results from studies with adults show that ALRN-6924 may stop tumor growth and, in some cases, may cause tumor cells to die.
45785766|NCT02386098|Drug|Dolutegravir (DTG)|Dolutegravir
45785767|NCT02386098|Drug|Tenofovir (TDF)|Tenofovir
45785768|NCT01089062|Drug|MAP0004|1.0 mg orally inhaled MAP0004 administered in Treatment B as per protocol
45785769|NCT01089062|Drug|IV Placebo (Saline)|IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol
45785770|NCT01089062|Drug|Placebo Inhaler|Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.
45785771|NCT01089062|Drug|IV Dihydroergotamine Mesylate (DHE)|IV DHE administered in Treatment A as per protocol
45785772|NCT02412618|Drug|Mifepristone|Progesterone antagonist
45785773|NCT02412618|Drug|Misoprostol|Prostaglandin E1
45785774|NCT02412618|Dietary Supplement|Placebo|Tasteless, odorless, sugar based pill
45785775|NCT01040858|Behavioral|Cognitive Strategy Training|Cognitive Strategy Training will consist of weekly 120-minute group sessions for 10 weeks.
45785776|NCT01040858|Other|Placebo comparison group|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study).
45785777|NCT01091948|Device|Intubation with Fiberoptic laryngoscope|Subjects will be intubated with the Fiberoptic laryngoscope.
45785778|NCT01091948|Device|GlideScope® Video Laryngoscope|Patients will be intubated with the GlideScope® Video Laryngoscope.
45785779|NCT01109576|Behavioral|DSL Workshop|A series of 6 weekly 2 hour interactive workshops for Veterans with age-related Dual Sensory Loss that provide instruction, skills training, exercises and facilitated interaction among peers.
45785780|NCT01041248|Drug|Tocilizumab|8mg/kg every 2 weeks i.v.
45785781|NCT02179892|Drug|Bupivacaine Extended-Release Liposome Injection (Exparel)|266mg/30mL of Exparel will be injected via unilateral TAP block
45785782|NCT02179892|Drug|Bupivacaine and Dexamethasone Injection|As a combination injection, 28 ml of 0.375% bupivacaine and 8 mg/2ml of dexamethasone will be injected via unilateral TAP block.
45785783|NCT02179892|Drug|IV Acetaminophen|Intravenous (IV) acetaminophen 1000 mg every 8 hours for 8 doses.
45785784|NCT02179892|Drug|Oral Acetaminophen|Oral acetaminophen 650 mg every 6 hours.
45785785|NCT01092338|Drug|Cholecalciferol (Vit D3)|To test two oral daily doses (4000 vs. 7000 IU) of cholecalciferol (D3) dietary supplement (capsules or liquid) over a 3-month period in 44 children, adolescents and adults with HIV/AIDS.
45644339|NCT03654716|Drug|Cytarabine|Cytarabine belongs to the category of chemotherapy called antimetabolites. Antimetabolites are very similar to normal substances within the cell. When the cells incorporate these substances into the cellular metabolism, they are unable to divide
45785786|NCT01110434|Drug|Topiramate|Topiramate (200 mg daily)
45785787|NCT01110434|Drug|Placebo|Placebo (daily)
45785788|NCT01042496|Drug|Lamotrigine|12 week open trial: 25mg/day for 2 weeks, 50mg/day for 2 weeks, 100mg/day for 2 weeks, 200mg/day for 6 weeks. Flexible titration for early response and/or side effects.
45785789|NCT01042496|Procedure|1H-MR|Proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC).
46070930|NCT00822601|Device|Sham Comparator|sham rTMS (using a placebo coil), 4 weeks of stimulation, will mimic the active treatment mentioned above.
46070931|NCT03560882|Drug|Atorvastatin|Atorvastatin tablet, 80mg
45644340|NCT03653611|Other|On-site Practice Assessment|The assessment takes place in three parts; the pre-observation practice overview (conducted with the 2 practice clinicians - 60 minutes), the ½ day practice workflow observation (observation by one member of the Aim 2 research team of common and testing areas used for the respiratory patient). There is no patient engagement and no collection of patient-specific identification or health information), and the post-observation practice summary (conducted with the same 2 practice clinicians - 30 minutes).
45644341|NCT03653611|Other|Clinical Staff Questionnaires|"Written or on-line questionnaires are provided to participating and consented staff personnel at two practice levels -- Non-Prescribing clinical (also known as support) staff and Prescribing (PR) clinical (also known as provider) staff."
45644342|NCT03653611|Other|Patient Opinion Surveys|200 Eligible participants will complete a one-time 5 to 10 minute CAPTURE opinion survey.
45644343|NCT03653611|Other|Modular online COPD Education|Access to free, COPD on-line, continuing education is provided for all clinical staff at each practice. Each module will take 20 minutes or less. Aim 2 clinician participant access and completion of COPD education modules is assessed by clinician questionnaires and focus group item response over 12 months (between months 2 and 14 of Aim 2 timeline).
45785790|NCT01111058|Drug|Everolimus (RAD 001)|10mg of Everolimus or Placebo taken by mouth once daily for 1 year or until progression (whichever comes first).
45785791|NCT01111058|Other|Placebo|
45785792|NCT02246738|Other|Blood Collection|
45785793|NCT01111370|Device|DexCom™ G4 Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
45785794|NCT01112228|Procedure|Bariatric surgery|Bariatric surgery: Gastric bypass, Sleeve gastrectomy, or Gastric banding
45785795|NCT03013244|Behavioral|The Body Project: More Than Muscles|Participants complete a variety of activities designed to counter internalization of the lean, muscular body ideal for men.
45785796|NCT01112696|Device|Sensor wear|All subjects to wear sensors
45785797|NCT03013478|Behavioral|Standard Treatment As Usual (TAU)|Treatment normally offered at this primary care clinic
45785798|NCT03013478|Behavioral|CBT4CBT program|
45785799|NCT01094522|Drug|Methadone|"0.2 mg/kg (IV) for the Initial Loading Dose; followed by PRN (as needed) doses (given by the ICU Nurses) starting at 0.035 mg/kg (IV) every 30 minutes, for postoperative pain. The PRN dose of methadone may be increased by the ICU doctors until the dose is adequate to relieve the patient's pain."
45785800|NCT01094522|Drug|Morphine|"0.2 mg/kg (IV) for the Initial Loading Dose; followed by PRN (as needed) doses (given by the ICU Nurses) starting at 0.035 mg/kg (IV) every 30 minutes, for postoperative pain. The PRN dose of morphine may be increased by the ICU doctors until the dose is adequate to relieve the patient's pain."
45785801|NCT02178800|Drug|GSK1265744 Tablets|30-mg tablets, taken orally
45785802|NCT02178800|Drug|Injectable GSK1265744|"Cohort 1: 800-mg injection, administered as two 400-mg intramuscular (IM) gluteal injections~Cohort 2: 600-mg injection, administered as one IM gluteal injection"
45785803|NCT02178800|Drug|Placebo for GSK1265744 Tablets|Taken orally
45785804|NCT02178800|Drug|Injectable Placebo for GSK1265744|"Cohort 1: Sodium Chloride for Injection USP, 0.9%; administered as two 400-mg IM gluteal injections~Cohort 2: Sodium Chloride for Injection USP, 0.9%; administered as one 600-mg IM gluteal injection"
45785805|NCT01044212|Drug|Docusate|Docusate 100mg BID
45785806|NCT01044212|Drug|Bowel medications|Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID
45918157|NCT00005978|Drug|melphalan|
45785807|NCT02174510|Drug|20mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
45785808|NCT02174510|Drug|40mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
45785809|NCT02174510|Drug|80mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
45785810|NCT02174510|Drug|placebo|
45785811|NCT01113008|Procedure|Remote ischemic postconditioning|Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated
45785812|NCT01113008|Procedure|Control group|In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.
45785813|NCT00585195|Drug|PF-02341066|Escalating doses of PF-02341066 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg to 2000 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days (or 21 days depending on the cohort).
45918158|NCT00005978|Procedure|autologous bone marrow transplantation|
45785814|NCT00585195|Drug|Rifampin|600 mg QD administered from Cycle 1, Day 16 to Cycle 2, Day 1 (14 days of dosing) in combination with PF-02341066.
45785815|NCT00585195|Drug|Itraconazole|Multiple Dose Design: 200 mg QD administered from Cycle 1, Day 1 to Cycle 1, Day 16 (16 days) in combination with PF-02341066.
45785816|NCT01113398|Drug|AMG 102|AMG 102 will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg every 2 weeks over 60 or 30 minutes.
45785817|NCT01113398|Drug|Avastin|Avastin will be administered as a continuous intravenous infusion at 10 mg/kg every 2 weeks (6-week study cycle) over 60 or 30 minutes. Avastin will be given prior to AMG 102.
45785818|NCT03013556|Drug|Group A, TDF|TDF for 96 weeks
45785819|NCT03013556|Drug|Group B:TDF then TDF and Peginterferon alfa-2a|Subjects will be treated by TDF in the first 48 weeks, then will be treated by the combination of TDF and Peginterferon alfa-2a for another 48 weeks
45785820|NCT03013556|Drug|Group C:TDF and Peginterferon alfa-2a then TDF|Subjects will be treated by the combination of TDF and Peginterferon alfa-2a for the first 48 weeks, then will be treated by TDF for another 48 weeks.
45785821|NCT01113632|Drug|Ofatumumab|IV infusion once weekly for a total of 8 weeks. Patients will visit the study center once weekly to receive their IV infusion of ofatumumab. To reduce the possibility of infusion reactions, the first dose of ofatumumab will be administered at a dose of 300 mg. If the initial 300 mg dose of ofatumumab is well tolerated, without occurrence of any infusion-associated AEs of ≥ grade 3, subsequent doses of ofatumumab (i.e., Week 2 through Week 8) will be at a dose of 2000 mg.
45785822|NCT01114334|Behavioral|Guideline-Based Medical Management|We used the Colorado Clinical Guidelines Collaborative treatment guideline for Major Depression. It recommends treatment options e.g. specialty mental health counseling, antidepressant treatment, physical activity, depending upon presenting symptoms severity and other factors. The assessor notifies the clinician at the baseline visit about the patient's PHQ-9 depressive symptom severity score.
45785823|NCT01114334|Behavioral|Motivational Interviewing for Depression|Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.
45785824|NCT00458835|Drug|Ciclesonide|
45785825|NCT01044758|Drug|Levetiracetam 62.5mg|62.5mg twice daily (2 weeks)
45449116|NCT03732105|Drug|Apatinib|Patients in apatinib group will receive oral apatinib at an initial dose of 500mg daily until recurrence, death,patient withdrawal or unacceptable toxic effects. At the first occurrence of grade 3 or 4 toxicities, apatinib was delayed until recovery to grade 2 or below, and then treatment was resumed with a reduction to 500 mg and 250 mg taken on alternate days. At the second occurrence of grade 3 or 4 toxicities, apatinib was delayed until recovery to grade 2, and then treatment was resumed with a reduction to 250 mg once daily.
45644344|NCT03653611|Other|COPD in Primary Care/CAPTURE Introduction Focus Groups|Two 45 to 60-minute focus group discussions occur at each Aim 2 practice. Focus groups are informed by practice demographics, practice assessment data, as well as patient opinion from CAPTURE surveys and past CAPTURE study. Focus group candidate themes and prompts are developed for non-prescribing clinical staff (NPR) and prescribing clinical staff (PR) and are presented at separate on-site focus group sessions to allow more detailed discussion of role responsibility in the context of daily practice workflow.
45644345|NCT03653390|Behavioral|EnhanceWellness for Disability (EW-D)|Participants work one-on-one with the study Wellness Coach to identify health self-management problems, consider options, develop goals and an action plan, and make adjustments to that plan over time.
45644346|NCT03653390|Behavioral|Wellness Education|Sessions will cover: (1) blood pressure management; (2) smoking cessation; (3) cancer screening; (4) regulation of blood glucose; (5) decreasing LDL cholesterol; (6) physical activity; (7) bone, joint, and muscle health; and (8) immunizations.
45644347|NCT03648437|Drug|Paracetamol 10Mg/mL|Experimental drug
45644348|NCT03648437|Drug|0.45% Sodium Chloride|Placebo comparator
45785826|NCT01044758|Drug|Levetiracetam 125mg|125mg twice daily (2 weeks)
45785827|NCT01044758|Drug|Levetiracetam 250mg|250mg twice daily (2 weeks)
45644349|NCT03648437|Drug|Ibuprofen|Standard therapy
45644350|NCT03648437|Drug|Indomethacin|Standard therapy
45644351|NCT03646058|Drug|Buprenorphine|Buprenorphine, 0.4mg pills, sublingual
45785828|NCT01044758|Drug|Placebo|placebo capsule twice daily (2 weeks)
45785829|NCT02439216|Drug|Edasalonexent|
45785830|NCT02439216|Drug|Placebo|
45785831|NCT01115582|Drug|Cholic acid|"The IUPAC name for cholic acid is 3 alpha,7alpha,12 alpha-trihydroxy-5 beta-cholanoic acid. The international nonproprietary name (INN) is cholic acid.~Each patient will be given a box containing a 1 month supply of study drug. Each bottle will contain 90 capsules; each capsule will contain either 50 or 250 mg of manufactured cholic acid depending upon the child's weight. The study drug will be taken orally, in divided doses (as determined by the investigator), for a total daily dose of 10-15 mg/kg body weight. Parents of infants and young children who are unable to swallow the TBM cholic acid capsule will be instructed to sprinkle the contents of the capsule over 1-2 teaspoons of plain applesauce and feed it to the child."
45785832|NCT03013400|Drug|Ebselen|Ebselen is an opaque capsule containing 200 mg of ebselen is a selenium-based GPx mimic and IMPase inhibitor.
45785833|NCT03013400|Drug|Placebo oral capsule|Placebo is identical in appearance to the ebselen capsules
45785834|NCT02439138|Drug|GS-1101|Oral twice daily for 6 months followed by once daily until disease progression or unacceptable toxicity.
45918159|NCT00005978|Procedure|peripheral blood stem cell transplantation|
45644352|NCT03646058|Drug|Placebo|Placebo pills, sublingual, specifically made to mimick buprenorphine pills
45644353|NCT03644485|Drug|Tacrolimus immediate-release formulation|oral
45644354|NCT03644485|Drug|Tacrolimus prolonged-release formulation|oral
45644355|NCT03644485|Drug|Induction therapy|All participants will receive induction therapy. The dosage and administration of induction immunotherapy will be a single kind of drug determined by the investigator.
45644356|NCT03644485|Drug|Mycophenolic acid drugs|All participants will receive mycophenolic acid drugs in combination with corticosteroids. The dosage and administration of mycophenolic acid will be determined by the investigator.
45785835|NCT01097642|Drug|Cetuximab|Cetuximab will be given at 400mg/m^2 IV over 120 minutes for its initial loading dose on day 1 of the first of four 21 day cycles. It will then be administered on a weekly basis at 250 mg/m^2 IV over 60 minutes.
45644357|NCT03644485|Drug|Corticosteroids|All participants will receive corticosteroids in combination with mycophenolic acid drugs. The dosage and administration of corticosteroids will be determined by the investigator.
45644358|NCT03643042|Other|Transfusion|Transfusion with Hb maintain between 80 and 100g/L or Hb maintain between 100 and 120g/L
45644359|NCT03641560|Drug|Enzalutamide|Enzalutamide will be administered orally
45644360|NCT03641560|Drug|Androgen deprivation therapy (ADT)|All participants will be required to maintain ADT during study treatment, either using a Gonadotropin Releasing Hormone (GnRH) agonist/antagonist or having a history of bilateral orchiectomy
45644361|NCT03641209|Drug|Paracetamol 10mg/mL infusion solution|Intravenous paracetamol solution for infusion
45644362|NCT03641209|Other|Placebo|Half physiological saline solution as the non-active placebo solution
45644363|NCT03626688|Drug|Ralinepag|Active
45644364|NCT03626688|Drug|Placebo|Placebo
45644365|NCT03622593|Drug|Aflibercept|Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
45644366|NCT03622593|Drug|Faricimab|Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.
45644367|NCT03622593|Procedure|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable visits to maintain masking among treatment arms.
45644368|NCT03620058|Biological|CART22-65s cells|Autologous T cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
45644369|NCT03620058|Biological|huCART19 Cells|Autologous T cells transduced with lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB
45644370|NCT03618186|Combination Product|Tau PET scan|Patient will receive a dose of flutaucipir and be scanned appropriately
45644371|NCT03614260|Device|Paradise Renal Denervation System|Following renal angiogram according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
45644372|NCT03614260|Procedure|Renal Angiogram|Following renal angiogram to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure.
45918160|NCT00005978|Radiation|iobenguane I 131|
45918161|NCT00005978|Radiation|radiation therapy|
45918162|NCT00014404|Drug|celecoxib|
45918163|NCT00001332|Procedure|CHPP with cisplatin|
45918164|NCT00014482|Procedure|pain therapy|
45918165|NCT00014482|Procedure|psychosocial assessment and care|
45644379|NCT03604835|Other|No Intervention|Access to any treatment is through authorized commercial use or available expanded access programs only and not as a part of this DMP.
45644380|NCT03602066|Drug|Chlorine Dioxide Sterilization|Given via oral rinse
45644381|NCT03602066|Other|Laboratory Biomarker Analysis|Correlative studies
45644382|NCT03602066|Other|Placebo|Given via oral rinse
45785836|NCT01097642|Drug|Ixabepilone|Ixabepilone will be given at 40mg/m^2 IV over 180 minutes on day 1 of each of four 21 day cycles.
45644383|NCT03597581|Drug|RGX-202-01|RGX-202-01 is a small molecule inhibitor of the creatine transporter, SLC6a8.
45644384|NCT03597581|Drug|FOLFIRI|FOLFIRI is a chemotherapy regimen consisting of irinotecan, leucovorin, and 5-fluorouracil. Irinotecan is a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
45644385|NCT03597581|Drug|Bevacizumab|Bevacizumab is a vascular endothelial growth factor inhibitor.
45644386|NCT03593655|Device|Dapivirine vaginal ring|Vaginal ring containing 25 mg of dapivirine
45644387|NCT03593655|Drug|FTC/TDF|Tablet containing 200 mg FTC/300 mg TDF
45644388|NCT03592888|Drug|mDC3/8-KRAS Vaccine|Mature dendritic cell (mDC3/8) vaccine (primer and booster) in subjects with resected pancreatic adenocarcinoma
45785837|NCT02442687|Drug|JKB-121: 5 mg twice daily|
45785838|NCT02442687|Drug|JKB-121: 10 mg twice daily|
45644389|NCT03591133|Drug|TS-143|
45785839|NCT02442687|Drug|Placebo|
45785840|NCT01115660|Behavioral|stroke education|call by medication coach 2 weeks after hospital discharge
45918166|NCT00014521|Drug|karenitecin|
45644390|NCT03591133|Drug|Placebo|
45644391|NCT03586661|Drug|Copanlisib|Given IV
45644392|NCT03586661|Drug|Niraparib|Given PO
45644393|NCT03585764|Drug|MOv19-BBz CAR T cells|intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy.
45644394|NCT03585764|Device|Alpha Folate Receptor expression test|Patients will first be pre-screened for alpha folate receptor expression. The test for alpha folate receptor expression is a laboratory developed test+, developed and conducted by the Hospital of the University of Pennsylvania Pathology and Laboratory Medicine lab to determine subject eligibility. This test is not an approved FDA device and its use is investigational.
45644395|NCT03583099|Other|COPD plus CAPTURE education and patient-level information|Basic COPD Education plus CAPTURE education and patient-level CAPTURE information will be provided to all practice personnel randomized to the 'CAPTURE + COPD Education' arm.
45644396|NCT03583099|Other|COPD Education Only|Practice clinicians will receive basic COPD education only. Patient-level CAPTURE information will not be provided.
45644397|NCT03581500|Drug|Hyperpolarized Carbon C 13 Pyruvate|Given IV
45644398|NCT03581500|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
45785841|NCT00841178|Procedure|Surgery|Saphenopopliteal junction ligation, stripping of the Short Saphenous vein where possible, perforator ligation and ambulatory phlebectomy, where necessary.
45785842|NCT00841178|Procedure|EVLT|EVLT of the Short saphenous vein with perforator ligation and / or ambulatory phlebectomy as required.
45918167|NCT00014599|Drug|paclitaxel|
45918168|NCT00005981|Drug|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.
45644399|NCT03581318|Device|MRI|MRI for up to two hours, some without- and some with- administration of intravenous gadolinium based contrast agents (GBCAs), as well as some without and some with pharmacologic or physical stress.
45785843|NCT04341519|Behavioral|PTSD|"family members: post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days~Patients:~post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days"
45785844|NCT04341519|Behavioral|Burnout|Symptoms of burnout as assessed by the Maslash Burnout Inventory
45785845|NCT01048424|Device|RESPeRATE|"RESPeRATE is a commercially available, walkman-like device manufactured by Intercure, Ltd. that measures chest/abdominal excursion during respiration using an elastic belt with a sensor placed around the torso over clothing. The device senses respiration and uses musical tones keyed to inhalation and exhalation to help the user slow respiration and prolong exhalation to a recommended goal of less than 10 breaths per minute. RESPeRATE is approved by the FDA for treatment of mild hypertension and has also been shown to decrease self-reported anxiety and stress, oxygen consumption, and respiratory rate."
45785846|NCT01048424|Other|Urinary Incontinence Pamphlet|The urinary incontinence pamphlet will provide information about classification, pathophysiology, and management of urinary incontinence, including management strategies such as timed urination and pelvic muscle exercises.
45644400|NCT03578419|Device|Small-Volume Blood Collection Tubes|Small-volume vacuum (< 4 mL) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and serum blood collection tubes.
45644401|NCT03578419|Device|Standard-Volume Blood Collection Tubes|Standard-volume (≥ 4 mL) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and serum blood collection tubes.
45644402|NCT03577106|Device|Transcranial magnetic stimulation (TMS)|Theta Burst Stimulation (TBS), a form of TMS, will be targeted to the Inferior Parietal Cortex based on neural navigation software. TBS will be delivered for about 5-6 minutes, five days a week for two weeks, for a total of ten sessions.
45785847|NCT02444715|Behavioral|Standard care|Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.
45785848|NCT02444715|Behavioral|CAPSYS|In addition to the usual care, patients are asked to call the CAPSYS system twice a week.
45644403|NCT03574597|Drug|Semaglutide|Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.24 mg; dose will gradually be increased every 4 weeks up to 2.4 mg.
45644404|NCT03574597|Drug|Placebo (semaglutide)|Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
45785849|NCT01048658|Drug|Sevoflurane|Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
45785850|NCT01048658|Other|No Sevoflurane|Subject only standard of care drug regimens for anesthesia with this procedure.
45785851|NCT04341675|Drug|Sirolimus|Sirolimus 6mg daily on Day 1 followed by 2mg daily for the next 13 days for a total treatment duration of 14 days or hospital discharge, whatever happens sooner.
45785852|NCT04341675|Drug|Placebo|Matching placebo
45785853|NCT02445807|Drug|DFD06-Cream|Twice daily topical application for 14 days.
45785854|NCT02445807|Drug|Vehicle Cream|Twice daily topical application for 14 days.
45785855|NCT00362973|Other|laboratory biomarker analysis|
45785856|NCT00362973|Procedure|needle biopsy|
45644405|NCT03572530|Drug|5-Azacytidine (5-AZA) group 1|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 1 will receive two 5-AZA infusions per week (typically Monday and Thursday but may be given on other days based upon logistical considerations) for 8 consecutive weeks."
45785857|NCT00362973|Procedure|positron emission tomography|
45785858|NCT00362973|Procedure|radionuclide imaging|
45785859|NCT00362973|Radiation|fludeoxyglucose F 18|
45785860|NCT01116986|Behavioral|Counseling before quit attempt|Participants randomized to this condition will have 20-minute in-person counseling sessions 1 and 3 weeks before their target quit day and a 20-minute phone counseling session 2 weeks before their target quit day. In the in-person counseling session, the case manager will address issues such as smoking reduction, withdrawal coping, environmental restrictions on smoking, intra-treatment social support, autonomous motivation, and practice quit attempts. Participants will be asked to engage in two practice quit attempts. These attempts will each last 8 hours and will be assigned (in collaboration with the smoker) to occur on one weekend day and one weekday the second and third weeks after the quit day.
45785861|NCT01116986|Behavioral|Minimal In-person counseling during quit attempt|Participants randomized to minimal in-person counseling will receive one 3-minute in-person session occurring one week before their target quit day. The clinician will also inform the participant of the sort of phone counseling follow-up that s/he will receive in 1 and 2 weeks after their quit date. (This resembles the real-world situation in which the clinician discusses the sort of follow-up intervention a patient will receive.)
45918169|NCT00005981|Drug|carmustine|Carmustine IV over 1 hour (beginning 1 hour after completion of BG infusion) on day 1. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.
45918170|NCT00014638|Drug|letrozole|
45918171|NCT00001341|Drug|ZD1694 (TOMUDEX)|
45918172|NCT00014677|Biological|interleukin-4 PE38KDEL cytotoxin|
45918173|NCT00014677|Procedure|conventional surgery|
45918174|NCT00391534|Drug|modified release formulation of oxcarbazepine (OXC MR)|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
46070932|NCT04044547|Drug|Rotigotine, extended-release microspheres|"Four stable dose levels of LY03003 at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks."
46070933|NCT04044547|Drug|Placebo, extended-release microspheres|"Four stable dose levels of placebo at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks."
45644406|NCT03572530|Drug|5-Azacytidine (5-AZA) group 2|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 2 will receive three 5-AZA infusions per week (typically Monday, Wednesday, and Friday but may be given on other days based upon logistical considerations) for 8 consecutive weeks."
45644407|NCT03572530|Drug|5-Azacytidine (5-AZA) group 3|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 3 will receive four 5-AZA infusions per week (on any 4 weekdays based upon logistical considerations) for 8 consecutive weeks."
45785862|NCT01116986|Behavioral|Intensive in-person counseling during the quit attempt|Participants randomized to intensive in-person counseling will receive three 20-minute face-to-face counseling sessions: one during the week before the target quit day, one on the target quit day and one during the week after the target quite day. The counseling will include intra-treatment social support and skill-based competence intervention components.
45644408|NCT03570619|Drug|Nivolumab|"Patients in arms Metastatic CRPC and Experimental: Solid Tumors (non-prostate) will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 104 weeks of total therapy.~Patients in arm Metastatic CRPC will receive therapy with monotherapy nivolumab therapy at flat dose 480 mg IV every 4 weeks for up to 104 weeks of total therapy."
45785863|NCT01116986|Behavioral|Minimal phone counseling during the quit attempt|Participants randomized to this condition will receive minimal phone counseling consisting of one 10-minute phone counseling session on the morning of the target quit day. This session will address motivation to quit, strategies for coping with urges to smoke and use of the medication, and will provide support. Thus, all participants will get some counseling support on the quit day, which reflects the fact that initial lapses often occur on the target quit day, and quit day smoking is an important determinant of ultimate outcome.
45785864|NCT01116986|Behavioral|Intensive phone counseling during the quit attempt|Participants randomized to this condition will receive intensive phone counseling consisting of three 15-minute phone sessions (on the morning of the target quit day and on days 2 and 10 after the quit day). The content of the target quit day phone call will emphasize intra-treatment social support, skill execution and avoidance of danger situations. The quit day phone call is intended to augment any other clinician counseling received either on the phone or in person; such interventions tend to have additive effects and produce strong dose-response effects as a function of the duration of the counseling intervention.
45785865|NCT01116986|Drug|Long Term Nicotine Patch+ Nicotine Gum During Quit Attempt|"If randomized to this condition:~After the target quit day:~Patch:~IF > 10 cigs/day: one 21 mg nicotine patch per day for 12 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.~IF < or = 10 cigs/day: one 14 mg nicotine patch per day for 12 weeks, then one 7 mg for 4 weeks.~Gum:~IF > 24 cigs/day: ten 4 mg nicotine gum per day for 16 weeks. IF < or = 24 cigs/day: ten 2 mg nicotine patch per day for 16 weeks."
45785866|NCT01116986|Drug|Short Term Nicotine Patch + Nicotine Gum during the quit attempt|"If randomized to this condition:~After the target quit day:~Patch:~IF > 10 cigs/day: one 21 mg nicotine patch per day for 4 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.~IF < or = 10 cigs/day: one 14 mg nicotine patch per day for 4 weeks, then one 7 mg for 4 weeks.~Gum:~IF > 24 cigs/day: ten 4 mg nicotine gum per day for 8 weeks. IF < or = 24 cigs/day: ten 2 mg nicotine gum per day for 8 weeks."
45785867|NCT01116986|Drug|Pre-Quit Nicotine Gum|"If randomized to only the Pre-Quit Nicotine Gum condition (and not the Pre-Quit Nicotine Patch):~Before quitting: Everyone will have ten 2 mg nicotine gum per day for 2 weeks before the target quit day."
45918175|NCT00391534|Drug|immediate release formulation of oxcarbazepine (OXC IR)|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
45918176|NCT00391573|Procedure|Polyglactin sutures for suturing of conjunctival autograft in pterygium surgery|
45785868|NCT01116986|Drug|Pre-Quit Nicotine Patch|"If randomized to only the Pre-Quit Nicotine Patch condition (and not the Pre-Quit Nicotine Gum):~Before quitting: Everyone will have one 14 mg nicotine patch per day for 2 weeks before the target quit day."
45918177|NCT00391573|Procedure|Nylon sutures for suturing of conjunctival autograft in pterygium surgery|
45918178|NCT00005984|Drug|cyclophosphamide|intravenously over 2 hours on day 1 and on days -7 and -6
45918179|NCT00005984|Drug|filgrastim|filgrastim (G-CSF) daily subcutaneously (SQ) starting on day 5 and continuing until completion of leukapheresis. Patients also receive G-CSF IV starting on day 0 and continuing until blood counts recover
45918180|NCT00005984|Drug|recombinant interferon alfa|Beginning on Day 1, subcutaneous (SQ) daily administration in the absence of unacceptable toxicity or disease progression
45644409|NCT03570619|Drug|Ipilimumab|Patients in arms Metastatic CRPC and Experimental: Solid Tumors (non-prostate) will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 104 weeks of total therapy.
45644410|NCT03569280|Combination Product|Enzalutamide or Abiraterone or Apalutamid|Antitumor treatment
45644411|NCT03568383|Drug|Delamanid (DLM)|"Adults and children ≥30 kg: delamanid 200 mg orally once daily.~Children ≥2.5 kg to <30 kg: weight-band dosing orally once daily as per the study protocol. As children gain weight, their DLM dose should be adjusted, typically every month or as the visit schedule permits."
45785869|NCT01116986|Drug|Pre-Quit Nicotine Patch + Pre-Quit Nicotine Gum|"If randomized to both the Prequit Patch and Prequit Gum Conditions:~Before quitting: Everyone will have ten 2 mg nicotine gum per day for 2 weeks and one 14 mg nicotine patch per day for 2 weeks before the target quit day."
45644412|NCT03568383|Drug|Isoniazid (INH)|"Adults and children ≥24 kg: INH 300 mg orally once daily.~Children ≥2.5 kg to <24 kg: INH weight-band dosing orally once daily as per the study protocol. As children gain weight, their INH dose should be adjusted."
45785870|NCT04743843|Device|Omnyx Dynamyx Software|Digital pathology image management and viewing software.
45785871|NCT01098422|Device|Yttrium-90 Radioactive Resin Microspheres|An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.
45785872|NCT01098500|Drug|Tyrosine kinase inhibitors|Lapatinib, erlotinib, gefitinib, dasatinib, imatinib, nilotinib (analyzed as a class of drugs, not by individual drug)
45785873|NCT01098578|Drug|Floseal|Received 1 syringe of Floseal as treatment for posterior epistaxis.
45785874|NCT01099202|Drug|Procrit (epoetin alfa)|Starting dose 40,000 Units subcutaneously once a week during your regularly scheduled chemotherapy for up to 6 courses of chemotherapy (around 5 months).
45785875|NCT02448303|Drug|Pembrolizumab|
45785876|NCT02448303|Drug|Acalabrutinib|
45785877|NCT02415855|Drug|Dabigatran|
45785878|NCT02449473|Biological|Tralokinumab|Subcutaneous Injection
45918181|NCT00005984|Procedure|peripheral blood stem cell transplantation|Patients receive the PBSC transplantation on day 0.
45918182|NCT00005984|Procedure|radiation therapy|total body irradiation twice a day on days -4 through -1
46070934|NCT05332652|Device|trancranial magnetic stimulation|A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
45644413|NCT03568383|Dietary Supplement|Pyridoxine (vitamin B6)|All HHCs in Arm B must receive pyridoxine (vitamin B6) with each dose of INH based on the current local dosing guidelines. For children up to 3 years of age and nursing women, pyridoxine will be given as per local standard of care. Pyridoxine is not supplied through the study.
45644414|NCT03567889|Drug|Daromun|Patients will receive intratumoral administrations into injectable cutaneous, subcutaneous, and nodal tumors of Daromun once weekly for up to 4 weeks. Surgery will follow within 4 weeks.
45644415|NCT03567889|Procedure|Surgery|Patients in Arm 2 will receive surgery within 4 weeks from randomisation.
45785879|NCT02449473|Other|Placebo|Subcutaneous Injection
45785880|NCT02450799|Device|Acrylic IOL|Acrylic IOL for long-term implantation in the cataract patient
45918183|NCT00391612|Device|Exhale® Drug-Eluting Stent|Bronchoscopic procedure in which up to six Exhale Drug-Eluting Stents are placed in the lungs; total procedure time is 1 to 2 hours
45918184|NCT00391612|Device|Sham control|5-10 minute bronchoscopic procedure in which the lungs are examined and a bronchial lavage is performed; the bronchoscope is then retracted to a point above the carina and below the vocal folds for the remained of the time; total procedure time is about 1-2 hours
45918185|NCT00391651|Drug|Nitrofurantoin 100mg twice daily x 5 days|Nitrofurantoin 100mg twice daily x 5 days
45785881|NCT02450799|Device|Silicone IOL|Silicone IOL for long-term implantation in the cataract patient
45785882|NCT02450799|Device|PMMA IOL|Polymethylmethacrylate IOL for long-term implantation in the cataract patient
45785883|NCT02416713|Device|Cellcontrol DriveID|Technology that blocks incoming and outgoing calls and texts.
45785884|NCT02416713|Other|Education Only|No active intervention, educational materials will be provided
45785885|NCT02419521|Device|Resolute Onyx Stent - 2.25 mm - 4.0 mm|
45785886|NCT00363285|Biological|gonadotrophin releasing hormone|
45785887|NCT00363285|Drug|cyproterone acetate|
45785888|NCT00363285|Procedure|quality-of-life assessment|
45785889|NCT00363363|Behavioral|Physical Activity|Children in this arm of the study will be provided with specific activities to be completed on most days of the week. The selected activities will be based on the child's interests and results of the baseline measures of health-related PA, MVPA and gross motor skill. The resources and facilities available to the family and season of the year will also influence the choice of activities. The frequency and duration of the required activities will be gradually increased until the child's baseline MVPA has been increased by a minimum of 30 minutes per day, most days of the week. Once that increase is achieved, the activities will be modified to maintain and reinforce the higher PA level.
45918186|NCT00391651|Drug|TMP/SMX DS twice daily x 3 days|TMP/SMX DS twice daily x 3 days
45785890|NCT00363363|Behavioral|Education|Children in this arm of the study will be provided with puzzles, stories and games to be completed each week. The selected activities will be based on the child's interests and designed to increase the child's knowledge of activity options, perceptions of activity benefits, self-confidence for activity participation and motivation for daily activity. The activities introduced will vary with the resources available to the family and the season of the year, and will include information about healthy eating, injury prevention, and healthy lifestyle options.
45785891|NCT02423577|Drug|FF-3 dry powder|FF-3 dry powder administered by nasal inhalation
45785892|NCT02423577|Drug|Placebo|Placebo dry powder administered by nasal inhalation
45918187|NCT00391690|Drug|Zoledronic acid|In case of bone metastases: Zoledronic acid every 4 weeks for 3 months.
45785893|NCT02424357|Drug|5%povidone iodine ophthalmic solution|one drop of 5% povidone iodine instilled into the conjunctival fornix.
45785894|NCT02424357|Drug|routine post-operative ophthalmic ointment|patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
45918188|NCT00005987|Drug|carmustine|
45918189|NCT00005987|Drug|cyclophosphamide|
45918190|NCT00005987|Drug|dexamethasone|
45918191|NCT00005987|Drug|etoposide|
45785895|NCT02425449|Drug|Succinylcholine|will be administered succinylcholine in a dose of 0.1 mg/kg in Arm 1, 0.15 mg/kg in Arm 2, 0.2 mg/kg in Arm 3, 0.25 mg/kgin Arm 4, 0.3 mg/kg in Arm 5.
45785896|NCT02429115|Other|Mentoring|Six months of peer-mentoring.
45785897|NCT02454075|Drug|YF476|Gastrin receptor antagonist
45785898|NCT02454153|Device|REMStar Positive Airway Pressure|Positive airway pressure therapy is the standard of care for managing obstructive sleep apnea
45785899|NCT02454153|Behavioral|LifeStyle Counseling|Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
45785900|NCT04744233|Other|Orange juice|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed were: freshly squeezed (FS), commercially available low pasteurized juice (LP) and juices treated by high-pressure processing (HPP) and by pulsed electric fields (PEF). All participants consumed the LP and the HPP orange juices. Six subjects consumed PEF-orange juice and other six consumed the FS-orange juice.
45785901|NCT02455167|Drug|Simeprivir (SMV)|Experimental Single arm study. All participants will get the same treatment.
46070935|NCT05064787|Behavioral|Digital Health Coaching|The digital health coaching program consists of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. The program is 6-months in duration and designed for engagement following CAR T cell infusion.
46070936|NCT00827047|Procedure|Total hemihepatic vascular exclusion|A long vascular clamp is inserted along the midline of the anterior surface of the vena cava,proceed cranially up to the space between the right and the middle hepatic vein trunks. Two tapes are seized with the clamp passing between the anterior surface of the IVC and the liver parenchyma.One tape is use to pass around the hepatic parenchyma for occlusion of the bleeding from the remnant liver;the other is used to loop the right (or left )hepatic vein trunk and short hepatic vein,as well as inferior right hepatic vein,if present. Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection.Thus total hemihepatic vascular exclusion is achieved.
46070937|NCT00827047|Procedure|Hemihepatic vascular Clamping|Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection. Selective clamping can be achieved after carefully dissecting the right from the left hilar branches or after inserting a clamp between the right and left hilar branches without prior hilar dissection and looping the right or left portal structures with a tape.
45644416|NCT03567889|Drug|Adjuvant therapy|Patients will receive adjuvant therapy at the investigator's discretion following the surgery.
45644417|NCT03558087|Drug|Nivolumab|Nivolumab 360mg will be administered on Day 1 of each 21 day cycle for four 21-day cycles. Based on response and a balanced patient-physician discussion, subjects may receive nivolumab 240 mg for 8 cycles (cycle = 14 days).
45644418|NCT03558087|Drug|Gemcitabine|Gemcitabine 1000mg/m^2 will be administered on Days 1 and 8 for four 21-day cycles.
45918192|NCT00005987|Drug|filgrastim|
45918193|NCT00005987|Drug|mitoxantrone hydrochloride|
45918194|NCT00005987|Drug|recombinant interferon alfa|
45918195|NCT00005987|Drug|sargramostim|
45918196|NCT00005987|Procedure|bone marrow ablation with stem cell support|
45644419|NCT03558087|Drug|Cisplatin|Cisplatin 70mg^m2 will be administered on Day 1 for four 21-day cycles.
45644420|NCT03549442|Combination Product|BCMA CART + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
45918197|NCT00005987|Procedure|peripheral blood stem cell transplantation|
45918198|NCT00005987|Procedure|radiation therapy|
45918199|NCT05442450|Drug|oral semaglutide|Participants in Experimental group will receive oral Semaglutide along with diet and exercise. Treatment will be initiated with the 3 mg once-daily dose. The dose will be increased to 7 mg and then maximum of 14mg per day in 2-4weeks interval based on patient tolerance.
45918200|NCT00391729|Drug|ABT-089|Subjects will take 2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD, 40 mg BID for 4-6 weeks
45918201|NCT00391729|Drug|Placebo|Subjects will take placebo QD, BID for 4-6 weeks
45918202|NCT00014755|Drug|anti-thymocyte globulin|
45918203|NCT00014755|Drug|cyclophosphamide|
45918204|NCT00014755|Drug|filgrastim|
45918205|NCT00014755|Drug|prednisone|
45918206|NCT00014755|Procedure|peripheral blood stem cell transplantation|
45918207|NCT00014755|Procedure|irradiation|
45918208|NCT00014794|Drug|15-O labeled water|
45918209|NCT00005990|Drug|tipifarnib|
45918210|NCT00005990|Drug|topotecan hydrochloride|
45918211|NCT00001344|Drug|dextromethorphan|
45918212|NCT00014833|Other|No intervention|No intervention
45918213|NCT00014950|Procedure|CF newborn screening|
45918214|NCT00014989|Drug|magnesium sulfate|
45918215|NCT00005993|Drug|aldesleukin|
45918216|NCT00005993|Drug|filgrastim|
45918217|NCT00005993|Drug|recombinant human stem cell factor|
45918218|NCT00005993|Procedure|peripheral blood stem cell transplantation|
45918219|NCT00015028|Drug|Buprenorphine/naloxone|
45918220|NCT00015067|Drug|Methylphenidate|
45918221|NCT00015106|Drug|Lamotrigine|
45918222|NCT00005996|Drug|cisplatin|
45918223|NCT00005996|Drug|gemcitabine hydrochloride|
45644421|NCT03549442|Combination Product|CART BCMA or CART BCMA + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Cohort 1 refers to the group of subjects assigned to receive CART-BCMA alone; Cohort 2 refers to the group of subjects assigned to receive CART-BCMA + huCART19. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
45644422|NCT03549442|Combination Product|Single-dose infusion of CART BCMA or CART BCMA + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Cohort 1 refers to the group of subjects assigned to receive single dose infusions of CART-BCMA alone; Cohort 2 refers to the group of subjects assigned to receive single dose infusions of CART-BCMA + huCART19. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
45785902|NCT02455167|Drug|Sofosbuvir (SOF)|Experimental Single arm study. All participants will get the same treatment.
45785903|NCT02455167|Drug|Ribavirin (RBV)|Experimental Single arm study. All participants will get the same treatment.
45785904|NCT02457897|Drug|Liothyronine|Oral supplement given every 8 hours
45785905|NCT02431455|Device|Incentive spirometer|Incentive spirometer is provided to the patient, this is the current standard of care, and is the control arm.
45785906|NCT02431455|Device|No incentive spirometer|No incentive spirometer is provided to the patient, this is the study arm.
45785907|NCT04341753|Other|pulmonary rehabilitation|"the strength' measure of the deltoids, triceps and brachial biceps will be carried out by another technique: the 1-RM technique (with dumbbells);~- 2 other times, the strength' measure of the deltoids, triceps and brachial biceps will be carried out by handheld dynaometry."
45918224|NCT00005996|Drug|semaxanib|
45918225|NCT00001359|Drug|Penicillin or Placebo|
45918226|NCT00015223|Drug|Methylphenidate|
45918227|NCT00015301|Drug|Methylphenidate|
45918228|NCT00015340|Drug|Buprenorphine/naloxone|
45918229|NCT00015652|Drug|Ribavirin|
45918230|NCT00015652|Drug|Aldesleukin|
45918231|NCT00015652|Drug|Peginterferon alfa-2b|
45918232|NCT00005999|Drug|arsenic trioxide|
45918233|NCT00015691|Drug|Metformin hydrochloride|
45918234|NCT00015691|Drug|Rosiglitazone maleate|
45918235|NCT00015769|Drug|levetiracetam|
45918236|NCT00015808|Drug|Idebenone|
45918237|NCT00015886|Drug|docetaxel|75 milligrams per meter squared intraveneously
45918238|NCT00015886|Drug|fluorouracil|350 milligrams intraveneously
45918239|NCT00006002|Drug|dexamethasone|
45918240|NCT00006002|Drug|semaxanib|
45918241|NCT00001365|Drug|dextromethorphan|
45918242|NCT00015925|Drug|entinostat|
45918243|NCT00006005|Drug|thalidomide|
45918244|NCT00001368|Procedure|cytokine and leukocyte activation profile|
45918245|NCT00015964|Drug|ZD1839|
45918246|NCT01630213|Dietary Supplement|Vitamin D3 + fish oil/fish oil placebo|Vitamin D3 2000 IU/day and fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo per day
45918247|NCT01630213|Dietary Supplement|Vitamin D3 placebo + fish oil/fish oil placebo|Vitamin D3 placebo/day + fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo/day
45918248|NCT00001386|Drug|PCLUS 3-18 MN|
45918249|NCT00001386|Drug|PCLUS 6.1 MN|
45918250|NCT00006008|Drug|arsenic trioxide|
45918251|NCT00016042|Biological|lymphokine-activated killer cells|
45918252|NCT00016042|Biological|recombinant interferon alfa|
45918253|NCT00016042|Biological|sargramostim|
45918254|NCT00016042|Drug|fluorouracil|
45918255|NCT00016081|Drug|ribavirin|
45918256|NCT00016159|Biological|filgrastim|
45918257|NCT00016159|Biological|lintuzumab|
45918258|NCT00016159|Drug|arsenic trioxide|
45918259|NCT00016159|Drug|idarubicin|
45918260|NCT00016159|Drug|tretinoin|
45918261|NCT00016198|Drug|FOLFOX regimen|
45918262|NCT00016198|Drug|fluorouracil|
45918263|NCT00016198|Drug|leucovorin calcium|
45918264|NCT00016198|Drug|oxaliplatin|
45918265|NCT00001398|Drug|Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF)|
45918266|NCT00016237|Biological|tucotuzumab celmoleukin|
45918267|NCT00016276|Drug|dexrazoxane hydrochloride|Given IV
45918268|NCT00016276|Drug|doxorubicin hydrochloride|Given IV
45918269|NCT00016276|Drug|cyclophosphamide|Given IV
45918270|NCT00016276|Drug|paclitaxel|Given IV
45918271|NCT00016276|Biological|trastuzumab|Given IV
45918272|NCT00016276|Procedure|therapeutic conventional surgery|Undergo breast conservation surgery, modified radical mastectomy, or mastectomy
45918273|NCT00016276|Radiation|radiation therapy|Undergo radiation therapy
45918274|NCT00016276|Drug|tamoxifen citrate|Given orally
45918275|NCT00016276|Other|laboratory biomarker analysis|Correlative studies
45918276|NCT00016315|Drug|carboplatin|
45918277|NCT00016315|Drug|gemcitabine hydrochloride|
45644423|NCT03549442|Combination Product|BCMA CART + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
45785908|NCT02458365|Behavioral|Teen Choices: A Program for Healthy Nonviolent Relationships|A 3-session online, multimedia TTM-based intervention for teen dating violence prevention. For most students, the intervention seeks to reduce risk for dating violence by facilitating progress through the stages of change for using healthy relationship skills; daters are encouraged to use those skills in their dating relationships, and non-daters in their peer relationships, as relationships with peers serve as the foundation for experiences in romantic relationships. For victims of dating violence experiencing fear, the intervention does not focus on healthy relationship skills; instead, it seeks to facilitate progress through the stages of change for keeping oneself safe in relationships.
45785909|NCT02458365|Behavioral|Health In Motion|A 3-session online, multimedia, TTM-based intervention which targets physical activity, screen time, and healthy eating for obesity prevention. Health In Motion sessions were administered following the baseline, 6-month, and 12-month assessments to increase the benefits of study participation for Comparison schools and students.
45785910|NCT00363441|Procedure|Intensity Modulated Radiotherapy|
45785911|NCT02434497|Drug|Rosuvastatin 20mg|Active drug 1 or 2 tablets will be taken taken orally, QD, either in the morning or in the evening
45785912|NCT02435901|Drug|alemtuzumab (Campath IH)|Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17
45785913|NCT02435901|Drug|Fludarabine|Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.
45785914|NCT02435901|Drug|Melphalan|Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.
45785915|NCT02435901|Drug|Cyclosporine|Immunosuppressant to prevent graft vs host disease is given on Day -1 prior to stem cell infusion
45785916|NCT02435901|Drug|Mycophenolate mofetil|Immunosuppressant to prevent graft vs host disease is given on Day -1.
45785917|NCT02435901|Drug|Tacrolimus|Immunosuppressant to prevent graft vs host disease is given Day -1 prior to stem cell infusion
45785918|NCT02435901|Biological|Hematopoietic Stem Cell Transplantation|Human Leukocyte Antigen (HLA) matched or mismatched; related or unrelated hematopoietic stem cells to be transplanted on Day 0.
45785919|NCT04744077|Behavioral|Influencer Instagram account|Participants randomized to this group will follow a public Instagram account. This account was chosen because they have a strong following (over 600,000 followers) and it is a public account that anyone can follow. The content shared on this page is motivational and community driven. There is a focus of healthy living with an emphasis on exercise. Additionally, there are no paid sponsorships or radical exercise advice, which is common on other influencer pages. The Co-PIs determined that this page accurately represents the exercise-related content that is readily available on Instagram. The research team will not have control over the content of this account, but the account holder will be notified about the study.
45785920|NCT04744077|Behavioral|Research study Instagram account|Intervention arms will deliver the same exercise-related content on the same schedule on the intervention Instagram accounts. The arms will deliver 13-weeks worth of content which goes through the last possible day of the intervention. The structure was based on feedback from stakeholders in a formative focus group. All of the content delivered through the accounts is evidence-based and referenced from reputation organizations/agencies such as the American College of Sports Medicine, American Heart Association, Center for Disease Control, and World Health Organization. Each Co-PI will post videos to answer participant questions. To ensure that the content between both groups is the same, the Co-PIs will meet to determine which questions to answer and draft the response.
45785921|NCT02438826|Drug|Galcanezumab 300 mg|Administered SC
45785922|NCT02438826|Drug|Placebo|Administered SC
45918278|NCT00016315|Drug|paclitaxel|
45918279|NCT00016315|Radiation|radiation therapy|
46070938|NCT00827047|Procedure|Pringle's Maneuver|Hepatic pedicle clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
45918280|NCT00001410|Drug|Lysodase|
46070939|NCT05332184|Procedure|aortic valve surgery|
46070940|NCT05242874|Drug|Fosaprepitant , Tropisetron and Olanzapine|fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. tropisetron 5mg i.v. on day 1 before undergoing chemotherapy. olanzapine 5mg p.o. on day 1-4
45644424|NCT03542695|Procedure|Computed Tomography|Undergo PET/CT
45644425|NCT03542695|Drug|Copper Cu-64-DOTA-alendronate|Given IV
45918281|NCT00006014|Drug|semaxanib|
45918282|NCT00016393|Drug|ixabepilone|
45918283|NCT00001416|Drug|CEREDASE™|
45918284|NCT00006017|Drug|becatecarin|Arm I: Patients receive rebeccamycin analogue IV over 1 hour on day 1. Arm II: Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment for both arms repeats every 3 weeks for 6-8 courses in the absence of disease progression or unacceptable toxicity.
45918285|NCT00016432|Drug|exemestane|25 mg for 5 years
45918286|NCT00016432|Drug|Placebo|Placebo
45918287|NCT00389376|Drug|Placebo|Placebo
45644426|NCT03542695|Other|Pharmacokinetic Study|Correlative studies
45644427|NCT03542695|Procedure|Positron Emission Tomography|Undergo PET/CT
45644428|NCT03541902|Drug|Cabozantinib|Given PO
45918288|NCT00389376|Drug|Silymarin|140 mg every 8 hours
45785923|NCT04920630|Behavioral|Cognitive Behavioral Therapy - Insomnia (CBT-I)|CBT-I will be delivered via 5 weekly virtual group therapy sessions. Session content is manualized and adapted from existing CBT-I protocols to be relevant to a virtual adolescent group and will include: Session 1 - Introduction of group members, group rules, psychoeducation regarding sleep, and instructions on completion of sleep log. Session 2 - Review sleep log, sleep hygiene, relaxation training, and stimulus control. Session 3 - Review sleep log, sleep restriction, and cognitive strategies (positive self-statements, worry management). Session 4 - Review sleep log and sleep restriction, and problem-solving barriers. Session 5 - Maintenance and relapse prevention.
45785924|NCT05370066|Device|CS6BP watches will be used in the study.|CS6BP watches will be used with FDA approved Blood pressure monitors
45785925|NCT02438280|Device|AcceleDent, Vibrational Device|20 minutes of vibration each day
45644429|NCT03541902|Drug|Sunitinib Malate|Given PO
45644430|NCT03541876|Other|Collection of data|"The following data will be collected by the physician :~sociodemographic profile (age, sex, country of birth of child and parents); clinical manifestations; endoscopic aspects (esophagus, duodenum, stomach); different methods of diagnosis of infection; different primary and secondary bacterial resistance profiles ; different first and second line therapeutic combinations; different first and second line bacterial eradication rates ; different signs of side effects and tolerance of first and second line treatments; different methods of bacterial eradication control."
45644431|NCT03534180|Other|Laboratory Biomarker Analysis|Correlative studies
45644432|NCT03534180|Drug|Romidepsin|Given IV
45785926|NCT02437383|Drug|Propranolol ER|Capsules given orally according to schedule at Visit 1, Visit 2, Visit 3, and Visit 4.
45785927|NCT02437383|Drug|Placebo|Gelatin capsules with a microcrystalline cellulose filler manufactured to mimic propranolol ER 60 mg capsules
45785928|NCT02385708|Drug|2% Chlorohexidine Gluconate Standard of Care|Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery.
45785929|NCT02385708|Drug|2% Chlorohexidine Gluconate Chin to Toe|Patients will perform treatment with 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative until post op day 4 or discharge
45785930|NCT01099358|Drug|Cetuximab|Administered Intravenously
45785931|NCT01099358|Drug|Cisplatin|Administered Intravenously
45785932|NCT01099358|Drug|5 - Fluorouracil|Administered Intravenously
45785933|NCT03388034|Procedure|Nasopharyngeal sampling|A nasopharyngeal sample collected from each nostril by swabbing
45785934|NCT03388034|Procedure|Blood Sampling|Blood sample by the tip of a finger (fingerprick)
45785935|NCT01118624|Drug|Pralatrexate Injection|"Intravenous (IV) push administration over 3-5 minutes.~Initial dose: 190 mg/m2~Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
45785936|NCT01118624|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks prior to first dose of pralatrexate, every 8-10 weeks throughout the study and for at least 30 days after the last dose of pralatrexate."
45918289|NCT00389376|Drug|Silymarin|280 mg single dose
45644433|NCT03534180|Drug|Venetoclax|Given PO
45644434|NCT03524183|Behavioral|Virtual Fitness Buddy Ecosystem|The Virtual Fitness Buddy Ecosystem allows parents to stay involved in the intervention and support their children's PA efforts even when they cannot be with their children. A virtual pet, designed to mimic human-pet relationships in the physical world, will guide children to set and meet PA goals and offer tailored support. In collaboration with YMCA, 480 children and 480 parents in 24 afterschool programs will be randomly assigned to treatment and control groups. Afterschool programs in the treatment group will receive the Ecosystem intervention for 6-months; afterschool programs in the control group will not experience the Ecosystem. All children will complete baseline assessments, a 3-month posttest, and a 6-month and 12-month follow up. Parents and children will provide self-report data on their perceived social support, motivation, and PA self-efficacy. PA will be assessed with activity monitors, which children will wear throughout the project.
45644435|NCT03516942|Other|Quality-of-Life Assessment|Ancillary studies
45644436|NCT03516942|Other|Questionnaire Administration|Ancillary studies
45644437|NCT03516279|Drug|Dasatinib|Given PO
45644438|NCT03516279|Drug|Imatinib Mesylate|Given PO
45644439|NCT03516279|Other|Laboratory Biomarker Analysis|Correlative studies
45644440|NCT03516279|Drug|Nilotinib|Given PO
45644441|NCT03516279|Biological|Pembrolizumab|Given IV
45644442|NCT03512405|Biological|Blinatumomab|Given IV
45785937|NCT01118624|Dietary Supplement|Folic Acid|"1.0-1.25 mg orally~Administered daily for at least 7 days prior to first dose of pralatrexate, throughout the study and for at least 30 days after the last dose of pralatrexate."
45785938|NCT02461563|Drug|200 mg MK-1075|Two 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
45785939|NCT02461563|Drug|400 mg MK-1075|Four 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
45785940|NCT02461563|Drug|800 mg MK-1075|Eight 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
45918290|NCT00389376|Drug|Silymarin|280 mg single dose + every 8 hours
45918291|NCT00389376|Drug|Silymarin|560 mg single dose + every 8 hours
45918292|NCT00389376|Drug|Silymarin|560 mg single dose + every 8 hours
45918293|NCT00389376|Drug|Silymarin|280 mg every 8 hours
45918294|NCT00389376|Drug|Silymarin|700 mg single dose + every 8 hours
45918295|NCT00006020|Drug|nelarabine|1.5 gm/m2 IV over 2 hours days 1, 3, 5 q21 days
45644443|NCT03512405|Other|Laboratory Biomarker Analysis|Correlative studies
45644444|NCT03512405|Biological|Pembrolizumab|Given IV
45918296|NCT00016471|Procedure|Audiogram|
45918297|NCT00016471|Procedure|Electroretinogram|
45918298|NCT00016549|Biological|Bevacizumab|
45785941|NCT02438475|Device|Mynx Vascular Closure System|MynxGrip is being used to seal femoral vein access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.
45918299|NCT00006023|Drug|capecitabine|
45918300|NCT00016588|Drug|Tenofovir disoproxil fumarate|
45918301|NCT00006026|Drug|rubitecan|
45918302|NCT00016666|Drug|Propranolol|
45644445|NCT03508934|Device|GTS (Continuous Glucose Monitoring)|Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS)
45644446|NCT03508934|Other|POC (Point of Care)|Hospitalized patients with DM2 will be monitored with POC (Point of Care) blood glucose levels.
45785942|NCT02438475|Other|Manual Compression|manual pressure applied to your groin for approximately 5-10 minutes
45785943|NCT02439879|Drug|Alpha lipoic acid|Alpha lipoic acid 1800 mg PO divided in 3 doses for 4 weeks . If total symptoms score decreased >3 points patients received alpha lipoic acid 600 mg PO each day or no treatment for 16 weeks.
45785944|NCT03371108|Biological|Gan & Lee Insulin Glargine Injection|Route of administration: subcutaneous injection
45785945|NCT03371108|Biological|Lantus®|Route of administration: subcutaneous injection
45785946|NCT02517567|Device|Delefilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
45644447|NCT03506594|Device|Radiofrequency non ablative|The application of RF was performed by physical therapist trained in the technique of radiofrequency through the Capenergy® brand device with capacitive transfer method using non-ablative handle with active electrode placed intra-vaginal and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration above 20 minutes. The temperature was measured by an infrared thermometer and when it reached 41graus radiofrequency was maintained for 2 minutes in the anterior wall and 2 other minutes in the posterior wall of the vagina.
45644448|NCT03505320|Drug|zolbetuximab|Zolbetuximab will be administered as a minimum 2-hour IV infusion.
45644449|NCT03505320|Drug|oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion.
45644450|NCT03505320|Drug|leucovorin|Leucovorin will be administered as a 2-hour IV infusion.
45644451|NCT03505320|Drug|fluorouracil|Fluorouracil will be administered as IV bolus over 5 to 15 minutes and continuous IV infusion over 46 to 48 hours or per institutional guidelines.
45785947|NCT02517567|Device|Narafilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
45785948|NCT02517567|Device|Somofilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
45918303|NCT00001476|Drug|Gene Therapy Method for CGD|
45918304|NCT00001476|Device|Isolex 300i Magnetic Cell Selector|
45918305|NCT00016744|Drug|Sodium 4-Phenylbutyrate (4PBA)|The standard oral adult dose is 20g/day (tablets) for 4 days.
45918306|NCT00016744|Drug|Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)|Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.
45918307|NCT00016744|Drug|Placebo|The placebo dose will match the oral tablets in arm 1, maintaining the study blind.
45918308|NCT00016861|Drug|irinotecan hydrochloride|
45918309|NCT00386633|Biological|MVA-mBN32|3 immunizations; first study group: 10E7_TCID50
45918310|NCT00386633|Biological|MVA-mBN32|3 immunizations; second study group: 10E8_TCID50
45644452|NCT03505320|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes.
45644453|NCT03505320|Drug|folinic acid|Folnic acid will be administered as a 2-hour IV infusion.
45785949|NCT02980172|Other|Pain evaluation|Evaluation of pain using a numerical scale (1 to 10)
45785950|NCT01100606|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® [pancrelipase] delayed release capsule) from open capsule, mixed with a small amount of apple juice, will be given orally daily using a syringe nurser at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day.
45785951|NCT01100606|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® [pancrelipase] delayed release capsule) from open capsule, mixed with a small amount of apple sauce, will be given orally daily using a spoon at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kg of body weight per day.
45785952|NCT03013010|Drug|Tegafur-Gimeracil-Oteracil Potassium|The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.
45785953|NCT03013010|Radiation|Chemoradiotherapy|"Chemotherapy: S-1 40-60mg/m2 orally, oral tablet twice daily, days 1-5 of each week of radiotherapy.~Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks."
45918311|NCT00016900|Drug|liposomal paclitaxel|
45918312|NCT00016939|Drug|alvocidib|
45918313|NCT00386672|Dietary Supplement|Reduced energy (lite) OJ fortified with Calcium and Vitamin D|Three 240ml servings of lite OJ fortified with 350mg Ca and 100U VitD per day.
45918314|NCT00386672|Behavioral|Nutrition Counseling|Individual and group nutritional counseling by a registered dietician.
45918315|NCT00386672|Dietary Supplement|Reduced energy (lite) OJ without Calcium and Vitamin D|Three 240ml servings of lite OJ without 350mg Ca and 100U VitD per day.
45918316|NCT00016978|Drug|FOLFOX regimen|
45918317|NCT00016978|Drug|fluorouracil|
45918318|NCT00016978|Drug|leucovorin calcium|
45918319|NCT00016978|Drug|oxaliplatin|
45918320|NCT00017017|Drug|paclitaxel poliglumex|
45918321|NCT00386711|Behavioral|training on identification of suicide risk and depression|
45918322|NCT00017056|Drug|ixabepilone|
45918323|NCT00017095|Biological|filgrastim|
45918324|NCT00017095|Drug|cyclophosphamide|
45644454|NCT03505320|Drug|nivolumab|Nivolumab will be administered intravenously according to institutional standards.
45785954|NCT03013010|Procedure|Gastric resection|A standard D2 gastrectomy was recommended. The type of gastrectomy performed depended on the location and extent of the primary lesion. For middle third tumors, the gastric margin was recommended to be more than 5 cm, and a total gastrectomy was performed. For lower third tumors, a 2 cm duodenal margin was recommended and a subtotal or total gastrectomy was considered. For upper third tumors, a 3 cm esophageal margin was recommended and a total gastrectomy or esophagogastrectomy was performed. Billroth I or Roux-en-y gastrojejunostomy was performed for distal gastrectomy patients, Roux-en-y esophagojejunostomy was performed for total gastrectomy patients.
45918325|NCT00017095|Drug|docetaxel|
45644455|NCT03500107|Device|Blue Light Emitting Diode (LED) 401 +/- 5nm|The participant will be naked, in a gynecological stretcher and lithotomy position, and the apparatus of the LED will be positioned in front of the vulva and vaginal region, 5 cm away, it will be statically, externally, and supported on a tripod. The protocol will consist of only one session.
45644456|NCT03497676|Drug|Oral Cabotegravir (CAB)|30 mg tablets administered orally
45644457|NCT03497676|Drug|Oral Rilpivirine (RPV)|25 mg tablets administered orally
45785955|NCT03013010|Drug|Oxaliplatin|The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
45644458|NCT03497676|Drug|Long-Acting Injectable Cabotegravir (CAB LA)|Administered by intramuscular (IM) injection
45785956|NCT01100762|Device|Cranial Electric Stimulation (CES)|We will follow the procedure described by several investigators as safe and effective. The participant will sit on a standard chair. Two commercially available surface electrodes will be embedded in an elastic head cup. Each electrode will be covered with a water soaked absorbent fabric. One positive (+) electrode will be placed over the primary motor cortex (M1) and pre-motor areas. One negative (-) electrode will be placed over the skin overlying the contra lateral supra-orbital region. The electrodes will be connected via 2 leads to a battery powered direct current stimulator. The stimulator will be programmed to deliver 0.975mA (peak 4mA) over 20 minutes.
45785957|NCT01100762|Device|Treadmill|The participant will walk on a treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
45785958|NCT01100762|Device|CES and Treadmill|Participants will have a combined session with CES while walking on the treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
45785959|NCT02462967|Drug|GR-MD-02|GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3
45644459|NCT03497676|Drug|Long-Acting Injectable Rilpivirine (RPV LA)|Administered by intramuscular (IM) injection
45785960|NCT02462967|Drug|Placebo|Placebo for GR-MD-02
45785961|NCT03013166|Other|Corticosteroid medication|Patients will be grouped into Cohort 1 (IR hydrocortisone), cohort 2 (IR prednisolone), cohort 3 (MR hydrocortisone), or cohort 4 (IR to MR hydrocortisone) depending on which oral corticosteroid medications were received during the observation period.
45785962|NCT02518191|Drug|GnRHa|3.6mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.
45785963|NCT03012464|Other|Pathologic and functional assessment|Random biopsies will be taken from the pelvic floor muscles, external anal sphincter, and the lateral supportive ligaments of the rectum during surgical treatment of rectal prolapse whether via the abdominal or perineal approach. Tissue samples will be subjected to immunohistochemistry to calculate the ratio between collagen type I and type III, and to reveal any myopathic or degenerative changes
45785964|NCT02524119|Drug|LEE011|600 mg PO once daily will be given orally on days 1-21 of a 28 day cycle (3 weeks on / 1 week off) :until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason
45644460|NCT03497676|Drug|Combination Antiretroviral Therapy (cART)|Participants will continue their pre-study cART regimen. The antiretroviral drugs in participants' cART regimens will not be provided through the study.
45644461|NCT03493425|Drug|Carboplatin|Given IV
45644462|NCT03493425|Drug|Cisplatin|Given IV
45644463|NCT03493425|Drug|Docetaxel|Given IV
45644464|NCT03493425|Radiation|Image Guided Radiation Therapy|Undergo image guided IMRT
45644465|NCT03493425|Radiation|Intensity-Modulated Radiation Therapy|Undergo image guided IMRT
45918326|NCT00017095|Drug|epirubicin hydrochloride|
45918327|NCT00017095|Drug|fluorouracil|
45918328|NCT00017095|Genetic|microarray analysis|
45918329|NCT00017095|Other|immunohistochemistry staining method|
45918330|NCT00017095|Other|laboratory biomarker analysis|
45918331|NCT00017095|Procedure|biopsy|
45644466|NCT03493425|Other|Laboratory Biomarker Analysis|Correlative studies
45644467|NCT03493425|Other|Questionnaire Administration|Ancillary studies
45644468|NCT03493425|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
45644469|NCT03491215|Drug|Ruxolitinib|Ruxolitinib taken orally (5mg tablets) or oral pediatric formulation and dosage based on age group
45644470|NCT03490565|Behavioral|Exercise training|Structured, supervised, high-intensity combined aerobic and resistance exercise. Based on patients' individual capacity (Wattmax and 1RM), a personalized exercise program will be prescribed. Following a 5 minutes warm up, the patients will perform 21 min of aerobic interval training on a stationary bicycle consisting of three 4 minute high intensity intervals (85-95% HRmax) with 3 minutes of active pause between each interval. The resistance training comprises 4 functional exercises by performed using bodyweight, elastic resistance bands or kettlebells followed by resistance exercises in machines for the major muscle groups: chest press, leg press, seated rows, and leg extension with 1 warm-up set followed by 3-4 sets of 8 to 12 repetitions.
45644471|NCT03478865|Drug|Vitamin A palmitate|Provide vitamin A to participants with pre/post assessments of vision.
45644472|NCT03464097|Drug|Ozanimod|Specified dose on specified days
45644473|NCT03464097|Other|Placebo|Specified dose on specified days
45644474|NCT03464045|Drug|empagliflozin|drug
45644475|NCT03464045|Drug|DPP-4 inhibitors|drug
45918332|NCT00017095|Procedure|conventional surgery|
45918333|NCT00017095|Procedure|neoadjuvant therapy|
45918334|NCT00017095|Radiation|radiation therapy|
45449117|NCT03732105|Drug|Radiotherapy+apatinib|Patients in radiotherapy+apatinib group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50 Gy/25 fraction after randomization and after radiotherapy they will receive oral apatinib at an initial dose of 500mg daily until recurrence, death, patient withdrawal or unacceptable toxic effects. Two dose reductions were permitted for apatinib (500 mg and 250 mg taken on alternate days, and 250 mg once daily). At the first occurrence of grade 3 or 4 toxicities, apatinib was delayed until recovery to grade 2 or below, and then treatment was resumed with a reduction to 500 mg and 250 mg taken on alternate days. At the second occurrence of grade 3 or 4 toxicities, apatinib was delayed until recovery to grade 2, and then treatment was resumed with a reduction to 250 mg once daily.
45449118|NCT02154334|Drug|Esketamine|Participants will self-administer one Intranasal spray of 14 mg esketamine solution in each nostril on Day 1 at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 and Period 2.
45449119|NCT02154334|Drug|Mometasone|Healthy participants will self-administer 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril prior to 1 intranasal spray of esketamine solution 14 mg in each nostril at Time 0 and 5 minutes for a total dose of 56 mg on Day 16 in Period 2.
45644476|NCT03464045|Drug|SGLT-2 inhibitors|drug
45644477|NCT03462719|Drug|Ibrutinib|Participants will receive ibrutinib 420 mg orally once daily up to 15 cycles.
45785965|NCT02524119|Procedure|Chemoembolization|Patients will be treated with chemoembolization once every 4 weeks with up to 4 total chemoembolizations within the first 6 months from the initial chemoembolization.
45785966|NCT01119794|Drug|Ofatumumab and Bortezomib|Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression
45785967|NCT02926196|Drug|MSB0010718C|MSB0010718C-Avelumab is formulated as vials of 200 mg strength for IV administration
45785968|NCT02464449|Behavioral|Behavioral: AI-CBT|AI CBT engine will make recommendations to step-down or step-up intensity of CBT follow-up based on what patient reports and what other similar patients report. Stepped care model.
45785969|NCT02464449|Behavioral|Behavioral: Standard Telephone CBT|Controls receive 10 hour-long standard telephone CBT sessions, a pedometer/log after baseline, and a Patient Handbook.
45785970|NCT02914496|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT is a specific form of Cognitive behavior therapy (CBT) which will be given as a course consisting of seven sessions where each session is two hours long.
45785971|NCT02464917|Device|Device: simple facemask to administer supplemental oxygen|
45785972|NCT01120808|Procedure|Paper tape|Paper tape assigned to each participant's randomly selected foot.
45785973|NCT02835950|Device|Therapeutic Intra-Vascular UltraSound (TIVUS™) System|"The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.~Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation."
45785974|NCT02465073|Device|NXTSC wound gel|Subjects will receive NXTSC wound gel only.
45785975|NCT02465073|Device|NXTSC wound gel plus Standard of Care|Subjects will be randomized to the NXTSC wound gel plus Standard of Care of only.
45785976|NCT02465073|Device|Standard of Care Group|Subjects will receive Standard of Care only.
45785977|NCT02524977|Behavioral|Decision Support|Provision of recommended antithrombotic therapy based on atrial fibrillation decision support tool that uses both stroke and bleeding risk
45785978|NCT02524977|Behavioral|Educational Intervention Only|Educational conference series
45785979|NCT01103414|Drug|Mitoglitazone|50 mg capsules, once daily for 84 days
45785980|NCT01103414|Drug|Mitoglitazone|Mitoglitazone 100 mg capsules, once daily for 84 days
45785981|NCT01103414|Drug|Mitoglitazone|Mitoglitazone 150 mg capsules, once daily for 84 days
45785982|NCT01103414|Drug|Pioglitazone|Pioglitazone 45 mg, once daily for 84 days
45785983|NCT01103414|Drug|Placebo|Placebo, once daily for 84 days
45785984|NCT01103492|Device|HALO90 Ablation catheter|FDA approved endoscopic device for use in coagulation of tissue in the digestive tract using radiofrequency energy.
45785985|NCT03012932|Behavioral|HPV self-sampling|All participants will receive HPV self-sampling intervention. HPV self-sampling is a cervical cancer screening that can be done in private, using a device that is similar to a tampon. This intervention tests for high-risk HPV, the primary cause of cervical cancer. Each participant will complete the intervention one time only.
45785986|NCT02525055|Other|Infectious titre 1 (H3N2)|Infectious titre 1: 2.8 x 10*3 TCID50/mL
45785987|NCT02525055|Other|Infectious titre 2 (H3N2)|Infectious titre 2: 2.5 x 10*4 TCID50/mL
45644478|NCT03462719|Drug|Venetoclax|Participants will receive venetoclax in combination with ibrutinib for a total of 12 cycles, beginning at Cycle 4. For the first 5 weeks of venetoclax treatment, the treatment dose will be ramped up from 20 to 400 mg.
45644479|NCT03462719|Drug|Chlorambucil|Participants will receive chlorambucil at a dose of 0.5 mg/kg body weight on Days 1 and 15 of Cycles 1 to 6.
45644480|NCT03462719|Drug|Obinutuzumab|Participant will receive obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, and Day 1 of Cycles 2 to 6.
45644481|NCT03462719|Drug|Ibrutinib (as Subsequent Therapy)|Participants will receive ibrutinib 420 mg orally once daily until disease progression or unacceptable toxicity during the subsequent therapy phase.
45785988|NCT02525055|Other|Infectious titre 3 (H3N2)|Infectious titre 3: 3.6 x 10*5 TCID50/mL
45785989|NCT02525055|Other|Infectious titre 4 (H3N2)|Infectious titre 4: 4.7 x 10*6 TCID50/mL
45785990|NCT02525055|Other|Infectious titre 5 (H3N2) (Subjects aged 18 to 45 years old)|Infectious titre 5: 3.5 x 10*5 TCID50/mL
45785991|NCT02525055|Other|Infectious titre 5 (H3N2) (Subjects aged 46 to 64 years old)|Infectious titre 5: 3.5 x 10*5 TCID50/mL
45785992|NCT02180828|Drug|Clotrimazole vaginal tablet|2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
45785993|NCT02180828|Drug|Fluconazole|2 doses of 150 mg oral Fluconazole (at day1 and day4)
45785994|NCT02466087|Drug|Mg Cl|Four supplements a day for 6 weeks.
45644482|NCT03458416|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
45785995|NCT01105754|Behavioral|Multifaceted Prompting Intervention MPI|"Practices assigned to the MPI group will receive a simple prompt given to the provider at the time of the visit with information regarding the child's symptoms, medication use, environmental exposures, and recommendations for guideline-based preventive care. Practices will receive brief interactive seminars, resource guides, access to free asthma education programs, and practice-level feedback regarding their performance on key outcome measures.~Caregivers will receive a simple prompt, community resources, and a blank asthma action plan form."
45785996|NCT02525523|Drug|Alicaforsen|
45785997|NCT02525523|Drug|Placebo|
45785998|NCT02528409|Drug|Vortioxetine|Medication currently approved for major depression.
45918335|NCT00006029|Drug|gemcitabine hydrochloride|
45918336|NCT00006029|Drug|pegylated liposomal doxorubicin hydrochloride|
45918337|NCT00006029|Drug|vinorelbine tartrate|
45918338|NCT00371059|Drug|Memantine|Memantine 10mg BD
45918339|NCT00371059|Drug|Placebo|Placebo 10 mgs BD
45918340|NCT00001482|Drug|Lamotrigine (Lamictal® (Registered Trademark)|
45785999|NCT02528409|Drug|Placebo|
45786000|NCT02467179|Device|Amigo™ Robotic Catheter Manipulation|"Ablation is a standard procedure that patients may undergo for the atrial flutter.~In this study, this group will be assigned to robotic catheter manipulation."
46070941|NCT05242874|Drug|Fosaprepitant , Tropisetron, Dexamethasoneand Olanzapine|"On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administrated, and on day 2-4, the given dose of dexamethasone is 8 mg.~fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. tropisetron 5mg i.v. on day 1 before undergoing chemotherapy. olanzapine 5mg p.o. on day 1-4"
46070942|NCT02768948|Drug|telmisartan during 6 months|telmisartan during 6 months
45644483|NCT03452332|Biological|Durvalumab|Given IV
45644484|NCT03452332|Other|Laboratory Biomarker Analysis|Correlative studies
45918341|NCT00001482|Drug|Gabapentin (Neurontin® (Registered Trademark))|
46070943|NCT02768948|Drug|Losartan during 6 months|Losartan during 6 months
46070944|NCT02768948|Procedure|blood sample|blood sample
46070945|NCT02761382|Other|Mindfulness-based psychological treatment|
46070946|NCT02761382|Other|Non-specific psychological treatment|
46070947|NCT00640315|Drug|Riociguat (Adempas, BAY63-2521) 1.0 mg|1.0 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
46070948|NCT00640315|Drug|Riociguat (Adempas, BAY63-2521) 2.5 mg|2.5 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
46070949|NCT00904748|Drug|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose without water
46070950|NCT00904748|Drug|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose with water
46070951|NCT00904748|Drug|Viagra®|sildenafil citrate 100 mg film-coated tablet (Viagra®), single dose
45644485|NCT03452332|Radiation|Stereotactic Radiosurgery|Undergo SABR
45644486|NCT03452332|Biological|Tremelimumab|Given IV
46070952|NCT02721758|Behavioral|Brief Motivational Intervention|
45644487|NCT03451292|Drug|Albutein 20% Injectable Solution|Within 96 hours after discharge and following randomization, subjects will receive the first Albutein 20% infusion at the dose of 1.5 g/kg body weight (maximum 100 grams per subject). Thereafter, subjects will receive Albutein 20% infusions at the dose of 1.5 g/kg body weight (maximum 100 grams per subject) every 10 ± 2 days for the rest of the study (up to a maximum of 12 months). Subjects in this treatment group will also receive SMT.
45644488|NCT03451292|Other|Standard medical treatment|Subjects will receive SMT according to published guidelines for the management of decompensated cirrhosis.
45786001|NCT02467179|Device|Manual Catheter Manipulation|"Ablation is a standard procedure that patients may undergo for the atrial flutter.~In this study, this group will be assigned to manual catheter manipulation."
45786002|NCT01122446|Other|Placebo comparator|"Placebo comparator day 1 and 30 in non-diabetic children with multiple islet autoantibodies.~Post diagnosis: Two doses of 20 microgram Diamyd day 1 and 30 in children originally receiving placebo."
45918342|NCT00017134|Drug|fenretinide|
45918343|NCT00017134|Procedure|conventional surgery|
45918344|NCT00319540|Behavioral|Control with depression course (CWD)|
45918345|NCT04734418|Drug|Remifentanil|Intravenous pump injection.The initial dose of remifentanil is 0.05 μg/kg/min.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of remifentanil is 0.12 μg/kg/min
45918346|NCT04734418|Drug|Dexmedetomidine|Intravenous pump injection.The initial dose of dexmedetomidine is 0.5 μg/kg/h.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of dexmedetomidine is 1.0 μg/kg/h.
45918347|NCT00006032|Drug|etoposide|
45918348|NCT00006032|Drug|ifosfamide|
45918349|NCT00006032|Drug|topotecan hydrochloride|
45918350|NCT00006032|Procedure|peripheral blood stem cell transplantation|
45918351|NCT00017173|Biological|Ad5CMV-p53 gene|2 intraoperative and one post-operative injection of Ad5CMV-p53.
45918352|NCT00017173|Drug|cisplatin|100 mg/m2 IV Day 1 every 21 days for 3 cycles
45918353|NCT00017173|Procedure|conventional surgery|conventional surgery
45918354|NCT00017173|Radiation|radiation therapy|200 cGy per day Days 105 every week for 6 weeks
45918355|NCT04734223|Diagnostic Test|Neuroimaging Findings in Patients With COVID-19|MR and BT Imaging
45918356|NCT00001509|Drug|IFN-alpha with retinoic acid|
45918357|NCT04734340|Procedure|EIT-guided PEEP setting|Ventilator parameter setting by EIT
45918358|NCT04734340|Procedure|ARDS-net PEEP setting|Ventilator parameter setting according to ARDS-net table
45918359|NCT00006035|Biological|bleomycin sulfate|
45918360|NCT00006035|Drug|electroporation therapy|
46070953|NCT00574405|Drug|MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®])|MDI = 3-4+ insulin injections/day, using NPH + regular insulin or Lantus + insulin lispro; 12 month treatment duration.
45644489|NCT03441308|Behavioral|Educational method of group treatment|
45918361|NCT00017212|Drug|exatecan mesylate|
45918362|NCT04734184|Diagnostic Test|DCFPyL|Single dose injection
45918363|NCT00017251|Biological|oblimersen sodium|Given IV
45786003|NCT01122446|Drug|Diamyd|"20 microgram day 1 and 30 in non-diabetic children with multiple islet autoantibodies.~Post diagnosis: Two doses of Diamyd followed to children originally receiving Diamyd"
45918364|NCT00017251|Drug|carboplatin|Given IV
45918365|NCT00017251|Drug|etoposide|Given IV
45918366|NCT00017251|Other|pharmacological study|Correlative studies
45644490|NCT03441113|Drug|MMB|Tablet(s) administered orally once daily
45644491|NCT03440372|Drug|Ozanimod|Specified dose on specified days
45786004|NCT02530281|Drug|glycopyrronium Topical Wipes|Topical wipes containing glycopyrronium
45786005|NCT02530281|Other|Vehicle|Vehicle (placebo) topical wipes
45918367|NCT00017251|Other|laboratory biomarker analysis|Correlative studies
45918368|NCT00001515|Device|virtual bronchoscopy|
45918369|NCT00006038|Drug|cisplatin|
45644492|NCT03440372|Other|Placebo|Specified dose on specified days
45644493|NCT03430219|Device|Subchondroplasty Procedure|AccuFill is an injectable, self-setting, macro-porous, osteoconductive, calcium phosphate bone graft substitute material that is intended for use to fill bony voids or gaps of the lower extremities (pelvis through foot) that are not intrinsic to the stability of the bony structure
45786006|NCT02236832|Device|transcranial magnetic stimulation|
45786007|NCT02236832|Other|MRI imaging|
45918370|NCT00006038|Drug|docetaxel|
45644494|NCT03428009|Other|Magnetic Resonance Imaging|Study interventions are minimal risk.
46070954|NCT00574405|Device|CSII (Animas Corporation insulin pump, model IR 1200)|CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
46070955|NCT00827125|Device|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
45644495|NCT03419234|Drug|Abiraterone Acetate|Given PO
45644496|NCT03419234|Drug|Antiandrogen Therapy|Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist
45644497|NCT03419234|Drug|Cabazitaxel|Given IV
46070956|NCT03859609|Procedure|Spinal Fusion|Spinal alignment was evaluated according to two different score-systems
46070957|NCT00818935|Dietary Supplement|Low-Intermediate-Glycemic Index diets|
46070958|NCT00818935|Dietary Supplement|High GI diet|
46070959|NCT00971243|Drug|MP-513 Lowest Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
45644498|NCT03419234|Other|Laboratory Biomarker Analysis|Correlative studies
45644499|NCT03419234|Procedure|Orchiectomy|Undergo standard of care surgical castration with bilateral orchiectomy
45644500|NCT03419234|Other|Pharmacological Study|Correlative studies
45786008|NCT02236832|Other|EEG recording|
45786009|NCT02236832|Behavioral|Neuropsychological examination|
45918371|NCT00006038|Drug|floxuridine|
45918372|NCT00006038|Drug|fluorouracil|
45918373|NCT00006038|Drug|leucovorin calcium|
45918374|NCT00006038|Procedure|conventional surgery|
45918375|NCT00017290|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
45918376|NCT00017290|Biological|keyhole limpet hemocyanin|
45918377|NCT00017290|Biological|sargramostim|
45918378|NCT00017290|Drug|cyclophosphamide|
45918379|NCT00017290|Drug|prednisone|
45918380|NCT00017290|Drug|vincristine sulfate|
45918381|NCT00017329|Drug|bortezomib|
45918382|NCT00017368|Biological|filgrastim|
45918383|NCT00017368|Biological|sargramostim|
45918384|NCT00017368|Drug|carboplatin|
45918385|NCT00017368|Drug|cisplatin|
45918386|NCT00017368|Drug|cyclophosphamide|
45918387|NCT00017368|Drug|doxorubicin hydrochloride|
45918388|NCT00017368|Drug|etoposide|
45918389|NCT00017368|Drug|etoposide phosphate|
45918390|NCT00017368|Drug|ifosfamide|
45918391|NCT00017368|Drug|isotretinoin|
45918392|NCT00017368|Drug|melphalan|
45918393|NCT00017368|Drug|thiotepa|
45918394|NCT00017368|Drug|vincristine sulfate|
45918395|NCT00017368|Procedure|conventional surgery|
45918396|NCT00017368|Procedure|peripheral blood stem cell transplantation|
45918397|NCT00017368|Radiation|radiation therapy|
45918398|NCT00001524|Drug|Thalidomide|
45918399|NCT00006041|Biological|MUC1-KLH conjugate vaccine|
45918400|NCT00006041|Biological|MUC1-KLH vaccine/QS21|
45918401|NCT00006041|Biological|QS21|
45918402|NCT00017446|Drug|CP4071|
45918403|NCT00017485|Drug|HPPH|
45918404|NCT00017524|Drug|pelitrexol|
45786010|NCT02467491|Device|Jintronix|The participants will perform light exercises using the Jintronix software. Jintronix is an easy-to-use virtual physical activity platform designed for physical and occupational therapy. It combines common exercise movements, virtual games and motion sensing cameras to offer a fun and effective tool for physical activity.
45918405|NCT05681000|Drug|Utidelone Capsule|"At least 4 dose cohorts are planned, and 16-28 cases are expected.~Cohort 1 and 2: 2 cases are planned for each. In cohort 1, the subjects will receive Utidelone Capsule at a dose of 25 mg/m2/d for 5 days, in a 21-day cycle. In cohort 2, the subjects will receive Utidelone Capsule at a dose of 50 mg/m2/d for 5 days, in a 21-day cycle.~Other dose-escalation cohorts: 3-6 cases are planned in each cohort, following the 3 + 3 design. The subjects in these cohorts will receive Utidelone Capsule at 75 mg/m2/d for 5 days, 100 mg/m2/d for 5 days, 100 mg/m2/d for 7 days, and 120 mg/m2/d for 7 days in a 21-day cycle respectively."
45918406|NCT02971813|Behavioral|Facebook|"Volunteers will be recruited during inpatient stay, or via phone call or in person after discharge and prior to beginning cardiac rehabilitation.~Participants will be given a baseline BREQ-3 survey and a PNSE scale.~Patients will be randomized to Facebook™ versus comparison groups using a blocked randomization.~The Facebook™ intervention will include peer support, education, provider support and text message prompts when new posts are added.~Educational posts will cover topics that will cover healthcare information.~Provider support will be posted much like the educational posts.~The data collection for this study will take place prior to beginning cardiac rehabilitation, at which time the participants will receive the BREQ-3 and PNSE surveys either in person or via email link.~Post-testing will include a BREQ-3 and PNSE surveys and count of the number of sessions completed in a 3 month period of time."
45918407|NCT00017602|Biological|oblimersen sodium|
45918408|NCT00017602|Drug|dexamethasone|
45918409|NCT00001533|Drug|cyclosporine|
45918410|NCT00017641|Drug|anti-thymocyte globulin|
45918411|NCT00017641|Drug|cyclophosphamide|
45918412|NCT00017641|Drug|filgrastim|
45918413|NCT00017641|Procedure|CD34+ Peripheral Blood Stem Cell Reinfusion|
45918414|NCT05680961|Device|Monitoring Device|Monitoring Device
45918415|NCT00017680|Drug|Melphalan|100 mg/m2 twice a day from Days -2 and -1 as induction therapy
45918416|NCT00017680|Procedure|Autologous Stem Cell Transplantation|Bone marrow and peripheral blood stem cells harvested
45918417|NCT00017719|Drug|Lamivudine|
45918418|NCT00017719|Drug|Lamivudine/Zidovudine|
45918419|NCT00017719|Drug|Nelfinavir mesylate|
45918420|NCT00017719|Drug|Nevirapine|
45918421|NCT00017719|Drug|Zidovudine|
45918422|NCT00001542|Drug|fluconazole|
45918423|NCT05680922|Biological|LB2102|DLL3 directed autologous Chimeric Antigen Receptor T-cells
45918424|NCT00017758|Drug|Pravastatin sodium|
45918425|NCT00017758|Drug|Simvastatin|
45918426|NCT00017758|Drug|Atorvastatin calcium|
45644501|NCT03419234|Drug|Prednisone|Given PO
45918427|NCT00017758|Drug|Nelfinavir mesylate|
45644503|NCT03408613|Procedure|Positive Airway Pressure|See arm/group description
45644504|NCT03408613|Procedure|Supplemental Oxygen|See arm/group description
45644505|NCT03408613|Procedure|Sham|See arm/group description
45644506|NCT03395236|Combination Product|"StellarexTM 0.014 Over-The-Wire Drug-coated Angioplasty Balloon"|"The Stellarex balloon (0.014) is indicated for the treatment of de-novo or re-stenotic lesions in the lower extremities to establish blood flow and to maintain vessel patency."
45918428|NCT00017758|Drug|Efavirenz|
45918429|NCT00017992|Drug|Lopinavir/Ritonavir|
45918430|NCT00017992|Drug|Emtricitabine|
45644507|NCT03394079|Procedure|PCI|Percutaneous Coronary Intervention
45644508|NCT03394066|Device|TMS (MagVenture MagPro 100 with MagOption)|TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-eight TMS coil. An MRI compatible version of the figure-of-eight coil will be used inside the MRI scanner with an appropriate TMS coil holder.
45644509|NCT03393520|Drug|Placebo|oral capsules
45644510|NCT03393520|Drug|AVP-786|oral capsules
45644511|NCT03391466|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously following a conditioning chemotherapy regimen of fludarabine and cyclophosphamide
45786011|NCT01106456|Behavioral|All Nations Breath of Life (ANBL)|ANBL consists of in-person group sessions and individual telephone calls. We have successfully conducted a pilot study of ANBL and have found very promising results. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence.
45918431|NCT00017992|Drug|Stavudine|
45918432|NCT00001554|Device|intraoperative infrared (IR) neuroimaging|
45918433|NCT04734067|Other|Immune checkpoint inhibitors(ICIs) therapy|Patients with malignant tumors who first received ICIs
45918434|NCT00018070|Procedure|Angiography|
45918435|NCT00018070|Procedure|Laser Treatment|
45918436|NCT05680805|Drug|Metformin Hydrochloride|Metformin 1500 mg/day in 3 divided dose for 24 weeks
45918437|NCT00018109|Drug|glutamine|
45918438|NCT00018109|Drug|creatine monohydrate|
45918439|NCT00018148|Drug|nortriptyline|Dose titrated to 75 mg daily as tolerated combined with transdermal nicotine 21 mg
45918440|NCT00018148|Drug|transdermal nicotine|Transdermal nicotine 21 mg, titrated down plus placebo
45918441|NCT00001563|Biological|Filgrastim|Filgrastim after EPOCH-R from Day 6 for 10 days every cycle.
45918442|NCT00001563|Biological|Rituximab|EPOCH-R every 3 weeks for up to 6 cycle
45918443|NCT00001563|Drug|EPOCH|EPOCH-R every 3 weeks for up to 6 cycle
45918444|NCT00018187|Drug|Bupropion|
45918445|NCT00018187|Drug|Mecamylamine|
45918446|NCT00018187|Drug|Nicotine Patch|
45918447|NCT00018226|Behavioral|Case Management|
45786012|NCT01106456|Behavioral|Nontailored program (NT)|"The nontailored intervention includes the medicines listed above to all participants and targeted counseling delivered by non-American Indian counselors who have worked closely with the American Indian communities and respect the cultures, values, and traditions of the Indian people. Therefore, our intervention includes the current best practice recommendations for smoking cessation. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence."
45786013|NCT01106456|Drug|Pharmacotherapy|All participants in the study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT)
45786014|NCT03013634|Drug|Dexmedetomidine|Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
45918448|NCT00018265|Behavioral|Task specific endurance training|
45918449|NCT00018265|Behavioral|Tai Chi|
45644512|NCT03391466|Drug|Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.|Platinum-containing salvage chemotherapy (R-ICE, R-DHAP, R-ESHAP, or R-GDP as selected by treating investigator) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.
45644513|NCT03391466|Drug|Cyclophosphamide|Administered intravenously
45918450|NCT05680766|Other|Cardiovascular endurance training|Based on the results of a maximal effort test, investigators will provide a personalised training program. Results of a submaximal effort test after 6 weeks, will allow for adaptation of the training program for the remaining training period.
45918451|NCT00018343|Drug|estrogen|
45918452|NCT00001566|Biological|therapeutic autologous dendritic cells|3 syringes containing 1 x 10^6peptide pulsed dendritic cells
45918453|NCT00001566|Drug|indinavir sulfate|Oral dose, 350 mg/m^2 administered every 8 hours. Maximum dose is 800 mg every 8 hours.
45918454|NCT00001566|Procedure|peripheral blood stem cell transplantation|Harvested autologous T cells, minimum dose 1 x 10^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
46070960|NCT00971243|Drug|MP-513 Low Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
45644514|NCT03391466|Drug|Fludarabine|Administered intravenously
45644515|NCT03389230|Biological|HER2(EQ)BBζ/CD19t+ T cells|Given via catheter
45644516|NCT03389230|Other|Laboratory Biomarker Analysis|Correlative studies
45644517|NCT03389230|Procedure|Leukapheresis|Undergo leukapheresis
45644518|NCT03388242|Other|No intervention|Patients will be recruited into the study in their initial visit before patients are on any drug treatments for their AD or MCI. The study does not include use of any interventions.
45786015|NCT03013634|Drug|Normal saline|Equal volume normal saline substitute for dexmedetomidine
45786016|NCT02980094|Dietary Supplement|Milk Antioxidant group(A)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+selenium and vitamin E (A).
45918455|NCT00018382|Drug|rosiglitazone|
45918456|NCT00018421|Procedure|Treadmill Exercise|
45918457|NCT00018460|Drug|Vitamin B|
45918458|NCT00018538|Drug|calcifidiol|
45918459|NCT04394572|Biological|Blood sample|All patients included in the study will have blood sample
46070961|NCT00971243|Drug|MP-513 Medium Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
45644519|NCT03384914|Biological|DC1 Vaccine|"Vaccination Phase: DC1 vaccine will be administered weekly via intranodal injection in weeks 1 to 6 (window 8-21days between vaccines).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
45644520|NCT03384914|Biological|WOKVAC Vaccine|"Vaccination Phase: WOKVAC vaccine will be administered via intradermal injection on weeks 1, 4 and 7 (window +21 days).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
45644521|NCT03382561|Drug|Carboplatin|Given IV
45644522|NCT03382561|Drug|Cisplatin|Given IV
45918460|NCT00386750|Drug|Artemether-lumefantrine|
45918461|NCT00001575|Biological|Y-90 Humanized Anti-Tac|10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).
45918462|NCT00001575|Drug|Calcium-DTPA|Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body
45918463|NCT04340245|Other|NA (Observational)|No interventions will be carried out. Comparisons will be made between patients whose cancer has progressed over the course of one year and patients whose cancer hasn't.
45918464|NCT05680649|Other|Breathing exercise|Diaphragmatic breathing exercises were taught to the individuals by the researcher and they were asked to start breathing exercises before starting PIVC. While the PIVC was being placed, the individuals continued the breathing exercise and the breathing exercise was terminated at the end of the application.
45918465|NCT04247191|Behavioral|P-Chat|The P-Chat is a brief individually delivered intervention based on the principles of Motivational Interviewing (MI) and focuses on increasing parents' motivation to reduce permissiveness toward underage alcohol use while reducing defensiveness and barriers to implementing these rules with their teen.
46070962|NCT00971243|Drug|MP-513 High Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
46070963|NCT00971243|Drug|Placebo and Metformin|Placebo tablets once a day, and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
46070964|NCT04017169|Other|No intervention as observational study|
46070965|NCT00822835|Biological|ILV-095|
46070966|NCT00822835|Biological|Placebo|
46070967|NCT00822913|Drug|Intravesical injection of Botulinum A toxin|One treatment, 200 U vials diluted in 20 ml normal saline
46070968|NCT00827203|Drug|Elesclomol Sodium|Chemotherapy agent
45786017|NCT02980094|Dietary Supplement|Milk Oil group(O)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+sunflower oil (O).
45449120|NCT02154334|Drug|Oxymetazoline|Nasal rhinitis participants will self-administer 2 intranasal sprays of Oxymetazoline 0.05% w/v solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 1or Period 2.
45644523|NCT03382561|Drug|Etoposide|Given IV
45786018|NCT02980094|Dietary Supplement|Milk Antioxidant and oil(AO)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets:control (C)+selenium, vitamin E and sunflower oil (AO).
45786019|NCT02980094|Dietary Supplement|Milk Control group(C)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)
45786020|NCT02530515|Biological|Ex Vivo-activated Autologous Lymph Node Lymphocytes|Given IV
45449121|NCT02156440|Dietary Supplement|SierraSil Joint Formula 14|667 mg SierraSil® hydrothermal mineral complex
45644524|NCT03382561|Biological|Nivolumab|Given IV
45644525|NCT03375320|Drug|Cabozantinib S-malate|Given PO
45786021|NCT02530515|Other|Laboratory Biomarker Analysis|Correlative studies
45786022|NCT03013322|Drug|Physostigmine|
45786023|NCT03013322|Drug|Isotonic Saline|
45786024|NCT02532933|Device|DePuy Synthes Attune PS RP|
45786025|NCT01123928|Behavioral|Video and counseling for cataract patients|Intervention includes: (1) a 5-10 min video consisting of testimony from a previous cataract patient and a doctor; (2) a 10-15 min pre-operative counseling session with a trained nurse, and (3) a 5 min post-operative counseling session with a trained nurse.
45786026|NCT02469597|Drug|Furosemide|1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose
45786027|NCT02469597|Drug|Placebo|0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose
45786028|NCT02183792|Drug|Tolvaptan|
45786029|NCT02183792|Drug|Furosemide|
45786030|NCT02533089|Other|KT intervention|Multifaceted KT intervention employing peer-trainer led educational outreach, a point of care reminder tool, and a peer mentoring network.
45449122|NCT02156440|Dietary Supplement|Placebo|
45644526|NCT03375320|Procedure|Computed Tomography|Undergo CT
45644527|NCT03375320|Procedure|Magnetic Resonance Imaging|Undergo MRI
45644528|NCT03375320|Other|Placebo Administration|Given PO
45644529|NCT03375320|Other|Quality-of-Life Assessment|Ancillary studies
45644530|NCT03375320|Procedure|X-Ray Imaging|Undergo x-ray
45786031|NCT02533167|Other|skin to skin|initiating skin to skin is not currently the standard of care at our facility so there is 1 interventional arm for this study. control group of no skin to skin until recovery room already established as is the standard of care.
45786032|NCT02538783|Behavioral|Escalating Lottery|Participants in the lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
45786033|NCT00363519|Drug|Placebo|Double-blind period (12 wk); placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
45786034|NCT00363519|Drug|Sitagliptin phosphate|Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
45786035|NCT02471313|Drug|[18F] FMISO|[18F] Fluromisonidazole, 1 h-(3-[18F]-fluro-2hydroxyl-propy10-2-nitro-imidazaole is an investigational positron emission tomography (PET) radiopharmaceutical for injection and used to visualize hypoxia imaging agent. Each patient will receive up to 10 mCi of [18F] FMISO PET imaging post TACE procedure.
45786036|NCT04743687|Drug|Zanubrutinib|Oral Zanuburutinib, 160mg twice a day
45786037|NCT04341285|Procedure|ECMO Implantation|Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.
45786038|NCT02542761|Device|Fiberglass Composite foot|The Rush foot is a fiberglass composite energy storage and return prosthetic foot.
45786039|NCT02542761|Device|Carbon Fiber Composite Foot|All types of currently commercially available carbon fiber energy storage and return prosthetic feet will be considered appropriate.
45786040|NCT02474901|Biological|Quadrivalent Live Attenuated Influenza Vaccine|
45449123|NCT01078961|Drug|bortezomib|Given intravenously on days 1, 8 and 15 of each 28 day cycle
45644531|NCT03364231|Drug|Umbralisib|Oral Daily Dose
45644532|NCT03346135|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo standard of care ASCT with a conditioning regimen of melphalan
45644533|NCT03346135|Biological|Daratumumab|Given IV
45644534|NCT03346135|Other|Laboratory Biomarker Analysis|Correlative studies
45644535|NCT03346135|Drug|Melphalan|Undergo standard of care ASCT with a conditioning regimen of melphalan
45644536|NCT03343093|Behavioral|Restore Rehabilitation Program|Multi-component, structured, biopsychosocial, online interactive program to address the sexual and urinary effects of prostate cancer treatment
45786041|NCT02475837|Drug|Vorapaxar sulfate|The study drug (12-week supply of study drug) will be dispensed to enrolled patients on the first day following surgery.
45786042|NCT02475837|Drug|Placebo|The placebo will match the study drug, vorapaxar sulfate, in appearance. A 12-week supply will be dispensed to enrolled patients on the first day following surgery.
45786043|NCT02477319|Other|Observational|
45786044|NCT01124786|Drug|CO-1.01|1250 mg/m2 intravenous infusion weekly for 3 weeks every 4 weeks
45786045|NCT01124786|Drug|Gemcitabine|1000 mg/m2 intravenous infusion weekly for 7 weeks followed by 1 week rest, then weekly for 3 weeks every 4 weeks
45786046|NCT02477709|Drug|Gefapixant|Gefapixant oral tablet (150 mg administered as three 50 mg tablets) - single dose only
45786047|NCT01933958|Drug|Regorafenib (Stivarga, BAY73-4506)|The usual dosage is 160 mg of Regorafenib/ STIVARGA taken orally after meal once daily for 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks.
45786048|NCT01108406|Device|Sonitus SoundBite System|Non Surgical Bone Conduction Device
45918466|NCT04247191|Behavioral|PBI|"The PBI is currently a model prevention resource at NIAAA's College Alcohol Intervention Matrix and the research was discussed in the most recent Surgeon General's Report as one of the two prevention approaches that met the rigorous criteria to be considered efficacious. The first section of the PBI provides an introduction to the problem of substance use. The second section focuses on specific skill building strategies that parents can use to improve communication channels with their teen. Third, is a section that addresses peer influence and provides strategies for developing assertiveness. The fourth section is an in-depth discussion of underage drinking, physiological and psychological effects, mixing alcohol with other drugs, motives for why students drink and don't drink, warning signs, risky binge-type drinking, impaired driving, riding with impaired drivers, alcohol and sexual assault, and how to communicate about parents' experiences when they were young."
45918467|NCT04247191|Behavioral|P-Chat+|The P-Chat+ is a combination of the P-Chat and PBI described above. Parents in this arm of the study will receive both interventions.
45918468|NCT00001596|Drug|Pirfenidone|Treatment with pirfenidone 801 mg (3 pills of 267 mg each), three times daily.
45918469|NCT00001596|Drug|Placebo|Placebo (3 pills), three times daily.
45786049|NCT01108406|Device|SoundBite Hearing System|
45918470|NCT05680571|Device|BulbiCam|BulbiCam is an non-invasive, multi-test device which combined eye tracking; pupil metric; video graphic dual device including the f10 tests under development and ready for validation
46070969|NCT04400383|Drug|AB011 Injection|"Stage 1 Single treatment: AB011 Injection with dose escalation of 1mg/kg up to 40mg/kg, as well as dose expansion with recommended dose level from dose escalation.~Stage 2 Combo Treatment: AB011 combine XELOX( GC) or Gem/nab-P (PC) Injection with dose escalation of 10mg/kg up to 30mg/kg, as well as dose expansion with recommended dose level from dose escalation."
45644537|NCT03343093|Behavioral|Control|usual care, surveys every 3 months
45644538|NCT03339128|Drug|Eluxadoline|Oral tablets
45644539|NCT03339128|Drug|Placebo|Oral tablets
45644540|NCT03337698|Drug|Atezolizumab|Atezolizumab is administered by IV on Day 1 of each 21 day cycle or on Days 1 and 15 of each 28 day cycle.
45644541|NCT03337698|Drug|Cobimetinib|Cobimetinib is administered orally on Days 1-21 of a 28 day cycle.
45644542|NCT03337698|Drug|RO6958688|"Cycle 1:~RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle at increasing dosage.~Subsequent cycles:~RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle."
45786050|NCT01125098|Other|PRO-CT values|"continue antibiotics for 10 days if a single PRO-CT value is 0.25 mcg/L or greater, that will be judged suggestive of bacterial infection~continue antibiotics from day 3 to day 10 if one or more PRO-CT values are 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, PLUS acute respiratory failure or clinical instability~stop antibiotics on day 3, if one or more PRO-CT values are between 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, BUT the patient has not acute respiratory failure or clinical instability~stop antibiotics if all the PRO-CT values are < 0.1 mcg/L or if there is a consistent trend to normalization of PRO-CT with the last value < 0.1 mcg/L, that will be judged suggestive of absence of bacterial infection."
45786051|NCT02179424|Behavioral|Workshop|Intensive psychological intervention included motivation of quitting enhancement, stress management and smoking triggers, craving and relapse are used to provide smoking cessation intervention
45786052|NCT02179424|Behavioral|Face-to-face counseling|Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
45918471|NCT05680532|Dietary Supplement|Black raspberry|Experimental group subjects were requested to take 50 g of Black Raspberry powder for 4 weeks.
45918472|NCT05680532|Other|Placebo|Placebo group subjects were requested to take 50 g of dextrin for 4 weeks.
45918473|NCT03276676|Drug|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor > 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.
45918474|NCT04733872|Dietary Supplement|placebo|subjects drank 50 ml , 1 bottle a day for 8 week
45644543|NCT03337698|Drug|Docetaxel|Docetaxel is administered by IV on Day 1 of each 21 day cycle.
46070970|NCT04381429|Drug|A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP)|A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
46070971|NCT04381429|Drug|F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid)|A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
45449124|NCT01078961|Drug|sorafenib|400mg taken orally twice a day
45449125|NCT02156518|Procedure|Vocal Function Exercises|Vocal Function Exercises
45644544|NCT03337698|Drug|CPI-444|CPI-444 is administered orally twice daily on Days 1- 21, of a 21 day cycle.
45644545|NCT03337698|Drug|Pemetrexed|Pemetrexed is administered by IV on Day 1 of a 21 day cycle.
45644546|NCT03337698|Drug|Carboplatin|Carboplatin is administered by IV on day 1 of the first 4 or 6 cycles out of a 21 day cycle.
45644547|NCT03337698|Drug|Gemcitabine|Gemcitabine is administered by IV on Days 1 and 8 of the first 4 or 6 cycles out of a 21 day cycle.
45644548|NCT03337698|Drug|Linagliptin|Linagliptin is administered orally once daily on Days 1 to 21 out of a 21 day cycle.
45644549|NCT03337698|Drug|Tocilizumab|Tocilizumab is administered for the management of cytokine-release syndrome in the RO6958688-containing arms.
45644550|NCT03337698|Drug|Ipatasertib|Ipatasertib will be administered orally once a day on Days 1-21 of each 28-day cycle.
45644551|NCT03337698|Drug|Bevacizumab|Bevacizumab is administered by IV on Day 1 of each 21-day cycle.
45644552|NCT03337698|Drug|Sacituzumab Govitecan|Sacituzumab Govitecan is administered by IV on Day 1 and 8 of each 21-day cycle.
45786053|NCT02179424|Behavioral|Phone counseling|Use motivational interview strategies through phone counseling to provide smoking cessation intervention.
45786054|NCT02179424|Behavioral|Health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
45786055|NCT02179424|Behavioral|Booklet|A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting.
45786056|NCT02179424|Behavioral|SMS|Fifteen SMS were sent to subjects included welcome messages, risk of smoking, correction of myths about smoking or quitting, quitting tips, benefits of quitting, encouragement of quitting
45786057|NCT02478489|Drug|Oral naltrexone (PO-NTX)|oral naltrexone
45786058|NCT02478489|Drug|Extended-release injectable naltrexone (XR-NTX)|injectable naltrexone
45786059|NCT02480439|Drug|TAK-648 Tablet|Tak-648 tablet
46070972|NCT00568555|Drug|Low Dose Naltrexone|3-4.5mg Naltrexone once daily
45644553|NCT03337698|Other|Radiation|Radiotherapy up to 21 days
46070973|NCT00568555|Drug|Placebo - sugar pill|Placebo pill once daily
45644554|NCT03337698|Drug|Evolocumab|Evolocumab is administered subcutaneously at a dose of 140 mg on Days 1 and 15 of each 28-day cycle.
45644555|NCT03337698|Drug|Tiragolumab|Tiragolumab is administered on Day 1 of each 21 day cycle.
45644556|NCT03337698|Drug|XL092|XL092 is administered orally once a day on Day 1 to Day 21 of a 21 day cycle.
45644557|NCT03337698|Drug|Camonsertib|Camonsertib is administered orally on Days 1-3, Days 8-10 of a 21 day cycle.
45644558|NCT03335228|Device|Eclipse Easy Spin for PRP|Autologous platelet rich plasma is prepared from subject's blood with the Eclipse Easy Spin centrifuge and injected into affected areas.
45644559|NCT03319940|Drug|Tarlatamab|Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
45644560|NCT03319940|Drug|Pembrolizumab|Pembrolizumab is a potent humanized IgG4 monoclonal antibody (mAb) with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and PD-L2
45644561|NCT03319940|Drug|CRS Mitigation Strategies|Participants will be treated with one of the CRS mitigation strategies.
45786060|NCT02480439|Drug|TAK-648 Oral Solution|TAK-648 oral solution
45786061|NCT02322320|Drug|Lenalidomide|In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.
45786062|NCT02551653|Drug|[11C]-GSK2256098 500 MBq|[11C]-GSK2256098 injection will be provided as IV infusion, 20 mL, containing up to 5% ethanol in saline.
45786063|NCT05308160|Drug|Dapagliflozin 10Mg Tab|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention & Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
45786064|NCT05308160|Drug|Placebo|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention & Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
45786065|NCT03013088|Device|CTO Crossing|With confirmation that the target vessel is completely occluded by the target CTO lesion, the operator shall initially attempt crossing the proximal end of the target CTO lesion by advancing ShockWireTM device ≥ 1cm. The SoundBite Crossing device can be activated as needed to perform the procedure and may be used for the entire length of the lesion(s).
45786066|NCT03010358|Drug|Entospletinib|Given PO
46070974|NCT00819325|Drug|pioglitazone|pioglitazone 30mg p.o. once a day for 6 months
46070975|NCT00819325|Drug|oral hypoglycemic agents|sulfonylurea or metformin
46070976|NCT00904670|Drug|Quillivant Oral Suspension XR|Oral Suspension 25mg/5mL; 20-60 mg/day
46070977|NCT00904670|Drug|Placebo|Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day
46070978|NCT00904670|Drug|Placebo|Matching placebo was a solution that was identical in taste and appearance to the Active drug that was used in this study.
46070979|NCT00827281|Drug|D-cycloserine|Single dosage prior to sessions 3, 4 & 5
46070980|NCT00827281|Drug|Placebo|Single dosage prior to sessions 3, 4 & 5
45449126|NCT02156518|Procedure|Vocal Hygiene|Vocal Hygiene
45644562|NCT03303625|Biological|Ad26.RSV.preF (1*10^11 vp)|Participants will receive two doses of 0.5 milliliter (mL) (1*10^11 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
45644563|NCT03303625|Biological|Ad26.RSV.preF (5*10^10 vp)|RSV seropositive participants will receive two doses of 0.25 mL (5*10^10 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
45644564|NCT03303625|Drug|Placebo|Participants will receive either 0.5 mL (cohort 0) or 0.25 mL (cohort 1) of placebo via IM route on Day 1 and 29.
45644565|NCT03303248|Behavioral|Web-based Educational Intervention|A web-based educational tool, created for patients with congenital heart disease, will be given to patients using an ipad. This additional educational tool will be used with the standard of care visit with provider.
45644566|NCT03299816|Behavioral|Coaching DASH group (C-DASH)|Participants assigned to the C-DASH diet advice group will be provided $30/week worth of fruits, vegetables, nuts and beans ordered through the study coach and delivered to a community location to reach a certain goal of potassium intake (months 0-4). During phase 2 of the study (months 5-12), a study coach will continue telephonic contact with the participants to set goals for following a DASH-like diet without the weekly food allowance.
46070981|NCT00827437|Other|Parent Interview|To include the PI, Nursing Research Specialist,Clinical Research Associate or Clinical Nurse Specialist
45918475|NCT04733872|Dietary Supplement|Vegetable and Berry Drink|subjects drank 50 ml , 1 bottle a day for 8 week
46070982|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fasted state
46070983|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fed state
46070984|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fasted state
46070985|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fed state
46070986|NCT02708654|Behavioral|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherence to this medication
45644567|NCT03299816|Behavioral|Self-Shopping DASH group (S-DASH)|Participants will be given a brochure containing information about the DASH diet which will be reviewed with a study team member. In months 1-4, participants will receive a gift card equivalent to a weekly allowance of $30 to Klein's ShopRite stores of Maryland for purchases of food and beverages of their choice. During phase two (months 5-12), they will be asked to continue following a DASH-like diet but will not receive a gift card for purchases.
45786067|NCT03010358|Other|Laboratory Biomarker Analysis|Correlative studies
45786068|NCT03010358|Biological|Obinutuzumab|Given IV
45786069|NCT03010358|Other|Pharmacological Study|Correlative studies
45786070|NCT01163162|Drug|Paricalcitol|2 mcg oral Paricalcitol once per day for 7 days
45786071|NCT05307848|Other|No intervention|No intervention
45786072|NCT01127438|Drug|fospropofol disodium Subgroup 1 Lower Dose|Dose of Initial IV (Titration) Bolus 6.5mg/kg) (administered to Subgroup 1, Weight < 60 kg and Age < 65 years and ASAI and II)
45786073|NCT01127438|Drug|fospropofol disodium Subgroup 1 Approved Dose|(Dose of Initial IV (Titration) Bolus 385mg) (Administered to Subgroup 1, Weight <60 kg and Age <65 years and ASAI and II)
45786074|NCT01127438|Drug|fospropofol disodium Subgroup 2 Lower Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (administered to Subgroup 2, Weight < 60 kg and Age >/=65 years and ASA 3 or 4
45786075|NCT01127438|Drug|fospropofol disodium Subgroup 2 Approved Dose|(Dose of Initial IV (Titration) Bolus 297.5mg) (Administered to Subgroup 2, Weight <60 kg and Age >/=65 years and ASA 3 or 4
45786076|NCT01127438|Drug|fospropofol disodium Subgroup 3 Lower Dose|(Dose of Initial IV (Titration) Bolus 3.9mg/kg) (Administered to Subgroup 3, Weight >/= 60 kg and Age >/= 65 years and ASA 3 or 4
45786077|NCT01127438|Drug|fospropofol disodium Subgroup 3 Approved Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (Administered to Subgroup 3, Weight >/= 60 kg and Age >/= 65 years and ASA 3 or 4
45786078|NCT02481141|Drug|5-ALA-SFC|Study product will be in the form of white-opaque capsules for oral administration, containing either 50, 75, or 100 mg of active 5-ALA - SFC
45786079|NCT02481141|Drug|Placebo|
45918476|NCT00001605|Biological|Nontypeable Haemophilus influenzae|
45918477|NCT05576545|Device|The Breast Cancer Self-Care App|The Breast Cancer Self-Care App includes several parts- introduction to breast cancer, types of treatment, side effects care, nutrition, relaxation videos, insurance, medical news and recording side effects, etc. The researcher assisted in installing the App on the patient's mobile phone, entered the personal account, and asked the patient to fill in questionnaires. Patients were given individual health education task in the Breast Cancer Self-Care App every week according to the type of chemotherapy drugs. After four weeks, they filled in questionnaires again.
46070987|NCT02708654|Behavioral|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
46070988|NCT02708654|Behavioral|Support Partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
45786080|NCT05307614|Drug|Moksi® 400mg Tablet|Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
45786081|NCT05307614|Drug|Drug: Avelox® 400Mg Tablet|Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
45786082|NCT02481219|Device|PillCam® COLON 2 procedure-CONTROL|
45786083|NCT02481219|Drug|Senna tablets|
45786084|NCT02481219|Drug|PEG|
45786085|NCT02481219|Drug|Metoclopramide|
45786086|NCT02481219|Drug|Erythromycin|
45786087|NCT02481219|Drug|SUPREP oral sulfate solution|
45786088|NCT02481219|Drug|Bisacodyl|
45786089|NCT02481219|Drug|SUPREP oral sulfate solution with Gastrografin|
45786090|NCT02481297|Drug|Lirilumab|3 mg/kg by vein given on Day 1 of each 28 day cycle.
45786091|NCT02481297|Drug|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks on Days 1,8, 15, and 22 of Cycle 1. After Cycle 1, given on Day 1 of Cycles 2 - 12.
45786092|NCT02481375|Dietary Supplement|Multiple micronutrients|12-wk supplementation of vitamin A, B1, B2, B6 ,B12, D, E, niacin, folic acid, zinc, copper, selenium, iodine
45786093|NCT02481375|Dietary Supplement|Iron|12-wk supplementation of iron
45786094|NCT02481375|Dietary Supplement|Placebo|12-wk supplementation of placebo
45786095|NCT01164098|Drug|Rituximab|Induction therapy
45786096|NCT02551809|Biological|UB-311|Intramuscular injection
45786097|NCT02551809|Drug|Placebo|Intramuscular injection
45786098|NCT01164644|Drug|Arnica montana|Subjects will take twelve pills by mouth three times a day over four days.
45786099|NCT01164644|Drug|Placebo|Subjects will take twelve pills by mouth three times a day over four days.
45918478|NCT05680493|Procedure|Manual pressure release|lengthens the muscle up to the increasing resistance, then gradually applies gentle pressure on MTrp until fingers feels a definite increase in tissue resistance (first barrier). Pressure would maintain until clinician sense relief of tension
46070989|NCT02708654|Behavioral|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
46070990|NCT00822991|Device|CE-US (Sonazoid™)|screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
46070991|NCT00822991|Device|B-mode US|screening by conventional B-mode US every 3-5 months
46070992|NCT05213156|Drug|Oxatrex|0.3% ofloxacin eye drops in single doses
46070993|NCT00823147|Behavioral|Pain Catastrophizing Induction|Participants will undergo a psychologist-guided 10-minute induction of negative cognitive focus on the theoretical future worsening of one's pain condition.Biological stress response will be measured via heart rate, blood pressure and serum cortisol.
45786100|NCT02551887|Behavioral|Automated Reminder|Automated reminder shown to provider
45786101|NCT02551887|Behavioral|Automated Reminder Plus Script|Provider sees both reminder and script.
45786102|NCT03010280|Dietary Supplement|Immunonutrition|Balanced high-protein formula enriched with Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
45786103|NCT03010280|Dietary Supplement|Balanced high-protein formula|Balanced high-protein formula, without Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
45786104|NCT02553135|Biological|Injection of AAV2-REP1 (10e11 vg)|Single Group: single arm study
45786105|NCT01165112|Drug|Bendamustine Hydrochloride|Given IV
45786106|NCT01165112|Drug|Carboplatin|Given IV
45786107|NCT01165112|Biological|Rituximab|Given IV
45786108|NCT01165112|Drug|Etoposide|Given IV
45786109|NCT01165112|Other|Laboratory Biomarker Analysis|Correlative studies
45786110|NCT02555631|Behavioral|lifestyle|In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
45644568|NCT03297554|Behavioral|m-Health Intervention|Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981).
46070994|NCT00823225|Procedure|standard therapy|wound debridement, moist wound dressing
46070995|NCT00823225|Drug|Urokinase|"Daily infusion up to 21 applications, dose dependent on fibrinogen level:~> 2,5g/l 1 000 000 IU, < 2,5g/l 500 000 IU"
45644569|NCT03291431|Device|Intermittent theta burst transcranial magnetic stimulation|20 iTBS sessions (active or sham) administered over the course of 2 weeks
45786111|NCT01129778|Drug|Zegerid (proton pump inhibitor)|
45786112|NCT01129778|Procedure|Bravo pH monitoring|
45786113|NCT05307224|Device|Mandala|Experimental group will paint mandala for 30 minutes/day in the evenings for six consecutive days. Six pre-selected mandalas were planned to be printed separately on A4 paper. Each patient will be given a new mandala each day. Additionally, At the beginning of the study, the experimental group will be given six colors (yellow, blue, green, red, purple, brown).
45786114|NCT02484807|Other|no intervention, only observation of different groups|
45786115|NCT05307146|Device|macro/micro electrode recording|intracranial macro/micro-electrode placement at the cerebral cortex or in deeper brain areas with te use of macro/micro electrode recording. Macro/micro electrodes are placed at the cerebral cortex or in deeper brain areas in order to precisely identify the epileptogenic focus
45786116|NCT02556333|Drug|FTC/TAF|Tenofovir alafenamide (TAF) is an investigational oral prodrug of tenofovir. This trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part of a salvage antiretroviral regimen for HIV-1-infected adults and adolescents (greater than or equal to 14 years) who experienced virologic failure.
45786117|NCT01166126|Drug|temsirolimus|Given IV
45786118|NCT01166126|Drug|selumetinib|Given orally
45786119|NCT01166126|Other|laboratory biomarker analysis|Correlative studies
45786120|NCT05306990|Drug|Atorvastatin 40 Mg Oral Tablet|patients followed up for 3 months
45786121|NCT05306990|Drug|Rosuvastatin 20 Mg Oral Tablet|patients followed up for 3 months
45786122|NCT02557035|Drug|Palonosetron|
45786123|NCT02557035|Drug|Dexamethasone|
45786124|NCT02385084|Drug|LY2409021|Administered orally
45786125|NCT04341207|Drug|Hydroxychloroquine|Hydroxychloroquine 200 mg 3 times a day for 10 days
45786126|NCT04341207|Drug|Azithromycin|Azithromycin 500 mg on day 1 followed by 250 mg/day for 4 days
45786127|NCT02411292|Drug|Enoxaparin|Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
45786128|NCT01166984|Drug|AB103|Single intravenous infusion at doses of 7.5 µg/kg, 37.5 µg/kg, 150 µg/kg, or 450 µg/kg administered over approximately 10 minutes
45786129|NCT01166984|Drug|Placebo|Single intravenous infusion of normal saline (0.9% sodium chloride) administered over approximately 10 minutes
45786130|NCT02486211|Drug|Amantadine|100mg twice per day for 7 days at 0600 and 1200
45786131|NCT02486211|Drug|Placebo|Placebo comparator
45918479|NCT05680493|Procedure|Dry needling|A filiform needle is inserted at 45 degree in to trigger point and then twirl the needle up and down to release trigger point
45918480|NCT05680493|Procedure|Heat therapy|Hydro collator pack will be placed on affected area for relaxation and pain relief for 15 min
45918481|NCT05576311|Other|Focus Group|Focus Groups to capture information about the need for innovation in the diagnosis and monitoring of urinary symptoms.
46070996|NCT00823381|Dietary Supplement|resveratrol|one pill of resveratrol (Resvida™) 75 mg once a day with breakfast
46070997|NCT00823381|Other|placebo|one placebo pill taken once a day with breakfast
46070998|NCT00823381|Behavioral|Calorie Restriction|supervised calorie restriction diet: 30% reduction in caloric intake
46070999|NCT02850380|Other|"FLIP SWITCHES DOWN IN WEIGHTLESSNESS"|"The circular instrument panel that subjects will see into the cylindrical mask consists of one switch surrounded by a luminous ring (left part of the figure below). The switch can be flipped into any direction within the full 360° range. The switch provides no visual cues about down, but the experimenter can add such cues by means of visually polarized labelling displayed on a circular black screen at the center of the panel (right part the figure below)."
45918482|NCT05576194|Device|TauroPace|All the hardware (leads, suture sleeves, pulse generator) is washed and the device pocket irrigated with an adjunct antimicrobial solution containing Taurolidine (TauroPace™, Tauropharm, Bavaria, Germany), during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system since January 2019
46071000|NCT02850224|Behavioral|Motivational interviewing to elicit PCO in pediatrics|A motivational interviewing style webinar. Physicians watch the webinar, incorporate communication techniques.
46071001|NCT00638443|Drug|Pregabalin|Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
46071002|NCT00638443|Drug|Diphenhydramine|diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
46071003|NCT00632684|Behavioral|Interviews with a single treatment planning session|Participants in Phase 1 will attend four 90-minute interviews over 4 months. During interviews, participants will be asked about their experiences caring for their relatives, physical and emotional well-being, and ideas on helpful types of assistance. Participants will also receive information about programs and services that may help them carry out caregiving activities.
45449127|NCT01077167|Drug|Omecamtiv mecarbil|Oral dosing twice each day or three times each day, depending on the cohort assignment, of Omecamtiv mecarbil for 8 days. Omecamtiv mecarbil comes in 2 formulations: modified release and immediate release, and the formulation given will depend on the cohort assignment.
45449128|NCT03738280|Diagnostic Test|Endoscopic ultrasound-fine needle biopsy|Patients with non-hypovascular solid pancreatic lesion undergo endoscopic ultrasound-fine needle biopsy
45786132|NCT04743531|Behavioral|HEROs|Intervention Description: The intervention will consist of a 6-week family workshop series, held one evening per week for six consecutive weeks. The intervention modules will be delivered by trained researchers at two preschool sites in rural Colorado in Fall 2019 and Spring 2020. The primary caregiver and preschool child will be the targets of the study. Each of the workshops will be structured to include joint caregiver-child activities and programming that is tailored for caregivers and children individually. Caregivers will learn about and engage in activities related to healthy eating and picky eating; physical activity and motor development; and parenting strategies. Children will participate in activities focused on healthful eating and physical activity that supports content their parents are learning.
45786133|NCT01167452|Drug|Sulfamethoxazole/trimethoprim|2 DS tablets of trimethoprim/sulfamethoxazole x 1 dose
45786134|NCT04352192|Other|Kinesiotaping|For kinesiotaping, the elbow positioned in 30°-45° flexion and kinesiotaping facilitation technique is applied origin to insertion of biceps brachii muscle.
45786135|NCT02487225|Drug|Pentoxifylline|Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cyclic adenosine monophosphate (cAMP), activates protein kinase A (PKA), inhibits Tumor Necrosis Factor (TNF) and leukotriene synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability (known as a haemorrheologic effect), reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation.Pentoxifylline is also an antagonist at adenosine 2 receptors
45786136|NCT02487225|Drug|Placebo|A harmless pill that has no therapeutic effect, used as a control in testing of investigational drug
45449129|NCT03736252|Device|Orthosis provision|Hely and Weber CMC controller
45449130|NCT03818399|Drug|SUBLOCADE|SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
45786137|NCT02384850|Drug|Selinexor|Dose Level 1: 40 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 2: 60 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 3: 80 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level -1: 20 mg on day 1, 3 and 8 in a two-weeks cycle.
45449131|NCT02154646|Drug|LY2157299|Administered orally
46071004|NCT00632684|Behavioral|Adaptive treatment model|The adaptive treatment model will include up to ten 60- to 75-minute planning sessions. The sessions will focus on psychosocial issues and will be tailored to participants' specific risk factors.
46071005|NCT05184218|Drug|IGM-6268|Active Comparator
46071006|NCT05184218|Drug|Placebo|Placebo Comparator
46071007|NCT00636181|Device|Auto AFlex|Positive pressure therapy treatment
46071008|NCT00636181|Device|Auto CPAP|Positive pressure therapy treatment
45449132|NCT02154646|Drug|Gemcitabine|Administered IV
45449133|NCT03642873|Drug|Humibid®|Humibid® 1200 mg (single extended release) tablet
45449134|NCT03642873|Drug|Hydrocodone Bitartrate|Hydrocodone Bitartrate (3.33 mg q4h X 3)
45449135|NCT03642873|Drug|Humibid® and Hydrocodone Bitartrate tablet|Humibid® 1200 mg (single extended release) tablet and Hydrocodone bitartrate (3.33 mg q4h X 3)
45786138|NCT02384850|Drug|Oxaliplatin|85 mg/m² IV over 2 hours, Day 1 of a two-weeks cycle
46071009|NCT00636181|Device|CPAP|Positive pressure therapy treatment
46071010|NCT00968669|Biological|MEDI528 30 mg|MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
46071011|NCT00968669|Biological|MEDI528 100 mg|MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
46071012|NCT00968669|Biological|MEDI528 300 mg|MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
46071013|NCT00968669|Other|Placebo|Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
45449136|NCT01079819|Drug|BMS-708163|Capsule, Oral, 50 mg, once daily, 1 Day
45449137|NCT01079819|Drug|BMS-708163|Capsule, Oral, 125 mg, once daily, 14 Days
45449138|NCT01079819|Drug|Placebo|Capsule, Oral, 0 mg, One daily, 1 Day
45449139|NCT01079819|Drug|Placebo|Capsule, Oral, 0 mg, One daily, 14 Day
45449140|NCT02156596|Drug|IV NSAI|100 mg of ketoprofen in 50 ml volume given in 30 minutes by IV root
45449141|NCT02156596|Drug|NM|3 nebulisations of 5 mg morphine chlorhydrate each given over 30 minutes (10 minutes per nebulisation)
45449142|NCT02156596|Drug|IV Serum Saline|50 ml of SS is given by IV root over 30 minutes
45449143|NCT02156596|Drug|Nebulised Serum Saline|3 nebulisations of 5ml SS each are given over 30 minutes
45918483|NCT05576194|Device|Hydrogen Peroxide|All the hardware (leads, suture sleeves, pulse generator) was washed and the device pocket irrigated with an adjunct antimicrobial solution containing 3% hydrogen peroxide (H2O2) during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system at the authors' institute before 01/01/2020
45786139|NCT02384850|Drug|5-FU|400 mg/m² IV bolus, Day 1 of a two-weeks cycle 2,400 mg/m² continuous infusion IV, Days 1-3
45786140|NCT02384850|Drug|Folinic Acid|400 mg/m2 IV over 2 hours, Day 1 of a two-weeks cycle
45786141|NCT01167608|Other|No Intervention. This is a cross-sectional survey study.|No intervention.
45786142|NCT02558829|Drug|Macimorelin|macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose
45786143|NCT02558829|Drug|Insulin|Insulin, 0.10 U/kg (0.15 U/kg if BMI > 30 kg/m2), intravenous injection, single dose
45918484|NCT05576194|Drug|Taurolidine|All the hardware (leads, suture sleeves, pulse generator) was washed and the device pocket irrigated with an adjunct antimicrobial solution containing taurolidine in a galenic formulation during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system at the authors' institute before 01/01/2019
45644570|NCT03288493|Biological|P-BCMA-101 CAR-T cells|"P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA. P-BCMA-101 cells are produced using a non-viral vector carrying the gene for an anti-BCMA Centyrin-based (small, fully human binding domain, designed to increase T cell persistence and decrease exhaustion) chimeric antigen receptor (CAR). Secondary to the large carrying capacity of the non-viral vector, P-BCMA-101 cells carry two additional genes, a selection gene used to manufacture a purified product and a safety switch gene to allow the cells to be eliminated if desired. Rimiducid (safety switch activator) may be administered as indicated."
45644571|NCT03288493|Drug|Rimiducid|Rimiducid (safety switch activator) may be administered as indicated.
45644572|NCT03287349|Other|Blood draw|Two 12.5 mL blood draws
45786144|NCT01132508|Device|Norian Drillable Bone Void Filler|Norian Drillable Bone Void Filler is a moldable, biocompatible bone void filler with added reinforcing fibers. Norian Drillable is intended to be placed into bony voids either before or after final fixation. The material can be drilled and tapped, and screws can be placed through it at any time during the setting process. Norian Drillable is a composite, two-component, self-setting calcium phosphate bone void filler
45786145|NCT02487303|Drug|Acetaminophen Intravenous|IV 1 gram f3 doses over 24 hours
45786146|NCT02487303|Drug|Acetaminophen Oral|Oral 1 gram 3 doses over 24 hours
45786147|NCT04341051|Other|Case|Mesure with NIRS regional saturation in patients undergoing popliteal block during vascular surgery for chronic obliterating arteriopathy (IIa to III Fontaine Classification)
45786148|NCT02560701|Other|Patient Interview|Investigators will conduct in-depth interviews with approximately 40 commercially insured individuals with bipolar disorder or their family caregivers to explore how they navigate deductibles, copayments, and other complex insurance features. Investigators will also determine the health care services that patients most value and assess how they prioritize difficult health care cost tradeoffs.
45786149|NCT03011762|Device|Computer controlled mandibular positioner|Participants in this arm will complete the computer controlled mandibular positioner test. The study participant, study dentist, and PI are all blinded to the outcome of the CCMP test. Those participants predicted to experience therapeutic success with OAT will have their oral appliance set at the predicted protrusive level; those participants predicted to experience therapeutic failure will have their oral appliance set at a default position. Outcome home sleep tests with the oral appliance in place will be used to determine the accuracy of the prediction.
45918485|NCT00391885|Device|Closed-loop anesthesia system|
45786150|NCT02488317|Other|Decision Aid|Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
45786151|NCT01168934|Drug|crizotinib|Treatment A: Intravenous dose of 50 mg crizotinib will be administered as directed.
45918486|NCT00001623|Procedure|Allogeneic Bone Marrow Transplant|
45918487|NCT00391924|Drug|Dehydroepiandrosterone|
45918488|NCT00391963|Device|Bispectral index, Entropy|
45918489|NCT00392002|Drug|Esomeprazole|
45918490|NCT00392080|Drug|CJ-023,423|75 mg BID
45918491|NCT00392080|Drug|placebo|placebo
45918492|NCT00392080|Drug|naproxen|naproxen
45918493|NCT05680259|Other|Maela connected follow-up|Measures of pain, quality of life and health related variables (coping, self-efficacy, beliefs about pain) will be done at four times before and after surgery.
45918494|NCT05680259|Other|traditional follow-up|medical recommendations and prescriptions at hospital discharge. Measures of pain, quality of life and health related variables (coping, self-efficacy, beliefs about pain) will be done at four times before and after surgery.
45644573|NCT03287349|Other|Photograph|Photograph of severe reaction, will be anonymized
45644574|NCT03287349|Diagnostic Test|Autoimmune testing|Autoimmune testing in patients without prior testing
45644575|NCT03281902|Procedure|Biopsy|Undergo tumor biopsy
45644576|NCT03281902|Procedure|Biospecimen Collection|Undergo collection of blood, urine, stool, and saliva
45644577|NCT03281902|Other|Laboratory Biomarker Analysis|Correlative studies
45786152|NCT01168934|Drug|crizotinib|Treatment B: Oral dose of 250 mg crizotinib as 1 × 50-mg Immediate Release Tablet and 2 × 100-mg Immediate Release Tablets will be administered in the fasted state as directed.
45786153|NCT05305508|Drug|Calcium Dobesilate|The treatment (CaD, Calcium Dobesilate 500 mg) will be administered orally twice a day for 7 days.
45786154|NCT05305508|Drug|Mannitol|The comparator (placebo, Mannitol 500 mg) will be administered orally twice a day for 7 days.
45786155|NCT01170884|Drug|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution|1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution (Combigan®) taken approximately 12 hours apart, up to 2 times a day and 1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken once every 24 hours.
45786156|NCT01170884|Drug|bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops|1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken approximately every 24 hours; mild lubricant eyedrops (Gen Teal® Mild) for masking purposes
45786157|NCT01171118|Drug|Physostigmine|Physostigmine is a centrally acting acetylcholinesterase inhibitor that has been proposed as a treatment for sleep disordered breathing. It is currently FDA approved and used commonly by Anesthesiologists in the post anesthetic setting to reverse confusion caused by central anticholinergic medication effects.
45786158|NCT01171118|Drug|Oxygen|The administration of nasal cannula-administered oxygen at a flow rate of 2 liters/minute is commonly performed during clinical sedation practice. Thus, this experiment employed its use to compare respiratory effects of oxygen versus room air.
45786159|NCT01171118|Drug|Placebo|The administration of placebo versus physostigmine was untertaken in the same sedation conditions on the alternate day in each subject (and with both room air and oxygen)
45786160|NCT03011918|Other|Data Collection prior to first fall for all fallers|Weight history. Descriptive analysis of weight history in single event fallers compared to multiple event fallers. Information on use of any nutrition supplementation exposure will also be collected
45786161|NCT03011918|Other|Hgb value|Hgb decline. Descriptive analysis of single event fallers compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure will be collected
45786162|NCT03011918|Other|Vitamin D|Descriptive analysis of vitamin D status of single event fallers compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure will be collected..
45786163|NCT03011918|Other|C-Reactive Protein|Descriptive analysis of C-RP value status of single event fallers as compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure data will be collected.
45786164|NCT05296460|Drug|Dapsone gel|The patients will use topical dapsone gel 7.5% once daily on left side of face ,The patients will use TCA20% peeling as a peeling session every 2 weeks (6 sessions) on right side of face
45786165|NCT05288894|Diagnostic Test|Cardiac magnetic resonance imaging|A routine cardiac magnetic resonance imaging with biventricular function evaluation, atrial volumes, LGE acquisitions, and pulmonary and aortic assesment.
45786166|NCT01136798|Drug|Exenatide|Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
45449144|NCT03729843|Radiation|CBCT and intraoral digital radiography|Simulated periodontal bone defects will be measured by 2 techniques: group I detected and measured using CBCT and group II intraoral digital radiography and all the measurements will be compared with the gold standard real measurements on the dry jaws
45644578|NCT03280563|Drug|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|Atezolizumab will be given as 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle. This regimen will apply to all arms except when given with entinostat in Stage 1, or exemestane or tamoxifen in Stage 2, in which atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle.
45644579|NCT03280563|Drug|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 15 of each 28-day cycle in the regimen containing fulvestrant. When given with exemestane or tamoxifen, bevacizumab will be given as 15 mg/kg via IV infusion on Day 1 of each 21-day cycle.
45644580|NCT03280563|Drug|Entinostat|Entinostat will be given as 5 mg orally once a week on Days 1, 8 and 15 of each 21-day cycle.
45644581|NCT03280563|Drug|Exemestane|Exemestane will be given as 25 mg orally QD in each 21-day cycle.
45644582|NCT03280563|Drug|Fulvestrant|Fulvestrant will be given as 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and thereafter on Day 1 of each 28-day cycle.
45644583|NCT03280563|Drug|Ipatasertib|Ipatasertib will be given as 400 mg orally QD on Days 1-21 of each 28-day cycle.
45644584|NCT03280563|Drug|Tamoxifen|Tamoxifen will be given as 20 mg orally QD in each 21-day cycle.
45644585|NCT03280563|Drug|Abemaciclib|Abemaciclib will be given as 150mg twice daily during each 28-day cycle.
45644586|NCT03274258|Biological|Ipilimumab|Given IV
45644587|NCT03274258|Biological|Nivolumab|Given IV
45786167|NCT01136798|Drug|Placebo|Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
45786168|NCT01172522|Drug|Fexofenadine|Fexofenadine 1%
45786169|NCT01172522|Drug|Placebo|Placebo
45786170|NCT01172600|Other|Entonox|Those randomized to Entonox will inhale the gas through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.
45786171|NCT01172600|Other|Oxygen|Those randomized to oxygen will inhale it through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.
45786172|NCT01137032|Drug|Pandel Cream 0.1%|A thin coat of cream will be applied and rubbed into the affected areas, as well as normal skin, twice daily for 21 days
45786173|NCT02246816|Drug|0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)|0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
45786174|NCT01137890|Drug|Zonisamide|Eight capsules administered daily in split doses at 22:00 and 09:00.
45786175|NCT01137890|Drug|Placebo|capsules administered in split doses at 22:00 and 09:00.
45786176|NCT01137890|Drug|Cocaine Hydrochloride|Cocaine Challenge Sessions: Human laboratory sessions with administration of moderate doses of cocaine by the intravenous route under controlled conditions and cardiovascular monitoring.
45786177|NCT01137890|Behavioral|Neurocognitive and Performance Battery|Participants will complete tests to assess their abilities and performances on a number of tasks given by a computer or other type of equipment.
45786178|NCT01137890|Behavioral|Smoking Assessments|Participants answer questions about smoking and smoking behaviors are monitored.
46071014|NCT04512547|Drug|Hyperpolarized 129XeMRI|Images obtained using 129XeMRI will be obtained on both obese asthmatic and non-asthmatics
46071015|NCT04479787|Device|Spinal Cord Stimulation|Utilization of BURSTDR stimulation
45449145|NCT03965429|Other|Blood samples (additional tubes from care) longitudinal|Some sampling times will be systematic, while others will only be performed in the presence of specific post-transplant clinical events (eg relapse, GVH ...).
45644588|NCT03269669|Drug|Bendamustine Hydrochloride|Given IV
45786179|NCT01138124|Drug|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulary codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to the index date (the exposure window). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose. These parameterizations will also be examined with a 2 year lag time from the index date, limiting the exposure window from entry into the study cohort up to 2 years prior to the index date.
45786180|NCT02437890|Biological|ALX-0061|
45786181|NCT02437890|Biological|Placebo|
45786182|NCT02560779|Drug|Carotuximab (TRC105)|Bi-weekly iv TRC105 (15 mg/kg) will be given with 400mg sorafenib twice daily in the phase 1B portion of the study. Weekly iv TRC105 (10 mg/kg) will be given with 400mg sorafenib twice daily in the phase 2 portion of the study.
45786183|NCT02560779|Drug|Sorafenib|400 mg of sorafenib will be given twice daily.
45786184|NCT01138514|Drug|Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)|Applied to the entire face twice daily for 10 weeks
45786185|NCT01138514|Drug|Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)|Applied to the entire face twice daily for 10 weeks
45786186|NCT01138514|Drug|Placebo|Placebo
45786187|NCT02561481|Drug|Sulforaphane|See under active arm description
45786188|NCT02561481|Drug|Placebo|See under placebo arm description
45786189|NCT01173848|Drug|Ergocalciferol|1.25mg weekly for 12 weeks then once a month for 3 months. or 1.25 weekly for 4 weeks then once a month for 5 months. or 1.25 monthly for 6 months
45786190|NCT01173848|Drug|Cholecalciferol|1.25 weekly for 12 weeks then monthly for 3 months or 1.25 weekly for 4 weeks then monthly for 5 months or 1.25 monthly for 6 months
46071016|NCT04479787|Other|Conventional Medical Management|Assessing type of CMM, location and frequency.
45449146|NCT03965429|Other|Blood samples (additional tubes from care) at inclusion|"In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor. A single blood sample of 28 mL (7 EDTA tubes) will be made.~In order not to represent an additional sample for the donor, this sample will be taken before the mobilization of the hematopoietic stem cells, during the biological assessment required for the biological donation qualification."
45449147|NCT02156752|Behavioral|ACT|Treatment is based on Acceptance and Commitment Therapy
45644589|NCT03269669|Procedure|Biopsy|Undergo biopsy
45644590|NCT03269669|Procedure|Biospecimen Collection|Undergo collection of blood
45644591|NCT03269669|Procedure|Computed Tomography|Undergo PET/CT scans
45644592|NCT03269669|Drug|Cyclophosphamide|Given IV
45644593|NCT03269669|Drug|Doxorubicin Hydrochloride|Given IV
45644594|NCT03269669|Procedure|Echocardiography|Undergo ECHO
45644595|NCT03269669|Drug|Lenalidomide|Given PO
45644596|NCT03269669|Procedure|Multigated Acquisition Scan|Undergo MUGA
45644597|NCT03269669|Biological|Obinutuzumab|Given IV
45786191|NCT02384538|Biological|ABT-981|ABT-981 administered by subcutaneous injection
45786192|NCT02384538|Biological|Placebo for ABT-981|Placebo for ABT-981 administered by subcutaneous injection
45786193|NCT01174082|Biological|KLH Vaccine|"Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI."
45786194|NCT01174082|Biological|KLH-id Vaccine|"Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI."
46071017|NCT00568399|Drug|sodium thiosulfate|sodium thiosulfate 12.5-25 gm/M2 after each thrice weekly hemodialysis treatments for 5 months.
45644598|NCT03269669|Procedure|Positron Emission Tomography|Undergo PET/CT scans
45644599|NCT03269669|Drug|Prednisone|Given PO
45644600|NCT03269669|Drug|Umbralisib|Given PO
45644601|NCT03269669|Drug|Vincristine Sulfate|Given IV
45644602|NCT03267810|Device|TENS|TENS: TENS 7000 - : TENS applies low-level electrical current via four pads, 2 pads affixed paraspinally, at the level of the spinal cord injury, and 2 affixed on the ventral side to areas within the dermatome corresponding to the level of injury. 15 minutes of high frequency followed by 15 minutes of low frequency will be applied at each session
45786195|NCT01174082|Drug|GM-CSF|250 mcg/m2 subcutaneously daily for 4 days after each vaccine
45786196|NCT01174082|Procedure|Apheresis|Day 0 (day of lymphocyte collection) donors undergo a steady state pheresis to obtain lymphocytes.
45786197|NCT01174082|Procedure|Donor Lymphocyte Infusion (DLI)|Day 0, infusion to patient of collected donor cells.
45786198|NCT02566083|Device|non-toric intraocular lens|TECNIS One-piece Monofocal Model ZCB00
45786199|NCT02566083|Device|toric intraocular lens|TECNIS One-piece Toric Models ZCT300 or ZCT400
45786200|NCT02410824|Device|stenfilcon A toric lens|toric contact lens
45786201|NCT02410824|Device|etafilcon A toric lens|toric contact lens
45644603|NCT03267810|Other|Sham TENS|Inactive electrodes - for two 15 minute trials, neither high nor low frequency.
45918495|NCT05574595|Other|Music theraphy|In each session, the desired type of music will be played approximately 6 minutes before the procedure (Shabandokht-Zarmi et al., 2017). After the end of the music, the cannulation process will be performed by the dialysis nurse. The level of pain experienced by the patient immediately after needle insertion into the fistula will be evaluated with VAS by a research-independent nurse working in the dialysis unit.
45918496|NCT05574478|Behavioral|Patients and Caregivers Qualitative Interview|Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications & Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.
45918497|NCT05680220|Device|Neurostimulation System (NSS): Active Setting|Exposure to the active device for 1 hour a day for 6 weeks
45918498|NCT05680220|Device|Neurostimulation System (NSS): Sham Setting|Exposure to the sham device for 1 hour a day for 6 weeks
46071018|NCT00827593|Behavioral|Standard behavioral weight loss treatment|Participants will receive 12 months of university-based behavioral weight loss treatment
46071019|NCT00827593|Behavioral|Weight Watchers|Participants will receive 12 months of Weight Watchers
45786202|NCT05185778|Biological|stool examination, blood sample collected|"Stool examination macroscopically for consistency, color, and presence of blood and/or mucus and microscopically using the following methods:~Saline and iodine wet mount.~Formalin-ethyl acetate sedimentation method.~Modified Ziehl-Nielsen staining : It was done to all cases with manifestations suggestive of protozoa.~Collection of peripheral blood samples for Automated CBC and blood indices evaluation.~Molecular detection of inflammatory cytokines level (IFNγ, TNFα) and antiinflammatory cytokines (IL4, IL10) by Real-time PCR(polymerase chain reaction)."
45786203|NCT02491359|Drug|Carfilzomib|Given IV
45786204|NCT02491359|Other|Laboratory Biomarker Analysis|Correlative studies
46071020|NCT00827593|Behavioral|Combined Treatment|Participants will receive university-based behavioral weight loss treatment followed by Weight Watchers
46071021|NCT00975143|Drug|CIP-Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
45918499|NCT05574283|Procedure|Erector spinae plane block and transmuscular quadratus lumborum block|"All blocks were performed after securing the airway before the start of surgery.~ESPB group will receive bilateral ultrasound-guided erector spinae plane block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side.~TQLB group will receive bilateral ultrasound-guided transmuscular quadratus lumborum block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side"
45918500|NCT05574205|Other|Resistance Exercise|Supervised single-leg (unilateral) exercise will be undertaken every other day throughout the dietary intervention
46071022|NCT00975143|Drug|Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
46071023|NCT04286087|Procedure|neck incisions closed at bedside at the time of drain removal under local anesthesia|Participants allocated to the investigational group will have neck incisions closed at bedside at the time of drain removal under local anesthesia
46071024|NCT04286087|Procedure|standard treatment|Participants in the control group will have standard treatment performed as per current practice,their incision will be left to close by secondary intention
45918501|NCT05574205|Dietary Supplement|Protein supplementation|Participants will consume a protein supplement alongside a provided diet to control protein amount and quality.
45449148|NCT02156752|Behavioral|SR|Treatment is based on Self-Regulation theory.
45786205|NCT02491359|Other|Quality-of-Life Assessment|Ancillary studies
45918502|NCT05574166|Drug|SP-8356|SP-8356 demonstrates anti-atherosclerotic and anti-ischaemic activity as a novel CD147 inhibitor.
45918503|NCT05574166|Drug|Placebo|Placebo for SP-8356 powder
45918504|NCT00001644|Drug|Indinavir|
45918505|NCT00001644|Drug|Zidovudine|
45918506|NCT00001644|Drug|Lamivudine|
45449149|NCT02156752|Behavioral|WLO|Treatment is based on cooking tips and demonstrations.
45644604|NCT03267433|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo HCT
45644605|NCT03267433|Other|Laboratory Biomarker Analysis|Correlative studies
45918507|NCT00001644|Drug|Nevirapine|
45918508|NCT00001644|Procedure|Blood testing|
46071025|NCT04288349|Procedure|perineal block with usage of one of solutions|Perineal block using solution of ropivocaine and epinephrine for the first group was performed. Anococcygeal ligament is infiltrated with 10 ml of the solution after the intracutaneous infiltration in 2 cm from the anus. Ten ml of the solution is injected in ischiorectal fat on each side. The needle is orienteered at the angle of 45 degrees cranially and laterally, and to the surface what allows the surgeon to anesthetize the deep branches of the pudendal nerve. In addition, 10 ml of solution is injected transdermal on the front edge of the anus with further subcutaneous infiltration on each side of the anus to provide anesthesia to the nerve branches laying more superficial. The total amount of the injected solution is 50 ml.
45644606|NCT03267433|Biological|Rituximab|Given IV
45644607|NCT03264989|Drug|crizanlizumab|SEG101 (crizanlizumab) drug at a dose of 5.0 mg/kg (or 7.5 mg/kg for exploratory group) by IV infusion
45644608|NCT03253848|Other|Best Practice|Discussion between doctors and APL expert
45644609|NCT03253848|Other|Laboratory Biomarker Analysis|Correlative studies
45644610|NCT03253848|Procedure|Supportive Care|Receive simplified guidelines and support
45786206|NCT02491359|Other|Questionnaire Administration|Ancillary studies
45918509|NCT00001644|Procedure|Lymph node biospy|
45918510|NCT00001644|Procedure|Leukapheresis|
45918511|NCT05574049|Drug|Tetrahydrocannabivarin|The subjects will take once daily oromucosal strip with intervention drug for 90 days.
45918512|NCT05574049|Other|Placebo|The subjects will take once daily oromucosal strip with no drug on it for 90 days
46071026|NCT04288349|Drug|epinephrine + ropivacaine +saline|epinephrine + ropivacaine +saline
46071027|NCT04288349|Drug|epinephrine + saline|epinephrine + saline
46071028|NCT03667313|Combination Product|sirolimus-eluting balloon (SEB) MagicTouch|Patients with coronary in-stent restenosis treated with sirolimus-eluting balloon
45786207|NCT01175798|Drug|Cholecalciferol|50,000 IU PO weekly x 6 weeks
45786208|NCT02246894|Biological|Optivate® (Human Coagulation Factor VIII)|
45786209|NCT03012074|Behavioral|Type 2 Diabetes Self-Management|Patients with Type 2 Diabetes
45786210|NCT05177510|Drug|Mifepristone|Progestin Antagonist
45644611|NCT03242642|Device|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)|mitral valve replacement
45644612|NCT03242642|Device|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) mitral valve replacement
45786211|NCT05177510|Drug|Placebo|Placebo
45786212|NCT02181140|Device|EUS guided FNA and fine needle punction|punction of a suspect area by a EUS guided fine needle as well as pro core fine needle to evacuate histology and smear biologics
45786213|NCT02384460|Drug|SD-101-6.0 cream|applied topically once a day for 90 days
45786214|NCT02384460|Drug|Placebo (SD-101-0.0) cream|applied topically once a day for 90 days
45786215|NCT02184494|Device|pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)|"Subjects will be exposed to vertical vibration with a frequency and peak-to-peak displacement of 30 Hz and 1 mm, respectively, which provides a peak-to-peak acceleration of about 4.16 G.~Whole Body Vibration"
45786216|NCT03012542|Dietary Supplement|Diet 1|Diet controlled in amount and source of carbohydrates or fiber containing foods.
45786217|NCT03012542|Dietary Supplement|Diet 2|Diet controlled in amount and source of carbohydrates or fiber containing foods.
45786218|NCT03011996|Drug|CLR 500mg|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
46071029|NCT03667313|Combination Product|paclitaxel-eluting balloon (PEB) Sequent Please|Patients with coronary in-stent restenosis treated with paclitaxel-eluting balloon
46071030|NCT03796091|Behavioral|Educational Brochure|Participants will read an educational brochure from the National Eating Disorders Association and will receive treatment referral resources.
46071031|NCT03796091|Behavioral|Body Project Traditional|Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Traditional group therapy program (see Stice & Shaw, 2001).
45644613|NCT03238690|Device|Controlled Cardiac Reloading through LVAD Speed Adjustment|LVAD speed is reduced at a fixed rate according to the particular LVAD device model implanted. LVAD speed reduction adjustments will be performed at visits occurring every 2 - 3 weeks, up to a total of 8 visits. Reduction of LVAD speed will continue until the soonest of: minimum operating setting as recommended in the LVAD Operator's manual is reached; the minimum setting tolerated by the subject is reached; the subject completes 8 visits; or until the subject receives a heart transplant.
46071032|NCT03796091|Behavioral|Body Project Expanded|Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Expanded group therapy program (see Green et al., 2017).
45786219|NCT03011996|Drug|CJ-12420 100mg|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
45786220|NCT03011996|Drug|CJ-12420 50mg|Cohort 2: bid for 7 days
45786221|NCT03011996|Drug|AMX 1g|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
45786222|NCT03011996|Drug|Pantoprazole 40mg|Cohort 2: bid for 7 days
45786223|NCT01178216|Biological|Rituxan|Rituximab (1gm) given on day# 15. Transplanted patients will receive an additional dose of Rituximab at 3M if DSA remains or 6M if denovo DSA present.
45786224|NCT02384382|Drug|Enzalutamide|
45786225|NCT01178528|Drug|ivabradine|7.5 mg bd
45786226|NCT01178528|Drug|"Drug:Carvedilol and Drug:Ivabradine"|up to 12.5/5 mg bd
45786227|NCT01178528|Drug|Carvedilol|25 mg bd
45786228|NCT03012854|Procedure|short-myotomy|"Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~Endoscopic myotomy is carried out in a proximal to distal direction to a total length less than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
45786229|NCT03012854|Procedure|long-myotomy|"Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
45786230|NCT03012854|Procedure|full-thickness myotomy|"Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
45918513|NCT05573971|Other|with verbal encouragement|Each athlete swam a maximal 200m freestyle trial in two different conditions: one trial with verbal encouragement and the other without verbal encouragement
45786231|NCT03012854|Procedure|circular myotomy|"Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~Myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact.~Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
45786232|NCT02437188|Behavioral|ACT (Acceptance and Commitment Therapy)|The 1-day training session with ACT proposed for this study is designed to reduce behavioral avoidance and to enhance acceptance-based coping. The intervention includes: 1) Behavioral Change Training (2.5 hours) involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training (2.5 hours) emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from, unhelpful thoughts and learning how to willingly face experiences that cannot be changed.
45786233|NCT02980250|Drug|Low dose|0.2mg group-The premature infant will be fed with 0.2mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
45786234|NCT02980250|Drug|normal dose|0.4mg group-The premature infant will be fed with 0.4mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
46071033|NCT02863523|Behavioral|Integrated Behavioral Care|Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
46071034|NCT00629759|Genetic|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|The total dose is divided between 1-3 tumors located within the liver. Patients are treated with JX-594 once every 3 weeks until progression at the site(s) of injection or until the patient has received a maximum of 4 treatments.
46071035|NCT00974675|Biological|CAT-354 1mg/kg|CAT-354 1 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
46071036|NCT00974675|Biological|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
46071037|NCT00974675|Biological|CAT-354 10mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
45644614|NCT03238300|Drug|N-Acetylcysteine|N-Acetylcysteine; 600mg capsules by mouth, two pills twice daily (total 2400 mg/day). Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.
46071038|NCT00974675|Other|Placebo|Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.
46071039|NCT03655769|Device|transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 20 min
45644615|NCT03238300|Drug|Placebo Oral Capsule|N-acetylcysteine-matched placebo tablet two pills twice daily. Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.
45644616|NCT03235544|Drug|Parsaclisib|Parsaclisib tablets administered orally with water and without regard to food.
45644617|NCT03233191|Procedure|Digital Mammography|Undergo DM
45644618|NCT03233191|Procedure|Digital Tomosynthesis Mammography|Undergo TM
45644619|NCT03233191|Other|Laboratory Biomarker Analysis|Correlative studies
45644620|NCT03215511|Drug|Selitrectinib (BAY2731954)|Selitrectinib is administered as capsules or liquid formulation.
45644621|NCT03214003|Radiation|SIB|patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy
45786235|NCT02980250|Drug|over dose|0.6mg group-The premature infant will be fed with 0.6mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
45786236|NCT02980250|Drug|Glucose|Glucose group-The premature infant will be fed with glucose and will be tested the residual glucose everyday in a 7-days period.
45786237|NCT02491437|Drug|Dydrogesterone 30 mg|Oral Dydrogesterone 10 mg tablets tid
45786238|NCT02491437|Drug|intravaginal progesterone gel 90 mg|
45786239|NCT04919772|Other|Assessment|The participants walk 4-meter and 10-meter and 5-repetition sit-to-stand twice.
45786240|NCT05071196|Other|Facilitated Vegan Diet|Vegan boxed meal kits
45786241|NCT05071196|Other|Omnivorous Diet|Non-vegan boxed meal kits
46071040|NCT03655769|Device|sham transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 30 sec
46071041|NCT04925531|Drug|Antibiotics|to examine if either the utility of antibiotics administered for 3 days or 5 days make a difference in the clinical outcomes after facial fractures in trauma patients.
46071042|NCT04288037|Diagnostic Test|fetal heart rate variability|observational study. no intervention
46071043|NCT00634933|Drug|TRU-015|IV 800 mg TRU-015 at Baseline (both arms) and Week 24 (both arms); corresponding IV Placebo at Week 12 and Week 36 (both arms).
45644622|NCT03214003|Radiation|Standard|patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy
45644623|NCT03211663|Device|MOTO Medial® UKA|Knee replacement surgery with the MOTO Medial® UKA
45644624|NCT03191149|Procedure|Biospecimen Collection|Undergo collection of blood samples
45644625|NCT03191149|Procedure|Computed Tomography with Contrast|Undergo CT with contrast
45644626|NCT03191149|Procedure|Magnetic Resonance Imaging|Undergo MRI
45644627|NCT03191149|Drug|Osimertinib|Given PO
46071044|NCT00634933|Drug|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 1a) and Week 24 (both arms); corresponding IV Placebo at Week 12 (Arm 1b) and Week 36 (both arms).
45644628|NCT03186898|Radiation|Proton Therapy (Radiation Therapy)|Undergo proton therapy
46071045|NCT00634933|Drug|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 1a), and Week 24 (both arms); corresponding Oral Placebo at Week 12 (Arm 1b) and Week 36 (both arms)
46071046|NCT00634933|Drug|TRU-015|IV 800 mg TRU-015 at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 24 (both arms).
45918514|NCT05573854|Dietary Supplement|Gastric emptying after an oral supplement containing carbohydrates and whey protein|Ingestion of an oral supplement containing carbohydrates and whey protein
45918515|NCT05573854|Dietary Supplement|Overnight Fast|Residual Gastric Volume assessed by MRI after overnight fast (8h)
45918516|NCT00001647|Procedure|White blood cell infusion|
45918517|NCT05573815|Device|BT-M01|Clinical decision support system for detecting brain metastasis
45918518|NCT05573776|Other|Exercise Therapy, High Protein supplement|patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.
45918519|NCT05573659|Other|time of cutaneous recoloration|In the shortest time possible (less than 3 minutes), realization of three successive measurements of the time of cutaneous recoloration by a pressure by the so-called visual method by two intensivists trained at the CRT of the surgical resuscitation service familiar with the technique of time of cutaneous recoloration. The measurements will be carried out blindly from each other.
46071047|NCT00634933|Drug|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 36 (both arms).
45644629|NCT03186898|Radiation|Photon Therapy (Radiation Therapy)|Undergo photon therapy
45644630|NCT03186417|Biological|2 million hMSC/kg|2 million hMSCs/kg infusion
45644631|NCT03186417|Biological|4 million hMSC/kg|4 million hMSC/kg infusion
45644632|NCT03186417|Biological|6 million hMSC/kg|6 million hMSC/kg infusion
45644633|NCT03186417|Biological|placebo|placebo infusion
45786242|NCT02383758|Drug|Glycerin Suppository|Nursing staff will administer one glycerin suppository in the bathroom if there is no continent bowl movement in the first 30 minutes. Subjects will be taken to the bathroom 5 minutes after the suppository is administered for a 30 minute sit or until a continent void occurs. If continent bowel movements maintain on two subsequent days (after bisacodyl suppositories are discontinued) the glycerin suppository will be discontinued. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
45786243|NCT02383758|Drug|Bisacodyl suppository|If a subject does not have a bowel movement during the 30 minute sit following administration of the glycerin suppository, they will be given a 1 hour break, after which a bisacodyl suppository will be administered. The participant will then sit for an additional 30 minutes.If continent bowel movements maintain for two subsequent days (after senna is discontinued) bisacodyl suppositories will be discontinued if it was required. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
45786244|NCT02383758|Drug|Senna|If no continent bowel movements occur for two consecutive treatment days, caregivers will be asked to administer senna each evening thereafter until medication tapering begins. Once there have been two successive days with continent bowel movements, senna will be removed from the intervention if it was required.
45786245|NCT02492451|Other|Endometrial Injury|Endometrial injury in luteal phase of preceding cycle by pipelle canula
45918520|NCT05573659|Other|video assisted cutaneous recoloration|"Compression of the nail bed of the index of the subject studied until whitening of the pressed area, then release, the force will be equivalent to 300 g on a kitchen scale TPA 808S Techwood™ and time of compressions being of 5 seconds. Smartphone camera recording of the procedure (Iphone 7™, Apple Inc., Cupertino, CA). An assistant is in charge of timing the TRC between two tops given by the operator, the tops corresponding to the release of the pressure on the index so the beginning of the TRC and the total recoloration of the bleached area. This wizard records the three results in seconds with the associated tenth of a second."
46071048|NCT00634933|Drug|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 2a) and Week 36 (both arms); corresponding Oral Placebo at Week 12 (Arm 2b) and Week 24 (both arms).
46071049|NCT00634933|Drug|TRU-015|IV 800 mg TRU-015 at Week 24 (both arms) and Week 36 (arm 3a); corresponding IV Placebo at Baseline (both arms), Week 12 (both arms) and Week 36 (arm 3b).
46071050|NCT00634933|Drug|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms), and Week 36 (arm 3a); corresponding IV Placebo at Week 12 (arm 3b) and Week 36 (arm 3b).
46071051|NCT00634933|Drug|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms) and Week 36 (arm 3a); corresponding Oral Placebo at Week 12 (Arm 3b) and Week 36 (arm 3b).
46071052|NCT00967499|Drug|Ondansetron|"Subjects will receive ondansetron 4 mg intravenously (IV) and will be followed for 72 hours.~Ondansetron is a selective 5-HT3 receptor antagonist. It is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin and prevention of postoperative nausea and/or vomiting."
45644634|NCT03181100|Drug|Atezolizumab|Given IV
45644635|NCT03181100|Biological|Bevacizumab|Given IV
45644636|NCT03181100|Drug|Cobimetinib|Given PO
45644637|NCT03181100|Drug|Nab-paclitaxel|Given IV
45644638|NCT03181100|Drug|Paclitaxel|Given IV
45644639|NCT03181100|Drug|Vemurafenib|Given PO
45644640|NCT03180996|Device|Vascutek Fenestrated Anaconda™ Custom AAA Stent Graft System|Fenestrated Endovascular Aortic Repair (FEVAR)
45644641|NCT03180502|Radiation|IMRT (Intensity-Modulated Radiation Therapy)|Undergo IMRT
45644642|NCT03180502|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
45644643|NCT03180502|Drug|Temozolomide|Chemotherapy drug
45644644|NCT03180268|Other|Clinical Observation|Undergo observation
45644645|NCT03180268|Radiation|Radiation Therapy|Undergo radiation therapy
45786246|NCT02492451|Drug|progesterone (Crinone® %8 vaginal progesterone gel)|Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
45918521|NCT05679947|Other|Mobilization protocol|The mobilization protocol includes six levels. Protocol levels are applied from the day the patient is operated and ends on the day of discharge. The researcher explains the protocol levels to the patient before surgery.The patient is mobilized within the first 24 hours after surgery. Implement mobilization protocol three times during the day and more as tolerated. Mobilization protocol:Level 1: Repositioning should occur every two hours. Level 2: Range of motion (PROM) should occur at least three times a day. Level 3: The head of bed (HOB) >30 degrees. Duration goal: 5-15 minutes. HOB 65≥ degrees with patient sit in the bed. Duration goal: 5-15 minutes. Progress to level 4. Level 4: HOB 65≥ degrees with legs in dependent position (recliner chair). Duration goal: 5-15 minutes. Progress to level 5. Level 5: Stand/pivot/step to chair. Sitting in chair. Duration goal: 5-15 minutes. Progress to level 6. Level 6: Patient is able to ambulate at least three times a day.
45644646|NCT03178045|Other|Team Monitoring|In this cohort, the electronic system will provide advanced informatics support for push notifications to the care team based on the severity of the symptoms reported. This platform promotes early detection and intervention. The care team is alerted when patients experience symptoms out of the expected range or if symptoms are worsening. Nurses receive secure message notifications and will contact the patient by phone depending on symptom severity. If a patient responds with a moderate-severe answer, the office team gets an alert and calls the patient during business hours.
45918522|NCT05573386|Drug|Filgrastim|human granulocyte colony-stimulating factor (G-CSF) protein obtained from the bacterial fermentation of a strain of E. coli. transformed with a genetically engineered plasmid containing the human G-CSF gene; administered via syringe
45918523|NCT05573386|Drug|Pegfilgrastim|long-acting covalent conjugate of recombinant methionyl human filgrastim and monomethoxypolyethylene glycol (PEG); administered via syringe
45918524|NCT00001656|Drug|Olanzapine|tablet; 5-20mg/day; 8 weeks
45918525|NCT00001656|Drug|Clozapine|tablet; 12.5-900mg/day; 8 weeks
45918526|NCT05573347|Procedure|Rotator Cuff Repair|Surgical repair of one or more ligament(s) that form the rotator cuff shoulder complex (supraspinatus, infraspinatus, subscapularis, and teres minor)
45918527|NCT05573347|Procedure|Bone Marrow Harvest|Procedure in which bone marrow cells are extracted, or harvested, from a given location in the body
45918528|NCT05573308|Device|Clear Aligners with Dental Monitoring|Dental Monitoring™ (DM ™). This digital technology software allows orthodontists to monitor patients remotely through continuous analytics using control vision technology, metaheuristics, and artificial intelligence.31 This app utilizes a patented artificial intelligence machine learning algorithm to calculate 3-dimensional (3D) tooth movements from intraoral photos and videos that patients capture using their smartphone cameras.
45786247|NCT01180478|Device|White Light|White Light Cystoscopy
45786248|NCT01180478|Device|Narrow Band Imaging|Narrow Band Imaging
45786249|NCT02566239|Other|Share activity data with care team|Share participant in-home activity data with retirement community care team.
45918529|NCT05573308|Device|Clear Aligners|Removabale orthodontics appliances
45644647|NCT03178045|Other|Enhanced Feedback|In this cohort, the electronic system will provide tailored normative data visualizations that offer context and education to patients regarding expected symptom severity. The information provided to patients in the Enhanced Feedback group will be procedure specific and based on continuously updated PRO-CTCAE data from previous patients. Patients are thus able to see their own recovery trajectory relative to that of patients who have undergone the same procedure. Care is patient activated in that patients will use the information about expected symptoms to decide whether they should call the care team (e.g., if they are experiencing symptoms that are more severe or more prolonged than expected). If a patient reports severe symptoms, they are instructed to immediately contact their physician's office or seek medical attention.
45786250|NCT02410278|Drug|dimethyl fumarate|Starting dose of 120 mg twice daily orally After 7 days, maintenance dose of 240 mg twice daily orally
45786251|NCT02410278|Drug|montelukast|As described in the treatment arm
45786252|NCT02410278|Drug|Placebo|Matched placebo
45786253|NCT02566317|Device|Sit-Stand workstation|Installation of a sit-stand desk at work
45786254|NCT02566317|Behavioral|Move|A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace
45786255|NCT01181258|Drug|Rituximab|375 mg/m^2 administered intravenously (IV) weekly * 4, (day -7, -1, +6, +13) pre-infusion with natural killer cells (NK)
45918530|NCT05679869|Other|Masking Sound|Prerecorded environmental noise and masking sounds played from headphones
45918531|NCT05679869|Other|No masking sound|Prerecorded environmental noise but no masking sounds played from headphones
45918532|NCT05573269|Dietary Supplement|FOPE (fish oil + pine extract)|During the experiment period the participants will receive a capsule of pine bark extract (Oligopin® 100mg) and a capsule of fish oil (EPA 350mg + DHA 250mg) a day. Blood collecting (biomedical parameters and antioxidative status) and cognitive function evaluation will be examined at the 0, 12, 24th week. Body composition, 24-hour dietary recall and blood pressure measurement will be measured at 0, 4, 8, 12, 16, 20, 24th week.
45918533|NCT05573269|Other|FO (fish oil +placebo)|During the experiment period the participants will receive a capsule of placebo (maltodextrin + magnesium stearate) and a capsule of fish oil (EPA 350mg + DHA 250mg) a day. Blood collecting (biomedical parameters and antioxidative status) and cognitive function evaluation will be examined at the 0, 12, 24th week. Body composition, 24-hour dietary recall and blood pressure measurement will be measured at 0, 4, 8, 12, 16, 20, 24th week.
45644648|NCT03175744|Device|Stellarex DCB|Intervention with the Stellarex DCB
45644649|NCT03175744|Device|PTA Catheter|Intervention with an uncoated Standard PTA
45644650|NCT03171311|Procedure|Angiographic guided PCI|Angiographic guided PCI is percutaneous coronary intervention performed by standard angiographic guided techniques
45786256|NCT01181258|Biological|Interleukin-2|subcutaneously administered 9 million international units (IU) every other day * 6 doses over 2 weeks begin 1 to 24 hours after NK cell infusion. If weight < 45 kilograms, give IL-2 at 5 million units/m2 on same schedule.
45786257|NCT01181258|Biological|Natural killer cells|administered intravenously 1.5 to 8 * 10^7 cells/kg on Day 0 (day of NK cell infusion)
45786258|NCT01181258|Drug|Cyclophosphamide|60 mg/kg administered intravenously (IV) for 2 hours on day -5 after Fludarabine.
45918534|NCT05573191|Drug|Lidocaine|The experimental group was injected with lidocaine 1.5mg/kg, and propofol was pumped intravenously at 90s after lidocaine injection.The dose of propofol was further set according to groups. The heart rate, mean arterial pressure, pulse oxygen saturation and NTI values of subjects were recorded in tne basic state,during the 90s after lidocaine administration, 60s after propofol administration and consciousness loss.The control group simply replaced lidocaine with equal volume normal saline
45918535|NCT05573191|Drug|Normal saline|Normal saline
45918536|NCT05573152|Procedure|Control|All previously selected patients will be under passive warming by means of blankets
45918537|NCT05573152|Procedure|Nursing|All previously selected patients will be under active air flow warming device at 43 Celsius
45918538|NCT05679830|Drug|Cannabidiol|Cannabidiol is a non-psychoactive cannabinoid obtained from the cannabis plant.
45918539|NCT05572996|Drug|Inhaled Treprostinil|
45918540|NCT05572957|Drug|Guideline-Directed Medical Therapy(GDMT)|"Quadruple anti-heart failure drug therapy: BB, ACEI/ARB/ARNI, MRA, and SGLT2i. If the initial dose according to guidelines is tolerated, the protocol would then direct the uptitration of medication dose over time to a specified target dose, unless not well tolerated.~*Criteria for <3 months of optimized (complete) GDMT: 1) according to the latest management of HF, any of the new quadruple therapy is not used if the condition allowed; Or 2) the dose of any drug dose not reach the maximum tolerated target; Or 3) under the maximum tolerated dose of BB, ivabradine is not added with a heart rate still ≥70 bpm at rest."
45644651|NCT03171311|Procedure|OCT guided PCI|OCT guided PCI is percutaneous coronary intervention (PCI) guided by intra vascular optical coherence tomography (OCT) scans
45644652|NCT03168750|Device|Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup.|Total hip arthroplasty (THA) is one of the most commonly performed and successful orthopaedic operations in improving a patient's quality of life. Orthopaedic surgeons are continually striving to improve all aspects of care relating to this procedure whether this is improvements in implant technology, instrument improvement, or the technique involved in performing the procedure.The results of this study will establish the performance of the femoral component and acetabular component, and provide a general estimate of survivorship, clinical effectiveness and complications.
45644653|NCT03160079|Drug|blinatumomab|"Cycle 1 Blinatumomab Day 1-7 Continuous IV infusion for 28 days (9 mcg/day) Blinatumomab Day 8-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle 2-5 Blinatumomab Day 1-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle length 42 days"
45644654|NCT03160079|Drug|pembrolizumab|"Cycle 1 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)~Cycle 2-5 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)"
45786259|NCT01181258|Drug|Methylprednisolone|1 mg/kg on Days -2 through +9 as an intravenous (IV) infusion.
45786260|NCT01181258|Drug|Fludarabine|25 mg/m^2/day administered as a 1 hour IV infusion once a day for 5 doses (day -6 through day -2).
45786261|NCT02568345|Drug|sugammadex ED90|"The first patient received the dose of 2.4 mg/kg and if there was a negative response, the next patient would be allocated to receive the next higher dose of 2.6 mg/kg.~In case that 2.4 mg/kg did produce a positive response, the next patient would be randomized with 10% of probability to receive the next dose of 2.2 mg/kg or 90% probability to receive the same dose of 2.4 mg/kg."
45786262|NCT03010124|Procedure|Blood sample|
45786263|NCT02570139|Device|Cavilon Advanced Skin Protectant|The liquid barrier film flows from the applicator and dries quickly on the skin. It is durable for 72-96 hours under conditions of incontinence.
45786264|NCT02570139|Device|ConvaTec Sensi-Care Protective Barrier|Sensi-Care is commercial paste product applied to protect denuded and weeping skin from incontinence.
45786265|NCT02410200|Drug|dimethyl fumarate|
45918541|NCT05572957|Combination Product|left bundle branch pacing combined with Guideline-Directed Medical Therapy(LBBP+GDMT)|"GDMT is the same as Drug intervention. LBBP is confirmed when: 1) the LBBB morphology disappeared and the paced RBBB pattern (typical or atypical) is observed in V1; and 2) LVAT is ≤100 ms at low output(≤3 V/0.5 ms); and at least 1 of the following is achieved: a) abrupt shortening of LVAT by >10 ms during mid/deep septal lead placement with a RBBB pattern in V1 at high output, which then remains short and constant at high and low output with further advancement of the lead to the final position; b) transition from nonselective to selective LBBP (QRS morphology transition from atypical RBBB to typical rsR' pattern in V1 and wide/large S-wave in V6 , with the appearance of an isoelectric segment and no LVAT change at high and low outputs); and c) transition from nonselective LBBP to LV septal pacing (lengthening of LVAT by at least 10 ms with or without obvious QRS morphology transition during threshold testing).~HBP or BiVP is attempted using the standard-of-care technique."
45918542|NCT00001662|Drug|CX516 (Ampalex)|
46071053|NCT00967499|Drug|Palonosetron|"Subjects will receive palonosetron HCl 0.075 mg IV and will be followed for 72 hours.~Palonosetron hydrochloride (Aloxi®) is a potent and selective 5-HT3 receptor antagonist for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy, the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, and the prevention of postoperative nausea and vomiting for up to 24 hours following surgery."
45644657|NCT03155620|Procedure|Biopsy|Undergo biopsy
45644658|NCT03155620|Procedure|Biospecimen Collection|Undergo blood sample collection
45644659|NCT03155620|Procedure|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow and/or biopsy
45644660|NCT03155620|Procedure|Bone Scan|Undergo a bone scan
45918543|NCT05679791|Device|Dynamometer|to assses hand grip
45918544|NCT05572801|Diagnostic Test|AMR B: HPV positive ctDNA guided imaging in follow-up|Blood samples in follow-up positive for ctDNA leads to an extra PET-CT scan to detect early treatment failure
45786266|NCT02494323|Device|Functional Electrical Stimulation|Single channel and dual channel FES for balanced dorsiflexion for patients with dropfoot
45918545|NCT05572762|Device|Cannula plastic part while applying peribulbar block|Using the cannula and introducing it peribulbar to apply regional ophthalmic anesthesia avoiding by this causing trauma to the globe, as the normal globe consistency is marble-like, the cannula can't puncture except in case of presence of staphyloma, so the cannula will either curve around it or will be kinked causing failure of the technique.
45918546|NCT05572762|Procedure|traditional technique|the patients are going to receive the local anesthetic standard of care technique by using 23- or 24-gauge needle introduced through the skin extra-conal and local anesthetic solution will be injected with volume AND concentration according to the surgery going to be done
45918547|NCT05572723|Drug|Remifentanil 2 MG|Remifentanil is an opioid; it has sedative, analgesic, and sympatholytic properties.
45786267|NCT01143272|Drug|Saccharomyces boulardii|Units: 500 mg per day Route of administration : Oral Use Hard-Capsule
45786268|NCT01143272|Drug|Placebo|Placebo
45786269|NCT02383056|Device|Omnilux|Photomodulation irradiated with a 633 +/- 3 mm light source for 20 minutes (105 mW/cm, 126 J/cm)
45786270|NCT02383056|Device|Omnilux Sham|Sham light instead of phototherapy from the same light device
45786271|NCT02409732|Drug|aminolevulinic acid hydrochloride|
45786272|NCT02409732|Procedure|Photodynamic therapy with blue light|
45786273|NCT02494713|Drug|Degarelix|Subcutaneous injection, once/month for 4 months
45644661|NCT03155620|Procedure|Computed Tomography|Undergo CT, PET/Ct, and/or CT/MRI
45644662|NCT03155620|Drug|Ensartinib|Given PO
45644663|NCT03155620|Drug|Erdafitinib|Given PO
45918548|NCT05572723|Drug|dexmedetomidine|"Studies show that dexmedetomidine is superior to currently commonly used remifentanil in terms of intraoperative blood pressure control and postoperative pain.~Dexmedetomidine, an alpha-2-adrenoceptor agonist, has sympatholytic, sedative, anesthetic, analgesic, and vasoconstrictor effects. It lowers blood pressure by decreasing plasma norepinephrine and epinephrine levels, thereby reducing intraoperative bleeding. Dexmedetomidine is defined as an analgesic that is now widely used to induce and maintain anesthesia and to control postoperative pain, and is defined as an analgesic that does not cause respiratory depression and neurocognitive impairment. Many studies have shown that the use of perioperative dexmedetomidine reduces the stress response to anesthetic induction and surgery and provides hemodynamic stability."
45918549|NCT05570071|Device|physical therapy|medical treatment of pelvic floor
45918550|NCT04733716|Procedure|Using Tourniquet|The purpose of this prospective randomized double blinded study was to compare the effect of using a tourniquet on early-stage pain and 1-year postoperative functional outcomes when patients were divided into two groups according to the pain threshold.
45918551|NCT00001683|Drug|COL-3|
45918552|NCT05563753|Drug|ABT|any antibiotic therapy in the first week of life
45644664|NCT03155620|Other|Laboratory Biomarker Analysis|Undergo molecular analysis
45644665|NCT03155620|Drug|Larotrectinib Sulfate|Given PO or via nasogastric- or gastric-tube
45786274|NCT02494713|Drug|Doxorubicin|20 mg/m2 as a 24-hour intravenous infusion on day 1 each week, weeks 1, 3, and 5
45786275|NCT02494713|Drug|Ketoconazole|400 mg orally 3 times daily for 7 days, in weeks 1, 3, and 5
45786276|NCT02494713|Drug|Docetaxel|35 mg/m2 intravenously on day 1 of each week, weeks 2, 4, and 6
45644666|NCT03155620|Procedure|Magnetic Resonance Imaging|Undergo MRI, PET/MRI, and/or CT/MRI
45644667|NCT03155620|Procedure|Mutation Carrier Screening|Undergo tumor tissue mutation screening
45644668|NCT03155620|Drug|Olaparib|Given PO
45644669|NCT03155620|Drug|Palbociclib|Given PO
45644670|NCT03155620|Other|Pharmacological Study|Correlative studies
45644671|NCT03155620|Procedure|Positron Emission Tomography|Undergo PET, PET/CT, and/or PET/MRI
45644672|NCT03155620|Procedure|Radionuclide Imaging|Undergo radionuclide imaging
45644673|NCT03155620|Drug|Samotolisib|Given PO
45786277|NCT02494713|Drug|Estramustine|280 mg orally 3 times daily for 7 days, in weeks 2, 4, and 6
45786278|NCT01650636|Behavioral|Patient-Partner Videotelephone-delivered Health Information (PP-T-HI)|Ten (10) 90-min sessions of Health Information delivered via videophones
45786279|NCT01650636|Behavioral|Patient-Partner Videotelephone-delivered Cognitive Behavioral Stress Management intervention (PP-T-CBSM)|Ten (10) 90-min sessions of T-PP-CBSM
45786280|NCT02436876|Drug|MBN-101|MBN-101 is a locally administered, anti-infective drug product
45786281|NCT02436876|Other|Placebo|The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient
45786282|NCT02495103|Drug|Vandetanib|PHASE I: Vandetanib by mouth (PO) daily at 300mg in combination with escalating doses of metformin.
45786283|NCT02495103|Drug|Metformin|Phase I: Metformin starting dose 250mg by mouth (PO) daily in combination with Vandetanib
45644674|NCT03155620|Drug|Selpercatinib|Given PO
45786284|NCT02495103|Drug|Vandetanib/Metformin|Phase II: Vandetanib and metformin by mouth (PO) daily at determined maximum tolerated dose (MTD).
45786285|NCT02382276|Drug|Nalmefene hydrochloride|
45786286|NCT02495259|Device|ZU-bend stylet|Laryngoscopy and intubation after induction of anesthesia will be done using the GlideScope and the ZU-bend stylet. The ZU-bend is a specific shaping technique of the intubating stylet that is closely related to the GlideScope blade curvature. Zu-bend stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
45786287|NCT02495259|Device|GlideScope|Laryngoscopy and intubation after induction of anesthesia will be done using the the GlideScope technique. The GlideScope is a video laryngoscope that provides a real-time view of the airway and tube placement during intubation. GlideScope is removed after DLT is in the trachea, and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
45644675|NCT03155620|Drug|Selumetinib Sulfate|Given PO
45644676|NCT03155620|Drug|Tazemetostat|Given PO
45786288|NCT02495259|Device|GlideRite stylet|Laryngoscopy and intubation after induction of anesthesia will be done with the GlideScope using the GlideRite stylet. The GlideRite stylet is specifically designed to work with the GlideScope and provides the necessary rigidity and curvature to an otherwise flexible tube. GlideRite stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
45786289|NCT02495259|Device|Macintosh blade|Direct laryngoscopy and intubation after induction of anesthesia will be done with the Macintosh blade and a regular double-lumen endobronchial tube (DLT) stylet. The Macintosh blade is used to facilitate visualization of the larynx during double or single lumen endobronchial tube placement. After intubation the Macintosh laryngoscope is removed and the confirmation of the successful placement of the double-lumen endobronchial tube in done in the standard fashion.
45786290|NCT02495259|Device|Regular Double-lumen endobronchial tube (DLT) Stylet|Direct laryngoscopy and intubation after induction of anesthesia will be done with a regular double-lumen endobronchial tube (DLT) stylet and the Macintosh blade. The DLT stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, Macintosh laryngoscope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
45786291|NCT02570295|Other|Swiss Army Physical Fitness Training|2 x 90 minutes strength training and sport games and 2 x 30 minutes endurance training per week during 18 weeks of basic military training
45786292|NCT02571153|Drug|Ketamine 0.4 mg/kg|Intravenous ketamine 0.4 mg/kg after induction of anesthesia
45786293|NCT02571153|Drug|Normal saline|Intravenous normal saline 0.9% 5 mL
45786294|NCT02571153|Drug|Ketamine 0.2 mg/kg|Intravenous ketamine 0.2 mg/kg after induction of anesthesia
45786295|NCT02436408|Drug|Vismodegib|
45786296|NCT04573322|Drug|Trans Sodium Crocetinate|TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days
45786297|NCT04573322|Drug|Normal saline|Normal Saline, in an equivalent volume by participant body weight, administered via IV bolus every 6 hours for up to 15 days
45644677|NCT03155620|Drug|Tipifarnib|Given PO or via nasogastric or gastric tube
45644678|NCT03155620|Drug|Ulixertinib|Receive PO
45644679|NCT03155620|Drug|Vemurafenib|Given PO
45644680|NCT03155620|Procedure|X-Ray Imaging|Undergo an x-ray
45644681|NCT03154307|Device|Low frequency repeated TMS (LF-rTMS)|Each patient will then begin treatment with 14 minute sessions of 1 Hz rTMS or sham rTMS, 120% minimum threshold (MT), and 800 stimuli on the position of the calculated 3D source using EEG, MRI, and digitized electrode locations. Two different timelines of delivering the rTMS will be compared against a sham/delayed treatment group.
45644682|NCT03150433|Behavioral|Behavioral symptom management|Individual sessions focused on behavioral and cognitive strategies for managing sleep disturbance, pain, and other symptoms of sickle cell disease
45786298|NCT02436330|Behavioral|Exergaming|"6 months of weight management programming consisting of 10 weekly sessions:1 hour of session was spent exergaming, which included active video game play and traditional group exercises. Some examples include: Dance, Dance, Revolution, Exerbike, Treadwall, Yoga, Spin class, etc."
45786299|NCT02436330|Behavioral|Didactic health teaching|6 months of weight management programming consisting of 10 weekly 1-hour sessions of didactic classes teaching behavioral and dietary curricula. Followed by monthly 1 hour didactic health teaching sessions for the remainder of the 6 month period.
45786300|NCT01143818|Drug|AndroGel (testosterone gel) 1%|AndroGel is topical testosterone gel 1% and is prescribed for once daily use.
45786301|NCT02573181|Biological|V114|V114 contains 2 µg of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F, and 4 μg of serotype 6B; and 30 µg of CRM₁₉₇ and 125 µg of Aluminum Phosphate Adjuvant (APA) per 0.5 mL dose.
45786302|NCT02573181|Biological|Prevnar 13™|Prevnar 13™ contains 2.2 μg of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and 4.4 μg of serotype 6B; and 34 μg of CRM₁₉₇ and 125 μg of aluminum per 0.5mL dose.
45786303|NCT02974491|Other|Fuji apple juice|On two different days, each volunteer consumed 300 mL Fuji apple juice (AJ), immediately after a dialysis section. After a washout period of 3 weeks, the volunteers drank 150 mL Fuji AJ in a similar manner as described above. Before and after 30 and 60 min of AJ consumption, blood samples were withdrawn for biochemical analysis.
45644683|NCT03150433|Other|Sickle cell disease management|Individual sessions focused on understanding and managing sickle cell disease
45644684|NCT03139825|Other|Exploring the feasibility of learning during cognitive tasks (EEG-NIRS)|Exploring the feasibility of the study in its aspects of recruitment and tolerability of tasks and acquisition of electrical and hemodynamic data that can be used during cognitive tasks
45644685|NCT03139370|Drug|KITE-718|A single infusion of autologous genetically modified MAGE-A3/A6 T-cell receptor (TCR) transduced autologous T cells (KITE-718).
45644686|NCT03139370|Drug|Cyclophosphamide|Administered intravenously
45644687|NCT03139370|Drug|Fludarabine|Administered intravenously
45644688|NCT03139370|Device|MAGE - A3/A6 Screening Test|A screening test for MAGE-A3/A6+ tumors
45786304|NCT02498769|Drug|Botulinum Toxin Type A|The botulinum toxin will be injected into epicardial fat pads shortly after cardiopulmonary bypass is initiated.
45786305|NCT02498769|Drug|Placebo|
45786306|NCT04441749|Device|Images acquired by needle-based Confocal Laser Endomicroscopy (nCLE)|Patients who are scheduled to undergo Robotic Navigational Bronchoscopy for a peripheral lung lesion will be enrolled. During bronchoscopy, confocal images will be captured using Cellvizio 100 Series Confocal Laser Imaging systems and their Confocal Miniprobes (Mauna Kea Technologies Paris, France). The Cellvizio system and miniprobes are FDA approved by 510(k) for use in through the respiratory tracts by endoscopy or endoscopic accessories. Only images and needle aspiration/ biopsy results from the expansion phase (20 patients) will be analyzed
45786307|NCT01650558|Drug|Standard of Care prophylaxis|Daily trimethoprim sulfamethoxazole
45786308|NCT01650558|Drug|Chloroquine (CQ) prophylaxis|Discontinue standard of care and start weekly CQ.
45786309|NCT02579343|Device|Auricular Acupuncture|Auricular acupuncture is a form of acupuncture which utilizes the surface of the external ear to identify points of inflammation in the body. It does this, in this case, by utilizing the Pointer Excel II probe which can pick up a change in electrical conductivity on the surface of the ear, which reflects an internal point of inflammation or stress. Once the point of inflammation is identified, the Pointer Excel II is equipped with a sensor that it will not only illuminate by way of a small light on the front of the probe will also identify the point of inflammation by way of an auditory signal. Once the point of inflammation is identified auricular acupuncture will treat that point with a micro-current of electricity for several seconds.
45786310|NCT02579343|Drug|Sham Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants will be treated twice weekly during their follow-up visits with sham auricular acupuncture (No micro-current).
45644689|NCT03133221|Drug|Zydelig|Zydelig given at 150mg continuously in 28-day cycles
45644690|NCT03113500|Drug|Brentuximab Vedotin|Given IV
45786311|NCT01144286|Drug|arasertaconazole nitrate|Arasertaconazole nitrate pessary, placebo pessary
45786312|NCT01144286|Drug|placebo|placebo, single dose
45786313|NCT01144442|Drug|Hyperthermic intraperitoneal chemotherapy with Carboplatin|Carboplatin at a dose of 1000mg/m^2 will be added to the perfusate once circulating levels reach 1000-1500cc/minute. The circulation of the chemotherapy impregnated perfusate will be performed for 90 minutes.
45786314|NCT01144442|Other|Isotonic saline (perfusate)|The HIPC infusion will be performed with a closed abdomen technique. The perfusate will be isotonic saline heated to 40-42° Celsius.
45786315|NCT01144442|Procedure|Surgery|"The abdominal incision will be performed in a vertical fashion extending from the supra-pubic region to around the umbilicus.~If cytoreductive surgery is required, it will be performed at this time and proceed in standard approach."
45786316|NCT01144442|Drug|Carboplatin|The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
45644691|NCT03113500|Drug|Cyclophosphamide|Given IV
45786317|NCT01144442|Drug|Paclitaxel|The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
45918553|NCT05560984|Combination Product|cervical internal os plasty|A long Allis forceps will be passed through the uterine incision and used to grasp the anterior lip of the cervix, pulling the cervix upwards into the uterine cavity. An assistant sometimes needs to elevate the cervix upwards from the vaginal aspect. The anterior lip of the cervix will be sutured to the anterior wall of the lower uterine segment using two or three simple interrupted absorbable stitches (Vicryl or Vicryl rapid no. 0). This aids to compress the bleeding sites of the placental bed and support the very thin lower uterine segment. If the placenta was implanted posteriorly and the bleeding areas will be mainly from the posterior wall of the uterus, the same procedure could be repeated using the posterior lip of the cervix. A Hegar dilator (size 12) will be inserted in a retrograde manner from the abdominal aspect toensure patency of the cervical canal .
45918554|NCT05557786|Device|Transcranial Alternating Current Stimulation|Cerebellar Transcranial Alternating Current Stimulation（CB-tACS）
45918555|NCT05544487|Procedure|Colorectal Anastomosis|Differences in intra-operative techniques and surgeon grades
45644692|NCT03113500|Drug|Doxorubicin|Given IV
45644693|NCT03113500|Drug|Doxorubicin Hydrochloride|Given IV
45644694|NCT03113500|Drug|Etoposide|Given IV
45644695|NCT03113500|Drug|Etoposide Phosphate|Given IV
45644696|NCT03113500|Other|Laboratory Biomarker Analysis|Correlative studies
45644697|NCT03113500|Drug|Prednisone|Given PO
45644698|NCT03112928|Device|Phantom Motor Execution|"Neuromotus - PME decodes motor volition applying machine learning to surface electromyography. Once the intention of movement is known, this is use to control serious games in virtual and augmented reality.~A treatment session of MPE consists of:~Pain evaluation~Placement of the electrodes and fiducial marker~Practice of motor execution in Augmented Reality (AR)~Gaming using phantom movements~Practice of motor execution by matching random target postures of a virtual limb.~Step 3 to 4 are repeated for different phantom joints, initially one at the time progressing to several joints simultaneously. A treatment session last 2 hours."
45644699|NCT03112928|Device|Phantom Motor Imagery|The only difference between PME and PMI is that in the former myoelectric signals are used to give the participants control over the virtual environments, whereas in PMI the presence of myoelectric activity is used as an alarm to remind the participant that it must imagine rather than execute the phantom movement. In PMI the virtual environments act autonomously to guide the participant in imagination of movement.
45644700|NCT03108131|Drug|Atezolizumab|Given IV
45644701|NCT03108131|Drug|Cobimetinib|Given PO
45786318|NCT02408484|Biological|Octafibrin|Plasma-derived Fibrinogen concentrate
45786319|NCT04909788|Behavioral|a long-distance running (over 3 km)|Complete a long distance running（over 3 km） within the specified time (30 minutes)
45918556|NCT05536453|Device|Lumbar Interbody Fusion Devices|Posterior Lumbar Interbody Fusion device placed to treat symptoms associated with degenerative disc disease
45786320|NCT02499081|Drug|Ixazomib|
45786321|NCT02380248|Other|Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops|
45786322|NCT01146704|Dietary Supplement|Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass|Standard protein diet as control, based on 0.5 gram protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 15% protein and 55% carbohydrate.
45786323|NCT01146704|Dietary Supplement|Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate|High level of protein diet, based on 1 gram of protein per pound of subject's lean body mass, isocaloric (same number of calories) and consisting of 30% protein and 40% carbohydrate.
45786324|NCT04909320|Behavioral|AWARD advice|Ask about smoking history; Warn about the high risk; Advise to quit; Refer smokers to smoking cessation services (with a referral card); Do it again
45786325|NCT04909320|Other|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include (1) highlights of the absolute risk of death due to smoking; (2) the whole list of diseases caused by active and second-hand smoking; (3) ten horrible pictorial warnings of health consequences of smoking and second-hand smoking in one page to maximize the impacts; (4) benefits of SC and (5) simple messages to encourage participants to quit smoking and remind them to call the Department of Health SC hotline 183 3183.
45786326|NCT04909320|Other|Referral card|The contents consist of brief information and highlights of existing SC services, contact methods, motivation information, and strong supporting messages or slogans.
45786327|NCT04909320|Other|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
45786328|NCT04909320|Behavioral|Positive psychological support through 3-people group chat using instant messaging apps|Each IM chat group will consist of a trained SC counselor (HKU staff), a peer supporter (former smoker), and a participant (smoker). The 3-month group chat-based intervention will consist of regular messages and real-time support through group chat. Regular messages will generally include goal setting, health warnings, abstinence support, positive psychological exercises, and encouragement and will be delivered in a tapering style. During the real-time chatting, SC counsellors and peer supporters will provide real-time chat-based support, and peer supporters will share their quitting experience as appropriate.
45786329|NCT04909320|Behavioral|E-messages via SMS|Regular e-messages via SMS at twice per month within 3 months (total 6).
45918557|NCT05530759|Procedure|Biopsy Specimen|Undergo collection of tissue samples
45918558|NCT05530759|Procedure|Biospecimen Collection|Undergo collection of blood and buccal swab samples
45918559|NCT05530759|Procedure|Biospecimen Collection|Undergo collection of archived tissue and blood samples
45918560|NCT05530759|Other|Medical Chart Review|Review of medical record
45918561|NCT05679713|Diagnostic Test|Comprehensive risk assessment algorithm|Risk assessment algorithm including clinical and patient-centered information and a novel RNA-based biomarkers using next-generation sequencing technology.
45644702|NCT03099174|Drug|Xentuzumab|Once weekly administrated through one hour intravenous infusion
45644703|NCT03099174|Drug|Abemaciclib|Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort A) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours
45644704|NCT03099174|Drug|Letrozole|Once a day
45644705|NCT03099174|Drug|Anastrozole|Once a day
45644706|NCT03099174|Drug|Fulvestrant|Once a month, with an additional dose given two weeks after the first dose. Each dose is given as two slow injections lasting one to two minutes, with one injection being given into the muscle of each buttock
45644707|NCT03099174|Drug|Abemaciclib|Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort D) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours
45644708|NCT03089203|Biological|CART-PSMA-TGFβRDN cells|autologous CAR T cells
45786330|NCT02501265|Behavioral|Varenicline Standard Protocol|"4 weeks pre-TQD: Start Placebo Varenicline~1 week prior to TQD: Switch to Active Varenicline~1 week prior to TQD: Start Placebo Bupropion Varenicline + Placebo Bupropion to 12 weeks post TQD"
45918562|NCT05525104|Device|Narcotrend Monitor (MT MonitorTechnik, Hannover, Germany)|"This trial is designed to investigate the additional value of Density Spectral Array monitoring, on the speed of emergence after general anaesthesia. We will compare traditional general anaesthesia with sevoflurane using a MAC value and subjective clinical parameters to the objective and continuous approach using DSA depth of hypnosis. The investigational product is the validated Narcotrend monitor, an electroencephalographic monitor, that is regularly used in anaesthesia practice in the Sophia children's hospital and will be used according to intended purpose. The extended version as used in the operating room in the Sophia Children's hospital offers a diversity of diagrams including Density Spectral Array.~The electroencephalographic Narcotrend monitor records frontal EEG-activity. Standard paediatric ECG electrodes are used for EEG registration"
45918563|NCT05520775|Drug|Semaglutide|Semaglutide (subcutaneous)
45918564|NCT05520775|Drug|Sham/placebo|Sham subcutaneous injection
45918565|NCT00389415|Drug|Vildagliptin|
45644709|NCT03089203|Drug|Cyclophosphamide|300 mg/m2/day given over 3 days
45644710|NCT03089203|Drug|Fludarabine|30 mg/m2/day given over 3 days
45644711|NCT03087071|Other|Laboratory Biomarker Analysis|Correlative studies
45644712|NCT03087071|Biological|Panitumumab|Given IV
45644713|NCT03087071|Drug|Trametinib|Given PO
45644714|NCT03079037|Device|Stimulation|Traditional deep brain stimulation
45644715|NCT03076554|Drug|Avelumab|Avelumab will be administered at a dose of 10 mg/kg intravenously once every two weeks until disease progression or development of intolerable adverse events.
45918566|NCT05679635|Device|Evone|The conventional tube adapter (CTA) from the Evone ventilator (Ventinova Medical B.V., Eindhoven, The Netherlands), equipped with an tracheal pressure measurement catheter will be connected to the tracheal tube of intubated intensive care unit patients. Subsequently tracheal pressure values will be displayed and recorded from the ventilator.
45918567|NCT05679635|Device|Evita Infinity V500|Displayed airway pressure values will be directly recorded from the Evita Infinity V500 ventilator (Dräger Medical, Lübeck, Germany)
45918568|NCT05465317|Drug|Empagliflozin|Empagliflozin
45786331|NCT02501265|Behavioral|Nicotine Patch Standard Protocol|"4 weeks pre-TQD: Start Placebo Nicotine Patch TQD: Start active Nicotine Patch~1 week prior to TQD: Start Placebo Bupropion Nicotine Patch + Placebo Bupropion to 12 weeks post TQD"
45786332|NCT02501265|Drug|Varenicline Adaptive Protocol|"VARENICLINE RESPONDER 4 weeks pre-TQD: Start Varenicline 2 weeks pre-TQD: DOES reduce cigs/day by > 50% 1 week pre-TQD: Start Placebo Bupropion Varenicline + Placebo Bupropion to 12 weeks post TQD~VARENICLINE NON-RESPONDER 4 weeks pre-TQD: Start Varenicline 2 weeks pre-TQD: DOES NOT reduce cigs/day by > 50%~1 week pre-TQD: Start active Bupropion Varenicline + Bupropion to 12 weeks post TQD"
45786333|NCT02501265|Drug|Nicotine Adaptive Protocol|"NICOTINE PATCH RESPONDER 4 weeks pre-TQD: Start Patch 2 weeks pre-TQD: DOES reduce cigs/day by > 50% 1 week pre-TQD: Start Placebo Bupropion Patch + Placebo Bupropion to 12 weeks post TQD~NICOTINE PATCH NON-RESPONDER 4 weeks pre-TQD: Start Patch 2 weeks pre-TQD: DOES NOT reduce cigs/day by > 50%~1 week pre-TQD: Start Bupropion Patch + Bupropion to 12 weeks post TQD"
45786334|NCT02408016|Biological|Aldesleukin|Given SC
45786335|NCT02408016|Biological|Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Given IV
45786336|NCT02408016|Drug|Cyclophosphamide|Given IV
45644716|NCT03072927|Device|MILD|MILD is performed under fluoroscopic image guidance through an ipsilateral interlaminar dorsal approach to the spine. Following epidurography, partial decompression is performed through the removal of tissue and bone at the symptomatic level confirmed with correlated MRI and clinical findings.
45918569|NCT05465317|Drug|Dipeptidyl Peptidate-4 inhibitors|Dipeptidyl Peptidate-4 inhibitors
45918570|NCT05465317|Drug|Sodium glucose co-transporter-2 inhibitors|Sodium glucose co-transporter-2 inhibitors
45918571|NCT05465317|Drug|Glucagon-like Peptide-1 Receptor Agonists|Glucagon-like Peptide-1 Receptor Agonists
45449150|NCT03729765|Device|hemoperfusion|The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.
45449151|NCT01079117|Drug|Sevre-Long™|The subjects will be randomised to either 10 weeks of treatment with methadone or SROM. After an adjustment phase of one week they first will be medicated for 10 weeks with the treatment to which they have been randomised. The cross-over, in which all subjects change to their opposite treatment, will serve for an additional adjustment phase of one week. After the second and new adjustment phase they are treated for 10 weeks with the newly adjusted medication. After the end of week 22 all participants continue with or switch back to SROM for another 6 month (week 23 to 47).
45449152|NCT01079117|Drug|Slow release oral morphine|
45449153|NCT01079117|Drug|Methadone|
45644717|NCT03072602|Dietary Supplement|Study diet|Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
45644718|NCT03072602|Other|Glucose Challenge|Participants will come in fasting state on the main study visit day and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
45644719|NCT03070366|Drug|Chemotherapy|"cisplatin~5FU~carboplatin~cetuximab"
45644720|NCT03070366|Radiation|Stereotactic radiotherapy|Stereotactic radiotherapy
45644721|NCT03068819|Drug|CIML NK Cell Infusion|-Day 0
45644722|NCT03068819|Procedure|CD3+ T Cell Product Infusion|-Day -1
45644723|NCT03054298|Biological|huCART-meso cells|Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..
45644724|NCT03049540|Drug|Tadalafil 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
45918572|NCT05455099|Radiation|Carotid ultrasound examination 1|Participants will be assigned to obese group (body mass index 24.0-27.9 kg/m²). Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's explorer ultrasound system.
45918573|NCT05455099|Radiation|Carotid ultrasound examination 2|Based on the inclusion criteria, 1200 overweight Han people（body mass index ≥28.0 kg/m²） and both sexes will be recruited in the analysis. The values of ultrafast pulse wave velocity will be obtained.
46071054|NCT04286399|Drug|Renin-angiotensin-aldosterone system inhibitors|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
45449154|NCT04992286|Other|questionnaire|questionnaire to evaluate fragility
45449155|NCT04992286|Other|accelerometer|To evaluate physical activity level
45449156|NCT03732963|Drug|Placebo (Group P)|Group P: 20 patients will receive a placebo tablet preoperatively.
45449157|NCT03732963|Drug|Melatonin (Group M)|Group M: 20 patients will receive an oral melatonin tablet 10 mg preoperatively.
45644725|NCT03049540|Drug|Placebo 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
45644726|NCT03040596|Drug|Fluticasone propionate|fluticasone inhaler 44mcg/puff, 2 puffs twice a day for 4 weeks
45644727|NCT03040596|Behavioral|Standard voice therapy|Standard voice therapy sessions
45644728|NCT03012880|Biological|Daratumumab|Given IV
45644729|NCT03012880|Drug|Dexamethasone|Given PO
45644730|NCT03012880|Drug|Ixazomib Citrate|Given PO
45644731|NCT03012880|Other|Laboratory Biomarker Analysis|Correlative studies
45644732|NCT03012880|Drug|Lenalidomide|Given PO
45644733|NCT03012880|Other|Questionnaire Administration|Ancillary studies
45449158|NCT02154724|Device|aDBS|The aDBS is applied for 2 hours for two days with two different modalities (aDBS and DBS) in random order.
45786337|NCT02408016|Other|Laboratory Biomarker Analysis|Correlative studies
45786338|NCT02408016|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
45786339|NCT02579421|Drug|Progesterone|generic progesterone
45786340|NCT02579421|Drug|placebo|placebo
45786341|NCT01181804|Drug|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
45786342|NCT01181804|Drug|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
45786343|NCT01181804|Drug|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
45918574|NCT05419921|Diagnostic Test|Hysterosalpingo-lidocaine-foam-sonography combined with power doppler (HyLiFoSy-PD)|"Women in the reproductive age group between 18- and 40-years old presenting with primary or secondary infertility who underwent HSG in the previous 5 years as a part of their infertility work-up with availability of good-quality HSG images, & did not get pregnant in this period, and gave no history of incidences that might affect their tubes, such as : abdominal surgery or laparoscopy, pelvic inflammatory disease, smoking, and intrauterine device insertion.~Women fitting these inclusion criteria and scheduled for LDT as part of their infertility work up will be considered. HyLiFoSy-PD will be carried out few days before the already scheduled LDT."
45918575|NCT05391841|Drug|NOVOCART Inject|Autologous Chondrocyte Implantation
45786344|NCT01181804|Drug|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
45786345|NCT00363987|Drug|Ketosteril®|1 tablet Ketosteril/5kgBW/d
45786346|NCT00363987|Other|diabetic diet|Energy 30-35 Kcal/kg BW/d + protein 0.8 g/kg BW/d
45786347|NCT04352114|Drug|LY3461767 - SC|Administered SC.
45786348|NCT04352114|Drug|LY3461767 - IV|Administered IV.
45786349|NCT04352114|Drug|Placebo - SC|Administered SC.
45786350|NCT00364065|Device|Ferris PainWrap|
45786351|NCT00422175|Drug|BAF 312|
45786352|NCT01186250|Drug|Pioglitazone|15mg pioglitazone taken daily for one month, 30mg pioglitazone taken daily for another month, 45mg pioglitazone taken daily for remaining ten months
45918576|NCT04733794|Procedure|Stoma reversal|Patients will receive a comprehensive intervention to addresses bowel, sexual, and urinary dysfunction. Patients meeting appropriate inclusion criteria will be approached at a clinic visit with their surgeon. If they agree to participate, they will complete an initial baseline questionnaire. Questionnaires will be distributed on iPads during their clinic visit
45786353|NCT01186250|Drug|Placebo|placebo taken daily for one year
45786354|NCT01186406|Drug|Gliadel|Patients will have 1-8 wafers of Gliadel inserted at the time of surgical resection.
45786355|NCT01186406|Radiation|Radiation Therapy|At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy.
45918577|NCT04733755|Dietary Supplement|Beauty Image|1.97g/package; 2 packages one day for 8 weeks
45918578|NCT04733755|Dietary Supplement|Placebo Control|Placebo Control; 1.97g/package; 2 packages one day for 8 weeks
45918579|NCT00386828|Drug|Bevacizumab:|
45918580|NCT05367271|Drug|Botulinum Toxin A|20 units of Onabotulinum A in 200 µL of saline injected into the flexor digitorum brevis via ultrasound-guidance
45918581|NCT05367271|Drug|Dexamethasone|1 mL of 4 mg/mL dexamethasone with 2 mL of 1% lidocaine OR 1 mL of 4 mg/mL dexamethasone, 1 mL of 2% lidocaine and 1 mL saline injected into the plantar fascia
45918582|NCT05365672|Biological|MIC|Single intravenous infusion of 1.5x10exp8 MIC per kg of body weight
45644736|NCT02999087|Drug|Cetuximab|Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of RT.
45644737|NCT02999087|Drug|avelumab|IV infusion of avelumab (10 mg/kg over 1 hour) once every 2 weeks. Avelumab will start on Day-8 together with cetuximab and subsequently every 2 weeks during the course of RT. Avelumab with be continued every 2 weeks for an additional 12 months following RT.
45449159|NCT02154724|Device|DBS|The aDBS s applied for two hous in DBS modality.
45449160|NCT03729687|Combination Product|radiotherapy, capecitabine, oxaliplatin|5x5 Gy radiotherapy in 1 week, 4 cycles of CAPOX (capecitabine 1000 mg/m2 x2 d 1-14, oxaliplatin 130 mg/m2 d 1 every third week), surgery
45644738|NCT02999087|Drug|Cisplatin|100 mg/m² IV after hyperhydration and at a maximal rate of 1 mg/min, on days 1, 22, 43.
45786356|NCT01186406|Drug|Avastin|"Avastin (10 mg/kg) will be given every 14 days, and will begin a minimum of 42 days post-operatively.~Beginning two to three weeks after the last radiation therapy, but not greater than eight weeks, subjects will be treated with Avastin (10mg/m2) every 14 days."
45786357|NCT01186406|Drug|Temodar|At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy and daily Temodar (75mg/m2) for 6.5 weeks of the radiation. In addition, beginning 2-3 weeks after the last radiation therapy, but not greater than 8 weeks, patients will be treated with 5 day Temodar (200 mg/ m2).
45786358|NCT02504073|Other|No intervention|No intervention
45786359|NCT04743375|Other|wound dressing application|Sericin dressing with collagen or Bactigras will be used as a primary dressing for treating the STSG donor site.
45786360|NCT02407704|Drug|Venlafaxine XR|
45786361|NCT02407704|Other|Aerobic Exercise|
45786362|NCT02407704|Drug|Lorazepam|Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. Patients taking another benzodiazepine will be asked to convert from their current benzodiazepine to an equivalent dose of Lorazepam (2mg or less in 24 hours). This will be administered in pill form.
45786363|NCT02504619|Biological|CordIn|CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.
45786364|NCT04431843|Dietary Supplement|Spirulina maxima extract|once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 1.5 g/day) for 12 week
45786365|NCT04431843|Dietary Supplement|Placebo|once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 0 g/day) for 12 week
45786366|NCT04431765|Other|Eye Movement Desensitization Reprocessing therapy|The Eye Movement Desensitization Reprocessing therapy uses bi-alternating (right-left) sensory stimulation through eye movements. The patient follows the therapist's fingers from right to left in front of his eyes and also by auditory stimuli. The patient wears a helmet that alternately makes him hear a sound to the right, then to the left or touch the patient holds in his hands buzzers that alternately vibrate from right to left, or alternatively the therapist taps the patient's knees or the back of his hands.
45786367|NCT04431765|Behavioral|Trauma-Centred Cognitive and Behavioural Therapy|A CBT is a short, scientifically validated therapy that focuses on the interactions between thoughts, emotions and behaviours. These therapies focus on the current problems of the person, while taking into account their historical causes. They help gradually overcome disabling symptoms and aim to strengthen adaptive behaviours. A CBT relies on different techniques that help the patient to identify the mechanisms at the origin of his difficulties, to experiment with new behaviors and thus to gradually come out of vicious circles that perpetuate and aggravate the psychic suffering.
45786368|NCT02406612|Device|X-Seal 6F Vascular Closure Device|
45786369|NCT02976363|Radiation|Radiotherapy breast cancer|
45786370|NCT02976363|Other|Evaluation Maximal Respiratory Pressures|
45786371|NCT04430049|Procedure|Covid ICU containment measures|The french containment measures during Covid-19 pandemic result in a restrictive visitation for relatives in ICU
45786372|NCT02581839|Drug|Eribulin Mesylate|Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
45786373|NCT02581839|Device|MRI|An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
45786374|NCT02581839|Drug|Pre-Medication: Zofran|Zofran at 8mg orally. Given at the discretion of the treating physician
45786375|NCT02581839|Drug|Pre-Medication: Decadron|decadron at 8mg orally. Given at the discretion of the treating physician
45786376|NCT02504775|Drug|Mejoral® 500 Tablets|500 mg tablet of paracetamol
45918583|NCT05365672|Other|Standard of Care|No application of the investigational medicinal product MIC
45449161|NCT03818321|Drug|Methenamine Hippurate 1 g tablet|Methenamine Hippurate (study drug) is an FDA approved medication in the prevention of UTI. Methenamine Hippurate 1g contains Hippuric acid salt of Methenamine (hexamethylene tetramine), Magnesium Stearate, Povidone, Saccharin Sodium, FD&C Yellow No. 5 (tartrazine) (www.iodine.com/drug/hiprex/fda-package-insert).
45449162|NCT03818321|Drug|Placebo tablet|Placebo is a tablet that will be provided to you that looks like the study drug but does not contain any medication. These pills are comprised of gelatin and minimal amounts of lactose powder. The pills are designed to have no effect on the patient.
45449163|NCT02154802|Behavioral|video: community member|
45449164|NCT02154802|Behavioral|video: physician|
45449165|NCT02154802|Behavioral|video: choice of video|
45449166|NCT03616977|Drug|LY900014 U-200|Administered SC
45786377|NCT02504775|Drug|Tylenol® Caplets|500 mg tablet of paracetamol
45786378|NCT02504931|Drug|Sertraline|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Sertraline is the active medication treatment arm.
45786379|NCT02504931|Drug|Placebo|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Placebo is the control medication treatment arm.
45786380|NCT02582151|Device|EV-906 Digital Transcutaneous electrical nerve stimulation (TENS) machine|Percutaneous patch electrodes are used to deliver low level electrical currents.
45786381|NCT02584725|Drug|Tranexamic Acid|Comparison of 3 different doses of the drug
45786382|NCT04423029|Drug|DF6002|Specified dose on specified days
45786383|NCT04423029|Drug|Nivolumab|Specified dose on specified days
45786384|NCT01186562|Drug|Sitagliptin|100 mg PO daily
45786385|NCT01186562|Drug|Placebo|Placebo
45786386|NCT04431752|Radiation|Magnetic Resonance Imaging Scan|The selection of patients with different level of OA will be made using the existing Kellgren-Laurence grading systems. The recruited patients will receive MRI exams with our enhanced sequencing. The OA level of each patient will be determined objectively through our quantitative OA grading system on MRI, which will be compared to Kellgren-Laurence grading results to evaluate the clinical performance of the MRI.
45918584|NCT05319496|Device|Intermittently scanned continuous glucose monitor (isCGM)|"A wearable sensor the size of 2 stacked quarters, that allows individuals to scan their glucose levels on demand. No fingerstick is required. The device measure interstitial glucose through a filament that is inserted under the skin. The application process is painless, and each sensor lasts 90 days. Sensors can be scanned with certain smart phones. This device is marketed as the FreeStyle Libre 2 glucometer (Abbott Laboratories, IL)."
45918585|NCT05319496|Behavioral|Education and coaching|Two encounters with a certified diabetes educator, who will assess lifestyle and medications, and provide individualized advice on diet, physical activity, and medication changes to improve glycemic control.
45449167|NCT03616977|Drug|LY900014 U-100|Administered SC
45449168|NCT02767570|Other|Gait Training; Altered Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with real-time, haptic feedback to encourage them to adopt a new foot progression angle. Participants will walk for an additional ten minutes per day to internalize their new foot progression angle over 52 weeks.
45449169|NCT02767570|Other|Gait Training; Consistent Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with haptic feedback to encourage them to maintain a consistent foot progression angle. Participants will walk an additional ten minutes per day to internalize the consistency of their foot progression angle over 52 weeks.
45449170|NCT03732885|Device|densah burs osseo densification drills|maxillary sinus floor elevation during implant placement using Densah burs
45786387|NCT01187498|Behavioral|Behavioral training|Comprehensive behavioral training program using delayed voiding, urge suppression techniques, pelvic floor muscle training, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
45786388|NCT01187498|Drug|Oxybutynin chloride, extended-release|Individually titrated, extended-release oxybutynin chloride, initiated at 10 mg, fluid management handout, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
45786389|NCT01147406|Drug|N6022|This is an injectible formulation which will be given at 5, 15 & 45 mg over 1, 3 and 9 minutes respectively, in single ascending doses.
45786390|NCT01147406|Drug|Placebo|This will be 0.9% normal saline given over 1, 3, or 9 minutes IV bolus.
45786391|NCT01148420|Drug|Medroxyprogesterone 17-Acetate|Medroxyprogesterone 20mg orally 3 times a day for 3 days
45786392|NCT01148420|Drug|medroxyprogesterone acetate|Depo Provera 150mg Intramuscular injection
45786393|NCT01149434|Drug|JI-101|JI-101 inhibits angiogenesis, and subsequently tumor growth, by inhibiting three receptor tyrosine kinases: VEGF Receptor Type 2 (VEGFR 2), platelet derived growth factor receptor beta (PDGFR β and Ephrin B4 (EphB4). JI-101 selectively inhibits kinases critical for all three stages of tumor angiogenesis.
45786394|NCT01149434|Drug|Everolimus|Everolimus is a signal transduction inhibitor that selectively inhibits mTOR (mammalian target of rapamycin), a key and highly conserved serine-threonine kinase, that is present in all cells and is a central regulator of protein synthesis and ultimately cell growth, cell proliferation, angiogenesis, and cell survival. mTOR is the only currently known target of everolimus (1).
45449171|NCT03732885|Device|Summer's Osteotomes|maxillary sinus floor elevation during implant placement using Summer's Osteotomes
45786395|NCT04375124|Biological|Biological/Vaccine: Angiotensin peptide (1-7) derived plasma|angiotensin peptide (1-7) derived plasma will be given to COVID-19 positive participants
45786396|NCT03012698|Device|Ocular Repetitive Magnetic Stimulation (RMS) treatment|"First stage: Patients will be asked to undergo a one-time treatment with Epitech Corneal Magnetic Stimulation Device on one eye. The worst eye will be treated; if both eyes are equal, the right eye will be treated.~Second stage: will be treated on both eyes, applying treatment to both eyes sequentially during the same visit."
45786397|NCT04352348|Other|blood samples|"All arms:~1 blood sample at inclusion (T0)~COVID-19 positive, severe only:~1 blood sample at D3, at D7, in case of transfer to intensive care unit or in case of aggravation of symptoms, eventually, at discharge from hospital if the last blood sample was more than 3 days old, in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~1 blood sample in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization"
45786398|NCT04352348|Other|feces samples (COVI-BIOME ancillary study)|"All arms:~1 feces sample at inclusion (T0)~COVID-19 positive, severe only:~1 feces sample at D3, at D7, in case of transfer to intensive care unit or in case of aggravation of symptoms and, eventually, at discharge from hospital"
45786399|NCT04352348|Other|sweat samples (COVIDOG ancillary study)|"All arms:~2 sweat samples at inclusion (T0)"
45786400|NCT04352348|Other|saliva samples|"All arms:~1 saliva sample at inclusion (T0)~COVID-19 positive, severe only:~1 saliva sample at D7, at discharge from hospital, in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~1 blood sample in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization"
45786401|NCT04352348|Other|6 minutes walk test|"COVID-19 positive, severe only:~6 minutes walk test in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~6 minutes walk test at inclusion (T0) and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization."
45786402|NCT04352348|Other|Phone call|"All arms except COVID-19 negative:~1 phone call 3 months after COVID-19 infection.~All arms except COVID-19 negative:~1 phone call 6 months after COVID-19 infection.~All arms except COVID-19 negative:~1 phone call 12 months after COVID-19 infection."
45786403|NCT04352348|Other|Urine samples|"All arms:~1 urine sample at inclusion (T0)~COVID-19 positive, severe only:~1 urine sample at D3, at D7, at discharge from hospital, in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~1 urine sample in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization"
45786404|NCT01150760|Drug|Alvimopan|At least 1 dose of alvimopan 12 mg during the hospitalization for bowel resection
45644739|NCT02999087|Radiation|IMRT|RT will be performed using IMRT (intensity modulated radiotherapy), with a simultaneous integrated boost (SIB) technique. RT dose to the GTV will be 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions). Prophylactic dose will be 52.8 Gy in 1.6 Gy daily fractions over 6.5 weeks (33 fractions).
45786405|NCT01150838|Drug|propofol|Initial dose: Propofol 2 mg/kg, then dose changes separately based on the last subject in the same age group and sevo time range
45918586|NCT05676983|Other|Spiky balance disc|Balance discs consist of smooth and rough surface. Balance training is given to children with cerebral palsy on these two surfaces. Thanks to its balance disc structure, it plays an active role in the development of balance.
45644740|NCT02997228|Drug|Atezolizumab|Given IV
45449172|NCT04996719|Drug|Rapamune|We will start the dose at 0.5mg capsule every other day for 2 weeks. If participants tolerate this dose and trough blood levels are (≤4ng/mL), the dose of rapamycin will be increased to 0.5mg daily for the duration of the study. If necessary, dose can remain at 0.5 mg every other day, depending on the trough level. To avoid immunosuppression, we will target lower dose of rapamycin, maintain lower trough serum levels (≤4ng/mL).
45644741|NCT02997228|Biological|Bevacizumab|Given IV
45644742|NCT02997228|Procedure|Biospecimen Collection|Undergo collection of blood samples
45644743|NCT02997228|Procedure|Computed Tomography|Undergo CT or CT/PET
45644744|NCT02997228|Drug|Fluorouracil|Given IV
45644745|NCT02997228|Drug|Leucovorin|Given IV
45644746|NCT02997228|Procedure|Magnetic Resonance Imaging|Undergo MRI
45786406|NCT02405442|Drug|Andecaliximab|Andecaliximab administered via subcutaneous (SC) injection
45786407|NCT02405442|Drug|Placebo|Placebo to match andecaliximab administered via SC injection
45786408|NCT01189136|Device|PTNS Active Treatment|34 gauge needle inserted 3cm above the medial ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period.
45786409|NCT01189136|Other|Sham treatment|34 gauge needle inserted 3cm above the medial ankle, but nonconductive cables are connected, so that no electrical stimulation is applied, over a 30-minute treatment period
45786410|NCT01189292|Drug|Dexamethasone|8mg (2ml) of dexamethasone (Mephameson®) administered intravenously preoperatively before thyroid surgery
45644747|NCT02997228|Drug|Oxaliplatin|Given IV
45644748|NCT02997228|Procedure|Positron Emission Tomography|Undergo CT/PET
45786411|NCT01189292|Other|NaCl 0.9%|2ml of NaCl 0.9% administered intravenously preoperatively before thyroid surgery
45786412|NCT01189370|Drug|sorafenib|"Dose Level:~400mg twice daily, continuous.~600mg twice daily, days 1-5 of each week.~800mg twice daily, days 1-5 of each week."
46071055|NCT04286399|Drug|Beta blocker|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
45786413|NCT04352504|Other|Almond|Consume 1.5 oz. serving almonds (246 calories) daily for 12 weeks
45786414|NCT04352504|Other|Pretzel|Consume 2 oz. serving of pretzels (216 calories) daily for 12 weeks
45786415|NCT04187378|Device|Surgical Underbody Blanket|Surgical blanket is used to maintain normothermia during abdominal surgery
45786416|NCT04187378|Device|Surgical access blanket|Surgical blanket is used to maintain normothermia during abdominal surgery
45786417|NCT01189760|Biological|onabotulinumtoxinA 24 U|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
45786418|NCT01189760|Biological|onabotulinumtoxinA 44 U|44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart
45786419|NCT01189760|Drug|normal saline|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
45786420|NCT03010202|Drug|Dexamethasone|Comparing the effect of Rituximab infusion With or without Dexamethasone
45786421|NCT03010202|Drug|Rituximab|Comparing maintenance dose of 500mg Rituximab at week 1 and week 24 to Placebo
45918587|NCT05676983|Other|Pediatric neurodevelopmental therapy|Bobath therapy
45449173|NCT02154880|Procedure|PFT|Lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder on a NDD EasyOne Pro system before and after bronchodilator administration.
45786422|NCT01191320|Drug|Placebo|Placebo capsule 1x daily for 3 months
45786423|NCT01191320|Drug|Androxal|Capsules 12.5 mg or 25 mg 1x daily for 3 months
45918588|NCT05676983|Other|smooth balance disc|Balance discs consist of smooth and rough surface. Balance training is given to children with cerebral palsy on these two surfaces. Thanks to its balance disc structure, it plays an active role in the development of balance.
45918589|NCT00001725|Drug|Dextromethorphan|
45918590|NCT05311618|Drug|NGM438|NGM438 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
45918591|NCT05311618|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
45918592|NCT00001728|Drug|Fosamax (Alendronate)|
45918593|NCT05266183|Other|Simultaneous Variety|3 different foods served
45918594|NCT05266183|Other|Single-Food|1 food served
45918595|NCT05266183|Other|Small Portion|Small meal portion size
45449174|NCT02154880|Procedure|lab work|The blood will be processed for serum, plasma, and PBMCS, and a portion stored to be used for future use. A hemoglobin and Carboxyhemoglobin will be done in order to calculate the DLCO.
45449175|NCT02154880|Procedure|6MWT|The six-minute walk tests are performed in a 100-foot segment of straight hallway marked at 1-foot intervals.
45449176|NCT02154880|Other|questionnaires|TEAL, MMRC and ST. George's Questionnaire will be administered. They are paper questionnaires that inquire about respiratory symptoms, quality of life, smoking history and other health issues
45644749|NCT02997228|Other|Quality-of-Life Assessment|Ancillary studies
45644750|NCT02997228|Other|Questionnaire Administration|Ancillary studies
45644751|NCT02983461|Drug|Sildenafil|Sildenafil, 20mg x 3 times a day for 10 weeks
45644752|NCT02983461|Drug|Placebo|Placebo oral tablet, 3 times a day for 10 weeks
45644753|NCT02973789|Device|NovoTTF-200T|"Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the chest. The treatment enables the patient to maintain regular daily routine.~Other Name: TTFields~Drug: Immune checkpoint inhibitors or docetaxel Patients receive standard of care with Immune checkpoint inhibitors or docetaxel"
45644754|NCT02973789|Drug|Immune checkpoint inhibitors or docetaxel|Patients receive standard of care with Immune checkpoint inhibitors or docetaxel
45918596|NCT05266183|Other|Large Portion|Large meal portion size
46071056|NCT04286399|Drug|SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
46071057|NCT00629837|Biological|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|Low dose of BAY 79-4980 [13mg of liposomes/kg] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU).
45786424|NCT01151852|Drug|Imatinib|Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.
45786425|NCT01151852|Drug|Placebo|Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
45918597|NCT05673629|Drug|Utidelone Injection in combination with AC|"The treatment group will be treated with Utidelone Injection at 30 mg/m2/d administered intravenously once daily on days 1-5 of each cycle, and Doxorubicin Injection at 50mg/m2 and Cyclophosphamide Injection at 500 mg/m2, administered intravenously respectively once daily on day 1 of each cycle. One treatment cycle has 21 days, and there are 6 cycles in total.~After the neoadjuvant therapy, all patients suitable for surgery will have the operation, and they will be evaluated pre-operatively for clinical remission according to RECIST 1.1. For patients unsuitable for surgery, they will receive other treatments according to the clinical practice at each site.~Safety evaluation will be performed 28 days after the last dose, and patients will be followed up for at least 3 years for disease recurrence."
45918598|NCT05673629|Drug|Docetaxel Injection in combination with AC|"The control group will be treated with Docetaxel Injection at 75 mg/m2, Doxorubicin Injection at 50 mg/m2, and Cyclophosphamide Injection at 500mg/m2, administered intravenously once on day 1 of each cycle. One cycle has 21 days, and there are 6 cycles in total.~After the neoadjuvant therapy, all patients suitable for surgery will have the operation, and they will be evaluated pre-operatively for clinical remission according to RECIST 1.1. For patients unsuitable for surgery, they will receive other treatments according to the clinical practice at each site.~Safety evaluation will be performed 28 days after the last dose, and patients will be followed up for at least 3 years for disease recurrence."
45918599|NCT00001731|Drug|Cyclosporin A|
45918600|NCT00392119|Device|MR-guided Laser Interstitial Thermal Therapy System|
45918601|NCT00392158|Device|Closed-loop anesthesia system|
45918602|NCT00392275|Drug|Ofloxacin 0.3%|
45644755|NCT02950987|Device|Whole Body MRI|
45644756|NCT02945085|Other|Home Based Care Team|Clinical team will conduct comprehensive clinical assessments focused on cognitive impairment and depression, conduct comprehensive medication review and reconciliation, offer Problem Solving Therapy, and offer brief occupational therapy, physical therapy, nutrition, and social support services.
45644757|NCT02945085|Other|Telephone Based Care Team|Telephone contact will be made by nurses. Depending on level of need, follow up telephone and, in some cases, in home visits will be made by nurse or social worker from care management program.
45644758|NCT02936102|Drug|FAZ053|Anti-PD-L1 Antibody
45786426|NCT02586909|Drug|RVT-101 35 mg tablets|once daily, oral tablets
45786427|NCT04073810|Diagnostic Test|PET imaging|Coronary 68Ga-DOTATATE PET-MRI or PET-CT at baseline and 3 months
45786428|NCT04073810|Diagnostic Test|Coronary CT angiography|CTCA at baseline and 2 years
45786429|NCT04073810|Diagnostic Test|Cardiac MRI|Cardiac MRI at 1 year
45786430|NCT03011606|Procedure|Robotic Surgery|Robotic Surgery after Focal Ablation Therapy
45786431|NCT03011138|Procedure|Gait velocity|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk on the treadmill in barefoot at selected gait speed.
45918603|NCT00392275|Drug|Ciprofloxacin 0.3%|
45918604|NCT00392275|Drug|Levofloxacin 0.5%|
45918605|NCT00392275|Drug|Ofloxacin 400mg|
45918606|NCT00392275|Drug|Ciprofloxacin 400mg|
45918607|NCT00392275|Drug|Levofloxacin 250mg|
45918608|NCT02972047|Behavioral|Diaphragmatic Breathing|Subjects in this are practice diaphragmatic breathing for 30 minutes after each meal.
45918609|NCT02972047|Behavioral|Sham Comparator|Sham therapy (listening to music/watching TV for 30 minutes after each meal
46071058|NCT00629837|Biological|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|High dose of BAY 79-4980 [22mg of liposomes/kg] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU)
46071059|NCT00629837|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to low dose of BAY 79-4980 [13mg of liposomes/kg]
45644759|NCT02936102|Drug|PDR001|Anti-PD-1 Antibody
45786432|NCT01191398|Drug|Atropine (0.01mg/kg)|Atropine will be given at 0.01mg/kg with a minimum dosage of 0.1mg and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
45786433|NCT01191398|Drug|Glycopyrrolate (0.01mg/kg)|Glycopyrrolate will be given at 0.01mg/kg with no minimum dosage and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
46071060|NCT00629837|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to high dose of BAY 79-4980 [22mg of liposomes/kg]
45918610|NCT05673356|Procedure|Arthroscopic anterior cruciate ligament reconstruction with quadriceps tendon bone autograft (QTB)|Arthroscopic anterior cruciate ligament reconstruction with quadriceps tendon bone autograft (QTB) will be performed in these patients. QTB autografts will be harvested as described in the published technique: K. Malinowski, J. Paszkowski, M. Mostowy, A. Góralczyk, R.F. LaPrade, K. Hermanowicz, Quadriceps Tendon-Bone Full-Thickness Autograft: Reproducible and Easy Harvesting Technique Using Simple Surgical Tools, Arthrosc. Tech. 10 (2021) e1165-e1172. https://doi.org/10.1016/j.eats.2021.01.003. ACLR will be performed utilizing anteromedial technique with management of any accompanying intraarticular lesions.
45644760|NCT02935543|Biological|CART 19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Subjects will receive 1-5 x 10^8 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction: 1-5x10^7 CART19 cells, Day 2, 30% fraction: 3x10^7-1.5x10^8 CART19 cells, Day 3, 60% fraction: 6x10^7-3x10^8 CART19 cells
45786434|NCT01191398|Drug|Normal saline 0.9%|Normal Saline of 0.9% will be given at a volume of 2mL. This medication will be given once by IV 30 minutes before the administration of Ketamine
45918611|NCT05233384|Biological|Blood test|For each patient included, this study will involve the collection of 20 ml of blood during a blood test carried out as part of routine care. One EDTA tube (4,5 ml) will be withdrawn and frozen for genetic testing. 15 ml of citrated blood sample (3 to 5 tubes, depending on the used tubes) are necessary for the study of fibrin clot structure. Citrated tubes will be double centrifugated and frozen (-80°C) according to Groupe Français d'Études sur l'Hémostase et la thrombose guidelines (centrifugation protocol: 1500 to 2000g at least 15min, or 2000 to 2500g at least 10min with an intermediate decantation).
45918612|NCT00001749|Drug|Antithymocyte globulin|
45918613|NCT00001749|Drug|Cyclosporine|
45918614|NCT00001752|Drug|L-arginine|
45918615|NCT00001752|Drug|Estrogen|
45918616|NCT05171179|Procedure|Breast Reconstruction (Mammaplasty)|Breast Reconstruction (mammaplasty) surgery with implant-based tissue expander
46071061|NCT00827671|Drug|cetuximab|cetuximab initial dose 400 mg/m2 iv 1 week before start radiotherapy and subsequent weekly doses of 250 mg/m2 iv for the duration of the radiation treatment
45918617|NCT05171179|Device|Pecs blocks|Pectoral nerve (Pecs) blocks I and II function by blocking the pectoral, intercostal, intercostobrachial nerves, and/or long thoracic nerve. These are used primarily for breast surgeries and are gaining momentum as simple administers of local analgesics. Pecs blocks utilize ultrasound to guide injection of local analgesic. It is less invasive and more accurate than most current modes of analgesia administration.
45918618|NCT05171179|Drug|Exparel|Exparel is a sterile, non-pyrogenic white to off-white preservative-free aqueous suspension of multivesicular liposomes (DepoFoam® drug delivery system) containing bupivacaine. Bupivacaine is present at a concentration of 13.3 mg/mL. After injection of Exparel, bupivacaine is released from the multivesicular liposomes over a period of time.
45918619|NCT05171179|Drug|Bupivacaine|This is an anesthetic delivered during breast reconstruction surgery that will be given to participants in arms 2 and 3.
45918620|NCT05171179|Drug|Lidocaine|This is an anesthetic delivered during breast reconstruction surgery that will be given to participants in arm 1.
45918621|NCT05668364|Other|Outdoor cold air exposure|Exposure to outdoor cold air (<10°C or <50°F, intervention group) for 30 minutes. On completion of the intervention, participants remained under observation at indoor ambient air from 30 minutes to 60 minutes from the intervention.
46071062|NCT00827671|Radiation|radiotherapy to oesophageal tumour|45 Gy delivered in 25 fractions of 1.8 Gy 5d/wk
46071063|NCT03909971|Drug|Lorlatinib|ALK inhibitor-treated ALK-positive NSCL treatment
45918622|NCT05156905|Drug|Cirmtuzumab|Cirmtuzumab will be given in combination with docetaxel.
45918623|NCT00001758|Drug|Abacavir|
45644761|NCT02928497|Device|WATCHMAN LAAC Device Implant|WATCHMAN LAAC Implant
45644762|NCT02928497|Drug|Single Antiplatelet Therapy or No Therapy (Control)|Single Antiplatelet Therapy or No Therapy at the discretion of the study physician.
45644763|NCT02927301|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab was given as 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
45644764|NCT02925364|Radiation|magnetic resonance imaging (MRI)|all participants will undergo a functional MRI and an anatomical MRI in a single session
46071064|NCT00823537|Procedure|therapeutic electrical stimulation|
46071065|NCT03473483|Other|SREC|"The Standardized Research E-Cigarette (SREC) was developed by NIDA to help researchers assess uncertainties in electronic nicotine delivery devices.~Tank:~Sealed and disposable~Minimum 350 puffs per tank~Volume of e-liquid per tank ~ 3ml~E-Liquid Characteristics:~Tobacco flavored~Nicotine concentration: 15 mg/ml~Propylene Glycol:~ 50% (wt / wt)~Glycerin: ~ 50% (wt / wt)~Cotinine: <1 μg/g~Nornicotine: 5 μg/g~Myosmine : 3 μg/g~Anabasine: <1 μg/g~Anatabine: <1 μg/g~Beta:nicotyrine: <1 μg/g~Diacetyl: <2 μg/g~2,3:Pentanedione: <1 μg/g~Arsenic: <0.1 μg/g~Cadmium: <0.1 μg/g~Chromium: <0.1 μg/g~Lead: <0.1 μg/g~Nickel: <0.1 μg/g~Mercury: <0.05 μg/g"
46071066|NCT00819481|Device|3DKnee™ System|Total knee replacement joint for subjects with knee osteoarthritis and willing to participate in the study.
46071067|NCT02550145|Drug|Exendin (9-39)|IV infusion of Exendin (9-39) during standardized oral glucose tolerance test (OGTT).
45786435|NCT04418271|Behavioral|Prehabilitation- new form of care|The participants in the intervention group take part in a shared decision-making (SDM) conference to plan the intervention. The therapeutic content of the prehabilitation is defined individually for each patient in the SDM conference. Prehabilitation will be a structured and individually tailored 3-week program.
45786436|NCT05249595|Device|Surface electromypgraphy-based interface to predict human ankle joint motion intent and use in ankle assistive devices|The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by the sEMG signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
46071068|NCT02550145|Other|Placebo|IV infusion of Placebo (normal saline) during standardized oral glucose tolerance test (OGTT)
46071069|NCT00823693|Drug|Bimosiamose Cream|
46071070|NCT00823693|Drug|Placebo Cream|
45786437|NCT05249595|Device|Ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices|The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by the ultrasound imaging signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
45786438|NCT05249595|Device|Surface electromypgraphy and ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices|The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by combining sEMG and ultrasound imaging signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
45918624|NCT00001758|Drug|Amprenavir|
45786439|NCT01191476|Drug|Sevoflurane Inhalational Induction and Maintenance|Sevoflurane was administered at a concentration of 8% via vital capacity induction and sevoflurane 0.8-1.5 minimum alveolar concentration (MAC) with a rate of 1 L/min fresh gas flow for maintenance.
45918625|NCT00001758|Drug|Efavirenz|
45918626|NCT05144269|Other|Multimodal exercises|Telehabilitation including pilates, breathing, progressive relaxation training, posture and pelvic floor strengthening exercises
45918627|NCT05139979|Behavioral|Breathing and Wellness Webinar|"Simha Kriya : a 3-minute energizing breathing practice to expand lung capacity and improve immunity, to be practiced twice daily.~Nadi Shuddhi - a gentle 4-minute breathing practice for creating mental balance and relaxation, to be practiced for a minimum of 4 minutes daily.~Isha Kriya - a 15-minute guided meditation that incorporates the breath and the awareness to create mental clarity and health, to be practiced at least once (ideally twice) daily."
45918628|NCT05139979|Other|Routine Daily Activity|Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm.
45918629|NCT05095441|Biological|C5252|A single dose of C5252 will be administered up to 2mL as intratumoral injection on Day 1.
45918630|NCT05080738|Other|Upper Extremity Home Exercises|"The exercises will be performed as follows:~Stretching exercises: It will be applied in the form of 10 seconds*10 repetitions for fingers, wrists, elbows and shoulders.~Strengthening exercises: It will be applied as 2 sets*10 repetitions for fingers, wrists, elbows and shoulders."
45918631|NCT00001764|Drug|Mycophenolate Mofetil|
45918632|NCT05037799|Drug|Rb-82 Radioisotope|Quadratic dosing: Rubidium-82 activity prescribed as a squared function of body-weight instead of linear function of body-weight or fixed activity independent of body-weight
45449177|NCT03816761|Drug|Fast-acting insulin aspart|In each cohort, participants will receive fast-acting insulin aspart using the iLet™ in a cross-over manner for 14 days (7days per period). Dose modification will be handled autonomously by the iLet™ based on the CGM sensor readings and the user interaction with the iLet™ e.g. meal announcements.
45644765|NCT02924727|Drug|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
45644766|NCT02924727|Drug|Ramipril|Ramipril 1.25 mg, 2.5 mg, and 5 mg oral capsules
45644767|NCT02924727|Drug|Placebo of LCZ696|Matching placebo of LCZ696 tablets
45644768|NCT02924727|Drug|Placebo of ramipril|Matching placebo of ramipril capsule
45644769|NCT02924727|Drug|Valsartan|Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day to patients who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization
45918633|NCT05650853|Other|Transrectal ultrasound|Examinations for observation of the pre, per and post-ejaculatory phases
45449178|NCT03816761|Device|iLet™|The bionic pancreas including pigtail adapters, used in insulin-only configuration
45449179|NCT05665413|Device|TENS|strocking technique, HOT PACK and Ergon instrument
45644770|NCT02924727|Drug|Placebo of valsartan|matching placebo of valsartan for one day to patients who will be randomized to received ramipril
45644771|NCT02907398|Device|Inspire therapy|
45644772|NCT02907398|Other|No intervention|
45644773|NCT02905110|Drug|Methotrexate|Methotrexate 4 mg into fourth ventricle of the brain via the Ommaya Reservoir 2 days a week for 6 weeks. Each patient will have 12 infusions.
45644774|NCT02905110|Drug|Etoposide|Etoposide 1 mg into fourth ventricle of the brain via the Ommaya Reservoir 5 days a week for weeks 1, 3, and 5. Each patient will have 15 infusions.
45918634|NCT05650853|Other|Urethroscopy|Examinations for observation of the pre, per and post-ejaculatory phases
45918635|NCT05026333|Other|Cognitive Stress Testing|Cognitive and stress study with no product intervention and noninvasive. The high stress/anxiety group will be compared to the low stress/anxiety group in terms of changes from baseline to after the cognitive and stress tests (i.e., 4 laboratory tasks) and metabolite measures.
45918636|NCT05023252|Other|mobile application|VetThrive is a mobile smartphone application that monitors and transmits mobile sensor and utilization data. This app is deployed in Veteran patients who passively self-track their behaviors and psychiatric symptoms.
45918637|NCT00001776|Device|Cadwell Rapid Rate Magnetic Stimulator|
46071071|NCT03643133|Drug|Mifamurtide|48 doses overall over 36 weeks
45449180|NCT03639831|Dietary Supplement|Proprietary, standardized botanical extract|2 capsules/ day providing the proprietary botanical extract as unique active ingredient
45449181|NCT03639831|Dietary Supplement|Placebo (maltodextrin)|2 capsules/ day providing no active component
45449182|NCT02157142|Device|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
45449183|NCT01079273|Biological|egg-derived A/H1N1 pandemic influenza vaccine|One 0.50 mL IM dose injection (7.5 µg of vaccine + 9.75 mg MF59)
45644775|NCT02905110|Procedure|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
45918638|NCT04993807|Other|Shared decision-making tool|Participants will use an interactive web page intended to aid patient decision-making (i.e., a decision aid) while undergoing consultation for atrial fibrillation ablation.
45918639|NCT04983901|Drug|Cefepime|Given IV
46071072|NCT03643133|Combination Product|EI or M-API regimen depending on patient age|"M-API regimen:~One course of high-dose Methotrexate (optional) followed by 5 courses of API, every 21 days~EI regimen :~5 course of EI, every 21 days"
46071073|NCT00827749|Device|respiratory plethysmography by inductance|contribution of respiratory plethysmography by inductance and informatic tool
46071074|NCT00967343|Biological|Donor lymphocyte preparation depleted of host functional alloreactive T-cells|Single intravenous infusion with 2x10E6 T-cells/kg
45644776|NCT02901626|Device|Arabin Cervical Pessary|"The Arabin cervical pessary is a soft, flexible silicone pessary and fits high around the cervix with no rigid metal framework or inflexible edges that put increase pressure on the vaginal wall. It is available in a variety of sizes however three sizes will be used in this study:~Pessary Size upper diameter, lower diameter~Nulliparous 65 mm, 32 mm~Multiparous 70 mm, 32 mm~Alternative 70 mm, 35 mm"
45644777|NCT02893163|Behavioral|CHANGE Intervention|Canadian Health Advanced by Nutrition and Graded Exercise Protocol
45786440|NCT01191476|Drug|Propofol Target Controlled Infusion for Induction and Maintenance|Propofol IV 4 ug/mL was administered with target controlled infusion (TCI) for induction and propofol 3 to 6 ug/mL was administered with TCI for maintenance.
45786441|NCT01191476|Drug|Propofol Target Controlled Infusion for Induction and Sevoflurane Inhalation for Maintenance|Propofol was administered as a bolus IV dose of 1.5 mg/kg for induction at a rate of 40 mg/10 seconds. During maintenance, a sevoflurane concentration of 0.8-1.5 minimal alveolar concentration (MAC) was administered at a rate of 1 L/min fresh gas flow.
45786442|NCT02404350|Biological|Secukinumab|Anti IL-17a monoclonal antibody
45786443|NCT02508207|Drug|Tezacaftor/Ivacaftor|Tezacaftor/Ivacaftor FDC
45786444|NCT02508207|Drug|Ivacaftor|
45644778|NCT02893163|Other|Usual Care|Usual Care by Family Doctor
45786445|NCT02508207|Drug|Tezacaftor/Ivacaftor matching placebo|
45786446|NCT02508207|Drug|Ivacaftor matching placebo|
45786447|NCT04063670|Other|Video Intervention|Peri-operative video series focusing on expanded education and coping skills before and after scoliosis surgery for adolescent idiopathic scoliosis
46071075|NCT00973973|Drug|Placebo|Matching placebo tablets taken orally once a day
46071076|NCT00973973|Drug|Elagolix|Immediate release (IR) tablets taken orally once a day
45644779|NCT02872337|Behavioral|Preoperative Physical Therapy Session|This was a one-on-one preoperative physical therapy session on preoperative education. These patients were also given access to a surgery specific web-based microsite
45786448|NCT04063670|Other|Control|Routine, Standard-of-Care
45786449|NCT02181530|Other|No Intervention|No treatment (intervention) is being administered as part of this study.
45918640|NCT04983901|Drug|Imipenem/cilastatin-relebactam|Given IV
45918641|NCT04983901|Drug|Daptomycin|Given IV
45918642|NCT04983901|Drug|Linezolid|Given IV or PO
46071077|NCT00633139|Biological|Recombinant human Arylsulfatase A (rhASA)|intravenous infusion, every other week for 26 weeks
45644780|NCT02872337|Behavioral|Group Preoperative Education Session (per the standard of care)|
45644781|NCT02856815|Biological|Immuncell-LC|Activated T lymphocyte : intravenous dripping of 200ml (1 x 10^9 ~ 2 x 10^10 lymphocytes / 60kg adult) for 1 hour
45644782|NCT02823652|Other|Counseling|Undergo usual care
45644783|NCT02823652|Other|Genetic Counseling|Complete remote counseling
45644784|NCT02823652|Other|Genetic Testing|Undergo germline testing
45786450|NCT05249439|Other|I-SatPro weight loss programme|I-SatPro weight loss programme: patients asked to make changes to food choices, the timing of eating, exercise, sleep, eating habits and behaviour changes related to self-care and wellbeing
45786451|NCT01193114|Behavioral|Ecologically Based Treatment (EBT)|Substance abuse treatment (the Community Reinforcement Approach), case management and housing.
45786452|NCT01193114|Behavioral|Treatment as Usual (TAU)|Treatment/intervention as normally provided by community service agencies that service substance abusing homeless families.
45786453|NCT02509065|Device|Bionic Pancreas|Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm for type 1 diabetes patients will deliver insulin and glucagon. The 100 mg/dl arm for type 2 diabetes patients will deliver just insulin. The 115 mg/dl arm will deliver insulin and glucagon. The 120 mg/dl arm will deliver just insulin. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl and 110 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.
45786454|NCT02509065|Other|Usual Care|Participant cares for their diabetes according to their usual practice, with blinded CGM monitoring. No medication will be administered by the study in this intervention.
45918643|NCT04983901|Drug|Meropenem|Given IV
45918644|NCT04983901|Drug|Piperacillin-Tazobactam|Given IV
45918645|NCT04983901|Drug|Vancomycin|Given IV
45918646|NCT04981639|Procedure|IVPCA|Intravenous patient controlled analgesia will be performed.
45918647|NCT04981639|Procedure|TAP|Transversus abdominis plane block will be performed.
45918648|NCT04981639|Procedure|IMS|Intramuscular electrical stimulation will be performed.
45918649|NCT05634200|Procedure|Bronchoscopy|During bronchoscopy endobronchial biopsy, transbronchial biopsy, transbronchial needle aspiration, bronchial washing, bronchoalveolar lavage, EBUS-TBNA and EUS-B-FNA may be performed
46071078|NCT04044235|Behavioral|PrEP Cohort|AGYW who are eligible for PrEP will be educated about the risk and benefits. For AGYW (aged 18-24 years) who consent to PrEP, an ART provider (nurse or clinician) certified by the MOH will provide PrEP (package of disoproxil fumarate/emtricitabine (Truvada)) on the same day that the client is determined eligible. Peer navigators will ensure linkage to facilities for follow-up care. The initial follow-up visit will occur one month from PrEP initiation to ensure that the client is tolerating the regimen and to answer any questions, with three-month follow-up visits thereafter.
45918650|NCT04971343|Diagnostic Test|Access HIV_blood donor|"Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Roche - Cobas - Elecsys® HIV Duo .~All initially reactive specimen results will be tested in duplicate per IFU .~All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested)."
45644785|NCT02823652|Other|Internet-Based Intervention|Complete on-line genetic education
45644786|NCT02823652|Other|Survey Administration|Ancillary studies
45786455|NCT01194674|Drug|Microplasmin|Participants received an intravitreal injection of 125 µg in 100 µL of microplasmin at baseline.
45644787|NCT02819037|Procedure|gas chromatography|
45644788|NCT02819037|Procedure|Stool analysis for detection of malabsorption|
45918651|NCT04971343|Diagnostic Test|Access HIV_Hospitalized patient|"All samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay for hospitalized patient.~All initially reactive specimen results will be tested in duplicate per IFU .~All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested)."
45786456|NCT02509767|Drug|Subcutaneous depot medroxyprogesterone acetate|Based on study arm, subjects will either be taught to self-inject or will be administered DMPA sc by qualified clinic personnel.
45786457|NCT01154192|Drug|Dexamethasone|Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
46071079|NCT00827905|Device|RSpot Non-Contact Respiratory Rate Spot Check|The Kai Sensors RSpot 100 provides a measurement of respiratory rate at a single point in time. It uses a low-power radar to detect respiratory effort, and analyzes the respiratory effort signal to provide a respiratory rate.
46071080|NCT02549521|Dietary Supplement|Oral magnesium substitution|The elderly was given tablets two times daily with calsium and vitamin D. They were further given magnesium tablets 120 mg two times daily for 28 days.
45644789|NCT02808507|Other|Active TB case finding|Active TB case finding (ACF) refers to any number of strategies used to identify individuals with active TB disease, outside of passive case finding. In passive case finding, individuals with symptoms present at health centers for diagnosis. In active case finding, the health system makes an effort to identify TB cases before they present passively.
46071081|NCT02549521|Dietary Supplement|Placebo tablets without magnesium|The elderly was given tablets two times daily with calsium and vitamin D. They were further given placebo without magnesium two times daily for 28 days.
46071082|NCT02864615|Radiation|SBRT|Dose and schedule will be depended on metastases location.
46071083|NCT00823849|Drug|Cilostazol|From 50mg, Bid, PO after breakfast and dinner. After 1-week of administration, if no significant study drug related discomfort, the dose can increase to 100mg, Bid, PO. Otherwise, remain at the 50 mg level.
46071084|NCT00823849|Drug|Probucol|250 mg Bid, PO after breakfast and dinner.
46071085|NCT00823849|Drug|Cilostazol+Probucol|
46071086|NCT00823849|Other|Control Group|Routine treatment
46071087|NCT02864459|Other|Muscular ultrasound|Muscular ultrasound is done before extubation
46071088|NCT04284683|Other|DRINK - Water, Protein, Fat, Carbohydrate|Following exercise participants will consume a drink (with different composition in each visit) and than RMR will be evaluated.
46071089|NCT02550067|Drug|DMPA|Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
46071090|NCT02550067|Drug|LNG|Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
46071091|NCT02550067|Drug|Copper IUD|Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
45449184|NCT02157220|Device|Fixed bearing prosthesis|
45644790|NCT02798523|Drug|Methylprednisolone sodium succinate(Solu-Medrol)|"Methylprednisolone sodium succinate for injection, USP (SOLU-MEDROL sterile powder, Pfizer, Inc.) is an anti-inflammatory glucocorticoid which occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.~125-milligram Act-O-Vial (AOV) System: Each 2 mL AOV (when mixed) contains methylprednisolone sodium succinate equivalent to 125 milligrams methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; and 17.4 mg dibasic sodium phosphate dried."
45786458|NCT01154192|Drug|recombinant human chorionic gonadotropin (r-hCG)|Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin (r-hCG). Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
45786459|NCT02511561|Drug|OTO-201 (ciprofloxacin)|
45786460|NCT03884270|Behavioral|Hypnotherapy|7 sessions of self-administered gut-directed hypnotherapy for functional dyspepsia
45786461|NCT02511717|Other|Transcutaneous tibial nerve stimulation|Patch electrodes applied posterior to the medial malleolus, and 5-10 cm above the medial malleolus of the same leg, just behind the medial tibial edge. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be titrated up to patient's maximum nonpainful tolerance (between 0.5-10mA). This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
46071092|NCT03873935|Other|Evaluation of periodontal status|Clinical examination
46071093|NCT02862509|Drug|Budesonide nasal instillation|
46071094|NCT02862509|Drug|Normal saline nasal instillation|
46071095|NCT02550379|Behavioral|Intervention|Emotion Recognition Training
45449185|NCT02157220|Device|Mobile bearing prosthesis|
45918652|NCT04971343|Diagnostic Test|Access HIV_known HIV-1 antibody positives|"Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay .~All initially reactive specimen results will be tested in duplicate per IFU .~For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays.~In case of discrepant results or concordant negative results between Access and Reference HIV Ag/Ab combo assay among known HIV-1 antibody positive patients, the IB/WB test will be repeated by the site to confirm sample status. If this IB/WB result is negative or indeterminate, the sample will be excluded from the statistical analysis"
45918653|NCT04971343|Diagnostic Test|Access HIV_known HIV-2 antibody positives|"Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay.~All initially reactive specimen results will be tested in duplicate per IFU .~For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays."
45449186|NCT02770612|Other|Prescribed opioids|Making a shared decision with post-cesarean delivery mothers about quantity of opioids prescribed at discharge
45449187|NCT03542110|Drug|Alirocumab 150 MG/ML subcutaneous injection|Single-dose, pre-filled, disposable, subcutaneous injection pen
45918654|NCT04971343|Diagnostic Test|Access HIV_known HIV-1 p24 Ag positive|"All samples will be tested with both Reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFUs/study guide to determine non-reactive (NR), initially reactive (IR), and repeatedly reactive (RR). Reference assay will be Abbott - ARCHITECT HIV Ag/Ab Combo Assay.~Due to volume constraints, all known HIV-1 p24 Ag positive samples that will be tested during the EU HIV clinical trial will be tested in singulare only with the Reference HIV Ag/Ab combo assay, and in singulare and then in duplicate if IR with Access HIV Ag/Ab combo assay.~For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays"
45918655|NCT04971343|Diagnostic Test|Access HIV_Canada's requirements_Blood donor|"To fit with Canada's requirements:~4,000 additional blood donor samples from geographically distinct regions will be collected and tested. Blood donor sample testing will be equally distributed over three blood donor sites, using 3 different lots of reagents: the first 2,000 blood donor samples from CE-marking study (out of the 6,000 tested) will be used plus the 4,000 additional blood donor samples.~Retesting of 1000 blood donor samples will be done internally with 1 lot close to expiration to satisfy Canadian requirements"
45918656|NCT04971343|Diagnostic Test|Access HIV_Canada's requirements_HIV positive|"To fit with Canada's requirements:~o HIV positive samples will be equally distributed and tested at leat three (3) testing sites, using 3 lots of reagents."
46071096|NCT02550379|Other|Placebo|Placebo Training
45786462|NCT02511717|Other|Sham transcutaneous tibial nerve stimulation|Patch electrodes applied posterior to the lateral malleolus, and 5-10 cm above the lateral malleolus of the same leg. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be set a 1mA. This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
45786463|NCT02512419|Behavioral|Text-Enhanced Physical Activity Intervention Arm|Participants in the Text-Enhanced Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, print-based + text-message physical activity intervention that specifically addresses the physical activity barriers and intervention needs/preferences of Mexican and Mexican American men.
46071097|NCT04285775|Device|Application of device which monitors for bleeding - Blood Warning Technology with Continuous Hemoglobin sensor (BWATCH)|A stand-alone disc-shaped device (approximately 5 cm in diameter and <1 cm thick) which can be placed over dressings. Once switched on and put in place, continuous monitoring for bleeding takes place. Detection occurs in 2 phases. First, the system monitors for the appearance of fluid in the dressing by detecting a change in capacitance. Next, a light sensor differentiates blood from other fluids by detecting that a unique spectrum of light (525nm) is absorbed, a property unique for hemoglobin. The presence of fresh blood triggers a loud alarm, alerting medical staff to attend to the patient. The device can be used over transparent plastic dressings and does not require direct contact with blood.
46071098|NCT02864537|Other|Training|Patients were trained to measure INR and dose warfarin
45449188|NCT03542110|Drug|Matching Placebo subcutaneous injection|Single-dose, pre-filled, disposable, subcutaneous injection pen
45449189|NCT03542032|Other|i-gel placement maneuvers|the i-gel was inserted with triple airway maneuver (mouth opening, head extension and jaw thrust) In the classic maneuver , the index finger used as a guide, pushes the back of i-gel towards the hard palate, inserting it into the pharynx till a resistance is felt and the i-gel is then fixed it its place.
45449190|NCT03542734|Other|multimodal magnetic resonance imaging|multimodal magnetic resonance imaging included T1, FLAIR, MRA, PWI and/or ASL, DTI, DKI, SWI, fMRI
45449191|NCT03542656|Drug|amyloid PET|Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).
45786464|NCT02512419|Behavioral|Health Education Control Arm|Participants will receive a Spanish language, print-based Wellness Contact control intervention addressing relevant health topics other than physical activity.
45786465|NCT02512419|Device|Actigraph GT3X|
45918657|NCT04971343|Diagnostic Test|Access HIV_Canada's requirements_P24 Positive|"To fit with Canada's requirements:~HIV positive samples will be equally distributed and tested at leat three (3) testing sites, using 3 lots of reagents.~Collection and testing of maximum 210 additional HIV-1 Ag positive sample beyond the 50 required by CTS"
45449192|NCT02155036|Other|Exercise|The intervention will include 2 sessions of gym-based exercise per week, both of which will be supervised for 3 months, supervision will then decrease to once-weekly until 6 months, and then be through phone support for the remaining 6 months. Warm up and cool down of minimum of five minutes on stationary exercise cycle, rate of perceived exertion (RPE) ~11, followed by gentle stretching. Progressive resistance training (PRT) will use eight PRT machines training large muscle groups (e.g. bench press, latissimus pulldown, bicep curl, triceps pull down, leg press, knee extension, hamstring curl, calf raises). Intensity will be 80% of one repetition maximum (1RM), building up to 3 sets of 8 repetitions. 1RM will be re-assessed monthly, and program adjusted accordingly.
45786466|NCT02186210|Device|prewarming|recovery slope StO2
45786467|NCT01195922|Drug|Sirolimus|21 evaluable subjects will take rapamycin (sirolimus) orally once per day for 21 days. Before and after dosing tumor assessments to include: photographs, CT & amp; PET scans will be done for tumor measurement.
45786468|NCT03870386|Procedure|EUS-BD with LAMS|Endoscopic ultrasound guided insertion of lumen apposing metal stent forming a choledochoduodenostomy
45449193|NCT03575871|Drug|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks
45644791|NCT02798523|Drug|Topical methylprednisolone (Advantan emulsion 0 /1%)|1 g Advantan emulsion 0.1% (Bayer) contains methylprednisolone aceponate (21-acetoxy-11beta-hydroxy-6alpha-methyl-17-propionyloxy-1,4-pregnadiene-3,20-dione) 1 mg, as the active ingredient. It is an oil-in-water emulsion containing medium chain triglycerides, caprylic-capric-stearic triglyceride, polyoxyethylene alcohol 2-stearyl ether, polyoxyethylene alcohol-21-stearyl ether, benzyl alcohol, disodium edetate, glycerol, and purified water.
45644792|NCT02797977|Drug|SRA737, gemcitabine, cisplatin|
45644793|NCT02797977|Drug|SRA737, gemcitabine|
45644794|NCT02787785|Device|Subcutaneous Implantable Cardioverter Defibrillator|The S-ICD is an entirely subcutaneous implantable cardioverter defibrillator.
45786469|NCT03870386|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography to localize and cannulate the bile duct using the guidewire-assisted technique.
45786470|NCT01197326|Device|use of the MP5 EWS patient monitor|All patients on the study ward receive the same care in Groups 1 and 2. The only difference is the device used to collect the vital signs. In Group 2, the MP5 EWS spot check monitor (FDA approved and CE marked) is the vital signs collection device.
45918658|NCT04962256|Procedure|Enhanced recovery after surgery|ERAS management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
45918659|NCT04954573|Radiation|infrared-A (wIRA)|Local-water filtered infrared-A (wIRA) irradiation
45918660|NCT04951804|Procedure|EUS-CPN without bupivacaine|Under conscious sedation, an echoendoscope is advanced into the stomach, just distal to the gastro-esophageal junction. The region of the celiac plexus is identified around the takeoff of the celiac artery from the aorta. Then, under real-time ultrasound guidance, a 19g needle is used to inject a neurolytic agent such as absolute alcohol around the base of the celiac artery.
45918661|NCT04951804|Procedure|EUS-CPN with bupivacaine|Under conscious sedation, an echoendoscope is advanced into the stomach, just distal to the gastro-esophageal junction. The region of the celiac plexus is identified around the takeoff of the celiac artery from the aorta. Then, under real-time ultrasound guidance, a 19g needle is used to firstly inject bupivacaine and secondly a neurolytic agent such as absolute alcohol around the base of the celiac artery.
45918662|NCT00001797|Drug|Recombinant human interleukin-10|
45449194|NCT03575871|Drug|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks
45644795|NCT02786589|Biological|Blood-stage infection of P. vivax|Each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1×10^7 Plasmodium parasites.And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples.The treatment will last at least 12 weeks from the day of finding the Plasmodium from peripheral blood and will be terminated by chloroquine phosphate or Artemisinin compound preparation or Artesunate injection.
45644796|NCT02772588|Drug|ARN-509|
45644797|NCT02772588|Drug|Abiraterone|
45644798|NCT02772588|Drug|Leuprolide|
45449195|NCT03575871|Drug|Placebo|Placebo, administered as two tablets to be taken orally once daily for 12 weeks
45449196|NCT02157454|Other|Website access|Access to the colorectal cancer module of the website www.krankheitserfahrungen.de which provides free, reliable information about health issues by sharing people's real-life experiences
45449197|NCT02155192|Drug|No Intervention|
45449198|NCT02155270|Procedure|Corneal precut 600µm|
45449199|NCT02155270|Procedure|Corneal stabincision|
45644799|NCT02772588|Radiation|stereotactic, ultra-fractionated radiotherapy|
45786471|NCT02512575|Drug|AZD9567 Monohydrat|AZD9567 oral suspension 0.5 to 10 mg/ml
45449200|NCT03543670|Dietary Supplement|Oncoxin-Viusid|Support treatment with Oncoxin-Viusid (75mL/day) during chemotherapy/Radiotherapy until two weeks after (a total of 8 months).
45449201|NCT02155348|Procedure|Bilateral cataract surgery with implantation of multifocal IOLs|Lentis LS-313, multifocal, target refraction of the distance-dominant eye: 0.00D, target refraction of the other eye: -0.50D
45786472|NCT02512575|Drug|Placebo oral suspension/ Placebo capsule|Matching placebo
45786473|NCT02512575|Drug|Prednisolone|Prednisolone 60mg oral capsules (12 capsules of 5 mg each).
45449202|NCT02155348|Procedure|Bilateral cataract surgery with monovision|Lentis L-313, monofocal, target refraction of the distance-dominant eye: 0.00D to -0.25D, target refraction of the other eye: -1.50D
45786474|NCT01199744|Drug|zanamivir|zanamivir
45786475|NCT03702374|Drug|Combined antioxidant therapy|It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide 20mg), copper (copper sulfate 1mg), taken once a day for 12 months
45644800|NCT02767973|Other|Wood Smoke Particles (WSP)|After baseline (pre-exposure) assessment (which includes recovery of induced sputum), these volunteers will then undergo an exposure to 500μg/m3 wood smoke particles for 2 hours, with alternating 15 min of exercise (cycle ergometer) with 15 min rest to achieve 25 l/m2 body surface/min minute ventilation, followed by sputum induction after 6 and 24 hours after initiation of the challenge.
45786476|NCT03702374|Other|Placebo|It consists in a capsule with 100mg of magnesium oxide.
45918663|NCT04949620|Behavioral|REThink therapeutic game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.
45644801|NCT02766582|Drug|Pembrolizumab|IV every 21 days at 200 mg
45644802|NCT02766582|Drug|Carboplatin|IV every 21 days
45644803|NCT02766582|Drug|Paclitaxel|IV infusion (80mg/m2) every 7 days for 6 cycles
45644804|NCT02759419|Drug|Adempas (Riociguat, BAY63-2521)|0.5 to 2.5 mg in 0.5 mg increments (according to individual adapted optimal dose determined in originating study) administered three times daily (tid)
45644805|NCT02757794|Other|computerized cognitive remediation program|a computer program online re-educating the working memory is completed by the parents and the child. The child made a series of interactive exercises accompanied by parents or a practitioner. The exercises are adapted automatically and individually to the performance at each session.
45644806|NCT02757794|Other|standard remediation|A speech therapy and / or academic support is realized.
45918664|NCT04949620|Behavioral|Online parenting program|The online parenting intervention consists of a newly developed parenting program, including rational emotive behavioral therapy and schema therapy principles
45918665|NCT05620628|Drug|Durvalumab|Durvalumab will be administered at 1500mg every 4 weeks from cycles 1 day 1.
45918666|NCT05620628|Drug|Savolitinib|Savoritinib 600mg will be administered orally a day for 28 days as one cycle.
45644807|NCT02748668|Other|Blood specimen collection|
45644808|NCT02742025|Other|Inclusion visit|This visit takes place between days -15 and -7 preceding a coronarography scheduled for Day 0. It is part of standard care and corresponds to a required cardiology consultation.
45644809|NCT02742025|Other|Nurse consultation|This visit takes place on the same day as the inclusion visit and includes practical advice concerning the hospital stay, explanations concerning the surgical act and practical advice on its implementation, information on the length of stay and after. An explanatory booklet concerning the surgical procedure is provided to the patient.
45644810|NCT02742025|Other|Telephone contact|A nurse will telephone the patient 72h to 48h before the coronarography scheduled for day 0. During the telephone conversation the nurse will assess the patient's knowledge about his/her pathology, his/her examination and the course of hospitalization. The nurse will answer any questions and if needed provide further information.
45786477|NCT02512809|Drug|Isoflurane|
45449203|NCT02155348|Device|Lentis LS-313|
45644811|NCT02742025|Procedure|Coronarography on day 0|This coronarography is scheduled as part of the patient's routine care. This is not an experimental intervention under evaluation.
45644812|NCT02730299|Drug|NiCord® (omidubicel)|
45644813|NCT02730299|Other|Cord Blood Unit|Cord blood unit
45644814|NCT02720692|Drug|N1539|
45644815|NCT02720692|Drug|Intravenous Placebo|
45786478|NCT02512809|Drug|Dexmedetomidine|
45918667|NCT04940650|Diagnostic Test|exercise testing|To define the strenuous physical exercise in this study, each participant will be asked to perform two hours of high intensity (HIT)-effort during the endurance exercise of at least 6 to 7 hours. Therefore all participants will have exercise testing approximately 1 week before the physical exercise to set aerobic and anaerobic gas exchange thresholds, as well as VO2max.
45918668|NCT04940650|Diagnostic Test|Echocardiography|Measurements of mass, volumes and function will be obtained of both the left and right ventricles at rest enabling comparisons with cardiac MRI and traditional echo measures.
45918669|NCT04935307|Diagnostic Test|MRI and paraclinical tests|The patients and controls will be evaluated using MRI and furthermore a large test battery of questionnaires and paraclinical tests. Including the following test: MCS checklist, BDS-Checklist, Symptom Checklist-92 (SCL-92), Whiteley-8, SF-36, Major Depression Inventory (MDI), GAD-10 anxiety scale, and related questionnaire, behavioral olfactory test (TDI), habituation test, pain measurement thresholds tests, Heart Rate Variability and cognitive testing.
45918670|NCT00001806|Other|Genetic Education and Counseling|Group Education and Counseling
45449204|NCT02157688|Other|no intervention : case control study|
45449205|NCT02157766|Behavioral|Intensive Meditation Practice|Long term meditators complete three days of of mindfulness or compassion/loving kindness meditation at T2 and T3 (one meditation type per visit).
45644816|NCT02713269|Procedure|Computed Tomography|Undergo CT scan
45644817|NCT02713269|Other|Quality-of-Life Assessment|Ancillary studies
45644818|NCT02713269|Other|Questionnaire Administration|Ancillary studies
45644819|NCT02713269|Radiation|Stereotactic Radiosurgery|Undergo CT-guided SSRS
45644820|NCT02713269|Procedure|Thermal Ablation Therapy|Undergo thermal ablation therapy
45644821|NCT02712151|Procedure|Abdominal Wall Block|bilateral TAP and RS blocks.
45786479|NCT03527810|Procedure|Sleeve Gastrectomy Without Interrogation of Hiatus|Weight-loss procedure to reduce the stomach.
45786480|NCT03527810|Procedure|Sleeve Gastrectomy With Interrogation of Hiatus|Weight-loss procedure to reduce the stomach with hiatal repair.
45918671|NCT00001806|Other|Genetic Education and Counseling|Individual Education and Counlseing
45449206|NCT02157766|Behavioral|Mindfulness Based Stress Reduction|8 week class designed to enhance well-being through training in mindfulness.
45449207|NCT02157766|Behavioral|Health Enhancement Program|8 week class designed to enhance well-being through training in physical activity, functional movement, music therapy and nutrition.
45786481|NCT01201772|Drug|Prasugrel|Prasugrel 10mg, 30mg, or 60mg
45786482|NCT02513121|Other|Dietary modification|The intervention is a modification of the family's habitual diet with a low sugar version of their diet.
45786483|NCT01202162|Drug|Desflurane|Administratino of Desflurane
45449208|NCT02155504|Drug|ASP3700|oral
45644822|NCT02712151|Procedure|Surgical infiltration|distributed between the 4 laparoscopic port sites.
45644823|NCT02712151|Drug|Sterile saline|Placebo injection
45644824|NCT02712151|Drug|Ropivacaine 0.2%|Ropivacaine 0.2% 1.0 ml/kg total in divided doses for bilateral TAP and RS blocks.
45786484|NCT01202162|Drug|Administration of Sevoflurane|Administration of Sevoflurane
45786485|NCT04411641|Drug|Tolebrutinib|Pharmaceutical form: Film-coated tablet Route of administration: Oral
45644825|NCT02712151|Device|Ultrasound|For nerve localization
45449209|NCT02155504|Drug|itraconazole|oral
45644826|NCT02712151|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% 0.4 ml/kg total in divided doses distributed between the 4 laparoscopic port sites
45786486|NCT04411641|Drug|Placebo to match Tolebrutinib|Pharmaceutical form: Film-coated tablet Route of administration: Oral
45449210|NCT02155504|Drug|Placebo|oral
45644827|NCT02707484|Drug|Thalidomide (100mg)|Patients were randomly assigned to receive a 120-days course of 100 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
45644828|NCT02707484|Drug|Thalidomide (50mg)|Patients were randomly assigned to receive a 120-days course of 50 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
45644829|NCT02707484|Drug|placebo|Patients were randomly assigned to receive a 120-days course of placebo (Pharmaceutical Co., Ltd. of ChangZhou, China).
45644830|NCT02703623|Drug|Abiraterone Acetate|Given PO
45644831|NCT02703623|Drug|Apalutamide|Given PO
45644832|NCT02703623|Drug|Cabazitaxel|Given IV
45786487|NCT02246972|Behavioral|Virtual Reality Exposure Therapy (VRET)|6 to 12 90-minute individual treatment sessions. During VRET sessions patients will wear a head-mounted display with stereo earphones that will provide visual and audio cues consistent with Iraqi or Afghan military scenarios or other base-related scenarios as appropriate for the individual patient.
45786488|NCT01158716|Other|Remote Ischemic Preconditioning|Patients are subjected to a 5-minute ischemia of the non-dominant arm with the use of a blood pressure cuff (inflated at 200mm Hg)
45786489|NCT04405479|Behavioral|Examination of tremor and upper hand functions|Participants will be only examined. They will not undergo any intervention.
45786490|NCT04380987|Biological|Biological sampling|For every symptomatic adult tested positive by RTqPCR, up to 45 mL of blood will be taken, nasopharyngeal and oropharyngeal swab will be performed, an induced sputum and a stool samples will be recovered at the inclusion. As follow-up, 3 weeks after inclusion, up to 45 mL of blood will be taken and a new induced sputum will be recovered.
45786491|NCT01159262|Drug|Midazolam|Per package insert, N-PASS (Neonatal Pain, Agitation, and Sedation Scale) scores and investigator discretion
45786492|NCT01159262|Drug|Fentanyl/Morphine|Per package insert, N-PASS scores and investigator discretion.
45786493|NCT01159262|Drug|Dexmedetomidine|
45786494|NCT04378959|Drug|Lidocaine patch|Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.
45786495|NCT04378959|Drug|Placebo patch|Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.
45786496|NCT03011060|Procedure|Neo-adjuvant Chemotherapy|A preoperative chemotherapy based on anthracyclines and taxanes.
45786497|NCT03011060|Drug|Capecitabine|Capecitabine 1000mg/m2 tablets twice a day for 8 cycles.
45786498|NCT03010670|Drug|Oxytocin|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
45786499|NCT03010670|Other|Placebo|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
45644833|NCT02703623|Drug|Carboplatin|Given IV
45644834|NCT02703623|Biological|Ipilimumab|Given IV
45644835|NCT02703623|Other|Laboratory Biomarker Analysis|Correlative studies
45644836|NCT02703623|Drug|Prednisone|Given PO
45644837|NCT02692664|Device|Endovascular aorto-iliac repair|
45644838|NCT02687243|Device|Interactive Virtual Application|Online application via tablet
45644839|NCT02677896|Drug|Enzalutamide|Oral
45644840|NCT02677896|Drug|Placebo|Oral
45786500|NCT03010748|Device|Scheimpflug tomography system (Pentacam) measurement|The Scheimpflug tomography system (Pentacam,Oculus GmbH, Wetzlar, Germany) is a rotating Scheimpflug camera that measures 138,000 true elevation points to compute corneal topography. Patients were asked to blink twice and then look at the fixation device. Image acquisition was a 2-second scan of 50 rotational Scheimpflug images through the corneal sighting point, the point where the ray of light from the fovea to the fixation device crossed the cornea. All measurements were performed just after a blink to minimize the effect of tear film alteration on the data. Acceptable maps had at least 10.0 mm of corneal coverage with no extrapolated data in the central 9.0 mm zone.
45786501|NCT04377711|Drug|Ciclesonide|160mcg Inhaler
45786502|NCT04377711|Drug|Placebo|Matching Placebo Inhaler
45786503|NCT03480464|Behavioral|App-technology to increase physical activity|The application will send daily reminders to register and notices with information about the health benefit of physical activity, medication, supplementary vitamins and diet after surgery
45644841|NCT02674971|Behavioral|Common components of intervention|12-week standard lifestyle intervention for obesity, which consists of weekly meetings. Each meeting will last 60 minutes, with participants attending group meetings specific for their condition. In all meetings, participants will be weighed, homework assignments will be verbally reviewed, and a behavioral lesson will be presented. Basic behavioral lessons, will be similar to those that have been successfully used in the Diabetes Prevention Program (DPP) and Look AHEAD. Topics to be covered in the meetings will focus on the dietary prescriptions and dietary information for each condition, the physical activity goal, energy balance, and behavioral strategies. Each session will conclude with reminding participants of their dietary and physical activity goals, and having participants self-monitor these behaviors every day and implement the behavioral strategies discussed in the session.
45786504|NCT04366713|Drug|Neratinib|Administered orally once daily as a single daily dose of 240 mg
45644842|NCT02659215|Device|Hyalofast|Implantation of Hyalofast scaffold with autologous bone marrow aspirate concentrate via arthroscopy/mini-arthrotomy.
45918672|NCT04922710|Behavioral|Home-based aerobic exercise|Guidelines for exercise programming (ACSM, 2018) will be followed including a warmup and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise for 60 minutes per day, three times a week, for 12 weeks. The prescribed intensity will be based on estimated heart rate reserve, calculated using resting heart rate and age-adjusted heart rate maximum (220-age in years). Participants will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.
45918673|NCT04905121|Drug|Psilocybin|Psilocybin will be provided in form of dry filled capsules and administered orally in three ascending doses
45918674|NCT00001818|Drug|Hydroxyurea|
45644843|NCT02659215|Procedure|Microfracture|Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
45918675|NCT04887805|Drug|Lenvatinib Mesylate|Given PO
45918676|NCT04887805|Biological|Pembrolizumab|Given IV
45918677|NCT05583812|Drug|FB2001 for inhalation|FB2001 once or twice daily inhalation
45918678|NCT05583812|Drug|FB2001 for inhalation placebo|FB2001 placebo once or twice daily inhalation
45918679|NCT00392314|Other|PET/CT post 2 cycles of chemotherapy|sintigraphy with PET/CT following 2 cycles of chemotherapy on day 12-14 following chemotherapy
45918680|NCT00000102|Drug|Nifedipine|
45918681|NCT04878757|Behavioral|CFI - Classwide Fraction Intervention|40 sessions (2 sessions per week; 25-31 minutes per session) of explicit fraction intervention designed to improve students understanding of fraction magnitude and fraction operations.
45918682|NCT04872127|Device|proximal embolism protection device|a proximal occlusion Mo.Ma will be used as the embolism protection device during CAS
45918683|NCT04872127|Device|distal embolism protection device|a distal SpiderFX will be used as the embolism protection device during CAS
45918684|NCT04837027|Behavioral|Aerobic training|Aerobic training on stationary bike 5x a week for 30 minutes a day
46071099|NCT04285619|Other|Positive expectation|"After heating, the physiotherapist will apply the bandage with flossing on both ankles, using 2 Voodoo Floss Bands (Power Guidance model). The distal to proximal bandage will begin with a tension of 50-70% and each lap of the bandage will cover 50% of the previous lap. There will be 3 figures of 8 that will cover the hindfoot and the distal third of the leg.~With the bandage applied on both feet, the runners will perform plantar flexion and active dorsal flexion movements in a range of complete joint movement with both ankles, at a constant rate of 2 seconds of plantar flexion, followed by another 2 of dorsal flexion, during A period of 2 minutes. Next, the therapist will remove the bandages and the athlete will walk barefoot for a minute, to restore normal blood flow.~During the first application of the bandage, the investigator will induce the positive expectation through a standardized phrase for all subjects"
45644844|NCT02656303|Biological|Ublituximab|Ublituximab IV infusion
46071100|NCT04285619|Other|Neutral expectation|"After heating, the physiotherapist will apply the bandage with flossing on both ankles, using 2 Voodoo Floss Bands (Power Guidance model). The distal to proximal bandage will begin with a tension of 50-70% and each lap of the bandage will cover 50% of the previous lap. There will be 3 figures of 8 that will cover the hindfoot and the distal third of the leg.~With the bandage applied on both feet, the runners will perform plantar flexion and active dorsal flexion movements in a range of complete joint movement with both ankles, at a constant rate of 2 seconds of plantar flexion, followed by another 2 of dorsal flexion, during A period of 2 minutes. Next, the therapist will remove the bandages and the athlete will walk barefoot for a minute, to restore normal blood flow.~During the first application of the bandage, the researcher will not induce any expectations to the athletes."
45644845|NCT02656303|Drug|Umbralisib|Umbralisib tablets
46071101|NCT00965081|Drug|Duloxetine|30 milligrams (mg) dose daily (QD) by mouth (po) at the same time each day for 12 weeks
46071102|NCT00965081|Drug|Placebo|QD po at the same time each day for 12 weeks
46071103|NCT00961649|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
45786505|NCT04366713|Drug|Capecitabine|Administered orally twice daily at 750 mg/m^2 for 14 days of each 21 day treatment cycle
46071104|NCT00961649|Drug|Brinzolamide ophthalmic suspension, 1%|
46071105|NCT00961649|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
46071106|NCT00961649|Other|Vehicle|Inactive ingredients used as placebo
46071107|NCT04267601|Drug|Anagliptin|Anagliptin treatment for 24weeks
45786506|NCT04366713|Drug|Loperamide|Administered orally for prophylaxis for 28 days and then as needed
45786507|NCT05249361|Other|no intervention|no intervention
45786508|NCT03413384|Drug|Ceftriaxone|1 g ceftriaxone per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle
45786509|NCT03413384|Other|Placebo|Placebo per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle
45918685|NCT04837027|Behavioral|Balance training|Training 5x a week for 30 minutes. Standard of care
45918686|NCT05641623|Drug|OSU6162|OSU6162
45918687|NCT05641623|Drug|Placebo|Placebo
45786510|NCT05249049|Device|e-OPRA Implant System for Transtibial Amputees|The e-OPRA System for transtibial use consists of an anchorage element (Fixture), which is surgically inserted in the medullary canal of the amputated skeleton of the lower limb. The skin penetrating e-Abutment is then inserted and secured with the e-Abutment screw. To allow the system to be used with an external neuro-mechanical prosthesis, soft tissues from the distal limb are preserved incorporated into the residual limb. Muscle electrodes are then placed in the neuro-muscular constructs. After a rehabilitation program, in everyday use, the implanted e-OPRA device will be used by the patient with the Axor TC and their commercially available prosthesis. However, the modified version of the implant will allow the patient to use a powered neuro-mechanical prosthesis during specified testing scenarios.
45644846|NCT02651662|Drug|cemiplimab|Administration via intravenous (IV) infusion. The dose(s) received will be according to dose level (DL) cohort assignment, as described in the protocol.
45644847|NCT02651662|Drug|odronextamab|Administration IV infusion. The dose(s) received will be according to DL cohort assignment, as described in the protocol.
45644848|NCT02650622|Procedure|Skin Biopsy|Skin biopsy will only be performed on the proband children in the cohort 3. A small piece of skin (less than 1/8'') will be removed using a local anesthetic cream and a punch, which will then be used for culture of skin cells and other laboratory tests on metabolic function.
45644849|NCT02646683|Drug|vedolizumab|
45644850|NCT02640586|Device|three MR examination|Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.
45918688|NCT05573672|Combination Product|Dietary Counselling combined with Omega-3 Supplementation|"Dietary Counselling: Seven, bi-weekly counselling sessions over 12-weeks conducted by a licensed Naturopathic Doctor. Each session will be 45-60 minutes in length. The recommendations will be based on the Mediterranean diet and the results of a recent scoping review which summarized the research related to diet and anxiety. The intervention will include motivational interviewing, mindful eating techniques, goal setting and action planning. A range of resources related to meal planning, recipes, cooking education, shopping lists and tracking sheets will be provided in an individualized manner.~Dietary Supplement: AquaOmega High EPA Omega-3 capsules will be taken at a dose of four capsules, once daily (containing a total of 3456 mg of omega-3 fatty acids: 2659mg of Eicosapentaenoic acid (EPA), 532mg of docosahexaenoic acid (DHA), and 800IU of Vitamin D), with a meal."
45918689|NCT04828018|Other|Coffee Morning|Coffee mornings (a maximum of n=2) will be held to raise awareness of the project and to promote participant recruitment. These will be held remotely via video conference if Covid-19 restrictions prevent in-person attendance by the researcher.
45918690|NCT04828018|Other|Recruitment Leaflets|Recruitment leaflets will be hand-delivered to all In-Pensioner residents at Royal Hospital Chelsea. Leaflets will be delivered internally by Royal Hospital Chelsea internal mail-room
45918691|NCT04828018|Other|Consent Form completion|All participants will be asked to complete Consent Forms before engaging in the study. The researcher will be available to answer any questions via phone calls if required.
45918692|NCT04828018|Other|Participant Information Sheet|All participants will receive Information Sheets which they will read in their own rooms (or elsewhere for Key Staff). The researcher will be available to answer any questions via phone calls if required.
45918693|NCT04828018|Other|New In-Pensioner Resident Information Pack|New In-Pensioner resident information packs will be distributed by a member of RHC staff as part of their 'arrivals' process and six months after residency at RHC. The researcher will be available to answer any questions via phone calls if required.
45918694|NCT04828018|Other|Key Staff Interviews|Key Staff interviews will take place with the Researcher in a private space at Royal Hospital Chelsea. If Covid-19 restrictions are in place, 'online' interviews will take place using a digital platform such as 'Skype', 'Teams' or 'Zoom'.
46071108|NCT04284917|Drug|Carglumic Acid (Carbaglu®)|"A. Study period: 24 months; treatment period: 12 months.~B. Patients will receive Carglumic Acid (Carbaglu®) 50 mg/kg/day in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and vitamin B12)~C. Patients need to regularly come back for follow up examination on Day 0, month 3, month 6, and month 12. (Check Plasma Amino Acid Analysis, Ammonia, acylcarnitine profile, Urinary organic acid analysis.)~D. Patients should report any adverse event that occur during treatment period.~E. Patients' number of emergency visits due to hyperammonemia, ammonia level, acylcarnitine, urinary organic acid analysis, plasma amino acid analysis will be recorded during treatment period."
46071109|NCT02861261|Drug|1. Berberine hydrochloride tablets ; 2. ProMetS probiotics powder|"0.6g (6 pills) of Berberine tablets administered twice a day orally before meal ;~4g (2 strips) of ProMetS probiotics powder administered orally every night"
45644851|NCT02640209|Biological|CART 19|The target dose range administered in this study is 1-5x108 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x107 CART19), 30% on Day 1 (3x107-1.5x108 CART19), 60% on Day 2 (6x107-3x108 CART19).
46071110|NCT02861261|Drug|1. Berberine placebo tablets ; 2. ProMetS probiotics powder|"6 pills of Berberine placebo tablets administered twice a day orally before meal;~4g (2 strips) of ProMetS probiotics powder administered orally every night"
45644852|NCT02628626|Drug|Colesevelam|Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
45786511|NCT03012152|Procedure|Standard conservative breast surgery|
45786512|NCT03012152|Procedure|Oncoplastic breast surgery|
45786513|NCT02976441|Radiation|Radiation therapy|
45786514|NCT02976441|Drug|Temozolomide|
45786515|NCT02976441|Procedure|Stem cell collection|
45786516|NCT02976441|Procedure|Stem cell infusion|
45786517|NCT00363753|Drug|aspirin versus clopidogrel|
45786518|NCT02434770|Biological|BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 1|Each dose of bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10^6 cell culture infectious dose 50% (CCID50)/dose and 10^5.8 CCID50/dose, respectively.
45786519|NCT02434770|Biological|BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 2|Each dose of bOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 10^6 CCID50/dose and 10^5.8 CCID50/dose, respectively.
45918695|NCT04828018|Other|In-Pensioner Resident Interviews|In-Pensioner resident interviews will take place with the Researcher in a private space at Royal Hospital Chelsea. If Covid-19 restrictions are in place, 'online' interviews will take place using a digital platform such as 'Skype', 'Teams' or 'Zoom'.
45644853|NCT02628626|Drug|Clonidine|Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
45786520|NCT02434770|Biological|BioFarma Bivalent Oral Poliomyelitis Vaccine|Each dose of the WHO prequalified Bio Farma bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10^6 and 10^5.8 infective units per dose, respectively.
45918696|NCT04828018|Other|ICECAP-A Quality of Life Questionnaire|New In-Pensioner residents and In-Pensioner residents taking part in the Qualitative Interviews will be asked to complete n=2 QoL questionnaires. New In-Pensioners will be asked to complete their QoL measures when the individual takes up residence at Royal Hospital Chelsea, the second six months later. In-Pensioner residents taking part in the interviews will be asked to complete the questionnaire at the start of the interview.
45918697|NCT04828018|Other|WHOQOL-BREF Quality of Life Questionnaire|New In-Pensioner residents and In-Pensioner residents taking part in the Qualitative Interviews will be asked to complete n=2 QoL questionnaires. New In-Pensioners will be asked to complete their QoL measures when the individual takes up residence at Royal Hospital Chelsea, the second six months later. In-Pensioner residents taking part in the interviews will be asked to complete the questionnaire at the start of the interview.
45918698|NCT04820842|Drug|TAK-994|TAK-994 tablets.
45918699|NCT04820842|Drug|Placebo|Placebo-matching tablets.
45918700|NCT05641545|Biological|IVAC|IVAC is a personalized peptide vaccine
45918701|NCT04805437|Device|3D TLSO|Brace treatment with Boston 3D 20 hours a day until skeletal maturity.
45918702|NCT04805437|Device|Standard TLSO|Brace treatment with standard Boston brace 20 hours a day until skeletal maturity.
45918703|NCT05641506|Drug|Yangzheng Xiaoji|Chinese patent medicine Yangzheng Xiaoji capsule， 0.36g*4 tid，28 days as one cycle，up to 3 cycles.
45918704|NCT05641506|Drug|Niraparib|"Niraparib 200 or 300mg* QD PO continually;~*The starting dose of niraparib was individualized based on patients' bodyweight and baseline platelet count; 200 mg QD for Patients with baseline body weight <77 kg or platelets count <150,000/μL;300 mg QD for Patients with baseline body weight ≥77 kg and platelets count ≥150,000/μL."
45918705|NCT04766710|Other|Community-based ART delivery (CAD)|The frontline workers to implement the CAD model intervention will be people living with HIV recruited from the community who will plays roles as CAWs. The CAWs will receive intensive training, coaching, and mentoring from their respective ART clinics and implementing partners' field staff on ARV dispensing, drug storage, patient's vital sign assessment and recording, HIV education and counseling, medication adherence, referral systems, mental health, stigma and discrimination, and sexual and reproductive health of people living with HIV. To closely monitor the work of the CAWs, a respective ART clinic team, consisting of an ART counselor and a physician, will be tasked to conduct regular supervision along with the program team of the implementing partners to the community groups at least once a month in the first six months. After the six months, supervisory visits will be extended to once every two months.
45918706|NCT04766710|Other|ART multi-month dispensing (MMD)|The control arm participants will receive routine services under the MMD model based on standard community-based prevention, care, and support practices in Cambodia. The NCHADS has introduced MDD in all ART sites across the country. However, so far, not all ART sites currently operate the MMD. The MMD is designed to help ART service providers implement MMD for eligible patients-that is, patients whose condition is determined to be stable-which will reduce the need for frequent visits and providers' workload. Stable people living with HIV receive care and support from counselors and ARVs at the clinics every four to six months.
45644854|NCT02628626|Other|Placebo|Placebo will be identical in appearance to the active drug.
45918707|NCT04747600|Procedure|surgical resection|surgical resection
45918708|NCT04734730|Drug|Abiraterone Acetate|Given PO
45644855|NCT02625961|Biological|Pembrolizumab|Participants receive pembrolizumab 200mg via IV infusion once every 3 weeks for up to 35 administrations
45644856|NCT02625961|Biological|Pembrolizumab/vibostolimab coformulation|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion once every 3 weeks for up to 35 administrations
45644857|NCT02625961|Biological|Favezelimab/pembrolizumab coformulation|Participants receive favezelimab/pembrolizumab (coformulation of 800mg favezelimab and 200 mg pembrolizumab) via IV infusion once every 3 weeks for up to 35 administrations
45918709|NCT04734730|Drug|Bicalutamide|Given PO
45918710|NCT04734730|Drug|Degarelix|Given SC
45786521|NCT05248971|Other|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is an evidence-based treatment method for children and adolescents who have been exposed to trauma and experience posttraumatic stress symptoms. The treatment model has a family and caregiver focus, and non-offending caregivers are included in the treatment. TF-CBT is normally provided through 8-12 treatment sessions.
45786522|NCT01203644|Drug|SKY0402|Single dose of SKY0402 administered locally into the surgical wound.
45786523|NCT01203644|Drug|Bupivacaine HCl|Single dose of bupivacaine HCl (100 mg) administered locally into the surgical wound.
45918711|NCT04734730|Drug|Goserelin Acetate|Given SC
45918712|NCT04734730|Drug|Leuprolide Acetate|Given IM
45786524|NCT00363831|Drug|Oxaliplatin|130mg/m² infusion day 1, repeat every 21 days
45786525|NCT01220726|Drug|Botox|Botox injection
45786526|NCT01220726|Drug|Placebo|Placebo injection
45786527|NCT04354077|Device|DBS of the NAc|Deep Brain Stimulation of the Nucleus Accumbens
45786528|NCT02433834|Drug|Glycopyrronium MDI|GP MDI
45786529|NCT02433834|Drug|Serevent Diskus 50 μg|
45786530|NCT02433834|Drug|Placebo|
45786531|NCT05248737|Dietary Supplement|DHA/EPA bioenhanced chicken|Chicken fed on a high DHA/EPA diet
45918713|NCT04734730|Drug|Prednisone|Given PO
45918714|NCT04734730|Other|Questionnaire Administration|Ancillary studies
45918715|NCT04734730|Drug|Talazoparib|Given PO
45918716|NCT04727710|Behavioral|Mindfulness-based Intervention|A self-directed, web-based mindfulness training. Investigators recommend one module a week for 6 weeks. Each module is approximately 1 hour long and consists of didactic components as well as meditation and mindfulness exercises.
45918717|NCT04727710|Behavioral|Usual Care|Standard pre-operative survivorship seminar, offered monthly to all patients at Michigan Medicine about to undergo prostatectomy and their partners is aimed at promoting realistic expectations of prostatectomy outcomes, typical side effects, rehabilitation and emotional adjustment.
45918718|NCT05641428|Drug|ARI-0001|Infusion with a single target dose of 2.0 x 10^6 Point of Care CAR T-cells/kg BW (range 1 -2.0x 10^6 CAR T-cells /kg BW).
45918719|NCT05641428|Drug|Axi-cel|Infusion with a single target dose of 2.0 x 10^6 Standard of Care CAR T-cells/kg BW (range 1 -2.0x 10^6 CAR T-cells /kg BW).
45644861|NCT02617797|Device|Radiofrequency|The radiofrequency is a noninvasive technique that will be applied to the external urethral meatus region.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes
45786532|NCT05248737|Dietary Supplement|25(OH)D bioenhanced chicken|Chicken fed on a high 25(OH)D diet
45786533|NCT04346745|Behavioral|Peer Mentoring Program|The Peer Mentoring Program (PMP) is a 3-month intervention to provide one-on-one mentoring support via phone calls to reduce the stress of Chinese dementia caregivers. The PMP will address the following topics: cultural beliefs about dementia and family caregiving, culturally effective coping strategies, and culturally appropriate social support.
45786534|NCT01221194|Behavioral|Standard therapy|Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.
45786535|NCT01221194|Device|PFC Stockings|A pressure and friction reducing stocking. The novelty of the PFC Sock stems from its innovative double layer structure and technological fibre composition. These simultaneously and significantly reduce both pressure and friction in a format that is practical for everyday wear with therapeutic shoes in high-risk cases.
45786536|NCT02433678|Drug|dapagliflozin|SGLT-2 inhibitor for the treatment of type 2 diabetes
45786537|NCT02433678|Drug|Placebo|
45918720|NCT04723108|Other|Destek V4 Virtual Reality Headset|The DESTEK V4 is a smartphone VR headset made by DESTEK, a manufacturer based in the US. This mobile virtual reality headset is compatible with most iOS and Android smartphones, as long as their screen size is between 4.5 and 6.
45918721|NCT04699747|Drug|F-18 3F4AP|Subjects will be injected once per imaging session (a maximum of 2 imaging sessions) with up to 10 mCi (±20%) of 18-F 3F4AP as a rapid intravenous bolus (within 1 min).
45918722|NCT04651816|Behavioral|Financial Incentives|Participants will be entered into a lottery to receive a gift card for class attendance.
45918723|NCT04651816|Behavioral|Motivational Message|Participants will be sent motivational messages through out their participation in the PSH DPP program.
45918724|NCT04651816|Behavioral|DPP Program|All Participants will be enrolled in the DPP program.
45918725|NCT05641389|Other|Monitoring|Participants will be monitored for alcohol use.
45918726|NCT05555888|Drug|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
45644862|NCT02617797|Device|Radiofrequency OFF|Will be used to put off radio frequency will be heated glycerin to occur masking for the patient.
45644863|NCT02616965|Drug|Romidepsin|Romidepsin at the dosage 10mg/m2 or 14mg/m2 will be given ONCE 14 days prior to cycle one and then on days 1,8,15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
45644864|NCT02616965|Drug|Brentuximab vedotin|Brentuximab vedotin at the dosage 0.9mg/kg or 1.2 mg/kg will be given on days 1 and 15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
45644865|NCT02613546|Behavioral|Cognitive behavioral therapy (CBT)|"The study group will undergo 10 sessions of guidelines and cognitive behavioral therapy (CBT) about an hour long, once a week. Of these:~evaluation session;~sessions of psychoeducation about the CBT model~5 sessions of cognitive restructuring 2 sessions of preventing relapse"
45644866|NCT02613546|Behavioral|Control therapy|The control group will be subjected to 10 weekly sessions (1 time per week) approximately one hour guidelines.
45786538|NCT00363909|Drug|citalopram hydrobromide|
45786539|NCT00363909|Other|placebo|
45786540|NCT01205828|Drug|Temozolomide|Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days
45918727|NCT05555888|Drug|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
45786541|NCT01205828|Drug|ABT-888|ABT-888 40 mg BID PO Days 1-7 every 28 days
45786542|NCT02433288|Other|Smart phone based patient support tool|The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.
45786543|NCT02433288|Other|Control application: only for data collection|the patients will have no access to the smart phone-based patient support tool. However, a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
45918728|NCT05555888|Drug|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
45918729|NCT05555888|Radiation|Short-course radiotherapy|Shor-course radiotherapy: 25Gy/5Fx
45918730|NCT04619680|Drug|Nintedanib|150 mg PO twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
45918731|NCT04619680|Drug|Placebo|placebo 150 mg equivalent twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
45918732|NCT04591834|Other|Observational|An observational study in subjects with the severe form of MPS II.
45918733|NCT03444324|Biological|BT524|BT524 is administered intravenously, patient specific dosage calculated based on body weight and fibrinogen level.
45918734|NCT03444324|Biological|FFP/Cryo|FFP/Cryo is administered intravenously; dosage according to local standards in mL per kg body weight.
45786544|NCT04341597|Other|cervical ultrasound|All volunteer patients for whom a cervical ultrasound is indicated will have with a first operator the performing the usual technic, and with a second operator performing the trans perineal technic without being aware of the first measurement.
45918735|NCT00386867|Drug|800 mcg misoprostol via oral or buccal administration|
45918736|NCT04733365|Other|ERIC protocol|ERIC protocol is an aerobic exercise protocol with 5 levels of intensity
46071111|NCT02861261|Drug|1. Berberine hydrochloride tablets; 2. Probiotics placebo powder|"0.6g (6 pills) of Berberine tablets administered twice a day orally before meal;~2 strips of probiotics placebo powder administered orally every night"
45786545|NCT05248347|Device|Bronchoscopy training simulator LM-092 (Koken Co., Ltd, Tokyo, Japan)|Participants who passed the theory test and was enrolled in this group will use this device to practice. After the appropriate time of practice, the test will be taken to evaluate the efficacy.
45786546|NCT05248347|Device|The BRONCH Mentor (Simbionix, GI-Bronch Mentor, USA)|Participants who passed the theory test and was enrolled in this group will use this device to practice. After the appropriate time of practice, the test will be taken to evaluate the efficacy.
45786547|NCT04333017|Device|Percutaneous radiofrequency ablation of parietal endometriosis|Treatment is carried out under local anaesthesia after surgical asepsis, in interventional radiology room. Radiofrequency needles are inserted percutaneously under ultrasound guidance. Number of needles depends on the size of lesion (1 or 2 or 3 needles). In case of proximity between lesion and peritoneum, artificial ascites can be performed. Treatment is carried out in accordance with device's instructions for use (thyroid nodules treatment algorithm), with a gradual increase in power every 5 minutes, without exceeding the maximum authorised power (depending on number and length of needles). State of coagulation is monitored under visual ultrasound control of ablation area (diffusion of Co bubbles), until a decrease in effective power is obtained. Several ablation zones are performed on the same nodule with overlapping of the different impacts. An ice pack is applied to the treated area. An analgesic PO treatment of step 1 and/or 2 is prescribed for 5 days.
45918737|NCT04560712|Procedure|Acupuncture Therapy|Undergo acupuncture
45918738|NCT04560712|Other|Best Practice|Undergo usual care
45918739|NCT04560712|Other|Questionnaire Administration|Ancillary studies
45918740|NCT03354585|Behavioral|Meditation training|A well-validated brief mindfulness-based mental training regimen [20 min/session(s)] will be used to teach patients to independently practice mindfulness. Participants will be asked to close their eyes acknowledge distracting thoughts and feelings.
45918741|NCT03354585|Behavioral|Meditatin training|A well-validated brief meditation-based mental training regimen [20 min/session(s)] will be used to teach patients to independently practice mindfulness. Participants will be asked to close their eyes acknowledge distracting thoughts and feelings.
45918742|NCT03354585|Behavioral|Book Listening Control|Study volunteers will listen to The Natural History and Antiquities of Selborne throughout the intervention.
45918743|NCT05547425|Device|Blur Obfuscation|Blurring is applied to objects and people in the background of images.
45918744|NCT05547425|Device|Edge Obfuscation|Objects and people in the background of images are replaced with an outline of the object.
45918745|NCT05547425|Device|Cartoon Obfuscation|Blurring is applied to objects and people in the background of images and the wearer's face is concealed with cartoon faces.
45918746|NCT05547425|Device|Raw images|No editing is performed on images.
46071112|NCT02861261|Drug|1. Berberine placebo tablets; 2. Probiotics placebo powder|"6 pills of Berberine placebo tablets administered twice a day orally before meal;~2 strips of probiotics placebo powder administered orally every night"
45449211|NCT03543592|Diagnostic Test|3 dimensional ultrasonography and Doppler|Three-Dimensional images will be recorded. The volumes will be generated by the automatic rotation of the mechanical transducer 360 degrees. Visualization of the endometrium and myometrium in the three planes will be done to detect endometrial cavity and any lesions. The power Doppler gate will be activated for blood flow mapping of the endometrium and endometrial-myometrial interface (sub-endometrial area). The pulsed Doppler sample volume will be activated to obtain a flow velocity waveform (FVW). Vascularization index (VI), flow index (FI) and vascularization-flow index (VFI) will be automatically calculated from three consecutive FVWs.
45449212|NCT03642717|Drug|JARDIANCE DUO®|empagliflozin and metformin
45644867|NCT02609542|Other|Eye Tracking|Eye tracker will allows the recording of various information concerning eye fixation (number, duration, location) and saccadic eye movement (speed, range, number, duration) in order to determine the interplay between linguistic and visual information processing during tests performance
45644868|NCT02595424|Drug|Capecitabine|Given PO
45644869|NCT02595424|Drug|Carboplatin|Given IV
45449213|NCT03729531|Procedure|Conventional vein harvesting technique|Long incision will be used to expose the vein, the perivascular tissue will be dissected carefully by scissors, to check for leakage, the vein will be distended by injecting saline.
45449214|NCT03729531|Procedure|no-touch vein harvesting technique|The vein will be harvested by low-frequency electrotome, about 5mm surrounding tissue will be preserved with the vein, distention should be avoided, the vein will not be cut off until being anastomosed.
45644870|NCT02595424|Drug|Cisplatin|Given IV
45644871|NCT02595424|Drug|Etoposide|Given IV
45644872|NCT02595424|Other|Laboratory Biomarker Analysis|Correlative studies
45644873|NCT02595424|Drug|Temozolomide|Given PO
45644874|NCT02588456|Biological|CART22 cells|CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB administered by IV infusion.
45644875|NCT02559609|Behavioral|Contingency management for alcohol abstinence|Participants will earn reinforcement (incentives) for each alcohol negative breath test provided (when prompted to submit a test) during the 12-week intervention period.
45644876|NCT02559609|Behavioral|Contingency management for completing job related activities|Participants will earn reinforcement (incentives) for completing specific job-related activities during the 12-week intervention period.
45644877|NCT02559609|Behavioral|Job relelated activity contracting|Participants will complete job-related activity contracts each week with the goal of obtaining employment.
45786548|NCT01206062|Drug|Intensive control of SBP|"Participants in the Intensive arm have a goal of SBP <120 mm Hg. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics~Combination products will be available, depending on cost, utility, or donations from pharmaceutical companies."
45786549|NCT01206062|Drug|Standard control of SBP|Participants in the Standard BP arm have a goal of SBP <140 mm Hg. The same medications used in the Intensive BP arm will be used for the Standard BP arm.
45918747|NCT04551664|Drug|Best medical management|All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
45918748|NCT04551664|Procedure|Endovascular therapy|In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy (recommended with Solitaire、EMBOTRAP、Trevo or Reco revascularization device) or aspiration thrombectomy (recommended with Penumbra) will be recommended as the primary treatment.
45786550|NCT02433210|Device|ELISIO-15H|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
45786551|NCT02433210|Device|Revaclear|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
45786552|NCT02433210|Device|Optiflux|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
45786553|NCT04328103|Behavioral|Cognitive Behavior Therapy (CBT)|Following established procedures at the DES at NYSPI, 12 sessions of individual manual-driven CBT (Emery, 2000) will be conducted by highly trained master degree clinicians.
45786554|NCT04328103|Behavioral|Nonspecific Supportive Therapy (PBO)|As a non-CBT intervention that includes warmth, genuineness and empathy (Linde et al., 2011), nonspecific supportive therapy (PBO) will be administered in a parallel format to CBT, also consisting of 12 individual sessions.
45918749|NCT05536310|Device|Transcatheter Aortic Valve Implantation (TAVI)|TAVI with the JenaValve Trilogy Heart Valve System
45918750|NCT04526119|Drug|Acotiamide hydrochloride hydrate|A white film-coated tablet containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase Administered orally, one tablet a time and three times a day before meals for 28 days in the open-label phase
45918751|NCT04526119|Drug|Placebo|A white film-coated tablet not containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase
45918752|NCT04487236|Drug|ZN-A-1041 50mg BID|Orally 21days for one cycle
45918753|NCT04487236|Drug|ZN-A-1041 100mg BID|Orally 21days for one cycle
45786555|NCT03010046|Drug|ANX005|Single ascending dose intravenous infusion
45918754|NCT04487236|Drug|ZN-A-1041 200mg BID|Orally 21days for one cycle
45918755|NCT04487236|Drug|ZN-A-1041 400mg BID|Orally 21days for one cycle
46071113|NCT04283435|Drug|Sildenafil Citrate|Sildenafil Citrate 50 mg tablets taken from the first day of the cycle till the day we start progesterone (we stop 3 days before embryo transfer)
45449215|NCT02766478|Drug|Genistein|Genistein is a natural supplement that comes from soy. Genistein will be taken orally (30 mg twice daily) for 12 weeks.
45918756|NCT04487236|Drug|ZN-A-1041 600mg BID|Orally 21days for one cycle
45918757|NCT04487236|Drug|ZN-A-1041 800mg BID|Orally 21days for one cycle
45918758|NCT04487236|Drug|ZN-A-1041 1000mg BID|Orally 21days for one cycle
45918759|NCT04487236|Drug|ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|ZN-A-1041 level 1 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
45918760|NCT04487236|Drug|ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|ZN-A-1041 level 2 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
45918761|NCT04487236|Drug|ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|ZN-A-1041 MAD BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
45918762|NCT04487236|Drug|ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle|Base on 1b ZN-A-1041 dose Base on 1b Capecitabine dose Base on 1b Trastuzumab dose
45918763|NCT03327714|Behavioral|Mindfulness and compassion|
45449216|NCT02766478|Drug|Placebo|A placebo pill will be taken orally for 12 weeks.
45449217|NCT03729375|Drug|10cc injection of bupivacaine|10cc intra-operative injection of bupivacaine into the carpal tunnel of the operative hand/wrist
45918764|NCT00392431|Drug|amiodarone|
46071114|NCT04283435|Other|Placebo|Placebo tablet (multivitamins),Pregnacare vitamins (Vitabiotics,UK)
45449218|NCT03729375|Drug|20cc injection of bupivacaine|20cc intra-operative injection of bupivacaine into the carpal tunnel of the operative hand/wrist
45449219|NCT02149576|Procedure|Low Dose Computed Tomography Imaging|
45449220|NCT02149576|Procedure|Chest Radiograph Imaging|
45449221|NCT03732027|Procedure|Surgical Transversus Abdominis Plane Block|At the end of operation and after hemostasis, 20 ml of 0.25% bupivacaine will be injected intra-abdominally into the Transversus Abdominis plane at the midpoint of the line connecting the crista iliaca and inferior costal margin and at two locations in the lateral abdominal wall at 3-4 cm inferior to the previous midline injection. The same procedure will be repeated on the opposite side using an identical amount of local anesthetic.
45644878|NCT02555384|Other|crowded drawing task|Marking inverted signs on a sheet where symbols are presented close to one another
45644879|NCT02555384|Other|uncrowded drawing task|Marking inverted signs on a sheet where there is a larger distance between symbols
45644880|NCT02554812|Drug|Avelumab|Anti-PD-L1 antibody
45644881|NCT02554812|Drug|Utomilumab|Anti-4-1BB antibody
45644882|NCT02554812|Drug|PF-04518600|OX40 Agonist
45644883|NCT02554812|Drug|PD 0360324|Anti-M-CSF
45644884|NCT02554812|Drug|CMP-001|TLR9 agonist
45644885|NCT02546167|Biological|CART-BCMA|
45644886|NCT02544815|Drug|Digoxin|Digoxin 0.25 mg pills
45644887|NCT02544815|Drug|Placebo|Placebo pills
45644888|NCT02531880|Drug|Mangafodipir|Patients will be imaged interictally with a gadolinium enhanced MRI session. The administration of mangafodipir will be done as an inpatient during long-term video EEG recording, to ensure administration in the peri-ictal period.
45644889|NCT02527707|Drug|lonafarnib|antiviral farnesyltransferase inhibitor
45644890|NCT02527707|Drug|Ritonavir|Cytochromes P450 3A4 inhibitor used to boost lonafarnib
45644891|NCT02521363|Device|KIBUR MICRODEVICE|This device contains 16 reservoirs, each with a unique single agent or drug combination in microdose amounts of less than one millionth of a systemic patient dose. The device is implanted directly into the tumor during a biopsy procedure, and remains in situ for ~24 hours.
45918765|NCT04463641|Device|Implantation of the Axone 4LV Lead|Implantation of the Axone 4LV Lead
45918766|NCT05641311|Drug|ALXN1840|Tablet for oral use.
45918767|NCT04452331|Other|Open Access Audio|Patient obtains secure access to an audio recording of the medical encounter post-visit that is accessible from any internet enabled device.
45786556|NCT03010046|Drug|IVIg|IVIg infusion in Cohorts 4b and 5b only. Randomized to ANX005 followed by IVIg or placebo followed by IVIg.
45918768|NCT04452331|Other|No Access, Patient and Provider Aware of Recording|Patient does not obtain access to audio recording but both patient and provider are aware visit is being recorded.
45918769|NCT04452331|Other|No Access, Provider Unaware of Recording|Patient does not obtain access to audio recording and provider is unaware visit is being recorded.
45918770|NCT02972086|Behavioral|Behavioral Parent Training (BPT)|A specific intervention modality that has been shown to improve key functional outcomes in youth with ADHD.
45918771|NCT04212169|Drug|MEDI3506|multiple doses
45644892|NCT02521363|Drug|anthracycline and taxane based chemotherapy|Conventional, standard of care neoadjuvant chemotherapy delivered irrespective of device readout
45918772|NCT04212169|Drug|Placebo|multiple doses
45918773|NCT05641272|Biological|3,000 MM09|Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 3.000 UTm/mL for sublingual immunotherapy.
45918774|NCT05641272|Biological|9,000 MM09|Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 9.000 UTm/mL for sublingual immunotherapy.
45918775|NCT05641272|Other|Placebo sublingual|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
45918776|NCT05529992|Drug|Velaglucerase Alfa|VPRIV intravenous infusion every other week for 60 minutes.
45918777|NCT04172506|Drug|AK105|Anti-PD-1 antibody
46071115|NCT04283435|Drug|Estradiol Valerate|Estradiol valerate tablets 2mg every 8 hours daily starting from the fist day of the cycle till 12th day of the menstrual cycle.
45644893|NCT02479698|Biological|Allogeneic BK-specific Cytotoxic T-lymphocytes|Given IV
45644894|NCT02479698|Other|Laboratory Biomarker Analysis|Correlative studies
45644895|NCT02470754|Device|Tobacco Cigarette|Usual brand tobacco cigarette smoked by study participant.
45644896|NCT02470754|Device|Electronic Cigarette|Usual brand electronic cigarettes smoked by study participant.
45644897|NCT02453191|Drug|Talimogene Laherparepvec|Talimogene Laherparepvec
45644898|NCT02453191|Radiation|Radiotherapy|Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
45644899|NCT02447692|Other|PSV ventilation strategy|An algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria
45786557|NCT03010046|Drug|Placebos|0.9% saline intravenous infusion
45644900|NCT02447692|Other|PAV+ ventilation strategy|An algorithm for adjusting the level of support (gain) to maintain a predefined range of respiratory muscle pressure; patients not tolerating PAV+ (Puritan Bennett™ 840 or 980 ventilator) will be switched to Assist/Control mode according to predefined criteria
45644901|NCT02446262|Behavioral|Instructions|In sub-study 1, half the participants are instructed about outcomes, half learn through experience.
45786558|NCT02515305|Drug|Clindamycin and Benzoyl Peroxide Gel (combination)|
45786559|NCT02515305|Drug|Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)|
45786560|NCT02515305|Drug|Placebo gel (combination)|
45786561|NCT01222286|Drug|IPH2101|0.2 mg/Kg or 2mg/Kg, every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
45786562|NCT01206452|Drug|Prednisone|60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure
45786563|NCT01206452|Other|Placebo|60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure
45786564|NCT01206452|Procedure|Ablation Procedure|Atrial Fibrillation (AF) ablation
45786565|NCT01206608|Drug|SKY0402 + bupivacaine HCl|Low-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
45786566|NCT01206608|Drug|Mid-dose SKY0402 + bupivacaine HCl|Mid-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
45918778|NCT04144036|Biological|Neihulizumab, 3 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
45918779|NCT04144036|Drug|Neihulizumab, 6 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
45918780|NCT04144036|Drug|Neihulizumab, 9 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
45918781|NCT04144036|Drug|Neihulizumab|This arm will receive the Maximum Tolerated Dose determined in the Drug Escalation phase.
45918782|NCT04141891|Behavioral|Driving Decision Aid|Healthwise DDA
45918783|NCT04141891|Behavioral|Older Drivers Website|National Institute on Aging (NIA) Older Drivers Website
45918784|NCT04134169|Other|Not applicable(observational study)|Not applicable(observational study)
45918785|NCT05495204|Drug|Ibalizumab|Participation in clinical trials vs. routine care in OPERA
45786567|NCT04917042|Drug|Tazemetostat|Subjects will receive 520 mg/m2/dose (subjects 12-17 years old) or 800 mg of tazemetostat orally twice daily in 28 day cycles. Subjects will receive treatment with tazemetostat up to 2 years or until disease progression or unacceptable toxicity occurs.
45918786|NCT04118374|Other|Standard Carb Diet|Approximately 50% of caloric intake will come from carbohydrate consumption.
45918787|NCT04118374|Other|Low Carb Diet|Approximately 25% of caloric intake will come from carbohydrate consumption.
45918788|NCT05641233|Radiation|Stereotactic radiotherapy|Preoperative radiotherapy delivered in a single fraction of 12 Gy focussed on 4cm pancreas at the intended (i.e. future) anastomotic site.
45918789|NCT04114942|Behavioral|Never Coach|20 weeks of didactic training and 10 weeks of internship, but no coaching.
45918790|NCT04114942|Behavioral|Internship Only Coach|20 weeks of didactic training with no coaching and 10 weeks of internship with coaching.
45644902|NCT02446262|Behavioral|Attention|In sub-study 4, participants learn about outcomes and we manipulate attention toward or away from the pain.
45918791|NCT04114942|Behavioral|Constant Coach|20 weeks of didactic training and 10 weeks of internship, with coaching throughout.
45918792|NCT00392470|Biological|cetuximab|
45918793|NCT00392470|Drug|irinotecan hydrochloride|
45918794|NCT00392470|Procedure|conventional surgery|
45918795|NCT00392470|Procedure|neoadjuvant therapy|
45918796|NCT00392470|Radiation|3-dimensional conformal radiation therapy|
45918797|NCT00392470|Radiation|intensity-modulated radiation therapy|
45918798|NCT00392509|Procedure|ALDH-br bone marrow cells vs. mononuclear bone marrow cells|Surgery
46071116|NCT03434717|Other|Individualised rehabilitation|Patients will get access/support to individualised rehabilitation based on their needs identified through the distress thermometer
45644903|NCT02446262|Behavioral|Thermal Pain|In sub-studies 2 and 3, participants are exposed to thermal stimuli and/or tastants (sugar water, salt water, neutral rinse) and we are measuring how learning varies based on the type of outcome.
45644904|NCT02446262|Behavioral|Placebo instructions|In sub-study 5, we test whether placebo effects and expectancy cues modulate pain through similar mechanisms.
45644905|NCT02446132|Drug|AVP-786|
45644906|NCT02437136|Drug|entinostat|An orally available histone deacetylases inhibitor (HDACs)
45644907|NCT02437136|Drug|pembrolizumab|A selective humanized monoclonal antibody (mAb)
45644908|NCT02422524|Drug|PA-824|Pretomanid (PA-824) is a nitroimidazooxazine. All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.
45644909|NCT02421939|Drug|gilteritinib|tablet, oral
45644910|NCT02421939|Drug|LoDAC (Low Dose Cytarabine)|subcutaneous (SC) or intravenous (IV) injection
45786568|NCT01207466|Device|Nelfilcon A investigational contact lens|Investigational, soft contact lens for astigmatism worn on a daily disposable basis.
45644911|NCT02421939|Drug|Azacitidine|SC or IV injection
45644912|NCT02421939|Drug|MEC (Mitoxantrone, Etoposide, Cytarabine)|IV injection
45786569|NCT01207466|Device|Nelfilcon A commercial contact lens|Commercially marketed, soft contact lens for astigmatism worn on a daily disposable basis.
45918799|NCT04045210|Other|Psychological Support Based on Positive Suggestions|Eligible patients will be randomized at the earliest possible time after meeting inclusion criteria. Patients will be randomized 1:1 to intervention by ICU doulas or a non-intervention arms stratified by ICU location. Both intervention and controls will receive standard medical care at the discretion of the ICU team. The intervention arm will receive PSBPS as soon as feasible and continue on a daily basis. Doulas will also liaise with family, the team, and with the nursing staff. Both intervention and standard of care arms will complete follow-up questionnaires measuring symptoms of anxiety, depression, acute stress and cognitive function after ICU discharge and at 3 months follow up by phone. All the patients randomized to the intervention arm will receive the same intervention.
45918800|NCT05478512|Drug|VenObi+Ven or VenObi+VenZan|"Patients will receive obinutuzumab 1000mg IV (cycle 1: day 1,8,15; Cycle2-6: day1) + venetoclax 400mg/d (preceded by a ramp-up phase) until cycle 9, day 28.~At cycle9:~if uMRD = Venetoclax 400 mg/d orally until cycle 13.~if residual disease in the BM or PB = Venetoclax 400 mg/d + Zanubrutinib 160 mg orally twice daily until cycle 21.~then, at cycle 21:~if uMRD = stop treatment~if residual disease in the BM or PB = zanubrutinib 160 mg orally twice daily until disease progression"
45918801|NCT05641038|Other|Peloid treatment|The patients in the first group; Peloid was applied to both feet at 42 °C for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session. Peloid was applied in a layer of approximately 1.5-2 cm thick, then the foot was wrapped in a nylon bag and covered with a towel. After 20 minutes of application, the peloid layer was removed and disposed of in medical waste. The treatment area was cleaned with soft cloths moistened with hot water and the session was ended. In addition to peloid therapy, a home exercise program including joint range of motion, stretching and strengthening exercises for the 1st MTF with 3 sets of 10 repetitions was described for the patients to do simultaneously.
45918802|NCT05641038|Other|Paraffin treatment|The patients in the second group were given paraffin treatment on both feet by dipping method, for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session. After the foot was dipped and removed 10 times, it was wrapped in a nylon bag and left for 20 minutes. Then the paraffin was peeled off the feet and disposed of in medical waste. Likewise, a home exercise program including joint range of motion, stretching and strengthening exercises for the 1st MTF with 3 sets of 10 repetitions was described for them to do simultaneously.
45918803|NCT04027777|Device|Aktiia.product-P0|The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference double auscultation BP readings. A reference-control volume clamp BP reading is recorded simultaneously.
46071117|NCT03434717|Other|Care as usual|Patients will get care as usual
46071118|NCT04284761|Combination Product|Bicalutamide implant|Biolen bicalutamide implant
46071119|NCT04265885|Other|collection of testimonies from transgender people|guided interview
45644913|NCT02421939|Drug|FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)|SC (G-CSF) and IV (Fludarabine, Cytarabine, Idarubicin) injection
45644914|NCT02386371|Procedure|tumorectomy|"Tumorectomy will be performed according to the current standards, obtaining clear margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams."
45644915|NCT02386371|Radiation|Intra Operative Radiotherapy|After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure
45786570|NCT04916496|Behavioral|Acceptance and Commitment Therapy-based lifestyle counselling programme|"The ACT-LCP Group will receive an ACT-based lifestyle counselling programme, which composes of 5-weekly group sessions (2 hours per each, 15 hours in total). Acceptance, mindfulness, values clarification skills/exercises will be used to help patients to increase self-perspective taking and willingness to experience distressing sensations, discomfort and urges while engaging in healthy lifestyle behaviours.~One month after the programme, the participant will receive one 'booster' session (2 hours), followed by 2-weekly telephone follow-up calls (20-30 minutes per call) to evaluate the effort of behavioural change."
45918804|NCT05470517|Drug|Ceftriaxone|"Ceftriaxone is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous, intramuscular, or intra-peritoneal administration.~Ceftriaxone is a white powder, which is soluble in water. In this study ceftriaxone crystalline powder will be dissolved in 0.9% sodium chloride solution prior to intra-peritoneal instillation.~Antibiotic instillation will be introduced into the RLQ/pelvis after the appendectomy is completed and all intra-peritoneal fluid is aspirated. Ceftriaxone solution will be used depending on availability and pharmacy stock for use at Johns Hopkins All Children's Hospital. The ceftriaxone powder (2g) will be dissolved in 9ml of sterile normal saline, for a total instillation volume of 10ml. This fluid will then be instilled and left to dwell in the area of the peritoneal cavity where the appendix was removed."
45918805|NCT05470517|Procedure|Intra-peritoneal Fluid Aspiration|Intra-operative aspiration of intra-peritoneal fluid after successful appendectomy.
45918806|NCT04017910|Device|EchoMark/EchoSure|Each subject will have an EchoMark implanted at the time of arteriovenous fistula creation, and undergo EchoSure and duplex imaging follow-up.
45918807|NCT03992521|Genetic|Nucleosome positioning|Stratification of patients based on nucleosome positioning from plasma DNA.
45918808|NCT05466929|Behavioral|TeACH System Resources|Patients who screen positive for anxiety will receive psychoeducation and mental health recommendations (e.g., evidence-based apps) selected for use with the TeACH System through a collaborative, stakeholder-engaged approach completed in phases 1 and 2 of this project.
45918809|NCT03960190|Device|Using Eureka Breast Pump with Expression Kit|Each subject will undergo two expression sessions for single and double electric pumping in randomized order to reduce the variation.
45918810|NCT03960151|Drug|Rolapitant|Rolapitant 180mg PO, Days 1 and 5
45644916|NCT02367924|Drug|trabectedin|The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
45644917|NCT02364726|Procedure|Acupuncture|Each treatment session will be approximately 40 minutes in duration, 10 minutes to insert needles, 30 minutes to leave needles in. Patients will receive one acupuncture treatment each week until the end of chemotherapy. Adverse effects related to the administration of acupuncture will be collected each week before and after each treatment by the acupuncturist or research study assistant. All Integrative Medicine Service acupuncturists are licensed, credentialed employees of MSK.
45644918|NCT02364726|Behavioral|Neuropathic Pain Scale (NPS) questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session before the last chemotherapy session.
45644919|NCT02364726|Behavioral|FACT/GOG-Ntx questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session but before the as the last chemotherapy session, and then once again 3 months (+/-2 weeks) after chemotherapy completion.
45918811|NCT03960151|Drug|Palonosetron|Palonosetron 0.25 mg IV, Days 1,3, and 5.
45918812|NCT03960151|Drug|Olanzapine|Olanzapine 10 mg PO PM, Days 2,3,4,5,6-8
45918813|NCT03960151|Drug|Dexamethasone|Dexamethasone 20 mg AM, Days 1,2 and 3
45918814|NCT04733326|Drug|Ketorolac Tromethamine|final rinse with non-steriodal anti-inflammatory drug or cold saline during single visit endodontic treatment
45918815|NCT05464355|Procedure|Intraoperative electroencephalography recording|Intraoperative electroencephalography measurements, a non-invasive routine monitoring device used during anaesthesia to measure the brain's electrical activity
45918816|NCT05464355|Procedure|Neurofilament light chain measurement|Measurement of the level of neurofilament light chain in a blood sample
45644920|NCT02352090|Drug|Ethinyl estradiol / dienogest|One tablet orally for 9 weeks, continuous use
45644921|NCT02352090|Drug|Estradiol valerate / dienogest|One tablet orally for 9 weeks, continuous use
45644922|NCT02352090|Drug|Dienogest|One tablet orally for 9 weeks, continuous use
45644923|NCT02294461|Drug|Enzalutamide|Oral
45918817|NCT05464355|Procedure|Tau protein measurement|Measurement of the level of tau protein in a blood sample
45918818|NCT05640921|Behavioral|Gi-CBT|Gi-CBT designed to cover relevant aspects of tackling trauma, and the CBT component will involve addressing negative thoughts, building more positive ones and building resilience.
45918819|NCT05640921|Other|Media Orientation|The MO sessions will embed media content to create awareness of the government's approaches to reintegration.
45918820|NCT03960112|Device|mpMRI|mpMRI in the detection of prostate cancer in a per patient analysis using cystoprostatectomy specimen
45644924|NCT02294461|Drug|Placebo|Oral
45644925|NCT02277522|Biological|RNA anti-CD19 CAR T cells|intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART19)
45644926|NCT02261883|Drug|IV Remodulin|Treprostinil is a chemically stable tricyclic analogue of prostacyclin.
45644927|NCT02261883|Drug|Placebo|matching placebo
45644928|NCT02226432|Procedure|- Postoperative Antagonistic Peripheral Magnetic Stimulation|"Selected patients will be treated with Selective peripheral Neurotomy followed by an standartized cycle of Selective Peripheral Magnetic Stimulation and classic post operative Kinesic Therapy.~Sham patients (n 10) will be treated with classic post operative Kinesic Therapy.~Comparision of both groups will be statistified"
45918821|NCT03959995|Other|High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT)|Ambulatory, consistently supervised group exercise training (3 training sessions of 40-45 min/week each). 10-12-week blocks of non-linearly periodized high intensity resistance and high impact aerobic dance exercises (HIT-setting) intermitted by 4-6-week periods of endurance-type exercise with high volume and lower intensity. Indi-vidualized training schedules for the RT-section.
45918822|NCT03959995|Other|Wellness|control group: 3x 10 week blocks, 1 training session/week à 45 min; stretching, light functional gymnastics, yoga with less strengthening techniques over 13 months.
45644929|NCT02226432|Device|Selective Peripheral Magnetic Stimulation|"Peripheral 1.5 tesla intensity, 10 Hz of Frequency, with eight saped bovine, of 30 minutes, aplied on antagonistic muscles, twice a week. Intensity will be infrathreshold, 80 per cent of the individual threshold (minimal amount of intensity producing always a muscle motor response in each particular patient)"
45918823|NCT00386945|Behavioral|Brief counseling (Ask, Advise, Arrange)|Providers are trained to provide Ask, Advise and Arrange (brief cessation counseling) to all tobacco using patients. A Fax-to-Quit referral to a tobacco quit line and written materials on local cessation resources and pharmacotherapy are provided.
45918824|NCT03959956|Diagnostic Test|Recording lung sound by a Smartscope|Lung sound will be recorded from four chest points by an electronic stethoscope called Smartscope which can also classify the recorded lung sound.
45918825|NCT03959917|Procedure|transurethral resection of the prostate|Surgical removal of benign prostatic tissue
45918826|NCT03959839|Procedure|ESD|Rectal Endoscopic Submucosal Dissection
45918827|NCT03959839|Procedure|TAMIS|Transanal Minimally Invasive Surgery
45918828|NCT03959839|Procedure|TEO|Transanal Endoscopic Operation
45918829|NCT00386984|Drug|Somatostatin (octreotide)|
45918830|NCT03959761|Drug|Intraperitoneal (IP) nivolumab infusion|"Patients will be treated according to three dose-levels of nivolumab, starting 5 to 7 days after surgery + Hyperthermic Intraperitoneal Chemotherapy (HIPEC), through an Intraperitoneal (IP) catheter :~Level 1 : 0.5 milligrams/kilogram (mg/kg) IP infusion, repeated every 2 weeks for 4 infusions~Level 2 : 1 mg/kg IP infusion, repeated every 2 weeks for 4 infusions~Level 3 : 3 mg/kg IP infusion, repeated every 2 weeks for 4 infusions~Level -1 : 0,3 mg/kg IP infusion, repeated every 2 weeks for 4 infusions"
45918831|NCT03959722|Dietary Supplement|Ecologic® PERFORMANCE|"Ecologic® PERFORMANCE is a probiotic formulation consisting of different probiotic bacterial strains, namely:~Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Enterococcus faecium W54 Lactobacillus acidophilus W22 Lactobacillus brevis W63 Lactococcus lactis W58~Except for the bacterial strains, Ecologic® PERFORMANCE contains the following other ingredients:~maize starch and maltodextrins~fructo-oligosaccharides (FOS) P6 and Polydextrose P4 (strain specific prebiotics)~vegetable protein~mineral mix (Potassium chloride, Magnesium sulphate, Manganese sulphate)"
45918832|NCT03959722|Dietary Supplement|Placebo|"The placebo contains no bacterial strains, but the following ingredients:~maize starch and maltodextrins~fructo-oligosaccharides (FOS) P6 and Polydextrose P4 (strain specific prebiotics)~vegetable protein~mineral mix (Potassium chloride, Magnesium sulphate, Manganese sulphate)"
45918833|NCT00387062|Device|Computer-based Cognitive Training|
45918834|NCT00392587|Drug|GW856553|
45918835|NCT03959605|Genetic|blood sample for genetic test|detection of pathogenic variants among the 19 genes known to be involved in albinism
45918836|NCT03959605|Diagnostic Test|Ophtalmological examination|measurement of visual acuity, OCT and OCTA
45918837|NCT00387101|Device|Dermal - Living Skin Replacement (Dermal - LSR)|
45918838|NCT00387140|Drug|MK2295|
45918839|NCT05640882|Other|VRET|10 week prolonged exposure protocol, using Virtual Reality for imaginal exposure
45918840|NCT05640882|Other|VRET OLFACTION|10 week prolonged exposure protocol, using Virtual Reality for imaginal exposure with the addition of olfaction
45918841|NCT03959449|Behavioral|Action Observation plus motor imagery|Action observation (video) and motor imagery of running.
45918842|NCT03959449|Behavioral|Motor imagery|Motor imagery of running
45644930|NCT02226432|Other|Kinesics|Session of classic Kinetic Rehabilitation and motor exercises, twice a week on Physicians´s office and dayly on patient´s home.
45644931|NCT02159742|Other|Data Collection|
45644932|NCT02135107|Drug|Rabeprazole|Rabeprazole 10 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
45644933|NCT02135107|Drug|Rabeprazole|Rabeprazole 20 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
45644934|NCT02135107|Drug|Rabeprazole|Rabeprazole 10 mg or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered once daily during the maintenance period (double-blind).
45644935|NCT02135107|Drug|Rabeprazole|Rabeprazole 10 or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered twice daily during the maintenance period (double-blind).
45644936|NCT02135042|Drug|Cisplatin|Given IV
45644937|NCT02135042|Other|Clinical Observation|Undergo clinical observation
45918843|NCT03959449|Behavioral|Exercise plus action Observation and motor imagery|Real exercise of running during 6 min plus action observation (video) and motor imagery of running.
45918844|NCT03959371|Drug|Ruxolitinib|"Observational study including patients with myelofibrosis being treated with ruxolitinib in a real world setting. Patients are treated according to current indications."
45918845|NCT00387179|Drug|Melatonin|5mg, pill, once
45918846|NCT00387179|Drug|Methylxanthine|2.9 mg/kg, pill, once
45918847|NCT00387179|Procedure|Light Therapy|Bright light exposure
45918848|NCT02972385|Procedure|Mouthwash sample|A one time mouthwash sample will be performed.
45918849|NCT02972385|Procedure|Blood Draw|Patients who are receiving a blood draw during their regular clinical appointment will be asked for a blood sample of 15 milliliters. Genomic DNA will be isolated for genotyping and patient plasma samples will also be stored.
45918850|NCT03959332|Drug|Baloxavir Marboxil|Participants will receive either 40 mg or 80 mg of baloxavir marboxil on Day 1 as a single oral dose.
45644938|NCT02135042|Drug|Fluorouracil|Given IV
45786571|NCT04916496|Behavioral|Healthy lifestyle talk|"The Control Group will receive one 2-hour, healthy lifestyle education talk (at least 10 patients in the talk) based on the HEARTS technical package as recommended by the WHO as routine care. This package includes a collection of evidence-based protocols which standardizes a clinical approach to promote a healthy lifestyle among adults. The Control Group will receive routine psychiatric outpatient/rehabilitation services as provided by the clinic in NDH/community centre.~One month after the talk, three weekly follow-up telephone calls (20-30 minutes) will be arranged for each patient in the Control Group to evaluate the effort of behavioural change."
45918851|NCT03959293|Drug|Durvalumab|1500 mg by 1-hour IV infusion - Every 4 weeks
45918852|NCT03959293|Drug|Tremelimumab|75 mg by 1-hour IV infusion - Every 4 weeks
45918853|NCT03959293|Drug|FOLFIRI Protocol|"Irinotecan: 180 mg/m² by 2-hour IV infusion,~Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,~5-FU bolus: 400 mg/m² by 10-minutes IV bolus,~Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
45918854|NCT05441072|Device|BulbiCam|"The multi-test device, BulbiCam (BCAM), is a combined eye tracking; pupil metric; video graphic dual device which include the following 10 tests under development and ready for validation:~26 grids glaucoma screening perimetry~64 grids full perimetry (NeuroField64)~Pupil and Relative Afferent Pupil Defect (RAPD) assessment~Semi-automatic ptosis (droopy eyelid) grading~Video-based nystagmus test~Dynamic acuity and contrast sensitivity test~Dark adaptation test~Smooth pursuit eye movements~Saccade movements~Eye fixation stability~BCAM is connected to the BulbiHub software where measured data is stored and presented in numbers, diagrams, and graphs."
46071120|NCT00632125|Drug|HX575 recombinant human erythropoietin alfa|HX575 epoetin alfa i.v. will be administered according to the SmPC
46071121|NCT00819559|Radiation|PCRT|Preoperative chemoradiotherapy
46071122|NCT00903968|Drug|Plerixafor|
46071123|NCT00903968|Drug|bortezomib|
45644939|NCT02135042|Drug|Gemcitabine Hydrochloride|Given IV
45644940|NCT02135042|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45644941|NCT02135042|Other|Laboratory Biomarker Analysis|Correlative studies
45644942|NCT02135042|Drug|Paclitaxel|Given IV
45644943|NCT02135042|Other|Quality-of-Life Assessment|Ancillary studies
46071124|NCT00903968|Drug|Dexamethasone|
46071125|NCT04220450|Diagnostic Test|T1 mapping on Cardiovascular Magnetic Resonance Studies|On clinically indicated Cardiovascular Magnetic Resonance Imaging Studies, native T1-times and extracellular volume will be determined
45644944|NCT02099058|Drug|Osimertinib|It is administered orally everyday.
45644945|NCT02099058|Drug|Nivolumab|It is an intravenous infusion administered every 14 days.
45644946|NCT02099058|Drug|Telisotuzumab vedotin|It is administered by infusion in 21-day dosing cycles.
45644947|NCT02099058|Drug|Telisotuzumab vedotin|It is administered by infusion in 28-day dosing cycles.
45786572|NCT03010436|Drug|Benralizumab|one injection 30 mg under the subjects skin every 4 weeks for 8 weeks and then every 8 weeks for 24 weeks for a total of 5 treatments.
45449222|NCT03732027|Procedure|Surgical Rectus Sheath Block|At the end of operation and after hemostasis,20 ml 0.25% bupivacaine will be administered slowly under direct vision after careful aspiration to the rectus sheath space which is present inbetween rectus abdominis muscle and the posterior layer of its sheath at the upper pole of the midline incision by time of closure of the anterior abdominal wall. The procedure will be repeated on the opposite side.
45786573|NCT02432040|Drug|Atorvastatin|Atorvastatin is a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor used to treat dyslipidemia
45786574|NCT02432040|Drug|Placebo|Placebo tablets, made to look like the interventional drug
45786575|NCT03009968|Other|Post-void residual free voiding trial|Will proceed with voiding trial and assess bladder emptying based on voided amount without checking a post-void residual.
45786576|NCT02517021|Drug|Pro-netupitant/Palonosetron|
45449223|NCT03541954|Other|Sensory testing of lower urinary tract.|Non invasive lower urinary tract sensitivity testing: provoked diuresis with sonographic estimates of sensory thresholds.
45449224|NCT03541954|Other|Sensory testing of lower rectal tract|Lower digestive tract sensitivity testing: rectal electronic barostat with ascending pressure (phasic distension).
45644948|NCT02099058|Drug|Erlotinib|It is administered orally everyday.
45644949|NCT02097706|Drug|NMDA receptor antagonist (active drug)|
45644950|NCT02097706|Other|Lactose packed capsule (inert/inactive arm)|
45644951|NCT02085148|Drug|Regorafenib (BAY73-4506)|Regorafenib will be given orally once a day, across cycles of 21 days each. During each cycle regorafenib is taken for 2 weeks followed by one week off the drug. Doses of the study drug used in this study are age-dependent and the children's dose will been adjusted based on the age and the body surface area and given either as tablets or granulate.
45644952|NCT02085148|Drug|Vincristine (Cellcristin®)|Vincristine will be given at a dose of 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg, maximum 2.0 mg) on Day 1 and Day 8 in 21-day cycles.
45786577|NCT02517021|Drug|Netupitant/Palonosetron|
45786578|NCT02517021|Drug|Dexamethasone|
45786579|NCT02981498|Procedure|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
45786580|NCT02981498|Drug|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
45786581|NCT01207934|Dietary Supplement|placebo|saline placebo
45786582|NCT01207934|Drug|low-dose leptin|30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
45786583|NCT01207934|Drug|high-dose leptin|80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
46071126|NCT00632606|Drug|magnesium sulfate|magnesium sulfate 2 grams intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
46071127|NCT00632606|Drug|metoclopramide|metoclopramide 10 mg intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
45918855|NCT03959254|Procedure|Physiotherapy post-surgical protocol for femoroacetabular impingement|"The intervention is structured in 14 weeks. Gradually the level of demand for the exercises increases over the weeks. Isometric and concentric exercises of the affected muscle groups are combined in the first weeks, as well as mobilization exercises of the joints involved in the injury. In addition, the time of permanence in a sitting, prone or supine position is prescribed. The return to the march and activities of daily life are staggered.~The number of series and repetitions to be performed is described in each exercise."
45644953|NCT02085148|Drug|Irinotecan (Irinotecan Cell pharm®)|Irinotecan will be administered at a starting dose of 50 mg/m2/day from Day 1 to Day 5, in 21 day cycles.
45644954|NCT02081378|Drug|ABL001|ABL001 will be administered orally in a dose escalation schedule.
45644955|NCT02081378|Drug|ABL001 + Nilotinib|ABL001 and Nilotinib will be administered orally in CML patients
45918856|NCT04733521|Drug|SC-43|SC-43 oral, every day of 21-day cycle
45918857|NCT04733521|Drug|Cisplatin|cisplatin 75mg/m2 on day 1 of 21-day cycle
45918858|NCT03959215|Behavioral|Back in the Game|"A six-month programme of cognitive-behavioural therapy delivered by smartphone application. The intervention commences in the first week after ACL reconstruction. The smartphone app is delivered in parallel with usual rehabilitation care.~Usual rehabilitation care: all participants will be referred to physiotherapy following ACL reconstruction. Overall treatment aims, content and progressions of rehabilitation will follow current clinical guidelines. The choice of specific therapies, exercises and the number of treatment sessions needed to achieve the treatment aims is at the clinical discretion of the treating physiotherapist."
45918859|NCT03959215|Other|Usual rehabilitation care|Following ACL reconstruction, as per routine clinical practice, all participants will be referred to physiotherapy. Overall treatment aims, content and progressions of rehabilitation will follow current clinical guidelines. The choice of specific therapies, exercises and the number of treatment sessions needed to achieve the required treatment aims is at the clinical discretion of the treating physiotherapist.
45918860|NCT05640726|Drug|PD-1|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
45918861|NCT05640726|Radiation|SCRT|Radiotherapy dose: 5×5 Gy
45918862|NCT05640726|Drug|Bevacizumab|Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 of every 2 weeks
45918863|NCT05640726|Drug|Oxaliplatin|Participants will receive Oxaliplatin，85mg/m2，day1
45644956|NCT02081378|Drug|ABL001|ABL001 will be administered orally in Ph+ ALL patients
45644957|NCT02081378|Drug|ABL001+imatinib|ABL001 and imatinib will be administered orally in CML patients
45644958|NCT02081378|Drug|ABL001+dasatinib|ABL001+dasatinib will be administered orally in CML patients
45918864|NCT05640726|Drug|Calcium folinate|Participants will receive calcium folinate ，400mg/m2，day1
45918865|NCT05640726|Drug|5-fluorouracil|Participants will receive 5-fluorouracil ，400mg/m2，day1
45918866|NCT03959176|Drug|Brimonidine|2 drops administered once in the left eye in both study arms
45918867|NCT03959176|Drug|Tropicamide|1 drop administered at two different times points in both eyes in both study arms
45918868|NCT03959176|Drug|Phenylephrine Ophthalmic Product|1 drop administered at two different time points in both eyes in both study arms
45918869|NCT05437757|Device|Surgical implantation of the PCL Breast scaffold with autologous fat grafting|Single shot of prophylactic perioperative antibiotics is given to the patient. A suitable incision is made to provide access followed by mobilisation of the breast gland.If present, the silicone implant is removed and capsulectomy performed. The implant pocket shall be rinsed with saline or antiseptic and a surgical drain shall be placed in the pocket at the discretion of the PI. The PCL Breast scaffold shall be inserted into the pocket and fixed using 2 to 4 sutures. The incision is closed. Liposuction is performed from another area of the body and lipofilling is performed within the breast scaffold. Sterile bandaging is applied and a daily wound revision is performed whilst an inpatient. A prophylactic antibiotic shall be administered to the patient.The patients shall be hospitalized overnight for clinical observation.
46071128|NCT02602574|Other|heparinized peripheral venous blood and urine sample.|All patients will be taken heparinized peripheral venous blood and urine sample
46071129|NCT02849834|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|20Hz and Theta Burst stimulation, both at 80% of motor threshold in contralateral intrinsic hand muscles. Five consecutive days of each mode of stimulation, separated by a minimum of 4 weeks. Daily self-monitoring of pain, sleep quality and fatigue by mans of a 10-item questionnaire
46071130|NCT02849912|Other|questionnaire|
45644959|NCT02039557|Genetic|NiCord®/CordIn™ (omidubicel)|
45644960|NCT02038660|Device|Balloon angioplasty|
45644961|NCT02036931|Device|Metal on Polyethylene articulation|G7 Acetabular Cup System with Metal head on Polyethylene liner articulation (MOP)
45644962|NCT02036931|Drug|Ceramic on Polyethylene articulation|G7 Acetabular Cup System with Ceramic head on Polyethylene liner articulation (COP)
45918870|NCT03959059|Device|Mixed Reality technology|combine image with real body
45918871|NCT03959020|Procedure|Anti-reflux surgery|Anti-reflux surgery for verified GERD
45918872|NCT03958981|Drug|Castor Oil|The intervention group will be given 60 mL of castor oil in 140 mL of orange juice
45918873|NCT03958981|Drug|placebo|the control group will be given a sunflower oil as a placebo with a similar texture to castor oil
45918874|NCT03958942|Other|Ultrasound quadratus lumborum block with bupivacaine 25%|echogenic needle will be inserted in-plane with the ultrasound beam in a posterior-to-anterior direction through the quadratus lumborum muscle until the ventral fascia of the muscle penetrated. At this point, the needle directed toward the fascial plan between the quadratus lumborum and the Psoas muscle
45918875|NCT03958942|Other|lumbar epideural block with bupivacaine 25%|lumbar epidural will be performed for patients in group II using a 16-gauge Touhy epidural needle by a median approach. The T12 - L1 or L1 - L2 interspaces will be chosen for the injection. The epidural space identified by the loss of resistance technique.
45918876|NCT03958864|Drug|CC-90001|CC-90001
45918877|NCT03958825|Procedure|laparoscopic hepatic sectionectomy|patients undergoing a laparoscopic left hepatic sectionectomy within an enhanced recovery after surgery programme
45918878|NCT03958825|Procedure|open left hepatic sectionectomy|patients undergoing open left hepatic sectionectomy within an enhanced recovery after surgery programme
45786584|NCT05859321|Other|Virtual reality Exercises|Virtual reality exercises along with transcutaneous electrical nerve stimulation, Heat Therapy and Stretching and strengthening exercises
45786585|NCT05859321|Other|Routine Physiotherapy|transcutaneous electrical nerve stimulation, Heat Therapy and Stretching and strengthening exercises
45918879|NCT03958786|Other|Simplified Geriatric Evaluation|"Questionnaires~Self assessment questionnaires~Mobility and balance tests"
45918880|NCT03958786|Other|Sampling|- Blood samples : 35 ml will be collected at baseline, after signature of written informed consent, 7 ml at M12
45918881|NCT03958708|Drug|Rifaximin 550 MG|Rifaximin 550 MG, TWICE A DAY, FOR 7 DAYS
45918882|NCT05640609|Combination Product|Capeox regimen combined with Sintilimab and Bevacizumab|Stage Ib：Oxaliplatin +Capecitabine Tablets +Sintilimab +Bevacizumab Stage II：Bevacizumab (the dose determined in phase Ib clinical study)，the dosage of other drugs was the same as before
45918883|NCT03958591|Drug|CSII and thereafter combination therapy, followed up with wearable devices|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Wearable devices and smart apps will be used to manage and follow-up the participants.
45918884|NCT03958591|Drug|CSII and thereafter combination therapy, followed up in traditional ways|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Traditional ways such as telephone contact will be used for follow up.
45786586|NCT05859282|Behavioral|Survey|A short 25-item tool was developed and can be applied in clinics to assess the awareness of pregnancy hypertension.
45918885|NCT03958591|Drug|Traditionally upgrading therapy, followed up in traditional ways|The participants will be applied the combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks. Traditional ways will be used for follow up.
45449225|NCT03541954|Other|Sensory testing of vulva muscles|Vulvar sensitivity testing: pressure pain threshold evaluated using vulvagesiometer.
45786587|NCT05859269|Drug|Methylprednisolone|"Patients will receive a single intraoperative dose of 10 mg intravenous dexamethasone followed with a 6-day oral methylprednisolone taper course.~Patients will also receive a standardized multimodal postoperative pain management regimen which includes nonsteroidal anti-inflammatory medication (e.g., NSAIDs) and opioid pain medications, both in the hospital and at home as part of standard care."
45918886|NCT05411861|Drug|Analgesic Non Narcotic|Injection of protocol-specified volume of local analgesic
45918887|NCT03958513|Drug|Bupivacaine|1.5 ml 0.25% bupivacaine for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
45449226|NCT03541954|Other|Sensory testing of pelvic muscles|Myofascial sensitivity testing: piriformis, levator ani and obturator internus muscles pressure pain threshold evaluated using intra-vaginal algometer.
45449227|NCT02159326|Drug|Microgynon|single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
45449228|NCT02159326|Drug|Riociguat (Adempas,BAY63-2521)|multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment
45918888|NCT03958513|Drug|0.9% normal saline|1.5 ml 0.9% NACl for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
45918889|NCT05640570|Drug|The individualized Jade Wind-Barrier Herbal Tea Bag|The individualized Jade Wind Barrier Herbal Tea Bag is composed of Astragali Radix (Zhi Huangqi) 4g, Saposhnikoviae Radix (Fangfeng) 2g, Atractylodes macrocephala Koidz (Baizhu) 2g, Nelumbinis Folium (Heye) 1g, Chrysanthemum morifolium Ramat (Juhua) 1g.
45918890|NCT03958396|Drug|Remifentanil Infusion|15 minute remifentanil Infusion of either 0.05, 0.1, 0.15 or 0.2 mcg/kg/min
45918891|NCT03958357|Device|Advanced Gynecological Applicator configuration|The Advanced Gynecological Applicator Venezia configuration is a gynaecological applicator for intracavitary and interstitial brachytherapy. The applicator consists of tubes, caps and templates to place needles, which can be combined to reach a wide range of target areas. The tubes and possibly used needles, guide the radioactive source of the afterloader to the target volume. Dose optimization and dose fractionation is performed with the goal of adapting the dose to the target volume without exceeding the dose volume constraints for the surrounding normal tissues according to the standard cervical cancer treatment of the centre.
45918892|NCT03958318|Other|Exercise plus nutritional suplementation|For 6 months, all participants in the exercise plus nutritional supplementation group will be performing a three-week non-consecutive exercises programme at the facility. All exercises will be undertaken in a large indoor room. The exercise routine will be based on the Otago exercise programme.
45918893|NCT03958318|Other|Exercise|For 6 months, all participants in the exercise group will be performing a three-week non-consecutive exercises programme at the facility. All exercises will be undertaken in a large indoor room. The exercise routine will be based on the Otago exercise programme.
46071131|NCT02849756|Other|older in intensive care unit|It is an observational study with no intervention.
45644963|NCT02036931|Device|Ceramic on Ceramic articulation|G7 Acetabular Cup System with Ceramic head on Ceramic linear articulation (COC) - Outside the United States ONLY
45644964|NCT02034526|Device|DDDR-60|DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
45644965|NCT02034526|Device|DDD-40|DDD, lower pacing rate 40 bpm, RR function off
45644966|NCT02030847|Biological|CART-19|CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 10^8 transduced CAR T cells
45644967|NCT02030847|Biological|CART-19|As of June 2014, dose was reduced to a single dose of 1-5x10^7 CART-19 cells.
45644968|NCT02030847|Biological|CART-19|In the protocol amendment in November 2014, the dose remained 1-5 x 10^7 CART-19 cells, but was revised to be administered via split dosing: 10% on Day 1, 30% on Day 2, 60% on Day 3.
45644969|NCT02030847|Biological|CART-19|In the protocol amendment in May 2015, the dose was changed to 1-5 x 10^8 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x10^7), 30% on Day 2 (3x10^7-1.5x10^8), 60% on Day 3 (6x10^7-3x10^8).
45786588|NCT05859269|Other|Standard of Care|"Patients will receive a single intraoperative dose of 10 mg intravenous dexamethasone (control group, IV dexamethasone is standard of care).~Patients will also receive a standardized multimodal postoperative pain management regimen which includes nonsteroidal anti-inflammatory medication (e.g., NSAIDs) and opioid pain medications, both in the hospital and at home as part of standard care."
46071132|NCT00903344|Drug|Vitamin D3|4000IU vitamin D3 tablet taken daily
45644970|NCT02030834|Biological|CART-19|Single infusion of CART-19 cells administered by i.v. injection (total dose of 1 - 5 x108 CART-19 cells, calculated as a range of 2-50% transduced cells in total cells).
45644971|NCT02025010|Drug|abiraterone acetate|Abiraterone acetate is a selective and irreversible inhibitor of CYP17 which has demonstrated clinical efficacy in patients with CRPC. Currently, AA is administered with concomitant prednisone.
45644972|NCT02016924|Drug|ATV|Capsules administered once daily according to dosing recommendations per product monograph
45786589|NCT05859230|Dietary Supplement|Experimental: The probiotic drink study group|The 100 ml volume of milk drink containing 10 billion Lacticaseibacillus paracasei strain Shirota is consumed once a day for 12-week intervention period, followed by a 6-week follow-up period. The intervention is double-blinded by study team members and subjects. The milk drink bottles are coded by the manufacturing company.
45786590|NCT05859230|Dietary Supplement|Placebo Comparator: The placebo drink study group|The 100 ml volume of milk drink without containing Lacticaseibacillus paracasei strain Shirota is consumed once a day for 12-week intervention period, followed by a 6-week follow-up period. The intervention is double-blinded to study team members and subjects. The milk drink bottles are coded by the manufacturing company.
45644973|NCT02016924|Drug|DRV|Tablets administered once daily according to dosing recommendations per product monograph
45786591|NCT05859217|Drug|Cabozantinib|Oral once per day, Days 1 - 21 every 21 days
45786592|NCT05859217|Drug|Atezolizumab|Intravenous (IV) once every 21 days
45786593|NCT05859204|Behavioral|OT-led Exercise Group|Participants will complete pre-intervention self-report surveys about mood, anxiety, energy, self-esteem, and activity handed out by the research team. At this point, an occupational therapist (OT) will begin 10-minute educational session that describes the purpose of the exercise intervention and methods to remain safe during the intervention such as self-monitoring techniques. Following completion of the educational session, participants will complete a 30-minute exercise intervention under the guidance of the OT, which includes warm-up, high intensity interval training cardio, strength, kick boxing, cool-down, and yoga. Following completion of the exercise regimen, participants will participate in a 10-minute discussion and reflection with the OT and complete post-intervention self-report surveys. Participants in the intervention arm will also receive routine daily occupational therapy educational sessions received by the treatment as usual arm.
45786594|NCT05859204|Behavioral|Treatment as Usual - OT Groups|Participants will complete pre-session self-report surveys about mood, anxiety, energy, self-esteem, and activity handed out by the research team. At this point, an occupational therapist (OT) will begin daily educational session about the topic of choice for that day. Treatment groups are largely discussion-based and include the following topics: coping skills, self-esteem, sleep management, leisure, time management, life skills, decision making, and goal setting. Following completion of the educational session, participants will complete post-intervention self-report surveys.
45786595|NCT05859165|Dietary Supplement|Nutren Diabetes|Product replace phase: 1-5 days, tube feeding, 25kcal/kg/day Formal intervention phase:7 days, tube feeding, 25kcal/kg/day
45786596|NCT05859165|Dietary Supplement|Fresubin Diabetes|Product replace phase: 1-5 days, tube feeding, 25kcal/kg/day Formal intervention phase:7 days, tube feeding, 25kcal/kg/day
45786597|NCT05859139|Other|DA Scaling Strategies|For this study the intervention will consist of different DA scaling strategies : 1) dissemination of an online DA; 2) dissemination of a paper-based DA; 3) online training for healthcare professionals.
45786598|NCT05859126|Dietary Supplement|Maternal Choline Supplementation 930 mg/d|Mothers were supplemented with choline (930mg/d) from second trimester through birth. This is a 13 year follow up of their offspring.
45786599|NCT05859126|Dietary Supplement|Maternal Choline Supplementation 480 mg/d|Mothers were supplemented with choline (480 mg/d) from second trimester through birth. This is a 13 year follow up of their offspring.
45786600|NCT05859113|Device|Ziacom Galaxy dental implant with internal connical prosthetic connection|Placement and restoration of a single Ziacom Galaxy dental implant with internal connical prosthetic connection
45918894|NCT03958279|Diagnostic Test|Ultrasound measurement of residual volume in the urinary bladder|Aim of this study is to asses post voiding residual volume by ultrasound scan 3th day after delivery with consecutive scan after 6 weeks, and determination of data dispersion among the population of primiparas.
45918895|NCT03958279|Diagnostic Test|Questionnaire|Simple questionaire concerning voiding problems, infectious complications, medicaments and breastfeeding during puerperium period (6weeks)
45918896|NCT05640531|Drug|WCK 771 IV Infusion|subjects will receive intravenous infusion of WCK 771
46071133|NCT00903344|Dietary Supplement|Multivitamin|Multivitamin containing 400IU vitamin D in tablet taken daily
45644974|NCT02016924|Drug|Cobicistat|Tablets administered orally once daily with food
45644975|NCT02016924|Drug|BR|Background Regimen (BR) include Food and Drug Administration (FDA)-approved nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), and emtricitabine (FTC).
45918897|NCT05640531|Other|Placebo IV Infusion|subjects will receive matching placebo intravenous infusion
45918898|NCT03958240|Other|Blood samples, tumor biopsy specimens and ascites samples will be collected.|"Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):~at Baseline.~at every surgical procedure or tumor biopsy.~every 6 months (± 2 months) (only blood sample).~at the time of the progression or recurrence, if applicable.~For patients undergoing a RT treatment, blood samples will be collected before the RT (i.e. at the time of planning CT-scan), at the last session of RT (± 2 days) and 3 months after the end of the RT (± 2 weeks)."
45918899|NCT03958162|Diagnostic Test|lung biopsy|transbronchial lung cryobiopsy
45918900|NCT03958123|Drug|100 μg cebranopadol|Encapsulated 100 μg cebranopadol tablet.
45918901|NCT03958123|Drug|200 μg cebranopadol|Encapsulated 200 μg cebranopadol tablet.
45918902|NCT03958123|Drug|400 μg cebranopadol|Encapsulated 400 μg cebranopadol tablet.
46071134|NCT02847416|Device|BreatheMAX breathing device|
46071135|NCT02849444|Other|Anti-myeloma treatment at physician discretion|non Interventional Study
45644976|NCT02016924|Drug|F/TAF|Tablets administered orally once daily
45644977|NCT02016924|Drug|LPV/r|Solution administered orally
45918903|NCT03958123|Drug|Placebo to cebranopadol encapsulated tablets|Matching placebo to cebranopadol encapsulated tablet.
45918904|NCT03958123|Drug|400 mg Moxifloxacin|Encapsulated 400 mg moxifloxacin tablet.
45918905|NCT03958123|Drug|Placebo to moxifloxacin encapsulated tablets|Matching placebo to moxifloxacin (400 mg) encapsulated tablet.
45918906|NCT05640492|Behavioral|Metacognitive Training for Depression in Later Life (MCT-Silver)|"MCT-Silver consists of eight modules, each of which begins with psychoeducational and normalizing elements. A mastery is presented through examples and exercises, and the fallibility of human cognition is discussed and illustrated. In a second phase, the pathological extremes of each cognitive bias are highlighted and the participant is shown how the exacerbation of (normal) thinking biases can lead to problems in daily life. It is intended with this exercise that participants learn how to identify and mitigate cognitive traps. Dysfunctional coping strategies (social isolation and negative thoughts) are highlighted, and suggestions for replacing them with adaptive strategies are given. Homework assignments are distributed at the end of each session (Schneider et al., 2018)."
45918907|NCT03933865|Drug|HYDROmorphone Injectable Solution|Hydromorphone will be given via intramuscular injection (8 mg)
45918908|NCT03933865|Drug|Ketamine|Ketamine will be given via intramuscular injection (0.1, 0.2 or 0.4 mg/kg)
45786601|NCT05859113|Device|Ziacom Zinic dental implant with internal hexagonal prosthetic connection|Placement and restoration of a single Ziacom Zinic dental implant with internal hexagonal prosthetic connection
45786602|NCT05859087|Behavioral|Counseling|Bedside pregnancy intention screening and family planning counseling with offer of bedside contraception initiation.
45918909|NCT03933865|Drug|Placebos|Placebo will be normal saline solution given via intramuscular injection.
45786603|NCT05859087|Behavioral|Flyer|Handing flyer to patient that discusses the importance of talking with their doctor about pregnancy intention and contraception use.
45786604|NCT05859061|Device|cryoICE® system (AtriCure, Inc) with CryoSphere (CryoS) probe|Per manufacturer instructions, the cryoprobe will be positioned under direct visualization and ablation of the intercostal nerve will be performed 2-4 cm lateral to the internal mammary artery near the mid-clavicular line. The study team plans to perform each cryoablation (-50°C to -70°C) for 120 seconds to sustain an ablation length of 2-3 cm at each intercostal nerve (bilateral T2 - T6). The probe will be removed after defrosting to avoid mechanical damage to the intercostal nerve. Cryoablation will be performed once hemostasis is achieved and prior to sternal wire placement and chest closure by a provider from the cardiac surgery team.
45786605|NCT05859035|Device|KIOS Informational App|"The KIOS informational app will contain a user interface that includes a login page, true/false questions for the user to answer, verified public domain educational information about drug and alcohol use, Likert-type questions regarding the information presented, and a closing Thank You screen."
45786606|NCT05858983|Genetic|FT-001 Low Dose|Comparison of different dosages of FT-001
45786607|NCT05858983|Genetic|FT-001 Mid Dose|Comparison of different dosages of FT-001
45786608|NCT05858983|Genetic|FT-001 High Dose|Comparison of different dosages of FT-001
45786609|NCT05858944|Drug|Intensive Home BP control|If the target home BP level is not achieved during the follow-up periods, type and dosage of antihypertensive drugs will be adjusted according to current guidelines and physician's clinical experience.
45786610|NCT05858944|Drug|Standard Home BP control|If the target home BP level is not achieved during the follow-up periods, type and dosage of antihypertensive drugs will be adjusted according to current guidelines and physician's clinical experience.
45786611|NCT05858892|Other|usual care|usual care(rehabilitation program)
45786612|NCT05858879|Other|Notification of patients and clinicians|"Notification Patients randomized to notification will receive a message sent by either the electronic health record (EHR) patient portal or US mail that will inform them of the CAC identified on their previous chest CT scan and a recommendation that they discuss this finding and initiation or intensification of lipid-lowering therapy with their clinician. The clinicians will be notified of these findings by an earlier EHR message that will be sent 2 weeks before the patient notification.~Usual Care The usual care arm will not receive any additional notification beyond this standard of care."
45786613|NCT05858866|Other|Piper Fatigue Scale|The Piper Fatigue Scale (PFS) was developed by Piper et al. to measure fatigue in a multi-dimensional manner. The scale assesses the behavioural, affective, sensory and cognitive/mood attributes of fatigue and contains 22 items and 5 open-ended questions. Each item is scored between 0 and 10 using a Visual Analogue Scale. Sub-scale scores are obtained by dividing the scores from the sub-scale items by the number of the items in the sub-scale. The same method is used to calculate the total score
45786614|NCT05858775|Device|Pregnolia System|Cervical stiffness assessment with the Pregnolia System at 3 locations on the uterine cervix.
45786615|NCT05858762|Diagnostic Test|Breast digital tomosynthesis|Introduction of an almost three-dimensional imaging technique called breast digital tomosynthesis
45786616|NCT05858736|Drug|AI-061|A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC- 392 (Anti-CTLA-4) Antibodies.
45918910|NCT03921385|Device|Augmented Reality Headset|Patients undergoing navigated cranial or spine procedures will acquire standard of care clinical high-resolution imaging to be used for registration purposes intraoperatively. VGA output on the navigation machine will be utilized to project imaging information to the augmented reality headset. The holographic image will then be recorded to assess feasibility and ease of use.
46071136|NCT02385812|Procedure|Low-dose computed tomography Annual scan x3|Annual scan x3
46071137|NCT02385812|Procedure|Low-dose computed tomography Baseline scan only|Baseline scan only
46071138|NCT02383160|Device|Bioventus Exogen 4000: Low-intensity pulsed ultrasound|Active low-intensity pulsed ultrasound
46071139|NCT02383160|Device|Sham device|Placebo device with no active therapy
46071140|NCT04466072|Diagnostic Test|Stool test for microbial analysis|Fecal samples will be analyzed by shotgun metagenomics and sample from the high ventricular arrhythmia burden will be compared with those from comparable control patients with low ventricular arrhythmia burden.
45786617|NCT05858723|Diagnostic Test|ROAT|Repeated Open Application Test
45786618|NCT05858710|Drug|DPPG2-TSL-DOX|DPPG2-TSL-DOX is a thermosensitive liposomal formulation of doxorubicin.
45786619|NCT05858697|Other|Declining participation in the Aarhus intervention|Each year a fraction of the children invited into the Aarhus intervention decline to participated.
45786620|NCT05858697|Behavioral|Participation in the Aarhus intervention|A community-based multicomponent family-centered lifestyle intervention which included visits at home and weekly supervised physical activity. The intervention has a maximum duration of one year.
45918911|NCT03878953|Drug|rhPTH(1-84)|Participants will receive a SC injection of initial dose of 50 mcg of rhPTH(1-84) once daily (QD) in the thigh (alternate thigh every day). If albumin-corrected serum calcium (ACSC; [mg/dL] = serum calcium [mg/dL] +0.8*[4-serum albumin (g/dL)]) is >2.25 mmol/L (>9.0 mg/dL), a starting dose of 25 mcg will be considered. At 4 week intervals the rhPTH(1-84) dose may be increased in 25 mcg increments to a maximal dose of 100 mcg SC QD. At any time during the study as needed for safety reasons, rhPTH(1-84) doses may be decreased in 25 mcg decrements to a minimum of 25 mcg QD. If the ACSC is >2.97 mmol/L (>11.9 mg/dL), then the investigational product should be stopped until the calcium level is corrected.
45786621|NCT05858684|Drug|GC012F injection|Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) by intravenous infusion on Day 0.
45786622|NCT05858671|Other|Fenugreek Seed Tea|Fenugreek seeds will be delivered at a dose of 5g/day, drunk as a tea (2.5g/per tea bag), p.o. twice a day at a 12-hour interval) for 8 weeks (56 days). The tea bags will be brewed in a cup (200ml) of boiled hot water for 10 minutes before drinking. This will be self-administered by the subjects, twice a day at a 12-hour interval.
45918912|NCT03877744|Behavioral|interactive virtual presence|parents will install car seat through remote guidance via interactive virtual presence
45786623|NCT05858671|Other|Black Tea|A control black tea (2.5g/bag), self-administered by the subjects, twice in a day at a 12-hour interval.
45786624|NCT05858645|Drug|deucravacitinib|Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment
45918913|NCT03877744|Behavioral|live technician|parents will install car seat through guidance from a live certified technician who is present
45918914|NCT03830671|Drug|18-month regimen containing 6 anti-TB drugs|Investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is 18 months
45918915|NCT05292326|Device|PacePress|an electronically-controlled compression site which, thanks to a well-selected compression force, may contribute significantly to preventing hemorrhagic complications following electrotherapy procedures, including to increasing safety of CIED implantation procedures and accelerate wound healing significantly
45918916|NCT05292326|Device|standard compression band|standard used compression band/sand bag
45918917|NCT03826342|Behavioral|Health Check-up for Expectant Moms|A brief intervention (one session plus two booster sessions)
46071141|NCT02847338|Drug|Amlodipine|Amlodipine 5mg and Amlodipine 10mg will be one of the treatments in which patients will receive on the monotherapy arm and on the dual therapy arm.
45644978|NCT02016924|Drug|Third Unboosted Drug|ATV (administered orally), DRV (administered orally), and LPV/r (administered orally) would be general list but unspecified for sites.
45644979|NCT02016924|Drug|Cobicistat TOS|Tablets for oral suspension
45644980|NCT02016924|Drug|F/TAF TOS|Tablets for oral suspension
45786625|NCT05858632|Drug|Guselkumab|Guselkumab treatment for ~ 9 months
45644981|NCT01983241|Biological|Alpha-1 MP|
45786626|NCT05858619|Drug|Dupilumab|dupilumab
45786627|NCT05858606|Diagnostic Test|Evaluation of the prevalence of truly (authentified) idiopathic short stature after multidisciplinary clinico-radiological evaluation|"pre-inclusion consultation~inclusion consultation~personal history~height, weight, cranial perimeters, and spans of both parents~clinical examination of the child~photographs of the child~additional X-rays"
45644982|NCT01983241|Other|0.9% Sodium Chloride for Injection, USP|
45786628|NCT05858606|Procedure|analysis in a multidisciplinary consultation meeting via a secure platform (ShareConfrère) for evaluation by multidisciplinary team|"multidisciplinary team (geneticist, orthopedist, radiologist, pediatric endocrinologist) which will assign each patient an orientation:~either to the non idiopathic short stature group (syndromic diagnostic orientation or to a constitutional bone pathology)~or to the authentified idiopathic short stature group"
45786629|NCT05858606|Genetic|Whole genome analysis for authentified idiopathic short stature|"For the first 30 patients included in the authentified idiopathic short stature group, a whole genome analysis in trio (child + parents) will be performed as part of the research.~For these 30 patients in the authentified idiopathic short stature group, the teleconsultation carried out for the submission of the multidisciplinary consultation meeting conclusions will make it possible to establish the family tree, to explain the interest and limits of the analysis, and to submit the consents dedicated to the genetic analysis."
45918918|NCT03826342|Behavioral|Time, attention, and information-matched control|We will include facts about alcohol/drug use and risky sex during pregnancy, along with informational brochures that provide face validity.
45918919|NCT03819322|Drug|sofosbuvir/velpatasvir|12 week, oral, fixed dose
45918920|NCT03806491|Behavioral|Cognitive Behavioral Therapy for Insomnia|Study therapists will follow the 2014 CBT-I in Veterans manual developed by leading researchers in the behavioral sleep medicine field. Intervention components include (1) sleep hygiene: limiting naps; avoiding caffeine, tobacco, alcohol, and rich/heavy foods before bedtime; exercising; establishing a bedtime routine; and creating a comfortable sleep environment; (2) sleep restriction: limiting time in bed in order to improve sleep efficiency, or the percentage of time in bed that is actually spent sleeping; time in bed will be titrated each week based on sleep efficiency; (3) stimulus control: strengthening association between bedroom and sleep to decrease conditioned arousal; (4) relaxation: diaphragmatic breathing, progressive muscle relaxation, and visual imagery to reduce arousal; and (5) cognitive therapy: identifying and challenging thoughts that interfere with sleep.
45644983|NCT01982448|Drug|Cisplatin|
45644984|NCT01982448|Drug|Paclitaxel|
45644985|NCT01980264|Device|Harmonic Generation Microscopy|Harmonic Generation Microscopy is a nonlinear optical microscopy.
45644986|NCT01938261|Drug|paracetamol|
45644987|NCT01938261|Drug|0.45 % saline solution|Placebo
45786630|NCT05858593|Behavioral|Virtual reality curriculum|Rather than rely on mere exposure to devices, participants in the treatment group will receive a curriculum that integrates the devices into traditional content delivered through the after school program.
45918921|NCT03806491|Behavioral|Sleep Hygiene|Study therapists will review a one-page handout on sleep hygiene with all participants. This is the only intervention that participants assigned to the sleep hygiene condition will receive. This is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
45918922|NCT03806491|Behavioral|Alcohol Use Disorder Treatment as Usual|CBT-based groups for Alcohol Use Disorder will focus on the acquisition of skills needed to cope effectively with urges and cravings to drink and manage high-risk situations.
45918923|NCT05640141|Procedure|MRI evaluation|"Multimodal MRI evaluation :~T1 structural,~Resting echo planar imaging~Diffusion-weighted imaging~Arterial sping labeling~Fluid-attenuated inversion recovery"
45918924|NCT05640141|Behavioral|Actimetry & IMU|"Evaluation of daily activities and life rythms (physical activity, inactivity, sleep) using actimeters (Motion 8), inertial sensors (GaitUP) and questionaires during 14 days :~Actimetry : evaluation of daily activity and inactivity, sleep rythms~Inertial sensors : gait evaluation during daily activities~Questionaires : sleep (Spiegel & St Mary's Hospitral) and fatigue (MFI-20)"
45786631|NCT05858593|Behavioral|No Virtual reality curriculum|Children will be able to use the same devices but will not have access to a curriculum that integrates the devices with traditional content delivered through the after school program.
45786632|NCT05858580|Behavioral|Bennett Kids PowerUP Project|Information targeting dietary and activity behaviors while also identifying and addressing barriers to permanent lifestyle change. The foundation of the curriculum is the Diabetes Prevention Program Lifestyle Balance and its subsequent adaptations for non-Native adult, Native adult, and Native child populations.
45918925|NCT05640141|Behavioral|Gait evaluation|"Evaluation of gait characteristics (spatio-temporal parameters & non-linear characteristics) in virtual environment :~Locomotor simple task : gait only in congruent environment~Locomotor dual task : gait in similar environment combined with a visually displayed Stroop task~Sensorimotor gait adaptaition : evaluation of the adaptation capability throughout a split-belt treadmill sequence (realized in simple or dual -combined with the visual Stroop task-)"
45918926|NCT05640141|Behavioral|Neuropsychological evaluation|"Complete neuropsychological examination including attentional and executive functions, learning and retrieval abilities in episodic memory and general cognitive skills :~Divided attention (TAP; test of attentional performance)~California Verbal Learning Test~The Rey-Osterrieth Complex Figure~Symbol search and coding (WAIS-IV)~Go/No-go (TAP)~Flexibility (TAP)~Original task of multimodal integration~Verbal fluencies (GREFEX)"
45918927|NCT03694561|Other|Observational|This study is a systematic investigation of the natural history of late-onset Pompe disease in infancy and childhood
45918928|NCT03641287|Other|Exercise Counseling|Meet with exercise physiology
45918929|NCT03641287|Other|Aerobic Exercise|Receive prescription for moderate aerobic exercise
45918930|NCT03641287|Other|Physiological Support|Receive motivational support via telephone care
45918931|NCT03641287|Other|Quality-of-Life Assessment|Ancillary studies
45918932|NCT03641287|Other|Questionnaire Administration|Ancillary studies
45918933|NCT03641287|Other|Best Practice|Undergo habitual level of physical activity
45918934|NCT03618784|Biological|FURESTEM-RA Inj|"The allogeneic umbilical cord blood-derived mesenchymal stem cells of each dose level as below were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.~Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump.~Dose level 1: 5.0 x 10^7 cells /body 3 repeated intravenous injection at 4 week intervals~Dose level 2: 1.0 x 10^8 cells /body 3 repeated intravenous injection at 4 week intervals"
45918935|NCT03618784|Other|sterile saline|"sterile saline 3 repeated intravenous injection at 4 week intervals~Placebo were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.~Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump."
45918936|NCT05243810|Device|EPC Silver Wound Gel|Re-application of EPC-123 will occur within 48 hours of the initial application. Secondary dressings will be selected at the discretion of the clinician or home care provider, based upon best practice guidelines for moisture management and will consist of a selection between the following secondary dressings: Mesorb® (Molnyke), Gauze, Cling (self-adherent gauze), or MediporeTM (3M). Application of EPC-123 will be executed at the Lawson Health Research Institute every second visit, where interim applications will be facilitated by home care. To support home care applications, a study kit will be provided to home care professionals inclusive of the EPC Silver Wound Gel, secondary dressings required, and instructions for removal/re-application.
45918937|NCT05239715|Diagnostic Test|Ocular biometry|Biometry using swept-source OCT Argos, swept-source OCT IOLMaster 700, swept-source OCT Anterion, PCI Pentacam AXL, OcuScan RxP and Itrace measurement
45918938|NCT05640063|Other|Enhanced Delivery and Newborn kit|Under this study enhanced delivery and newborn kits will be provided to the identified pregnant women to utilize at home or at health facility and avoid delays at facility. After the training of community and health care providers, the intervention package will be delivered in the intervention clusters primarily through the LHWs and CMWs.
45918939|NCT05238389|Device|AI-based upper limb robotic therapy|"Patients will be treated using MOTORE, a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints. The intervention will consist of 30 sessions, 1 per day and 5 per week. Therefore, each patient will be treated for 6 weeks~The parameters of the serious games will be proposed by a Decision Support System (DSS), based on an AI-based algorithm trained using data collected during a previous Randomized Controlled Trial.~The DSS will be fed, at the enrollment, with patient's demographics, clinical characteristics, clinical scales and kinematic/kinetic data measured by the robot during an evaluation session (unassisted reaching movements) and updated every 2 sessions with kinematic/kinetic data only, to tailor the treatment to the patient's current abilities.~The therapists will be free to use or not the suggested parameters, on the basis of their previous experience with the robot (over 3 years)."
45918940|NCT05206175|Other|Affect Treatment Program for Methamphetamine Use Disorder|Telemedicine based group and individual therapy, drug screens, contingency management, therapeutic app engagement, psychiatric interventions for adjuvant medications.
45918941|NCT00392743|Procedure|pet/spect scan|
45786633|NCT05858567|Drug|Envafolimab|"Drug: Envafolimab This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).~Other Names:~KN053 Drug: Oxaliplatin 130mg/m2，ivgtt，d1~Drug: Capecitabine 1000mg/m2，po，bid，d1-14~Radiation: Short-course Radiation Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.~Procedure/Surgery: Biopsy, local excision or TME surgery (total mesorectal excision) Biopsy can choose endoscopic or needle biopsy, colcal excision refers to excison of the local lession after total neoadjuvant therapy The total mesorectal excision can choose open, laparoscopic or robotic according to the specific condition of the patient."
45918942|NCT00392899|Drug|UFT adjuvant chemotherapy|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
46071142|NCT02847338|Drug|Lisinopril|"Lisinopril 10mg and Lisinopril 20mg will be one of the treatments in which patients will receive on the monotherapy arm.~Lisinopril 20mg will be one of the treatments in which patients will receive on the dual therapy arm."
46071143|NCT02847338|Drug|Amiloride|Amiloride 10mg will be one of the treatments in which patients will receive on the dual therapy arm.
45644988|NCT01932125|Drug|Bevacizumab|Participants will receive five cycles of bevacizumab 15 mg/kg concurrently with six cycles of the standard chemotherapy every three weeks (q3w), followed by extended cycles of bevacizumab 15 mg/kg q3w as a single agent for additional 16 cycles. A total of 21 cycles of bevacizumab will be administered in this study.
45786634|NCT05858528|Diagnostic Test|PEST screening questionnaire|PEST questionnaire to screen for PsA performed every 6 months
45644989|NCT01896999|Procedure|Biopsy|Undergo biopsy
45786635|NCT05858515|Drug|Baricitinib 4 MG|Nonproprietary name: Baricitinib
45786636|NCT05858502|Biological|Blood sample collection|Blood sample collection between inclusion and 3 months max 55 ml at each visit
45786637|NCT05858502|Other|Saliva sample collection|Saliva sample collection between inclusion and 3 months
45786638|NCT05858502|Other|Nasopharyngeal and nasal sample collection|Nasopharyngeal and nasal sample collection between inclusion and 3 months
45786639|NCT05858502|Other|Exhaled Breath Condensate (EBC)|Exhaled Breath Condensate (EBC) between inclusion and 3 months
45644990|NCT01896999|Procedure|Biospecimen Collection|Undergo collection of blood
45786640|NCT05858489|Other|Mini-Mental State Examination (MMSE)|Each patient will be evaluated by MMSE then by the adapted version of MMSE
45786641|NCT05858476|Other|21-Day Detox and Green Drink supplement|"Detox plan description:~7AM Water 16oz. 8AM Green Drink 16oz. 9AM Ultra Shake 16oz. 9-12PM Water 24 - 48oz. 12PM Green Drink 16oz. 12:30 - 2PM Water 24 - 48oz. 2PM Green Drink 16oz. 3PM Ultra Shake 16oz. 3:30- 6PM Water 24 - 48oz. 6PM Green Drink 16oz. 7PM Detox Soup 16oz. 7:30 - 10PM Water 24 - 48oz. This 21-day period will be followed by 7 days of consuming the Green Drink Supplement."
45786642|NCT05858437|Dietary Supplement|Sodium propionate|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
46071144|NCT02847338|Drug|Chlortalidone|Chlortalidone 25mg will be one of the treatments in which patients will receive on the dual therapy arm and monotherapy arm.
46071145|NCT02847104|Other|dynamic insulin protocol|Adaptation of insulin infusion rate according to hourly capillary blood glucose and dynamic insulin protocol
46071146|NCT02847104|Other|static insulin protocol|Adaptation of insulin infusion rate according to hourly capillary blood glucose and static insulin protocol
45644991|NCT01896999|Drug|Brentuximab Vedotin|Given IV
45644992|NCT01896999|Procedure|Computed Tomography|Undergo CT
45644993|NCT01896999|Biological|Ipilimumab|Given IV
45644994|NCT01896999|Biological|Nivolumab|Given IV
45644995|NCT01896999|Procedure|Positron Emission Tomography|Undergo PET
45786643|NCT05858437|Other|Placebo|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
45918943|NCT05190419|Drug|Orismilast modified release tablets|Orismilast modified release is a next generation PDE4 inhibitor with high selectivity for the PD4 subtypes linked to inflammation.
45918944|NCT05190419|Drug|Placebo|Matching placebo tablets
45918945|NCT05638893|Drug|Placebo Tablet|Placebo (tablet/12hr) + celecoxib (200mg/day) for three months.
45918946|NCT05638893|Drug|Metformin Hcl 500Mg Tab|Metformin (500mg/12hr) + celecoxib (200mg/day) for three months.
45644996|NCT01885299|Radiation|SRS/SBRT|Intervention varies by condition being treated.
45918947|NCT00392938|Drug|antiandrogen therapy|
45918948|NCT00392938|Drug|docetaxel|
45918949|NCT00392938|Diagnostic Test|C-11 acetate PET scan|
45918950|NCT00392938|Diagnostic Test|F-18 FDG PET scan|
45918951|NCT00392938|Diagnostic Test|Tc-99m bone scan|
45918952|NCT00392938|Diagnostic Test|CT scan of the chest, abdomen and pelvis|
45918953|NCT00392977|Dietary Supplement|remove Mn from PN if evidence of increased brain Mn on MRI|trace element cocktail will be withheld and zinc, copper and chromium added to PN individually.
45918954|NCT05637567|Drug|Acetylsalicylic acid|100 mg per os once daily
45918955|NCT05637567|Drug|Placebo|Placebo pill per os once daily
45786644|NCT05858424|Other|Multidisciplinary day hospitalization|"This multidisciplinary day hospitalization will consist at least of a psychological interview, an interview with a social worker and a medical interview. The objectives of this medical interview, conducted by a clinician researcher, are to summarize the pathology, the treatment(s) received, and to develop a personalized after-cancer plan.~The psychological interview will assess the needs for further care, and will refer the former patient if necessary.~The social interview will take stock of the former patient's return to school and/or professional life, and direct him/her to possible applications for social assistance if needed.~If needs of supportive care emerge from the history of treatment period, some consultations can be added during the day hospitalization, like an interview with a dietician or an adapted physical activity assessment."
45786645|NCT05858411|Procedure|SRP+rhPDGF|The infrabony defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of a collagen sponge soaked in rhPDGF.
45786646|NCT05858411|Procedure|SRP+collagen sponge|The infrabony defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and will be treated with the application of a collagen sponge soaked in saline solution.
45786647|NCT05858411|Procedure|SRP alone|The infrabony defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and no further treatment will be performed.
45786648|NCT05858398|Biological|pharmacokinetics blood sample assessment|pharmacokinetics blood sample assessment during the first exposure to docetaxel
45786649|NCT05858372|Dietary Supplement|Chios Mastiha essential oil|1 soft gel capsule containing 200 mg of CMO and 100 mg of other excipients being medium chain triglycerides, while the shell was made of bovine gelatin and glycerol
45786650|NCT05858372|Other|Placebo|Placebo
45786651|NCT05858359|Behavioral|ImPACT program|"During the ImPACT program, the brain cancer survivor and a carer collaborate on:~Becoming aware of the patient's core strengths and difficulties~Helping the patient to be optimally responsive to the guidance of the carer, and~Creating compensatory strategies to respond to real-world manifestations of the patient's difficulties and helping the patient implement these strategies at home."
45786652|NCT05858346|Behavioral|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and [positive] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
45786653|NCT05858346|Behavioral|Cognitive Behavioral Therapy for Social Anxiety Disorder|To provide an evidence-based comparison for the TBT condition, the research-supported psychological treatment of CBT for SAD will be used. CBT for SAD demonstrates efficacy in improving SAD symptoms and quality of life for patients with SAD, with durable improvements evidenced at follow-up assessments. CBT for SAD was used as a comparison to TBT in previous preliminary research. CBT for SAD involves several primary components, including: 1) psychoeducation, 2) training in cognitive restructuring, 3) exposures, 4) advanced cognitive restructuring, and 5) termination.
45786654|NCT05858333|Other|Extended culture for Group 2: (day 3-5 group)|To investigate thawing day three embryos and culturing them to be transferred as blastocyst that will improve pregnancy rate when compared to transfer thawed frozen blastocyst.
45786655|NCT05858320|Other|SmartHF application|Adaptive medication recommendations that can be shared with the participants HF provider.
45786656|NCT05858294|Behavioral|Cognitive Behavioral Therapy programme|This mobile application comprised CBT-based therapy for social anxiety based on the Clark and Wells model
45786657|NCT05858255|Behavioral|Exergaming|Please see Arms description.
45786658|NCT05858229|Drug|RP1|Recombinant Herpes Simplex Virus Type 1 - hGM CSF/GALV-GP-R-
45786659|NCT05858216|Drug|Chlor-Trimeton.|Package dose of Chlor-Trimeton will be administered
45449229|NCT02149654|Device|Engager Transcatheter Aortic Valve Implantation System|The Engager Transcatheter Aortic Valve Implantation System is indicated for use in patients with symptomatic severe aortic valve stenosis requiring aortic valve replacement and are at high or extreme risk for operative mortality or comorbidity judged by the heart team to pose an absolute or relative contraindication for conventional aortic valve replacement. The system is intended for use in patients with a life expectancy of at least one year following TAVI. The intended performance of the system is to provide relief of aortic valve obstruction without inducing significant regurgitation, thereby restoring effective hemodynamic function of the diseased aortic valve. The intended purpose of the system in this clinical study is in line with the intended purpose in the Instructions for Use.
45449230|NCT02149732|Biological|cultivated oral mucosal epithelial sheet transplantation|Autologous cultivated oral mucosal epithelial cell sheet transplantation using oral mucosal adult stem cells in the patients with intractable corneal limbal deficiency
45644997|NCT01851369|Drug|TRC102|TRC102 has been shown to potentiate the activity of temozolomide by preventing BER and allowing cleavage of TRC102 bound DNA, which will cause DNA strand breaks in cancer cells. We hypothesize that oral TRC102 can be safely co-administered with TMZ and would potentiate DNA damage caused by TMZ resulting in antitumor responses.
45644998|NCT01844986|Drug|Olaparib 300mg tablets|Olaparib/placebo tablets p.o 300mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
45644999|NCT01844518|Biological|Abatacept|
45645000|NCT01839838|Radiation|Proton Therapy|
45786660|NCT05858203|Other|ATAC-seq and ChIP-seq|CD138+ cells will be isolated from the bone marrow of MM patients and will be subjected to ATAC-seq and ChIP-seq analyses, by useing specific antibodies, to better understand the involvment of Che-1 in MM tumorogenesis.
45918956|NCT00393055|Dietary Supplement|xylitol|1g xylitol lozenges to be dissolved in mouth. Five lozenges daily for three years
45918957|NCT00393055|Dietary Supplement|inactive lozenge|1g inactive lozenge, dissolved in mouth. Five/day for three years
45918958|NCT05162651|Behavioral|Contingency-management|In addition to structured assessments at baseline, four, eight and twelve months, subjects randomized to the contingency-management group will receive a contingent bonus if the participants show successful abstinence at the end of weeks 4, 8 and 12.
45786661|NCT05858190|Procedure|Parallel Assignment|intervention group: treated with drug eluting balloon（paclitaxel-coated balloon； Orchid, Acotec Scientific Holdings Limited, Beijing, China)； control group :treated with plain old balloon
45918959|NCT05162651|Other|Enhanced usual care|Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve weeks.
45918960|NCT05636943|Behavioral|Adapted Intimacy Enhancement|Participants attend four virtual sessions (60-75 minutes) with a couples' coach consisting of education and skills training to enhance physical and emotional intimacy.
45918961|NCT05636943|Behavioral|Intimacy Facts and Resources|Self-guided booklet of readings/resources about intimacy and metastatic breast cancer
45918962|NCT03435484|Other|Arm A|Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants in this group will receive one version (out of two) of instructions for completing the Health Assessment Questionnaire.
45918963|NCT03435484|Other|Arm B|Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants in this group will receive another version (out of two) of instructions for completing the Health Assessment Questionnaire.
45918964|NCT05160428|Biological|COVID-19 vaccination|different types of covid-19 vaccinations.
45918965|NCT03432091|Drug|melatonin|Ramelteon RMT (RMT, Rozerem®), a novel MT1 and MT2 agonist, has been approved for treatment of insomnia, and provides a strong phase shift signal to the circadian timing system. Melatonin receptor agonists have recently become available for treatment of sleep and psychiatric disorders
45918966|NCT03426943|Biological|Arterial blood sampling|All patients will have arterial blood sampling to assess pre-filter and post-filter plasma endotoxin mass and activity and plasma cytokine levels
45918967|NCT03426943|Biological|Ultrafiltrate sampling|All patients will have ultrafiltrate sampling to assess cytokine levels
45918968|NCT03426943|Device|CVVH using oXiris™ filter|Patients included in the experimental arm will have renal replacement therapy by performing CVVH using oXiris™ filter
45918969|NCT03426943|Device|CVVH using PrismafleX HF1400 filter|Patients included in the experimental arm will have renal replacement therapy by performing CVVH using PrismafleX HF1400 filter
45918970|NCT00387218|Behavioral|Exercise, Physical therapy|
45918971|NCT05636475|Other|Manual hand massage after laparoscopic cholecystectomy surgery|Manual hand massage is applied to a group of patients at 0, 4 and 8 hours after the patient returns from laparoscopic cholecystectomy surgery. It is applied to each hand for ten minutes.
45918972|NCT05636475|Other|Machine-based hand massage after laparoscopic cholecystectomy surgery|Machine-based hand massage is applied to a group of patients at 0, 4 and 8 hours after the patient returns from laparoscopic cholecystectomy surgery. It is applied to each hand for ten minutes.
45918973|NCT05155163|Behavioral|SC-POWR|Patients assigned to SC-POWR receive 12 Cognitive Behavioral Therapy (CBT) sessions over 24 weeks.
45918974|NCT03339505|Dietary Supplement|Salovum|Dietary supplement with high concentration of anti-secretory factor
45918975|NCT03339505|Dietary Supplement|Placebo|Placebo for Salovum
45918976|NCT05636085|Device|Mainz Biomed Colorectal Cancer Screening Test|There is no intervention.
45918977|NCT03216421|Other|Quality of Life Questionnaires|Quality of Life questionnaires will be completed by each subject.
45645001|NCT01837602|Biological|cMet RNA CAR T cells|
45449231|NCT02255266|Drug|liraglutide|No treatment given.
45449232|NCT02766400|Behavioral|Guided Training|
45645002|NCT01815749|Biological|autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
45645003|NCT01815749|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation
45645004|NCT01815749|Other|laboratory biomarker analysis|Correlative studies
45786662|NCT05858177|Drug|Temozolomide capsule|Temozolomide was given orally per day for 5 days, every 28 days until disease progression or intolerable toxicities.
45786663|NCT05858138|Other|Jing-Si Herbal Tea|patient will receive twice in a day for 24 weeks
45786664|NCT05858138|Other|Placebo Jing-Si Herbal Tea|Placebo Jing-Si Herbal Tea
45786665|NCT05858112|Diagnostic Test|SuperTROPO novel assay to measure the long forms of cTnT|SuperTROPO novel assay to measure the long forms of cTnT
45449233|NCT02766400|Behavioral|Directed Training|
45449234|NCT00104650|Genetic|AMG 162 180 mg (SC) q 12 weeks|A 180 mg AMG 162 (SC) administered every 12 weeks for 2 doses (Day 1 and wk 13) in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 12 weeks for 9 doses.
45645005|NCT01809041|Drug|Sevoflurane|
45645006|NCT01809041|Drug|propofol|
45645007|NCT01809041|Drug|remifentanil|
45786666|NCT05858086|Other|Novel same-day discharge protocol after total joint arthroplasty|Preoperative gait/stair training with physical therapy, then postoperative ambulation with nursing after total joint arthroplasty
45786667|NCT05858086|Other|Conventional postoperative physical therapy clearance|Physical therapy evaluation and clearance after total joint arthroplasty
45786668|NCT05858047|Drug|Placebo|Administered orally, once daily (QD)
45786669|NCT05858047|Drug|SYHX1901|Administered orally, once daily (QD)
45918978|NCT05154578|Biological|GBS-NN/NN2 Vaccine|0.5 mL GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS-NN2 and 0.5 mg of aluminium, given by intramuscular injection.
45918979|NCT05154578|Biological|Placebo|0.5 mL normal saline given by intramuscular injection
45918980|NCT05635188|Procedure|Intestinal ostomy confection|Surgical procedure for fecal diverting
45918981|NCT03152305|Other|Intracranial pressure variations|Self-measure of ICP will be performed outside and during menstrual migraine attacks.
45918982|NCT03152266|Other|No intervention. Observational study|Follow up of the function of the hip after reduction of the impacted fragment which associated with acetabular fractures
45918983|NCT05012930|Other|Baby Foods - Meat|Commercially available baby foods
45918984|NCT05012930|Other|Baby Foods - Dairy|Commercially available baby foods
45918985|NCT05012930|Other|Baby Foods - Plant|Commercially available baby foods
45918986|NCT05012930|Other|Foods from the home|Caregiver will provide participant with usual foods from the home
45449235|NCT00104650|Drug|IV Bisphosphonate q 4 weeks|IV Bisphosphonate (eg pamidronate or zoledronic acid) every 4 weeks for 6 doses as described by package insert during the treatment phase. If enrolled to the extension phase, subject will be assigned to the AMG 162 180mg (SC) every 4 weeks for 26 doses.
45449236|NCT00104650|Genetic|AMG 162- 180 mg q 4 weeks|A 180 mg AMG 162 (SC) administered every 4 weeks for 6 doses in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 4 weeks for 26 doses.
45918987|NCT05634564|Drug|Tislelizumab|Tislelizumab 200mg administered intravenously on Days 1 of every 3 weeks.
45918988|NCT05634564|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 administered intravenously on Days 1 & 8 of every 3 weeks.
45918989|NCT05634564|Drug|Nab paclitaxel|Gemcitabine 125 mg/m^2 administered intravenously on Days 1 & 8 of every 3 weeks.
45918990|NCT05634564|Radiation|Hypofractionated radiotherapy with simultaneous integrated boost|Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy*10 fractions, Planning target volume (PTV) 3Gy*10 fractions.
45918991|NCT03152227|Other|ACGG|50 high-producing chicks to households along with provision of technical input on production
45918992|NCT03152227|Behavioral|BCC|Nutrition sensitive BCC on poultry-specific aspects of nutrition, WASH, women's empowerment, and use of income combined with home gardening.
45918993|NCT03152188|Drug|FMT|Fifteen FMT Openbiome capsules administered at the same time
45786670|NCT05858021|Diagnostic Test|Physical examination|"Per participant, two colorectal surgeons, will separately and consecutively each perform disease assessment in accordance with the 'usual' clinical approach (direct visualisation with 'naked eye') with the exception that for each lesion identified they will undertake a series of measurements, obtain photographs of each lesion and record their findings on the proforma provided.~Once all lesions identified have been recorded diagrammatically and photographically, EP and PM will confer and collate lesions of suspicion for biopsy. All lesions suspicious for aHSIL will be biopsied/excised in keeping with usual care.~During the study period we anticipate HRA to become available within the LTHTR and incorporated into usual care for the clinical assessment of patients with aHSIL. HRA will be used in addition to direct visualisation such that 'usual care' comprises clinical assessment with direct visualisation and HRA."
45786671|NCT05857995|Behavioral|Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program|KLCLCSC is a survivor or survivor plus caregiver-focused psychosocial and behavioral intervention designed to engage lung cancer survivors and improve lung cancer outcomes.
45918994|NCT03152188|Other|Placebo|Fifteen placebo capsules administered at the same time
45918995|NCT03152149|Drug|Tiotropium & olodaterol|Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months
45918996|NCT03152149|Drug|fluticasone furoate & vilanterol|Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
45918997|NCT03152071|Procedure|Robot assited thoracic surgery|The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is robot assisted thoracic surgery
45918998|NCT03152071|Procedure|Video assited thoracic surgery|The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is video assisted thoracic surgery.
45918999|NCT04999826|Procedure|Biospecimen Collection|Undergo biospecimen collection
45786672|NCT05857995|Behavioral|Enhanced Usual Care|EUC involves a combination of the standard of care plus a bibliotherapy intervention and assessment.
45919000|NCT04999826|Other|Quality-of-Life Assessment|Ancillary studies
45786673|NCT05857982|Drug|Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab|Dexamethasone 20 mg/d, on the same day of daratumumab injection; Mitoxantrone hydrochloride liposome injection: 20 mg/m2, d1; Daratumumab: 16 mg/Kg, once a week for the first 8 weeks; then changed to once every two weeks; Each cycle is 4 weeks long and the maximum number of cycles is 6.
45919001|NCT04999826|Other|Questionnaire Administration|Complete questionnaires
45919002|NCT03152032|Behavioral|In-House Vocational Training Programs|At the beginning of the IHVT programs, the job placement for each participant was determined jointly by the participant's interest, the demands of local job markets and the team evaluation. The programs covered 6 to 10 months in length, 5 days a week and 4 to 6 hours a day. The programs contained three sessions: (a) the work-related behavior training session, such as proper appearance, communication and self assertion, and workplace social skills, (b) the on-the-job skill training session where participants gained job-specific training and interventions from job coaches and occupational therapists, and (c) the life balance counseling session including individual and group counseling that aimed to enhance the participants' ability to tackle potential hardships and barriers to work.
45449237|NCT02157922|Drug|alginate oligosaccharide|Inhalation
45449238|NCT02158078|Device|PaQ® Insulin Delivery Device|PaQ is a 3 day insulin delivery device. Utilizes U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
45449239|NCT02158156|Behavioral|Exercise|Ten weeks of home-training on a cycle ergometer 3 times a week for 30 minutes.
45449240|NCT03732807|Drug|PF-06651600 Induction Dose|Oral tablets taken once daily (QD)
45919003|NCT03151993|Drug|Recombinant staphylokinase|10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
45919004|NCT03151993|Drug|Alteplase|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
45919005|NCT05633472|Other|Vitamin D|Vitamin D (2000IU/day) for 6 months
45919006|NCT05633472|Other|Placebo|Placebo
45919007|NCT04996238|Procedure|Blood and nasal fluid sampling before and after COVID-19 vaccination|Blood and nasal fluid sampling take place just before the first COVID-19 vaccination and at 14-30 days after the second dose with the same vaccine. Sampling will be repeated at 6 months after the second vaccination, at 14-30 days after the third vaccination and at 6 months after the third vaccination. At all moments, a questionnaire is filled in.
45919008|NCT03151954|Procedure|functional endonasal sinus surgery|collect nasal polyps from patients
45919009|NCT03151954|Procedure|nasal septal construction|collect inferior turbinates from patients as control arm
45919010|NCT03151876|Drug|Chidamide|30 mg oral twice weekly for 2 weeks
45919011|NCT03151876|Drug|Cladribine|6 mg/m2 intravenously daily for 5 days
45919012|NCT03151876|Drug|gemcitabine|2500 mg/m2 intravenously twice weekly for 1 week
45919013|NCT03151876|Drug|Busulfan|3.2 mg/kg intravenously daily for 4 days
45919014|NCT03151876|Procedure|Autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
45919015|NCT04984655|Device|30-minute Virtual Reality (VR) Experience delivered through Oculus Quest 2 VR headset|All participants will go through the same intervention described above
45786674|NCT05857956|Other|Proper Wild energy shot|100% plant-based energy shot containing natural caffeine, L-Theanine, purified water, pineapple juice concentrate, natural flavors, kiwi juice concentrate, organic lemon juice concentrate, organic strawberry juice concentrate, monk fruit juice concentrate, pink himalayan sea salt.
45919016|NCT03151837|Dietary Supplement|Greenyn Momordica charantia extracts|Extracts from Momordica charantia containing Momordica charantia insulin receptor binding protein (mcIRBP)
45919017|NCT03151837|Dietary Supplement|Placebo control|Starch
45919018|NCT03151759|Radiation|Neoadjuvant radiotherapy|Neoadjuvant radiotherapy prior to rectal cancer surgery
45919019|NCT03151720|Drug|loratadine (Xisimin [Test Treatment])|Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
45919020|NCT03151720|Drug|loratadine (Clarityne [Reference Treatment])|Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
45919021|NCT00387257|Drug|Rilapladib (SB-659032)|
45919022|NCT03151642|Radiation|Chemotherapy|Patients will have their chemotherapy coordinated through the Medical Oncology department at the University of Pennsylvania, and will be followed by Medical Oncology at Penn during chemoradiation. As part of the standard of care for locally advanced esophageal cancer, neoadjuvant concurrent chemotherapy will likely consist of weekly carboplatin and paclitaxel, beginning within 1 day of starting radiation therapy and continuing until the completion of radiation treatment. Alternative chemotherapy regimens, dose adjustments or delays in administration will be determined at the discretion of the treating medical oncologist and recorded in the patient's chart.
45919023|NCT03151642|Radiation|Radiation Therapy|Patients will have their radiation therapy coordinated and performed through the Radiation Oncology Department at the University of Pennsylvania. The development and delivery of the patient's radiation treatment plan will be at the discretion of the treating radiation oncologist, and details will be recorded in the patient's chart.
45786675|NCT05857943|Device|AEYE-DS Software|Eligible participants will undergo the following procedures: Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis. -Additional photographic and OCT images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis. -All study subjects will have their pupils dilated using dilation drops.
45919024|NCT03151642|Procedure|Surgery|Patients will have their surgery coordinated and performed through Thoracic Surgery department at the University of Pennsylvania. Patients will undergo esophagectomy 4-8 weeks after the completion of neoadjuvant chemoradiation as part of the standard of care.
45919025|NCT03151642|Device|MRI Imaging|A total of 40 paired MRI examinations from eligible participants will be collected in the Department of Radiology at the Hospital of the University of Pennsylvania. Participants will undergo two 1.5T MRI studies performed at two time points: (1) within 28 days prior to starting neoadjuvant chemoradiation, and (2) between radiation fraction 8-13 during treatment. The quantitative imaging studies for the trial (DWI) will be performed with and without respiratory gating using a navigator, with B values of 0, 100, 600 and 800 s/mm2.
45449241|NCT03732807|Drug|PF-06651600 Maintenance Dose #1|Oral tablets taken QD
45786676|NCT05857917|Device|Virtual Reality|Virtual reality in PD catheter insertion surgery in the pre- and intraoperative setting.
45919026|NCT03151642|Other|Blood Draws|The procedure of blood collection for each patient will be as follows: the total amount being drawn each time will be approximately 30 cc. Approximately 25 ml of blood will be collected into heparinized tubes, and immediately placed on ice in a prepared plastic bag and transported to the laboratory for processing within 1 hour. If necessary, we may need up to 2 hours in order to begin processing the blood; in the event that longer than this time period has transpired, the sample will be deemed inadequate for processing purposes. The first blood draw will be obtained prior to the first fraction of radiation treatment and will be coordinated to occur at the time of pre-treatment MRI. Thereafter, the second sample will be obtained during chemoradiation therapy, between fraction 8-13 and the blood draw will be coordinated with the on-treatment MRI scan.
45919027|NCT03151603|Drug|Arctuvan|application of a herbal drug
45919028|NCT03151603|Drug|Fosfomycin|application of an antibiotic drug
45449242|NCT03732807|Drug|PF-06651600 Maintenance Dose #2|Oral tablets taken QD
45449243|NCT03732807|Drug|PF-06651600 Maintenance Dose #3|Oral tablets taken QD
45449244|NCT03732807|Drug|Placebo|Oral tablets taken QD
45786677|NCT05857904|Device|CT-FFR|CT -FFR(coronary computed tomography angiography drived fractional flow reserve derived) uses routine coronary computed tomography angiography (CTA) images and applies a specific algorithm to extract both anatomical and physiological information of the coronary arteries. By combining these two pieces of information, a fluid dynamics model of the coronary arteries can be established, allowing the calculation of FFR at any location of the coronary arteries.
45919029|NCT03151603|Drug|Placebo to Arctuvan|application of Placebo to Arctuvan
45919030|NCT03151603|Drug|Placebo to Fosfomycin|application of Placebo to Fosfomycin
45919031|NCT00387296|Device|functional microarray|functional microarray application
45449245|NCT00104416|Drug|lamotrigine (LAMICTAL) extended-release|Primary experimental dosage form
45449246|NCT00104416|Drug|Placebo|Placebo control
45449247|NCT02158312|Device|Magstim Eldith DC-stimulator(Magstim Co., Whitland, UK)|2 mA for 20 minutes transcranial direct current stimulation
45449248|NCT02159638|Device|Guardian Enlite sensor|Sensor insertion
45449249|NCT02159638|Device|Dexcom G4 platinum sensor|Sensor insertion
45449250|NCT03732729|Device|massage chair|Patient should use massage chair, twice per day, for 30minutes
45449251|NCT04817254|Drug|TMZ|150 mg/m2 on days 1-5 of cycles 1-6
45449252|NCT04817254|Drug|ipilimumab 3mg/kg|3 mg/kg q 4 weeks for cycles 1-4
45645008|NCT01805466|Device|EVADO|EVADO (Extracorporeal Vacuum-Assisted Device Optimized) device enables separation of cardiotomy suction blood, which is stored in a separate reservoir, and, if re-infusion into the CPB circuit is required, this is performed only after selective filtering and by cell saver procedures. Moreover, by using a vacuum-assisted system for blood aspiration, EVADO allows complete elimination of roller pumps, therefore reducing the extent of mechanical cellular trauma. EVADO contains a phosphorylcholine-coated oxygenator, that confers superior biocompatibility. Finally, by requiring relatively limited priming volumes, it allows reducing haemodilution.
45919032|NCT03151564|Diagnostic Test|Computed Tomography Scan - 50% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.
45919033|NCT03151564|Diagnostic Test|Computed Tomography Scan - 70% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
45919034|NCT03151564|Diagnostic Test|Deep Learning Image Reconstruction (DLIR)|Participants to receive standard-of-care imaging without the artificial intelligence software and imaging technique.
45645009|NCT01805466|Device|Conventional CPB|conventional miniature cardiopulmonary bypass technique
45645010|NCT01773421|Drug|E7820|"FOOD EFFECT STUDY:~Each subject (a minimum of 12 subjects) will be assigned according to a randomization code to receive a single 50 mg dose of E7820 on Day 1, either after fasting for 10 hours, or immediately after consuming a high fat breakfast. Following a 7-day washout period, the subjects will crossover and a second 50 mg dose of E7820 will be administered on Day 8."
45645011|NCT01773421|Drug|E7820|"MTD DETERMINATION FOR BID DOSING SCHEDULE~The initial dose of E7820 will be 50 mg BID. If allowed by the rules for dose escalation, the dose escalations will be to 60 mg BID, 80 mg BID, and 100 mg BID."
45919035|NCT03151525|Drug|Azathioprine|AZA treatment after IFX withdrawal for maintenance of remission
45919036|NCT03151525|Drug|Infliximab|IFX treatment for maintenance of remission
45919037|NCT03151486|Drug|JNJ-55308942 0.5 mg|Participants will receive JNJ-55308942 0.5 mg as an oral solution after an overnight fast on Day 1.
45645012|NCT01757535|Drug|Oral Azacitidine|300 mg oral azacitidine on days 1 to 14 of each 28-day treatment cycle.
45645013|NCT01757535|Drug|Placebo|Identically matching placebo tablets on days 1 to 14 of each 28-day treatment cycle.
45786678|NCT05857904|Device|QFR|Quantitative flow ratio (QFR) is a new method for evaluating the functional significance of coronary artery stenosis based on angiography. It can be used for real-time detection of hemodynamic abnormalities in the coronary arteries in the catheterization lab. Unlike traditional methods that require the use of pressure wires and vasodilators such as adenosine, the QFR examination process only requires routine coronary angiography. By reconstructing the three-dimensional structure of the blood vessels and analyzing the hemodynamics, the QFR can evaluate the fractional flow reserve (FFR) without the need for pressure wires and vasodilators.
45786679|NCT05857891|Drug|Human erythropoietin injection|Each subject in the test group received 40000iu of human erythropoietin intravenously
45786680|NCT05857891|Drug|0.9%NaCl|Each subject in the control group was injected with an equal volume of 0.9%NaCl
45786681|NCT05857865|Behavioral|SPYKids|SSIs will be tailored to the parent areas of primary concern as identified in the pre-questionnaire. Participants will meet with the parent coach in a virtual 90-minute session to discuss coping strategies relevant to the identified concerns. Content will be informed by the baseline questionnaire and include psychoeducation with an explanation of 1 or 2 skills to manage a primary mental health issue (e.g., Emotion Regulation, Distress Tolerance, Communication), a brief practice of the skills (as appropriate), and an action plan for the family to apply the skills at home. Families will also be provided with recommendations for relevant services from our family-focused resource list. Please note, the session length may be extended to 120 minutes if an interpreter is required in order to provide equal opportunity for understanding the session content.
45919038|NCT03151486|Drug|JNJ-55308942 1.5 mg|Participants will receive JNJ-55308942 1.5 mg as an oral solution after an overnight fast on Day 1.
45919039|NCT03151486|Drug|JNJ-55308942 4 mg|Participants will receive JNJ-55308942 4 mg as an oral solution after an overnight fast on Day 1.
45919040|NCT03151486|Drug|JNJ-55308942 12 mg|Participants will receive JNJ-55308942 12 mg as an oral solution after an overnight fast on Day 1.
45919041|NCT03151486|Drug|JNJ-55308942 36 mg|Participants will receive JNJ-55308942 36 mg as an oral solution after an overnight fast on Day 1.
45919042|NCT03151486|Drug|JNJ-55308942 100 mg|Participants will receive a single oral dose of JNJ-55308942 100 mg as an oral solution after an overnight fast on Day 1.
45919043|NCT03151486|Drug|JNJ-55308942: Fed State|Participants will receive JNJ-55308942 as an oral solution in fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.
45919044|NCT03151486|Drug|JNJ-55308942: MAD Part|Participants will receive JNJ-55308942 once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
45919045|NCT03151486|Drug|Placebo|Participants will receive matching placebo in all cohorts.
45919046|NCT00387374|Biological|bevacizumab|Given IV
45919047|NCT00387374|Drug|paclitaxel|Given IV
45449253|NCT04817254|Drug|Nivolumab|1 mg/kg IV q2weeks for cycles 1-4, then 480 mg q 4 weeks for cycles 5-16
45449254|NCT04817254|Drug|ipilimumab 1mg/kg|1 mg/kg q 4 weeks for cycles 1-4
45645014|NCT01747486|Biological|CART-19|CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR zeta and 4-1BB costimulatory domains)
45645015|NCT01733238|Drug|PNT2258|
45645016|NCT01689727|Drug|Technetium Tc 99m EC20|
45645017|NCT01689714|Drug|Tc 99m EC20|
45645018|NCT01689662|Drug|Tc 99m EC20|
45645019|NCT01689636|Drug|Tc 99m EC20|
45645020|NCT01686256|Drug|Tc 99m EC20|Each subject will receive 1 mg of folic acid injected 1-3 minutes prior to administration of Technetium Tc 99m EC20.
45645021|NCT01684098|Drug|Tc 99m EC20|
45919048|NCT00387374|Drug|carboplatin|Given IV
45919049|NCT00387374|Radiation|radiation therapy|Undergo radiotherapy
45645022|NCT01659151|Drug|High Dose Interleukin-2 (IL-2)|A high dose regimen of IL-2 will be given after participants receive the infusion of the T-cells.
45786682|NCT05857865|Other|Services as Usual (SAU)|Participants will receive links to the Manitoba 211 websites and a local organization's resource website with resources for adults and children. This resource is used to locate crisis, distress, and support phone lines, and counselling. Following completion of the 3-month survey, participants will receive a lab-developed comprehensive list of resources (also provided to participants in the SPYKids arm).
45786683|NCT05857852|Device|Low-Intensity Focused Ultrasound|Low-Intensity Focused Ultrasound administration to right dorsal anterior insula, in one of two sessions
45786684|NCT05857852|Device|Sham LIFU device|Sham LIFU device administered in one of two sessions
45786685|NCT05857839|Other|Myofascial release|Patients will get myofascial release technique to sacroiliac joint area for up to 600 seconds and total treatment sessions will be 12 in 4 weeks
45786686|NCT05857839|Other|pelvic Support belt|The support belt will be worn for less than two to three hours at a time and it will be used 4 times a week
45786687|NCT05857826|Other|soft tissue release|Patient will be asked to lie in hook lying position using a clean glove will apply some water based lubricant gently sweep vaginal muscle from superficial to deep until find a trigger point press it and release it using circle motion for 1 to 2 minute until the trigger point is completely released.
45645023|NCT01659151|Procedure|ACT with TIL Infusion|Special immune T-cells will be taken from a sample of the participant's tumor tissue that will be surgically removed. Certain parts of these cells will be multiplied, or grown, in the laboratory. They will then be given back to the participant by an infusion in their veins. These cells are called tumor infiltrating lymphocytes (TIL).
45919050|NCT04733443|Device|Biolimus|140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the Biolimus treatment group
45919051|NCT04733443|Device|SeQuent® Please Neo|140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the SeQuent® Please Neo treatment group
45919052|NCT03151447|Radiation|stereotactic body radiation therapy|"In patients with metastatic triple negative breast cancer, stereotactic body radiation therapy will be combined with anti-PD-1 antibody.~Stereotactic body radiation therapy: SBRT is delivered to 1~5 measurable metastatic lesions of liver, lung, bone, brain or lymph nodes in limited fractions .~Anti-PD-1 treatment: anti-PD-1 antibody (JS001) is injected intravenously 120mg or 240mg or 360mg every two weeks."
45786688|NCT05857826|Other|vaginal dilators|Vaginal dilators will be used according to the patient's condition starting from small sizes to the wider ones.
45786689|NCT05857813|Behavioral|Program for the Education and Enrichment of Relational Skills (PEERS®)|developed at the University of California, Los Angeles (E. A. Laugeson & F. Frankel, 2010). This is a parent-assisted, manualized social skills training program that addresses crucial areas of social functioning for adolescents. Psycho-education and cognitive-behavioral therapy techniques are employed to help adolescents develop ecologically valid skills for making and maintaining friendships.
45786690|NCT05857787|Device|Ultrasound with nerve track function|The nerve track function installed in some ultrasound devices is software that accumulates ultrasound data obtained from humans and uses ultrasound to identify the target nerve through deep learning. Well-trained pain physicians use this feature to educate subjects before seeking brachial plexus and median nerve.
45786691|NCT05857787|Device|Ultrasound without nerve track function|The nerve track function installed in some ultrasound devices is software that accumulates ultrasound data obtained from humans and uses ultrasound to identify the target nerve through deep learning. Well-trained pain physicians use ultrasound alone without this feature to educate subjects before seeking brachial plexus and median nerve.
45786692|NCT05857774|Other|Sonographic measurements|Diaphragm thickness, diaphragm tidal thickening fraction, abdominal muscle thickness, rectus femoris cross-sectional area, maximal diaphragm thickening fraction, abdominal muscle thickening fraction
45645024|NCT01659151|Drug|Vemurafenib|Vemurafenib is used to slow the growth of certain types of cancer cells. This drug will be given for about 3 weeks while T-cells are being grown in the lab and then again after T-cell infusion for up to 2 years.
45786693|NCT05857774|Other|Physiological measurements|Airway occlusion pressure, maximal inspiratory pressure, muscle research council score
45919053|NCT05628675|Other|Baby CHAT|Baby CHAT is an approximately 90-minute group intervention to be delivered during pregnancy. The group is comprised of psychoeducational material about a baby's social development after birth and while the baby is growing in the womb. Attendees are encouraged to think about when an infant's social development begins and consider whether this occurs before or after birth. Participants are then shown a video clip of Reissland et al.'s (2016) study showing 4D ultrasound images of foetuses mouthing in response to sounds that are presented to them outside the womb. During Baby CHAT, parents are encouraged to reflect on this information in the context of their own baby's development, including their likes and dislikes, routine and personality. The final section of the group involves generating ideas for social activities that parents can try with their baby prior to birth, such as singing to, massaging or reading to their baby.
45786694|NCT05857774|Other|Biological measurements|Skeletal troponin-I
45786695|NCT05857748|Drug|lifitegrast|patient newly started on medication will be followed for 6 months
45786696|NCT05857735|Other|Observational registry with no intervention.|No intervention
45786697|NCT05857722|Behavioral|Jóvenes Capibara|Jóvenes Capibara is a 10-session group intervention that was culturally adapted from the Youth Readiness Intervention, which was originally developed in Sierra Leone for conflict-affected youth. Jóvenes Capibara was adapted to the Colombian context using the ADAPT-ITT framework, which ensured that the intervention was relevant to the needs of Colombian and Venezuelan youth.
45786698|NCT05855161|Other|Trampoline exercise|Participants will receive exercise-based training on a trampoline
45786699|NCT05855161|Other|Exercises on a stable surface|Participants will receive exercise-based training on a stable surface
45786700|NCT05858073|Other|Kinesio Taping|"Standard 5 cm Kinesio Tex will be used. Initially, a Y-strip was paper-off (without tension) from the starting point to the insertion of the supraspinatus, while the participants were reaching with their upper extremities behind their backs and flexing their necks to the contralateral side. Second, an I-strip from the coracoid process will be applied around the posterior deltoid using approximately 50% to 75% downward flexion. Initially, the shoulder will be externally rotated without elevation, and then slightly horizontally adduction and forward elevation as the end of the band is applied without stretching. This I strip is shaped like a Y at the end of the tape.~Finally, a Y-strip will be applied using paper-off tension from the T10-T12 region to the medial border of the scapula to facilitate the lower trapezius muscle. For this technique, the shoulder was adducted horizontally and the middle tail was applied with the hands crossed over the chest."
45786701|NCT05858073|Other|Placebo Kinesio Taping|Standard placebo taping will be applied to the placebo Kinesio taping group with a standard 5 cm Kinesio Tex. Two tension-free strips will be applied separately to the acromioclavicular joint and lower trapezius muscle. Suspicious participants will be excluded from the study.
45645025|NCT01659151|Drug|Lymphodepletion|"The purpose of lymphodepletion in this study is to temporarily reduce the number of normal lymphocytes circulating in the participant's body before they are given the T-cells that were grown in the lab. This is so that there will be more space for the lymphocytes (T-cells) that will be infused in their veins. Fludarabine and cyclophosphamide, 2 types of chemotherapy drugs will be used for what is called lymphodepletion."
45919054|NCT03151369|Drug|Morphine|patients with the visual analog scale over 3 will receive morphine
45919055|NCT03151330|Other|Screened Arm|Woman who are identified as high risk will be advised of potential interventions which will include support through care link(nurse education), cervical surveillance, consider vaginal progesterone, low dose aspirin if not already taking.
45786702|NCT05854316|Diagnostic Test|Comprehensive Biomechanical assessment|Magnetic resonance images, electromyography and dynamometry data will be used, together with data from the gait assessment and clinical questionnaires/measures, to characterize the biomechanics of the participants, and to develop and inform personalised musculoskeletal models
45786703|NCT05853913|Behavioral|Exercise|Exercise will be walking/jogging at a medium to hard intensity for 1 hour.
45786704|NCT05850247|Drug|[18F]DPA-714 PET|To assess the association between plasma ficolin-2 levels and plaque and brain inflammation assessed by [18F]DPA-714 PET/MRI in patients managed for transient ischaemic attack or ischaemic stroke related to carotid stenosis.
45786705|NCT05844618|Drug|Triamcinolone Acetonide (Aristocort® C)|On Day 1, Day 2, and Day 3, subjects will receive 2 applications of 3 mg/cm2 on the same lesional area, at an interval of approximately 12 ± 2 hours.
45786706|NCT05844618|Drug|Vehicle|On Day 1, Day 2, and Day 3, subjects will receive 2 applications of 3 mg/cm2 on the same lesional area, at an interval of approximately 12 ± 2 hours.
45786707|NCT05843552|Other|no intervention|no intervention, this is an observational study
45786708|NCT05843513|Other|Monitoring (observational study)|The relationship between dental wear and the behaviour of the participants will be analysed.
45786709|NCT05842291|Device|Active rTMS with short inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 20 min for 5 days. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
45786710|NCT05842291|Device|Sham rTMS with short inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 20 min for 5 days, using sham stimulation coils that comprehensively mimic the active condition. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
45786711|NCT05842291|Device|Active rTMS with long inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 50 min for 5 days. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
45786712|NCT05841693|Drug|Carbohydrate|The experimental group of patients will consume the carbohydrate rich fluid 2 hours before the elective CD.
45645026|NCT01593254|Drug|Imatinib|
45645027|NCT01593254|Drug|Dasatinib|
45786713|NCT05841693|Drug|Placebo|The control group will be offered same amount of placebo fluid.
45786714|NCT05837585|Device|Air quality sensors|The air quality sensors detect air quality, including temperature, humidity, carbon dioxide, respirable suspended particulates (PM10 or PM2.5), total volatile organic compounds (TVOC) and formaldehyde (HCHO), which may influence health of residences. The managers of the service unit will decide the changes of activities to improve air quality and long-term measures based on the detected air quality indexes. The care staff will follow these decisions.
45786715|NCT05836025|Drug|Rapamycin|5mg/week of rapamycin orally for 12 weeks
45786716|NCT05836025|Other|Placebo|5mg/week of placebo orally for 12 weeks
45919056|NCT03922646|Behavioral|Neurocognitive Empowerment for Addiction Treatment (NEAT)|NEAT will be conducted in person, in groups of 6-14, and consist of 14, 1.5-hour sessions. Each NEAT session will consist of (1) a didactic, psychoeducation portion describing the concepts and skills of focus, (2) written material with descriptions of the concepts/skills in verbal and pictorial (cartoon) formats, (3) practicing with cognitive tasks relevant for each skill, (4) discussion of how they can monitor and practice each skill in their daily life. Specifically, we will provide psychoeducation, cognitive exercises, time-management and daily practice focused on domains of attention (focused and divided attention; attentional biases), memory (declarative, prospective, emotional memory), flexibility and inhibition, and problem-solving. Each session will discuss the relevance of these functions for the recovery from drug addiction and for managing affective/motivational symptoms commonly related to substance use (i.e., craving, anxiety, depression, trauma).
45645028|NCT01581489|Procedure|Time to clamping of the umbilical cord after delivery|The time after delivery of the newborn until the midwife stops the circulation in the umbilical cord with a clamp.
45645029|NCT01570998|Radiation|Intraoperative Radiation Therapy|Undergo IORT
45645030|NCT01570998|Other|Laboratory Biomarker Analysis|Correlative studies
45645031|NCT01559818|Biological|IMM-101|IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
45645032|NCT01553214|Drug|Filgrastim|Donors shall receive G-CSF 480 mcg as a single 1.6-mL subcutaneous injection 12 to 24 hours prior to donation.
45786717|NCT05833633|Diagnostic Test|MUSCLE MAGNETIC RESONANCE IMAGING (MRI)|To assess longitudinally at baseline and 1 year later changes on muscle MRI, genetic test, functional motor and respiratory assessments in the DMD group with different type of small mutations and the DMD group with non sense mutations treated with Atarulen in order to better define natural history of these patients. .
45786718|NCT05833347|Diagnostic Test|Distance between Skin-Hyoid Bone(DSHB)|Hyoid bone-skin distance Other Name: DSHB
45786719|NCT05833347|Diagnostic Test|Distance between Skin-Vocal Cord Anterior Commissura(DSAC)|Vocal cord anterior commissura-skin distance Other Name: DSAC
45786720|NCT05833347|Diagnostic Test|Distance between Skin-Epiglottic(DSE)|Skin-epiglottic distance Other Name: DSE
45786721|NCT05829564|Other|virtual reality|The individuals participating in the study will experience virtual reality.
45786722|NCT05829564|Other|cervical mobilization|The individuals participating in the study will be applied cervical mobilization techniques.
45786723|NCT05829564|Other|exercise|The individuals participating in the study will performed neck-specific exercises.
45786724|NCT05828186|Device|Shockwave Coronary Intravascular Lithotripsy (IVL) catheter|Patients with coronary artery calcification who are planned to undergo PCI and are deemed in need of Shockwave IVL catheter treatment by their physicians.
45786725|NCT05827718|Behavioral|Method of Contact|Behavioral Intervention studied here is the method of contact (text vs. email vs. email+text).
45786726|NCT05827718|Behavioral|Source of Contact|Behavioral Intervention studied here is source of contact (personal physician vs. research team)
45786727|NCT05827718|Behavioral|Framing Method (Appeal to Altruism)|"Behavioral Intervention studied here is the framing method appeal to altruism"
45786728|NCT05827718|Behavioral|Framing Method (Social Proof or Perceived Scarcity)|"Behavioral Interventions studied here are the framing methods social proof and perceived scarcity"
45786729|NCT05827718|Behavioral|Framing Method (Opt-Out)|"Behavioral Intervention studied here is the opt-out framing method"
45786730|NCT05827718|Behavioral|Incentive Structure|Behavioral Interventions studied here are gain-framed vs. loss-framed incentives as well as guarantees incentives vs. lottery incentives.
45786731|NCT05823727|Dietary Supplement|SOLUGEL|Bovine collagen peptide supplement
45786732|NCT05823727|Dietary Supplement|Placebo|Maltodextrin
45786733|NCT05822596|Device|Tablet-based interactive games experimental group intervention|"The program consists of 24 facilitated sessions and, depending on the capability of the participants, the availability of mobile devices and the service setting, 0 - 84 non-facilitated sessions.~In 30-minute facilitated session, a program facilitator will lead 1-8 participants in playing the tablet-based interactive games and helpers (e.g., health workers, program workers, and volunteers) will assist the program facilitator in running the sessions. The games may be played individually or together with other participants. In non-facilitated sessions, the participants can play cognitive games depending on the capability of themselves and at their own pace for 10 - 30 minutes"
45786734|NCT05819853|Drug|Wegovy Injectable Product|10 months of semaglutide, with dose escalation as recommended by manufacturer. Maximum dose used will be 1.7mg
45786735|NCT05819853|Drug|Metformin and Wegovy|Participants already on Metformin as part of their clinical care, and still having irregular periods will be enrolled in the Metformin and Semaglutide arm. Semaglutide will be added in addition to the Metformin they are currently taking. 10 months of semaglutide, with dose escalation as recommended by manufacturer. Maximum dose used will be 1.7mg
45786736|NCT05818501|Device|The dysphagia cups|"After the training period of the one of dysphagia cups, participants will start using cup to consume water during a designated period of time every day.~Participants consuming water with Cup A will drink from a static position with their chins towards their chests, the so-called Chin-Tuck maneuver. This position leads epiglottal naturally covering the trachea and causes liquid only ﬂowing to the esophagus and thus stomach. The restoring force of the membrane ensures a constant level of liquid at the upper edge of the cup and thus enables this preferred and safe drinking position.~Cup B limits the maximum volume of water flowing out of the Cup B designated by the staff. Controlled liquid flow prevents overflowing the mouth and gulping, thus reduces the risk of choking and liquid aspiration. Participants can choose to drink the water from Cup B with a straw when necessary."
45786737|NCT05818254|Behavioral|HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) Intervention|The HOP-STEP Intervention is simple with 3-steps: (1) ascertain and document current pregnancy intention and contraceptive use, (2) patient and provider collaboratively arrive at her optimal contraceptive and/or pregnancy plan using a Decision Guide directed conversation, and (3) create a warm handoff with a patient-specific SLE risk assessment and guideline-aligned recommendations.
45786738|NCT05818254|Behavioral|Routine Care|Providers will continue to provide reproductive healthcare in their current manner.
45786739|NCT05816187|Behavioral|Education program on healthy habits|6-week supervised educational program.
45786740|NCT05816187|Behavioral|Habitual|The same therapeutic exercise protocol will be scheduled which will be carried out autonomously without supervision with telephone tracking
45645033|NCT01553214|Drug|Dexamethasone|Donors shall ingest dexamethasone 8 mg (two 4-mg tablets) orally 12 hours prior to donation.
45786741|NCT05811143|Device|Spinal Cord Stimulator|SOC Implantation of Spinal Cord Stimulator for Lipomatosis and Low Back Pain.
45645034|NCT01537601|Procedure|Circumcision|Circumcision
45645035|NCT01537601|Other|Antibiotic prophylaxis alone|Antibiotic prophylaxis alone
45645036|NCT01525394|Drug|Lenvatinib|32 mg will be administered orally as three 4 mg and two 10 mg capsules as a single dose.
45645037|NCT01525394|Drug|Moxifloxacin 400 mg|Moxifloxacin 400 mg will be administered orally as one 400 mg tablet.
45645038|NCT01525394|Drug|Placebos (matched to 4 mg and 10 mg lenvatinib capsules).|The Placebo dose will consist of three 4 mg and two 10 mg placebo capsules.
45786742|NCT05808920|Genetic|Molecular Analyses|Nucleic acid extraction, protein analysis. Tumour tissue, blood and saliva samples collected.
45919057|NCT03922646|Behavioral|Active Control|The active control intervention will be composed of active, but non-essential aspects of the larger treatment program (i.e., those that treatment programs do not believe are necessary or central to their program, for example, art classes, exercise classes, chore time, or extra 12 steps meetings). This will ensure that subjects are not being prevented from accessing treatment that is already known to be helpful in substance use recovery, that the active control condition and NEAT intervention have equivalent credibility and expectancies, and optimizing the generalizability of findings.
45919058|NCT03151291|Dietary Supplement|β-hydroxy-β-methylbutyrate (HMB)|daily intake of 3 g HMB
45919059|NCT03151291|Dietary Supplement|L-carnitine (LC)|daily intake of 4 g LC
45645039|NCT01517945|Behavioral|AIM materials and assessments|"Phase 1 (complete) - dev of AIM materials targeting fear of cancer recurrence in BCS (n = 10).~Phase 2 (complete) - randomized, single-blind, placebo-controlled, proof-of-concept pilot trial.~Phase 3:~Part 1 of Phase 3 (complete) - dev of of iThrive app for BCS~Part 2 of Phase 3 (complete) - usability testing by observing navigation with BCS in a laboratory setting~Part 3 of Phase 3 - acceptability of iThrive will be assessed through a small RCT (n=30)~Phase 4:~Part 1 of Phase 4 (complete) - dev of iThrive app for RCS~Part 2 of Phase 4 (complete) - usability testing completed by observing navigation with RCS remotely~Part 3 of Phase 4 - acceptability of iThrive will be assessed through a small RCT (n=90)~For Phases 3 and 4, Part 3: We will work with participants to ensure that sessions are completed over < 12 weeks if unavoidable delays occur. A follow-up session will be scheduled 3 months after completion of the last session."
45786743|NCT05805657|Behavioral|Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
45919060|NCT03151291|Dietary Supplement|Eicosapentaenoic acid (EPA)|daily intake of 2.2 g EPA
45919061|NCT03151291|Other|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
45919062|NCT04712266|Drug|Glucagon|calculated IV insulin:Glucagon molar ratio
45919063|NCT04712266|Drug|Insulin|calculated IV Insulin dose infused at a constant rate
45919064|NCT03151252|Diagnostic Test|Cytobrush|During the endoscopic Investigation the mucosa cells were collected by brushing the colon via cytobrush.
45919065|NCT03912818|Drug|Carboplatin|Given IV
45919066|NCT03912818|Drug|Cisplatin|Given IV
45786744|NCT05805657|Behavioral|Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
45786745|NCT05805657|Other|Usual Care Delayed Treatment|Usual care in the partner CMHCs typically starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
45786746|NCT05804266|Procedure|Coventional coagulation|Coventional coagulation
45786747|NCT05804266|Procedure|Underwater coagulation|Underwater coagulation
45786748|NCT05804266|Procedure|Peroral endoscopic myotomy|Peroral endoscopic myotomy
45786749|NCT05796752|Drug|Memantine|Cognition-enhancing medication
45786750|NCT05796752|Behavioral|ComB Behavioral Therapy|Therapy for BFRBs
45786751|NCT05794971|Drug|Regorafenib and DIBIRI|"Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)~Drug: Irinotecan it will be mixed in eluting-beads and injected in the tumor.~Procedure: TACE Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to decrease the tumor's blood supply.~Device: drug eluting-bead The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer."
45786752|NCT05794971|Drug|Regorafenib|Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)
45786753|NCT05793138|Behavioral|Geriatric Care Model|First, older adults complete the Geriatric screen for OLder adults receiving Dialysis (GOLD), a battery of validated, self-administered geriatric screening instruments, used to identify Geriatric 5M-related problems. Then, a research team with geriatrics expertise leads patient prioritization of GOLD-identified problems in a telehealth visit and provides the dialysis team with guideline-directed, individualized recommendations for geriatric problem management.
45919067|NCT03912818|Procedure|Cystectomy|Undergo cystectomy
45919068|NCT03912818|Drug|Doxorubicin|Given IV
45919069|NCT03912818|Biological|Durvalumab|Given IV
45919070|NCT03912818|Drug|Gemcitabine|Given IV
45919071|NCT03912818|Drug|Methotrexate|Given IV
45919072|NCT03912818|Drug|Vinblastine|Given IV
45919073|NCT03151213|Drug|Pregabalin 150mg|Pregabalin 150mg before RFA of liver cancer
45919074|NCT03151213|Other|Placebo|Placebo before RFA of liver cancer
45919075|NCT03151174|Drug|Vitamin D 10000 UNT|10000 IU Vitamin D per day
45919076|NCT03151174|Drug|Vitamin D 5000 UNT|5000 IU Vitamin D per day
45919077|NCT05616312|Behavioral|Educational Teach Back|Patients will receive teach-back education while they fill out questionnaires.
45919078|NCT00393172|Behavioral|exercise|5 days per week exercise for 4 months
45919079|NCT03151096|Dietary Supplement|Riboflavin|one pill of Riboflavin will be taken orally with water
45919080|NCT03151096|Dietary Supplement|Placebo|one pill of placebo will be taken orally with water
45919081|NCT03906539|Drug|Atorvastatin 10mg|Atorvastatin 10 mg per day
45919082|NCT03906539|Dietary Supplement|Virgin Coconut Oil (VCO)|Capsule VCO (1000 mg/day)
45919083|NCT03906539|Other|Placebo|Placebo capsule - 1 capsule per day
45919084|NCT00389688|Drug|cisplatin|
45919085|NCT00389688|Drug|pemetrexed disodium|
45919086|NCT00389688|Procedure|adjuvant therapy|
45919087|NCT00389688|Procedure|conventional surgery|
45919088|NCT00389688|Procedure|neoadjuvant therapy|
45919089|NCT03151018|Device|Resolute Onyx|
45786754|NCT05793138|Behavioral|Usual Care|Participants will continue to receive standard of care. Then after 12 months, they will follow the Geriatric Care Model. They will complete the Geriatric screen for OLder adults receiving Dialysis (GOLD), a battery of validated, self-administered geriatric screening instruments, used to identify Geriatric 5M-related problems. Then, a research team with geriatrics expertise leads patient prioritization of GOLD-identified problems in a telehealth visit and provides the dialysis team with guideline-directed, individualized recommendations for geriatric problem management.
45919090|NCT03150979|Other|Provision of a cane|The participants will receive a single-point cane and will be instructed to use it all the time during locomotion. Weekly, they will receive a phone call, to ensure that they are using the cane and to clarify any doubts. A home visit may be conducted, if necessary.
45919091|NCT03150979|Other|Control|The control group will be instructed to to perform stretching of the lower limb muscles daily and keep their daily activities, without the use of a cane. They will also receive weekly phone calls, to ensure similar level of attention to that of the the participants in the experimental group.
45919092|NCT03150940|Diagnostic Test|ECG|12 lead electrocardiogram used to demonstrate cardiac function
45919093|NCT03150940|Diagnostic Test|bedside cardiac ultrasound|bedside cardiac ultrasound to see 2D images of each participants heart. Without the use of radiation.
46071147|NCT02849522|Procedure|Prostatic Artery Embolisation|"The aim of PAE for LUTS (due to BPH) is to reduce the blood supply of the prostate gland, causing some of it to undergo necrosis with subsequent shrinkage.~The procedure is usually performed with the patient under local anaesthetic and sedation. Using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation involves the introduction of microparticles to block these small prostatic arteries. Embolisation agents include polyvinyl alcohol (PVA), gelatine sponge and other synthetic biocompatible materials.~NICE published Interventional Procedures Guidance (IPG453) in April 2013. The evidence at the time of assessment was deemed inadequate in quantity and quality. Therefore, the procedure was given a 'Research-only' recommendation."
45645040|NCT01510678|Behavioral|Increase Fruits and Vegetables|Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables. Both parent and child will self-monitor these behaviors. As one barrier to consuming F&Vs is perceived cost of these foods, information regarding lower-cost options for F&Vs will be included in the manual.
45645041|NCT01510678|Behavioral|Decrease Snack Foods|This condition will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to < 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
45645042|NCT01510678|Behavioral|Increase Fruits and Vegetables and Decrease Snack Foods|Will combine the goals of the increase and decrease conditions.
45645043|NCT01454934|Drug|Eribulin|Administration of eribulin mesylate at a dose of 1.4 mg/m2 i.v. over 2 to 5 minutes on Days 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.
45645044|NCT01454934|Drug|TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed|"Vinorelbine 30 mg/m2 i.v. on Day 1, every 7 days~Gemcitabine 1250 mg/m2 i.v. on Days 1 and 8, every 21 days~Docetaxel 75 mg/m2 i.v. on Day 1 every 21 days~Pemetrexed 500 mg/m2 i.v. on Day 1 every 21 days (nonsquamous histology only)."
45645045|NCT01442246|Drug|Leuprorelin Acetate|Leuprorelin Acetate 45 mg, one injection every 6 months for 24 months
45645046|NCT01439282|Drug|eribulin mesylate|Cohort I & II: eribulin mesylate (E7389) 1.4 mg/m2 intravenously over 2 - 5 minutes on Day 1 and Day 8 for 4 cycles
45645047|NCT01439282|Drug|capecitabine|Cohort 1: capecitabine 900 mg/m2 orally twice daily on Days 1 - 14 of a 21-day cycle for 4 cycles Cohort II: fixed dose of 1500 mg oral capecitabine twice daily, 7 days on then 7 days off for 4 cycles
45786755|NCT05789979|Device|The resident-handling device|Care staff will perform resident-handling tasks using the new resident-handling devices. For low dependency during trial, the device helps care staff to assist residents in making a transition from a sit to a standing posture, vice versa. This device is used for functional activities and transferring and lifting participants. For high dependency during trial, when care staff are performing resident-handling tasks, the device moves with little force in any direction.
45919094|NCT05608512|Other|interview|The first phase included a qualitative study. We conducted a qualitative phenomenological method to better explicate and understand palliative care nurses' emotional labor experiences, as well as the dilemmas and solutions they encounter when physical, mental, and emotional labor intertwine at work. In the early stage, we compiled an interview outline by a written qualitative meta-analysis about the emotional labor, and added the contents in the interview outline according to the actual situation in the later interview process.
45919095|NCT03899090|Behavioral|Float pool|Subject floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
45919096|NCT03899090|Behavioral|Float chair|Subject floats supine in a zero-gravity chair in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
45919097|NCT03150901|Diagnostic Test|no drug|laboratory tests
45919098|NCT03150823|Procedure|Upward Direct Current (Ascending Effect)|Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the ascending stream direct current (Ascending effect) the proximal cathode and distal anode are placed, a excitatory effect on the nervous system being described in theory.
45786756|NCT05785195|Device|Nitric Oxide Generation and Delivery System|The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
45786757|NCT05783336|Behavioral|Stepping Stones and Crating Futures Plus (SSCF+)|Group-based intervention delivered to small friendship networks, by a facilitator.
45786758|NCT05774496|Other|Estimation of the occurrence of retinochoroiditis in women with congenital toxoplasmosis and previous retinochoroiditis lesions (recurrence) during pregnancy and postpartum.|All fundus examinations completed during pregnancy and postpartum in women with congenital toxoplasmosis and previous retinochoroiditis lesions are going to be checked.
45786759|NCT05763901|Diagnostic Test|Clinical tests and motor control evaluation using Inertial Measurement Units|Each patient is evaluated using clinical tests (Movement ABC2, Test of Motor Competence), a screening questionnaire (DCD-Q), and wearable Inertial Measurement Units to assess balance and motor control during a Natural Walking and Tandem Walking test.
45786760|NCT05738720|Device|Teknikel Spirobank Home Type Respiratory Function Tester (Homespirometer)|Pulmonary Function Test (PFT): Pulmonary function test will be performed with a Teknikel Spirobank home pulmonary function test device. In the study group, the patient will make weekly measurements at home and send it to the physiotherapist. In the control group, evaluation will be made with the device only at the beginning and end of the treatment.
45786761|NCT05738720|Other|Exercise Programme|"Exercise Program~Breathing exercises: Chest, diaphragmatic breathing and lower basal breathing exercises will be performed with 10 repetitions.~Resistance exercises: Strengthening exercises will be performed on the major muscle groups of the upper and lower extremities by using medium hardness therabant. During the exercises, the patient's fatigue and dyspnea levels will be questioned using the Borg scale, and breaks will be given when necessary. The exercises will be performed with a medium-hardness therabband. Exercises will be given for the upper extremity and lower extremity, and the patients will be asked to do 10 repetitions.~Gait training: In line with the data obtained from the 6-minute walking test, gait training will be given on flat ground at 60% workload (land-based walking). Patients will be allowed to walk on flat ground at 60% workload, at a time calculated based on the results of the 6-minute walk test."
45786762|NCT05737810|Other|No treatment given|No treatment given
45919099|NCT03150823|Procedure|Downward Direct Current (Descending Effect)|Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the descending stream direct current (Descending effect) the proximal anode and distal cathode are placed, a sedative and analgesic effect on the nervous system being described in theory.
45919100|NCT03150823|Procedure|Sham Direct Current|Installation of electrotherapy equipment off (Sham tratment).
45919101|NCT03150784|Other|EPIC Club|Weekly exercise gym sessions. Participants will start with a warm-up of 20-25 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. In addition to the above, a novel rhythmical stepping task will be performed over 10 mins.
45919102|NCT05605665|Drug|low-dose interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10~6 IU once every other day, for 4 weeks.
45919103|NCT05605665|Drug|rapamycin|Rapamycin 0.5ml was taken orally once per day
45919104|NCT03150745|Procedure|3- Cervical Pap smears|Cervical Pap smears will be obtained using the long tip of an Ayre's spatula that will be placed in the endocervical canal with the proximal bulge resting on the ectocervix. The spatula will be carefully rotated around the cervix so that a representative sample of the whole cervix will be obtained. An additional endocervical sample will be obtained by placing a cytobrush or by the other end of the Ayer's spatula in the endocervical canal and gently rotated through 360 degrees as previously described. The samples will be then immediately plated on a slide, fixed by immersing the slide in 95% ethyl alcohol fixative for 15 to 20 minutes and stained by modified Papanicolaou stain using a hand staining procedure
45645048|NCT01391962|Drug|Cediranib|Cediranib, a small molecule inhibitor of VEGF receptor tyrosine kinases, is showing preliminary evidence of activity in patients with ASPS.
45645049|NCT01391962|Drug|Sunitinib|Sunitinib, a small molecule inhibitor of VEGF receptor tyrosine kinases, is showing preliminary evidence of activity in patients with ASPS.
45645050|NCT01391026|Behavioral|Enhanced patient-centered care|The experimental arm will be referred to a multi-disciplinary clinic
45645051|NCT01352520|Drug|SGN-35|1.8 mg/kg administered by outpatient IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
45645052|NCT01351545|Drug|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
45645053|NCT01351103|Drug|LGK974|
45786763|NCT05736588|Behavioral|Elimisha HPV|Elimisha HPV is a multi-level stigma-responsive cervical cancer prevention service delivery model that incorporates stigma-responsive education, peer navigation and a patient-centered delivery strategy, addressing drivers while mitigating harms from stigma.
45786764|NCT05735717|Drug|Fludarabine|Fludarabine 25mg/m2 IV on days -8 to -6 or days -4 to -2. 40mg/m2 IV on days -5 to -2.
45786765|NCT05735717|Drug|Busulfan|Busulfan 82.1 mg*hr/L IV on days -5 to -2 or days -8 to -5
45786766|NCT05735717|Drug|Melphalan|Melphalan 50 mg/m2 IV on days -4 to -2
45786767|NCT05735717|Drug|Rituximab|200 mg/m2 intravenous given once on day-1
45786768|NCT05735717|Drug|Levetiracetam|As seizures have occurred following high dose busulfan, all patients will be treated with Keppra beginning day -6 and continuing until day -1 per institutional guidelines.
45786769|NCT05733455|Drug|Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg)|Participants will ingest two overencapsulated tablets of alpelisib at 23:00, along with a saltine cracker.
45786770|NCT05733455|Drug|Placebo (microcrystalline cellulose), 2 capsules|Participants will ingest two capsules filled with microcrystalline cellulose at 23:00, along with a saltine cracker.
45786771|NCT05733455|Device|FreeStyle Libre Pro|Continuous glucose monitoring for 24 hours (double blinded)
45786772|NCT05733455|Diagnostic Test|Oral glucose tolerance test (OGTT) with Trutol glucose beverage|Participants will drink Trutol glucose beverage (D-glucose 75 g in 10 fl oz) and blood will be sampled at baseline and at 15, 30, 60, 90, 120, 150, and 180 minutes.
45919105|NCT03150745|Procedure|Colposcopic examination|"0.9% saline technique to assess the cervical lesion and vasculature of the cervix, 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment using (Bossman forceps or endocervical speculum or counter pressure with Q stick).~e- Biopsy using the punch biopsy forceps. Biopsy will be obtained from every abnormal colposcopic examination"
45919106|NCT03150745|Procedure|Office hysteroscopy|0.9% saline technique to assess the cervical lesion and vasculature of the cervix. 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment. Endometrial cavity evaluation whenever possible. Biopsy. Biopsy will be obtained from every abnormal hysteroscopic examination.
45645054|NCT01351103|Biological|PDR001|
45786773|NCT05733455|Dietary Supplement|BOOST Plus nutritional beverage|Participants will consume a quantity of BOOST Plus calculated to match their daily caloric needs, divided over three liquid meals.
45786774|NCT05733143|Other|cardiopulmonary exercise stress test (CPEST)|The study is observational and purely exploratory. We will utilise cardiopulmonary exercise stress testing to assess levels of fitness and causes for symptoms in proposed groups.
45919107|NCT03150706|Drug|Avelumab|"Patients will receive 10 mg/kg of avelumab via intravenous infusion every 2 weeks.~Response evaluation will be performed every 6 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study."
45919108|NCT03150667|Drug|Ticagrelor|Ticagrelor in patients with CKD presenting with ACS.
45919109|NCT03150667|Drug|Clopidogrel|Clopidogrel in patients with CKD presenting with ACS.
45919110|NCT03150628|Drug|Perioperative chemotherapy|Perioperative chemotherapy
45786775|NCT05729282|Drug|Diazoxide oral suspension, 1 mg per kg per dose|Diazoxide oral suspension provided in label-obscured single-use oral syringes at 1 mg per kg per dose (total of 27 doses over 14 days).
45786776|NCT05729282|Drug|Diazoxide oral suspension, 2 mg per kg per dose|Diazoxide oral suspension provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).
45786777|NCT05729282|Drug|Placebo|Flavor-approximate placebo consisting of peppermint extract in diet tonic water, thickened with xanthan gum, provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).
45919111|NCT03150628|Procedure|Cytoreduction|Cytoreductive surgery
45645055|NCT01326312|Drug|GTx-758 1000mg|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
45645056|NCT01326312|Drug|Lupron Depot|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
45645057|NCT01326312|Drug|GTx-758 2000mg|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
45645058|NCT01321554|Drug|Lenvatinib|Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
45645059|NCT01321554|Drug|Placebo|Matching placebo (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously.
45786778|NCT05729282|Device|FreeStyle Libre Pro|All participants will wear a FreeStyle Libre Pro continuous glucose monitor (CGM) to track glycemic trends in response to study treatments. Investigators and participants will be blinded to CGM readings until after each participant has completed the trial.
45786779|NCT05722743|Behavioral|Harmony at HOME|The Harmony at HOME (Help Online Modifying the Environment) intervention builds on prior successful foundations of dementia care interventions with a novel approach combining remote implementation, antecedent education, and home environment intervention. The intervention will teach caregivers how to 1) assess the home environment as an antecedent to behavior for the person with ADRD, and 2) design and implement individualized environmental modification through an environmental cueing approach to address the needs of the person with ADRD in a supportive environment.
45786780|NCT05722743|Behavioral|National Institute on Aging Program|"Standard of care will address behaviors and psychiatric symptoms of dementia (BPSD) for persons with ADRD, as recommended by their medical provider. Caregivers will receive training regarding home safety via a home safety handout based on National Institutes on Aging Home Safety and Alzheimer's Disease webpage."
45786781|NCT05713500|Other|TCI|Temperament and character inventory
45786782|NCT05713500|Other|BPI|Brief Pain Inventory
45919112|NCT03150628|Drug|HIPEC|Hyperthermic intraperitoneal chemotherapy (HIPEC) with 100mg/m2 cisplatin
45919113|NCT00393250|Other|Hypnosis|Subjects receive hypnosis (experimental intervention) during 4 weeks of face-to-face encounters with a physician trained in hypnosis. For 6 weeks following the instruction period, the participants will perform daily self- hypnosis using customizable digital media.
45919114|NCT00393250|Other|Control|Subjects in the control arm of the study will receive face-to-face education regarding sickle cell disease for the same length and frequency as the treatment group hypnosis encounters before crossing over to the experimental intervention arm of the study
45919115|NCT03150550|Behavioral|Mindfulness practice|Mindfulness interventions are behavioral cognitive psychotherapies which allow patient to identify, pay attention and accept external (sensory stimuli) and internal (cognition and emotions) phenomena.
45919116|NCT03150550|Behavioral|Relapse prevention|It's a conventional relapse prevention program which allow to measure the alcoholic relapse in the first glass consumed.
45919117|NCT03150472|Device|Graft Matrix|Both Graft matrix products are supplied sterile, for single use only and packed in vials or a syringe-like applicator. All products consist of the same bone graft particles with the only variants being due to different amounts per package or different containers.
45919118|NCT04895852|Device|TEAS|The self-adhesive gel electrode pad will be placed at the center of DU20 (Baihui), EX-HN3 (Yintang) and both sides of LI4 (Hegu), LR3 (Taichong) in strict accordance with the World Health Organization Standardized Acupuncture Location. Electric stimulation will be used with a TEAS apparatus (HANS200A Beijing Huawei Co., LTD.) . The frequency of the electrical stimulation will be set as alternating 2/100Hz to relieve anxiety. The current intensity will be adjusted individually, starting at 1 mA and increasing gradually until the patient can perceive and tolerate it (preferably slight twitching of local muscles without pain).
45919119|NCT04895852|Device|Sham TEAS|The STEAS group selects the same acupoints as the TEAS group and other intervention measures are the same as the TEAS group except for the current intensity is set to 0-mA. The acupuncturist responsible for the operation will tell patients in STEAS group that this is a type of stimulus without perception.
45645060|NCT01321554|Drug|Lenvatinib|"Lenvatinib 20 mg (two 10-mg capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.~The dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013. Thus, more subjects were treated with 24 mg starting dose and the treatment duration was longer for these participants than those whose starting dose was 20 mg."
45786783|NCT05713500|Other|CPAQ-8|Chronic Pain Acceptance Questionnaire-8
45919120|NCT03150394|Dietary Supplement|GASTRUS|Gastrus will be given from the first day of eradication treatment to completion after 30 days of treatment
45919121|NCT03150394|Other|PLACEBO|Placebo will be given from the first day of eradication treatment to completion after 30 days of treatment
45919122|NCT03150355|Procedure|Arthroplasty or open reduction and internal fixation|fixation of proximal femoral fractures or replacement with prosthesis
45919123|NCT05600283|Diagnostic Test|Self-collected vaginal sample (with Evalyn brush) HPV testing|Patient self-sampling swab kit to collect a vaginal sample for HPV testing
45645061|NCT01308437|Biological|Wosulin (N or 70/30 with R)|Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
45645062|NCT01308437|Biological|Novolin® (N or 70/30 with R)|Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
45645063|NCT01273168|Drug|Z-Endoxifen|Genetic polymorphisms in CYP2D6 and concomitant medications alter tamoxifen metabolism, limiting exposure to the active metabolite endoxifen. These factors are associated with a higher rate of recurrence and shorter disease-free survival in breast cancer patients receiving tamoxifen. Administration of endoxifen directly to patients is anticipated to bypass the effects of CYP2D6 polymorphisms and concomitant medications and provide adequate active drug levels in all treated patients, resulting in clinical benefit.
45786784|NCT05713500|Other|SF-MPQ|short-form McGill Pain Questionnaire
45919124|NCT05600283|Diagnostic Test|Clinician-collection of cervical sample for HPV testing|Speculum exam and collection of a cervical specimen using standard endocervical brush and spatula placed into ThinPrep medium for HPV testing
45919125|NCT03150316|Drug|Treat Regimen|CKD-581(investigational Drug): on days 1, 8, 15 of repeated 28day cycles Lenalidomide: on days 1~21 of repeated 28 day cycles Dexamethasone: administrated once weekly every 28day cycles
45919126|NCT04893317|Device|Ablation in the ventricles with the Adagio Medical VT Cryoablation System|The Adagio Medical VT Cryoablation System is indicated for the treatment of monomorphic ventricular tachycardia by ablation of arrhythmogenic tissue that drives and maintains these arrhythmias
45919127|NCT03150277|Behavioral|Plyometric exercise|2 sets of 10 ankle hops, 3 sets of 5 hurdle hops, 5 drop-jumps from a height of 50 cm
45449255|NCT02158390|Behavioral|Jasper-EMT with words and AAC|"Jasper-EMT with words and AAC~A therapist plus parent implemented social communication intervention which include use of the iPad for a mode of communication. A total of 6 hour long workshops with the parent and 42 hour long intervention sessions with the child occur; half include the parent as therapist and occur in the home. The treatment lasts approximately 4 months."
45449256|NCT03639987|Drug|Aducanumab|Administered as specified in the treatment arm.
45449257|NCT03639987|Drug|Placebo|Administered as specified in the treatment arm.
45449258|NCT02158468|Device|Combined intrahospital pre- and postconditioning|After admission to hospital 3 cycles of preconditioning with 5-min inflation and 5-min deflation of a blood-pressure cuff. After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion)
45645064|NCT01269346|Drug|Eribulin Mesylate|"Eribulin mesylate 1.4 mg/m2 administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.~Trastuzumab 8 mg/kg will be administered as in IV infusion over a 90-minute period on Day 1 of Cycle 1. Thereafter, trastuzumab 6 mg/kg will be administered as an IV infusion over a 30-minute period on Day 1 of each subsequent cycle."
45786785|NCT05713500|Other|KPPS|King's Parkinson's Disease Pain Scale
45786786|NCT05713500|Other|Hospital Anxiety and Depression scale|Hospital Anxiety and Depression scale questionary
45786787|NCT05713500|Other|PCS|Pain Catastrophism Scale
45786788|NCT05713500|Other|ORT|Opioid Risk Tool
45786789|NCT05713500|Other|SSQ6|Social Support Questionnaire
45786790|NCT05713500|Other|IPQ-R|Illness Perception Questionnaire Revised
45786791|NCT05713500|Other|WCC-R|Ways of Coping Checklist Revised
45786792|NCT05713058|Behavioral|eTRC diet|12-week dietary prescription with moderate energy restriction (200 kcal/day) focusing on the distribution of macronutrients within the day so as to avoid carbohydrate consumption after lunch
45919128|NCT03150277|Behavioral|Heavy resistance exercise|10 single repetitions of back half squats at 90% of 1 repetition maximum
45786793|NCT05713058|Behavioral|Control diet|12-week dietary prescription with moderate energy restriction (200 kcal/day) without any recommendations on the distribution of macronutrients within the day
45786794|NCT05709977|Other|Acupuncture|Fixed set of acupuncture points
45919129|NCT02972125|Drug|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 100 mg tablet
45449259|NCT02158468|Device|Postconditioning|After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion)
45786795|NCT05709977|Drug|Antihistamine nasal spray|Carelastin® (1 mg/ml) azelastine nasal spray
45786796|NCT05706129|Drug|[68Ga]Ga-DPI-4452|[68Ga]Ga-DPI-4452, administered as IV injection.
45786797|NCT05706129|Drug|[177Lu]Lu-DPI-4452|[177Lu]Lu-DPI-4452, administered as IV infusion.
45786798|NCT05704985|Biological|DK210 (EGFR)|Solution for SC administration
45919130|NCT02972125|Drug|Lacosamide (LCM) dry syrup|Treatment B: Single dose of Lacosamide (LCM) 100 mg given as dry syrup
45919131|NCT05597553|Other|Premixed MTA|The premixed Bio-ceramic putty during setting become hard and expand slightly providing a superior long-term seal
45919132|NCT05597553|Other|Powder/liquid MTA|Mineral trioxide aggregate (MTA) is a silicate material that is said to aid in faster bridge formation with fewer tunnel defects, less pulpal inflammation, and the maintenance of pulpal integrity. It is widely used in pediatric dentistry due to its excellent sealing properties.
45919133|NCT03150238|Other|observation of prognostic factors for relapse|The identification of the most relevant prognostic factors and the definition of their weight in predict the risk of re-intervention will be the basis for the definition of a combined score
45919134|NCT03086044|Drug|Sofosbuvir/velpatasvir|2 weeks of treatment beginning on the day of transplant
45919135|NCT03086044|Other|Monitoring|Close HCV viral load monitoring Will receive direct acting antiviral treatment with 6 weeks of sofosbuvir/velpatasvir if the recipient develops HCV viremia during the post-transplant HCV viral load testing
45919136|NCT03083665|Drug|Placebo|"Pharmaceutical form: Film-coated tablets~Route of administration: Oral use"
45919137|NCT03083665|Drug|Brivaracetam|"Pharmaceutical form: Film-coated tablets~Concentration: 25 mg tablets and 50 mg tablets~Route of administration: Oral use"
46071148|NCT02849522|Procedure|TURP|Transurethral resection of the prostate. A cystoscope is passed up the urethra to the prostate, where the surrounding prostate tissue is excised. This is a common operation for benign prostatic hyperplasia (BPH), with around 15,000 procedures performed in the UK per year (NHS Choices). The conventional TURP method of tissue removal utilizes a wire loop with electrical current flowing in one direction (monopolar) through the resectoscope to cut the tissue. Bipolar TURP allows saline irrigation and eliminates the need for an ESU grounding pad thus preventing TUR syndrome and reducing other complications.
45449260|NCT03729297|Drug|Cabozantinib|cabozantinib tablets (Cabometyx®) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw for a maximum duration of 2 years.
45645065|NCT01268293|Drug|E7080|This arm will be a dose-escalation evaluation of 9-18 subjects to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle). Administration of the study drug can continue until subjects meet discontinuation criteria such as disease progression, intolerable toxicity, and withdrawal of study consent.
46071149|NCT02849522|Procedure|Open prostatectomy|In an open prostatectomy the prostate is accessed through an incision that allows manual manipulation and open visualization through the incision. The most common types of open prostatectomy are retropubic prostatectomy (RP) or transvesical prostatectomy (TVP).
45449261|NCT02149888|Drug|Tenofovir/emtricitabine|Once daily Tenofovir/emtricitabine (Truvada®)
45645066|NCT01268150|Drug|Eribulin mesylate|Eribulin mesylate 1.4 mg/m2 will be administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.
45645067|NCT01267175|Device|X54 insulin pump with low suspend feature|Change from current insulin pump to new X54 pump
45786799|NCT05704985|Radiation|Radiation therapy|Short regimen radiation therapy (10 fractions or less)
45449262|NCT03729219|Biological|E. coli ETVAX|Oral suspension Sterile water is added to dmLT . Vaccine is poured to the effervescent solution and needed amount of dmLT is added.
45449263|NCT03729219|Other|Placebo|Oral suspension
45645068|NCT01259908|Procedure|Laparoscopic vs open Ygraft|Patients with aorto-iliac occlusive disease TASC type D operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared.
45645069|NCT01231841|Drug|cyclosporine|Given orally
45645070|NCT01231841|Biological|anti-thymocyte globulin|Given IV
45786800|NCT05704985|Biological|Immune checkpoint blockers|IV administration of approved PD1 blocker
45786801|NCT05704985|Drug|Chemotherapy|Single agent or combination of not more than two
45786802|NCT05704426|Device|Impulse Dynamics Optimizer Device|The Impulse Dynamics Optimizer is indicated for patients with New York Heart Association (NYHA) class III congestive heart failure (CHF) with left ventricular ejection fraction (LVEF) between 25 and 45% who are not candidates for cardiac resynchronization therapy. The Optimizer device requires a minimally invasive implant by a cardiac electrophysiologist with two transvenous pacemaker wires implanted into the right ventricular septum and attached to a generator in an infraclavicular region, much like a pacemaker. The Optimizer device provides CCM through improved calcium handling and has been shown to reverse the negative remodeling of the left ventricle seen in HFrEF and improve left ventricular contractile strength.
45919138|NCT05588973|Other|MEDISKIN cream|MEDISKIN cream with collagen
45919139|NCT05588973|Other|Panthenol cream|Panthenol cream
45919140|NCT04712344|Biological|COVID-19 convalescent plasma|Infusion of a total of three units of COVID-19 convalescent plasma administered on three separate occasions during Day 1 and Day 2 in Addition to standard treatment.
45919141|NCT02977468|Drug|Merck 3475 Pembrolizumab|Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of one to two cycles.
45919142|NCT02977468|Radiation|Intraoperative radiation therapy (IORT)|Participants will receive Intraoperative radiation therapy (IORT) on the day of surgery.
45919143|NCT05585853|Other|virtual reality|Virtual reality glasses application is a method without any side effects. Patients will be treated for an average of 10 minutes. Data will be collected before, during, immediately after the application, at the 15th and 30th minutes.
45919144|NCT02866006|Drug|BVAC-C|Autologous B cells and monocytes transfected with E6E7 gene of HPV
45919145|NCT02866006|Drug|Topotecan|
45919146|NCT05575752|Other|high temperature (32℃) group|The exposure group will be exposed to high temperature (32℃) in a chamber for about 2 hours, resting during the whole periods.
45786803|NCT05698095|Drug|5-methoxy-N,N-dimethyltryptamine succinate salt|The 5-MeO-DMT drug product is comprised of the appropriate concentration of 5-MeO-DMT succinate salt drug substance in solution with 0.9% sodium chloride injection solution (USP) in a 5 mL glass vial, and is administered intramuscularly.
45645071|NCT01175993|Other|Elliptical exercise|Each participant with TBI will participate in an exercise intervention which will be done in the home. The exercise device in this protocol will be an elliptical trainer that requires coordinated reciprocal movements of both the legs and the arms. Primary emphasis will be placed on maintaining a near maximal speed of movement and to progressively increase this over time. Mild resistance to the leg motion will be provided initially and will be progressively increased once speed and coordination are optimized. The device will be loaned to them to use in the home, and will be delivered to the home fully assembled. Participants will be monitored by phone the first week and thereafter every two weeks and progressed as indicated. The exercise program will be performed 5 days a week for 30 minutes per session, for a total duration of 12 weeks. All will record the length, speed and resistance of each session on a paper-based log sheet.
45786804|NCT05698095|Drug|Placebo|The placebo is commercially available 0.9% sodium chloride solution (USP) for injection. The placebo is provided by the pharmacy in single-use sterile syringes of the appropriate dose.
45786805|NCT05696847|Drug|Tirzepatide|Administered SC
45786806|NCT05696847|Drug|Placebo|Administered SC
45786807|NCT05693675|Drug|Postoperative methadone|Participants will receive intraoperative methadone (0.2 mg/kg ideal body weight intravenously but not exceeding 20mg) followed by oral/IV methadone postoperatively according to the following scheme: A) Opioid naïve patients will receive 5mg twice daily dosage of methadone on postoperative days 1 and 2 followed by 5 mg daily on postoperative days 3, 4, and 5. B) Patients taking opioids preoperatively will continue to receive their regular opioids and additionally receive 5 mg twice a day of methadone on postoperative days 1 and 2, followed by 5 mg per day on days 3, 4 and 5.
45786808|NCT05693675|Drug|Postoperative placebo|Participants will receive intraoperative methadone intravenously 0.2mg/kg followed by oral placebo postoperatively according to the following scheme: Opioid naïve patients and patients taking opioids preoperatively will receive placebo tablets twice daily on day 1 and day 2 and once daily day 3, 4 and 5. Patients taking preoperative opioids will be able to return to their baseline opioids immediately after surgery.
45786809|NCT05693675|Drug|Rescue Analgesia|PACU analgesia for both groups will be the usual care regime of fentanyl or hydromorphone bolus as prescribed by the physician anesthesiologist doing the case. All patients receive IV intravenous patient-controlled analgesia and rescue opioids which is usual care for postoperative pain.
45919147|NCT05575752|Other|moderate temperature (22℃) group|The exposure group will be exposed to thermoneutral temperature (22℃) in a chamber for about 2 hours, resting during the whole periods.
45919148|NCT04826159|Drug|IMB-1018972|Modified release tablet for oral administration
45919149|NCT05573919|Device|VivAer Stylus|This device will be used to complete its corresponding procedure, which involves reshaping a patient's nasal sidewall tissue through the delivery of radiofrequency heating.
45919150|NCT02764138|Behavioral|Building a Strong Identity and Coping Skills|Psychoeducational program to teach children coping skills, healthy identity development, and collective social action.
46071150|NCT02849522|Procedure|Laser prostate surgery|"This surgical method (HoLEP or KTP/Greenlight) utilizes laser energy to remove tissue. With laser prostate surgery a laser fibre inserted via an endoscope is used to transmit laser energy to enucleate (HoLEP) or vaporise (KTP) the tissue. The specific advantages of utilizing laser energy rather than a traditional electrosurgical TURP is a decrease in the relative blood loss, elimination of the risk of TUR syndrome, the ability to treat larger glands, as well as treating patients who are actively being treated with anti-coagulation therapy for unrelated diagnoses."
46071151|NCT02849366|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
45919151|NCT04804046|Dietary Supplement|Synbiotic|Eighteen participants with Crohn's disease that are undergoing an ileocecal resection will supplement their normal diet with three Bifidobacterium spp. (3x10^9 CFU) plus three dietary fibers (24 g fiber) daily for six months.
45919152|NCT04804046|Other|Digestible Maltodextrin|Eighteen participants with Crohn's disease that are undergoing an ileocecal resection will supplement their normal diet with Maltodextrin daily for six months.
45645072|NCT01143454|Drug|11C-Acetate|
45919153|NCT05570721|Behavioral|Trier Social Stress Test|The TSST has both social-evaluative and arithmetic components. During the social-evaluative component, the participant is asked to prepare and then deliver a brief speech to the research team. After this component there is a surprise arithmetic problem. This challenge paradigm has been well-established to rapidly and robustly induce psychological stress as well as physiological indices of stress (e.g., cortisol response, heart rate response). This task takes approximately 15 minutes to complete.
45919154|NCT02719327|Drug|icosapent ethyl (IPE)|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
45919155|NCT02719327|Other|gel cap placebo|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
46071152|NCT02849366|Biological|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
46071153|NCT02849288|Device|Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS)|Automated Insulin Delivery System
46071154|NCT02846948|Other|Focused assessed echocardiography|Focused assessed transthoracic echocardiography is non-invasive, painless procedure. The transducer is placed on the chest at certain locations and angles to get the required information on patient's condition.
46071155|NCT02848976|Other|Re-training to effort (RE)|The RE program includes three weekly sessions, supervised individually by a teacher in adapted physical activity, during 1:30, for four weeks, for a total of 12 sessions
46071156|NCT02847026|Biological|IPV at 14 and 22 weeks of age, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
45786810|NCT05688410|Other|Exercise|"Participants who are randomized to exercise will be perform exercise on stationary bikes. Participants randomized to Voluntary Exercise will exercise on a standard stationary bike where they will pedal at their voluntary rates. Participants randomized to Assisted Exercise will exercise on a special bike that assists them to pedal faster than they do voluntarily on their own (assisted (exercise) bike)."
45786811|NCT05688410|Behavioral|Psychotherapy Pain and Addiction (I-STOP)|"Participants who are randomized to receive I-STOP will receive the Self-regulation Treatment for Opioid addiction and Pain (STOP) program modified for inpatients/residential drug treatment (I-STOP). I-STOP uses empirically validated pain psychotherapy approaches targeted to patients with an OUD using psycho-physiological self-regulation components and biofeedback with Bio-dots."
45786812|NCT05682170|Drug|ZN-d5 ZN-c3|Oral agent
45786813|NCT05682170|Drug|ZN-c3|Oral agent
45919156|NCT02633098|Drug|Artesunate 200mg|Artesunate 200mg PO OD for 14 days prior to colorectal resection surgery
45919157|NCT02633098|Drug|Placebo|Matched placebo PO OD for 14 days prior to colorectal resection surgery
45919158|NCT04798196|Behavioral|ElderTree on laptop (ET- LT)|"ElderTree (ET) is an existing intervention providing tools, motivation, and support on a computer platform to help older adults manage their health.~ET is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-LT arm will access ET on Laptop (ET- LT)"
45919159|NCT04798196|Behavioral|ElderTree on smart system (ET- SS)|"ElderTree (ET) is an existing intervention providing tools, motivation, and support on a computer platform to help older adults manage their health.~ET is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support.~ElderTree on smart system (ET- SS) will use voice-activated smart speakers connected to the Internet. Because they are used by talking and listening rather than typing and reading, many barriers associated with laptop use can be avoided."
45919160|NCT04798196|Behavioral|Treatment as usual (TAU)|Treatment as usual (TAU)
45919161|NCT05565144|Other|None, pure observational study|None, pure observational study
45919162|NCT04796831|Drug|Quizartinib dihydrochloride|Single oral dose of 60 mg quizartinib (2 x 30 mg tablets)
46071157|NCT02847026|Biological|IPV at 14 and 22 weeks of age, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
46071158|NCT02847026|Biological|IPV at 14 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
46071159|NCT02847026|Biological|IPV at 14 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
45645073|NCT01143454|Drug|13N-Amonia|
45645074|NCT01133756|Drug|Lenvatinib|lenvatinib (as 1mg, 4mg, and 10mg tablets) was administered orally, once daily continuously for each 21-day treatment cycle.
45786814|NCT05676619|Device|3D foot scanner|Reliability of 3D foot scanner during repeated scans
45786815|NCT05675345|Device|HFNC only|HFNC for 1 hour, with FiO2 titrated to SpO2 of 92-96%
45786816|NCT05675345|Device|HFNC + CNEP10|HFNC with CNEP of 10 cmH2O for 1 hour, with FiO2 titrated to SpO2 of 92-96%
45786817|NCT05675345|Device|HFNC + CNEP20|HFNC with CNEP of 20 cmH2O for 1 hour, with FiO2 titrated to SpO2 of 92-96%
45786818|NCT05675345|Device|HFNC + CNEP30|HFNC with CNEP of 30 cmH2O for 1 hour, with FiO2 titrated to SpO2 of 92-96%
45786819|NCT05674981|Dietary Supplement|Probiotic group|Two-strain probiotic supplement includes Lactobacillus reuteri ADR-1 (alive) and Lactobacillus rhamnosus GM-020 ( alive).
45786820|NCT05674981|Other|Placebo group|Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin.
45645075|NCT01133756|Drug|Carboplatin|Carboplatin was to be administered on Day 1 of every 21-day cycle at a dose AUC 4 over 30 minutes.
45786821|NCT05672017|Behavioral|Dietary Instructions|Dietary Instructions
45786822|NCT05667181|Device|Surform|Da Vinci linear cutting stapler
45786823|NCT05658380|Drug|atropine|patients will receive 0.01 mg/kg intravenous atropine in 5 ml normal saline 0.9 % before induction of spinal anaesthesia
45786824|NCT05658380|Drug|Isotonic saline|patients will receive the same volume of isotonic saline 0.9% 5ml (control group) before induction of spinal anaesthesia
45786825|NCT05655273|Drug|Prograf|Participants randomized to the Prograf (control) arm will continue with their current twice daily dosing of Prograf.
45919163|NCT04796831|Drug|14C-Quizartinib solution for infusion|50 μg solution for infusion containing NMT 22.84 kBq 14C in 5 mL; administered once as a 15-minute infusion
45645076|NCT01133756|Drug|Gemcitabine|Gemcitabine was to be administered on Day 1 and Day 8 of every 21-day cycle at a dose of 1000 mg/m2 over 30 minutes.
45919164|NCT00393289|Behavioral|Calcium controlled diet|
45786826|NCT05655273|Drug|Envarsus|Participants randomized to Envarsus arm will have their current daily dose of Prograf converted to once-daily Envarsus dose according to the following ratio: 0.7 x the current daily Prograf dose. Envarsus is available in 3 dose strengths- 0.75mg, 1.0mg, and 4.0mg. The actual dose of Envarsus will be rounded to an amount that can be administered using the above tablet strengths.
45786827|NCT05654207|Behavioral|WeCare|WeCare combines two evidence-based strategies -- universal screening using the Computerized Adaptive Screen for Suicidal Youth and an adapted version of the SAFETY-ACUTE, which incorporates PI Lindsey's extensive work with Black youth, their families, and community stakeholders to develop culturally tailored strategies for addressing treatment barriers.
45786828|NCT05653414|Other|short early psychological care associated with encouragement of early support consultation with generalist practitioner or midwife|4 consultations with a psychologist over 2 months maximum
45786829|NCT05653414|Other|encouragement of early support consultation with generalist practitioner or midwife|encouragement of early support consultation with generalist practitioner or midwife
45786830|NCT05651061|Biological|SS109|27 patients are enrolled in cohorts ,and will continue to be followed up until 28 days after SS109 administration for evaluating safety, PK/PD and immunogenicity.
45645077|NCT01126736|Drug|eribulin mesylate|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
45786831|NCT05645068|Diagnostic Test|Optical Coherence Tomography Angiography|Optical Coherence Tomography Angiography
45786832|NCT05645068|Other|multidisciplinary care program|multidisciplinary care program including sports activity
45786833|NCT05642078|Biological|Investigational Vaccine(0.25ml/vial)|Subjects were vaccinated with a dose of low-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
45786834|NCT05642078|Biological|Investigational Vaccine(0.5ml/vial)|Subjects were vaccinated with a dose of high-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
45786835|NCT05642078|Biological|Active compared Vaccine|Subjects were vaccinated with a dose of active compared vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
45786836|NCT05641896|Drug|[18F]FAPI-74 PET/CT|[18F]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with gastrointestinal cancers.
45786837|NCT05641402|Other|Text messages|Text messages based on behaviour change techniques
45786838|NCT05640245|Drug|Sonelokimab|randomized treatment; parallel group
45786839|NCT05640245|Drug|Placebo|randomized treatment; parallel-group
45786840|NCT05640245|Drug|Adalimumab|randomized treatment; parallel-group
45645078|NCT01126736|Drug|pemetrexed|Pemetrexed given at a dose of 500 mg/m2 as an IV infusion on Day 1 of a 21-day cycle. Patients will also receive dexamethasone and vitamin supplements as recommended in the prescribing information for pemetrexed.
45645079|NCT01126736|Drug|Eribulin mesylate (eribulin; E7389)|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
45645080|NCT01117844|Radiation|Proton Radiation|Protons have been demonstrated for medulloblastoma and prostate cancer, and comparative treatment planning using protons versus photons have shown a clear advantage to protons in terms of dose distribution.
45786841|NCT05637814|Diagnostic Test|SpO2/PIx Measurement and ML Algorithm|Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured and an online ML inference model will be used to classify a newborn as healthy versus CCHD as new pulse oximetry data is collected.
45786842|NCT05630235|Drug|CBD|Participants will be administered a one time dose of 250mg of CBD orally.
45786843|NCT05630235|Other|Placebo|The placebo equivalent of the CBD oil administered orally.
45786844|NCT05624710|Drug|INCB054707|INCB054707 75 mg will be administered orally on Day 1.
45786845|NCT05624528|Drug|Tolcapone|catechol-O-methyl transferase inhibitor
45786846|NCT05624528|Drug|Placebo|Pill that contains no medicine
45786847|NCT05624151|Drug|Dexmedetomidine +Bupivacaine|infraorbital nerve block by dexmedetomidine plus bupivacaine
45786848|NCT05624151|Drug|Magnesium Sulfate + Bupivacaine|infraorbital nerve block by magnesium sulphate plus bupivacaine
45786849|NCT05624151|Drug|Bupivacaine|infraorbital nerve block by bupivacaine only
45786850|NCT05623527|Device|cardiac electronic implants|Cardiac electronic implants(CIED) includes permanent pacemaker (PPM), implantable cardioverter defibrillator (ICD), three-chamber pacemaker for cardiac resynchronization therapy defibrillator, lead free pacemaker, etc.
46071160|NCT02847026|Biological|IPV at 6 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
45786851|NCT05620914|Drug|Patritumab deruxtecan|Patritumab deruxtecan (HER3-DXd) will be administered IV 5.6 mg/kg as a single dose 1-3 days prior to planned craniotomy and resection of brain metastasis
45786852|NCT05612477|Procedure|Autotransfusion|blood is collected from the surgical field, washed, processed and transfused back into the patient
45786853|NCT05610449|Diagnostic Test|Testing Done Simple SARS CoV-2 Antigen Test|Collections of specimens from subjects presenting with Covid-19 like symptoms or known/suspected exposure to SARS CoV-2 via nasal swabs administered by trained medical personnel.
45919165|NCT05543538|Other|multimedia audio-visual program|Participants in the control group will receive teaching method with multimedia audio-visual material.
45786854|NCT05609409|Behavioral|FlexED|Intervention consists of eight 20-30 minute sessions of a digital intervention based on Acceptance and Commitment Therapy (ACT). Participants learn skills of body image flexibility by following an avatar through a story line and completing interactive exercises.
45786855|NCT05599178|Other|Ultrasound examination in early labor|Combined trans-abdominal and trans-perineal ultrasound examination
45919166|NCT05543538|Other|experiential learning programmes|Participants in the experimental group will receive teaching method with experiential learning.
45919167|NCT05543538|Other|teachers' personal demonstration|Participants in the experience group will receive teachers' personal demonstration.
45786856|NCT05596825|Device|Mandibular Advancement Device|"To analyze the phenotypic characteristics of different subgroups of patients with obstructive sleep apnea syndrome who respond better (complete responders) or worse (partial responders or non-responders) to treatment with mandibular advancement devices.~Responders will be defined as a post-treatment AHI of less than 10/h and at least a 50 percent reduction in their AHI. Partial responders will be defined as a post-treatment AHI greater than 10/hour but at least a 50 percent reduction in AHI, and non-responders as less than a 50 percent reduction compared to baseline."
45786857|NCT05594238|Behavioral|Telephone Engagement|Brief phone session with a study counselor.
45786858|NCT05594238|Behavioral|Portal Engagement|Access to a virtual portal where participant messages with study counselors.
45786859|NCT05594238|Behavioral|MI-CBT|8 one-on-one sessions done over the phone or video chat with a study counselor
45786860|NCT05593146|Behavioral|modified anteversion angle placement(( α-15°)±10°)|"Preoperative examination was conducted to determine a safe surgical margin in all patients. A 3D printed osteotomy guide combined with a 3D printed prosthesis pre- designed anteversion angle is assembled for reconstruction after tumor resection.~Once completed, intraoperative X-ray fluoroscopy was applied to evaluate the anteversion angle of the acetabular component. If the anteversion angle doesn't meet the predetermined criteria, it needs to be adjusted until it does."
45786861|NCT05593146|Behavioral|conventional anteversion angle placement ( α±10°)|"Preoperative examination was conducted to determine a safe surgical margin in all patients. A 3D printed osteotomy guide combined with a 3D printed prosthesis with predesigned anteversion angle is assembled for reconstruction following tumor resection.~Once completed, intraoperative X-ray fluoroscopy was applied to evaluate the anteversion angle of the acetabular component. If the anteversion angle doesn't meet the predetermined criteria, it needs to be adjusted until it does."
45786862|NCT05590884|Drug|Gadopiclenol|Patients will receive a single dose of gadopiclenol calculated according to their BW on the day of MRI examination. Gadopiclenol will be administered at a dose of 0.05 mmol/kg BW (0.1 mL/kg BW).
45919168|NCT02287090|Other|Observational Cohort|
45919169|NCT02285179|Drug|GDC-0032|Dose of GDC-0032 given orally, once daily (total daily dose) level -1: 2 mg Q.O.D GDC-0032 level 1: (starting) 2 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd level 2: 4 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd
46071161|NCT02847026|Biological|IPV at 6 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
45645081|NCT01111461|Drug|Lenvatinib|Lenvatinib 24 mg administered orally, once daily continuously in 28-day cycles to participants with advanced endometrial cancer and disease progression following first-line chemotherapy. Participants continued to receive study drug until disease progression, development of unacceptable toxicity or withdrawal of consent. 'Treatment interruption and subsequent dose reduction' was allowed for participants who experienced lenvatinib-related toxicity.
45645082|NCT01104155|Drug|eribulin mesylate + erlotinib|21-day Regimen: Eribulin mesylate given at a dose of 2 mg/m2 as a 2-5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 2-16 of a 21-day cycle.
45645083|NCT01104155|Drug|eribulin mesylate + erlotinib|28-day Regimen: Eribulin mesylate given at a dose of 1.4 mg/m2 as a 2-5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15-28 of a 28-day cycle.
45645084|NCT01067287|Drug|CT-011|Infusions starting one to three months following autologous transplant at 6 week intervals for a total of 3 doses
45645085|NCT01067287|Biological|Dendritic Cell Fusion Vaccine|One week following each infusion of CT-011
45645086|NCT01065597|Device|Nonconvulsive electrotherapy|An electrical stimulus will be given as in electroconvulsive therapy (ECT)using bifrontal electrode placement and a Thymatron System IV device; however, the device will be set at a lower energy level that is 12.5%(1/8) of the expected energy needed to induce a seizure rather than at an energy level that is at or above the seizure threshold.
45919170|NCT02285179|Drug|Tamoxifen|daily dose of 20 mg
45919171|NCT04744220|Other|Yoga Training Program (exercises)|Training: Before the yoga program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters used in the evaluation, tests and the content of the yoga session. The patients will start with breathing exercises, then relaxation exercises, warm-up exercises, asanas (posture exercises) and finally the yoga training program will be completed with deep relaxation technique.
45919172|NCT02250937|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
45919173|NCT02250937|Drug|Busulfan|Given IV
45919174|NCT02250937|Drug|Cladribine|Given IV
45919175|NCT02250937|Drug|Fludarabine Phosphate|Given IV
45919176|NCT02250937|Other|Laboratory Biomarker Analysis|Correlative studies
45919177|NCT02250937|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
45919178|NCT02250937|Other|Pharmacological Study|Correlative studies
45919179|NCT02250937|Drug|Venetoclax|Given PO
46071162|NCT02847026|Biological|fIPV at 6-14-22 weeks of age, Rotarix|Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
45645087|NCT01051856|Device|SEAMGUARD with bioabsorbable staple|In the SEAMGUARD group, pancreatic resection and transection of the pancreatic body will be executed using an endoscopic linear stapling device.
45645088|NCT01051856|Procedure|TissueLink with radiofrequency ablation|After pancreatic transection with the method of choice of the operating surgeon, the pancreatic remnant will be treated with Tissuelink alone for an ablation depth (thickness) of approximately 7 mm.
45786863|NCT05588778|Behavioral|BAILAMOS™ @home/en casa|The BAILAMOS™ dance program and dance manual. BAILAMOS™ originally encompassed four dance styles: Merengue, Cha Cha Cha, Bachata, and Salsa. These four styles of Latin dance are generally considered the most popular in terms of recognition and preference. We have added two styles to appeal to the largely Mexican-origin Latinos in Chicago (i.e., Cumbia and Samba). The dances were jointly choreographed by the PI and Mr. Mendez, a professional dance instructor and owner of The Dance Academy of Salsa and http://www.salsachicago.com/. The PI and dance instructor co-developed the extensive manual is used by program instructors and includes background information on the authors, an introduction describing the goals of the program, and descriptions of the various styles of dance. The manual also has photos and descriptions of each dance broken down into its component parts.
45786864|NCT05588778|Behavioral|¡En Forma y Fuerte! @home/en casa|The ¡En Forma y Fuerte! Program. ¡En Forma y Fuerte! is designed to be delivered in Spanish by bilingual, bicultural, qualified exercise instructors. Instructors are required to have an exercise instructor/specialist certification through a national organization such as the American College of Sports Medicine, American Council on Exercise, or Aerobics and Fitness Association of America, or to have an undergraduate degree in an exercise science related field. The 8 hour training uses both didactic and hands-on role modeling for delivering both the exercise and health education components of the program. Instructors in the online version will also participate in a 60 minute training designed for this new version of the program. We have previously developed an asynchronous, online instructor training for the customary program and will translate it to Spanish for this proposal.
45786865|NCT05588713|Procedure|Brief assessment protocol|The intervention constitutes of a brief assessment protocol for assessing ADHD.
45645089|NCT01044069|Biological|gene-modified T cells targeted|Pts will undergo leukapheresis. The leukapheresis product will be washed & frozen until the GTF is directed to start T cell production by the PI. CD3+ T cells will be isolated from the leukapheresis, & transduced with the 19-28z chimeric receptor & expanded. All relapsed (either MRD+ or morphologic) & refractory pts get re-induction chemo whenever feasible to optimally reduce the tumor burden prior to the T cell infusion. The re-induction chemo regimen will be selected by the treating dr. based on prior therapy, adverse reactions to chemo & highest likelihood to achieve an optimal response. Once pts recover from the toxicities of the re-induction chemo the disease status will be re-evaluated by repeating bone marrow aspirate or biopsy. Pts get conditioning chemo (min 2 weeks from end of re-induction chemo) followed 2-7 days later by the 19-28z+ T cells. Pts will be tx in 2 cohorts with diff doses of T cells according to the amount of disease immediately prior to the T cell infusion.
45645090|NCT01029366|Biological|CART-19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
45645091|NCT01005745|Procedure|Surgery|Surgery to remove a tumor for growth of TIL
45786866|NCT05588713|Procedure|Comprehensive assessment protocol|The intervention constitutes of a comprehensive assessment protocol for assessing ADHD.
45786867|NCT05588609|Drug|Afatinib Oral Tablet|anti epidermal growth factor receptor (EGFR)/HER2 agent
45786868|NCT05588609|Drug|Enzalutamide Pill|second-generation androgen receptor antagonist
45786869|NCT05588609|Drug|Abiraterone acetate tablets|androgen synthesis inhibitor
45786870|NCT05588609|Biological|MCLA-128|full length IgG1 bispecific antibody targeting HER2 and HER3
45786871|NCT05584007|Drug|Flucloxacillin Only Product in Oral Dose Form|Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by blinded flucloxacillin 500mg for 2 days, reaching a total of 7 days of antibiotic treatment
45786872|NCT05584007|Drug|Placebo Only Product in Oral Dose Form|Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by a blinded placebo for 2 days, reaching a total of 5 days of antibiotic treatment
45786873|NCT05643976|Behavioral|KardioPAC Mobile Application|"Like those in the SOC CR arm, participants assigned to the CR+KardioPAC arm will receive standard of care and attend CR as prescribed by their physician. Additionally, they will receive access to the digital app, KardioPAC, & a BP device for home use that will record their BP readings in the app.~KardioPAC is a remote patient monitoring system that allows providers to monitor patients and send out daily reminders. It integrates with BP monitors and fitness watches to collect patient health information at home. The information is uploaded to the HIPAA-compliant server and presented on the website for providers to read. Its reminder system can be customized to meet diverse clinical needs.~Lastly, the Kura Care in-house Registered Nurse will provide 20-30 min of health coaching to intervention arm participants on a weekly or bi-weekly basis via the app. The coaching will include greetings, review of medication adherence, encouragement to exercise, and symptom management, if applicable."
45786874|NCT05643976|Other|Standard of Care|During the prescribed cardiac rehabilitation, the SOC CR intervention participants will receive standard of care by attending the 36-72 sessions of CR as prescribed by his/her physician and administered by the University of California San Diego Health Cardiac Rehabilitation Center.
45786875|NCT05582356|Dietary Supplement|Carbohydrate group (Group OC)|Carbohydrate group (Group OC)
45786876|NCT05582356|Dietary Supplement|Placebo group (Group OP|Placebo group (Group OP
45786877|NCT05570292|Drug|Domperidone|ultrasound guieded assesment of gastric residual volume will be done 2 h after oral injestion of domperidone tablet
46071163|NCT02847026|Biological|fIPV at 6-14-22 weeks of age, RotaTeq|Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
46071164|NCT02849054|Device|Measurement of PTPdi|Insertion of pressure transducer catheter to measure gastic and oesophadgeal pressures for calculation of PTPdi
46071165|NCT02849054|Device|TTV at 4ml/kg|Provision of targetted tidal volume of 4ml/kg
46071166|NCT02849054|Device|TTV at 5ml/kg|Provision of targetted tidal volume of 5ml/kg
46071167|NCT02849054|Device|TTV at 6ml/kg|Provision of targetted tidal volume of 6ml/kg
45786878|NCT05570292|Drug|Folic acid|ultrasound guieded assesment of gastric residual volume will be done 2 h after oral injestion of folic acid tablet
45786879|NCT05559905|Drug|Molnupiravir|Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
45786880|NCT05559905|Drug|Placebo|Placebo capsule matched to molnupiravir taken twice daily by mouth.
45786881|NCT05559905|Biological|RSV A Memphis 37b|RSV A Memphis 37b viral challenge given once by intranasal administration at a dosage of ~4 Log10 plaque forming units (PFUs).
45786882|NCT05554939|Biological|Allogenic CD19-CAR-γδT cell|Phase 1 dose escalation (3+3) : dose 1 (2 × 10^6 cells/kg) , dose 2 (6 × 10^6 cells/kg), dose 3 (1.8 × 10^7 cells/kg); Phase 2 : dose of RP2D.
45786883|NCT05554939|Drug|Fludarabine|Intravenous fludarabine 25~30 mg/m^2/day on days -5, -4, and -3.
45786884|NCT05554939|Drug|Cyclophosphamide|Intravenous cyclophosphamide 300~500 mg/m^2/day on days -5, -4, and -3.
45786885|NCT05554939|Drug|Doxorubicin Hydrochloride Liposome|Intravenous doxorubicin hydrochloride liposome 10~15 mg/m^2/day on day -6.
45786886|NCT05554939|Drug|Mechlorethamine Hydrochloride|Intravenous mechlorethamine hydrochloride 8~10 mg/m^2/day on day -6.
45786887|NCT05545891|Drug|Placebo|A drug that contains no medicine
45786888|NCT05545891|Drug|Aripiprazole|Atypical antipsychotic medication
45786889|NCT05545007|Radiation|Hypofractionated Radiosurgery (HSRS)|HSRS converges multiple radiation beams to deliver a single, large dose of radiation to a discrete tumor target with high precision, thereby minimizing radiation dose to the surrounding normal tissue.
45786890|NCT05545007|Procedure|Brain metastases surgical resection|Complete surgical resection of brain lesions with adeguate margins.
45786891|NCT05544526|Biological|GD2 CAR T cells|Infusion with: GD2 CAR T-cells
45786892|NCT05543629|Biological|BMS-986442|Specified dose on specified days
45645092|NCT01005745|Drug|Administration of Lymphodepletion|Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo
45786893|NCT05543629|Biological|Nivolumab|Specified dose on specified days
45786894|NCT05543629|Drug|Docetaxel|Specified dose on specified days
45786895|NCT05543629|Drug|Carboplatin|Specified dose on specified days
45786896|NCT05543629|Drug|Pemexetred|Specified dose on specified days
45786897|NCT05543629|Drug|Paclitaxel|Specified dose on specified days
45786898|NCT05535166|Procedure|Surgical resection|"All participants enrolled will undergo surgical resection prior to treatment. The maximal resection that can be achieved without undue risk to the patient will be attempted, with decisions about feasibility and extent of resection left to the discretion of the neurosurgeon. In instances where an STR is the best extent of resection achieved prior to start of therapy, a second-look surgery may be performed between cycles of chemotherapy after discussion with the principal investigator."
45786899|NCT05535166|Procedure|Ommaya/VPS|All participants enrolled on S-1 will undergo
45786900|NCT05535166|Drug|Methotrexate|Route of administration: Intravenously (IV)
45786901|NCT05535166|Drug|Cisplatin|Route of administration: Intravenously (IV)
46071168|NCT02849210|Biological|Allergovac depot with Olea europaea pollen extract|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly increasing dose injections at the initiation phase plus 3 maintenance monthly injections.
45645093|NCT01005745|Other|Adoptive Cell Transfer|T-cell infusion
46071169|NCT02849132|Drug|Entecavir|oral entecavir 0.5mg daily for 8 years
45645094|NCT01005745|Drug|High Dose IL-2|Beginning approximately 12 - 16 hours after cell infusion.
45645095|NCT00978458|Drug|temozolomide|Given orally
45645096|NCT00978458|Radiation|3-dimensional conformal radiation therapy|Given once daily 5 days a week for 5½ weeks
45786902|NCT05535166|Drug|Vincristine|Route of administration: Intravenously (IV)
45786903|NCT05535166|Drug|Cyclophosphamide|Route of administration: Intravenously (IV)
45786904|NCT05535166|Drug|Carboplatin|Route of administration: Intravenously (IV)
45786905|NCT05535166|Drug|Topotecan|Route of administration: Intravenously (IV)
45786906|NCT05535166|Drug|Etoposide|Route of administration: Intravenously (IV)
45645097|NCT00978458|Radiation|intensity-modulated radiation therapy|Given once daily 5 days a week for 5½ weeks
45645098|NCT00956007|Biological|cetuximab|Given IV
45786907|NCT05535166|Drug|Pegfilgrastim|Route of administration: subcutaneous (SQ)
45786908|NCT05535166|Drug|Filgrastim|Route of administration: subcutaneous (SQ) or Intravenously (IV)
45786909|NCT05535166|Radiation|Irradiation|All participants in stratum N will undergo craniospinal irradiation (CSI) with boost to the primary tumor site once they reach 36 months of age. The dose given is based on the molecular risk group and disease response to chemotherapy as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
45786910|NCT05535166|Other|Educational and Media Intervention|Participants watch a 75-minute caregiver education video program and receive access to interactive games on a smartphone or tablet throughout the optional cognitive study.
45786911|NCT05535166|Other|SOC, Educational and Media Intervention|Standard-of-care (SOC) treatment during main cognitive study. After the one-year serial cognitive evaluation, participants will be offered participation in the cognitive study group I intervention.
45786912|NCT05534880|Other|Binaural beats|Condition 02- will be used binaural beats, since they are referred through studies with the ability to drive neural oscillations in the beat frequency through differential hemispheric synchronization frequencies, it is expected that a neuromodulation and repercussion of the symptomatological reduction of CS.
45786913|NCT05533697|Biological|mRNA-4359|Intramuscular Injection
45786914|NCT05533697|Biological|Pembrolizumab|Intravenous infusion
45786915|NCT05528458|Drug|Osimertinib 80Mg Tab|Subjects have a osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection
45919180|NCT02122081|Radiation|radiation therapy|Undergo organ-sparing marrow irradiation BID on days -6 to -4
45919181|NCT02122081|Drug|cyclophosphamide|Given IV over 1-2 hours every 24 hours on days -3 to -2.
45645099|NCT00956007|Radiation|intensity-modulated radiation therapy|Patients undergo radiotherapy.
45786916|NCT05524909|Genetic|Genetic Risk Estimate|The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).
45786917|NCT05524909|Device|Genetic Risk Estimate + Fitbit Functions|"The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate."
45919182|NCT02122081|Biological|anti-thymocyte globulin|
45919183|NCT02122081|Drug|tacrolimus|Given IV or PO
46071170|NCT02321228|Procedure|Salpingectomy with delayed oophorectomy|Early salpingectomy upon completions of childbearing with postponement of oophorectomy until between 40 and 45 in BRCA1 mutation carriers and between age 45 and 50 in BRCA2 mutation carriers.
45645100|NCT00897767|Other|biologic sample preservation procedure|
45645101|NCT00887146|Drug|concomitant temozolomide (TMZ)|75 mg/m^2, orally daily
45645102|NCT00887146|Radiation|radiotherapy|
45645103|NCT00887146|Drug|procarbazine|Days 8-21: 60 mg/m^2 orally
45645104|NCT00887146|Drug|adjuvant temozolomide (TMZ)|150 or 200 mg/m^2 orally
45645105|NCT00887146|Drug|CCNU|Day 1: 110 mg/m^2 orally
45645106|NCT00887146|Drug|vincristine|Days 8 and 29: 1.4 mg/m^2 IV
45645107|NCT00879086|Drug|Eribulin Mesylate|"E7389 (eribulin mesylate) given at a dose of 1.4 mg/m^2 as a 2 to 5 minute intravenous (IV) bolus on Days 1 and 8 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment."
45919184|NCT02122081|Drug|methotrexate|Given IV
45645108|NCT00879086|Drug|Ixabepilone|"Ixabepilone given at a starting dose of 32 or 40 mg/m^2 (as per approved labeling) as a 3-hour IV infusion on Day 1 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment."
46071171|NCT02321228|Procedure|Risk-reducing salpingo-oophorectomy|This is the current guideline procedure, usually performed between age 35 and 40 in BRCA1 mutation carriers and between age 40 and 45 in BRCA2 mutation carriers.
46071172|NCT02846870|Other|Visually enhanced prostate cancer educational presentation|Receive visually enhanced prostate cancer educational presentation
45786918|NCT05524571|Drug|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
45919185|NCT02122081|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant on day 0
45919186|NCT02122081|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
45919187|NCT02122081|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
45919188|NCT02122081|Other|laboratory biomarker analysis|Correlative studies
45919189|NCT04710173|Procedure|ECMO|VV-ECMO
46071173|NCT02846870|Other|Standard prostate cancer education presentation|Receive standard prostate cancer education presentation
46071174|NCT05116826|Drug|Nitazoxanide|500 mg Twice Daily for 7 days
46071175|NCT04268264|Procedure|Incremental haemodialysis|twice weekly haemodilysis at the start, gradually building up to full dose dialysis over a period of 15 weeks
46071176|NCT04268264|Procedure|Conventional haemodialysis|three times weekly 4-hour long haemodialysis sessions from the start
46071177|NCT04862078|Diagnostic Test|Shared decision making|"Shared decision making and decide surveillance strategy between standard follow-up according to the institutional practice and decide what to do advanced imagings for surveillance and guideline-based surveillance"
46071178|NCT04862078|Diagnostic Test|Usual care|standard follow-up according to the institutional practice
45645109|NCT00832429|Procedure|Lymph Node Mapping|Undergo lymph node mapping
45645110|NCT00832429|Procedure|Sentinel Lymph Node Biopsy|Undergo SLN biopsy
45645111|NCT00832429|Drug|Technetium Tc-99m Sulfur Colloid|Given ID
45645112|NCT00796263|Drug|HAART|"2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications or Kivexa (ABC300/3TC300) orally once daily~Dolutegravir(DTG) 50 mg orally once daily"
45645113|NCT00769379|Other|Laboratory Biomarker Analysis|Correlative studies
45645114|NCT00769379|Biological|Trastuzumab|Given IV
45645115|NCT00769379|Radiation|Whole Breast Irradiation|Undergo standard whole breast irradiation
45645116|NCT00715442|Drug|Sunitinib|50 mg by mouth daily for 28 consecutive days
45645117|NCT00715442|Procedure|Nephrectomy|Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
45645118|NCT00697684|Drug|Antithymocyte Globulin|
45919190|NCT04708886|Drug|Romosozumab|Year 1 study drug
45919191|NCT04708886|Drug|Alendronate|Year 2 study drug
45919192|NCT00393328|Drug|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg as 2-150mg + RTV 100mg, single dose, 7 days washout crossed over to Treatment B.
45919193|NCT00393328|Drug|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg as single cap + RTV 100mg, single dose, 7 days washout.
45786919|NCT05524571|Drug|Placebo|Matching Placebo
45786920|NCT05520333|Behavioral|BIPAS Alcohol|Provider education at well-visit and weekly text messages for six months.
45786921|NCT05519566|Diagnostic Test|Retrograde Urethrogram|Fluoroscopy Retrograde Urethrogram Vs the Traditional Retrograde Urethrogram
45786922|NCT05517421|Drug|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
45786923|NCT05517421|Drug|Placebo|Matching Placebo
45786924|NCT05507723|Other|Treat-to-target|Treatment to achieve urate target using supported self-management approach
45786925|NCT05507723|Other|Treat-to-flare|Treatment escalation based on reported flares of gout
45919194|NCT05530551|Other|Antibiotic dosage practice|"Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years.~All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered.~In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines."
45919195|NCT01843504|Biological|platelet rich plasma|A blood draw of 15 mL of the subject's own blood will be performed. The study coordinator will then place the sample in the Platelet Separator System (a centrifuge) and spin the blood sample in using a two-stage spinning: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets. This will be spun by centrifuge to yield 6 mL of concentrated autologous platelet. Under continuous ultrasound evaluation, 1.0-2.0 mL of the prepared PRP will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
45786926|NCT05494762|Drug|BGB-B167|Intravenous administration
45786927|NCT05494762|Drug|Tislelizumab|Intravenous administration
45786928|NCT05493215|Drug|Imatinib|Therapeutic drug level monitoring with plans to increase to adjust drug dosage based on levels and patient symptoms.
45919196|NCT01843504|Other|saline|A blood draw of 15 mL of the subject's own blood will be performed to maintain blinding. Under continuous ultrasound evaluation, 1.0-2.0 mL of the saline solution will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
45919197|NCT01807468|Procedure|haploidentical stem cell transplantation and NK cell therapy|
45919198|NCT04667468|Biological|Cold Stored Platelets (CSP)|early infusion of urgent release CSP
45786929|NCT05490706|Behavioral|Bodyweight interval exercise|Performing 15 minutes of bodyweight interval exercise after dinner at home by following a video
45786930|NCT05490706|Behavioral|Walking|Performing a 30 minute minute walk after dinner at home
45919199|NCT04667468|Biological|Standard Care|standard care including blood and blood component therapy
45919200|NCT01807429|Drug|Ketamine-midazolam|Ketamine 300-500mcg/kg plus midazolam 0.03 mg/kg once.
45919201|NCT01807429|Drug|Morphine|morphine 0.05 mg/kg
45919202|NCT01807312|Device|Endoscopic CO2 regulation unit and accessories|Olympus UCR Endoscopic CO2 Regulation Unit
45919203|NCT01807312|Device|Placebo|
45919204|NCT01807273|Other|Walking test|
45919205|NCT01807195|Other|contrast medium usage|
45786931|NCT05489744|Drug|[14C]Afuresertib|Suspension containing approximately 125 mg of Afuresertib (containing 150 µCi of [14C]Afuresertib) is administered orally on an empty stomach, with approximately 240 mL of water for suspending and drug taking.
45786932|NCT05480228|Drug|NRD135SE.1|The double-blind treatment phase is up to 13 weeks.
45786933|NCT05480228|Other|Placebo|A matching placebo will be taken for up to 13 weeks.
45786934|NCT05478278|Drug|Psilocybin|The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains psilocybin (API only in a capsule).
45786935|NCT05478278|Drug|Moxifloxacin|The positive comparator used in this study is a 400 mg moxifloxacin tablet.
45786936|NCT05478278|Drug|Micro-Crystalline Cellulose|The placebo used in this study is encapsulated using a HPMC capsule and contains micro-crystalline cellulose.
45786937|NCT05471986|Device|Color Fundus Photography/Non-Mydriatic Opthalmic Cameras|Subjects will have underwent Fundus Photography using FDA approved non-mydriatic fundus cameras compatible with EyeCheckup which are either TOPCON NW400, CANNON CR2, CANNON CR2 Plus or OPTOMED AURORA IQ
45786938|NCT05470478|Device|Mobile neural decoding platform (mobile iBCI)|An embedded neural signal processor device will be evaluated for its ability to provide accurate and reliable closed-loop control in a home-based brain-computer interface.
45786939|NCT05467761|Drug|Oral Psilocybin|25mg orally
45786940|NCT05467761|Drug|IV Psilocybin|5mg intravenously
45786941|NCT05462834|Other|Compressed Air|Participants will be instructed to use compressed air during sleep as a placebo control.
45919206|NCT01807078|Drug|Ezetimibe|10 mg p.d. of ezetimibe
45919207|NCT01807078|Dietary Supplement|Nutraceuticals|1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg
45919208|NCT01807039|Procedure|hip fracture surgery|we evaluate the relationship between the monitored parameters and 30 day survival
45919209|NCT05526885|Diagnostic Test|CAD4TB|A posterior anterior digital chest X-ray incoporated in a mobile diagnostic unit is analysed by CAD4TB version 7 (Delft Imaging, NL). A trained and qualified person in compliance with national regulations will operate the digital chest X-ray.
45449264|NCT02766088|Procedure|Blood sample collection|All participants will have an enrolment visit with collection of a blood sample and a termination contact/visit. Participants or their parents/guardians will be contacted weekly or every two weeks to monitor the occurrence of febrile episodes. Additional visits will be made if febrile episodes occur. In case of dengue suspicion, a blood sample will be collected.
45449265|NCT03639675|Drug|Aflibercept (EYLEA, BAY86-5321)|2 mg (0.05 mL), Intravitreal injection (IVT), single dose.
45449266|NCT03639675|Drug|Topical IOP-lowering drugs|A combination of at least 3 topical IOP-lowering drugs will be administered during a run-in phase before treatment and should be kept unchanged until IOP evaluation at Week 1, after which they may be reduced according to the investigator's opinion
45645119|NCT00697684|Drug|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
45645120|NCT00697684|Drug|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
45645121|NCT00697684|Drug|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
45645122|NCT00675922|Drug|Sulfamylon 5% and Silver Nitrate Soaks|Application of Sulfamylon and Silver Nitrate Solution to burn wound daily
45645123|NCT00591812|Device|ComPreSs Distal Femoral Replacement System.|ComPreSs system of intramedullary fixation along with the Finn Knee system
45919210|NCT05526885|Diagnostic Test|POC-CRP|A quantitative POC-CRP LumiraDx (LumiraDx Limited, UK) triage test will be performed by finger-prick if CAD4TB scores is within the defined threshold window of study approach 2 triage testing
45919211|NCT05526885|Diagnostic Test|Xpert MTB/RIF Ultra|Depending on CAD4TB (approach 1 & 2) or POC-CRP score (approach 2) a confirmatory Xpert MTB/RIF Ultra(Cepheid, USA) rapid sputum molecular testing follows for both Mycobacterium tuberculosis complex and rifampicin resistance;
45449267|NCT03543436|Drug|Temocillin|Intravenous temocillin disodium 2g intravenously/8h Or Renally Adjusted Equivalent (ORAE) in 30-40 min infusion or continuous intravenous (6g/24h) .
45449268|NCT03543436|Drug|meropenem or imipenem|Intravenous carbapenem (meropenem 1g intravenously/8h Or Renally Adjusted Equivalent (ORAE) or imipenem 1g intravenously/8h ORAE)
45645124|NCT00466531|Biological|therapeutic autologous lymphocytes|
45645125|NCT00466531|Drug|cyclophosphamide|
45645126|NCT00458653|Biological|Dendritic Cell Tumor Fusion|"Post-Transplant (Groups A and B): Given under the skin every four weeks for three doses.~Pre-Transplant (Group B): Injected under the skin in upper part of leg or arm prior to stem cell collection for ASCT"
45645127|NCT00302146|Drug|15-0 H20|
45645128|NCT00244933|Dietary Supplement|genistein|Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
45645129|NCT00244933|Drug|gemcitabine|Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days
45645130|NCT00244933|Procedure|Tumor biopsy|Biopsy of tumor prior to dose of genistein (Novasoy)
45786942|NCT05462834|Other|Supplemental Oxygen|Participants will be instructed to use supplemental oxygen at rate of 2lpm during sleep.
45645131|NCT00165425|Procedure|Echo/Stress Echo|Participants will under resting echocardiogram and stress echocardiogram (echo and stress echo) and the results will be interpreted by a cardiologist
45645132|NCT00121719|Drug|Lenvatinib|Lenvatinib tablets taken orally, once daily.
45645133|NCT00065676|Other|Quercetin|1 or 2 grams of quercetin or placebo will be given while patients undergo 6-hour OGTT
45645134|NCT00065676|Other|Placebo|
45645135|NCT00053209|Drug|gemcitabine hydrochloride|
45645136|NCT00053209|Drug|pemetrexed disodium|
45645137|NCT00039429|Drug|atrasentan hydrochloride|
45645138|NCT00014508|Biological|sargramostim|
45645139|NCT00014508|Drug|cyclophosphamide|
45786943|NCT05460585|Device|Cerebral oximetry using Rheopatch|"On the study visit, baseline demographic data (age and gender, BMI) are collected. In supine position the sensor patches (left and right) of the device are applied to the forehead and the cerebral oxymetry values are recorded during 120sec. The sensor patches are then removed and the patches of the second device are applied on the same position on the forehead and the measurement is carried out as described before. For the first measurement of each sensor, a total of 5 minutes equilibration and sensor output power adjustment is allowed. A total of 10 measurements are taken, 5 with each device.~The volunteer is then placed in Trendelenburg position and another 4 measurements are made (2 with each device) as previously described."
45919212|NCT01349803|Drug|PT005 MDI|PT005 MDI administered as two puffs BID for 14 days
45919213|NCT01349803|Drug|PT001 MDI|PT001 MDI administered as two puffs BID for 14 days
45919214|NCT01349803|Drug|PT003 MDI|PT003 MDI administered as two puffs BID for 14 days
45919215|NCT01349803|Drug|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol Fumarate 12 μg (Foradil® Aerolizer®) administered BID for 14 days
45919216|NCT01807000|Drug|Radiolabeled Prucalopride Succinate|A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.
45919217|NCT04636853|Biological|Subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP)|"A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.~A complete morpho-functional ophthalmological evaluation will be performed in all patient at each control."
45919218|NCT01806922|Behavioral|Yoga|
45919219|NCT01806883|Behavioral|WII Rehabilitation|"30 patients will receive Wii rehabilitation of 15 minutes (tennis, boxing and golf), in comparison with 10 healthy subjects."
45645140|NCT00014508|Drug|cyclosporine|
45645141|NCT00014508|Drug|fludarabine phosphate|
45645142|NCT00014508|Drug|melphalan|
45449269|NCT03732651|Procedure|alteration of PaCO2 level|step changes between 30, 40 and 50 mmHg
45645143|NCT00014508|Procedure|peripheral blood stem cell transplantation|
45786944|NCT05460585|Device|Cerebral oximetry using NIRO-200NX|"On the study visit, baseline demographic data (age and gender, BMI) are collected. In supine position the sensor patches (left and right) of the device are applied to the forehead and the cerebral oxymetry values are recorded during 120sec. The sensor patches are then removed and the patches of the second device are applied on the same position on the forehead and the measurement is carried out as described before. For the first measurement of each sensor, a total of 5 minutes equilibration and sensor output power adjustment is allowed. A total of 10 measurements are taken, 5 with each device.~The volunteer is then placed in Trendelenburg position and another 4 measurements are made (2 with each device) as previously described."
45786945|NCT05456620|Other|Exercise therapy|"The intervention treatment consists of a progressive 4-stage, criteria-based exercise protocol, in which the amount of tendon compression is limited. This includes:~Education: Specific information on the importance of limiting tendon compression during rehabilitation, as well as general information on load management, the importance of active exercise therapy and setting expectations.~Orthotic treatment: heel inserts to reduce ankle dorsiflexion during daily activities and sports~Physiotherapy: Progressive tendon-loading exercise therapy (4 phases) restricting the amount of tendon compression by limiting dorsiflexion of the ankle and prohibiting stretching"
45449270|NCT03729141|Dietary Supplement|Added Cholesterol|Participants assigned to the added cholesterol group will receive snacks containing added cholesterol (1g/day) for 3 weeks prior to surgery.
45645144|NCT00006390|Biological|alemtuzumab|
45786946|NCT05456620|Other|Exercise therapy (usual care)|"The control treatment consists of a progressive 4-phase, criteria-based exercise protocol, in which the amount of tendon compression is not limited. This includes:~Education: general information on load management, the importance of active exercise therapy and setting expectations.~No orthotic treatment.~Physiotherapy: Progressive tendon-loading exercise therapy (4 phases) without any restriction around tendon compression and encouraging stretching"
45786947|NCT05454254|Other|Individualised muscle strengthening exercise training protocol.|Based on the results of muscle function tests at baseline an individualised exercise protocol will be designed.
45786948|NCT05448014|Behavioral|Compassion focused group therapy online|Seven sessions of therapist-led online compassion-focused therapy in groups of 4-8 adolescents with mild to moderate symptoms of distress, anxiety, or depression. Trained therapists administer the CFT program in face-to-face meetings.
45786949|NCT05443919|Device|TwiFlow-Thrombectomy Catheter System|Patients with acute pulmonary embolism and meeting the conditions of this clinical trial will accept the pulmonary embolism removal operation by the novel device named 'TwiFlow-Thrombectomy Catheter System'.
46071179|NCT02848586|Other|ECIGS|15 subjects will receive ECIGs and 5 control subjects will continue to smoke their chosen usual brand of combustible cigarettes (UB). Each group will receive either ECIG or UB for a total of 4 weeks and undergo pulmonary and behavioral assessments during this period. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. Participants in the UB group will also undergo mCM procedures, but contingencies will differ. After 4 weeks, the ECIG group will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks with additional pulmonary and behavioral assessments. All subjects will undergo three respiratory assessments in the DCRU.
45919220|NCT01806883|Behavioral|Traditional rehabilitation|30 patients will receive the traditional rehabilitation.
45919221|NCT04604873|Other|Hospital day care follow-up|Regular follow up every month in hospital day care
45449271|NCT03729141|Other|No Added Cholesterol|Participants assigned to the no added cholesterol group will receive snacks containing no added cholesterol for 3 weeks prior to surgery.
45449272|NCT02149966|Drug|AG-348|A range of doses of AG-348 will be tested based on the assessment of safety and tolerability. AG-348 will be administered by mouth (orally) each day for a period of 14 days.
45449273|NCT02149966|Drug|Placebo|Placebo will be administered by mouth (orally) each day for a period of 14 days.
45449274|NCT03729063|Other|Twice-daily expired carbon monoxide (CO) measurements|Patients included in this arm will have expired CO measurements every morning and evening during their initial hospitalization.
45449275|NCT03729063|Other|Minimal control|Patients included in this arm will have one expired CO measurement on the morning just after initial hospital admission and a second expired CO measurement one the morning prior to discharge.
45645145|NCT00006390|Biological|filgrastim|
45645146|NCT00006390|Drug|cyclophosphamide|
45645147|NCT00006390|Procedure|peripheral blood stem cell transplantation|
45645148|NCT00006390|Radiation|radiation therapy|
45645149|NCT00005962|Biological|sargramostim|
45645150|NCT00005962|Drug|cyclophosphamide|
45645151|NCT00005962|Drug|cytarabine|
45645152|NCT00005962|Drug|gemtuzumab ozogamicin|
45645153|NCT00005962|Drug|liposomal daunorubicin citrate|
45645154|NCT00005962|Drug|topotecan hydrochloride|
45645155|NCT00005847|Biological|recombinant interferon alfa|
45645156|NCT00005847|Drug|estramustine phosphate sodium|
45645157|NCT00005847|Drug|isotretinoin|
45645158|NCT00005847|Drug|mitoxantrone hydrochloride|
45645159|NCT00005847|Drug|paclitaxel|
45645160|NCT00005847|Drug|vinorelbine ditartrate|
45645161|NCT00005644|Drug|gemcitabine hydrochloride|
45645162|NCT00005644|Drug|paclitaxel|
45786950|NCT05440864|Drug|Tremelimumab|Pre-operatively Tremelimumab will be administered first for 1 hour; the Durvalumab infusion (1hr) will start approximately 1 hour (maximum 2 hours) after the end of the Tremelimumab infusion. Post-operatively patients will receive Durvalumab Q4W to complete up to 12 months of treatment or a maximum of 11 cycles of adjuvant Durvalumab
45786951|NCT05418361|Drug|ACE inhibitor ,angiotensin receptor blockers|patients taking ACEI or ARBs with cardiovascular disease
45919222|NCT05520060|Other|Physical support|Pharmacological and non-pharmacological methods in pain management, Mobilization, Position preferred by the woman, Fluid and nutritional support, Massage applications, Sacral pressure, Listening to music, Breathing and relaxation exercises
45786952|NCT05417438|Behavioral|Wearable device deployment|Participants will receive a Fitbit to be synced with a smartphone app (MyDataHelps). Participants will receive push notifications to complete surveys via the MyDataHelps app. The Fitbit will sync with the app for data collection.
45919223|NCT05520060|Other|Psychospiritual support|Effective communication, Encouragement to speak up and express fears, Support for faith-oriented practices
45919224|NCT05520060|Other|Environmental and sociocultural support|egulating the temperature, light and sound of the room, Environment that promotes respect for privacy, Reducing environmental noise, Information, Social support, Talking about cultural practices, Social support
45919225|NCT05520060|Other|Routine care|Admission to the delivery room, preparation for birth, delivery, postpartum care, etc.
45919226|NCT01806805|Drug|zonegran|
45919227|NCT01806805|Drug|placebo|
46071180|NCT02848586|Behavioral|mobile contingency management (mCM)|"mCM procedures are a novel smoking cessation tool previously used in the field by our colleagues in the Beckham research group. This equipment is part of a procedure called mobile contingency management or mCM. The participant will use a study smartphone to record his/her CO levels and moods at random times of the day and to verify his/her cigarette usage. The mCM program will reward the participant for each CO level and data transmitted to the study team. The study team will provide detailed information and training to allow them to participate in this part of the study."
45449276|NCT02159716|Biological|CART-meso|CART-meso are autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor SS1 fused to the 4-1BB and CD3ζ signaling domains.
45786953|NCT05410548|Other|Standard-of-Care|Participants with a major unilateral transfemoral or transtibial amputation will undergo a standardized medical history and medication review, complete questionnaires evaluating prosthesis use, comfort, and mobility, receive a clinical examination of height, weight and limb circumference, and complete three performance-based mobility outcome measures.
45919228|NCT01806766|Procedure|Ceramic on Ceramic bearing|cementless Total Hip Arthroplasty with Ceramic on ceramic bearing
45919229|NCT01806766|Procedure|Ceramic on Highly crosslinked polyethylene bearing|Cementless Total Hip Arthroplasty with Ceramic on Highly crosslinked polyethylene bearing
45919230|NCT01806727|Behavioral|Community Lifestyle Weight Loss (LWL)|Changing dietary and physical activity behavior to promote weight loss
45919231|NCT01806727|Behavioral|Diabetes Self Management (DSM)|Changing diet, physical activity, self monitoring, and medication related behaviors to improve diabetes control
45919232|NCT01806688|Other|gluten-free high protein snack #1|buckwheat groats 30g serving
45919233|NCT01806688|Other|gluten-free snack with similar energy density but 1/2 the protein as snack #1|32g serving of corn nuts
45919234|NCT01806688|Other|non-caloric control|water
45919235|NCT01806688|Other|gluten-free high protein and high fibre snack #2|buckwheat and pinto bean flour pita bread 50g serving
45919236|NCT01806688|Other|gluten-free snack with similar energy density, but less protein and fibre than snack #2|50g serving of rice bread
45919237|NCT00387413|Drug|Duloxetine|Subjects will be receive hard gelatin capsules of Duloxetine at 30mg once daily for one week and 60mg once daily for the second week in Treatment Arm B.
45919238|NCT00387413|Drug|GSK189254|Subjects will receive film coated tablet of GSK189254 at 50 mcg once daily for a one week and 100 mcg once daily for the second week in Treatment Arm A.
45919239|NCT00387413|Drug|GSK189254 Placebo|Subjects will receive Placebo matching GSK189254 for 3 weeks in each period.
45919240|NCT00387413|Drug|Duloxetine Placebo|Subjects will receive Placebo matching Duloxetine for 3 weeks in each period.
45919241|NCT01806649|Drug|BKM120|
45919242|NCT01806610|Drug|BPS804|Single dose BPS804 administration.
45919243|NCT01806610|Drug|Placebo|Single dose placebo administration.
45919244|NCT05517291|Device|paclitaxel-coated balloon angioplasty or bare mental stents implantation|paticipants who enrolled in this study will received paclitaxel-coated balloon angioplasty plus bailout stenting or primary bare mental stents implantation randomly
45919245|NCT03864731|Device|Bone conduction device (ADHEAR)|adhesive bone conduction device
45919246|NCT03852836|Other|ultra-rapid acquisition of bile ducts images|On top of the conventional SPACE sequence, 2 supplementary sequences will be performed with the ultra-rapid sequence (sequence CS-SPACE) either acquired in apnoea or synchronized with the breath.
45919247|NCT05492955|Behavioral|Community Health Worker Care Model|Participants will be given a digital BP Cuff and a standardized training on its operation, and assigned a CHW from their local Community Health Team. The participant will be instructed to take 6-10 measurements BP per week and record them in a logbook. CHWs will return to participant homes every 2-4 weeks to collect BP measurements and enter them into a data collection system, assess for symptoms, and discuss treatment adherence and lifestyle recommendations. BP readings will be brought by the CHW to their assigned nursing supervisors at their local clinic, who will initiate and tailor medications based on a standardized clinical decision support algorithm, based on SA DoH hypertension control guidelines. All treatment decisions will be made by the nursing supervisors. Participants will either obtain medication(s) at the pharmacy or, as possible, have them delivered by a CHW.
46071181|NCT02848586|Other|Usual brand|"The usual brand of cigarettes is the control group in this study. 5 participants will be allowed to continue using their usual brand of combustible cigarette in this arm of the study."
46071182|NCT02848898|Device|Equistasi|
46071183|NCT02848898|Other|Placebo|
45449277|NCT01310361|Drug|Amoxicillin|
46071184|NCT02848742|Device|Dermal Cooling System|Dermal cryotherapy
45919248|NCT05492955|Behavioral|Enhanced Community Health Worker-based with Mobile Health Blood Pressure Monitoring Model|Participants in this arm will also be given a BP Cuff, (but with cellular network capability, such that BP data can be directly transmitted to trial server), given training on its operation, and assigned a CHW from their local Community Health Team. The participant will be instructed to take 6-10 measurements BP per week, which will be automatically uploaded onto the server to be made available by the nurse supervisors. CHWs will return to participant homes every 2-4 weeks to ensure functionality of the devices and transmission, collect BP measurements if the system is not functional, assess for symptoms, and discuss treatment adherence and lifestyle recommendations. Nursing supervisors at the clinic will use the remotely collected BP data to initiate and tailor medications based on the same standardized clinical decision support (CDS) algorithm, based on SA DoH hypertension control guidelines. All treatment decisions will be made by the nursing supervisors.
45919249|NCT05492955|Behavioral|Standard of Care Model|Participants in the SOC arm will be referred to their clinic for active care as per standard clinical protocols. All care will be provided at the clinic. Routine care consists of regular visits to the clinic until BP is under control (<140/90 mmHg) and then at 6 monthly intervals. BP measurements to guide management decisions will be made at the clinic using standard clinic equipment. Symptoms related to hypertension and/or medications will be assessed at each visit. Medications available will include medications on the South African Essential Drug list and which are available in the pharmacy. Prescriptions are picked up at the clinic pharmacy by patients as per routine protocol at the clinics. CHWs may also conduct monitoring as guided by clinical guidelines and as advised by their clinical supervisors during the study period to assess for adherence and provide education.
45919250|NCT04590248|Drug|Adavosertib|The subjects will receive oral adavosertib 300 mg, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
45786954|NCT05410548|Other|Clinical Screening|Participants will complete the following self-report questionnaires: (a) the Patient Health Questionnaire-9 item, which may suggest major depression and/or suicidal ideation; and (b) the STarT Back Screening Tool, a 6-item tool used to screen for greater than low-risk for persistent, bothersome and disabling low back pain. Prosthetists will perform palpation of the contralateral dorsalis pedis and posterior tibial pulses and note presence or absence, as an indicator of peripheral arterial disease. Prosthetists will evaluate protective sensation of the contralateral foot through Semmes-Weinstein monofilament assessment of the great toe, the 1st and 3rd metatarsal heads. The prosthetist will record the results in a letter that is sent to the patient's primary care provider, and provide a copy of the letter to the patient after discussing the results for each of the screens.
45919251|NCT05490693|Other|Experimental group|Experimental group: 26 control group group: 26
45919252|NCT01806454|Drug|calcium|
45919253|NCT03846089|Procedure|Graft reperfusion|antegrade (forward) or retrograde (backward) blood reperfusion of the liver graft
45919254|NCT01806415|Drug|Fenobam|Oral administration of 50, 100, or 150mg of Fenobam or placebo (lactose)
45919255|NCT01806415|Drug|Placebo|Oral administration of placebo or lactose 150 mg
45786955|NCT05407168|Other|Best Practice|Receive standard of care
45786956|NCT05407168|Other|Health Promotion and Education|View decision aid
45786957|NCT05407168|Other|Questionnaire Administration|Ancillary studies
45786958|NCT05399498|Drug|Psilocybin|Psilocybin 25mg capsule
45786959|NCT05391113|Diagnostic Test|MRI|an fMRI measurement of the BOLD physiological signal for sensory responses
45786960|NCT05391113|Diagnostic Test|EEG|These tests, through videos with a social or non-social content (human presence or absence on the stereoscopic projection), will allow us to study two types of sensorialities (visual and interoceptive). Thus, it will be possible to obtain inter- and exteroceptive profiles of the participants, a direct reflection of the processing of the internal bodily sensations of the body.
45786961|NCT05388110|Behavioral|SKY Breath Intervention|Sudarshan Kriya Yoga (SKY) is a breath-based meditative practice that entails a sequence of specific breathing techniques to help practitioners achieve a state of calm alertness. It has offered benefits as a therapeutic option for mild-to-moderate depression and anxiety disorders and as an adjunctive treatment in patients with major depressive disorder, but the neurological mechanism of SKY breath intervention is still not fully understood.
45786962|NCT05379530|Diagnostic Test|Thromboelastography (TEG)|Thromboelastography (TEG) is a type of Viscoelastic testing (ROTEM is another example) and is a validated point of care method of dynamically assessing intraoperative coagulopathy via functional assay.
45786963|NCT05379530|Other|Anesthesia Provider Survey|Pre-operative and post-operative provider surveys will be distributed to anesthesiologists caring for study subjects to assess knowledge, practice, and attitudes about TEG.
45919256|NCT05489445|Device|KODEX - EPD|A patient that is already clinically indicated to undergo cryoballoon ablation for atrial fibillation will use the The KODEX - EPD™ Cardiac Imaging and Navigation electrophysiological (EP) System. This is an imaging system which allows the physician real-time visualization of the catheters in a patients heart during the procedure, as well as display of cardiac images of the patients heart in a number of different formats. The KODEX - EPD system used in this study is cleared for commercial use by the FDA and therefore, it's use in this study constitutes as standard clinical use.
45919257|NCT01806376|Drug|Subutinib Maleate capsules|Dose escalation will be dependent on any dose limiting toxicities
45919258|NCT01806337|Drug|Alemtuzumab|Consolidation after CHOP induction
45919259|NCT04581317|Other|meals|Participants will receive meals delivered to them by the Meals oN wheels(MOW) program for 6 weeks.
46071185|NCT04623710|Drug|ALXN2050|ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
45786964|NCT05377294|Other|Method of Levels therapy|MOL therapy aims to help people develop awareness of their personal goals so they can identify incompatibilities and find potential solutions. In MOL, the therapist uses a specific style to help people focus attention on the problem at hand, long enough to consider the issues from different perspectives, including reflection on the associated emotions. This process is usually very experiential and requires the client to be actively engaged in controlling the focus of the session and decision making.
45786965|NCT05373706|Behavioral|Alcohol Cue Reactivity Personalized Feedback Intervention|This online brief intervention provides personalized feedback using EMA data focused on alcohol cue reactivity to reduce alcohol misuse among young adults.
45919260|NCT04581317|Other|AES 8 basic usage|For the second 6 weeks, participants will continue to have meal deliveries and will now have the AES 8 device which can be used by the cognitively impaired participant and their caregiver. AES 8 devices will be installed in participant's homes by the study team and participants will be given basic instructions on using the device as well as a one-page handout that will include instructions on how to use and maintain privacy with their device. The study staff will continue to call twice a week to ask the 5 questions. At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure FFP, MHS, CES-D, MOCA, ADL/IADLs, NSI, ZCBI, and TAM.
45919261|NCT04581317|Other|AES 8 advanced usage|In the third 6 weeks, the participants will continue to have meal deliveries and the AES 8 will be upgraded to provide an active intervention by asking the twice a week 5 questions through the device. The questions should be answered by the cognitively impaired older adult using the device, though the caregiver can still use the device for other basic services. The participant will be able to answer the questions verbally or by touch screen options displayed on the device.At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure FFP, MHS, CES-D, MOCA, ADL/IADLs, NSI, ZCBI, and TAM.
45919262|NCT01806259|Drug|Ketorolac 30 mg IV|Active drug
45919263|NCT01806259|Drug|Placebos|Placebo looking like the Active drug
45919264|NCT05482542|Other|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
45919265|NCT05482542|Drug|Cyclophosphamide/ATG|Cyclophosphamide/ATG
45919266|NCT05482542|Drug|Cyclophosphamide/Rituximab|Cyclophosphamide/Rituximab
45919267|NCT01806220|Procedure|Biopsy of the retrocrycoid laryngeal mucosa|Biopsies of the retrocrycoid laryngeal mucosa were performeed under sedation using a forceps introduced by the working channel of the endoscope
45919268|NCT01806220|Procedure|Biopsy of the distal esophageal mucosa|Biopsies were performeed under sedation using a forceps introduced by the working channel of the endoscope during upper digestive endoscopy
45919269|NCT04579757|Drug|Surufatinib and Tislelizumab _ Part 1|Part 1 (all cohorts): oral surufatinib at a dose based on cohort level and intravenous tislelizumab at a 200-mg dose
45919270|NCT04579757|Drug|Surufatinib and Tislelizumab _ Part 2|Part 2 (all cohorts): oral surufatinib at the RP2D dose selected in Part 1 and intravenous tislelizumab at a 200-mg dose
45919271|NCT00393445|Drug|GLP-1 control|intravenous infusion of GLP-1
45919272|NCT00393445|Drug|GLP-1 and Exendin(9-39) 300|intravenous infusion of exendin(9-39) at 300 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
45919273|NCT00393445|Drug|saline control|intravenous infusion of saline
45645163|NCT00003871|Biological|fowlpox virus vaccine vector|
45645164|NCT00003871|Biological|recombinant vaccinia prostate-specific antigen vaccine|
45645165|NCT00003809|Biological|cetuximab|
45919274|NCT00393445|Drug|GLP-1 and Exendin(9-39) 600|intravenous infusion of exendin(9-39) at 600 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
45919275|NCT00393445|Drug|GLP-1 and Exendin(9-39) 900|intravenous infusion of exendin(9-39) at 900 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
45645166|NCT00003809|Drug|cisplatin|
45645167|NCT00003808|Drug|theophylline|
45645168|NCT00003800|Other|immunohistochemistry staining method|
45645169|NCT00003800|Other|laboratory biomarker analysis|
45919276|NCT00393445|Drug|GLP-1 and Exendin(9-39) 1200|intravenous infusion of exendin(9-39) at 1200 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
45919277|NCT05482425|Other|Autologous facial fat graft injection|Participants will received either a washed or unwashed autologous facial fat graft injection to both sides of the face, as determined by randomization.
45919278|NCT00393562|Drug|modafinil|
45919279|NCT00393562|Drug|methylphenidate|
45919280|NCT01806181|Other|Exercise|
45919281|NCT01806142|Other|Medium-chain triglycerides|During Medium-Chain Triglycerides (MCT period), participant will asked to consume two pastries per day that will provide a total of 20 g of MCT/day for 4 weeks.
46071186|NCT04202198|Biological|A-PRF|local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla.previously prepared PRF membranes are placed through the access hole and the flap is advanced. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
45645170|NCT00003800|Procedure|radionuclide imaging|
45645171|NCT00003649|Biological|Ad5CMV-p53 gene|
45645172|NCT00003592|Drug|methotrexate|
45645173|NCT00003592|Drug|paclitaxel|
45645174|NCT00003518|Drug|gemcitabine hydrochloride|
45645175|NCT00003518|Drug|paclitaxel|
45645176|NCT00003444|Biological|recombinant interferon alfa|
45645177|NCT00003444|Radiation|radiation therapy|
45645178|NCT00003388|Biological|filgrastim|
45645179|NCT00003388|Drug|cyclophosphamide|
45645180|NCT00003388|Drug|cytarabine|
45645181|NCT00003388|Drug|methotrexate|
45645182|NCT00003388|Drug|pegylated liposomal doxorubicin hydrochloride|
45645183|NCT00003388|Drug|prednisone|
45645184|NCT00003388|Drug|vincristine sulfate|
45645185|NCT00003388|Radiation|radiation therapy|
45919282|NCT01806142|Other|Corn oil|During Corn oil period (Control period), participant will asked to consume two pastries per day that will provide a total of 20 g of corn oil/day for 4 weeks.
45786966|NCT05371691|Device|Myofunctional appliance|Myifunctional appliance will be used for growing patients who have Cl.II div.1 malocclusion, two types of appliances are involved myobrace and twin=block appliance
45786967|NCT05361135|Diagnostic Test|PET/CT|Enhanced imaging with PET/CT
45786968|NCT05359887|Other|standardized liquid mixed meal Nutridrink®|Administration of food in controlled situation
45786969|NCT05356013|Drug|Caplyta|Atypical antipsychotic
45645186|NCT00003376|Drug|carboplatin|
45645187|NCT00003376|Drug|cisplatin|
45645188|NCT00003376|Drug|doxorubicin hydrochloride|
45645189|NCT00003376|Drug|methotrexate|
45645190|NCT00003376|Drug|paclitaxel|
45645191|NCT00003376|Drug|vinblastine|
45645192|NCT00003353|Biological|filgrastim|
45645193|NCT00003353|Drug|melphalan|
45645194|NCT00003353|Procedure|bone marrow ablation with stem cell support|
45786970|NCT05356013|Drug|Placebo|Pill that contains no medicine.
45786971|NCT05330676|Procedure|coronary artery bypass grafting, valve repair/replacement|cardiovascular surgery with cardiopulmonary bypass
45786972|NCT05319782|Other|Urethral stenosis assesment|Auto-questionnaires + Clinical examination + Flow metry and post-mictional residue
45786973|NCT05308472|Drug|DISC-1459|Oral dose level 1, once a day for 120 days
45786974|NCT05308472|Drug|DISC-1459|Oral dose level 2, once a day for 120 days
45645195|NCT00003353|Procedure|peripheral blood stem cell transplantation|
45645196|NCT00003309|Biological|filgrastim|
45645197|NCT00003309|Drug|cisplatin|
45645198|NCT00003309|Drug|cyclophosphamide|
45645199|NCT00003309|Drug|etoposide|
45645200|NCT00003309|Drug|vincristine sulfate|
45645201|NCT00003309|Procedure|adjuvant therapy|
45786975|NCT05308472|Drug|Placebo|Oral dose, once a day for 120 days
45786976|NCT05308472|Drug|DISC-1459|Oral dose level 1, once a day for up to 8 months
45645202|NCT00003309|Radiation|radiation therapy|
45645203|NCT00003308|Radiation|stereotactic radiosurgery|
45645204|NCT00003237|Drug|cisplatin|
45645205|NCT00003237|Drug|paclitaxel|
45645206|NCT00003237|Procedure|surgical procedure|
45645207|NCT00003129|Drug|valrubicin|
45645208|NCT00003027|Biological|aldesleukin|
45645209|NCT00003027|Biological|filgrastim|
45645210|NCT00003027|Biological|recombinant interferon alfa|
45645211|NCT00003027|Drug|cisplatin|
45645212|NCT00003027|Drug|dacarbazine|
45645213|NCT00003027|Drug|vinblastine|
45645214|NCT00002934|Procedure|long-term screening|
45645215|NCT00002914|Drug|piritrexim|
45645216|NCT00002872|Biological|bleomycin sulfate|
45645217|NCT00002872|Drug|doxycycline|
45645218|NCT00002872|Other|talc|
45645219|NCT00002868|Biological|filgrastim|
45645220|NCT00002868|Biological|recombinant interferon alfa|
45645221|NCT00002868|Drug|busulfan|
45645222|NCT00002868|Drug|cytarabine|
45645223|NCT00002868|Drug|etoposide|
45645224|NCT00002868|Drug|hydroxyurea|
45645225|NCT00002868|Drug|idarubicin|
45645226|NCT00002868|Procedure|peripheral blood stem cell transplantation|
45645227|NCT00002695|Genetic|DNA stability analysis|
45645228|NCT00002695|Genetic|microsatellite instability analysis|
45645229|NCT00002695|Genetic|mutation analysis|
45645230|NCT00002695|Other|laboratory biomarker analysis|
45645231|NCT00002668|Behavioral|Observation|
45645232|NCT00002668|Behavioral|Educational Intervention and Behavioral Skills Training|
45645233|NCT00002667|Other|cytology specimen collection procedure|
45645234|NCT00002667|Other|immunoenzyme technique|
45786977|NCT05308186|Behavioral|Auditory stimulation|The patient will be exposed to music that he used to enjoy (from the family's or guardian's report) through headphones. In case no report is given, nature (brook) sounds will be streamed.
45786978|NCT05308186|Behavioral|Auditory and tactile stimulations|The patient will be exposed to music that he used to enjoy (from the family's or guardian's report, otherwise nature (brook) music will be streamed) through headphones combined with deep tissue massage will be given on the upper limbs.
45786979|NCT05299216|Other|Manual Diaphragm Technique|Treatment group will receive Manual Diaphragm Technique in addition to Conventional Physical Therapy. Therapist will make physical contact to the underside of the 7th to 10th rib costal cartilages. During the inspiratory phase, the therapist will use both hands to gently pull the points of contact in the direction of the head. During exhalation, the therapist will maintain resistance. The procedure will be done in two sets of ten deep breaths, separated by a one-minute pause.
45786980|NCT05299216|Other|Conventional Physical Therapy|"Conventional Physical Therapy group comprises electrotherapeutic treatment and exercise plan. Subjects will undergo a thermal continuous ultrasound, conventional transcutaneous electrical nerve stimulation and a hot pack.~Stretching activities for the back, iliopsoas, and hamstring muscles, as well as abdominal muscle strengthening exercises, will be included in the workout."
45919283|NCT00387452|Behavioral|Aerobic Exercise and Strength Exercise|6 months of aerobic training exercise. regulated by heart rate; work up to 80% of maximal heart rate on treadmill or stationary bike; 3 hours a week, 90% attendance.
45919284|NCT00387452|Behavioral|Strength training|6 months of strength training exercise using weight machines involving legs and arms: 12-15 repetitions of weights per exercise; 3 hours a week, 90% attendance.
45919285|NCT01806103|Behavioral|Antimicrobial Stewardship Bundle|Guidelines, Education, Audit and Feedback
45919286|NCT01806025|Other|no intervention|
45919287|NCT01805947|Behavioral|Lifestyle Modification|Lifestyle Modification
45919288|NCT04551131|Drug|Ruxolitinib|Given orally (PO) or per nasogastric tube (NGT) twice a day for 8 weeks
45919289|NCT04551131|Drug|Dexamethasone|Given intravenously (IV) or orally (PO) twice a day for 8 weeks
45645235|NCT00002667|Procedure|study of high risk factors|
45786981|NCT05299216|Other|Sham Diaphragm Manual Technique|The Control group will also receive a sham diaphragm release technique. The therapist and participant will have the same manual contacts, duration, and placement as the treatment group, but the therapist will simply use a light touch with the same anatomical landmarks and will not apply pressure.
45786982|NCT05282901|Drug|Pembrolizumab 25 MG/1 ML Intravenous Solution|Taken together, we hypothesize that combining pembrolizumab with lenvatinib in metastatic UM may target essential cellular oncogenic pathways while normalizing tumor vascularization, thus allowing an increased infiltration of the tumor by immune cells and an improved immune response.
45919290|NCT04551131|Drug|Etoposide|Given intravenously (IV) once a week for 8 weeks
45919291|NCT01805908|Other|111In-Pertuzumab + SPECT-CT|111In-PmAb will be provided ready for injection in a vial by Dr. Reilly's laboratory.
45919292|NCT01805830|Drug|MP513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
45919293|NCT01805830|Drug|Placebo|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
45919294|NCT04527107|Drug|THR-149 dose level 1|3 intravitreal injections of THR-149 dose level 1, 1 month apart
45919295|NCT04527107|Drug|THR-149 dose level 2|3 intravitreal injections of THR-149 dose level 2, 1 month apart
45919296|NCT04527107|Drug|THR-149 dose level 3|3 intravitreal injections of THR-149 dose level 3, 1 month apart
45919297|NCT04527107|Drug|THR-149 0.13mg|3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by a sham (pretend) injection
45645236|NCT00002650|Dietary Supplement|folic acid|
45645237|NCT00001529|Drug|G-CSF|
45645238|NCT00001465|Device|Toshibia Aquilion One CT|The Toshiba Aquilion ONE CT system is currently being used for studies in both general CT radiology and CT cardiac imaging. One of the unique aspects of the Aquilion ONE CT system is its ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy. In line with the evolutionary changes to CT systems, the Aquilion ONE will be upgraded with new technology that will expand its capabilities. The changes being made to the Aquilion ONE will provide enhancements to image acquisition capabilities, reduce ionizing radiation dose, and improve subject access to the system. All of these features assist in enhancing the safety of the currently installed Aquilion ONE CT system.
45645239|NCT00001337|Drug|EPOCH|Combination chemotherapy given with Rituximab (EPOCH-R) IV every 3 weeks for 6 cycles.
45645240|NCT00001337|Biological|Rituximab|Rituximab given on Day 1 of combination chemotherapy (EPOCH-R) every 3 weeks for 6 cycles.
45645241|NCT03145987|Dietary Supplement|Vitis vinifera extract|
45645242|NCT03145987|Other|Placebo|
45645243|NCT05007665|Biological|SARS-COV-2 VACCINE|the antibody titer and adverse reactions were observed.
45645244|NCT04477915|Other|Core exercises|Core stabilization exercise include, plank, lateral plank, swimmer, flutter kick and bridge exercises.
45645245|NCT04477915|Other|Auxiliary respiratory exercises|Auxiliary respiratory exercises include, strengthening and stretching exercises for trapezius, sternocleidomastoideus, pectoralis major and serratus anterior muscles.
45645246|NCT05007353|Behavioral|Structured Lifestyle Intervention|Structured Lifestyle Intervention (SLI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors.
45919298|NCT04527107|Drug|THR-149 0.13mg + aflibercept 2mg|3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by an intravitreal injection of aflibercept 2mg
45919299|NCT04527107|Drug|aflibercept 2mg + THR-149 0.13mg|3 intravitreal injections of aflibercept 2mg, 1 month apart, followed after 1 month by an intravitreal injection of THR-149 0.13mg (selected dose level)
45645247|NCT05007353|Behavioral|Self-Guided Intervention|In the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided.
45645248|NCT03146065|Biological|PF-06730512|Comparison of different dosages of PF-06730512 to Placebo
45786983|NCT05280392|Other|Self-administered questionnaires|4 self-questionnaires given to EHVA T02 participants: at inclusion (Q1, week 0), at the beginning of the ATI period (Q2, week 18), at the end of the ATI period (Q3, date depending on the participant) and at the end of the follow-up period of the clinical trial (Q4, week 54 at the latest)
45786984|NCT05280392|Other|Semi-directive individual interviews|With EHVA T02 participants (n=10 to 15): at the end of the follow-up period of the clinical trial.
45919300|NCT04527107|Drug|Aflibercept 2mg|3 intravitreal injections of aflibercept 2mg, 1 month apart, followed after 1 month by a sham (pretend) injection
45919301|NCT01805791|Drug|HMPL-004 1800 mg/day|Subjects randomized to the arm of HMPL-004 1800 mg/day will receive HMPL-004 600 mg TID (total dose 1800 mg/day) for 56 days (8 weeks).
45919302|NCT01805791|Drug|Placebo|Subjects randomized to the arm of Placebo will receive matching Placebo three times daily for 56 days (8 weeks).
45919303|NCT01805791|Drug|HMPL-004 2400 mg/day|Subjects randomized to the arm of HMPL-004 2400 mg/day will receive HMPL-004 800 mg TID (total dose 2400 mg/day) for 56 days (8 weeks).
45919304|NCT01805752|Other|Task-shifting to lower-cadre providers at PMTCT sites|
45919305|NCT01805752|Other|POC CD4+ cell count testing|
45919306|NCT01805752|Other|integrated mother-infant care|
45919307|NCT01805752|Other|Prominent role for influential family members (male partners) in collaboration with CHWs|
45919308|NCT04493645|Behavioral|Standard of Care Rehabilitation (SOC)|6 weeks of standard of care rehabilitation will be given designed to restore ankle joint range of motion, strength, postural control, and functional movement. Each participant will be expected to complete 2 supervised sessions and 3 unsupervised at home sessions per week.
45786985|NCT05280392|Other|Semi-directive individual interviews|With patients who refused to participate to EHVA T02 or patients not included because of negative screening results (n=10 to 15): within 21 days after the refusal or the results of the screening
45786986|NCT05272605|Biological|Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59)|Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 [mRNA]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.
45645249|NCT03146065|Drug|Placebo|Comparison of Placebo to different doses of PF-06730512
45919309|NCT04493645|Behavioral|Foot Intensive Rehabilitation (FIRE)|6 weeks of FIRE will be given along with elements of SOC. Each participant will be expected to complete 2 supervised sessions and 3 unsupervised at home sessions per week.
45919310|NCT01805674|Dietary Supplement|isoflavones combined with magnolia|1 tablet/day duration: 12 weeks
45645250|NCT03088397|Behavioral|Patient Decision Aid|One sheet of postpartum contraceptive information arranged in a grid.
45786987|NCT05272605|Biological|SARS-CoV-2 beta variant RBD mRNA vaccine|Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 [mRNA]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.
45786988|NCT05272605|Other|Normal Saline|Placebo comparator
45786989|NCT05265286|Drug|FRSW117|"Subjects of high dose group are being received four doses(50 IU/kg,once a week or every 7 days) of FRSW117.~Subjects of low dose group (40 IU/kg,once a week or every 7 days)are being received four doses of FRSW117."
45919311|NCT05437887|Dietary Supplement|Fucoidan|All patients consumed fucoidan.
45919312|NCT01805635|Other|No intervention|No intervention
45919313|NCT01805596|Drug|clopidogrel|
45919314|NCT01805596|Drug|Ticagrelor|
45919315|NCT01805557|Drug|R-DHAP|"Rituximab 375 mg/sqm iv day 0 or 1~Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~Dexamethasone 40 mg day 1-4~Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy"
45919316|NCT01805557|Drug|BR-DHAP|"Rituximab 375 mg/sqm iv day 0 or 1~Bortezomib SC 1.5 mg/sqm day 1, day 4~Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~Dexamethasone 40 mg day 1-4~Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy Chemotherapy R-DHAP and BR-DHAP will be repeated every 28 days."
45919317|NCT04477343|Drug|SX-682|Allosteric inhibitor to human CXCR1 and CXCR2 receptor
45919318|NCT04477343|Drug|Nivolumab Injectable Product|humanized monoclonal antibody to program cell death receptor 1 (PD1)
45645251|NCT03088397|Behavioral|Website|Patient directed to website with information on various contraceptive methods.
45645252|NCT03088397|Behavioral|Shared- Decision Making Counseling|Counseling using principles of shared-decision making
45919319|NCT00389727|Drug|Radiotherapy|Radiotherapy
45919320|NCT01805518|Dietary Supplement|Scelectium Tortuosum|"One arm has subjects 3 weeks on Scelectium Tortuosum 25gm po/d then 3 weeks off and then 3 weeks on Placebo.~The other arm has subjects 3 weeks on placebo, then 3 weeks off and then 3 weeks on Scelectium Tortuosum 25mg po/d."
45645253|NCT03146455|Other|no intervention|no intervention
45919321|NCT01805479|Other|aerobic exercise|the active arm will be asked to perform 60% of maximum heart rate
45919322|NCT01805479|Other|stretching and flexibility program|stretching and flexibility program for the Placebo Comparator Arm
45919323|NCT04474223|Drug|Dexamethasone|"In mother in whom 2° AVB or AV interval >170 ms has been diagnosed in the fetus:~Dexamethasone 8 mg po/day for 10 days. Then dexamethasone 4 mg po/ day through 28 weeks 6 days gestational age (GA); then 3 mg/day from 29 wks 0 days to 29 wks 6 days GA; then 2 mg/day until delivery"
45645254|NCT03078725|Drug|Glyburide|oral hypoglycemic agent
45645255|NCT03078725|Drug|Metformin|oral hypoglycemic agent
45645256|NCT02346409|Device|tACS of the cerebellum|tACS of the cerebellum
45645257|NCT05007119|Procedure|Mckenzie Extension Protocol|"Moist Heat Pack for 10 mins McKenzie Extension Protocol Sequence~Static:~Lying Prone~Lying prone in extension~Sustained extension~Posture correction~Dynamic:~Extension in lying~Extension in lying with clinician overpressure~Extension mobilization~Extension in standing"
45645258|NCT05007119|Procedure|Cupping|Cupping with blood letting
45786990|NCT05264376|Behavioral|Diabetes Body Project|The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.
45786991|NCT05264376|Behavioral|Educational Control|We selected a T1D management/Eating disorder psychoeducational comparison condition previously tested (Olmsted et al., 2002) to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures by Dr. Olmsted will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
45786992|NCT05263934|Biological|Depemokimab|Depemokimab will be administered
45786993|NCT05263934|Biological|Mepolizumab|Mepolizumab will be administered
45786994|NCT05263934|Drug|Placebo matching mepolizumab|Placebo matching to mepolizumab will be administered.
45786995|NCT05263934|Drug|Placebo matching depemokimab|Placebo matching to depemokimab will be administered.
45919324|NCT04474223|Drug|IVIG|"In a mother in whom 2° AVB has been diagnosed in the fetus:~One dose of IVIG [1g/kg of maternal weight (max dose 70 g)] at diagnosis of 2° AVB (within 12 hours of detection by mother via home monitoring and within 6 hours of confirmation by echocardiogram). A fetal AV interval > 170 ms will not be treated with maternal IVIG, only dexamethasone."
45919325|NCT05430477|Device|Electrical impedance imaging (EII) probe|novel small field-of-view EII probe
45919326|NCT01805440|Drug|Uridine|Uridine is the active treatment in this clinical trial.
45919327|NCT01805440|Drug|Placebo|Pill placebo is the inactive treatment comparator in this clinical trial.
45919328|NCT03819803|Biological|Fecal microbiota transplantation|200 ml of a tested stool suspension of a healthy donor is instilled into the patient´s caecum or terminal ileum
45919329|NCT01515124|Behavioral|Exercise Intervention|The Exercise Intervention combines the twice-weekly weight-lifting intervention from PAL with the 180 minutes of weekly aerobic exercise from the recently completed WISER trial and the ongoing WISER Sister Trial. Women will be trained by certified fitness professionals in both the PAL weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions.
45919330|NCT01515124|Behavioral|Weight Loss Intervention|The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day.
45919331|NCT05426928|Other|Additional temperature monitoring/recording|All patients in this study will receive the same standard of care treatment for their HIPEC procedure. The only difference will be the use of additional temperature probes to collect more robust data regarding intraabdominal temperature, and the prospective collection of actual boundary conditions of the system.
45919332|NCT04406558|Other|Questionnaire|An online questionnaire on the experience of the period of confinement and deconfinement will be sent to the cohort of adolescents followed at the CHI Creteil for a chronic disease or not. Forty adolescents will be randomly selected for a remote interview on the experience and memorization of the period of confinement and deconfinement.
45786996|NCT05258305|Device|AuraGen 1-2-3 with AuraClens|Autologous fat transfer (AFT) is a minimally invasive medical procedure that includes aspirating adipose tissue from one part of the body, and washing, filtering and re-injecting the processed fat tissue into a different part of the body with the primary purpose of adding volume. The AuraGen 1-2-3 with AuraClens is a lipoaspirate wash system designed to be used in the operating room in conjunction with a user-provided liposuction cannular, a vacuum source, and waste canister.
45645259|NCT02346487|Drug|LPV/RTV pellets and AZT/3TC or ABC/3TC|"Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight:~Between 3 and 5.9kg: 2 capsules twice a day~Between 6 and 9.9kg: 3 capsules twice a day~Between 10 and 13.9kg: 4 capsules twice a day~Between 14 and 19.9kg: 5 capsules twice a day~Between 20 and 24.9kg: 6 capsules twice a day~Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight:~Between 3 and 5.9kg: 1 tablet twice a day~Between 6 and 9.9kg: 1.5 tablets twice a day~Between 10 and 13.9kg: 2 tablets twice a day~Between 14 and 19.9kg: 2.5 tablets twice a day~Between 20 and 24.9kg: 3 tablets twice a day"
45786997|NCT05237804|Other|Patient component|Video, booklet, website
45645260|NCT03086837|Behavioral|Mobile phone based intervention|Participants will receive supporting messages through a mobile phone based intervention.
45645261|NCT02341963|Drug|Oral Ketamine|Oral ketamine (Ketamine HCL injection, 100 mg/ml, USP, Hospira)
45786998|NCT05237804|Other|Organisational component|Coronarography, CT-scan, anesthesia...
45786999|NCT05233202|Drug|Levosimendan|Levosimendan administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin 24H to 48H before anesthetic induction.
45787000|NCT05233202|Drug|PLACEBO|Placebo (isotonic sodium) administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin <48H before anesthetic induction.
45787001|NCT05232123|Drug|Placebo|Placebo oral product formulated in MCT (medium chain triglyceride) oil
45787002|NCT05232123|Drug|Cannabidiol|Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil
45787003|NCT05229055|Drug|Ketamine|giving ketamine intranasal
45787004|NCT05219734|Diagnostic Test|Personalized Cancer Monitoring (PCM)|personalized molecular test for solid tumor cancer patients that may detect the presence of circulating tumor DNA (ctDNA) and molecular residual disease (MRD), also known as minimal residual disease
45787005|NCT05199337|Drug|ZN-d5|ZN-d5 will be administered orally
45919333|NCT01466569|Drug|AbGn-7|Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks
45919334|NCT01466569|Drug|AbGn-7|Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
45919335|NCT01466530|Drug|Placebo|received sublingual two moistened white coated placebo tablets which looked identical in size, colour, and packing to misoprostol tablet.
45919336|NCT01466530|Drug|Misoprostol|sublingual misoprostol was given by putting two moistened tablets of misoprostol (400 µg) under the tongue and allowing them to dissolve (Misotac®, Sigma Pharmaceutical Industries, Egypt) (200 µg/tablet).
45919337|NCT01466452|Drug|Aspirin|single-dose aspirin in 100 mg 1 tablet every 24 hours
45919338|NCT01466452|Drug|Aspirin|single-dose aspirin 200 mg 1 tablet every 24 hours
45919339|NCT01466452|Drug|Aspirin|double-dose aspirin 100 mg 1 tablet every 12 hours
45919340|NCT04404257|Radiation|ControlRad System|Cardiac Catheterization or electrophysiology implant procedures with Control Rad system device installed in the cath lab room #5.
45919341|NCT04404257|Radiation|Without ControlRad System|Cardiac Catheterization or electrophysiology implant procedures in cath lab room 5 without the ControlRad system device.
45919342|NCT01466413|Device|Tropoelastin|"Multiple intradermal implants comprising of three treatments, 3 weeks apart, each consisting of 16 injections in total, each 10mm apart in a grid formation over a 3cm x 3cm area of the mid to deep dermis of the medial aspect of the upper arm. Each injection will consist of 20-30ul of product delivered using a 30Gx¼ needle. Each subject will also receive Restylane® Vital Light (control) to the opposite arm following the same treatment regimen and using the same technique. The treatment will be administered on Day 1, 22 and 43."
45919343|NCT01466374|Drug|Placebo|Normal Saline, Intravenous (IV), 0 mg, Once a week for the first week and every other week thereafter, 11 weeks
45919344|NCT01466374|Drug|Placebo|Normal Saline, Intravenous, 0 mg, Every other week, Up to 337days
45919345|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 10 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
45919346|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 20 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
45645262|NCT05007197|Behavioral|The Effect of Diabetes Education Based on Learning Modality|"After controlling the metabolic values of the individuals in the intervention group, the education were carried out according to the learning modality of the people; Visual learners; education booklet, brochure, slides (enriched with pictures and videos), lecture, insulin injector-pen, glucose meters, introduction and demonstration of blood glucose tracking book Auditory learners; education booklet, slides, videos, lecture, question-answer, group work, peer group discussion, experience sharing Tactile learners; education booklet, slides, demonstration, insulin injector-pen, glucose meter doing the application of tools and equipment such as on the model, on himself, on his friend, filling in the blood glucose tracking book.~Group-specific diabetes trainings were completed in 2 training sessions. Each training session lasted an average of 1.5 hours The learning modality of the control group were determined and standard group training was provided with the education booklet."
45787006|NCT05198921|Device|repetitive Transcranial Magnetic Stimulation|"To apply the rTMS will be used the device Neuro-MS/D Variant-3 therapeutic advanced (Neurosoft, Russia) with double cone shape coil. The coil will be placed at Cz according to 10-20 system. The rTMS protocol will be:~Train frequency - 10 Hz Train duration - 10 sec~Inter train interval - 50 seconds~Number of train - 25~-------------------------------------~Total pulses - 2500 Total session duration - 1500 seconds"
45787007|NCT05198921|Device|sham repetitive Transcranial Magnetic Stimulation|Neuro-MS/D magnetic stimulator (Neurosoft, Russia) with Neuro-MS.NET software will be used. The synchronous sound will be performed using monitor speaker connected to magnetic stimulator via trigger unit and located near discharging coil. The 10-Hz electrical stimulation will be given trough electrodes fixed on the head along the front edge of the coil to mimic the sensation
45787008|NCT05195632|Drug|Encorafenib|Hard capsule
45787009|NCT05195632|Drug|Binimetinib|Film-coated tablet
45787010|NCT05192707|Diagnostic Test|TcPO2 measurement on the upper limb|Measurement of the transcutaneous Oxygen Pressure in the upper limb of 30 healthy volunteers and of at least 30 patients.
45787011|NCT05188040|Other|Virtual Reality Exercises|Hand Therapy Exercises utilizing Oculus Quest 2 VR system with augmented feedback for patient to perform active hand therapy. Specific interventions / games will be selected by the participants individual therapist.
45787012|NCT05179109|Procedure|Minimally invasive surgery|Minimally invasive surgery for severe deep endometriosis
45787013|NCT05166057|Other|Synchronized online telerehabilitation exercise program|Breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be applied to the patient by videoconference.
45919347|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 7.5 mg/kg, Every other week, Up to 337 days
45919348|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 15 mg/kg, Every other week, Up to 337 days
45919349|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 15 mg/kg or optimal dose, Every other week, Open
45919350|NCT01466335|Drug|Ronacaleret (100mg tablet)|100mg tablet
45919351|NCT01466335|Drug|Placebo|matching placebo tablet
45787014|NCT05166057|Other|Videobased telerehabilitation exercise program|A video containing breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be given to the patient and will be asked to exercise regularly.
45645263|NCT05255029|Device|POD T 49P implantation experimental|The investigational lens will be implanted within the capsular bag after removal of the natural crystalline lens following phacoemulsification and alignment the toric axis of investigational lens to the intend axis which was calculated by the Toric calculator software. When enroll the test lenses into both eyes, the lens is implanted first to the eye with more advanced cataract. If both eyes have a similar degree of cataract, perform the surgery first for the right eye. The timing of surgery the investigational lens into the fellow eye will be determined after the investigator and the investigator (hereinafter referred to as the investigator) have confirmed the safety of the previously operated eye.
45645264|NCT05006651|Device|McGrath MAC|Intubaion with McGrath MAC
45645265|NCT05006651|Device|Trachway|Intubaion with Trachway
45645266|NCT05014685|Drug|Rabeprazole|20mg bid
45645267|NCT05014685|Drug|Bismuth potassium citrate|0.6g bid
45645268|NCT05014685|Drug|Metronidazole|0.4g tid
45645269|NCT05014685|Drug|Amoxicillin|1g tid
45645270|NCT03111823|Behavioral|Exercise Intervention|Undergo aerobic exercise sessions
45645271|NCT03111823|Other|Quality-of-Life Assessment|Ancillary studies
45645272|NCT03111823|Other|Questionnaire Administration|Ancillary studies
45645273|NCT02346097|Device|Cardiac Resynchronization Therapy (St. Jude Qaudripolar LV lead)|"Optimal electrical resynchronization vs. routine CRT strategy, imaging guided. For more details refer to Arm descriptions"
45645274|NCT05014763|Procedure|connective tissue graft|Connective tissue graft surgery will be done for increasing soft tissue volume. In this methods connective tissue will be harvested from lateral palate or tuberosity area.
45645275|NCT05015309|Drug|SH3765 tablet|Starting dose 2.5mg, oral administered once daily. If tolerated subsequent cohorts will test increasing doses (5mg, 10mg, 15mg, 20mg, 25mg, 30mg) of SH3765.
45645276|NCT02345785|Other|urologic surgery and caudal block|
45645277|NCT05006495|Procedure|C3 laminectomy|C3 laminectomy preserving semispinalis cervicis inserted into the axis.
45645278|NCT05006495|Procedure|C3 laminoplasty|Conventional C3-6 laminoplasty, resulting in injury of semispinalis cervicis.
45787015|NCT05166057|Other|Hospital based outpatient exercise program|Breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be applied to the patient in the hospital..
45787016|NCT05163964|Behavioral|Lifestyle Intervention|Circadian misalignment contributes to the high glycemic outcome. To adjust meal timing earlier and avoid late-night meal eating patterns, to switch from the evening chronotype to morning chronotype possibility to reverse glucose fluctuation conditions.
45787017|NCT05153369|Behavioral|Enhanced Care|Enhanced care aims to educate participants about bipolar disorder using a didactic approach, in addition to teaching and practicing DBT skills in an applied and relevant manner based on the participant's needs. Participants will receive a total of four sessions (approx. 60 minutes in duration), to occur once a month, at a minimum. The content will be split up into psychoeducation (2 sessions) and selected DBT skills (2 sessions). Psychoeducation will be specific to youth bipolar disorder, covering topics such as symptoms of depression and hypo/mania, medications used to treat bipolar disorder, the role of biology and the environment in emotions, and vulnerability and protective factors to emotion dysregulation and mood episodes. The content of skills sessions will be individualized and based on participant needs and goals (e.g., learning and applying skills to optimize their overall functioning, address problem behaviors and/or stressors, and/or maintain commitment to treatment).
46071187|NCT04202198|Procedure|pinhole surgical technique only|local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla followed by advancement of the flap. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
45645279|NCT03111901|Drug|Pembrolizumab|Pembrolizumab solution
45645280|NCT03111901|Drug|Interleukin-2|Interleukin-2 solution
45645281|NCT02345941|Other|Parent Action Report|Parent Action Report will be displayed after the baseline assessment and contain educational safety messages.
45645282|NCT02345941|Other|Parent Portal|Parents will have access to the Parent Portal, and they will be encouraged to visit it at any time.
45645283|NCT05014607|Biological|Personalized multi-peptide vaccine|"Peptide vaccine: Personalized multi-peptide vaccine cocktails consisting of 200-300µg each of 5-10 tumor-associated peptides selected individually based on the patient-individual HLA allotypes and HLA ligandome analysis of tumor cells Peptides are synthesized in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen and will be formulated at the GMP-Center of the University Hospital Tübingen.~Peptides will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG as adjuvant.~Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned.~Treatment schedule:~Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned, depended on the induction of peptide-specific T-cell responses."
46071188|NCT02848508|Drug|Metformin|
45645284|NCT04816357|Other|Questionaire|only questionaire
45645285|NCT02341729|Drug|ticagrelor|crushed tablets and non-crushed tablets
45645286|NCT05014373|Combination Product|Favipiravir + Standard of Care|"1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily~Plus Standard of Care"
45645287|NCT05014373|Procedure|Standard of Care|Best supportive care includes Standard treatment included oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs & the medication any patient is on due to any concomitant diseases.
45787018|NCT05153369|Behavioral|DBT Skills Training|In DBT Skills Training, participants will only receive skills training and can choose to do this individually and/or with their individual family unit by including their parent(s) and/or sibling(s). Participants will receive 20-25 sessions (approx. 60 minutes in duration), to occur at least biweekly. Skills training will include the five standard youth DBT modules: psychoeducation about DBT and bipolar disorder, mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness, and walking the middle path. The primary focus of the skills training is to impart knowledge and acquire and strengthen pragmatic skills to replace dysfunctional behaviors. If participants choose to include their family members, they will be encouraged to coach one another in effective use of skills.
45787019|NCT05153369|Behavioral|Dialectical Behavior Therapy Full Intervention|The DBT full intervention is based on Miller et al.'s DBT for suicidal youth, with modifications for youth with BD. DBT will be conducted over 1 year with approximately 40-50 sessions. Sessions will alternate between individual and skills training sessions. Family involvement in skills training will be strongly encouraged, however will be up to the participant to decide. Participants in Level 3 will complete diary cards tailored for this population, assessing daily mood, suicidality, sleep, and medication adherence. Participants will report use of specified DBT skills on the diary card, and individualized treatment goals will be incorporated into the diary card (e.g., alcohol use). In addition, Level 3 will include skills coaching by phone (via phone and/or text). These brief, structured calls and/or texts function to promote skills generalization by helping the participant and any participating family member(s) use skills to achieve goals and solve problems.
45787020|NCT05151471|Drug|MT-1186|Oral edaravone
45645288|NCT02039245|Drug|CANA/MET XR FDC|Each tablet contains Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) of 150 mg/1,000 mg, to be taken orally (by mouth)
45919352|NCT01466296|Device|Chaotic Perturbation|"Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will perform basic stretching and muscle strengthening, then wear the random shoes and perform a set of exercises following specific verbal tasks, e.g., Walk 5 strides forward, or, Walk to the right side until I ask you to stop. During this stage of walking the device will impose perturbations in the range tolerated by the subject. The therapist will make a written report of each session."
45919353|NCT01466296|Device|Dummy not active shoes|"Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will perform basic stretching and muscle strengthening, then wear the dummy shoes and perform a set of exercises following specific verbal tasks, e.g., Walk 5 strides forward, or, Walk to the right side until I ask you to stop. During this stage of walking the device will not impose perturbations. The therapist will make a written report of each session."
45919354|NCT01466296|Device|Treadmill training|Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will exercise basic stretching and muscle strengthening, then walk on the treadmill. A physiotherapist according the subject's rate of improvement will determine the increase in treadmill velocity and slope. The therapist will make a written report after each session.
45919355|NCT03818204|Device|Magnetic Levator Prosthesis (MLP)|Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin. Tegaderm, which is essentially the same adhesive, is even FDA approved as an eye covering (we used Tegaderm in early studies but switched to IV 3000 for its superior ease of handling based on packaging technique).
45645289|NCT03083951|Procedure|Complete mesocolon excision|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric vein and a high tie ligation of the inferior mesenteric artery (complete mesocolon excision)
45645290|NCT03083951|Procedure|Conventional locoregional lymphadenectomy|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric artery and a high tie ligation of the inferior mesenteric artery with or without section of inferior mesenteric vein.
45645291|NCT04762459|Drug|Almonertinib|Almonertinib 110mg PO once daily
45787021|NCT05151471|Drug|Placebo|Oral
45919356|NCT01466257|Biological|cetuximab|
45919357|NCT01466257|Drug|cisplatin|
45919358|NCT01466257|Genetic|DNA analysis|
45919359|NCT01466257|Genetic|gene expression analysis|
45919360|NCT01466257|Genetic|mutation analysis|
45919361|NCT01466257|Other|laboratory biomarker analysis|
45919362|NCT01466140|Other|Writing down request for help|Patients in the intervention group could write down their request for help on a request card (with a maximum of 2 questions).
45919363|NCT01466101|Drug|Placebo administration|Administration of placebo
45919364|NCT01466101|Drug|Pregabalin administration|Administration of pregabalin
45919365|NCT00393640|Procedure|Early and regular breast milk expression|Breast pump given to be used on regular intervals
45919366|NCT05420025|Other||
45919367|NCT01465984|Drug|Paracetamol|paracetamol , 1 gram Iv infusion Morphine Sulfate0.1 Mg/Kg Iv
45919368|NCT04328246|Device|IES System|The IES system is composed of a stimulator and self-adhesive surface gel electrodes.
45919369|NCT04328246|Other|Standard of Care Therapy|Standard institutional practices for treating pressure injury.
45919370|NCT01465945|Procedure|Defect Unsutured|The defect is not sutured after the rectal tumor is removed by TEM.
45919371|NCT01465945|Procedure|Defect Sutured|Defect is sutured after the rectal tumor has been removed by TEM.
45919372|NCT01465906|Drug|tulobuterol|patch, 2mg, qN, 3 months
45645292|NCT04762459|Drug|Pemetrexed|500 milligrams per square meter (mg/m²) Pemetrexed
45645293|NCT04762459|Drug|Cisplatin|75mg/m² Cisplatin taken intravenously (IV) once every 3 weeks concurrently
45787022|NCT05139251|Other|Recovering from Intimate partner violence through Strengths and Empowerment (RISE)|RISE intervention will be implemented for a period of 4 weeks at the beginning of the program. Four components/modules of the RISE intervention which includes a) education on health effects of violence, b) improving coping and self-care, c) enhancing social support, and d) addressing sexual violence will be used. Toward the beginning of each session the participant will complete a brief survey including a 10-item general self-efficacy scale to be graphed and discussed together to provide more immediate feedback to women about their progress, and at times, inform module selection. At the conclusion of each RISE session, women are asked to set a goal related to the topic in consultation with the clinician
45787023|NCT05139251|Other|ePALS|"Participants and their children will then receive 6 weekly sessions of ePALS. The ePALS sessions include rapport building, recognizing and understanding children's signals, contingently responding to signals, labeling objects and actions, learning book reading strategies, maintaining children's focus of attention, helping children with self-regulation, and language scaffolding techniques. Each parent will have a personal parenting coach who remotely supports their progress through the program.~After a parent views a PALS coaching session, they will videotape themselves trying the strategy for that week with their child. Then their coach sets up a zoom call and together they talk about the PALS strategy and view the video. The coach facilitates parental appraisal of their behavior and discuss what they thought worked with their child and what they want to do differently."
45787024|NCT05127421|Drug|Ruxolitinib cream|"Ruxolitinib cream 1.5% applied twice a day (BID)"
45787025|NCT05127421|Drug|Vehicle|Vehicle cream applied twice a day (BID) to affected areas
45919373|NCT01465906|Drug|Tiotropium Bromide|18ug, inhale, qD, 3 months
45919374|NCT01465906|Drug|tiotropium bromide|18ug, inhale, qD, 3 months
45919375|NCT05408832|Behavioral|Personalized Trial ABCCBA|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (ABCCBA), where A=mindfulness meditation, B=yoga, and C=brisk walking.
45919376|NCT05408832|Behavioral|Personalized Trial CBAABC|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (CBAABC), where A=mindfulness meditation, B=yoga, and C=brisk walking.
45645294|NCT03078569|Drug|Testosterone gel|treatment with testosterone gel
45919377|NCT05408832|Behavioral|Stress Management Techniques with No Randomization Sequence (or order)|Participants will have access to all 30-minute videos for A=mindfulness meditation, B=yoga, and C=brisk walking, during the 12-week phase of the study. They will be limited to 12 total views per stress management technique.
45919378|NCT01465867|Dietary Supplement|Selenium|83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour
45919379|NCT01465867|Other|Sugar Pill Placebo|Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour.
45645295|NCT03078335|Other|Glove based care|Described in Experimental Arm: Glove based care
45645296|NCT03078335|Other|Standard of Care - Hand Hygiene|Hand Hygiene - hand washing with soap and water, or alcohol based hand rub
45645297|NCT02345863|Drug|Bendamustine|"Debulking:~2 cycles of Bendamustine (70 mg/m² iv) will be administered before induction unless a contraindication is existing or it is not clinically indicated."
45645298|NCT02345863|Drug|GA101|"Induction~GA101 iv infusion:~Cycle 1: Day 1 100 mg Day 1 (or 2) 900 mg Day 8 1000 mg Day 15 1000 mg Cycle 2-6: Day 1 1000 mg~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~GA101: Cycle 1-8 Day 1 1000 mg"
45645299|NCT02345863|Drug|Ibrutinib|"Ibrutinib will be administered as a daily oral dosage of 420 mg starting on cycle 2 day 1.~Cycle 2-6: Day 1 420 mg daily~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~Ibrutinib: Cycle 1-8 420 mg daily"
45787026|NCT05125809|Biological|Setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
45645300|NCT03078257|Drug|tirofiban in PV|"a loading dose of 10ug/kg tirofiban is given in 3 min through PV,followed by a maintenance dose of 0.15ug/kg*min for 48h.~(clopidogrel 600 mg+aspirin( ASA) 300 mg)x1 day."
45787027|NCT05125809|Other|Placebo|A 5% dextrose/glucose solution administered QM via IV infusion
45787028|NCT05125497|Procedure|In Vitro Fertilisation (IVF)|Natural Cycle In Vitro Fertilisation (IVF): without hormonal stimulation Conventional In Vitro Fertilisation (IVF): conventional hormonal stimulation Minimal Stimulation In Vitro Fertilisation (IVF): low dose of hormonal stimulation will be applied
45787029|NCT05099445|Drug|INCB000928|INCB000928 200 mg will be administered on Day 1 of each treatment period.
45787030|NCT05098210|Biological|Neoantigen Peptide Vaccine|Given IM
45787031|NCT05098210|Biological|Nivolumab|Given IV
45787032|NCT05098210|Drug|Poly ICLC|Given IM
45787033|NCT05097703|Behavioral|Sleep Resource|The sleep resource is a card game to be played by children and caregivers as part of their bedtime routine. It includes exercises to help prepare the child for sleep, including deep breathing, mindfulness and light movement. Caregivers will be asked to use the resource for a minimum of three nights a week over a four week period, and complete pre and post outcome measures as well as sleep and resource use diaries for their children
45787034|NCT05087680|Behavioral|ACTPrEP|ACTPrEP will include a 60-minute initial session and a series of 30-minute follow-up sessions. Sessions will focus on the Thoughts, Emotions, Associations, Memories, and Sensations (TEAMS) relevant to PrEP uptake and adherence.
45645301|NCT03078257|Drug|tirofiban in IC|"a loading dose of 10ug/kg tirofiban is given in 3 min through IC,followed by a maintenance dose of 0.15ug/kg*min for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
45787035|NCT05087680|Behavioral|Enhanced Standard of Care|Enhanced Standard of Care (ESOC) will include one 30-minute PrEP education session.
45787036|NCT05084209|Behavioral|Parkinson's medical decision making support|Participants will be asked to view and work through medical decision making support resources. The resources will include information on medical decisions that may occur in Parkinson's disease, and general medical decisions that anyone may need to make (i.e. choosing a medical decision maker). The resources will also include suggestions on how to discuss these decisions.
45787037|NCT05069285|Other|self-help book|information and advice given in the self-help book
45787038|NCT05069285|Other|sleep hygiene advice|information and advice given on the sheet of paper with sleep hygiene
45787039|NCT05063877|Drug|Placebo|Matched placebo
45645302|NCT03078257|Drug|antiplatelet thrombolysin|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
45645303|NCT03078257|Drug|placebo|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
45645304|NCT03078257|Drug|Clopidogrel|loading dose of 300 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
45645305|NCT03078257|Drug|Aspirin|loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.
45645306|NCT03078257|Drug|Clopidogrel|loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
45645307|NCT02341573|Drug|experienced chinese herbal formulas|At the acute stage of asthma :Shegan mixture ; At the remission stage:Huangqi Bushen mixture; 10-30 mL , 2 times a day, for 3 months.
45645308|NCT02341573|Drug|leukotriene receptor antagonist and bronchial relaxant|At the acute stage of asthma : etinoline,twice a day for 7 days; At the remission stage: Singulair, once daily for 3 months.
45787040|NCT05063877|Drug|EQU-001|EQU-001 in 10 mg and 20 mg capsules
45787041|NCT05059691|Other|Electronic Health Record Review|Review of medical records
45787042|NCT05059691|Procedure|Transbronchial Cryobiopsy Guided by Three-Dimensional Fluoroscopy|Undergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy
45787043|NCT05058911|Behavioral|Internet-delivered exposure-based cognitive behavior therapy|The primary treatment component is exposure to stimuli (situations and activities) that give rise to pain, distress, and unwanted emotional responses. The treatment proceeds in accordance with functional analysis. Exercises are tailored for the patient so that, for example, individuals whose main coping strategy is to be overly active (i.e., persistence behavior) are encouraged to sit down and observe pain and other aversive bodily sensations as they arise. The protocol also includes regular exercises where the participant is encouraged to observe and name physical sensations without acting on them.
45787044|NCT05058911|Behavioral|Internet-delivered traditional cognitive behavior therapy|This treatment is based on components typical of T-CBT for FM, such as relaxation, activity planning or pacing, cognitive restructuring techniques and stress management strategies.
45787045|NCT05056727|Drug|Sodium Zirconium Cyclosilicate (SZC)|"Powder for oral suspension in a sachet. Unit dose strength: 5 or 10 g SZC. Single dose will consist of 1-3 sachets.~During Initiation Phase:~S-K > 5 to ≤ 6.5 mmol/L (measured by L-Lab): Single dose contains 10 g SZC that should be suspended in 45 mL of water. The 10 g SZC single dose should be administered three times daily for up to 72 hours until normokalaemic (S-K 3.5-5.0 mmol/L); the total daily dose is 30 g SZC.~S-K ≥ 3.5 to ≤ 5 mmol/L (measured by L-Lab): Single dose contains 5 g SZC that should be suspended in 45 mL of water and administered once daily for 48 hours.~During Run-in and Maintenance Phases:~- Single dose contains 5 g SZC administered every other day or 5, 10, or 15 g SZC administered once daily that should be suspended in 45 mL of water."
45645309|NCT02346019|Procedure|Medial thighplasty with or without thigh liposuction|Perform a standard medial thighplasty with or without additional thigh liposuction on up to three obese transfemoral amputee subjects. The subjects will be transfemoral amputees who are successful ambulators and have a body mass index (BMI) of 30 or greater with excessive adipose tissue in their residual limb. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
45787046|NCT05056727|Drug|Placebo|"Powder for oral suspension in a sachet. Placebo to match 5 or 10 g. Single dose will consist of 1-3 sachets.~During Maintenance Phase:~- Single dose contains 5 g placebo administered every other day or 5, 10, or 15 g placebo administered once daily that should be suspended in 45 mL of water."
45787047|NCT05056727|Drug|Lisinopril|Tablet for oral administration. Unit dose strength: 2.5, 5, 10 or 20 mg. Dosage level: 5, 10, 20, or 40 mg administered once daily.
45787048|NCT05056727|Drug|Valsartan|Tablet or capsule for oral administration. Unit dose strength: 40, 80 or 160 mg. Dosage level: 40, 80, 160, or 320 mg administered once daily.
45645310|NCT05005715|Drug|Dexmedetomidine|Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
45645311|NCT05005715|Drug|normal saline|Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
45787049|NCT05056727|Drug|Irbesartan|"Tablet for oral administration. Unit dose strength: 75, 150 or 300 mg. Dosage level: 75, 150, or 300 mg administered once daily.~The study is designed to use valsartan as the selected ARB therapy adjunct to SZC. However, if an actual shortage of valsartan in a local market jeopardises the ability of participants to enter or continue in the study, valsartan can be temporarily substituted with irbesartan until the shortage of valsartan is resolved."
45645312|NCT02341651|Other|Multicomponent intervention|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
45787050|NCT05022550|Device|DEEP VR|DEEP VR is a virtual reality experience (i.e., video game using a head-mounted display) wherein participants ('players') traverse through a serene underwater adventure for approximately 15 min. Movement through the environment is facilitates through the cued use of regularized, diaphragmatic breathing, captured through a respiratory belt.
45787051|NCT05009992|Drug|ONC201|Given orally (PO)
45787052|NCT05009992|Radiation|Radiation Therapy|Undergo radiation therapy
45787053|NCT05009992|Drug|Paxalisib|Given PO
45787054|NCT05005975|Drug|MT-7117|MT-7117
45645313|NCT03083795|Behavioral|Social relationships intervention|Participants randomized to the social interaction cohort will meet on a monthly basis for a two hour group session designed to build social connections. In addition, participants will be paired with another study participant in this group, and will be asked to meet on a monthly basis for a minimum of 45 minutes. All participants in the social support cohort will continue to receive best standard diabetes management.
45787055|NCT04999982|Other|Screening|Parent-report screening for remediable, unmet social needs.
45787056|NCT04999982|Other|Resource Packet|"Provision of packet of resource sheets (Family Resource Booklet) detailing local community-based resources to address these needs, with needs that respond to family's requests highlighted."
45787057|NCT04999982|Other|Resource Navigation|Navigation to resources, care coordination, and parent support provided by a trained bachelors-level interventionist.
45787058|NCT04999982|Other|Care as usual|Screening for social needs annually at well-child visits as recommended by the AAP followed by provision of information as needed by the family.
45919380|NCT01465867|Other|Selenium + L-Thyroxine (LT4)|"83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour~+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)"
45645314|NCT02345707|Drug|Cabotegravir 30 mg current formulation|Cabotegravir 30 mg current formulation (Treatment A) is a film coated tablet with a weight of 824 mg
45645315|NCT02345707|Drug|Cabotegravir 30 mg micronized new formulation 500 M|Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) is a film coated tablet with a weight of 515 mg
45645316|NCT02345707|Drug|Cabotegravir 30 mg unmicronized new formulation 500 U|Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) is a film coated tablet with a weight of 515 mg
45645317|NCT02345707|Drug|Cabotegravir 30 mg micronized new formulation 650 M|Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) is a film coated tablet with a weight of 670 mg
45787059|NCT04992312|Drug|Glucagon Nasal Powder [Baqsimi]|Administered intranasally
45787060|NCT04986072|Drug|Sodium Nitroprusside|Half of participants will receive Intravenous Sodium Nitroprusside (0.5 μg/kg/min) for 4 hours.
45787061|NCT04986072|Drug|5% Dextrose solution|Half of participants will receive intravenous 5% Dextrose solution for 4 hours.
45787062|NCT04983173|Drug|Ovarian Stimulation with CC+rFSH|: CC 50 mg/day (Omifin®) + rFSH 150 IU (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)
45919381|NCT01465867|Other|Sugar Pill Placebo + L-Thyroxine (LT4)|"Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour~+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)"
45919382|NCT04244864|Behavioral|Cross-sectoral psychosocial intervention|The intervention seeks to integrate working with social stressors alongside treatment for trauma-related mental health problems. This is done in two ways; by a cross-sectoral collaboration with the patient's case counsellor in the municipality including three collaborative meetings and by a systematic focus on social stressors during the treatment.
45919383|NCT04244864|Behavioral|Treatment as usual (TAU)|"Medical doctor, 10 sessions: Pharmacological treatment according to standard algorithm and psychoeducation.~Psychologist 16-21 sessions: Manual-based cognitive behavioural therapy."
45919384|NCT01465828|Drug|Clopidogrel|Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 14 days we will change their therapy with standard dose of prasugrel (crossover).
45919385|NCT01465828|Drug|prasugrel|Patient will be randomized to this intervention will receive in the first time the standard dose of prasugrel and after 14 days we will change their therapy with high dose of clopidogrel (crossover).
45919386|NCT05408052|Procedure|Dural Puncture Epidural (DPE)|"Using the 18G Tuohy needle in the sitting position, the epidural space will be determined from the L3-L4 or L4-L5 space using the loss-of-resistance method After Dural puncture will be performed using a 25G Whitacre needle from the Tuohy needle to patients in the DPE group and free CSF flow will be observed, but no medication will be applied to the subarachnoid space. Afterwards, epidural catheter will be placed and when the catheter is fixed, a test dose of 3 mL will be administered through the catheter to check for intravascular or subarachnoid catheter placement.~An epidural local anesthetic will be administered throughout the catheter for intraoperative analgesia at 0,1% (bupivacaine+fentanyl+ saline) concentration with the NoL monitor guidance."
45919387|NCT05408052|Procedure|Standart Epidural|"The neuraxial procedure will be performed in the sitting position using the 18G Tuohy needle, in the L3-L4 or L4-L5 range using the loss-of-resistance method.~The epidural catheter will be placed so that it remains 4 to 5 cm in the epidural space. After the catheter is fixed, a test dose of 3 mL will be administered through the catheter to check for intravascular or subarachnoid catheter placement.~An epidural local anesthetic will be administered throughout the catheter for intraoperative analgesia at 0,1% (bupivacaine+fentanyl+ saline) concentration with the NoL monitor guidance."
45919388|NCT01465633|Drug|levothyroxine|
45919389|NCT01465633|Drug|levothyroxine|
45919390|NCT05395026|Other|electrical stimulation of vagus nerve|VNS electrical stimulation parameters (pulse duration, pulse amplitude, and pulse frequency) will be systematically changed to determine the effect on vagus nerve activation, laryngeal muscle contraction, and heart rate.
45919391|NCT01465594|Procedure|transurethral catheter after EERPE/ RALP|transurethral catheter after EERPE/ RALP
45919392|NCT01465594|Procedure|suprapubic catheter after EERPE /RALP|suprapubic catheter after EERPE /RALP
45919393|NCT04208321|Other|Placebo|Placebo will be supplied as matching tablets (to 40 mg and 80 mg VT-1598 tablets) containing the inactive components of VT-1598.
45919394|NCT04208321|Drug|VT-1598|VT-1598 is a novel oral agent for the treatment of fungal infections. It will be supplied as 40 mg and 80 mg tablets.
45919395|NCT01465516|Drug|Boceprevir|"Baseline assessments must be obtained on the day of or prior to enrollment and prior to administration of the first dose of any study drug (BOC, PEG-IFN alfa-2b, or ribavirin).~Using the RGT guidelines in patients who are previously untreated: all patients will receive a lead-in treatment of PR for 4 weeks, then BOC will be added to PR for 4 weeks; based on patient's week 8 HCV RNA results"
45919396|NCT05394636|Other|None, pure observational study|None, pure observational study
45919397|NCT01465477|Biological|Inactivated split virion Influenza vaccine|WHO recommended 2011 Influenza vaccine
45919398|NCT01465477|Biological|WHO recommended 2011 Influenza vacccine|WHO recommended 2011 Influenza vacccine
45919399|NCT01465438|Drug|Adalimumab|Adalimumab 40 mg every other week
45919400|NCT01465399|Biological|Plasma Rich in Growth Factors PRGF-Endoret|
45919401|NCT01465399|Procedure|Conventional closure of the lesion|
45645318|NCT02345707|Drug|Cabotegravir 30 mg unmicronized new formulation 650 U|Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) is a film coated tablet with a weight of 670 mg
45787063|NCT04983173|Drug|Ovarian Stimulation with rFSH|rFSH 300 IU rFSH (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)
45919402|NCT01465282|Drug|CT327 0.05%|0.05% CT327 (w/w) ointment
45919403|NCT01465282|Drug|CT327 0.1%|0.1% CT327 (w/w) ointment
45919404|NCT01465282|Drug|CT327 0.5%|0.5% CT327 (w/w) ointment
45919405|NCT01465282|Drug|Placebo|Placebo
45919406|NCT05393505|Drug|Meropenem Injection|Given if patient has no known allergies at 1 g IV bolus within 1 hour of ED registration, then every 8 hours
45919407|NCT05393505|Drug|Levofloxacin|Given if patient is allergic to beta lactam at 500 g IV in 100 mL 0.9% sodium chloride solution, infused over 1 hour started within 1 hour of ED registration, then every 24 hours. If the patient can tolerate oral drugs, 500 mg daily after the first IV dose.
45919408|NCT05393505|Drug|Amoxicillin Clavulanate|Given if patient has no known allergies at 1.2 g IV bolus within 1 hour of ED registration, then every 8 hours. If the patient can tolerate oral drugs, 1 g twice daily after the first IV bolus.
45645319|NCT02341339|Procedure|Laparoscopic Surgery (Biopsies of fallopian tube lumen) using a laparoscopic brush/biopsy device|
45645320|NCT05005481|Other|NIL intervention|NIL intervention will be performed on patients.
45645321|NCT02345473|Genetic|Detection of circulating tumor cells in blood samples|Ficoll based isolation of mononuclear cells from the peripheral blood of patients undergoing radical cystectomy, nucleic acids extraction and, finally, PCR based detection of sequences specific to cytokeratins.
45645322|NCT05005637|Drug|Anti Tuberculosis Drug|ATT will be given in the form of fixed drug combination (FDC). Each patient will get a regimen of 2RHZE (2 months of FDC intensive phase, which contains of Rifampicin, Isoniazide, Pirazinamide, Ethambutol) + 4RH (4 months of FDC continuation phase, which contains of Rifampicin and Isoniazid). The dosage will be according to body weight, 30-37 kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets, more than 70 kg: 5 tablets. FDC drugs have to be consumed daily during intensive phase and three times a week during continuation phase.
45787064|NCT04976153|Biological|aSMDC|Autologous Muscle Derived Cells for injection into the external anal sphincter
45919409|NCT05393505|Drug|Antibiotic|"Any antibiotic for empirical therapy of common infections as recommended by the fifth version of Hospital Authority Interhospital Multi-disciplinary Programme on Antimicrobial ChemoTherapy (IMPACT) guideline, with reference to previous bacterial sensitivity pattern"
45787065|NCT04976153|Other|Placebo|Placebo control is the vehicle solution used for the study product
45787066|NCT04969978|Behavioral|Enhanced Academic Detailing|"Group training of clinic staff prior to activation of the eReferral system and 12 months post-activation~Follow-up booster sessions~Monthly performance audit and feedback~Written training materials for all providers and staff"
45787067|NCT04969978|Other|Informational Intervention|Receive overview of Quitline services and use of Quitline eReferral via online materials
45787068|NCT04965935|Drug|Dapagliflozin 10 MG Oral Tablet|Dapagliflozin will be administered in a dose of 10 mg/day for 12 weeks.
45787069|NCT04965935|Drug|Placebo Matching Dapagliflozin Oral Tablet|Placebo will be administered for 12 weeks.
45787070|NCT04964869|Procedure|epinephrine solution injection|epinephrine solution injection at least 1 ml to the post- sphincterotomy wound
45787071|NCT04950075|Drug|INBRX-109|Tetravalent DR5 Agonist Antibody
45787072|NCT04950075|Drug|Placebo|Placebo
45787073|NCT04943731|Device|Provox Life|Phase 1: Like for like transition, Phase 2: Provox Life day/night regimen
45787074|NCT04936841|Drug|NKTR-214|Bempegaldesleukin (NKTR-214) is an immunotherapeutic protein prodrug specifically designed to activate the patient's immune system for the treatment of cancer by providing a controlled, sustained signal to the interleukin-2 (IL-2) receptor pathway (pharmacological classification: immunostimulatory interleukin cytokine)
45787075|NCT04936841|Drug|anti-PD-1 therapy|immunotherapy drug, monoclonal antibody
45787076|NCT04936841|Radiation|Palliative Radiation|radiation to relieve symptoms
45787077|NCT04930536|Drug|Acalabrutinib capsule|The recommended dose of Acalabrutinib is 100 mg given per oral (PO) twice daily
45787078|NCT04923126|Drug|Mirdametinib|By mouth, nasogastric (NG) tube or gastrostomy tube (G-tube) BID, days 1-28
45787079|NCT04921917|Other|neoadjuvant exercise therapy|brief exercise regimen completed immediately prior to neoadjuvant radiation therapy. Rubber bands will be used for the exercise training of patients with lower extremity tumors while an electronic hand-held dynamometer will be used for the exercise training for patients with upper extremity tumors.
45919410|NCT01465243|Drug|Icotinib|125 mg Tid (375 mg per day) 250 mg Tid (750 mg per day)
45645323|NCT05005637|Drug|Prednisone tablet|Oral prednisone will be given at the dose of 1 mg/kgBW/day (max 60 mg/day) until the uveitis is controlled or up to 4 weeks of administration, after that the dose will be tappered off gradually.
45787080|NCT04915040|Behavioral|Behavioral Activation for Depression|Behavioral Activation (BA) is an effective treatment for depression, and its components may increase social connection. Generally, caregivers are with the older adult care recipient on a regular basis and may be able, with the correct training, to help enhance certain features of the Behavioral Activation treatment, even under pandemic restrictions on social contact. Therefore, we propose to (a) integrate & (b) gather feasibility data for home-based Behavioral Activation + Caregiver
45787081|NCT04899271|Drug|Ladarixin|400 mg b.i.d. for 13 cycles of 14 days on/14 days off
45787082|NCT04899271|Other|Placebo|Placebo will be administered orally with the same scheme of administration of LDX to preserve blinding
45787083|NCT04893291|Device|Everolimus Eluting Stent|Patients assigned to this Arm will have an EES implanted after pre-dilatation, the angiography will be conducted as standard of care
45787084|NCT04893291|Device|Sirolimus Coated Balloon|Patients assigned to this Arm will be treated with Magic Touch Drug Coated Balloon (DCB) after pre-dilatation, the angiography will be conducted as standard of care
45787085|NCT04892797|Other|Covid-19+ observational|This is observational--there is no intervention
45787086|NCT04888039|Other|quality of life questionnaires (EORTC QLQ-C30 ; EORTC QLQMY20 ; EQ-5D-5L ; Cohen's stress scale)|"Excepted the delivery of quality of life questionnaires (a maximum of 5 times during the course of treatment) specific to this study, only the data available during the course of patient care will be collected.~The quality of life questionnaires and the perceived stress questionnaire will be given to patients :~At diagnosis (before starting 1st line of treatment),~after the induction phase (before autologous transplantation for patients who will be transplanted),~after the consolidation phase,~after the maintenance phase : 1 year and 2 years after the start of the maintenance."
45787087|NCT04881760|Drug|LY3437943|Administered SC
45787088|NCT04881760|Drug|Placebo|Administered SC
45919411|NCT04201457|Drug|Dabrafenib|Dabrafenib capsule; Dabrafenib Dispersible Tablet
45919412|NCT04201457|Drug|Trametinib|Tablet; Powder for Oral Solution
45919413|NCT04201457|Drug|Hydroxychloroquine|Tablet
45919414|NCT01465204|Behavioral|Total Sanitation and Sanitation Marketing|"Total Sanitation and Sanitation Marketing (TSSM) program is designed to promote demand for and supply of improved sanitation. On the demand side, it includes Community-Led Total Sanitation (CLTS). On the supply side, TSSM incorporates sanitation marketing interventions. Both CLTS and sanitation marketing draw heavily on the behavior-change communication and social marketing approaches that have been well developed in other sectors. The basic TSSM approach also builds sustainability and scalability through the strengthening of the national level sanitation sector enabling environment."
45919415|NCT01465204|Behavioral|Scaling Up Handwashing Behavior Change|The Handwashing with soap (HWWS) behavior change program expands and improves existing hygiene behavior change efforts with new and innovative promotional approaches in order to generate widespread and sustained improvement in handwashing with soap practices. These approaches include social marketing to deliver handwashing messages; broad and inclusive partnerships with government, private commercial marketing channels, and concerned consumer groups and NGOs.
45787089|NCT04866264|Device|eNutrition Optimizer|The eNutrition optimizer is based on the electronic food frequency questionnaire (FFQ) used in the multicentre randomized controlled trail DO-HEALTH [56] developed by the CAM. The FFQ is split up in sections of 33 food groups and contains 216 items. It asks the user on the relative frequency of consumption of the different foods showing a picture of the food in the portion size of interest. Within the eNutrition Optimizer, the FFQ will be extended to create an output of the user's adherence to the Mediterranean diet, the MIND diet and the adherence with the current dietary recommendations for micro- and macronutrients provided by the Swiss Society for Nutrition and the DACH-references, compare it to the DO-HEALTH population and give recommendations on how to improve the score.
45787090|NCT04864743|Drug|ADVATE|a single dose.
45787091|NCT04864743|Drug|FRSW117|a single dose.
45787092|NCT04847453|Procedure|Biospecimen Collection|Undergo blood specimen collection
45787093|NCT04847453|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
45787094|NCT04847453|Procedure|Computed Tomography|Undergo CT scan
45787095|NCT04847453|Drug|Dexamethasone|Given PO
45787096|NCT04847453|Drug|Ixazomib Citrate|Given PO
45787097|NCT04847453|Procedure|Magnetic Resonance Imaging|Undergo MRI
45787098|NCT04847453|Procedure|Positron Emission Tomography|Undergo PET scan
45787099|NCT04847453|Procedure|Transabdominal Ultrasound|Undergo transabdominal ultrasound
45787100|NCT04847453|Drug|Venetoclax|Given PO
45787101|NCT04847453|Procedure|X-Ray Imaging|Undergo x-ray
45787102|NCT04845503|Radiation|MR-guided Radiotherapy|Total Dose 37,5 Gy, Single Dose 7,5 Gy, 5 Fractions applied in 1-2 weeks
45787103|NCT04829955|Other|Eccentric manual resistance training|Eccentric bodyweight resistance training
45787104|NCT04829955|Other|Concentric manual resistance resistance training|Concentric bodyweight resistance training
45787105|NCT04813354|Device|ELLIPTA|"ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2"
45919416|NCT04712188|Diagnostic Test|Musculoskeletal ultrasonography|The ultrasonographic assesment will be used to examine the supraspinatus tendon thickness, the long head of the biceps brachii tendon thickness and acromio-humeral distance before and after wheelchair propelling test.
45645324|NCT03078179|Dietary Supplement|Commercial Dairy Cow Milk|After obtaining parent´s informed consent and the baseline examination, from 3 to 5 years old, will start commercial dairy cow milk intake without probiotic (placebo) for 3 months. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and demineralization in early Stage Decay and quantification of Streptococci of the mutans group.
45645325|NCT03078179|Dietary Supplement|Commercial Cow Milk with Probiotic|The children will initiate the milk intake with probiotic one week after having ingested the milk without probiotics. They will drink the milk with probiotic for 3 months. Clinical and microbiological testing of saliva will be performed. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and demineralization in early Stage Decay and quantification of Streptococci of the mutans group.
45787106|NCT04813354|Device|BREEZHALER|"ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2"
45787107|NCT04809766|Biological|Autologous Mesothelin-specific TCR-T Cells|Receive FH-TCR Tᴍsʟɴ IV
45787108|NCT04809766|Drug|Cyclophosphamide|Given IV
45787109|NCT04809766|Drug|Fludarabine|Given IV
45787110|NCT04804020|Procedure|NC|The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to the patients' uterus or adnexa. The second ultrasound will be performed on the sixth day of the cycle. Daily ultrasound and serum estradiol and LH level evaluation will be performed when the mean diameter of the dominant follicle of ≥14 mm. LH surge initiation is defined as a concentration of 180% above the latest serum value available in that patient with a continued rise thereafter9 to a level of 20 IU/l or more10 detected by the ECLIA method (Roche Cobas® E 801, Roche Diagnostics, Germany). Embryo transfer will be scheduled by the time of the initiation of LH and embryo stages.
45787111|NCT04804020|Procedure|mNC|The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to patients' uterus or adnexa. A second ultrasound scan will be performed on the sixth day of the cycle; if there is at least one follicle with a diameter of ≥12 mm, an ultrasound scan will be performed daily. When the dominant follicle's mean diameter is ≥16 mm, human chorionic gonadotropin (Ovitrelle® 250 μg; Merck, Kenilworth, NJ, USA) will be injected to trigger ovulation. Embryo transfer will be scheduled by the time of the hCG injection and embryo stages.
45787112|NCT04804020|Procedure|AC|The endometrium is prepared using oral estradiol valerate (Valiera®; Laboratories Recalcine) 8 mg/day, ranging from the second or fourth menstruation day. The endometrial thickness will be monitored from day six onwards, and vaginal progesterone (Utrogestan®; Besins) 800 mg/day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must be lasting for ≥9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages.
45919417|NCT04712188|Other|Wheelchair propelling test|Participants will use their own wheelchairs with their preferred stroke pattern for 20 minutes at a speed of 1 m / s on a motorized treadmill for a wheelchair propelling test. Wheelchair propelling videos will be recorded during the test. Shoulder kinematics will be analyzed using Kinovea motion analysis software and stoke pattern will be confirmed
45919418|NCT04712149|Device|Weekly digital follow up|weekly digital follow-up by sending a questionnaire to patients and sending alerts based on the questionnaire to the care team
45645326|NCT02341183|Device|tPAD|7% NaCl administered continuously for 8 hours, overnight, via the tPAD device
45787113|NCT04803422|Drug|Antibiotic|The study aims to test whether oral antibiotics is non-inferior compared to intravenous antibiotics.
45787114|NCT04795973|Behavioral|time-restricted fasting for 4 weeks|eat ad libitum from 7am to 5pm and fast in other time
45645327|NCT02341183|Device|7% hypertonic saline (510K approved as a device)|Subjects will receive overnight treatments of 7% HS via the tPAD device in both comparators, but in a randomly assigned order as described.
45645328|NCT05013515|Drug|Surufatinib|"Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), A total of 2 cycles were performed, and efficacy evaluation was performed at the end of each cycle or was determined to be required by the investigator. If disease progression or unacceptable toxicity occurred during the period, induction therapy was terminated early, and after corresponding treatment, surgical treatment was entered as early as possible.~Surufatinib treatment was interrupted 4-7 days before surgical treatment to maintain organ function; Note: Postoperative radiotherapy or chemoradiotherapy is permitted after radical surgery at the discretion of the investigator."
45645329|NCT02345551|Behavioral|Exercise|Moderate-vigorous aerobic activity in line with published guidelines for cancer prevention
45645330|NCT05013671|Other|repositioning maneuvers|The calcium crystals floating in the endolymphatic fluid will put back in place by putting the patient in several sitting and lying positions during specific repositioning maneuvers. During these maneuvers the calcium crystals will float from the semicircular canals back into the utriculus, after which the dizziness symptoms should disappear
45787115|NCT04795973|Behavioral|5:2 regimen for 4 weeks|chose two non-consecutive days per week to eat very little and eat ad libitum the other 5 days of the week
45787116|NCT04791943|Drug|Melatonin 10 MG|3 melatonin 10mg capsules will be given to the treatment arm
45787117|NCT04791943|Drug|Lactose pill|3 lactose pills will be provided to the control arm
45787118|NCT04786223|Drug|C-11 ER-176|Participants will receive a one-time administration of C-11 ER176 and undergo a PET/CT imaging study. Blood samples for plasma biomarker testing will be obtained as part of the study.
45787119|NCT04786223|Diagnostic Test|Blood Test|Participants will undergo a one time venipuncture blood collection to evaluate the presence of inflammatory and genetic markers.
45787120|NCT04785677|Behavioral|Resiliency in Stressful Experiences (RISE) Program|The Resiliency in Stressful Experiences (RISE) Program is a multi-phased comprehensive trauma based reentry program designed based on the transitional nature of reentry. Participants will receive up to 4 sessions prior to release and up tp 15 session post release from prison. The RISE program is a trauma intervention paired with reentry services, including housing support and employment assistance.
45787121|NCT04783428|Other|No intervention|Access to any treatment is through authorized commercial use and not as part of this DMP
45787122|NCT04779957|Drug|Tocilizumab|Tocilizumab will be administered at 8 mg/kg before or immediately after graft nephrectomy.
45787123|NCT04770532|Drug|Insulin degludec|Participants will receive subcutaneous (s.c.) injections of insulin degludec once daily for 26 weeks
45787124|NCT04770532|Drug|Insulin Icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 26 weeks
45787125|NCT04741984|Biological|MT-201-GBM monocyte vaccine|monocytes isolated from patient's leukapheresis loaded with CMV pp65-LAMP (Lysosomal-associated Membrane Protein) mRNA (Messenger Ribonucleic Acid)
45645331|NCT05013671|Other|balance|compare the balance of residents with BPPV with residents without BPPV
45645332|NCT02341261|Behavioral|Standard Care Counseling|
45919419|NCT01465087|Other|NA-NOSE artificial olfactory system|NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
45919420|NCT01465048|Biological|Plasmodium falciparum sporozoites 2sites|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intradermal injection sites
45919421|NCT01465048|Biological|Plasmodium falciparum sporozoites 1 site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intramuscular injection sites
45645333|NCT02341261|Behavioral|Supervised Exercise and Counseling|
45645334|NCT02336893|Behavioral|Training|The final training was provided to a group of 34 residents --from internal medicine, anesthesiology, gynecology, and intensive care-- in charge of giving information to the patient's family members in the ICU. They were trained in the semi-structured interview PACIENTE (Present oneself and greet, Attend and listen, Call diagnosis, Inform treatment, Expose prognosis, Name introductory phrases to bad news, Take time to provide empathetic comfort, Explain an action plan involving the family) conjointly while participating in simulated difficult clinical cases with family members-actors. Four training programs were performed from February to September 2014.
45645335|NCT05013203|Diagnostic Test|Tissue culture|Discarded tissue collected during surgery will be sent to the hospital microbiological lab for aerobic and anaerobic
45919422|NCT01465048|Biological|Plasmodium falciparum sporozoites 1site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 25,000 sporozoites, 50ulx2, 2 intramuscular injection sites
45919423|NCT01465009|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Single Administration of 2 tablets Acetylsalicylic acid (500 mg each); in addition, 2 tablets matching placebo to Paracetamol
45919424|NCT01465009|Drug|Paracetamol|Single Administration of 2 tablets Paracetamol (500 mg each); in addition, 2 tablets matching placebo to Acetylsalicylic Acid
45919425|NCT01465009|Drug|Placebo|Single Administration of 2 tablets matching Placebo to Acetylsalicylic Acid together with 2 tablets matching placebo to Paracetamol
45919426|NCT00389766|Drug|iodine I 131 metaiodobenzylguanidine|
45919427|NCT00389766|Drug|topotecan hydrochloride|
45919428|NCT00389766|Procedure|chemotherapy|
45919429|NCT00389766|Procedure|peripheral blood stem cell transplantation|
45919430|NCT00389766|Procedure|radioisotope therapy|
45919431|NCT00389766|Procedure|radionuclide imaging|
45919432|NCT00389766|Procedure|radiosensitization|
45919433|NCT00389766|Procedure|total-body irradiation|
45919434|NCT01464970|Procedure|Both Superficial Inferior Artery and Vein Clamped|Perfusion assessed in Zone IV of the DIEP flap whilst both the contralateral Superficial Inferior Epigastric Artery and Vein are clamped
45919435|NCT01464970|Procedure|Superficial Inferior Epigastric Vessels both unclamped|Perfusion assessed in Zone IV of the DIEP flap whilst both the contralateral Superficial Inferior Epigastric Artery and Vein are unclamped
45645336|NCT05013203|Diagnostic Test|Next Generation Sequencing|Discarded tissue collected during surgery will be sent to an outside lab for testing using next generation sequencing (NGS)
45645337|NCT03082469|Device|CytoSorb|Two consecutive 24h treatments with the CytoSorb-device
45645338|NCT02336659|Drug|exendin 9-39|Exendin 9-39 is a specific GLP-1 receptor antagonist
45645339|NCT02336659|Drug|sitagliptin|DPP-4 Inhibition
45787126|NCT04739722|Diagnostic Test|Colosense Stool Sample Collection Kit|The Colosense Collection Kit provides information on how to collect a stool swab using a fecal immunochemical test (FIT) and how to collect a stool sample using the Colosense Collection Kit. After a stool sample is produced, patients will swab the stool sample using the FIT tube according to instructions and return the stool sample via mail courier to Geneoscopy's Laboratories. Patients will then be directed to receive a colonoscopy. If a lesion is removed during the colonoscopy, the tissue sample will be sent for histopathology review. The colonoscopy report and the histopathology report will be reported to Geneoscopy. Stool samples returned to Geneoscopy's Laboratories will be subjected to the Colosense test system, which includes targeted nucleic acid enrichment and biomarkers quantification via droplet digital polymerase chain reaction. The FIT returned in the Colosense Collection Kit will also be read by laboratory technologists at Geneoscopy.
45787127|NCT04736550|Behavioral|Exercise|"Participants who are randomized to exercise will be perform exercise on stationary bikes. Participants randomized to Voluntary Exercise will exercise on a standard stationary bike where they will pedal at their voluntary rates. Participants randomized to Assisted Exercise will exercise on a special bike that assists them to pedal faster than they do voluntarily on their own (assisted (exercise) bike)."
45787128|NCT04736550|Behavioral|Psychotherapy for Pain (I-STOP)|"Participants who are randomized to receive I-STOP will receive the Self-regulation Treatment for Opioid addiction and Pain (STOP) program modified for inpatients/residential drug treatment (I-STOP). I-STOP uses empirically validated pain psychotherapy approaches targeted to patients with an OUD using psycho-physiological self-regulation components and biofeedback with Bio-dots."
45787129|NCT04731779|Drug|cannabidiol|Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil
45787130|NCT04731779|Drug|Placebo|Placebo oral product formulated in MCT (medium chain triglyceride) oil
45787131|NCT04719000|Drug|rhFSH+rhLH|300 IU of rhFSH and 150 IU of rhLH (Pergoveris®) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) Recombinant human chorionic gonadotropin (rhCG) 6500 IU (Ovitrelle® - Merck) micronized progesterone 90 mg (Crinone 8% ® - Merck)
45787132|NCT04719000|Drug|rhFSH|300 IU rhFSH (Gonal-F®- Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) rhCG 6500 IU (Ovitrelle® - Merck) micronized progesterone 90 mg (Crinone 8% ® - Merck)
45787133|NCT04717765|Device|Preventive, LLL Phototherapy and topical Vit E|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
45787134|NCT04717765|Device|Curative, LLL Phototherapy and topical Vit E|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
45787135|NCT04717765|Device|Preventive, LLL Phototherapy and LPRF|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
45787136|NCT04717765|Device|Curative, LLL Phototherapy and LPRF|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
45645340|NCT02336659|Other|Placebo|Saline
45645341|NCT03082625|Drug|Transdermal Magnesium|Magnesium
45787137|NCT04715568|Drug|Losartan|50 mg tablets taken orally
45787138|NCT04715568|Drug|Placebo|Tablets taken orally
45787139|NCT04708548|Other|Health-related Quality of Life|Health-related quality of life (HRQOL) is an individual's or a group's perceived physical and mental health over time.
45787140|NCT04708548|Other|Psychological Distress|Measured of the distress experienced by patients
45787141|NCT04708548|Other|Fatigue|Measure of the extreme tiredness resulting from mental or physical exertion or illness
45787142|NCT04708548|Other|Cognitive Functioning|Cognitive functioning refers to multiple mental abilities, including learning, thinking, reasoning, remembering, problem solving, decision making, and attention. This will be measured through self-report and cognitive testing.
45919436|NCT01464970|Procedure|SIE Artery Unclamped, Vein Clamped|Perfusion assessed in Zone IV of the DIEP flap whilst the contralateral Superficial Inferior Epigastric Artery is unclamped and the Vein is clamped
45645342|NCT03082625|Drug|Placebo|
45645343|NCT02336581|Behavioral|Acceptance and Commitment Therapy (ACT)|individual + group + follow-up phone contacts
45645344|NCT02336581|Behavioral|Enhanced Treatment as Usual (eTAU)|individual + group + follow-up phone contacts
45645345|NCT03081923|Drug|Durvalumab|anti-PD-L1 mono therapy
45645346|NCT03081923|Drug|Tremelimumab|anti-CTLA4 drug Tremelimumab mono therapy
45645347|NCT02345395|Procedure|Aneurysm Clipping|All Patients will be submitted to a surgical intervention in order to clip their unruptured brain aneurysm
45645348|NCT03081845|Dietary Supplement|Oral consumption of milk A1 in study phase 1|Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 1.
45645349|NCT03081845|Dietary Supplement|Oral consumption of milk A2 in study phase 1|Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 1.
45645350|NCT03081845|Dietary Supplement|Oral consumption of milk A1 in study phase 2|Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
45645351|NCT03081845|Dietary Supplement|Oral consumption of milk A2 in study phase 2|Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
45645352|NCT02341105|Procedure|Catheter ablation|Pulmonary vein isolation by catheter ablation
45645353|NCT02341105|Drug|Amiodarone|antiarrhythmic therapy using Amiodarone
45645354|NCT03078101|Drug|Empagliflozin 10 MG [Jardiance]|administered orally once daily
45645355|NCT03078101|Drug|Placebo Oral Tablet|administered orally once daily
45645356|NCT03082079|Procedure|ESD|Patient in ESD group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate
45787143|NCT04702035|Device|Characterization of walking pattern characteristics in an ambulatory setting using wearable IMUs (ZurichMOVE sensors)|All participants receive a set of 5 wearable IMUs for a period of 3 days. The IMUs are fixed at both wrists, ankles and one over the sternum. A 10-meter walking test, 180 degree turnaround test and normal walking at home are performed. Afterwards, the IMUs are removed for data extraction and evaluation. The patient group is examined a second time after CSF diversion surgery.
45787144|NCT04696133|Other|fine motor skills|stretching and strengthening exercises in addition to exercises to enhance fine motor skills
45787145|NCT04696133|Other|sensory integration|"Tactile stimulation~Proprioceptive stimulation~Heavy work activities (i.e., proprioceptive input)"
45787146|NCT04684524|Drug|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
45787147|NCT04684524|Drug|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
45787148|NCT04682652|Device|Embozene MicroSpheres|Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery in the knee going to the region of pain. One of the causes of pain in the setting of knee arthritis is increased blood flow going to the specific area of pain. The goal of this procedure is to decrease the blood flow (embolize) to the specific region of the knee that is causing your pain. This is done by infusing Embozene particles into the specific blood vessel (genicular artery) supplying the area of pain in the knee.
45787149|NCT04676711|Drug|GFH312|Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses
45787150|NCT04676711|Drug|Placebo|Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses
45787151|NCT04676646|Drug|Sodium zirconium cyclosilicate|Investigational medicinal product
45919437|NCT01464970|Procedure|SIE Artery clamped, Vein unclamped|Perfusion assessed in Zone IV of the DIEP flap whilst the contralateral Superficial Inferior Epigastric Artery is clamped and the Vein is unclamped
45645357|NCT02345239|Drug|Pantoprazole|proton pump inhibitor
45645358|NCT02340871|Genetic|Genetic testing|Patients suspected of harboring a genetic neurological disease will be summoned to take a blood test. DNA will be extracted from the blood and sent to the collaborating hospital labs for next generation sequencing.
45645359|NCT03081767|Diagnostic Test|Digital PET/CT scan|The Division of Nuclear Medicine and Molecular Imaging at Stanford has installed the first ever GE-made digital PET/CT scanner worldwide. The investigators wish to determine if the digital PET/CT scanner offers equivalent image quality as the standard PET/CT scanner.
45645360|NCT02340793|Dietary Supplement|Counterweight Plus|A non-surgical, nutritionally replete weight management programme comprising a Total Diet Replacement Plan (TDR) of 800+ calories/day to produce a weight loss of >15kg over 12-20 weeks; followed by a structured Food Reintroduction phase for 6-8 weeks and a Weight Loss Maintenance phase; total intervention period 2 years.
45787152|NCT04676646|Drug|Placebo|Placebo comparator
45787153|NCT04676646|Other|Spironolactone|"Background intervention.~During the run-in phase, spironolactone will be initiated/uptitrated up to a maximum of 50 mg per day. During the randomized withdrawal phase the spironolactone dose at the end of the run-in phase will be maintained."
45787154|NCT04675216|Procedure|Posterior fossa intracranial pressure measurement|Measurement of posterior fossa pressure in an invasive way
45787155|NCT04671732|Procedure|Fenestrated endovascular aortic aneurysm repair|Fenestrated endovascular aortic aneurysm repair consists in excluding a juxtrenal or suprarenal aneurysm by deploying a covered stent (stent graft) in the aorta so as to created sealing zones on both sides of the aneurysm. Since the proximal sealing is located in the visceral segment of the aorta, fenestrations are created to maintain blod flow in renal and visceral arteries. These fenestrations are custom made for each patient. Brindging covered stents are deployed between each fenestration and corresponding target arteries in order to insure sealing of the system.
45787156|NCT04671732|Procedure|open repair of abdominal aortic aneurysm.|Open repair of abdominal aortic aneurysms consists in cross-clamping the aorta on both sides of the aneurysm and replace the diseased segment by a prosthetic graft.
45787157|NCT04667221|Device|Active transcranial direct current stimulation|A high-definition tDCS set-up will be used with a battery-driven stimulator (Starstim 8, Neuroelectrics). Active stimulation will be conducted with 1.5 milliampere (mA) with two electrodes using three reference electrodes for each active one for 20 minutes.
45919438|NCT04169477|Device|CEFAR Primo Pro (TENS device)|"During the first month: Patients will have to test 3 sessions of TENS 1 hour/day. Depending on their arm assigned by randomization, patients will begin with c-TENS or m-TENS.~[Cross-over] During the second month: Patients will test the other type they do not have used yet according to the following scheme: 3 sessions of 1 hour, each day.~In this way, all patients will test successively the 2 different modes. After the end of the second month and up to the end of their participation (6 months after randomization) patients will be free to use the mode of TENS they prefer."
45919439|NCT01464892|Behavioral|Imagery Rescripting and Reprocessing Therapy|This intervention is comprised of 16 sessions (twice a week) of trauma-focused imagery rescripting
45919440|NCT01464892|Behavioral|STAIR + Imagery Rescripting|A two-phased treatment. Phase 1 is comprised of 8 (weekly) sessions of Skills Training in Affective and Interpersonal Skills (STAIR). Phase 2 consists of 16 sessions (twice weekly) of trauma-focused imagery rescripting.
45645361|NCT03081065|Dietary Supplement|Mediterranean Diet|Nutritional advice to follow a Mediterranean diet and supplementation with extra virgin olive oil and nuts
45645362|NCT04688203|Drug|Magnesium Sulfate Injection|will receive IV bolus dose of 40mg/kg magnesium sulfate in 100 ml saline solution over ten minutes then continuous infusion of 10-15mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
45787158|NCT04667221|Device|Sham transcranial direct current stimulation|A high-definition tDCS set-up will be used with a battery-driven stimulator (Starstim 8, Neuroelectrics). Sham stimulation will have a 40 seconds ramp-up and down. No stimulation will be applied after this 40 seconds.
45787159|NCT04665947|Drug|[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.|PET imaging using [68Ga]Ga DOTA-5G will be used to diagnose patients who are eligible for treatment with the [177Lu]Lu DOTA-ABM-5G.
45787160|NCT04660175|Other|non-resistance therapy|The non-resistance technique, created in Jaseng Hospital, is a combination of ischemic compression and mobilization It is a treatment that improves the limited range of motion of the cervical spine and relieves pain by applying ischemic pressure to the induration of the neck and at the same time firmly supporting the patient's head to give passive joint movements and completely relax.
45787161|NCT04660175|Other|acupuncture|According to the judgment of the oriental medicine doctor, select acupuncture point and tender spots such as BL10, TE14, GB20, GV16, etc. to a depth of 10 mm 6 -Self needle in 12 blood spots.
45787162|NCT04660175|Other|chuna|Chuna treatment is administered once a day during the hospitalization period. Chuna is Korean manual therapy using methods such as joint mobilization, joint distraction, fascia relaxation and manipulation.
45787163|NCT04660175|Other|pharmacoacupuncture|This is an oriental medical practice in which a certain amount of a drug extracted from a specific herbal medicine is injected with an injector to treat the patient's constitution, disease state, etc., and then injected into the treatment acupuncture points and body surface reaction points. Depending on the condition of the inpatient, acupuncture is used in parallel.
45787164|NCT04660175|Drug|Korean herbal medicine|Formulated with herbal medicinal and pack the extract in a pouch, and have the hospitalized patient take it once in the morning and afternoon for 30 minutes after meals.
45787165|NCT04658849|Drug|Pioglitazone 30 Mg Oral Tablet|"Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily."
45787166|NCT04658849|Drug|Pioglitazone placebo tablet|Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
45787167|NCT04656795|Drug|MT-7117|MT-7117
45787168|NCT04630652|Drug|Risankizumab-Rzaa|Risankizumab at a dose of 150 mg with injections administered at baseline, week 4 and week 16 following FDA-approved dosage and time periods
45645363|NCT04688203|Drug|Labetalol Injectable Solution|will receive IV bolus does of labetalol 0.25 mg/kg over ten minutes then continuous infusion of 0.5-1mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
45787169|NCT04630652|Procedure|Punch biopsies of the skin at baseline visit|Two 6 mm punch biopsies of the skin at baseline visit
45787170|NCT04630652|Procedure|Punch biopsies of the skin at week 28 visit|One 6 mm punch biopsy of the skin at week 28 visit
45787171|NCT04616313|Diagnostic Test|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
45787172|NCT04616313|Diagnostic Test|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
45787173|NCT04616313|Diagnostic Test|Pulmonary Function Tests (PFT)|Participants will have their lung function evaluated using PFT
45787174|NCT04616313|Diagnostic Test|Cardiopulmonary exercise testing (CPET)|Participants will perform cardiopulmonary exercise testing as a measure of exercise capacity
45787175|NCT04616313|Diagnostic Test|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
45645364|NCT03145753|Other|HIV/HCV Education plus Testing|Education included a half day educational program and the provision of supporting materials to enhance HIV testing, such as a clinical decision algorithm to perform HIV test and clinical remainders to help meet with the current Spanish Early Diagnosis HIV Testing Recommendations. Half day educational program, to promote early diagnosis of HIV, HCV, in a Primary Care Health Area.To Improve knowledge and current trends in the prevention, diagnosis and management of HIV infection among non health professionals specialists in infectious diseases.DRIVE 03 program will offer rapid HIV tests, and testing staff to conduct all study procedures.The study activities will be carried out by the trained testing staff.
45645365|NCT03145753|Other|HIV/HCV Education|Only education and support will be provided in this arm
45787176|NCT04616313|Diagnostic Test|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
45787177|NCT04616313|Other|Questionnaires|Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.
45787178|NCT04604834|Other|PFAT first|Week 1 to week 4: one eyedrop of PFAT (preservative-free artificial tears) every 2 hours. Week 5 to week 8: one eyedrop of APRP (autologous plasma rich platelet) every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.
45787179|NCT04604834|Other|APRP first|Week 1 to week 4: one eyedrop of APRP every 2 hours. Week 5 to week 8: one eyedrop of PFAT every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.
45787180|NCT04601974|Genetic|lentiviral gene therapy|lentiviral gene therapy to treat drug resistant epilepsy
45787181|NCT04577404|Drug|MT-1186|Treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period up to 96 weeks of treatment or until the drug is commercially available in that country.
45787182|NCT04569084|Drug|MT-1186|Oral edaravone
45787183|NCT04569084|Drug|Placebo|Oral
45787184|NCT04566887|Drug|Acalabrutinib|Administered as 100mg tablets.
45787185|NCT04566887|Drug|R-CHOP chemotherapy|R-CHOP chemotherapy
45645366|NCT04679233|Other|Prescription aerobic exercise|high intensity interval training, 5 weeks, 2 sessions/week - supervised by a clinician.
45645367|NCT03145597|Device|Laminate veneer of composite|Composite laminate veneers, 2-4-6 veneers per patient
45645368|NCT03145597|Device|Laminate veneer of ceramic|laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
45645369|NCT02336035|Procedure|Volar plate|Flexor carpi radialis (FCR)-approach. Standard surgical procedure with a volar locking plate
45787186|NCT04565054|Drug|Abemaciclib 50 MG; 150mg 1-0-1 per os|Experimental: Abemaciclib plus ET Abemaciclib 150 mg, 2 x daily, resulting in 300 mg/day, oral, 24 months plus endocrine treatment of physician´s choice
45645370|NCT05254951|Diagnostic Test|Tidal Volume Challenge|Tidal Volume Challenge to predict fluid responsiveness with stroke volume variation and pulse pressure variation
45645371|NCT05254561|Biological|Intralesional antigen immunotherapy|Randomized double-blinded comparative effectiveness and safety clinical trial
45787187|NCT04564742|Drug|Dapagliflozin|Dapagliflozin 10 mg tablets given once daily, per oral use
45787188|NCT04564742|Drug|Placebo|Placebo matching dapagliflozin 10 mg tablets given once daily, per oral use
45919441|NCT01464853|Other|Enteral nutrition with fatty acids|Enteral Feeding to provide 25 kcal/Kg/day
45919442|NCT01464853|Other|Standard Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
45919443|NCT01465711|Procedure|All abdominal surgical procedures|Laparotomy, Laparoscopy
45787189|NCT04560036|Diagnostic Test|FAZA PET/MRI scan|FAZA PET/MRI scan before and after the standard of care chemotherapy
45787190|NCT04552899|Drug|PRM-151 (Zinpentraxin Alfa)|A 10 mg/kg IV infusion of PRM-151 based on the participants weight will be administered on Days 1, 3 and 5 followed by infusions Q4W to Week 48.
45919444|NCT01465711|Procedure|Intubation|Ventilatory support
45919445|NCT01465711|Radiation|Imaging|Abdominal ultrasound Computer Tomography Magnetic Resonance Imaging
45919446|NCT03226548|Other|Paycheck Plus|A four-fold increase in the Earned Income Tax Credit
45919447|NCT01464814|Dietary Supplement|probiotic plus fish oil capsule|Lactobacillus casei (4B CFU) plus fish oil capsule, T.I.D., for seven (7) days.
45919448|NCT01464814|Dietary Supplement|Fish oil capsule|Fish oil capsule, T.I.D., for seven (7) days
45919449|NCT04140734|Device|Spacer Graft|In this prospective, randomized clinical trial, patients who will already be undergoing lower eyelid retraction repair with a spacer graft will randomly be assigned via a randomization web-site to receive 1 of 3 spacer grafts: hard palate, autologous auricular cartilage, and porcine acellular dermal matrix (Enduragen). Both the patient and the surgeon will know which of the three possible grafts are being used.
45919450|NCT01464775|Other|Narrow Band Imaging (NBI)|Women will be randomized to white light/NBI versus white light/white light laparoscopic surgery
45919451|NCT01464775|Other|Standard White Light Laparoscopy|Women will be randomized to white light/NBI versus white light/white light laparoscopic surgery
45919452|NCT01464736|Other|physical training|For both groups, the approximately hour-long sessions occurred three times a week on alternate days for six consecutive weeks (18 sessions). Each session began with five minutes of stretching that included the cervical muscles and the upper and lower limbs, which was followed by five minutes of warm-up on a treadmill at 2Km/h and 30 minutes of aerobic physical training at a constant 3% incline.
45919453|NCT04120610|Diagnostic Test|FlowMet-R|FlowMet-R is a noninvasive blood flow measurement.
45919454|NCT04120610|Diagnostic Test|ABI|Ankle Brachial Index is a ratio-metric blood pressure measurement in the ankle and arm.
45919455|NCT04120610|Diagnostic Test|TBI|Ankle Brachial Index is a ratio-metric blood pressure measurement in the toe and arm.
45919456|NCT01464697|Drug|Oral micronized progesterone|300 mg as 3-100 mg capsules taken orally at bedtime daily for 12 weeks
45919457|NCT01464697|Drug|placebo|placebo comparator, taken as 3 round capsules at bedtime daily for 12 weeks
45919458|NCT04109846|Other|Non-euploid embryo transfer|Other than choice of embryo for transfer, all other medical interventions will be at discretion of treating provider
45787191|NCT04552899|Drug|Placebo|Placebo matching PRM-151 will be administered by IV infusion on Days 1, 3 and 5, followed by infusions Q4W to Week 48.
45787192|NCT04500587|Drug|ZN-d5|Oral agent; 25 mg or 100 mg formulation
45919459|NCT04109846|Other|Euploid Transfer|Standard of Care Protocol
45919460|NCT01464658|Procedure|panniculectomy|surgery
45919461|NCT01464541|Procedure|operative fracture size vs CT fracture size|comparing actual intraoperative fracture size to the CT fracture size
45645372|NCT04536025|Other|Qualitative focus group interviews|Prosthetists and/or expert working group members will participate in qualitative focus group interviews up to 120 minutes in length.
45645373|NCT04536025|Other|Qualitative semi-structured interviews|People with lower limb amputation and/or expert working group members will participate in qualitative individual, semi-structured interviews approximately 60 minutes in length.
45645374|NCT04509973|Drug|Dexamethasone|ATC code: H02AB02
45645375|NCT02637557|Drug|IW-3718|
45645376|NCT02637557|Drug|Matching Placebo|
45645377|NCT02637557|Drug|PPI|All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium sesquihydrate, rabeprazole or rabeprazole sodium) during the study.
45645378|NCT04496167|Drug|EN3835|Collagenase clostridium histolyticum or placebo comparator
45645379|NCT04491253|Behavioral|Social support for diabetes self-management|Four individualized intervention sessions, every two weeks with a duration of 40 minutes.
45645380|NCT04480645|Device|CivaDerm|radioactive bandage
45645381|NCT05254249|Drug|Lactobacillus Plantarum IS-10506|Indonesian original probiotic, given in capsule form with a dose of 2 x 1010 CFU
45645382|NCT05254249|Other|Placebo|Placebo is an empty drug, given in capsule form with a dose of 2x1 sachets
45645383|NCT03145909|Drug|ABBV-176|Intravenous infusion
45787193|NCT04479358|Drug|Tocilizumab|Tocilizumab 40mg
45787194|NCT04479358|Drug|Tocilizumab|Tocilizumab 120mg
45919462|NCT01464541|Procedure|orbital fracture intraoperative measurement|comparing intraoperative fracture size to the CT orbital fracture size
45919463|NCT01464502|Procedure|Standard CRT Implant|
45919464|NCT01464502|Procedure|Pressure-wire guided CRT implant|A pressure wire will be sited in the left ventricle to measure dP/dT max. The LV lead position that gives the highest dP/dT max will be the final position used.
45919465|NCT04083950|Biological|Vivotif Typhoid Oral Vaccine|One capsule is swallowed on alternate days, e.g. days 15, 17, 19, and 21, for a total of 4 capsules.
45919466|NCT04083950|Drug|Aspirin (Positive Control)|Three tablets (325 mg aspirin in each tablet or 975 mg total) are swallowed on days 2 and 3.
45919467|NCT00393679|Drug|amodiaquine-artesunate (ASAQ)|A fix-dose combination tablet containing artesunate-amodiaquine in three different dosages, to be used according to patient age and weight: 25mg/67.5mg; 50mg/135mg; 100mg/270mg
45919468|NCT00393679|Drug|dihydroartemisinin-piperaquine (DHAPQ)|DHAPQ tablets contain either 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively.
45919469|NCT00393679|Drug|artemether-lumefantrine (AL)|Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine.
45645384|NCT02344927|Other|Non-Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care
45645385|NCT02344927|Other|Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care, and clinically assisted hydration.
45645386|NCT02344849|Drug|mesenchymal stem cell|Patients will receive single injection of Cellgram-ED( 30,000,000 mesenchymal stem cell) intracavernously.
45645387|NCT02336113|Behavioral|multidisciplinary treatment|The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug information (written and oral) to the patient before discharge, as well as written drug information to the next level of care
45787195|NCT04479358|Other|Standard of Care|Tocilizumab-Free Standard of Care
45645388|NCT03145363|Behavioral|Intervention|The intervention group will receive 2-5 interactive text message sequences per week. These messages will invite students to reply using keywords and short free text replies. Messages come from a library of strength-based peer quotations (reviewed for safety), psychoeducational interactions, and games designed to promote emotional skills and use of resources.
45645389|NCT03145363|Behavioral|Control|"The control group will receive 1-2 (non-interactive) text messages per week containing general SoS concepts (e.g., Remember: more strengths are better when times get tough)."
45787196|NCT04479358|Other|Standard of Care|Tocilizumab 400mg or 8mg/kg
45787197|NCT04472728|Drug|BIO101|BIO101 capsules
45787198|NCT04472728|Drug|Placebo|placebo capsules
45787199|NCT04458883|Procedure|Cardiac Magnetic Resonance Imaging|Cardiac Magnetic Resonance Imaging - Cardiac Scan
45787200|NCT04458883|Procedure|Fast Field Cycling - Magnetic Resonance Imaging|Fast Field Cycling - Magnetic Resonance Imaging Cardiac Scan
45787201|NCT04458883|Procedure|Electrocardiogram|Electrocardiogram
45787202|NCT04458883|Procedure|Echocardiogram|Echocardiogram
45787203|NCT04458649|Device|Dexcom continuous glucose monitor|Measurement of interstitial glucose
45787204|NCT04453774|Device|Covidfree@home|Mobile phone, Covidfree@home app, thermometer, pulse oximeter, smart watch
45645390|NCT02336191|Procedure|living donor liver transplantation|living donor liver transplantation
45645391|NCT02336347|Drug|AVP-786|
45645392|NCT02336347|Drug|AVP-923|
45787205|NCT04452747|Procedure|Vaginal Dinoprostone system (Propess®)|Labour will be induced using the vaginal Dinoprostone system (Propess®) as a first strategy
45787206|NCT04452747|Procedure|Dilatation balloon|Labour will be induced using a cervix dilatation balloon as a first strategy
45787207|NCT04446845|Drug|Double Stimulation (Elonva+rFSH) in luteal /follicular phase|Following the 2nd oocyte retrieval, the patient will start luteal phase support (LPS) with vaginal micronized progesterone 200mg x 3 times a day until the day of the pregnancy test. All embryos will be cultured until day 5 in time-lapse incubators. In case of no blastocyst in the second cycle, or in case of poor embryo quality and in case of availability of frozen embryos from the first stimulation cycle, 1 frozen blastocyst from the first cycle will be thawed and will be transferred 5 days following the 2nd oocyte retrieval. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of ovarian hyperstimulation syndrome (OHSS) or progesterone elevation which is considered clinically relevant on the day of human chorionic gonadotropin (hCG) trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
45787208|NCT04446845|Drug|Conventional Stimulation (Elonva+rFSH) in follicular phase|From the day of oocyte retrieval, the patients will be asked to start the LPS with vaginal micronized progesterone 3 times a day until the day of the pregnancy test. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of OHSS or progesterone elevation which is considered clinically relevant on the day of hCG trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
45787209|NCT04421339|Dietary Supplement|Melatonin|Participants will receive melatonin 5 mg once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.
45919470|NCT00393679|Drug|Lapdap (Chlorproguanil-Dapsone) + artesunate (AS)|"Lapdap tablets contain 15/18.75mg or 80/100mg of Chlorproguanil Hydrochloride and Dapsone, respectively. Arsumax® tablets contain 50mg Artesunate.~TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008."
45919471|NCT00393835|Drug|Azithromycin SR|
45919472|NCT04712032|Drug|ICG-guided bowel perfusion assessment|ICG will be injected prior to anastomosis creation, to assess perfusion status of the bowel.
45919473|NCT05352867|Biological|SARS-CoV-2 (LVRNA009) 50μg group|50μg/person
45919474|NCT05352867|Biological|SARS-CoV-2 (LVRNA009) 100μg group|100μg/person
45919475|NCT05352867|Other|Placebo|0.5ml/person
45645393|NCT02341027|Device|Jadelle|within 5 days of delivery and before discharge from hospital
45645394|NCT02341027|Device|Jadelle|6-8 weeks (42-56 days) postpartum
45645395|NCT03112291|Procedure|Apexification|Apexification forms a calcified barrier in teeth with open apexes and pulp necrosis. It is used to treat immature teeth, but it does not promote the continuity of root formation.
45645396|NCT02340637|Behavioral|Coping Kids|The first half (10 sessions) of Coping Kids focuses on building skills that are common to both anxiety and depression. The children practice strategies to regulate their mood, learn problem-solving, and behavioral activation is used to break the cycle of withdrawal. The second half of Coping Kids (10 sessions) is focused on the youth's specific problem; for depressive symptoms, building a positive self-schema and behavioral activation; for anxiety problems, gradual exposure to fear-inducing situations. Cognitive restructuring directed at different maladaptive thoughts is also emphasized.
46071189|NCT00903032|Behavioral|Intervention|The multi-faceted patient centered intervention will adapt elements of prior successfully adherence interventions and include the following core components: collaborative care (between pharmacists, primary care providers, and cardiologists), patient education (tailored to patient needs and provided on a regular ongoing basis), tailoring of medication regimens (i.e., simplification of dosing, use of pill boxes, synchronization of refill dates), and tele-monitoring via IVR technology as well as patient-specific aides based on identified needs.
45645397|NCT02340637|Behavioral|TAU|Treatment as usual
45645398|NCT02335879|Biological|Gonal-F|
45645399|NCT05005325|Other|Experimental group(Male)|Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam
45645400|NCT05005325|Other|Experimental group(Female)|Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam
45787210|NCT04421339|Other|Placebo|Participants will receive placebo once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.
45787211|NCT04418661|Drug|SAR442720|Pharmaceutical form: Varies Route of administration: Varies
45787212|NCT04418661|Drug|Pembrolizumab|Pharmaceutical form:Sterile Lyophilized powder for reconstitution Route of administration: Infusion
45787213|NCT04418661|Drug|Adagrasib|Pharmaceutical form:Sterile Tablet Route of administration: Oral
45787214|NCT04418076|Device|Group A_No feedback|In the control (Group A), the feedback option will be deactivated on the device on the TowerView Health® smart pill box, effectively serving to only monitor natural pill-taking patterns.
45787215|NCT04418076|Device|Group B_Automated feedback|For participants in Group B (automated feedback), missed dosages will prompt an automated text message to be sent to the participants' smartphone. The TowerView Health® pill box consists of in-built alarm and flashing color lights, and the ability to send text messages to the participants' phone either as reminder in the event of missed dosage or a message of encouragement when all dosages are taken.
45787216|NCT04418076|Device|Group C_Automated feedback + Clinician feedback|For participants in Group C, the survey app responses will be assessed each week by the RA who in turn will communicate the results to a clinical nurse. The clinical nurse will be funded through this study; he/she will be responsible for providing personalized feedback to all Group C participants. The clinic nurse will contact the subject with appropriate feedback about their health behavior and suggestions for sustained adherence.
45645401|NCT02344537|Behavioral|Kundalini Yoga|Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
45645402|NCT03077945|Behavioral|heart rate variability biofeedback and cognitive reappraisal|
45645403|NCT03077945|Behavioral|control tasks|
45645404|NCT02039479|Drug|Lithium Carbonate|Lithium as Add on to every necessary treatment as usual
45787217|NCT04418076|Device|Group D_Automated feedback + Social Network feedback|For participants in Group D, a social network designee will be chosen based on the names provided by the participants during screening. One social network designee will be consented and chosen to send the participant a weekly text reminder the participant to take their medication. The text for the message will be chosen by the social network designee.
45787218|NCT04401020|Drug|SAR442257|Pharmaceutical form: Sterile powder for reconstitution Route of administration: Intravenous infusion
45787219|NCT04391049|Drug|Carboplatin|Given IV
45787220|NCT04391049|Drug|Paclitaxel|Given IV
45787221|NCT04391049|Radiation|Radiation Therapy|Undergo radiation therapy
45787222|NCT04391049|Biological|Telomerase-specific Type 5 Adenovirus OBP-301|Given by intratumoral injection
45787223|NCT04381208|Diagnostic Test|Complete clinical examination|Medical history-taking, physical examination with provocative maneuvers, radiographic imaging (if relevant), and sacroiliac joint block (if indicated), facet joint block (if indicated)
45787224|NCT04342572|Drug|Melphalan|-The drug is commerically available
45645405|NCT02039479|Drug|Placebo|Placebo as ADD-on to every necessary treatment as usual
45645406|NCT05013281|Procedure|Suprachoroidal hemorrhage associated with pars plana vitrectomy|SCH has a higher incidence rate after a second intraocular surgery in a vitrectomized eye which is associated with the lack of vitreous support and easier fluctuation of intraocular pressure. SCH associated with PPV is more localized and has a relatively good prognosis; high myopia and aphakic/ pseudophakic eyes are risk factors. Active treatment can effectively improve visual prognosis.
45787225|NCT04335656|Dietary Supplement|Lactiplantibacillus plantarum|Probiotic capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages
45787226|NCT04335656|Other|Placebo|Placebo capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages
45787227|NCT04327544|Behavioral|Frailty Intervention|In overall, participants will attend one session of frailty talk, 22 sessions of low to moderate intensity of multi-components exercise course and 6 session of nutrition education interventions. Both nutritional education and exercise intervention will be conducted concurrently for a 12-week (3-month) of intervention period. Noted that every session will be held in PPR flats' facility area or hall around 60 minutes that will be conducted by the dietitian or nutritionist and physiotherapist from the research team.
46071190|NCT00903032|Behavioral|Usual care|Usual care following ACS hospital discharge.
46071191|NCT02113592|Behavioral|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
45787228|NCT04307849|Behavioral|Adolescent Health Club|Sexual health/HIV-related evidence-based interventions
45787229|NCT04307849|Other|Wait-list Control|The wait-listed group will begin the intervention after the intervention group
45787230|NCT04295759|Drug|INCB7839|INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).
45787231|NCT04294160|Drug|Dabrafenib|Capsule for oral use
45787232|NCT04294160|Drug|LTT462|Capsule for oral use
45787233|NCT04294160|Drug|Trametinib|Tablet for oral use
45787234|NCT04294160|Drug|LXH254|Tablet for oral use
45787235|NCT04294160|Drug|TNO155|Capsule for oral use
45787236|NCT04294160|Biological|Spartalizumab|Liquid in vial (Concentrate for solution for infusion) for intravenous use
45787237|NCT04294160|Biological|Tislelizumab|Liquid in vial (Concentrate for solution for infusion) for intravenous use
45787238|NCT04287621|Drug|DUPIXENT®|There is no investigational product provided by the study sponsor and no therapeutic intervention regulated by this protocol. As a condition for eligibility, patients are required to initiate DUPIXENT® for asthma, according to the country-specific prescribing information, prescribed by their physician as part of their normal care (ie, not for the purpose of enrolling in the registry). Once patients enter the study, there are no protocol requirements regarding DUPIXENT® or any other treatments.
45787239|NCT04285892|Device|CAPA-IVM|"CAPA medium keeps oocytes in meiotic arrest for 22-24 hours. IVM medium allows oocytes to resume meiosis.~CAPA medium: 10% human serum albumin (HSA) + 10nM estradiol (E2) + 25nM CNP + 5ng/ml Insulin + 1mIU/ml follicle stimulating hormone (FSH) IVM medium: 10% HSA + 10nM E2 + 5ng/ml Insulin + 101mIU/ml FSH + 100ng/ml AREG CNP: peptide naturally occurring in follicles to maintain meiotic arrest, E2: estrogen, enhances effects of CNP, Insulin: basic growth factor used in cell cultures and component of commercially available LAG medium of the standard IVM system, AREG: downstream effector of the LHCG receptor which helps meiotic resumption. HSA, FSH and hCG are CE labeled. CAPA IVM medium is currently not yet available as CE marked commercially available medium and needs to be prepared in house."
45787240|NCT04267055|Device|Valiant Navion Thoracic Stent Graft System|Placement of the Valiant Navion for endovascular repair of a dissection in the thoracic aorta.
45787241|NCT04252677|Behavioral|Obesity Prevention|This intervention includes content specific to obesity behaviors-related health information, motivation, and behavioral skills.
45787242|NCT04252677|Behavioral|Health Literacy|This intervention includes content specific to improving health literacy.
45787243|NCT04250051|Drug|Cytarabine|Given IV
45787244|NCT04250051|Biological|Filgrastim|Given SC
45787245|NCT04250051|Drug|Fludarabine|Given IV
45919476|NCT01373515|Biological|DCP-001|4 bi-weekly vaccinations
45645407|NCT05013125|Diagnostic Test|ENDO-AID CADe assisted Colonoscopy|ENDO-AID is a dedicated endoscopy Computer-Aided Diagnosis (CADe) system where suspicious lesions are automatically detected and highlighted on the main monitor in real-time, alerting the endoscopist during the procedure.
45645408|NCT02340481|Drug|Loperamide hydrochloride + simethicone chewable tablet|Each tablet contains 2 milligram (mg) of loperamide hydrochloride and 125 mg of simethicone.
45645409|NCT02340481|Drug|Loperamide hydrochloride|Each capsule contains 2 mg of loperamide hydrochloride
45645410|NCT02340481|Drug|Loperamide hydrochloride + simethicone chewable placebo tablet|Placebo matched to loperamide hydrochloride and simethicone chewable tablet.
45645411|NCT02340481|Drug|Loperamide hydrochloride placebo capsule|Placebo matched to loperamide hydrochloride capsule.
45645412|NCT05012579|Device|Cala Device|transcutaneous afferent patterned stimulation (TAPS)
45645413|NCT03077867|Procedure|sinus floor augmentation with bone graft|sinus floor augmentation with lateral approach with bone graft
45787246|NCT04250051|Drug|Fludarabine Phosphate|Given IV
45787247|NCT04250051|Drug|Ivosidenib|Given PO
45787248|NCT04249245|Other|Nasal Swab|All
45787249|NCT04246879|Other|MRI|Subjects undergo one additional delayed MRI sequence
45787250|NCT04243915|Other|Percutaneous neuromuscular electrical stimulation (PNMES) plus motor control exercise program|The technique consists of a muscular stimulation of the deep lumbar multifidus by means of a TENS current applied through four dry needling or acupuncture needles introduced by ultrasound guidance in said muscle 30 minutes. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
45787251|NCT04243915|Other|Sham PNMES (introducing the needle) plus motor control exercise program|The same procedure will be performed as in the experimental treatment, but in this case, the electric current will be placebo and only the first 15 seconds will slightly notice it. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
45919477|NCT04078568|Drug|IVIG|IVIG at a single dose of 2 g/kg, with the maximum dose of 60g
45919478|NCT04078568|Drug|Aspirin|Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
45919479|NCT04078568|Drug|Prednisolone|Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses, with the maximum dose 60mg of prednisolone ) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days. If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued.
46071192|NCT00902564|Drug|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
45787252|NCT04243915|Other|TENS plus motor control exercise program|Transcutaneous electrical nerve stimulation will be applied through 4 patches / adhesives placed in your lower back for 30 minutes. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
45787253|NCT04243915|Other|Sham PNMES (without inserting the needle) plus motor control exercise program|The same procedure will be performed as in the experimental treatment, but in this case, the needle will not be inserted and the electric current will be placebo and only the first 15 seconds will slightly notice it. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
45787254|NCT04236271|Device|connected objects|a combination of connected devices for measuring physiological parameters and for clinical self-assessment by the patient, for early postoperative coronary bypass surgeries.
45787255|NCT04207060|Drug|Indomethacin|50 mg twice a day by mouth.
45787256|NCT04207060|Drug|Placebos|Lactose capsules not containing active study drug will be taken twice a day.
45787257|NCT04206124|Procedure|Brown Fat Harvest During Anterior Neck Surgery|During previously indicated thyroid gland removal or anterior cervical spine surgery, as scheduled at UNMHSC, the surgeon will identify the large muscle on the side of the neck in the surgical field. Using minimal dissection adjacent to the muscle, they will then remove 5-10mg of brown fat from this region. These samples will be further analyzed using various biochemical tools.
45787258|NCT04204980|Drug|Daratumumab dose escalation|- Step I: dose-escalation 3 patients treated weekly during four weeks with 4 mg/kg of daratumumab, then 3 patients treated weekly during four weeks with 8 mg/kg of daratumumab, then 3 patients treated weekly four weeks with 16 mg/kg of daratumumab
45787259|NCT04204980|Drug|Daratumumab full dose|- Step II: expansion cohort to 13 patients (with 10 new patients included and the last 3 patients from the step I) with eight weekly doses of 16 mg/kg daratumumab
45787260|NCT04165824|Drug|MT-1186|"An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug free period~Subsequent treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period. Treatment cycles are every 4 weeks."
45787261|NCT04158258|Drug|Bevacizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
45787262|NCT04158258|Drug|Trastuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
45787263|NCT04158258|Drug|Ado-trastuzumab emtamsine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
45787264|NCT04158258|Drug|Pertuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
45787265|NCT04158258|Drug|Atezolizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
45787266|NCT04158258|Drug|Capecitabine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
45787267|NCT04154865|Other|Hypercapnia|Eligible subjects will undergo transcranial Doppler assessment before and after hypercapnia exposure.
45787268|NCT04154865|Device|Transcranial Doppler|A transcranial Doppler ultrasound probe will be used to assess middle cerebral artery velocity to quantify cerebral blood flow at various time points throughout the study visit.
45787269|NCT04154865|Device|Cycle ergometer|A cycle ergometer will be used to acutely increase cerebral blood flow.
45787270|NCT04154865|Other|Cognitive Tests|A battery of cognitive tests will be completed by the subject.
45787271|NCT04116476|Drug|MT-7117|Single Dose of MT-7117
45787272|NCT04108039|Drug|GnRh antagonist|In the antagonist cycle, LH suppression will be accomplished by subcutaneous (SC) injections of 0.25 mg of Cetrorelix or Ganirelix starting in the presence of follicles >14mm or E2 levels >400 pg/ml and continuing until ovulation triggering to avoid LH surge in COS
45787273|NCT04108039|Drug|Micronized progesterone|Micronized progesterone protocol to avoid LH surge in COS, from stimulation day 1 and continuing until ovulation triggering.
45645414|NCT04426279|Other|questionnaire assesment|15-minute face-to-face questionnaire
45645415|NCT05012501|Diagnostic Test|test NETs markers|NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3), tissue factor, endotoxin, factor X, TAT complex, and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits.
45645416|NCT02344771|Procedure|Elective colon cancer surgery|
45645417|NCT03077633|Procedure|Cervical Cerclage placement|Cervical Cerclage placement
45645418|NCT03077633|Drug|Vaginal Progesterone|200mg tab of vaginal progesterone administered daily from time of randomization until delivery.
45645419|NCT05005169|Diagnostic Test|SGB PCR|"This is a multi-center, randomized cluster and crossover study, and is open-label. The cluster is defined by the hospital center. Each center will therefore experiment with both strategies and the hospital centers will be randomized according to two arms:~Arm n°1 : 1st period with SGB culture strategy and 2nd period with SGB PCR strategy.~Arm n°2 : 1st period with SGB PCR Strategy and 2nd period with SGB culture Strategy Each inclusion period will last 6 weeks, with a 1-month wash-in period before each of the two inclusion periods of the study (training of the teams in intrapartum PCR detection). A wash-out period is not necessary in this study because the PCR machine will be removed from the centers when switching to the GBS culture strategy.~During these two periods, all patients meeting the inclusion and non-inclusion criteria will be included in the study after presentation of the study and oral consent."
45787274|NCT04096950|Biological|MT-3921 Low dose|MT-3921 Low dose, intravenous, single dosing
45787275|NCT04086745|Drug|Baricitinib|Administered orally.
45787276|NCT04086745|Drug|TNF Inhibitor|Administered SC
45787277|NCT04069169|Drug|Lidocaine|Intervention group (A) will receive P-IVLT in addition to the standard multimodal analgesia. P-IVLT will consist of 1 mg/kg bolus at start of anesthesia (T0), followed by 2 mg·kg-1·hr-1 infusion for 8 hours (T1), then continued at 1 mg·kg-1·hr-1 infusion thereafter and postoperatively until T0 + 48 hours (T2).
45919480|NCT01057069|Drug|Carboplatin and Paclitaxel|Carboplatin AUC = 6, Q 3 weeks, 3 courses Paclitaxel 80 mg/m2, weekly, 9 administrations
45645420|NCT05005169|Diagnostic Test|SGB culture|"This is a multi-center, randomized cluster and crossover study, and is open-label. The cluster is defined by the hospital center. Each center will therefore experiment with both strategies and the hospital centers will be randomized according to two arms:~Arm n°1 : 1st period with SGB culture strategy and 2nd period with SGB PCR strategy.~Arm n°2 : 1st period with SGB PCR Strategy and 2nd period with SGB culture Strategy Each inclusion period will last 6 weeks, with a 1-month wash-in period before each of the two inclusion periods of the study (training of the teams in intrapartum PCR detection). A wash-out period is not necessary in this study because the PCR machine will be removed from the centers when switching to the GBS culture strategy.~During these two periods, all patients meeting the inclusion and non-inclusion criteria will be included in the study after presentation of the study and oral consent."
45645421|NCT05253781|Drug|Low-dose aspirin|Low dose aspirin (LDA) group will receive 100mg aspirin daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
45645422|NCT05253781|Other|Placebo|Placebo group will receive one tablet of the placebo which has same shape, size, thickness and colour as the LDA daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
45645423|NCT05012423|Drug|Placebo|"Matching Placebo~Placebo will be administered as oral capsules."
45645424|NCT05012423|Drug|ECC0509|"ECC0509 1 mg and 10 mg capsules~ECC0509 will be administered as oral capsules."
45787278|NCT04069169|Drug|Saline Solution|Control group (B) will receive a placebo (0.9% sodium chloride also known as normal saline), made to mimic the intervention protocol described above, in addition to the standard multimodal analgesia.
45787279|NCT04067336|Drug|Ziftomenib|Oral administration
45787280|NCT04065880|Other|TachoSil®|topical absorbable fibrin sealant patch applied directly on the lung area with air fistula.
45787281|NCT04065880|Other|Neoveil®|bioabsorbable soft-tissue reinforcement material applied on the normal shape of the lung at the end of the operation.
45787282|NCT04038229|Other|Enhanced recovery pathway|The applied protocol include psychological screening for yellow flags, preoperative gabapentin, peroperative multimodal preemptive management and postoperative holistic evaluation short -and long term
45787283|NCT04002674|Drug|Placebo oral capsule|"Thirty (30) patients in arm 1 will receive the matching placebo (sugar pill) one (1) capsule orally (without food) once daily for 6 months (180 days)."
45787284|NCT04002674|Drug|Nilotinib Oral Capsule|Thirty (30) patients in arm 2 will receive the 200 mg of Nilotinib one (1) capsule orally (without food) once daily for 6 months (180 days).
45645425|NCT05012423|Drug|Placebo|"Matching Placebo~Placebo will be given orally during each dosing day."
45645426|NCT05012423|Drug|ECC0509|"ECC0509 1 mg and 10 mg capsules~Placebo will be given orally during each dosing day."
45787285|NCT03997097|Drug|Sildenafil|Patients randomised in the group 1 will receive sildenafil in 3 oral doses of 20 mg per day
45787286|NCT03997097|Drug|Placebos|Patients randomised in the group placebo in 3 oral doses of per day
45645427|NCT03077477|Drug|AMXT 1501|Study treatment will be provided in tablet form; each containing 128 mg AMXT 1501 dicaprate salt, 80 mg of which is AMXT 1501 freebase (active drug), plus excipients and are orally administered.
45645428|NCT03077477|Drug|Placebo Oral Tablet|"Reference Therapy, Dose and Route of Administration:~Placebo Tablets, orally administered"
45787287|NCT03995849|Diagnostic Test|Cone Beam CT Scan|In this study, children will receive one CBCT scan before starting RT as part of standard approach. Then after RT, another CBCT scan will be used to measure movement between the beginning and end of RT.
45787288|NCT03991065|Diagnostic Test|high digestive endoscopy|high digestive endoscopy with biopsies performed according to the sydney protocol
45787289|NCT03988036|Drug|Pembrolizumab|Intravenous infusion; 200 mg; every 3 weeks
45787290|NCT03988036|Drug|Trastuzumab Biosimilar ABP 980|Intravenous infusion; 8 mg/kg loading dose, thereafter 6 mg/kg; every 3 weeks
45787291|NCT03988036|Drug|Pertuzumab|Intravenous infusion; 840 mg/kg loading dose, thereafter 420 mg/kg; every 3 weeks
45919481|NCT01057069|Drug|Doxorubicin, cyclophosphamide|Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.
46071193|NCT05055362|Other|Honey Spice Group|Consume baked good daily for 10 days and provide samples of saliva, urine and dietary habits and spice intake.
45787292|NCT03965897|Behavioral|Acceptance and Committment Therapy (ACT)|Overall, the goal of the ACT intervention is to cultivate psychological flexibility: to help Veterans respond to life events in ways which do not exacerbate difficulties or restrict engagement in meaningful activities. It increases patients' awareness of behaviors that exacerbate the pain (such as struggling with it) and recognition of avoidance strategies that interfere with life engagement.
45787293|NCT03965897|Other|Attention Control (AC)|Information on any other coping practices will be omitted. The group facilitators will present one topic at a time, using the Pain Manual, and the participants will discuss and reflect about issues and experiences related to each topic. If necessary, the group facilitators will raise specific discussion questions to facilitate group dialogue and participant involvement.
45787294|NCT03932214|Device|ACCUVEIN|The nurse uses the Accuvein® device to identify the veins before puncture and then proceeds as usual, under illumination of the device.
46071194|NCT00626197|Drug|Corticosteroids|Intravenous and oral repeating dose
46071195|NCT00626197|Drug|Cyclophosphamide|Cyclophosphamide was administered at a IV dose 500 mg every 2 weeks for up to 6 doses followed by maintenance treatment with azathioprine.
46071196|NCT00626197|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil was administered orally at maximum dose of 3 g/day.
46071197|NCT00626197|Drug|Ocrelizumab|Ocrelizumab was administed at a dose and as per schedule in arm description
46071198|NCT00626197|Drug|Placebo|Placebo was administered as per schedule in arm description
46071199|NCT00626197|Drug|Azathioprine|Azathioprine was administered at a dose up to 2 mg/kg/day with a maximum dose of 200 mg.
45787295|NCT03899987|Drug|Aspirin|Given PO
45787296|NCT03899987|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
45787297|NCT03899987|Biological|Recombinant Interferon Alfa-2b|Given IV
45787298|NCT03899987|Drug|Rintatolimod|Given IV
45787299|NCT03885739|Other|Continuous Pericapsular Nerve Group block|Continuous Pericapsular Nerve Group block to standardize the approach. Injections were performed using a curvilinear low-frequency ultrasound probe (3.5- to 5-MHz). The lateral border of iliopsoas tendon in an oblique axial plane at level of iliopectineal eminence provides target for needle placement. Toggling the transducer was necessary to optimize visualization of the iliopsoas tendon secondary to anisotropy. Injections were performed using an 18-gauge Tuohy needle under sterile conditions. Then, 10 mL 0.25% bupivacaine was administered and a 20-G polyamide catheter (connect to a filter) was advanced into the space. The end point of the catheter placement was the direct visualization of microbubbles in a peritendinous distribution using a bolus of agitated saline applied through threaded catheter connected to not purged filter. After catheter placement patients received a 0.1% bupivacaine continuous infusion at a constant rate.
45787300|NCT03876314|Behavioral|Physical Activity Condition|Subjects will attend virtual group exercise sessions 3x/week for 1 year. Each subject will be encouraged to walk at a moderate intensity (target heart rate (HR)= 40-59% HR reserve) dependent on resting HR and age. Subjects will perform aerobic exercise on their own and resistance exercises will be completed in virtual exercise sessions with an instructor 1 hour/day for 3 days/week for 1 year. At the exercise sessions, these participants will be asked to record measures of the exercises completed and may be asked to provide measures of heart rate (assessed by palpation for 20-seconds) and rate of perceived exertion (RPE). They will be asked to submit exercise logs providing this information. Data from exercise logs and exercise specialist records will be reviewed for evidence of progression, consistent attainment of moderate intensity, and with respect to the prescribed duration of the aerobic and strength training components.
45787301|NCT03857061|Device|smartphone, smartwatch, WearCOPDv2 application|"WearCOPD2 consists of hardware and software components.~6.1 Hardware The hardware for wearCOPDv2 consists of three main components; (1) a smartwatch, (2) a phone, and (3) a server.~6.2 Software~The wearCOPDv2 system has two main software components:~Data collection service~Participant user interface"
45787302|NCT03850028|Other|89Zr-atezolizumab PET scans|"The anti-PDL1 antibody atezolizumab, labeled with Zirconium-89 (89Zr) will be used as a molecular imaging tracer for PET scanning.~These 89Zr-atezolizumab PET scans will be performed before and after induction therapy (R-CHOP) and at suspected relapse during or after consolidation treatment with atezolizumab (treatment trial HOVON 151)."
45787303|NCT03840993|Drug|MT-2990|IV
45787304|NCT03840993|Drug|Placebo|IV
45787305|NCT03834961|Drug|Larotrectinib Sulfate|Given PO or via NG or G tube
45645429|NCT02344615|Procedure|NS-guided infraclavicular block|Patients received a standard single injection infraclavicular block using the lateral sagittal approach of Klaastad. The infraclavicular brachial plexus is identified using an insulated needle connected to a nerve stimulator. Placement of the needle is considered adequate if motor response of radial nerve in the hand or wrist is still present at 0.2 - 0.5mA. Ropivacaine 0.5% 35ml is used.
45645430|NCT02344615|Procedure|US-guided infraclavicular block|Infraclavicular block is performed under ultrasound guidance. Linear probe is placed in a parasagittal positon below the clavicle medial to the coracoid process and adjusted to achieve a cross-sectional image of the axillary artery. Using in-plane technique, an 22-gauge insulated needle is advanced caudally and posteriorly to the axillary artery. Subsequently, 35 ml of 0.5% ropivacaine is incrementally injected.
45787306|NCT03813407|Drug|Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level|Sodium Zirconium Cyclosilicate (SZC) Dose: Paediatric dose based on body weight equivalent to an adult 2.5 g
45787307|NCT03813407|Drug|Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1)|Sodium Zirconium Cyclosilicate (SZC)Paediatric dose based on body weight equivalent to an adult 5 g
45787308|NCT03813407|Drug|Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2)|Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 10 g
45787309|NCT03813407|Drug|Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3)|Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 15 g
45787310|NCT03813407|Drug|Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase|A 28-day period during which SZC is administered orally once daily (QD) to maintain normokalaemia. A dose titration regimen starting with QD administration of the dose of SZC the participants received TID in the CP will be studied in the MP and continued in the LTMP. The maximum dose that can be used is the calculated body weight equivalent to the 15 g adult dose
45787311|NCT03810365|Behavioral|Brief behavioral treatment for insomnia|Healthy eating control involves healthy eating content with 1 month 3 month 12 month follow-up visits.
45787312|NCT03809039|Drug|MT-6345|MT-6345
45787313|NCT03809039|Drug|MT-6345 Placebo|MT-6345 Placebo
45787314|NCT03801954|Behavioral|Educational Videos|15 videos that are about 3 minutes long each and cover nutritional advice for patients with bladder cancer undergoing RC and/or chemotherapy.
45787315|NCT03767530|Device|Mibo Thermoflo|Thermal therapy with Mibo Thermoflo for 11 minutes per eye, during each session.
45787316|NCT03767530|Other|Warm compresses and eyelid massage|Warm compresses plus eyelid massage 2 times per day 11 minutes per eye.
45787317|NCT03762447|Drug|INCB086550|INCB086550 will be orally administered once or twice daily in continuous or intermittent dose schedules.
45787318|NCT03759873|Behavioral|Incentives|Patient earns financial incentives (gift cards) on an escalating schedule for completing cardiac rehabilitation sessions.
45787319|NCT03759873|Behavioral|Case Management|A case manager is available by phone to assist patient with attending cardiac rehabilitation sessions as well as to provide advice about cardiac symptoms and healthy behavior change.
45645431|NCT03145519|Device|Vasofix Certo Catheter|Placement of IV-catheter
45645432|NCT03145519|Device|OptiVein Catheter|Placement of IV-catheter
45645433|NCT02340559|Behavioral|Meta-cognitive Training|
45645434|NCT02340559|Behavioral|Psychoeducational group|
45787320|NCT03744468|Drug|BGB-A425|Humanized IgG1-variant monoclonal antibody against TIM-3
45645435|NCT02340325|Drug|Acute Application of kynurenic acid cream|Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area. The pouch order will be random, generated by the www.random.org list generator each application. The study team member applying the cream will randomly choose the application sites of different concentrations of the FS2 creams and mark the corresponding cream code name on a separate sheet. This study member will not be evaluating the results and the evaluating study member will be blinded to the randomization. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
45645436|NCT02340325|Drug|Chronic application of kynurenic acid cream|Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30
45645437|NCT05229367|Other|Eccentric isokinetic training|Eccentric exercises of the hamstring muscles were performed with the use of an isokinetic dynamometer device.
45787321|NCT03744468|Drug|Tislelizumab|Humanized, IgG4-variant monoclonal antibody against PD-1
45787322|NCT03744468|Drug|LBL-007|Human anti LAG-3 IgG4-kappa antibody
45787323|NCT03742895|Drug|Olaparib|Olaparib 300 mg administered BID as two, 150 mg oral tablets.
45787324|NCT03725436|Drug|MDM2/MDMX Inhibitor ALRN-6924|Given IV
45787325|NCT03725436|Drug|Paclitaxel|Given IV
45787326|NCT03688022|Drug|MT-7117|MT-7117
45787327|NCT03688022|Drug|PPI|Proton pump inhibitor
45787328|NCT03688022|Dietary Supplement|Acidic beverage|Acidic beverage
45787329|NCT03681210|Device|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
45787330|NCT03678688|Drug|10 mg OPC-167832|Once daily oral dose of 10 mg OPC-167832 from Day 1 through Day 14.
45787331|NCT03678688|Drug|30 mg OPC-167832|Once daily oral dose of 30 mg OPC-167832 from Day 1 through Day 14.
45787332|NCT03678688|Drug|90 mg OPC-167832|Once daily oral dose of 90 mg OPC-167832 from Day 1 through Day 14.
45787333|NCT03678688|Drug|3 mg OPC-167832|Once daily oral dose of 3 mg OPC-167832 from Day 1 through Day 14.
45787334|NCT03678688|Drug|RHEZ|"RHEZ will be used in both Stage 1 and Stage 2. Each tablet contains 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol. Participants will receive a single-dose from Day 1 through Day 20. The total number of tablets per day will be based on the pretreatment body weight:~Participants weighing 30 to 37 kg will receive 2 tablets per day~Participants weighing 38 to 54 kg will receive 3 tablets per day~Participants weighing 55 to 70 kg will receive 4 tablets per day~Participants weighing > 70 kg will receive 5 tablets per day"
45787335|NCT03678688|Drug|30 mg OPC-167832 plus 300 mg delamanid|Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid from Day 1 through Day 14.
45787336|NCT03678688|Drug|30 mg OPC-167832 plus 400 mg Bedaquiline (BDQ)|Once daily oral dose of 30 mg OPC-167832 plus 400 mg BDQ from Day 1 through Day 14. Subjects will receive a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ will be 400 mg QD for Days 3 to 14.
45787337|NCT03678688|Drug|30 mg OPC-167832 plus 300 mg delamanid plus 400 mg Bedaquiline (BDQ)|Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid plus 400 mg BDQ from Day 1 through Day 14. Subjects will receive a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ will be 400 mg QD for Days 3 to 14.
45787338|NCT03672864|Behavioral|Intensive exercise|Intensive, child-initiated movement of the lower extremity: 1 hour/day, 4 days/week, 2 sessions delivered by a physical therapist, 2 delivered by a parent. All activities are play based, and exercise intensity is enhanced by small weights placed on the dorsum of the foot and the ankle of the affected limb. Intervention is delivered over 12 weeks for a target of 48 hours of training.
45787339|NCT03655912|Device|Red/green glasses|The use of red/green glasses and electronic devices for two hours a day during 4 months.
45787340|NCT03655912|Device|Electronic Tablet|The use of eye patch on the fellow eye and electronic tablet for 2 hours a day during 4 months.
45787341|NCT03655912|Device|Eye patch|The use of eye patch on the fellow eye and near vision activities for 2 hours a day during 4 months.
45787342|NCT03614481|Genetic|Sampling|Sampling
45787343|NCT03610763|Device|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS) is a portable neurostimulation method that modulates cortical excitability. The technique involves placing two saline-soaked electrodes (anode and cathode) on the scalp and passing a small direct current (1.5 milliamps; mA) between them. Cortex underlying the anode is more easily excited due to lowered thresholds for depolarization of glutamatergic neurons, while thresholds are increased in neurons beneath the cathode, making them less excitable. Sham stimulation is easily implemented, and the technique can be effectively double-blinded.
45787344|NCT03610763|Behavioral|Modified Constraint Induced Movement Therapy|In CIMT, patients are required to wear a mitt that restricts use of the unaffected limb while they practice structured tasks and also engage in activities of daily living.
45787345|NCT03602612|Drug|Cyclophosphamide|300 mg/m^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
45787346|NCT03602612|Drug|Fludarabine|30 mg/m^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on day -5, -4, -3
45787347|NCT03602612|Biological|Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells|0.75x10^6 - 12.0X10^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
45787348|NCT03576937|Diagnostic Test|GUARDANT360|GUARDANT360 is a validated cfDNA next-generation sequencing assay that identifies variants in 73 genes associated with several cancers.
45787349|NCT03573973|Other|Improved product placement of fresh fruit and vegetables|The intervention includes the creation of a new fresh fruit and vegetable section at the store entrance with expanded range thus improving the placement (availability and position) of fresh fruit and vegetables.
45787350|NCT03573973|Other|Sham comparator|The control condition is the existing store layout with a limited range of fresh fruit and vegetables that are placed at the back of the store.
45787351|NCT03554044|Drug|Anastrozole|Given PO
45787352|NCT03554044|Drug|Exemestane|Given PO
45645438|NCT05229367|Other|Concentric isokinetic training|Concentric exercises of the hamstring muscles were performed with the use of an isokinetic dynamometer device.
45645439|NCT02340247|Other|Water|
45645440|NCT02340247|Drug|Ursodeoxycholic Acid|
45645441|NCT02340247|Drug|Chenodeoxycholic Acid|
45645442|NCT02340013|Drug|Medroxyprogesterone acetate|Women in this arm of the study will be assigned to start medroxyprogesterone acetate 10mg per os x 10 days. This will be followed by vaginal bleeding. On the 3rd day of vaginal bleeding, women will start clomiphene citrate 50mg per os x 5 days for ovulation induction.
45645443|NCT02339857|Procedure|No-touch harvesting technique|The saphenous vein is harvested with a pedicle of surrounding tissue.
45645444|NCT02638337|Drug|Ospemifene|60 mg tablet
45645445|NCT02638337|Drug|Placebo|Tablet identical to the ospemifene tablet without drug
45645446|NCT02339935|Behavioral|Brief Analogue Functional Analysis|The Brief AFA seeks to identify the function of the challenging behavior by creating controlled test conditions in which specific responses are provided for challenging behavior (e.g., attention, escape from task demands, access to tangible - including variants of each as needed), as well as a control condition in which continual access to attention and preferred items is provided. It consists of a 30-90-minute abbreviated analysis comprised of a single exposure to 2-5-minute test and control conditions, along with replication of applicable test conditions and a treatment probe, which provides evidence of challenging behavior function faster than other methods.
45645447|NCT02339935|Other|No Brief AFA|These participants will receive typical standard of care procedures while hospitalized, but will not receive the additional behavioral intervention
45787353|NCT03554044|Drug|Fulvestrant|Given IM
45787354|NCT03554044|Drug|Letrozole|Given PO
45787355|NCT03554044|Drug|Paclitaxel|Given IV
45787356|NCT03554044|Biological|Talimogene Laherparepvec|Given IT
45787357|NCT03554044|Drug|Tamoxifen|Given PO
45787358|NCT03554044|Drug|Nab paclitaxel|Given IV
45787359|NCT03554044|Drug|Gemcitabine|Given IV
45787360|NCT03554044|Drug|Carboplatin|Given IV
45787361|NCT03547518|Device|PTNS treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
45787362|NCT03547518|Device|Sham treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
45787363|NCT03542097|Other|MGMT methylation evaluation|The MGMT methylation will be evaluated by extracting DNA from fresh and Formalin Fixed paraffin Embedded (FFPE) tumor samples
46071200|NCT05054894|Other|Therapeutic Plasma Exchange (TPE)|"Following all necessary screening and consenting protocol, patients will be scheduled for the plasmapheresis procedure.~Plasmapheresis~On the days of the scheduled procedure, patients will undergo up to 1.5 hours of plasmapheresis treatment. Patients will be awake and situated in a relaxed position in a reclined chair. The plasmapheresis device to be used is the Fresenius Kabi 'Amicus', which is currently FDA approved for a variety of clinical conditions. In one treatment, roughly 60-70% of a patient's plasma can safely be replaced; by using six consecutive treatments, more of the patient's plasma (approaching 100%) will be replaced in an exponential fashion."
46071201|NCT01940822|Other|Energy Drink|
46071202|NCT01940822|Other|Placebo Drink|
46071203|NCT02848430|Dietary Supplement|Humulus lupulus|Extract of spent hops standardized to xanthohumol, isoxanthohumol, 6-prenylnaringenin, and 8-prenylnaringenin
46071204|NCT04804514|Drug|KH001|The study drug is applied to teeth
45645448|NCT02339623|Device|Ultrasound imaging|"- Fetal adrenal gland volume calculation using 3D ultrasound~- Assessment of the fetal central adrenal zone enlargement by 3D ultrasound~- CL measurement using 2D ultrasound"
45645449|NCT05178823|Drug|Chlorhexidine mouthwash|Comparison of oral rinses
45645450|NCT02335567|Other|there is no intervention|
45645451|NCT03105583|Drug|Medication use during pregnancy|
45645452|NCT03105583|Dietary Supplement|Supplement use during pregnancy|
46071205|NCT04804514|Drug|Placebo|The placebo is applied to teeth
46071206|NCT00828217|Other|adapted physical activity|one session of adapted physical activity per day (30 minutes each session), during the whole stay at the hospital
46071207|NCT02848352|Other|Placebo nasal spray|
46071208|NCT02848352|Other|Film Sequence|
46071209|NCT00626275|Drug|ADL5859|
46071210|NCT00626275|Drug|Naproxen|
46071211|NCT00626275|Drug|Placebo|
46071212|NCT00626275|Drug|ADL5859|
46071213|NCT00626275|Drug|Placebo|
45787364|NCT03541200|Drug|MT-8554|MT-8554 Oral
45787365|NCT03524937|Drug|MELATONIN (HIGH DOSE)|Enteral melatonin (3mg) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days
45787366|NCT03524937|Drug|MELATONIN (LOW DOSE)|Enteral melatonin (0.3mg ) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days
45787367|NCT03524937|Drug|PLACEBO|Study drug will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days.
45787368|NCT03520036|Drug|MT-7117 low dose|MT-7117 low dose QD, oral, 16 weeks
45787369|NCT03520036|Drug|MT-7117 high dose|MT-7117 high dose QD, oral, 16 weeks
45787370|NCT03520036|Drug|Placebo|Placebo QD, oral, 16 weeks
46071214|NCT02848118|Device|A nasal-oral cannula of capnography|After propofol infusion, the complete induction is defined when capnography shows hypoventilation and bronchoscope is then introduced to patients.
46071215|NCT02848118|Other|Observer Assessment of Alertness and Sedation scale|After propofol infusion, the complete induction is defined when OAAS is 3 to 2 (conscious sedation) and bronchoscope is then introduced to patients.
46071216|NCT02847884|Biological|Infliximab|Patients will be prescribed Infliximab as a standard of care regardless of study participation.
46071217|NCT00623935|Drug|Fludarabine|Fludarabine (40 mg/m2/day x 4 days)
46071218|NCT00623935|Drug|Busulfan|Busulfan (3.2 mg/m2/day x 2 days or x 4 days).
46071219|NCT00623935|Radiation|Total Body Irradiation|Patients who receive Busulfan 3.2 mg/m2/day x 2 days and a mismatched allograft (7/8 HLA match) will also receive 200 cGy of total body irradiation (TBI) pre-transplant.
46071220|NCT00623935|Procedure|Stem Cell Transplant|Allogeneic stem cell transplant from related or unrelated donor
46071221|NCT03782246|Behavioral|MBCT|Mindfulness- based Cognitive Therapy
46071222|NCT03782246|Behavioral|CBT|Cognitive Behavioral Therapy
46071223|NCT00623779|Drug|AZD0837|ER formulation
46071224|NCT00623779|Drug|Aspirin|Oral form
46071225|NCT04202042|Other|Psychological first aid|PFA responders (peer support workers) are trained to deliver 8 core actions: contact and engagement, safety and comfort, stabilization, information gathering, practical assistance, connection with social supports, information on coping, and linkage with collaborative services
46071226|NCT04202042|Other|Usual organisational intervention|Emergency intervention by workplace psychologist and limited therapeutic sessions with employee aid program
46071227|NCT04043845|Drug|Ibrutinib|Ibrutinib inhibits the function of Bruton's tyrosine kinase (BTK). Ibrutinib blocks signals that stimulate malignant B cells to grow and divide uncontrollably.
45645453|NCT03105583|Other|Vitamin status of a pregnant woman|Haemoglobin, RBC count + hematocrits, thrombocytes count, folate (serum), vitamin B12, WBC count, ferritin, iron (serum), transferrin % and saturation, TSH, T4, free glucose, LDH, ALT, AST, GGT, bilirubin (total), CRP, albumin, total protein, ureum, uric acid, creating, calcium (total), 25-hydroxy vitamin D, Na, K, Mg
45645454|NCT03105115|Drug|fentanyl|intrathecal fentanyl will be added as adjuvant for spinal anesthesia using heavy bupivacaine, while dexmedetomidine will be infused intravenously during operation
45645455|NCT03105115|Drug|bupivacaine only|heavy bupivacaine will be injected intrathecally during spinal anesthesia, without fentanyl, while dexmedetomidine will be infused intravenously during operation
45645456|NCT03080831|Drug|NaCl 0.9% in Glucose 5% + 40mmol/L Potassium|Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
45645457|NCT03080831|Drug|Glucion 5%|Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
45645458|NCT03105349|Drug|elbasvir/grazoprevir|16 weeks treatment
45787371|NCT03511209|Behavioral|CBTI plus taper method A|This intervention includes CBTI plus the novel hypnotic tapering method.
45787372|NCT03511209|Behavioral|CBTI plus taper method B|This intervention includes CBTI plus the usual hypnotic tapering method used by the VA.
45787373|NCT03505710|Drug|Trastuzumab deruxtecan|Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.
45787374|NCT03503266|Drug|[14C] MT-7117|14-C MT-7117
45787375|NCT03473145|Behavioral|Health Coaching|Health Coaching sessions will be aimed at goal setting, implementing strategies, overcoming barriers, & relapse prevention.
45787376|NCT03473145|Device|activPAL inclinometer|Participants in the intervention study arms (B & C) will wear the ActivPAL device for the first 4 weeks of the program and then again in weeks 8 and 9. The device will monitor their sitting and standing time and will allow Health Coaches to provide feedback and will assist the participant in developing an action plan.
45787377|NCT03473145|Other|Tools to Prompt Standing or Prompt Sit-to-Stand Transitions.|Participants in the intervention study arms (B & C) will receive tools to prompt standing or sit-to-stand transitions such as wearable wrist devices, standing desks or tables (Group B only), mechanical and/or electronic timers, or access to mobile apps or computer programs.
45787378|NCT03471130|Drug|MT-8554 Low dose|Oral, 7 days
45787379|NCT03471130|Drug|MT-8554 High dose|Oral, 7 days
45919482|NCT01057069|Drug|Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide|"One course of of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin. PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.~This course is followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion."
45919483|NCT04060316|Drug|GLS-1200|GLS-1200 is given as a nasal spray using an atomizer
45919484|NCT04060316|Drug|Placebo|Placebo is given as a nasal spray using an atomizer
45645459|NCT03105349|Drug|Sofosbuvir|16 weeks treatment
45645460|NCT03105349|Drug|Ribavirin|16 weeks treatment
45645461|NCT03077555|Drug|Zoely|quick start of combined hormonal contraception containing 1.5 mg estradiol /2.5 mg nomegestrol acetate
45645462|NCT03077555|Drug|Meliane ED|quick start of combined hormonal contraception containing 20 mcg ethinyl estradiol /75 mcg gestodene
45645463|NCT02335723|Device|Alteco LPS Adsorber|"Alteco® LPS Adsorber is a Class IIa medical device developed in accordance with existing international standards. Alteco® LPS Adsorber does not contain any pharmaceutical or toxic components.~Alteco® LPS Adsorber is used for the adsorption of LPS as endotoxins. The capturing component is a specially designed synthetic peptide developed for adsorption of endotoxin. The capturing component has high affinity to Lipid A, i.e. a constant component in the endotoxin molecule, which ensures efficient reduction of endotoxins from different bacterial species."
45645464|NCT02335723|Device|Placebo|Exactly the same as Alteco LPS Adsorber but no peptide component has been attached to the matrix (i.e. there is no adsorber functionality)
45645465|NCT05005091|Dietary Supplement|Oral carbohydrate|100 ml oral carbohydrate two hours ago preoperatively
45653067|NCT05125263|Other|mulligan taping group|"Mulligan taping will be applied while patient in standing position and the hip, knee will be internally rotated and flexed to 20 degree. Rigid tape will be applied from neck of fibula which will be passing anteriorly over the tibia to secure internal rotation of tibia at the knee, and passing below the medial joint line and behind the knee, 2 superimposed layers of 38-mm rigid tape will be applied in a spiral fashion. Tape will be applied for 24, 48 and 72 hours. And it must come off immediately if any pain and skin irritation is experienced. Along with conventional therapy.~Stretching of hamstrings 10 reps 10 sec hold. Straight leg raise 3 sets* 10 reps, 1 min interval. Strengthening of Quadriceps (quads isometric) and VMO with 10 reps and 3 sets, 1 min interval) Squatting (10 reps* 3 sets, 1 min interval)"
45787380|NCT03471130|Drug|Placebo|Oral, 7 days
45787381|NCT03459729|Drug|Antitumor B|Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours).
45787382|NCT03445559|Behavioral|Clinical Order Check|A Clinical Order Check is an evidence-based, systems-level method to affect significant behavior change. It addresses the intervention functions of education, enablement and incentivization which are effective methods to change behaviors driven by beliefs about capabilities, knowledge, social influences, beliefs about consequences, and environmental context and resources. All VA facilities currently use locally adapted clinical reminders. This strategy is technologically simple, straightforward, and is considered to be a best practice within the VA IT community. The reminder will be self-explanatory and non-intrusive to workflow.
45787383|NCT03445559|Behavioral|Academic Detailing|Academic detailing is an individual and facility-level intervention consistently shown to improve provider behavior. This strategy addresses the intervention functions of persuasion, coercion, modeling, and education which are effective methods for affecting behaviors driven by beliefs about capabilities, knowledge, social influences, beliefs about consequences, and environmental context and resources. During the meeting, the detailer will follow a script explaining that the visit is part of an experimental program to provide physicians with up-to-date, unbiased information about imaging to stage prostate cancer.
45787384|NCT03445559|Behavioral|Audit and Feedback|Audit and feedback is an effective, individual-level intervention for changing healthcare provider behavior, resulting in small but potentially clinically important benefits. Audit and feedback addresses the intervention functions of education, persuasion and incentivization, all of which are important for addressing beliefs about capabilities and consequences, knowledge, and social influence.
45919485|NCT00847990|Other|Maternal blood screening test for fetal aneuploidy|One blood draw of 20 to 30 mL
45919486|NCT00847951|Procedure|3D Ultrasound Imaging|Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys in pre-mature and/or very low birth weight babies. This is a measure of perfusion and an indication of how well the kidneys are working.
45919487|NCT00847873|Behavioral|substance abuse/domestic violence treatment|This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse
45919488|NCT00847873|Behavioral|Cognitive behavioral therapy addressing substance abuse|This intervention is comprised of 16 sessions of cognitive behavioral therapy addressing substance abuse.
45919489|NCT00847834|Drug|Irbesartan 150mg / Hydrochlorothiazide 12.5mg|Once a day
45919490|NCT00847834|Drug|Irbesartan 150mg|Once a day
45787385|NCT03435458|Combination Product|Balloon catheter + oral misoprostol|The pharmacological cervical ripening will be administered just after the balloon catheter insertion (after coming back in her room) and will consist of misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
45787386|NCT03435458|Drug|Oral misoprostol alone|Patients will receive a pharmacological cervical ripening alone that consist of Misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
45787387|NCT03381404|Drug|[14C] MT-8554|14-C MT-8554
45787388|NCT03338959|Biological|Pembrolizumab|Given IV
45787389|NCT03338959|Radiation|Radiation Therapy|Undergo radiation therapy
45787390|NCT03323476|Other|Discontinuation (or not initiation) of Immunosuppressive Therapy|Discontinuation (or not initiation) of Immunosuppressive Therapy
45787391|NCT03323476|Drug|Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®|Maintenance (or initiation) of Immunosuppressive Therapy: Imurel®, Mabthera®,Cellcept®, Cortancyl®
45787392|NCT03291067|Drug|MT-8554 1mg|MT-8554 1mg QD, oral, 12 weeks
45787393|NCT03291067|Drug|MT-8554 5mg|MT-8554 5mg QD, oral, 12 weeks
45787394|NCT03291067|Drug|MT-8554 10mg|MT-8554 10mg QD, oral, 12 weeks
45787395|NCT03291067|Drug|Placebo|Placebo QD, oral, 12 weeks
46071228|NCT04043845|Drug|LY3214996|LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
46071229|NCT00828373|Drug|Placebo|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the Placebo group this will be physiologic saline. The infusion will be stopped after complete recovery from the neuromuscular block.
46071230|NCT00828373|Drug|Lidocaine|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the lidocaine Arm this regimen corresponds to 1.5 mg kg-1 lidocaine bolus injection and 2 mg kg-1 h-1 lidocaine continuous infusion. The infusion will be stopped after complete recovery from the neuromuscular block.
45653068|NCT05197595|Behavioral|Attachment-based compassion therapy|Compassion program consists of 6 sessions of 90 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
45653069|NCT05197595|Behavioral|Relaxation program|Relaxation program consists of 6 sessions of 90 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
45787396|NCT03265379|Other|FACT-B and Brief Pain Inventory|Quality of Life Questionnaires
45787397|NCT03260569|Drug|Inhaled Nitric Oxide|Patients randomized to this arm will receive inhaled nitric oxide 20 parts per million.
45787398|NCT03260569|Drug|Placebo|Nitrogen plus oxygen
45787399|NCT03248908|Diagnostic Test|Pupillary dilation reflex|Perioperative pupillary dilation reflex assessment is executed every 10 minutes from start sedation until extubation in patients allocated to study arm Intervention 1 and Intervention 3
45787400|NCT03248908|Other|Standard of care|Perioperative opioid administration based on the attending anesthesiologist decision (mainly including assessment of heart rate, blood pressure, and limb movement)
45787401|NCT03188796|Drug|Cholecalciferol|oral/enteral loading dose of 37.5 ml MCT including 540,000 IU vitamin D3 followed by 10 drops daily (4000 IU) for 90 days
45787402|NCT03188796|Drug|Placebo|oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days
45787403|NCT03184233|Procedure|Rapid ventricular pacing|Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short periods of time during dissection or rupture of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. The technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations (AVMs) and can be lifesaving in the case of an intraoperative bleeding or rupture
45787404|NCT03184233|Procedure|No rapid ventricular pacing|No rapid ventricular pacing is applied perioperatively.
45787405|NCT03184194|Drug|nivolumab-daratumumab|nivolumab-daratumumab will be given without low-dose cyclophosphamide until progression
45787406|NCT03184194|Drug|nivolumab-daratumumab with low-dose cyclophosphamide|nivolumab-daratumumab with low-dose cyclophosphamide will be given until progression
45787407|NCT03171129|Device|Adaptive Dynamic Inspiratory Nasal Apparatus|Oxygen will be administered via ADINA
46071231|NCT03573518|Drug|BTX 1503|BTX 1503 Dose 1 liquid formulation, or BTX 1503 Dose 2 liquid formulation
46071232|NCT03573518|Drug|Vehicle|Placebo
45787408|NCT03171129|Device|High flow Nasal Canula|Oxygen will be administered via nasal canula
46071233|NCT02550301|Other|Mean Platelet Volume|Ten milliliters (mls) of blood will be drawn from eligible, consented patients at the time of the admission, collected in ethylenediamine tetraacetic acid (EDTA) tubes, and tested for CBC. Platelets have an average life span that can vary from 8-10 days or 10-36 days. To minimize this bias, three additional MPV samples will be collected on day 1, day 7 and day 30 post PCI.
45653070|NCT04805515|Behavioral|Nicotine Corrective Messages|Messages communicating misperceptions of nicotine's role in health harms as well as misperceptions about reduced nicotine content cigarettes and e-cigarettes.
45653071|NCT05124873|Device|Moisture Management Liner|A prototype liner designed to reduce heat that builds up on the limb.
45653072|NCT05195177|Drug|Anti-histamine cream 1 hour|At the start of session 1, one area of the middle forearms of the participant will be located (4x4cm). On the area, anti-histamine cream will be applied for approximately 1 hour.
45653073|NCT05195177|Drug|Local anesthetic cream 1 hour|At the start of session 2, one area of the middle forearms of the participant will be located (4x4cm). On the area, local anesthetic cream (2.5% lidocain/2.5 prilocaine) will be applied for approximately 1 hour.
45653074|NCT05729971|Procedure|nasogastric tube|The intervention consists in removing or not the nasogastric tube at the end of the surgery.
45787409|NCT03157128|Drug|LOXO-292|Oral LOXO-292
45787410|NCT03111667|Behavioral|Teen Marijuana Check Up|Two session Motivational Enhancement Therapy intervention. The first MET session relies on the use of motivational interviewing skills to hear the student's history and current concerns with marijuana. The second session involves the provision of a personalized feedback report based on the student's baseline assessment that reviews normative feedback on marijuana use, consequences experienced, money spent on marijuana, other drug and alcohol use, social supports for quitting and life goals.
45787411|NCT03111667|Other|Treatment as Usual|Referral to community resources
45787412|NCT03111667|Behavioral|Gold Standard Coaching|Weekly coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in a group setting.
45787413|NCT03111667|Behavioral|As Needed Coaching|As needed coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in an individual setting.
45787414|NCT03108456|Device|Orbital Atherectomy|Vessel preparation with Orbital Atherectomy followed by balloon pre-dilatation
45787415|NCT03108456|Device|Balloon|Vessel preparation with conventional and/or specialty balloons
45787416|NCT03103971|Biological|Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|Given IV
45787417|NCT03103971|Drug|Cyclophosphamide|Given IV
45645466|NCT02335645|Other|Body Weight Supported Treadmill Use of Patients with ACL Reconstruction|"Standard ACL protocol will be followed throughout the treatment of each patient. The only variance from treatment will be using body weight supported treadmill and video gait analysis to help guide treatment.~The first analysis will be performed at week 6 after surgery. Motion capture sensors will be placed on the patient at different anatomical positions. The patient will then run in a body weight supported treadmill. During this run, video capture will be performed and later analyzed to determine biomechanical kinematics.~Based on findings of video gait analysis, exercise progression will be altered to improve deficits found. This process will be repeated at week 8 of rehabilitation in the body weight supported treadmill.~At week 10 and 12, the patient will shift treatment from the body weight supported treadmill, to a standard treadmill. The process will be repeated using the same anatomical landmarks and video capture."
45645467|NCT03080285|Device|over-glasses patch|Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
45645468|NCT03080285|Device|Conventional patch|Conventional patch (Opticlude Eye Patch, 3M, Maplewood, MN, USA) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
45787418|NCT03103971|Drug|Fludarabine|Given IV
45787419|NCT03103971|Other|Laboratory Biomarker Analysis|Correlative studies
45787420|NCT03103971|Procedure|Leukapheresis|Undergo leukapheresis
45787421|NCT03103971|Other|Pharmacological Study|Correlative studies
45787422|NCT03096132|Behavioral|Family Based Behavioral Treatment|Treatment includes 20 90 minute visits over 6 months which include 60 min parent and child separate groups and 30 min behavioral coaching. FBT includes information regarding nutrition and physical activity, as well as behavior therapy skills, including parenting skills, self-monitoring, problem solving skills, motivation systems, emotional regulation, stress management, stimulus control, and relapse prevention.
45787423|NCT03096132|Behavioral|Guided Self-Help Fam. Based Bx Treatment|Treatment includes 14 20 minute visits over 6 months. gshFBT is delivered to parent/child dyads and includes the same content in the FBT groups but it is provided in a manual. The 20-minute visits focus on clarifying information in the manuals, collecting weight and self-monitoring logs, and problem solving any barriers to implementation.
45787424|NCT03096041|Device|Auriculotherapy for analgesic use|The ASP will be applied to specific pain points
45919491|NCT04059146|Other|Pain Education and Exercise|Participants will be randomly assigned to a pain education group, following biopsychosocial model, or standard of care education, following biomedical model. The goals of the pain education intervention are for patients to 1) address fear of movement and pain catastrophizing specific to AT, 2) learn about the neurophysiology of pain, 3) develop coping skills, and 4) promote exercise participation through pacing. This program enables patients to have a conceptual change in their understanding of what causes pain, gain greater control over the psychological aspects of pain, and reduce the perceived threat of chronic pain. Participants will be given weekly online exercises to promote engagement with the material, give individual feedback to participants, and assess understanding. In person sessions with the physical therapist will reinforce self-learning and application to a home exercise program.
45919492|NCT04059146|Other|Standard Education and Exercise|The comparison group will be given education based on standard of care resources that primarily utilize a biomedical model, which assumes that AT pain is primarily caused by tissue damage. The videos, handouts, and exercises will be equivalent to the pain education group in terms of time and learning requirements.
45645469|NCT02335333|Other|No treatment|
45653075|NCT05180331|Behavioral|Mobile Application to Prevent Suicide (MAPS)|Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
45653076|NCT05170919|Drug|Mirtazapine|Patients will be prescribed a dosage of 15 mg per day. Dose will not be escalated.
45787425|NCT03096041|Device|Placebo auriculotherapy|The ASP will be applied to placebo points (not specific to pain)
45787426|NCT03092323|Drug|Pembrolizumab|Pembrolizumab will be administered at 200 mg intravenously every 3 weeks for patients on the treatment arm.
45787427|NCT03060096|Other|Severe Anxiety/depression: High Intensity Stepped Care|The stepped-care Telehealth high intensity intervention is tailored to participants with severe anxiety and depression. Ppts randomized to this group will have 12 weekly psychotherapy sessions delivered by phone with a licensed therapist. Participants will also receive a CBT (cognitive behavioral therapy) workbook including daily exercises to supplement understanding.
45787428|NCT03060096|Other|Moderate Anxiety/depression: Low Intensity Stepped care|The stepped care Telehealth low intensity intervention is tailored to participants with moderate anxiety and depression. Ppts randomized to this group will receive a self-guided CBT workbook and biweekly (every 2 weeks) check-in calls from a research staff person to assess changes in symptom severity and need for treatment/support.
45787429|NCT03060096|Other|Enhanced Usual Care Control|"Participants with moderate to severe anxiety/depression that are randomized to Enhanced Usual Care Control (EUC) will receive information about referrals/resources in their local area (support groups, mental health providers), NCI materials (Facing Forward: Life after Cancer Treatment, self-help workbooks, copy of the CBT (cognitive behavioral therapy) workbook on completion of the study."
45787430|NCT03035409|Drug|Anamorelin Hydrochloride|Given PO
45787431|NCT03035409|Behavioral|Exercise Intervention|Undergo physical activity
45787432|NCT03035409|Other|Laboratory Biomarker Analysis|Correlative studies
45787433|NCT03035409|Other|Nutritional Assessment|Undergo nutritional counseling
45919493|NCT05341011|Behavioral|PEERS® Social Skills Training|"The PEERS® consisted of 14 weekly 90-min didactic sessions. Adolescents and their parents attended separate concurrent sessions.~Each session began with a review of the homework assignment from the previous week and allowed time for troubleshooting problems encountered in completing the behavioral assignment. This was followed by a didactic lesson on the weekly topic. Didactic lessons included content related to various social skills and peer interactions. Parents attendance was a mandatory component of PEERS® intervention. Parents were expected to enhance generalization of social skills through in vivo social coaching in natural social settings and increase homework compliance as well as practice of newly learned social skills. A 10-min reunification between adolescents and caregivers was arranged at the end of each session to review the skills taught in the session and assign corresponding homework for the next session."
45919494|NCT00847795|Drug|Avotermin|Intradermal administration
45449278|NCT01310361|Drug|Intramuscular Benzathin Penicillin G|It is mentioned underlined in page 10 in research. (Once the throat swab was taken and cultured on plate at the place where the child was examined, hygiene teacher was trained about how to prepare the oral amoxicillin suspension and how to give it to the child. 750 milligrams of amoxicillin was thereafter given to the patient and in order not to infect other school children, the patient was sent home. The following morning, the patient would come to school and was given the second dose of amoxicillin by the hygiene teacher. All oral drugs were bought from a creditable company. In the injection group, 600000 units of penicillin was administered to children who weigh less than 27 kilograms and 1200000 units of penicillin was administered to children who weigh more. After 48 hours, patients were examined again when the result of first culture was ready)
45449279|NCT02159794|Device|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
45449280|NCT03731949|Diagnostic Test|Ultrasonography|Ultrasonography to assess placental volume
45645470|NCT03077321|Behavioral|CARE plus Peer Mentor|A parent who has completed the standard CARE program will be recruited to be a peer mentor. The peer mentor will attend the CARE training for group leaders and will also be trained in motivational interviewing. These skills will then be used strategically in weekly phone discussions between the peer mentor and parent about practicing the CARE parenting skills in the home setting and planning for attending the 6 training sessions. The parent mentor will co-facilitate the CARE groups in the peer mentor arm along with 2 additional CARE therapists. The peer mentor will also call the parents in the peer mentor arm before each session to discuss progress on homework, and to address barriers for program attendance.
45653077|NCT05170919|Drug|Olanzapine|the participant will be prescribed a dosage of 2.5mg per day if > 65 yrs. and 5 mg/per day if <65 yrs. per day. Per physician discretion, participants are allowed a dose escalation of a maximum of 10mg.
45653078|NCT05729893|Other|root canal sealers|different sealer used in obturating root canals (resin and bio ceramic)
45787434|NCT03035409|Other|Quality-of-Life Assessment|Ancillary studies
45787435|NCT03035409|Other|Questionnaire Administration|Ancillary studies
45787436|NCT03018366|Drug|17beta Estradiol|Participants will use a dose of transdermal estradiol 0.1 mg/day patch for 12 weeks +/- 1week. PAT index vascular measures and serum immune markers will be measured after 6 and 12 weeks +/- 1week on estrogen patches. Patches will be applied by the participant to the lower abdomen twice weekly, alternating sides.
45787437|NCT03018366|Drug|Transdermal placebo patch|Participants will use a dose of placebo patches for 12 weeks +/- 1 week. Placebos will be applied by the participant to the lower abdomen twice weekly, alternating sides.
45787438|NCT03018366|Drug|Progesterone|After 12 weeks +/- 1week of transdermal estradiol patch, participants will use estrogen patch plus progesterone for 2 additional weeks +/- 3 days. Progesterone is a peanut based product and for patients with a peanut allergy we will replace this with a synthetic progestin at an equivalent dose, medroxyprogesterone 10mg.
45787439|NCT03018366|Drug|Placebo Pill|After 12 weeks +/- 1week of transdermal placebo patch, participants will use placebo patch plus placebo pill for 2 additional weeks +/- 3 days.
45787440|NCT03012529|Drug|Rifampin|Subjects who are randomly assigned to adjunctive rifampin will receive a 600 mg oral daily dose targeted for a six-week period. If a subject experiences gastrointestinal intolerance on once daily dosing, the study drug may be administered as rifampin 300 mg twice a day.
45787441|NCT03012529|Drug|Riboflavin Placebo|A placebo capsule will be administered daily to match frequency and duration of rifampin interventional drug. For the purpose of mimicking urine discoloration when taking rifampin, riboflavin will be added to the placebo to produce a urine discoloration effect.
45919495|NCT00847795|Drug|Placebo|Placebo
45919496|NCT00847756|Other|questionnaire|Identification of risk factors
45919497|NCT00847756|Procedure|blood sample|venal puncture, 5ml. A blood sample will be taken at the day of surgery and after 2-3 months.
45919498|NCT00847756|Procedure|collection of middle ear fluid|During routine surgery middle ear fluids are collected per patient.
45919499|NCT00847756|Procedure|nasopharyngeal swab|A nasopharyngeal swab is taken at the end of the surgical procedure and after 2-3 months.
45919500|NCT00847717|Procedure|Selective neck dissection|Level IIb preserving neck dissection
45919501|NCT00847717|Procedure|Conventional Neck dissection|Conventional neck dissection (MRND type III or Supraomohyoid)
45919502|NCT00847678|Biological|Efungumab (Mycograb)|
45919503|NCT00847678|Biological|placebo|
45919504|NCT00847678|Biological|Amphotericin B|
45919505|NCT00847678|Biological|5 flucytosine|
45787442|NCT02984124|Behavioral|Informed Assent Discussion|"Participants randomized to the intervention arm will participate in a discussion about CPR with a study doctor that follows these steps:~Patient's values and preferences for therapies and outcomes elicited from patient and family; overall therapeutic goals formulated~Description of CPR and dying process provided~Personalized explanation provided about probable lack of achieving any reasonable therapeutic goal with CPR (i.e. why s/he is a poor candidate for CPR due to underlying illness)~Patient and family informed that due to severe underlying illness and high likelihood that CPR will be burdensome/harmful and will not provide benefit, CPR will not be offered unless they disagree (except in rare circumstance where overall therapeutic goals from step 1 are to preserve life regardless of quality of that life) Assessment of patient's and family's understanding of issues discussed; patients may actively disagree and request CPR be performed, but CPR not explicitly offered"
45787443|NCT02984124|Behavioral|Usual Care with Attention Control|Participants who are randomized to the usual care arm will receive a friendly visit in the hospital from research personnel to ask if they have any questions or concerns. Follow up assessments and time windows will be explained. Importance of their participation in the study will be emphasized.
45787444|NCT02917473|Behavioral|In-person counseling|"In-person counseling~Sun protection"
45645471|NCT03077321|Behavioral|CARE|CARE involves 6 weekly 90-minute sessions administered to 6-10 parents by 2 therapists. The initial phase focuses on developing parenting skills aimed at increasing attention to children's pro-social behaviors while ignoring minor attention seeking misbehaviors. The second phase teaches techniques for giving children effective commands in order to set age-appropriate limits and increase compliance. Children do not attend the training but parents are expected to practice the skills with their children between sessions.
45787445|NCT02917473|Behavioral|Written advice|Written advice
45787446|NCT02917473|Behavioral|Medical skin screening|Medical skin screening
45787447|NCT02916004|Device|Measurement of NFR and PDR|Feasibility testing of NFR and PDR in sedated, ventilated patients. Comparison of NFR and PDR with standard routine care of pain assessment
45787448|NCT02905838|Device|Anatomic e.max Abutment|Implant-supported single crown was fabricated using a prefabricated stock abutment made of yttrium oxide partially stabilized tetragonal zirconia polycrystalline (Y-TZP) (Anatomic IPS e.max Abutment, straight, color M1, Ivoclar, Liechtenstein) and pressed ceramic (fluorapatite glass-ceramic, IPS e.max ZirPress, Ivoclar, Liechtenstein) using the cut-back technique and hand veneered with a thin layer of fluorapatite veneering ceramic (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
45787449|NCT02905838|Device|CAD/CAM CARES Abutment|"Implant-supported single crown was fabricated using an individualized CAD/CAM abutment made of Y-TZP (CARES® Abutment, Institut Straumann AG, Basel, Switzerland) and hand build-up veneering ceramic technique (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).~All implant-supported crowns were fabricated in the same dental laboratory by the same dental technician (Dominique Vinci, Geneva, Switzerland). The implants were placed by experienced oral surgeons in a prosthetic ideal position."
45787450|NCT02889159|Biological|Candida albicans antigen|0.1 milliliter (mL) injection into superficial dermis making small bleb at Baseline Visit.
45787451|NCT02889159|Biological|histamine phosphate|0.01 milliliter (mL) of histamine phosphate injected into the superficial dermis making a small bleb at Baseline Visit.
45787452|NCT02889159|Biological|imiquimod 5% cream|Pea sized amount of 5% cream to be applied to designated areas once daily for 4 days, beginning at Baseline Visit.
45787453|NCT02889159|Procedure|Tape Stripping|At Baseline Visit, adhesive tape firmly applied to designated area for 2 seconds, then removed. Procedure repeated between 20 and 50 times until skin is slightly red and tacky.
45787454|NCT02847598|Drug|BIIB059 (litifilimab)|Administered as specified in the treatment arm.
45787455|NCT02847598|Drug|Placebo|Administered as specified in the treatment arm.
45787456|NCT02841280|Drug|Chlorthalidone|This is a forced-titration study and the study drug will be increased if goal BP is not achieved (dosage of chlorthalidone not to exceed 50 mg)
45787457|NCT02841280|Drug|Placebo|This is a forced-titration study and placebo will be increased if goal BP is not achieved.
45787458|NCT02837510|Behavioral|Standard smoking cessation counseling|Participants will discuss reasons for quitting, the model of smoking as a learned habit, triggers for smoking, and trigger management; receive brief training in how to manage withdrawal symptoms and relapse prevention counseling and receive the NCI Clearing the Air self-help smoking cessation booklet. The target quit date (TQD) session will be scheduled to occur up to 2 weeks following the pre-quit session. Participants will then meet with a smoking cessation counselor for a 15 minute booster counseling session. During the first week following TQD there will be two monitoring visits to closely monitor abstinence. Weekly thereafter for four weeks, participants will attend a brief booster counseling session.
45787459|NCT02813356|Drug|naloxegol|non-interventional study where naloxegol is prescribed during normal clinical practice
45449281|NCT03541798|Procedure|positions of patients for combined spinal-epidural anesthesia|Patients in groups will be positioned according to the study groups for performing combined spinal epidural anesthesia.
45645472|NCT02335255|Drug|Naftifine Hydrochloride Gel 2%|Naftifine Hydrochloride Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
45645473|NCT02335255|Drug|Naftin® Gel 2%|Naftin® Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
45787460|NCT02813356|Drug|non-PAMORA|non-interventional study where patients are exposed to non-peripherally acting mu-opioid antagonists during the normal course of clinical practice
45653079|NCT05602285|Device|Dislodgement device|Breakaway device that prevents IV dislodgement
45645474|NCT02335255|Drug|Placebo Topical Gel|Placebo Topical Gel applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
45645475|NCT02344459|Device|mechanical pre-induction cervical ripening|The balloon catheters have been used to provide mechanical dilation to the cervix as a method of pre-induction cervical ripening.
45645476|NCT05012345|Procedure|Below Elbow cast|below-elbow cast ( 4 or 6 weeks )
45645477|NCT02344381|Dietary Supplement|Sucrose|
45787461|NCT02782715|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Patients will be treated on study with a course of SBRT treatment by a radiation oncologist. Three SBRT dose levels targeting the primary tumor will be evaluated; level I: 6 Gy x 5 fractions (a common palliative dose), level II: 8 Gy x 5 fractions, and level III: 10 Gy x 5 fractions (a common definitive dose).
45787462|NCT02782715|Procedure|Microwave Ablation (MWA)|Performed under sedation using ultrasound and computed tomography (CT) guidance for percutaneous antenna placement and confirmation. Depending on size and location of tumor, one to three antennas (Certus 140; NeuWave Medical) will be used. The system is an FDA-approved, high-powered third-generation MW device that uses CO2 gas cooling to prevent shaft heating. The gas cooling allows the probes to be stuck into tissue by creating a small ice ball at the tip using the Joule-Thomson method, similar to the tissue cooling mechanism of cryoablation systems. Probes are 17-gauge, and various ablation zone configurations are available depending on the probe selected. An ablation protocol using the 65W power setting for 5 minutes will be used for most patients. Ultrasound will be used for real-time monitoring of the extent of ablation to achieve a 5mm margin beyond tumor, and immediate post-procedure imaging performed using contrast-enhanced CT (CECT) for patients with adequate renal functions.
45787463|NCT02760329|Procedure|Blood draw|Biomarkers analyses
45787464|NCT02760329|Procedure|Urine|Biomarker analyses
45787465|NCT02760329|Procedure|Lung function measurements|FEV1, FVC, PEF, FEF25-75%, IC, calculated FEV1/FVC ratio and calculated FEV1 % predicted
45787466|NCT02760329|Procedure|Fractional Exhaled Nitric Oxide (FENO)|Measures level of exhaled nitric oxide.
45787467|NCT02731703|Device|Overdenture treatment|Conventional, FDA-approved prosthetics will be used in accordance with their labeling and pre-study prescribed standard treatment approach
45787468|NCT02723500|Device|Hyperpolarized Xenon MRI|Hyperpolarized noble gas imaging using Xenon-129 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 129Xe gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
45787469|NCT02678182|Drug|Capecitabine|1250 mg/m2/day, 21 day cycle
45787470|NCT02678182|Drug|MEDI4736|IV treatment on days 1&15 of 28 day cycle
45787471|NCT02678182|Drug|Trastuzumab|6mg/kg on day 1 cycle every 21 days
45919506|NCT05337852|Behavioral|Emotional Freedom Technique|"To the pregnant women in the experimental group;~Emotional freedom technique will be applied online with the researcher, 3 sessions every other day for 1 week,~PUQE, PRAQ-2 tests will be applied before the intervention,~SUE and PUQE will be applied before and after each session,~After 3 sessions, post-test data will be obtained with PUQE, SUE, PRAQ-2."
45919507|NCT04042259|Device|Abthera|Negative Pressure Wound Therapy Device
45919508|NCT04042259|Procedure|Open adbdomen for post-laparotomy without NPWT device|Historic cohort treatment of open abdomen for dirty wounds without use of negative pressure therapy device
45645478|NCT02344381|Dietary Supplement|Glucose|
45645479|NCT05012033|Other|No intervention - prednisolone is taken as part if routine clinical care.|Prednisolone given orally prior to taking timed samples for levels
45645480|NCT03145831|Drug|Somavaratan|All subjects will receive somavaratan 3.5 mg/kg twice monthly (every 15 days ± 2 days). Administered as a subcutaneous bolus injection.
45645481|NCT05011877|Device|High-flow nasal cannula therapy|High-flow nasal cannula therapy (HFNC) (from 25 - 60 L/min based on patient's tolerance) will be used in 21 participants during one additional sleep study to investigate its acute impact on reducing sleep abnormalities. Inspired fraction of oxygen will be titrated to maintain patient SpO2 similar to the levels during standard oxygen therapy.
45645482|NCT03080051|Drug|[18F]MNI-952|Subjects will undergo PET imaging using [18F]MNI-952, a PET radioligand for imaging tau.
45645483|NCT03080051|Drug|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a [18F]florbetapir scan to compare distribution of tau in the brain compared to that of [18F]MNI-952.
45645484|NCT02344303|Drug|TRV130|
45645485|NCT02344303|Drug|Moxifloxacin|
45787472|NCT02678182|Drug|Rucaparib|600mg PO twice daily
45919509|NCT00847639|Drug|lenalidomide|"Lenalidomide maintenance therapy will start within 60 to 90 days after allogeneic HCT at a starting dose of 10mg PO once daily.~Dose escalation and de-escalation are performed depending on tolerability of lenalidomide.~The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days)."
45919510|NCT00847600|Dietary Supplement|Pregnenolone|50 mg, caps.
45919511|NCT00847600|Dietary Supplement|Placebo|caps
45919512|NCT00847522|Drug|Fluorescein|Fluorescein is an orange-red powdered compound, designated by the formula C20H12O5, which exhibits intense greenish-yellow fluorescence in alkaline solution. It has been used extensively in surgery and medicine for decades for diagnostic purposes. Topical fluorescein is routinely used in ophthalmology to assess corneal lesions. Intravenous fluorescein is used in vascular surgery to measure vascular perfusion and in skin and melanoma surgery to assess the viability of skin flaps.
45919513|NCT04039139|Behavioral|Mind Body Intervention 1: Mind-Body-Syndrome-Therapy (MBST)|Mind body techniques for Intervention 1 will be taught in lectures and group discussion sessions.
45645486|NCT02344303|Drug|Placebo|
45653080|NCT05120973|Procedure|multispectral imaging|Sentinel node biopsy with Indocyanine Green -Technetium - Nanocolloid + fluorescein
45787473|NCT02678182|Drug|Ramucirumab|ramucirumab 8mg/kg IV day 1 and day 8
45787474|NCT02644070|Device|alveolar bone preservation with mp3|graft with corticocancellous porcine bone and collagen (MP3, Osteobiol, Coazze, Italy)
45787475|NCT02644070|Device|alveolar bone preservation with apatos|graft with cortical porcine bone (Apatos, Osteobiol, Coazze, Italy )
45787476|NCT02644070|Device|stabilization with membrane|socket stabilization with a collagen membrane (Evolution, Osteobiol, Coazze, Italy)
45787477|NCT02620865|Biological|Aldesleukin|Given SC
45787478|NCT02620865|Biological|Antibody Therapy|Given anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV
45787479|NCT02620865|Drug|Fluorouracil|Given IV
45787480|NCT02620865|Drug|Gemcitabine Hydrochloride|Given IV
45787481|NCT02620865|Drug|Irinotecan Hydrochloride|Given IV
45787482|NCT02620865|Other|Laboratory Biomarker Analysis|Correlative studies
45787483|NCT02620865|Drug|Leucovorin Calcium|Given IV
45787484|NCT02620865|Drug|Oxaliplatin|Given IV
45787485|NCT02620865|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
45787486|NCT02620865|Biological|Sargramostim|Given SC
45787487|NCT02595879|Procedure|Biospecimen Collection|Undergo collection of blood samples
45787488|NCT02595879|Radiation|Brachytherapy|Undergo LDR brachytherapy
45787489|NCT02595879|Drug|Cisplatin|Given IV
45787490|NCT02595879|Procedure|Computed Tomography|Undergo FDG-PET/CT
45645487|NCT05011955|Behavioral|Mindfulness, compassion and intercare based Intervention|"The mindfulness based intervention was a short version of the Mindfulness based intercare program (IBAP). The intervention consists of four synchronic group sessions via ZOOM of one hour each, one peer week and home practice. A total of four groups were conducted of 15 students each.~The IBAP program was inspired by first and second generation mindfulness based interventions, such as Mindfulness based cognitive training, Self-Compassion and Cognitive based Compassion training. Also compassionate communication, conservation of resource theory and habits theory.~Each module consists in meditation practices, inquiry and self or group reflections on different topics such as mindfulness, automatic pilot, mind wandering , acceptance, gratitude and compassion, care resources and intercare."
45645488|NCT05011955|Behavioral|Psychoeducational based intervention|Four week, one hour peer week, online group intervention plus home work base on psychoeducation about stress, anxiety, selfcare and effective communication. Plus general curricular intervention. Delivered by psychologist.
45787491|NCT02595879|Radiation|External Beam Radiation Therapy|Undergo pelvic EBRT
45787492|NCT02595879|Other|Fludeoxyglucose F-18|Undergo FDG-PET/CT
45787493|NCT02595879|Radiation|High-Dose Rate Brachytherapy|Undergo HDR brachytherapy
45787494|NCT02595879|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45787495|NCT02595879|Procedure|Magnetic Resonance Imaging|Undergo MRI
45787496|NCT02595879|Other|Pharmacological Study|Correlative studies
45787497|NCT02595879|Procedure|Positron Emission Tomography|Undergo FDG-PET/CT
45787498|NCT02595879|Drug|Triapine|Given IV and PO
45787499|NCT02576574|Drug|Avelumab|Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities.
45787500|NCT02576574|Drug|Pemetrexed|Participants received Pemetrexed 500 milligrams per square meter (mg/m^2) by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
45787501|NCT02576574|Drug|Paclitaxel|Participants received Paclitaxel 200 mg/m^2 by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
45787502|NCT02576574|Drug|Gemcitabine|Participants received Gemcitabine 1250 mg/m^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles when combined with cisplatin of IV injection until disease progression or unacceptable toxicities.
45787503|NCT02576574|Drug|Gemcitabine|Participants received Gemcitabine 1000 mg/m^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with carboplatin until disease progression or unacceptable toxicities.
45919514|NCT04039139|Behavioral|Mind Body Intervention 2|Mind body techniques for Intervention 2 will be taught in lectures and group and/or individual sessions.
45919515|NCT00847483|Drug|latanoprost 0.005% ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
45919516|NCT00847483|Drug|Travoprost 004% sterile ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
45919517|NCT00847483|Drug|Bimatoprost .03% sterile ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
45787504|NCT02576574|Drug|Carboplatin|Participants received Carboplatin area under concentration curve (AUC) 5 mg/mL*min in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with gemcitabine until disease progression or unacceptable toxicities.
45787505|NCT02576574|Drug|Cisplatin|Participants received Cisplatin 75 mg/m^2 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
45787506|NCT02576574|Drug|Carboplatin|Carboplatin AUC 6 mg/mL*min by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with pemetrexed, or paclitaxel until disease progression or unacceptable toxicities.
45787507|NCT02576574|Drug|Avelumab Weekly|Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks.
45787508|NCT02550652|Drug|Mycophenolate Mofetil/Mycophenolic Acid|MMF/MPA will be administered as per schedule specified in the respective arm.
45787509|NCT02550652|Drug|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
45787510|NCT02550652|Other|Placebo|Placebo matching to obinutuzumab will be administered as per schedule specified in the respective arm.
45787511|NCT02550652|Drug|Methylprednisolone|Methylprednisolone IV will be administered as per schedule specified in the respective arm.
45787512|NCT02550652|Drug|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
45787513|NCT02531425|Biological|IT-pIL12-EP|Intratumoral pIL-12 injections followed immediately by electroporation into accessible tumor lesions
45787514|NCT02526498|Radiation|Accelerated Partial Breast Irradiation|Undergo accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy
45787515|NCT02526498|Radiation|High-Dose Rate Brachytherapy|Undergo APBI using HDR brachytherapy
45787516|NCT02526498|Other|Questionnaire Administration|Ancillary studies
45645489|NCT05011955|Other|General curricular intervention|"All participants were offered psychological sessions if a high score on depression or anxiety symptoms were detected. Psychological sessions consists of 4 to 8 sessions with specific objectives and then referral to continue the mental health process according to the student's welfare system.~Participants also have academic breaks of two week per semester, apart from holidays, and academic flexibility in submitting work, attending practical activities and taking exams."
45645490|NCT02335177|Behavioral|Interventional arm|At home patients have both technologies for autonomy (walkers, treadmill) and tailored physical activity program performed with the help of the home carer. Intervention takes 3 months. Assessment at hospital discharge et at 3 months.
45787517|NCT02509988|Dietary Supplement|Study nutritional drink|Study nutritional drink containing a mix of micronutrients, probiotics and myo-inositol.
45787518|NCT02509988|Dietary Supplement|Standard nutritional drink|Standard nutritional drink containing a mix of micronutrients.
45787519|NCT02505477|Drug|N-acetylcysteine|N-acetylcysteine is a safe, widely available supplement currently FDA-approved for treatment of acetaminophen antidote and as a mucolytic. It has effects on glutamate in the brain via the NMDA receptor as well as the glutathione antioxidant system (it is a precursor to glutathione).
45787520|NCT02505477|Other|Treatment as Usual|Treatment for schizophrenia which may include medications, therapy, or other types of treatment as determined by the subject's VA or community psychiatrist or mental health treatment team
45787521|NCT02484885|Other|Hyperpolarized Xenon MRI|Hyperpolarized noble gas imaging using Xenon-129 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 129Xe gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
45787522|NCT02483403|Other|Hyperpolarized Helium-3|Hyperpolarized noble gas imaging using Helium-3 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, Helium-3 gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
45787523|NCT02483403|Device|MRI|
45787524|NCT02446093|Biological|Aglatimagene besadenovec|Three courses of CAN-2409 + prodrug (valacylovir or acyclovir) will be delivered and timed with different phases of therapy: 1) after induction chemotherapy 2) during CR or post-SBRT, and 3) at time of surgery. Up to 2 additional courses of CAN-2409 + prodrug, if feasible, for subjects with disease progression or metastases.
45787525|NCT02446093|Radiation|Chemoradiation|CR will start not more than 2 months after completion of induction chemotherapy. The chemotherapy component of CR may be selected as per institutional standard of care (SOC) and protocols for administration, and may include capecitabine, 5-FU, or gemcitabine. Radiation should consist of a total dose of 45-54 Gy in 1.8-2.0 Gy fractions concurrent with chemotherapy over 3-5.5 weeks.
45787526|NCT02446093|Radiation|Stereotactic body radiation therapy|SBRT should start no more than 2 months after completion of induction chemotherapy. For SBRT, the radiation should consist of a total dose of 25-50 Gy in divided fractions over 1-2 weeks.
45919518|NCT00847444|Drug|Drug-based intervention|Randomization A AA: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicine 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22 AB: 6 cycles of Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² i.v. body surface area i.v. (DC), administered on day 1, repeated on day 22
45919519|NCT00847444|Behavioral|Lifestyle-based Intervention|"All Patients with a Body Mass Index (BMI) of 24 - 40 kg/m² at the time of enrollment will be subsequently randomized as follows:~Second randomization B BA: Lifestyle intervention program to reduce body weight comprising individual weight loss, diet and physical activity goals in the framework of a 2-year standardized and structured telephone and mail-based intervention."
45919520|NCT04034927|Drug|Olaparib|Given PO
45449282|NCT03541798|Procedure|Combined spinal epidural anesthesia|After positioning, a combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia after identification of subarachnoidal space.
45787527|NCT02446093|Procedure|Surgery|Surgical resection should be performed within 8 weeks after completing CR or SBRT.
45787528|NCT02418572|Drug|Testosterone gel|"Patients will receive once daily application of 0.55 gr testosterone gel-TTG (GROUP A) (Testosterone gel 1%; Laboratories Besins International, Paris, France) with a 5.5 mg/d nominal delivery rate of testosterone starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.~TTG will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of TTG or placebo will continue for 35 days (21days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG). Ovarian stimulation will commence the day after last testosterone gel application. (GROUP A)"
45919521|NCT04034927|Biological|Tremelimumab|Given IV
45919522|NCT00847366|Drug|Perifosine|All patients should continue therapy on their current regimen until disease progression. The trial specific intervention is specified in the arms descriptions.
45919523|NCT00847366|Drug|Trastuzumab|Trastuzumab was given 6mg/kg i.v. daily or 2 mg/kg i.v. on day 1, 8 and 15.
45919524|NCT00847366|Drug|Tamoxifen|Endocrine therapy with tamoxifen will be evaluated in combination with perifosine to determine if the combination overcomes resistance to endocrine therapy .
45787529|NCT02418572|Drug|Placebo gel|"Patients will receive once daily application of 0.55 gr of placebo gel from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.~Placebo gel will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of placebo gel will continue for 35 days (21 days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG"
45787530|NCT02411409|Behavioral|HealtheRx|The HealtheRx is a prescription for community self-care resources. It includes a printed list of self-care resources provided to the patient at an ambulatory visit and tailored based on data from the electronic medical record.
45787531|NCT02361944|Drug|Oxygen - normoxia|Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
45787532|NCT02361944|Drug|Oxygen - hyperoxia|Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
45787533|NCT02351141|Other|Hyperpolarized Noble Gas MRI|"Hyperpolarized Helium-3 and/or Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.~Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function."
45787534|NCT02345330|Biological|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
45787535|NCT02345330|Device|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
45787536|NCT02320955|Procedure|Reimplantation of cryoconserved bone flap|A bone flap, which was explanted for decompression of a swollen brain or following severe head trauma and which was cryoconserved in the meantime is reimplanted. This procedure is the gold-standard therapy after decompressive hemicraniectomy and is routinely performed.
45787537|NCT02297256|Procedure|BMAC & Allograft|Use of Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest during posterior lumbar/lumbosacral spinal fusion.
45787538|NCT02297256|Procedure|Iliac Crest Bone Graft|Use of iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion.
45645491|NCT03076931|Procedure|Microlaryngoscopy|Standard clinical procedure, used to perform airway sizing and vocal fold calibration. Controls receive one as a research procedure, while study patients receive one as part of standard of care.
45787539|NCT02281084|Drug|Oral Azacitidine|Oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.
45787540|NCT02281084|Drug|Durvalumab|Durvalumab 1500 mg by IV infusion on Day 1 of each 28 day treatment cycle.
45787541|NCT02272491|Device|ZrO2 (Straumann CARES)|"Straumann CARES Variobase Abutment RN~Straumann CARES Full Contour Zerion HT The monolithic zircona crown (2) will be bonded to the titanium base (1)"
45787542|NCT02272491|Device|PFM crown (Straumann Gold)|Porcelain-fused-to-metal crown consisting of a gold abutment, a gold core, and veneering ceramic
45787543|NCT02054689|Radiation|Fractionated Stereotactic Radiosurgery|SRS SBRT CyberKnife Trilogy True Beam Radiosurgery
45449283|NCT05665803|Procedure|Pediatric rotary files|Mechanical preparation of primary tooth canals with pediatric rotary files
45449284|NCT05665803|Procedure|Manual flare files|Mechanical preparation of primary tooth canals with manual flare files
45645492|NCT03076931|Procedure|Voice Evaluation|Standard clinical procedure that includes aerodynamic, acoustic, and perceptual voice assessments, a pediatric voice handicap index questionnaire, videostroboscopy, and high-speed videoendoscopy. Controls will receive one as a research procedure, while study patients will receive three, one before their airway reconstruction, and two more in the year afterward, as part of standard of care.
45645493|NCT03076931|Procedure|Airway Reconstruction|This includes many types of invasive surgical procedures such as Laryngotracheoplasty to repair a patient's compromised airway. Only study patients will be receiving one, and it will be as part of standard of care unrelated to this study, but the data from surgery and outcomes being pertinent to the study.
45787544|NCT02050113|Device|Custom Made Fenestrated or Branched Stent Graft|The surgeon will place a custom made graft, t-Branch device or modify commercially available stent grafts to match the anatomy of the patient being treated. Small fenestrations (holes) will be made in the stent graft so that additional stents can be inserted through the fenestration and into the blood vessels that lead to the kidneys, intestines or liver. These stents allow blood to flow freely to these organs. If the aneurysm is in the aortic arch stents may be placed in the carotid and subclavian arteries. This surgery is done through small incisions in the groin and sometimes in the upper arm.
45449285|NCT04815616|Radiation|Radiotherapy|Capecitabine with adjuvant radiotherapy in treatment of Early Stages Breast Cancer
45449286|NCT03541642|Behavioral|Enhanced Intervention|Targeted PrEP counseling; targeted written/visual materials; follow up supportive text messages; distribution of PrEP at the syringe exchange
45653081|NCT05729737|Diagnostic Test|Contrast-enhanced ultrasound(CEUS)|CEUS is a quantitative kinetic imaging modality that can assess intravascular blood flow in pancreatic tumors, it is safe and widely used in liver and pancreatic disease.
45787545|NCT01938677|Radiation|Initial Gamma knife radiosurgery|
45787546|NCT01790152|Other|Assessment of Therapy Complications|Ancillary studies
45787547|NCT01790152|Other|Laboratory Biomarker Analysis|Correlative studies
45787548|NCT01790152|Other|Quality-of-Life Assessment|Ancillary studies
45787549|NCT01790152|Other|Questionnaire Administration|Ancillary studies
45787550|NCT01705119|Other|Standing|
45787551|NCT01678638|Procedure|IH repair before NICU discharge|The IH repair is performed prior to NICU discharge (within 1-2 weeks of enrollment and randomization)
45787552|NCT01678638|Procedure|IH repair at 55-60 weeks post-menstrual age|The IH repair will be performed as an outpatient between approximately 55-60 weeks post-menstrual age.
45787553|NCT01665677|Drug|Atorvastatin calcium|40 mg PO daily
45787554|NCT01649531|Procedure|1 Implant|
45787555|NCT01649531|Procedure|2 Implants|
45787556|NCT01530373|Drug|solifenacin|oral solifenacin 5.0 mg daily for 3 weeks
45787557|NCT01530373|Drug|Clonidine|oral clonidine 0.1 mg daily for 3 weeks
45787558|NCT01513343|Behavioral|Parent and child groups focused on self-regulation of eating|
45787559|NCT01499953|Drug|Rivaroxaban|Dose: 10 mg Duration: 45 (±5) days Frequency: once daily Application: oral
45787560|NCT01499953|Drug|Fondaparinux|Fondaparinux Dose: 2.5 mg Duration: 45 (±5) days Frequency: once daily Application: subcutaneous
45787561|NCT01461226|Behavioral|Exercise training|Individualized and progressively increased supervised aerobic exercise program on a daily base (3-4hours per day, hypocaloric diet and psychological guidance
45787562|NCT01461226|Behavioral|Usual care|Nutritional assessment and dietary advice by general practitioner, promotion of sports activities
45787563|NCT01440816|Biological|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
45919525|NCT05321160|Drug|Esketamine|0.5 mg/kg esketamine for induction and 0.25 mg/kg esketamine at the beginning of surgery
45787564|NCT01440816|Device|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
45787565|NCT01348919|Drug|CEP-18770|CEP-18770 will be administered per dose and schedule specified in the arm description.
45787566|NCT01348919|Drug|Lenalidomide|Lenalidomide will be administered per dose and schedule specified in the arm description.
45787567|NCT01348919|Drug|Dexamethasone|Dexamethasone will be administered per dose and schedule specified in the arm description.
45787568|NCT01341054|Other|mouthwash with Chamomilla|The Chamomile recutita mouthwash was administered two times daily for 30 days. 10 mL of this solution was swished around in the mouth for approximately one minute and then expectorated.
45787569|NCT01341054|Other|Standard oral care protocol|The standard protocol at the unit, which comprises mouthwash with chlorhexidine 0,12% twice a day; oral hygiene teaching, recommended at least three times per day and always after meals. For brushing, brushes with extra-soft bristles and non-abrasive toothpaste are used. In case the toothbrush cannot be used due to gingival or oral mucosa bleeding, gauze is used to replace it.
45787570|NCT01333046|Biological|Antigen-Escalation Stage|"Antigen-Escalation Stage~Each patient will receive 2 injections at the same dose (5 x 10^6 cells/m2), 28 days apart, according to the following schedules:~Schedule One:~Day 0: PRAME-specific T cells~Day 28: PRAME- and SSX-specific T cells~Schedule Two:~Day 0: PRAME- and SSX-specific T cells~Day 28: PRAME/SSX/MAGE-specific T cells~Schedule Three:~Day 0: PRAME/SSX/MAGE-specific T cells~Day 28: PRAME/SSX/MAGE/NY-ESO specific T cells~Schedule Four:~Day 0: PRAME/SSX/MAGE/NY-ESO specific T cells~Day 28: PRAME/SSX/MAGE/NY-ESO/Survivin-specific T cells"
45787571|NCT01333046|Biological|Dose-Escalation Stage|"Dose-Escalation Stage~Three different dosing schedules will be evaluated. Each patient will receive 2 injections at the same dose, 14 days apart, according to the following dosing schedules:~DL1: Day 0 and Day 14: 5 x 10^6 cells/m^2~DL2: Day 0 and Day 14: 1 x 10^7 cells/m^2~DL3: Day 0 and Day 14: 2 x 10^7 cells/m^2"
45787572|NCT01333046|Biological|azacytidine and multiTAA T cells Stage|"Up to 15 patients will be treated with 3 cycles of aza at a dose of 75 mg/m2 I.V. administered for 5 days/cycle followed, within 28 days of the last aza dose, by two infusions (on Day 0 and Day 14) of multi-TAA specific CTLs at a fixed dose of 1x10^7 cells/m2. If drug-related myelosuppression occurs aza dosing will be modified, according to the following:~ANC >1,000 or Platelets >50,000 (or any other grade I AE attributable to aza)~Adjustment: None~ANC 500-1000 or Platelets 25,000-50,000 (or any other grade II-III AE attributable to aza)~Adjustment: 50% dose reduction~ANC <500 or any episode of febrile neutropenia or platelets <25,000 or any episode of bleeding attributed to thrombocytopenia (or any other grade IV or higher AE attributable to aza)~Adjustment: Discontinue drug, can proceed with CTL infusion if eligible within 28 days of last aza infusion"
45787573|NCT01333046|Biological|Pediatric multiTAA T cells Stage|Patients < 18 years old will receive two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10^7 cells/m2. We will enroll and infuse at least 5 adolescents on the pediatric arm before opening to all patients.
45787574|NCT01280994|Drug|Hyperpolarized 129Xenon Gas|Hyperpolarized 129Xenon Gas will be administered in multiple doses in volumes that are tailored to the subject's total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
45919526|NCT05321160|Drug|Sevoflurane|5% sevoflurane for induction and 3-4% sevoflurane for maintain
45919527|NCT00847327|Behavioral|Parental Support|The intervention utilizes cognitive behavioral strategies. Session 1 uses relaxation and cognitive reframing and explores parents' responses to the challenges of parenting a child with diabetes. Session 2 focuses on the emotional impact of having a child with diabetes and utilizes problem solving techniques. Session 3 focuses on child behavior and strategies for effective parenting. To facilitate support and community, Session 4 is a group session via conference call to discuss issues related to social support. Session 5 focuses on the impact diabetes has on the family and parents are taught cognitive reframing to help with managing diabetes. Parents are invited to participate in an Internet bulletin board moderated by trial personnel.
45787575|NCT01217970|Drug|Ibudilast 20mg|Ibudilast 20mg BID
45787576|NCT01217970|Drug|Ibudilast 50mg|Ibudilast 50mg BID
45787577|NCT01217970|Drug|Placebo oral tablet|
45787578|NCT00999765|Behavioral|Mindfulness-Based Cognitive Therapy|eight-week (two hours a week) group therapy (8-12 patients per group)
45787579|NCT00996541|Behavioral|STRIVE family intervention|Adolescent and parent attend a 5-session family-oriented cognitive-behavioral intervention aimed at giving runaway youths and their parents the tools to effectively deal with conflict.
45787580|NCT00979238|Genetic|Gene Transfer|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant
45787581|NCT00979238|Drug|scAAV2/8-LP1-hFIXco|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant.
45787582|NCT00968500|Behavioral|Questionnaires/Interviews|"Prior to the interview, the measure of prolonged grief disorder symptoms, the PG-13, will be re-administered to participants as a quality assurance check. We will administer 7 self-report measures, which participants can complete in our office, at home, or via telephone, depending on their preferences. These questionnaires should take approximately 75 to 80 minutes to complete. If you are asked to take part in the in-depth interview and you choose to take part, the interview that will take approximately 60 to 90 minutes to complete, depending on the length of the responses to the questions asked.~The participant may also be asked if they would be willing to fill out an additional questionnaire about parents' thoughts on the most appropriate timing for raising the topic of a postmortem examination and factors that are important to include in discussions. Despite its importance, autopsy is often not discussed with parents whose child is dying from cancer."
45787583|NCT00966381|Other|Exercise and weight loss intervention|randomized control trial, stratified by parity
45787584|NCT00082745|Other|Laboratory Biomarker Analysis|Correlative studies
45787585|NCT00082745|Other|Questionnaire Administration|Ancillary studies
45787586|NCT02431806|Drug|Placebo|Matched over-encapsulated placebo capsules administered orally on Day 1 to Week 8.
45787587|NCT02431806|Drug|Levomilnacipran|Over-encapsulated levomilnacipran ER capsules administered orally on Day 1 to Week 8.
45787588|NCT02431806|Drug|Fluoxetine|Over-encapsulated fluoxetine tablets administered orally on Day 1 to Week 8.
45787589|NCT05247801|Behavioral|Psychoeducational intervention for safe medication use at home + Medication dosing device|"The intervention is yet to be defined. Psychoeducational intervention based on virtual reality, demonstrations, and psychoeducational content using virtual reality. Contents:~Most frequent medication errors at home. Approaches to risk management in the home. Correct use of the most common medications in different patient profiles. Strategies to avoid medication errors. Guidance to alleviate the burden of responsibility suffered by women as a result of the gender bias derived from assuming the caregiver role.~Other."
45787590|NCT05247801|Device|Medication dosing device|Use of medication dosing device.
45787591|NCT01209260|Device|Radiofrequency energy needle|Radiofrequency energy needle for transseptal access
45787592|NCT01209260|Device|Mechanical Needle|Mechanical needle for transseptal access
45787593|NCT05159193|Drug|pegylated liposomal doxorubicin (PLD)|pegylated liposomal doxorubicin (PLD) 30 mg/m^2, i.v., d1, q3w
45787594|NCT05159193|Drug|cyclophosphamide (C)|cyclophosphamide (C) 600 mg/m^2, i.v., d1, q3w
45787595|NCT05159193|Drug|trastuzumab (H)|trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w
45787596|NCT05159193|Drug|pertuzumab (P)|pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w
45787597|NCT05159193|Drug|docetaxel (T)|docetaxel (T) 90~100 mg/m^2, i.v., d1, q3w
45787598|NCT05159193|Drug|docetaxel (T)|docetaxel (T) 75 mg/m^2, i.v., d1, q3w
45449287|NCT03541642|Behavioral|Basic Intervention|General messaging from medical personnel; reminder text messages; distribution of PrEP at the syringe exchange
45787599|NCT05159193|Drug|carboplatin (Cb)|carboplatin (Cb) AUC 6, i.v., d1, q3w
45787600|NCT05159193|Drug|trastuzumab (H)|trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w
45787601|NCT05159193|Drug|pertuzumab (P)|pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w
45787602|NCT01210820|Device|iFS™ Femtosecond Laser System|intrastromal arcuate cuts made with iFS™ femtosecond laser
45787603|NCT04916340|Behavioral|Muscular Strength Training Group|"Week 1 3 days/week Bench Press - 1 set at 80% of one repetition maximum~(1RM) Bent Over Row - 1 set at 80% 1RM Back Squat - 1 set at 80% 1RM Romanian Deadlift - 1 set at 80% 1RM~Week 2 3 days/week Bench Press - 2 sets at 80% 1RM Bent Over Row - 2 sets at 80% 1RM Back Squat - 2 sets at 80% 1RM Romanian Deadlift - 2 sets at 80% 1RM~Weeks 3-10 3 days/week Bench Press - 3 sets at 80% 1RM Bent Over Row - 3 sets at 80% 1RM Back Squat - 3 sets at 80% 1RM Romanian Deadlift - 3 sets at 80% 1RM"
45787604|NCT04916340|Behavioral|Muscular Fitness Training Group|"Week 1 3 days/week Bench Press - 1 set at 65% 1RM Bent Over Row - 1 set at 65% 1RM Back Squat - 1 set at 65% 1RM Romanian Deadlift - 1 set at 65% 1RM~Week 2 3 days/week Bench Press - 2 sets at 65% 1RM Bent Over Row - 2 sets at 65% 1RM Back Squat - 2 sets at 65% 1RM Romanian Deadlift - 2 sets at 65% 1RM~Weeks 3-10 3 days/week Bench Press - 3 sets at 65% 1RM Bent Over Row - 3 sets at 65% 1RM Back Squat - 3 sets at 65% 1RM Romanian Deadlift - 3 sets at 65% 1RM"
45787605|NCT05220813|Drug|Lidocaine|local infiltration by lidocaine in the surgical site
45787606|NCT05220813|Drug|Bupivacain|44patients will receive bupivacaine in ilioinguinal & iliohypogastric nerve blocks
45787607|NCT01211600|Other|Staples|Interrupted Ethicon Staples
45787608|NCT01211600|Other|Suture|Subcuticular continuous suture (4-0 Monocryl Plus on PS2 needle or 4-0 Vicryl Plus on FS2 or PS2 needle)
45787609|NCT01650246|Drug|lesinurad|Tablets, 400 mg QD
45449288|NCT03635775|Device|Active tDCS|Low-level (1.5 milliampere) current delivered to the scalp using saline-soaked sponges.
45449289|NCT03635775|Device|Sham tDCS|Sham-setting--no electrical current delivered.
45449290|NCT02150122|Dietary Supplement|Vitamin D3|
45787610|NCT01212302|Drug|Optimizing ASA and clopidogrel treatment|"ASA 100 mg, ASA 300 mg, ASA 500 mg~Clopidogrel 75 mg, Clopidogrel 150 mg, Ticlopidine 2x 250 mg, Prasugrel 10 mg. Intervention List:~In the case of clopidogrel low-response, the maintenance dose was doubled (repeated loading dose followed by 150 mg daily), and when still ineffective ticlopidine or prasugrel, if available and not contraindicated, were used. ASA low-responders were treated by increasing the dose to 300 mg in a first step or to 500 mg ASA when the first modification was not sufficient."
45787611|NCT05110677|Device|Multispectral Optoacoustic Tomography (MSOT)|non-invasive transcutaneous imaging of subcellular muscle components
45645494|NCT02339467|Other|GO-OUT program|Participants attend the walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes. Each session includes a 10-minute warm-up and cool down, and a planned walk in an outdoor community environment. Continuous walking exercise will gradually increase from 10 to 60 minutes, as well increase difficulty. Balance exercises will be included in the warmup and walk. There will be a variety of surfaces and environmental factors to challenge the participants, e.g., carrying objects, diverting the walker's attention, crossing at a light, walking up and down curbs, slopes, and level or uneven surfaces. Supervision will be on a 1:3 facilitator-to-participant ratio to allow for assistance and individualization of the intervention where necessary.
45653082|NCT05179629|Drug|M TAPA block|Under aseptic conditions, a high frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with totally 30 ml (15 ml for each side) of %0,25 bupivacaine.
45787612|NCT05107479|Behavioral|COVID-19 Vaccine IVR Training|The intervention consists of 5 interactive voice response (IVR) modules conveying information about COVID-19 vaccines and vaccine administration best practices. Module topics include the following: 1) the importance of COVID-19 vaccines and recipient eligibility, 2) overview of and differences between approved COVID-19 vaccines , 3) surveillance of adverse vaccine events, 4) organizing a vaccination site, and safe storage and handling COVID-19 vaccines, and 5) micro planning and communication strategies for COVID-19 vaccination efforts. The training will be offered in five local languages: French, Lingala, Swahili, Kikongo, and Tshiluba.
45787613|NCT05107479|Behavioral|Control Condition|The control arm will receive the COVID-19 Vaccine IVR Training after an estimated month-long delay. The control arm will be told upon completion of the baseline survey that the training will commence at a later estimated date and will not receive any additional information until the treatment group completes training.
45787614|NCT03009812|Procedure|Longitudinal uterine incision|
45787615|NCT03009812|Procedure|Transverse uterine incision|
45787616|NCT04908072|Device|Orbis-FundamentalVR MSICS Simulator|Cataract surgery training device, using virtual reality software combined with existing gaming technology for simulated surgery
45787617|NCT01284296|Drug|Lidocaine digital block|One dose of lidocaine 2% injected locally into one finger (2 mls total)
45787618|NCT01284296|Device|Masimo SpHb continuous hemoglobin monitor|Masimo SpHb continuous hemoglobin monitor
45787619|NCT00364143|Drug|IHL-305 (irinotecan liposome injection)|
45787620|NCT01285076|Other|Other: Retrospective chart review; one participant encounter visit.|Participants will be selected based on medical record review in the office of their treating cardiologist, nephrologist, neurologist, or family practice doctor. Participants will have one encounter visit to fill out questionnaires and have a blood draw and recording of weight, blood pressure and waist circumference.
45787621|NCT01652664|Drug|Travoprost 0.004% PQ ophthalmic solution|
45787622|NCT01652664|Drug|Timolol, 0.5% or 0.25% ophthalmic solution|Patients 2 months to < 3 years of age received 0.25%
45787623|NCT01652664|Drug|Travoprost Vehicle|Inactive ingredients used to maintain masking
45787624|NCT04308759|Other|Experimental Smoking Cessation Program|Participate in Quitbot experimental cessation program
45787625|NCT04308759|Other|Control Smoking Cessation Program|Participate in Quitbot control cessation program
45787626|NCT04055649|Drug|Akt/ERK Inhibitor ONC201|Given orally (PO)
45919528|NCT00847327|Behavioral|Diabetes Education|The education comparison group also participates in 5 sessions across 9 weeks. This group provides educational and resource support that is specific to managing diabetes in young children. Education topics include blood glucose monitoring, nutrition, and physical activity. Print materials are provided to participants and intervention sessions focus on talking points raised in these reading materials.
45787627|NCT04055649|Drug|Paclitaxel|Given IV
45787628|NCT04055649|Other|Questionnaire Administration|Ancillary studies
45787629|NCT04899492|Behavioral|Motivational Interviewing (MI)|1 to 3 Motivational Interviewing (MI) should be performed after randomization by a psychotherapist
45787630|NCT04899492|Behavioral|Cognitive Behavioural Therapy (CBT)|6 Cognitive Behavioural Therapy (CBT) sessions should be performed after motivational interviewing up to 6 months by a psychotherapist
45787631|NCT04899492|Behavioral|Hypnotherapy|About 3 Hypnotherapy sessions should be performed after motivational interviewing up to 6 months by a hypnotherapist
45787632|NCT04899492|Drug|Nicotine Replacement Therapy (NRT)|All patients will receive Nicotine Replacement Therapy (NRT) from randomization up to 6 months
45787633|NCT01286324|Dietary Supplement|Chamomile High Grade Extract|three tablets each (equivalent to 7.5 g of dried herb) p.o. twice daily for 28 days
45449291|NCT03731871|Diagnostic Test|Ultrasonography|ultrasound to evaluate parameters of fetal maturity during pregnancy
45787634|NCT01286324|Drug|Placebo Tablet|
45787635|NCT00364221|Drug|Rosiglitazone|
45787636|NCT01286402|Drug|Bupropion SR|"150mg, taken orally, taken daily for the 1st 3 days~300mg, taken orally, taken daily for the rest of the 8 weeks of drug treatment"
45787637|NCT01286402|Other|Placebo|-Avicel PH 302, Emcocel 50M, Cab-O-Sil M5P, Magnesium Stearate (appearance, taste, and dosing instructions were identical to the bupropion group), i.e., 1 pill orally, taken daily for the 1st 3 days; 2 pills, taken orally, taken daily for the rest of the 8 weeks of drug treatment
45787638|NCT03940677|Procedure|Brain MRI|3 Tesla brain MRI for structural and perfusion evaluation, resting state analysis and functional MRI
45787639|NCT03940677|Procedure|TMS-EEG|Transcranial magnetic stimulation (TMS) coupled with electroencephalogram (EEG) study
45787640|NCT03940677|Behavioral|Behavioral and cognitive battery|Emotional, attentional and behavioral assessment using predefine scales and measures
45787641|NCT03940677|Other|Clinical evaluation and clinical scales|Neurological evaluation, ophthalmologic assessement, Montreal cognitive assessment (MoCA), movement disorder society (MDS)- UPDRS
45787642|NCT01222832|Drug|Bacitracin|Bacitracin soaked nasopore sponge
45919529|NCT00847288|Other|Monthly Review Arm|Monthly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
45919530|NCT00847288|Other|Quarterly Review Arm|Quarterly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
45787643|NCT01286870|Device|Mentor Becker 25 Expander/Breast Implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
45787644|NCT01286870|Device|Mentor Becker 50 Expander/Breast Implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
45787645|NCT04297605|Drug|Pembrolizumab|Pembrolizumab 200 mg
45787646|NCT04297605|Other|Pemetrexed (Chemotherapy)|500 mg/m2 day 1 of 21 day cycle (for non-squamous only)
45787647|NCT04297605|Other|Nab-paclitaxel (Chemotherapy)|100 mg/m2 days 1,8 of 21 day cycle x 4 cycles
45787648|NCT02379390|Drug|Cabazitaxel XRP6258|
45787649|NCT02379390|Drug|Ezalutamide|
45787650|NCT02379390|Drug|Abiraterone acetate|
45787651|NCT02379390|Drug|Prednisone|
45449292|NCT03610581|Biological|Ad26.HPV16|Participants will receive Ad26.HPV16 as a solution for intramuscular injection.
45645495|NCT02339467|Other|Task-oriented outdoor walking workshop|The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
45645496|NCT02343991|Device|Transcranial ExABlate|MR Guided Focused Ultrasound
45787652|NCT04742517|Drug|ASP1128|Intravenous
45787653|NCT04742517|Drug|Placebo|Intravenous
45787654|NCT02379078|Other|Shared decision-making aid|The IP-SDM toolkit consists of an online shared decision-making aid, 1-page provider enabler, a provider training video,1-page patient enabler, and a patient training video.
45787655|NCT02379078|Other|Generic hard copy diabetes resources|A hard copy of the executive summary of the CDA CPG and postcard outlining online resources, CDA patient education pamphlet
45787656|NCT02379078|Other|Generic online diabetes resources|Provider- and patient-directed guideline dissemination tools (not incorporating SDM) publicly accessible from the CDA website
45787657|NCT04708197|Device|rTMS (repetitive transcranial magnetic stimulation )|applying high frequency TMS over the damaged hemisphere in chronic post stroke aphasic patients
45787658|NCT04290663|Drug|Systematic RAI-treatment|Administration of 3.7 GBq (100 mCi) or 1,1 GBq (30 mCi) of I131 at the choice of the investigator after rhTSH-stimulation
45787659|NCT04290663|Other|Decision of RAI-treatment guided by a post-operative assessment|"The decision-making for the administration of an adapted RAI-treatment will be taken according to the following criteria:~No RAI treatment if Tg/LT4 ≤1 ng/mL and rhTSH-sTg ≤10 ng/mL and normal diagnostic RAI-scintigraphy~1.1 GBq after rhTSH if Tg/LT4>1 ng/mL or rhTSH-sTg>10 ng/mL and normal diagnostic RAI-scintigraphy.~3.7 GBq after rhTSH if metastatic lymph-node(s) detected on diagnostic RAI-scintigraphy without distant metastasis~3.7 GBq after hormone withdrawal if distant metastasis detected on diagnostic RAI-scintigraphy or on the hybrid CT scan of the SPECT-CT acquisition"
45787660|NCT04932915|Drug|Niclosamide|Niclosamide is a broad spectrum, host targeting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide solution is administered directly to the nasal cavity via a nasal spray.
45787661|NCT04932915|Drug|Placebo|The placebo formulation contains purified water, sodium chloride as common isotonizing agent and the FAO/WHO approved colorant FD&C Red 40 to match the red-orange colour of the active solution. The solution is administered directly to the nasal cavity via a nasal spray.
45787662|NCT04926051|Drug|BMS-986172|Specified dose on specified days
45787663|NCT04926051|Other|Placebo|Specified dose on specified days
45787664|NCT01223378|Drug|BOL-303259-X|ophthalmic solution, various concentrations, once daily (QD) 28 days
46071234|NCT00819949|Device|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs through position controlled trajectories that mimic normal human gait patterns. This is accomplished by utilizing high quality computer-controlled motors that are precisely synchronized with the speed of the treadmill. The hip and knee joint angles are controlled in real time by software to achieve kinematically correct stepping behaviors. Each of the four motor-driven joints is individually controlled to correspond precisely to the desired joint angle trajectories. This system assures a precise match between the speed of the limb trajectory and the treadmill. In addition, sensors in the motors provide an indirect indicator of the amount of effort the patient is generating to achieve walking in an upright posture.
45787665|NCT01223378|Drug|Latanoprost|0.005% ophthalmic solution, QD 28 days
45787666|NCT04708119|Procedure|The follicular tissues were also excised after tooth extraction.|The follicular tissues were also excised after tooth extraction. Soft tissue samples taken during surgical removal of ILTM were evaluated in the department of pathology.
45449293|NCT03610581|Biological|Ad26.HPV18|Participants will receive Ad26.HPV18 as a solution for intramuscular injection.
45449294|NCT03610581|Biological|MVA.HPV16/18|Participants will receive MVA.HPV16/18 as a solution for intramuscular injection.
45787667|NCT04844307|Other|Shorter duration higher frequency PT|The standard PT session (30 mins) will be divided into two 15 minute sessions spread out during the day. Therefore, the total number of minutes of PT will not vary from the standard.
45449295|NCT03610581|Biological|Placebo|Participants will receive matched placebo as a solution for intramuscular injection.
45787668|NCT04844307|Other|Standard PT|The standard PT session is 30 minutes once daily. It routinely involves exercises designed to strengthen and increase mobility of the patient such as bed mobility, transfers, and ambulation. In this study group there will be no variation from this standard treatment.
45449296|NCT03731793|Biological|Non-Animal Chondroitin Sulphate|Mythocondro® is an ichthyic-like chondroitin sulfate produced by chemical sulfation of a non-sulfated chondroitin backbone obtained by thermo-acid hydrolysis of the capsular polysaccharide naturally produced by an Escherichia coli strain.
45787669|NCT04285983|Drug|Trelagliptin|Trelagliptin tablets
45787670|NCT01224236|Drug|Iron Supplement|2 mg/kg/day elemental iron as multivitamin with iron solution
45787671|NCT01224236|Drug|control|multivitamin solution without iron
45787672|NCT03780075|Drug|1.11GBq of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 1.11GBq (30 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
45449297|NCT03731793|Other|Placebo|Placebo
45449298|NCT03610269|Device|INVSENSOR00026 (Pulse CO-Oximeter and sensor)|Noninvasive Pulse CO-Oximeter and sensor that measures noninvasive hemoglobin (SpHb)
45449299|NCT03728907|Device|Hearing aid fitting technique- audiologist or user-adjusted|See information under 'arm' description
45787673|NCT03780075|Drug|2.00 GBq of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 2.00 GBq (54 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
45787674|NCT03780075|Drug|3.70GBq of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 3.70GBq (100 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
45787675|NCT00361491|Drug|SSR149415|
45787676|NCT01224626|Drug|Zyvox (linezolid)|Patients should be treated with Zyvox (linezolid) 600 mg every twelve hours.
45787677|NCT03700437|Other|Fasting-Mimicking Diet|Chemo-immunotherapy + FMD (fast-mimicking diet)
45787678|NCT01225250|Device|Polydioxanone (PDS) plates|0.5 mm PDS Flexible Plate made of poly-p-dioxanone, an aliphatic polyester which is manufactured by polymerization of the monomer p-dioxanone. Polydioxanone is a resorbable material degraded by hydrolysis and has been successfully used for bone discontinuities and septal reconstruction.
45787679|NCT01225250|Procedure|Caudal septal extension graft performed through endonasal rhinoplasty|The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
45787680|NCT01225250|Procedure|Caudal septal extension graft performed through endonasal rhinoplasty|The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
45787681|NCT01289522|Biological|cetuximab IV|"Cetuximab 400 mg/m² over 120 minutes on day 1 of cycle 1 only.~Cetuximab dose will be 250 mg/m² IV over 60 minutes weekly on subsequent administrations during the four cycles of chemotherapy.~Cetuximab dose will be 500mg/m2 IV every 2 weeks during the maintenance therapy.~Drug: Cisplatin IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles~Drug: Docetaxel IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles~G-CSF support with lenograstim 150 microg./m2/day is delivered after each cycle of chemotherapy."
45787682|NCT01289522|Other|Biopsies|No intervention, only biopsy for translational project.
45787683|NCT03547245|Biological|eOD-GT8 60mer + AS01B/ DPBS sucrose/IM|20 μg
45787684|NCT03547245|Biological|eOD-GT8 60mer + AS01B/ DPBS sucrose/IM|100 μg
45787685|NCT03547245|Biological|DPBS Sucrose|Placebo
45787686|NCT01226420|Drug|Alefacept|Given intravenously Days 1 and 4 of Week 1, then subcutaneously once weekly for Weeks 2-12
45787687|NCT05440227|Drug|PG2 Lyo. Injection 500mg|PG2 Lyo. Injection 500mg (reconstituted with 0.9% normal saline 500ml) will be administered weekly for 8 weeks.
45787688|NCT05440227|Drug|Placebo 0.9% normal saline|0.9% normal saline 500ml will be administered weekly for 8 weeks.
46071235|NCT00824239|Procedure|Intermittent sedation|Patients under intermittent sedation stay without any continuous sedation since intubation and/or admission but receive analgesics as needed and sedatives only when agitated (SAS of 5 or more).
45449300|NCT03728829|Drug|Trastuzumab+TP|Trastuzumab (4 mg/kg loading dose, then 2 mg/kg I.V., every week, totally 17 weeks (6 cycles)) combined with TC neoadjuvant chemotherapy (Docetaxel 75 mg/m2 I.V., day 1, Carboplatin 400 mg/kg, I.V., day 2, every 3 weeks, totally 6 cycles).
45449301|NCT00121667|Drug|Saxagliptin + Metformin|Tablets, Oral, 2.5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
45449302|NCT00121667|Drug|Saxagliptin + Metformin|Tablets, Oral, 5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
45449303|NCT00121667|Drug|Saxagliptin + Metformin|Tablets, Oral, 10 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
45449304|NCT00121667|Drug|Placebo + Metformin|Tablets, Oral, 0 mg, Once daily (24 weeks ST, 42 months LT)
45449305|NCT00121667|Drug|Pioglitazone|Tablets, Oral, 15 - 45 mg (as needed for rescue)
45449306|NCT02954601|Drug|ORMD-0801 (qd)|Dose 1 = ORMD-0801 (qd)
45449307|NCT02954601|Drug|ORMD-0801 (bid)|Dose 2 = ORMD-0801 (bid)
45449308|NCT02954601|Drug|ORMD-0801 (tid)|Dose 3 = ORMD-0801 (tid)
45449309|NCT02954601|Other|Placebo|fish oil placebo
45449310|NCT03633903|Behavioral|Mindfulness|Mindfulness based stress reduction adapted for teens is a mindfulness intervention designed to aid adolescents in understanding stress, better coping with stress, and promoting resilience
45449311|NCT03728751|Procedure|Dry needling|Paravertebral dry needling C7-T4. Total of 8 needles.
45449312|NCT03607695|Other|Gait training|Walking on a treadmill and receiving audio cues to improve gait
45787689|NCT04743453|Drug|Dapagliflozin|Dapagliflozin 10 mg: Study drug will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.
46071236|NCT00824239|Procedure|Daily interruption of sedation|Patients under daily interruption of sedation stay on continuous sedation with midazolam and fentanyl and are submitted to a daily interruption of sedation to a neurological evaluation until they reach a SAS of 4 or more, then continuous sedation is re-started in the half previous dosage.
45645497|NCT02339311|Other|Educational intervention of Lifestyle and patient activation in diabetics|Participants underwent a one hour group didactic session led by Community Health Representatives (CHRs) who subsequently carried out monthly home-based educational interventions to encourage healthy lifestyles, including diet, exercise, and alcohol and cigarette avoidance until follow up at 6 months, when clinical phenotyping and the PAM survey were repeated.
45645498|NCT02334943|Biological|Blood test|Blood test
45787690|NCT04743453|Drug|Placebo|Placebo will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.
45787691|NCT04678557|Combination Product|VC-01 Combination Product|PEC-01 cells loaded into an Encaptra Drug Delivery System
45787692|NCT04274517|Other|Sterile Water|1L of sterile water used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
45787693|NCT04274517|Other|3.5% Betadine|1L of 3.5% betadine used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
45787694|NCT04274517|Other|0.05% Chlorhexidine Gluconate|1L of clorhexidine gluconate used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
45787695|NCT00365001|Drug|tocilizumab [RoActemra/Actemra]|10mg/kg iv on day 8
45787696|NCT00365001|Drug|Methotrexate|10-25mg po/week
45787697|NCT00365001|Drug|Simvastatin|40mg po on days 1, 15 and 43
45787698|NCT04741971|Dietary Supplement|Probiotics group|Will give Probiotics with Vitamin D3 one drop per day for 90 days
45787699|NCT04741971|Dietary Supplement|Non-probiotics group|Will give Vitamin D3 five drops per day for 90 days
45919531|NCT04009343|Drug|Artemether-lumefantrine|Children will receive artemether-lumefantrine (20/120 mg) dosed according to weight (5 to <15 kg: 1 tablet, 15 to <25 kg: 2 tablets) at 0, 8, 24, 36, 48 and 60 hours. Medications will be administered according to the manufacturer's instructions.
45645499|NCT02335021|Dietary Supplement|Sucralose|2 packets per 12 fl oz
45787700|NCT01289912|Drug|RAD001|"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast."
45787701|NCT01289912|Drug|Placebo|"Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast."
45787702|NCT03192345|Biological|SAR439459|"Pharmaceutical form: powder for solution for infusion~Route of administration: intravenous infusion"
45787703|NCT03192345|Drug|Cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
45787704|NCT05440071|Device|JX- XFINE lead|Pacemaker subjects implanted with one JX - XFINE passive pacing lead
46071237|NCT04777760|Drug|one dose of surfactant replacement|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant
45919532|NCT04009343|Drug|Dihydroartemisinin-piperaquine|Children will receive dihydroartemisinin-piperaquine (40/320 mg) dosed according to weight (5 to <8 kg: 1/2 tablet, 8 to <11 kg: 3/4 tablet, 11 to <17 kg: 1 tablet, 17 to <25 kg: 1 1/2 tablets) at 0, 24, and 48 hours. Medications will be administered according to the manufacturer's instructions.
45919533|NCT00847249|Drug|AZD9164|Each subject will receive a single-dose starting dose 4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
45645500|NCT02335021|Dietary Supplement|Sucrose|equisweet to sucralose
45645501|NCT02335021|Dietary Supplement|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
45645502|NCT02335021|Dietary Supplement|Sucralose + Sucrose|half the amount of sucralose plus equicaloric sucrose
45787705|NCT04392453|Device|Robotic therapy|The treatment with the robot Icone will include 30 sessions, each session lasting 45 minutes, with a frequency from three to five times a week. The treatment will be provided in the patient's room. Patients will execute upper limb movement involving elbow flexion-extension, shoulder protraction-retraction, internal-external rotation, flexion-extension, and abduction-adduction. Visual and auditory feedback will be provided during the tasks. The exercises will train both motor and cognitive functions.
45919534|NCT00847249|Drug|Placebo|Each subject will receive a single-dose.
45919535|NCT03969641|Biological|Quadrivalent Recombinant Influenza Vaccine|The first recombinant inactivated influenza vaccine (RIV) using an insect baculovirus expression system and recombinant DNA technology
45919536|NCT03969641|Biological|Quadrivalent Inactivated Influenza Vaccine|Standard inactivated influenza vaccine (IIV) manufactured involving the use of embryonated hen eggs.
45919537|NCT00847210|Drug|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to 7 days.
45919538|NCT00847210|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 7 days.
45645503|NCT02344069|Drug|Fibrinogen|Human fibrinogen concentrate as a injection
45787706|NCT04742127|Diagnostic Test|Single surgical debridement|To describe the clinical factors associated with failure of a single surgical debridement in patients with septic arthritis of the native hip.
45919539|NCT05318196|Biological|Biological samples collection|"SOT patients: samples will be collected at the time of the protocol follow-up visit (registration on the transplant list, on the day of the transplantation, and then at day 15, month 1-3-6-9-12 and then annually, as well as if complications or therapeutic modifications).~Dialysis patients: at the start of the dialysis and then at M3, M12, and if complications or modification of the dialysis protocol.~Non-dialysis or cancer patients: the sampling frequency will be individualized according to the pathology studied (acute or chronic) and the purpose of the sampling (diagnostic, mechanistic, prediction, evaluation of the therapeutic response). Samples for diagnostic and mechanistic purposes will be taken only once. Samples for prognostic purposes will be taken at regular intervals, adapted to the natural history of the disease while respecting the maximum volume of blood samples defined by the French law. Samples will be collected during a sampling performed as part of routine care."
45919540|NCT00847171|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|"Day 0 : Allogeneic GM-CSF-secreting Breast Cancer Vaccine administered as:~12 intradermal injections of a divided total dose of 5 x108 cells."
45919541|NCT00847171|Biological|trastuzumab|"Patient HAS received prior Trastuzumab within the last two weeks, give Trastuzumab 2 mg/kg weekly on Day -1 for 5 weeks.~Patient has NOT received Trastuzumab within the last two weeks, give On Cycle 1, Day -1 ONLY, Loading dose 4 mg/kg"
45919542|NCT00847171|Drug|cyclophosphamide|Cyclophosphamide 200mg/m2 IV in NS 100ml over 30 minutes on Day -1 ONLY. Note: there are no dose modifications for Cyclophosphamide.
45919543|NCT00847171|Other|flow cytometry|Samples will be analyzed by flow cytometry using Cell Quest software
45919544|NCT00847171|Other|immunoenzyme technique|
45919545|NCT00847171|Other|immunohistochemistry staining method|Measuring Immune Priming In Vivo By Vaccine Site Biopsies
45919546|NCT00847171|Other|laboratory biomarker analysis|
45919547|NCT00847171|Other|pharmacological study|
45919548|NCT00847171|Procedure|biopsy|skin biopsy to be performed on day 3 and day 7 for cycle 1 and 3 only
45449313|NCT03732573|Behavioral|Text messages|Text messages conveying 3 specific behaviour change techniques
45645504|NCT02344069|Drug|Placebo|Saline 0.9% as a injection
45645505|NCT02343913|Device|PAC checklist|
45645506|NCT02334475|Biological|Platelet Rich Plasma|single intraarticular injection of 3 ml of leukocyte free platelet rich plasma with 0.5 ml of calcium chloride(total volume 3.5 ml)
45645507|NCT02334475|Biological|methylprednisolone|single injection 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml)
45653083|NCT05613491|Drug|Intranasal insulin|Put insulin injection into nasal special drug delivery device.Before anesthesia induction, give the first insulin nasal spray, once per hour, 20 IU each time, until the end of the operation
45787707|NCT03069963|Drug|Z0063|"Pharmaceutical form: chewable tablets~Route of administration: oral"
45787708|NCT03069963|Drug|Gaviscon|"Pharmaceutical form: chewable tablets~Route of administration: oral"
45787709|NCT03000855|Procedure|EUS-guided choledocho-duodenostomy|"The CBD would be identified by a linear echoendoscope and a suitable puncture site in the bulb of the duodenum would be located. The common bile duct would be punctured with a 19-gauge needle and the position would be confirmed by aspiration of bile and contrast injection. A 0.025 or 0.035 guide wire would be passed through the needle in to the CBD. A fully covered metal stent would then be inserted after track dilation."
45919549|NCT05314608|Combination Product|IntraOsseous BioPlasty® (IOBP®) Surgical Technique into the knee|Injection of a biologic mixture (BMC and allograft) into the subchondral bone lesion
45919550|NCT03940586|Drug|Letermovir oral granules|Granules administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
45919551|NCT03940586|Drug|Letermovir tablet|Tablet administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
45787710|NCT03000855|Procedure|Endoscopic retrograde cholangiopancreatography with covered metallic stent|After cannulation of the CBD, a cholangiography would be performed to assess the diameter of the CBD, the length and position of the biliary stricture. The endoscopist would decide on the appropriate size of SEMS to be placed. The stents should be visible from the duodenal lumen after deployment.
45787711|NCT00361647|Procedure|Diagnostic screening for occult malignancy|
45787712|NCT02835261|Other|Sleep Restriction|Mild sleep restriction (-1.5 h/night) over a period of 6 weeks
45787713|NCT01227434|Drug|PD 0332991 (pre-surgery)|PD 0332991 for 7 days prior to an indicated, intended surgical resection for progression
45787714|NCT01227434|Drug|PD 0332991|PD 0332991 daily for 21 consecutive days followed by a 7 day break off therapy, repeating cycles
45787715|NCT01227434|Procedure|Resection as clinical care|Indicated, intended, surgical resection as clinical care
45787716|NCT01714739|Drug|Lirilumab|Specified dose on specified days.
45787717|NCT01714739|Drug|Nivolumab|Specified dose on specified days.
45787718|NCT01714739|Drug|Ipilimumab|Specified dose on specified days.
45787719|NCT01290536|Device|Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere)|Administration of Yttrium-90 glass microspheres (TheraSphere) into the hepatic artery
45787720|NCT05440383|Drug|KLH-2109|Oral administration
45787721|NCT05440383|Drug|Leuprorelin|Subcutaneous administration
45787722|NCT01290614|Other|Pharmacist based QI program|Per a study protocol, the pharmacist will call each subject (who has not opted out) and discuss their CKD. In brief, the pharmacist will introduce themselves, ask the subject if they have time to discuss their medical care, inform the subject that they have CKD, briefly discuss CKD, ask the subject if they can come for labs, discuss hypertension management as appropriate, and answer any questions. In addition, for subjects with poorly controlled hypertension, the study pharmacist will arrange for a nutrition consult for a low sodium diet, a mainstay of hypertension management in patients with CKD. Finally, for patients with advanced CKD (GFR <30 mL/min per 1.73 m2) who are not seeing a nephrologist, the study pharmacist will arrange for a nephrology outpatient appointment to assess the need for placement of access for renal replacement therapy.
45787723|NCT01290614|Other|Usual Care|"Patients in the control arm will continue to receive usual care from their VA providers."
45787724|NCT02377479|Drug|Clomiphene|Taken for controlled ovarian hyperstimulation.
45787725|NCT02377479|Drug|Letrozole|Taken for controlled ovarian hyperstimulation
45787726|NCT02065011|Drug|Blood draw for the laboratory assessment|
45787727|NCT05459207|Other|Moderate Fat Meal|A liquid meal consisting of powdered protein and complex carbohydrates blended with coconut oil and peanut butter in ratios required to achieve the desired calorie and macronutrient distributions of a normal/moderate fat meal.
45787728|NCT05459207|Other|High Fat Meal|A liquid meal consisting of powdered protein and complex carbohydrates blended with coconut oil and peanut butter in ratios required to achieve the desired calorie and macronutrient distributions of a high-fat meal.
45787729|NCT01227980|Drug|Pexacerfont|300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
45787730|NCT01227980|Drug|Placebo|300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
45787731|NCT03866655|Device|OWise|OWise Breast Cancer is a supportive care digital tool for breast cancer patients. The tool can be accessed as a mobile phone application or as a website. The tool has various tools for self-managing and self-monitoring treatment and symptoms such as an appointment calendar, a symptom-tracker, a modifiable question list and a recording device for consultations.
45787732|NCT01291160|Device|Epiflo|During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
45787733|NCT01291160|Other|Moist Wound Therapy|During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
45787734|NCT02595567|Device|Indwelling tunneled pleural catheter (ITPC)|ITPCs have been shown to successfully and safely control dyspnea in patients with malignant pleural effusions. Compared to the large amount of published data regarding the use of indwelling tunneled pleural catheters in malignant effusions, there is a paucity of data regarding the use of ITPC in liver disease for the treatment of hepatic hydrothorax.
45787735|NCT01291784|Biological|monoclonal antibody to TGF-beta|starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses
45787736|NCT03626883|Procedure|single-bundle, single-hamstring ACL reconstruction|anterior cruciate ligament reconstruction with single hamstring tendon
45787737|NCT03626883|Procedure|single-bundle, double-hamstring ACL reconstruction|anterior cruciate ligament reconstruction with 2 hamstring tendons
45787738|NCT00364299|Device|Automatic control of tracheal tube cuff pressure|
45787739|NCT00609791|Drug|paclitaxel albumin-stabilized nanoparticle formulation|100 mg/m2 3 weeks on 1 week off
45787740|NCT00609791|Other|pharmacological study|Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours
45787741|NCT00609791|Other|physiologic testing|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
45787742|NCT00609791|Other|questionnaire administration|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
45787743|NCT00609791|Other|study of socioeconomic and demographic variables|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
45787744|NCT00609791|Procedure|cognitive assessment|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
45787745|NCT00609791|Procedure|psychosocial assessment and care|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
45787746|NCT05457959|Biological|Dendritic Cell Tumor Peptide Vaccine|Given ID
45787747|NCT05457959|Biological|Ipilimumab|Given IV
45787748|NCT05457959|Procedure|Leukapheresis|Undergo leukapheresis
45787749|NCT05457959|Biological|Nivolumab|Given IV
45787750|NCT05457959|Drug|Placebo Administration|Given ID
45787751|NCT05457959|Drug|Placebo Administration|Given IV
45787752|NCT05457959|Drug|Poly ICLC|Given IM
45787753|NCT05457959|Procedure|Resection|Undergo standard of care surgical resection
45787754|NCT05457647|Device|Riboflavin/UV-A corneal cross-linking|Corneal cross-linking procedure will be performed using the theranostic software module of the C4V CHROMO4VIS™ system in all participants. Participants will receive a single dose of the 0.22% riboflavin ophthalmic solution, RitSight™. Application of the riboflavin eye drop will be done for 15 minutes for the EpiOFF CXL treatment and 20 minutes for the EpiON CXL treatment. Estimates of riboflavin concentration into the cornea will be monitored by the C4V CHROMO4VIS™ system during the dosing phase of treatment. Once the dosing phase is completed, the C4V CHROMO4VIS™ system provides the Operator the access to the UV-A irradiation of the cornea with 5.4 J/cm2 total energy dose and 7.00 mm light beam diameter in all participants. Estimates of treatment efficacy by calculation of theranostic score will be performed by the C4V CHROMO4VIS™ system during UV-A irradiation.
45787755|NCT01213316|Drug|Raltegravir|Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 48 or 144 weeks
45787756|NCT01213316|Drug|Raltegravir|Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 96, 144, or 48 weeks
45787757|NCT05446025|Diagnostic Test|Blood sample|Orexigenic hormones (appetizing) Orexin, galanin and anorexigenic hormones (decreasing appetite) aMSH and CART blood levels will be measured
45787758|NCT05439629|Drug|BAT5906 injection|4.0 mg/eye/time, 50 μl, intravitreal injection
45787759|NCT05439629|Drug|Lucentis|0.5 mg/eye/time, 50 μl, intravitreal injection
45645508|NCT02343835|Device|NanoKnife LEDC System|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels and bile ducts. With IRE, multiple electrical pulses are applied to tumorous tissue. These pulses alter the existing transmembrane potential of the cell membranes, and create 'nanopores', after which the cell dies through loss of homeostasis.
45645509|NCT02334553|Drug|S1226(8%)|The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.
45787760|NCT01229228|Drug|Naproxen Test|200-mg single dose
45919552|NCT03940586|Drug|Letermovir intravenous|Letermovir administered intravenously based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
45919553|NCT00847093|Drug|LMX4|One inch every six hours
45645510|NCT02334553|Drug|Placebo|Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response
45919554|NCT00847093|Drug|LMX4 Placebo|One inch every six hours
45449314|NCT03728439|Device|LED before|Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules (J) per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
45645511|NCT02334709|Radiation|Stereotactic body radiotherapy|A first line TKI will be administered according to the standard dosing of the drug for metastatic RCC during a 1-week run-in period after which SBRT will be delivered to the largest metastatic lesion concurrently with the TKI. The SBRT dose will be escalated in 3 dose levels, starting at 24Gy (8 Gy per fraction), followed by 30 Gy (10 Gy per fraction) and 36 Gy (12 Gy per fraction).
45645512|NCT02334631|Drug|High Volume Simethicone|High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
45645513|NCT02334631|Drug|Standard Volume Simethicone|Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
45919555|NCT04733482|Behavioral|Cosmetic care|
45645514|NCT02334397|Behavioral|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program.
45645515|NCT02334319|Drug|Ganetespib|Given IV
45645516|NCT02334319|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45645517|NCT02334319|Other|Laboratory Biomarker Analysis|Correlative studies
45645518|NCT02338765|Behavioral|mHealth Physical Activity|
45645519|NCT02338765|Behavioral|Buddy-partnered exercise|
45645520|NCT02338687|Dietary Supplement|calcium|one chewable tablet daily, at bedtime, containing 500 mg elemental calcium (1250 mg calcium carbonate)
45645521|NCT02338687|Behavioral|Educational sessions|Women will participate in at least 2 interactive group educational sessions lasting 30 minutes each. Session content: importance of calcium during pregnancy and how to modify their diets to include calcium-rich foods that are available locally
45645522|NCT02338531|Drug|PF-03084014|
45787761|NCT01229228|Drug|Naproxen Test|400-mg (2 x 200-mg)
45787762|NCT01229228|Drug|Naprosyn|single dose
45787763|NCT01229228|Drug|Naprosyn|single dose
45787764|NCT01229228|Drug|Placebo|single dose
45787765|NCT01213706|Device|Whole Body Periodic Acceleration (WBPA)|Subjects will undergo to the Whole Body Periodic Acceleration platform for treatment (shaking period) for 45 min.
45787766|NCT01213706|Device|Sham WBPA|The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge.
45787767|NCT01213940|Behavioral|pre-bariatric weight loss program|standard 6 month physician directed pre-bariatric weight loss program
45787768|NCT01213940|Procedure|bariatric surgery|bariatric surgery for weight loss
45787769|NCT01292252|Biological|teriparatide|Teriparatide 20 ug subcutaneous injection daily for 12 weeks
45787770|NCT01292252|Biological|Placebo|Saline solution
45787771|NCT02192684|Drug|Pioglitazone|45 mg daily Insulin sensitizing
45787772|NCT02192684|Drug|placebo|Compare with pioglitazone
45787773|NCT02243579|Other|Laboratory Biomarker Analysis|Correlative studies
45787774|NCT02243579|Biological|Pembrolizumab|Given IV
45919556|NCT05313633|Other|Designed physical therapy|Attention was given to improve strength, enhance postural control, promote normal walking-pattern, and optimize function. The program incorporated manual passive and functional flexibility, progressive strengthening, postural and advanced balance exercises, and functional walking exercises
46071238|NCT04777760|Drug|two and more doses of surfactant replacement|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant
46071239|NCT02548975|Drug|Statin, beta blocker|Patients receiving either statin or beta blockers prior to cardiac surgery.
45787775|NCT02195414|Device|NeoVas BCS|The NeoVas First-in-Man study is a prospective, two centers, single arm trial, which will enroll a total of 30 patients. The hypothesis of this study is to evaluate clinical feasibility, safety, and efficacy of NeoVas sirolimus-eluting bioresorbable coronary scaffold in the treatment of patients with de novo coronary lesion. The primary endpoint is a composite endpoint of cardiac death, target vessel related myocardial infarction, and ischemia driven target lesion revascularization (TLF) at 1 month follow up. At 6 months, 1, 2, 3, 4 and 5 years follow-up, clinical endpoints include TLF (its individual components), Patient-oriented cardiac event (all cause death, all MI, and all revascularization) target vessel revascularization, scaffold thrombosis.
45645523|NCT02338531|Procedure|Breast cancer surgery|
45645524|NCT02338453|Behavioral|Active Attention Bias Modification Treatment|Attention bias is modified using a dot-probe task. Each trial begins with a fixation cross presented in the center of the screen for 500 ms. Next, participants are presented with two stimuli depicting two faces of the same individual for 500 ms, either of two neutral faces or with one neutral face and one disgust face (i.e., the socially-threatening stimulus). Then, one of two optional probes appears in the location former occupied by one of the faces. Participants are instructed to discriminate as fast as possible between the two variants of the probe, without compromising accuracy, by pressing on two corresponding keys. The probe remains on the screen until the participant responds, after which the next trial commences. This protocol is designed to divert attention away from socially-threatening stimuli as in 80% of trials the probe appears in the location formerly occupied by the neutral face. The remaining 20% of trials include two neutral faces, with no predictive value
45787776|NCT00003407|Drug|amifostine trihydrate|
45787777|NCT00003407|Drug|cytarabine|
45787778|NCT00003407|Drug|mitoxantrone hydrochloride|
45787779|NCT04838717|Drug|BPG|intramuscular injection of 2.4 million units
45787780|NCT04838717|Drug|Doxycycline|Oral: at a dose of 100 mg bid for 14 days
45787781|NCT01214330|Device|Patient-Collected Cervical Pap Smear|Patient-Collected Cervical Papanicolaou Smear
45787782|NCT01710137|Drug|Varenicline|
45787783|NCT01710137|Drug|Placebo|
45787784|NCT01710137|Behavioral|Smoking Cessation Counseling|
45787785|NCT02248727|Device|somofilcon A|somofilcon A lens
45787786|NCT01710839|Drug|0.5mg Ranibizumab|intravitreal injections
45787787|NCT01710839|Procedure|Targeted Pan Retinal Photocoagulation|Targeted Pan Retinal Photocoagulation based on wide field angiography
45787788|NCT01215110|Drug|TMC207|
45787789|NCT01215110|Drug|Rifafour e-275 mg|
45787790|NCT02980757|Drug|Gliclazide 120 mg MR Tablets Formula A|
45787791|NCT02980757|Drug|Gliclazide 120 mg MR Tablets|
45787792|NCT02980757|Drug|Gliclazide 120 mg MR Tablets Formula B|
45653084|NCT05613491|Drug|Intranasal saline|Put 0.9% sodium chloride into nasal special drug delivery device.Before anesthesia induction, give the first equal volume saline nasal spray, once per hour, 20 IU each time, until the end of the operation
45787793|NCT01229462|Drug|brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of brimonidine tartrate/timolol fixed combination ophthalmic solution (Combigan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
45787794|NCT01229462|Drug|brimonidine tartrate ophthalmic solution|One drop of brimonidine tartrate ophthalmic solution (Alphagan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
45449315|NCT03728439|Device|LED interval|Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
45787795|NCT01229462|Drug|timolol ophthalmic solution|One drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
45787796|NCT01229462|Other|fixed combination vehicle|Fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
45787797|NCT01712711|Drug|H.pylori eradication|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
45787798|NCT01292642|Behavioral|Cognitive Behavioral Therapy|individual CBT once weekly, 50 minutes, for 10 weeks
45787799|NCT01292642|Drug|Nicotine Replacement Therapy|"21 mg patch for 6 weeks, 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks~14 m g patch for 8 weeks, then 7 mg patch for 2 weeks"
45787800|NCT01231334|Drug|Dapsone plus Adapalene|Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
45787801|NCT01231334|Drug|Clindamycin/benzoyl peroxide plus Adapalene|Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks
45787802|NCT04771481|Drug|Metoclopramide|metoclopramide 10 mg intravenous form
45787803|NCT04771481|Drug|Normal Saline 10 mL Injection|Normal saline 10 ml intravenous form
45787804|NCT01292798|Drug|Ranibizumab|0.05ml of 0.5mg or 2.0mg ranibizumab injected intravitreally
45787805|NCT04751201|Behavioral|Mindfulness open and circular program|"At the end of the first and the last cycle, as well as 3 weeks after the last cycle, the patient will be invited to answer different questionnaires evaluating his or her quality of life (HADS, QLQC30, FA12). This is why the observation period is 3 months (3 cycles of 3 weeks + 3 weeks).~Similarly, some of the patients included in the study will be asked to complete a semi-structured interview at the end of the MAEva programme.~Patients and nursing staff participating in the study will be asked to complete a satisfaction questionnaire"
45787806|NCT03009500|Drug|Bupivacaine|
45787807|NCT03009500|Drug|Depo-Medrol Injectable Product|
45787808|NCT03009500|Other|Saline (Sodium Chloride) solution|
45787809|NCT03009500|Drug|Lidocaine|Each injection of study medications will be preceded by subcutaneous injections of 1 mLs of 2% lidocaine at each injection site to reduce discomfort of the study participants from the injections
46071240|NCT02548975|Other|Cardiopulmonary bypass|Patients exposed to cardiopulmonary bypass during cardiac surgery.
46071241|NCT02847962|Other|Corn Soy Blend Plus (CSB+)|
46071242|NCT02847962|Other|Corn Soy Blend 14 (CSB14)|
46071243|NCT02847962|Other|White Sorghum Cowpea Blend Variety 1|
45787810|NCT02189954|Procedure|The placement according to the manufacturer's instructions|Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique®(LMU)) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than five years experience
45787811|NCT02189954|Procedure|Cuff inner pressure was held below 44 mmHg|cuff pressure limitation (Group Pressure Limiting (PL), n=45) cuff inner pressure was held below 60 cmH2O (44 mmHg)
45787812|NCT01714505|Device|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
45787813|NCT01715207|Drug|Aliskiren|
45787814|NCT01715207|Drug|Atenolol|
45787815|NCT03795623|Other|Voice-Weaning|Audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
45787816|NCT03795623|Other|Sham control|Muted audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
45645525|NCT02338453|Behavioral|Placebo Attention Bias Modification Treatment|the Placebo ABMT is similar to the active ABMT except that this protocol is not designed to divert attention away from or toward socially-threatening stimuli as in 40% of trials the probe appears in the location formerly occupied by the neutral face and in 40% it appears in the location formally occupied by the threatening face. The remaining 20% of trials include two neutral faces
45787817|NCT01716221|Drug|bupropion & Citalopram|
45787818|NCT01716221|Drug|Bupropion & Placebo|
45787819|NCT01716221|Drug|Placebo & Citalopram|
45787820|NCT01716221|Drug|Placebo & Placebo|
45787821|NCT01215344|Drug|VELCADE|1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle
45787822|NCT01215344|Drug|Lenalidomide|25 mg by mouth on days 1-4 of each cycle
45787823|NCT01215344|Drug|Dexamethasone|20 mg the day before and the day after receiving VELCADE
46071244|NCT02847962|Other|White Sorghum Cowpea Blend Variety 2|
45449316|NCT03728439|Device|LED after|Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
45787824|NCT01215344|Drug|DVT prophylaxis|At least one asprin 81 mg per day. Other option per physician's choice
45645526|NCT02332213|Procedure|Breath sampling for volatile marker detection|Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology
45787825|NCT01215344|Drug|Bisphosphonates|Zoledronic acid by IB or pamidronate by IV can be used as per standard of care.
45787826|NCT01215344|Drug|Liposomal doxorubicin|30 mg/m2 on day 4 of each cycle
45787827|NCT01215344|Drug|Dexamethasone|40 mg by mouth on days 1-4, 8-11, and 15-18 of cycle 1 and days 1-4 on cycle 2-4
45787828|NCT04618055|Device|NiTiDent Tuah Porous NiTi Dental Implants|A newly developed NiTiDent Tuah porous NiTi cylindrical bone level dental implant measuring 4.5 mm in diameter and 10 mm in length and an abutment system of different heights and angulations produced by Nitium Technology Sdn Bhd.
45787829|NCT04618055|Device|Control Dental Implant Systems|A market approved bone level dental implant systems measuring 4.5 mm in diameter and 10 mm in length and an abutment system of different heights and angulations
45645527|NCT02332213|Procedure|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
45645528|NCT02332213|Procedure|Colonoscopy with biopsies or lesion removal when required|Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
45787830|NCT04610645|Device|OCT|3x3 OCT volume scans on treated and opposite side of the irreadiated area on head and neck
45787831|NCT04610645|Device|Dermatoscope|2x2 pictures taken with a dermatoscope
45787832|NCT04610645|Genetic|3-Colour FISH|Blood sample is examined for breaks per metaphase to determine radiation sensibility of the individual
45787833|NCT01231412|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
45787834|NCT01231412|Drug|Cyclosporine|Given PO or IV
45787835|NCT01231412|Drug|Fludarabine Phosphate|Given IV
45787836|NCT01231412|Drug|Mycophenolate Mofetil|Given PO
45787837|NCT01231412|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
45787838|NCT01231412|Drug|Sirolimus|Given PO
45787839|NCT01231412|Radiation|Total-Body Irradiation|Undergo TBI
46071245|NCT02847962|Other|Red Sorghum Cowpea Blend|
46071246|NCT02847962|Other|White Sorghum Soy Blend|
45645529|NCT02332213|Procedure|Plasma/serum sampling|Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination
45787840|NCT03682991|Other|Aggressive Risk Factor Control|"Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.~Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (>5 drinks at one setting).~Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.~Blood Pressure management to achieve a target systolic blood pressure (SBP) of <120/80 mm/Hg~Smoking cessation facilitated through local resources already established at each site"
45787841|NCT03682991|Other|Standard of Care|Recommendations based on current guidelines
45787842|NCT01719653|Drug|MiraLAX|MiraLAX consumed as described in each arm.
45787843|NCT01719653|Other|Gatorade|Gatorade consumed as described in each arm.
45645530|NCT02332213|Procedure|Faecal sample acquisition|Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
45645531|NCT02332213|Procedure|Histological evaluation of the surgery material|The material obtained during surgery (stomach or colorectal) will be used for confirmation of the diagnosis in cancer groups. Surgery itself will be performed according to the clinical indications, and will not be extended (i.e. cannot be considered a study intervention)
45787844|NCT01719653|Drug|MoviPrep|MoviPrep consumed as described in each arm.
45787845|NCT01719653|Drug|SUPREP|SUPREP consumed as described in each arm.
45787846|NCT01716455|Drug|SSP-004184|
45645532|NCT02332135|Procedure|microwave ablation|First, the investigators detect the iPTH levels of all the patients in the investigators' blood purification center. The patients whose iPTH are between 300pg/ml and 800pg/ml and who have parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan are chosen to involve in this study. Patients are divided into 2 groups at random, the control group and the microwave ablation group. In the microwave ablation group, patients will accept microwave ablation. Oral medicines, if needed, will be taken according to the the suggestions in K/DOQI guideline.
45787847|NCT04580771|Drug|Cisplatin|Given IV
45787848|NCT04580771|Biological|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Given SC
45787849|NCT04580771|Radiation|Radiation Therapy|Undergo radiation therapy
45787850|NCT04568993|Procedure|Proximal phalangeal level|Injection of methyl prednisone and lidocaine in the tendon sheet at the level of the proximal phalanx
45787851|NCT04568993|Drug|Volar to the MCP-joint|Injection of methyl prednisone and lidocaine in the tendon sheet volar to the MCP-joint
45787852|NCT04559711|Other|Strengthening coverage and quality of nutrition services during ANC|Intervention clusters will receive inputs both at facility level and community level. The supply side inputs will include efforts for improving facility readiness, quality of nutrition services during ANC, multiple micronutrient supplementation(MMS) and strengthening monitoring and supervision for ANC. On the other hand, community mobilization interventions will be carried out for demand creation. All public health facilities providing ANC services in the intervention area will be included; Union Health & Family Welfare Center, Community Clinic and Satellite Clinic.
45787853|NCT01294748|Device|MiStent DES|The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
45787854|NCT01294748|Device|Endeavor DES|The Endeavor is a device/drug combination comprised of two components; a stent and a drug product (everolimus within a durable polymer coating).
45787855|NCT01720277|Biological|HD Fluzone Vaccine|Nursing home residents over 65 years are allocated to receive high dose trivalent vaccine. Residents under 65 years are provided standard dose trivalent vaccine (TIV).
45787856|NCT01720277|Biological|SD Fluzone Vaccine|Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
45787857|NCT01231646|Other|No intervention|No intervention. This is a cross-sectional study.
45787858|NCT04539665|Procedure|Extended mesenteric resection.|Patients will undergo an ileocolic resection involving high ligation of the ileocolic pedicle, complete mobilization of the mesentery off of the retroperitoneum, and resection of the entire mesentery related to the specimen.
45787859|NCT01295216|Behavioral|Mobile technology to promote lifestyle modification|Effects of an intervention using mobile health (mHealth) technology, including short message services (SMS) and one-to-one telephone calls, to promote lifestyle modification focused on reducing blood pressure among participants
45787860|NCT04514393|Drug|Methotrexate|Intravenous methotrexate at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 of all cycles，for up to 4 cycles.
45919557|NCT05313633|Other|Occupational therapy|Both groups received a designed occupational therapy program for 30 minutes that included exercises facilitating hand skills, such as reaching, grasping, carrying, releasing, in-hand manipulation, and bilateral hand use. The children performed these exercises while they sat on a chair, with the therapist sitting beside to guide and assist them in performing the exercises correctly
45787861|NCT04514393|Drug|Ibrutinib|Oral ibrutinib will be given at a dose of 560 mg daily and will be continued daily after completion of methotrexate and temozolomide.Ibrutinib is continued until disease progression, intolerable toxicity or death.
45787862|NCT04514393|Drug|Temozolomide|Oral temozolomide will be given at 150mg/m2 from day1 to day 5 every 4 of all cycles，for up to 4 cycles.
45787863|NCT01232504|Drug|rhGM-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] > 1.5×10(9)/L for 2 consecutive days).
45787864|NCT01232504|Drug|rhG-CSF+rhGM-CSF group|a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] > 1.5×10(9)/L for 2 consecutive days).
45787865|NCT01232504|Drug|rhG-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] > 1.5×10(9)/L for 2 consecutive days).
45449317|NCT05666037|Behavioral|Mobile health intervention(mHealth)|The intervention group will receive mobile health messaging intervention on behavior change to uptake early postpartum modern contraceptive method.
45449318|NCT03557775|Device|Inspiratory Muscle Strength Training (IMST)|IMST will be conducted using an inspiratory pressure threshold trainer (Philips Respironics® Threshold IMT or POWERbreathe® Medic Plus), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
45449319|NCT03557775|Device|Expiratory Muscle Strength Training (EMST)|EMST will be conducted using an expiratory pressure threshold trainer (EMST150®), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing out forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
45449320|NCT03557775|Behavioral|Voice Exercises|Voice exercises will consist of the Vocal Function Exercises (VFE) protocol, developed by Stemple (2005). It contains 4 steps: (a) sustain the vowel /i/ on the musical note F for as long as possible. Repeat as judged by the SLP. (b) Glide from the lowest note to the highest note. Repeat as judged by the SLP. (c) Glide from the highest note to the lowest note. Repeat as judged by the SLP. (d) Sustain the notes C-D-E-F-G for as long as possible. Each note will be repeated until the participant finds the right placement (forward-focused voice), as judged by the SLP. Humming will be used to facilitate placement.
45787866|NCT01721447|Drug|Optison echocardiography contrast agent|Subjects undergoing transesophageal echocardiography who will receive the Optison contrast agent during the procedure to test if the image quality improves to provide accurate assessment of the presence of left atrial thrombus.
45787867|NCT02249819|Device|transcranial direct current stimulation|Soterix 1x1 anodal tDCS
46071247|NCT04044703|Drug|Vancomycin - model-based dosing regimen|A dosing calculator based on a population pharmacokinetic model for vancomycin will be used to generate a participant's intermittent vancomycin dosing regimen. The participant's post-menstrual age, weight, creatinine and the target trough vancomycin level will be entered into the dosing calculator and the dose will be generated (intermittent infusion, dosing frequency will be from 1 to 4 times per day according to the corrected gestational age).
46071248|NCT02848040|Other|IDK Bile Acids|colourimetric in-vitro laboratory diagnostic test
45449321|NCT00121199|Biological|rituximab|Given IV
45787868|NCT01295840|Device|Cardiac Resynchronization Therapy Defibrillator|Cardiac Resynchronization Therapy Defibrillator
45787869|NCT01737281|Behavioral|Proactive outreach|Proactive contact (mail and phone) offering smoking cessation medications and telephone counseling.
45787870|NCT01737281|Behavioral|Usual care|Usual smoking cessation care from VA clinical staff.
45449322|NCT00121199|Biological|bevacizumab|Given IV
45449323|NCT00121199|Drug|cyclophosphamide|Given IV
45449324|NCT00121199|Drug|doxorubicin hydrochloride|Given IV
45449325|NCT00121199|Drug|vincristine sulfate|Given IV
45645533|NCT02332135|Drug|active vitamin D|The control group will be treated by active vitamin D and other general treatment,such as dietary phosphate restriction and phosphate binders,according to the suggestions in K/DOQI guideline.
45645534|NCT03518359|Behavioral|Enhanced Stress Resilience Training (ESRT)|ESRT involves six weekly 90-minute group classes and one 2 - 4 hour retreat. Classes focus on developing mindfulness skills (i.e. sustained attention, open monitoring, emotional regulation, meta-cognition) in the context of skills and concepts for managing stress, particularly in practicing medicine. Homework consists of 20 minutes per day of mindfulness exercises following guided meditation CDs or videos of movement-based practice, and practice will be reported periodically by text. A 3-hour outdoor retreat occurs at week six. The central exercises of ESRT are the body scan, sitting meditation, chi gong and yoga. For both arms, the weekly teaching sessions occur on a workday morning during protected time at Parnassus, Mission Bay or Zuckerberg San Francisco General Hospital campus.
45787871|NCT01216748|Other|quiet breathing|Subjects were instructed to breath normally at room air.
45787872|NCT01216748|Other|Hypocapnic Hyperventilation|hypocapnic hyperventilation, the subjects were instructed to breathe fast and deep until their end-tidal pCO2 fell to 30 mmHg, corresponding to a systemic pH increase of about 0.1 pH units.
45787873|NCT01216748|Other|Hypercapnic Hyperventilation|For hypercapnic hyperventilation, a modification of a previously described procedure (15). While monitoring SaO2 using pulse oximetry and end-tidal CO2 by mass-spectrometry on a breath by breath basis, CO2 was bled into the inspired air to achieve an end-tidal pCO2 of at least 55 mmHg
45787874|NCT01216748|Other|eucapnic hyperventilation|For eucapnic hyperventilation, the subjects were instructed to increase their ventilation to the highest level of ventilation recorded in the previous two hyperventilation maneuvers, while CO2 was bled into the inspired air to maintain end-tidal pCO2 at 40 mmHg.
45787875|NCT01233518|Device|FFR|Fractional flow reserve measured during cardiac catheterization
45787876|NCT01737593|Drug|Acetaminophen|
45787877|NCT01217840|Drug|Drisdol (Ergocalciferol) Vitamin D2|Ergocalciferol 150,000 IU every 12 weeks for total of 24 weeks.
45787878|NCT01217840|Drug|Placebo|Placebo pill - 3 pills every 12 weeks for total of 24 weeks
46071249|NCT00824317|Drug|methylphenidate|(15 mg daily), medium (25 mg daily) and high (40 mg daily)
46071250|NCT00824317|Drug|Placebo|
46071251|NCT02847806|Biological|Estradiol (Insulin sensitivity)|
46071252|NCT02847806|Biological|Testosterone (Insulin sensitivity)|
46071253|NCT00820105|Drug|ADX10059|oral administration
46071254|NCT00820105|Drug|ADX10059|Oral administration
46071255|NCT00820105|Drug|ADX10059|Oral administration
45449326|NCT00121199|Drug|prednisone|Given PO
45449327|NCT00121199|Other|laboratory biomarker analysis|Correlative studies
45449328|NCT03964805|Other|20% oxygen|culture excusively at 20% O2 (Day 0 to Day 6)
45449329|NCT03964805|Other|5% oxygen|culture excusively at 5% O2 (Day 0 to Day 6)
45449330|NCT03964805|Other|20 % and 5 % oxygen|culture at 5% from Day 0 to Day 3, then at 20% from Day 3 to Day 6)
45449331|NCT03728283|Procedure|implant placement in combination with connective tissue grafting|A connective tissue graft of standardised dimensions was harvested from the palate under local anaesthesia and was stabilised over the implant's neck
45449332|NCT03728283|Other|Implant placement|Implants were placed following teh manufacturer's instructions
45787879|NCT02250521|Device|McGrath MAC enhanced direct laryngoscope|"The McGRATH® MAC enhanced direct laryngoscope (EDL) combines the familiarity of direct laryngoscopy with an inline video camera for an enhanced view.~All 100 patients will be intubated using the McGRATH® MAC video laryngoscope, either through direct or indirect vision laryngoscopy. The LCD monitor of the McGRATH™ MAC was initially covered; if the anesthesiologist visualized a modified C-L grade 1-3 view, the patient was intubated utilizing this direct view. If the anesthesiologist observed a modified C-L grade 4 view during their initial direct view, the patient was intubated using the indirect method. If intubation via direct laryngoscopy was unsuccessful on the first attempt, the patient was intubated using the indirect view. If both methods of laryngoscopy were unsuccessful, the rescue intubation technique was performed at the discretion of the anesthesiologist."
45449333|NCT03728205|Behavioral|Yoga|Twice weekly yoga sessions for 12 weeks
45645535|NCT03518359|Behavioral|Active Control|Control group participants will meet for 6 weeks, 90 minutes each week, for classes focuses on stress management through rest and exercise, with equivalent protected time and small group bonding but without the use of contemplative practices. Topics will include the history of surgery, patient perspective, the physician personality, technical mastery, fallibility and limits, balancing compassion and detachment and knowing when not to operate. For daily practice, control participants will be asked to devote 20 min per day to stress management through rest and exercise again reported daily by text.
45645536|NCT05134675|Dietary Supplement|Homemade beer|The data of patients who consume and do not consume homemade beer will be cross-sectionally evaluated and compared.
45449334|NCT03725865|Biological|Induction of neural stem cells|Brain injection iNSC
45787880|NCT01218542|Radiation|Volumetric modulated arc therapy|Using volumetric modulated arc therapy to give simultaneous infield boost to gross metastatic brain lesions during whole brain radiation therapy.
45787881|NCT01721603|Drug|Dabrafenib|150 mg capsule by mouth twice daily
45787882|NCT01721603|Procedure|Gamma Knife Radiosurgery|This will be delivered using Gamma Knife technology. Patients will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
45787883|NCT01721603|Drug|Trametinib|2 mg by mouth once daily from beginning at Cycle 3 Day 1, until progression of disease, withdrawal of consent, or the development of intolerable treatment associated toxicity.
45787884|NCT01296542|Drug|Moxifloxacin Ophthalmic|
45787885|NCT01296542|Drug|Besifloxacin Ophthalmic|
45919558|NCT05313633|Other|Plyometric training|"The designed plyometric training program basically focuses on upper extremity strength training and is developed according to the guidelines of the National Strength and Conditioning Association. The exercise load is progressively increased and conducted in two phases; each phase lasted for six weeks. To ensure safety and optimal performance, every child performed a pre-workout warming up before each session for five minutes including static and dynamic stretching and moving through the exercises planned for each day's workout at a lower intensity. Another set of cool down exercises for five minutes is considered to stretch and relax the entire body after each session.~The exercises include:~Two-hand chest pass Downward slam throw Push-ups against wall Clap push-ups against wall Bench push-ups Two-hand overhead throw Two-hand underhand side throw Single-Arm Throw"
45919559|NCT05313633|Other|Wii training|The dose of Wii training was 40 minutes, three times a week for 12 weeks which is an interactive motion-based device. The Wii has a multiplayer mode and different levels of difficulty. The content of Wii training consisted of practicing four Wii games: (1) tennis; (2) boxing; (3) bowling; and (4) basketball. These games are chosen because they target the upper limbs, are fun, provide immediate feedback, and are easy to learn and play, and progression is built into the game. Also, fine motor coordination and sensory deficits are targeted through pressing buttons and vibration feedback from the Wii Remote. The children are instructed that they could stop at any point if discomfort or undue fatigue is experienced. The therapist randomly presented the games to eliminate any effect of order
46071256|NCT00820105|Drug|ADX10059 Matching Placebo|Oral administration
45787886|NCT01234766|Drug|Bendamustine|90mg/m2, IV - Days 1 and 2 of every cycle
45449335|NCT01079897|Device|Atopiclair|topical applied cream, twice daily
45653085|NCT05082207|Other|Remote Ischemic Preconditioning|Three cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure of systolic blood pressure plus 50 mm Hg.
46071257|NCT02847572|Procedure|Cataract Surgery|All patients wil be having intraocular lens surgery
46071258|NCT01780220|Drug|Abiraterone|Abiraterone acetate 1000mg/day + prednisone alone for one month before initiating the sequence of radiotherapy
45449336|NCT01079897|Device|EHK02-01|topical applied cream containing 7% ectoine
45449337|NCT00119015|Drug|Placebo|
45449338|NCT00119015|Drug|Montelukast|
45449339|NCT00119015|Drug|Fluticasone propionate|
45449340|NCT01981850|Biological|RO7490677|IV infusion
45449341|NCT01981850|Drug|Ruxolitinib|IV infusion
45449342|NCT03557307|Biological|Benralizumab|Benralizumab subcutaneous injection
45449343|NCT00118703|Drug|GW685698X|
45449344|NCT01079351|Drug|Intravenous Carbamazepine|10 mg/mL of intravenous Carbamazepine (CBZ) dissolved in 250 mg/mL of Captisol® (cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by intravenous infusion every 6 hours.
45449345|NCT00104104|Drug|zoledronic acid|4 mg zoledronic acid in 250 mL of calcium-free solution (i.e., 0.9% sodium chloride or 5% glucose) administered intravenously.
45653086|NCT05082207|Other|sham group|a deflated cuff placed on the upper arm for 30 min
45787887|NCT01234766|Drug|Rituximab|375mg/m2, IV - Cycle 1 only: Day -7 (+1 day) Day 1 of every cycle
45787888|NCT01234766|Radiation|Y-90 ibritumomab|0.4mCi/kg, IV - Within 4 hours of rituximab, give over 10 minutes
45787889|NCT04346420|Other|Standard interface|The standard interface for administering oxygen (nasal cannula or oxygen mask) is worn by the patient. Oxygen output is adapted to reach a SpO2 target of 94%.
45787890|NCT04346420|Device|Double-Trunk Mask|The standard nasal cannula interface accompanied with the DTM is worn by the patient. Oxygen output is adapted to reach a SpO2 target of 94%.
45787891|NCT01234922|Drug|lisinopril|Given orally
45787892|NCT01234922|Drug|losartan potassium|Given orally
45787893|NCT01234922|Other|laboratory biomarker analysis|Correlative studies
45645537|NCT04987177|Other|Workload of Manual Wheelchair Propulsion|Participants will complete 20 one-minute manual wheelchair propulsion bouts. Each one minute propulsion bout will be followed by a 2 minute rest period. Each propulsion bout will be at a different workload. After every 10 propulsion bouts, participants will be provided with an extended rest period (5 to 30 minutes). For each participant, the maximum workload to be tested is based on their estimated maximum workload. Estimate maximum workload is based on the HR-Workload relationship documented during a prior sub maximal test to 80% of age adjusted maximum heart rate.
45645538|NCT02334241|Device|Sorbact®|Sorbact® is available in many types and sizes. These different presentations are available allowing management of quite all types of wounds of various anatomical locations, sizes or depths. Application of any of these presentations is allowed and may change during study course according to wound evolution.
45645539|NCT02334241|Device|Best local cares|Participating centers will provide a list of dressings they planned to use in the best local cares arm. This list must be validated by the study Steering Committee members
45787894|NCT01234922|Drug|benazepril hydrochloride|Given orally
45787895|NCT01234922|Drug|ramipril|Given orally
45787896|NCT01337336|Drug|fluticasone propionate/salmeterol xinafoate|combination fluticasone priopionate and salmeterol xinafoate 250/50mcg
45787897|NCT01337336|Drug|Anticholinergics|tiotropium; ipratropium alone; or ipratropium + albuterol
45645540|NCT02334163|Drug|Nitazoxanide|500 mg nitazoxanide tablets twice daily
45645541|NCT02334163|Drug|Oral lactulose|Oral lactulose (65%)
45787898|NCT01338506|Behavioral|Concurrent Treatment with Prolonged Exposure (COPE)|12 weeks of concurrent prolonged exposure treatment for PTSD combined with cognitive behavioral therapy for substance use disorders (alcohol or drugs).
45787899|NCT01236326|Procedure|Laparoendoscopic single site donor nephrectomy|Patients randomized to this arm will undergo laparoendoscopic single site donor nephrectomy
45787900|NCT01236326|Procedure|Conventional laparoscopic donor nephrectomy|Patients randomized to this arm will undergo conventional laparoscopic donor nephrectomy
45787901|NCT01239056|Procedure|Endoscopy|Endoscopic drainage of a pancreatic pseudocyst using a metal stent per medical indication.
45787902|NCT01302860|Drug|ACZ885|
45787903|NCT01239212|Drug|levetiracetam|50 mg/kg single loading dose of IV levetiracetam
45787904|NCT01242644|Device|pain pump containing ropivacaine|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour
45919560|NCT04733248|Other|Kinesiotaping group|"HOT PACK (10 MINTS)~TENS(10 MINTS)~STRETCHING EXERCISES(10 reps 3sets) hold for 2 sec~Apply KINESO- TAPE on upper trapezius (from I-O for Inhibition purpose)~HOME PLAN OF EXPERIMENTAL GROUP:~SELF STRECHINGS (10 reps 3 sets)~AROMS~NECK ISOMETRICS (10 reps 3 sets)hold for 10 sec (In neck flexion, In neck extension, In side bending) In experimental group kinesiotape was applied on upper trapezius from insertion to origin for inhibition purpose. As it had increased the functional status of the patient. Post -intervention assessment was taken on 1 st, 2nd and 3rd visit."
45919561|NCT04733248|Other|stretching group|"HOT PACK (10 MINTS)~TENS(10 MINTS)~STRETCHINGS EXERCISES (10 reps 3sets) hold for 2 sec 5.9HOME PLAN OF CONTROL GROUP:~SELF STRECHINGS (10 reps 3 sets)~AROMS~NECK ISOMETRICS (10 reps 3 sets)hold for 10 sec In neck flexion In neck extension In side bending Post-intervention assessment was taken on 1 st, 2nd and 3 rd visit"
45919562|NCT00847054|Drug|MORAb-004 (monoclonal antibody to TEM1)|Intravenous administration
45919563|NCT03887741|Biological|Plasmapheresis|Patient will have monthly plasma exchange with young ApoE 33 plasma. Each exchange will be 1.5 volume of patient's plasma
45919564|NCT03887741|Biological|Plasma infusion|Infuse every two weeks with ApoE33 young plasma (1unit) for 6 months
45919565|NCT00846976|Drug|Bicalutamide|200mg daily
45919566|NCT03147768|Device|Distal Pancreatectomy Sealing Using LTW|The device's intended use is to seal the pancreatic surface using a laser to weld human albumin based biomaterials after surgical removal of pancreatic tumors during a partial pancreatectomy.
45645542|NCT02334163|Drug|Metronidazole|250 mg metronidazole tablets every 8 hours
45787905|NCT01242644|Device|saline pain pump with injectable medication|30mL of ropivacaine(0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100-mL of normal saline administered at 4 mL/hour
45787906|NCT01242644|Drug|ropivacaine, ketorolac , morphine sulfate|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected
45787907|NCT01303406|Drug|Idebenone|All PROTI patients randomised to idebenone treatment will receive high dose idebenone. This is defined according to body weight. In patients weighing 45 kg or less, it is 1350 mg/day (3 x 150 mg tablets three times per day with meals). In patients weighing more than 45 kg, it is 2250 mg/day (5 x 150 mg tablets three times per day with meals).
45787908|NCT01303406|Drug|Placebo|
45787909|NCT01304966|Procedure|biopsy|excisional biopsy
45787910|NCT02597127|Drug|ALN-PCSSC|ALN-PCSSC is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis and is given as SC injections
45787911|NCT02597127|Drug|Normal Saline|Saline (sterile, normal, 0.9%) solution given as SC injections
45787912|NCT02597673|Other|Home Exercise Program (HEP)|All participants will receive a standard home-based exercise rehabilitation protocol for PFPS. HEP teaches muscle strengthening exercises and self-management strategies to prevent recurrence. This program includes sessions with the study coordinator. A handout and given a demonstration of the daily exercises to be performed at home and weekly communication from the study coordinator regarding compliance with the exercises.
45787913|NCT02597673|Device|NMES|To ensure consistent interventions across participants, a specified percentage of baseline maximal voluntary contraction (% MVC) will be used to determine the intensity of the training contraction. The electrical amplitude to obtain the desired intensity will be determined for each participant. Participants will train at 20-30% of MVC during weeks 1-3, 30-40% of MVC during weeks 3-6, and 40-50% of MVC during weeks 6-9. Incremental increases will be made at the 3 and 6 week clinic visits. Individualized instructions for adjusting the amplitude dial settings, with a return demonstration, will be used to maintain the appropriate percentage of MVC. During the home training sessions, participants will adjust the amplitude required to achieve the desired goal, as tolerated.
45919567|NCT00846937|Dietary Supplement|Plant stanolester and fatty acid|Plant stanol ester 2gr/day and fatty acid in a beverage compared to plant stanol ester 2gr /day and placebo
45787914|NCT02597673|Device|TENS|The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks. The Active device delivers a pre-set program of pulsed electrostimulation using a patented asymmetrical simple modulated pulse (SMP) waveform. SMP delivers a group of pulses as a repeating 12-second cycle.
45787915|NCT04720677|Other|Turkish Version of The Italian Spine Youth Quality of Life (ISYQOL) Questionnaire|Turkish Version of The Italian Spine Youth Quality of Life (ISYQOL) Questionnaire
45787916|NCT03619707|Drug|Progesterone|Patients will be randomly assigned during the treatment follow up, at the time of addition of progesterone to the regimen, following computerized random number generator in procedure, to one of the study groups. Patients will be aware of the allocated arm since the treatment drugs have different route of administration. Group I will receive the oral dydrogesterone, while group II will receive the vaginal microprogesterone.
45787917|NCT02597907|Drug|aprepitant|aprepitant 80 mg is given to all patients before surgery
45787918|NCT02597907|Drug|palonosetron|palonosetron 0.075 mg is given to patients in the aprepitant plus palonosetron group after induction of general anesthesia
45787919|NCT02597907|Drug|Ramosetron|ramosetron 0.3 mg is given to patients in the aprepitant plus ramosetron group after induction of general anesthesia
45787920|NCT02976285|Procedure|arthroscopic rotator cuff repair with a polyester patch|Patients were operated under general anesthesia and a supraclavicular nerve block, in a beach-chair position with 80° forward shoulder flexion and traction between 3-5 kg. After washing and draping a standard viewing portal was placed at the dorsal softspot. Further portals included, a lateral, a dorso-lateral, an antero-lateral and an anterior portal. If additional pathologies were present, they were treated simultaneously and mostly involved the long head of the biceps tendon, treated with tenodesis or tenotomy respectively. After a thorough bursectomy, the rupture was fully visualized and thereafter its size was estimated. Following debridement of the footprint, we used a triple row repair and implanted the patch.
45787921|NCT02600325|Drug|Grazoprevir/Elbasvir 100mg/50mg|Grazoprevir/Elbasvir 100mg/50mg
45787922|NCT03498729|Other|Peripheral Blood Sample|30mL peripheral whole blood sample
45787923|NCT03438747|Device|P-15L Bone Graft|The investigational group will be treated with P-15L in an instrumented TLIF
45787924|NCT03438747|Other|Local autologous bone in a TLIF with Instrumentation|The active control group will be treated local autologous bone in an instrumented TLIF
45919568|NCT00846898|Dietary Supplement|cinnamon 2g per day for 12 weeks|Subjects in intervention group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
45919569|NCT00846859|Drug|varenicline (Champix/Chantix)|14 weeks of per oral tablet treatment in an escalating dosing regimen (0.5 mg - 1.0 mg/day; 1 - 2 tablets/day).
45645543|NCT02334163|Drug|Rifaximine|Two 200 mg rifaximine tablets every 8 hours
45645544|NCT02039635|Dietary Supplement|Korean Red Ginseng|Given Orally
45645545|NCT02039635|Dietary Supplement|Placebo|Given Orally
45645546|NCT02332057|Drug|Diclofenac plus lidocaine|The study nurse will instruct the patients to swallow diclofenac tablets (100 mg) 1 hour before IUD insertion. Three millilitres of the lidocaine gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the lidocaine gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
45645547|NCT02332057|Drug|Placebo|The study nurse will instruct the patients to swallow placebo tablets 1 hour before IUD insertion. Three millilitres of the placebo gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the placebo gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
45645548|NCT02331745|Drug|Granulocyte colony-stimulating factor|Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).
45645549|NCT02331745|Drug|standard treatment|Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time
45645550|NCT02638259|Drug|GP2015|Enbrel comparator
45787925|NCT02600403|Diagnostic Test|Optical Coherence Tomography (OCT)|Optical Coherence Tomography (OCT) is a machine that scans eyes and has the capability of measuring thickness of various layers of the retina and nerve fiber layer (NFL).
45787926|NCT02600403|Diagnostic Test|Visual evoked potential (VEP)|Visual Evoked Potential (VEP) is an imaging system that measures electrical activity from the eye to the brain by using electrodes placed on forehead and back of the head similar to electroencephalogram (EEG).
45787927|NCT02600403|Diagnostic Test|Humphrey Visual Field (HVF)|Humphrey Visual Field (HVF) is a test done to evaluate how much peripheral (side) vision has been lost due to glaucoma.
45787928|NCT04340973|Device|Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
45787929|NCT02600637|Behavioral|MBSR|Mindfulness-based Stress Reduction is an 8-week course designed to teach a number of mindfulness techniques to help improve stress- and depression-related symptoms.
45787930|NCT02600637|Behavioral|Brain Health class|An 8-week course on brain health will be administered to participants as an active control group.
45787931|NCT03378141|Behavioral|Maternal Nutrition Behavior change|Counseling and community mobilization
45787932|NCT02600715|Drug|Onabotulinumtoxin A (BoNT)|
45787933|NCT02600715|Drug|belladonna|Part of dosage of the compounded active B&O suppository of belladonna 16.2mg and morphine 7.5mg.
45787934|NCT02600715|Drug|Morphine|Part of dosage of the compounded active B&O suppository of belladonna 16.2mg and morphine 7.5mg.
45787935|NCT02600715|Drug|Placebo|matching placebo to B&O suppository
45787936|NCT02600715|Drug|Active B&O suppository of belladonna|belladonna 16.2mg and morphine 7.5mg
45787937|NCT02601105|Other|Placebo Vehicle Cream|Lipoderm Cream alone
45787938|NCT02601105|Other|Centella Asiatica Cream|1% Centella Asiatica in lipoderm
45919570|NCT00846859|Drug|placebo for varenicline|14 weeks of per oral tablet treatment in an escalating dosing regimen (1 - 2 tablets/day)
45645551|NCT02333929|Device|STA- Rivaroxaban Calibrator&Control|One sample blood collected per patient the day of the treatment (drawn soon after the the drug intake)
45787939|NCT02603211|Device|tactile imaging sensor or system made in our laboratory|This is a camera with elastomer tip and LED lights. It is a harmless device.
45787940|NCT03331497|Procedure|Tonsillotomy|About 2/3 of the palatine tonsil tissue is removed with coplator or bipolar knife.
45787941|NCT04743297|Drug|Prostaglandin E2 (Propess)|Propess - The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour or at the occurrence of hyperstimulation.
45787942|NCT04743297|Drug|Prostaglandin E2 (Prostin)|Prostin - 3 mg vaginal tablet is placed in the posterior vaginal fornix. Dose can be repeated every 8 hours till onset of active labour or the occurrence of hyper-stimulation.
45787943|NCT04176783|Drug|Opioids|narcotic pain medicine
45787944|NCT04176783|Drug|Opioid-Free|non narcotoc pain medication
45787945|NCT00365313|Drug|celecoxib, esomeprazole|
45787946|NCT03232203|Drug|STRIMVELIS|It is the Autologous cluster of differentiation (CD) 34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA complementary Deoxyribonucleic acid (cDNA) sequence. HCP who have previously referred a patient for STRIMVELIS treatment or a parent's/carer's child who previously received treatment with STRIMVELIS will be recruited to the study
45645552|NCT02333851|Drug|Mixtard 30:70 Novonordisk® twice daily|Premixed insulin twice daily before breakfast and before dinner
45787947|NCT00365469|Dietary Supplement|Probiotic|Bifidobacterium longum [BL999] and Lactobacillus rhamnosus [LPR]
45787948|NCT00365469|Other|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
45787949|NCT02605395|Drug|IDIAZOLE 20mg DR tabs|IDIAZOLE 20mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
45787950|NCT02605395|Drug|PARIET 20 mg DR tabs|PARIET 20 mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg rabeprazole sodium.
45787951|NCT04166721|Drug|Atezolizumab|Immunotherapy
45919571|NCT03885830|Drug|Bosutinib|Subjects will be enrolled into this group if they are receiving bosutinib per standard of care. This is an observational study and no interventions will be made.
45919572|NCT03885830|Drug|Dasatinib|Subjects will be enrolled into this group if they are receiving dasatinib per standard of care. This is an observational study and no interventions will be made.
45645553|NCT02333851|Drug|Lantus® once daily and Apidra® before meals|Injection of Lantus® insulin once daily and rapid insulin Apidra® before breakfast, lunch and dinner
45645554|NCT02334007|Drug|LMWH: Dalteparin|Dalteparin is a low-molecular weight heparin. The dosage used will be 5000 units once daily (administered as a subcutaneous injection). This is an established prophylactic dose used to prevent the incidence of VTE after surgery.
45645555|NCT02334007|Other|Placebo|Upon hospital discharge, half of the patients will be assigned to receive saline placebo injections for up to 35 days after surgery. These injections will have no effect.
45645556|NCT02333695|Device|Spinal Magnetic Stimulation|Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
45645557|NCT02338375|Biological|Cartistem|Cartistem is allogenic umbilical cord blood-derived stem cell product. Cartistem is 500uL/cm2 applied according to the lesion.
45645558|NCT02338063|Behavioral|Virtual Reality|4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using 3-D goggles for some activities.
45645559|NCT02338063|Behavioral|Health Promotion|4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using traditional role-plays for some activities.
45645560|NCT02637323|Drug|FX006 32 mg|Single 5 mL IA injection
45645561|NCT02637323|Drug|TCA IR 40|Single 1 mL IA injection
45653087|NCT05597839|Drug|DF9001|Immunotherapy agent targeting NK cells.
45653088|NCT05597839|Drug|Nivolumab|Anti-PD-1 immunotherapy agent
45787952|NCT04343001|Drug|Aspirin|Aspirin 150mg
45787953|NCT04343001|Drug|Losartan|Losartan 100mg
45787954|NCT04343001|Drug|Simvastatin|Simvastatin 80mg
45787955|NCT02865135|Drug|DPX-E7 vaccine|Therapeutic vaccine for the treatment of incurable HPV16-related oropharyngeal, cervical and anal cancer in HLA-A*02 positive patients.
45787956|NCT01739231|Biological|ACE527|"3x10^9 cfu ACE527 vaccine strain. Comprised of three genetically attenuated and engineered strains of E. coli, with antigen profiles covering a wide range of ETEC surface colonization factor antigens (CFA/I, CFA/II [CS1, CS2, CS3] and CFA/IV [CS5, CS6]) and also expressing LTB, the inactive subunit of LT (ETEC heat labile toxin). The constituent strains of ACE527 were:~ACAM2025: a live, attenuated, CFA/I, LTB positive strain~ACAM2022: a live, attenuated, CS5, CS6, LTB positive strain, and~ACAM2027: a live, attenuated, CS1, CS2, CS3, LTB positive strain."
45787957|NCT01739231|Biological|dmLT|A derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine (13). These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
45919573|NCT03885830|Drug|Imatinib|Subjects will be enrolled into this group if they are receiving imatinib per standard of care. This is an observational study and no interventions will be made.
45919574|NCT03885830|Drug|Nilotinib|Subjects will be enrolled into this group if they are receiving nilotinib per standard of care. This is an observational study and no interventions will be made.
45919575|NCT00846781|Drug|Denufosol tetrasodium Inhalation Solution|60 mg by oral inhalation three times daily
45919576|NCT00846703|Drug|6-mercaptopurine, Methotrexate|"6-mercaptopurine p.o. qd~Methotrexate p.o. qw"
45919577|NCT00846703|Drug|6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone|"(1)6-mercaptopurine p.o. qd x 7w Methotrexate p.o. qd x 7w~(2)Vincristine qw x 1w Dexamethasone p.o. qd x 7d~Go to (1) and (2)"
45645562|NCT02338141|Device|Portable colposcopy (Cerviscope)|HPV-positive women will be evaluated with portable colposcopy (with a novel portable colposcope known as the Cerviscope) after visual inspection with acetic acid and prior to biopsy in the experimental group.
45787958|NCT01739231|Biological|CeraVacx placebo|CeraVacx® is used to neutralize gastric acidity upon ingestion of vaccine. It was also used as the placebo in this study. CeraVacx® was prepared from the commercial product (Cera Products, Inc.); 9.5 grams were added to sterile water for each dose and mixed. Each dose contained 7 grams of rice syrup, 2 grams of sodium bicarbonate, and 0.5 grams of trisodium citrate.
45787959|NCT01739231|Biological|H10407 challenge strain|Approximately 2 x 10^7 cfu of the fully virulent ETEC strain. Previously administered to 91 volunteers at this challenge dose by the CIR clinical team over the previous 4 years in conjunction with other Phase 1/2b trials.
45787960|NCT02605863|Drug|Enzalutamide|160 mg by mouth daily for 12 months
45787961|NCT04742205|Drug|Tranexamic Acid 500 MG|Loading dose of trial (1g of tranexamic acid in 10ml) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial mixed in 500ml sodium chloride 0.9% is given over 8 hours
45787962|NCT02822469|Other|Manual Therapy Treatment|"Treatment starts with 10 deep breathing movements for global relaxation. The anterior and posterior neck muscles, shoulder girdle and subdiaphragmatic will be addressed with myofascial techniques repeated 10 times in each stroke. The cervical spine will be pulled in the longitudinal direction. The draw will be held 1 time, lasting 1 minute. The thoracic region will receive mobilization technique in the anteroposterior direction,10 repeated movements involving all thoracic segment.~The treatment will be applied previously trained therapists, 4 weeks, 2 times a week, totaling eight sessions. The treatment time per session is about 25 minutes."
45787963|NCT02822469|Device|Placebo Ultrasound|A detuned pulsed ultrasound will be applied to regions of the muscles around the shoulder girdle and anterior posterior cervical, for 25 minutes (2.5 minutes in each zone ). The device will be used with the internal cables disconnected for the placebo effect . However, you can handle it and adjust the doses and alarms as it is connected in order to simulate clinical practice and increase the credibility of the use of this device in the voluntary . The placebo treatment will be applied by previously trained therapists. Treatment will have 4 weeks, 2 times a week, totaling eight sessions.
45787964|NCT04743063|Drug|sacubitril/valsartan|Initiation of sacubitril/valsartan, identified using prescription fill in pharmacy claims
45787965|NCT04743063|Drug|Angiotensin II Receptor Blockers|Initiation of ARBs, identified using prescription fill in pharmacy claims
45787966|NCT04742985|Dietary Supplement|Green tea combined extracts group|Green tea combined extracts 320 mg/day (main compound 62,5 mg for A group, 125 mg for B group) during 8 weeks
45787967|NCT04742985|Dietary Supplement|Placebo group|Placebo 320 mg/day during 8 weeks
45787968|NCT01739699|Drug|Acetaminophen|
45787969|NCT01739699|Drug|Placebo|
45787970|NCT04340817|Diagnostic Test|Proteomics|Mass-spectometry proteomics
45787971|NCT04340817|Diagnostic Test|Transcriptomics|Next generation sequencing
45787972|NCT04340817|Genetic|Genomics|Targeted genetics
45787973|NCT04154787|Drug|LNP023|Investigation of LNP023
45787974|NCT04154787|Drug|Rituximab|Comparison of rituximab dose
45787975|NCT01721681|Biological|FACTOR X|
45787976|NCT04742049|Other|Telerehabilitation-based|15 pediatric cystic fibrosis patients who are at home during the self- isolation process due to the COVID-19 pandemic will be included in this group. Online exercise training protocol will be apply for patients. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks with a physiotherapist. Exercise protocol will start with the warm-up exercises and finish with cooling exercises.
45787977|NCT04742049|Other|Follow-up based|15 pediatric cystic fibrosis patients who are at home during the self- isolation process due to the COVID-19 pandemic will be included in this group. An exercise document including the same exercise protocol in study group will be sent the patients. Patients will be called by the physiotherapist once a week for follow-up. .
45787978|NCT04741893|Device|EndoFLIP|Use of Endoluminal Functional Lumen Imaging Probe to assess anal canal function
45645563|NCT02338141|Device|Conventional colposcopy (Wallach Zoomscope)|HPV-positive women will be evaluated with conventional colposcopy (with the Wallach Zoomscope) after visual inspection with acetic acid and prior to biopsy per usual standard of care.
45645564|NCT02338297|Procedure|TACE|Transarterial chemoembolisation (TACE)
45645565|NCT02338297|Drug|EGM|Occlude arterioportal shunts(APS) with ethanol/gelfoam mixture(EGM)
45787979|NCT01740713|Drug|Deferiprone, dose level 1|a solution at 80 mg/mL will be administered orally
45787980|NCT01740713|Drug|Deferiprone, dose level 2|a solution at 80 mg/mL will be administered orally
45787981|NCT01740713|Drug|Deferiprone, dose level 3|a solution at 80 mg/mL will be administered orally
45787982|NCT02609841|Device|Cardiac rhythm remote monitoring system|Non-invasive wearable remote cardiac rhythm monitoring system used throughout 12 days of study.
45787983|NCT02613117|Device|Potassium Oxalate Gel|Self applied
45787984|NCT02613117|Device|Potassium Oxalate Liquid|Professionally Applied
45787985|NCT02613117|Drug|Stannous fluoride paste|SnF2 Paste
45787986|NCT01742117|Drug|Clopidogrel|One 75 mg tablet per day by mouth for one year
45787987|NCT01742117|Drug|Ticagrelor|One 90 mg tablet twice per day by mouth for one year
45787988|NCT04149795|Diagnostic Test|Online questionnaire|Online questionnaire via SoSciSurvey
45787989|NCT01777035|Other|early PT OT|"Passive range of motion (ROM) in pts who remain unresponsive despite sedative interruption.~active assisted ROM in supine position.~treatment is advanced to bed mobility activities~sitting balance activities followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.~progression to transfer training, and finally pre-gait training and ambulation.~progression of activities dependent on patient tolerance and stability~therapy sessions continue on a daily basis throughout hospital stay until return to prior level of function or is discharged."
45787990|NCT02613897|Drug|Saxagliptin|Saxagliptin (Onglyza™) is approved by the US FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. The 5 mg dose will be used for this study as it is the dose that is routinely used in the clinic. In addition, this dose is used in the pivotal studies in the saxagliptin/dapagliflozin clinical program.
45787991|NCT02613897|Drug|Dapagliflozin|Dapagliflozin (Farxiga) is approved by the FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Dapagliflozin (Farxiga) is also approved in the EU as an adjunct to diet and exercise to improve glycemic control in patients with T2DM for whom metformin use is considered inappropriate due to intolerance, and in combination with other glucose-lowering medicinal products when these, in combination with diet and exercise do not provide adequate glycemic control. The 10 mg dose was chosen for this study because it has been extensively studied in Phase 3 trials and has demonstrated a favorable benefit-risk profile. In addition, this dose is the most commonly used dose in most countries.
45787992|NCT02613897|Drug|Placebo|Placebo
45787993|NCT01305356|Device|Augment® Injectable Bone Graft|Implantation of up to 9cc of Augment® Injectable Bone Graft
45787994|NCT01305356|Procedure|Autologous bone graft|Implantation of up to 9cc of autologous bone graft
45645566|NCT02338297|Drug|PVA|Occlude arterioportal shunts(APS) with PVA
45787995|NCT02615535|Device|EEG neurofeedback-assisted meditation|meditation with auditory feedback regarding EEG status
45787996|NCT02615535|Device|Non-EEG feedback-assisted meditation|meditation without auditory feedback regarding EEG status
45787997|NCT05732181|Drug|The skin lidocaine patch.|The skin patch is applied before RFA while admission and is changed every day till discharge. Pain severity is evaluated by visual analogue scale using a 10-point scale recorded before RFA and after the procedure.
45787998|NCT05732181|Drug|Placebo|patch without drugs
45787999|NCT02589171|Device|Neo Close Abdominal Closure|Neo Close Abdominal Closure
45788000|NCT02589171|Device|Carter Thomason Device|Carter Thomason Device
45788001|NCT05732025|Device|Electrohydraulic shock wave lithotripsy|Pre-treatment of severe calcified coronary lesions with electrohydraulic shock wave lithotripsy
45645567|NCT05011799|Behavioral|Cancer Educational Materials|Receive prostate cancer educational materials
45645568|NCT05011799|Other|Questionnaire Administration|Ancillary studies
45645569|NCT05011799|Other|Educational Intervention|Attend peer-led education sessions
45788002|NCT05732025|Device|Rotary atherectomy|Pre-treatment of severe calcified coronary lesions with rotary atherectomy
45645570|NCT02338219|Other|postpartum female pelvic floor muscle affection|"transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology."
45645571|NCT02338219|Other|postpartum sexual function in Egyptian women.|answering of the validated female sexual function index (F.S.F.I) three months postpartum period for same cases submitted to ultrasound.
45645572|NCT05011643|Other|Moderate-intensity exercise|Participants will walk either 30km, 40km or 50km for four consecutive days during the Nijmegen Four Days Marches. Measurements will be performed after the finish of the first, second and third walking day.
45645573|NCT03111979|Dietary Supplement|beta-alanine|
45788003|NCT02591511|Device|smart phone and pad|Smart phone and pad is the mobile include the smart phone and pad, that can download the APP from internet.
45788004|NCT02591511|Other|stroke-related health education manual|stroke-related health education manual is the manual mainly contained information regarding the prevention of stroke risk factors.
45645574|NCT03111979|Dietary Supplement|Placebo|
45645575|NCT05004623|Device|Sentinel Lymph Node Biopsy|Detection of sentinel lymph nodes by indocyanine green (ICG) fluorescent dye technique, using a prototype of the Easy Light device.
45645576|NCT05004779|Procedure|human stem cell conditioned media was applied after non-ablative laser therapy|After laser treatment on hypertrophic scars, human stem cell media was applied to one side
45645577|NCT05004779|Procedure|normal saline was applied after non ablative laser therapy|physiological saline was applied to the other side.
45645578|NCT05011019|Drug|AL2846 capsules|AL2846 is a multi-target receptor tyrosine kinase inhibitor.
45788005|NCT05731869|Other|epicondylitis band|An off-the-shelf lateral epicondylitis tape in S-M-L dimensions was used distal to the lateral epicondylitis.
45788006|NCT05731869|Other|wrist orhosis|Wrist orthosis of the shelf was used in sizes S-M-L, covering the hand and wrist.
45788007|NCT02976051|Radiation|HART-CN|HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cis-platin and daily nimorazole
45788008|NCT01342172|Drug|Lenalidomide|"Patients will receive gemcitabine 1000 mg/m2 IV on days 1 + 8 and cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Lenalidomide will be given orally on days 1-14 and the dose will be escalated in successive cohorts during the phase Ib portion to define the recommended phase II dose. Patients will continue gemcitabine, cisplatin, plus lenalidomide for up to 6 cycles, in the absence of disease progression or prohibitive toxicity. After completion of 6 cycles of therapy, patients who have achieved at least stable disease will proceed with maintenance lenalidomide given orally on days 1-21 of each 28-day cycle. Treatment will continue, in the absence of prohibitive toxicity, until the time of disease progression."
45788009|NCT01243112|Drug|1% Lidocaine with Epinephrine (1:100,000)|0.2ml Intradermal injection once.
45788010|NCT01243112|Drug|0.25% Bupivacaine with Epinephrine (1:200,000)|0.2ml Intradermal injection once.
45788011|NCT01243112|Drug|0.5% Lidocaine, 0.125 Bupivacaine, and epi (1:150,000)|0.2ml Intradermal injection once.
45788012|NCT01243112|Drug|1% Lidocaine, 0.5% Bupivacaine, and epinephrine (1:150,000)|0.2ml Intradermal injection once.
45788013|NCT05731635|Diagnostic Test|plantar pressure values|Walking enables for extremely accurate and pointwise ground response force measurement because to plantar pressure measurement (pedobarography). It allows for the objective comparison and evaluation of the dynamic pressure put on the ground by the foot in contact with it. It is often used in clinics to assess foot mechanics and associated disorders that affect the foot sole. Additionally, plantar pressure analysis is useful for identifying, treating, and monitoring conditions that impact the lower extremity's axial alignment.
45788014|NCT01243580|Drug|Ortho-Cyclen|Ortho-Cyclen is an oral contraceptive containing 35 µg of EE and 250 µg of norgestimate (NGM) in a 21 - 7 day regimen.
45788015|NCT01243580|Drug|AG200-15|AG200-15 is a transdermal contraceptive delivery system delivering 100 - 120 mcg of LNG and 25 - 30 mcg EE
45788016|NCT02975817|Other|Hibler's|Passive body heat retention using multiple-layer tight wrapping of patient
45788017|NCT02975817|Other|Warm Air|Active, convective warming of patient using warm air blanket
45788018|NCT05372211|Other|not use of any intervention|not use of any intervention
45788019|NCT01306292|Drug|SonoVue|dose of 4.8 mL administered intravenously one time
45788020|NCT01306292|Drug|Placebo|Placebo is normal saline 0.9% for injection used as the comparator administered at 4.8 mL (same dose as SonoVue)
45788021|NCT05731401|Other|Explanations of the cause of pain|"When analyzing the responses to the question Why do you think you have or have had this pain? two themes emerged from the data: 'explanations associated with damage', and 'explanations not associated with damage'.~The themes were sub-classified into sub-themes, according to the type of explanation"
45788022|NCT01743521|Drug|TPV/PEG-IFN/RBV|"Drug Telaprevir (TPV): dosed 1125mg twice daily (given as three 375 mg film-coated tablets) orally, except in the situation where a patient is on efavirenz in which case the dose of telaprevir will be 1125mg three times daily.~Drug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing <75kg and 1200mg for patients weighing ≥ 75kg).~Drug PEG-IFN (other name: Pegasys): 180mcg in 0.5ml (pre-filled syringes) administered subcutaneously once weekly."
45788023|NCT05371821|Device|Echocardiography|Echocardiographic parameters in obese and overweight
45788024|NCT00361803|Drug|topotecan|topotecan
45788025|NCT00365703|Procedure|Feeding tube insertion|"Orogastric feeding tube~Nasogastric feeding tube"
45788026|NCT00361881|Drug|ME-609|Cream, dose 5 times daily during 5 days.
45788027|NCT00361881|Drug|acyclovir in ME-609 vehicle|Dose 5 times daily for 5 days
45919578|NCT00846664|Procedure|Logan Short Arc Banding|Group 1 wil perform short arc banding twice a week for four weeks and have diagnostic ultrasound of multifidus measured before and after intervention
45919579|NCT03772964|Drug|MetFORMIN Hydrochloride ER|Subjects will be exposed to 500mg, 1000mg, or 1500mg of daily ER Metformin, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.
45788028|NCT00361881|Drug|Vehicle|Dose 5 times daily for 5 days
45788029|NCT00365781|Drug|ISIS 113715|
45788030|NCT01743677|Drug|CP-690,550|Single dose 100 mg (5 x 20 mg tablets)
45788031|NCT01743677|Drug|Placebo|Single dose placebo tablets (5 tablets)
45788032|NCT01743677|Drug|Moxifloxacin|Single dose Avelox 400 mg tablet
45788033|NCT00365937|Biological|Immunological peptides and immunological adjuvants|
45788034|NCT00365937|Biological|HLA-A2 peptides|Tyrosinase.A2: lyophilized powder, 326 mcg, 5 injections every 3 weeks MAGE-C2.A2: lyophilized powder, 320 mcg, 5 injections every 3 weeks NY-ESO-1b.A2: lyophilized powder, 290 mcg, 5 injections every 3 weeks MAGE-4.A2: lyophilized powder, 299 mcg, 5 injections every 3 weeks MAGE-3.A2: lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-1.A2: lyophilized powder, 298 mcg, 5 injections every 3 weeks NA17.A2 (GnTV): lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-10.A2: lyophilized powder, 309 mcg, 5 injections every 3 weeks
45788035|NCT00365937|Biological|Montanide ISA51|Oil emulsion (W/O: droplet test S57 IN 001), conductivity less than 10mcs.cm-1, viscosity: 1500 mPas (brookfield DVI - spindle 2- Speed 30). For human applications. Injected 5 times every 3 weeks.
45788036|NCT00365937|Biological|IMP321|"Official name of the LAG-3 molecule is CD223. Chemical structure: hLAG-3Ig is a soluble human recombinant LAG-3 protein comprising the extra-cellular Ig-like domains.~The IMP321 drug product is composed of a soluble recombinant protein at a 1.18 mg/ml concentration, in PBS (Na2HPO4 2H2O 8.1mM, KH2PO4 1.47mM, NaCl 137mM, KCl 2.68mM, PH 7.2). Batch number: S017/LC1/041011.IMP321 will be provided in 250mcl aliquots in brosilicate siliconized vials."
45919580|NCT03772964|Drug|Placebo|Subjects will be exposed to placebo, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.
45919581|NCT00846625|Drug|triamcinolone|Intravitreal injection (4 mg/0.1 ml)
45919582|NCT00846625|Drug|ranibizumab|Intravitreal injection, 0.5 mg
45788037|NCT01246076|Drug|Lenalidomide|
45788038|NCT00364455|Drug|Epoetin alfa|
45788039|NCT01745627|Device|755nm Alex laser|
45788040|NCT05731245|Drug|Ropeginterferon Alfa-2B Prefilled Syringe [Besremi]|Eligible subjects will receive Ropeginterferon alfa-2b subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards
45788041|NCT01307462|Drug|fluticasone propionate|Given inhaled PO
45788042|NCT01307462|Drug|montelukast sodium|Given PO
45788043|NCT01307462|Drug|azithromycin|Given PO
45788044|NCT04071951|Behavioral|Pharmacist-led Hospital Discharge Care Intervention|"Pharmacists will address medication reconciliation, medication adherence, and polypharmacy issues as appropriate. Pharmacists will rely most on their prior training, but study investigators will also encourage the use of documentation templates with reminders, Beers list, deprescribing, motivational interviewing, the Medication Adherence and Literacy tool, and post-discharge phone calls.~Pharmacists will assess patient needs and customize accordingly. All patients will receive one discharge counseling visit and one post-discharge phone call, but pharmacists will find that some patients need further phone calls, interventions, referrals, or other interactions. Some or all of the pharmacist activities may take place over the phone."
45645579|NCT02331823|Drug|Isoniazid Aminosalicylate Tablets|a regimen consists of 5 anti-TB drugs (Isoniazid Aminosalicylate Tablets+pyrazinamide tablets+ethambutol tablets+rifabutin capsules+moxifloxacin tablets)to treat retreatment pulmonary tuberculosis patients. The total treatment course is 5 months.
45645580|NCT02331823|Drug|Streptomycin injectable|standardized regimen 2 months of streptomycin injectable + isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules or 3 months of isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules to treat Arm B patients as a control to arm A.The treatment course is 8-9 months.
45919583|NCT00846547|Drug|Arbaclofen|variable dose from 1mg bid to 10 mg tid, oral capsule, 8 week treatment period
45919584|NCT00846508|Drug|Cisplatin|Cisplatin is available commercially as a sterile lyophilized white power in single-dose amber vials containing 10 mg or 50 mg of cisplatin for administration by IV infusion. Every effort should be made to obtain and record the lot numbers of the batches of cisplatin used. Unopened vials of cisplatin are stable for the shelf-life indicated on the package when stored in accordance with the manufacturers' instructions.
45919585|NCT00394030|Drug|GSK716155 subcutaneous injections|GSK716155 will be available as lyophilize uniform cake in 10 milliliter (mL) clear glass vials with 20 millimeter (mm) closure. Subjects will administer dose of either 16mg or 64mg of GSK716155 via subcutaneous injection(s). For dose of 16 mg 1 injection of 0.62 mL will be administered and for dose of 64 mg 3 injections of 0.82 mL each will be administered.
45919586|NCT00394108|Procedure|Determination of neuropsychological status|
45919587|NCT03721172|Drug|Apremilast|Apremilast, oral, twice daily
45645581|NCT05011097|Drug|Y150|Subjects will receive an intravenous infusion of Y150 in a dose escalation once a week for a 28-day treatment cycle until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
45645582|NCT02890459|Other|Prize incentive - Low|Low expected prize value.
45919588|NCT03721172|Other|Placebo|Placebo, oral, twice daily
45645583|NCT02890459|Other|Prize incentive - High|High expected prize value.
45645584|NCT02890459|Other|Escalating payment incentive|"The incentives will increase in value when participants are found to meet the pre-specified virologic suppression criteria at 6 weeks, 3 months and 6 months.~If the virologic threshold for an incentive is missed at the 6 week or 3 month time-point, the subsequent incentive for an undetectable HIV viral load will be reset to the initial incentive value."
45645585|NCT02890459|Other|Travel Voucher|Travel voucher to assist with linkage to care.
45645586|NCT02890459|Other|Standard care|Includes HIV viral load and treatment adherence counseling.
45645587|NCT02890459|Behavioral|Fixed Incentive - Prize|Men are informed that if they come for HIV testing, they will receive a specific prize (gain framing). The prize will be an item worth the same amount in US dollars as loss aversion and the expected value of a lottery prize. This gain-framed incentive resembles the form that incentives usually take in most studies and serves as a comparison to the lottery-based and loss-framed incentives.
45645588|NCT02890459|Behavioral|Loss Aversion - Prize|The prizes are worth approximately the same amount as the fixed incentive and expected value of a lottery prize. At the time of randomization, study staff will inform the participant that he has won a prize. Staff will ask the participant to choose a specific prize from several choices, and then provide an opportunity for the participant to see the prize. Study staff will then tell participants that they will lose the prize if they do not participate in HIV testing. In this way, the incentive is framed as a loss rather than a gain, thereby leveraging loss aversion while not requiring men in very low-income settings to experience an actual loss.
45645589|NCT02890459|Behavioral|Lottery - Prize|"Men are entered in a lottery that offers a chance to win high-value prizes after testing for HIV at a community health campaign. Staff will emphasize that only those who come for HIV testing will be entered into the lottery and that not everyone will win a prize. Participants were informed at enrollment about the list of prizes and corresponding probabilities of winning them, in terms that are understandable to men with low numeracy (e.g., 1 in 20 rather than 5%). The probabilities of winning prizes varied between 1-5%, with higher value prizes having lower probability."
45645590|NCT02890459|Behavioral|Fixed Incentive - Voucher|A standard gain-framed incentive arm in which participants will be offered a voucher for coming for a repeat HIV test in the future.
45645591|NCT02890459|Behavioral|Loss Aversion - Deposit|A loss-aversion framed incentive in which participants will be asked to voluntarily make a deposit that can be retrieved, with interest on the deposit, if they come for an HIV test in the future (i.e. for repeat testing)
45645592|NCT03077009|Drug|Hyaluronic Acid|Ultrasound guided injection for plantaris friction syndrome
45788045|NCT04340427|Drug|TQB3455|TQB3455 tablets is a small molecule oral drug inhibiting IDH2 mutation.
45788046|NCT05731167|Behavioral|Multidomain frailty prevention method|We use the nutrition, physical training, medication consultation, cognition training to prevent the occurrence of frailty or other adverse outcome.
45788047|NCT05731167|Other|Regular follow up|Subjects will receive regular follow up and suggestion in outpatient department.
45788048|NCT05731089|Procedure|Phacoemulsification with IVI of aflibercept|IVI was either before or after cataract surgery
45788049|NCT01307618|Biological|NA17.A2 Peptide Vaccine|Given SC or ID
45788050|NCT01307618|Biological|Recombinant MAGE-3.1 Antigen|Given SC or ID
45788051|NCT01307618|Biological|Recombinant Interleukin-12|Given SC or ID
45788052|NCT01307618|Biological|MART-1 Antigen|Given SC or ID
45788053|NCT01307618|Other|Laboratory Biomarker Analysis|Correlative studies
45919589|NCT00846469|Procedure|CCTA (coronary computed tomography angiography)|A CCTA (coronary computed tomography angiography) scan is a CT scan of the blood vessels of the heart. This CCTA (Coronary Computed Tomography Angiography)will be performed and a contrast medication will be injected through an IV line to help make the CT pictures more clear. Medication may or may not be given to control your heart rate during the scan. After the scan is completed it will be read. Your emergency room physician will use the CT results to determine your treatment.
45919590|NCT00846469|Other|Control section|Normal emergency room treatment for symptoms of chest pain.
45919591|NCT00846352|Procedure|Variation in the time for performing bronchoscopy|The study will compare outcomes amongst patients assigned to receive early bronchoscopy (within 36 hours of enrollment)versus those in whom bronchoscopy is delayed (5 days after enrollment).
45645593|NCT02333773|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Portal venous tumor emboli guide with ultrasound or/and CT.
45788054|NCT05371431|Other|Traditional rehabilitation training|The non-BFR group undertook traditional rehabilitation training only. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks. Clinical assessment of grip strength, pinch strength (tip pinch strength, key pinch strength and tripod pinch strength), ROM of wrist, PRWE score, muscle stiffness and radiographic outcomes, was conducted at the 6th and 12th week from the date of initial DRF.
45788055|NCT05371431|Other|Blood flow restriction combined with traditional rehabilitation training|BFR group completed the traditional rehabilitation training with a medical grade tourniquet applied on the upper arm. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks. Clinical assessment of grip strength, pinch strength (tip pinch strength, key pinch strength and tripod pinch strength), ROM of wrist, PRWE score, muscle stiffness and radiographic outcomes, was conducted at the 6th and 12th week from the date of initial DRF.
45788056|NCT05653557|Other|Shen Que Moxibustion|Herb-partitioned moxibustion was administered at RN8 (Shen Que), once every 72 hours from the beginning of ovarian stimulation until embryo transfer. Approximately 10 moxa cones will be used for this procedure, which will take approximately two hours. It is recommended that patients close their eyes during the procedure and rest. Following moxibustion, the umbilicus will be affixed and sealed with a medical applicator and removed after 24 hours.
45788057|NCT01307930|Drug|Anidulafungin|Anidulafungin 100 mg IV (each volunteer will only receive one dose of the study drug)
45788058|NCT05731011|Other|antioxidative stress|blood interventions
45788059|NCT05731011|Device|electrotherapy|hotpack,Tens, ultrasound
45788060|NCT02974179|Biological|Subjects from Study AG-CLI-0206 who received AMG0001|Subjects from Study AG-CLI-0206 who received the study product AMG0001
45788061|NCT05371197|Drug|Neoadjuvant therapy with PD-L1 inhibitor|Neoadjuvant therapy with PD-L1 inhibitor (Envafolimab), 300mg, Q3W for 4 cycles
45788062|NCT01309646|Biological|Infanrix™-IPV+Hib|Intramuscular, 3 doses
45645594|NCT05011175|Other|Survey|Participants responded to questions about their exercise habits and perceived levels of intensity as well as demographic information.
45788063|NCT01309646|Biological|Infanrix™ IPV|Intramuscular, 3 doses
45788064|NCT01309646|Biological|Hiberix™|Intramuscular, 3 doses
45788065|NCT01309646|Biological|Synflorix™|Intramuscular, 3 doses
45788066|NCT01309646|Biological|Rotarix™|Oral, 2 doses
45788067|NCT05730855|Diagnostic Test|Real-time Polymerase Chain Reaction technique|Real-time Polymerase Chain Reaction technique
45788068|NCT01746095|Drug|Vancomycin hydrochloride inhalation powder|There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1 active to placebo) and treated patients (adults ≥18 and children ≥12 years of age). In Cohort 1, patients will be enrolled and randomized to receive the 32 mg dose of AeroVanc bid or placebo bid. Prior to starting enrollment in Cohort 2, a safety evaluation will be carried out by the Data Monitoring Committee (DMC) based on treatment data from the first 20 patients in Cohort 1. Subject to the Sponsor's written communication of the DMC's opinion of acceptable safety, the dose for the active arm in Cohort 2 will be escalated to 64 mg bid. Optionally, the active arm for Cohort 2 may also be kept the same (32 mg bid), or reduced to 16 mg bid, depending on the outcome of the DMC's safety evaluation.
45788069|NCT01746095|Drug|Placebo inhalation powder|
45788070|NCT05371119|Other|Exercise Intervention|Training with light load with blood flow restriction (BFR)
45788071|NCT00366015|Procedure|Robotic-assisted Coronary Surgical Revascularization|Robotic assistance of coronary artery bypass grafting using the DaVinci surgical robotic console
45788072|NCT00366015|Procedure|PCI- Drug Eluting Stents|Drug eluting stents performed by cardiologist within the same operating theatre following robotic assisted coronary artery bypass surgery
45919592|NCT05288985|Device|Erector spinae plane catheter group in addition to Systemic Analgesia|Erector spinae plane catheter is placed in the post-interventional surveillance room in the operating theatre by an anaesthetist-intensive care physician or in the MIR department by the intensive care physician in charge of the patient within 2 hours after randomisation. The local anaesthetic injected into the catheter is Ropivacaine, prescribed according to a protocol of continuous flow, bolus and refractory period. The catheter is repositioned if a secondary displacement occurs.
45919593|NCT05288985|Drug|Systemic Analgesia Only Group|Systemic analgesia alone consists only of the 3 levels of analgesic treatment
45919594|NCT00846313|Other|Individual dietary counseling.|Dietary advice based on individual requirement and symptom burden. Dietary intervention may be dietary advice, energy rich foods and drinks, oral nutritional supplements, appetite stimulation with Megestrol Acetate, enteral or parenteral nutrition.
45645595|NCT02331979|Device|Electromagnetic Neuromodulation|Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.
45645596|NCT03079817|Other|Yoga Meditation|Yoga meditation using motor imagery to perceive movement patterns
45645597|NCT03079817|Other|Proprioceptive Drills|Active balance and proprioception drills
45788073|NCT05730777|Drug|Bifidobacterium Bifidum Oral Capsule|Bifidobacterium Bifidum Oral Capsule for 6 months in addition to conventional treatment
45788074|NCT05730777|Drug|Cisplatin|Patients in the control group will receive conventional antitumor treatment only.
45919595|NCT00846274|Biological|SK Antithrombin III|
45919596|NCT00846235|Other|Aqualan L, Aqualan Plus, Aqualan L + glycerol ad 20%|moisturising cream twice daily three weeks
45919597|NCT00846196|Drug|risedronate DR (Phase III clinical supply)|Reference - (Phase III clinical supply) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
45653089|NCT05157425|Dietary Supplement|Food Supplement|Probiotic multistrain formulation containing Lactiplantibacillus plantarum CECT30292, CECT7484, CECT7485 and P. acidilactici CECT7483 for 28 days, starting the same day of influenza vaccination
45653090|NCT05157425|Dietary Supplement|Placebo|One maltodextrin-containing capsule/day for 28 days, starting the same day of influenza vaccination
45653091|NCT05179317|Drug|QL1706|"Drug: QL1706 Intravenous Infusion~Drug: Paclitaxel injection Intravenous Infusion~Drug: Cisplatin/Carboplatin Intravenous Infusion~Drug:Bevacizumab Intravenous Infusion"
45645598|NCT04477525|Procedure|Ultrasound Guided Erector Spinae Plane (ESP) Nerve Block|The planned intervention is a bilateral erector spinae nerve block for patients undergoing bariatric surgery. This intervention will be performed in the PACU for patients with an NRS pain score >5. All eligible candidates who have consented for this study will be present in the PACU, have all standard ASA monitoring placed. The patient will then be placed in a sitting position. The patient will then be prepped with chlorhexidine in the thoracic region and draped in a sterile fashion. The ultrasound will be brought in over the patient and the T7 Transverse Processes (TP) will be identified. An echogenic needle will be placed under direct ultrasound guidance on the TP. Then, 20 cc of 0.25% bupivacaine will be injected.
45645599|NCT04477525|Drug|Bupivacaine Injection|20 cc of 0.25% bupivacaine will be injected
45645600|NCT03079973|Drug|P-3073 (calcipotriene 0.005%)|Topical solution P-3073 (calcipotriene 0.005%) once daily for 24 weeks.
45788075|NCT05730777|Drug|Carboplatin|Patients in the control group will receive conventional antitumor treatment only.
45788076|NCT05730777|Drug|Paclitaxel|Patients in the control group will receive conventional antitumor treatment only.
45788077|NCT05730777|Drug|Atlizumab|Patients in the control group will receive conventional antitumor treatment only.
45788078|NCT04425239|Drug|Panitumumab|Continuous administation
45788079|NCT04425239|Drug|Panitumumab|Intermittent administation
45919598|NCT00846196|Drug|risedronate 35 mg DR (Commercial Tablet)|Test - (Commercial tablets) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
45788080|NCT01309802|Drug|onabotulinum toxin type-A|up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
45645601|NCT03079973|Drug|Vehicle of P-3073|Once daily for 24 weeks.
45645602|NCT03861871|Drug|Fenfluramine Hydrochloride|Oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL. Manufactured by Andersonbrecon, Inc. on behalf of Zogenix International Limited.
45788081|NCT00366093|Drug|Eszopiclone|eszopiclone 3 mg
45788082|NCT00366093|Drug|Placebo|placebo tablet
45919599|NCT00846157|Biological|NKM injection|NKCell about 100mg IV for 6times in each chemotherapy period.
45919600|NCT00846118|Drug|Pitavastatin|1-4mg/day
45919601|NCT00846079|Device|Regadenoson (Lexiscan) [muti-detector computed tomography]|Regadenason, typical dosing
45919602|NCT00846001|Procedure|Coronary artery bypass grafting|Standard coronary surgry according guidelines
45788083|NCT04379999|Drug|Atorvastatin 20mg|No history of colorectal cancer and no colorectal adenomas within 5 years.
45788084|NCT04379999|Drug|Atorvastatin 20mg AND Aspirin 325 mg|History of colorectal cancer and/or history of colorectal adenomas within 5 years.
45919603|NCT00846001|Device|Epicardial implantation of cardiac resynchronization therapy device|During the cardiac surgery, the CABG+CRT arm patients will be implanted with epicardial leads to the right atrium, right and left ventricles. Left ventricle leads will be fixed to the posterolateral wall provided that there is no scar or fat tissue (behind and 2-3 cm apical than obtuse marginal artery). Right atrial and right ventricular leads will be fixed in a traditional way. Then the leads will be guided into a preformed pocket (left subclavian region) and connected with the CRT device.
45919604|NCT03651401|Device|Scapular muscle endurance test|The SME test, developed by Edmondston et al. 17, is based on an exercise used to improve the performance of the serratus anterior and trapezius muscles. The test was carried out while the subjects were facing the wall in standing position and with their shoulders and elbows flexed to 90 degrees. While both scapulae were in neutral position, an appropriate size of stick (18-36 cm) was selected and placed between the elbows, and they were asked to hold the dynamometer (Feta 137 F0202 1 kg/10 N) between their hands.
45919605|NCT03651401|Other|Pain intensity|"Pain intensity assessment was performed by questioning rest, activity, night, and measuremant pain using a visual analogue scale (VAS) on a 10 cm line with marks at both ends to define the limits of the pain experience as no pain (0) and maximum pain experienced (10), with higher scores indicating greater pain 20."
45919606|NCT03651401|Device|Upper Limb Functional Performance|The Functional Impairment Test-Hand and Neck/Shoulder/Arm (FIT-HaNSA) protocol, which was developed by MacDermid et al. 21, was used to evaluate the functional performance of the upper extremity when performing 3 tasks.
45919607|NCT00845962|Drug|chloroprocaine|spinal administration of chloroprocaine 2%, 40 mg (2 mL)
45645603|NCT03076853|Other|Opening of the Pharmaceutical Record|After a first prescription without the pharmaceutical record, the study investigator has to open the pharmaceutical record to obtain some additional data. After, he has to choose between maintain or modify his first prescription.
45788085|NCT00422253|Behavioral|dietary intervention|
45788086|NCT01309880|Device|Test lens|Investigational silicone hydrogel contact lens worn on a daily wear basis
45788087|NCT01309880|Device|Air Optix Aqua|Air Optix Aqua contact lens worn on a daily wear basis
45788088|NCT04332887|Behavioral|Multidimensional Exercise Program|Patients in experimental group will receive a 12 week exercise program; patients in control group maintain their usual life activities.
45788089|NCT05370807|Drug|Regorafenib 40 MG Oral Tablet|Patients take 2 regorafenib oral tablets of 40 mg daily
45788090|NCT03009422|Drug|Local application pentostam|
45788091|NCT03009422|Drug|intra-lisional pentostam|
45788092|NCT03009422|Device|fractional CO2 laser|
45788093|NCT05730621|Drug|Sarpogrelate Sustained Release/Aspirin|Aspirin 100mg qd and Sarpogrelate Sustained Release 300mg qd for 12 weeks
45788094|NCT05730621|Drug|Aspirin|Aspirin 100mg qd for 12 weeks
45788095|NCT01346072|Drug|tolvaptan|oral, 30 mg, single dose, one time administration
45788096|NCT04313231|Diagnostic Test|Next Generation Sequencing|"Sequencing of patient samples will be performed in the facilities of ZIMCL. Following DNA extraction, the sequencing of granulocytes as well as of lymphocytes (control) will be carried out. IN addition to whole exome sequencing, a panel from SOPHIA GENETICS (which is also available for routine diagnostics) will be applied including the following MDS specific genes: ASXL1, BRAF, CBL, CEBPA, CSF3R, DNMT3A, EZH2, FLT3, HRAS, IDH1, IDH2, KRAS, MPL, NPM1, NRAS, RUNX1, SF3B1, SRSF2, TET2, TP53, U2AF1, WT1, ZRSR. Each patient sample will be bulk sequenced, meaning that relevant mutations are detected down to an allele frequency of 2%."
45788097|NCT04313231|Diagnostic Test|Tumorimmunological examinations - multiplex assays/quantitative polymerase chain reaction|"Inflammasome activation is quantified by analyses of inflammasome-associated cytokine patterns. Multiplex assays for the quantification of the inflammasome-specific cytokines will be done from serum as well as from supernatants the stimulated blood cells. Cytokine quantification is carried out with Luminex FlexMap 3D. Serum cytokine levels will be quantitated in parallel.~Quantification of RNA expression levels of inflammasome-related gene products will be performed by qPCRs from unstimulated and stimulated (=cryotube) blood cells. The necessary RNA extraction will be performed using a RNA extraction kit."
45788098|NCT04313231|Diagnostic Test|flow cytometry|A detailed evaluation of the individual immune status is being conducted by the analysis of two specialized panels: Panel A provides a broad overview over various immune cell populations, while Panel B identifies T-cell sup-populations.
45788099|NCT04313231|Diagnostic Test|Metagenomics of stool samples|DNA will be extracted from frozen fecal samples applying a bead-beating method using a GNOME DNA Isolation Kit (MP Biomedicals). DNA quality will be assessed using an Agilent 4200 TapeStation (Agilent Technologies). After final precipitation, DNA samples will be re-suspended in TE buffer and stored at -80 °C for further sequencing analysis. To this end, sequencing libraries will be generated using a Nextera XT DNA Sample Prep Kit (Illumina). Library quality will be confirmed using an Agilent 4200 TapeStation. Whole-genome shotgun sequencing of fecal samples will be carried out on a HiSeq2500 platform (Illumina).
45788100|NCT04313231|Diagnostic Test|Clinical/demographic data|Demographic and clinical data include: age, age at initial diagnosis, sex, diagnosis, actual comorbidities, medication at inclusion in study, cytogenetic and molecular profiles and standard laboratory parameters (blood count, differential leukocyte count, biochemistry, iron status, inflammatory markers like CRP, albumin, fibrinogen).
45788101|NCT04313231|Other|Elicitation of the HRQoL|Evaluation of HRQOL, of functional activities and of performance status will be done by the patient and/or the physician using validated scores.
45788102|NCT03008720|Device|Transcranial direct current stimulation (tDCS)|
45788103|NCT03008720|Device|Functional electrical stimulation (FES)|
45788104|NCT03008720|Device|Sham stimulation|
45645604|NCT05004545|Drug|Propofol|Propofol infusion according to body weight will be compared with sevoflurane acording to MAC % to see the lactate level and hemodynamic parameters of CABG patients
45645605|NCT03079895|Behavioral|Thrive|Thrive is an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy principals.
45645606|NCT02337595|Biological|CD45RA-depleted peripheral blood mononuclear cells|Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
45645607|NCT05003999|Device|HPC - SpeediCath ®|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a hydrophilic catheter
45645608|NCT05003999|Device|Non-HPC - Self-Cath ®|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a non-hydrophilic catheter; Lubrication jelly (MUKO ®, 3.5g package, Cardinal Health Canada Inc, Toronto, ON, Canada) was provided
45645609|NCT02337439|Behavioral|Sensory Information Processing Training|Computer exercises requiring identification of visual stimuli on computer screen and response with keyboard
45645610|NCT02337439|Behavioral|Active Control Training|Commercially available educational software
45788105|NCT04292483|Drug|Nitric Oxide|Inhaled vasodilator to increase pulmonary capillary perfusion
45788106|NCT01346852|Drug|Asthma treatment with an asthma-related medication and at least one asthma controller medication|participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol.
45788107|NCT05727501|Other|Post isometric relaxation|post isometric relaxation in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
45788108|NCT05727501|Other|Post facilitation stretching|post facilitation stretching in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
45788109|NCT01347008|Drug|Sildenafil citrate|Oral sildenafil citratre, 50mg b.i.d., 8 weeks
45788110|NCT01347008|Drug|Placebo (Sugar pill)|Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks
45788111|NCT05725005|Drug|ASN51|ASN51 formulation for oral capsule
45788112|NCT05357235|Drug|PEG-IFN|PEG-IFN 180 or 135 micrograms, subcutaneously injected once a week, with a personalized treatment course of 24 weeks
45645611|NCT04463615|Drug|Leflunomide|Given PO
45645612|NCT05003765|Drug|Bupivacaine 0.25% Injectable Solution|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block.
45788113|NCT01347788|Drug|cabozantinib|Cabozantinib PO QD
45788114|NCT05343429|Drug|Benzydamine hydrochloride|In BN group,15 ml of 0.15 % Benzydamine hydrochloride (BN) will be dissolved in 15 ml plain water in a sterile container and given to participants before anesthesia for surgery
45788115|NCT05343429|Drug|Aspirin|In group AP, Aspirin (AP) 600 mg Aspirin tablets dissolved in 30 ml of plain water in a sterile container will be given to participants for gargling before anesthesia for surgery
45788116|NCT01349114|Drug|aliskiren 300 mg once daily|aliskiren 300 mg daily
45788117|NCT01349114|Drug|Placebo/sugar pill|Sugar pill/placebo
45788118|NCT01310582|Drug|Desflurane|
45788119|NCT01310582|Drug|Sevoflurane|
45788120|NCT02247050|Behavioral|Commitment invitation|Clinicians will be invited to commit to follow 3 Choosing Wisely recommendations. Those that choose to commit will also receive point-of-care commitment reminders, point-of-care Choosing Wisely patient education handouts, and weekly emails with decision support resources.
45919608|NCT00845962|Drug|bupivacaine|spinal administration of bupivacaine 0,75% 7,5 mg (1 mL)
45788121|NCT04741737|Procedure|reSLNB arm|Radioisotope, blue dye, dual mapping methods are all allowed for re-SLNB mapping. Positive finding in re-SLNB is defined according to AJCC 8th edition, as micrometastasis or macrometastasis. Isolated tumor cell is considered negative. When sentinel lymph node is not identified, axillary operation is via physician's choice. When re-SLNB finding is negative, no further axillary lymph node dissection is performed. If there is node metastasis from re-SLNB, axillary lymph node dissection or radiation therapy can be performed as in physician's choice.
45645613|NCT05003765|Drug|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate as adjuvant.
45645614|NCT05003765|Drug|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Buprenorphine 300 mcg|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate and 300 mcg buprenorphine as adjuvants.
45645615|NCT05010863|Other|Blood collection|The subject will be drawn a 5ml blood sample
45788122|NCT01311362|Drug|St. Johns wort|"Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~Administration of SJW: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
45788123|NCT04741191|Other|Cycle ergometer training|Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown), 3x/week on alternate days for 6 weeks at 40-60% of VO2max.
45788124|NCT04741191|Other|Conventional therapy|In bed activities (Active ankle and hand pumping exercise* 15 Rep* BD AROMS of extremities* 15 Rep* BD, Deep breathing exercises* 15 Rep* BD, Ambulation (walk 10-15 minutes below fatigue and onset of symptoms level* BD) for 6 weeks.
45788125|NCT05193591|Other|Autoantibodies evaluation in lupus|"Biological analysis: anti-C1s, anti-HMGB1 and anti-C1q autoantibodies; C1s, HMGB1 and C1q proteins.~Purification of patients' autoantibodies (anti-C1s, anti-HMGB1and anti-C1q). Identification of the molecular targets recognized by anti-C1s, anti-HMGB1 and anti-C1q autoantibodies purified from the SLE patients' serum."
45788126|NCT05165901|Device|Scrambler Therapy|LG Medipain is a type of non-invasive neuromodulation.
45788127|NCT01311674|Biological|hepatitis B vaccine|Primary vaccination series 20 µg/1.0 mL at baseline, month 1, month 6; followed by booster vaccinations 20 µg/1.0 mL
45788128|NCT01311674|Biological|hepatitis B vaccine|Primary vaccination series 40 µg/2.0 mL at baseline, month 1, month 2, month 6; followed by booster vaccinations 20 µg/1.0 mL
45645616|NCT05003375|Behavioral|High-challenging cognitive protocol to provoke stress and (cognitive) fatigue|"Baseline measurement is done in two parts: 1) resting for five minutes (no talking, no movement) and 2) speaking at normal pace (2 minutes).~This is immediately followed by a measurement of the physiological response variables during the testing, in which the following protocol is performed in the order presented: 1) SDMT-NBack task-SDMT*-NBacktask**, 2) NBack task-SDMT-NBack task-SDMT. Participants will run either sequence to check for effects of the previous testing. During the conduct of the study, it will be ensured that half of the participants in each group followed Sequence 1 and the other half of the group followed Sequence 2.~During all these measurements, the participant will sit at a table with a computer on which the tests are performed.~*SDMT: Symbol Digit Modalities Test: see description in outcome measures~**N-Back Task: see description in outcome measures"
45788129|NCT04742829|Dietary Supplement|INTRAVIT ®|2 tablets per day morning and evening before meals
45788130|NCT05578209|Device|intermittent theta burst stimulation|stimulatory protocol
45788131|NCT05561751|Drug|GPC-100|GPC-100 is to be administered at a dose of 3.14 mg/kg GPC-100 free base via IV infusion. The corresponding volume of the reconstituted GPC-100 solution calculated based on the patient weight will be administered via IV infusion over 15 min
45788132|NCT05561751|Drug|Propranolol|propranolol
45788133|NCT05561751|Drug|G-CSF|G-CSF
45788134|NCT05081193|Drug|Testosterone Undecanoate|198mg taken twice daily
45645617|NCT05010239|Other|30-minute Mindfulness-Based Supportive Therapy|The MBST consists of a session that involves interviewing patients with open-ended questions on suffering experiences. During the session, the practitioner will practice mindful breathing simultaneously while listening to patients. The practitioner will acknowledge the distress of patients when it is appropriate, but without losing their attention on mindful breathing.
45645618|NCT05010239|Other|30-minute supportive listening|Patients in the control group will receive a 30-minute supportive listening session by a palliative care physician who has no experience in mindfulness practice. The session involves interviewing patients with the same open-ended questions on suffering experiences. The practitioner will acknowledge the distress of patients when it is appropriate. Outcomes will be measured at baseline and at minute 30.
45645619|NCT03111589|Biological|Inactivated influenza A (H1N1) virus vaccine|All groups of patients and the control group will receive the new annually recommended inactivated influenza A (H1N1) virus vaccine.
45645620|NCT03111589|Diagnostic Test|Blood sampling|Testing of the different humoral immune responses to vaccines or to erythrocyte alloantigens.
45788135|NCT05081193|Drug|Enzalutamide|160mg taken once daily
45788136|NCT01349972|Drug|alvocidib|Given IV
45788137|NCT01349972|Drug|daunorubicin hydrochloride|Given IV
45788138|NCT01349972|Drug|mitoxantrone hydrochloride|Given IV
45788139|NCT01349972|Drug|cytarabine|Given IV
45788140|NCT01248104|Drug|Tranexamic Acid|Infusion during cardiac surgery
45788141|NCT01248104|Drug|Aminocaproic Acid|Infusion during cardiac surgery
45919609|NCT00845923|Drug|Civamide Patch|Patch containing Civamide (zucapsaicin) 0.015%, containing 0.210 mg Civamide per patch, applied once a day for four weeks.
45919610|NCT00667030|Behavioral|Weight loss and aerobic exercise training|Weight loss and aerobic exercise training
45645621|NCT05003297|Other|hemogram inflammatory parameters|Neutrophil to Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR)
45645622|NCT02337283|Drug|BI 425809|Tablets
45788142|NCT01725815|Behavioral|HARP Intervention|The HARP intervention is a 6-week, 6-session, group format intervention to improve self-management of chronic medical diseases. Each group lasts 90 minutes and has 8-12 attendees. Between groups, participants work with partners from the group to troubleshoot problems and accomplish action plans identified during the session. At the end of the program, monthly alumni groups meet for six months to reinforce lessons from the intervention, monitor progress, and maintain peer support.
45788143|NCT01351064|Other|CHICA ADHD Module|This module was added to CHICA to help diagnose and manage ADHD
45788144|NCT05019651|Device|Apollo Wearable System|Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phone. Participants will use the Apollo for at least 30 minutes after waking up in the morning and at least 30 minutes before bed on the corresponding settings for those times of day. They will be given the Apollo Device TVS (10-200 Hz) to borrow which they will be instructed to wear for 6 +/- 2 weeks. They will be asked to continue to wear the device until all study data is collected.
45645623|NCT02337283|Drug|Placebo|Tablets
45919611|NCT03620942|Drug|Phenylephrine|"Phenylephrine will be administered with conditions as below:~When systolic blood pressure is between 90-110% of baseline, 25mcg phenylephrine will be given either in infusion or bolus if heart rate ≥ 60 beats/min;~When systolic blood pressure is less than 90% of baseline, 25 to 75mcg phenylephrine will be given either in infusion or bolus if heart rate ≥ 60 beats/min."
45919612|NCT03620942|Drug|Ephedrine|"Ephedrine will be administered with conditions as below:~When systolic blood pressure is between 90-110% of baseline, 2mg ephedrine will be given either in infusion or bolus if heart rate < 60 beats/min;~When systolic blood pressure is less than 90% of baseline, 2 to 6mg ephedrine will be given either in infusion or bolus if heart rate < 60 beats/min."
45919613|NCT03620942|Device|ADIVA System|"When systolic blood pressure (SBP) is 100-110% of baseline, 25mcg phenylephrine (infusion) is given if heart rate ≥ 60 beats/min, and 2mg ephedrine (infusion) is given if heart rate < 60 beats/min;~When SBP is 90-100% of baseline, 25mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 2mg ephedrine (infusion or bolus) is given if heart rate < 60 beats/min;~When SBP is 80-90% of baseline, 50mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 4mg ephedrine (infusion or bolus) is given if heart rate < 60 beats/min;~When SBP < 80% of baseline, 75mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 6mg ephedrine (infusion or bolus) is given if heart rate < 60 beats/min."
46071259|NCT02549053|Procedure|esophagus biopsies (pathologic and healthy zones)|Biopsies were realised in the distal third of esophagus : 4 for Barrett esophagus patients (2 in healthy zone, 2 in pathological zone).
46071260|NCT02549053|Procedure|esophagus biopsies (healthy zones)|Biopsies were realised in the distal third of esophagus :2 for control patients in healthy zone
46071261|NCT01461278|Device|iStent supra|Cataract surgery and implantation of one iStent supra
46071262|NCT01461278|Procedure|Cataract surgery|Cataract surgery alone
46071263|NCT00828529|Drug|TMC207|
46071264|NCT02846402|Other|Oral HIV Self-Testing|The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
46071265|NCT00824551|Procedure|Hyperbaric Oxygen Therapy|2 sessions of HBOT ( HDMC 14)
46071266|NCT00824551|Other|Standard care|Patient will undergo standard care
45788145|NCT01747343|Behavioral|Underwear/Differential Reinforcement|Participants are going to be placed in underwear. Differential reinforcement will then be implemented.
45788146|NCT01351376|Device|Low Level Laser Therapy|Placebo LLL combined with CDT
45788147|NCT01351376|Device|Low Level Laser|Active LLL combined with CDT
45788148|NCT01748045|Drug|inhaled nitric oxide|
46071267|NCT00632762|Drug|mantadix|dose greater or equal to 200 mg/day and progressively increasing doses (100mg every 3 days until the pre-study dose is reached).
46071268|NCT00820183|Other|Quality Improvement plan for Hypertension Control|"Implementation of a plan of quality improvement addressed to health professionals in Primary Health Care Teams. It includes:~Specific training programme on how to diagnose hypertension , and measure blood pressure correctly To send feed back information to primary care health professionals about poorly controlled hypertensive patients An audit will be performed, every 6 months, to see the adhesion to the recommended clinical guidelines , and the information will be diffused among the participant primary health care professionals Each participant primary health care team will have a designated reference person, that will provide support on any doubts on the programme implementation"
45788149|NCT01748045|Drug|Placebo Comparator - nitrogen gas|
45788150|NCT03009266|Drug|Sonazoid|Myocardial contrast echocardiography ischemic memory imaging using intravenous administration of Sonazoid
45788151|NCT01312766|Drug|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
45788152|NCT01312766|Drug|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
45788153|NCT01749215|Drug|Topiramate|Experimental study drug
45645624|NCT05010395|Behavioral|Letter intervention|Letter intervention
45645625|NCT02331433|Drug|APN1125|APN1125 orally at ascending doses
45645626|NCT02331433|Drug|Placebo|Matching Placebo
45645627|NCT02327221|Drug|Ovasave|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
45645628|NCT02327221|Drug|Placebo|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
45645629|NCT02327065|Device|EUS-FNA (EchoTip Ultra)|FNA,Fine needle aspiration
45645630|NCT02327065|Device|EUS-FNB (EchoTip ProCore)|FNB,Fine needle biopsy
45645631|NCT02333539|Behavioral|Adherence behaviors and recommendations for improvement.|
45788154|NCT01749215|Drug|placebo|Placebo comparator
45788155|NCT01749215|Behavioral|Medical Management|Brief alcohol counseling
45645632|NCT02333539|Behavioral|Adherence behavior that needs improvement is targeted|
45645633|NCT02333617|Other|Dry Needling|Dry Needling will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will use the appropriate needle based upon patient's size and location of trigger point [No. 5 (0.25 x 40mm), No. 8 (0.30 x 50mm), or No. 11 (0.30 x 75mm)]. They will target trigger points identified in the ipsilateral gluteus medius. Once the needling is inserted into the trigger point the needle will be moved in multiple directions until the first local twitch response is noted. Once the first local twitch response is obtained, the needling will be performed in an up-and-down fashion, performing 2- to 3-mm vertical motions with no rotations (fast-in and fast-out technique), at approximately 1 Hz for 25 to 30 seconds, with the aim of eliciting local twitch responses. The treating therapist can dry needle each trigger point identified in the gluteus medius with a maximum treatment time of 5 minutes.
45645634|NCT02333617|Other|Soft Tissue Mobilization|Soft tissue mobilization will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will apply firm pressure with the palm and side of their hand. The treating therapist will mobilize the gluteus medius muscle in 4 separate directions (Proximal-Distal, Distal-Proximal, Medial-Lateral, and Lateral-Medial). The treating therapist will apply the pressure to reach the upper limit of the patient's tolerable discomfort. At any point in time the patient can request for the therapist to decrease the pressure applied. The treating therapist will perform soft tissue mobilization for 20 mobilizing strokes in each of the 4 directions.
45788156|NCT04522167|Drug|FYB203 (Proposed aflibercept biosimilar)|Patients will receive 1 IVT injection of FYB203 every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
45788157|NCT04522167|Drug|Eylea® (Aflibercept)|Patients will receive 1 IVT injection of Eylea® every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
45788158|NCT01726673|Device|Transcranial Direct Current Stimulation (tDCS)|
45788159|NCT01726673|Device|Placebo sham|
45919614|NCT03620942|Device|DIVA System|"DIVA system works as below:~When systolic blood pressure is between 90 to 100% of baseline, 25mcg phenylephrine (bolus) will be given if heart rate ≥ 60 beats/min, whereas 2mg ephedrine (bolus) will be given if heart rate < 60 beats/min;~When systolic blood pressure is less than 90% of baseline, 50mcg phenylephrine (infusion or bolus) will be given if heart rate ≥ 60 beats/min, whereas 4mg ephedrine (infusion or bolus) will be given if heart rate < 60 beats/min."
45919615|NCT04711798|Other|passive leg raising maneuver (PLR)|Passive leg raising maneuver (PLR) for preload status evaluation using the PICCO system will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).
45919616|NCT04711798|Other|lung recruitment maneuver (LRM)|lung recruitment maneuver (LRM) will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).
45919617|NCT04711798|Other|echographic evaluation of the right cardiac function|echographic evaluation of the right cardiac function will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).
45919618|NCT00277108|Drug|Escitalopram (Lexapro)|
45919619|NCT00277069|Drug|Carboplatin|Carboplatin given at 300mg/m2 IV over 30 minutes day 1, q 21 days
46071269|NCT02846480|Other|physical therapy|"Pre-surgical Physical Therapy: physical therapy aimed to correct the posture, to the awareness and the strengthening of the pelvic floor muscles.~Post-surgical Physical Therapy: checking the correct contraction of the pelvic floor muscles and hypopressive exercises."
45645635|NCT02333617|Other|Placebo Control|Treating therapist will place hands on the patient's gluteus medius muscle and gently rub, but not apply enough pressure to treat the muscles trigger point. This placebo control is designed to account for hands on time from therapist in the 2 other treatment groups, as well as blinding patient to treatment group.
45788160|NCT01248416|Drug|Aromatase Inhibitor|
45788161|NCT01248416|Drug|Growth Hormone|
45788162|NCT01248416|Drug|Aromatase Inhibitor and Growth Hormone|
45788163|NCT01749293|Procedure|Haploidentical Transplant|Subjects will be dosed with pre-transplant Fludarabine (180mg/m2)and Busulfan total AUC 2400 μmol*min/L or 6.4mg/kg. Subjects will then undergo total body irradiation 2Gy. Subjects will undergo haploidentical allogeneic bone marrow transplant, followed by Cyclophosphamide, Tacrolimus and MMF based GVHD prophylaxis.
45788164|NCT01749293|Drug|Fludarabine|Subjects in this trial will receive Fludarabine 30 mg/m2 IV QD, adjusted for CrCl from Days -8 through -3.
45788165|NCT01749293|Drug|Busulfan|Subjects in this trial will receive Busulfan total AUC 2400 μmol*min/L or 6.4mg/kg in 4 doses with seizure prophylaxis from Days -6 through -3.
45788166|NCT01749293|Radiation|Total Body Irradiation|Subjects in this trial will receive total body irradiation (2Gy fractionated) from Day -2 or -1.
45788167|NCT01749293|Drug|Cyclophosphamide|Subjects in this trial will receive Cyclophosphamide 50 mg/kg IV QD on Days 3 and 4 post-transplant.
45788168|NCT01727765|Other|inspiratory muscle training|Both groups will undertake six weeks of inspiratory muscle training (POWERbreathe, H&B International Ltd, UK), six days per week, with the only difference being the load set on the inspiratory muscle training device. For the real inspiratory muscle training group this load will be set to around 50% of maximal inspiratory mouth pressure and for the sham inspiratory muscle training group this load will be set to around 5% of maximal inspiratory mouth pressure.
45788169|NCT04893213|Other|Manipulation of availability of lower energy meal options|Menus provided differ in % of menu options that are higher vs. lower in energy
45788170|NCT01250210|Drug|levonorgestrel and ethinyl estradiol|pregnancy prevention
45788171|NCT01749605|Drug|Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days|
45788172|NCT01749605|Drug|ciprofloxacin 250 mg BID x 3 days|
45919620|NCT00277069|Device|Capecitabine|Capecitabine is administered at 1500mg/m2 PO qd in 2 divided doses day 1-14 q 21 days
45919621|NCT00277069|Drug|Vinorelbine|Vinorelbine: 25mg/m2 IV over 10 minutes day 1, 8 q 21 days
45919622|NCT05247255|Drug|Active Comparator|QL block with 0.25% ropivacaine
45919623|NCT05247255|Drug|Placebo Comparator|QL block with saline
46071270|NCT02846480|Other|surgical treatment|Surgical correction of POP.
45919624|NCT00277030|Drug|Surfactant|
45645636|NCT02333617|Other|Hip and core strengthening exercises|Patient will perform standardized hip and core exercises using body weight, and elastic bands for resistance. Exercises will take approximately 40 minutes to complete.
45645637|NCT02333305|Dietary Supplement|CoQ10|• 2 dosages according to patient weight: Weight < 50kg : 20 drops 3 times a day (150 mg / d) Weight ≥ 50 kg : 40 drops 3 times a day (300 mg / d)
45645638|NCT02333305|Other|Sanomit Placebo|• according to patient weight: Weight < 50kg : 20 drops 3 times a day Weight ≥ 50 kg : 40 drops 3 times a day
45645639|NCT02326909|Device|Optical Coherence Tomography|Single Optical Coherence Tomography measurement of upper urinary tract tumour taken during ureterorenoscopy
45645640|NCT02326909|Device|Optical Coherence Tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
45645641|NCT02326987|Drug|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
45645642|NCT02326987|Drug|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
45645643|NCT02039713|Device|DeSyne drug eluting stent group|
45645644|NCT02333461|Dietary Supplement|Placebo|Participants were randomly assigned to receive one of four botanical interventions or placebo.
45645645|NCT02333461|Dietary Supplement|Apple|Participants were randomly assigned to receive one of four botanical interventions or placebo.
45645646|NCT02333461|Dietary Supplement|Grape|Participants were randomly assigned to receive one of four botanical interventions or placebo.
45645647|NCT02333461|Dietary Supplement|Raspberry|Participants were randomly assigned to receive one of four botanical interventions or placebo.
45645648|NCT02333461|Dietary Supplement|Apricot/Nectarine|Participants were randomly assigned to receive one of four botanical interventions or placebo.
45645649|NCT02333227|Dietary Supplement|Xylitol gum|This is a cluster randomized trial, whereby 4 sites will receive the intervention of xylitol gum in the prepregnancy and early pregnancy interval.
45645650|NCT02332837|Behavioral|Intervention A: Questionnaire accuracy|Participants will be tested by questionnaire to measure how well consent is understood
45645651|NCT02332837|Behavioral|Intervention B: Questionnaire speed of completion|Time to complete questionnaire from time of presentation
45645652|NCT02332837|Behavioral|Intervention C: Questionnaire Completion rate|Number of participants who complete the questionnaire
45645653|NCT02326753|Device|No. 7 oral airway|the use of 7 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
45645654|NCT02326753|Device|No. 8 oral airway|the use of 8 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
45645655|NCT02326753|Device|No. 9 oral airway|the use of 9 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
45645656|NCT02332993|Dietary Supplement|FPP|Made from Carica papaya and represents a sweet and granular substance available over the counter. FPP possesses antioxidant properties that can provide benefit against age-related complications..
45645657|NCT03104881|Device|3D exoskeleton type robot|3 dimension exoskeleton type upper extremity robot
45645658|NCT03104881|Device|2D end-effector type robot|2 dimension end-effector type upper extremity robot
45645659|NCT02326675|Other|Ice|This group will receive cryotherapy, saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
45645660|NCT02326675|Other|Normal Saline Solution|This group will receive saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
45645661|NCT02331667|Other|Seafood|The aim is to investigate the effect of meals consisting of mackrel and herring on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
45788173|NCT00366171|Drug|Bifeprunox|
45788174|NCT01312844|Drug|Scopolamine|Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT
45788175|NCT01729247|Device|NIOX MINO® Instrument (09-1100)|
45645662|NCT02331667|Other|Non-seafood|The aim is to investigate the effect of meals consisting of meat on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
45645663|NCT02331511|Drug|placebo|placebo administration for 3 months after device(PPM,ICD,CRT) implantation
45645664|NCT02331511|Drug|Aspirin 80 mg daily|Aspirin 80 mg daily administration for 3 months after device(PPM,ICD,CRT) implantation
45645665|NCT02331511|Drug|Clopidogrel 75 mg daily|Clopidogrel administration for 3 months after device(PPM,ICD,CRT) implantation
45645666|NCT02331277|Drug|BI 655064|subcutaneous injection
45645667|NCT02331277|Drug|Placebo|Placebo
45645668|NCT02326441|Drug|KX2-361|
45645669|NCT03144271|Drug|semaglutide|A single dose of 0.625, 1.25, 2.5, 5, 10, 20, 40 or 80 μg/kg semaglutide will be administered subcutaneously (s.c. under the skin).
45645670|NCT03144271|Drug|Placebo|A single dose of placebo will be administered subcutaneously (s.c. under the skin)
45788176|NCT04510389|Dietary Supplement|Maltodextrin|Bariatric patients with or without sarcopenia receiving maltodextrin
45788177|NCT04510389|Dietary Supplement|Whey|Bariatric patients with or without sarcopenia receiving whey protein
45788178|NCT04351568|Other|quesionnair|questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality
45788179|NCT01750931|Drug|Meloxicam GSK 15mg|To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH &amp; Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
45919625|NCT00277030|Device|Nasal CPAP|
45919626|NCT03619655|Procedure|SPECT CT|MDP (99mTc-MDP) administration, about 180 min post-injection: whole body scan followed by a SPECT CT of regions designated by a board certified Nuclear Medicine physician after review of the whole body scan.
45919627|NCT03619655|Drug|18F-DCFPyL PET/CT|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
45645671|NCT02332525|Device|Oral Vibrational Stimulation|"Oral application of vibratory stimulus~: With the oral equipment, which is similar to the device generally used to prevent teeth grinding in dental clinics, 15-second vibratory and 15-second non-vibratory stimulus are given repeatedly for about 5 minutes using a vibrator that has a strength less than or equal to the vibratory stimulus of a smartphone (3.3V, 166Hz, maximum 180Hz). A stimulus of two times for 5 minutes, a total of at least 10 minutes is conducted for 10 days in a hospital or designated place."
45788180|NCT01750931|Drug|Mobic 15mg|To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH & Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
45645672|NCT02039791|Biological|Nimotuzumab|200mg/w,weekly, 6 weeks
45788181|NCT01352468|Other|Multifaceted cognitive training|Four computerized training tasks
45788182|NCT05516277|Behavioral|Behavioral Sleep Education Intervention|Manual-based education program focusing on behavioral sleep provided in individual 60-minute sessions for 5 weekly sessions.
45788183|NCT05516277|Behavioral|General Sleep Education Intervention|Manual-based education program focusing on general sleep provided in individual 60-minute sessions for 5 weekly sessions.
45788184|NCT01731041|Drug|Ticagrelor 180mg|Patients will receive 180 mg of ticagrelor
45919628|NCT03619655|Drug|18F-NaF PET/CT|A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose. At the 1 hour post injection time, total Whole Body Images take approximately 40 - 60 minutes depending on the height of the patient.
45919629|NCT03619655|Procedure|WB-MRI|Whole body MRI exam (total examination time < 50 minutes)
45645673|NCT02039791|Drug|Carboplatin|AUC 6, d1，1 cycle/21d, 2 cycles
45645674|NCT02039791|Drug|Paclitaxel|"175 mg/m2, d1~1 cycle/21d, 2 cycles."
45645675|NCT02330887|Other|Group Antenatal Care|The group antenatal care intervention will match pregnant women by gestational age in the intervention village clusters and assign them to peer group sessions facilitated by local healthcare clinic staff.
45645676|NCT02330887|Other|Individual Antenatal Care|Pregnant women in control village clusters will have individual antenatal care sessions with their healthcare provider.
45645677|NCT03573817|Drug|Revefenacin|Revefenacin is administered via a nebulizer.
45645678|NCT03573817|Drug|Placebo|Placebo version of Revefenacin is administered via a nebulizer.
45645679|NCT03573817|Drug|Formoterol|Administered sequentially in both revefenacin and placebo arms using a nebulizer.
45788185|NCT01731041|Drug|Ticagrelor 90mg|Patients will receive 90 mg of ticagrelor
45788186|NCT04831671|Other|Surgical Approach - Infra-patella nailing|The intra-medullary nail will be introduced via an infra-patella incision.
45788187|NCT04831671|Other|Surgical Approach - Supra-patella nailing|The intra-medullary nail will be introduced via a supra-patella incision.
45788188|NCT01352546|Biological|BOTOX|150 units of Botox injected intravaginally into the bulbocavernosum, pubococcygeus and puborectalis muscles along the lateral side walls, left and right as a one time injection under anesthesia.
45788189|NCT01313936|Drug|Metaiodobenzylguanidine (MIBG)|Chemotherapy will be given over 5 days for each course, with a single dose of 131I-MIBG on the second day of irinotecan. A total course will be defined as 42 days, or longer if hematopoietic recovery to eligibility criteria occurs after day 42.
45788190|NCT00364767|Dietary Supplement|A|Alcohol consumption (32 g/day) for 4 weeks
45788191|NCT00364767|Dietary Supplement|B|Water
45788192|NCT01751399|Drug|LY2605541|
45788193|NCT03009656|Other|No study specific interventions|
45788194|NCT04414215|Behavioral|Emotional working memory training|Participants will complete an emotional working memory n-back training program that progressively increases difficulty and has been shown to enhance prefrontal activity in a non-psychiatric sample
45788195|NCT04414215|Behavioral|Placebo working memory training|Working memory training that does not involve emotional stimuli using an N-back training program
45788196|NCT01752413|Dietary Supplement|Ferrous gluconate 325mg|Participants with low ferritin (<30 micrograms/L (males) or <20 micrograms/L (females)) will be asked to take two tablets of Ferrous Gluconate 325 mg (36 mg elemental iron) per day.
45788197|NCT01752413|Behavioral|Nutrition counseling|All blood donors receive current dietary counseling recommending iron rich foods
45788198|NCT05492253|Other|Infant fruit|Infants will be fed prune puree
45788199|NCT05492253|Other|Infant vegetable|Infants will be fed carrot puree
45788200|NCT05492253|Other|Infant meat|Infants will be fed beef puree
45788201|NCT05492253|Other|Infant grain|Infants will be fed oatmeal cereal
45788202|NCT01314014|Drug|Imexon|Amplimexon will be administered daily on Days 1-5 of 21-day treatment cycles as an intravenous infusion over a time course of 60 minutes. Subjects will receive 17 cycles of therapy for a total of one year on treatment. The Amplimexon starting dose for each subject in this study is 1000 mg/m² on each treatment day. Dose may be reduced by 25% for toxicity; after 2 dose reductions, subjects must be withdrawn from treatment.
45788203|NCT05490459|Device|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)|Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
45788204|NCT01731119|Drug|Latuda©|All subjects will be started on 20-40mg of Latuda© at night (suggested intake with food). Subsequently, the dose may be increased as clinically indicated and based on tolerability every 7 days by 20-40mg to a maximum of 160mg per day with food which may be given as a single or twice daily dose depending on participant's preference. The maintenance dose will be determined solely by the clinician in accordance with the best interests of each participant.
46071271|NCT02846480|Other|behavior therapy|At hospital discharge, patients will receive a fact sheet on the sanitary and behavioral measures recommended for the prevention of POP and urinary incontinence (proper weight, prevent constipation, avoid weight bearing and cough and high impact exercise).
46071272|NCT00824629|Procedure|Afterloading embryo transfer procedure|Afterloading embryo transfer procedure
45788205|NCT02326649|Device|Physioflow|impedance cardiography instrument that measures cardiac output non-invasively
46071273|NCT00824629|Procedure|Direct embryo transfer procedure|Direct embryo transfer procedure
45788206|NCT04750707|Drug|Hydroxyurea|The study intervention will be daily oral Hydroxyurea given in single doses starting at approximately 20mg/kg/day and escalated to a maximum 30mg/kg/day depending on clinical need and according to standard guidelines.
45788207|NCT04692519|Behavioral|Duet Language Intervention Modules|The Duet 2.0 intervention modules promote the following guiding principles that help build effective communication. Below are the 5 principles covered in the six Duet modules: 1) General Awareness: Awareness and knowledge of child development 2) Creating Opportunities: Opportunities for communication during everyday activities 3) Conversational Duets: Rhythmic and reciprocal early language interactions 4) Scaffolding: Providing just enough help to support child independence 5) Harmonizing: Using the strategies together. These modules, which include behavioral strategies, real-life and animated examples of high-quality early language interactions, and interactive scenarios. The modules were informed and narrated by community members and carefully designed to address specific needs of high-risk communities. The modules have also been translated into Spanish, making sure to encompass specific cultural and dialect needs. Translation accuracy was verified by a qualified Spanish translator.
45788208|NCT01732445|Drug|ruxolitinib phosphate|Given PO
45788209|NCT01732445|Drug|danazol|Given PO
45788210|NCT01732445|Other|quality-of-life assessment|Ancillary studies
45788211|NCT01732445|Other|questionnaire administration|Ancillary studies
45788212|NCT01250834|Drug|Atorvastatin|Administered orally.
45788213|NCT01250834|Biological|LY2189265|Administered subcutaneously.
45788214|NCT04387695|Radiation|SBRT+TACE+Sorafenib|SBRT first for the PVTT +TACE for HCC within a week next +Sorafenib with 2 weeks later
45645680|NCT03112057|Diagnostic Test|harmonic generation (HGM) microscopic methods.|a frequency-dependent optical microscopy system with a near-infrared light source with a wavelength of 1230 nm was used to detect the diseased site and normal skin.Use erbium-Jacob (Er-YAG) laser exfoliation. the participants need to lie down, wear goggles. The lens sucker device to help fix the skin examination site. Based on the experience of the past 118 subjects, the participants did not discomfort. The total time of the laser irradiation on the same skin is no more than 30 minutes, the maximum laser power is no more than 0.15 watts, irradiation in the skin of the total energy of the laser does not exceed 270 joules. After the experiment, the investigators immediately check the skin for the participants
45645681|NCT02331043|Dietary Supplement|Plant stanol ester|
45645682|NCT02331043|Dietary Supplement|Placebo|
45645683|NCT03111511|Drug|Drospirenone/Ethinylestradiol|A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets on Days 1 and 21.
45645684|NCT03111511|Drug|Midazolam|Midazolam 2 mg orally on Days 1 and 21.
45788215|NCT04387695|Drug|Sorafenib|Sorafenib 800 mg/day orally
45788216|NCT04638075|Device|Supplemental Nursing System|The SNS is a device designed to deliver supplemental milk by suckling at the mother's nipple. A specially designed bottle attaches to the mother's breast and serves as the reservoir for milk. Attached to the bottle is a small tube which runs down to and is placed on the tip of the mother's nipple. With an adequate latch the neonate obtains supplementation by suckling. Additionally, this suckling stimulates milk production (Lawrence & Lawrence, 2016).
45788217|NCT01354652|Drug|entecavir, lamivudine|"entecavir: 0.5mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and participants will be followed for the duration of hospital stay, an expected average of 8 weeks.~lamivudine: 100mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and and participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
45788218|NCT01753739|Drug|Bepotastine besilate|Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
45919630|NCT00276991|Drug|"Kallunk oxide (Immunotherapy) "|"The study was assigned only one Arm >450 cu/mm^3 of baseline CD + T cells. HIV type-1 subjects were received one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine(Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 0.100 mg and 0.200 mg Kallunk oxide molecules with 199.900 mg, and 499.800 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 200 mg for children and 500 mg for adults. This powder form sample size product was administered once daily dose on 5 days treatment. The Botanical name of the antidote is Piper Longum."
45919631|NCT00276952|Drug|Gonyautoxin|
45919632|NCT00276913|Drug|STA-5312|
45919633|NCT00276874|Drug|Aripiprazole|Aripiprazole; 0-30 mg; oral; daily
45919634|NCT00276874|Drug|Placebos|Placebo; 0 mg; oral; daily
45919635|NCT00276835|Biological|High-dose interleukin-2|Administered days 1-5, and 15-19; the patient will receive 600,000 IU/kg IL-2 by intravenous infusion over 15 minutes every 8 hours (on day 1 and day 15, patients will receive a maximum of 2 doses per day; on all other days in the cycle patients will receive a maximum of 3 doses per day)
45919636|NCT00276835|Dietary Supplement|genistein|Starting on day 10 and continuing through day 19, genistein will be administered orally at a dose of 600mg/day in two divided doses (i.e. 300mg po bid x 10 days)
45919637|NCT00276796|Drug|cisplatin|
45788219|NCT01753739|Drug|Placebo|Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
45788220|NCT01250990|Drug|Niacin|Niacin taken orally for 12 weeks at the highest tolerated dose (up to 6 grams), and at least 2 grams daily and up to the maximum approved dose. Subjects will initiate therapy with Niaspan and will advance to Niacor as tolerated.
45788221|NCT01250990|Other|Placebo|Placebo
45788222|NCT01754207|Device|755nm Alexandrite Laser|755nm Alexandrite Laser
45788223|NCT01754207|Device|755nm Alexandrite Laser with CAP Array|755nm Alexandrite Laser with CAP Array
45788224|NCT05458167|Device|Hedia Diabetes Assistant bolus calculator with a physical activity module|Hedia Diabetes Assistant bolus calculator with a physical activity module is a software device that calculates an insulin bolus based on blood glucose, carbohydrates and physical activity.
45788225|NCT02990975|Drug|ketamine|
45919638|NCT00276796|Drug|paclitaxel|
45919639|NCT00276796|Drug|topotecan hydrochloride|
45788226|NCT01315574|Drug|Travoprost|One drop Travatan Z (0.004% ophthalmic solution) in affected eye once daily.
45788227|NCT01315574|Drug|Latanoprost|One drop Xalatan (0.005% ophthalmic solution) in affected eye once daily.
45645685|NCT03111511|Drug|JNJ-56136379|JNJ-56136379 dose will be administered orally at a dose of 250 mg (as 2 tablets of 100 mg + 2 tablets of 25 mg) on Days 6 and 7 and at a dose of 170 mg (as 1 tablet of 100 mg+ 2 tablets of 25 mg + 4 tablets of 5 mg) on Days 8 to 25.
45788228|NCT04462107|Other|Surveys|All participants will complete surveys that range in time from baseline to 3 months post partum.
45645686|NCT02330965|Procedure|Blood Draw|Blood draws (65 mLs [~4 tablespoons] per blood draw) at 4 time points: Prior to study medication initiation, and at +6, +12 and+24 months post treatment initiation.
45645687|NCT02330965|Procedure|CSF collection by lumbar puncture (Optional)|For participants who volunteer to donate CSF samples: up to 25 mLs (<2 tablespoons): prior to study medication initiation, and at month 24 post treatment initiation.
45645688|NCT03144505|Behavioral|MCT combined with RT Group|
45645689|NCT03144505|Behavioral|HIIT combined with RT Group|
45788229|NCT00422331|Drug|Lithium Carbonate Capsule|
45788230|NCT01754519|Procedure|Therapeutic Conventional Surgery|Undergo wide local excision breast surgery
45788231|NCT01754519|Radiation|Radiation Therapy|Undergo SFRT
45788232|NCT01754519|Other|Laboratory Biomarker Analysis|Correlative studies
45788233|NCT01754519|Other|Quality-of-Life Assessment|Ancillary studies
45788234|NCT01316042|Drug|sugar pill|2 pills per day for 12 months
45788235|NCT01316042|Drug|Metformin, glucophage|2 212.5mg pills/day for 12 months
45788236|NCT04308135|Diagnostic Test|Neuro-radiological tools:|"MRI brain: to measure white matter~c) Ultrasonographic examination of extracranial vessels: The intimal medial thickness of the common carotid artery (CCA-IMT) will be measured in B-mode. The carotid arteries will be evaluated for the presence of atherosclerotic lesions (plaques) either soft or hard .The residual lumen and degree of stenosis will be measured. The peak systolic velocity will be detected."
45788237|NCT04308135|Diagnostic Test|cognitive tests|"All patients will be evaluated for global cognitive assessment by: Montreal Cognitive Assessment (MoCA) (Arabic version) Visuospatial skills will be assessed by Clock Drawing Tests from MoCA test and copy the intersecting pentagons from Addenbrooke's test (Arabic version) Language will be examined by semantic fluency from Addenbrooke's test (Arabic version) and similarities from Wechsler Adult Intelligence Scale (WAIS) Attention will be evaluated by digit span from Wechsler test),and by the number of seconds needed to sequence numbers using a pencil (Trail making test A) from MoCA test . For the evaluation of memory, participants will complete Wechsler memory subset~, and the investigators also will use their three-item recall from the Mini-Mental State Examination( MMSE). Executive functions will be measured by Wisconsin card sorting test and also verbal fluency test from Addenbrooke's test. Frontal Assessment Battery (FAB) scale"
45788238|NCT04308135|Diagnostic Test|lab investigations|Each patient will undergo full lab investigations:[lipid profile ,complete blood count, uric acid ,Hemoglobin A1c (HbA1c), liver functions, renal functions, and electrolytes]
45788239|NCT04308135|Diagnostic Test|Beck depression inventory (BDI)(Arabic version)|Clinical Tool for depression
45788240|NCT04308135|Diagnostic Test|Clinical Tools for Urinary symptoms:|the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Scale (Arabic version)
45645690|NCT03144115|Drug|Oxytocin|
45788241|NCT04308135|Diagnostic Test|Freezing of gait questionnaire|"Clinical Tools for Gait (in on and off state ), Gait will be assessed by:~.Freezing of gait questionnaire~Berg balance scale.~10 meter walk test .~Timed up and go test."
46071274|NCT01351766|Drug|Transdermal Nicotine Patch|Transdermal Nicotine: Participants will use 8 weeks of the nicotine patch at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level.
45645691|NCT03144115|Drug|Placebos|
45645692|NCT02326519|Other|Intracardiac electrode catheter|All patient in the study will have the same data collected using the Steerable intracardiac electrode catheter
45645693|NCT02326285|Drug|Gefitinib|Patients will be treated for 12 days with gefitinib 250 mg/day p.o. (d -12 to -1) and induced with chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
45788242|NCT04308135|Diagnostic Test|non-motor symptoms scales (NMSS).|Clinical Tool for assessment of non-motor symptoms of PD
45788243|NCT04308135|Diagnostic Test|Movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS):|"Clinical Tools for assessment of the neurological severity and stage of disease Clinical Tool for assessment of the neurological severity and stage of disease during OFF and ON states, Hoehn and Yahr scale. The presence of lower limb parkinsonism will be determined by a two-point difference between upper limb and lower limb scores of bradykinesia, rigidity or postural instability from part III of the MDS-UPDRS. Patients will be examined in the early morning, in 'OFF' state, with MDS-UPDRS, Hoehn and Yahr and freezing of gait questionnaire(FOG-Q) scales. Immediately afterwards, they will take their regular first dose of levodopa. After 1 hour, patients will be examined again with the same tests and scales.~Response to levodopa will be determined as patients who reached a percentage reduction exceeding 25% in part III of the MDS-UPDRS"
45788244|NCT04308135|Diagnostic Test|ELIZA for alpha-synuclein|measuring serum of alpha-synuclein, tau and their autoantibodoies
45645694|NCT02326285|Drug|docetaxel|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
45645695|NCT02326285|Drug|cisplatin|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
45645696|NCT02326285|Procedure|Surgery|Surgery should be performed in the 4th or at the latest 5th week after d1 of the last cycle of chemotherapy (d64 to 78).
45788245|NCT04308135|Other|transcranial color-coded duplex(TCCD)|TCCD using phase array 2.4 Hz probe for evaluation of cerebral vasomotor reactivity (CVR) by measuring the Breath holding index(BHI),flow velocities and pulsatility index of middle cerebral artery and posterior cerebral artery on both sides.
45645697|NCT02332603|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
45645698|NCT02332603|Drug|Isotonic Sodium Chloride|Placebo
45788246|NCT04308135|Other|extracranial carotid duplex|to assess atherosclerosis, stenosis of carotids
45645699|NCT02332447|Drug|naloxone|"A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.~The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS."
45788247|NCT04308135|Other|The Arabic version of Parkinson's Disease Questionnaire( PDQ-39)|Clinical tool for quality of life of PD patients
45645700|NCT02332447|Drug|Placebo|"Placebo will be isotonic sodium chloride which preparation in 1 ml vials will be centralized by the pharmaceutical department of Edouard Herriot Hospital to ensure its indistinguishability from naloxone A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.~The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS."
45788248|NCT01754909|Drug|Enalapril|Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
45919640|NCT05231070|Other|TeleSPC|Multidisciplinary video consultations with the SPC team. The team is multiprofessional and composed by physician, nurse, psychologist, social worker, physiotherapist and a chaplain, which is in line with the staffing of most SPC teams in Denmark and abroad. Video consultations will follow the same approach already used in physical consultations at the Section of Palliative Medicine, considering patients' changing needs and providing differentiated treatment and support, with the addition of a psychological intervention for dyadic coping between patient and closest informal caregiver
45645701|NCT02331199|Device|Amniotic fluid lamellar body count|The LBC (the unit of measurement is number of lamellar bodies counted per microliter of amniotic fluid) will be determined using the platelet channels on the Hematology Flow Cytometer.
45919641|NCT00276757|Drug|leucovorin calcium|
45645702|NCT02331199|Device|Fetal pulmonary artery Doppler|A fetal pulmonary artery Doppler will be performed using color Doppler ultrasound. Doppler flow velocity measurements, including systolic/diastolic ratio, pulsatility index, resistance index, and acceleration-time/ejection-time ratio using spectral Doppler ultrasound.
45919642|NCT00276757|Drug|methotrexate|
45919643|NCT00276757|Drug|prednisolone|
45919644|NCT00276757|Drug|vinblastine sulfate|
45919645|NCT00276718|Biological|bleomycin sulfate|
45788249|NCT01754909|Drug|placebo|Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
45919646|NCT00276718|Drug|carboplatin|
45919647|NCT00276718|Drug|etoposide|
45919648|NCT00276718|Procedure|conventional surgery|
45919649|NCT00276679|Drug|temozolomide|
45919650|NCT00276601|Drug|arsenic trioxide|
45919651|NCT00276601|Drug|cytarabine|
45788250|NCT04297995|Drug|HLX10|Part 1: HLX10 3 mg/kg biweekly. Part 2: HLX10 300 mg every three weeks.
45788251|NCT04297995|Drug|HLX07|Part 1: HLX07 600 mg weekly (stage 1L). Part 1: HLX07 800 mg weekly (stage 1H). Part 2: HLX07 1000 mg every three weeks.
45788252|NCT04297995|Drug|HLX07 placebo|HLX07 placebo 1000 mg every three weeks
45788253|NCT04297995|Drug|Cisplatin/Carboplatin|Cisplatin 100 mg/m2 every three weeks. Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles.
45788254|NCT04297995|Drug|5-FU|5-FU 1000 mg/m2/day, 1-4 days, every three weeks. Up to 6 cycles.
45919652|NCT00276601|Drug|daunorubicin hydrochloride|
45919653|NCT00276601|Drug|mercaptopurine|
45919654|NCT00276601|Drug|methotrexate|
45919655|NCT00276601|Drug|tretinoin|
45919656|NCT00276523|Biological|PEG-interferon alfa-2b|Study medication begins on Day 1 and taken subcutaneously once each week with the last dose being taken within 1 week prior to surgery or biopsy.
45919657|NCT00276523|Procedure|Conventional surgery|Participants on the control arm may undergo surgery at anytime within 3 weeks of randomization, and those randomized to PEG-Intron will undergo surgery on Days 16-22 following initiation of treatment.
45919658|NCT00276523|Procedure|Neoadjuvant therapy|
45919659|NCT05198778|Drug|URC102|tablet
45919660|NCT05198778|Drug|URC102|tablet
45919661|NCT00276445|Drug|beta-1,3-glucan|
45645703|NCT02331121|Behavioral|Family First Aid Online Training|Web-based interactive multimedia program comprised of videos, interactive animations and text information designed to teach parents of children aged birth to 12 years old basic first-aid and CPR skills, including the option to practice skills as needed.
45645704|NCT02331121|Behavioral|Text-only Online Training|Online text created from the American Heart Association's 2010 guidelines for CPR training via a computer, depicting infant, child and adult CPR skills and choking relief.
45788255|NCT04340349|Drug|Hydroxychloroquine Sulfate|A daily low dose of Hydroxychloroquine Sulfate. Increase the endosomal pH and inhibits of ACE2 glycosylation receptor.
45645705|NCT02330809|Other|Daily extra water intake|Amount of extra daily water intake to consume
45645706|NCT02330809|Other|Timing of daily extra water intake|Intervention-A: Timing of daily extra water intake specified Intervention-B: at any time during 24 hour period
45788256|NCT04340349|Drug|Bromhexine 8 MG|TMPRSS2 blocker
45788257|NCT01755143|Other|Magnetic Resonance Imaging scan sequences of the head, neck, and chest|
45788258|NCT01755143|Device|Pacemaker System|
45788259|NCT04246125|Procedure|Interventional radiology : skin dose measurements|"Therapeutic interventional radiology procedure for the following anatomical regions:~cerebral (neuroradiology)~thoracic (cardiology, lungs)~abdominal~Assessment of peak skin dose and dose mapping with use of Gafchromic film dosimeter and the estimation of the absorbed dose to the skin with use of RDM software program."
45788260|NCT04272047|Other|Knee Control+ program|15-20 minute training program to be performed at all team training sessions during the season.
45788261|NCT04272047|Other|Adductor strengthening program|Adductor strengthening program to be performed 2-3 times per week, one set per side, during the pre-season, and 1 time per week, one set per side during the in-season.
45788262|NCT04272047|Other|Knee Control program|15-20 minute training program to be performed as per the team's usual routines (no intervention from the researchers).
45788263|NCT04276311|Device|Percutaneous transluminal angioplasty|The purpose of this study is to evaluate the efficacy and the feasibility of atherectomy, using the Jetstream™ artery preparation associated to DCB treatment (Ranger™ Paclitaxel-Coated balloon), in symptomatic patients with claudication (Rutherford 2 and 3) and with complex de novo femoropopliteal arterial lesions (TASC C).
45919662|NCT00276406|Drug|Pyridostigmine|Pyridostigmine will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
45919663|NCT00276406|Drug|Placebo|If subject is randomized to placebo, placebo pills will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
45919664|NCT00389883|Drug|Comparison of two anesthetics protocol|Comparison of two anesthetics protocol
45788264|NCT04268771|Biological|Experimental: Arm A: DRL_RI|Proposed rituximab biosimilar, 100mg or 500mg, concentrate for solution for infusion
45788265|NCT04268771|Biological|Arm B: Rituxan®/Mabthera®|Reference product US- rituximab (Rituxan®) or EU-rituximab (MabThera®), 100mg or 500mg, concentrate for solution for infusion
45788266|NCT04267809|Drug|Metformin Hydrochloride|Metformin 500mg tablets are registered and licensed in Singapore. For the study, we will be sourcing the Metformin tablets from Singapore General Hospital Formulary.
45788267|NCT04267809|Drug|Calcium and Vitamin D|Calcium and Vitamin D tablets are registered and licensed in Singapore. For the study, we will be sourcing the Calcium and Vitamin D tablets from Singapore General Hospital Formulary.
45788268|NCT02242409|Drug|Gemcitabine and Abraxane|Gemcitabine 1000 mg/m2 followed by abraxane 125 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
45788269|NCT04258085|Other|Early diagnosis program combined with electronic medical record|Implementation of early diagnosis approach targeting symptomatic women, combined with use of electronic medical record to facilitate documentation, patient tracking across levels of the health care system, and patient contact
45788270|NCT04227639|Procedure|T-piece trial|T-piece trial will be performed for around 1 hour with a T-piece connected to the extremity of the endotracheal tube by simply disconnecting the patient from the ventilator and by providing additional oxygen (≤ 6 L/min)
45788271|NCT04227639|Procedure|Pressure-support trial|Pressure-Support trial will be performed for around 1 hour without disconnecting the patient from the ventilator, by using a low level of pressure-support (PS 8 cm H2O) with a FiO2 ≤ 40% and without positive end-expiratory pressure (PEEP), while continuously monitoring the respiratory rate and tidal volume on the ventilator display.
45788272|NCT01755455|Drug|Ferrous sulfate 325mg|Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks
45788273|NCT01755455|Drug|Placebo|Matching placebo capsule
45788274|NCT00366873|Procedure|Calcium absorption|formula with or without prebiotics
45788275|NCT00366951|Procedure|Foley catheter only|
45788276|NCT00366951|Procedure|Extraamniotic saline infusion|
45788277|NCT05317325|Biological|OCDC vaccine; NeoDC vaccine|OCDC vaccine and NeoDC vaccine are administered in a prime-boost regimen by subcutaneous injection.
45788278|NCT05395923|Procedure|Suture|The pressure application will be applied before the incision on the palate.
45788279|NCT05395923|Procedure|No Suture CTG -Control|A graft will be taken from the palate before the procedure is applied.
45788280|NCT04182399|Drug|Zonisamide Capsules|anti-epileptic drug that recently used as add on therapy of wearing off and fluctuation complications of dopaminergic drugs in PD patients
45919665|NCT03308435|Diagnostic Test|Geriatric assessment|the assessment includes functional tests (hand grip strength, SPPB (Short Physical Performance Battery)) and questionaires Euro-QoL 5D, LUTS, GDS, ADL, iADL, dietary recall).
45919666|NCT03308435|Diagnostic Test|Psychiatric assessment|Psychiatric assessments includes HAMD-17 as well as Beck depression inventory, hospital anxiety and depression scale, SF36, PTSS-10
45919667|NCT03308435|Diagnostic Test|Inflammatory assessment|analysis will include arginase, ADMA, SDMA, homoarginine, aminoacids + metabolites, tryptophan, kynurenine, kynurenine acid, cortisol, ACTH, Metanephrine, myeloperoxidase,
45919668|NCT03308435|Diagnostic Test|Cardiological assessment|ECG, echocardiography
45919669|NCT00276328|Drug|Diosmectite (Smecta®)|
45919670|NCT00389922|Drug|lapatinib ditosylate|Given orally for 28 days per dose level (Dose level 1: 250mg; Dose level 2: 500mg; Dose level 3: 1000mg; Dose level 4: 1250mg; Dose level 5: 1500mg; Dose level 6: 1500mg)
45788281|NCT05383365|Other|Suboccipital Myofascial Release(MFR) with sham Deep Neck Flexor(DNF)exercise|"The treatment includes Suboccipital MFR in the supine position.The therapist places the supinated forearm on the bed and positions the tips of the middle three fingers inferior to the occiput bone and the head is supported by the thenar eminences.The therapist will develop a line of tension through the suboccipital tissues by supinating the forearms and pulling apart two hands from each other;Then, for the second level in the first position of hands,pressure is applied to the anterior and superior direction.The pressure is held and increased until the therapist feels the decrease of muscle tone.These techniques last 10 minutes.~Another intervention in this group is the sham DNF exercise with a Pressure Biofeedback Unit(PBU).Considering that minimum detective change with PBU is 15 mmHg; After placing the airbag of PBU under the occiput bone in the supine position and inflating it to a base pressure of 11 mmHg,the participant will increase the pressure to 12 mmHg by nodding action."
45788282|NCT05383365|Other|Deep Neck Flexor(DNF)exercise with sham Suboccipital Myofascial Release(MFR)|"The treatments include the DNF exercise with a PBU. The treatment is performed in the supine position and the airbag is placed under the occiput bone and is inflated to a base pressure of 20 mmHg. The participant will increase and hold the pressure to a special point by nodding action. The exercise is repeated for 3 sets, in each set 2 mm Hg is added to the pressure. The pressure will be increased from 22 to 32 mm Hg during 4-week of treatment, and each goal is held for 10 seconds and repeated 10 times. There will be 5 sec of rest between each repetition and 2 min of rest between each set.~Another intervention in this group is sham MFR. The therapist's hands will be placed only inferior to the occipital bone and a superficial touch is applied without any upward or lateral pressure. sham treatment in this group, like the opposite group, lasts 10 minutes."
45919671|NCT00389922|Drug|vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 20mg/m2; Dose level 4: 20mg/m2; Dose level 5: 20mg/m2; Dose level 6: 25mg/m2)
45449346|NCT03557151|Other|Usual Care|Usual Care participants will receive the same excellent multidisciplinary Care they would receive at the same center were they not enrolled in the trial. In clinic visits scheduled at approximately 3-month intervals, they will see subspecialty board certified or eligible pediatric endocrinologists, supplemented as needed with involvement of certified diabetes educators, dietitians, social workers or psychologists. HbA1c target is < 7.5% with no severe hypoglycemia and acceptable quality of life. About half are expected to be on insulin pumps and carbohydrate counting, while the great majority of others are following basal-bolus multiple daily injection regimens, also based on carbohydrate counting. A rising proportion of patients use continuous glucose monitors and this trend is likely to accelerate during the study.
45645707|NCT05077813|Combination Product|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
45788283|NCT04246619|Drug|Pregabalin|"Pregabalin Krka (pregabalin) hard capsules of different strenghts: 25 mg, 75 mg, 150 mg, 300 mg.~Duration: 12 weeks"
45788284|NCT04246619|Drug|Duloxetine|"Dulsevia® (duloxetine) hard gastro-resistant capsules of different strenghts: 30 mg and 60 mg.~Duration: 12 weeks"
45788285|NCT04740957|Other|Distal limb reintroduction of ileostomy effluent|"Patients will undergo water soluble contrast enema to confirm anastomotic healing 8 weeks post operatively as per standard practice at Imperial.~Patients will be educated in how to reintroduce ileostomy output to the distal (downstream) loop of their ileostomy. They will be asked to reintroduce 50ml of ileostomy output using a conventional long-tipped bladder syringe daily until surgery to close the stoma."
45788286|NCT02618031|Procedure|Endovascular Treatment (EVT)|EVT is an endovascular procedure in which a catheter is inserted into an artery and directed to the site of the blocked blood vessel in the brain. The clot is removed using a mechanical device with or without an injection of tPA (tissue plasminogen activator) directly at the site of the clot. The protocol calls for use of the Trevo stent retriever (Stryker Neurovascular) for the first pass of clot removal.
45919672|NCT00389922|Genetic|comparative genomic hybridization|Molecular correlative study
45919673|NCT00389922|Genetic|cytogenetic analysis|Molecular correlative study
45919674|NCT00389922|Genetic|gene expression analysis|Molecular correlative study
45919675|NCT00389922|Genetic|mutation analysis|Molecular correlative study
45919676|NCT00389922|Genetic|polymerase chain reaction|Molecular correlative study
45919677|NCT00389922|Genetic|polymorphism analysis|Molecular correlative study
45919678|NCT00389922|Genetic|proteomic profiling|Molecular correlative study
45919679|NCT00389922|Genetic|reverse transcriptase-polymerase chain reaction|Molecular correlative study
45919680|NCT00389922|Other|immunohistochemistry staining method|Molecular correlative study
45919681|NCT00389922|Other|laboratory biomarker analysis|Molecular correlative study
45919682|NCT00389922|Drug|lapatinib ditosylate|Given orally on Days 2-5, 9-12 and 16-25 per dose level (Dose level 1: 1250mg; Dose level 2: 1500mg; Dose level 3: 1500mg; Dose level 4: 1700mg)
45919683|NCT00389922|Drug|Vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 25mg/m2; Dose level 4: 25mg/m2)
45919684|NCT00276289|Drug|Spironolactone|
45919685|NCT00276250|Drug|Efalizumab|Efalizumab was a medication approved for use in psoriasis which was being explored to determine efficacy with immunosuppression following organ transplantation. Efalizumab was administered subcutaneously on a weekly basis. Upon efalizumab being withdrawn from the US market, the protocol was amended to alter the immunosuppressive regimen to abatacept for the study participants.
46071275|NCT02548897|Device|Deep brain stimulation|The programming of DBS settings in all participants with bilateral DBS implants in the globus pallidus internus (GPi) and pedunculopontine nucleus (PPN) will be performed.
45449347|NCT03557151|Behavioral|Transdisciplinary Care-In Person & Telehealth|TC participants will receive all elements of the Usual Care intervention but they will do so in the context of face to face or telehealth delivery of TC follow-up visits with simultaneous involvement of an advanced practice nurse, dietitian and psychologist at each visit.
45449348|NCT02150200|Other|shorter hospitalization stay|
45645708|NCT05077813|Combination Product|9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 9 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
45919686|NCT00276250|Drug|Abatacept|Abatacept is drug used to treat autoimmune diseases. Abatacept is administered intravenously, monthly, in weight-based doses and is given for as long as transplanted islets are functioning.
45653092|NCT03276065|Device|Laser depilation|Fitzpatrick skin type classification will be assessed during the initial visit. The Fitzpatrick skin type classification is based on the level of pigmentation of the skin and its response to ultraviolet light (See Appendix). It will be used to select the best laser to perform hair removal for each patient. The laser treatment group will consist of an 810 nm (for Fitzpatrick skin types I-IV) or Nd:YAG (for Fitzpatrick skin types V-VI) 28 joule application at auto pulse duration for 400 ms. A cooling platform and application of 7% lidocaine/ 7% tetracaine cream, applied 45 minutes prior to treatment, will minimize any discomfort associated with the heat of the laser treatments.
45449349|NCT02150200|Other|questionnaires|
45788287|NCT05317091|Other|Laughter yoga practiced|"In this study, 8 sessions of laughter yoga were applied to the nurses in the experimental group as an intervention, twice a week for 4 weeks. Due to the Covid-19 pandemic; Laughter Yoga sessions were held on the web through the 'ZOOM' program.~For this reason, it is recommended that the laughter yoga sessions be done with a group and that the group should consist of at least five people in order to provide group dynamics. Sessions are planned according to the days and hours that nurses can attend. Sessions 1st group Monday-Thursday between 12:00-13:00; 2nd group Tuesday-Friday between 17:00-18:00; The third group was held on Wednesday-Saturday between 20:00-21:00. The nurses were constantly contacted (whatsapp, phone) to ensure that they attend the sessions regularly and that there is no interruption in the sessions. No experiment was performed on the control group during the study. However, after the research, a 4-week laughter yoga was given to the nurses who wanted it."
45788288|NCT01757561|Procedure|propofol|use total intravenous anesthesia with propofol
45788289|NCT01757561|Procedure|sevoflurane|use inhalation anesthesia with sevoflurane
45919687|NCT00276250|Drug|Belatacept|Belatacept is a medication to provide extended graft survival while limiting the toxicity generated by standard immune suppressing regimens. Belatacept is administered intravenously. The protocol for this study was amended to substitute belatacept for abatacept for all newly enrolling participants (current participants remained on abatacept).
45919688|NCT05161767|Diagnostic Test|Brain MRI (neuroimaging)|Structural and functional brain scans will be taken.
45919689|NCT00394186|Drug|GW427353|
45449350|NCT03725787|Device|CuroCell S.A.M. ® pro mattress|During 30 days, participants will use the static air mattress.
45919690|NCT00394186|Drug|Placebo|
45919691|NCT03813290|Device|Neuro-technological Intervention|During the intervention sessions, participants will don a head-mounted VR display set and a mobile EEG-biosensor. Each session will begin with a brief audio-guided mindfulness practice, follow by a 15 minutes VR game. Game performances will be influenced by individual's level of anxiety arousal and ability to regulate it.
45449351|NCT02158624|Drug|Intravitreal Lucentis 0.5mg|
45449352|NCT00115739|Drug|Imatinib|Imatinib 400 mg capsules were administered twice daily with food for 4 week cycles.
45919692|NCT00394225|Drug|Oxygen|
45919693|NCT00394225|Drug|Helium|
45919694|NCT00394264|Procedure|Soft Tissue|
45919695|NCT00394264|Procedure|Myofascial release|
45919696|NCT00394264|Procedure|Counterstrain|
45919697|NCT00394264|Procedure|Muscle energy|
45919698|NCT00394264|Procedure|Sacro-iliac articulation|
45919699|NCT00394264|Procedure|High-velocity, low amplitude|
45449353|NCT03639519|Drug|Ascorbic Acid 500Mg Chew Tab|Ascorbic acid will be administered at the night before surgery and will be continued for five days
45449354|NCT03639519|Other|Carbonated orange beverage|The carbonated orange beverage will be administered at the night before surgery and will be continued for five days
45449355|NCT05665179|Behavioral|Removing Barriers to Recovery|Experimental patients are provided no-cost legal services in-person at addiction treatment centers using an online platform
45449356|NCT01079429|Genetic|Genetic study of DNA copies|Gene expression profiling, DNA copy number variation
45919700|NCT05158413|Dietary Supplement|High dose|Patients will receive a high dose of sesame paste or flour (1200 mg of sesame protein) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
45449357|NCT02158702|Drug|Pomalidomide and Dexamethasone|Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle. Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
46071276|NCT02548897|Other|Electroencephalography|An electroencephalography (EEG) will be performed on all participants to better understand the neurophysiological underpinnings of the symptom.
45449358|NCT01347086|Drug|Matching placebo (low dose)|single dose of matching placebo
45449359|NCT01347086|Drug|BI 207127 NA (medium dose)|Single does of BI 207127 NA
45449360|NCT01347086|Drug|BI 207127 NA (low dose)|single dose of BI 207127 NA
45449361|NCT01347086|Drug|Matching placebo (medium dose)|Single dose of matching placebo
45449362|NCT01347086|Drug|BI 207127 NA (high dose)|Single dose of BI 207127 NA
45449363|NCT01347086|Drug|Matching placebo (high dose)|Single dose of matching placebo
45788290|NCT01757717|Radiation|Ir-192 high dose rate (HDR)|Patients will be followed at 2 months (+/- 2 weeks) post-treatment and then approximately every 3 months (+/- 2 weeks) until approximately 11 months of follow up. They will be evaluated for pain referable to the treated site, clinical and radiographic evidence of local progression, and treatment related toxicity. Thereafter, patients will be followed as clinically indicated.
45788291|NCT02618187|Drug|SER-287|
45449364|NCT02150278|Behavioral|Brief intervention|The brief intervention consist of one face to face minimal advice to reduce drinking-driving behavior and it was personalized according to the state of change of the patient (based on the Prochaska and DiClemente model). An additional informative pamphlet is offered to the participant. The intervention was done by the general practitioner or nurse that regularly attends the patient.
45449365|NCT02158780|Procedure|Scrotal Orchidopexy|Single incision
45788292|NCT02618187|Drug|Placebo|
45449366|NCT02158780|Procedure|Inguinal Orchidopexy|Double Incision (Standard)
45645709|NCT05077813|Combination Product|All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)|Active Comparator: All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D 50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
45653093|NCT03276065|Other|Standard of care hair depilation|Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
45788293|NCT02618187|Drug|Placebo Pre-Treat|
45788294|NCT02618187|Drug|Vancomycin Pre-Treat|
45919701|NCT05158413|Dietary Supplement|Low dose|Patients will receive a low dose of sesame paste or flour (300 mg of sesame protein) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
45919702|NCT00276172|Drug|Natalizumab|Natalizumab 300 mg by IV infusion, every 4 weeks, for up to 24 months
45788295|NCT05316857|Drug|Orelabrutinib + Rifampin|Orelabrutinib + Rifampin
45788296|NCT05316857|Drug|Orelabrutinib + Itraconazole|Orelabrutinib + Itraconazole
45788297|NCT01759277|Drug|Control: Femoral perineural local anesthetic infusion|The control group will receive a femoral nerve block and postoperative ropivacaine 0.2% infusion
45788298|NCT01759277|Drug|Experimental: Adductor Canal perineural local anesthetic infusion|The control group will receive an adductor canal nerve block and postoperative ropivacaine 0.2% infusion
45788299|NCT02618343|Drug|IPA|IPA Aromatherapy for the experimental arm
45788300|NCT02618343|Drug|Ondansetron|Zofran will be administered to the Control arm. This is the drug historically administered by prehospital personnel.
45788301|NCT05346939|Device|dynamic taping|The athletic trainer will intervene with spiral dynamic technique by using a dynamic tape for the first test and a sham dynamic tape for the second test, or reverse the order.
45788302|NCT02991053|Drug|ketamine|
45788303|NCT04040907|Drug|XNW3009|XNW3009 is a small molecule hURAT1 inhibitor
45919703|NCT03230006|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The UP will be conducted in a standardized fashion, over 16 sessions, following the published therapist guide with minor refinements for application in the proposed comorbid population.
45919704|NCT03230006|Behavioral|Take Control|TC is a psychotherapy platform derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA) self-help approach, Rethinking Drinking. In this study, TC, originally designed as a computerized treatment has been modified to be administered by the therapist to control for effects that may be related to patient-therapist interaction (as opposed to elements of the treatment itself). Specifically, on a weekly basis, therapists will review material from TC and offer general advice on implementation of the alcohol reduction skills in daily life.
45919705|NCT00276133|Drug|Effects of atorvastatin versus probucol on small dense LDL|
46071277|NCT01179932|Other|No Intervention Used|Our study is observational; therefore, there is no type of intervention being used.
45788304|NCT04040907|Drug|Placebo|Placebo and active drug will have the same appearance
45788305|NCT04116749|Other|Water|Drink water freely until 2 hours before anesthesia.
45788306|NCT05341791|Other|Cartoon video describing study information notice|The video will be 20-minutes long, and will consist of graphic depictions (in cartoon style) of the study information content presented in the same flow as the written notice, and explained by a voice-over in the background. The participant will view the video in a quiet room, on a tablet provided by the study staff. The participant will be able to pause the video or rewind it as needed, and view it at his/her desired pace. The video will have an embedded knowledge check at the end of each section, consisting of a background voice asking some questions, pausing (for the participant to think through the correct answers) and then providing the right answers.
45788307|NCT05316389|Procedure|Breast reconstruction|Muscle sparing Latissimus Dorsi Flap or prothesis
45788308|NCT04094285|Drug|SAUERSTOFF|"SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for 30 minutes"
45788309|NCT04094285|Drug|STICKSTOFF|"STICKSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~88% with 12% oxygen, breathing for 30 minutes"
45788310|NCT05325255|Other|Myofascial release of subscapularis|It is the application of manual pressure over myofascial trigger point that induces ischemia and causes release of trigger points
45788311|NCT05325255|Other|Maitland mobilization|It is the type of mobilization technique that uses passive accessory mobilization to reduce pain and stiffness and increasing range of motion
45788312|NCT05325255|Other|Stretching exercises|It is the technique use to increase flexibility and range of motion of short and hypomobile structures
45788313|NCT05325255|Other|Cold pack|It is the application of cold to provide analgesic effects
45788314|NCT05315427|Other|one music therapy session|Edmonton Symptom Assessment System (ESAS) scale (before and after music therapy session), Numerical pain scale (before and after music therapy session)
45653094|NCT05179083|Other|High-Impact Aerobic Exercise|Participants will be submitted to a 12-week high-impact aerobic exercise program using a recliner bike with three sessions per week. The exercise protocol takes 45 minutes per session and consists of five minutes of warm-up, 30 minutes of cycling with progressive increase in intensity until the target heart rate (80% of maximum) is reached, followed by 10 minutes of cool down.
45788315|NCT01251536|Drug|Dose escalation of cetuximab|"Dose, frequency & treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly"
45788316|NCT01251536|Drug|Standard first line treatment with cetuximab + Folfiri|"Dose, frequency & treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab: 250 mg/m2 weekly."
45788317|NCT02619591|Other|Ultrasound Imaging|views of a hemithorax was obtained using the Zonare Ultrasound machine.
45788318|NCT02620683|Drug|Lidocaine|See above
45788319|NCT02621463|Device|Noninvasive Ventilator (V60, Philips)|The clinician will determine the concentration of oxygen that shall be delivered to the patient. The ventilator is capable of providing concentrations between 21% - 100% of oxygen. Unless otherwise directed by the clinician, the default setting of 40% will be used.
45788320|NCT01355588|Drug|Ketorolac Tromethamine|30 mg Ketorolac Tromethamine intranasal (IN)
45788321|NCT01355588|Drug|Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)|30 mg Ketorolac Tromethamine with 4% Lidocaine HCl IN
45788322|NCT01355588|Drug|Ketorolac Tromethamine with 5% Lidocaine HCl|30 mg Ketorolac Tromethamine with 5% Lidocaine HCl IN
45788323|NCT01355588|Drug|30 mg Ketorolac Tromethamine with 6% Lidocaine HCl|30 mg Ketorolac Tromethamine with 6% Lidocaine HCl IN
45788324|NCT02621619|Drug|IV acetaminophen + 0.5 mg IV hydromorphone|1 gram (100 ml) IV acetaminophen in addition to 0.5 mg IV hydromorphone
45788325|NCT02621619|Drug|Normal saline + 0.5 mg IV hydromorphone|100 cc normal saline placebo in addition to 0.5 mg IV hydromorphone
45788326|NCT01253642|Procedure|Biopsy of Prostate|Undergo transrectal ultrasound (TRUS) guided prostate biopsy OR image-guided (CT or ultrasound) core bone or soft tissue biopsy
45788327|NCT01253642|Drug|Docetaxel|Given IV
45788328|NCT01253642|Other|Laboratory Biomarker Analysis|Correlative studies
45788329|NCT01253642|Drug|Phenelzine Sulfate|Given PO
45788330|NCT04022499|Behavioral|Presessions|"The Pre-NDPP arm includes a pre-session with three components: 1) education about diabetes risks, 2) motivational interviewing (MI) to encourage participation in the NDPP and, 3) problem-solving of barriers to engagement."
45919706|NCT00276055|Drug|Gemcitabine, Docetaxel and Bevacizumab|During the treatment phase, pts. will receive the drug combination of gemcitabine, docetaxel, and bevacizumab every 2 weeks for a period of 4 weeks. This 4-week period is called a cycle of treatment. The treatment consists of receiving docetaxel IV over a 60-minute period and gemcitabine IV over a 30-minute period. Pts. will then receive bevacizumab IV over a 30-minute period. Pts. will receive this treatment once every 2 weeks. Pts. will receive at least 2 cycles of treatment unless you have progression of your disease or unmanageable side effects. As long as the size of pts.'s tumor stays the same or gets smaller, pts may continue receiving treatment
45919707|NCT05156853|Dietary Supplement|Insect menus|The insect menus will consist of 6 different products: flatbread, spice-mix, paste, minced meat, sausage and falafels. The products are based on either crickets, mealworms or buffaloworm larvae.
45788331|NCT04022499|Behavioral|National Diabetes Prevention Program|The Diabetes Prevention Program was a successful clinical trial demonstrating that intensive lifestyle support for weight loss reduced diabetes incidence by 58%. The intervention was translated into the National Diabetes Prevention Program (NDPP) and disseminated by the Centers for Disease Control and Prevention as a yearlong group-based program since 2012.
45788332|NCT04741113|Other|An online 15-minute educational module|"An online 15-minute educational module with four sections: a) Knowledge about obesity; b) Weight bias definition and impact; c) Strategies to reduce weight bias; d) A short quiz.~The module will be based on relevant literature and expert opinion"
45788333|NCT01355978|Device|Noninvasive Open Ventilation System|Noninvasive ventilation system
45788334|NCT01357148|Drug|Sitagliptin Phosphate/Metformin HCl (JANUMET®)|Participants prescribed Sitagliptin Phosphate/Metformin HCl (JANUMET®) in routine clinical practice.
45788335|NCT03008798|Drug|Herbal Medicine C-117|C117 formula including 2 herbals and 2 insects
45788336|NCT03008798|Drug|The Placebo of Herbal Medicine C-117|
45788337|NCT02623803|Drug|Lidocaine|
45788338|NCT02623803|Drug|Placebo D5W|
45788339|NCT03921021|Drug|Telomelysin|OBP-301, the investigational product (IP) is formulated in 20 mM Tris pH 8.0, 25 mM NaCl with 2.5% glycerin, USP by volume. OBP-301 will be injected into the target tumor lesions.
45788340|NCT02322788|Drug|Terbutaline sulphate|Bricanyl Turbuhaler M2
45788341|NCT02322788|Drug|Terbutaline sulphate|Bricanyl Turbuhaler M3
45788342|NCT02322788|Drug|Placebo for terbutaline sulphate|Placebo Turbuhaler M2
45788343|NCT02322788|Drug|Placebo for terbutaline sulphate|Placebo Turbuhaler M3
45788344|NCT03832023|Other|Screening and initiating preventive therapy in communities|Symptom-based screening of tuberculosis household child contacts by community health workers; initiation of preventive therapy (3 months of a fixed-dose combination of rifampicin-isoniazid or 6 months isoniazid for HIV+ children on protease inhibitors) in the household by a nurse; follow-up of children under preventive therapy by a community health worker for eligible children at community level, and referral of presumptive tuberculosis cases (children and adults) to the facility.
45788345|NCT01316510|Dietary Supplement|Bifidobacteria infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge
45788346|NCT01316510|Other|Placebo|Dilute Nutramigen formula
45919708|NCT05156853|Dietary Supplement|Plant menus|The plant menus will be based on products which can be purchased in normal supermarkets and chosen to be as equal to the insect-based products as possible.
45645710|NCT05077813|Combination Product|All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
45788347|NCT01318538|Behavioral|The Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
45788348|NCT01318538|Behavioral|Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances including alcohol; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
45788349|NCT02625207|Drug|Maraviroc (Part 1)|300 mg twice daily x 5 days
45788350|NCT02625207|Drug|Maraviroc (Part 2)|150 mg once daily x 10 days
45788351|NCT02625207|Drug|Darunavir/cobicistat (Part 2)|800/150 mg once daily x 10 days
45788352|NCT01763333|Drug|BI 1026706 Placebo|Placebo to BI 1026706
45919709|NCT00275977|Procedure|Coronary catherization and stem cell infusion|
45788353|NCT01763333|Drug|BI 1026706|different dose formulations
45788354|NCT05315999|Drug|Palonosetron Hydrochloride|Palonosetron (500µg): single dose per os 1-2 hours before the start of opioid-therapy (WHO III)
45788355|NCT05315999|Drug|Placebo|Placebo: single dose per os 1-2 hours before the start of opioid-therapy (WHO III)
45788356|NCT01763645|Drug|Bevacizumab|Patients will receive 6 courses of bevacizumab in combination with carboplatin and paclitaxel. Bevacizumab will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
45788357|NCT01763645|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion on Day 1 of each 3-week course (6 courses totally)
45788358|NCT01763645|Drug|Carboplatin|Carboplatin will be administered (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel on Day 1 of each 3-week course (6 courses totally).
45919710|NCT03226028|Procedure|Music listening|Patient is given an ipod with earphone and with saved playlists of different music genres. Music listening session will be given for 30 minutes before and after surgery. Questionnaires will be asked to fill in. All the earphones will be disinfected following the hospital's infection control guideline.
45788359|NCT02253173|Drug|Estradiol|
45919711|NCT00275938|Drug|interferon alpha 2b plus ribavirin|
45919712|NCT00275938|Drug|interferon alpha 2b plus placebo|
45919713|NCT00275743|Procedure|MRI|
45919714|NCT00275704|Drug|Flaxseed|
46071278|NCT04044391|Diagnostic Test|CardioFlux Magnetocardiograph|CardioFlux is a noninvasive diagnostic modality which can measure and image the heart's intrinsic magnetic field created by ion transit across cardiac cell membranes.
45788360|NCT02253173|Drug|Placebo|
45788361|NCT03951779|Diagnostic Test|Exercise cardiac magnetic resonance imaging|Subjects will exercise on a treadmill and immediately following the completion of the stress protocol, subjects will undergo cardiac magnetic resonance imaging
45788362|NCT03924791|Drug|Lidocaine|In combination with dexamethasone or methylprednisolone acetate
45788363|NCT03924791|Drug|Methylprednisolone Acetate|In combination with lidocaine
45788364|NCT03924791|Drug|Dexamethasone|In combination with lidocaine
45788365|NCT03908567|Drug|Intranasal Drug|Intranasal administration of solution with betahistine dihydrochloride; Dosing 3 times a day
45788366|NCT03908567|Drug|Oral Tablet|Oral dosing with tablets 3 times a day
45788367|NCT03908567|Other|Intranasal Placebo|Intranasal administration of solution without betahistine dihydrochloride; Dosing 3 times a day
45788368|NCT05315609|Behavioral|VR Meditation|This 4-week VR program will use the Oculus Pro-Quest 2 headsets for the 15-minute seated VR meditation twice per week for a total of 8 sessions over the 4 weeks.
45645711|NCT05077813|Combination Product|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
45788369|NCT01318694|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
45449367|NCT03605745|Device|Prostatic Vapor Ablation|"Rezūm uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow, weak stream, straining and getting up at night to urinate.~Inside a hand-held device, radiofrequency energy is applied to a few drops of water to create vapor (steam). The water vapor is injected into the prostate tissue that is blocking the flow of urine from the bladder, where it immediately turns back to water, releasing the energy stored in the vapor into the cell membranes. At this point, the cells are gently and immediately damaged, causing cell death. Over time, the body absorbs the treated tissue through its natural healing response."
45449368|NCT02150356|Other|Aleurone|Diet based in aleurone-enriched products for a period of 8 weeks.
45788370|NCT01318694|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
45449369|NCT02150356|Other|Control|Diet based on refined cereal products for a period of 8 weeks.
45449370|NCT03725709|Procedure|spinal anesthesia|Plan to enroll 120 Type 2 diabetes and 120 non-diabetes patients with received spinal anesthesia.Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
45788371|NCT01318694|Drug|Ribavirin|RBV 200 mg tablets (weight-based dose: < 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
45788372|NCT01318694|Drug|ALV Placebo|ALV placebo soft gel capsules administered orally
45788373|NCT01319318|Procedure|Pars Plana Vitrectomy|Pars plana vitrectomy performed in study eye on Day 0.
46071279|NCT02845934|Other|blood sample|additional sampling of blood (estimated volume 6 mL for each sampling) on day of suspicion of the mucormycosis and then twice a week up to a maximum of 8 weeks.
46071280|NCT00820261|Other|oral rehydration therapy for diarrhea cases|Since rotavirus infection is a viral infection with no drug remedy, diarrhea cases will be managed according to the standard WHO protocol for the management of diarrhea. This will include oral rehydration treatment.
45788374|NCT01319552|Procedure|Fresh transfusion|1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions
45788375|NCT01319552|Procedure|Old transfusion|1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions
45788376|NCT03009578|Drug|Iron Sucrose Injection|iron Intramuscular injections
45788377|NCT03009578|Drug|Ferrous Bisglycinate|oral iron tablets
45788378|NCT02324660|Other|screening test|screening test with peak expiratory flow and respiratory health screening questionnaire to discriminate patients at risk for COPD
45788379|NCT01359410|Device|Mesh reinforced staple line (SEAMGUARD)|Reinforce the pancreatic transaction with SEAMGUARD®
45788380|NCT01359410|Device|Stapled without mesh reinforcement (PER-STRIPS DRY)|Stapled without mesh reinforcement (PERI-STRIPS DRY®)
45788381|NCT01361048|Drug|oral metronidazole|2 gm oral once
45788382|NCT01361048|Drug|neo penotran forte|neo penotran forte intravaginal twice a day for 7 days
45788383|NCT01361048|Drug|neo penotran forte once a day|neo penotran forte intravaginally once a day for 7 days
45788384|NCT01258790|Device|Sham Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Sham intervention uses a sham magnetic coil.
45788385|NCT01258790|Device|Active Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Active intervention uses an active magnetic coil.
45788386|NCT01766219|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
45788387|NCT05315531|Dietary Supplement|Water Intake|Participants will increase plain water consumption to at least 70% of the daily adequate intake for Americans depending on their sex.
45788388|NCT01767155|Drug|AEZS-108 / zoptarelin doxorubicin|267 mg/m^2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles for a maximum of 9 cycles
45788389|NCT01767155|Drug|doxorubicin|60 mg/m^2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
45788390|NCT01362686|Drug|Donepezil|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
45788391|NCT01362686|Drug|Galantamine|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
45788392|NCT01362686|Drug|Rivastigmine|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
45645712|NCT05077813|Other|The standard therapy|The standard therapy 100 infected patients with confection of COVID-19 and MDR-TB will receive the standard therapy for tuberculosis for 30 days
45919715|NCT03194789|Device|Footwear Generated Bio-Mechanical Manipulation (using shoes with pertupods) along with Traditional Pelvic Floor Therapy|Participants will have FGBMM using shoes with pertupods along with traditional pelvic floor therapy over the course of six months. This will include five sessions of gait assessment and re-calibration with daily at home exercise with the device (shoes) over the course of six months. Along with that, participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
45919716|NCT03194789|Other|Traditional Pelvic Floor Therapy|Participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
45919717|NCT00275665|Drug|Valganciclovir|
45919718|NCT05149599|Drug|Saccharomyces cerevisiae|Saccharomyces cerevisiae, which is a pro-biotic, was given in capsule form, 500mg twice daily for 1 month
45919719|NCT00276640|Drug|vincristine, carboplatin|"vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21~carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21"
45919720|NCT00276640|Drug|vincristine, carboplatin, etoposide|"vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21~carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21~etoposide: 100 mg/m² i.v., week 1,4,7,10"
45919721|NCT00276640|Radiation|radiation therapy|"intracranial tumor site: 30 fractions, dose per fraction: 1.8 Gy, total dose: 54 Gy, duration 6 weeks~spinal tumor site: 28 fractions, dose per fraction: 1.8 Gy, total dose: 50.4 Gy duration 5 1/2 weeks"
45919722|NCT00275548|Drug|Pegasys|135-180 micrograms administered sc once weekly
45919723|NCT00275548|Drug|Copegus|400-1200 mg/day for 48 weeks
45919724|NCT00275431|Drug|AT-101|Oral
45919725|NCT05567107|Other|massage|Classical foot massage was applied by the researcher with efflorescence, superficial friction and petrissage techniques for 10 minutes on each foot.
45919726|NCT03152318|Drug|rQNestin|rQNestin is an oncolytic viral vector. It is administered via intratumoral injection during biopsy surgery.
45788393|NCT01322048|Drug|IV Propranolol and Per Tube Clonidine|1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days
45788394|NCT01322048|Drug|Placebo|Placebo IV q6h and Per Tube q12, both for 7 days
45788395|NCT01322360|Drug|Morphine Sulfate|
45788396|NCT05315375|Device|corpectomy|vertebral corpectomy using expandable cage
45788397|NCT05315219|Procedure|Endoscopic Thyroidectomy Bilateral Areola Approach|The endoscopic thyroidectomy achieves better cosmetic effects than open thyroidectomy, and is one of the most widely applied approach in China, meanwhile its safety and effectiveness has been broadly discussed since being introduced.
45919727|NCT03152318|Drug|Cyclophosphamide|Cyclophosphamide is an immunomodulating agent. It is administered intravenously in a single dose 2 days (+/- 6 hrs) before surgery.
45919728|NCT03152318|Procedure|Stereotactic biopsy|In both arms, subjects will undergo standard of care stereotactic biopsy in the intraoperative MRI operating room. The stereotactic needle will be placed stereotactically into the tumor bed using intraoperative MRI guidance to collect the biopsy, and again to administer the rQNestin oncolytic virus.
45919729|NCT05566990|Biological|LIV-GAMMA SN Inj.10%|LIV-GAMMA SN Inj. 10% is administered intravenously at a dose of 1 g/kg daily for 2 consecutive days to patients with primary immune thrombocytopenia.
45645713|NCT02326051|Drug|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously once positive pregnancy test is established and the therapy will continue until termination of pregnancy
45645714|NCT02326051|Drug|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously after sonographic confirmation of fetal cardiac pulsation and the therapy will continue until termination of pregnancy
45645715|NCT02325973|Device|PressureWire Certus guidewire|Assessment of IMR index in coronaries through PressureWire Certus guidewire
45645716|NCT00914251|Drug|Hesperidin|Administration of oral Hesperidin, 500 mg/daily
45645717|NCT00914251|Drug|Placebo|Administration of oral Placebo, 500 mg/daily
45645718|NCT02330731|Procedure|injection sclerotherapy for gastric varices|The intravariceal technique of injection
45919730|NCT05566912|Other|filling out a survey|This research is a descriptive study
45919731|NCT05566054|Drug|Chidamide|Chidamide 10mg orally daily for 7 days (d1-d7)
45919732|NCT05566054|Drug|Azacitidine|azacytidine 75mg/m2 daily for 7 days (d1-d7)
45919733|NCT05566054|Drug|Venetoclax|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28)
45919734|NCT05565430|Other|Acute Hyperventilation|Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.
45645719|NCT05076955|Drug|vancomycin-tobramycin-itraconazole|Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.
45645720|NCT02330575|Behavioral|Exercise|The participant exercise sessions will be conducted in small groups of 5 to 10 participants under the direct supervision of the community-based exercise specialist. Participants will have the choice between taking part in a bridging exercise class (e.g., Beauty program and Bridging to Fitness - Cancer) or group-based supervised fitness centre exercise training.
45788398|NCT04351724|Drug|Chloroquine or Hydroxychloroquine|Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available
45788399|NCT04351724|Drug|Lopinavir/Ritonavir|Lopinavir/Ritonavir 200mg/50mg 2-0-2
45788400|NCT04351724|Other|Best standard of care|best standard of care
45788401|NCT04351724|Drug|Rivaroxaban|2.5mg 2-0-2 or 10mg 1/2-0-1/2, as applicable
45788402|NCT04351724|Drug|Thromboprophylaxis|as local standard, most likely to be low molecular weight heparin
45788403|NCT04351724|Drug|Candesartan|starting dose 4mg once daily, titrated to normotension
45645721|NCT02330575|Behavioral|Education|Participants allocated to the standard care group will receive standard advice and counseling on physical activity and will serve as the 'control group' for a 16-week period.
45788404|NCT04351724|Drug|non-RAS blocking antihypertensives|This excludes angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (AT-blockers, sartans) and includes alpha-receptor antagonists, calcium antagonists, amongst others
45788405|NCT04351724|Drug|Remdesivir|200mg on day 1, thereafter 100mg for a total of 5-10 treatment days, according to local standards
45788406|NCT04351724|Drug|Asunercept 400mg|asunercept 400mg once per week, up to 4 doses in total
45788407|NCT04351724|Drug|Asunercept 100mg|asunercept 100mg once per week, up to 4 doses in total
45788408|NCT04351724|Drug|Asunercept 25mg|asunercept 25mg once per week, up to 4 doses in total
45788409|NCT04351724|Drug|Pentaglobin|7ml/kg/day for 12h for 5 days
45919735|NCT05565430|Other|Chronic hyperventilation|Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.
45919736|NCT05565430|Drug|Effects of anticholinergic medication|Laryngoscopy to assess vocal cord function after administration of anticholinergic medication.
45919737|NCT05559970|Drug|Inhalational sedation|Inhalational sedation with isoflurane for 12 hours
45645722|NCT05076721|Other|Simulation training|The participants in the simulation group will receive simulation training with high-fidelity manikin to practice and implement one-hour bundle sepsis
45788410|NCT01767701|Drug|Raltegravir|400mg twice daily for 3 months
45788411|NCT01322594|Biological|MEDI2338|MEDI2338 single intravenous (IV) dose (lowest dose)
45788412|NCT01322594|Biological|MEDI2338|MEDI2338 single IV dose (next highest dose)
45788413|NCT01322594|Biological|MEDI2338|MEDI2338 single IV dose (next highest dose)
45788414|NCT01322594|Biological|MEDI2338|MEDI2338 single IV dose (next highest dose)
45788415|NCT01322594|Biological|MEDI2338|MEDI2338 single IV dose (highest dose)
45788416|NCT01322594|Other|Placebo|Placebo single IV dose
45788417|NCT01767935|Procedure|cryosurgery|Undergo cryosurgery
45788418|NCT01767935|Radiation|radiation therapy|Undergo radiation therapy
45449371|NCT01761890|Behavioral|Dasatinib discontinuation|Treatment decision is at the discretion of the investigator and must not be made on the basis of this observational study. Patients should have their treatment initiated in accordance with the summary of product characteristics.
45449372|NCT02150434|Device|Automated oxygen titration|Automated oxygen titration every second to maintain stable SpO2 at a predefined value (94% in the present study)
45645723|NCT05076721|Other|Case-based discussion training|The participants in the conventional group will only do a case-based discussion in implementing one-hour bundle sepsis
45645724|NCT03144193|Other|Topical anti-aging cosmetic cream|Topical anti-aging cosmetic cream
45788419|NCT01767935|Procedure|quality-of-life assessment|Ancillary studies
45788420|NCT01363388|Drug|Placebo|BID for 84 days
45788421|NCT01363388|Drug|CCX168|BID for 84 days
45788422|NCT01768013|Drug|LEO 90105|Once daily for four weeks
45788423|NCT04351412|Other|Gluma|Gluma is desensitizing agent by (Heraeus Kulzer, Armonk, NY, USA) claimed to treat dentine hypersensitivity in exposed cervical teeth surfaces and was applied to participants using a mini brush applicator tip onto the exposed hypersensitive tooth surface requiring treatment and was allowed to dry for 60 seconds. Then Dentine hypersensitivity (DH) was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
45788424|NCT04351412|Other|fluoride varnish|fluoride varnish is usually applied to patients to prevent caries development but was claimed in some cases to also relief dentine hypersensitivity and was applied as a thin layer to the surface of the tooth using an applicator. The varnish set rapidly, and thereafter moisture contamination was not a concern. Patients were advised to not brush or floss their teeth for a couple of hours and to abstain from hot beverages. DH was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
45788425|NCT04351412|Other|Tetric N-Bond self-etch adhesive|Tetric N-Bond self-etch adhesive is one step dental adhesive and is also claimed to relief dentine hypersensitivity due to blockage of dentinal tubules. It was applied according to the manufacturer's instructions, in a thick layer, for at least 30 seconds, using a light brushing motion. Then, it was dried with a steady stream of air for 3 seconds and light-cured for 10 seconds. DH was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
45919738|NCT05559970|Drug|Convention sedation|Conventional sedation receiving analgosedation with fentanyl
45919739|NCT05140746|Diagnostic Test|68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT|Baseline 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT scans before NAC followed by abdomen 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT scans after one cycle of NAC treatment or before surgery.
45788426|NCT01768325|Device|EUS-TCB needle (QuickCore) standard of care|"The number of needle passes requiring to acquire adequate specimen were tallied.~Length of core tissue obtained~Diagnostic contribution of immunohistochemical staining~Rates of complications"
45788427|NCT01768325|Device|EUS-Guided biopsy needle (ProCore)|"The number of needle passes requiring to acquire adequate specimen were tallied.~Length of core tissue obtained~Diagnostic contribution of immunohistochemical staining~Rates of complications"
45788428|NCT05315141|Other|No Intervention|No Intervention
45788429|NCT02989883|Other|peroral endoscopic myotomy|The procedure consists of four steps: 1) mucosal incision 10-15 cm above the esophagogastric junction to allow entry into the submucosa, 2) creation of a submucosal tunnel until the lower esophageal sphincter is reached, 3) myotomy of the circular muscle layer, and 4) closure of the mucosal entry with endoclips.
45645725|NCT05077111|Procedure|Thoracic Epidural Anesthesia|Group A pre-medicated once using Midazolam 3-4mg intravenous (IV) and Fentanyl 50mcg, placed in the setting position. Using a winged 18G (Gadge), 9cm length Tuohy Epidural needle, a 20G springwound closed tip epidural catheter be inserted between T3-T4. A test dose (5ml) 2% Lidocaine given, followed by 5-8 ml Bupivacaine 0.5% and 50mcg Fentanyl as a loading dose. Further top-up dose of 5 ml Bupivicaine 0.5% after 45 minutes.
45788430|NCT01364090|Drug|Pegylated interferon alfa 2b|Pegylated interferon alfa 2b 1.5 mcg/kg/week to a maximum of 150 mcg/week administered subcutaneously once weekly directly observed.
45788431|NCT01364090|Drug|Ribavirin|Ribavirin - 800-1400 mg daily according to weight taken orally with food, self administered in split doses.
45788432|NCT05314907|Device|Explanation on how to use self-sampling device and training in the screening visit.|"During the screening visit, woman is offered to participate in the study. If she accepts, informed consent is signed, a sociodemographic questionnaire is collected, and a cervical sample is collected for HPV detection by the health professional in the consultation.~Then, the professional informs the woman of how to carry out the self-collection using Evalyn Brush and after the woman collects an HPV sample by self-sampling in the same medical center as a trainning.~Finally, a new cervibrush (Evalyn brush) is given to the woman for home self-sampling, together with written and picture-based instructions on how to obtain the sample and an acceptability questionnaire. After one month from the screening visit, woman is requested to return the self-collected sample together with the questionnaire in person to the recruitment centre."
45788433|NCT05314907|Other|Only explanation on how to use self-sampling device.|"During the screening visit, woman is offered to participate in the study. If she accepts, informed consent is signed, a sociodemographic questionnaire is collected, and a cervical sample is taken for HPV detection by the health professional in the consultation.~Then, the professional informs the woman of how to carry out the self-collection using Evalyn.~Finally, a Evalyn brush is given to the woman for home self-sampling, together with written and picture-based instructions on how to obtain the sample and an acceptability questionnaire. After one month from the screening visit, woman is requested to return the self-collected sample together with the questionnaire in person to the recruitment centre."
45788434|NCT03684785|Drug|Cavrotolimod|Intratumorally dosed cavrotolimod.
45788435|NCT03684785|Biological|Pembrolizumab|Pembrolizumab dosing as per the US prescribing information.
45788436|NCT03684785|Biological|Cemiplimab|Cemiplimab dosing as per the US prescribing information.
45788437|NCT03684785|Drug|Cavrotolimod|Subcutaneously dosed cavrotolimod
45788438|NCT01364558|Drug|Diazepam|Diazepam will be administered as a 5 mg dose given IV. The two nasal formulations will be given as a 10 mg dose.
45788439|NCT01364558|Drug|Diazepam|IV diazepam will be given as a 5 mg dose. The two nasal formulations will be given as 10 mg doses.
45919740|NCT05495971|Device|NaturalVue Multifocal|EDOF
45919741|NCT00387491|Drug|MOA-728|
45919742|NCT05132205|Procedure|Radiofrequency Ablation|Radiofrequency Ablation using RFMedical device.
45653095|NCT05179083|Other|Low-Impact Aerobic Exercise|Participants will be submitted to a 12-week low-impact aerobic exercise program using a recliner bike with three sessions per week. The exercise protocol takes 45 minutes per session and consists of five minutes of warm-up, 30 minutes of cycling with progressive increase in intensity until the target heart rate (40% of maximum) is reached, followed by 10 minutes of cool down.
45449373|NCT02150434|Drug|Compressed air|compressed air delivered at a fixed flow of 2 L/min
45449374|NCT02150434|Drug|Oxygen constant flow|oxygen delivered at a fixed flow of 2L/min
45788440|NCT05297513|Drug|ActiveMatrix|All patients will receive weight based prophylactic antibiotics i.e. Ancef, vancomycin, or clindamycin. Drains will be used in fusion cases only. Intrawound vancomycin will be used for all instrumented cases.No negative pressure devices will be used. Anatomic layers will be closed in similar, standard fashion for all cases. For those randomized to the treatment group, the ActiveMatrix product will be administered on top of the dura mater and again on the closed fascia. Those in the control group, will forgo this step.
45788441|NCT01323140|Drug|testosterone matrix transdermal system|
45788442|NCT04769999|Behavioral|Simple cognitive task|A brief memory reminder cue followed by playing the computer game Tetris for 25 minutes using mental rotation instructions. Option for subsequent booster sessions (self-administered/researcher-assisted).
45788443|NCT03516305|Drug|Staccato Alprazolam 1 mg|alprazolam I mg administered via the Staccato hand-held inhaler device system.
45788444|NCT03823287|Drug|Faricimab|Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
45919743|NCT05467345|Device|Contour Next and Contour Plus Elite BGMS testing of neonatal blood|The purpose of this study is to extend the intended use of two BGMSs to include testing of neonatal blood by Health Care Professionals in a clinical setting for the quantitative measurement of glucose levels in neonates.
45788445|NCT03823287|Drug|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
45919744|NCT05464732|Device|Vivity IOL|The Vivity IOL will be implanted bilaterally in all subjects.
46071281|NCT02844608|Other|Quality of Life Questionnaires|Patients will be asked to complete standardized HRQoL questionnaires: the EORTC QLQ-C30 with its specific module by cancer site (QLQ-BR23, QLQ-CR29, QLQ-LC13) at first visit before starting treatment and then before every medical consultation during four months.
45788446|NCT03823287|Procedure|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
45788447|NCT01260272|Other|Alternative Snack Comparator|Any prepackaged commercial snack is permitted as an alternative comparator snack, as long as it is 100 kcal/serving, does not contain raisins, does not contain solely fruits, and/or does not contain solely vegetables. Preferred comparator snack examples include: Keebler® Cheez-It® Crackers, Fudge Shoppe ® Grasshopper® Cookies, Fudge Shoppe ® Mini Fudge Stripes ™ Cookies, Nabisco Chips Ahoy! Baked Chocolate Chip Snacks, Honey Maid Cinnamon Roll Thin Crisps, Lorna Doone Baked Shortbread Cookie Crisps, Oreo Baked Chocolate Wafer Snacks, Pepperidge Farm® Goldfish® Baked Snack Crackers
45788448|NCT01260272|Other|Raisins|Raisins are dry grape fruits that may be eaten raw, or used in cooking, baking, and brewing. Raisins are mostly composed of carbohydrates (mostly fructose). They are also high in fiber and antioxidants, relatively high in potassium, and low in sodium.
45645726|NCT05077111|Procedure|General Anesthesia with One Lung Ventilation|Group B premedicated once by 3-4mg Midazolam IV, Ranitidine 50mg, Metoclopramide 10mg and Dexamethasone 4mg. Preoxygenation with 100% O2. Induction of anesthesia with Propofol (2mg/kg) and Fentanyl (1mcg/kg). Tracheal intubation by 37-39 Fr Double Lumen Endotracheal Tube insertion facilitated with Cisatracurium 0.1mg/kg. and confirmation of its position by Fiberoptic Bronchoscopy. Selective Lung Ventilation strategy can be performed through the endobroncheal tube of the non operated lung once needed. Anesthesia maintained with Isoflurane (1-2%) and Cisatracurium (0.05mg/kg per dose). Later, anesthesia discontinued and extubation after full neuromuscular recovery after reversal of muscle relaxant by Neostigmine (0.05mg/kg) and Atropine (0.02mg/kg).
45788449|NCT01769573|Biological|RG-HRV16|A suspension of the RG-HRV16 virus in Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin
45788450|NCT01769573|Drug|Placebo|The placebo to be used will be Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin. Placebo will be supplied in 2 ml borosilicate glass vials sealed with butyl stoppers containing 0.5 ml.
45788451|NCT02244671|Procedure|fat, PRP, botulinum toxin|fat injection with platelet-rich-plasma (PRP) after immobilizing the extraocular muscles with botulinum toxin
45788452|NCT02244671|Drug|botulinum toxin|botulinum toxin used to immobilize extra-ocular muscles prior to fat injection.
45788453|NCT02244671|Device|PRP|autologous PRP is prepared with a dedicated centrifuge at the time of fat harvesting
45788454|NCT05288543|Drug|IPG7236- Single ascending dose|Subjects will receive IPG7236 tablets orally once on Day 1 in a fasted state
45788455|NCT05288543|Drug|IPG7236- Multiple ascending dose|Subjects will receive IPG7236 tablets orally once daily for 10 days from Day1 to Day 10 in a fasted state
45449375|NCT02160028|Other|anesthetics and extended information before dental treatment|The extended information is a comprehensive explanation about what to expect of the treatment and the anesthetic method, phrased in positive words and opening up for questions after information is given.
45449376|NCT02160028|Other|anesthetics and standard information before dental treatment|The standard information is short and concise, telling in neutral words what to expect.
45788456|NCT05288543|Other|Placebo (Part A)|Subjects will receive IPG7236 tablets orally once on Day 1 (Part A) or once daily for 10 days from Day1 to Day 10 (Part B) in a fasted state
45788457|NCT02193152|Drug|Pazopanib|
45788458|NCT05282147|Device|Neocam|Screening within 72 hours of birth will be completed using the digital imaging device Neocam which painlessly images the eye's reflection firstly to infrared light and then to a brief green light flash.
45645727|NCT02330497|Procedure|Radiofrequency Ablation under EUS|Pancreatic radiofrequency ablation under endoscopic ultrasonography guidance Procedure under general anesthesia Punction of the pancreatic lesion and aspiration of the liquid if present / then thermal ablation with a 18G needle (50 W during 10 secondes) - only one session
45645728|NCT05075863|Drug|Letrozole|Letrozole as 5mg from day 3 to 7 of menstrual cycle
45645729|NCT05072119|Device|Device implantation|Implantation of single chamber, dual chambers or triple chambers PM/ICD
45645730|NCT02330419|Drug|Placebo|
45645731|NCT02330419|Drug|Naltrexone|
45645732|NCT03143803|Drug|Polyherbal capsule coccinia, bougainvillea, catharanthus|A unique combination of 3 herbs that lower blood sugars
45788459|NCT01323998|Drug|5ARI|Dutasteride or Finasteride
45788460|NCT01323998|Drug|AB|Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
45788461|NCT02258477|Dietary Supplement|Sequence 1|100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
45788462|NCT02258477|Dietary Supplement|Sequence 2|Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
45788463|NCT02258477|Dietary Supplement|Sequence 3|50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
45788464|NCT02258477|Dietary Supplement|Sequence 4|10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
45919745|NCT02979977|Drug|cetuximab|30-60 minutes after the recommended pre-medications, cetuximab will be administered intravenously at a dose of 400mg/m2 on cycle 1, day 1 of treatment (loading dose) and at a dose of 250mg/m2 every 7 days (+/- 1 day) thereafter. Alternatively, patients can be treated at a dose of 500mg/m2 every 14 days (+/- 2 days).
45449377|NCT03246152|Drug|Bevacizumab|Repeated intravitreal injections of Bevacizumab monthly
45645733|NCT03143803|Drug|Placebo|Similar looking inactive powder
45645734|NCT05076331|Diagnostic Test|PI-2620 tracer for Tau PET scan|Tau PET scans are obtained using PI-2620 tracer provided by Life Medical Imaging.
45645735|NCT05070325|Other|Cold application group|Cold application group (Group 1): In the children in this group, the injection site was cleaned before the injection using antiseptic cotton and then the gel pad was placed on the injection site. In line with the literature, the cold gel pad was applied to the intramuscular injection site for 30-45 seconds before the injection and then the injection was delivered. The children were told to breathe deeply and not to tense up during the injection.
45788465|NCT03008954|Device|GSP3|Each capsule of GSP3 (previously Attiva) contains 700 mg of a mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.
45788466|NCT03008954|Dietary Supplement|Avicel (modified Cellulose)|Each capsule of Avicel contains approximately 350 mg of microcrystalline cellulose
45788467|NCT02626611|Drug|Omalizumab|Omalizumab is an anti-Immunoglobulin E antibody injection and will be administered per product insert from weeks 0 through 16 of the study.
45788468|NCT02626611|Drug|Food Flour Buildup|Food flours identified as allergic (based on food challenge), will be introduced at week 8. The food dose will be escalated every 2 weeks up to 2000 milligrams of each of the food flours. Subjects are required to reach 300 milligrams at week 16 to continue to week 30. Subjects must tolerate 2000 milligrams per food by week 28 in order to be randomized.
45788469|NCT01260662|Drug|Propofol|1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
45788470|NCT01260662|Drug|1:1 Propofol/Ketamine|Propofol and ketamine mixed 1:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
45788471|NCT01260662|Drug|4:1 Propofol/Ketamine|Propofol and ketamine mixed 4:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
45788472|NCT02327117|Drug|Tranexamic Acid|
45788473|NCT02327117|Drug|Normal saline|
45788474|NCT03819543|Device|Transcranial Direct Current Stimulation|Application of transcranial direct current stimulation via scalp electrodes over presumed epileptogenic focus for 20 minutes at 2.0 mA.
45449378|NCT03571581|Behavioral|Mindfulness Training (MT)|Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 20 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
45449379|NCT03541564|Drug|BMS-986165|Specified dose on specified days
45788475|NCT03781089|Drug|Patiromer Oral Powder Product|Patients randomized to the patiromer arm will initiate on 8.4 g/day (one pack) given once a day with breakfast or lunch (in place of the full dose of phosphate binder), to start at the end of Week 0. The patiromer dose will be titrated based on serum potassium concentrations drawn on HD1 of Weeks 1, 2, and 3. Patiromer will be increased by 8.4 g/day if K ≥ 5.1 meq/L, decreased by 8.4 g/day if K < 4.0 mEq/L, and patiromer will be discontinued if K < 3.5 mEq/L. Patients randomized to the usual care arm will undergo monitoring with laboratory measurements as outlined in the study protocol
45788476|NCT01365650|Drug|Ketorolac Tromethamine|Single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 1
45788477|NCT01365650|Drug|Oxymetazoline Hydrochloride|Single intranasal dose of oxymetazoline hydrochloride followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) 30 minutes later on Day 1 of Period 2
45788478|NCT01365650|Drug|Fluticasone Propionate|Seven days of treatment with intranasal fluticasone propionate (between Periods 2 and 3) followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 3
45788479|NCT02327351|Other|Biological: TCR alfa beta T cell depletion|
45449380|NCT03541564|Drug|Moxifloxacin|Specified dose on specified days
45645736|NCT05070325|Other|Shotblocker group|Shotblocker group (Group 2): The injection site was cleaned using antiseptic cotton. The surface of the Shotblocker with the contact points was placed on the site just before the injection in a way not to contaminate the injection point. Injection was carried out through the opening in the middle of ShotBlocker. The children were told to breathe deeply and not to tense up during the injection. After the injection was completed, ShotBlocker was removed from the skin.
45645737|NCT05070325|Other|Control Group|Control Group (Group 3): The routine IM injection was applied to the children in this group. The injection site was cleaned using antiseptic cotton. The children were told to breathe deeply and not to tense up during the injection.
45645738|NCT05068141|Drug|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg, i.v., q2w
45919746|NCT02979977|Drug|afatinib|Patients will take a single oral dose of afatinib each day at a dose of 30 mg. Afatinib dose will not be escalated beyond the 30 mg daily oral dose; dose reductions of afatinib can occur to manage treatment related adverse events.
46071282|NCT00820339|Procedure|Selective Hepatic Vascular Exclusion|Inflow occlusion with extraparenchymal control of major hepatic veins results in total liver isolation from the systemic circulation but without interruption of caval flow.
45645739|NCT05068141|Drug|Nab-paclitaxel|Paclitaxel for Injection (Albumin Bound), 100 mg/m^2, i.v., D1, D8, D15 of every 4-week cycle
45788480|NCT02627001|Device|NuMask Intraoral Airway Device|NuMask Intraoral Airway Device
46071283|NCT00820339|Procedure|Pringle's Maneuver|Hepatic pedical clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
45788481|NCT02627001|Device|Bag Valve Mask|Conventional bag valve mask
45919747|NCT05428657|Other|EC Brain After-school Program|"Computerized Eye-tracking Attention and Impulse Control Training~Computerized Temporal Processing Training~Education on Relaxation, Stress Management and Healthy Balanced Diet"
45919748|NCT05428657|Other|conventional intervention|Conventional cognitive training on their language and learning capacities (e.g., learning adjectives, logical reasoning, composition, reading words and story) and attention ability
46071284|NCT02844686|Other|Cardiac SPECT|3-D dynamic acquisition of cardiac SPECT at rest and after pharmacological stress
46071285|NCT00828685|Procedure|CRPP|Closed reduction, percutaneous pinning
46071286|NCT00828685|Procedure|ORIF|Open reduction, internal fixation
45449381|NCT03541564|Other|Placebo|Specified dose on specified days
45449382|NCT00115349|Drug|Deferoxamine|Deferoxamine will be given daily for 12-24h/day 7 days a week either subcutaneous or intravenous at up to 50-60 mg/kg/day.
45449383|NCT00115349|Drug|Deferiprone (L1)|The dose of L1, 75mg/kg in three divided oral doses, is the maximum dose at which toxicity has been tested in prospective trials
45449384|NCT04804696|Drug|Toripalimab|Patients received toripalimab 240 mg I.V. drip on days 1 and 22.
45645740|NCT03142477|Other|Questionnaires|Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. No true or placebo therapeutic touch intervention will be performed.
45788482|NCT01261052|Device|The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm|"The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.~The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin."
45788483|NCT01261052|Device|The Adaptive Proportional Derivative Algorithm|"The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.~The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin."
45788484|NCT01770431|Drug|Huaier Granule|Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.
45788485|NCT03707925|Procedure|Cone-Beam Computed Tomography|Undergo CBCT
45788486|NCT03707925|Procedure|Conventional Surgery|Undergo standard resection
45788487|NCT03707925|Procedure|Laser Ablation|Undergo bronchoscopic laser ablation
45788488|NCT01771055|Procedure|Galactose|Galactose dripped into the abdomen after surgery
45788489|NCT01771055|Procedure|Standard surgical methods|
45919749|NCT05424757|Drug|PEG 3350|"Data and biospecimens will be collected from two groups of children:~Children who have taken PEG 3350 daily for at least 30 days.~Children who have NOT taken PEG 3350 for at least 30 days.~No changes to medicines are recommended as part of this study."
45449385|NCT04804696|Drug|Paclitaxel|Patients received paclitaxel of 175mg/m2 I.V. drip on days 1 and 22.
45449386|NCT04804696|Drug|Cisplatin|Patients received cisplatin of 70mg/m2 I.V. drip on days 1 and 22.
46071287|NCT00629707|Other|intravenous fluid treatment|infusion of intravenous fluids (0.9% saline and 0.45% saline)
46071288|NCT02846090|Drug|Dexmedetomidine to reduce the IOP|Dexmedetomidine 50 micrograms group (D50) in which peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
45788490|NCT02628093|Device|THUNDERBEAT|Tissue dissection and vessels ligation
45919750|NCT05415163|Procedure|vascular photobiomodulation|application of photobiomodulation with the device O Ecco ILIB (Eccofibras, São Paulo, Brazil) containing its red wavelength 660 nm ± 10 nm and power 100 mW, with an application time of 30 minutes. The device will be positioned with the spot located in the radial artery of the participant's arm (right or left), and fixed to the wrist with a specific bracelet.
46071289|NCT02550613|Device|The imaging biomarkers determined by MR-PET|The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients. This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).
46071290|NCT04323098|Biological|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
46071291|NCT00828763|Drug|[14c}-GSK1349572|HIV-Integrase inhibitor labelled with a carbon 14 marker
45449387|NCT03727815|Other|Mindfulness Pain Management Arm|Mindfulness Pain Management intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for 2 weeks prior to participant's scheduled procedure and continue with the pain management mindfulness module for 4 weeks postoperatively with periodic survey assessments using validated psychometric tools.
45449388|NCT03727815|Other|Mindfulness Self Esteem Arm|Mindfulness Self Esteem intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for 2 weeks prior to participant's scheduled procedure and continue with the self esteem mindfulness module for 4 weeks postoperatively with periodic survey assessments using validated psychometric tools.
45449389|NCT04753528|Device|AuriMod CT01_A|AuriMod CT01 is a wearable medical device for personalised pain treatment through auricular vagus nerve stimulation. AuriMod CT01 is a battery-operated electrical stimulation device, to be placed behind the ear on the neck. AuriMod CT01 connects to three needle electrodes, which are placed in vagally innervated regions of the auricle. It emits electrical signals with a personalized set of stimulation parameters and adjustable amplitude.
45449390|NCT04753528|Device|AuriMod CT01_B|AuriMod CT01 with a fixed set of stimulation parameters and adjustable stimulation amplitude.
45449391|NCT04753528|Device|AuriMod CT01_C|AuriMod CT01 with a fixed set of stimulation parameters and amplitude.
45788491|NCT02628093|Device|LIGASURE|Tissue dissection and vessels ligation
45788492|NCT01771991|Drug|Topical Sodermix Dismutase in the form of Sodermix (SOD)|Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.
45788493|NCT01771991|Drug|Placebo|Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.
45788494|NCT01324700|Drug|High severity group: Escitalopram|Participants within high severity group were stratified to receive escitalopram.
45788495|NCT01324700|Drug|High severity group: Placebo|Participants within high severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
45788496|NCT01324700|Drug|Low severity group: Escitalopram|Participants within low severity group were stratified to receive escitalopram.
45788497|NCT01324700|Drug|Low severity group: Placebo|Participants within low severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
45788498|NCT03698487|Other|Intervention|Pharmacist-led medication optimization intervention using an electronic tool (DBI Calculator©). The DBI Calculator is an electronic tool which calculates a score from the medication reconciliation list (medications taken prior to admission). It also creates a 'DBI report' which includes their full medication list, their DBI score, an explanation of the risks associated with their DBI score and highlighted medications which are contributing to their DBI score (that is, high risk medications which may be suitable for deprescribing).
45788499|NCT03401879|Device|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
45645741|NCT03142477|Other|Placebo therapeutic touch|Placebo therapeutic touch will be done by graduate students without any specific training. The students are instructed to perform the placebo therapeutic touch with no objective intention of improving the patient's health.
45645742|NCT03142477|Other|Therapeutic touch|Therapeutic touch will be done by therapeutic touch trained professionals graduate students without any specific training with the intention of improving the patient's health.
45788500|NCT03401879|Device|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT.
45788501|NCT03401879|Device|Optical coherence tomography (OCT)|Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
45788502|NCT03401879|Device|Optical coherence tomography angiography (OCTA)|Retinal microvasculature will be assessed using OCTA.
45788503|NCT03641703|Biological|FLT180a|FLT180a is a replication-incompetent adeno-associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
45645743|NCT02330263|Dietary Supplement|carbohydrate beverage|400ml of 12.8 g/100 ml carbohydrate beverage
45788504|NCT03556293|Behavioral|AKI Prevention Toolkit|AKI Prevention Toolkit. Intervention: All sites will receive the AKI Prevention Toolkit including 3 core interventions: 1. Standardized order sets; 2. IV and oral fluids; and 3. Reduced contrast volume. The interventions adhere to the KDIGO guidelines and add interventions developed and tested in our pilot intervention to implement AKI preventive strategies.
45645744|NCT05050435|Procedure|Early extubation|Patients of the 2 groups are extubated at different moments: either immediately postoperatively, in the operating room, or after a few hours monitoring in ICU
45788505|NCT03556293|Behavioral|Technical Assistance (TA)|Technical Assistance (TA). Intervention: TA will be offered to the 8 teams randomized to the TA condition and will receive the AKI Prevention Toolkit plus monthly technical calls independently. TA arms will include TA with and without automated surveillance reporting (ASR).
45788506|NCT03556293|Behavioral|Virtual Learning Collaborative (VLC)|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 8 teams and will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator [CAC] and Systems Redesign). VLC arms will include VLC with and without automated surveillance reporting (ASR).
45788507|NCT03556293|Behavioral|Automated Surveillance Reporting (ASR)|Automated Surveillance Reporting (ASR). Intervention: The ASR will be offered to 8 teams. In addition to either TA or VLC, ASR teams will receive automated monthly reports in the form of an dashboard focused on AKI outcome and preventative measures overtime. The ASR report will be customized to each team and each individual operator and linked to their national VA-CART registry.
45788508|NCT01262846|Biological|Fluzone®|Fluzone® Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
45788509|NCT01262846|Biological|Fluzone®|Fluzone® High dose or Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
45919751|NCT05351359|Behavioral|mHealth|A mHealth-enabled just-in-time adaptive intervention that is based on the HealthReact system developed by the participating centre at the Faculty of Science of the University of Hradec Kralove. The HealthReact system consists of a server-side application that is connected to the Fitbit server. As such, the system allows for just-in-time text messages triggered by pre-defined context as recorded by the Fitbit wearable monitor. For example, a prompt to take a break from sedentary behaviour can be triggered after 30 sedentary minutes, a suggestion to increase walking cadence can be triggered when continuous, but slow walking is detected, or a motivational message with a specific goal to take more steps to reach their usual daily step count can be triggered when the total daily steps are too low. The mHealth component will be delivered for the entire duration of the study (i.e., 12 months).
45788510|NCT04769297|Drug|Sublingual Micro-Dose Ketamine|daily micro-dosing of frontline healthcare workers suffering from acute stress disorder due to the COVID-19 pandemic
45788511|NCT03461757|Drug|Rimegepant|75 mg ODT QD
45788512|NCT03461757|Drug|Placebo|Placebo ODT to match rimegepant dose QD
45788513|NCT03315377|Procedure|Lunate-Capitate Fusion (LCF)|Operation with lunate-capitate-fusion (LCF)
45788514|NCT03315377|Procedure|Four Corner Fusion (4CF)|Operation with four-corner-fusion (4CF)
45788515|NCT01325714|Behavioral|PAVeD Intervention|In the PAVeD Intervention, the caregiver will receive six to eight 45-minute visits to teach caregiver about pain and memory problems. The person with dementia will also be able to learn from these visits. These visits will take place over three months.
46071292|NCT00824707|Drug|Entecavir|Entecavir 0.5mg per day
46071293|NCT00824707|Drug|conventional therapy|conventional therapy including protecting the liver function, anti-tumor and so on
46071294|NCT00824785|Drug|epirubicin, oxaliplatin, capecitabine (EOX)|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 130mg/m(2) IV on day 1 with hydration capecitabine 1250mg/m(2)/day PO in two divided doses continuously from days 1-21
45449392|NCT00115037|Drug|Naltrexone|100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.
45645745|NCT03142165|Drug|BMS-986263|3 weekly doses of 90 mg infused intravenous administration
45645746|NCT03142165|Other|Placebo|Placebo
45645747|NCT03142165|Drug|Diphenhydramine|50 mg intravenous administration
45645748|NCT03142165|Drug|Famotidine|20 mg intravenous administration
45788516|NCT01325714|Behavioral|Enhanced Usual Care|"In Enhanced Usual Care, the caregiver will receive information in the mail about memory problems and pain; and the caregiver will receive eight short telephone calls to check on how the person with dementia is doing.~Primary Care providers will be notified through electronic medical records about any significant behavioral problems or pain."
45788517|NCT03244475|Device|IASIS Micro Current Neurofeedback|The EEG interface device is the J&J Engineering I-330 C2, provided specifically for IASIS. The EEG sampling frequency is 256 Hz on each of 2 EEG acquisition channels. The feedback LIP-tES is delivered via the 4 EEG leads (A+, A-, B+, B-), with respect to the Common Neck Reference (isolated). During each session, 2 electrodes (A- and B-) are attached to the participant's left and right mastoids, while the remaining two electrodes (A+ and B+) are moved to various locations on the scalp to record EEG signals. All four (A+, A-, B+, B-) electrodes are involved in applying weak electric current pulses back to the brain (the feedback process). The feedback signal consists two types of narrow pulse trains, both with 150 mV in amplitude: A Type 1 pulse is 25 ms in duration and contains carrier waves at ~50 KHz. The repetition rate of Type 1 pulse train is fixed at 3.6 Hz; A Type 2 pulse is 120 ns in duration and contains carrier waves at ~100 MHz.
45788518|NCT03244475|Device|Nexalin|The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a waveform that provides tES to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. There is evidence that this waveform, at this frequency, results in improved clinical outcomes in terms of anxiety and pain. The specific mechanisms of action are not known, but available evidence suggests that this waveform alters the function of the hypothalamus and related structures. In particular, tES may lead to increases in levels of enkephalins and beta-endorphins in brain and CSF. Other data suggest that tES can alter endogenous levels of both substance P and serotonin. Regardless of which neuropeptide or neurotransmitter is ultimately found to be modulated by tES, it is hypothesized that repeated TES treatments over time serve to stimulate long-term neurochemical changes.
45788519|NCT03234569|Procedure|sonoHSG|This procedure uses agitated saline to produce air bubbles at the time of the Sonohysterogram which optimizes fallopian tube visualization. The sonoHSG is free of radiation and use of contrast. In this study, in order to produce the air bubbles at the time of the sonohysterogram, the investigators will be using a continuous saline-air device that may produce a technically superior image. For the ultrasound images, General Electric will be supporting us by providing us the Voluson E10 and RIC5-9-D.
45919752|NCT05351359|Behavioral|phone counselling|Regular monthly phone calls by trained counsellors support participants in their effort to increase physical activity and reduce sedentary behaviours. The counsellors will use various behaviour change techniques, such as goal-setting, feedback, action planning, etc. The phone counselling will be provided during the first six months, i.e. 6 phone calls will be delivered.
45919753|NCT05351359|Behavioral|Fitbit tracker|Fitbit Inspire 2 will be provided by the general practitioner to study participants at the start of the study to enable objective self-monitoring of physical activity.
45919754|NCT05351359|Behavioral|brief advice|A brief advice will be provided by the general practitioner at the start of the study.
45919755|NCT05346835|Drug|Cilta-cel OOS Therapy|Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) will be provided as a one-time administration as an intravenous infusion.
45919756|NCT02921555|Drug|Methylprednisolone|Intravenous bolus of methylprednisolone 0.5g/day for 3 consecutive days followed by a decreasing conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
45919757|NCT02921555|Drug|Prednisone|Conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
45919758|NCT05120427|Dietary Supplement|Lipid based nutrient Supplements (LNS):|LNS are 20 g/~110 calorie nutrient supplements that provide energy, protein, essential fatty acids and a wide range of micronutrients critical for children ages 6 to 24 months of age. They are designed to complement diets without displacing breastmilk and local dietary preferences and can be mixed into the child's meal or eaten directly from the sachet.
45919759|NCT05120427|Device|Growth Charts|Growth charts have been locally developed to allow parents an easy assessment of their children's height at their home. Charts will be placed on walls inside homes and will provide parents the opportunity to measure their child whenever they want, and will also contain information on the most suitable local foods as well as the importance of diverse diets and frequent feeding.
45919760|NCT05282446|Drug|INV-202|tablet
45919761|NCT05282446|Drug|Placebo|matching tablet
45919762|NCT05070585|Dietary Supplement|Isothiocyanate rich sprouts|Isothiocyanate rich sprout juice consumption for 1 week
45919763|NCT05070585|Dietary Supplement|Placebo Juice|Sprout juice devoid of isothiocyanates for 1 week
45645749|NCT02330029|Drug|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
45645750|NCT02330029|Device|Atractylodes|Atractylodes (~10-15g)
45645751|NCT02330029|Device|Paeonia Lactiflora|Paeonia Lactiflora (~15-30g)
45645752|NCT02330029|Device|Tangerine Peel|Tangerine Peel (~10g)
45645753|NCT02330029|Drug|Ledebouriella Root|Ledebouriella Root (~10g)
45645754|NCT02330029|Drug|Radix codonopsitis|Radix codonopsitis (~10-15g)
45645755|NCT02330029|Drug|Radix curcumae|Radix curcumae (~10g)
45645756|NCT02330029|Drug|Fingered citron|Fingered citron (~10g)
45645757|NCT02330029|Drug|Tuckahoe|Tuckahoe (15g)
45645758|NCT02330029|Drug|Placebo|Placebo is blindly given to patients.
45645759|NCT03142555|Behavioral|Health talk plus intensive social media intervention|Subjects in this group will receive treatments including a general health education talk about smoking cessation. Subjects will also get involved in the personalized what's app interaction (up to 2 months duration) to receive social support to quit smoking. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
45449393|NCT00115037|Drug|placebo|placebo comparer for 16 weeks in phase 2.
45449394|NCT00115037|Behavioral|Medication Management (MM)|Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.
45645760|NCT03142555|Behavioral|Health talk plus less intensive social media intervention|Subjects in this group will receive treatments including a general health education talk about smoking cessation but without the information of active referral to other smoking cessation services. Subjects will receive less intensive reminders via social media. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
45645761|NCT02638103|Drug|Fremanezumab|Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
45788520|NCT01325792|Device|GORE® BIO-A® Tissue Reinforcement|Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure after single-staged open complex ventral incisional hernia repair of primary or recurrent anterior abdominal wall hernia.
45788521|NCT02989961|Other|Resticutis|Autologous, Activated-Platelets type of Preparation
45788522|NCT02989961|Other|Platelet-Poor Plasma (PPP)|A preparation of low platelet plasma obtained by a high-speed centrifugation step.
45788523|NCT02631057|Drug|Dabigatran|Dabigatran 110 mg capsule twice a day or 75 mg x 2 capsules twice a day
45788524|NCT02631057|Drug|Warfarin|Warfarin tablet (adjustment by each patients)
45788525|NCT01325870|Device|ACD-CPR|
45788526|NCT01325870|Device|ITPR|standard CPR with use of the CirQlator intrathoracic pressure regulator (ITPR)
45788527|NCT01325870|Procedure|S-CPR|standard manual CPR
45788528|NCT01325870|Device|Impedance Threshold Device (ITD)|
45788529|NCT01775735|Device|Occipital nerve stimulator|Electrical stimulation of the greater occipital nerve
45788530|NCT02631525|Drug|Desflurane|Balanced anesthesia with remifentanil and desflurane guided by bispectral monitoring
45788531|NCT02631525|Drug|Propofol|Total intravenous anesthesia based on propofol
45788532|NCT03162497|Drug|Azithromycin|Azithromycin 15mg/g eyedrops
45788533|NCT03162497|Drug|Doxycycline|Doxycycline 100 mg per os
45788534|NCT05190315|Drug|Chlorpromazine|"Concurrent Phase: Oral chlorpromazine at 25 mg daily for the first 3 patients, then dose escalate to 50 mg if no dose limiting toxicity (DLT). Starting 7 days prior to radiation start.~Interim Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will continue post radiation and prior to beginning adjuvant temozolomide.~Adjuvant Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will be continued daily (7 days per week) concomitant with Temozolomide."
45788535|NCT05190315|Drug|Temozolomide|"Concurrent Phase: Oral temozolomide at 75 mg/m2 per day concomitant with focal radiation and chlorpromazine. Temozolomide should be started on day 1 of radiation therapy, either at bedtime or morning as per patient preference.~Adjuvant Phase: Oral Temozolomide concomitant with Chlorpromazine, starting Temozolomide dose (Cycle 1) is 150 mg/m2 daily with a single dose escalation to 200 mg/m2 daily in subsequent cycles if no treatment-related adverse events > grade 2 are noted. Temozolomide to be taken once daily for 5 consecutive days (1-5) of a 28 day cycle."
45788536|NCT05190315|Radiation|Radiation Therapy|Concurrent Phase: Radiation therapy administered daily, M-F, to a total dose of 60 Gy in 2 Gy Fractions for a total of 30 fractions.
45788537|NCT01327274|Device|Magnetic Mini-Mover Procedure (Magnimplant)|This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI > 3.5) will undergo the Magnetic Mini-Mover procedure outpatient surgery. The Magnimplant or Magnetic Mini-Mover device implant will surgically implanted on the sternum. Patients will be required to wear a custom-fitted orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo brace treatment for 18-24 months, enough to attempt to improve their PSI (< 3.25). Patients will be seen in clinic at least monthly until treatment is complete and the magnimplant device will be explanted from their sternum.
45788538|NCT05167643|Drug|Enituzumab injection+Abesili tablets+Anastrozole tablets|According to the current clinical guidelines combined with clinical practice, the treating physicians recommended the treatment plan to the subjects, and decided to enroll HR+/HER2+ advanced breast cancer patients treated with H combined with CDK4/6 inhibitor + AI±OFS into this study
45788539|NCT03162341|Procedure|ultrasonography|The tophus volume will be assess using ultrasonography.
45449395|NCT00115037|Behavioral|Combined Behavioral Intervention (CBI)|45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.
45449396|NCT00115037|Behavioral|Telephone Counseling|Bi-weekly telephone calls lasting 15-20 minutes focused on the same content as MM.
45645762|NCT02638103|Drug|Placebo|Placebo matching to fremanezumab will be administered as per schedule specified in the respective arms.
45653096|NCT05151263|Drug|Acetyl Salicylate|Aspirin is an effective antiplatelet agent, exhibiting its action by irreversibly inhibiting platelet cyclooxygenase-1 enzyme, thus preventing the production of thromboxane A2 (TXA2). It has been used in the primary and secondary prevention of thromboembolic vascular events
45788540|NCT03162341|Procedure|DECT|The tophus volume will be assess using dual-energy computed tomography (DECT).
45788541|NCT00367029|Behavioral|Individualized Print-Based Motivational Program|"Study researchers will develop individualized reports, manuals, and tip sheets that include feedback and strategies for increasing physical activity for each participant. Materials will be mailed to participants 14 times throughout the year.~Participants in the enhanced intervention will receive additional materials that focus on increasing social support, self regulation, and outcome expectations, as well as materials on how to effectively monitor physical activity levels. They will also attend one study visit to assess their goals with the research staff."
45788542|NCT05152199|Procedure|Cystoscopy - with use of obturator sheath|The intervention arm will include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy.
45788543|NCT05152199|Procedure|Cystoscopy - without use of obturator sheath|The intervention arm will not include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy, but will consist of using the telescope under direct visualization.
45788544|NCT01366196|Drug|Pregabalin 150 mg|Patients will receive two 75 mg capsules of pregabalin 1 hour before surgery. They continue to take 2 capsules of 75 mg (total 150 mg) until POD 14.
45788545|NCT01366196|Drug|Placebo|Patients will first receive two capsules of the placebo drug (with no active ingredients per dose) one hour before surgery. Patients will continue taking two capsules per day until POD 14.
45788546|NCT03403257|Other|No interventions|No intervention
45788547|NCT03155321|Other|It's an observational study - no intervention is planned|No intervention is planned
45788548|NCT05184933|Other|At-home Polysomnography|Participants will complete one night of unattended polysomnography in their home environment (SOMNOtouch RESP, SOMNOmedics America Inc., FL, USA).
45788549|NCT05184933|Other|Circadian Protocol|Participants will spend 4 days/3 nights in the laboratory to uncover circadian rhythms. After 2 nights for acclimatization and baseline measurements, participants will stay awake for 28 hours in dim light, constant temperature, and semi-recumbent posture. Participants will be provided with standardized snacks regularly. Polysomnography, core body temperature, sleep, finger oximetry, electrocardiogram (ECG), and beat-to-beat BP will (except microneurography) be measured throughout. Blood will be drawn every 2-4h to analyze catecholamines, renin activity, and aldosterone. All other measurements, including BP, heart rate (HR), and flow-mediated dilation will be performed regularly. Salivary samples will be collected every 2hrs (when awake) to analyze melatonin levels. A recovery sleep period will be provided and baseline testing procedures will be performed. Investigators may acquire direct recordings of sympathetic activity using microneurography.
45788550|NCT05184933|Other|Rested Wakefulness Trial|Participants will start wearing an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm. Participants will receive a standardized snack, and dinner ~4 hours before the start of the trial. Participants will be instrumented for microneurography. Participants will be awake in bed in dim light (<8 lux). An investigator will constantly be present in the control room to monitor and ensure constant supine posture and wakefulness. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Flow-mediated dilation will be conducted before bed and after bed. The two trials will be conducted ~one month apart to accommodate the menstrual cycle phase in pre-menopausal females.
45788551|NCT05184933|Other|Overnight Sleep Trial|Participants will wear an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm, and then participants will receive a standardized snack, and dinner 4 hours before the start of the trial. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Participants will be instrumented for microneurography. Participants will begin an 8-hour sleep opportunity (<0.1 lux) at their chosen sleep time. At the end of the sleep episode, participants will be gently awoken in a standardized fashion by use of a mild auditory stimulus. Flow-mediated dilation will be conducted before bed and after sleep. The two trials will be conducted one month apart to accommodate the menstrual cycle.
45788552|NCT05184933|Behavioral|Regularized Sleep Schedule|All participants will be asked to maintain a self-selected bedtime (sleep duration not controlled) for two weeks as an intervention after the completion of the constant routine and both the resting wakefulness and overnight sleep trials. During this time, participants will be asked to call a time-stamped voicemail box upon waking and going to bed, as well as complete a daily sleep diary and wear an Actigraph device on their wrist. Ambulatory blood pressure will be measured at home before and at the end of the two-week intervention.
45788553|NCT01366976|Drug|Acetaminophen|Acetaminophen 1g every 6 hours for 4 doses over 24 hours
45788554|NCT01777217|Drug|Solifenacin succinate|IGRT with VESIcare
45788555|NCT01777217|Drug|Placebo|IGRT with placebo
45449397|NCT02160106|Drug|TEW-7197|Single daily doses by oral administration on Days 1, 2, 3, 4, 5, Days 8, 9, 10, 11, 12, Days 15, 16, 17, 18, 19 and Days 22, 23, 24, 25, 26 of each 28 day cycle. Starting dose is 30 mg, with escalation to 60 mg, and subsequent dose escalation using a modified Fibonacci algorithm.
45788556|NCT03021707|Device|WaveLight® Ultraviolet Femtosecond (FS) Laser System|Utilizes ultraviolet (UV) light with a wavelength of 347 nanometers (nm) for refractive error correction
45788557|NCT03021707|Procedure|Laser Assisted Lenticular Extraction|Used for refractive error correction
45788558|NCT02251379|Drug|Flovent Diskus|Inhaled corticosteroids
45449398|NCT02160184|Device|Artificial pancreas system consisting of a predictive rule-based algorithm integrated on the Medtronic Portable Glucose Control System (PGCS)|
45449399|NCT03964961|Other|Functional massage|It's a massage combined with a stretching of the muscles.
45788559|NCT02251379|Other|Home Environmental Intervention|Mouse, Cockroach, Furry pets, Dust mites, Smoking, air purifiers, laundered bedding
45788560|NCT02251379|Drug|Advair Diskus|inhaled corticosteroids + long-acting beta agonist
45788561|NCT02948231|Device|Mistral implantation|Mistral Implant is implanted in the Mitral valve
45449400|NCT03964961|Other|Conventional massage|It's a regular massage made with the therapist's hands.
45788562|NCT02255513|Drug|HLD200|
45788563|NCT02255513|Drug|Placebo|
45788564|NCT01778465|Behavioral|Low salicylate diet|Participants followed a 7 days period under a Low salicylate diet
45449401|NCT03555435|Other|Moving Forward On Your Own|Participants in this group will use the online program on their own for 6 weeks.
45788565|NCT01778465|Behavioral|Normal Diet|Participants followed a 7 days period under a Normal Diet
46071295|NCT00824785|Drug|EOX + panitumumab|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 100mg/m(2) IV on day 1 with hydration capecitabine 1000mg/m(2)/day PO in two divided doses continuously from days 1-21 panitumumab -9 mg/kg every 21 days
45449402|NCT03555435|Behavioral|Moving Forward with Peer Support|Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
45449403|NCT03555435|Behavioral|Wait|Participants in this group will wait 6 weeks.
45449404|NCT02254876|Other|Standard physical therapy program|Standard physical therapy program in this study involves joint health and passive mobility at the level of the shoulder girdle and upper limb affected by Painful Shoulder Syndrome associated with the modulation of hypertonic muscle groups.
45788566|NCT01779167|Drug|Thalidomide|Thalidomide 50 mg (every ODD day of a 28 day cycle: Days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 & 27)
45788567|NCT01779167|Drug|Lenalidomide|Lenalidomide (every EVEN day of a 28 day cycle: Days 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 & 28). Lenalidomide will be initiated at a starting dose of 5 mg.
45788568|NCT01779167|Drug|Rituximab|Rituximab 375 mg/m2 IV on Days 1, 8, 15 and 22 (+/- 2 days) and then again on the same weekly x 4 schedule every 6th cycle thereafter (Cycle 7, 13, 19, etc).
45449405|NCT02254876|Other|NeuroMuscular Taping (NMT)|"The NeuroMuscular Taping (NMT) consists of the application on the skin of an adhesive tape with a particular structure to elastic waves and with characteristics comparable to those cutaneous. Because of these characterises it allows activation of endogenous analgesic, structural and muscular support, vascular and lymphatic activation.~In this study the NMT is applied with decompressive mode on Pectoralis Major, Deltoids, Supraspinatus."
45788569|NCT01780337|Drug|Oxytocin|Intranasal dose of 20 IU oxytocin
45788570|NCT01780337|Other|Saline|Intranasal dose of saline
45788571|NCT02251613|Drug|Olopatadine HCl ophthalmic solution, 0.1%|
45788572|NCT02251613|Drug|Epinastine HCl ophthalmic solution, 0.05%|
45788573|NCT04769219|Other|Secondary prevention training|Secondary prevention training will be given after acute myocardial infarction
45788574|NCT02865473|Drug|Pilocarpine|topical instillation into the study eye
45788575|NCT02850419|Drug|ThermoDox (Thermally Sensitive Liposomal Doxorubicin)|A dose of 40 mg/m2 will be administered at each cycle for a total of 6 cycles. ThermoDox will be administered in conjunction with hyperthermia.
45449406|NCT03214640|Device|Rivanna Accuro US Device|When the subject is ready for neuraxial procedure, the location for the epidural or spinal needle insertion will be identified with Rivanna Accuro U/S device. For subjects in group C-R or L-R, the needle insertion site will be the site identified by the Rivanna Accuro U/S device. After placement of spinal for Cesarean or epidural for labor, the usual standard dose of medication will be administered as in usual manner for patients regardless in this study or not.
45449407|NCT03214640|Other|Palpation|When the subject is ready for neuraxial procedure, the location for the epidural or spinal needle insertion will be identified with Palpation method using conventional landmarks (spinous process and iliac crest). For subjects in group C-P or L-P, the needle insertion site will be the site identified by the Palpation method. After placement of spinal for Cesarean or epidural for labor, the usual standard dose of medication will be administered as in usual manner for patients regardless in this study or not.
45449408|NCT03214640|Procedure|Neuraxial Analgesia|Labor analgesia will be provided utilizing the standard medications to provide labor analgesia
45449409|NCT03214640|Procedure|Spinal Block|Spinal anesthetic medications will be utilized in providing surgical block for cesarean delivery as is standard of care
45645763|NCT02330107|Other|MAT & LAT|"For MAT, the magnetic pellets will have ~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm, to be put on the 6 selected acupoints of the ear.~For LAT, a laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear."
45645764|NCT03713983|Other|Observational study|Observational study
45788576|NCT02850419|Radiation|Radiation Therapy|A total of 40 Gy in 20 fractions of 2 Gy per fraction will be administered. Up to 66 Gy of radiation therapy can be administered however institutional guidelines should be followed.
45788577|NCT02850419|Device|Superficial Hyperthermia|Thermal dose is an one-hour treatment at a temperature between 40 and 43 degrees Celsius at the target site.
45788578|NCT02841371|Radiation|99mTc-DTPA|a 99mTc-DTPA renal dynamic imaging measurement as the reference glomerular filtration rate (rGFR).
45788579|NCT04769063|Other|Kinesio Tape|Gluteus medius facilitation and knee spiral taping techniques will be applied to treat dynamic knee valgus
45788580|NCT01782833|Other|This is Non-interventional study|
45788581|NCT01783847|Drug|Recombinant human erythropoietin (EPO)|4000 units per vial
45788582|NCT01783847|Other|Observation|Just observation
45788583|NCT01783847|Drug|Methyl prednisolone|250 mg every 6 hours for 3 days.
45788584|NCT02663531|Device|DVA|
45645765|NCT02330185|Device|ultrasonography|spinal anesthesia guided with ultrasonography
45645766|NCT03143725|Drug|GLPG1972|Oral administration of GLPG1972 in four different treatment conditions (Treatments A throug D)
45645767|NCT04988971|Drug|a compound glutamine capsule|A compound glutamine capsule was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
45788585|NCT02663531|Device|FDOCT|
45788586|NCT02663531|Device|Pattern ERG|
45645768|NCT04988971|Drug|a compound glutamine capsule simulated placebo|a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
45645769|NCT03076619|Other|clinical ophthalmoscopy|To study the role of clinical ophthalmoscopy in PIH in diagnosis, prognosis, differential diagnosis, line of treatment and effect of treatment.
45788587|NCT02663531|Device|Optical Coherence Tomography|
45788588|NCT02585375|Drug|Preservative-free latanoprost 50µg/ml|
45788589|NCT02585375|Drug|Preserved latanoprost 0.005%|
45788590|NCT02516813|Drug|MSC2490484A (M3814)|Phase Ia: Subjects will receive a starting dose of 100 milligram (mg) or 50 mg of MSC2490484A as Capsule or tablet orally once daily 1.5 hours prior each RT.
45788591|NCT02516813|Radiation|Fractionated RT|Phase Ia: Subjects will receive fractionated palliative RT (3 Gray [Gy] * 10 in Arm A and 2 Gy * 33 to 35, 5 fractions per week [F/W]) in Arm B.
45788592|NCT02516813|Drug|Cisplatin|Cisplatin will be given twice at a dose of 100 milligram per square meter (mg/m^2) or weekly at a dose of 40 (mg/m^2).
45788593|NCT02516813|Drug|MSC2490484A (M3814)|Phase Ib: Subjects will receive the assigned dose of MSC2490484A once daily orally.
45788594|NCT02516813|Drug|MSC2490484A (M3814)|Ancillary cPoP Study: Subjects will receive a single oral MSC2490484A capsule on Day 2, 1.5 hours before the start of RT.
45788595|NCT02516813|Radiation|Fractionated RT|Phase Ib: Subjects will receive fractionated RT (2 Gy x 33, 5 F/W).
45788596|NCT02516813|Radiation|Fractionated RT|Ancillary cPoP study: Subjects will receive a single high dose of RT (10-25 Gy) capsule on Day 1 given on Lesion 1 and a single high dose of RT (10-25 Gy) on Day 2 given on Lesion 2.
45788597|NCT05009147|Other|Home-based massage by caregivers for dementia|A total of 40 patients with dementia and their family caregivers will be included and randomly allocated to experiment (n=20) or control group (n=20). The experiment and control group will receive whole body manual massage and placebo intervention (30 minutes once per week for 8 continuous weeks), respectively.
45449410|NCT04800094|Device|Investigational Liver Fat Quantification Software|All subjects enrolled in this study will undergo two abdominal ultrasound examinations using the investigational Liver Fat Quantification feature on the Philips EPIQ Ultrasound System. In addition, all subjects will also undergo one MRI-PDFF examination according to the clinical standard of care.
45449411|NCT03214406|Drug|Arm & Hammer Advance White Brilliant Sparkle (Test product)|20% sodium bicarbonate
45449412|NCT03214406|Drug|Crest Cavity Protection Regular Toothpaste (Negative Control)|Negative control
45645770|NCT02329873|Behavioral|Respiratory rehabilitation exercise training|The respiratory rehabilitation exercise training package was conducted twice a day and 10-30 minutes per session for 4 days: (a) disease awareness, (b) sputum clearance treatments, (c) pursed lip breathing training, (d) upper-limb exercise with breathing pranayama, (e) walking training with breathing pranayama, and (f) assign a pulmonary rehabilitation program coordinator.
45645771|NCT03143881|Behavioral|Education|Standardized information on the etiology of HF, mechanisms and side effects of medications prescribed, strategies for minimizing exacerbations, and warning signs of worsening clinical status will be discussed with the patient.
45645772|NCT03076541|Device|standard 24-h ambulatory polysomnography|A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
45788598|NCT01785095|Drug|FSH (Follicle Stimulating Hormone)|
45788599|NCT02990429|Procedure|Forced Air warmer|"record room temperature~record core temperature (tympanic membrane)~General anesthesia~using forced air warmer (bair hugger)~Intravenous fluid at room temperature~room temperature and core temperature q15 minutes~anesthesia finish, stop bair hugger~record core temperature before recovery room"
45788600|NCT02990429|Procedure|Intravenous Fluid Warmer|"record room temperature~record core temperature (tympanic membrane)~General anesthesia~using ranger warmer~Intravenous fluid at room temperature~room temperature and core temperature q15 minutes~anesthesia finish, stop ranger warmer~record core temperature before recovery room"
45788601|NCT01786187|Behavioral|Light Physical Activity|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light physical activity program to help manage a specific symptom related to cancer and cancer treatment.
45449413|NCT02150512|Device|Transpulmonary Thermodilution|Initial trigger for fluid loading when circulatory insufficiency is present will be SVV. If SVV ≤10% in patients on controlled mechanical ventilation with tidal volumes of ≥8 ml/kg, fluid loading will not be performed. If SVV >10% or spontaneous breathing efforts are present, a fluid challenge should be performed. Also if patients are on controlled mechanical ventilation with tidal volumes of ≤7 ml/kg, a fluid challenge should be performed. If fluid responsiveness is present and SVV decreases to ≤10%, further fluid loading should be stopped. If SVV is still >10%, the increase in EVLW will decide whether to continue fluid loading or not; if EVLW is ≥12 mL/kg PBW and EVLW increases upon fluid loading, further fluid loading should be stopped.
45788602|NCT01786187|Other|Symptom Experience Report|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive planned, structured, weekly telephone visits to report the experience of symptoms and health-related quality of life information.
45449414|NCT02150512|Device|Surviving Sepsis Guidelines (SSG)|Initial trigger for fluid loading when circulatory insufficiency is present will be the CVP (target ≥12 mmHg). If circulatory insufficiency is absent, fluid loading will not be initiated or stopped independently of the actual CVP level.
45449415|NCT03727659|Behavioral|SHADE therapy + CONNECT FaceBook support|"See study arms description."
45449416|NCT03731481|Behavioral|Lifestyle Medicine|Lifestyle Medicine programs provide instruction in plant-based nutrition, food preparation, methods of stress reduction and incorporation of physical activity into daily routine.
45645773|NCT04931875|Device|Total body PET/CT (uExplorer)|A total-body PET/CT scanner (uEXPLORER) with a 194-cm scan range will be applied in patients affected with lymphoma.
45788603|NCT01367444|Drug|SAR422459|"Pharmaceutical form: sterile solution, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection"
45788604|NCT01786343|Drug|Decitabine|20 mg/m2 by vein daily for either 5 or 10 days.
45788605|NCT02327429|Behavioral|A Chinese menu plan for type 2 diabetes|The intervention is a menu plan, recipes and tips on healthy eating delivered one-on-one between the participant and the facilitator. There will be 4 such one-on-one meetings. The goal is to facilitate behaviour change that results in a healthier diet.
45788606|NCT03362775|Drug|Propofol|Target-controlled infusion of propofol with an effect-site concentration of 0.0 µL/mL; 0.5 µL/mL and 1.0 µL/mL.
45788607|NCT01786967|Drug|Fesoterodine Fumarate|FDA approved anticholinergic medication used for treatment of urge urinary incontinence
45788608|NCT02392871|Radiation|Palliative radiotherapy|
45788609|NCT02392871|Drug|Dabrafenib and trametinib (combination)|Patients should be taking dabrafenib and trametinib for at least 2 weeks prior to enrolment into the study.
45788610|NCT02382575|Drug|Rituximab|Two to four rituximab infusions (over 2-4 weeks) will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2)depending on circulating B cells level.
45788611|NCT02382575|Drug|Tacrolimus|Standard dose with oral Tacrolimus 0.2 mg/kg/day in two divided doses till 6 month of relapse free survival.
45788612|NCT01807637|Device|transcranial direct current stim (tDCS)|During anodal tDCS, participants will receive 20 min at 2mA over motor cortex (with 30 seconds of ramp-up and ramp-down). During sham stimulation the stimulator is turned off.
46071296|NCT02550457|Other|Functional elastic tape tensioned|Application of Kinesio Taping with tension in the erector spine muscles.
46071297|NCT02550457|Other|Functional elastic tape non-tensioned|Application of Kinesio Taping without tension in the erector spine muscles.
45788613|NCT02034617|Behavioral|LiMoNid|One LiMoNid observation will be performed on day 1-3 post birth, one in time of discharge, and one in the home when the infant has reached 40 weeks (+/- 2 week). All observations are performed in presence of and in collaboration with the parents with the outspoken aim to guide the parents to learn how to read and respond to their infant' signals
45788614|NCT01263314|Drug|MK-8266|Oral capsules, 0.1 mg potency
45788615|NCT01263314|Drug|Placebo|Oral placebo capsules to match MK-8266 capsules
45788616|NCT01612949|Other|photographing head and neck|Taking three photographs of head and neck-one photograph from front, one from left and one fron right. The photographs are analyzed by facial structure software to create face model.
45788617|NCT02261597|Behavioral|Cold Pressor Test|Repeated immersion of hand in ice-cold water
45919764|NCT05223049|Other|painDETECT questionnaire|The painDETECT questionnaire was specifically developed to detect neuropathic pain components in adult patients with low back pain. It is also used in detecting the neuropathic pain in rheumatic diseases. A score between ≤12 represents a nonneuropathic pain, ≥13 and ≤18 represents a possible neuropathic pain, while a score of ≥19 represents a neuropathic pain.
45788618|NCT01327508|Device|TRIGEN SURESHOT Distal Targeting Instrumentation.|image-guided localization system
45919765|NCT05223049|Other|Douleur Neuropathique 4 questionnaire (DN4)|DN4 is a clinician-administered questionnaire consisting of 10 items. Seven items related to pain quality (i.e. sensory and pain descriptors) are based on an interview with the patient and 3 items based on the clinical examination. A score of ≥4 represents a neuropathic pain.
45645774|NCT03076463|Dietary Supplement|GRAPOM|The whole intervention will be divided in 2 periods, control (CTR) and dried and milled grape pomace (GRAPOM). The two periods will have a duration of 6 weeks. During the CTR period, subjects will follow their normal dietary habits and samples will be collected at the beginning and at the end. No proper placebo could be found for the product, so this CTR period was chosen. During the GRAPOM period, the subjects will daily consume 8 g of the product solved in water and samples will be collected at the beginning and at the end.
45788619|NCT01327508|Other|Free-hand technique|Free-hand technique utilizes x-rays to find screw holes.
45788620|NCT01807871|Drug|nicotine patch, experimental use|nicotine patch-transdermal, continue during lapses Nicotine patches are used according to normal package label, except if the participant lapses and smokes, they will continue to use the patch.
45788621|NCT01807871|Drug|nicotine patch, labeled use|nicotine patch-transdermal, discontinue during lapses Participants will use the nicotine patch while abstinent, but will remove the patch if there is a lapse and smoking resumes. This is the use indicated on current FDA approved labeling.
45788622|NCT01091831|Drug|Cyclophosphamide|Cyclophosphamide will be given orally at the dose of 300 mg/m2 on days 1, 8, 15 for 6 cycles every 28 days
45788623|NCT01091831|Drug|Lenalidomide|Lenalidomide will be given orally at the dose of 25 mg/d for 21 days followed by a 7 days rest period (day 22 to 28)for 6 cycles every 28 days
45788624|NCT01091831|Drug|Dexamethasone|Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 for 6 cycles every 28 days
45645775|NCT02329795|Radiation|Radiotherapy|60 Gy in 30 fractions, 5 days a week, modulated arc therapy.
45645776|NCT02329795|Drug|Temozolomide|Concomitant: 75 mg/m2 5 days a week from start of radiotherapy. Adjuvant: 150/200 mg/m2 in 5 days per 28 days in 6 months.
45788625|NCT01091831|Drug|Melphalan|Melphalan will be given iv at the dose of 200 mg/m2 for 1 day followed by stem cell support. The second MEL200 was performed 120 days after the first if ≤ PR was achieved after the 1st MEL200.
45788626|NCT01327976|Device|vBloc (Active Device)|Active device will deliver vBloc Therapy
45645777|NCT05002907|Other|Questionnaire|After signing the informed consent sheet, a standardized face-to-face questionnaire will be conducted by the doctor, nurse or coordinator to collect socio-demographic data, lifestyle data, sex life and other potential risk factors and knowledge about viral hepatitis.
45788627|NCT01327976|Device|Sham (Non-active Device)|Functional non-active control device will deliver no vBloc Therapy
45645778|NCT05002907|Other|Biocollection|After answering the questionnaire, the nurse or the doctor will take a sample of capillary blood from the fingertip on the side of the distal phalanx of a middle or ring finger. The puncture site will be prepared by warming and massage to optimize blood flow and disinfected with a disposable 70% alcohol wipe. After drying, the puncture will be performed using a single use safety lancet. A total of 7 capillary blood spotswill be collected and deposited on the filter paper (each spot is about 50µL of capillary blood), 5 for the study and 2 for the biological collection.
45788628|NCT00507299|Behavioral|Enhanced pediatric primary care|Residents received special training to address targeted psychosocial problems. Parents bringing in children (0 - 5 years) completed a screening questionnaire and gave this to their doctor. The resident briefly assessed the identified problems and helped address them. A social worker was present to assist.
45788629|NCT00507299|Behavioral|Standard pediatric primary care|Residents did not receive special training on the targeted psychosocial problems. They did not use the parent screening questionnaire, and they did not have a dedicated social worker.
45788630|NCT01263938|Drug|Atorvastatin|"For subjects on PI-based HAART therapy: 10mg/day X 2weeks followed by 20mg/day.~For subjects on non PI-based HAART therapy: 20mg/day X 2weeks followed by 40mg/day."
45788631|NCT01789775|Drug|Drug: CD07805/47 gel|
45788632|NCT01789775|Drug|CD07805/47 gel Placebo|
45788633|NCT02327741|Drug|plavix|taking plavix more than 12 months
45788634|NCT02327741|Drug|plavix|taking plavix less than 12 months
45788635|NCT00498875|Behavioral|Questionnaire|Questionnaire regarding mood, coping with cancer, how closely you follow your treatment schedule, your thoughts, your demographic information (such as age and race), and your medical history. If the answers to your questionnaire indicate that you may be depressed, you will be offered the intervention portion of the study.
45788636|NCT00498875|Behavioral|Depression Intervention|"Sessions given over 7 weeks and each lasting 30-45 minutes, that use cognitive-behavioral techniques."
46071298|NCT02550457|Other|Rigid Tape|Application of Micropore tape in the erector spine muscles.
46071299|NCT00902330|Procedure|energy-based therapy|Given once a day for 18 weeks
46071300|NCT00902330|Procedure|sham intervention|Given once a day for 18 weeks
45645779|NCT05002907|Other|Delivery of results|After receiving the individual biological analysis results, in coded form (results only identified by the anonymity number), at the investigation center and lifting the anonymity by the coordinator of the study in each study center (in Cayenne or Paramaribo depending the country where the inclusion took place) with the help of the correspondance list, the participants' results will be delivered to the referral doctor of each health centre and the infectious disease specialist responsible for each area of inclusion. All positive participants will be contacted if they do not spontaneously come to retrieve their results (within approximately 1 month after result's availability), and invited to come to the health centre to retrieve their results individually and be oriented towards the heathcare circuit.
45788637|NCT01264952|Procedure|Electrochemotherapy|"Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin (15 mg/m2), within 5-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.~The maximum duration of procedure is 90 minutes."
45788638|NCT01810289|Behavioral|START|"INTERVENTION: START is clinic-level (not individual-patient) intervention to catalyze the process of ART initiation among HIV-infected adults who meet CD4-based criteria for combination ART (e.g., adults with a CD4 T cell level < 350/ul). The three START components are: (1) real-time point-of-care CD4 testing using the Alere PIMA platform to ascertain treatment eligibility in real time at first presentation to care, (2)targeted knowledge transfer(i.e., dissemination) of recent scientific evidence regarding effects rapid ART initiation on survival to front line health care workers; and 3)feedback and reporting to clinic and providers. There three components represent empirically validated steps in the PRECEED implementation model.~This intervention will be implemented at all Makerere Joint AIDS Program (MJAP) clinics in Kampala and Mbarara districts in a step-wedge design."
45788639|NCT01733069|Device|APTIMA COMBO 2 Assay (AC2 Assay)|APTIMA COMBO 2 Assay (AC2 Assay
45788640|NCT02634177|Genetic|Assay-guided treatment (AGT)|The assay provides information to guide pharmacotherapeutic decisions personalized to a patient's genetic profile, to maximize improvement in symptomatology and minimize treatment failure and treatment intolerability.
45788641|NCT02634177|Other|Treatment-as-usual (TAU)|Subjects are treated-as-usual without the aid of the assay.
45788642|NCT05168319|Device|Repetitive transcranial magnetic stimulation|Participants received 10HZ rTMS protocol consisted of 5 sessions over 5 consecutive workdays
45788643|NCT05168319|Device|Repetitive transcranial magnetic stimulation|Participants received pcTBS protocol consisted of 5 sessions over 5 consecutive workdays
45788644|NCT05168319|Device|Sham stimulation|Participants received Sham rTMS stimulations consisted of 5 sessions over 5 consecutive workdays
45788645|NCT00367185|Drug|Thalidomide|
45788646|NCT02635035|Drug|Lisdexamfetamine|Vyvanse (Lisdexamfetamine Dimesylate) manufactured by Shire, is a Drug Enforcement Administration (DEA) class two,sympathomimetic amine, used for the treatment of attention-deficit hyperactivity disorder. The initial adult dosage is 30mg with allowed adjustments in increments of 10mg or 20mg at weekly intervals. Subjects are initiated on these doses and then they were titrated up by 20mg with a maximum dose of 70mg.
45788647|NCT02635035|Drug|Placebo|Placebo looks just like Vyvanse but has no active ingredients, like a sugar pill.
45645780|NCT05002907|Other|Results and advices on transmission prevention methods|The results will be revealed by the health centre's doctor/infectiologist, individually and confidentially, with an explanation of the results and advices on transmission prevention methods.Non-immunized patients against HBV will be offered a status determination (Anti-HBs Ab quantification on whole blood sample) and if necessary a catch-up vaccination according to the national immunization schedule.
45788648|NCT01369706|Device|Hand-held metal detector|2 different hand-held metal detectors: (1) PD 140 (CEIA S.p.A., Arezzo, Italy) and (2) MH 5 (Vallon GmbH, Eningen, Germany)
45788649|NCT02635425|Procedure|7 eggs collection|vaginal US
45788650|NCT02635425|Procedure|Full eggs collection|vaginal US
45788651|NCT04740489|Behavioral|Phase 3 Cardiac rehabilitation|Phase 3 CR is a comprehensive outpatient programme, considered the core rehabilitation phase, in which participants receive structured exercise, health education, risk factor modification and psychological support. Upon discharge from clinically supervised phase 3 CR participants are generally signposted to long-term community-based exercise classes (phase 4). The current study will take place within a core phase 3 CR programme in the UK.
45788652|NCT02636049|Drug|Triferic|Triferic is supplied as sterile 5 mL ampules containing 5.44 mg/mL of iron in water for injection. Each 5 mL ampule contains 27.2 mg of Triferic iron.
45788653|NCT01370174|Other|Physical Training Interventions|Subjects will be assigned to one of four training groups. Training will occur three times weekly for twelve consecutive weeks. The IST group will receive waist-pulls by a motorized machine to produce stepping. Subjects in the HST group will perform muscle resistance exercises. Subjects in the combined IST and HST will receive both IST and HST interventions. Participants in the SFR group will perform flexibility and relaxation exercises.
45788654|NCT03283137|Drug|TGR-1202|TGR-1202 will be given at a dose of 600mg (dose level 1) or 800mg (dose level 2). If the dose of 600mg is tolerated in the first cohort, then the dose will be increased to 800mg which is the only and final dose escalation. If the dose of 600mg is not tolerated, then the dose will be decreased to 400mg daily.
45788655|NCT03283137|Drug|Pembrolizumab|Pembrolizumab will be given at 200 mg every 3 weeks. The dose will not be adjusted throughout the course of the study.
45788656|NCT01267136|Drug|Codeine with acetaminophen|Liquid codeine/acetaminophen (Capital® 5mL= 120mg acetaminophen/12 mg codeine) 0.72 mg/kg [=0.3 mL/kg] (max. 36 mg) PO Q6h, plus 0.72 mg/kg (max. 36 mg) PO Q3h pro re nata (PRN) (max. of 3 PRN doses/day)
45645781|NCT05002907|Other|Confirmation of results on a blood test (In the event of a positive result)|In case of a positive result, the doctor will explain the need to confirm these results on a blood test, prescribe the initial assessment and take an appointment with the infectious disease specialist. He will guide the patient towards accompaniment for the opening of medical coverage rights if necessary and support by an association if desired.
45788657|NCT01267136|Drug|Tramadol suspension|Liquid tramadol 1.05 mg/kg [=0.3 mL/kg] (max. 52.5 mg) PO Q6h, plus 1.05 mg/kg (max. 52.5 mg) PO Q3h PRN (max. of 3 PRN doses/day).
45788658|NCT05139771|Device|THE ENDOART® IMPLANTATION (Artificial Endothelial layer)|Implantation of EndoArt® is similar to other anterior segment surgical procedures such as DSAEK/DMEK.
45788659|NCT05134311|Device|PIUR tUS Imaging System|PIUR imaging has developed PIUR Infinity tUS, a 3D freehand tomographic ultrasound system capable of rapid, safe and accurate reconstructive 3D quantifiable vascular imaging.
45788660|NCT01370564|Drug|Diuretics|Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
45788661|NCT00367263|Drug|Alvesco (Ciclesonide) 160 ug/day|
45788662|NCT02637999|Drug|PEG IFN alfa-2a|
45788663|NCT02637999|Drug|Myrcludex B|
45788664|NCT01790243|Device|Lutonix Drug Coated Balloon|Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.
45788665|NCT01790243|Device|Standard PTA Balloon|Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.
45788666|NCT03235479|Drug|Rimegepant|75 mg tablet QD
45788667|NCT03235479|Drug|Placebo|Placebo tablet to match rimegepant dose QD
45788668|NCT01371110|Drug|Ketamine|Ketamine hydrochloride is a nonbarbiturate anesthetic. It is formulated as a slight acid (pH 3.5 to 5.5) sterile solution for intravenous or intramuscular injection in concentrations containing the equivalent of either 50 or 100mg ketamine base per milliliter.
45788669|NCT01371110|Drug|Midazolam|Midazolam is a short-acting benzodiazepine central nervous (CNS) depressant.
45788670|NCT01791491|Drug|Belatacept|Single intravenous infusion of belatacept, 7.5 mg/kg
45788671|NCT00367419|Drug|Erythromycin|
45788672|NCT01810991|Device|Nd:YAG Laser|Nd:YAG 1440nm Laser
45788673|NCT05100381|Other|dry needling|The patients will be placed in a prone position with a pillow under their belly to accommodate lumbar lordosis. Two lengths of sterile, disposable, 0.30 mm x 75 mm and 0.30 mm x 50 mm solid filament needle (Tony, China) will be used in this study. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted into the lumbar multifidus muscle, 1.5 - 2 cm lateral to the spinous process of two or three painful segments, perpendicular to lamina (after piercing the skin, needles are directed inferomedially). The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes.
45788674|NCT05100381|Other|sham (placebo) dry needling|The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes.
45788675|NCT01372202|Drug|Paclitaxel|Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.
45788676|NCT01372202|Drug|Cisplatin|"Paclitaxel and cisplatin:~Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.~Cisplatin 30 mg/m² days 1, 8, 15, 22, 29.~Cisplatin and 5-fluorouracil:~5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1- 4 and 29 - 32.~Cisplatin 75 mg/m² days 1, 29."
45788677|NCT01372202|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 days 1, 15, 29.
45788678|NCT01372202|Drug|5-Fluorouracil|"Oxaliplatin and 5-fluorouracil:~Oxaliplatin 85 mg/m2 days 1, 15, 29.~5-Fluorouracil 180 mg/m2 prolonged infusion starting day 1 of radiation and completing on the final day of radiation (up to 40 days)~Cisplatin and 5-fluorouracil:~5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1-4 and 29-32.~Cisplatin 75 mg/m² days 1, 29."
45919766|NCT05223049|Other|Short form-36|The 36-Item Short Form Survey (SF-36) is a self-reported measure of health. It comprises 36 questions which cover eight domains of health. 1) Limitations in physical activities because of health problems. 2) Limitations in social activities because of physical or emotional problems 3) Limitations in usual role activities because of physical health problems 4) Bodily pain 5) General mental health (psychological distress and well-being) 6) Limitations in usual role activities because of emotional problems 7) Vitality (energy and fatigue) 8) General health perceptions. Each domain is scored between 0 and 100 and a higher score represents a better outcome.
45788679|NCT01372202|Radiation|Radiotherapy|Patients will be treated 5 days/week at 1.8 Gy/day to a total dose of 45Gy.
45788680|NCT01372202|Procedure|Esophagectomy|The type of resection (Ivor-Lewis, Transhiatal, etc.) will be left to the discretion of the operating surgeon. Resection will be completed between 5 and 8 weeks starting from the completion of chemotherapy and radiation (days 36 - 56).
45788681|NCT05098899|Genetic|MyGeneMyDiet® Recommendations for Weight Management|This group will receive Nutrition and Lifestyle recommendation based on SNPs known to have an impact to body weight and body composition, and responses to physical activity and dietary fat intake
45788682|NCT05098899|Other|Usual Standard of Care for Weight Management|This group will receive the conventional and standard nutrition lifestyle recommendation for weight management
45788683|NCT01792817|Device|GammaCore|Treatment with active gammacore vagus nerve stimulator
45788684|NCT01792817|Device|Sham GammaCore device|Treatment with sham stimulator
45788685|NCT03193437|Drug|Open Label Selinexor|Selinexor 40 mg oral tablets will be administered twice weekly, either on Monday/Wednesday, Tuesday/Thursday, Wednesday/Friday, Thursday/Saturday, or Friday/Sunday in a 3-weeks-on and 1-week-off schedule.
45788686|NCT03179631|Drug|Ataluren|10, 20 mg/kg
45788687|NCT03179631|Drug|PLACEBO|10, 20 mg/kg
45788688|NCT01811147|Drug|Selective Serotonin Reuptake Inhibitor (SSRI)|Subjects with depression will be treated with a Selective Serotonin Reuptake Inhibitor (SSRI) or a Serotonin-norepinephrine reuptake inhibitor (SNRI) for 24 months.
45788689|NCT01373450|Drug|Oxyntomodulin|3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)
45645782|NCT05002907|Other|Information for care|A document with all contact information for a comprehensive and specialized care (professionals and associations for access to medical coverage and support, associations proposing support, general practitioners and specialists) will be given to positive participants. Patient monitoring and treatment will be carried out according to the national guidelines in each country.
45788690|NCT01373450|Drug|Liraglutide 0.6 mg|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
45788691|NCT01373450|Drug|Liraglutide 1.2 mg|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
45788692|NCT01373450|Drug|Placebo for Oxyntomodulin|IV infusion in the morning of the day of GGI (Day 1)
45788693|NCT01373450|Drug|Placebo for Liraglutide|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
45788694|NCT04749719|Device|remotely supervised transcranial direct current stimulation|Low levels of electrical current are applied across the scalp to induce small changes in brain activity. This is done using remote supervision.
45788695|NCT05069415|Device|Eyhance IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target emmetropia OU.
45788696|NCT05069415|Device|Eyhance IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target mini monovision in the non-dominant eye.
45645783|NCT05002907|Other|Monitoring and treatment|Consequently, all positive participants will be able to be monitored and treated by a specialist of the disease. They will give post-test counselling and will conduct patient follow-up and treatment according to the usual standards of care of each country.
45788697|NCT01811303|Other|D-fagomine|Measure the changes produced on the postprandial Glycaemic response to 50 g of sucrose in 200 ml water if added 40 mg D-fagomine
45788698|NCT02906787|Behavioral|BAS+|The goal of the BAS+ is to maintain a level of overall reward after cessation by structuring and enhancing opportunities for reinforcement to: (1) ensure that not smoking is as reinforcing as smoking; and (2) prevent an over-reliance on food as a substitute reinforcer for smoking so that PCWG does not precipitate smoking relapse.
45788699|NCT02906787|Behavioral|SC|Overeating and weight gain are common concerns reported during smoking cessation treatment. Per convention, SC will address these concerns through standard recommendations to consume low-calorie snack foods, drink water, eat nutritious meals, and exercise, but will not include skills to shape the use of these suggestions.
45788700|NCT01330394|Device|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation (tDCS, 5 x 7 cm2, 1 mA, during 10 min) will be applied over the left dorsolateral prefrontal cortex once a week for 5 consecutive weeks.
45788701|NCT05068869|Other|Dignio Digital Remote Care intervention group|"The intervention consists of Dignio Prevent (for healthcare professionals) and MyDignio (for patients). The system is CE marked and the system satisfies all regulatory requirements for privacy and information security. Various components can be added for an individualized follow-up of the patients.~Elements of the digital outpatient service in Dignio include patient reported outcomes and other questionnaires, tasks, objective measures, reminders and information, in addition to a chat function for asynchronous contact with healthcare personnel and video consultations for real-time consultations."
45788702|NCT05068869|Other|Usual Care Control group|Participants in the control group will receive follow-up at the outpatient clinic as per their needs.
45788703|NCT04340271|Other|Extracorporeal shock wave therapy|ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave (Fig. 2). ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
45788704|NCT04340271|Other|conventional occupational therapy|Standard accupational therapy consist of range of motion exercise, strengthening exercises, and activities of daily living exercises
45788705|NCT01793285|Drug|ETANERCEPT|"During the LoadET study (0881A3-102090), subjects were treated with etanercept 100 mg versus 50 mg weekly. After completing this study, the subjects were allowed to continue the treatment with etanercept 50 mg weekly, etanercept 100 mg weekly, another drug, or abandoned medication at the discretion of their physician.~This is a non-interventional study in which historic data will be collected retrospectively from the patient's clinical history. During the historical period covered in the Study, patients would have received the treatment and the medical care that their treating physicians considered appropriate under the conditions of standard clinical practice."
45788706|NCT05049525|Drug|Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.|Itraconazole capsules of 100 mg, antifungal agent. Terbinafine tablets 250 mg (as terbinafine hydrochloride), antifungal agent.
45919767|NCT05223049|Other|Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC)|SPARCC was created as a measure for enthesitis in spondyloarthritis in general. It assesses 16 enthesial sites. Total number of the enthesitis is the total score of the evaluation. Total score is between 0 and 16, and higher scores represent a worse outcome.
45919768|NCT05223049|Other|Numeric Rating Scale|Self reported pain scored between 0 (minimum)-10 (maximum). Higher scores represent a worse outcome.
45788707|NCT05049525|Drug|Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally.|Matching placebo of itraconazole capsules of 100 mg, antifungal agent. Matching placebo of terbinafine tablets 250 mg, antifungal agent.
45788708|NCT01811693|Drug|Glycerly Trinitrate|5mg/24hour (0.2mg/hour) transdermal
45645784|NCT02329561|Drug|Tramadol extended release 200 mg|Tramadol extended release 200 mg: Administration of a single 200mg tramadol extended-release tablet
45449417|NCT03213938|Device|Acupuncture|"For acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Bilateral SP6, BL33, BL23, and BL35, were selected as acupoints protocol.~Acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks)."
45645785|NCT02329561|Behavioral|CP/T|Subjects were evaluated for perception and tolerance of electrical current. An experimentally induced pain model utilizing electrical stimulation from the FDA approved Neurometer, as the painful stimulus was used to assess Current Perception Threshold and Pain Tolerance Threshold (CP/T) in young and elderly subjects following administration of tramadol and of placebo.
45645786|NCT02329561|Drug|Placebo|Administration of a single placebo tablet identical in appearance to a 200mg tramadol extended-release tablet
45788709|NCT01811693|Drug|Glycerly Trinitrate|10mg/24hour (0.4mg/hour) transdermal
45788710|NCT01811693|Drug|Glycerly Trinitrate|0.4 mg sublingual single metered spray
45788711|NCT02639637|Drug|Sitagliptin|Subjects will receive sitagliptin 100 mg daily for 7 days prior to one of the study days.
45788712|NCT02639637|Drug|Placebo|Subjects will receive a placebo capsule daily for 7 days prior to one of the study days.
45788713|NCT02639637|Drug|Neuropeptide Y|During the study days, neuropeptide Y will be infused through an intra-arterial line. There will be four doses of neuropeptide Y used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
45788714|NCT02639637|Drug|Enalaprilat|Ninety minutes after the last dose of neuropeptide Y, enalaprilat will be infused through the intra-arterial line at 0.33 µg/min/100mL of forearm volume. After 30 minutes, a second infusion of neuropeptide Y will begin. Similar to the previous neuropeptide infusion, four doses of neuropeptide Y will be used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
45788715|NCT02639637|Drug|Valsartan 160mg|Valsartan 160 mg/d for 7 days prior to one of the study days.
45919769|NCT05223049|Other|Disease activity in psoriatic arthritis (DAPSA)|DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level. The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (< 4) and low disease activity (< 14).
46071301|NCT04016701|Device|Floreo Joint Attention Module|Two sessions per week for eight weeks of the Floreo VR Joint Attention Module, delivered via a Google Cardboard compatible VR headset. Each session includes one or two 5-minute VR episodes and an intermission that is at least 3 minutes long
46071302|NCT04016701|Behavioral|Regularly Scheduled Therapy|therapy as regularly scheduled at therapy center
45449418|NCT03213938|Device|Sham acupuncture|"For sham acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be used to insert vertically about 2-3 mm without manipulation into non-acupoints bilateral sham SP6, sham BL33, sham BL23, and sham BL35, which were located at different physical locations than SP6, BL23, BL 33, and BL35.~Sham acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks)."
45645787|NCT05000879|Behavioral|MMB for Moms|12-week program that emphasizes mindfulness and cognitive behavioral skills
45645788|NCT02329639|Genetic|genetic interaction analysis|VEGFR-2 rs11133360/IL-8 rs4073 genetic interaction analysis
45645789|NCT05003063|Drug|Donepzil|Test
45645790|NCT05003063|Drug|Placebo oral tablet|Test
45788716|NCT01793909|Other|Single Leg Exercise Training|Following the completion of baseline testing, all 3 subject groups will undergo supervised single leg, exercise training of the index (dominant) calf muscle 5 days per week for two weeks - alternating weight-bearing single leg calf raises and single leg calf extensions by endurance resistance training (weight machine apparatus).
45449419|NCT03604497|Behavioral|beacon alerts|alerts via unidirectional communication from beacons to smartphones when smartphones are approaching pedestrian crossing at activated intersection
45449420|NCT03604497|Behavioral|no alerts retention|no alerts will appear, but we will measure retention of behavior learned during the active intervention stage
45788717|NCT01332188|Drug|AC-170 0.05%|1 drop in each eye at 3 separate times during a 21 day period
45788718|NCT01332188|Drug|AC-170 0.1%|1 drop in each eye at 3 separate times during a 21 day period
45788719|NCT01332188|Drug|AC-170 0.24%|1 drop in each eye at 3 separate times during a 21 day period
45788720|NCT01332188|Drug|AC-170 0%|1 drop in each eye at 3 separate times during a 21 day period
45788721|NCT01794455|Drug|Sertraline|50mg - 200mg daily
45788722|NCT01794455|Drug|Candesartan|4mg - 32mg daily
45788723|NCT01795079|Device|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
45788724|NCT04769141|Combination Product|CURATE.AI|"CURATE.AI is one example of an artificial intelligence guided dosing decision tool. It is customized to each individual and can be applicable across many different conditions, as it is disease agnostic.~This platform has already demonstrated initial success in cancer and transplant populations but yet to be applied to chronic disease patients."
45788725|NCT04749329|Device|Mesh Group|"All MG patients underwent the procedure with ante rectus positioned prophylactic mesh according to the following standardized technique. A BIO-A circular-shaped mesh measuring 8X10 cm in diameter is prepared with an internal 2 cm hole to let the bowel pass.~An at least 8x8 cm space is created between the anterior rectus sheath and the rectus abdominis muscle and, then, the mesh is positioned. The bowel is passed through the rectus muscle via the circular incision in the middle of the mesh. Single absorbable monofilament sutures anchored the mesh laterally in the ante rectus pocket, while medially the mesh is fixed with four stitches to the colon and to both the anterior rectal sheet. The stoma is attached to the skin similarly to CG patients."
45788726|NCT01271036|Device|Formula PD-F-7716|Apply a dime-size amount on each application site as instructed during the 1-week study period
45788727|NCT04749485|Drug|HX008|Patients will receive HX008 3mg/kg by intravenous (IV) infusion on Day 1, every 3 weeks (Q3W), till progressed disease or withdrawal.
45788728|NCT01332500|Drug|Sumatriptan/Naproxen combination|Sumatriptan and Naproxen Sodium
45788729|NCT01332500|Drug|other oral triptans|almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan
45788730|NCT01812005|Drug|alisertib|Given PO
45788731|NCT01812005|Biological|rituximab|Given IV
45788732|NCT01812005|Other|laboratory biomarker analysis|Laboratory correlative studies will be performed
45788733|NCT01332578|Drug|Paracetamol|Present in both test and active comparator
45788734|NCT01332578|Drug|Phenylephrine|Test product
45449421|NCT03725631|Diagnostic Test|Imaging and serologic evaluation of fibrosis and steatosis|Imaging evaluation: Fibroscan, MRI scan for evaluation of fibrosis and steatosis in biopsy proven NAFLD patients Serologic evaluation: serologic test for evaluation of fibrosis and steatosis in biopsy proven NAFLD patients
45449422|NCT02159014|Behavioral|Facilitated group-based aerobic dance|Physical activity facilitated by instructor
45449423|NCT02159014|Behavioral|Online, video prompted, individual aerobic dance|Supported online activity intervention
45449424|NCT02159014|Behavioral|Facilitated group-based nutritional intervention|Education, skill training, access and use of NHS Change4Life Eat Well web resource
45449425|NCT02159014|Behavioral|Self-paced online aerobic dance activity|Self paced physical activity
45449426|NCT02159014|Behavioral|Individual self-paced nutritional intervention|Individual use of online nutritional advice resources.
45645791|NCT03143491|Drug|SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.
45645792|NCT05002673|Device|DENTAL LOCAL ANESTHESİA|doing local and topical anesthesia with two different device
45645793|NCT02329717|Drug|PBI 05204|PBI 05204 daily dosing
45645794|NCT05001035|Other|Time of assessment|Immediate and after one month and after two months
45645795|NCT03076151|Drug|Tacrolimus monohydrate (ADOPORT®)|Pharmacokinetic of Tracrolimus (ADOPORT®) on 9 blood sampling by kinetics on 4 kinetics
45645796|NCT05032651|Device|novel artificial intelligence assisted platform|Use of a novel artificial intelligence assisted platform
45788735|NCT01332578|Drug|Ascorbic Acid|Test product
45449427|NCT02160418|Behavioral|Financial Incentives|
45449428|NCT02160418|Behavioral|Cognitive Incentives|
45449429|NCT02160418|Behavioral|Financial and Cognitive Incentives|
45645797|NCT05000723|Other|Standard of care|"Standard of care consisting of~clearance of infection~treatment with antibiotics (antisuppressive, DAIR) or surgery (1 stage, 2 stage Girdlestone)~Radiology: X-ray pelvis and hip, X-ray pelvis with kingmark, CT scan pelvis/hip"
45645798|NCT05002517|Drug|Tociliziumab group|Tocilizumab is a humanized recombinant IgG1 monoclonal antibody to human interleukin-6 (IL-6) receptor, produced in Chinese hamster ovary cells by recombinant DNA technology.
45645799|NCT05002517|Drug|Methylprednisolone group|Methylprednisolone belongs to a group of medicines called corticosteroids (it works at the cellular level by reducing the production of substances that cause inflammation or allergy).
45645800|NCT03473275|Diagnostic Test|Cold Pressor test|Both feet in icy waterbath alternated with body temperature water
45449430|NCT03725553|Drug|Intramyometrial Vasopressin|a bolus injection of vasopressin (4 IU) diluted to 2 mL with saline into the myometrium of the placental bed during slow (30-seconds) immediately after delivery, as soon as the umbilical cord was clamped.
45645801|NCT03473275|Diagnostic Test|PinPrick test|Pricking both feet with a needle using gravity (without penetrating) alternated with cotton swap
45788736|NCT01795859|Drug|SD-809|SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white).
45788737|NCT01795859|Drug|Placebo|Placebo tablets are identical in appearance to SD-809 tablets.
45788738|NCT01333592|Drug|KAD-1229|
45788739|NCT01812473|Other|Blood sampling|During the treatment of voriconazole, at steady plasma concentrations of voriconazole, one plasma sample and one serum sample are taken.
45788740|NCT01375946|Drug|AG200-15|There will be three treatment periods. Subjects will be randomly assigned to one of the five conditions for the treatment period. The subject will be exposed daily to the condition assigned while wearing the patch. The study patch will be worn for a 7 day treatment period, followed by a 7 day washout period. The total duration of the study is 6 weeks.
45788741|NCT01371032|Device|VideoMiller|Video-Miller laryngoscope, using the screen (Video laryngoscopy group)
45788742|NCT01371032|Device|Direct Laryngoscopy|Video-Miller laryngoscope, without screen (Direct laryngoscopy group)
45788743|NCT01267292|Drug|Buspirone|[week 1: Buspirone 30 mg twice a day (9am and 6pm) on Monday through Sunday] [weeks 2-3: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday]
45788744|NCT01267292|Drug|Placebo for Buspirone|[week 1: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday] [weeks 2-3: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday]
45788745|NCT01267292|Drug|Methylphenidate|Methylphenidate serves as an acute stimulant challenge. [week 1: no Methylphenidate or Methylphenidate placebo] [week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)] [week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)]
45788746|NCT01267292|Drug|Placebo for Methylphenidate|[week 1: no Methylphenidate or Methylphenidate placebo] [week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)] [week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)]
45788747|NCT04749095|Drug|Erector spinae plane block|bilateral ESP block will be injected with 20 ml of 0.25% bupivacaine
45788748|NCT04749095|Drug|sham subcutaneous infiltration|bilateral ESP block will be injected with 20 ml of normal saline
45788749|NCT01797029|Biological|SIIL Live Attenuated Influenza Vaccine|A single dose of SIIL Trivalent LAIV--2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
45788750|NCT01797029|Biological|Placebo|A single dose of inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
45788751|NCT01377584|Behavioral|Couple-oriented intervention|The first session will occur before the patient receives his/her CPAP and will last approximately 2 hours. This session will provide the couple with education on sleep apnea and CPAP and information on different types of PAP therapy and cleaning procedures, explore patient's concerns about starting CPAP treatment, and provide a goal setting exercise. The second face to face session will occur one week after the patient receives his/her CPAP and will last approximately one and a half hours. The second session will provide the couple with information on CPAP usage and pre- and post-treatment AHI, explore barriers to CPAP use and benefits of CPAP use, and provide a goal setting exercise. The individual telephone follow-up sessions will occur two weeks after the patient has received his/her CPAP and will last approximately 20 minutes. This session will review CPAP usage and explore barriers and facilitators of CPAP use.
45645802|NCT05002205|Other|Questionnaires|Participants will be followed up by means of online surveys and 2 study visits.
45788752|NCT01377584|Behavioral|Patient-oriented intervention|The first session will occur before the patient receives his/her CPAP and will last approximately one and a half hours. This session will provide the patient with education on sleep apnea and CPAP and information on different types of PAP therapy and cleaning procedures, explore patient's concerns about starting CPAP treatment, and provide a goal setting exercise. The second face to face session will occur one week after the patient receives his/her CPAP and will last approximately 45 minutes. The second session will provide information on CPAP usage and pre- and post-treatment AHI, explore barriers to CPAP use and benefits of CPAP use, and provide a goal setting exercise. The telephone follow-up session will occur two weeks after the patient has received his/her CPAP and will last approximately 20 minutes. This session will review CPAP usage and explore barriers and facilitators of CPAP use.
45788753|NCT01377584|Device|Continuous positive airway pressure (CPAP)|CPAP is treatment for obstructive sleep apnea. CPAP therapy keeps the airway open during the night by providing a stream of air through a mask that is worn while sleeping.
45788754|NCT01377584|Other|No intervention|No intervention will be received.
45788755|NCT01734161|Drug|Dexamethasone|8mg IV dexamethesone given
45788756|NCT01734161|Drug|Placebo|Subjects randomized to placebo receive 50cc normal saline
45788757|NCT01272284|Device|Altis® Single Incision Sling System (SIS)|The Altis® SIS is a permanently implantable synthetic sling for females placed at the mid-urethra to provide a scaffold for tissue in-growth and support for stress urinary incontinence.
45788758|NCT01734239|Biological|Pneumovax™ 23|Vaccine contains 25 µg of each of the 23 pneumococcal polysaccharides serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F
45788759|NCT04346576|Dietary Supplement|Probiotics prevent health problems in children|A controlled field trial was conducted with 1,036 children (3-5 years old) in Thanh Hoa province in Vietnam. The probiotic group (n=518) consumed fermented milk 65 mL/day containing 108 CFU/mL of LcS for the 12-week intervention period, whereas the control group (n=493) were not given any. The incidence of constipation, diarrhea, ARI, and anthropometry in children was determined at baseline, after 4, 8, and 12-week intervention and after the 4-week follow-up period.
45788760|NCT01734317|Device|Mepilex Transfer Ag|A soft silicone wound contact layer.
46071303|NCT00824863|Drug|ketoconazole 2% foam|topical antifungal foam to be applied to the folliculitis BID for 2-4 weeks.
45449431|NCT03725553|Drug|Placebo|the group received a 10-mL bolus injection of saline into the myometrium during slow (30-seconds)as soon as the umbilical cord was clamped.
45449432|NCT03213626|Drug|Cabozantinib 40 MG|To be taken orally once daily
45645803|NCT05002205|Other|spirometry|During two study visits, the lung function will be measured (FVC, FEV1)
45645804|NCT05002205|Other|ECG|During two study visits, the presence of arrhythmia will be explored.
45645805|NCT05002205|Other|1 minute sit to stand test|Physical endurance is tested during 2 study visits.
45645806|NCT05002205|Other|Vital parameters|blood pressure, pulse, weight
45645807|NCT02039401|Biological|VM202|
45788761|NCT01334216|Other|CHICA Smoking Cessation Module|The CHICA module helped to screen parents for smoking and assist them in quitting.
45788762|NCT01334216|Other|CHICA Placebo|This was CHICA without the study module.
45449433|NCT03213626|Drug|Erlotinib 100Mg Tab|To be taken orally once daily
45645808|NCT05002361|Drug|Dexamethasone|24 mg intravenous Dexamethasone (6 ml)
45645809|NCT05002361|Drug|Isotonic saline|6 ml of isotonic saline
45645810|NCT02329405|Drug|Rifampicin|
45645811|NCT02329405|Drug|Placebo|
45645812|NCT05002283|Other|patient specific guide|harvesting palatal free gingival graft using the patient specific guide
45645813|NCT02329171|Drug|Imiquimod|Imiquimod 5% cream will be administered in a vaginal applicator, containing 12,5 mg of imiquimod (one sachet). The cream will be self-administered three times per week, by use of a vaginal applicator.
45788763|NCT02640807|Drug|Interleukin-7|IM (intra-muscular) administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR (International Normalized Ratio) >2.5 or platelet count < 35,000
45788764|NCT02640807|Drug|Placebo|IM administration of Placebo (SC administration for patients with INR>2.5 or platelet count < 35,000
45788765|NCT01797575|Drug|Aspirin|aspirin 1000mg (2 capsules of 500mg) every morning in addition to his/her antidepressant and/or mood stabilizer medicine
45788766|NCT01797575|Dietary Supplement|N-acetyl-cysteine (NAC)|taking N-acetyl-cysteine (NAC) 1000mg (2 capsules of 500mg) two times a day in addition to his/her antidepressant and/or mood stabilizer medicine
45788767|NCT01797575|Drug|Sugar Pill|research subject will be taking placebo in addition to his/her antidepressant and/or mood stabilizer medicine
45788768|NCT01335308|Behavioral|Standard Care|Practitioners will receive 2 hour obesity lecture and ½ day protocol training. Families recruited are given parent education materials. Outcomes will be collected at 1 year and 2 years after enrollment
45788769|NCT01335308|Behavioral|Moderate Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner. Outcomes will be collected at 1 year and 2 years after enrollment
45645814|NCT02329171|Procedure|LLETZ|Standard treatment consists of a LLETZ procedure, in which excision of the transformation zone and macroscopic lesions is performed by a monopolar loop electrode, under local anaesthesia. The excision is usually performed in two or three steps, depending on the size of the lesions.
45645815|NCT05001971|Drug|Anlotinib Plus Penpulimab|Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
45645816|NCT05000801|Biological|DC vaccine|Autologous/or HLA-matched donors' DCs loaded with WT1/TERT/survivin
45788770|NCT01335308|Behavioral|Higher Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner and 6 x visits (in phone or in person) with a Registered Dietitian, also trained in Motivational Interviewing. Outcomes will be collected at 1 year and 2 years after enrollment
45788771|NCT03009032|Dietary Supplement|PMT25341|
45788772|NCT03009032|Dietary Supplement|Placebo|Lactose
45788773|NCT02641353|Drug|Apremilast Tablet|30 mg tablet
45788774|NCT02641353|Drug|Apremilast Oral Suspension|30 mg oral suspension
45788775|NCT01335542|Procedure|Peri-Articular Injection|Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), dexamethasone (6mg) Anesthetic:: Combined Spinal-Epidural with 0.5% bupivacaine. IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Postoperative pain management: hydromorphone/bupivacaine PCEA (4/4/10/20, initially). Meloxicam (7.5 or 15mg), Oxycodone/Acetaminophen (5/325 3hr PRN)
45788776|NCT01335542|Procedure|Epidural Pathway (PCEA+FNB)|Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), extended release oxycodone (10mg or 20mg), dexamethasone (6mg), clonidine patch (100 mcg/24 hr) Anesthetic: Spinal with 0.5% bupivacaine, IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Post-operative analgesia:Prilosec (20mg), Meloxicam (7.5mg or 15 mg PO), extended release oxycodone (10mg or 20mg), Oxycodone (5mg q 3 hr PRN), Acetaminophen (1000mg), ketorolac 15mg IV
45788777|NCT02974023|Device|Pain Gear|PainGear [ActiPatch®] (BioElectronics Corporation, MD, USA) has been recently introduced as an 'topical' analgesic for localized musculoskeletal pain. PainGear is a noninvasive, low power, easy to use, pulsed shortwave therapy device for localized musculo¬skeletal pain.
45788778|NCT01378520|Drug|ketoconazole|600 mg capsule oral once
45788779|NCT01378520|Drug|inert powder|oral once
45788780|NCT01378988|Drug|Dexmedetomidine|For sedation according to protocol
45788781|NCT05027139|Drug|Zanidatamab|Administered intravenously (IV)
45788782|NCT05027139|Drug|Evorpacept|Administered IV
45788783|NCT01335620|Drug|Raltegravir|400 mg twice daily
45788784|NCT01335620|Drug|Tenofovir|245 mg once daily
45788785|NCT01335620|Drug|Emtricitabine|200mg once daily
45645817|NCT02329093|Procedure|To MRI-detecting bone signal changes in radiographic hip OA|To examine whether or not non-weight bearing reduced OA progression
45645818|NCT02329249|Behavioral|Smokefree Partners: 21 Days to Freedom|Treatment subjects, who chose a quit date, were given 21 sessions to be viewed one session (i..e, one day) at a time, and an in-person smoking cessation coach to support them through their quit process via tailored email or phone coaching messages. Treatment users were encouraged to use pharmacological aids in their quit attempt, but smoking cessation aids were not provided.
45788786|NCT01272830|Drug|Placebo|Two capsules taken twice daily with meals
45788787|NCT01272830|Drug|Apatone®B|Two capsules taken twice daily with meals
45788788|NCT01335932|Drug|IV Ganciclovir|For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
45788789|NCT01335932|Drug|Placebo|"For first 5 days, dosing of intravenous placebo is daily, given every 12 hours. After first 5 days (up to 28 days), IV placebo QD. A minimum interval of 6 hours is required between the first and second dose.~The placebo is an IV solution that does not contain any active medications."
45788790|NCT01273766|Drug|deferasirox|Given orally
45788791|NCT01273766|Other|laboratory biomarker analysis|Correlative studies
45788792|NCT01273766|Other|enzyme-linked immunosorbent assay|Correlative studies
45788793|NCT01379222|Device|Endurant Stent Graft System|The Endurant Stent Graft System is designed to treat infrarenal abdominal aortic aneurysms using an endovascular approach. When placed within the aneurysm, the Endurant Stent Graft is designed to provide a permanent, alternative conduit for blood flow within the patient's vasculature by excluding the aneurysmal sac from blood flow and pressure.
45788794|NCT01379924|Behavioral|Parenting/Life Skills Intervention|Modules adapted from the Ansell-Casey Life Skills Assessment Curriculum, the Women's Negotiation Project Curriculum for Teen Mothers and the Nurturing Curriculum. Goal is to help teen mothers develop positive parenting skills, decrease repeat pregnancy and acquire skills of daily living. The series of five, one-hour long, structured, one-on-one interactive modules aims to help teens build positive, empathetic relationships with their children, while enhancing self-efficacy and increasing the sense of self- worth for parents and children. Domains addressed include child development/discipline, safety, house/money management, social relationships, career planning, substance abuse and community and interpersonal violence.
45788795|NCT01379924|Other|Teen-tot medical home|Medical, mental health, and social services provided to teen parents and their children
45788796|NCT00366483|Drug|Lecozotan SR|
45788797|NCT01275092|Device|CorPath robotic-assisted PCI|CorPath 200® robotic-assisted percutaneous coronary intervention
45788798|NCT04741269|Diagnostic Test|Find a link between lack of knee flexion and meniscal posterior luxation fixed|"Measure the full flexion angle of the knee using a goniometer. Measure the heel-buttom distance. All measurements are carried out in bilateral and comparative ways.~Search for the meniscal position on MRI and intraoperatively: no shift, anterior, medial, posterior shift."
45788799|NCT02979938|Other|Semen analysis and semen PCR for Zika virus|Every two weeks subjects provide a semen sample which is analysed and then frozen for RT-PCR and viral load. Semen sample testing for the presence of ZIKV (Institute of Tropical Medicine, Belgium) will be performed using both a ZIKV-specific, in-house duplex real-time RT-PCR, targeting a 102bp and 121bp sequence of the NS5 gene and the RealStar® Zika Virus RT-PCR Kit (Altona). Quantitative viral load RNA measurements will be expressed utilizing threshold cycle values because a standardized viral load reference method is not available. To test for infectivity of ZIKV in semen, ZIKV isolation will be attempted in semen samples with a high viral ZIKV load (i.e. positive ZIKV PCR result and Ct-values below 30) by inoculation in Vero cells.
45788800|NCT02642835|Procedure|vaginal wall mesh|retrospective review of case series
45788801|NCT01403090|Device|Angel Catheter|The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.
45788802|NCT02642991|Device|Phenacite|contact lens
45788803|NCT02642991|Device|comfilcon A|contact lens
45788804|NCT01403246|Drug|Lenalidomide; Chlorambucil|MTD of lenalidomide given in combination with chlorambucil
45788805|NCT01734551|Drug|Morphine|"Start at 0.4mg/kg/day (divided every 3-4 hours, given with feeds. Dose may be increased 25% of initial dose until symptoms are stable, up to 1 mg/kg/day.~Once stable for 72 hrs, weaning may begin (decrease 10% of max dose, every other day). When total dose is <0.1mg/kg/day, may discontinue."
45788806|NCT01734551|Drug|Clonidine|Initial dose is 5 mcg/kg/day (divided every 3-4 hrs, given with feeds). Will increase 25% of initial dose every 12-24 hrs until stable, up to 12 mcg/kg/day. Dose is unchanged for 72 hours once stable, then may decrease by 10% every other day. If re-escalation is required, the previous dose may be used with 72 hours for stabilizing.
45645819|NCT02329249|Other|Wait-List Control|Subjects randomized to the control condition were placed on a wait-list and given access to the smoking cessation program after 120 days and completion of the 120-day follow-up assessment.
45645820|NCT05001893|Device|S53P4 bioactive glass putty|Bonalive putty/putty MIS paste is a synthetic, bioactive, osteoconductive, osteostimulative bone void filler for filling, reconstruction, and regeneration of bone defects.
45645821|NCT03143335|Procedure|Retropectoral immediate breast reconstruction|Immediate reconstruction with the implant placed in a standard fashion, i.e. retropectoral in combination with an acellular dermal matrix.
45645822|NCT03143335|Procedure|Prepectoral immediate breast reconstruction|Immediate breast reconstruction with the implant placed prepectoral supported by acellular dermal matrix alone.
45645823|NCT05001659|Other|computer simulator and mannequin simulator|compared two different training simulators with respect to training effectiveness in ACLS training.
45645824|NCT02328781|Device|Drug-eluting stent|
45645825|NCT05000099|Other|video calls|A tablet for video-calls will be available for patients and families. Two video-calls of maximum 15' will be organized every week; in addition, patients will be allowed to do video-call upon request. Video-calls will be performed using Skype or WhatsApp video or Face-time
45645826|NCT05653531|Other|Blood sample|Liver blood tests (AST, ALT, PAL, GGT, bilirubin, PT) will be performed before each ICI injection during the first three injections and again at 6 months.
45788807|NCT01276184|Behavioral|SMS Text Message|Women in the SMS Text Message group that reschedule a vaccination visit will receive text message reminders one per day for each of the seven days prior to the rescheduled visit (or as many days as possible depending on when the rescheduled visit will take place - for example, if they call in and reschedule the visit to take place in 4 days, they will receive text messages for the 3 days prior to the rescheduled visit). Participants in both the Usual Care group and the SMS Text Message group will receive the standard reminder from the clinic for their re-scheduled appointment(s).
45788808|NCT01815515|Drug|18F-DCFBC|"18F-DCFBC is a radiofluorinated small-molecule inhibitor of prostate-specific membrane antigen (PSMA).~A bolus of 10 mCi (370 MBq) [9-11 mCi (333-407 MBq)] of 18F-DCFBC will be injected into the IV line by slow IV push."
45788809|NCT01404260|Drug|Gefitinib|Gefitinib 250mg/d every cycle d15-25,and Gefitinib 250mg/d from d15 of last cycle until disease progression
45788810|NCT01404260|Drug|Gemcitabine +Carboplatin|Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles
45645827|NCT05000255|Behavioral|Intervention 1: According to DGP|The first intervention is designed according to a current recommendation of the Deutsche Pneumologen Gesellschaft e.V. Its approach is resource-oriented, psychoeducational and is expected to have a positive effect on the symptomatology of depression and anxiety in the short and medium term. An additional focus was added to the intervention: planning more physical activity in daily life after discharge. The DPG intervention focuses more on the current state and aims to activate patients' resources in the short and long term. To ensure randomization of study participants, interventions will alternate weekly.
45788811|NCT01735877|Other|Mirror therapy|During the mirror practices, patients were seated close to a table on which a mirror (35×35cm) was placed vertically. The practice consisted of non paretic-side wrist and finger flexion and extension movements while patients looked into the mirror, watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. Patients could see only the noninvolved hand in the mirror; otherwise, the noninvolved hand was hidden from sight. During the session patients were asked to try to do the same movements with the paretic hand while they were moving the non paretic hand.
45645828|NCT05000255|Behavioral|"Intervention 2: According to Cacioppo E.A.S.E."|"The second intervention, E. A. S. E. according to Cacioppo and Patrick (2008), addresses the social action radius of patients (here assuming that loneliness is a predictor of depression). This intervention is about planning social activities against loneliness. Cacioppo's intervention aims to encourage more social activity in the long term."
45645829|NCT04498741|Drug|EDP-938|Subjects will receive EDP-938 once daily on Days 10 through 27 (Part 1)
45788812|NCT01735877|Other|Control group|The control group performed the same exercises for the same duration but used the nonreflecting side of the mirror in such a way that the paretic hand was hidden from sight. The same therapist delivered the control therapy to the patients. Both the treatment and the control group received limb activation.
45788813|NCT02235909|Drug|Azilsartan Medoxomil Low-dose|
45788814|NCT02235909|Drug|Losartan|
45645830|NCT04498741|Drug|EDP-938|Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 2)
45645831|NCT04498741|Drug|EDP-938|Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 3)
45645832|NCT04498741|Drug|Tacrolimus|Subjects will receive tacrolimus once daily on Day 1 and Day 24
45788815|NCT02235909|Drug|Placebo for Azilsartan Medoxomil|
45645833|NCT04498741|Drug|Dabigatran|Subjects will receive dabigatran once daily on Day 1 and Day 13
45788816|NCT02235909|Drug|Placebo for Losartan|
45788817|NCT02235909|Drug|antihypertension medication - Add-on Therapy|add-on therapy (e.g., a calcium channel blocker, such as amlodipine, a diuretic, such as hydrochlorothiazide, or a beta-blocker such as metoprolol) per PI's clinical judgment.
45788818|NCT02235909|Drug|Azilsartan Medoxomil Medium-dose|
45788819|NCT02235909|Drug|Azilsartan Medoxomil High-dose|
45788820|NCT01404572|Drug|Atazanavir (current formulation)|Solution, oral, atazanavir 15 mg/5 mL with 10% aspartame, single dose
45788821|NCT01404572|Drug|Atazanavir, powder for oral use 1 (POU1)|Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame, single dose
45788822|NCT01404572|Drug|Atazanavir (POU2)|Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame and sucralose, single dose
45788823|NCT01798589|Drug|Ethylenediamine dihydrochloride allergen patch|1 allergen panel containing 2 allergen and 2 control patches
45788824|NCT05588817|Genetic|PCR polymorphism|PCR polymorphism in Rhomatoid arthritis patients in Egypt
45788825|NCT01799135|Other|DCE-MRI scan|
45788826|NCT01799135|Radiation|Stereotactic Body Radiation Therapy|
45788827|NCT01799135|Other|4D-CT scan|
45788828|NCT01381172|Device|Optimizer System|The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
45788829|NCT01381172|Other|No intervention: Optimal medical therapy|The control group receives optimal medical therapy only.
45788830|NCT05588661|Other|Perturbation Exercises|"Perturbation exercises will be performed 3 times in a week for 6 weeks for 10-15 minutes per session with baseline treatment for total 30 minutes.~Total 18 sessions will be given to the patients."
45788831|NCT05588661|Other|Whole Body Vibration|"It will be performed 3 times in a week for 10-15 minutes per session with baseline treatment for total 30 mints.~Total 18 sessions will be given for 6 weeks"
45788832|NCT01736267|Device|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
45645834|NCT04498741|Drug|Rosuvastatin|Subjects will receive rosuvastatin once daily on Day 1 and Day 13
45645835|NCT04498741|Drug|EDP-938|Subjects will receive EDP-938 once daily on Days 3 through 16 (Part 4)
45788833|NCT05588427|Dietary Supplement|Ketone ester|A total of 240g ketone ester supplementation will be provided in one of the 28h experimental sessions in order to establish intermittent exogenous ketosis. Sucralose (5% w/w) is added to the ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
45645836|NCT04498741|Drug|Midazolam|Subjects will receive midazolam once daily on Day 1 and Day 16
45645837|NCT04999943|Biological|DC vaccine|EDC cell therapy collection and administration process. Collection of PBMC for preparation of DC cells for patients with autologous DC cells, patient PBMC was collected 10-16 weeks before administration for the preparation and large-scale culture of DC cells. For the patients with matched DC cells, a small amount of peripheral blood was taken for HLA typing 4 weeks before administration, and then the matched DC cells were cultured on a large scale.
45788834|NCT05588427|Dietary Supplement|Placebo|Water, 5% sucralose (w/w), octoacetate (1 mM)
45788835|NCT01381406|Drug|TIO|Patients receiving tiotropium bromide at index within the study period.
45788836|NCT01381406|Drug|TIO+FSC|Patients receiving tiotropium bromide plus fluticasone propionate-salmeterol xinafoate combination at time of index within the study period.
45788837|NCT04949919|Other|aerobic training by a cycle ergometer and Biodex system 4 pro|cyclic aerobic training in moderate-intensity and high-intensity interval training plus isokinetic resistance training prior to HD. 60 training sessions in 6 months.
45788838|NCT01799213|Drug|Meloxicam 15 mg po QD|Eligible subjects will be take Meloxicam 15 mg po QD
45788839|NCT01799213|Behavioral|Cognitive Behavioral Therapy|Subjects originally assigned to placebo will receive cognitive behavioral therapy for 10 weeks
45788840|NCT04928781|Behavioral|Smoking Cessation Counseling|Smoking cessation counseling will be provided following standards set by the institution patients are receiving care at (Dartmouth-Hitchcock Medical Center).
45788841|NCT01381952|Radiation|Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology.|Digital substraction angiography (DSA) with reduced dose settings (75% reduction expected) in combination with conventional X-ray imaging technology.
45788842|NCT01381952|Radiation|Normal dose DSA with conventional X-ray technology|Digital substraction angiography (DSA) with normal dose settings in combination with conventional X-ray imaging technology.
45788843|NCT01815671|Procedure|colonoscopy in the lateral horizontal position|colonoscopy in the lateral horizontal position with tilt down
45788844|NCT01816451|Other|running training|The present study was designed to compare the physiological effects between the two training regimes and the control group.The subjects from interval and continuous group performed others activities as resistance training, swimming or soccer. Those activities wasn't controlled by our study, but the individual didn't do physical activities at least 3 hours before started our running sessions. The control group simply performed their normal physical activities (resistance training, swimming or soccer). But, each 3 weeks we had a contact with control group to check about any injury or illness that could affect the final results. None were found.
45788845|NCT02107443|Behavioral|Geriatric Assessment Summary|Complete summary of results from the Geriatric Assessment
45788846|NCT02107443|Behavioral|Geriatric Assessment Targeted Recommendations|"Recommendations are made based on areas patients were impaired in on the Geriatric Assessment. They include referrals, tests, medication review, instructions, and support services. The choice of which recommendation to implement is left to the discretion of the physician.~Treatment modifications"
45449434|NCT02159092|Behavioral|Contingency Management|Monetary incentive for the CM groups is contingent on a saliva cotinine reading that indicates smoking abstinence. Participants were assessed 10 times (Mondays/Thursdays) for abstinence from smoking waterpipe verified by saliva cotinine. The maximum monetary incentives this group can receive is $192.50. The CM groups followed an escalating schedule where: 1) the dollar amount of the incentive increases by $.50 as long as the participant is abstinent at each visit;; and 2) resets to the starting incentive ($14) if the participant was non-compliant at the previous visit, but is compliant at the current visit. Also, Participants were given $10 bonus for every three consecutive compliant visits.
45788847|NCT02107443|Behavioral|Geriatric Assessment (GA)|A GA measures the issues important to older patients, including function, psychological status, cognitive abilities, social support, and the impact of medical problems on quality of life.
45788848|NCT01383200|Drug|Tetracaine drop|0.5% Tetracaine Right eye / 2% Lidocaine Left eye
45788849|NCT01383200|Drug|Lidocaine gel|0.5% Tetracaine Left eye / 2% Lidocaine Right eye
45788850|NCT04893135|Other|pratice physical activity|treadmill walking : walk at a speed of 2.7 km.h-1 in 3 stages of 3 mins with an incline of 0%, 5% and 10%
45788851|NCT01404650|Drug|AUY922|AUY922: 70 mg/m2 IV over 60 minutes on Days 1, 8, and 15 of each cycle. Treatment cycles will be repeated every 21 days. Patients will be evaluated for response at 6 and 12 weeks and then every 9 weeks (i.e., every 3 cycles) thereafter. Patients may continue treatment until evidence of disease progression.
45788852|NCT04859673|Device|radial extracorpeal shock wave|Swiss DolorClast® Master - Shockwave Therapy System will be used to apply the radial extracorporeal shock wave. It consists of master console, Evo Blue hand-piece, 15mm and 36mm interchangeable contact heads (applicators), contact gel, cart, and external compressor
45788853|NCT01276652|Behavioral|Environmental modification|Environmental modification consists of nursing-related efforts to optimize daytime light exposure, to minimize nighttime light and noise exposure, and to batch nursing care at night.
45788854|NCT05588193|Behavioral|PVO|post-visit outreach
45788855|NCT05588193|Behavioral|TS|tele-sexual health visit during the ED visit
45788856|NCT02050347|Genetic|CD19.CAR-CD28Z T Cells - dose escalation 2|"Patients will receive one of the following dose levels:~Dose Level 1: 5 ×10^5 cells/kg~Dose Level 2: 1×10^6 cells/kg~Dose Level 3: 5×10^6 cells/kg"
45788857|NCT02050347|Genetic|CD19.CAR-CD28Z T Cells - dose escalation 1|"Patients will receive one of the following doses:~Dose Level one: 1x10^5 cells/kg~Dose Level 2: 5x10^5 cells/kg~Dose Level 3: 1x10^6 cells/kg"
45788858|NCT05588037|Procedure|FLACS +PPV+IOL + air|The procedures are combined the FLACS +PPV+IOL + air.
45788859|NCT05588037|Procedure|FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex|The procedures are combined the FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex.
45788860|NCT05588037|Procedure|FLACS + PPV+IOL + internal limiting membrane peeling + air|The procedures are combined the FLACS + PPV+IOL + internal limiting membrane peeling + air.
45788861|NCT05588037|Procedure|FLACS + PPV+IOL|The procedures are combined the FLACS + PPV+IOL.
45788862|NCT02194088|Drug|Diclofenac and Atropine combination drug|Diclofenac will be associated with a small dose of atropine 1.2mg
45788863|NCT02194088|Drug|Placebo|For each capsule of active medication, a capsule of placebo will be provided, identical looking.
45788864|NCT02023593|Drug|FOLFIRI|Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
45788865|NCT03009734|Drug|ATx201 dermal formulations 2%|Topical application of ATx201 dermal formulations 2%
45788866|NCT01978431|Drug|cocaine hydrochloride|
45788867|NCT01978431|Drug|methylphenidate|
45788868|NCT01406444|Drug|rhIGF-1|Study participants will be started at a dose of 30 mcg/kg BID and will be titrated.
45788869|NCT01406444|Drug|Risedronate|Risedronate 35mg PO one time weekly
45788870|NCT01406444|Drug|Placebo|Placebo injections 30 mcg/kg BID, Placebo tablet PO once weekly
45788871|NCT05442177|Procedure|Chemotherapy and Integrated Chinese Medicine With Western Medicine for cancer treatment|
45788872|NCT00366639|Other|Acute Decompensated Heart Failure|Treatment & outcomes during hospital admission for Acute DHF
45788873|NCT01407068|Biological|AA4500 collagenase clostridium histolyticum|2 concurrent injections (0.58 mg) into 2 cords on the same hand
45788874|NCT01385306|Device|AlphaCore System|Non-invasive neurostimulation of the vagus nerve
45645838|NCT04999865|Other|4-part educational program to build patient-engagement methodology capacity|We created four online training sessions. Our first training for patients/caregivers only (Research 101) was an exception, however, in which we produced a 25-minute asynchronous, self-directed learning seminar intended to be viewed before the subsequent interactive PCOR sessions. Of the three following synchronous interactive training sessions, two included both learner working groups (patients/caregivers and researchers/providers) together (PCOR 101 and PCOR Team Dynamics) and one session (PCOR Study Design) was for researchers/healthcare providers only.
45788875|NCT02685267|Drug|Docetaxel|
45788876|NCT02685267|Drug|Enzalutamide|
45788877|NCT02685267|Drug|Prednisone|
45788878|NCT01277354|Behavioral|Cognitive Processing Therapy|"CPT utilizes a combination of a) exposure therapy aimed at extinguishing fear and distress induced by memories and external cues associated with the trauma, and b) cognitive behavioral techniques that address faulty thinking patterns developed to promote a sense of control over possible future traumas, but that instead perpetuate PTSD symptoms. In CPT, exposure to the traumatic memory occurs through writing and reading for periods of time determined by the client and is confined to the week of the 4th and 5th sessions. These sessions are otherwise used to identify stuck-points, i.e., distorted interpretations regarding the trauma and unrealistic beliefs regarding self and others."
45788879|NCT01277354|Behavioral|Waitlist Placebo|Behavioral ratings are conducted by a blind rater.
45919770|NCT05205928|Drug|Outpatient therapy: 8 weeks of drug therapy with usual treatment + 5 weeks of closed-loop therapy|The blinded drug will be used with participant's routine therapy (+ continuous glucose monitoring if not already in use) for 8 weeks with follow-up from qualified research personnel concerning pump settings, side effects, and incremental dose increase. While continuing to use the medication, there 5 weeks of closed-loop pump therapy and drug use; glycemic outcomes will be taken from the last 4 weeks. This will be followed by laboratory and anthropometric testing, followed by 2 weeks of wash-out.
45919771|NCT05197855|Device|Deem 3 Headband|The patient will wear the Dreem 3 headband and pulse oximeter at home before initiation of CPAP (for 7 nights) and during a month of treatment (for a minimum of 9 nights), after the initiation of CPAP. He will also wear a glucose sensor and a pedometer during the entire study period before and after CPAP treatment.
45645839|NCT04938635|Drug|VIT-2763 60 mg QD|Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally in the morning, and 2 Placebo capsules orally in the evening, for 24 weeks.
45788880|NCT04530123|Drug|Placebo|TAK-101 placebo-matching intravenous infusion
45788881|NCT04530123|Drug|TAK-101|TAK 101 intravenous infusion
45788882|NCT04530123|Dietary Supplement|Gluten|Powder form (vital wheat gluten)
45788883|NCT01280552|Biological|ICT-107|Autologous dendritic cells pulsed with immunogenic antigens
45788884|NCT01280552|Biological|Placebo DC|Autologous dendritic cells (DC) that have not been pulsed with antigens
45788885|NCT02257541|Drug|BGJ398|
45788886|NCT02257541|Drug|Imatinib Mesylate|
45788887|NCT01385696|Device|Genuair® (Almirall S.A.)|Inhaler with only placebo, once daily, 14 days
45788888|NCT01385696|Device|HandiHaler® (Boehringer Ingelheim's)|Inhaler with only placebo, once daily, 14 days
45788889|NCT05587803|Device|Neurowave and Sedline indices in view|3 additional electrodes are attached on the patients forehead. After electrode placement, the indices of both the SEDLINE device and the NEUROWAVE device are noted every 5 seconds for 1 minute
45788890|NCT01817855|Drug|AZD7624|Multiple ascending doses (starting from 300 µg lung deposited dose up to 1200 µg) inhaled IMP via a nebulizer
45788891|NCT01817855|Drug|Placebo to match|Multiple doses inhaled placebo via a nebulizer
45788892|NCT05587647|Other|Transition to Adulthood Education Program|"YEGEP was developed by the authors based on the information in the literature, based on the needs of mothers of children who have reached adulthood or are going through. Three training modules are planned in line with current requirements. Education will also be supported by audio-visual and written materials. It is planned that the trainings, which will last for 3 weeks in total, for 1 hour a week for each group, in the form of 3 sessions of 1 hour with these contents, will be held at a disabled center. Titles of training modules:~Developmental Period Characteristics of Young Adults with Intellectual Disabilities (Transition to Adulthood, Future Planning / Social Life (employment, peers, etc.)~Protecting and Sustaining the Health of Young Adult with Intellectual Disabilities~Coping with Stress"
45645840|NCT04938635|Drug|VIT-2763 60 mg BID|Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally, twice daily for 24 weeks.
45645841|NCT04938635|Drug|VIT-2763 120 mg BID|Participants receive two VIT-2763 60 mg capsules orally, twice daily for 24 weeks.
45645842|NCT04938635|Drug|Placebo|Participants receive two Placebo capsules matching VIT-2763 orally, twice daily for 24 weeks.
45645843|NCT03551743|Combination Product|PRT064445/Edoxaban|
45645844|NCT03551743|Combination Product|Placebo/Edoxaban|
45645845|NCT03551743|Drug|Placebo|
45919772|NCT02965222|Device|the time-lapse videography|The all oocytes will be placed in the Time-Lapes .The third day the top-grade embryo will be selected by time-lapse imaging (TLI) .
45919773|NCT05190757|Other|Airway and Ventilation|Insertion of Laryngeal Mask airway for ventilation or use of Face Mask
45645848|NCT04932395|Drug|Anshen Buxin Liuwei Pill|15 capsules/time, 2 times/day, orally.
45645849|NCT04932395|Drug|Placebo|Placebo simulated as the Anshen Buxin Liuwei Pills with same appearance，smell and taste,15 capsules/time, 2 times/day, orally.
45645850|NCT04932239|Other|first aid education|To teach commercial motorcyclists first aid for post-crash while waiting for medical team to reach the scene
45645851|NCT04714879|Other|Device: anodal tDCS|anodal current modulated by an oscillatory component including a fixed (0,75 Hz) versus individually adapted so-tDCS frequency with three different stimulation durations (5 min, 2 min, 30 sec)
45645852|NCT04714879|Other|Device: no stimulation|sham stimulation
45645853|NCT04698811|Behavioral|VIRTUAL ENEAGRAM|"Presentation of the Virtual Enneagram and its content and realization of the first battery of tests (World Health Organization Quality of Life - (WHOQOL-BREF). Stress Perception Scale 10 (EPS-10) The Trait-State Anxiety Inventory: IDATE E and T.) .~Guidance and training on personality and the Enneagram, its classification system, personality subtypes and dynamics of stress and growth allowing self-recognition.~Second test battery ((World Health Organization Quality of Life - (WHOQOL-BREF). Stress Perception Scale 10 (EPS-10) The Trait-State Anxiety Inventory: (IDATE E and T.) and Enneagram Questionnaire."
45645854|NCT03142399|Dietary Supplement|whey protein|Supplementation with whey protein isolate or maltodextrin (30 grams per day) for 12 weeks associated with supervised exercise and nutritional counseling in patients with heart failure.
45645855|NCT03076307|Behavioral|Procedural Motor Skills with mirror-drawing of figures|Evaluation of error rate and speed for completion of a procedural motor task
45645856|NCT03076229|Behavioral|Healthy Marriage Program|Provide the following allowable activities 1) marriage and relationship education/skills, 2) relationship enhancement, 3) premarital education, and 4) divorce reduction.
45645857|NCT03076073|Other|Impact of physical activity on tendons|Single vs. multiple (up to 12 weeks) of different types of physical exercises (aerobic vs. anaerobic activities).
45645858|NCT02328859|Other|Virtual Reality Gait Training|A Virtual Gait Retraining System (VGRS) will be used to train amputees for six weeks. the system consists of an actuated treadmill, a virtual environment and an avatar
45645859|NCT02328859|Other|Treadmill Gait Training|A conventional treadmill with no visual display will be used to gait train amputees for a period of six weeks.
45788893|NCT00368121|Drug|Cetuximab +/- Dexamethasone|"Cetuximab dosing schedule:~• Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly over 16 weeks. Mode of administration: intravenous infusion~Dexamethasone dosing schedule:~• 20 mg administered on day 1-3, q1w, starting week 5 if evidence of tumor progression or week 9 if no PR or CR to Cetuximab alone.~Mode of administration: orally"
45788894|NCT01801241|Device|Anatomic TSA using IRI Instrumentation|Anatomic Total Shoulder Arthroplasty (TSA) will be performed using the SmartBone and Intelligent Reusable Instrument (IRI) to transfer the pre-operative plan for glenoid implant positioning to the patient's anatomy.
45919774|NCT05186077|Other|Magnetic Resonance Imaging|Imaging data for research purposes (high-resolution T1 structural and DWI MRI) will be acquired
45919775|NCT05186077|Other|Psychiatric testing|Subjects will be evaluated using psychiatric assessments
45449435|NCT03604341|Drug|Dronabinol 5mg Cap|Subjects randomized to Dronabinol 5mg Cap and ibuprofen 800mg for pain
45449436|NCT03604341|Other|Placebo|Subjects randomized to placebo and ibuprofen 800mg for pain
45645860|NCT04993937|Other|Intervention|Interventional group will receive 6 weeks of plyometric training and receive training for week and three sessions in a week.
45645861|NCT04993937|Other|Control Group|Control group will follow their daily routine activities and may involve in any other exercise program rather than plyometric exercises.
45653097|NCT05151263|Diagnostic Test|Optical Platelet Aggregation test|The evaluation of platelet aggregation was performed using an optical aggregometer (AggRAM, using fresh citrated blood. Platelet-rich plasma was obtained by centrifugation of the citrated blood at 190 g for 5 min. The platelet count was adjusted to 200,000 to 300,000 platelets/mm3. Platelet-rich plasma (250 μl) was deposited in each equipment channel, and the activators adenosine diphosphate, epinephrine, collagen, and arachidonic acid were used according to the manufacturer's instructions. aspirin resistance was defined as platelet aggregation ≥ 20% with arachidonic acid and ≥70% with adenosine diphosphate.
45788895|NCT01801241|Procedure|Anatomic Total Shoulder Arthroplasty|Anatomic Total Shoulder Arthroplasty will be performed by the two surgeons of the study as their Standard of Care. All procedures associated with the surgery will be the same in the two arms, with the exception of the tools used to place the guide pin for placement of the glenoid implant.
45449437|NCT02160496|Behavioral|Weight loss interventional study with 20% protein-diet|
45788896|NCT02686437|Other|TheraBand Kinesiology Tape|Kinesiology taping technique is designed to target muscles and lymphatic system. Limited research is available for specific conditions, including low back pain, but it is theorized to correct muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment.
45788897|NCT04351139|Other|modification of the planned therapeutic management|to evaluate the changes in therapeutic management, during the COVID-19 pandemic, of patients suffering from gynecological cancers
45645862|NCT03143257|Device|Sophono Bone Conduction Hearing Systems|"The Sophono Bone Conduction Hearing Systems are a family of sound processors and accessories that operate on the principle of BC of sound vibrations. The Sophono Bone Conduction Hearing Systems transmits audio vibrations through the skin into the bone where sound is sensed by the inner ear/cochlea.~The Sophono Sound Processor is magnetically attracted to the Magnetic Implant and Magnetic Spacer. The Magnetic Implant, which is secured to the skull bone, affixes the Magnetic Spacer to the head transcutaneously through magnetic attraction forces, and the Sound Processor is magnetically affixed to the Magnetic Spacer. Vibration from the Sound Processor is transduced through the Magnetic Spacer to the Magnetic Implant and through the bone to the inner ear."
45788898|NCT00367497|Drug|Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin|
45788899|NCT02687139|Drug|18F-DCFPyL|
45788900|NCT02687139|Procedure|PET/CT|Positron Emission Tomography - Computed Tomography (PET/CT)
45788901|NCT01818245|Drug|LY2605541|
45788902|NCT02687217|Drug|oxygen|"Hyperoxygenation ≥50% of oxygen by mask(non-rebreathing) was given through out the surgery.~Received 6L/min of oxygen through venturimask upto 2 hours in post operative period.~Hyperoxygenation refers to provision of ≥50% of oxygen by mask(non-rebreathing) through out the surgery."
45788903|NCT01386632|Drug|DCA (dichloroacetate)|DCA orally 12.5mg/kg PO or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m^2 IV over 30-60minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
45788904|NCT01386632|Drug|Placebo|Placebo PO or per G-tube twice a day for 8 weeks given in combination with Cisplatin.
45788905|NCT02266277|Other|Arm 1: E-portal message with IVR call|Active electronic patient portal users will be randomized to receive an e-portal message and IVR calls. Both methods of outreach will provide patients with educational information about influenza vaccination, notify patients of local flu clinic schedules and elicit patient response to vaccination status and barriers.
45919776|NCT05186077|Other|Eye-Tracking|Eye-tracking assessments will be done to biases toward positive and negative stimuli including images of neutral, fearful/threatening, sad, and happy.
45919777|NCT05186077|Other|Neuropsychology Evaluation|The neuropsychology evaluation will measure verbal learning/memory, attention/working memory, psychomotor speed, verbal fluency/processing speed, and executive function
45449438|NCT02160496|Behavioral|Weight loss interventional study with 27% protein-diet|
45449439|NCT02160496|Behavioral|Weight loss interventional study with 35% protein-diet|
45449440|NCT03636698|Other|chorioamnionitis|It is a observation research. We didn't intervene anything. The chorioamnionitis groups included the infants whose mothers were diagnosed chorioamnionitis by placental histopathology.
45449441|NCT02160574|Drug|ChloraPrep|The degree of skin irritation caused by ChloraPrep will be graded and compared to ZuraPrep and ZuraPrep without IPA.
45449442|NCT02160574|Drug|0.1% Sodium Lauryl Sulfate|The degree of skin irritation caused by 0.1% Sodium Lauryl Sulfate will be graded and compared to ZuraPrep and ZuraPrep without IPA.
45449443|NCT02160574|Drug|0.9% Physiological Saline|The degree of skin irritation caused by 0.9% Physiological Saline will be graded and compared to ZuraPrep and ZuraPrep without IPA.
45788906|NCT02266277|Other|Arm 2: E-portal message with no IVR call|Active electronic patient portal users will be randomized to receive only an e-portal message. The e-portal message will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
45788907|NCT02266277|Other|Arm 3: No e-portal message with IVR call|Active electronic patient portal users will be randomized to receive an IVR call. The IVR call will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
45788908|NCT02266277|Other|Arm 5: IVR call|Non electronic patient portal users will be randomized to receive an IVR call with educational information about influenza vaccines, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
45788909|NCT02687529|Device|CST001|
45788910|NCT01387178|Drug|fluticasone propionate/salmeterol 250µg/50µg (FSC)|Patient records with evidence of COPD and prescription claims for FSC
45788911|NCT01387178|Drug|tiotropium bromide (TIO)|Patient records with evidence of COPD and prescription claims for TIO
45788912|NCT05587335|Behavioral|PREP|Relationship intervention to improve communication and conflict resolution for couples
45788913|NCT05587335|Behavioral|OurRelationship|Relationship intervention to improve communication and conflict resolution for couples
45788914|NCT01819415|Dietary Supplement|Anti-VEGF plus AREDS-2|Omega-3 metabolites supplementation
45788915|NCT01819415|Dietary Supplement|Anti-VEGF plus AREDS-1|Patients receiving intravitreal anti-VEGF and AREDS-1 supplementation plus Lutein, without Omega-3.
45788916|NCT01805297|Drug|Intravitreal Aflibercept Injection|One time 2.0mg aflibercept injection, following pars plana vitrectomy.
45788917|NCT01805297|Other|Standard Vitrectomy|Surgical intervention
45788918|NCT04350749|Biological|PRF is added in the test group.|The PRF membrane can be considered as a biological membrane
45919778|NCT05184439|Procedure|Adductor magnus tenodesis for recurrent patellar dislocation|In all 33 patients (39 knees) adductor magnus tenodesis was performed to stabilise the patella. Adductor magnus tendon was harvested, cut proximally and fixed to the patella with proper tension.
45919779|NCT00387530|Drug|oral sodium phenylbutyrate|
45919780|NCT00387530|Drug|valganciclovir|
45449444|NCT02160574|Other|ZuraPrep without IPA|Results from exposure to ZuraPrep will be compared statistically those from exposure to ZuraPrep without IPA
45788919|NCT01822301|Procedure|Repeat Fat grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat grafting is considered a standard of care procedure in plastic surgery. In brief, fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the facial deformity using specialized injection cannulas. In this study, we will treat 5 subjects from protocol (IRB # PRO09060101) with an additional fat graft treatment to assess whether this will increase fat graft retention over time. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101) with be used for comparison.
45788920|NCT01389284|Drug|Naproxen Sodium ER (BAYH6689)|660 mg Naproxen Sodium extended release tablet, orally administered once daily for 24 hours
45788921|NCT01389284|Drug|Naproxen Sodium IR (Aleve, BAYH6689)|220 mg Naproxen Sodium instant release tablet, orally administered 3 times daily (TID) for 24 hours
45788922|NCT01389284|Drug|Naproxen Sodium ER Placebo|Matching placebo of 660 mg Naproxen Sodium ER for 24 hours
45788923|NCT01389284|Drug|Naproxen Sodium IR Placebo|Matching placebo of 220 mg Naproxen Sodium IR (Aleve) for 24 hours
45788924|NCT01794143|Drug|Sulfonylurea (glimepiride)|Used in accordance with labeling and/or usual practice.
45788925|NCT01794143|Drug|DPP-4 inhibitor (sitagliptin)|Used in accordance with labeling and/or usual practice
45788926|NCT01794143|Drug|GLP-1 receptor agonist (liraglutide)|Used in accordance with labeling and/or usual practice.
45788927|NCT01794143|Drug|Insulin (glargine)|Used in accordance with labeling and/or usual practice.
45788928|NCT01408862|Other|venous puncture|Blood for in vitro studies will be drawn
45788929|NCT01409096|Drug|Pregnenolone|Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and central nervous system.
45788930|NCT01409096|Drug|Placebo|Inactive ingredient matching the active medication in appearance.
45788931|NCT01547741|Drug|Doxorubicin|
45645863|NCT04993547|Other|Parent and peer presence|Does the presence of fellow pupils and parents improves a pupil's resistance to undergo a nasopharyngeaal swab test?
45788932|NCT01547741|Drug|Cyclophosphamide|
45788933|NCT01547741|Drug|Docetaxel|
45788934|NCT01547741|Drug|Paclitaxel|
45788935|NCT01410812|Behavioral|Control|Receive weekly emails asking participants about their exercise and receive cash.
45788936|NCT01410812|Behavioral|Suggested Tying Intervention|Participants receive 4 iTunes audio novels for their own iPods to listen to only at the gym
45449445|NCT03620552|Drug|18F-S16|A single dose of nearly 370MBq 18F-S16 were intravenously injected into the subjects immediately before the PET/CT scans
45449446|NCT02150590|Drug|Oxygen|Nocturnal nasal oxygen during stay at 2048 m
45645864|NCT04654429|Drug|IV Ondansetron 4mg|IV ondansetron 4mg
45645865|NCT04654429|Other|Higher OT temperature range|OT temperature set to 19-22 degree celsius
45788937|NCT01410812|Behavioral|Forced Tying Intervention|Participants receive cash and also 4 iTunes audio novels for a loaned iPod accessible only at the gym to listen to only at the gym.
45919781|NCT00387530|Genetic|polymerase chain reaction|
45919782|NCT00387530|Genetic|protein expression analysis|
45449447|NCT02150590|Drug|sham oxygen (room air)|
45645866|NCT04654429|Drug|Placebo|IV Normal Saline 2cc will be given
45645867|NCT04654429|Other|Lower OT temperature Range|OT temperature set to 17-19 degree celsius
45645868|NCT03075683|Behavioral|Cognitive behavioural therapy|Eight sessions of internet-based CBT for insomnia comorbid with chronic pain, with active therapist support.
45645869|NCT03075683|Behavioral|Applied relaxation|Eight sessions of internet-based applied relaxation for insomnia comorbid with chronic pain, with active therapist support.
45645870|NCT03075995|Other|hight-fat breakfast|It's divided into two stages.For the first stage,the subjects take lapatinib on an empty stomach,the steady state plasa concentration is examined on the 9th and 10th days after lapatinib is administered.The second stage,the subject take lapatinib with hight-fat breakfast,the steady state plasa concentration is examined as the first stage.
45788938|NCT01390064|Biological|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG|All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule
45788939|NCT01280942|Behavioral|EWS Nursing Alerts|An automated algorithm (EWS) will identify patients at potential risk of clinical deterioration. When a patient satisfies the algorithm, a nurse on the patient's ward will be notified. S/he will assess the patient and institute any interventions that are clinically required.
45788940|NCT01280942|Device|Wireless Remote Sensor|A subset of patients will be consented to wear a wireless sensor device which will monitor heart rate and level of oxygen in the blood.
45788941|NCT01472822|Dietary Supplement|Omija extract.|Omija extract 1.2g/day for 12weeks
45788942|NCT01472822|Dietary Supplement|Placebo|Placebo 1.2g/day for 12weeks
45788943|NCT03008486|Device|Real soft splint (6 cm)|
45788944|NCT03008486|Device|Placebo soft splint (1 cm)|
45788945|NCT01411592|Other|Multilink|After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using an adhesive bonding system with a phosphonic acid acrylate primer for the zirconia ceramic (Multilink-Automix bonding system with Metal/Zirconia primer)
45788946|NCT01411592|Other|Panavia 21 TC|After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using a phosphate monomer containing resin (Panavia 21 TC) without any primer
45788947|NCT01473368|Dietary Supplement|Saccharomyces boulardii|500 mg, 2 times daily for 14 days
45919783|NCT00387530|Procedure|biopsy|
45788948|NCT01473368|Drug|Amoxicillin Clavulanate|875/125 mg 2 times daily at least 1 hour before meals for 7 days
45788949|NCT04351490|Dietary Supplement|Zinc gluconate|Zinc gluconate capsule 15 mg x 2 per day during 2 months
45788950|NCT04351490|Dietary Supplement|25-OH cholecalciferol|25-OH cholecalciferol drinkable solution 10 drops (2000 IU) per day during 2 months
45788951|NCT01391312|Biological|botulinum toxin Type A|botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.
45788952|NCT01391312|Drug|normal saline (placebo)|Normal saline (placebo) injected into the glabellar region on Day 0.
45788953|NCT01299935|Behavioral|Transcendental Meditation|The Transcendental Meditation program is the principal mind-body approach of Maharishi Ayurveda, originating from the ancient Vedic tradition and introduced 50 years ago by Vedic scholar and teacher Maharishi Mahesh Yogi. The Transcendental Meditation technique is described as a simple and natural procedure that is practiced 20 minutes twice a day while sitting comfortably with the eyes closed. Practice of the Transcendental Meditation technique does not require any changes in personal beliefs, philosophy or lifestyle. During the practice a unique state of restful alertness is gained. Acute and chronic physiological effects have been documented. The course is taught by instructors certified by Maharishi Foundation - USA.
45788954|NCT01299935|Behavioral|Health Education|health education is taught in a clinical setting using standard AHA recommendations for proper diet, exercise and control of substance usage but without a stress management component.
45788955|NCT01473992|Device|Otto Bock C-Leg|Amputees' preferred prosthetic knee.
45919784|NCT05177575|Procedure|Thoracotomy application|The chronic pain findings of the patients who underwent thoracotomy will be questioned at the postoperative 3rd and 6th months.
45919785|NCT04729660|Device|Kinesio Tex Gold|The Kinesio Tex Gold is a kinesio tape that had been certified and patented.
45645871|NCT04639999|Other|Echocardiography|LV vortex flow in Echocardiography
45645872|NCT04993079|Device|Clotild®|Use of Clotild® as neurovascular guidewire
45919786|NCT02687906|Drug|Vabomere|Vabomere (meropenem-vaborbactam) for IV injection
45919787|NCT05048407|Device|Gynaecological laparoscopic surgery (Sirius System)|"The laparoscopic procedures were done in the usual manner. The only difference was for the study participants, the Sirius System was used in place of the usual conventional laparoscope. All other procedures and instruments including the number of ports remained the same.~For every procedure using the Sirius System, a conventional laparoscope was on immediate standby to replace the Sirius System should there be an unanticipated equipment failure so that the procedure could be completed without delay."
45449448|NCT05181566|Procedure|Total hip replacement arthroplasty using modular dual mobility cup|In a total hip replacement (also called total hip arthroplasty), the damaged bone and cartilage is removed and replaced with prosthetic components
45645873|NCT04993235|Behavioral|NEPSY-II|Participants with SS and BWS are administered with selected subtests assessing six different neuropsychological domains
45645874|NCT04993235|Behavioral|CBCL and AQ questionnaires|Parents of participants with SS and BWS are administered with questionnaires assessing behavioral problems and autistic traits
45645875|NCT04993235|Behavioral|BUT questionnaire and experimental tasks|A questionnaire, a computer-based task, a body-illusion paradigm and two psychophysical tasks assessing diverse levels of body perception and representation. These tasks are administered to adolescents of the three groups
45645876|NCT03111355|Dietary Supplement|Brazil nut|one nut a day for 2 months, no intervention for 2 months
45645877|NCT04999397|Other|standards clinical management|outcomes seen in cardiac injuries post clincal care
45788956|NCT01473992|Device|Otto Bock Genium|Study knee.
45788957|NCT05329181|Behavioral|Integrated cognitive behavioral treatment|Integrated cognitive behavioral treatment adapted specifically for homeless individuals and developed to treat substance use and depressive symptoms simultaneously
45788958|NCT05329025|Drug|QL1706|QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
45788959|NCT01391468|Dietary Supplement|Probiotics|intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations
45788960|NCT01391468|Dietary Supplement|Cornstarch|placebo will be given in 6 months
45788961|NCT05328869|Other|Relaxation training|Relaxation training will be performed under the supervision of a physiotherapist. The training is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
45788962|NCT05328869|Other|No intervention|No intervention will be applied. The natural process will be followed from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
45788963|NCT03008252|Other|Lactose breath test|Lactose breath test in NCWS patients with symptoms related to milk and/or milk derivates ingestion.
45788964|NCT03008252|Other|DBPC cow's milk protein challenge|DBPC cow's milk protein challenge in NCWS patients with symptoms related to milk and/or milk derivates ingestion.
45919788|NCT04996069|Device|Crest Whitening Emulsions|Subjects with Xerostomia will be asked to apply the study intervention product to their teeth up to 4 times per day for 1 week to investigate if the study intervention product increases saliva production in this dry mouth populaiton.
45919789|NCT02680184|Drug|CMP-001|CMP-001 will be administered as per the dose and schedule specified in the respective arms.
45919790|NCT02680184|Drug|Pembrolizumab|Pembrolizumab will be administered as per the schedule specified in the respective arms.
45919791|NCT00390000|Drug|vatalanib|Given orally
45919792|NCT00390000|Drug|pemetrexed disodium|Given IV
45919793|NCT00390000|Other|pharmacological study|Correlative study
45919794|NCT00390000|Procedure|ultrasound imaging|Correlative study
45788965|NCT01822457|Device|Nike FuelBand (NFB)|The Nike Fuel Band (NFB) is a wrist-worn sensor with a built-in accelerometer for motion quantification. It is programmed to estimate the number of steps taken per day, and also predict energy expenditure in units known as Nike Fuel. Accompanying software allows the user to set daily targets and monitor their activity through a graphical user interface.
45788966|NCT05328635|Drug|Candesartan|Multdisciplinary approach
45788967|NCT01391858|Drug|lyrica|150mg of pregabalin/placebo
45645878|NCT02328703|Other|Reiki Therapy|Reiki is a biofield energy therapy that is based on the idea that there is a universal energy that supports the body's innate healing abilities. A trained Reiki Master uses their hands as a conduit of the energy that goes naturally to any area of the recipient's body where it is needed. This provides a means for life force energy to recharge and rebalance the human energy fields, creating optimal conditions needed by the body's natural healing system.
45788968|NCT00103181|Radiation|3-dimensional conformal accelerated partial breast irradiation|
45788969|NCT00103181|Radiation|brachytherapy|
45788970|NCT00103181|Radiation|whole breast irradiation|Patients undergo radiation therapy once daily (days 1-5) for up to 7 weeks
45919795|NCT04955275|Other|Cognitive Remediation Therapy Program (BrainHQ)|Brain HQ games involving training cognitive abilities like memory and attention, made up of adapting tasks or creating our own.
45449449|NCT05181566|Procedure|Total hip replacement arthroplasty using conventional acetabular cup|In a total hip replacement (also called total hip arthroplasty), the damaged bone and cartilage is removed and replaced with prosthetic components
45645879|NCT04999007|Other|Artificial intelligence algorithm|Temporary ileostomy will be performed in the patients with high-risk of anastomotic leakage and not performed in the patients with low-risk of anastomotic leakage.
45645880|NCT03979339|Procedure|Blood sample collection|A total volume of 32 ml of blood will be collected in each subject and separated in 4 10-mL EDTA vacutainer tubes EDTA tubes of 8 mL each.
45645881|NCT04998929|Other|complementary therapy|traditional techniques of treatment including, (a)cupping therapy, (b)Backstroke for young people, (c)Sitting on all fours while the other person holds both knees firmly with the hands, the patient is asked to bend at the back so that the abdominal muscles are stretched, (d)taking a nerve that passes under the armpit with two index fingers and thumbs and applying intense pressure to the extent that the patient goes unconscious due to the severity of the pain, (e)Hanging the patient from the horizontal bar and stretching the abdominal muscles, (f)Tie an onion-sized object such as, a bag of wheat or salt, with a scarf on the navel for one hour, (g) taking the gum of mountain pistachio tree which is the same as turpentine and halve a walnut and fill it with raw turpentine and put it inside the navel for 72 hours, and then move it in the umbilical region by twisting hand movements, (h)cupping therapy.
45645882|NCT03073499|Procedure|Oncological Home Hospitalization|
45788971|NCT00103181|Radiation|MammoSite or other single-entry intracavitary device|
45449450|NCT03603639|Drug|Placebo|Participants will receive E2730-matched placebo capsule, orally.
45449451|NCT03603639|Drug|E2730|Participants will receive E2730 capsule, orally.
45449452|NCT02159170|Biological|NGF injection|single injection of NGF into the volar forearm / single injection of NaCl into the volar forearm
45645883|NCT03970993|Biological|R21 Matrix-M vaccination|Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly
45788972|NCT02201420|Drug|Tc 99m tilmanocept|
45788973|NCT02690181|Biological|GBS Trivalent Vaccine|Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 .
45788974|NCT01823861|Behavioral|Mobile phone-based intervention|Automated voice message to support post-abortion contraception use every two weeks for total of three months. Direct follow up phone call by family planning counsellor depending on response to voice message.
45788975|NCT02273063|Device|Transcranial Magnetic Stimulation (TMS)|Up to 40 sessions of TMS delivered with the first 35 sessions delivered over 7 weeks, and final 5 treatments delivered in taper schedule over 3 weeks. Treatment is adjunct to ongoing stable pharmacotherapy.
45788976|NCT05587257|Device|Fractional CO2 laser|"Each patient will receive 6 sessions 2 weeks apart, after the laser treatment, a topical 5% minoxidil tincture will immediately applied.~All patients will advised not to use any other treatment during the study"
45788977|NCT05587257|Device|Derma pen|, will be treated by microneedling using dermapen ( automated Derma Pen, DR Pen Ultima A6, China) which under complete aseptic precaution with a cartridge containing 12 needles moved diagonally, vertically, and horizontally for 4-5 times in each direction with 1.5 mm depth and speed 4-5(new cartridge every session), the application has been extended 1-2 cm perilesionally. The pinpoint bleeding will be considered an endpoint. topical 5% minoxidil tincture will immediately applied. Each patient will receive 6 sessions 2 weeks apart.
45788978|NCT05587257|Drug|Niosome minoxidil|The patient of alopecia areata will be treated by topical nanominoxidil preparation twice daily for 3 months with no other treatment.
45788979|NCT05587257|Drug|Minoxidil Topical Spray|The patient of alopecia areata will be treated by topical minoxidil 5% preparation twice daily for 3 months with no other treatment.
45788980|NCT05585463|Procedure|acupuncture|Acupuncture with needles and intracutaneous needles in the ear or body. The insertion is done with gloves, a guide to puncture the needle, and exhaustive skin disinfection.
45919796|NCT04941781|Drug|PIPE-307|"Each dose cohort will receive a single oral dose of PIPE-307. Doses to be tested in subsequent cohorts will be determined by the analysis of the exposure from PK data and the PET scans with [11C] PIPE-307.~Subjects will receive an intravenous dose of the radioligand [11C] PIPE-307 prior to PET imaging."
45449453|NCT03560960|Drug|Pramlintide challenge test|Enrolled subjects will have a pre-trial blood draw (3 ml) and will be placed with an IV needle for future blood draws. Pramlintide will be subcutaneously injected in the abdominal area. For each arm the participants will be randomized so that half will be given a dose of 0.8 mcg/kg and the other half of the arm a dose of 1.6 mcg/kg. Blood will be drawn before and at 5, 30, 60, and 180 min after injection. Vital signs and blood glucose will also be checked at these time points. Thirty minutes after the injection, subjects will be offered a standard meal. Subjects will have a final check of vital signs and blood glucose approximately 15 min before discharge.
45919797|NCT04899622|Behavioral|MBSR|Participants will attend weekly online classes (two hours duration) of MBSR for eight weeks. The classes will be delivered live online to groups of up to fifteen participants and will be led by Mindfulness instructors with MSc degrees in Mindfulness Based Interventions. The programme content will be based on the standard MBSR programme and is tailored towards key concerns and difficulties experienced by individuals with chronic pain.
45919798|NCT04899622|Behavioral|Exercise|"Participants will attend weekly classes of supervised classes (1 hour) for eight weeks, following the MBSR class. The exercise class will be delivered live online to the group by an experienced Physiotherapist and will consist of a range of flexibility and strengthening exercises which will be advanced every two weeks for the duration of the eight week programme. The exercises will also be available in video format on the mobile application Physitrack which each participant will be invited to download. This will allow the participants to review the exercises between sessions, record online if they have completed each exercise and in addition rate their pain experience while completing the exercises."
45449454|NCT01186640|Drug|Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab|"I. First treatment phase: Chemoimmunotherapy A-FMC~Alemtuzumab:~Cycle 1+2:~10 mg s.c., days 1-3~Cycle 3+4:~CR: 10 mg s.c., days 1-3 PR/SD: 30 mg s.c., days 1-3 Fludarabine: 20 mg/m2 i.v., days 1-3 Mitoxantrone: 6 mg/m2 i.v., day 1 Cyclophosphamide: 200 mg/m2 i.v., days 1-3 Repeat day 29, maximum 4 cycles. II. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c. The maintenance therapy will start one month after the Final Staging and will be administered monthly during the first six months plus once in month 10 and 13."
45449455|NCT01186640|Drug|Alemtuzumab|maintenance with Alemtuzumab following a induction with combined immunochemotherapy consisting of Fludarabine, cyclophosphamide, mitoxantrone and alemtuzumab
45645884|NCT03970993|Biological|R21 Matrix-M vaccination and CHMI|Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly. Volunteers then have the option to be challenged with malaria by mosquito bite
45645885|NCT03970993|Biological|R21 Matrix-M vaccination booster|Optional R21 Matrix-M vaccination booster following a three dose vaccination schedule
45645886|NCT04998695|Other|Olive pomace oil|Volunteers consumed during 4 weeks 45 g/d of olive pomace oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
45788981|NCT01825655|Drug|Cetirizine|
45788982|NCT01825655|Drug|Placebo or sugar pill|
45788983|NCT04272489|Device|EMG-Pattern Recognition Controller|Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device in a home trial.
45645887|NCT04998695|Other|Sunflower oil|Volunteers consumed during 4 weeks 45 g/d of sunflower oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
45645888|NCT03935971|Drug|Dupilumab|See arm/group description
45645889|NCT04998461|Biological|urine collection|To isolate urine stem cells, a sample of 30ml minimum an 100ml maximum as a function of the patient, will be collected in a single time in a sterile flask during collection for the nephrologic exams. A transcriptome analysis of USC will be performed.
45645890|NCT03111121|Drug|Sugammadex|receive reversal with sugammadex 4mg/kg
45645891|NCT03111121|Drug|neostigmine|receive reversal with neostigmine 0.04 mg/kg
45645892|NCT03111121|Drug|glycopyrrolate|receive reversal with glycopyrrolate (0.01 mg/kg)
45645893|NCT03073421|Other|Qualitative interview|This interview will be 2 hours in length and will be conducted with a Peer Research Assistant (PRA). The PRAs will be women living with HIV.
45645894|NCT04532359|Device|Implant placement|Implant placement
45788984|NCT02249663|Drug|Azelastine hydrochloride and Fluticasone propionate|137/50 mcg Nasal Spray
45788985|NCT02249663|Drug|Dymista™|137/50 mcg Nasal Spray
45788986|NCT02249663|Other|Placebo|Nasal spray with no pharmaceutically active content
45788987|NCT02692209|Device|FFDM Plus DBT|"FFDM + DBT Images~FujiFilm Aspire Cristalle System"
45788988|NCT02692209|Device|FFDM Alone|FFDM Alone Images
45788989|NCT04250727|Device|ZYN|30 current non-treatment seeking adult smokers will be switched from smoking cigarettes to ZYN oral nicotine pouches containing either 3mg or 6mg concentration nicotine salts.
45788990|NCT04237623|Drug|Sargramostim|250mcg/m2/day IV starting Day +5
45788991|NCT04237623|Other|Control Arm|Standard G-CSF given to those who decline to receive GM-CSF
45919799|NCT04899622|Behavioral|Online Self-Management Guide|Participants will receive standard evidence based self-guided information which they will access independently via the members area of the study website. This 'Online Self-Management Guide' will consist of eight categories of self-management; (1) What is chronic pain? (2) Chronic pain and nutrition (3) Sleep issues with chronic pain (4) Activity and exercise (5) Pacing (6) Using a pain diary (7) Relaxation and mindfulness and (8) Course summary. The information will be presented in the form of general text, links to online resources and videos. The information in this area will be updated biweekly during the eight week programme with the participants receiving bi-weekly email reminders.
45645895|NCT04998383|Device|HVNI|High velocity nasal insufflation (Fisher &Paykel, Auckland, New Zealan High-velocity nasal insufflation (Precision Flow;Vapotherm, Inc, Exeter, NH) (Figure 2) using a smallborenasal cannula was initiated with a flow rate set to 35 L/min, with a starting temperature between 35C and 37C and FiO2 at 1.0. Adjustments in flow (up to 40 L/min) and temperature (typically between 35C and 37C) were made to alleviate respiratory distress and optimize comfort.
45645896|NCT02328469|Drug|symptomatic therapy|patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline
45645897|NCT02328469|Drug|Ceftriaxone or Doxycycline|beside symptomatic therapy (metamizole, paracetamol, thiethylperazine, saline), patients with proven or probable Lyme neuroborreliosis will be treated with ceftriaxone 2 g intravenously once daily for 14 days OR doxycycline 100 mg orally twice daily for 14 days
45645898|NCT02328469|Other|questionnaire|Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms.
45645899|NCT02328469|Drug|Acyclovir|Patients will be treated with intravenous acyclovir 10 mg per kg three times daily for 14 to 21 days.
46071304|NCT02846246|Other|Person-centred and health-promoting home care service|Firstly, staff will take part in an educational program on the content and operationalization of the central theoretical components person-centeredness and health exploratory conversation. Secondly, staff will participate in supervised skill training in how to accomplish person-centered and health exploratory conversation. Thirdly, the staff will have a person-centred and health exploratory conversation with purpose to evaluate the extent to which current home care service practice meet the older person´s need and maintain or make rearrangement in provided care to maximise older people's health. Finally, staff will participate in clinical supervisory sessions with an aim to support and facilitate ongoing operationalization phase.
46071305|NCT02846246|Other|Care as usual|The control group will be offered a lecture about dementia based on staff wishes and a usual care paradigm will guide the control units, i.e. a continuation with practice as usual. Control units will receive the intervention protocol and study results at the end of the study.
46071306|NCT02548819|Other|MRI|MR imaging of patients with implanted cardiac devices
45645900|NCT03141853|Other|Equine-assisted Therapy|Participants will groom and ride horses. Horses will be kept at a walk with tasks such as serpentine, circles, and zig zags to complete. Stretching, and tasks like throwing a ball into a net from horseback will be completed
45645901|NCT03141853|Other|Arthritis Exercise Education|Standard of Care from the Arthritis Foundation - How-to Exercise With Arthritis. (n.d.). Retrieved April 18, 2016, from http://www.arthritis.org/living-with-arthritis/exercise/how-to). This intervention will consist of 6 -1 hour education sessions once a week on exercise to improve symptoms of arthritis
45645902|NCT03075371|Other|Glucose|75 g of glucose dissolved in 300 ml of water
45645903|NCT03075371|Other|Placebo|300 ml of tap water
45788992|NCT05583279|Behavioral|Dialetical Behavioral Therapy for Adolescents|DBT is an evidence-based treatment for individuals with complex clinical presentations, including borderline personality disorder (BPD), suicidality, and NSSI. Standard DBT (which includes individual therapy, skills group, between-session skills coaching, and peer consultation for therapists) is associated with symptom reductions in patients across a variety of domains, including BPD symptoms, SA, NSSI, hospitalizations, and social functioning. DBT focuses on teaching skills (e.g., emotion regulation) and facilitating the replacement of impulsive and/or ineffective behaviors (e.g., NSSI), with more effective/skillful behaviors.
45788993|NCT01825889|Drug|Evacetrapib|
45919800|NCT04856176|Drug|Granulocyte-Macrophage Colony-Stimulating Factor|250 mcg
45919801|NCT04856176|Drug|Pembrolizumab|200mg every 3 weeks
46071307|NCT02844530|Drug|90Y-epratuzumab tetraxetan|"The Primary objective is to compare the complete response rate (CR + CRp) after 2 injections of 370 MBq/m² of 90Y-epratuzumab tetraxetan RIT at day 1 and day 8 versus standard of care salvage chemotherapy regimens in adult CD22+ relapsed/refractory B-ALL.~A second RIT cycle (consolidation) will be allowed in the experimental group in case of response (CR or CRp).~From an ethical point of view, it will be also permitted to propose the RIT experimental treatment in the control group in case of treatment failure or relapse during the 6 months following inclusion. Follow-up will be also 12 months from the RIT for these patients"
45919802|NCT04856176|Drug|pemetrexed|500mg/m2
45919803|NCT04856176|Drug|Paclitaxel|200mg/m2
45919804|NCT04856176|Drug|Carboplatin|AUC 5/6
46071308|NCT02844530|Drug|chemotherapy/ immunotherapy|
46071309|NCT04242992|Behavioral|CETA|CETA is a modular, multi-problem, flexible psychotherapy approach that trains a lay provider in nine evidence-based CBT elements so providers can treat a variety of common problems, including violence, substance use, depression, anxiety, risky behaviors (sexual, non-adherence), and other trauma-related symptoms. Patients randomized to CETA will meet weekly with a lay provider or community health worker member of the study staff for about an hour once each week, approximately 6-12 times depending on presentation and symptom level. This treatment arm will include SMS reminders of their HIV care appointments, similar to the active control group.
46071310|NCT04242992|Other|Short Message Service (SMS) text reminders|Short Message Service (SMS) text reminders for upcoming appointments will be sent monthly.
46071311|NCT00820417|Drug|Cetuximab/Gefitinib combination and/or monotherapy|
46071312|NCT04224038|Other|The Inspire Bio-resource Research Platform for Healthy Aging|Several follow-up visits will be undertaken during the 10-year time frame of this project. Some of these visits are not regularly scheduled and will be conditioned by the remote monitoring of intrinsic capacity (IC) and the onset of other major clinical conditions. Other visits correspond to the regularly scheduled (yearly or every two years (biannual visits), depending on the outcome measures) waves of data collection.
46071313|NCT00820495|Behavioral|Web + Phone|Web + Phone
45449456|NCT03727503|Other|PPV from the capstesia|we will challenge the application by doing 2 maneuvers: the first one is to increase the PEEP level from 5 to 15 cmH2O and the second one is the infusion of a mini-fluid challenge (100 ml) followed by the other 400 ml.
45449457|NCT04949516|Drug|Aspirin|Aspirin is discontinued the day after drug-eluting stent implantation
45449458|NCT04949516|Drug|Colchicine|Colchicine is started the day after drug-eluting stent implantation
45645904|NCT04998071|Drug|Bupivacaine hydrochloride|Analgesic efficiency comparison between two concentration of bupivacaine hydrochloride using for posterior quadratus lumborum block in LPEC
45645905|NCT03734263|Drug|sodium phenylbutyrate|Enrolled subjects will receive a four-week period of treatment with sodium phenylbutyrate (oral use)
45645906|NCT03075293|Other|Determination of pain management|Determine of pain management given to children with appendicitis in ER according to their medical records
45645907|NCT03145051|Other|Saline solution|a nasal irrigation care
45449459|NCT00114959|Drug|Homoharringtonine|"Participants are administered homoharringtonine (omacetaxine) 2.5 mg/m^2 by continuous 24-hour intravenous (IV) infusion daily on Days 1-5 of each 4 week treatment cycle. Participants who do not achieve a meaningful hematologic or cytogenetic response by the end of the fourth cycle are discontinued from the study. Otherwise, participants may continue additional cycles of this combined treatment for a maximum of 12 cycles.~Participants who achieved a molecular or cytogenetic response, or a complete hematologic remission (CHR), could undergo subsequent cycles with a maintenance schedule of homoharringtonine 2.5 mg/m^2 by continuous 24-hour IV infusion daily for 2 days every 4 weeks. Dose escalations in subsequent cycles were allowed by one day at a time if the participant was unable to maintain CHR in the maintenance schedule."
45449460|NCT00114959|Drug|Imatinib Mesylate|Taken by mouth with a daily dose of 400 mg for participants in the chronic phase of chronic myeloid leukemia (CML) or 600 mg for participants in the accelerated or blast phase of CML. For the first cycle of therapy only, imatinib was started on Day 4 of homoharringtonine treatment.
45645908|NCT03145051|Other|Respimer Netiflow|a nasal irrigation care
45645909|NCT03075059|Behavioral|Child Life|For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
45788994|NCT02202746|Drug|Lucitanib|Lucitanib is a potent, orally available selective inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors (FGFR1-3), vascular endothelial growth factor receptors (VEGFR1-3), and platelet-derived growth factor receptors alpha and beta (PDGFR alpha and beta)
45645910|NCT03671473|Device|Extracorporeal shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.
45645911|NCT03073343|Dietary Supplement|Betaine (trimethyglycine)|Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.
45645912|NCT03075137|Device|External counter pulsation (ECP)|standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
45788995|NCT01826513|Device|Standard AutoSet algorithm|An AutoSet device with a standard algorithm developed for sleep breathing parameters that are specific to a particular gender.
45788996|NCT01826513|Device|Modified AutoSet algorithm|An AutoSet device with an algorithm developed for sleep breathing parameters specific to females.
45788997|NCT02692755|Drug|Palbociclib + Letrozole or Fulvestrant|Palbociclib x 21 days with a 7 day rest plus 2.5 mg Letrozole QD (no break) or Fulvestrant 500mg IM every 2 weeks for 3 doses and then every 4 weeks until progression or maximum of 12 months
45449461|NCT01079585|Dietary Supplement|Nutrigal Okara - 100|
45449462|NCT02778100|Drug|Nasal Glucagon|Administered intranasally.
45449463|NCT02778100|Drug|Oxymetazoline|Administered intranasally.
45788998|NCT01829399|Drug|Bupivacaine with Epinephrine|10-15 mL 0.25% Bupivicaine with epinephrine 1:200,000 subcutaneous axillary ring
45788999|NCT01829399|Drug|Normal Saline|
45789000|NCT01394510|Drug|N-acetylcysteine|600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.
45645913|NCT03074981|Device|Combined TopClosure & Vcare Alpha|"Combined TopClosure & Vcare Alpha Treatment. The investigators will debride the wound if necessary. Wound biopsies will be taken to determine the existing pathogens and direct the antibiotic treatment.~Wound measurements will be taken. Afterwards the wound will be approximated by the TopClosure device and the patient will be connected to a Negative Wound pressure device Vcare Alpha.~The investigators will change dressings according to schedule. If the wound is clean the investigators will change dressings every 3-5 days, If the wound is infected the investigators will change dressings every 2-4 days, If the investigators encounter a severe infected wound with a lot of pus the investigators will change dressings every 1-3 days, The investigators will determine the time to heal when the wound is clean and there is no further need for Negative Pressure Wound Treatment (ROI-NPT) up to 10 weeks."
45645914|NCT03340051|Behavioral|Episodic Future Thinking (EFT)|EFT participants will generate positive future events they are looking forward to and that could happen at different future time points (e.g., in 2 weeks, 1 month, 6 months, 1 year). Participants will be instructed to use and think about their episodic cues as they make decisions.
45645915|NCT03340051|Behavioral|Episodic Recent Thinking (ERT)|ERT participants will list positive recent events (events that have already happened) that they enjoyed that occurred at different past time points (e.g., 12 hours ago, 24 hours ago, a week ago). Participants will be instructed to use and think about their episodic cues as they make decisions.
45645916|NCT03073265|Device|STA-Apixaban Calibrator & Control|Measurement of apixaban level will be done using anti-Xa assay (IVD).
45645917|NCT03145129|Device|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure
45645918|NCT04438915|Behavioral|Effect of Obesity on incidence of Postoperative cognitive in Gynecological Day- Day- case surgery|The effect of obesity on the incidence of postoperative cognitive dysfunction in Gynecological day-case surgery
45645919|NCT04997837|Drug|PD-1 inhibitor|Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.
45645920|NCT04997837|Drug|Oxaliplatin|"CapeOx: 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~FOLFOX: 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off."
45645921|NCT04997837|Drug|Capecitabine|CapeOx: 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
45645922|NCT04997837|Drug|Tegafur-gimeracil-oteracil potassium|SOX: 40 - 60 mg bid orally in 14 days, followed by 7 days off
45645923|NCT04997837|Drug|5-FU|FOLFOX：2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W
45645924|NCT04997837|Radiation|Radiotherapy|1.8 Gy/Fx, 45-50.4 Gy
45645925|NCT04997837|Drug|Chemotherapy|Capecitabine 625mg/m2 bid orally with radiotherapy; ORegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy
45645926|NCT04299295|Device|YVOIRE Y-Solution 360|Hyaluronic acid dermal filler
45645927|NCT04299295|Device|Juvéderm VOLBELLA|Hyaluronic acid dermal filler
45645928|NCT04997603|Other|Accelerometer|Fitbit brand
45645929|NCT02328157|Device|Vitrectomy with cataract surgery and toric IOL|
45645930|NCT02328157|Device|Vitrectomy with cataract surgery and common IOL|
45645931|NCT02328313|Behavioral|Walk with Ease Program|The Walk With Ease Program sets a goal for participants to walk 30 minutes a day five times a week and gives helpful hints on how to achieve this goal.
45645932|NCT04997447|Behavioral|Step-reduction/Exercise Rehab|2-week limited daily steps (<2000), and then 4 weeks of typical strength+endurance exercise for older adults
45645933|NCT04202263|Drug|Minocycline Topical|Placement of minocycline cream 0%, 1%, 2% or 3% at one of four identical allergen skin test sites.
45645934|NCT04202263|Drug|Placebos|Placement of minocycline cream 0%
45645935|NCT04996979|Drug|Ropivacaine 0.5% Injectable Solution|Local anaesthetic solution composed of ropivacaine 0.5%(intervention group)
45645936|NCT04996979|Drug|Placebo|Standard care
45645937|NCT03145285|Drug|Abiraterone Acetate|"Cohort 1:~Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy will be treated with single agent AA.Mitotane and chemotherapy will be interrupted and AA will be continued till progression and/or until progression of Cushing's syndrome.~Cohort 2:~Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection will be treated with AA for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month (i.e. 2 or 3 weeks from Abiraterone start), then Mitotane +/- chemotherapy can be started upon the clinician's decision."
45645938|NCT04997291|Drug|Dexrazoxane|Twelve enrollees will be consecutively assigned to a dosing regimen of 400 mg/m2/dose. The medication will be administered in the operating room 30 minutes prior to starting cardiopulmonary bypass (dose #1), prior to aortic cross clamp removal (dose #2), and on the morning after surgery in the cardiac intensive care unit (dose #3).
45645939|NCT02328079|Drug|Steroids (Prednisolone) and Steroids plus Antiviral (Prednisolone + acyclovir)|Group allocations: Steroid group (prednisolone 60 mg /day IM /IV), Steroid plus Antiviral group (Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days) were placed in serially-numbered opaque closed envelopes. Each patient was placed in the appropriate group after opening the corresponding sealed envelope.
45645940|NCT04190641|Device|Ambu aScope 4 Cysto and aView Urologia|Visualization of the urethra and the bladder
45645941|NCT04992455|Other|Older Patients Receiving Chemotherapy|No Intervention
45645942|NCT03074903|Device|Intrauterine system|Women having the Skyla intrauterine system at different times during their menstrual cycle report their bleeding patterns through daily texts.
45653098|NCT05177757|Other|Yoga Intervention|The yoga exercise program will be conducted at the Marquette campus and will consist of one session per week for 12 weeks. The duration of each session will be approximately one hour. The program the investigators will use is the Mindful Resilience for Trauma Recovery Program (https://www.veteransyogaproject.org/), an evidence-informed practice adapted for veterans with PTSD based on clinical and neuroscientific knowledge. This program is a 12-week protocol developed by a licensed clinical psychologist and is publicly available. All yoga sessions will be standardized based on the resilience program guidelines.
45653099|NCT04410679|Biological|injectable PRF|blood sample and centrifuged to obtain i-PRF
45645943|NCT04992377|Drug|R-EPOCH in Combination With Ibrutinib|"Induction:~(21-day per cycle) Ibrutinib:420mg given orally , once daily.~Details of R-DA-EPOCH are as follows:~Rituximab: 375 mg/m2 given intravenously (IV) on day 0 Etoposide: 50 mg/m2 given CIV from day 1-4 Doxorubicin: 10 mg/m2 given CIV from day 1-4 Vincristine: 0.4 mg/m2 given CIV from day 1-4 Cyclophosphamide: 750 mg/m2/day IV on day 5 Prednisone: 60 mg/m2 given orally bid on days 1-5. Patients who achieve CR after 4 cycles enter the consolidation treatment ; Patients with PR after 4 cycles would receive another 2 cycles of R-EPOCH + ibrutinib induction therapy, they could enter the consolidation treatment if they achieve CR ,withdrawn from the study if they achieve ≤ PR; Patients with SD/PD after 4 cycles of treatment are withdrawn from the study.~Consolidation:~2 cycles of R-EPOCH + Ibrutinib (dose as before) treatment~Maintenance:~Ibrutinib 420 mg/day for 24 months or until disease progression or intolerable toxicity"
45645944|NCT02747329|Device|BuMA Supreme™ stent|
45645945|NCT02747329|Device|Xience V/Prime stent|
45645946|NCT04992533|Procedure|Long-duration tourniquet|Tourniquet is used in arthroscopic exploration and high tibial osteotomy
45645947|NCT04992533|Procedure|Short-duration tourniquet|Tourniquet is only used for arthroscopic exploration
45645948|NCT04997213|Other|Biofeedback exercises|Biofeedback system is a center of pressure-controlled video game-based exercise system designed for patients with neurological and orthopedic diseases and provides balance training using auditory, visual, and pressure biofeedback. The system contains several games, each designed to focus on a different component of balance. Biofeedback is provided by means of a monitor in front of the patient. The balance exercises program was involved a total of 18 sessions, each lasting 20 min, three times a week for six weeks, and was individually tailored based on the patient's tolerance and current motor and sensorial capacities. All patients performed conventional exercises.
45645949|NCT04997213|Other|Conventional Exercises|Classic balance exercises were performed (two-leg stance, semi-tandem stance, tandem stance, standing on one leg, tandem walking, turning completely around, heel-to-toe stance, and standing with the eyes closed). Patients with balance disorder first could be commenced balance training in a seated position before progressing to standing exercises, to the extent that these could be tolerable.
45645950|NCT02328001|Behavioral|Debriefing endoscopists of the procedure accessory costs|Informing endoscopists of the number of accessories used and the dollar value of the accessories
45645951|NCT04996745|Behavioral|Tablet-based educational intervention|"POSNA's Orthokids website and the article on pediatric forearm fracture will be provided on a tablet. The article provided has two separate tabs, labeled Condition and FAQs, that caregivers will be able to read through. Those who speak Spanish will have the Spanish translated version of Orthokids."
45645952|NCT02578069|Device|NOVA Intracranial Sirolimus Eluting Stent System|A sirolimus eluting intracranial stent system with polylactic-co-glycolic acid (PLGA) biodegradable drug carrier and electro-grated polybutyl methacrylate (PBMA) base coating. The stent platform is made of 316L stainless steel.
45645953|NCT02578069|Device|Apollo Intracranial Stent System|A 316L stainless steel balloon-expandable intracranial stent system
45645954|NCT03141775|Other|Treatment of CDI|Treatment (e.g. antibiotics, fecal microbiota transfer (FMT), probiotics) for patients with Clostridium difficile associated diarrhea
45645955|NCT03142087|Other|exercises|exercise
45645956|NCT03074825|Drug|Chiauranib|Take 50mg orally once daily
45645957|NCT02327767|Device|Resonating Arm Exerciser|Participants in the exercise group will exercise using the device for 8 exercise sessions for 45 minutes per session for 3 consecutive weeks.
45645958|NCT03074747|Diagnostic Test|questionnaires|After filled the questionnaires, the patients will receive the PSG monitoring
45645959|NCT03072485|Drug|Sirolimus|Topical sirolimus applied to the skin
45645960|NCT03072485|Drug|Metformin|Topical metformin applied to the skin
45645961|NCT03072485|Drug|Diclofenac|Topical diclofenac applied to the skin
45645962|NCT05080543|Drug|Albumin 20% and terlipressin|Evaluation the effect of adding 20% HSA and terlipressin on microvascular ﬂow index (MFI), flow heterogeneity index, total vessel density (TVD), and perfused vessel density (PVD) in comparison to the standard care in patient with septic shock.
45645963|NCT03144973|Diagnostic Test|periosafe|mouth rinsing quick-test
45645964|NCT03074591|Drug|Ferric Carboxymaltose 50Mg/Ml Inj 15Ml|After baseline assessments patients will be randomised in a 1:1 ratio to receive Ferric Carboxymaltose IV or placebo/saline (normal saline: 0.9% w/v NaCl). In the Treatment group, Ferric Carboxymaltose will be administered according to the dosing schedule.
45645965|NCT03074591|Drug|Saline Solution for Injection|In the placebo/saline group, patients will receive the aequivalent number of normal saline infusions.
45645966|NCT03143413|Other|Ultrasonography|"Patient will be enrolled in the rheumatology department of University hospital of Clermont-Ferrand (France).~Salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated."
45645967|NCT03074669|Behavioral|ACT program|ACT program consists of seven modules that have been adapted for the online environment. Each module is structured like a therapy session with at least two homework assignments.
45645968|NCT05080309|Dietary Supplement|carbohydrate oral intake|During labor the women will have free access to water and 20 ml commercial fruit juice bricks containing between 430 or 660 kcal/l. Every 2 hours the midwife or the nurse will measure the fruit juice oral intake volume and will advise women to drink the planned volume (1 brick/2hours)
45645969|NCT05080309|Other|free water only|Women will have free access to water only
45645970|NCT04991675|Behavioral|pelvic floor muscle exercises|During the first visit, the anatomy of the pelvic floor and the purpose of the program were explained. Exercises were taught in the supine position, as described by Kegel (1948), it was confirmed that the women learned to use the correct muscles with vaginal palpation. During the exercise, the participants were informed not to pull the abdomen inwards, not to tighten their legs and hip muscles, and not move their pelvis.
45789001|NCT05580549|Diagnostic Test|Alcohol biomarker Phosphatidylethanol (PEth)|The prevalence of hazardous alcohol use will be mapped through the biomarker PEth and the questionnaire AUDIT.
45789002|NCT01396226|Drug|AZD2927|A single dose of AZD2927 administered as an iv infusion
45789003|NCT01396226|Drug|Placebo|A single dose of placebo administered as an iv infusion
45789004|NCT05327621|Drug|Pamiparib|40 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.
45789005|NCT05327387|Other|model-based electrical brain stimulation|Electrical pulse train stimulation delivered to medication refractory epilepsy patients with electrodes already implanted based on clinical criteria for standard monitoring unrelated to this study. The delivery of the electrical brain stimulation can be guided by neural biomarkers of symptom levels computed from ongoing neural activity and by input-output models of neural response to stimulation therapy. The parameters of electrical stimulation will be constrained to be within clinically safe ranges.
45645971|NCT04991675|Behavioral|diaphragmatic breathing exercises|During the first visit, the anatomy of the diaphragm and abdominal wall and the purpose of the program were explained. Diaphragmatic breathing exercise was taught in supine position. The movement of the symphysis pubis was examined to confirm that the pelvic floors' movement was also involved breathing. Abdominal palpation was used to elicit unawareness of the diaphragmatic breathing and to assess whether contractions were performed correctly.
45645972|NCT05080153|Dietary Supplement|Ocufolin forte|start of ocufolin forte 1 dd after RVP measurement, till 90 tablets are finished (3 months)
45645973|NCT04991909|Drug|HRS4800|HRS4800
45789006|NCT02694315|Other|Bishop score|calculation of modified Bishop score in numbers by digital vaginal examination
45789007|NCT02694315|Other|cervical length|measuring cervical length by trans-vaginal ultrasound
45789008|NCT01396382|Radiation|68Ga-DOTATATE PET scan|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography (PET). Efficacy of the 68Ga-DOTATATE PET scan was assessed and compared to 111In-Pentetreotide scan and to scans with CT and/or MRI. Safety and toxicity were also assessed with pre-injection and post-imaging vital signs, pulse oximetry on room air, 12 lead ECGs, and blood laboratory tests, including tumor markers, liver and renal functions and blood counts, and direct patient questioning. Late delayed tumor markers, liver and renal functions and blood counts were assessed when available.
45789009|NCT05327309|Drug|Bleomycin|
45789010|NCT00367731|Drug|Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI)|
45789011|NCT05326841|Drug|Vitamin D3|cholecalciferol tablet, the dose is 5000 international unit /day for 12 weeks
45789012|NCT05326763|Drug|Platelet Rich Plasma|Preparing 2 mL of PRP with concentration of 4-6 times the average normal values, 20mL of blood will be first collected from the patient's upper limb cubital vein using an 18G needle. A local subcutaneous anesthesia (2 ml of 1% lidocaine) will be finished by the orthopedist.
45919805|NCT05054790|Biological|"Neo-Bladder Construct"|Subjects will undergo an open full thickness bladder biopsy from which autologous urinary bladder smooth muscle and urothelial cells will be procured and expanded ex vivo. After approximately 5 - 7 weeks, expanded cells will be seeded on a biodegradable scaffold to produce the neo-bladder construct that will be surgically implanted onto an opened native bladder during an augmentation cystoplasty.
45645974|NCT04991909|Drug|Placebo|Placebo
45645975|NCT05079997|Device|MAGNETIC RESONANCE IMAGING|s a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body. MRI scanners use strong magnetic fields, magnetic field gradients, and radio waves to generate images of the organs in the body. MRI does not involve X-rays or the use of ionizing radiation, which distinguishes it from CT and PET scans. MRI is a medical application of nuclear magnetic resonance (NMR) which can also be used for imaging in other NMR applications, such as NMR spectroscopy.
45653100|NCT04788407|Drug|Nitazoxanide|Subjects will receive nitazoxanide 500 mg TID for 7 days
45789013|NCT05326763|Drug|Dextrose 50%|The group will use 4 ml of PRP + 4 ml of 0.9% saline -h 2 ml of 1% lidocaine (10-ml syringe).
45789014|NCT01412372|Drug|Mesalamine|2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo
45789015|NCT01412372|Drug|Placebo|This is an inactive pill
45789016|NCT05748275|Diagnostic Test|Argos|Biometry measurements first with the Argos device, then the IOLMaster 700 device.
45789017|NCT05748275|Diagnostic Test|IOLMaster 700|Biometry measurements first with the IOLMaster 700 device, then the Argos device.
45789018|NCT01412918|Device|The Inhibitor™ Tinnitus Masking Device|The Inhibitor™ Tinnitus Masking Device
45789019|NCT02989415|Other|Mechanical Ventilation|Mechanical ventilation during robotic surgery
45789020|NCT01414010|Dietary Supplement|Trametes versicolor extract|1,200 mg, 3 times daily on an empty stomach for 14 days
45789021|NCT01414010|Dietary Supplement|Saccharomyces boulardii|250 mg, 3 times daily on an empty stomach for 14 days
45789022|NCT01414010|Drug|Amoxicillin|250 mg 3 times daily at least 1 hour before meals for 7 days
45789023|NCT01414244|Drug|Glutamine|Drug
45789024|NCT01832753|Drug|Levothyroxine|
45789025|NCT05311397|Drug|A166|A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.
45789026|NCT05280041|Behavioral|SOLENA - Online self-help program for older adults who lost the partner|SOLENA follows the most relevant CBT elements of interventions for prolonged grief: 1) Exposure, e.g., telling the story of the loss; 2) cognitive reappraisal or restructuring of individual dysfunctional thoughts associated with the loss; 3) integration and restoration including self-care and social reengagement; and 4) behavioural activation. SOLENA's content is provided through a conversational virtual agent, Sol, who guides the user through the Study section the CBT intervention itself. In 10 study modules that address either the acceptance of the loss or the restoration and adaptation to a new life, SOLENA includes 1) readings, i.e., texts based about grief related topics that provide the background and rational for the module; and 2) exercises to encourage mourners to actively reflect on their grief and apply their new knowledge to their daily life and to practise the new routines regularly. SOLENA also provides users with the Notebook, Activities, and My Support sections.
45919806|NCT02632760|Drug|Ferric carboxymaltose|treatment for Iron deficient anaemia
45919807|NCT02632760|Drug|Placebo|placebo - no active drug
45919808|NCT04824859|Behavioral|Behavioral|eGAP that allows patients to complete validated questionnaires, and these questionnaires will be summarized and recommendations provided to the treating team
46071314|NCT00820495|Behavioral|Web Only|Web Only
46071315|NCT00820495|Behavioral|Phone Only|Phone Only
46071316|NCT00820495|Behavioral|Usual Care|Usual Care
45789027|NCT01414634|Biological|ETIMS|injection of peptide-coupled PBMC by i.v. infusion
45789028|NCT05748119|Drug|MEB-1170|Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both
45789029|NCT05748119|Drug|Placebo|Equivalent number and size of capsules containing placebo
45919809|NCT04810195|Device|Boston Scientific Acurate neo2 TAVR device|The newest generation of the Acurate neo2 TAVR device, launched in Europe in 2020.
46071317|NCT04923854|Other|No intervention|No intervention
46071318|NCT04923620|Drug|cetuximab+mFOLFOX6|cetuximab 500mg/m2 d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles
45645976|NCT04996433|Behavioral|inpatient CBASP individual therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 individual CBASP therapy sessions (duration: 50 min per session).
45645977|NCT04996433|Behavioral|inpatient CBASP group therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 CBASP group therapy sessions (duration: 100 min per session).
45645978|NCT04996433|Behavioral|inpatient CBASP nurse contact|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 CBASP nurse contact (duration: 30 min per session).
45645979|NCT04996433|Behavioral|inpatient CBASP exercise therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 CBASP exercise therapy (duration: 75 min per session).
45645980|NCT04996433|Behavioral|outpatient CBASP group therapy|During the 6-week outpatient treatment all patients in this arm will receive 1 CBASP group therapy session (duration: 100 min per session).
45645981|NCT04996433|Behavioral|inpatient BA individual therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 individual BA therapy sessions (duration: 50 min per session).
45645982|NCT04996433|Behavioral|inpatient BA group therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 BA group therapy sessions (duration: 100 min per session).
45645983|NCT04996433|Behavioral|inpatient BA nurse contact|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 BA nurse contact (duration: 30 min per session)
45645984|NCT04996433|Behavioral|inpatient BA exercise therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 BA exercise therapy (duration: 75 min per session).
45645985|NCT04996433|Behavioral|outpatient BA group therapy|During the 6-week outpatient treatment all patients in this arm will receive 1 BA group therapy session (duration: 100 min per session).
45645986|NCT04996433|Drug|algorithm-based study medication|"All patients will receive an optimized, algorithm-based antidepressant medication following the current S3-Guidelines on Unipolar Depression. In case of nonresponse:~1st line dose escalation (if appropriate)~2nd line lithium augmentation~3rd line augmentation with 2nd generation antipsychotics or evidence-based combinations of antidepressants~4th line change of antidepressant."
45645987|NCT04082377|Procedure|Recruitment maneuver with tidal volume (RM TV)|"The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, inspiratory-to-expiratory (I:E) ratio at 1:2, and respiratory rate (RR) set to normocapnia (end-tidal CO2 partial pressure between 35 and 40mmHg, TV 6 mL/kg PBW and 5 cmH2O PEEP.~RMs were conducted under volume controlled ventilation with initial settings of a limit of peak inspiratory pressure at 40cmH2O, TV at 6 mL/kg PBW (PBW = 50.0+0.905*((height in cm)-152.4) for men, and = 45.5+0.905*((height in cm)-152.4) for women) Brower, et al. 1999, RR at 7 breaths/min, PEEP at5 cmH2O, and I:E ratio at1:1. The TV was then increased by steps of 4 mL/kg PBW until plateau airway pressure (Pplt) was 40 cmH2O, after which 3 breaths were allowed. Finally, the limit of peak inspiratory pressure, TV, RR, and I:E ratio were reset at values equal to those preceding the RM."
45645988|NCT04082377|Procedure|Recruitment maneuver by PEEP (RM PEEP)|The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, in RMs was conducted under pressure controlled ventilation so ventilation technique will be changed, pressure-control mode will be started and inspiratory time is increased to 50% (inspiratory: expiratory ratio will be set to 1:1). Peak airway inspiratory pressure (Ppeak) will be initially set to 20 cmH2O for three breaths, and then PEEP will be increased in steps from 5 to10 cmH2O for five breaths, from 10 to 15 cmH2O for seven breaths, from 15 to 20 cmH2O for ten breaths while Ppeak increased to 40 cmH2O and will be maintained for three more breaths. Following ARM, volume control will be re-established using Vt 6 mL/kg and step-wise reductions in PEEP from 20 to 15 cmH2O for three breaths,and then to 5 cmH2O until the end of recruitment maneuver
45645989|NCT04073875|Diagnostic Test|18F-GP1|18F-GP1 PET-CT scan
45645990|NCT04996511|Device|PulseOn|Postoperative HRV measurement
45919810|NCT02505074|Procedure|Valve replacement with the Melody valve|This study will only review patients who have had the Melody valve surgically inserted into the Mitral and/or Tricuspid positions. We will not be reviewing any other intervention type.
46071319|NCT04923620|Radiation|short-course radiotherapy|25Gy/5Fx short-course radiotherapy between the forth and the fifth cycle of cetuximab+mFOLFOX6
45645991|NCT03144739|Other|Training in management of children's mental health problems|"General practitioners will be trained using internationally-developed materials, including the World Health Organization's mental health need/service gap (mhGAP) materials and others, adapted for the trial setting (based on formative work that is part of the project). They will be assisted and monitored as part of the ongoing collaborative care program in which they are participating."
45645992|NCT03144739|Other|Current collaborative care protocol|General practitioners have been trained to recognize children's mental health problems and to refer them to a partner community mental health center. They receive feedback about the referral but are not encouraged to take on care for the child themselves.
45919811|NCT04802434|Behavioral|Strengthening Skills Program|The Strengthening Skills Program is a new, multi-component intervention. It includes three components: (1) Forming habits to compensate for the difficulties many adults with ASD have with thinking flexibly, planning, and time management. It will emphasize habit-forming behaviors to compensate for weaknesses in functional skills by training on practical techniques; (2) Content from the PEERS Social Skills program to target social challenges, and (3) strategies derived from Mindfulness Based Stress Reduction to target emotion regulation.
45919812|NCT04802434|Behavioral|PEERS Social Skills Program|PEERS® is a well-established social communication training program, initially developed for adolescents, and more recently extended to young adults with ASD. Program content will be adapted slightly so as to be appropriate for older adults.
45645993|NCT03072407|Biological|PB-119 injection|
45789030|NCT03008564|Other|Ultrasound scanning of the lower limb in volunteers|"Several reference points will be marked by anatomical landmarks and/or ultrasound: the anterior superior iliac spine; base of patella; apex of the femoral triangle A measuring tape will be used to measure the anterior superior iliac spine (landmark); the base of the patella (landmark); apex of femoral triangle (ultrasound); and distal most portion of adductor canal (Point B described earlier; ultrasound). We will then measure the ASIS to: 1) base of patella; 2) apex of femoral triangle; and 3) Point B. We will repeat the same procedure on the opposite leg. Once complete, the volunteer will be allowed to dress and leave. The procedure should take approximately 10-20 minutes for each volunteer. The following things will be recorded for each subject:~Age~Gender~Weight~Height~BMI~Distance of ASIS to base of patella~Distance of Point A to base of patella~Distance of Point B to base of patella~Distance of apex of femoral triangle to base of patella"
45789031|NCT02696967|Drug|CLR325|CLR325 Concentrate for solution for infusion
45789032|NCT02696967|Other|Placebo|Normal saline
45789033|NCT01415960|Drug|Leuprolide acetate 22.5 mg depot, GP-Pharm SA|Administered by im injection, twice during the study, three months apart
45789034|NCT01833845|Drug|Ribavirin|weight-based doses (1000 mg/day administered BID [twice daily] for subjects ≤ 75 kg and 1200 mg/day administered BID for subjects > 75 kg). Those subjects receiving 1000 mg/day RBV will take 2 tablets of 200 mg/tablet in the morning and 3 tablets in the evening, and those subjects receiving 1200 mg/day RBV will take 3 tablets morning and evening.
45789035|NCT01833845|Drug|Hydroxychloroquine|subjects will receive HCQ 575 mg administered as a single tablet once daily (QD)
45789036|NCT01416194|Drug|Bazedoxifene|Patients receiving Bazedoxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
45789037|NCT01416194|Drug|Bisphosphonate|Patients receiving Bisphosphonates in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
45789038|NCT01416194|Drug|Raloxifene|Patients receiving Raloxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
45919813|NCT04732507|Combination Product|1% plain lidocaine and 0.25% plain bupivacaine|A 5- or 10-ml syringe will be filled equally with 1% plain lidocaine and 0.25% plain bupivacaine. A 1.5-inch 25-gauge needle will be attached to the syringe. The needle will be carefully inserted at the first trigger point and 2 mls of the mixed local anesthetic will be infiltrated. At that point, the needle will be carefully inserted into the trigger point based on the group assigned. Once needling is done for the first trigger point, the process will be repeated in exactly the same fashion for the remaining points.
45789039|NCT01416584|Behavioral|methadone contingency|Participants had to enroll in methadone treatment and take daily doses of methadone to gain access to the workplace.
45789040|NCT01416584|Behavioral|Methadone & Abstinence Contingency|Participants had to enroll in methadone treatment and take daily doses of methadone to gain access to the workplace and they had to provide opiate and cocaine negative urine samples to maintain the maximum pay.
45789041|NCT02698215|Drug|Varenicline|Varenicline 1 mg twice daily
45789042|NCT02698215|Drug|Varenicline plus Naltrexone|Varenicline 1 mg twice daily plus Naltrexone 50 mg once daily
45789043|NCT05506605|Drug|Doravirine 100Mg Tab|Switch from Etravirine to Doravirine
45789044|NCT04172961|Drug|nanomicellular cyclosporine 0.09%|topical ophthalmic drop prior to elective surgery for eligible patients
45597785|NCT04467385|Other|VR training + Sensory Integration therapy + conventional therapy|"After the baseline assessment,~Coconut ShootersVR - 5 min/day~Ninja flipVR - 5 min/day.~Sensory integration training include Exercises on BOSU ball and mini-trampoline. It will involve:~Passive bouncing with child standing with his/her feet shoulder width apart for 2.5 and 2.5 minutes on both.~Active bouncing (the child bounces and therapist will control the rate) for 2.5 and 2.5 minutes on both.~Mini-squat exercises with feet apart and feet together for 2.5 and 2.5 minutes on both.~Conventional exercises include:~passive stretching exercises for the hip flexors, hip adductors, hamstring, and calf muscle; stretching will be applied for 30 sec with 30 sec rest for each muscle group within pain limit.~Strengthening of abdominal and back muscles, hip abductions and knee joint extensors and ankle dorsiflexors will be performed."
45645994|NCT03072407|Biological|PB-119 injection placebo|
45645995|NCT03144895|Procedure|Laying a radial or femoral arterial catheter|Laying a radial or femoral arterial catheter
45645996|NCT03144661|Drug|INCB062079|In Part 1, initial cohort dose of INCB062079 at the protocol-defined starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended dose(s) from Part 1 will be taken forward into Part 2 cohorts.
45653101|NCT04788407|Drug|Placebo|Subjects will receive placebo TID for 7 days
45653102|NCT05119335|Drug|Oral NKT2152|Oral HIF2α inhibitor
45653103|NCT03066427|Drug|Sunitinib|Sunitinib 50 mg/d
45653104|NCT04788485|Drug|Diosmectite|use of diosmectite as a food thickener in neonates in with gastroesophageal reflux in noenates
45789045|NCT04172961|Drug|Lifitegrast|topical ophthalmic drop prior to elective surgery for eligible patients
45789046|NCT01480232|Drug|EVP-6124|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
45789047|NCT01480232|Drug|Placebo Capsule|One placebo capsule ingested orally daily for 12 weeks (84 days)
45789048|NCT01480232|Drug|NicoDerm Patch (Active)|One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
45789049|NCT01480232|Drug|NRT Patch (Placebo)|One NRT patch (Placebo) daily for first 6 weeks (42 days).
45789050|NCT01480232|Behavioral|Brief Supportive and Behavioral Treatment|Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.
45789051|NCT04049799|Other|Medically-supervised withdrawal|6-8 day withdrawal with buprenorphine/naloxone
45789052|NCT04049799|Other|Opioid agonist treatment|Induction and maintenance with buprenorphine/naloxone
45789053|NCT04049799|Behavioral|Comprehensive clinical care|Obstetrical visits, counseling, case management, psychiatry services, and urine drug screening
45789054|NCT02700165|Device|The ZELTIQ CoolSculpting System|The CoolSculpting device will be used to perform the treatments.
45789055|NCT01481558|Device|Transcranial direct current stimulation|tDCS 2 mA, dorsolateral pre-frontal cortex
45645997|NCT04991441|Dietary Supplement|Controlled Dietary Sodium Restriction|Participants will be provided with 2 meals and snacks daily, for 30 days (days 1-30) and 1 meal and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg & 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (<2,000g/day) and will be ordered and delivered through momsmeals.com
45645998|NCT04991441|Dietary Supplement|Control Diet & Controlled Dietary Sodium Restriction|Participants will follow a Observational Control Diet (CON) diet (Months 1-5) followed by an Controlled Dietary Sodium Restriction (INT) diet (Months 6-7).
45645999|NCT03111433|Dietary Supplement|Coenzyme Q10|Coenzyme Q10 soft gelatin capsule 100mg
45646000|NCT03111433|Drug|Insulin|multiple dose insulin injection therapy
45646001|NCT04915313|Device|Remote ischemic conditioning (RIC)|RIC is a non-invasive therapy which is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol include five cycles of 5-min inflation to 200mmHg and 5-min deflation.
45646002|NCT04915313|Device|Sham remote ischemic conditioning (Sham-RIC)|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
45646003|NCT03143023|Drug|arginine toothpaste|acid neutralizer toothpaste
45646004|NCT03143023|Drug|fluoride toothpaste|bactericidal toothpaste
45646005|NCT04914455|Diagnostic Test|Echocardiography and transhepatic inferior vena cava assessment using ultrasound.|"For all participant :~Inferior vena cava diameter will be measure before and after fluid expansion 'which administration will be decided by a physician other that the investigator).~Stroke volume using primarily VTI in TTE or a cardiac output monitoring device (Swan ganz catheter (Edwards life science), EV 1000 (edwards life science), PiCCO(Getinge))~Absence of significant pericardial effusion of hematoma~Whenever possible:~Subcostal measurement of IVC, ejection fraction, cardiac outcput, mitral E, A and E' waves, TAPSE, tricupid S' wave, Right ventricle fractional area change.~venous congestion assesment : hepatic vein, portal vein and renal vein Doppler to define the VEXUS Score;"
45646006|NCT05079529|Drug|β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma Lucidum Group|Takes β-1,3/1,6-D-Glucan capsule 3 times daily for 90 days
45646007|NCT05079529|Drug|Placebo Group|Takes placebo capsule 3 times daily for 90 days
45646008|NCT03074435|Device|Insecticidal paint|Houses will be painted with insecticidal paint
45646009|NCT03074435|Device|Larvicide|Larval breeding sites will be treated with larvicide
45646010|NCT03074435|Biological|Ivermectin|Doses of Ivermectin will be injected to peri-domestic animals
45646011|NCT03074435|Behavioral|IEC|A reinforced information, education and communication strategy will be implemented.
45646012|NCT03142945|Other|Traditional Physical Therapy|Physical therapy-based interventions
45646013|NCT03142945|Other|MDT based physical therapy|MDT based physical therapy
45646014|NCT04996277|Procedure|angiography|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
45646015|NCT04996277|Procedure|Thrombus suction|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
45646016|NCT04996277|Procedure|Fibrinolytic therapy|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
45646017|NCT04996277|Behavioral|Medication stabilized the condition|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
45646018|NCT03111199|Other|Cryotherpy|Cryotherapy will be used by means of ice packs over a painful region. The ice will be crushed inside a bag so that it is in an ideal size that provides a coupling in a painful column in the lumbar spine; Once it has been inserted in the plastic bag and before closing it all the air must be removed to avoid a faster thawing of the ice and have difficulties of coupling.
45646019|NCT03111199|Other|TENS Burst|The TENS Burst therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be at the maximum amplitude To generate visible muscle contraction without generating pain / discomfort. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
45646020|NCT03111199|Other|TENS Burst Placebo|The TENS Burst placebo therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be on but without Produce the effects of visible muscle contractions because the channel will not be properly coupled in the apparatus so that the stimulation does not reach the patient. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
45653105|NCT05118087|Procedure|Webril Padded Plaster Splint|Patients in the coaptation splint group will have a webril padded plaster splint that is placed around the humerus. The forearm and wrist are then suspended in a cuff and collar.
45919814|NCT05047770|Biological|HZ/su|2 doses of HZ/su vaccine administered intramuscularly, either sequentially (HZ/suSeq Group) or simultaneously (HZ/suCoAd Group) with the mRNA-1273 booster dose. The second dose of HZ/su is administered 8 weeks after the first dose of HZ/su vaccine.
46071320|NCT00828919|Drug|axitinib|BID oral tablets. dose of axitinib (AG 013736) will be the same as they were taking in the previous trial
45789056|NCT01420016|Other|Prioritized Clinical Decision Support|Eighteen primary care clinics were blocked on size and on patient characteristics. Each clinic was randomly assigned to one of 2 study arms. All consenting PCPs were allocated to the study arm that their clinic was assigned to and the estimated 400 eligible adults with 10-year CVR >= 10% under the care of each consenting physician were allocated to the same treatment arm as their PCP.
45789057|NCT02701101|Device|Use of SEM200 Scanner daily|From enrollment to exit,daily SEM Scanner readings collected on Sacrum and Heels
45919815|NCT05047770|Combination Product|Flu D-QIV|1 dose of Flu D-QIV vaccine administered intramuscularly, either sequentially (FluD-QIVSeq Group) or simultaneously (FluD-QIVCoAd Group) with the mRNA-1273 booster dose.
45597786|NCT04467385|Other|VR training + conventional therapy|"After the baseline assessment,~The Your Shape: Fitness Evolved 2012TM game is selected for VR training (walking and walking with obstacles) for 8 min~Coconut ShootersVR - 8 min/day~Ninja flipVR - 8 min/day~Conventional Therapy - 20 min per day~Passive stretching exercises for the hip flexors, hip adductors, hamstring, and calf muscle; stretching will be applied for 30 sec with 30 sec rest 3-5 times for each muscle group within pain limit.~Strengthening of abdominal and back muscles, hip abductions and knee joint extensors and ankle dorsiflexors will be performed."
45597787|NCT02295280|Drug|Metoclopramide|IV
45646021|NCT03111199|Other|Education|After the electrophysical intervention, a moment of education and awareness will be held, in which the participants will receive information about the purpose of the treatment; Anatomy and biomechanics of the lumbar spine; Chronic non-specific back pain; Cognitive, emotional, genetic, social, and lifestyle factors; Intrinsic and extrinsic physical factors, biopsychosocial model: beliefs of pain and hypervigilance; Concepts of joint protection; Energy conservation and general guidelines.
45646022|NCT03833089|Combination Product|Targeted serum potassium level|In the following order, following advices end prescriptions will be provided: 1) Potassium rich dietary advice, 2) Potassium supplementation, 3) mineralocorticoid receptor antagonists,
45646023|NCT03071939|Other|Assessment of the insight of schizophrenic patients by themselves, their relatives and caregivers|"This study will evaluate the insight of the patient, something carried out in common practice within the Eastern Pole (CH Le Vinatier). This assessment will take place in the specific services where patients are cared for. It will make it possible to evaluate insight more closely by comparing the opinions of the three actors. There is no risk in this study.~The study will be carried out over 2 years with a recruitment of 119 patients responding to the diagnosis of schizophrenia, taken care of within the Eastern Pole (Intra and Extrahospital services)."
45646024|NCT03142789|Drug|Initial bolus (Certa and standard catheter groups)|10 ml of ropivacaine 0,75% will be used to ensure correct position of the needle and to expand the adductor canal, followed by injection of another 10 ml of ropivacaine 0.75% via the catheter during real time US imaging to ensure correct placement of the catheter.
45646025|NCT03142789|Drug|Initial bolus (Single bolus group)|20 ml of ropivacaine 0.75%
45646026|NCT03142789|Drug|Intermittent boluses (Certa and standard catheter groups)|20 ml of ropivacaine 0.2% every 8 hour in the catheter
45646027|NCT03142789|Drug|Intermittent boluses (Single bolus group)|0.1ml of ropivacaine 0.2% every 8 hour in the sham catheter
45646028|NCT04996355|Other|comprehensive treatment after MDT discussion|"The comprehensive treatment plan was determined through MDT discussion, which was completed by the Department of Gastrointestinal Surgery, Peking University People's Hospital.~The following regimens will be tested with organoids-on-a-chip：~5-FU~Oxaliplatin~Irinotecan~5-FU+ Oxaliplatin~5-FU+ Irinotecan~5-FU+ Oxaliplatin+ Irinotecan~5-FU+Cetuximab~Cetuximab~Regorafenib"
45646029|NCT03072329|Procedure|Pudendal nerve block|
45646030|NCT03072329|Drug|Bupivacaine|
45646031|NCT02327689|Drug|Emtricitabine plus adefovir dipivoxil|emtricitabine plus adefovir dipivoxil were given to each patients for 96 weeks
45646032|NCT03142711|Other|No Medical Intervention|Validation of phone ePRO
45646033|NCT03141697|Device|Carbon Dioxide|Insufflation of Carbon Dioxide
45646034|NCT03141697|Device|Room air|Insufflation of room air
45789058|NCT02701101|Other|Assessment and treatment of Pressure Ulcers using SOC|Nurse review of Skin risk and skin assessment, notes in chart to assess the frequency to turn patient, use of a specialist bed to prevent or treat early pressure ulcers
45789059|NCT01398566|Behavioral|SuperBetter play|average 10 min of game play per day for 6 week period
45789060|NCT05477979|Other|Gut microbiota detection|The baseline fetal is collected and assessed by 16S rRNA sequencing
45789061|NCT05477979|Other|Peripheral immune cells signature detaction|The baseline peripheral venous blood is collected and assessed by flow cytometry, including T lymphocytes, B lymphocytes, NK lymphocytes, macrophagocyte, and DC cells
45919816|NCT05047770|Biological|mRNA-1273|1 booster dose of mRNA-1273 vaccine administered intramuscularly at Day 1 (all groups).
45919817|NCT02453984|Other|89Zr-MPDL-3280A-PET scans|89Zr-MPDL3280A tracer injection and 89Zr-MPDL-3280A-PET scans
45919818|NCT05029362|Behavioral|SmokefreeSGM|Participants will have access to a text-based smoking cessation program tailored to sexual minority individuals (SmokefreeSGM). The text-based program will be beta-tested by these participants for a period of 2 weeks before and 10 weeks after their quit date. Messages originated from the text-based smoking cessation program will be sent by a fictitious quit coach who will offer evidence-based advice on quitting smoking based on real-life experiences of sexual minority individuals.
45919819|NCT04599478|Drug|Naltrexone and Bupropion medication|NB medication will be taken daily in pill form.
45919820|NCT04599478|Behavioral|Behavioral Weight Loss|Behavioral Weight Loss (BWL) counseling includes weekly sessions.
45919821|NCT04599478|Other|Placebo|Placebo will be inactive and taken daily in pill form.
45919822|NCT04574245|Procedure|Gastrectomy; Hepatectomy|
45597788|NCT02295280|Drug|Diphenhydramine|iv
45597789|NCT02295280|Drug|Codeine|PO
45597790|NCT05263505|Drug|Baricitinib 2 MG [Olumiant]|Two tabs daily
45597791|NCT05263505|Drug|Methotrexate|Target dose: 20mg weekly
45597792|NCT05263505|Drug|Azathioprine|Target dose: 2mg/kg daily
45597793|NCT05263505|Drug|Mycophenolate|Target Dose: 1g twice daily
45646035|NCT03072017|Behavioral|MBAT|Breathing-based intervention
45646036|NCT02327923|Drug|Lidocaine|Lidocaine intravenous 1.5mg/kg IV bolus at the time of induction followed by IV infusion @ 1.5 mg/kg/hr till the last suture.
45919823|NCT04556617|Drug|PLX2853|PLX2853 tablets
45646037|NCT02327923|Drug|Esmolol|Esmolol intravenous bolus 0.5 mg/kg at the time of induction followed by infusion @ 5-15 microgram/kg/min till the last suture.
45789062|NCT01399268|Drug|Hydrocortisone|Prepared by pharmacy, 100 mg, IV, every 8 hours, 3 times
45789063|NCT01399268|Drug|Saline|Prepared by pharmacy same volume as study drug, IV, every 8 hours 3 times
45789064|NCT05459493|Drug|TJAOA101|Once enrolled, participants will be administrated TJAOA101
45789065|NCT05437575|Drug|Ketamine Hydrochloride|ketamine hydrochloride 2.5mg/ml packaged in pre-filled syringe
45646038|NCT02327923|Drug|Paracetamol|Inj. Paracetamol 1 gm IV at the time of induction
45789066|NCT05437575|Drug|Fentanyl Citrate|fentanyl citrate 10mcg/ml packaged in pre-filled syringe
45789067|NCT03008876|Drug|Acetaminophen|infants receive acetaminophen for treatment of their PDA
45789068|NCT03008876|Drug|Ibuprofen|infants receive ibuprofen, standard of care in our unit, for treatment of a PDA
45789069|NCT05414487|Drug|Ofatumumab|There is no treatment allocation. Patients with MS or NMOSD administered Ofatumumab by prescription will be enrolled. Participants will receive 20mg ofatumumab (20 mg/0.4 ml) by subcutaneous injection. Ofatumumab is administrated at baseline, Day 7, Day 14 and monthly thereafter until the end of the study.
45789070|NCT01483352|Device|Accu-Chek DiaPort|
45789071|NCT02701257|Device|iPhone bionic pancreas|An experimental device composed of three parts: a continuous glucose monitor, control algorithms running on an iPhone, and drug delivery using Tandem insulin pumps
45646039|NCT02327923|Drug|Lidocaine|Inj. Xylocaine 2% 3 ml will be infiltrated in skin in all port sites prior to incision.
45646040|NCT02327923|Drug|Propofol|Inj. Propofol 2- 2.5 mg/kg will be given for induction
45789072|NCT02701257|Device|iLet bionic pancreas|An experimental device that combines the functions of the iPhone-based bionic pancreas into one device.
45789073|NCT02701257|Drug|Xeris Xerisol glucagon|A stabilized formulation of human glucagon in a solvent based primarily composed of dimethyl sulfoxide (DMSO) that has prolonged stability and can be used for multiple days in a pump
45919824|NCT04556617|Drug|Olaparib|Olaparib tablets
45919825|NCT04556617|Drug|Abiraterone acetate|Abiraterone acetate tablets
45919826|NCT04556617|Drug|Prednisone|Prednisone (or equivalent) tablets
45919827|NCT04554862|Drug|Magnesium sulfate|magnesium sulfate will be added to the block
45919828|NCT04554862|Drug|Ketorolac Tromethamine|ketorolac will be added to the block
45919829|NCT04554862|Procedure|supraclavicular block|it is done by ultrasound- guided
45919830|NCT02337686|Other|Laboratory Biomarker Analysis|Correlative studies
45919831|NCT02337686|Biological|Pembrolizumab|Given IV
45597794|NCT04467307|Device|Rigit bronchoscopy|After general anesthesia, the airway is checked with a rigid bronchoscope suitable for the age. If there is a foreign body, it is removed by forceps.
45597795|NCT02208635|Other|Biofortified Maize|Participant in this arm were fed zinc biofortified maize (~30 µg Zn/g).
45597796|NCT02208635|Other|Fortified Maize|Participants in this arm were fed zinc-oxide fortified maize (total level of ~60 µg Zn/g).
45597797|NCT02208635|Other|Control Maize|Participants in this arm were fed maize that was not fortified or biofortified (~15 µg Zn/g maize).
45597798|NCT04881214|Other|Pulmonary rehabilitation|pulmonary rehabilitation for 12 weeks, 3 times a week. control will take place at 3, 6 and 12 months
45597799|NCT04467151|Drug|anti-SARS-CoV-2 plasma|Administration of anti-SARS-CoV-2 convalescent plasma
45597800|NCT04467151|Other|Placebo|Administration of placebo (albumin 5%)
45597801|NCT02204033|Drug|99mTc - labelled hMAb BIWA 4|
45597802|NCT02204033|Drug|186 Re - labelled hMAb BIWA 4|
45597803|NCT02204033|Drug|unlabelled hMAb BIWA 4 - low dose|
45646041|NCT02327923|Drug|Fentanyl|Inj fentanyl 1.5mg/kg will be given at the time of induction.
45646042|NCT02327923|Drug|Vecuronium|Inj Vecuronium 0.1mg/kg will be given at induction and for maintenance.
45646043|NCT02327923|Drug|Atropine|Inj Atropine 0.4 mg IV will be given for bradycardia (HR < 50/min)
45646044|NCT02327923|Drug|Ephedrine|
45789074|NCT02701257|Drug|Lilly glucagon|An aqueous formulation of human glucagon with limited stability that must be changed daily
45789075|NCT02701257|Device|iLet infusion set|The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
45789076|NCT02701257|Device|Contact Detach infusion set|The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
45789077|NCT01836029|Drug|VTX-2337|TLR8 Agonist
45789078|NCT01836029|Drug|Carboplatin|
45789079|NCT01836029|Drug|Cisplatin|
45789080|NCT01836029|Drug|5-fluorouracil|
45789081|NCT01836029|Drug|Placebo|
45789082|NCT02701647|Device|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive TMS (rTMS) is a painless and non-invasive technique for activation of cerebral cortex based on the principle of electromagnetic induction of an electric field in the brain. rTMS will be delivered to the scalp over the leg area of the bilateral motor cortex by using a Magstim Rapid magnetic stimulator. (Magstim Company, Whitland, UK) and 90 mm double cone coil.
45789083|NCT02701647|Other|Treadmill training|Participants will proceed to 30 minute of treadmill training after rTMS. A safety harness without body weight support will be provided. 80% of participant's over ground maximum walking speed will be halved and used for warm-up. After warming up, walking speed will be increased by 0.2 km/h every 5 minutes. Progression will be given if patients could tolerate the belt speed with appropriate step length and walk with good stability for 5 minutes. Participants will maintain the maximum speed achieved for the rest of the session or adjusted as needed. Positive verbal feedback will be given to encourage large strides and upright posture during training. The participants will be instructed to walk on treadmill without holding onto the handrails if possible. Participants will perform warm up and cool down exercise to minimize training related-injury.
45919832|NCT02337686|Other|Pharmacological Study|Correlative studies
45919833|NCT02337686|Procedure|Therapeutic Conventional Surgery|Undergo surgery
46071321|NCT00828919|Drug|crizotinib|BID oral Capsules. Dose of crizotinib will be the same taken in previous axitinib trial.
45646045|NCT02327923|Drug|Morphine|
45789084|NCT05209139|Dietary Supplement|Beetroot juice|One serving 70 mL of beetroot juice (6.4 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
45789085|NCT05209139|Dietary Supplement|Beetroot juice placebo|One serving 70 mL of beetroot juice placebo (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
45789086|NCT05114213|Radiation|SBRT|online adaptive MR-guided hypofractionated stereotactic radiotherapy
45789087|NCT05114213|Drug|SOC chemotherapy|The chemotherapy is given according to current standard of care, consisting of in minimum doublet - chemotherapy and excluding monotherapy regimens.
45789088|NCT05747729|Drug|Surufatinib and Serplulimab|"Surufatinib: Safety lead-in : Oral, QD, starting dose 250 mg, adjusted according to DLT. Dose expansion: administration according to the dose determined in the safety lead-in phase.~Serplulimab: 300 mg intravenous infusion on day 1, repeated every 3 weeks."
45789089|NCT02703909|Drug|Rocuronium|Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment
45789090|NCT02703909|Device|Insufflation pressure|The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment
45789091|NCT05747651|Biological|Blood sample|Total volume of blood (on each sampling occasion): 54,5mL.
45789092|NCT05747651|Biological|Urine sample|Urine: 100 mL which will be centrifuged. The pellet will be frozen, and the urine supernatant will be aliquoted.
45789093|NCT05747651|Biological|Saliva sample|Saliva: will be collected in special container for saliva microbiome and methylation.
45789094|NCT05747651|Biological|Stool sample|Stool: One sample for microbiome to be sent to the biobank, frozen at -80 °C.
45646046|NCT02327923|Drug|Ketorolac|
45789095|NCT05747651|Biological|Tissue sample|"Tissue samples for organ-specific manifestations:~Kidney tissue in lupus nephritis: one small fragment of the fresh kidney biopsy will be stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~Skin tissue (at selected centers) from inflamed lesion and non-inflamed skin from the gluteal region will be obtained through punch biopsy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~Synovial tissue (at selected centers) will be obtained through ultrasound-directed arthroscopy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~Aspirate from swollen lymph nodes (at selected centers) will be obtained and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment."
45789096|NCT03759561|Procedure|intubation with videolaryngoscope vs fiberoptic bronchoscope|Tracheal intubation was performed using either videolaryngoscope or fiberoptic bronchoscope under cervical collar application according to the group allocations
45789097|NCT05096975|Other|Evaluation of the CBCL-A-A-A and HiPIC in children with ADHD and with ED or without ED|"The intervention involves the completion of two questionnaires by parents at child psychiatry unit of Montpellier University Hospital when children come to participate in a psychometric assessment or when parents or children participate in therapeutic group.~All parents completed Child Behavior Checklist (CBCL; Achenbach & Rescorla, 2001), a 118-item questionnaire to measure emotional and behavior problems in 4 to 18-years-old children in the past six months and Hierarchical Personality Inventory for Children (HiPIC, Mervielde & De Fruyt, 1999, a 144-item questionnaire to obtain a profile of the personality of 6 to 12-year-old children."
45789098|NCT04740411|Behavioral|The Common Elements Toolbox (COMET)|COMET is an online unguided self-help intervention that lasts approximately 60-80 minutes.
45789099|NCT02703987|Other|Fermented infant milk formula|
45597804|NCT02204033|Drug|unlabelled hMAb BIWA 4 - medium dose|
45597805|NCT02204033|Drug|unlabelled hMAb BIWA 4 - high dose|
45646047|NCT02327923|Drug|Ondansetron|
45646048|NCT02327923|Drug|Bupivacaine|Inj. Bupivacaine 0.25% 10 ml will be infiltrated at incision site after closure.
45597806|NCT03526705|Device|NB-UVB|Phototherapy
45597807|NCT03533309|Procedure|Computer guided surgical cutting guide|comprised 6 patient undergoing surgical alveolar ridge splitting using computer guided surgical cutting stent
45597808|NCT03533309|Procedure|Conventional alveolar ridge splitting|comprised 6 patient undergoing surgical alveolar ridge splitting using conventional technique.
45597809|NCT05488795|Behavioral|Team-Based Home Blood Pressure Monitoring|Implementation of best practices for hypertension control using a practice wide team-based home blood pressure monitoring intervention
45646049|NCT02327923|Drug|Tramadol|Inj tramadol 50 mg IV will be given on SOS basis in ward.
45646050|NCT02327923|Drug|Neostigmine|50 mcg/kg for reversal of residual neuromuscular blockade
45597810|NCT02200133|Other|Individualized Survivorship Care Plan (SCP)|The individualized SCP incorporates patient specific treatment exposures and provides a framework for long term followup based on those exposures and subsequent risks for late complications.
45597811|NCT05488405|Drug|Mesalamine Oral Product|Mesalamine oral suspension for oral use
45597812|NCT02208713|Biological|Intramuscular injection|Intramuscular injection of stem cells in patients with FSHD.
45646051|NCT02327923|Drug|Glycopyrrolate|10 mcg/kg with neostigmine
45646052|NCT04991207|Drug|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
45646053|NCT04991207|Drug|bosentan|Oral Tracleer (bosentan) 125 mg film coated tablets
45646054|NCT03072173|Drug|Xylometazoline|Patient will be given a nasal decongestant (Xylometazoline) prior to their 2nd or 3rd night of PSG.
45789100|NCT02703987|Other|Non-fermented infant milk formula|
45789101|NCT01836185|Drug|Evacetrapib|
45789102|NCT05073341|Other|Nurse-led family intervention|Nurse-led family intervention having three components first is infarmation about the patient's condition and guidance will be given to solve there queries and the emotional support will be given to the primary caregivers of CLD patient's admitted in HDU
45789103|NCT02706249|Drug|Enoxaparin|
45789104|NCT00559949|Other|Laboratory Biomarker Analysis|Correlative studies
45789105|NCT00559949|Drug|Selumetinib|Selumetinib was administered orally as a free base suspension at a dose of 100 mg twice daily for 28-day cycles. Those participants experiencing Common Terminology Criteria for Adverse Events (CTCAE) v3.0 grade 3 toxicity or worse had their dose reduced to 50 mg twice daily and then to 50 mg once daily, if necessary.
45789106|NCT04740021|Drug|LP002|10 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
45646055|NCT03072173|Drug|placebo (saline)|Patient will be given a placebo nasal spray (saline) prior to their 2nd or 3rd night of PSG.
45646056|NCT03141463|Biological|Vvax001 therapeutic cancer vaccine|Vvax001 is a vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks.
45789107|NCT04740021|Drug|Carboplatin|AUC 5 administered as IV infusion on Day 1 of each 21-day cycle.
45789108|NCT04740021|Drug|Etoposide|100 mg/m^2 administered as IV infusion on Day 1, 2 and 3 of each 21-day cycle.
45449464|NCT02159248|Drug|Tolfenamic acid + gemcitabine + radiation|"Cohort 1: 200mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 2: 400mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 3: 600mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 4: 800mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day)."
45646057|NCT03072095|Behavioral|Text-only|Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit.
45789109|NCT03724695|Other|Clinician nudge or opt out approach for AHCAH liaison visit|"This study is a nudge or opt-out approach of an AHCAH liaison visit to eligible seriously ill HF patients prior to hospital discharge to discuss the AHCAH program and to subsequently facilitate enrolling them in the AHCAH program if they are amenable, compared to the opt-in approach (usual care)."
45789110|NCT05747417|Other|prismatic glasses|prism glasses ranging from 4-10 prism diopters
45789111|NCT03663777|Other|Isometric handgrip training|Intervention period will last 12 weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of eight sets of bilateral handgrip contraction of two minutes of isometric contraction, with 30% of maximum voluntary contraction, and two minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. The patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.
45789112|NCT03663777|Other|Control Group|Intervention period will last 12 weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
45789113|NCT01837901|Device|Transcorneal electrostimulation|
45789114|NCT03601143|Other|Blood samples prior to a new line of AR-targeted therapy|Blood will be drawn at baseline prior to a new line of AR-targeted therapy.
45449465|NCT00118157|Other|Laboratory Biomarker Analysis|Correlative studies
45449466|NCT00118157|Drug|Lapatinib Ditosylate|Given PO
45449467|NCT00118157|Drug|Tamoxifen Citrate|Given PO
45449468|NCT02160652|Procedure|Laparoscopic ureteral re-implantation.|Laparoscopic ureteral re-implantation for the treatment of malignant ureteral obstruction.
45646058|NCT03072095|Behavioral|Text + Lottery|Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit and a 1 in 5 chance to win a $100 gift card for completing the kit.
45789115|NCT02708433|Drug|Lidocaine|Lidocaine
45789116|NCT05038085|Behavioral|progressive muscle relaxation exercise|"36-37 with pregnant women in the experimental group. There will be two online interviews starting from week one. Before the first interview, the PMRE video will be sent to the women, explained by the researcher. In the first meeting, basic information about postpartum depression and what to do to prevent postpartum depression and its treatment will be explained. The women will then be asked to describe the PKGE. Relaxation Exercises CD Audio Recordings belonging to the Turkish Psychological Association will be sent to women, and they will be asked to perform PMRE at least 3 days a week until delivery, accompanied by the instructions on the CD. In the second meeting; maternal attachment will be explained. In this interview, women will be asked to continue to do PMRE at least 3 days a week from the day they feel ready, starting at the latest 1 week after delivery."
45789117|NCT03575013|Drug|Avelumab|Avelumab is a fully human anti-programmed death ligand 1 (PD-L1) IgG1 antibody
45789118|NCT03575013|Drug|Docetaxel|Docetaxel is a antineoplastic agent belonging to the taxoid family
45789119|NCT05035043|Other|Determination of the economic burden NAFLD patients|Determination of the economic burden NAFLD patients (Healthcare costs, patient costs, burden of disease
45789120|NCT04339569|Diagnostic Test|Biomechanical analysis|3D analysis of landing manoeuvres.
45449469|NCT02762500|Drug|LYC-30937-EC|
45449470|NCT02762500|Drug|Placebo|
45646059|NCT02327611|Drug|Custodiol|
45646060|NCT02327611|Drug|Enriched Ringer's lactate solution|
45646061|NCT03826849|Behavioral|Insomnia Coach|Insomnia Coach is a mobile application that provides psychoeducation and self-management tools for insomnia symptoms based on cognitive behavioral therapy for insomnia (CBT-I)
45646062|NCT03072641|Dietary Supplement|ProBion Clinica|
45789121|NCT04339569|Other|Fatigue protocol|A circuit of different tasks (e.g. jumping, sprinting forward and backward, side-stepping exercise) was performed to induce fatigue.
45789122|NCT01839695|Device|Valiant Mona LSA Stent Graft System|All subjects will be implanted with this device
45789123|NCT04339647|Behavioral|The SIMS programme|The intervention targets 5-6-year-old preschool children and their parents. Apart from the usual care, 5-6-year-old children receive oral health lessons and supervised daily tooth brushing (1000ppm F) at school over a period of 6 months, as well as home tooth brushing supervision by parents for 6 months. Parents/guardians attend a meeting with a DT team at school to discuss on child's oral health status, receive OHE and free toothbrush and fluoride toothpaste (1000ppm F) for child home tooth brushing, and receive 10 oral health infographic messages from DT over a period of 5 months (with printed versions available).
45789124|NCT04986683|Diagnostic Test|Brain magnetic resonance imaging|Brain magnetic resonance imaging (MRI) will be done using multiple sequences to evaluate the presence, type, and severity of brain abnormalities in enrolled subjects.
45646063|NCT03074279|Other|Interview with a psychologist and self-reported questionnaires|The family members or patients who decide to participate in the study will be asked to complete an interview with a psychologist (semistructured interview, standard form, questionnaires) and self-reported questionnaires
45449471|NCT03543202|Drug|Transversus abdominis plane block|will receive 20ml bupivacaine for Transversus abdominis plane block and intravenous patient controlled analgesia
45449472|NCT03543202|Drug|local infiltration anesthesia|will receive 20ml bupivacaine for local infiltration anesthesia and intravenous patient controlled analgesia
45449473|NCT03543202|Drug|Intravenous patient controlled analgesia|will not receive any regional anesthetic intervention will receive intravenous patient controlled analgesia
45646064|NCT04991363|Procedure|Bleaching|Digital images for each patient will be taken once with the camera fixed on the classic tripod and again when the camera was fixed on the ISD , then horizontal and vertical measurements of the canines will be recorded by using a computer software on the digital images, then bleaching will be fine for all patients, then a second set of images will be taken again with the tripod and then with ISD, then measurements will be repeated and compared with the first set of images
45789125|NCT04986683|Behavioral|Neuro-psychology testing|Participants will undergo age-appropriate neuro-psychology testing to assess motor, language, and other neurocognitive functions potentially affected by drug-resistant epilepsy.
45919834|NCT04553185|Other|Study procedure|All participants will undergo a collection of demographic data, personal and family history for PD, a neurological examination and administration of clinical scales. All participants will undergo a collection of venous blood sample. At the end of the visit they will receive a wristwatch to monitor their sleep at home (Actigraph) and a sleep diary, together with a prepaid envelope to post the watch and the diary back to the investigators. They will also receive a link for a series of online tests for non-motor symptoms related to Parkinson's disease that they can complete remotely at home.
45646065|NCT03764371|Diagnostic Test|KAPA Hyper Prep Kit + Agilent SureSelectQXT|We initiated this prospective clinical study to detect lung cancer related genes in tumor tissues and patients with at least 2 tumors that were confirmed as invasive adenocarcinoma by pathology after sMPLC resection (residual non-resectable or non-qualitative pulmonary nodules). At the same time, application of KAPA Hyper Prep Kit + Agilent SureSelectQXT technology to test lung cancer related genes in patients' tumor tissues and blood, patients with lung cancer drive genes were followed up to explore whether different drive genes had an impact on patients' disease progression. In order to investigate the type of gene that causes disease recurrence in patients, tissue or blood test was performed again when disease recurrence occur.
45646066|NCT03074123|Diagnostic Test|low-dose cosyntropin stimulation test|Each subject recruited in the study will undergo low dose cosyntropin stimulation test via intravenous short 2.5 cm plastic tube. 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). For each subject, serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
45919835|NCT05027490|Other|CANUT support|CANUT support includes delivery of the CANUT guide (food guide developed by Paul Bocuse Institute from previous results) ; it will be given to patient with explanations about the use of the guide. This also includes 2 calls from a dietician, performed between the 1st and the 3rd chemotherapy cycle to help patient personally with their food side effects.
45919836|NCT05027490|Other|Anthropometric measures|These measures include weight, waist size, hip size and brachial circumference
45919837|NCT05027490|Other|Prehension strength measurement|Prehension strength will be assessed thanks to a hand grip device, that makes it possible to measure strength of all fingers, hands, wrists and forearms muscles
45449474|NCT03552549|Biological|PEG-Intron|Polyethylene glycol (PEG)12000 Interferon alfa 2-b subcutaneous injection.
45789126|NCT02708745|Behavioral|Intervention Survey|
45919838|NCT05027490|Behavioral|QVA Questionnaire|Food quality of life questionnaire
45919839|NCT05027490|Behavioral|QLQ C30 Questionnaire|Quality of Life questionnaire Core 30
45919840|NCT05027490|Behavioral|Scratch & Snif Test|The Scratch & Snif Test is used to assess olfactory capacities : patient has to scratch a box on a card, smell it and recognize the scent amongst a list of propositions
45919841|NCT05027490|Behavioral|Taste Strip Test|The Taste Strip Test is used to assess taste capacities : strips impregnated with different concentrations of the 5 basic taste qualities (sweet, sour, acid, bitter, umami) are successively placed on patient's tongue ; patient has to identify the taste bit by bit.
45449475|NCT03552549|Biological|INTRON A|Interferon alfa-2b, recombinant for intravenous injection.
45449476|NCT00117845|Biological|Denileukin diftitox (Ontak)|Patients will be treated with Denileukin Diftitox 9 mcg/kg/d intravenously for 5 days every 2 weeks.
45789127|NCT02708745|Behavioral|Placebo Survey|
45789128|NCT05251779|Drug|Volatile Oil of Cang-Ai|The test group will be given Volatile oil of Cang-Ai (hereafter referred to as CAVO) for inhalation
45789129|NCT05251779|Drug|Bergamot essential oils|The control group will be given Bergamot essential oils for inhalation.
45789130|NCT00559637|Drug|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously once a month. The starting dose will be 1.2 mcg/kg of body weight. Further dose adjustments will be performed during the study depending on the hemoglobin value. Total duration of treatment will be 9 months for all participants in the study and up to 11 months for participants who will be shifted to the dialysis.
45919842|NCT05027490|Behavioral|24 H feed back questionnaire|This questionnaire describes patient's food and drink intakes during the last 24 ours
45919843|NCT05027490|Behavioral|Condiment questionnaire|This questionnaire used to assess condiments consumption
45789131|NCT03349281|Drug|Pevonedistat|Administered each cycle on days 1, 3 and 5.
45789132|NCT03349281|Drug|Vincristine|Administered each cycle on days 2, 9, 16 and 23.
45789133|NCT03349281|Drug|Dexamethasone|Taken orally each cycle on days 2 through 15.
45789134|NCT03349281|Drug|PEG-asparaginase|Administered via intramuscular injection (IM) each cycle on days 9 and 23.
45789135|NCT03349281|Drug|Doxorubicin|Administered via IV each cycle on day 2.
45789136|NCT03349281|Drug|Cytarabine|Administered to all subjects via IT injection on day 1; and on days 9, 16, and 23 to CNS positive subjects.
45789137|NCT03349281|Drug|Methotrexate|Administered via IT injection to CNS negative subjects on day 16; and to CNS positive subjects on days 9, 16 and 23.
45789138|NCT03349281|Drug|Hydrocortisone|Administered via IT injection to CNS positive subjects on days 9, 16, and 23.
45789139|NCT03287817|Biological|AUTO3|Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 50 x 10⁶ to 900 x 10⁶ CD19/ CD22 Chimeric Antigen Receptor (CAR) positive T cells followed by limited duration of anti-PD1 antibody (pembrolizumab).
45646067|NCT05078749|Other|Exercise training group|A regular advanced exercise program will be given and followed.
45919844|NCT05027490|Behavioral|Tobacco questionnaire|This questionnaire used to assess tobacco consumption
45646068|NCT05078749|Other|Control training group|Basic exercises will be given at the beginning and will do the same exercises
45646069|NCT04433663|Other|Mentalization -based therapy using novel tool to demonstrate eating behavior and control axis|"To address the gap between theory and practice in the treatment of eating disorders we y developed a novel axis, ECOSA, to better conceptualize the complex interaction between eating style, control conditions, and the impact of the emotional brain versus the thinking brain. A randomized pilot study was used to evaluate the integration of this tool in a mentalization-based treatment compared to treatment as usual (IPT).~Methods: The suggested tool was tested in a randomized blinded feasibility study using the Eating Attitudes Test (EAT-26) and the Reflective Functioning Questionnaire RFQ - as the main outcome."
45646070|NCT02327299|Dietary Supplement|Bouillon fortified with FePP|
45646071|NCT02327299|Dietary Supplement|Bouillon fortified with FePP + Stabilizer|
45646072|NCT02327299|Dietary Supplement|Bouillon fortified with FeSO4|
45646073|NCT02327299|Dietary Supplement|Bouillon fortified with FeSO4 + Stabilizer|
45646074|NCT03494569|Drug|Fludarabine|Given IV
45919845|NCT05027490|Other|Nutrition interview|This interview will be conducted by a dietician
45646075|NCT03494569|Other|Laboratory Biomarker Analysis|Correlative studies
45646076|NCT03494569|Drug|Melphalan|Given as per City of Hope Standard Operating Procedure
45789140|NCT00367809|Behavioral|Mindfulness-Based Stress Reduction (MSBR)|Mindfulness-Based Stress Reduction (MBSR) is the intervention of primary interest. It is a psycho-educational program of 8-weekly classes, 2.5 hours long taught by a trained instructor. Over the course of the program participants receive training in several formal meditation techniques: a body-scan meditation, sitting meditation, walking meditation and mindful Hatha yoga that involves simple stretches and movements. Participants are requested to practice meditation at home and to integrate informal mindfulness practices into their daily lives. The content of MBSR is described in the book Full Catastrophe Living by Jon Kabat-Zinn.
45789141|NCT00367809|Behavioral|Health Education (HE)|The active control condition was a peer-led chronic disease self-management program comprised of 8 weekly, 2.5 hour meetings. Led by trained peer-leaders, groups of participants discussed health challenges and problem-solved using a technique called action-planning. The curriculum described by Lorig and colleagues in the book Living a Health Life was the core of this program, and transplant-specific issues were covered in two meetings to match MBSR for time and attention.
45789142|NCT00367809|Behavioral|Delayed Intervention|A temporary wait-list control group; after 6 months, those in the Delayed Intervention were randomized a second time, to one of the active treatment arms (MBSR or HE).
45646077|NCT03494569|Radiation|Total Marrow Irradiation|Undergo TMLI
45646078|NCT03071627|Other|New items with spin|Interpretation of news items with spin
45646079|NCT03071627|Other|New items without spin|Interpretation of news items without spin
45646080|NCT03071783|Device|Vacuum extraction intelligent system|Vacuum extraction intelligent system - this is the intervention
45646081|NCT02327377|Behavioral|Online Cognitive Behavior Therapy|
45646082|NCT02327377|Behavioral|Online Education|
45646083|NCT03071549|Drug|Trichloroacetic acid peel|Skin degreasing will be performed before every session using acetone. Trichloroacetic acid 25% will be applied on one side of the face.
45646084|NCT03071549|Drug|combined azaleic and salicylic acids|Skin degreasing will be performed before every session using acetone. Azaleic acid 20% with salicylic acid 20% will be applied to the other side of the face.
45646085|NCT03144817|Other|Dialysate Sodium Lowering|Dialysate sodium is lowered until nadir sodium level is reached. Participant dialyzes at this sodium level until end of follow-up.
45789143|NCT02713425|Device|Entertaining Video Game|Children between 7 & 17 with a social anxiety disorder will be invited to participate in this study. They will attend a single visit. During the visit they will use the therapeutic game. They will be monitored while using the game. After the completion, they will be asked questions regarding their experience with this therapeutic game.
45789144|NCT03206151|Drug|CMAB009|for injection only
45789145|NCT03206151|Drug|Irinotecan|for injection only
45789146|NCT03206151|Drug|Folinic acid|for injection only
45919846|NCT04550728|Combination Product|Ankle robot training group|Patients will be seated with the paretic foot strapped to the footplate the knee at full extension. The operator will set up and measure (using the robot) ankle passive DF and PF ROM limits. The robot training will include passive stretching, robot interactive game-based training, and cool-down stretching.
46071322|NCT00828997|Biological|Prevenar vaccination|vaccination with Prevenar vaccine in patients with arthritis
45919847|NCT04550728|Combination Product|Ankle robot training and functional electrical stimulation(FES) group|Patients will use the ankle robot device as the ankle training group. Also, water-based FES electrodes positioned inside a soft garment will be secured over the DF and PF muscles by wrapping the garment around the leg just below the knee joint. Stimulation intensity will be increased to maximal tolerance of each participant. Electrically induced contraction timing will be triggered by the ankle robot in synchrony with the ankle dorsi and plantar flexion movements.
45789147|NCT03206151|Drug|5-fluorouracil|for injection only
45789148|NCT04964765|Diagnostic Test|Mapping|CardioInsightTM Cardiac Mapping System is a non-invasive single beat cardiac mapping system that provides three-dimensional electroanatomic maps of the heart. The CIT vest is attached to the patient's torso for non-invasive mapping. To ensure correct and rapid mapping of the NOAF by the CIT device, it is essential to briefly slow down the patient's heart rate below 50bpm for a few seconds. Therefore 6mg adenosine as a rapid i.v. bolus will be administered. The adenosine application will slow down the patient's heart rate and allow for correct mapping by the CIT device. Medical therapy of atrial fibrillation is started immediately according to local protocol. Since non-invasive mapping is performed within a few minutes, the therapy of atrial fibrillation will not be critically delayed. Consecutively, a low-dose thoracic computed tomography (CT) scan (neck to upper abdomen) will be performed independent from the patient's rhythm.
45789149|NCT04964765|Diagnostic Test|Computed tomography scan|The CT scans will follow a standardised protocol as predefined by the manufacturer of the CIT vest, Medtronic (Dublin, Ireland). After the sensor array has been placed on the patient, the patient is ready to undergo a CT scan to register each electrode's locations with respect to the body surface. All CT scans cover a body region from neck to the upper abdomen, have no cardiac gating performed or any contrast agent given. The CT scans are acquired on 3 CT scanners manufactured by Siemens Corporation (Berlin, Germany) with a fixed tube voltage of 80 kVp and 250 effective mAs (=mAs/pitch). The reconstruction parameters are of 3 mm slice thickness and of 1.5 mm increment (slice overlap) The estimated effective dose (ED) is 3.2 mSv per patient.
45789150|NCT04339725|Other|DNA extraction|Extraction fecal DNA and compare disease group to normal group
45789151|NCT01841021|Drug|Brentuximab vedotin|Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day 1 of every 21 day cycle.
45789152|NCT02713659|Behavioral|Early Literacy Promotion|Parents will receive a book with developmentally appropriate advice about reading at each well child visit from one week through 5 months of age, as well as weekly text reminders related to reading. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
45789153|NCT02713659|Behavioral|Standard Literacy Promotion|Parents will receive weekly text messages about child safety, and no books before the age of 6 months from their provider. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
45789154|NCT01842815|Device|755 nm alexandrite laser|755 nm alexandrite laser for the treatment of unwanted, non cosmetic, tattoos.
45789155|NCT02714283|Drug|inhaled corticosteroid therapy|We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
45789156|NCT02714283|Drug|macrolide therapy|We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
45789157|NCT04814927|Drug|Copper IUD|Participants randomized to Copper IUD will receive Paragard IUD at Visit 2.
45789158|NCT04814927|Drug|Etonogestrel implant|Participants randomized to ETG implant will receive the implant at Visit 2.
45789159|NCT04814927|Drug|Levonorgestrel IUS|Participants randomized to LNG intrauterine system will receive the IUS at Visit 2.
45919848|NCT02280356|Radiation|external beam radiation therapy|
45919849|NCT02280356|Radiation|brachytherapy|
45919850|NCT02280356|Behavioral|questionnaires|
45919851|NCT04526782|Drug|Encorafenib 75 MG|450 mg (6 × 75 mg capsule) per day
45646086|NCT04995575|Procedure|collection of the biopsy, blood samples|"for the patients recruited retrospectively collection of biopsy is not considered intervention, as the relapse samples were collected according to standard of care in the participating hospitals.~For the prospective collection of samples, the relapsed patients will be asked to donate tissue and blood samples"
45919852|NCT04526782|Drug|Binimetinib 15 MG|45 mg (3 × 15 mg tablet) twice daily
45919853|NCT02241863|Behavioral|Multifaceted intervention|Supportive intervention: care giver, health care providers, and patient's family members (including disease knowledge, treatment t of the disease, medication problems or adverse effects, the importance of medication adherence, supervision taking medications by the patients as prescribed). patient education: about the disease and treatment, consuming regularly the pills motivational intervening, self-monitoring planning. Patients will attend in five motivational interviewing sessions regularly to facilitating and engaging intrinsic motivation within the patients in order to change medication adherence behavior.
45919854|NCT02241863|Behavioral|Routine counseling|
45646087|NCT03074201|Procedure|Cholangioscopy|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
45646088|NCT03074201|Device|Spyglass DS Cholangioscope|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
45919855|NCT04420702|Device|MRI with DBSI analysis|-The procedure will take approximately 1 hour of the participant's time
45919856|NCT05014074|Other|Theater/Pilot Testing|Participants will take part in a theater/pilot testing in order to receive adequate feedback and make substantive change in the intervention
45919857|NCT03802097|Procedure|No use of antimicrobial prophylaxis|Do not use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer
45919858|NCT03802097|Procedure|Use of antimicrobial prophylaxis|Use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer
45646089|NCT03734965|Device|AWAKEN INTUBATION|Intubation
45646090|NCT04994951|Drug|Triamcinolone Acetonide Acetate and Urea Cream.|10g/tube and CalcipotriolOintment,10g/tube are used alternately.
45646091|NCT04994951|Drug|Qing-Re-Liang-Xue Decoction.|One dose of granules is mixed, poured into 500ml of boiling water, and taken twice in the morning and afternoon. Women stop taking Chinese medicine during the first 3 days of menstruation.The period of treatment will be 10 weeks.
45646092|NCT03717181|Drug|Lixivaptan|Daily dose of lixivaptan optimized using a predetermined titration protocol.
45646093|NCT03073889|Procedure|Scalp Nerve Block|A scalp nerve block involves regional anesthesia to the nerves that innervate the scalp, including the supraorbital and supratrochlear nerves, branches of the ophthalmic branch of the trigeminal nerve; the zygomaticotemporal nerves, terminal branch of division two of the trigeminal nerve; the auriculotemporal nerves, terminal branch of the mandibular division of the trigeminal nerve; the greater and lesser occipital nerves. The scalp block is performed bilaterally with 10 solution of 0.75% ropivacaine.
45646094|NCT03073889|Procedure|Scalp infiltration|Scalp infiltration before incision. Neurosurgeons infiltrate the planned incision by a 22-gauge needle penetrated deeply to the skin at a 45°angle with 10ml solution of 0.75% ropivacaine throughout the entire thickness of the scalp.
45646095|NCT03073889|Drug|Ropivacaine|
45646096|NCT03699709|Behavioral|Budgeting, purchasing and cooking educational intervention|Receive culturally-tailored healthy food budgeting, purchasing, and cooking skills curriculum
45646097|NCT03071471|Device|MID-C|"The MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues accommodate any incremental correction.~The MID-C System inherent benefits are:~Only two screws are used~Incision size is much smaller~Simpler operation with shorter operative time~Less complication thanks to the three points above.~Minimal spinal mobility loss"
45646098|NCT03645967|Device|ReadyCleanse Cloths|ReadyCleanse cloths and the standardized cleansing procedure will be the standard-of-care for catheter care and maintenance; patients will undergo routine perineal care for a minimum of twice per day and after each incontinent episode.
45646099|NCT03570931|Drug|RT001|RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 960 mg of RT001.
45646100|NCT05078515|Diagnostic Test|PREDICT score|Predictive score for local recurrence after TME for rectal cancer that includes 8 parameters
45646101|NCT04477369|Drug|DWJ1439|300mg single dose
45646102|NCT04477369|Drug|DWJ1464|300mg single dose
45646103|NCT04477369|Drug|DWC202003|300mg single dose
45646104|NCT04477369|Drug|DWC202004|300mg single dose
45449477|NCT02761642|Drug|Epoetin Beta|All participants will receive epoetin beta at a dose of 30000 International Units (IU) as SC injection once every week for a total of 12 weeks. Adjustments in the dose will be implemented based on the participant's blood hemoglobin levels.
45646105|NCT02636699|Biological|Viaskin Peanut 250mcg|Peanut extract cutaneous patch
45646106|NCT02636699|Biological|Placebo|Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract
45646107|NCT05080855|Procedure|modified Millard technique vs Tennison-Randall technique|evaluate the quantitative (anthropometric) assessment of modified Millard technique in comparison to Tennison-Randall technique in unilateral cleft lip (ucl) repair. Inclusion criteria: Patient with ages from 2 months old to 6 months old, Patient with unilateral cleft lip complete or incomplete type.
45646108|NCT03140839|Behavioral|Imaginal Rescripting|A stand-alone single session intervention for social anxiety disorder
45646109|NCT03140839|Behavioral|Imaginal Exposure|A stand-alone single session intervention for social anxiety disorder
45646110|NCT03140839|Other|Supportive Counselling|Non-specific talk therapy focused on non-directive and empathic listening and on supporting patients' existing coping skills and strategies.
45646111|NCT03071705|Drug|Metformin|500 mg PO BID
45646112|NCT03071705|Drug|TKI|standard dose
45646113|NCT04995185|Radiation|(18)F-fluoromisonidazole (FMISO)|Patients do not need to be fasted prior to intravenous injection of 370MBq ± 10% (18)F-fluoromisonidazole. Scanning will be performed two hours after the injection. Patients will be scanned with their thermoplastic shell used in routine radiotherapy treatment for 10 minutes, followed by approximately 5 minutes scan of the upper chest.
45646114|NCT03351439|Drug|Zopiclone|Group 2 - Zopiclone 7.5 mg orally, nightly for 7 days
45646115|NCT03351439|Drug|Gabapentin|Group 3 - Gabapentin 600 mg orally, 1 hour pre-operatively and 600 mg orally, 8 hours post-operatively
45646116|NCT03351439|Drug|Celebrex|Group 4 - Celebrex 400 mg PO, 1 hour pre-operatively
45646117|NCT03351439|Drug|Percocet|Standard of Care
45646118|NCT03351439|Drug|Naprosyn|Standard of Care
45919859|NCT04276558|Drug|Udonitrectag|Eye drop solution in single dose unit.
45789160|NCT04814927|Drug|DMPA Sub-cutaneous|Participants randomized to DMPA SC will receive the injection at Visit 2.
45789161|NCT04810949|Dietary Supplement|Vitamine D3 supplementation|1. The supplementation treatment will consist of prescribing vitamin D3 consumption of 4000 U 13 single dose tablets each month (52,000 IU).
45789162|NCT04810949|Dietary Supplement|Diet and sun exposure|"2. Hygienic-dietary recommendations will consist of 2 steps~Sun exposure at least 10 minutes a day from 10: 00-6: 00 pm~Consumption of foods rich in vitamin D: milk, fish, almonds, mushrooms"
46071323|NCT03454334|Device|multifocal intraocular lens IOLs|clinical outcome of different multifocal intraocular lenses (IOLs) in patients with presbyopia or cataracts
45449478|NCT03621033|Procedure|colonic transendoscopic enteral tubing|The procedure colonic transendoscopic enteral tubing is as follows:The TET tube was inserted into the ileocecal junction through the endoscopy channel at the first time of the cecal intubation after examination and evaluation of the whole colon. Then, the colonoscope was removed from the colon while the TET tube was maintained at the ileocecal junction. Then the endoscopy was inserted into the ileocecum again for affixing the TET tube to cecum with titanium clips.
45449479|NCT01310595|Procedure|Manual mobilization on cervical spine|Manual mobilization provided on selected cervical spine in patients with chronic mechanical neck apin
45646119|NCT03071393|Device|Hypoxico Hyp-123|During acute intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of low oxygen air (9-15% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
45449480|NCT01310595|Procedure|Infra-red therapy with self exercise pamphlet|Infra-red radiation therapy on cervical spine with self exercise pamphlet given to patients with chronic mechanical neck pain.
45646120|NCT03071393|Device|Hypoxico Hyp-123|During sham intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of normal oxygen air (21% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
45646121|NCT05034601|Procedure|ESPB group|A 21-gauge 100-mm needle will be inserted into the fascial layer beneath the iliocostalis, longissimus, and spinalis muscles. A bolus of 0.25% ropivacaine 0.5 ml/kg will be injected into the fascial layer. Contralateral ESPB will be performed similarly.
45789163|NCT02718963|Device|Synchronized Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
45789164|NCT04795583|Drug|Prednisone|Prednisone 25 mg capsules
45789165|NCT04795583|Device|Point of Care testing device for C-reactive protein|Determination of C-reactive protein blood levels by point of care testing device
45789166|NCT05139147|Device|DAISe Thrombectomy System|DAISe Thrombectomy System for mechanical thrombectomy
45789167|NCT05746949|Procedure|oxygenization techniques|to compare the effects of high-flow nasal oxygen and jet ventilation on oxygenation in patients who will receive general anesthesia for endolaryngeal surgery.
45789168|NCT02902107|Device|CivaSheet|
45919860|NCT04276558|Other|Vehicle|Eye drop solution with no active substance in single dose unit.
45789169|NCT02902107|Radiation|Brachytherapy|
45789170|NCT02902107|Procedure|surgical resection|
45789171|NCT05746871|Device|Agilik|The Agilik is a powered orthosis system that can assist or resist motion independently in each gait phase. It is used as a pair of knee-ankle-foot orthosis (KAFO), one for each leg. The device applies up to 12 Nm across the knee in the direction of either flexion or extension. The system consists of an orthosis for each leg integrated with an electro-mechanical actuator, a battery, a carry pack, cabling and application software running on a computer. A foot pressure sensor is embedded in the footbed of the KAFO and connected to the actuator. The foot sensor and angular velocity are used to detect the gait phase of the patient and communicate with the motor controller to provide a unique torque for each gait phase. The torque ramp and intensity can be modified through the Agilik App to cater towards individual patients by assisting or resisting motion during their gait. This allows for the clinician working with the patient to adjust the settings of the device for the patient's needs.
45789172|NCT05746871|Other|standard care|Subjects will continue with their standard care for 5 weeks
45789173|NCT02835807|Behavioral|Health Chat including Indoor Tanning|Participants in the intervention join a private Facebook group to participate in the Health Chat program. The group is not viewable to the public, including other Facebook users. The content of Health Chat is designed primarily for mothers, the participants in the group. Posts will occur twice daily for 12 months for a total of 720 posts. Each group will be hosted by a moderator who is responsible for managing the intervention goals and mothers' engagement. Mothers likely will not continuously engage with a social media campaign that is limited only to indoor tanning. To engage mothers in the Health Chat program, content addressing several major health and wellness topics relevant to adolescent girls and their mothers will be posted.
45789174|NCT02835807|Behavioral|Health Chat excluding Indoor Tanning|In the comparison condition, 25% of the posts will be about prescription drug abuse and misuse. Prescription drug abuse was selected as control content because it is a) completely unrelated to tanning, and b) an emerging issue of great interest and relevance to young adults in east Tennessee. This 25% segment of posts is the only difference between the intervention and comparison conditions.
45789175|NCT02658669|Behavioral|Cognitive-Behavioral Therapy for Insomnia|Intervention includes strategies designed to improve sleep such as: sleep restriction, stimulus-control techniques, sleep hygiene education, and relaxation training.
45789176|NCT02658669|Behavioral|Sleep Education|Intervention includes sleep hygiene education and education regarding the impact of TBI on sleep.
45919861|NCT04230499|Drug|Encapsulated Rapamycin (eRapa)|eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.
45919862|NCT04188964|Drug|Burosumab|Burosumab is a sterile clear colourless to slightly yellow and preservative free solution supplied in single use 5ml vials containing 1 mL of Burosumab at a concentration of 10mg/mL,20 mg/mL or 30mg/mL, administered by SC injections every 2 weeks.
46071324|NCT00829075|Drug|r-FSH|
46071325|NCT00829075|Drug|HP-hMG|
46071326|NCT00829075|Drug|r-FSH plus HP-hMG|
45646122|NCT05034601|Procedure|TPVB group|A 21-gauge 100-mm insulated needle will be inserted into the paravertebral space via an in-plane parasagittal approach. After perforating the costotransverse ligament, 0.25% ropivacaine 0.5 ml/kg will be injected. Anterior movement of the pleura indicated the appropriate spread of the local anesthetics in the paravertebral space. The process will be repeated on the contralateral side.
45646123|NCT04990661|Behavioral|intradialytic massage|intradialytic massage for lower extremity ( the massage included both feet and legs up to and including the knee) applied to the intervention group in three sessions a week and a total of six sessions for two weeks
45646124|NCT03141385|Other|remote ischemic preconditioning|Remote ischemic preconditioning (RIPC) will be induced after the general anesthesia prior to the cardiopulmonary bypass by four cycles of right limber ischemia (5-min blood pressure cuff inflation to a pressure of 200mmHg or a pressure that is 50 mmHg higher than SAP and 5-min cuff deflation)
45646125|NCT03141385|Other|Control|Four cycles of right upper limb pseudo ischemia and reperfusion, which will be induced by 5-minute blood pressure cuff inflation to a low pressure of 20 mmHg followed by 5-minute cuff deflated.
45646126|NCT03139747|Drug|Lenvatinib|Lenvatinib is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.
45646127|NCT03139747|Drug|Everolimus|It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.
45646128|NCT04433429|Dietary Supplement|Liposcudil Plus|
45646129|NCT02037919|Other|Immediate Nexplanon Insertion|Patient will have a Nexplanon inserted within 15 minutes of her abortion
45646130|NCT02037919|Other|Post-op Nexplanon Insertion|Place Nexplanon at post operative visit rather than at surgery
45646131|NCT04990583|Behavioral|Face-to-Face PrEP Adherence Intervention Based on LifeSteps|This single session intervention, based on LifeSteps, will occur with a study adherence coach either in-person or remotely via HIPAA compliant videoconferencing software. The topics covered during the session will include: experience taking PrEP, risk behavior education, mental health and substance use as barriers to adherence, other barriers to adherence, formulating a dosing schedule, storing and transporting medications, and response to slips in adherence. Participants assigned to the Carium condition will also receive an introduction to the Carium app.
45449481|NCT00113555|Device|ACT (Adjustable Continence Therapy)|surgically implanted device
45646132|NCT04990583|Behavioral|Adherence Coaching Facilitated by Carium Adherence App|The Carium app will be used to deliver medication reminders to participants, track medication adherence, engage in two-way secure messaging with participants, and connect with participants through a secure video feature. The adherence coach will use the secure messaging feature to support the participant with their adherence
45646133|NCT04990271|Drug|Conbercept ophthalmic injection|Monthly injection of Conbercept from 0~5 months
45646134|NCT04911049|Diagnostic Test|Blood Pressure measurement|Blood Pressure measurement
45646135|NCT04990349|Drug|Oxygen gas|Targeted PO2 postoxygenator is obtained by modulating ECMO Membrane oxygen fraction.
45646136|NCT04990193|Other|Conventional Physical Therapy Protocol|The conventional physical therapy protocol was designed to improve axial stability and trunk steadiness during standing and walking. The conventional therapeutic protocol for every child was 3 sessions/week for 12 consecutive weeks. Every treatment session was conducted for 2 hours with a 15-minutes rest between the two training hours.
45646137|NCT04990193|Other|TheraTog orthotic undergarment with its strapping system|TheraTog orthotic undergarment with its strapping system was applied for eight hours every day for twelve consecutive weeks.
45646138|NCT03141541|Behavioral|Group based pain management intervention|The intervention is delivered as six separate sessions of each two hours duration over a four month period. The sessions are managed by a multidisciplinary team from the Spine Center, led by a psychologist. Before the first session, each patient in the intervention group participates in an individual consultation with the psychologist or nurse, with the aim of matching expectations for the group intervention, and hereby ensure the patients compliance throughout the intervention.
45789177|NCT02722239|Drug|Xigduo XR|a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release
45789178|NCT02722239|Drug|Metformin ER (Glucophage® long)|co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).
45449482|NCT02150668|Behavioral|Homework, Organization, and Planning Skills (HOPS) Intervention|
45449483|NCT02150668|Behavioral|Homework Support Intervention (HSI)|
45449484|NCT03731403|Other|MI varnish|CPP- ACP with 5 % sodium fluoride GC
45449485|NCT02150746|Procedure|Peripheral/Central Venous Blood Draw|Baseline sample of whole blood to be assessed for circulating tumor cells. Samples will be acquired via venipuncture unless a pre-existing central venous catheter is in place in which case the sample will be drawn from this.
45449486|NCT02150746|Procedure|Peritoneal Wash|Prior to the start of the surgical resection, irrigation of the abdominal cavity will be performed and collected to determine baseline pancreatic cancer cells that may be present in the abdominal cavity.
45646139|NCT03071315|Other|CCT|CCT focuses on behavioral approach, mainly punitive punishment measures.
45646140|NCT03071315|Other|MMT|MMT is a combination of pharmaceutical and behavioral intervention.
45646141|NCT02888821|Behavioral|CLS-FUERTE|The CLS-FUERTE program is an approximately 6-week program and includes school (behavioral consultation with teachers), caretaker (caretaker skills groups), and student (skills groups) components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
45789179|NCT02722239|Drug|Dapagliflozin (Forxiga)|co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).
45789180|NCT04775147|Other|Intensive BP lowering|The aim is to achieve a systolic BP level of <120mmHg within 1hour after successful recanalization and to maintain this BP level for the next 72 hours (or until hospital discharge or death of this should occur earlier)
45789181|NCT02581917|Other|Cytology Specimen Collection Procedure|Undergo collection of PBMC samples
45789182|NCT02581917|Other|Laboratory Biomarker Analysis|Undergo metabolic analysis
45789183|NCT01845155|Behavioral|Neuro-Music-Therapy according to the Heidelberg Model|"The neuro-music therapy according to the Heidelberg Model for tinnitus is a manualized short term music therapeutic treatment lasting for nine consecutive 50-minutes sessions of individualized therapy. Therapy takes place on five consecutive days (from Monday to Friday) with two therapy sessions per day. It comprises both active and receptive forms of music therapy. The interventions are structured into the following modules Directive Counseling, Resonance Training, Neuroauditive Cortex Training, Tinnitus Reconditioning.~For more details on the music therapy see Argstatter et al. 2012"
45789184|NCT01845155|Behavioral|Counselling|Duration: single session of 50 min Tinnitus specific procedures: The counseling group receives the identical counselling procedure as the music therapy group.
45789185|NCT02578641|Biological|autologous EBV specific Cytotoxic T cells|The CTL line will be prepared by co-cultivation of the irradiated EBV-LCL with patient PBMC. A proportion of peripheral blood will be used to generate EBV specific CTLs.
45789186|NCT02578641|Drug|combination IV gemcitabine and IV carboplatin (AUC2)|4 cycles for Arm A and 6 cycles for Arm B
45789187|NCT05084859|Drug|SM08502|SM08502 to be administered orally.
45789188|NCT05084859|Drug|Abiraterone|Abiraterone to be administered orally.
45789189|NCT05084859|Drug|Prednisone|Prednisone to be administered orally.
45789190|NCT05084859|Drug|Docetaxel|Docetaxel to be administered intravenously.
45789191|NCT05084859|Drug|FOLFIRI Protocol|FOLFIRI Protocol to be administered intravenously.
45789192|NCT05084859|Drug|Panitumumab|Panitumumab to be administered intravenously.
45789193|NCT00367575|Procedure|Internet personalized alcohol feedback (PAF)|
45449487|NCT03189524|Drug|Zanubrutinib|Zanubrutinib is a white to off-white solid that is slightly hygroscopic. The drug product was formulated as 20-mg (blue, size 3) and 80-mg (white, size 0) hard gelatin, opaque oral capsules. Zanubrutinib is classified as a Biopharmaceutics Classification System Class II compound.
45449488|NCT02150824|Drug|Placebo|BI 187004 high dose matching placebo once daily
45646142|NCT03073655|Other|Negative Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been limited evidence of KT is effective during application.
45646143|NCT03073655|Other|Neutral Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been not known that KT is effective or not during application.
45646144|NCT03073655|Other|Positive Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been known that KT has excellent result during application.
45646145|NCT04770805|Procedure|Fetoscopy|After an exteriorization of the uterus through a laparotomy, humidified and warmed gas will be insufflated with low pressure (6 to 8mmHg mmHg). Fetoscopic repair surgery will consist in a dissection of the placode, its reintegration into the spinal canal and the closure of the lesion, through a three ports access. After fetal surgery, the gas will be exsufflated and the trocar ports will be closed. The uterus will be reintegrated before suturing the maternal abdominal wall.
45653106|NCT05118087|Procedure|Pre-Fabricated Fracture Brace|Patients in the sarmiento group will be given a fitted pre-fabricated fracture brace with a cuff and collar for the forearm. The patients will be educated on brace maintained, tightening, and care during at the time of the ER encounter.
45789194|NCT01846871|Drug|Tivozanib|
45449489|NCT02150824|Drug|Placebo|BI 187004 medium dose matching placebo once daily
45789195|NCT02431260|Drug|INCB054329 Monotherapy|Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the treatment group A (TGA), with subsequent cohort escalations in the three treatment groups (TGA, TGB, and TGC) based on protocol-specific criteria
45789196|NCT05745545|Biological|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine|One dose was administered by intramuscular injection, 100μg，1.0ml/dose
45919863|NCT04996680|Device|Blood Flow Restriction (by using smart-cuff pro devices, acting as pressurized tourniquet) combined low load strengh training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with optimal pressurized blood flow restriction
45449490|NCT02150824|Drug|Placebo|BI 187004 high dose matching placebo once daily add on to background metformin
45449491|NCT02150824|Drug|BI 187004|BI 187004 high dose once daily add on to background metformin
45449492|NCT02150824|Drug|Placebo|BI 187004 low dose matching placebo once daily
45789197|NCT05745545|Drug|Saline solution|One dose was administered by intramuscular injection, 0.5ml/vial
45449493|NCT02150824|Drug|BI 187004|BI 187004 medium dose once daily
45449494|NCT02150824|Drug|BI 187004|BI 187004 low dose once daily
45449495|NCT02150824|Drug|BI 187004|BI 187004 high dose once daily
45789198|NCT01847027|Drug|NutraStem|"Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.~Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress."
45789199|NCT01847027|Drug|Placebo|Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.
45789200|NCT02055963|Drug|Minocycline|100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
45789201|NCT02055963|Drug|Placebo|Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
45919864|NCT04996680|Other|Standardised low load strength training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises
45919865|NCT04996680|Device|Sham-BFR (by using smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with blood flow restriction, but pressurized so the occlusion cuff has no significant effect on the lower limb blood flow.
45919866|NCT04712435|Drug|N-acetylcysteine|Eligible patients will be randomised to receive N-acetylcysteine versus matching placebo
45919867|NCT04712435|Drug|Placebo|Eligible patients will be randomised to receive N-acetylcysteine versus matching placebo
45919868|NCT04121962|Behavioral|Peer Mentor|Participants will be trained to be Peer Mentors and promote home-based testing to their social network
45919869|NCT04121962|Behavioral|Website only|Participants will be given instructions on how to use the project website to request kits to test for HIV at home and collect specimens for lab testing.
45919870|NCT04104022|Behavioral|Prolonged Exposure Therapy|Within the general population, prolonged exposure therapy (PET) is a widely-used, empirically-supported and manualized therapy that is regarded as a first-line cognitive-behavioral treatment for posttraumatic stress disorder (PTSD). PET is designed to disrupt the cycle of anxiety and avoidance that characterizes PTSD via sustained imaginal and in-vivo exposure exercises that deliberately and systematically expose patients to painful memories and current, real-life trauma reminders that were previously avoided, yet not inherently harmful. Overall, PET has well-documented efficacy for reducing PTSD symptom severity in both civilian and veteran populations. PET is effective for reducing PTSD symptoms regardless of whether it is delivered remotely or face-to-face. Recent data also suggest that PET can improve PTSD symptoms without exacerbating substance use or craving among patients with substance use disorders when PET and substance use disorder treatment are delivered concurrently.
45919871|NCT04104022|Behavioral|Attendance-based monetary incentives|Participants will earn vouchers that have monetary value for attending scheduled PET appointments. Each consecutive attended session will increase the voucher amount so that each consecutively attended appointment is worth an incrementally higher dollar amount. To support completion of the full 12-week PET protocol, we will also incorporate additional strategically-placed bonuses into the reinforcement schedule with the goal of maximizing the percentage of subjects who complete the full 12-session protocol. First, to support consistent (vs. sporadic) attendance, participants will receive a bonus for every two consecutive sessions attended. Second, to support completion of the full PET protocol, participants will receive an additional bonus upon completion of Session 12.
45919872|NCT04993482|Other|No intervention|This project contains a longitudinal observational study design. The investigator will collect data out of a group with type 2 diabetes mellitus patients and out of group with control adults on three time points (baseline, follow-up after one year, and follow-up after two years). Therefore, the investigator will only collect observational data and the participants will not be exposed to a certain intervention.
45919873|NCT04102579|Drug|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
46071327|NCT04849676|Other|visual neurofeedback|"Neurofeedback is a neuromodulatory intervention that does not require applying external stimuli. It relies on displaying participants' brain activity in real time, with the aim of modifying it. Electrical activity (EEG) will be recorded from participants and displayed in real time on a computer screen, in the form of three bars. They will be asked to increase the middle bar, while keeping the side bars low.~The intervention requires training to achieve voluntary control of the targeted brain activity."
46071328|NCT02550223|Procedure|radial artery Catheterization|Insertion of radial artery catheter for sampling and blood pressure measurement
45646146|NCT03139591|Drug|lidocaine inhalation; intravenous dexamethasone|1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection; Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone.
45646147|NCT03071237|Procedure|Gastrectomy|Patients with gastric cancer that needs receiving total or distal gastrectomy. During the surgery, IPA needs to be exposed and transected.
45646148|NCT02553967|Device|Functional MRI|Functional MRI
45646149|NCT04990115|Other|root canal shaping|root canal treatment
45646150|NCT04756375|Device|Virtual Reality|Use of virtual reality in the management of sickle cell patients with VOS
45646151|NCT04756375|Other|Usual Care|Usual management of sickle cell patients with VOS
45646152|NCT04987619|Dietary Supplement|Beetroot juice|Subjects will drink juice 120 minutes before each visit
45646153|NCT04987619|Other|Capri-Sun|70 mL of blackcurrant beverage, which is depleted of NO3- will be taken 120 min before each visit.
45646154|NCT03139357|Other|GAD7, SF12, medical utilization, helpfulness questionnaire|The questionnaires are administered to track stress level and medical utilization over a 2 year period.
45646155|NCT03140917|Diagnostic Test|Multimodal liver function assessment|HBS, MRI, CE-CT and ICG
45646156|NCT04469101|Procedure|Lumbar Epidural|Parturients will have an epidural placed in the upright seated position as per institution standard. After epidural placement, they will be positioned as per their randomization. They will then have a total of 20 cc of epidural solution (0.08% ropivacaine with 2 mcg per cc of fentanyl) injected into the epidural in boluses of 5 cc every 5 minutes.
45646157|NCT04987853|Diagnostic Test|Clinical and functional analysis|"General blood analysis - Complete blood count on an analyzer with differentiation of 5 classes of cells, the ratio of neutrophils to lymphocytes; Blood chemistry - ALT, AST, total bilirubin, direct, LDH, CRP, alpha-amylase, creatinine, urea, glucose, ferritin, glycosylated hemoglobin, vitamin 25 - OH vitamin D, vitamin B12; Coagulogram - D-dimers, fibrinogen, INR, APTT; Other - NT-pro BNP, Homocysteine, IL 6, Troponin, blood group determination; Linked immunosorbent assay - Determination of IgG and IgM antibodies to SARS-CoV-2 coronavirus (COVID-19) in blood serum, RBD; Functional diagnostics • ECG~EchoCG + strain~CT scan of the lungs~Holter~SMAD~Kidney ultrasound~Ultrasound~Doppler ultrasonography of veins and arteries~Chalder Scale, EQ Questionnaire"
45653107|NCT03067909|Other|CIED surgery|
45653108|NCT03121469|Device|Papillon +TM|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
45653109|NCT05177133|Drug|Capecitabine|PO Capecitabine
45653110|NCT05177133|Drug|Oxaliplatin|IV Oxaliplatin
45653111|NCT05177133|Drug|Retifanlimab|IV retifanlimab
45789202|NCT02055963|Behavioral|Questionnaires|Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21.
45789203|NCT01848041|Drug|RVL-1201|RVL-1201 0.1% Ophthalmic Solution
45789204|NCT01848041|Drug|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
45789205|NCT02724033|Procedure|regional nerve block|regional nerve block
46071329|NCT02844140|Procedure|DE-CT's and SE-CT|Patients included in the trial will receive 3 extra DE-CT's and 3 extra SE-CT's
45789206|NCT02724033|Drug|Antiemetic|Antiemetic
45919874|NCT04102579|Drug|Placebo|non-active dosage form
45646158|NCT04987853|Diagnostic Test|Neurological analysis|"Neurological examination with the isolation of neurological syndromes (motor, cognitive impairments, sleep disorders, asthenic-depressive syndromes, etc.).~2. Neuropsychological methods - research on the scales of anxiety and depression, MMSE, etc.~3. Instrumental method - EEG, polysonography, ultrasound of the neck vessels, CT perfusion.~4. Laboratory research methods:~The study of antibodies to some neurospecific antigens - myelin basic protein (MBP), neurospecific enolase (NSE).~Study of cellular immunity (CD3 +, CD4 +, CD8 +) and general indicators of humoral immunity (IgG, IgA, IgM, circulating immune complexes)."
45919875|NCT04712513|Diagnostic Test|Dynamic cardiac CT perfusion imaging|Multiple images of the heart are acquired with a clinical CT scanner after an intravenous bolus injection of contrast solution. The images are then analyzed to provide fractional flow reserve and myocardial perfusion values.
45919876|NCT03999853|Drug|BKR-017|BKR-017
45646159|NCT04987853|Diagnostic Test|Immunological analysis:|A comprehensive immunological analysis will be carried out to determine the level of the immune response. Calculation of the level of CD4 +, CD8 + and NK cells. The level of antibodies of the IgG and IgM classes to the proteins of the coronavirus S1, RBD and N was determined
45646160|NCT04987853|Diagnostic Test|Genetic analysis:|Isolation (extraction) of DNA will be performed from whole blood using commercial kits according to the manufacturer's instructions. To analyze a large number of genetic markers, it is planned to carry out genome-wide sequencing followed by analysis of genetic polymorphisms of candidate genes encoding coronavirus receptors and immunological factors.
45646161|NCT05154565|Behavioral|Guided meditation|App-based guided meditation intervention through Headspace. This can be accessed through various mobile devices.
45646162|NCT02634983|Drug|QVA149|QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.
45646163|NCT02634983|Drug|Placebo|Matching placebo
45646164|NCT05115799|Other|Manual Therapy, Physiotherapy, Kinesiology, Scar Massage|"The physiotherapist performs passive kinesitherapy on the mastectomized patient with lymphatic thrombus, and scar massage when the arm maintains its greater range of mobility.~The patient will never present pain during the rehabilitation session above 5 in Pain Scale Analog Scale."
45789207|NCT02724423|Drug|NRL-1|
45789208|NCT02267837|Device|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
45789209|NCT05745311|Drug|The KPCXM18 injection|Intravenous infusion
45919877|NCT03979729|Other|Routine Screening Mammogram (3D + 2D)|Subjects that have undergone a routine screening mammogram (3D + 2D) will be interviewed by a member of the research team who will ask a few questions to better understand how the subject made this decision and what things may have influenced her decision between different types of mammograms.
45919878|NCT03979729|Other|Routine Screening Mammogram (2D)|Subjects that have undergone a routine screening mammogram (2D) will be interviewed by a member of the research team who will ask a few questions to better understand how the subject made this decision and what things may have influenced her decision between different types of mammograms.
45919879|NCT03979729|Other|No Screening Mammogram|Subjects will participate in a one-time facilitated focus group.
45919880|NCT04991376|Diagnostic Test|Blood-specific miRNA levels|Blood-specific miRNA levels associated with renal tubular damage change in patients treated with vancomycin or gentamicin compared to septic patients treated with other antimicrobials.
45449496|NCT03600909|Drug|Busulfan|"A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity."
45789210|NCT05745311|Drug|Placebo|Intravenous infusion
45789211|NCT02726451|Other|Basic Skin Care|Facial Wash, Hydrator Plus Broad Spectrum SPF 30, and Rebalance skin care products (PCA SKIN®)
45789212|NCT02726451|Other|Active Skin Care|Sensi Peel®, Rejuvenating Serum, and C&E Strength Max skin care products (PCA SKIN®) in addition to the Facial Wash, Hydrator Plus Broad Spectrum SPF 30, and Rebalance skin care products (PCA SKIN®)
45789213|NCT02989259|Drug|Apatinib|apatinib 500mg p.o. qd
45789214|NCT02730663|Device|Niti-S SPAXUS Stent|Endoscopic Ultrasound-Guided Transluminal drainage
45789215|NCT05743205|Behavioral|voluntary consultative wellness session|Professional wellness counseling sessions provided to health care professionals through voluntary enrollment. Consultative sessions will conducted throughout the course of 1 year and number of subsequent sessions will be determined by the participant.
45919881|NCT04712084|Procedure|Positive pressure|Inspiratory support of 8 cmH2O was applied associated with PEEP at 6 cmH2O. After extubation, same support was applied by facemask for 3 minutes
45919882|NCT03977194|Drug|Carboplatin|AUC 6 every 4 weeks
45919883|NCT03977194|Drug|Paclitaxel|90 mg/m² D1, 8, 15, every 4 weeks
45919884|NCT03977194|Drug|Atezolizumab|1200 mg every 3 weeks
45919885|NCT04729465|Drug|Propofol|Propofol
45919886|NCT04729465|Device|Bispectral Index Monitor|Bispectral Index Monitor
45919887|NCT04712162|Other|Other|Compare time to awakening and quality of recovery after general anesthesia between two groups.
45919888|NCT03953443|Other|Not interventional|
45789216|NCT04985253|Other|prediction of overall survival using Web based PREDICTV2.0 portal|"Predict is an online prognostication and treatment benefit tool developed in the UK, using cancer registration and survival data recorded by the Eastern Cancer Registration and Information Centre (ECRIC) for 5694 women diagnosed in East Anglia from 1999-2003.~The model was validated in a second cohort of 5468 women from the West Midlands Cancer Intelligence Unit and is available online (www.predict.nhs.uk) providing 5-and 10-year survival estimates and treatment benefit predictions. Wong et al, tested the predictive accuracy of PREDICT V1.0 in the southeast Asian population. There were 67% Chinese patients while 13% were Indians. They showed concordance in observed and predicted OS in most subgroups except for women whore less than 40 years of age."
45789217|NCT01848821|Device|OASIS Ultra|Porcine derived intestinal submucosa
45789218|NCT01848821|Device|Wound VAC Standard Therapy|Negative pressure wound device aka wound VAC will be placed on the standard therapy half of the wound
45789219|NCT04950621|Drug|remimazolam|Remimazolam will be administered during induction and maintenance for general anesthesia.
45449497|NCT03600909|Drug|Fludarabine|Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.
45449498|NCT03600909|Drug|Cyclophosphamide|Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
45789220|NCT04950621|Drug|propofol|Propofol will be administered during induction and maintenance for general anesthesia.
45789221|NCT01578135|Drug|somatropin|Patients are to fill in a questionnaire at inclusion in registry
45789222|NCT01578135|Drug|somatropin|Patients are to fill in a questionnaire 6 months after inclusion into registry and then annually until adult height is reached
45646165|NCT05115799|Other|Kinesiotherapy, Physiotherapy, Health Education|These users will be instructed in hygienic-postural care and active auto-kinesitherapy assisted to perform daily for 30 minutes. The investigators will value following the instructions every 30 days
45789223|NCT04575155|Behavioral|TEAM Strategy|"Pharmacists will have read/write EHR access with established Epic security points~Pharmacists will initiate medication reconciliation activities by calling the patient for a Comprehensive Medication Review. Pharmacists will add notes in their medication list for the prescriber, requesting the removal or discontinuation of prescribed drugs that patients report they are not taking and adding medications omitted from the provider's list. The pharmacist will provide notifications via secured Epic messaging direct to prescribers of any patient concerns.~At 6 month if poor adherence is determined, the pharmacist will initiate Therapy Management Review which is a call from the pharmacist to the patient specifically about the medication(s) for which they have poor adherence. If necessary, the pharmacist will create notes and send an in-basket message to the prescriber.~The prescriber will make changes to the patient's EHR and/or contact the patient as they see fit."
45789224|NCT01469247|Radiation|Radiation Therapy|Starting Dose 24 Gy in 2 Gy fractions.
45789225|NCT01848899|Drug|Iodixanol|contrast media used during coronary angiography
45789226|NCT01848899|Drug|Ioxaglate|contrast media used during coronary angiography
45789227|NCT01848899|Drug|Bivalirudin|A direct thrombin inhibitor
45789228|NCT00422409|Procedure|Endoscopic stenting|
45789229|NCT01848977|Device|vascular occlusion test|Using Invos® probe attacted to one thenar muscle, tissue oxgyenation is measured by VOT.
45919889|NCT03941782|Drug|Alpelisib|As a single agent, alpelisib will be administered at a starting dose of 350 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this protocol. No pretreatment will be given prior to the medication.
45919890|NCT02965183|Other|Temperature measurements|
45919891|NCT04729309|Drug|[12C] RO7049389|Participants will receive oral [12C] RO7049389.
45919892|NCT04729309|Drug|[13C] RO7049389|Participants will receive IV [13C] RO7049389.
45919893|NCT04729309|Drug|[14C] RO7049389|Participants will receive an oral suspension of [14C] RO7049389.
45919894|NCT04712357|Drug|Vitamin C 500 MG Oral Tablet|Vitamin C 500 MG per day for 10 days
45919895|NCT04712357|Drug|Tenofovir disoproxyl fumarate 300 MG Oral Tablet|Tenofovir disoproxyl fumarate 300 MG per day for 10 days
45919896|NCT04712357|Drug|Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet|Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG per day for 10 days
45919897|NCT03041844|Device|Low Frequency, Low Intensity Ultrasound|Therapeutic ultrasound (20 kHz, <100 mW/cm2 spatial peak-temporal peak)
45646166|NCT02405845|Radiation|Computed Tomographic Angiogram|1 additional non-clinical CTA per patient enrolled in the study. The estimated radiation risk from a single CTA of the neck and brain is approximately 3.6 millisieverts (mSv), an exposure similar to a single airplane flight across Canada.
45646167|NCT04037215|Other|STUDY OF THE COGNITIVE TREATMENT OF DIETARY STIMULI AND BODY IMAGE|"Describe the cognitive treatment of patients with early onset anorexia nervosa in response to specific stimuli of the disorder (eating and body images), compared to age- and sex-matched control subjects:~children controls not achieved with normal BMI;~children with unbalanced insulin-dependent type 1 diabetes, therefore subject to a strict diet that requires good nutritional knowledge and no weight judgment disorders."
45646168|NCT04987151|Other|Experimental-Strength training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength training exercise involving the major muscle groups
45789230|NCT01848977|Device|vascular occlusion test|Using Inspectra™ probe attacted to another thenar muscle, tissue oxgyenation is measured by VOT.
45789231|NCT02731833|Other|stannous fluoride|0.454% weight by weight (w/w) stannous fluoride containing 1100ppm fluoride
45789232|NCT02731833|Other|sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
45919898|NCT03041844|Device|Sham Applicator|Sham ultrasound applicator
45449499|NCT03600909|Drug|Anti-Thymocyte Globulin (Rabbit)|Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment
45789233|NCT01852019|Drug|Cangrelor|Cangrelor IV administered as a 30 µg/kg bolus, followed by 4 µg/kg/min infusion for two hours on study Days 1 and 8
45919899|NCT03794908|Device|Light therapy A (Bright) via the Re-Timer®|Subjects will conduct light treatment in the mornings at home for one hour using Re-timer®.
45789234|NCT01852019|Drug|Prasugrel|"Day 1: Subjects received prasugrel (60 mg) either during the initial cangrelor infusion (at 1.0 hours or 1.5 hours after infusion start) or within 5 minutes of discontinuing the cangrelor infusion.~Subjects will be given either 5 or 6 additional 10-mg doses to be taken every 24 hours between Day 1 and Day 8."
45789235|NCT00422487|Drug|MBX-2044|MBX-2044 1.5 mg one capsule daily for 14 days
45789236|NCT00422487|Drug|MBX-2044|MBX-2044 4.5 mg three 1.5 mg capsules daily for 14 days
45789237|NCT00422487|Drug|MBX-2044|MBX-2044 15 mg one capsule daily for 14 days
45789238|NCT00422487|Drug|MBX-2044|MBX-2044 30 mg two 15 mg capsules daily for 14 days
45789239|NCT00422487|Drug|MBX-2044|MBX-2044 60 mg one capsule daily for 14 days
45919900|NCT03794908|Device|Light therapy B (Dim) via the Re-Timer®|Subjects will conduct light treatment in the mornings at home for one hour using Re-timer®.
45449500|NCT03600909|Device|The CliniMACS device|The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device)
45919901|NCT04712201|Procedure|En bloc transurethral resection of bladder tumor (TURBT)|En bloc transurethral resection of bladder tumor using thulium:yttrium aluminium garnet, monopolar and bipolar energy
45919902|NCT04712201|Procedure|Conventional TURBT|Conventional transurethral resection of bladder tumor using monopolar and bipolar energy
45449501|NCT03600909|Drug|G-CSF|All patients will also receive G-CSF post-transplant to foster engraftment.
45919903|NCT00390039|Drug|Intranasal Morphine|MNS075 7.5mg q1h PRN
45919904|NCT00390039|Drug|Placebo|IN Placebo q1h PRN
45919905|NCT00390039|Drug|IV morphine|IV morphine 7.5mg q3h PRN
45449502|NCT03727269|Other|Wii Fit Training Experimental Group|Experimental group receiving wii fit game based abdomino-pelvic training. A specific protocol was developed by the researchers. Wii fit games which promote exercises focusing on the abdominopelvic cavity strengthening, using as a therapeutic means a Wii™ console with a Wii Fit Plus™ CD game. The protocol was design that which playing games participant perform different pelvic movements such as anteversion, retroversion, lateral tilt and circumduction that maintain trunk control and stabilization with mild abdomino-pelvic muscle activation. Duration of each game is 5 minutes with 90 seconds interval between them twice a week. After performing the sequence of virtual games, a series of abdominopelvic and lower limb muscle stretching exercises will done.
45449503|NCT03727269|Other|Conventional Training|"Control group (n=20) receiving conventional pelvic floor exercises. Conventional exercises includes:~Knack Maneuver (Ashton -Miller 1998, 2008)~Pelvic floor strengthening: kegel Exercise.~-Lumbo-Pelvic Stabilization Exercise.~Functional Training/ PFM Contraction during ADL~Correction of biomechanical/structural deformities"
45449504|NCT03189446|Radiation|Vaginal Cuff Brachytherapy|Within 12 weeks of surgery. Either LDR or HDR brachytherapy will be permitted
45919906|NCT00390039|Drug|Placebo|IV Placebo q3h PRN
45646169|NCT04987151|Other|Experimental-Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to brisk walking.
45646170|NCT04987151|Other|Experimental-Strength/Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching), 15 minutes are allocated to brisk walking and 25 minutes are allocated to strength training involving the major muscle groups.
45919907|NCT00390039|Drug|Intranasal morphine|MNS075 15mg q3h PRN
45919908|NCT00390039|Drug|Placebo|IN Placebo q3h PRN
45919909|NCT01838369|Drug|BI-505|
45449505|NCT03189446|Drug|Carboplatin|Carboplatin IV on day 1 of a 21 day cycle for 3 cycles
45449506|NCT03189446|Drug|Paclitaxel|Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles
45449507|NCT02151136|Drug|24% sucrose|
45646171|NCT03141229|Behavioral|Mindfulness based stress reduction|
45646172|NCT04412291|Drug|Anakinra Prefilled Syringe|A total dose of 400mg per day (divided in 4 doses of 100 mg iv every 6 hours) for 7 days.
45789240|NCT00422487|Drug|MBX-2044|MBX-2044 90 mg one 60 mg capsule and two 15 mg capsules daily for 14 days
45789241|NCT00422487|Drug|Placebo for MBX-2044|Placebo Intervention
45789242|NCT02430870|Drug|TAK-648|TAK-648 solution
45789243|NCT02430870|Drug|Placebo|TAK-648 placebo-matching solution
45789244|NCT04768751|Diagnostic Test|kidney assessment|Urea, BUN, and Creatinine BLOOD LEVELS
45789245|NCT04340037|Procedure|percutaneous nephrolithotomy|percutaneous surgery using nephroscope
45789246|NCT05731505|Behavioral|theory-based education-consulting|Parents in the study groups were provided with training and support in line with their needs in the educational issues specified in the Family Education-Support Booklet for a Child with Cerebral Palsy. The control group was not trained. Research data were collected using the Child and Parent Information Form, Needs Determination Form, Relaxed Behavior Checklist (KDKL), Quality of Life for Children Parent Form (PIDQ) and Self-Efficacy Scale. The comfort and quality of life of the children in the study group and the self-efficacy of the parents were evaluated before the education, 1 month and 3 months after the education.
45789247|NCT04457219|Device|Haemostatic Dressing|A Hemostatic Dressing is applied at the radial access site, following a transradial angiographic procedure. This is a mineral-based dressing with a hydrophilic polymer that works independently of the clotting cascade to seal the site, by accelerating topical hemostasis.
45789248|NCT04457219|Device|Conventional Dressing|A Conventional Absorbent Dressing is applied at the radial access site, following the transradial angiographic procedure.
45789249|NCT04457219|Device|120 Minutes External Compression|A radial compression device is applied at the radial access site to achieve patent hemostasis. The device remains in situ for 2 hours. Prolonged time of compression may be required.
45789250|NCT04457219|Device|60 Minutes External Compression|A radial compression device is applied at the radial access site to achieve patent hemostasis. The device remains in situ for 1 hour. Prolonged time of compression may be required.
45789251|NCT04450979|Dietary Supplement|Bioactive hydrolysate|Participants given a bioactive vegetable hydrolysate to take one dose each morning and one dose each evening for the duration of the study.
45789252|NCT04433273|Device|Electrical vestibular nerve stimulation|Electrical vestibular nerve stimulation using a headset device
45449508|NCT02151136|Drug|Sterile water|
45789253|NCT02732145|Diagnostic Test|"Three Rings Vulvoscopy (TRIV)"|"Mapping of the vulvar lesions according to the three vulvar rings and specificity of the lesions during Three Rings Vulvoscopy technique (TRIV Form Data). Assessing of the data by the Vulvoscopy Index and the N-S-P Scheme."
45789254|NCT02732145|Procedure|Histopathology|Biopsy of the vulva in symptomatic patients, vulvar samples after labiaplasty in asymptomatic patients.
45789255|NCT04372979|Drug|Transfusion of SARS-CoV-2 Convalescent Plasma.|2 Convalescent Plasma units of 200-230mL each, inactivated by amotosalen.
45789256|NCT04372979|Drug|Transfusion of standard Plasma.|2 Standard Plasma units of 200-230mL each, inactivated by amotosalen.
45789257|NCT02430480|Drug|Goserelin|10.8mg administered subcutaneously every 12 weeks (2 doses)
45789258|NCT02430480|Drug|Enzalutamide|160mg orally, daily for 24 weeks
45789259|NCT02430480|Device|mpMRI|Multiparametric MRI - One at baseline and after 6 months of treatment
45449509|NCT02151136|Other|Standard care|The current standard of care at the study site is use of topical anesthetic (Ametop or EMLA), upright holding of toddler by parent/caregiver during procedure, use of age appropriate nurse directed distraction, and sucking on a pacifier (if normally used by child)
45449510|NCT03212690|Drug|Local standard of care|Local standard of care will include fluid resuscitation, use of vasopressor drugs and renal support.
45646173|NCT04412291|Drug|Tocilizumab Prefilled Syringe|8mg/kg for a single infusion iv up to max 800 mg. If no clinical response is obtained, another dose of 8mg/kg may be administered after earliest 2 days after inclusion with the following condition: The clinical symptoms are worsened (as assessed by decreasing PaO2/FiO2 and/or need of increased ventilatory support such as NIV, HFNC or mechanical ventilation).
45789260|NCT01852175|Drug|Prasugrel|Prasugrel 60mg loading dose and 10mg maintenance dose
45789261|NCT01852175|Drug|Ticagrelor|Ticagrelor 180mg loading dose and 90mg bid maintenance dose
45789262|NCT02429934|Biological|abatacept also known as Orencia also known as CTLA4-Ig|125mg injected subcutaneously weekly for 16 weeks
45919910|NCT03675022|Drug|Dupilumab|The investigational drug is dupilumab, 300mg in 2ml solution for subcutaneous application. All Patients will receive dupilumab, 300mg, every two weeks (8 subcutaneous injections total).
45919911|NCT04954326|Drug|Lyophilized S95014|"Lyophilized S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.~Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol."
45919912|NCT04954326|Drug|Liquid S95014|"Liquid S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.~Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol."
45919913|NCT00399919|Drug|Propionyl-L-Carnitine|2 grams per day for six months
45919914|NCT00399919|Drug|PLC|2 grams/day for six months
45449511|NCT03212690|Procedure|Mechanical ventilation|Mechanical ventilation will be based on volume-assist control mode, with a target tidal volume of 6-8 milliliter per kg (mL/kg) and a target plateau pressure of 30 centimeter of water (cmH2O).
45646174|NCT04412291|Drug|Standard-of-care treatment|"SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2>93%. Thrombosis prophylaxis (Fragmin or Innohep and Klexane® or new oral anticoagulants including dabigatran, apixaban or rivaroxaban).~Steroids (Betapred 6 mg po) Broad spectrum antibiotics (only in arm B and C)"
45646175|NCT03141073|Drug|HMS5552|BID oral administration
45646176|NCT03141073|Drug|Placebo|BID oral administration
45646177|NCT04456361|Biological|Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords|Mesenchymal Stem Cells as a single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.
45646178|NCT03139513|Drug|Cobimetinib|Participants will receive cobimetinib as per local guidelines and/or routine clinical practice.
45646179|NCT03139513|Drug|Vemurafenib|Participants will receive vemurafenib as per local guidelines and/or routine clinical practice.
45789263|NCT02429934|Drug|Placebo|
45789264|NCT01852799|Drug|PAD Followed by ASCT|"Drug: Bortezomib, Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11, of each 28 day cycle)~Drug: Adriamycin (Doxorubicin) /EPI, Adriamycin (Doxorubicin) (9 mg/m2, iv, on days 1-4 of each 28 day cycle) or EPI (15mg/m2, iv, on days 1-4 of each 28 day cycle)~Drug: Dexamethasone, Dexamethasone (20mg, iv, on days 1-4, 8-11of each 28 day cycle)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators."
45646180|NCT03071081|Drug|TOP1288|Oral TOP1288
45646181|NCT03071081|Drug|Placebo to TOP1288|Oral placebo to TOP1288
45789265|NCT02429856|Device|SCORPIO™|subjects randomized at surgery to receive 1 of the 2 specified implants
45789266|NCT02429778|Behavioral|Diaphragmatic Breathing|Deep or diaphragmatic breathing is taught prior to relaxation.
45789267|NCT02429778|Behavioral|Progressive Muscle Relaxation|Tensing and releasing muscle groups in a specified order to help reduce tension and anxiety.
45789268|NCT02403180|Device|DACP MF|Nelfilcon A multifocal contact lenses
45919915|NCT00399997|Behavioral|Exercise on Prescription|
45789269|NCT02403180|Device|PROCLEAR 1D MF|Omafilcon A multifocal contact lenses
45919916|NCT00400036|Behavioral|Cod protein NCEP-diet|
45789270|NCT01852955|Drug|IV acetaminophen|Administration of IV acetaminophen 1000 mg over 15 minutes at the start of surgical closure
45789271|NCT01852955|Drug|Placebo|Administration of placebo (sterile normal saline)group-same volume of saline solution administered in the same fashion as the acetaminophen
45789272|NCT00558467|Drug|pramipexole immediate release (IR)|
45789273|NCT00558467|Drug|Placebo|
45789274|NCT02402166|Drug|SPD489|All subjects will begin with 5mg of SPD489 daily and will be titrated until optimal dose is reached (5, 10, 15, 20, and 30mg)
45789275|NCT02378220|Genetic|Pharmacogenetic testing|Pharmacogenetic testing via YouScript® Personalized Prescribing System
45789276|NCT04226495|Drug|Sufentanil Infusion|Intra-operative sufentanil infusion
45789277|NCT04226495|Drug|Sufentanil Bolus|Intra-operative sufentanil bolus
45789278|NCT02401308|Procedure|Deep Brain Stimulation surgery|Deep Brain Stimulation surgery: awake vs. asleep
45789279|NCT02401230|Drug|Truvada|Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
45919917|NCT04935801|Biological|LD vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
45919918|NCT04935801|Biological|LD PepGNP-Dengue|Two intradermal injections in the upper arm spaced 21 days apart
45919919|NCT04935801|Biological|HD vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
45919920|NCT04935801|Biological|HD PepGNP-Dengue|Two intradermal injections in the upper arm spaced 21 days apart
45919921|NCT03393013|Drug|KZR-616|Subcutaneous Injection of KZR-616
45919922|NCT01269593|Drug|PET Imaging using 124 IPUH71|A dose of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71 will be administered intravenously with the patient at rest. 124I-PUH71 scans will be performed at immediately and/or 3-4 hours, 20-24 hours, and 40-80 hours after injection of the radiotracer. Optionally, in willing patients scans will be performed 160-200 hours (~7-8 days) after injection of the radiotracer. At each time-point, a 45-60 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point. A 30-45 minute scanning timeperiod is typical for clinical PET studies.
45919923|NCT03239041|Behavioral|Social navigation team|Social navigation team
45449512|NCT05390216|Procedure|Partial capsule decortication|The anterior wall of the capsule was removed during the operation.
45449513|NCT03568461|Biological|tisagenlecleucel|Tisagenlecleucel is single infusion.
45646187|NCT04986995|Drug|Opicapone|Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
45646188|NCT04987073|Procedure|skin biopsy|A skin biopsy to cultivate fibroblasts.
45646189|NCT03139435|Procedure|Biopsy|Undergo skin biopsy
45646190|NCT03139435|Other|Questionnaire Administration|Ancillary studies
45646191|NCT03139435|Diagnostic Test|Ultrasound Tomography|Undergo peripheral nerve ultrasound
45646192|NCT03070067|Other|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
45919924|NCT02965105|Device|Coloplast Test Catheter|This is a newly developed intermittent catheter
45919925|NCT02965105|Device|Speedicath|This is a marketed Catheter which is used as comparator
45646193|NCT03971929|Drug|SHR0532|once daily(QD) for 4weeks
45646194|NCT03971929|Drug|SHR placebo|once daily(QD) for 4weeks
45646195|NCT03971929|Drug|Hydrochlorothiazide 25 mg|once daily(QD) for 4weeks
45646196|NCT03071159|Device|FreeStyle Flash Libre glucose monitoring system|glucose monitoring system with sensors
45646197|NCT03626389|Other|Physiotherapy|
45646198|NCT03071003|Drug|SENS-401|Oral Administration
45646199|NCT03071003|Drug|Placebo|Oral Administration
45646200|NCT03139201|Device|OxyAqua|OxyAqua (olifilcon D) silicone hydrogel soft contact lens
45646201|NCT03139201|Device|Si-Hy|Si-Hy (oliflcon B) silicone hydrogel soft contact lens
45789280|NCT02401230|Device|Gel lubricant|Five ml of an over the counter sexual lubricant will be dispensed using an applicator.
45789281|NCT01854359|Drug|Idebenone|
45789282|NCT01854593|Drug|Bevacizumab|0.16 mg/0.05 ml bevacizumab (single injection on 1 day before operation)
45789283|NCT01854593|Procedure|Vitrectomy|vitrectomy of 25 gauge system.
45789284|NCT01854593|Device|Sham injection|Sham injection one day before vitrectomy
45789285|NCT02429310|Device|Revitive IX|This is a neuromuscular electrical stimulation device
45789286|NCT05706935|Diagnostic Test|MeMed BV® test|The MeMed BV® test is an automated semiquantitative immunoassay that measures three nonmicrobial (host) proteins (TRAIL, IP-10, and CRP) in serum samples and is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection.
45789287|NCT04017143|Behavioral|HPV app intervention|Participants assigned to this group will receive an HPV app that targets a dyad of parent and a teen boy or girl.
45789288|NCT01854905|Other|No Treatment|Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.
45789289|NCT01855997|Drug|Peg-IFN alfa-2a|Participants received Peg-IFN alfa-2a prior to enrollment for at least 24 weeks. Dosing was chosen according to standard of care or at the discretion of the treating physician.
45789290|NCT02734953|Drug|Nitric Oxide|Ambulatory inhaled nitric oxide delivery system and 6 minute walk distance test
45789291|NCT04899141|Device|Percutaneous Coronary Intervention|stenting with the ihtDEStiny® sirolimus eluting stent
45789292|NCT00573729|Other|Pulsed Dye Laser 577 nm|Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
45789293|NCT00573729|Other|Pulsed Dye Laser 595 nm|Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
45789294|NCT00555711|Device|Modulated Imaging|Modulated Imaging
45789295|NCT02428608|Biological|DWP-450 (Botulinum purified neurotoxin, Type A)|Botulinum toxin, Type A
45789296|NCT02735187|Device|Blue light treatment|Phototherapy of localized psoriasis vulgaris plaque with a wearable device emitting blue light at 453nm.
45789297|NCT02735187|Drug|Vitamin D|Treatment of contralateral localized psoriasis vulgaris plaque with Vitamin D creme (Daivonex)
45789298|NCT02428296|Drug|Sirolimus|Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
45646202|NCT04986761|Procedure|Treatment of implant single crown|Digital or Conventional Workflows for treatment of implant single crown and materials used.
45919926|NCT03016156|Other|CRADLE|"A smartphone software application designed to detect leukocoria using a sophisticated photoluminic analysis.~The investigator or designee will perform tests with CRADLE in separate patient cohorts with known diagnosis of retinoblastoma, congenital glaucoma, or cataracts."
45646203|NCT03139123|Other|Hemodynamic monitoring during passive leg raising|Measurement of hypotensive episodes related to preload dependance.
45919927|NCT03016156|Other|Red reflex testing|Traditional red reflex testing for leukocoria using a direct ophthalmoscope on routine eye examination. Red reflex testing via direct ophthalmoscope will be performed before dilation, using the ophthalmoscope held close to the examiner's eye, focused on the pupil, viewed at 12 to 18 inches from the patient's eyes, with the room lights dimmed, in accordance with the American Academy of Pediatrics guidelines.
45919928|NCT02966665|Other|Maximum Exercise Tests|Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.
45919929|NCT02966665|Drug|BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.
46071330|NCT02548741|Drug|Metformin Hydrochloride (500-mg capsule)|Metformin hydrochloride tablets (500-mg) are manufactured by Heritage Pharma INC. Noha Ashy & David Lee will ground the tablets and put them in capsules to avoid differentiation between treatment and placebo. Using USP 797 compounding standers, Noha Ashy & David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona. New empty capsules (size 0, ½ blue-opaque and ½ white-opaque capsule which will be supplied by Letco Medical) will be provided to the treatment (metformin hydrochloride) arm participants that are similar to the placebo (comparator) capsules in term of color and size to conceal placebo from the investigators and participants.
45646204|NCT03070925|Device|PuraPly™ Antimicrobial Wound Matrix|PuraPly AM consists of a collagen sheet coated with polyhexamethylene biguanide hydrochloride (PHMB) intended for the management of wounds. PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single patches.
45646205|NCT05067829|Device|Train of four(TOF)|Train of four(TOF) monitoring after anesthesia induction
46071331|NCT02548741|Drug|Calcium carbonate (placebo)|Investigators will use powder of calcium carbonate as filler of placebo capsules. Placebo capsules (size 0,½ blue-opaque and ½white-opaque capsule which will be supplied by Letco Medical),will be provided to the comparator arms' participants that are similar to the metformin hydrochloride capsules in term of color and size to conceal placebo from the investigators and participants.Using USP 797 compounding standers, Noha Ashy & David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona.
46071332|NCT02548741|Other|Glucometer (One Touch glucometer), strips and lancets|Investigators will provide glucometer (One Touch glucometer), strips and lancets to the treatment and placebo groups. They will be provided to patients who never had glucometer before enrolling to our study.Also, a logbook will be provided to each participant to record their blood sugar measurements at home.
45646206|NCT04986371|Drug|Niraparib|Usage following drug insert is recommended
45646207|NCT05066971|Combination Product|Self-adjustment of medication|Each week, based on the information provided by HM (heart rate and hours of activity each day), the rate control medication is adjusted to increase the total of activity time.
45646208|NCT04989023|Other|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper or lower limb with the addition of blood flow restriction or sham-blood flow restriction.
45789299|NCT05446545|Drug|platinum-sensitive EOC|For platinum-sensitive patients: platinum-based combined chemotherapy or bevacizumab will be used for adjuvant treatment, followed by maintenance therapy with poly adenosine diphosphate-ribose polymerase (PARP) inhibitor or bevacizumab
45789300|NCT05446545|Drug|platinum-resistant and rEOC|For platinum-resistant patients or refractory relapsed patients: non-platinum single-drug chemotherapy or combined anti-angiogenic targeted chemotherapy
45646209|NCT05021965|Procedure|different combined of tooth bleaching procedure|The participants will be randomly allocated into 4 groups and receive different kind of tooth bleaching protocol.
45789301|NCT01856933|Drug|PSMA ADC|2.5 mg/kg, IV, over 60 minutes every 3 weeks
45789302|NCT02427984|Other|Metal ions dosage and evaluation of local/systemic reaction|"Dosage of Chromium and Cobalt on several biological matrices deriving from each patients.~Determination of local/systemic reaction"
45789303|NCT02427984|Other|Noise registration and metal ions determination|"Dosage of Vanadium and Titanium on several biological matrices deriving from each patients.~Determination of range of noise"
45789304|NCT02427984|Other|Metal ions dosage, evaluation of local/systemic reaction, noise registration|"Dosage of Chromium, Cobalt, Vanadium and Titanium on several biological matrices deriving from each patients.~Determination of local/systemic reaction"
45646210|NCT03069833|Diagnostic Test|Computer-aided diagnosis|computer-aided diagnosis to assist colonoscopists
45646211|NCT04986007|Behavioral|Digital Cognitive Behavioral Therapy for Insomnia|Digital cognitive behavioral therapy for insomnia is an automated, internet-based delivery system for the core components of cognitive behavioral therapy for insomnia (CBT-I). For this trial, dCBT-I will be delivered using Sleep Healthy Using the Internet (SHUTi), which delivers the core content of CBT-I in 6 interactive lessons called Cores: Getting Ready; Sleep Scheduling; Sleep Practices; Thinking Differently; Sleep Hygiene; and Moving On. The primary therapeutic approaches deployed through these cores are stimulus control and sleep restriction. The minimum acceptable dose for this study is completion of 4 out of 6 cores; completion of fewer than 4 cores will be considered a dropout.
45646212|NCT04988945|Procedure|TACE|Procedure of TACE will be standardized.
45646213|NCT04988945|Radiation|SBRT|SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.
45646214|NCT04988945|Drug|Durvalumab|1500mg Durvalumab administered IV over 60 minutes on Day 1 of each immunotherapy treatment every 4 weeks until disease progression (PD)
45646215|NCT04988945|Drug|Tremelimumab|300mg Tremelimumab administered over 60 minutes on Day 1 of cycle 1.
45646216|NCT03070847|Drug|Tranexamic Acid|Dose: 5mg/kg
45646217|NCT03070847|Drug|Tranexamic Acid|Dose: 10mg/kg
45646218|NCT03070847|Drug|Sodium Chloride|Tranexamic Acid would be diluted in 0,9% Sodium Chloride (0,9% NaCl) to cumulative volume of 20 ml.
45646219|NCT03140995|Behavioral|Walking Programme|The programme will be devised using incremental targets for daily walks based on the 6-20 Borg of rating of perceived exertion scale (Borg RPE). They will be instructed that they should be moderately short of breath on exertion i.e. unable to comfortably hold a conversation while walking
45646220|NCT03069911|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA (29 units for women; 40 units for men) diluted with 0.9% sodium chloride (saline) solution to 40 units per milliliter (mL) (0.725 mL for women, 1 mL for men)
45646221|NCT03069911|Biological|Control|0.9% sodium chloride solution (saline) solution injections (0.725mL for women, 1mL for men)
45646222|NCT03069755|Other|No intervention|No intervention
45646223|NCT04109521|Other|Training, certification and marketing|The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
45646224|NCT03539575|Other|[11-C]OMAR|The radiotracer, [11-C]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
45646225|NCT04989257|Drug|Ticagrelor-based dual-antiplatelet therapy|Aspirin with ticagrelor
45646226|NCT04989257|Drug|Clopidogrel-based dual-antiplatelet therapy|Aspirin with clopidogrel
45646227|NCT03140527|Drug|PTI-801|Active
45646228|NCT03140527|Drug|Placebo|Placebo
45646229|NCT03140527|Drug|PTI-808|Active
45646230|NCT03140527|Drug|Placebo|Placebo
45789305|NCT02264249|Other|Esophagogastroduodenoscopy and colonoscopy split dose prep|"Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive the Split dose colonoscopy prep~split dose colonoscopy preparation- ½ evening before and ½ early AM (4L volume or 2L volume bowel preparation)"
46071333|NCT02548741|Other|Urine container for 24-hour urine collection|During visit 2 (day 0) and visit 3 (day 42), urine container will be provided to the study participant for 24-hour urine collection. Patient will be instructed to bring the container back to the collaboratory. Investigators will transfer the urine container to Dr.Lau's lab to measure the IMZ concentration/content.
45646231|NCT04988633|Behavioral|Intervention CFG App|Online healthy lifestyle education through an App. The intervention will consist of viewing educational videos on diet and exercise through an App. Videos will be uploaded to the app on a weekly basis, lasting 2-3.
45646232|NCT04988633|Behavioral|Control Group|Standard tips for healthy lifestyles that are carried out in regular Primary Care practice. After day 1, where standard advice is received, follow-up visits are conducted at week 2, week 4, month 3, and month 6.
45646233|NCT03070769|Procedure|Venous blood collection for biomarkers measurements|Venous blood was collected in all subjects for measurements of hs-C-reactive protein (hs-CRP), fibrinogen, erythrocyte sedimentation rate (ESR) and Uric Acid (UA) between 8:00 and 9:00 AM, following an overnight fast, shortly after the conclusion of the overnight polysomnography (PSG).
45646234|NCT03069443|Other|IHG home training|Participants of the intervention group will follow the IHG home training protocol for 20 weeks. The IHG training consists of isometric contractions applied with the hands on a Wii.
45646235|NCT04025983|Dietary Supplement|GastimunHp Plus|Each sachet contains 6mg of IgY and 50 mg of heat-killed Lactobacillus johnsonii No. 1088.
45646236|NCT04025983|Other|Placebo|The placebo contains neither IgY nor L. johnsonii.
45646237|NCT04892069|Drug|Insulin Degludec/Insulin Aspart|All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in Lebanon. Decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
45646238|NCT04986059|Other|Pre-event massage|Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands on gastrocnemius and hamstring muscles
45789306|NCT02264249|Other|Esophagogastroduodenoscopy and colonoscopy Evening before colonoscopy prep|Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive Evening before (4L, 2L or miralax bowel preparation)
45646239|NCT03140449|Drug|Rapamycin|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
45919930|NCT02966665|Drug|BQ-123|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with endothelin-1 receptor antagonist BQ-123 (D-tryptamine-D-aspartic acid-L-proline-D-valine-L-leucine).
45919931|NCT02966665|Drug|Fexofenadine, Ranitidine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with Histamine H1 receptor antagonist fexofenadine (Allegra) and Histamine H2 receptor antagonist ranitidine (Zantac).
45919932|NCT02966665|Other|Angiotensin-II, Valsartan|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement, and exercise bouts at baseline and following treatment with Angiotensin-II receptor agonist (angiotensin-II) and antagonist Valsartan (Diovan).
45646240|NCT03140449|Drug|Calcitriol|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
45646241|NCT03140449|Drug|Rapamycin-calcitriol combination|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
45646242|NCT03138811|Drug|CSJ117|inhaled once daily dose
45646243|NCT03138811|Drug|Placebo Comparator|inhaled once daily dose
45646244|NCT04889105|Behavioral|Smart MOVE!|"Multi-component behavioral intervention of PAD consisting of:~guideline-directed HBET prescription~active behavioral coaching (via MOVE! program or other)~mobile health monitoring"
45646245|NCT04889105|Behavioral|General walking advice|Basic guidance on performing walking exercises for PAD according to established guidelines. Participants will receive a mobile health device for self-tracking only but not receive any behavioral coaching.
45646246|NCT04889105|Behavioral|Performance evaluation|"Preliminary performance evaluation determine the optimal components of the Smart MOVE! intervention. Specific procedures will include:~Provider and stakeholder interviews~PAD patient interviews~2) N-of-1 trials to refine the intervention"
45646247|NCT02895451|Behavioral|Extended behavioral intervention|The exercise goal is set in liaison between the patient and the physiotherapist, based on activities and target behaviors that the patient thinks is relevant and important. The patients are asked to self-monitor the defined exercise goal by completing an exercise diary. The exercise diary includes specification of the performed exercise dose (frequency, intensity and duration). The exercise diary is followed up by a physiotherapist every third week by a phone call or a personal meeting. Visual feed-back on the performed dose of exercise is given once by accelerometry. At end of intervention (16 weeks) the patient is offered a follow-up meeting with the physiotherapist to discuss a long-term exercise goal.
45646248|NCT02659813|Device|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed brace
45646249|NCT04095143|Diagnostic Test|Portal vein flow|Doppler assessment performed on day 0, 3 and 7.
45646250|NCT04095143|Diagnostic Test|Intra-renal flow|Doppler assessment performed on day 0, 3 and 7.
45646251|NCT04095143|Diagnostic Test|Hepatic vein flow|Doppler assessment performed on day 0, 3 and 7.
45646252|NCT04095143|Diagnostic Test|Pulmonary B-lines|Ultrasound assessment of performed on day 0, 3 and 7.
45646253|NCT04095143|Diagnostic Test|Dimensions of the inferior vena cava|Ultrasound assessment of performed on day 0, 3 and 7.
45646254|NCT04095143|Diagnostic Test|Left ventricular function|Ultrasound assessment of performed on day 0, 3 and 7.
45646255|NCT04095143|Diagnostic Test|Right ventricular function|Ultrasound assessment of performed on day 0, 3 and 7.
45646256|NCT04917445|Behavioral|Spikes-focused bad news protocol|Nurses trained to deliver bad news to IVF patients based on the Spikes-protocol for compassionately delivering bad news to patients.
45646257|NCT04904653|Device|Hemopatch|"HEMOPATCH Sealing Hemostat (HEMOPATCH) consists of a soft, thin, pliable, flexible pad of collagen derived from bovine dermis, coated with NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate).~Due to its flexible structure, the application of HEMOPATCH to the site where hemostasis / sealing is desired is easily controlled. For differentiation, the non-coated side is marked with blue squares using a biocompatible colorant.~HEMOPATCH is supplied in the following 3 sizes:~HEMOPATCH 27 x 27 mm~HEMOPATCH 45 x 45 mm~HEMOPATCH 45 x 90 mm"
45646258|NCT04904653|Other|Control group|No sealant (liquid, gel or patch) + suction drain
45789307|NCT02264249|Other|Esophagogastroduodenoscopy and colonoscopy Same day prep colonoscopy preparation|Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive Same day prep (4L volume or 2L volume or Miralax bowel preparation)
46071334|NCT02844374|Other|Functional stereotaxic exploration|Visual analysis : in order to define the level of cortical resections. Epileptogenic maps : calculated for each crisis and for all crisis in general. Connectivity maps : calculated for each site stimulated at low-frequency. Post-operative evaluation : in order to assess the extent of resection.
45789308|NCT01857713|Device|Reza Band UES Assist Device|Device is worn by patient to reduce or eliminate laryngopharyngeal reflux
46071335|NCT02845856|Drug|Cetuximab|400 mg/m2 IV over 120 minutes on day 1 of cycle 1 only, and 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations
46071336|NCT02845856|Biological|NK immunotherapy|For each procedure, 10 billion cells will be infused in 4 times
45646259|NCT03070691|Drug|LDE225B|Cream, 2x daily
45646260|NCT03070691|Drug|Vehicle|cream, 2x daily
45789309|NCT02643459|Behavioral|suPAR measurement|The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.
45789310|NCT02643615|Device|VEP under TIVA|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
45646261|NCT03137953|Procedure|Clinical Evaluation|The skin pinch test would be done by three independent oncologists to assess ability for skin conservation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
45646262|NCT03137953|Diagnostic Test|Radiological Imaging|Computed Tomography or Magnetic Resonance Imaging would be done by a radiologist and used to measure the distance between tumor and skin which would guide the decision for skin presevation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
45789311|NCT02643615|Device|VEP under balanced anesth.|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
45789312|NCT02643615|Drug|Propofol|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
45789313|NCT02643615|Drug|Desflurane|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
45789314|NCT05687279|Biological|RSVt Vaccine|Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal
45789315|NCT05687279|Other|Control Group|Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal
45789316|NCT02643849|Device|The Spanner Temporary Prostatic Stent|
45789317|NCT02265341|Other|Laboratory Biomarker Analysis|Correlative studies
45789318|NCT02265341|Drug|Ponatinib Hydrochloride|Given PO
45789319|NCT02265341|Other|Quality-of-Life Assessment|Ancillary studies
45789320|NCT05679479|Biological|Meplazumab for injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
45789321|NCT05679479|Other|Normal saline|0.9% normal saline
45789322|NCT01421186|Drug|MOR03087 phase 1 dose escalation|"Treatment cycles will be 28 days. Initial MOR03087 doses will be 0.01 mg/kg in part A, 4 mg/kg in parts B and C and 8 mg/kg in parts D and E; in all parts MOR03087 doses will be escalated to a maximum of 16 mg/kg. In part A, patients will receive a biweekly intravenous infusion of MOR03087 which will be administered on days 1 and 15 of the cycle. In parts B to E patients will receive a weekly intravenous infusion of MOR03087 which will be administered on days 1, 8, 15, and 22 of the cycle.~In all parts a loading dose of MOR03087 will be additionally administered on day 4 of cycle 1."
45789323|NCT01421186|Drug|MOR03087|MOR03087 will be administered according to the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen for MOR03087 from parts A-E of the phase I dose escalation. The biweekly MOR03087 regimen as described in part A; the weekly regimen as described for parts B-E.
45789324|NCT01421186|Drug|Dexamethasone|Dexamethasone will be administered to patients orally; 40 mg (≤ 75 years old) or 20 mg (> 75 years old) on days 1, 8, 15, and 22 of the 28-day cycle. An additional dose will be administered in cycle 1 on day 4.
45789325|NCT01421186|Drug|Pomalidomide|Pomalidomide will be administered to patients orally 4 mg on days 1-21 of the 28-day cycle.
45789326|NCT01421186|Drug|Lenalidomide|Lenalidomide will be administered to patients orally 25 mg on days 1-21 of the 28-day cycle.
45919933|NCT02966665|Drug|Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement; vasodilation with nitroglycerin followed by Angiotensin-II and Alpha Adrenergic blockade with infusions of Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine and Phentolamine (Regitine).
45919934|NCT02966665|Drug|BQ-123, MitoQ, BH4|Catheter placement in femoral artery and femoral vein and muscle biopsy; Nuclear Magnetic Resonance (NMR) scanning and exercise bouts at baseline and following treatment with BQ-123 with or without oral mitochondria-targeted antioxidant (MitoQ) or oral BH4.
46071337|NCT00825019|Drug|amibegron (SR58611A)|oral administration of 2x 700 mg/day in 12h intervals
45646263|NCT04985591|Procedure|Liposuction|A small, inconspicuous incision was made in the liposuction group to dislodge fat out of the body.
45646264|NCT04985591|Procedure|Other plastic surgery|Other plastic surgery like blepharoplasty or keloid excision.
45646265|NCT04985747|Other|Polished palatal surface|Polishing of the anterior palatal surface using a polisher
45646266|NCT04985747|Other|Roughened palatal surface|Roughening of the anterior palatal surface using a sandblaster
45789327|NCT05675969|Other|Blood sample|Collection of 2 additional tubes of 4.5mL of citrate blood
45646267|NCT04985747|Other|Opened palatal surface|Opening of the anterior palatal surface using acrylic bur
45646268|NCT04985435|Drug|Filgotinib|200 mg tablet once daily or 100 mg once daily
45646269|NCT04985435|Drug|Anti-Tumor Necrosis Factor Alpha Drug (Product)|Adalimumab subcutaneous injections 40 mg once every two weeks Etanercept subcutaneous injections 50 mg weekly
45789328|NCT03697967|Procedure|supine or prone position|"Before delivery, a sealed enveloppe is opened by the physician or nurse present at delivery. Immediately at birth the team in charge of delivery place the newborn in skin to skin contact on the mother's chest where he is dried. Umbilical cord clamping is delayed in both intervention arms to 1 minute after birth.~The newborn is placed in the prone or in the supine position depending on allocation. The nurse in charge of the newborn uses a stopwatch to check the time at which clamping was accomplished.~All subsequent nursery care are conducted according to hospital protocol."
45789329|NCT02645253|Drug|AZD7594 inhalation powder (200 μg)|200 μg AZD7594 inhalation powder via multi-dose dry powder inhaler (DPI)
45789330|NCT02645253|Drug|AZD7594 inhalation powder (400 μg)|Cohort 2: 400 μg AZD7594 inhalation powder via multi-dose DPI Cohort 3: 1600 μg (4 x 400 μg inhalations) AZD7594 inhalation powder via multi-dose DPI
45789331|NCT02645253|Drug|AZD7594 pressurized inhalation suspension (200 μg)|400 μg (2 x 200 μg inhalations) AZD7594 pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
45789332|NCT02645253|Drug|AZD7594 placebo inhalation powder|AZD7594 placebo inhalation powder via multi-dose DPI
45789333|NCT02645253|Drug|AZD7594 placebo pressurized inhalation suspension|AZD7594 placebo pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
45789334|NCT03636347|Drug|Placebo Oral Tablet|twice daily administration
46071338|NCT00825019|Drug|placebo|oral administration in 12h intervals
45789335|NCT03636347|Drug|Alvelestat oral tablet - dose 1|twice daily administration
45789336|NCT03636347|Drug|Alvelestat oral tablet - dose 2|twice daily administration
45789337|NCT01484288|Device|Barostim Neo System|Baroreflex Activation Therapy using the Barostim Neo System
45789338|NCT01860287|Drug|Buprenorphine 0.2 MG Sublingual Tablet|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.2)
46071339|NCT00825019|Drug|paroxetine|oral administration of 20 mg/day
45789339|NCT01860287|Drug|Placebo|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive a placebo
45789340|NCT01860287|Drug|Buprenorphine 0.4 MG Sublingual Tablet|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.4)
45789341|NCT01421498|Drug|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: 12 weeks
45449514|NCT05181254|Behavioral|health dialogue|The visual health assessment formulary is based on detailed questions about food, physical activity, heredity, smoking, alcohol, stress and mental illness and measurements such as BMI, blood pressure and blood fats. Patients fill in a web-based questionnaire resulting in a visual colorful scale showing a risk assessment (Figure 1). The Health Dialogue is a prognostic tool that provides an estimate of the increase in risk with current lifestyle habits. The use has shown improvement of lifestyle habits such as smoking cessation, lower intake of fat and higher physical activity level as well as reduced mortality in a long-term follow-up.
45789342|NCT01421498|Drug|Placebo|Dosage Form: Ophthalmic Solution Frequency: BID Duration: 12 weeks
45789343|NCT04701723|Other|cardiac coherence|standard care associated to cardiac coherence training during 3 months
45449515|NCT01314482|Drug|Minocycline|200mg bd for 3 days before surgery
45646270|NCT04985435|Behavioral|50 patients will have a Free Choice between Filgotinib and anti TNF|50 patients will be given the opportunity to choose between either TNFi (etanercept 50 mg SC once a week or adalimumab 40 mg SC once every two weeks) or filgotinib, an oral JAKi, 200 mg once a day while another group of 50 patients will be randomized to the same treatment arms.
45449516|NCT03188120|Drug|Spiriva Respimat|Drug
45449517|NCT02895945|Biological|Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)|In case of major surgery, FVIII target level is ≥80% for major surgeries/ procedures and ≥50% for minor surgeries/ procedures.
45646271|NCT05084365|Drug|Sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
45646272|NCT05084365|Drug|Placebo|Placebo
45646273|NCT03070457|Other|Early discharge|Patients randomised to early discharge or not
45789344|NCT04677621|Other|Nurse Telehealth|Subjects will receive nurse telehealth Mobile Decision Support System (MAP) DBS care
45789345|NCT04677621|Other|STANDARD DBS|Subjects will receive standard in-person clinic-based DBS care administered without the use of Mobile Decision Support System (MAP) DBS
45789346|NCT01421654|Device|S9 Elite with Acclimate|S9 Elite Flow Generator with Acclimate feature activated
45789347|NCT01421654|Device|S9 Elite|S9 Elite Flow Generator
45789348|NCT05446311|Drug|Dinalbuphine sebacate|After giving the birth, subjects are intramuscularly injected with a single dose of 150 mg of dinalbuphine sebacate (DS). DS is a prodrug of nalbuphine. After injeciton, DS are released to blood stream and hydrolyzed immediately. The onset of action is 12 to 24 hours and the analgesic effect can last about 5 to 7 days.
45789349|NCT04739085|Diagnostic Test|Defocus curves - Monocular distance visual acuity with trial lenses added to the best correction for distance|The monocular distance visual acuity of each participant' eye is evaluated using trial lenses of -3.00 sph, -2.50 sph, -1.75 sph, and -1.25 sph (added to the best correction for distance), which correspond to distances 30 cm, 40 cm, 60 cm and 80 cm, respectively.
45789350|NCT04739085|Diagnostic Test|wDDART - Monocular near visual acuity using the best correction for distance|The same participants undergo visual acuity test via the web-based digital near vision reading test wDDART at 30 cm, 40 cm, 60 cm and 80 cm, having their best correction for distance.
45789351|NCT01422200|Biological|2011-2012 seasonal flu vaccine Subcutaneous|
45789352|NCT01422200|Biological|2011-2012 seasonal flu vaccine Intramuscular|
45646274|NCT03070457|Other|Conventional protocol|Discharge as usually done 48-72 hours after surgery
45646275|NCT03140683|Device|non-stress test|antepartum fetal monitoring
45646276|NCT03070613|Drug|Fluorescent Lectin Application|Fluorescein conjugated wisteria floribunda (a lectin).
45789353|NCT05445765|Biological|anti-CD33 CAR T cells|Anti-CD33 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
45789354|NCT01860521|Procedure|Programmed Intermittent Epidural Bolus|An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine®, Abbott, Chicago, USA) plus sufentanil 10 µg (Fentatienil®, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 µg/mL, 10 mL every hour, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score ≥ 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.
45646277|NCT03441139|Other|Cryotherapy + Medical analgesics|"Percutaneous cryotherapy: A complete cycle of treatment will require 2 freezing 10-minutes periods, separate by a 9-minutes passive and 1-minute active thaw, with the cryoablation system. Dimension of the iceball coverage above the tumor will be monitored by non-contrast CT or MRI during the freezing cycle.~Medical supportive care: Best analgesic therapy at investigator's discretion"
45646278|NCT03441139|Drug|Medical Analgesics|Best analgesic therapy at investigator's discretion
45449518|NCT02777554|Drug|Apremilast IR|Apremilast immediate release tablet
45449519|NCT02777554|Drug|Apremilast XL|Apremilast extended release formulation tablet
45449520|NCT03225482|Behavioral|Motivationally Enhanced Compensatory Cognitive Training|ME-CCT is a manualized group-based behavioral intervention (8 weeks, 2 hours per week, 20 hours total) designed to improve cognitive and everyday functioning in patients with MCI.
45449521|NCT03225482|Behavioral|Goal-focused Supportive Contact|SC is a group therapy intervention that provides the same frequency and amount of therapist and other group member contact as ME-CCT, but does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement. The SC intervention focuses on setting and achieving short or long-term goals.
45646279|NCT04988789|Drug|Paclitaxel Drug Coated Balloon|Failing AVF/AVGs treated with Paclitaxel Drug Coated balloons are captured in this database
45789355|NCT01860521|Procedure|Continuous Epidural Infusion|An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine®, Abbott, Chicago, USA) plus sufentanil 10 µg (Fentatienil®, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 µg/mL at a rate of 10 mL/h, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score ≥ 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.
45789356|NCT01860521|Procedure|Procedure of interruption of pregnancy|Patients were administered 1 mg of gemeprost pessaries (Cervidil®, Merck Serono SPA, Roma, Italy) in the posterior fornix of the vagina every 3 hours up to 5 doses. If the expulsion of the fetus did not occur, the therapeutic regimen was repeated after 24 hours from the initiation of the treatment. Induction-to-abortion time (hours) was considered the period of time comprised between the first gemeprost pessary administration and fetal expulsion. Failure of induction of abortion was defined as women undelivered after two completed cycles (48h).The evacuation of the uterus under general anesthesia was performed if ultrasonography showed retained productions of conception.
45789357|NCT01860521|Drug|Drug used for analgesia procedures|Levobupivacaine (Chirocaine®, Abbott, Chicago, IL, USA) and sufentanil(Fentatienil®, Angelini, Rome, Italy) were administered in both study groups according to the regimen of each intervention arm (Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion).
45919935|NCT04927143|Device|App-Based Contingency Management|Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.
45919936|NCT04927143|Behavioral|Sham Control|Participants get access to the DynamiCare app but will not be provided with financial incentives.
45789358|NCT01860521|Device|Pump for programmed intermittent bolus.|Pump administering programmed intermittent epidural bolus for the maintenance of analgesia was used.
45789359|NCT01860521|Device|Pump for continuous epidural infusion.|Pump administering continuous epidural infusion for the maintenance of analgesia was used.
45789360|NCT01860521|Drug|Drug used for termination of pregnancy procedure.|Gemeprost pessaries.
45789361|NCT04592523|Other|No Intervention|This is a non-interventional study.
45789362|NCT02648919|Drug|Noni extract|Intervention will be administered on an outpatient basis.Six bottles containing 60 capsules will be dispensed to all participants upon enrollment. Then 12 bottles (at 30-day visit) and 18 bottles (at 3, 6 and 9 month visits) will be dispensed to all participants.
45789363|NCT03542045|Device|Cemented ATTUNE® Knee System|This product is for total knee arthroplasty. Four implant configurations are permitted: Cruciate Retaining Fixed Bearing (CR FB), Cruciate Retaining Rotating Platform (CR RP), Posterior Stabilizing Fixed Bearing (PS FB) and Posterior Stabilizing Rotating Platform (PS RP)
45919937|NCT00379652|Behavioral|Medical Practice Improvement|The details for the medical practice improvement intervention will be decided at a later date.
45919938|NCT00379652|Behavioral|Patient Education and Support|The details for the patient education and support intervention will be decided at a later date.
45919939|NCT00379652|Other|Combination Intervention to Include Medical Practice Improvement and Patient Education and Support|The details for this combination intervention will be decided at a later date.
45919940|NCT02832544|Drug|Rivaroxaban (20 mg)|Rivaroxaban is non-inferior to VKAs for the prevention of stroke or systemic embolism in patients with AF/flutter and RVHD and potentially superior to VKAs.
45919941|NCT02832544|Drug|Vitamin K antagonists (VKA)|
45919942|NCT00006044|Drug|therapeutic testosterone|
45919943|NCT02490241|Drug|Lithium|Patients taking lithium as a mood stabilizer during pregnancy are eligible to participate in the study. Their dose and serum concentration levels of lithium will be monitored throughout pregnancy and up to three months postpartum.
45919944|NCT02395705|Drug|cisplatin and paclitaxel|"Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles."
45919945|NCT01863745|Drug|nilotinib|Nilotinib can be provided as 200 mg and 150 mg hard gelatin capsules. The starting dose of nilotinib should be the same as the last dose that was given in the parent nilotinib study. After this, the dose of nilotinib is based on the investigator's judgment.
45919946|NCT00006047|Drug|Oral Etoposide|
45919947|NCT00006047|Drug|Oral 9-Nitrocamptothecin|
45919948|NCT04895943|Procedure|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
45449522|NCT02160886|Behavioral|child-goal|"The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.~The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.~The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks.~The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions."
45449523|NCT02160886|Behavioral|parent-goal|"The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.~The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.~The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks. .~The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions."
45646280|NCT04985279|Device|Position and Angle Marking System|Position and Angular Marking System (PAMS) attaches on to the ultrasound probe. When the desired insertion site is identified by ultrasound, the doctor gently presses PAMS into the patient's back to create skin indentations demarcating the needle insertion point. These indentations are not affected by skin sterilisation, and may improve accuracy and reduce the time taken to perform the epidural procedure. Next, the angle between the ultrasound probe and the patient's back can be measured using PAMS, and this angle can be maintained using a needle guide during the epidural procedure.
45646281|NCT04985279|Device|Standard clinical practice|When the desired insertion site is identified by ultrasound, the doctor demarcate the needle insertion point using marker pens.
45919949|NCT04895943|Procedure|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
45449524|NCT03220178|Drug|Palbociclib|Palbociclib 125mg/day orally dosed for 3 weeks followed by 1 week off; repeated for each treatment cycle
45919950|NCT00083824|Drug|Estrogens, Conjugated (USP)|0.625 mg/day QID for 3 years
45919951|NCT00083824|Drug|Medroxyprogesterone 17-Acetate|2.5 mg/day QID for 3 years
45919952|NCT00083824|Drug|Placebo|2 pills/day QID for 3 years
45919953|NCT00083902|Drug|Thalidomide|
45919954|NCT00083902|Drug|Dexamethasone|
45919955|NCT00006050|Drug|FOLFOX regimen|
45919956|NCT00006050|Drug|fluorouracil|
45919957|NCT00006050|Drug|isolated perfusion|
45919958|NCT00006050|Drug|leucovorin calcium|
45919959|NCT00006050|Drug|oxaliplatin|
45919960|NCT00083980|Drug|Venlafaxine ER|75 to 225 mg daily
45919961|NCT00083980|Drug|Sugar pill|Upto 3 per day for venlafainxe and 4 per day for kava placebos.
45919962|NCT00083980|Drug|Kava|140 to 280 mg per day
45789364|NCT05445687|Behavioral|Narrative language intervention program|"Narrative language targets improving narrative macrostructure and microstructure.~The program will include 24 illustrated story sequences with a minimum of 5 sequences representing the main story elements: characters and setting; problems; internal response; actions; and consequence. Story icons will be designed to represent the main 5 elements to accompany storytelling and act as visual prompts.~Each story will reflect specific content with several target vocabulary words and complex morphosyntax. Each story will be followed by comprehension questions to facilitate understanding and answering question about stories.~The following procedure will be implemented with each story: Modeling, answering comprehension questions, retelling with icons and colored illustrations, retelling with icons only, and retelling without icons. This procedure is adapted from story champs intervention program"
45789365|NCT05445687|Behavioral|Conventional language intervention|Language rehabilitation targets improving semantics, syntax, pragmatics and phonology.
45646282|NCT04985669|Drug|Prucalopride 2mg|one group of patient will receive prucalopride once daily one group of patient will receive lubiprostone twice daily
45646283|NCT05083897|Other|hip adduction isometric contraction|addition of isometric hip adduction contraction to the knee extension for measuring knee extension peak torque by the isokinetic dynamometer
45789366|NCT04566861|Behavioral|Cognitive Behavioral Therapy (CBT) for anxiety during pregnancy|Women who are randomized to the intervention group will receive six core Cognitive Behavioral Therapy (CBT) sessions for anxiety during pregnancy (and possible booster sessions) to treat symptoms of anxiety.
45646284|NCT04988711|Diagnostic Test|Hb Oxymeter|Measurement of Hb Oximeter
45646285|NCT04753957|Drug|micronized Progesterone|200mg micronized progesterone placed vaginally
45789367|NCT01400906|Drug|100 micrograms Fluticasone propionate|100 micrograms micronized drug blended with lactose in dry powder inhalator
45646286|NCT03070379|Procedure|Topical lidocaine pharyngeal anesthesia|Topical pharyngeal anesthesia by lidocaine was administrated 4-5 min before propofol sedation in patients who underwent esophagogastroduodenoscopy.
45919963|NCT04893174|Biological|UMC119-06-05|"Subjects will receive a single-dose IA injection of UMC119-06-05 followed by an IA injection of hyaluronic acid.~Cohort 1: Low does UMC119-06-05 Cohort 2: High does UMC119-06-05"
45919964|NCT04893174|Device|Hyaluronic acid|IA injection of hyaluronic acid.
45919965|NCT00084019|Drug|Atazanavir|
45919966|NCT00084019|Drug|Ritonavir|
45646287|NCT03227263|Drug|Bevacizumab|Bevacizumab (Avastin®) concentrate at 25mg/mL is diluted at 5 mg/kg for infusion every 14 days for 6 consecutive administrations
45646288|NCT03227263|Drug|sodium chloride 0.9%|0.9% of sodium chloride is infused every 14 days for 6 consecutive administrations
45646289|NCT04985201|Drug|Irinotecan|Irinotecan intravenous infusion was administered at a dose of 60 mg/m^2 on Day 1,8 of each 21-day cycle.
45789368|NCT01400906|Drug|500 micrograms Fluticasone propionate|500 micrograms micronized drug blended with lactose in dry powder inhalator
45789369|NCT01400906|Drug|lactose powder|lactose powder in dry powder device : placebo comparator
45789370|NCT00367653|Drug|Azithromycin plus Chloroquine|Azithromycin 1000 mg by mouth (PO) (two 500 mg tablets) once daily (QD) for 3 days(Days 0, 1, 2) plus chloroquine 600 mg base PO once daily for 3 days (Days 0, 1, 2)
45789371|NCT00367653|Drug|Mefloquine|Mefloquine 1250 mg PO given as a split dose (750 mg [three 250 mg capsules]) initial dose followed by 500 mg PO (two 250 mg capsules) given 6 to 10 hours later on Day 0
45789372|NCT01861301|Other|Laboratory Biomarker Analysis|Correlative studies
45789373|NCT01861301|Drug|Tivantinib|Given PO
45789374|NCT05445531|Diagnostic Test|Low-field magnetic resonance imaging|Functional and morphologic imaging of the lungs
45789375|NCT05445531|Diagnostic Test|Nailfold capillaroscopy|Imaging of nailfold microvasculature
45789376|NCT05445531|Diagnostic Test|Spiroergometry|Cardiopulmonary exercise testing
45789377|NCT05445531|Diagnostic Test|Realtime deformability cytometry|High-throughput measurement of cell deformability and physical properties
45789378|NCT03478007|Device|Intervention Technology|Subjects will perform their exercises using the provided monitoring device. They will be able to contact the investigators with questions regarding the use of the monitoring device, however, no encouragement or coaching will be provided
45789379|NCT03478007|Device|Intervention Technology Plus Coaching|Subjects will perform their exercises using the provided monitoring device. They will also be coached by a trained health coach through a weekly call.
45789380|NCT01485380|Drug|dexmedetomidine|The dexmedetomidine infusion will be individualized to each study participant by a target plasma concentration where loss of consciousness is initially observed. Loss of consciousness will be assayed by specific auditory and verbal stimuli.
45919967|NCT00084058|Drug|Lopinavir/ritonavir|
45919968|NCT00084058|Drug|Saquinavir|
45919969|NCT00006053|Drug|imatinib mesylate|
45919970|NCT04889352|Other|Access to colonoscopy web app|There is a very high utilization of colonoscopy at both shorter and longer time intervals than the recommended guidelines. Investigators have developed a clinical support tool in which the characteristics of the patients can be inputted and the guideline recommended time interval for surveillance colonoscopy is then provided. This tool uses the recommendations from the current North American national guidelines. The tool has been developed as a web-based application as well as a smart phone application.
45919971|NCT00084097|Drug|Omalizumab|
45646290|NCT04985201|Drug|Simvastatin|Simvastatin 40 mg daily oral tablet taken.
45646291|NCT03156595|Behavioral|Nurse interview|Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.
45646292|NCT03156595|Behavioral|Hypnosis sessions|Hypnosis sessions with a nurse or psychologist, with deepening sessions to facilitate self-hypnosis learning.
45646293|NCT04985123|Device|Pre-Formed Penile Silicone Block Implant|Implantation of Pre-Formed Penile Silicone Block Implant
45646294|NCT03092713|Behavioral|Combined cognitive (Compensatory Cognitive Training - CCT) and vocational rehabilitation (Supported Employment)|The CCI-SE Group receives a manualized Group-based cognitive psycho-educational intervention (10 sessions), combined with supported employment at their work-place.
45646295|NCT03092713|Behavioral|Control Group|The Control Group receives usual assessment and treatment at Oslo University Hospital.
45646296|NCT04985045|Other|Evaluation|Individuals' menstrual status, pain, menstrual symptoms and genital hygiene behaviors will be evaluated.
45789381|NCT05445453|Other|Museum visit|"The intervention is a visit of the MMFA. This visit can be done alone or accompanied.~The visit of the MMFA is free for the patient."
45789382|NCT05445297|Drug|Pharmacological cardioversion with Amiodarone|"Patients in this group will receive intravenous amiodarone according to the following scheme:~administration of 5 mg/kg body weight of amiodarone diluted in 250 ml of 5% glucose solution intravenously for 20-60 minutes, depending on the tolerability of the drug.~if there is no effect (recovery of SR did not occur within 60 minutes from the start of the drug administration), continue the infusion of amiodarone intravenously at a dose of 100 mg/hour until a total dose of 1200 mg is reached."
45646297|NCT04988243|Other|All aortic valve products on the market|"Subjects with severe aortic valve stenosis~Subjects who plan (or have) to use the transcatheter aortic valve replacement system for percutaneous aortic valve replacement~The patients agreed to join the study, voluntarily signed the informed consent and completed the follow-up;~Be able to contact the subjects or their legal guardians / relatives;~The medical record records the subjects who have died and can't get any contact information of the subjects（ (for dead cases only)~Sign the informed consent form, then check the inclusion and exclusion criteria, register after meeting the criteria, obtain the registration number, perform aortic valve replacement surgery, follow-up 24 hours, discharge, 30 days, 1 year, 2 years, 3 years, 4 years and 5 years after operation according to the test requirements, and carry out relevant follow-up according to the scheme requirements to collect data"
45789383|NCT05445297|Drug|Pharmacological cardioversion with Refralon|"Patients in this group will receive intravenous refralon according to the following scheme:~the introduction of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight, diluted in 20 ml of saline intravenously for 2-3 minutes;~in the absence of effect (SR recovery did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight (total dose of the drug 10 μg / kg of body weight);~in the absence of effect (SR recovery did not occur), after 15 minutes, the next intravenous injection of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight (total dose of the drug 20 μg / kg of body weight);~in the absence of effect (recovery of SR did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight. Thus, the maximum total dose of the drug will be 30 μg/kg of body weight."
45789384|NCT01539980|Device|Sericin scaffold|Device: wound dressing containing silk sericin A scaffold from silk sericin-polyvinyl alcohol-glycerin blending are applied on one half of the skin graft donor site Device: fine mesh gauze impregnated with paraffin and 0.5%chlorhexidine acetate (Bactigras, Smith&Nephew, London, UK) are applied on the other half of the skin graft donor site
45789385|NCT05445063|Biological|Autologous iPSC-derived RPE|Autologous transplantation of iPSC-derived RPE
45789386|NCT00556673|Drug|indacaterol maleate/mometasone furoate|Indacaterol maleate 250 μg / mometasone furoate 200 μg delivered via the Twisthaler device.
45789387|NCT00556673|Drug|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
45789388|NCT00556673|Drug|fluticasone proprionate / salmeterol xinafoate|Fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg delivered via the Accuhaler® device.
45789389|NCT05437029|Drug|Q-Griffithsin 3.0|This is an open-label dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of a multiple dosing schedule of low dose Q GRFT intranasal spray DP
45646298|NCT02031601|Drug|Erlotinib|150mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive erlotinib150mg po once a day daily until progression
45646299|NCT02031601|Drug|Gefitinib|250mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive gefitinib 250mg po once a day daily until progression
45919972|NCT00084175|Behavioral|Behavior Therapy|
45646300|NCT02031601|Drug|Icotinib|125mg po three time a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive icotinib 125mg po three time a day daily until progression
45646301|NCT02031601|Drug|Docetaxel|75 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
45646302|NCT02031601|Drug|Pemetrexed|500 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
45919973|NCT00084214|Drug|STA-4783|
45919974|NCT00084214|Drug|Paclitaxel|
45919975|NCT00006056|Drug|anti-thymocyte globulin|
45919976|NCT00006056|Drug|busulfan|
45919977|NCT00006056|Drug|cyclophosphamide|
45919978|NCT00006056|Drug|cyclosporine|
45919979|NCT00006056|Drug|etoposide|
45919980|NCT00006056|Drug|filgrastim|
45919981|NCT00006056|Drug|methotrexate|
45919982|NCT00006056|Procedure|allogeneic hematopoietic stem cell transplantation|
45646303|NCT02031601|Drug|Platinum (cisplatin or carboplatin)|cisplatin -- 75mg/m2 ivgtt on day 1 of each 3 week cycle for 4 cycles or carboplatin -- 5 x AUC ivgtt on day 1 of each 3 week cycle for 4 cycles
45789390|NCT05437029|Drug|Q-Griffithsin 6.0|This is an open-label dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of a multiple dosing schedule of high dose Q GRFT intranasal spray DP
45789391|NCT01422434|Drug|LEO 90105 = calcipotriol + betamethasone dipropionate|Applied once daily for 4 weeks.
45789392|NCT01422434|Drug|Dovonex® = calcipotriol|Applied twice daily for 4 weeks.
45789393|NCT01422434|Drug|Rinderon® - DP = betamethasone dipropionate|Applied once daily for 4 weeks.
45789394|NCT05434065|Drug|Celecoxib 200mg|Using celecoxib (200 mg/day) for 21 days starting within 6 hours after onset of ICH
45789395|NCT02402322|Behavioral|Scheduled support|Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone weekly.
45789396|NCT02402322|Behavioral|Non-scheduled support|Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone when they required it.
45919983|NCT04870047|Device|Endovascular treatment of unruptured aneurysms with p64 MW HPC Flow Modulation Device|Patients suffering from a distal intracranial aneurysm will be treated endovascularly with the p64 MW HPC Flow Modulation Device.
45919984|NCT00084370|Drug|celecoxib|Patients receive ora celecoxib twice daily for 3 months prior to prophylactic oophorectomy.
45449525|NCT03220178|Drug|Fulvestrant|500mg per use-after first application, again at wk2, then once per month
45449526|NCT03220178|Drug|Anastrozole|1mg per day
45449527|NCT03220178|Drug|Letrozole|2,5mg/day
45449528|NCT03220178|Drug|Exemestane|25mg/day
45646304|NCT02031601|Drug|Erlotinib|150mg po once a day daily until disease progression
45646305|NCT02031601|Drug|Gefitinib|250mg po once a day daily until disease progression
45646306|NCT02031601|Drug|Icotinib|125mg po three times a day daily until disease progression
45646307|NCT04988165|Drug|Traditional Chinese Medicine|It is a common prescription used in traditional Chinese medicine to treat diarrhea with remarkable efficacy.
45789397|NCT01861457|Other|Nozin® Nasal Sanitizer®|The treatment agent tested was the alcohol and natural oil preparation that comprises the commercially available over-the-counter (OTC) product, NOZIN® Nasal Sanitizer® antiseptic, by Global Life Technologies Corp, with the addition of benzalkonium chloride (0.13%), as described for the patented and safety-tested formulation.
45789398|NCT01861457|Other|Placebo|The placebo preparation, utilized to account for the potential mechanical effects of the application process, was phosphate buffered saline (PBS).
45789399|NCT02651103|Device|NIRS|Cerebral oxygenation monitor which is standard of care for this surgery.
45789400|NCT05444907|Other|No Intervention / Exposure|No intervention / exposure since this is an observational study
45789401|NCT02269631|Behavioral|Legume diet group|about 1 1/2 cups of legumes included in lunch and dinner meals
45789402|NCT02269631|Behavioral|Control diet group|no legumes in lunch or dinner meals
45789403|NCT02269631|Device|Smartpill|to assess how long food takes to pass through the digestive system
45789404|NCT02269631|Other|legumes|about 1 1/2 cups of legumes included in lunch and dinner meals
45789405|NCT02270255|Procedure|Superior hypogastric nerve block|21g Chiba needle advanced into the superior hypogastric plexus via an anterior infraumbilical approach using the arterial catheter as a fluoroscopic landmark to target the vertebral body below.
45789406|NCT02270255|Drug|0.75% Ropivacaine|20 ml of 0.75% Ropivacaine
45919985|NCT00084370|Procedure|oophorectomy|
45919986|NCT00084448|Drug|celecoxib|
45646308|NCT02772679|Biological|PolyTregs+IL-2|PolyTregs will be infused into the patient in a single infusion. The first cohort will receive 3 x10^6 cells. The second cohort will receive 20x10^6 cells. Following the day 0 infusion of polyclonal Tregs, subjects will receive two 5-day courses of IL-2 (1 x 106 IU daily), the first on days 3-7 and the second on days 38-42. Administration of the second course of IL-2 may be delayed or withheld depending on threshold criteria for peripheral blood Treg frequencies and MMTT-stimulated C-peptide levels determined on day 28.
45789407|NCT02270255|Procedure|Subcutaneous injection|Injection into subcutaneous tissues in periumbilical region
45789408|NCT02270255|Drug|1% Xylocaine|5ml of 1% Xylocaine
45789409|NCT02270645|Device|595/1064 multiplex laser|595/1064 multiplex laser will be used 3 times spaced by a four week interval (+/- 3 days), it will be administered in an outpatient clinic setting.
45789410|NCT02651259|Drug|Rifapentine (RPT)|900 mg of RPT
45789411|NCT02651259|Drug|Isoniazid (INH)|900 mg of INH
45789412|NCT02651259|Dietary Supplement|Pyridoxine (vitamin B6)|25 mg to 100 mg of pyridoxine, based on the current local, national, or international dosing guidelines.
45789413|NCT02271425|Drug|Evacetrapib Tablet|Oral administration
46071340|NCT05337956|Procedure|Erector spinae plane block catheter|All ESP blocks will be performed in lateral position after general anesthesia induction. ESPB will be performed under ultrasonographic guidance using a linear 6- to 10-MHz ultrasound probe. The linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T6-10 spinous process. The erector spinae muscles will be identiﬁed superﬁcial to the tip of the transverse process. A 21-gauge 10-cm needle will be inserted using an in-plane superior-to-inferior approach or an out of plane approach. The tip of the needle will be placed into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be conﬁrmed by visible ﬂuid spread lifting erector spinae muscle oﬀ the bony shadow of the transverse process on Ultrasonographic imaging. A total of 10-15 ml of 0.2% ropivacaine will be injected each side. A catheter will then be placed leaving 5 cm in place.
46071341|NCT04546555|Device|Dual chamber pacemaker|Dual chamber pacemaker implantation with Bachmann's bundle lead and His bundle lead placement.
46071342|NCT04546555|Other|Accelerated Physiologic Pacing|The lower rate limit will be programmed to an individualized heart rate.
46071343|NCT04546555|Other|Nocturnal Pacing|In addition to adjustment of the lower rate limit to an individualized heart rate, nocturnal pacing a moderate HR elevation of 110bpm will be implemented between 8pm and 6am.
46071344|NCT02844218|Other|Age of patient|"Historical Comparison Between Patients Aged 60 to 69 and Patients Aged ≥ 70 Years Treated With Intensive Chemotherapy.~Comparison between Intensive Chemotherapy and Low-Intensity Treatments in Patients Aged ≥70 Years.~Improvement of Treatments Over Time~Overall Survival (OS) of patients aged ≥ 70 Years during3 study periods. Period 1, from 1985 to 1999, during which all patients with acute Myeloid Leukemia received an intensive chemotherapy regimen at the University Hospital. Period 2, from 2000 to 2006, during which all patients received an Intensive Chemotherapy regimen, Improved Supportive Care and follow-Up protocol at the University Hospital. Period 3, From 2007 to 2014, during Which patients received Improved Supportive Care and follow-up protocol at the University Hospital and Personalized Therapy (Intensive Chemotherapy or Low-Dose Intensity Treatment)"
46071345|NCT02550691|Procedure|blood sampling|A blood sample will be taken on subject carrying specific genotype
45789414|NCT02271425|Drug|Evacetrapib Intravenous|Intravenous administration
45789415|NCT01862159|Procedure|laparoscopic gastric bypass surgery|laparoscopic gastric bypass surgery
45789416|NCT02651337|Device|Cerebrospinal Fluid (CSF) Drainage|Placement of Alivio in line flusher during CSF drainage
45789417|NCT01863017|Device|tDCS|
45646309|NCT04456127|Procedure|Fractional CO2 Laser|The UltraPulse® fractional ablative CO2 Laser will be employed with the DeepFX™ hand piece. Number of passes and laser settings, including fluency, density, spot size, will be chosen during the time of treatment as determined by the operating surgeon.
45646310|NCT04984577|Drug|Compound Edaravone Injection-Low dose|Compound Edaravone Injection 30mg/dose (Edaravone 30mg, Taurine 600 mg), one dose every 12 hours, continue for 14 days
45789418|NCT05442411|Drug|Ropivacaine 0.75% Injectable Solution|comparison of scalp block vs conventional post operative parecoxib
45789419|NCT03390569|Behavioral|Exercise|The patients meet with a registered physiotherapist and receive individualized exercise programs starting the second week of treatment, and continuing up to 3 months later.
45789420|NCT05444829|Device|specific screw holes locating surgical guide and pre-bent plates|Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the pre-bent plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa.
45789421|NCT05444829|Device|classical reduction and internal fixation.|mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
45919987|NCT00084448|Drug|paclitaxel|
45646311|NCT04984577|Drug|Compound Edaravone Injection-High dose|Compound Edaravone Injection 50mg/dose (Edaravone 50mg, Taurine 1000 mg), one dose every 12 hours, continue for 14 days
45646312|NCT04984577|Drug|Edaravone Injection|Edaravone Injection 30mg/dose, one dose every 12 hours, continue for 14 days
45646313|NCT04984577|Drug|Placebo injection|Placebo injection, one dose every 12 hours, continue for 14 days
45646314|NCT05083429|Drug|Salmeterol|Salmeterol inhaler dispensing claim is used as the reference
45646315|NCT05083429|Drug|Tiotropium|Tiotropium dispensing claim is used as the reference
45646316|NCT04984187|Other|high intensity laser plus exercise|high intensity laser plus exercise
45646317|NCT04984187|Device|high intensity laser only|high intensity laser only
45919988|NCT00084526|Procedure|computed tomography|
45919989|NCT00084526|Procedure|ultrasound imaging|
45919990|NCT00084565|Drug|estramustine phosphate sodium|
45919991|NCT00084565|Drug|paclitaxel|
45919992|NCT00084565|Drug|topotecan hydrochloride|
45789422|NCT05654363|Procedure|Administration of morphine by intrathecal route|Lumbar puncture was performed before the induction of general anesthesia, in the operating room. Spinal anesthesia was performed in sitting position using a midline approach into the L3-L4 or L4-L5 interspaces with a 25ga pencil-point spinal needle administering 75-100 mcg morphine, with or without local anesthetic (levobupivacaine 0,5% 10-15 mg or bupivacaine 0,5% 10-15 mg or ropivacaine 0,5% 10-15 mg), depending on the anesthesiologist's preference. General anesthesia was then conducted according to clinical practice. All patients were transferred in the Post-Anesthesia Care Unit (PACU) at the end of surgery. Throughout the first 48 postoperative hours, all patients were regularly evaluated in the hospital ward by a member of the Acute Pain Service Team.
45789423|NCT05654363|Procedure|Administration of morphine by intravenous route|General anesthesia was conducted according to clinical practice and a morphine bolus was administered before emergence from anesthesia according to clinical needs. All patients were then transferred in the Post-Anesthesia Care Unit (PACU) at the end of surgery and received Patient-Controlled Analgesia (PCA) with morphine 1mg/mL (CADD®-Solis 2110 Infusion System, Smiths Medical ASD, Inc., USA, 1 mL bolus on demand, no background infusion, 7 minute lockout, max 8 mg/h). Throughout the first 48 postoperative hours, all patients were regularly evaluated in the hospital ward by a member of the Acute Pain Service Team.
45789424|NCT01423760|Biological|Tecemotide|Subjects who received tecemotide (L-BLP25) for the treatment of non-small cell lung cancer (NSCLC) or multiple myeloma in a feeder trial will continue to be treated with tecemotide (L-BLP25) and have safety assessments performed until the discontinuation criteria in the respective feeder trial protocol are met.
45789425|NCT01423760|Other|No intervention|Subjects who had not received tecemotide in the feeder study, or who had discontinued treatment with tecemotide (L-BLP25), will only be observed for progressive disease (PD) (if applicable) and survival in 6-month intervals and will not be provided treatment with tecemotide (L-BLP25).
45789426|NCT02651415|Drug|Regorafenib|"Stivarga® will be used as per the marketed indication (on label), Coversyl will be used off-label and as such a Clinical Trial Application will be filed with Health Canada.~Regorafenib will be administered 160 mg daily for 21 days of a 28 day cycle. Regorafenib will be administered with low fat breakfast, one hour after perindopril. A low fat breakfast as defined by the Stivarga ® (regorafenib) Product Monograph is one that is <30% fat, ~300-550 calories."
45789427|NCT02651415|Drug|Perindopril|COVERSYL® (perindopril erbumine) 4 mg will be administered daily for 21 days of a 28 day cycle. Perindopril will be administered orally, first thing in the morning on an empty stomach.
45789428|NCT00555425|Behavioral|Behavioral: Buprenorphine/naloxone maintenance (Mtn)|Mtn is designed to reflect usual care by primary care physicians and includes weekly drug counseling (DC) and referral to ancillary services. Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Mtn, Bup will continue unchanged for the remainder of the study.
45789429|NCT00555425|Behavioral|Behavioral: Buprenorphine/naloxone detoxification (Dtx)|Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Dtx, the dosage of Bup will be tapered to zero over the next 3 weeks, and patients will not receive additional Bup for the remainder of the study. Dtx patients will be offered thrice-weekly DC beginning during the taper and naltrexone will be offered 7 days following the last dose of Bup.
45789430|NCT05444751|Drug|General anesthetic|"Maintenance of general anesthesia: propofol infusion (50-150 μg.kg.min-1); ketamine infusion (up to 50 mg total); and inhaled anesthetic agent (isoflurane or sevoflurane) up to 0.5 MAC. N20 is not permitted.~Emergence from general anesthesia: N20 may be used during closure of the surgical incision to facilitate rapid emergence."
45646318|NCT04984187|Other|exercise|exercise only
45646319|NCT05088343|Drug|Rosuvastatin|Single oral dose of rosuvastatin on Day 1 or co-administered with hetrombopag on Day 11.
45646320|NCT05088343|Drug|Hetrombopag|7.5 mg hetrombopag was administered on Day 6 to Day 11.
45646321|NCT04984265|Radiation|Stereotactic Body Radiation Therapy|SBRT targeting the area of the circuit of Ventricular Tachycardia
45646322|NCT03070145|Other|Exercise Intervention|12-week moderate-intensity aerobic and strength training exercise intervention
45646323|NCT03137485|Procedure|Conventional open lumbar discectomy|Removal of single level lumbar disc herniation through conventional discectomy.
45449529|NCT03550209|Drug|LCPUFA Oil Supplement|25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
45449530|NCT03550209|Dietary Supplement|Canola Oil Placebo|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
45449531|NCT03733366|Other|Desk surface|The participants will test all 10 desk surfaces and will be randomly allocated to one of the desks each time.
45449532|NCT03725241|Dietary Supplement|Glutathione Supplement|1000 mg/day Glutathione
45646324|NCT03137485|Procedure|Percutaneous Endoscopic Translaminar lumbar discectomy.|Removal of single level Lumbar disc herniation using endoscope.
45646325|NCT03137485|Device|Easy Go system Endoscopy|This system will be used to remove herniated disc in endoscopic group
45646326|NCT03068507|Behavioral|Trimodal prehabilitation management|Trimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence).
45646327|NCT03137641|Other|Nurses urine samples|Collected urine samples from nurses in contact with antineoplastic drugs.
45646328|NCT04640701|Other||
45646329|NCT04983641|Other|Pre-Visit Messages|"Patients in both experimental arms (E-mail and Digital Patient Portal MyChart) were sent pre-visit messages regarding PROMIS form completion via each respective modality at 1 week and also 3 days prior to their respective Orthopaedic clinic visits"
45646330|NCT03068429|Drug|Sertraline Hydrochloride|first week: sertraline hydrochloride 50mg/day, second week: sertraline hydrochloride 100mg/day, third week: sertraline hydrochloride 150mg/day, fourth week: sertraline hydrochloride 200mg/day OBS.: Other SSRIs (fluoxetine, paroxetine, escitalopram) with equivalent dosage schedules can be used if patients report prior intolerance to sertraline
45789431|NCT05444751|Drug|SA + ESP|"The choice of local anesthetic for spinal anesthesia will be confirmed after consultation with the attending surgeon to determine duration of surgery. For expected surgical times less than 90 minutes, up to 4 mL 1.5% mepivacaine (60 mg) will be used. Where the anticipated surgical duration is longer than 90 minutes, 2 mL 0.5% bupivacaine (10 mg) may be substituted. After patient (prone) positioning, maintenance of sedation will be achieved with a target RASS score of 0 to -1.~Propofol (25-50 μg.kg.min-1) and ketamine (up to 50 mg total dose) infusions will be titrated to effect. Intermittent boluses of propofol (10-20mg) may be used to achieve the desired sedation, as needed.~Patients will be offered to option of awake surgery, where no sedation will be provided, if preferred. Patients will be informed that at any time before or during the procedure, they may change their mind, and receive sedation."
45789432|NCT01485770|Drug|ADX-N05|150 mg once a day for seven days followed by 300 mg once a day for seven days
45789433|NCT01485770|Drug|Placebo|Placebo to match ADX-N05 once a day for 2 consecutive weeks
45789434|NCT01863563|Device|QuickClot|1 application of treatment to each tonsil/adenoid removal area
45789435|NCT05444673|Drug|Paprizumab combined with cisplatin and 5-FU|Patients with advanced temporal bone cancer were treated with pabulizumab combined with cisplatin and 5-FU
45789436|NCT05444439|Genetic|detection of vacuolating cytotoxin A (Vac A) and cytotoxin-associated gene A (Cag A) virulent H.Pylori genotypes by polymerase chain reaction amplification(PCR) in gastric biopsies :|Extraction of DNA, using Wizard® Genomic DNA Purification Kit (Promega-USA), will be done following the manufacturer instructions. For detection of vacuolating cytotoxin A and cytotoxin-associated gene A gene, polymerase chain reaction amplification will be performed with a 9 minutes' initial denaturation at 94˚C, followed by 35 cycles of 1 minute at 94˚C, 45 seconds at 60˚C, and 45 seconds at 72˚C. Final extension will be performed for 5 minutes at 72˚C. For detection of vacuolating cytotoxin A (S1/S2, m1, m2), PCR will be performed with a 9 minutes' initial denaturation at 94˚C, followed by 35 cycles of 1 minute at 94˚C, 45 seconds at 56˚C, and 45 seconds at 72˚C. Final extension will be performed for 5 minutes at 72˚C. Amplified DNA will be analyzed by agarose gel electrophoresis. A positive sample will give bands at DNA fragment 138-bp for cytotoxin-associated gene A, at 259/286-bp for vacuolating cytotoxin A s1/s2, and 290-bp and 352-bp for m1 & m2, respectively
45789437|NCT05444439|Diagnostic Test|Culture and sensitivity of endoscopic gastric biopsies:|During endoscopy, three biopsies will be taken from antrum and/or corpus of and will be examined by rapid urease test also known as Campylobacter-like organism test (Kimberly-Clark,USA). Culture of the bacterium on Columbia agar plus 5-7% defibrinated horse or sheep blood and selective Dent supplement under microaerophilic condition at 37degree Celsius for 3-5days.
45789438|NCT05444439|Other|Histopathological examination endoscopic gastric biopsies:|Histological sections from the antrum and body regions will be stained with Giemsa stain. Giemsa stain working solution was prepared as follows: 40 ml Giemsa stock solution with 60 ml of distilled water. Giemsa stock solution will be prepared as follows: Giemsa powder 4 g, glycerol 250 ml and methanol 250 ml. Histological sections will be examined by a gastrointestinal pathologist to standardize the classification of gastritis. Histopathological classification will be recorded as following (acute gastritis, mild-moderate- severe chronic gastritis, Glandular atrophy or Intestinal metaplasia).
45789439|NCT05444439|Procedure|Upper endoscopy|it will be done patient before start empirical therapy and multiple antrum and/or corpus biopsies will be taken . Patient will be fasting at least 8 hours.Upper and findings will be recorded in the report as presence of gastroesophageal reflux disease, diffuse or localised gastric and/or duodenal redness, mucosal swelling, atrophy of mucosa, nodularity, intestinal metaplasia, erosions or ulcers.
45789440|NCT05444439|Drug|empirical H.pylori regimens|Start empirical antibiotics regimens patient triple therapy ((levofloxacin 400 mg once , amoxicillin 1000 mg twice for 2 weeks) and (Proton pump inhibitor twice for 1 month)). Follow up after 2 weeks after finishing regimen by Stool Ag in stool
45789441|NCT05444439|Diagnostic Test|H.Pylori Ag in stool|"Any symptomatic patient is above 18 years old with H pylori infection patients diagnosed by positive H pylori Ag in stool will be included.~assessment of laboratory response, 2 weeks after finishing empirical therapy."
45789442|NCT01424072|Other|auriculotherapy by needles|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
45646331|NCT03068351|Drug|RO6870810|RO6870810 will be administered subcutaneously (SC) at ascending-dose levels (from 0.30 milligrams/kilogram [mg/kg] to 0.65 mg/kg). In Cycle 1, RO6870810 will be given on Day 1 (omitted on Day 2) and then every day from Day 3 through to Day 15. Starting at Cycle 2, it will be given every day from Day 1 to Day 14 of each 21-day cycle. In the first combination therapy cohort RO6870810 will be administered at one dose-level below the maximum tolerated dose (MTD).
45646332|NCT03068351|Biological|daratumumab|Daratumumab will be administered intravenously (IV) at a dose of 16 milligrams/kilogram (mg/kg) of body weight weekly for the first 8 weeks, every two weeks for the following 16 weeks, and every four weeks thereafter, until disease progression.
45789443|NCT01424072|Other|auriculotherapy by seeds|We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
45789444|NCT04738929|Other|Extra virgin coconut oil or extra virgin olive oil|"Subjects consumed standard breakfast meals containing extra virgin coconut oil or extra virgin olive oil"
45789445|NCT01540370|Other|No Treatment|No treatment
45449533|NCT03725241|Dietary Supplement|Placebo Supplement|Crystalline cellulose
45646333|NCT03137563|Other|questionnaire|The questionnaire will be distributed and collected by the same investigator in one of the eight centers involved in the study. The investigator will verify the inclusion criteria and the absence of exclusion criteria.
45646334|NCT03140293|Drug|Lidocaine injection|Injectable anesthesia is 1-2mL of 2% lidocaine via a 22 gage needle, given at the anticipated site of CVS needle puncture immediately before procedure.
45789446|NCT04338633|Drug|Conventional calcium hydroxide paste|Conventional calcium hydroxide paste (Ultracal) will be removed in second visit.
45789447|NCT04338633|Drug|Calcium hydroxide nanoparticle|Calcium hydroxide nanoparticle. manufactured in NanoTech. institute, will be removed in second visit.
45789448|NCT04338633|Drug|Combined Calcium hydroxide with silver nanoparticle|Combined Calcium hydroxide with silver nanoparticle will be removed in second visit.
45789449|NCT01866839|Device|Graft Manipulation (CD34+ Selection)|
45789450|NCT01487954|Dietary Supplement|alkaline water|Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.
45789451|NCT01487954|Dietary Supplement|distilled water|Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy.
45789452|NCT01487954|Radiation|external beam radiation therapy (EBRT)|Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks.
45789453|NCT00368511|Procedure|Music Listening|Listen to music and posture measurements
45789454|NCT01541384|Device|Vitality GlowCaps|"The main research instrument is an electronic pill bottle called GlowCaps that has the ability to transmit reminder messages via email, text, and phone to the subject, and adherence data to special servers. The messages will be sent twice a day, if a subject misses a dose of their immunosuppression medication (tacrolimus). Each time the pill bottle is opened (or not opened), a date- and time-stamped wireless signal is sent to the Vitality server via the AT&T cellular network. No extra cellular or wireless service is required from subjects for the GlowCap to function.~Note: GlowCaps are a Class 1 Medical Device registered with the FDA. Because of this Class 1 designation, they are not subject to FDA testing or approval."
45789455|NCT05444205|Behavioral|Text4Baby or Bright by Text Referral|Passive texting programs where participants receive free text messages on topics such as child development and parenting tips three times per week. Text4Baby serves parents of children under one year. Bright by Text serves parents of children under eight years of age.
45789456|NCT05444205|Behavioral|Nurture Program Warm Referral|Nurture Program is a nonprofit organization that promotes healthy development in young children by pairing moms with experienced and knowledgeable mentors who use text messaging to answer questions and provide helpful information, while offering support and encouragement throughout the child's first few years of life.
45789457|NCT05444205|Behavioral|Video Interaction Project|The Video Interaction Project is a program to support parents and their young children. Video Interaction Project is typically offered at a convenient location, such as a pediatric clinic. Parents are observed and videotaped for 3 to 5 minutes while interaction with their child. The Video Interaction Project coach then watches the video with the parent and talks about their interaction, highlighting how best to support the child's growth and language development.
45789458|NCT05444205|Behavioral|Family Check-UP|"The Family Check-Up is brief, taking place over the course of three sessions, each about an hour long. A Family Check-Up family coach will spend time getting to know the family during an Initial Interview. Second, parents complete questionnaires that assess child and family adjustment, relationships, and other areas that influence children and families. The assessment includes videotaped family interaction tasks, where parents take part in activities with their child like playing together with toys and puzzles. Third, the Feedback session consists of sharing feedback - including strengths and challenges - about child and family well-being based on survey responses and video clips. Parents are invited to set goals for their family to support and maintain strengths and address areas of concern. Parents are paid 25 dollars after the Feedback Session. Parents have the option to continue meeting with the family coach to support the child's development and improve parental well-being."
45789459|NCT05444205|Behavioral|Smart Beginnings|Smart Beginnings consists of delivering both Video Interaction Project and the Family Check-up packed together as a single intensive intervention.
45646335|NCT03140293|Drug|Gebauer Ethyl Chloride Spray|Gebauer Ethyl Chloride Spray is a topical anesthetic spray which is sprayed continuously for 3-7 seconds from a distance of 3-9 inches at the site where the chorionic villus sampling is expected to take place.
45646336|NCT04983563|Device|Actigraphy, eTact|Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy.
45789460|NCT05444205|Behavioral|Healthy Families America Warm Referral|As part of Healthy Families America, professionally trained Nurse Home Visitors provide information during weekly home visits so that parents can provide the best for your new baby. Topics addressed are ways to keep the baby safe, how to take care of the baby, and activities parents can enjoy with their babies.
45646337|NCT03137329|Behavioral|Exercise program|Physical therapy for aerobic and resistance training exercises
45646338|NCT03137329|Dietary Supplement|Nutrition|Nutrition supplementation via HMR for lifestyle arm only
45646339|NCT03137329|Procedure|WLS|Weight loss surgery as planned
45646340|NCT04452695|Device|Doctor Spot|Robotic platform (Boston Dynamics) controlled by clinician with video interface to facilitate telemedicine triage
45789461|NCT05444205|Behavioral|Family Center Warm Referral|There are 27 Family Centers across Allegheny County provide services to families of young children 5 and under. These centers focus on three primary activities: 1. enhancing child development; 2. facilitating parent education, and 3. ensuring parents are supported and connected.
45789462|NCT05413395|Other|topical colloidal oatmeal formulation with a modified plant oil|"Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation with a modified plant oil (Activated Oil, AO). The AO contains proprietary blends of plant oils that have selective antimicrobial properties."
45789463|NCT05413395|Other|topical colloidal oatmeal formulation|Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation
45789464|NCT01488188|Biological|Influenza vaccine|Administration of 1 dose (0.2 ml) by nasal route
45646341|NCT04584541|Biological|blood tests|Memory T and B cell response assessment Humoral response assessment (Specific anti-Sars-Cov-2 antibodies characterization)
45789465|NCT01488188|Biological|Influenza vaccine|Administration of 1 dose (0.2 ml) by sublingual route
45646342|NCT04584541|Biological|Nasopharyngeal swabs|SarS-Cov-2 viral load assessment
45646343|NCT04584541|Biological|Stools|SarS-Cov-2 viral load assessment
45646344|NCT04982861|Drug|Cefixime Trihydrate 100 mg/5 mL Dry Syrup|Participants received a single dose of 5 mL of cefixime dry syrup with 240 mL of water
45646345|NCT04982861|Drug|Suprax 100 MG in 5 mL Oral Suspension|Participants received a single dose of 5 mL of Suprax with 240 mL of water
45646346|NCT04456049|Drug|Enzalutamide|40 mg oral tablets once daily for a maximum of 28 days.
45789466|NCT05406609|Other|Cost|Costs of operating room, drugs and equipments which are used by anesthesia
45789467|NCT05406609|Other|Time|Time of using operating room
45789468|NCT01489670|Drug|bimatoprost 0.01% ophthalmic solution|Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
45789469|NCT04738851|Other|Therapy Mirror task|"The protocol has 3 conditions:~A virtual TM task (TMV~A classic TM task (TMC)~A control task (TC)~The order of the 3 conditions will then be randomized to avoid potential biases linked to the sequence of conditions."
46071346|NCT02844452|Device|Acupuncture|Acupuncture is a form of alternative medicine and a key component of traditional Korean medicine (TKM) involving thin needles inserted into the body at acupuncture points. It can be associated with the application of heat, pressure, or laser light to these same points. Acupuncture is commonly used for pain relief, though it is also used for a wide range of other conditions. Clinical practice varies depending on the country.
46071347|NCT02844452|Device|Sham Acupuncture|Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders. In an ideal controlled study, subjects would not know whether they were getting true or sham acupuncture. We are going to use Park Sham Acupuncture, which is composed of sham acupuncture needle not penetrating the skin of subjects and Park sham acupuncture device attacted on the subject's skin in order to block the seeing whether the acupuncture needle penetrates skin or not.
45789470|NCT01542398|Behavioral|Family-Focused, Community-Based, Resilience-Targetting Psychosocial Intervention|A 12-module manualised intervention focusing on reducing psychological distress, improving family and community functioning and boosting daily functioning of adolescents through the use of Mobile Cinema Screenings and task-based, participatory, group-sessions
45789471|NCT01427504|Drug|boceprevir; etravirine|boceprevir tablets 800 mg, every 8 hours x 11-14 days. etravirine tablets 200 mg, every 12 hours x 11-14 days.
45789472|NCT03183323|Behavioral|Telerehabilitation|Activity trackers. Mio Slice is worn through the whole study. Actigraph is worn for one week, at 4 different timepoints through the study.
45789473|NCT03169361|Drug|Ixazomib|Ixazomib capsules
45789474|NCT02265965|Drug|intravenous nitroglycerin|Infusion at started at time of hysterotomy and stopped at neonate delivery
45789475|NCT03113981|Device|Total Hip Arthroplasty|Implanting THA grafted with PolyNass or not
45789476|NCT03073811|Dietary Supplement|Protein enhanced nutrition intervention|Participants will be provided 30 grams of high quality protein (Ensure Max) three times a day for two weeks before surgery and four weeks after surgery.
45789477|NCT03073811|Other|Education Control|provided educational on the role of nutrition to prepare for and heal from surgery, and Registered Dietitian will instruct participant to follow instruction on handout and one oral nutrition supplement per day for two week before surgery.
45789478|NCT03021083|Device|IONSYS Patch|Patient controlled transdermal fentanyl patch, IONSYS, applied to patient in place of a PCA.
45646347|NCT04572217|Drug|Topiramate|Topiramate (starting dose 25 mg daily, max dose 100 mg daily)
45789479|NCT03000257|Drug|Venetoclax|Tablet taken orally
45789480|NCT03000257|Drug|Rovalpituzumab Tesirine|Intravenous infusion
45789481|NCT03000257|Drug|ABBV-181|Intravenous infusion
45789482|NCT02654769|Drug|Ingenol Mebutate (Picato®)|Brand product
45789483|NCT02654769|Drug|Generic Ingenol Mebutate|Generic formulated to have the same therapeutic effect of the brand
45789484|NCT02654769|Drug|Vehicle Foam|It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
45789485|NCT02945813|Drug|Metformin|850mg PO BID; 48 weeks
45646348|NCT04572217|Drug|Phentermine|Phentermine (starting dose 8 mg, max dose 16 mg)
45646349|NCT04455503|Drug|EVX-02A|Up to 8 patients will receive EVX-02A administered IM.
45789486|NCT02945813|Radiation|Salvage Radiotherapy SRT|SRT 35 x 2Gy; 7 weeks
45789487|NCT05443581|Behavioral|dietary intervention|Dietary guidance will be given to participants through monthly face-to-face interviews and biweekly telephone calls to change their dietary structure and energy intake.
46071348|NCT05337878|Drug|Placebo|Pelacarsen-matching placebo administered by SC injection.
46071349|NCT05337878|Drug|Pelacarsen|Pelacarsen administered by SC injection.
45789488|NCT02865707|Dietary Supplement|Synergy-1|Synergy-1 is chicory-derived β-fructans inulin plus FOS (1:1).
45646350|NCT04455503|Drug|EVX-02B|Up to 8 patients will receive EVX-02B administered IM.
45646351|NCT04455503|Drug|EVX-02A OR EVX-02B|EVX-02A or EVX-02B will be used. Patients: 24 to 30
45646352|NCT04553809|Procedure|ENB|ENB for biopsy sampling of peripheral lung lesion
45646353|NCT04553809|Procedure|ENB in combination with rEBUS|The combination of ENB and rEBUS for biopsy sampling of peripheral lung lesions
45646354|NCT05376371|Other|CJC-TraC|CJC-TraC utilizes a nurse case manager (NCM) to coordinate the participant's transitional care through release from a correctional facility. The NCM will visit either in person or via telehealth with the participant up to 4 times while incarcerated, and up to 4 times after release.
45789489|NCT02865707|Dietary Supplement|Maltodextrin|Maltodextrin is carbohydrate adsorbed in the small bowel.
45789490|NCT02656485|Drug|B244|10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
45789491|NCT02656485|Drug|Placebo|10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
45789492|NCT05391711|Behavioral|Culturally Smart Relationships|"Mentors assigned to the intervention will receive the following trainings and support:~Online Justice, Equity, Diversity, and Inclusion (JEDI) trainings (self-paced)~Culturally Smart Relationships Training (live, virtual)~JEDI enhanced monthly supervision from case managers~Monthly emails with activity suggestions for mentors and youth"
45789493|NCT05387811|Combination Product|Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy|Adherence to International Club of Ascites recommendations for the management of AKI
45919993|NCT04865718|Diagnostic Test|ICGA imaging|subjects undergoing intraoperative ICGA imaging
45919994|NCT00084604|Drug|irinotecan hydrochloride|Given IV
45789494|NCT05443269|Dietary Supplement|Jump Start Nutritional Program|Nutri-meal Active meal replacement shake and Metabolism pill at breakfast, lunch, and dinner, morning and evening Health Pak (multivitamin), 1 probiotic stick, and 300 calories fruits and vegetables daily
45789495|NCT05443113|Diagnostic Test|Genetic analysis|Genetic analysis by geneticists
45789496|NCT02656875|Drug|TRV130|
45789497|NCT05442801|Drug|Cyclopentolate|Well known eye drop used for cycloplegic refraction among children.
45789498|NCT05442801|Drug|Tropicamide|Well known eye drop used for cycloplegic refraction among children.
46071350|NCT00929006|Drug|Micronized progesterone suspension|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
45789499|NCT05442723|Procedure|On-Pump CABG|coronary artery grafting by using cardiopulmonary bypass machine
45789500|NCT05442723|Procedure|Off-Pump CABG|coronary artery grafting by beating heart technique
45789501|NCT04739631|Other|acupuncture|use disposable sterile needles to insert to the acupuncture point
45789502|NCT04739631|Other|minimal acupuncture|The sham-controlled group will be performed with minimal acupuncture(superficial needling) at non- acupoints.
45646355|NCT05083195|Other|Home-based Telerehabilitation|Balance, walking, strengthening exercise videos etc. taken in different positions will be uploaded to the telerehabilitation system. A personalized exercise program will be created from these exercises. This program will be defined to the account of the patient and the follow-up of the person will be carried out through the system.
45789503|NCT05339373|Drug|Aceclofenac film-coated tablet 100 mg|Aceclofenac is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 100 mg of aceclofenac.
45919995|NCT00084604|Biological|bevacizumab|Given IV
45919996|NCT00084604|Drug|cisplatin|Given IV
45449534|NCT03725163|Behavioral|Acceptance and Commitment Therapy Enhanced Behavior Therapy (AEBT)|This treatment approach blends traditional behavior therapy elements of habit reversal training and stimulus control techniques with the more contemporary behavioral elements of Acceptance and Commitment Therapy (ACT). The first phase of the treatment, clients are taught skills for stopping and preventing their unconscious pulling episodes. The second phase, clients are introduced to ACT. Unlike interventions that aim to change the type or frequency of pulling-related cognitions, this treatment uses strategies to change the function of these cognitions. Clients are taught to see urges for what they really are and to accept their pulling-related thoughts, feelings, and urges without fighting against them. Over the course of 10 session clients will learn to be aware of their pulling and warning signals, use self-management strategies for stopping and preventing pulling, stop fighting against their pulling-related urges and thoughts, and work toward increasing their quality of life.
45646356|NCT05083195|Other|Exercise Brochure|Photos and explanations of exercises taken in different positions such as balance, walking, strengthening etc. will be uploaded to the telerehabilitation system. A personalized exercise brochure will be created from these exercises. This program will be defined for the patient's account and the patient will be asked to follow the exercises with this brochure.
45789504|NCT05339373|Drug|Airtal® film-coated tablet 100 mg|"Airtal ® is manufactured by Gedeon Richter- RUS, Russia / Gedeon Richter, Hungary. Each tablet contains 100 mg of aceclofenac."
45789505|NCT05331729|Radiation|FMISO-PET Protocol|"injection of 18F-FMISO~Monitoring for 2 h~PET scan (30 min) 2h post injection~Monitoring for 2h~PET (30min) 4h post injection~Discharge of the subject with appropriate recommendations after a PET/CT"
45789506|NCT05439993|Drug|Tepotinib plus paclitaxel|Paclitaxel 80mg/m2 on D1, 8, 15 tepotinib 250mg or 500mg daily on D1-28 Q 4weeks
45789507|NCT04739553|Device|His Pacing|The patients will receive a pacemaker implant with a traditional right ventricular pacing lead and an additional His pacing lead in a basal high septal position at the level of the proximal electrical conduction system (His). An atrial lead is implanted if dual chamber pacing is needed. All leads are connected to a biventricular pacemaker with the His lead in the LV port.
45789508|NCT05439135|Other|washed microbiota transplantation|Each patient will receive two units of washed microbiota each day for three consecutive days. After WMT, participants will receive free diet plus 50% PEN (providing 50% calculated energy requirement) at home for 4 weeks.
45789509|NCT05300997|Diagnostic Test|Biomarker blood draw and saliva collection|Three peripheral 10mL blood sample (if available) Three 1 - 3mL salivary samples (if available)
45789510|NCT05295225|Device|Green Light Emitting Diode|GLED exposure for two hours
45789511|NCT05295225|Device|White Light Emitting Diode|WLED exposure for two hours
45449535|NCT03032510|Drug|Eravacycline|
45449536|NCT03032510|Drug|Ertapenem|
45919997|NCT00084604|Procedure|computed tomography|Correlative studies
45919998|NCT00084604|Other|laboratory biomarker analysis|Correlative studies
45449537|NCT03032510|Drug|Placebo|
45919999|NCT00084643|Biological|GTI-2040|Given IV
45920000|NCT00084643|Drug|oxaliplatin|Given IV
46071351|NCT00929006|Drug|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
45789512|NCT04133493|Device|Kerecis Omega3 Wound|"The intervention group will receive, in addition, a fish skin graft (KerecisTM Omega3 Wound) secured with Steristrips, sutures or staples, covered with a nonadherent dressing (Adaptic, Systagenix, Yorkshire, UK or equivalent), the product bolstered down to the wound bed with a foam dressing (HydraFoam, DermaRite) and hydrogel as needed to retain adequate moisture balance and padded with stretch gauze and self adherent wrap as needed.~The wound will be dressed by the site investigator 1 day a week."
45789513|NCT04133493|Device|Fibracol|The Standard of Care Group will receive Fibracol covered with DSD. Change three times per week
45920001|NCT00084643|Drug|capecitabine|Given orally
45920002|NCT00084643|Other|pharmacological study|Correlative studies
45920003|NCT00084643|Other|laboratory biomarker analysis|Correlative studies
45920004|NCT00006062|Drug|oxaliplatin|
45920005|NCT00084721|Drug|celecoxib|
45920006|NCT00084721|Drug|irinotecan hydrochloride|
45920007|NCT00084877|Drug|triapine|Given IV
45920008|NCT00084877|Drug|irinotecan hydrochloride|Given IV
45920009|NCT00084877|Other|laboratory biomarker analysis|Correlative studies
45920010|NCT00084877|Other|pharmacological study|Correlative studies
45646357|NCT03137251|Device|TENS 1|A portable TENS unit will be used by the principal investigator to apply the experimental intervention. Two pairs of electrodes measuring 5 x 9 cm will be fixed on the paravertebral regions of the participants of the experimental group using hypoallergenic surgical tape. Two paired electrodes will be placed 1 cm laterally on either side of the spine at the T10 to L1 and S2 to S4 levels.
45646358|NCT03137251|Device|TENS 2|An intervention similar to arm 1 will be performed but with different doses.
45789514|NCT05268315|Behavioral|Brief Psychoeducational Intervention|The 1-session psychoeducational intervention is divided into three brief modules. Topics that are covered include thinking, learning, emotional, and behavioral functioning as they relate to childhood cancer, educational and school supports, and the role of neuropsychological and school-based assessments.
45789515|NCT02660853|Diagnostic Test|FEV1|Participants have FEV1 test
45646359|NCT03137251|Device|Placebo TENS|An intervention similar to arm 1and 2 will be performed but,in this case, it is a sham device.
45789516|NCT02662023|Drug|Bolus|A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later.
45789517|NCT02662023|Drug|Basal|A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours.
45789518|NCT00554099|Drug|Mesalamine|6 - 400 mg tablets once daily
45789519|NCT00554099|Drug|Probiotic|Once capsule daily Bifidobacterium infantis 35624 added at Visit 2 (Day 10 + 4 days)
45646360|NCT05635955|Drug|Remimazolam|"Total intravenous anaesthesia will be induced with 0.3mg/kg remimazolam and 0.3mg/kg esketamine, slow injection.~During the painless abortion surgery, if the MOAA/S scores > 1 or body movements occur, supplemental 0.2 mg/kg remimazolam (IV) will be administrated."
45646361|NCT05635955|Drug|Propofol|"Total intravenous anaesthesia will be induced with 2mg/kg propofol and 0.3mg/kg esketamine, slow injection.~During the painless abortion surgery, if the MOAA/S scores > 1 or body movements occur, supplemental 0.25 mg/kg propofol (IV) will be administrated."
45789520|NCT00554099|Drug|Placebo|6 placebo tablets for first 10 (+4) days followed by once daily placebo tablets.
45789521|NCT00554099|Other|Dietary Advice|Dietary advice
45789522|NCT00554099|Drug|Antibiotic for Diverticulitis|Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.
45789523|NCT04339335|Procedure|Pulsed radiofrequency of the occipital nerves|pulsed radiofrequency of the greater and lesser occipital nerves bilaterally
45789524|NCT04048161|Drug|Tacrolimus|"The patients will be divided into two groups randomly. Tacrolimus dose: 0.05-0.10 mg/kg/day, BID. The concentration for tacrolimus is 5-10 ng/ml，then reduce the dosage of drugs to maintian the concentration for tacrolimus is < 5ng/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day."
45646362|NCT05635955|Drug|Esketamine|0.3mg/kg esketamine will be co-administrated in both arms
45789525|NCT04048161|Drug|Mycophenolate Mofetil|"The patients will be divided into two groups randomly. Mycophenolate Mofetil dose: 20~30mg/kg/day，BID. The concentration for MPA-AUC is 30~50 μg.h/ml，then reduce the dosage of drugs to maintian the concentration for MPA-AUC is ≤40 μg.h/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day."
45789526|NCT05625191|Diagnostic Test|Acoustic voice analysis|Acoustic recordings will involve the five repetitions of three vowels (/ɑ, i, u/) and a standard reading passage (Rainbow Passage) in different voice conditions. Control participants will produce voice in breathy, typical, and pressed conditions. Patient participants will produce voice in typical production and in a resonant voice production. High-speed videoendoscopy and simultaneous acoustic recording will occur on one repetition of a sustained /i/ in each requested condition. Data will be collected using a head-mounted microphone.
45789527|NCT05625191|Diagnostic Test|High-speed videoendoscopy|High-speed videoendoscopy will occur on one repetition of a sustained /i/ in each requested condition. Exams will be recorded using the Phantom V311 high-speed camera (Vision Research, Wayne, NJ) connected to a Storz 70° rigid laryngoscope using a 400 Watt Xenon light source (Titan 400E).
45789528|NCT02664909|Drug|Tranexamic Acid|
45789529|NCT02664909|Drug|Placebo (saline)|
45789530|NCT02664987|Other|Patients receiving cancer pain treatment|
45789531|NCT03967275|Other|bone marrow harvest|During bone marrow harvest, an additional 10 mL sample will be collected for the study.
45789532|NCT00368589|Drug|atorvastatin|
45789533|NCT02377362|Drug|GLWL-01, Part A|Capsules administered orally, in 2 out of 3 periods
45789534|NCT02377362|Drug|Placebo, Part A|Capsules administered orally in 1 out of 3 periods
45789535|NCT02377362|Drug|GLWL-01, Part B|Capsules administered orally either once or twice daily for 27 days, with a single dose on Day 28
45789536|NCT02377362|Drug|Placebo, Part B|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
45789537|NCT02377362|Drug|GLWL-01, Part C|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
45789538|NCT02377362|Drug|Placebo, Part C|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
45789539|NCT03928041|Device|Device: EVOS Lumbar Interbody System (EVOS-HA)|All subjects will receive the EVOS Lumbar Interbody System (EVOS-HA) device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease and spondylolisthesis.
45789540|NCT00553631|Biological|velaglucerase alfa|IV infusion, 60 U/kg every other week for 9 months
45789541|NCT00553631|Biological|imiglucerase|IV infusion, 60 U/kg every other week for 9 months
45789542|NCT02667951|Other|A home-based caregiver-training program|A home-based caregiver-training program consisted of two weekly sessions, each lasting 2 to 3 hours. Following the training sessions, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
45646363|NCT05083117|Drug|XW001|It is anticipated that inhalation of 1 mg XW001 solution up to 14 days will result in a relatively lower systemic exposure in COVID-19 patients on oxygen therapy compared to that in healthy participants as COVID-19 patients tend to have impaired lung function of diffusive, restrictive, obstructive, or mixed origins.
45789543|NCT03849573|Behavioral|"OncoTool Intervention (MBSR + HT education)"|OncoTool is a website intended to improve self-management practices for helping cancer patients cope with stress and improve health-related quality of life. OncoTool provides mindfulness-based education and management for dealing with the numerous physical and mental side effects associated with hormone therapy (e.g., muscle and joint pain, vaginal dryness, depressive symptoms). OncoTool is a website designed to improve hormone therapy adherence by improving quality of life, and hormone therapy associated symptom burden. Both intervention and active comparator conditions are administered to participants for 8 weeks.
45789544|NCT03849573|Behavioral|"Oncotool Control (health +HT education)"|OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to breast cancer survivors, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar HT education content as the experimental content but without the CBT and MBSR state. Both intervention and active comparator conditions are administered to participants for 8 weeks.
45789545|NCT05210985|Behavioral|Affordances in the Home Environment for Motor Development-Infant Scale|Affordances in the Home Environment for Motor Development-Infant Scale is a parent-filled assessment to determine the nature and amount of factors affecting infant motor skill development in the home environment, including the availability of toys, materials, and the availability of spaces.
45789546|NCT05210985|Behavioral|Peabody Developmental Motor Scales-2|"Peabody Developmental Motor Scales | Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children from birth through 5 years."
45789547|NCT05210985|Behavioral|Test Of Sensory Functions In Infants (Tsfı)|This test helps you identify infants with sensory integrative dysfunction-including those at risk for developing learning disabilities as they grow older. The TSFI provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old, the TSFI provides an overall measure of sensory processing and reactivity, as well as scores on the following subdomains: Reactivity to Tactile Deep Pressure Visual Tactile Integration Adaptive Motor Function Ocular Motor Control Reactivity to Vestibular Stimulation
45789548|NCT00369135|Procedure|combined intervention|
45789549|NCT00553319|Drug|Placebo|Placebo group
45789550|NCT00553319|Drug|Adderall-XR|Adderall-XR 60mg/day
45789551|NCT00553319|Drug|Adderall-XR|Adderall-XR 80mg/day
45789552|NCT05443893|Device|Application Research of key points detection technology|"Artificial intelligence human key point detection model mainly has traditional algorithm, top-down algorithm and bottom-up algorithm three methods, three methods have advantages. This project will comprehensively use the above three methods to conduct algorithm and parameter debugging in the public data set and test in the private data set, so as to obtain the most suitable human key point recognition method for gait analysis"
45789553|NCT00369213|Device|Additional spermicidal lubricant to condoms|
45789554|NCT04768673|Drug|CKD-393 formulation I|single, oral administration of 2 tablets under fed condition
45789555|NCT04768673|Drug|CKD-393 formulation II|single, oral administration of 2 tablets under fed condition
45789556|NCT04768673|Drug|D501, D759, H053|single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition
45789557|NCT05197179|Drug|FB2001|Subjects will be administered with FB2001 by intravenous (IV) infusion
45789558|NCT05197179|Other|FB2001 placebo|Subjects will be administered with FB2001 by intravenous (IV) infusion
45789559|NCT00369291|Biological|keyhole limpet hemocyanin|KLH is a foreign protein to humans, it will be used to assess the immune response to a neo-antigen given as a single injection, 1 mg subcutaneously in the arm (per MT1999-06).
45789560|NCT00369291|Biological|tetanus toxoid|Tetanus toxoid booster 0.5 ml intramuscularly (IM) in the opposite arm (per MT1999-06)
45789561|NCT01868633|Drug|Dexamethasone|
45789562|NCT01868633|Drug|Placebo|
45789563|NCT04738773|Drug|Naltrexone|On the active drug group, naltrexone will be prescribed on flexible dose mode, receiving 50mg per day on the first week, with an increase of 25mg each week until a maximum of 200 mg per day or as much as tolerated by the patient.
45646364|NCT05083117|Drug|Placebo|It is anticipated that inhalation of 1 mg Placebo solution up to 14 days will result in a relatively lower systemic exposure in COVID-19 patients on oxygen therapy compared to that in healthy participants as COVID-19 patients tend to have impaired lung function of diffusive, restrictive, obstructive, or mixed origins.
45646365|NCT04452461|Drug|mFOLFIRINOX|mFOLFIRINOX, including: Oxaliplatin 85 mg/m2 IV over 2 hours, Leucovorin 400mg/m2 IV over 2 hours, Irinotecan at 150 mg/m2 IV over 90 min, 5-Fluoruracil continuous infusion of 2400 mg/m2 IV over 46h.
45646366|NCT04452461|Drug|Gemcitabine / Nab-paclitaxel|Both drugs are administered once weekly for three weeks (days 1, 8, 15) followed by a week of rest (28-day cycle) for 3 cycles prior to imaging. Gemcitabine: 1000 mg/m2 intravenous infusion over 30 to 40 minutes. Nab-paclitaxel: 125 mg/m2 intravenous infusion over 30 to 40 minutes.
45646367|NCT03137017|Drug|Norco 5Mg-325Mg Tablet|Single oral dose in one of the four cross-over trial periods.
45789564|NCT04738773|Drug|Placebo|Placebo
45789565|NCT01868789|Radiation|Weightbearing CT|
45789566|NCT04739397|Device|Glare Testing|Vision in Cataract patients were tested with and without the EpiGlare Tester
45789567|NCT01869647|Radiation|Ultra low dose CT scan|Ultra low dose CT scan
45789568|NCT01869647|Radiation|Regular CT or Low Dose CT scan|Regular CT or Low Dose CT scan
45789569|NCT01869647|Radiation|No imaging|No imaging
45449538|NCT03032510|Drug|Levofloxacin|
45646368|NCT03137017|Drug|GRT7014 - Abuse Deterrent Tablet|Single oral dose in one of the four cross-over trial periods.
45646369|NCT04412681|Diagnostic Test|Enhanced PE Screening|To better identify women at risk for pre-eclampsia during pregnancy.
45646370|NCT03019003|Drug|Oral Decitabine|Hypomethylating agent
45646371|NCT03019003|Drug|Durvalumab|anti-PD-L1
45789570|NCT03833063|Drug|botulinum toxin A|glabellar injections with botulinum toxin A
45789571|NCT03833063|Drug|Placebos|glabellar injections with sodium chloride
45789572|NCT02674659|Behavioral|resistance training|resistance training consists of lower and upper extremities exercises. We focus on biceps and hamstring to be trained. One session was held for around 30 minutes.
45449539|NCT03599349|Device|Microfocused ultrasound w/ visualization|
45920011|NCT03038373|Procedure|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy will be conducted based on standard protocol.
45646372|NCT05635565|Other|Individualized goal training|This group will be submitted to individualized goal training, 3 hours/day, 5 times/week, over the course of two weeks, totaling 30 hours. Training will happen in a clinical setting. Adolescents will select their functional goals to be trained during the intervention period.
45646373|NCT05635565|Other|Individualized goal training with educational strategies|This group will be submitted to individualized goal training with their caregivers, for 2 weeks, with 5 face-to-face meetings lasting 3 hours a day at the rehabilitation center. The other 5 meetings will be held online with the adolescent and their caregiver at the same time, via video communication platform. Adolescents will select their functional goals to be trained during the intervention period.
45646374|NCT03013933|Drug|Brentuximab Vedotin|Given IV
45646375|NCT03013933|Drug|Cyclosporine|Given PO
45646376|NCT03013933|Other|Pharmacokinetic Study|Correlative studies
45646377|NCT03013933|Drug|Verapamil|Given PO
45646378|NCT03013933|Drug|Verapamil Hydrochloride|Given PO
45646379|NCT04437745|Device|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
45646380|NCT04383925|Biological|BCG-Japan|Infant (<1 year) 0.05 ml dose of resuspended BCG-Japan (Tokyo strain 172, Japan BCG Laboratory, 1-5-21 Otsuka, Bunkyo-ku, Tokyo, 112-0012 Japan).
45646381|NCT04383925|Biological|BCG-Russia|Infant (<1 year) 0.05 ml dose of resuspended BCG-Russia (Serum Institute of India)
45646382|NCT05635253|Other|Hydrogen Peroxide 35%|Group that received only bleaching treatment. Soft tissue protection was performed with a Top Dam light-curing gingival barrier (FGM, Santa Catarina, SC, Brazil). Application of whitening gel (Whitness HP 35%/FGM) on the buccal surface from premolar to premolar in the upper and lower arches. Three 45-minute sessions were held with an interval of seven days between them.
45646383|NCT05635253|Other|Hydrogen Peroxide 35% + Polishing whitened teeth|Group that received only bleaching treatment followed by polishing. Soft tissue protection was performed with a Top Dam light-curing gingival barrier (FGM, Santa Catarina, SC, Brazil). Application of whitening gel (Whitness HP 35%/FGM) on the buccal surface from premolar to premolar in the upper and lower arches. Three 45-minute sessions were held with an interval of seven days between them. After bleaching, the vestibular surfaces were polished for 20s on each bleached tooth, with polishing paste and felt disc (Diamond Flex, FGM, Santa Catarina, SC, Brazil) in low rotation.
45646384|NCT03069599|Procedure|irreversible electroporation (IRE)|Irreversible electroporation is an emerging, mainly non-thermal ablative modality. It circumvents some downsides of thermal ablation and has the potential for broad application among patients with pancreatic cancer.
45646385|NCT05634941|Device|Active ON-tDCS|DC was transmitted via a saline-soaked pair of surface sponges and delivered by specially developed, battery-driven, constant current stimulator with a maximum output of 2 mA. For each participant receiving ON-tDCS, the anodal electrode placed over the left C2 nerve dermatome, and cathodal electrode placed over the right C2 dermatome. A constant current of 1.5 mA was applied for 20 min.
45646386|NCT05634941|Device|Sham ON-tDCS|For sham group, placement of the electrodes was identical to that of active ON-tDCS. ON-tDCS was first switched on in a ramp-up fashion over 5 s. Current intensity (ramp down) was gradually reduced (over 5 s) as soon as ON-tDCS reached a current flow of 1.5 mA. Hence, sham ON-tDCS only lasted 10 s (as opposed to 20 min in the active group).
45646387|NCT05074069|Procedure|Gynaecological reconstruction|Methods of vulvovaginal reconstruction, e.g. flap formation, neovagina formation
45646388|NCT04286425|Other|seminal plasma|Seminal plasma free of sperm, from donor men with normal sperm parameters, and tested for HIV1, HIV2, Hepatitis B, Hepatitis C, Syphilis, Chlamydia and Gonorrhea on blood and urine
45646389|NCT04286425|Other|saline solution|saline solution
45646390|NCT04262479|Drug|recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel|3 intra-inguinal injections (into the lymph nodes) of GAD-alum one month apart. Supplier Diamyd Medical AB in Stockholm, Sweden
45646391|NCT04262479|Drug|Vitamin D|1 tablet/day, total daily dose of 2000 IE given per os from day -30 through day 90. Supplier Meda, Solna, Sweden
45646392|NCT04275323|Genetic|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
45646393|NCT04275323|Other|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
45646394|NCT04133311|Drug|DE-130A|Latanoprost 50 microg/ml eye drops emulsion, eye drops emulsion in single-dose containers
45789573|NCT02674659|Behavioral|aerobic training|aerobic exercise consists of warming up session, treadmill exercise (around 20-30 minutes), and wrap-up session (for all session about 1 hour)
45789574|NCT02676375|Drug|Combination Bupropion + NRTs|
45449540|NCT02161120|Other|Traditional Finnish rye bread|
45449541|NCT02161120|Other|Low FODMAP rye bread|
45449542|NCT02161198|Dietary Supplement|Y-75|Y-75 (1 g) and starch (1 g) as a diluting agent and were packed to contain 2 g/package
45449543|NCT02161198|Dietary Supplement|Placebo|Caramel syrup (0.03 g) and starch (1.97 g) were packed identically to the active treatment
45646395|NCT04133311|Drug|Xalatan®|Latanoprost 50 microg/ml eye drops solution, eye drops in 2.5 ml dropper containers
45789575|NCT02676375|Other|Extended Treatment|
45789576|NCT02676375|Other|Home Visits & Calls|
45789577|NCT02676375|Drug|Monotherapy|
45789578|NCT01871441|Radiation|Total-body irradiation|Undergo TBI
45789579|NCT01871441|Biological|Donor lymphocytes infusion (DLI)|Undergo DLI
45789580|NCT01871441|Drug|Cyclophosphamide|Given IV
45789581|NCT01871441|Procedure|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo haploidentical allogeneic HSCT
45920012|NCT00084916|Drug|temsirolimus|Given IV
45920013|NCT00084916|Other|laboratory biomarker analysis|Correlative studies
45920014|NCT00006068|Procedure|Pancreatic Islet Transplantation|
45920015|NCT00085111|Biological|bevacizumab|Given IV
45789582|NCT01871441|Drug|Tacrolimus|Given IV
45789583|NCT01871441|Drug|Mycophenolate mofetil|Given IV
45789584|NCT02676843|Drug|18F-AV-1451|A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan.
45789585|NCT05134935|Device|Defocus Incorporated Multiple Segment (DIMS) Spectacles|18 months of therapy.
45789586|NCT05134935|Device|Orthokerathology lenses (OKL)|18 months of therapy.
45789587|NCT04338711|Drug|tofacitinib modified release (MR)|"Single oral 10 mg multi particulate dose of dose of tofacitinib MR with different levels of enteric coating (MR E1, MR E2, and MR E3) in the fasted state. Additionally, the lowest and highest enteric coating levels will also be evaluated in the fed state.~Treatment F: a 10 mg oral dose of tofacitinib IR solution"
45789588|NCT03609177|Other|Clinician Communication Skills Training|Communication skills training
45789589|NCT03609177|Other|Advance Care Planning (ACP) Decisions Videos Decisions Aids|ACP Decisions video decision aids
45789590|NCT03609177|Other|Video Declarations (ViDec)|Recording of patient advance care planning videos
45789591|NCT01874951|Drug|Naltrexone|1 mg of naltrexone will be given twice daily to all patients assigned to active drug.
45789592|NCT01874951|Drug|Placebo|Placebo identical in appearance to naltrexone will be given twice daily to all patients assigned to placebo.
45789593|NCT05111691|Procedure|Dry needling|Dry needling
45789594|NCT05590403|Biological|RSVPreF3 OA investigational vaccine|One dose administered intramuscularly at Day 1.
45789595|NCT05590403|Drug|Placebo|One dose administered intramuscularly at Day 1.
45804071|NCT05718505|Device|Atmo Motility Gas Capsule System|"The Atmo System measures whole gut and regional gut transit times. Measurements of GI tract transit times are used for evaluating motility disorders.~Gastric emptying time (GET) is indicated for the evaluation of patients with suspected gastroparesis. Delayed GET is implicated in such disorders as idiopathic and diabetic gastroparesis and functional non-ulcer dyspepsia.~Colonic transit time (CTT) is indicated for the evaluation of colonic transit in patients with chronic constipation, to aid in differentiating slow and normal transit constipation. In the case where ileocecal junction transit cannot be determined the system will report combined Small and Large Bowel Transit Time (SLBTT).~Transit times are derived from measures of temperature, relative humidity, hydrogen concentration, and carbon dioxide concentration, in conjunction with indicators of fermentation activity, capsule tumble, and antenna reflectance. Not for use in pediatric patients."
45646396|NCT04237025|Other|Nordic walking exercise|Supervised Nordic Walking (NW) exercise will be conducted in a small group setting with a 2:1 participant to trainer ratio providing individualized training instruction. Training will be conducted for a total of 14 one-hour sessions over a 6-week period. Training will take place at an outdoor community track with progression tasks on hills or grassy terrain. The one-hour training sessions will include a 10-minute warm-up period, 45 minutes of individualized NW training, and a 5-minute cool down period. The target training duration goal for NW exercise will be 45 minutes of continuous walking at moderate intensity based on target heart rate and Rating of Perceived Exertion. NW exercise program will be customized and progressed for each participant by trainers with ongoing assessment of participant's gait pattern, NW technique, and exercise responses during the training sessions. Group comradery and accountability will be facilitated through training in small group training context.
45646397|NCT03217825|Drug|Rostafuroxin|This is a potent, selective and safe inhibitor of this altered mechanism and has been proved to be effective in reducing blood pressure levels in Adducin mutated rat strains and in chronic Ouabain infused rat model.
45646398|NCT03217825|Drug|Losartan|COZAAR (losartan potassium) is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a nonpeptide molecule, is chemically described as 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole- 5-methanol monopotassium salt.
45646399|NCT05183009|Device|eXciteOSA|eXciteOSA
45646400|NCT04035187|Drug|fast itraconazole tablet|100mg dose
45646401|NCT04035187|Drug|medium itraconazole tablet|100mg dose
45646402|NCT04035187|Drug|slow itraconazole tablet|100mg dose
45646403|NCT04035187|Drug|oral itraconazole solution|100mg dose
45646404|NCT00157963|Drug|MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks|
45646405|NCT05105789|Diagnostic Test|BinaxNOW Test|diagnostic test for SARS-CoV-2
45804072|NCT05718505|Device|SmartPill Monitoring System|"The SmartPill GI Monitoring System (Medtronic) offers a method for measuring gastric emptying time (GET), small bowel transit time (SBTT), colonic transit time (CTT), small bowel large bowel transit time (SLBTT) and whole gut transit time (WGTT) with a single test, which can be used as an aid for the diagnosis of both gastroparesis and slow transit constipation.~The SmartPill System measures pH, temperature and pressure. It is approved for use in the measurement of GI transit times by the FDA."
45804073|NCT05718349|Other|Biospecimen sampling|From the patients participating in the study i) blood, ii) tissue from resected material, iii) bile, iv) stool, v) urine, vi) jejunal content and vii) information on the itch severity will be collected.
45804074|NCT00354757|Drug|rabeprazole|
45804075|NCT03328819|Other|Acupuncture|The following depression-specific acupoints: Baihui (Du-20), Yintang (EX-HN3), Sishencong (EX-HN1), bilateral Cuanzhu (BL2), bilateral Toulinqi (GB15), bilateral Neiguan (PC6), bilateral Shenmen (HT7), bilateral Sanyinjiao (SP6), and bilateral Taichong (LR3). These depression-specific acupoints could raise up the qi, calm the mind, smooth liver qi stagnation, promote blood circulation, remove blood stasis, and nourish yin. The following pain-specific acupoints: bilateral Fengchi (GB20), bilateral Jianjing (GB21), bilateral Quchi (LI11), bilateral Shousanli (LI10), bilateral Hegu (LI4), bilateral Wangu (SI4), bilateral Shenshu (BL23), bilateral Huantiao (GB30), bilateral Weizhong (BL40), bilateral Feiyang (BL58), bilateral Yanglingquan (GB34), bilateral Yinlingquan (SP9), and bilateral Taixi (KI3). These pain-specific acupoints could eliminate wind, relax muscles, promote blood circulation, and supplement the kidney.
45804076|NCT02376283|Drug|Prasugrel|
45804077|NCT02376283|Drug|Clopidogrel|
45804078|NCT02376283|Drug|ticagrelor|
45804079|NCT02376361|Device|Transonic|"Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).~Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines~Recirculation, access flow will be performed according to HD03 Manual.~Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist."
45789596|NCT05108337|Procedure|Superficial cervical plexus block|Ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml 0.5% ropinacaine.
45789597|NCT05108337|Other|Control group|Ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml normal saline.
45789598|NCT04739241|Drug|premixed insulin therapy|Premixed insulin treatment: 30% of the calculated dose was administered before breakfast and before lunch (biphasic insulin lispro 50% or biphasic insulin aspart 50%) and the remaining 40% of the dose before dinner (biphasic insulin lispro 25% or biphasic insulin aspart insulin 30%).
45789599|NCT04739241|Drug|basal bolus insulin therapy|Basal-bolus insulin treatment: 50% dose in insulin glargine and 50% dose in insulin lispro or aspartic, distributed in equal parts in the 3 main meals
45789600|NCT03024437|Drug|Atezolizumab|Atezolizumab will be given intravenously every 3 weeks at 1200 mg.
45789601|NCT03024437|Drug|Bevacizumab|Bevacizumab will be given intravenously every 3 weeks at 15 mg/kg.
45789602|NCT03024437|Drug|Entinostat|Entinostat will be given orally every 7 days at 1, 3, or 5 mg depending upon phase. In Phase I, dose levels will be tested in up to 3 cohorts starting at 1 mg. In Phase II, the dose will be the recommended phase II dose that was determined during Phase I (i.e., 1, 3, or 5 mg).
45789603|NCT04707807|Diagnostic Test|IIEF-5|IIEF-15 form will be filled out by all participants
45789604|NCT03549273|Dietary Supplement|Glizigen® + Ocoxin-Viusid®|"Glizigen® spray, topical use, 2 times a day for 6 months with an interruption for 2 months at the end of the third month.~Ocoxin®-Viusid® 60 ml daily (1 vial every 12 hours) by oral route for 8 months, preferably administered after breakfast and lunch, without interruption."
45789605|NCT04707963|Dietary Supplement|Peanut protein powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
45789606|NCT04707963|Behavioral|Full body resistance training|Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
45789607|NCT05089227|Drug|"treatment intervention"|for a total of 12 weeks, prophylactic heparin therapy during hospitalization followed by prophylactic oral anticoagulation with apixaban
45789608|NCT05089227|Drug|"treatment standard"|during hospitalization prophylactic heparin therapy followed by management without prophylactic anticoagulation.
45789609|NCT05089227|Biological|biological assessment|CBC, reticulocytes, haptoglobin, LDH, bilirubin
45789610|NCT03475173|Device|LSFG-NAVI|laser-speckle blood flow of ocular arteries and veins
45646406|NCT05105789|Diagnostic Test|"Lollipop swab"|A lollipop swab, is an oral swab to collect saliva, sucked on like a lollipop for 20 seconds.
45646407|NCT04014829|Diagnostic Test|Pain-Pressure Threshold|Performed on bilateral trapezius muscles. Pressure will be applied at 90 degrees downward with an algometer, with the speed of pressure increase approximately 1kgf/s. Upon the sensation of pain, the patient will vocalize or raise her hand to terminate the test, and the highest reading will be recorded (up to maximum 6kgf). If two values are recorded within 0.2kgf of each other, the mean value will be recorded. If two values are greater than 0.2kgf of each other, a third test will be performed and the mean obtained.
45789611|NCT01489826|Drug|Dexanabinol|Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.
45789612|NCT01489826|Other|Cremophor|Drug vehicle.
45789613|NCT05070975|Other|Epidemiology|Assessment of the discrepancy of clinical severity of RSV-infections between twin infants.
45789614|NCT02677623|Drug|Pyridium|
45789615|NCT02677623|Drug|Sodium Fluorescein|
45789616|NCT02677623|Drug|Mannitol|
45789617|NCT02677623|Other|Normal Saline|
45789618|NCT02677701|Drug|azithromycin|500mg tablet over-encapsulated to match placebo
45789619|NCT02677701|Drug|placebo (for azithromycin)|
45449544|NCT03022292|Drug|Aflibercept Ophthalmic|IAI given for active exudative macular degeneration (CNV, SRF, PED) per SOC
45789620|NCT02677701|Drug|inhaled tobramycin|clinically prescribed inhaled tobramycin used by subjects participating in the study
45449545|NCT03022292|Device|optovue angiovue|FDA approved Optovue Angiovue will be used to monitor progression and responsiveness of active exudative macular degeneration to IAI.
45789621|NCT03375255|Drug|SRP-5051|Single dose of SRP-5051 administered as an intravenous (IV) infusion.
45789622|NCT01543178|Drug|open-label rifaximin|550 mg three times a day (open-label)
45789623|NCT01543178|Drug|double-blind placebo|3 times a day (double-blind)
45789624|NCT01543178|Drug|double-blind rifaximin|550 mg three times a day (double-blind)
45789625|NCT02677779|Procedure|CO2 laser|Single session of CO2 laser debridement
45789626|NCT02677779|Procedure|traditional surgery|Single session of traditional debridement
45789627|NCT02679807|Biological|Bifidobacterium animalis subsp. lactis Bl-04|
45789628|NCT02679807|Other|sucrose|
45789629|NCT05051631|Other|Intervention plus 12 months maintenance|The intervention will include 2 months of data collection in the control period, 4 months of education and awareness training, and 12 months of data collection in the maintenance time period.
45789630|NCT05051631|Other|Intervention plus 10 months maintenance|The intervention will include 4 months of data collection in the control period, 4 months of education and awareness training, and 10 months of data collection in the maintenance time period.
45789631|NCT05051631|Other|Intervention plus 8 months maintenance|The intervention will include 6 months of data collection in the control period, 4 months of education and awareness training, and 8 months of data collection in the maintenance time period.
45789632|NCT05051631|Other|Intervention plus 6 months maintenance|The intervention will include 8 months of data collection in the control period, 4 months of education and awareness training, and 6 months of data collection in the maintenance time period.
45789633|NCT05051631|Other|Intervention plus 4 months maintenance|The intervention will include 10 months of data collection in the control period, 4 months of education and awareness training, and 4 months of data collection in the maintenance time period.
45789634|NCT05037357|Diagnostic Test|Plasma EBV DNA qPCR test|Peripheral blood will be collected from each subject into an EDTA tube for the isolation of plasma.
45789635|NCT03297645|Behavioral|School|CHWs will ensure that families submit required health paperwork (e.g., asthma action plan, medication release form) and confirm with school nurses that children have the appropriate medications. School nurses will be given a standardized protocol to follow with clear guidelines for caring for students with asthma. The CHW assigned to the family will work with the school nurse to ensure that communication with the medical provider is occurring.
45789636|NCT03297645|Behavioral|Asthma education|CHWs will deliver evidence-based asthma education to parents and children. Content is drawn from existing asthma management programs, and adapted for families in Richmond. Between sessions, CHWs will call parents at least monthly to check in and assess family asthma management, including healthcare utilization since the last contact.
45789637|NCT03297645|Behavioral|Home environmental remediation|Healthy Homes will complete home-based environmental assessments using evidence-based protocols. Healthy Homes will provide real-time education and share information about their findings and recommendations for action. Families are provided with low-cost intervention materials (e.g., filters, pillow covers), as well as behavioral modifications to aid in the reduction of asthma triggers in the home.
45789638|NCT03297645|Behavioral|Informational mail|Family will be mailed publicly available asthma information every 3 months.
45646408|NCT04014829|Diagnostic Test|Mechanical Temporal Summation|"Pinprick hyperalgesia will be evoked using a Von Frey filament, applied to the volar aspect of the dominant forearm. Participants will report using the numerical rating scale the intensity of pain from the first stimulus. Subsequently, ten repetitive stimuli one second apart will be applied with the same filament within an area of 1cm diameter of the same forearm. Subjects will report the rate the pain intensity of the tenth stimulus. The magnitude of MTS is calculated as the difference between the last to the first pain scores. The investigators will classify the participants according to evoked MTS if the last stimulus is rated higher than the first, or no MTS if the last stimulus is rated equal or lower than the first. The research team administering the test will follow a set script."
45646409|NCT04014829|Diagnostic Test|Hospital Anxiety and Depression Scale|Standardized questionnaire to determine the level of anxiety and depression.
45789639|NCT01649856|Drug|CHOP|CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles
45789640|NCT01649856|Drug|rituximab [MabThera/Rituxan]|The first rituximab dose will be administered intravenously on Day of Cycle 1 at a dose of 375 mg/m2. Subsequent doses of 1400 mg are administered subcutaneously on Day 1 of each cycle, for a further 7 cycles
45789641|NCT01649856|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously on Day 1 of each cycle, 8 cycles
46071352|NCT00877214|Drug|Rituximab|Follicular Lymphomas: induction therapy with bendamustine + rituximab. If CR or PR: Maintenance therapy with rituximab every 2 months for 4 years Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years
46071353|NCT00877214|Drug|Rituximab / observation|Follicular Lymphomas:induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years (standard) Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: observation (standard)
46071354|NCT00667238|Behavioral|Questionnaire|
46071355|NCT00474032|Drug|Botulinum Toxin (Type A) injection (10 U/Kg)|See Detailed Description.
46071356|NCT02845622|Dietary Supplement|Hazelnut|This dietary supplement contains 30 g of hazelnut.
45449546|NCT02161276|Drug|TNTL capsule|Patients were asked to taken drugs 3 times a day, with each time 3 grains
45646410|NCT04014829|Diagnostic Test|Pain Catastrophizing Scale|Standardized questionnaire to determine the level of pain catastrophizing.
45646411|NCT04014829|Diagnostic Test|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization.
45646412|NCT04014829|Diagnostic Test|Fear-Avoidance Component Score|Standardized questionnaire to determine the level of fear and avoidance.
45646413|NCT04014829|Diagnostic Test|EQ-5D|Standardized questionnaire to assess generic health-related quality of life.
45646414|NCT04014829|Diagnostic Test|heart rate variability|Heart rate variability will be determined from the R-to-R intervals obtained from a 5-minute ECG recording.
45646415|NCT04014829|Diagnostic Test|Anxiety, anticipated pain, anticipated analgesia|Preoperative anxiety (0 to 100), anticipated pain (0 to 100), and anticipated analgesia requirement (0 to 5).
45646416|NCT04014829|Diagnostic Test|State-trait anxiety inventory|Standardized questionnaire to assess anxiety.
45646417|NCT04014829|Diagnostic Test|Beck's Depression Inventory|Standardized questionnaire to assess depressive symptoms.
45789642|NCT01543568|Drug|aflibercept 2.0 mg|Intravitreal aflibercept injection 2.0 mg
45789643|NCT05031663|Dietary Supplement|Almond group|Participants in the Almond group will receive 15% of their daily energy intake in the form of almonds as a snack
45789644|NCT05031663|Dietary Supplement|Control Group|Participants in the control group will receive an isocaloric carbohydrate based commercial snack (pretzel)
45789645|NCT05009199|Drug|[18F]MNI-444|Subjects will undergo PET imaging using [18F]MNI-444.
45789646|NCT05007483|Dietary Supplement|BodyBio Balance Oil|nutraceutical supplement
45789647|NCT05007483|Dietary Supplement|Kirunal Fish Oil|nutraceutical supplement
45789648|NCT05007483|Dietary Supplement|BodyBio PC|nutraceutical supplement
45789649|NCT05007483|Behavioral|Modified Paleolithic Elimination diet|"Complete elimination of all gluten-, dairy-, and egg-containing foods.~Increase fruit and vegetable intake to 6-9 servings/day comprising of 2-3 servings each of the following categories: intensely colored, sulfur-rich, and leafy greens.~Consume 6-12 ounces/day protein including organ meats and fatty fish.~Consume fermented foods daily.~Consume daily servings of algae, seaweed, and nutritional yeast."
45789650|NCT05007483|Behavioral|Time Restricted Olive Oil Based (TROO) Ketogenic Diet|"Restriction of dietary carbohydrates to < 50 grams/day.~Use olive oil (cold-pressed extra virgin preferred) to increase fat intake to >160 grams/day.~Consume <100 grams/day protein.~Limit dairy to 2 servings/day of whole fat options (completely exclude reduced fat dairy).~Consume at least 3 servings/day non-starchy vegetables."
45804080|NCT00425347|Drug|HuLuc63|Not applicable for HuLuc63.
45804081|NCT02301793|Behavioral|Nurse education in contemporary format|Education about VTE was delivered through a web-based contemporary interactive format
46071357|NCT02845622|Dietary Supplement|Cocoa|This dietary supplement contains 2.5 g of cocoa powder.
45789651|NCT05007483|Behavioral|Usual diet with Dietary Guidelines for Americans Diet information|"Limit sodium to < 2,300 mg/day.~Limit added sugar and saturated fat intake to <10% of kcal/day, respectively.~Consume 5 servings of fruits and vegetables per day.~Consume 6-9 ounce equivalents/day of grains, making at least half whole grain options.~Consume 3 servings of reduced fat dairy per day.~Consume 6 ounces/day protein foods."
45789652|NCT02681757|Device|triple antibiotic ointment dressing|used for control group under soft cast
45789653|NCT02681757|Device|Mepitel Ag|used for variable/experimental group under soft cast
45789654|NCT03294135|Biological|Encepur Adults|One dose of the vaccine can be administered at any one unscheduled visit depending on the detection of NT below 10. It will be administered intramuscularly into the non-dominant deltoid.
45789655|NCT02375724|Drug|Aclidinium Bromide|Inhaled Aclidinium 400 μg twice per day by Eklira Genuair Inhaler
45789656|NCT02375724|Drug|Placebo|Inhaled dose-matched placebo, twice per day by Eklira Genuair Inhaler
45646418|NCT05634629|Procedure|Anterior Lamellar Recession|ALR is a common surgical treatment that splits the skin and orbicularis oculi muscle from the tarsus and conjunctiva to recede the anterior lamella and expose the tarsus. Interlamellar separation can be accomplished via a grey line technique, an eyelid crease approach, or a combination of the two
45646419|NCT05634629|Procedure|Bilamellar Tarsal Rotation|the full-thickness transverse blepharotomy combined with everting sutures to rotate the inferior portion of the upper lid outwards and this procedure has a low recurrence risk
45789657|NCT03267849|Other|wearing swimming goggles or having laser suturelysis|Two images will be compared in each subject at two different eye pressures with the higher pressure having been produced by the interventions
45789658|NCT02398188|Drug|LIPO-202|
45646420|NCT05088031|Device|shock waves therapy|"Group (A): 20 patients would undergo shock waves plus traditional physical therapy. One thousand shock waves (7 times per sec) were applied at 2.5 Hz at low energy flux densities of 0.01-0.16 mJ/mm2 using a 17 mm head 2-Group (B): 20 patients would undergo intermittent mechanical traction plus conventional physical therapy. Participants would undergo 30 minutes of mechanical traction (with 10-second pull and 5-second rest)"
45789659|NCT02398188|Drug|Placebo|
45789660|NCT02426580|Behavioral|wechat|The wechat model of dietary education every 1 month by cellphone
45789661|NCT01651260|Other|Experimental ET Tube Securement Device|Experimental Hollister device with bite block was substituted for standard-of-care device during the study period.
45789662|NCT03110133|Drug|Full Spectrum Microbiota|Orally administered donor derived microbiota
45789663|NCT03110133|Drug|Placebo|Placebo for CP101
45789664|NCT05448066|Diagnostic Test|Component resolved diagnosis|Physicians in this group will have access to allergen molecular component sensitization profile, using ImmunoCAP ISAC E112i and to all standard diagnostic tolls
45789665|NCT05448066|Diagnostic Test|Standard diagnosis|Physicians will only have access to standard diagnostic tools namely skin prick tests and sIgE sensitization (not molecular IgE) and clinical history.
45789666|NCT02682069|Device|MolecuLight i:X Imaging Device|The intended use of the device is to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device will be used as part of the current clinical wound assessment process which may include examination for characteristic signs and symptoms of infection. The device can capture and document either an image or video of the chronic wound where the presence of florescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
45789667|NCT02425098|Biological|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
45920016|NCT00085150|Biological|LMB-2 immunotoxin|
45920017|NCT04843800|Procedure|Manual therapy|Acupuncture, Chiropractic are recognized complementary medicines and Therapeutic Massage is an alternative healing practice.
45920018|NCT00400075|Drug|azathioprine|
45789668|NCT02425098|Biological|Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)|High-dose TDV subcutaneous injection
45789669|NCT02424630|Device|Ultrasound-guided ISB|ISB was performed by one anesthesiologist under ultrasound-guidance. The superior, middle, and inferior trunks of the brachial plexus were identified approximately 2 cm above the clavicle. A 50 mm 22-gauge needle was introduced percutaneously using an out-of-plane technique. The needle was placed beside each trunk in succession, and 2.5 mL ropivacaine was injected into each site. The total volume of ropivacaine used for ISB was 7.5 mL.
45920019|NCT00400075|Drug|cyclophosphamide|
45920020|NCT00400114|Drug|Irinotecan|Irinotecan (50mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
46071358|NCT02845622|Dietary Supplement|No hazelnuts / No cocoa|This dietary supplement does not contain hazelnut nor cocoa powder.
46071359|NCT02845622|Dietary Supplement|Cream|This dietary supplement is just a cream obtained by grinding hazelnuts.
46071360|NCT02845622|Dietary Supplement|Snack|This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
45804082|NCT02301793|Behavioral|Nurse education in traditional format|Education about VTE was delivered through a web-based traditional linear Powerpoint format with voice over.
45804083|NCT02380183|Device|Civco Needle Guidance Device|Needle guidance device will be used while nerve block is performed.
45804084|NCT02380261|Other|Systane® Lid Wipes|Commercially-marketed, individually-packaged, pre-moistened eyelid wipe for daily cleaning
45920021|NCT00400114|Drug|Cisplatin|Cisplatin (65mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
45920022|NCT00400114|Procedure|Radiation|Radiation 50 Gy (weeks 4-9)
45920023|NCT00400114|Procedure|Surgery|Esophagectomy
45920024|NCT00400114|Drug|sunitinib (Sutent)|sunitinib (Sutent), dose range of 12.5mg - 50mg OD x 1 year post op.
45920025|NCT00085189|Biological|gp100 antigen|Given SC
45920026|NCT00085189|Biological|tyrosinase peptide|Given SC
45920027|NCT00085189|Biological|recombinant MAGE-3.1 antigen|Given SC
45920028|NCT00085189|Biological|multi-epitope melanoma peptide vaccine|Given SC
45920029|NCT00085189|Biological|incomplete Freund's adjuvant|Given SC
45789670|NCT02424630|Device|Arthroscopy-guided SSNB|At the end of the surgery, SSNB was performed under arthroscopic guidance by one shoulder arthroscopist. The suprascapular ligament was found using the lateral portal for visualization. The supraclavicular ligament was visualized at the end of the conoid ligament when the arthroscope was advanced following the coracoclavicular ligament. A 23-gauge spinal needle was introduced in a posteroanterior direction at a 20° angle percutaneously and 7 cm medial to the lateral margin of the acromion. Then, the needle was placed at the upper margin of the suprascapular ligament and advanced slightly under arthroscopy-guidance. After suctioning the saline from the portal, the injection material was administered according to the random assignment.
45789671|NCT02424630|Drug|Placebo|All the regional blocks in this study were performed using ropivacaine, except for arthroscopy-guided SSNB using placebo (10 mL normal saline)
45789672|NCT02424630|Drug|Ropivacaine|All the regional blocks in this study were performed using 10mL ropivacaine.
45789673|NCT02397408|Drug|Carbon C 11 Choline|Given intravenously (IV) prior to imaging
45789674|NCT02397408|Drug|Fluorine F 18 Choline|Given intravenously (IV) prior to imaging
45789675|NCT02397408|Procedure|Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI)|Undergo whole-body PET/MR imaging
45920030|NCT00085189|Drug|Montanide ISA 51 VG|Given SC
45789676|NCT02397096|Drug|Doravirine, Tenofovir, Lamivudine|Single tablet containing MK-1439 (doravirine) 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg
45789677|NCT02397096|Drug|Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor|Baseline regimen of antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) administered according to the product circular
45789678|NCT02397096|Drug|Baseline regimen of cobicistat-boosted elvitegravir|Baseline regimen of antiretroviral therapy with cobicistat-boosted elvitegravir administered according to the product circular
45789679|NCT02397096|Drug|Baseline regimen of a non-nucleoside reverse transcriptase inhibitor|Baseline regimen of antiretroviral therapy with a NNRTI (efavirenz, nevirapine, or rilpivirine) administered according to the product circular
45789680|NCT02397096|Drug|Baseline regimen of two nucleoside reverse transcriptase inhibitors|Baseline regimen of antiretroviral therapy with two NRTIs administered according to the product circular
45920031|NCT00085189|Drug|agatolimod sodium|Given SC
46071361|NCT04887350|Behavioral|Student-Senior Isolation Prevention Partnership (SSIPP)|The Student-Senior Isolation Prevention Partnership partners medical students with older adults in the community to provide social support and connection through regular phone calls. The goal of SSIPP is to reduce rates of anxiety, depression, and loneliness, while fostering resilience among seniors in our communities. This intervention will be delivered by phone to study participants once a week for a 30-60 minute session over a 12-week period.
45646421|NCT05087953|Diagnostic Test|Head-Up Tilt table test|Autonomic response assessment in the orthostatic head up tilt test.
45646422|NCT05087953|Diagnostic Test|Heart Rate Variability|Assessment of heart rate variability on 24-hour Holter monitoring..
45646423|NCT05087797|Drug|nicorandil|Patients in the nicorandil group were also given nicorandil (Tohoku Nipro Pharmaceutical Corporation, Japan) orally 5 mg three times per day for 3 months
45646424|NCT05087719|Combination Product|experimental group|patients will receive the hot pack initially for 15 minutes .Then for proprioception training of graphesthesia for 15 mints,stereognosis will be of 15 minutes. For motor training patients will practice 15 mints motor tasks
45646425|NCT05087719|Combination Product|conventional treatment|patients will receive the baseline treatment of hot pack for 15 minutes. The patients in this group will get muscle strengthening exercise of the hand, Range of motion, and stretching of the hand muscles, 3 sets of 8 repetitions were given to the patient, gap of 2 minutes will be given between regimes. For 20 minutes this session will be given to patient by the therapist.
45789681|NCT02372058|Device|BiliCare|"Three non invasive measurements of TcB:~Two measurements with the BiliCare device and one measurement with a competitive FDA approved device"
45789682|NCT02396316|Drug|Aflibercept (Eylea, BAY 86-5321)|After the first aflibercept IVT injection on Day 1, subjects may receive sham injection at Week 1, and aflibercept injection at Week 5 and/or Week 9 if the re-treatment criteria are met.
45789683|NCT02396316|Drug|Sham Injection|After the first sham injection on Day 1, subjects may receive aflibercept IVT injection at Week 1, Week 5 and/or Week 9 if re-treatment criteria are met.
45789684|NCT02395536|Other|office setting|An office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not including ambulatory surgical centers
45789685|NCT02395536|Other|hosptial setting|A hospital setting was defined as an operating room or electrophysiology lab inside the walls of a hospital.
45789686|NCT00552929|Drug|Sugammadex|"After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered."
45789687|NCT02395302|Device|Dual Action Pneumatic Compression|Wear in sustained mode for 14 hours and pneumatic compression mode for 3 hours during the 4 week treatment period.
45789688|NCT02682381|Drug|Teduglutide 0.05mg/kg|0.05 mg/kg
45789689|NCT02682381|Drug|Teduglutide 0.025 mg/kg|0.025 mg/kg
45920032|NCT00085189|Other|laboratory biomarker analysis|Correlative studies
45920033|NCT00085228|Biological|oblimersen sodium|
45920034|NCT00085228|Drug|docetaxel|
45920035|NCT04838457|Behavioral|Alcohol and CVD Management and Engagement through Telehealth and mHealth (ACME-TM)|Participants will obtain 4 sessions of telehealth cognitive behavioral therapy (CBT) focused on reducing alcohol misuse. Participants will receive a 5th telehealth coaching call to develop a plan for ensuing treatment regarding their elevated cardiovascular risk factors. Participants will then receive daily texts for one month aimed at helping them decrease these cardiovascular risk factors.
45920036|NCT00085306|Biological|recombinant interferon beta|recombinant interferon beta
45920037|NCT00006077|Drug|NS2330|
45920038|NCT00006077|Drug|Levodopa and Domperidone|
45920039|NCT04729348|Drug|Pembrolizumab|Oral, daily, dosage per protocol
45789690|NCT02682381|Other|Standard of Care|Observational cohort for the 24-week treatment period and 4 week follow-up.
45789691|NCT04915950|Drug|Temanogrel|Participants will receive a single oral dose of temanogrel during the treatment visit.
45789692|NCT04915950|Drug|Placebo|Participants will receive a single oral dose of temanogrel matching placebo during the treatment visit.
45789693|NCT04976595|Drug|Natesto|Nasal gel containing testosterone 11 mg/dose (5.5 mg/nostril) three times daily.
45646426|NCT05087017|Other|Intervention group|Patients with medical condition to follow the rehabilitation program will be asked to answer questionnaires to assess their sleep quality.
45789694|NCT03033303|Biological|Hu3F8|Day 1: hu3F8 infused iv over ~30 to 90 minutes. Day 3: hu3F8 infused iv over ~30 to 90 minutes. Day 5: hu3F8 infused iv over ~30 to 90 minutes.
46071362|NCT04887350|Behavioral|Problem Solving Therapy (PST).|Problem Solving Therapy is a psychotherapeutic intervention that teaches community members to identify and clarify problems at hand, set clear, achievable goals, brain-storm solutions to the problem, select their preferred solution, implement this solution, and evaluate the outcomes. This intervention will be delivered by a trained healthcare professional by phone to study participants once a week for a 30-60 minute session over a 12-week period.
46071363|NCT00187226|Procedure|Radiation Therapy|External Beam Radiation Therapy: 54Gy administered at 1.8Gy per day for low-grade glioma, craniopharyngioma and selected ependymoma.
45646427|NCT05086861|Device|Oesophageal pacing after left atrial posterior wall isolation|Following AF ablation with the aim of isolating the left atrial posterior wall oesophageal pacing and sensing is performed to check for left atrial posterior wall. entrance and exit block.
45646428|NCT05086783|Other|Video-based coaching|The coaching session will follow the Wisconsin Coaching Framework (Greenberg 2015). The surgical coaching session will last at maximum 30 minutes and will occur within 1-2 week following the procedure. The surgical coaching session will occur over Zoom. The second attempt will occur within 1 week following the coaching session.
45646429|NCT05086783|Other|Standard surgical teaching (master-apprentice model - (MAM))|Standard surgical teaching that conventionally occurs in the operating room follows a master-apprentice model (MAM).
45789695|NCT03033303|Drug|GM-CSF|Days -4 to 0: GM-CSF 250 mcg/m2/day, subcutaneously. Days 1 to 5: GM-CSF 500 mcg/m2/day, subcutaneously.
45789696|NCT03033303|Drug|Isotretinoin|Isotretinoin is administered at 160 mg/m2/d, divided into two doses, x14 days.
45789697|NCT00367965|Drug|Eszopiclone|eszopiclone 3 mg
45789698|NCT00367965|Drug|placebo|placebo tablet
45789699|NCT03006315|Device|Garmin Vivofit device|Participants will be bio-monitored using the Garmin Vivofit mobile wearable device at baseline (at least 1-7 days prior to treatment initiation) and during induction chemotherapy up to completion of 6 cycles. For those patients continuing with ASCT, patients will be bio-monitored up to 90 days post ASCT.
45789700|NCT03006315|Behavioral|Mobile Health quality of life assessements|
45789701|NCT02975505|Other|Strict blood pressure control|Systolic Blood Pressure Target < 120 mm Hg (measured at home)
45789702|NCT02683083|Biological|[131I]-SGMIB Anti-HER2 VHH1|
45789703|NCT02904291|Drug|Amlodipine|Patients are tested for their normal prescription amlodipine medication
45449547|NCT02161276|Drug|Placebo|Patients were asked to taken drugs 3 times a day, with each time 3 grains
45449548|NCT03599193|Drug|Tazarotene Lotion, 0.1%|DFD-03 (Tazarotene Lotion, 0.1%) applied Twice Daily for 1 minute and rinsed off
45449549|NCT03599193|Drug|Tazarotene Cream, 0.1%|Tazorac® (tazarotene) Cream, 0.1% applied Once Daily and left for approximately 12 hours
45449550|NCT02161354|Drug|NTC-510 capsules|Subjects will be randomized to one of 3 groups and NTC-510 will be given as a single oral dose of 2.0 mg, a split dose of 2.0 mg followed by 2.0 mg an hour later, or 6.0 mg for acute pain relief (PR) following third molar extraction.
45449551|NCT02161354|Drug|Placebo Capsules|Subjects will be randomized to one of 3 groups and placebo capsules will be given as a single oral dose of for acute dental pain following third molar extraction.
45449552|NCT02161354|Drug|NTC-510A Capsules|Subjects will be randomized to one of 3 groups where NTC-510A or placebo will be given as a single oral dose of 2.0, 4.0, or 6 mg for acute pain relief (PR) following third molar extraction
45449553|NCT02161432|Drug|BI 187004|single dose BI 187004 given as tablet in fed state
45449554|NCT02161432|Drug|BI 187004|single dose BI 187004 given as tablet in fasted state
45449555|NCT02161432|Drug|BI 187004|single dose BI 187004 given as oral solution
45449556|NCT03166124|Drug|LY900014|Administered SC
45789704|NCT02683161|Drug|Varenicline|Varenicline will be administered as clinically indicated and will begin approximately 4-6 weeks prior to surgery. All participants will receive a 1-week dose induction period before transitioning to a full maintenance dose.
45789705|NCT02683161|Behavioral|Contingency Management|Contingency Management payments will begin on the target quit date (week 2) and will be in place for 5 weeks or until surgery (whichever is sooner). Participants will receive monetary incentives for biochemical evidence of smoking abstinence.
45789706|NCT02683161|Behavioral|Behavioral Counseling|All participants will complete a 3-session behavioral counseling intervention with a trained member of our study staff during 3 of the pre-surgical study visits. This brief counseling intervention provides participants with information about the experience of quitting smoking, including a benefits/disadvantage analysis, functional analysis of craving/risk periods, and skills-building exercises to prevent lapse and relapse.
45449557|NCT03166124|Drug|Insulin Lispro|Administered SC
45646430|NCT05086705|Device|EMBr Wave|Use EMBr Wave
45646431|NCT05086705|Other|Questionnaire Administration|Ancillary studies
45646432|NCT05070949|Behavioral|Mindful Self-Compassion|Bi-weekly meeting will involve six lessons: What is Self-Compassion , Practicing Self-Compassion, Discovering your Compassionate Voice, Self-Compassion and Resilience , Self-Compassion and Burnout and Making it Count
45789707|NCT02683707|Other|Removal of Fentanyl from peri-procedural analgesia|Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for PCI)
45789708|NCT02683707|Drug|Fentanyl|IV peri-procedural analgesia
45789709|NCT02683707|Drug|Lidocaine|Local Anesthetic
45646433|NCT04011787|Dietary Supplement|bolus NGT feeding|Participants randomised to bolus NGT feeding will receive this for 7 days at mealtimes
45646434|NCT04011787|Dietary Supplement|Continuous NGT feeding|Participants randomised to bolus NGT feeding will receive this continuously for 7 days as per hospital protocol
45646435|NCT04011787|Diagnostic Test|Continuous Glucose Monitoring|Both participant groups will have continuous glucose monitoring performed for 5 days while in the study
45646436|NCT04011787|Diagnostic Test|Metabolic Profile|Bloods will be taken to assess all patients metabolic profile
45646437|NCT04011787|Radiation|Chest X-ray|A chest X-ray will be performed on patients receiving study interventions on day 7 to confirm/exclude pneumonia
45646438|NCT03906877|Procedure|Acid hyaluronic injection laryngoplasty|Hyaluronic acid is injected into the paralyzed vocal fold
45646439|NCT03906877|Behavioral|Voice therapy|"15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will be specific to unilateral vocal fold paralysis and will focus on three objectives: reinforcement of the vocal muscle, glottal closure and glottal opening. These three objectives will be worked through different vocal exercises (on voiced phonemes) and breathing exercises"
45646440|NCT03906877|Other|Sham of injection|Injection of physiological saline under the skin of the neck (sham of injection).
45646441|NCT03906877|Other|Sham of voice therapy|"15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will not be specific to UVFP but may allow patients to improve their vocal gesture."
45646442|NCT03867799|Drug|Nivolumab|Immunotherapy
45646443|NCT05086081|Drug|Ticagrelor 90mg|Any ticagrelor dispensing claim is used as the exposure group
45646444|NCT05086081|Drug|Prasugrel 10mg|Any prasugrel dispensing claim is used as the reference group
45646445|NCT05085925|Behavioral|Cognitive behavioral mindfulness intervention|The group that receives mindfulness-based stress reduction at their entry into the study will have 7 sequential sessions during 3 months, and later have a booster session in month 5
45646446|NCT05085925|Behavioral|Cognitive behavioral mindfulness intervention after 3-month wait list|Wait-list control patients will get no intervention at the start of the study and instead will be contacted by study personal 7 times to care for the patient in order to control for the 7 sessions performed in the intervention group. After three months they will be offered mindfulness-based stress reduction as 8 sequential sessions.
45646447|NCT05085769|Procedure|Bariatric surgery|A procedure for morbidly obese patients whose body mass index (BMI) is higher than 40 kg/m2 or 35 kg/m2 and having comorbidities of obesity.
45646448|NCT05085457|Diagnostic Test|ExPreS Protocol|Prof, aqui explicamos o que é o ExPreS????? Já que ele fala para não repetir informação
45646449|NCT05085301|Diagnostic Test|Rapid diagnostic test|The performance of three index tests and two comparator tests will be compared to reference tests and gold standard microscopy.
45646450|NCT03730753|Device|Programmed intermittent epidural bolus|Programmed intermittent epidural bolus added to patient controlled epidural analgesia
45646451|NCT03730753|Device|Continuous infusion|Continuous infusion added to patient controlled epidural analgesia
45646452|NCT03726073|Device|Transcutaneous acupoint electrical acupoint stimulation(TEAS) and auricular acupressure|Bilaterally Hegu (LI4), Neiguan (PC6) and Zusanli (ST36) will be used as the TEAS acupoints. Six acupoints (Shenmen, Point Zero, subcortex, heart, liver, and endocrine) located on ears will be used as the auricular acupressure points.
45449558|NCT03567291|Drug|TEV-50717|6, 9, and 12 mg oral tablets
45449559|NCT03567291|Drug|Placebo|Placebo comparator
45449560|NCT02777242|Combination Product|Testosterone enanthate auto-injector|SC injections of QST 50 mg or 75 mg or 100 mg
45449561|NCT03212144|Other|High Intensity Interval Training|Subjects will exercise according the the high intensity aerobic interval training regiment four times a week for four weeks
45646453|NCT03726073|Other|Usual care|Patients in this group only receive usual care developed by the study hospital
45646454|NCT04873297|Drug|Metoclopramide 10mg|Tab. Metoclopramide 10mg TDS via NG tube
45646455|NCT04873297|Drug|Placebo|Placebo 10 ml of plain water Via NG
45646456|NCT02633501|Drug|P03277|Single intravenous (IV) bolus injection at a rate of 2 mL/second
45646457|NCT02633501|Drug|Gadobenate dimeglumine|Single IV bolus injection at a rate of 2 mL/second
45646458|NCT02633501|Device|MRI|
45646459|NCT05634473|Drug|Methacholine Chloride|Cholinergic agonists
45646460|NCT03138499|Biological|Nivolumab|Specified dose on specified days
45646461|NCT03138499|Biological|Brentuximab vedotin|Specified dose on specified days
45646462|NCT05634317|Behavioral|Smartphone delivered Behavioral activation|"Outline:~Session 0 45-minute psychoeducation on caregiving and depression~Session 1 Review the present use of time and use the monitoring form~Session 2 Brain-storm pleasant events and schedule pleasant activities~Session 3 Review scheduling of events and discuss how to improve~Session 4 Review modifications and consolidate gains on scheduling~Session 5 Review present social support and explore new sources of support~Session 6 Examine communication skills and explore new options~Session 7 Review new communications and discuss how to improve~Session 8 Review modification and consolidate gains on support"
45646463|NCT05634317|Behavioral|Smartphone delivered Mindfulness|"Outline:~Session 0 45-minute psychoeducation on caregiving and depression~Session 1 The Raisin exercise (eating meditation) and12-min body scan~Session 2 Exercises on thoughts and feelings 12-min body scan~Session 3 Exercises focusing on unpleasant experiences, practicing seeing and hearing , sitting meditation, 3-min breathing space, and mindful stretching and breath meditation~Session 4 Practicing seeing and hearing, mindful communication, 3-min breathing space, and sitting meditation~Session 5 Mindful walking, 3-min breathing space, and sitting meditation~Session 6 Sitting meditation, exercises on thoughts and alternative viewpoints, and 3-min breathing space (responsive)~Session 7 Sitting meditation, activity and mood exercise, identifying habitual emotional reactions to difficulties, and 3-min breathing space (responsive)~Session 8 12-min body scan, exercise on looking forward, and exercise on preparing for the future"
45646464|NCT05085145|Biological|Coronavirus vaccine|Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
45646465|NCT05634239|Behavioral|Health Education|"Interview, clinical examination and health education conducted by the clinic nurse.~Appointment with the physiotherapist including the assessment of physical functioning, use of assistive mobility devices, and amount of help needed in activities of daily living."
45789710|NCT02683707|Drug|Midazolam|IV sedation
45789711|NCT02371980|Drug|Vortioxetine|Vortioxetine capsules
45789712|NCT02371980|Drug|Placebo|Vortioxetine placebo-matching capsules
45789713|NCT04922463|Device|PLASOMA|Treatment with cold plasma device
45789714|NCT02867865|Drug|Gemcitabine|Those randomized to systemic chemotherapy alone will proceed to receive Chemotherapy Gemcitabine gemcitabine 1000 mg/m2delivered day 1 and 8 every 3 weeks for 4 cycles
45789715|NCT02867865|Drug|Cisplatin|Inj. cisplatin 25 mg/m2 delivered. day 1 and 8 every 3 weeks for 4 cycles
45789716|NCT02867865|Radiation|Chemoradiation|Radiotherapy will be for 5 weeks and will be given only in the study arm. The radiation dose will be 50-55 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2).
45789717|NCT02867865|Procedure|PETCECT|All the patients will undergo PETCECT to rule out metastatic disease
45789718|NCT02867865|Procedure|Laparoscopy|Patients will be subjected to staging laparoscopy with 16b1 lymph node biopsy to rule out metastatic disease.
45789719|NCT02833233|Procedure|Cryoablation|
45789720|NCT02833233|Drug|Ipilimumab|
45789721|NCT02833233|Drug|Nivolumab|
45789722|NCT04914507|Device|Anterior Vertebral Body Tethering|Subject will receive anterior vertebral body tethering surgery.
45789723|NCT04910373|Other|Experimental Extensively Hydrolyzed Formula|experimental powder formula
45789724|NCT04910373|Other|Placebo Extensively Hydrolyzed Formula|placebo powder formula
45789725|NCT02408757|Procedure|Sonographic monitoring|Sonographic monitoring during weaning of cerebrospinal fluid drainage catheters
45449562|NCT03212144|Other|Peanut Consumption|Subjects will consume peanuts twice a day to replace 20% of their daily caloric intake for four weeks.
45449563|NCT02163070|Dietary Supplement|whey drink,|consumption of 220 milliliters of whey drink three times a week,
45646466|NCT04858711|Drug|ketamine-lidocaine-dexmedetomidine|In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution.
45449564|NCT02163070|Dietary Supplement|whey drink fortified with vitaminE|consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
45449565|NCT02163070|Dietary Supplement|vitamin E|consumption of 400 milligrams of vitamin E three times a week,
45449566|NCT02748200|Radiation|external beam radiotherapy (EBRT)|EBRT: 3 dose escalation levels
45646467|NCT04858711|Drug|fentanyl|In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
45789726|NCT04885179|Other|no intervention|No interventions are involved in this observational study.
45789727|NCT05448027|Device|Low intensity laser therapy|It will be applied for Group (A), by a pulsed diode low intensity laser device (Endolaser 422 Cp 400, Enraf - nonius apparatus) (Enraf, Rootterdam, Netherlands). with a wave length of 905 nm, mean power output of 400 mWatt, frequency of 10000 Hz and dose of 300 J/cm² . Laser probe will be applied perpendicularly and directly with an irradiation time of 30 sec for each point
45789728|NCT05448027|Device|High intensity laser therapy|It will be applied for Group (B), by pulsed high intensity laser therapy with pulsed Nd:YAG laser produced by HIRO 3.0 devices (ASA, Arcugnano, Vicenza , Italy). The high intensity laser therapy apparatus used postulates (Nd:YAG), with pulsed emission of wave length ( 1064nm ), very high power peaks (3kW), high intensity obtained (up to 15,000 W/cm2), high level of fluency/energy density (510-1,780 mJ/cm), very short pulse duration (120-150 μs), low frequency (10-40 Hz), duty cycle of about 0.1 % and total energy of 880 J
45789729|NCT04338867|Radiation|Whole-brain radiotherapy|Patients were randomized 1:1 and allocated to either the control arm who received whole-brain radiotherapy (WBRT) or the experimental arm who received WBRT and the addition 36 mg of transdermal nitroglycerin (TN)
45789730|NCT05447949|Procedure|Adjuncts to levobupivacaine in Erector Spinae Plane Block|The block level will be at T5 with the patient in a sitting position and full aseptic precautions. T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. In a longitudinal US view, in which the following layers will be visible superficial to the transverse processes: skin, subcutaneous tissue, trapezius, erector spinae muscle . Skin is topicalized, then echogenic block needle inserted in plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration; to avoid intravascular injection, 30 ml of injectate is injected and separation will be seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used (18-19).
45789731|NCT02324751|Biological|Vi-TCV|Each 0.5mL vaccine dose contains 25μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain) conjugated to non-toxic tetanus toxoid. The vaccine will be administered 28 days prior to typhoid challenge
45789732|NCT02324751|Biological|Vi-PS Vaccine|Each 0.5 mL vaccine dose contains 25 μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain). The vaccine will be administered 28 days prior to typhoid challenge
45789733|NCT02324751|Biological|Control (Men ACWY)|Each vaccine dose contains N. meningitidis oligosaccharides (10μg MenA oligosaccharide, 5μg of each of MenC, Men Y and MenW-135 oligosaccharides) conjugated to 32.7 μg to 64.1μg Diphtheria CRM197 protein with residual formaldehyde dose less than 0.30μg. The vaccine will be administered 28 days prior to typhoid challenge
45789734|NCT02313207|Dietary Supplement|FODMAP|patients will undergo a specific FODMAP diet for a period of 2 weeks.
45920040|NCT04729348|Drug|Lenvatinib|Oral, daily, dosage per protocol
45920041|NCT00085345|Drug|arsenic trioxide|
45920042|NCT00085345|Drug|ascorbic acid|
45920043|NCT00085345|Drug|melphalan|
45920044|NCT00085345|Procedure|chemosensitization/potentiation|
45920045|NCT00085345|Procedure|chemotherapy|
45789735|NCT05447871|Procedure|Ultrasound guided single injection modified 4 in 1 block technique|A high-frequency ultrasound probe is placed over the femoral condyle and vastus medialis muscle is identified. The probe is slid proximally till the superficial femoral artery appeared. The probe is slid proximally till the descending genicular artery branching from the superficial femoral artery. The point of interest is 8-10 cm above the femoral condyle. The needle is guided into the Vastus medialis muscle till the nerve to Vastus medialis. At this point, 5-7 mL of the local anaesthetic drug is injected. The needle is guided further in-plane from lateral to medial side to reach the perivascular region and after negative aspiration 25 ml local anaesthetic drug is injected.
45789736|NCT05447871|Procedure|Ultrasound guided adductor canal block technique|The Adductor canal is identified in the middle of the thigh beneath the sartorius muscle using a high-frequency ultrasonic transducer. the probe is slid till the superficial femoral artery appeared in the adductor canal between vastus medialis and adductor longus muscle. A 22-gauge spinal needle is inserted in a lateral to medial plane to reach the perivascular region and after negative aspiration 20 ml local anaesthetic drug is injected, visualised to push the femoral artery.
45789737|NCT05447871|Drug|Bupivacaine 0.25%|bupivacaine 0.25%
45789738|NCT02157129|Device|LipoAerosol© inhalation|LipoAerosol© inhalation, 5x/d for 30min
45789739|NCT02157129|Other|Physiologic saline inhalation|Physiologic saline inhalation, 5x/d for 30min
45646468|NCT05084677|Combination Product|Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy|Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) concurrent with chemoradiotherapy; 6 cycles of Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) after chemoradiotherapy; Toripalimab 240mg intravenously(IV) every 6 weeks (Q6W) thereafter until the whole treatment period reached one year since the beginning.
45789740|NCT05447793|Device|Fitostimoline plus|Formulation in gauzes and cream
45789741|NCT05447793|Device|Connettivina bio plus|Formulation in gauzes and cream
45789742|NCT00369447|Procedure|External radiotherapy|Radiotherapy for first 2 weeks, 10 daily fractions of 30Gy 2 additional fractions to be added if desirable
45789743|NCT00369447|Biological|nimotuzumab|weekly dose until disease progression
45789744|NCT01892397|Device|Optune (NovoTTF-100A)|
45789745|NCT05447715|Drug|Fruquintinib|Fruquintinib sequential BEV+FOLFIRI vs. BEV+FOLFIRI sequential fruquintinib in the treatment of metastatic colorectal cancer that has failed previous fluorouracil/oxaliplatin therapy
45789746|NCT05447637|Diagnostic Test|Invitae multi-cancer gene panel|Invitae's multi-cancer panel tests for 84 genes associated with hereditary cancer risk.
45646469|NCT04794491|Drug|JZP-258|Maximum nightly dosage of 9 grams, administered once, twice or thrice nightly, with no single dose > 6 g
45646470|NCT03138187|Behavioral|Moderate exercise|The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets
45646471|NCT03138187|Behavioral|Vigorous exercise|The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
45646472|NCT03069209|Biological|Stem Cells|Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
45646473|NCT04771819|Device|SWIS|Bilateral experimental blister wounds on each forearm. The wound on one arm is rinsed with experimental solution (SWIS) and the contralateral wound on the other arm is rinsed With Saline as a comparator.
45789747|NCT00914823|Drug|kisspeptin 112-121|one or more intravenous or subcutaneous doses of kisspeptin 112-121, and/or short infusion (up to 12 hours) of kisspeptin 112-121
45789748|NCT00914823|Drug|GnRH|One or more intravenous doses of GnRH
45789749|NCT05447481|Dietary Supplement|chicory inulin-type fructan|Dietary supplement: chicory inulin-type fructan
45789750|NCT04772235|Drug|Repotrectinib|"Repotrectinib will be taken orally once daily with or without food Part A: Dose escalation phase, with 3 dose levels for repotrectinib: (1) 80 mg QD, (2) 160 mg QD and (3) 160 mg QD for 14 days followed by 160 mg BID; in combination with 80 mg QD of osimertinib~Part B: at the RP2D for all patients in combination with osimertinib."
45789751|NCT04772235|Drug|Osimertinib|"Osimertinib will be taken orally at 80 mg once daily with or without food. Part A: lead in dose in monotherapy at 80 mg QD during 14 days. In combination with repotrectinib afterwards. Depending on the safety and PK/ dose dependent interactions (DDIs) readout during the DLT assessment period, osimertinib dose may be adjusted.~Part B: at the RP2D level in combination with repotrectinib"
45789752|NCT04766463|Drug|SHR8554 Injection|SHR8554 Injection; high dose
45789753|NCT04766463|Drug|SHR8554 Injection|SHR8554 Injection; low dose
45789754|NCT04766463|Drug|Placebo|Saline Solution
45789755|NCT04766463|Drug|Morphine|Morphine
45789756|NCT00823563|Procedure|30 cc blood draw|
45789757|NCT00823563|Procedure|Intravascular ultrasound (IVUS)|
45789758|NCT00823563|Procedure|Coronary pressure/flow wire testing|
45789759|NCT00823563|Procedure|Coronary pressure/flow testing: Acetycholine challenge|
45789760|NCT00823563|Procedure|Procedure: Coronary pressure/flow testing: Nitroglycerin challenge|
45789761|NCT00823563|Procedure|Procedure: Procedure: Coronary pressure/flow testing: Adenosine challenge|
45789762|NCT05452707|Other|Observation and questionnaire of active therapy|There will be an observation of the usual care; no intervention will be added.
45789763|NCT04763889|Behavioral|CBT|CBT for those with an allergy and anxiety
45804085|NCT02382913|Biological|aP booster|"Acellular pertussis vaccine:~Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Biological: Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine."
45646474|NCT03068975|Drug|Alvimopan|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive Alvimopan ( post operative dose only) and will monitor for post operative ileus.
45789764|NCT04743921|Device|Reparel Knee Sleeve|Patients who are recommended for non-operative management of knee osteoarthritis and have been consented in clinic to participate in the study will be given a Reparel™ knee sleeve to wear for knee osteoarthritis management. Each device will be numbered and recorded in the patient's REDCap entry for future reference if needed. Following administration of the Reparel™ knee sleeve, patients will be given instructions on how to use/wear the sleeve while performing activities of daily living or sports that had previously resulted in knee pain and also be asked to do the follows: wear the sleeve as much as they possibly can; not change their usual activities and diet during the time they are on this study; record in a diary the number of hours sleeve was worn per day; record any adverse eﬀects or discomfort due to sleeve use; refrain from altering treatment for knee osteoarthritis.
45789765|NCT04724499|Behavioral|High-Intensity Intervals Training|16 week exercise program with stationary bike.
45789766|NCT04724499|Other|Attention Control|16 week stretching program.
45789767|NCT05452629|Behavioral|Mindfulness induction (MI)|In the MI condition, participants were guided to focus on present experiences regarding the thoughts, emotions and sensations through the three classic mindfulness exercises (i.e., focused breathing, meditation, and body scanning). The duration of MI was 30-minutes.
45789768|NCT05452629|Behavioral|Relaxation (RI)|In the RI condition, participants were guided to relax each muscle group following the audio for 30-minutes.
45789769|NCT05452395|Other|Post-acute care|"A personalized care program, focusing on managing geriatric syndromes and improving functional performances.~Strength training, activities of daily living (ADL) and instrumental activities of daily living (IADL) practice, basic mobility training, reconditioning exercise, and home environment assessment and modification."
45789770|NCT05447169|Diagnostic Test|EBV antibodies test|ELISA test of VCA-IgA，EBNA1-IgA，EA-IgA， Zta-IgA ，Rta-IgG and BNLF 2b in nasopharyngeal brushing and plasma
45789771|NCT05447169|Diagnostic Test|EBV DNA test|quantitative polymerase chain reaction, CRISPR-associated protein 12a and target sequencing of EBV DNA in nasopharyngeal brushing and plasma
45789772|NCT04704453|Drug|Capsaïcin patch (Qutenza®)|Treatment by application of capsaicin 8% (Qutenza®) patches 3 months apart (Month 1, Month 4 and Month 7).
45789773|NCT04704453|Drug|Amitriptyline (Laroxyl®)|Treatment by amitriptyline (oral solution 40mg/ml), for 9 months at the recommended dose of 25 mg to 75 mg daily.
45789774|NCT04656561|Drug|ANX007|Form: solution for injection; Route of Administration: IVT
45789775|NCT04656561|Other|Sham comparator|Form and Route of Administration: pressure to mimic IVT injection
45789776|NCT04652193|Procedure|Recovery profile from general anesthesia|It includes the phases during recovery from general anesthesia: Time to spontaneous ventilation, Laryngeal Mask Airway (LMA) removal time, open eyes, and Post-Anesthesia Care Unit (PACU) discharge.
45789777|NCT05446701|Diagnostic Test|serum level of FAM19A5|Detection of serum level of FAM19A5 of patients and controls by using ELISA technique.
45789778|NCT05451459|Other|12-week FMS Intervention|4 virtual workshops (2-3 hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) Sports (during intervention)
45789779|NCT05451459|Behavioral|Physical Activities & Activity Booklets (via FitFamilies app)|expected to engage in physical activity at least 3 hours per week, virtual workshops provide them with resources to engage in Physical activity
45789780|NCT05451147|Drug|Chhinnavahni Kashaya Vati along with Agnimantha Kwatha|Drug: Chhinnavahni Kashaya Vati Form : Tablet Dose: 1g TDS (2x500 mg), Before meals Mode of Administration: Oral Anupaan: 20 ml of Agnimantha Kwatha Duration: 3 Months
46071364|NCT00187226|Procedure|Radiation Therapy|External Beam Radiation Therapy: 59.4Gy administered at 1.8Gy per day for high-grade glioma and selected ependymoma.
45789781|NCT05451147|Drug|Metformin Hydrochloride|Drug: Metformin Form: Tablet Dose: 500mg BID/TDS, Before meals Mode of Administration: Oral Anupaan: Plain water Duration: 3 Months
46071365|NCT05337800|Behavioral|stress managment program|A four-session stress management program will be applied to the experimental group students.
46071366|NCT05242796|Device|Low frequency magnetic therapy|
45789782|NCT05450991|Procedure|Pull through|Children diagnosed with Hirschpsrung's Disease or an anorectal malformation, with or without operative intervention will be included
45789783|NCT05445375|Other|PAD education video|20-min online multi-media video
45789784|NCT01429064|Drug|ODM-201|ODM-201 administered orally daily
45789785|NCT00368823|Device|Electronic point-of-care delivery system|
45789786|NCT04555551|Biological|Infusion of MCARH109 T cells|Patients will be admitted to Memorial Hospital as inpatient prior to the infusion of CAR T cells. The T cell infusion will be planned to start at 2 days following the completion of the conditioning chemotherapy (up to 7 days is allowed if clinically indicated to delay).Cohorts of 3-6 patients each will be treated with escalating doses of modified T cells.
45789787|NCT02204150|Device|OFDI Capsule|Imaging of the esophagus using the OFDI Capsule and system
46071367|NCT05242718|Dietary Supplement|N-Acetyl-L-cysteine (NAC)|Health Canada Natural Product Number (NPN) 80056946
46071368|NCT05242718|Dietary Supplement|Echinacea purpurea|Health Canada Natural Product Number (NPN) 80093896
46071369|NCT05242718|Dietary Supplement|Curcumin|Health Canada Natural Product Number (NPN) 80043455
46071370|NCT05242718|Dietary Supplement|Palmitoylethanolamide|Health Canada Natural Product Number (NPN) 80097472
45449567|NCT02151214|Other|Parenteral nutrition|Administration of standard intravenous nutritional products. The products are commonly used in the department where the research is conducted
45646475|NCT03068975|Drug|Placebo|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive the Placebo Pill (post operative dose only) and will monitor for post operative ileus.
45789788|NCT04553367|Drug|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
45920046|NCT04838028|Procedure|TEP|Laparoscopic totally extraperitoneal mesh repair of groin hernia
45646476|NCT02034331|Drug|Insulin iontophoresis|For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin. For preparation and instrumentation, the arms will be uncovered below the elbow; the participant's lower extremities will be uncovered below knee for leg evaluations. The laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.
45449568|NCT03484520|Drug|Venetoclax|tablet, oral
45646477|NCT02034331|Drug|Placebo Iontophoresis|For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
45646478|NCT02034331|Drug|Acetylcholine Iontophoresis|For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
45646479|NCT02034331|Other|Heat application|For the provocation with heat, an insulated thermal heat pack (~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.
45646480|NCT03592225|Behavioral|Educational workshop|the intervention is a 3 hours educational workshop designed to address all the potential questions that the general practitioners (GP) and their patients might have regarding HPV vaccination.
45646481|NCT04166981|Procedure|Instrumented posterolateral spine fusion.|Posterolateral fusion with autologous and allogenic bone graft with supplementary pedicle screw fixation.
45646482|NCT04166981|Procedure|Non-instrumented posterolateral spine fusion.|Posterolateral fusion with autologous and allogenic bone graft.
45646483|NCT03068117|Other|Regular Early Specialist Symptom Control Treatment (RESSCT)|"Participants will be seen within three weeks of randomisation by the Specialist Palliative Care Team (SPCT), (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).~Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death."
45646484|NCT03570229|Other|Hyperbaric oxygen treatment|"Participants in this study will receive hyperbaric oxygen treatment (HBOT) but the investigators do not assign this specific intervention to the study participants. Thus, the patients in this study will receive HBOT as part of routine medical care. Consequently, we regard this as an observational study because the patients will get HBOT independently of the study and they are NOT assigned prospectively to HBOT according to a protocol to evaluate the effects.~HBOT for pelvic radiation injury typically involves a treatment pressure of 2.4 ATA (Atmospheres Absolute) breathing oxygen for 90 minutes. The treatment is delivered as series treatment, usually daily treatment up to 30 dives."
45646485|NCT03538873|Behavioral|Physical activity|
45646486|NCT05077189|Other|Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale|"4 items of the DC/TMD scale were used in this study to evaluate the TMJ disorders.~Demographics Survey~DC/TMD Symptom Questionnaire (SQ)~Graded Chronic Pain Scale (GCPS)~Jaw Functional Limitation Scale-20 (JFLS-20)"
45646487|NCT04766957|Device|Idracare|Treatment will last 3 months (12 weeks). The treatment will be applied 2 times a week, preferably at night before going to bed.
45646488|NCT05393869|Other|Health communications|Participants are assigned to view health communications with risk and efficacy statements.
45646489|NCT03068039|Other|Oats breakfast porridge|Isoenergetic and isovolumteric oats breakfast porridge
45646490|NCT03068039|Other|Pearl (bajra) breakfast porridge|Isoenergetic and isovolumteric pearl (bajra) breakfast porridge
45646491|NCT05632991|Other|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block 20 ml local anesthetic each side
45646492|NCT05632991|Other|Subcostal Transversus Abdominis Plan Block Group|ultrasound guided Subcostal Transversus Abdominis Plan Block Group 20 ml local anesthetic each side
45646493|NCT05073601|Diagnostic Test|ELISA,DNA extraction|quantitative measurement of (Thyroid stimulating hormon (TSH), free triiodothyronine (FT3)& Free tetraiodothyronine(FT4)) measured using ELISA . Serum 25-OH vitamin D measured using ELISA. Serum 25-OH vitamin D will be classified based on 2012 American Endocrine Society guidelines into deficient (< 20ng/ml), insufficient ( 21 -30 ng/ml) and sufficient (> 30 ng/ml).vitamin D receptor polymorphisms was done in 3 steps: a) DNA extraction from whole blood using Gene Jet gene DNA Purification kits . b) PCR: three Vitamin D receptor polymorphisms were tested [Taq I (restriction enzymes according to single nucleotide polymorphism ) (rs731236), Apa I (rs7975232) and Bsm I (rs1544410)] using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Genomic DNA was amplified using certain primers
45789789|NCT04553367|Procedure|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
45789790|NCT04553367|Device|ventilator|ventilator
45789791|NCT00369759|Other|Emergency Dept. Subjects with LRI or Apnea|No intervention; Epidemiological Study
45920047|NCT04838028|Procedure|TAPP|Laparoscopic transabdominal mesh repair of groin hernia
45449569|NCT03484520|Drug|Dinaciclib|intravenous
45449570|NCT03566979|Drug|Test naproxen sodium tablet|Single dose of 2 test naproxen sodium 220 mg tablets
45449571|NCT03566979|Drug|Commercial naproxen sodium tablet|Single dose of 2 naproxen sodium 220 mg tablets
45449572|NCT03566979|Drug|Commercial naproxen sodium liquid gels capsule|Single dose of 2 naproxen sodium 220 mg liquid gel capsules
45449573|NCT03566979|Drug|Placebo tablet|2 placebo tablets
45646494|NCT03068195|Procedure|microwave ablation|KY2000 microwave ablation system was used in the experimental group. A power output of 60 W for 1-3 min for 1-3 cycles to treat the renal cysts according to the cysts size and classification.Percutaneous microwave ablation will be performed under the guidance of ultrasound while the laparoscopic microwave ablation will be performed under direct vision
45646495|NCT03068195|Procedure|laparoscopic decortication|conventional laparoscopic decortication will be performed to treat the renal cysts
45646496|NCT03140059|Procedure|Open flap debridement|Open flap debridement will be performed to decontaminate root surface
45646497|NCT03140059|Procedure|Repeated application of aPDT|Repeated application of photodynamic therapy (aPDT) at 0, 1, 2, 7 and 14 days post-operatively.
45646498|NCT03067883|Drug|Ombitasvir, Paritaprevir and Ritonavir|"A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.~These patients will receive an intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.~Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).~Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session )."
45646499|NCT05631821|Procedure|differential rod bending with rod contours (MESA Spinal System)|differential rod bending with rod contours and Mesa Spinal system evaluate the correction of adolescent idiopathic scoliosis deformity achieved utilizing a technique of differential rod bending with rod contours pre-operatively determined from a best-fit measure utilizing a computer-based software tool
45646500|NCT03404245|Behavioral|Education, Fitbit/self-management app, physiotherapist counselling.|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex paired with a self-management app, and remote counseling by a PT. Intervention will be received immediately.
45646501|NCT03404245|Behavioral|Same intervention with a 6 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 6 month delay.
45646502|NCT05630963|Device|Aversive stimuli|Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).
45646503|NCT05630963|Drug|PET radiotracer|"A Nociceptin/Orphanin FQ (N/OFQ) peptide tracer ([11C] NOP-1A) will be used as the PET radiotracer. Approximately 10 mCi of this tracer will be delivered intravenously as a slow bolus over 60 seconds with beginning of the PET imaging acquisition. Approximately 60 ml of blood will be drawn from an artery throughout the dynamic PET acquisition in order to measure the blood N/OFQ levels."
45646504|NCT05393167|Device|Echo_CT_MRI_US_x ray|Examination: General and systemic examinations of the studied neonates. Investigation will be done to the neonates according to the clinical examination including imaging studies as X-rays, U/S, echocardiography, CT and MRI studies
45646505|NCT02936843|Drug|Salsalate|1 gram, 3 times daily by mouth (total of 3 grams daily)
45646506|NCT02936843|Drug|PLACEBO|Placebo for Salsalate; 2 Tabets, 3 times daily by mouth (total of 3 grams daily)
45646507|NCT03285763|Drug|Atezolizumab|Participants will receive 1200 milligrams (mg) of atezolizumab administered by intravenous infusion on Day 1 of every 3-week cycle until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
45646508|NCT03231631|Behavioral|Education plan and adherence to exercise|"Send text messages with motivational sense at any time of the day, every 3 or 4 days.~They will be given the option of performing directed exercise at the cardiac rehabilitation center.~It will be recorded in an Excel table every time that text is sent to the patient.~At the beginning and monthly, a brochure will be sent out explaining how physical activity is performed at home in case you can not walk.~A monthly survey will be applied where the adherence to the exercise during the previous month is measured.~These activities will be carried out for 12 weeks. At the end of week 12, patients will be referred to the cardiac rehabilitation unit in order to perform the aerobic capacity test again."
45646509|NCT05051059|Other|Functional outcome|3D-motion analysis and strength assessment
45646510|NCT05051059|Other|Health related quality of life (HRQoL) assessment|Quality of Life Questionnaire C-30 (QLQ-C30), Impact on Participation and Autonomy Questionnaire (IPAQ) and Musculoskeletal Tumor Society Score (MSTS)
45646511|NCT03067805|Behavioral|Sexual Infidelity Condition|
45646512|NCT03067805|Behavioral|Emotional Infidelity Condition|
45646513|NCT03067805|Behavioral|Neutral Condition|
45646514|NCT03067805|Behavioral|Player in Jealousy Condition|
45646515|NCT03067805|Behavioral|Player in Non-Jealousy Condition|
45646516|NCT05393011|Drug|human chorionic gonadotropin|10000 IU when at least three follicles become more than 16 mm
45789792|NCT00369837|Drug|clevidipine|Clevidipine was required to be administered continuously for a minimum of 18 hours and a maximum of 96 hours and was not to exceed a rate of 32.0 mg/h at any time. Use of an additional or alternative intravenous antihypertensive agent was allowed if the blood pressure target range was not achieved or maintained. If transition to an oral antihypertensive agent is required, then approximately 1 hour prior to the anticipated cessation of clevidipine infusion, but no less than at the 18-hour time point, an oral antihypertensive agent was allowed to be administered as clevidipine was down-titrated or terminated as needed in order to achieve the desired blood pressure level..
45789793|NCT05450445|Device|myHealthHub|myHealthHub is a multimodal patient engagement platform delivered on bedside terminals to provide hospital inpatients with social connection, meal ordering services, entertainment (TV, etc.), and access to medical care team.
45789794|NCT05450445|Device|TV-only|myHealthHub device equipped with the TV-only entertainment option.
45789795|NCT05450367|Other|Data collection|Data collection
45789796|NCT05450289|Drug|Nigella Sativa Oil|In this study, we use nigella sativa oil (NSO), which are packed in capsule. One capsule contained 550 mg of nigella sativa oil.
45789797|NCT05450289|Drug|Allergen Specific Immunotherapy|In this study, we use the house dust mite allergen immunotherapy (Teaching Industry Allergen by Dr. Soetomo Hospital-Airlangga University, Surabaya, Indonesia) used was an extract of Dermatophagoides pteronyssinus via subcutaneous injection.
45789798|NCT05450289|Drug|Standard pharmacotherapy|Standard pharmacotherapy as indicated based on patient's symptoms i.e none, antihistamine, corticosteroids, bronchodilators, etc.
45789799|NCT01493024|Drug|Zirconium silicate (ZS)|Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated microporous Zirconium Silicate, an oral sorbent) administered 3 times daily (tid) with meals.
45789800|NCT01493024|Drug|Placebo|Randomized to mimic escalating doses of experimental drug administered 3 times daily (tid) with meals.
45789801|NCT05443815|Device|HaemoCer-PLUS|HaemoCer-PLUS
45789802|NCT05449899|Drug|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
45789803|NCT05449899|Drug|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
45789804|NCT05449899|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
45789805|NCT05449899|Drug|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
45789806|NCT05449899|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
45789807|NCT05449665|Other|Phase 1 - Control|"Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d).~Fed to energy balance (1.5 x Resting Metabolic Rate, RMR)."
45646517|NCT05034835|Device|usual treatment with compression garments (CERECARE)|For 3 months, the pain will be assessed every week, tolerance and compliance with compression garments will also be monitored. Participants will be reviewed specifically at a follow-up consultation for the 6-month and 1-year study. Various assessments will be carried out during these visits : assessment of pain, range of motion, muscle strength, sensitivity test, assessment of anxiety, depression and even quality of life.
45646518|NCT05034835|Other|usual treatment without compression garments (CERECARE)|For 3 months, the pain will be assessed every week, tolerance and compliance with compression garments will also be monitored. Participants will be reviewed specifically at a follow-up consultation for the 6-month and 1-year study. Various assessments will be carried out during these visits : assessment of pain, range of motion, muscle strength, sensitivity test, assessment of anxiety, depression and even quality of life.
45789808|NCT05449665|Other|Phase 2 - High Fibre|High Fibre diet (30% Fat, 15% Protein, 55% Carbohydrate, 30g/day Fibre). Fed ad libitum, contains 20g/day pectin (split over breakfast, lunch and dinner) in drinks/yoghurts which will be compulsory to consume and 10g/day fibre coming from the diet provided.
45789809|NCT05449665|Other|Phase 3 - Low Fibre|Low Fibre diet (30% Fat, 15% Protein, 55% Carbohydrate, 10g/day Fibre). Fed ad libitum.
45789810|NCT04338789|Other|Piezocision|Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.
45789811|NCT01429454|Drug|Omega-3 Long Chain Fatty Acid|: The Omega-3FA compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
45789812|NCT01429454|Drug|Placebo|The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them. The dose will be 2 capsules per day.
45789813|NCT05441631|Drug|Insulin|"Preparation: 50 IU of rapidly acting insulin in 50 ml of 0.9% saline solution was delivered through a 50-ml syringe-driven pump.~Monitoring: The insulin dose was adjusted to whole-blood glucose levels using glucometer every hour and insulin infusion was continued till BG level (Targeted level) was 80-110 mg, and then BG levels were estimated four-hourly~Insulin dose was titrated according to the Leuven titration protocol (15)"
45789814|NCT05441631|Drug|Subcutaneous Insulin|"Insulin dose was titrated according to the Blood glucose level~monitoring according to glucose in urine"
45789815|NCT05449353|Behavioral|Trauma-informed Cognitive Behaviour Therapy (TiCBT)|Group: Experimental (n=24 participants) will receive the TiCBT which consists of a total of 8-group integrated sessions lasting approximately 60 minutes per session every 3 days interval with 24 persons in the single group.
45789816|NCT01429532|Procedure|phacoemulsification|Cataract surgery performed with three incision-size-dependent phacoemulsification systems (1.8, 2.2 and 3.0 mm)
45789817|NCT03008330|Biological|High-activity natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
45789818|NCT01546454|Drug|Ethinyl Estradiol-Levonorgestrel combination|0.03 mg ethinyl estradiol, 0.15 mg levonorgestrel oral daily for 21 days
45789819|NCT01546454|Drug|leuprolide acetate|single 22.5 mg subcutaneous depot suspension
45789820|NCT01546454|Drug|Estradiol|0.05 to 0.3 mg transdermal daily for 26 days
45789821|NCT01546454|Drug|Progesterone|50 to 100 mg vaginal suppositories twice daily for 13 days
45789822|NCT05449041|Device|Bulbicam|Measurement of eye pressure; Accuracy diagram; Contrast chart; Visual field, Pupil size
45789823|NCT00368901|Drug|Darbepoetin alfa|Aranesp administered every other week SC titrated to not exceed Hb 12 g/dL
45789824|NCT05430867|Drug|Memantine Oral Tablet|Memantine 20mg once-daily
45789825|NCT05430867|Drug|GV-971 capsule|GV-971 450mg twice a day
45789826|NCT05448885|Drug|Tislelizumab|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (25mg per square meter on day 1-3) and tislelizumab(200mg) every three weeks for 2 cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy ,then followed by adjuvant therapy with tislelizumab(200mg) every three weeks for 13 cycles after radiotherapy
45789827|NCT01547000|Drug|placebo|Administered up to 8 weeks.
45449574|NCT00116831|Drug|Glipizide|oral anti-diabetic medication
45449575|NCT00116831|Drug|rosiglitazone maleate|oral antidiabetic medication
45646519|NCT03138421|Drug|ABX-1431 HCl|ABX-1431 HCl, capsules, 20 mg
45646520|NCT03138421|Drug|Placebo|Matching placebo
45789828|NCT01547000|Drug|extended-release guanfacine (Intuniv)|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks.
45789829|NCT02980016|Drug|rifapentine + isoniazid|Rifapentine + isoniazid Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), with adjustment for participants weighing ≤50 kg
45789830|NCT02980016|Drug|Isoniazid|Daily self-administered isoniazid (at a dose of 300 mg/daily), with adjustment for participants weighing ≤24 kg
45646521|NCT04705727|Drug|Budesonide Formoterol Drug Combination|This combination will be used to treat the asthma exacerbation, patients will take one inhalation of budesonide/formoterol Turbuhaler® 100/6 μg every 5 minutes (Maximum 12 inhalations).
45789831|NCT05448417|Device|Non-invasive high-frequency oscillatory ventilation|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
45646522|NCT04705727|Drug|nebulisation of terbutaline|Patients will receive 0.1 mg/kg nebulized terbutaline 5 mg/2 ml of Terbutaline dilution diluted with 2 ml normal saline delivered by an air compressor nebuliser driven by oxygen at a flow rate of 8l/min. The duration of one dose will be approximately 20 minutes and a total of 3 doses will be administered.
45646523|NCT03110497|Radiation|Single application multi-fraction brachytherapy|Single application brachytherapy procedure to deliver high dose rate fractions of 9Gy, 7Gy and 7Gy with 6-12 hours apart under strict image guidance
45789832|NCT05448417|Device|Noninvasive Bilevel Positive Pressure Ventilation|Noninvasive Bilevel Positive Pressure Ventilation
45789833|NCT05420649|Procedure|Non-intubated Laryngomicrosurgery|Non-intubated LMS was performed with assistance of Optiflow (HFNO).
45789834|NCT05419947|Drug|VERDYE powder for solution for injection 25 mg|Verdye 25 mg contains sodium VI powder for solution for injection. VI is a water-soluble agent with a spectral absorption peak of 800 nm. It is a drug approved for diagnostic use only and is indicated for the measurement of the excretory function of the liver.
45789835|NCT01493180|Drug|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension 2%
45789836|NCT01493180|Drug|Sodium hyaluronate ophthalmic solution|Sodium hyaluronate ophthalmic solution 0.1%
45789837|NCT05416905|Device|STN-DBS|"The patients will be treated with deep brain electrode placement of STN target under local and general anesthesia. Switching the system on: the stimulator will be switched on 3 weeks after surgery to allow time for the brain edema and stun effect to wear off. Postoperative medication: The subject taking medication in the past will continue the medication. If the subject with no medication before, will be required not to take medication related to dystonia."
45789838|NCT05416905|Device|GPi-DBS|The patients will be treated with deep brain electrode implantation of GPi target under local and general anesthesia. Except that the surgical target was GPi, the operation process, stimulator switch-on time, and postoperative medication were the same as those in the STN-DBS group.
45789839|NCT01431014|Drug|"Dexamethasonelow-dose"|5mg
45789840|NCT01431014|Drug|"Dexamethasonehigh-dose"|15 mg
45789841|NCT05405283|Biological|2nd booster with Comirnaty® (Pfizer-BioNTech)|In participants previously vaccinated with 3 doses of mRNA vaccine, he/she will receive one dose of Comirnaty® (Pfizer-BioNTech) vaccine as a second booster
45789842|NCT05405283|Biological|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|In participants previously vaccinated with 3 doses of mRNA vaccine, he/she will receive one dose of CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK vaccine as a second booster
46071371|NCT04202120|Other|Age-related stereotyping priming|The priming intervention was performed using the E-prime 2.0 software (Psychology Software Tools, Pittsburgh, PA). To ensure the primes flashed on screen were beyond awareness, the similar adjustment procedure was taken (see Levy, 1996; Stein et al., 2002). After the trial block, participants were asked to try to report any words viewed during each trial. The stimulus onset asynchrony (SOA) will be reduced or enhanced whenever 2 words or above were correctly reported or no single word could be reported respectively. The priming SOA for this study ranged from 32 ms to 208 ms (M = 98.70 ms. SD = 48.60).
45789843|NCT04375605|Drug|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
45789844|NCT04375605|Drug|Calcium folinate|Day 1 q2w: 200 mg/m² IV over 2 hours
45789845|NCT04375605|Drug|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
45789846|NCT04375605|Drug|Docetaxel|Day 1 q2w: 50 mg/m² IV over 2 hours
46071372|NCT04202120|Other|Non age-related stereotype priming|he priming intervention was performed using the E-prime 2.0 software (Psychology Software Tools, Pittsburgh, PA). To ensure the primes flashed on screen were beyond awareness, the similar adjustment procedure was taken (see Levy, 1996; Stein et al., 2002). After the trial block, participants were asked to try to report any words viewed during each trial. The stimulus onset asynchrony (SOA) will be reduced or enhanced whenever 2 words or above were correctly reported or no single word could be reported respectively. The priming SOA for this study ranged from 32 ms to 208 ms (M = 98.70 ms. SD = 48.60).
46071373|NCT02846012|Other|CSCM2|
45646524|NCT03110731|Behavioral|Physical training|Physical training (2x / week) was performed for 12 weeks
45646525|NCT04677413|Radiation|Ultrafractionated radiotherapy for rectal cancer|To determine the toxicity of dose-escalated hypofractionated RT, in patients with locally advanced rectal cancer treated with RT, FOLFOX or CAPOX chemotherapy and selective omission of surgery.
45646526|NCT03085771|Drug|desferal|It is a blinded randomized cross-over study that investigates the efficacy of DFO (50mg/kg) given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
45646527|NCT03085771|Drug|Isotonic saline|It is a blinded randomized cross-over study that investigates the efficacy of isotonic saline given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
45789847|NCT04375605|Radiation|Radiation|25 fractions (5 each week over 5 weeks) each 1,8 Gy to a total of 45 Gy
45789848|NCT04375605|Drug|Oxaliplatin during radiotherapy|Day 1, 8, 15, 22, 29: 45 mg/m² IV over 2 hours
45789849|NCT04375605|Drug|5-Fluorouracil during radiotherapy|day 1 - 33: 225 mg/m²/day IV continuously
45789850|NCT01431170|Drug|Besivance Treatment Group|Subjects Receive Besivance™ ophthalmic suspension, 0.6% one drop in the study eye three times daily (TID) for 10 days.
45789851|NCT01431170|Drug|Polytrim Treatment Group|Subjects receive Polytrim ophthalmic solution one drop in the study eye three times daily (TID) for 10 days.
45789852|NCT05448183|Drug|Toripalimab, Gemcitabine,Oxaliplatin|Toripalimab, 240mg, IV infusion, every 3 weeks (q3w), combined withTACE (Gemcitabine 1000mg/m2 , Oxaliplatin 135mg/m2) in a cycle of 3 weeks(q3w).
45789853|NCT04732455|Drug|Lidocaine in Saline|Lidocaine IV infusion (2 mg/kg) in 200 ml saline over forty minutes with a maximum upper limit of 200 mg pre each chemotherapy session until end of the cycle.
45449576|NCT02777086|Behavioral|StaySafe|StaySafe is a self-administered tablet computer app designed to improve decision-making around health risk behaviors.
45646528|NCT05619965|Drug|sedative|dexmedetomidine 1 mic/kg IV over 10 minutes then 0.4 mic/kg/h continuous IV infusion
45646529|NCT05619965|Device|Awake endotracheal intubation by Glidescope videolaryngoscope|Awake endotracheal intubation by Glidescope videolaryngoscope of cervical trauma patient
45646530|NCT05619965|Device|Awake endotracheal intubation by Fiberoptic bronchoscope|Awake endotracheal intubation by Fiberoptic bronchoscope of cervical trauma patient
45646531|NCT04659629|Drug|NL-201|NL-201 is a de novo protein therapeutic.
45646532|NCT04659629|Drug|Pembrolizumab Injection [Keytruda]|A programmed death receptor-1 (PD-1)-blocking antibody
45646533|NCT02998567|Drug|Guadecitabine|In arm 1 (escalation) and 2 (expansion).
45646534|NCT02998567|Drug|Pembrolizumab|In arm 1 (escalation) and 2 (expansion).
45646535|NCT04609787|Device|Immersive Virtual Reality|Participants are placed in three-dimensional, life-sized computer-generated environments via a computer headset shows potential as a treatment for chronic pain and central sensitization.
45646536|NCT02985619|Drug|Bevacizumab Injection [Avastin] (IVB-I)|0,05ml intravitreal injection
45646537|NCT02985619|Drug|Triamcinolone Acetonide 10mg/mL (IVT-II)|0,03ml intravitreal injection
45646538|NCT02985619|Drug|Bevacizumab Injection [Avastin] (IVB-III)|0,05ml intravitreal injection
45646539|NCT05587205|Biological|EO2002|Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery
45646540|NCT05587205|Other|Sham injection|Sham injection
45646541|NCT04958005|Diagnostic Test|ELISA|Enzim linked immunoabsorbant assay
45646542|NCT05583929|Other|GAITRite gaitway system, Bertec Balance System|GAITRite gaitway system will use to assess gait parameters, Bertec Balance System will use to assess limit of stability
45646543|NCT03110419|Other|Physical Exercise|The intervention program will follow the recommendations of the American College of Sports Medicine (ACSM, 2009), including aerobic, muscle strength, flexibility and balance exercise. The duration of the intervention will be 16 weeks with sessions 60 min performed in three alternate days.
45789854|NCT04732455|Drug|Duloxetine 30 MG|Oral Duloxetine tablet 30 mg once per day starting from the night pre chemotherapy during the whole period of chemotherapy cycle which expected to be three month
45789855|NCT04732455|Drug|Normal saline|200 ml normal saline over forty minutes pre each chemotherapy session until end of the cycle.
45449577|NCT03549429|Device|Medical tapes: TegadermTM and EyeGard®|TegadermTM and EyeGard® will be placed over patients' eyes during surgery with general anesthesia.
45449578|NCT02161510|Drug|MK-2248|MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days
45449579|NCT02161588|Drug|semaglutide|Once-daily oral administration as tablets. The dose level of oral semaglutide used in the 'Dose escalation period', 'Treatment period 1', 'Treatment period 2' and 'Treatment period 3' will be 5, 10, 20 and 40 mg per day, respectively.
45449580|NCT02161588|Drug|placebo|Once-daily oral administration as tablets.
45449581|NCT02163148|Behavioral|Massed speech exposure session|One session consisting of 4 speech exposures, each 5 minutes long.
45646544|NCT04123613|Drug|DM199|A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug
45646545|NCT03110653|Drug|Remifentanil|Remifentanil will be continued postoperatively, while being decreased (gradually by 30% every 15 mins)
45646546|NCT03110653|Drug|NaCl 0.9%|NaCl 0.9% will be administered postoperatively, while being decreased by 30% every 15 mins.
45646547|NCT02157025|Device|Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry|
45449582|NCT02161744|Biological|ADSCs administration|100- 240 cc of lipoaspirate will be extracted from the patient. The stromal vascular fraction (SVF) will be isolated with minimal manipulation. The cell pellet will be reconstituted in saline solution and administered intravenously to the patient.
45449583|NCT02784704|Drug|Eravacycline|
45449584|NCT02784704|Drug|Meropenem|
45449585|NCT02784704|Drug|Placebo|
45646548|NCT02157025|Other|Usual Care procedures during Humphrey perimetry for children|
45646549|NCT04116593|Behavioral|Nutrition education|Our intervention will be school based nutrition education.Nutrition education session will be delivered using audio-visual techniques (audio-visual presentation).Components of eight educational sessions will include overview of 16 food groups of individual dietary diversity score (IDDS) chart, detail description of 16 food groups presenting dietary diversity, overview of basic food components, importance of consuming diversified foods, strategies to select a diversified meal and remove monotony in food, proper timing and frequency of taking meals during 24 hours, selecting diversified meal in low expense, consequences of absence or scarcity of dietary diversity in meal.
45646550|NCT05392387|Other|Standard antiviral therapy|pegylated interferon or/and nucleos(t)ide analogues
45646551|NCT04601051|Biological|NTLA-2001|A clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration
45646552|NCT02037529|Drug|Eribulin Mesylate|Given IV
45646553|NCT02037529|Other|Laboratory Biomarker Analysis|Correlative studies
45646554|NCT02037529|Drug|Paclitaxel|Given IV
45646555|NCT02037529|Other|Quality-of-Life Assessment|Ancillary studies
45646556|NCT04583579|Device|DMV inserter (DMV® MagicTouch™) with an open end|This is a device used to help apply scleral lenses.
45789856|NCT01495286|Device|EMPI Select Transcutaneous Electrical Nerve Stimulation|Experimental: EMPI Select TENS unit For analgesia, StimCare electrodes will be placed on the baby's legs at specific acupuncture points and electrical stimulation will be administered via a standard EMPI Select TENS unit. For the main study, a low continuous current will be provided with voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 5±1 min after the heel stick. Two sub studies will precede the main safety study, with 6 infants in each, using electrical stimulation intensities that are a fraction of the planned intensity. Infants in sub study 1 will receive electrical stimulation at 1 mA and 2 Hz. Infants in sub study 2 will receive electrical stimulation at 2 mA and 10 Hz.
45920048|NCT00085384|Biological|PEG-interferon alfa-2b|Starting dose 1.0 mg/kg/week given subcutaneously
45646557|NCT04583579|Device|DMV inserter (DMV® MagicTouch™) with a closed end|This is a device used to help apply scleral lenses.
45646558|NCT04583579|Device|Three fingers (Patient's Hand)|This is a device used to help apply scleral lenses.
45646559|NCT04583579|Device|O-ring (Hardware Store Product)|This is a device used to help apply scleral lenses.
45789857|NCT05393193|Diagnostic Test|Point-of-Care Cepheid Xpert HIV-1|Post-partum HIV-positive women with pre-determined risk factors for vertical HIV transmission will be offered point-of-care HIV testing for their newborns for early infant HIV diagnosis.
45789858|NCT05393193|Drug|DTG/ABC/3TC|Infants will be started on a combination of NVP/ZDV/3TC. A switch to DTG/ABC/3TC will occur for all infants at or after 4 weeks (28 days) post-delivery for those weighing ≥3kg. Dosing of all ART will be weight-based by the Botswana treatment guidelines.
45789859|NCT04721145|Device|Dexcom G6 Continuous Glucose Monitor|Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
45789860|NCT04309227|Other|Strength Training|"Strength training traditionally requires use of high intensity loads to stimulate muscle growth and strength improvements. Some participants will be randomized to a traditional strength training program.~Blood Flow Restriction (BFR) training is used to stimulate muscle hypertrophy and strength improvements in a variety of populations. Results of BFR training are comparable to traditional high intensity training (HIT) despite using weight that are at a low intensity (low percent of 1 repetition maximum). This intervention has not been extensively studies in the rheumatoid or osteoarthritis populations, nor the myositis populations despite idealogical benefit for each group of low-load strengthening."
45789861|NCT04306965|Drug|Apremilast|30 mg BID
45789862|NCT02371746|Drug|ENV515-3 Travoprost XR|
45789863|NCT02371746|Drug|ENV515-1 Travoprost XR|
45789864|NCT02371746|Drug|ENV515-3-2 Travoprost XR|
45789865|NCT01431794|Drug|LDE225-600mg|"Phase I: oral LDE225 (Sonidegib), 600mg daily.~Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days."
45920049|NCT00085384|Drug|PEG-interferon alfa-2b|"Biological/Vaccine: PEG-interferon alfa-2b~Dose 1.25 mg/kg/week given subcutaneously"
46071374|NCT05242328|Procedure|Ultrasound-guided erector spinae plane block|Ultrasound-guided erector spinae plane block
46071375|NCT05242328|Procedure|surgical thoracoscopic intercostal nerve block|surgical thoracoscopic intercostal nerve block
45646560|NCT04583579|Device|Tea light candle (Generic Deparment Store Product) with DMV inserter (DMV® MagicTouch™)|This is a device used to help apply scleral lenses.
45646561|NCT04450199|Drug|Vitamin D2|Vitamin D tablets
45646562|NCT04450199|Other|Placebo|Over encapsulated sugar pills
45646563|NCT03067649|Behavioral|Motivational Interview|90-minute interview to discuss their concerns and possible barriers to seeking treatment for themselves
45789866|NCT01431794|Drug|Gemcitabine|Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.
45789867|NCT01431794|Drug|nab-paclitaxel|Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.
45789868|NCT01431794|Drug|LDE225-400mg|Phase I: oral LDE225 (Sonidegib), 400mg daily.
45789869|NCT01431794|Drug|LDE225-800mg|Phase I: oral LDE225 (Sonidegib), 800mg daily.
45920050|NCT00085384|Biological|PEG-interferon alfa-2b|"Biological/Vaccine: PEG-interferon alfa-2b~Dose 1.5 mg/kg/week given subcutaneously~EG-Intron"
46071376|NCT05337644|Drug|Indocyanine green solution|"5 ml of ICG were then injected intravenously to identify the stomach, carefully assessing the angle of His (preoperative written informed consent was obtained from the patient).~Adequate perfusion was defined as the direct and clear visualization of the fluorescence around the gastric tube, after an estimated time of 150-180 s followingi.v. administration."
46071377|NCT05242172|Diagnostic Test|CRP/Albumin ratio|it is aimed to investigate prognosis and severity of covid-19 infection with using CRP/Albumin ratio in pregnant patient
45449586|NCT03541096|Behavioral|Winter Swimming|Supervised Winter Swimming in Copenhagen
45646564|NCT03067649|Behavioral|Information only control|Participants are provided with a pamphlet containing referral information
45646565|NCT04543877|Dietary Supplement|Inulin|Consume 12 grams/day of inulin for 5 weeks (Day 9 - 43).
45646566|NCT04543877|Dietary Supplement|Maltodextrin|Consume 12 grams/day of maltodextrin for 5 weeks (Day 9 - 43).
45789870|NCT04254237|Procedure|Infraumbilical Hasson trocar incision|Infraumbilical Hasson trocar incision
45789871|NCT04254237|Procedure|Supraumbilical Hasson trocar incision|Supraumbilical Hasson trocar incision
45789872|NCT02421666|Behavioral|PNMI|Eligible patients received patient navigator led plus mobile phone text messaging intervention (PNMI) or standard care. Bilingually trained patient navigators were recruited from our existing patient navigator training network, received intensive training on HBV prevention, diagnosis and treatment management, and served as a liaison with respective clinical partners. The PNMI intervention offered three education sessions on HBV management and weekly CHB patient-designed educational phone-based text messages for five weeks.
45789873|NCT04204005|Dietary Supplement|Probiotics|"Active composition: 5x109 of Bifidobacterium longum (mix DLBL), 1x 109 Lactobacillus reuteri LRE02 (DSM 23878) and maltodextrin (total 2 grams). The probiotic species employed were granted the Qualified Presumption of Safety (QPS) status by the European Food Safety Authority (EFSA) in 2007. Two envelopes per day and one envelope per day will be recommended for one and two months, respectively.~Placebo composition: maltodextrin (2 grams). Two envelopes per day and one envelope per day will be recommended for one and two months, respectively."
45789874|NCT01497860|Drug|Vinorelbine|IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
45789875|NCT02394756|Device|Marketed Soft Contact lens|Replacement schedule every 2 weeks
45789876|NCT02394756|Device|AIR OPTIX® AQUA|Replacement schedule every 4 weeks
45789877|NCT02394756|Device|Biofinity®|Replacement schedule every 4 weeks
45920051|NCT00006080|Drug|fenretinide|
45920052|NCT00085462|Biological|aldesleukin|
45920053|NCT00085462|Biological|filgrastim|
45920054|NCT00085462|Biological|gp100-fowlpox vaccine|
45920055|NCT00085462|Biological|therapeutic autologous lymphocytes|
45920056|NCT00085462|Biological|therapeutic tumor infiltrating lymphocytes|
45920057|NCT00085462|Drug|cyclophosphamide|
45646567|NCT04543877|Biological|Ty21a Typhoid Fever Vaccine|All participants will receive the vaccine. One capsule is swallowed on alternate days, e.g. days 30, 32, 34, and 36 for a total of 4 capsules.
45646568|NCT01884259|Drug|Docetaxel|75 mg/m² on day 1 of 21-days cycle
45646569|NCT01884259|Drug|Cisplatin|75 mg/m² on day 1 of 21-days cycle
45646570|NCT01884259|Drug|5-fluorouracil|750 mg/m² day 1 to 5 during 24 hours of 21-days cycle
45646571|NCT01884259|Biological|Cetuximab Induction|weekly, starting with 400 mg/m² during 120 min.(saturation) then continuing with 250 mg/m²; duration 3 cycles with 21 days
45789878|NCT03239613|Other|POHIM-CCRT|postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
45449587|NCT03541096|Behavioral|Control group|No winter swimming activities.
45646572|NCT01884259|Biological|Cetuximab Radioimmunotherapy|weekly, starting with 400 mg/m² during 120 min.(saturation only arm A) then continuing with 250 mg/m²; duration 7 weeks
45789879|NCT02213900|Drug|Haloperidol|0.5mg IV Push immediately after surgery and Q8H following for a total of 4 days
45789880|NCT02213900|Drug|Placebo|
45789881|NCT02370888|Drug|Lenalidomide|Subjects will be enrolled in cohorts of three (3). Lenalidomide will be administered for 21 consecutive days in a 28 day cycle X 2 cycles. The starting dose will be 2.5 mg given orally every other day for 21 days.
45789882|NCT05358873|Device|Human IgG1 anti-SARS-CoV-2 antibody cocktail|Hypromellose-based nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibody cocktail
45789883|NCT05358873|Device|Placebo|Normal saline
45449588|NCT02166658|Drug|Cabazitaxel|Cabazitaxel 25 mg/m2 i.v. infusion (infusion time about 1h) on D1 of each 21-day cycle. Continuation of treatment until progression of brain metastases or unacceptable toxicity.
45646573|NCT01884259|Radiation|Boost irradiation|First 18 irradiations once daily with single dose of 1,8 Gy for 5 days per week. In addition by day 19 a second irradiation boost will be applied for further 12 days(1,5 Gy per day with at least 5 hours interval to 1,8 Gy dose. This results in total clinical target dose of 72 Gy and total subclinical target dose of 54 Gy. Duration of irradiation: 6 weeks
45646574|NCT04930549|Drug|Dapagliflozin 10Mg Tab|Patients receive dapagliflozin 10mg tablets once a day during 12 weeks
45646575|NCT04930549|Drug|Placebo|Patients receive placebo tablets once a day during 12 weeks
45920058|NCT00085462|Drug|fludarabine phosphate|
45449589|NCT03566823|Biological|Ontamalimab|Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.
45789884|NCT02214212|Device|Bright White Light (BWL)|The device emitting BWL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
45789885|NCT02214212|Device|Red Light (RL)|The device emitting RL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
45789886|NCT05336565|Other|Electronic medical record analysis|"Medical information system (MIS) BARS will be used for inclusion and retrieval of relevant data of cardiovascular patients aged 75 years and older enrolled in the reimbursement programs in the Tomsk Region. Incidence rates and patterns of PIM prescription, polypharmacy, and PDDIs in the time of COVID-19 pandemic will be studied."
45789887|NCT02394600|Drug|Grastek®|one tablet daily for four months
45789888|NCT02394600|Drug|Placebo|one tablet daily for four months
45789889|NCT04709601|Drug|Hiprex|Patients with negative urine culture will be prescribed Hiprex 1 g PO BID x 1 yr and patients with a positive urine culture will be prescribed antibiotics.
45920059|NCT00085501|Drug|cetuximab|"Arm 1: 400 mg/m2 (Initial dose), 2 hour IV infusion on Day 1, Week 1 only. 250 mg/m2 (Subsequent doses), 1 hour IV infusion, on Day 1 weekly starting at Week 2.~Arm 2: 400 mg/m2 (Initial dose), 2 hour IV infusion on Week 13 ONLY 250 mg/m2 (Subsequent doses), 1 hour IV infusion, weekly starting at Week 14."
45920060|NCT00085501|Drug|carboplatin|"Arm 1: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 2~Arm 2: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 1"
45449590|NCT03566823|Other|Placebo|Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
45646576|NCT04930549|Procedure|impedance cardiography|impedance cardiography (PhysioFlow® PF-05 Lab1TM, Manatec Biomedical) is done for evaluation of cardiac function
45646577|NCT04930549|Procedure|Applanation tonometry|Applanation tonometry will be done using SphygmoCor®, Hogimed) is done for evaluation of arterial stiffness
45646578|NCT04930549|Procedure|post-ischemic hyperemia of forearm|An arterial occlusion cuff will be placed on the forearm, and will be deflated to allow post-ischemic hyperemia with the continuous measurements of brachial artery diameter and blood flow velocity by high-resolution echotracking coupled to a Doppler system (ArtLab system®)
45920061|NCT00085501|Drug|paclitaxel|"Arm 1: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 4.~Arm 2: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 1."
45920062|NCT00006083|Drug|Fragmin|Fragmin at 5000 IU injected subcutaneously daily
45646579|NCT04930549|Procedure|haemodynamics parameters|haemodynamics parameters will be evaluated using automatic oscillometric recorder
45789890|NCT05289297|Procedure|Karydakis Flap Procedure|Pilonidal sinus surgery will be performed with the Karydakis Flap procedure.
45789891|NCT05289297|Procedure|Burow's Triangle Advancement Flap Procedure|Pilonidal sinus surgery will be performed with the Burow's Triangle Advancement Flap procedure.
45449591|NCT02163304|Other|Sucrose|
45449592|NCT02163304|Other|Artificial Sweetner|
45449593|NCT02163304|Other|Tasteless Solution|
45789892|NCT02214290|Drug|Caffeine|A 200 mg caffeine tablet was given to subject to examine the drugs effect on arterial function.
45789893|NCT02214290|Drug|Placebo|A 750 mg placebo capsule (maltodextrin) was given to subjects to examine the effect of the drug on arterial function.
45789894|NCT02214290|Dietary Supplement|L-citrulline|L-citrulline was used to examine the effect of the supplement on arterial function.
45789895|NCT04689009|Device|EmoLED|The treatment with EmoLED, in addition to the SOC, will be performed during each visit for 60 seconds on each 5 cm diameter sub-area of the selected lesion.
45646580|NCT04508621|Drug|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
45646581|NCT04508621|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
45646582|NCT05392153|Other|Myofascial therapy|Running is a sport that involves repetitive movement and is particularly vulnerable to injury in the lower extremities. Myofascial release, on the other hand, is a manual method that is effective in increasing blood and oxygen permeability between tissues, renewing the tissue, protecting it from injury and increasing performance. The aim of our study is to investigate the effect of Myofascial therapy on sportive performance balance and injury risk in runners. The study will carry out on runners with a 3-month running history.
45646583|NCT05525585|Dietary Supplement|Early HMF|Mom's milk or donor milk will be fortified between postnatal day 4 and 7
45789896|NCT04689009|Procedure|current Standards Of Care|"The lesions will be cleansed with saline solution and, if necessary, surgical debridement will be performed with the most suitable method. At this point, if patient is included in EmoLED Group, the EmoLED treatment starts. After EmoLED application (EmoLED Group) or after cleansing (SOC Group), a polyurethane foam dressing will be applied on the lesion. In case of clinical signs of infection, a silver dressing will be applied.~Then an elasto-compressive double layer dressing of the limb with cohesive fixation bielastic latex-free bandage will be carried out."
45789897|NCT03160911|Device|Over-the-scope clip (OTSC)|The device provides a robust and strong tissue apposition. The system was developed to close perforations and treat bleeding in the gastrointestinal tract. In chronic ulcers, an anchor device can be used to pull the ulcer base toward the aspiration cap to facilitate accurate clip application. Endoscopic haemostasis would be achieved with the use of this device and/or injection of adrenaline
45789898|NCT03160911|Device|Conventional Endoscopic Haemostasis|This includes the use of heater probe, endoscopic clipping and injection of adrenaline for endoscopic haemostasis
45789899|NCT04685499|Drug|OBP-301|Telomerase-specific Type 5 Adenovirus. OBP-301 OBP 301 will be injected intratumorally into tumor lesions.
45789900|NCT04685499|Drug|Pembrolizumab|Standard dose pembrolizumab 200 mg IV every 3 weeks for up to one year
45789901|NCT04678869|Drug|Ciprofloxacin|prophylactic ciprofloxacin (10mg/kg BD, enteral/IV)
45789902|NCT04678869|Drug|Antibiotic|Standard of care antibiotic as per local policy
46071378|NCT00045968|Drug|Dendritic cell immunotherapy|Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment. Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.
45646584|NCT05525585|Dietary Supplement|Delayed HMF|Mom's milk or donor milk will be fortified between postnatal day 10 and 14
45646585|NCT04897945|Behavioral|Shared decision-making for diabetes prevention|Pharmacists and/or nurses will engage patients with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) recognized diabetes prevention program (DPP), and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
45646586|NCT03067727|Drug|Dinoprostone|The DVI contains 10 mg Dinoprostone
45646587|NCT03067727|Drug|Placebo|The placebo product is identical with the active product except that it does not contain Dinoprostone.
45789903|NCT04668339|Biological|ARCT-021 single dose priming|ARCT-021 higher dose (one dose) + placebo (one dose)
45789904|NCT04668339|Biological|ARCT-021 two lower dose priming|ARCT-021 lower dose (two doses, Day 0 and Day 28)
45789905|NCT04668339|Biological|ARCT-021 two higher dose priming|ARCT-021 higher dose (two doses, Day 0 and Day 28)
45789906|NCT04668339|Biological|Placebo (two doses), priming|Placebo (two doses, Day 0 and Day 28)
46071379|NCT02845778|Drug|Melatonin|Each sachet contains 0.5 g
46071380|NCT05242016|Other|structured individual reminiscence|reminiscence therapy
46071381|NCT05242016|Other|unstructured social interview|placebo
46071382|NCT05241938|Procedure|PSLT|PSLT will be performed under topical anesthesia (proxymetacaine hydrochloride 5mg/ml eye drops) using a mirrored gonioscopy lens (Latina Ocular Instruments). A α2 agonist hypotensive eye drops (0.2% brimonidine tartrate) and 2% pilocarpine eye drops are applied 40 minutes before the procedure. After laser treatment, the patient will be instructed to use non-steroidal anti-inflammatory eye drops (thrice daily for 7 days).
46071383|NCT05241938|Drug|Prostaglandin analogue eye drops|Prostaglandin analogue eye drops will be prescribed to be used continuously once a day in the fellow eye.
45646588|NCT01794793|Drug|Pasireotide|Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.
45646589|NCT01794793|Drug|Cabergoline|Cabergoline tablet 0.5mg or 1.0mg taken by mouth once daily may be combined with subcutaneous formulation of pasireotide for Cushing's Disease or Acromegaly. Dose is dependent on parent study guidelines.
45646590|NCT01794793|Drug|Pasireotide|Long Acting Release is administered by monthly injection. The strengths are 10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
45646591|NCT03067103|Drug|Tramadol|Patients will receive injections in peritonsillar fossa of tramadol (2 mg/kg-2 ml)
45646592|NCT03067103|Drug|Ketamine|Patients will receive injections in peritonsillar fossa of ketamine prior to surgery
46071384|NCT02845544|Other|Pilates-based exercises|
45646593|NCT03067103|Drug|Placebos|Patients will receive 2mL of saline solution in peritonsillar fossa prior to surgery
45646594|NCT05492123|Drug|Nivolumab 40 mg in 4 ml Injection|Nivolumab 1mg/kg every 3 weeks for 4 cycles prior to radiation and 240mg every 2 weeks with concurrent radiation
45646595|NCT05492123|Drug|Ipilimumab 200 MG in 40 ML Injection|Ipilimumab 3mg/kg every 3 weeks for 4 cycles prior to radiation
45789907|NCT04668339|Biological|Randomized booster|ARCT-021 (single dose) OR placebo, booster
45789908|NCT04668339|Biological|Placebo booster|Placebo (single dose)
45789909|NCT00369603|Drug|Razadyne ER|4-weeks 8mg. Razadyne ER, then 4-weeks 16mg. Razadyne ER, and a subsequent 4-weeks of 24mg. Razadyne ER
45789910|NCT00369603|Drug|Aricept|8-weeks 5mg. Aricept and a subsequent 4-weeks of 10mg. Aricept
45449594|NCT03540472|Drug|tacrolimus|On refractory PRCA patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study
45449595|NCT05241548|Procedure|BMAC on PCL Scaffold|Horizontal ridge augmentation in aesthetic zone by using bone marrow aspirate concentrate on PCL scaffold
45646596|NCT05492123|Radiation|Chemoradiation|Radiation to a dose of 45Gy over 25 1.8Gyfractions and brachytherapy with concurrent weekly cisplatin 40mg/m2/w or carboplatin AUC 2/w
45646597|NCT01398319|Behavioral|Group Brief Alcohol Intervention|The BAI contained components of effective interventions developed for young adult drinkers both in health care and educational settings and was specifically tailored to the unique needs and risk factors of Airmen. The 1-hour group intervention was administered using the principles of motivational interviewing (MI) in an interactive Socratic style to generate feedback and discussion. Open-ended questions, reflections, as well as the decisional balance scale were used to increase Airmen's motivation to remain alcohol free.
45646598|NCT01398319|Behavioral|Group Brief Alcohol Intervention Booster|The 1-hour booster intervention was delivered using MI to extend the effective elements found in the original BAI intervention with elements from behavioral economic theory. A behavioral economic approach to alcohol use suggests that decisions to drink are more likely when 1) there is a lack of access to or engagement in alternative alcohol-free reinforcing activities, and 2) there is a greater relative focus on immediate, relative to delayed, rewards (i.e., steep delayed reward discounting). The intent of the intervention is to bring important long-term goals into the present so that the immediate awareness of this goal might diminish the relative benefit of drinking. Another goal was to have the Airmen identify enjoyable and goal-consistent alcohol-free activities they could engage in during their free time. The booster also included a reminder of the U.S. Air Forces rules and policies on alcohol use and harm reduction drinking strategies.
45646599|NCT01398319|Behavioral|Bystander Intervention|"The 1-hour Bystander intervention was a non-alcohol related briefing that served as the control condition. The intervention focused on increasing Airmen's awareness of the qualities of being a good wingman (e.g., watching for their peers) and how those are tied to the Air Force Core Values. It aimed to increase participants' perceived responsibility to act in certain situations. The intervention draws on the philosophy that members in a community have a role in shifting social norms to prevent violence (Coker et al., 2011). While the intervention did not directly discuss alcohol use, the focus on military values and taking responsibility for one's self and others could contribute to healthier drinking-related choices."
45646600|NCT01365169|Behavioral|Exercise Intervention|Participate in walking and/or strengthening program
45449596|NCT02166736|Device|iFR|Treatment guided by Instantaneous wave-free ratio (iFR®)
45646601|NCT01365169|Other|Health Telemonitoring|Use accelerometers, blood pressure monitor, heart rate monitor, GPS device, and smart phone
45789911|NCT01432886|Drug|E7389|Eribulin mesylate (iv) will be administered on Day 1 and Day 8 of each cycle (3 weeks as 1 cycle). Trastuzumab (iv) will be administered as weekly use or tri-weekly use. Trastuzumab will be administered immediately after eribulin mesylate administration when used concomitantly.
45789912|NCT05239455|Device|Reveos® Automated Blood Processing System|This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from WB processed with the Reveos System.
45646602|NCT01365169|Other|Health Telemonitoring|Use accelerometers, blood pressure monitor, weight scale, and smart phone
45646603|NCT01365169|Other|Health Telemonitoring|Use smart phone
45646604|NCT01365169|Other|Health Telemonitoring|Use CO monitor and smart phone
45646605|NCT01365169|Other|Health Telemonitoring|Use Fitbit, weight scale and iPhone- or web-based app for self-reported data
45789913|NCT01433042|Device|capsule endoscopy|capsule endoscopy procedure
45789914|NCT04635189|Drug|Daratumumab|Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks
45789915|NCT04635189|Drug|Lenalidomide|Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle
45789916|NCT04635189|Drug|Dexamethasone|Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab
45789917|NCT01551056|Drug|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
45789918|NCT01551056|Drug|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
46071385|NCT05241782|Other|auricular acupressure|"Auricular therapy, as defined by Oleson, refers to a healthcare modality by stimulating the external surface of the ear to alleviate pathological conditions in other parts of the bodyExperimental group will receive acupressure treatment by the second week, trice daily, 3~5minutes each session for a course of four weeks"
46071386|NCT05337332|Drug|Triamcinolone Acetonide|Suprachoroidal injection of triamcinolone acetonide
46071387|NCT02850302|Other|PET with FDG|A PET with FDG will be performed before the treatment is started and after 6 cycles of chemotherapy.
45789919|NCT04614753|Other|Dealcoholized Muscadine Wine|300 ml of Dealcoholized Muscadine Wine
46071388|NCT02850302|Other|Tumor exome analysis|A biopsy of the tumor will be performed before the treatment is started and after 6 cycles of chemotherapy. Tumor exome analysis will be performed before treatment is started and after 6 cycles of chemotherapy.
45449597|NCT02166736|Device|FFR|Intervention guided by Fractional Flow Reserve
45646606|NCT01365169|Other|Quality-of-Life Assessment|Ancillary studies
45646607|NCT01365169|Other|Questionnaire Administration|Ancillary studies
45646608|NCT01365169|Other|Health Telemonitoring|Use Fitbit and Actigraph
45646609|NCT03068585|Drug|Neovasculgen (Cambiogeneplasmid)|treatment
45646610|NCT01305889|Behavioral|problem solving therapy|12 weeks of weekly 45 minute sessions of problem solving therapy
45646611|NCT01305889|Drug|Sertraline|12 weeks of sertraline; 25 mg for one week, 50 mg for 3 weeks; then 100 mg/day for 4 weeks; then 150 mg/day for 4 weeks based on tolerability and response
45646612|NCT00756379|Other|Comprehensive therapy program for risk factor modification|Patients enrolled in the comprehensive therapy arm will have a baseline myocardial perfusion PET and the support of a team of professionals aiming to modify and minimize all the known CAD risk factors. During the 5 year follow-up they will be educated and guided toward a healthy lifestyle by a dietician, an exercise physiologist/cardiovascular physician specialist.
45789920|NCT04614753|Other|Control Beverage|300ml of Sugar Water and Acid Content
45646613|NCT05392075|Biological|Pfizer COVID-19 mRNA vaccine|vaccinated people who received the Pfizer COVID-19 mRNA vaccine
45646614|NCT05392075|Biological|Moderna COVID-19 mRNA vaccine|vaccinated people who received the Moderna COVID-19 mRNA vaccine vaccine
45646615|NCT03138265|Behavioral|HIIT Device: ergometer|Supervised exercise training.
45646616|NCT05391997|Other|Modified Cervical and Shoulder Retraction exercises|11 patients will receive cervical traction and modified cervical and shoulder retraction exercises (10 to 12 repetitions). The total treatment session will be of 20-25 minutes with a total intervention period of 6 weeks with 3 sessions per week on alternative days.
45646617|NCT05391997|Other|Cervical Extension Traction exercises|11 patients will receive cervical traction force for 10 seconds and extend the cervical spine. The total treatment session will be of 20-25 minutes with a total intervention period of 6 weeks with 3 sessions per week on alternative days
45646618|NCT03136939|Other|No intervention|No intervention
45646619|NCT03591107|Other|PTSD Care Management (PCM)|Collaborative care for PTSD facilitated by a trained CM who will engage the patient into care, monitor progress over 6 months, coordinate care with primary care and behavioral healthcare providers and social services, and receive monthly supervision by the study psychiatrist in addition to education and feedback
45646620|NCT03591107|Other|Minimally Enhanced Usual Care (MEU)|Education and feedback alone
45646621|NCT00223171|Drug|Androgen blockade + radiation therapy|Androgen blockade + radiation therapy
45789921|NCT04585503|Device|Electrode implantation|The intervention consist in implanting 6 electrodes in subdural or intra cortical position and monitor the central nervous system activity. This monitoring will be additional to the usual monitoring.
45789922|NCT05227131|Drug|Margetuximab|Margetuximab (15 mg/kg) will be administrated by intravenous infusion on Day 1 of each cycle.
45789923|NCT05227131|Drug|Tucatinib|Tucatinib (300 mg) will be administrated orally twice daily (every 12 hours) continuously in 21-day cycles.
45789924|NCT05227131|Drug|Capecitabine|Capecitabine (1000 mg per square meter of body-surface area) will be administrated orally twice daily on days 1 to 14 of each 21-day cycle
45789925|NCT03008096|Procedure|Laparoscopic Sleeve Gastrectomy|Routine Laparoscopic Sleeve Gastrectomy is performed on obese patients supported by Left-Ventricular Assist Device in order to reach a Body Mass Index sufficient for heart transplantation listing.
45789926|NCT05218239|Behavioral|Active Comparator: Routine education group|Behavior guidance on pelvic floor muscle function training , including Knack method education , and Kegel exercise and other pelvic floor muscle training methods were taught to postpartum women.
45789927|NCT05218239|Behavioral|Experimental: Global training group|Global training was added on the basis of control group. The 30min-training plan is divided into 9 sections, of which, groups 1 to 8, each group takes about 3 minutes, the ninth group is cool down section, including stretching for 5 minutes and foam axis stretching for 1 minute.
46071389|NCT02845232|Other|Transfusion|The number and type of blood products administered were registered from the time of diagnosis to the time of death corresponding for all patients to the time of last follow-up. Transfusion of a single unit of packed red blood cell (PRBC) or one whole blood-derived platelet concentrate (PC) or fresh frozen plasma (FFP) was considered a transfusion event and considered for statistical analysis.
45789928|NCT01435304|Device|method of returning residual CPB blood ( Hemobag®)|The Hemobag® is a collection reservoir used to facilitate ultrafiltration of the CPB circuit after the patient has been disconnected from CPB).
45789929|NCT03024567|Dietary Supplement|Salt|10 capsules daily for 14 days
45789930|NCT03024567|Dietary Supplement|Placebo|10 capsules daily for 14 days
45789931|NCT01499498|Drug|Sildenafil and Boceprevir|25mg once/800mg three times a day
45789932|NCT04564911|Combination Product|Flash Glucose Monitoring and Education|Participants will wear the flash glucose monitoring system, and receive an education package on how to self-manage their glucose levels. They will use the flash glucose monitoring system continuously for 6 weeks. From week 6 to week 24, the frequency of use of flash glucose monitoring will be reduced to one sensor every 4 weeks. They will receive education at weeks 0, 2, 8 and 16. They will also wear a blinded sensor for the last 2 weeks of the intervention period (week 25 to week 26). After the first 24 weeks, participants enter the observation phase (weeks 38 to 52) wherein they will be encouraged to continue monitoring their glucose levels through capillary glucose monitoring, during pre-meals and bedtime daily.
45789933|NCT04564911|Combination Product|Capillary glucose monitoring and Education|Participants will use a capillary glucose meter and receive an education package on how to self-manage their glucose levels. Participants will be encouraged to test their blood glucose levels at least twice a day, but preferably 4 times daily: pre-meal and bedtime blood glucose levels. They will receive education at weeks 0, 2, 8 and 16. They will wear a blinded sensor again after the last 2 weeks of the intervention period (week 24 to week 26). After the first 24 weeks, participants enter the observation phase (weeks 38 to 52) wherein they will be encouraged to continue monitoring their glucose levels through capillary glucose monitoring, during pre-meals and bedtime daily.
45789934|NCT04551729|Behavioral|Lifestyle advice for liberal fluid intake|Lifestyle advice for liberal fluid intake for 3 months
45789935|NCT05201391|Behavioral|"Eat Right Now (ERN) mobile application"|"Eat Right Now (ERN) is an app-based (28 daily modules, self-paced) Mindfulness-Based Intervention (MBI), which uses mindfulness to target craving-based eating. The program is designed to take 6-8 weeks to complete."
45920063|NCT00006083|Other|placebo|placebo injected subcutaneously daily
45920064|NCT00085579|Biological|aldesleukin|
45920065|NCT00085579|Biological|sargramostim|
45920066|NCT00085579|Procedure|adjuvant therapy|
46071390|NCT02850458|Device|implant-retained overdentures|patients treated with an implant-retained overdenture in the mandible
46071391|NCT04793204|Drug|fezolinetant|oral
46071392|NCT00901394|Drug|B12-Folic Acid, nitrous oxide|"IV vitamin B12 (cyanocobalamin) 1 mg, single administration over 30 min.~IV folic acid, 5 mg, single administration over 30 min.~Both diluted in 250 ml normal saline."
46071393|NCT00901394|Drug|Nitrous oxide (NO) and placebo|60% nitrous oxide anesthesia plus saline
45449598|NCT02166814|Drug|Fimasartan and Rosuvastatin|
45449599|NCT02166814|Drug|Fimasartan|
45646622|NCT04452305|Procedure|Spermatogonial Stem Cell Transplant and Testicular Tissue Grafting|Spermatogonial stem cell transplant and testicular tissue grafting is performed to produce sperm.
45789936|NCT01499654|Drug|Half-dose of the Tc99-m sestamibi (Cardiolite)|Researchers will administer half of the radiotracer (Cardiolite), obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.
45789937|NCT04532151|Diagnostic Test|Non-invasive skin imaging assessment|"Intervention Description : (Limit: 1000 characters) Do not repeat information already included in arm/group descriptions. Specify details not covered in associated Arm~One session of Non-invasive skin imaging assessment contained:~an examination on LC-OCT~an examination on LC-OCT-doppler~a fluid silicone molding~an examination on HD ultrasound~The measurements will be applied on 3 skin sites: the dorsal surface of the finger, the inner face and the outer surface of the forearm.~The imaging assessment lasts 30 minutes in a dimly lit room where the humidity and temperature are stable."
45789938|NCT04505085|Behavioral|Active Dads Healthy Families: Outdoor Education|The intervention will include outdoor education and physical activity opportunities at various outdoor parks. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Each session will have a special theme relevant to the outdoors. Families will also receive a home toolbox to facilitate activity and learning outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
45789939|NCT04505085|Behavioral|Active Dads Healthy Families: Fitness|The intervention will include physical activity opportunities at a community center. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Families will also receive a home toolbox to facilitate activity outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
45920067|NCT04811664|Biological|Moderna COVID-19 Vaccine|A lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available). It is a suspension for intramuscular injection administered as a series of two doses (0.5 mL each) 1 month apart.
45920068|NCT00085696|Drug|VELCADE and rituximab|
45789940|NCT01500746|Procedure|Pulse lavage treatment|A pulse lavage machine will be used to irrigate the wound with a total of 4 liters of water, twice daily, for a total of 4 days (8 treatments).
46071394|NCT00901394|Other|Placebo|Saline
45789941|NCT01500746|Other|Dressing changes|Wounds will be treated with moist gauze dressing changes twice daily for a total of 4 days (8 treatments).
45804086|NCT02382913|Biological|TdaP booster|"Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
45920069|NCT00006086|Drug|BMS-188797|
45920070|NCT00006086|Drug|carboplatin|
45920071|NCT04729426|Other|Peanut Ball Position|The group of healthy pregnant women who meet the inclusion criteria will be determined by randomization according to the order of application to the delivery room. A group (intervention group) will be given positions using the peanut ball tool in active phase and transition phase and the positions will be changed every 30 minutes.
45920072|NCT00085813|Drug|Ispinesib|
45920073|NCT04798638|Drug|TY-9591 Tablets under Fasted Condition - Arm1|Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
46071395|NCT00901394|Other|oxygen nitrogen|60% air and oxygen mix.
46071396|NCT05241704|Procedure|Fat grafting|Under general or local anaesthesia, fat will be harvested from either abdomen or lower limb. After harvesting the fat by liposuction, the lipoaspirate will be injected underneath the ulcer under complete aseptic operative setting
46071397|NCT05241704|Procedure|Endovenous ablation of superficial venous reflux|Endovenous ablation of the main truncal venous reflux to the lowest point of incompetence, where possible (routine practice)
46071398|NCT05241626|Diagnostic Test|AS-OCT|Optical Coherence Tomography (OCT) creates detailed cross-sectional images of the anterior and posterior segments using low coherence interferometry. OCT is a noninvasive, real-time method for evaluating the tear meniscus, total corneal thickness (CT), and corneal epithelial thickness
45646623|NCT04563481|Other|Hand Therapy via Telerehabilitation|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~3 days / week with physiotherapist~2 days / week as home program 30 minutes / day 12 repetitions"
45646624|NCT04563481|Other|Hand Therapy by Physiotherapist|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~3 days / week with physiotherapist~2 days / week as home program 30 minutes / day 12 repetitions"
45920074|NCT04798638|Drug|Osimertinib Mesylate Tablets under Fasted Condition - Arm1|Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.
45920075|NCT04798638|Drug|TY-9591 Tablets after a High-fat Meal - Arm1|Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
45920076|NCT04798638|Drug|Osimertinib Mesylate Tablets under Fasted Condition - Arm2|Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.
45920077|NCT04798638|Drug|TY-9591 Tablets under Fasted Condition - Arm2|Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
45920078|NCT04798638|Drug|TY-9591 Tablets after a High-fat Meal - Arm2|Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
45449600|NCT02166814|Drug|Rosuvastatin|
45789942|NCT04707729|Diagnostic Test|ROX index algorithm|"The thresholds of the ROX index for intubation are the following:~After 2 hours of HFNC: ROX <2.85.~After 4 and 6 hours of HFNC: ROX <3.47~After 8, 10 and 12 hours of HFNC: ROX <3.85 If the ROX index is between the abovementioned thresholds and 4.88, the NHF support will be also increased to the maximum tolerated flow (up to 60L/min) and FIO2 of 1 and subsequently titrated with the target SpO2. If the patient is already treated with to 60L/min) and FIO2 of 1 and no further increase could be done and the ROX index will be recalculated after 30 minutes of full NHF support. The ROX index will be recalculated in 30 minutes: 1) if the ΔROX is <0 the patient will be intubated; 2) if the ΔROX is 0-0.5, the ΔROX will be reassessed in 20 minutes; and 3) if the ΔROX is >0.5 the patient will not be intubated, NHF will be managed as protocolized and respiratory condition will be reassessed every two hours or at any new clinical deterioration."
45789943|NCT02838069|Biological|Injection (2x106 ASC/5ml).|Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
45789944|NCT02838069|Biological|Injection (10x106 ASC/5ml).|Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
45789945|NCT02838069|Other|Placebo|Injection of placebo 0.5% glucose in saline with 4.5% alb/5ml The patient of this group will receive one single administration and will be followed for 12 months. A final follow up visit will occur at Month 24.
45789946|NCT04487613|Drug|Moringa oleifera leaf|450 mg capsule
45789947|NCT04487613|Drug|Placebo|placebo capsule
46071399|NCT05337254|Drug|Dihydroergotamine|Dihydroergotamine intranasal powder
46071400|NCT05337254|Drug|Dihydroergotamine|Dihydroergotamine intramuscular injection
45789948|NCT02421588|Drug|Lurbinectedin (PM01183)|
45789949|NCT02421588|Drug|Pegylated liposomal doxorubicin (PLD)|
46071401|NCT05337254|Drug|Dihydroergotamine|Dihydroergotamine intranasal spray
45646625|NCT04497493|Device|Transcranial Direct Current Stimulation (tDCS)-active|Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type，participants receive 20 min sessions of 2 mA direct current delivered over the dorsolateral prefrontal cortex, 5 days per week, for 4 weeks
45789950|NCT02421588|Drug|Topotecan|
45789951|NCT04479969|Behavioral|Video Chat|Video chat with health coach using a computer tablet.
45789952|NCT05140473|Behavioral|perceived workload|Perceived workload takes into account the acts and care performed but also the pressure felt of having been efficient in its task, the efforts made and the level of frustration felt.
45789953|NCT02815917|Drug|[18F]FTP PET/CT|All PET/CT imaging sessions will include an injection of [18F]FTP. Pilot data will be collected to evaluate preliminary information on brain uptake of [18F]FTP in healthy volunteers and cocaine-dependent volunteers.
45789954|NCT00370227|Biological|10 valent pneumococcal conjugate (vaccine)|
45789955|NCT02768727|Drug|Xenon|drug given in concentrations of 0% to 60% over period of 2 hours
45789956|NCT02748291|Other|Walking|"The intervention group will be asked to walk a minimum 6,000 steps per day (7 days a week).~Participants will be provided with a pedometer and daily diary to record step counts.~Weekly scores will be collected via telephone contact.~Followup questionnaires will be at 6, 12 and 24 months."
45646626|NCT04497493|Device|Transcranial Direct Current Stimulation (tDCS)-sham|Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min 5 days per week, for 4 weeks
45646627|NCT04445987|Drug|ARQ-154|ARQ-154 foam 0.3% applied once daily for 52 weeks
45789957|NCT02748291|Other|Department of Health Physical Activity Guidelines|"Adults should aim to be active daily. Over a week, activity should add up to at least 150 minutes (2½ hours) of moderate intensity activity in bouts of 10 minutes or more - one way to approach this is to do 30 minutes on at least 5 days a week.~Alternatively, comparable benefits can be achieved through 75 minutes of vigorous intensity activity spread across the week or combinations of moderate and vigorous intensity activity.~Adults should also undertake physical activity to improve muscle strength on at least two days a week.~All adults should minimise the amount of time spent being sedentary (sitting) for extended periods."
45789958|NCT02694393|Drug|sodium nitrite|inhalation of 46 or 80 mg of sodium nitrite by electronic nebulization
45789959|NCT02688309|Drug|Ozurdex|Patients from the clinic will be considered for enrollment if they are receiving an intraocular injection of a steroid as part of standard care for macular edema or progressive fibrosis. Clinic patients who are receiving an intraocular injection of steroid (Ozurdex) as part of standard care who agree to participate will have an AC tap just prior to the intraocular injection of steroid and a second AC tap at a follow up visit 6 ± 2 weeks after the steroid injection.
45920079|NCT00085852|Biological|BLVR|10 mL Hydrogel
45920080|NCT00006089|Other|Laboratory Biomarker Analysis|Correlative studies
45920081|NCT00006089|Biological|Trastuzumab|Given IV
45920082|NCT00085891|Drug|Quetiapine Fumarate|
46071402|NCT00896532|Drug|Placebo to Romosozumab|Administered by subcutaneous injection QM or Q3M.
46071403|NCT00896532|Drug|Alendronate|Administered orally once a week
46071404|NCT00896532|Drug|Teriparatide|Teriparatide 20 μg administered by subcutaneous injection once a day
46071405|NCT00896532|Drug|Romosozumab|Administered by subcutaneous injection
46071406|NCT00896532|Drug|Denosumab|Denosumab 60 mg administered by subcutaneous injection Q6M
46071407|NCT00896532|Drug|Placebo to Denosumab|Administered by subcutaneous injection Q6M
46071408|NCT00896532|Drug|Zoledronic acid|Zoledronic acid 5 mg administered intravenously
46071409|NCT00574873|Drug|Bosutinib|500 mg once daily, by mouth (tablet) with food preferably in the morning. Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
45789960|NCT02688309|Procedure|Surgery|The 60 patients from the operating room will be patients undergoing surgery for one of the following conditions: (1) Proliferative Diabetic Retinopathy, (2) rhegmatogenous retinal detachment with PVR, (3) rhegmatogenous retinal detachment without PVR, (4) macular pucker, (5) macula hole. All patients will be administered an AC (Anterior Chamber) tap just prior to the surgical procedure while in the OR.
45789961|NCT02688309|Procedure|Anterior Chamber (AC) Tap|A paracentesis removing about 0.1 ml of fluid from the front part of the eye (the aqueous chamber) will be performed in the operating room just prior to surgery or in the clinic. In the operating room, the AC tap is done after the eye is anesthetized and cleaned with 5% povidone iodine for the surgery. A 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is removed. The wound is self-sealing and has no effect on the surgery. In the clinic, the AC tap is done after drops of proparacaine and 5% povidone iodine is placed in the eye and a lid speculum is inserted. The patient is seated at a slit lamp and a 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is aspirated and then the needle is removed.
46071410|NCT00574873|Drug|imatinib|400 mg once daily, by mouth (tablet). Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
45789962|NCT00370851|Drug|Avastin (Bevacizumab)|Intravitreal injection of 125 mg Avastin
45789963|NCT05124171|Biological|BNT162b2|"ARM 1 receiving Pfizer-BioNTech vaccine~Group 1.A: 18-64 years old~Group 1.B: 65 years and older"
45789964|NCT05124171|Biological|CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK|"ARM 2 receiving SP/GSK subunit D614 vaccine~Group 2.A: 18-64 years old~Group 2.B: 65 years and older"
45789965|NCT05124171|Biological|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|"ARM 3 receiving SP/GSK subunit B.1.351 vaccine~Group 3.A: 18-64 years old~Group 3.B: 65 years and older"
45789966|NCT00370305|Drug|rosiglitazone|89 mg BID for 8 weeks, orally
45920083|NCT00085969|Drug|Placebo 0.04 mL twice daily|Subcutaneously injected, 0.04 mL, twice daily
45920084|NCT00085969|Drug|Placebo 0.04 mL once daily|Subcutaneously injected, 0.04 mL, once daily
45646628|NCT05391685|Other|Scar release techniques + therapeutic ultrasound|Control group will be treated by therapeutic ultrasound only for2 sessions per week for two weeks Study group) will be treated by various scar release techniques in addition to therapeutic ultrasound, 2 sessions per week for two weeks.
45646629|NCT03138031|Procedure|Percutaneous ethanol alcohol injection|"Day-case procedure; weekly sessions; uses absolute alcohol; under close monitoring; maximum dose of 30 ml; no anesthesia needed and a maximum pain score of 8 limits the procedure. Post-procedure analgesia may be required."
45646630|NCT04854265|Other|Mindfulness Meditation|Mindfulness meditation will include mindfulness based stress reduction program, Qigong, Tai Chi exercise, Yoga, and Pranayama breathing exercise.
45646631|NCT02735057|Drug|Carboplatin|
45646632|NCT04433507|Procedure|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is performed through a standard 5-port technique. After dissection of the greater curvature of the stomach, a narrow tube-like stomach is created after stapling off the lateral aspect of the stomach using a 40 French bougie as a guide.
45646633|NCT04433507|Procedure|Hiatal Hernia repair|Hiatal hernia repair consists in a circumferential dissection of the diaphragmatic crura to achieve an intra abdominal esophageal length of 2-3 cm. The crura will then be closed anteriorly and posteriorly using nonabsorbable sutures.
45646634|NCT04363385|Biological|Biological test|Blood sample
45646635|NCT04800991|Device|Rhexium Onco Nutrition|"The research devices in this study are classified into subject mobile application and investigator web portal with no invasive action on the human body"
45920085|NCT00085969|Drug|Placebo 0.08 mL once daily|Subcutaneously injected, 0.08 mL, once daily
45920086|NCT00085969|Drug|B - Exenatide 10 mcg twice daily|Subcutaneously injected, 10 mcg (0.04 mL), twice daily
45920087|NCT00085969|Drug|C - Exenatide 10 mcg once daily|Subcutaneously injected, 10 mcg (0.04 mL), once daily
45920088|NCT00085969|Drug|Exenatide 20 mcg once daily|Subcutaneously injected, 20 mcg (0.08 mL), once daily
45920089|NCT04798092|Procedure|parathyroidectomy|surgical removal of parathyroid adenoma(s) with postoperative biological cure
45920090|NCT00086086|Drug|Darbepoetin Alfa|
45920091|NCT00006092|Drug|Arsenic Trioxide|
45920092|NCT00086125|Drug|ridaforolimus|AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
45920093|NCT00086164|Drug|edifoligide (E2F Decoy)|
45789967|NCT05124093|Procedure|Apnoeic oxygenation|"After 2mins 45 seconds of pre-oxygenation with high-flow nasal oxygen at Fio2 1.0 at 50L/min, anaesthesia is induced with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions administered until study conclusion.~At the onset of apnoea, 1mg/kg rocuronium administered. Jaw thrust performed. High-flow nasal oxygen adjusted to the randomised flow rate. Videolaryngoscopy after 1 minute of apnoea. Airway patency maintained. Tracheal intubation after 4 minutes of apnoea.~Positive pressure ventilation commenced at Spo2 92%. Failure to obtain view of glottis with videolaryngoscope results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after each minute of apnoea until six minutes of apnoea, and every two minutes of apnoea thereafter, until Spo2 92%."
45646636|NCT05431361|Other|Prehabilitation|A Registered Kinesiologist (RKin) will provide the exercise prescription, consisting of 4-5 days of aerobic exercise training and 2-3 days of resistance exercise training of major muscle groups, during a remotely delivered familiarization session using Microsoft Teams. The 60-minute remote program introduction will include a description and demonstration of all of the exercises that will follow the baseline assessment. Patients will be prescribed an individualized exercise program considering: (1) their exercise preferences, (2) their current physical capacity, (3) previous medical history, and (4) presence of underlying comorbidities, mobility, and skeletal fragility concerns [NOTE: the location/impact of a tumour is not applicable for PROPELLER as it was in REB#5901, and is thus not included here]. The participant will have an opportunity to execute the exercises in the remote presence of the RKin who will provide corrective feedback where applicable.
45646637|NCT04790851|Biological|COVAX+IIV4; COVAX+PPV23|1st dose : combined vaccination of COVAX+IIV4; 2nd dose: combined vaccination of COVAX+PPV23
45646638|NCT04790851|Biological|COVAX only (1st and 2nd dose)|1st dose: COVAX only; 2nd dose: COVAX only
45646639|NCT04790851|Biological|IIV4 for the 1st dose and PPV23 for the 2nd dose|1st dose: IIV4 only; 2nd dose: PPV23 only
45646640|NCT05431283|Drug|Tofacitinib|This study aims to assess the effectiveness of TOFA
45646641|NCT05391529|Behavioral|Interview|Semi structured patient interview via telephone
45646642|NCT03208985|Drug|Use Phase (Ulipristal Acetate, 30 mg)|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take 30 mg of ulipristal acetate.~Subjects are to use the investigational product based on their understanding of the directions on the outer packaging including Drug Facts Label and inside the product packaging (in the Consumer Information Leaflet)."
45789968|NCT05119803|Device|Spinal Mouse (IDIAG M360 )|This device is an electronic computer-aided measuring december that measures the range of motion of the spine, evaluates the angle and shape of the spine in the sagittal and frontal planes. The device provides data to the computer via Bluetooth, and the measured curvatures are displayed on the computer screen. The method has no medical risks or dangers. The device has two rotating wheels that follow the spinous protrusions of the spine, and the distance and angle measurements are transferred from the device to the computer.
45789969|NCT05119803|Other|Nine Hole Peg Test|The nine-hole peg test is a simple, fast and manual skill test that has been proven to be valid and reliable in measuring upper limb function in Parkinson's patients. While the patient is sitting, he is asked to insert nine sticks into the holes of the test box with nine holes one by one as fast as possible and remove them back when he is finished
45789970|NCT00370929|Behavioral|Meditation|
45789971|NCT04390737|Drug|HH2853 Tablets|Proposed daily dose (BID): 50mg, 100mg, 200mg, 400mg, 600mg, 800mg, 1000mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the MTD in order to better understand safety, PK or PD.
45789972|NCT00371007|Drug|MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks|
45789973|NCT00371007|Drug|Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks|
45789974|NCT05099289|Device|AtaCor EV-ICD Lead|Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
45789975|NCT02421510|Drug|Sotagliflozin|High dose Sotagliflozin, once daily, before the first meal of the day
45789976|NCT02421510|Drug|Sotagliflozin|Low dose Sotagliflozin,once daily, before the first meal of the day
45789977|NCT02421510|Drug|Placebo|Placebo, once daily, before the first meal of the day
45789978|NCT05099133|Drug|LEO 138559|LEO 138559 is an antibody given by injection just under the skin.
45789979|NCT05099133|Drug|LEO 138559 Placebo|LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except the medical ingredient LEO 138559.
45789980|NCT00552617|Drug|Sugammadex|"After induction of anesthesia an intubation dose of (Neuromuscular blocking agent) NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered"
45789981|NCT00552617|Drug|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arm 1) or 0.1 mg/kg vecuronium (arm 6).~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of Placebo IV was administered"
45789982|NCT00552617|Drug|Rocuronium|"After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary."
45789983|NCT00552617|Drug|Vecuronium|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV. Maintenance doses of 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.
45789984|NCT04387305|Drug|Tranexamic acid injection|Active drug is provided to participants as described based on the TXA arm they are randomized to.
45789985|NCT04298307|Other|Intracoronary lithotripsy (ICL)|ICL using the Shockwave catheter.
45920094|NCT00086203|Drug|Talabostat mesylate (PT-100) tablets|
45920095|NCT00086203|Drug|Rituximab|
45920096|NCT00006095|Drug|irinotecan hydrochloride|
45920097|NCT00006095|Drug|vincristine sulfate|
45789986|NCT05585021|Dietary Supplement|Wonderlab Kids instant probiotics|"During study intervention, subjects are required to take the randomly assigned product based on the randomization list.~Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, take it half an hour after meal.1 bottle a day. Lasting for 24 weeks intervention period."
45789987|NCT05585021|Dietary Supplement|Instant probiotic placebo|"Subjects are required to take the randomly assigned Instant probiotic placebo based on the randomization list.~Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, half an hour after meal.~1 bottle a day. Lasting for 24 weeks intervention period."
45646643|NCT03644953|Drug|Hydroxyurea|Participants will be started on hydroxyurea 20 ± 2.5 mg/kg/day in addition to continuing simple chronic transfusion every 4 weeks ± 1 week. Hydroxyurea will be dose escalated to achieve a HAT target dose (HAT-TD). Hydroxyurea will be increased by 5 mg/kg/day after 8 weeks of a dose if HAT-TD is not achieved (maximum daily dose 2,000 mg). After HAT-TD has been achieved, minor dose increases may occur if subject grows a significant amount to maintain the same mg/kg dose.
45646644|NCT03630835|Other|99mTc-Annexin-V-128 uptake on scintigraphy|"An intravenous catheter will be placed in the forearm and a dose of 370 Mega-Becquerels of 99mTc-Annexin-V-128 (1-2 ml) over 10 seconds will be injected through the catheter. The patient will wait for 90 minutes in semi-supine position for the clearance of the radiotracer from blood. At 90 minutes p.i., the patient will be placed in a supine position on the bed of a SPECT-CT gamma-camera. A SPECT acquisition including the heart and the brain will be performed over 20 minutes. At the end of the SPECT acquisition, the bed will move to the CT of the imaging system. A CT angiography will be acquired during the intravenous injection of 30-40 ml of iodinated CT contrast agent from the heart to the brain to localize the signal on the SPECT images. The iodinated contrast agent that is currently available at Bichat Hospital for CTA is Iomeron 400 provided by Bracco Imaging.~The total duration of the imaging study will be 2 hours."
45789988|NCT05056077|Other|Counseling|Receive support person coaching
45789989|NCT05056077|Other|Educational Intervention|Receive personal report and booklet on nutrition and physical activity for patients with colon or rectal cancer
45789990|NCT05056077|Behavioral|Health Education|Receive health coaching
45789991|NCT05056077|Other|Health Promotion and Education - Direct Text Messaging|Receive text messages
45789992|NCT05056077|Other|Health Promotion and Education - Digital health tool kit|Receive digital health tool kit
45789993|NCT05056077|Other|Questionnaires|Quality of Life and Behavioral Questionnaires
45789994|NCT02421120|Drug|Ceftolozane/Tazobactam|1 hour intravenous infusion
45789995|NCT04897542|Drug|Gallium-68 NODAGA-JR11|Each patient receive a single intravenous injection of Gallium-68 NODAGA-JR11 (40ug/150-200MBq) PET/CT, and undergo PET/CT scan at 40-60 min post-injection.
45789996|NCT03022877|Drug|Levosimendan|In a prospective randomized setting, patients are included with an acute STEMI of the anterior wall. A bolus administration Levosimendan with/without following continuous infusion over 24 hours compared to a control group (placebo) will be examined. The initiation of therapy is carried out for 10 min. prior to reperfusion. The coronary Intervention is performed immediately after inclusion at the latest within 6 hours after the onset of symptoms. The administration of Levosimendan is based on a fixed schema: Bolus: 12 µg/kg over 10 min I. V., starting 10 min before recanalization and an addition of 0.1-0.2 µg/kg/min i. v. for 24 hours in the continuous infusion group.
45789997|NCT05053581|Other|Survey|Patients will complete 7 questionnaires at inclusion (T0) and 1,3 and 6 months after start of CPAP treatment
45789998|NCT04279587|Behavioral|Residential camp|Intensive education at a residential camp.
45789999|NCT02420262|Drug|insulin degludec/liraglutide|Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
45790000|NCT02420262|Drug|insulin glargine|Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
45790001|NCT02420262|Drug|insulin aspart|Injected s.c./subcutaneously (under the skin) before each main meal.
45790002|NCT04276701|Biological|blood sample|35 ml whole blood for Peripheral blood mononuclear cell (PBMC), serum and plasma
45790003|NCT04276701|Other|Ultrasonography assessment|assessment of atherosclerotic plaques and measurement of carotid intima-media thickness (cIMT)
45790004|NCT04276701|Behavioral|questionnaires|Food and exercise questionnaires validated by the American heart Association
45790005|NCT05037747|Behavioral|Time-restricted feeding(TRF)|The TRF group was asked to restrict the eating window to 8 hours a day, during waking hours and also continue a low-protein diet.
45790006|NCT02468427|Other|hands-on teaching|Training session of 30 minutes duration with every proband performing a vacuum extraction on a pelvic training model.
45790007|NCT02468427|Other|Frontal teaching|Training session of 30 minutes duration consisting of a video which demonstrates how to perform a vacuum extraction on a pelvic training model.
45790008|NCT04264455|Device|Biomonitor|Patients receive a Biomonitor only
45790009|NCT04264455|Device|Life Vest|Patients receive a Wearable Cardioverter-Defibrillator; a Biomonitor is implanted additionally
45790010|NCT04264455|Device|Implantable Cardioverter-Defibrillator (ICD)|Patients receive an Implantable Cardioverter-Defibrillator (ICD)
45790011|NCT04237077|Other|telephone coaching program|telephone coaching program : 7 phone calls by nurse
45790012|NCT04237077|Other|no telephone coaching program|no telephone coaching program : 7 phone calls by nurse
45790013|NCT04176549|Other|Management of Ectopic Pregnancy|Expectant, Medical or Surgical management of Ectopic Pregnancy
45790014|NCT04176549|Other|Management of termination of pregnancy|Surgical termination of pregnancy
45790015|NCT04176549|Other|Elective management of gynaecology patients|Elective hysterectomy and salpingo-oophorectomy
45790016|NCT00369993|Drug|fluticasone propionate/salmeterol|
45790017|NCT04174755|Drug|Semaglutide Injectable Product|Semaglutide 0.25 mg subcutaneously once weekly for 4 weeks, then Semaglutide 0.5 mg subcutaneously once weekly for 4 weeks, then Semaglutide 1 mg subcutaneously once weekly for 20 weeks. Total treatment duration 28 weeks.
45790018|NCT04174755|Behavioral|Standard of care|Diet and exercise advice for 40 weeks
45790019|NCT00552305|Drug|lacosamide|50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial
45646645|NCT03067337|Device|Stainless Steel Crown (Group A)|Full coverage restoration for multi-surface carious teeth
45646646|NCT03067337|Device|NuSmile Zirconia Crowns (Group B)|Full coverage restoration for multi-surface carious teeth
45646647|NCT04764097|Drug|Dapagliflozin|SGTL2 Inhibitor
45790020|NCT04738305|Other|Dignity Therapy|"The Italian version Dignity Therapy intervention (Chochinov HM 2015) has been delivered. Intervention questions were not previously delivered to patients.~DT interview was provided to patients by Specifically trained Nurses. Interviews were audio-recorded and transcribed then revised by the patients to develop the final Generativity Document. Generativity Document was delivered to patients that could share it with their loved ones."
45646648|NCT04764097|Drug|Placebo|Placebo
45790021|NCT02298777|Procedure|- Skin biopsy - Urine sample - Blood sample|
45790022|NCT02278887|Procedure|Translational research|Before during and at progression/regression biopsies and blood will be taken for translational research
45790023|NCT02278887|Drug|Cyclophosphamide|The patient receives 2 days cyclophosphamide via IV to deplete T-cells.
45790024|NCT02278887|Drug|Fludarabine|The patient receives 5 days fludarabine via IV to deplete T-cells.
45790025|NCT02278887|Drug|Interleukin-2|After infusion of the TIL, the patient receives IL-2 to keep the TIL active.
45646649|NCT02922023|Device|Ambulatory blood pressure monitor (ABPM)|"ABPM allows providers to obtain blood pressure readings over a 24 hour period, to assess blood pressure at night to determine dipping status, and to evaluate the efficacy of anti-hypertensive therapy."
45790026|NCT02278887|Drug|Ipilimumab infusion|In arm A patients will be treated with 4 infusion of ipilimumab
45646650|NCT02922023|Other|Chronotherapy|Chronotherapy group will receive a shift in the timing of one of their antihypertensive medications to nighttime dosing without consulting their ABPM results.
45646651|NCT04761211|Device|smart bra|This is a patented infrared breast examination bra
45646652|NCT03605017|Behavioral|Virtual Reality Executive Function Training (VREFT)|
45790027|NCT02989181|Device|Continues Positive Airway Pressure (CPAP)|Mask with positive airway pressure during exhalation which maintains the airway open
45790028|NCT04168671|Diagnostic Test|Continuous laryngoscopy during exercise test|Continuous laryngoscopy during exercise test
45790029|NCT02664077|Drug|Regorafenib|3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
45790030|NCT02664077|Drug|Placebo|3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
45790031|NCT04168203|Drug|Apixaban 2.5 MG|apixaban 2.5 mg orally twice daily for a duration of 12 months
45790032|NCT04168203|Drug|Placebo oral tablet|placebo oral tables twice daily for a duration of 12 months
45790033|NCT04152993|Device|NeuroPace® RNS® System|In this intervention, patients suffering from PTSD undergo a surgical procedure to implant the responsive neurostimulation device (RNS, NeuroPace). This procedure involves the placement of a depth lead bilaterally in the amygdala and hippocampus following a trans-occipital trajectory. The two leads are then connected to a pulse generator fixated to the skull. RNS is able to detect specific signals from the target and to respond with a programmed electrical stimulation. One month after the implantation of the system, the patients will undergo 3 tasks: a fear conditioning task, the international affective picture system and the subsequent memory recall paradigm. These tasks will yield electrophysiological biomarkers of arousal and re-experiencing. We will then program RNS to detect and respond to those biomarkers. The patients will be followed longitudinally for improvement and evidence of target engagement as seen on cerebral metabolism and global electroencephalography.
45646653|NCT02902757|Procedure|Computed Tomography|Undergo FDG PET/CT
45790034|NCT02618993|Procedure|Realization of the V3 block in maxillofacial surgeries|bilateral mandibular block in maxillofacial surgeries
45646654|NCT02902757|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
45646655|NCT02902757|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
45790035|NCT02277665|Behavioral|CUD Treatment|
45790036|NCT02277665|Behavioral|Tobacco Treatment|
45646656|NCT05391451|Procedure|efficacy of quadratus lumborum block in post-operative analgesia in kidney transplant surgery|no premedication for anxiolytic purposes before surgery. Cimetidin 200mg can be administrated for Mendelson syndrome prevention. After general anesthesia induction, echo-guided quadratus lumborum block is performed by applying 20ml of levobupivacaine
45646657|NCT05391451|Procedure|general anesthesia|general anesthesia is the current technique for kidney transplant surgery. The protocol involves the combination of several drugs: Propofol, Remifentanil, Ketamin, Atracurium or Cisatracurium. Curarization monitoring is systematic.
45790037|NCT04135989|Device|Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.|Implantation of polymer-free, amphilimus-eluting, drug-eluting stents
45790038|NCT04135989|Device|Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.|Implantation of biodegradable-polymer, everolimus-eluting, drug-eluting stents
45790039|NCT04135989|Drug|Personalized DAPT duration|Duration of dual antiplatelet therapy according to DAPT score for 3- or 6- months in patients with low DAPT score (stable CAD or ACS, respectively) or for 24-months in patients with high DAPT score
45790040|NCT04135989|Drug|Standard DAPT duration|Duration of dual antiplatelet therapy for 12 months.
45790041|NCT04987749|Device|intermittent theta burst stimulation|stimulatory protocol
45646658|NCT03140137|Drug|Checkpoint inhibitor therapy|Treatment by ipilimumab, nivolumab or pembrolizumab for advanced cancer in clinical practice
45646659|NCT03520309|Procedure|Dental treatment|Treatment of all dental restorations of the children according to the diagnosis criteria
45646660|NCT03110341|Drug|Erythropoietin|rhEPO 750U/kg was injected within 72h after birth, subsequent injection was given every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections.
45646661|NCT03110341|Drug|Normal saline|placebo (Normal saline 3 ml/kg birth weight) was injected within 72h after birth, subsequent injection was given every other day for 2 weeks.
45646662|NCT03140215|Device|laryngeal mask insertion (Baska)|
45646663|NCT03140215|Device|laryngeal mask insertion (I-gel )|
45790042|NCT02988479|Other|Out of pocket payments in patients|
45790043|NCT02011971|Drug|Vinpocetine|Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drug
45790044|NCT04690439|Device|Photobiomodulation therapy (PBMT)|The MLS M6 laser from ASA will be used to apply the laser therapy.
45790045|NCT04690439|Procedure|Manual Lymphatic drainage|Patients will receive twice weekly MLT executed by trained physiotherapist
45646664|NCT04720729|Biological|Chemotherapy monitoring by circulating tumor DNA analysis|"During the screening step (2nd chemotherapy line, cycle 1) : at each time point (L2C1D1 & L2C1D15), 30 ml of blood will be drawn on special tubes with conservative suited for ctDNA analyses (e.g. STRECK® tubes).Then cell-free circulating DNA (cfcDNA) will be extracted from plasma following the manufacturer recommendations. cfcDNA will be quantified, and minimum 500-1000 copies will be analyzed by droplet digital PCR (ddPCR). Analyses will define if ctDNA could be detected during L2.~For the interventional step, from L3 (3rd chemotherapy line) : 20 ml of blood will be drawn at L3C1D1 and L3C1D15. If ctDNA at D15 shows a major drop (> 40%) from D1, treatment will be continued. If ctDNA at D15 shows no major drop from D1, chemotherapy will be changed."
45646665|NCT03511417|Device|over-the-counter hearing device|Individuals will use commercially-available over-the-counter hearing devices for specified periods of time.
45790046|NCT03168971|Behavioral|Managing Anxiety from Cancer (MAC)|The intervention consists of seven telephone-administered sessions. Session topics include psychoeducation on anxiety, behavioral strategies for managing anxiety, cognitive restructuring, communication skills training, acceptance techniques, problem-solving strategies, and planning for future anxiety. Session content is tailored for older adults and caregivers of older adults with cancer.
45790047|NCT01854255|Drug|doxorubicin and cisplatin|doxorubicin and cisplatin as intraperitoneal chemotherapy
45790048|NCT01555281|Drug|Nelfinavir|In phase II, the recommended dose of nelfinavir will be administered orally twice daily (in the morning and in the evening) on d1-d21 every 28 days for a maximum of 4 cycles
45790049|NCT01555281|Drug|Lenalidomide|25 mg of lenalidomide (capsules) will be administered orally daily on d1-d21 every 28 days for a maximum of 4 cycles
45790050|NCT01555281|Drug|Dexamethasone|40 mg (for patients <75 years) or 20 mg (for patients ≥75 years) of dexamethasone (tablets) will be administered orally once per day on d1, 8, 15 and 22 every 28 days for a maximum of 4 cycles
45790051|NCT04945629|Drug|Alveolar ridge preservation with a PRP (PRGF-Endoret)|Filling of the alveolus with PRGF clot and fibrin plug.
45790052|NCT04945629|Drug|Blood clot and simple suture|Filling the alveolus with blood clot
45790053|NCT04939389|Diagnostic Test|Orthelligent Pro|The sensor is attached to the knee of the participant and eight different movement exercises are performed
45790054|NCT04938765|Drug|Magnesium sulfate|Effect of 40mg/kg Magnesium sulfate bolus dosed to ideal body weight on intraoperative neuromonitoring
45790055|NCT04938765|Drug|Normal Saline|20 ml of normal saline bolus will be administered to the control group over 10 mins.
45790056|NCT04932369|Behavioral|Emotion Regulation training based on DBT|trained about emotion regulation and problem solving during eight 90-min group sessions
46071411|NCT02843334|Biological|Dried blood spot (DBS) sampling|DBS be collected during a hemodialysis session and deposited on an anonymized blotting paper. Laboratory ARCHIMED Life Science GmbH, based in Austria will perform all the biological analysis. For the diagnosis, men will have a measure of the alpha-galactosidase activity level, whereas screening in women will be established on the association of alpha-galactosidase activity and lyso-GB3 analyses. If results are compatible, genetic mutation will be searches in order to confirm the diagnosis for women.
45646666|NCT03440437|Drug|FS118|Dosing of participants will occur intravenously (IV) weekly in 3-week treatment cycles until iCPD (i.e., immune confirmed progressive disease), unacceptable toxicity, or discontinuation.
45790057|NCT00370539|Drug|verteporfin, bevacizumab, triamcinolone acetonide|
45790058|NCT03996057|Drug|Methenamine Hippurate 1000 MG|Discussed in arm/group description
45790059|NCT03996057|Drug|Vaginal estrogen|Any form of low dose vaginal estrogen, whether ring, cream, tablet, or capsule. Depends on what patient is already using.
45790060|NCT03996057|Dietary Supplement|D-mannose|Powder or tablet, depending on what patient is already using.
45790061|NCT04338243|Drug|Glumetinib|Phase Ib is a dose escalation study, the initial dose of Glumetinib is 300mg, then will be escalated to 400mg，according to the result of Phase Ib， will confirm the RP2D
45790062|NCT01330719|Procedure|Diseased periodontal treatment|"Treatment includes scaling and root planing with systemic antibiotics, Amoxicillin 500 mg and Metronidazole 250 mg tid 7 days. At certain intervals after the scaling and root planing, your gums will be reevaluated. You will receive further surgical gum therapy only if your gums haven't shown improvement after first treatment on the reevaluation appointments. If surgery is needed, a bone substituting material may be necessary to fill the spaces where bone has been destroyed by the disease. Extraction of teeth might also be part of gum treatment if the disease is very severe. Re-treatment with antibiotics also may be necessary depending on the response after treatment. You are usually re-examined and receive additional cleanings every 3 to 6 months to ensure the disease does not come back."
45790063|NCT01330719|Procedure|Conventional periodontal treatment|Scaling and gum measurement will be taken to compare to the treated group.- If it is determined that you do not have this disease, a conventional cleaning is done, usually every 6 months. This is all part of normal clinical care.
45790064|NCT03966729|Other|Time (outcome)|
45790065|NCT04910919|Dietary Supplement|Honey|Participants 51 - 100 will receive the standard of care treatment as usual plus 1 tsp of honey with every dose of acetaminophen.
46071412|NCT05335746|Diagnostic Test|Optical coherence tomography angiography (OCT-A)|Optical coherence tomography angiography scanning will be done for all subjects in the study.
46071413|NCT02843490|Drug|Ranibizumab|Three injections (o.5 mg Ranibizumab) within the first three months is followed by an individual therapy interval based on the clinical progress (PRN)
46071414|NCT00902174|Drug|imatinib mesylate|Two or 4 imatinib mesylate (QTI571) 100 mg film coated tablets once daily.
46071415|NCT00902174|Drug|Placebo|Placebo to imatinib 100 mg film coated tablets
45646667|NCT03273751|Procedure|Remote Ischemic Preconditioning|After induction of anesthesia, RIPC consisted of four 5-min cycles of limb ischemia induced by a blood pressure cuff placed on the upper arm and inflated to 250 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated.
45646668|NCT03273751|Procedure|Sham control|After induction of anesthesia, sham control consisted of the placement of a blood pressure cuff on the upper arm with no inflation during the surgery.
45920098|NCT00086242|Behavioral|Psychosocial Telephone Counseling (PTC)|Eligible patients are randomized to receive psychosocial telephone counseling (PTC) or usual care.The PTC intervention was specifically designed to help women cope with the stressful events and feelings of distress associated with cervical cancer. The PTC arm of the study received six counseling sessions, ~45 to 50 min in length, in their preferred language, consisting of five consecutive weekly sessions and a 1-month booster session, delivered by a psychologist. A review letter, generated by the counselor after each session, recapitulated the session's contents and reinforced adaptive coping strategies.
45790066|NCT04910919|Other|Standard of Care|The first 50 participants will receive treatment as usual (alternating weight-based dosing of acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic).
45790067|NCT04905225|Procedure|Ascending aortic replacement|Surgical access will be performed through a median sternotomy. Ascending aortic repair is performed under conditions of cardiopulmonary bypass (CPB) and MHCA with unilateral ACP via innominate artery with a flow rate of 8-10 ml/kg/min and perfusion pressure of 60-80 mmHg. Once CPB is instituted, the aortic cross-clamp is applied, and the heart is arrested with antegrade cardioplegia. Hemiarch replacement involves resection lesser curve of the aortic arch from the base of the innominate artery (Zone 0) to a point immediately distal to the nadir of the lesser curvature (Zone 3 or Zone 2 if the left subclavian artery was too far).
45790068|NCT03928509|Other|No intervention|No intervention
45790069|NCT03150875|Drug|IBI308|Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.
45790070|NCT03150875|Drug|Docetaxel|As 2nd line treatment to subjects with squamous NSCLC
45790071|NCT04900623|Device|NavDx HPV ctDNA Testing|Blood will be collected and shared with an outside lab for analysis. This test will be done at Week 4 and at End of Treatment. This test will be done at at End of Treatment and in follow-up at 3, 6, 9, and 12 months after completing the study treatment. In years 2 and 3 after treatment, the test will be collected every 6 months or twice a year. The specimens will be identifiable. The specimens will be banked for future use.
45790072|NCT04900623|Radiation|Radiotherapy|Radiation Therapy (administered daily, Monday-Friday). Higher risk participants will receive standard radiation dose for up to 7-8 weeks. Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.
45790073|NCT04900623|Drug|Chemotherapy drug|"Chemotherapy and radiation therapy are both considered standard treatments~Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy."
45920099|NCT00086320|Drug|Paliperidone ER|
45646669|NCT03136315|Other|INFERNAL Intervention|The intervention consists in serum and urinary dosage (creatinine and Cystatin C) at the beginning and the end of the 110 km race.
45646670|NCT03152539|Radiation|MRI|
45646671|NCT03152539|Device|EEG|
45790074|NCT04893837|Device|Standard care plus infrascans|Hourly infrascans to detect expanding intracranial hematomas
45790075|NCT00552071|Drug|Octreotide LAR 30 MG Injection|Stable dose of 30 mg octreotide LAR, or a dose determined by historical dosing, delivered every 28 days for 3 months.
45790076|NCT00673335|Drug|letrozole|
45790077|NCT00673335|Drug|Placebo|
45790078|NCT04687865|Other|Biobank|"For each patient included in the study the following samples will be collected at the indicated time points after transplantation:~Serum samples and plasma sample: Day1, Month 1, Month 3, Month 6, Month 12, month 60, month 120 and at the time of each allograft biopsy.~Urines samples: Month 3 and Month 12 and at the time of each allograft biopsy.~Peripheral Blood Mononuclear Cell (PBMC): for each organ allograft biopsy.~Allograft biopsies: systematically at Month 3, and Month 12, and for cause in case of allograft dysfunction."
45790079|NCT02988557|Procedure|walking on a treadmill with a sloped surface|walking on a treadmill with a sloped surface
45790080|NCT02988557|Device|treadmill|walking on a treadmill with a sloped surface
45790081|NCT00483249|Device|Endovascular Branched Stent-Graft|Industry manufactured branched stent-graft for treatment of TAAA/PVAAA.
45790082|NCT05530889|Device|TEST Lens|ACUVUE® Theravision® with Ketotifen
45790083|NCT05530889|Device|CONTROL Lens|1-DAY ACUVUE® MOIST.
45790084|NCT04880889|Drug|BL 3000|capsule 500 mg
45790085|NCT04880889|Drug|Reference Pantogar|capsule
45790086|NCT04880889|Drug|BL3000 Placebo|capsule 500 mg
45790087|NCT04880889|Drug|Pantogar - Placebo|capsule
45920100|NCT00086359|Drug|Abacavir sulfate, lamivudine, and zidovudine|one pill twice daily
45646672|NCT03152539|Device|NIRS|
45646673|NCT04648189|Drug|Cetuximab|A single dose of cetuximab, 400mg/m2, will be administered 72 to 48 hours prior to surgery
45920101|NCT00086359|Drug|Lamivudine/zidovudine|one pill twice daily
45920102|NCT00086359|Drug|Lopinavir/ritonavir|four pills twice daily
46071416|NCT01609842|Other|Multifaceted Intervention with pharmacist and IVR|An alerted inpatient pharmacists will bring the clopidogrel medication to the patient who has received a stent. The patient will return home and receive IVR messages about the importance of their medication as well as a refill reminder call.
45646674|NCT04551313|Behavioral|social skill group|We plan to address basic interactional and conversational skills first, then focus on teaching perspective-taking and theory of mind skills.
45646675|NCT03136549|Other|Thermo-softening|The thermosoftening treatment of the tubes was performed by using a warm cabinet set to 45°C (approximately 117°F). One bottle of normal saline (1 L) containing a thermometer and three tubes (6.0 -7.0 mm ID) was put into a chamber of the cabinet 30 min before intubation.
45920103|NCT04788771|Procedure|Tracheal intubation in laparoscopic extraperitoneal hernia repair|laryngeal mask airway in laparoscopic extraperitoneal hernia repair
45920104|NCT00086398|Behavioral|Behavior Therapy|
45920105|NCT00006098|Drug|bortezomib|
45920106|NCT00086593|Drug|lamotrigine|
45920107|NCT00387569|Biological|MnB vaccine rLP8026|MnB vaccine at 20ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
46071417|NCT05337176|Other|app-coo application|"The Montreal Cognitive Assessment (MoCA) is a measure designed specifically for detecting mental cognitive impairment(MCI) APP-Coo-Balance-Test can assess the oscillation of the trunk in different static positions: Feet Together, On a Broad Base (medial malleoli 30 cm apart) , and during the gait Dynamic(Arcuria et al., 2020)."
45646676|NCT03136549|Other|Room temperature|nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
45646677|NCT05377801|Behavioral|Multi-dimensional fall prevention intervention program for 12 weeks|The intervention group of this study is a multi-dimensional intervention conducted by nursing students over a 12-week period, consisting of four parts: individualized balance and strength training, vision screening, drug evaluation, home risk assessment and home repair and transformation. These components were carried out through a combination of personal home visits and telephone interviews.
45646678|NCT04537897|Drug|BI 474121|BI474121
45646679|NCT04537897|Drug|Midazolam|Midazolam
45646680|NCT04537897|Drug|Placebo|Placebo
45646681|NCT04543513|Other|Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
45646682|NCT04421053|Behavioral|prenatal care for women with GDM|we conduct prenatal care for GDM pregnancies through both prenatal clinic and app.
45646683|NCT04405063|Device|Paclitaxel Coated PTCA Balloon Catheter|Drug coated balloon
45646684|NCT02876185|Other|Monitoring by an orthoptist then by an ophthalmologist|At each visit, the usual monitoring tests will be collected and viewed by the orthoptist then by the ophthalmologist concerning the necessity of an anticipated ophthalmological consultation
45646685|NCT05090527|Diagnostic Test|Risk stratification|advanced penicillin challenge after risk stratification
45646686|NCT04400305|Behavioral|Digital Health Online Platform|"The website has 10 lessons that the participant will gain access to on a bi-weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity"
45646687|NCT04381039|Device|Insole|3D printing insole (Nylon), 3D printing insole (TPU), CNC machine insole (EVA), shoe only
45646688|NCT01672853|Biological|Simtuzumab|Subcutaneous injections weekly for a total of 96 injections
45790088|NCT04738383|Procedure|Version 1: Paramedic|Instead of a physician, who is constantly present, a paramedic is present next to the instructor during the sessions, who can give first aid in case of an emergency and bridge the time until the ambulance arrives on site. The physician still acts as a supervisor visiting the group roughly every six weeks.
45790089|NCT04738383|Procedure|Version 2: Physician-on-call|This version implicates that a physician is not physically present but is on call during the sessions and must be constantly accessible by phone and able to arrive within three minutes in case of an emergency. To ensure this, version two should be implemented in facilities, which are linked to cardiac or rehabilitation center.
46071418|NCT04201808|Drug|Tenofovir Alafenamide 25 MG|All patients will receive Tenofovir Alafenamide, 25mg PO, to treat chronic hepatitis B and their previous suboptimal response over the study duration of 48 weeks. Patients will be followed every 12 weeks for medication adherence, medication refill, and follow up as per standard of care.
45646689|NCT01672853|Biological|Placebo|Subcutaneous injections weekly for a total of 96 injections
45646690|NCT05090449|Drug|Chlorthalidone (HIGROTON® 50)|Tablets with 50mg of Chlorthalidone, product de Sandoz, S.A. de C.V.
45646691|NCT05090449|Drug|Losartan (COZZAR®)|Losartan potassium 100 mg tablet, a product of Schering-Plough, S.A. C.V.
45646692|NCT05090449|Drug|A1+ A2 Co-administration of Chlorthalidone and Losartan|50mg chlorthalidone + 100 mg losartan potassium
45646693|NCT05090449|Drug|Chlorthalidone + Losartan Fixed-Dose combination|Tablets with fixed combination of Chlorthalidone 25 mg and Losartan Potassium
45790090|NCT04738383|Procedure|Version 3: Trained instructor|The sessions take place with the instructor only, who receives a comprehensive emergency training before and during the model phase and replaces the constantly present physician. Just like in the previous versions the physician still acts as a supervisor visiting the group roughly every six weeks.
45790091|NCT03844347|Behavioral|Stress management sessions|Stress management sessions are proposed to the patients and consist of small exercises focused on breathing and bodily sensations. Each accompanying person has access to different exercises. The sessions are adapted to the state of the patient to promote his well-being, before or after his/her operation. The duration of a preoperative session is 1 hour, the duration of the postoperative sessions is 15 minutes.
45790092|NCT04866771|Other|Transcranial Direct Current Stimulation (tDCS)|Noninvasive brain stimulation
45790093|NCT04866771|Other|Sham tDCS + anodal tDCS|Fake noninvasive brain stimulation or anodal noninvasive brain stimulation
45790094|NCT03833427|Drug|Selumetinib|Selumetinib oral capsules administered BID at escalating dose levels. Selumetinib administered only in weeks 1&2 of each 3-week treatment cycle.
45790095|NCT03833427|Biological|Pembrolizumab|Pembrolizumab administered by IV infusion at 200 mg Q3W, given on cycle day 1 of each 3-week treatment cycle.
45790096|NCT00371085|Behavioral|education|Video-based educational program for heart failure focus on daily weights, medication taking, and salt restriction
45920108|NCT00387569|Biological|MnB vaccine rLP8026|MnB vaccine at 60ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
45920109|NCT00387569|Biological|MnB vaccine rLP8026|MnB vaccine at 200ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
45920110|NCT04784637|Device|Web Simulation Tool (WST)|WST will allow users of the Control-IQ system replay treatment scenarios in computer simulation, thereby allowing user training with carbohydrate and insulin action.
45646694|NCT05090137|Other|Diuretics|As per group descriptions
45790097|NCT00551759|Drug|5-Fluorouracil|given IV
45790098|NCT00551759|Drug|Oxaliplatin|given IV
46071419|NCT01341600|Drug|Clopidogrel|Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days.
46071420|NCT01341600|Drug|Omeprazole/Clopidogrel|After a washout of at least 1 week, participants will have the option to participate in a final intervention in which they will be given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
46071421|NCT04201886|Other|serum calprotectin|serum calcium binding leucocyte protein
45646695|NCT03067025|Device|Actigraphy|Actiwatch Spectrum Plus will be worn on the non-dominant wrist 24 hours/day for seven days. Actigraphy is a valid and reliable objective measure of sleep patterns, including sleep quality, duration, and timing when compared to polysomnography (PSG).
45646696|NCT05090059|Device|Lower limb myofascial trigger points f-ESWT|3 weekly sessions of focused Extracorporeal Shockwave treatment with a frequency of 5 Hz, an energy flux density of 0.05-0.167 mJ(millijoule)/mm2, administered on 3-4 myofascial lower limb trigger points (identified according to the approach of Fascial Manipulation), 1500 shocks per point.
45790099|NCT00551759|Drug|Cetuximab|given IV
45790100|NCT00551759|Drug|Docetaxel|given IV
45920111|NCT04784637|Device|Behavioral Adaptation Module (BAM)|BAM provides on-demand information to the participant primarily on glycemic risks.
45920112|NCT04784637|Device|Auto Titration Module (ATM)|ATM provides recommendations to the participant to periodically update insulin parameters.
45646697|NCT03067415|Drug|D565H(Latanoprost 25㎍/㎖)|D565H twice daily
45646698|NCT03067415|Drug|D565(Latanoprost 50㎍/㎖)|D565 once daily
45646699|NCT05089981|Drug|N acetyl cysteine|Intravenous use of N acetyl cysteine in prescribed doses
45920113|NCT04784637|Device|Automated Insulin Delivery (AID) System|The t:slim X2 insulin pump with Control-IQ technology, Tandem Diabetes Care will be the AID in this study.
46071422|NCT05334966|Other|Maternal Hyperoxygenation|Oxygen is given to mothers at 8L through a non-rebreather mask.
45646700|NCT05089981|Drug|Placebo of N acetyl cysteine|Intravenous Placebo of N Acetyl cysteine in look alike form (Normal saline)
45646701|NCT04271189|Drug|Metformin-Sitagliptin-Empaglifozin-Pioglitazone|1000 mg metformin (extended release) b.i.d., pioglitazone 15 mg b.i.d., sitagliptin 100 mg q.d., empaglifozin 10 mg q.d..
45646702|NCT04271189|Drug|Standard of care|Usual medical care to treat diabetes.
45646703|NCT05089747|Biological|Blood sampling for biomarker analysis (microRNA, circulating DNA…)|From one to four blood samplings: at diagnosis, after the first cycle of treatment, end of treatment, progressive disease (or end of study).
45790101|NCT00551759|Procedure|Surgery|Patients underwent surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab.
45920114|NCT00086632|Drug|oregovomab|
45920115|NCT00086710|Drug|Fuzeon|
45920116|NCT00006104|Biological|trastuzumab|
45920117|NCT00006104|Drug|docetaxel|
45920118|NCT00086827|Drug|romidepsin|Given IV
45920119|NCT00086827|Other|laboratory biomarker analysis|Correlative studies
46071423|NCT02845388|Drug|Sildenafil citrate|
46071424|NCT02845388|Drug|estradiol valerate|
46071425|NCT02843412|Procedure|choose two tumor tissue paraffin blocks|
46071426|NCT04357184|Other|Blood flow restriction training|BFRT is done with 4 exercises with low load resistance of 30% 1 repetition maximum
46071427|NCT02840760|Device|Repetitive Transcranial Magnetic Stimulation|Stimulate the primary motor cortex for 2 weeks.
46071428|NCT02845466|Biological|Becaplermin|0.25 cm of 100 µg/g Becaplermin gel topically per 1cm² of ulcer area applied 3 times per week for 6 weeks.
46071429|NCT02845466|Device|Promagran Dressing|44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC wound dressing applied 3 times per week for 4 weeks.
45790102|NCT00551759|Radiation|Radiotherapy|Patients underwent radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33.
45790103|NCT03817905|Other|Patient navigator|Intervention will utilize staff at the Seidman Cancer Center who are trained in patient navigation and have experience in navigating patients for breast cancer screening as well as sickle cell disease. The staff will undergo training for this study by study principal investigators which will include the target participant population, necessary steps in the navigation process and data that will be collected. In addition, they will receive brief training in supportive, listening technique. They will also be furnished with a telephone script for the initial participant contact.
45790104|NCT04856241|Other|Coaching|Physiotherapists (trained by the research team) train the coaches to deliver Prep-to-Play. The Physiotherapists will also provide face-to-face one-to-one support to each coach at their team's training session (two visits), with all their players.
45920120|NCT04784130|Behavioral|Physical Activity|Respondents will complete activity logs (step count, using pedometer) and surveys (two items from the Summary of Diabetes Self-care activities measure) for physical activity.
45920121|NCT04784130|Behavioral|Medication Adherence|Respondents will provide information on their medication adherence using a survey (questionnaire - MMAS-8).
45920122|NCT04784130|Behavioral|Dietary Modification|Respondents will complete food logs and surveys (three items from the Summary of Diabetes Self-care activities measure) for dietary intake.
45920123|NCT00086866|Biological|D1/3-MAGE-3-His fusion protein|
45920124|NCT00086866|Biological|SB-AS02B adjuvant|
45920125|NCT00086866|Biological|SB-AS15 adjuvant|
45920126|NCT00086944|Biological|oblimersen sodium|Given IV
45920127|NCT00086944|Biological|rituximab|Given IV
45920128|NCT00086944|Drug|ifosfamide|Given IV
45920129|NCT00086944|Drug|carboplatin|Given IV
46071430|NCT02845466|Device|Placebo Dressing|Inactive wound dressing.
46071431|NCT04345796|Drug|Carvedilol+Empagliflozin|Group A
46071432|NCT04345796|Drug|Carvedilol|Group B
46071433|NCT04345796|Drug|Empagliflozin|Group C
46071434|NCT04345796|Drug|Placebo|Group D
46071435|NCT00623623|Procedure|primary PCI|Standard primary PCI
46071436|NCT00623623|Drug|enoxaparin|Adjunctive treatment
46071437|NCT00623623|Procedure|catheterisation|Routine or rescue coronary intervention
46071438|NCT00623623|Drug|tenecteplase|Single, weight-adjusted i.v. bolus of tenecteplase
45790105|NCT04856241|Other|Peer support|Coaches shed. Coaches provide each other with support and ideas. Strategies to overcome barriers and motivate players.
45790106|NCT04856241|Other|Educational materials|Prep-to-Play program resources are available online for coaches and players to view
45790107|NCT04849377|Radiation|RT 50 Gy|Radiation Therapy (RT) 50 GY
45790108|NCT04849377|Radiation|RT 54 GY|Radiation Therapy (RT) 54 GY
45646704|NCT05730491|Behavioral|Social Learning and Cognitive Behavioral Therapy (SLCBT)|Participants assigned to this group will complete an online program with 3 modules, which will include strategies to promote wellness behaviors, use adaptive cognitive coping strategies, model wellness behaviors for their children, and determine when it is appropriate to take further action re: potential illness in their child. The website is interactive and self-guided. All participants will have access to the same resources and content, although based on responses to quizzes and skills practice questions, the automated feedback may differ slightly. The website includes treatment modules that share content via text, images, videos and recordings, a skills library that includes audio recordings of relaxation exercises, videos of other parents, and infographics to support skills practice, and behavioral assignments to record skills practice and receive automated feedback. Participants will review their knowledge at the end of each treatment module with brief quizzes.
45790109|NCT04849377|Radiation|RT 60 GY|Radiation Therapy (RT) 60 GY
45646705|NCT05730491|Behavioral|Attention Education Control|Participants assigned to the control group will receive access to a web program and complete 3 modules focused on child health and safety behaviors, such as sports and water safety. These participants will review written/visual content on the above topics, take quizzes to test knowledge gained, and will be provided with brief assignments to increase child safety behaviors. All participants assigned to the control group will have access to the same educational content.
45646706|NCT03349801|Other|No intervention|According to clinical practice.
45790110|NCT04849377|Other|Induction Therapy|Induction Therapy: Cisplatin, Docetaxel, Fluorouracil
45790111|NCT04849377|Drug|Carboplatin|Carboplatin AUC 9.0
45790112|NCT04849377|Drug|Cisplatin 200|200 mg/m2
45790113|NCT04849377|Drug|Cisplatin 240|240mg/m2
45790114|NCT03032237|Other|Nutritional intervention - protein-rich|"Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.~To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.~Intervention group will receive protein-rich meals and protein-rich foods and drinks."
45790115|NCT03032237|Other|Nutritional intervention - standard|"Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.~To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.~Control group will receive standard (not protein-rich) meals and standard foods and drinks."
45790116|NCT04738227|Radiation|Low-Level Laser Therapy|Low level laser will be applied and post laser results will be seen to assess any improvements.
45790117|NCT05441553|Genetic|VGB-R04|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant
45790118|NCT04768595|Dietary Supplement|Placebo|Two, 1g capsules taken daily with food
45790119|NCT04768595|Dietary Supplement|Ceto 10|Two, 1g capsules daily with food
45790120|NCT04768595|Dietary Supplement|Fish oil|Two, 1g capsules daily with food
45790121|NCT02874443|Other|Knowledge Translation of labor management guidelines|
45790122|NCT04738539|Drug|Contrast Enhanced Voiding Urosonography with Urodynamic Testing|We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.
45790123|NCT04738539|Diagnostic Test|Urodynamic Testing|We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.
45790124|NCT03784131|Drug|P-TEV|Replacement of vein with failing valves with personalized tissue engineering vein containing functional valves
45790125|NCT03770403|Biological|ARGX-113|Intravenous administration of ARGX-113
45790126|NCT03757533|Behavioral|Health Coaching|10 phone calls with a trained health coach
45790127|NCT03757533|Other|Surveys|Surveys to assess Behavioural and Psychosocial measures
45790128|NCT03023735|Other|None. This is an observational study|
45790129|NCT05511779|Drug|Brincidofovir|BCV 0.3 mg/kg BIW or 0.4 mg/kg BIW administered as a continuous IV infusion over 2 hours
45790130|NCT04832139|Drug|Marstacimab PFP|300 milligrams (mg) subcutaneous injection marstacimab PFP
45790131|NCT04832139|Drug|Marstacimab PFS|300 mg subcutaneous injection of marstacimab PFS
45790132|NCT03743415|Behavioral|Handbook|see arm/group descriptions
45790133|NCT03743415|Behavioral|TIP-C plus Handbook|see arm/group descriptions
45790134|NCT05510921|Other|Minimalist music group|Participants in this group will listen individually a live session of minimalist music piano piece, in a break room in the oncology sector, lasting between 10 and 15 minutes.
45790135|NCT05510921|Other|Minimalist music + birdsongs group|Participants in this group will listen individually a live session of minimalist music piano piece with the superposition of bird song sounds, in a break room in the oncology sector, lasting between 10 and 15 minutes.
45790136|NCT04817475|Other|Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of patients with a out-of-hospital cardiac arrest will be performed with tele-supervision.
45790137|NCT05454501|Other|Exercise Training|For eight weeks, they will receive real-time online exercise training for 30 minutes, three days a week, with a peer group of 5-6 people. Before starting the exercise, physical activity will be monitored for seven days.
45790138|NCT05454501|Other|Patient Education|After the first face-to-face evaluation session, these patients and their families will receive a 1-hour patient education program specific to the disease and exercise. Information brochures containing physical activity and exercise recommendations will be given. They will be followed up with weekly phone calls throughout the study period. At the end of 8 weeks, the second evaluation interview will be held. Afterward, the patients in the control group will be able to participate in the online exercise training program if they request it.
45646707|NCT03066401|Procedure|echography|The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
45646708|NCT05089591|Device|Intense Pulsed Light therapy|The LacryStim System is a CE marked device for treatment of meibomian gland dysfunction. It stimulates and reactivates meibomian glands and improves the related dry eye condition. Intense pulsed light is emitted with a light spectrum from 610nm to 1200nm. Each treatment consists of short individual pulses lasting for 4ms separated by a 26ms lasting interval to hinder tissue temperature increase, thermal damage to the skin and inflammatory reaction. During this phase 8 to 12 J / cm2 are delivered. Selection of total energy levels depends on the skin type (Fitzpatrick Skin Types) as recommended by the manufacturer.
45646709|NCT05089591|Device|Sham Treatment|The fellow eye serves as the control eye. Study eye receives the standard energy dose as recommended by the manufacturer (between 8 and 12J/cm2, in accordance with the manufacturer's recommendations). The control eye is treated using low energy dose energy (1J/ cm2) as sham treatment, ensuring blinding of the respective patient.
45646710|NCT05730413|Drug|Bisoprolol|Bisoprolol dose was divided to be taken as 2.5 mg twice per day from hospital admission to discharge.
45646711|NCT05730413|Drug|Bisoprolol|Bisoprolol was taken as 5 mg per day from hospital admission till discharge.
45646712|NCT04223557|Device|High-intensity focused ultrasound|"High-intensity focused ultrasound(HIFU) is an externally delivered, completely noninvasive focused therapeutic ultrasound device.It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume,which leads to the rapid elevation of the peri-renal adipose tissue temperature and the modification of target tissue eventually."
45646713|NCT04223557|Device|Sham treatment|Participants will receive the same procedure as those in the HIFU treatment including peri-renal fat ultrasonic measurement and localization and focused ultrasound treatment parameters setting, except that no energy will be delivered to the peri-renal fat.
45646714|NCT04206059|Radiation|MRI|A non-contrast brain MRI will be acquired for localizing EEG slow waves
45646715|NCT04206059|Diagnostic Test|Quantitative Sensory Testing (QST)|Quantitative sensory testing (QST) using increasing ramp thermal stimulation (32-52 ºC) will be delivered to compare arousal thresholds between conditions.
45646716|NCT04206059|Diagnostic Test|Home sleep study|Unattended home sleep studies will be conducted on the night preceding sedation and on the night following sedation to assess changes in slow wave homeostasis.
45646717|NCT04206059|Other|Acoustic stimulation (65db) up-slope of EEG with QST|Acoustic stimulation (65 db) synchronized in-phase with the up-slope of EEG slow waves
45646718|NCT04206059|Other|Acoustic stimulation (65db) down-slope of EEG with QST|65 dB acoustic stimulation synchronized with the down-slope of the EEG slow waves (anti-phase)
45646719|NCT04206059|Other|0 db with QST|sham stimulation (0 dB volume)
45920130|NCT00086944|Drug|etoposide|Given IV
46071439|NCT00623623|Drug|clopidogrel|Adjunctive treatment
45646720|NCT04206059|Drug|Dexmedetomidine|All participants will receive dexmedetomidine with sedation titrated step-wise to 2, 3 or 4 ng/ml
45646721|NCT04206059|Other|Breathe-Squeeze Task|All participants will be asked to perform the breathe-squeeze task throughout the experiment. This will allow us to determine loss and return of responsiveness.
45646722|NCT04166929|Biological|Haplo SCT with NK cells|Patients in this arm receive haplo-SCT followed by one boost of NK cells one/two weeks after the transplant. Lymphocyte are collected by apheresis from the donor one-two weeks after BM harvest. CD3 negative/CD56 positive cells are selected by immunomagnetic columns (other lymphocytes are stored to be used as DLI)
45646723|NCT04166929|Biological|Haplo SCT|Patients in this arm receive a standard haplo-SCT. All administerd therapies are the same as in other arm, except for the NK cell boost..
45646724|NCT05730335|Device|Rapid Acoustic Pulse|Transdermal Rapid Acoustic Pulse Treatments
45646725|NCT01038193|Other|Cognitive assessment|Cognitive and functional assessments at 2-4 weeks, 3 months and 12 months.
45646726|NCT05377645|Other|Cyriax mobilization + traditional physiotherapy|TENS, US, exercise
45790139|NCT00551525|Radiation|Radiotherapy|3D-CRT or IMRT 64.8-70.2 Gy to the prostatic fossa begins 12 weeks (+/- 1 week) after Samarium 153 administration. Daily tumor doses of 1.8 - 2.0 Gy per day, 5 days per week x 7-8 weeks.
45790140|NCT00551525|Drug|Samarium 153|Samarium 153 lexidronam dose 2.0 mCi/kg by IV injection one time within 2 weeks (+/- 3days) after registration.
45790141|NCT03716349|Diagnostic Test|Pulp vitality testing|each tooth will be tested to determine if the pulp of the tooth responds to cold
45790142|NCT03716349|Other|Photos|Photos of teeth (Photos will be taken with a DSLR camera settings will be determined with optimal settings) and captured periodically throughout the study. Photographs will be made of the cavity preparation. Photographs will be made post-operatively
45790143|NCT03716349|Drug|local and/or topical anesthetic|Local and/or topical anesthetic will be applied as necessary to the teeth or gingiva
45790144|NCT03716349|Device|rubber dam|The area will be isolated with rubber dam isolation
45790145|NCT03716349|Other|tooth surface cleaned|The tooth surface will be cleaned with flour of pumice on a prophy cup only, cavity preparation will be performed as usual for caries removal.
45790146|NCT03716349|Procedure|enamel margins|Enamel margins will be beveled with a long flame diamond bur (8863.314.012 Komet) at 45 degrees to the external tooth surface to achieve the desired bevel length. Along with the use of the diamond bur, infinite invisible margins will be created by contouring and smoothing with a dark orange Sof-LexTM extra-thin contouring and polishing disc (3M).
45920131|NCT00086944|Biological|filgrastim|Given SC
45920132|NCT00086944|Biological|pegfilgrastim|Given SC
45920133|NCT00086944|Other|laboratory biomarker analysis|Correlative studies
45920134|NCT00006107|Drug|Taxotere|
45920135|NCT00006107|Procedure|Surgery|
46071440|NCT04281134|Device|Summit RC+S System|"Summit RC+S System consists of:~(i) One Model B35300R Olympus RC+S neurostimulator; (ii) One Model 4NR009 Patient Therapy Manager; (iii) One Model 4NR011 Clinician Telemetry Module; (iv) Two Model 3387 DBS leads; (v) Two Model 37087-60 DBS extensions; and (vi) One Model 97755 Recharger."
45920136|NCT00006107|Radiation|radiation therapy|
45920137|NCT00086983|Drug|becatecarin|Given IV
45646727|NCT05430737|Radiation|stereotactic body radiotherapy|The radiation dose to the primary tumor was 40 or 45 Gy in five fractions according to the clinical determination of the radiologist. The dose to the positive lymph nodes and the prostate and seminal vesicles was 37.5Gy in five fraction. And internal iliac, external iliac, obturator, and presacral pelvic drainage regions received 25 Gy/5f, simultaneously. The treatment was delivered every other day. The volumetric modulated arc radiotherapy (VMAT) or intensity-modulated radiotherapy (IMRT) was used to complete treatment. Image-guided radiotherapy(IGRT) was performed for every treatment.
45646728|NCT05431049|Procedure|Percutaneous nephrolithotomy surgery (PNL)|Percutaneous nephrolithotomy (PNL) surgery was performed in all arms of the study to remove the renal stones. This surgery was performed with 2 anesthesia methods, CSEA and GA. These formed the groups of the study.
45646729|NCT04148573|Drug|NFX88 - 1|3 times a day
45646730|NCT04148573|Drug|NFX88 - 2|3 times a day
45646731|NCT04148573|Drug|NFX88 - 3|3 times a day
45646732|NCT04148573|Drug|PLACEBO - 4|3 times a day
45646733|NCT03136783|Other|Development of the most specific physiologically relevant experimental patient models|Development of the most specific physiologically relevant experimental patient models: organotypic culture of biopsies, reconstituted skin (equivalents of dermis with melanoma, dermis equivalents and epidermis with melanoma), and in vitro evaluation The response of tumor cells to different combinations of targeted therapy molecules
45646734|NCT05430503|Diagnostic Test|Lung volumes, spirometry and standard single-breath DLCO were measured at rest while combined DLNO and DLCO were measured at rest and post-exercise|DLNO and DLCO were measured at rest and 5-10 s after a bout of treadmill exercise simulating usual walking
45646735|NCT03110263|Other|Multicomponent internet-based self-help|Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., & Posner, D., 2006). The self-help program consists of eight text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
45646736|NCT03110263|Other|Internet-based sleep restriction|Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., & Posner, D., 2006). The self-help program consists of five text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
45646737|NCT05730023|Device|Active tDCS|Active tDCS (anode will be applied over the left DLPFC with the cathode over the right supraorbital region);
45646738|NCT05730023|Behavioral|individualized language training|individualized language training
45646739|NCT05730023|Device|Placebo tDCS|Placebo tDCS (the current will be turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period);
45646740|NCT05089045|Biological|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
45646741|NCT04132817|Biological|Nivolumab|specified dose on specified days
45646742|NCT04132817|Biological|Ipilimumab|specified dose on specified days
45646743|NCT04132817|Drug|Nab-paclitaxel|specified dose on specified days
45646744|NCT05088811|Diagnostic Test|WRAP53, UCA-1|Diagnostic value of UCA-1 and WRAP53 in HCC
45646745|NCT05729945|Behavioral|home visiting|The intervention is a three year program that serves families and their first born children through home visiting using paraprofessionals to deliver a hybrid curriculum using the Partners for a Healthy Baby curriculum developed by Florida State University in January 2015.
45646746|NCT03066635|Drug|Botulinum Toxin Type A 25 IU|injection with 25 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
45646747|NCT03066635|Drug|Botulinum Toxin Type A 12.5 IU|injection with 12.5 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
45646748|NCT05077267|Biological|ABNCoV2 100ug|IM injection 100ug dose
45646749|NCT05077267|Biological|ABNCoV2 50ug|IM injection 50ug dose
45646750|NCT05075083|Biological|Inactivated COVID-19 vaccine|receive two doses inactivated COVID-19 vaccine with the interval of 21 days
45646751|NCT04073771|Device|Continuous renal replacement therapy with oXiris|Continuous renal replacement therapy with oXiris in patient with septic shock
45646752|NCT03136237|Drug|BCX7353|Day 11-18 for Cohort 1, Day 7-14 for Cohort 2, Day 1 for Cohort 3
45646753|NCT03136237|Drug|Digoxin|Day 1 of Cohort 1
45646754|NCT03136237|Drug|BCX7353 + digoxin|Day 19 of Cohort 1
45790147|NCT03716349|Procedure|Adhesive Systems|Adhesive systems will be applied according to manufacturer's instructions and selective etching of the enamel will be performed. The dental composite will be incrementally placed using a two- layer or one-layer technique based on the cavity size and light-cured (detailed adhesive instruction sheet will be chairside for reference)
45646755|NCT03136237|Drug|Rosuvastatin|Day 1 of Cohort 2
45790148|NCT03716349|Procedure|cavity preparation|The technique to be used will be determined by the size of the final cavity preparation. For small preparations a one-layer technique will be used. No backing material is necessary for the Tokuyama system, Filtek Supreme Ultra will be determined by manufacturer's wheel. A two-layer technique will be used for a large cavity preparation. Large cavity preparation is defined as being 4mm in length or more and/or at least 2mm in depth.
45646756|NCT03136237|Drug|rosuvastatin + BCX7353|Day 15 of Cohort 1
45646757|NCT03136237|Drug|Cyclosporine + BCX7353|Day 14 of Cohort 3
45646758|NCT05430425|Other|respiratory safety|Which of the 3 lma selection methods is effective in ensuring respiratory safety?
45646759|NCT04001309|Other|Implementation of prospective audit and feedback stewardship interventions to reduce unnecessary use of antimicrobials and improve quality of prescriptions|Prospective audit and feedback of antimicrobial therapy at hospital wards, by interventions performed by infectious diseases specialists alone or using a team-based approach.
45790149|NCT03716349|Other|Shade selection using Easy Shade 5|A1 (shade determined by Easy Shade 5), ECM-001/Backing material, A1E/A2D (shade will be selected by shade wheel) A4 (shade determined by Easy shade5), ECM-001/Backing material, A3E/A6D (shade will be selected by shade wheel
45646760|NCT03136081|Diagnostic Test|Candidiasis infection occurence|Candidiasis infection occurence
45646761|NCT03135925|Other|Supervised Exercise Program|Participants will be invited to attend a weekly supervised exercise program over six weeks, in the time before their bone marrow transplantation
45790150|NCT03716349|Procedure|Light Curing|A Valo Grand curing unit (Ultradent) with an exitant irradiance with no less than 500 and no greater than 1500 mW/cm2 as measured with MARC Light Collector will be used in standard mode to deliver the required radiant exposure J/cm2 for adhesive and dental composite increments.
45646762|NCT05729789|Behavioral|Group Written Exposure Therapy|Group Written Exposure Therapy (GWET) is a brief cognitive behavioural therapy for PTSD aimed at allowing patients to process their traumatic experiences in a safe environment. GWET will consist of 6 group sessions (1 orientation session and 5 weekly group sessions). Participants will be asked to complete weekly in-session written exposures where they will recount their traumatic experience. The written exposure will be followed by a guided discussion about the experience of writing the exposure. There is no homework assigned between sessions. However, group members will be asked to refrain from avoiding thinking about the trauma between sessions.
45646763|NCT04021381|Dietary Supplement|Potassium and magnesium citrate|Patients are treated with potassium and magnesium citrate 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
45646764|NCT04021381|Dietary Supplement|Placebo|Patient are treated with placebo 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
45646765|NCT03930797|Behavioral|Intimacy Enhancement|The IE intervention is grounded in cognitive behavioral couple therapy and sex therapy, and includes education and skills training with a focus on the following major topics: understanding effects of breast cancer on sex and intimacy; goal-setting; communication skills; problem-solving and engaging in activities to build intimacy; identifying and restructuring negative or inflexible thoughts; and planning ahead and preparing for challenges. Participants will be asked to participate in written and behavioral activities at home between sessions to strengthen skills acquisition.
45646766|NCT03930797|Behavioral|Living Healthy Together|The Living Healthy Together (LHT) intervention focuses on delivering education and support to breast cancer survivors and their partners across a range of topics including social support, sleep and fatigue, stress and stress management, nutrition, and physical activity. Participants will be asked to engage actively with the material and to review readings and intervention material between sessions.
45790151|NCT03716349|Procedure|Contoured and polished|The restoration will be contoured and polished with - Long flame diamond bur (8863.314.012 Komet), Sof-Lex Medium (orange) Contouring and Polishing Discs (3M), Green Jiffy cup pre-polisher (Ultradent Products, Inc.), Blue and grey silicone points composite polisher gloss plus finisher (Kerr Hawe)
45790152|NCT03716349|Other|Consent|The consent form will be signed, copy will be provided to the patient
45790153|NCT03716349|Other|Health Questionnaire|The health questionnaire will be completed at initial visit and updated at each follow-up visit
45790154|NCT03716349|Radiation|xray|When necessary a radiograph (xray) will be obtained
45790155|NCT03716349|Other|Release of medical information signed|The release of medical information form will be signed
45790156|NCT03716349|Other|Oral Exam|An Oral Exam will be completed
45790157|NCT03716349|Other|Teeth Assessment|The teeth assessment by subject will be completed using the Visual Analog Scale (VAS) and Verbal Rating Scale (VRS) at the follow-up visits 1 month after restoration, 1 year, 2 years and 3 years post restoration.
45790158|NCT03716349|Other|Clinical Assessment|A clinical assessment will be completed by the evaluators
45790159|NCT03716349|Device|Tokuyama Universal Bond|Tokuyama Universal Bond (TUB) single component self-etching 1-step adhesive system with Tokyuama supra-nanofilled dental composite (ECM) (Tokuyama Dental Corp., Japan)
45646767|NCT04020523|Other|MRI sequence|The MR sequences added to the protocol are dedicated sequences for perfusion and diffusion imaging of breast lesion.
45646768|NCT04158401|Device|Pregnolia|The Pregnolia measurement device (CE Mark for commercialization in the EU) will be used to measure the cervical stiffness (Pcl) on all subjects.
45646769|NCT03066479|Device|Fitbit|Wearable activity & sleep tracker.
45646770|NCT03066479|Other|OSA questionnaire|Parents will complete a questionnaire assessing the potential symptoms their child is experiencing that are related to obstructive sleep apnea (OSA).
45646771|NCT03066479|Diagnostic Test|Polysomnography|All participants will be undergoing a sleep study as part of their clinical care.
45646772|NCT03955081|Device|Deep enteroscopy|A deep enteroscopy conducted with the new medical device PowerSpiral.
45646773|NCT03066791|Dietary Supplement|Turmeric tablets|
45646774|NCT03066791|Dietary Supplement|Curcumin and Bioperine tablets|
45790160|NCT03716349|Device|ScotchBond|Scotch Bond Universal one-step adhesive system with Filtek Supreme Ultra™, nanofilled dental composite (3M)
45790161|NCT05454423|Other|the Aquatic exercises +Traditional physical therapy programs +anti-hyperuricemia medication|"-Aquatic exercises: At the beginning of the exercises, aquatic exercises technique was educated to the participants out of water. Then, the aquatic exercises were conducted in a chest warm pool (28-30°C) for 30 minutes, three sessions a week for eight weeks.~-Traditional physical therapy programs : which included using hot packs (20 minutes), ultrasound (5 minutes), and electrotherapy using TENS (15 minutes) in addition to stretching exercises for the calf, hamstring muscles and big toes and strengthening exercises for the quadriceps muscles for 30 minutes. The stretching exercises were performed in 3 weekly sessions over 8 weeks, each with a 30 second holding and a 30-second relaxation repeated three times. One group of strengthening exercises consisted of 10 repeats with a 5 second holding"
45804087|NCT02382913|Biological|Licensed TdaP booster (Boostrix®)|"Licensed TdaP booster vaccine Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
45646775|NCT03066791|Dietary Supplement|Placebo tablets|
45646776|NCT03066869|Drug|H.P. ACTHAR GEL|H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated for ophthalmic diseases.
45790162|NCT05454423|Other|traditional physical therapy + anti-hyperuricemia medication|"traditional physical therapy programs, which included using hot packs (20 minutes), ultrasound (5 minutes), and electrotherapy using TENS (15 minutes) in addition to stretching exercises for the calf, hamstring muscles and big toes and strengthening exercises for the quadriceps muscles for 30 minutes. The stretching exercises were performed in 3 weekly sessions over 8 weeks, each with a 30 second holding and a 30 second relaxation repeated three times. One group of strengthening exercises consisted of 10 repeats with a 5 second holding17."
45790163|NCT04806321|Other|Project SOLVE|This 30-minute, self-guided, digital program is designed to help adolescents solve, rather than be overwhelmed by, everyday problems.
45790164|NCT04806321|Other|Project SUCCESS|This 30-minute, self-guided, digital program is designed to help adolescents develop study skills.
45646777|NCT04200131|Diagnostic Test|Biopsy of the cyst wall with the Moray™ forceps.|Tissue sample of the wall of the pancreatic cyst with micro Moray™ forceps during an ultrasound-guided puncture of a pancreatic cyst with a 19G needle.
45790165|NCT04802031|Biological|Rapid Infusion Isatuximab|Given IV
45646778|NCT05729633|Other|Robot mediated upper limb therapy|"The OR is classified as a Class A device with the Health Sciences Authority. The OR is capable of both delivering RMIT as well as RMTT. It can provide zero, partial, or full assistance to the patient to complete the movement or task. Its teach-and-follow mode allows a movement to be performed by the therapist, with the device then replaying the movement at either zero, partial, or full assistance, for the patient.~Impairment oriented training will focus on the following movements:~Diagonal movement~Shoulder abduction~Shoulder adduction~Shoulder flexion~Shoulder extension~Elbow flexion~Elbow extension~Task-specific training will focus on the following activities:~Picking up a cup/glass by the side and drink~Brushing hair~Cleaning unaffected upper limb (hand to arm)~Wiping table~Wiping wall~Sliding card on table to a designated location~Clipping a clothe peg"
45646779|NCT05729555|Drug|Compound ibuprofen polyrelease tablets|Specification: Each tablet containing ibuprofen 400 mg, diphenhydramine hydrochloride 50 mg Batch number: 22082801 Content: Ibuprofen 96.9%, diphenhydramine hydrochloride 102.4% Effective: August 27,2024 S torage conditions: sealed, room temperature. Manufacturers: Overseas Pharmaceuticals, Ltd. Usage and dosage：Once a day, one tablet at a time
45646780|NCT05729555|Drug|reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)|"Specification: 200 mg Batch number: 2CE2330 Content: 100.5% Expiry date: December 2023 Storage conditions; Storage in 20℃ -25℃ manufacturer: JOHNSON & JOHNSON CONSUMER INC. Usage and dosage：Once a day, two tablets at a time~Specification: 25 mg Batch number: BCC009 Content: 99.2% Effective to: December 2023 storage conditions; storage at 20℃ -25℃, shading manufacturer: JOHNSON & JOHNSON CONSUMER INC Usage and dosage：Once a day, two tablets at a time"
45790166|NCT03706989|Procedure|EEG|EEG samples will be recorded before and during the cardiac surgery in order to perform spectral and coherence analyses
45790167|NCT03706989|Genetic|Apolipoprotein genotype|APOE genotyping will be performed for each patient
45790168|NCT03706989|Biological|Serum NfL measurements|5 perioperative blood samples will be taken to measure the evolution of NfL in the serum (before and until postoperative day 5)
45790169|NCT03706989|Other|Preoperative neurocognitive evaluation|Each patient will benefit from a complete neurocognitive evaluation before surgery (battery of validated cognitive tests)
45790170|NCT05454345|Drug|Sitafloxacin|In our Intervention group, sitafloxacin replace the ethambutol, 200mg/d
45646781|NCT01603459|Drug|IncobotulinumtoxinA|"Subjects to receive up to 3 injection cycle, with the dose titrated from 400 units to up to 800 units.~For each injection session: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400-800 units, volume 2.0 mL per 100 units; Mode of administration: intramuscular injection."
45646782|NCT03066245|Biological|MSC-PLGA|Bone marrow derived MSC seeded on biodegradable PLGA, supplemented with PL.
45790171|NCT05454345|Drug|SMZ/TMP|In our The three-month Rifapentine&Isoniazid&Pyrazinamide&Sitafloxacin&SMZ/TMP-containing regimen, Six weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and Sitafloxacin, followed by seven weeks of daily treatment with rifapentine, isoniazid, ,SMZ/TMP and Sitafloxacin, SMZ 80mg/kg/d, TMP16mg/kg/d
45790172|NCT05454345|Drug|Rifampin|Rifampin is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, Rifampin 600mg (8-12mg/kg/d)
45790173|NCT05454345|Drug|Pyrazinamide|Pyrazinamide is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, 2000mg (20-30mg/kg/d)
45646783|NCT03066323|Other|Rice with tea extract|Rice with tea extract
45646784|NCT03066323|Other|Rice without tea extract|Rice without tea extract
45646785|NCT05424185|Behavioral|different type of scapular dyskinesis|rapid arm elevation to see the different of EMG rise and force development
45790174|NCT05454345|Drug|Rifapentine|In our Intervention group, rifapentine replace rifampin, 600mg/d
45790175|NCT05454345|Drug|Isoniazid|Isoniazid is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, 300mg (4-6mg/kg/d)
45790176|NCT05454345|Drug|Ethambutol|Ethambutol is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, 1200mg (15-25mg/kg/d)
45790177|NCT05454345|Drug|Moxifloxacin|Moxifloxacin is a fourth-generation fluoroquinolone with potent activity against M. tuberculosis in vitro and in vivo, 400mg (7.5-10mg/kg/d)
45920138|NCT00086983|Drug|oxaliplatin|Given IV
45646786|NCT02926027|Drug|Vascepa|Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.
45646787|NCT02926027|Drug|placebo|placebo
45790178|NCT05454111|Procedure|Multiscale entropy-guided ablation plus PVI|The multiscale entropy is calculated based on intracardiac electrical signals, higher multiscale entropy value indicates closer to the core of rotors which maintains the persistent atrial fibrillation.
45790179|NCT05454111|Procedure|CARTO-Finder-guided ablation plus PVI|CARTO-Finder-guided ablation plus PVI
45920139|NCT00086983|Other|pharmacological study|Correlative studies
45646788|NCT05037305|Other|Educational video|The brief educational video provides information about pharmacogenetic testing, the results of pharmacogenetic testing, and how to find these results in the patient portal.
45790180|NCT04707417|Other|Home care|Advanced home care
45646789|NCT03136003|Drug|DDAVP|The participant will take either 1 or 2 nasal sprays of IN DDAVP (known as Octostim® in Canada). After receiving IN DDAVP, the participant will rest for 30 minutes.
45646790|NCT03136003|Behavioral|Exercise|The participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise until they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or exhaustion (whichever is first). Upon completion of planned exercise, work load is decreased to zero watts and participants will continue cycling at this cool-down rate for an additional 3-minutes, before getting off the ergometer.
45646791|NCT03798353|Combination Product|PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.|A matrix-cell construct (PeriCord) will be placed on the ischemic area of the non-candidate revascularization area during a surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.
45646792|NCT03798353|Procedure|Surgery by sternotomy|The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed only the by-pass.
45646793|NCT04962685|Other|Rapid Maxillary Expansion|"Subjects in the experimental group (with unilateral posterior crossbite) will be treated with Maxillary Rapid Expansion using a disjunctor fixed with two bands on the upper first permanent molars and a mesh cemented to the upper first premolars or upper first primary molars (depending on the eruptive stage of the patient).~The breaker screw will be activated twice a day until a transverse overcorrection of 2 mm is achieved in the first permanent molars. When the active disjunction phase is completed, the screw will be blocked out with light-curing flowable resin and the patient will wear the cemented disjunctor as a retainer for a minimum of six months."
45646794|NCT04945213|Drug|Biperiden|5mg of biperiden diluted in 10 ml of 0.9% saline - every 6 hours for 10 consecutive days - IV
45646795|NCT04945213|Other|Placebo|1ml of 0.9% saline diluted in 10 ml 0.9% saline - every 6 hours for 10 consecutive days - IV
45646796|NCT05410847|Drug|Camrelizumab Nab-Paclitaxel S-1|Camrelizumab+S-1+Intraperitoneal nab-paclitaxel and intravenous nab-paclitaxel
45646797|NCT05407571|Behavioral|Significance of Echogenic Amniotic Fluid on Perinatal Outcome|To estimate the nature of echogenic amniotic fluid.and To overcome unnecessary intervention due to turbid amniotic fluid, assess neonatal outcome and estimate gestational age at time of delivery in patients with echogenic amniotic fluid.
45646798|NCT04540939|Behavioral|Mindfulness-Based Cognitive Therapy|"There will be 8 sessions and these will be approximately 2 hours long. Over the 8-weeks participants will learn several mindfulness meditation techniques. Each session will involve group discussion and feedback. Participants will be asked to practice these techniques at home, and keep a log of mood, and stress ratings.~Audio files with exercises will be given to participants so that they can practice at home between sessions."
45646799|NCT04540939|Behavioral|Muscle Relaxation Therapy|Each MR session is approximately 2 hours. Over the 8-weeks you will learn how to relax your body using a step-by-step process in which you alternate between squeezing and relaxing your muscles. You will learn about your body's natural response to stress and how to use muscle relaxation during your everyday life. Each session will also involve group discussion and feedback. You will be asked to practice these techniques at home, and keep a log of your mood, and stress ratings. You will receive audio files with exercises so you can practice at home between sessions.
45646800|NCT05729477|Device|miCOR System|The miCOR system is a lens fragmentation device used to break up the cataract prior to IOL implantation during cataract surgery.
45646801|NCT05729477|Device|Phaco Subject Cohort|Phaco Subject Cohort
45646802|NCT04750291|Drug|Botulinum toxin type A|1 infiltration in the biceps muscle with botulinum toxin (100 IU)
45646803|NCT04750291|Other|Placebo|1 infiltration in the biceps muscle with placebo or sterile saline
45646804|NCT05729399|Biological|GT201|Autologous tumor infiltrating lymphocyte injection
45646805|NCT04708951|Device|ENDOCUFF VISION® device|ENDOCUFF VISION® is a disposable cap placed on the tip of a standard colonoscope, intended to flatten colonic folds and assist in controlling the colonoscope's field of view and tip positioning
45646806|NCT04708951|Device|G-EYE® colonoscope|The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning
45646807|NCT03726749|Drug|Tocilizumab|Tocilizumab is an interleukin-6 (IL-6) receptor inhibitor
45646808|NCT03726749|Drug|Prednisone|Prednisone is an anti-inflammatory medication
45646809|NCT04593745|Device|Intraocular pressure measurment|Intraocular pressure measurmentt using iCare devise: TONOPEN
45646810|NCT03821077|Biological|Allergen Immunotherapy (AIT)|Immunotherapy vaccine with 2 allergenic extracts mixtures (pollens or mites)in polimerized-depot formulation
45646811|NCT03680963|Procedure|Non-invasive strategy|"No indwelling arterial catheter insertion will be allowed during the first 28 days, excepted if predefined safety criteria (indicating absolute need of indwelling arterial catheter insertion) are reached.~In the non-invasive group, automated oscillometric monitor will be used to monitor BP (blood pressure)."
45790181|NCT04459611|Biological|sintilimab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
45790182|NCT04459611|Drug|pemetrexed|500 mg/m^2 by IV infusion Q3W, given on cycle day 1.
45790183|NCT04459611|Drug|Carboplatin|AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 1.
45790184|NCT04459611|Drug|albumin-bound paclitaxel|260 mg/m^2 by IV infusion Q3W, given on cycle day 1.
45790185|NCT03551457|Diagnostic Test|Biopsy|Patient-derived xenograft treatment response phenotype.
45790186|NCT01437098|Device|MDT-2111 CoreValve for TAVI|CoreValve Transcatheter Aortic Valve Implantation (TAVI) using the MDT-2111 system.
45646812|NCT03680963|Procedure|Control strategy|An indwelling arterial catheter will be inserted as soon as possible (within the first four hours after randomization) and will be maintained except in case of indwelling arterial catheter futility, suspected or proven indwelling arterial catheter related infection or thrombosis (at discretion of attending physician) until day 28 or ICU (Intensive Care Unit) discharge (whichever comes first). After day 28, clinicians may choose to maintain or to remove indwelling arterial catheter.
45790187|NCT03514875|Dietary Supplement|MitoQ|MitoQ is a mitochondria-targeting antioxidant, which should improve NO bioavailability, and therefore vasodilation
45790188|NCT03514875|Dietary Supplement|Placebo|A placebo will be used in a double blinded, randomized, cross-over design
45790189|NCT03497871|Device|HeartMan system|The HeartMan system uses wristband sensors to monitor patients' physical activity and physiological parameters. These data are connected to a decision support system, providing medical advice to patients concerning physical exercise, nutrition, medication intake, clinical measurements, environment management, and mental support. The decision support system is based on predictive models, clinical care guidelines and expert knowledge. The advice will be personalized according to each individual patient's medical and psychological profile, and will be presented to the patient through the user interface of a mobile application on a smartphone.
45790190|NCT00370617|Drug|metformin|
45790191|NCT01553708|Drug|Epidermal growth factor with silver sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
45790192|NCT01553708|Drug|Silver zinc sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
45790193|NCT00370773|Device|Precision Spinal Cord Stimulation System|
45790194|NCT02370498|Biological|pembrolizumab|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
45646813|NCT03756337|Device|Neuro 1 & Neuro 2|participant common fitting map used for tests
45790195|NCT02370498|Drug|paclitaxel|80 mg/m^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.
45790196|NCT01554488|Drug|Inhaled Fluticasone Propionate|Inhaled corticosteroid
45790197|NCT03440853|Behavioral|TASCCI|TASCCI is a stepped-care collaborative care approach of pharmaco- and/or behavioral-therapy for a 12 week period. The intervention will target 1 or more symptoms based on patients' report of clinical levels of each symptom and patient preference. A trained behavioral therapist will deliver weekly video conferencing sessions during dialysis treatment.
45790198|NCT03440853|Other|Technology Delivered Health Education Intervention|The Technology Delivered Health Education Intervention will deliver weekly video conferencing sessions to deliver online educational material from the National Kidney Foundation. These sessions will be delivered by a care coordinator.
45790199|NCT05453331|Procedure|bilateral STN deep brain stimulation|bilateral deep brain stimulation of the subthalamic nucleus in people with Parkinson's disease
45790200|NCT01437488|Drug|Cabazitaxel|"Cycle 1: 20 mg/m2 in 250cc NS via IV on Day 1 every 21 days~Following cycles: 20 mg/m2 or escalated to 25 mg/m2 or reduced by 5 mg/m2 in 250cc NS via IV on Day 1 every 21 days at investigator's discretion~Treatment continues until disease progression, intercurrent illness preventing further treatment, unacceptable adverse event(s), patient withdraws from the study, or changes in the patient's condition which render further treatment unacceptable in the judgment of the investigator"
45790201|NCT01437488|Drug|Neulasta|6 mg via SQ on Day 2 (24-48 hours post-cabazitaxel) every 21 days
45790202|NCT01437488|Procedure|CT Scan|CT scan of chest, abdomen, and pelvis to assess disease following every 3rd cycle of treatment (approximately every 9 weeks)
45790203|NCT01437488|Biological|Blood Draw|Approximately 2 tablespoons of blood will be taken to test complete blood count, glucose, hematology, electrolytes, liver function, creatinine clearance, and a chemistry profile. This week be done weekly during the first cycle of treatment
45790204|NCT02347332|Drug|Vinflunine|
45790205|NCT02347332|Drug|Methotrexate|
45646814|NCT03756337|Device|Neuro 2 & Neuro 1|participant common fitting map used for tests
45790206|NCT01502306|Behavioral|Telephone counseling|Telephone counseling is conducted in the appropriate language (Spanish and English) by counselors at the California Smokers' Helpline. Counselors use a structured protocol and there is a record for each call. Quantitative information that will be available for analysis include: timing, length, and frequency of counseling calls.
45790207|NCT01502306|Drug|Nicotine patches|Clients will be screened for contraindications to nicotine patch use, and a doctor's approval will be necessary before patches are sent if a contraindication exists.
45790208|NCT01502306|Behavioral|Incentive|They will be given their choice of gift cards from one of 4 major business chains: Wal-Mart, Target, Vons/Safeway, or Ralph's/Kroger card.
45790209|NCT03325959|Device|Hyperbaric oxygen therapy|60 HBOT sessions at 2 ATA 100% oxygen
45920140|NCT04783155|Device|POWERBreathe Plus®|Commercially available pressure-threshold device
45646815|NCT03136705|Drug|Nicotinamide|Nicotinamide tablet
45790210|NCT03325959|Drug|Cymbalta / lyrica|one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica.
45790211|NCT03325959|Device|Crossover Hyperbaric oxygen therapy|60 HBOT sessions at 2 ATA 100% oxygen after crossover
45790212|NCT04337463|Drug|ATG-008|Tablet
45790213|NCT04337463|Drug|Toripalimab|IV infusion
45790214|NCT02347176|Other|Placebo|Subcutaneous injection with placebo
45790215|NCT02347176|Biological|Tralokinumab Dose 1|Subcutaneous injection with tralokinumab
45646816|NCT03136705|Drug|Lanthanum Carbonate|Lanthanum Carbonate tablet
45646817|NCT03136705|Drug|Lanthanum Carbonate Placebo|Sugar pill manufactured to look like Lanthanum Carbonate tablet
45646818|NCT03136705|Drug|Nicotinamide Placebo|Sugar pill manufactured to look like Nicotinamide tablet
45790216|NCT02347176|Biological|Tralokinumab Dose 2|Subcutaneous injection with tralokinumab
45790217|NCT02347176|Biological|Tralokinumab Dose 3|Subcutaneous injection with tralokinumab
45646819|NCT03066713|Other|Skin Off French Fry|Skin Off French Fries will be provided at breakfast and lunch
45646820|NCT03066713|Other|Skin On French Fry|Skin On French Fries will be provided at breakfast and lunch
45646821|NCT03066713|Other|Hash brown|Hash brown potatoes will be provided at breakfast and lunch.
45790218|NCT05451381|Drug|Propofol|sedation after cardiac surgery
45790219|NCT05451381|Drug|Dexmedetomidine|sedation after cardiac surgery
45790220|NCT05451381|Drug|Dexmedetomidine and Propofol|sedation after cardiac surgery
45790221|NCT05450913|Drug|Priformis intramuscular injection with %2 lidocain|Priformis intramuscular injection will be administered with 5 cc 2% lidocaine, accompanied by a nerve stimulator under ultrasound guidance
46071441|NCT04281134|Other|One Month Blinded Discontinuation Period:|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
45646822|NCT03066713|Other|Carbohydrate control|A pancake will be provided at breakfast, and pretzels will be provided at lunch.
45646823|NCT04540861|Drug|Siponimod|1 or 2 mg film-coated tablets. The tablets have to be taken orally once daily and swallowed whole with water, with or without food.
45646824|NCT03066557|Procedure|TACE and Apatinib|TACE and Apatinib 250mg po qd
45790222|NCT05446779|Diagnostic Test|Adrenal aldosterone synthase (CYP11B2) staining|Immunoshistochemical diagnosis of primary aldosteronism
45790223|NCT05446779|Diagnostic Test|Adrenal cortisol synthase (CYP11B1) staining|Immunoshistochemical diagnosis of adrenal hypercortisolism
45790224|NCT05446779|Diagnostic Test|Histopathological analysis|Diagnosis of any endocrine neoplasia other than primary aldosteronism or adrenal hypercortisolism
45646825|NCT03066557|Procedure|TACE|TACE
45646826|NCT04574401|Drug|IS-002|Intravenous injection of IS-002 Investigational Drug
45646827|NCT05729087|Behavioral|Blended intervention group|"Face-to-face workshops will be delivered in the neighborhood elderly center every week. Each workshop will consist of two sections (a) a 60-minute PA session, including a Health talk (20 minutes), and a physical exercise training (40 minutes); and (b) a 60-minute healthy diet promotion, including group discussion and sharing (30 minutes), and knowledge of diet and nutrition (30 minutes).~In addition, a 15-minute online psychological session will be implemented following the PA and diet session."
45646828|NCT05308667|Other|Rehabilitation (modified constraint-induced movement therapy)|Modified constraint-induced movement therapy (mCIMT): It is an intervention used to improve functionality and mobility in the more affected upper extremity post-stroke.
45790225|NCT05423301|Procedure|Experimental|Respiratory care consists of manual and instrumental bronchial clearance techniques: Expiratory Flow Enhancement (EFE), suctioning, manual cough assist techniques, instrumental clearance techniques (suctioning and Cough Assist) and swallowing disorder management.)
45790226|NCT05423301|Procedure|Control|The control group will receive early respiratory care and rehabilitation by nurses, nurses' aides and doctors until D7. Respiratory care includes aerosol therapy, oral and pharyngeal clearance with aspirations, verbal coughing and sputum removal, and possibly bronchial fibroscopy for clearance if necessary. Early rehabilitation consists of alternating postures in bed, passive chair positioning (patient lift), or active positioning via a bed rail and standing.
45790227|NCT05404425|Procedure|Visioconference: live visual injury evaluation|For patients randomized in the intervention group, a live visual evaluation of the injury is performed by the Emergency Medical Call Center physician using a dedicated, secure smartphone app
45790228|NCT05404425|Procedure|Control|For patients randomized in the control group, the evaluation is performed by the Emergency Medical Call Center physician only by pone call
45790229|NCT02370420|Biological|Platelet-Rich Plasma|Autologous Platelet-Rich Plasma will be applied by a intra-articular injections
45790230|NCT02370420|Behavioral|rehabilitation exercises|Patients would been shown rehabilitation exercises, to perform them at home
45790231|NCT02215070|Drug|Pasireotide|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.
45790232|NCT04338477|Drug|Nephrosolid tablets|Adminstration of drug
45790233|NCT04000737|Drug|YIV-906+Sorafenib|Patients will be given sorafenib (400 mg BID) daily for a 28-day course with YIV-906 (3 capsules, BID) 4 days on and 3 days off weekly in each course.
45790234|NCT04000737|Drug|Placebo+Sorafenib|Patients will be given sorafenib (400 mg BID) daily for a 28-day course with placebo (3 capsules, BID) 4 days on and 3 days off weekly in each course.
45646829|NCT05308667|Other|non-invasive brain stimulation (intermittent theta-burst stimulation)|Intermittent theta-burst stimulation (iTBS): It is a form of repetitive transcranial magnetic stimulation and it increases the facilitation of the motor cortex.
45646830|NCT05728931|Biological|Test of biological samples|Different tests can be use on biological sample : western bloc, dot blot, immune-fluorescence, immunoprecipitation, CBA, functional test, epitope research, IgG title
45790235|NCT02209064|Device|Pericardial access|Access to the pericardium to enable further treatments.
45790236|NCT02347098|Device|intensive LDL-lowering therapy|The intensive LDL-lowering therapy uses LDL-apheresis in addition to the standard statin therapy. The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks.
45790237|NCT02347098|Drug|standard statin monotherapy|The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
45790238|NCT01556204|Procedure|Robotic surgery|The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
45790239|NCT01556204|Procedure|Laparoscopic Surgery|The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
45790240|NCT03910413|Diagnostic Test|Duel Energy CT|Enrolled subjects will complete a dual energy ct for evaluation of esophageal varices
45790241|NCT03708237|Drug|Ropinirole|ROPINIROLE has been approved by Health Canada for the treatment of idiopathic Parkinson's disease. Immediate release ropinirole is an orally administered non-ergoline dopamine agonist that is extensively metabolized by the liver. Ropinirole has not been approved by Health Canada for the treatment of moderate to severe RLS.
45790242|NCT03708237|Drug|Gabapentin|GABAPENTIN has been approved by Health Canada for the management of epilepsy. Immediate release gabapentin is an orally administered anticonvulsant primarily excreted through the kidneys. Gabapentin has not been approved by Health Canada for the treatment of moderate to severe RLS.
45790243|NCT03708237|Drug|Placebos|Opaque gel capsules filled with methylcellulose 1500 filler
45790244|NCT03702777|Drug|ASP8302|Oral Capsule
45790245|NCT03702777|Drug|Placebo|Oral Capsule
45646831|NCT05595317|Device|Non-immersive Virtual Reality|The traditional physiotherapy program will consist of hot pack (15 minutes), TENS (20 minutes), and 1 set of /10 repetitions of knee flexion/extension exercise for the right and left in a sitting position with hands clasped on opposite shoulders. In the non-immersive virtual reality application, Microsoft Kinect Xbox 360 Adventures games will be applied at the light level exercise level under the supervision of a physiotherapist. The participant will play a game in which he stands in a standing boat in a boat going on a flowing river and has to overcome obstacles by jumping, crouching and stepping left and right (River rush game).
45790246|NCT02346708|Device|Real TMS|real treatment
45790247|NCT02346708|Device|Sham TMS|placebo treatment
45790248|NCT01556594|Drug|Nasal Glucagon 1 mg|
45790249|NCT01556594|Drug|Nasal Glucagon 2 mg|
45790250|NCT01556594|Drug|SC Glucagon|
45790251|NCT01556594|Drug|Nasal Glucagon 3 mg|
45790252|NCT05374473|Behavioral|Lifestyle modification|Content in the intervention arm was adapted from an evidence-based lifestyle modification program for people with MS outlined in print previously presented in a face-to-face format. The integrated lifestyle modification program translates the research evidence regarding modification of lifestyle related risk factors and health outcomes based on a detailed review of the literature around modifiable lifestyle risk factors that may influence MS disease progression, as outlined in the book Overcoming Multiple Sclerosis: the 7-step recovery program.
45790253|NCT05374473|Behavioral|Standard-care|Content in standard-care arm was adapted from MS-related websites
45790254|NCT02974101|Other|registration of AdaptiveStim|
45790255|NCT01556906|Drug|Lomitapide|Oral administration with escalating doses administered once daily
45790256|NCT00371319|Drug|tacrolimus|0.06-0.1 mg/kg/day
45790257|NCT00371319|Drug|mycophenolate mofetil|2-3 gm/day
45790258|NCT03602079|Drug|A166|A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.
45790259|NCT01439594|Device|MGH OFDI Imaging|Imaging of Esophagus with OFDI system
45790260|NCT04337853|Device|Intraoral stent|Radiotherapy with intraoral stent
45790261|NCT04337853|Other|No intraoral stent|Radiotherapy without intraoral stent
45790262|NCT01439672|Dietary Supplement|Mixed meal and insulin challenge|The subject will undergo a mixed meal and insulin challenge as follows: an insulin bolus will be administered and a mixed meal nutrition drink will be consumed over 1-5 minutes. The mixed meal nutrition drink will be selected for that individual to be most likely to raise the glucose levels by 100mg/dl and then return to baseline within a four-hour time period. The nutrition drink will selected from the following types of product lines: Boost products (Nestle Nutrition), Ensure products (Abbott Nutrition), Carnation Instant Breakfast (Nestle Nutrition) or Glucerna (Abbott Nutrition).The pre-meal insulin bolus will be calculated to bring the subject to ~100mg/dl at 1100.
45790263|NCT03465111|Drug|ACTH (adrenocorticotropic hormone) gel|The dose of H.P. Acthar Gel is 80 Units administered subcutaneously
45790264|NCT02209532|Device|PINPOINT|PINPOINT® Near Infrared Fluorescence Imaging to identify lymph nodes
45790265|NCT02755935|Device|Cochlear Nucleus CI532|cochlear implantation
45646832|NCT05595317|Device|Sham Non-immersive Virtual Reality|The traditional physiotherapy program will consist of hot pack (15 minutes), TENS (20 minutes), and 1 set of /10 repetitions of knee flexion/extension exercise for the right and left in a sitting position with hands clasped on opposite shoulders. As a sham application, the participants will sit in a chair in front of the screen and try to prevent the balls sent from the opposite direction by using their upper extremities while their bodies are fixed with the help of a belt, under the supervision of a physiotherapist (Rally ball game).
45790266|NCT03424941|Device|FFR-guided PCI and TAVI|Treatment of subjects with multivessel coronary artery disease and aortic stenosis for FFR-guided PCI and TAVI (Medtronic CoreValve Evolut R or Medtronic CoreValve Evolut R PRO)
45790267|NCT03424941|Device|CABG and SAVR|Treatment of subjects with multivessel coronary artery disease and aortic stenosis for CABG and SAVR
45790268|NCT01440764|Drug|Furosemide|
45646833|NCT05737927|Drug|Glucose 8 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 8 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
45646834|NCT05737927|Drug|Glucose 12 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 12 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
45790269|NCT01440764|Drug|Saline|
45790270|NCT01557452|Drug|Givinostat|ready-to-use oral suspension, administered in fed condition and on a outpatient basis, especially intended for paediatric patients
45790271|NCT03386799|Device|E-motion device|Powered assisted Wheelchair with the E-motion device. Outdoor and indoor runs
45790272|NCT05283837|Biological|Pertuzumab (ZRC-3277)|Pertuzumab in combination with Trastuzumab and Docetaxel will be administered via intravenous (IV) infusion every 3 weeks for 06 cycles.
45790273|NCT05283837|Biological|Pertuzumab (Perjeta®)|Pertuzumab in combination with Trastuzumab and Docetaxel will be administered via intravenous (IV) infusion every 3 weeks for 06 cycles.
45790274|NCT01440920|Drug|OCV-501|subcutaneously administered once a week, 4 times at the dose of 0.3 mg
45646835|NCT05737927|Drug|Glucose 16 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 16 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
45646836|NCT05737927|Drug|Glucose 12 g uncoated beads|After an overnight fasting of about 10 hours, the subjects were administered the uncoated Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
45646837|NCT05737927|Drug|Glucose 12 g coated beads (60% w/w)|After an overnight fasting of about 10 hours, the subjects were administered the coated Glucose beads formulation (60 % w/w glucose/bead; 12 g glucose) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
45790275|NCT01440920|Drug|OCV-501|subcutaneously administered once a week, 4 times at the dose of 1 mg
45790276|NCT01440920|Drug|OCV-501|subcutaneously administered once a week, 4 times at the dose of 3 mg
45790277|NCT05261685|Procedure|Single-step transepithelial PRK|Single-step transepithelial Photorefractive keratectomy (PRK) is a corneal refractive surgical procedure utilized to correct myopia, hyperopia and astigmatism where excimer laser is used in a single step to remove the corneal epithelium followed by stromal laser ablation to correct the patient's refractive error.
45790278|NCT02209610|Device|Electrical and Magnetic Nerve Stimulators|Stimulation of motor nerve and central nervous system
45790279|NCT02209610|Drug|Intrathecal Fentanyl|Mu-opioid receptor agonist
45790280|NCT05251389|Other|Fecal microbiota transplantation|Fecal microbiota transplantation of an ICI responding or Fecal microbiota transplantation from an ICI non-responding donor, in combination with ICI.
45790281|NCT00371709|Device|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent System
45790282|NCT00371709|Device|TAXUS™ Express|Paclitaxel-Eluting Coronary Stent System
45646838|NCT05737927|Drug|Glucose 12 g coated beads (47% w/w)|After an overnight fasting of at least 10 hours, the subjects were administered the new developed Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position. Treatment duration: Day 1 - Day 4
45646839|NCT05728853|Radiation|Assessment of body composition|Assessment of body composition using BIA and DXA
45646840|NCT04152967|Device|new-designed PTFE valved conduits|In this prospective comparative research, all patients will be divided into two groups randomly with 100 patients in each group. One group will use the new-designed PTFE valved conduits and another one will implant the bovine jugular vein valved conduits.
45790283|NCT01441076|Drug|Anakinra|Anakinra/Kineret[registered] is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra)
45790284|NCT05244993|Drug|AK105|AK105: 100mg per bottle, 200mg IV Day 1, cycled every 21 days
45790285|NCT05244993|Drug|Anlotinib hydrochloride|Anlotinib Hydrochloride: 12mg per capsule, 12 mg PO once daily on Days 1-14, cycled every 21 days
45790286|NCT05244993|Drug|Albumin Paclitaxel|Albumin paclitaxel: 100mg per bottle, 125mg/m2 IV Days 1, 8, cycled every 21 days
45790287|NCT03008018|Drug|KA2507|KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
45790288|NCT02756949|Other|Smartphone application|Laboratory result data will be presented in the app with simple explanations on every screen. English and Zulu languages will be offered in the same app and written at a grade 4 reading level (as per WHO guidelines on literacy). Laboratory results will be supplemented with informative and relevant information explaining the result that has been shown and the recommended action for the patient to take. Patients will also be able to view additional HIV-related information and a Frequently Asked Questions (FAQ) through the app.
45790289|NCT02756949|Device|Smartphone|
45646841|NCT04152967|Device|Bovine jugular vein valved conduits|In this prospective comparative research, all patients will be divided into two groups randomly with 100 patients in each group. One group will use the new-designed PTFE valved conduits and another one will implant the bovine jugular vein valved conduits.
45646842|NCT05737771|Drug|DWC202213|DWC202213
45790290|NCT03289299|Drug|Carfilzomib|56 mg/m2 IV given on days 1, 8, and 15 of each cycle during induction and consolidation phases of the study.
45790291|NCT03289299|Drug|Lenalidomide|"25 mg po given on days 1-21 of each cycle during the induction and consolidation phases.~10 mg po given on days 1-21 of each cycle during the maintenance phase."
45790292|NCT03289299|Drug|Daratumumab|16 mg/kg IV given on days 1, 8, 15, and 22 of cycles 1-2; days 1 and 15 of cycles 3-6; day 1 of cycle 7-12; Day 1 of odd cycles for cycles 13-24.
45646843|NCT05737771|Drug|DWJ1563|DWJ1563
45646844|NCT05737771|Drug|DWP16001|DWP16001
45646845|NCT05728697|Device|Endoscopic ultrasound shear wave elastography|To perform the portion of the endoscopic ultrasound exam using this device, the endoscopic ultrasound probe is placed onto the surface of the stomach with the probe facing the left liver. The probe then transmits shear waves that propagate through the tissue. The waves themselves are ultrasound waves and are harmless. This is repeated 10 times on a region of interest as guided by the endoscopic ultrasound probe. The device used in question is the linear EUS (Aloka Arietta 850, Olympus America, Center Valley, PA).
45790293|NCT03289299|Drug|Dexamethasone|40 mg oral given on days 1, 8, 15, and 22 of cycles 1-6 20 mg oral given on days 1, 8, 15, and 22 of cycles 7-12
45646846|NCT04477135|Other|upper extremity pain|upper extremity pain in perinatologists due to working actively and performing ultrasonography every day
45790294|NCT01504958|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Each subject will receive up to 1800 pulses of up to 20Hz per day to all simulated brain regions together. Treated brain areas will be alternated each day (only 3 a day).~Sham participants will receive the same study procedures as patients receiving active rTMS."
45790295|NCT01504958|Behavioral|NICE Cognitive Training|"12 levels of difficulty in tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left superior temporal gyrus, left inferior frontal gyrus).~A particular cognitive exercise will start 200msec after the termination of each TMS train.~Sham participants receive sham cognitive training that follows the same procedures as the active group."
45790296|NCT03181971|Behavioral|Water First|The Water First intervention consists of increased access to safe and appealing drinking water in schools, school-wide promotion to increase students' intake of water, and education directed to 4th grade students and their families to increase intake of water.
45646847|NCT04477135|Procedure|ultrasonography|ultrasonography
45790297|NCT02973945|Device|High Flow Nasal Cannula|"During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the intervention arm will receive oxygen trough High Flow Nasal Cannula (HFNC) at 50 lpm and 40% of oxygen.~The aerobic capacity training plan will be conducted three times a week over 24 sessions."
45790298|NCT02973945|Device|The Venturi Mask|"During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the control arm will receive oxygen trough The Venturi Mask (VM) at 40% of oxygen.~The aerobic capacity training plan will be conducted three times a week over 24 sessions."
45790299|NCT01441466|Other|Isolation|Patients in this arm are nursed together (in the same room) independent of viral agent
45790300|NCT05107167|Device|Electromagnetic stimulation|Electromagnetic stimulation of the phrenic nerve
45790301|NCT01558700|Drug|Duloxetine|Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
45790302|NCT01558700|Drug|Sugar pill|Matching capsule given once a day for a total of 17 weeks.
45790303|NCT01506362|Drug|BL-7040|"BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.~Study duration can last up to 8 weeks, including up to 9 days in the screening period, up to 5 weeks of treatment with BL-7040, and up to 2 weeks for follow up.~BL-7040 12 mg QD for 19-21 days followed by BL-7040 40 mg QD for 14 days."
45790304|NCT02757105|Drug|BEKINDA|
45790305|NCT02757105|Drug|Placebo|
45804088|NCT05718115|Diagnostic Test|CT scan|Biphasic CT scan including arterial phase and portal venous phase after intravenous injection of 80-100 mL of non-ionic iodinated contrast at rate of 4ml/s using pressure injector.
45804089|NCT05718037|Biological|Recombinant Zoster Vaccine|0.5mL, Intramuscular
45804090|NCT05718037|Biological|Placebo|0.5mL, Intramuscular
45804091|NCT05718037|Biological|Zoster Vaccine Recombinant, Adjuvanted|0.5mL, Intramuscular
45646848|NCT04446377|Drug|Apilimod Dimesylate Capsule|LAM-002A is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, Size 0.
45646849|NCT04446377|Other|Placebo|Microcrystalline cellulose in Swedish orange, Size 0 capsules
45646850|NCT05728619|Drug|HTMC0435|Oral administration.
45646851|NCT05728619|Drug|Temozolomide|Oral administration.
45646852|NCT05737615|Diagnostic Test|PET Scan|Participants will be imaged up to 4 time points post-injection to allow for biodistribution and dosimetry determination
45646853|NCT05737615|Drug|hu5B1-TCO|On study day 0, a single slow infusion of hu5B1-TCO will be administered intravenously. Subsequently, either 3 days (n = 3) or 5 days (n = 3) later, a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously.
45790306|NCT01559948|Behavioral|Lumbopelvic stabilization exercise|The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine. Participants will complete 4 different exercises daily: one in supine, one in standing, one in quadruped, and one in a side-bridge position. The dosage for each exercise is 20 reps with an 8 second hold. In supine, the first exercise is the abdominal drawing-in maneuver. In standing, the first exercise is the abdominal drawing-in maneuver. In quadruped, the first exercise is alternating arm lifts. The final exercise is the side-bridge hold. Participants will then be asked to attend supervised physical therapy sessions twice a week for 2 weeks and once a week for another 2 weeks. They will be instructed to perform the exercises at home daily for a total of 12 weeks as well as complete a compliance log. Progression of the stabilization program will be determined by the physical therapist based on pre-established criteria.
45790307|NCT01559948|Device|Sacroiliac joint belt|The belt should be worn low around the pelvis just above the greater trochanter and instructed to wear the belt during all waking hours of the first four weeks of the study. The treating physical therapist will monitor the placement of belts during each exercise session. Belt usage logs will be given to each participant to assess compliance with wearing the belt.
45646854|NCT05737615|Drug|64Cu-Tz-SarAr|On study day 0, a single slow infusion of hu5B1-TCO will be administered intravenously. Subsequently, either 3 days (n = 3) or 5 days (n = 3) later, a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously.
45790308|NCT02758119|Other|Serious Game|
45790309|NCT02758119|Other|Online course|
45790310|NCT01443494|Other|NE|norepinephine
45790311|NCT05085171|Other|Enhanced care package|The intervention is an improved package of care for patients with advanced HIV disease with point of care CD4 testing, more sensitive screening tests for opportunistic infections and more intensive pre-emptive treatment for opportunistic infections
45790312|NCT05083845|Procedure|Same blocks with different local anesthetic volume|Erector spinae plane block with different local anesthetic volumes will be applied to the patients under real-time ultrasound guidance.
45790313|NCT00371553|Drug|SU011248 (Sunitinib)|
45790314|NCT04337385|Behavioral|Interrupting 3 hours of prolonged sitting with high intensity interval exercise|Breaking up a prolonged bout of sitting in adolescents using high intensity interval exercise
45790315|NCT04337385|Behavioral|3 hours of prolonged sitting|Participants will be asked to remain seated for 3 hours and refrain from moving their lower limbs
45646855|NCT05737615|Diagnostic Test|Pharmacokinetics|All participants receiving 64Cu-Tz-SarAr will have serial blood samples drawn.
45646856|NCT05737537|Diagnostic Test|procalcitonin ,CRP and 1, 3- β -D- glucan in early diagnosis of invasive infections|using of blood biomarkers (CRP ,procalcitonin and 1, 3- β -D- glucan) in early differentiation between fungal and bacterial infections in pediatric cancer patients in comparison to blood culture.
45646857|NCT05238779|Other|Standard of care including palliative care|Usual care includes laboratory evaluations, imaging, and certain procedures and medications. In some cases of patients undergoing transplant evaluation, usual care will also include multiple visits with members of the liver transplant team. A palliative care consult will also be part of standard of care. The primary goal of the palliative care consult is not to arrange hospice (though that can be done in appropriate situations) but to identify and try to address the impacts of the disease and its symptoms on patient's life.
45646858|NCT05576831|Procedure|Re-excision|Re-excise (one take back only) Excise scar aiming for 1-2cm margin
45790316|NCT01560260|Other|Laboratory Biomarker Analysis|Correlative studies
45790317|NCT01560260|Drug|Linsitinib|Given PO
45790318|NCT01560260|Other|Pharmacological Study|Correlative studies
45790319|NCT04337541|Other|Surgical facial mask|Participants will follow normal Authority recommendations AND wear mask outside their homes, or when receiving visits in their home.
45790320|NCT02979782|Procedure|Endo-CABG|minimal invasive cardiac intervention
45790321|NCT02979782|Procedure|PCI|stenting procedure
45790322|NCT02892201|Drug|Pembrolizumab|a constant dose of 200 mg every three weeks, for four cycles.
45790323|NCT04337229|Other|Artifical intelligent|it is planned to create a technology that determines the comfort level of the newborn quickly and simply, easy to use, time-saving and can be used by the mobile device.
45790324|NCT01507220|Drug|morphine sulfate|Patients in this group will receive IV morphine sulfate (or Sponsor-approved equivalent) via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour. All morphine sulfate (Group 1) patients will receive the same opioid in their PCA pump.
45790325|NCT01507220|Drug|bupivacaine liposome extended-release injectable suspension|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
45790326|NCT02703597|Behavioral|Surveys|Surveys include questions related to tobacco use behavior and attitude toward tobacco, as well as demographic and personality questions. Psychosocial surveys and social network surveys are also completed to capture adolescents' network of friends and opinion leaders.
45790327|NCT02703597|Behavioral|ASPIRE|Participants engage in four to five 70-minute sessions of ASPIRE spread over a period of 4 weeks. During ASPIRE use, participants face a screen and individually watch videos and engage in computer-based activities related to the negative effects of tobacco.
45790328|NCT02703597|Behavioral|GSA-ASPIRE-Network|In groups, participants engage in four to five 70-minute sessions of ASPIRE conducted over a period of 4 weeks. However, during each session, ASPIRE use is coupled with game-based social activities (GSAs). During ASPIRE use, participants watch videos and engage in computer-based activities on the same computer screen. Also, in groups, participants engage in the paper-based GSAs as a team and collaborate as they complete the activities. The GSAs contain games about the effects of tobacco. Groups are allocated based on adolescents' network of friendships.
45804092|NCT05717959|Behavioral|Oropharyngeal Exercises|Oropharyngeal Exercises
46071442|NCT02845310|Procedure|Restricted fluid therapy group|Patients will receive restricted fluid management (2ml/Kg/h) with concomitant SVV monitoring using ICON cardiometry device. GDT protocol will be used to fulfil the two targets (SVV < 10% - MAP >65 mmHg). A fluid bolus of 200 ml Lactated ringer will be infused if SVV is more than 10% for 5 minutes, the dose will be repeated every 10 minutes if SVV is still above 10%. If the total fluid boluses reached 20 ml/Kg in a patient with MAP > 65 mmHg, no fluid boluses will be infused unless there is evident blood loss or hypotension. If MAP was achieved (>65mmHg) at any time, the first three steps in the protocol will be bypassed. If MAP was not achieved after reaching 20 ml/Kg , norepinephrine (inotropes) will be given as shown in fig. 1 with dose of 0.01ug/kg/min.
45790329|NCT01507688|Behavioral|Stroke Self-Management|Stroke self-management program- Participants randomized to this program will receive 6 bi-weekly telephone sessions during the first 3 months followed by 3 monthly reinforcement telephone sessions coupled with 3 monthly group sessions during months 4-6.
45790330|NCT02366403|Behavioral|SKY meditation|SKY (Sudarshan Kriya Yoga) meditation is a standardized, manual-based and replicable program that includes relaxation techniques as well as periods of discussion. The format is a 7-day intensive group class (2 1/2 hours/day intensive format) followed by five weeks of sessions twice per week (1hr/session). SKY meditation incorporates several types of breathing exercises involving arousal and attentional control. Initial breathing exercises are calming and focusing. Subsequent breathing exercises are more fully engaging energizing, allowing the practitioner to focus more fully in each moment.
45646859|NCT05737303|Drug|nab-paclitaxel combined with carboplatin|"Nab-Paclitaxel/carboplatin q3weeks Nab-Paclitaxel 260 mg/m² IV followed by carboplatin AUC（area under the curve） 5 IV Day1 Repeat every 21 days x 6 cycles Nab-Paclitaxel/carboplatin weekly Dose-dense Nab-Paclitaxel 100 mg/m2 IV followed by carboplatin AUC（area under the curve）2 IV Davs 1. 8, and 15 ·Repeat every 21 days x 6 cycles Paclitaxel 175 mg/m² IV followed by carboplatin AUC（area under the curve）5 IV Day·1Repeat every 21 days x 6 cycles~Paclitaxel weekly/carboplatin weekly Paclitaxel 60 mg/m2 followed by carboplatin AUC（area under the curve）2 IV Days 1.8. and 15: repeat every 21 days 6 cycles (18 weeks)"
45646860|NCT04824547|Other|exercise|All exercises programs will applied two sessions per week, totally eight week..
45790331|NCT02366403|Behavioral|CPT-C|CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
45790332|NCT02244411|Behavioral|individual diet & physical activity counselor and website through Healthways at Hopkins|Phone and web-based weight loss intervention (via Healthways at Hopkins counselor and website) focused on increasing physical activity and adhering to a healthy diet. Participants will log diet, physical activity, and weight in web-hub. Counselors will have access to this information to direct participants to goals and achievements.
45790333|NCT02244411|Behavioral|self directed weight loss|Participants will be given information and links to CDC and American Cancer Society recommendations for healthy eating and physical activity.
45790334|NCT02244411|Behavioral|questionnaires|Participants will complete behavioral questionnaires as well as diet and physical activity assessments through CCSS-based study website as baseline, 12 and 24 months.
45790335|NCT02244411|Other|fasting blood draw, measurement of height, weight and waist circumference, and blood pressure|During three time periods, at baseline and at 12 and 24 months.
45790336|NCT01509404|Drug|Valganciclovir|Valcyte per package insert guidelines for 200 days post transplant
45790337|NCT01509404|Biological|CMV hyperimmune globulin|100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
45790338|NCT01509404|Drug|Valganciclovir|valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
45790339|NCT04987593|Dietary Supplement|Probiotics|Once a day daily intake of probiotics, at least for 28 consecutive days before giving birth and for at least 28 consecutive days after giving birth
45790340|NCT04337151|Device|MAGEC Spine Rod|Magnetically controlled growing spine rod used for the surgical treatment of scoliosis.
45790341|NCT04337151|Diagnostic Test|Titanium blood test|A blood test captured to measure the level of titanium
45790342|NCT01562132|Drug|Flucytosine and fluconazole|Flucytosine 100mg/kg/day in 4 divided doses orally for 14 days given in combination with fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
45646861|NCT03066089|Drug|Fenfuro|
45646862|NCT04648501|Other|Dual-task training|Dual-task (CIBT- experimental) group participants will receive 10 minutes of warm up, 40 minutes of CIBT training and 10 minutes of cool down exercises. CIBT program includes performing four types of cognitive tasks during sit to stand, standing with feet apart, one leg, tandem standing, multidirectional reaching, stair climbing and walking (10 metres) tasks. The four cognitive tasks will include: counting backwards by subtracting 4 numbers (for mental tracking ), naming fruits, vegetables, or animals (for working memory), auditory cues for performing activities, example, perform heel raise when you hear the alphabet H (for improving attention and auditory discrimination), short story telling (for verbal fluency). In addition, falls prevention strategies will be taught.
45790343|NCT01562132|Drug|Fluconazole|fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
45790344|NCT04336761|Diagnostic Test|nasopharyngeal swab|Data collection and nasopharyngeal swab
45804093|NCT05717881|Dietary Supplement|Propolis|"Propolis supplements were packaged in marine capsules and consisted of poplar propolis powder (propolis concentrate, carob powder, magnesium stearate and silicon dioxide), concentrated to 30% total polyphenols.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed."
46071443|NCT02845310|Procedure|Standard fluid management|Patients will receive standard fluid management of 6 ml/Kg/h plus rescue fluid boluses of 200 ml lactated ringer if Mean arterial pressure (MAP) decreased less than 65 mmHg and central venous pressure less than 8 mmH2o.
46071444|NCT02845154|Other|bolus purge|complete and uninterrupted purge
46071445|NCT02845154|Other|Intermittent purge|intermittent portal purge
45790345|NCT04849923|Other|Strength training session|Conduct of an 8-week strength training intervention of key muscle-tendon groups associated with knee joint stability in the training-specific setting of each participant. Participants are randomly allocated into three study groups with increasing levels of loading (Group#1: no training, Group#2: 1 training per week, Group#3: 3 trainings per week) with the same number of subjects and gender distribution in each group (n=12 per group, 6F and 6M). The same guidelines for the warm-up and the type of exercises will be given prior to the intervention study to each participant. Participants are asked to record exercise load and volume as well as monitor training-related variables and 1RM using the iOS Strength Control app. Participants perform the strength training self-directedly in their chosen fitness/training facilities as it fits into their weekly routine. Contact to the study investigator is ensured at all times in case of questions.
45790346|NCT04837989|Behavioral|Diabetes Body Project|Six virtually delivered Diabetes Body Project groups over six weeks (one hour a week); 5-6 participants and 2 group facilitators
46071446|NCT02845076|Other|Protocol for weaning of noninvasive ventilation|3 protocols for weaning of noninvasive ventilation will be compared
45653112|NCT03065803|Procedure|Buccal plate expansion technique for dental socket preservation|"An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0)."
45790347|NCT04837989|Behavioral|Psychoeducation|Individuals assigned to the psychoeducational control condition will receive an educational brochure, and complete similar assessments and assessment time points as the experimental condition. Individuals in the control group will be offered Diabetes Body Project group participation after six months.
45790348|NCT02762331|Drug|Ascorbic Acid|Comparing safety and efficacy of IV Vitamin C in CABG patients
45790349|NCT02762331|Drug|Placebo|Placebo intervention
45790350|NCT04338087|Other|Questionnaire and personal interviews.|Questionnaire and personal interviews.
45790351|NCT02762799|Biological|Leucostim®|Leucostim® is filgrastim biosimilar.
45790352|NCT02762799|Biological|Neupogen®|
45790353|NCT02737917|Other|Oxygen|15 L of oxygen will be delivered to the patient by nasal cannula during the apnea period of rapid sequence intubation.
45790354|NCT02737917|Other|Standard of care|Rapid sequence intubation
45790355|NCT02958813|Behavioral|IMARA|Morning and afternoon sessions begin with an icebreaker and/or poem to enhance ethnic and gender pride. IMARA's goals and motto are presented to emphasize strong mother-daughter relationships, foster sisterhood, build group cohesion, and increase motivation. Ground rules are reviewed, and each woman and girl signs the IMARA pact to confirm her commitment to the program. At the end of day 1, mothers and daughters receive homework for the week. Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.
45790356|NCT02958813|Behavioral|FUEL|FUEL™ Health Promotion Control Group: mothers and daughters randomly assigned to FUEL™ will participate in separate 2-day workshops identical in length and intensity to IMARA. FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior. Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
45790357|NCT02767011|Other|Tele-Health Electronic Monitoring (THEM)|Patients in the intervention group (THEM) will receive a tablet computer and home monitoring medical devices with sensors to transmit the information to a central website that will be monitored by care managers. Medical devices will include weight scales, blood pressure cuffs and blood glucometers. Clinical care mangers will remotely monitor the patients and all electronic readings. Clinical care managers will call or send text messages to the patients based on alerts generated by the tele-health monitoring system.
45790358|NCT01447706|Drug|MM-121|MM-121 (SAR256212) (IV)
45790359|NCT01447706|Drug|Paclitaxel|Standard dosing Paclitaxel (IV)
45790360|NCT02739789|Device|tDCS|tDCS
45790361|NCT02739789|Device|Sham tDCS|Sham tDCS
45790362|NCT01509638|Drug|Group 1 Standard of Care|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via PCA pump, as needed.
45790363|NCT01509638|Drug|Group 2 EXPAREL|Patients in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
45790364|NCT04336917|Drug|Rhomboid Intercostal and Subserratus Plane Block with local anesthetic|Local anesthetic will be injected in the tissue planes between the rhomboid and the intercostal muscles and the serratus anterior and external intercostal muscles with ultrasound guidence.
45790365|NCT01448486|Drug|Raltegravir|Oral raltegravir, 400 mg tablet, twice daily for one year.
45790366|NCT00371475|Device|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary 38 mm Stent
45790367|NCT00371475|Device|TAXUS™ Express|Paclitaxel-Eluting Coronary Stent System
45790368|NCT01562678|Drug|Liraglutide|In the experimental arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject Liraglutide once per day for 18 days. Subjects will start the treatment with a dose of 0.6 mg for the first week, then 1.2 mg for the second week and 1.8 mg for 3 days in the third week.
46071447|NCT00896454|Drug|denosumab|120 mg subcutaneously (SC) every 4 weeks with a loading dose of 120 mg SC on study days 8 and 15.
46071448|NCT04224584|Drug|Duloxetine|Duloxetine will be administrated with a two weeks up titration followed by a 10 weeks full treatment (60 mg/daily) and finalized by a two weeks discontinuation.
46071449|NCT04224584|Drug|Placebo oral tablet|Placebo will act as a control for duloxetine.
46071450|NCT04168892|Drug|150 IU of HMG in patients with age ≤ 35 years|The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.
45920141|NCT04783155|Other|Cardiopulmonary rehabilitation post lung transplant|Pulmonary function, lung diffusing capacity for carbon monoxide, inspiratory muscle strength, and diaphragm dimensions will be assessed in each patient. Each patient will also undergo a cardiopulmonary exercise test (CPET), 6 minute walk test, and an inspiratory muscle endurance test
45920142|NCT00087061|Drug|gimatecan|
45646863|NCT05558501|Other|Mild Intermittent Hypoxia|The MIH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve two-minute episodes of hypoxia [partial pressure of end-tidal oxygen (PETO2)= 50 mmHg]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The final episode will be followed by a 30-minute end-recovery period. The partial pressure of end-tidal carbon dioxide (PETCO2) will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol. To rapidly induce a PETO2 of 50 mmHg participants will inspire a gas mixture comprised of 8 % oxygen and 92 % nitrogen from a non-diffusible bag. To maintain PETO2 (i.e. 50 mmHg) and PETCO2 (i.e. 2 mmHg above baseline) at the desired levels supplemental oxygen and carbon dioxide will be added to the inspiratory line from the output of a flow meter device that receives inputs from tanks of 100 % oxygen and 100 % carbon dioxide.
45646864|NCT05558501|Other|Sham MIH|"During sham MIH the participants will be exposed to compressed air (the equivalent of room air)."
45790369|NCT01562678|Drug|Placebo|In the placebo arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject placebo once per day for 18 days.
45646865|NCT04647565|Other|interviews|interviews (human and social sciences)
45646866|NCT03066167|Other|Validation of different dysphagia scores|
45653113|NCT03065803|Procedure|Guided bone regeneration technique for post-extraction dental socket preservation|After full-thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed.The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension-free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone.. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0)
45920143|NCT00087100|Drug|pemetrexed disodium|
45790370|NCT01562756|Other|HVLA-SM|High velocity, low amplitude spinal manipulation
45790371|NCT02767869|Drug|Banaba|Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.
45790372|NCT02767869|Drug|placebo|Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg
45790373|NCT01449266|Drug|Dotarem® IV injection at 0.1 mmol/kg|Dotarem® was IV administered at a dose of 0.1 mmoL/kg (0.2 mL/kg).
45920144|NCT00006113|Biological|MART-1 antigen|
45790374|NCT04496349|Drug|APG-115|APG-115 given orally for first 5 consecutive days each cycle
45790375|NCT04496349|Drug|APG-2575|APG-2575 given orally each day in cycle
45790376|NCT01509872|Behavioral|Trauma Focused Cognitive Behavioral Therapy|9 sessions of manualised, culturally modified, group-based trauma-focused cognitive behavioral therapy
45920145|NCT00006113|Biological|aldesleukin|
45920146|NCT00006113|Biological|gp100 antigen|
45920147|NCT00006113|Biological|recombinant CD40-ligand|
46071451|NCT04168892|Drug|225 IU of HMG in patients with age > 35 years|The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.
45790377|NCT01509872|Behavioral|Child Friendly Space|9 sessions of a manualised, culturally appropriate, non trauma-focused psychosocial intervention
45790378|NCT02767947|Drug|Luliconazole Cream 1%|Luliconazole cream will be applied per schedule specified in the arm.
46071452|NCT05336318|Behavioral|Peer support|patients were supported by a mentor
46071453|NCT02789670|Other|Blood sample collection|Peripheral blood will be collected in patients at the different time of the study to analyze phenotypic and functional properties of B cells in MS patients and control group
46071454|NCT04044157|Other|non-invasive measurement of cardiac output|cardiac output will be non-invasivaly measured by means of electrical cardiometry
45790379|NCT02767947|Drug|Vehicle Cream|Vehicle cream will be applied per schedule specified in the arm.
45790380|NCT04461171|Procedure|Enhanced Recovery After Surgery|Undergo an enhanced recovery after surgery program
45790381|NCT01509950|Procedure|Staples|Staples for closure of cesarean section skin incision
45790382|NCT01509950|Procedure|Prolene non-absorbable sutures|Prolene non-absorbable sutures for closure of cesarean skin incision
45790383|NCT01509950|Procedure|Absorbable Sutures|Absorbable sutures for closure of cesarean skin incision
45790384|NCT02769351|Device|periph. minimal invasive ultrafiltration|ultrafiltration via a peripheral single-needle
45920148|NCT00006113|Biological|recombinant interferon gamma|
45920149|NCT00006113|Biological|recombinant interleukin-4|
45920150|NCT00006113|Biological|sargramostim|
45920151|NCT00006113|Biological|therapeutic autologous dendritic cells|
45920152|NCT00006113|Biological|therapeutic tumor infiltrating lymphocytes|
45920153|NCT00006113|Biological|tyrosinase peptide|
45920154|NCT00006113|Radiation|Candida albicans skin test reagent|
45920155|NCT00087217|Drug|tanespimycin|Given IV
45920156|NCT00087217|Drug|paclitaxel|Given IV
45920157|NCT00087217|Other|laboratory biomarker analysis|Correlative studies
45920158|NCT00087217|Other|pharmacological study|Correlative studies
45920159|NCT00087256|Drug|Celecoxib|
45920160|NCT00087256|Other|placebo|
45920161|NCT00006116|Drug|cisplatin|
45920162|NCT00006116|Drug|gemcitabine hydrochloride|
45920163|NCT00087295|Drug|Depsipeptide|Depsipeptide wil be given 13 mg/m^2 through an intravenous (IV) over 4 hours on day 1, 8, and 15 for every 28 days (1 cycle = 28 days) until progression. Patients achieving a complete response (CR) will receive two additional cycles of treatment, and then be removed from protocol treatment.
45920164|NCT04762953|Drug|Paclitaxel|Intraperitoneal Paclitaxel
45920165|NCT04762953|Drug|Paclitaxel|IV Paclitaxel
45920166|NCT04762953|Drug|Leucovorin|IV Leucovorin
45920167|NCT04762953|Drug|Fluorouracil|IV 5-FU
45790385|NCT02770287|Device|Venus Freeze Diamond Polar|The Venus Freeze Diamond Polar is a non-invasive dermatological treatment system that combines Multi Polar Radiofrequency and Pulsed Magnetic Fields. The radiofrequency energy penetrates the skin and results in tissue heating that has known effect on skin laxity, the magnetic field that is simultaneously induces increases fibroblast collagen production through non thermal mechanism and contributes to the clinical effect of skin laxity improvement. Only the Diamond Polar applicator will be used in this study for the treatment of the Mons pubis, vaginal introitus and Labia. Minor modification to the hand-piece for operator and/or patient comfort may occur mid-study, however no change in range of energy modality or amount of energy delivered will occur at any point during the study.
45790386|NCT02770365|Drug|estrace cream (Perrigo)|
45653114|NCT02994563|Device|Thrombectomy Device|The Amnis Thrombectomy Device is intended to restore blood flow by removing thrombus from intracranial vessels in patients experiencing ischemic stroke
45653115|NCT03066505|Device|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/EKG resonance therapy (MeRT) treatment that is tailored specifically to each patient's higher harmonic frequency of heart rate, which is nearest to the characteristic frequency of alpha EEG frequency.
45653116|NCT03066505|Device|Sham MeRT Treatment|A personalized biometrics-guided protocol similar to MeRT treatment that mimics magnetic EEG/EKG resonance therapy (MeRT) but does not emit active stimulation.
45790387|NCT02770365|Drug|estrace cream (Reference)|
45790388|NCT02770365|Drug|Placebo cream|
45790389|NCT04336449|Drug|Eptinezumab|Eptinezumab - single intravenous infusion
45790390|NCT04336449|Drug|Placebo|Placebo - single intravenous infusion
45790391|NCT01510652|Procedure|BiP Group|Implantation of standard Left Ventricular (LV) lead
45790392|NCT01510652|Device|Quad Group|Implantation of quadripolar Left ventricular (LV) lead Quartet
45790393|NCT02770521|Drug|Treprostinil|Administered SC.
45790394|NCT02770521|Drug|Placebo|Administered SC.
45790395|NCT02770521|Drug|LY900014|Administered SC.
45920168|NCT00087334|Drug|capecitabine|
45790396|NCT02770521|Drug|Insulin Lispro|Administered SC.
45920169|NCT00087334|Drug|gefitinib|
45920170|NCT00087334|Drug|oxaliplatin|
45920171|NCT00087373|Biological|recombinant fowlpox-TRICOM vaccine|Given intratumorally
46071455|NCT02749422|Diagnostic Test|MagStim RapidStim2|Repetitive transcranial magnetic stimulation (TMS)
45790397|NCT02346240|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 200 mg/ mL~Route of Administration: Subcutaneous use"
45790398|NCT02346240|Biological|Etanercept|"Active Substance: Etanercept~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 50 mg / mL~Route of Administration: Subcutaneous use"
45790399|NCT02346240|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 0.9 % saline~Route of Administration: Subcutaneous use"
45790400|NCT01511978|Drug|Continuous 3,4-DAP|Subjects were maintained on their usual personal dose and schedule of 3,4-DAP base
45790401|NCT01511978|Drug|Taper 3,4-DAP to Placebo|Subjects were tapered over 3 days from their usual regimen of 3,4-DAP base to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base
45790402|NCT02772783|Other|high GI meal|High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A high glycemic index of ~90 is achieved by using corn syrup as a carbohydrate source.
45790403|NCT02772783|Other|low GI meal|High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A low glycemic index of ~40 is achieved by using uncooked corn starch as a carbohydrate source.
45790404|NCT02772783|Drug|euglycemic insulin clamp|Insulin will be given intravenously for 5 hours. During the entire clamp protocol, glucose levels will be measured every 5 minutes. A basal insulin infusion will be started at 80% of the patients insulin pump basal rate, and will be adjusted between 0.1 and 2.5 mU/kg•min, depending upon the patient's plasma glucose level in relation to the target range target of 90-100 mg/dl.
45790405|NCT02772783|Drug|primed-variable insulin infusion|A primed-variable infusion of insulin will be administered at the rate established to achieve euglycemia after a low glycemic index meal. This is expected to result in moderate hyperglycemia as the high GI meal is associated with higher insulin requirements. For patient safety, glucose levels will be measured every 30 minutes. If glucose levels are > 400 mg/dl or < 60 mg/dl, insulin infusion will be adjusted to maintain glucose levels target of 60-400 mg/dl.
45920172|NCT00087373|Other|laboratory biomarker analysis|Correlative studies
45920173|NCT00006119|Drug|hydroxyurea|
45920174|NCT00087412|Drug|erlotinib hydrochloride|Given orally
45920175|NCT00087412|Other|laboratory biomarker analysis|Correlative studies
45920176|NCT00087724|Drug|FK962|
45920177|NCT00390078|Biological|MVA-mBN32|3 immunizations: 1x 10E8_TCID50 MVA-mBN32
45920178|NCT00390078|Biological|IMVAMUNE|3 immunizations: 1x 10E8_TCID50 IMVAMUNE
45920179|NCT00006122|Drug|cytarabine|
46071456|NCT00820651|Dietary Supplement|Diamel|Diamel, a nutritional supplement, 2 oral pills (660 mg), every 8 hours, daily, during 52 weeks
46071457|NCT00820651|Other|Placebo and lifestyle counseling|Hypocaloric diet of 1620 kcal daily (The dietary pattern will be distributed in carbohydrates 64%, fat 22% with <10% of saturated fatty acids and protein 14%, and exercise)
46071458|NCT02993198|Drug|Carvedilol|
45920180|NCT00006122|Drug|etoposide|
45920181|NCT00006122|Drug|gemtuzumab ozogamicin|
45920182|NCT00006122|Drug|idarubicin|
45920183|NCT00006122|Drug|mitoxantrone hydrochloride|
45920184|NCT00087763|Drug|Macugen ™ (pegaptanib sodium injection)|
45920185|NCT00087802|Drug|gemcitabine/Eloxatin (GEMOX)|GEMOX [gemcitabine/Eloxatin™ (Oxaliplatin) - 21 day cycle] Gemcitabine 1000 mg/m2 will be administered over 30 minutes on Days 1 and 8 and Eloxatin™ 130 mg/m2 will be administered over 2 hours on Day 1, after gemcitabine administration, every 21 days [3-week cycle]
45646867|NCT04599049|Other|six sessions of online classes and virtual training day camps through Zoom in two days|"The Smoke-free teens will join six sessions of online classes via an e-platform in October 2020 and followed by virtual training day camps through Zoom in two days in December 2020 organized by COSH. The online classes will educate students the knowledge on smoking hazards, tobacco control and smoking cessation. In addition, the teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model. After the online classes, the teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the online classes (T2), and 3 months later (T4). They will be asked to complete a process evaluation form immediately after the training camp (T3). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 months (T4), respectively."
45646868|NCT03065699|Device|DIALIVE Liver Dialysis Device|ACLF patients will receive dialysis treatment for 8-12 hrs/day and on three to five consecutive days over a 10-day time period. Dialysis treatment is performed by using the DIALIVE device provided by YAQRIT Ltd.
45646869|NCT03065855|Procedure|Early removal group|Participants assigned to the experimental arm will have their urethral catheters removed at 2 days after after laparoscopic anterior resection of the rectum.
45790406|NCT02774343|Drug|Pioglitazone|Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.
45790407|NCT02774343|Drug|Placebo|Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
45790408|NCT02774343|Behavioral|Therapy|Cognitive-behavioral therapy 1 hour per week
45646870|NCT03065855|Procedure|Normal removal group|Participants assigned to the control group will have their urethral catheters removed at 7days following surgery, as is standard practice in our institution.
45920186|NCT00087802|Drug|carboplatin/paclitaxel (CP)|"CP [carboplatin/paclitaxel - 21 day cycle]~o Paclitaxel 225 mg/m2 will be administered over 3 hours on Day 1 followed by carboplatin at a dose calculated to produce an area under the concentration-time curve (AUC) of 6.0 over 30-60 minutes on Day 1 every 21 days [3-week cycle]"
45920187|NCT04760613|Drug|Cannabidiol|600 mg oral daily use (each capsule of active drug contains 50 mg of CBD)
45920188|NCT04760613|Drug|Placebo|identical capsules containing placebo (taken daily by mouth)
45646871|NCT01678807|Biological|MK-8237 6 DU|
45646872|NCT01678807|Biological|MK-8237 12 DU|
45646873|NCT01678807|Biological|Placebo|
45646874|NCT05199545|Dietary Supplement|Dietary supplement|Dietary supplement under study is based on Rhodiola rosea L. and Crocus sativus L. extracts
45646875|NCT05199545|Other|Placebo|Placebo of the dietary supplement
45646876|NCT05737225|Device|Near Infrared Spectroscopy (NIRS)|We will place Near Infrared Spectroscopy (NIRS) electrode on the foot to evaluate regional tissue oxygen saturation in both lower extremities before the performing regional anesthesia (popliteal sciatic nerve block) and then during the procedure.
45646877|NCT05188313|Drug|Trastuzumab|Intravenous administration of study drug
45646878|NCT05188313|Drug|Pertuzumab|Intravenous administration of study drug
45646879|NCT05188313|Drug|Paclitaxel|Intravenous administration of study drug
45646880|NCT05188313|Drug|Carboplatin|Intravenous administration of study drug
45790409|NCT02774343|Behavioral|Contingency Management|Prize-based contingency management for attendance
45790410|NCT05349045|Drug|an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor|This is an observational study
45790411|NCT02392104|Drug|Warfarin|If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.
45920189|NCT00006125|Drug|doxorubicin hydrochloride|
45646881|NCT04540315|Behavioral|MobiMD|MobiMD is a mobile app. This is an app available to IOS and Android devices only. The app provides a digitized version of the discharge instructions and provides push notifications to remind the participant of important instructions. In addition, the app allows participants (and their care teams) to record and track relevant clinical data.
45646882|NCT03065777|Device|ONE ENDO|single file rotary system
46071459|NCT02843256|Device|Isomark Canary|The Isomark Canary will analyze the exhaled air and generate a breath delta value.
45646883|NCT03065777|Device|F6 SKYTaper|single file rotary system
45646884|NCT03065777|Device|ProTaper Universal|multi-file rotary system
45646885|NCT04310137|Behavioral|Therapist-Directed Re-loading|Therapist will specifically direct participant to increase walking by 10% as measured at each of the activity monitoring assessments. In addition, the participant will be asked to monitor foot temperature to mitigate risk for breakdown.
45790412|NCT04336605|Other|Age & Development|Age, sex, pubertal onset and development
45790413|NCT04336605|Other|Socioeconomy|Family structure and economy
45790414|NCT04336605|Other|Traumatic Events|Violence and other traumatic events
45790415|NCT04336605|Other|Psychosocial conditions|Family/social support
45790416|NCT04336605|Other|Lifestyle|Physical activity, BMI, nutrition, smoking …
45790417|NCT04336605|Other|Chronic conditions|I.e. Epilepsy or juvenile rheumatoid arthritis ...
45790418|NCT04336605|Other|Somatic symptoms|Headache, pain, sleep disturbances ...
45790419|NCT04336605|Other|Psychological symptoms|PTSS, anxiety, depressive symptoms & loneliness ...
45790420|NCT04336605|Other|Non-prescription analgesics|Non-prescription analgesics
45790421|NCT04336605|Other|Prescription drugs|Analgetic, sedative & anxiolytic medication
45790422|NCT04737915|Behavioral|Exposure Therapy (In Vivo)|Participant completes a single session of exposure therapy for fear of heights by looking over railings into an atrium at various floor levels in a virtual environment.
45920190|NCT00006125|Drug|topotecan hydrochloride|
45920191|NCT00087841|Behavioral|Self-hypnotic relaxation|
45920192|NCT04747470|Drug|GS-3583|Administered as an intravenous (IV) infusion
45790423|NCT04737915|Behavioral|Exposure Therapy (Virtual Reality)|Participant completes a single session of exposure therapy for fear of heights by looking over railings into an atrium at various floor levels in a real environment.
45790424|NCT01450826|Drug|aprepitant|On day 1, eligible patients will receive a single oral dose of Aprepitant 125 mg p.o, 1 hour before first dose of the 5-day oral temozolomide regimen. This will be followed by Aprepitant 80 mg p.o. on days 2 -5 (1 hour prior to temozolomide).
45790425|NCT01450826|Drug|ondansetron|On Days 1-5, eligible patients will receive a single oral dose of Ondansetron, 30 minutes before first dose of the 5 -day oral temozolomide regimen.
45790426|NCT05350137|Procedure|100% oxygen|During one-lung ventilation with an open chest, the non-ventilated lung collapses initially due to the inherent elastic recoil properties of the lung. Once passive venting has ceased, further collapse will then be wholly dependent on ongoing gaseous uptake and absorption atelectasis. Improved inflation-deflation method is currently the most widely used method in clinical practice. After dividing all the targeted vascular and bronchial structures, the lung of the operating side was re-inflated with 100% oxygen. After the operative lungs is completely expanded, perform pure oxygen mechanical single lung ventilation for the healthy lung, waiting for clear presentation of the plane between the targeted segment and the other segments.
45790427|NCT05350137|Procedure|Carbon dioxide|During one-lung ventilation with an open chest, the non-ventilated lung collapses initially due to the inherent elastic recoil properties of the lung. Once passive venting has ceased, further collapse will then be wholly dependent on ongoing gaseous uptake and absorption atelectasis. The solubility coefficient for carbon dioxide is 0.57. The rapid diffusion properties of carbon dioxide would be expected to speed lung collapse and so facilitate surgery. After the targeted segment structures were successfully dissected, the collapsed intraoperative lung was completely re-expanded with carbon dioxide. After the operative lungs is completely expanded, perform pure oxygen mechanical single lung ventilation for the healthy lung, waiting for clear presentation of the plane between the targeted segment and the other segments.
45790428|NCT04335357|Drug|TBR-760|TBR-760 is intended for SC administration. The target dose to be studied in this study is 6 mg SC given once weekly.
45790429|NCT04335357|Drug|Placebo|Placebo
45790430|NCT05350059|Device|High Intensity Focused Ultrasound (HIFU) to the Breast Cancer|Breast cancer will be ablated using high intensity frequency ultrasound prior to breast surgery
45646886|NCT05172557|Behavioral|Wellness Program|Wellness Program involves participation in classes with topics involving resiliency, stress, physical activity, and nutrition to be completed within a few months of study participation
45646887|NCT05172557|Behavioral|Wellness Coaching|Wellness coaching sessions throughout 12 months of study participation
45646888|NCT02514655|Device|Nosten® pressure control (it's not an antibiotic, but simple device)|One experimental group with the control of the cuff pressure by Nosten® device
45646889|NCT02514655|Other|Manual pressure control|One control group with the manual monitoring of the cuff pressure and inflation of the balloon
45646890|NCT03066011|Drug|Isavuconazonium sulfate|Oral and Intravenous
45646891|NCT03066011|Drug|Voriconazole|Oral and Intravenous
45790431|NCT05349903|Other|Rice flour|Rice flour made into rice porridge will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
45790432|NCT05349903|Other|Alternanoligosaccharide 15|Alternanoligosaccharide 15 incorporated into rice porridge will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
45790433|NCT05349903|Other|Inulin|Inulin incorporated into rice porridge will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
45790434|NCT05349903|Other|Waxy potato starch|Retrograded waxy potato starch made into porridge meal will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
45790435|NCT05349903|Other|Waxy potato starch + epigallocatechin gallate (EGCG)|A combination of retrograded waxy potato starch and EGCG made into porridge meal will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
45790436|NCT05349903|Other|Chickpea flour + epigallocatechin gallate (EGCG)|A combination of chickpea flour and EGCG made into porridge meal will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
45790437|NCT01564628|Device|CADScor1|Acoustic recording
45790438|NCT05348655|Other|epidemiology|To review of medical records to describe diagnosis and severity of the disease
45790439|NCT05348655|Other|epidemiology|To compare pre- and per-Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
45790440|NCT01564706|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
46071460|NCT01012596|Behavioral|Creighton Model System of Natural Family Planning|Participants will learn the Creighton Model, a standardized method of natural family planning, from FertilityCare Practitioners from established FertilityCare Centers. The learning can be done in-person or long distance.
45646892|NCT03066011|Drug|Posaconazole|Oral and intravenous
45646893|NCT03135769|Drug|Avelumab administration at 10mg/kg|Avelumab administration at 10 mg/kg as a 1 hour IV infusion once every 14 days during 6 months (maximum).
45646894|NCT03781297|Other|Narrative Exposure Therapy|Narrative Exposure Therapy attempts to place the trauma within a narrative of the person's life. Anecdotal evidence of using this approach in the homeless population is that constructing an autobiography helps to give meaning to their problems and provide the initial steps in constructing a core sense of belonging and identity. Six sessions of individual therapy allows for participants to work with a therapist one-on-one to position their experiences of trauma within their life story.
45646895|NCT03781297|Other|Genealogical Services|At the start of their involvement in the, study participants randomized to this group will be provided with the option to access services from a professional genealogist, to trace their family history. Participants will be made aware of the fact that new family information will be revealed through this process, and also be informed of the standard methods that will be used to extract this information which could involve research through publicly available historical records or voluntary DNA testing.
45646896|NCT05539313|Device|High-density mapping|Patients will undergo magnetic resonance imaging of both atria, and interventional high-density mapping of both atria.
45790441|NCT05349825|Diagnostic Test|Genetic analysis and Losartan plazma level measurement|20 ml of blood was collected from the enrolled patients. 10 ml of blood was stored in the tubes with ethylene diamine tetraacetic acid (EDTA) until Deoxyribonucleic acid (DNA) isolation was performed at -20 degrees and plasma level was identified. The remaining 10 ml was centrifuged at 3500 rpm for 10 min, and the plasma was separated. The resulting plasmas were stored in the eppendorf tubes at -20°C until the tandem mass spectrometry measurement. The blood samples in EDTA tubes were then transferred for DNA analysis. . To measure plasma losartan concentration, after the frozen plasma samples stored in the eppendorfs were thawed and brought to room temperature, plasma losartan and EXP3174 levels of the patients were calculated using tandem mass spectrometry
45646897|NCT05728463|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is defined as total or subtotal desection of the gallbladder laparoscopically.
45790442|NCT00371943|Procedure|band ligation|
45790443|NCT01451996|Drug|Claritin|Subject will be given 10mg Claritin tablet.
45790444|NCT04335825|Procedure|phacotrabeculectomy|combined antiglaucoma procedure: trabeculectomy with phacoemulsification
45790445|NCT04335825|Procedure|ExPress antiglaucoma surgery combined with phacoemulsification|combined antiglaucoma procedure: ExPress device implantation with phacoemulsification
45790446|NCT04903860|Device|total hip replacement with single use ancillary|Comparison of the use of conventional ancillary reaming and single-use ancillary reaming material in total hip replacement
45790447|NCT04903860|Device|total hip replacement with conventional ancillary|Comparison of the use of conventional ancillary reaming and single-use ancillary reaming material in total hip replacement
45790448|NCT02742129|Drug|Nebulized Sodium Nitrite|Inhaled, nebulized inorganic sodium nitrite vs. inhaled, nebulized placebo at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
45790449|NCT02742129|Drug|Placebo|Inhaled, nebulized placebo vs. inhaled, nebulized inorganic sodium nitrite at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
45790450|NCT05349747|Biological|Biologic drugs|Assess the results of treatment with biologic drugs
45790451|NCT04335747|Other|COVID-19 infection|Hospitalisation due to a confirmed COVID-19 infection
45790452|NCT04336059|Procedure|pericapsular nerve group block|"The regional block will be performed with the patient in the supine position under complete sterile technique. A low frequency curvilinear ultrasound probe will be initially placed in a transverse plane over the anterior inferior iliacspine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminance(IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will observed.~A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly after local infiltration of the site of the block with 3 ml lidocaine 2%. Following negative aspiration,the normal saline solution will injected in 5-mL increments while observing for adequate fluid spread in this plane."
45790453|NCT05348187|Diagnostic Test|therascreen® KRAS RGQ PCR Kit|The primary objective is to utilize a clinical trial assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 2 of Amgen clinical trial, in order to identify patients (with NSCLC and CRC) with KRAS G12C mutation positive tumors
45790454|NCT01512446|Drug|Alendronate|70 mg per week
45646898|NCT03123211|Drug|Veliparib|Veliparib will be administered orally.
45646899|NCT05736991|Diagnostic Test|PET/CT-based Radiomics Signature|Radiomics Signature Based on PET-CT for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
45646900|NCT05527457|Drug|BAY2586116|160 μg BAY2586116 nasal spray application
45790455|NCT01512446|Drug|Placebo|1 pill per week
45790456|NCT00372021|Procedure|optic nerve neurotomy|
45790457|NCT04334967|Drug|Hydroxychloroquine|Treatment arm medication will be administered on an outpatient basis. Due to the emergent health crisis, study drug will be delivered to patients by institution staff or contract courier using a non-contact protocol.
45790458|NCT04334967|Dietary Supplement|Vitamin C|Control arm supplement will be administered on an outpatient basis. Due to the emergent health crisis, study supplies will be delivered to patients by institution staff or contract courier using a non-contact protocol.
45790459|NCT01565330|Drug|florbetapir F 18|single dose IV injection
45790460|NCT04335123|Drug|Losartan|25 mg QD from day 0 to day 3. Dose escalation to 50 mg QD until study completion
45790461|NCT05455125|Diagnostic Test|CMR CGI|High resolution ECGI plus advanced CMR
45646901|NCT05527457|Drug|Placebo|Placebo (saline) nasal spray application
45790462|NCT05347953|Device|Single night downgraded home polygraphy|All patients will be outfitted with the ambulatory downgraded polygraphy device (Nox A1, Nox Medical Global, Reykjavik) for 24 hour monitoring. The data exported by the polygraphy device is in European Data Format and will be filtered and annotated using custom MATLAB-software.
45790463|NCT05453565|Other|Vasopressors|A haemodynamic resuscitation strategy based upon the restriction of IV fluids (by either volume or rate of infusion) with initiation or change of rate of vasopressors if required to meet perfusion targets
45790464|NCT05453565|Other|Fluids|A strategy of resuscitation with intravenous fluids as the primary intervention to achieve perfusion targets with subsequent initiation or change of rate of vasopressors if required.
45790465|NCT02742987|Drug|Ticagrelor|Ticagrelor 90 mg twice daily
45790466|NCT02742987|Drug|Clopidogrel|Clopidogrel 150 mg once daily
45790467|NCT02742987|Drug|Standard medical therapy|Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
45790468|NCT05452473|Other|CDSS-assisted upper GI endoscopy|Expert endoscopists perform screening upper gastrointestinal endoscopy while looking at the monitor (CDSS system: automatic detection or lesion classification function) and listening to the sound of the monitor next to the original endoscopy monitor system.
45790469|NCT05452473|Other|no intervention|Expert endoscopists perform routine screening upper gastrointestinal endoscopy without CDSS's help.
45790470|NCT04737993|Drug|licocain|pulsed radiofrequency stimulation
46071461|NCT04981808|Device|Telemonitoring|Telemonitoring of CGM and insulin pen data
46071462|NCT00629239|Drug|AZD4818|Dry Powder, inhalation, b.i.d., 4 weeks
46071463|NCT00629239|Drug|Placebo|
45790471|NCT04737993|Other|pulsed radiofrequency stimulation|pulsed radiofrequency stimulation of joint capsel
45790472|NCT00372333|Drug|IDEA-033|
45790473|NCT05450055|Procedure|intraperitoneal lidocaine analgesic or normal saline as control|Before the end of surgery, patients in the experimental group (L group) were extensively sprayed with 20mL (100mg) 0.5% lidocaine intraperitoneally before the peritoneum was sutured. The surgeon placed intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. The intraperitoneal catheter was connected to the electronic analgesia pump, and the infusion of 0.5% lidocaine 10mL/h was interrupted from 1 to 72h after surgery, with a total volume of 720mL in the pump.
45790474|NCT02743377|Other|Brain PET Imaging with 11C Rolipram|Brain PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan
45790475|NCT02743377|Drug|Whole Body PET Baseline with 11C Rolipram|Whole Body Baseline PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan
45790476|NCT02743377|Drug|Whole Body PET Blocked with Roflumilast|Whole Body PET Imaging scan after blockade with Roflumilast 500 mcg PO, given 1-2 hours prior to start of scan
45790477|NCT05437965|Drug|glucocorticoid and immunosuppressants|This study will include patients with isolated coronary arteritis, whose condition could not be controlled by current clinical treatment. After Multiple Disciplinary Team consultation, these patients may be given glucocorticoid and immunosuppressants.
45790478|NCT01512758|Drug|Alisertib|Alisertib enteric-coated tablets
45790479|NCT02746107|Other|decision aid|decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself
45790480|NCT01513538|Device|TherapyGuide|Use of TherapyGuide function to help programming the device
45646902|NCT04096807|Other|Standard TEE exam including measurement of left upper pulmonary vein diameter and collapsibility, compared with PCWP measured continuously by a pulmonary arterial catheter|TEE takes part of the standard perioperative hemodynamic monitoring in cardiac surgery. Patients enrolled in the study are also monitored by a pulmonary arterial catheter
45646903|NCT05520749|Drug|Luspatercept|Luspatercept treatment in adults with transfusion-dependent anaemia due to MDS
45646904|NCT05092243|Device|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
45790481|NCT00372099|Drug|Salmon calcitonin|nasal salmon calcitonin 200UI/day during 2 years
45790482|NCT01453166|Other|Brazilian heart-prevent meal|Nutrient profile of the diets used was based on the Brazilian guidelines to cardiovascular disease treatment.The main difference between this group involves a Brazilian version of accessible and energy density concept dietary therapy to cardiovascular diseases. Furthermore, it explores a set of tools and educational materials that help the patient understand and follow the principles of balanced and healthy diet weekly session with the dietitians which could be in person, by phone or in a gourmet shop. During attendances at the gourmet shop, patients received tips for eating in restaurants, instruction on label reading and a list of typical foods. The menus were based on typical foods consumed in Brazil, all foods included in the menu were low-cost and widely available at local markets
45790483|NCT01453166|Other|Heart prevent control meal weekly|received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts). The difference between groups B and C was the number of sessions with the dietician. Group B received weekly sessions, which could be in person or by phone, and group C had monthly in person sessions
45790484|NCT01453166|Other|Heart prevent control Meal monthly|received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A and B, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts) at the same of group B. The difference of group C was the number of sessions with the dietician. That happen monthly in person sessions.
45790485|NCT04334733|Other|Cartoon group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography process.
45790486|NCT04334733|Other|Kaleidoscope group|The children in the groups were distracted by kaleidoscope during echocardiography, until the process was over.
45790487|NCT04334733|Other|Cartoon+Kaleidoscope group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography process and then the children in the groups were distracted by kaleidoscope during echocardiography, until the process was over.
45790488|NCT05382897|Other|Plant-based fasting-mimicking diet|Participants will be on a low caloric plant-based diet or a caloric-sufficient plant-based diet for 3 x 5 day cycle each month followed by 3 weeks of eating normally for a total period of 3 months.
45646905|NCT03609697|Behavioral|group-based lifestyle intervention|Involve education about pre-diabetes self-management, weight loss, behavioural modification skills, nutrition and physical activity.
45646906|NCT03609697|Behavioral|Minimal intervention (SMS intervention)|Text message related to general information about T2DM, pre-diabetes, and lifestyle modification.
45646907|NCT04943861|Behavioral|weCare/Secure|The weCare intervention is based on the social cognitive and empowerment theories and social support and is currently designed to reduce missed HIV care appointments and increase viral suppression among PWH who are newly diagnosed or out of care through the use of peer navigation and mHealth
45646908|NCT04943861|Other|Usual Care|There is no peer navigation within usual care.
45646909|NCT03073525|Biological|Vigil|The Vigil vaccine is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
45790489|NCT01514162|Device|Trifecta valve|surgical replacement of aortic valve
45790490|NCT05244135|Procedure|Pulmonary rehabilitation|An in-patients 3-week high intensity rehabilitation program, five times a week, was used as the intervention treatment. A holistic pulmonary rehabilitation program for SARS-CoV-2 patients with combined treatment focused on increasing exercise capacity, restoring lung function, and supporting mental health, developed by a multidisciplinary team, was introduced. Rehabilitation program includes exercise capacity training on a cycle ergometer, breathing exercises, general fitness exercises, resistance training, and relaxation.
45646910|NCT03073525|Drug|Atezolizumab|"Atezolizumab was prepared and administered at the FDA approved dose and schedule as described in the U.S. Package Insert (USPI). The initial dose was administered over one hour and if well tolerated, subsequent infusions may have been administered over 30 minutes.~Atezolizumab in formulation F03 (1200 mg per vial) was administered in 250 mL 0.9% NaCl IV infusion bags and infusion lines equipped with 0.2 μm in-line filters."
45646911|NCT05728307|Device|neoGuard vital signs monitor|"The neoGuard device is a 4-in-1 wearable vital signs monitor developed by Neopenda, PBC (Chicago, Illinois). The system is designed to continuously measure temperature, pulse rate (PR), respiratory rate (RR) and blood oxygen saturation (SpO2). It contains two non-invasive sensors: an optical reflectance pulse oximeter and a digital temperature sensor. These sensors measure signals from the surface of the patient's skin, and algorithms within the device calculate the pulse rate, respiratory rate, SpO2 and temperature.~The device is made of medical grade polyetherimide plastic and can be worn on the forehead through an adjustable band. The PR, RR, temperature and SpO2 data are collected, recorded and transmitted via Bluetooth Low Energy (BLE) to a tablet which can be placed within a range of 20-30 meter distance. The neoGuard technology has received CE mark certification and is also registered with the Kenya Pharmacy and Poisons Board (KPPB)."
45646912|NCT02563015|Dietary Supplement|cholecalciferol|liquid drops
45790491|NCT02748525|Other|Milk|Milk, in the form of 8 oz. half and half, administered after CCK scan, and patient is rescanned and ejection fraction measured to determine if ejection fraction is low.
45790492|NCT02748525|Biological|CCK|CCK is standard of care, used in HIDA scans for gallbladder function evaluation. It is given intravenously to cause the gallbladder to contract. The usual dose of CCK is 0.02mg/kg slowly over 3 minutes as per standard.
45790493|NCT01454414|Other|Permethrin Impregnated Uniforms|Uniforms treated with permethrin according to proprietary process used by Insect Shield, Inc.
45790494|NCT04335513|Other|Early CGM-guided education and initiation of insulin therapy.|Careful monitoring of children progressing from stage 2 to stage 3 T1D using continuous glucose monitor (CGM) technology, staged education targeted to assist families in recognizing evolving dysglycemia, and addressing glycemic abnormalities with early initiation of insulin can substantially reduce the HbA1c and risk of DKA at diagnosis, thereby changing the trajectory of the disease course.
45790495|NCT04335513|Other|Usual care: glucometer surveillance and basic education.|"Usual education and advice on glycemic surveillance based on protocols of TEDDY/DAISY/ASK.~Blinded CGM for 10 days every 3 months to collect data on glycemic profile with basic feedback regarding changes."
45646913|NCT02563015|Dietary Supplement|Reference 400|liquid drops
45646914|NCT02382445|Device|Anesthesia depth monitor|
45790496|NCT01514318|Device|Revelation Hip Stem (Revelation)|Subjects who received the Revelation Hip Stem prior to 2002 and still maintain the original device.
46071464|NCT04208100|Device|PicoPlus|The PICOPLUS Laser System (K173700) is indicated for use in surgical and aesthetic applications in the medical specialties of dermatology and general and plastic surgery. The 595nm and 660nm wavelengths of the Lutronic PicoPlus Laser system are used for the treatment of benign pigmented lesions.
46071465|NCT03797378|Other|eM2M|The eM2M intervention involves three 60-minute sessions per week for 12 weeks. All sessions are delivered remotely in real-time through videoconferencing technology. The intervention uses combinations of movement patterns that target range of motion, muscle strength, cardiorespiratory fitness, balance, and breathing. Each session consists of movement routines choreographed to music, and every routine can be adapted to participants' functional ability.
45790497|NCT01514396|Device|Surgiseal|surgical glue
46071466|NCT02842944|Device|open loop weaning group (Beacon)|mechanical ventilation following advice from the Beacon Caresystem
45646915|NCT02382445|Device|Sham control|Standard care as usual. Bis m Standard care as usual. Bispectral index monitor is not visible for anesthesia provider.
45646916|NCT02382445|Drug|propofol and sevoflurane|
45646917|NCT05094973|Device|Carriere Motion Appliance®|To analyze the distalization or distal tooth displacement and derotation angle produced by Carriere Motion Appliance® in a period of 4 months.
45646918|NCT02875535|Behavioral|RLAS|"The implementation model for this intervention will increase school-based supports and safety for gender and sexual minorities and broader student bodies, and be applicable to addressing other priority child and adolescent health and mental health issues within schools. The investigators refer to the model as RLAS (Implementing School Nursing Strategies to Reduce LGBTQ Adolescent Suicide)."
45790498|NCT05263557|Dietary Supplement|Dehydroepiandrosterone (DHEA)|Dehydroepiandrosterone (DHEA) at a dose of 150mg once daily for 7 days.
45790499|NCT05263557|Dietary Supplement|11-ketoandrostenedione (11KA4)|11ketoandrostenedione (11KA4) at a doses of 150mg once daily for 7 days.
45790500|NCT01514630|Drug|Creatine monohydrate|Five grams of creatine monohydrate will be administered for eight weeks.
45790501|NCT04140669|Device|Automated Myocardial Performance Index (MPI)|Automated Myocardial Performance Index will be performed using Samsung HERA W10 prior too fetal surgical interventions, during surgery, and following surgery.
45790502|NCT01568528|Drug|Oxytocin|OT intervention will be administration of OT intranasally at a dose of three 4 IU puffs per nostril for a total dose of 24 IU. This dose has been used in a number of other similarly designed challenge studies examining the effects of a single dose of OT (Kirsch et al. 2005; Kosfeld et al. 2005; Guastella et al. 2008a; Guastella et al. 2008b; Rimmele et al. 2009; Andari et al. 2010).
45790503|NCT01568528|Drug|Placebo|The PBO/control will consist of the OT vehicle only delivered as 3 puffs of saline per nostril for a total of 6 puffs. Each puff contains 0.1 ml in volume, so the total delivered will be 0.6 ml intranasally.
45790504|NCT01568528|Other|Control|Participants who have no psychiatric diagnosis and will be controls for this project. These controls will NOT receive oxytocin or PBO. They will only receive psychiatric screening interview, MCCB Consensus Cogntive Battery assessment, urine drug screen, vision testing, and the three social cognition tasks.
45790505|NCT05199207|Behavioral|Physical activity programm|adapted physical activity during 3 month
45790506|NCT05065359|Drug|Rodatristat Ethyl 300 mg BID|Tablets, oral, 300 mg, BID 14 days
45790507|NCT05065359|Drug|Rodatristat Ethyl 600 mg BID|Tablets, oral, 600 mg, BID 14 days
45790508|NCT05065359|Drug|Placebo|Tablets, oral, 0 mg, BID for 14 days
46071467|NCT02842944|Other|Routine care|Standardized routine care
45790509|NCT01568606|Device|Body Composition Analysis InBody Scale|"Patients will have their ICD interrogated using a pacemaker Programmer specifically designed from one of the 4 pacemaker manufacturers: St. Jude, Medtronic, Guidant, and Biotronik. Depending on the type of pacemaker, interrogation can be done either wirelessly or by placing a wand over the pacemaker. The ICD will be turned to a monitor-only mode to disable risk of ICD shock by the supervising electrophysiologist. Patient will be asked to step on the InBody 520 scale to have their body composition analyzed. Patient will continue to have their ICD actively monitored. Analysis will take approximately 30 - 50 seconds. At the end of analysis, ICD device will be returned to default settings by supervising electrophysiologist."
45790510|NCT01460732|Device|Blood Pressure Monitoring|Home Blood pressure Monitoring Nocturnal-Home Blood Pressure Monitoring Ambulatory Blood Pressure Monitoring
45790511|NCT05013255|Drug|Pioglitazone 15mg|PIO 15mg orally once daily for 2 weeks
45790512|NCT05013255|Drug|Pioglitazone 30 mg|PIO 30mg orally once daily for 2 weeks
45790513|NCT01514786|Behavioral|Colorectal Web|The intervention arm will allow participants on Colorectal Web to manipulate their preferences for CRCS
45790514|NCT04088643|Device|transcranial alternating current stimulation|The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with 4Hz frequency and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
45790515|NCT04088643|Device|sham stimulation|Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
45790516|NCT01461668|Drug|Retapamulin|Two times a day for 5 days
45790517|NCT01461668|Drug|Placebo|Two times a day for 5 days
45790518|NCT04998825|Dietary Supplement|Proteoglycan F|Salmon proteoglycan (Proteoglycan F) was extracted from salmon (Oncorhynchus keta) nasal cartilage. Salmon cartilage PG (Proteoglycan F) was manufactured in the form of a hard capsule by Ichimaru Pharcos, Co., Ltd. (at 318-1 Asagi, Motosu-shi, Gifu 501-0475 Japan) and consisted of 50 mg proteoglycan.
45790519|NCT04998825|Other|Placebo product|The placebo capsule contained only dextrin powder (Ichimaru Pharcos, Co., Ltd.).
45790520|NCT00372177|Radiation|Fab-fragment of Anti-human CD4|Sterile lyophilized Powder for Preparation of a Solution and sterile labelling Buffer labelling with Tc99m-Pertechnetat Intravenous injection
45646919|NCT05736835|Biological|CVXGA1|CVXGA1 is a live viral vector, consisting of a recombinant parainfluenza virus type 5 that carries the SARS-CoV-2 S-protein from WA.1 strain.
45646920|NCT05736757|Drug|Tissue Plasminogen Activator|Injection of 50 ug tissue plasminogen activator into the suprachoroidal cavity or subretinal space to assist in bleeding liquefaction
45646921|NCT04483817|Device|Transcutaneous tibial nerve stimulation|Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.
45790521|NCT04902417|Other|Dairy Foods (Yoghurt, Cheese, Milk)|Participants will be provided with a combination of dairy products (Yoghurt, Cheese, Milk) to be consumed daily, for a total of 3 servings per day
45790522|NCT05177991|Drug|Liposomal Bupivacaine|20cc of Liposomal Bupivacaine for TAP block
45790523|NCT05177991|Drug|Bupivacaine|20cc of Bupivacaine for TAP block
45646922|NCT04483817|Device|Percutaneous tibial nerve stimulation|Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.
45790524|NCT01461824|Drug|Depot medroxyprogesterone acetate (DMPA)|75mg, 104mg and 150mg DMPA, IM, every 12 weeks for 12 months
45790525|NCT04080843|Drug|Anlotinib Hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
45790526|NCT04080843|Drug|Capecitabine|Capecitabine is a capsule in the form of 500 mg, orally, 850 mg/m2, twice daily, 2 weeks on/1 week off.
45790527|NCT04080843|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2,D1
45790528|NCT04076397|Procedure|autologous transplant reinjection|The patient is placed under loco-regional anesthesia. After sterilization of the upper limb and abdomen, the fat is removed at a fold by micro-incision by the Coleman method. The fat is decanted and micro-reinjected into the pulp of the patient's finger with 2 or 3 punctiform incisions. The quantity of fat injected is 2 to 3 mL. Incision of the abdomen and fingers is closed by points at monocryl 4/0. Finally, a fatty dressing is performed on the finger. Patients will benefit from nursing care every 2 days
45790529|NCT04076397|Other|desensitization|Patients will have to stimulate the pulp of your finger on a daily basis
45790530|NCT04869189|Device|JJVC Marketed Contact Lens|Acuvue Oasys® 1-Day
45790531|NCT05141253|Drug|RD133|The enhanced MSLN-CAR-T cell design of this study is obtained by co-infecting T cells with two lentiviral vectors. One lentiviral vector expresses CD19-CAR and tEGFR molecular safety switch, and the other lentiviral vector expresses MSLN- CAR and dnTGFβRII receptors. dnTGFβRII receptor without intracellular signal is used to resist the inhibition of T cell function by the immune microenvironment of tumor tissue. In addition, for the safety of CAR-T cell application in vivo, tEGFR is used in the CAR design as a molecular safety switch for CAR-T cells.
45920193|NCT00087880|Drug|Bupropion and NRT|All participants receive standard 12 week treatment of NRT, bupropion and five group counseling sessions. At week 11, subjects are randomly assigned to one of five treatment groups (1) Bupropion/Low Contact; (2) Placebo/Low Contact; (3) Bupropion/Relapse Prevention; (4) Placebo/Relapse Prevention; (5) No Further Treatment. Data is collected at Week 0, and at weeks 12, 24, 52, 64, and 104.
45920194|NCT00087958|Drug|XRP9881|
45920195|NCT00087997|Drug|STA-4783|
45920196|NCT00088036|Drug|Olanzapine|
45920197|NCT04727619|Behavioral|SLEEP program|SLEEP is a 6-week educational program designed to improve sleep hygiene and habits.
45920198|NCT00088075|Drug|Risperidone|
45646923|NCT05733481|Device|CapBuster System Medical Device for the Crossing of Chronic Total Occlusions in Coronary Arteries|The CapBuster System is a medical device intended to facilitate the intraluminal placement of conventional guidewires beyond chronic total occlusions prior to the utilization of interventional devices. The device system, manufactured by Praxis Medical, comprises the CapBuster support catheter and CapBuster penetrating wire which are mated together with a screw thread.
45790532|NCT05457309|Procedure|malignant fungating wounds care regimen|1) Preliminary construction of regimen: The researchers summarized the literatures and guidelines about malignant fungating wounds care, and then formed a preliminary draft of the regimen.2) Expert consultation: Experts in malignant fungating wound care, breast cancer and rehabilitation were consulted by email, and the researchers revised the protocol according to the experts' comments, and the final draft was determined after multiple rounds of consultation with experts. 3) Pre-experiment: The researchers investigated the enrolled patients to assess the feasibility of the protocol, and adjusted the content based on the feedback.4) Final Determining: including health records establishment, the intervention time, implementers, location, method and frequency. A wound care team was formed, interventions were carried out in terms of somatic care, wound home care, psychological support, and rehabilitation guidance, and the enrolled patients would be regularly followed by the researchers.
45790533|NCT04334265|Drug|Anluohuaxian|6g each time, twice a day
45790534|NCT05457231|Other|specific feedback based on an in-depth assessment tool for communication skills training|In addition to the specific feedback based on an in-depth assessment tool, four strategies modified from common strategies in the previous studies were incorporated into the intervention protocol, including lecture, patient interview, brief feedback, and self-reflection
45790535|NCT04866849|Other|examination|"The presence of bruxism was based on self-reported bruxism and examination. Self reported bruxism was recorded as yes or no . Participants were examined for the existence of four clinical signs of bruxism: (I) abnormal tooth wear, (II) impressions of teeth in the buccal area, (III) impressions of teeth on the tongue, and (IV) hypertrophy of the masseter muscle. In this study, clinical signs of bruxism were considered present if one of the four items was answered yes."
45790536|NCT05457153|Other|Well-Being Process Program (WEBEPROP)|Technology-Based Well-Being Process Program (WEBEPROP)
45790537|NCT04835961|Other|Maintenace and As needed|This study will record the use of budesonide / formoterol either as maintenance treatment or / or as needed according to standard clinical practice and at the discretion of the treating physician.
45790538|NCT04737837|Drug|lacosamide|lacosamide as first add on therapy
45790539|NCT04826133|Drug|Calcitriol|Subjects will receive an oral administration of calcitriol (1,25-dihydroxyvitamin D3) 1.5 μg (three capsules of 0.5 μg each) at 9 pm, night before each cocaine session, and at 8 am, morning of each cocaine session. This dose of calcitriol is lower than doses safely administered in other human studies and for a duration of time shorter than doses safely administered in other trials. In addition, this dose has been already tested by our group, subject of a different grant application, and should be effective at enhancing stimulant's induced dopamine release, in comparison to placebo.
45790540|NCT04826133|Other|Placebo|Subjects will receive an oral administration of three capsules of placebo at 9 pm the night before each cocaine session, and at 8 am, morning of each cocaine session.
45790541|NCT05456919|Other|SFQ28 Questionnaire|SFQ28 Questionnaire
45790542|NCT04737447|Device|Whole Body Vibration Training|Galileo® Trainer is a vibration board. The movement alternating to different sides during walking correlates with the movement on the board due to variable amplitudes and frequencies. Movements of the vibration board are quickly changing and thus simulating the tilting movements of the pelvic during walking but with higher frequency. Muscles of legs and core are activated reflexively. In our study there are performed static practices and pelvic activating practices. Each physiotherapist is experienced in the technical and practical handling of the device.
45790543|NCT04774809|Drug|Low Dose SHR0302 Ointment BID|Low Dose SHR0302 Ointment BID
45790544|NCT04774809|Drug|High Dose SHR0302 Ointment BID|High Dose SHR0302 Ointment BID
45790545|NCT04774809|Other|Placebo Comparator: Vehicle|Placebo
45790546|NCT04750239|Drug|Nivatrotamab|Anti GD2×CD3 monoclonal bi-specific antibody
45790547|NCT05456763|Dietary Supplement|sodium butyrate|add-on therapy irrespective of standard treatment depending on severity (according to the guidelines)
45646924|NCT04483739|Drug|Carfilzomib Lenalidomide Dexamethasone|Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation
45646925|NCT04483739|Drug|Isatuximab Carfilzomib Lenalidomide Dexamethasone|Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation
45646926|NCT05732935|Behavioral|Time Restricted Eating intervention|"In the TRE intervention, participants will be asked to fast for a target of 16 hours per day for a period of 24 weeks. The first few weeks will involve of a ramp up to a full 16-hour fasting period (Week 1 - fast for 12-14 hours per day, Week 2 - fast for 14-16 hours per day, Week 3 - 16 - fast for 16 hours per day). Participants will be allowed to consume calorie-free beverages, tea, black coffee, sugar-free gum, and they will be encouraged to drink plenty of water throughout the entire intervention period. Participants will be asked to record the time of first and final food/drink consumption each day.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks."
45646927|NCT05732935|Behavioral|Successful Aging Comparison Group (LEARN)|"In the Successful Aging Comparison Group (LEARN), participants will attend lectures on topic relevant to healthy aging at the same frequency as the group meetings in the TRE intervention.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks."
45653117|NCT02866643|Drug|Etonogestrel-Immediate|The investigational intervention will be to insert the contraceptive implant immediately postpartum in the delivery room insertion (0-2 hours following delivery).
45653118|NCT02866643|Drug|Etonogestrel-Delayed|The investigational intervention will be to insert the contraceptive implant 24-48 hours following delivery.
45790548|NCT05456763|Other|placebo|placebo
45790549|NCT02958657|Other|Exercise Training|Supervised exercise training program that includes two workouts per week for three months at a rehabilitation unit.
45920199|NCT00088114|Drug|STA-4783/paclitaxel|
45920200|NCT00088192|Drug|pegaptanib sodium|
45920201|NCT00006131|Drug|Valacyclovir|
45790550|NCT05456451|Device|noninvasive vagus nerve srimulation|Non-invasive Vagus nerve stimulation (VNS) stimulates the vagus nerve through the ear via a headset. VNS is a non-pharmacological intervention with the potential to improve walking, cognition, fatigue, and autonomic functions in the treatment of Parkinson's disease.
45790551|NCT04334421|Device|Composite mesh|Pelvic floor is reconstructed by synthetic composite mesh (Symbotex, Medtronic) to improve healing and prevent perineal herniation.
45790552|NCT04556175|Behavioral|Oral Health|Motivational interviewing for mothers pre-and postpartum; fluoride varnish for infants/children.
45790553|NCT04556175|Behavioral|Healthy Lifestyle|Didactic maternal and child health educational sessions for mothers pre-and postpartum; fluoride varnish for infants/children.
45790554|NCT03775161|Device|V-LAP™ System|Delivery of the V-LAP™ implant via a catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
45790555|NCT02973711|Drug|Nilotinib|Nilotinib 300 mg BID
45790556|NCT02973711|Drug|Ruxolitinib|Ruxolitinib, 10, 15 or 20mg BID
45790557|NCT05456217|Other|admission to ICU|admission to an intensive care unit or high dependency unit in Kenya
45790558|NCT04550715|Behavioral|Brief intervention (BI)|A remote brief intervention delivered by health coaches that uses Motivational Interviewing to address opioid misuse and risk factors. Remote health coaches use a web-based clinician support guide to maintain fidelity, while tailoring the session to unique participant factors.
45790559|NCT04550715|Behavioral|Portal|Remote health coaches will push tailored messages to participants over a 4-week period. The messages will use Motivational Interviewing strategies. The messages are designed to elicit a response from the participant. Health coaches will also respond to participant replies consistent with Motivational Interviewing over a course of 4 weeks.
45790560|NCT04550715|Behavioral|Enhanced Usual Care (EUC)|The brochure covers educational topics like opioid storage and disposal and overdose prevention, as well as resources such as naloxone, suicide hotlines, mental health, and substance use treatment. It will be available online and in print.
45790561|NCT05456061|Drug|3% diquafosol eyedrops|Diquas® (Santen, Osaka, Japan), six times per day.
45790562|NCT05456061|Procedure|Silicone punctal plug insertion|a silicone punctal occluder (Parasol® Punctal Occluder, BVI, Waltham, Massachusetts, USA), inserted into the lower eyelid
45790563|NCT04300413|Other|High-Intensity Rehabilitation plus Mobility (HeRo)|Progressive, high-intensity strengthening and functional intervention coupled with structured mobility based in principals of behavioral economics.
45790564|NCT05455983|Biological|covid19 vaccines|different types of (COVID-19) vaccination
45646928|NCT05728385|Dietary Supplement|Modified Specific carbohydrate diet for 3 months|"All children at the start of the study will be subjected to:~Full history taking including demographic and medical history~Full nutritional assessment including: Through clinical examination for any signs of vitamins and mineral deficiency, with full chest examination.~Laboratory tests: Complete blood picture with differential white blood cells, and Serum IgE level~At the beginning of the study and at the end~The patients will be assessed using the childhood-asthma control test (C-ACT) as a subjective method~Pulmonary function tests will be performed using spirometry (Spirostik, Geratherm) that includes Forced vital capacity (FVC), forced expiratory volume in the first second of FVC (FEV1), and FEV1/FVC.~Anthropometric measurements: Weight, Height, and Body mass index (BMI). All measures will be plotted on specific percentile curves for age and Z score"
45646929|NCT05728229|Drug|Supplement with SiderAl® Med|Nutritional supplementation with special purpose food
45790565|NCT02369874|Drug|MEDI4736|MEDI4736 Monotherapy
45790566|NCT02369874|Drug|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
45790567|NCT02369874|Drug|Standard of Care|Standard of Care
45790568|NCT04335045|Drug|Placebo|1~8 Placebo capsule(s) corresponding to each PH100 dose
45790569|NCT04335045|Drug|PH100 100mg|1 x 100 mg PH100 oral capsule
45790570|NCT04335045|Drug|PH100 200mg|1 x 200 mg PH100 oral capsule
45790571|NCT04335045|Drug|PH100 400mg|2 x 200 mg PH100 oral capsules
45790572|NCT04335045|Drug|PH100 800mg|4 x 200 mg PH100 oral capsules
45790573|NCT04335045|Drug|PH100 1200mg|6 x 200 mg PH100 oral capsules
46071468|NCT00625807|Behavioral|RR|A well-validated 8 week stress reduction course. Classes meet once a week for 1.5 hours. Participants will be asked to perform stress reduction techniques each night for 20 minutes throughout the entire 8-week course. Stress reduction techniques use meditative techniques that focus primarily on inducing relaxation
45790574|NCT04335045|Drug|PH100 1600mg|8 x 200 mg PH100 oral capsules
45790575|NCT03671889|Device|Blood Brain Barrier (BBB) Disruption|Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
45790576|NCT03628989|Behavioral|Use of Virtual Technology|If parent and child consent to be in the study, the clinician will offer the use of one of the technologies: Virtual Reality (VR) headset or Augmented Reality (AR) headset. Active content includes video games, interactive avatars, and interactive experiences, while passive content includes video clips and movies. All patients will be offered the opportunity to use these technologies during their minor procedures if they meet eligibility criteria. Those who decline or who are switched over to the standard of care due to patient preference, health providers monitoring and assessment during the procedure will be noted in the database.
45790577|NCT00372645|Dietary Supplement|Folic acid (supplement)|200 µg folate per day from supplemental folic acid
45790578|NCT00372645|Dietary Supplement|Metafolin (supplement)|200 µg folate per day from supplemental Metafolin®
45790579|NCT00372645|Drug|Placebo|Placebo
45790580|NCT00372645|Other|Folate rich foods|200 µg folate per day from folate-rich foods
45790581|NCT00372723|Drug|Remicaide (infliximab)|a single dose infusion of 5mg/kg Remicade (Infliximab)
45790582|NCT05455827|Other|fMRI neurofeedback (A)|Participants will be shown feedback about the BOLD activation within the subgenual anterior cingulate cortex to enhance differences between the self-blame and other-blame conditions
45790583|NCT05455827|Other|fMRI neurofeedback (B)|Participants will be shown feedback about the BOLD activation within the subgenual anterior cingulate cortex to minimise differences between the self-blame and other-blame conditions
45790584|NCT04335435|Dietary Supplement|Oat Bran Consumption|Oat bran (120 g), single dose.
45790585|NCT04279431|Device|EEG Recording|EEG recording acquired on BrainScope One device.
45646930|NCT05483855|Other|Objective 1 Only: Telehealth Satisfaction Survey|Participants must complete a telehealth satisfaction survey rating their standard of care telehealth visit on a scale of 1 to 10, with 1 denoting low satisfaction and 10 denoting high satisfaction.
45646931|NCT05483855|Other|Objective 2 Only: ArthritisPower Joint Assessment|RA patients must complete a self-assessment examination of their joints using the ArthritisPower app prior to their in-office visit, where a repeat joint assessment is performed by participating physician.
45646932|NCT05732233|Device|Ultivision AI|Ultivision AI is a computer-assisted detection (CADe) device intended to aid endoscopists in the real-time identification of colonic mucosal lesions (such as polyps and adenomas) in adult patients undergoing colorectal cancer screening and surveillance examinations.
45653119|NCT05729581|Behavioral|The educational programme on sustainable and healthy diet and breastfeeding|In the interventional group the educational programme of sustainable diet and breastfeeding will be provided before the delivery to see the impact on the prevalence of the breastfeeding at 1 and 6 months after delivery (compared with the group of control, without intervention)
45653120|NCT05176821|Drug|esomeprazole plus amoxicillin|amoxicillin 750mg QID + esomeprazole 20mg QID for 14 days
45790586|NCT04279431|Other|Neurocognitive Tests|Cognitive performance tests performed on BrainScope One device.
45790587|NCT04279431|Other|Clinician Evaluation|Clinician evaluation performed as part of standard of care at the clinical site.
45790588|NCT04279431|Other|22-item CSI|Self assessed 22-item Concussion Symptom Inventory (CSI).
45790589|NCT00372801|Drug|Ibuprofen|
45790590|NCT04275843|Dietary Supplement|Traditional Diet|Consuming an traditional whole foods based diet for 4 weeks.
45790591|NCT04275843|Dietary Supplement|Modern Diet|Consuming an processed formulation of the traditional diet for 4 weeks.
45790592|NCT04797429|Other|Peer Support Intervention via Instant Messaging Service Tool (IMS-Tool)|Peer Support via the IMS-tool increases diabetes self-management, improves self-efficiacy, adherence and glycaemic control
45790593|NCT04797429|Other|antidiabetic therapy according to the current guidelines|In contrast, the control group has to manage their diabetes mellitus type 2 with standard support and without online exchange.
45790594|NCT03523143|Other|early screening and intervention|The early screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 18-20 weeks of gestational age (GA). Gestational diabetes mellitus (GDM) is diagnosed according to the IADPSG criteria. Subjects diagnosed with GDM will receive nutrition counseling, and lifestyle intervention. Pharmacologic therapies exclusively with human insulin or insulin analogues will be given when the target of glycemic control is not achieved within 4 weeks. The process of screening and intervention in the early screening group is all the same with that in the standard screening group. The only difference between two groups is the time of screening and intervention (18-20 weeks vs. 24-28 weeks of GA).
45790595|NCT03523143|Other|standard screening and intervention|The standard screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 24-28 weeks of gestational age (GA). Gestational diabetes mellitus (GDM) is diagnosed according to the International Association of Diabetes and Pregnancy Study Group (IADPSG) criteria, ie. if one of the plasma glucose levels at fasting, 1-hour, and 2-hour during OGTT is above 92 mg/dL, 180 mg/dL, and 153 mg/dL, respectively. Subjects diagnosed with GDM will receive nutrition counseling, and lifestyle intervention. Pharmacologic therapies exclusively with human insulin or insulin analogues will be given when the target of glycemic control is not achieved within 4 weeks.
45790596|NCT03473535|Combination Product|BEACON + Problem Solving Therapy|Six sessions of face-to-face PST delivered by a trained Research Therapist and access to the BEACON Suicide Prevention smartphone application.
45790597|NCT03473535|Behavioral|Problem-Solving Therapy|Six sessions of face-to-face PST delivered by a trained Research Therapist.
45790598|NCT03464955|Behavioral|Technology Based Distractions|Technology based distractions (VR headsets, AR headset, tablets, or BERT projector)
45790599|NCT01462292|Drug|GSK2402968 3mg/kg/week|Comparison of 2 doses of GSK2402968
45790600|NCT01462292|Drug|GSK2402968 6 mg/kg/week|Comparison of 2 doses of GSK2402968
45790601|NCT01462292|Drug|Placebo to match GSK2402968 3 mg/kg/week|Matched placebo
45790602|NCT01462292|Drug|Placebo to match GSK2402968 6 mg/kg/week|Matched Placebo
45790603|NCT05455749|Dietary Supplement|holoBLG|holo-BLG (beta-lactoglobulin) - a major component of the protein fraction of raw milk, loaded with ligands (vitamin A, zinc and polyphenol-iron complexes)
45790604|NCT05455593|Behavioral|Water aerobics|1-hour session of water aerobics per week, for 3 months. A specialized trainer will carry out water aerobics sessions and will focus on motor coordination, strength and cardiovascular workout.
45790605|NCT05455593|Behavioral|Metacognitive Training (MCT)|1-hour session of MCT per week, for 3 months. A trained psychologist will carry out the MCT sessions. MCT addresses the most common cognitive biases in psychosis. Each session will focus on one topic, such as attributional style, jumping to conclusions, theory of mind, emotion recognition, memory or empathy.
45790606|NCT05455593|Behavioral|Combined intervention|Patients in this arm will participate in both in water aerobics and MCT sessions, once a week for each intervention.
45790607|NCT02958735|Other|Exercise Challenge|Participants randomized to an exercise condition will perform treadmill exercise for 30 minutes. Participants will self-select a comfortable walking speed. The treadmill grade will be adjusted to elicit and maintain the target heart rate.
45790608|NCT05455359|Drug|Prucalopride|Prucalopride 0.04 mg/kg/day
45790609|NCT05455359|Drug|Famotidine|Famotidine 0.4 mg/kg/day
45790610|NCT04716309|Procedure|Open reduction and volar locking plate and closed reduction and K-wires.|DVR Anatomic Plate, K-wires
45790611|NCT05441007|Other|Hypoxic|Hypoxic gas mixture Gas mixture of 10% O2 and 90% N2 for six minutes.
45646933|NCT04157231|Other|Acute stroke care Intervention arm|"Training and education of the site staff about the treatment protocol for the different components of the management plan will be provided on two occasions. The aim of these sessions will be to educate stroke champions and other site staff on the management protocols. Available training resources will be accessed (including online materials) and simulation training will be used. New skills such as dysphagia assessment will be emphasized based on existing knowledge and competencies. After training, staff will have another assessment (Post-test) in order to determine whether they have been adequately trained and are able to adhere to the essential acute stroke care management plan. A standardised Power Point presentation and accompanying handouts will be made available for further use in the ward.~Refresher training will be provided monthly during the intervention."
45790612|NCT05441007|Other|Hypercapnic|Hypercapnic gas mixture Gas mixture of 21% O2, 5% CO2 74% N2 for six minutes.
45790613|NCT05441007|Other|Hypoxic and Hypercapnic|Hypoxic and Hypercapnic gas mixture Gas mixture of 10% O2, 5% CO2 85% N2 for six minutes.
45790614|NCT04694001|Device|Use of the Atalante exoskeleton|A session includes stand-up, walks, exercises with or without the assistance of the exoskeleton, rotation, side and back step, squat and sitting.
45790615|NCT00373503|Drug|Lofexidine|alpha 2 adrenergic agonist, hypothesized to decrease noradrenergic activity
45920202|NCT00088231|Drug|Imatinib Mesylate (Gleevec)|"600 mg by mouth every day (for AML, CML-BP) for a 28 day cycle.~400 mg by mouth every day (for AMM) for a 28 day cycle."
46071469|NCT00625807|Behavioral|MBSR|A well-validated 8 week stress reduction course. Classes meet once a week for 1.5 hours. Participants will be asked to perform stress reduction techniques each night for 20 minutes throughout the entire 8-week course. Stress reduction techniques use meditative techniques that focus primarily on inducing mindfulness
46071470|NCT02907242|Other|Revealment|Cerebroplacental ratio revealment
46071471|NCT04251000|Device|Joovv Mini|the smallest photomodulation device in the Joovv infrared light product line.
45646934|NCT05092087|Behavioral|nutrition counseling|nutrition counseling
45653121|NCT05176821|Drug|amoxicillin, furazolidone, bismuth potassium citrate , esomeprazole|amoxicillin 1000mg BID + furazolidone 100mg BID + bismuth potassium citrate 600mg BID + esomeprazole 20mg BID for 14 days
45790616|NCT00373503|Drug|dronabinol|cannabinoid agonist hypothesized to decrease MJ withdrawal
45790617|NCT00373503|Drug|Marijuana|marijuana intoxication, withdrawal and relapse assessed
45790618|NCT03215199|Other|NAPT|Web-based depression and distress monitoring application
45790619|NCT04333797|Other|Risk and Protective Factors Assessment|First assessment at baseline (T0) - 17 y.o. Follow-up 2 years later (T1) - 19 y.o.
45790620|NCT02923323|Device|MRI including DTI , EEG, CGMS|Will be connected to continuous simultaneous systems
45790621|NCT02923323|Behavioral|Neurocognitive tests|Will perform multiple tests of neurocognitive functions after lunch
45790622|NCT02696265|Procedure|CFAE guided ablation|CFAE/spatiotemporal dispersions mapping and ablation during AF aimed at restoring sinus rhythm during ablation. Pulmonal vein isolation will be checked before and after ablation using a mapping catheter.
45790623|NCT02696265|Procedure|PVI guided ablation|Wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals
45790624|NCT04737525|Device|Dental implant placement, bone and soft tissue augmentation on buccal site|"Atraumatic extraction~Palatinal positioning of tapered implant (BLX) 3.75mm diameter~3-4 mm below vestibular gingival line or 1 mm below bone crest~Implant placement~Allogenic bone packing of the jumping distance and soft tissue grafting~Connective tissue graft (CTG) or porcine-derived membrane~Provisional restoration out of occlusion and mandibular movements~X-ray"
45790625|NCT02633397|Drug|Riociguat|Riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
45790626|NCT02633397|Drug|Placebo|Matching placebo to riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
45790627|NCT01515176|Drug|Dinaciclib|Given IV
45790628|NCT01515176|Other|Laboratory Biomarker Analysis|Correlative studies
45790629|NCT01515176|Biological|Ofatumumab|Given IV
45790630|NCT01515176|Other|Pharmacological Study|Correlative studies
45790631|NCT02539407|Other|Pharmacokinetics|
45790632|NCT01515410|Drug|DM-1992|72.5mg carbidopa/230mg levodopa
45790633|NCT01515410|Drug|Sinemet IR|Immediate-release tablet containing 25mg carbidopa and 100mg levodopa
45790634|NCT01515488|Other|Nurse-initiated triage|Nurse-assisted triage for obtaining medical history and presenting problem(s)
45790635|NCT01515488|Other|Self-triage kiosk|Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
45790636|NCT01515566|Drug|Fentanyl|Fentanyl SQ dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before 6 minute walk test.
45790637|NCT01515566|Other|Placebo|Normal saline 0.9% preservative free SQ 15 minutes before walk test.
45920203|NCT00088231|Drug|PTK 787 (vatalanib)|"For 1 week prior to receipt of the study combination regimen, all patients will receive single agent PTK 787 at the dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels.~Starting dose: 250 mg by mouth every day for a 28 day cycle."
45920204|NCT00088270|Drug|OSI-7904L|
45920205|NCT00088270|Drug|5-Fluorouracil/Leucovorin|
45920206|NCT00088309|Procedure|Eye exam|
45920207|NCT00088309|Procedure|Oral exam|
45920208|NCT00088309|Procedure|CT scan|
46071472|NCT02520908|Procedure|HSCT|Hematopoietic stem cell transplantation
45790638|NCT01515566|Other|Walking Tests|6 minute walk test at baseline and 15 minutes after Fentanyl or Placebo.
45790639|NCT01515566|Behavioral|Questionnaires|Questionnaires completed at baseline (two) and after study visit (one) taking about 5 ot 10 minutes to complete.
45790640|NCT02522715|Drug|Cabazitaxel|Given IV
45790641|NCT02522715|Drug|Enzalutamide|Given PO
45790642|NCT02522715|Other|Laboratory Biomarker Analysis|Correlative studies
45790643|NCT02522715|Other|Pharmacological Study|Correlative studies
45790644|NCT02522715|Drug|Prednisone|Given PO
45790645|NCT02445105|Behavioral|Autism Navigator Enhanced Practice|Community service providers will receive training in Autism Navigator for Primary Care, a 6-hour online professional development course with extensive video illustration of the early signs of autism in toddlers, collaborating with families, developmental milestones, screening and referral practices, and early intervention basics. This web-based platform includes an automated screening for communication delay and autism, an automated monthly electronic monitoring, and digital tools for families to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
45646935|NCT04413643|Device|Noninvasive Ventilation|The use of non-invasive ventilation (NIV) has been extensively evaluated in both patients with stable disease in the home setting and in AECOPD during hospitalization. It is widely accepted that NIV used during AECOPD in the inpatient setting reduces rates of endotracheal intubation, as well as length of ICU and hospital stay. Long-term use of NIV, particularly at higher pressures, in the home setting in COPD patients with evidence of chronic compensated respiratory acidosis (PaCO2 >45mmHg) decreases elevated PaCo2 and serum bicarbonate levels, improves pulmonary function, and improves quality of life. Little is known about whether patients initiated on NIV during an AECOPD and subsequently transitioned to long-term home NIV on discharge demonstrate reduced AECOPD rates, readmission rates, or differences in morbidity and mortality.
45790646|NCT02445105|Behavioral|Family Engagement plus Autism Navigator|Community service providers will receive a 6-hour training on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler. Community service providers will also receive a 6-hour training with the Autism Navigator for Primary Care professional development course and use of the web-based platform that includes an automated communication and autism screening and monthly electronic monitoring to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
45790647|NCT00708045|Drug|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with imaging tracer to assess brain tumor metabolism
45790648|NCT00187473|Procedure|liver biopsy|Liver biopsy every 5 years
45790649|NCT02777931|Drug|NFC-1|NFC-1 is supplied as size 2 hard gelatin capsules.
45790650|NCT02777931|Drug|Placebo|Matching placebo capsules
45790651|NCT01515956|Drug|BMN 110|Patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/wk over a period of approximately 4 hours every week for up to 208 weeks.
45790652|NCT02779491|Behavioral|5-a-day fruit and vegetable mobile phone application|5-a-day fruit and vegetable mobile phone application
45646936|NCT05727475|Procedure|Minimal invasive restorative treatment|Composite veneer facing without drilling or removal of enamel
45790653|NCT02207972|Device|Use of Ultrasound|The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
45790654|NCT02207972|Procedure|No ultrasound used|Palpation of anatomical landmarks is used for placement of labor analgesia
45790655|NCT02780349|Device|WIRION|Embolic Protection System
45920209|NCT00088309|Procedure|Neuropsychological testing|
45646937|NCT05727475|Procedure|Fluoride gel application|Fluoride gel application 1.23%
45646938|NCT05725655|Other|Thermotherapy|Hot baths directly after an exercise session
45646939|NCT05094583|Behavioral|Use of SmokeFree app|Intervention Arm
45646940|NCT05091775|Drug|Asacol is used to treat and prevent mild to moderate acute fissure disease|Comparison of two groups after 2 weeks in fissure wound healing, pain relief, pruritus, burning, bleeding, incontinence. Preliminary results of the study show the rate of fissure improvement 6 weeks after treatment, which is observed by clinical examination. Restoration is defined by complete epithelialization of the fissure site without scarring or residual cracks, and the secondary results will be a reduction in the amount of pain and other symptoms.
45790656|NCT01516268|Drug|Sufentanyl|"As intervention 1cc sufentanyl is added to bupivacain in case group for TAP block.~As comparator 1cc normal saline is added to bupivacain in control group for Tap block."
45790657|NCT02780661|Device|Denture Cleanser Daily Use Period|One denture cleansing tablet will be soaked in a cup of very warm water (150 ml) with dentures for Day 0 to Day 7 for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds.
45920210|NCT00088309|Procedure|Electrocardiogram|
45920211|NCT00088309|Procedure|Echocardiogram|
46071473|NCT02520908|Other|Standard Care|
46071474|NCT00829153|Device|U Clip|Interuppted nitional clips
46071475|NCT00829153|Procedure|Conventional prolene anastomosis|Continuous prolene anastomosis
46071476|NCT02843022|Behavioral|standardized electronic messages|supportive and educational short messages
46071477|NCT02843022|Behavioral|nurse phone call if requested|"If participant responds yes to an offer for a phone call, a nurse calls them within a week of this response"
45790658|NCT02780661|Device|Denture Cleanser Weekly Use Period|One denture cleansing tablet will be soaked in cup of very warm water (150 ml) from Day 0 to Day 6 for 15 mins; and in cup of very warm water (150 ml) with 1 denture cleansing tablet on Day 7 at site for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds.
45790659|NCT02780661|Other|Water|A cup of very warm water will be used to soak one denture cleansing tablet and dentures for per day (Day 0 to Day 7) or weekly (Day 0 and Day 7) treatment regimen.
45790660|NCT05440968|Other|Point of Care - Glycated Hemoglobin (A1c)|Test for diagnosis of Diabetes through a Point of care device
45790661|NCT05440968|Other|Oral Glucose Tolerance Test|Routinary diagnosis diabetes test by venous blood sample
45790662|NCT02781051|Behavioral|Print-based education|All subjects will be given a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors. Topics covered within the book include benefits of exercise in breast cancer survivors; recommendations on type, duration, frequency and intensity of exercise; goal-setting; and advice on overcoming barriers.
45790663|NCT02781051|Device|Fitbit|Subjects will be provided with a commercially available activity monitor (i.e., Fitbit) and instructed to wear the device daily.
45790664|NCT02781051|Behavioral|Active Living counseling|The Active Living counseling program consists of 12 weekly group educational sessions, facilitated by project interventionists. These sessions will involve discussion of topics related to increasing physical activity, including: identifying and overcoming barriers, setting goals, and time management.
45646941|NCT05091541|Drug|Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection|CT120 is an autologous CD19/22 targeted CAR-T cells injection. The dosage form is a cryopreserved injection solution. The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
46071478|NCT02843022|Behavioral|Staff nurse phone follow-up|Usual care: hospital nurse or lactation consultant calls patient within 2-3 weeks prior to discharge. Message left if patient is not reached.
45790665|NCT02781051|Other|Facility Access|Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills, stationary bikes, etc.).
45790666|NCT01516424|Drug|Blonanserin|Blonanserin tablets: 8 - 24mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
45790667|NCT01516424|Drug|Risperidone|Risperidone tablets: 2 - 6mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
45646942|NCT05376085|Drug|DA-5215 Tab|"single oral administration of 1 tablet of DA-5215 Tab with 150mL water"
45646943|NCT05376085|Drug|DA-5215-R Tab|"single oral administration of 1 tablet of DA-5215-R Tab with 150mL water"
45646944|NCT04821869|Drug|ProAir Digihaler|Monitor parameters transmitted from the Proair Digihaler to the Digihaler Dashboard, including peak inspiratory Flow, inspiratory volume and frequency of rescue use
45646945|NCT04821869|Device|Digihaler|Monitor parameters transmitted from the Proair Digihaler to the Digihaler Dashboard, including peak inspiratory Flow, inspiratory volume and frequency of rescue use
45646946|NCT05091463|Device|Biostim-5/Neostim transcutaneous spinal stimulator|Transcutaneous spinal stimulation (scTS): The 5-channel stimulator capable of generating pain-free biphasic rectangular waveform of 0.3 to 1.0 ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels. Transcutaneous stimulation will be delivered in combination with activity based locomotor training in 5-10 minute bouts of stimulation at sub-motor threshold during daily sessions (5x/week) lasting for 90 minutes for a total of 60 sessions of therapy. The sessions will consist of 55-60 minutes on the treadmill for facilitated standing/stepping followed by 30 minutes of activities off the treadmill in sitting, standing, or stepping.
45646947|NCT05091385|Biological|Mepolizumab given SC 100mg every 4 weeks between Dec 2017 and Dec 2019|Mepolizumab administered within the frame of a severe asthma treatment program financed by National Health Fund in Poland for patients fulfilling specific criteria of asthma severity.
45646948|NCT02631551|Drug|GSP 301 NS|FDC of olopatadine HCl and mometasone furoate: 2 sprays in each nostril twice daily for 14 days
45646949|NCT02631551|Drug|Olopatadine HCl NS|2 sprays in each nostril twice daily for 14 days
45646950|NCT02631551|Drug|Mometasone furoate NS|2 sprays in each nostril twice daily for 14 days
45646951|NCT02631551|Drug|GSP 301 Placebo NS|2 sprays in each nostril twice daily for 14 days
45790668|NCT02782065|Other|Not an interventional study|
45790669|NCT02368314|Drug|Sodium Enoxaparine|30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).
46071479|NCT04024280|Other|Physical exercise program|Frequency: 3 weekly sessions. Intensity of aerobic training: reporting 12-17 in the Borg scale. Time of aerobic training: 10 minutes in the first and second weeks and then 2 added minutes at each 2 weeks. Type of aerobic training: walking and stepping. Intensity of resistance training: without load in the first week and, then, 15 submaximal repetitions. Time of resistance training: 30 minutes. Type of resistance training: using free weights; the lower body exercises will be squat, leg extension, leg curl and calf raise; the upper body exercises will be frontal and lateral arm raise, chest press, seated row and bicep curl.
46071480|NCT04910438|Other|STIs screening and care|"Screening for anal dysplasia, HPV infection, HIV infection and several STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis, HSV-2 and HBV).~Offering comprehensive care including prevention strategies adapted to the various STIs mentioned above and their complications, particularly the progression to anal cancer for HPV infections in MSM."
46071481|NCT00629083|Device|Bulkamid|Bulking injection with Bulkamid injection device
46071482|NCT00629083|Device|Contigen|Transurethral bulking injection
46071483|NCT02640690|Behavioral|Trauma Center Trauma Sensitive Yoga Intervention (TCTSY)|(10) 1-hour sessions of trauma sensitive yoga
45790670|NCT04492839|Device|Intestinal adsorbent|Participants will consume the 15ml of the intestinal adsorbent (3.5 g Silicon dioxide in 100 ml Silicic acid gel, Preservatives: Sorbic acid (E 200), Sodium benzoate (E 211). ) three times daily for 10 days. There are no known side effects of the medical device. The product is a class IIa medical device under the European council directive and the product will be used within it's current indications.
45790671|NCT01518530|Device|Occiflex Robotic Intervention System|Occiflex is a robotic system which is comprised of a cradle moved in a three dimension space with six degrees of freedom. It allows the therapist to tailor a personalized course of 3-D mobilization of the head and neck.
45790672|NCT02366910|Device|omafilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
45646952|NCT05706961|Other|Power Walking|"For 1- 2 Week 60% of the target heart rate with 5,000 to 7,500 steps/day Total 30 min Session The exercise intensity was set at 60% of the target heart rate during the first 2 weeks.~For 3- 4 week 70 % of the target heart rate with 7,500 to 10,000 steps/day Total 30 min Session B) Progressive increase walk according to 6MWD as improved Low intensity"
45790673|NCT02366910|Device|delefilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
45790674|NCT02783469|Genetic|Identification of genetic causes of diabetic neuropathic pain|
45790675|NCT01463384|Drug|Minocycline|50mg, twice daily for 6 months.
45790676|NCT01649232|Device|Active tDCS|tDCS applied to left dorsolateral prefrontal scalp area through a saline-soaked pair of surface sponge electrodes (35 cm2). The anode electrode was placed over F3 (based on the 10-20 International EEG System) of each subject. The cathode was placed over the contralateral mastoid area. A constant current of 1.1 mA was applied for 25 min/day (administered for 12 alternated days).
45790677|NCT01519466|Device|FreeStyle InsuLinx|FreeStyle InsuLinx is a blood glucose meter with a built-in insulin calculator feature.
45790678|NCT01519466|Device|FreeStyle Freedom Lite|FreeStyle Freedom Lite is a blood glucose meter
45790679|NCT02785185|Drug|IDP-122 Vehicle Lotion|Vehicle
45790680|NCT02785185|Drug|IDP-122 Vehicle Cream|Vehicle
45790681|NCT02785185|Drug|IDP-122 Lotion|Lotion
45790682|NCT02785185|Drug|Ultravate Cream|Cream
45790683|NCT02786355|Other|Frova bougie|Squeezing an Ambu bag and delivering air through a Frova bougie. Measuring mean volumes of air delivered and peak pressures generated.
45790684|NCT02787057|Drug|vancomycin|IP vancomycin 1g every 5 days
45790685|NCT02787057|Drug|moxifloxacin|oral moxifloxacin 400mg QD
45646953|NCT05706961|Other|Standardized Outpatient Cardiac Rehabilitation|"For 1- 2 week Standardized Outpatient Cardiac Rehabilitation (includes warm up of 5 min, aerobic 60 % of of target heart rate, resistive ex with 1- 3 kg of weight for 20 min and 10 min of cool down)~For 3 - 4 week Standardized Outpatient Cardiac Rehabilitation (includes warm up of 5 min, aerobic 70 % of target heart rate, resistive ex with 2- 3 kg of weight for 20 min and 10 min of cool down)"
45646954|NCT05094193|Procedure|Trocar-site infiltration|20 mL of ropivacaine 0.375% (6 mL in 10 mm trocar site and 4 mL in 6 mm trocar site)
45646955|NCT05094193|Procedure|TAP block|bilateral ultrasound-guided TAP block with 20 mL of ropivacaine 0.375% in each side
45646956|NCT05094193|Procedure|Trocar site infiltration placebo|20 mL of normal saline
45646957|NCT05094193|Procedure|TAP block placebo|bilateral ultrasound-guided TAP block with 20 mL of normal saline in each side
45646958|NCT05723393|Procedure|Erector spinae plane block|fascial plane injection guided by ultrasound
45790686|NCT02787057|Drug|ceftazidime|IP ceftazidime 1g QD
45790687|NCT01466972|Drug|Pazopanib|Oral, 800mg tablet daily per cycle
45790688|NCT02787291|Device|Ellipse VR ICD and Durata/Optisure lead|Non-diagnostic MRI Scan sequence of head and chest
46071484|NCT02640690|Behavioral|Cognitive Processing Therapy|(12) 1.5 hour sessions of cognitive processing therapy
46071485|NCT02840058|Other|Biological samples|blood and tumor tissue samples
46071486|NCT02840058|Drug|Anti PD1/PDL1 treatment|
45790689|NCT02787681|Device|NEMO Gauge|Measurement and adjustment of endotracheal tube position by stylet.
45790690|NCT01972347|Drug|Dabrafenib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintenance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
45790691|NCT01972347|Drug|Trametinib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintainance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
45790692|NCT04442373|Diagnostic Test|Rotational thromboelastometry|1.8 ml blood sample
45790693|NCT04440501|Device|Virtual Reality Goggles to provide education a regarding the gluten free diet.|To watch and participate in a virtual reality educational experience regarding the gluten free diet.
45790694|NCT02792049|Device|Modified Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with integrated internal handle
45790695|NCT02792049|Device|Conventional Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
45790696|NCT04420845|Behavioral|Diabetes Self-Management and Support (DSMES) and Sleep Hygiene Education and Support (SHES)|SHES outlines the importance of sleep for people with type 2 diabetes mellitus and provide practical information and guidance about sleep habits. Specifically, the focus will be on: avoiding consumption of caffeine, nicotine, alcohol; avoiding use of light emitting devices before bedtime; avoiding excessive intake of fluids or heavy meals before bedtime; promoting regulation of light, noise, and temperature in the bedroom; timing of and importance of exercise; maintaining consistent sleep and wake times; establishing a pre-bedtime routine; and managing stress.
45790697|NCT05106309|Drug|10 mg CVL-231 as IR formulation|Tablets
45790698|NCT05106309|Drug|30 mg CVL-231 as slow-release MR formulation|Capsules
45790699|NCT05106309|Drug|30 mg CVL-231 as medium release MR formulation|Capsules
45790700|NCT05106309|Drug|30 mg CVL-231 as fast release MR formulation|Capsules
45790701|NCT05106309|Drug|30 mg CVL-231 Target Release, Fasted|Capsules
45790702|NCT05106309|Drug|30 mg CVL-231 Target Release, Fed|Capsules
45790703|NCT01520558|Biological|CNDO-109-AANK Cells|Single dose, infusion
45790704|NCT00373035|Genetic|proteomic profiling|
45790705|NCT00373035|Other|immunological diagnostic method|
45790706|NCT00373035|Other|laboratory biomarker analysis|
45790707|NCT00373035|Other|mass spectrometry|
45790708|NCT00373035|Procedure|biopsy|
45790709|NCT00373035|Procedure|ultrasound imaging|
45790710|NCT01468532|Drug|docetaxel|Given IV
45790711|NCT01468532|Drug|pasireotide|Given IM
45790712|NCT01468532|Drug|prednisone|Given PO
45790713|NCT05062317|Drug|Leucovorin|Given by PO
45790714|NCT05062317|Drug|5-FLUOROURACIL|Given by IV
45790715|NCT05062317|Drug|Oxaliplatin|Given by PO
45790716|NCT05062317|Drug|Irinotecan|Given by IV
45790717|NCT05062317|Drug|Capecitabine|Given by IV
45790718|NCT05062317|Drug|Bevacizumab|Given by IV
45790719|NCT01469234|Drug|loratadine|loratadine, one 10 mg tablet, orally
45790720|NCT01469234|Drug|fexofenadine|fexofenadine, one 180 mg tablet, orally
45790721|NCT01469234|Drug|placebo to loratadine|one tablet, orally
45790722|NCT01469234|Drug|placebo to fexofenadine|one tablet, orally
45790723|NCT04349319|Device|Digital preoperative planning|Before the osteosynthesis of distal humerus fracture, we perform digital preoperative planning.
45790724|NCT05049993|Device|Aequalis Pyrocarbon Humeral Head|Hemi Shoulder Arthroplasty using the Aequalis Pyrocarbon Humeral Head
45790725|NCT05045937|Drug|Ivermectin|Ivermectin treatment of outpatients dosing at 0.4mg/kg until recovered along with supplemental treatment using a multi-modal approach.
45790726|NCT01521026|Behavioral|Cognitive Training|12-week compensatory cognitive training in group format
45790727|NCT00373581|Drug|Vigabatrin|
46071487|NCT04841564|Procedure|ultrasound approach of serratus anterior block|After induction of general anesthesia, the ultrasound probe will be placed longitudinally oblique just below the mid-clavicle. After identifying the second rib, the probe will be moved caudally and laterally (obliquely), towards the mid-axillary line to identify the 3rd, 4th and 5th ribs.. The fascial plane between the serratus anterior muscle and latissimus dorsi muscle will be identified over the 4th rib in the mid-axillary region. The block will be performed with a needle (22-G, 50-mm) introduced in-plane to enter deep to the serratus anterior muscle, and 30 ml 0.25 bupivacaine will be injected.
45790728|NCT00373581|Drug|Cocaine|
45790729|NCT01470170|Drug|Alfentanil|Give Alfentanil before TCI Propofol sedative bronchoscope
45790730|NCT01470170|Drug|Normal saline|Normal Saline (placebo comparator) was given in equivalent amount of alfentanil dosage in each arm, for double blinded purpose.
45790731|NCT01470170|Device|Targeted controlled infusion|The Propofol dosage was according to the effect site concentration to reach OAAS-3 ( loss of conscious), using Schneider model
45790732|NCT01470170|Drug|Propofol|The Propofol dosage is according to the effect site concentration to reach OAAS-3 ( loss of conscious), using TCI Schneider model during the whole procedure of bronchoscope
45790733|NCT04311567|Drug|Tofacitinib|Open-label tofacitinib for 48 weeks. All subjects (both arms) receive prednisone starting at 20 mg QD with tapering for 6 weeks. Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib 5 mg BID + methotrexate 20 mg weekly up to week 48.
45790734|NCT04311567|Drug|Methotrexate|Open-label methotrexate for 48 weeks. All subjects (both arms) receive prednisone starting at 20 mg QD with tapering for 6 weeks. Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib 5 mg BID + methotrexate 20 mg weekly up to week 48.
45790735|NCT04259775|Device|Automated Insulin Dose Adjustment|The system originally developed at Boston Children's Hospital, obtains CGM, insulin delivery, and activity data, from the cloud each day at approximately 8:00 PM using an Application Program Interface (API) calls to commercial companies (primarily Glooko and Tidepool) that aggregate data from different devices used to manage glucose levels in individuals. A detailed statistical and control analysis (see preliminary data study 1 for algorithm details) of the data are then conducted to determine if a change in therapy is required. If the analysis indicates a change in therapy is required, the patient or parent is notified by text or email directing then to a web portal detailing the change. The patient or parent can accept or modify the recommended change. If a change is made, the AIDA system confirms that the change is correctly implemented into the patient's pump or Bluetooth enabled pen when the patient next uploads the device data to the cloud.
45790736|NCT04259775|Device|Control|Standard Care - change in therapy settings effected at regularly scheduled patient visits
45790737|NCT01572428|Procedure|Inspection with Narrow-Band Imaging(NBI)|Narrow-Band Imaging(NBI)of the colon rather than the standard white light in the inspection of the colon during colonoscopy.
45790738|NCT01572428|Procedure|Standard White Light|Use of Standard White Light on the colon rather than Narrow-Band Imaging(NBI)in the inspection of the colon during a colonoscopy.
45790739|NCT05037825|Drug|Checkpoint Inhibitor, Immune|anti-PD-1, anti-PD-L1, or anti-CTLA-4 as a single agent or in combination with another checkpoint inhibitor or other treatment agent or modality (e.g., targeted therapy, chemotherapy, surgery, radiation, etc.) in accordance with FDA-labeled use of the agent
45790740|NCT01573052|Drug|Chlordiazepoxide|25mg four times daily x 3 days then tapered over 3 days
45790741|NCT01573052|Drug|Gabapentin|300mg four times daily x 3 days then tapered over 3 days
45790742|NCT04993599|Device|Social robot interaction|The participants interact with the social robot which is controlled by the researcher behind the scene (wizard of oz. method).
45790743|NCT01521260|Procedure|placebo|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
46071488|NCT04841564|Procedure|open approach of serratus anterior block|After resection of the breast and identification of the serratus anterior muscle, the surgeon will be asked to palpate the ribs below the clavicle and localize the fourth rib. A 22-G, 50-mm needle will be introduced deep to the serratus anterior muscle contacting the rib, and 30 ml 0.25 bupivacaine will be injected.
46071489|NCT02842710|Device|GeneXpert®|Detection is carried out after a sample within the patient's nasal cavity. The swab containing the sample is placed in the PLC GeneXpert® Cepheid . The analysis takes one hour . The results leave automatically.
46071490|NCT00829231|Drug|Sorafenib (Nexavar, BAY43-9006)|Mildly Hepatic Impaired Subjects
45646959|NCT03037255|Other|long term conditions|Long term conditions including diabetes mellitus, chronic obstructive pulmonary disease or asthma, chronic heart failure, chronic renal failure, cerebrovascular disease or peripheral vascular disease.
45646960|NCT05093725|Device|flow cytomery|take sample of Wharton jelly and culturing it to know the best time for mesenchymal stem cell growth
45646961|NCT05721911|Genetic|whole genome sequencing|Partecipants will be assessed for disease progression: Stadio di Hoehn and Yahr, MDS-UPDRS part III, MOCA test, no motor symptoms, therapy and LID occurrence, Sleep disorders. Partecipants will be subjected to peripheral blood sampling for the purification of DNA, plasma, serum, PBMC and generation of hiPSC. DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate PD genes
45646962|NCT04165811|Other|Exercise treatment|A program consisting of aerobic dance based exercises and physical activity counseling accompanied by physiotherapists will be applied to the study group.
45646963|NCT04165811|Other|Counselling|Only physical activity counseling will be given to the subjects in this group.
45646964|NCT05091151|Drug|Intranasal dexmedetomidine at dose of 2 mcg/kg and 4 mcg/kg|Intranasal dexmedetomidine were given 45 minutes before the MRI procedure through both nostrils using a 1 mL syringe.
45646965|NCT04752917|Device|Noise Cancelling headphones|Use of headphones playing patients choice of music
45646966|NCT05377021|Behavioral|Lifestyle change|"In the project, 33 women in the first group will receive diet intervention for 12 weeks, and 33 women in the second group will receive diet and exercise combination intervention."
45646967|NCT05466539|Drug|AbobotulinumtoxinA|Participants randomized to receive aboBoNTA will receive a maximum of 200 units of aboBoNTA distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior (60 units), Extensor Digitorum Longus (20) and Extensor Hallucis Longus (20); (L) Fibularis Brevis (50) and Fibularis Longus (50). Tibialis Anterior (60U); Extensor Digitorum Longus (20); Extensor Halluces Longus (20); Fibularis Brevis (50), and; Fibularis longus (50). Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing and SWE imaging.
45646968|NCT05466539|Drug|Placebo|Participants randomized into the normal saline group will receive injections distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior, Extensor Digitorum Longus, and Extensor Hallucis Longus; (L) Fibularis Brevis and Fibularis Longus. Tibialis Anterior; Extensor Digitorum Longus; Extensor Halluces Longus; Fibularis Brevis, and; Fibularis longus. Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing.
45646969|NCT05093257|Diagnostic Test|Laboratory investigations for control|"Complete blood picture .~Erythrocyte sedimentation rate(ESR).~Liver function tests .~Kidney function tests.~CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry"
45646970|NCT05093257|Diagnostic Test|Laboratory investigations for patients|"Complete blood picture .~Erythrocyte sedimentation rate(ESR).~Liver function tests .~Kidney function tests.~Anti-nuclear antibodies test by immunoflourescence for ITP patients.~Bone marrow aspiration (for diagnosis of ITP).~CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry."
45646971|NCT05093179|Procedure|Deep tissue massage|Administered as a soft tissue mobilization performed by the therapist with fingertips, knuckles, elbows and/or fists on the tissues that manifest symptoms of fascial restrictions. The techniques were performed with individually adjusted force until the change (eg. increased mobility) in the tissue being treated was stated by the therapist.
46071491|NCT00829231|Drug|Sorafenib (Nexavar, BAY43-9006)|Moderately Hepatic Impaired Subjects
46071492|NCT00829231|Drug|Sorafenib (Nexavar, BAY43-9006)|Healthy Subjects
46071493|NCT02839824|Procedure|Bowel preparation|Bowel preparation for bowel cleansing in a real clinical practice
45646972|NCT05093179|Procedure|Classic massage|The subject was lying supine on the table, with a roller placed under the knee joints, the upper limbs along the body. The following sequence of techniques was used in the longitudinal and transverse strands and in the intercostal spaces (excluding the breast in women): effleurage, friction, petrissage, pressures, tapotement and vibrations.
45790744|NCT01521260|Procedure|Chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
45790745|NCT01523834|Drug|Panobinostat|"Induction Phase: Patients will receive panobinostat for 6 courses (1 course = 28 days). Consolidation phase (courses 7-12). Maintenance phase (course 13-end of therapy).~Panobinostat should be taken p.o. at the dose of 40 mg/day 3-times every week (QW) as part of a 4 week treatment cycle. The dose of panobinostat may be modified: the 1st dose adjustment consists in the modification of drug administration from 3 times every week (QW) to 3 times every other week (QOW). Levels lower than 30 mg 3 times QOW is not permitted."
46071494|NCT00901628|Drug|ropivacaine|300mg (0.75%, 40cc) intraoperative periarticular injection
46071495|NCT00901628|Drug|morphine sulfate|10mg intraoperative periarticular injection
46071496|NCT00901628|Drug|ketorolac|30 mg intraoperative periarticular injection
46071497|NCT00901628|Drug|epinephrine|300 microgram (1:1000) intraoperative periarticular injection
45646973|NCT04626167|Procedure|Concomitant Renal and Urinary Bladder Allograft Transplantation|This is a single-center, prospective, single-group unblinded phase I study that will enroll subjects with chronic kidney disease secondary to bladder dysfunction or bladder absence that is refractory to medical treatment and requires surgical intervention to prevent long-term sequelae. Patients will undergo a cadaveric donor bladder transplant in addition to or after their kidney transplant rather than using intestinal segments for bladder reconstruction or contruction.
45790746|NCT01575080|Device|Contour TS Blood Glucose Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm and forearm using the Contour TS Blood Glucose Monitoring System. All BG results are compared to a reference laboratory glucose method.
45790747|NCT01472432|Drug|Placebo|Placebo is added to the standard good medical practice. Plus Metformin and/or Sulfonylurea
45790748|NCT01472432|Drug|vildagliptin|50 mg per os b.i.d. for 4 months of treatment, added to the standard good medical practice.Plus Metformin and/or Sulfonylurea
45790749|NCT02797821|Drug|Asfotase alfa|
46071498|NCT00901628|Drug|cefuroxime|750mg intraoperative periarticular injection
45790750|NCT05566028|Drug|D745 formulation I|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
46071499|NCT00623545|Drug|Exenatide|Exenatide dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks of treatment.
45920212|NCT04704336|Behavioral|Task-shifting strategy for HTN control (TASSH) protocol|The TASSH protocol include the following 4 steps: 1). Identify HIV patients with uncontrolled HTN: trained HIV nurses will take patients' medical history (whether or not they have a diagnosis of diabetes, heart attack, stroke, heart failure, smoking). 2) Next, they will measure the patients' weight, height, waist circumference and BP with a valid automated device following standard procedures and then conduct lab tests with point-of-care testing on blood glucose, lipids and urine dip stick. 3) Initiate lifestyle counseling and medication treatment every 1-3 months: The nurses will next counsel eligible patients on lifestyle behaviors for 20 to 30 minutes (increased intake of fruits and vegetables, moderate physical activity and reduce salt intake). 4). Refer patients with complicated HTN to physicians for further care
46071500|NCT02840214|Device|transcranial direct current stimulation|Soterix tDCS RCT device given over left DLPFC for 20 minutes at 2mA.
46071501|NCT02840214|Device|sham tDCS|Soterix tDCS RCT device given over left DLPFC with 30 second ramp on and off of current
45790751|NCT05566028|Drug|D745 formulation II|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
45790752|NCT05566028|Drug|D745 Placebo|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
45790753|NCT02798289|Device|Oculeve Intranasal Neurostimulator|Neurostimulation device
45790754|NCT01524302|Drug|Ceftaroline|600 mg Q12h
45790755|NCT01524302|Drug|Levofloxacin|750 mg QD
45790756|NCT04202991|Other|Exposure - pain|Groups are defined by their naturally occurring exposure to pain or not
45790757|NCT02247284|Device|RNFL and BMO-MRW SD-OCT|Masurement of peripapillary RNFL measurements with Heidelberg Spectralis SD-OCT (Heidelberg Engeneering GmbH, Heidelberg, Germany) old protocoll and in addition with the new Glaucoma Premium Module (software version 6.0) tocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
45790758|NCT01525862|Device|Balloon sinus dilation|
45790759|NCT02802111|Drug|Albuterol|Patient receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
45790760|NCT02802111|Drug|Levalbuterol|Patient receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention
45790761|NCT05565794|Drug|Pemigatinib|Intake of up to 3 tablets of pemigatinib (4,5 mg each) daily per oral for 14 days in a 21-day cycle (maximum of 18 cycles in total)
45790762|NCT01576874|Drug|Oxytocin|40 IUs of oxytocin administered intranasally one time
45790763|NCT01576874|Drug|placebo|placebo administered intranasally one time
45790764|NCT01528124|Drug|LY3025876|Given as a subcutaneous injection
45790765|NCT01528124|Drug|Placebo|Given as a subcutaneous injection
45790766|NCT01576952|Drug|ISV-303|Bromfenac in DuraSite
45790767|NCT01576952|Other|DuraSite Vehicle|DuraSite Vehicle
45790768|NCT01577108|Dietary Supplement|Probiotic|oral taking 2 capsules before sleeping per day for 14 days
45790769|NCT01577108|Dietary Supplement|Placebo|oral taking 2 capsules before sleeping per day for 14 days
45790770|NCT01577732|Biological|Infanrix-IPV+Hib™|Single dose administered intramuscularly (IM) into the anterolateral side of the right thigh.
45790771|NCT01577966|Drug|Sulfasalazine|"Sulfasalazine has been the parent aminosalicylate in use for over 40 years in the treatment of inflammatory bowel disease. The drug is a conjugate of sulfapyridine linked to 5-aminosalicylic acid. In inflammatory bowel disease, the 5-ASA component is the active moiety~Sulfasalazine is a prodrug that consists of sulfapyridine bonded to mesalamine (5-ASA). Sulfasalazine is cleaved by colonic bacterial azo-reductases into sulfapyridine and the 5-ASA moiety. 5-ASA is metabolized to N-acetyl-5-ASA by an enzyme in the intestinal epithelium and the liver and then excreted in the urine as a mixture of free 5ASA and N-acetyl-5-ASA."
46071502|NCT00825097|Procedure|Selective tibial neurotomy|Selective tibial neurotomy is a neurosurgical intervention consisting in partially and selectively cutting the motor nerve branches destinated to the spastic muscles.
46071503|NCT00825097|Drug|Botulinum toxin injection|Botulinum toxin type A
45646974|NCT04538989|Drug|RZ358 Sequential Group Cohort 1|IV infusion for 8 weeks (3 mg/kg bi-weekly for 8 weeks)
45646975|NCT04538989|Drug|RZ358 Sequential Group Cohort 2|IV infusion for 8 weeks (6 mg/kg bi-weekly for 8 weeks)
45790772|NCT01578044|Behavioral|Intervention|"Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients.~Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescriptions.~Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban have not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication."
45790773|NCT01578044|Other|Control|Usual care
45790774|NCT02345226|Drug|FTC/RPV/TAF|200/25/25 mg FDC tablets administered orally once daily
45790775|NCT02345226|Drug|EFV/FTC/TDF Placebo|Tablets administered orally once daily
45790776|NCT02345226|Drug|EFV/FTC/TDF|600/200/300 mg FDC tablets administered orally once daily
45790777|NCT02345226|Drug|FTC/RPV/TAF Placebo|Tablets administered orally once daily
45790778|NCT02802501|Drug|Tafenoquine|This intervention is provided as tablet containing 150 mg of tafenoquine. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.
45920213|NCT00088387|Drug|Divalproex|
45920214|NCT00088387|Drug|Lithium|
45920215|NCT00088504|Drug|Merimepodib|
45920216|NCT00088504|Drug|PEG-Interferon-alpha 2a (Pegasys®)|
45920217|NCT00088504|Drug|Ribavirin (Copegus®)|
46071504|NCT02844764|Biological|[StroMed + platelet rich plasma (PRP)]|Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit (AUCRU) and Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated with direct injections to the joint with Platelet Rich Plasma processed by RegenLab (RegenKit BCT-3) PRP product. Day 0 [StroMed + platelet rich plasma (PRP)], Day 7, 14 and 30 [PRP]
45646976|NCT04538989|Drug|RZ358 Sequential Group Cohort 3|IV infusion for 8 weeks (9 mg/kg bi-weekly for 8 weeks)
45646977|NCT04538989|Drug|RZ358 Sequential Group Cohort 4|IV infusion for 8 weeks (bi-weekly fixed dose-titration from 3 to 9 mg/kg for the first 4 weeks, followed by a fixed 9 mg/kg dose amount thereafter for the remaining 4 weeks)
45646978|NCT05704907|Other|gallbladder ultrasound|gallbladder ultrasound
45646979|NCT05093023|Genetic|Real-Time PCR|Genomic DNA was extracted from 2 ml of venous blood. ABCB1 1236 G>A and 3435 G>A were genotyped using predesigned TaqMan SNP genotyping assays on a stepOne PCR instrument in accordance with the manufacturer's protocol.
45646980|NCT04413175|Other|music therapy|"Patients in the music group were provided music therapy that was prepared by the Turkish Psychological Association. They listened to the music that has a calming and relaxing effect for 20 min before and during the procedure.~A portable MP3 player connected to double earphones was used in the present study. After patients took the lithotomy position for cystoscopy, their headphones were inserted and music began to be played. Music was played to the individuals for 20 minutes before and during the procedure. Headphones were removed immediately after the procedure was completed and the double earphones were cleaned with antiseptic solution after each application."
45646981|NCT05439551|Diagnostic Test|MeMed BV®|Patients Serum and Whole blood samples will be examined using the MeMed BV® test. Test results will have no impact on patient management.
45646982|NCT05092867|Other|Po Tra tool|Healthcare workers filled the 2 VAS of the tool but it did not impact or change the care of the patient. (observational)
45653122|NCT05555641|Drug|Nafamostat Mesylate|ECMO patients were given continuous anticoagulation with nafamostat mesylate, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
45790779|NCT02802501|Drug|Matched-Placebo for Tafenoquine|This intervention contains tafenoquine matched-placebo. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.
45790780|NCT02802501|Drug|Primaquine|This intervention is provided as over-encapsulated tablet containing 15 mg of primaquine. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).
45790781|NCT02802501|Drug|Matched-Placebo for Primaquine|This intervention contains primaquine matched-placebo. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).
45920218|NCT00006137|Drug|enalapril|
45920219|NCT04700865|Diagnostic Test|AF screening|Continous ECG monitoring for minimum 3 days
45920220|NCT00088543|Biological|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|total dose 4.5 mg/kg
45920221|NCT00088543|Biological|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|total dose 8.5 mg/kg
45920222|NCT00088582|Drug|Pasireotide (SOM230), Octreotide (Sandostatin)|
45920223|NCT00006143|Drug|Somatropin|
45920224|NCT00088660|Biological|PANVAC™-VF|
45920225|NCT04695444|Device|nasotracheal tube (Ring-Adair-Elwin)|different materials for nasotracheal intubation conventional PVC tube
45920226|NCT04695444|Device|nasotracheal tube (Ring-Adair-Elwin)|different materials for nasotracheal intubation conventional PVC tube with rubber suction catheter
45920227|NCT04695444|Device|nasotracheal tube (portex)|different materials for nasotracheal intubation velvet soft PVC tube.
45920228|NCT00088738|Drug|[18F] SPA-RQ|
45920229|NCT00088777|Behavioral|Behavioral coping skills training plus physical therapy|10 hours coping sessions, 6 hours activating physical therapy, 4 hours physical therapy education
45920230|NCT00088777|Behavioral|Stress management education plus physical therapy|10 hours stress management education, 6 hours activating physical therapy, 4 hours physical therapy education
45920231|NCT00006146|Biological|Approved influenza virus vaccine.|
45920232|NCT00088816|Drug|cisplatin|
45790782|NCT02802501|Drug|Dihydroartemisinin-piperaquine (DHA-PQP)|This formulation is provided as tablet containing 320 mg of piperaquine tetrasphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). This tablet will be administered orally as single dose for 3 days. For subjects weighing <75 kg, 3 tablets will be administered per day. For subjects weighing >=75 kg, 4 tablets will be administered per day. Dose will be taken at least 3 hours after last food intake. No food will be allowed for at least 3 hours after dosing.
45790783|NCT02802501|Drug|ACT plus PQ (Rescue medication)|Subjects with relapse during the 180 day follow up period will be given an ACT plus PQ 0.5 mg/kg for 14 days as rescue medication.
45790784|NCT02802501|Drug|PQ (End of study treatment)|Subjects who do not relapse during the study will receive PQ 0.5mg/kg for 14 days at the end of the study.
45790785|NCT05565326|Device|Low field (0.35 T) MR-images of the brain at a MRIdian® linac system|Low field (0.35 T) MR-images of the brain at a MRIdian® linac system using CE marked low-field MR coils as provided by the company will be taken for volunteers in phase I. In phase II and III, after therapy beginning those images will be taken once per week per subject using CE marked low-field MR coils as provided by the company. This is done over the entire course of radiotherapy, which takes between 3 and 6 weeks.
45790786|NCT01528592|Drug|Carbidopa-Levodopa|Equivalent amount of carbidopa-levodopa will be provide to you
45790787|NCT01578278|Drug|Bepotastine besilate formulation|Nasal Spray
45790788|NCT01578278|Drug|Fluticasone propionate|Nasal Spray
45790789|NCT01578278|Drug|Bepotastine besilate-fluticasone propionate|Nasal Spray
45790790|NCT01578278|Drug|Placebo Comparator|Nasal Spray
45790791|NCT01578902|Radiation|Stereotactic ablative body radiotherapy|35Gy/5 fractions/29 days
45790792|NCT02803749|Drug|Buspirone|
45790793|NCT02803749|Drug|Placebo|
45790794|NCT01578980|Device|Outpatient Control-to-Range|Subjects will spend two nights (~42 hours) in a local hotel during which the AP Platform will be remotely monitored in an adjacent hotel room for validation that remote system monitoring can successfully occur.
45790795|NCT01529060|Drug|Phenylbutyrate|Dosage of phenylbutyrate powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day, the standard UCD dose studied in our preliminary studies, for 14 days.
45790796|NCT01529060|Drug|Placebo powder|Dosage of inactive placebo powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day for 14 days. Subjects will receive the same amount of powder for each arm of the study.
45790797|NCT05565014|Drug|Virus Activated Killer immune Cells|The VAK made from Pleural Effusion should be given to treat Malignant Pleural Effusion.The VAK made from Peritoneal Effusion should be given to treat Malignant Peritoneal Effusion.
45790798|NCT05565014|Drug|Saline|The use of saline was the same as VAK group.
45920233|NCT00088816|Drug|tegafur-gimeracil-oteracil potassium|
45920234|NCT00088816|Procedure|adjuvant therapy|
46071505|NCT04712864|Biological|LB1901|LB1901 - an autologous CD4-targeted CAR-T immunotherapy
46071506|NCT02839668|Drug|Lidocaine|Continuous infusion of lidocaine
46071507|NCT02839668|Drug|Sevoflurane|maintenance of hypnosis during anaesthesia with sevoflurane
45646983|NCT05421689|Biological|Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)|The study will treat 62 patients at 2 clinical sites: UC Davis Center for Voice and Swallowing and UCSF Voice and Swallowing Center. Patients will be randomized 1:1 to receive either 2 AMDC-GIR doses of 150 x 10⁶ cells or 2 doses of identical placebo composed of the same cryopreservation medium used for AMDC-GIR. Enrollment is expected to be completed within 2 years of initiating the study. Patients will be followed for 24 months post-treatment.
45646984|NCT05421689|Other|Placebo|two doses of placebo will be administered and spaced 4-6 weeks apart.
45646985|NCT05377957|Other|Quality of life questionnaires|Collection of patient-reported outcomes concerning general and health-related quality of life and impact of uveal melanoma diagnosis
45646986|NCT05377957|Other|Discrete choice experiment|Assessment of patient preferences for outcomes of proton therapy and enucleation
45646987|NCT05377957|Other|Shared decision-making analysis|Assessment of shared decision-making from the perspective of the patient (by questionnaire), physician (by questionnaire) and a neutral observer (by audiotape), combined with patient-reported satisfaction and regret of the treatment decision (by questionnaire)
45790799|NCT00372879|Dietary Supplement|Vitamin E|Vitamin E 800IU bid
45790800|NCT01579214|Other|Cellular Phone Text Messages|Cellular phone text message formats to be sent to participants after abnormal laboratory results to communicate information and request early return to clinic.
45790801|NCT02806869|Drug|Single dose of ibuprofen (800 mg tablet)|
45790802|NCT02806869|Dietary Supplement|Pulmocare, two 8.0 oz (236.6 mL) cans|
45790803|NCT02809911|Device|Provant|
45920235|NCT00088816|Procedure|conventional surgery|
45920236|NCT00088816|Procedure|neoadjuvant therapy|
45920237|NCT04688736|Drug|Placebo|The tablet resembles chlorpheniramine but has no therapeutic value.
45920238|NCT04688736|Drug|Chlorpheniramine|An antihistamine that reduces the natural chemical histamine in the body.
45920239|NCT00088855|Drug|Bortezomib|Given IV
45920240|NCT00088855|Other|Laboratory Biomarker Analysis|Correlative studies
45920241|NCT00088855|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
45920242|NCT00088894|Drug|gemcitabine hydrochloride|Given IV
45920243|NCT00088894|Biological|bevacizumab|Given IV
45920244|NCT00088894|Other|placebo|Given IV
46071508|NCT02839668|Drug|TIVA-TCI|maintenance of hypnosis during anaesthesia with sevoflurane
46071509|NCT02839668|Drug|Acetaminophen|administration of 1 g acetaminophen for postoperative analgesia
46071510|NCT02839668|Drug|Tramadol|administration of tramadol for postoperative analgesia
46071511|NCT02839668|Drug|Neostigmine|A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.
45920245|NCT00088894|Other|laboratory biomarker analysis|Correlative studies
45920246|NCT00088894|Other|pharmacogenomic studies|Correlative studies
45790804|NCT03910101|Procedure|Hand surgery and intensive rehabilitation|Spasticity-correcting upper-limb surgery comprised lengthening of tendons, release of muscles, and occasionally correction of deformities. Rehabilitation starts the first post-operative day and comprised physiotherapy and occupational therapy. Patients are also taught a home-training program. Up to 1 week of intensive in-hospital rehabilitation followed 3 weeks after surgery and a new home-training program are designed.
45646988|NCT05377957|Other|Impact of side-effects analysis|Assessment of the impact of side-effects by questionnaire
45646989|NCT05675735|Behavioral|Clinic-Level Multidimensional Intervention|The proximal goal of the intervention will be to increase OTP uptake of flexible THD. The intervention addresses facilitators and barriers to THD practices as identified by existing studies as well as those found during the first phase of the current project. The intervention will be designed to address the information gaps, training needs, and beliefs of individuals across the organizations.
45790805|NCT01529450|Drug|LDE225|800-mg (4 200-mg capsules/day) capsule
45646990|NCT05411315|Other|Restricted-use of arterial catheter|The investigator will restrict the use of arterial catheters unless exclusion criteria is met.
45646991|NCT05411315|Other|Standard-use of arterial catheter|The investigator will allow standard-use of arterial catheters
45920247|NCT00088894|Other|pharmacological study|Correlative studies
45920248|NCT00006152|Drug|Ritonavir|
45920249|NCT00006152|Drug|Abacavir sulfate|
45920250|NCT00006152|Drug|Amprenavir|
45920251|NCT00088933|Drug|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given intradermally
45920252|NCT00088933|Drug|recombinant vaccinia-CEA(6D)-TRICOM vaccine|Given intradermally
45920253|NCT00088933|Drug|docetaxel|Given IV
45920254|NCT00088933|Drug|sargramostim|Given subcutaneously
46071512|NCT02839668|Drug|Atropine|A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine
46071513|NCT02839668|Device|BIS|For the groups receveing TIVA-TCI anesthesia the bispectral index will be monitored
46071514|NCT04701788|Biological|23-valent pneumococcal polysaccharide vaccine|The study group and the control group were injected with a dose of 23-valent pneumococcal polysaccharide vaccine. One month later, blood was collected and serum was separated.
45646992|NCT05667623|Drug|1% OPA-15406 Ointment|Twice-daily administration for 4 weeks.
45646993|NCT05667623|Other|0% OPA-15406 Vehicle|Twice-daily administration for 4 weeks.
45646994|NCT05663333|Other|Dynamic full-field optical coherence tomography analysis of temporal artery biopsy|Dynamic full-field optical coherence tomography analysis of temporal artery biopsy in the dermatology department before conventional histopathological analysis
45920255|NCT00089050|Drug|cyclosporine|
45646996|NCT05623865|Other|kinesiotaping|"Kinesio tape will be attached with lymphedema technique.~The bands will be removed prior to each assessment so that they do not affect the evaluator's blinding. After evaluation, the new tape will be fitted by the invesitgatör"
45790806|NCT03795675|Device|Cochlear Implant|Cochlear implant device to be implanted at time of surgical intervention.
45790807|NCT01580072|Other|self-monitoring for patients with severe COPD|Intervention Group entering vital parameters via Web Portal or automatic call center.
45790808|NCT01580072|Other|nurse-monitoring for patients with severe COPD|Nurses are entering vital parameters of the patient with mobile devices.
45790809|NCT01580306|Drug|BI 201335|Relevant treatment dose capsule (A) for oral administration
46071515|NCT04700618|Biological|23-valent pneumococcal polysaccharide vaccine|The study group and the control group were vaccinated with one dose of vaccine and blood was collected after 28-40 days.
45646997|NCT05623865|Other|exercise|"Wrist, finger, elbow range of motion and stretching exercises will be taught to the patients and given as home exercises.~In addition, patients will be given a leaflet containing illustrated and explanatory exercise visuals."
45920256|NCT00089050|Drug|gemtuzumab ozogamicin|
45790810|NCT01580306|Drug|BI 201335|Relevant treatment dose capsule (B) for oral administration
45790811|NCT02813265|Drug|KPI-121 0.25% Ophthalmic Suspension|
45920257|NCT00006155|Drug|SU5416 and carboplatin|
45920258|NCT04664205|Other|High Intensity Interval Exercise|One session of high intensity interval exercise
45920259|NCT04664205|Other|Moderate Intensity Continuous Exercise|One session of calorically matched moderate intensity exercise
45920260|NCT00089089|Drug|decitabine|Given IV
45920261|NCT00089089|Other|pharmacological study|Correlative studies
45920262|NCT00089089|Other|laboratory biomarker analysis|Correlative studies
45920263|NCT00089167|Biological|filgrastim|
45920264|NCT00089167|Drug|dexamethasone|
45920265|NCT00089167|Drug|melphalan|
45920266|NCT00089167|Drug|thalidomide|
45920267|NCT00089206|Biological|incomplete Freund's adjuvant|
45920268|NCT00089206|Biological|multi-epitope melanoma peptide vaccine|
45920269|NCT00089206|Biological|sargramostim|
45920270|NCT00400231|Drug|Study drugs: Metformin and fenofibrate|145mg fenofibrate once/day and 2000mg/day of metformin for arm 3.
45920271|NCT00400231|Drug|Study Drug: Metformin|2000mg/day
45920272|NCT00400231|Drug|Study Drug: fenofibrate|145mg/day of fenofibrate
45920273|NCT00400231|Drug|Metformin and Fenofibrate placebo|placebo metformin and fenofibrate
45920274|NCT00006158|Drug|Testosterone|
45920275|NCT00423826|Drug|Busulfan|3 mg/kg intravenously over 3 hours
45920276|NCT00423826|Drug|Cytarabine|Patients with previous history of CNS involvement will receive pre-transplant intrathecal Cytarabine (Ara-C) (30 mg/M2) therapy.
45920277|NCT00423826|Drug|Fludarabine phosphate|25 mg/M2/day IV
45920278|NCT00423826|Drug|mycophenolate mofetil|Orally at the dose of 1 gm every 8 hours.
45920279|NCT00423826|Drug|tacrolimus|0.015 mg/kg IV every 12 hours by continuous infusion.
45790812|NCT02813265|Drug|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
45790813|NCT02247206|Behavioral|Behavior Therapy for Tics (CBIT)|CBIT is an 8-session 10-week behavioral treatment for chronic tic disorders, including Tourette Syndrome. The first two sessions are 90 minutes, with subsequent sessions lasting 60 minutes. The treatment consists of Habit Reversal Training (awareness training, competing response training, and social support), and function-based assessment to reduce the impact of environmental or other stimuli on tic severity. The treatment also consists of relaxation techniques to reduce tic-related stress and tension, and behavioral rewards to motivate treatment compliance.
45790814|NCT05564858|Drug|FDA022 Monoclonal antibody-drug conjugate for injection|FDA022-BB05, intravenously infusion, q3w
45790815|NCT05564780|Drug|RASI and/or a single pill combination based RASI|The participants in the Treatment group will begin with a single category antihypertensive drug to control their blood pressure, for example, perindopril. If the blood pressure cannot be controlled under 130/80 mmHg, another type of antihypertensive drug will be added.
45790816|NCT05564234|Procedure|laparoscopy then primary cytoreductive surgery|Laparoscopy was used to calcautation of fagotti PIV score , if less than 8 primary cytoreductive surgery were done.
45790817|NCT05564234|Procedure|laparoscopy then neoadjuvant chemotherapy followed by interval cytoreductive surgery|Laparoscopy was used to calcautation of fagotti PIV score and provides the histological diagnosis , if score more than 8 the patient were received neoadjuvant chemotherapy followed by interval cytoreductive surgery
45920280|NCT00423826|Procedure|allogeneic hematopoietic stem cell transplantation|10 days post drug intervention
45790818|NCT05564000|Other|Dating Violence Prevention Program|We designed and constructed the e-learning platform as an education program on dating violence based on the theory of planned behavior to evaluate the effectiveness of the programs in improving dating violence myths, bystander help-giving attitude, subjective norms, self-efficacy, intention, and behavior.
45790819|NCT02814279|Procedure|CAF plus connective tissue graft|Periodontal surgery for root coverage by the trapezoidal flap associated with connective tissue graft.
45790820|NCT02814279|Procedure|Tunnel plus connective tissue graft|Periodontal surgery for root coverage by the tunnel flap associated with connective tissue graft.
45790821|NCT02814279|Drug|Sodium dipyrone|All participants were instructed to take 500 mg sodium dipyrone just in case of pain.
45790822|NCT02814279|Drug|chlorhexidine rinse|All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
45790823|NCT03786003|Procedure|VATS|Standard video assisted thoracic surgery, no use of rib-spreader.
45920281|NCT00423826|Procedure|umbilical cord blood transplantation|10 days post drug intervention
45920282|NCT00423826|Radiation|total-body irradiation|10 days post drug intervention
45920283|NCT00423865|Drug|cisplatin|cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15)
45920284|NCT00423865|Drug|everolimus|escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle)
45920285|NCT00423865|Genetic|gene expression analysis|Each biopsy specimen will be formalin-fixed and paraffin-embedded for IHC, and analysis of p53 and p21 will follow methods previous reported by our group. The avidin-biotin immunoperoxidase technique will be employed.
45647000|NCT04447469|Drug|mavrilimumab|anti-granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSF-Rα) monoclonal antibody (human isoform immunoglobulin G [IgG4])
45647001|NCT04447469|Other|Placebo|matching placebo
45920286|NCT00423865|Other|immunohistochemistry staining method|After the phase 2 recommended dose is established in the phase I portion of the study (Part A), we plan to enroll an additional 6 patients for pharmacodynamic studies (Part B). Entry into Part B requires the patient have tumor tissue which is easily accessible for research biopsy. The patients will be asked to provide written informed consent for the research biopsies. Patients also will be asked to provide written informed consent to allow the use of their tissue for future research studies. The research biopsies are not mandatory for any patient. Patients who do not consent to the research biopsies or who withdraw consent for the research biopsies may still receive RAD001 + cisplatin in the study
46071516|NCT02842632|Other|theoretical test|The theoretical test is a multiple choice test which consists of 50 questions with 1 point per question (max. 50 points). It will be done before the teaching, after the 2 teaching sessions and 3 Months after the study
45647002|NCT04447235|Drug|Placebo|Use of the combination of ivermectin-placebo plus losartan-placebo as early treatment for COVID-19 in cancer patients
45647003|NCT04447235|Drug|Ivermectin|Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
45647004|NCT04447235|Drug|Losartan|Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
45647005|NCT01680991|Drug|Obinutuzumab|Multiple doses of obinutuzumab.
45790824|NCT03786003|Procedure|Thoracotomy|Standard thoracotomy
45790825|NCT03658083|Procedure|Thoracotomy|Open surgery
45790826|NCT03658083|Procedure|Robotic-assisted thoracic surgery|Minimally invasive surgery
45790827|NCT01533038|Device|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, New Zealand, Canada, Serbia, and Turkey. It was developed for the intended use of soft tissue approximation and for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
45790828|NCT01533038|Procedure|Transurethral Resection of the Prostate|Transurethral Resection of the Prostate (TURP) is a surgical procedure which removes prostatic tissue by electrocautery dissection. During the procedure the tissue at the bladder neck and the adjacent adenoma are resected in quadrants. Resection continues into the midportion of the gland and concludes at the apex. Any remaining residual tissue is cleared, leaving a void from verumontanum to bladder neck.
45790829|NCT00373659|Drug|Ranibizumab (Lucentis)|
45790830|NCT05563064|Drug|Karika Syrup|To evaluate the effects of Karika syrup on complete blood count specifically thrombocytes (platelets) collected from blood samples of patients after treatment of 15 days long period.
45790831|NCT05562440|Other|Focus Group Discussion|Each focus group will consist up to five participants in every session, two sessions each for both low and high risk group. Every FGD sessions will last for 1 to 2 hours and be conducted in Indonesian, and will be recorded. Both groups will be asked the following questions: 1) What is your opinion regarding the clarity of information in the dummy breast cancer risk prediction report?; 2) What is your opinion regarding the completeness of information in the dummy breast cancer risk prediction report?; and 3) What is your impression regarding the results presented in the dummy breast cancer risk prediction report?.
45790832|NCT02885025|Dietary Supplement|Broccoli Sprout Extract|Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.
45790833|NCT02885025|Drug|fluticasone nasal|fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.
46071517|NCT02842632|Other|practical test|The practical test is an evaluation of 11 basic perioperative TEE examination on the simulator (CAE Vimedix Simulator). Each view is evaluated on a scale of 0 to 10 according to predetermined criteria including image angle, overall clarity and visualization of 3 major anatomic structures pertinent to each view. Each view can receive a maximum score of 10 and each study a maximum of 109 (ME asc. aortic LAX has only 2 main structures). It will be done after the first and second teaching session, and 3 Months after the study.
45449601|NCT05241236|Device|Image Fusion (MR/US) Software Registration Guided Laser Ablation of Prostate Cancer|Subjects diagnosed by a transperineal fusion or random transperineal or random transrectal prostate biopsy. Laser treatment plan generated by biopsy results +/- MRI is uploaded into the device. In procedure suite, a transperineal anesthetic block is conducted following by Bianco - USPTO PCT/US18/24404. On lithotomy a transrectal ultrasound probe is advanced, the prostate scanned. The images are acquired by fusion device. Co-registration is performed by surgeon delimiting boundaries of prostate. Medical device delivers real-time fusion guidance outlining prostate contours, ablation goals and laser introduce location. Surgeon executes plan or adjust as needed. Surgeon activates laser device, performs ablation monitored by medical device in real-time. The fusion device will deliver great perspective between the ablation areas and critical anatomical landmarks such as: NVB, membranous urethra, etc. Patient is dismissed to the recovery room and discharged afterwards
45647006|NCT03065231|Device|Extraventricular Drain|As mentioned above, intervention will take place to promote subarachnoid blood diversion from cerebrospinal fluid after ruptured intracranial aneurysm.
45647007|NCT03065231|Device|Lumbar Drain|
45449602|NCT01310283|Other|xylitol mints and fluoride varnish|Subjects in the intervention group will receive additional diet, oral hygiene handouts, more frequent professional fluoride application, and xylitol mints based on their caries risk levels.
45647008|NCT01700569|Drug|Temozolomide|All the Patients are treated by oral Temozolomide 75 mg/m²/day every day during 42 days, 30 minutes after Folinic acid and 120 min before the radiation dose to the brain tumor. After one month rest, the maintenance phase consists of:Temozolomide is given orally (30 min after Folinic acid), at 200 mg/m²/day every day during 5 days: one course every month during 6 months (6 maintenance course).
45647009|NCT01700569|Drug|folinic acid at pharmacological dose is the escalated drug|
45449603|NCT02161822|Drug|simvastatin|simvastatin 80mg qd for 5weeks
45449604|NCT02163382|Device|Neurovent Monitor XIII|Nasogastric tiube installation to monitor EAdi
45449605|NCT02163382|Device|Neurovent Monitor XIII|RIP jacket installation
45449606|NCT02163382|Device|Neurovent Monitor XIII|Ventilator change (if a different ventilator was used prior to the study).
45449607|NCT02163382|Device|Neurovent Monitor XIII|Determination of NAVA parametersVentilator
45449608|NCT02163382|Device|Neurovent Monitor XIII|Second period with conventional NIV settings
45449609|NCT03549117|Device|Breathe Right Tan (small/medium) nasal strips|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (Breathe Right Tan), small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
45647010|NCT01700569|Radiation|High voltage radiation therapy (linear accelerator)|Brain tumor field is irradiated Five days a week, during Stupp regimen during 6 weeks. During the sams time, Folinic acid and Temozolomide are given orally every days (six weeks).
45647011|NCT04443023|Device|chosen TAVI valve|chosen TAVI valve
45790834|NCT02885025|Dietary Supplement|broccoli sprout extract placebo|a tablet similar to the actual broccoli sprout extract though without BSE.
45449610|NCT03549117|Other|Placebo nasal strip|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips, small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
45790835|NCT02885025|Drug|normal saline nasal spray|normal saline to replace nasal fluticasone in specific arms of the study
45790836|NCT01580618|Drug|normal saline|Injection of 60 ml normal saline twice a day for three days using the existing chest tube.
45790837|NCT01580618|Drug|TNK (Tenecteplase)|Injection of 4 mg of TNK with 59 ml normal saline into the existing chest tube twice a day for three days.
45449611|NCT03183908|Biological|FLUAD®|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
45449612|NCT03183908|Biological|Fluzone® High-Dose|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
45647012|NCT05095675|Behavioral|psychological questionnaires|Participants have to fulfill psychological questionnaires in different time points during medical oncological treatment
45790838|NCT03612687|Device|Minimally invasive hemodynamic monitoring|Use of advanced minimally invasive hemodynamic monitoring with PreSep™ Central Venous Oximetry Catheter, Vigileo™ monitor, and FloTrac™ sensor for perioperative fluid management
45920287|NCT00423865|Other|laboratory biomarker analysis|Laboratory data (complete blood count, comprehensive metabolic panel including magnesium) regarding adverse events will be collected on each cisplatin treatment day. Additional adverse event data will be collected at regularly scheduled clinic visits at which history and physical are performed by the investigator (Cycle 1 - Days 1, 8, 15, and 21. Cycle 2 - Days 1 and 15. Cycle 3 and beyond - Day 1)
45790839|NCT01581008|Other|Collaborative Care to Alleviate Symptoms and Adjust to Illness|A palliative symptom management and psychosocial care intervention named Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (b) a 6-session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (c) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.
45790840|NCT01581008|Behavioral|Psychospiritual|A psychospiritual intervention that is home-based, self-guided, and requires minimal resources. It will be delivered in written modular form via US Mail along with brief weekly telephone support.
45790841|NCT01581710|Drug|Montelukast to placebo|Subjects will receive montelukast (4 mg or 5 mg) Each treatment period consists of 2 weeks
45790842|NCT01581710|Drug|Placebo to montelukast|Subjects will receive matching placebo. Each treatment period consists of 2 weeks
45790843|NCT01582490|Drug|Instillation - EXPAREL|Intravenous (IV) morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.
45790844|NCT01582490|Drug|Infiltration - EXPAREL|IV morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.
45790845|NCT01582880|Drug|Riboflavin|Used to treat donor cornea before implantation
45790846|NCT02889393|Drug|Teduglutide|Daily 0.05 mg/kg Teduglutide administered subcutaneously.
45790847|NCT02889393|Other|Standard of Care|The standard of care treatment of ECF which includes meticulous wound care, optimizations of nutrition, use of acid-suppression medications and anti-motility agents as per treating physician discretion.
45790848|NCT02818569|Drug|Dexmedetomidine|Oral form
45790849|NCT02818569|Other|Saline Placebo|Saline Placebo
45647013|NCT04442867|Other|Case management|Based on the clients' problems, individualized and specific health education such as recognition of the early signs and symptoms of an exacerbation or deterioration of disease condition, the frequency, dosage, duration of each health-promoting activity that was of therapeutic value, and the techniques required to perform these activities will be provided by the Nurse Case Manager.
45647014|NCT04442867|Other|Social call|Provide social call to participants, such as ask the participants what TV program do you like most, and how are you recently.
45790850|NCT02819973|Other|Educational Video1|
45790851|NCT02819973|Other|Educational Video 2|
45790852|NCT02819973|Other|Usual Care 3|
45790853|NCT03581409|Drug|Aspirin|Aspirin protect tablet
45790854|NCT03581409|Drug|Prasugrel|Prasugrel tablet
45790855|NCT03581409|Drug|Clopidogrel|Clopidogrel 75mg tablet
45790856|NCT03581409|Drug|Cilostazol|Cilostazol tablet
45790857|NCT03566667|Drug|Metoprolol|Betablocker
45790858|NCT03566667|Drug|Standard care|Standard care
45790859|NCT01533116|Drug|BIA 9-1067|
45790860|NCT01533116|Drug|Placebo|
45790861|NCT01533116|Drug|levodopa/carbidopa|
45790862|NCT01533116|Drug|levodopa/benserazide|
45790863|NCT02821455|Procedure|Lung Surgery with One-Lung Ventilation|A single cohort of patients undergoing one-lung ventilation during lung surgery
45790864|NCT03510741|Drug|Sodium Benzoate|Sodium Benzoate will be administered at 1000mg daily
45920288|NCT00423865|Other|pharmacological study|For patients in Part A, research bloods for pharmacokinetics are drawn on Day 1 and Day 8.
46071518|NCT03855709|Diagnostic Test|microbiological culture and sensetivity|microbioloical culture will be used to detect microbiological profile in hepatic patients with infections, drug sensitivity to detect resistent bacteria which will be confirmed using PCR detection of resistent gene
45647015|NCT05090761|Drug|Bupivacaine 0.25% Injectable Solution|Injection of Bupivacaine 0.25% Injectable Solution for SAPB
45790865|NCT03510741|Drug|N-Acetylcysteine|N-Acetylcysteine 1000 mgs twice daily dose
45790866|NCT03510741|Drug|Placebo|Placebo added to TAU
45790867|NCT03510741|Drug|Sodium Benzoate Plus N-Acetylcysteine|Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose
45790868|NCT01533974|Other|Acceptance & Commitment Therapy (ACT)|We will use a five-session (90 minutes per session) group-delivered adaptation of Dr. Bricker's ACT treatment program.
45790869|NCT01533974|Other|Cognitive Behavioral Therapy (CBT)|The control condition will be the current group-delivered CBT smoking cessation program at GH.
45790870|NCT03500835|Behavioral|App|"6 month app intervention: Problem Food Withdrawal, Snacking Elimination and Food Amount Reduction~Daily Weigh In~App based reminders~Follow Up: Face-to-face clinic visits at 3,6,12 and 18 months."
45790871|NCT03500835|Behavioral|Coaching|"6 month addiction based intervention: Problem Food Withdrawal, Snacking Elimination and Food Amount Reduction.~Daily Weighing~Daily Text messages from Coach~Weekly 15 minute phone meetings with Coach~Follow Up: Face-to-face clinic visits at 3,6,12 and 18 months post consent"
45790872|NCT03500835|Behavioral|Clinic: Modified KidsNFitness|"6 month in-clinic, evidence-based, multi-disciplinary intervention~90 minute sessions, in clinic that occur every month for 6 months~Follow Up: Face-to-face clinic visits Monthly x 6 months followed by face-to-face visit at12 and 18 months."
45790873|NCT05556980|Procedure|totally laparoscopic distal gastrectomy|all the surgical procedure would be finished under laparoscopy
45790874|NCT05556044|Drug|Empagliflozin 10 MG|This is an investigator-initiated, prospective, single-centre, non-randomized open label study that evaluates the efficacy and safety of initiating empagliflozin during index hospitalization for acute heart failure regardless of LVEF.
45790875|NCT03314337|Device|Pancreatic stent: PSOF COOK®|After removing the distal pancreas, PSOF COOK will be place in the main pancreatic duct
45790876|NCT04333719|Other|Type of sedations|Estimate the prevalence of deep sedations (i.e. with a -4 or -5 score at the Richmond scale at the induction time) for patients in terminal phase and receiving cares from a specialized palliative care facility
45790877|NCT02899689|Device|Dilapan|Using a sterile speculum, the cervix is visualized and cleaned with iodine. Under direct visualization, synthetic osmotic dilators (Dilapan-S) are inserted into the cervical canal with special attention to cross through the internal os.
45790878|NCT02899689|Device|Foley Catheter|Using a sterile speculum, the cervix is visualized and cleaned with iodine. Under direct visualization, a Foley catheter is inserted into the cervix and the balloon is filled with 60 ml of sterile 0.9% NaCl.
45790879|NCT03237897|Behavioral|Preoperative education class|The preoperative enhanced recovery after surgery education class will be offered twice a week in coordination with anesthesia preoperative appointments to minimize inconvenience for patients. Patients will need to attend only one class. All participants will be offered the class. This class will be one hour in duration and will be taught by a surgical advanced care practitioner familiar with the details of colorectal surgery. The class will include detailed information about preoperative care, intraoperative care, and postoperative care.
45790880|NCT03237897|Behavioral|Pedometer|A pedometer will be affixed to patients in the immediate postoperative period and removed at time of discharge
45790881|NCT01534052|Drug|Enzalutamide|Oral
45790882|NCT03207945|Drug|Alirocumab|Alirocumab (Sar236553/REG 727) is a fully humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), and is developed by Regeneron Pharmaceuticals/Sanofi.
45790883|NCT03207945|Other|Placebo|Placebo
45647016|NCT05090761|Drug|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg|Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate as adjuvant
45790884|NCT01584518|Drug|Furosemide|Based on clinical standard per clinician
45790885|NCT05541770|Other|Survey|Healthcare workers/Physicians involved in cancer diagnosis & management in the Arab countries should respond to a survey
45790886|NCT03138369|Device|Vestibular nerve stimulator|Battery powered headset that can be recharged when not being used.
45790887|NCT03138369|Device|Sham vestibular stimulation|Identical in external appearance to the vestibular nerve stimulation device, this device is also powered by a battery and needs to be periodically recharge when not being used. However it discharges into an internal resistor and does not stimulate the vestibular nerve.
45449613|NCT03724851|Drug|TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) at the same time in the morning and evening (BID) approximately 12 hours apart.Pembrolizumab will be administered as a dose of 200 mg every 3weeks.
45790888|NCT01534910|Drug|aged garlic extract|2400 mg a day
45449614|NCT03724773|Device|Long-Arm Cast|A long-arm cast is a circumferential wrapping of the arm from the fingers to above the elbow with casting material.
45647017|NCT05090761|Drug|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg|Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate and 300mcg Buprenorphine as adjuvants
45647018|NCT05084443|Dietary Supplement|Drink|Roselle and placebo drink for 6 months
45647019|NCT03064529|Device|Accelerometer|All participants receive a wrist worn accelerometer to measure physical activity continuously before and after surgery
45790889|NCT01534910|Drug|placebo|placebo
45920289|NCT00423865|Procedure|biopsy|"Pre-treatment Research Biopsy: Within 14 days prior to treatment, research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be performed. Baseline labs should be drawn within 14 days of the research biopsy. The biopsy sample will be formalin-fixed and paraffin-embedded for immunohistochemistry. Post-treatment Research Biopsy: Research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be requested again for Day 15 of Cycle 1, prior to administration of RAD001 and cisplatin on that day."
45920290|NCT00423904|Behavioral|Brief intervention|
45920291|NCT00423982|Drug|Rifampin-combination therapy|Rifampin 300 mg x 3 po and cloxacillin 2 g x 4 iv for two weeks. Then rifampin 300 mg x 3 po and cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, rifampin 300 mg x 3 po and vancomycin 1 g x 2 iv for 6 weeks.
45920292|NCT00423982|Drug|Monotherapy|Cloxacillin 2 g x 4 iv for two weeks, then cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, vancomycin 1 g x 2 iv for 6 weeks.
45449615|NCT03724773|Device|Sugar-Tong Splint|A sugar-tong splint is the application of hard splinting material on the front and back of the arm.
45647020|NCT05082649|Other|Face to Face Exercise|Face to face (in clinic) progressive spinal stabilization exercises.
45647021|NCT05082649|Other|Telerehabilitation|Remotely (with video) progressive spinal stabilization exercises.
45790890|NCT03101007|Device|ATTUNE Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with cementless ATTUNE rotating platform Knee Prosthesis by DePuy
45790891|NCT03101007|Device|LCS Knee Prosthesis by DePuy|Total Knee Replacement Surgery with cementless LCS rotating platform Knee Prosthesis by DePuy
45790892|NCT03007706|Procedure|Women undergo cesarean section delivery|
45790893|NCT02901249|Drug|sertraline|
45790894|NCT02901249|Drug|Nortriptyline|
45790895|NCT02901249|Drug|Lithium|
45790896|NCT02212028|Drug|prasugrel|the effects of whole tablets versus crushed tablets will be compared
45790897|NCT03007784|Device|transcranial direct current stimulation (tDCS) / Comparison of current intensities|
45920293|NCT00390117|Drug|CDKI AT7519|AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
45790898|NCT03091413|Diagnostic Test|diaphragm ultrasound|"For each patient intubated and ventilated in our ICU we will performed diaphragm ultrasound during the weaning process.~We will performed the measurement of diaphragmatic maximum excursion during a maximal inspiration using an abdominal standard preset with M-mode, with the so called anatomical M-mode.~We will put the probe in the right subcostal window to use the hepatic window to assess the movement of the diaphragm. We will performed the measure of the diaphragm excursion with patient in semi-recumbent position and through a transhepatic transverse oblique scan while the patient is on mechanical ventilation and undergo a Pimax maneuver, that consists in a temporary occlusion of the airway with an expiratory pause.~We will performed the measure three times, and we will take into account the best one made by the patient."
45790899|NCT00373815|Drug|Everolimus|
45790900|NCT02901951|Biological|Engerix-B|Intramuscular administration of single challenge dose of Engerix-B vaccine in the deltoid region of the non-dominant arm.
45647022|NCT05608109|Behavioral|Alcohol personalized normative feedback (APNF)|Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's drinking compared to other same-university students will include: (a) drinking days per week, (b) average drinks per occasion, (c) drinks per week, and (d) drinking percentile rank.
45790901|NCT01586312|Other|Allogenic mesenchymal stromal cells injection|Mesenchymal stem cells prepared from bone marrow of healthy donors and expanded for 3-4 weeks according to our procedure described in PEI Num. 10-134, authorized by the Spanish Medicine Agency
45647023|NCT05608109|Behavioral|Social media personalized normative feedback (SMPNF)|Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's alcohol related content posts on social media and drinking compared to other same-university students will include: (a) alcohol related posting days per week, (b) average alcohol related posting per week, (c) posting percentile rank, (d) drinking days per week, (e) average drinks per week, and (f) drinking percentile rank.
45790902|NCT01586312|Drug|Hyaluronic Acid|Intra-articular injection of 60 mg of hyaluronic acid (Durolane) in a single injection (3 ml)
45790903|NCT00373893|Drug|Lidoderm Patch|
45790904|NCT02977299|Drug|Aripiprazole|Oral adjunctive therapy with aripiprazole, dose adjusted for effectiveness and tolerability.
45790905|NCT02977299|Device|Repetitive transcranial magnetic stimulation (rTMS)|Adjunctive therapy with transcranial magnetic stimulation, dose adjusted for effectiveness and tolerability.
45790906|NCT02977299|Drug|Venlafaxine XR|Oral switch therapy with venlafaxine, dose adjusted for effectiveness and tolerability.
45790907|NCT02212106|Biological|bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)|Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
45790908|NCT02212106|Biological|Comparator Quadrivalent Influenza Virus Vaccine|Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
45790909|NCT02903121|Drug|Tamoxifen|Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
45790910|NCT02903121|Drug|Placebo|Placebo orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
45790911|NCT02903121|Drug|Tamoxifen (open label)|Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the second 90 days of the study
45790912|NCT02975895|Device|Hydrophobic IOL: Vivinex (HOYA)|Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
45790913|NCT02975895|Device|Hydrophilic IOL: INCISE (Bausch+Lomb)|Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
45790914|NCT02869425|Drug|arbaclofen ER Tablets|arbaclofen ER tablets, 10 mg, 15 mg, or 20 mg
45790915|NCT02869425|Drug|Placebo for arbaclofen ER tablets|matching placebo tablets to arbaclofen ER tablets 10 mg, 15 mg or 20 mg
45790916|NCT02638701|Drug|Infliximab|Please see protocol for details.
45790917|NCT02904057|Device|Radiesse (+) Injectable Implant|Treated subjects will receive a maximum volume of 3.0 cc of Radiesse (+) per jawline.
45790918|NCT02904915|Drug|Lidocaine|Intrauterine device (IUD) placement with paracervical block with 1% lidocaine.
45790919|NCT02904915|Other|No analgesia|IUD placement without analgesia.
45790920|NCT02904915|Device|Intrauterine device (IUD)|IUD placement with or without paracervical block with 1% lidocaine.
45790921|NCT04737291|Device|drug coated balloon|use of drug coated balloon in treatment of critical limb ischemia
45790922|NCT00373191|Drug|chemotherapy|N/A- not dictated by study
45790923|NCT00373191|Drug|endocrine therapy|N/A- not dictated by study
45790924|NCT00373191|Genetic|DNA methylation analysis|laboratory analysis
45790925|NCT00373191|Genetic|protein analysis|laboratory analysis
45790926|NCT00373191|Other|laboratory biomarker analysis|laboratory analysis
45790927|NCT00373191|Other|questionnaire administration|questionnaire
45790928|NCT00373191|Procedure|adjuvant therapy|N/A- not dictated by study
45790929|NCT00373191|Procedure|conventional surgery|N/A- not dictated by study
45790930|NCT00373191|Radiation|radiation therapy|N/A- not dictated by study
45790931|NCT02907489|Other|triple antibiotic paste with an anti-inflammatory drug|Mixture of ciprofloxacin, metronidazole and minocycline.and diclofenac potassium 50 mg (Catafast)
45790932|NCT01535924|Drug|gemcitabine hydrochloride|Given IV
45790933|NCT01535924|Drug|bendamustine hydrochloride|Given IV
45790934|NCT02909439|Drug|Sugammadex|Sugammadex will be given for reversal of neuromuscular blockade.
45790935|NCT02909439|Drug|Neostigmine|Neostigmine will be given for reversal of neuromuscular blockade.
45790936|NCT02193009|Behavioral|SipSmarter|6-month behavioral trial
45790937|NCT02193009|Behavioral|MoveMore|6 month behavioral trial
45790938|NCT01587950|Drug|Potassium Nitrate|250 μL of Potassium nitrate solution (either 5% or 2.5%)
45790939|NCT01587950|Drug|Placebo|Sterile Water
46071519|NCT04698122|Other|Biological sample collection|Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
45920294|NCT00390117|Other|laboratory biomarker analysis|Pharmacokinetic bioanalysis of the AT7519 plasma concentration data will be performed by BioDynamics Northhampton, U.K. The pharmacokinetic parameters for AT7519 will be determined by Astex Therapeutics as data permits.
45790940|NCT02833857|Drug|Etelcalcetide|A single IV-bolus dose of 0.035 mg/kg etelcalcetide into the venous line of the dialysis circuit at the end of a hemodialysis session.
45790941|NCT01536938|Drug|LEO 90100|
45790942|NCT01536938|Drug|Calcipotriol|
45920295|NCT02965261|Drug|Torrent's Fluoxetine Tablets|
45920296|NCT02965261|Drug|Warner Chilcott LLC Sarafem Tablets|
45920297|NCT00089323|Procedure|Bone Marrow Aspiration|
45920298|NCT00006161|Procedure|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|
45920299|NCT00006161|Procedure|Distal Splenorenal Shunt|
45920300|NCT00089362|Drug|alvespimycin hydrochloride|Given IV
45920301|NCT00089362|Other|laboratory biomarker analysis|Correlative studies
45790943|NCT01536938|Drug|Betamethasone|
45790944|NCT01588418|Drug|Exenatide|Exenatide (5mcg) was administered in random order 30 min before OGTT-PET study, crossover study
45790945|NCT01588418|Drug|Placebo|Placebo was administered in random order 30 min before OGTT-PET study in the same subject
45790946|NCT03007550|Procedure|Laparoscopic total gastrectomy|LTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma
45449616|NCT03731325|Behavioral|Episodic Future Thinking Group|"Participants in the Episodic Future Thinking (EFT) Group will train with EFT throughout the entire study. As part of the training, research staff will help participants create cues. Cues are descriptions of future events the participant can vividly imagine as happening right now.~Participants will be instructed to think about the EFT cues they created to help them focus on the future and importance of reaching their weight-loss goals. Participants will be instructed to use their EFT cues at least once per day, but will be encouraged to use their cues with every eating and physical activity decision."
45647024|NCT05607095|Biological|Lifileucel (LN-144)|Lifileucel (LN-144) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process. Lifileucel is infused as part of a treatment regimen that includes preparative NMA-LD, followed by one-time autologous TIL infusion, and a short course of high-dose IL-2.
45790947|NCT03007550|Procedure|Open total gastrectomy|OTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma
45647025|NCT04139057|Drug|EBV-specific TCR-T cell with anti-PD1 auto-secreted element|Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with anti-PD1 auto-secreted element
45920302|NCT00089362|Other|pharmacological study|Correlative studies
45920303|NCT00390156|Biological|bevacizumab|5 mg/kg
45920304|NCT00390156|Drug|cyclophosphamide|Current dose 50 mg
45920305|NCT00390156|Drug|imatinib|Current dose 400 mg
45920306|NCT00089401|Drug|isolated perfusion|
45647026|NCT04127903|Other|the Length of Right Main Stem Bronchus|The distance between the carina and the proximal margin of the right upper lobe orifice on the coronal plane measured by computerised tomography
45647027|NCT03065309|Drug|Remifentanil|bolus dose
45647028|NCT02819479|Drug|25% Mannitol|"Route of administration:~In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery."
45920307|NCT00089401|Drug|melphalan|
45920308|NCT00089401|Procedure|conventional surgery|
45920309|NCT02958397|Biological|Anti-CD33-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD33-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
45920310|NCT00089440|Drug|Aripiprazole|
45920311|NCT00089518|Drug|Valsartan|
45647029|NCT02819479|Drug|Low-dose Intra-arterial Bevacizumab|"Route of administration:~In this study, the second step of the treatment will be administering intra-arterial targeted bevacizumab into the appropriate cervical artery."
45790948|NCT01657383|Procedure|HPB Surgery|Hepatopancreatico Biliary Surgery
45790949|NCT03001856|Procedure|Oblique Intradermal Suture|
45790950|NCT03001856|Procedure|Intradermal Suture|
45790951|NCT02911857|Biological|Canakinumab (AIN457)|Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution
45790952|NCT03007316|Procedure|VIP graft|surgical soft tissue grafting concomitant to implant placement
45920312|NCT00089557|Drug|Capsaicin Dermal Patch|
45790953|NCT03007160|Drug|Potassium Citrate Extended-release Tablets|Daily 3.24g, Po ,Tid, each 1.08g/tablets
45790954|NCT03004911|Device|ProFibro (Mobile application)|ProFibro, a mobile Android application in Brazilian Portuguese to promote self-care in patients with fibromyalgia
45920313|NCT00087451|Drug|AP23573|ridaforolimus
45920314|NCT00089596|Procedure|Expansion of umbilical cord stem cells|
45920315|NCT00089713|Drug|alagebrium chloride (ALT-711)|
45920316|NCT00089830|Drug|MSI-1256F (Squalamine Lactate)|
45920317|NCT00089869|Drug|olanzapine|
45920318|NCT00089869|Drug|atomoxetine|
45920319|NCT00089869|Drug|placebo|
45920320|NCT00089908|Biological|rDEN1delta30|Live attenuated rDEN1delta30 vaccine
45920321|NCT00089908|Biological|Placebo|Placebo for rDEN1delta30
45920322|NCT04656990|Behavioral|Integrated Intervention|Gross motor and social-emotional integrated intervention
45920323|NCT00006167|Drug|oxandrolone|
45920324|NCT00006167|Behavioral|Progressive Resistance Training|
45920325|NCT00089947|Drug|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|
45920326|NCT00090025|Drug|becatecarin|Dose: 140 mg/m2 x day Mode of administration: i.v. via central venous catheter Duration of treatment: Days 1 through 5 of a 28 day cycle
45920327|NCT00090025|Drug|5-Fluorouracil Plus Leucovorin|5-Fluorouracil (5-FU) + Leucovorin (LV) Dose: 375 mg /m2/day + 25 mg/m2/day Mode of administration: i.v. via central venous catheter or alternative i.v. administration.Duration of treatment: Days 1 through 5 of a 28 day cycle
45790955|NCT03004911|Device|Paper booklet|A 64-page booklet with content similar to the mobile application
45790956|NCT03007004|Drug|Botulinum toxin type B (2500 units / vial)|BTX-B (E2014, Eisai, NerBloc®) was injected subcutaneously from the palmar side into seven locations around interphalangeal metacarpophalangeal joints, targeting the neurovascular bundles just proximal to the A1 pulley (the radial and ulnar sides of the first finger, the radial side of second finger, the ulnar side of the fifth finger and between the second to fifth fingers). Three locations between the second and third fingers, the third and fourth fingers, and the fourth and fifth fingers were injected with 400 U (0.2 ml) of BTX-B. In addition, the radial and ulnar sides of the first finger, the radial side of the second finger, and the ulnar side of the fifth finger were injected with half a dose of BTX-B (200 units; 0.1 ml). A total of 2000 U (1.0 ml) of BTX-B was injected into one hand. Injections were performed using a 30-gauge needle.
45647030|NCT05095285|Other|Swaddling|"Babies in this group were wrapped with a white cheesecloth 2 minutes before ES in addition to incubator cover and nesting.~Common procedure steps:~Legal representatives of the infants will sign an informed consent form.~İncubator cover and nesting~Endotracheal suction(ES) was performed in the supine position.~ES was done at the time of care the baby needed.~No painful procedure was applied until 2 hours before ES and 15 minutes after ES.~Aspiration was performed sterile at 80 mmHg pressure.~A second nurse assisted in the suction process and the procedure took no more than 15 seconds.~The amount of oxygen taken by the baby was increased by 10% 30 seconds before the suction procedure and returned to its original value 60 seconds after the procedure.~Beginning 3 minutes before the ES procedure, during the procedure and until 15 minutes after the procedure, the infants' behaviors and bedside monitor indicators were video recorded."
45790957|NCT03007004|Drug|Physiological saline|Saline solution was injected subcutaneously from the palmar side into seven locations around interphalangeal metacarpophalangeal joints, targeting the neurovascular bundles just proximal to the A1 pulley (the radial and ulnar sides of the first finger, the radial side of second finger, the ulnar side of the fifth finger and between the second to fifth fingers). Three locations between the second and third fingers, the third and fourth fingers, and the fourth and fifth fingers were injected with saline (0.2 ml). In addition, the radial and ulnar sides of the first finger, the radial side of the second finger, and the ulnar side of the fifth finger were injected with half a dose of saline (0.1 ml). A total of 1.0 ml of saline was injected into one hand. Injections were performed using a 30-gauge needle.
45790958|NCT03007082|Device|Revive SE intracranial thrombectomy device|"Intra-arterial mechanical thrombectomy with Revive SE；~According to patient condition, the investigator could determine intravenous thrombolysis or not at his/her discretion"
45790959|NCT02914119|Drug|Rocuronium|
45790960|NCT02914119|Drug|Succinylcholine|
45790961|NCT02914119|Drug|Cisatracurium|
45790962|NCT02914119|Drug|Mivacurium|
45790963|NCT02914119|Device|Objective neuromuscular monitoring (acceleromyography)|
45647031|NCT05095285|Other|Oropharyngeal colostrum|"Common procedure steps~In addition to incubator cover and nesting, babies in this group were given 0.4 ml of colostrum with an insulin injector on the inside of the cheeks and on the tongue."
45647032|NCT04081025|Other|EpiWux|A cross-sectional and longitudinal study including a questionnaire and a clinical examination
45790964|NCT02914119|Drug|Sugammadex|
45647033|NCT05376943|Drug|Direct Acting Antivirals|Our observational study will assess the exposure to direct acting antivirals - the specific drugs, dose, duration of the therapy and the effect of the treatment.
45647034|NCT04074785|Drug|Abemaciclib|Abemaciclib 150 mg po bid
45790965|NCT02914119|Drug|Neostigmine|
45790966|NCT01589510|Drug|bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.01% ophthalmic solution (Lumigan® 0.01%) as prescribed by physician per standard practice for up to 14 weeks.
45790967|NCT02914509|Drug|Travoprost|
45790968|NCT02914509|Other|Placebo Vehicle|
45790969|NCT02837913|Device|VitaHeat underbody heating mattress|Use of VitaHeat underbody heating mattress will be used for the intervention arm to reduce hypothermia post operatively
45790970|NCT02840097|Drug|Tranexamic Acid|Active drug is provided to participants as described based on the TXA arm they are randomized to.
45790971|NCT02840097|Drug|Placebo|Normal saline is provided to participants if randomized to this treatment arm.
45790972|NCT02841033|Drug|daratumumab|Daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month until progression or inability to tolerate.
45790973|NCT02841189|Device|King Vision video Laryngoscope|The King Vision video laryngoscope (Ambu) will be used for tracheal intubation.
45790974|NCT02738489|Biological|SHR-1210|A fully human monoclonal immunoglobulin (IgG4 subtype)
45647035|NCT04074785|Drug|Bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
45647036|NCT04533841|Drug|Misoprostol|Pt will receive misoprostol for labor induction then after 30 minutes will receive ether propranolol or misoprostol
45647037|NCT04533841|Drug|Placebo|placebo
45647038|NCT04533841|Drug|Propranolol|Propranolol
45790975|NCT02988089|Drug|Clarithromycin susceptibility dependant strategy|"Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. Antimicrobial susceptibility testing (AST) will be used to test the susceptibility of clarithromycin.~If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen."
45920328|NCT00090337|Procedure|acupuncture therapy|Patients undergo acupuncture for 20-30 minutes once weekly for 4 weeks
45920329|NCT00090337|Procedure|standard follow-up care|Patients undergo standard care
45647039|NCT04537663|Drug|Bacille Calmette-Guérin (BCG)|Participants in the intervention group will be vaccinated with the licensed BCG vaccine (Danish strain 1331, SSI, Denmark) using the standard vaccination technique for this vaccine (intradermal injection in the left upper arm).
45647040|NCT04537663|Drug|Placebo|Intradermal injection of sterile 0.9% NaCl.
45647041|NCT04536805|Drug|Metformin|Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)
45647042|NCT04536805|Radiation|Stereotactic Body Radiation Therapy (SBRT) 30 Gray (Gy)|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 6 Gy day 0 to day 10
45647043|NCT04536805|Radiation|Stereotactic Body Radiation Therapy (SBRT) 36 Gy|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 6 x 6 Gy day 0 to day 12
45790976|NCT02988089|Drug|2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline )|Patients in this group will receive a a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, Colloidal Bismuth Pectin and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
45790977|NCT02988089|Drug|proton pump inhibitor (PPI) and Colloidal Bismuth Pectin|all patients need these two drugs.
45790978|NCT02988089|Drug|amoxicillin and clarithromycin or amoxicillin and furazolidone|patients in the 6 antibiotics dependant group will use these intervention.
45790979|NCT02988089|Drug|amoxicillin and furazolidone or amoxicillin and tetracycline|salvage therapy for negative culture when the results of culture are negative
45790980|NCT02988089|Drug|amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin|salvage therapy for failed eradication if failed with AST guided eradication therapy
45790981|NCT02430233|Drug|micronized progesterone 400 mg (Utrogestan)|participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
45790982|NCT00551369|Radiation|SBRT|SBRT delivered in 3 fractions of 20 Gy/fraction over 1.5 to 2 weeks for a total of 60 Gy
45647044|NCT04536805|Radiation|Stereotactic Body Radiation Therapy (SBRT) 25 Gy|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5x 5 Gy day 0 to day 10
45647045|NCT05376865|Dietary Supplement|Vitamin D supplement|The intervention group receives 50000 IU of vitamin D every week as vitamin D supplements for 12 weeks, provided monthly.
45647046|NCT05058157|Dietary Supplement|different ketogenic formulae|The research product may be in a form of powder to reconstitute or in a ready-to-drink format.
45647047|NCT04064411|Combination Product|abaloparatide|Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.
45647048|NCT04064411|Combination Product|abaloparatide solid microstructured transdermal system|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide coated onto a sMTS array for transdermal administration of abaloparatide.
45647049|NCT02004691|Drug|placebo (saline)|"Pharmaceutical form: solution administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to placebo.~Route of administration: intravenous infusion"
45647050|NCT02004691|Drug|GZ402665|"Pharmaceutical form: Powder for concentrate for solution for infusion administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to olipudase alfa, and during the extension treatment period for all participants.~Route of administration: intravenous infusion"
45647051|NCT04058795|Behavioral|Cancer Distress Coach (CaDC) App|an app that provides participants with tools to manage their stress in the moment they experience it.
45790983|NCT01589978|Device|PROMUS Element Plus Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent) and a drug product (a formulation of everolimus contained in a polymer coating).
45790984|NCT01589978|Drug|Aspirin|Aspirin should be taken daily (81 mg) for 3 days prior to the procedure or as a peri-procedural loading dose of 250-500 mg. A maintenance dose of aspirin of at least 81 mg daily, or as indicated by the treating physician, should be continued indefinitely.
45790985|NCT01589978|Drug|P2Y12 antagonist|"Patients to take one of the following P2Y12 antagonists; maintenance doses to be continued per ACC/AHA/SCAI guidelines for PCI.~Clopidogrel: Per treating physician, peri-procedural loading dose (300-600 mg), subsequent maintenance dose (75 mg daily)~Prasugrel: Per treating physician, peri-procedural loading dose (60 mg), subsequent maintenance dose (10 or 5 mg daily per product labeling)~Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses >100 mg may reduce ticagrelor effectiveness and should be avoided.~Ticlopidine: Per treating physician, if allergy/intolerance to clopidogrel, prasugrel, and/or ticagrelor, loading dose (500 mg), subsequent maintenance dose (250 mg 2x daily)"
45790986|NCT05484011|Biological|odetiglucan|Odetiglucan is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Odetiglucan acts as a Pathogen-Associated Molecular Pattern (PAMP).
45790987|NCT05484011|Biological|CDX-1140|A fully human agonist anti-CD40 monoclonal antibody
45920330|NCT00090376|Drug|GPI 1485|
46071520|NCT04698122|Other|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
46071521|NCT04698122|Other|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
45647052|NCT04058795|Behavioral|CaDC + mCoaching|The CaDC app plus weekly clinician support which provides support in navigating the app, encouraging adherence to the use of the CaDC, and providing guidance in choosing treatment strategies.
45647053|NCT04058795|Behavioral|mCBT|8 mobile sessions with a therapist to receive cognitive behavioral therapy.
45647054|NCT05086159|Behavioral|Pain Neuroscience Education|"Weekly education sessions lasting approximately 30 minutes each, once a week for four weeks.~Session 1: the nervous system is like an alarm to protect.~Session 2: common ways the nervous system becomes sensitive.~Session 3: importance of gradual conditioning and neuroplasticity.~Session 4: common ways to decrease nervous system sensitivity."
45647055|NCT05086159|Behavioral|Exercise|"The exercise protocol for each group will be identical and modeled after the Back to Fitness program. This program will consist of a 5-10-minute cardiovascular warm-up of walking in place or riding an exercise bike. Next is a 15-minute circuit consisting of 10 different general exercises for 1-minute each. Finally, a 5-minute cool down will consist of light stretching and trunk range of motion exercises. Each exercise will be tailored as easy, medium, or hard depending on the individual patient's tolerance. This program has been shown to be equally as effective as motor control exercises for long-term outcomes in patients with non-specific LBP."
45790988|NCT05474807|Behavioral|Internet-delivered strengths use intervention|"The online strengths use intervention program, will be based on Miglianico et al.'s (2020) general framework, following the theorized five stages: (1) preparation and commitment, (2) identification, (3) integration, (4) action, and (5) evaluation.~As to increase participant engagement and motivation, gamification components will be embedded in several of these stages.~The entire intervention will be delivered online via an LMS software solution."
45790989|NCT02417285|Drug|Obinutuzumab|1000 mg administered IV on Days 2, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 though 8.
45790990|NCT02417285|Drug|CC-122|CC-122 1mg, 2mg, 3mg, 4mg or 5mg administered orally once daily on a 5/7-day schedule in each 28-day cycle. In addition, subjects will be enrolled on the CC-122 formulated capsule (F6) and evaluated for safety and tolerability in combination with GA101 (Obinituzumab) in a separate cohort. The CC-122 dose will be escalated until the MTD is established on the CC-122 formulated capsule (F6) in combination with GA101 (Obinituzumab).
45790991|NCT01592006|Drug|Peginterferon alfa-2a|Patients will be treated with pegylated interferon alfa-2a (Pegasys®) 180 mcg SQ per week for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
45790992|NCT01592006|Drug|Ribavirin|Patients will be given ribavirin 600-1200 mg PO per day for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
45790993|NCT01592006|Drug|telaprevir|Patients will be given telaprevir 750 mg tid (Incivek®) for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
45790994|NCT00551291|Drug|Mycophenolate mofetil|1 gm twice daily orally until end of study.
45790995|NCT00551291|Drug|Prednisone|10 mg/day orally until end of study.
45790996|NCT00551291|Drug|Erythropoietin Beta|Recombinant human erythropoietin beta at doses of 30,000 IU/week by the subcutaneous route for 6 weeks.
45790997|NCT01592396|Biological|Tralokinumab 300 mg|Participants aged 12 to 14 years and 15 to 17 years will receive a single dose of tralokinumab (CAT-354) 300 mg, subcutaneously on Day 1.
45790998|NCT02988323|Other|Cervicovestibular Physio (CV PT)|See description in CVPT arm
45790999|NCT02988323|Other|Low-Level Aerobic Exercise (LLAE)|See description in LLAE arm
45791000|NCT02988323|Other|Combination (LLAE and CV PT)|See description in LLAE and CVPT arm
45791001|NCT02981420|Behavioral|Safety planning|Safety Planning Intervention. This brief one-session intervention, based on cognitive behavioral principles, is designed to help individuals identify a concrete list of coping strategies and social supports that youth can utilize preceding or during a crisis to lower imminent risk of suicidal behavior. In youth who also report nonsuicidal self-injurious behavior (NSSI), the safety plan will address both suicidal and nonsuicidal behavior. The plan helps youth identify possible triggers to SI/crisis including self-monitoring of suicidal thoughts, feelings, and behaviors; advance planning to remove lethal means; determine distress tolerance/emotion regulation skills that may be helpful; identify accessible social supports to target hopelessness/sense of isolation; reinforce the commitment to seek treatment; and, how and where to access emergency care.
45791002|NCT02278289|Device|ultrasound|Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
45791003|NCT02278289|Procedure|paraffin therapy|Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
45791004|NCT03001622|Biological|IFX-1|chimeric, monoclonal antibody
45791005|NCT02981264|Drug|Transcricoid Injection|
45791006|NCT02981264|Drug|Spray as you go|
45647056|NCT05086159|Behavioral|Traditional Education|"Weekly education sessions lasting approximately 30 minutes each, once a week for four weeks.~Session 1 will include a basic overview of the anatomy of the spine.~Session 2 will discuss an overview of stress symptoms to include hypervigilance, avoidance, and re-experiencing.~Session 3 will cover common recommendations delivered in stress education: the do's and don'ts of stress management.~Session 4: review and mindfulness."
45647057|NCT05085223|Other|Daily urine collection for biochemical analysis|For every patient in ICU, a daily morning urine sample will be collected from the already collected urine via catheter.
45791007|NCT05470985|Drug|Ozanimod|Specific dose on specific days
45791008|NCT01593722|Drug|Diethylcarbamazine|single dose
45791009|NCT01593722|Drug|Ivermectin|single dose
45791010|NCT03001934|Other|No intervention|Registration of all NS patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
45791011|NCT03001544|Biological|TS23|comparison of different doses
45791012|NCT01594424|Drug|Tocilizumab|Tocilizumab 8mg/kg on Days 0, 15, 30, 45, 75, 105, 119, 135, 149, and 180
45791013|NCT01594424|Drug|Intravenous Immunoglobulin|All HS who meet criteria for desensitization will receive IVIG 10% (2.0 g/kg [maximum 140 g per dose] on days 1 and 30).
45791014|NCT01595282|Drug|Ketorolac|For subjects weighing over 50 kg, ketorolac 60 mg in 2cc administered via intramuscular injection 30-60 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ketorolac 30 mg in 1 cc administered via intramuscular injection 30-60 minutes before suction curettage procedure
45791015|NCT01595282|Drug|Ibuprofen|For subjects weighing over 50 kg, ibuprofen 800 mg tablet administered orally 60-90 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet administered orally 60-90 minutes before suction curettage procedure.
45791016|NCT01595516|Drug|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
45791017|NCT01595516|Drug|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
45791018|NCT01595516|Drug|Placebo|Gelatin capsule to be taken by mouth once per day for 12 weeks
45647058|NCT05085223|Other|Subanalysis for comparison of 24hour urine collection versus spot-check measurements|For a subgroup of 30 sedated patients, 24 hour urine collection will be collected. In addition, every 2 hours a 10ml urine sample will be collected.
45791019|NCT01595516|Other|Bradykinin|Bradykinin is infused into the brachial artery at doses of 12.5, 25.0 and 50.0 ng/100 mL of forearm tissue /min. BDK stimulates the endothelial cells to release tissue type plasminogen activator (t-PA). Blood flow in mL/100 mL tissue/min is also measured to BDK.
45791020|NCT01595516|Other|Saline|Baseline or resting forearm blood flow is measured in response to saline for 5 minutes before each drug infusion. t-PA release in response to the saline is also measured.
45791021|NCT01595516|Other|Vitamin C|The acute effects of into-arterial vitamin C on the ability of the endothelium to release t-PA was determined before and after the nebivolol and metoprolol intervention. After allowing sufficient time (~20 minutes) for FBF and plasma t-PA concentrations to return to baseline following the initial infusion of BDK, vitamin C (24 mg/min) was infused at a constant rate while the BDK dose-response curves were repeated. t-PA and FBF were measured.
45791022|NCT03006770|Biological|PLX-PAD|Local intramuscular (IM) injections of PLX-PAD in the index leg.
45791023|NCT03006770|Biological|Placebo|Local intramuscular (IM) injections of Placebo in the index leg.
45449617|NCT03731325|Behavioral|Healthy Thinking Group|"Participants in the Healthy (HT) Group will train with HT throughout the entire study. As part of the training, research staff will help participants create cues. Cues are statements about the nutrition of food and the health benefits of physical activity.~Participants will be instructed to think about the HT cues they created to help them focus on the future and importance of reaching their weight-loss goals. Participants will be instructed to use their HT cues at least once per day, but will be encouraged to use their cues with every eating and physical activity decision."
45791024|NCT03001700|Device|Serranator™ Alto PTA Serration Balloon Catheter|The Serranator™ is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
45647059|NCT03064997|Dietary Supplement|Synergy 1|a daily dose: 7 g/day of Synergy1 (oligofructose enriched inulin) consumed for 12 weeks together with a strict gluten-free diet
45791025|NCT01596842|Drug|Omega-3 fatty acid ethylester 90|Omega-3 fatty acid ethylester 90, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
45791026|NCT01596842|Other|Olive oil|Olive oil, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
45791027|NCT01596842|Other|cholecalciferol|if baseline 25-hydroxyvitamin D levels are < 15 ng/mL : 10,000IU/week, if baseline 25-hydroxyvitamin D levels are 16-30 ng/mL : 50,000IU/week, Duration : 12 weeks
45791028|NCT02217800|Drug|saline|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
45647060|NCT03064997|Dietary Supplement|Placebo|a daily dose: 7 g/day of placebo (maltodextrin) consumed for 12 weeks together with a strict gluten-free diet
45791029|NCT02217800|Drug|DG3173|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
45791030|NCT02217800|Drug|octreotide|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
45791031|NCT02218190|Drug|Alvimopan|
45449618|NCT03565887|Drug|RVL-1201|RVL-1201 ophthalmic solution 0.1%
45647061|NCT05083663|Drug|Hyaluronidase|using hyaluronidase as an additive to bupivacaine
45791032|NCT02218190|Drug|Placebo|
45791033|NCT03006614|Drug|NVB|
45791034|NCT03006614|Drug|EPI|
45920331|NCT00090415|Behavioral|Intensive behavioral therapy|Participants will undergo a magnetic resonance imaging (MRI) scan and will complete various activities to determine brain functioning. In addition, children with autism will take part in intensive behavioral therapy at least 4 hours every day for the duration of the study.
45920332|NCT00090532|Drug|AG-013,958|
45647062|NCT05082415|Drug|Brolucizumab|Participants received brolucizumab injection during the index period
45791035|NCT03006614|Drug|DDP|
45791036|NCT03006614|Drug|CAP|
45791037|NCT03006614|Drug|GEM|
45791038|NCT03006614|Drug|H|
45791039|NCT03006614|Drug|CTX|
45920333|NCT04633902|Drug|Olaparib|Olaparib 300 mg BID daily
45920334|NCT04633902|Drug|Pembrolizumab|Pembrolizumab 200 mg IV eveyr 3 weeks (for up to 2 years)
46071522|NCT00820807|Other|Novel dietary fiber|oral consumption in beverage
45647063|NCT05050825|Other|Patient clinical management based on the CDSA strategy|The CDSA strategy is a combination of point of care tests (rapid diagnostic tests targeting malaria, dengue fever and streptococcus group a sore through) and a mHealth tool that provides patient management recommendations, including treatment, based on an algorithm integrating patient clinical signs and symptoms, history and diagnostic test results.
45647064|NCT04012931|Drug|Rilpivirine|Rilpivirine 25 mg tablets for the 25 mg daily dose, or tablets for or a weight-adjusted dose. Administered orally once daily.
45647065|NCT04012931|Drug|ARV Background Regimen|The investigator-selected ARVs, including but not limited to N(t)RTIs (example, azidothymidine [AZT], abacavir [ABC], tenofovir alafenamide [TAF], or tenofovir disoproxil fumarate [TDF] in combination with emtricitabine [FTC] or lamivudine [3TC]), whichever are approved and marketed or considered local standard of care for children aged between 2 and < 12 years in a particular country are to be administered. Integrase inhibitors (for example, dolutegravir [DTG] or raltegravir) can also be administered in combination with RPV, as appropriate.
45647066|NCT05333393|Behavioral|DİABOT (mobile application robot )|Thanks to the trainings given through the mobile application robot developed for pediatric diabetes management, it is aimed to have an effect on the quality of life, diabetes self-management and physiological parameter levels of children with Type 1 diabetes, and to easily obtain the information they need even when they cannot come to the outpatient clinic. In addition, thanks to the application robot, he will be able to create his own exercise program and determine his diet.
45647067|NCT05331287|Other|Head position|Influence of different head position on nasal endotracheal intubation
45647068|NCT03063359|Drug|Intranasal fentanyl + Oral Placebo|Administration of intranasal fentanyl (1.5µg/kg) and Oral placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
45647069|NCT03063359|Drug|Oral Morphine + Intranasal Placebo|Administration of oral morphine (0,4mg/kg) and intranasal placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
45647070|NCT05304611|Biological|L9LS (VRC-MALMAB0114-00-AB)|Administered one time via subcutaneous route.
45647071|NCT05304611|Other|Normal saline|Administered one time via subcutaneous or intravenous administration.
45647072|NCT02629133|Behavioral|SHE Program|The SHE program is specifically tailored, innovative and relevant to diverse, racial, and ethnic sheltered, battered women in a number of ways including the images and content used in the intervention. It is also tailored to participants' alcohol or substance use status, and designed to reach participants across levels of motivation for change. The content of SHE is theory-driven, consistent with the motivational interviewing model of behavior, and consistent with the literature on effective interventions that address IPV and substance use.
45647073|NCT02660359|Biological|Botulinum toxin type A|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points.
45647074|NCT02660359|Biological|Botulinum toxin type A|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
45647075|NCT02660359|Drug|Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
45647076|NCT02660359|Drug|Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
45647077|NCT03063281|Other|BIological analysis|Biological analysis : ficolin-2 et anti-ficolin-2 antibodies
45647078|NCT05287373|Device|Nalu Neurostimulation System for PNS|The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator
45647079|NCT05287373|Other|conventional medical management|Conventional medical management
45647080|NCT03982511|Behavioral|PCIT-Health|PCIT-Health (also known as Parents Active in Their Children's Health; PATCH) is an adaptation of Parent-Child Interaction Therapy. PCIT-Health targets (1) the parent-child relationship and (2) parenting efficacy both in general contexts (child play time and clean up time) and specifically in the context of obesity risk-related behaviors (child feeding, family mealtime, and child screen time).
45791040|NCT03006614|Drug|T|
45791041|NCT03001466|Drug|urea-loaded nanoparticles eye drops|one drop five times a day for 8 weeks
45920335|NCT04729153|Drug|DAAD Compound|Sofosbuvir , Daclatasvir and ribavirin
45449619|NCT03565887|Other|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
45647081|NCT04901299|Drug|NERATINIB|Neratinib will be given orally once daily on a continuous daily dosing schedule i.e., no break in dosing. Dosage per protocol
45647082|NCT04901299|Drug|FULVESTRANT|Fulvestrant will be given via injection every two weeks for the first 28-day cycle and every four weeks thereafter, dosage per protocol
45647083|NCT04820959|Biological|Biopsies|"Three endomyocardial intraoperative biopsies were performed on the left ventricle.~Resection of the left atrium in the event of atrial fibrillation."
45791042|NCT03001466|Drug|Balance Salt Solution eye drops|one drop five times a day for 8 weeks
45791043|NCT03006380|Drug|oxytocin|Ecbolic used to reduce blood loss
45791044|NCT02981030|Drug|Mifepristone|Women seeking medical abortion will be offered the option to take mifepristone at home
45791045|NCT02981030|Drug|Misoprostol|Women seeking medical abortion will be offered the option to take misoprostol at home. Misoprostol will be administered buccally.
45791046|NCT02980952|Other|High-fat overfeeding|
45791047|NCT02980952|Other|Forearm immobilization|
45791048|NCT03006692|Other|With arterial blood gas, parameters not being normal can be corrected|If arterial blood gas is analysed answers provide the possibility to make more accurate diagnosis and treat specific abnormal parameters (e.g. electrolytes, oxygenation and so forth).
45920336|NCT00090649|Drug|DVS-233 SR|
45920337|NCT00006182|Procedure|Blood Transfusion|
45920338|NCT00090688|Biological|meCS6 + LT(R192G)|
45920339|NCT00090727|Drug|AQ4N|
45920340|NCT00090961|Other|educational intervention|
45920341|NCT00090961|Other|supervised exercise program|
45920342|NCT00006185|Drug|Avandia administration for 6-12 weeks|
45920343|NCT00091039|Biological|recombinant fowlpox GM-CSF vaccine adjuvant|
45920344|NCT00091039|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
45791049|NCT03006536|Device|Li-ESWT|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
45647084|NCT04820959|Biological|Blood sampling|Pre-operative blood sampling
45647085|NCT01290055|Biological|Yellow fever vaccine|The yellow fever vaccine (YFV-17D) manufactured by Sanofi Pasteur as a one-dose vial will be purchased from the manufacturer. Vaccine will be stored at the Emory Investigational Drug Service (IDS) between 2 to 8 degrees Celsius as per the manufacturer's instructions. It will be transported to the Hope Clinic per the Standard Operating Procedures.
45647086|NCT01290055|Other|Deuterium (70% enriched 2H2O) labeled water|70% enriched 2H2O will be obtained from Cambridge Isotope Laboratories (Andover, MA) in sterile 1 Liter containers. An Emory Investigational Drug Service (IDS) pharmacist will prepare sterile 50 milliliter aliquots with a tamper seal which will be transported to the Hope Clinic at room temperature.
45647087|NCT05376397|Behavioral|THRIVE 365|THRIVE 365 is a multicomponent intervention that combines mHealth features and institutional to support community priorities identified in formative CBPR. In line with best-practices for trials of intervention principles (TIPs) of interventions with mHealth features, THRIVE 365 deploys intervention elements that serve to accomplish intervention strategies. THRIVE 365 intervention strategies are to promote: 1)Health knowledge and motivation; 2)Social support coping; 3)Access to culturally-affirming healthcare; and 4)Housing and other economic resources. THRIVE 365 pursues these strategies via these intervention elements: 1)Weekly HIV and psychological health information and motivation content and daily health notifications; 2)Online moderated forums, interpersonal chats, and community calendars; 3)Linkage to biopsychosocial healthcare via THRIVE SS's network of BSMM-affirming providers; and 4)Housing and economic resources through THRIVE SS's direct support and referral network.
45647088|NCT04955899|Device|Active Stimulation|The Galvani System will be implanted in eligible participants, and stimulation will be turned ON
45647089|NCT04626505|Drug|Ziltivekimab|Administered subcutaneously (s.c., under skin) once every 4 weeks for 12 weeks
45647090|NCT04626505|Drug|Placebo (ziltivekimab)|Administered s.c. once every 4 weeks for 12 weeks
45647091|NCT05276609|Drug|HS-20093 (Phase Ia: Dose escalation)|Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
45647092|NCT05276609|Drug|HS-20093 (Phase Ib: Dose expansion)|IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
45647093|NCT04909099|Other|Standard treatment|"Participants shall fill the EARS-Ar questionnaire three times within one month in addition to other questionnaires including the Roland Morris Disability Questionnaire (RMDQ) for low back pain (LBP) patients, and the Knee injury and Osteoarthritis Outcome Score (KOOS) for knee OA patients, in addition to the Fear-Avoidance Beliefs Questionnaire (FABQ), the Numeric Pain Rating Scale (NPRS), and the Global Rating of Change Scale (GRoC).~The first time will be one week after enrolling in the study and receiving the prescribed home exercise program. the second time will be 3-6 days later to test the reliability of the EARS-Ar. After another week, participants will refill the EARS-Ar and the GRoC to test responsiveness."
45647094|NCT05068297|Other|Incrediwear Germanium-Embedded Knee Brace following ACL reconstruction|Germanium-Embedded Knee Brace will be applied to the effected limb following ACL reconstruction
45647095|NCT05068297|Other|Replica Knee Brace|Replica Knee brace will be applied to the effected limb following ACL reconstruction
45647096|NCT05067985|Procedure|covid 19 spinal anesthesia|this group description covers that all the covid 19 pregnant women which we gave spinal anesthesia for cesarean section procedures. The investigators analyzed them retrospectively.
45647097|NCT02672761|Behavioral|MBSR meditation|"Adopted from buddhism for western societies by Jon Kabat-Zinn, MBSR has been described as a group program that focuses upon the progressive acquisition of mindful awareness, of mindfulness. The MBSR program is an eight-week workshop taught by certified trainers that entails weekly group meetings, homework, and instruction in three formal techniques: sitting mindfulness meditation, body scanning and simple yoga postures. Sitting meditation includes concentration on the breathing while not adhering to the flow of thoughts or emotions as well as the development of empathy and loving kindness for all persons. Body scanning is the first prolonged formal mindfulness technique taught during the first four weeks of the workshop, and entails quietly lying on one's back and focusing one's attention on various regions of the body, starting with the toes and moving up slowly to the top of the head."
45647098|NCT02672761|Behavioral|MBT training|"A specific memory brain training stimulates by a validated program according to Kawashima from the Industry University Research Project the according areas in the prefrontal lobe for calculation, logical reflection, optic/episodes and memory. The computerized program adopts to the difficulty level of the trainee. Selected were trainings for the categories working/semantic and episodic/optical memory and logic/calculation adjusted to the individual's selection from all categories but various themes (like sports, cars etc.)."
45653123|NCT05555641|Drug|Unfractionated Heparin|ECMO patients were given continuous anticoagulation with unfractionated heparin, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
45653124|NCT05116527|Drug|Marijuana, Hash, THC, or Grass|Marijuana flower with a high THC content
45791050|NCT05566808|Other|Autologous Costal Cartilage Graft|Subjects undergoing either reconstructive or cosmetic rhinoplasty will choose which graft will be used in their intervention.
45791051|NCT05566808|Other|Costal Cartilage Allograft.|Subjects undergoing either reconstructive or cosmetic rhinoplasty will choose which graft will be used in their intervention.
45920345|NCT00091039|Biological|recombinant vaccinia-CEA(6D)-TRICOM vaccine|
45920346|NCT00091039|Drug|carboplatin|
45920347|NCT00091039|Drug|paclitaxel|
45920348|NCT00091039|Radiation|radiation therapy|
45920349|NCT00091078|Biological|oblimersen sodium|Given IV
45920350|NCT00091078|Drug|imatinib mesylate|Given orally
45791052|NCT03001232|Behavioral|Movement-oriented Dementia Care|The intervention is a new multidisciplinary approach that focuses on optimizing physical activity and independence in daily care and activities. MDC intended to incorporate all persons surrounding the patients. The nursing staff was intensively trained by an expert in MDC, and played a central role in continuously stimulating patients to function as independently as possible. Geriatric physicians and physiotherapists advised the nursing staff about participants' medical and physical limitations to ensure safe stimulation. Consequently, a plan was created for each resident to determine the daily routines they were capable of performing themselves. Caregivers and volunteers were informed about the benefits of an active lifestyle during several open meetings.
45791053|NCT05566418|Other|mulligan mobilization|Mulligan mobilization belt will be wrapped around the subject's proximal forearm, close to the elbow joint line, and then wrapped around the therapist's shoulder. This will be done with the therapist's other hand on the distal humerus. The belt will give the subject's forearm a 10-to 15-second lateral glide.
45791054|NCT05566418|Other|myofascial release|Myofascial release will be performed on the patient, commencing at the common extensor origin and progressing all the way to the extensor retinaculum in the wrist. The periosteum will be engaged with the fingertips, with contact progressing inferiorly to the common extensor tendon and then to the wrist's extensor retinaculum
45791055|NCT05566340|Procedure|mitral valve repair|Repair of mitral valve concomitant to aortic valve replacement.
45791056|NCT03006224|Other|One Lung Ventilation|
45791057|NCT03006146|Drug|Sargramostim|Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)
45791058|NCT03005990|Other|Exercise training group|The conditioning period (24 weeks) of the exercise intervention was under the supervision of an exercise physiologist. The conditioning protocol included aerobic exercise sessions 3 times per week with 70-85% of maximal heart rate(max HR) for 30 mins and resistance sessions 3 times per week with an intensity of 80% of one-repetition maximum(1RM), 3 sets of 8 repetitions maximum. Each participant will measured the borg rating of perceived exertion scale and heart rate monitor during exercise. Exercise sessions were conducted in the afternoon (3-5 PM).
45791059|NCT03001154|Behavioral|Face-to-face Virtual Reality Exposure Therapy|In session, systematic, hierarchical exposure to feared stimuli with therapist.
45791060|NCT03001154|Behavioral|Internet-administered Virtual Reality Exposure Therapy|Therapist-guided, Internet-administered Virtual Reality Exposure Therapy self-help program
45791061|NCT03001154|Other|Waiting-list|Weekly assessments of public speaking
45791062|NCT00551213|Biological|Robatumumab|
45791063|NCT00551213|Drug|Irinotecan|
45791064|NCT00551213|Biological|Cetuximab|
45791065|NCT00551213|Drug|Capecitabine|
45449620|NCT03183518|Other|Facial micellar cleanser|Each participant will have the test product applied topically via semi occlusive patch, on-site by a technician.
45647099|NCT02672761|Behavioral|Wellness|"The Brain Light Wellness chair is assessed for the stress reduction in industry and public Enterprises. In a European study 97% of subjects reported a stress reduction, improved well-being, performance and increased vitality, less fatigue and petulance. The chair 3D-Float-plus system comprises of a massage chair in sitting to lying position, a headset with earphones a lighted glasses for visual and audio Stimulation. One standardized session of 45 min duration was chosen for the study that combined a short massage period with a relaxation trance session."
45647100|NCT02672761|Behavioral|Control|The waiting period for the MBSR training to start simply should include no changes in lifestyle, recreational activity or intellectual training
45653125|NCT05116527|Drug|Placebo|Placebo THC - marijuana flower with no THC content
45791066|NCT00551213|Drug|FOLFOX|Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ oxaliplatin (OX)
45791067|NCT00551213|Drug|CAPEOX/XELOX|Capecitabine (CAPE) or Xeloda® (XEL) + oxaliplatin (OX)
45791068|NCT00551213|Drug|FOLFIRI|Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ irinotecan (IRI)
45791069|NCT02247830|Other|Chamomilla recutita gel|Such intervention will be characterized by topical application of C. recutita gel, concomitantly to the initiation of radiotherapy, should be applied on the irradiated region three times daily throughout the period of realization of radiotherapy sessions area, and nursing consultations with equipment instructional (usual care).
45791070|NCT02247830|Drug|Urea cream|Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the irradiated region three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
45791071|NCT04769882|Device|Er:YAG Laser|"Selected Er:YAG settings: enamel removal program for adult, with normal modality (frequency: 20 Hz, energy: 400 mJ, power: 8.0 W, air: 80%, water: 60%) and dentin removal program for adult, with normal modality (frequency: 20 Hz, energy: 200 mJ, power: 4.0 W, air: 90%, water: 30%)"
45653126|NCT03067831|Biological|Stem Cells|Transplantation of purified autologous bone marrow-derived stem cells.
45653127|NCT04989647|Radiation|No adjuvant therapy|Patients will not receive any type of adjuvant therapy.
45791072|NCT03005834|Other|incidence of cancers|With a continuous surveillance system to track all subsequent incidents of CVD and/or non-CVD via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified.
45791073|NCT03005912|Device|Conventional acoustic telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
45791074|NCT03005912|Device|Conventional bluetooth telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
45791075|NCT03005912|Device|VoIP acoustic telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
45791076|NCT03005912|Device|VoIP bluetooth telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
45791077|NCT02841267|Drug|PF 06252616|
45791078|NCT03005756|Device|Needle guiding robot|This intervention is to evaluate the safety and efficacy of a needle guiding robot for assisting targeting in CT-guided radiofrequency ablation of hepatocelluar carcinomas.
45791079|NCT02213003|Biological|Islet transplantation|Transplantation of at least 5000 islet equivalents/kg of body weight onto the Omentum.
45647101|NCT04449913|Behavioral|10 days intensive meditation retreat|The intervention consists in a 10 days contemplative retreat, with 6 to 8 hours of sitting and walking meditation per day, and 1 or 2 hours of meditation teachings. The meditation practice will mainly train in mindfulness practice. Mindfulness meditation intends to train attention to detect and regulate afflictive cognitive and emotional patterns. Mindfulness practice requires skills involved in openness to experience, in monitoring the focus of attention and in detecting distraction, disengaging attention from the source of distraction, and flexibly (re)directing and engaging attention to the intended object. A brief introduction to loving-kindness and compassion meditation will also be present throughout the retreat.
45920351|NCT00091078|Other|laboratory biomarker analysis|Correlative studies
45920352|NCT00091117|Drug|bortezomib|Given IV
45920353|NCT00091117|Other|pharmacological study|Correlative studies
46071523|NCT00820807|Other|Novel dietary fiber|oral consumption in beverage
45647102|NCT04449913|Behavioral|Waiting for a 10 days intensive meditation retreat|At the time of measure, participants in this group are waiting to participate to the same meditation retreat as the active group. They may perform their own daily meditation practices as usual.
45647103|NCT05374759|Diagnostic Test|neutrophil gelatinase-associated lipocalin|When the patient is diagnosed with sepsis and on the 3rd day of the follow-up, blood samples will be taken and NGAL levels will measured.
45647104|NCT05374759|Diagnostic Test|renal resistive index|When the patient is diagnosed with sepsis and on the 3rd day of the follow-up, renal resistive index will measure and record.
45647105|NCT04262869|Drug|Carboplatin|Given IV
45791080|NCT03000920|Other|SMS before invitation|A couple of days before the invitation letter, an SMS will be sent to announce the arrival of the invitation letter to the mammogram
45791081|NCT03000920|Other|SMS Reminder 1|If it is necessary for the women to have a reminder 1, the usual mail will be replaced by an SMS.
45791082|NCT01999361|Drug|Myfortic|treatment with myfortic
45647106|NCT04262869|Biological|Durvalumab|Given IV
45647107|NCT04262869|Drug|Paclitaxel|Given IV
45647108|NCT04262869|Drug|Pemetrexed|Given IV
45647109|NCT02628743|Drug|Olesoxime|Participants will receive homogeneous suspension of olesoxime.
45791083|NCT03006471|Drug|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
45791084|NCT03006471|Drug|Placebo - Cap|one per day before breakfast during 12 weeks.
45791085|NCT05044052|Behavioral|Emphasis on the Choosing Wisely Viral Prescription Pad|We will investigate the effects of emphasizing the use of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing.
45791086|NCT02988947|Other|PNE+HyP|This is a combined PNE and Hypnosis psychological intervention. PNE is a cognitive based approach that highlights the biopsychosocial model of pain and focuses on neurophysiological and neurobiological processes and pain representation. Hypnosis aims at promoting pain control, increasing positive coping strategies, and targeting positive psychological variables.
45791087|NCT05042726|Device|cTBS First|Continuous θ-burst stimulation (cTBS) is characterized by plexus stimulation. The stimulation intensity was 80% resting motor threshold (RMT) at 50Hz of intra plexus pulse while the frequency of inter plexus pulse is 5Hz, the duration was 33.2s, and the number of stimulation pulses was 600. Two groups of stimulation were repeated in each cerebellar dentate nucleus with an interval of 5 min in each group.
45920354|NCT00091156|Drug|gefitinib|
45920355|NCT00091156|Procedure|adjuvant therapy|
45920356|NCT00091195|Drug|romidepsin|
45920357|NCT00091234|Drug|gemtuzumab ozogamicin|
45920358|NCT00091312|Drug|FOLFIRI regimen|
45920359|NCT00091312|Drug|fluorouracil|
45920360|NCT00091312|Drug|irinotecan hydrochloride|
45920361|NCT00091312|Drug|leucovorin calcium|
45920362|NCT00091312|Procedure|adjuvant therapy|
45920363|NCT00006194|Behavioral|Exercise|
45920364|NCT00091351|Procedure|conventional surgery|
45920365|NCT00091351|Radiation|radiation therapy|
45920366|NCT04619706|Drug|FSD201|Tablets for oral administration.
45920367|NCT04619706|Drug|Placebo|Placebo tablets matched to FSD201 for oral administration.
45920368|NCT04619706|Other|Standard of Care for Covid-19|Standard of care for Covid-19 as determined by site PI
45920369|NCT00091429|Drug|Ranolazine|
46071524|NCT00820807|Other|Placebo|oral consumption in beverage
45791088|NCT05042726|Device|Pseudo-stimulation First|The transcranial magnetic stimulator operating system has a built-in control group option, in which the stimulation parameters are set consistent with the research group, which can realize the operation of only sound without stimulation.
45449621|NCT03183518|Other|Saline Solution: Sodium Chloride (NaCl; 0.9%)|Each participant will have the reference product applied topically via semi occlusive patch, on-site by a technician.
45647110|NCT04437823|Biological|Intravenous Infusions of Stem Cells|Cultured stem cells will be injected at days 1, 3 and 5 intravenously. While patients will be monitored and evaluated for various hematological and organ functions at baseline (day 0) and days 1, 3, 5, 7, 14, 21 and 30
45647111|NCT04822753|Procedure|Platelet Rich Plasma injection to the lumbar facet joint|Using standard fluoroscopic view, place a needle at the target facet joint. Inject about 1ml of study injectate.
45647112|NCT05254613|Drug|ALXN1830|ALXN1830 will be administered as SC infusion(s).
45647113|NCT05254613|Drug|Placebo|Placebo will be administered as SC infusion(s).
45647114|NCT05092165|Drug|Methylene Blue|1 mg per kilogram bolus, followed by 0.1 milligram per kilogram during renal replacement therapy
45647115|NCT05092165|Other|Control|Usual care during renal replacement therapy
45647116|NCT04682821|Other|Artificial intelligence assistant system|The intervention is the use of the artificial intelligence assistant system in addition to the common training. The system is an non-invasive AI system which could help the endoscopists to diagnosis and monitor the blind spot during the gastroscope.
45791089|NCT03000842|Device|transcutaneous vagal nerve stimulation on|electrical current on positioned in the ear to estimate vagal branch of auricular nerve
45791090|NCT03000842|Device|transcutaneous vagal nerve stimulation off|an electrical current off positioned in the ear to estimate vagal branch of auricular nerve
45647117|NCT03062813|Drug|Tacrolimus &entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus (0.05-0.1 mg/kg/day) combined with entecavir. Tacrolimus was divided into two daily doses at 12-hour intervals. Subsequent doses were adjusted to achieve a whole blood 12-hour trough level between 5 and 10 ng/ml.All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
45647118|NCT03062813|Drug|placebo & entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus placebo (0.05-0.1 mg/kg/day) combined with entecavir.Tacrolimus placebo was divided into two daily doses at 12-hour intervals. All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
45647119|NCT04643431|Diagnostic Test|Perflutren|The ultrasound contrast agent is used to improve the quality of ultrasound imaging and is infused over 5-10 minutes. The contrast agent consists of the gas-filled microbubbles smaller than the capillary size which circulate in the vascular system. The contrast agent is cleared from the body naturally within 30 minutes.
45647120|NCT05088577|Dietary Supplement|Whole egg|Daily consumption of two whole eggs during 8 weeks
45647121|NCT05088577|Dietary Supplement|Annatto-enriched egg|Daily consumption of two whole eggs enriched with annatto during 8 weeks
45647122|NCT05088577|Dietary Supplement|Egg whites - Control|Daily consumption of two eggs whites during 8 weeks
45791091|NCT03000764|Other|skin biopsies|"Biopsies (12 G) will be performed :~in non-irradiated breast skin~in irradiated breast skin"
45791092|NCT03000764|Other|blood samples|"blood samples are collected:~10 ml in EDTA tube~2,5 ml in PAXgene Blood RNA tube~4 ml in EDTA tube"
45791093|NCT01684397|Biological|Bevacizumab|Given IV
45791094|NCT01684397|Other|Laboratory Biomarker Analysis|Correlative studies
45791095|NCT01684397|Drug|Pazopanib Hydrochloride|Given PO
45791096|NCT01684397|Other|Pharmacological Study|Correlative studies
45791097|NCT03005678|Drug|Denosumab|active treatment group
45791098|NCT03005678|Drug|Alendronate|comparator
45920370|NCT00091468|Drug|Transdermal nicotine patch|double-blind phase: 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks open label phase: 5mg for 1 week, 10mg. for 2 weeks, 15mg. for 23 weeks taper down: 10mg. for 2 weeks, 5mg. for 1 week
45920371|NCT00091468|Drug|Placebo transdermal patch|placebo patch, 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks
45449622|NCT00116753|Drug|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (40 mg/mL) at months 1, 3, 6 and 9
45449623|NCT00116753|Drug|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 3, 6 and 9
45449624|NCT00116753|Drug|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 4, 7 and 10
45449625|NCT03422198|Radiation|Vaginal Cuff Brachytherapy|Undergo standard of care vaginal cuff brachytherapy
45449626|NCT03422198|Radiation|Short course vaginal cuff brachytherapy|Undergo short course vaginal cuff brachytherapy
45449627|NCT00113399|Biological|filgrastim|
45449628|NCT00113399|Drug|cisplatin|
45449629|NCT00113399|Drug|docetaxel|
45449630|NCT00113399|Drug|fluorouracil|
45449631|NCT00113399|Drug|paclitaxel|
45791099|NCT02247908|Other|Surgeon General's Warning|"Participants will be randomly assigned to receive warnings with one of the four Surgeon General's Warnings on their cigarette packs for 4 weeks:~SURGEON GENERAL'S WARNING: Smoking Causes Lung Cancer, Heart Disease, Emphysema, and May Complicate Pregnancy.~SURGEON GENERAL'S WARNING: Quitting Smoking Now Greatly Reduces Serious Risks to Your Health.~SURGEON GENERAL'S WARNING: Smoking by Pregnant Women May Result in Fetal Injury, Premature Birth, and Low Birth Weight.~SURGEON GENERAL'S WARNING: Cigarette Smoke Contains Carbon Monoxide."
45791100|NCT02247908|Other|Graphic Warning|"Participants will be randomly assigned to receive one of the following four graphic warnings on their cigarette packs for 4 weeks:~Text: WARNING: Cigarettes are addictive. Image: Man smoking through tracheotomy hole.~Text: WARNING: Cigarettes causes fatal lung disease. Image: Healthy lungs next to diseased lungs.~Text: WARNING: Cigarettes cause cancer. Image: Mouth with cancerous lesion on lip.~Text: WARNING: Smoking can kill you. Image: Woman dying from cancer."
45791101|NCT03000296|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Hematopoietic stem cell transplantation Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
46073674|NCT02820636|Behavioral|S-CBT|The SCBT-SB protocol has 3 phases. Phase I, which is fixed (core sessions), includes 9 sessions (1 family, 5 individual & 3 caretakers sessions). Topics include: understanding the suicidal crisis, identity in adolescence, chain analysis, communication skills, the power of thought and decision making, parenting skills, rearing in a different culture, and family communication. Phase II is flexible and consists of coping skills modules (thoughts, emotional regulation, social interactions, activities, substance abuse, family communication & trauma). The treatment plan is adjusted to adolescents' needs. Family and primary caregiver sessions are flexible, depending on the family/caregivers' needs. Participants have received an adequate course of treatment if they at least complete the core sessions. This protocol should take 3-6 months. Once the active phase ends, booster sessions are recommended.
45647123|NCT03964259|Drug|Intravenous fluids|Administration of post HDMTX intravenous fluids (IVF)
45647124|NCT04942327|Behavioral|Interview|This will be evaluated through a specific questionnaire that will be systematically gone over with the participants during an interview in the first and third phases.
45647125|NCT04893161|Drug|Belimumab|All patients with SLE will be enrolled in one year and administrated belimumab 10mg/kg intravenous infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 48.
45791102|NCT03008889|Drug|N-acetylcysteine|"Participants will start with taking 900mg of NAC once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63."
45791103|NCT03008889|Drug|Placebo|"Participants will start with taking 900mg of the placebo once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events. The dosing for the placebo will increase in the same fashion as the active treatment.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63."
45791104|NCT04980482|Drug|AB-729|subcutaneous injection
45791105|NCT04980482|Drug|Peg-IFNα-2a|subcutaneous injection
45791106|NCT00373971|Behavioral|Involving the patients in their own nutritional care|
45791107|NCT03005210|Drug|Magicbuvir Plus|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
45791108|NCT03005210|Drug|Harvoni (fist dose)|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
45791109|NCT03005210|Drug|Harvoni (second dose)|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
45791110|NCT03010137|Procedure|Incisional Negative Pressure Wound Therapy|
45791111|NCT03010137|Procedure|Standard Closure with Skin Glue|
45791112|NCT03010137|Device|PICO (Smith&Nephew)|Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager sized) suction device/canister.
45791113|NCT03010137|Device|Dermabond|Final wound closure with skin glue.
45791114|NCT03000218|Drug|Ursodeoxycholic acid|Ursodeoxycholic acid 300mg bid for 8 weeks
45653128|NCT04989647|Radiation|Adjuvant radiotherapy|Patients will receive adjuvant treatment composed of either pelvic radiotherapy external beam radiotherapy ± brachytherapy or concomitant chemoradiotherapy (pelvic radiotherapy + chemotherapy).
45653129|NCT05175729|Diagnostic Test|Comprehensive Ophthalmologic Examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters,corneal topography
45791115|NCT03000218|Drug|Metformin|Day 29 to 56: Metformin 500mg bid
45791116|NCT03000218|Drug|Placebo|Day 1 to 56: Placebo bid
45791117|NCT03010683|Drug|Liraglutide|Stimulation of Glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8mg once daily as a subcutaneous injection
45791118|NCT03010683|Drug|Metformin|Antidiabetic drug-biguanide class (Glucophage) 1000mg twice daily per os
45791119|NCT05467046|Device|Smartwatch system|The Atopic Dermatitis patient cohort is exposed to using a smartwatch system for 5 weeks.
45791120|NCT04877678|Drug|Bepotastine|10 mg Bepotastine, twice a day
45791121|NCT04877678|Drug|Placebo|Identical looking placebo, twice a day
45791122|NCT02918097|Drug|Lithium Carbonate|
45791123|NCT02918097|Drug|Sertraline|
45791124|NCT02918097|Drug|Nortriptyline|
45791125|NCT02918097|Drug|Risperidone|
45791126|NCT03000140|Behavioral|High Intensity Interval Training|High Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.
45791127|NCT03000140|Behavioral|Control group|Moderade Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.
45791128|NCT03000062|Behavioral|Intervention group|Please see the preceding section
45791129|NCT05420207|Other|No intervention|No intervention included
45791130|NCT02999516|Other|Motor imaginary|Participants imagine doing a motor task watching a video recording
45791131|NCT02999516|Other|Non Motor imaginary|Participants watch a television documentary
45791132|NCT02999516|Other|tDCS|transcranial direct current stimulation (tDCS) stimulation during 20 minutes in the motor cortex (bilaterally) at 1mA of intensity.
45791133|NCT02999516|Other|tDCS sham|tDCS stimulation during 30 seconds in the motor cortex (bilaterally) at 1mA of intensity and then 19 minutes and 30 seconds without any stimulation.
45791134|NCT02999516|Other|Neurofeedback|EEG monitoring of the cerebral cortex in real time with positive feedback in the computer screen when participants motor cortex is activated. The positive feedback consist in an object that moves to the top of the screen when activation occurs in the motor cortex. This task last during 20 minutes.
45791135|NCT02999516|Other|Neurofeedback sham|EEG monitoring of the cerebral cortex in real time with randomized feedback in the computer screen despite motor cortex activation. The positive feedback consist in an object that moves to the top of the screen in a randomized time. This task last during 20 minutes.
45791136|NCT05408585|Other|Regional Anesthesia Techniques|Fascial Plane Blocks
45920372|NCT00006200|Drug|thalidomide|
45791137|NCT03005132|Other|Normal brain tissue|The investigators will extract total protein, DNA and RNA from the samples.
45791138|NCT04749407|Genetic|biomarker detection|PBMC and ctDNA analysis
45791139|NCT05460182|Other|CAF+CTG|Coronally Advanced Flap + Connective Tissue Graft
45791140|NCT05460182|Other|CAF|Coronally Advanced Flap
45791141|NCT02999204|Drug|Vitamin D3|Two different doses of Vitamin D3
45791142|NCT03012477|Drug|Cisplatin|chemotherapy
45791143|NCT03012477|Drug|AZD1775|Wee1 tyrosine kinase inhibitor
45791144|NCT02276963|Drug|Ublituximab|Monoclonal antibody that specifically binds to the trans-membrane antigen CD20, which induces immune response that causes lysis of B cells.
45791145|NCT02999048|Drug|Panax Notoginseng Saponins|Panax Notoginseng Saponins integrated with conventional therapy
45647126|NCT04601311|Behavioral|Guided self-determination|"Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'….~The goal is registered.~Patients go through a guided self-determination intervention preparing themselves by completing reflection sheets, analogue or digital by patient's choice, and individually facilitated by a guided self-determination-certified nurse, face-to-face, over video or over telephone. Sessions scheduled every second week. Number of sessions 3-5 is decided at session 2.~A relative may take part in one session completing an analogue reflection sheet as preparation.~Participants continue usual care."
45791146|NCT04827914|Behavioral|Enhanced Care|Smokers in the enhanced care group will receive live counseling (either in person or telehealth consult) while hospitalized combined with post-hospital discharge automated calls using interactive voice recognition (IVR) technology.
45791147|NCT04827914|Behavioral|Basic Care|Smokers assigned to the basic care group will only receive the post-discharge IVR phone calls.
45791148|NCT03017937|Device|Q-collar|capture ultrasound images at each pressure point
45791149|NCT02999282|Device|Anodal transcranial direct current stimulation|10 sessions of anodal transcranial direct current stimulation (5 days/week for 2 weeks)
45647127|NCT04601311|Behavioral|Personal support in goal-pursuing|"Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'….~The goal is registered.~Patients receive personal goal pursuing support up to five sessions, lasting up to one hour with a communication trained healthcare professional following up on the goal, face-to-face, digitally, or over telephone. The sessions are scheduled every second week. A relative may take part in one session.~Participants continue usual care."
45647128|NCT04884035|Drug|CC-220|CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
45647129|NCT04884035|Drug|Rituximab|Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles
45647130|NCT04884035|Drug|Cyclophosphamide|Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
45791150|NCT02999282|Device|Sham transcranial direct current stimulation|10 sessions of sham transcranial direct current stimulation (5 days/week for 2 weeks)
45791151|NCT04813172|Behavioral|Symptom Assessment|"Examine the symptomatology of head and neck cancer patients undergoing treatment that includes radiation by completing the M.D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN), the Brief Pain Index (BPI)and the Functional Assessment of Cancer Therapy for Head and Neck Cancer (FACT-H&N). They will also be asked to complete the Hearing Handicap Inventory for Adults - Screening (HHIA-S) and the Tinnitus Handicap Inventory - Screening (THI-S) as well as the Flourishing Measure.~Each patient enrolled will be followed by a nurse and speech-language pathologist, twice a week, throughout their treatment (from start until 3-month post completion) All assessments are collected on a secure Ipad through REDcap database. If any significant changes occur, within 2 points from their last assessment, the nurse will notify the oncology physician and provide plan of care to avoid emergency room or hospital visit."
45791152|NCT03019107|Device|Breath synchronized abdominal NMES|VentFree prototype (VF03) that delivers electrical stimulation pulses to the abdominal muscles during exhalation with a frequency of 30 Hz, a pulse width of 350 µs and 90% of the maximum current that the participant can tolerate. These stimulation parameters were selected to cause a tetanic (continuous) contraction of the abdominal muscles, without pain for the patient. Stimulation will be administered for 30 minutes 2 times per day, 5 days per week, for 6 weeks; or until the patient is weaned from mechanical ventilation.
45791153|NCT03019107|Device|Sham breath synchronized abdominal NMES|Modified VentFree prototype (VF03) that delivers stimulation pulses to the abdominal muscles during exhalation with a frequency of 10 Hz, a pulse width of 100 µs and current set to 10 milliamp. These stimulation parameters were chosen to cause a twitch contraction of the abdominal wall muscles. Stimulation will be administered for 30 minutes, 2 times per day, 5 days per week, for 6 weeks; or until the patient is weaned from mechanical ventilation.
45791154|NCT04784780|Drug|Elobixibat 10mg|Patients with chronic constipation are administered Elobixibat 10mg for 12 weeks
45791155|NCT04784780|Drug|Placebo|Patients with chronic constipation are administered placebo for 12 weeks
46073675|NCT02820636|Behavioral|Treatment as Usual|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
45449632|NCT00113399|Radiation|radiation therapy|
45449633|NCT01326611|Drug|Clarithromycin|
45449634|NCT01326611|Drug|Dextrose|
45791156|NCT04770584|Other|Fear Conditioning|Participants will be administered increasing intensities of mild electric shock via electrodes connected to the foot. New Biopac stimulators that can deliver higher shock intensity, provided participants agreement will be used to assure adequate conditioning levels. Stimulation is measures in milliamps (mA), and each delivered stimulation will be 0.5 seconds long (500 milliseconds). To colored (blue, red, & yellow) light stimuli (CS). The light stimulus is followed by a shock or no shock depending on color (blue & red - shock; yellow - no shock).
45920373|NCT00006200|Drug|dacarbazine|
45920374|NCT04612140|Procedure|Radiosurgery|The study subjects randomized in this study arm will undergo a radiosurgery procedure.
45920375|NCT04612140|Procedure|Repeated catheter ablation|The study subjects randomized in this study arm will undergo repeated catheter ablation.
45647131|NCT04884035|Drug|Doxorubicin|Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
45647132|NCT04884035|Drug|Vincristine|Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
45791157|NCT04770584|Other|Avoidance conditioning|Via button pressing. Only one stimulus-CS (i.e. blue colored light) will enable control over experiencing the shock: the participant can press the button during the first 2 seconds of the light presentation to avoid the shock. CS stays on for 6 seconds after the button is pressed. If the button is pressed, no shock will be administered. After 6 seconds, the light ends and the relief epoch ('good feeling') begins. Pressing the button to the other CS (i.e. red colored light) will not prevent the shock from occurring- the participant will still receive the mild shocked at CS offset (after 6 seconds). The third CS (i.e. yellow light) will serve as a control CS, so while the button is available, pressing it or not is of no consequence.
45791158|NCT04770584|Other|Pavlovian fear extinction learning|After avoidance conditioning, the CS+ associated with avoidance responding (i.e. blue light) appears with no button to press and no shock is administered.
45791159|NCT04770584|Other|Willingness to pay to avoid shock|"On the next day, participants receive a monetary stipend to use to pay to guarantee that they are not to receive any shocks if they press a button from the CS+. No shocks will be delivered on day 2, regardless of money paid.~This and all previously described experimental phases noted above will occur inside of the fMRI scanner."
45791160|NCT02919111|Drug|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
45791161|NCT02919423|Device|transcranial magnetic stimulation|
45791162|NCT03004898|Behavioral|multidisciplinary renal education|multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
45791163|NCT02919657|Dietary Supplement|Genepro Protein|weekly blood draws to measure blood protein levels
45791164|NCT02919657|Dietary Supplement|Whey Protein|weekly blood draws to measure blood protein levels
45791165|NCT03004742|Dietary Supplement|Flavonoid|Flavonoid rich supplement
45791166|NCT03004742|Dietary Supplement|Placebo|Placebo
45791167|NCT03004820|Device|Remote Ischemic Conditioning|RIC consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral upper limbs twice a day. Medication strategy is based on physician's best judgement.
45791168|NCT02850159|Device|rTMS and tDCS|Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
45920376|NCT00400270|Procedure|Breathing and relaxation exercises: the Papworth Method|
45920377|NCT00400309|Biological|REPEVAX® after REVAXIS®|Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after tetanus, diphtheria, poliomyelitis (inactivated)
45647133|NCT04884035|Drug|Prednisone|Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
45647134|NCT04884035|Drug|CC-99282|CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
45647135|NCT04884035|Drug|Polatuzumab vedotin|Polatuzumab vedotin 1.8 mg/kg on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
45647136|NCT04884035|Drug|Rituximab|Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
45647137|NCT04582981|Drug|Fruquintinib and raltitrexed|Fruquintinib 5mg qd plus raltitrexed 2mg/m2, q2w
45791169|NCT02850159|Device|rTMS|Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and sham anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
45791170|NCT02999126|Drug|Propofol|Propofol intravenously by a stepwise TCI titration with Marsh pharmacokinetic model
45791171|NCT02999126|Drug|Remifentanil Hydrochloride|Remifentanil intravenously 6 ng/ml by TCI effect site, 3 min prior to intubation and maintained at that concentration throughout the study. If clinical signs of inadequate analgesia are present, remifentanil target concentration will be increased by 1 ng/ml.
45791172|NCT03019887|Drug|reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine|
45791173|NCT02998970|Drug|Empagliflozin|single oral tablet once daily.
45791174|NCT02998970|Drug|Placebo|single oral tablet once daily.
45791175|NCT05422742|Procedure|SRP + MM|Subjects will be randomized into either SRP only or SRP +MM. Periodontal therapy will consist of one visit full-month SRP alone or in-combination with MM placed at all sites regardless of probing pocket depth. Each site will recieve 1mg of MM for a total of 6mg of MM per tooth.
45920378|NCT00400309|Biological|REPEVAX® after Placebo|Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after placebo
45920379|NCT00006203|Drug|naltrexone (Revia)|
45920380|NCT00091585|Drug|SNS-595|
45920381|NCT00091624|Drug|CC-5013|
45920382|NCT00091663|Drug|Tarceva (erlotinib HCl)|
45920383|NCT02972307|Other|wheelchair skills|the extent to which caregivers enhance the wheelchair skills of powered wheelchair users
45920384|NCT00006206|Drug|naltrexone (Revia)|
45920385|NCT00006206|Drug|acamprosate (Campral)|
45920386|NCT00091702|Biological|Cold-adapted live attenuated influenza vaccine (FluMist)|
45920387|NCT00091702|Biological|Inactivated influenza vaccine (IAIV)|
45920388|NCT04596423|Diagnostic Test|Fetal echocardiography|fetal heart examination by medical ultrasound
45920389|NCT00091741|Drug|Etanercept (Enbrel)|
45920390|NCT00006209|Drug|Tucaresol|
45920391|NCT00091858|Drug|Darbepoetin Alfa|6.75 mcg/kg Q4W
45920392|NCT00091858|Drug|Placebo|Placebo Q4W
45920393|NCT00390195|Drug|RAD001 (everolimus)|Arm 1: 2.5, 5, 7.5 or 10 mg of RAD001 daily
45791176|NCT05422742|Procedure|Scaling and Root Planing (SRP)|Procedure involving removal of dental plaque and calculus (scaling or debridement) and then smoothing, or planing, of the (exposed) surfaces of the roots, removing cementum or dentine that is impregnated with calculus, toxins, or microorganisms, the etiologic agents that cause inflammation.
45791177|NCT02919813|Behavioral|Mindfulness Based Group Cognitive BehaviorTherapy|Mindfulness Based Group Cognitive Behavior Therapy is a type of counseling that teaches women to have more control over their pain.
45791178|NCT02919813|Behavioral|Educational Seminars|Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
45791179|NCT05406752|Drug|paracetamol Uniflash (125 mg/ 1.25 mL)|Oromucosal solution (125 mg/ 1.25 mL) for buccal route
45791180|NCT00550043|Drug|INCB018424|
45791181|NCT00550043|Drug|Placebo|
45791182|NCT02247362|Biological|VAX2012Q|Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM
45647138|NCT04582981|Drug|Fruquintinib|Fruquintinib 5mg qd monotherapy
45791183|NCT02247362|Other|Placebo|Vaccine Diluent
45791184|NCT02920749|Drug|Sevoflurane group A|In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane dosing was adjusted for the same MAP range.
45791185|NCT02920749|Drug|Sevoflurane group B|In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
45791186|NCT02920749|Drug|Propofol group C|In this group anaesthesia was maintained with propofol. Propofol was administered according to protocol. Propofol dosing was adjusted for the same MAP range.
45791187|NCT02920749|Drug|Propofol group D|In this group anaesthesia was maintained with propofol. Propofol dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
45791188|NCT02248142|Drug|Pramipexole|
45791189|NCT05331482|Other|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
45647139|NCT03760627|Behavioral|Refugees Mindfulness Resiliency Training|The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
45647140|NCT03760627|Behavioral|Mindfulness Resiliency Training|The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
45647141|NCT03579667|Behavioral|Diet intervention|12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al, Am J Clin Nutr 2012;96:698.), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
45791190|NCT05331482|Other|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with conventional training protocol.
45791191|NCT04667780|Drug|Colchicine|Colchicine tablet 0.5 mg
45791192|NCT04667780|Drug|Standard COVID-19 care|As per the hospital guidelines
45791193|NCT02854059|Biological|IdeS (0.25 mg/kg)|Single i.v. infusion of IdeS (0.25 mg/kg). Following an evaluation of efficacy and safety in the first 3 patients the dose may be increased in the following 3 patients to 0.5 mg/kg.
45791194|NCT02854059|Biological|IdeS (0.50 mg/kg)|Single i.v. infusion of IdeS (0.50 mg/kg).
45647142|NCT03278821|Behavioral|Self Match|Video presentation of treatment option are shown to the patient whereafter the patient must choose between the five possible treatment options.
45647143|NCT03278821|Behavioral|Expert Match|Referral as usual to one of five possible treatment options. The referral is based on baseline data from the patient and by the means of an algorithm, used in daily clinical praxis.
45791195|NCT02248220|Drug|Pramipexole|
45791196|NCT03004508|Dietary Supplement|Gingko Biloba Extract|120mg/day, twice a day, 6 month
45791197|NCT03004508|Dietary Supplement|Placebo|120mg/day, twice a day, 6 month
45791198|NCT03021759|Behavioral|Active choice|Statin options are framed to physicians as an active choice to prescribe or not prescribe a statin
45791199|NCT03021759|Behavioral|Social comparison feedback|Statin prescribing rates are communicated to physicians and along with how their performance compares to their peers
45647144|NCT04873427|Genetic|clonal heterogeneity evaluation|Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis
45791200|NCT03004586|Device|25-Gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.
45791201|NCT03004586|Device|22-Gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.
45791202|NCT03004586|Procedure|Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed.
45791203|NCT03004430|Behavioral|Mantra Meditation|Silent mantra meditation with spiritual mantra
45791204|NCT03004430|Behavioral|Progressive Muscle Relaxation|Progressive Muscle Relaxation
45791205|NCT02921061|Drug|Cladribine|Given IV
45791206|NCT02921061|Drug|Cytarabine|Given IV
45791207|NCT02921061|Drug|Decitabine|Given IV
45791208|NCT02921061|Biological|Filgrastim|Given SC
45791209|NCT02921061|Other|Laboratory Biomarker Analysis|Correlative studies
45791210|NCT02921061|Drug|Mitoxantrone Hydrochloride|Given IV
45920394|NCT00390195|Drug|RAD001 (everolimus)|Arm 2: 20, 30, 50 or 70 mg of RAD001 daily
45920395|NCT00091897|Drug|Rituximab|
45920396|NCT00091897|Drug|rituximab or placebo|A fixed dose of Rituximab or placebo 1GM on Day 1 and 1GM on day 15 (+/- 2 days)
45920397|NCT00006212|Drug|cisplatin|
45791211|NCT03004352|Other|retrograde flow|Two pneumatic cuffs were placed on the experimental arm, one on the lower forearm, and the other on the upper arm. Two cuffs were simultaneously inflated for 20 minutes. The distal cuff was inflated to 75 mm Hg and the proximal cuff was inflated to 40 mm Hg. The contralateral (control) arm was cuff free during this intervention.
45791212|NCT03004352|Other|oxygen|Supplemental 100% oxygen administered through a nasal cannula.
45791213|NCT05310422|Drug|Tivanisiran sodium ophthalmic solution|1 drop in the affected eye(s) once daily
45791214|NCT05310422|Drug|Vehicle ophthalmic solution|1 drop in the affected eye(s) once daily
45791215|NCT02921295|Device|Sidekick Stubbies|
45791216|NCT05289674|Dietary Supplement|High Calorie Formula|The high calorie formula is given as much as 300 kcal/day for 90 days after the subject were diagnosed with tuberculosis (TB) or urinary tract infection (UTI), determine as day 1. the diagnosis were determined by pediatrician. Before the intervention (day 0) and after the intervention (day 61), the subjects were taken the blood by laboratory employee of the private hospital in Surabaya, Indonesia
45791217|NCT03023553|Biological|Fluzone®|Influenza Virus Vaccine Suspension for Intramuscular Injection
45791218|NCT03023553|Biological|FluMist®|Influenza Virus Vaccine Live, Intranasal Spray
45791219|NCT02248298|Drug|2h-AFL-PDT|AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 2 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
45791220|NCT02248298|Drug|3h-AFL-PDT|AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
45647145|NCT04862741|Drug|NX-13 250mg IR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
45647146|NCT04862741|Drug|NX-13 500mg IR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
45647147|NCT04862741|Drug|NX-13 500mg MR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
45647148|NCT04862741|Drug|Placebo|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
45647149|NCT04683055|Procedure|Phacoemulsification combined with trabeculectomy|Patients with chronic angle closure glaucoma assigned to this group will have fornex based trabeculectomy at superior limbus and then phacoemulsification via temporal incision
45647150|NCT04683055|Procedure|Phacoemulsificaiton combined with ab-externo trabeculotomy|Patients with chronic angle closure glaucoma assigned to this group will have Deep Sclerectomy with ab externo trabeculotomy at superior limbus and then phacoemulsification via temporal incision
45647151|NCT02508493|Other|THINC-it Tool|"Digitalized cognitive test application administering the following cognitive test components:~Digit Symbol Substitution Test (DSST)~Choice Reaction Time (CRT)~One-back working memory tool~Trail Making Test B (TMT-B)~Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"
45647152|NCT02508493|Other|Pencil-and-paper Cognitive Tests|"Pencil-and-paper versions of the following cognitive tests:~Digit Symbol Substitution Test (DSST)~Trail Making Test B (TMT-B)~Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)~Variant of Choice Reaction Time (CRT)~Variant of the One-back working memory tool"
45647153|NCT04613089|Other|Natural History|Natural History and Clinical Follow Up.
45647154|NCT05098639|Behavioral|BASICS|In the BASICS condition, individuals receive information about alcohol use on campus and discuss safe drinking practices. They also receive personalized normative feedback based on their alcohol use and their use of protective behavioral strategies.
45653130|NCT05729425|Procedure|Ultrasound Microvessel Imaging|Undergo microvessel ultrasound imaging
46073676|NCT00849355|Drug|RCOMP-14 + rituximab|"Pretreatment: vincristine 1mg at day -6 and Methylprednisolone 100 mg from -6 to day 0.~Treatment: rituximab 375m/m2 + ciclophosphamide 750 mg/m2 + Vincristine 1.4 mg/m2 + Doxorrubicine 50 mg/m2 at day 1 and every 14d. Prednisone 100 mg/d from day 1 to 5 and every 14 d."
45920398|NCT00006212|Drug|vinblastine sulfate|
45920399|NCT00006212|Radiation|phosphorus P32|
45920400|NCT00006212|Radiation|radiation therapy|
45920401|NCT00091936|Drug|Didanosine|
45920402|NCT00091936|Drug|Efavirenz|
45920403|NCT00091936|Drug|Lamivudine|
45449635|NCT01326689|Drug|KW-2246|Rescue medication at an optimal dose, which is determined by dose titration
45449636|NCT01326689|Drug|Placebo|
45449637|NCT00113087|Drug|Enalapril|Enalapril to target dose of .4mg/kg/day divided to twice per day (BID)
45449638|NCT00113087|Drug|Placebo|Participants will receive placebo
45449639|NCT01082861|Biological|Cervarix|Cervarix, HPV vaccin
45791221|NCT02248298|Drug|3hr-MAL-PDT|an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2.
45791222|NCT04534556|Device|Active Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper limb rehabilitation. VNS stimulation as described in the current study consists of 0.5 second trains of 0.8 mA; 100 µsec biphasic pulses at 30 Hz. Stimulation trains are delivered only during rehabilitation.
45791223|NCT04534556|Device|Placebo Vagus Nerve Stimulation|During Phase 1 of the study, the placebo group will receive a minimal amount of stimulation that fails to sufficiently activate the nerve, unknown to the participant and therapists. All participants will receive active stimulation during the Phase 2 open-label portion of the study.
45791224|NCT02921841|Behavioral|D*STAR|
45647155|NCT05098639|Behavioral|Deviance Regulation Theory (DRT)|The Deviance Regulation Intervention comprises tailored intervention messages based on perceived norms. Participants complete an initial session that focuses on perceived norms of protective behavioral strategy (PBS) use and heavy drinking among peers. The therapist engages participants in a tailored discussion based on their perceived norms. If individuals believe PBS use is uncommon, the therapist discusses the positive social image that PBS use portrays. If the participant believes PBS is common, the therapist engages the participant in discussion of the negative aspects of non-PBS use. A similar strategy is taken for common and uncommon heavy alcohol use. Finally, the participant carries a mobile device which provide real-time adaptive positive or negative messages (consistent with the initial session) based on the perceived drinking and PBS norms of their current drinking environment.
45791225|NCT02921841|Behavioral|D*HEALTH|Digital general health promotion intervention. Time and attention matched intervention that targets health behaviors relevant to youth including exercise, nutrition, sleep, and smoking. Basic information about HIV and sexuality is also included.
45791226|NCT03004118|Dietary Supplement|Nutridrink|Liquid meal of 200ml
45647156|NCT04469179|Biological|SAB-185|SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
45647157|NCT04469179|Other|Normal Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
45647158|NCT04437121|Other|Online Survey about Dietary and Lifestyle Habits|"An online survey was conducted in a random sample of families. Parents self-reported their child's and their own dietary and lifestyle habits, as well as information about their sociodemographic status.~The survey consisted of 70 questions in 3 sections."
45647159|NCT04531579|Drug|Valproic Acid Solution|Valproate sodium in 5-ml single-dose vials containing 100 mg/ml of VPA. The appropriate dose of 140 mg/kg, based on the subject's weight at study entry, will be diluted in isotonic saline solution to a final volume of 300 ml for administration
45647160|NCT04531579|Drug|Isotonic saline solution|Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
45647161|NCT04362085|Drug|Therapeutic Anticoagulation|The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
45791227|NCT03004118|Device|High resolution manometry probe|Catheter inserted via the nose into the stomach to measure intragastric pressure.
45791228|NCT03004118|Device|perfusion catheter|Catheter inserted via the nose into the stomach to perfuse the nutridrink intragastricly.
45791229|NCT03004118|Drug|Placebo Oral Tablet|4 week oral intake (daily)
45791230|NCT03004118|Drug|Ursochol oral tablet|4 week oral intake (daily) (dose of 10.5mg/kg/day)
45791231|NCT03004118|Device|Duodenal fluid aspiration catheter|Catheter inserted via the nose into the duodenum to aspirate duodenal fluids for 2.5 hours.
45791232|NCT03004118|Procedure|Duodenogastroscopy|Catheter inserted via the mounth into the duodenum to take duodenal biopsies.
45791233|NCT03004118|Procedure|Blood sample|Blood sample will be taken to measure liver enzyme serum levels and marker for bile acid synthesis.
45791234|NCT03004196|Drug|Probiotic Toothpaste|G.D Probiotic Toothpaste bacteriocin Lactic Acid Bacteria
45791235|NCT03004196|Drug|Dr. Reddy's Clohex|0.20% Chlorhexidine Mouthwash
45791236|NCT03004196|Other|Control Group|No Probiotic toothpaste & Chlorhexidine Mouthwash
45791237|NCT03004274|Other|Running sutures|
45791238|NCT03004274|Other|Interrupted sutures|
45791239|NCT02281409|Biological|Mogamulizumab (KW-0761)|
45791240|NCT04523480|Drug|Testopel 75mg Drug Implant|75 mg Testosterone pellets administered subcutaneously.
45791241|NCT04523480|Drug|Testopel 100mg Drug Implant|100 mg Testosterone pellets administered subcutaneously.
45791242|NCT04523480|Drug|Testopel 200mg Drug Implant|200 mg Testosterone pellets administered subcutaneously.
45791243|NCT02858349|Behavioral|No intervention|No intervention
45449640|NCT01082861|Biological|Engerix-B|Engerix-B, HBV vaccin
45449641|NCT00112463|Drug|romidepsin|DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpatient setting.
45791244|NCT02858349|Behavioral|High-intensity interval training|High-intensity walking exercise using bursts of concentrated effort alternated with recovery periods
45791245|NCT02282111|Device|22-gauge Procore needle (ProCore, Cook Medical Inc., Winston-Salem, NC)|Using a linear EUS with color and pulsed Doppler to scan the area for vessels, the lesion was then sampled with a 22-gauge beveled needle (using the slow capillary suction and fanning techniques with 5 to 15 to-and-fro movements with each pass). A total of 4 passes were performed and after that, the procedure terminated.
45791246|NCT02282111|Device|conventional needle-knife sphincterotome (Microknife XL; Boston Scientific Inc, Natick, Mass)|Using a conventional needle-knife sphincterotome connected to an electrosurgical unit, and under direct endoscopic vision, a 6-12mm linear incision was made from the periphery of the lesion to its highest convexity zone. A conventional biopsy forceps was then deeply introduced through the hole, and 2 bites were obtained per pass. A total of 4 passes were performed by passing the biopsy forceps through the incision on each occasion. The mucosal incision was then closed with endoclips whenever possible.
45791247|NCT05250908|Device|INTIBIA Therapeutic|INTIBIA implantable tibial nerve stimulator with therapeutic stimulation
45791248|NCT05250908|Device|INTIBIA Non-Therapeutic|INTIBIA implantable tibial nerve stimulator with non-therapeutic stimulation for 3 months, then therapeutic stimulation
45791249|NCT03023709|Biological|Fluzone®|quadrivalent, inactivated influenza virus vaccine, intramuscular
45791250|NCT03023709|Biological|FluMist®|quadrivalent, live, attenuated influenza vaccine, intranasal spray
45791251|NCT05215184|Device|Zeto WR19 EEG Recording|15 minutes of EEG recording to be obtained from eligible participants
45791252|NCT02248376|Drug|Gel|Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
45647162|NCT04354597|Drug|HCQ & AZ|Subjects will receive weekly HCQ 400mg PO and AZ PO 500mg X 3 Days; weekly for 16 weeks.
45791253|NCT05200442|Drug|VS-6766|An oral anti-cancer medication.
45791254|NCT05200442|Drug|Cetuximab|A chemotherapy drug used to treat head, neck and colorectal cancer.
45791255|NCT05200442|Other|Pill Diary|A diary where participants in phase 2 of study will log their medications and times they are taken on study.
45791256|NCT02859441|Drug|Ranibizumab|Intravitreal injections of the commercially-available 10 mg/mL formulation of ranibizumab. Ranibizumab is formulated as a sterile solution (pH 5.5) with histidine, trehalose and polysorbate 20. The vial contains no preservative. Each vial contains 0.5 mL of 10 mg/mL ranibizumab aqueous solution. The intravitreal injection volume of ranibizumab is 50 microliter, which correlates to 0.5 mg of dry ranibizumab.
45791257|NCT02859441|Drug|E10030|E10030 is not a commercially available drug product, and will be provided by Ophthotech Corp. The drug product is provided as a sterile aqueous solution of E10030 at a concentration of 30 mg (oligo weight)/mL. The solution contains monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate as buffering agents as well as sodium chloride as a tonicity adjuster. The intravitreal injection volume of E10030 is 50 microliter, which correlates to 1.5 mg of dry E10030.
45791258|NCT03004040|Biological|Flu Vaccine|
45791259|NCT05198882|Procedure|Laser technology for intracerebral thermocoagulation|One intervention : LITT (Laser Interstitial Thermal Treatment), technology that uses laser energy to thermally destroy (photo-thermal treatment) a brain injury under continuous MRI control (Validated by FDA - CE marking). The operator console + surgical laser generator + software that manages the power delivered by the laser is connected to an MRI - Provided by MEDTRONIC - FDA approved and CE certified.
45791260|NCT02859597|Device|High flow nasal cannula|High flow nasal cannula at 50 liters per minute and 50% oxygen will initially be used for oxygenation.
45791261|NCT02859597|Device|Nasal Cannula|Control group will receive oxygen via standard flow nasal cannula at 5 liters per minute (approximately an FiO2 of 0.35)
45791262|NCT01880099|Drug|placebo|placebo compared to 8mg of Galantamine
45791263|NCT01880099|Drug|Galantamine 8mg|8mg of galantamine compared to placebo
45647163|NCT03839459|Drug|Denosumab|120mg of Denosumab will be administered subcutaneously once every 4 weeks
45647164|NCT04413409|Procedure|Metastasectomy for the metastatic sites|patients randomized to this group will receive metastasectomy for the metastatic sites then followed by the systemic therapy
45647165|NCT05375461|Drug|TQB3616 capsules|The dose of TQB3616 capsules is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
45647166|NCT05375461|Drug|TQB3616-matching placebo|The dose of placebo is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
45791264|NCT01880099|Drug|Galantamine 16mg|16mg of galantamine compared to placebo
45791265|NCT05183204|Drug|Paxalisib|Patients will receive paxalisib starting at a dose of 45 mg/day. If well tolerated after 28 days, the dose of paxalisib will be increased to 60 mg/day.
45791266|NCT05183204|Drug|Metformin|Patients will receive metformin on Cycle 1, Day 1 at a starting dose of 850 mg QD, and if tolerated, will be increased to 850 mg BID on Cycle 2, Day 1 (1700 mg/day). If that dose is tolerated, metformin will be increased to 850 mg TID (2550 mg/day) beginning on Cycle 3, Day 1.
45791267|NCT05183204|Other|Ketogenic Diet|The ketogenic diet is high-fat, low carbohydrate diet. Ketogenic diet will be maintained on a continuous basis starting on Cycle 1, Day 1 and continuing throughout the trial.
45791268|NCT04287803|Drug|Methoxyflurane|Methoxyflurane 3mls will be self administered by patients meeting the inclusion criteria with acute traumatic pain scores >=4
45791269|NCT02860845|Device|Boric acid and probiotics|Vaginal capsules administered once a day during 7 days.
46073677|NCT00835393|Drug|Pantoprazole Sodium 40 mg delayed-release tablets|1 x 40 mg
45647167|NCT05375461|Drug|Fluvestrin injection|Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days.
45449642|NCT01083017|Drug|chlorthalidone|chlorthalidone 25mg/d vs. chlorthalidone 50mg/d
45647168|NCT05097781|Drug|PD-1 blocking antibody|All patients with more than one distant metastatic lesions will accept at least one site of radiotherapy and PD-1 blockade at the same time.
45653131|NCT05115513|Drug|Medium THC|Marijuana flower with medium THC
45653132|NCT05115513|Drug|Placebo THC|Marijuana flower with no THC
45791270|NCT02860845|Drug|Antibiotic (Clindamycin)|Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.
45920404|NCT00091936|Drug|Standard TB treatment|
45920405|NCT00091975|Drug|Zemplar Capsule|
46073678|NCT00835393|Drug|PROTONIX® 40 mg delayed-release tablets.|1 x 40 mg
46073679|NCT02690610|Procedure|EBUS TBNA of mediastinal lesions or lymph nodes|Through endo-bronchial ultrasound, a transbronchial needle will be introduced to take biopsies from mediastinal lesions under ultrasonic guidance.
45791271|NCT02860845|Drug|Antifungal (Clotrimazole)|Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.
45791272|NCT03003884|Drug|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary.
45791273|NCT03003884|Drug|Propofol|Initial dose plus supplemental doses as necessary.
45791274|NCT01880723|Drug|Albuterol|2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
45647169|NCT05374213|Behavioral|Mindfulness-Based Intervention|Mindfulness practices use a non-stigmatizing approach, combining secularized eastern meditative practices with western psychological advances to improve stress-management and self-care. Participants learn to generate less distress, engage more positively and fully in their lives and experiences, and respond more adaptively to challenges instead of reacting in automatic and unhelpful ways.
45647170|NCT03062969|Procedure|Cleavage stage biopsy group|"intracytoplasmatic sperm injection (ICSI)- (Invitro Fertilization)IVF~Time lapse embryo culture~Cleavage stage biopsy~aCGH analysis~Fresh euploid embryo transfer"
45791275|NCT01880723|Drug|Placebo saline|nebulized 3mL normal saline) using a Power Neb2 nebulizer
45791276|NCT02923167|Device|Robotic-assisted training of the hand|Training will be performed using the Amadeo®. The computer-controlled device maintains participants' forearm in a secure position using Velcro straps. Each training session will include 30 minutes of active movements that can be divided into up to 3 bouts of 10 minutes depending on participant's fatigue. Training will take place up to 4 times per week for a total of 18 sessions over up to 7 weeks. Sessions will last approximately 60 minutes (including setup, training, and rest between each bout).
45647171|NCT03062969|Procedure|Trophectoderm biopsy group|"ICSI-IVF~Time lapse embryo culture~Day 3 zona pellucida opening~Trophectoderm biopsy~aCGH analysis~Frozen-thawed euploid embryo transfer"
45791277|NCT02248454|Drug|Lispro|Increasing insulin doses
45791278|NCT04466618|Biological|Saline|Saline infused during the study
45791279|NCT04466618|Biological|Exendin-9,39|Exendin-9,39 infused during the study
45791280|NCT04466618|Biological|Saline + Intralipid/Heparin|Saline infused during acute insulin resistance
45791281|NCT04466618|Biological|Exendin-9,39 + Intralipid/Heparin|Exendin-9,39 infused during acute insulin resistance
45791282|NCT01881113|Drug|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
45791283|NCT01881113|Drug|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
45791284|NCT05155280|Other|PET imaging using [11C]DASB radioligand.|Subjects will be asked to complete a food choice task in PET/MRI. During the task, PET and MRI scans will be acquired simultaneously. This will allow us to see in real time during food choices the brain activations of the subjects. For imaging we will inject the DASB tracer intravenously. This radio ligand is a tracer that allows us to see the cerebral serotoninergic transmission by positron emission tomography.
45791285|NCT05155280|Behavioral|Eye Tracker|"The second technique used is the eye tracker that will allow us to analyze food avoidance behaviors through the eyes. With a TOBII eye tracker we wil be able to follow the gaze of the subjects during the food preference task. It is a non-invasive approach."
45791286|NCT05140694|Drug|Empagliflozin|Empagliflozin 10 mg p.o. once daily (available to control over ~25mg)
45791287|NCT05140694|Drug|Dulaglutide|Dulaglutide 0.75mg s.c. once a week (available to control over ~1.5mg)
45791288|NCT05140694|Drug|Empagliflozin and Dulaglutide|Empagliflozin 10 mg p.o. once daily with Dulaglutide 0.75mg s.c. once weekly
45791289|NCT03003806|Device|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro
45791290|NCT03003806|Other|Medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
45647172|NCT04245475|Behavioral|Virtual Reality psychological pain reduction|attention distraction
45791291|NCT02987699|Drug|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dose of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
45791292|NCT02987699|Drug|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 1400 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
45791293|NCT02987699|Drug|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 85 mg/m2 (3) leucovorin: 400mg/m2
45791294|NCT05673044|Procedure|modified Studer ileal neobladder|orthotopic ileal neobladders
45791295|NCT03003728|Drug|Elotuzumab|Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26
45791296|NCT03003728|Drug|Melphalan|Melphalan 200 mg/m2 Ivia intravenous infusion on day -3
45791297|NCT03003728|Procedure|Autologous Stem Cell Transplant (ASCT)|ASCT on day -2
45791298|NCT03003728|Biological|Expanded Natural Killer (ENK) Cells|ENK cell infusion on day 0
45791299|NCT03003728|Drug|ALT-803|ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22
45791300|NCT01883141|Procedure|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots
45791301|NCT05672810|Diagnostic Test|serum level of Ferritin and D-dimer|Blood venous sample
45791302|NCT00559247|Drug|BMS-650032 or Placebo|Oral, Once daily, Single Dose
45791303|NCT00558311|Drug|Clazosentan|Intravenous clazosentan administered by continuous infusion at 5 mg/h
45791304|NCT00558311|Drug|Placebo|Placebo administered by continuous infusion matching clazosentan administration
45791305|NCT03003650|Device|ACURATE TF™|ACURATE TF™Transfemoral Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement .
45791306|NCT02248610|Other|Non-interventional study|
45791307|NCT03003338|Drug|OBV/PTV/r and DSV|OBV/PTV/r (12.5 mg/ 75 mg/ 50 mg) in combination with DSV (250 mg): Two tablets of OBV/PTV/r in the morning and one tablet of DSV in the morning and one tablet of DSV in the evening orally with a meal without regard to fat or calorie content.
46071525|NCT04688918|Procedure|Retrolaminar block|A high-resolution 5-12 MHz linear probe with a sterile cover will be used to perform the block. The patient will be placed in a prone position with a pillow under the chest. The spinous process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vertebral lamina. A 50 mm 22-gauge needle will be inserted in an in-plane technique from cranial to caudal direction and will be advanced till hitting the laminae of fourth thoracic vertebrae and then we will try to inject the local anesthetic, if the resistance to injection is very high, hence we will withdraw the needle slowly and its tip will be kept in its position immediately after disappearance this high resistance. Bupivacaine 0.25%, 0.4mL/kg will be injected.
46071526|NCT04688918|Procedure|paravertebral group|A high-resolution 5-12 MHz linear probe with a sterile cover will be used to perform the block. The patient will be placed in a prone position with a pillow under the chest. The transverse process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vcostotransverse ligament, 0.4mL/kg will be injected
46071527|NCT02839590|Device|HiFU|Ciliary Ablation Treatment ( HiFu ultrasound treatment)
46071528|NCT02839590|Device|Baerveldt implant|External (sub-conjunctival) Drainage Surgery (Baerveldt implant)
46071529|NCT02839590|Device|Ahmed implant|External (sub-conjunctival) Drainage Surgery (Ahmed Implant)
46071530|NCT02839590|Device|STARflo|Suprachoroidal Shunt Surgery (STARflo)
46071531|NCT02839590|Device|Hydrus Microstent implant|Trans-trabecular meshwork implants (Hydrus Microstent implant).
46071532|NCT02839590|Device|iStent implant|Trans-trabecular meshwork implants (iStent implant).
46071533|NCT02839590|Device|Kahook Dual Blade|It removes part of the trabecular meshwork
46071534|NCT00829465|Drug|Licartin|Licartin
46071535|NCT00829465|Procedure|Transcatheter arterial chemoembolization|TACE
46071536|NCT05336708|Other|Acupressure Group|In the acupressure group, acupressure will be applied to the heart meridian 7th point (HT7), large intestine meridian 4th point (LI4), stomach meridian 36th point (ST36) and spleen meridian 6th point (SP6). After pressing each point for a certain period of time, a total of two minutes of rest periods will be applied by the researcher.
46071537|NCT05336708|Other|Sham Acupressure Group|In the sham acupressure group, acupressure will be applied on the bone region where the meridians do not pass, approximately 1-1.5 cm away from the HT7, LI4, ST36, SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
46071538|NCT02839356|Drug|epinephrine|20-mL irrigation with epinephrine diluted to 0.02% in saline over the entire papilla
46071539|NCT02839356|Drug|normal saline|20-mL irrigation with physiological saline over the entire papilla
46071540|NCT03860701|Procedure|Remote ischemic conditioning|An appropriately sized blood pressure cuff will be inflated around a limb (systolic blood pressure + 15 mmHg) for different periods of time (1 to up to 4 minutes), times (1 to up to 4 times) and consecutive days (1 to up to 2).
45647173|NCT05097547|Behavioral|Contingency Management|Contingency management involves receiving monetary prizes in exchange for negative urine drug screens.
45647174|NCT05096221|Genetic|SRP-9001|Single IV infusion of SRP-9001.
45647175|NCT05096221|Genetic|Placebo|Single IV infusion of matching placebo.
45791308|NCT03003338|Drug|Placebo to match OBV/PTV/r and DSV|Placebo to match OBV/PTV/r and DSV
45791309|NCT00557609|Drug|ARQ 197|360 mg administered twice daily until disease progression or other discontinuation criterion is met
46071541|NCT04674410|Drug|Antibiotic|Empiric antibiotic therapy, subdivided according to Community Acquired Pneumonia coverage vs Hospital Acquired Pneumonia coverage
46071542|NCT00829543|Procedure|guide-free sacroiliac corticosteroid injection|guide-free sacroiliac injection of triamcinolone acetonide 40 mg in each sacroiliac joint
45791310|NCT05672654|Diagnostic Test|Blood draw|Blood draw
45791311|NCT05351723|Other|Exercise + cognitive training + education|"The research team will record videos for the Intervention group. The intervention procedure includes 3 sections: (1) 50 min of physical exercise, (2) 20 min of break time or lecture on dementia and lifestyle habits, and (3) 50 min of cognitive training. Investigators will be recruited from the National Geriatrics Hospital and trained the technicians for 1 week.~Prior to intervening, patients who agree to participate will be screened and evaluated cognitive function, physical function, assessment of Activities of Daily Living, quality of life, depression, anxiety, stress, and sleep quality.~Technicians will record every training session, monitor participants' health, and ensure that those in the intervention group do the exercises correctly.~We will evaluate the participants in the group after 3 months and after 6 months of intervention."
45791312|NCT03003416|Drug|dexamethasone intravitreal implant|Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
46071543|NCT02840526|Procedure|Paravertebral blockade (PVB)|preoperative ThPVB performed unilaterally at Th10 level
46071544|NCT02840526|Drug|Sopodorm|midazolam 0,1 mgkg-1 intravenously (anesthesia induction)
46071545|NCT02840526|Drug|Propofol WZF|propofol 2 mgkg-1intravenously (anesthesia induction)
46071546|NCT02840526|Drug|Nimbex|cis-atracurium 0,15 mgkg-1 intravenously (anesthesia induction)
46071547|NCT02840526|Drug|Fentanyl WZF|fentanyl 1,5 µgkg-1 intravenously (anesthesia induction)
45449643|NCT01083017|Behavioral|motivational intervention for non-compliant individuals|motivational interview(s) vs. repeated calls vs. no particular intervention
45647176|NCT03987139|Other|Hypertension|"Hypertension is induced by an infusion of noradrenaline within acceptable limits Baseline recording (10 minutes) is performed. MAP gradually increases in steps of 5-10 mmHg during ongoing TCD. When the desired maximum MAP is reached, measurement is made at steady state (10 minutes).~Noradrenaline infusion is stopped. When MAP is stabilized, new baseline is measured for 10 minutes."
45791313|NCT02988869|Drug|Tiotropium/Formoterol|Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
45791314|NCT02988869|Drug|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
45791315|NCT02988869|Drug|Formoterol|Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer
45791316|NCT02988869|Drug|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
45791317|NCT03028467|Drug|GSK3196165 Dose 1|GSK3196165 is supplied as liquid and will be administered as SC injection.
45791318|NCT03028467|Drug|GSK3196165 Dose 2|GSK3196165 is supplied as liquid and will be administered as SC injection.
45647177|NCT03987139|Other|Hyper- and hypoxia|The mechanical ventilator is adjusted to mild hypoxia, normoxia and mild hyperoxia. Measurements are made for 10 minutes at normoxia and after steady state is reached, respectively. hyperoxia and hypoxia. Oxygenation is controlled by arterial blood gas before and during steady state.
45791319|NCT03028467|Drug|GSK3196165 Dose 3|GSK3196165 is supplied as liquid and will be administered as SC injection.
45791320|NCT03028467|Drug|Methotrexate|Methotrexate capsule/tablet 8-16 mg per week is given orally.
45791321|NCT03028467|Drug|Placebo|Placebo is supplied as liquid as sterile 0.9% sodium chloride solution and will be administered as SC injection.
45791322|NCT03028467|Drug|Folic acid|Folic acid tablet 5 mg per week is given orally.
45791323|NCT03003260|Other|CBD chewing gum|
45791324|NCT03003260|Other|Placebo|
45791325|NCT04251143|Procedure|corneal cross-linking|UV-A Irradiation and riboflavin
45791326|NCT04251143|Diagnostic Test|corneal topography and tomography|Detailed Information about corneal tomography is used for diagnosis
45791327|NCT02981186|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
45791328|NCT02981186|Device|IOL implantation comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
45791329|NCT04249973|Other|Collection of urine and feces|Urine and feces are collected at the families home. A short questionnaire is filled in by the parents
46071548|NCT02840526|Drug|Sevorane|sevoflurane in 1 MAC (Minimal Alveolar Concentration) - anesthesia maintenance
46071549|NCT02840526|Device|Intubation|Intratracheal intubation with a single lumen endotracheal tube
46071550|NCT02840526|Drug|Oxynorm|1 mgml-1 concentration oxycodone solution intravenously
45791330|NCT04327310|Drug|Meplazumab for Injection|humanized mAb against CD147
45791331|NCT04327310|Drug|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
46071551|NCT02840526|Drug|Paracetamol Kabi|1g paracetamol intravenously every 6 hours
46071552|NCT02840526|Drug|Ketonal|100 mg ketoprofen intravenously every 12 hours
46071553|NCT02840526|Drug|Bupivacaine WZF|0,3 ml kg-1 0,5% plain bupivacaine (regional anesthesia - paravertebral blockade)
46071554|NCT02342444|Drug|Enoxaparin Sodium Injection 30 mg BID|
45449644|NCT01083017|Drug|standardized anti-hypertensive treatment|olmesartan, amlodipine, chlorthalidone, +- spironolactone
46071555|NCT02342444|Drug|Enoxaparin Sodium Injection 40 mg QD|
46071556|NCT00825253|Drug|biphasic insulin aspart 30|
46071557|NCT00825253|Drug|biphasic human insulin 30|
46071558|NCT04591028|Drug|Indocyanine green|A one time injection of IDC prior to the day of scheduled surgery.
46071559|NCT02840370|Device|transcranial direct current stimulation|In tDCS, the prefrontal cortex is stimulated during 20minutes through a weak constant electric current (1-2 mA) through two electrodes in a non-invasive and painless manner.
46071560|NCT02840370|Device|Sham tDCS|S-tDCS refers to a control condition in which the subject will receive a brief current in the beginning in order to induce a similar sensation on the scalp as in tDCS, and then the stimulator remains off for the rest of the stimulation time.
45449645|NCT01066481|Drug|PF-01913539 5 mg|PF-01913539 5 mg three times daily for 6 months
45449646|NCT01066481|Drug|PF-01913539 5 mg|PF-01913539 5 mg three times daily for 6 months
45449647|NCT01066481|Drug|Placebo|Placebo three times daily for 6 months
45647178|NCT03987139|Other|Hyper- and hypocapnia|The mechanical ventilator is adjusted to a delta PaCO2 on the ventilator for both hypocapnia and hypercapnia. Measurements are made for 10 minutes at normocapnia and after steady state is reached, respectively. hyper- and hypocapnia.
45647179|NCT01117441|Drug|PEG-L-asparaginase|see detailed protocol description
45647180|NCT01117441|Drug|cyclophosphamide|see detailed protocol description
45647181|NCT01117441|Drug|cytarabine|see detailed protocol description
45647182|NCT01117441|Drug|daunorubicin hydrochloride|see detailed protocol description
45791332|NCT01883999|Device|GORE® EXCLUDER® Iliac Branch Endoprosthesis|
45791333|NCT02218424|Drug|Magnesium|
45791334|NCT02218424|Drug|Normal saline|
45791335|NCT00374049|Drug|MUC_1|Pretreatment with Poly-ICLC alone week 1 &2 (50 ug/kg 3 days/week) Weeks 3-7 Poly-ICLC, 2 days/week; MUC-1 vaccine (100ug) admixed with GM-CSF (100ug), administered subcutaneously at weeks 3, 5 and 7 Tetanus toxoid, administered via intramuscular injection, 1x at week 3 GM-CSF 100ug, administered subcutaneously on days 2-4
46071561|NCT00820885|Drug|teduglutide|subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.
46071562|NCT00820885|Drug|teduglutide|Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water
45791336|NCT02861937|Procedure|non surgical periodontal therapy|and root planing (SRP) was performed in two to four appointments lasting approximately 60 minutes each under local anaesthesia (2% lignocaine hydrochloride with 1:2,00,000 adrenaline) using area specific Gracey periodontal curettes and an ultrasonic device. The treatment was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy, which included professional plaque control and reinstruction of oral hygiene.
45791337|NCT01885871|Device|Picosecond QS Nd:YAG Laser|Up to 2 laser treatments delivered 6 weeks apart
45791338|NCT02222870|Biological|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2014-2015 formulation)
45791339|NCT02222870|Biological|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2014-2015 formulation)
45791340|NCT03029741|Drug|AZD0284|Subjects will receive a single oral dose of 4 to 120 mg AZD0284 oral suspension 5 mg/mL in the fasted state
45791341|NCT03029741|Drug|[14C]AZD0284|Following administration of the AZD0284 oral suspension subjects will receive an IV infusion of 20 μg [14C]AZD0284 solution
45791342|NCT02223260|Drug|dabigatran|Experimental dose chosen based on age and weight
45791343|NCT02863263|Device|Foam Dressing|The purpose of the study is not to compare between the 2 devices, but to determine the efficacy of each type of device on its own. Subjects are randomised to one of 2 arms.
45791344|NCT02863263|Device|Foam Dressing with Povidone Iodine|The purpose of the study is not to compare between the 2 devices, but to determine the efficacy of each type of device own. Subjects are randomised to one of 2 arms.
45791345|NCT01886807|Device|TrueView PCD Video Laryngoscope|
45791346|NCT02223338|Drug|Ciprofloxacin|Use of topical ciprofloxacin 4x daily for 3 days after intravitreal injection using standard aseptic techniques with Povidone-Iodine is a common practice intervention in the United States, and is thought by some to reduce the risk of post-injection endophthalmitis.
45791347|NCT02223338|Drug|Standard Aseptic Technique|Patients in this group will have received Povidone-Iodine Only following injections of anti-VEGF agents at least 3 times in the last 6 months.
45791348|NCT01887587|Drug|MLN9708|
45791349|NCT01887587|Drug|Vincristine|
45791350|NCT01887587|Drug|Doxorubicin|
45791351|NCT01887587|Drug|Dexamethasone|
45791352|NCT05672420|Biological|umbilical cord derived mesenchymal stem cells|umbilical cord derived mesenchymal stem cells, intravenous infusion
45791353|NCT03029091|Drug|Losartan Potassium|Losartan potassium
45791354|NCT02997410|Device|Ozone|
45791355|NCT02997410|Device|Placebo (for Ozone)|
45791356|NCT02997410|Device|Dental treatment with occlusal splint|
45791357|NCT02864355|Device|Goal Directed Therapy|Participants in this group will have a FloTrac monitor attached to their arterial line and the Goal Directed Therapy algorithm will be followed to manage blood pressures.
45791358|NCT02980796|Behavioral|Exercise|Each experimental day participants will complete an acute bout of exercise on a recumbent bike.
45791359|NCT02980796|Behavioral|Practice|Each experimental day participants will complete a session of skilled motor practice.
45791360|NCT03003104|Drug|DMT210 Topical Gel 5%|
45791361|NCT03003104|Other|Vehicle Control|
45791362|NCT00374205|Drug|Artesunate plus Amodiaquine|Artesunate 50 mg and Amodiaquine 153 mg co-blister tablets: 3 days once daily weight-adjusted dosing according to manufacturer
45791363|NCT00374205|Drug|Artemether-Lumefantrine|Artemether 20 mg/Lumefantrine 120mg fixe-dose-combination tablets: 3 days twice daily weight-adjusted dosing according to manufacturer
45791364|NCT02248844|Biological|Botulinum Toxin Type A|Botulinum toxin Type A injected into crow's feet line areas per clinical practice.
45791365|NCT03029715|Drug|Propofol|Total intravenous anaesthesia.
45791366|NCT03029715|Drug|Remifentanil|Narcotics
45791367|NCT03029715|Drug|Dexmedetomidine|Total intravenous anaesthesia
45791368|NCT03029715|Drug|Desflurane|Inhalation anaesthesia.
45791369|NCT04064762|Device|Paired Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with Prolonged Exposure Therapy.
45791370|NCT03035487|Device|Ultrasound guided prostate exam using SOC ultrasound system|
45791371|NCT03035487|Device|mpMRI guided prostate examination using PI-RADS v2|mpMRI guided prostate examination using standard of care MRI system
45791372|NCT03035487|Device|High-resolution micro-ultrasound guided prostate biopsy|
45791373|NCT05672264|Other|Whole-Body Electromyostimulation|Consistently supervised, video-guided WB-EMS application 1.5 times per week for 28 weeks. Bipolar electric current with a frequency of 85Hz, an impulse-width of 350 µs will be used in an interval approach with 6 sec of EMS stimulation with a direct impulse boost and 4 sec of rest. Low intensity movements or exercises in a standing position were performed during the 6 s stimulation period.
45791374|NCT05672264|Other|Physiotherapy|Six standardised physiotherapy sessions (20 min each)
45791375|NCT00555035|Drug|GSK1349572|
45791376|NCT02988635|Other|Early Palliative Care|Subjects who are randomized to the Standard Oncology Care with Early Palliative Care will meet with the palliative care team at their next medical oncology or infusion visit. They will meet with the palliative care clinician at least every three weeks. They will complete questionnaire at 12 weeks after enrollment.
46071563|NCT00820885|Drug|tedguglutide|lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.
45647183|NCT01117441|Drug|dexamethasone|see detailed protocol description
45791377|NCT05430464|Device|1726nm Laser System|Subjects will receive 1726nm laser treatments on one side of the face
45791378|NCT05430464|Device|Sham Laser System|Subjects will receive sham laser treatments on the other side of the face.
45791379|NCT02926677|Behavioral|Cue-Centered Treatment (CCT)|Identify stress reactions and develop coping skills to deal with them independently. Helps address ongoing traumatic stressors.
46071564|NCT03845582|Drug|ALK-001 oral capsule|Daily administration for 24 months
46071565|NCT03845582|Drug|Placebo oral capsule|Daily administration for 24 months
45449648|NCT03548415|Drug|IONIS-GHR-LRx|IONIS GHR-LRx administered subcutaneously.
45647184|NCT01117441|Drug|doxorubicin hydrochloride|see detailed protocol description
45647185|NCT01117441|Drug|etoposide|see detailed protocol description
45647186|NCT01117441|Drug|ifosfamide|see detailed protocol description
45647187|NCT01117441|Drug|mercaptopurine|see detailed protocol description
45647188|NCT01117441|Drug|methotrexate|see detailed protocol description
45647189|NCT01117441|Drug|prednisone|see detailed protocol description
45647190|NCT01117441|Drug|thioguanine|see detailed protocol description
45647191|NCT01117441|Drug|vincristine sulfate|see detailed protocol description
45791380|NCT02926677|Behavioral|Trauma-Focused CBT (TF-CBT)|Identifies negative cognitive/emotional patterns and helps re-frame them. Uses active support from guardians and focuses on emotional and cognitive conditioning. Focuses on discrete past incidents.
45791381|NCT02926677|Behavioral|Treatment as Usual|The control group. The standard treatment utilized at Stanford Youth Solutions
45791382|NCT02926677|Device|NIRScout|The device is a portable Functional Near-Infrared Spectroscopy (fNIRS) recording unit. NIRS technology uses specific wavelengths of light, introduced at the scalp to enable the non-invasive measurement of changes in the relative ratios of deoxygenated hemoglobin (deoxy-Hb) and oxygenated hemoglobin (oxy-Hb) in the capillary beds during brain activity.
45791383|NCT04177511|Device|Transcutaneous Auricular Vagus Nerve Stimulation|"Transcutaneous Auricular Vagus Nerve Stimulation has an eartip connected to an external stimulator. The device used in this study is the TENS Eco Plus commercialized by Schwa Medico and European Compliance (CE) marked.~The electrode is positioned in the cymba concha of the left ear."
45791384|NCT03002948|Other|Orgasm|"clitoris volume, suprapubic angle, urethra-levator gap, suburethral triangle area measurement could made using 4 D transperineal ultrasonography. Clitoris fourchette distance, clitoris perineal body distance, clitoris urethra distance could made with special compasses.~Female Sexual Function Index orgasm domain score"
45791385|NCT02996630|Procedure|Sonography|Fetal Ultrasound exploration
45791386|NCT02996630|Device|Magnetic Resonance Imaging|Fetal MRI for brain study
45791387|NCT02996630|Other|Bailey Test|Neurodevelopment paediatric assessment test performed at 2 years of age.
45791388|NCT02996630|Procedure|Surgical intervention|Congenital Heart Disease repair
45791389|NCT02996630|Procedure|Brain monitoring|EEG and continuous brain oximetry before surgery.
45791390|NCT02996630|Procedure|cord blood sample|Cord blood samples will be taken after birth in both groups.
45647192|NCT01117441|Drug|vindesine|see detailed protocol description
45791391|NCT02988011|Procedure|Gastric by-pass surgery|Gastric by-pass surgery is expected to achieve a mean weight loss of 7-8kg in 4 weeks, which is similar weight-loss achieved in the other arm (low-caloric diet) during this time period.
45791392|NCT02988011|Dietary Supplement|Low-caloric diet|Energy restricted diet with a total energy intake of 800-1200kcal/day
45791393|NCT03035955|Drug|Azelaic acid|15% gel twice daily for four weeks to one side of face
45791394|NCT04133675|Device|BTL Emsella|The Emsella Chair is a novel high-intensity focused electromagnetic (HIFEM) technology for the treatment of SUI, in addition to other pelvic floor related disorders. HIFEM technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes. The treatment paradigm consists of 3 different phases. The phases consist of an intense stimulation of the pelvic floor muscles (PFM), which consists of stimlulation and relaxation. The repetition of the phases and focused electromagnetic energy delivery leads to pelvic floor stimulation, adaptation, and remodelation.
45791395|NCT04133675|Device|Sham BTL Emsella|Sham subjects will be positioned on the device in the same manner as the active treatment group. The sham treatment will be provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (<10% power).
45647193|NCT01117441|Drug|daunoxome|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
45647194|NCT01117441|Drug|fludarabine|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
45791396|NCT03830060|Diagnostic Test|Measurement of cortisol|Cortisol will be measured by immunofluorescence and correlated with ANA and hs-CRP
45647195|NCT01117441|Radiation|Radiation Therapy|for eligibility for radiotherapy see detailed protocol description
45647196|NCT04829123|Drug|HEC88473 injection|HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen
45647197|NCT04829123|Drug|Placebo|Placebo will be administered by subcutaneous injection in the abdomen
45791397|NCT02927223|Drug|Atropine|
45791398|NCT02927223|Procedure|Exercise treadmill test|
45647198|NCT05177705|Behavioral|Restricted access task|In the restriction period participants will have their preferred (chosen after doing a preference task, including liking) food and similar alternatives restricted by their parent for 2 weeks. In the no restricted period, participants and their parents will be given several portions of the preferred food and will consume it throughout the two-week period.
45647199|NCT05177159|Other|The regional cerebral oxygen saturation (rSO2)|Measurement of rSO2 with non-invasive near-infrared light spectrum monitor. The average, left and right frontal regions absolute rSO2 values will be collected every 30 seconds during the whole surgery until postoperative 2 hours, and the mean values will be calculated. Absolute rSO2 value and AUT (area under the threshold) send beneath the absolute threshold limits of 40%, 50% and 20%, 30% under the baseline. AUT will be calculated based on this formula: AUT (present)=AUT (past)+(rSO2 threshold-rSO2 value)×sample rate
45647200|NCT05177159|Other|The glial fibrillary acidic protein (GFAP)|Venous blood sample will be collected and tested for plasma GFAP. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.
45647201|NCT05177159|Other|The brain-derived-neurotrophic factor (BDNF)|Venous blood sample will be collected and tested for plasma BDNF. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.
45791399|NCT04350437|Drug|induction of labor|Giving drugs to facilitate uterine contractions and fasten the process of delivery
45791400|NCT03002792|Procedure|general anesthesia|nitrous oxide, sevoflurane, propofol, cisatracurium, fentanyl for induction and maintenance with sevoflurane
45791401|NCT03002714|Other|Exercise|
45791402|NCT02927457|Drug|GSK2646264 1%|A cream for topical application with a concentration of 1% GSK2646264.
45791403|NCT02927457|Drug|Placebo|Subjects will receive matching Placebo topically.
45791404|NCT01891331|Drug|VT-1161|
45791405|NCT01891331|Drug|Fluconazole|
45791406|NCT02247518|Drug|Cialis Tab. 5mg|
45791407|NCT02247518|Drug|Harnal-D Cap. 0.2mg|
45791408|NCT05671952|Other|Application of integrated intervention system programs|Application of integrated intervention system programs
45791409|NCT02867163|Drug|Tranexamic Acid|Intravenous or local administration of TXA, in any dosage
45920406|NCT02972346|Drug|ACTH|routine treatment plus ACTH 0.4 Unit/kg/day (Maximum 25Unit) for three consecutive days every 4 weeks
45920407|NCT00092170|Drug|MK0826, ertapenem sodium|
45449649|NCT03548415|Drug|Placebo|Placebo administered subcutaneously.
45791410|NCT03002480|Other|Thromboelastography-Guided Treatment Regimen|"The thromboelastograph (TEG) will be used to determine the best bypassing agent for the management of subjects with severe hemophilia A with inhibitors. Patients will be assigned that bypassing agent and dose for the treatment of their bleeding episodes and subsequently will be followed for a period of 6 months to determine their annual bleeding rate."
45791411|NCT03835754|Device|OCS Heart System|The OCS Heart System preserves the heart in a near-physiological, beating state by perfusing the heart with a warmed, donor-blood based perfusate that is supplemented with nutrients and oxygen in a controlled and protected environment
45647202|NCT03939949|Behavioral|High Mindfulness|"Those in the high mindfulness group will also receive questions about their current pain intensity and unpleasantness in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their pain throughout the day and asked to report on how their pain is changing over time as a part of each text message prompt."
45791412|NCT04067609|Drug|Dexamethasone|subjects will receive a single administration of either 0.1 mg/kg of intravenous dexamethasone in 90mL of normal saline
45791413|NCT04067609|Other|placebo|100mL of normal saline (placebo)
45791414|NCT05671718|Other|Nurse-Led Treatment in Primary Care|At a primary care clinic intervention site, a nurse will be available once or twice weekly. The days/times will be dependent on clinic volume (i.e., cluster size), with scheduled rotations between PCCs. This rotation between PCC sites will mimic the physician's responsibilities/availability at a district hospital and creates parity between the trial arms. In this trial, we will have nurses dedicated to the management of RR-TB treatment, yet the volume at each site will not require the presence of a full-time nurse.
45791415|NCT03037203|Drug|JZP-110|75 mg, 150 mg, 300 mg
45791416|NCT03037203|Other|Placebo|
45791417|NCT03806738|Other|Intervention-specific Carevive questionnaire|includes standard of care questions with additional decision-making questions
45791418|NCT03806738|Other|Standard of Care questionnaire|includes the standard of care questions that are already in place for Carevive questionnaires
45791419|NCT01892267|Device|PEG-J placement|PEG-J placement
45791420|NCT03705104|Behavioral|EPIO|App for self-management of chronic pain An app consisting of 9 modules focusing on cognitive behavioral pain self-management.
45647203|NCT03939949|Behavioral|Low Mindfulness|"Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 9pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9pm text to report on their pain intensity and unpleasantness at that time."
45647204|NCT03939949|Behavioral|Active Control|"Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 9pm) asking them to report on the activity they are currently engaged in."
45647205|NCT04434599|Device|Fluoroscopically guided ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by fluoroscopy
45791421|NCT03022097|Drug|Aclidinium bromide/formoterol Fixed-Dose Combination|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination, twice per day via Genuair
45791422|NCT03022097|Drug|Aclidinium bromide|Inhaled Aclidinium bromide 400 μg, twice per day via Genuair
45791423|NCT03022097|Drug|Formoterol Fumarate|Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler
45791424|NCT03022097|Drug|Placebo|Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler
45791425|NCT03002636|Procedure|anesthesia|Anesthesia : (1) General Anesthesia (GA)(2) Epidural Anesthesia (EA) (3) Combined Spinal-Epidural Anesthesia (CSEA)
45791426|NCT03037281|Diagnostic Test|Septic|30mls of blood will be sampled by venepuncture, or sampled from indwelling lines (in the case of septic patients on intensive care). Blood will be sampled using standard techniques, and transferred to EDTA containing blood bottles, and undergo processing immediately.
45791427|NCT03002324|Behavioral|Baseline Survey|The baseline survey is a combination of the Vaccine Confidence Scale, and a short form of the Parents' Attitudes about Childhood Vaccines (PACV) Scale. Participants will be asked an additional 10 questions developed as a part of a behavioral phenotyping questionnaire to assess behavioral biases at baseline within the study population. Demographic information and intent to vaccinate will also be collected.
45920408|NCT00092170|Drug|Comparator: Ticarcillin/Clavulanate|
45449650|NCT00112385|Drug|Etanercept|Etanercept 50 mg will be injected subcutaneously once per week for 52 weeks
45449651|NCT00112385|Drug|Placebo|Placebo, contained in 50mg syringes, will be injected subcutaneously once per week for 52 weeks.
45449652|NCT03548337|Biological|13vPnC|13vPnC MultiDose Vial with preservative compared to a Prefilled syringe containing 13vPnC without any preservative
45647206|NCT04434599|Device|Contact force guided ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by contact force measurement and 3D electroanatomic mapping
45791428|NCT03002324|Behavioral|Current CDC Message|Participants randomized to the current CDC message arm will read a message taken almost directly from the CDC Vaccine Information Sheet (VIS) on HPV. This message was minimally altered for length and clarity.
45791429|NCT03002324|Behavioral|Cervical Cancer Message|Participants randomized to the cervical cancer messaging arm will receive a message developed by the study team to appeal tenants of the Health Belief Model (self-efficacy, perceived benefit) and on the purity tenant of the moral foundations theory.
45920409|NCT00006215|Biological|filgrastim|
45920410|NCT00006215|Drug|docetaxel|
45920411|NCT00006215|Drug|vinorelbine tartrate|
45920412|NCT00092287|Drug|lanreotide Autogel (somatostatin analogue)|
45920413|NCT00092287|Drug|Sandostatin long acting release (LAR) Depot (somatostatin analogue)|
45920414|NCT00092326|Drug|MK0966, rofecoxib|
45920415|NCT00092326|Drug|Comparator: oxycodone with acetaminophen, placebo|
45920416|NCT00092365|Drug|MK0966, rofecoxib|
45920417|NCT00092365|Drug|Comparator: celecoxib, placebo|
46071566|NCT00633048|Drug|NSA-789|
45791430|NCT03002324|Behavioral|Control Message|Participants randomized to the non-vaccine related control arm will read a bird-feeding passage.
45791431|NCT03002324|Behavioral|Post-Intervention Survey|The immediate post-intervention survey will include questions from the Vaccine Confidence Scale and the PACV short scale. Intent to vaccinate will be assessed.
45791432|NCT03037905|Device|SignatureSuite OR Integration System by STERIS Corporation|SignatureSuite OR Integration System by STERIS Corporation is a device that controls audio and visual components of the operating room environment in order to provide a more relaxing and calming operating room environment for patients prior to surgery and on emergence from anesthesia after surgery.
45791433|NCT03002402|Behavioral|Internet-based CBT-I|Internet-based cognitive-behavioral treatment for insomnia
45791434|NCT01893983|Behavioral|Motivational Coaching|Telephone-based Motivational Interviewing aimed at getting Veterans to engage or retain mental health treatment
45791435|NCT03037983|Device|Repetitive transcranial magnetic stimulation|rTMS is a non-invasive procedure, in which the administration of a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention will be administered in 20 sessions lasting 50 minutes each over the course of 2-6 weeks. Up to two sessions may be scheduled per day with a one-hour interval in-between.
45791436|NCT03037983|Device|Sham|Subjects will still attend treatment sessions as outlined in the rTMS intervention. However, the device will not deliver any stimulation to the subject.
45791437|NCT02988791|Dietary Supplement|probiotic (BIfidobacterium, BB-12®)|probiotic (Bifidobacterium, BB-12®)
45647207|NCT04434599|Device|Local impedance guide ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by local impedance measurement and ultra-high density 3D electroanatomic mapping
45791438|NCT02988791|Dietary Supplement|Placebo|Placebo
45791439|NCT03039543|Drug|Rocuronium|Intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2) neuromuscular blockade for patients with moderate neuromuscular blockade whereas intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade for patients with deep neuromuscular blockade.
45791440|NCT03039543|Drug|Sugammadex|Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2 and patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
45791441|NCT04047875|Drug|Norethisterone 10mg/day|NET-only pill (Norethisterone, Primolut-Nor®), 10 mg/day, 1 pill per day until 2 consecutive days without bleeding/spotting
45791442|NCT04047875|Drug|Placebo|Identically appearing placebo to Primolut-Nor®, 1 pill per day until 2 consecutive days without bleeding/spotting
45791443|NCT03610568|Behavioral|Growing up GREAT! Intervention|The Growing up GREAT! intervention is built around the socio-ecological model. For young adolescents, a suite of materials provides information and prompts discussion about puberty, gender equality, healthy relationships, violence, and other related themes during weekly club sessions. For parents, group sessions featuring six testimonial videos foster discussion around non-violent parenting, equal sharing of household tasks, and girls' education. Other materials for teachers, health workers, and community members complement the core toolkit materials.
45791444|NCT03002246|Other|Ultrasound Examination|Research volunteers will be invited to have a 2D/3D ultrasound research scan 4-7 days from delivery.This ultrasound scan will take approximately 30 minutes to complete.
45791445|NCT05662280|Device|Active Intermittent Theta Burst Stimulation|Standard iTBS protocol with active coil
45791446|NCT05662280|Device|Sham Intermittent Theta Burst Stimulation|Standard iTBS protocol with active coil
45791447|NCT02870205|Drug|GSP 301 NS|2 spray in each nostril twice daily for 14 days
45791448|NCT02870205|Drug|GOM-NS|2 spray in each nostril twice daily for 14 days
45920418|NCT00092404|Biological|measles, mumps, and rubella virus vaccine live|
45647208|NCT01101451|Drug|Cisplatin|Given IV
45647209|NCT01101451|Radiation|External Beam Radiation Therapy|Undergo radiotherapy
45647210|NCT01101451|Radiation|Intensity-Modulated Radiation Therapy|Undergo radiotherapy
45791449|NCT02870205|Drug|GMM-2 NS|2 spray in each nostril twice daily for 14 days
45791450|NCT02870205|Drug|GSP 301 placebo NS|2 spray in each nostril twice daily for 14 days
45647211|NCT01101451|Other|Laboratory Biomarker Analysis|Correlative studies
45647212|NCT01101451|Other|Quality-of-Life Assessment|Ancillary studies
45647213|NCT01101451|Other|Questionnaire Administration|Ancillary studies
45791451|NCT03002168|Dietary Supplement|Alpha-cyclodextrin|Alpha-cyclodextrin is approved by the Food and Drug Administration as a dietary ingredient.
45791452|NCT03002168|Dietary Supplement|Placebo|Placebo tablets identical in appearance to the active comparator
45791453|NCT03002168|Radiation|Triolein radiolabeled with 100 microcuries of 3^Hydrogen|A MicroCurie (µCi) is a measure of radioactivity.
45791454|NCT03002168|Radiation|Tripalmitin radiolabeled with 20 microcuries of 14^Carbon|A MicroCurie (µCi) is a measure of radioactivity.
45791455|NCT03002090|Dietary Supplement|Iron trained|"Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.~Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate."
45791456|NCT03002090|Dietary Supplement|Iron Untrained|1. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.
45920419|NCT00092404|Biological|Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|
45920420|NCT00006218|Drug|triapine|
45920421|NCT00092482|Biological|V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years|
45920422|NCT00092872|Drug|MK0557|
45920423|NCT00092911|Drug|DVS-233 SR|
45920424|NCT04728880|Drug|Remdesivir|This study is a retrospective trial to assess the efficacy of Remdesivir in adult patients diagnosed with COVID-19 in Mansoura University Isolation Hospital. In this study we will analyze the data collected during treatment.
45920425|NCT00006221|Drug|ixabepilone|
46071567|NCT00633048|Drug|placebo|
45791457|NCT03002090|Dietary Supplement|BZKL Trained|"BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.~Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate."
45791458|NCT03002090|Dietary Supplement|BZKL Untrained|1. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.
45791459|NCT03002090|Dietary Supplement|Placebo Trained|1. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate.
45647214|NCT03064919|Behavioral|Curriculum Testing|An evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals was developed by refining an existing curriculum. State-of-the art theories in early childhood science education, innovative virtual technology to provide more realistic simulations of hunger and fullness, and a parent training component to improve long-range sustainability were incorporated. This 9-wk intervention will be tested by forty children (ages 4-5). Key outcomes will be children's adjustment in intake in response to a first course (energy compensation) and children's intake of tasty snacks when not hungry (eating in the absence of hunger). Additionally, the investigators will measure other variables likely to impact the success of the curriculum, for example: child gender/age, parent feeding practices, parent education, infant feeding practices, child/parent weight status, and others.
45791460|NCT03002090|Dietary Supplement|Placebo Untrained|No intervention
45791461|NCT02328755|Drug|peg-IFN-α|
45791462|NCT02328755|Procedure|Hematopoietic Cell Transplant (HCT)|
45791463|NCT02328755|Drug|Tacrolimus|Calcineurin inhibitor administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis. Cyclosporine may be substituted if patients cannot tolerate tacrolimus.
45791464|NCT02328755|Drug|Methotrexate|Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.
45791465|NCT02870283|Drug|Lithium|
45647215|NCT03656627|Drug|Nivolumab|"Nivolumab will be given as an IV infusion every two weeks, in an outpatient setting. One cycle is a 28-day period, with Nivolumab given on days 1 and 15 of a 28-day cycle.~For each cohort, all patients will be dosed at 240 mg IV. There will be no dose de-escalation or escalation from this dose level."
45791466|NCT02870283|Drug|Valproic Acid|
45791467|NCT02870283|Drug|Carbamazepine|
45791468|NCT02931045|Drug|Ticagrelor|Comparison of ticagrelor with another antiplatelet drug (clopidogrel)
45791469|NCT02931045|Drug|Clopidogrel|Comparison of clopidogrel with another antiplatelet drug (ticagrelor)
45920426|NCT04576416|Other|AI augmented training and clinical feedback|"The educational platform has two modules:~The training module includes AI enhanced case training on a library of 10,000+ benign and malignant skin lesion cases each coupled to written learning modules. Participants will be able to track their progression through automatically generated performance statistics and discuss difficult cases with peers within the application.~Clinical feedback is defined as diagnostic feedback on all cases registered in the registration module. Feedback during the trial will be based on either histopathology or the consensus agreement of domain experts (if no biopsy is taken). Feedback on referred or dismissed skin lesions will be provided by independent experts in skin cancer diagnostics ( >10 years of experience) through a web-based review system developed by our group."
45920427|NCT00092950|Behavioral|Physical activity|
45920428|NCT00093028|Drug|CC-5013 (Revlimid™)|N/A Study Complete
45647216|NCT04773665|Biological|VBI-2902a|VBI-2902a is an intramuscular injection of VBI-2902a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
45647217|NCT04773665|Biological|Placebo|0.9% sodium chloride
45791470|NCT02224820|Biological|IdeS|Doses are administered in ascending doses
45791471|NCT03040011|Drug|Dexamethasone|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
45791472|NCT03040011|Drug|Bupivacaine|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
45791473|NCT03040011|Procedure|Bilateral Pudendal Nerve Block|Performed transvaginally. The ischial spines will be palpated transvaginally and the sacrospinous ligament identified as a firm band running medially and posteriorly from the ischial spine to the sacrum. The needle guide will be inserted and positioned against the vaginal mucosa on the sacrospinous ligament approximately 1 cm medial and inferior to the ischial spine. When the needle guide is properly positioned, the spinal needle is advanced approximately 1cm through the vaginal mucosa into the sacrospinous ligament. The needle will be aspirated to ensure no intravascular needle placement. With a negative aspirate, 5 milliliters of solution are injected. This same procedure will be performed on the contralateral side.
45920429|NCT00093028|Drug|bortezomib|N/A Study Complete
45920430|NCT00093067|Drug|daptomycin|
45920431|NCT00093184|Drug|Angiomax (bivalirudin) anticoagulant|
45920432|NCT00006224|Drug|gemcitabine hydrochloride|
45791474|NCT03040011|Procedure|Bilateral Levator Ani Muscle Injection|Performed transperineally. With thumb, superomedial aspect of obturator foramen is palpated 2-3 cm lateral to the clitoris. The index and middle finger are in the vagina to confirm obturator foramen. A spinal needle is inserted through the the obturator foramen into the obturator internus muscle. The needle is angled slightly posteriorly towards the ischial spine, parallel to the arcus tendineus levator ani and arcus tendineus fascia pelvis. The needle is advanced to the level of the ischial spine, the vaginal hand ensuring that the needle has not perforated the vaginal wall. Once the needle tip is at a depth of the ischial spine, aspiration is performed to ensure no intravascular needle placement. 5 milliliters of solution is injected along the length of the needle tract.
45791475|NCT03040011|Drug|Saline|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
45791476|NCT02225132|Drug|Hydroxyurea|"The precise mechanism by which hydroxyurea produces its cytotoxic and cytoreductive effects is not known. However, various studies support the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein.~The mechanisms by which DROXIA produces its beneficial effects in patients with sickle cell anemia (SCA) are uncertain. Known pharmacologic effects of DROXIA that may contribute to its beneficial effects include increasing hemoglobin F levels in RBCs, decreasing neutrophils, increasing the water content of RBCs, increasing deformability of sickled cells, and altering the adhesion of RBCs to endothelium."
45791477|NCT03598166|Diagnostic Test|Septin9|Septin9 is a FDA-approved blood test for colorectal cancer screening
45791478|NCT02223650|Device|Overminus treatment|2.50D overminus spectacles
45791479|NCT02223650|Device|Non-overminus treatment|spectacles without overminus or no spectacles
45791480|NCT03040479|Drug|lasmiditan 200 mg|single dose
45791481|NCT01895855|Biological|PXVX0200|Single dose; liquid suspension after reconstitution with buffer; 5x10^8
45791482|NCT01895855|Biological|placebo|
45920433|NCT00093223|Drug|Paclitaxel Nanoparticle Albumin Bound|Single or duel doses of 35mg/m^2 ABI-007, administered IV, administered after placement of denovo stent(s).
45647218|NCT04773665|Biological|VBI-2905a|VBI-2905a is an intramuscular injection of VBI-2905a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
45647219|NCT03064607|Other|Fluid collection|Fluids tested for biomarker S100beta
45647220|NCT04759703|Drug|Pramipexole|0.25 mg pramipexole tablets
45647221|NCT04759703|Drug|Placebo|Matching placebo tablets
45647222|NCT03595787|Procedure|Coaching and Habilitation|nutritional support, adapted physical activity and coaching
45791483|NCT03531164|Other|kAYAK ERGOMETER GROUP|Kayak ergometer training for 30 min 5 times a week for 6 weeks. The training includes a warming (pre charge) during 3 minutes, a training (charge) characterised by 3-5 intervals with medium to high intensity during 2-4 minutes and pauses of 1-2 minutes between active phases and 2 minutes of cooling down (post charge) to complete 30 minutes of training.
45791484|NCT03531164|Other|CONTROL GROUP|Proprioceptive neurofacilitation exercises focused in trunk control during 30 minutes 5 times a week for 6 weeks.
45791485|NCT03442400|Device|Volcano iFR/FFR Verrata Plus coronary pressure/flow wire|We will measure the degree of flow-limitation of intermediate severity coronary steonses using the iFR/FFR Verrata Plus coronary pressure/flow wire before and after transcatheter aortic valve replacement.
45920434|NCT00093223|Drug|Paclitaxel Nanoparticle Albumin Bound|
45920435|NCT00093223|Drug|Paclitaxel Nanoparticle Albumin Bound|35mg/35 infusion time is 3.5 minutes
45647223|NCT05087407|Procedure|Decomprssion and drainage seton|Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
45920436|NCT00093262|Drug|clevidipine|
45920437|NCT00093262|Drug|placebo|
45647224|NCT05087407|Procedure|Cutting seton|Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
45647225|NCT05086003|Combination Product|Combined kidney and bone marrow transplantation|Combined kidney and bone marrow transplantation
45647226|NCT05122247|Other|Machine learning algorithm|machine learning directed identification of chemotherapy patients at high-risk for emergency department acute care and/or hospitalization
45791486|NCT02872857|Drug|Placebo|Placebo will match drug capsules.
45791487|NCT02872857|Drug|8mg galantamine twice daily|Drug will be administered within 36 hours of hospitalization and continued for 90 days.
45791488|NCT02872857|Drug|12mg galantamine twice daily|Drug will be administered within 36 hours of hospitalization and continued for 90 days.
45791489|NCT03958409|Diagnostic Test|measurements to evaluate metabolic bone disease|The participants will be evaluated for a) Mineral metabolism: blood calcium, phosphorus, PTH, 25(OH) vitamin D; b) Bone turnover markers: bone-specific alkaline phosphatase, cross-linked C-telopeptide of type I collagen (CTx), and N-terminal propeptide of type I collagen (PINP); c) Bone Mineral Density using a Dual energy x-ray absorptiometry which is the standard method by which bone mass is measured clinically. The bone mass at the lumbar spine, wrist, hip and total body bone mass at 3, and 18 months.
45920438|NCT00093301|Drug|Levosimendan|
45920439|NCT00093301|Drug|Dobutamine|
45920440|NCT00093418|Drug|tipifarnib|Given orally
45647227|NCT05084131|Other|Use of an online questionnaire as follow-up after abdominal colorectal surgery|Patients were asked to complete a questionnaire via the institutional patient portal. Participants were also asked to upload a photo of their respective incisions. Participants then had an in-person follow-up visit.
45920441|NCT00387608|Drug|veliparib|
45920442|NCT00387608|Other|pharmacological study|
45920443|NCT00387608|Procedure|biopsy|
45920444|NCT00093457|Drug|sorafenib tosylate|BAY 43-9006 given orally at 400 mg BID in a 28 day cycle
45920445|NCT00093613|Drug|sorafenib tosylate|Given PO
45920446|NCT00093613|Other|pharmacological study|Correlative studies
45920447|NCT00093652|Drug|gefitinib|
45920448|NCT00093652|Drug|oxaliplatin|
45920449|NCT00093652|Procedure|conventional surgery|
45920450|NCT00093652|Procedure|neoadjuvant therapy|
45920451|NCT00093652|Radiation|radiation therapy|
45920452|NCT00006230|Drug|rubitecan|
45920453|NCT02964832|Device|Grasp method|
45791490|NCT03958409|Diagnostic Test|standard care|Blood tests (Ca, Phos, PTH- mineral lab, 25OHVitD);Pregnancy Test (if applicable); dual energy X-ray absorptiometry (DXA); Bone Biopsy only if clinically indicated; treatment as clinically indicated.
45791491|NCT02996318|Device|Paclitaxel coated balloon (SeQuent Please)|Paclitaxel coated balloon (SeQuent Please)
45791492|NCT02996318|Device|Sirolimus coated balloon|Sirolimus coated balloon
45791493|NCT00374673|Device|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation of the motor cortex (10 Hz) every day during 5 days then every week for 3 weeks then every two weeks for 2 months then every month for 3 additional months
45791494|NCT02219282|Other|Laryngeal Mask Unique insertion|Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than three years experience.
45791495|NCT03945461|Other|Chewing gum|xylitol based, peppermint flavored gum
45647228|NCT05090501|Behavioral|High Intensity Circuit Training|The participants will execute a 12-exercise High Intensity Circuit Training protocol. Each exercise will have an active part taking 30 seconds, in which exercisers are encouraged to do as many repetitions as possible, and a resting part taking 10 seconds in which the participants rest and are informed of the next exercise. Before and after the 12-exercise routine, the participants rate their affect, arousal and perceived exertion, while using a heart rate monitor and two IMU sensors on their arms and legs.
45791496|NCT02873481|Behavioral|Centering Pregnancy Care plus Yoga (CPC+Y)|Gentle prenatal yoga for 30 minutes at the end of the Centering Pregnancy Care session
45791497|NCT05197751|Biological|MSP3-CRM-Vac4All/ Alhydrogel®|The Investigational Medicinal Product (IMP) or in short Investigational Product (IP) is the MSP3-CRM-Vac4All/ Alhydrogel® vaccine
45791498|NCT03921281|Other|scalp acupuncture treatment|"The parameters for scalp acupuncture are set as follows:~Scalp acupoint selection: The Motor Area of Jiao's Scalp acupuncture and Si shencong (EX-HN1).~Acupuncture manipulation: Disposable stainless steel needles will be manually inserted in at an approximately 15-degree angle to a depth of 1.5-2.0 cm respectively along the upper point and middle point of the motor area on the scalp. The acupuncture direction of Si shencong (EX-HN1) acupoint is toward the Baihui (GV20) acupoint. the needles will be rotated for at least 200 revolutions per minute for 1 minute every 20 minutes for a total of 60 minutes.~Treatment course: three times a week, 12 weeks in total."
45791499|NCT03921281|Other|Rehabilitation Treatment|The children with CP will receive the conventional rehabilitation programs as mentioned above. The rehabilitation programs will be carried out three times a week (once every other day) for 12 weeks, and every time, the rehabilitation treatment (PT and OT) will last approximately for 1 hour. All rehabilitation treatments will be carried out by qualified therapists.
45791500|NCT02876055|Drug|Single shot interscalene nerve block|Peripheral regional anesthesia nerve block - Single shot interscalene nerve block
45647229|NCT05026801|Drug|Azithromycin plus hydroxychloroquine|All patients will receive active comparator. One group will receive placebo on D1-3 followed by active comparator D4-9, while the other group will receive active comparator D1-6 followed by placebo D7-9.
45647230|NCT03063047|Other|PD21871AA|A 100s size menthol cigarette.
45791501|NCT02876055|Drug|Continuous interscalene nerve block|Peripheral regional anesthesia nerve block - continuous catheter interscalene nerve block
45791502|NCT02876055|Drug|Local Infiltration Analgesia (LIA)|Injection of local anesthetic into the peri-articular tissues and intra-articular capsule in a systematic approach for orthopedic surgery
45791503|NCT02994602|Drug|Nestorone + Testosterone Combination Gel|The combined gel is a transdermal treatment that will be applied as three single applications to a male subject's arms and shoulders on three different treatment days. The formulation will be a hydro alcoholic gel containing about 1.43% T (14.3 mg T/g gel). About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume. The gel application volume will contain 62.5 mg of T that will deliver approximately 6 mg T to the body per day (Swerdloff et al., 2000; Wang et al., 2000). This gel volume will also contain 8.3 mg of NES that will deliver about 0.8 mg of NES to the body per day (NES 8 mg/d + T 60 mg/d (NES8/T60) gel).
45791504|NCT01897025|Device|real-tDCS with MI-BCI|As in Arm Description
45791505|NCT02934555|Drug|Ubiquinol|300 mg Ubiquinol (3 mL liquid Ubiquinol).
45791506|NCT02934555|Dietary Supplement|Ensure|50 mL Ensure
45791507|NCT03297710|Other|Quality-of-Life Assessment|Ancillary studies
45791508|NCT03297710|Radiation|Radiation Therapy|Undergo radiation therapy
45791509|NCT03297710|Drug|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
45791510|NCT04350671|Drug|Interferon Beta-1A|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Interferon-β 1a in COVID-19 patients.
45791511|NCT04350671|Drug|Lopinavir / Ritonavir|This Drug will be used in all arms as mandated by our governmental guidelines.
45791512|NCT04350671|Drug|Single Dose of Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
45791513|NCT03029507|Behavioral|ACT Enhanced ShipShape|The ACT components focus on: a) thoughts, feelings, and bodily sensations that are often present in the context of efforts to lose weight or improve fitness; b) limitations of previous efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness of experiences; and e) identification of personal values and setting and pursuing values-consistent goals in order to achieve improved quality of life.
45920454|NCT02964832|Device|Armband-in-hand method|
45920455|NCT02964832|Device|Armband-on-arm method|
45920456|NCT00093730|Drug|BMS-59926|
46071568|NCT02844842|Biological|Allergovac Poliplus|
46071569|NCT04533464|Biological|MultiStem|Intravenous Infusion
46071570|NCT04533464|Biological|Placebo|Intravenous Infusion
45647231|NCT03063047|Other|PD21872AA|A 100s size menthol cigarette.
45647232|NCT05020795|Procedure|Endovascular thrombectomy|Clot retrieval for large vessel occlusion in acute ischaemic stroke
45791514|NCT03029507|Behavioral|Standard ShipShape (SS)|The materials and format of the Standard SS-only protocol are based on recommendations from the Navy and Marine Corps Public Health Center. These include: a) education for nutrition and physical activity; b) creating and documenting goals for weight loss and physical fitness; c) a food diary to track eating habits throughout the program; d) developing behavioral strategies to initiate/maintain an exercise program; e) monitoring of physical activity (pedometer provided by the study); and f) identifying and overcoming personal triggers for over-eating.
45791515|NCT02935179|Dietary Supplement|White sweet potato diet|The diet were supplied 516 kcal daily
45791516|NCT03248258|Other|Qualitative Interview or Focus group discussions|"The purpose of this study is to identify factors that influence decision-making in treatment selection and the optimal approach for sharing information about prognosis and guideline-based care.~Secondly, to further understand patient perspective on the concept of de-escalation, in which patients reduce the amount of chemotherapy to avoid side effects and (2) consider how prognosis would impact their decision-making about reducing chemotherapy (as standard or care or within a clinical trial)."
45791517|NCT00374751|Drug|Samarium (153SM)|The Samarium is introduced into the vertebral cavity using a 2-way valve by the radiation oncologist. The cement is then introduced via the same 2-way valve into the vertebral cavity by the neurosurgeon.
45791518|NCT01898429|Device|SCC DBS|Deep Brain Stimulator
45791519|NCT02249000|Device|BIOVALVE prosthesis|Transcatheter Aortic Valve Replacement (TAVR)
45791520|NCT00374829|Behavioral|An IT-based patient follow-up and reminder system|
46071571|NCT02839434|Procedure|Blood sample|This blood sample does not require specific puncture because it is made on the occasion of a sample justified by the patient monitoring.
45791521|NCT03188822|Device|Bioabsorbable steroid releasing sinus implant|After completion of indicated frontal sinus surgery, patients will have a bioabsorbable steroid releasing implant placed in the frontal sinus opening, which will remain in place for 14 days.
45791522|NCT03188822|Device|Bioabsorbable nasal dressing impregnated with steroid|After completion of indicated frontal sinus surgery, patients will have a bioabsorbable nasal dressing impregnated with steroid placed in the frontal sinus opening, which will remain in place for 14 days.
45791523|NCT02876757|Drug|5ARI|Exposure to finasteride/dutasteride
45791524|NCT01899677|Other|distilled water|0.5 cc distilled water twice daily will be added to the breast milk or formula during 30 days
45791525|NCT01899677|Drug|symbiotic|Symbiotic 1/2 sachet twice daily will be added to the breast milk or formula during 30 days
45791526|NCT03044691|Behavioral|ResearchACTS software|screen patients for tobacco and nicotine product use (using the anticipate and ask components of the 6As) by having youth complete a tobacco and nicotine use screening tool using the ResearchACTS software.
45791527|NCT04850846|Drug|Metformin XR|Orally by mouth
45791528|NCT04850846|Other|Placebo|Orally by mouth
45791529|NCT05166083|Other|Testosterone Hormon Therapy|Testosterone isocaproate, ... ml, once per 21 days for 6 months period.
45791530|NCT04826354|Drug|Rosuvastatin and Ezetimibe|Rosuvastatin Versus Rosuvastatin plus Ezetimibe
45791531|NCT04826354|Drug|Rosuvastatin|Rosuvastatin
45791532|NCT03028961|Other|Stanford Letter|Receive and complete the Stanford Letter
45791533|NCT03028961|Other|Interview|Undergo semi-structured, research staff-led interview
45791534|NCT03028961|Other|Questionnaire Administration|Ancillary studies
45791535|NCT03028961|Other|CA Advance Health Care Directive Form|Receive and complete the CA Advance Health Care Directive Form
46071572|NCT00820963|Drug|temozolomide|Given orally
46071573|NCT00820963|Radiation|hypofractionated radiation therapy|Patients undergo hypofractionated radiotherapy
46071574|NCT00820963|Radiation|radiation therapy|Patients undergo standard radiotherapy
46071575|NCT02834676|Drug|Gelified Ethanol|Pain relief with chemonucleolysis by using gelified ethanol regard to age, sex, ASA score, and complications.
45647233|NCT03062735|Other|Inspiratory Muscle Training|The Inspiratory Muscle Training (IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure.
45791536|NCT03027323|Device|AxoTrack System|The AxoTrack system is a novel ultrasound guidance system intended to facilitate central venous cannulation (CVC) by a single operator as well as to reduce complications and time associated with CVC. The AxoTrack has a small ultrasound scan head which facilitates imaging of the subclavian vein.
45791537|NCT04743440|Device|Bronchoscopic endotracheal intubation through a supraglottic airway device|Prior to trial commencement, participants will be asked to watch a video demonstrating preparation and conduction of the procedure (bronchoscopic endotracheal intubation through a supraglottic airway device) in a patient not involved in the project. Afterwards they will submit an online test, examining knowledge of the procedure relating to the procedure checklist. After participants have watched the demonstration video and submitted the online test, trial investigator will demonstrate the procedure in the manikin; subsequently, they have the opportunity to train the procedure in the manikin with both Igel and Auragain - training estimated to take less than 30 minutes. Afterwards, they will have the opportunity to train the procedure on manikins, on their own discretion, as per usual standards for maintaining airway competence at the Anaesthesiology Department.
46071576|NCT00632840|Drug|Atorvastatin and fenofibrate|atorvastatin (40mg/day) fenofibrate (200mg/day)
46071577|NCT02834598|Device|high-density electroencephalography|Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
45647234|NCT03062735|Other|Sham Inspiratory Muscle Training|The Sham Inspiratory Muscle Training (Sham-IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 15% of maximal inspiratory pressure.
45647235|NCT03818659|Other|Self-Guided M.A.P. BP Improvement Program|Active Clinics randomized to the Self-Guided Arm will receive access to an AHA/AMA web platform that includes the posted M.A.P. materials and limited access to AMA Staff who are available to answer questions. The study team will facilitate access to staff by hosting a kick-off webinar for program participants that will include an orientation to the materials on the website, general advice and practical tips about what works for implementation, and time for answering questions and discussion with the group.
45791538|NCT04707794|Drug|Sevoflurane|Sevoflurane delivery will will be titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
45791539|NCT04707794|Drug|Desflurane|Desflurane delivery will be titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
45791540|NCT01899911|Device|Vital Signs Patch (VSP)|Infrared and red absorbance measurement
45647236|NCT03818659|Other|Full Support M.A.P. BP Improvement Program|"Active Clinics randomized to the Full Support Arm will receive online access to M.A.P. materials and orientation webinar and also a Practice Change Facilitator who will lead the health center clinical staff, site champions and physician leads at each clinic over the course of 6 months to support the implementation of the MAP Program. With support from an AMA Improvement Advisor, the Practice Change Facilitators will perform a baseline assessment of current workflows and assess each domain of M.A.P. The goal of the Full Support program is to help care teams develop skills and sustainable workflows that are effective at attaining and maintaining high levels of BP control."
45791541|NCT04701866|Other|Music|Music will be provided via headphones during all 6 ketamine treatments, beginning at the commencement of each infusion and ending 55 minutes later. On the day of each infusion, before the treatment begins, clinicians will discuss music choices with participants in order to select amongst one of several options that have been designed for this purpose (length, genre, intensity, etc.).
45791542|NCT04667312|Drug|Durvalumab|Durvalumab
45791543|NCT01900067|Device|BARRIER® EasyWarm Active Self-Warming Blanket|
45791544|NCT02995928|Procedure|Decompressive craniectomy|Decompressive craniectomy: All patients in the treatment group will receive decompressive craniectomy of at least 12 cm according to institutional guidelines and a published surgical protocol during the clipping surgery within 48 hours form the onset.
45791545|NCT02995928|Procedure|Best medical treatment|Best medical treatment: Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2012 and 2013 respectively.
45791546|NCT01902953|Drug|Lymphoseek and VBD Sln dissection|See detailed description of study design
45647237|NCT03789877|Other|Physical Activity|Participate in home-based walking program
45647238|NCT03789877|Other|Questionnaire Administration|Ancillary studies
45791547|NCT02902250|Procedure|Decompression|vertebral body decompression in compression fracture
45791548|NCT02902250|Procedure|Conservative Treatment|Conservative Treatment in vertebral compression fracture
45791549|NCT02759588|Biological|GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab|GL-ONC1 is a genetically-engineered oncolytic vaccinia virus, which is administered via intraperitoneal infusion as multiple doses.
45791550|NCT02219438|Drug|Bolus|An adductor canal catheter was inserted and ropivacaine 0.2% administered as hourly bolus doses of 8 mL each: one at time point zero and then on the hour for 7 additional doses.
45791551|NCT02219438|Drug|Basal|An adductor canal catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for a total of 8 hours.
45791552|NCT03045861|Drug|GSK2838232|GSK2838232 capsules will be supplied as swedish orange, unmarked capsule (50 mg), and white, unmarked capsules (10 mg) in high-density polyethylene bottles.
45791553|NCT03045861|Drug|Cobicistat|Cobicistat tablets 150 mg will be supplied as an orange, round, biconvex, film-coated tablet in bulk containers for individualized dosing.
45647239|NCT03789877|Procedure|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
45647240|NCT03789877|Procedure|Sham Intervention|Undergo sham rTMS
45791554|NCT01903187|Device|EnligHTN Renal Denervation|Renal artery angiogram plus bilateral renal denervation with the EnligHTN renal denervation system
45791555|NCT01903187|Procedure|Sham|Renal artery angiogram
45791556|NCT02249078|Drug|E6011|E6011 solution for injection
45791557|NCT02249078|Drug|Placebo|Placebo 2-mL vial solution for injection
45791558|NCT03029975|Behavioral|Resistance Training Exercise|Participants will undergo 10 weeks of progressive resistance exercise training while following their randomly assigned nutritional intervention.
45791559|NCT03029975|Behavioral|Beef Protein Consumption|Following each resistance training sessions, participants will consume either a 3oz or 6oz beef patty (corresponding to the randomly assigned nutritional intervention group). Participants will also be provided with beef protein powder and beef snack bars to help them achieve their assigned protein goals during the intervention period.
45791560|NCT02697344|Drug|Dexamethasone|Given PO
45791561|NCT02697344|Other|Laboratory Biomarker Analysis|Correlative studies
45791562|NCT02697344|Drug|Lenalidomide|Given PO
45791563|NCT02697344|Other|Pharmacological Study|Correlative studies
45791564|NCT02697344|Drug|R-(-)-Gossypol Acetic Acid|Given PO
45791565|NCT01903265|Drug|TNX-102 SL 2.8mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
45791566|NCT01903265|Drug|Placebo|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
45791567|NCT04594616|Device|Smartphone-delivered CBT for MDD|8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
45791568|NCT03049215|Device|Lumen Apposing Metal Stent (LAMS)|The AXIOS Stent and Electrocautery-Enhanced Delivery System is an endoscopic device designed to enable the ultrasound trained interventional endoscopist to deliver a transenteric stent between the gastrointestinal tract and a pancreatic pseudocyst.
46071578|NCT00829699|Procedure|euinsulinemic euglycemic glucose clamp|euinsulinemic euglycemic glucose clamp with lipid infusion 48 ml/hr for 4 hours
45791569|NCT03049215|Device|LAMS plus double pigtail stent|The AXIOS Stent and Electrocautery-Enhanced Delivery System is an endoscopic device designed to enable the ultrasound trained interventional endoscopist to deliver a transenteric stent between the gastrointestinal tract and a pancreatic pseudocyst. The double pigtail stent is a routinely used plastic biliary stent.
45791570|NCT03688139|Behavioral|Engage Therapy|"Engage therapy is designed to help individuals with depression become involved in activities they previously enjoyed but have not been participating in since developing depression. In Engage therapy, individuals with depression work with a therapist to develop action plans to pursue rewarding activities of their choice."
45791571|NCT03688139|Behavioral|Supportive Therapy|Supportive therapy is designed to provide a warm and supportive environment in which individuals with depression can feel comfortable expressing their thoughts and feelings. In supportive therapy, therapists help patients identify themes in their thinking, provide reassurance, emphasize coping skills, and provide guidance as needed.
45791572|NCT01907321|Behavioral|Expiratory muscle strength training|Small hand held device that provides calibrated (cmH20) resistance to expiratory pressure. Once sufficient pressure is achieved (participant blowing out into the device) a valve is released, letting air flow through.
45791573|NCT01907321|Behavioral|Placebo expiratory training|Device with the same look and feel as the active EMST, but which provides no resistance to airflow.
45791574|NCT01907321|Drug|Measures performed on all subjects|Capsaicin is a cough-inducing vapor that will be inhaled by participants to induce coughing. The airflow of the cough will be recorded and measures of compression phase duration, peak expiratory flow rate, and post-peak plateau phase will be made.
45791575|NCT01907321|Behavioral|Pulmonary function test|Measures of forced vital capacity (FVC) and Forced expiratory volume in the 1st second (FEV1), and the ratio between the two measures (FEV1/FVC). Also included is the measure of maximum expiratory pressure. Airflow from the voluntary cough will also be recorded and measured using the spirometric system. These measures will be identical to those made on the capsaicin-induced cough.
45791576|NCT01907321|Radiation|Fluoroscopic swallow study|Images from the swallow study will be used to determine the modified barium swallow impairment profile (MBSImp) score, as well as the penetration-aspiration score (PA).
45791577|NCT02940249|Dietary Supplement|Apple polyphenols|Drinks will be delivered in random order at 4 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
45791578|NCT02940249|Dietary Supplement|Placebo|
45791579|NCT02219516|Drug|RDEA3170|
45791580|NCT04580654|Biological|CSL312|Fully human immunoglobulin G4/lambda recombinant monoclonal antibody against Factor XIIa
45647241|NCT03511625|Drug|Acthar Injectable Product|Acthar is a non-specific melanocortin receptor agonist
45791581|NCT04976777|Device|Updated DEX PS DDS Applicator|Intravitreal Administration
45791582|NCT04976777|Device|Approved DEX PS DDS Applicator|Intravitreal administration
45791583|NCT04976777|Drug|Dexamethasone|Dexamethasone 0.7 mg in a solid polymer drug delivery system
45791584|NCT02247596|Drug|Resveratrol|1g tds 2 weeks
45791585|NCT02247596|Drug|Placebo|Sugar pill 1g tds for 2 weeks
45791586|NCT04522232|Procedure|conventional Total laparoscopic hysterectomy|"the ascending branch of the uterine artery was identified close to the isthmus then ligated at this level, close to the uterus or coagulated, using bipolar diathermy. The utero-vesical fold was dissected and the bladder was pushed down done, thus moving the ureters laterally, which decreases the risk of including them in a suture. The vasculature of the uterus is now secured and this is evidenced by the pale color of the fundus.~Using either bipolar diathermy or the harmonic ultracision, the cornual pedicles on one side were desiccated and cut. Also, both the uterosacral and cardinal ligaments were desiccated and cut. So that, the opposite side pedicles can be taken care of, the direction of manipulator was changed. The infundibulopelvic ligaments were desiccated and cut if it is necessary to remove both ovaries. A vaginal cuff was inserted into the vagina to identify the vault, which was then cut laparoscopically using a monopolar hook, where the specimen was completely detached."
45791587|NCT04522232|Procedure|Total laparoscopic hysterectomy with prior uterine artery ligation at its origin|"the uterine artery was dissected using the lateral approach; where dissection begins from the anterior leaf of the broad ligament. The triangle enclosed by the round ligament, external iliac artery, and infundibulopelvic ligament was opened. The areolar space was dissected and the origin of the uterine artery from the internal iliac and the ureter was identified. The uterine artery was then isolated from the surrounding structures and ligated by Hem-o-lok clips.~then same steps as conventional Total laparoscopic hysterectomy"
45791588|NCT03686657|Drug|Metformin|1000 mg metformin-HCL XR once-a-day or maintenance dose of metformin for 26 weeks
45647242|NCT03511625|Drug|Depo medrol|Depo medrol is an anti-inflammatory glucocorticoid
45647243|NCT03786991|Other|No intervention|No intervention
45647244|NCT04965727|Procedure|Device implantation|The intervention involves the insertion of lead electrodes (Medtronic SenSight Directional Lead) in the right and left lateral hypothalamus through craniotomy and an implantable pulse generator (Medtronic Model B35200 Percept™ PC) in the upper part of the pectoralis major (under the clavicle).
45791589|NCT03686657|Drug|Val, Cel and Met XR Low|500 mg metformin-HCL XR plus 100 mg celecoxib once-a-day in the morning and 160 mg valsartan 6 hours later once-a-day in the afternoon for 26 weeks.
45791590|NCT03686657|Drug|Val, Cel and Met XR High|1000 mg metformin-HCL XR plus 200 mg celecoxib once-a-day in the morning and 320 mg valsartan once-a-day 6 hours later in the afternoon for 26 weeks.
45791591|NCT02993510|Procedure|Microfracture|Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
45791592|NCT02993510|Device|Chondro-Gide sutured|Implantation of Chondro-Gide membrane using atraumatic sutures following microfracture via mini-arthrotomy
45791593|NCT02993510|Device|Chondro-Gide glued|Implantation of Chondro-Gide membrane using Fibrin glue following microfracture via mini-arthrotomy
45791594|NCT03587987|Device|Neopff|manual ventilation
45791595|NCT03587987|Device|rPap|Manual ventilation
45791596|NCT02476058|Drug|JNJ-42847922|JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
45791597|NCT02476058|Drug|Diphenhydramine|Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
45791598|NCT02476058|Drug|Placebo|Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
45791599|NCT03049917|Behavioral|Financial incentive|Conditional cash transfer upon HIV testing
45791600|NCT05473208|Device|Exoskeleton|Lumbar assistive exoskeleton evaluation
45791601|NCT03526835|Drug|MCLA-158|full-length IgG1 bispecific antibody targeting EGFR and LGR5
45791602|NCT02249156|Behavioral|Financial incentive for choosing a lower-cost provider|Employees of the intervention group receive money (either as a payment to their health savings account or directly as a check) if they obtain a radiology test or laboratory test from what a low-cost or rewards provider. The amount of money per test varies by the employer and type of test. A provider is identified as low-cost or rewards if their costs are in the lowest 10-20% among all providers in the community. Again there is a range because the relative cutoff has varied across the employers that have implemented this program.
45791603|NCT03050541|Drug|MDMA|This is a between subjects, double-blind, placebo controlled design. We are administering oral MDMA to healthy volunteers to measure its effects on the encoding, consolidation, and retrieval stages of memory.
45791604|NCT03050541|Drug|Placebo|
45791605|NCT02143466|Drug|Part A - AZD9291 in combination with AZD6094|Part A - AZD9291 and AZD6094 administered in different doses to investigate the safety and tolerability of this combination and define the combination dose for further clinical evaluation in Part B.
45791606|NCT02143466|Drug|Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)|Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in Asian subjects and to define the combination dose for further clinical evaluation in Part B.
45791607|NCT02143466|Drug|Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)|Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in non-Asian subjects and to define the combination dose for further clinical evaluation in Part B.
45791608|NCT02143466|Drug|Part A - AZD9291 in combination with intermittent selumetinib|Part A - AZD9291 and selumetinib (intermittent treatment) administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.
45791609|NCT02143466|Drug|Part A - AZD9291 in combination with MEDI4736|"Part A - AZD9291 and MEDI4736 administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.~Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study."
45791610|NCT02143466|Drug|Part B - AZD9291 in combination with AZD6094|Part B - AZD9291 and AZD6094 administered in the dose identified in Part A (AZD9291 80mg OD + AZD6094 600mg OD) to further investigate the safety and tolerability of this combination.
45647245|NCT05066009|Device|NextSense EEG-enabled earbuds|Each NextSense EEGBud device comes with a custom-fit earmold with biometric sensors to detect the EEG, motion (via tri-axial accelerometers), and heart rate. A unique custom mold is created employing a 3D printer to capture the geometry of a patients' ear and external auditory canal with a ring laser scanner to an accuracy of within 0.1 mm. This design process allows for a custom fit, and therefore both comfort and complete, consistent contact with the inner surface of the ear canal, providing high quality signal capture of brain activity, and head and eye movements.
45647246|NCT05066009|Device|Ellcie Healthy eyeglasses|Ellcie Healthy glasses frames are embedded with multi-modal sensors for measuring eye movements, head movement, and ECG.
45647247|NCT05066009|Other|Drug Holiday|Participants will not take their prescribed wakefulness promoting medication(s) for one day to complete the study assessments. Medications typically used to promote wakefulness include amphetamine salts (Adderall), armodafinil (Nuvigil), clarithromycin (Biaxin), flumazenil, methylphenidate (Ritalin), and modafinil (Provigil).
45791611|NCT02143466|Drug|Part B - AZD9291 in combination with selumetinib|Part B - AZD9291 and selumetinib administered in the dose identified in Part A (AZD9291 80mg OD + selumetinib 75 mg BD intermittent [4 days on/3 days off]) to further investigate the safety and tolerability of this combination.
45791612|NCT02143466|Drug|Part B - AZD9291 in combination with MEDI4736|"Part B - AZD9291 and MEDI4736 administered in the dose identified in Part A to further investigate the safety and tolerability of this combination.~Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study."
45791613|NCT02143466|Drug|Part C - AZD6094 monotherapy (Japan only)|Part C - AZD6094 monotherapy to assess the safety, tolerability and pharmacokinetics of the monotherapy of AZD6094 in Japanese patients with advanced NSCLC.
45791614|NCT02143466|Drug|Part C - AZD9291 in combination with AZD6094 (Japan only)|Part C combination cohort - AZD9291 80mg OD administered in combination with AZD6094 400mg OD (AZD6094 dose in which DLTs have not been identified in the Japanese monotherapy cohort) in order to confirm the safety, tolerability, pharmacokinetics and preliminary anti-tumor activities of this combination in Japanese subjects. The 400mg OD dosing schedule will be initiated in the first cohort. The dose may be subsequently reduced in further cohorts in response to emerging safety, or PK findings or other reasons identified in the savolitinib programme.
45791615|NCT02143466|Drug|Part D - AZD9291 in combination with AZD6094|Part D - AZD9291 80mg OD administered in combination with AZD6094 300mg OD to further evaluate the safety, tolerability, pharmacokinetics and antitumor activity in terms of ORR and PFS in patients with locally advanced or metastatic cMET positive EGFRm+ and T790M-negative NSCLC, following progression on EGFR-TKI treatment. The choice of AZD6094 dose of 300 mg is based on results from preclinical and clinical studies. Clinical testing of the 300 mg OD dose will enable better assessment of impact of lower AZD6094 exposure on overall tolerability and hepatotoxicity risk as well as exploration of the efficacy and overall safety profiles with a dose meaningfully lower than the current dose of 600 mg OD.
45791616|NCT01910831|Drug|DerMend Moisturizing Bruise Formula|DerMend Moisturizing Bruise Formula, a skin care cream containing a proprietary blend of retinol, ceramides, arnica oil, and alpha hydroxy acids and other ingredients.
45791617|NCT01910831|Drug|Non-active placebo control|Non-active placebo control
45791618|NCT03050619|Drug|Empagliflozin|
45791619|NCT03050619|Drug|Other SGLT2 inhibitors|
45791620|NCT03050619|Drug|Other non-insulin GLDs|metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists
45791621|NCT02071394|Drug|Xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.
45791622|NCT02071394|Other|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
45791623|NCT01911065|Biological|Zostavax™|In the Vaccination arm, healthy individuals will be vaccinated with the licensed zoster vaccine, Zostavax.
45791624|NCT04430348|Drug|PTX-35|Monoclonal antibody PTX-35
45791625|NCT04420130|Drug|Camrelizumab|Camrelizumab was administered 200mg iv every 3 weeks
45791626|NCT04420130|Drug|Chemotherapy|The chemotherapy regimen may be a standard regimen for routine treatment of advanced pancreatic cancer.
45791627|NCT04420130|Procedure|Ablation|First give pancreatic cancer patients with liver metastases to ablation of liver metastases
45791628|NCT01911221|Biological|rMenB+OMV NZ|Recombinant MenB with Outer Member Vesicle (OMV) from the New Zealand strain
45791629|NCT03050697|Device|HARMONI® Modular Toric Intraocular Lens|Two-component system consisting of a base and a separate toric optic
45791630|NCT03050697|Procedure|Cataract extraction with intraocular lens (IOL) implantation|Cataract removal via manual phacoemulsification, followed by HMTIOL implantation
46071579|NCT00829699|Procedure|euinsulinemic hyperglycemic glucose clamp|euinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
45647248|NCT03943693|Device|Double shock|Patients randomized to the dual shock group will have two near-simultaneous 200-Joule shocks delivered through the two sets of pads (antero-posterior position and right infraclavicular-axillary position). The first of these shocks will be synchronized. If the first attempt with this approach fails to terminate atrial fibrillation a second attempt will be made using the same approach. If the second attempt fails the dual shock approach will be considered to have failed and further treatment will be determined by the primary team/attending cardiologist.
45653133|NCT02622581|Other|data collection|Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.
45791631|NCT02995772|Drug|Aromatase Inhibitors (Arimidex)|Comparison of efficacy with chemotherapy
46071580|NCT00829699|Procedure|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
45653134|NCT01672801|Drug|Placebo|oral administration
45653135|NCT01672801|Drug|Nimodipine|oral administration
45791632|NCT02995772|Drug|Tamoxifen|Comparison of efficacy with chemotherapy
45791633|NCT02995772|Procedure|SOB|Comparison of efficacy with chemotherapy
45791634|NCT02995772|Drug|FAC|Comparison of efficacy with hormonal therapy
46071581|NCT00829699|Procedure|Hyperinsulinemic hyperglycemic glucose clamp|Hyperinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
45791635|NCT02995772|Drug|Aromatase Inhibitors (Femara)|Comparison of efficacy with chemotherapy
45791636|NCT02995772|Drug|Aromatase Inhibitors (Aromasin)|Comparison of efficacy with chemotherapy
45791637|NCT04280822|Drug|Neoadjuvant immunochemotherapy|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, >30min, 3week, 2 cycles~Surgery:~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).~After surgery/ maintain period:~JS001, 240mg ivgtt, d3, >30min, 3week (8 cycles at most)"
45791638|NCT03050775|Device|Heated Ventilator Circuit|active heat and humidification during anesthesia by warming inspire gases without a heat-moisture exchanger
45791639|NCT03050775|Device|Standard Ventilator Circuit|no active heat and humidification during anesthesia
46071582|NCT05334030|Device|High Swing Assistance|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~Sitting program - Min lean;~Standing program - Auto lean;~Step initiation program - ProStep+,~Training mode - Off,~SmartAssist option - 2Free;~Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
45791640|NCT02987465|Drug|Darbepoetin Alfa|Darbepoetin is not a study drug and is prescribed as part of routine treatment of anaemia in CKD1. Darbepoetin is licensed for use for the treatment of anaemia in the context of CKD. It will be provided as part of the standard clinical care of the renal patients in this study. Healthy Volunteers will not be treated with Darbepoetin.
45791641|NCT02987465|Drug|Acetylcholine|Acetylcholine is being used as a challenge agent in this study and assesses NO-mediated vasodilation
45791642|NCT02987465|Drug|Noradrenaline|Noradrenaline is being used as a challenge agent in this study and is an endogenous a1 adrenoceptor agonist
45791643|NCT02987465|Drug|BQ 123|BQ 123 is being used as a challenge agent in this study and is an (Endothelin A) ETA receptor agonist.
45791644|NCT04895579|Drug|Durvalumab|Durvalumab will be delivered at 10mg/kg via IV infusion at days 1 and 15 every 28 days or 1500 mg on D1, q4w.
45791645|NCT04895579|Drug|Copanlisib|Copanlisib will be delivered at various doses (30-60mg/kg) via IV infusion at days 1 and 15 every 28 days.
45791646|NCT03051633|Behavioral|Be Under Your Own Influence|School based anti-drug use communications campaign
45791647|NCT02227316|Drug|IV Ibuprofen|Uterine fibroid embolization
45449653|NCT05665335|Device|Renuvion APR System|"The treatment area is defined as superior most not to exceed a horizontal line from the superior aspect of the axilla to the midline; inferior most not to cross the junction of the breast with the abdomen (inframammary fold). Lateral border to the outermost curvature of the breast or a vertical line drawn from the preaxillary line to the IMF; medial most to the innermost curvature of the breast up to 1 cm lateral to the sternal midline. The procedure will be in the intradermal and subdermal planes in the full breast area, without penetrating the breast gland.~Renuvion APR System settings will be 60-70% Power, 1.5 LPM, and up to 6 retrograde or 3 antegrade/retrograde passes, with a minimum of 2 incision sites."
45449654|NCT03596151|Device|Click Device|A single-use device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for detection of deoxyribonucleic acid (DNA) from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in self-collected vaginal specimens.
45647249|NCT03943693|Device|Single shock|Patients randomized to single shock will then be treated initially with a 200 Joule shock through the antero-posterior pads only. A repeat attempt will be made using the same approach if the initial shock fails. If the second attempt fails, the single shock approach will be considered to have failed. Patients will be crossed over to dual shock therapy while under the same sedation episode. For cross-over patients, two near-simultaneous 200-Joule shocks will be delivered through the two sets of pads already in position. If this fails further treatment will be determined by the primary team/attending cardiologist.
45647250|NCT03493061|Drug|Irinotecan|Irinotecan 150 mg/m2 IV over 90 minutes on Day 1, 15
45791648|NCT02227316|Drug|IV Acetaminophen|Uterine fibroid embolization
45791649|NCT02227316|Drug|Intravenous placebo/Intravenous placebo|Uterine fibroid embolization
45791650|NCT00555971|Drug|Omalizumab|Subjects randomized to Omalizumab prior to aspirin desensitization
45791651|NCT00555971|Drug|placebo|Subjects randomized to Placebo prior to aspirin desensitization
45791652|NCT02943213|Drug|Chlorpromazine Hydrochloride|Chlorpromazine Hydrochloride (25 mg Tablet) - Generic US Applicant holder is USL Pharma Inc.
45647251|NCT03493061|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
45791653|NCT01850108|Drug|Thymoglobulin|"Day 9 - 0.5 mg/kg IV before BMT~Days 8 & 7 - 2mg/kg IV before BMT"
45791654|NCT01850108|Drug|Fludarabine|On Days -6 to -2 before BMT, 30 mg/m2/day IV
45791655|NCT01850108|Drug|Cyclophosphamide (CTX)|Days 6 & 5 before BMT, 14.5 mg/kg IV; 50 mg/kg each day on 3rd & 4th day after BMT
45791656|NCT01850108|Drug|Mesna|Days 3 & 4 after BMT: 40 mg/kg IV
45791657|NCT01850108|Drug|Sirolimus|Adjusted to maintain a serum trough level of 3-12 ng/mL, taken orally beginning on 5 days after BMT and taken to 1 year after BMT.
45791658|NCT01850108|Drug|Mycophenolate mofetil (MMF)|15 mg/kg orally with maximum dose 3 mg/day beginning 5 days after BMT and taken to day 35 after BMT
45791659|NCT01850108|Procedure|Bone marrow transplantation|Day 0 - Transplantation of hematopoietic cells derived from bone marrow of a donor to a recipient as treatment for hematologic disorders
45791660|NCT01850108|Radiation|Total body irradiation|200 cGy on the day before BMT. Radiation delivered to the entire body of the recipient to eradicate bone marrow cells in the recipient to prepare the recipient to receive the transplanted
45791661|NCT01822652|Genetic|iC9-GD2 T Cells - frozen|"Subjects will receive the iC9-GD2 T cells through an IV over 5 to 10 minutes.~Subjects will receive one of the following dose levels (cells/m2):~Dose Level 1 = 1 x 10^7~Dose Level 2 = 1 x 10^8~Dose Level 3 = 2 x 10^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
45791662|NCT01822652|Genetic|iC9-GD2 T Cells - fresh|"For subjects who will receive a fresh T cell product:~Dose Level 1 = 1 x 10^8~Dose Level 2 = 1.5 x 10^8~Dose Level 3 = 2 x 10^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
45791663|NCT01822652|Drug|Cytoxan|Cyclophosphamide (500 mg/m2/day x 2 days, for patients <12 kg = 16.7 mg/kg/day x 2 days)
45791664|NCT01822652|Drug|Fludara|Fludarabine (30 mg/m2/day x 3 days, for patients <12 kg = 1 mg/kg/day x 3 days)
45791665|NCT01822652|Drug|Keytruda|Pembrolizumab (2 mg/kg on Day -1 and on Day 21).
45791666|NCT01822652|Genetic|iC9-GD2 T cells|"For subjects who will receive a fresh T cell product:~Dose Level 1 = 1.5 x 10^8~Dose Level 2 = 2 x 10^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
45791667|NCT02987855|Procedure|Lipoaspiration|Closed syringe harvesting subdermal fat
45791668|NCT02987855|Procedure|ADcSVF isolation|Isolation of AD-cSVF from lipoaspirate via enzymatic digestion
45791669|NCT02987855|Procedure|Normal Saline IV|Normal Saline IV containing autologous AD-cSVF
45791670|NCT03052257|Behavioral|Educational - glaucoma|Discussion of glaucoma and the potential for blindness, facilitated by the glaucoma educator using a 3-dimensional model eye and photographic representation of glaucomatous vision loss; One-one-one demonstration of eye drop instillation techniques, Provision of a mnemonic aid which alerts the participant to missed doses; Review of the participant manual: An illustrated brochure on glaucoma and eye drop instillation. An individualized schedule for dosing of glaucoma medications. Individualized suggestions for improving adherence based on the subject's responses to the (SASES).
45791671|NCT03052257|Behavioral|Dose monitoring and reminder|"Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened. For participants in the intervention arm only, a reminder through AdhereTech will be activated."
45791672|NCT03052257|Behavioral|Educational - general|The control information session will include review of a Powerpoint presentation on general eye health, including but not specific to glaucoma.
45791673|NCT03052257|Behavioral|Dose monitoring|"Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
45791674|NCT01777802|Radiation|SBRT|
45791675|NCT01777802|Radiation|IMRT|
45791676|NCT01777802|Radiation|Brachytherapy|
45791677|NCT02249234|Drug|Botox|
45791678|NCT02249234|Drug|Placebo|
45791679|NCT05410106|Device|PneuX Endotracheal Tube|The PneuX Endotracheal Tube is a CE marked device produced by Venner. The purpose of this product is to provide invasive ventilation for patients in the ICU. The defining features of the intervention treatment are the multi-modal approach to prevent microaspiration during long term ventilation.
45647252|NCT03493061|Drug|Floxuridine|0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
45791680|NCT05410106|Device|Standard care (Taperguard, Covidien)|Standard care is to intubate patient using the Taperguard endotracheal tube (ETT). The Taperguard ETT is designed with a tracheal shaped cuff made of PVC. This has a single lumen subglottic port.
45791681|NCT03054051|Behavioral|Tumaini Mobile Phone Game|Tumaini is a scenario-based role-playing game application, optimized for use on low-cost Android smartphones. Participants will be invited to play the game for at least ten hours over a period of three weeks. The game is designed to: educate players about sexual health and HIV/AIDS; build risk-reduction skills and related self-efficacy for prevention of HIV/STIs and unintended pregnancy; challenge HIV stigma and harmful gender norms; and promote parent-child dialogue.
45791682|NCT01338740|Drug|Adalimumab and Infliximab|Patients with moderately to severely active Crohn's disease with primary non-response or loss of response to Adalimumab switch to Infliximab.
45791683|NCT04226768|Other|"Enhanced Haematology Palliative Care (Fast-track) Group"|Early and proactive multidisciplinary care
45791684|NCT04226768|Other|Conventional Care|Conventional care and referral as indicated
45791685|NCT02944461|Drug|Dapsone 7.5 % gel|Dapsone gel 7.5% applied once daily to truncal acne
45791686|NCT04737213|Drug|SGM-101|Fluorescence guided surgery
45791687|NCT04169282|Device|nPEP (non-invasive positive expiratory pressure) mask|Positive end expiratory pressure (PEEP) mask
45791688|NCT02945553|Device|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) will be performed 5 times/week for one hour each day. NMES will start within 1 week of injury and continue till 3 weeks following surgery.
45791689|NCT02945553|Device|Microstimulation|Microstimulation will be performed 5 times/week for one hour each day. Microstimulation will start within 1 week of injury and continue till 3 weeks following surgery.
45647253|NCT03809533|Drug|sofosbuvir/velpatasvir|12-week, oral, fixed-dose
45647254|NCT03410017|Other|Functional Listening Index|Functional Listening Index questionnaire to assess acquisition of listening skills.
45791690|NCT05376722|Drug|pamiparib|pamiparib 40 mg orally, twice a day
45791691|NCT05376722|Drug|abiraterone|biraterone acetate 1000 mg orally, once a day
45791692|NCT05376722|Drug|prednisone|prednisone acetate tablets (prednisone) 5 mg, once a day
45647255|NCT03654547|Drug|TT-00420|"TT-00420 is an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor microenvironment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors.~TT-00420 capsule will be administered once daily on a continuous schedule. A treatment cycle consists of 28 days.~The proposed dosage form for early clinical research is powder filled hard gelatin capsule (PIC) with dosage strengths as of 1 mg, 5 mg and 20 mg."
45791693|NCT05349500|Behavioral|OA CARE Intervention|"Once assigned, participants will be contacted by the OA CARE Navigator to coordinate initiating a YMCA Medical Membership. Then, YMCA personnel will contact the participant to schedule the first Weight Loss Program (Program) group session. The Program will be delivered in groups with other OA CARE participants. Participants will also have access to all exercise facilities and programs at the YMCA during the study, and will be assigned a YMCA health coach.~After initiation of the YMCA Medical Membership, the OA CARE Navigator will discuss participant's interests in referrals to other services related to osteoarthritis (OA) management. The Navigator will provide the participant's primary care provider (PCP) with a summary of this discussion and help the participant connect to any programs or resources that do not require provider referrals."
45647256|NCT04110613|Dietary Supplement|noFast: Start tube feeds within 1 hour of procedure|Earliest possible initiation of tube feeding after bedside PEG tube procedure.
45791694|NCT05349500|Behavioral|Usual Care control group|Participants assigned to the usual care group will receive no additional treatment from the study for about 12 months. However, this group will be offered a 12-month Medical Membership to a local YMCA after completing the final assessment.
45791695|NCT02946021|Device|Head and neck garments for pneumatic compression device|Pneumatic compression device cleared for use by patients who are under medical supervision for the treatment of 1) lymphedema (primary or secondary); 2) edema resulting from mastectomies, trauma, sports injuries or post immobilization; 3) venous insufficiencies; 4) wounds; and 5) stasis dermatitis, venous stasis ulcers, arterial leg ulcers and diabetic foot ulcers and treatment of head and neck lymphedema
45791696|NCT02946021|Drug|NIRFLI with ICG|Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic movement in subjects.
45791697|NCT03110601|Device|Control - Conventional SCS|Conventional SCS Parameters
45647257|NCT03516877|Behavioral|Enhanced Stress Resilience Training for Faculty Physicians|Enhanced Stress Resilience Training (ESRT) is derived from Mindfulness-Based Stress Reduction with modifications to language, activities and contextualization to tailor the training to physicians involved in the operating room environment. ESRT consists of 5 weekly 1-hour group classes and 2-4 hour retreat. Classes focus on developing sustained attention and open monitoring in addition to training focused on stress and coping. Increasing duration (3-20 minutes per day) of guided mindfulness exercises are assigned each week. A 2-4 hour intensive retreat occurs at week 4 or 5. The central exercises of the training are the body scan, sitting meditation, qi gong and yoga. The weekly teaching sessions will be offered at various days and times each week in order to accommodate complicated physicians schedules that vary at each site. Participants can attend whichever session is most convenient. Daily practice will occur independently, with the duration reported weekly through text or email.
45647258|NCT04800523|Device|UroMonitor System|Implantable device to wirelessly and without catheters monitor the neurogenic bladder on an ambulatory basis
45791698|NCT03110601|Device|Test - Stimgenics SCS|Stimgenics SCS Parameters
45791699|NCT04737057|Procedure|SDF|Apply this topical medication through : 1)Dry with a gentle flow of compressed air to decayed tooth surfaces. 2) Bend micro sponge brush to remove excess liquid before application apply SDF directly to only the affected tooth surface. 3) Apply the SDF material 4)Dry with a gentle flow of compressed air for at least one minute. and Remove excess SDF with gauze
45791700|NCT04737057|Procedure|Hall technique|this technique is performed through :1) Orthodontic separator being stretched between two pieces of floss, then placed between the contact points of primary molars (for five days.) 2)The correct size of crown will not impinge on the teeth on either side, and a slight 'spring back' will be felt when the PMC is gently pushed up to (but not through) the contact points and the PMC has been filled with a Riva self-cure capsule cement, extruded cement is quickly wiped away and the child is asked to keep biting on the crown for two minutes, until the cement is set, to prevent 'spring back' of the PMC from the fully seated position
45791701|NCT03111381|Drug|Toradol|IV toradol
45791702|NCT02946489|Drug|CI-581a|CI-581a will be administered in wk2 and potentially in wk 3 or 4.
45791703|NCT03059901|Other|Caminamos App|Mobile phone that encourages Latina women to walk together through social support.
45791704|NCT02949141|Device|Lung Ultrasound|All patients will receive lung ultrasound, chest x-ray and computed tomography
45791705|NCT02949141|Device|Chest X-ray|All patients will receive chest x-ray as per usual care for evaluation for pneumonia
45791706|NCT02949141|Device|Chest Computed Tomography (CT)|All enrolled patients will receive a CT scan as the gold standard for diagnosing pneumonia
45791707|NCT02949921|Device|Radiesse injectable implant and 2% lidocaine HCL|Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
45647259|NCT04654897|Drug|[14C]-NT-814|120 mg radioactive labeled elinzanetant ([14C]-NT-814) oral suspension containing NMT (not more than) 5.6 MBq (megabecquerel) [14C].
45647260|NCT03236077|Behavioral|Fit and Fab|participate in a targeted exercise program at the YMCA. Will include: Targeted exercise classes, Strength-training, Group support sessions
45653136|NCT04939259|Device|New Music Program|A mini behind-the-ear hearing aid that amplifies sounds and directs them into the ear. The music program within the hearing aid will provide amplification specifically tuned for listening to music.
45653137|NCT04939259|Device|Standard Listening Program|A mini receiver-in-the-ear hearing aid that amplifies sounds and directs them into the ear. The standard listening program within the hearing aid will provide amplification specifically tuned for listening to speech and daily general sounds in the environment.
45791708|NCT03112473|Behavioral|Task-orientated training|Task-Oriented Training (TOT) is a goal-directed exercise therapy, which help the people derive optimal control strategies for solving specific motor problems in real environment. In this study, TOT included stretching exercises, mobilizing exercise, strengthening exercises, seated reaching tasks, dexterity training and bimanual practice.
45791709|NCT03112473|Device|Transcutaneous electrical nerve stimulation (TENS)|The stimulator was 120z Dual-Channel TENS Unit (ITO PHYSITHERAPY&REHABILITION CO., LTD, Tokyo, Japan). The parameter (100 Hz, 0.2 ms square pulses, intensity barely below the motor threshold) of TENS followed our previous study
45653138|NCT05080257|Device|Lung Ultrasonography|"The ultrasonography will be done using the curved probe of the SONOACE R3 SAMSUNG ultrasonography machine, SN: S0GYM3HCC00016M, manufacture date: 12-2012.~Assessment of lung condition using the Lung Ultrasonography Score (total score calculated from the 12 standard examined areas, from 0 to 3 in each area, with a minimum of 0 up to 36)"
45791710|NCT03112473|Device|Sham electrical nerve stimulation|A identical-looking TENS devices that electrical circuit has been disconnected.
45791711|NCT02227706|Biological|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
45791712|NCT02227706|Device|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
45791713|NCT03112863|Drug|Bakuchiol|This group will receive bakuchiol
45653139|NCT05729269|Diagnostic Test|Sarcopenia_CT|measurement of skeletal muscle through abdominal computed tomography
45791714|NCT03112863|Drug|Retinol|This group will receive retinol
45791715|NCT02228174|Device|Intrauterine Ultrasound-Guided Radiofreq. Ablation System|The Sonata System combines intrauterine ultrasound (IUUS) with radiofrequency (RF) ablation in a single handpiece. Sonata is suitable in an inpatient or outpatient setting, and is intended for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, including those associated with heavy menstrual bleeding(HMB).
45791716|NCT02950467|Drug|Psilocybin|One individual oral psilocybin treatment session
45791717|NCT02950467|Behavioral|Modified brief Supportive Expressive Group Therapy|Ten sessions of twice-weekly manualized group therapy
45791718|NCT02280317|Drug|VAL201|VAL201-001 Sub-cutaneous injection.
45791719|NCT02249312|Drug|BIIL 284 BS|
45791720|NCT02249312|Drug|Placebo|
45791721|NCT01930487|Dietary Supplement|dietary supplement with antioxidants|Formulation contains vitamins, a mineral, dietary antioxidants, amino acids, polyphenols and polyunsaturated fatty acids
45791722|NCT01930487|Dietary Supplement|Placebo|Placebo - Softgels manufactured to mimic the appearance of active, dietary supplement with antioxidants
45791723|NCT03060759|Device|Light Therapy box|"The light box used for LT (SunRay by The Sunbox Company, Gaithersburg, Maryland, USA) is approximately 15.5 tall x 23 wide x 3.25 deep and is designed to stand on a desk or tabletop. It can be used both in the home or office. The light is delivered at a downward angle to maximize the effectiveness. The box runs on 124 watts and contains full spectrum 5000k 10,000 lux bulbs."
45791724|NCT02247674|Procedure|Bilateral movement training|Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
45791725|NCT03864068|Other|Placebo|Placebo
45791726|NCT03864068|Drug|Inositol|1gm/bid, 2gm/bid or 3gm/bid of Inositol powder
45791727|NCT03063255|Drug|Obturator block|Subjects allocated to the obturator block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to post-anaesthesia care unit (PACU) or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
45653140|NCT04787861|Other|motorized movement therapy|The study group received an aerobic exercise regimen using a motorized movement therapy device 3 times /week in addition to the same traditional program used with the control group.
45653141|NCT05522803|Device|TMS followed by sham TMS|Transcranial Magnetic Stimulation followed by sham TMS
45791728|NCT03063255|Drug|Neuromuscular block|Subjects allocated to the neuromuscular block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to PACU or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
45791729|NCT05249114|Drug|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
45791730|NCT05249114|Drug|Lu-177|Currently, the only FDA-approved PRRT consists of dotatate, a somatostatin analogue, radiolabeled with Lutetium-177 (Lu177), a beta-minus emitter (brand name Lutathera). Lu177 induces cell death via DNA strand breaks, caspase-3 apoptosis, and interfering with DNA-PK expression (which is associated with DNA repair). PRRT with Lu-177 DOTATATE is a targeted, intravenous therapy inducing DNA damage by delivering ionizing radiation to somatostatin receptor positive tumors.
45791731|NCT03065205|Device|Propeller Health device + asthma navigator|The patients will be monitored using the propeller health device for 6 months. The patients will be contacted at 2 month intervals by an asthma health educator to discuss barriers to adherence to asthma medications
45791732|NCT05245292|Drug|3BNC117-LS|Intravenous infusion of 3BNC117-LS at 30 mg/kg
45791733|NCT05245292|Drug|10-1074-LS|Intravenous infusion of 10-1074-LS at 10 mg/kg
45791734|NCT05245292|Drug|N803|Subcutaneous injections of N803 at 6 mcg/kg
45791735|NCT01930643|Device|EMS|HELEX 573 : strength aggravation mode with middle frequency carrier(1500Hz), minimal voltage for visible muscle contraction(maximum output is 75mA) , 32 minutes per day.
45791736|NCT03115827|Drug|Droxidopa|Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
45791737|NCT03115827|Drug|Carbidopa|Carbidopa 200mg twice a day
45791738|NCT02993432|Device|Foley catheter filled to 80cc|A Foley catheter is inserted through the cervix and filled to 80cc
45791739|NCT02993432|Drug|prostaglandin of the clinician's choice|Insertion of the prostaglandin (Prostin (1mg dinoprostone vaginal gel) or Cervidil (10mg vaginal slow release insert)) of the clinicians choice into the vagina for the purpose of cervical ripening
45791740|NCT03694028|Other|Limb Loading|Participants will be assigned to one of two interventions. The intervention will occur 3 times a week for six weeks (18 sessions) each session for one hour.
45653142|NCT05522803|Device|Sham TMS followed by TMS|Sham Transcranial Magnetic Stimulation followed by TMS
45791741|NCT03694028|Other|Conventional Training|Participants will be assigned to one of two interventions. The intervention will occur 3 times a week for six weeks (18 sessions) each session for one hour.
45791742|NCT01915823|Drug|azelastine hydrochloride and fluticasone propionate|
45791743|NCT01915823|Drug|Dymista vehicle|
45791744|NCT03065283|Procedure|Diaphragm lift|The purpose is to generate the stretch of the peripheral fibers of the diaphragm, being performed with the patient in the supine position and the physiotherapist standing on the patient's head and Pulling the Your costal arch In the cephalic direction, for one minute, twice
45791745|NCT03065283|Procedure|Relaxation of the diaphragm pillars|Second technique aims to promote the rhythmic stretching of the double psoas diaphragm pillars, being performed with The patient in the ventral position and the therapist standing at his side placing the ulnar border of his cephalic hand on the last ribs and his caudal hand flattened in front of the popliteal fossa of the popliteal fossa, stretching was done for one minute
45791746|NCT05199194|Drug|Tenecteplase|Intravenous thrombolysis with tenecteplase 0.25mg/kg
45791747|NCT05199194|Drug|Placebo|Intravenous administration of placebo, matching the volume of tenecteplase 0.25mg/kg
45791748|NCT03068091|Device|Chest CT|Inspiration and expiration chest CT
45791749|NCT03068091|Diagnostic Test|Pulmonary Function Testing|Measure lung function
45791750|NCT05014880|Behavioral|ICR (Intensive Cardiac Rehabilitation)|Participants in this arm will not have to adopt a 10-hour eating window while taking part in UCSD's 9-week ICR program.
45791751|NCT05014880|Behavioral|ICR x TRE (Intensive Cardiac Rehabilitation x Time-Restricted Eating)|Participants in this arm will adhere to a daily, consistent 10-hour eating window while undergoing UCSD's 9-week ICR program to see if there is an improvement on cardiometabolic parameters.
45791752|NCT04978454|Biological|Influenza RG-A/Texas/71/2017 (H3N2) Challenge|RG-A/Texas/71/2017 (H3N2) is an infectious influenza virus and requires handling at BioSafety Level 2. The challenge virus will be administered intranasally in a volume of approximately 0.5 mL per nostril. Intranasal challenge will be carried out using the Intranasal Mucosal Atomization ( MAD Nasa(TM)) Device attached to a 1 mL syringe.
45791753|NCT04978454|Other|Placebo|Sucrose phosphate glutamate (SPG) inoculum
45791754|NCT03116841|Drug|Vonoprazan|Vonoprazan 20 mg
45791755|NCT01916681|Device|Cervical Foley & Misoprostol|A cervical foley combined with misoprostol will be used to induce the patient.
45791756|NCT01916681|Drug|Misoprostol Alone|Misoprostol will be used alone to induce the patient
45791757|NCT01916681|Device|Cervical Foley Alone|A cervical foley alone will be used to induce the patient
45791758|NCT01916681|Device|Cervical Foley & Pitocin|A cervical foley combined with pitocin will be used to induce the patient
45791759|NCT05735951|Drug|STIRIPENTOL oral administration|"Oral administration of:~Days 1 and 2: 1000 mg of stiripentol (single dose at the end of breakfast),~Day 3 to Day 14: 1000 mg of stiripentol bis in die (BID) (approximately 12 hours apart, at the end of breakfast and at the end of dinner),~Day 15: 1000 mg of stiripentol (single dose at the end of breakfast)."
45791760|NCT01917773|Drug|Octreotide|Average MI for all patients was calculated over 15-minutes, 30-minutes and 45- minutes before and after administration of octreotide
45791761|NCT01917773|Drug|Bisacodyl|
45791762|NCT02283749|Biological|Xofigo|This is a radio-isotope
45653143|NCT05612087|Device|Confocal laser endomicroscopy|Confocal laser endomicroscopy at jejunum, duodenum and stomach
45653144|NCT05114187|Other|Education Intervention|"Participants in the intervention group will be provided e-learning about dementia and promoting brain health, consisting of the following components:~Ten selected multimedia e-learning lessons;~A series of 16 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lessons.~Participants will have 8-weeks to complete the intervention. The total time to complete is approximately 5-6 hours."
45791763|NCT01934231|Drug|Amoxicillin-Potassium Clavulanate Combination|The drug is available in two sachets (CVA/AMPC Dry Syrup 0.505 g and CVA/AMPC Dry Syrup 1.01 g). CVA/AMPC Dry Syrup 1.01 g sachet contains 42.9 mg of Potassium Clavulanate and 600 mg of Amoxicillin Hydrate. It is a white to yellowish white powder and has strawberry flavor and it is white to yellowish white suspension when it is suspended before use.
45791764|NCT01935791|Other|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Vehicle|Temperature
45791765|NCT01935791|Drug|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Glucagon|Hormone
45791766|NCT01935791|Other|Period 1 Visit 1 - Cold PET-CT Vehicle, no visit 2 as BAT negative|Temperature
45791767|NCT01935791|Drug|Period 2 - Visit 1 Warm Control vehicle, Visit 2 Warm Glucagon, Visit 3 Cold control|Hormone
45791768|NCT01935791|Drug|Period 2 - Visit 1 Warm Glucagon, Visit 2 Cold control , Visit 3 Warm control|Hormone
45791769|NCT01935791|Drug|Period 2 -Visit 1 cold control, Visit 2 warm control, Visit 3 Warm glucagon|hormone
45791770|NCT01935791|Drug|Period 2 -Visit 1 cold control, visit 2 warm glucagon, visit 3 warm control|hormone
45791771|NCT01935791|Drug|Period 2- Visit 1 Warm glucagon, visit 2 warm control, visit 3 cold control|hormone
45791772|NCT01935791|Drug|Period 2 - Visit 1 Warm control, visit 2 cold control, visit 3 warm glucagon|Hormone
45791773|NCT01936259|Device|Mini Stem|The humeral stem component is manufactured from Ti6Al4V alloy. The taper has a machine finish and accepts the taper adaptor of the humeral head component. The proximal region of the bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy, while the distal portion is polished. Seventeen stem diameters are available - 4 mm to 20 mm, in 1-mm increments.
45791774|NCT01936259|Device|Nano|The stemless humeral component is manufactured from Ti6Al4V alloy. It consists of a central tapered region and six outer wings. The taper has a machine finish and accepts the taper adaptor of the humeral head component. A small groove is included just below the taper to accept an inserter/impactor. The bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy for cementless fixation in the proximal humerus. Six sizes are available - 30 mm, 32 mm, 34 mm, 36 mm, 38 mm, and 40 mm.
45791775|NCT05735873|Other|Low-energy diet|Twenty-one pre-made, low-energy meals delivered weekly to the subject for 12 weeks.
45791776|NCT05735795|Other|Carbon Black Tattoo|SPOT ENDOSCOPIC MARKER is an FDA (American Food and Drug Administration) approved Carbon Black Tattoo paint that has been used for a long time to mark lesions in the gastrointestinal tract.
45791777|NCT01937195|Device|AccuCath Intravenous Catheter System|AccuCath IV Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal. Results will be compared to published literature for conventional IV catheters.
45791778|NCT03068949|Biological|FluBlok|FluBlok trivalent Influenza Vaccine .5 mL given Intramuscularly
45791779|NCT03068949|Biological|Fluzone|Fluzone Quadrivalent Influenza Vaccine .5 mL given intramuscularly
45791780|NCT03068949|Biological|FluCelVax|FluCelVax Quadrivalent Influenza Vaccine .5 mL given intramuscularly
45791781|NCT03068949|Biological|Fluzone HD|Fluzone HD Trivalent High Dose Influenza Vaccine .5 mL given intramuscularly
45791782|NCT03074409|Drug|oxytocin|self-administration of oxytocin (nasal spray)
45791783|NCT03074409|Drug|placebo|self-administration of placebo (nasal spray)
45791784|NCT00374439|Behavioral|Cognitive-behavioral|Cognitive-behavioral approach
45791785|NCT00374439|Behavioral|Interpersonal Therapy|Interpersonal therapy approach
45791786|NCT02955147|Drug|Ustekinumab|Ustekinumab is a humanized monoclonal antibody that targets the p40 subunit of IL-12 and IL-23 and inhibits cytokine - cytokine receptor coupling and signaling
45791787|NCT02955147|Drug|Prednisone|Prednisone is an anti-inflammatory medication
45791788|NCT03119025|Biological|Autologous DC-vaccines|"Patients will be vaccinated via intracutaneous injection of autologous DCs (5×106) combined with adjuvant subcutaneous injection of recombinant hIL-2 (250 000 IU).~Initiating course: one vaccination per week, during 1 month. Maintaining course: one vaccination per month, during 6 month. Patients will be monitored in a 2 months (after completing of initiating course), 7 months (after completing of maintaining course) and 13 months (in a 6 months post-vaccination follow-up)."
45647261|NCT05358925|Other|Psychoeducational Videos|"A total of ten videos will be delivered daily Monday-Friday over approximately 2 weeks (days 1-15). The videos will each feature a mental health professional who is an expert in BPD explaining the topic in relatable language that can be understood by the general public. Each video will be approximately 10-12 minutes long, for a total of ~120 minutes of video. Videos will be shared via a hyperlink in a text message.~The psychoeducational videos will cover the following topics: the history of the diagnosis of BPD and current diagnostic criteria, challenging BPD-related stigma, developmental pathways to BPD and biological predisposition, prevalence of BPD and its common comorbid disorders, the naturalistic course of BPD without treatment, available psychotherapeutic treatment options for BPD, current research on the neurobiological and genetic markers related to BPD, the interpersonal hypersensitivity model of BPD, lifestyle changes that are beneficial for people with BPD"
45791789|NCT03119181|Drug|Tymbion Lidocaine/epinephrine solution|The external ear canal will be filled with Tymbion drug solution
46071583|NCT05334030|Device|Neutral Swing Assistance|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~Sitting program - Min lean;~Standing program - Auto lean;~Step initiation program - ProStep+,~Training mode - Off,~SmartAssist option - 2Free;~Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
45791790|NCT03119181|Combination Product|Device: Iontophoresis System (IPS) with Drug: Tymbion lidocaine/epinephrine solution|The external ear canal will be filled with Tymbion drug solution. The Iontophoresis System (IPS) will be used to deliver current to the Tymbion solution to facilitate drug penetration into the tympanic membrane (TM) tissue to anesthetize (numb) the TM
45791791|NCT03119571|Procedure|Initial CCL admission|Admission to the cardiac catheterization lab to evaluated coronary artery disease and if present fix the culprit lesion/lesions
45791792|NCT03119571|Diagnostic Test|Initial ICU admission|Evaluate for additional testing and/or procedures
45791793|NCT01691534|Drug|TMC207 (J)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14
45791794|NCT01691534|Drug|PA-824 (PA)|PA-824 200mg Days 1-14
45791795|NCT01691534|Drug|pyrazinamide (Z)|1500mg Days 1-14 Dosed by Weight
45791796|NCT01691534|Drug|clofazimine (C)|clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14
45791797|NCT01691534|Drug|Rifafour|Rifafour e-275 mg dosed by weight
45791798|NCT04967066|Diagnostic Test|Serum Levels of Adipocytokines|Serum leptin and adiponectin: venous blood samples (3 ml) will be obtained from children with FS (within 3 hours of seizures) as well as the two control groups. The serum will be obtained by centrifugation at 3,500 rpm for 5 min at 4 ℃. The serum will be immediately separated and stored at -70 ℃. Serum leptin and adiponectin will be assessed through enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions.
45791799|NCT04959344|Biological|Kleb4V target dose|Two doses of the non-adjuvanted Kleb4V target dose will be administered intramuscularly 2 months apart
45791800|NCT04959344|Biological|Kleb4V target dose + AS03|Two doses of the adjuvanted Kleb4V target dose will be administered intramuscularly 2 months apart
45791801|NCT04959344|Biological|Kleb4V low dose|Two doses of the non-adjuvanted Kleb4V low dose will be administered intramuscularly 2 months apart
45791802|NCT04959344|Biological|Kleb4V low dose + AS03|Two doses of the adjuvanted Kleb4V low dose will be administered intramuscularly 2 months apart
45791803|NCT04959344|Biological|Placebo|Two doses of the Placebo will be administered intramuscularly 2 months apart
45647262|NCT05358925|Other|Neuropsychological Feedback|In the second phase of the study, participants randomized to the Feedback condition will receive an email with a personalized summary of their symptom endorsement and neuropsychological performance. The feedback will include the relevant scores or sub-scores for each cognitive test (CPT, RMET, BEST, DST) from all time points. For each score and sub-score, there will be a description of the cognitive domain that the metric assesses (e.g., attention span in the CPT). The investigators will tailor the feedback to each participant's scores. The investigators may adjust the format or wording of the feedback based on participant responses (i.e., if a participant alerts the investigators that some wording is unclear or confusing). The investigators may also alter the feedback if they learn new information about the relevance or interpretability of these cognitive tests, as this is a growing field of research.
45791804|NCT01691690|Drug|Acetaminophen (paracetamol)|Acetaminophen IV (15 mg/kg).
45791805|NCT01691690|Drug|Normal Saline Flush|Saline placebo will be infused intraoperatively.
45791806|NCT01691690|Drug|Midazolam|Midazolam (0.5mg/kg to maximum dose of 20mg) given 15-20 minutes before induction.
45791807|NCT01691690|Drug|Sevoflurane|Sevoflurane for anesthesia induction.
45791808|NCT01691690|Drug|Nitrous Oxide/Oxygen|Combination of NO2 & O2 for anesthesia induction.
45791809|NCT01691690|Drug|Propofol|Propofol 1-1.5 mg/kg to facilitate endotracheal intubation.
45791810|NCT01691690|Drug|Morphine|Morphine 0.1 mg/kg given prior to intubation.
45791811|NCT01691690|Drug|Ondansetron|Ondansetron (0.15 mg/kg, maximum dose of 4 mg) for postoperative nausea prophylaxis.
45791812|NCT01691690|Drug|Dexamethasone|Dexamethasone (0.25 mg/kg, maximum dose of 20 mg) for postoperative nausea prophylaxis.
45791813|NCT03538574|Behavioral|CBT-I|CBT-I is a behavioral treatment for insomnia
45791814|NCT03538574|Behavioral|MAP-I|MAP-I is a mindfulness meditation treatment for insomnia
45647263|NCT05358925|Other|Non-BPD-related Educational Videos|The non-BPD-related educational videos will be matched in length and frequency to the BPD-related videos. These videos will discuss aspects of mental and physical health that are not related to BPD. Examples may include: nutrition and healthy eating, lifestyle changes to combat stress, what is psychotherapy?, prevalence of depression and anxiety in the general population, healthy sleep habits.
45647264|NCT04554043|Drug|SHR7280|treatment
45647265|NCT04554043|Drug|Placebo oral tablet|blank control
45647266|NCT04523935|Other|Placebo|Fructose powder identical with the drugs was used
45647267|NCT04523935|Drug|Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.|Drugs were used either singly or in combination guided by clinical findings and investigations.
45791815|NCT01694108|Biological|BCG-vaccine (SSI)|
45791816|NCT03499418|Other|modified Silverman scale|Clinical assessment of severity of respiratory failure
45791817|NCT03499418|Diagnostic Test|echocardiography|echocardiographic evaluation of haemodynamic problems
45791818|NCT01694186|Drug|FAI insert|
45791819|NCT01694186|Drug|Sham injection|
45791820|NCT02283827|Drug|BIA 2-093|
45791821|NCT02283827|Drug|Phenytoin|
45791822|NCT03402854|Device|active transcranial direct current stimulation|Participants will receive 20 min of tDCS over the scalp during the first 20 min of bimanual training.
45647268|NCT02630693|Drug|Palbociclib 100mg|100mg PO daily
45791823|NCT03402854|Behavioral|bimanual training|Participants will engage in movements that use both hands, by playing with toys and games.
45791824|NCT01626092|Drug|Campath-1H|A daily dose of 0.3 mg/kg IV over 2 hours will be administered on days - 12, -11, -10, -9, and -8.
45791825|NCT01626092|Drug|Clofarabine|"A daily dose of 40 mg/m2 will be administered IV over 2 hours on days -9,~-8, -7, -6, and -5."
45791826|NCT01626092|Drug|Melphalan|A single dose of 140 mg/m2 will be given IV on day -4 over 15 minutes.
45791827|NCT01626092|Radiation|Total Body Irradiation with Marrow Boosting|"Dose to total body 200 cGy in single dose~Dose to bone marrow of the following bones 800 cGy in 5 divided daily fractions (160 cGy x 5 doses ). Treated with up to 3 abutting VMAT photon arcs from top of head to maximum inferior border."
45791828|NCT01626092|Biological|Hematopoietic stem cell transplantation|Patients will be transplanted using either a related or unrelated allograft. The cell source may be marrow, peripheral blood or cord blood based on donor availability.
45791829|NCT01626092|Drug|Cyclosporine A|Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose IV; if the recipient body weight is <40 kg, dosing will be 3 times daily, and if > 40 kg, twice daily. An attempt will be made to maintain a trough cyclosporine level of 200 mg/L to 400 mg/L.
45791830|NCT01626092|Drug|Mycophenolate mofetil|Patients will receive mycophenolate mofetil (MMF) therapy beginning on day -3. Dosing of MMF will be 1 gram three times daily (total daily dose 3 grams/day) if the recipient is >50 kg, or 15 mg/kg/dose three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously.
45791831|NCT01694966|Drug|Methylene Blue MMX®|
45791832|NCT01694966|Drug|Placebo|Sugar pill manufactured to mimic Methylene Blue MMX® tablet.
45791833|NCT01937975|Drug|Grazoprevir|100 mg oral tablet administered once a day for 10 days
45791834|NCT01937975|Drug|Elbasvir|50 mg oral tablet administered once a day for 10 days
45791835|NCT01628042|Drug|Vibegron 100 mg|Vibegron tablets, orally, on Day 1
45791836|NCT01628588|Drug|bimatoprost 0.01%|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
45791837|NCT03399656|Dietary Supplement|Avmacol tablets|The active components of Avmacol® are ground broccoli seeds that provide glucoraphanin and freeze-dried broccoli sprouts that provide a stabilized form of the enzyme myrosinase, which converts glucoraphanin to sulforaphane.
45791838|NCT03399656|Dietary Supplement|Placebo tablets|MCC 90M Emcocel
45791839|NCT03377660|Other|Clinical treatment|Patients undergo clinical treatment as indicated, they are studied before and after.
45791840|NCT03119649|Drug|GLPG2222 50 mg|Oral tablet(s) containing GLPG2222
45791841|NCT03119649|Drug|GLPG2222 100 mg|Oral tablet(s) containing GLPG2222
45791842|NCT03119649|Drug|Placebo|Matching oral tablet(s) containing placebo
45791843|NCT03119649|Drug|GLPG2222 200 mg|Oral tablet(s) containing GLPG2222
45791844|NCT03119649|Drug|GLPG2222 400 mg|Oral tablet(s) containing GLPG2222
45647269|NCT02630693|Drug|Palbociclib 125mg|125mg PO daily 3 weeks out of 4
45791845|NCT00374985|Drug|Docetaxel, Oxaliplatin|weekly doses
45791846|NCT00374985|Procedure|Radiotherapy|regular fractions
45920457|NCT00093769|Drug|bortezomib + rituximab|"Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.~Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients in either arm may crossover to the other arm if treatment is found to be ineffective."
45647270|NCT02630693|Drug|Fulvestrant or Tamoxifen or Aromatase Inhibitor|given at the standard doses/schedules
45647271|NCT05059301|Biological|RSVPreF3 OA investigational vaccine|One dose of a unique combination of the RSVPreF3 antigen lots (Lot 1, Lot 2 or Lot 3) and extemporaneously reconstituted with AS01E adjuvant lots (Lot A, Lot B and Lot C), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1.
45597813|NCT04189159|Behavioral|PROMPT|PROMPT treatment is consistent with the principles of motor learning, in that every session includes a blocked pre-practice followed by variable and distributed practice and a gradual, hierarchical increase of complexity. Speech motor goals are integrated in goals for language and functional communication. During a PROMPT session tactile-kinesthetic-proprioceptive inputs are consistently provided, in order to shape speech movements, to give information on sequencing and timing and to introduce constraints for the reduction of degrees of freedom at the articulators' level in favour of motor control.
45597814|NCT02204111|Other|Intervention|Individualized treatment proposals (e.g. pain therapy, physiotherapy, psychological contact) from expert consensus, based on Patient Reported Outcomes
45597815|NCT02204189|Drug|TongFuSan|TongFuSan 1g
45791847|NCT01695044|Drug|PSMA ADC|PSMA ADC administered IV at 2.5 mg/kg Q3W for 8 cycles or 2.3 mg/kg Q3W for 8 cycles.
45597816|NCT02204267|Other|prolonged ECG monitoring|Start of long-term ECG immediately after admission to the stroke unit by using a portable ECG recorder for a max. duration of 7 days (or hospital discharge)
45791848|NCT03121365|Behavioral|Digital/E-Book Arm|Promotion of early reader digital e-book reading
45791849|NCT03121365|Behavioral|Standard/Board Book Arm|Promotion of early reader board book reading
45791850|NCT01695668|Drug|Lotemax|Ophthalmic corticosteroid. It decreases inflammation of the eye
45791851|NCT01695668|Drug|Restasis|Restasis is an immunosuppressive agent. Cyclosporine may reduce inflammation in the eye.
45791852|NCT03284138|Device|rTMS treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)
45791853|NCT03284138|Device|placebo treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled
45791854|NCT03270020|Drug|Denosumab 70 MG/ML [Xgeva]|As already described in arm description
45791855|NCT01921751|Radiation|low intensity radiation therapy|50.4 Gy in 28 1.8 Gy fractions (IMRT or 3D-CRT), 5 days/week, starting 3-5 weeks after the last dose of induction chemotherapy
45791856|NCT01921751|Drug|Capecitabine|825 mg/m2 PO twice daily, 5 days/week, beginning on the first day of radiation therapy and ending on the last day of radiation therapy.
45791857|NCT01921751|Drug|Gemcitabine|1000 mg/m2 weekly as a 30 minute infusion after nab-Paclitaxel, three weeks on and 1 week off [1 cycle = 4 weeks]
45791858|NCT01921751|Radiation|high intensity radiation therapy|63 Gy intensity-modulated radiation therapy (IMRT) in 28 2.25 Gy fractions, 5 days/week, starts 3-5 weeks after the last dose of induction chemotherapy
45597817|NCT02204267|Device|ECG|
45597818|NCT05263271|Drug|Gentulizumab|Gentulizumab will be administered by intravenous infusion once a week, with every 28 days as a dosing cycle .
45647272|NCT03450473|Device|SurgiMend® MP|SurgiMend MP® is an acellular dermal tissue matrix derived from bovine dermis. The device is supplied sterile in a variety of sizes to be trimmed by the surgeon to meet the individual patient's needs. SurgiMend MP® will be used for abdominal wall reinforcement in patients with complex ventral hernia repair.
45791859|NCT01921751|Drug|nab-Paclitaxel|125 mg/m2 weekly as a 30-40 minute infusion, three weeks on and 1 week [1 cycle = 4 weeks]
45791860|NCT03238040|Other|None, observational study|Observational study, no interventions
45791861|NCT02958345|Biological|Zostavax|Vaccination with one dose of Zostavax per Zostavax package insert
45791862|NCT02958345|Other|Placebo|Injection of 0.65 mL of sterile normal saline
45791863|NCT01629134|Device|Crosslinked hyaluronic acid gel|All treatments are carried out according to the physician's experience and the Directions for Use
45791864|NCT04333329|Device|NEUROLITH|transcranial pulse stimulation (TPS)
45791865|NCT01922219|Behavioral|Cognitive Behavioral Therapy|14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks
45791866|NCT00375063|Procedure|Percutaneous Coronary Intervention|
45791867|NCT00375063|Procedure|Coronary Artery Bypass Grafting|
45791868|NCT01629290|Device|Enamel Pro|Varnish treatment containing 5% NaF
45791869|NCT01629290|Device|Duraphat|Varnish treatment containing 5% NaF
45791870|NCT01629290|Device|Vanish|Varnish treatment containing 5% NaF
45647273|NCT01938430|Drug|LDV/SOF|LDV/SOF FDC tablet administered orally once daily
45791871|NCT01629290|Device|Placebo|Bland varnish containing no NaF
45647274|NCT01938430|Drug|RBV|RBV tablets administered orally in a divided daily dose
45791872|NCT05735561|Diagnostic Test|X-Ray|Consenting participants will be asked to come into the clinic for a single visit, during this visit they will be asked to complete an x-ray to check for evidence of avascular necrosis.
45791873|NCT03076359|Behavioral|Traditional Healer Support Program|"Traditional Healers will provide the traditional healer support program assistance, as previously described, to all newly diagnosed patients."
45791874|NCT03076359|Drug|Standard of Care|First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
45791875|NCT01696760|Drug|acetylsalicylic acid|325 mg twice a day
45791876|NCT01696760|Drug|enoxaparin|40 mg once daily
45647275|NCT01937884|Drug|Parenteral Nutrition|
45647276|NCT04625530|Drug|ferric carboxymaltose|Ferric carboxymaltose 20 mg/kg (with a maximum dose of 1000 mg ferric carboxymaltose in a single Infusion) (Ferinject® 1000 mg/20ml, Vifor (International) AG, St. Gallen, Switzerland) will be diluted in 250 ml of 0.9% m/V sodium chloride solution and administered over 15 minutes intravenously between day -27 and day -7. The colour of ferric carboxymaltose is dark brown. A single Ferinject administration should not exceed 20 mg iron/kg body weight.
45791877|NCT01696760|Device|PCD|Wear PCD (Flowtron calf compression). Patients will continue to use PCDs for the duration of their hospitalization. If patients refuse to wear the PCDs, they will be withdrawn from the study.
45791878|NCT01924169|Drug|Lenalidomide|"5 mg/day by mouth on Monday, Wednesday and Friday for 3 months. Process repeated for up to 2 years.~If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day by mouth for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years."
45791879|NCT01924169|Biological|Influenza Vaccine|Administered as injection yearly, during the fall/winter season.
45791880|NCT01924169|Biological|Pneumovax Vaccine|Administered by injection once between month 6 and month 21. Patients, who have received the Pneumovax vaccine within last 5 years, will not receive Pneumovax vaccination.
45791881|NCT02958969|Drug|Apixaban|apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
45791882|NCT02238782|Drug|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
45791883|NCT02238782|Other|[14C] selumetinib IV solution|single, radiolabeled, IV (infused), microdose (80 μg) of [14C] selumetinib, infused using a syringe pump as a 15-minute infusion, administered 1h 15 min after receiving the oral dose
45791884|NCT01924559|Other|standard clothing|
45791885|NCT01924559|Other|Biohazard gear|
45791886|NCT01924559|Device|Direct Laryngoscopy|
45791887|NCT01924559|Device|Glidescope|
45791888|NCT01924559|Device|Supraglottic Airway|
45791889|NCT02959827|Drug|Iodinated contrast agents|Use of iodine contrast agents and doses following the decision of the treating physician.
45791890|NCT03137108|Device|Transcutaneous electrical spinal cord stimulation|Study intervention consists of the application of tSCS at three different frequencies (15 Hz, 30 Hz, 50 Hz) using the CE certified electrostimulator RehaMove 3. Stimulation will only be applied by an investigator during the two testing sessions. During the overground walking, the participants will be secured and assisted with the cable-driven body-weight support system FLOAT.
45791891|NCT01630694|Procedure|3D Laser Scanning of the Head|Five scans will be collected from different angles, each scan taking approximately 3 seconds. Each scan will consist of a thin beam of light flashing of your head.
45647277|NCT04625530|Drug|tranexamic acid|Tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively. The colour of the medicament is transparent.
45647278|NCT04625530|Drug|ferric carboxymaltose and tranexamic acid|Ferric carboxymaltose (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively.
45791892|NCT01630694|Procedure|Measurements and Digital Photo's of the head, neck and Mouth|Prior to the photographs, certain bone and soft tissue areas such as angle of the jaw, neck and chin will be gently touched and marked with self-adhesive paper stickers. Using the self-adhesive paper stickers and a measuring tape, we obtain measurements of your head and neck. You will be also asked to open your mouth and a digital photograph of the back of the mouth will be taken, as well as, pictures of the front and side of the head and neck.
45791893|NCT01630694|Procedure|Ultrasound Exam of the Tongue|The ultrasound study of the tongue will be performed after the series of laser scans. You will be examined in the sitting position. A small,handheld, curved ultrasound instrument will be placed under the chin to take images of the tongue. This exam should take less than a minute
45791894|NCT01630694|Procedure|3D Laser Scanning of the Head|Five scans will be collected from different angles, each scan taking approximately 3 seconds. Each scan will consist of a thin beam of light flashing of your head.
45791895|NCT01630694|Procedure|Measurements and Digital Photo's of the head, neck and Mouth|Prior to the photographs, certain bone and soft tissue areas such as angle of the jaw, neck and chin will be gently touched and marked with self-adhesive paper stickers. Using the self-adhesive paper stickers and a measuring tape, we obtain measurements of your head and neck.Digital Photographs of your Mouth - You will be also asked to open your mouth and a digital photograph of the back of the mouth will be taken, as well as, pictures of the front and side of the head and neck.
45791896|NCT01630694|Procedure|Ultrasound Exam of the Tongue|The ultrasound study of the tongue will be performed after the series of laser scans. You will be examined in the sitting position. A small,handheld, curved ultrasound instrument will be placed under the chin to take images of the tongue. This exam should take less than a minute.
45647279|NCT01916824|Drug|Any FDA Approved Antidepressant|Any FDA-approved antidepressant prescribed within standard dose range to treat Major Depressive Disorder will be taken for 6 weeks. Psychiatric follow-up will be performed during the study participation. At the end of the study, these participants will receive assistance in transitioning their care to another provider, depending on their individual circumstances.
45791897|NCT01924871|Drug|Desflurane with remifentanil|During the emergence from anesthesia,extubation was performed under 1.0 MAC desflurane with 1.0ng/ml remifentanil
45791898|NCT01924871|Drug|Desflurane|During the emergence from anesthesia,extubation was performed under 1.5 MAC desflurane
45791899|NCT03076983|Device|Lung Monitoring with EIT device (PulmoVista 500)|"Patient's lungs will be monitored during clinical routine interventions with Dräger's EIT device (PulmoVista 500).~No medical interventions to routine patient care required."
45791900|NCT01698710|Drug|Albumin bound paclitaxel|Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
45791901|NCT01924949|Drug|LDV/SOF|Ledipasvir (LDV)/sofosbuvir (SOF) 90/400 mg FDC tablet administered orally once daily
45791902|NCT01938989|Device|Clear clip-on glasses|Clip-on glasses with no light filtering properties
45791903|NCT01938989|Device|Blue light filter clip-on glasses|Clip-on glasses with blue light filtering properties equivalent to AcrySof IOLs
45791904|NCT02960295|Device|1-Self-monitoring of blood glucose|"Self-monitoring of blood glucose 4 times daily: fasting and 1-hour after each meal. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Intervention: At every office visit and at every telephone (virtual) visit the patient's physician will review glucose results and make adjustments in diet, activity, or medication to bring glucose into desired range."
45647280|NCT01915732|Drug|Duac™Once Daily Gel|1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide
45791905|NCT02960295|Device|2-Self-weighing|Self-weighing on electronic scale at least once a week. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Consultation with the nutritionist will be obtained for women gaining in excess of or less than that indicated for her pre-pregnancy BMI, per Institute of Medicine (IOM) standards.
45791906|NCT02960295|Device|3-Self-checking of blood pressure|Self-checking of blood pressure at least weekly with sphygmomanometer. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Patients with elevated blood pressure will be requested to come to Obstetrics Triage immediately for further assessment.
45791907|NCT02960295|Device|4-Checking fetal heart rate|Patient will record her fetus' heart rate with a Doppler device at least once weekly. The patient will immediately report to Labor and Delivery for any fetal heart rate below 100 beats per minute or greater than 160 beats per minute over a 10 minute observation period.Those reporting a fetal heart rate outside of the normal range will be requested to come to ObstetricTriage for further assessment.
45791908|NCT02960295|Procedure|5-Visits with caregivers|Telephone visits will alternate with in-office visits.Those failing to keep appointments will be contacted and reappointed at a mutually convenient time.
45647281|NCT01915732|Drug|1% clindamycin phosphate gel|1% clindamycin as clindamycin phosphate
45653145|NCT05114187|Other|Education Control|"Participants in the control group will be provided e-learning about dementia and promoting brain health, consisting of the following components:~One selected multimedia e-learning lesson;~A series of 16 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lessons.~Participants will have 8-weeks to complete. The total time to complete is approximately 1-2 hours.~Note: All participants will receive access to all e-learning at the conclusion of the study."
45791909|NCT01939145|Drug|Normal saline|Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation. This solution has high tolerability. Normal saline has been used as the instillation solution for NPWTi. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies
45791910|NCT01939145|Device|Prontosan|Prontosan (B Braun, Bethlehem, PA) is 0.1% polyhexanide, 0.1% betaine, sodium hydroxide, and purified water. The polyhexanide is an antiseptic and betaine is a surfactant. This solution is an FDA approved device indicated for topical irrigation. This solution has high tolerability with robust antimicrobial activity. Polyhexanide has been utilized as the instillation solution for NPWTi with positive clinical results. Prontosan is currently being used as the instillation solution for NPWTi in this facility as the SOC. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies.
45791911|NCT01939301|Drug|Inhaled Nitric Oxide|Nitric Oxide + oxygen
45791912|NCT01939301|Drug|Sham|Nitrogen + Oxygen
45597819|NCT02204423|Procedure|Trans-Radial Percutaneous Coronary Intervention (TR-PCI)|
45597820|NCT02917187|Drug|BIIB074|Administered as specified in the treatment arm
45597821|NCT02917187|Drug|Placebo|Matched placebo
45597822|NCT02204501|Drug|Midazolam 5mg Syrup|"All twenty four subjects will receive 5 mg midazolam syrup at four different time points during the study for a total of four non-subsequent dosing days.~On Study Days 0 and 12, subjects will receive only 5 mg midazolam syrup dosed in the morning.~On Study Days 6 and 9, subjects will have 5 mg midazolam syrup co-administered with their assigned dose of vapendavir in the morning. Co-administration of midazolam will not occur at the time of the evening dose for Group B."
45791913|NCT01941485|Device|WaveLight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
45791914|NCT01941485|Procedure|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
45791915|NCT03078075|Drug|Naltrexone: Vivitrol®|Naltrexone: 380 mg vial, 4 intramuscular injections administered every 3 weeks
45791916|NCT03078075|Drug|Placebo (PLB) Injectable|Placebo: 4 intramuscular injections administered every 3 weeks
45791917|NCT03078075|Drug|Bupropion: Wellbutrin XL®|Bupropion: 450 mg oral dose daily
45791918|NCT03078075|Drug|Placebo (PLB) Oral|Placebo: once-daily oral placebo tablets
45791919|NCT01926977|Drug|Ranibizumab 0.5mg|Patient will receive intravitreal injection of Ranibizumab 0.5mg.
45791920|NCT01926977|Drug|Aflibercept 2.0mg|Patients will receive intravitreal injection of Aflibercept 2.0mg.
45791921|NCT05735405|Behavioral|Neuropsychological evaluation|Each participant will undergo a complete neuropsychological evaluation, both before and at the end of the clinical trial, with the aim of detecting any changes or improvements.
45791922|NCT05735405|Biological|BDNF evaluation|During the first and last clinical trial session, each participant will undergo two blood samples, one before and one at the end of the ride, to check levels of Brain Derived Neurotrophic Factor (BDNF).
45647282|NCT04635436|Other|Pathologic group|"Participants will walk on a split-belt treadmill mounted on force sensors with the belts running at the same or at different velocities. They will walk freely without hanging to any support. The test sequence will be the following:~Baseline phase. 3 minutes walking at increasing speed from 0.2 m s-1 to 0.6 m s-1, speed will be increased of 0.1 m s-1 every 30 s. A brief pause of around 1 minute will follow.~Habituation phase. 30 seconds walking at 0.2 m s-1.~Adaptation phase. The velocity of the belt under the non-affected lower limb will be increased to 0.6 m s-1, while the other belt will maintain its velocity of 0.2 m s-1 for 6 minutes.~Post-adaptation phase. Belts' velocities will be restored at 0.2 m s-1 for 6 minutes.~Participants will be informed before the changes in belts' velocities with a verbal warning.~Participants will repeat the same protocol with the affected lower limb on the fast belt after one week."
45791923|NCT05735405|Behavioral|Pedaling as a moderate intensity aerobic exercise|During each session, each participant will perform 30 minutes of pedaling as a form of moderate intensity physical activity.
45791924|NCT05735405|Other|Cognitive Training|During each session, each participant will carry out 60 minutes of cognitive training through specific exercises for the attentional, executive and working memory functions.
45647283|NCT04634968|Behavioral|Brief Motivational Interviewing interaction|Telephone peer counselling+ Brief Motivational Interviewing interaction, and telephone-based interview after receiving all information.
45791925|NCT05735405|Diagnostic Test|VO2 assessment|"To determine the individual moderate intensity for each patient, a VO2 consumption assessment will be made. The examination will be carried out using an exercise bike and a mask for the calculation of metabolic oxygen consumption.~The 3 MET threshold to reach in pedaling will be calculated (to define it of moderate intensity), in order to elicit the release of BDNF."
46071584|NCT05334030|Device|High Swing Resistance|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~Sitting program - Min lean;~Standing program - Auto lean;~Step initiation program - ProStep+,~Training mode - Off,~SmartAssist option - 2Free;~Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
45791926|NCT05735249|Drug|ARN-75039 oral capsules|SAD: Up to 5 single escalating doses MAD: Up to 3 escalating doses Food-effect: Selected single dose
45791927|NCT05735249|Drug|Placebo|Given at frequency and amounts matching ARN- 75039 dosing regimen
45791928|NCT01928693|Drug|Besivance 0.6% Ophthalmic Suspension|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
45791929|NCT01928693|Drug|Zymaxid 0.5% Ophthalmic Solution|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
45791930|NCT01928693|Drug|Vigamox 0.5% Ophthalmic Solution|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
45791931|NCT01928849|Drug|Valproic Acid|"Intervention patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital."
45791932|NCT01928849|Other|Cherry Syrup|Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.
45791933|NCT01631552|Drug|Sacituzumab Govitecan-hziy (SG)|Administered via intravenous (IV) infusion
45791934|NCT03081117|Drug|Insulin, intranasal|Regular insulin administered by specialized, non-commercial intranasal drug delivery device
45791935|NCT03081117|Drug|Placebo, intranasal|Saline solution administered by specialized, non-commercial intranasal drug delivery device
45791936|NCT03124797|Device|RD DCI Sensor|Noninvasive pulse oximeter sensor
45647284|NCT04634968|Behavioral|General health communication|Telephone peer counselling+ General health communication, and telephone-based interview, and telephone-based interview after receiving all information.
45647285|NCT04634266|Device|Transcatheter tricuspid valve treatment (TTVT)|Percutaneous CE-mark approved techniques for transcatheter tricuspid valve treatment (TTVT): These include (I) transcatheter annuloplasty devices (Tricuspid Cardioband) and (II) transcatheter edge-to-edge repair (TriClip, PASCAL).
45653146|NCT05729113|Behavioral|Distraction technique|Distribution of an anti-stress ball before the moment of cannulation of the vascular access and instructing to place it in hand opposite the limb of the vascular access
45791937|NCT01944293|Drug|Ketamine|Single dose of 0.5 mg/kg of Ketamine given intravenously (in the vein) over 40 minutes
45791938|NCT01944293|Drug|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
45791939|NCT03083379|Device|Volumetric Incentive Spirometry|"A study investigator will provide instruction on Incentive Spirometry procedure performance before supervised therapy and monitoring begins.~Five minutes of eupneic ventilation EIT monitoring will occur before I.S. therapy commences.~Study participants will be asked to take 10 deep breaths through the incentive spirometer's mouthpiece, followed by a 60 second pause.~The 10-breath cycle will be repeated three times with respiratory therapist coaching.~Five minutes of eupneic ventilation EIT monitoring will occur following the last I.S. lung expansion therapy breath cycle.~Incentive Spirometry therapy and monitoring session will last about 15 minutes"
45791940|NCT03083379|Device|EzPAP® POSITIVE AIRWAY PRESSURE|"A study investigator will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins. A second study investigator will perform EIT device set-up and monitoring only.~Five minutes of eupneic ventilation EIT monitoring will occur before EzPAP® therapy commences.~Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.~The 10-breath cycle will be repeated three times with respiratory therapist coaching.~Five minutes of eupneic ventilation EIT monitoring will occur following the last EzPAP® lung expansion therapy breath cycle.~EzPAP® therapy and monitoring sessions will last about 15 minutes"
45791941|NCT01944371|Drug|Disulfiram|This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.
45791942|NCT02343120|Drug|Zanubrutinib|Oral administration by capsule
45791943|NCT03125031|Device|Rainbow adhesive adult/pediatric sensor|
45791944|NCT03125031|Device|Rainbow adhesive adult/neonatal sensor|
45791945|NCT01946243|Drug|Florbetapir F18|No Florbetapir F 18 will be administered in this study.
45791946|NCT03086265|Device|THRIVE|active nasal oxygen delivery system
45791947|NCT03086265|Device|Endotracheal tube|Plastic tube for supporting ventilation during surgery
45791948|NCT01631630|Drug|Pioglitazone|Pioglitazone is a thiazolidinedione antidiabetic. It works by lowering blood sugar by making the cells of the body more sensitive to the action of insulin.
45791949|NCT01631630|Drug|Placebo|Placebo is an inactive tablet design to look exactly like pioglitazone
45791950|NCT01947335|Device|IVUS-guided PCI|Intravascular ultrasound guided percutaneous coronary intervention
45791951|NCT01947647|Behavioral|Transdiagnostic Behavior Therapy|A new transdiagnostic CBT protocol for the depressive/anxiety disorders was developed and revised through two demonstration studies and one focus group. The resulting protocol involves several primary components, including psychoeducation on the symptoms of depression and anxiety (session 1), assessment of motivation and setup of treatment plans (session 2), exposure therapy (sessions 3-15), and relapse prevention (final session). In addition to these primary components, optional modules are included to supplement exposure therapy later in treatment to address secondary symptoms (e.g., anger, sleep, hypervigilance, drinking to cope). The goal of these modules is to allow providers to tailor treatment to specific symptoms that may be present in any single or set of diagnoses that may be reducing the effects from the primary exposure approach. Session will be weekly for 45-60 minutes with homework assignments to be completed between sessions.
45791952|NCT01947647|Behavioral|Behavioral Activation Therapy|To provide an evidence-based comparison for the transdiagnostic CBT condition, a second group of participants will receive manualized BAT. In general, BAT involves teaching patients to monitor their mood and daily activities with the goal of increasing pleasant, reinforcing activities and reducing unpleasant events. In the present study, the BAT condition will be manualized, following an existing protocol in the literature. BAT will be structurally equivalent to the transdiagnostic CBT with the same session length (45-60 minutes), frequency of sessions (weekly), duration of treatment (12-16 sessions), and amount of homework.
45791953|NCT04333251|Biological|high-titer anti-Sars-CoV-2 plasma|Recipients will receive 1-2 units of ABO matched donor plasma at neutralization antibody titer >1:64 vs best supportive care
45791954|NCT04333251|Other|oxygen therapy|oxygen therapy
45597823|NCT02204501|Drug|Vapendavir 264 mg BID|Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
45597824|NCT02204501|Drug|Vapendavir 528 mg QD|Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
45597825|NCT05471089|Device|Diathermy by emission of Radiofrequency|Applied only to experimental group
45791955|NCT03837860|Drug|Oxycodone/Placebo|Oxycodone 20 mg plus placebo
45791956|NCT03837860|Drug|Oxycodone/Risperidone|Oxycodone (20mg) plus Risperidone (2 mg)
45791957|NCT03837860|Drug|Oxycodone/Ziprasidone|Oxycodone (20mg) plus Ziprasidone (80 mg)
45791958|NCT02289989|Drug|Oregano extract cream|An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
45791959|NCT02289989|Drug|Hydrocortisone|An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
45597826|NCT05471089|Other|Therapeutic exercise|Applied to both arms/groups
45597827|NCT02204735|Behavioral|Eat majority of calories in the morning|
45597828|NCT02204735|Behavioral|Eat the majority of calories in the evening|
45791960|NCT03091179|Device|THRIVE|active nasal oxygen delivery system
45791961|NCT03091179|Device|Endotracheal tube|a plastic tube for mechanical ventilation
45791962|NCT03076112|Drug|Ipragliflozin|Ipragliflozin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes
45791963|NCT03076112|Drug|Sitagliptin|Sitagliptin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes
45791964|NCT03129945|Drug|Nifedipine|Subjects will be given nifedipine 10mg orally and repeated every 20 minutes for a maximum dose of 30mg in the first hour followed by 20mg every 6 hours for the first 48 hours.
45791965|NCT03129945|Drug|Indomethacin|Those randomized to indomethacin will be given 100mg orally as a loading dose followed by 50mg every 6 hours for the first 48 hours of treatment.
45791966|NCT01948739|Device|MAHI EXO-II exoskeleton augmented with BMI system|In this longitudinal study, adult subjects with hemiparesis due to acute or chronic stroke will receive robotic-assisted training through an EEG-based BMI control of robotic exoskeleton to study the changes in upper extremity motor function, cortical plasticity (using the EEG and fMRI). The training will be provided 3x/week for 12 sessions over one-month period.
45647286|NCT01936948|Procedure|Clip closure|Patients will be randomized to either closing the mucosal defect after polyp removal or not closing the mucosal defect using clips (main intervention and comparison). The resection margins will be approximated using clips. Complete closure is defined as approximated margins with less than 1cm gap between clips. All patients will further be randomized to two different settings of electrocautery (EndoCut or Coagulation) to standardize otherwise variable electrocautery practice, and for explorative analysis.
45791967|NCT01700036|Drug|Alpha-1-Antitrypsin (AAT)|AAT (Zemaira) will be administered at a dose of 60mg/kg (actual weight) on D1, 4, 8, 12, 16, 20, 24, and 28. A second course of treatment will not be given.
45791968|NCT02965989|Procedure|Online training of a nursing technique|The professionals with participant in the experimental arm receive an online training of a technique of extraction of blood culture and other arm the professionals no receive any training. They work as usual.
45791969|NCT04768205|Device|Kinesio tape|The Kinesio tex tape is a medical tape that had been certified and patented.
45791970|NCT02971748|Biological|Pembrolizumab|Given IV
45791971|NCT01700816|Device|Bright light therapy|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
45647287|NCT01936870|Drug|Fesoterodine (Toviaz)|Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.
45791972|NCT01700816|Device|Sham light|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
45791973|NCT01950299|Drug|Anakinra 100 mg|Anakinra 100 mg starting immediately and then every 24 hours
45791974|NCT01950299|Drug|Anakinra 100 mg|Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours)
45791975|NCT01950299|Drug|Placebo|Placebo 0.67 ml injections twice daily
45791976|NCT02967393|Drug|ccIIV4|
45791977|NCT02967393|Drug|IIV4|
45791978|NCT05734703|Drug|Nutraceutical Topical|Once daily application of the topical nutraceutical to two by two inch area of skin for 90 days.
45791979|NCT03093207|Procedure|Open flap debridement|Open flap debridement will be performed to decontaminate root surface
45791980|NCT03093207|Other|Placebo|Placebo pills over a period of 180 days
45647288|NCT04632940|Drug|Pamrevlumab|Pamrevlumab will be administered per dose and schedule specified in the arm description.
45791981|NCT03093207|Dietary Supplement|Omega-3 polyunsaturated fatty acids|3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
45791982|NCT03093207|Drug|Aspirin|100 mg of aspirin daily supplementation over a period of 180 days
45791983|NCT01703702|Drug|florbetapir (18F)|Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
45791984|NCT02986763|Biological|Questionnaire, blood, urine, hair and dust samplings|
45920458|NCT00400348|Drug|Panzem Nanocrystal Colloidal Dispersion (NCD)|Panzem NCD 1,000 mg, four times daily for 28 consecutive days
45920459|NCT00006233|Biological|therapeutic allogeneic lymphocytes|
45647289|NCT04632940|Drug|Placebo|Placebo will be administered per schedule specified in the arm description.
45791985|NCT03096873|Behavioral|Combined Exercise Training|The combined exercise training were consisted with 5 minutes of warm-up, 20 minutes of resistant band exercises (Upper: seated rows, biceps curl, shoulder flexion, elbow flexion, pushup; Lower: hip flexion, hip extension, calf raise, leg press, squat), 30 minutes of treadmill walking, and 5 minutes of cool-down. Intensity of the training was gradually increased from 40-50% heart rate reserve in 1-4 weeks to 60-70% HRR in 9-12 weeks.
45791986|NCT02646098|Procedure|CD34+ cell selection|CD34+ cell selection applying a CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany). This method for CD34+ cell selection will be used in this study and is considered as the standard treatment.
45791987|NCT02969031|Behavioral|Enhanced SCOPE training|Intervention is integrated into the American Board of Internal Medicine (ABIM) Maintenance Of Certification (MOC) process.
45791988|NCT02969031|Behavioral|Standard Communication training|Standard Communication training
45791989|NCT05482451|Drug|Nivolumab|Nivolumab, an immune checkpoint inhibitors targeting PD-1, represents a popular treatment option for patients with cancers via immunological mechanism. However, previous studies using nivolumab alone in pancreatic cancer have failed.
45920460|NCT00006233|Drug|cyclosporine|
45920461|NCT00006233|Drug|fludarabine phosphate|
45920462|NCT00006233|Drug|mycophenolate mofetil|
45920463|NCT00006233|Procedure|peripheral blood stem cell transplantation|
45920464|NCT00006233|Radiation|radiation therapy|
45920465|NCT04544709|Drug|Low back intradiscal injection of platelet rich plasma (PRP)|SOC Intradiscal Lumbar PRP Procedure : A small amount of blood is drawn from you, then it is spun in a centrifuge to obtain only the platelets and few other cells. After being spun the small amount of platelets will be injected into the specific disc that is believed to be causing pain in an attempt to help reduce inflammation and pain at the site. The injection will be done under fluoroscopic guidance (x-ray) that allows very careful and precise placement of the needle.
45791990|NCT05482451|Drug|all trans retinoic acid|Our previous basic studies revealed that all-trans retinoic acid repressed pancreatic adenocarcinoma cell growth and colony formation. All-trans retinoic acid represses ADAR1, a member of interferon-stimulated genes and a negative regulator of IFNs signaling. On the other hand, all-trans retinoic acid simultaneously increases PD-L1 expression for cancer cells to evade immune surveillance. Since combination of anti-PD1 antibody and all-trans retinoic acid may block self-regulating negative feedback loops of IFNs response, this therapeutic strategy may improve outcomes of pancreatic adenocarcinoma patients.
45791991|NCT02969421|Other|Cough method for placement of tenaculum|The intervention in this arm is the placement of tenaculum via cough method
45791992|NCT02969421|Other|Slow Tenaculum Placement of tenaculum|The intervention in this arm is the placement of tenaculum via slow method
45791993|NCT04350203|Procedure|Laparoscopic right colectomy with intracorporeal anastomosis (IA)|First, the right colon dissection was completed by laparoscopy. An isoperistaltic side-to-side ileocolonic mechanical anastomosis was then performed by using a linear cutting stapler. The enterotomy used to enter the stapler was closed with a running suture (3-0 absorbable monofilament or a 3-0 barbed suture). Finally, the specimen was extracted through a Pfannenstiel mini-laparotomy (4-5 cm).
45791994|NCT04350203|Procedure|Laparoscopic right colectomy with extracorporeal anastomosis (EA)|First, the right colon was widely mobilized. A small laparotomy was performed in the mid/upper abdomen to exteriorize the colon and to perform a side-to-side mechanical anastomosis, using a linear cutting stapler (GIA). The bowel opening was closed either with a manual suture or by a second firing of the GIA.
45791995|NCT03134313|Device|Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor|
45647290|NCT04632940|Drug|Corticosteroids|Systemic deflazacort or equivalent potency of corticosteroids administered orally
45647291|NCT01618864|Device|Luxe|Self treatment at home in the peri-orbital and cheeks areas. Frequency: Daily treatment for 4 weeks followed by bi-weekly treatments for additional 4 weeks.
45791996|NCT05463263|Drug|STP938|Small molecule
45791997|NCT02228408|Drug|Hydralazine/Isorsorbide Dinitrate|"Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.~Target Dose:~Hydralazine 75 mg 3x day Isorsorbide Dintrate 40 mg 3x/day~Allowable Dosage Forms:~ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35 mg-3x/day ISD/HY 40 mg/75 mg-3x/day~Dose Titration:~ISD/HY will be administered at a starting dose ISD/HY 10 mg/10-3x/day and titrated to ISD/HY 20 mg/35 mg-3x/day after 4 days and to ISD/HY 40 mg/75 mg-3x/day at 4 weeks. Dose will be decreased as necessary for dose-limiting side effects."
45791998|NCT02228408|Drug|Placebo|Placebo titration will mimic titration of active study arm
45791999|NCT03134703|Drug|Methadone|Infants in the Methadone Treatment Group will receive the study drug, methadone, instead of morphine to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
45792000|NCT03134703|Drug|Morphine|Infants in the Comparison Group will receive standard of care narcotic (morphine) to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
45792001|NCT01951391|Other|Control Hand Soap|Commercially available soap will be used to wash the subject's forearms
45792002|NCT01951391|Other|Benzalkonium Chloride Soap|Commercially available soap containing benzalkonium chloride will be used to wash the subject's forearms
45792003|NCT01951391|Other|Triclocarban Soap|Commercially available soap containing triclocarban will be used to wash the subject's forearms
45792004|NCT01953575|Device|Mucosal Impedance|A tiny tube will be placed through the endoscope into the esophagus. 5 cm above where the stomach and esophagus meet for 5 seconds. At 10 cm above where the stomach and esophagus meet the catheter will be placed for 5 seconds. And at 20 cm above where the stomach and esophagus meet the catheter will be placed for 5 seconds.
45792005|NCT01953575|Procedure|Upper Endoscopy|Esophagogastroduodenoscopy, also called by various other names, is a diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum.
45792006|NCT05734469|Other|Forefoot bone surgery|Elective forefoot bone surgery under popliteal sciatic nerve
45792007|NCT05734469|Other|Forefoot bone surgery|Elective forefoot bone surgery under an ankle block
45792008|NCT02342886|Drug|Moxifloxacin|Oral
45792009|NCT02342886|Drug|PA-824|Oral
45792010|NCT02342886|Drug|Pyrazinamide|Oral
45792011|NCT02342886|Drug|HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)|Oral
45647292|NCT01618708|Device|Synvisc-One (hylan G-F 20)|6-mL IA injection
45647293|NCT01618708|Device|Placebo|6 mL injection of phosphate buffered saline
45647294|NCT04434521|Behavioral|Questionnaire|Questionnaire about habits in terms of near vision activities
45647295|NCT04434521|Other|Eye examination|"The eye examination involves the following measurements:~Distant vision phoria with Thorington method~Close vision with Thorington method~Objective eye-to-eye refraction with self-refractometer~Binocular objective refraction with autorefractometer~Monocular/biocular/binocular refraction with Nidek TS610~SiView automatic refraction~Humphriss binocular refraction~MOU Binocular refraction"
45792012|NCT02342886|Drug|HR (rifampicin plus isoniazid combination tablets)|Oral
45792013|NCT04350281|Drug|Interferon Beta-1B|Daily subcutaneous injection of interferon β-1b 1mL (0.25mg; 8 million IU) consecutively on day 1 to day 3
45792014|NCT04350281|Drug|Hydroxychloroquine|Hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days
45653147|NCT05613335|Procedure|Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement|Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement
45792015|NCT04350047|Procedure|Radical nephrectomy with inferior vena cava thrombectomy without thoracotomy|The abdomen was accessed through a Makuuchi incision. After mobilization of the liver and assessment of the inferior vena cava infiltration (IVC), IVC was clamped below the level of the renal veins. In order to get access to the intrapericardial IVC, an incision was made through the tendon of the diaphragm and a clamp was placed first in the hepatoduodenal ligament (Pringle maneuver) and then in the endopericardial portion of the IVC, in that order. A longitudinal 3-4 cm incision was made incorporating the junction of IVC and right renal vein. After tumor removal thrombus was removed and a fine clamp was placed at the IVC just below the hepatocaval junction and immediate release of the clamping of the hepatoduodenal ligament. Total endopericardial clamp time was 4 minutes. Patients then underwent radical nephrectomy in a standard fashion with en bloc resection of the IVC thrombus.
45792016|NCT03097341|Drug|xisomab 3G3- Dose 1|Participants will receive a single intravenous dose of 0.1 mg/kg xisomab 3G3.
45792017|NCT03097341|Drug|xisomab 3G3-Dose 2|Participants will receive a single intravenous dose of 0.5 mg/kg xisomab 3G3.
45792018|NCT03097341|Drug|xisomab 3G3-Dose 3|Participants will receive a single intravenous dose of 2.0 mg/kg xisomab 3G3.
45792019|NCT03097341|Drug|xisomab 3G3- Dose 4|Participants will receive a single intravenous dose of 5.0 mg/kg xisomab 3G3.
45647296|NCT04615234|Device|Pharmacogenomics test (PGx)|"The clinicians of the TGTG group patients receive the PGx test report within 48 hours and all the participants start the new treatment within 72 hours. According with both Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) guidelines, the PGx report places the most ADs widespread in Italy, into three recommended categories: 1) use as directed (labelled as Green), 2) use with caution (labelled as Yellow), 3) use with extreme caution (labelled as Red)"
45647297|NCT03315455|Drug|Emicizumab|Emicizumab will be administered via subcutaneous (SC) injection, as described for each treatment arm.
45792020|NCT03097341|Other|Placebo|Participants will receive a single intravenous dose of placebo.
45792021|NCT04891692|Device|StimaWell 120MTRS system|Medium-frequency electrotherapy device that delivers current via up to 12 channels. The device also provides heat therapy up to 40°C.
45792022|NCT05732987|Other|Analysis of samples|DNA extraction from blood or saliva samples for the identification of gene variants by next generation sequencing;
45647298|NCT03301805|Drug|BLEX 404|"BLEX 404 Oral Liquid is administered twice daily during the Gemcitabine monotherapy period. The dose of Gemcitabine 1,000 mg/m2 IV fusion at Day 1, 8, 15 of every cycle~28 days a cycle."
45647299|NCT03064139|Behavioral|MCG|Community-based in person group training n mindful walking over 11 sessions in 6-months+ Activity monitor with feedback on activity levels
45647300|NCT03064139|Behavioral|SCG|Community-based in person group education in management of knee osteoarthritis (importance of physical activity, weight management, etc.) over 11 sessions in 6 months + Activity monitor with feedback on activity levels
45653148|NCT05613335|Procedure|Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement|Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement
45792023|NCT05732987|Other|Analysis of samples|RNA extraction from blood and skin samples for Nanostring analyses, quantitative RT-PCR or RNA sequencing.
45792024|NCT05732987|Other|Analysis of samples|Biobanked skin samples will be analyzed by immunostaining and imaging techniques to identify cell types in lesions and compare them to healthy skin.
45792025|NCT05732987|Other|Analysis of samples|Cells isolated from biobanked blood and skin samples will be cultured in vitro and proteins will be analyzed by ELISA (secreted proteins) and western blot (cell proteins).
45792026|NCT02390076|Device|Left Low Level Light Therapy|Administration of left LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Left LLLT will target the left forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
45792027|NCT02390076|Other|Attention bias modification|The task will consist of a modified dot-probe paradigm. A pair of stimuli depicting a negative word and a neutral word will be presented, randomly located to the right and left side of the computer screen. The words will be presented for 1000 ms. The words will then disappear and a dot-probe will appear in the center of the screen location of one of the words (i.e., O or Q). This probe will appear on the screen until the participant presses one of two response buttons to indicate the identity of the probe. The presentation of the probe will be staggered to maximize attention for the neutral stimulus. Latency and accuracy of the button press responses are recorded by the computer.
45792028|NCT02390076|Device|Right Low Level Light Therapy|Administration of right LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Right LLLT will target the right forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
45792029|NCT02390076|Device|Sham Low Level Light Therapy|Administration of sham LLLT is designed to resemble active LLLT from the participant's perspective, but uses a dosage markedly below the minimal necessary threshold to elicit a response.
45792030|NCT03097653|Other|Decision-aid|Web platform with a multilevel information and an aid for the decision to be taken. The content is splitted in 16-20 screens; each screen contains the answer to a common question (i.e. What is mammography screening? What are its benefits and harms? What results can be expected from the participation to mammography screening? What is breast cancer?). The information covers also controversial topics as overdiagnosis, overtreatment and the disagreement among scientists about harms and benefits' quantification.
45792031|NCT03097653|Other|Standard information|Web platform with a standard brochure. This standard brochure represents a combination of the best information available from the three participate centre' brochures.
45792032|NCT02389998|Other|Placebo Suspension|The study is divided into three phases: 1 one-week baseline assessment followed by 2 three-week study phases (phase A and phase B). Phase A will require subjects to take 1/4 teaspoon placebo suspension 2 times a day (morning and night), and a third dose if necessary. In phase B subjects will not take the placebo. After 3 weeks in initial phase (either Phase A or B), subjects will switch to the alternate phase and continue the study for another 3 weeks. Hyoscyamine is available as a rescue medication during Phase A and Phase B. Half of the subjects will be randomized to begin with Phase A and half will be randomized to begin with Phase B.
45920466|NCT02964715|Drug|Empagliflozin|25 mg daily for 6 months
45920467|NCT00093886|Drug|clevidipine|
45920468|NCT00093886|Drug|nitroglycerin|
45920469|NCT00093925|Drug|clevidipine|
45920470|NCT00093925|Drug|nicardipine|
45920471|NCT00006239|Drug|sodium phenylbutyrate|
45920472|NCT00006239|Drug|tretinoin|
45920473|NCT00094003|Drug|NS-9 [Poly I: Poly C]|
45792033|NCT02389998|Drug|Hyoscyamine|While not an intervention of interest to our study, patients will have hyoscyamine available as a rescue medication throughout the study. This can be taken on a PRN basis for breakthrough pain a maximum of 4x daily.
45792034|NCT02330627|Behavioral|Positive Valence System Treatment|Clinician-administered one-hour treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) between sessions.
45792035|NCT02128958|Drug|CF102|orally q12h
45792036|NCT02128958|Drug|Placebo|orally q12 hours
45792037|NCT02389764|Drug|BIBF 1120|Initial dose is 200 mg twice daily orally for a 28 day cycle.
45792038|NCT02389764|Behavioral|Phone Call|Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. These calls should last about 2 minutes.
45792039|NCT03135015|Other|Placebo capsules|250ml water with 16 x 250mg placebo capsules
45792040|NCT03135015|Other|2g capsules|250ml water with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules
45647301|NCT02229149|Drug|Trastuzumab|"Treatment for all patients will consist of trastuzumab, given as a loading dose of 8 mg/kg IV on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter.~Patients randomized to the chemotherapy plus trastuzumab arm (without pertuzumab) can receive trastuzumab 6 mg/kg IV every 3 weeks if they are receiving docetaxel or capecitabine on a 3-week cycle, or 4 mg/kg IV every 2 weeks if they are receiving vinorelbine, paclitaxel, or nab-paclitaxel on a 4-week cycle. The loading dose for all patients remains 8 mg/kg.~For patients randomized to the chemotherapy plus trastuzumab plus pertuzumab arm, both trastuzumab and pertuzumab need to be administered every 3 weeks regardless of which chemotherapy agent they are receiving."
45792041|NCT03135015|Other|4g capsules|250ml water with 16 x 250mg capsules containing Axulin powder
45792042|NCT03135015|Other|Water Control|250ml water
45792043|NCT03135015|Other|2g tablets|250ml water with 2 x 1g tablets containing Axulin powder
45792044|NCT03135015|Other|4g tablets|250ml water with 4 x 1g tablets containing Axulin powder
45792045|NCT04903470|Drug|Bisacodyl|Biscodyl a stimulant laxative is expected to stimulate rectal contraction and enhance expulsion of Fecobionics
45792046|NCT04903470|Drug|Atropin|Atropin is an anticholinergic drug that is expected to inhibit rectal contractions and make defecation more difficult.
45792047|NCT01647932|Drug|hydrochlorothiazide|hydrochlorothiazide according to clearance of creatinine; >50ml/min 25mg daily, 20-50ml/min 50mg daily amd <20ml/min 100mg daily.
45792048|NCT01647932|Drug|Placebo|Placebo according to clearance of creatinine; >50ml/min 1/2 pill daily, 20-50ml/min 1 pill daily amd <20ml/min 2 pills daily.
45647302|NCT02229149|Drug|Pertuzumab|pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks.
45792049|NCT04903002|Drug|24-IU oxytocin|Patients will self-administer a 2-week course of 24-IU intranasal oxytocin [4-IU per puff (12-IU delivered to each nostril); Syntocinon, Novartis, Switzerland], twice per day (once in the morning and once in the evening).
45792050|NCT04903002|Drug|48-IU oxytocin|Patients will self-administer a 2-week course of 48-IU intranasal oxytocin [4-IU per puff (24-IU delivered to each nostril); Syntocinon, Novartis, Switzerland], twice per day (once in the morning and once in the evening).
45792051|NCT04903002|Drug|Placebo|Patients will receive an intranasal placebo containing the same ingredients as the oxytocin nasal spray with the exception of active oxytocin. Administration schedule and procedure will be identical to that described in 24-IU oxytocin.
45920474|NCT04540887|Device|Pulsed Electromagnetic Field (PEMF) Therapy|PEMF therapy will be self-administered by all trial participants using the B. Body, B. Pad, and Control Unit. Participants will administer this therapy twice a day (morning and evening) for 8-minute sessions over a four week period.
45920475|NCT00094042|Drug|Iron Supplement, 120mg|
45792052|NCT04902846|Diagnostic Test|Early kidney damage biomarkers|In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.
45792053|NCT04902846|Diagnostic Test|Predisposition to kidney injury biomarkers|In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured.
45792054|NCT01597856|Behavioral|SBIRT|"SBIRT Therapy overview-~Therapist explains purpose of the therapy.~Inquiry about Compensation examination-ask if Veteran has questions about determination process and address concerns.~Discuss relationship between PTSD and substance use- long-term substance use is a form of avoidance and barrier to recovery.~Discuss treatment needs, administer screening, provide feedback."
45792055|NCT02366130|Drug|Ra-223 dichloride|55 kBq/kg by vein on Day 1 of each 28 day cycle, and then every four weeks thereafter for 6 cycles.
45792056|NCT02366130|Drug|Denosumab|120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.
45792057|NCT02366130|Drug|Hormone Therapy|A single hormonal agent administered daily while on study. Physician to decide what type of hormone therapy participant will receive.
45920476|NCT00094081|Drug|tirapazamine (SR259075)|
45792058|NCT01633892|Procedure|Fat Grafting|
45792059|NCT03098745|Device|Omafilcon A|contact lens
45792060|NCT03098745|Device|Somofilcon A|contact lens
45792061|NCT03098745|Device|Omafilcon A - Proclear (PC)|contact lens
45792062|NCT01635062|Drug|Calcitriol|Subjects will receive calcitriol (up to 0.75 mcg daily) for 3 weeks.
45792063|NCT01635062|Drug|Placebo|Subjects will receive placebo for 3 weeks.
45792064|NCT03099369|Behavioral|Daily Step-based Exercise|A 12-week step-based exercise prescription with the eventual goal of walking at least 5,000 steps a day.
45792065|NCT03099369|Behavioral|Symptom-based Exercise|A 12-week symptom-based exercise prescription adapted from clinical practice guidelines.
45792066|NCT03099369|Other|Fitbit Fitness Monitor|Used by the experimental group to assess outcome and to guide exercise therapy; used by the active comparator group to assess outcome only
45920477|NCT00094081|Drug|cisplatin|
45920478|NCT00094081|Procedure|Radiation Therapy|
45920479|NCT00094120|Drug|MSI-1256F (Squalamine Lactate)|
45920480|NCT00006242|Drug|BMS-214662|Given IV
45920481|NCT00006242|Other|laboratory biomarker analysis|Correlative studies
45920482|NCT00006242|Other|pharmacological study|Correlative studies
45647303|NCT02229149|Drug|Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine|"physician's choice of chemotherapy:~Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~Docetaxel 75 mg/m2 IV every 3 weeks; OR~Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off."
45792067|NCT01637090|Drug|Everolimus|"The study drug everolimus will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Everolimus should be administered orally once daily, preferably in the morning, at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed.~Everolimus will be administered orally as once daily dose of 10 mg continuously from study day 1 until progression of disease or unacceptable toxicity.~If vomiting occurs, no attempt should be made to replace the vomited dose. All dosages prescribed and dispensed to the patient and all dose changes during the study must be recorded."
45792068|NCT01637246|Drug|Any Fixed Combination Therapy|Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy. This was a retrospective chart review study, so no treatment was administered in this study.
45792069|NCT02389452|Drug|Synvisc-One|intraarticular injection
45792070|NCT01637870|Device|Prevena negative pressure wound system|Placement of negative pressure wound system at the time of cesarean delivery for those at increased risk for wound complication
45792071|NCT01955837|Drug|TAS-102|TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
45792072|NCT01955837|Drug|Placebo|Placebo orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
45792073|NCT01638416|Other|Blood transfusion|Blood transfusion in ICU patients aged 18 and over.
45792074|NCT02971293|Drug|AZD8871 100 µg|The subjects will receive one dose of AZD8871 100 µg single dose DPI.
45792075|NCT02971293|Drug|AZD8871 600 µg|The subjects will receive AZD8871, 600 µg single dose DPI.
45920483|NCT00094159|Drug|SNS-595|
45920484|NCT04538430|Device|SPRINT percutaneous peripheral nerve stimulator placed|Placement of a SPRINT percutaneous peripheral nerve stimulator targeting the bilateral medial branches at the suspected level of pain generation. This procedure is done as standard of care.
45647304|NCT04642469|Drug|Durvalumab|Intravenous administration of Durvalumab
45920485|NCT00094276|Behavioral|Facilitated Asthma Communication Intervention (FACI)|A caregiver/PCP communication intervention designed to facilitate communication between parents and PCPs about a child's asthma severity and recommended therapy.
45647305|NCT04642469|Other|Placebo|Placebo Comparator
45647306|NCT03259295|Device|Digiclamp (Skin tag removal initial plus follow-up)|Skin tag will be assessed for size, location, and overall appearance. After assessment and confirmation that the skin tag is not infected or possibly malignant, the site will be photographed, prepped with an antimicrobial solution, anesthetized, and removed using the Digiclamp. A bandaid will be applied to the site. Site of skin tag removal will be photographed to document lesion recurrence and presence of scar tissue or hyperpigmentation. Subjects will be asked to complete a brief survey about their satisfaction with the use of Digiclamp.
45792076|NCT02971293|Drug|Placebo|The subject will receive Placebo single dose DPI.
45792077|NCT02365584|Drug|lanreotide (Autogel formulation)|Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
45792078|NCT01956071|Device|WAPD|The objective was to assess workers' acceptability of the Pennington Pedal Desk.
45792079|NCT02342418|Drug|Tedizolid phosphate|Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
45792080|NCT01957085|Other|observation only|This is an observational only, nonintervention study. There will be no patient contact. This was a de-identified point prevalence study of hepatitis C infection in hospitalized patients in an inner city hospital.
45792081|NCT04902378|Device|Tandem t:slim X2 insulin pump with Control IQ technology|The intervention group will be fitted with the Tandem t:slim X2 insulin pump with Control IQ technology during pregnancy.
45792082|NCT05727449|Procedure|General Anesthesia|General Anesthesia was intruduced for Cesarean Delivery
45792083|NCT05727449|Procedure|Spinal Anesthesia|Spinal Anesthesia was intraduced for Cesarean Delivery
45920486|NCT00094276|Behavioral|Breathmobile intervention|A community-based service that is specifically designed to deliver asthma screening and special consultation directly to families and children in high-risk neighborhoods.
45792084|NCT03102645|Drug|Placebo Oral Tablet|Placebo film coated tablet: Lactose monohydrate, potato starch, gelatine, magnesium stearate, talc
45792085|NCT03102645|Drug|Imipramine Hydrochloride 25 MG|Two Imipramin DAK film coated tablets 25 mg each, single dose
45920487|NCT00006245|Drug|alvocidib|
45920488|NCT00006245|Drug|paclitaxel|
45920489|NCT00094315|Drug|Cocaine (IV)|
45792086|NCT01639352|Biological|SOM230|Patients will be given a starting of 60mg of SOM230 via injection, intramuscularly every 28 days.
45792087|NCT05740085|Other|Patient information form|Patients will be asked to fill out a patient information form and an osteoporosis awareness form
45920490|NCT00094432|Drug|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
45920491|NCT00094432|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
45920492|NCT00006248|Drug|cisplatin|
45920493|NCT00006248|Drug|fluorouracil|
45920494|NCT00006248|Drug|paclitaxel|
45920495|NCT00094549|Drug|olanzapine|
45920496|NCT00094549|Drug|divalproex sodium|
45792088|NCT03102879|Procedure|Regenerative Endodontic Procedure|Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with stem cells.
45647307|NCT04871399|Procedure|Conventional Right hemicolectomy (Non-CME)|Transecting the Ileocolic Vein and Artery close to the Superior Mesenteric Vessels without clearing the superior mesenteric vein (SMV) from the adipose tissue. Transecting the Right Colic Vein and Artery and superior right colic vein (when present) peripherally. Transecting the Right branches of the Middle Colic Vein (MCV) and the Middle Colic Artery (MCA) peripherally, without clearing the main trunk of the MCV and the MCA. The Right Gastroepiploic Vein and artery are never transacted.
45647308|NCT04871399|Procedure|Right hemicolectomy with CME+CVL|"Separation of the visceral fascia from the parietal fascia by sharp dissection leaving intact mesocolon coverage. Transecting the supplying vessels at their origin from the main vessels, particularly:~The Ileocolic Vessels, The Right Colic Vessels,The superior right colic vein (when present), The Right branches of the Middle Colic Vein and of the Middle Colic Artery~The MCV and MCA at their origin in case of cancer of the hepatic flexure or of the proximal third of the transverse colon, as well as The Right Gastroepiploic Vessels at their origin from the gastrocolic trunk of Henle (GCTH) and the gastroduodenal artery.~The SMV should be cleared from all adipose tissue all along its anterior surface until its intrapancreatic entrance."
45647309|NCT04869761|Drug|Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion|Single MSC infusion of 150x10^6 cells at time zero; intravenous delivery
45647310|NCT04869761|Drug|Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions|Two MSC infusions of 75x10^6 cells at time zero and three months; intravenous delivery
45647311|NCT04432025|Procedure|Bariatric surgery + goal directed medical therapy|Patients will undergo bariatric surgery (RYGB or SG) with goal directed medical therapy titrated to specific end points for BP, HbA1c and lipids
45792089|NCT03102879|Procedure|Conventional Root Canal Treatment|Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with gutta-percha.
45792090|NCT02365506|Drug|Eleclazine|Tablets administered orally in a single dose
45647312|NCT04432025|Procedure|Bariatric surgery|Patients will undergo bariatric surgery (RYGB or SG) with usual care for diabetes mellitus undertaken by their primary care provider/general practitioner
45792091|NCT02365506|Drug|Placebo|Placebo to match tablets administered orally in a single dose
45792092|NCT01639664|Device|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): >0.20 L/kg/day of plasma treated in the first 3 days after randomization.
45792093|NCT03104985|Device|LASMIK|the physiotherapeutic device LASMIK (Registration Certificate in Russia № RZN 2015/2687 dated 25.05.2015).
45792094|NCT03104985|Other|Conventional therapy|"An elastic compression of lower extremities,~Pharmacotherapy,~Topical treatment"
45792095|NCT01705496|Radiation|[124I]FIAU|This is a single dose study of 5 mCi [124I]FIAU in subjects presenting with pain in a prosthetic knee or hip joint. Subject will receive two PET-CT scans after [124I]FIAU injection.
45792096|NCT02287415|Drug|BIA 2-093|
45792097|NCT02287415|Drug|Warfarin|
45792098|NCT00375141|Device|Pulsed dye laser, Intense pulsed light|
45792099|NCT02312934|Drug|Transdermal nicotine|Nicotine patches are currently FDA approved for smoking cessation. Nicotine has effects that have been well studied for many years. Studies have shown that nicotine by itself does not appear by itself to be cancer causing. The use of the nicotine patch is not expected to increase risk of breast cancer recurrence.
45792100|NCT02312934|Other|Placebo Transdermal Patch|Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.
45792101|NCT04707027|Drug|Aflibercept Injection (2 mg/0.05 ml)|Intravitreal aflibercept injections (treat and extend regimen)
45792102|NCT04707027|Other|Defer treatment|Follow up with fundus photo and OCT every 4 weeks
45792103|NCT05418491|Other|No intervention is used in the current study. Interventions were given in the original A.R.T. study|The current study is a post-intervention study; interventions were given in the original A.R.T. study
45792104|NCT01602068|Drug|Dexamethasone Phosphate Ophthalmic|Transcleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
45792105|NCT01602068|Drug|100 mM Sodium Citrate Buffer|Transcleral iontophoresis delivery of 100 mM sodium citrate buffer solution
45792106|NCT05726669|Other|Self-help materials for depression|Self-help materials for depression based on cognitive behavioural therapy have been created and tailored to those with PH by researchers involved in this project, using the evidence base and theory plus clinical experience. The Medical Research Council Frameworks for complex interventions (Craig et al., 2008; Skivington et al., 2021) have been followed as well as the quality appraisal tool for self-help interventions in depression (Cape, 2015). The self-help materials will be shared for feedback with a readership panel of people with PH and caregivers who are members of Pulmonary Hypertension Association UK (a charity for people with PH) prior to being given to participants. The self-help materials will be provided online or posted in paper form to the intervention group and will take four weeks for the person to complete at home (one booklet per week).
45792107|NCT02978157|Drug|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.
45647313|NCT04867889|Device|iTBS (intermittent theta-burst stimulation)|"The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro X100 stimulator and a Cool-B65 A/P coil or a conventional cool-B65 coil.~The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The non-shielded side of the cool-B65 A/P coil is placed towards the patient, or if using the cool-B65 coil the centre of the butterfly is placed towards the patient head"
45792108|NCT02978157|Drug|esomeprazole+bismuth+tetra+levo|esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
45792109|NCT01705964|Drug|IM epinephrine 1:1000|IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
45792110|NCT01705964|Other|No intervention|A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.
45792111|NCT02341482|Drug|PF-04958242|Administered as specified in the treatment arm
45792112|NCT02341482|Drug|Itraconazole|Administered as specified in the treatment arm
45647314|NCT04867889|Device|Sham iTBS|"The sham iTBS is delivered with MagPro X100 stimulator and a Cool-B65 A/P coil.~The coil is placed over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. For all patients electrodes for transcutaneous electrical nerve stimulation (TENS) are applied and if the patient is randomized to sham treatment the shielded side of the coil will be pointing towards the patient's head and there will be a weak TENS current applied instead synchoronously. If the cool-B65 is used the coil is instead angled 90 degrees delivering the pulses into air instead"
45792113|NCT03140631|Drug|Protamine Sulfate|Protamine sulfate is a highly basic protein that forms stable compounds with acidic heparin to rapidly neutralize the anticoagulation effects.
45792114|NCT04420260|Dietary Supplement|Group A: oropharygeal spray and immunostimulant emulsion|"Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of 3 natural bioactive substances of routine use in humans, that feature homologous molecular structures to the native viral receptor.~Intervention 2. Preparation in an emulsion functional food presentation for oral administration, that contains the 8 bioactive compounds that have demonstrated antiviral activity and modulation of the inflammatory response recognized at the moment in the immune activation against the virus."
45792115|NCT04420260|Dietary Supplement|Group D:Placebo oropharyngeal spray + Placebo taken PO|"Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of Placebo substances of routine use in humans.~Intervention 2. Preparation in an emulsion presentation for oral administration that contains the Placebo compounds"
45792116|NCT00422643|Drug|Sodium hyaluronate (hyaluronic acid)|
45792117|NCT05405907|Other|PuraBond haemostatic agent|Application of Purabond to surgical field
45647315|NCT04440371|Combination Product|Tacrolimus 0.1% ointment twice daily plus NBUVB 3 times weekly|Tacrolimus ointment plus phototherapy NBUVB (Tacrolimus arm)
45792118|NCT00374517|Drug|Pimonidazole hydrochloride|
45792119|NCT02312856|Device|PulseRider|Adjunctive device for endovascular embolization of intracranial aneurysms
45792120|NCT00375453|Drug|SH U04722|
45792121|NCT01706588|Drug|Diclofenac sodium|One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
45792122|NCT02987075|Other|Compacting embryo transferring|transfer of 2 utilizable compacting embryos
45792123|NCT02987075|Other|Non- compacting embryo transferring|transfer of 2 utilizable non-compacting embryos have 7-9 cells with under 20% fragmentation.
45792124|NCT01602692|Drug|Tumescent solution with dilute lidocaine and epinephrine|Tumescent Solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000)
45792125|NCT01602692|Drug|Tumescent Solution with dilute epinephrine|Tumescent Solution containing dilute epinephrine (1:1,000,000) only
45647316|NCT04440371|Combination Product|Calcipotriol/Betamethasone ointment plus NBUVB|Calcipotriol/Betamethasone ointment once daily plus NBUVB 3 times weekly
45647317|NCT04431401|Device|Magstim rTMS|The device is made in London,UK
45792126|NCT02984709|Behavioral|Positive Psychology Intervention|Health Behavior Contract - Baseline visit Education Packet - Baseline visit Positive psychology training for teen and parents - baseline visit Parent praise reminder (text message) - one time per week (over 8 week intervention period) Teen gratitude message (text message) - every Monday (over 8 week intervention period) Teen positive value message (text message) - every Wednesday (over 8 week intervention period) Teen mood booster (text message) - every Thursday and Saturday and alternative Sundays (over 8 week intervention period) Small gift ($5 gift card code sent every 2 weeks for 8 weeks)
45792127|NCT02984709|Behavioral|Education|Health Behavior Contract - Baseline visit Education Packet - Baseline visit
45792128|NCT05397353|Other|Sleepio (TM)|Sleepio is a mobile Digital Cognitive Behavior Therapy for Insomnia (dCBT-I) app.
45792129|NCT05405205|Dietary Supplement|synbiotic|Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8- Lb1, L. fermentum K11-Lb3, acacia gum (gum arabic), maltodextrin, sucralose and flavour twice a day resolved in drinking water
45792130|NCT05405205|Dietary Supplement|probiotic|Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8- Lb1, L. fermentum K11-Lb3, maltodextrin, sucralose and flavour twice a day resolved in drinking water
45792131|NCT05405205|Dietary Supplement|placebo|Consumption of 6 g powder containing microcrystalline cellulose, maltodextrin , sucralose and flavour twice a day, resolved in drinking water
45792132|NCT05739851|Drug|DA-1229_01 2.5/500mg (Before)|single dose administration (one tablet once a day)
45792133|NCT05739851|Drug|DA-1229_01 2.5/500mg (After)|single dose administration (one tablet once a day)
45792134|NCT01603940|Drug|Benazepril|Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.
45792135|NCT01603940|Drug|Losartan|Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.
45792136|NCT05739773|Other|five-element music therapy|music therapy
45792137|NCT05710445|Other|Augmented Reality|Mixed reality smart glasses will be used to view a virtual monitor which mirrors the ultrasound screen in real-time.
45792138|NCT01605032|Drug|Busulfan|Given IV
45792139|NCT01605032|Drug|Melphalan|Given IV
45792140|NCT01605032|Drug|Bortezomib|Given IV
45792141|NCT01605032|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
45792142|NCT01605032|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
45792143|NCT05739695|Diagnostic Test|Virtual bronchoscopy navigation|It is planned to use VBN as the only navigation technique to compare it with rEBUS
45792144|NCT05739695|Diagnostic Test|radial EBUS|It is planned to use rEBUS as the only navigation technique to compare it with VBN
45920497|NCT00094549|Drug|placebo|
45792145|NCT05739539|Diagnostic Test|optical coherence tomography angiography|optical coherence tomography angiography will be done postoperatively in both groups to assess the retinal microvascular changes
45792146|NCT05739539|Diagnostic Test|spectral domain optical coherence tomography|optical coherence tomography for ganglion cell complex (GCC) measurement and assessment of macular edema or epiretinal membrane formation will be done postoperatively in both groups
45792147|NCT01706666|Drug|bortezomib|Given SC
45647318|NCT04430543|Behavioral|Cognitive Bias Modification|"CBM sessions are computer tasks that take 15 minutes each. CBM is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. CBM will involve pushing 90% of alcohol stimuli (pulling 10%) and pulling 90% of neutral stimuli (pushing 10%)."
45920498|NCT04519827|Other|New Rice-based hydrolysate|A rice-based hydrolysed infant formula with new ingredient
45920499|NCT04519827|Other|Amino Acid-based infant formula|An amino acid-based infant formula
45647319|NCT04430543|Behavioral|Sham Training|"Sham training sessions are computer tasks that take 15 minutes each. Sham training is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. Sham training will involve pushing and pulling 50% of each type of stimuli (alcohol and neutral)"
45647320|NCT02087267|Procedure|1- or 2-level spinal fusion|1- or 2-level lumbar or lumbar-sacral spinal fusion with the icotec CF/PEEK Pedicle System in combination with the icotec CF/PEEK TLIF Cage ETurn™
45647321|NCT03213119|Procedure|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
45647322|NCT03213119|Procedure|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
45792148|NCT01706666|Drug|cyclophosphamide|Given PO
45792149|NCT01706666|Drug|lenalidomide|Given PO
45792150|NCT01706666|Other|laboratory biomarker analysis|Correlative studies
45792151|NCT01706666|Drug|dexamethasone|Given PO
45792152|NCT01706666|Procedure|quality-of-life assessment|Ancillary studies
45792153|NCT03149991|Drug|Brexpiprazole|Administration of up to 3mg brexpiprazole
45792154|NCT03149991|Drug|Ketamine|administration 6 times over two weeks of inhaled ketamine
45792155|NCT03149991|Drug|Placebo|Administration of placebo which matches brexpiprazole in size and number of tablets per dose
45792156|NCT05708807|Other|Observational - all|All stroke patients are included.
45792157|NCT05739461|Other|Dental implant|Dental implants with triangular cross-section neck design
45792158|NCT05704439|Drug|Neurologist Initiated Treatment|Neurologist Initiated Treatment for Hypertension or Hyperlipidemia
45792159|NCT05704439|Other|Placebo|Usual care
45792160|NCT01706822|Device|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients arlaedy selected to undergo a laparoscopic LAR using the Radial Reload stapler
45792161|NCT01706978|Procedure|Bone Trephination|
45792162|NCT01706978|Procedure|Soft Tissue Trephination|
45920500|NCT00094627|Drug|gaboxadol|Duration of Treatment - 6 weeks
45920501|NCT00094627|Drug|Comparator: placebo (unspecified)|Duration of Treatment - 6 weeks
45792163|NCT05380427|Drug|CU-40101|CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%
45792164|NCT05405127|Other|traditional physical therapy|breathing exercises 10 repetitions, 1set, 3 days/week and targeted abdominal muscles. Total 6 sessions were given each consisting of 30 minutes.
45792165|NCT05405127|Other|core stability exercises|core stability along with breathing exercise 10 repetitions, 1set, 3 days/week and targeted core muscles. Total 6 sessions were given consisting of 30 minutes.
45792166|NCT00375531|Behavioral|Mindfulness Meditation (MfM)|
45792167|NCT01707368|Drug|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
45792168|NCT05739305|Other|Risk factor|No diagnostic or therapeutic intervention; the characteristics of subgroups will be analyzed by the cause of death certificated in the registry.
45920502|NCT00094666|Drug|MK0928, gaboxadol / Duration of Treatment - 6 weeks|
45920503|NCT00094666|Drug|Comparator: placebo / Duration of Treatment - 6 weeks|
45920504|NCT00094705|Biological|rDEN2/4delta30(ME) Vaccine|Live attenuated rDEN2/4delta30(ME) vaccine (one of two doses)
45920505|NCT00094705|Biological|Placebo|Placebo for rDEN2/4delta30(ME) vaccine
45920506|NCT00006251|Radiation|total-body irradiation|Undergo TBI
45920507|NCT00006251|Drug|fludarabine phosphate|Given IV
45920508|NCT00006251|Drug|cyclosporine|Given PO
45920509|NCT00006251|Drug|mycophenolate mofetil|Given PO
45792169|NCT05404347|Diagnostic Test|Next generation sequencing|NGS is carried out on DNA isolated from paraffin embedded tissue
45792170|NCT05400993|Combination Product|Chidamide|Chidamide: take orally twice a week,4 tablets/time (20mg/ time), the interval between two doses should not be less than 3 days (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), the day before chemotherapy, 30 minutes after breakfast； Chidamide: 20mg, orally, twice a week, oral for two weeks and one week, a total of 8 cycles； Epirubicin 90mg/m2 , ivgtt, d1 Cyclophosphamide 600mg/m 2, ivgtt, d1 Q3w, 4 cycle； sequential Docetaxel 100 mg/m 2, IVGtt, D1 Q3w, 4 cycle。
45792171|NCT01605890|Drug|emtricitabine / tenofovir disoproxil fumarate / raltegravir .|"emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.~raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID."
45792172|NCT05121285|Other|Delivery of contrast fluid by lower GI endoscopy|Each participant will receive one delivery of 440 ml contrast fluid by lower GI endoscopy to the cecum of the colon. The participants perform a bowel lavage using Sodiumpicosulphate/Magnesiumcitrate (Picoprep, Ferring) 24 hours before the delivery of contrast fluid. An colon X-ray is obtained within 10 minutes after the contrast fluid is delivered. The participants is in a supine position fram delivery and until the colon x-ray is obtained.
45792173|NCT05121285|Other|Delivery of contrast fluid by enema with and without positioning|"Each participant will receive one delivery of 440 ml contrast fluid by enema. The participants perform a bowel lavage using Sodiumpicosulphate/Magnesiumcitrate (Picoprep, Ferring) 24 hours before the delivery of contrast fluid. The enema procedure includes:~The participant lies on his/her left side in neutral position when the enema is delivered~X-ray of the colon is obtained with the participant lying on his/her back.~The participant is positioned back to his/her left sided position and tilted in a Trendelenburg position. The position is held for two minutes~The participant is turned to an abdominal position while the bed remains tilted in Trendelenburg position.~Participant turne to the right side. When positioned the bed is tilted the opposite way (anti-Trendelenburg.) The position is held for two minutes.~A second colon X-ray is obtained after the participants has rested for ten minutes in a supine neutral position"
45792174|NCT02288273|Drug|Bydureon|Once weekly injection of 2mg bydureon (extended release exenatide) for 10 weeks.
45792175|NCT02288273|Drug|Placebo|Placebo
45792176|NCT03160287|Behavioral|Motivaltional interviews and infrequent motivational text messages|A self-management intervention will integrate use of mobile technology to prompt older adults to be physically active, provides ongoing monitoring of the amount of their physical activity and includes self-efficacy enhancements is a novel non-pharmacological intervention both for prevention and treatment of sleep deficiency in persons with OA
45792177|NCT01606124|Drug|defined green tea catechin extract|Given PO
45792178|NCT01606124|Other|placebo|Given PO
45792179|NCT01606124|Other|questionnaire administration|Ancillary studies
45792180|NCT01606124|Other|laboratory biomarker analysis|Correlative studies
45792181|NCT03163017|Device|2D Fluoroscopy|Patients with syndesmotic instability will undergo reduction of the syndesmosis followed by provisional fixation with a clamp or Kirshner wire. The reduction quality will be initially compared to the contralateral ankle mortise and talar-dome lateral radiographs using the technique of Summers et al i.e. 2D Fluoroscopy using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system.
45792182|NCT03163017|Device|3D Fluoroscopy|After the attending surgeon is satisfied with the reduction quality from 2D Fluoroscopy, 3D fluoroscopy using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system will be used to generate additional images to assess syndesmotic and fibular reductions.
45792183|NCT05739227|Other|allogenic CD19-CAR-NK cells|The relapsed/refractory B-cell hematologic malignancies patients will receive allogenic CD19-Targeted CAR-NK cells infusion up to 3 dose levels (1x10^6/kg, 5x10^6/kg, 2x10^7/kg) after FCE chemotherapy
45792184|NCT05739071|Dietary Supplement|JING SI HERBAL TEA|JING SI HERBAL TEA is a food, contain with herbal extracts
45792185|NCT05739071|Dietary Supplement|Placebo|Placebo will have the same appearance as JING SI HERBAL TEA
45792186|NCT01607450|Drug|GLP-1 Low Dose|0.5mmol/kg/hr GLP-1 for 12 hours prior to PET study
45792187|NCT01607450|Drug|GLP-1 Mid-Range Dose|1.5mmol/kg/min for 12 hours prior to PET study
45792188|NCT01607450|Drug|GLP-1 High Dose|4.0mmol/kg/min GLP-1 for 12 hours prior to PET study
45792189|NCT01607450|Drug|Saline|Normal saline placebo infusion for 12 hours prior to PET study
45792190|NCT05668637|Other|Artificial Intelligence-based Decision support|Decision support to optimise invasive mechanical ventilation settings
45920510|NCT00006251|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
45920511|NCT00006251|Biological|donor lymphocytes|Undergo DLI
45792191|NCT05738993|Drug|BCD-178|A single intravenous (IV) infusion at a dose of 420 mg
45792192|NCT05738993|Drug|Perjeta|A single intravenous (IV) infusion at a dose of 420 mg
45792193|NCT01709474|Drug|Vitamin D3 6000 IU|Subjects will receive 6,000 IU of vitamin D3 by mouth daily until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose will be reduced to 4,000 IU/day. Note: Subjects weighing <40 kilograms (kg) at study entry will receive their dose five days a week and all other subjects seven days a week.
45792194|NCT01709474|Drug|Vitamin D3 400 IU|Subjects will receive 400 IU/day of vitamin D3 daily by mouth.
45792195|NCT05738915|Diagnostic Test|CRP/Albumin ratio in IBD|Role of C-Reactive Protein /Albumin Ratio in evaluation of Disease Activity in Patients with Inflammatory Bowel Disease.
45792196|NCT02992808|Drug|recombinant gonadotropins|
45792197|NCT02992808|Drug|HP-HMG|
45792198|NCT02992886|Radiation|Preoperative radiation|Radiation treatment before surgery
45792199|NCT02992886|Drug|Raltitrexed|concurrent chemotherapy
45792200|NCT02992886|Procedure|Pelvic surgery|
45792201|NCT02331095|Drug|Atorvastatin|"Atorvastatin belongs to the statin class of drugs, and is routinely used for prevention of cardiovascular diseases and/or reduction of cholesterol levels. It has been shown to decrease the risk of first venous thromboembolism in an otherwise healthy population with elevated high-sensitivity C-reactive protein (hs-CRP)."
45920512|NCT00006251|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
45920513|NCT00006251|Other|laboratory biomarker analysis|Correlative studies
45920514|NCT00094744|Device|Eye patch|adhesive eye patch used to cover the sound eye
45792202|NCT02331095|Drug|Anticoagulation Therapy|Warfarin is a standard anticoagulation in the treatment for venous thromboembolism. The dose will be adjusted to goal INR of 2-3.
45792203|NCT01640834|Drug|LY2409021|Administered orally
45792204|NCT01640834|Drug|Placebo|Administered orally
45792205|NCT01640834|Drug|Glucagon|Administered via intramuscular injection
45792206|NCT03029273|Drug|Cyclophosphamide and Fludarabine|Seven days prior to infusion of TCR-T cell, subjects receive cytoreductive chemotherapy with cyclophosphamide (250-500mg/m2/day) plus fludarabine (25mg/m2/day) for 3 days.
45792207|NCT03029273|Biological|Anti-NY-ESO-1 TCR transduced T cells|A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×109) will be intravenously (i.v.) administered Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, IL-2 subcutaneous injections (500,000 IU/day) will be administered for 14 days concomitantly to each subject.
45792208|NCT01641380|Behavioral|Text Messaging Intervention|"Online enrollment in the Compliance for Life® (CFL) system through iReminder)~Welcome Message 24 hrs after enrollment~Appointment Reminder prior to 3 month injection cycles~Monthly health reminders i. Condom use ii. Weight control iii. Side Effect Management 5.6-month STD testing reminder~6.Call for missed appointment or no reply to appointment reminder (or other text message)"
45792209|NCT05327855|Drug|OPL-0301 Dose 1|Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
45647323|NCT03213119|Procedure|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function. The SHAM condition uses body-temperature water, and thus does not result into vestibular unbalance.
45792210|NCT05327855|Drug|OPL-0301 Dose 2|Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
45792211|NCT05327855|Drug|Placebo|Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
45792212|NCT05321147|Biological|lacutamab|Patients will receive a fixed dose of 750mg as 1-hour IV infusion
45792213|NCT05316935|Drug|GnRHa|Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks , and the maximum using courses will be 6.
45792214|NCT05316935|Drug|Letrozole 2.5mg|2.5mg po qd and no more than 24 weeks
45647324|NCT04432649|Biological|4SCAR-276|The 4SCAR-276 T cells can recognize and kill tumor cells through the recognition of CD276 .This study will evaluate the side effects and effective doses of 4SCAR-276 T cells in treating refractory and recurrent solid tumors
45647325|NCT01750073|Drug|Cyclophosphamide|Given IV
45647326|NCT01750073|Drug|Doxorubicin Hydrochloride|Given IV
45647327|NCT01750073|Other|Laboratory Biomarker Analysis|Correlative studies
45792215|NCT05316935|Drug|Diane-35|Periodic use. Patients will receive one pill po qd for 21 days, and next period should be started after 7 days.
45792216|NCT05316935|Drug|MET|500mg po tid
45792217|NCT05711186|Other|Structured SDM|The conversation between the heart team member and the patient will be structured according the adapted three-talk model for patients with symptomatic aortic stenosis and using the American College of Cardiology's decision aid for patients deciding between TAVR and SAVR
45792218|NCT05711186|Other|Usual Care|Usual care will include baseline visits without a structured SDM approach. Usual care includes at least one decision making talk with a heart team member discussing information about the disease, treatment options as well as benefits and risks of each procedure.
45792219|NCT05738759|Drug|Epidural Anesthetic Cocktail|The anesthetic cocktail, consists of triamcinolone 40 mg, marcaine 5 mg, and morphine 3 mg, is soaked in the gelfoam size 1x2 cm and applied on the epidura before removal of the endoscope.
45597829|NCT02204813|Drug|Placebo|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of albumin alone (placebo) will be administered for 5.25 hours."
45597830|NCT02204813|Drug|Lo-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 4 pmoles/kg/min will be administered for 5.25 hours."
45792220|NCT05738759|Drug|Placebo|The placebo is soaked with NSS in the gelfoam size 1x2 cm as well and applied on the epidura before removal of the endoscope.
45792221|NCT05738681|Drug|N acetyl cysteine|N acetyl cysteine 1,200 mg/day for 8 weeks in NAC group
45792222|NCT05738603|Device|Hypotension Prediction Index|Hemodynamic perioperative monitoring with the Hypotension Prediction Index
45597831|NCT02204813|Drug|Hi-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 12 pmoles/kg/min will be administered for 5.25 hours."
45597832|NCT02204813|Drug|Extra Hi-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 24 pmoles/kg/min will be administered for 5.25 hours."
45792223|NCT05738447|Biological|HBV mRNA vaccine|With 20ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and the intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1-month interval.
45792224|NCT05644925|Device|PiCSO Impulse System|The PiCSO Impulse System is intended to reduce infarct size by intermittently occluding the coronary sinus outflow in patients undergoing a percutaneous coronary interventional procedure for myocardial infarction and presenting with Thrombolysis in myocardial infarction (TIMI) flow of 0 or 1.
45792225|NCT05644925|Procedure|Percutaneous Coronary Intervention (PCI)|Minimally invasive procedures used to open clogged coronary arteries
45792226|NCT01642082|Biological|Dalantercept|Given SC
45792227|NCT01642082|Other|Laboratory Biomarker Analysis|Correlative studies
45792228|NCT02288819|Device|Weight monitoring|The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
45920515|NCT00094783|Procedure|MRI|
45920516|NCT00094822|Other|PI Discretion|PI Discretion
45647328|NCT01750073|Drug|Paclitaxel|Given IV
45647329|NCT01750073|Radiation|Radiation Therapy|Undergo RT
45792229|NCT02288819|Drug|Loop diuretic downtitration|"The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.~In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.~In case of a total daily maintenance dose >40 mg furosemide OR >1 mg bumetanide OR >20 mg torsemide, the loop diuretic dose is halved."
45792230|NCT05280509|Drug|TL-895|TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
45792231|NCT05280509|Drug|Ruxolitinib|Ruxolitinib is an FDA-approved janus kinase inhibitor anticancer drug taken by mouth.
45792232|NCT01642238|Drug|Ticagrelor + ASA + Bivalirudin|Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
45792233|NCT01642238|Drug|Clopidogrel + ASA + Bivalirudin|Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
45792234|NCT05638607|Behavioral|Intensified occupational therapy|The intervention is an intensified occupational therapy effort, which does not take time away from other occupational therapy efforts.
45792235|NCT05738369|Dietary Supplement|Biogaia L. reuteri Prodentis® lozenges|Participants were instructed to use the lozenges twice daily after brushing their teeth; once in the morning and once in the evening
45597833|NCT02294734|Drug|GSK2269557|Dry powder for inhalation via DISKUS 'device' with unit dose strength of 500 micrograms (mcg) per actuation with total dose of 1000 mcg daily
45792236|NCT05738369|Dietary Supplement|Hersheyland Ice Breakers Mints sugar free lozenges|Hersheyland Ice Breakers Mints sugar free lozenges
45792237|NCT01643876|Behavioral|Palatal brushing|Participants will be instructed to brush their palate with a manual soft-bristle brush after each meal and before sleeping for a period of 3 months. They will be asked to keep to their usual oral and denture hygiene routine during the trial to allow the isolation of the effect of palatal brushing.
45792238|NCT05710874|Other|CPP-ACP paste|Daily application of CPP-ACP (Casein phosphopeptide amorphous calcium phosphate) paste (Tooth Mousse®) in addition to twice daily use of conventional toothpaste.
45792239|NCT05710874|Other|CPP-ACPF paste|Daily application of CPP-ACPF (Casein phosphopeptide amorphous calcium phosphate in combination with fluoridepaste) (MI Paste Plus®) in addition to twice daily use of conventional toothpaste.
45792240|NCT05710874|Other|1.25% fluoride gel|Weekly application of 1.25% fluoride gel (Elmex Medical Gel®) in addition to twice daily use of conventional toothpaste.
45792241|NCT05710874|Other|Conventional|Twice daily use of conventional toothpaste.
45792242|NCT05737745|Behavioral|Self-monitoring|Tracking physical activity and fruit/vegetable intake.
45792243|NCT05737745|Behavioral|Group-dynamics|Survivors act as team captains, facilitating interactions between themselves and their support team members and providing goal directed feedback.
45792244|NCT05737745|Behavioral|Weekly virtual sessions- Standard|Weekly 30 minute virtual sessions include support group/team building sessions and 15 minutes of physical activity.
45792245|NCT05737745|Behavioral|Newsletters- Standard|Weekly newsletters support attainment of physical activity and nutrition goals.
45792246|NCT05737745|Behavioral|Newsletters- Yoga|Weekly newsletters support attainment of physical activity and nutrition goals, while including mindfulness principles.
45792247|NCT05737745|Behavioral|Weekly virtual sessions- Yoga|Weekly 30 minute virtual sessions include support group/team building sessions and 15 minutes of yoga.
45792248|NCT05259995|Device|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
45792249|NCT05625269|Other|Education|The first session of the individual training will be held for the patients in the intervention group on the first day of the service hospitalization, covering the issues related to the procedure and the hospital process. Afterwards, the second session of individual education will be held the day before discharge on issues related to the patient's home care, such as treatment site care, nutrition, exercise, medication and symptom management. In addition to the patients, their families will also participate in the training sessions. The training will be given face-to-face in a quiet environment to increase intelligibility in patients' rooms. The patients will be given a booklet and magnet prepared by the researcher in addition to the oral explanation.
45792250|NCT03028883|Other|Dose adjustments|Do higher doses of buprenorphine result in a higher rate of neonatal abstinence syndrome as compared to lower doses of buprenorphine
45792251|NCT02986919|Drug|CPI-0610|"Optional tumor biopsy will be obtained prior to Day 1 of CPI-0610 administration.~CPI-0610 will be administered 200mg orally once a daily for 14 consecutive days followed by a 7-day break. The 14 days of CPI-0610 dosing and the 7-day break together constitute 1 cycle of treatment. The dose will not be adjusted for body weight or body surface area."
45920517|NCT00006254|Biological|salmonella VNP20009|
45920518|NCT02964754|Device|CT scan for internal fixation|In the observation group, digital three-dimensional models will be established by CT scan for internal fixation.
45597834|NCT02294734|Drug|Placebo|Dry powder for inhalation via DISKUS 'device'
45597835|NCT03581383|Behavioral|PREP-C|The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) is an interactive online tool that enables providers to provide a thorough assessment of a patient's psychosocial readiness to begin Hepatitis C treatment, and make a treatment plan to improve treatment readiness.
45647330|NCT01750073|Procedure|Therapeutic Conventional Surgery|Undergo mastectomy or breast conserving surgery
45647331|NCT01750073|Biological|Trastuzumab|Given IV
45647332|NCT03125447|Other|speed and accuracy answer to visual stimuli|A yellow fish swimming over a blue-green background will appear on the screen of virtual glasses. The child will have to give as fast as possible the direction of the fish pushing the left or right button of a computer mouse
45647333|NCT03118037|Device|Sonata System|Transcervical access for radiofrequency ablation of uterine fibroids
45920519|NCT02964754|Procedure|conventional internal fixation|In the control group, patients will undergo conventional internal fixation.
45920520|NCT00094978|Drug|Depsipeptide|
45920521|NCT00094978|Drug|Flavopiridol (alvocidib)|
45920522|NCT00095095|Device|Lumbar Interbody Fusion|
45920523|NCT00095134|Drug|risperidone|
45920524|NCT00006257|Drug|paclitaxel|
45792252|NCT05616767|Other|Training on self-screening and HPV vaccination administration|Participants will be taught how to do self-screening for HPV-associated cancers using Training on self-screening and HPV vaccination administration. They will also be given HPV vaccination series.
45792253|NCT05238467|Other|COVID antibody titers in the blood|COVID antibody titers will be quantitatively assessed at baseline, 8 weeks and approximately 6, 9, and 12 months from date of study enrollment. Titers will be compared to levels in 25 age matched adult participants with no prior history of cancer or prior history of non-metastatic solid cancer invasive cancer treated with a curative intent,.and in 25 age matched cancer participants who are on non-immunosuppressive treatments as defined below.
45792254|NCT02290613|Drug|Ambrisentan|"Titration:~As common practice of the clinic, the patient will adapt the dose from 5 mg to 10 mg after 1 to 4 weeks according to tolerability and after consultation (by phone or personally) with one of the investigators.~Additionally, at each study visit the investigator needs to decide, based on the patient's well-being, patients´ assessment, safety parameters, and tolerance of ambrisentan, if the study medication should be modified. The respective decision (increase, maintain or decrease dose) must be documented.~Maximum dose allowed: not to exceed 10 mg/day.~Administration:~Ambrisentan and placebo will be administered orally with or without food intake."
45792255|NCT02290613|Drug|Placebo|Placebo tablet (one to two tablets corresponding to one to two verum tablets)
45647334|NCT01550003|Drug|Certolizumab Pegol (CZP)|"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Reduced CZP regimen (after implementation of protocol amendments 4 and 5):~10 to < 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc);~20 to < 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);"
45792256|NCT02331407|Device|Robotic arm therapy|Training with the ReoGo device
45792257|NCT05736575|Genetic|BDNF analysis (Elisa KIT)|Analysis of peripheral BDNF will be performed
45792258|NCT05611697|Procedure|Single anastomosis sleeve ileal bypass|The abdominal cavity is entered directly (visual trocar) with or without the use of Verres needle. A 6-port set up and a liver retractor is utilized. A sleeve gastrectomy is performed as described below, but division of the stomach starts 6 cm proximal to the pylorus. The small bowel is measured 300cm from the ileocecal valve, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 3.0 cm of 45 mm stapler is used the anastomosis; completed with a 2-0 PDS running suture. The biliopancreatic limb is anchored to the sleeve 4 cm proximal to the anastomosis (non-resorbable V-loc 3-0). Fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.
45792259|NCT05611697|Procedure|Sleeve gastrectomy|In the laparoscopic sleeve gastrectomy, the abdominal cavity is entered directly with a visual trocar with or without the use of Verres needle. The set up includes a total of 5 ports. The Natanson liver retractor is utilized. The greater omentum is separated from the major side of the stomach from the pylorus to the angle of His. The left crus is visualized and the hiatus is inspected for the presence of hernia. A 36 French bougie is introduced and the stomach is divided along this from 4-5cm proximal to the pylorus to 1cm lateral to the angle of His using two purple cartridges (Medtronic Tri-Staple™ technology) followed by beige 60mm cartridges to the angle of His, 1 cm lateral to the esophagus. The sleeve is tested for leaks with instillation of 50ml methylene blue in the tube. The fascia defect is closed with suture for the port site where the specimen is extracted.
45792260|NCT05736419|Drug|Fludarabine|PK-guided fludarabine dosing will be used for each of the 2 cycles, using the InsightRx DoseMeRx platform.
45792261|NCT05736419|Drug|Cyclophosphamide|Cyclophosphamide will be administered Post-Transplant
45792262|NCT05736419|Drug|Tacrolimus|Tacrolimus will be administered beginning on day +5
45920525|NCT00006257|Drug|semaxanib|
45920526|NCT00095251|Drug|Dexmedetomidine|a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.
45792263|NCT05736419|Drug|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) will be administered three times daily starting on day +5.
45920527|NCT00095251|Drug|Lorazepam|Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.
45920528|NCT00006260|Drug|cisplatin|cisplatin IV over 30 minutes on days 1-3.
45920529|NCT00006260|Drug|etoposide|etoposide IV over 60-90 minutes on days 1-3.
45792264|NCT05736419|Biological|Rabbit ATG|The dose and schedule of ATG will be determined according to the nomogram in Appendix A
45792265|NCT05736419|Drug|Dexamethasone|Standard Regimen: Dexamethasone on days -68 to -64 and days -40 to -36.
45792266|NCT05736419|Drug|Bortezomib|Bortezomib on days -71, -68, -65, -61, -43, -40, -37, and -33
45792267|NCT05736419|Drug|Rituximab|Rituximab on days -71, -58, -43, and -30.
45792268|NCT02986685|Drug|Trimebutine Maleate|Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage ,then oral trimebutine maleate 200mg three times daily combined with rabeprazole 20mg once daily were administered to the experimental arm for 4 weeks.
45920530|NCT00006260|Drug|ifosfamide|ifosfamide IV over 30 minutes on days 1-3.
45920531|NCT00006260|Drug|Mesna|Mesna is administered IV over 15 minutes 30 minutes prior to and 4 hours after ifosfamide, then orally at 8 hours post infusion.
45920532|NCT00095329|Biological|sirolimus|
45792269|NCT02986685|Drug|rabeprazole|Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage,and rabeprazole 20mg once daily was administered to other arm for additional 4 weeks.
45792270|NCT05604209|Biological|C62|C62 administered at Day 0 and M4 on Day 28
45792271|NCT05604209|Biological|C1C62|C1C62 administered at Day 0 and M3M4 on Day 28
45792272|NCT05604209|Other|Placebo|Placebo administered on Day 0 and 28
45792273|NCT05604209|Biological|M4|M4 administered at Day 28
45792274|NCT05604209|Biological|M3M4|M3M4 administered on Day 28
45792275|NCT01610570|Drug|Mithramycin|Phase I Portion: Mithramycin will be administered in escalating doses to children and adolescents intravenously over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression. If maximum tolerated dose (MTD) in this Phase differs from the recommended adult dose for Phase II, the protocol will be amended. Using a Simon two stage design, mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults with Ewing sarcoma with Ewings sarcoma - friend leukemia integration 1 transcription factor (EWS-FLI1) fusion transcript Both Phases will enroll patients simultaneously. Phase II Portion: mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults.
45792276|NCT05736341|Drug|Remimazolam besylate|After delivery, patients in this group receives 5mg of remimazolam to induce sedation during the remaining procedures of Cesarean section.
45792277|NCT05736341|Drug|Midazolam|After delivery, patients in this group receives 2mg of midazolam to induce sedation during the remaining procedures of Cesarean section.
45792278|NCT05598749|Dietary Supplement|Placebo|Arabic gum, sucrose and silicon dioxide mix
45792279|NCT05598749|Dietary Supplement|Verum|Propolis dry extract ESIT12 and carriers (arabic gum, sucrose and silicon dioxide mix)
45647335|NCT01550003|Drug|Certolizumab Pegol (CZP)|"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Original CZP regimen (prior to implementation of protocol amendments 4 and 5 and after implementation of protocol amendment 9):~10 to < 20 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~20 to < 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc,); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);~≥ 40 kg: Loading dose = 400 mg Q2W (2 x 1.0 mL sc); treatment dose = 200 mg Q2W (1 x 1.0 mL sc);"
45647336|NCT04602923|Diagnostic Test|Corneal topography: OPD-Scan|Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography.
45792280|NCT05736263|Behavioral|Moderate intensity exercise|moderate intensity aerobic exercise trial
45792281|NCT05736263|Behavioral|High intensity interval exercise|High intensity interval exercise trial
45792282|NCT05736263|Behavioral|Combined exercise|Combined aerobic and resistance exercise trial
45647337|NCT04602923|Diagnostic Test|Corneal topography: Pentacam|Corneal topography photography, taken by Scheimpflug imaging (Pentacam) by measuring corneal curvature, thickness and topography.
45653149|NCT05508997|Device|respiratory parameters on mechanical ventilator (PEEP)|"The 3rd & 4th phases of operation in the group (A) and (B): Each patient received one single session inside the Operation Room (OR) as one shot of the treatment procedure. Arterial Blood Gases (ABGs) were obtained to measure:~Oxygenation by PaO2/FiO2 ratio with constant FiO2 = 100% (oxygen) through the procedure time as a primary outcome.~Secondary outcome.~Ventilation by PaCO2 value from ABGs.~Static compliance (Cstat) was measured as the amount of recruitment of alveoli in the lung.~Blood pressure (systolic/diastolic) one of the hemodynamics measurements was measured pre/post the procedure in the two groups."
45792283|NCT05736263|Behavioral|Resistance exercise|Resistance exercise trial
45792284|NCT05213273|Behavioral|nutritional guidelines to promote healthy diet and increase fish intake|"Nutritional guidelines based on the Mediterranean diet will be provided to both groups (gropu A and group B) through infographic material, recipes and menus.~Both groups will be guided to increase their fish consumption to 3 servings per week. Group A will do that through the consumption of fresh or frozen fish and group B through fresh, frozen and canned fish."
45792285|NCT03029663|Procedure|Transurethral resection of the bladder tumour|
45792286|NCT01611662|Drug|gemcitabine hydrochloride|Given IV
45792287|NCT01611662|Drug|cisplatin|Given IV
45792288|NCT01611662|Procedure|therapeutic conventional surgery|Undergo radical cystectomy
45792289|NCT01611662|Other|laboratory biomarker analysis|Correlative studies
45792290|NCT05589467|Other|DASH-FP|Dash diet with only fried potatoes
45792291|NCT05589467|Other|DASH-NFP|Dash diet with only non-fried potatoes
45792292|NCT05589467|Other|Control|Dash diet with no potatoes
45792293|NCT05736185|Device|PEEP selection|Electric impedance tomography-guided PEEP titration
45792294|NCT05200481|Drug|Brigatinib 180 MG|Patients will receive brigatinib orally at a dose of 90 mg QD for a 7 days lead-in period followed by 180 mg QD continuously, with or without food, in 28-day cycles until progression. Dose reductions are possible.
45792295|NCT05200481|Drug|Carboplatin|Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.
45792296|NCT05200481|Drug|Pemetrexed|Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.
45792297|NCT02239562|Drug|sPIF|
45792298|NCT02239562|Drug|Placebo|
45920533|NCT00095368|Drug|Amoxicillin Pulsatile Release Multiparticulate Tablet (drug)|
45920534|NCT04504149|Behavioral|Patient Readiness for Improvement through Motivation, Engagement, and Decision-making for PTSD|A primary care-based shared decision making intervention
45792299|NCT05587517|Behavioral|EMPOWER|"EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment."
45792300|NCT05587517|Other|Supportive Conversation|The Supportive Conversation will match the time and attention offered through EMPOWER, so will be about 1.5-2 hours and will have two additional follow-up calls.
45792301|NCT01613768|Drug|eribulin mesylate|Given IV
45792302|NCT04768049|Other|Tool Translation|Data Collection procedure will be done in two phases. The first phase will revolve around the translation of the instrument. Firstly the tool will be translated into Urdu with help of two professional translators and then it will be back translated into English to cross check the clarity of text. The translation will focus more on the context and understanding of the text rather literal word-to-word meanings. The translation will be done according to the WHO guidelines
45647338|NCT01484093|Other|R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.|INDUCTION: R-CHOP-14 CHEMOTHERAPY: 4 cycles every 2 weeks ± 1 day All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR. Patients will undergo restaging scans 12 to 14 days following completion of R-CHOP 14, with CT, and FDG-PET. Patients demonstrating at least a PR may proceed to consolidation with R-HIDAC. CONSOLIDATION: R- HIDAC CHEMOTHERAPY: 2 cycles every 3 weeks ± 2 days After R-HIDAC, restaging will occur 17-21 days post cycle 2 with CT scan (or FDG-PET, if this was positive following R-CHOP-14). Radioimmunotherapy Dosimetric dose is given approximately 4-5 weeks after completing cycle 2 of R-HIDAC. This is to be preferred 1 week post restaging scans 17-21 days post cycle 2 of RHIDAC, and up to 2 weeks post-scans will be acceptable only if required by 131 I Tositumomab availability.
45792303|NCT01614392|Behavioral|High velocity low force Power Training|Lower Extremity high velocity power training performed at lower external resistance (40% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
45920535|NCT00095446|Drug|insulin aspart|
45920536|NCT00006263|Biological|filgrastim|
45920537|NCT00006263|Drug|carboplatin|
45920538|NCT00006263|Drug|temozolomide|
45647339|NCT00694655|Biological|Yellow Fever Virus Vaccine|Participants will receive the FDA-approved YFV-17D vaccine, at the FDA approved dose and route of administration.
45647340|NCT04433975|Behavioral|Psychosocial Pain Management (PPMI)|The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
45647341|NCT04433975|Behavioral|Enhanced Usual Care (EUC)|The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
45647342|NCT04432805|Device|Performing of lung ultrasound|Performing of lung ultrasound at bedside in labor ward or in COVID unit
45792304|NCT01614392|Behavioral|Low velocity high force Power Training|Lower extremity low velocity power training performed at high external resistance (70% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
45792305|NCT05176691|Drug|HMPL-760|Administered orally QD for 28-day cycles
45792306|NCT02233478|Dietary Supplement|Pomegranate Juice|Pomegranate Juice alone
45792307|NCT02233478|Dietary Supplement|Soybean Flour Protein|Soybean Flour Protein combined with Pomegranate Juice
45792308|NCT02233478|Dietary Supplement|Soy Isolate Protein|Soy Isolate Protein combined with Pomegranate Juice
45792309|NCT05736029|Other|blood, stool and tissue samples collection|blood, stool and tissue samples collection before and during the treatment, as applicable
45792310|NCT02324972|Drug|AQX-1125|Synthetic SHIP1 activator
45792311|NCT02324972|Drug|Placebo|
45792312|NCT02992184|Device|HCV RNA detection with Genedrive assay|
45792313|NCT02992184|Device|HCV RNA detection with RealTime HCV|
45920539|NCT00095524|Drug|Aripiprazole|
45920540|NCT04492566|Device|Automated Insulin Delivery|"Participants will use the Automated Insulin Delivery (AID) iAPS system for 48-60 hours in a medically supervised session.~For subjects who wish to continue use of the system, they will be offered the option of continuing use of the system at home in an extension phase, for the rest of their pregnancy."
45920541|NCT00095641|Drug|capecitabine|
45920542|NCT00095641|Procedure|adjuvant therapy|
45920543|NCT00095641|Procedure|chemotherapy|
45920544|NCT00006269|Drug|irinotecan hydrochloride|
45920545|NCT00006269|Drug|octreotide acetate|
45920546|NCT02964793|Other|intervention group|"The intervention will include~clinician training sessions, designed to raise awareness of the importance of monitoring for FGR and standardizing SFH measurements~the use of SFH charts and EFW customised charts, built with the same software allowing all information to be recorded on an unique document~the use of the EFW values mentioned on US report, to plot EFW on the customised chart~and explicit recommendations about interpretation of longitudinal values of SFH and EFW measurements. If slopes through consecutive plots are not parallel to either of the predicted centile lines (90th, 50th, 10th) on the chart, and either of the centile lines are 'crossed', fetal biometry by ultrasound scan will be recommended."
45920547|NCT04476030|Drug|SAGE-217|Oral capsules
45920548|NCT04476030|Drug|Matching Placebo|Oral capsules
45920549|NCT04476030|Drug|Sertraline|Oral tablets
45920550|NCT04476030|Drug|Escitalopram|Oral tablets
45920551|NCT04476030|Drug|Citalopram|Oral tablets
45920552|NCT04476030|Drug|Duloxetine|Oral capsules
45647343|NCT04432493|Device|Active repetitive transcranial magnetic stimulation (rTMS)|rTMS will be used to stimulate neuronal activity of the dorsolateral prefrontal cortex (DLPFC). Participants will receive no more than 2000 pulses of rTMS at 110% of participants' resting motor threshold at 10 Hz continuously for the duration of the t-maze task.
45647344|NCT04432493|Device|Sham repetitive transcranial magnetic stimulation (rTMS)|Sham TMS will be used to mimic the auditory sensation of the Active rTMS condition. Protocols for the sham condition will be the same as the active condition, however the TMS coil will be flipped 180 degrees so that participants in this condition will not receive any active stimulation.
45647345|NCT04982939|Drug|Sintilimab|Sintilimab, 200mg IV d1 Q3W
45647346|NCT04982939|Drug|S-1|S-1, 40-60mg BID d1-14 Q3W
45647347|NCT04982939|Drug|Oxaliplatin|Oxaliplatin，130mg/m2 d1 Q3W
45647348|NCT04982549|Drug|Durvalumab|Durvalumab (intravenous infusion)
45647349|NCT04982549|Drug|Carboplatin/ Paclitaxel|Carboplatin /Paclitaxel, as per standard of care
45792314|NCT01615484|Procedure|Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™|After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™, and taken to UNCH where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNC Hospitals and Duke University Medical Center based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice.
45792315|NCT01615484|Device|STEEN Solution™|This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs.
45792316|NCT05146661|Device|NEURESCUE device|The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending to redirect blood flow towards the upper body.
45792317|NCT01616576|Device|Control first, then Experimental|Control condition is currently marketed sound processing strategy.
45792318|NCT01616576|Device|Experimental first, then Control|Experimental condition is newly modified sound processing strategy.
45647350|NCT04982549|Drug|Pemetrexed/ Cisplatin|Pemetrexed / Cisplatin, as per standard of care
45792319|NCT05139563|Other|Placebo injection: Intralipid 20% fat emulsion|placebo intralipid 20% intramuscular (IM) injection
45792320|NCT05139563|Other|Placebo implant|placebo subdermal implant rod
45792321|NCT05034185|Device|Computer-aided diagnosis (CADx) support tool|"The CADx support tool operates when the Clinician switches the preconfigured CAD EYE function on using a button on the controller while the scope system is in BLI mode. This is performed after the Clinician first makes an optical prediction of polyp histology using IEE as described. The CADx support tool will make a prediction of polyp histology as hyperplastic or neoplastic."
45920553|NCT04476030|Drug|Desvenlafaxine|Oral tablets
45920554|NCT00095680|Drug|SCIO-469|two 30-mg capsules three times daily
45792322|NCT05546801|Other|questionnaire|questionnaire on postnatal development
45647351|NCT04982549|Drug|Pemetrexed/ Carboplatin|Pemetrexed / Carboplatin , as per standard of care
45647352|NCT04982549|Radiation|Radiation|5 fractions/ week for ~6 weeks (±3 days) (Total 60 Gy)
45647353|NCT02875223|Drug|CC-90011|Specified dose on specified days
45647354|NCT02875223|Drug|Rifampicin|Specified dose on specified days
45792323|NCT01646762|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
45792324|NCT01646762|Other|Laboratory Biomarker Analysis|Correlative studies
45792325|NCT05136131|Procedure|Electrical cardioversion|"Shocks are delivered as per the Ottawa Cardioversion Protocol in the shock arm. 1) 200J shock delivered using self-adhesive electrodes in an anteroposterior configuration. 2) 200J shock delivered using self-adhesive electrodes in an anterolateral configuration while applying pressure over the electrodes with disconnected standard handheld paddles. 3) 360J shock delivered using the same technique as in (2). 4) As per the treating physician's discretion."
45920555|NCT00095680|Drug|SCIO-469 and bortezomib|The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
45920556|NCT00095719|Drug|Aripiprazole|IM Solution, IM, Cohort 1 - 2.5mg (.33cc) maximum dose 5.0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 5.0mg (.67cc) maximum dose 10 mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 10 mg (1.3cc) or 5.0 mg (.67cc) maximum dose 15mg; 1 injection, 24 hour observation for all cohorts.
45920557|NCT00095719|Drug|Placebo|IM Solution, IM, Cohort 1 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 0mg; 1 injection, 24 hour observation for all cohorts.
45647355|NCT02875223|Drug|Itraconazole|Specified dose on specified days
45647356|NCT04982627|Behavioral|BNI Chatbot|The BNI Chatbot is a web application that guides participants through a brief motivational intervention that motivates them to engage in treatment for opioid use disorder.
45647357|NCT04982627|Behavioral|OUD Education & Treatment Resources|The OUD Education & Treatment Resources intervention is a web application that provides OUD education and treatment resources.
45647358|NCT03064061|Device|Virtual reality|a device with virtual reality is given to the patients with a film of 18 minutes
45647359|NCT04981691|Biological|anti-MESO CAR T cells|Autologous genetically modified anti-MESO CAR T cells
45647360|NCT02621021|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day over 1 hour X 2 days.
45647361|NCT02621021|Drug|Fludarabine|Days -7 to -3, Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days.
45792326|NCT05136131|Other|Sham electrical cardioversion|No shock is delivered in the sham procedure arm.
45792327|NCT02289755|Drug|ALLN-177|ALLN-177 is orally administered oxalate decarboxylase (OxDc). The goal of oral therapy with ALLN-177 is to enzymatically degrade both dietary oxalate and endogenously produced oxalate secreted in the gastrointestinal tract resulting in decreased absorption and reduced urinary oxalate excretion.
45920558|NCT00095758|Drug|Antidepressant + Placebo|Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
45920559|NCT00095758|Drug|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
45920560|NCT02964637|Other|Observational Study|
45920561|NCT04463979|Other|Impact of Cerebellar Functional Topography on Cognition and Motor Ataxia|"Participants in this study will undergo surgical resection of their cerebellar or brain tumor (as per standard of care), as well as clinical and radiographic assessment, including: neurological physical examination (including Karnofsky Performance Scale (KPS) if conducted per Standard of Care), and magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography, prior to, immediately after, at one-month, 6-month, and 1-year follow-up status post-surgical resection. These data will also be collected at 18-month (±60 days) and 24-month (±60 days) visits post-surgery, if regular office visits with the neurosurgeon are scheduled at these two time points.~Only at baseline, the following will be conducted: Brief Ataxia Rating Scale (BARS) assessment score, Cerebellar Cognitive Affective Scale (CCAS/Schmahmann syndrome) scale score, Montreal Cognitive Assessment (MoCA) assessment, and a quality of life (QoL) assessment using the SF-36 questionnaire."
45920562|NCT00095797|Drug|R(+)XK469|Given IV
45920563|NCT00095797|Other|pharmacological study|Correlative studies
45920564|NCT00095797|Other|laboratory biomarker analysis|Optional correlative studies
45920565|NCT00095914|Drug|paclitaxel|
45449655|NCT03724617|Drug|umbilical cord mesenchymal stem cells combined with collagen scaffold|3-7 days after the end of menstruation, we underwent hysteroscopic exploration and separation if there was intrauterine adhesions. Intraoperative endometrial biopsy, recording biopsy location, endometrial specimens sent to HE examination and immunohistochemistry (vwf detection of microvessel density). The umbilical cord mesenchymal stem cell combined with collagen scaffold was spread on the balloon scaffold and placed in the uterine cavity. 5 ml of saline was filled into the balloon, and B-ultrasound confirmed that the scaffold was attached to the uterine wall. The patient was hospitalized for 2 hours and the patient's vital signs were recorded.
45647362|NCT02621021|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
45920566|NCT00095914|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
45920567|NCT00095953|Drug|ispinesib|SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks.
45920568|NCT00095992|Drug|ispinesib|SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks
45647363|NCT02621021|Drug|Pembrolizumab|(Cohort 1, Arm 2 and Cohort 2) On day -2, and days 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days) following cell infusion: Pembrolizumab 2mg/kg IV over approximately 30 minutes. (Cohort 1, Arm 1 Retreatment) 4 doses every 3 weeks (+/- 2 days): Pembrolizumab 2mg/kg IV over approximately 30 minutes.
45647364|NCT02621021|Biological|young TIL|Day 0: Cells will be administered intravenously (IV) on the Patient Care Unit over 20-30 minutes.
45920569|NCT04432428|Drug|Sufentanil Sublingual Tablet|"all patients will receive tablets for sublingual use, containing 15 microgram of sufentanil. The sufentanil tablets come in a cartridge (40 tablets) and are administered with a special patient-controlled device that uses thumb tag recognition.~max dose per hour : 3 tablets of 15µg sufentanil"
45647365|NCT02592317|Drug|JNJ 56021927|JNJ 56021927 will be administered once daily orally in a dose of 240 mg from Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
45647366|NCT02592317|Drug|Drug Cocktail|Drug cocktail comprise of midazolam (2 mg), warfarin (10 mg), vitamin K (10 mg), omeprazole (40 mg), and fexofenadine (30 mg) will be administered on Study Day 1 and 43.
45920570|NCT00096070|Radiation|radiation therapy|Undergo radiation therapy
45647367|NCT02592317|Drug|Pioglitazone|Pioglitazone 15 mg will be administered orally on Study Day 8 and 50.
45647368|NCT02592317|Drug|Rosuvastatin|Rosuvastatin 15 mg will be administered orally on Study Day 9 and 51.
45792328|NCT04997525|Drug|Estradiol Tablets|Combined with progesterone
45792329|NCT04997525|Drug|Progesterone|Combined with estradiol
45792330|NCT04997525|Drug|Follitropin Alfa|Combined with hCG
45920571|NCT00096070|Drug|oxaliplatin|Given IV
45920572|NCT00096070|Drug|fluorouracil|Given IV
45647369|NCT03062423|Drug|Sofodelevier|1 tablet contains 400 mg sofosbuvir
45647370|NCT03062423|Drug|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
45792331|NCT04997525|Drug|Chorionic Gonadotropin, Alpha|In etiher natural cycle or combined with Follitropin Alfa
45920573|NCT00096070|Drug|gemcitabine hydrochloride|Given IV
45647371|NCT03062423|Drug|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
45647372|NCT00790933|Drug|Vedolizumab|Vedolizumab intravenous infusion
45792332|NCT01648322|Drug|F-627|subcutaneous injection given 1 per chemotherapy.
45792333|NCT01648322|Drug|Neulasta® (pegfilgrastim)|Single dose injection given once per chemotherapy cycle.
45920574|NCT00006275|Drug|calcitriol|
45920575|NCT00096148|Drug|idarubicin|Given IV
45920576|NCT00096148|Drug|cytarabine|Given IV
45920577|NCT00096148|Biological|bevacizumab|Given IV
45920578|NCT00096148|Other|laboratory biomarker analysis|Correlative studies
45920579|NCT00096187|Drug|pemetrexed disodium|
45920580|NCT04431960|Drug|blackcurrant (BC) extract|A calcium citrate caplet (Bayer AG, Germany) will be taken by all 3 groups to avoid bone deterioration related to calcium and vitamin D deficiency
45920581|NCT00096304|Drug|docetaxel|
45920582|NCT00096304|Drug|epirubicin hydrochloride|
45920583|NCT00096343|Drug|carboplatin|
45792334|NCT04432571|Behavioral|SOC-REC/SOC-OIC|Standard of care - routine education and counseling (SOC-REC)/SOC-Outreach and Intensified Counseling (OIC). SOC-REC is a stage 1 intervention to prevent lapses in HIV engagement through routine care. If an adolescent (1) misses an appointment >14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after >3 months of treatment he/she is re-randomized to a stage 2 intervention. SOC-OIC is a stage 2 intervention to treat lapses in HIV engagement through routine care which may include tracing and counseling to return to the clinic.
45792335|NCT04432571|Behavioral|SOC-REC/CCT|SOC-REC/Conditional Cash Transfer (CCT). SOC-REC is a stage 1 intervention to prevent lapses in HIV engagement through routine care. If an adolescent (1) misses an appointment >14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after >3 months of treatment he/she is re-randomized to a stage 2 intervention. CCT is a stage 2 intervention to treat lapses in HIV engagement by providing a small cash incentive for on-time clinic attendance and/or viral load suppression (following per current MOH guidelines).
45792336|NCT04432571|Behavioral|SOC-REC/IP-NAV|SOC-REC/In-Person Peer Navigation (IP-NAV). SOC-REC is a stage 1 intervention (routine care) to prevent lapses in HIV engagement. If an adolescent (1) misses an appointment >14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after >3 months of treatment he/she is re-randomized to a stage 2 intervention. IP-NAV is a stage 2 intervention to treat lapses in HIV engagement. Trained peer navigators will develop rapport with the participants and provide psychosocial support, case management, and assess retention and adherence barriers in a systematic manner and work with the participant to develop social support and clear, feasible plans to address barriers. The peer navigator will meet with the participant at least monthly, and no more than weekly, until HIV care engagement is demonstrated.
45792337|NCT04432571|Behavioral|E-NAV/SOC-OIC|E-Nav is a stage 1 intervention to prevent lapses in HIV engagement. Trained e-peer navigators will develop rapport and provide support through phone calls and/or patient preferred social media platforms. They will meet once in person and then weekly electronically for 8 weeks, and then monthly. If an adolescent (1) misses an appointment >14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after >3 months of treatment he/she is re-randomized to a stage 2 intervention. SOC-OIC is a stage 2 intervention to treat lapses in HIV engagement through routine care which may include tracing and counseling to return to the clinic.
45792338|NCT04432571|Behavioral|E-NAV/CCT|E-Nav is a stage 1 intervention to prevent lapses in HIV engagement. Trained e-peer navigators will develop rapport and provide support through phone calls and/or patient preferred social media platforms. They will meet once in person and then weekly electronically for 8 weeks, and then monthly. If an adolescent (1) misses an appointment >14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after >3 months of treatment he/she is re-randomized to a stage 2 intervention. CCT is a stage 2 intervention to treat lapses in HIV engagement by providing a small cash incentive for on-time clinic attendance and/or viral load suppression (following current MOH guidelines).
45792339|NCT04432571|Behavioral|E-Nav/IP-NAV|E-Nav is a stage 1 intervention to prevent lapses in HIV engagement. Trained e-peer navigators will develop rapport and provide support through phone calls and/or patient preferred social media platforms. They will meet once in person and then weekly electronically for 8 weeks, and then monthly. If an adolescent (1) misses an appointment >14 days, or (2) has unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after >3 months of treatment he/she is re-randomized to a stage 2 intervention. IP-NAV is a stage 2 intervention to treat lapses in HIV engagement by providing in person navigation and counseling to a cash incentive for on-time clinic attendance and/or viral load suppression (MOH guidelines). Trained peer navigators will provide psychosocial support, case management, assess retention and adherence barriers in a systematic manner and work with the participant to develop social support and clear, feasible plans to address barriers
45792340|NCT01649180|Drug|Axitinib|Axitinib 5 mg orally with food every 12 hours. One cycle=28 days.
45792341|NCT04429607|Device|Erbium:YAG Laser|Erbium:YAG 2940nm will be performed using single spot, multiple pulses on lesions.
45792342|NCT04429607|Device|Pulsed Dye Laser|PDL will be performed using settings of 6-10 J/s2 on lesions.
45792343|NCT04429607|Device|Nd:YAG Laser|Nd:YAG 1064nm will be performed using settings of 60-110 J/s2 on lesions.
45792344|NCT04429607|Procedure|Electrodessication and curettage|Electrodessication and curettage will be performed using an epilating needle, followed by curettage on lesions.
45792345|NCT04427033|Device|Bone Conduction Implant|Bonebridge system BCI 602
45792346|NCT04408313|Drug|XR-B|Individuals will receive extended-release buprenorphine, administered as a subcutaneous injection, is available in seven different dosage strengths for weekly (8, 16, 24, and 32 mg) and monthly (64, 96, and 128 mg) administration by a health care professional.
45792347|NCT04408313|Drug|XR-NTX|Injectable naltrexone will be used, at a dose of 4cc (380mg of naltrexone), administered by intramuscular injection to the buttocks (alternating sides monthly). Individuals will receive monthly injections.
45792348|NCT01619774|Drug|GSK2118436|Starting dose 150 mg by mouth twice a day.
45792349|NCT01619774|Drug|GSK1120212|2 mg by mouth daily.
45792350|NCT01650584|Drug|ISTA Tears|sterile ophthalmic solution
45647373|NCT04981457|Drug|Misoprostol and iso sorbide mononitrates|drug
45647374|NCT02161211|Behavioral|De-coupling|Six sessions of CBT for anxiety-alcohol de-coupling
45647375|NCT02161211|Behavioral|Anxiety Reduction|Six sessions of CBT for anxiety reduction.
45647376|NCT02161211|Behavioral|Combined|Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
45647377|NCT04558931|Drug|CellProtect|In vitro expanded and activated autologous NK cells
45647378|NCT04558931|Drug|Isatuximab|Naked immunoglobulin (Ig) G1 monoclonal antibody (mAb) that selectively binds to the human cell surface antigen molecule classified as cluster of differentiation (CD) 38
45647379|NCT01676701|Drug|Tabalumab Auto-Injector|Administered SC by auto-injector
45647380|NCT01676701|Drug|Tabalumab Prefilled Syringe|Administered SC by prefilled syringe
45647381|NCT04981379|Drug|Hydroxychloroquine|Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval + Placebo [Favipiravir (1600 mg)], as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval.
45792351|NCT01650584|Drug|Systane|Sterile ophthalmic solution
45792352|NCT01651442|Behavioral|Behavioral Insomnia Therapy|Sleep hygiene, stimulus control, and sleep restriction presented in four sessions.
45792353|NCT01651442|Drug|Zolpidem|5mg or 10mg
45792354|NCT01651442|Drug|Trazodone|50mg to 150mg
45792355|NCT01651442|Behavioral|Cognitive Therapy|Cognitive restructuring, constructive worry, behavioral experiments presented in four sessions.
45792356|NCT04960553|Device|Exufiber® and Mepilex® Border Flex|Post Market Clinical Follow-up Investigation applying Exufiber® and Mepilex® Border Flex to 102 subjects who meet the study criteria for up to 12 weeks
45792357|NCT04941599|Drug|2-Hydroxybenzylamine|2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
45792358|NCT04941599|Other|Placebo|Placebo 250 mg three tabs TID (po) for 6 weeks.
45792359|NCT04901975|Drug|Spironolactone|Spironolactone is a mild diuretic. Drug dosage will be those used clinically and per the CHOP formulary: 3 mg/kg/day in divided doses every 6-24 hours; the drug will be weight adjusted every ~0.5 kg with a maximum dosage of 200 mg/24 hours. Maximum single dose is 100 mg. Spironolactone, the aldosterone antagonist to be utilized in Specific Aim 2 of this study, is FDA approved, has been on the market for many years and is routinely administered to all types of children with congenital heart disease including SV patients. The choice of which patient this should be administered to is up to the clinician and their patients and therefore, not all SV patients are on this medication.
45792360|NCT05428592|Biological|LVRNA009|50μg /0.5 mL/Vial/person
45792361|NCT05428592|Biological|CoronaVac®|0.5 mL/Vial, 0.5mL per human dose containing 600SU of inactivated SARS-CoV-2 antigen
45792362|NCT04901741|Drug|Olaptesed pegol|400 mg per week as continous infusion until progression or intolerable toxicity
45792363|NCT05421416|Drug|Loratadine|Loratadine is 2nd generation inverse agonist that exerts its effect by targeting H1 histamine receptors.
45792364|NCT05421416|Drug|Placebo|Placebo sugar pill
45792365|NCT05078489|Other|Action-observation therapy|Action observation therapy involves the observation and perception of human movement performed by others. The observation of actions performed by others activates in the perceiver the same neural structures responsible for the actual execution of those same actions.
45792366|NCT05078489|Other|Placebo|Participants will watch a natural landscape without any human.
45792367|NCT05710250|Behavioral|6-week MBSR program|"Participants will follow a 6-week program of mindfulness meditation. MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 6 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences."
45792368|NCT05710250|Behavioral|6-week muscular relaxation program|"Control group : This group will follow a 6-week program of progressive muscle relaxation training in order to learn achieving a deep relaxation of the body through voluntary tensing and relaxing muscles. It proceeds by the individual sequentially tensing and then releasing specific groups of muscles throughout the body, and noticing how tension feels relative to relaxation.~The accomplishment of physical relaxation promotes mental calmness in a parallel manner. This program is based on the work of Bernstein and Borkovec and Jacobson, and will be structured in 6-week group with weekly two and half hours sessions and out-of-session assignments for at-home practice (30-min daily)."
45792369|NCT05074277|Behavioral|Simulated short term night shift work schedule|Participant sleep schedules (in the experimental arm) will be modified to simulate short-term (3 consecutive nights) night shift work schedule (kept awake at night and offered sleep opportunities during the day instead) in each of two inpatient stays.
45792370|NCT03206645|Drug|Unesbulin|Unesbulin will be given in combination with carboplatin and paclitaxel for up to 7 cycles depending on which cohort the patient is in.
45792371|NCT04876235|Procedure|endoscopic ultrasound|All patients were implanted with stents（DPPS or LAMS）under the EUS
45792372|NCT04876235|Device|lumen-apposing metal stent|In the LAMS group, patients were stented with LAMS
45792373|NCT04876235|Device|double-pigtail plastic stents|In the DPPS group, patients were stented with DPPS
45792374|NCT04868045|Drug|Thyrotropin Releasing Hormone (TRH)|TRH administration will be given as a 200-mcg single IV bolus on Day 1 and Day 5.
45792375|NCT04868045|Drug|levothyroxine|"Patients maintenance dose of levothyroxine will be taken throughout the study. On Day~1 and Day 5, the levothyroxine will be taken after the TRH test is complete. On Days 2- 4, the levothyroxine will be taken in the morning."
45792376|NCT04868045|Other|Hypothyroidism QOL questionnaire|Administer standardized Hypothyroidism QOL questionnaire.
45792377|NCT04863443|Device|Ultrasound|ultrasound scanner to collect sonographic imaging data from the breast
45792378|NCT04311983|Behavioral|Tobacco Quitline|"Tobacco quitlines provide phone counseling from a quit coach, often supplemented with NRT (nicotine replacement therapy), a quit guide, text messages, or other support. Smokers can call directly or consent to be called by the quitline (fax-back)."
45792379|NCT04311983|Behavioral|Smoke Free Home|The intervention guides participants though a 5-step process: (1) deciding to create a smoke-free home; (2) talking about it with household members; (3) setting a date for the home to become smoke-free; (4) making the home smoke-free; and (5) keeping the home smoke-free. Progress from one step to the next is facilitated over a 6-week period by three mailings sent to participants' homes and one telephone counseling call delivered by a trained smoke free homes coach.
45920584|NCT00096343|Drug|paclitaxel|
45597836|NCT03581383|Behavioral|Modified ECHO|The heart of the ECHO (Extension for Community Health Outcomes) model is its hub-and-spoke knowledge-sharing networks, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. The key modification is one patient visit in the specialty center resulting in co-management of patients with data sharing.
45792380|NCT04841135|Other|Multiomics quantification|One time blood, stool and urine samples will be taken.
45920585|NCT00096421|Behavioral|Tight control of blood glucose levels|
45920586|NCT00096421|Behavioral|Conventional control of glucose levels|
45792381|NCT04841135|Other|Polysomnography|Facultative polysomnography
45792382|NCT01654796|Device|Low Field Magnetic Stimulation (LFMS)|The LFMS devices produces a unique magnetic field that may help alleviate symptoms of depression.
45792383|NCT01654796|Device|Sham LFMS|Sham LFMS looks and sounds like the active treatment but does not produce any magnetic stimulation.
45792384|NCT04803539|Drug|capecitabine|capecitabine is proved to improve 5-year disease-free survival among women with early-stage triple-negative breast cancer who received standard adjuvant treatment(The SYSUCC-001 Randomized Clinical Trial)
45647382|NCT04981379|Drug|Favipiravir|Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Placebo [Hydroxychloroquine (200 mg)], as two tablets per day for 5-day interval.
45647383|NCT04981379|Drug|Favipiravir + Hydroxychloroquine|Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
45792385|NCT04803539|Drug|capecitabine + camrelizumab + apatinib|Camrelizumab combined with apatinib is a safe and effective combination proved in patients with advanced TNBC in our early study
45792386|NCT04799015|Drug|Dexamethasone|Dexamethasone 10mg IV
45792387|NCT04799015|Drug|Metoclopramide 10mg|Metoclopramide 10mg IV
45792388|NCT05710094|Drug|SoftOx Biofilm Eradicator (Groups 1 to 7)|SBE is a water-based formulation containing hypochlorous acid (HOCl) at concentrations of 500-1000 µg/mL and acetic acid (HAc) at concentrations of 1-3 %. Both active ingredients are naturally occurring molecules and have a long history of safe use in medicinal products and in solutions approved as medical devices. Both molecules, exhibit broad-spectrum antimicrobial activity at the concentrations present in SBE. The antimicrobial effect of HOCl is rapid and powerful by acting on and disrupting the function of key microbial molecules such as proteins, lipids, and nucleic acids, while remaining safe to mammalian cells and not promoting the emergence of new resistant microbes. Moreover, HOCl is active against biofilms, and some studies suggest that HOCl may also increase oxygenation of the wound site leading to improved healing.
45792389|NCT05710094|Device|Sterile isotonic saline (Groups 1 to 4)|Sterile isotonic saline was used as placebo because it is part of standard of care, used as an irrigation solution at dressing change and has the same appearance as SBE
45792390|NCT05391932|Behavioral|MINDGAPS|Utilize wearable sensor technology to provide simple, precise measures of gaze and postural stability, as well as remote monitoring of patient adherence to vestibular exercises during a 6-week training period. Additionally, NIH Toolbox data will be used to display patient status compared to normative values and to indicate progress over time relative to measurement error.
45597837|NCT03581383|Behavioral|Patient Telemedicine Questionnaire|The patient questionnaire includes questions about patient experiences with telemedicine visits with providers
45597838|NCT02204891|Dietary Supplement|Probiotics in SIBO|Mixture of the four probiotics in one capsule. One capsule twice daily for 30 days
45647384|NCT04981379|Drug|Placebo|Placebo [Favipiravir (1600 mg)], as two tablet per day at the first day and then Placebo Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
45647385|NCT04389775|Drug|Cohort A|"Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of XW003 on Day 1 after overnight fasting by body weight range:~Proposed XW003 Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg and 0.6mg respectively for Cohorts A1 to A6.~Proposed XW003 Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - XW003 dose level will not exceed 2.0 mg."
45792391|NCT05376176|Drug|STN1010904 ophthalmic suspension 0.03% BID|0.03% STN1010904 ophthalmic suspension BID
45792392|NCT05376176|Drug|STN1010904 ophthalmic suspension 0.1% BID|0.1% STN1010904 ophthalmic suspension BID
45647386|NCT04389775|Drug|Placebo A|"Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of volume-matching placebo on Day 1 after overnight fasting by body weight range:~Proposed Placebo Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg, and 0.6mg respectively for Cohorts A1 to A6.~Proposed Placebo Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - dose level will not exceed 2.0 mg."
45792393|NCT05376176|Drug|Placebo (Vehicle) BID|Placebo (vehicle) BID
45792394|NCT04792775|Behavioral|PE+ER|PE includes the following components: a) psychoeducation about the common reactions to traumatic events and presentation of the treatment rationale b) repeated in vivo exposure to traumatic stimuli, c) repeated, prolonged, imaginal exposure to traumatic memories, and d) relapse prevention strategies and further treatment planning (session 12). DBT Emotion Regulation Skills is integrated as part of this intervention. DBT training provides skills to understand, name, experience and tolerate emotions, as well as skills to change negative emotional responses and to reduce vulnerability to emotion dysregulation (Linehan et al., 2015). The current project includes an adapted 3- session individual emotion regulation skills training intervention to be implemented concurrently with PE which consists of initial teaching/instruction and brief skills review for the remainder of PE treatment.
45920587|NCT00096499|Drug|ispinesib|Given IV
45920588|NCT00096499|Other|pharmacological study|Correlative studies
45920589|NCT00096499|Other|laboratory biomarker analysis|Correlative studies
45920590|NCT04398459|Drug|Ibrutinib|Each recruited subject will accept Ibrutinib treatment.
45920591|NCT00096616|Drug|Combivent® CFC MDI|
45920592|NCT00096616|Drug|Albuterol HFA MDI|
45920593|NCT00096655|Drug|Infliximab|
45920594|NCT00096694|Device|Levonorgestrel-releasing intrauterine device (IUD)|
45920595|NCT04381182|Device|Apollo Wearable Device|Participants wear Apollo device which generates vibration frequencies on skin and can be controlled by the user
45597839|NCT02204891|Dietary Supplement|Probiotics|One capsule twice daily for 30 days
45920596|NCT00006299|Drug|Celebrex|
45920597|NCT04375332|Device|HARPOON™ Beating Heart Mitral Valve Repair System|Repair of the chordae tendinae in the mitral valve.
45792395|NCT04788251|Other|Exercise-based fall prevention intervention (Modified Otago Exercise Programme and Modified Stepping On Programme)|"The modified OEP is a group exercise programme that consists of progressive strength and balance exercises led by trained exercise leaders (fitness instructors or health coaches). The supervised sessions will be conducted twice a week (1 hour each) for 7 weeks. Participants will be given an exercise booklet and encouraged to exercise at home.~The modified SOP is a group fall prevention programme that consists of exercise sessions and discussions on various falls prevention aspects facilitated by a trained programme leader and supported by programme facilitators and peer facilitators. The supervised sessions will be conducted once a week (2 hours each) for 7 weeks. Participants will be given homework and encouraged to exercise at home. In addition, there will be an optional home visit (Week 11), a 1-hour booster session (Week 19) and a telephone call (Week 31)."
45792396|NCT04788251|Other|Wait-list control|To receive fall prevention resources while waiting for their programme to start
45647387|NCT04389775|Drug|Cohort B|"Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of XW003 (n=8) once weekly for 6 weeks following an overnight fast of at least 10 hours.~Subject to change following SRC review of each cohort.~Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence."
45792397|NCT04349345|Diagnostic Test|sperm count|total progressive sperm motile count
45792398|NCT05369546|Diagnostic Test|q3CB|The q3CB/ncCEM/DBT acquisition protocol consists of a combination of DBT volume reconstructions and projection dual-energy mammograms acquired with a clinical contrast enhanced mammography (CEM) protocol, without contrast administration agent.
45792399|NCT03141359|Radiation|SBRT|Primary tumor SBRT
45647388|NCT04389775|Drug|Placebo B|"Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of matching placebo (n=2) once weekly for 6 weeks following an overnight fast of at least 10 hours.~Subject to change following SRC review of each cohort.~Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence."
45647389|NCT04352569|Device|transcranial direct current stimulation|transcranial direct current stimulation (tDCS) is a non invasive brain stimulation technic
45792400|NCT03141359|Drug|Carboplatin|concurrent chemotherapy
45792401|NCT03141359|Drug|Paclitaxel|concurrent chemotherapy
45792402|NCT03141359|Drug|cis Platinum|concurrent chemotherapy
45792403|NCT03141359|Drug|Etoposide|concurrent chemotherapy
45792404|NCT03141359|Radiation|IMRT|mediastinal radiation
45792405|NCT03141359|Drug|Durvalumab|adjuvant immunotherapy
45792406|NCT03028805|Other|Automatic inclusion of COPD orders in admission orders|Use of real-time data to identify a population of patients with COPD and prompt improved adherence to evidence-based guidelines through the automatic inclusion of a COPD order set in the admission orders.
45792407|NCT03028805|Other|Dynamic, end-user order set design|Use of a dynamic order set that has been end-user tested prior to launch rather than designed centrally by a committee to test use of order set components.
45792408|NCT03100487|Device|Apple iPod Shuffle|One session at least 5 days a week for a total of 8 weeks
45920598|NCT00096811|Drug|Entecavir|Tablets, Oral, 1 mg once daily. Until subject achieves a complete response or until ETV approved and marketed in a given country.
45647390|NCT05375383|Dietary Supplement|Streptococcus salivarius K12 lozenge|In this study, a lozenge will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
45647391|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 lozenges containing prebiotic A|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
45792409|NCT01602120|Drug|Lampalizumab|Lampalizumab 10 mg ITV injections as per the schedule specified in respective arms.
45792410|NCT04277117|Behavioral|Waitlist|"Phase 1 (6 months)~• Educational materials on such topics as healthy eating for diabetes."
45647392|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 lozenges containing prebiotic B|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
45792411|NCT04277117|Behavioral|Medically tailored meals - Daily delivery with human interaction|"Phase 1 (6 months)~Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~Food: 10 MTM a week: 5 hot, 5 frozen, and 5-10 snacks per week. Meals and snacks offer approx. 1200 kcal per day.~Delivery: 5x per week, daily home delivery of 1 hot and 1 frozen medically-tailored meals, plus 1-2 healthy snacks.~Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (at minimum in-person hand-off & visual check) with the participant."
45792412|NCT04277117|Behavioral|Medically tailored meals - Weekly delivery with no human interaction|"Phase 1 (6 months)~Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~Food: 10 frozen MTM and 5-10 healthy snacks (with the goal of providing 2 meals and 1-2 snacks for 5 days of the week). Meals and snacks offer approx. 1200 kcal per day. Nutritionally similar and frequently the same meal as that delivered in the daily delivery arm.~Delivery: 1x per week shipment.~Engagement: Meals are shipped to the participant's home. No human engagement."
45920599|NCT00096850|Drug|Atazanavir|From Days 9 to 19, participants will receive a 300 mg tablet orally daily. From Days 20 to 27, participants will receive a 400 mg tablet orally daily.
45920600|NCT00096850|Drug|Rifampin|From Days 1 to 27, participants will receive a 600 mg tablet orally daily.
45920601|NCT00096850|Drug|Ritonavir|From Days 9 to 19, participants will receive a 100 mg tablet orally daily. From Days 20 to 27, participants will receive a 100 mg tablet orally twice daily.
45920602|NCT00096967|Drug|Avastin (bevacizumab)|
45920603|NCT04340076|Drug|Secukinumab|Maintenance/normal dose is 300 mg/4 weeks. First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks.
45792413|NCT04277117|Behavioral|Medically tailored meals - Standard MOWCTX delivery with human interaction|"Phase 2 (6 months)~Food: 5 MTM a week plus snacks. Planned to offer approx. 600 kcal per day.~Delivery: 4x a week, daily delivery of 1 hot MTM plus a cold bag (with healthy snacks), with one day also including 1 frozen MTM for the 5th day of the week.~Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (check-in) with the participant.~MOWCTX Standard Wraparounds: Participants will have access to a case manager to assist with additional resources within the community and for additional support if needed (e.g., grocery shopping assistance, home repairs, and pet care)."
45792414|NCT01658228|Drug|Donepezil|Donepezil 5mg will be given for 6 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg per day is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
45792415|NCT01658228|Drug|Placebo|A placebo capsule will be given to randomized subjects for the starting at week 16 and continuing for the remainder of the study. This group will not receive donepezil as treatment.
45792416|NCT01658228|Drug|Citalopram|Citalopram tablet will be given to subjects during an 8 week flexible dosing open treatment. If subjects respond to citalopram treatment they will be randomized to add-on donepezil/placebo.
45792417|NCT01658228|Drug|Venlafaxine|Venlafaxine tablet will be given to subjects during an 8 week flexible dosing open treatment if they did not respond to citalopram. If subjects respond to venlafaxine treatment they will be randomized to add-on donepezil/placebo.
45792418|NCT05709938|Drug|Glargine and regular insulin versus NPH and regular insulin|"Patients with type 1 diabetes (T1DM) in group A received insulin glargine as basal therapy at night and regular insulin given prior to each main meal.~Patients in group B were given NPH and regular insulin in split and mix method in the morning and evening."
45792419|NCT03029039|Other|Blood samples|Blood samples will be collected at inclusion.
45792420|NCT01659866|Drug|Ciprofloxacin|500 mg orally 2 hours before prostate biopsy
45792421|NCT01659866|Drug|trimethoprim-sulfamethoxazole|1 double strength tablet orally 2 hours before the procedure and again 12 hours later
45792422|NCT01659866|Drug|cefuroxime|500 mg orally 2 hours before the procedure then again 12 hours later
45792423|NCT01659866|Drug|ceftriaxone|500 mg intramuscularly 2 hours before the procedure
45792424|NCT01659866|Drug|gentamicin|2 mg/kg intramuscularly 2 hours before the procedure
45647393|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 lozenges containing prebiotics A and B|In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
45647394|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 powder|In this study, a powder will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
45920604|NCT04340076|Drug|Ixekizumab|Maintenance/normal dose is 80 mg/4 weeks. First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks
45920605|NCT04340076|Drug|Brodalumab|Maintenance/normal dose is 210 mg/2 weeks. First dose reduction step: 210 mg/3 weeks. Second dose reduction step: 210 mg/4 weeks.
45647395|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 powder containing prebiotic A|In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
45647396|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 powder containing prebiotic B|In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
45647397|NCT05375383|Dietary Supplement|Probiotic S. salivarius K12 powder containing prebiotics A and B|In this study, a powder containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
45647398|NCT05375383|Dietary Supplement|Probiotic S. salivarius M18 lozenges|In this study, a lozenge containing will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
45647399|NCT05375383|Dietary Supplement|Probiotic S. salivarius M18 lozenges containing prebiotic A|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
45647400|NCT05375383|Dietary Supplement|Probiotic S. salivarius M18 lozenges containing prebiotic B|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
45647401|NCT05375383|Dietary Supplement|Probiotic S. salivarius M18 + lozenges containing prebiotic A and B|In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
45647402|NCT03062501|Drug|Hydroxyurea|Patients hospitalized for uncomplicated pain crisis with a pain scale of ≥ 6 during the last 24 hours will receive a dose of 30-40 mg / kg hydroxyurea. This same dose of hydroxyurea will be repeated at 24 h and 48 h after the first dose of hydroxyurea, with dose suspension if the patient is discharged within 48 hours. Patients will also receive the center's usual practice and analgesia protocol.
45792425|NCT01659866|Drug|amikacin|5 mg/kg intramuscularly 2 hours before the procedure
45792426|NCT01659866|Drug|aztreonam|500 mg intramuscularly 2 hours before the procedure
45792427|NCT01659866|Drug|imipenem|500 mg intramuscularly 2 hours before the procedure
45792428|NCT01659866|Drug|ceftriaxone|2000 mg intravenously 1 hour before the procedure
45792429|NCT01659866|Drug|gentamicin|2 mg/kg intravenously 1 hour before the procedure
45792430|NCT01659866|Drug|amikacin|5 mg/kg intravenously 1 hour before the procedure
45792431|NCT01659866|Drug|aztreonam|2000 mg intravenously 1 hour before the procedure
45792432|NCT01659866|Drug|imipenem|1000 mg intravenously 1 hour before the procedure
45792433|NCT04755335|Diagnostic Test|Ultrasound|In this project, The investigators will use Alpinion ECUBE-12R (Alpinion, Bothell, WA) US platform. This state-of-the-art research US machine provides beam formed as well as Plane-Wave imaging options that allow high frame rate imaging. The investigators have characterized the acoustic output of this system for safe human studies and obtained the IRB approval for human studies. It should be noted that our technique is not limited to the Alpinion system; the investigators can also use other US systems, such as Verasonics, Vantage, (Redmond, WA). This technique can be adapted to other modern US machines in the future.
45792434|NCT05709782|Procedure|Spine Radiosurgery|scan
45647403|NCT02987803|Other|Data|The tool displays star ratings of hospitals on how labor-friendly they are. The star ratings (1 through 5) are based on hospital-level cesarean delivery rates. The data comes from The Leapfrog Group and is supplemented by publicly available state data. The data displayed will be customized to the users geographic location.
45792435|NCT05709782|Device|Magnetic Resonance imaging|scan
45792436|NCT05709782|Radiation|MR-LINAC|scan
45792437|NCT03068663|Other|Sampling|Patients will receive their standard treatments, surgery with/without chemotherapy. A patient intervention consists in taking samples of blood, saliva, faeces, lung/tumour tissue, and bronchoalveolar lavage fluid.
45792438|NCT04184375|Behavioral|cognitive stimulation|"Patients participate in one session per week according to the following schedule:~2 sensory stimulation sessions: identify sensations, emotions, how to manage them.~2 sessions on association, verbal fluency, and imagination: language as a tool for expression in the face of illness.~2 voluntary attention sessions: improve daily attention.~2 sessions of intellectual structuring: stimulating and maintaining memory, carrying out external activities.~2 sessions of structuring through language: impact on social life.~2 sessions stimulating the temporal and spatial landmarks: agenda, daily trips."
45792439|NCT03024671|Other|Patch test application|test patch with cosmetic product will be applied to the back
45792440|NCT02249702|Drug|gemcitabine + docetaxel|
45792441|NCT02249702|Drug|trabectedin|
45792442|NCT02947529|Drug|Tranexamic Acid|intravenous dose
46071585|NCT05334030|Device|Max Trajectory Control|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~Sitting program - Min lean;~Standing program - Auto lean;~Step initiation program - ProStep+,~Training mode - Off,~SmartAssist option - Bilateral;~Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
45647404|NCT02102789|Drug|mFOLFOX6|Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
45792443|NCT02947529|Other|Placebo|intravenous dose
45792444|NCT01660802|Drug|700 μg Dexamethasone|700 μg Dexamethasone intravitreal injection in the study eye on Day 1.
45792445|NCT01660802|Other|Sham|Sham administered in the study eye on Day 1.
45920606|NCT04340076|Drug|Guselkumab|Maintenance/normal dose is 100 mg/8 weeks. First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks.
45653150|NCT05612009|Combination Product|Toothpastes|"Signal Expert Protection: Conventional toothpaste including Sodium Lauryl Sulphate and fluoride.~Colgate Hemp Seed Oil: Herbal toothpaste including hemp seed oil and also fluoride.~Gumgumix: Herbal toothpaste including ginger extract (no fluoride)."
45792446|NCT02899325|Drug|Diagnostic PET/CT scans|These PET/CT scans will be performed for diagnostic purposes of hepatocellular carcinoma.
45792447|NCT04725305|Device|BiZact|It has been described as describes a bipolar device that continuously measures impedance of clamped tissue, adjusting energy levels in real time and automatically stopping energy delivery when a seal is established. Their literature suggests the device permanently seals vessels up to 3mm with less thermal damage, resulting in less intraoperative blood loss, more efficient procedures, and possibly less pain
45792448|NCT04725305|Procedure|Standard of care|This method would involve removal of tonsils using electrocautery technique
45792449|NCT02986529|Drug|GV-971|
45792450|NCT02986529|Drug|Placebos|
45792451|NCT02753777|Other|Questionnaires|
45792452|NCT02296853|Drug|TAF|25 mg tablet administered orally
45792453|NCT01661114|Drug|Gemcitabine|
45792454|NCT01661114|Drug|5-FU|
45792455|NCT01661114|Drug|Cisplatin|
45792456|NCT02683265|Drug|Aptensio XR|Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg) administered orally, once daily
45792457|NCT02683265|Drug|Placebo|Placebo capsules
45792458|NCT02987829|Drug|TRC253|TRC253 is a high-affinity, small molecule antagonist of the androgen receptor (AR) with inhibitory activity against wild type AR and specific mutated variants of AR. TRC253 blocks AR nuclear translocation as well as AR binding to DNA and is an antagonist of transcription for wild type AR and mutated AR. TRC253 is orally active and does not have agonist activity towards either the wild type or mutated ARs. TRC253 treatment in the Hershberger assay results in complete inhibition of androgen sensitive organ development. TRC253 is efficacious in an LNCaP xenograft model driven by F876L (also known as F877L) mutant AR.
45792459|NCT02988843|Drug|Brentuximab Vedotin|Dose level 1: 1.8 mg/kg every 21 days (up to 180 mg) Dose level -1 :1.2 mg/kg every 21 days ( up to 120 mg)
45792460|NCT02988843|Drug|Bevacizumab|15 mg/kg every 21 days
45792461|NCT02989545|Device|Anal Tape|
45792462|NCT02991729|Other|iPad-based decision aid|This is a novel decision aid developed by genetic counselors and Maternal Fetal Medicine physicians. It is used via an iPad and is interactive. It is available in English and Spanish has been piloted by 20 English and Spanish speaking women. It takes approximately 15 minutes to complete.
45920607|NCT04340076|Drug|Risankizumab|Maintenance/normal dose is 150 mg every 12 weeks. First dose reduction step: 150mg/18 weeks. Second dose reduction step: 150mg/24 weeks.
45920608|NCT04340076|Drug|Tildrakizumab|Maintenance/normal dose is 100 mg or 200 mg every 12 weeks. First dose reduction step: 100 mg or 200 mg/18 weeks. Second dose reduction step: 100 mg or 200 mg/24 weeks.
45920609|NCT04340076|Drug|Bimekizumab|Maintenance/normal dose is 320 mg/8 weeks. First dose reduction step: 320 mg/12 weeks. Second dose reduction step: 320 mg/16 weeks.
45792463|NCT02991729|Other|Genetic counseling appointment|All participants will undergo an approximately 15 minute educational genetic counseling appointment regarding aneuploidy screening options. Should family history concerns be identified on intake, this visit may be extended to include a discussion of additional issues.
45792464|NCT02992197|Biological|Rotarix, dose 1|Rotarix, dose 1
45792465|NCT02992197|Biological|Rotarix, dose 2|Rotarix, dose 2
46071586|NCT00821197|Procedure|long-limb gastric bypass|Laparoscopic long-limb gastric bypass (150 cm alimentary limb, 50 cm biliopancreatic limb)
45792466|NCT02992197|Drug|Placebo (for Rotarix dose 2)|Sterile water to provide volume equivalent as a second dose of Rotarix
45792467|NCT02993445|Other|Alternate Nostril Breathing|
46071587|NCT00821197|Procedure|distal gastric bypass|Laparoscopic distal gastric bypass (150 cm common channel, 50 cm biliopancreatic limb)
45647405|NCT02102789|Drug|HAI|"Patients will receive HAI every 28 days: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump."
45647406|NCT02998879|Drug|Velmanase Alfa (e.g. Lamazym)|iv infusion treatment
45792468|NCT02993445|Device|Foot Reflexology|
45792469|NCT01661270|Drug|Aflibercept|Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
45792470|NCT01661270|Drug|Placebo|Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
45792471|NCT05108571|Drug|DA-5210 10/1000mg|single dose administration (one tablet once a day)
45792472|NCT05108571|Drug|DA-5210-R 10/1000mg|single dose administration (one tablet once a day)
45792473|NCT05098275|Drug|DA-5210 10/500mg|single dose administration (one tablet once a day)
45792474|NCT05098275|Drug|DA-5210-R 10/500mg|single dose administration (one tablet once a day)
45792475|NCT05031351|Drug|Withania somnifera|Nuclear Factor Kappa Beta Inhibitor
45792476|NCT05031351|Drug|Placebo|Placebo Comparator
45792477|NCT05709704|Diagnostic Test|Self-palpation via telehealth|This will be used to determine if the participant has the diagnosis
45792478|NCT05709704|Diagnostic Test|Real-time Ultrasound|This will be used in a subgroup of participants to confirm/rule out a diagnosis
45792479|NCT05709548|Drug|Indocyanine green|Subjects with a diagnosis of acute cholecystitis who undergo urgent laparoscopic cholecystectomy with the preoperative administration of indocyanine green (between 1-2 hours prior to surgery).
45792480|NCT04993209|Biological|NDV-HXP-S 1μg|NDV-HXP-S 1μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart
45792481|NCT04993209|Biological|NDV-HXP-S 3μg|NDV-HXP-S 3μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart
45792482|NCT04993209|Biological|NDV-HXP-S 10μg|NDV-HXP-S 10μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart
45920610|NCT00097045|Drug|omega interferon|
45920611|NCT00097045|Drug|Ribavirin|
45647407|NCT02926651|Drug|Conventional Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
45647408|NCT02926651|Drug|Multi-Dose Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
45647409|NCT02697487|Other|No treatment|This is an observational study with no intervention.
45792483|NCT04993209|Other|Adsorbed inactivated COVID-19 vaccine (CoronaVac)|Adsorbed inactivated COVID-19 vaccine 600 SU/0.5 mL 2 doses intramuscular (deltoid) 28 days apart
45792484|NCT02997735|Behavioral|Quitline Delivered Treatment|The PA Free quitline is funded by the Pennsylvania Department of Health and staffed by trained cessation counselors available 24 hours a day, 7 days a week. Counseling is available in English and Spanish and can be provided in at least 15 additional languages through a third party. All smokers who enroll in smoking cessation treatment will receive counseling and support consistent with accepted clinical practice guidelines. This treatment includes as many as 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between calls. The timing of counseling calls will be relapse sensitive and include a call 1-2 days after the quit date, another telephone call a week after the first call, and additional calls generally occurring at 2-3-week intervals thereafter.
45792485|NCT01662752|Drug|Indocyanine green|Please see arm description
45792486|NCT05274230|Device|Apollo Wearable|Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phone. Participants will use the Apollo for at least 30 minutes after waking up in the morning and at least 30 minutes before bed on the corresponding settings for those times of day. They will be given the Apollo Device TVS (10-200 Hz) to borrow which they will be instructed to wear everyday. They will be asked to continue to wear the device until all study data is collected.
45792487|NCT04905459|Diagnostic Test|ARDA software application|Subject images will be sent to the investigational ARDA software
45792488|NCT02999763|Device|SlimShape|SlimShape radiofrequency treatment to the abdomen
45792489|NCT05249192|Device|Immediate urinary catheter removal|Urinary catheter removal immediately after the end of the surgical procedure before exiting the operating room.
45792490|NCT05249192|Device|Early urinary catheter removal|urinary catheter removal on the first postoperative day (6 a.m)
45647410|NCT04305145|Drug|Infliximab|Infusion
45792491|NCT05231798|Drug|[18F]-FEOBV Radiotracer|Participants will be administered an [18F]-fluoroethoxybenzovesamicol (FEOBV) radiotracer for diagnostic imaging purposes (PET scan).
45792492|NCT03000309|Drug|Apremilast|
45792493|NCT05226104|Device|MOXI|Patients will receive treatment using f1927 devices and will be treated twice over the affected areas, once each month for a total of two months.
45792494|NCT02992028|Drug|Intravenous Nutrition (Vitamins) injection|
45792495|NCT02992028|Drug|Intravenous Saline injection|
45792496|NCT03165981|Biological|PCV13|ACIP Recommended vaccine
45792497|NCT03165981|Biological|DTaP|ACIP Recommended vaccine
45792498|NCT03165981|Biological|IIV|ACIP Recommended vaccine
45792499|NCT02249780|Procedure|Postoperative parathyroid function test|Calcium and parathormone dosage at 24 hours and ten day after surgery
45920612|NCT00097084|Drug|insulin detemir|
45920613|NCT00097084|Drug|insulin glargine|
45920614|NCT00097084|Drug|insulin aspart|
45920615|NCT04310709|Drug|Regorafenib/Nivolumab|Combination of regorafenib and nivolumab
45920616|NCT00006320|Procedure|determine blood levels of anti-HIV drugs|
45920617|NCT00097123|Drug|Misoprostol|
45920618|NCT00097279|Drug|biphasic insulin aspart|
45792500|NCT02249780|Procedure|No postoperative parathyroid dosage and supplementation|The patients will be clinically followed for 24 hours after surgery and caclium and parathormone dosage will be done at ten days after surgery. No supplementation will be given.
45792501|NCT02249780|Procedure|ICG parathyroid angiography|Injection of 3,5 mL of indocyanine green intravenously and perform angiography of parathyroid glands after thyroid removal.
45792502|NCT02249780|Drug|Parathyroid supplementation|Supplementration with Calcimagon D3 Forte (1gr Calcium and 800 IU of 25-OH-vitamin D) from surgery day to up to 10 days afeter surgery.
45792503|NCT03167541|Drug|Test|RB naproxen sodium tablets (2x220mg)
45792504|NCT03167541|Drug|Reference|Aleve naproxen sodium tablets (2x220mg)
45792505|NCT03168321|Drug|IDP-123 Lotion|Tazarotene 0.045% Lotion
45792506|NCT03168321|Drug|IDP-123 Vehicle Lotion|Vehicle Lotion
45792507|NCT04817085|Device|Visant Medical Canalicular Plug|Plug is inserted into the inferior canaliculi and assessed for 6 months
45792508|NCT04817085|Device|Commercially available canalicular plug|Plug is inserted into the inferior canaliculi and assessed for 6 months
45792509|NCT04786587|Diagnostic Test|blood test|"Each pregnant woman completes the self-report during her prenatal consultation and will have a unique blood sampling for dosage of phosphatidylethanol after she returned her self-report to the practitioner and if she is included in the study (informed consent given).~the blood test for dosage of phosphatidylethanol will be offered to all eligible pregnant women in each maternity clinic of the study during the recruitment period. There will not be different arms in this study."
45792510|NCT04786587|Other|self-administered questionnaire|"Each pregnant woman completes the self-report during her prenatal consultation and will have a unique blood sampling for dosage of phosphatidylethanol after she returned her self-report to the practitioner and if she is included in the study (informed consent given).~A self-report, including the T-ACE, is the usual prenatal consultation procedure in the three maternities of the study. The specific procedure for the study is to perform a blood test for dosage of phosphatidylethanol in eligible pregnant women after informed consent."
45792511|NCT04531293|Device|Respiratory Analysis System|Measurement of total lung capacity using total-breath method
45792512|NCT04531293|Device|Respiratory Analysis System|Measurement of total lung capacity using standard method
45792513|NCT03170661|Drug|Deep neuromuscular block|Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count
45792514|NCT03171051|Device|950 nm LED Device|Device to be used in aesthetic and cosmetic procedures which consists of a console and an applicator belt that delivers the treatment LED to the subject's skin.
45920619|NCT00097279|Drug|pioglitazone|
45920620|NCT00097279|Drug|metformin|
45792515|NCT03171051|Device|1050nm Diode Laser Device|FDA approved laser device that has been shown to reduce fat in the flanks by heating the fat cells and causing them to burst. The contents of the cells are then cleared naturally by the body.
45792516|NCT03175731|Drug|Proton Pump Inhibitors|Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
45792517|NCT03175731|Drug|Placebo|Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
45792518|NCT01662908|Drug|edoxaban tosylate|edoxaban tosylate (DU-176b), film-coated for oral use, 90 mg once daily (QD) for 10 days (±2 days) followed by 60 mg QD for a total of approximately 90 days of edoxaban treatment
45920621|NCT00390273|Drug|Metformin|
45647411|NCT04305145|Drug|Methylprednisolone|Infusion
45647412|NCT04305145|Drug|Prednisone|Orally
45647413|NCT04248673|Other|carbohydrate reduced bread|Consumption of carbohydrate reduced bread for three months.
45647414|NCT04248673|Other|carbohydrate rich bread|Consumption of carbohydrate rich bread for three months.
45647415|NCT01670279|Drug|Brexpiprazole|up to 3mg oral dose once daily
45792519|NCT01662908|Drug|enoxaparin/unfractionated heparin|enoxaparin - administered by subcutaneous injection;1 mg/kg/ twice daily or 1.5 mg/kg once daily unfractionated heparin - started with 5000 IU bolus intravenous administration, 1300 IU/h continuous infusion, minimum of 5 days of treatment and stopped when target INR (2.0 - 3.0) is achieved.
45792520|NCT01662908|Drug|warfarin|tablet for oral use; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; 90 days treatment.
45792521|NCT05709392|Procedure|Delayed cord clamping and early skin-to-skin contact|A new method for taking care of remature infants born in gestational weeks 30+0-34+6 will be introduced with delayed cord clamping and early skin-to-skin-contact with a parent. If the infant needs help with the breathing this can be given during the time when the cord is still intact.
45920622|NCT00097318|Drug|Interferon beta-1a|
45920623|NCT00097396|Biological|rF1V vaccine|
45920624|NCT00097435|Drug|Albuferon|
45647416|NCT01670279|Drug|Placebo|
45647417|NCT04226677|Other|aerobic exercise|Treadmill training is include warming, cooling and training phase according to rating of perceived exertion for participants.
45647418|NCT04226677|Other|Video based exercise|Exergame training include virtual reality games by xbox kinect.
45647419|NCT04226677|Other|Control group|first and last evaluations will be made
45792522|NCT02234180|Other|Placebo|Given PO
45792523|NCT02234180|Drug|Regorafenib|Given PO
45792524|NCT03177603|Drug|GSK2586881|GSK2586881 is a clear colorless liquid for IV infusion over 3- 5 minutes and will be administered a maximum dose of 0.8 mg/kg.
45792525|NCT00375297|Drug|sildenafil|
45920625|NCT00097435|Drug|Ribavirin|
45920626|NCT00006326|Drug|Indinavir sulfate|
45920627|NCT00006326|Drug|Ritonavir|
45920628|NCT00006326|Drug|Delavirdine mesylate|
45920629|NCT00390312|Drug|Intranasal Placebo|Intranasal placebo
45920630|NCT00390312|Drug|Intranasal Morphine 15 mg|Intranasal Morphine 15 mg
45920631|NCT00390312|Drug|Immediate Release Oral Morphine 60 mg|Immediate Release Oral Morphine 60 mg
45920632|NCT00390312|Drug|Intravenous morphine|Intravenous morphine 7.5 mg
45792526|NCT03717207|Other|ecg Holter,|all patients before to perform an head up tilt test for syncope evaluation will be steadied by ecg Holter to assess heart rate, heart rate variability.
45792527|NCT03717207|Diagnostic Test|cardiac scintigraphy|all patients before to perform an head up tilt test for syncope evaluation will receive a the 123I-MIBG, which is a norepinephrine analogous, to calculate the late heart-to-mediastinum ratio (H/Mlate) and washout rate (WR). Thus, we evaluated the H/Mlate as the index of global neuronal function due to norepinephrine uptake and the WR as the index of sympathetic tone.
45647420|NCT03062579|Drug|Tocilizumab|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible, without concurrent other immunosuppressive treatments.
45792528|NCT02234570|Drug|Oxfendazole|A benzimidazole carbamate antiparasitic drug. Oral Dose levels of 0.5,1, 3, 7.5, 15, 30, and 60 mg/kg will be evaluated sequentially, the dose increasing with each new cohort Group 1 to Group 7.
45792529|NCT02234570|Other|Placebo|Normal Saline administered with an oral dosing syringe. Group 1- Group 6
45792530|NCT03693105|Device|Accelerated theta burst stimulation|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
45792531|NCT03693105|Device|Sham stimulation|"Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system."
45792532|NCT05709314|Drug|AMDX-2011P|AMDX-2011P single bolus injection intravenous for diagnostic review
45792533|NCT03681249|Drug|ShenqiDihuang Decoction|ShenqiDihuang Decoction 150ml twice a day for 24 weeks 150ml twice a day for 24 weeks
45792534|NCT03681249|Drug|ShenqiDihuang Decoction placebo|traditional Chinese medicine placebo mimic ShenqiDihuang Decoction 150ml twice a day for 24 weeks
45792535|NCT04525599|Biological|ASP3772|Intramuscular (IM) injection
45792536|NCT04525599|Biological|PCV13|Intramuscular injection
45792537|NCT02240030|Drug|CVT-301 Low Dose|
45792538|NCT02240030|Drug|CVT-301 High Dose|
45792539|NCT02240030|Other|Placebo|
45792540|NCT03543111|Behavioral|Zest|Zest is an internet-based psychological health enhancement program for women with spinal cord injury. The intervention will occur in Second Life (SL), which is an online virtual word simulator with a group of women with spinal cord injury.The Zest program will consist of 10 weekly 2-hour group sessions with approximately 8 women using avatars to represent themselves.
45792541|NCT01663922|Drug|Boceprevir|Boceprevir as Victrelis(r) 200mg capsules
45792542|NCT01663922|Drug|St John's Wort|Each Ucalm(r) tablet contains 300mg of St Johns Wort extract
45792543|NCT03180489|Drug|Dapagliflozin Tablet|Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
45920633|NCT00390312|Drug|Intranasal morphine 7.5 mg|Intranasal morphine 7.5 mg
46071588|NCT00829777|Drug|6β-Naltrexol escalating doses from 0.05-0.5 mg IV|"Drug: Naloxone 0.1 mg IV/5 minutes to all subjects to determine tolerability to precipitated withdrawal during screening. Those that tolerate withdrawal proceed to Stage 1:~Drug: Lactulose 10 gm orally plus 3 IV infusions 30 minutes apart of Naloxone 0.1 mg IV and 2 placebo given randomly to all subjects. If tolerated, proceed to 5 additional medication dosing sessions with all subjects receiving oral Lactulose 10 GM plus IV escalating 6β-Naltrexol 0.05 mg, 0.15 mg, 0.5 mg with a randomized placebo."
45647421|NCT04188145|Drug|Fluoropyrimidine|"Option 1: Capecitabine 1250 mg/m2 twice daily (i.e. 2500 mg/m²/d) (D1 to D14, D1 = D22) For frail patients according to investigator evaluation capecitabine dose may be reduced to 1000 mg/m2 twice daily (2000 mg/m²/d).~Or Option 2: Capecitabine 625 mg/m2 twice daily (i.e. 1250 mg/m²/d) (D1 to D21, D1 = D22) Or Option 3: LV5FU2 simplified (folinic acid 200 mg/m² (or Elvorin 400 mg/m²) IV during 2h followed by 5-FU bolus IV of 400 mg/m² during 10 min and IV continuous 5-FU at 2400 mg/m² during 46h). (D1=D15)."
45647422|NCT04188145|Drug|Bevacizumab|"Option 1 and Option 2 : D1 bevacizumab 7.5 mg/kg IV (D1=D21). See smPCs for infusion time of bevacizumab.~Or Option 3: D1 bevacizumab 5 mg/kg IV (D1=D15). See smPCs for infusion time of bevacizumab"
45792544|NCT03180489|Drug|Placebo Tablet|Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
45792545|NCT02240186|Device|Microprocessor Knee (MPK)|MPKs are prosthetic knees that use a microprocessor to control the prosthetic knee mechanism and adjust knee stiffness.
45792546|NCT02240186|Device|Non-Microprocessor Knee (NMPK)|A NMPK is a mechanical knee with either hydraulic or pneumatic controls.
45792547|NCT05709236|Device|Maxillary screw-retained prosthesis|Maxillary screw-retained prosthesis with conventional full-arch impression with conventional or digital impression
45792548|NCT03471663|Drug|D-0502|oral tablets
45792549|NCT03471663|Drug|palbociclib|standard dose of palbociclib
45792550|NCT04360239|Dietary Supplement|Fish Oil|Fish-oil formulation of two capsules twice daily (3000 mg of EPA and DHA).
45792551|NCT01664858|Other|3T CMR|3Tesla Cardiac Magnetic Resonance Imaging
45792552|NCT01664858|Other|SPECT|SPECT: Single Photon Emission Computed Tomography
45792553|NCT01664858|Other|CT calcium score|CT calcium score
45792554|NCT01664858|Other|CT coronary angiography|CT coronary angiography
45792555|NCT01664858|Other|X-Ray coronary angiography|X-Ray coronary angiography
45792556|NCT05364801|Other|Survey|Online anonymous survey
45792557|NCT01665092|Drug|Levo-Carnitine|
45792558|NCT01665092|Drug|placebo|
45792559|NCT04348695|Drug|Ruxolitinib plus simvastatin|"Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.~Simvastatin 40 mg orally every 24 hours for 14 days"
45792560|NCT04348695|Other|Standard of Care|Patients will receive treatment according to usual clinical practice in the participant site.
45792561|NCT04344561|Other|Postural Positioning|Investigators will adjust the positioning of hospital beds to assess improvements in oxygenation and respiratory status.
45647423|NCT04981769|Diagnostic Test|Covid-19 test|PCR Covid-19 test
45647424|NCT04532125|Biological|ARGX-117|Subjects treated with ARGX-117
45792562|NCT04316871|Drug|1.5 mg of Morphine Sulfate|1.5 mg of Morphine Sulphate will be given epidurally.
45792563|NCT04316871|Drug|Normal saline|Normal saline will be given epidurally.
45792564|NCT04316871|Drug|3 mg of Morphine Sulfate|3 mg of Morphine Sulphate will be given epidurally.
45792565|NCT04316871|Drug|4.5 mg of Morphine Sulfate|4.5 mg of Morphine Sulphate will be given epidurally.
45792566|NCT02663063|Device|SSP treatment|SSP treatment 5 times a week
45792567|NCT01665170|Drug|Passiflora incarnata|3 x 1 tablet per day for 3 days
45792568|NCT01665170|Drug|Placebo|3 x 1 ablet per day for 3 days
45792569|NCT05364723|Other||no intervention
45792570|NCT01665872|Behavioral|Cognitive-Behavioral Group Therapy|CBT Group
45792571|NCT05364567|Drug|cholecalciferol (vitamin D3)|The study group with vitamin D deficiency was treated with intramuscular injection of 200,000 IU cholecalciferol (Kwangdong Pharmaceutical Co., Seoul, Korea) once at baseline.
45792572|NCT05364567|Procedure|Phototherapy|The phototherapy for treating depigmented areas was by using 308-nm xenon chloride excimer laser (E1, Jetema, Seoul, Korea) or NB-UVB (N-UVB 6000C, Choyang medical, Seongnam, Korea). The initial dose for excimer laser was decided based on the location of depigmented lesion with consideration of the previous results of the phototherapy;40-42 eye = 100mJ/cm2; head, face, ear, neck, axilla = 150mJ/cm2; arm, leg, trunk = 200mJ/cm2; wrist = 250mJ/cm2; elbow, knee = 300mJ/cm2; hand, foot = 400mJ/cm2; finger, toe = 600mJ/cm2; Meanwhile, initial dose for NB-UVB was 400mJ/cm2. If the erythema after laser disappears within 24 hours, the energy dose was increased by 50 mJ/cm2 for each treatment. But if the erythema sustained for 24-48 hours, the energy dose was maintained. If the erythema last longer than 48 hours, the energy dose was decreased by 50-100 mJ/cm2 at each session. If blistering or pain occured, the treatment was omitted until resolution of symptoms.
45792573|NCT00375765|Drug|Dutasteride|
45792574|NCT02298491|Drug|H.P. Acthar Gel|80 IU subcutaneously daily for 10 days then followed by 80 IU subcutaneously three times per week through Month 12
45792575|NCT03325647|Drug|Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution|Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
45792576|NCT03325647|Drug|Placebo injectable saline|Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
45792577|NCT01665950|Drug|Simvastatin|The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to simvastatin versus placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the simvastatin treatment effect. Subjects who respond in phase 1, and all subjects who receive simvastatin in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
45792578|NCT01665950|Drug|Placebo|Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to statin vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
45792579|NCT04707339|Procedure|Appendicectomy|Laparoscopic or Open Appendicectomy
45792580|NCT05698706|Device|TOOsonix System ONE-M|Selected BCC sites will be treated using high intensity focused ultrasound
45647425|NCT04532125|Other|Placebo|Subjects treated with placebo
45647426|NCT04532125|Biological|ARGX-117 + rHuPH20|Subjects treated with ARGX-117 + rHuPH20
45920634|NCT00390312|Drug|Oral placebo|Oral placebo
46071589|NCT05318586|Procedure|individual rTMS based on fNIRS|The rTMS parameters will be set according to fNIRS results.
45647427|NCT04532125|Other|placebo + rHuPH20|Subjects treated with placebo + rHuPH20
45647428|NCT04532125|Biological|ARGX-117 PH20 SC|Subjects treated with ARGX-117 PH20 SC
45647429|NCT04532125|Other|Placebo PH20 SC|Subjects treated with placebo PH20 SC
45647430|NCT04980989|Device|Mobile software for follow-up of early breast cancer|The patients were randomized to use mobile software or telephone calls as the follow-up modality for early breast cancer
45920635|NCT00390312|Drug|Intravenous placebo|Intravenous placebo
45920636|NCT00097630|Procedure|SAT: Spontaneous Awakening Trial|
45647431|NCT04532047|Drug|Aldurazyme (laronidase)|Enzyme replacement therapy for lysosomal storage diseases
45647432|NCT04102813|Behavioral|Functional Therapy|It consists in a group of body-mind techniques based on functional theory developed in Italy by prof. Luciano Rispoli. These techniques are oriented to stimulate a diaphragmatic breathing though a thoracic and abdominal manipulation, with the aim to activate the parasympathetic nervous system and therefore reducing inflammation
45647433|NCT03063983|Drug|Cyclophosphamide|Continuous oral cyclophosphamide
45647434|NCT03063983|Drug|Methotrexate|Continuous oral methotrexate
45647435|NCT03945721|Drug|Niraparib|"Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells by not allowing the cancer cells to repair its DNA damage or prevent DNA damage from occurring."
45920637|NCT00097630|Procedure|SBT: Spontaneous Breathing Trial|
45920638|NCT00006329|Procedure|Minimally invasive radioguided parathyroidectomy|
45920639|NCT00400387|Drug|Fragmin P Forte (dalteparin sodium)|subcutaneous injection, once daily supported by multivitamine supplement and close monitoring
45920640|NCT00400387|Dietary Supplement|Multivitamin supplement|general pregnancy support by multivitamin supplementation and close monitoring
45920641|NCT00390351|Device|optical coherence tomography|
46071590|NCT05318586|Procedure|Traditional rTMS strategy|The low-frequency rTMS to contralesional M1 will always be used.
46071591|NCT04450693|Biological|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
45792581|NCT04086615|Device|NMES and exercise supplemented with high BFR|"The BFR-NMES-Exercise training consists of 20-min sessions performed concurrently with NMES and exercise in the clinic 2x a week for a total of 18 in-clinic sessions. Using the Delfi PTS Personalized Tourniquet System for Blood Flow Restriction at 80% of LOP, the participant performs 4 exercise sets of 60 repetitions (5 seconds ea) for 5 minutes, with a 1-minute BFR deflation between sets. The standard exercise rehabilitation protocol for PFPS combines open chain and closed chain quadriceps strengthening exercises: active straight leg raises, quadriceps straightening, step up, and squats. NMES training consists of 20-minute sessions: a 2-min warm-up, 15-min work-out, and a 3-min cool down using the KneeHAB® XP Multipath stimulation system which changes the current pathways between the electrodes for preset periods within each pulse, allowing for higher stimulation intensities that maximizes muscle fibre recruitment and minimizes muscle fatigue."
45792582|NCT04086615|Device|NMES and exercise supplemented with low BFR|"The BFR-NMES-Exercise training consists of 20-min sessions performed concurrently with NMES and exercise in the clinic 2x a week for a total of 18 in-clinic sessions. Using the Delfi PTS Personalized Tourniquet System for Blood Flow Restriction at 20mmHG venous pressure (no blood flow restricted), the participant performs 4 exercise sets of 60 repetitions (5 seconds ea) for 5 minutes, with a 1-minute BFR deflation between sets. The standard exercise rehabilitation protocol for PFPS combines open chain and closed chain quadriceps strengthening exercises: active straight leg raises, quadriceps straightening, step up, and squats. NMES training consists of 20-minute sessions: a 2-min warm-up, 15-min work-out, and a 3-min cool down using the KneeHAB® XP Multipath stimulation system which changes the current pathways between the electrodes for preset periods within each pulse, allowing for higher stimulation intensities that maximizes muscle fibre recruitment and minimizes muscle fatigue."
45792583|NCT01667978|Drug|Norethindrone acetate|
45792584|NCT03282669|Drug|Intrathecal Morphine|Intrathecal Morphine administered in the operating room.
45792585|NCT03282669|Drug|Intravenous hydromorphone|Intravenous hydromorphone administered via IV in the post operative area.
45792586|NCT00375843|Drug|Escitalopram|Level 1 of the study involves open-label treatment with escitalopram, up to 30 mg/day for up to 12 weeks.
45792587|NCT00375843|Drug|Sertraline|Level 2 of the study involves open-label treatment with sertraline, up to 200 mg/day for up to 12 weeks.
45647436|NCT03945721|Radiation|Radiation Therapy|radiation therapy
45647437|NCT01876355|Drug|Clonidine|o The concentration of clonidine in the solution is 12.5 µg/ml. Continuous iv infusion of 0.02 ml/kg/h results in a dosage of 0.25 µg/kg/h. The maximum dosage achieved is 25 µg/h. The total amount of clonidine given to a person with a body weight 100 kg or more will be 600 µg a day. Since the doses chosen are in the low range, there will be no dosage adjustment for renal- or liver failure.
45792588|NCT05143814|Device|3D Printed Mask Adapter Designed from Facial 3D scans for Fit testing.|Given the high level of fit test failures, without the provision of improved fits of masks, patient care will be highly curtailed for frontline staff at risk of SARS-CoV-2. Therefore, a reusable bespoke mask adapter used with a soft FFP3 disposable mask might be an economical solution to address the passing of fit testing. Currently, this is a major challenge in delivery of healthcare and urgent action is needed.
45792589|NCT05136170|Drug|Oxervate|One drop of the test product will be instilled in both eyes TID
45920642|NCT00400426|Procedure|Radiotherapy|20 Gy in 4 fx
46071592|NCT04450693|Other|Standard care|"Standard care is defined in this protocol to consist of the following:~Debridement;~Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~Appropriate use of systemic antibiotics."
45920643|NCT00006332|Drug|Tetrathiomolybdate|
45647438|NCT01876355|Drug|SodiumChloride|Placebo. Pharmaceutical form: Injection. Route of administration: Intravenous use.
45647439|NCT03943303|Radiation|Natural gamma radiation from the monazite sands|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
45647440|NCT03943303|Radiation|Normal sands exposure patients|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the no-monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
45653151|NCT01655901|Behavioral|Active video gaming|
45792590|NCT05136170|Other|Vehicle|One drop of the placebo will be instilled in both eyes TID
45792591|NCT05364177|Drug|68Ga-Pentixather|After intravenous injection of 68Ga-pentixather, PET/CT scan will be performed.
45792592|NCT05364177|Drug|68Ga-Pentixafor|After intravenous injection of 68Ga-pentixafor, PET/CT scan will be performed.
45920644|NCT00400465|Procedure|Normal dressing|Normal dressing
45920645|NCT00400465|Procedure|Pressure dressing|Pressure dressing
45920646|NCT00390390|Drug|Lansoprazole|
45920647|NCT00097747|Drug|Placebo|
45920648|NCT00097747|Drug|peginesatide|
45920649|NCT00097825|Drug|Zoledronic Acid|
45792593|NCT05363943|Procedure|double plating|open reduction and internal fixation by using lateral and medial plates.
45792594|NCT05363943|Procedure|Distal femoral replacement|excision of the distal part of femur and replacement with distal femoral prosthesis
45792595|NCT01668602|Device|Fast Walking with Fast Functional Electrical Stimulation (FES) Training|Functional electrical stimulation (FES) is a technique that causes a muscle to contract through the use of an electrical current. The therapist applies an electrical current to either the skin over the nerve, or over the bulk of the muscle, and this will cause a muscle contraction. The FES is delivered to 2 muscle groups (dorsiflexor and plantarflexor) timed appropriately with the gait cycle. FastFES gait training sessions may comprise up to six 6-minute bouts of walking with rest breaks between bouts (total 30-minutes of walking). The last training bout (bout 6) may comprise 6-minutes of over ground walking, during which subjects will be asked to walk as fast as they can. For safety, a physical therapist will walk with and guard the subject during over ground walking.
45792596|NCT01668602|Other|Fast Walking|Fast walking training sessions will be similar to FastFES in duration, dosage, structure but no FES will be provided.
45792597|NCT03247569|Drug|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
45792598|NCT01668836|Drug|Resveratrol|1 pill daily containing 500 mg/d of resveratrol for 30 days
45792599|NCT01668836|Behavioral|Caloric restriction|Diet of 1000kcal per day for 30 days
45792600|NCT03857607|Genetic|Whole exome sequencing|Whole exome sequencing will be used to identify causative genes in ATP1A3 mutation negative patients, to confirm causality in ambiguous phenotypes and to identify modifier genes.
45792601|NCT03008733|Other|Ultrasound UHF peripheral nerves|Ultrasound UHF peripheral nerves
45792602|NCT03008733|Other|Electro myography surface nerves|Electro myography surface nerves
45792603|NCT03751449|Other|Educational Intervention|Receive nutrition education
45792604|NCT03751449|Behavioral|Exercise Intervention|Complete home-based aerobic and resistance exercise program
45792605|NCT03751449|Other|Quality-of-Life Assessment|Ancillary studies
45792606|NCT03751449|Other|Questionnaire Administration|Ancillary studies
45792607|NCT05690828|Behavioral|Cognitive remediation|The cognitive remediation programme shall be run either in video workshops or face to face workshops and in home sessions via a web app. The programme will run for 4 months during which there will be 3 different evaluations. A first evaluation after randomisation, a second evaluation 4 months after inclusion (corresponding to the end of the programme), and a third evaluation 8 months after inclusion for the experimental group (4 months after the end of the programme). The face to face workshops will take 8 to 10 participants and will be led by a neuropsychologist.
45647441|NCT03062345|Other|Single-User Virtual Reality Upper Extremity Therapy|Virtual Reality games with the user as the only person required for participation
45920650|NCT00390507|Procedure|Post-tetanic count frequency|
45920651|NCT00097903|Drug|Karenitecin (BNP1350)|Phase 1 study,dose-escalation design
45920652|NCT00400543|Device|Continuous positive airway pressure (CPAP)|
46071593|NCT00825487|Drug|ARQ 621|Treatment will be initiated at a dose level of 10 mg/m^2 IV infusion for an hour once weekly in 4-week (28 day) consecutive and continuous cycles. ARQ 621 should be infused IV over two hours at doses 200 mg/m^2 and higher (cohort 8 and above).
45647442|NCT03062345|Other|Multi-User Virtual Reality Upper Extremity Therapy|Virtual reality games in which more than one user is required for participation. Users interact in the virtual environment.
45647443|NCT02747407|Biological|Hepatitis A Vaccine|
45647444|NCT02747407|Other|Laboratory Biomarker Analysis|Correlative studies
45792608|NCT03744663|Drug|Suboxone® SL|Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized to two groups one of which will be Suboxone® SL.
45792609|NCT03744663|Drug|Sublocade®|Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized, either Suboxone® SL or Sublocade®. Subjects with significant opioid craving (> 20 mm on the Opioid Craving Visual Analog Scale) or withdrawal (a score of > 12 on the Clinical Opiate Withdrawal Scale) after 14 days of treatment will be started on Sublocade® only at the consensus of the research team. Otherwise they will undergo an additional 7 day titration period. Study drug with Sublocade® group: Patients assigned to this group will receive the study drug (300 mg subcutaneously) every 4 weeks for a total of 6 doses along with weekly therapy. The location and specifications of its application will follow the recommendations by the FDA previously published.
45792610|NCT05086952|Drug|Vericiguat (BAY1021189) - Intervention A|Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fed state.
45920653|NCT00097942|Drug|memantine HCl|
45920654|NCT00006341|Other|Implant|A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
45647445|NCT02747407|Biological|Tetanus Toxoid Vaccine|
45647446|NCT02747407|Biological|Trivalent Influenza Vaccine|
45647447|NCT01870193|Dietary Supplement|Glycine, cysteine (as n-acetylcysteine), alanine|"Young controls will receive cysteine plus glycine for 2 weeks~The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months"
45647448|NCT04531501|Diagnostic Test|Saliva and NPS test|N/A Our study will not impact their path of care as they will be doing an NHS test which will determine their path of care at the NHS
45647449|NCT03063905|Drug|Buprenorphine|Patients taking buprenorphine to wean off an opiate addiction
45647450|NCT04432415|Device|Silver Diamine Fluoride|Annual application od Silver Diamine Fluoride
45647451|NCT04432415|Device|Soduim Fluoride Varnish|biannual apllication of Sodium Fluoride Varnish
45647452|NCT04432415|Device|Placebo|biannual application of artificial saliva
45792611|NCT05086952|Drug|Vericiguat (BAY1021189) - Intervention B|Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fasted state.
45647453|NCT05331937|Combination Product|repetitive transcranial magnetic stimulation (rTMS)|rTMS (real versus sham) is used as adjuvant to ERP
45647454|NCT02627495|Device|transcranial Direct Current Stimulation (tDCS): (Soterix ©)|Subjects will undergo tDCS stimulation. We will use electrodes of 35cm^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated limb (or for bilateral amputees contralateral to the most painful side). The subject will undergo stimulation for 20 minutes. The subject will have 5 sessions of stimulation during a 1 week time period.
45792612|NCT05086952|Drug|Vericiguat (BAY1021189) - Intervention C|Single dose of 2.5 mg vericiguat low-concentration pediatric formulation (oral liquid formulation) in fed state.
45792613|NCT05086952|Drug|Vericiguat (Verquvo, BAY1021189) - Intervention D|Single dose of 10 mg vericiguat immediate release (IR) intact tablet in fed state.
45792614|NCT03689907|Other|Chimerism Evaluation|Blood collection for chimerism evaluation will be performed on days +14/15-post transplant and +30-post transplant for each study participant.
45792615|NCT01669538|Drug|Galantamine|
45792616|NCT01669538|Drug|Placebo|
45792617|NCT05363475|Device|ForeSite Intelligent Surface|The ForeSite IS is a continuous bedside pressure mapping system with machine learning and artificial intelligence (ML/AI). It consists of an overlay with over 1500 undetectable integrated sensors and a medical-grade bedside touchscreen monitor. The monitor displays a real-time coloured body pressure image, a turn timer, and a history of previous turns. The ML/AI software tracks 17 body locations and the patient's body position. The system has a centralized dashboard that shows the pressure injury risk and turn history, which can be transmitted to the nursing station. In addition, data is stored in an Amazon Web Services (AWS) secured cloud database, enabling access to individual reports on turn history and compliance and pressure exposure. Data is stored as both, raw pressure data files and real time event information on pressure exposure and turn data.
45647455|NCT02369575|Other|novel biomarkers of lung disease|we will be identifying molecular, genetic, and cellular markers of lung disease
45647456|NCT01402271|Drug|carboplatin|
45792618|NCT05690750|Other|No intervention|No intervention as this is an observational study.
45792619|NCT00375375|Drug|Lactulose|
45792620|NCT02757417|Drug|sodium fluorescein|
45792621|NCT02757417|Drug|phenazopyridine|
45792622|NCT01671176|Device|Wide diameter bone anchored implant|4.5 mm wide diameter bone anchored implant
45792623|NCT02746965|Device|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
45792624|NCT02746965|Device|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
45792625|NCT02746965|Other|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
45792626|NCT01672658|Device|Sensory Kinetics Balance System|Subjects will participate in balance/gait/functional mobility training twice a week for 8 weeks.
45792627|NCT01672658|Other|Traditional Vestibular Rehabilitation|Subjects will perform traditional vestibular/balance rehabilitation which will include gait training, balance retraining, vestibular retraining, and functional mobility.
45792628|NCT03505281|Biological|Blood samples|"Patients:~1 tube of 4 ml blood (Lithium Heparinate)~3 tubes of 7 ml blood (EDTA)~2 tubes of 7 ml blood (EDTA) for 20 NET Covid patients~Healthy volunteers:~1 tube of 4 ml blood (Lithium Heparinate)~3 tubes of 7 ml of blood (EDTA)~1 tube of 4 ml (citrate)"
45792629|NCT05067140|Drug|ARV-766 Part A|Part A: Daily oral dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.
45792630|NCT05067140|Drug|ARV-766 Part B|Part B Participants will be randomized to receive daily oral dosage at one of two selected Phase 2 doses based on data from Part A
45792631|NCT04333095|Drug|Liposomal bupivacaine|Sternal Block during Coronary Artery Bypass Graft Surgery and/or surgical aortic valve replacement through mini- or full sternotomy
45792632|NCT04333095|Drug|Normal Saline Flush, 0.9% Injectable Solution_#1|Sternal Block during Coronary Artery Bypass Graft Surgery and/or surgical aortic valve replacement through mini- or full sternotomy
45920655|NCT04294836|Drug|Curcumin|BCM-95® (CURCUGREEN®) is a 100 percent pure extract of turmeric with enhanced bio-availability and bio-efficacy. Its powerful health-promoting benefits are derived from the colorful and aromatic qualities of the Indian spice
45920656|NCT04294836|Drug|Placebo oral tablet|PLACEBO Capsules 500mg
45920657|NCT00098098|Biological|rBV A/B|
45920658|NCT00098137|Drug|Olmesartan|
45647457|NCT01402271|Drug|paclitaxel|
45647458|NCT01402271|Drug|pazopanib hydrochloride|
45647459|NCT01402271|Other|laboratory biomarker analysis|
45647460|NCT01402271|Other|pharmacological study|
45647461|NCT05095753|Device|Earbud|In ear headphone with embedded infrasonic hemodynography technology
45647462|NCT04980755|Other|Body Reprogramming|An educational intervention originally designed for patients with fibromyalgia.
45647463|NCT03485053|Drug|IOP Injection / MPB-1514|Dilute with 5% Dextrose solution (D5W)
45653152|NCT01655901|Behavioral|Passive video gaming|
45653153|NCT01655901|Behavioral|Resting|
45792633|NCT05045144|Combination Product|RSV MAT Lot 1 vaccine (GSK3888550A)|One dose of RSV MAT Lot 1 vaccine (GSK3888550A), administered intramuscularly in the deltoid region of the left arm, at Day 1.
45792634|NCT05045144|Combination Product|RSV MAT Lot 2 vaccine (GSK3888550A)|One dose of RSV MAT Lot 2 vaccine (GSK3888550A), administered intramuscularly in the deltoid region of the left arm, at Day 1.
45920659|NCT00098215|Behavioral|Pediatric residency training on tobacco|
45920660|NCT00006344|Radiation|radiation therapy|
45920661|NCT00098332|Drug|forodesine hydrochloride|
45920662|NCT04294680|Device|Cryotherapy|see opiate sparing description
45920663|NCT02958358|Other|CT imaging, functional PET imaging|Physiology study using CT and functional PET imaging with 13NN and FDG as radiotracers; images obtained before and 3 months after treatment with ambrisentan.
45792635|NCT05045144|Combination Product|RSV MAT Lot 3 vaccine (GSK3888550A)|One dose of RSV MAT Lot 3 vaccine (GSK3888550A), administered intramuscularly in the deltoid region of the left arm, at Day 1.
45792636|NCT05045144|Combination Product|Flu D-QIV vaccine|One dose of Flu D-QIV vaccine administered intramuscularly: - in the deltoid region of the right arm, at Day 1 for the RSV1+Flu, RSV2+Flu and RSV3+Flu groups. - in the deltoid region of the left arm, at Day 1 for the Flu+P group. - in the deltoid region of the non-dominant arm, at Day 31 for the RSV1, RSV2 and RSV3 groups, as an optional vaccination for participants to provide standard of care.
45792637|NCT05045144|Combination Product|Placebo|One dose of placebo, administered intramuscularly in the deltoid region of the right arm, at Day 1.
45792638|NCT03334149|Other|Self-Monitoring of Blood Pressure|"BUMP 1: Women randomised to the self-monitoring arm will be asked to measure blood pressures at least three times a week. They will perform two readings with a one minute interval and will be asked to act on the second reading if it falls outside their normal range thresholds described in their instructions, and aided by the tele monitoring system.~BUMP 2: Women randomised to the self-monitoring arm will be asked to measure blood pressures daily. They will perform two readings with a one minute interval and will be asked to act on the second reading if it falls outside their normal range thresholds described in their instructions, aided by a tele monitoring system."
45920664|NCT00098488|Drug|tanespimycin|Given IV
45920665|NCT00098488|Biological|rituximab|Given IV
45647464|NCT02356939|Device|intraductal removable stent custom-made segment (2 cm)|": In the IST group, the surgeon will place the IST in the bile duct, which is a custom-made segment (2 cm) of a 8 French T-tube. The stent is inserted in the biliary duct without suture fixation.~In order to minimize bias and to homogenize the technique, a short technical explanatory movie was realized by the promoter's team and edited on internet.~In the IST group, an endoscopic retrograde cholangio-pancreatography (ERCP) with sphincterotomy will be planned between the 4th and the 5th month post-transplantation, requiring a short stay in hospital, a general anesthesia, clinical and biological tests including plasmatic lipase dosage at Day 1."
45647465|NCT02356939|Procedure|stent extraction by ERCP|stent extraction by endoscopic retrograde cholangio-pancreatography
45647466|NCT01670045|Drug|Tocilizumab|Tocilizumab in accordance with the licensed label recommendation.
45647467|NCT05102461|Dietary Supplement|Florajen Digestion Supplementation|Subjects will take the placebo starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
45647468|NCT05102461|Dietary Supplement|Placebo Supplementation|Subjects will take Florajen Digestion starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
45647469|NCT05375227|Other|Teeth brushing|The participants will be invites to brush their teeth twice a day for 3 months using either an electric toothbrush or a mannual toothbrush and low abrasivity toothpaste
45647470|NCT04980131|Device|Pointed lotus root regulator and guide template aided PPSF|20 patients in group C received PPSF with pointed lotus-style regulator
45647471|NCT04980131|Device|Flat ended lotus root regulator and guide template aided PPSF|20 patients in group B received PPSF with flat ended lotus-style regulator
45647472|NCT04974203|Device|AptameX|DNA aptamer-based test using patient's saliva
45647473|NCT05102227|Device|Left bundle branch area pacing|A dual-chamber DF-1 defibrillator is implanted. Left bundle branch area pacing is performed for cardiac resynchronization therapy.
45792639|NCT05661968|Other|Online educational program|The intervention group will receive an online educational program, containing current information on low back pain management according to international clinical practice guidelines. Program content includes recommendations on assessment, diagnosis, and treatment of low back pain. The online program has 6 units of studies, with the content offered in the formats of video classes, infographics, texts, websites and clinical cases. The participant must complete the course within 6 weeks and will be able to set their own pace. Participants in the intervention group will receive their login and access password via email.
45792640|NCT03330093|Behavioral|Sleep Health in Preschoolers|In-person, family-based behavioral intervention
45792641|NCT03330093|Behavioral|Health and Safety Intervention|In-person, family-based behavioral intervention
45647474|NCT03063671|Drug|Ketamine, bupivacine,dexmedetomidine|thoracic epidural catheter insertion at T4-5
45647475|NCT03063827|Drug|OnabotulinumtoxinA 200 UNT|Patient in the treatment arm received a single injection of onabotulinumtoxinA 200 UNT to the detrusor muscle at 20 sites of the bladder body.
45647476|NCT03063827|Diagnostic Test|Urothelial sensory protein levels|Bladder tissues were investigated for urothelial barrier and inflammation proteins as well as urothelial sensory protein levels by Western blotting, between SCI patients and 10 controls, as well as successful and failed treatment groups.
45920666|NCT00098527|Drug|romidepsin|Given IV
45920667|NCT00098527|Other|laboratory biomarker analysis|Correlative studies
45920668|NCT00006347|Radiation|indium In 111 monoclonal antibody MN-14|
45920669|NCT00006347|Radiation|yttrium Y 90 monoclonal antibody MN-14|
45920670|NCT00098605|Drug|lapatinib ditosylate|Given orally
45920671|NCT00098605|Other|laboratory biomarker analysis|Correlative studies
45920672|NCT00098605|Procedure|quality-of-life assessment|Ancillary studies
45920673|NCT00098605|Other|questionnaire administration|Ancillary studies
45920674|NCT04290546|Drug|Interleukin-15 Superagonist (N-803)|"-- Starting the day after (Cycle 1, Day +1) CIML NK-enriched cell infusion, at least 12 hours after CIML NK cell infusion is completed and up to 48 hours after CIML NK cell infusion, each participant will receive N-803 dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles).~N-803 dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles) for cohorts 1 and 2, and 6 total doses in cohort 3. The dose should be calculated based on body weight at study entry, and recalculated only if greater than 10% change in weight."
46071594|NCT00821275|Procedure|Interventional radiological or surgical management|Uterine artery embolization will be done for the patients who enroll into UAE group and desire for future pregancy and reserving uterus.Myomectomy will be performed for the patients who enroll into SURGERY group and desire for future pregancy and reserving uterus.Hysterectomy will be done for the patients who enroll into SURGERY group and don't desire for reserving uterus and/or future pregnancy.
45792642|NCT03281031|Procedure|Additional MRI Examination|MRI will be performed using a short protocol within 6 hours from CT and with blinding from CT results
45792643|NCT00375687|Drug|Triptorelin|
45792644|NCT01658241|Drug|panobinostat|40mg, three times a week, oral pill over 12 cycles, 4 weeks per cycle
45792645|NCT01455051|Drug|Ofatumumab|We plan to add five doses of ofatumumab to the standard conditioning regimen (fludarabine + melphalan). Ofatumumab will be administered on days -20 (300 mg), -13 (2000 mg), -6 (2000 mg), +1 (1000 mg) and +8 (1000 mg) of the transplantation (day 0 being the day of the hematopoietic cell infusion). If the patient requires donor lymphocyte infusions within 3 years after the procedure, these infusions will also include one administration of 300 mg of ofatumumab, followed by a 1000 mg dose, 7 days later).
45647477|NCT05101837|Device|Home program|Regular mindfulness guided face-to-face program, by using the technology with android to receive mindfulness sessions for daily practice and to assess the feasibility and the effectiveness of behavioural approach base on mindfulness delivered with this modality
45647478|NCT04980209|Device|ultrasound evaluation|According to the sequential test, the enrolled patients were divided into ultrasound evaluation group and no ultrasound evaluation group.
45792646|NCT05352945|Device|HyPNOS self-hypnosis mask from DREAMINZZ|"The use of the HyPNOS self-hypnosis mask from DREAMINZZ allows patients to immerse themselves in a state of self-hypnosis.~A Hypnos session is a narrative accompanied by spatialized sounds (3D) and ambiance for an immersive experience.~We aim to evaluate the use of the HyPNOS mask in the management of pain and anxiety in botulinum toxin injections"
45792647|NCT01673828|Drug|Allopregnanolone injection|Allopregnanolone intravenous solution in 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
45792648|NCT01673828|Drug|Placebo injection|Placebo intravenous solution, 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
45792649|NCT05344053|Other|Community-based precise management|The community-based precise management is a modified management strategy beyond the traditional standard community-based care under the hierarchical medical system of China. In the intervention arm, the community doctors receive training to improve their skills on coronary artery disease management. Patients will be under management for 1 year according to the strategies of community-based precise management and rehabilitation model.
45792650|NCT05344053|Other|Standard community-based management|The standard community-based management is the usual community-based care under the hierarchical medical system of China. In this arm, the community doctors will not receive any training on precise management strategies to improve their skills on coronary artery disease management, and patients will be under usual care for 1 year.
45792651|NCT05343585|Device|PortionSize AI|For this pilot study, using a convenience sample, the investigators will recruit up to 25 adults to use the Nutrition AI technology in Openfit to identify and estimate portion size of foods provided and simulated plate waste, and food intake in a laboratory setting at Pennington Biomedical Research Center (PBRC) and/or Louisiana State University (LSU). Laboratory members within the Ingestive Behavioral Laboratory will also test the ability of Nutrition AI to identify foods and to quantify foods provided, plate waste and food intake, in the laboratory. Meals will be simulated, and participants will not consume the foods provided.
45792652|NCT02249858|Procedure|Cranial Vault Hold|
45647479|NCT03334201|Other|Western Diet|high fat (40%), high sugar (25%) and low fiber (15g/day)
45647480|NCT03334201|Other|Non-Western Diet|low fat (25%), low sugar (15%), high fiber (30g/day)
45792653|NCT02249858|Procedure|Cervical HVLA|
45792654|NCT05325099|Drug|Azacitidine|azacitidine (Vidaza) 1mg/BW(kg) (subcutaneous injection) QOD x 3 times
45792655|NCT05325099|Drug|Placebo|Placebo (subcutaneous injection) QOD x 3 times
45792656|NCT04974008|Drug|OST31-164|Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.
45792657|NCT05293509|Drug|Fludarabine|40 mg/m2/day i.v.- by vein
45792658|NCT05293509|Drug|Dexamethasone|25 mg/m2/day i.v.-by vein
46071595|NCT00830011|Behavioral|cognitive behavioral therapy|Ten sessions of manualized CBT delivered by a PhD level psychologist
45449656|NCT03547635|Other|AMNIOEXCEL Plus Amniotic Membrane|AMNIOEXCEL Plus is a human placental-based tissue consisting of dehydrated, tri-layer Placental (Amnion/Chorion/Amnion) Allograft Membrane (T-PAM) layers. T-PAM is a minimally manipulated placental membrane product made from tissues donated by pre-screened mothers during planned C-sections and is intended for use as a wound covering. This product is an allograft tissue intended for homologous use for the repair, reconstruction and replacement of skin at the direction of a physician. AMNIOEXCEL Plus contains Human Cellular and Tissue Based Products (HCT/P) as defined by US FDA 21 CFR Part 1271. All donor recoveries are performed by BioDlogics, LLC, and adhere to the regulations regarding HCT/P recovery and the screening and testing of the tissue donor as verified through supplier audits.
45647481|NCT01669421|Drug|Alpha-1 Antitrypsin (human)|Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
45647482|NCT03283033|Behavioral|New salad bar|New salad bar placed in school
45647483|NCT03283033|Behavioral|Marketing|Marketing conditions (printed material, displays, verbal announcements, prompts and taste tests)
45647484|NCT03210571|Device|eyeWatch system|The eyeWatch device is composed of an AGDD, a control unit and a draining plate
45792659|NCT05293509|Drug|Cyclophosphamide|100 mg/m2 IV-by vein
45792660|NCT05293509|Drug|Bortezomib|Four doses of bortezomib at a dose of 1.3 mg/m2 -injection under the skin
45792661|NCT05293509|Drug|Rituximab|Four doses of rituximab at a dose of 375 mg/m2- by vein
45920675|NCT04290546|Biological|CIML NK cell Infusion|(Dose 0 or -1) infused on Day 0
45920676|NCT04290546|Drug|Ipilimumab|single dose of lead-in ipilimumab via iv per protocol determined dose
46071596|NCT00830011|Other|standard medical care|any care recommended by physician for treatment of diabetic neuropathy including medication.
46071597|NCT02834832|Device|PECVD coating|SiO2/SiC coatings will be applied to the surface of removable partial dentures and denture teeth.
46071598|NCT04250610|Other|Survey|On-line survey.
46071599|NCT00623467|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol single injection 0.1 mmol/kg BW via IV bolus administration at 2mL/sec.
45792662|NCT05293509|Drug|Busulfan|110 mg/m2 i.v-by vein
45449657|NCT03547635|Device|A Marketed Comparator|bi-layered skin substitute: the epidermal layer is formed by human keratinocytes and has a well-differentiated stratum corneum; the dermal layer is composed of human fibroblasts in a bovine Type I collagen lattice. It is indicated for use with standard therapeutic compression for the treatment of non-infected partial and full-thickness skin ulcers due to venous insufficiency of greater than 1-month duration and which have not adequately responded to conventional ulcer therapy. This product is also indicated for use with standard DFU care for the treatment of full-thickness neuropathic DFUs of greater than three weeks' duration which have not adequately responded to conventional ulcer therapy and which extend through the dermis but without tendon, muscle, capsule or bone exposure.
45792663|NCT05293509|Drug|Cyclophosphamide (Cy)|by vein
45792664|NCT05293509|Drug|Tacrolimus (or cyclosporine)|by vein
45792665|NCT05293509|Drug|Mycophenolate mofetil (MMF)|given by PO
45792666|NCT05293509|Drug|Rabbit ATG|by vein
45792667|NCT04736433|Drug|ACE inhibitor|ACE inhibitor dispensing claim is used as the reference
45792668|NCT04736433|Drug|Sacubitril/Valsartan|Sacubitril/Valsartan dispensing claim is used as the reference
45792669|NCT02296775|Biological|DRL_RI|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
45792670|NCT02296775|Biological|Rituxan|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
45792671|NCT02296775|Biological|MabThera|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
45792672|NCT01675778|Drug|Hydromorphone|a fixed dose (1 mg) of hydromorphone will be given to the study subjects
45792673|NCT05240469|Device|Automated sperm selection software|"The software measures both morphology and motility similar to an embryologist but provides a more accurate and consistent measure of sperm characteristics. Embryologists use their experience to qualitatively judge if an individual sperm is suitable for injection based on morphology and motility. Similarly, the software follows a two-step process: firstly, a computer vision algorithm measures characteristics of all sperm in a given field, including motility and morphology; secondly, the software algorithm then uses a set of quantitative criteria to categorize and identify the most developmentally competent sperm with normal characteristics. All the characteristics that the software calculate are defined by the WHO guidelines, and the software does not propose or define new parameters."
45449658|NCT03547635|Other|Standard of Care|"Coban™~Conforming gauze~Optifoam® non-adhesive dressing~Cotton Gauze~Normal saline (liquid or gel)~Non-adhering dressings~Steristrips~An offloading boot (Pneumatic Short Leg Walker), as appropriate"
45449659|NCT03731169|Genetic|Voriconazole genotype-specific dosing|"Those in the intervention arm will receive an experimental dosage regimen of voriconazole based on their genetic status.~URM: 6 mg/kg voriconazole twice on the first day followed by 5 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~EM: 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~HEM and PM: 6 mg/kg voriconazole twice on the first day followed by 2 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy."
45449660|NCT03731169|Drug|Standard of Care|Participants are given 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy. After TDM is conducted on day 4 for all patients, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
45449661|NCT03724539|Device|STRIPA intervention|"STRIPA is a Dutch software-based tool for the support of the pharmaceutical analysis by 1) taking into account the predictable adverse medication effects, 2) advising safe and appropriate therapy using established STOPP/START criteria, 3) interaction monitoring, and 4) appropriate dosing in accordance with renal function. It represents a highly efficient and user-friendly software engine, which is capable of individually screening the clinical status and pharmacological therapy of older patients with multimorbidity, which can define optimal drug therapy, and which can highlight the adverse drug reaction risk. A summary of these outputs will be used as STRIPA recommendations, which will, if applicable, be implemented by GPs and patients.~Prior to the STRIPA medication review, the necessary patient information will be loaded from the FIRE database that contains data from more than 300 Swiss GP practices."
45449662|NCT03724539|Other|Sham intervention|Patients being assigned to the control arm will be treated in accordance with standard care. They will receive a sham intervention, which consists of a usual medication review by their GP and a shared decision making between patient and GP.
45792674|NCT04736589|Drug|Inetetamab|Initial dose of 8mg/kg, completed in 90 minutes IV infusion, and then 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.
45792675|NCT04736589|Drug|Rapamycin|Oral 2mg, once a day.
45449663|NCT03731091|Drug|Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%|Once daily for 4 weeks (28 days)
45653154|NCT05504551|Procedure|ultrasound guided superficial cervical plexus block|SCP block is given using high frequency linear ultrasound probe connected to an ultrasound machine to visualize SCP posterior to the midpoint of SCM muscle. Once SCP is identified, a combination of 5 ml bupivacaine (0.5%) and 5 ml lidocaine (2%) are injected after negative aspiration followed by injection of 1 ml to confirm the area, using a 22 gauge B-bevel needle Echogenic Needle.
45792676|NCT04736589|Drug|Pyrotinib|Oral 400mg, once a day.
45792677|NCT04736589|Drug|Chemotherapy|Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage.
45792678|NCT02970747|Drug|Carfilzomib|In accordance with SmPC.
45792679|NCT05201859|Drug|Sintilimab|Sintilimab is a humanized monoclonal antibody against Programmed death 1(PD-1).
45792680|NCT05201859|Drug|Capecitabine|An oral anticancer agent that can be converted into 5-Fu in vivo.
45792681|NCT02594111|Drug|Colchicine vs Placebo|Colchicine vs Placebo 1.8 mg PO over 1 hour
46071600|NCT00633204|Biological|MPHOSPH1 and DEPDC1|DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week after curative surgery 8 times and BCG in bladder simultaneously. Then, DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered once every month. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.
45920677|NCT04290546|Drug|Cetuximab|Starting day +15, every 14 days for 8 total doses via IV per protocol
45920678|NCT00098683|Drug|amifostine trihydrate|
45920679|NCT00387803|Device|Cardiac Resynchronization Therapy with Defibrillation|
45449664|NCT03731091|Drug|Enstilar® foam (LEO Pharma Inc.)|Once daily for 4 weeks (28 days)
45920680|NCT04284345|Procedure|Saline Pd/Pa|"Use of a ≥6F guiding catheter and the Verrata pressure guidewire. Administration of intracoronary nitroglycerin.~Verrata normalisation and placement of the Verrata sensor ≥3 vessel-diameter beyond the stenosis.~Whole cycle resting Pd/Pa and resting iFR measurements.~Measurement of contrast FFR: record 5 baseline heart beats, injection of contrast media, 10 ml in the left coronary system, 8 ml in the right coronary system, measure minimal Pd/Pa under stable hyperaemia.~Adenosine FFR: measurement: record 5 baseline heart beats, injection of intracoronary adenosine, 200 mcg in the left coronary system, 100 mcg in the right coronary system, measure minimal Pd/Pa under stable hyperaemia.~Saline-induced Pd/Pa measurement: record 5 baseline heart beats, injection of saline using the ACIST system during 5 heart beats, measure minimal Pd/Pa under stable hyperaemia.~Perform pressure guidewire pullback and check for drift: drift ±0.02 is accepted, if ≥0.03, repeat measurement."
45920681|NCT00098761|Drug|laromustine|This is a dose escalation study. Participants receive 20, 30, 45, 60, 78, 103, 137, 182, or 242 mg/m2/day intravenously over 30 minutes for 5 consecutive days every 6 weeks up to 48 weeks.
45920682|NCT00387842|Procedure|Laparoscopic surgery|
45449665|NCT03731091|Other|Placebo of Calcipotriene/ betamethasone dipropionate topical foam|Once daily for 4 weeks (28 days)
45449666|NCT03726801|Other|HEALTH EDUCATION|"The nursing intervention prior to surgery: (breast and colon cancer):~First phase: At first these subjects suffered a great emotional impact after knowing the diagnosis, which could generate intense anxiety reactions.~Second phase or phase of coping, in which they begin to be aware of their illness and the future changes they will suffer in their body. In this phase they react with fear, anger, anger, denial, ...~Third phase or phase of adaptation to the new situation, where there is a decrease in previous emotional reactions, the patient being able to start up the resources learned to reduce their psychological discomfort."
45449667|NCT03133676|Drug|KA34|50 µg - 400 µg intra-articular injection (single or multiple doses)
45449668|NCT03133676|Drug|Placebo|50 µg - 400 µg intra-articular injection (single or multiple doses)
45647485|NCT05104021|Device|game|"The game is played with a maximum of four people. Beginning points are marked with blue, red, yellow and green colors, the game progress direction is The starting color for the player is determined with the help of arrows. Dice with the biggest number The child who throws starts the game first from the starting point that belongs to him. Play ground Each child who completes a circuit around him reads from his second point. it tries to go inwards (to the world square) in the direction it points. Equivalent to card check box The next child draws one of the face down cards. the instruction written on the back of the card.~implements. Then he puts the card on the back of the other cards. Cards are reward (go forward), penalty (backward) git) cards. Coming second to the same frame during the game The child first starts the game from the starting point of the child in the square. First The child who manages to enter the world square wins the game."
45449669|NCT03182738|Behavioral|VIP app without HIV-related symptom strategies.|The control group will receive the VIP app without HIV-related symptom strategies
45449670|NCT03182738|Behavioral|VIP app that delivers HIV-related symptom strategies.|The Intervention group will receive the VIP app that delivers HIV-related symptom strategies
45647486|NCT05103865|Behavioral|Animal-assisted therapy (AAT)|
45647487|NCT05103865|Other|usual treatment|
45647488|NCT05323123|Behavioral|PrEP Romania|Enrolled participants will receive PrEP education and adherence counseling from trained counselors, and have a medical evaluation from a physician, who will prescribe PrEP.
45647489|NCT05103787|Procedure|deep parasternal intercostal plane block|Twenty milliliters of 0.25% bupivacaine will be placed bilaterally in the fascial plane between internal intercostal muscle and transversus thoracis muscle at intercostal space 4 or 5, lateral from sternum, with ultrasound guidance using high-frequency linear transducer.
45647490|NCT05103787|Procedure|control|Skin puncture with needle will be performed on the same location as the treatment group without administration of local anesthetics.
45647491|NCT03115021|Device|Active tPCS|A current intensity of 2na and a stimulation frequency range of 6-10 Hz will be used with a peri-auricular ear-clip electrode montage for 20 minutes.
45449671|NCT03547167|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
45449672|NCT03547167|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose
45449673|NCT03547167|Biological|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
45449674|NCT03726645|Other|Fecal microbiota transplantation|Fecal microbiota transplantation
45792682|NCT03186261|Drug|Nano silver fluoride solution|Nano silver fluoride that composed of silver nanoparticles, chitosan and fluoride that combines preventive and antimicrobial properties.
45449675|NCT03560739|Combination Product|ofatumumab with PRF|ofatumumab 20 mg subcutanious injection administered with pre-filled syringe (PRF)
45920683|NCT00387842|Procedure|Conventional surgery|
45449676|NCT03560739|Combination Product|ofatumumab with AI|ofatumumab 20 mg subcutaneous injection administered with autoinjector (AI)
45449677|NCT03724461|Behavioral|High Intensity resistance training (12 weeks)|High intensity resistance training (80% of 1 repetition maximum), 2 d/wk (Longitudinal)
45792683|NCT03186261|Drug|Cavity Cleanser|Moistens dentin surface after cavity preparation using a micro brush.
45792684|NCT02589353|Drug|Acarbose|Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain ~484 microgram acarbose; total maximum exposure of each subject to acarbose will be ~14-30 mg each session (1-20 sessions)
45920684|NCT00098800|Drug|fenretinide|
45920685|NCT00098878|Drug|carboplatin|
45792685|NCT02298803|Device|Holter and Glucose monitoring|"(i) Continuous Glucose Monitoring A sterile disposable glucose-sensing sensor will be inserted into the subcutaneous tissues in either the abdomen or the upper outer quadrant of the patient's buttock. This sensor automatically measures the change in glucose in interstitial fluid every 5 minutes. The monitor will be worn for two days.~(ii)Holter Monitoring The Holter monitor to capture cardiac conduction, specifically QT interval, will be worn for the same period as the continuous glucoe monitor with study participants encouraged to perform regular daily activities."
45792686|NCT01676714|Drug|Dovitinib|
45792687|NCT03187119|Behavioral|Pictorial Asthma Action Plan|Participants will receive a PAAP plan, personalized to their asthma treatment. Each participant will take part in a brief education session during which their asthma provider will outline the treatment plan summarized in their PAAP.
45792688|NCT03187119|Behavioral|Written Asthma Action Plan|Participants will receive a WAAP plan, personalized to their asthma treatment. Each participant will take part in a brief education session during which their asthma provider will outline the treatment plan summarized in their WAAP.
45792689|NCT01678196|Behavioral|VA-CRAFT|VA-CRAFT is an on-line training program that teaches family members how to communicate and interact with Veterans to promote their engagement in needed mental health services for PTSD or Alcohol Use Disorders. 12 on-line sessions.
45792690|NCT01678196|Other|Control|Participants will have the opportunity to complete the VA-CRAFT training program after 3 months; otherwise no intervention
45792691|NCT02941965|Procedure|ICSI without PGS|Selection of embryos are based on morphology criteria on the 5th day of ICSI.
45792692|NCT02941965|Procedure|ICSI with PGS|PGS will be applied to selected embryos on the 5th day of ICSI.
45792693|NCT04876742|Other|Beer|"As interventive agent 0.5 L organic alcohol-containing wheat beer produced by the brewery Unser Bier in Basel, Switzerland, is administered once a day at 8pm for 6 consecutive days after enrolment."
45792694|NCT04876742|Other|Water|For the interventional control group 0.5L water is administered once a day at 8pm for 6 consecutive days after enrolment.
45792695|NCT03029117|Procedure|correction of rheumatic valve lesions|
45792696|NCT03028727|Procedure|Ultrasonic Scaling and root planing|Procedure of scaling and root planing at day 0 and at 1 week
45449678|NCT03724461|Behavioral|Light-moderate intensity resistance training (12 weeks)|Light-moderate intensity resistance training (40% of 1 repetition maximum), 2 d/wk (Longitudinal)
45449679|NCT03724461|Behavioral|Control (12 weeks)|No resistance training during the intervention period.
45449680|NCT03724461|Behavioral|One High Intensity resistance training session|High intensity resistance training, 1 training session
45449681|NCT03724461|Behavioral|One Light-moderate intensity resistance training session|Light-moderate intensity resistance training, 1 training session
45449682|NCT03724383|Behavioral|Risk Factor Management Consult|Participants may be referred to an Internist to control risk factor management - this may require monthly visits until risk factor targets have been met.
45647492|NCT03115021|Device|Active tDCS|A current intensity of 2mA will be used for 20minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be place over the left prefrontal cortex and the cathode over the right supraorbitofrontal area.
45647493|NCT03115021|Device|Sham tPCS|Sham tPCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tPCS condition and the electrodes placement as well.
45449683|NCT03724383|Behavioral|Diet Classes|Group nutrition sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention) delivered by a registered dietitian.
45449684|NCT03724383|Behavioral|Stress Management Classes|Group sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention). Techniques taught will include awareness, coping, and relaxation strategies.
45647494|NCT03115021|Device|Sham tDCS|Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
45647495|NCT04980053|Other|massage|Intervention group Control group
45792697|NCT03028727|Procedure|980 nm diode laser irradiation|Procedure of scaling and root planing and application of 980 nm diode laser at day 0 and at 1 week
45792698|NCT02986607|Drug|parathyroid hormon 1-84|Hypoparathyroidism patients will receive Natpara in continous subcutaneous infusion delivered by a pump for 4-7 days.
45792699|NCT01678976|Drug|BIA 2-093|Tablets containing BIA 2-093 in doses of 300 and 600 mg
45792700|NCT01678976|Drug|Oxcarbazepine|Tablets containing 300 mg and 600 mg of Trileptal®
45792701|NCT05611892|Combination Product|18F-FDS PET/CT|20 mCi of 18F-FDS in adult patient age group and 2.5 mCi in children (age 12-18 years old) followed by a PET/CT scan.
45449685|NCT03724383|Other|Exercise Classes|Group sessions delivered two times per week (1 hr each), over 3 month period (months 3-6). Classes will include high intensity interval training, resistance training.
45449686|NCT03724383|Other|Home based exercise program|The interval and resistance training program will mirror the supervised exercise.
45449687|NCT01310673|Drug|Allopurinol|"Allopurinol 300mg po QD for 30 days.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days."
45449688|NCT01310673|Drug|Placebo|"Placebo tablet QD for 10 days, followed by delayed allopurinol 300mg po QD days 11-30.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days."
45449689|NCT03724227|Drug|ACE-011|ACE-011 will be administered subcutaneous injection
45449690|NCT03726567|Procedure|Bariatric surgery|Roux-en-Y surgery
45449691|NCT05665257|Device|Inspiratory muscle training|
45920686|NCT04273464|Procedure|Brava-group|Breast reconstruction by external tissue expansion and multiple fat transplantations(Brava group); Breast reconstruction with microsurgical DIEP-flap transfer.
45792702|NCT02479997|Drug|Indocyanine green|"ICG is cyanine dye used in medical diagnostics. It is used for determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography.~In this study, Investigator uses ICG as a fluorescent dye which is used in medicine as an indicator substance . And it will allow detection of SLN more convenientlty."
45792703|NCT02479997|Drug|Radioisotope|Nuclear medicine uses radiation to provide diagnostic information about the functioning of a person's specific organs, or to treat them. Diagnostic procedures using radioisotopes are now routine.
45792704|NCT03188523|Drug|MK-8504|After at least an 8-hour fast, a single oral dose of MK-8504 will be administered in capsule form.
45792705|NCT04115033|Device|Alpha-stim|The device for both groups is the Alpha-stim, a FDA-approved device similar to the Military Field Stimulator (MFS/Neuro-Stim System), a cranial electrical stimulation (CES) device.
45647496|NCT04973969|Other|Decapeptyl|diagnosis of predictio value
45792706|NCT01679600|Device|Feedback-controlled robotics-assisted treadmill exercise|Progressive cardiovascular exercise using feedback-controlled robotics-assisted treadmill exercise. The first training session is defined to start at 40% of peak work rate (determined from a previous exercise test) to approach 40% of heart rate reserve (Borg scale approximately 11-14). The intensity will then be adjusted on the basis of continuous heart rate data and rating of perceived exertion indications by modulating the target work rate in 5% increments for every subsequent session to reach the target intensity. The target heart rate is set at 40% to 70% of heart rate reserve.
45792707|NCT01679600|Device|Robotics-assisted treadmill exercise|Conventional robotics-assisted treadmill exercise, where therapists focus on gait quality only.
45792708|NCT04645667|Drug|Tacrolimus|Patients will be enrolled into this group if they receive tacrolimus per standard of care. This is an observational study and no interventions will be made.
45792709|NCT02249936|Drug|AZD1722|
45792710|NCT02249936|Drug|Omeprazole|
45792711|NCT02781129|Other|electrical stimulation|Stimulation applied will be within parameters commonly used for the treatment of epilepsy during periods of encoding, recall, and memory maintenance .
45792712|NCT05595122|Device|EUS-CDS|EUS-CDS with FCSEMS through LAMS
45449692|NCT05665257|Device|Mini-PEP|
45647497|NCT02961205|Dietary Supplement|Oral Nutritional Supplementation|"Participants randomized to this arm will receive one bottle of Ensure Enlive 2 times per day, for 30 days prior to their cardiovascular surgery, plus continue their usual diet.~After their CVS and throughout their hospitalization they will continue to receive 2 bottles of Ensure Enlive per day, plus the standard hospital menu (3 meals per day, plus snacks or as ordered by the medical team), ending at hospital discharge."
45647498|NCT04979975|Other|Placebo|PBO- placebo matching to UB-621
45647499|NCT04979975|Biological|UB-621 low-dose|fully human anti-HSV mAb
45647500|NCT04979975|Biological|UB-621 high-dose|fully human anti-HSV mAb
45647501|NCT02958709|Drug|High-dose: RIF, INH, PZA, EMB|high-dose rifampicin plus standard dose H,Z,E, given for 8 weeks in treatment Arms 1 and 2
45647502|NCT02958709|Drug|High dose: RIF, INH, PZA, LEVO|high-dose rifampicin plus standard dose H,Z, with levofloxacin substituted for ethambutol for 8 weeks in treatment Arm 2
45647503|NCT02958709|Drug|Standard of care: RIF, INH, PZA, EMB|standard doses of R,H,Z,E given for 8 weeks in treatment Arm 3, control arm.
45647504|NCT04979663|Combination Product|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks
45647505|NCT05307367|Behavioral|Exercise training|Patients will be enrolled in a 8 week, supervised, single-leg kicking training intervention (1h, or as long as possible, 60-70% peak workload (PWL), 2-5 days a week). Healthy age-, body weight-, gender- and activity level-matched control subjects will undertake the intervention matched to the %PWL obtained by the patients who complete the study.
45792713|NCT03190005|Drug|clopidogrel|routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)
45792714|NCT03190005|Drug|Placebos|no medication, healthy subjects.
45792715|NCT04637009|Drug|TAS1553|Form: tablet; Route of Administration: oral
45792716|NCT03190083|Device|2-dimensional mammogram|This is standard of care for breast cancer diagnosis. The new breast cancer patients will be scheduled for the mammogram after diagnosis at the time of surgical appointment. The radiologist reviewing the tomosynthesis images will be separate and blinded from the radiologist who reviewed the initial 2-D mammogram.
45792717|NCT03190083|Device|digital breast tomosynthesis (DBT)|The radiation dose from this/these procedure(s) will be no more than 0.4mSv for a bi-lateral breast tomosynthesis. The new breast cancer patients will be scheduled for the mammogram after diagnosis at the time of surgical appointment. The radiologist reviewing the tomosynthesis images will be separate and blinded from the radiologist who reviewed the initial 2-D mammogram.
45792718|NCT02431715|Drug|[18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)|"All patients will have their weight and baseline vital signs recorded.~The study subject will have an intravenous catheter inserted and receive a slow bolus intravenous dose of 185 - 370 MBq (5 -10mCi) 18F-FDOPA.~The patient will rest in a comfortable reclining chair in a warm, private shielded room for 45 to 60 minutes.~Patients are positioned supine and centered on the scanner bed for an average total scan time (CT and PET) of approximately 30 minutes.~Images will be interpreted by qualified and experienced physicians. Findings of significance from the PET/CT scan, and any incidental findings of significance from the CT scan, will be included in the single final report that will be issued to referring physicians."
45792719|NCT04627103|Device|Self Forming Magnetic (SFM) Anastomosis System|The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact Type 2 Diabetes. Following the diversion being created, a gastric sleeve will be created according to standard technique.
45792720|NCT04816214|Drug|capmatinib|film-coated tablet for oral use
45792721|NCT04816214|Drug|pemetrexed|concentrate for solution for intravenous use
45792722|NCT04816214|Drug|cisplatin|concentrate for solution for intravenous use
45792723|NCT04816214|Drug|carboplatin|concentrate for solution for intravenous use
45792724|NCT04816214|Drug|osimertinib|tablet for oral use
45792725|NCT04046003|Behavioral|Tai chi exercise|24-form Yang style Tai Chi (60 min/session, 3 sessions/week) for 8 weeks
45792726|NCT04814654|Behavioral|CHALO! 2.0|"The components of the intervention are:~Contents of digital-media (sent twice/week for 12 weeks) on the following topics: HIV testing, prevention, treatment, linkage-to-care; Personalized digital coupon for free testing; Webpage listing testing/ care sites; access to online outreach workers."
45792727|NCT04814654|Behavioral|Attention-matched control (AMC)|"The components of the intervention are:~Contents of digital-media (sent twice/week for 12 weeks) only related to general health information; Personalized digital coupon for free testing; Webpage listing testing/ care sites; access to online outreach workers."
45647506|NCT04979819|Other|Upper extremity endurance test (UULEX)|Patients will lift 5 bars consecutively rhythmically until they feel fatigued. The bars will weigh 200 grs 500 gr 1kgs and 2 kgs respectively. The duration of the test will be measured to determine the endurance levels of the patients.
45792728|NCT04814654|Behavioral|Digital coupon only (DCO)|"The components of the intervention are:~Digital coupon for free HIV testing; Webpage listing testing/ care sites; access to online outreach workers."
45792729|NCT04798118|Procedure|toilet bronchoscope|Toilet bronchoscopy will be done by infuse normal saline or N-Acetylcysteine with a syringe, observing the flow of saline at the distal tip of the bronchoscope then suction intra bronchial visible secretions during the procedure and also suction of specific lobe guided by radiological finding in the patient A chest X-ray will be routinely performed prior and after the procedure, HRCT is mandatory when chest x-ray not clearly defining the collapse monitoring of heart rate, oxygen saturation, ventilator parameters, and arterial blood pressure will be done
45792730|NCT03193593|Drug|Placebo|Placebo- Single injection of saline into Pectoralis Muscle
45792731|NCT03193593|Drug|EB-001|Single injection of EB-001 into Pectoralis Muscle
45920687|NCT04273464|Procedure|DIEP-group|Microsurgical reconstruction by DIEPO method
45792732|NCT05559866|Device|Apollo ESG with ERBE HAPC|Utilizing two approved devices in combination to assess durability of suturing.
45792733|NCT05559866|Device|Apollo ESG|Using only Apollo ESG as approved per label.
45792734|NCT04795934|Procedure|LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION|LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION VERSUS LAPAROSCOPIC NISSEN FUNDOPLICATION
45792735|NCT01461915|Drug|Nab paclitaxel|Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes. Nab-paclitaxel will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).
45792736|NCT01461915|Drug|Gemcitabine|Following the completion of nab-paclitaxel administration, gemcitabine IV infusion at 1000 mg/m2 will be administered over 30 minutes. Gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-cycle).
45792737|NCT01461915|Drug|Dociparstat|Following the completion of gemcitabine administration, dociparstat IV bolus at 4 mg/kg will be administered in 5 minutes immediately after completion of gemcitabine administration. Immediately following the dociparstat IV bolus administration, dociparstat 48-hour IV continuous infusion at 0.375 mg/kg/hr will be administered.
45792738|NCT01682642|Drug|Zoladex|after surgical vaporization patients are treated with Zoladex for 3 months before starting IVF treatment
45792739|NCT01682954|Behavioral|Lifestyle counseling|16-week nutrition, physical activity and behavioral intervention
45920688|NCT03633305|Drug|Hypnotics|Medication used 1 to 7 nights/week for 6 to 8 weeks.
45920689|NCT03633305|Behavioral|Online CBT|Internet self-help program for insomnia with 6 cores.
45920690|NCT03633305|Behavioral|Face-to-face CBT|Face-to-face therapy with 3 to 4 individual sessions in a period of 6 to 8 weeks.
45920691|NCT00098917|Drug|autologous tumor cell vaccine|
45647507|NCT04429217|Other|immediate post-operative complete weight-bearing after surgery|"Patients randomized to the experimental post-operative rehabilitation intervention will undergo to immediate complete weight-bearing starting immediately after surgery. Immediate complete weight-bearing consists in the possibility to undergo all the everyday activities without limiting weight-bearing and without the use of walking aids.~During the rehabilitation period, patients will wear an ankle brace (VACOankle® OPED); this will ensure the safety of the early recovery phases, protecting from dangerous movements while allowing the mobilization in the healthy range of movement."
45647508|NCT04429217|Other|delayed weight-bearing for 6 weeks after surgery|"Patients randomized to the control post-operative rehabilitation intervention will undergo to delayed weight-bearing starting at 6-weeks post-operatively. Delayed weight-bearing consists in the limitation of the weight-bearing to 20-30% of patient's total weight using crutches for the first 6 weeks after surgery.~During the rehabilitation period, patients will wear an ankle brace (VACOankle® OPED)."
45647509|NCT05094271|Other|Supplemental Oxygen|Subjects will be instrumented with a nasal cannula to receive 2L/min supplemental oxygen. The oxygen will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats >90% based on oximetry readings.
45647510|NCT05094271|Device|Continuous Positive Airway Pressure Machine|Continuous positive airway pressure is a form of positive airway pressure ventilation in which a constant level of pressure greater than atmospheric pressure is continuously applied to the upper respiratory tract of a person.
45647511|NCT05094271|Other|Room Air|Subjects will be instrumented with a nasal cannula to receive 2L/min pressurized room air. The room air will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats >90% based on oximetry readings.
45920692|NCT00098917|Drug|therapeutic autologous dendritic cells|
45647512|NCT04979585|Drug|Camrelizumab|200mg ,IV,d1,Q3W.
45920693|NCT00098917|Procedure|adjuvant therapy|
45920694|NCT00098917|Procedure|biological therapy|
45920695|NCT00098917|Procedure|conventional surgery|
45920696|NCT00098917|Procedure|surgery|
45920697|NCT00098917|Procedure|tumor cell derivative vaccine|
45920698|NCT00098917|Procedure|vaccine therapy|
45920699|NCT00098995|Drug|cisplatin|
45920700|NCT00098995|Drug|tirapazamine|
45920701|NCT00098995|Radiation|brachytherapy|
45920702|NCT00098995|Radiation|radiation therapy|
45920703|NCT00099112|Genetic|microarray analysis|
45920704|NCT00099112|Procedure|biopsy|
45920705|NCT00099112|Procedure|evaluation of cancer risk factors|
45920706|NCT02907372|Other|neuropsychologic evaluation|
45792740|NCT01683422|Radiation|Proton, Gemcitabine, Erlotinib, Capecitabine|"Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.~Post-proton chemotherapy: To be started in 4 to 6 weeks after completion of proton chemotherapy. Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days. The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles."
45792741|NCT01683422|Radiation|Proton Radiation|
45792742|NCT03194373|Drug|Palbociclib|"Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days~Maintenance Palbociclib:~Palbociclib (Ibrance) 125 mg PO daily, days 1-21, cycle length: 28 days"
45792743|NCT03194373|Drug|Carboplatin|Carboplatin (IV), dose= AUC 5, day= 1, cycle length: 21 days
45792744|NCT05066061|Other|control arm|usual process
45792745|NCT05066061|Other|anxiolytic and analgesic gas|add relaxing gas
45792746|NCT05066061|Device|Virtual reality mask|use Virtual reality mask Oculus Quest with age-appropriate software
45792747|NCT04781673|Drug|Ketamine|Will receive titratable infusion.
45792748|NCT04781673|Drug|Lidocaine|Will receive titratable infusion, will have daily lidocaine level labs drawn daily.
45792749|NCT02240810|Device|Percutaneous coronary intervention (Promus PREMIER)|Interventional coronary artery stenting with Promus PREMIER study stent.
45920707|NCT02907372|Other|oncogeriatric evaluation|
45920708|NCT00099151|Behavioral|Caloric Restriction (CR)|
45920709|NCT00099151|Behavioral|Exercise|
45449693|NCT03730935|Device|Respiratory muscle endurance training|Respiratory muscle endurance training performed over the duration of 4 weeks
45647513|NCT04979585|Drug|Anlotinib|8mg,oral, d1-14,Q3W.
45647514|NCT04979585|Drug|nab-Paclitaxel|260mg/m2,IV,d1,Q3W.
45647515|NCT05101603|Device|Air Abrasive|Applied with Nd:YAG Laser on periodontal pockets
45920710|NCT00099190|Drug|ARQ 501|
45920711|NCT04728763|Other|Protein profile|Analysis of the protein content by proteomics of bronchoalveolar lavage
45920712|NCT04728724|Drug|Sintilimab|"Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
45920713|NCT04728724|Drug|Chemotherapy|"Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Non-squamus: Carboplatin AUC 5 + Pemetrexed 500mg/m2; Squamous: Carboplatin AUC 5 + Gemcitabine 1000mg/m2 or Paclitaxel 200mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
45449694|NCT00101686|Drug|Modified Bolus 5-FU/LV with Irinotecan|Day 1 & 8: Irinotecan (125 mg/m2 IV over 90 minutes), LV (20 mg/m2 IV bolus), 5-FU (500 mg/m2 IV bolus). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID [two times a day] (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
45449695|NCT00101686|Drug|FOLFIRI + bevacizumab|"Day 1 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.~I m m e d i a t e l y f o l l o w e d b y :~5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Every 2 weeks~Amendment 2 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.~I m m e d i a t e l y f o l l o w e d b y :~5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Celecoxib/placebo 400 mg BID [two times a day] oral Every 2 weeks"
45792750|NCT01683812|Device|Cranial Cup|Study participants with dolichocephaly will be treated with the Cranial Cup for a minimum 12 hours per day.
45647516|NCT05101603|Device|Nd:YAG Laser|Applied with Air Abrasive on periodontal pockets
45647517|NCT05101603|Procedure|Non surgical periodontal therapy|The first phase, in which optimum plaque control is achieved and local etiological factors are removed, is the first step of all periodontal diseases and surgical procedures.
45647518|NCT04400513|Device|Use of Eko CORE and Eko DUO electronic stethoscopes|Auscultation of heart sounds using electronic stethoscopes
45647519|NCT02481817|Procedure|Endoscopic dilation of subglottic stenosis|This is accomplished with rigid instruments or inflatable balloons.
45792751|NCT03197025|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg (based on total body weight) intravenous (IV) infused over 15 minutes approximately every 12 hours for a maximum of two doses.
45920714|NCT04728568|Drug|Sintilimab|Sintilimab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
45920715|NCT04728529|Procedure|USSM protocol|"In the initial step, all subjects will receive emergency management: oxygen support, vascular access, and fluid therapy. Doppler ultrasonography by Ultrasound Cardiac Output Monitoring (USCOM) is also performed to record initial stroke volume (SV), cardiac index (CI), and systemic vascular resistance (SVR). The initial fluid resuscitation is 20 mL/kg body weight, then the response measured by clinical and USCOM examination. If any improvement of clinical sign and normal SVI, CI, SVR, intervention will be stopped. In contrary, if shock persist, subsequent fluid resuscitation and/or vasoactive therapy will be administered, guided by USCOM.~The therapeutic goal of USCOM: SVI 30-60 mL/m2, CI 3.3-6.0 L/minute/m2, and SVRI 800-1600 d.s/cm5/m2"
45647520|NCT02481817|Procedure|Endoscopic resection of the stenosis|This is accomplished with C02 lasers and paired with prolonged medical therapy after surgery.
45647521|NCT02481817|Procedure|Tracheal Resection|Resection of the affected tracheal segment with end-to-end anastomosis
45647522|NCT04979741|Other|No interventions|Observational study, no intervention is required
45792752|NCT03197025|Biological|E6 T Cell Receptor (TCR)|On day 0, the E6 TCR cells will be administered one time, intravenously over 20 to 30 minutes
45792753|NCT02249546|Drug|N-acetylcysteine + PPI-amoxicillin-clarithromycin|
45792754|NCT02249546|Drug|PPI-amoxicillin-clarithromycin|Triple therapy
45792755|NCT04333173|Procedure|endovascular procedure|Endovascular therapies for erectile dysfunction
45792756|NCT04663737|Drug|Silmitasertib|Capsules
45792757|NCT04663737|Drug|SOC|Some therapeutics for COVID-19 are available through EUA. SOC treatment availability is expected to change during the course of this trial.
45792758|NCT01684436|Device|Punctal Plug|Punctal plugs inserted into the study eye on Day 1.
45792759|NCT02303093|Biological|Octagam IVIG 5% or 10%|Octagam IVIG 5% or 10%
45792760|NCT02303093|Biological|Panzyga|Panzyga
45792761|NCT04960215|Drug|Coenzyme Q10|Coenzyme Q10 (myoquinon) capsule 100mg, 5 capsules a day.
45792762|NCT04960215|Drug|Placebo|A soft gelatin capsule containing soy oil, 5 capsules a day.
45792763|NCT01684592|Behavioral|Phone-based postpartum continuing care|PPCC Counselors will make initial contact with participants in the experimental group at 36 weeks gestation (i.e., one week prior to full-term), will call again within one week after the baby's birth, and eight additional times over the course of the first six months postpartum. The PPCC protocol will be developed based on the 5 A's (standard of care during pregnancy) and the Recovery Management Checkup model where relapse is expected and efforts are made to take a more proactive approach to identify women who are having cravings or have relapsed and re-intervene with them as soon as possible to assist them in regaining smoking abstinence. Women in the experimental group will also have the option of calling the PPCC line 24 hours a day, 7 days a week.
45792764|NCT01684592|Behavioral|Standard care|All women will receive the standard of care approach (5 A's and referral to a 24/7 quit line postpartum) from MWC during pregnancy. The 5 A's brief intervention was modified by American College of Obstetricians and Gynecologists (ACOG) for use with pregnant women and is recommended to help pregnant women quit smoking. It includes the following steps: Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, and Arrange follow-up.
45792765|NCT04555317|Combination Product|Musculoskeletal health package|3 month prehabilitation exercise program during radiotherapy with assessment of BMD at baseline with appropriate management according to fracture risk assessment (with either (a) lifestyle advice, (b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate))
45792766|NCT02333045|Drug|Truvada qd|Truvada 1 tablet PO daily for 7 days
45792767|NCT02333045|Drug|Maraviroc 300 qd|Maraviroc 300 mg PO daily for 7 days
45792768|NCT01684748|Drug|Olmesartan medoxomil|Crossover intervention comparing antihypertensive medication to no drug intervention.
45792769|NCT03200535|Other|EHR gaps|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient
45792770|NCT03200535|Other|Bulk outreach|A bulk letter or email will be sent
45792771|NCT03200535|Other|Dietician call|Patients will receive a personalized call by a registered dietitian
45792772|NCT04028063|Drug|doxorubicin with AGEN1884 and AGEN2034|The first cycle of treatment will consist of AGEN2034 and AGEN1884 alone. Beginning with Cycle 2, doxorubicin will be administered every 21 days for a maximum of 6 cycles (Cycles 2-7) with appropriate premedications and pegfilgrastim growth factor support. Doxorubicin will be administered as bolus infusion on day 1 with dexrazoxane cardioprotection. Patients must have central line access for this protocol, including pheresis or trifusion catheter, PICC line, or port. AGEN2034 will be administered every cycle (every 21 days) up to two years. AGEN1884 will be administered every other cycle (Cycle 1, 3, 5, and 7) with maximum of 4 infusions.
46071601|NCT02834754|Drug|Vedolizumab|Vedolizumab is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α₄β₇. Blocking the α₄β₇ integrin results in gut-selective anti-inflammatory activity. Vedolizumab was been approved by the Food and Drug Administration (FDA) in 2014 for achieving clinical response, achieving clinical remission, and achieving corticosteroid-free remission in adult patients with moderately to severely active Crohn's disease. We believe that use of vedolizumab constitutes a non-significant risk to the research subject. The dose of vedolizumab administered is 300mg IV
45792773|NCT03200925|Other|"Jumping into Kangaroo Care - a video created by the Ohio Department of Health"|The video is 8 minutes and 52 seconds in length. The video discusses the benefits and logistics of Kangaroo Care from professional's perspectives and from new mother's perspectives.
45792774|NCT01685684|Drug|Oxycodone DETERx|40-160 mg total daily dose of oxycodone DETERx, divided into 2 doses, q12h
45792775|NCT01685684|Drug|Placebo|Placebo, divided into 2 doses, q12h
45792776|NCT02305433|Other|Home-based physiotherapy (physical exercise)|Each physiotherapy (physical exercise) session includes muscle strength and endurance training (especially for lower limbs), balance and coordination training and functional training. Functional training includes walking exercises and ADL (activities of daily living) exercises. In addition the physiotherapist gives counseling on nutrition.
45792777|NCT04505319|Device|DEFINISSE CORE FILLER|"DEFINISSE CORE FILLER volume will be injected between 4.0 of 5.0 ml on the whole face (at the discretion of the treating physician to achieve an optimal aesthetic result).~A touch-up will be possible at the first follow-up visit (after one month) with a amount of product between 4.0 and 5.0 ml on the whole face"
45792778|NCT02295059|Dietary Supplement|omega 3 fatty acids|supplied as soft gelatin capsules for oral administration
45792779|NCT04472091|Device|Genicular artery embolization (GAE)|Participants will undergo GAE with HydroPearl® Microspheres (polyethylene glycol microspheres, Terumo Medical, Somerset NJ).
45792780|NCT04579679|Drug|Surufatinib|Surufatinib 300 mg oral once daily
45792781|NCT04438395|Device|Cardiac ablation via catheter|Cardiac ablation with a catheter to treat atrial flutter and/or atrial fibrillation
45792782|NCT04568213|Drug|Hypochlorous Acid Gel 0.02%|0.02% Hypochlorous Acid Gel (OCusoft Hypochlor GEL) will be sprayed onto the closed eyelid of the surgical eye while covering the fellow eye with palm of the hand, left for 60 seconds, then wiped off with a clean gauze, tissue, or cotton ball.
45792783|NCT03978767|Drug|Ibuprofen 600 mg|NSAID pain medication to be used in the experimental bundle for postpartum analgesia
45792784|NCT03978767|Drug|Ketorolac|NSAID analgesic to be used in the experimental bundle for postpartum analgesia in patients who underwent cesarean section
45792785|NCT03978767|Drug|Acetaminophen|Analgesic medication to be used in both treatment arms
45792786|NCT03978767|Drug|Oxycodone|Analgesic medication to be used in both treatment arms
45792787|NCT04436133|Biological|Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|Inject vaccine produced by ChinaVaccineSerum, containing HPV antigen protein, 270μg/1ml per bottle
45792788|NCT04436133|Biological|9-valent HPV vaccine（Gardasil 9）|Inject Gardasil 9 , containing HPV antigen protein, 270μg/0.5ml per bottle
45792789|NCT01685996|Drug|zonisamide|In addition to zonisamide vs placebo treatment, varenicline tablets will be dispensed with specific instructions to take at the recommended doses for smoking cessation Participants will receive brief smoking cessation counseling and referral to a quitline
45792790|NCT01685996|Drug|placebo|
45792791|NCT04550429|Device|MyoSure Hysteroscopic Morcellator Device|This device is normally used for this procedure, but I included it as intervention because we will lower the pressure for one arm of the study (treatment) and keep the pressure in the other arm (control) as the standard of care.
45792792|NCT03207399|Drug|Epclusa|Patients will be treated with this drug for 12 weeks post lung transplant.
45792793|NCT03931655|Diagnostic Test|Spectroscopic photoacoustic imaging|Spectroscopic photoacoustic imaging uses a laser that is pulsed for a nanosecond, applying laser light to the patient's skin. Hemoglobin and melanin absorb the laser's energy and convert it to heat, which rapidly expands local tissue and produces a broadband ultrasound wave and is detected with a clinical ultrasound transducer. Because the signal is proportional to the optical absorption in tissue, high resolution images of the lymph nodes can be acquired from the detected ultrasound waves, and can be used to measure saturated oxygen in the nodes.
45449696|NCT00101686|Drug|miFL + bevacizumab|Day 1 Bevacizumab 7.5mg/kg IV *over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Every 3 weeks Amendment 2 Day 1 Bevacizumab 7.5mg/kg IV over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo 400 mg BID [two times a day] oral Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo -- 400 mg po BID [two times a day] continues daily without interruption Every 3 weeks
45449697|NCT00101686|Drug|Infusional 5-FU/LV with Irinotecan|Day 1: Irinotecan (180 mg/m2) IV over 90 minutes, LV (racemic mixture 400 mg/m2) over 2 hours during irinotecan infusion but without mixing, immediately followed by 5-FU IV bolus (400 mg/m2) and 5-FU continuous infusion (2400 mg/m2) over 46 hours. FOLFIRI regimen is repeated every 2 weeks. Celecoxib/placebo treatment will commence on the same day at a dose of 400 mg po BID [two times a day](800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
45647523|NCT05103709|Other|MULTI-FORTIFIED|Treatment with multifortified bread for 120 days
45647524|NCT05103709|Other|FORTIFIED|Treatment with standard bread, fortified according to current Peruvian guidelines for 120 days
45653155|NCT05173779|Procedure|Left atrial isolation by catheter ablation|Procedure: Right pulmonary vein circumferential isolation + anterior left atrial line (superior mitral annulus to right superior pulmonary vein via the anterior wall) + para-septal line (para-septal mitral annulus to the right inferior pulmonary vein, including right atrial components-especially in and around the proximal coronary sinus) + posterior left atrial line (superior mitral annulus to right superior pulmonary vein via the posterior wall).
45792794|NCT04549103|Other|Baduanjin exercise program|Baduanjin (BDJ), also known as Eight-Section Brocades, is one of the forms of traditional Chinese Qigong exercises, characterized by symmetrical physical posture, movements, mindfulness, and breathing. Its primary focus is on the release of 'Qi' or internal body energy with the intent of improving health outcomes. BDJ encompasses eight simple movements involving combinations of postures, meditation, slow relaxing movements, and breathing exercises. It is a low intensity exercise, which have been found to improve range of motion, strength and general health. The simplicity and low intensity level is ideal for older adults to practice at home using instructional videos.
45792795|NCT04651790|Biological|SARS-CoV-2 inactivated vaccine|The vaccine contains inactivated SARS-CoV-2 virus, aluminum hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate and sodium chloride.The final product will be supplied in a pre-filled syringe containing 0.5 ml of solution for injection that corresponds to a dose of the vaccine.
45792796|NCT04543955|Drug|Telotristat (Low-Dose)|Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 750mg per day (250mg TID) for 20 months.
45792797|NCT04543955|Drug|Telotristat (High-Dose)|Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 1500mg per day (500mg TID) for 20 months.
45792798|NCT04633148|Drug|Cyclophosphamide (Non-IMP)|Intravenous infusion for 3 days
45920716|NCT04728529|Procedure|ACCM protocol|In the initial step, all subjects will receive emergency management: oxygen support, vascular access, and fluid therapy. Doppler ultrasonography by Ultrasound Cardiac Output Monitoring (USCOM) is also performed to record initial stroke volume (SV), cardiac index (CI), and systemic vascular resistance (SVR). The initial fluid resuscitation is 20 mL/kg body weight, then the response measured by clinical. If any improvement of clinical sign, intervention will be stopped. In contrary, if shock persist, subsequent fluid resuscitation and/or vasoactive therapy will be administered, guided by clinical parameter.
45653156|NCT05503693|Drug|AP303 50 μg|AP303 tablet
45653157|NCT05503693|Drug|AP303 150 μg|AP303 tablet
45792799|NCT04633148|Drug|Fludarabine (Non-IMP)|Intravenous infusion for 3 days
45792800|NCT04633148|Drug|UniCAR02-T-pPSMA|Intravenous Infusion for 21 days
45792801|NCT04633148|Drug|UniCAR02-T (IMP)|Intravenous infusion of single dose
45920717|NCT00097162|Procedure|Anodal stimulation|
45920718|NCT04253730|Other|Cold Stress|60-90 mins of cooling via a liquid perfused suit circulating ~4-10°C liquid.
45920719|NCT00099229|Drug|Licarbazepine|
45920720|NCT00099346|Drug|MK0457, VX-680 (Aurora Kinase Inhibitor)|
45792802|NCT04543409|Biological|Benralizumab|Solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
45792803|NCT04543409|Biological|Matching placebo|Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC), 1 mL fill volume
45792804|NCT04623554|Behavioral|Prehabilitation program|The prehabilitation program includes combined high-intensity interval training on a cycle ergometer and machine-based resistance exercise of large muscle groups supervised by a physiotherapist. Exercise sessions will take place in physiotherapy departments at local hospitals or in municipality rehabilitation centres 3 times a week during the neoadjuvant chemotherapy period and ending in the week before breast surgery (maximum estimated 29 weeks depending on number of chemotherapy cycles, dose delays and time of breast surgery). Participants will be screened for psychological distress four times and in case of moderate-severe distress be advised to visit the local Cancer Society Support Center where participants will be assessed and offered free services based on their psychosocial needs and available offers. Participation will be monitored.
45792805|NCT03209505|Device|Acuvue Oasys|FDA approved contact lens, fit for daily wear
45792806|NCT03209505|Device|Air Optix Night & Day Aqua|FDA approved contact lens, fit for daily wear
45792807|NCT02196155|Drug|Botulinum toxin A|"Researchers discovered in the 1950s that injecting overactive muscles with minute quantities of botulinum toxin type-A would result in decreased muscle activity. Botulinum toxin type-A has this effect because it prevents the vesicle where the acetylcholine is stored from binding to the membrane where the neurotransmitter can be released. Botulinum toxin type-A thus blocks the release of acetylcholine by the neuron. This will effectively weaken the muscle for a period of three to four months.~In addition to its cosmetic applications, Botox is currently used in the treatment of spasms and dystonias, by weakening involved muscles, for the 60-70 day effective period of the drug. The main conditions treated with botulinum toxin are: Cervical dystonia (spasmodic torticollis) (a neuromuscular disorder involving the head and neck), Blepharospasm (excessive blinking) etc.."
45792808|NCT02196155|Drug|cortisone|
45792809|NCT02196155|Drug|Saline|
45792810|NCT02175173|Drug|Rufinamide|Administration of Inovelon 100mg or 200mg Tablets
45792811|NCT02124941|Drug|N-acetyl cysteine|Upon completion of baseline (abstinence) 1H-MRS scanning, CU and HC subjects will participate in two additional 1H-MRS scans, including after 2 weeks of placebo and 2 weeks of NAC administration (3600 mg/day) given in double-blind, randomized, counterbalanced order.
45792812|NCT02124941|Diagnostic Test|[18F]FDG PET scan|All subjects will undergo [18F]FDG PET to establish previously demonstrated reductions in glucose utilization in PFC and assess VS/nucleus accumbent metabolism at baseline.
45792813|NCT02124941|Diagnostic Test|1H MRS|All subjects will undergo three magnetic resonance spectroscopy (1H-MRS) scans at 7T, including before and after two-weeks of placebo and NAC administration.
45792814|NCT02124941|Diagnostic Test|[11C]APP311 PET scan|All subjects will undergo [11C]APP311 PET imaging to investigate whether there are differences in synaptic integrity / neuronal plasticity in the brains of individuals abstinent from cocaine compared to healthy controls at baseline.
45792815|NCT03213405|Biological|rBCG-N-hRSV 1/100|5x10^3 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
45792816|NCT03213405|Biological|rBCG-N-hRSV 1/10|5x10^4 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
45792817|NCT03213405|Biological|rBCG-N-hRSV full dose|1x10^5 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
45792818|NCT03213405|Biological|Conventional BCG full dose|2x10^5 colony forming units (CFU) of conventional BCG will be administered as an intradermal injection.
45792819|NCT04736043|Other|Organoid|The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as adjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within pancreatic cancer patients eligible for surgery, the investigators aim to strategize appropriate adjuvant chemotherapy after surgery, thus developing a platform to predict the outcomes of each patient.
45792820|NCT03215901|Behavioral|A Beautiful Future Video|Video delivering information on the longevity gains due to HIV treatment in the area.
45647525|NCT04979897|Other|Intensive care unit stay during the COVID-19 pandemic|Patients will be screened daily for a potential ICU discharge. Each site coordinator, which is a clinician physiotherapist responsible for the site, will check that the patient is delirium-free (CAM-ICU negative) and cooperative (i.e. using 5 standardised questions: open [close] your eyes; look at me; open your mouth and stick out your tongue; nod your head; raise your eyebrows when I have counted up to five) within 72 hours from ICU discharge. Every patient deemed eligible will be invited to participate through a face-to-face visit by the assigned evaluator, receiving verbal and written information about the study
45647526|NCT05103553|Other|Outpatient Clinic|Follow-up in outpatient clinic
45647527|NCT04979195|Other|Patients with stable normal kidney function|Covid-19 patients with stable kidney function will represent group 1.
45647528|NCT04979195|Other|Patients with unstable kidney function|Covid-19 patients with unstable kidney function will represent group 2.
45647529|NCT05101525|Procedure|Ultrasound|Ultrasound to visualize the intra tendinous marker. If this is in place, healing is effective. On the other hand, if it has migrated, there is no scarring.
45653158|NCT05503693|Drug|AP303 300 μg|AP303 tablet
45792821|NCT03215901|Behavioral|Active Control Video|Video on another topic.
45792822|NCT04121403|Biological|Rituximab|Biosimilar rituximab concentrate for solution for infusion
45792823|NCT04121403|Drug|Cladribine|Mavenclad oral cladribine tablets
45792824|NCT05406141|Dietary Supplement|Amino acid formula (Neocate Jr)|"Use Neocate Jr for 4 weeks, either as sole source of nutrition or oral nutritional supplement:~Sole source of nutrition: as far as possible >7 days, especially newly diagnosed allergy children~Oral nutritional supplement (Neocate Jr ≥50% of daily total energy and the rest provided by food)"
45792825|NCT04058925|Device|NIRS device|Application of NIRS electrode to forehead and thenar eminence.
45792826|NCT04047537|Other|Medical Food Formulation 1|WBF-0011
45792827|NCT04047537|Other|Medical Food Formulation 2|WBF-0011 (0.2X concentration)
45792828|NCT04047537|Other|Placebo|Placebo Capsules identical to those containing Formulation 1 and 2
45792829|NCT03984201|Device|Intermittent Theta Burst Stimulation (iTBS)|Participants will receive active or sham transcranial magnetic stimulation delivered to the L-DLPFC.
45792830|NCT00422721|Procedure|realization of a family tree|
45792831|NCT00422721|Procedure|refractometry|
45792832|NCT00422721|Procedure|evaluation of the presence of a nystagmus|
45792833|NCT00422721|Procedure|ocular behavior|
45792834|NCT00422721|Procedure|test of baby vision|
45792835|NCT00422721|Procedure|test of keenness|
45792836|NCT00422721|Procedure|reading test|
45792837|NCT00422721|Procedure|visual field|
45792838|NCT00422721|Procedure|color vision|
45792839|NCT00422721|Procedure|electroretinographical activity|
45792840|NCT00422721|Procedure|biomicroscopical test|
45792841|NCT00422721|Procedure|retinal imaging|
45653159|NCT05503693|Drug|AP303 600 μg|AP303 tablet
45792842|NCT00422721|Procedure|retinal autofluorescence|
45792843|NCT00422721|Procedure|genotyping|
45792844|NCT03285555|Device|STRATIFIX|STRATIFIX symmetric PDS Plus; Stratifix knotless suture
45792845|NCT03285555|Device|VICRYL|Vicryl #1
45792846|NCT03221595|Device|Operative|This operation involves reducing and providing rigid fixation of displaced rib fractures with permanent plates or splints
45792847|NCT03425019|Device|Soterix 1x1 tDCS mini-CT Stimulator device|Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
45792848|NCT02049515|Drug|IPI-145|PI3K Inhibitor
45792849|NCT02049515|Drug|Ofatumumab|Monoclonal antibody
45653160|NCT05503693|Drug|Placebo 50 μg|Placebo tablet
45653161|NCT05503693|Drug|Placebo 150 μg|Placebo tablet
45653162|NCT05503693|Drug|Placebo 300 μg|Placebo tablet
45653163|NCT05503693|Drug|Placebo 600 μg|Placebo tablet
45653164|NCT05475353|Behavioral|Asyncronized Exercise|This group will be informed about ergonomics and protective exercises for the musculoskeletal system with an online seminar.
45653165|NCT05475353|Procedure|Syncronized Exercise|This group will be informed about ergonomics and protective exercises for the musculoskeletal system with an online seminar. Then, participants will complete the 6 weeks of exercise training at an online video conference program two times a week under the physiotherapist's supervise.
45792850|NCT01687244|Drug|INSTILADRIN|The INSTILADRIN components will be mixed with a diluent. The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be repeated every 3 months up to a maximum of 4 instillations.
45792851|NCT03224403|Drug|Test acetaminophen|single dose of 2 Test acetaminophen 500 mg tablets
45792852|NCT03224403|Drug|Commercial acetaminophen|single dose of 2 acetaminophen 500 mg caplets
45792853|NCT03224403|Drug|Commercial ibuprofen|Single dose of 2 ibuprofen 200 mg Liquid-filled Capsules
45792854|NCT03224403|Drug|Placebo|2 placebo caplets
45792855|NCT02334059|Drug|Ketamine|Ketamine infusion plus placebo infusion of normal saline
45792856|NCT02334059|Drug|Ketamine plus magnesium|Ketamine plus magnesium infusion
45792857|NCT02334059|Other|Placebo|2 placebo infusions
45792858|NCT02242994|Device|Dynavox Maestro|Receives commercially available communication device Dynavox Maestro to test speed and quality of communication.
45792859|NCT02242994|Device|Experimental App|Participant receives experimental app to test speed and error rate of communication.
45792860|NCT04501523|Drug|Tislelizumab|200mg, q3w, for 1 year
45792861|NCT04501523|Drug|capecitabine|600-750 mg/m2 PO Bid，continuous, for 1 year
45792862|NCT04499573|Drug|CD19/CD22 CAR-T|"The treatment plan will be based on stratification by the initial leukemia burden.~Patients with low disease burden will receive a lymphodepletion chemotherapy of fludarabine (total dose 120mg/m2) and cyclophosphamide (total dose 750mg/m2) over 5 days.~Patients will high disease burden will receive a lymphodepletion chemotherapy of fludarabine (total dose 120 mg/m2), cyclophosphamide (total dose 750 mg/m2), cytarabine (total dose 900 mg/m2), etoposide (total dose 450 mg/m2), dexamethasone (total dose 30 mg/m2) over 5 days.~Based on interim analysis the following dosing approach will be implemented starting April 2021:~Cohort 1: CD19+ disease, low and high burden: 1st dose - 150k/kg, 2nd dose - 850k/kg Cohort 2: CD19- disease, low and high burden: 1st dose - 500k/kg, 2nd dose - 500k/kg Cohort 3: HSCT+CAR-T: 100k/kg"
45792863|NCT01933295|Behavioral|Cognitive Behavioral Therapy for Insomnia|
45792864|NCT01933295|Behavioral|Sleep Education|
45792865|NCT01933295|Behavioral|Sleep Restriction Therapy|
45792866|NCT03425097|Drug|Fexofenadine|Fexofenadine 180 mg in the morning
45449698|NCT00101686|Drug|Oral Capecitabine with Irinotecan|Day 1: Irinotecan (250 mg/m2 IV) over 90 minutes; Day 1-14: capecitabine 1000 mg/m2 PO BID [two times a day] (28 single doses). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
45792867|NCT03425097|Drug|Placebo - Cap|Placebo cap in the morning
45792868|NCT03895697|Drug|dasiglucagon|Glucagon analogue
45792869|NCT04706871|Device|taVNS|"taVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily.~The two electrodes were placed on the cymba conchae and concha around the left ear."
45449699|NCT02166892|Other|Specially designed plates|
45792870|NCT04706871|Device|tnVNS|"tnVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily.~The two electrodes were placed on the antihelix around the left ear."
45792871|NCT01926041|Drug|Varenicline for tobacco smoking cessation|The 16-week varenicline course conforms to real-practice government regulations in Taiwan.
45792872|NCT01926041|Behavioral|Individualized counseling about both smoking cessation and weight control techniques|The FIT2 program also offers behavior coaching in diet and physical activity to restrict post-cessation weight gain, which is not covered in conventional smoking cessation services.
45449700|NCT02163460|Procedure|Drain|In group 1, a 4.8 mm diameter continuous closed-suction tubular drain (Medsharp Ind.Com.Prod.Hosp.Ltda - reg. MS (Ministério da Saúde [Health Ministry registry]): 80267170001) was placed between the aponeurosis and the subcutaneous tissue caudally to the incision.
45449701|NCT02163460|Procedure|Progressive Tension Sutures|Drains were not used in group 2, but separate absorbable polyglactin 920 2/0 sutures were placed from the subcutaneous mesh to the aponeurosis every 2 cm by means of the progressive tension suture (or Quilting Sutures) technique, as described by Pollock et al
45792873|NCT05440773|Other|Artemisia afra tea infusions|A. afra infusions of 5g/1litter of water, 3drinks a day, daily for 1week (7 days) (current recommendation).
45792874|NCT05440773|Other|Artemisia afra tea infusions|A. afra infusions of 5g/500ml of water, 2drinks a day, daily for 1week (7 days) (increase concentration and decrease dose frequency).
45792875|NCT05440773|Other|Artemisia afra tea infusions|A. afra infusions,5g/1liter of water, 3drinkss a day, weekly for 4weeks (decrease dose frequency and increase length of treatment).
45792876|NCT05440773|Other|Artemisia afra tea infusions|A. afra infusions, 5g/1liter of water, 3drinks a day, daily for1week (7 days) (current treatment with improved taste).
45792877|NCT05440773|Other|Artemisia afra tea infusions|A. afra infusions, 5g/500ml of water, 2drinks a day, daily for 1 week (7 days) (improved taste, increase concentration and decrease dose frequency).
45792878|NCT05440773|Other|Artemisia afra tea infusions|Group of 8 persons receiving flavored A. afra infusions, 5g/1liter of water, 3drinks a day, weekly for 4weeks (improved taste, decrease dose frequency and increase length of treatment).
45792879|NCT05440773|Other|Flavored placebo infusions|Flavored placebo infusions, 5g/liter of water, 3drinks a day, daily for 1week (7 days) (improved taste with no active molecule)
45792880|NCT05440773|Other|Regular tea placebo|Regular tea placebo taken as desired, daily for 1 week (7 days) (Regular tea with no active molecule).
45792881|NCT04736277|Other|Preoperative HbA1c|Documentation of the preopetative HbA1c in patients undergoing noncardiac surgery under general anesthesia
45792882|NCT01769027|Drug|Sertraline+Antibiotic (penicillin/azithromycin)|"12 weeks treatment with a combination of Sertraline (to a maximum of 200 mg/day) and an antibiotic (benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week.~Non-responder patients will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)"
45792883|NCT01769027|Drug|Sertraline+placebo|12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and placebo
45792884|NCT01769027|Biological|IVIG|Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
45792885|NCT04706637|Drug|Evogliptin|evogliptin 5mg + metformin, oral administration once a day for 48 weeks
45792886|NCT04706637|Drug|Dapagliflozin|dapagliflozin 10mg + metformin, oral administration once a day for 48 weeks
45792887|NCT04735809|Dietary Supplement|Whole Cell Algae Fermentate|Contains at minimum 50% Beta Glucan
45647530|NCT05103397|Drug|methyl prednisolone|Low dose group .Group (A) 10 mg/Kg methyl prednisolone will be received after induction and before separation to (CPB).
45792888|NCT04735809|Dietary Supplement|Placebo|microcrystalline cellulose
45792889|NCT03294213|Device|aScope 4 Broncho|"Investigator is asked: In your memory, compare your daily bronchoscope and the aScope 4 Broncho just evaluated on patients admitted to the OR or ICU undergoing at least one bronchoscopy procedure Patients will not be asked to consent to participate in this study, as no patient data are obtained and the CE-marked aScope™ 4 Broncho is used within its intended use"
45792890|NCT04706949|Drug|Pyrotinib combined with pemetrexed plus carboplatin|"Pyrotinib: oral administration within 30 minutes after breakfast, 400mg / day, continuous administration for 21 days as a cycle; each continuous pause time and the cumulative pause time of each cycle should not exceed 14 days. It is allowed to suspend the drug for many times due to adverse events.~Pemetrexed: the recommended dosage is 500mg / m2, once every three weeks. 3) Carboplatin: the dosage was determined according to Calvert formula, in which AUC was 5mg / ml / min."
45792891|NCT04454723|Procedure|Blood and/or platelet transfusion|The transfused patients will receive one unit each of blood and/or platelet transfusions once a week based on CTCAE symptom grade 2 or greater of anemia and/or thrombocytopenia.
45792892|NCT04454723|Procedure|Complete blood count (CBC) collection|CBC will be collected from patients weekly while on this protocol.
45792893|NCT03823157|Behavioral|Tai Chi|mind-body exercise
45792894|NCT04443257|Other|assessment of the sequelae after hospitalization for Sars-COV-2|the incidence of chronic respiratory failure and fibrosis, as well as of comorbidities including cardiovascular, metabolic, renal, hepatic, neurological, and psychological diseases
45792895|NCT02299349|Drug|bupivacaine liposome suspension|bupivacaine liposome suspension periarticular injection
45792896|NCT02299349|Drug|concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL|Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl
45792897|NCT01239095|Drug|Green Tea and Milk Thistle Supplements|Green Tea Extract: 3,200 mg per day Milk thistle extract with phosphatidylcholine: 2,700 mg per day
45792898|NCT03750461|Device|Mesh Implantation|Implantation of permanent mesh (BARD Soft Mesh) into the abdominal wall for reinforcement to prevent hernia formation
45792899|NCT03718637|Biological|Smith & Nephew Bioinductive Implant|A bioinductive implant that is supposed to foster healthy tendon regrowth after surgery.
45792900|NCT03718637|Procedure|Lateral Epicondylectomy|This procedure is the standard of care for lateral epicondylitis patients who fail conservative treatment options.
45792901|NCT03718637|Radiation|Ultrasound Imaging|An ultrasound will be performed on each patient both preoperatively and at 6 months.
45792902|NCT03296163|Drug|MB02 (Bevacizumab Biosimilar Drug)|15 mg/kg IV every 3 weeks on Day 1
45792903|NCT03296163|Drug|EU-approved Avastin®|15 mg/kg IV every 3 weeks on Day 1
45449702|NCT02166970|Device|Metallic stent deployment in hilar obstruction|Single stent insertion: metal stent deployment to right or left intrahepatic duct Multiple stenting: Stent-in-stent or side-by-side deployment
45647531|NCT05103397|Drug|Methyl Prednisolonate|High dose group.Group (B) 30 mg/Kg will be received after induction and before separation (CPB)
45647532|NCT05103397|Drug|Placebo|Placebo group.Group (C) (25 patients) patients will receive placebo in form of normal saline
45647533|NCT05101447|Drug|Mycophenolate Mofetil|At baseline, subjects will be randomized 1:1 to one of two treatment arms: the current standard of clinical care [MMFBSA: 600 mg/m2/dose; max: 3 gram/day] or pharmacokinetically-driven precision dosing [MMFPK: 12-hour target area under the exposure curve of MPA (MPA-AUC0-12) at 60 mg*h/L].
45647534|NCT05101291|Drug|Bupivacain|Interventional anaesthesia provided through an indwelling spinal catheter was administered according to protocol
45647535|NCT04342169|Drug|Hydroxychloroquine|HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days
45647536|NCT04342169|Drug|Placebo oral tablet|Placebo to be taken on the same schedule as HCQ.
45647537|NCT05103163|Other|Foot Reflexology|Reflexology application is an energy balancing system with its own pressure technique that provides recovery by rubbing the reflex (nerve endings) points, stroking and applying pressure during squeezing movements. Thanks to the pressure and massage applie
45792904|NCT03296163|Drug|Carboplatin|Carboplatin Area under the curve (AUC) 6 IV every 3 weeks on Day 1 for 6 cycles
45647538|NCT04979273|Drug|Dextrose 40 % in Water|injection of adrenaline 1:20.000, followed by dextrose 40% spray
45647539|NCT04979273|Drug|Adrenaline 1 Mg/mL Solution for Injection|injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip
45792905|NCT03296163|Drug|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 6 cycles
45792906|NCT01987349|Biological|Fluzone® (intramuscular)|Licensed seasonal trivalent inactivated influenza vaccine (IIV3)
45792907|NCT01987349|Biological|FluMist® (intranasal)|Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)
45449703|NCT02163616|Drug|Misoprostol|800 mcg of sublingual misoprostol
45647540|NCT04979273|Procedure|argon plasma coagulation|Thermocoagulation
45647541|NCT04979273|Procedure|Hemoclip|Hemoclip
45792908|NCT00376155|Drug|sulfadoxine /pyrimethamine plus amodiaquine|
45792909|NCT01987583|Procedure|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin.
45792910|NCT01987583|Other|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
45792911|NCT03435783|Behavioral|Brief Electronic Intervention|The brief electronic intervention will allow users to receive normative feedback based on their alcohol use and sexual activity. Users who show interest in changing their behavior will also be asked to create a plan to do so.
45792912|NCT03435783|Behavioral|Attention-Matched Control|Participants will view a video clip on general health promotion that is a similar length as the intervention arm.
45792913|NCT01988129|Other|Sleep disorders education and screening|Firefighters were instructed to attend an education presentation as operations allowed which provided information on firefighter mortality, fatigue-related health hazards and discussed the importance of sleep, and also included strategies to improve sleep hygiene and how to use caffeine and naps effectively to promote alertness. Firefighters were then invited to complete a voluntary sleep disorders screening survey. This survey used validated, self-report screening tools for obstructive sleep apnea, moderate to severe insomnia, restless legs syndrome and shift work disorder. All of those who screened positive for a high risk of any sleep disorder were notified by letter as to their risk and provided with contact information for a partnering sleep clinic if they chose to follow-up.
45792914|NCT02300285|Device|Continuous Glucose Monitoring|Continuous glucose monitors (CGM) will be used to monitor blood sugar levels in enrolled subjects. CGMs measure blood sugar in the tissue just under the skin every few seconds and report average blood sugar every 5 minutes. In our study, the CGMs will function as monitoring systems. In the CGM protocol group the CGM will let the medical team know if there is a concerning blood sugar level, so that the medical team can then check a blood sugar level by the standard way (usually in a small drop of blood) and then decide if they need to give any medical treatment. In the Standard of Care group the CGM data will not be visible to the medical team but the medical team will be informed by the researchers if there are multiple unrecognized episodes of severe hypoglycemia.
45792915|NCT01989221|Drug|Sancuso®|Sancuso® (granisetron transdermal system) 3.1 mg/24 hours
45792916|NCT03226899|Drug|Lesinurad|200 mg oral tablet
45792917|NCT03226899|Drug|XOI|All participants must be on a stable, medically appropriate dose of XOI as their sole urate-lowering therapy (ULT) indicated for the treatment of gout for at least 4 weeks prior to Screening and throughout the Screening Period. This stable dose of XOI will be maintained throughout the study period.
45792918|NCT03226899|Drug|Placebo|matching placebo oral tablet
45792919|NCT03226899|Drug|colchicine|Gout flare prophylaxis: commercially available colchicine is provided through the Month 6 study visit. Actual colchicine dose (0.5 or 0.6 mg qd) and frequency were adjusted based on the local label, subject medical history, and clinical judgement.
45792920|NCT03226899|Drug|corticosteroids|Gout flare prophylaxis: Participants unable to take colchicine are permitted to take a short course of low-dose oral corticosteroids up to the Month 3 study visit
45792921|NCT01990703|Drug|Levonorgestrel IUD|Timing of IUD insertion
45792922|NCT01958645|Drug|MEDI8111|MEDI8111 lyophilisate for solution for infusion
45792923|NCT01958645|Other|Placebo|Placebo for MEDI8111 saline solution for infusion
45920721|NCT00099385|Behavioral|Social Development Instruction|Weekly instruction during regular classroom time by classroom teacher using PATHS (Greenberg & Kusche) curriculum.
45920722|NCT00099424|Behavioral|High-intensity exercise training|
45920723|NCT00099463|Procedure|Blood Test|
45920724|NCT00099463|Procedure|Urine Test|
45920725|NCT00099463|Procedure|Physical Exam|
45920726|NCT00099463|Drug|Vaccine|
45647542|NCT05103007|Procedure|DEB-TACE|It is suggested that the tumor feeding artery should be selected for the microcatheter. The mixed volume of pirarubicin 80mg + microsphere 2g is about 2ml, and the mixture of at least 10ml and contrast medium is slowly injected with 5-10min.
45920727|NCT00099463|Drug|VRC-SRSDNA015-00-VP|
45920728|NCT00099502|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250mcg administered s.c. every other day
45449704|NCT02162056|Device|use of bioresorbable vascular scaffolds|Implantation of bioresorbable vascular scaffolds for coronary artery disease.
45647543|NCT05103007|Procedure|PVL/PVE+DEB-TACE|DEB-TACE will be performed after the liver function recovered within 7-10 days. After that, conventional transarterial chemoembolization（cTACE) was performed every 2 months, a total of 2-3 times of chemoembolization.
45792924|NCT03437031|Device|Virtual Reality device|For those patients randomized to VR, the study staff member will explain the use of the Samsung VR goggle set, and thereafter will allow the patient to use the device freely for up to 30 minutes. Intervals of 2-5 minutes is suggested for first-time use, and patients will be to allowed to discontinue it at any time as long as they are not experiencing any discomfort or side effects (dizziness, motion sickness, etc.). The study staff member will be present at all times, and will work with hospital staff as necessary to ensure the patient is receiving appropriate clinical care throughout the duration of the intervention.
45920729|NCT00099502|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|500mcg administered s.c. every other day
45920730|NCT00099502|Drug|Copaxone|20 mg administered s.c. once daily.
45920731|NCT04210596|Procedure|Soft tissue augmentation at the buccal aspect of single implants|Soft tissue augmentation is performed following mucoperiosteal flap elevation at the buccal aspect of single implants. The connective tissue graft (control) or collagen matrix (test) is inserted in the buccal pouch and attached with monofilament sutures.
45920732|NCT00387920|Drug|sunitinib malate|Given orally
45920733|NCT00387920|Other|pharmacological study|Correlative studies
45920734|NCT00387920|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
45920735|NCT00387920|Other|laboratory biomarker analysis|Correlative studies
45920736|NCT00099541|Drug|zoledronic acid|
45920737|NCT02888067|Drug|Rocuronium bromide 0.5 mg/kg|Moderate neuromuscular blockade with rocuronium bromide
45920738|NCT02888067|Drug|Rocuronium bromide 1.0 mg/kg|Deep neuromuscular blockade with rocuronium bromide
45920739|NCT02888067|Drug|Sugammadex sodium 2 mg/kg|Reversal with sugammadex sodium
45920740|NCT02888067|Drug|Sugammadex sodium 4 mg/kg|Reversal with sugammadex sodium
45920741|NCT00006350|Biological|daclizumab|
45920742|NCT00006350|Biological|therapeutic allogeneic lymphocytes|
45920743|NCT00006350|Drug|mycophenolate mofetil|
45920744|NCT00006350|Drug|tacrolimus|
45920745|NCT00006350|Procedure|peripheral blood stem cell transplantation|
45920746|NCT00400582|Drug|Candesartan up to 32 mg daily|Candesartan 4 to 32 mg daily
45920747|NCT00400621|Drug|acetaminophen|
45920748|NCT00006353|Drug|temozolomide|
45449705|NCT02163772|Procedure|Intracordal hyaluronate injection|
45792925|NCT01959113|Biological|Autologous Microbiome Transplant|
45792926|NCT01959113|Other|Placebo Arm|
45792927|NCT03438045|Behavioral|Partnered intervention|CHWs will provide dental education and counseling, lead interactive demonstrations of brushing with fluoride toothpaste and flossing, and improve access to dental care through dental coverage enrollment and linkage to local dentists.
45792928|NCT02301299|Behavioral|Community-based Stroke Awareness Program|A culturally-adapted stroke awareness and action program will be delivered by trained Stroke Promoters in the targeted neighborhoods in the south side of Chicago. Community Stroke Promoters will be trained on 1) the benefits of early recognition and EMS utilization for stroke (i.e. stroke centers, tPA), 2) culturally-adapted solutions to current barriers (i.e. misperceptions about vulnerability, severity, mistrust, costs), and 3) cues to aid in stroke recognition and immediate action. The intervention will take place at community settings throughout a 1-year period.
45792929|NCT03230175|Biological|TTAX01|TTAX01 will be applied directly to the wound surface and retained with non-absorbable sutures. A single layer of the test article should cover the entire open surface of the wound. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case dosing is suspended; or, if the test article has been accidentally dislodged, it may be replaced at any time.
45792930|NCT03230175|Procedure|Surgical resection and debridement|"Perform surgical sharp debridement in the OR, to remove:~infectious agents and biofilms (purulence),~all debris, eschar, callus and macerated non-viable tissue from the wound base, and~dead (suprabasal epidermis), scarred (elevated/edematous) and necrotic/macerated tissue from the wound edge.~Surgical Resection will be performed to remove as much of the necrotic bone detected by the radiographic evidence as is appropriate."
45792931|NCT03230175|Drug|Systemic antibiotics|Six (6) weeks of systemic antibiotic therapy is required. A definitive therapy will be guided by the microbiological results based on bone biopsy.
45792932|NCT03230175|Device|Off-loading|Provide off-loading device appropriate to the location of wound with full length boot or total contact cast
45792933|NCT01992185|Drug|Photocil for Vitiligo|Photocil for Vitiligo
45792934|NCT01992185|Other|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
45647544|NCT05092555|Diagnostic Test|Nasopharyngeal swap for Reverse transcription polymerase chain reaction|Nasopharyngeal swap and Blood sample is taken for doing previous tests and CT chest is done for all patients
45792935|NCT03231345|Procedure|US guided IJ|IV catheter placement
46071602|NCT02834754|Drug|placebo|Currently there are no clinical guidelines and no standard of care for the maintenance of surgically induced remission. There are no medications that have consistently been proven to be efficacious at preventing recurrent Crohn's disease and as such, no active equivalent arm is being used. Due to the lack of effective prophylactic therapy, many physicians and patients opt not to initiate medical therapy after surgery, rather wait until Crohn's disease recurs, or wait to perform a post-operative colonoscopy within 6-12 months of surgery, and decide on initiating Crohn's disease therapy based on endoscopic Rutgeerts; score. Therefore, acknowledging that many patients are not administered post-operative maintenance medications, we feel the placebo arm is justified.
45449706|NCT00101452|Drug|S-adenosyl-l-methionine|1600 mg per day with possibility of increasing to 3200 mg per day at 6 weeks
45449707|NCT00101452|Drug|Escitalopram|10 mg per day, with possibility of increasing to 20 mg/day at 6 weeks
45647545|NCT04155749|Drug|CART-ddBCMA|Chimeric Antigen Receptor T cells
45647546|NCT04155749|Drug|ARC-T Plus Anti-BCMA SparX|Chimeric Antigen Receptor T cells plus SparX protein
45647547|NCT05093881|Biological|Cellgram-LC|Patients who had administered Cellgram-LC in PMC-P-07 study
45647548|NCT04973423|Radiation|MRI|2 additional MRI will be done for the CALM + MRI group
45647549|NCT05073991|Procedure|Lung surgery|Patients underwent lung surgery including wedge resection, lobectomy, segmentectomy, and pneumonectomy.
45792936|NCT03231345|Device|Ultrasound|Ultrasound-guided Internal Jugular vein
45792937|NCT03665285|Drug|NC318|NC318 is an experimental antibody drug that may make the immune response more active against cancer.
45792938|NCT03296787|Drug|TAK-954|TAK-954 intravenous infusion.
45792939|NCT02301377|Device|Spiro PD personal spirometer|
45792940|NCT04332627|Drug|Sugammadex|sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg)
45449708|NCT00101452|Drug|Placebo|placebo capsules look like escitalopram capsules and SAMe capsules
45449709|NCT02167126|Device|Kinesio Taping|"using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, passing around the patella and finishing on the tibial tuberosity."
45647550|NCT05073991|Procedure|Open aortic surgery|Patients underwent open thoracic surgery or thoracoabdominal aortic surgery.
45647551|NCT05073991|Procedure|TEVAR|Patients underwent TEVAR.
45647552|NCT05073991|Procedure|EVAR|Patients underwent EVAR.
45647553|NCT05100433|Procedure|Ultrasonic irrigation|Ultrasonic irrigation will be used as a complementary step to chemomechanical procedures to test whether it can improve root canal disinfection.
45647554|NCT05099887|Biological|Procenta conformable barrier|Wound care dressing biologic allograft
45792941|NCT04332627|Drug|Neostigmine|with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg)
45792942|NCT03440229|Other|Emulsifier-containing diet|CMC is one of many synthetic dietary emulsifiers that are incorporated into a variety of processed foods. We have recently shown that, in mice, consumption of P80 and CMC, alters microbiota composition, have pro-inflammatory potential and promote microbiota encroachment into the colonic mucosa, low-grade inflammation, and metabolic syndrome. However, it is not known whether these compounds have similar effects in humans. We would like to study these effects in the human gut microbiota.
45792943|NCT01961921|Drug|ALN-TTR02 (patisiran) administered by intravenous (IV) infusion|
45792944|NCT03604913|Procedure|Aortic valve sparing operation|Aortic valve sparing instead of replacement during aortic root replacement
45792945|NCT03604913|Procedure|Bentall operation|Aortic root replacement with replacement of aortic valve
45792946|NCT01963091|Drug|oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo at 1:15pm. This dose and timing of administration was selected based on previous studies that have used similar doses of oxytocin (Ditzen, et al., 2009; Heinrichs, et al., 2003). Intranasal oxytocin and matching placebo will be compounded by Pitt Street Pharmacy Custom Compounding (Mt. Pleasant, South Carolina). Randomization will be done by a licensed pharmacist who will keep a record of the blind and be available should unblinding be necessary.
45792947|NCT01963091|Drug|saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo at 1:15pm. This dose and timing of administration was selected based on previous studies that have used similar doses of oxytocin (Ditzen, et al., 2009; Heinrichs, et al., 2003). Intranasal oxytocin and matching placebo will be compounded by Pitt Street Pharmacy Custom Compounding (Mt. Pleasant, South Carolina). Randomization will be done by a licensed pharmacist who will keep a record of the blind and be available should unblinding be necessary.
45792948|NCT01963169|Behavioral|TO-BoneHealth Program (Bone Power Program)|The 8-week TO-BoneHealth program include: (1) web learning modules, (2) moderated discussion boards, (3) an Ask-the-Experts section, and (4) a virtual library. In addition, a tool kit and video lecture library are also available to participants. The program will be closed after 8 weeks, and there will be no eNewsletter or bi-weekly follow-ups of bone health behavior goal attainment. After 8 weeks, participants will receive a monthly e-mail informing them of the upcoming surveys.
45792949|NCT01963169|Behavioral|TO-BoneHealth Plus Program (Bone Power Plus Program)|This intervention includes the 8-week TO-BoneHealth program followed by bi-weekly theory-based eNewsletters with follow-up of each individual's maintenance of bone health behaviors for 10 months.
45792950|NCT03298035|Device|NCPAP as mode for apnea prevention|With recurrence of apneic events, infants on NCPAP will have changes made in NCPAP settings per the clinical team's discretion in attempt to prevent future apneic events. If apneic events persist despite NCPAP adjustments, clinicians may intubate based on clinical judgment.
45792951|NCT03298035|Device|NIPPV as rescue mode for apnea prevention|With recurrence of apneic events, infants will be placed on NIPPV with settings and adjustments per the clinical team's discretion. If apneic events persist despite NIPPV placement and setting adjustments, clinicians may intubate based on clinical judgment.
45792952|NCT02306759|Drug|Ketamine|Ketamine 0.3mg/kg in 50ml normal saline, administered over 15 minutes
45792953|NCT02306759|Drug|Placebo|Normal saline 50ml, administered over 15 minutes
45792954|NCT03592589|Device|high flow nasal canula|high flow nasal canula to obtain a positive expiratory pressure
45792955|NCT03298113|Device|Cavilon Advanced Skin Protectant|Applicator contains a polymeric-cyanoacrylate solution intended to cover and protect intact or damaged skin. Upon application to skin, the liquid dries rapidly to form a primary long-lasting waterproof, highly durable film barrier.
45792956|NCT03298113|Device|IAD Hospital Standard Care|Devices such as local skin protectants will be used according to the hospital IAD care regime and under consideration of the respective manufacturers' instructions for use.
45792957|NCT03440619|Device|INVSENSOR00013|Investigational pulse oximeter device that will be placed on the subject's finger. This will be used as a spotcheck device
45647555|NCT03061799|Dietary Supplement|HPC-03|HPC-03 is extracts of danggui (angelica gigas nakai), taeunggung (cnidium rhizome), and broilers (cinnamon bark).
45647556|NCT03061799|Dietary Supplement|Placebo|Placebo is constituted of crystalline cellulose(50.5%), corn starch(33.10%), caramel color(1.90%), anhydrous citric acid(1.25%), silicon dioxide(1.90%), carboxymethylcellulose calcium(6.25%), magnesium stearate(2.50%), and coater (3.10%).
45647557|NCT05036473|Drug|WD-1603 Carbidopa-Levodopa Extended-Release Tablets|Taking WD-1603 tablets or placebo orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours (±30 minutes).
45647558|NCT05036473|Drug|Placebo|placebo tablets-matching the active groups.
45647559|NCT04979351|Other|Abdominal Massage|Abdominal massage will be applied twice a day.
45647560|NCT04985851|Drug|durvalumab + anlotinib|Approximately 64 patients who complete the 4 cycles of durvalumab + EP treatment and don't have progressive diseases (Non-PD patients) will be randomized in a 1:1 ratio to receive maintenance treatment durvalumab + anlotinib (Arm 1) or durvalumab (Arm 2) until confirmed progressive disease.
45647561|NCT04985851|Drug|Durvalumab|durvalumab
45647562|NCT04929769|Other|Total Laparoscopic or Robotic Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
45647563|NCT04929769|Other|Total Abdominal Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
45647564|NCT04930861|Drug|Covidir injections|administration of the investigational product CODIVIR at a dose of 20 mg twice a day subcutaneously.
45792958|NCT03232749|Procedure|intraarticular corticosteroid injections (IACSI)|ultrasound-guided IACSI will be administered
45792959|NCT03232749|Drug|corticosteroid injections|Corticosteroid will be administered is used to treat pain and swelling that occurs with arthritis and other joint disorder
45792960|NCT03232749|Device|Ultrasound|ultrasound-guided IACSI
45792961|NCT03232827|Behavioral|Flavored-Sweetened Waterpipe Tobacco|Pre-weighed flavored-sweetened waterpipe tobacco will be prepared.
45792962|NCT03232827|Behavioral|Unflavored-sweetened waterpipe tobacco|Pre-weighed unflavored-sweetened waterpipe tobacco will be prepared.
45792963|NCT03232827|Behavioral|Unflavored-very low sweetened waterpipe tobacco|Pre-weighed unflavored-very low sweetened waterpipe tobacco will be prepared.
45792964|NCT03232827|Behavioral|Flavored-very low sweetened waterpipe|Pre-weighed flavored-very low sweetened waterpipe tobacco will be prepared.
45792965|NCT01687400|Drug|decitabine|
45792966|NCT01687790|Device|molecular breast imaging (Discovery)|
45920749|NCT00006353|Radiation|radiation therapy|
45920750|NCT00400660|Drug|GSK615915A|GSK615915A inhaler will be given with a dose of 250 micrograms per metered actuation and 120 actuations per inhaler.
45920751|NCT00400660|Drug|Placebo|Subjects will also receive placebo inhaler.
45920752|NCT00400699|Other|counseling intervention|
45647565|NCT04930861|Diagnostic Test|One Step Test|rapid test for the diagnosis of COVID-19 based on the detection of anti-SARS-CoV-2 in the blood.
45647566|NCT04930861|Diagnostic Test|IgM and IgG dosage|blood collection for dosage of Anti SARS-CoV-2 antibodies.
45647567|NCT04930861|Diagnostic Test|RT-PCR SARS-CoV-2|detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
45647568|NCT04930861|Diagnostic Test|Screening blood test|complete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; fibrinogen, Pregnancy test for non-sterile women.
45647569|NCT04930861|Diagnostic Test|ECG|12-lead electrocardiogram with report.
45647570|NCT04930861|Diagnostic Test|Medical evaluation|evaluation by the principal investigator or assistant physician with a complete physical examination.
45647571|NCT04930861|Diagnostic Test|NEWS-2 score|assessment of the participant by the NEWS-2 score.
45792967|NCT05473598|Behavioral|Stand Down app|Patients in this condition will receive Usual Care (UC) and be provided a unique code and password to access Stand Down. The app is based on principles of motivational enhancement and cognitive-behavioral therapies and comprises 7 modules organized around 4 goals: 7 modules organized around 4 goals: (i) Enhance awareness of drinking patterns (assessment and personalized feedback), (ii) Establish and monitor progress towards drinking goal - i.e., moderation or abstinence, (iii) Manage cravings and other problems using in-the-moment tools, and (iv) Connect users with other types of support. App usage will be tracked by the research team for the duration of the study (32 weeks).
45792968|NCT05473598|Behavioral|Peer-Supported Stand Down|Patients assigned to this condition will receive UC and access to Stand Down, plus four phone sessions from a Peer over 8 weeks. Sessions will be bi-weekly, approx. 15-30 minutes in length, and focus on enhancing patients' engagement with the app.
45792969|NCT05473598|Other|Usual Care|All patients, regardless of condition, will have access to usual care for hazardous drinking in primary care. In this setting, usual care entails a spectrum of alcohol-related services including annual screening for hazardous drinking, brief intervention following a positive screen (advice from a provider to reduce their drinking), and referral (as needed) to specialty AUD treatment.
45792970|NCT01688102|Dietary Supplement|Oral Vitamin D3|50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed
45792971|NCT01688102|Radiation|Ultraviolet Light|16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes
45792972|NCT01994993|Drug|ampicillin and metronidazole and gentamicin|IV infusion of ampicillin and metronidazole and gentamicin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
45792973|NCT01994993|Drug|ampicillin and gentamicin and clindamycin|IV infusion of ampicillin and gentamicin and clindamycin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
45792974|NCT01994993|Drug|gentamicin and Piperacillin- tazobactam|IV infusion of gentamicin and Piperacillin- tazobactam for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
45792975|NCT01994993|Drug|standard of care antibiotics and metronidazole|IV infusion of standard of care antibiotics and metronidazole for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
45792976|NCT01994993|Drug|metronidazole, clindamycin, or piperacillin-tazobactam|IV infusion of metronidazole, clindamycin, or piperacillin-tazobactam with scheduled CSF procedures per standard of care. Study drug will be given for for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
45920753|NCT00400699|Other|study of socioeconomic and demographic variables|
45920754|NCT00400699|Procedure|psychosocial assessment and care|
45647572|NCT04930861|Diagnostic Test|WHO score|assessment of the participant by the score of the World Health Organization.
45647573|NCT04979507|Other|Uninterrupted sleep followed by functional neuroimaging.|2 within-subject sleep conditions: uninterrupted sleep; selective REM sleep reduction, followed by functional neuroimaging with emotion reactivity and regulation tasks the following morning
45647574|NCT05099575|Drug|Syntocinon, papal, misotac|Using different drugs to prevent atonic PPH during CD in high risk group
45647575|NCT03061955|Biological|influenza vaccination|administration of influenza vaccination
46071603|NCT02839512|Device|Jejunal to Ileal Diversion|The Jejunal to Ileal Diversion procedure will be performed using colonoscopes to place magnets to create a side to side compression anastomosis. The colonoscope delivered magnet creates the proximal end of the anastomosis approximately 100 cm distal from the ligament of Treitz. The colonoscope delivered magnets creates the distal end of the anastomosis approximately 100 cm proximal from the ileocecal junction.
45647576|NCT05099341|Other|HDRS-17 depression scale|Measuring the severity of depression
46071604|NCT02839122|Drug|Tadalafil|
46071605|NCT02839122|Drug|Dutasteride|
45647577|NCT05099341|Biological|Blood sampling|3 tubes of 5 ml
45647578|NCT04979039|Other|analgesia nociception index (ANI) monitoring|The ANI monitor starts lying on the bed in the waiting area before entering the operating room, and the monitoring period should be at least 15 minutes. After entering the operating room, monitoring begins again and is maintained during the operation.
45647579|NCT04919551|Drug|vicagrel|Oral administration after fasting/high-fat meal/low-fat meal
45647580|NCT03063515|Drug|Pyridostigmine|single oral dose of 60 mg pyridostigmine tablet
45647581|NCT04907773|Other|Capillary blood sampling|Each subject will have one to two capillary blood collections.
45647582|NCT04907773|Other|Venous blood sampling|Each healthy subject will also have a reference venous blood collection.
45647583|NCT04907773|Other|Arterio-venous blood sampling|Each hemodialysed subject will also have a reference arterio-venous blood collection.
45647584|NCT04973813|Behavioral|Guideline + Active Choice + action&coping planning (GA+)|Web-based intervention consisting of information and assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; action planning; identifying barriers to physical activity; coping planning
45792977|NCT04735887|Other|SADL-eM|The SADL-eM includes three elements essential to the intervention, namely: knowledge, skills, and advice. The manual includes 92 A5 pages with six detailed sections: an Introduction and five chapters: (1) Rehabilitation team, (2) Activities of Daily Living, (3) Assistive devices, (4) Home environment adaptation, and (5) Knowledge guide. The SADL-eM uses text and illustrative pictures that are carefully selected for contextual relevance. The manual is simple, easy, and suitable for people with a non-medical background.
45792978|NCT01688336|Drug|FOLFIRINOX|"FOLFIRINOX will be given intravenously on Days 1, 15, and 28 of each 28 day cycle. Drugs are given in combination in this order:~Oxaliplatin (85 mg/m2)~Leucovorin (400mg/ m2)~Irinotecan (180 mg/m2)~5FU (400mg/m2)bolus then 2400 mg/m2 over 46 hours"
45792979|NCT03300843|Biological|Peptide loaded dendritic cell vaccine|On days 0, 14 (+/- 5 days), 28 (+/- 5 days), and 42 (+/- 5 days). The vaccine will be administered as both an intravenous (IV) infusion and a subcutaneous (SQ) injection. The total dose will be divided equally between intravenous (IV) and SQ containing 1.0E7 to 8.0E7 cells per cycle depending upon the manufacturing yield.
45792980|NCT01963481|Drug|Exemestane|
45792981|NCT01963481|Drug|Cyclophosphamide|
45792982|NCT03301779|Device|Hemanext Red Blood Cell Processing System|Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.
45792983|NCT01689350|Genetic|Genotype Detection|To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM).
45792984|NCT03302091|Drug|BI 1467335|28 day treatment period
45792985|NCT03442725|Drug|Telotristat etiprate|Oral administration of 1 tablet of Xermelo® containing telotristat etiprate equivalent to 250 mg telotristat ethyl.
45647585|NCT04973813|Behavioral|Guideline + Active Choice (GA)|Web-based intervention consisting of information and several assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; identifying barriers to physical activity.
45792986|NCT04436744|Drug|Giredestrant|During the window-of-opportunity phase (first 2 weeks) giredestrant will be taken orally once per day (QD) as a single agent. During the neoadjuvant treatment phase, giredestrant will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.
45792987|NCT04436744|Drug|Anastrozole|During the window-of-opportunity phase (first 2 weeks), anastrozole 1 mg will be taken orally QD as a single agent. During the neoadjuvant treatment phase, anastrozole 1 mg will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.
45449710|NCT02167126|Device|Placebo Tape|"Micropore tape was applied using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, but because it is not elastic, the knee joint was not crossed and the end points were the medial and lateral aspects of the patella."
45449711|NCT02163850|Device|Direct Flow Medical|Direct Flow Medical Transcatheter Aortic Valve Replacement System (TAVR)
45647586|NCT04973813|Behavioral|Guideline + information (GI)|Web-based information about the national physical activity guideline, pros and cons of physical activity, and possible barriers to physical activity.
45647587|NCT04973813|Behavioral|Guideline (G)|Web-based information about the national physical activity guideline.
45647588|NCT04894981|Device|Immersive condition (CAVE)|Driving course with obstacles in a CAVE system
45449712|NCT02163850|Device|Commercially Available|Medtronic CoreValve Transcatheter Aortic Valve Replacement System (TAVR) or Edwards SAPIEN Transcatheter Aortic Valve Replacement System (TAVR)
45647589|NCT04894981|Device|Immersive condition (HMD)|Driving course with obstacles with a virtual reality headset
45647590|NCT04894981|Device|Non Immersive condition (Screen alone)|Driving course with obstacles on a screen with physical simulator
45449713|NCT02162134|Other|sugar free chewing gum|Sugar free chewing gum (orbit) was given to patients. They were asked to chew it 4 hours after surgery and continue to chew it 8 hourly for 20 to 25 min each time until oral feeding was started.
45449714|NCT02162134|Other|sugared chewing gum|Sugared chewing gum (singsong bubble gum) was given to patients. They were asked to chew it 4 hours after surgery and continue to chew it 8 hourly for 20 to 25 min each time until oral feeding was started.
45647591|NCT04894981|Device|Non Immersive condition (Screen with physical simulator)|Driving course with obstacles on a screen only
45647592|NCT04973501|Behavioral|Manual physiotherapeutic correction (MFK) Method|Patients undergo ambulatory physiotherapy :1-hour duration, twice a week for one month and once a week for next two months (16 therapies in total). Therapy was undertaken at the ambulatory section of the Department of Neurology, Kralovske Vinohrady University Hospital in Prague.
45792988|NCT04436744|Drug|Palbociclib|During the neoadjuvant treatment phase, palbociclib 125 mg will be taken orally QD on Days 1-21 of a 28-day cycle for a total of 4 cycles.
45792989|NCT04436744|Procedure|Surgery|Surgery must be performed within a maximum of 14 days after the final cycle in the neoadjuvant treatment phase and ideally should occur as soon as possible after the last dose of study treatment.
45792990|NCT00376779|Biological|Infanrix hexa Vaccine|
45792991|NCT03447015|Other|ambulation|"Ambulation during labour here will refer to moving from place to place during the first stage of labour that reduces the amount of time a woman spends laying down during this stage (measured by recording the number of minutes spend on walking)."
45449715|NCT02162134|Drug|Tab. Midazolam 7.5 mg|Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
45449716|NCT02162134|Drug|Inj. Midazolam 0.7mg/kg 45 min before surgery|Inj . Midazolam 0.7 mg/kg given as premedication.
45647593|NCT04973501|Behavioral|Dynamic Neuromuscular Stabilization (DNS) Method|Patients undergo ambulatory physiotherapy :1-hour duration, twice a week for one month and once a week for next two months (16 therapies in total).Therapy was undertaken at the Department of Rehabilitation and Sport Medicine, Motol University Hospital.
45653166|NCT05113797|Diagnostic Test|Lower Quarter Y-Balance Test|Dynamic balance assessment performed in a standing position while balanced on one leg, participants are asked to move a plastic box with their other foot in three directions (forward, back to the left, and back to the right) and a distance measurement is recorded. Each leg will be tested three times in each direction for the YBT-LQ assessment.
45792992|NCT03302793|Device|BreEStim|BreEStim will applied for 10 to 20 minutes.
45792993|NCT03302793|Device|tDCS|tDCS will be applied for 20 minutes.
45792994|NCT03302793|Device|tDCS sham|
45792995|NCT01963793|Drug|Aprepitant|Aprepitant gel (10 mg/g)
45792996|NCT01963793|Drug|Placebo|gel without active component
45449717|NCT02162134|Drug|Inj. Propofol 2.5mg/kg|It was given to induce anesthesia after 3 min of pre oxygenation.
45647594|NCT04858945|Behavioral|Teach-back method|During the trial, women from teach-back group and controlled group will receive three education sessions The topics discussed at the first session included delivery mode, labor process and pain relief, newborn health and care (common health issues and care skills), perinatal die and excises, and perinatal psychological health. The topics discussed at the second session includ postpartum recovery, postpartum maternal health, perineum care (diet, oral care, perineal care, and hygiene), breastfeeding, postpartum blue and depression, neonatal care, neonatal screening tests, newborn vaccination and early child development. At two-week postpartum, the educator answers questions raised by the woman and gives advices on the challenges and difficulties in postpartum recover and caring newborn faced by the woman.
45647595|NCT04973735|Drug|LY-CovMab|single IV infusion
45647596|NCT04860973|Device|Weighted blankets|Weighted blankets given to patient for 7 days/nights
45647597|NCT04973579|Procedure|Simutaneous (single anaesthesia) carotid artery stenting with MicroNet covered stent (CGuard) and cardiac surgery (CABG or surgical valve replacement / repair procedure)|"The registry enrolls patients qualified for treatment with the methods evaluated in the registry, using routinely applicable procedures and devices.~In cardiac surgery - surgical treatment systems for advanced ischemic heart disease and/or valvular disease (including - mechanical/biologic heart valves - regulatory approved for routine use and typically used at the Facility.~In the simultaneous treatment of stroke-threatening carotid artery atherosclerosis - temporary neuroprotection systems (proximal, distal, according to medical indications and local experience) - regulatory approved for routine use and typically used at the center (for over 20 years).~CGuard anti-embolic mesh stent system - a self-expanding nitinol carotid stent wrapped in MicroNet, which prevents fragments of atherosclerotic plaque from entering the lumen of the carotid artery - approved for routine use and typically used at the Center (over 5 years)."
45792997|NCT04359758|Behavioral|Proactive Streamlined Genetic Education and Testing|This intervention consists of the proactive delivery of genetic education print materials followed by streamlined and facilitated access to genetic testing.
45792998|NCT04359758|Behavioral|Usual Care|This intervention consists of a standard genetic referral letter that notified the participant that he qualified for genetic referral, recommends the scheduling of a genetic counseling session and provides a telephone number for scheduling.
45792999|NCT03449433|Drug|LY900014|Administered SC
45449718|NCT02162134|Drug|Inj. Atracurium 0.5 mg/kg|It was given to induce muscle relaxation during anesthesia.
45793000|NCT03449433|Drug|Insulin Lispro|Administered SC
45793001|NCT03449433|Drug|Insulin Aspart|Administered SC
45793002|NCT03449433|Drug|Insulin Aspart|Administered SC
45793003|NCT03241485|Drug|Intrathecal morphine|5 micrograms/kilogram of intrathecal morphine administered in the spinal space, not to exceed 1mg
45793004|NCT03241485|Drug|Placebo|Saline intrathecal given in the same manner as the intervention groups.
45793005|NCT04352270|Other|AD printed educational materials|Printed educational materials in Spanish and English about coping with Atopic Dermatitis, specifically geared towards children and parents will be given to participants.
45793006|NCT04352270|Other|AD educational videos|Short, educational videos in English and Spanish about coping with Atopic Dermatitis, specifically geared towards children and parents will be developed. There will be Spanish and English versions of the videos, minimal text, comprehensive language, animations, and it will be administered via user friendly platforms or websites.
45793007|NCT01965665|Device|MediHoney HCS dressing|
45647598|NCT04834063|Diagnostic Test|Serum Zinc a level|Diagnostic test
45793008|NCT04327154|Device|TISSIUM™ Nerve Coaptation Device|Placement of the TISSIUM™ Nerve Coaptation Device on repair site to achieve an end-to-end nerve coaptation.
45793009|NCT04313504|Drug|Niraparib|Niraparib & Dostarlimab combination
45449719|NCT02162134|Drug|Sevoflurane 2.5 vol %|It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
45449720|NCT02162134|Drug|Inj. Cefuroxime 1.5 g IV|It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
45449721|NCT02162134|Drug|Inj. Ketorolac 30 mg IV|3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period.
45647599|NCT04834063|Diagnostic Test|serum selenium level|Diagnostic test
45647600|NCT04834063|Diagnostic Test|Fibroscan measurement|Diagnostic test
45647601|NCT04978805|Behavioral|Progressive Relaxation Exercise|In the progressive relaxation technique, the tension and anxiety in skeletal muscles are relatively relieved.
45793010|NCT04313504|Drug|Dostarlimab|Niraparib & Dostarlimab combination
45793011|NCT01965899|Device|Insertable Cardiac Monitor Implant|The Reveal LINQ is a leadless device that is recommended to be implanted in the region of the thorax. Two electrodes on the body of the device continuously monitor the patient's subcutaneous ECG. The device stores ECG recordings from the patient-activated episodes and ECG recordings from automatically detected arrhythmias. Documentation of episode occurrence will be retained.
45793012|NCT03415880|Behavioral|Interactive workshops LiPAT intervention group|Workshops include practical behavior change strategies and address barriers to movement, awareness of the immediate benefits of movement and implementation-intentions. Participants will be encouraged to cultivate a learning mind-set in order to better tolerate potential set-backs and to apply strategies such as pre-planning their week to incorporate physical activity, engaging their social network, and setting up systems and habits. Participants' progress in changing their physical activity patterns which will be compared and discussed.
46071606|NCT02838810|Drug|peginterferon alfa|peginterferon alfa-2b or peginterferon alfa-2a
45449722|NCT02162134|Drug|Inj. Zantac 50mg IV|2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
45449723|NCT02163928|Other|Food-based intervention; increased fruits and vegetables|4-6 cups of fruits and vegetables daily for 8-weeks
45449724|NCT02164006|Drug|TGR-1202 + brentuximab vedotin|TGR-1202 an oral daily dose with an IV infusion of brentuximab vedotin
45647602|NCT04978961|Behavioral|Focused Acceptance & Commitment Therapy (FACT)|FACT is a brief form of Acceptance and Commitment Therapy and in this study, FACT focused on increasing patient functioning through connection with valued activities and increased acceptance.
45647603|NCT04978961|Behavioral|Enhanced Treatment as Usual (ETAU)|This active control intervention included 4 handouts focused on pain management based on cognitive behavioral science.
45793013|NCT03415880|Device|Wrist-worn feedback physical activity monitor|Participants receive the feedback monitor (Fitbit inspire®; commercially available consumer product (https://www.fitbit.com/inspire)
45793014|NCT03415880|Device|Smartphone application LiPAT|With a cloud-based platform the iHealth data is synchronized with a mobile phone app developed by the research team. The app is designed to help the participant to self-monitor their physical activity levels and includes information on total activity and number of steps taken.
45793015|NCT03415880|Behavioral|Telephone Coaching|participants in the intervention group will receive telephone coaching during the first 3 months of the intervention. Telephone coaching will be conducted twice in the first month and once each in months two and three. The researcher will enquire about the progress with increasing LiPA, about the experiences of applying the strategies discussed during workshops, and about the experience with Fitbit Inspire® and the corresponding app. If needed, the coach will offer suggestions to improve goal adherence.
45793016|NCT03415880|Behavioral|Workshops control group LiPAT|During the first 6 months of the study (the intervention period) participants in the control group will attend 4 workshops in which the benefits of physical activity and the health-risks of sedentary behavior will be discussed. Additionally, information will be provided on healthy lifestyle for patients with type 2 diabetes.
45793017|NCT03450369|Biological|NB01|Use an existing therapy designed to kill existing facial bacterial followed by populating facial skin with a single application of NB01
45793018|NCT01996943|Drug|Ethanol|6% volume/volume ethanol in 0.45% saline solution.
45793019|NCT01996943|Drug|Placebo|"The placebo with be 0.45% saline solution (half normal saline)."
45793020|NCT04812626|Drug|5-Fluorouracil|Group A: 1ml of 40mg/ml triamcinolone acetonide will be mixed with 1ml of normal saline Group B:1 ml of 40 mg/ml triamcinolone acetonide will be mixed with 1ml of 50 mg/ml FU Five units (0.125ml) of the mixture TAC 40mg/ml and 5-FU 50mg/ml (1:1) i.e. 2.5mg TAC and 3.125mg of 5-FU or TAC 40mg/ml and 2%xylocaine (1:1) i.e. 2.5mg of TAC will be given intralesional with the help of 1ml insulin syringe of 40units, that covers an area of about 0.5X0.5 cm2 of scar, thus, a scar of 1 cm2 will require 4 injections to cover the whole lesion. Each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs. For the larger lesions, dose can be increased but no more than 2ml in each group. Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks) Post treatment follow up: at 12 weeks.
45793021|NCT04265222|Device|Hipcheck Software|Software
45793022|NCT04265222|Other|Conventional Fluoroscopy|Conventional Fluoroscopy
45793023|NCT04249700|Device|Curve Sauna Dome|All participants receive WBH for 80-110 minutes in an infrared sauna. Participants lay supine in the sauna during this time, and their head is external to the sauna.
45793024|NCT04218812|Diagnostic Test|No electrical source imaging (ESI)|For all patients: MRI, semiology, visual interpretation of EEG, and in selected cases, PET, SPECT
45793025|NCT04218812|Diagnostic Test|Automated electrical source imaging (ESI)|"The automated source imaging consists of 2 phases~Automated detection of EDs~Source imaging of each spike cluster and seizure onset epoch."
45647604|NCT04794205|Drug|Low Dose Beta-Caryophyllene|5 mg BCP
45793026|NCT02935946|Other|Cold Liquid Barium|Cold Liquid is defined as being between 4-9 °C. One liter bottles of Poland Spring Natural Spring Water will be kept in the radiology suite to remain at room temperature. As described by Fink and colleagues,(42) the bottled water will be used to mix the barium powder to create a thin liquid consistency, with 50% dilution, which is found to be most similar to human milk and infant formula. After the barium is prepared, 2oz will be poured into a bottle and placed in a refrigerator set to 36°F; this will allow the barium to cool to approximately 4-9°C. Before oral administration, the barium mixture will be measured with a thermometer (TP3001 Digital Thermometer from Red Lantern®) to document the exact temperature.
45793027|NCT04755140|Behavioral|Questionnaires|The patient and an informant will be asked to complete a questionnaire about his or hers current and past physical thinking abilities.
45793028|NCT04755140|Behavioral|Interviews|Cognition and memory interviews will take place with the patient.
45793029|NCT04755140|Diagnostic Test|Blood Test|Three blood draws will occur to assess patients immune response, metal levels, and cardiac health.
45793030|NCT04755140|Diagnostic Test|Echocardiogram|Each echocardiogram takes about 3 hours and 30 minutes. This test uses sound waves to look at your heart. The person doing the test will press on your chest with a machine to obtain the pictures. The pressure may be uncomfortable. The echocardiogram will involve an image enhancement agent infusion to obtain better images.
45647605|NCT04794205|Drug|Medium Dose Beta-Caryophyllene|30 mg BCP
45647606|NCT04794205|Drug|High Dose Beta-Caryophyllene|150 mg BCP
45647607|NCT04794205|Drug|Placebo|Placebo drug.
45647608|NCT04973033|Drug|Tofacitinib|patients enrolled were prescribed tofacitinib 5mg twice a day orally.
45647609|NCT04436653|Device|Tricuspid Valve Replacement System|To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system.
45647610|NCT03061565|Drug|erythropoietin|Patients were given erythropoietin during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
45647611|NCT03061565|Drug|Placebos|Patients were given placebo during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
45793031|NCT04197986|Drug|Infigratinib|Participants randomly assigned to infigratinib will receive hard gelatin capsules for oral administration of infigratinib 125 mg once a day (administered as one 100-mg capsule and one 25-mg capsule) using a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.
45647612|NCT02660281|Radiation|Total Body Irradiation 1200 cGy|1200 cGy TBI in 8 fractions
45647613|NCT02660281|Drug|Fludarabine|Fludarabine
45647614|NCT02660281|Drug|Pre-Stem Cell Infusion Cyclophosphamide|Cyclophosphamide given prior to the stem cell infusion
45793032|NCT04197986|Drug|Placebo|Participants randomly assigned to placebo will receive placebo matching in appearance the investigational product (infigratinib), which will be provided as hard gelatin capsules for oral use and will be administered once daily on a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.
45793033|NCT01997411|Drug|Nasal Glucagon|
45793034|NCT01997411|Drug|Intramuscular Glucagon|
45793035|NCT01997723|Device|Portable monitoring|A device applied over 1 arm (on the wrist and finger), worn overnight by patients to detect OSA.
45793036|NCT01997723|Other|Polysomnography|One attended diagnostic sleep study.
45793037|NCT01997723|Device|Home portable monitoring|Portable monitoring with WP200 device - applied by participants once at home.
45793038|NCT01997723|Device|Laboratory portable monitoring|Portable monitoring with WP200 device - applied by technologist once in the laboratory simultaneously with polysomnography.
45793039|NCT03534635|Drug|Pembrolizumab|Pembrolizumab monotherapy at 200 mg every 3 weeks for 2 years maximum.
45793040|NCT03534635|Drug|Pembrolizumab - additional treatment|Patients may be retreated for one year of additional pembrolizubmab therapy (200 mg every 3 weeks).
45793041|NCT03464201|Drug|Enzalutamide 40 MG|Enzalutamide 160 mg p.o. every day
45793042|NCT02243306|Drug|GSK1278863|Round, biconvex, white film coated tablet containing 5 mg GSK1278863.
45920755|NCT00400738|Drug|Saquinavir, lopinavir, ritonavir|arm 1 = LPV/RTV 400/100 mg BID + SQV 1000 mg BID arm 2 = LPV/RTV 400/100 mg BID + SQV 600 mg BID arm 3 = LPV/RTV 266/66 mg BID + SQV 1000 mg BID arm 4 = LPV/RTV 266/66 mg BID + SQV 600 mg BID
45449725|NCT02162212|Other|Optimized Shoulder Movement Program|"A trained physical therapist will see the participant for a max of 6 visits over the 3 month intervention; for baseline instruction, and at 2, 4, 6, and 8 weeks to progress and check subject adherence before a final check-out and testing visit at 3 months. Participants will perform 3 assigned stretching motions a min of 2 sets of 10 reps each and will be instructed in active shoulder movements with a dose based on the subject's measured activity count at baseline and with enough duration to increase it by 10%. Exercise: 10-15 minutes 2x/day for 3 month duration. Participants will log their activity."
45647615|NCT02660281|Drug|Pre-Stem Cell Infusion Mesna|Mesna given prior to the stem cell infusion
45647616|NCT02660281|Drug|Busulfan|Busulfan
45647617|NCT02660281|Drug|Melphalan|Melphalan
45793043|NCT01999517|Drug|Intravenous Nitroglycerin|
45793044|NCT01999517|Drug|IV Fluids|
45793045|NCT04670198|Behavioral|Youth Empowerment Skills|The Youth Empowerment Skills (YES) programme is a novel psychoeducational intervention with simulation-based experiential learning tailored to the needs of young people. It is based on a social-cognitive learning model, and comprises attendance at 3 all-day YES sessions in non-healthcare settings (groups of 10); and then post-programme networking through social media and follow-up events facilitated by the youth worker. Sessions are led by a peer-educator and a health professional
45647618|NCT02660281|Procedure|Stem Cell Infusion|Stem cell infusion
45647619|NCT02660281|Drug|Post-Stem Cell Infusion Cyclophosphamide|Cyclophosphamide given after the stem cell infusion
45647620|NCT02660281|Drug|Post-Stem Cell Infusion Mesna|Mesna given after the Stem Cell Infusion
45793046|NCT04670198|Behavioral|Waiting-list control|Usual care for 6 months, followed by the YES programme.
45793047|NCT04170062|Device|Nasal Delivery of High-Flow Air and Oxygen Therapy|They will receive high-flow air and oxygen via a dual lumen nasal cannula at rest. Participants will be administered the high-flow air and then titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.
45793048|NCT04170062|Device|Nasal Delivery of Oxygen Therapy|They will receive oxygen via a dual lumen nasal cannula at rest. Participants will be titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.
45793049|NCT02657486|Drug|BGJ398|
45793050|NCT02566772|Drug|TAS3681|TAS3681 will be provided as 100 mg tablets to be administered orally in 28-day cycles. The number of cycles is approximately 6, or until discontinuation criteria is met.
45793051|NCT02385110|Drug|Alemtuzumab|"Group 1 and 2 Induction Phase: Alemtuzumab total dose of 1.0 mg/kg subcutaneously or by vein over 4 days (days 1-4) during the 8 week induction phase. Day 1 0.1 mg/kg, Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.~Group 1 Maintenance Phase: 0.2 mg/kg once every 4 weeks for 6 weeks."
45793052|NCT02385110|Drug|Etoposide|"Induction Phase: 150 mg/m2 given by vein once a week for 8 weeks.~Maintenance Phase: Participants who have evidence of refractory disease or budding relapse during the maintenance phase may revert back to receiving Etoposide."
45793053|NCT02385110|Drug|Dexamethasone|"Induction Phase: 10 mg/m2 for 1 week followed by Dexamethasone 5 mg/m2 for 2 weeks followed by Dexamethasone 2.5 mg/m2 for 2 weeks followed by Dexamethasone 1.25 mg/m2 for 2 weeks.~Maintenance Phase: 1.25 mg/m2 by mouth three times a week for 16 weeks."
45647621|NCT02660281|Drug|Thiotepa|Thiotepa
45920756|NCT00099580|Drug|AC2592|continuous subcutaneous infusion (via pump), dose based on subject body weight
45920757|NCT00099580|Drug|placebo|continuous subcutaneous infusion (via pump), dose based on subject body weight
45920758|NCT00006356|Drug|carboplatin|
45920759|NCT00006356|Drug|cisplatin|
45920760|NCT00006356|Procedure|conventional surgery|
45647622|NCT03061487|Procedure|Open Surgical Treatment of Aneurysm (Aneurysmectomy)|Aneurysmectomy is a surgical procedure in which a localized, dilated, weakened section of an artery (aneurysm) is removed (resected). The artery is either replaced with a synthetic graft, as seen in an aneurysm in the chest (thoracic aneurysm), abdomen (abdominal aneurysm) or leg (femoral or popliteal aneurysm).
45647623|NCT02438995|Drug|Intraarterial Cetxuimab (Erbitux)|Super-Selective Intraarterial Infusion of Cetuximab (Erbitux)
45647624|NCT03061409|Dietary Supplement|Pharmavite Nature Made Multi for Him 50+|To examine whether one tablet a day of Pharmavite Nature Made Multi for Him 50+ will increase micro-nutrient status in older people taking multiple medications as compared to placebo
45647625|NCT03061409|Dietary Supplement|Placebo|served as placebo
45793054|NCT02385110|Drug|Methotrexate|Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.
45793055|NCT02385110|Behavioral|Phone Call|If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes.
45647626|NCT04978883|Other|No intervention|No intervention
45647627|NCT05108311|Other|Manual therapy and therapeutic exercise|"Gliding over the deltoid superficial fascia.~Anterior-Posterior mobilization of the clavicle.~myofascial release of the shoulder joint complex techniques.~Myofascial release external rotation with glenohumeral decoaptation will be carry out in prone position facility the triangular space, quadrangular space and triceps hiatus.~anterior and posterior, superior and inferior glenohumeral inferior glide mobilization in adduction will perform in a prone position to facilitate glenohumeral re centration.~scapular musculature myofascial release including mobilization with a scapulothoracic joint decoaptation, and angular of the scapula.~Supine mobilization of the posterior capsule in 90º shoulder flexion and the adduction.~Finally the patient will be instructed to adapt the daily active biological stimulus at home to maximize the benefits of the manual therapy"
45793056|NCT02385110|Drug|Tocilizumab|Induction Phase: Tocilizumab at 4 to 8 mg/kg by vein. Day 1 0.1 mg/kg,Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.
45449726|NCT02162212|Other|ADA Guideline Instructed|The ADA guideline instructions are to include: blood sugar control (goal is A1c < 7.0%), physical activity (150 minutes/week of moderate intensity aerobic activity), foot care (examine feet daily, monofilament testing), and blood pressure control (goal is <130/80). Participants will receive a logbook to record daily outcomes. The goal of this intervention is to control for personal interactions with investigators and provide useful information for disease management but not provide intervention that likely would improve shoulder joint motion. The control group will be given instruction in the exercise program at the end of the 1 year study period.
45449727|NCT02167360|Drug|CTL019|A dose of CTL019 transduced cells will consist of a single infusion of 2 to 10 x 108 CTL019 transduced cells.
45449728|NCT03540784|Other|WB-EMS|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
45647628|NCT04155125|Drug|efepoetin alfa|The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period.
45793057|NCT01999985|Drug|Dasatinib - 1A|1A: Begins Day 8. Level 1 - 100 mg, Level 2 - 100 mg, Level 3 - 140 mg.
45793058|NCT01999985|Drug|Afatinib - 1A|1A: Begins Day 1. Level 1 - 30 mg, Level 2 - 40 mg, Level 3 - 40 mg.
45793059|NCT01999985|Drug|Dasatinib - 1B|In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
45793060|NCT01999985|Drug|Afatinib - 1B|In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
45793061|NCT01968317|Drug|Megestrol acetate and metformin|Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 160 mg by mouth daily for 3 months.
45793062|NCT01968317|Drug|Megestrol acetate|Patients will receive megestrol acetate 160 mg by mouth daily for 3 months.
45793063|NCT03428711|Drug|Mesoglycan Oral Tablet|"Experimental drug: mesoglycan, already used in the treatment of chronic venous ulcers, is a complex mucopolysaccharide, composed of a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.~Used in oral formulation, hard capsules, 50 mg, twice-a-day, for 12 months. Reference therapy: placebo, organoleptically indistinguishable from the experimental drug, twice-a-day, for 12 months."
45793064|NCT03428711|Drug|Placebo Oral Tablet|Indistinguible placebo tablet
45793065|NCT02002871|Device|PSO-CT02 device|The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light. A contralateral eczema area is left untreated and serves as control.
45793066|NCT03450915|Biological|M-001|A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.
45793067|NCT03450915|Biological|Saline|0.9% sodium chloride (NaCl)
46071607|NCT02838810|Drug|Nucleoside analogues|Nucleoside analogues
46071608|NCT02838888|Device|Automatic polyp detection software|A computer program for the detection of colonic polyps will be used during colonoscopy
46071609|NCT00830635|Other|educational intervention|
45449729|NCT03540784|Other|Nutritional support|dietary monitoring by dietary records; nutritional counselling by dietician, dietary advices: 1.5 g/kg bodyweight/day
45449730|NCT02164084|Drug|SB204|SB204 Gel with hydrogel
45449731|NCT02164084|Drug|Vehicle Gel|Vehicle Gel with hydrogel
45449732|NCT02164162|Device|Lokomat (Hocoma, Zurich, Switzerland)|Patients allocated to the Experimental group performed a Robotic Assistested Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.
45793068|NCT02004977|Behavioral|Improve access to the school breakfast program|Access to the school breakfast program is defined as implementation of a grab-n-go cart outside of the school cafeteria, policy change allowing students to eat in the hallway and marketing of the program. in rural high schools.
45793069|NCT01971593|Drug|Eplerenone|
45793070|NCT03454581|Procedure|Photobiomodulation|PBM was applied, three times a week for four consecutive weeks at 5 points in the TMJ region: superior, anterior, lateral, posterior and postero inferior to the condyle. In addition, all patients received laser application in the temporal muscle (anterior, middle and posterior), in the masseter (upper, middle and lower portion) and insertion of the medial pterygoid.
45793071|NCT03454581|Procedure|Manual Therapy (MT)|Patients were submitted to MT at temporal, masseter and pterygoid medial from both sides, during 3 minutes each muscle group (Extraoral) and at masseter and lateral pterygoid (Intraoral) for 3 minutes, each total 21 minutes. MT on the TMJ region was performed for 1 minute and 3 repetitions during three times a week .
46071610|NCT00830635|Other|informational intervention|
45920761|NCT00099619|Drug|exenatide/insulin glargine|Subcutaneously injected exenaide 10 mcg twice daily for 16 weeks; then insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels
45920762|NCT00099619|Drug|insulin glargine/exenatide|Subcutaneously injected insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels; then exenaide 10 mcg twice daily for 16 weeks
45920763|NCT00099658|Biological|Pneumococcal polysaccharide-protein conjugate vaccine|Injection administered three times before the age of 24 weeks
45920764|NCT00006359|Drug|LHRH agonist|Lupron: 22.5mg IM injection q 12 wks x 2 OR Zoladex: 10.8 mg subQ injection q 12 wks x 2
45920765|NCT00006359|Drug|antiandrogen|flutamide 250 mg PO tid for 4 wks OR casodex 50 mg PO daily for 4 wks
45920766|NCT00006359|Radiation|radiation therapy|4500 cGy total dose given days 1-5 for 5 weeks following initiation of androgen suppression (25 fractions)
45920767|NCT00006359|Radiation|Brachytherapy boost|Iodine 125 0.3 to 0.5 U per seed OR palladium 103 1.04 to 1.4 U per seed as implant; prescribed dose of I-125 100 Gy (TG-43) and Pd-103 90 Gy
45920768|NCT00099697|Drug|DHEA|
46071611|NCT00830635|Other|internet-based intervention|
46071612|NCT00830635|Other|questionnaire administration|
45793072|NCT01972061|Device|Foot stimulation|Foot stimulation electrically activates the somatic afferent nerves in the foot using FDA-approved, commercially available transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes attached to the foot.
45647629|NCT04155125|Drug|Mircera|The starting dosage of Mircera arm will be 0.6 μg/kg BW per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL.
45793073|NCT03243981|Device|Sciton SkinTyte (800-1800 nm) with Broadband Light Technology|This device has been used in the clinical setting to reduce cheek and submental laxity. SkinTyte delivers sequentially pulsed light (800-1200 nm, with a filter enabling focus on 590 nm) and broadband light (which can be turned on or off).
45793074|NCT02986451|Drug|clarithromycin|Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.
45647630|NCT04662307|Device|Intelligent cardiopulmonary rehabilitation system (ICRS)|Participants are required to wear a wristband heart rate monitor and exercise on a cycling ergometer-based ICRS for 30 minutes (5 minute of warm-up, 20 minutes of training followed by 5 minutes of cooldown). The target intensity for the 20-min training period is set at 60%~80% HRR determined in the pretest of cardiopulmonary exercise test.
45647631|NCT05107921|Drug|Bromfenac Sodium|The study participants will receive bromfenac sodium hydrate eyedrops twice daily for 14 days.
45647632|NCT04526041|Other|Nasofibroscopy|Laryngeal exploration performed using a flexible fibrescope while singing.
45793075|NCT02986451|Drug|Lenalidomide|Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle
45793076|NCT02986451|Drug|Dexamethasone|Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle.
45647633|NCT04526041|Other|Electroglottography|Electrography of glottal movement using the EG2-PCX2 system (Glottal enterprises) while singing.
45647634|NCT04526041|Other|Air flow measurement + acoustic signal recording|Air flow measurement and acoustic signal recording while singing using the EVA2 system (SQLab-LPL, Aix en Provence, France)
45647635|NCT04526041|Other|Questionnaire|Questionnaire on subject singing habits, the way it use and perceive the use of his body when singing.
45647636|NCT01669811|Drug|Esomeprazole (D961H) twice daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and in the evening
45793077|NCT03458871|Device|4-week TTNS home-based protocol|"4-week TTNS home-based protocol. Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is not contraction seen, maximal tolerable intensity will be used.~In addition, if the patient perceives pain, the intensity will be lowered until comfortable.~Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used."
45920769|NCT00099736|Drug|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
45920770|NCT00099736|Drug|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
45920771|NCT00099736|Drug|MMF 2 g + full-dose Neoral (FDN) + corticosteroids|mycophenolate mofetil (MMF) + full-dose Neoral (FDN) + corticosteroids
45920772|NCT04143711|Drug|DF1001|Immunotherapy agent targeting NK cells.
45920773|NCT04143711|Drug|Nivolumab|Anti-PD-1 immunotherapy agent
45920774|NCT04143711|Drug|Nab paclitaxel|A chemotherapy treatment combining paclitaxel with albumin
45920775|NCT00099775|Drug|Caspofungin|
46071613|NCT00830635|Other|study of socioeconomic and demographic variables|
46071614|NCT00830635|Other|survey administration|
46071615|NCT00830635|Procedure|psychosocial assessment and care|
46071616|NCT00830635|Procedure|quality-of-life assessment|
46071617|NCT00633282|Behavioral|Life style intervention|"calorie limited diet: to subtract 500 kcal from daily mean calorie intake when entering the treatment~activity: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate; or higher-intensity aerobic exercise for more than 90min per week with heart rate around 70% of the maximal heart rate"
45920776|NCT00006362|Drug|bortezomib|
45920777|NCT00099814|Procedure|Two different loop designs which deliver distinctive forces|
45920778|NCT00099892|Drug|vildagliptin|
45920779|NCT00099931|Drug|vildagliptin|
45920780|NCT00099970|Drug|M200 (volociximab) in Combination with Dacarbazine (DTIC)|
45920781|NCT00006365|Radiation|brachytherapy|
45920782|NCT00006365|Radiation|iodine I 125|
45920783|NCT00006365|Radiation|radiation therapy|
45920784|NCT00100009|Drug|TAC-PF|
45920785|NCT00100009|Drug|Triamcinolone Acetonide|
45793078|NCT01973777|Device|IUB|intrauterine contraceptive device
45793079|NCT01974089|Other|Dysphagia|Oropharyngeal dysphagia assessed by Volume-Viscosity Svallowing Test
45793080|NCT03245463|Other|Educational handout|The educational handout will include information on self-management strategies.
45793081|NCT03245463|Other|Verbal script|The verbal script will include details on self-management strategies that will be reviewed with the patient.
45793082|NCT03245463|Drug|Hyaluronic Acid|All study patients are undergoing injections with hyaluronic acid prior to the administration of the teaching method. The injections are standard of care and are required as part of the inclusion criteria.
45793083|NCT01974245|Drug|Cholecalciferol|100,000 IU/week for 12 weeks
45793084|NCT01974245|Drug|Placebo|100 drops/ week for 12 weeks
45793085|NCT03307005|Drug|Zolpidem Tartrate|Zolpidem tartrate 5 mg capsule one per night taken for 7 nights
45793086|NCT03307005|Drug|Placebo oral capsule|Placebo capsule one per night taken for 7 nights
45793087|NCT02005601|Drug|Placebo|Patients will receive placebo drug with no active ingredients per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
45793088|NCT02005601|Drug|Duloxetine 60mg|Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
45793089|NCT03214679|Other|Accessible Care|Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program.
45793090|NCT03214679|Other|Usual Care|Usual care entails referral to an on site HCV care coordinator (not provided by study)
45920786|NCT00100087|Device|Ocular Brachytherapy|
45647637|NCT01669811|Drug|Esomeprazole (D961H) once daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and one corresponding placebo capsule in the evening
45793091|NCT03308097|Behavioral|PrEP Mobile Messaging Intervention|See group description
45793092|NCT03308097|Behavioral|Enhanced Standard of Care|See group description
45920787|NCT00100126|Drug|Amoxicillin Pulsatile Release Multiparticluate Sprinkle|
46071618|NCT00633282|Drug|pioglitazone|pioglitazone tablet,15mg qd ,30 minutes before breakfast,for 16 weeks
46071619|NCT00633282|Drug|berberine|berberine tablet 0.5g tid,30 minutes before each meal,for 16 weeks
45647638|NCT05184361|Behavioral|Intermittent energy restriction (IER)|"Both groups will be accompanied by a registered dietitian in order to provide an individual and personalized diet plan that will suppress the respective daily requirements for each phase. Macronutrient distribution will be the following: 35% protein, 35% carbohydrate and 30% fat.~Daily energy requirements (DER) will be calculated by multiplying measured RMR (through indirect calorimetry) by physical activity level (PAL), assessed by accelerometry.~In order to achieve a neutral EB, 100% of their daily energy requirements (DER) will be prescribed for each participant. For both groups, an energy restriction of 33% of one's DER will be created. The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks.~The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks."
45793093|NCT02007863|Procedure|Umbilical Cord Blood Transfusion|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. Umbilical Cord Blood Transfusion will occur on Day 0
45793094|NCT02007863|Drug|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -13 through -9 for a total of 5 doses. Fludarabine will not be dose adjusted for body weight.
45793095|NCT02007863|Drug|Busulfan|Busulfan IV (Busulfex) will be administered IV every 6 hours on days -8 through -5 for a total of 16 doses. Seizure prophylaxis prior to first dose of busulfan till Day -3 will be administered.
45793096|NCT02007863|Drug|Melphalan|Melphalan 45 mg/m2/day will be administered over 60 minutes intravenous infusion on Days -4 through -2 for a total of 3 doses.
45793097|NCT03460899|Other|Euglycaemic Clamp|All 14 subjects will undergo an euglycaemic clamp at Visit 2 with a plasma Glucose target of 5.5 mmol/L +/- 10% (4 timepoints for platelet activity parameter blood sampling)
45793098|NCT03460899|Other|Hyperinsulinaemic/Hypoglycaemic Clamp|All 14 subjects will undergo a hypoglycaemic/hyperinsulinaemic clamp at Visit 3 with 4 timepoints for platelet activity Parameter blood sampling 30 minutes after reaching certain plasma glucose plateaus (5.5 mmol/L; 3.5 mmol/L; 2.5 mmol/L; after recovery again at 5.5 mmol/L)
45920788|NCT04097652|Biological|UMC119-06|Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
45920789|NCT00100243|Drug|Plenaxis|
45793099|NCT02009501|Device|VAC VeraFlo with Dakins Instillation|VAC VeraFlo with Dakins instillation will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
45793100|NCT02009501|Device|VAC Ulta Therapy|VAC ULTA will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
45793101|NCT03308799|Drug|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
45793102|NCT03308799|Drug|Cal/BDP combination|calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%
45793103|NCT03308799|Drug|Cream vehicle|Vehicle Cream
45793104|NCT02305277|Drug|BIA 9-1067 (clinical micronized, CM)|
45793105|NCT02305277|Drug|BIA 9-1067 (to-be-marketed, TBM)|
45793106|NCT03462927|Drug|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)
45793107|NCT03462927|Drug|CAL/BDP combination|Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)
45920790|NCT00100282|Drug|PPI-1019 (APAN)|
45920791|NCT04071756|Drug|Topical Tazarotene|This medicine works by making the skin less inflamed and reducing the thickness and pain from lesions of the skin
45920792|NCT04071756|Other|Placebo|A substance that has no therapeutic effect, used as a control in testing new drugs
45920793|NCT00100399|Biological|Fluarix|
45920794|NCT00006368|Radiation|yttrium Y 90-edotreotide|
45920795|NCT00100477|Drug|Topotecan|
45920796|NCT00100477|Drug|Mitozantrone|
45920797|NCT00100477|Drug|Etoposide|
45647639|NCT05184361|Behavioral|Continuous energy restriction (CER)|A dietary plan comprising 67% of DER will be prescribed to the CER group. Participants will be asked to follow this plan in a total of 16-weeks, without interruptions.
45647640|NCT05173285|Diagnostic Test|Baseline Assessment|At baseline (i.e. Pre-intervention) participants will complete several questionnaires online via Qualtrics.
45647641|NCT05173285|Behavioral|Brief Online ACT Intervention|Participants will complete the 4-week online intervention via Qualtrics
45793108|NCT03309657|Drug|Ceftolozane/tazobactam|This is an observational pharmacokinetic study whereby patients received a single dose of ceftolozane/tazobactam and plasma and cerebrospinal fluid samples were subsequently collected and analyzed to described the pharmacokinetics.
45793109|NCT04332705|Diagnostic Test|Detection of Cryptosporidium infection|A biopsy or a surgical sample will be collected from every participant
45793110|NCT03463161|Drug|Pembrolizumab|Pembrolizumab (200mg/kg) given by intravenous infusion every 3 weeks.
45793111|NCT03463161|Drug|Epacadostat|Epacadostat (100mg) taken by mouth twice a day.
45449733|NCT02164162|Other|Conventional physical treatment|Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and dual task activities and balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation (PNF) concept (lasting 30 minutes), with rhythmic initiation, slow reversal, and agonistic reversal exercises applied to the pelvic region, each 10 minutes long. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
45793112|NCT03463941|Behavioral|Peer Support Dyad Intervention|"Phase I: At baseline and at post-intervention, participant height, weight, BMI, fruit and vegetable intake and exercise habits will be measured. Participants will complete surveys and meet each week to learn about nutrition and exercise.~Phase II: Dyads will attend a communication training session to discuss 1) benefits of working with a partner; 2) supportive communication tips; and 3) expected activities for the next 8 weeks, including filling out daily logs. After the training session, the dyads will work together to achieve their health goals. The dyads will return to the church for two check in sessions. At these sessions, participants will turn in their logs, and be weighed. At the end of the intervention, BMI will be reassessed, and surveys and interviews will be completed."
45793113|NCT03466047|Dietary Supplement|Protein stomach|encapsulated protein stomach
45793114|NCT03466047|Dietary Supplement|Protein distal small intestine|encapsulated protein distal small intestine
45793115|NCT03466047|Dietary Supplement|CHO stomach|encapsulated CHO stomach
45793116|NCT03466047|Dietary Supplement|CHO distal small intestine|encapsulated CHO distal small intestine
45793117|NCT03466047|Dietary Supplement|Fat stomach|encapsulated Fat stomach
45449734|NCT02167438|Device|Hem-Avert Perianal Stabilizer|
45647642|NCT05173285|Diagnostic Test|Post-Intervention Assessment (i.e. between 4-6 weeks after baseline assessment)|Participants will complete several questionnaires online via Qualtrics.
45647643|NCT05173285|Diagnostic Test|Follow-up Assessment (i.e. between 8-12 weeks after baseline assessment)|Participants will complete several questionnaires online via Qualtrics.
45647644|NCT04972877|Other|Treatment group protocol|"For treatment group, two groups of acupoints will be used alternatively. The first group consists of some acupoints. The patients will be asked to stay in supine position. Disposable sterilized needles (Size: 0.25*40/50 mm) will be inserted into a depth of 15~35 mm and stimulated manually to evoke needle sensation. And then some acupoints will be thereafter connected to electrical stimulators and stimulated with low-frequency and the maximum tolerated intensity of the patients. The other needles without electrical stimulators will be manually stimulated to evoke Deqi every 10 minutes.~The second group consists of other acupoints. Patients will be asked to stay in prone position. The stimulation will be in the same way as the first group."
45793118|NCT03466047|Dietary Supplement|Fat distal small intestine|encapsulated Fat distal small intestine
45793119|NCT03467685|Device|Vibratory Anesthetic Device (VAD)|This is a handheld ~10cm long tool, battery operated, which provides vibration at a rate of ~150 Hz
45793120|NCT03468075|Drug|Ascorbate|Following 15g test dose, 75g administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle
45793121|NCT03468075|Drug|Gemcitabine|Administered on Days 1, 8 and 15, after the infusion of ascorbate
45793122|NCT03250689|Drug|Danirixin|Danirixin will be available as 35 mg oval shaped, white film coated HBr embossed tablets.
45793123|NCT03250689|Drug|Placebo|Placebo will be available as oval shaped, white film coated tablets.
45793124|NCT03250689|Drug|Rescue medication|Subjects may continue to use rescue medication(s) anytime during the study. The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
45793125|NCT03250689|Drug|Inhaled COPD maintenance medication|Subjects may continue to use inhaled COPD maintenance medication(s) during the study, at the discretion of the GSK Medical Monitor and/or Investigator. The following maintenance medications may be used: long acting bronchodilator medications (e.g. long-acting muscarinic antagonist [LAMA], long-acting beta-agonist [LABA]) and long-acting bronchodilator combination therapies (e.g. LAMA/LABA) and long-acting bronchodilator/inhaled corticosteroid steroid combination (ICS) therapies (e.g. LABA/ICS, LAMA/LABA/ICS)
45793126|NCT03468933|Drug|tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase)|Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 dose
45793127|NCT03468933|Procedure|Medical Thoracoscopy|Medical thoracoscopy will be performed as per standard protocols.
45793128|NCT03470493|Diagnostic Test|ApneaLink Air|ApneaLink Air to be used on each participant undergoing PSG
45920798|NCT04063878|Device|Conometric Abutment and Conometric Final Cap|Conometric concept developed by Dentsply Sirona Implants for implant systems Ankylos, Astra Tech Implant System and Xive.
45449735|NCT02167516|Drug|glucosamine sulfate|glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks
45920799|NCT00100555|Drug|zoledronic acid|
45920800|NCT00006371|Drug|aminoglutethimide|
45920801|NCT00006371|Drug|ketoconazole|
45920802|NCT00006371|Drug|therapeutic hydrocortisone|
45793129|NCT03471975|Procedure|direct laryngoscope|the trainee use McGrath video laryngoscope as direct laryngoscope the trainee is not allowed to watch the screen.
45793130|NCT03471975|Procedure|video laryngoscope|the trainee use McGrath video laryngoscope both trainee and trainer can watch the screen.
45793131|NCT02296580|Device|Nativis Voyager RFE Therapy|Nativis Voyager Radiofrequency Energy Therapy
45793132|NCT03472287|Drug|Diacerein 1% Ointment|Diacerein 1% Ointment administered topically
45793133|NCT02219984|Drug|Anticoagulants|
45920803|NCT04728685|Procedure|Mechanical Traction|Mechanical Traction will be applied to the lumbar region using a traction unit.
46071620|NCT00830089|Drug|Levobupivicaine 0.25%|40mls of 0.25% L-bupivicaine will be injected into the transversus abdominis plane (TAP) under ultrasound guidance - 20mls on either side of the abdomen.
46071621|NCT02838966|Dietary Supplement|Nestle IMPACT Advanced Recovery|
46071622|NCT02838966|Dietary Supplement|Nestle Boost High Protein Drink|
45449736|NCT02167516|Drug|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
45647645|NCT04972877|Other|Control group protocol|"For control group, four pseudo-acupoints are used, with two points on each shoulder and the two on each upper arm, which are not located on any meridians. The patients will be asked to stay in supine position and keep the whole body relaxed and comfortable. Disposable sterilized needles (Size: 0.18*25 mm) will be inserted superficially to a depth of < 5 mm without any manual stimulus and the needle sensation (Deqi in TCM) should not be evoked. Electrodes are connected to the needles, but the stimulators should be turned on at an intensity of zero. Each intervention lasts for 30 minutes."
45647646|NCT05164081|Combination Product|antibiotic loaded bone cement (gentamicin+clindamycin) COPAL G+C (Heraeus).|Hospitals are cluster-randomized to either arm for 2 years and then cross-over to the other arm for another 2 years.
45647647|NCT05164081|Combination Product|antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).|antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
45647648|NCT03061877|Other|Anxiety or depression|The presence of anxiety or depression measured by the Hospital Anxiety and Depression Scale (HAD)
45647649|NCT04601935|Biological|LCAR-BCX cells product|In this study, LCAR-BCX CAR+ cells will be evaluated at 5 dose levels including 0.25 × 10^6 cells/kg, 0.5 × 10^6 cells/kg, 1.0 × 10^6 cells/kg, 2.0 × 10^6 cells/kg, and 4.0 × 10^6 cells/kg, with 0.25 × 10^6 cells/kg as the starting dose, to determine RP2D for LCAR-BCX cell therapy
45647650|NCT04220723|Other|Frailty Assessment|"Liver Frailty Index measurements:~Grip strength: the average of three trials, measured in the subject's dominant hand using a hand dynamometer~Timed chair stands: measured as the number of seconds it takes to do five chair stands with the subject's arms folded across the chest~Balance testing: measured as the number of seconds that the subject can balance in three positions (feet placed side-to-side, semitandem, and tandem) for a maximum of 10 seconds each."
45793134|NCT04735029|Device|Thermal gun|"Thermal gun used a heat-generating ceramic head to apply a dual effect called heat-and-light-pressure on the acupuncture points."
45793135|NCT04735029|Other|Heat pack|A hydrocollator heat pack used to simulate traditional thermal therapy
45793136|NCT04604444|Behavioral|Multimodal Intensive Rehabilitation of Aphasia and Apraxia of Speech|Intensive Comprehensive Aphasia (ICAP) and Apraxia of Speech Program
45793137|NCT02067416|Drug|Anthracycline based chemotherapy|standard of care neoadjuvant treatment with anthracycline based chemotherapy
45793138|NCT02067416|Drug|taxane-based chemotherapy|neoadjuvant taxane based chemotherapy given as standard of care
45793139|NCT03258645|Drug|Dabigatran|Oral anticoagulant (NOAC) thrombin inhibitor
45793140|NCT01817192|Drug|Adjuvant Chemotherapy|Patients who have undergone complete resection of NSCLC that has been documented histologically to be non-squamous and that is pathological Stage I or IIA, will undergo testing with the 14-Gene Prognostic Assay. Patients determined to be intermediate or high risk and who meet all eligibility criteria will be randomized either to observation or to four cycles of adjuvant therapy with a standard NSCLC platinum-based doublet.
45793141|NCT01817192|Other|Radiographic surveillance|Serial radiographic surveillance is a current standard of care for Stage I or Stage IIA lung cancer. All intermediate or high risk patients randomized to observation or chemotherapy will have routine CT Scans at 6 month intervals until 5 years after enrollment and at yearly intervals thereafter until the end of the study period.
45793142|NCT01817192|Other|14-Gene Prognostic Assay|This CLIA-approved assay is a standard tool that is now available to all clinicians to improve the prognostic evaluation of patients after resection of Stage I or Stage IIA non-squamous NSCLC. It will be performed on tumor specimens for patients who are potentially eligible for this study. Patients identified through the assay as intermediate or high-risk will be randomized to either adjuvant chemotherapy or observation.
45793143|NCT02248766|Device|somofilcon A|somofilcon A lens
45920804|NCT04728607|Device|Compression device.|A compression device is a device that uses circumferential compression to reduce swelling around a stuck ring. The device is used by placing it near, but not overtop, the offending ring, and then is inflated compressing the finger. The device is applied, and the hand elevated, for approximately five minutes. The device is then removed, and with a small amount of lubricant, the ring is removed.
46071623|NCT00830245|Drug|Erlotinib|Erlotinib 150mg/day
46071624|NCT02837874|Procedure|Isoperistaltic|Same direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the distal part of remnant stomach
46071625|NCT02837874|Procedure|Antiperistaltic|Reverse direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the proximal part of remnant stomach
46071626|NCT02549911|Other|HIPEC,Chemotherapy AND surgery|"HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~chemotherapy(PS for 3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )~after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles"
46071627|NCT02838030|Drug|L-arginine|3 gr per day
46071628|NCT02838030|Drug|Placebo (for L-arginine)|3 gr per day
45647651|NCT04220723|Other|Functional Capacity Assessment|Shuttle Walk Test: The patient is required to walk around two cones set 9 metres apart (so the final track is 10 metres) in time to a set of auditory beeps played on a CD. Initially, the walking speed is very slow, but each minute the required walking speed progressively increases. The patient walks for as long as they can until they are either too breathless or can no longer keep up with the beeps, at which time the test ends. The number of shuttles is recorded. Each shuttle represents a distance of ten metres (i.e each time the patient reaches a cone is 1 shuttle).
45793144|NCT03477279|Behavioral|Enhanced Couple HIV Testing and Counseling|"Participants are provided study-specific partner referral cards and encouraged to bring male partners to antenatal care for a male engagement intervention. Those who do not present on their own are then traced.~Couples will receive three enhanced couple counseling sessions that include: pre-test counseling, return of joint results, and post-test counseling. HIV-infected men will be able to initiate cART at the antenatal clinic and the couple will be offered condoms from the HTC counselor. Between sessions, couple members can pick up condoms and cART for one another."
45647652|NCT04592887|Radiation|FLASH Radiotherapy|FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.
45647653|NCT04978181|Drug|Alteplase Injection|thrombolytic therapy for acute ischemic stroke in time window
45793145|NCT02248922|Drug|TIS or TIP|300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)
45793146|NCT03319173|Behavioral|Dietary intervention|"Subjects in the experimental group will receive clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation.~Subjects in the control group will follow the their current dietary protocol (Standard American Diet-SAD)."
45793147|NCT04577456|Device|The Insides System|Novel pump designed to return effluent from the ostomy bag to the distal gut
45793148|NCT03482583|Drug|Nicotine Replacement Therapy|Participants in CBT group will also be offered Nicotine Replacement Therapy if they are interested. NRT is the same regimen followed in AHEC and Quitline. In addition, weekly counseling will be provided to the participants remotely via vidyo, a video based platform.
45793149|NCT03482583|Other|Referral to AHEC/Quitline|Participants will be referred to local AHEC/Quitline for treatment
45793150|NCT02010203|Biological|HS-410|Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96
45793151|NCT02010203|Biological|Placebo|Injection containing sterile solution but no cells
45793152|NCT02010203|Biological|BCG|Vaccine derived from a live bacterium
45793153|NCT03323307|Device|OCT imaging|imaging of retina using OCT device
45793154|NCT03323853|Behavioral|Computerized Assessment and Referral System (CARS) Self-Assessment Screener|Subjects will take the CARS-SA Screener.
45793155|NCT03323853|Behavioral|CARS-SA Summary Results|Subjects will be evaluated by emergency care providers using the CARS-SA Summary Results Report.
45793156|NCT03460587|Device|Telerehabilitation|The Telerehabilitation system will deliver rehabilitation treatment sessions via an in-home internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned home-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system.During some of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
45793157|NCT03260595|Drug|Crisaborole ointment 2%|Crisaborole ointment 2%
45793158|NCT03260595|Drug|Vehicle|Vehicle
45793159|NCT03261999|Drug|Leuprolide Mesylate|Subcutaneous injection of 25mg Leuprolide Mesylate
45793160|NCT03482973|Drug|Bupivacaine Group|20cc bupivacaine hydrochloride will be administered on each side at two different time points (immediately post operatively and on day 1).
46071629|NCT02838030|Drug|acetylsalicylic acid|3 gr per day
45647654|NCT04978025|Drug|Colloidal Silver|"Orally: colloidal silver 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)~and By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days."
45647655|NCT04978025|Drug|Placebo|Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days.
45647656|NCT05269225|Other|Organic diet|Organically produced foods.
45647657|NCT05269225|Other|Conventional diet|Conventionally produced foods.
45793161|NCT03482973|Other|Placebo|20cc placebo (0.9% NaCl) will be administered on each side at two different time points (immediately post operatively and on day 1).
45793162|NCT02302157|Biological|AST-OPC1|One injection of 2 million or 10 million AST-OPC1 cells, or 2 injections of 10 million AST-OPC1 cells for a total of 20 million cells; cohort dependent
45793163|NCT01602380|Drug|faslodex 500mg|2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
45793164|NCT01602380|Drug|arimidex 1mg|oral tablet 1 daily
45793165|NCT01602380|Drug|faslodex dummy|2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
45647658|NCT05127811|Drug|ZN-d5|BION design
45647659|NCT04978103|Drug|Gum Arabic|A dietary supplement (Powdered exudates of Acacia Senegal (Gum Arabic E-414))
45647660|NCT04437173|Device|Virtual Reality Headset Distraction|Patient wears a virtual reality headset during interventional pain procedure
45793166|NCT01602380|Drug|arimidex dummy|oral tablet 1 daily
45793167|NCT02010359|Drug|Lovaza|Lovaza 4 grams per day
45793168|NCT02010359|Drug|Placebo|Placebo pill
46071630|NCT00825643|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation
46071631|NCT04250298|Dietary Supplement|sucrosomal iron|oral intake of iron as sachets or capsules
46071632|NCT04044079|Drug|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
45793169|NCT01976819|Device|TW speaking valve/HME|The TW speaking valve with HME will be used during the day, whereas during sleep patients will use an HME without an automatic speaking valve. Data from TW15 and TW22 will be combined.
45647661|NCT04154579|Behavioral|HeRe We Arts|Art Therapy interventions to promote health, resilience & well-being will discussed; & experiences such as key chain making, collaging on journal covers, creating sculpture garden will be utilized. Music therapy interventions such as lyric discussion, singing, instrument playing, & music-assisted relaxation techniques will be utilized; & discussion of use of music to elicit positive physical & emotional responses will be held. Drums Alive (drumming & movement) will be used to promote physical activity. Art appreciation will include discussion of public art forms. Journaling will include different techniques for journaling, writing poetry, etc. Theater games such as Password, Press Conference, Props Only, & Draw What You Hear will be utilized. Chair yoga will be introduced as a form of exercise. Education will be provided on the various topics.
45793170|NCT01412762|Behavioral|patient interviews|The pre-operative interview will be within 4 weeks of planned surgery and the postoperative interview within 8 weeks of surgery completion. This initial study is designed to develop an instrument to measure patient preoperative expectations in this patient population.
45647662|NCT04154579|Behavioral|HeRe We Ed|Educational components and some experiential components will be utilized to educate the participants on health, resilience, well-being, nutrition, healthy eating, weight management, eating disorders, obesity, exercise, physical activity, sleep hygiene and the importance of sleep, mental health, stress management, the importance of improving life satisfaction, holistic approaches, wellness, integrative medicine, complementary and alternative medicine, chronic illness, chronic pain, methods for dealing with chronic versus acute illnesses, changing behaviors and/or maintaining healthy behaviors in order to promote health and stay out of the hospital, and navigating the healthcare system. Specific experiential components will include Chair Yoga and Stress Management Techniques.
45647663|NCT04508179|Drug|7HP349 Single Ascending Dose|Part A: 7HP349 Capsules, Single Ascending Dose (SAD)
45793171|NCT01412762|Behavioral|CITSAV survey|Individual semi-structured qualitative interviews will be conducted with a total of 10 patients and 5 clinicians during this phase to identify and discuss levels of satisfaction, level of burden, potential obstacles to implementation, as well as suggestions for improving the intervention
45793172|NCT03483675|Biological|Immunosuppressive Therapy|Discontinued IST
45647664|NCT04508179|Drug|7HP349 Multiple Ascending Dose|Part B: 7HP349 Capsules, Multiple Ascending Dose (MAD)
45793173|NCT03483675|Biological|Immunosuppressive Therapy|Continued IST
45793174|NCT03483675|Other|Survey Administration|Ancillary studies
45793175|NCT02057081|Behavioral|Multifamily Group for mTBI for Couples|MFG-mTBI-C uses a structured problem-solving and skills training approach to provide Veterans and partners with tools and information to improve coping and help couples reconnect through positive behavioral exchanges.
45793176|NCT02057081|Behavioral|Group Health Education (GHE)|GHE is a 14-session, highly structured educational intervention providing general information on health problems that are common among the general OEF/OIF cohort including sleep and sleep problems, physical activity and exercise, and alcohol and drug use, as well as guidelines for improving health behavior in these areas.
45793177|NCT00376857|Drug|Surgery with and without the aid of Indocyanine Green (ICG)|
45793178|NCT01977599|Other|Text Message Reminder for Breast Screening Appointment|Non-clinical/administrative.
45793179|NCT03493815|Procedure|Transabdominal Ultrasound Guided IUD Insertion|Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
45793180|NCT03493815|Procedure|Traditional Blind IUD Insertion|Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
45793181|NCT01979159|Behavioral|Combined Aphasia and Apraxia of Speech Treatment (CAAST)|Therapy is delivered in a face-to-face format. The therapist uses picture stimuli, verbal modeling, feedback, reinforcement, forward-chaining to increase verbal production. For speech errors that occur, the therapist uses modeling, feedback, reinforcement, simultaneous production, articulatory instruction, and repeated practice to improve articulation.
45793182|NCT03273543|Device|Restylane® Defyne|hyaluronic acid filler injection
45793183|NCT03959072|Device|Robotic CTO PCI|Randomized to robotic CTO PCI.
45793184|NCT03959072|Procedure|Conventional (Manual) CTO PCI|Randomized to manual CTO PCI.
45793185|NCT03326895|Device|Left-sided colon resection|Left-sided colon resection with powered stapler
46071633|NCT04044079|Drug|Misoprostol|Misoprostol (200µg) will be administered vaginally 12 hours before office hysteroscopy.
46071634|NCT04044079|Drug|Placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
46071635|NCT02837484|Other|NuTech Affinity™ Membrane|NuTech Affinity™ Membrane is an aseptically produced hypothermically stored amniotic membrane patch.
45647665|NCT04508179|Drug|Placebo Single Ascending Dose|Part A: Placebo Capsules, Single Ascending Dose (SAD)
45647666|NCT04508179|Drug|Placebo Multiple Ascending Dose|Part B: Placebo Capsules, Multiple Ascending Dose (MAD)
45647667|NCT04508179|Drug|7HP349 Food Effect|Part C: 7HP349 Capsules, Food Effect
45793186|NCT04555226|Procedure|Lymph node dissection|Open/minimaly invasive pelvic and para-aortic lymph node dissection
46071636|NCT00830323|Drug|oseltamivir + zanamivir|oseltamivir (75mg bd for 5 days, oral) zanamivir (5mg bd for 5 days, inhaled by mouth)
46071637|NCT00830323|Drug|oseltamivir+ amantadine|oseltamivir (75mg bd for 5 days, oral) + amantadine (100mg bd for 5 days, oral)
46071638|NCT00830323|Drug|oseltamivir|oseltamivir (75mg bd for 5 days, oral)
46071639|NCT05333562|Other|Motor control exercise|Motor control exercise was given with total of 8 sessions for 30 min for 4 weeks twice a day. Each exercise was performed 10 repetitions for 10 sec.
45793187|NCT04555226|Radiation|Standard chemoradiation|"A point/HCR-CTV D90 ≥80Gy（+20%）~Extended-field EBRT: image-positive common iliac lymph nodes with short diameter ≥10mm and/or image-positive para-aortic lymph node~Target doses for the image-positive nodes can range from 55 to 60Gy~Concurrent 5 cycles platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period 1 week)~CCRT will be completed in 56 days~After CCRT if the cervix biopsy shows residual tumor and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes with short diameter ≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy (if point A or HR-CTV D90 < 96Gy) will be performed."
45793188|NCT04555226|Radiation|Chemoradiation|"A point/HCR-CTV D90 ≥80Gy（+20%）~Extended-field EBRT: Pathlogical positive para-aortic lymph node~Target doese for pelvic and/or abdomal lymph nodes is usually 45Gy. After operation, the residual lymph node need to be labeled and the target doses for it ranges from 55-60Gy.~Concurrent 5 cycles platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period 1 week)~CCRT will be completed in 56 days~After CCRT if the cervix biopsy shows residual tumor and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes with short diameter ≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy (if point A or HR-CTV D90 < 96Gy) will be performed."
45793189|NCT02980718|Behavioral|intensive olfactory training|
45793190|NCT02980718|Behavioral|ordinary olfactory training|
45793191|NCT03327051|Drug|Omeprazole|Proton pump inhibitor (PPI) that suppresses gastric acid secretion
45793192|NCT03327051|Dietary Supplement|VSL #3|Probiotics
45793193|NCT03327051|Drug|Placebo|Placebo to match omeprazole
45793194|NCT02057939|Drug|enzalutamide|160 mg orally once daily for six months
45793195|NCT02057939|Drug|Androgen Deprivation|Two injections each lasting three months, for a total of six months of androgen deprivation therapy. Doctor will help determine which androgen deprivation drug to use.
45793196|NCT02057939|Radiation|Radiation Therapy|Daily (Monday-Friday) for 6-8 weeks, final dose of approximately 66 Gy
45793197|NCT03496467|Combination Product|Nepafenac PPDS|A punctal plug delivery system (PPDS) is being developed as a device that can deliver a sustained release of a drug to a specific eye. The PPDS is made up of a medical grade silicone punctal plug which holds an insert (core) that contains nepafenac, a nonsteroidal anti-inflammatory drug.
45793198|NCT03496467|Combination Product|Placebo PPDS|A punctal plug delivery system (PPDS) is being developed as a device that can deliver a sustained release of a drug to a specific eye. The PPDS is made up of a medical grade silicone punctal plug which holds an insert (core) that does not contain nepafenac.
45793199|NCT00482690|Drug|nicotine polacrilex|
45793200|NCT00482690|Drug|nicotine transdermal system|
45793201|NCT00482690|Drug|nicotine inhaler|
45793202|NCT02058251|Drug|Oxytocin|One 40 IU dose of intranasal oxytocin will be self-administered (5 puffs in each nostril) by participants.
45793203|NCT02058251|Drug|Placebo|Each participant will self-administer a 40 IU dose of intranasal saline.
45793204|NCT03329937|Drug|Niraparib|Niraparib is a potent, orally active, highly selective poly adenosine diphosphate ([ADP]-ribose) polymerase 1 (PARP1) and PARP2 inhibitor. It will be supplied as 100 mg capsules and will be administered at starting dose of 200 mg PO daily throughout 28 days for 2 cycles (each cycle is 28 days), with the potential for an additional 4 cycles (maximum total of 6 cycles) at the assigned dose and schedule.
45793205|NCT02308787|Device|Spectra Optia Apheresis System|Platelet Depletion
45793206|NCT01710254|Drug|Regadenoson MRI|AF patients will be provided with a regadenoson stress MRI to see if coronary artery disease can be detected with more sensitivity /specificity.
45793207|NCT01710254|Drug|Gadobenate dimeglumine|Resting perfusion with Multihance Gd-BOPTA contrast agent will be performed first, then a regadenoson injection will be given and MR imaging performed with a Gd-BOPTA contrast agent bolus 60-100 seconds later.
45793208|NCT04768283|Other|Additional balance and resistance training - 1|"Additional exercise program with balance and resistance training three times per week.~The balance training included exercises to improve static as well as dynamic balance ability, for 15-20 minutes.~The resistance training included exercises with weights (0,5, 1 or 2 kg), elastic resistance rubbers, intensity 30-50% 1-RM, 10 repetitions with 3 sets and 3 minute rest between sets."
45793209|NCT04768283|Other|Additional balance and resistance training - 2|"Additional exercise program with balance and resistance training three times per week.~The balance training included exercises with static and dynamic balance training device Biodex Balance System TM SD, for 15-20 minutes. Exercises are performed with the following programs: Postural stability training, Limits of stability training, Weight shift training, Maze control training, Random control training, Percent weight-bearing training.~The resistance training included exercises with HUR strength training machines, intensity 30-50% 1-RM, 10 repetitions with 3 sets and 3 minute rest between sets. Strength training was performed with the following exercises: Leg press, leg extension, leg abduction, leg adduction."
45793210|NCT03496545|Drug|Bromocriptine 5 MG|Bromocriptine 5 mg every 4 hours PO/NG/FT
45793211|NCT03496545|Drug|Acetaminophen 650 MG|Acetaminophen 650 mg every 4 hours PO/NG/FT for 48 hours
45793212|NCT01710332|Drug|Intravitreal Aflibercept Injection|"GROUP A - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, and Month 4 (four injections total).~GROUP B - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, Month 3, Month 4, and Month 5 (six injections total)."
45793213|NCT02309489|Behavioral|Partner involvement|Partner is involved in maternity care
45793214|NCT03778658|Behavioral|Physical Activity Intervention|Participants will engage in a multimodal aerobic and strength training intervention.
45793215|NCT01711424|Drug|OPTIVE PLUS®|Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
45793216|NCT02311907|Drug|Carboplatin|Given IV, over 30 minutes per planned chemotherapy regimen
45793217|NCT02311907|Drug|Glutathione|Given IV, over 15 minutes, immediately before chemotherapy administration
45449737|NCT03730090|Device|zero flux skin termometer|Core temperature is monitored continously, non-invasively
45449738|NCT04687306|Diagnostic Test|X-rays- total of 4|X-rays of the sacral scope, pelvic femoral angle and cup ante-inclination in both sitting and standing positions
45793218|NCT02311907|Other|Laboratory Biomarker Analysis|Correlative studies
45647668|NCT04400149|Diagnostic Test|amniocentesis|amniocentesis will be performed to the pregnant women at 16-20 weeks who had a high-risk antenatal test. Furthermore, these women also give a blood sample (at 16-20 weeks) to compare the amniotic fluid and serum progesterone levels in association with pregnancy outcomes. We perform amniocentesis to evaluate genetic disorders in pregnant women who had his risk in the antenal test.
45793219|NCT02311907|Drug|Paclitaxel|Given IV, over 1 or 3 hours, per planned chemotherapy regimen
45793220|NCT02311907|Other|Placebo|Given IV
45793221|NCT02311907|Other|Quality-of-Life Assessment|Ancillary studies
45793222|NCT02013245|Biological|MTBVAC live vaccine|Live-attenuated Mycobacterium tuberculosis vaccine
45793223|NCT02013245|Biological|Commercially available BCG live vaccine|Live-attenuated Mycobacterium bovis vaccine
45793224|NCT01980485|Behavioral|Lung Age feedback and exhaled carbon monoxide|"In the intervention group, if the lung age is equal to or less than the individual's chronological age, he or she will be briefly informed that the test result was normal and that it is important to avoid potential future lung problems by stopping smoking. For those in the intervention group with a normal FEV-1, the intervention will focus on their exhaled carbon-monoxide.~If their lung age is greater than their chronological age, they will be given their lung age in years, and provided with a graph describing the possible decline in lung age if they continued to smoke and a full explanation.~Those in the Intervention Group will have their exhaled carbon-monoxide (CO) result explained in more detail. Non-smokers typically have an exhaled carbon-monoxide level of 0-4 parts per million, whereas smokers typically have a CO level of 8-50 ppm. CO levels return to normal within a few days of stopping smoking. Participants are provided with a full explanation."
45793225|NCT01980485|Behavioral|No Lung Age Feedback|Those allocated to the control group will simply be informed of their scores on the spirometry.
45793226|NCT01981967|Biological|IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous.
45793227|NCT01981967|Biological|IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous.
45793228|NCT01982123|Diagnostic Test|SPECT/CT|Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT mid-radiation and post-radiation
45793229|NCT01982123|Procedure|Single Photon Emission Computed Tomography|Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT
45793230|NCT01982123|Radiation|Technetium Tc-99m Albumin Aggregated|Undergo 99mTc-MAA SPECT/CT
45920805|NCT04062708|Drug|Durvalumab|"Preoperative Treatment:~Non-squamous NSCLC: durvalumab 1125 mg, followed by pemetrexed 500 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~Squamous NSCLC: durvalumab 1125 mg, followed by docetaxel 75 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~Adjuvant Therapy:~• 1-6 weeks after completion of radiotherapy, durvalumab 1500 mg IV every 4 weeks will be administered for 13 cycles."
45920806|NCT04062708|Procedure|Surgery|Patients will be re-evaluated following preoperative treatment to assess if patient is still medically fit to withstand surgery. Eligible patients will then undergo lobectomy, bilobectomy, sleeve lobectomy or other extended resection, or a pneumonectomy will be performed at the discretion of the attending thoracic surgeon.
45920807|NCT04062708|Radiation|Radiotherapy|4-10 weeks after surgery, patients will receive 54 Gy of radiotherapy with single daily fractions.
45647669|NCT04437017|Drug|Olanzapine+NK-1 RA+5-HT3 RA|On day 1-4, Olanzapine (5mg) is delivered orally after dinner.
45647670|NCT04437017|Drug|Dexamethasone+NK-1 RA+5-HT3 RA|On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administrated, and on day 2-4, the given dose of dexamethasone is 8 mg.
45647671|NCT03061253|Other|Electronic Cigarette and behavioural change support.|The nicotine strength of Group A (nicotine-inclusive e-cigarettes) cartridges will be 18 mg/ml of nicotine strength. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
45793231|NCT01982123|Drug|Technetium Tc-99m DTPA|Undergo 99mTc-DTPA SPECT/CT
45793232|NCT02061683|Drug|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.
45793233|NCT01711658|Radiation|IMRT|Intensity modulated radiation therapy (IMRT), 35 fractions over 6 weeks, 6 fractions per week for 5 weeks and 5 fractions per week for 1 week, 2 Gy per fraction to total dose of 70 Gy
45793234|NCT01711658|Drug|Cisplatin|100 mg/m^2 administered intravenously on days 8 and 29
45920808|NCT04728490|Other|Allogenic transplantation transplantation|Haplo-identical transplantation with the use of Treosulfan, Thiotepa and Fludarabine in conditioning regimen.
45920809|NCT00100594|Drug|Efavirenz|
45920810|NCT00100594|Drug|Lamivudine/zidovudine|
45920811|NCT00006374|Biological|filgrastim|
45920812|NCT00006374|Drug|cisplatin|
45793235|NCT01711658|Drug|placebo|1500 mg placebo daily by mouth or by feeding tube starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
45793236|NCT01711658|Drug|Lapatinib|1500 mg lapatinib by mouth or by feeding tube daily starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
45793237|NCT02063087|Other|Head CT Decision Aid|The decision aid, Head CT Choice, educates parents regarding how the clinician determined the severity of their child's head trauma, their child's quantitative risk for a clinically-important TBI, the pros and cons of cranial CT compared to active observation, and what signs and symptoms parents should watch for in the next 24 hours that should prompt a return visit to the ED.
45793238|NCT02395991|Drug|gadoxetic acid|standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration
45793239|NCT02395991|Other|Magnetic resonance imaging (MRI)|"Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.~precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state."
45793240|NCT01712360|Drug|NAFT500 (pediatric)|Applied to both feet and groin area
45920813|NCT00006374|Drug|etoposide|
45920814|NCT00006374|Drug|paclitaxel|
45920815|NCT00006374|Drug|topotecan hydrochloride|
45920816|NCT00100633|Drug|CpG7909 oligodeoxynucleotides (ODN)|
45793241|NCT01712360|Drug|NAFT600 (pediatric)|Applied to both feet only
45793242|NCT01712360|Drug|NAFT500 (adult)|Applied to both feet and groin area
45793243|NCT01712360|Drug|NAFT600 (adult)|Applied to both feet
45793244|NCT02396147|Drug|TAK-385 T2 Formulation|TAK-385 T2 Formulation tablets
45449739|NCT03728920|Other|Muscle strength measurement|Patients awaiting hip arthroscopy will undergo muscle strength testing pre- and post-operatively. There will be no deviation of treatment from their NHS care. Validated outcome measure questionnaires will be completed at five months post-operatively. Magnetic resonance imaging and electromyography tests will be performed on a subset of patients post-operatively.
45793245|NCT02396147|Drug|TAK-385 T4 Formulation B|TAK-385 T4 Formulation B tablets
45793246|NCT02396147|Drug|TAK-385 T4 Formulation C|TAK-385 T4 Formulation C tablets
45793247|NCT01713608|Drug|OZ439|OZ439 x mg once daily for 3 days with milk
45793248|NCT03562832|Drug|PARP inhibitor 2X-121|600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
45793249|NCT02018315|Drug|Triheptanoin|Triheptanoin is a 7-carbon medium chain triglyceride
45793250|NCT02018627|Drug|Xeris glucagon|The subject is given an injection of xeris glucagon
45793251|NCT02018627|Drug|Lilly glucagon|The subject is given an injection of lilly glucagon
45793252|NCT01714232|Device|Contour® PLUS BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
45793253|NCT01714232|Device|OneTouch® SelectSimple™ BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
45793254|NCT01714232|Device|Accu-Chek® Performa BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
45793255|NCT01714232|Device|Accu-Chek® Active BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
45793256|NCT01714232|Device|Freestyle Freedom® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
45793257|NCT03476330|Drug|Quercetin (dietary supplement)|Quercetin will be administered twice daily at an adjusted dose based on weight for a maximum total daily dose of 4000mg/day. If the patient is 70 kg or more, the dose will automatically be assigned at the maximum dose of 4000mg/day.
45793258|NCT02019563|Procedure|RCT Group|After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and the pulp tissue removed. The canal will be irrigated with water and then filled with non-reinforced ZOE.
45793259|NCT02019563|Procedure|MTA/FS pulpotomy Group|After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and vital coronal pulp to a depth of 2mm below free gingival margin will be removed. A solution of ferric sulfate will be applied to the amputated pulp surface and then flushed with water. MTA paste is then used to cover over the exposed amputated pulp surface.
45793260|NCT04413344|Drug|Bromocriptine|TW-012R: Each tablet contains 2.87 mg of bromocriptine mesilate (JP) (2.5 mg of bromocriptine)
45793261|NCT04413344|Drug|Placebos|Placebo: Identical tablets which contain no active ingredient
45793262|NCT03441152|Device|tDCS|Transcranial direct current stimulation
45793263|NCT02063867|Drug|Arm 2: Decolonization|"Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.~Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen."
45793264|NCT03435146|Combination Product|3HP plus DTG +2NRTIs|"HIV treatment: DTG will be dosed as described above and will be given with daily TDF/FTC (Groups 1 and 2) or with TDF/3TC (Groups 3 and 4).~LTBI treatment: 3HP will be given once-weekly for a total of 12 doses, with doses as follows:~Rifapentine: 900 mg; Isoniazid: 900 mg (Groups 1,2 and 4) Isoniazid at standard of care dosing (Group 3)"
45449740|NCT03546621|Drug|Myrcludex B|2 mg, once daily, subcutaneously
45449741|NCT03546621|Drug|Myrcludex-B|5 mg, once daily, subcutaneously
45449742|NCT03546621|Drug|Myrcludex-B|10 mg, once daily, subcutaneously
45449743|NCT03546621|Drug|Tenofovir|tenofovir disoproxil 245 mg, equivalent to tenofovir disoproxil fumarate 300 mg
45449744|NCT02761330|Drug|Ketamine|Ketamine will be used to induce general anesthesia with or without subsequent ECT. Within a single patient, the dose will remain consistent throughout the study and is estimated to be 2 mg/kg.
45449745|NCT02761330|Procedure|Electroconvulsive Therapy|Dose of the ECT charge will be determined during titration session prior to randomization.
45647672|NCT03061253|Other|Nicotine-Free Electronic Cigarette and behavioural change support.|Group B participants will receive nicotine-free cartridges for the period of the intervention. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
45647673|NCT03061253|Other|Nicotine Replacement Therapy and behavioural change support.|Group C participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy and up to 6 behavioural change support sessions over the 3-month intervention period, as per current guidelines.
45647674|NCT04972643|Dietary Supplement|EPA|EPA 2000mg Soft capsules
45647675|NCT04972643|Dietary Supplement|DHA|DHA 2000mg Soft capsules
45647676|NCT04972643|Dietary Supplement|Placebo|Placebo Soft capsules
45647677|NCT05107141|Procedure|Ridge preservation|Ridge preservation in molar areas using a xenograft or an allograft in combination with a barrier collagen membrane
45647678|NCT05107141|Device|bone graft plus a collagen membrane|
45647679|NCT05107063|Drug|Pravastatin|Routine initiation dose was 10 mg, 20 mg or 40 mg single dose once daily. Depending on patient response, dose could have been increased up to 40 mg. Maintenance dose was 10-40 mg once daily.
45647680|NCT04977713|Other|Acupressure|A researcher sat behind the women to comfortably access the sacral area and be in the appropriate position. The researcher then applied deep rotational pressure on the BL32 points until her nail bed colour changed to prevent any discomfort in the participants
45793265|NCT01715948|Device|CROS hearing aid|Participants were randomly assigned to be fitted with the CROS hearing aid either at the end of the first visit or at the end of the second visit. They were given a 2-week trial with the CROS and asked to refrain from wearing their BAHD during that time. At the end of the first visit, four participants were fitted with the CROS hearing aid and were subsequently tested with this device on their second visit, at which time they were instructed to use the BAHD for the next 2 weeks. This protocol was reversed in the other four participants, with testing after each device experience. Both devices were compared on head shadow effect reduction, speech perception measures in quiet and in noise, self-assessment questionnaires, and daily diaries.
45793266|NCT01715948|Device|Bone-anchored hearing device (BAHD)|All participants had received BAHD implantation prior to the study. They were randomly selected to continue wearing their BAHD for 2 weeks following the end of the first visit or the end of the second visit. Both devices were compared on head shadow effect reduction, speech perception measures in quiet and in noise, self-assessment questionnaires, and daily diaries.
45647681|NCT04977713|Other|Shower|During uterine contractions, these participants took a shower while standing, with a researcher on hand to assist her (average time: 20 minutes). The water's temperature was between 22°C and 26°C.
45647682|NCT05106907|Biological|ThisCART19 cells|0.2-60 x 10^6 CAR T cells per kg body weight
45647683|NCT04977401|Procedure|Endoscopic submucosal dissection|Dissecting superficial gastric or rectal lesion/polyp after injection of the submucosa for lifting, using a electrosurgical knife through the endoscope
45647684|NCT04977401|Device|use of Orise Gel as lifting agent for endoscopic submucosal dissection|Injection of some colloidal solution (ORISE gel) in the submucosal layer in order to obtain long lifting effect and thus allowing the endoscopist to dissect under the lesion.
45647685|NCT04977401|Device|use of glycerol as lifting agent for endoscopic submucosal dissection|Injection of some colloidal solution (glycerol) in the submucosal layer in order to obtain long lifting effect and thus allowing the endoscopist to dissect under the lesion.
45653167|NCT05113797|Behavioral|OPTIMAL motor learning theory|OPTIMAL theoretical framework instructions and coaching will be utilized to improve motor performance through three main components: promotion of autonomy support (AS), presence of an external focus (EF) of attention, and implementation of enhanced expectancies (EE) placed upon a task.
45793267|NCT04280354|Other|compare data patterns by data-driven algorithms to determine sepsis|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to reliably determine sepsis
45793268|NCT04280354|Other|compare data patterns by data-driven algorithms to predict sepsis-related mortality|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to to predict sepsis-related mortality
45793269|NCT02021669|Drug|Omega-3 supplement|Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks
45793270|NCT02021669|Drug|Placebo|Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
45793271|NCT01717742|Drug|TPA (Tissue Plasminogen Activator)|Intrapleural administration of tPA 4 mg in 10 ml (≤10 kg) or 20 ml (>10 kg) normal saline once daily for 3 days
45793272|NCT01717742|Drug|DNase|Intrapleural administration of DNase 5 mg diluted to 10 ml (≤10 kg) or 20 ml (>10 kg) normal saline once daily for 3 days
45793273|NCT01717742|Other|Placebo|Intrapleural administration of normal saline 10 ml (≤10 kg) or 20 ml (>10 kg)
45793274|NCT01717898|Drug|BEZ235|BEZ235 - 200 mg, 300 mg, or 400 mg; po, BID. BEZ235 will be supplied in 200 mg, 300 mg, and 400 mg sachets packaged in boxes.
45920817|NCT00100633|Biological|Hepatitis B virus vaccine|
45920818|NCT00100672|Drug|LErafAON-ETU|
45920819|NCT02958592|Other|two-dimensional shear-wave elastography (SWE)|performa two-dimensional shear-wave elastography (SWE) for staging hepatic fibrosis in the background liver parenchyma in patients with liver tumors before hepatic resection
45920820|NCT00100750|Drug|Gemcitabine Hydrochloride|Given IV
45920821|NCT00100750|Drug|Tipifarnib|Given PO
45920822|NCT00100750|Other|Laboratory Biomarker Analysis|Correlative studies
45920823|NCT00006377|Drug|carboplatin|
45920824|NCT00006377|Drug|doxorubicin hydrochloride|
45920825|NCT00006377|Drug|paclitaxel|
45920826|NCT01350102|Drug|Bacitracin|Participants will be treated with Bacitracin to their wound until 100% wound healing, which may take up to 6 months to achieve.
45920827|NCT01350102|Drug|AmeriGel®|Participants will be treated with AmeriGel® to their wound until 100% wound healing, which may take up to 6 months to achieve.
45920828|NCT01350102|Dietary Supplement|Vitamin C|Participants will be treated with Vitamin C supplements 1000 mg daily until 100% wound healing, which may take up to 6 months to achieve
45920829|NCT00424060|Drug|sagopilone|
45920830|NCT00424060|Genetic|fluorescence in situ hybridization|
45920831|NCT00424060|Genetic|gene expression analysis|
45920832|NCT00424060|Other|immunohistochemistry staining method|
45920833|NCT00424060|Other|laboratory biomarker analysis|
45920834|NCT00424060|Other|pharmacological study|
45920835|NCT00006380|Biological|monoclonal antibody muJ591|
45920836|NCT00006380|Radiation|iodine I 131 monoclonal antibody muJ591|
45920837|NCT00100906|Drug|IL-2|Immunotherapy with interleukin-2
45920838|NCT00100906|Drug|ATRA|
45920839|NCT00100945|Drug|gefitinib|
45920840|NCT00006383|Drug|liposomal vincristine sulfate|
46071640|NCT05333562|Other|Motor control exercise with mobilization|this was given motor control exercise for 30 min, 4 weeks twice a day plus neural gliding applied for 3 sets of 10 repetitions on each session. Neural gliding applied 5 min before motor control exercise. Total 8 sessions were given
45793275|NCT01717898|Drug|Prednisone|10/mg po daily. Prednisone can be modified at the investigator's discretion, but should not be discontinued.
45793276|NCT01717898|Drug|Abiraterone acetate|1000 mg, po. Abiraterone Acetate is supplied in 250 mg white tablets, four tablets are to be taken with a full glass of water on an empty stomach once daily.
45793277|NCT01718522|Device|sensor augmented pump (SAP)|
45793278|NCT02064959|Device|Temperature management Zoll Intravascular Temperature Management device|
45793279|NCT01736930|Device|Pump suspension|The study laptop will communicate to the pump causing suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
45793280|NCT02397707|Drug|Voxilaprevir|100 mg tablet administered orally
45793281|NCT01737944|Drug|Methotrexate (MTX)|Vibex MTX Device
45793282|NCT02397785|Device|ApexM|Subjects will apply conductive gel, insert the device to a minimum depth of 4 inches, and inflate until comfortably snug. The intensity is set exclusively by the physician to a tolerated sensory level, avoiding muscle contraction. At the target amplitude, patients will feel a non-painful fluttering or tapping sensation, Subjects will perform this for 6 sessions per week at 12 minutes per session for an additional 12 weeks. At each follow-up visit, investigators will re-evaluate the stimulation level and adjust to avoid muscle contraction.
45793283|NCT02397785|Device|Sham Device|Identical to ApexM but will not deliver any electrical stimulation
45793284|NCT01740206|Drug|Amphetamine and/or methylphenidate|Patients who took their stimulant medication the day of surgery.
45793285|NCT01740206|Other|Hold stimulant medication|Patients who held their stimulant medication the day of surgery.
45793286|NCT01740362|Drug|CP-690,550|10 mg (2 x 5 mg tablets), single dose
45793287|NCT01740362|Drug|CP-690,550|10 mg (2 x 5 mg tablets), single dose
45793288|NCT01740362|Drug|CP-690,550|10 mg (2 x 5 mg tablets), single dose
45793289|NCT01740362|Drug|CP-690,550|10 mg (2 x 5 mg tablets), single dose
45647686|NCT05106829|Other|Physical therapy program with treadmill training without using of ankle weights.|The physical therapy program include manual standing on the mat, manual standing on the mat with step forward and step backward, kneeling and half kneeling on the mat, changing position exercises from prone to standing and from supine to standing, equilibrium, protective and righting reactions using balance board and medical ball, balance training exercise from standing on the mat, strengthening exercises for weak dorsiflexors, stooping and recovery exercising from standing position, squatting to standing exercise, gait training in different directions and, stretching exercises for tight muscles (e.g: hip flexors, hamstrings and calf muscles in lower limb and for wrist flexors, pronators and elbow flexors in upper limb) + gait training on treadmill without ankle weights.
45793290|NCT03251937|Device|Spectra WaveWriter SCS System|Multiple modalities of stimulation therapy
45793291|NCT02068157|Other|Laboratory Biomarker Analysis|Correlative studies
45793292|NCT02068157|Drug|Photodynamic Therapy|Undergo image-guided I-PDT
45793293|NCT02068157|Drug|Porfimer Sodium|Given IV
45793294|NCT04232852|Dietary Supplement|Probiotic mix|The probiotic mix will contain strains of Streptococcus thermophilus, Saccharomyces cerevisiae, Lactobacillus acidophilus, L. rhamnosus L. helveticus, L. gasseri, L. plantarum, Bifidobacterium bifidum, Enterococcus faecium at a daily dose of 7 × 1010 CFU in the form of a capsule.
45920841|NCT04059549|Behavioral|PartnerCHESS|"Patients randomized to the PartnerCHESS group will receive all A-CHESS services plus the following services from ABCT:~Urge discussion. Daily EMAs will track preconditions for relapse (urges), review urge reduction options on PartnerCHESS, and encourage discussions between partners on the causes of and ways to reduce urges.~Homework checklist. Tracks which interventions the couple is using/practicing, along with resources to help.~Relapse plan. Monitoring and reminders of steps planned for relapse prevention. Reminders. Reminders to notice something positive in partner, of reasons to stay sober, to take meds, etc.~Trigger identification and removal. During set-up, patient and partner enter triggers. PartnerCHESS will quiz couples on upcoming trigger events and remind them of ways to address each."
45920842|NCT04059549|Behavioral|A-CHESS|A-CHESS control group
45653169|NCT05172687|Behavioral|Overprescribing letter to attributed physician|Letter telling patient's attributed physician they were under review for high prescribing
45793295|NCT04232852|Dietary Supplement|Placebo|Patients in the placebo group will receive an identical capsule of maltodextrin.
45793296|NCT02398409|Behavioral|ANSWERS - Acquiring New Skills While Enhancing Remaining Strengths|"Randomized trial to evaluate the efficacy of the telephone intervention Acquiring New Skills While Enhancing Remaining Strengthsin informal caregivers of Veterans with stroke and TBI."
45653170|NCT05172687|Behavioral|Placebo letter to attributed physician|Letter to patient's attributed physician about unrelated Medicare regulation
45793297|NCT02398409|Other|Control|8 week telephone usual care with education with nurse case manager
45793298|NCT01741454|Drug|Tamsulosin|0.4 mg by mouth once per day.
45793299|NCT01741454|Drug|Tolterodine ER|4 mg by mouth once a day.
45793300|NCT01720316|Drug|Glycine|Double-blind placebo controlled trial of glycine or placebo, followed by open-label glycine
45793301|NCT01720316|Drug|placebo|
45793302|NCT02399345|Drug|ombitasvir/paritaprevir/ritonavir, dasabuvir|tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
45793303|NCT02399345|Drug|sofosbuvir (SOF)|tablet
45793304|NCT02399345|Drug|ribavirin (RBV)|tablet
45793305|NCT02400437|Drug|Ixazomib|Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
45793306|NCT02400437|Drug|Dexamethasone|Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
45793307|NCT02400437|Drug|Rituximab|Doses given on Day 1 of induction and maintenance cycles.
45793308|NCT02402153|Device|Hyposafe device|Subcutaneous EEG recorder for EEG measurements
45793309|NCT02024477|Drug|Saxagliptin|5 mg tablet once daily for 12 weeks
45793310|NCT02024477|Drug|Placebo|1 tablet daily for 12 weeks
45793311|NCT02024711|Device|EYEFILL® C.-US Viscoelastic|EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
45647687|NCT05106829|Other|Physical therapy program with treadmill training with using of ankle weights.|he physical therapy program include manual standing on the mat, manual standing on the mat with step forward and step backward, kneeling and half kneeling on the mat, changing position exercises from prone to standing and from supine to standing, equilibrium, protective and righting reactions using balance board and medical ball, balance training exercise from standing on the mat, strengthening exercises for weak dorsiflexors, stooping and recovery exercising from standing position, squatting to standing exercise, gait training in different directions and, stretching exercises for tight muscles (e.g: hip flexors, hamstrings and calf muscles in lower limb and for wrist flexors, pronators and elbow flexors in upper limb) + gait training on treadmill with ankle weights.
45647688|NCT04432181|Other|ophthalmic examination|ophthalmic examination including; best corrected visual acuity, alternating prism cover test, retinoscopy, fundus examination, ocular vergence evaluation
45647689|NCT04422613|Diagnostic Test|pulmonary anomalies 4 months after documented COVID-19 pneumonia|Characterization of pulmonary damage with a complete pulmonary assessment 4 months after COVID-19 pneumonia,
45647690|NCT04971317|Behavioral|Sugar-Sweetened Beverage (SSB) Video|Participants will watch a video showing the decay of an egg in various SSBs (Coca-Cola, Sprite, Gatorade, and apple juice), followed by the evaporation of these beverages over a heat source, revealing their sugar content.
45647691|NCT04971317|Behavioral|Water Video|Participants will watch a video showing an egg maintaining its shell in water, followed by the evaporation of water.
45647692|NCT04971317|Behavioral|Control|Participants will watch a video of an egg maintaining its shell in rubbing alcohol, followed by the evaporation of rubbing alcohol.
45647693|NCT04249609|Other|HCHO meals and exercise|Exercise will be conducted after high carbohydrate dinner and prior to high carbohydrate breakfast
45647694|NCT04249609|Other|LCHO meals and exercise|Exercise will be conducted after high fat dinner and prior to high fat breakfast
45647695|NCT04971707|Other|Standardized exercise training|HRV index will be measured every morning during 5 min. This group will benefit from the standard cardiovascular rehabilitation program combining both continuous moderate exercise sessions (MICT) and high intensity interval exercise sessions (HIIT). MICT sessions will be performed 2 times per week and HIIT sessions will be performed once a week.
45647696|NCT04971707|Other|HRV-guided exercise training|HRV index will be measured every morning during 5 min. This group will benefit from the individualized cardiovascular rehabilitation program. Daily exercise (MICT, HIIT, or active recovery) will be prescribed according to the HRV-index measured on the morning of the session.
45647697|NCT05106751|Device|Hyaluronic acid dermal filler|Hyaluronic acid dermal filler used for facial volume or wrinkle correction
45793312|NCT02024711|Device|Healon® Viscoelastic (CONTROL)|Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
45793313|NCT02071823|Drug|BIA 9-1067|A single oral dose of 50 mg (2 x 25 mg capsules) was administered in the morning of each study period under fasting or fed conditions. The two single dose administrations were separated by a wash-out of 7 days.
45793314|NCT02026193|Procedure|oocyte vitrification|
45793315|NCT02026193|Procedure|embryo freezing|
45793316|NCT02029703|Device|Synvisc-One Injection|
45793317|NCT02029703|Other|Sham Injection|
45793318|NCT02405195|Procedure|cardiopulmonary bypass|During cardiac surgery, the subjects are routinely undergoing cardiopulmonary bypass
45793319|NCT02406443|Drug|Sitaglitpin|Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days
45793320|NCT02406443|Other|Placebo|Oral tablet (no medicinal ingredients) administered once daily for 28 days
45647698|NCT04383379|Behavioral|Experimental: Intervention group|The intervention NICUs (n = 6) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes toimprove the rate of breastfeeding . Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
45793321|NCT02339831|Device|CAMOPED|Camoped given after surgery
45793322|NCT02339831|Device|CPM passive motion device|passive motion device given after surgery
45653171|NCT04787081|Other|Sleep Care Positioning Training Program GRP1|Video-based tutorial covering six nighttime postural care topic areas which contained narration and closed captioning. This 2-hour online training program was delivered in a University classroom via D2L Brightspace.
45793323|NCT02340299|Device|nHFOV|Extubation to ventilator-derived nHFOV using binasal prongs
45793324|NCT02340299|Device|nCPAP|Extubation to ventilator-derived nCPAP using binasal prongs
45793325|NCT02409329|Behavioral|REACH|The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, text messages assessing user's adherence with feedback on progress, plus text messaging targeting other self-care behaviors.
45793326|NCT02409329|Behavioral|Helpline and A1c results|Participants complete study assessments, receive text messages advising how to access study A1c results, receive quarterly newsletters on healthy living with diabetes, and have access to a helpline for study- or diabetes medication-related questions.
45793327|NCT02409329|Behavioral|REACH + FAMS|The intervention consists of REACH individually-focused text messaging, plus family-focused phone coaching session, goal-focused text messaging, and the option to invite a family member/support person to receive text messaging.
45793328|NCT02032433|Drug|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®)
45793329|NCT02032433|Drug|Buprenorphine-Naloxone|Buprenorphine-Naloxone (Suboxone®)
45793330|NCT01721096|Device|XIENCE PRIME - Long Length (LL)|Long Length
45793331|NCT01721096|Device|XIENCE PRIME - Core Size|Core Size
45793332|NCT02403479|Drug|Silver Colloid|Topical silver colloid will be administered for 6 weeks. This will either occur before topical saline nasal spray. Participants are randomized as to the order of sprays. The commercially available silver colloid product, Sovereign Silver Mineral Supplement, will be used.
45793333|NCT02403479|Other|Saline|Topical saline will be administered for 6 weeks. This will occur before the topical silver colloidal nasal spray. Participants are randomized as to the order of sprays.
45920843|NCT00100984|Drug|FUZEON [enfuvirtide]|
45920844|NCT00101062|Drug|celecoxib|
45920845|NCT00101062|Drug|letrozole|
45647699|NCT05106673|Behavioral|Optimal pathways to care|The first implementation measure focuses on optimal ways of caring for mentally ill patients who are also parents with children living in the household. The main goals of this intervention are the specific information of the referring physician, the indicated referral of mentally ill parents and the consideration of underage children living in the household in the inpatient referral. The two main components are the evaluation of the attitudes of the medical and psychotherapeutic referrers towards the target group and the intervention as well as the development and implementation of an optimal care pathway. The optimization of the allocation is organized by Silke Pawils (University Medical Center Hamburg-Eppendorf).
45793334|NCT02340767|Device|Spectra Device|Spectra Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
45793335|NCT02340767|Device|DIAGNOdent|DIAGNOdent Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
45793336|NCT02341859|Device|stenfilcon A|contact lens
45793337|NCT02341859|Device|delefilcon A|contact lens
45793338|NCT02341859|Device|narafilcon A|contact lens
45793339|NCT02250092|Device|Transcranial Direct Current Stimulation (tDCS)|10 tDCS/CIMT Sessions
45647700|NCT05106673|Behavioral|Education and training program for the professionals|The second implementation intervention concerns the improvement of the professionals' attitudes, knowledge and skills. The two main components here being the assessment of the current state in all institutions within the clinical centers and the development and implementation of an education and training program. The employees of the randomized clinical centers in the intervention group will get a three-hour training. This intervention is organized by Svenja Taubner (University Hospital Heidelberg, Germany).
45647701|NCT05106673|Behavioral|Systematic screening|The third implementation intervention includes a systematic screening process to improve detection of mentally ill parents with affected children. Employees of the clinical centers fill out two short questionnaires with the parents. This intervention project is organized by Sibylle M. Winter (Charité, Berlin, Germany).
45793340|NCT02250092|Device|Placebo Comparator|
45647702|NCT05106673|Other|TAU|No Intervention: Treatment as usual These clinical centers will be the control group and will not get a specific implementation support during the implementation of CHIMPS.
45793341|NCT04194398|Device|OCS Lung System|Patients previously transplanted with lungs preserved on the OCS Lung System in the Expand Lung study.
45793342|NCT01742936|Device|CoaguChek|Hand held coagulation monitor.
45793343|NCT01742936|Other|Hospital Laboratory|Coagulation testing done by hospital laboratory.
45920846|NCT00006386|Drug|carmustine|
45647703|NCT04977557|Dietary Supplement|Thiamine|Injection Thiamine 200 mg daily intravenously for 1 week followed by Tablet Thiamine 100mg bid for remaining 11 weeks
45647704|NCT04316143|Drug|Zamicastat|Tablets for oral administration under fed conditions containing 100 mg of zamicastat (BIA 5-1058)
45647705|NCT04977323|Other|TICK-B group|These interventions will use as distraction techniques.
45647706|NCT04977089|Diagnostic Test|lipid profile test .|Assesment of lipid profile of patients (cholesterol level ,TG ,VLDL )
45647707|NCT05104801|Drug|sitravatinib|sitravatinib 100mg QD PO
45647708|NCT05104801|Drug|tislelizumab|tislelizumab 200mg Q3W IV
45647709|NCT04977011|Other|relaxing music|30 minutes relaxing music for continuity 3 days since admission
45647710|NCT04530877|Biological|Infliximab|Infliximab, a monoclonal antibody-targeting tumor necrosis factor (TNF), is one of the primary treatment strategies for active pediatric CD
45647711|NCT04530877|Dietary Supplement|Exclusive Enteral Nutrition|the administration of a liquid formula diet with the exclusion of all other regular food for 6-8 weeks， the volume was determined according to the energy needs of the patient. All patients received high energy intakes (>110%-120% of the average requirement).
45793344|NCT02312765|Behavioral|AirCare App|Tablet software to encourage adherence and support
45793345|NCT02252666|Device|Neuromodulation Rehabilitation|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
45793346|NCT02342015|Drug|Atorvastatin|Atorvastatin 40mg/day for three months
45920847|NCT00006386|Radiation|radiation therapy|
45647712|NCT04971083|Behavioral|Intervention Group|This study is designed to provide patients a tool with which they can record the nutrition related symptom burden (NRSB) they are experiencing in real time. A pre-defined algorithm then provides them with tailored nutrition information and behavioural tipps based on the severity grade of the symptom recorded. The aim is to increase the chances that such symptoms, when clinically relevant, are addressed in a timely matter and thus the nutrition status is stabilized.
45793347|NCT02342327|Other|switch to non-menthol cigarettes prior to cessation attempt|
45793348|NCT02342327|Other|continue smoking menthol cigarettes prior to cessation attempt|
45793349|NCT01721564|Drug|Bosentan|62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months
45793350|NCT02033213|Other|Restrictive group|"A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."
45793351|NCT02033213|Other|Liberal group|"A group of patients who received > 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."
45920848|NCT00006386|Radiation|stereotactic radiosurgery|
45920849|NCT00101140|Drug|anti-thymocyte globulin|
45920850|NCT00101140|Drug|fludarabine phosphate|
45920851|NCT00101140|Drug|thiotepa|
45920852|NCT00101140|Procedure|biological therapy|
45920853|NCT00101140|Procedure|bone marrow ablation with stem cell support|
45920854|NCT00101140|Procedure|chemotherapy|
45920855|NCT00101140|Procedure|non-specific immune-modulator therapy|
45920856|NCT00101140|Procedure|peripheral blood stem cell transplantation|
45920857|NCT00101140|Procedure|radiation therapy|
45647713|NCT04274023|Drug|TSR-042|TSR-042 is an IgG4 humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2.
45647714|NCT04971239|Drug|topical methotrexate micoemulsion|The selected microemulsion composition consists of 40% Jojoba oil, 45% Tween-80 and Span-85 at a ratio of 3:1 as surfactant and co surfactant, respectively and 15% water. The chosen concentration was based on preliminary studies conducted which delineated that these ratios provided the best skin deposition based on factorial skin modelling.The prepared microemulsions contains 0.1% methotrexate
45793352|NCT02410967|Behavioral|Attention Bias Modification|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.
45793353|NCT02410967|Behavioral|Placebo Attention Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
45647715|NCT04971239|Device|Excimer light|the excimer laser will be done twice weekly for a total treatment course of 12 weeks.
45793354|NCT02342561|Device|Ioban 2 incision drape, 3M|The anterior knee of the patient is covered with an Ioban 2 drape for 75 minutes. The drape is applied and removed in accordance with product instructions.
45793355|NCT02343575|Drug|Valproic Acid|"1.~Start:~VPA PO/NGT 500 mg BID~2.~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS~3.~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS~4.If need to increase in 24 or more hours:~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS"
45793356|NCT02343575|Drug|Placebo|Placebo 500 mg matched to VPA BID PO/NGT
45793357|NCT02343575|Drug|Haloperidol|Both arms (intervention VPA and placebo) will receive flexible as needed haloperidol: Rescue: HAL IV 2-5 mg Q4hr PRN
45793358|NCT01744340|Drug|Head and neck|"Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2 and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter~Dose Level 1: 0.7 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 2: 1.0 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 3: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
45793359|NCT01744340|Drug|Colon- Closed as of May 2014|"Eribulin Mesylate:~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
45793360|NCT04130906|Device|Intermittent Theta Burst Stimulation|iTBS will be delivered to the left dorsolateral prefrontal cortex (DLPFC) at 80% of resting motor threshold using standard stimulation parameters; triplet-bursts will be delivered at high frequency (50 Hz) with an inter-burst interval of 200 ms. Each TBS train will last 2 seconds and consists of 10 triplet-bursts (30 pulses). Each iTBS session will involve 10 TBS trains repeated every 10 seconds for 190 seconds, with a total number of 600 pulses delivered during each session.
45793361|NCT04130906|Device|Sham Intermittent Theta Burst Stimulation|Sham stimulation will be delivered left dorsolateral prefrontal cortex (DLPFC) using the same parameters as real iTBS however, a sham coil will be used. The sham coil makes the same noise and creates a similar sensation on the scalp as the real coil but does not produce a magnetic field.
45647716|NCT04971239|Device|Narrow band ultraviolet B|the Narrow band ultraviolet B will be done twice weekly for a total treatment course of 12 weeks.
45920858|NCT00101179|Drug|Azacitidine|Given SC
45647717|NCT03062111|Procedure|ProTouch Laser Enucleation of Prostate (LEP)|Laser enucleation of the prostate is a standard form of treatment for BPH used widely. The ProTouch laser is established to be safe and is newer than the holmium laser.
45647718|NCT03062111|Procedure|Transurethral Resection of Prostate (TURP)|TURP has been considered a gold standard for treatment of BPH in which rigid resectoscopes with bipolar cautery are used to endoscopically resect prostatic tissue.
45793362|NCT01744574|Other|Placebo|Placebo - subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
45793363|NCT01744574|Drug|Progesterone|The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
45793364|NCT01744574|Other|Smoking Cessation Behavioral Counseling|Subjects will receive weekly smoking cessation behavioral counseling.
45647719|NCT04903093|Drug|Abrocitinib tablet|Single dose of abrocitinib 200 mg tablet will be administered after an overnight fast of at least 10 hours.
45647720|NCT04903093|Drug|Abrocitinib Suspension F1|Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.
45647721|NCT04903093|Drug|Abrocitinib Suspension F2|Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.
45647722|NCT04903093|Drug|Abrocitinib Suspension F3|Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.
45647723|NCT04903093|Drug|Abrocitinib Suspension F4|Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.
45647724|NCT04903093|Drug|Abrocitinib Suspension F5|Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.
45647725|NCT04903093|Drug|Abrocitinib Suspension F6|Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.
45920859|NCT00101179|Drug|Entinostat|Given orally
45920860|NCT00400777|Drug|Valsartan, hydrochlorothiazide and amlodipine|
45920861|NCT04041570|Biological|cAd3-EBO S vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Ebola vaccine, VRC-EBOADC086-00-VP (cAd3-EBO S), is composed of a cAd3 vector that encodes Ebola Sudan wild type glycoprotein (WT GP).
45920862|NCT00400816|Drug|temozolomide|Schedule of Temozolomide administration: Temozolomide, 150 mg/m2/d x days 1-7 and 15-21, given every 28 days [i.e., 7 days on/7 days off]
45920863|NCT00400855|Drug|Fluticasone propionate|Study drug
45647726|NCT04903093|Drug|Famotidine|Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.
45793365|NCT01744730|Drug|Clindamycin|Schedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care.
45793366|NCT01722734|Behavioral|Text message reminders|Patients in the two treatment arms receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals to remind them to take their malaria medication as prescribed.
45793367|NCT04129970|Device|Intermittent Theta Burst Stimulation|iTBS will be delivered to the left dorsolateral prefrontal cortex (DLPFC) at 80% of resting motor threshold using standard stimulation parameters; triplet-bursts will be delivered at high frequency (50 Hz) with an inter-burst interval of 200 ms. Each TBS train will last 2 seconds and consists of 10 triplet-bursts (30 pulses). Each iTBS session will involve 10 TBS trains repeated every 10 seconds for 190 seconds, with a total number of 600 pulses delivered during each session.
45793368|NCT02033993|Drug|Nab-Paclitaxel|
45793369|NCT02033993|Drug|Paclitaxel|
45647727|NCT04970849|Other|observation|IBD doctors who perform the endoscopy perform the questionnaire
45647728|NCT04529785|Procedure|SVC only|Patients allocated to this arm will receive an RF ablation with the isolation of the SVC alone
45647729|NCT04529785|Procedure|SVC isolation with substrate modification and vein of Marshal ethanol infusion|Patients allocated to this arm will receive an RF ablation with the isolation of the SVC, substrate modification and vein of Marshal ethanol infusion
45793370|NCT02413151|Behavioral|Exercise training program|The exercise sessions will be hospital-based, 3 times a week for 60 minutes each, on non-consecutive days for 6 months. Selected the aerobic interval training (AIT) method for the development of cardiopulmonary system and the inclusion of resistance and sensorimotores exercises. The AIT comprises 4 interval training periods (high intensity) and 3 active pauses (moderate intensity) between interval training periods. The patient will warmup for 10 minutes at 50% to 60% of HRpeak from CPET, before walking to four 4 minutes intervals at 90 to 95% of peak HR. Each interval, including the last one, is separate by 3 minutes active pauses, walking at 60% to 70% of HRpeak. Total aerobic exercise time at this moment will be 28 minutes and will be maintain to the end of ExT intervention period.
45793371|NCT02413151|Device|Cardiac resynchronization therapy (CRT)|Implantation will be performed according to standard techniques of biventricular pacing. The CRT includes a generator and three leads, used to correct ventricular dyssynchrony.
45793372|NCT02346383|Device|preset program|Change to different present program using epidural and peripheral lead to cover pain
45793373|NCT02413463|Procedure|augmented recession|medial rectus muscle recession using augmented formula ( average of the distance angle with correction and the near angle without correction)
45793374|NCT02413463|Procedure|Faden|medial rectus muscle recession (using the distance angle with correction) with posterior scleral fixation( Faden)
45793375|NCT00354965|Drug|amoxicillin/clavulanate potassium|amoxicillin/clavulanate potassium
45920864|NCT00400933|Behavioral|psycho-education|six session psycho-educational group program for family members and close friends of persons with eating disorders and co-morbid personality disorders
45920865|NCT00006395|Drug|St. John's Wort|
45449746|NCT02164474|Behavioral|High-Intensity Interval Training|Specifically, individuals randomized to HIIT will begin the intervention with four intervals lasting 1-minute each at ~85-90% peak oxygen uptake [VO2peak] and increasing to 10 X 1-min intervals by day 10 of the intervention. Individuals randomized to moderate-intensity exercise condition will begin the intervention with 20 minutes of continuous activity at ~55-60% V02peak and gradually increase the duration to 50 minutes by day 10 of the intervention.
45449747|NCT02162290|Other|Interval exercise training|Exercise bouts in low and high intensities
45449748|NCT02162290|Other|Continuous exercise training|
45449749|NCT02162524|Behavioral|Aerobic Exercise|The exercise groups will be closely monitored during exercise sessions for six months in our exercise-training laboratory. The intensity will be 65% VO2peak and all exercise will occur on a treadmill. One exercise group will obtain 8 KKW (kcal/kg/week) over 3-4 sessions per week, which will result in each session lasting approximately 30 minutes. The other exercise group will obtain 20 KKW, performing 4-5 sessions per week for approximately 50-70 minutes per session. These groups are combined for this ancillary study.
45449750|NCT03559257|Drug|Galcanezumab|Administered SC.
45449751|NCT03559257|Drug|Placebo|Administered SC.
45647730|NCT04976465|Drug|Anticoagulation|"Drug:~Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~Other Names: HCQ~Aspirin 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.~Other Names: Asp~Low molecular weight heparin Enoxaparin 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.~Other Names: LMWH"
45793376|NCT02037347|Drug|Palifermin|
45449752|NCT03540316|Combination Product|Two short implants and 2 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 2 short dental implants and LLLT for 2 minutes.
45449753|NCT03540316|Combination Product|Two short implants and 4 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 2 short dental implants and LLLT for 4 minutes.
45647731|NCT04976465|Drug|Without Anticoagulation|"Drug:~Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~Other Names: HCQ"
45920866|NCT04034511|Other|Medically-tailored meal delivery and medical nutrition therapy|Home-delivered, medically-tailored meals for 3 months combined with monthly individual medical nutrition therapy sessions for 6 months
45920867|NCT00400972|Device|GlideScope videolaryngoscope|
45920868|NCT00101257|Biological|therapeutic autologous lymphocytes|
45920869|NCT00101296|Drug|tipifarnib|Given orally
45920870|NCT00101296|Other|pharmacological study|Correlative studies
45920871|NCT00101296|Other|laboratory biomarker analysis|Correlative studies
45920872|NCT00006398|Drug|Timolol Maleate|
45920873|NCT00006398|Drug|Placebo|
45647732|NCT04970615|Device|Three-dimensional printed model|Three-dimensional printers are able to print physical objects in real size and colours. As a respresentative of the real tumor, a personalized three-dimensional model enables visualization of the patient-specific tumor and eloquent areas.
45793377|NCT02037425|Drug|onabotulinumtoxinA|BOTOX® (Formulation Number 9060X) contains 200 International Units (IU) of Clostridium botulinum Toxin Type A, reconstituted with 4 cc of normal saline providing 5 units per 0.1 cc. At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).
45793378|NCT02346461|Drug|ManNAc|At doses of 3 g and 6 g twice daily for a total dose of 6 and 12 g per day.
45793379|NCT02346461|Drug|ManNAc|At doses of 6 g twice daily (12 g per day).
45793380|NCT00355043|Drug|Zinc sulphate 20 mg|
45793381|NCT01349465|Drug|No treatment|No treatment was given to patients during this study as this is a follow-up study of previous Phase IIb or Phase III in which they received a TMC435-containing regimen.
45793382|NCT02414243|Other|New Amino Acid formula|Ordesa's Amino-Acid based Infant Formula
45647733|NCT04271293|Drug|Edoxaban|Edoxaban will be administered via PEG in patients who are eligible for the anticoagulant treatment according to the current guidelines.
45793383|NCT02414243|Other|Commercially available Amino Acid Formula|Commercially available Amino Acid Formula
45793384|NCT02037893|Drug|Antipyrine and Benzocaine otic solution|antipyrine 54 mg and benzocaine 14 mg
45793385|NCT02037893|Drug|Antipyrine Otic Solution|Antipyrine 54 mg and glycerine dehydrated to 1.0 mL
45793386|NCT02037893|Drug|Benzocaine Otic Solution|benzocaine 14 mg and glycerine dehydrated to 1.0 mL
45793387|NCT02037893|Drug|Placebo Otic solution|Placebo otic solution will be glycerin that is dehydrated
45793388|NCT02353091|Device|Remote Microphone Hearing Aids|The ear receivers connect wirelessly with the microphone being worn by the teacher within a range of 25m.
45793389|NCT04349033|Behavioral|Emotional Disclosure and Brain Education|Patients are interviewed about a number of aspects of their lives (stress, other illnesses, personality, adverse childhood experiences), and these are explored as part of education of the brain's role in their pain.
45793390|NCT04349033|Behavioral|Emotional Disclosure Only|Patients are interviewed about a number of aspects of their lives, but without brain education
45793391|NCT04349033|Behavioral|Pain Information Control|Patients are interviewed about their pain history and other basic, non-disclosure information about their health.
45793392|NCT02040077|Behavioral|Computer + Fluency|
45647734|NCT04208659|Procedure|Self-administration of auricular acupuncture without prosthesis|Participants will insert semi-permanent acupuncture needles in their ears without the guidance of a prosthesis
45647735|NCT04208659|Procedure|Self-administration of auricular acupuncture with prosthesis|The same participants who previous self-administered a standardized auricular acupuncture will be given custom-molded prostheses midway through the study to assess how much the prostheses facilitate insertion.
45647736|NCT03060239|Other|Near Infrared Spectroscopy|Use of the near-infrared-spectroscopy (NIRS) to explore the cortical mechanism by which this sleep disorder would allow a disappearance of parkinsonian signs at night
45647737|NCT03059927|Procedure|Knee arthroplasty, Cruciate retaining|Legion total knee arthroplasty implant component, Smith & Nephew, Cruciate Retaining design
45647738|NCT03059927|Procedure|Knee arthroplasty, Anterior stabilized|Legion total knee arthroplasty implant component, Smith & Nephew, Anterior Stabilized design
45647739|NCT03059927|Procedure|Knee arthroplasty, Posterior stabilized|Legion total knee arthroplasty implant component, Smith & Nephew, Posterior Stabilized design
45647740|NCT04848025|Device|Custom-designed tracheobronchial prostheses|Computer-assisted segmentation of airways and stent from CT data (AnatomikModeling) Fabrication of a mold and then a silicon stent by mold injection and sterilization (NOVATECH) Insertion of the stent under rigid bronchoscopy and general anesthesia
45793393|NCT02040077|Behavioral|Computer Only|
45793394|NCT02040077|Behavioral|Treatment as Usual|
45920874|NCT00101335|Drug|celecoxib|
45920875|NCT00101374|Drug|Leflunomide|
45449754|NCT03540316|Combination Product|Four short implants and 2 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 4 short dental implants and LLLT for 2 minutes.
45647741|NCT03059849|Drug|Adalimumab|Dose of adalimumab will be increased by 40mg every 2 weeks.
45647742|NCT04822441|Other|data collection|Ultrasound follow-up maternal dengue serology PCR (Polymerase Chain Reaction) and dengue serology of the umbilical cord
45647743|NCT04976075|Other|no interventions|no interventions
45793395|NCT02040623|Drug|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day
45793396|NCT02040623|Drug|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day
45793397|NCT02040623|Other|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution 2 drops per eye twice a day
45793398|NCT02041325|Drug|Lenalidomide|Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.
45793399|NCT02041325|Drug|Placebo|Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
45793400|NCT01723514|Drug|Erenumab|Administered by subcutaneous injection once a month
45793401|NCT01723514|Drug|Placebo|Administered by subcutaneous injection once a month
45793402|NCT02044367|Drug|Dabigatran etexilate|Pellets (multiple dose of dabigatran)
45793403|NCT02044367|Drug|Dabigatran etexilate|Granules resolved in reconstitution solution (multiple dose of dabigatran)
45793404|NCT02044367|Drug|Dabigatran etexilate|Hard capsule (multiple dose of dabigatran)
45920876|NCT00101491|Behavioral|Health Communication DVD video|Interactive, testimonial-based, stage of change-matched Health Communication DVD video interventions
45920877|NCT00006401|Drug|iNO|Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
45920878|NCT00006401|Other|Placebo|Inhaled Nitrogen
45920879|NCT00101569|Drug|Aripiprazole|Tablets, Oral, 15 -30 mg, once daily, 2 weeks (days 1 -14).
45920880|NCT00101569|Drug|Aripiprazole|Oral Solution, Oral, 15-30 ml, once daily, 1 week (days 15 -21).
45920881|NCT03991884|Drug|Etoposide|Given IV
45793405|NCT02044991|Drug|Corticosteroid|40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
45793406|NCT02044991|Drug|Placebo Injection|A placebo injection
45793407|NCT05719259|Other|VAP|To continuously evaluate VAP clinical and microbiological epidemiology in European ICUs
45793408|NCT01745822|Drug|tenofovir disoproxil fumarate|administration: tablet 300 mg, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum
45793409|NCT01745822|Drug|placebo|administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum
45647744|NCT04796701|Other|Follow-Home-intervention|x
45647745|NCT04156165|Dietary Supplement|VLCD-Active|Lighter life formula products supplied to subjects, four sachets pr day. Dietetic advise given regularly.
45793410|NCT05719181|Biological|rhBMP-2|Recombinant Human Bone Morphogenetic Protein-2 with an Absorbable Collagen Sponge .
45793411|NCT04122950|Behavioral|Exergaming|The participants in the Exergaming group will use the PlayPulse exergame for 45 minutes a minimum of three times per week for 8 weeks. Between 8 and 12 weeks the exergaming group will be provided with free access to the exergame but without the two mandatory exergaming sessions
45793412|NCT04002050|Behavioral|Cognitive Behavioural Therapy with Mindfulness Course|The Cognitive Behaviour Therapy with Mindfulness (CBTm) Course for Public Safety Personnel is a brief psychoeducational course consisting of 5 classes (90 minutes each) occurring on a weekly basis. The CBTm course addresses the fundamentals of CBT and provides participants with practical strategies for managing stress (such as relaxation strategies, cognitive restructuring, goal setting, behavioural activation, and exposure therapy).
45793413|NCT05718947|Diagnostic Test|Brain MRI (3T, 7T, 9.4T)|All patients will undergo anatomical brain imaging on a 3T, 7T and 9.4T MRI scanner within the same day at baseline and again 6 months later. An optimized protocol for every separate field strength will be run. Sequences will include at least T1-weighted, T2*-weighted and a T2 SPACE or FLAIR sequence. No intravenous contrast will be used.
45793414|NCT05718869|Procedure|Biospecimen Collection|Undergo blood sample collection
45647746|NCT04156165|Other|Maintenance-Active|Weight loss maintenance diet with high protein and low glycemic index and load, high in fiber and whole grain, daily including 150 g minced beef.
45647747|NCT04156165|Dietary Supplement|VLCD-Control|Lighter life VLCD products
45647748|NCT04156165|Other|Maintenance-Control|Weight loss maintenance diet with moderate protein and low glycemic index and load, high in fiber and whole grain, daily including 25 g minced beef.
45793415|NCT05718869|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
45793416|NCT05718869|Procedure|Computed Tomography|Undergo CT scan
45793417|NCT05718869|Biological|Tafasitamab|Given IV
45793418|NCT05718869|Drug|Zanubrutinib|Given PO
45793419|NCT02354339|Dietary Supplement|Irvingia gabonensis|Intervention will be administered 30 minutes before meals
45793420|NCT02354339|Other|Placebo|Intervention will be administered 30 minutes before meals
45793421|NCT01747850|Behavioral|Motivational Enhancement/Cognitive Behavioral Therapy|All participants will receive a combination of pharmacotherapy (Sativex or Placebo) associated with a weekly intervention of combined Motivational Enhancement Therapy and Cognitive Behavioral Therapy.
45793422|NCT01747850|Drug|Sativex|Study subjects will gradually increase the maximal allowed dose of Sativex starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The medication treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Spray that will be decreased by 50% to avoid abrupt withdrawal). Then exposure to medications will be stopped (so there will be a total of 12 weeks medication treatment exposure).
45793423|NCT01747850|Drug|Placebo spray|Study subjects will gradually increase the maximal allowed dose of Placebo starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The Placebo treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Placebo Spray that will be decreased by 50%). Then exposure to Placebo will be stopped (so there will be a total of 12 weeks Placebo treatment exposure).
45793424|NCT02046005|Behavioral|PRE-RA|Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) is an online tool that provides education about RA, collects data about demographics and behaviors, and presents personalized RA risk information.
45793425|NCT02046005|Behavioral|PRE-RA Plus|Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) is an online tool that provides education about RA, collects data about demographics and behaviors, and presents personalized RA risk information. In addition, participants in this arm receive education from a health educator.
45793426|NCT02046005|Behavioral|General Rheumatoid Arthritis Education|Participants will receive general information about signs and symptoms of rheumatoid arthritis.
45793427|NCT01747928|Other|dual-chamber syringe|dual-chamber syringe for mock injection
45793428|NCT02046317|Drug|Femoral Nerve Block|Femoral Nerve Block for isolated femur fractures
45920882|NCT03991884|Drug|Doxorubicin|Given IV
45647749|NCT04970693|Drug|Furmonertinib|The different dose of furmonertinib will be given according to the generation of EGFR-TKI used as the first-line therapy. The doses and target volume of radiotherapy will be decided according to the oligoprogressive sites.
45647750|NCT04131751|Diagnostic Test|Next generation sequencing|we will investigate the sensitivity and specificity of next generation sequencing as a diagnostic tool in ascites infections.
45647751|NCT04970069|Other|Video on analgesic education|A four minute video informing the patient about opioids.
45647752|NCT04970069|Other|Video on general perioperative education|A four minute video informing the patient about general perioperative process.
45647753|NCT04918537|Dietary Supplement|Walnuts|30g of plain walnuts in addition to habitual food intakes
45647754|NCT04970303|Drug|Methylphenidate|Retina or Concerta
45793429|NCT02046317|Device|Echogenic needle|The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.
45793430|NCT02046317|Device|Standard of care needle|The control group will receive ultrasound-guided femoral nerve block using standard of care needles.
45449755|NCT03540316|Combination Product|Four short implants and 4 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 4 short dental implants and LLLT for 4 minutes.
45793431|NCT02046317|Device|Ultrasound|"The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.~The control group will receive ultrasound-guided femoral nerve block using standard of care needles."
45920883|NCT03991884|Drug|Vincristine|Given IV
45920884|NCT03991884|Drug|Prednisone|Given PO or IV
45793432|NCT02355275|Procedure|Home Exercise Program|All patients will be provided with a Thera-Band® Loop and Band and handout describing home exercises to be performed 3 times a week for 4 weeks.
45793433|NCT02046863|Device|Automated Programming|Prototype DBS-Expert software will be used to guide a clinician through DBS programming.
46071641|NCT00830401|Procedure|Treatment of predefined abnormality by hysteroscopic surgery|"Polyp resection with Hysteroscopic scissors or Versapoint~Resection of myoma with Resectoscope Storz or Versapoint~Septum resection with Resectoscope Storz or Versapoint~Resection of adhesions with Hysteroscopic scissors or Versapoint"
45793434|NCT01727180|Other|Questionnaire based on the McGill Pain Questionnaire|Interview questionnaire based on the short form of the McGill Pain Questionnaire
45793435|NCT02046941|Behavioral|Speech Production Treatment|This treatment employs a response-contingent hierarchy made up of verbal modeling/repetition, graphic cueing, integral stimulation, and articulatory placement instruction.
45449756|NCT03726411|Procedure|non-surgical periodontal therapy|scaling and root planing
45449757|NCT03723993|Device|Inflated cuff|After patient being draped, applying cuff inflation will be done to the upper arm not having the arterial line inserted of about 200 mmHg or 15 mmHg above patient's systolic pressure 3 cycles 5 minutes each followed by 5 minutes of pressure relieve
45793436|NCT01727414|Drug|OROS-Methylphenidate and placebo for inattentive type pts|Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
45793437|NCT01727414|Drug|OROS-Methylphenidate and placebo for combined type pts|Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
45920885|NCT03991884|Drug|Cyclophosphamide|Given IV
45920886|NCT03991884|Biological|Inotuzumab Ozogamicin|Given IV
45920887|NCT00101725|Drug|crofelemer|
45920888|NCT04729036|Procedure|open reduction and internal fixation|The same surgical team have treated all the patients through open reduction via an intra-oral mucosal flap under general anesthesia with insertion and fixation of a 4-6 holes 2.0 miniplate and 5 mm screws at the superior border of the mandible at Champy's osteosynthesis line
45920889|NCT00101764|Drug|Triamcinolone Acetonide|
45920890|NCT00101803|Drug|vildagliptin|
45920891|NCT00101842|Drug|Pemetrexed|
45920892|NCT00101842|Drug|Gemcitabine|
45920893|NCT00101842|Drug|Platinol|
46071642|NCT00830401|Drug|Ofloxacinum/Doxycycline|Treatment of endometrial inflammation: Ofloxacinum 400mg/day or Doxycyline 2x100mg on day one, followed by 100mg/day during 8 days.
46071643|NCT04249908|Drug|Besifovir Dipivoxil Maleate|Besifovir 150 mg q.d.
45449758|NCT03723993|Device|Non inflated cuff|non inflated cuff around the arm for the control group
45449759|NCT02892513|Device|Percutaneous auricular neurostimulation|The Bridge device (manufactured by Key Electronics [Jeffersonville, IN, USA] and distributed by Innovative Health Solutions [Versailles, IN, USA]) provides continual neurostimulation for five days with alternating current.
45449760|NCT02892513|Device|Sham percutaneous auricular neurostimulation|Identical in appearance to active, device, but no stimulation will be given.
45647755|NCT03942835|Other|experience 1 : Competitive attention test in healthy participants|Comparison of behavioral measures (reaction times and percentage of correct responses) obtained twice with the CAT test in healthy participants (2 to 6 weeks apart).
45647756|NCT03942835|Other|experience 2 : Competitive attention test in patients with ADHD with no treatment|Behavioral (reaction times and percentage of correct responses) and Electroencephalography (EEG) measures obtained with the CAT test in patients with ADHD with no treatment.
45647757|NCT03942835|Other|experience 3 :Competitive attention test in patients with ADHD with psychostimulant treatment|Behavioral (reaction times and percentage of correct responses) and EEG measures obtained with the CAT test in patients with ADHD before and after psychostimulant treatment.
45920894|NCT00101881|Device|Defibrillation (biphasic versus monophasic shock)|Administration of monophasic or biphasic waveform defibrillation
45920895|NCT00101920|Drug|ABX-EGF|2.5 mg/kg by an infusion pump over one hour
45920896|NCT00101959|Drug|Rebif|
45920897|NCT00102037|Drug|eptacog alfa (activated)|
45920898|NCT03967470|Biological|Bacterial spray|Bacterial spray containing bacteria that do not cause underarm malodor
45920899|NCT00006413|Procedure|Stem cell transplantation|
45920900|NCT00102115|Drug|Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)|
45920901|NCT00102154|Drug|MK0928, gaboxadol / Duration of Treatment: 10 months|
45920902|NCT00102193|Device|Adacolumn Apheresis System|
45920903|NCT00102232|Procedure|supplementation with phosphatidylcholine|
45920904|NCT00102271|Drug|Oxypurinol|
45920905|NCT00102271|Drug|Sodium Nitrite|
45920906|NCT00102310|Drug|YM443|
45920907|NCT00006422|Procedure|current standard of care treatments|
45920908|NCT03955029|Other|Progressive Interval training|heating up 7 minutes at 15 watt, then alternating 30% of the maximum power reached by the patient at Vo2 max for 3 minutes and first peak at 40% of max power, second at 45%, third at 50%, fourth at 55 % and fifth to 60%, then return to calm 3 minutes at 15 watt. Total duration of the endurance session: 30 minutes. The powers of the peak will be modeled according to the Borg (if <6, increase by 5 watt the value of each peak at the next session).
45793438|NCT02047643|Device|Computer algorithm to initiate pump suspension|If the computer algorithm senses impending risk for hypoglycemia it sends an alert to an on-site physician to recommend a manual suspension of the subject's insulin pump
45449761|NCT03726255|Procedure|Mesenchymal Stem Cell injection|curettage, closure of the internal opening (IO) and cell injection in IO (50%) and fistula tract (50%)
45647758|NCT04975529|Behavioral|Game on Philly: Engaging Underserved Middle School Youth in Out-of- School Time Sports and Nutrition Education|Two-group quasi experimental intervention with schools assigned to intervention or comparison.
45449762|NCT03730857|Drug|Olanzapine|olanzapine tablet
45449763|NCT03730857|Drug|risperidone|risperidone tablet
45793439|NCT02048891|Drug|GnRH agonist trigger|
45793440|NCT02048891|Drug|hCG trigger|
45793441|NCT01727726|Drug|Brexpiprazole|tablet/capsule
45793442|NCT01727726|Drug|Seroquel XR|tablet/capsule
45449764|NCT03730857|Drug|Paliperidone|paliperidone tablet
45793443|NCT01727726|Drug|Placebo|tablet/capsule
45793444|NCT05718401|Device|NMR|nuclear magnetic resonance in genomics
45793445|NCT02355821|Drug|Moxonidine|0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
45793446|NCT02355821|Drug|Bisoprolol|5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
45793447|NCT02252744|Other|No intervention|
45793448|NCT00354575|Drug|Chinese Herb: CCH1|1.5/3.0/4.5gm powder per day for mild/moderate/severe constipation
45793449|NCT01748240|Drug|Azacitidine and oral vorinostat|In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.
45793450|NCT03935360|Other|Oakland-Jairath Risk Score|Oakland and Jairath developed a clinical prediction rule for safe discharge among patients with LGIB using data from their UK National Audit. They defined safe discharge as the absence of rebleeding, blood transfusion, need for endoscopic/radiologic/surgical intervention for hemostasis, readmission with LGIB, and death and developed a seven variable risk score: age, sex, previous history of LGIB admission, presence of blood on digital rectal exam, heart rate, systolic blood pressure, and hemoglobin. Using a cut-off score ≤8, they reported excellent discrimination (AUC 0.84, 95% CI 0.82-0.86), good calibration, and a 95% probability of safe discharge.
45793451|NCT02049749|Behavioral|Immediate CARE|CARE is a group parent training informed by the principles of Parent Child Interaction Therapy and was developed by Trauma Treatment Training Center and CHOP Policy Lab. CARE has been used in many populations including residential treatment center/domestic violence shelter staff, daycare providers, graduate students, biological parents, and foster parents/caseworkers. Goals are to decrease stress for caregivers, improve child behavior, and enhance the caregiver-child relationship, family stability, and wellness. The training teaches parents to follow a child's lead thus building a connection and promoting positive behaviors. The focus is on giving attention to child's pro-social behavior and ignoring minor misbehavior. The second phase teaches techniques for giving effective commands.
45793452|NCT04769180|Other|Evaluation of extraintestinal manifestations|The researchers evaluated the prevalence and kind of extraintestinal symptoms in NCWS patients and the possible relationship between the clinical, serological, genetic and histological characteristics of the NCWS patients and the number and kind of extraintestinal manifestations, using, as control groups, CD and IBS patients.
45920909|NCT03955029|Other|Conventional Interval training|warm up 7 minutes at 15 watt, then alternating between plateau at 30% of the max power reached by the patient at VO2 max for 3 minutes and peak at 60% for 1 minute, return to calm 3 minutes at 15 watts. Total duration of the endurance session: 30 minutes. The power of the peak will be modeled according to the Borg (if <6, increase by 5 watt the value of each peak at the next session)
45920910|NCT00102349|Behavioral|Behavior Therapy|
45449765|NCT03726177|Drug|aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
45793453|NCT01748942|Drug|Dexamethasone|Given IV
45647759|NCT04902547|Behavioral|Patient Education Workshop (PEWs)|The comprehensive workshops will include a combination of didactic and interactive content on general pain and opioid education (1 hour workshop session to be co-presented by Drs Ryan Amadeo and Dana Turcotte) along with significant psychological content (co-presented by Drs Brigitte Sabourin and Gregg Tkachuk) making up the remainder of the day-long workshop. Content presented in PEWs will include opioid-related risks, identifying personal motivation for (or barriers to) tapering, goal setting, pain self-management, sleep hygiene and comprehensive focus on ACT and rethinking pain. During the interprofessionally co-facilitated sessions, participants will be provided with workbooks that will contain session specific content as well as take-home activities and information for their own personal use.
45793454|NCT01748942|Drug|Dexamethasone|Given PO
45793455|NCT01748942|Other|Placebo|Given PO
45793456|NCT01748942|Procedure|Quality-of-Life Assessment|Ancillary studies
45920911|NCT00102388|Drug|vildagliptin|
45920912|NCT00102388|Drug|Gliclazide|
45920913|NCT00102427|Behavioral|Telephone-based collaborative care management|
45920914|NCT03947307|Device|lymphtaping using Easytape®|lymphtaping using Easytape® on day 1 after surgery by specifically trained physiotherapists. If possible the taping will be left for 7 days.
45920915|NCT03947307|Procedure|compression treatment|manual lymphatic drainage followed by compression treatment using compressive stockings or compressive bandaging
45449766|NCT03726177|Drug|aspirin 81 mg|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first
45449767|NCT03726177|Drug|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
45449768|NCT03723837|Biological|Inactivated Polio Vaccine (IPV)|Children receive one or two doses of IPV based on study arm they fall in
45449769|NCT03726099|Drug|esomeprazole, amoxicillin, furazolidone，tetracycline|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day concomitant therapy containing esomeprazole 40mg bid, amoxicillin 1000mg bid , furazolidone 100mg bid and tetracycline 500mg qid.
45793457|NCT01748942|Other|Questionnaire Administration|Ancillary studies
45793458|NCT01748942|Procedure|Transoral Robotic Surgery|Undergo TORS
45793459|NCT02050841|Biological|octaplas|Octaplas S/D Plasma
45793460|NCT02355977|Drug|minocycline|Periocline dental ointment
45793461|NCT02355977|Procedure|surface and root planning|surface and root planning
45793462|NCT01749410|Biological|onabotulinumtoxinA|Previous treatment with onabotulinumtoxinA for Chronic Migraine.
45793463|NCT04769336|Device|Central Lab based CBC|lab samples will be sent to the central lab for CBC analysis
45793464|NCT04769336|Device|Point of Care CBC|lab samples will be analyzed at point of care
45793465|NCT02359955|Device|zero degree teeth|zero degree teeth complete denture was first prescribed to patients in group 1 while patients in group 2 were treated with anatomic teeth complete denture
45793466|NCT02359955|Device|anatomic teeth|when anatomic teeth complete denture was prescribed to patients in group 1, patients in group 2 were treated with zero degree teeth complete denture
45793467|NCT01729598|Drug|Valproic Acid|generic valproic acid tablets packaged in placebo-matched capsules.
45793468|NCT01729598|Drug|Placebo|Placebo capsule without active study medication in identical capsules as experimental medicine.
45793469|NCT05718089|Other|Continuous aerobic exercise|"The Continuous aerobic exercise session will be performed in total two times, as it will be repeated in sets on consecutive weeks (e.g. Two Tuesdays in a row) with a 1-week wash-out period. The  Continuous aerobic exercise intervention is matched to the other arms on the time spend for each bout equating a total of 50 minutes of exercise per session.~An oral glucose tolerance test will be performed 24 hours and 48 hours after the exercise bout."
45647760|NCT04902547|Procedure|Multidisciplinary Tapering Program|"The MTP will begin with a Baseline Tapering Visit and will include the same baseline health and well-being questionnaires, a medication review, relevant pain history, relevant opioid use history, discussion re: patient-specific tapering and functional goals, taper start date, and determination if a different opioid formulation will be required for the taper. A detailed taper plan will be prepared and reviewed by the study clinician(s) and provided to the patient. In general, tapers will begin with a 10% reduction of dose every 2 weeks until ⅓ of the original dose is met, or until taper goal has been met. If further tapering is planned once the patient reaches ⅓ of their original dose, the taper will be reduced to half the volume and rate noted above in order to improve tapering success.~Tapering plans and approaches may be changed (slowed, increased, halted etc.) based on follow up."
45793470|NCT05718089|Other|High intensity interval training|"The High intensity interval training session will be performed in total two times, as it will be repeated in sets on consecutive weeks (e.g. Two Tuesdays in a row) with a 1-week wash-out period. The High intensity interval training intervention is matched to the other arms on the time spend for each bout equating a total of 50 minutes of exercise per session.~An oral glucose tolerance test will be performed 24 hours and 48 hours after the exercise bout."
45793471|NCT05718089|Other|Resistance training|"The Resistance training session will be performed in total two times, as it will be repeated in sets on consecutive weeks (e.g. Two Tuesdays in a row) with a 1-week wash-out period. The Resistance training intervention is matched to the other arms on the time spend for each bout equating a total of 50 minutes of exercise per session.~An oral glucose tolerance test will be performed 24 hours and 48 hours after the exercise bout."
45793472|NCT05718011|Drug|Dexmedetomidine|0.5 micrograms/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
45920916|NCT03947307|Device|sham taping|sham taping with Leukotape® Classic, a non-elastic tape, that in all other respects resembles Easytape®.
45920917|NCT00102505|Drug|Motexafin Gadolinium Injection|
45793473|NCT05718011|Drug|Ketamine|0.5 milligrams/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
45793474|NCT05717933|Diagnostic Test|thyroid hormones|Thyroid function among pediatric patients with type1 diabetes mellitus at the first presentation, from patients' characteristics to disease severity
45793475|NCT01730846|Drug|Doxazosin 4mg/day|4 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
45793476|NCT01730846|Drug|Placebo|Placebo
45793477|NCT01730846|Drug|Doxazosin 8mg/day|8 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
45793478|NCT04348799|Other|BPD|It is a observation research.we didn't intervene anything.
45793479|NCT02314403|Drug|Belatacept|A selective T-cell (lymphocyte) costimulation blocker
45793480|NCT02314403|Drug|ATG|A T-Cell Depleting Agent
45793481|NCT02314403|Drug|Rituximab|B-Cell Depleting Agent
45793482|NCT02314403|Radiation|Total Body Irradiation|
45793483|NCT02314403|Radiation|Thymic Irradiation|
45793484|NCT02314403|Procedure|Combined Bone Marrow/Kidney Transplantation|
45793485|NCT03870230|Device|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT
45793486|NCT03870230|Device|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device
45920918|NCT00102583|Drug|Subconjunctival Cyclosporine Implant|
45793487|NCT03870230|Device|Pattern Electroretinography (pERG)|to assess the neuronal function of the retina, pattern ERG will be performed
45793488|NCT03870230|Device|Optical coherence tomography (OCT)|to assess the morphology of the retina, OCT will be performed
45793489|NCT03870230|Device|Laser Speckle Flowgraphy (LSFG)|to assess retinal blood flow, LSFG will be performed
45793490|NCT02052557|Drug|Bupivacaine|30ml of bupivacaine were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
45793491|NCT02052557|Drug|Bupivacaine liposome suspension|30ml of Bupivacaine liposome injectable suspension were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
45920919|NCT00102622|Biological|Intraperitoneal tgDCC-E1A|Starting Dose Level: 1.8 mg DNA/m^2 intraperitoneal every 7 days +/- 2 days for a total of 6 treatments each cycle.
45920920|NCT00102622|Drug|Paclitaxel|80 mg/m^2 intravenous (IV) every 7 days +/- 2 days for a total of 6 treatments.
45920921|NCT00006428|Drug|Amitriptyline|
46071644|NCT00830713|Procedure|Melanocyte-keratinocyte transplantation procedure (MKTP)|skin pigment cells are taken from areas of normal skin and placed on areas of that same person's body which have lost their color.
45647761|NCT04975685|Behavioral|SMART|SMART (Strengthening Mental Abilities Through Relational Training) is a web-based cognitive training program that directly trains 'relational skills' - skills necessary to understand how concepts relate to one another, which underpin complex cognition.
45793492|NCT02052635|Drug|ticagrelor|Single loading dose of 180mg of ticagrelor at time of bivalirudin administration. Beginning 12 hrs following study drug administration, all pts in the ticagrelor arm will receive ticagrelor 90 mg (maintenance dose) approximately every 12 hrs until Follow-up telephone contact.
45793493|NCT02052635|Drug|clopidogrel|Single loading oral dose of 600 mg of clopidogrel will be given at time of bivalirudin administration. Beginning 4 hrs following study drug administration, all pts in the clopidorgrel arm will receive ticagrelor 180 mg for the loading dose, followed by 90 mg maintenance dose approximately every 12 hours until the Follow-up telephone contact.
45793494|NCT01732718|Drug|Atorvastatin|40 mg tablet by mouth daily for 6 weeks
45793495|NCT01732718|Drug|Placebo|Matching placebo tablet by mouth daily for 6 weeks
45793496|NCT02053259|Behavioral|Adaptive Goals|
45793497|NCT02053259|Behavioral|Reinforcement|
45793498|NCT02053259|Behavioral|Static Goals|
45793499|NCT05317520|Procedure|Cold vapor|"The Ramsey Sedation Scale was used to assess wakefulness after patients were extubated and arrived at the recovery unit at the 0th hour postoperatively. Sore throat, localization of pain, hoarseness, dry throat, and swallowing difficulty were evaluated in patients with a score of 2 according to this scale. Sore throat of the patients was evaluated with Numerical Rating Scale. Then, cold vapor was applied for 15 minutes with a vapor machine used as a standard in the hospital by the researcher. After the cold vapor application was finished, the patients' sore throat, localization of pain, hoarseness, swallowing difficulty and dry throat were re-evaluated with the same forms.~Sore throat were evaluated before the application of cold vapor at the 2nd and 6th hours. Then cold vapor was applied for 15 minutes. After the cold vapor application was finished, sore throat were re-evaluated.~At the 24th hour, cold vapor was not applied to the patients. Only sore throat were evaluated."
45793500|NCT02362373|Drug|levonorgestrel IUS|placement of levonorgestrel intrauterine system
45793501|NCT02363621|Drug|Ranibizumab 0.3 mg|Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg
45793502|NCT02363621|Drug|Aflibercept 2.0 mg|Patient will receive intravitreal injection of Aflibercept 2.0 mg
45793503|NCT01749956|Radiation|Radiation|
45793504|NCT01749956|Drug|Aflibercept|
45793505|NCT01749956|Procedure|Surgery|Abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines
45793506|NCT01749956|Drug|FOLFOX6|
45793507|NCT02363933|Drug|Perampanel|Perampanel is a highly selective non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type glutamate receptor antagonist that has shown efficacy in a randomized phase III study for refractory partial-onset seizures
45793508|NCT05537051|Drug|PM1021, PM8001|Participants will be administered with PM1021 on Part A Day 1. Participants will be administered with PM1021 and PM8001 on Part B Day 1. PM1021 and PM8001 combination therapy administrated every 3 weeks from Part C Day 1 until disease progression, intolerable toxicity, until the patient withdraws/is withdrawn, or study completion.
45793509|NCT03868904|Device|OCS Lung System|No active interventions are part of this study. This study will collect long-term survival and BOS data in subjects who were part of the INSPIRE trial.
45793510|NCT02365961|Drug|ropivicaine|
45793511|NCT02365961|Drug|clonidine|
45793512|NCT02365961|Drug|Epinephrine|
45793513|NCT02365961|Drug|Noropin|
45793514|NCT05532059|Drug|Lenvatinib, tislelizumab, gemcitabine and cisplatin|Lenvatinib, tislelizumab, gemcitabine and cisplatin
45793515|NCT05532059|Drug|gemcitabine and cisplatin|gemcitabine and cisplatin
45793516|NCT03809234|Drug|Ondansetron 8mg with Saline & Tariquidar|Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
45793517|NCT03809234|Drug|Ondansetron 16mg with Saline & Tariquidar|Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
45647762|NCT04975685|Behavioral|Sham brain training (Sudoku)|Sudoku was selected to control for expectancy effects based on popular conceptions that it broadly improves cognitive functions, coupled with little evidence supporting this notion, and its use as an active control in similar trials.
45647763|NCT04880161|Biological|Ampion|Inhaled Ampion
45647764|NCT04880161|Other|Placebo|Inhaled Placebo
45793518|NCT05525039|Device|Low-magnitude High-frequency Vibration|0.3g, 35Hz, 20mins/day, at least 3 times/week
45793519|NCT05525039|Dietary Supplement|β-hydroxy β-methylbutyrate (HMB) supplement|Oral nutritional HMB supplement at 3g/day
45793520|NCT05525039|Dietary Supplement|Protein supplement|Daily protein supplement intake
45793521|NCT05317130|Other|Athlete health monitoring|Observational study
45793522|NCT05316974|Other|Prevalence of lymphoedema|Measures of lymphoedema
45793523|NCT00355433|Procedure|Urodymanics|
45793524|NCT03754244|Drug|TQB3456|Observe the safety and pk when the subjects take TQB3456 p.o. qd
45793525|NCT03711188|Drug|Nivolumab|Nivolumab is to be administered as a 3 mg/kg IV infusion every two weeks in accordance with the prescribing information.
45793526|NCT03711188|Drug|Ipilimumab|Ipilimumab, when used as subsequent treatment for patients in cohort B, is to be administered as a 3 mg/kg IV infusion over 90 minutes every three weeks for a maximum of 4 doses, in accordance with the prescribing information.
45793527|NCT03711188|Drug|IMM-101|A single 0.1 mL intradermal injection of IMM 101 (10 mg/mL) given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
45793528|NCT05316818|Drug|FOLFOXIRI Protocol|Triplet chemotherapy regimen consists from active three cytotoxic agents aiming to improve outcomes
45793529|NCT05316740|Other|No intervention|Repeated clinical evaluation and sample collection
46071645|NCT02837796|Procedure|transobturator tape|
45793530|NCT02366663|Radiation|90-Yttrium Ibritumomab tiuxetan|0.4 mCi/kg given IV
45793531|NCT02366663|Drug|Carmustine|Given IV
45647765|NCT04969679|Drug|E. coli Nissle 1917 (Mutaflor®)|Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)
45793532|NCT02366663|Drug|Etoposide|Given IV
45793533|NCT02366663|Drug|Cytarabine|Given IV
45793534|NCT02366663|Drug|Melphalan|Given IV
45793535|NCT02366663|Procedure|Autologous Hematopoietic Stem Cell Transplant|Autologous Hematopoietic Stem Cell Transplantation (ASCT)
45793536|NCT02366663|Biological|Rituximab|Given IV
45793537|NCT01754480|Biological|Fibrin Sealant Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin, in separate syringes assembled on a syringe holder (6 mL of solution in total), applied topically to the target bleeding site.
45793538|NCT01754480|Device|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
45793539|NCT05524961|Device|Bright light therapy|Regularly-timed exposure to 10,000lux bright light therapy for 60minutes a day for six weeks
45793540|NCT05524961|Device|Inactivated negative ion generator|Regularly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
45793541|NCT05524961|Device|Inactivated negative ion generator|Randomly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
45793542|NCT02367599|Drug|Vitamin D Supplement|Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks.
45793543|NCT02368457|Drug|Pentoxifylline and Tocopherol|pentoxifylline with tocopherol Pentoxifylline 800 mg/day, oral (1cp 400 mg twice a day) + Vitamin E (alfa-tocopherol) 1000 UI/day, oral (1cp 400UI twice a day + 1cp200UI once a day) during 24 months (maximum).
45793544|NCT01754714|Drug|SAMe 1000 mg|1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner
45647766|NCT04969679|Drug|Placebo|Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)
45647767|NCT04969757|Device|Predigraft group|"Patients in the interventional arm will use Predigraft (Class 1 medical device under MDD 93/42/EEC Cibiltech Society) to receive therapeutic education content (videos, facts sheets, short messages, questionnaires), exchange documents with their doctors and interact via messaging with them.~Physicians will be able to calculate their iBox score to predict their patients' allograft survival at 3, 5 and 7 years."
45793545|NCT01754714|Drug|SAMe 1500 mg|1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner
45793546|NCT01754714|Drug|SAMe 2000 mg|2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner
45793547|NCT02370407|Device|a laparoscopic simulator (Fundamentals of Laparoscopic Surgery (FLS), VT Medical Inc, Waltham, MA)|10 repetitions of practice on laparoscopic simulator.
45793548|NCT02370407|Device|Mimic da Vinci robotic simulator|10 repetitions of practice on Mimic da Vinci robotic simulator.
45793549|NCT03649958|Device|HIRREM-SOP or Cereset|HIRREM-SOP for ten 90 minute sessions
45920922|NCT00102661|Drug|Campath-1H|15 mg daily infused over 24 hours, continuous infusion x 7 days (Days 1 through 7). Each 15 mg dose prepared daily, immediately prior to starting the infusion. Starting day 10, CAMPATH-1H administered at dose of 30 mg subcutaneously three times weekly for 11 additional weeks.
45920923|NCT03923049|Diagnostic Test|hybrid PET/MRI|On the day of the procedure, subjects will undergo a PET scan followed by MRI scan.
45920924|NCT00102700|Drug|ARQ 501 in combination with gemcitabine|
45920925|NCT00102739|Drug|SB497115|
45920926|NCT00006431|Biological|DC RCC-RNA|
45920927|NCT00102778|Drug|GW873140|
45920928|NCT00102778|Drug|Kaletra (lopinavir/ritonavir)|
45920929|NCT03900429|Drug|MGL-3196|Tablet
45647768|NCT04432259|Drug|Dexamethasone|4 mg bid for 4 days
45647769|NCT04432259|Drug|Placebo|oral placebo
45647770|NCT03933085|Behavioral|Memory Support System (MSS)|A calendar/notetaking system focused on training a person with MCI to use a specific external memory compensatory strategy to complete relevant IADLs independently.
45647771|NCT04969523|Procedure|lobectomy|Intravenous es-ketamine 0.5mg/kg or saline during lobectomy
45793550|NCT03649958|Device|Cereset 2x|Cereset 2x for five 90 minute sessions
45793551|NCT05500391|Other|Oncological Follow-up|Post-cancer surveillance (including biological, clinical and imaging exams depending on the condition)
45793552|NCT01756976|Device|OrthoPat Advance|The device will be used initially in hysterectomy procedures. After a confirmation of product quality, the device will be used in routine orthopedic procedures.
45793553|NCT02371187|Drug|Dapagliflozin|Dapagliflozin tablets, 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
45793554|NCT02371187|Drug|Placebo|Matching placebo for Dapagliflozin 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
45793555|NCT02373137|Procedure|DSAEK|
45793556|NCT02373137|Procedure|DMEK|
45793557|NCT02373137|Device|Endoserter|The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.
45793558|NCT02373137|Drug|Prednisolone|Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
45793559|NCT02373137|Drug|Ofloxacin|Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
45793560|NCT02373137|Drug|Tropicamide|Tropicamide is a prescription drug used to dilate pupils during an eye exam.
45793561|NCT02373137|Drug|Phenylephrine|Phenylephrine is a prescription drug used to dilate pupils during an eye exam.
45793562|NCT02373137|Device|Jones Tube|The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.
45793563|NCT01757678|Procedure|ICA (Invasive Coronary Angiography)|Per the protocol, patients will have an Invasive Coronary Angiography.
45793564|NCT01757678|Procedure|FFR (Fractional Flow Reserve)|Per the protocol, patients will have a Fractional Flow Reserve procedure.
45793565|NCT01757678|Procedure|cCTA (coronary computed tomography angiography)|Per the protocol, patients will have a coronary computed tomography angiography.
45647772|NCT03578107|Behavioral|improvement of quality of stroke care|"hospital tool kits for quality improvement of reperfusion therapy ;~organizational stakeholder and opinion leader meetings;~data monitoring and feedback reports；~webinar for hospital teams"
45647773|NCT03059771|Behavioral|Mobile Enhancement of Motivation (MEMS)|The MEMS group will engage in a goal-setting session and then receive personalized text-messages to support goal attainment.
45647774|NCT03059771|Behavioral|Control|The control group will only engage in a goal-setting session.
45793566|NCT01757678|Other|FFRct Analysis (Fractional Flow Reserve Computed Tomography)|Per the protocol, patients will have a fractional flow reserve computed tomography.
45793567|NCT05316272|Behavioral|Exercise|Supervised bone-loading exercise on 3 days per week for 36 weeks
45793568|NCT05316272|Dietary Supplement|DHEA|DHEA in pill form 50 milligrams taken daily for 36 weeks
45793569|NCT05488067|Drug|atorvastatin|Oral atorvastatin treatment for ALGS children with xanthoma
45793570|NCT05316038|Diagnostic Test|Oral glucose tolerance test|The test is performed on an empty stomach for at least 10 hours. The first blood sugar level is taken on an empty stomach. Then ingestion of 75g of sugar. A second blood test takes place 1 hour after the sugar intake and the third blood sugar test takes place 2 hours after the sugar intake.
45793571|NCT02373371|Drug|Metvix®|
45793572|NCT02373371|Procedure|Photodynamic Therapy Blue light|Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug
45793573|NCT02373371|Procedure|Photodynamic Therapy Daylight|Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug
45793574|NCT01759160|Procedure|Marsh Plasma TCI with high initial target|plasma target-controlled infusion in Marsh model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
45647775|NCT03918031|Behavioral|PFI for Smoking & Distress Tolerance|Personalized Feedback Intervention for smoking and distress tolerance.
45647776|NCT03918031|Behavioral|PFI for Smoking Only|Personalized Feedback Intervention for smoking only (no distress tolerance component)
45793575|NCT01759160|Procedure|Schnider Plasma TCI with high initial target|plasma target-controlled infusion in Schnider model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
45647777|NCT03059693|Drug|HAT1 topical cream|
45647778|NCT03059693|Drug|Vehicle cream|
45647779|NCT05090683|Behavioral|Mind-body mobile application|Self-directed; Study team will recommend daily use of mobile app for 6 weeks with a minimum of 4 times/week usage of mobile app for 6 weeks. Frequency will be monitored via weekly surveys.
45793576|NCT00354653|Drug|LAMIVUDINE|
45793577|NCT05458739|Device|ClearCoast MR System|The removed specimen is scanned using the ClearCoast MR System.
45793578|NCT00354731|Drug|pentoxifylline|Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M
45793579|NCT00354731|Drug|Corticosteroid|Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
45793580|NCT03461978|Device|Ultrahigh resolution Spectral Domain OCT|A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
45793581|NCT00354809|Drug|GW679769|
45793582|NCT05455775|Device|Camera-based monitoring technology|Unobtrusive, vital sign measurement with remote photoplethysmography and laser speckle vibrometry
45793583|NCT04769492|Other|#ChopViolence/#ChopHIV|Tailored, community-based violence prevention intervention
45793584|NCT02979275|Procedure|Open heart surgery on cardiopulmonary bypass.|Brain oximetry and tissue saturation will be measured during operation. NGAL, cystatin-C, and Acute Kidney Injury Network (AKIN) criteria of AKI will be assessed durin first post-op day.
45647780|NCT04964219|Drug|S-ketamine|"After anesthesia induction, a bolus of 0.15 mg/kg S-ketamine is injected intravenously about 30 min before incision; this is followed by a continuous infusion at a rate of 0.15 mg/kg/h until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 25 mg, dexmedetomidine 100 microgram, and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
45647781|NCT04964219|Drug|Placebo|"After anesthesia induction, a bolus of placebo (normal saline) in the same volume is injected intravenously about 30 min before incision; this is followed by a continuous infusion of placebo at the same rate until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with placebo, dexmedetomidine 100 microgram and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
45647782|NCT04529395|Other|Blending of essential oils|The mixture of essential oils will be applied to the arch of the foot by massage every 8 hours (3 times a day, 6 drops per application with 3 drops per foot).
45793585|NCT03423758|Other|Blood sample|Blood sample
45793586|NCT05435339|Biological|GEN1053|GEN1053 will be administered as an intravenous (IV) infusion every 3rd week. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
45793587|NCT04769258|Biological|Pfizer Comirnaty vaccine|COVID 19 vaccines administered to the patients according to the times and modalities established by the Italian National Vaccination Plan. Further vaccines will be evaluated if and when they are available in Italy during the study period.
45793588|NCT02376179|Device|Cuffed ETT|
45920930|NCT03900429|Drug|Placebo|Matching Tablets
45920931|NCT00006434|Biological|tumor-pulsed dendritic cells|
45920932|NCT00102817|Drug|somatropin|
45793589|NCT01762904|Other|Bacterial culture of the prepared skin's areas with two antiseptics and two controls|Cultures will be taken with a scrub-cup of 5 cm2 of internal area pressed over the skin previously prepared with the substances, then it added a 3 mL of culture broth (D/E Neutralizing Broth, Difco TM) containing a neutralizing agent as washing solution. The skin will scrub with a sterile rubber policeman for 1 minute and the procedure will be conducted once again. Both aliquots will gather together in a sterile tube, and a sample of 50 microliters will spread in a plate containing a neutralizing agar (D/E neutralizing Agar, Difco TM) and incubate at 35°C for 24 hrs. After incubation, the colonies will be counted.
45793590|NCT01762904|Other|Preparing skin's areas to be tested with two antiseptics and two controls|All volunteers will be provided with a neutral soap and shampoo without antiseptics for use during a period of two weeks (phase of stabilization of the skin flora). Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 1% triclosan in 70% isopropyl alcohol) and two controls (Scrub the skin without prior application of any substance and Deionized water redistilled) will be tested as skin antiseptics. The intervention consists of preparing four skin's areas with antiseptics and controls, two in each arm of the volunteer. These ones were approximately 25 cm2 on the forearm for each antiseptic or control. The substances will be applied in an outward circular motion using a sterile swab soaked with the solutions. The solution will remain on the skin for 60 seconds, 3 hours and 24 hours before the bacterial culture will be conducted. For the control where it will be does not apply any substance, the scrub starts immediately.
45793591|NCT02376257|Drug|250 mg DCS|Drug
45647783|NCT04529395|Other|Apricot vegetable oil|The apricot vegetable oil will be applied to the arch of the foot by massage every 8 hours (3 times a day, 6 drops per application with 3 drops per foot).
45793592|NCT02376257|Drug|100 mg Modafinil|Drug
45793593|NCT02376257|Drug|Placebo|Drug
45647784|NCT04975451|Drug|Anlotinib|Anlotinib plus DCb
45793594|NCT01762982|Drug|0.13% Benzalkonium Chloride|Finn Chamber filled with benzalkonium chloride (0.13%) disinfectant spray water solution
45793595|NCT01762982|Drug|SLS Solution|Finn Chamber filled with SLS (0.3% w/v) water solution
45793596|NCT01762982|Drug|Normal Saline Water|Finn Chamber filled with Normal Saline water (0.9% w/v)
45793597|NCT01762982|Other|Empty Finn Chamber|Empty Finn Chamber
45793598|NCT05315492|Behavioral|Community Care Consortium (CCC)|The intervention will train community health workers to take an active role in the drug control and addiction service delivery in the community.
45647785|NCT04437043|Other|quality of life questionnaires|pain will be recorded in rest and activity (VAS) and patients will complete the quality of life questionnaires (CCS, BIQ). Also, the intake of analgesic medication will be registered. A clinical examination is conducted to evaluate the occurrence of seroma and to evaluate recurrence, defined as a protrusion of the contents of the abdominal cavity or preperitoneal fat through the defect, which is no longer covered by the mesh.
45647786|NCT04432337|Procedure|The role of the activation of the NLRP3 inflammasome after cardiac surgery|Determine the effect on the inflammatory response post extracorporeal circulation mediated by the NLRP3 inflammasome, in patients after cardiac surgery
45647787|NCT04975373|Drug|Intrauterine injection of hyaluronic acid|operative hysteroscopy - as a part of treatment in cases with retained placenta after delivery diagnostic hysteroscopy - as a routine evaluation after removal of placenta
45647788|NCT04974983|Other|Observation of neurological deficits|Observation of neurological deficits
45647789|NCT04975061|Drug|YY-20394|YY-20394 is a small molecule inhibitor.
45793599|NCT02990780|Radiation|Conventionally fractionated concurrent chemo-radiotherapy|5Fx/W,2Gy/Fx,Dt:PTV-G:60Gy/30F/6W.
45793600|NCT02990780|Radiation|Accelerated hypofractionated concurrent chemo-radiotherapy|5Fx/W,2.5Gy/Fx,Dt:PTV-G:55Gy/22F/4.4W.
45793601|NCT02990234|Procedure|Capsular Repair|
45793602|NCT02990234|Procedure|No Capsular Repair|
45793603|NCT03211286|Drug|Tranexamic Acid|1 g of intravenous tranexamic acid in 100 mL of saline solution
46071646|NCT00825721|Drug|LiquiTears|4 drops applied daily for 360 days
45647790|NCT04968977|Procedure|PCI vs. CABG|PCI vs. CABG
45647791|NCT04968665|Diagnostic Test|gait testing, functional MRI|diagnostic tests including the gait testing and functional MRI
45647792|NCT04963829|Biological|gel combined with lemongrass (Cymbopogon citratus) oil at 0.1% concentration|It is a gel that was used in chronic ulcers healing
45647793|NCT04963829|Biological|Collagenase ointment|Participants who were subjected to a standardized treatment (collagenase ointment)
45647794|NCT04963829|Biological|Gel with 10% peel powder of unripe banana|Participants who used a gel made of 10% peel powder of unripe banana (M. sapientum),
45793604|NCT03211286|Drug|Saline Solution|saline solution 100 mL intravenous
45793605|NCT01763606|Drug|Enoxaparin|Patients will be receive 6 months of subcutaneous enoxaparin (1 mg/kg BID with a maximum starting dose of 100 mg BID. Patients who weigh more than 100 kg will start at a dose of 100 mg BID; their subsequent dosing will be guided by hematology and may change.
45793606|NCT01763606|Drug|Aspirin|Patients will receive 6 months of oral aspirin (81 mg per day unless a higher dose is preferred by study physicians although the maximum acceptable dose will be 325 mg per day).
45793607|NCT05315180|Drug|BPI-421286|Characterize the pharmacokinetics (PK)，safety，effcicay of BPI-421286 following administration as an oral Tablet formulation
45793608|NCT03161756|Drug|Denosumab|Denosumab is a fully human monoclonal immunoglobulin type 2 (IgG2) antibody that binds with high affinity and specificity to RANK ligand (RANKL) and neutralises the activity of human RANKL, similar to the action of endogenous osteoprotegerin (OPG). Denosumab binding prevents the activation of RANK and inhibits the formation, activation, and survival of osteoclasts. As a consequence, bone resorption and cancer-induced bone destruction are reduced.
45793609|NCT03161756|Drug|Nivolumab|Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab inhibits the interaction of PD-1 with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation and interferon-gamma (IFN-γ) release in vitro.
46071647|NCT00825721|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
46071648|NCT00825721|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
46071649|NCT00825721|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
46071650|NCT02837640|Drug|levodopa-carbidopa|sinemet 200/50 1/2 tablet b.i.d. for 2 days and then t.i.d for 6 months
45647795|NCT04963985|Drug|Tafamidis Pill|Oral
45793610|NCT03161756|Drug|Ipilimumab|Ipilimumab is a fully human monoclonal immunoglobulin specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4), which is expressed on a subset of activated T cells. Ipilimumab is a monoclonal antibody(mAb) that binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, cluster of differentiation antigen 80 / cluster of differentiation antigen 86 (CD80 / CD86). Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor-infiltrating T-effector cells.
45647796|NCT04974905|Procedure|retrograde access for re-canalization of infra-inguinal arterial occlusive disease|after failed antegrade approach for re-canalization of infra-inguinal arterial occlusive disease( failed reentry into the distal true lumen), the retrograde approach will be attempted
45793611|NCT01765712|Procedure|Anterior Cruciate ligament reconstruction bone patellar tendon bone autograft|
45793612|NCT01765712|Biological|Platelet Rich Plasma|
45793613|NCT02378207|Biological|H4:IC31|H4 contains Mtb antigens Ag85B and TB10.4
45793614|NCT02378207|Biological|H56:IC31|H56 contains Mtb antigens ESAT-6, and Rv2660c
45647797|NCT01669577|Procedure|analysis of blood samples and clinical features|clinical follow up and biochemical analysis blood at 4 time points:1-prehospital; 2-emergency room; 3- surgical center; 4-intensive care unit . 30 days follow up
45647798|NCT04974827|Drug|Camrelizumab|200mg/3weeks
45647799|NCT04974827|Drug|Cisplatin or Carboplatin|Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
45793615|NCT02378207|Biological|BCG|
45793616|NCT02378207|Biological|Control Sodium Chloride 0.9%|
45793617|NCT01766024|Drug|Interferon beta-1a|Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.
45793618|NCT05404295|Other|Umbilical cord blood platelel lysate gel|For the treatment group, a gel from Umbilical cord blood platelel lysat will be applied in the ulcer, and then a few layers of sterile gauze, and non-compressible bandage will be used to cover the wound/ulcer area.
45793619|NCT00355511|Behavioral|education: disease, medication, self-care, diet|education on heart failure self care; medication initiation and titration, frequent follow-up
45793620|NCT01766102|Procedure|Intra-operative Mammography|The patient's breast specimen will be imaged in the operating room in an intra-operative imaging device - Biovision SN #30042
45793621|NCT01766102|Procedure|Standard Mammography|There is not an added device associated with this arm.
45793622|NCT05301920|Device|Elexir (trigeminal nerve electrical stimulator)|Elexir performs a personal electrical stimulation around the trigeminal nerves for 4weeks (6 times/week), 20 minutes each time.
45793623|NCT05297084|Procedure|non surgical periodontal therapy|Scaling and root planing
45793624|NCT05296850|Other|Manual Release|Individuals are placed in the prone position with their knees extended. The calcaneus is kept in eversion while maintaining talocrural dorsiflexion. As the toes are stretched in dorsiflexion, the therapist slides the big toe distally and proximally along the plantar fascia and flexor hallucis longus. Soft tissue mobilization depth will be applied according to the patient's tolerance and reactivity.
45793625|NCT05296850|Other|Kinesio Taping|"In the first technique, an I tape will be applied on the plantar surface of the foot from the metatarsal heads to the popliteal fossa. First, the middle of the band is attached to the inferior of the calcaneus as the first anchor, then the ankle is dorsiflexed and the upper part of the band is applied with 15-25% tension until the popliteal fossa. The plantar fascia is placed in a stretched position by dorsiflexing the ankle and fingers, and the ends of the tape, which is divided into 4 parts, are applied separately to the metatarsal heads with 75-100% tension. In the second technique, the application is made with an I tape. The initial anchor starts from the dorsal aspect of the 5th metatarsal on the lateral aspect of the foot. Then, the tape passes to the medial side of the foot with 75-100% tension and is adhered to the medial side of the foot and ankle over the navicular. The end anchor is applied without tension."
45793626|NCT04351022|Biological|CART-38|Split intravenous infusion of CART-38 cells [dose escalating infusion of (5-20)x10^6 CART-38 cells/kg].
45920933|NCT00101998|Drug|alvimopan|
45920934|NCT00101998|Drug|placebo|
45920935|NCT00102856|Drug|Pramipexole|
45920936|NCT00102856|Drug|Rivastigmine|
45647800|NCT04963595|Drug|Pyrotinib|400 mg once daily
45920937|NCT00102895|Drug|CP-724,714|
45920938|NCT00401050|Procedure|chiropractic manipulative therapy|
45647801|NCT04963595|Drug|Vinorelbine|Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsules on day 1 to be taken at the hospital, and on day 8 at home.
45647802|NCT04963595|Drug|Inetetamab|8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
45920939|NCT00401050|Procedure|knee exercises|
45920940|NCT00401050|Procedure|Graston Instrument Soft Tissue Mobilization (GISTM)|
45920941|NCT02805855|Drug|Autologous Adipose-Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices (cGMPs).
45647803|NCT03061721|Drug|Saroglitazar magnesium 1 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.
45647804|NCT03061721|Drug|Saroglitazar magnesium 2 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.
45647805|NCT03061721|Drug|Saroglitazar magnesium 4 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.
45920942|NCT00401089|Drug|Panax Ginseng|The standardized extract of Panax Ginseng was formulated by Boehringer Ingelheim Pharmaton, Switzerland and fulfills the criteria of cGMP. Quality control and safety are monitored regularly by Boehringer Ingelheim Pharmaton.
45920943|NCT00102934|Drug|Enfuvirtide-intensified HAART|90 mg tablet taken orally twice daily
45920944|NCT00006443|Drug|Indinavir sulfate|
45920945|NCT00006443|Drug|Nelfinavir mesylate|
45920946|NCT00006443|Drug|Lamivudine|
45920947|NCT00006443|Drug|Stavudine|
45920948|NCT00102973|Drug|TLK286 in Combination with Carboplatin|Experimental Arm
45920949|NCT00102973|Drug|Doxorubicin HCl Liposome Injection|Active Comparator
45793627|NCT05252936|Other|COVID-19 vaccine social media campaign exposure|A series of animated video clips will be promoted through Facebook Ads and randomized at the individual level across Facebook users throughout the entire country. To investigate the effectiveness of Mayan language content, we are testing three treatment arms - visually identical videos in the 1) Spanish, 2) K'iche', and 3) Kaqchikel languages. The videos are visually identical and follow the same audio script, translated into the three focal language. Local voiceover artists were used to record the scripts in the three languages. A control group that is not exposed to any of the social media campaign content will serve as active comparator to allow for comparison of outcomes with treatment arms.
45920950|NCT02739087|Procedure|MRI guided cardiac catheterization|Magnetic resonance imaging will be used to guide cardiac catheterization procedures whenever possible to avoid or minimize x-ray radiation exposure.
45920951|NCT02739087|Device|Magnetic resonance imaging|
45920952|NCT00006446|Procedure|Training in parenting skills and communication|
45920953|NCT00103051|Drug|cisplatin|
45449770|NCT03723759|Drug|Faster Aspart 200 U/mL|A single dose (0.15 U/kg) of five formulations of fast-acting insulin aspart 200 U/mL (formulations A, B, C, D, E) in a sequential manner via subcutaneous injection.
45449771|NCT03723759|Drug|Faster aspart 100 U/mL|A single dose (0.15 U/kg) of fast-acting insulin aspart 100 U/mL via subcutaneous injection.
45647806|NCT03061721|Drug|Placebos|Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.
45647807|NCT04963907|Device|Active Alpha-Stim CES|Active Alpha-Stim devices will be randomly assigned to participants for use daily for 8 weeks.
45647808|NCT04963907|Device|Sham Alpha-Stim CES|Sham Alpha-Stim devices will be randomly assigned to participants for use daily for 8 weeks.
45647809|NCT04963127|Diagnostic Test|Computed Tomography of the skeleton using a Dual-Energy-/Multi-Energy-/Spectral acquisition mode|CT acquisition using a Dual-Energy / Multi-Energy / Spectral acquisition mode
45647810|NCT04963127|Diagnostic Test|Computed Tomography of the skeleton using a conventional single-energy / non-spectral acquisition mode|CT acquisition using a standard single energy / non-spectral acquisition mode
45647811|NCT04963361|Other|patients were exposed to fear of movement|Patients completed the questionnaires independently
45647812|NCT04963361|Other|patients were not exposed to fear of movement|Patients completed the questionnaires independently
45647813|NCT04968431|Other|2D Echocardiography|Mitral valve area will be determined by 2 D echo-Doppler methods
45647814|NCT04968431|Other|3D Echocardiography|Patients included in the study will undergo 3D Echo after being evaluated with 2D Echo. Mitral valve area will be determined by real time 3D.
45647815|NCT03061019|Procedure|Oral Myofunctional Therapy with exercices|Oral-Motor training of oral muscles (tongue, lips) associated with nasal hygiene with daily repetition of exercices and parental support.
45647816|NCT03061019|Procedure|Oral Myofunctional Therapy with soft oral appliance|Ora-Motor training of oral muscles (tongue, lips) associated with nasal hygiene, with reduced parental support.
45647817|NCT04968509|Drug|PCSK9 inhibitor and Statin|Patients in experimental group were treated with PCSK9 inhibitors (140mg with Evolocumab or 75mg with Alirocumab subcutaneously every two weeks) and conventional intensive lipid-lowering therapy(Atorvastatin 40-80mg or Rosuvastatin 20-40mg or Atorvastatin 20mg+ Ezetimibe 10mg or Rosuvastatin 10mg+ Ezetimibe 10mg).
45793628|NCT05229068|Biological|RSV MAT|Single 120 µg dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
45793629|NCT02378753|Biological|rVSVΔG-ZEBOV|The rVSVΔG-ZEBOV vaccine is comprised of a single recombinant VSV isolate (11481 nontypeable) modified to replace the gene encoding the G envelope GP with the gene encoding the envelope GP from ZEBOV (Kikwit, 1995 strain).
45920954|NCT00103051|Drug|gefitinib|
45920955|NCT00103051|Drug|gemcitabine hydrochloride|
45920956|NCT00103051|Procedure|conventional surgery|
45920957|NCT00103051|Procedure|neoadjuvant therapy|
45920958|NCT00103168|Drug|imatinib mesylate|400 mg/day for 2 years
45920959|NCT02697474|Biological|Euvax B®: Hepatitis B vaccine|0.5 mL, Intramuscular
45920960|NCT02697474|Biological|Euvax B®: Hepatitis B vaccine|0.5 mL, Intramuscular
45449772|NCT03558555|Drug|Acetaminophen IV Soln|1000mg of IV acetaminophen
45449773|NCT03558555|Drug|Oral Acetaminophen|oral acetaminophen 975mg pills
45449774|NCT03558555|Drug|Placebo Pills|placebo match to acetaminophen
45449775|NCT03558555|Drug|Saline|Intravenous saline
45449776|NCT03726021|Drug|Irinotecan,Oxaliplatin, and S1|"Drug: Irinotecan is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.~Drug: Oxalipatin Oxaliplatin is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells~Drug: S1 is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells"
45449777|NCT03730779|Drug|Hyperoxia|Patients will receive nocturnal normobaric hyperoxia therapy
45449778|NCT03725943|Diagnostic Test|Dreem|Dreem Band to be worn by each participant while undergoing in-lab sleep study with PSG.
45449779|NCT03541317|Behavioral|Stage 1 Strategy: REP|Schools will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; and ongoing technical assistance in CBT implementation.
45647818|NCT04968509|Drug|Statin|Patients in control group were only treated with conventional intensive lipid-lowering therapy(Atorvastatin 40-80mg or Rosuvastatin 20-40mg or Atorvastatin 20mg+ Ezetimibe 10mg or Rosuvastatin 10mg+ Ezetimibe 10mg).
45647819|NCT04955015|Procedure|carotid endarterectomy|patients with carotid atherosclerosis refering to CEA
45647820|NCT04963049|Other|Protocol with Mask|Look at differences in group with facemask and no mask
45920961|NCT00103246|Drug|silicon phthalocyanine 4|Participants receive topical silicon phthalocyanine 4 (Pc 4). One hour later, participants undergo photodynamic therapy. Treatment repeats weekly for up to 3 weeks (up to 3 total treatments for the same lesion OR up to 3 lesions treated if multiple lesions are present).Cohorts of 3 participants receive escalating doses of Pc 4 and visible light until the maximum tolerated dose (MTD) is determined.
45920962|NCT00103324|Drug|lapatinib ditosylate|Given orally
45920963|NCT00103324|Other|laboratory biomarker analysis|Correlative studies
45920964|NCT00103363|Other|cytology specimen collection procedure|
45920965|NCT00103363|Other|physiologic testing|
45793630|NCT02990936|Other|Tumor delineation|Measurement of tumor volume and neck nodes volume on a diagnostic CT and a pre-treatment CT by computerized delineation in order to calculate tumor growth velocity and tumor doubling time and describe tumoral kinetics patterns
45793631|NCT01767506|Other|Surveillance and treatment with azithromycin of newcomer and traveler families|The intervention is a surveillance for newcomers and travelers in communities, and provision of azithromycin to them at the time of arrival, in advance of scheduled mass drug administration
45793632|NCT01767506|Other|Usual care|Scheduled mass drug administration (MDA) of azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.
45793633|NCT02381015|Genetic|Genetic Risk Score: Number Format|Genetic Risk Score: Number + Pictograph Genetic risk score based on validated panel of 46 single nucleotide polymorphisms previously identified to be associated with Prostate Cancer risk by Genome Wide Association Studies, presented to subjects as a number.
45793634|NCT02381015|Genetic|Genetic Risk Score: Number + Pictograph|Genetic Risk Score: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
45793635|NCT02381015|Behavioral|Family History: Number Format|Family History: Number Format Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
45793636|NCT02381015|Behavioral|Family History: Number + Pictograph|Family History: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
45647821|NCT04968041|Behavioral|Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program|The intervention using strategies from motivational interviewing and cognitive behavioral therapy to promote motivation and adherence to ketogenic nutrition in older adults at high risk for Alzheimer's disease. The program is a 6-week, group program led by a psychologist and nutrition expert.
45793637|NCT05370209|Device|Otinova® Ear Spray|Ear spray
45793638|NCT05365997|Other|Default Nudge|For patients whose clinician pods are randomized to the intervention arm, the care team pod will receive a message indicating that the patient is eligible for palliative care and that a default referral order has been pended for that patient. Clinicians will be given an opportunity to respond if they do not want their patient to be referred to palliative care. For clinicians who do not respond, after the allotted time, the Clinical Research Coordinator will reach out to the patient to introduce palliative care and ask if staff can schedule an appointment. For clinicians who respond no, the pended order will be removed and no patient contact by the research team will occur.
45793639|NCT02383043|Drug|Cocaine|
45647822|NCT03060941|Behavioral|Physical activity education|Participants will be given educational materials on how to increase physical activity levels.
45793640|NCT02383043|Drug|Sustained Release d-Amphetamine|
45647823|NCT03060941|Behavioral|Facility access|Participants will receive at 6 month membership to a local fitness facility.
45793641|NCT05176808|Behavioral|Early Achievements- Parent Coaching Intervention|Children, along with a caregiver, will be randomized into one of two conditions to receive parent coaching guided by NDBI principles.
45793642|NCT01768520|Drug|Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks|"morning : 1 tab. of active Entelon 150mg plus 1 cap. of placebo Celebrex~evening : 1 tab. of active Entelon 150mg"
45793643|NCT01768520|Drug|Celebrex cap. (celecoxib 200mg) : once daily, for 12 weeks|"morning : 1 tab. of placebo Entelon 150mg + 1 cap. of active Celebrex~evening : 1 tab. of placebo Entelon 150mg"
45793644|NCT01768520|Drug|Placebo|"morning : 1 tab. of placebo Entelon 150mg + 1 cap. of placebo Celebrex~evening : 1 tab. of placebo Entelon 150mg"
45793645|NCT05346965|Behavioral|Musical training|The musical training intervention comprised songs, rhythm and visual creativity to encourage the children to experience music-making as fun.
45793646|NCT01768832|Behavioral|Treadmill|
45793647|NCT01768832|Behavioral|Tango|
45793648|NCT01768832|Behavioral|Stretching|
45793649|NCT00355589|Drug|Ramipril and hydrochlorothiazide|
45793650|NCT01769222|Biological|Ipilimumab|Given intratumorally
45793651|NCT01769222|Radiation|Radiation therapy|Undergo local radiation therapy, 10 Gy x 3 fractions
45793652|NCT02383667|Device|Electrocardiogram holter|
45793653|NCT02386319|Drug|Melatonin|Gelatin capsules
45793654|NCT02386319|Drug|Placebo|Placebo capsules
45920966|NCT00103363|Procedure|annual screening|
45920967|NCT00103363|Procedure|study of high risk factors|
45920968|NCT00103519|Drug|DITPA (3,5-diiodothyropropionic acid)|
45920969|NCT00103519|Drug|Placebo|Placebo
45920970|NCT00103597|Drug|Fludrocortisone|
45920971|NCT00103597|Drug|Domperidone|
45647824|NCT03060941|Behavioral|Supervised exercise sessions|Participants will attend weekly supervised exercise sessions with an exercise interventionist.
45647825|NCT03060941|Behavioral|Self-monitoring (Fitbit)|Participants will be given a Fitbit to monitor their physical activity levels.
45647826|NCT03060941|Behavioral|Active living counseling|Participants will attend 12 biweekly educational sessions about how to increase their physical activity levels.
45793655|NCT05164562|Other|Data collection|Description: musculoskeletal disorders of upper limb evaluation
45793656|NCT02979353|Behavioral|Shed-Meds: A Patient-Centered Deprescribing Intervention|The goal of the intervention is to safely deprescribe medications, as defined by dose reductions and stopped medications, based on a combination of clinical criteria and patient preferences.
45920972|NCT00103597|Behavioral|Conservative Measures for Orthostatic Hypotension|
45920973|NCT00006449|Drug|naltrexone (Revia)|
45920974|NCT00006449|Behavioral|broad spectrum treatment|
45920975|NCT00006449|Behavioral|motivational enhancement therapy|
45920976|NCT00103636|Procedure|Extending peripheral intravenous (IV) cannula dwell times|
45920977|NCT00103675|Procedure|Acupuncture|
45920978|NCT00103714|Drug|denufosol tetrasodium (INS37217)|
45920979|NCT00103753|Drug|deferiprone|
45920980|NCT00006452|Drug|motexafin gadolinium|
45920981|NCT00006452|Radiation|radiation therapy|
45793657|NCT02240888|Biological|0,5 mg Prevenar i.m.|
45793658|NCT02240888|Biological|0,5 mg seasonal influenza vaccine i.m.|
45793659|NCT05129306|Other|Observational|In this observational study, participants with moderate to severe Allergic Rhinitis who were initiated on Ryaltris® nasal spray by their healthcare professional will complete an online survey before commencement of treatment and then at days 1, 7, and 14 from treatment initiation. Survey completion at day 28 after treatment initiation will be optional for participants based on ongoing use of RYALTRIS®.
45647827|NCT04962425|Drug|Trastuzumab|Trastuzumab [Herceptin] is a recombinant DNA-humanized monoclonal antibody that selectively targets the HER-2 receptor on the surface of tumor cells.
45647828|NCT04962269|Diagnostic Test|MRI|monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model
45793660|NCT05128994|Device|User-controlled FES system|Wearable FES sleeve with non-invasive user controls
45793661|NCT01769612|Other|No Intervention|
45793662|NCT02387801|Drug|Ixekizumab|Administered SC
45793663|NCT01770314|Behavioral|Experimental|Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.
45793664|NCT05295953|Device|TBS|Four sessions of TBS at 120 % resting motor threshold, delivered using MagVenture B65 A/P coil, each lasting 10 minutes and separated by 50 minutes intervals. Targeting will be done using neuronavigation and processed resting state brain scan.
45793665|NCT05295953|Device|Sham TMS|Four sessions of sham TMS delivered using MagVenture B65 A/P coil.
45793666|NCT05289791|Other|ultrasonic activation of bioceramic sealer|activation of bioceramic sealer using ultrasonic tip for 20 seconds in buccolingual and mesiodistal direction
45793667|NCT02259608|Biological|BCG vaccine SSI|BCG vaccination
45793668|NCT05284097|Drug|Ad26.ZEBOV, MVA-BN-Filo|"Ad26.ZEBOV - is an adenovirus serotype 26 vector expressing the glycoprotein (GP) of the Ebola virus (EBOV) Mayinga variant~MVA-BN-Filo - is a Modified Vaccinia Ankara (MVA) - Bavarian Nordic (BN) vector expressing the GPs of EBOV, Sudan virus (SUDV) and Marburg virus (MARV) and the nucleoprotein of Tai Forest virus"
45793669|NCT02326844|Drug|BMN 673 (talazoparib)|1 mg by mouth (p.o.) once daily on 28-day cycles until disease progression
45793670|NCT02548676|Device|Optical angiography based on OCT|This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
45793671|NCT05283629|Behavioral|Neuroplasticity-based Computerized Cognitive Remediation|"Behavioral: Neuroplasticity-based Computerized Cognitive Remediation The nCCR has two major components: Bottom up and Top down training.~Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
45793672|NCT05283629|Behavioral|Education Control Condition|The education control condition is a learning-based approach that utilizes DVDs on history, art, science, etc. This active condition is comparable to nCCR in length of exposure, audio-visual presentation, computer use and contact with research staff.
45793673|NCT02533154|Drug|Prosicca|Prosicca eyedrops Dosage: on demand Route of administration: topical
45793674|NCT02533154|Drug|Prosicca sine|Prosicca sine eyedrops Dosage: on demand Route of administration: topical
45793675|NCT02533154|Other|Bacterial culture|bacterial cultures obtained with conjunctival swabs
45647829|NCT03060707|Drug|Rocuronium Bromide|Continuously infuse, or bolus administer rocuronium.
45647830|NCT03060863|Behavioral|2. Executive Functioning|Interventions will occur in 3 biweekly visits plus technology-based practice. The investigators will use computer-based working memory training to improve Executive Functioning (EF) and will use a working memory training game that has been used with children this age (N-back task).
45647831|NCT03060863|Behavioral|3. Food Bias|The investigators will use attention-bias retraining techniques that have been tested in adults that have children practice approach and avoidance attentional strategies using a joystick and food images (healthy and unhealthy foods). Interventions will occur in 3 biweekly visits. Children in this arm will use a computer-based approach avoidance task to reduce attentional biases for food by using a joystick to push away images of nonhealthy foods and pull closer images of healthy foods.
45793676|NCT02388815|Device|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System masked for 14 days.~During these 14 days subjects will be asked to perform 4 blood glucose tests (meals time and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed."
45793677|NCT02239874|Dietary Supplement|Vitamin D and fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
45793678|NCT02239874|Dietary Supplement|Fish oil and vitamin D placebo|840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
45793679|NCT02239874|Dietary Supplement|Vitamin D placebo and fish oil placebo|placebo
45793680|NCT02239874|Dietary Supplement|Vitamin D and fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
45793681|NCT01771952|Device|Synvisc-One™|A single 6cc injection of Synvisc-One™ will be utilized in this study.
45793682|NCT01771952|Other|Sham Treatment|A single needle stick without arthrocentesis or injection.
45920982|NCT00103792|Drug|mycophenolate mofetil|2000 mg mycophenolate per day combined with steroids for induction remission, followed by azathioprine standard maintenance therapy
45920983|NCT00103792|Drug|cyclophosphamide|2 mg/kg/d, combined with steroids, for remission induction, followed by standard azathioprine maintenance therapy
45793683|NCT01772654|Device|Arterial Spin Labeled (ASL) MRI sequence|"The Arterial Spin Labeled (ASL) MRI sequence is an MRI technique in which arterial blood undergoes spatially selective inversion to label the arterial blood.~This is a magnetic technique and does not require contrast. The tagged blood is imaged and areas of hypoperfusion or hyperperfusion are revealed on the MRI sequence."
45793684|NCT02389361|Drug|Zaldiar|Postoperative analgesia with oral Zaldiar (combination of tramadol and paracetamol)
45793685|NCT02389361|Drug|Paracetamol-Tramadol|Postoperative analgesia with intravenous Paracetamol and Tramadol
45793686|NCT02251496|Other|In between meals snacks (Snacks-group)|In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
45647832|NCT03060863|Behavioral|4. Emotion Regulation|Interventions will occur in 3 biweekly visits plus home practice. The investigators will use assisted relaxation training where children are trained to monitor and control their heart rate and skin conductance using biofeedback in a computer-game context (Journey to Wild Divine).
45793687|NCT02251496|Other|Oral nutrition supplement (ONS-group)|The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
45793688|NCT05266001|Drug|GM-CSF|same as arm/group description
45793689|NCT05266001|Other|Placebo|same as arm/group description
45793690|NCT02251886|Other|Moxibustion in primiparae|Number of primiparae participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment
45793691|NCT02251886|Other|Moxibustion in multiparae|"Number of multiparae participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment"
45793692|NCT00421655|Drug|Grazax|Tablets 75,000 SQT and matching placebo. One tablet daily.
45793693|NCT02391701|Behavioral|Diet|diet program 1 day a month for 3 months in 120-minute diet sessions + freely receive Atlantic Diet food (vegetables, cheese, olive oil, mussels and wine)
46071651|NCT02548663|Other|Sport therapy|"Frequency: 60 min three times/week~20 min: aerobic training on bicycle ergometer.~20 min: strength training at 60% of maximal load.~20 min: proprioception and stretching exercises."
46071652|NCT02548663|Other|Osteopathic treatment|Frequency: 60 min weekly
46071653|NCT02837718|Procedure|bupivakain % 0,5|Bupivacaine 0,5% The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
45647833|NCT03060863|Behavioral|5. Future orientation|"Interventions will occur in 3 biweekly visits. Children will participate in an interview protocol designed to enhance their capacity to visualize upcoming future events and describe them in detail, with the goal to make the future become present."
45647834|NCT04953533|Other|no intervention|
45647835|NCT04967417|Drug|Pemetrexed, Carboplatin, Pembrolizumab|"Pemetrexed 500mg/m2~Carboplatin AUC 5.0~Pembrolizumab 200mg"
45647836|NCT04967417|Drug|Paclitaxel, Carboplatin, Pembrolizumab|"Paclitaxel 200mg/m2~Caboplatin AUC 6.0~Pembrolizumab 200mg"
45647837|NCT04966949|Procedure|lateral prostate capsule sparing or neurovascular bundles sparing|When resect the bladder and prostate, the lateral prostate capsule or neurovascular bundles will be preserved.
45793694|NCT05257499|Behavioral|On line debriefing|Online Debriefing in the Simulation Sessions of the Helping Babies Breathe Course
45793695|NCT02252354|Drug|[14C]-TAK-385 Oral Solution|TAK-385 oral radiolabelled solution
45793696|NCT02252354|Drug|TAK-385 Tablets|TAK-385 tablets 2 X 40 mg
45793697|NCT02252354|Drug|[14C]-TAK-385 Solution for Intravenous Infusion|TAK-385 intravenous (IV) radiolabelled solution
45793698|NCT05250869|Diagnostic Test|HPLC/MS|Quantification of MTX and its metabolites by HPLC/MS under various preanalytical conditions
45793699|NCT02393339|Drug|paracetamol|Pre-operative administration of Paracetamol syrup
45793700|NCT02393339|Drug|placebo|Pre-operative administration of placebo syrup
45793701|NCT05093660|Diagnostic Test|Blood specimen collection|Blood specimen collection for analysis of CRP (C-reactive protein), WBC (White blood cells) and LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels
45793702|NCT05093660|Diagnostic Test|Saliva specimen collection|Saliva specimen collection for analysis of LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels
45793703|NCT05235191|Drug|methadone tablets|The intervention with the active drug (methadone) will start with the dose of 1 tablet (5 mg) twice a day (every 12 hours) and titrated on subsequent visits up to the maximum dose of 6 tablets a day (totaling 30 mg divided into 2 daily doses to facilitate therapeutic adherence).
45793704|NCT05235191|Drug|Placebo|In this arm patients will take placebo tablets (the same number, color and physical aspects as the methadone tablets).
46071654|NCT02834442|Drug|MT-7117|
46071655|NCT02834442|Drug|Placebo|
46071656|NCT02834208|Other|MRI (Magnetic resonance imaging)|
46071657|NCT02834208|Genetic|Polymorphism (SNP in DNA)|
46071658|NCT02834208|Genetic|quantitative measures of mRNA|
46071659|NCT02834208|Other|Neuropsychological assessment|
46071660|NCT02834286|Drug|Rituximab|Rituximab 100 mg weekly days 1, 7, 14, 21
46071661|NCT02834286|Drug|Eltrombopag|Eltrombopag 50 mg PO days 1-28
46071662|NCT02834286|Drug|Dexamethasone|Dexamethasone 40 mg IV/PO days 1-4
45793705|NCT05072990|Drug|Chinese herb medicine|Patients took 200 ml Chinese herb decoction twice a day before breakfast and dinner.
45793706|NCT05066204|Other|Sequence of teaching-/learningmethod|see: arm/group descriptions
45793707|NCT01774604|Drug|Indomethacin|100 mg Indomethacin PR x 1
45793708|NCT01774604|Drug|Placebo|
45793709|NCT01774760|Drug|18F-EF5|
45793710|NCT01774760|Procedure|Pretreatment PET/CT-scan (performed two times)|
45793711|NCT02989922|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
45793712|NCT01775774|Biological|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
45793713|NCT02393417|Biological|CANDIN|Candida albicans Skin Test Antigen for Cellular Hypersensitivity
45647838|NCT04432103|Biological|Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients|Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 severe cases.
45647839|NCT04432103|Biological|Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients|Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 critical cases.
45647840|NCT02658175|Drug|Volanesorsen|300 mg volanesorsen administered via SC injection.
45647841|NCT03060005|Drug|Tears Naturale Forte|This medication is used to relieve dry, irritated eyes
45793714|NCT02393417|Other|Placebo|0.9% Sodium Chloride Injection USP (non-preserved)
45793715|NCT01775852|Behavioral|ACT-IM|1 hour discussion about migraine management (IM) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). IM covers symptoms and triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
45793716|NCT01776632|Behavioral|Physical activity|Promotoras led 6 free physical activity (PA) classes per week (2 walking groups, 2 cardio dance, and 2 strength training) at participating churches randomized to the intervention condition. Classes included prayer, warm-up, moderate-to-vigorous PA, cool-down, followed by discussion of a monthly health handout. Participants received copies of the handouts each month by mail, which promoted healthy PA habits. Promotoras conducted up to 5 motivational interviewing calls with each participant over the 2-year intervention using a guide to evaluate participants' PA engagement, barriers to being active, and solutions to those barriers. Promotoras advocated for changes to the social and built environments of the churches and surrounding neighborhoods in order to promote PA and healthy behaviors.
45793717|NCT01776632|Behavioral|Cancer screening|Promotoras provided a 6-session group-based workshop series on cancer screening and prevention (breast, cervical, colorectal, and skin cancers) at participating churches randomized to the attention-control condition. Participants received informational handouts developed by American Cancer Society and the National Cancer Institute to reinforce learning in addition to lists of local cancer screening resources. Promotoras conducted up to 4 motivational interviewing calls with each participant over the 2-year intervention to encourage screening, help overcome barriers to screening, and provide support for goals.
45793718|NCT05209061|Other|Biopsy|Participants included in the study, will have a full thickness biopsy of the middle of the appendix taken, after the resected bowel has been removed during surgery.
45793719|NCT01777412|Drug|Bevacizumab|
45793720|NCT04912895|Device|PneumoniaCheck|Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
45793721|NCT01777568|Drug|30% oxygen|Inspired oxygen will be maintained at 30%.
45793722|NCT01777568|Drug|80% oxygen|Inspired oxygen will be maintained at 30%.
45793723|NCT05200013|Biological|BAT7104|Symmetric IgG-like AntiPD-L1/CD47 Bispecific Antibody Solution for Injection BAT7104 injection available in 100 mg/2 mL (50 mg/mL) dosage
45793724|NCT05184023|Device|Pulse Electromagnetic Field|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions.
45793725|NCT05184023|Device|Sham Pulse Electromagnetic Field|Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions.
45793726|NCT02236910|Other|Lu-DOTA-TATE|
45647842|NCT03060005|Drug|liposic|Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.
45793727|NCT05173883|Drug|injection ，CU-20401|Subcutaneous injection，cohort A 6 sites
45793728|NCT05173883|Drug|injection ，placebo|Subcutaneous injection，just one site
45793729|NCT02166788|Procedure|Inguinal Lymphadenectomy|
45793730|NCT02166788|Procedure|Ilio-inguinal Lymphadenectomy|
45793731|NCT05166707|Device|BIXINK OC Free|OC Free is a 6-week ERP-based intervention to deliver Exposure and Response Prevention (ERP) to reduce the anxiety from obsessive thoughts and compulsive rituals.
45793732|NCT02057588|Procedure|LV pacing site|Patient will be paced in VVI mode from Left ventricle specific position for a short period of time per position in order to cover spontaneous ventricular activity
45793733|NCT05159297|Other|Reference values|Normative reference values of coordination tests will be obtained
45793734|NCT05153837|Other|saline intravenous administration|Administration of 500 mL of saline (NaCl 0.9%) administered by the venous route
45793735|NCT05153837|Other|oral water|500 ml oral water
46071663|NCT02837562|Other|Slit lamp eye examination|All participants in the trial will undergo a slit lamp eye examination
45647843|NCT04966715|Procedure|Epigastric lymph node biopsy|epigastric lymph node biopsy and analysis to evaluate rate dissemination of colorectal carcinomatosis by this way
45647844|NCT02774785|Device|MarginProbe|Surgery to take place as per standard care. When the surgery is nearly concluded, patient to be randomised. If randomised to device arm, the MarginProbe device will be used on the outer edge of the tumour and shavings. If the MarginProbe device indicates that cancer is detected, a further shaving is to be taken. Surgery then to be concluded as per standard care.
45647845|NCT04953455|Other|no intervention|no intervention
45647846|NCT03234361|Dietary Supplement|High Phosphate Phase|2 capsules of sodium phosphate with 500mg/day of phosphate.
45793736|NCT04911335|Combination Product|Faringel plus and oral hygiene|The expected frequency of administration of the study product is 2 / day, 10 minutes 'before main meals, for patients without mucositis (grade 1 according to the OAG scale, total score = 8). The frequency of administration will increase to 3 / day for patients with mild or moderate mucositis (grade 2 on the OAG scale, total score 9-18) and up to 4 / day in cases of severe mucositis (grade 3 on the OAG scale, score total 19-24). Each administration will contain 7 ml of oral suspension, to be kept inside the oral cavity for 1-2 minutes and then swallowed slowly.
45793737|NCT04899167|Other|MRI 1.5T and 3.0T|Magnetic Resonance Imaging for Renal Fibrosis
45793738|NCT05136755|Drug|NMDAE|Use of an NMDA enhancer for the treatment of antidepressant nonresponders with MDD
45647847|NCT03234361|Dietary Supplement|Low Phosphate Phase|2 capsules of sodium chloride.
45647848|NCT04953299|Behavioral|Functional Imagery training|Behavioural intervention focused upon motivation and reaching achievable goals.
45647849|NCT04953299|Behavioral|NHS 12 week weight loss programme|The plan is designed to help individuals lose weight at a safe rate of 0.5kg to 1kg (1lb to 2lb) each week by sticking to a daily calorie allowance and introducing exercise.
45647850|NCT04210141|Biological|lyophilized BPI viper antivenom|Antivenom
45647851|NCT04962191|Diagnostic Test|Idylla EGFR Mutation Test|This diagnostic test is performed on the BioCartis Idylla System for qualitative detection of exon mutations.
45793739|NCT05136755|Drug|Placebo Cap|Use of placebo as a comparator
45793740|NCT01809548|Other|Early intervention group|solid food will be introduced between week 10 and 12
45647852|NCT04186117|Other|Blood sample|Blood sample before any treatment
45647853|NCT04953221|Drug|YJ001|Skin spray
45647854|NCT04006951|Other|Biological collection|"Blood samples are collected at different times :~Before any treatment~After pre-operative radiochemotherapy and before surgery (if applicable)"
45793741|NCT01809548|Other|Late intervention group|solid food is introduced between 16-18th week of gestation corrected for prematurity
45793742|NCT04873349|Dietary Supplement|Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein)|two study groups; test group will receive Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein) while placebo group will receive starch group
45793743|NCT01780454|Drug|MEDI-507|T-Cell Depleting Agent
45793744|NCT01780454|Drug|Rituximab|B-Cell Depleting Agent
45793745|NCT01780454|Radiation|Total Body Irradiation|Bone Marrow Depletion
46071664|NCT02834130|Behavioral|Evaluation of psychological and psychopathological|
46071665|NCT04248270|Drug|18F-PM-PBB3|All scans will be acquired in pairs of 18F-florbetapir(18F-AV45) and/or18F-PM-PBB3 PET scans (if patient select), performed on separate days, and at least 2 days apart, with either scan performed first. The 18F-florbetapir and 18F-PM-PBB3 protocol will entail the inon of 5±2mCi of tracer followed by an uptake phase of 50 min during which time the state of the subject is not important. After 40 minutes, subjects will be positioned and 4 x 5 min frames of emission data will be collected right at 50 min after tracer injection. PET/MRI scans will precede this acquisition with a MRI scan for attenuation correction; PET-only scanners will perform a transmission scan following the emission scan.
46071666|NCT02837016|Device|Wearable biofeedback|
45647855|NCT02926417|Procedure|High Density-Electroencephalogram|
45647856|NCT04952987|Drug|Diquafosol|Diquafosol (Diquas) is a P2Y2 receptor agonist which improves mucin and tear secretion
45647857|NCT04418609|Other|further processing of health data|further processing of biological materials and health related personal data for research
45647858|NCT05106439|Behavioral|Intern Health Study competition-related mobile notification|Participants will receive three types of push notifications: 1. Alert of competition type (steps or sleep) and opponent (Sunday 9pm), 2. Competition score status update (Wednesday 9pm, Saturday 11am), and 3. Competition final results (Monday 12pm).
45647859|NCT05106439|Behavioral|Intern Health Study mobile app|The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
45647860|NCT05106439|Behavioral|Intern Health Study mobile app competition scoreboard and history|Participant can view their current competition scoreboard and competition history at any time via the study app.
45793746|NCT01780454|Radiation|Thymic Irradiation|
45793747|NCT04869449|Drug|Ketoconazole|400 mg (two 200 mg tablets) orally
45793748|NCT04867187|Other|Repetitive transcranial magnetic stimulation (rTMS)|20 minutes of high frequency (20Hz) rTMS.
45793749|NCT04867187|Other|Mirror therapy using virtual reality|active mirror-based therapy
45793750|NCT04867187|Other|Mirror therapy using sham mirror|20 minutes of sham mirror-based therapy
45793751|NCT05116709|Drug|BAT6005 injection|Six dose groups were set up, including 10mg (initial dose) group, 30mg group, 100mg group, 300mg group, 600mg group and 900mg group, respectively.
45793752|NCT01780922|Other|Low Calorie Cranberry Juice Cocktail|Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes
45793753|NCT01780922|Other|Cranberry Extract Beverage|Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes
45793754|NCT01780922|Other|Non-Cranberry Beverage|Beverage absent cranberry at a dose of 15.2 ounces consumed within 15 minutes
45793755|NCT04838951|Device|ENDO-AID CADe|ENDO-AID CADe will be used during the withdrawal process of the colonoscopy.
45793756|NCT05104619|Procedure|tongue surgery|In squamous cell carcinoma of the tongue, complete surgical resection of the tumor
45920984|NCT03891966|Procedure|Rigid Splint|50 patients undergoing operative fixation of isolated bothbone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a splint.
45647861|NCT04418531|Biological|Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients|Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria .
45647862|NCT05037019|Procedure|Radiation therapy|Women diagnosed with early stage breast cancer are given a single dose of stereotactic body radiation therapy (SBRT) prior to any other treatment in the context of delayed lumpectomy due to the COVID-19 pandemic.
45647863|NCT02615119|Drug|Isoproterenol|Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
45647864|NCT02615119|Drug|Normal saline|Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
45793757|NCT04835519|Biological|chimeric antigen receptor T cell|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 5 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m^2( body surface area) and cyclophosphamide 250 mg/m^2( body surface area) for 3 days. Then this study will be using the Bayesian optimal interval phase I/II (Boin12) trial design. The protocol preset 2 dose levels: Dose 1 (DL-1) was 5×10^5 (±20%) CAR T cells/kg, and dose 2 (DL-2) was 1×10^6 (±20%) CAR T cells/kg. If the above dose cannot be met, subjects can still enter the study upon investigator consideration but require documentation of dosing. The lowest dose is 1×10^5 CAR T cells/kg (±20%), and the highest dose is 1×10^6 CAR T cells/kg (±20%). If the dose is out of the range mentioned above, entry into the trial will not be considered.
45793758|NCT00355901|Drug|Visilizumab (Nuvion®; HuM291)|
45793759|NCT05099315|Other|not applicable, observational study|Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study
45793760|NCT00355979|Device|intragastric balloon|
45793761|NCT02979041|Behavioral|Interactive virtual reality training|"The proposed VR intervention program will provide active training to be performed individually 4 times a week for 20 minutes a session.~The intervention program will be supervised by qualified, experienced physiotherapists, and will include individual training and two follow up meetings during the study period. The intervention program will include strengthening and endurance exercises for the cervical and shoulder girdle muscles. Training will include sensorimotor control and functional, quick, accurate, neck motion, using interactive VR training systems. This type of advanced training is very relevant to the pilots function in the cockpit as it includes interactive tasks aimed to increase range, speed, smoothness, accuracy, and control of cervical motion."
45793762|NCT02979041|Other|Standard Care|physiotherapy and medical care as provided currently
45793763|NCT05066165|Genetic|Arm 1: NTLA-5001|"Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.~Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion."
45793764|NCT05066165|Genetic|Arm 2: NTLA-5001|"Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.~Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion."
45793765|NCT05063591|Other|Transfusion support|Patients will be offered symptom-driven transfusion support in addition to standard hospice care
45793766|NCT01648764|Drug|LY2334737|Administered orally
45920985|NCT03891966|Procedure|Soft Dressing|50 patients undergoing operative fixation of isolated both bone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a soft dressing post-operatively.
45920986|NCT00103870|Procedure|Electrodermal stimulation|
45920987|NCT00103870|Procedure|Music listening task|
45920988|NCT00103948|Drug|Aricept|
45920989|NCT00006458|Radiation|indium In 111 monoclonal antibody MN-14|
45647865|NCT05089201|Behavioral|Animal-assisted interaction|A dog-handler team or a handler alone will visit participants with a dog for approximately 20 minutes on 3 consecutive days during their inpatient hospital stay
45449780|NCT03541317|Behavioral|Stage 1 Strategy: REP + Coaching|"Schools will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; ongoing technical assistance in CBT implementation; and weekly visits from a CBT expert or Coach, for a minimum of 12 weeks."
45920990|NCT00006458|Radiation|yttrium Y 90 monoclonal antibody MN-14|
45920991|NCT00104065|Drug|CG53135-05, velafermin|
45920992|NCT00104143|Drug|A4I Antagonist|
45647866|NCT05089201|Behavioral|Conversational control|A handler alone will visit participants without a dog for approximately 20 minutes on 3 consecutive days during their inpatient hospital stay
45647867|NCT02555293|Drug|XIFAXAN® (Rifaximin)|
45647868|NCT05104255|Procedure|Spinal anesthesia|Twins delivered under under spinal anesthesia
45920993|NCT03879408|Drug|440 mg naproxen sodium with 1000 mg acetaminophen|440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets
45920994|NCT03879408|Drug|220 mg naproxen sodium with 650 mg acetaminophen|220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet
45920995|NCT03879408|Drug|10 mg hydrocodone + 650 mg acetaminophen|10 mg hydrocodone with 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets
45920996|NCT03879408|Drug|440 mg naproxen sodium|440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets
45920997|NCT03879408|Drug|Placebo tablet|Single dose of four placebo tablets
45920998|NCT00387998|Other|AHRQ staying healthy booklet|educational booklet about prevention
45920999|NCT00387998|Other|Risk primer|Know your chances booklet
45921000|NCT00104182|Drug|insulin detemir|
45921001|NCT00104182|Drug|insulin NPH|
45921002|NCT00104260|Drug|sapropterin dihydrochloride|
45921003|NCT00104338|Drug|FK778|
46071667|NCT02837016|Behavioral|Relaxation Treatment|group-based relaxation treatment based on mindfulness meditation principles
45793767|NCT04765241|Behavioral|Physical Activity|The intervention includes a physical activity prescription, a Polar activity tracker watch, access to a private AYA cancer survivor community through the Polar Flow community platform, mHealth nudges and surveys via text messaging, and regular phone or email contact from study staff.
45793768|NCT05051969|Behavioral|Remote Mindfulness-Based Stress Reduction Program|Enrolled participants will participate in a remote-delivered (online with audio and video) Mindfulness-Based Stress Reduction (MBSR) program. MBSR is a well established behavioral health intervention consisting of 10-sessions lasting 2.5 hours, with one session lasting 7.5 hours in an all-day retreat format over a 2-month period.
45793769|NCT05043623|Device|Rhinoswab Junior|Rhinoswab Junior is a single use self-administered nasal swab intended to collect clinical specimens from the patient's nasal passages
45793770|NCT05043623|Device|Combined nose and throat swab|Combined nose and throat swab (standard of care)
45793771|NCT05043623|Device|Saliva swab|Saliva swab
45449781|NCT03541317|Behavioral|Stage 2 Strategy: Augment with Facilitation|In addition to first-line treatment (REP or REP + Coaching), schools will also receive support from a Facilitator who is a member of the study team and has expertise in CBT, implementation methods, and use of EBPs in schools will support SPs in strategic thinking and leadership skills to address organizational barriers.
45793772|NCT05043623|Diagnostic Test|Abbott Panbio™ COVID-19 antigen self-test kit|COVID-19 antigen self-test kit for the screening of active COVID-19 infection. It is a single-use, in vitro, visually read rapid immunoassay that uses a human nasal swab specimen for the qualitative detection of nucleocapsid protein SARS-CoV-2 antigen. It is intended to be used manually by untrained lay users (self testing) in a private setting.
45793773|NCT04886622|Drug|DT2216|DT2216 will be administered by intravenous infusion
45793774|NCT00355667|Drug|furosemide|Patients with chronic heart failure receive furosemide and other standard treatment/
45793775|NCT00355667|Drug|azosemide|Patients with chronic heart failure receive azosemide and other standard treatment.
45921004|NCT00388076|Drug|Pazopanib|pazopanib in combination with paclitaxel in Part 1, paclitaxel and carboplatin in Part 2, and paclitaxel and lapatinib in Part 3
45449782|NCT03541317|Behavioral|Stage 2 Strategy: No augmentation|Schools will continue to receive their first-line treatment (REP or REP + Coaching); no additional support will be offered.
45449783|NCT03730623|Behavioral|Supervised exercise training|Supervised exercise training as a conservative management of intermittent claudication in a community setting based on cardiac rehabilitation program
45449784|NCT05665023|Drug|Bevacizumab + modified FOLFIRINOX|Bevacizumab 5mg/kg D1, oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,400 mg/m2 46h continuous infusion, every other week
45449785|NCT03723525|Combination Product|Package of HIV care|"A. Screening and management (Preventive / Pre-emptive therapies dosages) of different opportunistic infections (OI). Detail information mentioned in the manual (refer to uploaded protocol).~B. Rapid ART Initiation~PLHIV without suspicion or active OI: Initiate ART within seven days or same day after HIV serology disclosure~PLHIV with suspicion or active OI: Defer initiation if clinical symptoms suggest tuberculosis or cryptococcal meningitis. Detail information mentioned in the manual (refer to uploaded protocol).~C. Enhanced Adherence/Retention Support: mHealth: Receive text messages in mobile regarding appointment reminder (pill pick up, CD4 test, viral load test, early infant diagnosis (EID) test etc.) and general awareness messages (positive prevention, the importance of regular health check-up etc.). PLHIV with advanced HIV disease will also receive weekly/biweekly home-based adherence/ retention support linked to community care centre and community home-based care."
45647869|NCT05104255|Procedure|General anesthesia|Twins delivered under general anesthesia
45647870|NCT05087251|Behavioral|Five Psycho-educational Session(s)|5 psychoeducational sessions focused on skills for enhancing wellbeing, relationships, social support, and ability to cope with uncertainty
45647871|NCT05087251|Behavioral|One Psycho-educational Session(s)|1 session focused on exploring goals and expectations for post-treatment quality of life, including supportive listening; assessment of unmet needs; preferences for support, and tailored referral recommendations
45647872|NCT04436575|Device|Point-of-care ultrasound|Point-of-care ultrasound prognostic performance : echocardiography mainly
45647873|NCT03293017|Drug|Diazepam 10 MG|If a patient's linical Institute Withdrawal Assessment (CIWA-ar) is more than 15 and did not decrease with 4 points compared to the previous score, they will be given oral diazepam to supress their symptoms, in a tablet of 10 mg.
45647874|NCT03293017|Drug|Baclofen 30mg|Baclofen 30 mg/day given over three gifts daily
45647875|NCT03293017|Drug|Baclofen 60mg|Baclofen 60 mg/day given over three gifts daily
45653172|NCT04787081|Other|Sleep Care Positioning Training Program GRP2|Web-link based tutorial covering six nighttime postural care topic areas which contained mostly written content. This self-paced online training program was delivered in a University classroom via D2L Brightspace.
45653173|NCT05113017|Other|NO Intervention|NO Intervention
45793776|NCT00355745|Device|Ultrasound breast scanning|breast scanning
45793777|NCT05028881|Other|blood sampling|blood sampling for determining antibody responses
45793778|NCT05016401|Device|KONTACT PERIO LEVEL (KPL)|The Kontact™ Perio Level is an implant with a transgingival neck that facilitates one-step surgery.
45793779|NCT02364336|Drug|Peginterferon alfa-2a|
45793780|NCT04976933|Behavioral|mHealth adherence app|The mHealth app is designed to remind caregivers to give medication in the outpatient setting, track adherence, and capture real time barriers to adherence if medication is missed.
45793781|NCT04419948|Other|White bread|White bread (120g) containing 54 g CHO
45793782|NCT04419948|Other|Butter|Butter 39 g
45793783|NCT04419948|Other|Refined olive oil|Refined olive oil (40 ml).
45793784|NCT04419948|Other|EVOO with 250 mg/kg oleocanthal|Extra virgin olive oil containing 250 mg/kg oleocanthal.
45793785|NCT04419948|Other|EVOO with 500 mg/kg oleocanthal|Extra virgin olive oil containing 500 mg/kg oleocanthal.
45793786|NCT04419948|Other|Ibuprofen|Ibuprofen 400 mg
45793787|NCT01781078|Radiation|MRI|The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment
45793788|NCT01781078|Device|ImageReady System implant|Pacemaker and lead(s) implant
45793789|NCT03820739|Other|Follow-up|No investigational vaccine will be administered during this study
45647876|NCT04436809|Procedure|Sentinel Node Biopsy|"Colloidal radiotracer (99Tc) is injected into the breast near the cancer. The radiotracer moves in the lymph ducts to accumulate in the first lymph nodes (almost always in the axilla) to receive lymph from the breast area containing the cancer. Lymphoscintigraphy is used to check for the presence of radioactivity in the axilla. Some hours later, during breast surgery, a radioactivity-detecting probe is used to identify hot lymph nodes (sentinel nodes) and aid their surgical removal from the axilla. These nodes are examined histologically (intraoperatively) for the presence of cancer. If they are disease-free the axilla will be left intact (no further axillary treatment given); if they contain cancer most lymph nodes in the axilla will be removed surgically (axillary dissection)."
45647877|NCT04436809|Procedure|Axillary Dissection|Axillary dissection is the surgical removal of all Berg level I and II lymph nodes present in the axilla. The operation is carried out, at our Institute, during the surgery to treat the cancer in the breast (either breast-conserving surgery - quadrantectomy, or mastectomy).
45793790|NCT03820739|Other|Blood sample collection|Blood sampling to assess vaccine-induced immune responses will be conducted only in cohort 1 in a subsample consisting of approximately 102 adults and 165 children (55 from each of the three paediatric age groups that were enrolled in EBOVAC-Salone: 12-17 year olds, 4-11 year olds, and 1-3 year olds).
45793791|NCT03810755|Other|Personalized Supervised physical activity|personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources
45793792|NCT04657367|Other|Observational study - registry|Observational study - registry
45793793|NCT01312922|Drug|PNB01 fixed dose combination of pipamperone and citalopram|oral once daily administration
45647878|NCT04658251|Genetic|Blood and/or skin biopsy|Blood and/or skin biopsy will be withdrawn, for RNA extraction in order to test the effect of the variant on splicing.
45647879|NCT03198559|Drug|Disulfiram, (National Drug Code) NDC 0378-4141-01|This study will provide open label disulfiram. Participants will take 2 grams (4x500mg tablets) of disulfiram per day for a total of 28 days
45793794|NCT01312922|Drug|Citalopram|oral once daily administration
45793795|NCT01312922|Drug|Pipamperone|oral once daily administration
45793796|NCT04648709|Diagnostic Test|ELISPOT|measure of immune response by ELISPOT
45647880|NCT03198559|Drug|Vorinostat, NDC 00006-0568-40|This study will provide open label vorinostat. Participants will take 400mg (4x100mg capsules) of vorinostat per day on days 8, 9, 10 and days 22, 23, 24.
45647881|NCT04859491|Dietary Supplement|Carbohydrate|Participants have a one in three chance of consuming a carbohydrate beverage between two bouts of high-intensity exercise.
45647882|NCT04859491|Dietary Supplement|Carbohydrate-Protein|Participants have a one in three chance of consuming a carbohydrate-protein beverage between two bouts of high-intensity exercise.
45793797|NCT04648709|Diagnostic Test|QUANTIFERON|measure of immune response by QUANTIFERON
45647883|NCT04859491|Dietary Supplement|Placebo|Participants have a one in three chance of consuming a placebo beverage between two bouts of high-intensity exercise.
45647884|NCT05106049|Diagnostic Test|serum Adiponectin|serum adiponectin as early marker for renal impairment. Adiponectin is a recently identified adipose tissue-derived protein (adipocytokine) with important metabolic ,antiinflammatory, anti-atherogenic, and reactive oxygen species protective actions.
45647885|NCT05081791|Behavioral|Exercise Training|12-week exercise training program including a combination of endurance and resistance training for 45 minutes, twice a week.
45647886|NCT04523545|Device|cardiac ablation|cardiac ablation using pulsed electric field energy to cause pulmonary vein isolation
45793798|NCT00356213|Procedure|sleeve gastrectomy|laparoscopic sleeve gastrectomy
45921005|NCT00388076|Drug|Lapatinib|Lapatinib in combination with pazopanib and paclitaxel in Part 3
45921006|NCT00388076|Drug|paclitaxel|in combination with pazopanib
45921007|NCT00388076|Drug|carboplatin|in combination with pazopanib
45647887|NCT05105815|Biological|IPM001|IPM001 will be used against tumor cells
45793799|NCT00356213|Procedure|Roux-Y-gastric bypass|laparoscopic gastric bypass
45921008|NCT03872583|Other|Understanding MRI in MS (website)|Access to an innovative, interactive and evidence-based online education tool about MRI in multiple sclerosis.
45921009|NCT03872583|Other|Control website|Access to a specifically designed control website containing information on MRI in MS freely available on the websites of major European MS self-help organizations.
45793800|NCT03694145|Other|In-Person Eye Examination|Dilated in-person eye examination by a board-certified ophthalmologist or retinal fellow.
45793801|NCT01783574|Drug|Testosterone|
45793802|NCT01783574|Drug|Placebo|
45793803|NCT04371653|Drug|PRIM-DJ2727|administration orally
45793804|NCT04371653|Drug|Placebo|administration orally placebo
45793805|NCT00119912|Procedure|A 1 Intervention arm Flex Sig|Screening by flexible sigmoidoscopy
45793806|NCT00119912|Procedure|A 2 Intervention arm Flex Sig + iFOBT|In addition to Flexible Sigmoidoscopy, half of arm A (randomised 1:1) is invited to provide stool samples for FOBT
45793807|NCT00356837|Procedure|Ultrasound|use ultrasound to confirm diagnosis of extremity fractures
45793808|NCT03656783|Drug|Biktarvy|Open-label, multicenter, single-arm study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine/Dolutegravir (ABC/3TC/DTG) to the Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-Infected Adult Subjects
45793809|NCT01784588|Device|Solyx Single Incision Sling System|Solyx Single Incision Sling System
45793810|NCT01784588|Device|Obtryx II Sling System|Standard outside-in transobturator sling
45921010|NCT00104377|Biological|Grass MATA MPL|
45793811|NCT03632135|Diagnostic Test|ChemoID assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
45647888|NCT02625623|Drug|Avelumab|Avelumab was administered as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with best supportive care (BSC).
45793812|NCT03632135|Drug|Chemotherapy|Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent ovarian cancer
45793813|NCT01733186|Biological|CARTISTEM®|
45793814|NCT01734746|Procedure|Tracerinjection|The intervention concerns the tracerinjection for detection of the sentinel node.
45793815|NCT01785134|Procedure|Omentectomy|
45793816|NCT01785134|Procedure|Gastric bypass operation|
45793817|NCT03599843|Behavioral|Exercise|Participants will complete a 12 week exercise session that will be comprised of aerobic and/or resistance and/or flexibility training.
45793818|NCT01785680|Other|Integrated Protocol|Implement an integrated protocol in Sierra Leone for the management of MAM and non-complicated SAM that uses a single anthropometric indicator as well as the same food but in different doses to treat the continuum of malnutrition. MAM children will be given 75 g/kg/day of RUTF whereas SAM will be given 175 gr/kg/day of RUTF until MUAC>12.5 cm is reached. Then child will be given LNS, a bed net, albendazole, zinc, referral for immunizations compliant with current WHO recommendations, oral rehydration salts to give if the child has more than three loose watery stools in 24 hours, and asked to return for follow-up in 1, 3 and 6 months. Caretakers will be instructed to seek medical care sooner if the child has fever, poor appetite or signs of an acute illness.
45793819|NCT01785680|Other|Current protocol|Current protocol for treating MAM in emergencies is supplemental food distribution, often providing a fortified blended food (FBF) that requires cooking. This treatment is the standard today for treating children with MAM.
45793820|NCT03457493|Drug|DPA-714-PET/MRI|DPA-714-PET/MRI
45793821|NCT03454295|Behavioral|Focus Group|Participants will be asked to reflect on their caregiving experience and specifically, when the receipt of a supportive intervention that addresses existential distress would have been most appropriate and well received.
45793822|NCT03454295|Behavioral|Meaning-Centered Psychotherapy for Cancer Caregivers / MCP-C|MCP-C is structured as a 7-session (1-hour weekly or biweekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and cancer caregiving
45921011|NCT00104455|Drug|activated recombinant human factor VII|
45921012|NCT00104494|Drug|Zinc acetate (20mg/d)|Randomized to receive either 20mg/d zinc as zinc acetate or an identical placebo
45647889|NCT02625623|Drug|Irinotecan|Irinotecan was administered at a dose of 150 mg/m ^2 on Day 1 and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
45647890|NCT02625623|Drug|Paclitaxel|Paclitaxel was administered at a dose of 80 mg/m^2 on Day 1, 8, and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
45647891|NCT02625623|Other|Best Supportive Care (BSC)|BSC is defined as treatment administered with the intent to maximize Quality of life without a specific antineoplastic regimen and is based on investigator's discretion. BSC was administered once every 3 weeks.
45921013|NCT00388115|Procedure|conventional surgery|Standard of care lumpectomy or mastectomy following RFA
45921014|NCT00388115|Procedure|neoadjuvant therapy|Standard of care lumpectomy or mastectomy following RFA
45793823|NCT03454295|Behavioral|Enhanced Usual Care / EUC|"The enhancement to usual care in this study involves the inclusion of screening and targeted referral components as suggested by Reynolds et al. [79]. Research study assistants conducting the screening and providing feedback and referrals will be trained in the NCCN guidelines for distress management and will discuss the screening results and associated recommendations with the study PI (NCCN) [63]. As of November, 2017, ICs of patients seen in the Neurology Service at MSKCC are not consistently screened for distress and offered targeted referrals. Participants randomized to EUC will receive feedback about their level of distress (based on the Distress Thermometer administered at screening) after randomization. Within a week of randomization, and post-baseline, the study RSA will send EUC participants appropriate targeted referrals based on levels of distress and problem areas endorsed."
45647892|NCT05105893|Other|Dates group|Seven dates to be provided to patients
45647893|NCT02749513|Drug|Itraconazole|
45647894|NCT02684227|Drug|Carboplatin|Given IV
45647895|NCT02684227|Drug|Enzalutamide|Given PO
45793824|NCT03420989|Other|Active snack food|snack enriched with seaweeds and carob
45793825|NCT03420989|Other|Control snack food|the same snack food without seaweeds and carob
45793826|NCT01784666|Drug|Isradipine|The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to isradipine versus placebo add-on for 4 weeks, with the placebo nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the isradipine treatment effect. Subjects who respond in phase 1, and all subjects who receive isradipine in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
45793827|NCT01784666|Drug|Placebo|Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to isradipine vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
45793828|NCT04362293|Drug|hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus|"The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3 and low dose total body irradiation (TBI) 200 cGY on day -2 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10^6/kg recipient weight.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor."
45793829|NCT04362293|Drug|hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus|"The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3, plerixafor (0.24mg/Kg) subcutaneously every 12 hours on days -3 and -2 and low dose total body irradiation (TBI) 200 cGY on days -2 and -1 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10^6/kg recipient weight.~GVHD prophylaxis will be cyclophosphamide (50mg/Kg) intravenously on days +3 and +4 and sirolimus with a loading dose 3 mg/m2 starting on day +5. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor."
45793830|NCT04336397|Diagnostic Test|multi-target stool DNA test|Cluster randomized trial of high and medium intensity outreach with MT-sDNA compared with usual care
45793831|NCT04296695|Drug|B/F/TAF|randomized, multicentered, open-lable RCT, one arm with B/F/TAF and one arm with TDF/3TC/EFV
45793832|NCT04296695|Drug|TDF/3TC/EFV|TDF/3TC/EFV
45793833|NCT03283397|Drug|EK-12|10 mg metenkefalin acetate + 2 mg tridecactide acetate in 2 mL 0.9 % NaCl solution.
45647896|NCT02684227|Other|Laboratory Biomarker Analysis|Correlative studies
45793834|NCT03283397|Drug|INF beta-1a|Active substance is INF beta-1a, 44 mcg in 0.5 mL solution
45793835|NCT04281251|Procedure|Endoscopic retrograde appendicitis therapy|"Colonoscopy would be introduced until visualization of the appendiceal orifice. Catheter would be placed in the appendix and decompression performed. After removal of appendicolith, plastic stent would be placed for drainage of appendix.~For patients successfully treated with initial endoscopic drainage, they would be re-admitted at 1 weeks after index procedure for repeat colonoscopy. After reaching the appendiceal orifice, the previous plastic stent would be removed. A contrast appendicogram would be repeated by introducing a wire-guided catheter in the appendix, and any residual fecalith would be removed. Finally, a repeat contrast appendicogram would be performed to confirm complete clearance of fecalith."
45647897|NCT02684227|Drug|Paclitaxel|Given IV
45647898|NCT02684227|Other|Pharmacological Study|Correlative studies
45647899|NCT05110339|Drug|Ropivacaine plus dexmedetomidine|Erector spinae block with ropivacaine at a dose of 0.5% plus dexmedetomidine at 0.3 mcg / kg.
45647900|NCT05110339|Drug|Ropivacaine|Erector spinae block with ropivacaine at a dose of 0.5%.
45647901|NCT05111665|Behavioral|Mindfulness-based Cognitive Therapy (MBCT)|
45647902|NCT05111665|Behavioral|Relaxation Group Therapy (RGT)|
45647903|NCT05111665|Behavioral|Treatment as usual (TAU)|
45647904|NCT04966403|Other|Standard physical therapy|building strength, enhancing developmental skills, boosting balance, coordination, and postural control
45647905|NCT04966403|Other|trampoline-based stretch-shortening cycle exercises|muscle strength
45647906|NCT04830631|Device|Cathodal transcranial direct current stimulation (tDCS) over the contralesional motor cortex|Cathodal tDCS will be applied to the contralesional motor cortex with 2mA intesntisy for 30 mins/day. Total 10 sessions will be applied.
45647907|NCT04952831|Other|diffusion MRI (dMRI)|All participants underwent dMRI scan at baseline
45647908|NCT04965545|Dietary Supplement|low copper diet|All patients with wilson disease should receive low copper diet
45793836|NCT03240263|Procedure|Inspiratory Muscle Training|"Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device*. Resistance adjusted to the highest tolerable load.~*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK"
45793837|NCT03240263|Procedure|Endurance training|"Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device*. Low training resistance adjusted to <10% maximal inspiratory pressure.~*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK"
45793838|NCT04259645|Drug|Drug: Bupivacaine 0.375% 20 mL|Each block of 0.375% Bupivacaine x 20 mL
45793839|NCT04259645|Drug|Drug: Bupivacaine 0.375%|Each block of 0.375% Bupivacaine x 20 ml + Normal Saline Solution 20 mL
45793840|NCT00356291|Behavioral|Skill-Building (SB) plus Motivational Interviewing|SB is a 4 to 5 session individually-based psychoeducational intervention. Participants meet weekly with an interventionist for 3 to 4 weeks and then receive a booster session 3 months after baseline. The traditional Skill-Building intervention will be augmented with Motivational Interviewing techniques.
45793841|NCT00356291|Behavioral|Skill-Building (SB)|SB is a 4-session individually-based psychoeducational HIV risk reduction intervention. Participants meet weekly with an interventionist for 3 weeks and then receive a booster session 3 months after baseline.
45793842|NCT04219709|Other|Very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein."
45793843|NCT04219709|Other|Standard carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein."
45793844|NCT03218345|Procedure|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a generator
45793845|NCT01787006|Drug|Cetuximab|Initial doses 400mg/m2 (day 1), followed by weekly doses of 250mg/m2 for 14 weeks in total
45793846|NCT01787006|Drug|Cisplatin, 5-FU|"5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 of cycle 1 and 2, 750mg/m2/day as continuous infusion on day 1-4 of cycle 3 and 4~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle"
45793847|NCT01787006|Radiation|Radiotherapy|59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery.
45793848|NCT03208283|Diagnostic Test|Water method group|During the insertion phase of the initial 30 FS procedures, sterile water will be infused by a standard endoscopy water pump into the distal colon to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Air insufflation will not be used during the insertion phase. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
45793849|NCT03208283|Diagnostic Test|Air insufflation group|During the insertion phase of the initial 30 FS procedures, air insufflation will be used to allow passage of endoscope to at least 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
45793850|NCT02260622|Drug|rivaroxaban plus aspirin|Rivaroxaban 2.5 mg twice daily for 90 days (rivaroxaban will be started 6 to 8 hours after the finalization of the procedure) and 81 mg of ASA daily for 90 days
45793851|NCT02260622|Drug|clopidogrel plus aspirin|Clopidogrel 75 mg daily for 90 days (with a loading dose of 300 mg clopidogrel following PTA) and 81 mg of ASA daily for 90 days
45793852|NCT04219085|Device|Continuous Glucose Monitor|Wearing of a continuous glucose monitor to monitor blood glucose levels in women with gestational diabetes
45647909|NCT04965467|Diagnostic Test|Screening for Fabry disease|A questionnaire specifically designed to assess Fabry disease-associated phenotypes in infancy, childhood and adolescence: pain in the hands and feet, angiokeratomas, hypohidrosis, corneal whorls, unexplained renal failure, unexplained hypertrophic myocardiopathy and unexplained early onset stroke. The questionnaire consisted mainly of quantitative, closed questions with pre- defined response options.The diagnosis of FD will be performed by standard procedures following international recommendations. These require the search for a deficiency of alphagalactosidase A activity on leucocytes in males and genetic analysis of the GLA gene in females (Germain et al. 2010). In females plasma Gb3, globotriaosyl- sphingosine (lyso-Gb3) will be measured for screening.
45793853|NCT04219085|Other|Routine Care|Use of a glucometer to monitor blood glucose levels in women with gestational diabetes
45793854|NCT04207697|Biological|Beltavac® Polymerized with cat dander|Adminstration of Beltavac® Polymerized with cat dander according to the routine clinical practice
45921015|NCT00388115|Procedure|radiofrequency ablation|A small diameter needle is inserted through the skin and directly into the tumor for the purpose of supplying RF current. Initial power of the RF generator will start at 5-10 watts. The power will increase by 5-10 watts every minute until impedance of the system automatically stops the RF treatment.
45921016|NCT00104533|Device|Magnets|
45921017|NCT00390585|Drug|Iodixanol 320|Iodixanol 320 is used as contrast media while coronary intervention.
45921018|NCT00390585|Drug|Iomeprol 350|Iomeprol 350 is used as contrast media while coronary intervention.
45921019|NCT00104611|Device|Repetitive Transcranial Magnetic Stimulation|
45921020|NCT00104689|Drug|capecitabine|
45793855|NCT02261714|Biological|TG01|"TG01 and GM-CSF will be administered on days 1, 8, 15, 22 and 36. TG01 alone will also be given on days 36 and 50 for DTH assessment. Gemcitabine will start at least 3 weeks after TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.~Once chemotherapy is completed, GM-CSF and TG01 injections will resume and will be given every 4 weeks from the end of the chemotherapy period up to week 52 (plus once at week 5 post-chemotherapy) and then every 12 weeks from week 52 to week 104. TG01 alone will be given 8 weeks after the end of chemotherapy for DTH assessment.~TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.~Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes"
45647910|NCT04813939|Device|IB10 sphingotest® bio-ADM® apparatus (Sphingotec GmbH, Hennigsdorf, Germany)|Point of care assessment of bio-adrenomedullin concentration will be performed using the IB10 sphingotest® bio-ADM® apparatus (Sphingotec GmbH, Hennigsdorf, Germany) on the 1,3,5-day ICU stay in COVID-19 patients. The method used is a double monoclonal sandwich immunoassay to measure the concentration of C-terminal amidated, biologically active adrenomedullin (bio-ADM) in whole blood. Additional measurement of bio-ADM will be performed as standard monitoring in patients suspected of septic complications of the course of COVID-19.
45793856|NCT02261714|Biological|TG01|"For patients not able to start TG01 quickly after surgery, the vaccination can start at the same time as the chemotherapy as long as they start within 12 weeks from surgery. Gemcitabine will start at the same time as TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.~TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.~Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes"
45793857|NCT04204655|Diagnostic Test|BIA|Bioelectrical Impedance Analysis
45793858|NCT03186209|Biological|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 40 inclusive.
45793859|NCT03186209|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 40 inclusive.
45793860|NCT02261948|Drug|Levosimendan|Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
45793861|NCT02261948|Drug|Placebo|Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
45793862|NCT03278067|Other|Enhanced vaccine safety surveillance|Routinely collected primary care data from up to ten general practices to support passive surveillance. Additionally, this passive surveillance will be enhanced by the use of a customized card-based ADR reporting system.
45793863|NCT04187573|Device|Neqstent|Adjunctive device providing stable aneurysm neck coverage for the placement of embolization coils within the aneurysm sac and long term stable occlusion of the aneurysm.
45793864|NCT04141709|Radiation|local ablative radiotherapy|"Within the scope of the study, irradiation with two irradiation schemes is possible (the scheme applied is recorded in the CRF):~Scheme A 3*10 Gy (once a day, 2-3 days a week)~Scheme B 25*2 Gy (once a day, 5 days a week) The decision which irradiation scheme (3*10 Gy or 25*2 Gy) to use is made by the treating physician based on the anatomical position, the size of the metastases and the expected normal tissue load. Hypofractionated irradiation in three fractions is only possible if the limit values for the risk organs are adhered to. Radiotherapy should be performed with photons."
45793865|NCT01787240|Drug|Escitalopram 10mg|
45793866|NCT01787240|Drug|Placebo|
45793867|NCT00357149|Drug|Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy|
45793868|NCT00357149|Drug|Concomitant cisplatin, 5-FU and radiotherapy|
45793869|NCT04926116|Drug|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
45793870|NCT04926116|Drug|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
45921021|NCT00104689|Drug|oxaliplatin|
45921022|NCT00006461|Drug|cisplatin|Given IV
45647911|NCT04795375|Behavioral|Physical Activity counseling|"The Physical activity counseling techniques will be based on the Self Determination Theory and Five A's (Assess, Advise, Agree, Assist, Arrange). Guidelines for physical activity will include combined aerobic and resistance exercises.~Each participant in the intervention group will receive personal exercise prescriptions in accordance the post-surgical statues and exercise recommendations after bariatric surgery. Participants will receive long term follow-up and accompaniment during the first six months after the surgery, through Personal meetings with a certified nurse, Phone-calls, motivational massages, and Exercise Videos."
45647912|NCT04961411|Procedure|operation or non-operative treatment|type of operation or if possible non-operative treatment
45647913|NCT04425785|Other|Physical Exercise Program|A structured exercise program
45647914|NCT04425785|Behavioral|Cognitive Behavioural Therapy|A structured cognitive behavioural therapy program
45793871|NCT03172715|Procedure|Locking plate|Osteosynthesis
45921023|NCT00006461|Drug|cyclophosphamide|Given IV
45921024|NCT00006461|Drug|vincristine sulfate|Given IV
45921025|NCT00006461|Drug|etoposide|Given PO
45921026|NCT00006461|Procedure|therapeutic conventional surgery|Undergo surgery
45921027|NCT00006461|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
45921028|NCT00104767|Drug|celecoxib|
45921029|NCT02972268|Drug|Tamsulosin 0.2mg + Solifenacin 5mg|Tamsulosin 0.2mg + Solifenacin 5mg for 12wks
45921030|NCT02972268|Drug|Tamsulosin 0.2mg + Placebo(Solifenacin)|Tamsulosin 0.2mg + Placebo(Solifenacin) for 12wks
45921031|NCT00104806|Dietary Supplement|cholecalciferol|100 milligrams orally once a day for 28 days
45921032|NCT00104806|Drug|arsenic trioxide|0.3 milligram/kilogram weight intravenously for 5 days (loading) then 0.25/kg weight intravenously biweekly
45921033|NCT00401128|Drug|gemcitabine hydrochloride|
45921034|NCT00401128|Drug|irinotecan hydrochloride|
45921035|NCT00401167|Drug|memantine|Following the baseline visit, subjects will receive memantine 5 mg OD for one week, followed by 5 mg BID for one week, followed by 10 mg QAM and 5 mg QPM for one week, followed by 10 mg BID for the following 9 weeks.
45921036|NCT00006464|Drug|7-hydroxystaurosporine|
45921037|NCT00006464|Drug|cisplatin|
45921038|NCT00104845|Biological|human gp100 plasmid DNA vaccine|
45647915|NCT05105659|Diagnostic Test|Wechsler IQ for Adults|IQ test that measures the cognitive functions and intelligence using a scale and consists of many subtests assessing verbal and non-verbal performance.
45647916|NCT05105659|Diagnostic Test|MAS (Memory assessment scale)|tool that uses verbal and the visual tasks to assess memory, recall and cognition. The MAS consists of 12 subtests based on the following 7 memory tasks: Verbal Span, List Learning, Prose memory, Visual Span, Visual Recognition, Visual Reproduction and Names-Faces.
45449786|NCT03723525|Combination Product|Standard HIV care|Standard of HIV care includes screening and management of OI (OI- tuberculosis (TB), bacterial pneumonia, herpes, and candidiasis), baseline assessment (CD4 and other blood tests- complete blood count, hemoglobin, platelets, liver function test, renal function test, urine for albumin, chest x-ray), at 6 months CD4 test, viral load (twice a year) and then on a yearly basis, additional lab test at 3 months, 6 months, antiretroviral (ARV) toxicity monitoring like hemoglobin (Zidovudine), Serum Glutamic-Pyruvic Transaminase (Nevirapine/Efavirenz), Creatinine (Tenofovir), prophylaxis (Co-trimoxazole preventive therapy CD4<350 and WHO stage III and IV and Isoniazid preventive therapy if eligible) and ART / follow up (generally monthly/ bimonthly).
45449787|NCT03590613|Drug|GSK2982772|GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route
45793872|NCT03172715|Procedure|TKR|Total knee arthroplasty
45793873|NCT04910906|Device|Ectoin® Vaginal Gel|"Ectoin® Vaginal Gel is a clear, non-hormonal moisturizing gel containing only active ingredient Ectoin® for the relief of vaginal dryness/vaginal atrophy.~Other excipients in the formulation include:~Hydroxyethylcellulose (Gelling agent) Lactic acid (90 %) (pH stabiliser) DL-Sodium lactate (Buffer substance) Sodium benzoate (preservative) Propylene glycol (Humectant)"
45793874|NCT03127709|Behavioral|Trail Making Test, Parts A & B|Part A is a timed measure of visual scanning and graphomotor speed. Part B is a timed measure of cognitive flexibility.
45793875|NCT03127709|Behavioral|Brief Test of Attention|Assesses auditory working memory
45647917|NCT05105659|Diagnostic Test|Health-Related Quality of Life (HRQoL)|measures multiple aspects of the individual's life and the impact of the disease and treatment on the individual's life. It does so by assessing the individual's own views and perspective of the care and treatment they are receiving and whether consider it satisfactory or not.
45793876|NCT03127709|Behavioral|Symbol Span|Assesses visual working memory
45793877|NCT03127709|Behavioral|Controlled Oral Word Association Test|The COWA timed test of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S).
45647918|NCT05105659|Diagnostic Test|Symptom check list 90|a well-known scale that is used to identify and assess psychological symptoms. It consists of a 90-item checklist having a 5-point rating scale.
45793878|NCT03127709|Behavioral|The Hopkins Verbal Learning Test-Revised|HVLT-R is a test of verbal learning and memory. Scores obtained are the total number of words.
45793879|NCT03127709|Behavioral|Brief Visuospatial Memory Test-Revised|The BVMT-R is a test of visuospatial learning and memory.
45793880|NCT03127709|Behavioral|Hospital Anxiety and Depression Scale|The HADS is a brief assessment validated in many cancer populations.
45793881|NCT03127709|Behavioral|McGill Quality of Life Scale|This is a questionnaire that is a validated 17-item QOL instrument validated for ill patients and in the particular context of the ancer.
45647919|NCT05105659|Diagnostic Test|Socioeconomic level|scale for measurement of socioeconomic status in health research in Egypt. The new socioeconomic status scale has 7 domains with a total score of 84. Intra-and inter-observer variability and the internal consistency of the scale were assessed.
45647920|NCT05105581|Behavioral|Quality of life scale|"To assess the quality of life of patient~To assess the degree of OCD"
45793882|NCT03127709|Diagnostic Test|MR Brain Imaging|Standard of care brain MR imaging includes high-resolution 3D T1-weighted images in the axial plane. The axial T1-weighted images will be isotropic with a typical matrix size of 256 x 256, 256 mm field-of-view (FOV) and 1 mm slice thickness covering the whole brain.
45647921|NCT04425629|Drug|casirivimab+imdevimab combination therapy|Administered intravenously (IV) single dose
45647922|NCT05111275|Other|Cognitive exercises|Exercises that stimulate and train memory, attention, executive functions, language and gnosis.
45647923|NCT05105347|Drug|Adalimumab plus different doses of oral glucocorticosteroid|A loading dose of 80mg adalimumab will be given subcutaneously and then change to 40mg adalimumab every two weeks. Medium dose oral glucocorticosteroid (30mg/d prednisone or equivalent) will be given to the experimental dose group and high dose oral glucocorticosteroid (60mg/d prednisone or equivalent) will be given to the high dose group.
45647924|NCT05110963|Behavioral|Uniform Standard of Care Counseling|Routine HIV counseling services available to patients with protocol delivered services. Three sessions of patient education monitored for protocol adherence
45647925|NCT05110963|Behavioral|Behavioral Self-Regulation Skills Counseling|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context. This is a culturally tailored adaptation of CDC disseminated Phone-Delivered Support Counseling for HIV treatment Adherence.
45921039|NCT00104845|Biological|mouse gp100 plasmid DNA vaccine|
45921040|NCT00104923|Drug|fenretinide|Current dose level as an IV continuous infusion via central line over 5 days. Cycle is repeated every 3 weeks for up to 6 cycles
45449788|NCT03590613|Drug|Placebo|Placebo matching GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route.
45449789|NCT03557931|Drug|ASP4345|oral administration
45449790|NCT03557931|Drug|placebo|oral administration
45449791|NCT03557931|Drug|risperidone|oral or depot administration
45449792|NCT03557931|Drug|quetiapine|oral administration
45449793|NCT03557931|Drug|olanzapine|Oral or depot administration
45647926|NCT05110963|Behavioral|Behavioral Self-Regulation Skills Counseling + Stigma Management|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory with stigma management to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context with added components directly targeting stigma-related experiences and concerns.
45921041|NCT00104962|Drug|lenalidomide|Given orally
45793883|NCT03127709|Diagnostic Test|Resting state functional MRI|Scanning will be performed on a 3 Tesla General Electric scanner (Optima 750W) with a GEM HNU 24-channel head coil. rsFMRI matching the FLAIR and T1 post-contrast images will be obtained. For resting state fMRI, T2*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR = 2500 ms, TE = 30 ms, FA = 80°, slice thickness = 4 mm, FOV= 240mm2, matrix=64×64) covering whole brain. For the resting state fMRI portion of the scan, patients will be instructed by the technologist or research staff to leave eyes open, focus on looking at a crosshair, and not think about anything during the scan.
45647927|NCT04424537|Dietary Supplement|Control diet|Meal replacement beverages made with whey protein
45793884|NCT03127709|Behavioral|Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)|This is a validated 37-item QOL instrument for cancer patients with cognitive complaints. The measures consist of FACT-Cog total, perceived cognitive impairments, perceived cognitive abilities, and impact on quality of life.
45647928|NCT04424537|Dietary Supplement|Low branched-chain amino acids(BCAA) diet|meal replacement beverages (MRBs) made with BCAD2 powder (lacking BCAAs).
45647929|NCT04424537|Dietary Supplement|Low protein diet|meal replacement beverages(MRBs) containing low protein
45647930|NCT04965623|Device|Atrial Shunt|Transcatheter treatment of symptomatic left heart failure patients
45647931|NCT05105191|Diagnostic Test|Roche Cobas® Liat Influenza A/B & RSV assay|Performance of a rapid molecular assay to diagnose influenza and RSV infections
45647932|NCT04952441|Behavioral|RISE Program|Psychoeducational sessions designed to impact Resilience, Insight, Self-Compassion, and Empowerment
45793885|NCT04903652|Drug|Pyrotinib Maleate|Pyrotinib p.o. 400 mg once daily
45793886|NCT04903652|Drug|Vinorelbine|Vinorelbine p.o. 40 mg once every other day
45793887|NCT04769102|Device|seat cushions|flat versus contoured customized seat cushions
45793888|NCT04071821|Drug|cetirizine HCl Gummy|cetirizine HCl 10mg in a gummy formulation
45793889|NCT04071821|Drug|Zyrtec tablet 10mg|cetirizine HCl 10mg tablet
45793890|NCT01735214|Drug|Prostaglandin Analogue -Containing IOP-Lowering Therapy|Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
45793891|NCT03064295|Device|Myocardial Perfusion Cardiac MRI.|MRI with administration of a contrast drug and a stress agent, if no contraindications are present. The gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg) The IV stress agent is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
45793892|NCT03064295|Drug|Contrast|The intravenous gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg)
45793893|NCT03064295|Drug|Pharmacologic Stress Agent|The stress agent administered intravenously is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
45793894|NCT01789814|Drug|Prasugrel|Patients will be randomized to prasugrel or clopidogrel to assess the effect of these drugs on inhibition of platelet aggregation following the cessation of bivalirudin therapy.
45921042|NCT00006467|Drug|ISIS 2503|
45449794|NCT03557931|Drug|ziprasidone|Oral or depot administration
45647933|NCT05110651|Drug|Hydroxychloroquine|Oral Hydroxychloroquine 200mg once daily Dose tapered if blood-hydroxychloroquine levels > 2000ng/ml
45647934|NCT03060785|Drug|Tenofovir Disoproxil Fumarate/Emtricitabine|
45647935|NCT05104879|Other|Biosketch Card|The experimental group received a biosketch card during rooming, pre-clinician encounter that gave an overview of the midlevel providers qualifications.
45647936|NCT04952363|Device|A vertical vibration platform PowerVibe Zen Pro 5900|Subjects received the interventions twice a week for 8 weeks. HFCWO+WBVT group received additional 30 minutes WBVT treatment. In every WBVT session, three rounds of 3 minutes of vibration (amplitude: 2 mm; frequency: 20 Hz) were provided, with a 60-second rest between rounds.
45647937|NCT04952363|Device|HFCWO|Subjects received the interventions twice a week for 8 weeks. The HFCWO was delivered by a respiratory therapist using a percussive vest at 10-13 Hz oscillating frequency and at a pressure setting of 2 cm H2O. The treatment duration was 25 minutes, and the participants remained in a sitting position.
45647938|NCT05104645|Other|Analysis of the walk|Gait analysis in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Patients: S0, S1, S2, S4 and S6 Healthy volunteers: 2 times (between 3 and 20 days apart)
45793895|NCT01789814|Drug|Clopidogrel|Clopidogrel 600 mg as a loading dose immediately prior to the start of procedure and 75 mg daily thereafter
45793896|NCT02962973|Device|CARMAT TAH|
45793897|NCT02962973|Procedure|Surgical intervention|
45793898|NCT00356447|Drug|Estradiol/DRSP (Angeliq, BAY86-4891)|Drospirenone (DRSP) 2mg and Estradiol 1mg. One cycle consists of 28 days. One tablet daily for 28 days given for a total of 4 cycles. Oral administration.
45793899|NCT00356447|Drug|Placebo|Same administration.
45793900|NCT01736852|Device|CRB|Labor induction using the CRB
45793901|NCT01736852|Drug|Pitocin|Labor induction using Pitocin
45793902|NCT02944955|Drug|BLEX 404 Oral Liquid|"BLEX 404 Oral Liquid is orally administered twice daily in combination with azacitdine treatment cycles (2 cycles in Part I and 6 cycles in Part II).~Azacitidine treatment: SC or IV injections at 75 mg/m2, QD for 7 days each cycle. 28 days/cycle, and repeat cycles every 4 weeks."
45793903|NCT01790750|Device|PES first, then FFES|A 5-minute Pocket echocardiography system scan (PES) scan will be performed to detect PDA on neonates. This scan will be followed by a Full Featured Echocardiography System Scan (FFES) and scan results will be compared.
45793904|NCT04068623|Other|Blood sample|Blood samples will be collected at 12 months after radiation therapy and at the time of first metastatic recurrence
45793905|NCT01809938|Other|Black tea|300ml of tea without milk
45921043|NCT00006467|Drug|gemcitabine hydrochloride|
45921044|NCT00105040|Drug|Levetiracetam|Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.
45921045|NCT00105040|Other|Placebo (PB)|Oral tablets and oral solution
45921046|NCT00105118|Device|Magstim Super Rapid Magnetic Stimulator|
45647939|NCT05104645|Other|Analysis of the race|Analysis of running in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Healthy volunteers: 2 times (between 3 and 20 days apart)
45647940|NCT05104645|Other|Unipodal and bipodal jumps on flat ground|Healthy volunteers: 2 times (between 3 and 20 days apart)
45647941|NCT04961333|Behavioral|Multidisciplinary Rehabilitation|Body therapies to improve breathing, normalise dysfunction in the autonomic nervous system, relaxation, mindfulness, in some part Acceptance and Commitment Therapy given preferably through body therapies.
45647942|NCT05110573|Procedure|pancreatoduodenectomy|Patients included in the cohorts all underwent pancreatoduodenectomy, open or laparoscopic
45647943|NCT04952207|Drug|Direct-acting antiviral agents|The initial DAA treatment and its dose for all patients is determined by the infectionist or hepatologist based on the clinical diagnosis and treatment routine. The administration dose in the instructions for use for current DAAs marketed in China Mainland unnecessary to combine with any IFN is shown but not limited as follows: Sofosbuvir, Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, Daclatasvir, Asunaprevir, Elbasvir/Grazoprevir, Sofosbuvir/Velpatasvir and Ledipasvir/Sofosbuvir.
45647944|NCT04632589|Drug|Losartan Potassium|subjects ingest 50mg losartan potassium tablet daily for 6 weeks
45647945|NCT04632589|Drug|Placebo|subjects ingest placebo tablet daily for 6 weeks
45647946|NCT05002699|Diagnostic Test|Alzheimer's disease CSF biomarkers|Measurement of amyloid beta peptide 1-42, amyloid beta peptide 1-40, and total tau in cerebrospinal fluid.
45647947|NCT04961099|Drug|HY01|low-dose group: HY01 10mg（20mg/ml）, administrated on D1, D4 and D7 high-dose group: HY01 20mg（40mg/ml）, administrated on D1, D4 and D7
45647948|NCT04965233|Behavioral|DNA reports|The personalized DNA lifestyle reports cover the following topics: Healthy weight, Vitamin D, Alcohol, Lactose, Injuries, Caffeine, Fitness, Carbohydrates, The mind, Vitamin B, The senses, and Omega.
45647949|NCT04965233|Behavioral|Information reports|Reports containing general information on eczema
45793906|NCT01809938|Other|Tea with milk|250ml of black tea with 50ml of full fat milk
45647950|NCT04975009|Behavioral|Fear conditioning|Participants will learn to associate neutral stimuli with a mildly uncomfortable electrical stimulation to the wrist. The intensity of the electrical stimulus is calibrated prior to the start of the experiment to a level deemed highly annoying but not painful by the participant.
45793907|NCT02922413|Biological|Hemin for injection|Panhematin 4 mg/kg body weight reconstituted with 25% human albumin infused intravenously over at least 1 hour.
45793908|NCT02922413|Other|Placebo|Saline infusion
45793909|NCT01810952|Drug|Glargine insulin|In both protocols glargine dose was increased by 10% if the FSG value was 141-200 mg/dL and by 20% if the FSG value was more than 200 mg/dL, and decreased by 10% if the FSG was 70-89 mg/dL and by 20% if the FSG was less than 70 mg/dL.
45793910|NCT01810952|Drug|Lispro insulin|In both protocols lispro insulin was given to cover meals. Additional lispro insulin was Lispro insulin was administered before meals to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro Insulin Arm.
45793911|NCT01810952|Drug|NPH Insulin|NPH insulin was given once or twice a day to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro/NPH Insulin Arm
45921047|NCT00105313|Drug|MEDI-507|
45921048|NCT00006470|Biological|monoclonal antibody 11D10 anti-idiotype vaccine|
45647951|NCT04964999|Other|Exercise|Participants will undergo an exercise program during the 2-week bed rest period.
45647952|NCT05108701|Behavioral|Individual Psychotherapy|Psychotherapy using meditation, yoga, through being in the present moment a non judgmental way and open minded
45647953|NCT05108545|Drug|Amphotericin B liposomes|Amphotericin B liposomes for injection, 3 mg/kg, qd, IV
45647954|NCT04951973|Diagnostic Test|Deep Learning Based Early Warning Score (DEWS)|DEWS use 4 vital signs (systolic blood pressure, HR, respiratory rate, and body temperature) to predict in-hospital cardiac arrest. Deep-learning approach facilitates learning the relationship between the vital signs and cardiac arrest to achieve the high sensitivity and low false-alarm rate of the track-and-trigger system (TTS).
45647955|NCT05102695|Diagnostic Test|Serum CRP , ferritine and d-dimer|Correlation between the results of the tests with outcome of the patient
45647956|NCT04952129|Drug|Selenomethionine|Seleno-amino acid
45647957|NCT04952129|Drug|Methylselenocysteine|Seleno-amino acid
45647958|NCT05100043|Biological|IL-4 and IFN-γ measurements|Blood samples are withdrawn from participants and whole blood cultures are prepared and stimulated by bivalent HPV vaccine.IL-4 and IFN-γ are measured in culture supernatants
45647959|NCT03060395|Dietary Supplement|A2 milk 100|Days 1 and 2: 100 mL A2 milk twice a day
45647960|NCT03060395|Dietary Supplement|A2 milk 150|Days 3 and 4: 150 mL A2 milk twice a day
45647961|NCT03060395|Dietary Supplement|A2 milk 200|Days 5 and 6: 200 mL A2 milk twice a day
45647962|NCT03060395|Dietary Supplement|A2 milk 250|Days 7 to 14: 250 mL A2 milk twice a day
45647963|NCT03060395|Dietary Supplement|A1/A2 milk 100|Days 1 and 2: 100 mL A1/A2 milk twice a day
45647964|NCT03060395|Dietary Supplement|A1/A2 milk 150|Days 3 and 4: 150 mL A1/A2 milk twice a day
45647965|NCT03060395|Dietary Supplement|A1/A2 milk 200|Days 5 and 6: 200 mL A1/A2 milk twice a day
45793912|NCT02867033|Procedure|biopsy|pre-therapeutic or post-therapeutic biopsy or resected tissues
45793913|NCT02867033|Other|biobank constitution|Constitution of a biobank with pre-therapeutic or post-therapeutic biopsy or resected tissues
45793914|NCT02867033|Procedure|Coloscopy|For adult patients, a coloscopy with chromoscopy of ascending and sigmoid colon will be performed
45793915|NCT02867033|Procedure|Blood sampling (facultative)|Blood sample can be collected at diagnostic or after medically significant events (progressive disease, local or systemic treatment, pregnancy...)
45793916|NCT02867033|Other|Pain evaluation|Pain evaluation (EVA scale), anxiety (HADS questionnaire), quality of life questionnaire (EORTC-QLQ-C30)
45921049|NCT00006470|Biological|monoclonal antibody 3H1 anti-idiotype vaccine|
45921050|NCT00006470|Radiation|radiation therapy|
45647966|NCT03060395|Dietary Supplement|A1/A2 milk 250|Days 7 to14: 250 mL A1/A2 milk twice a day
45647967|NCT05081323|Behavioral|Self-applied treatment for phobias|The proposed treatment consists of four stages that use different visual elements to represent and replace a real rat in a gradual exposure treatment for specific phobia for animals. With the order of the stages, the intensity of the phobic stimulus increases. In each stage the participant is gradually exposed to a certain amount of elements that represent a phobic situation or object. Graduality considers an approach with realism, interaction, and intensity. The treatment also includes a virtual therapeutic assistant that guides, provides information, and tries to reduce any alteration captured by the participant's heart rate monitoring through deep breathing exercises.
45647968|NCT04431791|Drug|Regorafenib|oral regorafenib
45793917|NCT02867033|Procedure|Tumor biobank realization|Realization of a tumor biobank is part of classical procedure of participating centers
45793918|NCT04059887|Drug|Atezolizumab Injection [Tecentriq]|Blood sampling will be performed before and after 3rd cycle of atezolizumab for evaluation of tumor mutation burden
45793919|NCT04025411|Device|Intensive Visual Simulation 3 (IVS3) device|"Visual motor simulation with the Intensive Visual Simulation 3 (IVS3) device will be realized and consist of 5 sessions per week for 4 weeks (20 minutes).~The patient looks on a screen in front of him, mirroring the movements made by his healthy hand, while attempting to perform the same movement with his paretic hand."
45793920|NCT04025411|Device|traditional Mirror Therapy (TM)|Simulation with the traditional Mirror Therapy (TM) will be realized and consist of 5 sessions per week for 4 weeks (20 minutes).
45647969|NCT04431791|Drug|Fruquintinib|oral fruquintinib
45647970|NCT05007769|Drug|Ramucirumab|Will be supplied by Lilly Oncology, free of charge to the participant
45647971|NCT05007769|Drug|Atezolizumab|Atezolizumab will be commercially available.
45647972|NCT05007769|Drug|N-803|Will be supplied free of charge to the participants by ImmunityBio
45647973|NCT04952051|Drug|Enalapril Folic Acid Tablets Combined With amlodipine|Enalapril Folic Acid Tablets 10.8mg Combined With amlodipine 5 or 10mg
45647974|NCT04952051|Drug|Enalapril Folic Acid Tablets Combined With hydrochlorothiazide|Enalapril Folic Acid Tablets 10.8mg Combined With hydrochlorothiazide 12.5 or 25mg
45647975|NCT04979143|Procedure|Surgical Approach|The surgical laser used will be randomized. All lasers used during this trial are all FDA approved devices and used per routine clinical care.
45647976|NCT04960943|Drug|Pyrotinib with or without trastuzumab|After enrollment, patients of all the three cohorts were given 400 mg/d oral pyrotinib continuously, every 21 days as a cycle; Cohort 1 and 2 : Patients with gastric cancer or esophageal adenocarcinoma were combined with paclitaxel 80 mg/m2, intravenously, once on the first and eighth day. Cohort 3: Patients with colorectal cancer were given trastuzumab at an initial load dose of 8 mg/kg followed by 6 mg/kg every 3 weeks.
45793921|NCT04025411|Device|Electroencephalography (EEG)|Electroencephalography (EEG) will be performed during the 1st, 6th, 11th, 16th and 20th session of their programme will be made in order to evaluate brain activity.
45793922|NCT01877642|Drug|Lorazepam 1 mg IM|Lorazepam 1 mg intramuscular
45793923|NCT01877642|Drug|Inhaled loxapine 10 mg|Inhaled Staccato loxapine 10 mg
45793924|NCT01877642|Drug|Inhaled Placebo|Inhaler with no drug in it to mimic the ADASUVE inhaler
45793925|NCT01877642|Drug|Placebo IM|intramuscular placebo to mimic lorazepam 1 mg IM
45793926|NCT02819843|Drug|TALIMOGENE LAHERPAREPVEC (TVEC)|
45793927|NCT02819843|Radiation|Hypofractionated Radiotherapy|
45793928|NCT01811030|Device|755nm Alexandrite Laser|755nm Alexandrite Laser
45647977|NCT05077033|Drug|phIL12 GET|intratumoral phIL12 gene electrotransfer
45793929|NCT02810951|Genetic|FCX-007|FCX-007 is a genetically modified cell product obtained from the subject's own skin cells (Autologous fibroblasts). The cells are expanded and genetically modified to produce functional COL7. FCX-007 cell suspension is injected intradermally.
45793930|NCT01878656|Drug|Sevoflurane|The investigators decrease to 1 minimal alveolar concentration(MAC) of anesthetic combination of sevoflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, sevoflurane and nitrous oxide are discontinued.
45793931|NCT01878656|Drug|Desflurane|The investigators decrease to 1 MAC of anesthetic combination of desflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, desflurane and nitrous oxide are discontinued.
45793932|NCT04015895|Other|DEFCO tool|The Detection of social frailties and coordination of the path of patients in cancer: a new approach by an expert computer system DEFCO tool is questionnaire to identify their social vulnerabilities. A neural network instantly identifies the patient's fragility and sends the result by email to the professionals identified in the organization of each center. These professionals then relay to the social workers in order to take care of the patient's fragility.
45647978|NCT03058367|Dietary Supplement|IQP-AE-103 (330mg)|High dose capsules
45647979|NCT03058367|Dietary Supplement|IQP-AE-103 (165mg)|Low dose capsules
45647980|NCT03058367|Dietary Supplement|Placebo|Placebo identical to verum capsules
45653174|NCT05492695|Drug|Galcanezumab|Galcanezumab is a calcitonin-gene related peptide antagonist indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.
45793933|NCT01811654|Device|Intra-Articular Hyaluronic Acid-Euflexxa|IAHA was approved by the FDA in 1997 as a synovial fluid replacement device to help relieve the pain associated with knee osteoarthritis (OA) in patients who fail to respond adequately to conservative treatment and simple analgesics. In this study, IAHA, specifically Euflexxa, will be used off-label to determine whether patients afflicted with PFPS will experience similar analgesic effects as seen in those with OA.
45793934|NCT04012697|Behavioral|Peer Support|Participants randomized to the intervention group will be seen by the peer support worker during their stay in the emergency department. The goal of the peer support worker's practice is to address the participant's wellness from a holistic point of view that includes their relationships, connections to the community, general well-being, and sense of empowerment, with an overall focus on quality-of-life goals (Sunderland et al., 2013). The peer support worker will provide a multi-faceted intervention, which aims to foster a peer-to-peer relationship encompassing elements of empathic communication, brief supportive counseling, advocacy for non-medical needs in hospital, liaising and collaborating with medical and nursing staff, motivational interviewing, and connection with programs in the community.
45793935|NCT01794806|Procedure|Tooth extraction and grafting with allograft|Alveolar ridge preservation using a bone grafting material (allograft) and a synthetic dPTFE (dense Polytetrafluoroethylene) barrier membrane
45793936|NCT01794806|Procedure|Tooth extraction|Minimally traumatic single-rooted tooth extraction
45793937|NCT04010357|Drug|Abemaciclib,|Abemaciclib (CDK4/6 inhibitors) is an investigational drug that works by interrupting the rapid and uncontrolled growth of cancer cells. Some cancer cells develop because their cells overrun the molecular brakes that normally permit cell to divide only when they are needed to replace old ones. These brakes are regulated by a group of enzymes known as cyclin-dependent kinases (CDKs). Alterations causing over-activity of two of these enzymes, CDK4 andCDK6, are found in a variety of cancers, including small cell lung cancer with retinoblastoma (Rb) protein.The drugs work by selectively turning off the overactive CDK4 and CDK6. As a result, the cancer cells' division cycle is halted, preventing them from proliferating.
45793938|NCT03983603|Dietary Supplement|Soft chews containing 0.5g plant stanols (delivered as plant stanol esters)|Soft chews containing 0.5g plant stanols delivered as plant stanol esters
45793939|NCT03983603|Dietary Supplement|Placebo soft chew|Soft chew that does not contain plant stanols
45793940|NCT03496701|Device|Test lens|contact lens
45793941|NCT03496701|Device|control lens|contact lens
45793942|NCT02266472|Drug|metformin|single dose of metformin given as tablets
45793943|NCT02266472|Drug|empagliflozin/metformin|Single dose empagliflozin/metformin given as fixed-dose combination tablet
45793944|NCT02266472|Drug|empagliflozin|single dose of empagliflozin given as tablet
45793945|NCT02756507|Behavioral|video-based transdiagnostic REBT|The video-based transdiagnostic REBT consists of 6 sessions delivered in a group format.
45793946|NCT02756507|Behavioral|Wait list|Delayed intervention
45793947|NCT03500289|Drug|Ketamine|One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes
45793948|NCT03500289|Drug|Midazolam|One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes
45793949|NCT01812044|Drug|subtenons anesthetic - preservative-free bupivacaine 0.75%|
45449795|NCT03557931|Drug|aripiprazole|Oral or depot administration
45647981|NCT04890067|Other|Treatment of Osteosarcoma according the AIEOP/ISG OS 2021 recommendations (includes drugs, surgery, radiotherapy or any other received treatments)|This observational study collects all the treatments received by the patients according according the AIEOP/ISG OS 2021 and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments
45793950|NCT01812044|Drug|topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel|
45793951|NCT01812044|Drug|topical control - 0.5 cc of Hypromellose 0.3% gel|
45793952|NCT01812044|Drug|subtenons control - 0.5 cc of Normal Saline|
45793953|NCT03331185|Biological|Freeze Dried Bone Allograft|Human derived bone particles used in oral and periodontal grafting procedures
45793954|NCT03331185|Biological|L-PRF clot|L-PRF is a second-generation platelet rich plasma obtained from autologous blood and contains several different growth factors, platelets and leucocytes in a complex fibrin matrix to accelerate the healing of soft and hard tissues.
45793955|NCT03974789|Diagnostic Test|Blood test|Plasma cortisol level test
45793956|NCT03974789|Diagnostic Test|24-hour Urine test|Urinary free cortisol test
45793957|NCT03974789|Diagnostic Test|Saliva swab|salivette® for salivary cortisol quantification
45793958|NCT03974789|Diagnostic Test|Dexamethasone test|Dectancyl® 2 x 0.5 mg tablets (total 1 mg)
45793959|NCT01812668|Drug|cabozantinib-s-malate|Given PO
45793960|NCT01812668|Radiation|fluorine F 18 d-FMAU|Undergo 18F PET/FMAU PET scan
45793961|NCT01812668|Procedure|positron emission tomography|Undergo 18F PET/FMAU PET scan
45449796|NCT03557931|Drug|brexpiprazole|Oral administration
45449797|NCT03557931|Drug|paliperidone|Oral or depot administration
45449798|NCT03557931|Drug|lurasidone|Oral administration
45449799|NCT03522675|Device|NeoMatriX Wound MatriX Collagen Dressing|Collagen wound dressing
45449800|NCT03722199|Dietary Supplement|flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)|single intake of capsules with flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)
45449801|NCT03722199|Other|Placebo|single intake of capsules with a placebo
45647982|NCT03060317|Behavioral|Examination with neurological scales.|Coma Recovery Scale, Glasgo Coma Scale, FOUR scale
45647983|NCT04964531|Other|speckle tracking echocardiography|before and after closure of the PDA , echocardiographic loops of the apical 4, 3 , and 2 chamber will be acquired then processed by special software for measuring the speckle movements in the longitudinal and short axis views
45647984|NCT04525885|Drug|Gefapixant 45 mg twice daily (BID)|Gefapixant 45 mg tablet to be administered orally BID
45793962|NCT01812668|Other|pharmacological study|Correlative studies
45793963|NCT01812668|Other|laboratory biomarker analysis|Correlative studies
45793964|NCT02570477|Procedure|Fecal Microbiota Transplantation|Healthy donor is screened and donates feces. It will then be diluted with sterile saline, blended and filtered. Supernatant will be infused to recipient.
45793965|NCT02570477|Drug|Vancomycin|125mg Vancomycin four times per day
45793966|NCT04344821|Dietary Supplement|Curves Calcium|"Dietary Supplement: Curves Calcium~Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium [as calcium citrate malate and calcium citrate], 400 IU of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron)"
45793967|NCT04344821|Dietary Supplement|Placebo|Dextrose Placebo
45793968|NCT01878812|Biological|Fluarix/Influsplit Tetra® (2013-2014 season)|1 dose administered intramuscularly in the deltoid region of non-dominant arm
45921051|NCT00105352|Procedure|Mixed Meal Tolerance Test|
45921052|NCT00105352|Procedure|Glucagon Stimulation Test|
45921053|NCT03862950|Drug|Placebo Medication|Placebo liquid or capsules given in parallel to active medication.
45921054|NCT03862950|Drug|Metformin|Active medication
45921055|NCT00105430|Procedure|Deep Brain Stimulation|
45921056|NCT00105547|Drug|MPC-7869|oral 800 mg BID
45921057|NCT00105547|Drug|MPC-7869|Oral BID dosing
45921058|NCT00390624|Drug|URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE)|
45793969|NCT03949283|Diagnostic Test|ChemoID Assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill bulk of tumor cells, and cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
45793970|NCT03949283|Drug|Standard Chemotherapy|"Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin; Docetaxel; Paclitaxel; Carboplatin; Cisplatin; Gemcitabine; Topotecan; Carboplatin, Gemcitabine; Cisplatin, Gemcitabine; Carboplatin, Liposomal Doxorubicin; Carboplatin, Paclitaxel; Carboplatin, Docetaxel. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
46071668|NCT04248582|Device|Cryotherapy|LNSC will be performed with low-pressure liquid nitrogen (<5 psi) at 25 watts using a cryotherapy catheter passed through the working channel of the endoscope.We will plan to administer LNSC as follows: up to three cycles of 20 to 40 seconds each directed at the bulkiest aspect of the tumor. During each cycle, a surface area of approximately 2 to 3 cm2 is targeted. Up to three sites are treated during each session. Tissue thawing is verified between cycles by waiting at least 60 seconds before re-treatment, and by observing a return to baseline color of the tissue and complete disappearance of ice crystals after reperfusion. After the procedure is completed, patients will be monitored in the recovery unit for at least 30 minutes. Patients will be discharged after monitoring if they meet the endoscopy unit's standard discharge criteria.
45793971|NCT04351100|Drug|Diacerein|Diacerein prescribing by orthopedist. Dry eye sign and symptom was asses before start diacerein and after 2 months.
46071669|NCT02833896|Genetic|surgery|
46071670|NCT02833818|Dietary Supplement|CAKE-intervention|Increased protein and energy supplementation and conversations
46071671|NCT02833818|Dietary Supplement|CAKE-control|nutrition according to established procedures
46071672|NCT02837172|Other|Diffusion Weighted Imaging (DWI)|"MDS-UPDRS,Montreal Cognitive Assessment, PDQ-39, DTI imaging (MRI), and neurological examination.~Expert evaluation: Record review, PD Medical History and PD Family History Form, the Montreal Cognitive Assessment, PDQ-39. standard, full, neurological examination, and MDS-UPDRS"
45793972|NCT02310906|Drug|Placebo|SRP-4053 placebo-matching solution for IV infusion.
46071673|NCT04250532|Other|Drowning|Measurement of pulse oximetry, after lifeguard immersion during their morning training
46071674|NCT02839044|Dietary Supplement|Menaquinone-7|
45647985|NCT04525885|Drug|Gefapixant 15 mg BID|Gefapixant 15 mg tablet to be administered orally BID
45647986|NCT04525885|Drug|Placebo|Placebo tablet administered orally BID
46071675|NCT02839044|Dietary Supplement|Placebo|
45647987|NCT04964687|Procedure|Liver transplantation|Liver transplantation
45647988|NCT05081167|Drug|REL-1017|REL-1017 tablet
45647989|NCT05081167|Drug|Placebo|Placebo tablet
45647990|NCT03058445|Device|Echocardiography|Substernal 4 chamber view obtained, then MMode applied to RA, then 5ml of saline is injected
45647991|NCT03058445|Device|CVC|Injection of 5 ml of saline
45647992|NCT04431713|Drug|Exenatide Pen Injector [Bydureon]|Exenatide is a treatment licensed for use in Type 2 diabetes.
45647993|NCT04773925|Behavioral|Mindfulness counseling|Subjects three 60-minute mindfulness counseling sessions with a certified Mind-Body Counselor who has a degree in Social Work in the department of Integrative Medicine. The mindfulness sessions will be conducted entirely via telemedicine. The initial consultation will consist of a 60-minute individual session. The next session will be a group visit (plan for 5 subjects per group) lasting 60 minutes, which will be scheduled for 2 weeks after the initial session. The third session will be another 60-minute group session, which will be scheduled for 6 weeks after the initial session.
45647994|NCT05104333|Biological|Covid-19 vaccine (0-1-4 schedule)|Subjects receive the booster vaccine 3 months after the second dose.
45647995|NCT05104333|Biological|Covid-19 vaccine (0-1-6 schedule)|Subjects receive the booster vaccine 5 months after the second dose.
45793973|NCT02310906|Drug|SRP-4053|SRP-4053 (golodirsen) solution for IV infusion.
46071676|NCT02833740|Device|Click-MUAC prototype & regular MUAC tape|Screening of children using Click-MUAC and regular MUAC tape
46071677|NCT02833662|Other|Measure of ODI and heart rhythm|Record nocturnal respiratory and cardiac parameters before and after surgery.
45793974|NCT02978963|Behavioral|Cognitive behavioral therapy|CBT focused on reducing intolerance of uncertainty
45793975|NCT01796912|Other|Lipoprotein Apheresis|Weekly lipoprotein apheresis for 3 months
45793976|NCT01796912|Other|Sham Apheresis|Weekly sham (placebo) apheresis for 3 months
45793977|NCT02507141|Device|Reflectance Confocal Microscopy|Reflectance Confocal Microscopy imaging will be performed during surgery. The imaging procedure is expected to last no more than 15-20 minutes. The approach will be essentially similar to the imaging of skin cancer on patients, which is routinely performed in our Dermatology Service.
45793978|NCT04345133|Device|Dental Implants Insertion Drilling Sequence|Drilling sequence protocol to insert immediate Dental Implants at the Maxilla.
45793979|NCT05328674|Procedure|Arthroscopic reconstruction of cartilage defects in the knee joint with the use of autogenous cartilage transplant with PRP GF (platelet plasma with growth factor)|Arthroscopic reconstruction of cartilage defects in the knee joint using an autogenous PRP GF cartilage transplant.
45793980|NCT05328674|Procedure|Arthroscopic reconstruction of the cartilage defects of the knee joint using the microfracture method|Arthroscopic reconstruction of the cartilage defects of the knee joint using the microfracture method.
45793981|NCT01798316|Drug|IV Acetaminophen|Single dose, 1000g mg infusion over 15 minutes plus standard of care pain management regimen
45793982|NCT01798316|Drug|Standard of Care|Standard of care pain management regimen, no IV Acetaminophen,
45793983|NCT03883763|Drug|bupivacaine S75:R25 plus 8% glucose|Spinal anesthesia, 20 mg
45793984|NCT03883763|Drug|bupivacaine S50:R50 plus 8% glucose|Spinal anesthesia, 20 mg
45793985|NCT02421731|Device|Robot-assisted gait training|Patients will receive 12 training sessions, lasting for an hour with 30 minutes of real walking time, over 4 weeks (3 sessions/week) of RAGT. Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. During the first session we will set these parameters according to subject characteristics and demand level. As training will progress, adjustments in the three parameters previously described will be performed.
45449802|NCT00294047|Biological|Cervarix|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
45449803|NCT00294047|Biological|Placebo control|Subjects were planned to receive three doses of the control vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
45647996|NCT03058055|Behavioral|Placebo|The placebo group will have unstructured lifestyle activities (normal lifestyle activities without restraint).
45647997|NCT03058055|Behavioral|Origami|Origami lessons (one hour/week) with daily take home Origami activities to complete
45793986|NCT02421731|Other|Conventional therapy|The control group will receive 12 conventional therapy sessions over 4 weeks (3 sessions/week), that will focus on gait training. Subjects will receive 1 hour of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that, assisted over-ground walking training will be performed.
45793987|NCT02340780|Drug|Buparlisib|
45647998|NCT03058055|Behavioral|Reading|Book club that includes weekly one hour meetings and daily reading assignments
45793988|NCT01798394|Drug|Progesterone|Take micronized natural progesterone capsule by mouth, twice daily (approximately at 8 am and 8 pm) for four weeks beginning on postpartum day 4.
45793989|NCT01798394|Other|Placebo|Take placebo capsule by mouth, twice daily (approximately at 8 am and 8 pm) for 4 weeks beginning on postpartum day 4.
45793990|NCT02390297|Genetic|Blood tests|Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses
45793991|NCT02340078|Device|HA IDF II plus|
45793992|NCT02340078|Device|HA IDF II|
45793993|NCT01798550|Drug|Enoxaparin|Twice daily dosing
45449804|NCT03977987|Drug|nucleos(t)ide analogue|Pregnant women in this group agree to receive nucleos(t)ide analogue (tenofovir or telbivudine) daily from the 28 weeks of pregnancy to delivery.
45449805|NCT03977675|Drug|Ketamine|Patients are assigned to one of three ketamine doses (0.3, 0.5, or 0.7 mg/kg) that will be administered intravenously.
45793994|NCT00357305|Drug|vorinostat|Given orally
45793995|NCT00357305|Drug|cytarabine|Given IV
45793996|NCT00357305|Drug|etoposide|Given IV
45793997|NCT00357305|Other|pharmacological study|Correlative studies
45793998|NCT00357305|Other|laboratory biomarker analysis|Correlative studies
45921059|NCT00390624|Drug|MANNITOL|
45449806|NCT03977831|Procedure|Radical Cystectomy|Participants are randomly and blinded assigned
45647999|NCT04951895|Diagnostic Test|MRI|MRI of TMJ
45648000|NCT05094895|Procedure|Stretta|Radiofrequency energy delivered to the gastro-esophageal junction
45648001|NCT05094895|Procedure|Sham|Patients that have the sham condition will have a procedure using a 24Fr Savary bougie dilator over the guidewire, with the same sedation.
45648002|NCT04819763|Other|Physical therapy|"Coordination training for lateral movement of the mandible (spatula exercise):~A wooden spatula is loosely placed between the teeth of the upper and lower jaw; the head must be aligned with the body axis; the exercise should be performed in front of a mirror.~The lower jaw moves to the left and back to the center with little contact to the spatula~The lower jaw moves to the right and back to the center under contact with the spatula~Training of the left lateral pterygoid muscle:~The left palm is placed on the left temple region~Right hand forms a fist and is placed on the tip of the right chin~Both arms are aligned parallel to the surface of the floor~The lower jaw is moved to the right against a moderate resistance of the fist = concentric muscle work~With measured force of the fist, the lower jaw is brought back to the center = eccentric muscle work (Right lateral pterygoid muscle training with opposite hands.)"
45653175|NCT05492695|Other|Placebo|Galcanezumab' placebo. This is the same vehicle as the study intervention formulation but does not contain active galcanezumab-gnlm.
45653176|NCT05729035|Radiation|POCUS|Point of Care Ultrasound is complementary to a medical examination performed by primary care physicians
45793999|NCT03833414|Procedure|triceps lifting and olecranon osteotomy approaches|two different surgical approaches for distal humerus fracture
45648003|NCT04819763|Other|Appliance therapy|"Upper and lower jaw impressions are registered by using an intraoral scanner. The arbitrary hinge axis position is determined using a face bow.~The stabilization appliance with anterior canine guidance is manufactured in the Lexmann laboratory in Dresden.~The stabilization appliance is incorporated by the dentist and the static and dynamic occlusion is checked. A tension-free fit of the appliance on the lower jaw is necessary. Additionally, equal contacts in the side teeth area and incisors guidance in the case of mandibular protrusion are checked visually and by using occlusion foil. During mandibular lateral movement only the canine guidance takes place and is also registered optically and by using occlusion foil.Interference contacts should be adjusted.~The patient is instructed to wear the stabilization appliance while sleeping. The wearing rhythm is described as intermittent. (three nights - wearing the appliance, one night - not wearing the appliance)."
45794000|NCT02340000|Drug|standard dose amoxicillin/clavulanate|amoxicillin/clavulanate 875/125 + placebo bid x 7 days
45648004|NCT04960631|Diagnostic Test|Double site CT guided needle biopsy|Double site CT guided needle biopsy
45648005|NCT03059615|Drug|Nerofe|Nerofe is a first-in-class hormone-peptide with cancer suppressive properties. Nerofe is a derivative of the human hormone-peptide Tumor-Cells Apoptosis Factor (TCApF). It contains 14 amino-acids. Binding Nerofe to the T1/ST2 receptor caused a rapid activation both of Caspase 8 and Bcl-2 mediated downstream in proliferating cancer cells.
45794001|NCT02340000|Drug|high dose amoxicillin/clavulanate|Time Period I: extended-release amoxicillin/clavulanate 1000/62.5 two tablets bid x 7 days Time Period 2: immediate-release amoxicillin/clavulanate 875/125 plus amoxicllin 875 bid x 7 days
45794002|NCT01800890|Device|Coloplast A|Coloplast A is a newly developed 2-piece ostomy appliance
45794003|NCT01800890|Device|Coloplast B|Coloplast B is a newly developed 2-piece ostomy appliance
45794004|NCT01800890|Device|Coloplast C|Coloplast C is a newly developed 2-piece ostomy appliance
45794005|NCT01800890|Device|SenSura Click|The comparator product is the commercial and CE-marked SenSura Click (2-piece) manufactured by Coloplast A/S.
45794006|NCT02364180|Diagnostic Test|Electromyography (EMG)|
45794007|NCT01813214|Drug|Vemurafenib|
45794008|NCT01813214|Drug|Cobimetinib|
45794009|NCT01814774|Other|No Intervention|No treatment (intervention) was administered.
45794010|NCT01815008|Drug|Clopidogrel|Clopidogrel 75 mg daily
45794011|NCT01815008|Drug|Aspirin|Aspirin 81 mg daily
45794012|NCT01801124|Drug|EXPAREL|single dose 266 mg of undiluted EXPAREL
45794013|NCT05328596|Behavioral|CBT treatment|CBT-treatment
45794014|NCT05328596|Behavioral|Wait list control|No intervention
45794015|NCT03501069|Drug|TAK-418|TAK-418 capsules.
45794016|NCT03501069|Drug|TAK-418 Matching Placebo|TAK-418 matching placebo capsules.
45794017|NCT01819844|Device|Closed-loop blood glucose control|The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose > 2 u/kg).
45794018|NCT00357461|Biological|gp100:209-217(210M) peptide vaccine|
45794019|NCT00357461|Biological|gp100:280-288(288V) peptide vaccine|
45794020|NCT00357461|Biological|incomplete Freund's adjuvant|
45794021|NCT00357461|Biological|ipilimumab|
45794022|NCT01819922|Drug|PF-05175157|600 mg as powder in capsule, one dose within 5 minutes prior to AM meal
45794023|NCT01819922|Drug|Placebo|Placebo powder in capsule, one dose within 5 minutes prior to AM meal
45794024|NCT00357539|Drug|Azithromycin (T1225)|
45794025|NCT03331965|Drug|Metoclopramide 5 MG/ML Injectable Solution|A one-time dose of promotility agent (metoclopramide 10 mg in 10 mL saline IV) will be administered at the time of GJ placement.
45794026|NCT03331965|Drug|Saline|A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement.
45794027|NCT05328362|Behavioral|CanCope|Messages prompted participants to use mindfulness-based or distraction-based coping strategies, or a thank-you message which served as an attention control. If participants reported elevated craving (4 or greater) prior to a decision point, they received either a coping strategy message or a control message. If participants reported craving levels of less than 4 they received a control message.
45794028|NCT03278223|Device|Test solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.
45794029|NCT03278223|Device|Control solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.
45794030|NCT03279237|Drug|Irinotecan|May help shrink tumor before surgery.
45794031|NCT03279237|Drug|Oxaliplatin|May help shrink tumor before surgery.
45794032|NCT03279237|Drug|Leucovorin|May help shrink tumor before surgery.
45794033|NCT03279237|Drug|5-Fluorouracil|May help shrink tumor before surgery.
45794034|NCT03279237|Drug|Paclitaxel|Paclitaxel may stop cancer cells from growing and spreading.
45794035|NCT03279237|Radiation|Radiation Therapy|May help shrink tumor.
45794036|NCT03279237|Drug|Carboplatin|Carboplatin may stop cancer cells from growing.
45794037|NCT03501693|Device|DBT plus S-View|DBT plus S-View images
45794038|NCT03501693|Device|FFDM Alone|FFDM alone images
45794039|NCT03282591|Drug|5 mg Serlopitant Tablets|Serlopitant Tablets
45794040|NCT03282591|Drug|Matching Placebo Tablets|Placebo Tablets
45794041|NCT03502941|Dietary Supplement|6.3 g of EAAs mixture and whey protein isolate|A single dose of the mixture of EAAs/whey
45794042|NCT03502941|Dietary Supplement|12.6 g of EAAs mixture and whey protein isolate|A double dose of the mixture of EAAs/whey
45794043|NCT03502941|Dietary Supplement|12.6 g of whey protein isolate|Whey protein isolate alone, which is an equal amount to the double dose of the mixture of EAAs/whey
45794044|NCT03503565|Procedure|intraoperative neuromuscular blockade|The intensity of intraoperative neuromuscular blockade
45921060|NCT00105664|Procedure|Collaborative care model|
45921061|NCT00105664|Procedure|Group interventions|
45794045|NCT03506295|Device|Radial Endobronchial Ultrasound Probe|The radial EBUS procedure is performed by inserting a miniature ultrasound probe (radial EBUS probe) through the working channel of a flexible bronchoscope or catheter (guide sheath). Real-time imaging of the surrounding tissue enables the clinician to determine the lesion's exact location and size.
45794046|NCT03506295|Device|Flouroscopy|Real-time fluoroscopy will be used in all cases to guide the radial probe ultrasound and/or cryobiopsy probe placement.
45794047|NCT03509883|Drug|Drug: Apixaban sprinkle capsules|Single dose (25 x 0.1 mg capsules), oral administration
45794048|NCT03509883|Drug|Experimental: Apixaban tablets followed by apixaban sprinkle capsules|Apixaban sprinkle capsules Single dose (25 x 0.1 mg capsules), oral administration
45794049|NCT03336645|Drug|SHP615|SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
45648006|NCT03059615|Drug|Doxorubicin|Doxorubicin is an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis.
45648007|NCT04951505|Drug|cefepime-taniborbactam|IV infusion
45648008|NCT04951349|Drug|GX-03|Same dosage used in Bactroban Nasal studies.
45648009|NCT04951349|Drug|Petrolatum ointment|Viscous ointment similar in form to study drug.
45794050|NCT03510195|Other|MEDICORP HO PREPARATORY MODULE|3 DAY course module to prepare medical graduates to become house officers
45449807|NCT03977519|Procedure|MA|Huatuo Brand needles (0.30×25mm,0.30×40mm or 0.30×75mm) will be used.Participants will receive manual acupuncture for 30 minutes each time.After acupuncture,we will twist the needles every 10 minutes for about 30 seconds.The patients will be treated in their first day of dysmenorrhea, once a day for three consecutive days. And the treatments will last for three consecutive menstrual cycles.
45648010|NCT02658019|Drug|Pembrolizumab|Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle.
45794051|NCT00376311|Drug|oral salmon calcitonin|
45794052|NCT03511521|Drug|NPH Insulin|Intermediate acting insulin
45794053|NCT03511521|Drug|glargine|basal insulin
45794054|NCT03511521|Drug|Insulin Aspart|prandial insulin
45648011|NCT03059303|Drug|Simeprevir 75 mg|"Part 1: Simeprevir (SMV) 75 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent capsule in Treatment C.~Part 2: SMV 75 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 37.5 mg each), and G (2 tablets of 37.5 mg each), and as a single agent capsule in Treatment C2."
45794055|NCT00376077|Drug|Methylprednisolone and IVIG|Combination therapy (IV MP (Solu-Medrol®, Upjohn) 30 mg/kg (max. 1 g) over 1 hour followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous [Human], 10%; Bayer)* x 1 dose
45794056|NCT00376077|Drug|Placebo and IVIG|Placebo followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous [Human], 10%; Bayer)* x 1 dose
45794057|NCT03512067|Device|Patients given EMV Ventilation|Baseline mechanical ventilation data with conventional pressure-limited assist/control ventilation mode will then be collected for a 4-hour period. The patients will then be transitioned to pressure-limited entrainment-based ventilation for a 4-hour period. Baseline ventilation monitoring will be carried out either immediately preceding or immediately following EMV in the same patient. The sequence of the control/baseline phase and the experimental phase of the study will be randomized.
45794058|NCT03512457|Behavioral|Minimal Intervention|Women view an educational poster in changing room, and they receive a brochure.
45794059|NCT03512457|Behavioral|Intensive Intervention|Women view an educational poster in changing room, and they receive a brochure.
45794060|NCT03519243|Biological|BCD-131|subcutaneously monthly
45794061|NCT03519243|Biological|Mircera|subcutaneously monthly
45794062|NCT03577275|Drug|NST-4016 600mg|Likely maximum therapeutic dose of NST-4016
45449808|NCT03977519|Procedure|TENS|Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used.Participants will receive transcutaneous electric nerve stimulation for 30 minutes each time.They will be treated in their first day of dysmenorrhea, once a day for three consecutive days. And the treatments will last for three consecutive menstrual cycles.
45648012|NCT03059303|Drug|Odalasvir 25 mg|"Part 1: Odalasvir (ODV) 25 mg taken orally as a component of FDC tablet in Treatment A, D and E and as a single agent tablet in Treatment C.~Part 2: ODV 25 mg taken orally as a component of FDC tablet in Treatment A2 and F (2-tablets of 12.5 mg each), and as a single agent tablet in Treatment C2."
45648013|NCT03059303|Drug|Odalasvir 12.5 mg|Part 1: ODV 12.5 mg taken orally as a component of FDC tablet in Treatment B.
45648014|NCT03059303|Drug|Odalasvir 75 mg|Part 2: ODV 75 mg taken orally as a component of FDC tablet (2 tablets of 37.5 mg each) in Treatment G.
45648015|NCT03059303|Drug|AL-335 800 mg|"Part 1: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent tablet in Treatment C.~Part 2: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 400 mg each), and G (2 tablets of 400 mg each) and as a single agent tablet in Treatment C2."
45648016|NCT03059303|Drug|Lansoprazole 30 mg|30 mg lansoprazole once daily from Day 1 to Day 5.
45648017|NCT03059303|Drug|Omeprazole 20 mg|20 mg omeprazole once daily from Day 1 to Day 5.
45648018|NCT04586413|Other|No intervention - quality of life measure|Participants will be part of the creation of a Post-COVID-19 quality of life measure if involved in Phase One. In Phase Two participants will complete this post-COVID-19 quality of life measure monthly for 12 months
45794063|NCT03577275|Drug|Placebo oral capsule|Placebo for comparison with moxifloxacin and potential NST-4016 effects
45794064|NCT03577275|Drug|Moxifloxacin 400mg|Active comparator with known effect on QT interval
45794065|NCT03577275|Drug|NST-4016 2000mg|Supratherapeutic dose of NST-4016
45794066|NCT03581097|Other|Video Group|Patients in the film group watched the film using a laptop computer equipped with headphones, and Visual Analog Pain Scale (VAS) was repeated after the movie. Video was recorded by the Anaesthesiology department team, in order to explain and show in a detailed way on a model, the sequence of events, which occurs between the arrival of patients in the operating room and the performance of Intra-Venous Regional Anesthesia (IVRA)
45921062|NCT00105664|Procedure|Facilitated consultation|
45921063|NCT00105703|Behavioral|Case management using advanced nurse practitioners|
45648019|NCT04593199|Behavioral|Gamified Smartphone App|The primary objective was to determine the acceptability and satisfaction of the Draco app among children. Secondary objective was to evaluate if the Draco app could improve physical activity levels (steps, and moderate-to-vigorous physical activity) and intrinsic motivation for physical activity in children. The gamified smartphone app, Draco, is a virtual pet simulator where you care for a pet by exercising, walking, and answering healthy lifestyle questions.
45794067|NCT03521505|Drug|Dexmedetomidine arm|Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 < 90%) or hypotension (mean arterial pressure (MAP) < 65 mmHg, or systolic blood pressure (SBP) < 90 mmHg) in any duration
45794068|NCT03521505|Drug|Propofol arm|"5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3~2.~Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 < 90%) or hypotension (mean arterial pressure (MAP) < 65 mmHg, or systolic blood pressure (SBP) < 90 mmHg) in any duration."
45794069|NCT03522441|Drug|Clindamycin 1% Gel|Topical gel
45794070|NCT03522441|Drug|Placebo|Topical Placebo gel
45794071|NCT03529461|Device|Non-invasive positive pressure ventilation through nasal mask|Inspiratory pressure 12 cm H2O/Expiratory pressure 6 cm H2O which can be increased to meet a tidal volume (TV) of 300-800 mL (target is 450-500), with maximum Inspiratory pressure 18 cm H2O /Expiratory pressure 8 cm H2O on 100% FiO2.If TVs are more or less than 300 to 800 mL range, the pressure will be adjusted by 1-2 cm H2O) accordingly
45794072|NCT03529461|Device|Rescue non-invasive positive pressure ventilation through nasal mask|If desaturation below 90 %, nasal cannula removed and non invasive positive pressure nasal mask connected to machine: Inspiratory pressure 12 cm H2O/Expiratory pressure 6 cm H2O which can be increased to meet a tidal volume (TV) of 300-800 mL (target is 450-500), with maximum Inspiratory pressure 18 cm H2O /Expiratory pressure 8 cm H2O on 100% FiO2.If TVs are more or less than 300 to 800 mL range, the pressure will be adjusted by 1-2 cm H2O) accordingly
45794073|NCT03529461|Other|Secondary rescue maneuvers|If rescue non invasive positive pressure maneuver attempted (including adjustments in pressure) and O2 sat is not above 90 % within 3 min of starting non invasive positive pressure, scope removed and secondary rescue maneuver started. Secondary rescue maneuvers performed at the discretion of the anesthesiologist (chin lift, oral airway, bag mask, nasal trumpet, LMA, intubation). If sat > 90 % with secondary rescue maneuvers, resumption of scope exam to the discretion of anesthesia. If sat does not increase > 90 % with secondary rescue maneuvers, scope exam to be cancelled and patient care per anesthesiologist
45794074|NCT03585543|Behavioral|Voice Crisis Alert V2|Intervention consists of a mHealth app delivered via smartphone
45794075|NCT04332549|Drug|PICS (Reconstitution Method 1 or 2)|dose: 260mg/m2 Frequency: 2 period cross over study Route of administration : intravenous infusion duration of therapy: 2 cycles of PICS
45794076|NCT03346161|Other|"Usual care American Society of Plastic Surgeons booklet Breast Reconstruction"|-Booklet from the American Society of Plastic Surgeons about how to choose a breast reconstruction surgeon, what to expect during surgery, what is breast reconstruction, risks of breast reconstruction, recovery, costs, and questions to ask surgeon about breast reconstruction
45794077|NCT03346161|Other|Decision tool|-Interactive web based tool. Provides detail about breast reconstruction, asks participant questions about health and medications to personalize risks for breast reconstruction outcome. The tool also goes into pros/cons of breast reconstruction, talks about differences between types of reconstruction, helps people weigh when to have reconstruction (immediate vs. delayed), shows participants representative photos of breast reconstruction outcomes, and assesses patients' knowledge and preferences
45921064|NCT00006473|Drug|oxaliplatin|Given IV
45921065|NCT00105742|Procedure|Diagnosis|
45921066|NCT00105781|Behavioral|Exercise counseling|
45921067|NCT00006476|Drug|suramin|
45921068|NCT00006476|Procedure|conventional surgery|
45921069|NCT00105859|Behavioral|Education and Counseling|
45921070|NCT00105898|Procedure|Web-based care management|Participants interact with a care manager, sending and receiving messages using an internet portal that accepts uploads from glucose and BP meters
45921071|NCT00105898|Procedure|Telephone and face-to-face care management|Participants interact with a care manager via face-to-face and telephone contact
45921072|NCT00105898|Procedure|Internet access alone|Participants are given internet access and encouraged to seek diabetes information to help in their self management
45921073|NCT00105937|Drug|OraVescent fentanyl citrate|
45921074|NCT00105976|Drug|MM-093|
46071678|NCT05285592|Other|Fecal Transplantation|Fecal Transplantation
46071679|NCT05285592|Drug|Standard Medical Treatment|Standard Medical Treatment
45449809|NCT01066559|Procedure|High flux polymethylmetacrylate membrane|Patients will be hemodialysed with high flux polymethylmetacrylate membranes
45648020|NCT04593199|Behavioral|Physical activity tracking app|Participants were asked to use the Fitbit app to track and sync their daily physical activity.
45648021|NCT03059225|Device|repetitive transcranial magnetic stimulation (rTMS)|undergo contralesional 1Hz repetitive transcranial magnetic stimulation(rTMS) or high frequency ipsilesional rTMS for 10 daily sessions
45648022|NCT03059225|Device|Sham stimulation|2-week inhibitory non-dominate hemisphere rTMS program
45648023|NCT03059537|Drug|Oral chenodeoxycholic acid stimulation|oral intake of chenodeoxycholic acid to stimulate the ileal bile acid transporter and farnesoid X receptor
45921075|NCT00006479|Drug|FOLFOX regimen|
45921076|NCT00006479|Drug|fluorouracil|
45794078|NCT03346161|Other|Usual Care Group - Outcome Measures|"Section 1 Knowledge (primary outcome) - set of multiple choice questions about breast reconstruction, implants, flap surgeries, and side effects~Section 2 Decisional Conflict Scale - 4 questions with yes/no answers dealing with participant's certainty about surgery (it total score less than 4, indicates higher decisional conflict)~Section 3 Patient Activation Measures: 3 yes/no questions about participant's knowledge and trust of healthcare provider, sources of info about breast reconstruction, and different options available~Section 4 Breast Reconstruction Decision Quality Instrument: 18 multiple choice questions about thought and processes that went into deciding about breast reconstruction~Section 5 BREAST-Q: 3 questions about the breast reconstruction consultation appoint answers range from 0=no effort to 9=every effort."
45794079|NCT03346161|Other|Decision Group - Outcome Measures|"Section 1 Knowledge and Values Clarification Questions - set of multiple choice questions about the participants feelings on breast reconstruction, implants, flap surgeries, and side effects~Section 2 Decisional Conflict SURE measure - 4 questions with yes/no answers dealing with participant's conflicts on surgery (if total score less than 4, indicates higher clinical significant decisional conflict)~Section 3 Patient Activation Measures: 3 yes/no questions about participant's knowledge and trust of healthcare provider, sources of info about breast reconstruction, and different options available~Section 4 Breast Reconstruction Decision Quality Instrument: 18 multiple choice questions about thought and processes that went into deciding about breast reconstruction (for those who have a clinical visit)~Section 5 BREAST-Q: 3 questions about the breast reconstruction consultation appointment answers range from 0=no effort to 9=every effort (for those who have a clinical visit)."
45794080|NCT03346161|Other|Demographic and Background Questions|"Asks 15 questions~Age, education, ethnicity, race, combined household income, zip code, disease stage, (3) questions about health insurance, (4) questions about participant's ability to work with numbers, heath literacy, health insurance status, and (1) question on if participant spoke to another provider about breast reconstruction decision"
45794081|NCT03530631|Drug|Adderall|Participants will be administered Adderall
45794082|NCT03530631|Drug|Placebo|Participants will be administered placebo
45794083|NCT03533829|Device|Buzzy®|Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.
45794084|NCT03533829|Behavioral|Music|Music will be selected and listened to as a distraction before and during vaccination.
45794085|NCT03350217|Drug|Eleview|If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.
45794086|NCT03350217|Drug|Hetastarch|If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.
45794087|NCT04735107|Procedure|colorectal anastomosis reinforcement and trans-anal drainage|Circular mucosal flap created to cover stapled anastomosis + vacuum sponge drainage
45921077|NCT00006479|Drug|leucovorin calcium|
45921078|NCT00006479|Drug|oxaliplatin|
45921079|NCT00006479|Procedure|adjuvant therapy|
45921080|NCT00006479|Procedure|conventional surgery|
45921081|NCT00006479|Procedure|neoadjuvant therapy|
45921082|NCT00106054|Drug|Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.|
45921083|NCT00106132|Drug|Triamcinolone Acetonide|
45921084|NCT00106171|Drug|Highly active antiretroviral therapy (HAART)|Regimens will be assigned by investigators
45921085|NCT03815682|Biological|Arm A: RPTR-147:1|Escalating doses of RPTR-147:1 as a monotherapy
45921086|NCT03815682|Biological|Arm B: RPTR-147:1 and Pembrolizumab|Escalating doses of RPTR-147:1 in combination with Pembrolizumab
45921087|NCT03815682|Biological|Arm C: RPTR-147:2|Escalating doses of RPTR-147:2 in patients with HPV positive tumors
45921088|NCT00106210|Behavioral|Early intervention blending several tx approaches, w/ focus|Early intervention blending several different treatment approaches, with a focus on certain skills
45921089|NCT00106210|Behavioral|Early intervention blending several treatment approaches|Early intervention blending several different treatment approaches
45921090|NCT00106288|Drug|Micafungin|IV
45921091|NCT00106288|Drug|Liposomal Amphotericin B|IV
45921092|NCT00006482|Drug|cisplatin|
45921093|NCT00006482|Drug|gemcitabine hydrochloride|
45921094|NCT00106327|Behavioral|Exercise|6 months of supervised treadmill exercise or strength training, three times per week, followed by a 6 month home-based program.
45921095|NCT00106327|Behavioral|Diet|11 nutrition education sessions
45921096|NCT03809988|Drug|Palbociclib|Palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks
45921097|NCT03809988|Drug|Endocrine therapy|Endocrine therapy alone (letrozole or fulvestrant)
45921098|NCT00106366|Drug|insulin detemir|
46071680|NCT04249440|Procedure|Preoperative systemic treatment|neoadjuvant chemotherapy combined with trastuzumab as preoperative systemic treatment
46071681|NCT04249518|Behavioral|Videoeducation|No drugs used. The only difference in the to arms is the way the extradition is.
46071682|NCT04249206|Procedure|Root Canal Treatment|
46071683|NCT02833506|Other|Laboratory Biomarker Analysis|Correlative studies
46071684|NCT02833506|Biological|Recombinant NY-ESO-1 Protein|Given recombinant NY-ESO-1 protein SC
46071685|NCT02833506|Drug|Sirolimus|Given PO
46071686|NCT02838732|Dietary Supplement|L-carnitine|
46071687|NCT02838498|Device|ERCP Mechanical Simulator (EMS)|Hands on EMS training
46071688|NCT02833272|Behavioral|EMPOWER Educational Brochure|The EMPOWER educational brochure explains the risk of benzodiazepine and non-benzodiazepine sedative use to patients with a current prescription. The brochure also provides a tapering schedule if the patient chooses to discontinue taking the drug.
45921099|NCT00106366|Drug|insulin glargine|
45921100|NCT00106366|Drug|insulin aspart|
45921101|NCT00106405|Drug|Memantine HCl|
45921102|NCT00006485|Drug|alvocidib|
45921103|NCT00006485|Drug|irinotecan hydrochloride|
45648024|NCT04416685|Procedure|primary repair|For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.
45648025|NCT04416685|Procedure|segmental resection|For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.
45794088|NCT03350919|Device|Training in the blind field|A computer software and chin-rest necessary to perform visual training will be loaned to each patient to use at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a pre-determined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. They will train daily (about 40-60 minutes total), 5 to 7 days per week, for at least 24 weeks.
45794089|NCT03350919|Device|Training in the intact field|A computer software and chin-rest necessary to perform visual training will be loaned to each patient to use at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a pre-determined location in the intact field of vision. The computer program will automatically create a record of patient performance during each home training session. They will train daily (about 40-60 minutes total), 5 to 7 days per week, for at least 24 weeks.
45794090|NCT03351699|Drug|MK-4250|MK-4250 tablets for oral administration
45794091|NCT03351933|Biological|Immune Globulin (Human)|A single 0.2 mL/kg IM injection of Immune Globulin (Human) (GamaSTAN) was administered in healthy subjects.
45794092|NCT03352245|Behavioral|Prescribed Activity|Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)
45794093|NCT03594045|Drug|Apixaban|Apixaban is an anticoagulant that works by inhibiting the coagulation factor, Factor Xa.
45794094|NCT03595215|Device|TENS|Transcutaneous electrical nerve stimulation
45921104|NCT04728256|Behavioral|Laughter therapy+Music listening+Keeping diary|"Laughter therapy was carried out by the researcher as a total of three sessions every 15 days, and each session lasted 30 minutes.~Participants listened to the types of music that they like (pop, Turkish folk music). In the meeting room in FHC, Two professional artists performed music recitals with a guitar and saz (qopuz) to pregnant women, and pregnant women actively participated in this process. The performance was carried out as three sessions, once every 15 days, and each session took 40 minutes.~In addition to music listening and laughter therapy, the pregnant women were asked to keep a diary to write down their emotions about their health status, pregnancy and baby. Then, each participant had an opportunity to explain her emotions or replies to the questions during the group therapy sessions every 15 days so that pregnant women were able to express their feelings."
46071689|NCT02838576|Drug|Conjugated Equine Estrogen|Use of conjugated equine estrogen for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
46071690|NCT02838576|Drug|Placebo|Use of placebo for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
45648026|NCT04416685|Procedure|graft reconstruction|Regarding Level III tumors, complete resection of the tumor was done either by tangential excision or by partial venous excision and subsequent reconstruction. To maintain a secure anastomosis, the mesenteric root was mobilized completely or/and splenic vein was divided.
45648027|NCT04944407|Procedure|LHP|A skin microincision of 3 mm was made about 1 to 1.5 cm of distance from the anal verge at the base of each hemorrhoidal node. The probe (1.85 mm of diameter) was driven through the incision in the submucosal tissue until reaching the area underneath the distal rectal mucosa. Then, ten to twelve effective pulses (adjusted to respective node dimensions), 8 watt per 3 seconds each, of approximately 24 Joule using a 1470-nm diode laser generator (LEONARDO® DUAL 45 Biolitec® Jena, Germany) were fired. Half of them were fired in the submucosal tissue, the others in the intra-nodal compartment determining the shrinkage of the hemorrhoidal piles. The anal wounds were left open. At the end of the procedure an anal tampon was positioned.
45653177|NCT05172375|Behavioral|Shared Care Model|The Shared Care model consists of the following key elements: Shared care is a collaboration between general practice and mental health services and enables a 'best of both worlds' scenario with the opportunity to provide holistic care of high quality to support the recovery process of people with mental health difficulties.
45794095|NCT03595449|Drug|Lidocaine jelly|lidocaine 2% jelly applied during Mohs surgery
46071691|NCT02836860|Other|Tactile stimuli|Both groups will receive tactile stimuli: hand touch on the right and left lumbar multifidus muscles at L4-5
46071692|NCT00838539|Drug|Neratinib|
46071693|NCT00838539|Drug|Temsirolimus|
45794096|NCT03595449|Drug|Surgilube|surgilube (placebo) applied during Mohs surgery
45794097|NCT03597009|Drug|Talimogene laherparepvec (TVEC)|Talimogene laherparepvec (TVEC) (4ml of 108 pfu/ml) for up to 9 cycles, with or without nivolumab
45794098|NCT03597009|Drug|Nivolumab|Nivolumab (240 mg IV) will be co-administered with talimogene laherparepvec (TVEC) (4ml of 108 pfu/ml) for up to 9 cycles in the Dose Level 2 cohort
45794099|NCT03352323|Drug|Oxymetazoline|RLD
45794100|NCT04734639|Behavioral|CON . control condition without exercise / rest condition|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
45921105|NCT03803826|Device|CRT-D re-programming|"The previously implanted, ineffective CRT-D is reprogrammed under supervision of Trans-Thoracic Echocardiography (TTE) to:~adjust the atrioventricular interval so that E and A waves do not overlap~the interventricular interval is subsequently optimized to yield maximum improvement of the sum of longitudinal+radial+circumferential strains."
45794101|NCT04734639|Behavioral|Def-Mixed. Condition with a mixed energy deficit induced by exercise + dietary restriction.|Def-Mixed. Condition with an exercise-induced energy deficit The adolescents will received a calibrated lundh meal with a deduction of 250 kcal compared with the lunch meal of Con; and will be asked to realise an acute exercise set at 65% of their capacities (cycling) during the afternoon, inducing an energy expenditure of 250 kcal. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
45648028|NCT04944407|Procedure|MM|The hemorrhoidectomy was performed by radiofrequency (LigaSure TM Small Jaw® Covidien®, Colorado, USA) or ultrasound (Focus® Ultracision® harmonic scalpel; Ethicon Endo-Surgery®, Inc., Cincinnati, Ohio). The anodermal wedge was incised, eventually removing external fibrosis and/or skin tags when present. Upward dissection started at this level with en-bloc excision of mucosal and submucosal layers from the underlying internal anal sphincter up to the anorectal ring. A compressive haemostatic sponge was left in place for 12-24 hours.
45794102|NCT04734639|Behavioral|Def-EI. Condition with an energy-restriction energy deficit|Condition with an energy-restriction energy deficit The adolescents will receive a calibrated breakfast reduced from 500 kcal compare to their CON and Def-mixed conditions. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
45794103|NCT03597789|Behavioral|Helping the Noncompliant Child (HNC)|HNC is a mastery-based, family-focused, clinic-based treatment for young children aged 3-8 years with problem behavior.
45648029|NCT04428775|Drug|ALZT-OP1a (cromolyn)|"Mast cell stabilizer~Neuroinflammatory microglial modulator~anti-inflammatory"
45648030|NCT04944329|Procedure|Hip fracture surgery|Hip fracture surgery
45648031|NCT04436263|Behavioral|Supplement|A sufficient quantity of the winery by-products will be extracted on an industrial scale and capsules will be produced, each one containing 110mg of phenolic compounds (gallic acid equivalents).Volunteers will consume 6 capsules along with a standardized meal (1131 kcal, 19.7% carbohydrates, 11.2% protein, 66.7% fat) and blood will be drown before the meal consumption and at specific time points for the next 6h
45794104|NCT03598647|Behavioral|Affect and physical activity|The focus of this intervention is to help the participant to become more aware of their positive feelings and experiences related to exercise. They will learn about typical affective responses to exercise, view their own affective responses to exercise, and they will be taught cognitive strategies for altering affective responses to exercise. Participants will also receive general information about exercise safety, physical activity guidelines, and exercise intensity.
45794105|NCT03598647|Behavioral|Physical activity information|Participants will receive general information about exercise safety, physical activity guidelines, and exercise intensity.
45648032|NCT04436263|Behavioral|Placebo|A look-alike placebo containing maltodextrin will be prepared.Volunteers will consume 6 capsules along with a standardized meal (1131 kcal, 19.7% carbohydrates, 11.2% protein, 66.7% fat) and blood will be drown before the meal consumption and at specific time points for the next 6h
45648033|NCT04951271|Behavioral|Solution focused approach|The SFA intervention consists of seven sessions, one preparation and six solution-oriented sessions. Each session lasted 55 minutes. Filling in the applied scales was excluded from this period. Sessions were held once a week in two groups (Grade 10 and Grade 11 students).
45648034|NCT04272619|Behavioral|LIVE-R Life Education|A health educator will present participants with a 30-minute PowerPoint presentation containing educational information about liver cancer risk, screening, prevention, symptoms, and treatments, as well as introduce the concept of neighborhood health (e.g., rates of liver cancer and related risk factors in a census tract and how that might influence individual cancer risk).
45794106|NCT03599271|Device|Drug-Coated Device|3000 mcg mometasone furoate-coated sinus dilation device
45794107|NCT03599271|Device|Control Device|Sinus dilation device without drug
45794108|NCT04734561|Other|Inspiratory muscle training group|Participants will perform an inspiratory muscle training including warm-up, recovery between intervals and return to calm.
45648035|NCT04950569|Drug|levosimendan|On the basis of standard conventional anti-heart failure treatment, levosimendan was used for 24 hours. The first load was 12 μg/kg, intravenous injection for 10 minutes, followed by intravenous infusion of 0.1 μg/Kg/min for 24 hours.
45648036|NCT04944251|Behavioral|Regular Exercise|the third month, for 30 minutes or 1 hour, 3 days a week
45648037|NCT04411043|Behavioral|Molecular caracterization|Prospective and retrospective study evaluating the epidemiological, clinical, molecular and therapeutic data of prolymphocytic leukemias T
45648038|NCT04944641|Behavioral|education on epilepsy|education on epilepsy, including epilepsy diary, pamphlet，discussion between patients and phone visits and so on
45648039|NCT04944641|Drug|routine and proper antiepileptic drugs|routine and proper antiepileptic drugs
45648040|NCT04436419|Dietary Supplement|Alpha lipoic acid (plus full hospitalization)|"Women are included in an 8-weeks randomized double-blind against placebo supplementation study with ALA (eight per group) according to the following criteria:~Inclusion criteria: BMI> 30; aged between 18 and 75 years. Non-inclusion criteria: HLA-DRB1*04-03/06 polymorphisms; recent hospitalization (<1 month); food supplement based on antioxidant; medicated in fibrate / telmisartan (modulator of PPARs); patients presenting an acute inflammatory state.~Exclusion criteria: Pregnant and/or lactating women; not affiliated with social security; not mutual health insurance; person deprived of liberty; participation in clinical research in the last 6 months.~Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. α-LA (2x300mg/day of R-ALA) was administered double-blinded in the form of 2 capsules apart from meals."
45648041|NCT04436419|Dietary Supplement|Placebo (full hospitalization: dietary monitoring with an adapted physical activity program)|Women are included in an 8-weeks randomized in placebo group. Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. Placebo (2x300mg/day) was administered double-blinded in the form of 2 capsules apart from meals.
45794109|NCT04734561|Other|Inspiratory muscle training placebo group|Participants will perform an inspiratory muscle training including warm-up, recovery between intervals and return to calm.
45794110|NCT04734561|Other|Inspiratory + expiratory muscle training group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
45794111|NCT04734561|Other|Inspiratory + expiratory muscle training placebo group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
45794112|NCT03357393|Drug|Midazolam|Midazolam is givenas sedation to the Control arm.
45794113|NCT03357393|Drug|Propofol-Lipuro|Propofol is given as sedation to both intervention arms.
45794114|NCT03357393|Drug|morphine-scopolamine|Given as premedication for the Control arm and one of the interventions arms.
45794115|NCT03357393|Drug|Glycopyrrolate|Given as premedication for one of the intervention arms..
45648042|NCT02624687|Behavioral|Intervention|Participants participated in monthly, individual counselling with a trained interventionist to decrease sedentary behavior and improve pain self-management. Participants were provided with a sit-stand desk attachment and a wrist worn activity prompter..
45648043|NCT02624687|Other|No intervention|No contact control
45648044|NCT04943705|Device|Yin and Yang Regulating Moxibustion|Before making Wenyang Yishen moxibustion, the width and length of the patient's moxibustion site were evaluated by the same body measurement method. Take about 700g of fresh ground ginger with moderate dryness and wetness, and place it on the treatment towel to make a round cake with a diameter of about 20cm and a thickness of about 2.5cm. Spread 25g of moxa moxa with a diameter of about 18cm on top of ginger and light it. When the bottom temperature reaches about 37 degrees, the door can be placed on the patient's waist for treatment. According to the patient's tolerance, the temperature should be controlled at 43-45 degrees. It is better to replace the moxa biscuit every time when the moxa biscuit is burned for about 10 minutes. The patient's local skin has a slight redness and burning. The moxibustion time is 60 minutes. Peiyuan Guben moxibustion is centered on Shenque, and the operation is the same as that of WenYang and Yishen moxibustion.
45794116|NCT04734717|Diagnostic Test|Neurology test|movement examination of patients with covid19 disease
45794117|NCT03539211|Other|Rotation Exercises|The subjects received 7 trunk rotation stability exercises x 10 reps each
45794118|NCT03539211|Other|Control Exercises|The subjects received 7 traditional exercises x 10 reps each
45794119|NCT03358251|Device|Pocket-X Gel|Pocket-X Gel is a biodegradable in-situ gelling product that is inserted into a pre-cleaned periodontal pocket where it quickly turns into a gel that adheres to the periodontal pocket and acts as a filler and physical barrier against bacterial re-colonization at the site of application. Administration of this product typically causes no discomfort. The product naturally degrades after 1-3 weeks.
45794120|NCT03358251|Procedure|Scaling and root planing|Scaling and root planing is a conventional gold-standard treatment for periodontitis. As part of this procedure, subgingival plaque and tartar are removed and root surfaces are planed.
45794121|NCT03604263|Device|ArcticLine Cardiac Cryoablation Catheter|Cryoablation
45794122|NCT03540147|Device|Hokanson Cuffs|Each subject will participate in all (5) experimental arms. The order in which the experimental arms will be completed will be randomly assigned to the participant.
45794123|NCT03540147|Device|BStrong Bands|Each subject will participate in all (5) experimental arms. The order in which the experimental arms will completed will be randomly assigned to the participant.
45794124|NCT03541941|Drug|Exparel|Solution of: 266mg of Bupivacaine Liposome Injectable Suspension (Exparel) mixed with 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block
45794125|NCT03541941|Drug|Bupivacaine Hcl 0.25% Inj|Solution of: 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block
45794126|NCT03541941|Drug|Placebo|Normal saline administered intraoperatively through a transversus abdominis plane (TAP) block
45794127|NCT04734483|Diagnostic Test|spirometry|spirometry
45794128|NCT04734483|Radiation|MRI and CT|MRI and CT
45794129|NCT04734483|Other|Laryngoscopy|laryngoscopy
45794130|NCT04734483|Other|electromyography|electromyography
45794131|NCT03542019|Device|Dental prosthesis|Replacement of missing tooth structure using Lithium disilicate porcelain
45794132|NCT03542019|Device|Dental crown|Replacement og missing tooth structure using monolithic zirconia
45794133|NCT03542019|Device|Hybrid ceramic|Restroration of endodontically treated teeth using hybrid ceramic
45794134|NCT03550989|Other|Non-Exposure Event|Non-Exposure event of 4h duration for the individual participants, where no use of any tobacco or nicotine-containing product is allowed, designed to establish background measurements in the absence of exposure to IQOS.
45794135|NCT03550989|Other|Exposure Event|Exposure Event designed to measure urinary BoExp to selected HPHCs representative of ETS in all participant groups, with up to 5h of exposure to IQOS tobacco environmental aerosol for non-smokers, cigarette smokers (not using any tobacco or nicotine-containing product, including cigarettes), and IQOS passive users (not using IQOS). Additionally, this event includes up to 8h of exposure for IQOS active users (using IQOS).
45794136|NCT03611829|Behavioral|ACT Intervention|
45794137|NCT03611829|Behavioral|Standard Care|
45449810|NCT01066559|Procedure|Polysulfone membrane|Patients be hemodialysed with polysulfone membranes
45794138|NCT03359889|Drug|PraxbindTM|Drug
45794139|NCT00376467|Drug|Imatinib|
45794140|NCT03556761|Drug|Oral furosemide|Furosemide (Lasix), 20 milligram, PO, PO, daily
45794141|NCT03556761|Drug|Placebo Oral Tablet|Placebo, PO, daily
45794142|NCT03361917|Device|Endocuff Vision|Subjects that are randomized to undergo their colonoscopy procedure with the Endocuff Vision device will have the device placed on the colonoscope that will be used during their procedure.
45794143|NCT03559179|Other|Opioid Wizard|The Opioid Wizard is an OUD clinical decision support tool for primary care providers.
45794144|NCT03366207|Drug|Ciprofloxacin|Ciprofloxacin 250 mg PO twice daily (BID) x 3 days for women with uUTI.
45794145|NCT03368235|Drug|AZD9567|oral OD SGRM administered as suspension
45794146|NCT03368235|Drug|Prednisolone|oral capsules of 20 mg prednisolone administered OD for two weeks
45794147|NCT03615183|Drug|MK-8527|Single oral capsule
45794148|NCT02310750|Drug|PF-06700841 oral solution/suspension|Oral solution or suspension of study drug PF-06700841 (once daily or twice daily during multiple dosing periods)
45921106|NCT03803826|Diagnostic Test|Trans-Thoracic Echocardiography|"This intervention relates to the determination of strains and atrioventricular interval and supplies data for reprogramming the ineffective CRT-D~Transthoracic echocardiography performed to determine the left ventricular ejection fraction as an outcome measure is not considered intervention here (as it is also performed in the control group and that would cause an error cross-referencing."
45921107|NCT00106522|Drug|Methotrexate|10-25mg weekly
45648045|NCT04950491|Other|Modified Dental Anxiety Score (MDAS) questionnaire|MDAS was used to measure the patients' anxiety toward dental treatment before implant surgery (Humphris, Dyer, &Robinson, 2009). Originally, the MDAS questionnaire included five questions answered with a 5-category Likert scale. The original MDAS questionnaire does not cover anxiety toward implant surgery. Therefore, a question enquiring about patients' feelings towards implant surgery was added.
45648046|NCT04950491|Other|Pain questionnaire|Patients were asked to describe the worst pain feeling using a standard 10 cm Visual Analog Scale (VAS) and the proportion of time spent in severe pain using a 5 category Likert scale. The number of analgesics taken per day was also asked.
45648047|NCT04950491|Other|Oral Health-Related Quality of Life (OHRQoL) questionnaire|The OHRQoL comprises 14 questions covering problems the patient may in three main categories: oral function, daily activity, and post-operative symptoms (Chaushu, Becker, Zeltser, Vasker, & Chaushu, 2004). Patients answered using a 5-category Likert scale.
45648048|NCT04950335|Procedure|AOPT|The Osteochondral Autograft Transplant System (Arthrex) was used to create donor plugs. Osteoperiosteal grafts were harvested from the ipsilateral anterior superior iliac spine.
45648049|NCT04950335|Procedure|AOCT|Osteochondral grafts were harvested from the non-weight-bearing zone of the ipsilateral anterolateral distal femur.
45449811|NCT01066559|Biological|Hepatitis B serological control|It will be assessed at week 16, week 20 and week 40
45648050|NCT04950179|Other|PDRI patients|The study was conducted by retrospective data collection from medical records of 135 continuous ambulatory peritoneal dialysis (CAPD) patients at Phramongkutklao Hospital from January 1, 2016 to December 31, 2020.
45648051|NCT04944173|Drug|Durvalumab|Subjects will receive durvalumab 1500mg IV every four weeks for four cycles, undergo assessment for residual disease, then a subset of subjects will receive an additional eight cycles of durvalumab.
45648052|NCT04944173|Radiation|Stereotactic Body Radiotherapy|Subjects will receive stereotactic radiation therapy concurrent with cycle 2 of durvalumab to a dose of 48Gy in four fractions. Fractionation may be modified for central tumors.
45449812|NCT01066559|Biological|Seric sCD40 level|Ir will be measured at inclusion and week 12 by ELISA test according to the manufacturer instructions.
45449813|NCT00293813|Drug|Alendronate|Alendronate 70 mg PO QW
45648053|NCT04944173|Diagnostic Test|Circulating Tumor DNA assay|After four cycles of durvalumab, subjects will be evaluated at the MRD Landmark for residual ctDNA to determine subsequent treatment assignment.
45648054|NCT04960319|Device|Intravascular Lithotripsy|Coronary Angiography. When the anatomic inclusion criteria are met, traverse the lesion with a guidewire. If traversal fails, assign the subject to the registry. After wire traversal has been documented by cine angiography, angiographic, OCT-defined or balloon expansion criteria are met, subject is enrolled. Blood sample for Troponin (hs TnT) baseline measurement has to be taken. The subjects will be randomized in a 1:1 fashion to treatment with either IVL or RA.
45648055|NCT04950647|Drug|Nitrofurazone Group 1|Test group 1: Nitroketazine tablet 600 mg group (Nitroketazine 300 mg tablet X2 + placebo 300 mg tablet ×2 tablets each time; If the subject progresses and cannot take 300mg tablets, Nitroketazine 100mg tablets x6 + placebo 100mg tablets x6) can be replaced.
45794149|NCT02310750|Other|Placebo|Matching placebo given during the single ascending and multiple dose periods
45794150|NCT02310750|Drug|PF-06700841 tablet|PF-06700841 tablet formulation administered during the bioavailability / food effect investigation
45794151|NCT03615807|Procedure|Surgical debridement (if needed)|Surgical debridement
45794152|NCT03615807|Diagnostic Test|Microbiological sampling|Microbiological sampling
45794153|NCT03615807|Procedure|Revascularisation (if needed).|Revascularisation (if needed).
45794154|NCT03615807|Device|Off-loading|Off-loading by Special shoes
45794155|NCT03615807|Behavioral|Patient's education and instructions|Patient's education and instructions by specialized nurses
45921108|NCT00106522|Drug|Placebo|iv every 4 weeks
45449814|NCT00293813|Drug|Denosumab|denosumab 60 mg SC q 6 mos
45449815|NCT00293813|Drug|Placebo|Placebo for alendronate and placebo for denosumab
45449816|NCT01066715|Drug|XOMA 052|Sterile solution subcutaneously administered monthly for 6 months
45449817|NCT01066715|Drug|Placebo|Sterile solution subcutaneously administered monthly for 6 months
45449818|NCT00293579|Drug|Pemetrexed|500 mg/m2 IV every 3 weeks for 6 cycles
45449819|NCT00293423|Biological|HSPPC-96|25 mcg
45449820|NCT00293423|Procedure|Standard Surgical Resection|Patients will undergo standard surgical resection of intracranial tumor
45794156|NCT03615807|Procedure|Wound debridement|Regular wound debridement by specialized nurses
45921109|NCT00106522|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
45921110|NCT00106522|Drug|tocilizumab [RoActemra/Actemra]|4mg/kg iv every 4 weeks
45921111|NCT00006488|Drug|recombinant-methionyl human glial cell line-derived neurotrophic factor|
45921112|NCT00105820|Procedure|System level depression care quality improvement|
45648056|NCT04950647|Drug|Nitroketazine Group 2|Test group 2: Nitroketazine tablets 1200 mg group (each oral Nitroketazine 300 mg tablets x4 tablets; If the subject progresses and cannot take 300 mg tablets, Nitroketazine 100mg tablets x12 tablets can be taken instead).
45648057|NCT04950647|Drug|placebo group|Control group: placebo group (placebo 300mg tablets x4 tablets each orally; If subjects progress and cannot take 300mg tablets, they may take placebo 100 mg tablets x 12 tablets instead).
45648058|NCT01675765|Biological|Immunotherapy plus chemotherapy|live attenuated double deleted Lm
45648059|NCT01675765|Biological|Immunotherapy with cyclophosphamide plus chemotherapy|live attenuated double deleted Lm
45794157|NCT03615807|Drug|Antibiotic duration|Systemic antibiotic duration according to the study arms
45794158|NCT03563313|Device|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Participants will use the Tandem t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 6 months at home.
45794159|NCT03563313|Device|Sensor-augmented pump (SAP)|Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.
45794160|NCT02310672|Drug|Macitentan|All patients take open-label macitentan 10mg o.d.
45794161|NCT03616899|Drug|KPI-121 Ophthalmic Suspension|KPI-121 Ophthalmic Suspension
45648060|NCT04960163|Other|No intervention|No intervention
45648061|NCT04960085|Device|echocardiography|philips IE33
45648062|NCT04522453|Other|paper-based version of mental health Gap Action Program-Intervention Guide|A paper-based guide for diagnosis and management of mental disorders in primary care.
45648063|NCT04522453|Other|digital version of the mental health Gap Action Program-Intervention Guide|A digital guide and client data entry tool for diagnosis and management of mental disorders in primary care.
45648064|NCT04943237|Drug|Anti-TNF agents|Group of patients using anti-TNF for the last 5 years.
45648065|NCT04943237|Drug|Conventional therapy users for the last 5 years|Group of patients not using anti-TNF. Group of patients using conventional therapy (non -steroid anti-inflammatory drugs and/or salazopyrin) for the last 5 years
45648066|NCT05011435|Device|web-application for burnout|Use of burnout advisor web-application for detection of professional burnout
45648067|NCT04950413|Other|Conventional physical therapy program|Infrared, Exercises, Stretching exercise of Suboccepital muscle
45648068|NCT04950413|Other|IASTM by M2t blade|A lubricant (Vaseline) will be applied to the skin around the neck area prior to treatment and the M2t blade will be cleaned with an alcohol pad. First, the M2T blade will used to ﬁnd the exact areas of restriction in affected muscles. Then the M2T blade will use at an angle of 45 to apply slow strokes along the muscle. Changes in soft tissue consistency will detected by the clinician through vibrations of the instrument when it slides on areas of irregular fibrosis of the underneath connective tissue. Once an adhesion is discovered, strokes are repeated for 5 min.
45648069|NCT04950413|Device|Phonophoresis|It will be consisted of 1 MHz pulsed mode with an intensity set at 1.5 W/cm2 and. A 5 cm2 crystal head with an effective radiating area of 4.0 cm2 ±1.0 wills utilized for 5 Min for each trigger point of neck. lidocine gelwill applied instead of coupling US gel used for transmission.
45648070|NCT04285255|Drug|Fentanyl|opioids anaesthesia
45794162|NCT03616899|Drug|Vehicle|Vehicle for KPI-121 0.25% ophthalmic suspension
45794163|NCT03568539|Drug|IBI308|IBI308 200mg IV infusion, every 3 weeks.
45794164|NCT03569397|Other|Music Therapy|Patients will be administered music therapy during the operation.
45794165|NCT03570255|Device|RD SET Neo SpO2|All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
45794166|NCT03576183|Biological|VLA1701|VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)
45648071|NCT04285255|Drug|Ketamine|ketamine induction and analgesia as opioids free anaesthesia versus opioids analgesia
45648072|NCT04285255|Drug|Dexmedetomidine Injection [Precedex]|alpha 2 agonist with sedative, analgesic effect
45648073|NCT04285255|Procedure|Oblique subcostal transversus abdominis plane block|Bupivacaine 0.25% injected under ultrasound usage in the transversus abdominis plane
45794167|NCT03576183|Biological|Placebo|buffer component of VLA1701
45648074|NCT04285255|Drug|Lidocaine|infusion of lidocaine 2%(1mg/kg/h)
45653178|NCT04911803|Behavioral|Anxiety Application|The Intellect mobile app (containing the anxiety application) can be freely downloaded from the App store and Google Play store for free. The app provides access to the different programmes. The mobile app has been pilot tested by Intellect before the release on the App and Google Play store. However, for this research project Intellect is going to provide the the programmes as stand alone applications exclusively for the participants of this research.
45794168|NCT03576183|Other|Challenge Strain|LSN03-016011/A
45794169|NCT03377127|Behavioral|Pharmacy Managed Diabetes Clinic (PMDC)|The PMDC visit encounters will focus on patient identified goals for the management of their diabetes. Initial visit in the PMDC will be 60-90 minutes with follow up visits lasting 30-45 minutes.
45794170|NCT03377127|Other|Standard of Care (SOC)|Standard of care will be delivered at the physician discretion per the current American Diabetes Association recommendations
45794171|NCT03378921|Biological|Fecal microbiota transplantation|Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 4, 12, 26, and 52.
45921113|NCT00106561|Drug|Spironolactone|
45921114|NCT00106561|Drug|Irbesartan|
45921115|NCT00106600|Drug|Pixantrone IV infusion|
45921116|NCT00401206|Drug|dexmedetomidine|
45794172|NCT03378921|Biological|Placebo|Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 4, 12, 26, and 52.
45794173|NCT03626415|Drug|PF-04965842|PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.
45794174|NCT04373421|Drug|Chlorhexidine Gluconate 0.12 % Mouthwash + benzydamine hydrochloride|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
45648075|NCT04943003|Device|Transcranial Direct Current Stimulation (tDCS)|"Initially, a measuring tape will be used to make the markings and measurements necessary for placing the electrodes.~Regarding neurostimulation, the tDCS device is simple and portable, consisting of four main components: two electrodes (anode and cathode), an ammeter (electric current intensity meter), a potentiometer (voltage controller between electrodes) and a set of batteries. We will use the TCT-Research Neurostimulator, developed by Trans Cranial Technologies (Hong Kong, China), Regarding the protocols, the Active tDCS group will receive active tDCS for 30 minutes and for 5 consecutive days, in two weeks, with an anode positioned on the left DLPFC and a cathode electrode placed on the right supraorbital area. The 10-20 International EEG system will be taken as a reference. The current intensity will be defined from computational modeling, using Nuclear Magnetic Resonance (NMR) to estimate and individualize the dose to be administered."
45648076|NCT04963543|Other|FID123238|Lubricant applied to the ocular surface
45648077|NCT04943081|Procedure|Percutaneous nephrolithotomy|Percutaneous nephrolithotomy (PCNL) is a technique used to remove complex renal stones, or stones resistant to shockwave lithotripsy. A tube is placed through the incision in the kidney, under X-ray guidance, and renal stones are extracted by using nephroscope
45648078|NCT04930081|Behavioral|Positive Parenting Program, Mindful Parenting|"The Positive Parenting Program (Triple P) consists of 5 weekly group sessions (each lasting for 2 hours) plus three weekly individual telephone interview sessions (each lasting for around 20 minutes). Program materials is available in Chinese.~The Mindful Parenting program consists of 8 weekly group sessions, each lasting for 2 hours. Programme materials have already been translated into Chinese by local partners of the programme developer."
45648079|NCT04942691|Other|physical activity|training with trampoline. Each session lasted sixty minutes. Organization: a 5 minutes warm-up with breathing and mobility exercises from upper to lower body, central phase with jumping exercises involving the total body and 5 minutes of cool-down phase with total body active stretching exercise.
45648080|NCT04942847|Device|Sucking trainer|Repeated sucking for tongue flexibility training can improve the tongue muscle's ability to control and transmit food, and improve the swallowing function.
45648081|NCT04942847|Device|Cognitive card|To measure the patient's ability to focus, to calculate, to remember and to judge
45648082|NCT04121299|Drug|Carvedilol|Carvedilol 40mg Extended Release Once Daily
45648083|NCT04121299|Drug|Amlodipine|Amlodipine 10mg Once Daily
45648084|NCT04942769|Drug|Selenium|selenium 100ug ，take it orally twice daily
45794175|NCT04373421|Procedure|St. John's wort oil|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
45794176|NCT04373421|Procedure|Virgin olive oil|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
45794177|NCT03629535|Device|Non-invasive non-oscillometric blood pressure wristband device|The device is a band intended to be worn on the wrist for intermittent blood pressure measurements. The device applies no inflatable mechanics or moving parts. The wristband is watertight and can be worn as any type of bracelet.
46073680|NCT00591591|Device|OxiplexTS|OxiplexTS is a Frequency Domain Near-Infrared Tissue oximeter which provides absolute values of tissue oxygenation in real time. It also provides physiological quantities of oxy, deoxy and total hemoglobin concentration, which form the basis for the functional measurement of brain hemodynamics. Both the control and OSA groups will undergo standard overnight sleep study (PSG). In addition to the standard PSG, with or without Continuous Positive Airway Pressure (CPAP), we will add the OxiplexTS, allowing us to assess brain oxygenation and hemodynamics during sleep. The hemodynamic patterns of the healthy controls will be compared to the OSA sufferers. Participants with OSA who undergo PSG/CPAP will be also tested with the OxiplexTS. Their PSGs and PSG/CPAP data will be compared.
46073681|NCT04240548|Radiation|Regional Nodal Irradiation|
45794178|NCT03629535|Device|Invasive intra-arterial blood pressure monitors.|Because the subjects also have an intra-arterial blood pressure monitor in place, the subjects will serve as their own control
45794179|NCT03379545|Diagnostic Test|3-dimensional (3D) magnetic resonance (MR) imaging|MRI is performed using 3T scanners with a dedicated 16-channel shoulder array coils. The MRI sequences include 3-mm slice thickness and 0.5-mm gap width with a field of view of 14 or 15 cm. There were 6 diagnostic sequences with axial, coronal, and sagittal proton density weighting as well as coronal T2 with frequency selective fat suppression and sagittal T1 images.
45794180|NCT03379545|Diagnostic Test|3D computed tomography (CT) imaging|The CT protocol consists of 3-mm axial images of the glenoid reconstructed into 1-mm sagittal and coronal 2D reconstructions using the following parameters: 120 kV, 280 mA, and pitch of 0.9. The CT data were also used to produce a 3D reconstruction of each glenoid.
45794181|NCT04528017|Device|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
45794182|NCT04528017|Device|Somofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
45794183|NCT03382509|Drug|[14C]BI 1467335|Once Daily
45794184|NCT03382509|Drug|BI 1467335|Twice Daily
45449821|NCT01066949|Behavioral|Behavioral self mangement|Seven weekly, hour long group sessions focused on enhancing patient behavioral self management skills.
45794185|NCT03632109|Drug|gentamicin 360mg IM|360mg IM of gentamicin
45648085|NCT04253665|Behavioral|Nursing discharge teaching|Nurses will provide multimorbid seniors inpatients with teaching related to self-management to prepare them to be discharged home. The teaching delivery will be tailored to patients' activation level and priorities. The intervention begins by determining the level of activation at which patients are and identifying priorities to address related to patients' life situation. A Discharge Teaching Guide will be used by nurses to deliver the teaching and includes six domains of self-management. For each domain, nurses first report whether a priority has been identified and what intervention they have proposed to address it. Then for each domain, teaching objectives are described and differ according to the level of patient activation. These six domains of self-management are found in the patient-oriented discharge summary, which is a document for the patient that summarizes what has been addressed in discharge teaching.
45794186|NCT04332315|Procedure|Vaginally assisted laparoscopic sacrocolpopexy|"The VALS procedure consists of two steps. First, vaginal hysterectomy or laparoscopically assisted vaginal hysterectomy performed, anterior vaginal wall dissected up to bladder neck starting from initial vaginal incision, posterior vaginal wall dissected from rectum starting from initial vaginal incision up to distal third of posterior vaginal wall.The free arms of fixed meshes are introduced to the peritoneal cavity and the vaginal vault is closed with absorbable polyglactin suture. laparoscopy phase was performed with one intraumbilical (10 mm), 3 lateral abdominal (5 mm) trocars. Two mesh strips fixated to anterior longitudinal ligament of the sacrum with two separate no: 1 polypropylene sutures without tension.~AS was performed via Pfannenstiel incision after total or subtotal abdominal hysterectomy"
45794187|NCT02363946|Drug|ARC-AAT Injection|RNA interference-based, liver-targeted therapeutic
45794188|NCT02363946|Other|Placebo|0.9 % normal saline
45794189|NCT02363946|Drug|Diphenhydramine|Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.
45794190|NCT02363478|Drug|buspirone|buspirone 10 mg X2 for 4 weeks
45921117|NCT03759717|Other|Observation|Understanding the biology of skull base tumors will teach the investigators about the genesis and/or mechanisms of treatment resistance. The investigators hope to ultimately identify new targets which will add to the armamentarium by which to treat these tumors.
45921118|NCT00401284|Drug|EVT 201|
45449822|NCT01066949|Behavioral|Support and discussion|Seven, weekly hour long group sessions focused on information provision and supportive discussion amongst participants
45648086|NCT04942301|Drug|Endostar|This product combined with other combined chemotherapeutics is used to treat patients with stage III/IV NSCLC who are newly treated or relapsed
45449823|NCT03538743|Drug|Placebo|Tablet, 0 mg, twice daily, 28 days
45648087|NCT04942301|Device|use the vein pump to pump drugs|During the first 14 days of the first cycle, the experimental drug was pumped daily with an intravenous pump. During cycles 2-4, subjects in group A were pumped with experimental drugs for 3 days and subjects in group B were pumped with experimental drugs for 7 days.
45648088|NCT04942301|Combination Product|combination therapy|Combination therapy with chemotherapy drugs was used
45449824|NCT03538743|Drug|PF-06882961|Tablet, 15 mg twice daily, 28 days
45449825|NCT03538743|Drug|PF-06882961|Tablet, 50 mg twice daily, 28 days
45449826|NCT03538743|Drug|PF-06882961|Tablet, 150 mg twice daily, 28 days
45449827|NCT03538743|Drug|PF-06882961|Tablet, 300 mg twice daily, 28 days
45449828|NCT03538743|Drug|PF-06882961|Tablet, dose TBD, twice daily, Cohort 5, 28 days
45449829|NCT03538743|Drug|PF-06882961|Tablet, dose TBD, twice daily, Cohort 6, 28 days
45648089|NCT04085731|Procedure|Catheter ablation|Driver-guided catheter ablation of persistent atrial fibrillation
45794191|NCT02310126|Device|etafilcon A (multi-focal)|Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
45794192|NCT02310126|Device|etafilcon A (sphere)|Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
45794193|NCT02338362|Drug|Fluticasone propionate inhaler|fluticasone propionate 250 µg metered-dose inhaler
45794194|NCT02338362|Drug|Saline placebo inhaler|saline metered dose inhaler
45449830|NCT03538743|Drug|PF-06882961|Tablet, dose TBD, twice daily, Cohort 7, 28 days
45449831|NCT03538743|Drug|PF-06882961|Tablet, dose TBD, twice daily, Cohort 8, 28 days
45794195|NCT02363322|Drug|B/Current Standard of Care Plus ZMapp|Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus
45794196|NCT02363322|Other|A/Current Standard of Care Alone|Optimized standard of care for Ebola virus infection
45921119|NCT00401323|Drug|docetaxel (XRP6976)|
45921120|NCT00401323|Drug|cisplatin|
45921121|NCT00401323|Drug|5-fluorouracil (5-FU)|
45921122|NCT00401362|Drug|SC Methylnaltrexone|Dose 1
45921123|NCT00401362|Drug|SC Placebo|
45921124|NCT00401362|Drug|SC Methylnaltrexone|Dose 2
45921125|NCT03759639|Drug|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
45921126|NCT00106717|Procedure|Narrative medicine|
45794197|NCT02361762|Behavioral|Computerized executive control training|"Children will play computerized training games designed to improve executive control skills. Each training activity is structured to achieve a particular type of training related to executive control and/or attention shifting.~Sessions last for 1 hour each and the intensity of intervention ranges from 5-10 hours. Children will receive training until all levels of all tasks have been passed or 10 hours, whichever happens first. All training exercises have a number of levels, and children progress to the next level by meeting specific criteria for accuracy and/or speed.~A trainer will be present during all sessions to help children comply with the training demands and to teach skills involved in completing challenging tasks."
45648090|NCT04959539|Procedure|endoscopic transcanal tympanoplasty with attico-antrostomy|Transcanal approach followed by atticotomy to remove the attic cholesteatoma sac
45648091|NCT04959539|Procedure|endoscopic assisted canal wall up mastoidectomy|traditional canal wall up mastoidectomy followed by endoscopic evaluation of the attic to exclude any remnant cholesteatoma
45794198|NCT04420416|Other|Survey|The investigators will use the Spanish language validated version of the Academic Self-Concept Scale (ASCS), the Patient Health Questionnaire-9 (PHQ-9) depression screening scale, and the General Anxiety Disorder-7 (GAD-7) screening scale. Additionally, the sample will be asked about their gender, age, preference of teaching modality, and finally, if the participants have perceived a change in their performance or any change in their grades.
45794199|NCT02337738|Drug|TVP-1012 1mg|TVP-1012 1mg Tablets
45648092|NCT04184479|Behavioral|LEVAmethod by Bertz et al|Ordinary treatment
45794200|NCT02337738|Drug|TVP-1012 0.5mg|TVP-1012 0.5mg Tablets
45794201|NCT02337738|Drug|Placebo|Placebo Tablets
45794202|NCT02309112|Other|Yoga|A mind-body therapy that includes specified breathing, meditation and physical postures.
45648093|NCT04959227|Other|Sema activity|sema activity 3 days a week for at least a year
45648094|NCT04145011|Device|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe (18g, 4mm active tip)
45648095|NCT04145011|Device|Standard Radiofrequency|Delivery of energy to ablate sensory nerves via non-cooled standard radiofrequency probe (22g, curved 10mm active tip)
45648096|NCT04725175|Drug|PIPE-307|Single and multiple ascending oral doses of PIPE-307 tablets
45648097|NCT04725175|Drug|Placebo oral tablet|Single and multiple ascending oral doses of matching Placebo tablets
45648098|NCT02625233|Device|senofilcon C|
45648099|NCT02625233|Device|comfilcon A|
45648100|NCT04704349|Radiation|Scintigraphy|The scintigraphy of the patients will be carried out on 2 distinct devices and the images obtained will be compared.
45648101|NCT03059069|Drug|Chonline Alphoscerate|Patients treated with Chonline Alphoscerate as add on therapy to their medication
45794203|NCT02361216|Drug|Ingenol Mebutate|
45794204|NCT02361216|Other|Vehicle|Vehicle gel
45794205|NCT01803074|Drug|BMS-955176|BMS-955176
45794206|NCT01803074|Drug|Placebo matching with BMS-955176|Placebo matching with BMS-955176
45794207|NCT01803074|Drug|Atazanavir|Atazanavir
45794208|NCT01803074|Drug|Ritonavir|Ritonavir
45794209|NCT01803074|Drug|Tenofovir|Tenofovir
45794210|NCT01803074|Drug|Emtricitabine|Emtricitabine
45794211|NCT05328284|Device|PASCAL leaflet repair system|transcatheter Implantation of one or more PASCAL devices in the tricuspid valve
45794212|NCT05328206|Other|Standard of care for intubated children|Patient ventilated through a cuffed endotracheal tube and having a cuff leak test prior extubation
45648102|NCT03059069|Drug|Placebo Oral Tablet|Patients maintain their medication with either Gliatamin or placebo for 6 months.
45648103|NCT04942223|Device|guided bone regeneration|After local anesthesia, the surgery started with a mid-crestal incision with vertical releasing cuts followed by the full-thickness buccal and lingual/palatal flaps raising to expose the bone defect completely. The flaps were coronally extended to assure a complete closure with a passive suture above the titanium. Subsequently, an intra-oral mandibular ramus bone cortical block was harvested in the molar zone. The bone block was milled and mixed with freeze-dried. The particulate graft was put to fill the deficit above the mesh until its perfect stability and unity with the defect's borders. Two or three titanium mini-screws were used to stabilize the device , and the flaps were carefully sutured. Ceftriaxone was administered intravenously at a loading dose of 2 g; together with a non-steroidal analgesic, it was continued at two g/die per os beginning the day after surgery and continuing for six days.
45794213|NCT01805024|Drug|Omigapil|Cohort 1 0.02 mg/kg/day Cohort 2 0.08 mg/kg/day Cohort 3a 0.04 mg/kg/day Cohort 3b 0.06 mg/kg/day
45794214|NCT05328128|Behavioral|Toilet training|As the training model, Brazelton's child-oriented toilet training method was taken as the basis in study group. In addition, literature studies on toilet training in Turkey were scanned and the final form of training to be given to mothers was created. In the control group, families manage training process themselves.
45794215|NCT05327894|Drug|Blinatumomab|1st cycle: 15 μg/m2/day as a 4 week continuous IV infusion for patients with a M1 marrow. For patients with a M2/M3 marrow a step-dosing strategy is required with a dose of 5 μg/m2/day in week 1 followed by 15 μg/m2/day in weeks 2, 3, and 4.
45794216|NCT05327894|Drug|Blinatumomab|2nd cycle: 15 μg/m2/day as a 4 week continuous iv infusion
45794217|NCT02989766|Behavioral|Education on Breast Feeding|Subjects in the intervention arm will complete 3 activity sheets prenatally-study related.
45794218|NCT05327660|Combination Product|Quitline Treatment as Usual (TAU)|Quitline TAU is services provided by the state quitline and includes phone coaching, nicotine replacement, supplemental materials (e.g., text messaging, online content).
45794219|NCT05327660|Combination Product|Remote Carbon Monoxide (CO) Monitoring|Remote CO monitoring includes a smartphone app and a remote carbon monoxide monitor. The app tracks and prompts daily use of the CO monitor.
45794220|NCT05327660|Combination Product|Incentivized Remote CO Monitoring|Incentivized remote CO monitoring includes a smartphone app and a remote carbon monoxide monitor. The app tracks and prompts daily use of the CO monitor and delivers small monetary incentives for each use of the CO monitor.
45794221|NCT01822574|Procedure|Cutting Guide Technique|The guide is clamped onto the patella and tightened so that it remains stable. The guide has a slot that allows insertion of a standard sagittal saw blade, and this slot guides the blade as it is advanced across the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
45794222|NCT01822574|Procedure|Haptic Feedback Technique|It consists of a free hand cut (no guide used) with a standard sagittal saw that is oriented based on osteo-cartilaginous landmarks and haptic palpation of the patella by the surgeon. The resection thickness/obliquity can be altered based on haptic feedback (use of the sense of touch) of the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
46073682|NCT00706173|Drug|Hydrocortisone|Hydrocortisone 10-20 mg PO daily for 4 weeks.
46073683|NCT00706173|Drug|Placebo|"Placebo 10-20 mg PO daily for 4 weeks."
45449832|NCT03521817|Other|Alcohol|"The ethanol group will consume a 30% energy restriction diet that will also include ~2.5 standard drinks, or 35 grams of ethanol, administered as 80-proof distilled spirits (e.g. 80 proof gin, rum, vodka, whiskey, or tequila). In the United States, one standard drink contains roughly 14 grams of pure alcohol."
45449833|NCT03521817|Other|No Alcohol|This group will not consume alcohol. Thus 0 kcal/d will come from alcohol
45648104|NCT03710785|Behavioral|cervical spine extension exercise|cervical spine extension exercise for 4 weeks
45648105|NCT04949945|Behavioral|Self Help Culturally Cognitive Behavioral Therapy|Experimental group (CHF patients)will be screened on PHQ9 questionnaire for depression after receiving guided self help culturally adapted cognitive therapy they will be reassessed for their depression,improvement in functional disability ,improvement in classification of NYHA,reduction in hospital admission as compare to control group.
45648106|NCT04563715|Diagnostic Test|HIV counseling and testing|Receive HIV testing risk assessment and advice about risk reduction and future testing.
45648107|NCT04563715|Behavioral|Network intervention|Key individuals are trained to provide advice about regular testing and risk reduction.
45648108|NCT04941677|Other|no intervention|no intervention in this study
45648109|NCT03057899|Drug|TFG capsules (200 mg /capsule)|TFG capsules were prepared using extracts from Trigonella foenum-graecum seed and Lespedeza cuneata. During the study period, two capsules were taken daily for 8 weeks.
45648110|NCT03057899|Drug|Placebo oral capsule|During the study period, two capsules were taken daily for 8 weeks. Placebo and TFG capsules were identical in shape, color, and taste.
45648111|NCT03284827|Drug|NOAC|edoxaban (60 mg once daily [OD]) for at least 6 months
45648112|NCT03284827|Drug|DAPT|clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD) for at least 6 months
45648113|NCT04959071|Procedure|Vacuum assisted closure VAC vs conventional dressing|"In participants undergoing vacuum assisted closure a drainage tube was placed in the wound followed by dressing with sterile foam sheet and application of occlusive transparent film over the whole assembly. The drainage tube was connected to a suction machine. Intermittent negative pressure of -125mmHg was applied every 15 minutes; the suction was stopped for 10 minutes. The dressing was changed every 48 hours.~In participants with conventional dressings, after wound wash, pyodine soaked gauze pieces were used for initial 48 hours followed by dressings of normal saline soaked gauze pieces, twice daily."
45648114|NCT04949321|Other|Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL)|Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL)
45648115|NCT04434001|Drug|Fibrinogen Concentrate Human|Treatment of acquired postoperatively fibrinogen deficiency as assessed by ROTEM FIBTEM test.
45648116|NCT04434001|Drug|Prothrombin Complex Concentrate|Treatment of acquired postoperatively thrombin generation deficiency as assessed by ROTEM EXTEM test.
45648117|NCT04434001|Biological|Fresh Frozen Plasma|Treatment of acquired postoperative coagulopathy as assessed by ROTEM FIBTEM and INTEM tests.
45648118|NCT04958993|Drug|Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy|radiotherapy (five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy) AND chemotherapy (Squamous cell carcinoma selective platinum + docetaxel and Adenocarcinoma selective platinum + Pemetrexed) AND Anlotinib Hydrochloride capsule (12mg QD PO d1-14, 21 days per cycle)
45648119|NCT04683913|Behavioral|Foot rotation modification|"The instruction of gait modification provided via teleconferencing sessions (5 over 6 weeks) focusing on increasing toe-in or toe-out angles by as much as is comfortable."
45648120|NCT04683913|Other|Waiting Period - Delayed Group|Participants allocated to the Delayed Group will wait 6 weeks after their initial baseline, then complete a second baseline to provide a control condition. After the second baseline they will enter the intervention.
45648121|NCT03603925|Diagnostic Test|Positron Emission Test / Magnetic Resonance (PET/MR)|The Philips Ingenuity PET/MR is used for research scanning. Patients receiving a clinically indicated PET/CT, will be approached to be included in this study. There is no special preparation other than that needed for the prerequisite PET/CT scanning. At the completion of the PET/CT scanning, the subject will be taken to the PET/MR scanner, which is in close in proximity, for research scanning. The research scanning would take up to one hour or as tolerated.
45648122|NCT03603925|Diagnostic Test|Positron Emission Test / Computed Tomography (PET/CT)|Patients will receive PET / CT imaging for the detection of cancer or other clinically indicated anomalies. The completed study visit is expected to take approximately 2 hours and not longer than 3 hours.
45648123|NCT04958603|Procedure|"L type release surgery"|Lateral release of the lateral support belt
45648124|NCT03540901|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3100m
45794223|NCT01822574|Procedure|Four Quadrant Technique|Resection is performed in a free handed fashion, but after resection, the thickness of the patella is measured separately in all four quadrants (superolateral, superomedial, inferomedial, and inferolateral). Additional resection is performed as needed based on the quadrant measurements and the measurements are repeated after each resection until satisfactory resection thickness and symmetry are obtained.
45794224|NCT01822886|Drug|Romidepsin + Gemcitabine|Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD
46073684|NCT02822742|Drug|DE-117 ophthalmic solution|
45648125|NCT03540901|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3100m
46073685|NCT02822742|Drug|Latanoprost ophthalmic solution 0.005%|
45648126|NCT04958759|Other|Functional Inspiratory Muscle Training|The inspiratory muscle training program will be consist of 4 weeks of foundation inspiratory muscle training and 6 weeks of functional inspiratory muscle training
45648127|NCT04958759|Other|Inspiratory Muscle Training|The inspiratory muscle training program will be consist of 10 weeks of foundation inspiratory muscle training
45648128|NCT04958759|Other|Breathing exercises|The program will be consist of 10 weeks of breathing exercises
45449834|NCT03538431|Drug|Buspirone|Buspirone is an atypical anxiolytic medication.
45921127|NCT00106834|Drug|Infliximab|
45921128|NCT00006509|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
45921129|NCT00006509|Biological|gp160 MN/LAI-2|
45921130|NCT00107068|Procedure|[A] Aerobic isokinetic cycling exercise|
45921131|NCT00107068|Procedure|[B] Progressive Resistance Training|
45449835|NCT03521193|Device|patent foramen ovale closure|Pts undergoing PFO closure will receive 2-months of DAPT and 6 months of aspirin after patent foramen ovale (PFO) closure; they will be compared to healthy subjects on aspirin treatment
45449836|NCT03538041|Drug|Parsaclisib|Parsaclisib administered orally.
45648129|NCT03517735|Device|EasyTiva (algorithm is the property of Medsteer SAS)|Propofol and Remifentanil are administered automatically using a closed-loop system. Bispectral index is used as the input signal and an algorithm defines the appropriate concentrations of propofol and remifentanil. Adequate postoperative sedation is defined by a bispectral index between 55 and 75.
45648130|NCT03517735|Drug|Propofol|The dosage is modified automatically by the device or according to the new medical prescription.
45648131|NCT03517735|Drug|Remifentanil|The dosage is modified automatically by the device or according to the new medical prescription.
45648132|NCT04958915|Diagnostic Test|Knee joint 30° flexion scan|The patient was placed in the supine position, and the knee joint was naturally placed in the knee joint special coil, and the knee joint 30° flexion position scan.
45648133|NCT03489811|Other|Test Essential Oil Blend|The test essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
45648134|NCT03489811|Other|Active Essential Oil Blend|The active essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
45648135|NCT03489811|Other|Control Blend|The control blend consists of inert vegetable oils which are produced from plant matter.
45648136|NCT04941131|Drug|Chlorhexidine digluconate, povidone iodine|This is a mouth wash that can be used over the counter.
45648137|NCT03400501|Drug|Insulin Degludec|Single daily dose of insulin degludec based on their fasting blood glucose levels and current long acting insulin dose
45648138|NCT03400501|Drug|Insulin Glargine|Single daily dose of insulin glargine based on their fasting blood glucose levels and current long acting insulin dose
45648139|NCT04940975|Behavioral|Occupation-based sleep intervention program|A program composed of four occupation-based interactive workshops on sleep, insomnia, lifestyle, and change strategies, plus two individual coaching sessions on lifestyle and sleep hygiene.
45648140|NCT04940975|Behavioral|Insomnia Education Program at Integrated Mental Health Clinic (IMHC)|A program composed of four educational sessions on sleep and insomnia, plus relaxation training, plus two individual review sessions on sleep hygiene with participant.
45794225|NCT01823510|Drug|Ticagrelor + Aspirin|Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).
45794226|NCT01823510|Drug|Clopidogrel + Aspirin|Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).
45794227|NCT05327582|Drug|Durvalumab|Administered intravenously, 1000 mg on day 1 in a 3-week cycle
45794228|NCT05327582|Drug|Lenvatinib|Administered orally, 8mg/d once daily in a 3-week cycle
45794229|NCT05327582|Drug|Nab paclitaxel|Administered intravenously, 180-220 mg/m2 on day1 in a 3-week cycle
45794230|NCT00681200|Behavioral|Enhanced health education|health education and social support
45794231|NCT00681200|Behavioral|Transcendental Meditation program|The TM program plus didactic-based health education classes
45921132|NCT00107068|Procedure|[A] + [B]|
45921133|NCT03745287|Biological|CTX001|Administered by IV infusion following myeloablative conditioning with busulfan.
45921134|NCT00107107|Drug|pramlintide acetate|Syringe vial and Pen-cartridge
45449837|NCT03521115|Behavioral|Smart Choices 4 Teens|This is a web-based prevention program designed to convey information about alcohol and relationships and the types of choices that they are making regarding these topics. General communications was another core element of the program that provided parents and teens with some key elements of talking to each other.
45449838|NCT00293267|Drug|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
45449839|NCT00293267|Drug|Comparator: Placebo|Placebo b.i.d. p.o. with optimized background therapy. Treatment period of 48 weeks.
45921135|NCT00107185|Biological|therapeutic autologous dendritic cells|
45449840|NCT03520959|Biological|LV305|Administered via subcutaneous (SC) injection.
45921136|NCT00107263|Drug|letrozole|
45921137|NCT00107263|Drug|zoledronic acid|
45921138|NCT02964949|Drug|Edoxaban|Edoxaban will be provided in blister packs with active and placebo tablets maintaining the blind, i.e., one 60 mg active tablet and a 15 mg placebo or one 60 mg active tablet and a 15 mg active tablet. Transition doses of 30 mg + 15 mg edoxaban are provided in 14-tablet blister packs.
45921139|NCT00107341|Drug|bortezomib|
45921140|NCT00107341|Drug|carboplatin|
45921141|NCT00107341|Drug|paclitaxel|
45921142|NCT00107419|Drug|pemetrexed disodium|pemetrexed, 500 mg/m2, IV, every 21 days until two cycles after complete response or until progression
45921143|NCT03683667|Drug|Azithromycin Oral Product|Azithromycin oral suspension (10 mg/kg; 3 days) administered by study personnel at 6 and 9 months of age
45921144|NCT03683667|Drug|Placebos|Contain inert excipients only
45449841|NCT03520959|Biological|G305|Administered via intramuscular (IM) injection.
45449842|NCT03520959|Other|LV305-matching placebo|Administered via SC injection.
45921145|NCT03683667|Dietary Supplement|Protein Supplement|Blended food providing 125 kcal and 10 g protein as egg white powder prepared as porridge and fed daily to infants from 6-12 months of age
45648141|NCT04426591|Drug|Biotin Labeled Red Blood Cells|On the day of transfusion, a 20 mL aliquot will be sterilely withdrawn from each RBC unit, washed and labeled with sulfo-NHS-biotin for 30 minutes, washed to stop the labeling reaction, then resuspended in plasma to a hematocrit of ~60%. The biotin-labeled RBC (BioRBC) will be transfused along with the remainder of the RBC unit (unlabeled volume). Standard blood bank and CTT protocols and minor antigen matching for SCD patients will be followed. Exact transfusion volume will be determined based on pre-transfusion Hb, HbS, and body weight, per clinical protocol.
45648142|NCT04423679|Device|Evalyn Brush|a standard brush-based cervicovaginal self-collection device
45648143|NCT04383847|Behavioral|Sumadhur Aarambha|Group intervention for newly married women, their husbands, and mothers-in-law with information mainly about nutrition, but also pre-pregnancy health, reproductive/pregnancy health and gender equality.
45794232|NCT05327036|Other|collect information about all participants|collect information On age,pregnancy history,Height, weight,Gestational weeks of umbilical artery embolism,Gestational week of delivery, mode of delivery, newborn birth weight, birth height, Apgar score, umbilical cord length, umbilical cord placental insertion point, placental weight, pregnancy complications, coagulation function,after obtaining the consent of all participants.
45794233|NCT01824446|Drug|Radiolabeled SPD602 (FBS0701, SSP-004184)|A single oral dose of 3g of radio-labelled SSP-004184 on Day 1
45794234|NCT05299970|Other|Fermented porridge|A millet porridge (fermented or not, depending on group allocation) serving will be provided to participants daily, for consumption. consumption will be directly observed.
45794235|NCT02263040|Biological|Fluzone High-Dose|Influenza vaccine
45648144|NCT03231475|Drug|SPH1188-11|qd.po
45648145|NCT04419467|Biological|CSL346|VEGF-B antagonist monoclonal antibody
45648146|NCT04419467|Drug|Placebo|Normal saline
45648147|NCT03301363|Device|CRT|Subjects scheduled to be implanted for CRT by a Quadripolar Pacing System
45648148|NCT04415957|Other|Elastic Tape|The subject's trunk was passively extended for ET placement. The ET was placed on the chest wall and abdomen, considering the origins and insertions of the following muscles: rectus abdominis, internal oblique, and internal intercostal. The intervention lasted 14 days, therefore, the participants remained with the tapes for two consecutive weeks. Due to the adhesive durability of ETs (6 weeks on average), the participants were asked to return to change the ET after seven days.
45794236|NCT02263040|Biological|Fluzone (standard dose)|Influenza vaccine
45921146|NCT03683667|Dietary Supplement|Isocaloric Supplement|Blended food providing 125 kcal and 1 g protein as rice powder prepared as porridge and fed daily to infants from 6-12 months of age
45921147|NCT03683667|Dietary Supplement|Egg|Egg provided daily to infants from 6-12 months of age
45921148|NCT03683667|Behavioral|Nutrition Education|Monthly messaging on infant and young child feeding
45921149|NCT00006578|Drug|Ritonavir|
45921150|NCT00006578|Drug|Abacavir sulfate|
45921151|NCT00006578|Drug|Amprenavir|
45921152|NCT00006578|Drug|Lamivudine|
45794237|NCT02271698|Drug|Dexamethasone|Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group
45794238|NCT02271698|Other|Placebo|Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.
45794239|NCT02272244|Behavioral|Decision Support & Navigation|
45794240|NCT02272244|Behavioral|Standard|
45921153|NCT00006578|Drug|Filgrastim|
45921154|NCT00107458|Drug|valproic acid|
45921155|NCT00107497|Radiation|Radiation therapy|
45921156|NCT02964988|Drug|Injection of PET tracer 68Ga-NOTA-AE105|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to whole body PET/CT
45921157|NCT02964988|Device|PET/CT|Whole body PET/CT
45921158|NCT00107692|Behavioral|Physical activity and diet|
45921159|NCT03672825|Drug|REcycled CartiLage Auto/Allo IMplantation|Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).
45921160|NCT00006617|Drug|Abacavir sulfate|
45921161|NCT00006617|Drug|Amprenavir|
45921162|NCT00006617|Drug|Lamivudine|
45921163|NCT00006617|Drug|Zidovudine|
45921164|NCT00107731|Drug|quetiapine fumarate|
45794241|NCT02328404|Drug|50,000 IU vitamin D3|Film-coated tablet Biodal 50,000 IU containing cholecalciferol 50,000 IU
45921165|NCT00107731|Drug|lithium|
45921166|NCT00107731|Drug|divalproex|
45921167|NCT04712396|Drug|Capivasertib|Subects will be administered single doses of capiversatib on Day 1 and Day 6.
45921168|NCT04712396|Drug|Itraconazole|Subjects will be administered itraconazole twice daily on Day 3, followed by once daily doses in the morning for 4 days.
45921169|NCT03672747|Device|transcranial direct-current stimulation (tDCS)|20 minutes duration using high-definition system with center-surround configuration
45921170|NCT00107770|Drug|sodium phenylbutyrate|histone deacteylase inhibitor
45921171|NCT00107809|Drug|Modafinil|
45921172|NCT00006656|Drug|carmustine in ethanol|
45921173|NCT00006656|Procedure|conventional surgery|
45921174|NCT03667482|Drug|Cabozantinib|Cabozantinib will be initiated at 40 mg PO daily, with subsequent 20 mg or 40 mg doses as tolerated per the study design.
45921175|NCT03667482|Drug|Cetuximab|Cetuximab will be administered at 500 mg/m^2 intravenously every other week on Days 1 and 15 of each cycle, with a window of up to 3 days before the scheduled date. In an effort to prevent a hypersensitivity reaction, it is recommended that all patients pre-medications, hydration, and anti-emetics will be given according to institutional guidelines and/or per treating physician discretion.
45921176|NCT00107848|Drug|Modafinil|
45921177|NCT00107887|Drug|INH preventive therapy|Clinics will receive training regarding the use of IPT for prevention of Tuberculosis
45921178|NCT00107887|Drug|TST (tuberculin skin test)|Clinics will be trained in the use of TST for assessing exposure to TB
45794242|NCT02328404|Drug|Placebo|Placebo film-coated tablet of Biodal 50,000 IU
45794243|NCT05748314|Other|Questionnaire|KINDL-R; Morisky Medication Adherence Scale;
45794244|NCT05748236|Drug|Lamotrigine tablet|Lamotrigine: Starting dose 25mg once daily for 2 weeks, then 50 mg once daily for next 2 weeks . Then dose will be increased until seizure control or side effects develop (Maximum 500 mg/day).
45794245|NCT05748236|Drug|Carbamazepine-Containing Product in Oral Dose Form|Starting dose 100mg twice daily for 2 weeks, then 200 mg twice daily for next 2 weeks. Then dose will be increased until seizure control or side effects develop (Maximum 1600 mg/day).
45794246|NCT02989376|Procedure|After detection of occluded vessels by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment.|When the ratio of the end diastolic velocity in the common carotid arteries is greater than 1.4 or the diastolic flow in the internal carotid artery is not detected by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment. If vessel occlusion is not detected by carotid duplex ultrasound, additional vascular imaging including MR angiography or CT angiography is considered.
45449843|NCT03520959|Other|G305-matching placebo|Administered via IM injection.
45648149|NCT04958681|Other|exercise|The participants were subsequently asked whether the pandemic had altered their physical activity status and rate the severity of reduction in mobility level compared to the period before the Covid-19 with the following options: none, 0; mild, 1; moderate, 2; severe, 3. Then, the participants were also asked whether they perform a physical exercise in a home setting. We recorded regular outdoor physical activity and home-based exercises (only after the pandemic) as a dichotomous variable (yes or no). The number of physical activity days per week was also obtained.
45648150|NCT04949009|Drug|Avatrombopag|Avatrombopag is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders.
45648151|NCT04948541|Combination Product|osa treatment|different treatments can be included
45648152|NCT04948541|Other|no treatment|no treatment was undergone
45648153|NCT04948229|Other|Blood serum samples|Blood serum samples will be taken.
45648154|NCT04940819|Behavioral|Mobile Application for Dietary Management|A mobile application developed by a multi-disciplinary team will be used in the dietary management of CKD patients. The application is patient orientated. It has 4 core features including food searching, dietary logging, personalized key nutrient intake feedback and patient-caregiver interaction.
45794247|NCT01829516|Drug|Oxytocin|Intranasal oxytocin
45794248|NCT01829516|Drug|Placebo|Intranasal placebo
45794249|NCT01830140|Drug|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
45794250|NCT01830140|Drug|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
45794251|NCT01830842|Drug|Nicotine polacrilex|nonsmokers will be measured following nicotine administration
45794252|NCT01830842|Drug|Placebo|nonsmokers will be measured following placebo administration
45648155|NCT03058211|Diagnostic Test|Echocardiography|Standard protocols
45648156|NCT03058211|Diagnostic Test|Cardiac Magnetic resonance|MRI with late gadolinium increase and T1 mapping
45921179|NCT00006695|Drug|carmustine|300 mg/m2 IV on Day -6
45921180|NCT00006695|Drug|cytarabine|100 mg/m2 BID on Days -5 through -2
46073686|NCT00835471|Drug|erlotinib plus docetaxel or pemetrexed|"non-squamous carcinoma: pemetrexed 500 mg/m2 on Day 1 plus erlotinib 150 mg/day days 2-16, every 21 days. Pemetrexed will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression.~squamous carcinoma: Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days. Docetaxel will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression."
45449844|NCT03730545|Dietary Supplement|enteral immunonutrition|Enteral nutrition was started within 12h at an infusion rate of 20ml per hour for SEN group and 16ml per hour for EIN group in the first 24h. The rates of flow were gradually increasing with 50ml/h in SEN versus 40ml/h in EIN on day 2, 70ml/h versus 56ml/h on day 3 and 100ml/h versus 80ml/h until the 7th day depending on the feeding tolerance.
45648157|NCT04940429|Device|Neurofit|This involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed.
45921181|NCT00006695|Drug|etoposide|100 mg/m2 BID on Days -5 through -2
46073687|NCT00835471|Drug|erlotinib|erlotinib 150 mg/day continuously until disease progression
46073688|NCT02822898|Drug|NaCl 0.9% in Glucose 5% with 40mEq Potassium|NaCl 0.9% in Glucose 5% with 40mEq Potassium, administered at 25 mL/kg IBW/h for 48h
46073689|NCT02822898|Drug|Glucion 5%|Glucion 5% (premixed solution containing 54 mmol/L sodium and 26 mmol/L potassium amongst others), administered at 25 mL/kg IBW/h for 48h
45449845|NCT03977441|Drug|Agomelatine or PIacebo|control group:Pramipexole+pIacebo experimental group:Pramipexole+Agomelatine
45653179|NCT04911803|Behavioral|Procrastination Application|The Intellect mobile app (containing the procrastination application) can be freely downloaded from the App store and Google Play store for free. The app provides access to the different programmes. The mobile app has been pilot tested by Intellect before the release on the App and Google Play store. However, for this research project Intellect is going to provide the the programmes as stand alone applications exclusively for the participants of this research.
45794253|NCT01830842|Other|satiety|smokers will be measured in a smoking satiated condition
45794254|NCT01830842|Other|abstinence|smokers will be measured following 24-hours of smoking abstinence
45794255|NCT01831154|Drug|Tight Glycemic|The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
45794256|NCT01831154|Drug|Conventional Glycemic|The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
45794257|NCT01831154|Drug|Standard Glycemic|Insulin was Regular Insulin administered intravenous bolus.
45921182|NCT00006695|Drug|melphalan|140 mg/m2 IV on Day -1
45921183|NCT00006695|Procedure|peripheral blood stem cell transplantation|Following the chemotherapy, on Day 0 of treatment, the previously stored hematopoietic stem cells will be administered to the patient intravenously through a central line to the patient.
45648158|NCT04940429|Diagnostic Test|Psychometric hepatic encephalopathy score|During the number connection tests, the participant is asked to join dots between numbers or numbers and letters in a timed fashion and the number of seconds required is the outcome. In the line tracing test, participants are required to trace a line between two parallel lines and the time required is noted. Also, the number of times the subject strays outside the line (line tracing test error) is captured. In the digit symbol test, participants are required to pair numbers with special symbols. An individual's score reflects the number of correct pairs achieved in 120 seconds. In the serial dotting test, participants are asked to dot the center of a group of blank circles and the time required to complete the test is the outcome. Psychometric tests will be completed at their post-operative visits.
45648159|NCT02656693|Behavioral|Online weight management program|Patients who are enrolled in one of the two arms using the online weight management program (BMIQ) will complete structured educational sessions, follow specific calorie goals and meal plans, participate in self-monitoring activities (i.e., regular tracking of weight, diet, and physical activity), and interact with other features of the program.
45648160|NCT02656693|Behavioral|Population health management support|Patients will receive weight-related population health management support from their primary care practice; their online weight management program data will be monitored by the population health manager, who will conduct outreach with patients at designated points according to the protocol.
45648161|NCT04940507|Procedure|Magnetic Resonance Guided Focused Ultrasound Tumor Ablation and Liquid Biopsy Acquisition|Partial ablation of tumor using ExAblate Neuro 4000 device (InSightec Ltd, Tirat Carmel, Israel) and blood and CSF draws for liquid biopsy
45648162|NCT04940507|Procedure|Magnetic Resonance Guided Focused Ultrasound Thalamotomy|Ablation of VIM nucleus of thalamus with MRgFUS using ExAblate Neuro 4000 Device (InSightec Ltd, Tirat Carmel, Israel) and blood draws.
45794258|NCT04544787|Biological|Novel OPV2 candidate 1|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 1 (S2/cre5/S15domV/rec1/hifi3).~Modifications included the following:~Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~Two modifications in the polymerase 3D to further improve stability of the attenuation and reduce frequency of recombination events~Relocation of a key replication element from the 2C coding region to the 5'-untranslated region, to inhibit recombination."
45794259|NCT04544787|Biological|Novel OPV2 candidate 2|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 2 (S2/S15domV/CpG40).~Modifications included the following:~Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~silent non-coding modifications engineered within the capsid (VP1-4) designed to reduce replicative fitness and, potentially, to improve stability of the attenuated phenotype while also reducing transmission."
45794260|NCT04544787|Biological|Placebo|sugar syrup, propylene glycol (Sirupus simplex, Propylenglycolum, European Pharmacopoeia)
45794261|NCT02989220|Other|Positive Reappraisal Coping Intervention|
45794262|NCT01831232|Drug|pravastatin sodium|Given PO
45794263|NCT01831232|Drug|idarubicin|Given IV
45794264|NCT01831232|Drug|cytarabine|Given IV
45794265|NCT01831232|Other|laboratory biomarker analysis|Correlative studies
45794266|NCT04470375|Behavioral|Virtual Reality Pain Neuroscience Education|Use of virtual reality media to provide pain neuroscience education
45794267|NCT05257070|Diagnostic Test|fingerprick|In addition to the standard venous samples, dried blood spot samples trough a fingerprick will be collected.
45794268|NCT01831934|Biological|Fluzone®|This vaccine is given intramuscularly, either the 2010-2011 or 2011-2012 vaccination was given as appropriate
45794269|NCT01832090|Device|Radiesse® Injectable Dermal Filler|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier.
45794270|NCT01833026|Device|Spirometry test|For the initial visit for the intervention group, an initial demographics form and a health questionnaire will given to the subject to complete. To evaluate the breathing and quality of living, a spirometry test will be performed that will evaluate how well and how fast the subject can breath and blow out air.
45794271|NCT01833026|Drug|Levalbuterol|The spirometry test will be performed with a breathing medication called Levalbuterol (Xopenex®). Levalbuterol is used in standard practice for COPD and is commonly used during spirometry.
45794272|NCT03383523|Drug|Emodepside (BAY 44-4400)|2 tablets compared to the liquid formulation
45794273|NCT05748158|Behavioral|Weight loss|"A behavioral lifestyle program, lup to 20 weeks in duration, based on interventions shown to be successful for weight loss such as the Diabetes Prevention Program (DPP), Action for Health in Diabetes (Look AHEAD), and Comprehensive Assessment of the Long-term Effects of Reducing Intake of Energy Study (CALERIE). Weekly sessions, led by experienced interventionists, will provide education and behavioral strategies for weight loss focused an energy-reduced diet and physical activity.~Participants must meet the following milestones to continue in the study:~> 3% weight loss by 4 weeks after the start of the intervention~> 5% weight loss by 20 weeks after the start of the intervention~> 7% weight loss between weeks 20 and 37~After achieving >7% weight loss and weight stability between weeks 20 and 37, participants are observed, without further intervention, for 52 weeks."
46073690|NCT00828945|Device|Lipid Self Test|Self test for lipid levels, twice during study period
46073691|NCT00849511|Drug|melatonin|Circadin (melatonin) 2 mg ret. TAB vesp. for 8 weeks
46073692|NCT02822040|Other|Intraoral Scan|All patients will have an intraoral scan performed for measurements to be taken on.
45449846|NCT03537261|Behavioral|Parent-based Crisis Prevention Institute (CPI) physical management training program (P-CPI)|Parents of children with ASD will be randomly assigned to the 6-hour P-CPI group training session, which includes nonverbal, paraverbal, verbal, and physical intervention techniques. Baseline measures will be administered on the day of training and follow-up measures at 2-week, 1-month, 2-month, and 3-month post baseline. The treatment group will also participate in an in-person follow-up group qualitative interview.
45449847|NCT01080365|Drug|SKI-606 (Bosutinib)|500 mg commercial formulation film coated tablet, administered once daily
45794274|NCT03383757|Device|SpO2 Sensor application & blood draw|At the start of the procedure, one to two commercial sensors shall be applied to the subject. Readings will be allowed to stabilize. After at least 10 minutes of data collection, arterial blood will be collected and analyzed blood per hospital's standard procedure. Data collection will continue post blood draw for two minutes.
45794275|NCT05748080|Other|Eating apples|the eating of 2 apples a day for a period of 6 weeks
45794276|NCT03387033|Device|Relaxation response and virtual reality (VR) session|A 10-minute relaxation response (mindfulness and deep breathing) followed by 10-minute immersive VR session.
45794277|NCT05748002|Other|Pentacam and Corvis ST|morphological and biomechanical parameters of corneal were obtain by Pentacam and Corvis ST
45794278|NCT03387267|Device|Dysphagia Detection System|The Nestle Health Sciences (NHSc) Dysphagia Detection System (DDS) is a portable, non-invasive device designed for use at the bedside. The investigational DDS has 3 basic components: Sensor Unit (suspended on a necklace), Sensor Fixation and a personal computer (PC) for collecting data. The Sensor Unit consists of a dual-axis accelerometer in a plastic housing that is attached to the front of a patient's neck just below the thyroid cartilage by the single-use, disposable fixation unit. The Sensor Unit is connected via a cable to an A/D converter which then connects via cable to the PC. The PC collects the examination data, which is then sent to dedicated application software (installed at the CRO), which interprets the acceleration data and displays the examination result.
45794279|NCT02989688|Dietary Supplement|Nepro HP (Abbott Nutrition)|oral nutritional supplement drink with modified carbohydrate composition
45794280|NCT02989688|Dietary Supplement|Fortisip compact protein 125 ml + Calogen 20ml (Nutricia)|Fortisip compact protein 125 ml + Calogen 20ml (Nutricia) oral nutritional supplement drink macronutrient matched with standard carbohydrate composition
45794281|NCT02989688|Dietary Supplement|Fortisip compact 125 ml (Nutricia)|Fortisip compact 125 ml (Nutricia) oral nutritional supplement drink - standard
45648163|NCT04940273|Drug|Remifentanil Injection [Ultiva]|Continuous infusion of remifentanil at a dose of 0.02、0.04、0.06、0.08 ug/kg/min for 30 minutes in sequence.
45648164|NCT04958525|Procedure|Keyhole neuroendoscopic transfrontal ultrasound-guided hematoma removal|Keyhole neuroendoscopic transfrontal ultrasound-guided hematoma removal in basal ganglia region:According to the brain CT scan and reconstruct the operation plan, choose a side by 2 cm before the coronal suture line 4 cm and 3 cm center longitudinal incision formation of 2 cm bone drilling the hole, ultrasonic measurement and the size of hematoma puncture depth, and guide the puncture direction, the transparent channel under endoscopic direct placement hematoma backend, after entering the hematoma cavity, under the neural endoscopic removal of hematoma,Wash the hematoma cavity with warm salt water.Bipolar electrocoagulation hemostasis for active bleeding.An indwelling drainage tube was placed in the hematoma cavity, and ultrasonography determined that the hematoma was cleared satisfily without active bleeding.
45794282|NCT05011994|Behavioral|Maintenance intervention|"The intervention consists of action planning, text messages, and coordinator support.~At onset, each participant creates an action plan for physical activity with the help of a health professional:~What types of physical activities?~When and how often?~Where and with who?~2 auto-generated text messages are sent weekly for a duration of 12 weeks. The first prompts physical activity. The second asks if plans were reached. If yes, an automatic reply with positive reinforcement is generated. If no, an automatic reply asks if the participant wants to be contacted.~Participants are contacted by a coordinator either by answering text messages or if not answering the texts for a period of 2 weeks or more. Coordinator functions:~Call participants replying to texts that they wish to be contacted~Help participants establish contact to local activities involving physical activity~Follow-up on and adjustment of action plan~Offer guidance in physical activity"
45794283|NCT00377091|Drug|Fondaparinux|
45794284|NCT01835756|Device|Erchonia MLS|The Erchonia® MLS contains 10 independent diodes, each emitting 17 milliwatts (mW), 635 nanometers (nm) of red laser light. The Erchonia MLS is applied to the lower back and hips area for 15 minutes per treatment administration, 6 times across 3 weeks, 2 times per week.
45794285|NCT01835756|Device|Placebo Laser|The Placebo Laser has the same appearance and administration application as the Erchonia MLS but does not emit any therapeutic light.
45794286|NCT04462731|Procedure|Non-surgical root canal treatment filled with WVT|All eligible teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% Sodium hypochlorite was used as the main irrigant with a 31-gauge needle. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% sodium hypochlorite and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth. WVT was used to fill the tooth when the months were January, March, May, July, September, and November.
45794287|NCT04462731|Procedure|Non-surgical root canal treatment filled with SBT|All eligible teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% Sodium hypochlorite was used as the main irrigant with a 31-gauge needle. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% sodium hypochlorite and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth. SBT was used to fill the tooth when the months were February, April, June, August, October, and December.
45794288|NCT01835912|Other|Sodium Citrate Dihydrate|Dose sodium citrate dihydrate through 2 dosing protocols (Acute and Chronic)
45794289|NCT05747846|Procedure|Carpal tunnel release, WALANT technique|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release without a tourniquet.
45794290|NCT05747846|Procedure|Carpal tunnel release using a tourniquet|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release using a hemostatic cuff. The hemostatic cuff will be insufflated at the level of the arm at a pressure of 100 mmHg higher than the patient's systolic pressure. The cuff will be removed once wound closure is complete.
45794291|NCT05747768|Drug|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin were provided by the Department of Pharmacy, Peking University Third Hospital, and were dissolved and mixed with normal saline respectively, and the mixing process needed to be fully stirred. Then, according to the concentration of the drug mixed solution, the corresponding volume of mixed solution was given to achieve the dosage of 10 μg midazolam, 375 μg dabigatran etexilate, 10 μg pitavastatin, 50 μg rosuvastatin and 100 μg atorvastatin. In order to avoid the food effect, the test drugs were administered on an empty stomach on the administration day in this experiment.
45648165|NCT04958525|Procedure|Small bone window craniotomy for hematoma removal under microscope|Small bone window craniotomy for hematoma removal under microscope:Small bone window craniotomy in frontotemporal region, no blood vessels and non-functional areas of the hematoma nearest to the cortex was cut open, the hematoma was removed under the microscope and the cavity of the hematoma was washed with warm saline, and bipolar electrocoagulation hemostasis was performed for active bleeding.An indwelling drainage tube was placed in the hematoma cavity and the operation was completed without active bleeding.
45648166|NCT02642107|Radiation|Elective neck irradiation|Whole neck irradiation is given in the involved neck. Elective neck irradiation of Level II,III and Va lymph node area is given in the uninvolved neck, and Level IV and Vb lymph node area were not irradiated in the uninvolved neck.
45648167|NCT02642107|Radiation|Whole neck irradiation|Whole neck irradiation is given regardless of the involved or uninvolved neck.
45648168|NCT04948385|Drug|Propofol|deep sedation with propofol +/- adjuvants such as midazolam, sufentanil, lidocaine and/or dehydrobenperidol
45648169|NCT04948385|Procedure|No sedation|No sedation
45648170|NCT04940117|Dietary Supplement|Eefooton oral solution|Check eGFR value, liver and kidney function every month
45648171|NCT03057821|Other|3% hydrogen peroxide|The treatment group will also undergo skin preparation with 3% hydrogen peroxide.
45648172|NCT04947761|Drug|modified Tian Wang Bu Xin Dan hydrogel patch|modified Cheonwangbosimdan hydrogel patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
45648173|NCT04947761|Other|placebo patch|placebo patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
45648174|NCT04958213|Drug|Dextrose prolotherapy injection|15% dextrose prolotherapy injection into the knee and 15% dextrose prolotherapy injection will be applied to the painful adhesions of the ligaments around the knee.
45648175|NCT04958213|Combination Product|conventional physical therapy|4 weeks (20 sessions) physical therapy (Hotpack, TENS and Ultrasound) and home exercise program (isometric and isotonic exercises).
45648176|NCT04958135|Drug|Acoramidis|Film-coated immediate release oral tablet.
45648177|NCT04948151|Drug|Sildenafil|Patients will apply 2-gram applications up to 9 times per month.
45648178|NCT04948151|Drug|Placebo|Patients will apply 2-gram applications up to 9 times per month
45648179|NCT04939493|Other|Rhythmic Auditory Cueing|"Patients will perform the same movement sequence in time with the metronome beat. The frequency of the rhythmic auditory stimulation will be matched to the participants preferred movement speed, which will be assessed prior to the start of the trial, and participants typically started moving after they had heard the metronome beat two to three times. Participants will be given sufficient practice trials to ensure full understanding before the actual recording of data, and will be given 3-minutes break between trials.~On the 3rd and 5th week, the rhythm frequency was increased by 5%."
45794292|NCT01837550|Behavioral|Intervention group|The intervention group followed a five-week program that consisted of reading material, home training assignments, online and telephone interaction with an audiologist, and participation in a discussion forum.
45449848|NCT01080365|Drug|SKI-606 (Bosutinib)|500 mg (5 ×100 mg) phase 3 formulation film coated tablets, administered orally once daily
45449849|NCT01067027|Dietary Supplement|Lactobacillus reuteri|5 drops of study product 30 minutes before feeding.
45449850|NCT03536949|Drug|RVL-1201|RVL-1201 ophthalmic solution, 0.1%
45449851|NCT03536949|Other|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
45648180|NCT04939493|Other|Bilateral arm training|Training will consist of 20 minutes of bilateral arm training In each session, patients will be seated comfortably at a table in the following limb positions: ankles in neutral dorsiflexion, knees and hips placed at 90°, shoulders in 0° flexion, elbows in 60° flexion, and wrists in neutral position of flexion/extension
45648181|NCT04939493|Other|Conventional physical therapy program|Scapular mobilization. Thoracic spine mobilization. Mechanical assisted (active and passive) exercises. Therapeutic positioning as weight bearing on the paretic arm. Opening and closing closed fist. Strengthening exercise. Stretching of spastic muscles.
45648182|NCT04947995|Device|ctDNA multi-omics test|The ctDNA multi-omics test for gastric cancer will be built based on low-pass WGS, methylation, and target region sequencing.
45648183|NCT04939337|Drug|TH-SC01|Allogeneic Umbilical Cord-derived Mesenchymal Stem cells perilesional injection. Human TH-SC01 cell injection (human umbilical cord mesenchymal stem cells for injection, 5 million cells / ml, 6.0-10.0ml / bottle)
45754349|NCT03445520|Behavioral|Intervention Coaching Group|Parents in this group receive six, 1 hour, coaching sessions with a research staff coach, to discuss key information about transitions (knowing parent's rights about special education services, communicating effectively with school staff, knowing the roles of the school team members, how to develop and share your Snapshot, and what to do with your child over the summer to help with the transition). The coach will encourage the parent to identify a school staff member to help with preparing for the transition. If the post transition school team is not able to participate in a pre-transition meeting, then the coach will encourage the parent to share the Student Snapshot with the post-transition teacher(s) and school team when the new school year begins in the Fall.
45449852|NCT01080443|Drug|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
45794293|NCT01837550|Behavioral|Control group|The control group only had access to reading material.
45794294|NCT04452435|Drug|C21|C21
45794295|NCT04452435|Drug|Placebo|Placebo
45794296|NCT05747690|Device|KIO015|Innovative carboxymethyl chitosan-based biomaterial intended for intradermal injection
45794297|NCT04994210|Drug|Sintilimab|"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of newly diagnosed ENKTCL patients~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of newly diagnosed ENKTCL patients.~Exploring biomarkers that may have predictive effects."
45794298|NCT04994210|Drug|Chidamide|"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of newly diagnosed ENKTCL patients~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of newly diagnosed ENKTCL patients.~Exploring biomarkers that may have predictive effects."
45648184|NCT04939025|Procedure|Multi-interventional program|"Preoperative oral antibiotics and antibiotic enema of the rectal stump prior to the surgery~Routine and tailored lengthening measures of the mesentery~Intraoperative control of pouch vascularization using ICG~Early diagnosis and active assessment of the integrity of the anastomosis.~Routine CRP-measurements at day 4 and 6 (after removal pouch catheter) in the non-diverted pouches with CT-scan with rectal contrast if any suspicion on a leak (elevated or rise in CRP. symptoms).~Routine CRP-measurements at day 4 in the diverted pouches with endoscopy 10-14 days after pouch creation.~Endosponge vacuum assisted closure (EVAC) of the anastomotic defect aiming to close the defect within 10-14 days after diagnosis.~MRI assessment of the pouch after stoma closure preferably at one year to rule out chronic sepsis mimicking pouchitis or Crohn's disease."
45648185|NCT04957901|Drug|modified BFM-95 protocol|Clinical stage system, risk stratification and treatment for pediatric mature B-NHL were according to the modified BFM-95 protocol. The tumor tissue (FFPE) and plasma samples (bone marrow or cerebrospinal fluid samples if necessary) from the newly diagnosed patients were collected and sequenced by 475 genes panel before, during and post treatment.
45794299|NCT04410159|Drug|Povidone-Iodine|Gargle
45794300|NCT04410159|Drug|Essential oils|Gargle
45794301|NCT04410159|Other|Tap water|Gargle
45794302|NCT05314803|Behavioral|Yoga|Participants receive the yoga program, which is delivered by a trained yoga instructor (completed at least a 200-hour yoga teacher training, Yoga Thrive Teacher Training Certification (or similar), and/or practical experience working with individuals affected by cancer). The first class of the week is comprised of 45 minutes of gentle, progressive, hatha-based yoga sequencing and postures with the last 15 minutes focused on guided behaviour change and mindfulness techniques that varies week-to-week, based on the participants in the class. The second class of the week is 60 minutes of gentle, yin-based yoga sequencing and postures with an element of opening and relaxing.
45794303|NCT00559988|Drug|Home Monitoring Guided OAC|"Active monitoring for atrial episodes through the automatic HM notifications (email, fax, short message service) is required. If the total duration over 48 consecutive hours reaches the predefined anticoagulation condition, and AF/AFL diagnosis is confirmed using the IEGM online, the site instructs the patient by telephone to start OAC. Clinicians continue to monitor patients using HM, and if freedom from AF/AFL reaches the predefined interval, stop of OAC therapy is requested over the telephone. Following stop of anticoagulation, any recurrence of AF/AFL requires restart of OAC therapy.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA"
45794304|NCT00559988|Drug|Physician-Directed OAC|"Patients will receive physician-directed anticoagulation therapy based on conventional criteria.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA"
45794305|NCT03398265|Behavioral|Treatment Navigation (Intervention)|Subjects in the intervention arm will begin a discussion with the interventionist about whether they are interested in treatment and medication choices for opioid use disorder. The interventionist will use a decision tool informed by the Substance Abuse and Mental Health Services Administration (SAMSHA) guide to medication assisted treatment in order to help make an informed decision about treatment choices. Once a decision is reached, the Treatment Navigator will communicate with the subject periodically to assist with entering treatment and help with locating other social services as needed within the community. The Treatment Navigator will emphasize getting into treatment as quickly as possible once a decision is made. The Treatment Navigator and the subject will continue communicating throughout the 6 month study period. Subjects will also receive overdose education and be offered take-home naloxone.
45794306|NCT03398265|Other|Control|Subjects in the control arm will receive referrals from Department of Corrections (DOC) staff for treatment per DOC protocols. Subjects will not receive any treatment navigation or treatment decision making. Subjects will also receive overdose education and be offered take-home naloxone.
45449853|NCT01067183|Behavioral|portable biofeedback tool and relaxation breathing technique|The intervention group were trained in relaxation breathing technique and the use of a portable biofeedback tool that informs them of the success of the technique...thus behavioral therapy using a biofeedback device
45449854|NCT03639441|Procedure|dry needling|Dry needling, also known as myofascial trigger point dry needling, is an well-proved technique in alternative medicine similar to acupuncture. It involves the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, including pain related to myofascial pain syndrome. Dry needling is sometimes also known as intramuscular stimulation (IMS).
45794307|NCT03398421|Drug|Nemiralisib|Nemiralisib will be given as 100 mcg via ELLIPTA Dry Powder Inhaler with 30 doses per inhaler/ 100 mcg total dose. ELLIPTA® is a registered trademark of GlaxoSmithKline group of companies.
45794308|NCT03398421|Drug|Itraconazole|Itraconazole will be given as 100 mg per capsule per day administered orally with water
45794309|NCT01839110|Drug|Ranolazine|Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day and continue for a total of 26 weeks.
45794310|NCT01839110|Drug|Placebo|Placebo by mouth twice per day for a total of 26 weeks.
45794311|NCT04396665|Behavioral|Precam|6 months Web-App intervention related with: diet, physical activity, self-care and breast cacner risk prevention
45794312|NCT05314881|Genetic|TNFS4, NCF gene|study the gene polymorphisms from the blood sample of the included SLE patients
45794313|NCT03400449|Other|Video counseling|Video counseling
45794314|NCT03400449|Other|Conversational counseling|Conversational counseling
45794315|NCT00559754|Drug|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
45794316|NCT00559754|Drug|Docetaxel|75mg/m2 iv on day 1 of each 3 week cycle
45794317|NCT00559754|Drug|Standard chemotherapy|As prescribed
45794318|NCT03402243|Other|Menthol ban on cigarettes|Participants will have menthol and tobacco flavored e-cigarettes available but only non-menthol cigarettes
45794319|NCT03402243|Other|Menthol ban on cigarettes and e-cigarettes|Participants will have neither menthol flavored cigarettes or e-cigarettes available
45794320|NCT03402243|Other|No menthol ban|Participant will have menthol and tobacco flavored cigarettes and e-cigarettes available
45921184|NCT00006695|Radiation|tositumomab and iodine I 131 tositumomab|"Patients will receive two administrations of Iodine-131 Anti-B1 Antibody; the dosimetric dose and the therapeutic dose. The dosimetric dose will consist of an infusion of unlabeled Anti-B1 Antibody (450 mg) immediately followed by an infusion of Anti-B1 Antibody (35 mg) which has been trace labeled with 5 mCi of Iodine-131 Anti-B1 Antibody. Using whole body anterior and posterior gamma camera scans and serial imaging studies over approximately one week, the clearance of the whole body dosimetric dose will be used to calculate the subsequent therapeutic dose of Iodine-131 Anti-B1 Antibody which delivers a total body dose of 75 cGy to the subject"
45921185|NCT00107926|Drug|Licarbazepine|
45921186|NCT00107926|Drug|Placebo|
45648186|NCT04947371|Drug|Anlotinib Hydrochloride|Oral anlotinib hydrochloride 12 mg/d
45648187|NCT04957121|Other|on-hours|"If the begin time of anesthesia was between 8:00 to 17:59, it was defined as on-hours."
45648188|NCT04957121|Other|off-hours|"If the start time of anesthesia was between 18:00 to 7:59 or the end time of anesthesia was later than 20:00, it was defined as off-hours."
45921187|NCT03659565|Behavioral|Enhanced Pre-Visit Consultation|The Intervention Group will be given access to the optimized personal health record and will use Zoom as part of the pre-visit consultation.
45921188|NCT03659565|Behavioral|Usual Care Control|Caregivers and patients will participate in usual pre-visit process.
45921189|NCT00107965|Drug|PEP005|0.0025% PEP005 Topical Gel (Day 1,2 application)
45648189|NCT02633293|Drug|Inhaled Treprostinil|Inhaled treprostinil up to 15 breaths (90 mcg) four times daily
45648190|NCT04938713|Drug|Ketamine 50 MG/ML|Intravenous Ketalar® 0,30 mg/kg in 1 hour.
45921190|NCT00107965|Drug|PEP005|0.01% PEP005 Topical Gel (Day 1,2 application)
45921191|NCT00107965|Drug|PEP005|0.05% PEP005 Topical Gel (Day 1,2 application)
45921192|NCT00107965|Drug|PEP005|Vehicle Gel (Day 1,2 application)
45648191|NCT04938713|Drug|Esketamine 25 MG/ML|Intravenous Vesierra® 0,15mg/kg in 1 hour.
45648192|NCT04938401|Other||
45921193|NCT00107965|Drug|PEP005|0.0025% PEP005 Topical Gel (Day 1,8 application)
45648193|NCT04938011|Drug|progesterone|the transfer of day 6 blastocyst on the 6th day of progesterone supplementation
45648194|NCT04938011|Drug|progesterone|the transfer of day 6 blastocyst on the 7th day of progesterone supplementation
45648195|NCT04296019|Drug|Fruquintinib|Maintenance therapy with fruquintinib ( 5 mg qd for 3 consecutive weeks, followed by discontinuation for 1 week).
45648196|NCT04947215|Diagnostic Test|stress biomarkers|used to estimate the reference values of putative biomarkers of birth stress such asCTnT, CTnI, copeptin, NT-proBNP and hs-CRP in the cord blood of full term neonates
45648197|NCT05115565|Device|TENS (Transcutaneous Electrical Nerve Stimulation) Application|Conventional (traditional) TENS will be applied to the patients. The frequency will be 100 Hz, the pulse width (time) will be 150 μs, the current intensity (amplitude) will be 30 mA. In addition to routine care and treatment, TENS will be applied to intervention group patients.
45648198|NCT03057665|Device|Atomic Biomagnetometer|Measure magnetic field of fetal heartbeat
45648199|NCT04677907|Device|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
45648200|NCT04677907|Device|Persona (Zimmer) posterior stabilised cemented Trabecular Metal™ (Tibia and Femur) prosthesis|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
45648201|NCT03057509|Drug|Ga-68-DOTA-TOC|Ga-68-DOTA-TOC is a imaging radiotracer that is used for positron emission tomography imaging of a variety of the neuroendocrine tumors. This radiotracer in the body binds to several subtypes of the somatostatin receptor and accumulates in the tissue with high expression of these receptors. Therefore neuroendocrine tumors that express somatostatin receptors can be imaged using this radiotracer.
45754350|NCT03586778|Other|dry needling|Dry Needling targeting the posterior musculature of the thoraco-lumbar spine and hips
45794321|NCT03402555|Other|Stool pattern|Collection of stool images
45794322|NCT01841216|Device|Lower Body Exercises with and without resistance|lower body exercises with and without resistance designed to activate the gluteal/hip musculature
45794323|NCT01841606|Drug|Ondansetron|4mg of IV ondansetron
45794324|NCT01841606|Other|Normal saline|10mL of IV normal saline
45794325|NCT04392141|Drug|Standard Treatment|Standard Treatment for COVID-19 based on National Recommendations
45794326|NCT04392141|Drug|Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions|Colchicine plus a Herbal extraction containing a Phenolic Monoterpene Fractions will be added to standard treatment in patients with COVID-19.
45794327|NCT01842464|Procedure|Anterior Sacro-Spinous|Anterior Sacro-Spinous
45794328|NCT04838054|Drug|Stabilized chlorine dioxide oral rinse|Patients received stabilized chlorine dioxide rinse associated with periodontal basic therapy.
45921194|NCT00107965|Drug|PEP005|0.01% PEP005 Topical Gel (Day 1,8 application)
45921195|NCT00107965|Drug|PEP005|0.05% PEP005 Topical Gel (Day 1,8 application)
45921196|NCT00107965|Drug|PEP005|Vehicle Gel (Day 1,8 application)
45921197|NCT00108004|Drug|pramlintide acetate|Pramlintide (0.6 mg/mL) in 5.0-mL multiple-draw glass vials for SC injection for 12weekes and after Pramlintide (1.0 mg/mL) 1.5 mL pen-cartridge. Subjects who do not switch to the pen-cartridge device at Week 12 will continue to administer pramlintide using a syringe and vial.
45921198|NCT00006734|Biological|filgrastim|Given IV
45921199|NCT00006734|Drug|cyclophosphamide|Given IV
45794329|NCT04838054|Other|Placebo|Patients received a rinse containing no active ingredients and periodontal basic therapy.
45794330|NCT02263118|Other|Uni-directional SMS|Exposure to breastfeeding promoting SMSs
45794331|NCT02263118|Device|Feature phone|Participants were given a feature phone.
45794332|NCT02263118|Other|Virtual communities|Exposure to virtual community communication via SMS
45648202|NCT03057509|Device|Siemens PET/MR scanner|Positron emission tomography-magnetic resonance (PET/MR) is a hybrid imaging technology that incorporates magnetic resonance imaging (MRI) soft tissue morphological imaging and positron emission tomography (PET) functional imaging. The Siemens PET/MR system (Biograph mMR) received a CE mark and FDA approval for clinical diagnostic imaging.
45794333|NCT02263118|Other|Hybrid setup|Exposure to virtual community and access to communications with health professional via SMS
45794334|NCT05747300|Other|Premixed bioceramic paste wellroot PT|Vital pulpotomy primary Molars using premixed bioceramic paste wellrootPT
45794335|NCT04739462|Behavioral|mHealth Platform|All participants randomized to the intervention group will receive 2-4 informational texts each week and will also receive interactive health screening questions throughout enrollment. A participant will also receive appointment reminder texts. All SMS text messages will be transmitted through a local organization known as The Medical Concierge Group (TMCG) via an electronic system that allows for bulk messaging. TMCG also staffs a 24-hour call line for those using TMCG services to call in for medical related questions. This call line is staffed by doctors and nurses; SMS Maama participants randomized to the interventional group will be able to access this call line free of charge as part of their enrollment in SMS Maama.
45794336|NCT05747222|Other|Action Observation Tharapy|Using a 13-inch tablet, the patient will be shown, from a third-person lateral perspective framing the palmar side of the hand, a video that repeatedly plays a simple movement of daily life (grasping a glass on the table with the hand and bringing it closer to oneself) for 5 consecutive minutes. The video should be customized based on the side being treated (ex: right hemiparesis, video framing a right hand). After 1 minute of rest, the therapist will ask the patient to perform the newly observed movement for a minimum duration of 2 minutes and a maximum of 5 minutes. The cycle will be repeated a total of 3 times, for total treatment time between 25 and 35 minutes per session.
45794337|NCT05747222|Other|Conventional Therapy|Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc.).
45794338|NCT01846988|Device|crossover treatment (REMstar Auto A-Flex)|All subjects will use same device with 4 week crossover of settings of APAP and CPAP
45794339|NCT04625036|Diagnostic Test|Single passive leg movement|"The investigation consists of a non-invasive evaluation by ultrasounds performed on the common femoral artery investigating the speed of arterial blood flow [Leg Blood Flow LBF] and diameter of vessel with a dedicated ultrasound system (General Electric Medical Systems, Milwaukee, WI) using Doppler method, before and after a passive flexion-extension movement of the knee. A linear probe will be used with a frequency of 5 MHz. Using the diameter of the artery and the average volume (Vmean), the LBF will be calculated every second with the formula=Average volume*PiGreco*(vessel diameter / 2)2*60.~The subject will be placed in a sitting position for 20 minutes before the test. The protocol consists of image acquisition for 60 seconds (basal measurement), followed by a passive flexion-extension of the knee (single passive leg movement). The knee flexion will be performed by health care personnel at a rate of 1 Hz. At the end of the movement, the recording will continue for 60 seconds."
45921200|NCT00006734|Drug|doxorubicin hydrochloride|Given IV
45648203|NCT03057509|Other|Standard Siemens Software|The Siemens PET/MR scanner are equipped with a standard clinical visualization software with the advanced application tools based on the Siemens image interpretation engine called syngo.via. This software allows for visualization and interpretation of the image data-sets in the clinical environment.
45648204|NCT03057509|Drug|LAR Octreotide|LAR octreotide is a man-made protein that is similar to a hormone in the body called somatostatin. LAR Octreotide lowers many substances in the body such as insulin and glucagon, growth hormone, and chemicals that affect digestion. LAR octreotide is used to treat a variety of clinical conditions but most importantly to reduce flushing episodes and watery diarrhea caused by cancerous tumors such as neuroendocrine tumors.
45648205|NCT05115487|Diagnostic Test|digital dynamometer|Hand grip strength will be measured using a hand-held digital dynamometer with the patient sitting in a hard chair and elbow flexed to 90°. All assessments and measurements will be made by the same experienced physician blinded to patients' clinical data.
45648206|NCT04957199|Other||
45921201|NCT00006734|Drug|etoposide|Given IV
45653180|NCT05111925|Other|PREPARE Initial Clinical Assessment - Pilot (two iterations)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~Two-Minute Walk~Gait~Double Leg Squat~Single Leg Squat~Jump-Landing~Single Leg Triple Hop~Closed Kinetic Chain Upper Extremity Stability Test~Functional Movement Screen Shoulder Clearing Test~Prone Plank~Active Hip Abduction~Joint range of motion assessments:~Knee Extension~Hip Abduction~Hip Internal Rotation~Hip External Rotation~Ankle Dorsiflexion~Psychosocial assessments:~NIH PROMIS Physical Function, Pain Interference, Depression, & Anxiety~Tampa Scale of Kinesiophobia"
45648207|NCT04436887|Procedure|positioning of polypropylene strips for prophylactic purposes in closing the middle laparotomies to prevent the incisional hernia|Sub-lay mesh supported closure A 4 cm space is created between posterior rectus sheath and rectus muscle, widening 2 cm at each side of midline. Both posterior rectus sheath edges are sutured using a running slowly absorbable suture. Above arcuate line, posterior layer was performed suturing peritoneum and posterior rectus sheath; below arcuate line, posterior layer was performed suturing peritoneum and trasversalis fascia. Anterior layer was performed suturing anterior rectus sheath. A suture length to wound length ratio of 4:1 is recommended. A 4-cm Parietex Progrip Mesh strip was placed between the posterior rectus sheath and rectus muscle with an overlap of at least 2 cm at each side, suture less. In laparotomies >20 cm two stripes of 15 cm each were designed. The midline anterior rectus sheath was closed using a running slowly absorbable suture, covering the mesh. A suture length to wound length ratio of 4:1 is recommended.
45648208|NCT05115175|Behavioral|Mindfulness-Based Stress Reduction|Participants engaged in meditation and self-led exercises to help them understand and cope with stress.
45648209|NCT04946825|Drug|Nicotine replacement therapy patch|The nicotine patch is attached to the participant's skin and provides a slight constant stream of nicotine. The smaller dose is meant to reduce nicotine dependence.
45648210|NCT04946825|Drug|Nicotine replacement therapy lozenge|The nicotine lozenge contains small amounts of nicotine, which a participant slowly dissolves in their mouth. Like the patch, the smaller dose is meant to reduce nicotine dependence.
45648211|NCT04946825|Behavioral|Quit electronic cigarettes|Participants will receive instruction and text message support to quit electronic cigarettes when they quit combustible cigarettes.
45648212|NCT04946825|Behavioral|Continue electronic cigarettes|Participants will receive instruction and text message support to continue using electronic cigarettes after they quit combustible cigarettes.
45794340|NCT05746832|Procedure|Endoscopic stenting Retrograde Cholangiopancreatography (ERCP)|Assessment of the differences in stone size and the largest CBD diameter before and after stenting in one or two sessions. Stone clearance and complications were also determined with the ERCP, and factors associated with complete clearance were evaluated in patients with difficult CBD stones (a large [≥ 20 mm] or multiple [≥ 3 sized ≥ 15 mm] CBD stones). And also compared the outcomes with conventional procedure of open surgery.
45648213|NCT03800329|Device|Snap40 Monitor|Non-invasive, wearable armband device used to measure change in systolic blood pressure, respiratory rate, heart rate, body temperature, movement, and oxyhemoglobin saturation and streams this information to a cloud-based storage system. Patients will complete a questionnaire.
45648214|NCT03800329|Other|No Monitor|Patients will be discharged in the ordinary manner, without the Snap40 monitor. Patients will complete a questionnaire.
45648215|NCT04946513|Other|Muscle volumes were measured on pre- and postoperative MRI scans.|Muscle volumes were measured on pre- and postoperative MRI scans.
45648216|NCT05112133|Dietary Supplement|Mulberry leaf extract|Oral administration
45794341|NCT02268500|Biological|Influenza vaccine|Influenza vaccine
45794342|NCT00559364|Drug|Viokase® 16|Patients assigned to Viokase® 16 will be given 22 tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
45794343|NCT00559364|Drug|Placebo|Patients assigned to placebo will be given 22 matching placebo tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
45794344|NCT00559364|Drug|Proton pump inhibitor (PPI)|Patients on PPI during Screening will continue their usual PPI therapy throughout the study.
45794345|NCT00559364|Drug|Omeprazole|Patients not using PPI therapy at Screening will be given omeprazole 20 milligram orally once daily throughout the study.
45794346|NCT05746676|Drug|Insulin|in treatment of periodontal defects
45794347|NCT05746676|Drug|Hyaluronic acid|in treatment of periodontal defects
45794348|NCT01848158|Device|acupuncture|Patients randomized to active treatment will receive acupuncture treatment with press needles (small acupuncture needles manufactured with attached bandage that makes the needle flush with skin) at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a seed magnet at ear shen men position for 4 hours on treatment days.
45921202|NCT00006734|Drug|ifosfamide|Given IV
45648217|NCT05112133|Dietary Supplement|Water|Oral administration
45648218|NCT03058133|Other|fMRI study|Functional brain activations of face-voice processing during a gender task
45794349|NCT01848158|Device|sham acupuncture|Patients randomized to sham treatment will receive sham acupuncture with similarly appearing bandages placed without press needles attached at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a similarly appearing bandage without seed magnet underneath at ear shen men position for 4 hours on treatment days.
45794350|NCT04574336|Procedure|Surgical treatment|We anticipate that surgical treatment will include plate osteosynthesis (MIPO and ORIF), intramedullary nailing (antegrade and retrograde) and external fixation. Plate and nail types, screw configuration and surgical approaches will be decided by the surgeon. The procedure will be conducted or supervised by a senior consultant.
45921203|NCT00006734|Drug|vincristine sulfate|Given IV
45921204|NCT00006734|Procedure|adjuvant therapy|
45921205|NCT00006734|Procedure|conventional surgery|
45921206|NCT00006734|Procedure|neoadjuvant therapy|
45921207|NCT00006734|Radiation|brachytherapy|
45921208|NCT00006734|Radiation|radiation therapy|
45921209|NCT03638427|Diagnostic Test|Menstrual Blood Analysis (Menstrual Blood Analysis)|We will be testing women's menstrual blood to investigate the feasibility and efficacy of assessing HR-HPV DNA and HPV E6/E7 mRNA via self-collected menstrual blood from a menstrual pad.
45921210|NCT00108043|Procedure|FES-evoked functional upright gait|
45921211|NCT00108121|Drug|PEP005|
45921212|NCT00108199|Behavioral|Problem-Solving Training|
45794351|NCT04574336|Device|Non-surgical treatment|Non-surgical treatment will include sugar tong, splint, plaster splints, hanging casts, or functional bracing as the Sarmiento brace and will be worn until a surgeon removes it. If the surgeon deems it appropriate, participants will be offered to undergo early secondary surgery with a surgical procedure of their choice. The participants will be recorded and the reason will be noted. We anticipate the surgical procedures will be similar to the previous mentioned and perhaps with the addition of bone graft.
45921213|NCT00108199|Behavioral|Work-Related Social Skills Training|
45648219|NCT04798495|Other|Multimodal interdisciplinary rehabilitation programme (HAPPY)|A 6-month multimodal interdisciplinary rehabilitation programme abbreviated HAPPY was tested. The programme consisted of motivating interviewing technique, individual dialogues with fixed subjects, individual supervised physical exercise training, relaxation exercises, nutritional counselling, and group sessions (a combination of topics and exchange of experiences) with patients and relatives. To reach patients at home, the team phoned patients, who were also given tablets with access to the project's homepage and a digital physical exercise programme.
45648220|NCT05114707|Drug|camrelizumab|Camrelizumab was administrated with 200mg each time, every three weeks for a total of 11 cycles since the first day of induction chemotherapy.
45648221|NCT04937621|Diagnostic Test|ECG data analysis|Baseline ECG as well as follow-up ECG are analysed
45648222|NCT04937621|Drug|Treatment data collect|Baseline treatment data as well as follow-up treatment data are collected
45921214|NCT00108238|Drug|Estradiol followed by progesterone|
45921215|NCT00108238|Drug|Raloxifene|
45648223|NCT04937621|Biological|Biological check-up data collect|Baseline Biological check-up data as well as follow-up data are collected
46071694|NCT02836626|Procedure|deep fascial mobilization|Pelvic and abdominal myofascial release techniques as described by Barnes will be performed to facilitate independent mobility between tissue layers as needed following the direction of palpated fascial tension. Following this, direct scar mobilization techniques as described by Manheim will be done, applying a stretch in the direction of palpated restriction . This involves applying deep pressure whose force and direction is dictated by the tightness the therapist palpates and the subject reports. These are each held until a release is felt (defined as a sudden relaxation of tissue tension), usually 60-120 seconds. Total treatment time will last 25 minutes. Treatments will include all the above techniques but the therapist will tailor each treatment to address palpated restrictions. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.
45648224|NCT04937621|Other|Collection of clinical events of interest|Clinical events of interest at the baseline as well as follow-up clinical events are collected
45648225|NCT03632473|Diagnostic Test|multimodal evoked potentials (mmEP)|combination of visual evoked potentials (VEP) and motor evoked potentials (MEP) or the combination of VEP, MEP and somato-sensory evoked potentials (SSEP)
45648226|NCT04937855|Other|no intervention|no intervention
45648227|NCT03572413|Procedure|Low pressure pneumoperitoneum|Lowering intra-abdominal pressure during laparoscopic surgery
45648228|NCT03572413|Drug|Rocuronium bromide|Deep (PTC 1-2) versus moderate (TOF count 1-2) neuromuscular block
45648229|NCT04946747|Device|Modern microelectrical mechanical systems (MEMS) head-impact sensors|Both groups will wear our smart head-impact sensor system (MEMS head-impact sensors) to measure their response to training.
45921216|NCT03625323|Drug|Eftilagimod alpha|APC activator, MHC II agonist, LAG-3 fusion protein
45648230|NCT04946747|Other|Virtual Reality (VR) Goggle Use with consistent timing of Conditioned Stimulus and Unconditioned Stimulus|The Trained group will have the conditioned stimulus (CS, images of opposing players approaching) and the unconditioned stimulus (US, a voice cue to stiffen the neck by the coach) always being delivered with a consistent timing relationship (e.g. a 250 msec delay between the CS and the US), causing the conditioned response (neck stiffening) to emerge.
45648231|NCT04946747|Other|Virtual Reality (VR) Goggle Use with inconsistent timing of Conditioned Stimulus and Unconditioned Stimulus|The Control group will also receive the same CS and the same US as trained group, but the CS and the US will bear no consistent timing relationship, therefore never causing any CR to emerge.
45921217|NCT03625323|Drug|Pembrolizumab|anti-PD-1 antibody
45921218|NCT00108316|Drug|Fluoxetine (Liquid Prozac)|
45921219|NCT00108394|Drug|pamidronate|
45921220|NCT00108511|Drug|Gemfibrozil|
45921221|NCT00401440|Drug|Misoprostol|400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses
45648232|NCT04937933|Drug|Coolant spray (Cryos ®Spray, Phyto Performance, Italy)|The coolant spray treatment method is a cryotherapy non-pharmacological treatment choice.
45648233|NCT04937933|Drug|Saline solution|saline solution
45648234|NCT04956419|Drug|SHR8008 capsule|once daily for 2 days(Day 1 and Day 2),oral
45921222|NCT00401440|Drug|Misoprostol|400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses
45921223|NCT00108589|Drug|S-adenosylmethionine|
45648235|NCT04956419|Drug|Fluconazole capsule|once daily for 2 days(Every 72 hours) ,oral
45648236|NCT04956653|Other|Without additional intervention|Only patients' information was collected
45648237|NCT04615429|Biological|Mesenchymal stromal cells|Administration of one single dose of allogenic Mesenchymal stromal cells
45648238|NCT04615429|Other|Placebo|Administration of placebo (solution identical to experimental treatment, without the MSC)
45648239|NCT04956965|Radiation|Cardiac electro-mapping|Perform an high-resolution three-dimensional maps of cardiac electrical activity using EnSite Precision system.
45648240|NCT05114395|Other|Pelvic Floor Telerehabilitation Program|See experimental and active comparator arms.
45921224|NCT00108667|Drug|IV Levodopa|
45921225|NCT00108667|Drug|Talampanel|
45921226|NCT00006773|Drug|bortezomib|Given IV
45794352|NCT01849172|Other|electroacupuncture|Stick adhesive tapes to all points. For ST25, EX-CA1 and RN4, insert the needle vertically through the pads and the skin, and then slowly and vertically penetrate through the layer of fatty tissue, into the muscles of the abdominal wall .For RN4, manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times. Insert the needle vertically at SP6 to a depth of 1 cm. Manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times to reach de-qi. Put the electric stimulator on the pair of EX-CA1 and ST25 points with a dilatational wave, 10/50 Hz, 0.5-1.0mA. To turn on the current intensity till the abdomen shivers. The same manipulation methods for RN4 and SP6 will be given every 10 minutes (3 times in all).
45794353|NCT01849172|Other|sham electroacupuncture|"Non-points proximate to RN4 (P1), EX-CA1(P2)，ST25 (P3) and SP6 (P4) (double sides) are used.P1 and P3 are at the sites 1 cm (outward in horizontal direction) proximate to RN4 and ST25 respectively. P2 is 2 cm (outward in horizontal direction) proximate to EX-CA1. P4 is at the middle site of the spleen meridian and the kidney meridian (backward in horizontal direction proximate to SP6).~Stick adhesive tapes to all points. Blunt needles will be used to be inserted to but not piercing the skin. Even lifting, thrusting and twisting manipulation methods will be given for each non-point for 3 times. Put the sham electric stimulator on the pair of P2 and P3 with the same parameters as the acupuncture group. But there is no current intensity actually."
45648241|NCT05114395|Other|Pelvic Floor Face-to-Face Program|See experimental and active comparator arms.
45794354|NCT05746598|Drug|Cisplatin injection|Cisplatin 75mg/m2
45794355|NCT05745974|Diagnostic Test|lymphocytic count|taking blood samples and COVID-19 swab
45921227|NCT00108706|Drug|Candesartan|
45648242|NCT04946669|Drug|Abatacept|Abatacept is a CTLA-4 fusion protein that inhibits T cell activation by competitively binding to CD80/CD86 and blocking the second signal. To date, Abatacept has been approved by the FDA for the treatment of three types of rheumatoid immune diseases (refractory rheumatoid arthritis, juvenile idiopathic arthritis, and active psoriatic arthritis). The international consensus of experts recommends abacepil as a second-line regimen for the treatment of refractory dermatomyositis based on the evidence of case reports. However, to date, there is no relevant report or clinical study registration information of Abatacept in the treatment of dermatomyositis.
45648243|NCT04946357|Radiation|Protons|proton irradiation with a total dose of 39 Gy(RBE) in 3 Gy(RBE) fractions
45648244|NCT04946357|Radiation|carbon ions|carbon ion irradiation with a total dose of 39 Gy(RBE) in 3 Gy(RBE) fractions
45648245|NCT04956497|Device|extracorporeal membrane oxygenation (ECMO)|ECMO under ongoing cardiopulmonary resuscitation (eCPR) in patients with refractory cardiac arrest
45648246|NCT03219775|Biological|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 4)~If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo1 mg/kg i.V. and Ipi3 mg/kg i.V. / Q3W x 2)*~If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 1 mg/kg i.V. and Ipi 3 mg/kg i.V. / Q3W x 2)~If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~since June 5, 2019, the treatment in all four boost cycles (1+2) and (3+4) is performed with nivolumab 1 mg/kg + ipilimumab 3 mg/kg (NIVO1/IPI3)"
45648247|NCT04409015|Device|ROTEM - rotation thromboelastometry testing|The ROTEM® is a simple blood test that provides information about specific components involved in blood clotting and stopping hemorrhage.
45648248|NCT04946045|Other|Sensorimotor Interventions (Tactile/Kinesthetic Stimulation+Nonnutritive Sucking)|"Sensorimotor interventions were applied to in preterm infants between 30-33 weeks of age for 10 days. After that, preterms were included in the Six-phase feeding progression protocol."
45648249|NCT03057587|Device|NIRS Monitoring|NIRS data will be collected throughout the surgery
45648250|NCT03100045|Drug|Artesunate Suppositories|Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia
45648251|NCT02986087|Device|Fetal Tracheal Occlusion|Fetuses with congenital diaphragmatic hernia with an observed to expected lung-to-head ratio of <25%, LHR <1, o/e LHR<30% (moderate), singleton pregnancy, no known other anomalies, gestational age < 29 weeks 6 days, no maternal disease, maternal age > 18 years old meet criteria to be offered tracheal occlusion. We want to test feasibility and efficacy in our center as a requirement to enter the TOTAL trial.
45648252|NCT04946123|Dietary Supplement|L-carnitine+Selenium|Supplementation with L-carnitine and Selenium
45648253|NCT04945889|Diagnostic Test|Quick Sequential Organ Failure Assessment (qSOFA)|Clinical bedside tool that evaluates three vital parameters, scoring one point each if altered: respiratory rate (RR) ≥22 breaths/minute, systolic blood pressure (SBP) ≤100 mmHg and altered mental status (defined in our study as either Glasgow Coma Scale (GCS) score <15 or any worsening in the Italian Oriented, Disoriented, Agitated, Sleepy scale). A qSOFA score ≥2 points is considered indicative of sepsis.
45754351|NCT03586778|Other|manual therapy|Manual Therapy(mobilization/ manipulation) to address joint mobility of the thoraco-lumbar spine and hips
45794356|NCT04488536|Diagnostic Test|Clinical Frailty Scale|Frailty assessment
45794357|NCT05745038|Behavioral|SONATA|The SONATA intervention is composed of five components, network diagnostics, network engagement, opportunity creation, skill building and goal-setting, and feedback, that will be audio-recorded and held over six scheduled sessions.
45794358|NCT04297436|Biological|4CMenB (Bexsero®) vaccine|Tthe 4CMenB vaccine (Bexsero®) contains the MeNZB OMV component plus three recombinant antigens (NadA, fHBP-GNA2091, and NHBA-GNA1030. The 4CMenB vaccine (Bexsero®) induces antibodies in humans that recognise gonococcal proteins.
45921228|NCT00108784|Behavioral|Reduced-energy-density diet|
45921229|NCT03619551|Drug|Busulfan|Randomization between low and medium doses of busulfan for TCR αβ+/CD19+ depleted haploidentical related and unrelated donor HCT.
45921230|NCT03619551|Device|Cell processing for TCRαβ+/CD19+ depletion|T-cells and B-cells will be removed from the stem cells collected from the donor by an investigational process called alpha-beta CD3+/CD19+ t-cell depletion using a device called CliniMACS® prior to recipient infusion, hopefully minimizing the risk of significant graft vs. host disease (GVHD) or lymphoproliferative disorder.
45921231|NCT00108823|Drug|Roflumilast|
45921232|NCT00006812|Drug|capecitabine|
46073693|NCT00849589|Behavioral|Computerized screening and brief physician advice|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors
45794359|NCT05744492|Other|Vivifrail multicomponent exercise program|"Resistance: 3 sets of 2 repetitions of 3-4 exercises with a 1 to 3-minute break between sets. Intensity from 30-repetition maximum (RM) at weeks 1-6 to 20-RM at weeks 7-12.~Balance training: both static and dynamic. Subjects will increase the number of repetitions, the difficulty of the exercises or will add external perturbations to the tasks (unstable surfaces, obstacles, or visual deprivation) along the duration of the interventions to guaranteeing progression. In the case of high risk of falling the number, frequency and volume of balance exercises will be increased.~Flexibility: a set of stretching exercises at the end of each session. Subjects will be instructed to stretch until they feel tension in their muscles without reaching discomfort. Stretching will be maintained for 10 sec. and repeated 2-3 times.~Cardiovascular: walking-based activities oriented to increase cardiorespiratory fitness. They will range from 5-10 sec. to 45 min/session."
45648254|NCT04945889|Diagnostic Test|Modified Early Warning Score (MEWS)|Clinical bedside tool that evaluates five vital parameters, with multiple scoring according to alteration: respiratory rate (0-3 points), heart rate (0-3 points), systolic blood pressure (0-3 points), body temperature (0-2 points), mental status (0-3 points, evaluated using the Alert, Verbal, Pain, Unresponsive - AVPU scale). A MEWS score ≥5 points is considered indicative of an acute condition at risk of sudden clinical deterioration.
45648255|NCT04945889|Diagnostic Test|National Early Warning Score (NEWS)|Clinical bedside tool that evaluates seven parameters, with multiple scoring according to alteration: respiratory rate (0-3 points), oxygen saturation (0-3 points), need for any supplemental oxygen (0-2 points), body temperature (0-3 points), heart rate (0-3 points), systolic blood pressure (0-3 points), mental status (0-3 points, evaluated using the Alert, Verbal, Pain, Unresponsive - AVPU scale). A NEWS score ≥7 points is considered indicative of an acute condition at risk of sudden clinical deterioration.
45648256|NCT04945811|Diagnostic Test|Interlukein 6 and procalcitonin serum levels|Blood tests
45648257|NCT04955561|Other|Oxygen therapy|Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.
45648258|NCT04955561|Other|Medical Air|Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.
45648259|NCT04955561|Other|10L/min O2|Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.
45648260|NCT04955639|Other|Control|Standard of Care - Control Smoking Cessation Program
45648261|NCT04955639|Other|Pivot|Pivot Program Smoking Cessation Program
45794360|NCT05742386|Behavioral|Communication training|Clinics will host an AAT workshop. A trained facilitator will use a standard script and slides to deliver workshop in-person or over Zoom; clinical staff who are unavailable will take the workshop later on their own.
45794361|NCT05742386|Behavioral|Communication training enhanced with standing orders optimization|"Clinics will host an AAT workshop, as in the other trial arm.~Clinic representatives will attend working meetings on putting HPV vaccine standing orders into clinic workflow. Clinics will then orient their staff to the standing orders. Finally, clinic representatives will discuss their use of standing orders in a learning collaborative."
45794362|NCT01853774|Behavioral|Tailored navigation|
45794363|NCT01853930|Behavioral|Platform for Administering Eye-movement Control Training|The Platform for Administering Eye-movement Control Training (PAECT) meta program will incorporate all of the exercises that the investigators have developed and validated over the course of our previous Merit Review grants (Seiple, Szlyk et al., 2005, 2011). The PAECT platform will be designed to allow patients to easily run the training exercises in their homes and to practice at their convenience. The PAECT will employ an executive component that will keep track of the exercises that are practiced and record performance. Each time a subject opens the platform, it will choose the exercise for that subject based upon previous training and performance.
45794364|NCT01854242|Other|Glycogen Storage Disease type Ia patients|The participants will have one blood draw for this study. The test will be performed on the blood.
45794365|NCT04275752|Other|Exercise Program|Perform endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training twice a week for a period of one hour per session, for a total of 16 sessions.
45794366|NCT01854632|Biological|SIIL Live Attenuated Influenza Vaccine|Trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
45794367|NCT01854632|Biological|Matched placebo|Matched placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
45794368|NCT02989454|Other|Assessment of exercise capacity and cardiac energetics|Cardiopulmonary exercise testing and Magnetic Resonance Spectroscopy
45794369|NCT05735054|Procedure|endoscopic thyroidectomy|the patients who underwent endoscopic transaxillary thyroidectomy
45794370|NCT02308020|Drug|Abemaciclib|Administered orally
45794371|NCT05732870|Procedure|Relevant orthopaedic surgery|Inclusion criteria is purposefully broad to examine a range of discarded bone waste. Therefore, a large number of surgical interventions are relevant.
45648262|NCT04945577|Diagnostic Test|Inflammatory Parameters|Laboratory measurement of patient's inflammatory status in unit of % and mg/dl
45921233|NCT00108901|Behavioral|Aerobic exercise program|Vigorous intermittent physical activity in group format conducted in research gymnasium after school by research staff. Heart rate monitors documented each child's average heart rate on a daily basis. Small incentives were offered for achieving goal of >150 bpm average HR each day and attending at least 80% of sessions (4 days/week).
45794372|NCT04420494|Other|Umbilical Cord Blood|The diagnosis is definitely immune cytopenia (IRC), including autoimmune hemolytic anemia (AIHA, Hgb <100g / L, acquired pure red aplastic anemia (PRCA, Hgb <100g / L, EVANS syndrome , Hgb <100g / L and / or platelet count <30 × 109 / L, or blood cell reduction secondary to immune diseases (the same as the treatment indications, or neutrophils <0.5 × 109 / L), at least after hormone therapy Patients who are ineffective (did not reach PR after 4 weeks of hormone therapy) or who have not achieved PR after 3-5 mg / kg / d of cyclosporine. These patients would be treated with umbilical cord blood.
45794373|NCT02359890|Device|THERMOCOOL® SMARTTOUCH® (RF ablation treatment)|Radiofrequency Ablation Treatment
45794374|NCT02306850|Drug|Pembrolizumab|At the Treatment Initiation Visit (Baseline/Day 1), subjects will begin treatment with IV pembrolizumab 200 mg infusions every 3 weeks. As in previous pembrolizumab trials, eligible subjects will receive at least 24 weeks of therapy and may receive up to 2 years of pembrolizumab therapy depending on response to treatment.
45794375|NCT02306694|Drug|Advate|Patients who are currently taking Advate as their factor replacement will be eligible for the 5-day study.
45648263|NCT04945577|Other|25 OH Vitamin D Level|Laboratory measurement of patient's 25 OH vitamin D level in unit of ng/dl
45794376|NCT03647475|Combination Product|Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT|To evaluate the clinical safety of the Resolute Onyx stent with use of one-month DAPT in subjects deemed at high risk for bleeding and/or medically unsuitable for more than one-month DAPT treatment.
45794377|NCT01648140|Drug|GSK2336805 40 mg|20 mg tablet, round, 10-mm diameter, white to off-white, no markings
45794378|NCT01648140|Drug|GSK2336805 60 mg|30 mg tablet, round, 10-mm diameter, white to off-white, no markings
45794379|NCT01648140|Drug|Pegylated interferon alpha-2a|180 microgram per 0.5 mL prefilled syringe for single use
45648264|NCT04945343|Procedure|Growing Rods|Growing Rods(GR), are implants used to correct pediatric scoliosis deformity. They attempt to allow the growth of the spine and thorax while controlling curve progression to preserve normal lung volume.
45648265|NCT02623829|Drug|Botulinum Toxin|50 units of botulinum toxin diluted in 1ml of normal saline will be administered.
45648266|NCT02623829|Drug|Saline|1ml of normal saline will be administered
45794380|NCT01648140|Drug|Ribavirin|"200-mg tablet, capsule-shaped, light blue, film-coated, and debossed with 200 on 1 side and the logo 3RP on the other side"
45794381|NCT01648140|Drug|Telaprevir|375 mg film-coated tablet
45794382|NCT02336178|Drug|Benefix|"Subjects will be treated by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.~The treatment duration is approximately 6 months (±7 days) or approximately 50 Exposure Days (EDs) (±5 EDs) (see protocol definition on EDs) whichever occurs first."
45794383|NCT05369910|Behavioral|Light exposure (Flash)|Light exposure (Flash) is administered for one hour on 7 consecutive days. During the light exposure, participants are seated 120 cm in front of a white curtain that is illuminated by an LED light source (Dawe stroboscope type 1214B, 5 Hz).
45794384|NCT05369910|Behavioral|Light deprivation (Dark)|Light deprivation (Dark) is administered for one hour on 7 consecutive days. During the Dark intervention, participants are seated in a room in complete darkness.
45794385|NCT02357940|Drug|Experimental Product|1% Colloidal Oatmeal Balm
45794386|NCT02335242|Drug|Sildenafil 20 mg tablets|
45648267|NCT04945499|Drug|d-glucose|using d-glucose as an contrast agent on CEST MR Imaging
45794387|NCT02335242|Other|Placebo tablets (resembling Revatio)|
45648268|NCT04944875|Procedure|Group headphone|The patients in the first group wore the headphones but did not listen the music or maternal voice. The standard sedation method was applied to all patients.
45648269|NCT04944875|Procedure|Group music|The patients in the second group listened to classical music (Vivaldi's The Four Seasons violin concertos) by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
45648270|NCT04944875|Procedure|Group maternal voice|The patients in the third group listened to maternal voice by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
45648271|NCT02655679|Drug|VTP-38543|VTP-38543 topical cream
45648272|NCT02655679|Other|Vehicle with Transcutol®P|Vehicle matching VTP-38543 cream with Transcutol®P
45648273|NCT02655679|Other|Vehicle without Transcutol®P|Vehicle matching VTP-38543 cream without Transcutol®P
45648274|NCT04936295|Drug|Fulvestrant plus Anlotinib|Each patient receives Fulvestrant (500mg delivered by intramuscular injection every 4 weeks) plus Anlotinib(20mg taken orally for 14 days and stop for 7 days in one cycle)
45794388|NCT04883892|Procedure|BMAC|"patients will be injected with BMAC into the ankle joint, after treatment patients will be followed up to 24 months. In particular patients will be assessed after treatment at 1, 3, 6, 12 and 24 months.~During the injection, samples of BMAC will be collected for the characterization of the phenotype markers and clonogenic capability"
45794389|NCT04883892|Procedure|HA|patients will be treated with two injection of HA, one every 15 days, into the ankle joint. After treatment these patients will be followed up to 24 months. At 12 months patients can decide to cross.over in the BMAC arm treatment. After cross-over patients will be assessed for further 12 months.
45794390|NCT05437770|Other|BFR (Blood-Flow Restricted exercise)|The BFR group performs unilateral training with the knee-OA diagnosed leg first. BFR exercise is performed with a pneumatic cuff placed at the top of the thigh on the leg being trained. The cuff will be inflated to 60-80 % of the total arterial occlusion pressure (AOP). The participant will afterwards perform training of the knee extensors in a leg press exercise machine and a leg extension exercise machine with a load corresponding to 30 % of the maximal load (1RM = Repetition Maximum).
45794391|NCT05437770|Other|Standard rehabilitation|The GLA:D programme involves a circuit training program with four stations. Each station involves two to six exercises where the participants perform 10-15 repetitions over 2-3 sets, which depends on the participants pain- and functional level. Following the 8 weeks GLA:D programme, participants will continue 4 weeks of team group training performing similar neuromuscular lower limb exercises as for the first 8 weeks.
45921234|NCT00006890|Drug|prednisone|Prednisone 50mg on alternate days
45794392|NCT02334384|Biological|Antimicrobial TheraGauze|"In the intervention arm: Antimicrobial TheraGauze, tobramycin impregnated TheraGauze, will be used to pack the wound cavity after incision and drainage of the skin abscess.~In the comparator arm: Standard wound packing, plain cotton wick or iodoform gauze - at the discretion of the provider will be used to pack the wound cavity after incision and drainage of the skin abscess."
45648275|NCT04955873|Device|Treatment of the dental extraction socket using newly-released biomaterials|Treatment of the dental extraction socket with the combined use with the combined use of a newly-released xenogenic bone granules and a resorbable collagen membrane.
45648276|NCT04955873|Device|Treatment of the dental extraction socket using well-known biomaterials|Treatment of the dental extraction socket with the combined use of a well-known xenogenic bone granules and a resorbable collagen membrane
45648277|NCT05114239|Drug|Timolol 0.25% Ophthalmic Solution|Applied to treatment side prior to standard wound care
45648278|NCT05114239|Other|Standard Wound Care|Wound is washed twice a day with soap and then petrolatum and a bandage is applied.
45648279|NCT05114083|Other|symptom assessment|symptom assessment
45648280|NCT04945031|Other|cannabis|This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart.
45648281|NCT05113849|Biological|IN-B009 (Low-dose)|Two doses, intramuscular injection
45648282|NCT05113849|Biological|IN-B009 (High-dose)|Two doses, intramuscular injection
45648283|NCT04935827|Other|Season of Year|"We stratify patients into 4 groups based on the season of the year (between 12/1/2007-11/30/2017)~Winter: December, January, February~Spring: March, April, May~Summer: June, July, August~Fall: September, October, November"
45648284|NCT04935827|Other|Hospitalized 14 days prior to dialysis|"We further stratify patients into 3 groups based on whether they were hospitalized within 14 days prior to dialysis~Group 1: No hospitalization prior to dialysis~Group 2: Hospitalized within 14 days prior to dialysis for an acute infectious respiratory condition or one of the following acute cardiac conditions (arrhythmia, myocardial infarction, stroke, or fluid overload)~Group 3: Hospitalized within 14 days prior to dialysis for a condition not in Group 2"
45921235|NCT00006890|Drug|thalidomide|THALIDOMIDE 200 mg qhs
45921236|NCT00108979|Drug|Escitalopram|
45648285|NCT04944719|Diagnostic Test|nasopharyngeal aspirate|nasopharyngeal aspirate to determinate colonization by streptococcus pneumoniae
45648286|NCT04469725|Drug|KN046|KN046 5 milligram per kilogram, every 2 weeks
45648287|NCT04418999|Drug|dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use|Experimental
45648288|NCT04418999|Drug|Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly|Active Comparator
45648289|NCT04427527|Behavioral|Multi-level intervention to increase CRC screening|Intervention for the community, providers, patients, clinics and systems
45648290|NCT02623361|Drug|Peripheral Nerve Block|Regional Anesthesia by Local Anesthetic Injection
45648291|NCT02623361|Drug|Sham Block|Sham Block by saline injection
45648292|NCT05113459|Drug|Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy|disitamab vedotin：2.5mg/kg, iv,d1,q2w,6cycle PD-1(Sintilimab ):200mg,iv,d1,q2w,6cycle Capecitabine:1000mg/m2,po,bid,d1-14,q3w,4cycle
45648293|NCT04944485|Other|(FIT SA F03, SHOFU, USA)|Self adhesive giomer containing nanohybrid flowable composite
45648294|NCT04944485|Other|(Neo Spectra™ ST, Dentsply, Sirona, USA)|Conventional technique using putty nanohybrid resin composite
45648295|NCT04526197|Drug|ALXN1840|ALXN1840 was administered orally as a single dose as 4 x 15 milligram (mg) enteric-coated tablets with 240 milliliters (mL) of water (fasting), for a total dose of 60 mg.
45648296|NCT04526197|Drug|Celecoxib|Celecoxib was administered orally as a single dose as one 200-mg tablet with 240 mL of water (fasting).
45648297|NCT04935983|Other|High CHO|Diet with high carbohydrate content
45648298|NCT04935983|Other|Low CHO|Diet with low carbohydrate content
45648299|NCT04935749|Device|Ultra wide-field retinal imaging|Diabetic patients will be imaged with an ultra wide-field retinal imaging device (Optos, California). Patients will be imaged either with or without mydriasis.
45648300|NCT05113147|Other|In-depth individual interviews|In-depth individual interviews were based on a semistructured script designed to investigate the perceptions of the participants about the activity they performed, the ideal working conditions, the presence of disruptive behaviors, and their management.
45648301|NCT04955483|Diagnostic Test|Virtual single energy combined with MAR reconstruction group|combined with MAR reconstruction group
45794393|NCT04893486|Drug|PTX-022|QTORIN 3.9 % Sirolimus Topical Gel
45794394|NCT04893486|Drug|Vehicle comparator|Vehicle comparator topical gel
45794395|NCT02334306|Biological|AMG 557/MEDI5872|Participants will receive a fixed SC dose of 210 mg MEDI5872 (AMG 557/MEDI5872) QW for 3 weeks (Days 1 to 15) and then Q2W for 9 weeks (Days 29 to 85) in double-blind period of the study. In open-label period, all participants from double-blind period will receive a fixed SC dose of 210 mg MEDI5872 from Day 99 to Day 183 (QW from Days 99 to 113 for participants from Placebo arm and on Days 99 and 113 for participants from MEDI5872 210 mg arm; and Q2W from Days 127 to 183 for participants from both arms).
45794396|NCT02334306|Other|Placebo|The SC dose of placebo every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85) in double-blind period of the study. In open-label period, an additional dose of blinded placebo will be administered on Day 106 for participants who will receive MEDI5872 210mg in double-blinded period.
45794397|NCT02305758|Drug|Veliparib|200 mg oral dose beginning 2 days prior to the start of FOLFIRI and continuing twice a day (BID) for a total of 7 consecutive days
45794398|NCT02305758|Drug|Placebo|200 mg oral dose beginning 2 days prior to the start of FOLFIRI and continuing twice a day (BID) for a total of 7 consecutive days
45794399|NCT02305758|Drug|Modified FOLFIRI|Irinotecan 180 mg/m^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m^2 (90-minute infusion ± 30 minutes); and saline bolus (up to 15-minute infusion) on Day 1 of each 14-day cycle
45648302|NCT04447963|Device|Non-invasive treatment of facial wrinkles|Application of radiofrequency field which provides controlled heating to the skin.Therapeutic effect is observed when the tissue temperature reaches 40-45 degrees Celsius.
45648303|NCT04933019|Genetic|Detection of Clinclidamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR|Detection of Clindamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR
45648304|NCT04955093|Device|Biofeedback|Technology to provide Heart Rate Variability Biofeedback
45648305|NCT05060965|Drug|Nicotine lozenge|Nicotine replacement therapy
46071695|NCT02836626|Procedure|superficial fascial mobilization|This group will undergo four 25-minute sessions of gentle superficial effleurage to the abdomen and posterior trunk followed by superficial skin rolling to the scar. Each treatment session will be terminated a) after 25 minutes or 2) when the patient asks to stop due to discomfort. Reasons for termination will be documented. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.
45648306|NCT05060965|Drug|Nicotine gum|Nicotine replacement therapy
45648307|NCT05060965|Drug|Nicotine patch|Nicotine replacement therapy
45648308|NCT05060965|Other|Maryland Quitline|Telephone-based tobacco cessation service
45648309|NCT05060965|Other|John Hopkins Tobacco Treatment Clinic|Clinic-based tobacco cessation service
45648310|NCT04935281|Other|percutaneous repair with an intraoperative assisted ultrasound|Under general or regional anesthesia, the patient laid in prone position In group A, an intraoperative ultrasound was done by a radiologist before the repair .
45648311|NCT04935281|Other|percutaneous repair without an intraoperative assisted ultrasound|For patients in group B, the course of the sural nerve was determined according to the technique described by Blackmon et al.The medial and lateral borders of both stumps were outlined by palpation with identification of the gap in-between. We used the technique described byMaffulli et al with six stab incisions, one cm each. Four incisions were on medial and lateral edge of the proximal stump and the other two were around distal stump.
45648312|NCT04935515|Drug|Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins|Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D
45648313|NCT04935515|Drug|Oral low dose steroid|Low dose oral methyl prednisolone was added.
45648314|NCT04935515|Drug|Intravenous Antibiotics with Low dose steroid.|Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given
45648315|NCT04935515|Drug|Oral anti-coagulant|Rivaroxaban was given for minimum 4 weeks depending on D dimer levels
45648316|NCT04447729|Drug|fremanezumab|Two doses, each dose consists of 4 injections with prefilled syringes
45648317|NCT04090645|Device|TheraSphere|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with a relatively limited concurrent injury to surrounding normal tissue.
45648318|NCT04029025|Procedure|Workflow A|Dentalwings DWOS Intraoral Scan (IOS A) + Dentalwings DWOS Implant Prosthetics Lab-Software (CAD A)
45648319|NCT04029025|Procedure|Workflow B|3Shape TRIOS Pod Intraoral Scan (IOS B) + Straumann CARES Lab-Software (CAD B)
45648320|NCT04029025|Procedure|Workflow C|Conventional Impression + conventional porcelain-fused-to metal iFDP (LabS C/CAD C)
45648321|NCT04932551|Other|Questionnaire|physicians will participate in the questionnaire via WeChat. The questionnaire included six main items: physician demographic characteristics, awareness, diagnosis, medical prescription, assessment/education, and proposal.
45648322|NCT05110885|Other|Questionnaire|A questionnaire prepared by the researchers will be presented to the group.
45648323|NCT04935125|Procedure|Standard Program + Endurance and Strength training|Sessions of strength training added to a standard inpatient multidisciplinary programme
45648324|NCT04935125|Procedure|Standard Program|Standard inpatient multidisciplinary programme (including endurance training)
45648325|NCT05104177|Procedure|conservative tecchniques in management of PAS|"Meticulous complete dissection of the urinary bladder from the lower uterine segment.~Transverse uterine incision above the visible vascular bulge if visible in cases with anterior PAS, otherwise a transverse lower uterine segment incision is performed in the same site of previous CS scar.~Delivery of the baby, clamping of the cord and administration IV 10 IU oxytocin.~Bilateral uterine artery ligation at one or two levels below the lowermost part of the placenta.~Removal of the separable part of the placenta from above downwards, until the adherent part is encountered.~A decision is taken to either resect a wedge of the myometrium above the adherent placenta (in case the adherent area is small and anterior), or removing all the adherent placenta then inserting a rubber or plastic catheter inside the cervical canal then identifying and closing the placental pouch. Care is given to rapidly perform this step to decrease the blood loss after removing the placenta"
45648326|NCT03951883|Other|Increased Egg Consumption|Subjects will be instructed to use a weekly food purchase supplement for inclusion of 2 additional eggs per day to be added to subject's typical daily diet.
45648327|NCT03951883|Other|Typical diet|Subjects will be instructed to maintain their current dietary patterns.
45648328|NCT04376281|Drug|Noradrenaline|Noradrenaline infusion for patients undergoing liver transplantaion from living donor .
45794400|NCT02305758|Drug|FOLFIRI|Irinotecan 180 mg/m^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m^2 (90-minute infusion ± 30 minutes); and fluorouracil bolus 400 mg/m^2 (up to 15-minute infusion) on Day 1 of each 14-day cycle
45794401|NCT02305758|Drug|Bevacizumab|At the discretion of the Investigator, 5 mg/kg may be administered intravenously immediately preceding FOLFIRI dosing
45794402|NCT02305758|Drug|Fluorouracil infusion|2400 mg/m^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle
45794403|NCT02305446|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine|One dose (0.5 mL) vaccine administered by intramuscular (IM) injection in the deltoid area of the non-dominant arm.
45794404|NCT04392219|Drug|EIDD-2801|"Part 1:~Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo.~Part 2:~Two single oral doses of EIDD-2801 will be administered to participants, in an open-label manner.~Part 3:~Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo."
45921237|NCT03608397|Biological|DaxibotulinumtoxinA for injection|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
45648329|NCT04932629|Biological|Ex-vivo cultivated Allogeneic limbal stromal stem cells|n this prospective intervention study patients with unilateral superficial corneal scars will undergo a surgical procedure and in the second procedure, the eligible patients will undergo corneal transplant surgery, when the central corneal epithelium will be removed using a surgical sponge. 0.1ml of stromal cells in a concentration of 0.5x10*6 cells/µl diluted in the thrombin component of fibrin glue (TISEEL, Baxter) will be applied to the debrided corneal stroma. A soft bandage contact lens will be placed over the cornea at the end of the procedure. The patient will receive topical antibiotic and steroid eye drops in the post-operative period. Periodic comprehensive ophthalmic evaluation along with anterior segment optical coherence tomography (ASOCT) scanning and slit-lamp photography will be done at Day 1, Day 7, Day 30, Day 90, Day 180 and Day 360 and 720 Days post-surgery
45648330|NCT04332445|Other|Hyaluronic Acid Gel|Health care product - to be apllied on the subject's skin
45648331|NCT04954703|Other|Muscle energy technique of gluteus maximus and tensor fascia lata|it is used for lengthening of hypertonic muscles for relief of pain and range of motion.Position of patient is supine lying and therapist is at side of table .The patient leg is fully adducted to stretch IT band and then patient attempts to abduct the leg against resistance contracting the muscles being stretched at approximately 25% of maximum effort for 10 seconds. They then relax and the therapist lengthen it.
45921238|NCT03608397|Biological|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
45921239|NCT00109057|Drug|Avastin (bevacizumab)|
45921240|NCT00109096|Drug|Pemetrexed|
45648332|NCT04954703|Other|Myofascial release of iliotibial band syndrome|Myofascial release of IT band Syndrome. Therapist fingers track up and down your ITB with fingertips to find the most tender spots and use a tennis ball to apply small, circular, light release in those places.
45648333|NCT04932863|Biological|BNT162b2 mRNA Covid-19 Vaccine|Two injections, 21 days apart, of the BNT162b2 vaccine 30 μg per dose in the deltoid muscle.
45648334|NCT04278313|Procedure|PRP - Platelet Rich Plasma|Using a sterile vacutainer technique two 8 ml samples of whole blood is drawn into two Regen Lab A-PRP vacutainers with gel separator and citrate. Invert the tube to mix with citrate. The whole blood undergoes two centrifugations, once for 3 minutes and again for 5 minutes. Using a 20-gauge 6-inch spinal needle 2 ml of Platelet POOR Plasma will be drawn off the supernatant from each tube to leave 2.5 ml of Platelet Rich Plasma in the tube. The tube is inverted several times to suspend the platelet pellet. The prepared plasma labeled with the participants name and randomization code will be transported to the procedure room.
45794405|NCT04392219|Drug|Placebo|"Part 1:~Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo.~Part 3:~Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo."
45794406|NCT03649815|Combination Product|App4Independence|"The mobile, app-based platform was designed to:~Help prevent social isolation through personalized prompts, scheduling of activities, and connections to a range of resources relevant to social engagement~Enhance hopeful and informed engagement in the recovery process through functions that foster resilience and draw on evidence based strategies to enhance wellness (e.g., personalized affirmations; tip sheets; relaxation exercises)~Encourage and check-in on daily essential activities for patients - addressing memory, attention, and initiation challenges that often occur as a part of this illness~Provide basic health/safety functionality and track level of wellness~Provide an anonymous peer-peer online network for strategy sharing~Provide an ambient sound detector to assist with identifying hallucinations"
45794407|NCT04365153|Drug|Canakinumab Injection 600mg|Subjects will be given one-time intravenous infusion of 600 mg of canakinumab (8 mg/kg for patients </= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours
45794408|NCT04365153|Drug|Canakinumab Injection 300mg|Subjects will be given one-time intravenous infusion of 300 mg of canakinumab (4 mg/kg for patients </= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours
45794409|NCT04365153|Drug|Placebos|250 mL of 5% dextrose infused IV over 2 hours
45921241|NCT00109135|Drug|taranabant|
45921242|NCT00006929|Drug|suramin|Given IV
45921243|NCT00006929|Drug|carboplatin|Given IV
45921244|NCT00006929|Drug|paclitaxel|Given IV
45921245|NCT00006929|Other|pharmacological study|Correlative studies
45921246|NCT00006929|Other|laboratory biomarker analysis|Correlative studies
45921247|NCT00109213|Procedure|Lumbar Laminectomy with Instrumented Pedicle Screw Fusion|Removal of bone to decompress spinal nerves with placement of spinal screws and extra bone to strengthen the spine
45921248|NCT00109213|Procedure|Lumbar Laminectomy|Removal of bone to decompress spinal nerves
45921249|NCT03598920|Device|AsspireAssist|Endoscopic bariatric procedure using the AsspireAssist device
45921250|NCT03598920|Other|Nutritional consulting|Nutritional consulting provided by a specialized consultant.
45921251|NCT00109252|Drug|Raptiva (efalizumab)|
46071696|NCT02836548|Drug|Vorinostat|vorinostat 360 milligram once daily
46071697|NCT04249128|Dietary Supplement|Vegetarian Collagen|Collagen is a protein made up of amino-acids, which are in turn built of carbon, oxygen and hydrogen.
45921252|NCT00109291|Drug|Placebo|
45921253|NCT00109291|Drug|peginesatide|
45794410|NCT03654417|Drug|EMLA|Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
45648335|NCT04278313|Procedure|PPP - Platelet Poor Plasma|Using a sterile vacutainer technique two 8 ml samples of whole blood is drawn into two Regen Lab A-PRP vacutainers with gel separator and citrate. Invert the tube to mix with citrate. The whole blood undergoes two centrifugations, once for 3 minutes and again for 5 minutes. Using a 20-gauge 6-inch spinal needle 2 ml of Platelet POOR Plasma will be drawn off the supernatant from each tube. The prepared plasma will be transported to the procedure room. The prepared plasma labeled with the participants name and randomization code will be transported to the procedure room.
45648336|NCT04934735|Procedure|Rehabilitation program group|"The case-management rehabilitation program was conducted by a clinical social worker within the occupational medicine clinic and included several components:~Intake by a case manager~Referral to an occupational physician was within one week of the intake.~Charting an occupational rehabilitation program and timing the RTW date~Coordinating between the patients and their family, treating physicians, the employer, community services, and meeting with the patient's family - all on a needful basis.~Provision of a guidance booklet for employers on the RTW of cardiac patients.~The psychosocial intervention was tailored to the patient's emotional state, occupational needs, and specific requests.~Intensive follow-up sessions aimed to ensure that the rehabilitation program was carried out as planned."
45648337|NCT04232839|Drug|BI 894416 - Formulation A2|Tablet
45648338|NCT04232839|Drug|BI 894416 - Formulation C2|Tablet
45648339|NCT04232839|Drug|BI 894416 - Formulation D2|Capsule
45648340|NCT04232839|Drug|BI 894416 - Formulation F2|Capsule
45648341|NCT04232839|Drug|BI 894416 - Reference Formulation 1|Tablet
45648342|NCT04934813|Other|Alveolar ridge preservation|application of different bone graft and sealing means after tooth extraction
45794411|NCT03654417|Drug|Lidocaine|Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
45794412|NCT00376701|Drug|Avastin (Bevacizumab)|Avastin 1.25 mg intravitreal
45794413|NCT00376701|Drug|Bevacizumab|Intravitreal 1.25 mg
45794414|NCT00376701|Drug|Bevacizumab|Intravitreal 1.25 mg
45794415|NCT00376701|Drug|Bevacizumab|Intravitreal Avastin 1.25 mg and sham reduced fluence PDT
45794416|NCT04358991|Drug|Ceftazidime-avibactam|collection of blood samples around clinical dosing immediately pre-dose, then at the following times thereafter: 1, 2, 4, 6, 8, and 12 hours and EMR review.
45794417|NCT04338009|Other|Discontinuation of ARB/ACEI|The randomized intervention will be the discontinuation of ACEI/ARBs. In all participants randomized to discontinuation, treating clinicians will be reminded about the medication discontinuation upon discharge and will be prompted to consider re-initiation of the medication at that time if appropriate, per the clinician's discretion.
45648343|NCT04934423|Device|Direct Current Transcranial Stimulation - tDCS|Active intervention
45921254|NCT02964871|Device|Sofia Fluorescent Immunoassay Analyzer Influenza A+B|The Sofia Influenza A+B Fluorescent Immunoassay (FIA) uses advanced immunofluorescence-based lateral-flow technology to detect influenza A and influenza B viral nucleoprotein antigens.
45648344|NCT04934423|Device|Sham Intervention|Direct Current Transcranial Stimulation - Sham intervention
45648345|NCT03890887|Drug|BI 1291583|Tablet
45648346|NCT03890887|Drug|Itraconazole|Oral solution
45648347|NCT05098951|Device|Acupuncture|Patients with stiffness of joint receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.
45648348|NCT04934501|Diagnostic Test|High-frame-rate contrast-enhanced ultrasound measurements (echoPIV)|Patients will undergo high-frame-rate contrast-enhanced ultrasound measurements, within 6 to 8 weeks after the endovascular procedure, at the vascular center of Rijnstate hospital. Prior to these measurements a venous cannula will be placed to ensure venous access for the contrast administration.
45648349|NCT04934501|Diagnostic Test|Computed tomography angiography (CTA) scan|Patients will undergo a CTA scan of the lower extremities at the Radiology dept. of Rijnstate hospital the same day as the echoPIV measurements. This CTA scan serves as a reference for the vessel geometry and stent location.
45754352|NCT03586778|Other|therapeutic exercise|Exercise designed to improve performance of the paraspinal and abdominal musculature as well as the hip musculature. The exercise portion will also include a stretching program targeting the trunk and hip muscles which have been placed in a shortened position as a result of poor postures.
45754353|NCT04142528|Device|ParkinPal|Wear and periodic recording of motion data during daily wear
45794418|NCT04338009|Other|Continuation of ARB/ACEI|The randomized intervention will be the continuation of ACEI/ARBs at the doses previously prescribed for patients during their routine care. Clinicians will be encouraged to continue the randomized treatment but will be allowed to change the dose of ACEI/ARB or discontinue these medications if any compelling clinical reasons are identified (such as hypotension, hyperkalemia, acute kidney injury).
45794419|NCT03403491|Other|patientMpower application|electronic health journal for patient to record weight, blood pressure, medication adherence and symptoms
45794420|NCT03403491|Other|sham application|dummy application which does not allow recording of weight, blood pressure, medication adherence and symptoms
45794421|NCT02303574|Drug|AZD7986, oral solution, 1 to 50 mg/mL|Starting dose in single ascending dose part: 5 mg
45794422|NCT02303574|Drug|Placebo, oral solution|Matching placebo
45794423|NCT02354976|Drug|Placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
45794424|NCT02354976|Drug|Omega-3 carboxylic acid|4 g administered as 4 x 1 g capsules
45794425|NCT02354976|Drug|Fenofibrate 200mg|200mg capsule administered once daily
45794426|NCT02354976|Drug|Placebo|Placebo matching to fenofibrate 200mg
45921255|NCT02964871|Other|Usual care|Our team will discuss our interest in monitoring influenza antiviral treatment and prophylaxis courses, antibiotic courses, clinician and emergency room visits, respiratory infection-related hospitalizations, all-cause hospitalizations, and deaths during the anticipated 4-month influenza season over 3 years.
45921256|NCT00006968|Biological|filgrastim|
45794427|NCT02303262|Drug|Mocetinostat|Mocetinostat is taken orally at 70 mg/dose, 3 days per week, during cycle 1. Dose is increased to 90 mg starting at cycle 2.
45794428|NCT02303262|Drug|Gemcitabine|Gemcitabine is administered via intravenous infusion at 1,000 mg/m2 at a rate of approximately 10 mg/m2/minute, on days 5 and 12 of every cycle.
45648350|NCT04111861|Other|Singing|To investigate whether singing can help people to manage their chronic pain the applicants, working together with people with chronic pain, have developed a singing intervention, Singing for Chronic Pain (SCP). The development of the programme has been supported by Snape Moultings, an international centre for the arts which offered the team a residency to develop the programme (https://snapemaltings.co.uk/music/residencies/). The model takes a holistic approach using voice and singing, movement, sound, mindfulness and breath work to provide opportunities to connect body, voice, breath and mind. This is important given that people often use body dissociation as a way to cope with physical pain
45921257|NCT00006968|Drug|cyclosporine|
45921258|NCT00006968|Drug|pentostatin|
45648351|NCT04932161|Procedure|Titanium Granules|After degranulation of the intrabony defect, titanium particles will be placed in the defect and will be sutured.
45648352|NCT04932161|Procedure|Hydroxyapatite|After degranulation of the intrabony defect, hydroxyapatite will be placed in the defect and will be sutured.
45648353|NCT05073523|Other|Diet|All intervention meals consist of five different food groups including fruits, vegetables, legumes, dairy products, and whole grains. Differences in the proportion of these foods in Meal A-C is tested.
45648354|NCT04934345|Diagnostic Test|Fluid challenge|The fluid challenge consists of a bolus of 4 ml/kg of crystalloids, administered over 10 minutes.
46071698|NCT04249128|Dietary Supplement|Keratin|Keratin (/ˈkɛrətɪn/) is one of a family of fibrous structural proteins known as scleroproteins. α-Keratin is a type of keratin found in vertebrates. It is the key structural material making up hair, nails, feathers, horns, claws, hooves, calluses, and the outer layer of skin among vertebrates.
45648355|NCT04516993|Drug|Tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
45648356|NCT04516993|Drug|The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)|Best treatment arm
45648357|NCT04922177|Procedure|Indirect ceramic restoration|Indirect ceramic restoration using an optical impression.
45794429|NCT04889664|Drug|Ketamine|Repeated intravenous Ketamine infusions.
45794430|NCT04889664|Behavioral|Written Exposure Therapy|WET is a brief, 5-session evidence-based written trauma-focused therapy
45648358|NCT04922177|Procedure|Direct restoration|Restoration using a Glass Ionomer Cement
45794431|NCT00558896|Drug|dexamethasone|40 mg/day administered through PO (with food) at Days 1, 8, 15, 22 per cycle.
45794432|NCT00558896|Drug|pomalidomide|2 or 4 mg/day administered through PO at days 1 - 28 or days 1-21 (see Arm description for specific dosing).
45794433|NCT04125914|Behavioral|Behavioral Dietary Intervention|Record food intake
45921259|NCT00006968|Procedure|allogeneic bone marrow transplantation|
45648359|NCT03817957|Drug|Polyglucoferron|intravenous administration
45648360|NCT03817957|Drug|Ferric carboxymaltose|intravenous administration
45648361|NCT03817957|Drug|Ferrous Sulfate|oral administration
45648362|NCT04922489|Procedure|Dental implant placement|Dental implant placemente on edentulous jaw.
45648363|NCT04955171|Drug|BEOVU intravitreal injection|BEOVU intravitreal injection
45648364|NCT05015335|Drug|Adalimumab|ADA 40mg q2w
45648365|NCT05015335|Drug|Methotrexate|MTX 10mg qw
45648366|NCT03805243|Device|test of sensors for somnonaute device|test of sensors
45921260|NCT00006968|Procedure|peripheral blood stem cell transplantation|
45921261|NCT00109330|Biological|Combined diphtheria, tetanus, acellular pertussis vaccine|
46071699|NCT04249128|Dietary Supplement|Ceramides|Ceramides are a family of waxy lipid molecules. A ceramide is composed of sphingosine and a fatty acid. Ceramides are found in high concentrations within the cell membrane of eukaryotic cells, since they are component lipids that make up sphingomyelin, one of the major lipids in the lipid bilayer.
46071700|NCT04249128|Dietary Supplement|Astaxanthin|is a naturally-occurring carotenoid found in algae, shrimp, lobster, crab and salmon.
46071701|NCT02836938|Other|Collection of exhaled breath volatile organic compounds|
45648367|NCT03805243|Device|test of sensors for uronaute device|test of sensors
45794434|NCT04125914|Other|E-mail|Receive e-mails
45794435|NCT04125914|Behavioral|Exercise Intervention|Undergo exercise
45794436|NCT04125914|Other|Health Promotion and Education|Receive text messages
45794437|NCT04125914|Other|Internet-Based Intervention|Join Facebook page
45794438|NCT04125914|Other|Questionnaire Administration|Ancillary studies
45794439|NCT04125914|Behavioral|Telephone-Based Intervention|Receive telephone coaching
45794440|NCT05725772|Other|Location of Visit|Participants will perform visits 1) at-home via telemedicine, 2) in-person and 3) at a local regional clinic via telemedicine
45794441|NCT01857362|Drug|Nitisinone 20 mg|Nitisinone 20 mg capsules
45794442|NCT01857362|Drug|Nitisinone 10 mg|Nitisinone 10 mg capsules
45794443|NCT04057040|Drug|PTG-300|Active
45794444|NCT04057040|Drug|Placebo|Placebo
45794445|NCT01857986|Device|AnapnoGuard 100 control unit|
45921262|NCT03595917|Drug|ABL001|•ABL001 is administered daily per 28 day cycle
45921263|NCT03595917|Drug|Dasatinib|Fixed doses oral once a day per 28 day cycle
45921264|NCT03595917|Drug|Prednisone|Fixed doses oral once a day per 28 day cycle Prednisone will be tapered and stop during cycle 2.
45921265|NCT00109369|Other|Information and decision support for providers and patients|Laboratory-based decision support, reminders, and population report cards.
45921266|NCT00007007|Procedure|management of therapy complications|
45921267|NCT00007007|Procedure|quality-of-life assessment|
45921268|NCT00109408|Drug|Methotrexate|7.5-20mg po weekly
45648368|NCT03805243|Device|test of sensors for toconaute device|test of sensors
45648369|NCT03805243|Device|test of sensors for neuronaute device|test of sensors
45648370|NCT03805243|Device|test of sensors for cardioskin device|test of sensors
45648371|NCT03056261|Procedure|Combined general and epidural|Combined general and epidural anaesthesia
45648372|NCT03056261|Procedure|General anaesthesia|General anaesthesia
45648373|NCT04922099|Device|glycemic gap|"Measurements of HbA1c-based adjusted glycemic gap:~The estimated chronic average glucose levels (eAG) over the past 3 months will calculate from the equation AG = 28.7 × HbA1c - 46.7 Glycemic gap was calculated as the ADAG level subtracted from the admission glucose level."
45648374|NCT03534817|Behavioral|Early Access CR|Participants in the Early Access CR group will begin CR within 1-week post-hospital discharge following their MI, as opposed to Standard Access CR group which begins 7-weeks post-hospital discharge, and the Canadian average (10-14 weeks post-hospital discharge). No further intervention or differentiation between groups is applied; the actual CR program is standardized between groups, and follows the guidelines regularly practiced by the institution.
45648375|NCT04933799|Drug|PF-06650833|"PF-06650833 is an investigational, highly potent and selective, reversible inhibitor of IRAK4. IRAK4 is a serine, threonine kinase that is a key intracellular signaling node downstream of the myddosome-associated Toll-Like Receptors (TLR) 1, 2, 4, 5, 6, 7, 8, 9 and 10, and the interleukin (IL)-1 family receptors (IL-1R, IL-18R and IL-33R) that mediate much of the innate immune signaling.~As an inhibitor of TLR signaling, PF-06650833 targets a different part of the immune system from the Janus kinase (JAK) inhibitors. Given the partial redundancy of innate immune signaling through IRAK4-independent TLR pathways and the lack of direct suppression of T- and B-cell signaling, PF-06650833 is unlikely to lead to exaggerated immunosuppression."
45648376|NCT04933799|Drug|Matching Placebo|Placebo will match the study drug in dose, formulation, route and frequency.
45648377|NCT03921619|Device|Shoulder Sling|soft shoulder sling that is placed around the forearm, with a strap draped over the shoulder
45648378|NCT04931147|Drug|RXC007|RXC007 will be administered in the form of oral capsules at selected doses starting at 2 mg to 4 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one single dose on one occasion and for Part B, dosing frequency is single doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.
45648379|NCT04931147|Drug|RXC007 Matching Placebo|The matching placebo for RXC007 will be administered in the form of oral capsules matched to the number of active RXC007 capsules at each dose level to 2 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one placebo dose on one occasion and for Part B, dosing frequency is single placebo doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.
45648380|NCT04985383|Device|AKST1210|Procedure: Hemodialysis
45648381|NCT03533257|Drug|AMX0035|Combination Therapy of TUDCA and Sodium Phenylbutyrate
45648382|NCT03533257|Drug|Placebo|Placebo
45648383|NCT04933409|Procedure|3D printed replica of the donor tooth|3D printed replica of the donor tooth.
45648384|NCT04933409|Procedure|Conventional Autotransplantation of tooth|Conventional Autotransplantation of tooth without using the 3D printed guide
45648385|NCT04574479|Procedure|Supra-inguinal fascia iliaca compartment block|"Ultrasound guided loco-regional technique as described by Desmet et al. Fascia iliaca compartment block with in-plane 40 ml ropivacaine 0,375% injection between the ilio-psoas muscle and the internal oblique muscle.~Patients in SFICB group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump"
45648386|NCT04574479|Drug|Multimodal analgesia and PCA morphine pump|Patients in placebo group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump
45648387|NCT04933487|Device|IOL implantation experimental|Monolateral implantation of toric intraocular lenses Ankoris. (Manufactured by PhysIOL sa/nv, Liège, Belgium).
45794446|NCT02265224|Drug|N-acetylcysteine|The product was administered according to the randomisation list and cross-over design, with 150 mL of still mineral water under fasting conditions on study day 1 of periods 1 or 2 at 8:00±1 h.
45794447|NCT02265848|Other|High frequency stimulation|Implanted pulse generator of a spinal cord stimulator will programmed to deliver high frequency stimulation for pain relief. For our purposes, high frequency stimulation will be defined as 1000 hertz.
45648388|NCT03338257|Behavioral|Husky Reads Intervention|The Husky Reads curriculum now includes a series of 10 lessons designed to introduce preschool-age children to MyPlate while improving fruit and vegetable literacy. Each lesson includes reading at least one children's book, an activity or game, and food tasting to complement learning objectives related to MyPlate and fruit/vegetable literacy. Undergraduate students enrolled in the Husky Reads service- learning course at UConn or college students participating in the paid summer internship program deliver the preschool lessons. Each team of 2-3 undergraduate students is assigned 2-3 early care classrooms to visit and deliver Husky Reads lessons to on a weekly basis.
45648389|NCT04933955|Procedure|vital pulp therapy|pulpotomy
45648390|NCT02925013|Procedure|Blood sampling|Blood sampling for lipid profile
45921269|NCT00109408|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
45921270|NCT03581760|Other|Cycling Exercise|Cycling exercise will be performed in the patients once a day.
45648391|NCT02925013|Other|Dietary- Normal western diet|Normal western diet
45648392|NCT04933175|Drug|Fluzoparil|Fluzoparil: 150 mg, P.O, BID, d1-14, Q3W; Treatment until disease progression or intolerable side effects occur.
45648393|NCT04933175|Drug|Anlotinib|Anlotinib: 8mg, P.O, qd, d1-14, Q3W; Treatment until disease progression or intolerable side effects occur.
45648394|NCT02370901|Device|Helmet|Custom fitting helmet, FDA approved, to allow reshaping of the infant skull
45921271|NCT03581760|Other|Conventional Physiotherapy|Conventional physiotherapy will be performed in the patients twice a day.
45921272|NCT00109486|Drug|GW685698X|
45921273|NCT00109564|Drug|ispronicline (nicotinic acetylcholine receptor agonist)|
45921274|NCT00109603|Drug|Tenofovir disoproxil fumarate|
45648395|NCT02370901|Behavioral|home therapies|parents will be instructed to do home neck stretching exercises, as well as repositioning techniques to keep baby off the flat spot. They will also be offered reassurance.
45648396|NCT04431167|Behavioral|Living well with Lupus|The lifestyle change intervention will involve two constructs: increasing the level of physical activity and improving eating habits, each with its own specific domains and goals. It will be based on a structured program of physical exercises and selection of individualized goals in the domains of transportation, leisure and work to reduce sedentary behavior with the aim of increasing the level of physical activity, as well as establishing changes in dietary aspects, involving consumption domains, structure, behavior and eating attitude using nutritional counseling techniques.
45648397|NCT04931225|Drug|Landiolol|Intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours) up to a 15% decrease in HR on microcirculatory vascular reactivity.
45648398|NCT04516057|Drug|Nabilone|After the screening period, participants randomized to the nabilone arm will receive nabilone for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
45648399|NCT04516057|Other|Placebo|After the screening period, participants randomized to the placebo arm will receive placebo capsules for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
45648400|NCT04921709|Other|Medical tests|Blood tests
45648401|NCT04930835|Procedure|Implant supported dentures|Placement of dental implants with different loading protocols for supporting full arch dentures.
45648402|NCT04976725|Other|Osteopathic Manipulative Therapy|"75 individuals will be included in our study, including 3 groups: control group (N= 25), osteopathic manipulative technique (n= 25), myofascial relaxation group (n=25). Which group of individuals will be determined by randomizing them with closed envelope method.~Osteopathic Manipulative Therapy and myofascial relaxation treatment applications will be applied 2 days a week, for periods of 30 min for 4 weeks."
45648403|NCT04921553|Other|Data collection and quality of life questionnaire|"Data collection from the medical file~Quality of life questionnaire (QLQC30) at inclusion, at each change of treatment and then every 6 months"
45648404|NCT02195947|Drug|Growth Hormone|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
45648405|NCT04913207|Procedure|method of device size selection|device size selection based on 3D-CTA
45648406|NCT01698307|Other|Enhanced Treatment Algorithm|The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings. Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.
45648407|NCT01698307|Other|Conventional Step-care Algorithm|Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Score.
45648408|NCT03054545|Drug|Iguratimod|Iguratimod 25mg twice a day, oral administrated.
45648409|NCT04111757|Device|Technolas® TENEO 317 Model 2|LASIK eye surgery
45648410|NCT05119153|Dietary Supplement|Placebo Comparator|Placebo designed to mimic coffee color.
45648411|NCT05119153|Dietary Supplement|Light Roasted Coffee|12 oz light roast coffee
45648412|NCT05119153|Dietary Supplement|Medium Roasted Coffee|12 oz medium roast coffee
45648413|NCT05119153|Dietary Supplement|Dark Roasted Coffee|12 oz dark roast coffee
45648414|NCT04930913|Diagnostic Test|Three-dimensional Ultrasound|women suspected of having adhesions will perform 3D US
45648416|NCT04954339|Drug|Aatezolizumab plus Bevacizumab|Two cycles of naeoadjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) prior to surgical resection and four cycles of adjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) after the surgery will be administered.
45648417|NCT04930523|Other|Elongation Longitudinaux Avec Decoaption Osteo Articulaire|"Pre physiotherapy treatment~Gym (treadmill ,cycling,vibrator) according to ability and condition of patient Shortwave diathermy SWD for atleast 10 mins Decompression treatment i.e. Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes.~Post physiotherapy treatment~Conventional Tens and infrared heat for 10 minutes at low back region. TENS is modality to reduce pain and tension,by stimulating large diameter afferent fiber .IR give superficial heat for circulation and relaxation of muscles.~No exercises or walk were guided for home (till 24 hrs) Low back exs guided i.e knee to chest, pelvic rolling, bridging, SLR, pirformis exs is guided for home plan along with precautions.~No exertion ,drive carefully Avoid stairs climbing ,twisting ,bending ,weight lifting"
45449855|NCT03639441|Procedure|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (<10 Hz) with an intensity that produces motor contraction."
45648418|NCT04930523|Other|Decompression|"Pre physiotherapy treatment~Gym (treadmill ,cycling, vibrator) according to ability and condition of patient Shortwave diathermy SWD for at least 10 minutes. ELDOA positions are guided and performed by patients before decompression Low back exercises guided i.e. knee to chest, pelvic rolling, bridging, SLR, piriformis exercises is guided for home plan along with precautions.~Decoarctation of (C0/C1/C2),(C4/C5),(C5,C6),(C6/C7),(T4/T5),(T6/T7),(T8,/T9),(L4/L5),(L5/S1) Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes. Post physiotherapy treatment Tens and infrared heat for 10 minutes at low back region. TENS is modality to reduce pain and tension, by stimulating large diameter afferent fiber .IR give superficial heat for circulation and relaxation of muscles.~ELDOA exercises(positions)are guided for home plan after session (after 24 hrs) No exertion ,drive carefully Avoid stairs climbing, twisting bending, weight lifting"
45794448|NCT02265848|Other|Low frequency stimulation|Implanted pulse generator of a spinal cord stimulator will programmed to deliver low frequency stimulation for pain relief. Low frequency stimulation will be defined as conventional stimulation pulse generator programming.
45794449|NCT03403725|Drug|MEN1309|MEN1309 solution for intravenous infusion once every 3 weeks
45648419|NCT04304833|Other|Provider-Based Care Model Arm|The PI will be supplementing standard care by providing and training each patient in the use of an analog (not internet connected) vital sign kit for 6 months: weight scale, blood pressure cuff, pulse oximeter. A Log for recording their vital sign measures.
45794450|NCT04332081|Device|hyperbaric oxygen therapy (HBOT)|The patient will receive 90 minutes of hyperbaric oxygen at 2.0 ATA with or without airbreaks per the hyperbaric physician. Upon completion of the treatment the patient will then return to the medial unit and continue all standard of care. Additional treatments (up to 5) can be given if warranted and agreed upon by the patient and all members of the team caring for the patient.
45648420|NCT04304833|Behavioral|mHealth Model Arm|The PI will provide each patient with weight scale, blood pressure cuff, & pulse oximeter kit connected to a Bluetooth-paired Android Health Tablet for 6 months. Daily vital sign readings will be sent to the secure cloud-based software. If the readings are out-of-range, the Registered Nurse Call Center will be automatically alerted and triaged.
45648421|NCT04912661|Dietary Supplement|Ferinject|intravenous iron carboxymaltose
45648422|NCT04391959|Drug|AZR-MD-001 Active|AZR-MD-001 is an active ophthalmic ointment
45794451|NCT01859078|Drug|Baricitinib|Administered orally
45794452|NCT01859078|Drug|Digoxin|Administered orally
45794453|NCT03922334|Behavioral|Patient Navigation Program|A postpartum patient navigation program is designed to reduce barriers to care, enhance access, and improve multiple postpartum health outcomes, including retention in care, contraception uptake, vaccination, and depression screening.
45794454|NCT03662139|Other|Dynamic Gait Index|Dynamic Gait Index is a clinical tool for assessing functional balance and gait variability in people with neurologic conditions
45794455|NCT03663231|Device|Biotene|Biotène Dry Mouth Moisturizing Spray contains water, polyglycitol, propylene glycol, sunflower oil, xylitol, milk protein extract, potassium sorbate, acesulfame K, potassium thiocyanate, lysozyme, lactoferrin, lactoperoxidase. 3 sprays, approximately 15 mL.
45794456|NCT03663231|Device|Placebo|IND/IDE exempt device primarily water
45794457|NCT00558428|Drug|fixed dose combination of telmisartan+amlodipine|
45794458|NCT00558428|Drug|amlodipine|
45794459|NCT05314725|Drug|SGLT2 inhibitor|10 days of SGLT2 inhibitor after surgery
45794460|NCT05314725|Drug|Placebo|10 days of placebo after surgery
45794461|NCT04310085|Drug|Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet|artemether-lumefantrine 6 x of 4 tablets at approximately 0, 8, 24, 36, 48 and 60 h
45794462|NCT04310085|Biological|PfSPZ-DVI Challenge|3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
45794463|NCT03406377|Drug|OPK-88003|OPK-88003 subcutaneous injection
45794464|NCT03406377|Drug|Placebo|Placebo subcutaneous injection
45794465|NCT00558272|Drug|AZD0530|Daily oral dose
45794466|NCT00558272|Drug|Zoledronic Acid|
45794467|NCT03407313|Device|Rotational fractional resection (1.5mm diameter device)|Single treatment of skin resection and focal lipectomy (removal of loose skin and fat)
45794468|NCT01859312|Drug|Hydrocortisone (Solucortef)|Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA). Total daily hydrocortisone dose was calculated based on the patient's estimated cortisol clearance. Rates were established to achieve peak and trough concentrations within the normal circadian cortisol range.
45648423|NCT04391959|Drug|AZR-MD-001 Vehicle|AZR-MD-001 is a vehicle ophthalmic ointment
45648424|NCT03429985|Behavioral|FRRM Intervention|Fathers Raising Responsible Men (FRRM) is designed to facilitate important paternal parenting behaviors that influence adolescent decision-making. FRRM incorporates a novel, theoretically-based intervention highlighting the important and influential role that fathers have on the development and life trajectories of adolescent males.
45754354|NCT02138227|Behavioral|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills. OPO requesters will be assisted by having the CEaD DVD supplemented through working the scenarios with live simulated patients who will be trained to act out the scenarios with the OPO requesters and provide feedback.
45754355|NCT02138227|Behavioral|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
45794469|NCT01859312|Device|Insulin pump (Medtronic)|Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA)
45794470|NCT03407625|Other|Foley bulb plus Oral Misoprostol|"Although labeled experimental for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States."
45794471|NCT03407625|Other|Oral Misoprostol|Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.
45794472|NCT03408171|Device|19-gauge FNA needle|A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.
45794473|NCT03408171|Device|19-gauge FNB needle|A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.
45794474|NCT03803540|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation via duodenal infusion
45794475|NCT01860950|Device|anodal tDCS|a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder
45794476|NCT01860950|Device|cathodal tDCS|a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode attached to the right shoulder and the cathode electrode placed over the left DLPFC.
45794477|NCT01860950|Device|sham tDCS|Participants were provided pain education during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session
45794478|NCT03666663|Drug|Lidocaine|Nasal application using the Sphenocath device- cleared by FDA
45794479|NCT03666663|Drug|Bupivacaine|Nasal application using the Sphenocath device- cleared by FDA
45794480|NCT03666663|Drug|Ropivacaine|Nasal application using the Sphenocath device- cleared by FDA
45794481|NCT03666663|Drug|Placebo|Placebo Saline using the Sphenocath device- cleared by FDA
45794482|NCT05692154|Drug|Fexofenadine|Fexofenadine oral tablet
45648425|NCT04921319|Diagnostic Test|VExUS score|"The care team will be informed of the VExUS immediately after the ultrasound is performed and given a suggested target for the following 24 hours as follows:~VExUS 0: The patient will likely tolerate more fluid if clinically needed.~VExUS 1: The patient has evidence of mild venous congestion. The investigators recommend targeting a net neutral or negative fluid balance with diuresis.~VExUS 2-3: The patient has evidence of moderate to severe venous congestion. The investigators recommend targeting a fluid balance of negative 1-2L with diuresis. If the investigator cannot obtain ultrasound images of sufficient quality to calculate VExUS, the care team will be informed that there is no recommendation for that subject on that day."
45794483|NCT05692154|Drug|Placebo|Fexofenadine matching placebo oral tablet
45794484|NCT03670017|Device|OptiScanner® 5000 Glucose Monitoring System|The study population includes surgical critical care patients who require blood glucose monitoring. Subjects must have a vascular access device [i.e., Central Venous Catheters (CVC), Multi-lumen Access Catheters (MAC) either in place or to be placed with an expected usage of at least 48 hours. During Phase One of the trial, patients will be connected to the OptiScanner for up to 72 hours and the hospital's current standard of care for glucose management will be followed.
45794485|NCT04309617|Procedure|nephrectomy|Surgery performed within the study period
45794486|NCT01861574|Device|Real TMS 45 min|Real TMS 45 minutes after surgery, first determined resting motor threshold (rMT) by starting with 40% of the machine output and 0.5 Hz stimulus frequency. The coil was positioned over the motor cortex and then adjusted until each pulse results in movement of the right thumb. The machine output was then adjusted to the lowest intensity that reliably produces thumb movement. Parameter estimation by sequential testing was used to determine the amount of machine energy necessary to visibly move the thumb 50% of the time. rMT was assessed before each rTMS treatment. The left prefrontal cortex was the cortical target for rTMS treatment. The EEG-10-20 system was used to locate the prefrontal cortex (F3).
45794487|NCT01861574|Device|Sham TMS 45 min|Sham TMS 45 minutes after surgery used specifically designed rTMS coil that produces auditory signals identical to real (active) TMS coils but is shielded so that actual stimulation does not occur. The eSham system was used to mimic sensations of real rTMS. This system produces mild tingling on the scalp underneath the sham rTMS coil, making it difficult in differentiating between real and sham. The amount of electrical stimulation necessary to match real rTMS pulses was determined using an algorithm (parameter estimation by sequential testing). All subjects underwent the sham titration at the beginning of every rTMS session regardless of group assignment. The left prefrontal cortex was the cortical target for rTMS treatment, located using the EEG-10-20 system.
45921275|NCT03513042|Radiation|Intensity Modulated Proton Therapy (IMPT) +/- Chemotherapy|"Standard of care:~IMPT (conventional fractionation [35x1,55/2Gy, 5 fractions/week] or accelerated fractionation [35x1,55/2Gy, 6 fractions/week])~with or without concurrent cisplatin (100 mg/m2 [d1, d22 and d43] or 40 mg/m2 weekly) or cetuximab (weekly 400 mg/m2 in 2h followed by 250 mg/m2 in 1h)"
46071702|NCT05333484|Other|Programed Pilates|The 60 min Pilates sessions were held twice a week for 12 weeks. Each session included three stages: 10 min of warm-up exercises, 40 min of floor-based Pilates training, and 10 min of cool-down exercises. Each stage was adjusted according to the participants' physical capacity. Only participants with an attendance rate of > 80% were included in the final sample. The content of the exercise program was determined according to their muscular strength, flexibility, and fitness levels. The training course was divided into three levels: elementary, intermediate, and advanced. Each motion was performed in conjunction with a specific breathing pattern for effective muscle activations of each exercise.
46071703|NCT04030767|Drug|Botox Injectable Product|Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity
46071704|NCT02836704|Drug|INSULIN GLARGINE|"Pharmaceutical form: solution~Route of administration: subcutaneous injection"
45754356|NCT05629689|Drug|GEH200520 Injection / GEH200521 (18F) Injection - Part A|Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
45794488|NCT01861574|Device|Real TMS 4 Hours|Real TMS 4 hours after surgery, first determined resting motor threshold (rMT) by starting with 40% of the machine output and 0.5 Hz stimulus frequency. The coil was positioned over the motor cortex and then adjusted until each pulse results in movement of the right thumb. The machine output was then adjusted to the lowest intensity that reliably produces thumb movement. Parameter estimation by sequential testing was used to determine the amount of machine energy necessary to visibly move the thumb 50% of the time. rMT was assessed before each rTMS treatment. The left prefrontal cortex was the cortical target for rTMS treatment. The EEG-10-20 system was used to locate the prefrontal cortex (F3).
45794489|NCT01861574|Device|Sham TMS 4 Hours|Sham TMS 4 hours after surgery used specifically designed rTMS coil that produces auditory signals identical to real (active) TMS coils but is shielded so that actual stimulation does not occur. The eSham system was used to mimic sensations of real rTMS. This system produces mild tingling on the scalp underneath the sham rTMS coil, making it difficult in differentiating between real and sham. The amount of electrical stimulation necessary to match real rTMS pulses was determined using an algorithm (parameter estimation by sequential testing). All subjects underwent the sham titration at the beginning of every rTMS session regardless of group assignment. The left prefrontal cortex was the cortical target for rTMS treatment, located using the EEG-10-20 system.
45794490|NCT01863134|Drug|Eptifibatide|
45921276|NCT00109720|Behavioral|Diabetes Self-Management Consultant|services of a Diabetes Self-Management Consultant
45921277|NCT00109720|Behavioral|Enhanced Usual Care Control Group|Usual care plus results of metabolic assessments obtained during the study
45921278|NCT00007085|Device|Tomography, X-ray Computed|
46071705|NCT02836704|Drug|metformin|"Pharmaceutical form: table or capsule~Route of administration: oral administration"
45794491|NCT01863134|Drug|Placebo|
45794492|NCT03676803|Other|mixed spices|All spices in the spice mixture capsules contains 1g or 20% cinnamon, 1.5g or 30% oregano, 1.5g or 30% ginger, 0.85g or 17% black pepper, 0.15g or or 3% cayenne pepper for a total of 5.0g spice mixture. They are identical to herbs and spices sold in grocery stores for human consumption.
45794493|NCT03676803|Other|placebo capsule containing 5 g of maltodextrin|placebo capsule containing 5 g of maltodextrin
45794494|NCT04735419|Other|No intervention|No intervention
45794495|NCT01864538|Drug|TH-302|480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.
45921279|NCT00109759|Biological|RagweedMATAMPL|
45648426|NCT04939831|Other|Total Laparoscopic or Robotic Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
45648427|NCT04939831|Other|Total Abdominal Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
45648428|NCT04921085|Other|Cross-sectional obeservational survey|Cross-sectional obeservational survey
45794496|NCT04267575|Device|Canady Helios Cold Plasma Scalpel|Device used to distribute cold plasma energy at the resected tumor margins.
45794497|NCT05679596|Dietary Supplement|ketone monoester (R)-3-hydroxybutyl (R)-3- hydroxybutyrate|Provided twice a day between meals.
45794498|NCT05679596|Dietary Supplement|carbohydrate-fat placebo (fructose, corn and canola oil 50:50 ratio)|Provided twice a day between meals.
45794499|NCT03415581|Drug|Intranasal Oxycodone|Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.
45794500|NCT03415581|Behavioral|Cue Session|During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.
45794501|NCT00557492|Drug|Avastin (bevacizumab)|10 mg/kg, days 1, 15, 29 and 43
45794502|NCT00557492|Drug|Gemzar (Gemcitabine)|On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).
45794503|NCT00557492|Radiation|external beam radiotherapy|3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy
45794504|NCT03416985|Device|Oral B Healthy Clean Manual Toothbrush|Manual Toothbrush
45794505|NCT03416985|Device|BURST Sonic Oral Care|Electric sonic toothbrush
45648429|NCT03357523|Device|Omnilux new-U (Red LED)|The left wrist (including area of radial artery) will be illuminated with the Omnilux new-U (Red LED) light source, while the right wrist will not be illuminated
45794506|NCT03416985|Device|Philipps Sonicare DiamondClean 300 Series|Electric pulsating toothbrush
45794507|NCT05672186|Behavioral|Full-service market intervention|Full-service mobile market implementation: the market will visit intervention sites weekly. The market will carry items from all food groups including fresh, frozen and canned fruits and vegetables, whole grains, dairy/ dairy substitutes, proteins (e.g., frozen meat/fish, beans, eggs), and dry goods (e.g., cooking oil, spices). Prices on the market are affordable, approximately 10% lower than grocery stores.
45794508|NCT05672186|Other|No intervention|No intervention
45794509|NCT03682809|Drug|Systane Complete|Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.
45921280|NCT00109759|Drug|Placebo|
45921281|NCT00109798|Drug|temozolomide|Patient will take drug on day 1-5 of 28 day schedule
45794510|NCT03682965|Biological|Intra-lymphatic allergenic extract|Mountain Cedar pollen allergenic extract is an FDA-approved, commercially available product for diagnosis and hypo-sensitization treatment of allergies. The labeled use is deep subcutaneous or percutaneous injection. Hyposensitization treatment is typically a series of 30 - 70 injections over 3 - 5 years into the upper aspect of the arm. This investigation is a proof-of-concept study to evaluate an alternative hyposensitization regimen of 3 injections directly into an inguinal lymph node.
45794511|NCT03682965|Biological|Intra-lymphatic placebo|The control group will receive a regimen of 3 injections of diluent (placebo) directly into an inguinal lymph node on the same schedule as the active treatment group.
45921282|NCT00109798|Drug|topotecan hydrochloride|Patient will have IV on days 2-6 on a 28-day schedule
45921283|NCT03497832|Other|magnetic resonance spectroscopy (MRI)|Each healthy subject will get 3 MRI examinations at 7:30, 13:30 and 18:00. Each MRI scan lasts an average of 20 minutes.
45921284|NCT00109954|Drug|cisplatin|
45794512|NCT02989298|Other|No intervention|Registration of all PD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals，which have signed the contract in China.
45794513|NCT03683901|Device|TENS|Electrical Stimulation
45794514|NCT03683901|Device|t-NMES|Electrical Stimulation
45794515|NCT03683901|Other|No stimulation|No stimulation
45794516|NCT01865708|Drug|Ethanol Lock|Ethanol lock, utilizing 74% ethanol, will begin within 24 hours of urinary catheter placement. The lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After the 1 hour dwell time, the clamp will be removed and the alcohol in the lumen of the catheter will be flushed out by the patient's own urine output.
45921285|NCT00109954|Radiation|brachytherapy|
45921286|NCT00109954|Radiation|yttrium Y 90 glass microspheres|
45921287|NCT00109993|Biological|alemtuzumab|alemtuzumab IV over 2 hours on days 4-6, 18, and 32
45921288|NCT00109993|Drug|methylprednisolone|methylprednisolone IV on days 1-3 and then orally or IV on days 4-14
45921289|NCT00109993|Drug|tacrolimus|tacrolimus IV continuously on days 1-7 and then orally once or twice daily on days 8-180, followed by a taper in the absence of chronic graft-vs-host disease
45921290|NCT00110032|Drug|EF5|Given IV
45921291|NCT00110032|Procedure|conventional surgery|Undergo surgery
45921292|NCT00110032|Procedure|positron emission tomography|Undergo PET
45794517|NCT04203225|Drug|LET Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%) topical gel|Topical anesthetic
45794518|NCT03949335|Device|IOL Model ZFR00V|Bilateral implantation with Investigational IOL Model ZFR00V
45921293|NCT00110032|Radiation|fluorine F 18 EF5|Given IV
45921294|NCT00110032|Other|pharmacological study|Correlative studies
45921295|NCT03472716|Procedure|Biological Samples|"5 ml blood sample and one tumoural sample (either a fresh biopsy or the initial diagnosis biopsy).~In case of relapse, new samples will be performed (blood and tumoral samples)"
45921296|NCT00007163|Drug|J695|
45921297|NCT00110071|Drug|fludarabine phosphate|Given IV
45921298|NCT00110071|Procedure|peripheral blood stem cell transplantation|Undergo transplantation (infusion of autologous or syngeneic PBSC via central line)
45921299|NCT00110071|Radiation|iodine I 131 tositumomab|Given IV (dosimetric dose) or via central line (therapeutic dose)
45921300|NCT00110071|Other|laboratory biomarker analysis|Correlative studies
45921301|NCT00110071|Other|flow cytometry|Correlative studies
45921302|NCT00110071|Genetic|polymerase chain reaction|Correlative studies
45921303|NCT00110188|Drug|ridaforolimus|
45921304|NCT00110227|Behavioral|12-week Tai Chi Program|24 tai chi sessions. 2 sessions/week for 12 weeks.
45449856|NCT01067261|Device|Transcutaneous mechanical nerve stimulation (TMNS)|"Device: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)~A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum. A stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used. The treatment will be initiated 1 to 4 weeks before the radical prostatectomy and re-initiated 0 to 14 days after the operation. The treatment will then continue for 6 weeks. The stimulation will be preformed daily by the patients in their own homes."
45449857|NCT01067261|Other|Pelvic floor muscle training|Regular pelvic floor training which is offered to all patients undergoing a radical prostatectomy at Herlev Hospital.
45648430|NCT03357523|Device|Omnilux new-U (Near infrared LED)|The left wrist (including area of radial artery) will be illuminated with the Omnilux new-U (Near infrared LED) light source, while the right wrist will not be illuminated
45648431|NCT03357523|Device|RESPeRATE|The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm
45921305|NCT00110227|Behavioral|12-week Education Program|24 Educational sessions. 2 sessions/week for 12 weeks.
45921306|NCT03456141|Procedure|third molar surgery|The patient is asked to complete the diary each post-surgery day for 14 days. Recovery is organized into three QOL domains: lifestyle, oral function, and pain.
45921307|NCT00007202|Drug|Atazanavir|
45921308|NCT00007202|Drug|Stavudine|
45921309|NCT00007202|Drug|Didanosine|
45921310|NCT00110344|Drug|Nexavar (Sorafenib, BAY43-9006)|Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (Sorafenib, BAY 43-906; this arm) or matching placebo (see below) for 14 days. Dose range will be depending on hematologic and other toxicity between 400 mg (2 tablets of 200 mg) orally twice bid and 400 mg orally every 2 days. Cycle 2: patients who are eligible undergo nephrectomy. After the post-nephrectomy recovery period, all patients will receive 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.Cycle 3+: 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.
45921311|NCT00110344|Drug|Placebo|Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (see above) or matching placebo (this arm) for 14 days. Dose range will be depending on hematologic and other toxicity between 400mg (2 tablets of 200mg) orally twice bid and 400mg orally every 2 days. Cycle 2 and 3: see above (no placebo application)
46071706|NCT02836704|Drug|acarbose|"Pharmaceutical form: table or capsule~Route of administration: oral administration"
46071707|NCT02611947|Radiation|Low-dose chest CT scans|"Supine chest CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~35 quality ref mAs with care-dose ON 120 kV Pitch 1.4 Rotation time 0.33 s Acquired images 64 x 0.6 mm"
46071708|NCT04478604|Other|applied forms to pregnant women|
46071709|NCT02833584|Drug|Paracetamol|Paracetamol 500 mg x 1 tablets according to patient's body weight
46071710|NCT02833584|Drug|Placebo|Placebo 500 mg x 1 tablets according to patient's body weight
45449858|NCT03588741|Drug|Turoctocog alfa|"Intravenous (i.v., under the skin) administration.A maximum dose of 200 IU/kg daily.~The maximum treatment period for this trial is 24 months and the patient(s) will be called for visit to the clinic every 3rd month."
45648432|NCT03357523|Device|Heating bag|Applying a standard 10X13 [cm] heating bag on the surface of the hand at 43-45 degree Celsius for 10 seconds
45648433|NCT04912349|Procedure|TUSP|Patients received the transurethral split of the prostate(TUSP) treatment.
45648434|NCT04912349|Procedure|TURP|Patients received the transurethral resection of the prostate(TURP) treatment.
45794519|NCT03949335|Device|IOL Model ZCB00|Bilateral Implantation with control IOL Model ZCB00
45794520|NCT05314257|Drug|Granisetron Hydrochloride|IV granisetron 1mg
45794521|NCT05314257|Other|0.9% normal saline|IV 5ml of 0.9% normal saline
45794522|NCT03690375|Device|Broad Band Light (BBL)|Sciton's BBL treatment using a new protocol that utilizes a 590nm, 560nm, and skintyte filter
45794523|NCT00377715|Drug|Dimebon|
45794524|NCT00377715|Drug|Placebo|
45794525|NCT03695913|Other|Normal Diet|"Phase I (regular diet):~all participants will eat their normal diet and will log their food."
45794526|NCT03695913|Other|Low carb diet|"Phase II (low carb diet):~participants will be asked to eat a low carb diet and log their food"
45921312|NCT00110383|Behavioral|School-Based Supervised Asthma Therapy|Child's inhaled steroid use supervised daily at school
45921313|NCT00401479|Drug|Placebo|
45921314|NCT00401479|Drug|Solabegron (GW427353)|
45921315|NCT00007241|Device|Isometric exercise|
45921316|NCT00110500|Genetic|hVEGF-A|
45921317|NCT00110539|Behavioral|Complementary and alternative medicine education|
46071711|NCT00837759|Drug|Insulin|
46071712|NCT00837759|Drug|Lansoprazole|
45794527|NCT03695913|Device|CGM with no real time feedback|Phase I will collect CGM without real time feedback
45794528|NCT03695913|Device|CGM with real time feedback)|Phase II participants will be asked to scan their sensor at least every eight hours and document their blood sugar before and two hours after eating as well as before breakfast and before going to bed.
45794529|NCT03695913|Behavioral|Education material|"Phase I: participants will be given the book Always Hungry and be asked to read chapters 1-5 after a health check phone call approximately 5 days after the sensor is placed.~Phase II: participants will be taught about carbohydrates and the benefits and side effects. Additionally, they will be given multiple resources to assist them regarding carbohydrates as well as a book entitled The Calorie King, Calories, Fat, and Carbohydrates. Groceries will also be delivered for 2 recipes that the participants choose from to make."
45921318|NCT00110578|Procedure|Adoptive transfer of HIV-specific CD8+ T cells|
45794530|NCT04234425|Behavioral|Trauma-Informed Yoga|Trauma-Informed Yoga practice held within a high school weight training class
45794531|NCT03697083|Other|Reminders Through Association|Participants receive 8 text messages asking them to think of a reminder cue that will help them remember to pick up the prescription and use the cue.
45794532|NCT03697083|Other|Active Control|Participants receive 8 text messages asking them to think of where they plan to store their medication once they pick it up and to think about that location on their intended date of pickup.
45794533|NCT03697083|Other|Baseline Control|Participants receive 1 text message thanking participants for enrolling in the reminder program. Participants are not contacted further.
45794534|NCT02354586|Drug|Niraparib|
45794535|NCT00377247|Biological|autologous monocyte-derived dendritic cells (DC) transfected with DNA|The patients will receive 1 x 107 DC/vaccine delivered intranodally or perinodally to lymph nodes (LN) distant from the head and neck area (e.g., to inguinal LN)
45794536|NCT01866410|Drug|Cabozantinib S-malate|Given PO
45794537|NCT01866410|Drug|Erlotinib Hydrochloride|Given PO
45794538|NCT01866410|Other|Laboratory Biomarker Analysis|Correlative studies
45794539|NCT00377325|Drug|Cyclosporine|4 mg/Kg/day; daily; liquid form; 6 months
45794540|NCT04224753|Device|INVSENSOR00027|Investigational, noninvasive sensor that will be placed on the subject's chest. INVSENSOR00027 detects falls for each subject.
45794541|NCT04196907|Device|Rad-67 Pulse CO-Oximeter and DCI Mini sensor|Noninvasive Pulse CO-Oximeter device and sensor are used to measure hemoglobin.
45794542|NCT02332824|Drug|TAK-272|TAK-272 tablets
45794543|NCT02332824|Drug|TAK-272 Placebo|TAK-272 placebo-matching tablets
45921319|NCT00110578|Drug|Aldesleukin|
45921320|NCT00110656|Other|Observations|This is a non-interventional study- only observational.
45921321|NCT00388193|Drug|RITUXIMAB|375 mg/m2/d day 1
45921322|NCT00110695|Drug|Nanoparticle albumin bound paclitaxel followed by FEC|Nanoparticle albumin bound paclitaxel 100 mg/m2 IV for 30 minutes once weekly for 12 weeks followed by FEC (5-FU 500mg/m2 IV push; epirubicin 100 mg/m2 IV over 15 min. [or if given with trastuzumab 75 mg/m2 IV over 15 min.]; cyclophosphamide 500 mg/m2 IV over 30 min.) on Day 1 every 21 days
45449859|NCT00111917|Drug|Infliximab|anti-TNF
45648435|NCT04406207|Other|Demonstration of T cell responses|"Evaluation of HERVs-specific CD8+ T cells before and after hematopoietic stem cell transplantation. Comparison will be made in patients relapsing vs non relapsing patients.~The measurement of these responses will be done by dextramer, allowing precise and specific measurement of the lymphocytes directed against the HERVs of interest."
45648436|NCT04402541|Drug|CB-5339|25mg and 75mg capsules
45754357|NCT05629689|Diagnostic Test|Dynamic and Static - PET/CT scan|Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.
45754358|NCT05629689|Drug|GEH200520 Injection / GEH200521 (18F) Injection - Part B|Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
45794544|NCT02332824|Drug|Candesartan cilexetil|Candesartan cilexetil tablets
45794545|NCT02332824|Drug|Candesartan cilexetil Placebo|Candesartan cilexetil placebo-matching tablets
45794546|NCT03701061|Biological|Seasonal Influenza Vaccine|A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study
45794547|NCT03701061|Biological|Seasonal Influenza Vaccine|A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study
45794548|NCT03420014|Drug|Doxorubicin|75 mg/m2 doxorubicin will be administered once every 3 weeks (Day 1 of every 21-days cycle).
45921323|NCT00110734|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|
45921324|NCT00110773|Drug|S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)|S-Caine Peel, composed of a 1:1 (w:w) eutectic mixture of 7% lidocaine and 7% tetracaine, applied topically. S-Caine Peel applied at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
45921325|NCT00110773|Drug|Placebo Peel|Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
45921326|NCT00110851|Drug|rosiglitazone|
45921327|NCT00110851|Drug|metformin|
45921328|NCT00110851|Drug|PN2034|
45449860|NCT00111917|Other|Placebo|Placebo infusion
45449861|NCT03730389|Device|External Physical Vibration Lithecbole (EPVL)|Using the the way of external physical vibration to promote separation of stones from ureteral mucosa and promoting the excretion of ureteral stones
45794549|NCT03420014|Combination Product|L19TNF plus doxorubicin|13 μg/kg L19TNF will be administered on day 1, 3 and 5 of every 21-days cycle in combination with 60 mg/m2 doxorubicin on day 1 of every 21-days cycle.
45794550|NCT03705273|Drug|Dexamethasone IV for PO|Common pediatric emergency department practice
45921329|NCT00110929|Drug|AMG 073|
45921330|NCT00110968|Drug|Itopride hydrochloride|
45921331|NCT03433404|Procedure|Soft Tissue Mobilization|The technique has been described previously in other descriptions. However, the main goal of this treatment is to address the LDSIL in the manner described previously in order to mobilize the soft tissue in the area.
46071713|NCT00837759|Drug|Sitagliptin|
45794551|NCT03705273|Drug|Dexamethasone crushed tablets|Alternative route of administration for patients unable to swallow tablet whole
45648437|NCT04509739|Behavioral|Music intervention|"At 9 months of age, families will start the 12 - session intervention in a controlled laboratory space. In the initial session, caregivers will be given a brief orientation to intervention, including introducing them to the musical toys they will be using during the sessions with their infants and the lab environment. They will also be trained techniques through which they can synchronize the infant's movements to the experimenter's movements, such as clapping hand, tapping feet.~The remaining sessions will be scheduled in groups of 2-3 infant/parent dyads. In each session, a music CD with 15 minutes of selected children's music will be played and a musically trained experimenter will facilitate the sessions to engage the infants and parents to move to musical beats, using different musical toys, such as infant drums and maracas. Parents will be instructed to not to repeat any of these activities outside of the lab setting for the period of the study."
45794552|NCT03708393|Device|Imagio (IUS+OA)|The Imagio ultrasound and opto-acoustic images to be reviewed as part of the reader study
45794553|NCT03708393|Device|Imagio Ultrasound|Imagio ultrasound images to be reviewed as part of the reader study
46071714|NCT00837759|Biological|Diamyd|
46071715|NCT00837759|Drug|GAD65 (Diamyd)|
45794554|NCT03708393|Device|Mammography|Mammography images as available per standard of care
45794555|NCT03946059|Device|iTBS then cTBS|repetitive transcranial magnetic stimulation applied with intermittent theta-burst stimulation protocol applied in week 1 and continuous theta-burst stimulation protocol applied in week 2.
45449862|NCT01067417|Drug|Hydroxychloroquine|Taken orally 2x200mg capsules once daily for 48 weeks
45648438|NCT01966263|Procedure|LIA of the posterior capsule of the knee|the surgeon infiltrates the posterior capsule of the knee using 100 mL ropivacaine 0.2% with 0.5 mg epinephrine.
45648439|NCT01966263|Procedure|LIA of the anterior capsule of the knee|the surgeon infiltrates the anterior capsule of the knee using 50 mL ropivacaine 0.2% with 0.25 mg epinephrine.
45794556|NCT03946059|Device|cTBS then iTBS|repetitive transcranial magnetic stimulation applied with continuous theta-burst stimulation protocol applied in week 1 and intermittent theta-burst stimulation protocol applied in week 2.
45794557|NCT04184271|Drug|38% silver diamine fluoride|Topical application of SDF to teeth
45648440|NCT01966263|Procedure|LIA of the subcutaneous tissue of the knee|the surgeon infiltrates the subcutaneous tissue of the knee using 50 mL ropivacaine 0.2% before wound closure.
45794558|NCT03938337|Drug|Cohort 1 Not Previously Treated|Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
45648441|NCT01966263|Procedure|FNB with catheter|pre-operatively the anesthesiologist will ultrasound guided place a catheter close to the femoral nerve using sodium chloride (NaCl 0.9%) (no local anesthetic). During surgery, when the LIA of the posterior capsule is performed, 20 mL ropivacaine 0.2% will be administered through the catheter to create a femoral nerve block (FNB). Postoperatively patients will receive 20 mL ropivacaine 0.2% through the catheter 6 times daily for 24 hours
45794559|NCT03938337|Drug|Cohort 2 Treated Previously|Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
45794560|NCT03937791|Biological|E7 T Cell Receptor (TCR)|One dose of E7 TCR T cells (1x10^11 cells) will be administered intravenously over 20 to 30 minutes.
45794561|NCT03936387|Drug|Ropivacaine|Erector spinae blocks: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus. Repeated on contralateral side.
45794562|NCT04173429|Drug|Nadroparin calcium, warfarin|Nadroparin calcium subcutaneously every 12hs for 1 months followed by warfarin orally for 5 months. INR(international normalized ratio ) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
45794563|NCT03710187|Drug|Hydrocortisone|Hydrocortisone 50 mg IV Q6h
45794564|NCT03710577|Behavioral|Yoga|1 session
46071716|NCT02832960|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
46071717|NCT02832960|Drug|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
45794565|NCT03710577|Behavioral|Quiet Rest|1 session
45794566|NCT04167189|Drug|Lidocaine gel|Septodont 5% oral lidocaine gel (NDC 0362-0221-10), 75 mg
45794567|NCT03929367|Drug|Oxytocin|Single IV administration of oxytocin
45794568|NCT03715803|Device|Calistar A mesh to treat anterior and apical POP|Single incision surgery using Calistar A mesh to treat anterior and apical pelvic prolapses
45794569|NCT03715803|Device|Calistar S mesh to treat anterior and apical POP|Single incision surgery using Calistar S to treat anterior and apical pelvic prolapses
45449863|NCT01067417|Drug|Placebo|Taken orally 2x200mg capsules once daily for 48 weeks
45449864|NCT03520569|Drug|Octreotide|we are using it to block insulin secretion from the pancreas
45794570|NCT04155567|Drug|TAK-123|TAK-123 infusion
45794571|NCT04149405|Procedure|Phase 1 periodontal therapy|Scaling and root planning with ultrasonic and hand instruments under local anesthesia.
45794572|NCT04149405|Drug|Bisphosphonate therapy|Using aclasta: intravenous infusion of 5 mg of zoledronic acid once a year
45794573|NCT00556712|Drug|erlotinib [Tarceva]|150mg po daily
45794574|NCT00556712|Drug|Placebo|po daily
45794575|NCT04137783|Other|no intervention|there is no intervention in this study, only observation.
45794576|NCT03717051|Drug|Nicotine replacement therapy (NRT) sampling|1-week free NRT samples (patch or gum)
45921332|NCT03433404|Procedure|Soft Tissue Massage|For sMass, the subject will be positioned on her side opposite to the most painful side of the lumbosacral spine with the hips flexed to 45 degrees and knees flexed to 90 degrees (with a pillow positioned between them). The investigator will perform superficial (light stroke) massage to the painful side of the lumbosacral region for 5 minutes
45794577|NCT03717051|Behavioral|Medication counseling|Medication counseling
45794578|NCT04147455|Behavioral|Adapted RealConsent|The program is a novel, theory-driven, evidence-based serial drama and educational program tailored to young men and delivered in six episodes via the web. Participants will view six 30-minute modules designed to prevent sexual violence in young men
45794579|NCT04147455|Behavioral|Health Education Control Condition|Participants will view six 30-minute web-based serial drama modules designed to promote health.
45794580|NCT04350320|Drug|Colchicine Tablets|standard therapy for COVID-19 according to the stablished hospital protocols.
45794581|NCT04350320|Drug|Standard therapy for COVID-19 according to the stablished hospital protocols.|standard therapy for COVID-19 according to the stablished hospital protocols.
45794582|NCT04143945|Drug|Semaglutide (administered by DV3396 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
45794583|NCT04143945|Drug|Semaglutide (administered by PDS290 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
45794584|NCT04134429|Device|Everion|The Everion® device, by Biovotion, Zurich, is a on-skin wearable device measuring health data.
45794585|NCT03920865|Drug|Risdiplam|5 milligram (mg) oral dose administered in fasted state
45794586|NCT00556322|Drug|Alimta or Taxotere|500mg/m2 / 3 weeks (Alimta) or 75mg/m2 / 3 weeks (Taxotere)
45921333|NCT00111046|Drug|Ibuprofen|
45921334|NCT00111046|Drug|Tramadol|
45921335|NCT00388271|Drug|Alfuzosin (Xatral)|standard treatment plus alfuzosin
45921336|NCT00388271|Drug|standard treatment|standard treatment
45921337|NCT00111085|Drug|Clazosentan 1 mg/h|Subjects receive intravenous clazosentan at a rate of 1 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
45921338|NCT00111085|Drug|Clazosentan 5 mg/h|Subjects receive intravenous clazosentan at a rate of 5 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
45648442|NCT04930679|Drug|Andiabet|Each hard capsule includes: 200mg Gynostemma Pentaphyllum Leaf, 200mg Largerstroemia Speciosa Leaf, 133mg Anemarrhena Asphodeloides Whole
45648443|NCT04436185|Behavioral|Comparisons of procedural pain|This randomized experimental study with placebo and control groups
45921339|NCT00111085|Drug|Clazosentan 15 mg/h|Subjects receive intravenous clazosentan at a rate of 15 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
45921340|NCT00111085|Drug|Placebo|Subjects receive intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
45921341|NCT00111124|Drug|Enbrel®|
45794587|NCT00556322|Drug|erlotinib [Tarceva]|150mg po daily
45794588|NCT04137627|Drug|Melatonin 20 MG Oral Capsule|The administration of Melatonin 20 mg in addition to neoadjuvant chemotherapy to observe the antioxidant and onco-static effect.
45794589|NCT04137627|Drug|Placebo oral capsule|The administration of placebo capsule in addition to neoadjuvant chemotherapy
45794590|NCT00556166|Device|Enterra Therapy Gastric Stimulator|"The intramuscular stomach leads, implanted in a minimally invasive surgical procedure lasting 1-3 hours, are placed on the greater curvature of the stomach. The implanted pulse generator (IPG) is about 2 1/2 x 2 x 1/2 and is implanted in a subcutaneous pocket, generally created in the abdominal area, and is then connected to the leads. The IPG provides the energy source that delivers the electrical pulse to the stomach muscle through the stomach leads to improve the symptoms of gastroparesis.~The doctor will use an external programmer to change the settings of the neurostimulator and control the neurostimulator after implantation. Part of the programmer is held outside the body over the implant site and can adjust or change the settings of the neurostimulator using radio remote control."
45794591|NCT01869374|Device|MagVenture MagPro MST|Brain stimulation by magnetic means versus electrical standard unilateral Electroconvulsive Therapy (RUL ECT). Treatment will be administered 3 times a week.
45449865|NCT03520569|Drug|Insulin|we are using to replace basal insulin and in two protocols to raise insulin concentrations during the insulin clamp
45449866|NCT03520569|Drug|Dextrose 20% solution|We are using dextrose to maintain glycemia level
45921342|NCT03429114|Other|Magnetic resonance imaging|We will conduct MRI and fMRI brain scans to compare brain function between groups.
45921343|NCT00111163|Drug|sulfadoxine-pyrimethamine with artesunate|
45921344|NCT00111163|Drug|amodiaquine with artesunate|
45921345|NCT00111163|Drug|chlorproguanil-dapsone|
45921346|NCT00388310|Procedure|Culture|Culture
45921347|NCT03419052|Behavioral|Speed of processing training|Speed of processing training is provided by the Internet-based BrainHQ program from Posit Science, Inc. BrainHQ contains five different speed training modules (Hawk Eye, Visual Sweeps, Fine Tuning, Eye for Detail, Sound Sweeps) which tap time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory.
45648444|NCT04400201|Drug|Remimazolam Tosilate|Intravenous injection at a dose of 0.3mg/kg for sedation induction and continuous intravenous infusion at an initiative dose of 1 mg/kg/h for sedation maintenance.
45648445|NCT04400201|Drug|Propofol|Intravenous injection at a dose of 1.5~2.5mg/kg for sedation induction and continuous intravenous infusion at the dose of 0~12 mg/kg/h for sedation maintenance
45648446|NCT05434845|Other|Blood draw|An additional 8 mL of blood will be drawn during routine lab collection
45921348|NCT03419052|Behavioral|MIND foods|"The MIND diet (created by the Rush Aging & Memory group) specifically emphasizes foods high in polyphenols such as berries, nuts, cocoa, black beans, olive oil, and green leafy vegetables. Participants select these foods from the digital study application and receive them through home delivery."
46071718|NCT00703287|Other|Physiotherapy|Specialized physiotherapy programme developed by Jean-Pierre Bleton
45648447|NCT04920773|Other|Guduchi Ghanvati|500 mg of Samshamani vati or Giloy Ghanavati (Aqueous extract of Tinospora cordifolia) twice daily
45794592|NCT01869374|Biological|RUL ECT|RUL ECT using the Somatics Thymatron device with Ultrabrief stimulus. Treatment will be administered 3 times a week.
45794593|NCT04136145|Drug|Belimumab for IV|Belimumab will be available as white to off-white lyophilized cake at a unit dose strength of 400 mg to be reconstituted and diluted in normal saline to obtain 200 mg per dose.
45794594|NCT04136145|Drug|Belimumab for SC|Belimumab will be available as clear to opalescent, colorless to pale yellow sterile solution at unit dose strength of 200 mg/milliliter (mg/mL) for SC injection in a single-use, prefilled syringe contained within an auto-injector device.
45794595|NCT01869686|Biological|Denosumab|60 mg
45794596|NCT04109703|Device|High Level Pulsed Heat delivered by Generation 5 devices from Soovu Labs Inc.|The Soovu Labss Inc. battery powered device is a one inch diameter heating pod that attaches to the user via a ring system. The device may be programmed to deliver a wide variety of treatment algorithms. Control of the devices are through a phone-based bluetooth connection. For this study the treatment algorithm used for subjects in this arm (experimental) used a temperature that was ramped from skin temperature to a peak temperature of 45° C and cycled for 30 minutes.
45794597|NCT04109703|Device|Low Level (37 degrees C) delivered by the control device Generation 5 devices from Soovu Labs Inc.|The Soovu Labs Inc. battery powered device is a one inch diameter heating pod that attaches to the user via a ring system. The device may be programmed to deliver a wide variety of treatment algorithms. Control of the devices are via a phone-based bluetooth connection. For this control arm of the study the treatment algorithm held a steady temperature of 37 degrees C for a 30 minute period.
45794598|NCT01870388|Drug|Baricitinib|Administered orally
45794599|NCT03909009|Device|rTMS + Neuronavigation|Repetitive Transcranial Magnetic Stimulation (Neuro-MS/D) + Neural Navigator
45648448|NCT04920773|Other|Standard guidelines|Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask
45794600|NCT01870856|Device|Spectacles|Per participant's habitual prescription
45648449|NCT04423107|Drug|Acetaminophen, Ibuprofen|Acetaminophen (Tylenol) 15 mg/kg q6h and Ibuprofen (10 mg/kg) q6h
45794601|NCT01870856|Device|Delefilcon A contact lenses|Silicone hydrogel single vision contact lenses
45794602|NCT01870856|Device|Etafilcon A contact lenses|Hydrogel single vision contact lenses
45794603|NCT03739983|Device|Vaginal Renewal Program|Therapeutic vibrating wand.
45794604|NCT02270060|Other|Music Therapy|Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
45794605|NCT02270060|Other|Music Listening|Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
45794606|NCT03764007|Drug|18F-Fluorocholine|Given intravenously
45794607|NCT03764007|Procedure|Positron Emission Tomography (PET)|Imaging technique that uses radioactive agents known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities
45794608|NCT02271386|Behavioral|Supporting Practice for ADHD (SPA)|"The SPA intervention will last for 8 months for each study arm (first 8 months of the study for the intervention group, last 8 months for the control group). The intervention includes 3 components: 1) a series of web-based educational presentations to provide education to providers about evidence-based practice for managing ADHD and strategies for promoting effective communication with families 2) Collaborative consultation designed to address clinical issues arising in practice will be provided by members of the study team.~3) Providers will be given systematic performance feedback with regard to their use of evidence-based practices for ADHD every 2 months during the 8-month intervention period."
45794609|NCT04091061|Drug|PF-06865571 100 mg|PF-06865571 in 100 mg oral tablet will be administered on Day 1
45794610|NCT03360890|Drug|Pembrolizumab|Pembrolizumab will be administered via IV at 200mg every three weeks. Patients will receive pembrolizumab for about 2 years.
45794611|NCT03360890|Drug|Docetaxel|Docetaxel will be administered via IV at 75mg/m2 every three weeks for 3 to 6 cycles.
45794612|NCT01872338|Behavioral|Mindfulness-Based Cognitive Therapy for Suicide|Psychotherapeutic intervention that integrates mindfulness meditation with Safety Planning, with a specific focus on reducing suicide risk.
45794613|NCT01872338|Behavioral|Treatment as usual|VA standard care for suicide prevention
45794614|NCT04079127|Device|Patients who met the inclusion/exclusion criteria to receive the Avenir Müller stem.|Consecutive cohort of patients enrolled at every site who received the Avenir Müller stem.
45794615|NCT03862755|Drug|Chemoprophylaxis with Low Molecular Weight Heparin (LMWH)|Early chemoprophylaxis means low-molecular weight heparin (LMWH) 3075 IU (WHO Units) injection subcutaneously one time a day no later than 24 hours after surgery. Early ambulation means activity out of bed no later than 24 hours after surgery. According to different risk level, patients received different thromboprophylaxis strategies. Early ambulation alone was for patients at low risk (Caprini 0-4), early chemoprophylaxis plus early ambulation was for patients at moderate (Caprini 5-8) or high risk (Caprini ≥9).
45648450|NCT04423107|Drug|Acetaminophen, Ibuprofen, Oxycodone|Acetaminophen (Tylenol) 15 mg/kg q6h, Ibuprofen q6h, and Oxycodone 0.1 mg/kg q6h
45648451|NCT01675531|Drug|Targin|Single arm for Targin
45648452|NCT04920851|Device|cytokine hemadsorption|to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.
45648453|NCT05406999|Drug|ADT|The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.
45794616|NCT01874132|Behavioral|Exercise training|Both training programs were of moderate-to-vigorous intensity, three days per week for nine months.
45794617|NCT02332590|Drug|Sarilumab|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
45794618|NCT02332590|Drug|Adalimumab|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
45794619|NCT02332590|Drug|Placebo (for sarilumab)|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
45794620|NCT02332590|Drug|Placebo (for adalimumab)|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
45794621|NCT03869541|Other|Mobilization|Physical rehabilitation
45794622|NCT01874756|Drug|LY500307 150mg|LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks
45794623|NCT01874756|Drug|LY500307 75mg|LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks
45794624|NCT01874756|Drug|Placebo|6 placebo capsules daily for 8 weeks
45794625|NCT01874756|Drug|LY500307 25mg|LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks
45794626|NCT04076787|Drug|Sunitinib|patients who received sunitinib as first line therapy for mRCC
45794627|NCT04063371|Other|Self-Administered Gerocognitive Examination (SAGE) or Electronic Self-Administered Gerocognitive Examination (eSAGE)|The Self-Administered Gerocognitive Examination (SAGE) is a reliable and valid assessment that is used to detect MCI and early dementia. It is a pen and paper assessment that has 4 interchangeable versions. The digital version of SAGE (eSAGE; commercially known as BrainTest®) is made for tablet use, consists of the identical test questions as SAGE, and is strongly associated with the validated SAGE.
45648454|NCT05406999|Drug|Abiraterone Acetate|1000 mg (250 mg×4 tablets) once daily, orally
45648455|NCT05406999|Drug|Prednisolone tablets|5 mg once daily, orally.
45648456|NCT05406999|Drug|Enzalutamide|160 mg (40 mg× 4 tablets) once daily, orally.
45794628|NCT04063371|Other|Informant Conversation|If possible, the provider will have a conversation with an individual who knows the patient will to ascertain if a significant change (based on primary care provider opinion) occurred in the patient's cognitive skills over the previous year.
45794629|NCT03200678|Other|isokinetic assessment|muscle torque assessement
45648457|NCT05406999|Drug|Apalutamide|240 mg (60 mg×4 tablets) once daily, orally.
45648458|NCT05406999|Drug|Darotamide|600 mg (300 mg × 2 tablets) twice daily, orally.
45648459|NCT05406999|Drug|Rezvilutamide|240 mg (80 mg × 3 tablets) once daily orally
45794630|NCT00554840|Drug|varenicline|Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
45794631|NCT00554840|Drug|placebo|At the end of Pre-med week 1, subjects will receive study medication with the target quit date being the following week. Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
45794632|NCT05652140|Other|Data collections|Data collections of cognitive function, neuroelectrical activities, ApoE genotype, and physical fitness.
45794633|NCT04069221|Drug|Single oral dose of 800 mg OZ439|Single oral dose of 800 mg OZ439
45648460|NCT05406999|Drug|PARP inhibitor|The PARP inhibitors will be determined by the investigators at separate centers. The dosage and frequency of administration will be consistent with the prescribing information. Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.
45648461|NCT05406999|Procedure|Robot-assisted radical prostatectomy|Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
45648462|NCT05118607|Device|IG1|application of low intensity transcutaneous penile electrical stimulation for 45 minutes using frequency.
45648463|NCT04930211|Drug|Dexamethasone-Lidocaine|Kambin's triangle approach in transforaminal epidural injection: Kambin's triangle is defined as a right triangle over the dorsolateral disc. The hypotenuse is the exiting nerve root, the base is the superior border of the caudal vertebra, and the height is the dura/traversing nerve root. it is possible to inject agents at the entrance and middle zone as the main areas of nerve entrapment by injecting at the retrodiscal area of the entrance zone, as proximal area of the targeted nerve root.
45794634|NCT04069221|Drug|Single oral dose of 400 mg OZ439|Single oral dose of 400 mg OZ439
45648464|NCT03177265|Behavioral|Text messaging prior to first counseling call|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive up to 8 text messages prior to the first counseling phone call to provide education regarding cessation treatment.
45648465|NCT03177265|Behavioral|Text-to-Enhance|Two weeks following receipt of the letter (PrO condition) or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
45648466|NCT03177265|Behavioral|Mail Notice|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive a notice in the mail that they will receive a phone call in about 2 weeks to offer telephone cessation treatment.
45648467|NCT03177265|Behavioral|Telephone Counseling|Two weeks following receipt of the mailed notice or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
45648468|NCT03054311|Behavioral|Lifestyle Matters|
45754359|NCT05629689|Diagnostic Test|Static - PET/CT scan|Whole-body PET/CT scan (up to 30 min). Exact timing will be determined from Part A. An optional dynamic scan may be acquired in addition to the required whole-body PET/CT scan at each imaging visit.
45794635|NCT04069221|Drug|Single oral dose of cobicistat|Single oral dose of 150 mg cobicistat
45794636|NCT04069221|Drug|iv infusion of [14C]-OZ439|15-minute 10-mL iv infusion of 100 μg [14C]-OZ439
45794637|NCT03054038|Drug|Afatinib|Given by mouth
45794638|NCT03054038|Biological|Necitumumab|Given IV
45794639|NCT03054038|Other|Laboratory Biomarker Analysis|Correlative studies
45794640|NCT02302716|Drug|LY2963016|Administered SC
45921349|NCT03419052|Behavioral|Cognitive training control|Control training is provided by the Internet-based BrainHQ program from Posit Science, Inc.These are inert games such as tic-tac-toe, connect 4, battleship, etc.
45794641|NCT02302716|Drug|LANTUS®|Administered SC
45794642|NCT02302716|Drug|Oral Antihyperglycemic Medication|Administered as per standard-of-care.
45648469|NCT04851145|Diagnostic Test|Mass spectrometry-based proteomics of FFPE biopsies and urine samples|"The biopsy and urine samples will be processed by the OncoProt platform (University of Bordeaux) for proteomic analysis by tandem mass spectrometry (label-free quantification) as follows:~Biopsies: laser microdissection of the renal cortex, fixation reversion, protein extraction and electrophoretic migration, tryptic digestion.~Urines: samples concentration by centrifugation/filtration and tryptic digestion according to a protocol adapted from the FASP method (Filter-Aided Sample Preparation)"
45648470|NCT04912271|Drug|Granisetron transdermal patch|Granisetron transdermal delivery system (GTDS) is the first 5-HT3 drug to be transdermally delivered and represents a convenient alternative to oral and intravenous antiemetics for the treatment of chemotherapy-induced nausea and vomiting.
45648471|NCT04912271|Drug|Palonosetron|Palonosetron is a second-generation 5-HT3 receptor antagonist with proposed higher efficacy and sustained action for prophylaxis of postoperative nausea and vomiting (PONV).
45648472|NCT04912271|Drug|Aprepitant|Aprepitant is a licensed treatment for nausea and vomiting, which blocks substance P activation of NK-1 (neurokinin 1) receptors.
45794643|NCT03881007|Other|Mouthwash with LCM|Subjects will mouthwash daily with LCM and before/after sex
45794644|NCT03881007|Other|Mouthwash with placebo|Subjects will mouthwash daily with placebo and before/after sex
45794645|NCT03958071|Drug|Nintedanib|Nintedanib initiators
45794646|NCT03958071|Drug|Pirfenidone|Pirfenidone initiators
45794647|NCT03958071|Other|Untreated Cohort|Untreated
45794648|NCT00554606|Drug|Canakinumab|Canakinumab
45794649|NCT04332159|Procedure|Closed nasal fracture reduction|Closed nasal fracture reduction is performed under local anesthesia with addition of Methoxyflurane or placebo
45794650|NCT04066647|Drug|Dexamethasone 4mg|1 mg IV dexamethasone will be pushed and miRNA levels will be checked at baseline just before injection and then at 15, 30, 45, and 60 minutes after injection.
46071719|NCT00703287|Other|Physiotherapy|Generic physiotherapy
46071720|NCT02836782|Procedure|Blood sample withdrawal|Blood withdrawal for HIV-DNA or HCV resistance test
45648473|NCT04912271|Drug|Fosaprepitant|Fosaprepitant is a neurokinin-1 receptor antagonist, approved for the prevention of chemotherapy-induced nausea and vomiting.
45648474|NCT04912271|Drug|Dexamethasone|Dexamethasone, one of the glucocorticoids, has been suggested as a first-line drug for preventing low-level emetogenic chemotherapy- and radiotherapy-induced nausea and vomiting.
45794651|NCT04350632|Diagnostic Test|Shear wave elastography assessment of the external anal sphincter|"Assessment of the external anal sphincter viscoelastic properties using shear wave elastography technology~Women in lithotomy position with an empty bladder~The linear probe is applied on transversal plane on the perineal with a transperineal approach~The external anal sphincter will be identified in 2D ultrasound using a SL 18-5 linear probe~Viscoelastic properties of the muscle will be assessed by measuring the shear modulus at rest, Valsalva maneuver and contraction~Exactly the same investigations will be performed for the two visits planned in the protocol. In the first visit, it will be one single observer and for the second it will be 2 observers.~Data about the mode of delivery and the occurrence of OASI will be collected into women's medical fil"
45794652|NCT04041453|Drug|Ivermectin|Ivermectin at 600mcg/kg in addition to albendazole will be provided for 1 or 3 days.
45794653|NCT04041453|Drug|Albendazole|Albendazole will be provided as an active control or in experimental arms for 1 or 3 days with ivermectin.
45794654|NCT04350476|Diagnostic Test|VitalConnect Vital Sign Patch|"This patch provides continuous real-time monitoring of cardiac telemetry, heart rate, respiratory rate and oxygen saturation. Duration of monitoring is typically up to 7 days.~This patch is applied to the upper left side of the chest wall, attached with a hypoallergenic adhesive material. (This device is FDA approved for this indication)."
45794655|NCT03998163|Drug|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg administered three times/week
45794656|NCT02354508|Drug|Pasireotide LAR|Pasireotide 40 mg and 60 mg. Pasireotide 20 mg which was allowed for dose decrease in case of adverse event.
45794657|NCT00554216|Drug|VI-0521|3.75 mg phentermine/23 mg topiramate
45794658|NCT00554216|Drug|VI-0521|15 mg phentermine/92 mg topiramate
45794659|NCT00554216|Drug|Placebo matched phentermine/topiramate|Placebo matched phentermine/topiramate
45794660|NCT04001517|Drug|Neflamapimod|Double-Blind, Placebo-Controlled
45794661|NCT03040856|Dietary Supplement|Alpha Linolenic Acid|Alpha Linolenic Acid enriched diet
45794662|NCT03040856|Dietary Supplement|Omega 3 enriched diet ( DHA+EPA)|Omega 3 (DHA+EPA) supplementation enriched diet
45794663|NCT03040856|Other|Placebo|Placebo capsules containing olive oil
45794664|NCT02353572|Drug|Melphalan|Given IV
45794665|NCT02353572|Drug|Bortezomib|Given IV
45794666|NCT02353572|Drug|Dexamethasone|Given IV
45794667|NCT02353572|Procedure|Autologous Transplant|Undergo autologous hematopoietic stem cell transplant
45921350|NCT03419052|Behavioral|Control foods|Foods contain low polyphenols. Participants select these foods from the digital study application and receive them through home delivery.
45921351|NCT00111280|Drug|TMC125|
45921352|NCT00111319|Drug|bortezomib|
45921353|NCT00111358|Behavioral|Lifestyle Modification|
45921354|NCT00111358|Other|No lifestyle modification|
45921355|NCT00111397|Procedure|Cytokine therapy|
45921356|NCT00111397|Drug|Interferon Gamma, GM-CSF|
45921357|NCT00111436|Drug|Etanercept|Enbrel 50 mg once weekly or 50 mg twice weekly
45921358|NCT00111514|Biological|Leish-111f + MPL-SE vaccine|
46071721|NCT05602467|Device|Transcranial Pulse Stimulation (TPS)|"A global brain stimulation approach, which homogenously distributes the total energy of 6000 TPS pulses per session over all accessible brain areas.~Prefrontal, Temporal and Occipital brain areas were stimulated by ultrashort (3μs) ultrasound pulses with typical energy levels of 0.2-0.25 mJ/mm2 and pulse frequencies of 4-5 Hz (pulses per second)."
45648475|NCT02807779|Drug|Dexamethasone infusion|Participants will receive dexamethasone infusion following plain balloon angioplasty
45794668|NCT02990156|Device|Coil Embolization System|deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame, and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm. The intended use of the Microport NeuroTech Coil Embolization System is for the endovascular embolization of intracranial aneurysms.
45794669|NCT02990156|Device|Cotrol device from Medronic|Control device from Medronic (include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils) are manufactured by ev3 (Medtronic, Irvine, California, USA);
45794670|NCT03886701|Drug|Doravirine (DOR)|Non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection in adults in combination with other antiretroviral agents.
45794671|NCT03886701|Drug|Rifapentine (RPT)|Rifamycin anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
45794672|NCT03886701|Drug|Isoniazid (INH)|Anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
45794673|NCT00552578|Drug|buprenorphine/naloxone|sublingual tablets, 2/0.5 mg, three times a day for one month, twice a day for one month, once a day for one month, then every other day for one month. (dose may be adjusted based on an individual's response)
45794674|NCT00552578|Drug|buprenorphine/naloxone|sublingual tablets, 2/0.5 mg, one tablet three times a day for six months (doses may be adjusted based on an individual's response
45794675|NCT02301936|Drug|LDV/SOF|90/400 mg fixed dose combination (FDC) tablet administered orally once daily
45794676|NCT03881163|Drug|N-acetylcysteine (NAC)|Two ampoules of IMP (300 + 300 mg) corresponding to a total dose of 600 mg of NAC diluted in 10 mL of NaCl 0.9% sterile saline solution, will be administered by a 5-minute i.v. infusion.
45794677|NCT02895152|Behavioral|Feedback|Will receive feedback on the amount of activity that has been undertaken in the last week, will specialist advice on steps taken, active minutes each day, how much device has been worn and tailored advice on how to improve activity levels
45794678|NCT03848871|Drug|Enstilar|Enstilar foam applied to affected area once daily
45794679|NCT04032327|Drug|Exparel plus plain bupivacaine|10 mL of extended release liposomal bupivacaine (Exparel) plus 10 mL of 0.25% plain bupivacaine mixed to be injected vaginally prior to the start of posterior colporrhaphy
45794680|NCT04032327|Drug|Bupivacaine|20 mL of 0.25% plain bupivacaine to be injected vaginally prior to the start of posterior colporrhaphy
45794681|NCT04041219|Drug|Tacrolimus|Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), initially administered sublingually for four consecutive doses.
45794682|NCT04041219|Drug|Tacrolimus|Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), oral administration after sublingual four consecutive doses
45794683|NCT04037865|Drug|PF-06651600|PF-06651600 50 mg oral tablets will be administered on Days 1 to 10
45794684|NCT03847233|Device|Jetstream Atherectomy System|A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
45794685|NCT00552344|Biological|Cimzia|"Active substance: Certolizumab Pegol~Pharmaceutical form:first reconstituted, lyophilized powder formulation of CZP and after implementation of Amendment 2 (after 401 subjects were enrolled) prefilled syringe~Concentration: 200 mg/ml~Route of Administration: Subcutaneous use"
45794686|NCT02814968|Drug|Enzalutamide|
45794687|NCT02814968|Device|18-FDG PET/CT|
45794688|NCT02814968|Device|Whole body MRI|
45794689|NCT02814968|Device|Bone scan|
45794690|NCT05566964|Device|ME&MGopen smartphone application|Smartphone application includes digital tests and e-questionnaires
45794691|NCT03879603|Biological|VRC-WEVVLP073-00-VP|VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)
45794692|NCT03879603|Other|VRC-GENMIX083-AL-VP|VRC-GENMIX083-AL-VP is an adjuvant
45794693|NCT00553514|Drug|AS900672-Enriched 10 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone [r-hFSH]), 10 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
45794694|NCT00553514|Drug|AS900672-Enriched 20 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 20 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
45794695|NCT00553514|Drug|AS900672-Enriched 30 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 30 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
45794696|NCT00553514|Drug|AS900672-Enriched 40 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 40 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
45921359|NCT00111553|Biological|Leish-111f + MPL-SE vaccine|
45648476|NCT02807779|Device|Drug coated balloon|Participants will receive angioplasty with a drug-coated balloon following plain balloon angioplasty
45648477|NCT02807779|Device|Plain balloon angioplasty|Participants will receive plain balloon angioplasty only
45648478|NCT03057197|Procedure|new caudal injection technique|new caudal injection technique is applied to the Group B, which is that the needle only penetrates the sacrococcygeal ligament without being inserted into the sacral canal
45794697|NCT00553514|Drug|Follitropin alfa 75 international unit (IU)|Follitropin alfa (Gonal-f®) 75 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 14 (S14) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 10, 20, 30 and 40 mcg will also receive daily dose of follitropin alfa 75 IU subcutaneously from Stimulation Day 7 (S7) up to S14. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
45794698|NCT00553514|Drug|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, less than or equal to [=<] 3 follicles with a mean diameter of greater than or equal to [>=] 14 millimeter [mm], and one or two of these follicles with a diameter of >= 17 mm).
45648479|NCT05406531|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
45648480|NCT05406531|Behavioral|Positive Psychology - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
45648481|NCT05406531|Behavioral|Autogenic Training - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
45648482|NCT02769091|Drug|TEV-45478|80 mg (2x40mg) tablets once daily for up to 24 weeks
45794699|NCT03878745|Device|Terumo Nanopass® 34G pen needle|Insulin pen needle
45794700|NCT03878745|Device|BD Nano™ PRO 32G pen needle|Insulin pen needle
45794701|NCT00553436|Device|Tissue Apposition System (TAS) Device|Closure of defect following polypectomy using the Tissue Apposition System (TAS) Device.
45794702|NCT04034121|Device|DESolve Cx drug eluting coronary scaffold system|percutaneous coronary intervention
45794703|NCT02813642|Biological|Plasma osteoprotegerin level|dosage of plasma osteoprotegerin
45794704|NCT02813642|Biological|Plasma fibroblast growth factor 23 level|dosage of plasma fibroblast growth factor 23
45794705|NCT02813642|Procedure|Vascular calcification score|measurement of vascular calcification score by X-ray of the lateral abdominal aorta
45794706|NCT04714203|Other|sarcopenia assessment|evaluation of sarcopenia status
45794707|NCT02542514|Drug|Ibrutinib|p.o. 560 mg once a day (four 140 mg capsules) for one year (12 cycles of 28 days)
45794708|NCT04026399|Other|peripheral vibration stimulation|wearing a wristband that delivers imperceptible vibratory stimulation.
45794709|NCT04026399|Behavioral|therapy|practice of daily living tasks
45794710|NCT03852537|Drug|Methylprednisolone|Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.
45794711|NCT03852537|Other|Usual Care|Usual care as determined by the patients treatment team.
45794712|NCT03875859|Drug|Remetinostat|Topical 1% remetinostat gel
45794713|NCT00553202|Biological|anti-thymocyte globulin|Given IV
45794714|NCT00553202|Drug|busulfan|Given IV
45794715|NCT00553202|Drug|cyclophosphamide|Given IV
45794716|NCT00553202|Drug|cyclosporine|Given IV or orally
45794717|NCT00553202|Drug|methotrexate|Given IV
45648483|NCT02769091|Drug|Placebo|
45648484|NCT04912193|Drug|Antithrombin III|In liver transplant recipients with baseline antithrombin III levels lower than 50%, exogenous Antithrombin III was administrated during the anhepatic phase of the liver transplant surgery.
45794718|NCT00553202|Drug|methylprednisolone|Given IV
45794719|NCT00553202|Drug|tacrolimus|Given IV
45794720|NCT00553202|Other|laboratory biomarker analysis|Correlative studies
45794721|NCT00553202|Other|pharmacological study|Correlative studies
45449867|NCT01067495|Behavioral|Cardiac rehabilitation|Participants will participate in a 6-month cardiac rehabilitation exercise program. This program will include aerobic and resistance training, and education sessions on risk factor management.
45794722|NCT00553202|Procedure|allogeneic bone marrow transplantation|allogeneic bone marrow transplantation
45921360|NCT00111592|Procedure|current usual care|current usual care
45921361|NCT00111592|Procedure|treatment protocol with clear indications for therapy|treatment protocol with clear indications for therapy
45648485|NCT02680561|Drug|Fluticasone Propionate MDPI|
45648486|NCT02680561|Drug|Fluticasone Propionate/Salmeterol MDPI|
45648487|NCT02680561|Drug|Fluticasone propionate/salmeterol|
45648488|NCT02532543|Biological|Allograft, Membrane|Allograft, Membrane- Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
45648489|NCT02532543|Biological|Alloplast, Membrane|Alloplast, Membrane- Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
45648490|NCT02532543|Biological|Xenograft, Membrane|Xenograft, Membrane- OsteoGraf/N-300,Symbios OsteoShield Collagen Resorbable Membrane
45794723|NCT00553202|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic SCT
45794724|NCT04133415|Radiation|Lattice stereotactic body radiation therapy|-As long as radiotherapy fields do not overlap, treatment of up to 4 other tumor sites are allowed
45794725|NCT04133415|Procedure|Peripheral blood|-Before treatment, immediately after radiotherapy completion, 14 days after radiotherapy, and 30 days after radiotherapy
45794726|NCT02989142|Behavioral|INTER-ACT|"Pre-conception coaching sessions: We encourage less motivated women to participate to the trial by collaborating with Kind & Gezin from the very beginning, as most timepoints of the counselling sessions coincide with the time points of the Kind&Gezin vaccine scheme (postpartum week 6, week 8, week 12, 6 months). We will organize the coaching in a mother and baby friendly community-based setting or in the hospitals, as preferred by the mothers.~Pregnancy coaching sessions: take place in hospital, at the time of the three planned ultrasound scans.~By consequence, the applied methodology can be applied as such at the moment of global utilisation in Flanders."
45794727|NCT04016259|Device|Cranial Electrical Stimulation (CES)|CES will be applied for 60 minutes per session daily for 2 weeks (Monday to Friday) via the Alpha-Stim M Electromedical Products International, Inc., Mineral Wells, TX).
45794728|NCT04016259|Device|Sham-CES|For sham CES, the electrodes will be identical look and be placed in the same positions as for active stimulation, but the stimulator will not deliver electrical current.
45794729|NCT03874377|Behavioral|Mindfulness|Mindfulness refers to the experience of paying attention to the present moment in a nonjudgmental manner. The mindfulness intervention consists of 6 weekly sessions focused on: experiential mindfulness exercises, such as mindful eating, loving kindness practices, breath awareness, and mindful movement; hunger and satiety awareness; improving responses to emotions; practicing acceptance and being non-judgmental; and tolerating negative feelings and sensations, including those related to hunger and cravings. Participants will be assigned brief homework exercises (approximately 10 minutes) daily in between appointments.
45921362|NCT00111631|Drug|DPP-IV Inhibitor|Escalating doses po bid
45794730|NCT03874377|Behavioral|Usual Care|Participants will receive the recommended standard of medical management of overweight and obesity. The clinic team conducts a comprehensive evaluation of the patient to assess dietary and activity behavior change needs of each patient and family, as well as obesity-associated comorbidities. In addition to management of comorbidities, goals for improved physical activity and dietary behaviors are set with the patient and family at each visit.
45794731|NCT00552188|Drug|VIA-2291|100 mg, oral dosing, 1 time daily for 24 weeks
45449868|NCT03722043|Behavioral|Parenting Program|Parents will participate in a 5-week parenting program designed to uniquely work with veteran families. The program will target the following areas: mindful parenting strategies, emotional regulation, positive discipline, positive parenting/attachment, and sleep.
45648491|NCT02532543|Biological|Membrane|Membrane - Symbios OsteoShield Collagen Resorbable Membrane
45648492|NCT03057353|Device|lumbar CT imaging|Collecting lumbar CT imaging data of 104 patients with lumbar spinal stenosis to observed the incidence of ligamentum flavum hypertrophy of patients with different nationalities, sexes, heights, ages, and weights and explored risk factors affecting ligamentum flavum hypertrophy.
45794732|NCT00552188|Drug|Placebo|oral dosing, 1 time daily for 24 weeks
45794733|NCT05546294|Device|Aerobic and home exercise|"A total of 20 sessions of aerobic exercises using bicycle ergometer, five times a week and once a day for four weeks, were applied to the patients.Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor will be used to follow subjects' heart rate during aerobic exercise.~Then the patients were showed a daily home exercise program to apply once a day at their home.~As a daily home exercise program:ROM exercises and strengthening exercises for major muscle groups (such as abdominal muscles, erector spinae, hamstring, quadriceps, hip flexors, strengthening exercises for all extremities) were showed.~At the beginning of the treatment and at the end of the treatment (4th week), serum BDNF and irisin levels will be tested using the ELISA kit, with blood samples taken from the RA patients in the early morning."
45794734|NCT05546294|Other|Home exercise|"The patients were showed only a daily home exercise program to apply once a day at their home.~As a daily home exercise program:ROM exercises and strengthening exercises for major muscle groups (such as abdominal muscles, erector spinae, hamstring, quadriceps, hip flexors, strengthening exercises for all extremities) were showed.~At the beginning of the treatment and at the end of the treatment (4th week), serum BDNF and irisin levels will be tested using the ELISA kit, with blood samples taken from the RA patients in the early morning."
45794735|NCT05546294|Other|Healthy control group|Serum BDNF and irisin levels will be tested using the ELISA kit, with blood samples taken only once from healthy control group in the early morning. It will be checked whether there is a difference between the basal serum BDNF and irisin levels of rheumatoid arthritis patients and healthy control group.
45794736|NCT00377793|Drug|Levitra (Vardenafil, BAY38-9456)|
45794737|NCT00377793|Drug|Placebo|
45794738|NCT04027803|Biological|BCD-148|single intravenous infusion of BCD-148 (900 mg)
45794739|NCT04027803|Biological|Soliris|single intravenous infusion of Soliris (900 mg)
45794740|NCT00552110|Drug|OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)|MFNS 2 sprays per nostril with OXY 1 spray per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening (PM).
45794741|NCT00552110|Drug|OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)|MFNS 2 sprays per nostril with OXY 3 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening.
45794742|NCT00552110|Drug|mometasone furoate nasal spray (MFNS) once daily|MFNS 2 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every morning (AM) and every evening.
45794743|NCT00552110|Drug|oxymetazoline nasal spray (OXY) twice daily|OXY 2 sprays per nostril twice daily x 2 weeks. Matching placebo to MFNS given every morning.
45794744|NCT00552110|Drug|Placebo|Matching placebo to MFNS given every morning and every evening x 2 weeks.
45794745|NCT05313789|Device|Analgesia Nociception Index (ANI)|Monitorization of Analgesia Nociception Index in Intensive Care Patients
45449869|NCT03721887|Device|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
45449870|NCT00111839|Drug|Pemetrexed|Pemetrexed will be administered IV until PD or the occurrence of unacceptable toxicity.
45921363|NCT00111631|Drug|Metformin|As prescribed
45921364|NCT00111631|Drug|Placebo|po bid
45921365|NCT00111670|Drug|DPP-IV Inhibitor|Escalating doses po bid or qd
45921366|NCT00111670|Drug|Placebo|po bid or qd
45648493|NCT03054389|Other|Qualitative Interview - Participants/ Patients|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Participants/ Patients
45648494|NCT03054389|Other|Qualitative Interview - Investigators and Study Coordinators|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Investigators and Study Coordinators
45648495|NCT05118373|Behavioral|BEHAVIOURAL CHANGE CAMPAIGN FOR COVID-19 PREVENTION IN ZAMBIA|The intervention is a mass media campaign using TV, radio, billboard and posters to disseminate the message. The content are well-produced videos and pictures emphasising the need to wash hands, wear a mask, maintain social distance and clean surfaces. The English version of the video can be viewed at this link: https://youtu.be/tcjaLAxy4Ms.
45794746|NCT02051972|Device|Implanted with a Nanostim leadless pacemaker system|
45794747|NCT03854253|Procedure|Long introducer sheath|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using introducer sheath 6Fr-25cm
45794748|NCT03854253|Procedure|Short introducer sheath|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using introducer sheath 6Fr-10cm
45794749|NCT02301624|Biological|Eculizumab|Intravenous administration of eculizumab.
45648496|NCT03057275|Device|Abdominal fetal/maternal monitoring|A single patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
45794750|NCT02301624|Drug|Placebo|Intravenous administration of matching placebo. Participants received placebo only during the Blind Induction Phase.
45794751|NCT02007122|Other|Ceftaroline in CRRT|Plasma levels of ceftaroline will be measured in patients receiving CRRT
45794752|NCT02007122|Other|Ceftaroline in IRRT|Ceftaroline plasma levels will be measured in patients receiving intermittent renal replacement therapy
45794753|NCT03860181|Procedure|Subcuticular Sutures - Surgeon 1|This intervention closes incisions after shoulder arthroplasty using subcuticular sutures with Dermabond.The deep layer closure will require interrupted sutures.
45794754|NCT03860181|Procedure|Metal Staples - Surgeon 2|This intervention closes incisions after shoulder arthroplasty with metal staples. The deep layer closure will require interrupted sutures,
45794755|NCT03860181|Device|PRINEO - Surgeon 1|The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.
45794756|NCT03860181|Device|PRINEO - Surgeon 2|The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.
45794757|NCT03026582|Device|Intestinal ultra-sound monitoring|Children diagnosed with either CD or UC will be enrolled at diagnosis or at any time point during follow-up. Patients' characteristics will be retrieved from their medical files including demographic details, disease phenotype, endoscopic and radiologic variables, anthropometric measures, laboratory evaluation, complication and therapeutic regimens. At enrollment and every 3 months for a total period of 2 years all patients will perform intestinal US during regular clinic visits. All other measures including laboratory exams, anthropometric measurements and disease activity indices (either PCDAI for CD or PUCAI for UC) will be performed as part of standard of care.
45794758|NCT03250520|Drug|Platinum acetylacetonate (1% wt) supported by sol-gel technology functionalized titania|Sol-gel process Pt(acac)2- F-TiO2 nanostructured material with antitumoral activity used as an alternative in the treatment of cancer tumors. The biocatalysts were prepared by the sol-gel route using the complex Pt(acac)2.
45794759|NCT03865329|Behavioral|Intervention- Home-based Pulmonary Rehabilitation|Home-based Pulmonary Rehabilitation (PR) with health coaching using a remote system that will allow patients to complete PR at home. The program involves upper and lower extremity exercises, self-report of symptoms (fatigue, breathlessness, physical activity and overall well-being).
45794760|NCT02301546|Behavioral|computerized cognitive exercises|Each group will perform computerized cognitive exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks. The experimental group will use exercises shown to improve cognition, whereas the comparator group will use exercises without clear beneficial findings.
45794761|NCT02988284|Other|No intervention|
45794762|NCT04350554|Other|Pregnancy|To measure and characterize pregnancies and describe the clinical course during pregnancy
45794763|NCT04350554|Other|Pregnancy|To evaluate attitudes towards pregnancy (ie. planned pregnancy) and social support among women who become pregnant during the year 2020
45794764|NCT03847389|Drug|Clobetasol propionate 0.05% Topical Oil|thin film application of the oil twice daily
45794765|NCT02351934|Drug|Furosemide|
45794766|NCT02351934|Drug|Celecoxib|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain or inflammation.
45794767|NCT02351934|Drug|Gabapentin|Gabapentin is a oral drug used to treat seizures, postherpetic neuralgia, and restless legs syndrome.
45794768|NCT00377481|Drug|darbepoetin alfa|30 micrograms sc weekly (2 doses)
45794769|NCT00377481|Drug|epoetin beta [NeoRecormon]|6000 IU sc weekly (2 doses)
45794770|NCT00377559|Drug|Non pegylated liposomal doxorubicin and docetaxel|max. 6 courses
45794771|NCT04834778|Drug|HC-5404-FU|HC 5404-FU (hemi fumarate salt of HC 5404) is a novel, highly selective, and potent PERK inhibitor. Preclinical pharmacological studies demonstrated high specificity of HC 5404-FU to PERK and decreased viability of tumor cells. HC 5404-FU will be orally administered BID every day with food or within 30 minutes of completing a meal, starting at 25 mg, with doses escalating to 50, 100, 200, 400, 600, and 900 mg BID as safety allows for each 3-week treatment cycle.
45794772|NCT02987894|Device|ACURATE neo™ Aortic Bioprosthesis|TAVI, transcatheter aortic valve replacement. Transfemoral access.
45794773|NCT04280445|Other|Psychological therapy|Acceptance and Commitment Therapy (ACT) is a trans-diagnostic approach which aims to promote better living by supporting clients through six key processes (e.g. mindfulness, values). ACT does not aim to reduce distress, rather its goal is to promote better living or a better quality of life despite distress (Hayes, Strosahl & Wilson, 1999). ACT has been shown to have equal or superior efficacy to CBT with a number of psychological and physical health conditions (A-Tjak et al., 2015; Ruiz, 2012).
45794774|NCT04811924|Drug|Application of 0.02% MMC over 60 seconds post corneal crosslinking.|Topical application of 0.02% MMC on the surface of the cornea post CXL. The surface of the eye is washed thoroughly with Balanced Salt Solution (BSS) over 1 minute after MMC application.
45794775|NCT04811924|Drug|Corneal crosslinking without the application of 0.02% MMC|Topical application of placebo on the surface of the cornea post CXL. The surface of the eye is washed thoroughly with Balanced Salt Solution (BSS) over 1 minute after placebo application.
46071722|NCT05602467|Other|Treatment as usual (TAU)|Treatment-as-usual (TAU) in the Hong Kong outpatient clinic without TPS intervention was given. They would receive the standard care for mild NCD including counselling, lifestyle modification, cognitive training and antidementia medications occasionally depending on the case doctor's judgement.
46071723|NCT02836314|Other|Anorganic Bovine Bone Mineral (ABBM)|In the control group, periodontal intrabony defects were treated with ABBM alone.
45648497|NCT05116111|Drug|SYHA1402 tablets|SYHA1402 tablets, oral, twice daily
45648498|NCT05116111|Drug|Placebo|Placebo, oral, twice daily
45648499|NCT04929977|Device|Wearable device with smart mobile phone|The wearable device will act as a sensor designed to identify critical parameters such as Kangaroo Mother Care adherence and temperature of the infant 24/7 and of the mother-infant pairs during these sessions.
45754360|NCT05582876|Radiation|Radiopharmaceutical 68Ga-PSMA-11 PET/CT|The radiopharmaceutical will be administered intravenously in doses with an activity of 1.8-2.2 MBq / kg b.w.
45921367|NCT00111748|Drug|Velcade, Thalidomide, Dexamethasone|"Dosage and Administration Schedule Each cycle will consist of 3 weeks (21 days). AGENT DOSE ROUTE DAYS Velcade 1.0 mg/m2 IV 1, 4, 8, and 11 Thalidomide 100 mg PO Daily, hs Dexamethasone 20 mg PO Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg SQ Days 1-14~This 21-day period will be considered one treatment cycle; Cycle 2 would commence on Day 22 (Cycle 2, Day 1). The next cycle of treatment may be delayed up to day 29 due to non-toxicity reasons. Patients may continue to receive treatment every 21 days, provided there is no evidence of disease progression or no unacceptable toxicity for a maximum of eight cycles. At the discretion of the treating physician, patients may be eligible to receive treatment at their local physician after completion of the 1st cycle. These patients will need to return to MIRT prior to every cycle for cycles 2-4, cycles 6 and 8, and final visit."
45921368|NCT00111787|Drug|Lapatinib|Daily-monotherapy [1500 milligrams (mg)] for 14 days, then daily combination therapy (with weekly paclitaxel) for 12 weeks
45794776|NCT04321239|Behavioral|Positive STEPS|Individuals in the intervention group will meet with a community health worker at an in-person or virtual study orientation session. At this session, they will be introduced to the program, learn how to use the online modules and any associated materials, and choose a day and time for future weekly telephone sessions. Participants will also be given a wearable physical activity tracker at the orientation session to use throughout the course of the program. They can choose to report daily step counts either by automatically syncing to an app or by manual reporting via text message. The program will be delivered over 6 weeks. Each week participants will complete a web-based module and have one telephone session with the community health worker to discuss that module and to set a related goal. Participants will also set weekly goals related to walking, which will be informed and tracked by daily step-counts from the physical activity tracker.
45794777|NCT03218163|Drug|MEDI-551 Maintenance|Cycle 1 - Days 1, 8, 15, and 22: 4mg/kg IV Cycles 2-12 - Day 1: 4mg/kg IV
45794778|NCT03026348|Biological|RSV F Vaccine with Aluminum Phosphate Adjuvant|
45794779|NCT03026348|Biological|RSV F Vaccine|
45794780|NCT03026348|Biological|Matrix-M1 Adjuvant|
45794781|NCT03026348|Other|Phosphate Buffer|
45794782|NCT00377871|Device|biological heart valve prosthesis|Two heart valve designs
45648500|NCT05095051|Device|Paxman Cryocompression System (PCCS)|"Establishing optimal temperature and pressure for limb cryocompression therapy. Healthy subjects will undergo 3 hours of limb cryocompression.~The cryocompression device used in this study consists of a control unit, and limb wraps. The control unit contains the coolant reservoir and pump to circulate the coolant and air for compression. It is able to thermoregulate (control the temperature of the circulating coolant) and offer cyclic air pressure in the wraps. The wraps cover the limbs from the elbow/knee to the fingers/toes."
45794783|NCT03195465|Dietary Supplement|Dark Chocolate|Dark Chocolate bars with 70% cacao and 30% organic cane sugar where 4 squares of the dark chocolate will be administered twice daily between the hours of 6 a.m. and 6 p.m. daily for four weeks.
45794784|NCT04763408|Drug|Lenvatinib|Oral capsules.
45794785|NCT04763408|Drug|Sorafenib|Oral tablets.
45794786|NCT03165747|Drug|VSL#3|8 strains of live bacteria: Bifidobacterium breve, B. longum, B. infantis, L. acidophilus, L. plantarum, L. paracasei, L. bulgaricus and Streptococcus thermophilus. 900 billion CFU taken orally daily in a single administration.
45794787|NCT03165747|Other|Placebo|Two placebo sachets taken orally daily in a single administration.
45449871|NCT00111839|Drug|Matuzumab|Matuzumab will be administered IV until PD or the occurrence of unacceptable toxicity.
45754361|NCT03586700|Drug|Xiao zhong fang granules|Chinese medicine Xiao zhong fang was Professor Sun Chengxiang's experience formula in Massage Department of Dongzhimen Hospital. The function of the formula is to activate blood circulation and dredge collaterals, tonifying kidney and promoting dampness to soothe the liver and nourish tendons.
45794788|NCT03100617|Behavioral|Psychosocial caregiver intervention|Modified version of the REACH-VA intervention for family caregivers of persons with dementia. The intervention has several components including 1) caregiver education, 2) risk assessment, 3) caregiver needs assessment, 4) caregiver skill building and problem solving, and 4) caregiver stress reduction.
45794789|NCT02351856|Drug|ARRY-371797, p38 inhibitor, oral|multiple dose, single schedule
45794790|NCT03850275|Dietary Supplement|Intervention/treatment|Subjects received all 3 interventions Placebo ~3mg caffeine Caffeinated placebo ~100mg caffeine E+shots- The 4oz adaptogen-rich (E+shots) was E+ Shots (Isagenix International, LLC) containing approximately 90mg caffeine from green tea Camellia sinesis leaf extract (50%) and yerba maté extract (25%) along with a proprietary blend of adaptogenic herbs, including: eleutherococcus senticosus, crateagus oxycantha, rhodiola rosea and Schisandra chinensis.
45794791|NCT02349360|Biological|L. johnsonii N6.2|L. johnsonii N6.2 10^10 CFU in capsule form administered for 8 weeks
46071724|NCT02836314|Other|Anorganic Bovine Bone Mineral and Platelet Rich Fibrin (PRF)|In the test group, periodontal intrabony defects were treated with ABBM and PRF combination.
45449872|NCT03723291|Combination Product|Arm B: A combination of pentoxifylline and tocopherol acetate in addition to best standard care [a structured programme of rehabilitation exercises] for 6 months|• Arm B: A combination of pentoxifylline 800 mg/d in two 400-mg tablets and 1,000 IU/d of tocopherol acetate in two 500-IU aliquots in addition to best standard care [a structured programme of rehabilitation exercises] for 6 months
45794792|NCT02349360|Biological|Placebo|Encapsulated starch placebo administered for 8 weeks
45794793|NCT03825939|Drug|Intravenous Placebo|IV 0.9% sterile saline
45794794|NCT03825939|Drug|Intravenous Tranexamic Acid|1g TXA IVPB (intravenous piggyback)
45794795|NCT03988647|Drug|Pembrolizumab|Pembrolizumab administered at 200 mg IV every 3 weeks
45921369|NCT00111787|Drug|Paclitaxel|Weekly (80mg/m^2) combination therapy (with daily Lapatinib) for 12 weeks
45921370|NCT00111826|Device|Celacade™ system|
45921371|NCT00007280|Device|Bioengineered skin|
45794796|NCT03988647|Radiation|Radiation Therapy|9 Gy X 3 (27 Gy in 3 fractions), or 4-6 Gy X 5 (20-30 Gy in 5 fractions).
45794797|NCT00551642|Drug|Nitric oxide|Nitric Oxide vapour (gas) for inhalation (400 ppm)
45648501|NCT05095051|Device|Paxman Cryocompression System (PCCS)|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Limb cryocompression sessions comprised of a pre-cooling period (up to one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, limb cryocompression will be administered for no longer than four hours."
45794798|NCT00551642|Drug|Placebo|Placebo gas for inhalation
45794799|NCT03836859|Drug|rhNGF 20μg/mL|"Study Eye (For subjects randomized to rhNGF group) Day 1: One drop instilled into study eye (35 μL, corresponding to 0.70 μg of rhNGF).~Day 2, 3, 4, 5, 6: One drop six times a day (every 2h) into study eye (210 μL, corresponding to 4.20 μg of rhNGF).~Total dose in the study eye will be 31 drops (1085 μL, equivalent to 21.7 μg rhNGF) over 6 days."
45794800|NCT03836859|Other|Placebo|Vehicle: formulation containing L-methionine as excipient.
45794801|NCT02799212|Drug|somatostatin infusion|postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day.
45794802|NCT02799212|Drug|placebo infusion|Placebo infusion (50ml of 0.9% NaCl/day) during 6 days.
45794803|NCT02989064|Genetic|Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells|Infusion of autologous genetically modified MAGE A10ᶜ⁷⁹⁶T on Day 1
45794804|NCT03040323|Drug|Lumason 60.7Mg Powder for Injection|Lumason 60.7Mg Powder for Injection injected prior to ultrasound-guided biopsy
45794805|NCT03040323|Drug|Placebos|Placebos injected prior to ultrasound-guided biopsy
45794806|NCT04690322|Drug|Eloctate|Eloctate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.
45794807|NCT04690322|Drug|Adynovate|Adynovate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.
45794808|NCT04690322|Drug|Emicizumab|Emicizumab is FDA-approved to treat patients with Hemophilia A. This drug will be used for non-factor VIII-based replacement therapy.
45794809|NCT05313399|Device|Palatal Crib|An intraoral appliance approach can be used as an adjunct method to stop the habit. Appliances consisting of cribs in the anterior region are very efficient as reminders and physical restrainers. The palatal crib works as an obstacle in non-nutritive sucking and maintains the tongue in a more retruded position, halting its interposition between the incisors.
45794810|NCT05313399|Device|bonded spur|Spur appliances change tongue action, close the open bite, and boost treatment stability, as it induces a permanent modification of the tongue's anterior rest posture by altering orofacial function, resulting in a change in form. Finally, the spur adjusts the sensory input to the brain. This proprioceptive change leads to an altered motor response, resulting in a new normal tongue rest posture (change in function) that allows the incisors to erupt
45794811|NCT03036735|Device|steroid eluting spacer|The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer.
45794812|NCT02648282|Drug|Cyclophosphamide|200 mg/m2 is to be administered as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg/m2 as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 6 months for an additional 4 doses.
45648502|NCT05597631|Device|G-IVF PLUS|Experimental
45648503|NCT04912037|Device|artificial intelligence assistance system|the artificial intelligence assistance system can indicate abnormal lesions and real-time withdrawal speed, and feedback the overspeed percentage.
45754362|NCT03586700|Radiation|Short wave infrared radiation|Short waves infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
45794813|NCT02648282|Drug|GVAX Pancreatic Cancer Vaccine|2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells is to be administered one day after CY and pembrolizumab for a total of 8 doses. In the extended treatment phase, eligible patients may receive 2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells administered one day after CY every 6 months for an additional 4 doses.
45794814|NCT02648282|Drug|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion one day prior to the GVAX pancreas vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg as a 30 minute IV infusion every 21 days for an additional 9 doses.
45794815|NCT02648282|Radiation|SBRT|Patients will receive SBRT (6.6 Gy for 5 days) with the second dose of combined immunotherapy (CY/Pembrolizumab/GVAX Pancreas Vaccine).
45794816|NCT04004481|Drug|Postoperative analgesia using tramadol|Tramadol 100 mg will be given to the patients in the postoperative period.
45794817|NCT05453162|Behavioral|Prolonged Exposure Therapy for Posttraumatic Stress Disorder|Manualized procedures deliver ten 90-minute sessions targeted to occur weekly and administered via tele-health with the same study therapist. Session 1 will focus on psychoeducation. Session 2 involves construction of the in vivo exposure hierarchy. Sessions 3-10 focus on in-session imaginal exposures to the worst trauma memory for 45-60 min followed by 15-20 min of processing the imaginal exposure. For homework, participants will be instructed to confront situations on their hierarchy on a daily basis using recording of their imaginal exposure. Subjective Units of Distress (SUDS) ratings will be taken throughout imaginal exposure exercises.
45794818|NCT03997851|Drug|Acetaminophen|Topical acetaminophen gel
45794819|NCT03997851|Drug|Carbomer 980|Topical vehicle gel
45794820|NCT03989427|Other|Brushing first and Flossing later (BF)|Participants will follow Brushing first and flossing later (BF) sequence for 2 weeks, and after 1 week wash out period, Flossing first and Brushing later (FB) sequence for another 2 weeks.
45754363|NCT03586700|Drug|Placebo Xiao zhong fang granules|Made of starch,dextrin and edible pigment from Dongzhimen Hospital of Beijing university of chinese medicine.
45648504|NCT05406297|Procedure|pressure-temperature sensor guidewire-based measurement|"In brief, a 6-F angioplasty guiding catheter without side-holes will be used first used to engage the left main coronary artery. A pressure-temperature sensor guidewire ( PressureWire™ X Guidewire) will be used for physiology measurements including IMR measurements.~Pressure measurement from the wire was first equalized with that of the guiding catheter. Then the pressure sensor will be positioned two-thirds of the way down the LAD artery. Intracoronary nitroglycerin will be administered (100 to 200 μg). Hyperemia will be induced with adenosine intracoronary injections."
45754364|NCT02275923|Device|Reveal LINQ™ Insertable Cardiac Monitor|Insertable cardiac monitor
45794821|NCT03989427|Other|Flossing first and Brushing later (FB)|Participants will follow Flossing first and Brushing later (FB) sequence for 2 weeks, and after 1 week wash out period, Brushing first and flossing later (BF) sequence for another 2 weeks.
45794822|NCT01970306|Device|MatriStem PSM|All esophageal anastomoses will be reinforced circumferentially with ACell MatriStem PSM.
45921372|NCT00111865|Behavioral|Aerobic Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 days/week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 80% of their VO2 reserve over the course of the intervention.
45794823|NCT03007719|Drug|Fluorine F 18 Ara-G|Given IV
45794824|NCT03007719|Procedure|Positron Emission Tomography|Undergo PET/MR imaging
45921373|NCT00111904|Drug|paclitaxel-loaded polymeric micelle|
45921374|NCT03409809|Behavioral|Training|Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide and facilitator support website.
46071725|NCT00703365|Drug|Sorafenib and Gemcitabine|Sorafenib 400 mg po bid daily and Gemcitabine IV 1,000 mg/m2 on day 1,8, 15 of a 28-day cycle (up to 6 cycles), then followed by Sorafenib 400 mg po bid daily maintenance until disease progression.
46071726|NCT00891774|Device|EVOLENCE®|Single injection of material into the mid-dermis of the wrinkle - Second 'touch-up' injection is permitted approximately 14-Days later if needed to achieve satisfactory results
46071727|NCT00703521|Biological|Rabies vaccine|1.0 mL IM day 0,7,28 and 1 year
45449873|NCT03723291|Procedure|• Arm A: Best standard of care only [a structured programme of rehabilitation exercises] for 6 months|Prophylactic swallowing exercises consist of strap muscle exercises, airway protection exercises and base of tongue exercises
45449874|NCT01080521|Procedure|Cognitive Assessment|Ancillary studies
45449875|NCT01080521|Other|Quality-of-Life Assessment|Ancillary studies
45449876|NCT00111761|Drug|Irinotecan|Part 1: 125 mg/m^2 IV infusion once a week on weeks 1 through 4 of each 6-week treatment cycle. Part 2: 180 mg/m^2 IV infusion every other week until disease progression or unable to tolerate.
45794825|NCT03007719|Procedure|Magnetic Resonance Imaging|Undergo PET/MR imaging
45794826|NCT02985801|Drug|Pancrelipase|Lipase 16,000 United States Pharmacopoeia (USP) units, protease 57,500 USP units, and amylase 60,500 USP units
45794827|NCT02985801|Drug|Placebo Oral Capsule|Placebo Oral Capsule
45794828|NCT03021746|Behavioral|Diabetes Self Management Support (DSMS)|
45794829|NCT02988362|Drug|HL068 16/10mg|Candesartan 16mg and Amlodipine 10mg
45794830|NCT02988362|Drug|Candesartan 16mg and Amlodipine 10mg|
45794831|NCT02988518|Behavioral|COGMED program|"Patient should connect on his computer at home, 5 times a week, for 5 weeks. Every day, the patient has to do 8 exercises for a total duration of 30 to 45 minutes.~In total, the patient will have to complete 25 sessions. The difficulty level of the proposed items adjust automatically to the patient's maximum capacity to compel him to provide a cognitive effort. A progression index assesses the progress made by the patient.~Every week, the investigator will call the patient for 10 minutes in order to gather the patient's feelings, his difficulties, provide some advice and encourage him.~The investigator will have to analyze the results of curves available for each event, as well as the patient's progress index."
45794832|NCT02988440|Drug|PDR001|PDR001 will be administered intravenously
45794833|NCT02988440|Drug|Sorafenib|Sorafenib is formulated as a tablet.
45921375|NCT03409809|Behavioral|Training and Technical Assistance|Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide, and facilitator support website, plus half-day implementation training to further define goals, needs, leadership structure and strategy for adoption and recruitment.
45921376|NCT03409809|Behavioral|Training, Tech. Assistance, Quality Assurance/Improvement|"Level of Support: As for Training and Technical Assistance arm, plus 1-year of technical assistance, coaching, and quality assurance to enhance skills for implementation and sustainability."
45449877|NCT00111761|Biological|Panitumumab|Intravenous (IV) infusions of panitumumab 2.5 mg/kg once a week delivered in 6-week cycles.
45921377|NCT00111943|Drug|1% tenofovir gel|
45921378|NCT00111982|Biological|Liatermin|Liatermin
45921379|NCT00401596|Drug|Xolair (omalizumab)|
45921380|NCT03404505|Behavioral|Infant Achievements|Play-based intervention for caregivers and infants. The efficacy of the Infant Achievements intervention for improving communication and social behavior in infants who are at risk for communication, social, or developmental delay.
46071728|NCT05878899|Drug|Enoxaparin|Prophylactic dose of enoxaparin once daily for 10 days after delivery.
46071729|NCT05878886|Dietary Supplement|Emergency Food Product|Each subjects of treatment group consumed 50 g food bar during 15 days. Monitoring of compliance undertaken by home visit to recall daily food consumption three days a week and to record the food bar stocks at home during study, and also weekly weight measurement.
46071730|NCT05878873|Behavioral|Split-belt Treadmill|Split-belt treadmill training, where the speed of each leg is controlled independently has been shown to create gait adaptation where the coordination of each leg is altered, creating improved gait symmetry for people with walking impairments.
45449878|NCT00111761|Drug|5-Fluorouracil|Part 1: IV bolus 500 mg/m^2 on weeks 1 through 4 of each 6-week cycle. Part 2: IV bolus 400 mg/m^2 and infusional 2400-3000 mg/m^2 over 46 hours once every other week until disease progression or unable to tolerate.
45449879|NCT00111761|Drug|Leucovorin|Part 1: IV bolus 20 mg/m^2 on weeks 1 through 4 of each 6-week cycle. Part 2: 400 mg/m^2 every other week until disease progression or unable to tolerate.
45449880|NCT03519867|Drug|MK-8616|MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion. Doses are based on actual body weight.
45648505|NCT04824469|Other|intervention group|web based training: By establishing a website, training on drug use, symptom management and quality of life will be provided.
45648506|NCT04258059|Device|Active household UV water treatment device|This point-of-entry treatment device will use germicidal UV to treat all of the well water used in the home.
45648507|NCT04258059|Device|Inactive household UV water treatment device|This sham device will use a lamp not emitting germicidal UV.
45794834|NCT05405192|Drug|Dostarlimab|First four cycles of Dostarlimab will be given intravenously (IV) on day 1 of each of the 21-day cycle at a dose of 500 milligrams (mg). The next 16 cycles of Dostarlimab will be given on day 1 of each of the 42-day cycles at a dose of 1,000 mg.
45794835|NCT00550550|Drug|Placebo|Placebo sublingual tablet, once daily
45794836|NCT00550550|Biological|SCH 697243|Grass sublingual tablet, once daily
45794837|NCT00550550|Drug|Loratadine Syrup 1 mg/mL Rescue Treatment|Loratadine Syrup 1 mg/mL was dosed orally once daily at a dose of 5 mg for children aged 5 to <6 years of age and at a dose of 10 mg for children aged 6 to <18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
45794838|NCT00550550|Drug|Loratadine 10 mg Rescue Treatment|Loratadine 10 mg RediTabs tablets were dosed orally once daily at a dose of 10 mg for children aged 6 to <18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
45794839|NCT00550550|Drug|Olopatadine 0.1% Rescue Treatment|Olopatadine hydrochloride 0.1% ophthalmic solution was dosed intraocularly at a dose of 1 drop in each affected eye twice daily, in addition to loratadine, as rescue medication for participants with persistent eye symptoms due to rhinoconjunctivitis.
45921381|NCT03404505|Behavioral|Caregiver Education (CE)|Parents in the CE group will be taught about child development and well-being in their home, weekly, with a weekly follow-up phone call by trained research staff.
45921382|NCT00401635|Drug|liposomal doxorubicin|
45794840|NCT00550550|Drug|Mometasone furoate 50 mcg Rescue Treatment|Mometasone furoate monohydrate nasal spray 50 mcg was dosed intranasally at a dose of one spray in each nostril once daily for participants aged 5 to <12 years and a dose of 2 sprays in each nostril once daily for participants aged 12 to <18 years as rescue medication for nasal symptoms of rhinoconjunctivitis among participants with a total symptom score of ≥4 despite loratadine and mometasone furoate nasal spray.
45921383|NCT00401635|Drug|carboplatin|
45921384|NCT00401674|Drug|carboplatin|
45794841|NCT00550550|Drug|Albuterol 108 mcg Rescue Treatment|Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administered via inhalation at a dose of 2 inhalations every 4 to 6 hours as rescue medication among participants aged 5 to <18 years with asthma symptoms .
45794842|NCT00550550|Drug|Fluticasone 44 mcg Rescue Treatment|Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of 2 inhalations twice daily among participants aged 12 to <18 years up to a maximum dose of 10 inhalations twice daily, in combination with albuterol, among participants with ≥4 albuterol sulfate inhalations/day for 2 days as rescue medication for nocturnal asthma or shortness of breath.
45794843|NCT00550550|Drug|Prednisone 5 mg Rescue Treatment|Prednisone tablet 5 mg was administered orally at a dose of 1 mg/kg/day once daily up to a maximum of 50 mg/day on Day 1, and at a dose of 0.5 mg/kg/day once daily up to a maximum of 25 mg/day on Days 2, 3, 5, and 7 as rescue medication for asthma exacerbation at the discretion of the investigator.
45794844|NCT01590680|Radiation|I-131 MIBG|The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.
45794845|NCT02971839|Drug|VX-561|
45794846|NCT02971839|Drug|Placebo|
45794847|NCT02971839|Drug|IVA|
45794848|NCT03821259|Other|Psychological measures|Participants will be asked to provide basic demographic information and to complete five measures, screening for cognitive impermanent and measuring PTSD symptoms, lifetime trauma exposure, emotion regulation and group identification.
45921385|NCT00401674|Drug|paclitaxel|
45648508|NCT05406063|Radiation|SBRT|Stereotactic multiple fraction radiotherapy
45648509|NCT05037097|Biological|ARCT-165|Dose 3
45648510|NCT05037097|Biological|ARCT-154|Dose 2
45648511|NCT05037097|Biological|ARCT-021|Dose 1
45648512|NCT05025163|Drug|1.23% fluoride foam application|topical application of fluoride foam every 6 months
45921386|NCT00112021|Drug|pramlintide acetate|
45921387|NCT00007358|Drug|Dexamethasone or other corticosteroid|Administered during the third trimester of pregnancy
45921388|NCT00112060|Drug|PT-523 for Injection|
45921389|NCT03339492|Device|RCStim Model 1114|Active device emits PEMF signal; placebo/control device does not emit PEMF signal
45921390|NCT00112099|Procedure|Surgery: Splenectomy|Procedure/Surgery: Surgery: Splenectomy
45921391|NCT00112099|Procedure|Surgery: Spleen-preservation|Procedure/Surgery: Surgery: Spleen-preservation
45648513|NCT05025163|Drug|2.26% fluoride varnish application|topical application of fluoride varnish every 6 months
45648514|NCT02674321|Drug|SD-809|
45648515|NCT05070637|Procedure|No-touch laparoscopic radical nephrectomy|We aim to determine if a laparoscopic no-touch nephrectomy with an early renal pedicle ligation can decrease CTC release during surgery.
45754365|NCT02139007|Drug|Alendronate|
45754366|NCT03833115|Other|vaginal gel containing or not sodium lauryl sulfate|Prevention
45921392|NCT00112138|Drug|gabapentin|
45921393|NCT03330639|Other|Capsaicin|Capsaicin is a homeopathic medication and there for this drug is not subject to the requirements of the FDA.
45921394|NCT03330639|Other|Placebo|This group will receive the saline placebo solution.
45921395|NCT00007436|Drug|Tenofovir disoproxil fumarate|
45921396|NCT00112177|Drug|Itopride Hydrochloride|
45794849|NCT05376488|Other|One meal|One meal given to assess impact on ammonia levels serially
45794850|NCT03803085|Behavioral|Control condition|Participants in the control group only saw their own daily walking steps using the WeChat. They did not use WeChat to see other group members' daily steps and did not contact other group members. The participants were asked to use the app every day. A message (through WeChat) was sent to remind them to use the application if they had not done so within three days.
45794851|NCT03803085|Behavioral|Treatment condition|Participants in the experimental condition used WeChat for 4 weeks to see their own and other's walking steps and also were able to contact other group members. The participants were asked to use the application every day. A message (through the group chat) was sent to remind them to use the application if they have not done so within three days.
45794852|NCT02988206|Behavioral|Personalized Objects|personalized objects are based on the observation or the reports from family
45794853|NCT02988206|Behavioral|non-personalized Objects|non-personalized objects are based on the suggestion in CRS-R,which are comb and cup
45794854|NCT03022448|Other|No Intervention|This is a NIS. No intervention.
45794855|NCT00422877|Drug|Taxoprexin|DHA-paclitaxel
45794856|NCT04567706|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
45794857|NCT02974803|Drug|Dabrafenib|Dabrafenib 150 mg twice a day until progression or unaccepted toxicity.
45648516|NCT05070637|Procedure|Conventional laparoscopic radical nephrectomy|Conventional laparoscopic radical nephrectomy, which implies manipulation of the kidney, opening of the Gerota's fascia, and manipulation of peri-nephric fat during dissection, and renal pedicle isolation.
45648517|NCT05070637|Procedure|Laparoscopic total nephrectomy control arm|Control arm in which a laparoscopic total nephrectomy will be performed in non-cancer patients.
45921397|NCT00112216|Biological|Melan-A analog peptide|
45648518|NCT02532465|Device|Air-Q|
45794858|NCT02974803|Drug|Trametinib|Trametinib 2 mg once daily until progression or unaccepted toxicity.
45794859|NCT02281136|Drug|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
45921398|NCT00112216|Biological|FluMa peptide|
45921399|NCT00112216|Biological|Mage-A10 peptide|
45921400|NCT00112216|Biological|SB AS-2 adjuvant|
45921401|NCT00112216|Biological|Montanide adjuvant|
45921402|NCT00112255|Behavioral|Practice nurse-led partner notification|
45921403|NCT00112255|Behavioral|Referral to specialist genitourinary clinic|
45648519|NCT02532465|Device|i-gel|
45648520|NCT02665507|Device|GaAlAs 808nm laser|Hand held superpulsed GaAlAs 808 nm LLLI
45648521|NCT02665507|Device|Sham|Hand held laser that emits no LLLI
45648522|NCT02528331|Device|Transcranial magnetic stimulation|
45648523|NCT02528331|Behavioral|Cognitive behavioral therapy|
45921404|NCT00112333|Procedure|fMRI|A liquid meal (Ensure 1Kcal/cc) will be infused into the stomach via a nasogastric tube at a rate of 60cc/min till the subject reaches maximal satiety. The amount of liquid meal will differ per subject.
45648524|NCT02919241|Behavioral|Diagnostic interview|A profound interview to declare causes for negative thoughts, assumptions and beliefs towards dental care. Participants come from public and Private dental care.
45648525|NCT02919241|Behavioral|Combined interview and treatment.|Intervention for this group include both the diagnostic interview to declare causes for negative thoughts, assumptions and beliefs towards dental care and one session treatment. Participants come from the Institute of Dentistry.
45648526|NCT02592031|Drug|XM17|300 IU corresponds to an injection volume of 0.5 mL.
45648527|NCT02592031|Drug|Gonal-f®|300 IU corresponds to an injection volume of 0.5 mL.
45648528|NCT02592031|Drug|Zoladex®|3.6 mg
45794860|NCT02281136|Device|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
45794861|NCT02301156|Drug|Ublituximab|Administered as an IV infusion
45794862|NCT02301156|Drug|Ibrutinib|Administered orally
45794863|NCT03981939|Other|No intervention|This is an observational study, participants did not receive any intervention in this study and were only observed retrospectively.
45794864|NCT03830307|Device|NSS-2-Bridge|NSS-2-Bridge auricular therapy will be given in addition to standard of care
45794865|NCT04768712|Behavioral|Weight bearing aerobic exercise|Weight bearing aerobic exercise three times per week.
45794866|NCT04514276|Other|consecutive fetoneonatal healthcare pathway|(1) early perceiving of pregnant women with higher risks for early fetal growth restrictions via color Doppler sonography, fetal biometry, haemogram check (currently additional screenings) (2) structured care of the high risk women who are pregnant (3) concerted neonatal health care (4) adapted paediatric aftercare, certain dates and responsible persons are scheduled.
45794867|NCT03973905|Other|Not applicable / dataset analysis|Not applicable / dataset analysis
45794868|NCT02278484|Device|XprESS device and PathAssist confirmation tools|
45794869|NCT02900781|Device|Steprite™|Steprite™ Device shoe insert monitoring device
45794870|NCT02900781|Other|Standard of care|No Device. Standard of care physical therapy
45794871|NCT04350710|Other|PEEP trial|Measurement of Recruitment-to-Inflation Ratio
45794872|NCT03971721|Device|Wave 4.3|The Wave 4.3 mattress support is an insert, placed underneath the user's existing mattress, that when inflated increases the longitudinal incline of the mattress support, increasing in inclination in the direction of the head of the bed. The resulting mattress contours are such that the mattress has a lateral inclination of approximately 15 degrees in the head section and 10 degrees in the torso section. In addition to the features allowing the user to activate and deactivate creation of this Graduated Lateral RotationTM orientation, this device has sensors and monitoring system allowing for remotely monitoring the status of the system, including confirming that the supports are achieving the prescribed support angles, and that the system is working as planned.
45921405|NCT00112372|Drug|Ridaforolimus|10 mg tablet of ridaforolimus administered orally according to one of several different dosing regimens for a four-week treatment cycle.
45921406|NCT00112528|Biological|bevacizumab|
45921407|NCT00112528|Drug|gemcitabine hydrochloride|
45794873|NCT03979677|Behavioral|Lifestyle Modifications|Written suggestions on common migraine triggering food/beverages to avoid, restful sleep tips, exercise suggestions, and eating set mealtimes will be provided as the intervention.
45794874|NCT00558038|Drug|AST-120|AST-120
45648529|NCT05002231|Drug|Losmapimod 15 mg oral tablet|Subjects will receive one losmapimod 15 mg tablet by mouth under fasted conditions.
45648530|NCT05002231|Drug|Losmapimod two 7.5 mg oral tablets|Subjects will receive two losmapimod 7.5 mg tablets by mouth under fasted conditions.
45794875|NCT00558038|Drug|lactulose|lactulose
45794876|NCT01507233|Drug|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour.
45794877|NCT01507233|Drug|EXPAREL (bupivacaine liposome injectable suspension)|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac, a non-steroidal anti-inflammatory drug (NSAID), may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
45794878|NCT01517763|Device|Conventional CPAP Therapy|HC244 devices without Thermosmart or SensAwake
45794879|NCT01517763|Device|Fixed pressure ICON™ without ThermoSmart™|Fixed pressure CPAP therapy using ICON™ without ThermoSmart™ or SensAwake™
45794880|NCT01517763|Device|Auto ICON™ with SensAwake™ and ThermoSmart™|APAP therapy using Auto ICON™ with SensAwake™ and ThermoSmart™
45794881|NCT02301390|Drug|Amiodarone|Amiodarone is a Class III antiarrhythmic agent.
45794882|NCT02301390|Device|Catheter Ablation|The ablation procedure uses radiofrequency energy to destroy cardiac tissue at the origin of the arrhythmia.
45794883|NCT02278562|Drug|anakinra|100 mg in syringes; administered subcutaneously 3 times a week for 12 weeks (3 months)
45794884|NCT02278562|Drug|actos|30 mg capsules; administered orally 1 capsule per day for 12 weeks (3 months)
45794885|NCT02278562|Other|placebo|placebo capsules and injection
45794886|NCT01497171|Procedure|Elevate Mesh|Transvaginal mesh repair of anterior vaginal prolapse
45794887|NCT01497171|Procedure|Anterior Colporrhaphy|Traditional suture repair of anterior vaginal prolapse
45794888|NCT00378417|Biological|7-valent pneumococcal-CRM197 conjugate vaccine|
45449881|NCT03519867|Drug|Zemuron®|Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs. If needed, a maintenance dose of 0.15 mg/kg will be given. Doses are based on actual body weight.
45794889|NCT00378417|Biological|7-valent pneumococcal-OMPC conjugate vaccine|
45794890|NCT01487499|Drug|Cisplatin|40 mg in 40 mL of normal saline for each of 4 bronchoscopies
45794891|NCT01483209|Drug|Injection of botulinum toxin A|One-time injection of 100 units of botulinum toxin into hand to perform full chemical digital sympathectomy
45794892|NCT02281448|Drug|BIA 2-093|
45794893|NCT02281448|Drug|Contraceptives, Oral, Combined|
45794894|NCT00378729|Drug|Metformin and FSHr|treatment for infertility
45794895|NCT00378729|Procedure|Ovarian drilling by FERTILOSCOPY|surgical ovarian drilling
45794896|NCT00378495|Drug|Miltefosine: initially 2.5 mg/kg/day for 28 days|
45794897|NCT02281526|Drug|BIA 2-093|
45794898|NCT03802227|Drug|NKTR-181|A combination of NKTR-181 and oxycodone IR placebo
45794899|NCT03802227|Drug|Oxycodone IR|A combination of oxycodone IR and NKTR-181 placebo
45794900|NCT01879826|Device|Aculaser applied to kidney points|The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
45794901|NCT01879826|Device|Aculaser applied to sham points|"The patient will receive aculaser, performed by licensed acupuncturist, to sham acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure."
45794902|NCT01383681|Other|No treatment|There was no treatment in this study.
45794903|NCT04368728|Biological|BNT162b1|Intramuscular injection
45794904|NCT04368728|Biological|BNT162b2|Intramuscular injection
45794905|NCT04368728|Other|Placebo|Intramuscular injection
45794906|NCT04368728|Biological|BNT162b2SA|Intramuscular injection
45794907|NCT02749617|Drug|apixaban|2.5 mg PO BID
45449882|NCT01080599|Procedure|obturator nerve block|
45648531|NCT05002231|Drug|Losmapimod one 15 mg oral tablet|Subjects will receive one losmapimod 15 mg tablet by mouth under fed conditions.
45648532|NCT04423263|Procedure|Bilateral internal iliac artery balloon occlusion|Bilateral internal iliac artery balloon placement under fluoroscopic guidance preoperatively which will be occluded intraoperatively based on existing local protocol
45648533|NCT04423263|Procedure|Control|Surgical approach similar to intervention arm, except bilateral internal iliac artery occlusion
45648534|NCT02857543|Other|Plant-Based Diet|
45648535|NCT02857543|Other|American Heart Association Diet|
45648536|NCT02857543|Other|Mediterranean Diet|
45648537|NCT05377671|Diagnostic Test|IRM multimodale a ultra-haute camp|The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.
45648538|NCT04784299|Device|YVOIRE volume plus|Hyaluronic acid dermal filler
45648539|NCT04784299|Device|Restylane Lyft with Lidocaine|Hyaluronic acid dermal filler
45794908|NCT02749227|Drug|Pasireotide LAR|"Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use.~The starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained."
45794909|NCT02746263|Drug|IV acetaminophen|
45794910|NCT02746263|Drug|Oral acetaminophen|
45794911|NCT02746263|Drug|Morphine|Patient controlled analgesia
45794912|NCT01394211|Drug|anastrozole|Given PO
45794913|NCT01394211|Drug|pazopanib hydrochloride|Given PO
45794914|NCT01394211|Procedure|therapeutic conventional surgery|Undergo definitive surgery
45794915|NCT02278640|Device|Harmonic ACE®+7 Shears|Vessel/pedicle sealing performance assessed for transection and sealing of the of the uterine vasculature.
45794916|NCT02717949|Drug|sofosbuvir/ledipasvir|sofosbuvir ledipasvir fixed dose combination given once a day by mouth
45648540|NCT02765659|Behavioral|Mzake ndi Mzake T1|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after baseline
45794917|NCT02717949|Drug|sofosbuvir|sofosbuvir 400 mg given one a daily orally and weight-based ribavirin given twice a day orally
45794918|NCT02717949|Drug|Ribavirin|ribavirin 1200 mg given orally in divided dose for those >75kg and 1000 mg in divided dose for those <75 kg.
45794919|NCT02300610|Drug|Enzalutamide|Enzalutamide orally once a day. Dose Escalation Level 1: 80 mg; Level 2: 160 mg. Dose Expansion at recommended dose level, after dose escalation.
45794920|NCT02300610|Drug|Cisplatin|Cisplatin at 70 mg/m^2 IV on day 1, repeated every 21 days for total of 6 cycles.
45794921|NCT02300610|Drug|Gemcitabine|Gemcitabine at 1000 mg/m^2 IV on days 1, 8, repeated every 21 days for total of 6 cycles.
45794922|NCT01880840|Drug|205.5 mcg of azelastine hydrochloride|nasal spray
45794923|NCT01880840|Drug|137 mcg of azelastine hydrochloride|nasal spray
45794924|NCT03795753|Device|F2S Communicator|"The communicator will be attached to the BPAP/CPAP mask. The study coordinator will ENABLE the communicator. A list of single words and 5-word through 15-word sentences will be provided to the patient. Each single word may be read aloud up to two times. The partner must then select the read word out of a list of twelve possible words. Each sentence may be read aloud up to two times. The partner must transcribe each sentence on a standardized form. A survey will be provided to evaluate the mask on, communicator on period."
45794925|NCT03795753|Other|Non-functioning Communicator|"The communicator will be attached to the BPAP/CPAP mask. The study coordinator will DISABLE the communicator. A list of single words and 5-word through 15-word sentences will be provided to the patient. Each single word may be read aloud up to two times. The partner must then select the read word out of a list of twelve possible words. Each sentence may be read aloud up to two times. The partner must transcribe each sentence on a standardized form. A survey will be provided to evaluate the mask on, communicator on period."
45794926|NCT01377441|Drug|Ibuprofen|Patients will receive either 800mg IV ibuprofen or placebo pre-operatively. Post-operatively, patients will receive either 800mg IV ibuprofen or placebo 6 hours after the first dose.
45794927|NCT01377441|Drug|Placebo/Saline solution|Patients will receive placebo pre-operatively. Post-operatively, patients will receive placebo at least 6 hours after the initial dose.
45794928|NCT01882868|Drug|Aflibercept|Pharmaceutical form: Concentrated solution (100 mg/4 mL [25 mg/mL], 200 mg/8 mL [25 mg/mL]) for infusion; Route of administration: Intravenous
45921408|NCT00112528|Drug|oxaliplatin|
45921409|NCT02972190|Procedure|Bilateral decompression with TLIF|Bilateral decompression of neural elements combined with TLIF
45921410|NCT02972190|Procedure|laminectomy with PLIF|Decompression of neural elements using laminectomy combined with PLIF
45648541|NCT02765659|Behavioral|Mzake ndi Mzake T2|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T2 evaluation
45648542|NCT02765659|Behavioral|Mzake ndi Mzake T3|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T3 evaluation
45794929|NCT01882868|Drug|Levofolinate|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
45794930|NCT01882868|Drug|Irinotecan|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
45794931|NCT01882868|Drug|5-FU|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
45794932|NCT01383447|Drug|entinostat|Given PO
45794933|NCT01383447|Drug|imatinib mesylate|Given PO
45794934|NCT01383447|Other|laboratory biomarker analysis|Correlative studies
45794935|NCT01383447|Other|pharmacological study|Correlative studies
45794936|NCT01383447|Genetic|western blotting|Correlative studies
45794937|NCT01383447|Other|immunohistochemistry staining method|Correlative studies
45794938|NCT01383447|Other|flow cytometry|Correlative studies
45794939|NCT01383447|Genetic|polymerase chain reaction|Correlative studies
45794940|NCT01383447|Other|high performance liquid chromatography|Correlative studies
45921411|NCT02972190|Device|Pedicle screw and interbody cage|Pedicle screw and interbody cage
45921412|NCT00007592|Drug|Chlorthalidone|
45921413|NCT00007592|Drug|Furosemide|
45921414|NCT03288090|Other|FSS: Fatigue Severity Scale|Fatigue scale with 9 items rated from 1 to 7, assessing physical fatigue, fatigue in the psychosocial environment and fatigue in general (3 items in each category).
45794941|NCT01383447|Other|mass spectrometry|Correlative studies
45794942|NCT02300298|Drug|Nintedanib|Nintedanib
45794943|NCT02300298|Drug|Docetaxel|Docetaxel
45794944|NCT04332003|Device|Remote Ischemic Conditioning (RIC) Treatment|RIC treatment will be delivered by an automated device that delivers the RIC treatment (manufactured by LifeCuff Technologies).
45794945|NCT04749056|Behavioral|EPAS (electronic psycho-oncological adapative screening program)|"Adaptive tests assess depression, anxiety and distress. Only items with highest information value are selected. Furthermore, patients fill in a checklist to report supportive care needs.~The results page contains (i) the extent of distress and additional information to interpret these levels, (ii) a summary of the reported supportive care needs and (iii) individualized recommendations for the use of psychosocial services at the institution based on the care needs.~The supportive care needs are transformed into concrete recommendations to use the adequate psychosocial service at the institution. Highly distressed patients are recommended to use psycho-oncological service irrespective of whether they have reported such a need in the check list. Physicians of highly distressed patients are recommended on their results page to talk with the patient about his/her psychosocial condition and further issues within such an appointment are suggested."
45794946|NCT02300220|Drug|Ciprofloxacin|500 mg, twice daily for 1 week (oral)
45794947|NCT02300220|Drug|Placebo|One capsule, twice daily for 1 week
45648543|NCT02333149|Dietary Supplement|Melatonin|"Children <40 kg will take one tablet, melatonin 3 mg, oral, 30 - 60 minutes prior to bedtime.~Children ≥40 kg will take two tablets, melatonin 3 mg, oral, 30-60 minutes prior to bedtime."
45648544|NCT02333149|Drug|Placebo|Placebo frequency and volume are identical to the experimental arm
45794948|NCT04748978|Procedure|hysteroscopy|OPPIum and Myolysis
45794949|NCT01379469|Drug|Drug-Carbamazepine (Tegretol XR)|To reduce the likelihood of hypersensitivity reactions the subjects will be started on 400 mg/day in 2 doses and the dose will be increased weekly by 200mg/day until reaching a stable therapeutic concentration with a dose not exceeding 1200mg/day(or 1000mg/day in subjects less than 15 years of age). The CBZ tablets will be encapsulated..
45794950|NCT01379469|Drug|Carbamazepine (Tegretol XR) Placebo|Carbamazepine (Tegretol XR)Placebo-the subjects will be started on 400mg/day in 2 doses and the dose will be increased weekly by 200 mg/day until reaching a dose not exceeding 1200 mg/day (or 1000 mg/day in subjects less than 15 years of age). The placebo group will receive encapsulated tables without Carbamazepine.
45794951|NCT01309581|Drug|Ketamine|Ketamine 1-2 mg/kg IV as indicated for ECT
45794952|NCT01309581|Drug|Methohexital|Methohexital 1 mg/kg IV as indicated for ECT
45794953|NCT02327130|Device|Isomark Canary™|Isomark, LLC is a Madison, Wisconsin-based company that has developed an investigational device, the Isomark Canary™, that is intended to determine the breath delta value of breath samples collected from critically ill patients.
45921415|NCT03288090|Other|Neuropsychological evaluation battery|A standardized French neuropsychological battery for the cognitive evaluation of stroke patients.
45648545|NCT02315131|Drug|TV46017|TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.
45794954|NCT02665221|Other|No Treatment Arm|Participants randomized to the control group will have no topical treatment at the injection site of the first full dose of Plegridy.
45794955|NCT02665221|Drug|Topical Preparation H arm|Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.
45794956|NCT05289050|Drug|sodium chloride (NaCl; 0.9%)|For patients in the control group,anaesthesia will be maintained with intravenous sodium chloride (NaCl; 0.9%) infusion.while anaesthesia will be maintained with propofol infusion(4-12mg/kg/h),analgesia will be maintained with remifentanil(0.15-0.3ug/kg/min).The sufentanil dose at induction and the rate of intraoperative remifentanil and propofol infusions were at the discretion of the anesthesiologist in charge of the patient.The assessment of the depth of anesthesia was based on clinical evaluation,placebo-controlled infusion will be stopped 15 minutes before the end of surgery.Propofol and remifentanil infusion will be stopped at the end of surgery.
45794957|NCT05289050|Drug|S-ketamine|For patients in the s-ketamine group,anaesthesia will be maintained with s-ketamine infusion（0.3mg/kg/h),while anaesthesia will be maintained with propofol infusion(4-12mg/kg/h),analgesia will be maintained with remifentanil(0.15-0.3ug/kg/min).The sufentanil dose at induction and the rate of intraoperative remifentanil and propofol infusions were at the discretion of the anesthesiologist in charge of the patient.The assessment of the depth of anesthesia was based on clinical evaluation.S-ketamine infusion will be stopped 15 minutes before the end of surgery.Propofol and remifentanil infusion will be stopped at the end of surgery.
45794958|NCT00554294|Behavioral|environmental and behavioral change|In intervention schools a water dispenser was installed and children received water bottles as environmental intervention. Children also received a 6-hour-curriculum about the importance of water for the body that were held by the teachers.
45921416|NCT03288090|Other|Other functional scores|Rankin Score, Instrumental Activities of Daily Living (IADL) Score, Rivermead Mobility Index (RMI) scale, Hospital Anxiety Depression scale (HAD) scale for depression / anxiety, Stroke Specific Quality of Life scale for quality of life, Quality Index of Pittsburgh Sleep (PSQI), Vertical Analog Visual Scale for Pain and Vertical Digital Visual Scale
45921417|NCT00007631|Drug|Tretinoin 0.1% cream or placebo|
45921418|NCT00007631|Other|Placebo|Patients receive placebo for same amount of time
45921419|NCT00112567|Drug|fludarabine phosphate|
45921420|NCT00112567|Drug|thiotepa|
45648546|NCT02315131|Drug|Placebo|Placebo Comparator
45648547|NCT02029963|Device|Transcranial Magnetic Stimulation (rTMS)|A non-invasive method for brain stimulation
45648548|NCT02029963|Behavioral|Treatment as Usual|An individually-tailored maintenance plan as determined by a psychiatrist or primary care provider
45648549|NCT04514965|Other|Blood sampling|Blood sampling
45648550|NCT04514965|Device|Fibroscan|Measurement of liver stiffness
45648551|NCT04514965|Other|Question|Question about pruritus
45794959|NCT03782181|Device|Whole body vibration platform|A neuromuscular treatment using a rotational whole body vibration platform.
45794960|NCT02987738|Drug|Dapagliflozin|two administrations in the evening and 12 hours later
45648552|NCT05122429|Behavioral|e-Health Treatment|Self-guided e-health treatment with two of the arms providing delayed (44min) text or video support from a therapist.
45648553|NCT05122273|Device|Stella BIO|Individually planned therapeutic procedures, using, among others, the concept of EMG biofeedback
45794961|NCT02987738|Drug|Placebo Oral Tablet|two administrations in the evening and 12 hours later
45794962|NCT01292265|Biological|Certolizumab Pegol|Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.
45794963|NCT01885910|Drug|Doxycycline 100mg|Doxycycline 100mg by mouth once daily
45921421|NCT00112567|Procedure|peripheral blood stem cell transplantation|
45921422|NCT00112567|Radiation|radiation therapy|
45794964|NCT01885910|Drug|Aczone 5% gel|Aczone 5% gel twice daily
45921423|NCT00112645|Biological|anti-thymocyte globulin|
45794965|NCT02658357|Drug|Risperidone Implant|
45921424|NCT00112645|Drug|busulfan|
45921425|NCT00112645|Drug|cyclosporine|
45921426|NCT00112645|Drug|melphalan|
45794966|NCT02988908|Drug|Donepezil|"Participants received donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
45794967|NCT02988908|Drug|Placebos|"Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
45921427|NCT00112645|Drug|methotrexate|
45921428|NCT00112645|Drug|methylprednisolone|
45921429|NCT00112645|Procedure|allogeneic bone marrow transplantation|
45921430|NCT00112645|Procedure|peripheral blood stem cell transplantation|
45921431|NCT00112645|Procedure|umbilical cord blood transplantation|
45921432|NCT00112684|Drug|alvocidib|Given IV
45921433|NCT00112684|Other|pharmacological study|Correlative studies
45921434|NCT00112684|Other|laboratory biomarker analysis|Correlative studies
45921435|NCT02972229|Radiation|10x(3-5) Gy IMRT|10x(3-5) Gy IMRT on partial vertebral body for spinal metastases
45921436|NCT02972229|Radiation|10x3 Gy IMRT|10x3 Gy IMRT on whole vertebral body for spinal metastases
45921437|NCT00007670|Drug|Carbamazepine|
45794968|NCT05239208|Other|Oral Nutrition Supplement (ONS) Group|Oral nutritional supplement specifically designed for nutritionally-at risk children and dietary counseling
45794969|NCT05239208|Other|Control Group|Dietary counseling
45794970|NCT02326272|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 200 mg/mL~Route of Administration: Subcutaneous use"
45794971|NCT02326272|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 0.9 % saline~Route of Administration: Subcutaneous use"
45794972|NCT02279108|Drug|indocyanine green|One injection, 2.5 milligrams per patient, intradermal use
45794973|NCT02279108|Drug|isotope|One injection, 20 MBq techntium99, intradermal use
45648554|NCT01794715|Procedure|Ultrasound examination by nurses|Ultrasound examination performed by nurses. Focused examination of the pleural space and inferior vena cava.
45648555|NCT05118217|Other|This is a non-interventional study|This is a non-interventional study
45648556|NCT02654977|Drug|Metreleptin|MyaLept (Recombinant-methionyl Human Leptin (r-metHuLeptin) METRELEPTIN) subcutaneous injections
45648557|NCT05117983|Device|Repetitive transcranial magnetic stimulation (rTMS)|Real-time MRI-guided neuronavigation with a Visor neuronavigation system (ANT Neuro, Enschede, Netherlands) will be used for coil positioning. Left dorsolateral prefrontal cortex target is located in each participant.
45648558|NCT05117671|Other|data collection to classify infection status|Review of medical records of all selected cases (TKA/THA patients) to classify infection status according to different classifications (EBJIS, MSIS/ICM 2013, ICM 2018).
45648559|NCT05117437|Other|Physiological test|This test was conducted to determine the endurance levels of the participants.
45648560|NCT05117437|Other|Physical test|Height, weight, and BMI were determined
45921438|NCT00007670|Drug|Gabapentin|
45921439|NCT00007670|Drug|Lamotrigine|
45921440|NCT00112879|Drug|arsenic trioxide|
45921441|NCT00112879|Drug|ascorbic acid|
45921442|NCT00112879|Drug|dexamethasone|
45921443|NCT00112879|Drug|thalidomide|
45921444|NCT00112879|Procedure|anti-cytokine therapy|
45921445|NCT00112879|Procedure|antiangiogenesis therapy|
45921446|NCT00112879|Procedure|biological therapy|
45921447|NCT00112879|Procedure|chemotherapy|
45921448|NCT00112879|Procedure|drug resistance inhibition|
45921449|NCT00112879|Procedure|growth factor antagonist therapy|
45921450|NCT00112879|Procedure|non-specific immune-modulator therapy|
45921451|NCT00112996|Drug|alpha-lipoic acid|Oral two 300 mg ALA sustained release tablets initiated 4 days after last dose of platinum and discontinued 2 days before next scheduled platinum dose, continued for 24 weeks.
45921452|NCT00112996|Other|placebo|Given orally two similar color and sized placebo control tablets three times a day continued for 24 weeks.
45921453|NCT00390663|Procedure|Nasal Cautery|
45921454|NCT00113074|Drug|Nicotine Replacement Therapy|Nicotine replacement therapy program
45921455|NCT00113074|Behavioral|Diet|Diet program
45921456|NCT00113113|Drug|Rubitecan|
45921457|NCT00113308|Drug|GW406381|
45921458|NCT00390702|Device|transcatheter implantation of a VSD occluder (Nitinol coil)|transcatheter implantation, by first performing a arterial-venous loop through the defect
45921459|NCT02972528|Biological|Platelet Lysate|Direct injection of allogenic Platelet Lysate
45648561|NCT05117437|Other|Biochemical tests|BMP9, CTX1, COMP, oxLDL protein levels, ALP, GGT, TAS, TOS, OSI, NO, calcium, T-C, LDL-C, Triglyceride, HDL-C, glucose, CRP, AST, ALT, erythrocyte, mean erythrocyte volume (MCV), hematocrit, leukocyte, thrombocyte levels were determined from blood samples.
45794974|NCT04892862|Procedure|SCAHOİD GRAPHONAGE WITH AUTOGRAPH FROM DİSTAL RADİUS BY DORSAL APPROACH|ON GENERAL OR LOCAL ANESTESİA PATİENT N SUPİNE POSTİON EFFECTED WRİST ON ARM TABLE . LISTER TUBERCULA WITH 3 CM PROXIMAL AND 3 CM DISTAL IN INCISION MADE UNDER THE SKIN. 2,3 EXTENSOR COMPARTMENTS RADIAL 4. THE EXTENSON COMPARTMENT IS EARTHED TO ULNAR A AND THE WRIST JOINT CAPSULE IS REACHED. THEN THE CAPSULE IS OPENED AND THE SCAPHOLID PROXIMAL AND MIDDLE POLE IS VIEWED. THE PERSODOARTHOSIS FIELD IS REGENERATED WITH THE TURRET AND TURR ENGINE. Following the same incision ON DISTAL UNDER RADIUS metaphyseal area of 2CM. 2X2 centimeter WINDOW opened to get spongios bone GREFt, greft added in to field of pseudoarthrosis.After scaphoid HEIGHT AND anatomy recovered it has fixated one headless mini acuttrack screw under fluoroscopy guidance .skin and subcutaneous tissue closed with non absorbabl sutures.
45794975|NCT04892862|Procedure|SCAHOİD GRAPHONAGE WITH AUTOGRAPH FROM DİSTAL RADİUS BY VOLAR APPROACH|ON GENERAL OR LOCAL ANESTESİA PATİENT N SUPİNE POSTİON EFFECTED WRİST ON ARM TABLE . İNCİSİON STARTS 2 CM RADİAL TO SCAPHOİD TUBERCULE EXTENTS ITS 3 CM PROXİMAL . AFTER PASİNG SUBCUTANEOUS TİSSUE , FCR AND RADİAL ARTERY ARE İDENTİFİED AND DİVİDED SEPERATLY THEN THE CAPSULE IS OPENED AND THE SCAPHOLID PROXIMAL AND MIDDLE POLE IS VIEWED. THE PERSODOARTHOSIS FIELD IS REGENERATED WITH THE TURRET AND TURR ENGINE. Following the same incision WİTH PASSİNG PRONATOR QUADRATUS MUSCLE , ON DISTAL UNDER 2 CENTİMETER OF RADIUS metaphyseal area . 2X2 centimeter WINDOW opened to get spongios bone GREFt, greft added in to field of pseudoarthrosis.After scaphoid HEIGHT AND anatomy recovered it has fixated one headless mini acuttrack screw under fluoroscopy guidance .skin and subcutaneous tissue closed with non absorbabl sutures.
45794976|NCT04263818|Procedure|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for|"Carrying out the endoscopic procedure planned for the patient with the dedicated colonoscope which has magnetic coils over the entire length of the insertion tube. These magnetic coils generate a pulsed magnetic field at low frequency. These pulses are transmitted to an external receiver, refreshed at 15 images per second, then relayed to the processor to generate a 3D representation of the colonoscope next to it of the endoscopic image. There is no additional risk to the patient compared to current practice.~Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for."
45794977|NCT01887470|Drug|Full dose preparation|
45794978|NCT01887470|Drug|Split dose preparation|
45921460|NCT02972528|Biological|Platelet Poor Plasma|Direct injection of allogenic Platelet Poor Plasma
45921461|NCT00007748|Behavioral|Aerobic exercise|
45921462|NCT00007748|Behavioral|Cognitive behavioral therapy|
45921463|NCT00007787|Biological|Cyclosporine|
45794979|NCT02325414|Drug|Zoledronic acid|Intravenous infusion of zoledronic acid 5 mg.
45794980|NCT02325414|Drug|Placebo|Placebo (saline) infusion to match zoledronic acid
45794981|NCT01888484|Biological|octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
45794982|NCT02349048|Drug|Simeprevir 150 mg|Simeprevir 150 mg capsule orally once daily.
45921464|NCT00007787|Biological|Anti-human thymocyte globulin (rabbit)|Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5 mg/kg while undergoing transplantation. Second and subsequent doses of Thymoglobulin® will be administered if, at 24 hours post-anastomosis, the serum creatinine has not decreased by at least 20% from the pre-transplant level. Additional Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5mg/kg daily for a minimum of 5 days to a maximum of 7 days.
45648562|NCT05117359|Device|transcatheter paravalvular leak closure|transcatheter paravalvular leak closure on cardiac valve
45648563|NCT03807817|Other|Alcohol administration|Amount of alcohol to be administered.
45794983|NCT02349048|Drug|Daclatasvir 60 mg|Daclatasvir 60 mg tablet orally once daily.
45794984|NCT02349048|Drug|Sofosbuvir 400 mg|Sofosbuvir 400 mg tablet orally once daily.
45921465|NCT00007787|Drug|Tacrolimus|
45921466|NCT00390897|Drug|Glivec|
45648564|NCT03807817|Other|Placebo|Placebo Alcohol
45648565|NCT03807817|Other|No Alcohol|No Alcohol
45648566|NCT03508297|Diagnostic Test|In-vivo imaging|Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).
45921467|NCT00390897|Drug|Interferon|
45921468|NCT00113347|Drug|Erlotinib|Beginning on Day 2 of treatment, 100, 125, or 150 mg by mouth once a day every day while on treatment, except on days docetaxel is received.
45921469|NCT00113347|Drug|Docetaxel|15 mg/m^2 or 20 mg/m^2 by vein over 15 to 30 minutes on Days 1, 8, 15, and 22 of treatment.
45921470|NCT00113347|Radiation|Radiation Therapy|Radiation therapy to head/neck beginning on day 1 of treatment once daily 5 times per week (Monday through Friday), delivered in 40 fractions.
45921471|NCT00113503|Drug|Azathioprine weight-based dose|
45921472|NCT00113503|Drug|Azathioprine individualised dose|
45921473|NCT00113542|Drug|Tetrathiomolybdate (TM)|
45921474|NCT00007826|Biological|BCG vaccine|
45921475|NCT00007826|Biological|monoclonal antibody 105AD7 anti-idiotype vaccine|
45921476|NCT00007826|Drug|alum adjuvant|
45921477|NCT00113581|Drug|EMD 72000 (matuzumab) + ECX|
45921478|NCT02240472|Procedure|Omission of axillary clearance|The intervention is the omission of completion axillary clearance after the detection of sentinel node macrometastasis
45921479|NCT00113620|Drug|Neurodex|
45921480|NCT02958241|Other|MRI|Supine and weight bearing MRI
45921481|NCT00007865|Biological|rituximab|
45921482|NCT00007865|Drug|carboplatin|
45921483|NCT00007865|Drug|etoposide|
45921484|NCT00007865|Drug|ifosfamide|
45921485|NCT00113698|Drug|Enalapril|Up-titration period is to reach the highest tolerated dose up to a maximum of 0.4 mg/kg/day
45921486|NCT00113698|Other|Placebo|Placebo An inert preparation with similar appearance and taste to the drug
45921487|NCT00113737|Drug|fluoxetine|
45921488|NCT00113737|Behavioral|cognitive behavioral therapy|
45794985|NCT01280643|Drug|fluorouracil|Given IV
45794986|NCT01280643|Drug|leucovorin calcium|Given IV
45794987|NCT01280643|Drug|oxaliplatin|Given IV
45794988|NCT01280643|Drug|irinotecan hydrochloride|Given IV
45794989|NCT01280643|Biological|bevacizumab|Given IV
45794990|NCT01280643|Biological|cetuximab|Given IV
45794991|NCT01280643|Drug|capecitabine|Given PO
45794992|NCT01280643|Genetic|mutation analysis|Correlative studies
45794993|NCT01280643|Genetic|gene expression analysis|Correlative studies
45794994|NCT01280643|Other|laboratory biomarker analysis|Correlative studies
45449883|NCT03519087|Other|Interdisciplinary Evaluation for Nonarthritic Hip Disease|The hip arthroscopist will conduct his or her standard-care evaluation including subjective interview, patient history, imaging, and physical examination. The physical therapist will conduct an assessment of posture and movement during sitting, standing, squatting, and walking. After providers discuss their findings, they will discuss the plan of care with the participant.
45794995|NCT01280643|Other|immunohistochemistry staining method|Correlative studies
45794996|NCT01280643|Genetic|nucleic acid sequencing|Correlative studies
45794997|NCT01280643|Genetic|protein expression analysis|Correlative studies
45794998|NCT01280643|Genetic|polymerase chain reaction|Correlative studies
45794999|NCT01280643|Genetic|DNA analysis|Correlative studies
45795000|NCT01888952|Drug|Prednisone|Patients may receive additional courses of treatment with prednisone (and roflumilast) at the discretion of the investigator if they did not experience unacceptable toxicity and have stable disease or objectively responding disease.
45449884|NCT03519087|Other|Posture and Movement Training|Physical therapists will lead participants through an intervention protocol to normalize seated and standing posture and function movement. Verbal, visual, and tactile cues, along with strengthening exercises will be provided to train posture and movement.
45449885|NCT03519087|Other|Treatment-of-choice|Participants may proceed with any treatment-of-choice, which may or may not have been recommended by their health care provider(s). Treatments will be recorded, but not controlled.
45449886|NCT01067651|Device|Plaster of Paris (POP) casting using the Ponseti Method|
45449887|NCT01067651|Device|Semi-Rigid Fiberglass softcast using the Ponseti Method|
45648567|NCT02871115|Other|Pharmacy Intervention|Patients randomized to the pharmacy intervention (PRIME) will undergo evaluation with a clinical pharmacist at their second or third chemotherapy infusion who will: (1) perform detailed medication reconciliation and obtain allergy and vaccination history; (2) evaluate and document polypharmacy, potentially inappropriate medications, lack of appropriate medications; and (3) document their findings in the medical record and discuss their recommendations the oncology team.
45648568|NCT02871115|Other|Usual Care|Participants receiving usual oncology care will not meet with the pharmacist unless indicated as part of their routine clinical care. Study staff will obtain all patient-reported measures from the patient.
45648569|NCT02078947|Behavioral|High Intensity Exercise|
45648570|NCT02078947|Behavioral|Moderate Continuous Exercise|
45648571|NCT02078947|Behavioral|Usual Care|
45754367|NCT04142138|Other|DASH|DASH diet is based on low salt, high potassium components, and is comprised of mainly fruits and vegetables. During hospitalization we will collect laboratory data of blood and urine, and follow participants clinically by measuring blood pressure.
45795001|NCT01888952|Drug|Roflumilast|Patients may receive additional courses of treatment with roflumilast (and prednisone) at the discretion of the investigator if they did not experience unacceptable toxicity, and have stable disease or objectively responding disease.
45795002|NCT02299206|Drug|CeraVe Baby Diaper Rash Cream|Parents/caregivers of subjects will administer CeraVe Baby Diaper Rash Cream (ingredients: Zinc oxide 10mg in 1g (1%) and dimethicone 10mg in 1g) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
45795003|NCT02299206|Drug|Desitin Maximum Strength Original Paste|Parents/caregivers of subjects will administer Desitin Maximum Strength Original Paste (ingredients: Zinc Oxide 40%) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
45795004|NCT01892306|Behavioral|UP CBT|The UP is an 18-session weekly cognitive behavioral intervention for anxiety and mood disorders
45795005|NCT01892306|Drug|Treatment as usual|Existing optimized pharmacotherapy as delivered by treating psychiatrist
45795006|NCT02640573|Drug|Hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the AdultsQLTM 3.0 Sickle Cell Disease Module after 6 months at MTD, compared to entrance scores
45795007|NCT02298192|Drug|insulin degludec/liraglutide|For subcutaneous (s.c., under the skin) injection, once daily. Subjects will be instructed to continue with the same dose of OADs (metformin alone or in combination with pioglitazone), as prior to the trial.
45795008|NCT01893632|Drug|gabapentin|
45795009|NCT01893632|Drug|Placebo|
45795010|NCT01272141|Drug|Lapatinib and Everolimus|"Lapatinib: 1250 mg by mouth daily~Everolimus: 5mg by mouth daily"
45795011|NCT01270581|Other|High Flow Nasal Cannula|Humidified high flow nasal cannula (HFNC) has emerged as an alternative respiratory modality for late preterm newborns with respiratory distress. Like NCPAP, oxygen is delivered to the infant via nasal prongs and provides a continuous distending pressure. Unlike the nasal prongs for NCPAP (which fit tightly in the nares), the nasal cannula for HFNC have smaller, loose-fitting prong. With HFNC, positive airway pressure is achieved by high gas flow through the cannula into the external nares which provide resistance to expiration and facilitate inspiration. The distending pressure is determined by the size and structure of the nasal cannula, gas flow rate, and the neonate's airway anatomy 4,5,7.
45921489|NCT03272295|Other|Reference cigarette|The reference product is based on a commercially-available king-size cigarette design (length 83 mm, circumference 24.6 mm) with a single segment cellulose acetate filter and tobacco blend recipe without ingredients.
45921490|NCT03272295|Other|Cigarette with carob bean extract|Based on reference cigarette with added ingredient
45921491|NCT03272295|Other|Cigarette with cocoa powder|Based on reference cigarette with added ingredient
45921492|NCT03272295|Other|Cigarette with fenugreek extract|Based on reference cigarette with added ingredient
45795012|NCT01270581|Other|Bubble Nasal CPAP|NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.
45921493|NCT03272295|Other|Cigarette with fig juice|Based on reference cigarette with added ingredient
45795013|NCT01894178|Device|Parker Flex-Tip® tracheal tube|
45795014|NCT01894178|Device|Portex® Tracheal Tube|
45795015|NCT03836846|Behavioral|CBT Mobile App|TAU and the additional treatment of a Mental Health App (What's Up?). This app will be used to guide adolescents through cognitive behavioral therapy and acceptance commitment therapy techniques, as well as to assist in developing coping mechanisms to prevent readmission.
45795016|NCT03836846|Behavioral|Treatment as usual|TAU as per standard of care
45449888|NCT03721809|Biological|Blood samples|"There are 3 specific blood sampling times for each patient, on D1, D2 and D5 (D1 being the day of inclusion): cytokine samples (IL-1β, IL-6, IL-10, TNF-α, IFN-gamma) on 5ml dry tube.~On D1, a 2.5ml PAXgene tube will also be taken for each patient."
45449889|NCT03977285|Procedure|chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
45449890|NCT03730311|Drug|Elpida|elsulfavirine, capsules
45449891|NCT03730311|Drug|placebo|placebo
45795017|NCT02624739|Device|Reassure Non-Contact Respiration Monitor|Reassure uses a specially-designed, non-contact motion sensor to monitor body movement and continuous respiratory rate (CRR) during sleep. Reassure is used to monitor, over a prolonged period, the sleep patterns and respiration rate while the patient is asleep.
45795018|NCT01895036|Drug|Naltrexone|
45795019|NCT03781479|Drug|Amifampridine Phosphate|Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
45795020|NCT03781479|Drug|Placebo Oral Tablet|Placebo Oral Tablet
45795021|NCT04051814|Other|Micra Transcatheter Pacemaker System|A miniaturized single chamber pacemaker system that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart
45795022|NCT05110196|Drug|Capmatinib 150 mg|Capmatinib film-coated tablet 150 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
45449892|NCT03977207|Drug|Levothyroxine Sodium|Thyroid hormone supplement
45449893|NCT03977207|Drug|Placebos|Placebo oral capsule
45449894|NCT01067729|Device|AWBAT Wound Dressing|
45921494|NCT03272295|Other|Cigarette with glycerol|Based on reference cigarette with added ingredient
45921495|NCT03272295|Other|Cigarette with guaiacol|Based on reference cigarette with added ingredient
45921496|NCT03272295|Other|Cigarette with liquorice extract powder|Based on reference cigarette with added ingredient
45921497|NCT03272295|Other|Cigarette plus I-menthol|Based on reference cigarette with added ingredient
45921498|NCT03272295|Other|Cigarette with propylene glycol|Based on reference cigarette with added ingredient
45921499|NCT03272295|Other|Cigarette with sorbitol|Based on reference cigarette with added ingredient
45921500|NCT03272295|Other|Cigarette with multiple ingredients|Based on reference cigarette plus propylene glycol, glycerol, liquorice extract powder, cocoa powder, carob bean extract, fig juice concentrate, maltol, guaiacol, geraniol, fenugreek extract.
45921501|NCT00113776|Drug|ABX-EGF|
45921502|NCT00007904|Biological|filgrastim|Neupogen (G-CSF) given at a dose of 10 ugm/kg subcutaneously starting on day 5 and continuing until ANC > 10,000/uL x1 day after the nadir cycles 1-3.
45449895|NCT01067729|Device|AWBAT™, Biobrane®|Comparison of burn dressings on randomized body sites using patient as own control
45449896|NCT04883931|Drug|Normal Saline|0.5 ml 0.9% normal saline will drop on both eyes twice in a day.
45449897|NCT04883931|Biological|Breast milk|0.5 ml breast milk from all infant's own mother will drop both eyes twice in a day
45795023|NCT05110196|Drug|Capmatinib 200 mg|Capmatinib film-coated tablet 200 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
45795024|NCT01223001|Drug|Duloxetine|Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
45795025|NCT01223001|Drug|Sugar pill|Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
45795026|NCT01895972|Drug|Latanoprostene bunod|
45795027|NCT03779997|Behavioral|Video-based DOT Application|Participants will be asked to record daily videos of themselves confirming daily ingestion of their buprenorphine. Clinical staff (i.e. physicians, nurses and medical assistants) of patients enrolled in the intervention group will be given training and the opportunity to review medication taking videos.
45795028|NCT02988752|Device|Electronic Mobile Device|Measure C/D Ratio With An Equipment Attached To A Ophthalmoscope That Will Determine C/D Ratio Without Touching Patient's Eyes. To Perform It We Need Mydriatic Conditions.
45921503|NCT00007904|Drug|cyclophosphamide|cyclophosphamide 700 mg/m2 daily for 3 day every 3 weeks cycles 1-3
45795029|NCT02988752|Device|Optical Coherence Tomography|Measure C/D Ratio With OCT, Considered Gold Standard Equipment
45795030|NCT01896206|Device|CNAP monitor|Patients undergoing bariatric surgery and being monitored using the CNAP monitor.
45921504|NCT00007904|Drug|doxorubicin hydrochloride|Patients then receive doxorubicin IV on day 1.
45921505|NCT00007904|Drug|paclitaxel|Paclitaxel 160 mg/m2 given over 72 hours by continuous infusion days 1-3
45921506|NCT00007904|Drug|tamoxifen citrate|tamoxifen at a dose of 20 mg daily for 5 years after chemotherapy is completed
45921507|NCT00007904|Procedure|adjuvant therapy|Patients receive paclitaxel IV continuously and cyclophosphamide IV over 2 hours on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until day 14 or until blood counts recover. Treatment repeats every 21 days for 3 courses. Patients then receive doxorubicin IV on day 1 and G-CSF SC on days 2-11 every 21 days for 4 courses.
45921508|NCT00007904|Radiation|radiation therapy|Beginning 3-6 weeks after the completion of chemotherapy, patients receive radiotherapy 5 days a week for 6-7 weeks.
45921509|NCT00113815|Drug|topiramate|15 mg/kg/day
45921510|NCT00113815|Drug|topiramate|5 mg/kg/day
45921511|NCT00113815|Drug|topiramate|25 mg/kg/day
45921512|NCT00113815|Drug|placebo|placebo
45921513|NCT03109431|Behavioral|Level 1|"Youth will receive 1-5 text messages per day for at least 12 months. Banks of about 750 messages (70-120 messages per domain) focus on the HIV Treatment Continuum, with messages focused on dedicated to healthcare, wellness, sexual health, drug use and medication reminders. Youth will be able to choose the time and frequency that they receive daily texts. Preferences for the timing and type of messages can be updated at 4-month assessment points.~Youth will complete weekly monitoring surveys by text message. The survey will cover six domains related to the HIV Treatment Continuum. If YLH do not respond to the text, reminder messages will be sent to the youth. After three days of non-response a follow-up call by an interviewer will be made to the YLH."
45921514|NCT03109431|Behavioral|Level 2|"Youth will be enrolled in online, private discussion groups.~Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.~Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content."
45921515|NCT03109431|Behavioral|Level 3|Youth will have be assigned to a Coach trained in a strengths--based Coaching intervention, as well as common foundational theory, principles and skills used in adolescent HIV Evidence-Based Interventions (EBI). Youth preferences will drive the intervention delivery - whether in-person, electronically via the phone, email, text message, social media private messaging.
45921516|NCT00113854|Drug|Mannitol|
45921517|NCT00007943|Drug|gemcitabine hydrochloride|
45648572|NCT04212247|Behavioral|Well-Being Therapy|Well-Being Therapy (WBT) is a short-term psychotherapeutic strategy, that emphasizes self-observation with the use of a structured diary, interaction between patients and therapists and homework. WBT was based on the model of psychological well-being that was originally developed by Jahoda in 1958 and further refined by Ryff in 2014. The standard number of sessions is 8. The initial phase is concerned with self-observation of psychological well-being. Then, the patient is encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of wellbeing. The final part involves cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
45754368|NCT01590277|Drug|Active Ethanol|Target BrAC of 0.1% reached over 30 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 5 drinks. Administered over a total of 90 minutes.
45921518|NCT00113932|Procedure|High-Dose Density Therapy|Dexamethasone 40mg po 1-4, Thalidomide 200 mg po 1-6hrs then daily after transplant; Cisplatin* 10 mg/m2 Continuous infusion 1-4;Adriamycin 10 mg/m2 Continuous infusion 1-4;Cyclophosphamide 400 mg/m2 Continuous infusion 1-4; Etoposide 40 mg/m2 Continuous infusion 1-4; Pegfilgrastim 6 mg subcutaneously 6 and 13; Darbepoetin 200μg subcutaneously Between -6 to-1 +12, & every 2 weeks until HB >12 gm/dl***; Lovenox (or other LMWH) 40 mg subcutaneously Daily until Pltcount <30,000/μl
45921519|NCT00113971|Drug|epratuzumab|
45921520|NCT00114010|Drug|AMA1/Alhydrogel|
45754369|NCT01590277|Drug|Active Iomazenil|Active iomazenil, administered intravenously at a dose of 3.7 ug/kg. Administered over 10 minutes, beginning 10 minutes after the start of the ethanol/placebo clamp.
45754370|NCT01590277|Drug|Placebo|Control: no alcohol, administered for a total of 90 minutes.
45921521|NCT00114049|Drug|GW406381|
45921522|NCT00007982|Biological|filgrastim|
45921523|NCT00007982|Drug|carmustine|
45921524|NCT00007982|Drug|cisplatin|
45795031|NCT02608905|Drug|Dapagliflozin|Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
45921525|NCT00007982|Drug|cyclophosphamide|
45921526|NCT00007982|Drug|etoposide|
45921527|NCT00007982|Drug|thiotepa|
45921528|NCT00007982|Procedure|adjuvant therapy|
45921529|NCT00007982|Procedure|autologous bone marrow transplantation|
45921530|NCT00007982|Procedure|bone marrow ablation with stem cell support|
45921531|NCT00007982|Procedure|peripheral blood stem cell transplantation|
45921532|NCT00114088|Procedure|hysterectomy|
45921533|NCT00114088|Procedure|endometrial ablation|
45921534|NCT00401713|Procedure|Transplantation of autologous RPE|RPE cell suspension
45921535|NCT00401713|Procedure|Translocation of autologous RPE and Choroid|RPE patch
45795032|NCT02608905|Drug|Placebo|Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
45921536|NCT00114205|Drug|docetaxel|
45795033|NCT01213329|Drug|Alemtuzumab|All kidney transplant recipients received one 30mg dose (IV push) of Alemtuzumab in operating room per Standard of Care.
45449898|NCT02763046|Drug|Secukinumab (AIN457) 150 mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly Maintenance: 4 x 150 mg secukinumab s.c. every 4 weeks Delayed NSAID tapering (tapering following 4 weeks of secukinumab treatment).
45795034|NCT01897766|Drug|Somatropin|0.23 mg to 0.48 mg/kg/week
45921537|NCT00114205|Procedure|therapeutic thoracoscopy|
45921538|NCT00114283|Drug|lapatinib ditosylate|Given PO
45921539|NCT00114283|Other|laboratory biomarker analysis|Correlative studies
45921540|NCT00114322|Device|light exposure from LED source at narrow 468 nm or broader 400-700 nm wavelength|
45921541|NCT00114361|Drug|Ribavirin|1200 mg a day, 48 weeks
45921542|NCT00114361|Drug|Peginterferon alpha 2a|180 µg per week, 48 weeks
45921543|NCT03087396|Device|Treatment of insufficiency fractures|Filling of micro fractures or insufficiency fractures with a bone substitute material
45921544|NCT00114400|Drug|folic acid|
45921545|NCT00114400|Drug|vitamin B12|
45921546|NCT00114400|Drug|vitamin B6|
45648573|NCT04212247|Behavioral|Control condition|The control condition will include 8 sessions that will inform participants about well-being and lifestyles which can influence it. They will be articulated as follows. Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drug misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.
45921547|NCT00114439|Drug|Lithium carbonate|
45449899|NCT02763046|Drug|Secukinumab (AIN457) 150 mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly Maintenance: 3 x 150 mg secukinumab s.c. every 4 weeks Early NSAID tapering (tapering at the start of secukinumab treatment).
45754371|NCT01590277|Drug|Placebo|Control: no iomazenil, administered for a total of 10 minutes
45795035|NCT02528097|Drug|Standard Care|Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
45795036|NCT02528097|Drug|Experimental|25% salt poor albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 or later only to those individuals with renal insufficiency and risk for renal failure (Cr > 1.0 or BUN or Cr > baseline)
45795037|NCT02520297|Drug|TRV130|Drug
45795038|NCT03964532|Drug|Talazoparib|Talazoparib (formerly MDV3800 and BMN673) is an oral small molecule, selective inhibitor of PARP-1 and PARP-2.
45795039|NCT03964532|Drug|Avelumab|Avelumab (formerly MSB0010718C) is a human immunoglobulin G1 (IgG1) anti-PD-L1 monoclonal antibody131 that utilizes both adaptive and innate immune mechanisms.
45921548|NCT00114478|Drug|Epinephrine|
45921549|NCT00114478|Drug|albuterol (salbutamol)|
45921550|NCT00114556|Drug|zoledronic acid|
45921551|NCT00008021|Biological|filgrastim|
45921552|NCT00008021|Biological|monoclonal antibody Lym-1|
45921553|NCT00008021|Drug|cyclosporine|
45921554|NCT00008021|Drug|paclitaxel|
45921555|NCT00008021|Procedure|peripheral blood stem cell transplantation|
45921556|NCT00008021|Radiation|indium In 111 monoclonal antibody Lym-1|
45921557|NCT00008021|Radiation|yttrium Y 90 monoclonal antibody Lym-1|
45921558|NCT03079440|Drug|TEMCAP|Oral capecitabine 750 mg/m2 twice a day, Day 1 to 14 and oral temozolomide 200 mg/m2 once a day, Day 10 to 14
45921559|NCT04728178|Other|Crystalloid solution|Crystalloid solution is a true solution and is able to pass through a semipermeable membrane.
45921560|NCT04728178|Other|Colloid solution|Colloid solution is a heterogeneous mixture whose particle size is intermediate between those of a solution and a suspension.
45921561|NCT00114595|Drug|eicosapentaenoic acid|
45921562|NCT00008060|Drug|FOLFIRI regimen|
45921563|NCT00008060|Drug|FOLFOX regimen|
45921564|NCT00008060|Drug|fluorouracil|
45921565|NCT00008060|Drug|irinotecan hydrochloride|
45921566|NCT00008060|Drug|leucovorin calcium|
45921567|NCT00008060|Drug|oxaliplatin|
45921568|NCT03057288|Device|fiducial markers placement|The main objective of this study is to evaluate the feasibility of fiducial markers placement under EUS guidance for patients with esophageal or rectal cancer with an indication of radiotherapy
45921569|NCT00114790|Radiation|boronophenylalanine-based BNCT|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
45921570|NCT00114829|Procedure|MR colonography with dynamic contrast uptake|
45921571|NCT00114868|Drug|Vitamin A|
45921572|NCT00008099|Biological|MUC1 antigen/SB AS-2|
45921573|NCT03034200|Drug|ONC201|625mg ONC201 will be given on two consecutive days each week
45921574|NCT00114907|Behavioral|Consumption of black tea|
45921575|NCT00114946|Drug|Avastin|
45921576|NCT00115024|Drug|Micronized 17B-estradiol|
45921577|NCT00008177|Radiation|iodine I 131 monoclonal antibody BC8|Given IV
45921578|NCT00008177|Radiation|total-body irradiation|Undergo total-body irradiation
45921579|NCT00008177|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
45921580|NCT00008177|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
45795040|NCT03024320|Behavioral|M2M|An eHealth platform has been designed to deliver a home-based package using the extensive set of movement patterns that have been adapted for people with a range of physical/mobility disability, called Movement-To-Music (M2M). The M2M prescription will be based on the participant's baseline level of health, function and fitness. Each movement pattern will be available in three different positions - standing, standing with support (chair) and seated. The duration of each M2M session will be gradually increased during the Adoption phase from three 20-minute sessions (10 min. aerobic & 10 min. strength) during weeks 1 to 3 (60 min/wk), to 45-min sessions (30 min. aerobic & 15 min. strength) during weeks 4 to 6 (135 min/wk), and to 50-min sessions (150 min/week) during weeks 7 to 12 (excluding 5-min warmup and 5-min cool down).
45795041|NCT03024320|Behavioral|Attention Control|Telecoaching on health-based topics, not including physical activity.
45921581|NCT00008177|Drug|fludarabine phosphate|Given IV
45921582|NCT00008177|Drug|cyclosporine|Given orally or IV
45449900|NCT02763046|Drug|Placebo - Secukinumab (AIN457) 150 mg s.c.|Placebo for 15 weeks. From Week 16 on, 5 x 150 mg secukinumab s.c. weekly.
45648574|NCT05122117|Device|Methylene blue mediated Photodynamic therapy|Methylene blue (MB) with a concentration of 10 mg/mL was delivered inside the periodontal pocket. MB was injected inside in the selected periodontal pockets 4 - 6 mm with the help of a blunt needle and left for 1 min. Later, the periodontal pockets were flushed with distilled water for 3 min to remove the excess MB. The diode laser HELBO® TheraLite - Bredent Medical, Germany) of diameter 200 µm was used to deliver the light to initiate the disinfection process. Each participant underwent single session of laser exposure. The laser parameters such as wavelength, spot area, power output and laser energy were set at 660 nm, 0.028 cm2, 60 mW/cm2, and 150 mW, respectively. The laser was subjected for a period of 30 s in each pocket.
45648575|NCT05122117|Procedure|Non-surgical periodontal therapy|A single session of full-mouth ultrasonic scaling using a sterilized scaler was rendered to the control group. Deep pockets were additionally approached and cleaned by using manual 'After Fives' Gracey curette for root planning (Hu Friedy Gracey After Five Vision curette; HuFriedy, Chicago, USA). This session was followed by a polishing session. A motivational session was conducted where the patients were educated on the importance of maintaining a good oral hygiene by brushing their teeth twice daily followed by the regular use of dental floss and chlorhexidine mouth wash twice daily, respectively.
45921583|NCT00008177|Drug|mycophenolate mofetil|Given orally or IV
45921584|NCT00008177|Other|laboratory biomarker analysis|Correlative studies
45921585|NCT03007407|Drug|durvalumab|Following three doses of hypofractionated palliative radiation (Days -2, -1, and Day 0 prior to Cycle 1), patients will receive durvalumab (1500 mg IV infusion) on Day 1 for 4 cycles (in combination with tremelimumab). Beginning with Cycle 5 through Cycle 12, patients will receive durvalumab alone (1500 mg/IV infusion) on Day 1 of each 28 day cycle.
45921586|NCT03007407|Drug|Tremelimumab|Following three doses of hypofractionated palliative radiation (Days -2, -1, and Day 0 prior to Cycle 1), patients will receive tremelimumab (75 mg IV infusion) on Day 1 for 4 cycles (in combination with durvalumab).
45921587|NCT00115102|Drug|fentanyl|
45921588|NCT00115102|Drug|S-ketamine|
45921589|NCT00115141|Drug|Resiquimod|
45921590|NCT00115180|Other|No intervention|No intervention
45921591|NCT00115219|Drug|Etanercept|
45921592|NCT00008216|Procedure|Peripheral Blood Stem Cell Transplantation|
45921593|NCT00115258|Other|parenteral nutrition titrated to measured REE|
45921594|NCT00390936|Drug|Brivanib|Tablet, Oral, Brivanib 300 mg, 600 mg, 800 mg, 1000 mg, once daily (cycle 1: Day 1, Day 8 - 35), more than 5 weeks depending on response/toxicity
45449901|NCT02164552|Dietary Supplement|Vitamin D3 pills|Dietary supplement
45648576|NCT05117125|Diagnostic Test|Heparin-binding protein|Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.
45648577|NCT05117125|Diagnostic Test|Interleukin-26|Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.
45921595|NCT00115375|Drug|Clopidogrel (SR25990)|
45921596|NCT00115414|Drug|pegfilgrastim|
45921597|NCT00115414|Drug|docetaxel|
45921598|NCT00115414|Drug|doxorubicin|
45648578|NCT05117125|Diagnostic Test|Microbiome|Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.
45648579|NCT05117125|Diagnostic Test|Bacterial transcriptome|Evaluation of the specificity and sensitivity of the bacterial transcriptome as prognostic biomarker for treatment failure of VAP.
45795042|NCT02280408|Other|Placebo|Normal saline placebo.
45795043|NCT02280408|Biological|V920|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^6, 2x10^7, or 1x10^8 pfu.
45921599|NCT00115414|Drug|cyclophosphamide|
45921600|NCT00115453|Radiation|irradiation|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
45921601|NCT00115492|Drug|Fluticasone Propionate/Salmeterol Combination Product|
45921602|NCT00115492|Drug|Salmeterol|
45921603|NCT02993406|Drug|Bempedoic acid 180 mg tablet|Patients take bempedoic acid 180 mg tablet orally once daily
45921604|NCT02993406|Drug|Matching placebo tablet|Patients take matching placebo tablet orally once daily
45921605|NCT00008255|Drug|INS316|
45921606|NCT00008255|Other|sputum cytology|
45921607|NCT00115531|Biological|Trivalent inactivated influenza vaccine|Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.
45921608|NCT00115531|Biological|Trivalent inactivated influenza vaccine|High Dose Influenza Fluzone® Vaccine (60 µg HA / viral strain; 180 µg/0.5 mL dose) will be administered to Arm 2: 200 subjects intramuscularly on Day 0.
45921609|NCT00115570|Drug|Insulin glulisine|Subcutaneous injection
45921610|NCT00115570|Drug|insulin lispro|Subcutaneous injection
45921611|NCT00115570|Drug|insulin glargine|Subcutaneous injection once daily
45921612|NCT00115570|Drug|NPH insulin|subcutaneous injection twice daily
45921613|NCT00115609|Drug|efavirenz|800mg for patients treated by rifampicine 600mg for other patients
45921614|NCT00115609|Drug|tenofovir DF|300mg once a day
45921615|NCT00115609|Drug|emtricitabine|one pill of 200mg once a day
45921616|NCT00115648|Drug|Nevirapine|Oral NVP daily dosage
45921617|NCT00115648|Drug|AZT|Oral AZT daily
45921618|NCT00115648|Drug|NVP and AZT|Oral single dose NVP plus oral daily AZT during the first weeks
45921619|NCT00115648|Drug|NVP|Oral NVP daily to age 14 weeks
45795044|NCT01189071|Drug|Darifenacin|an M3 selective anticholinergic medication. M3 muscarinic receptors are felt to be related to bladder and ureteral contractility. The ureteral and bladder spasms related to ureteral stents are felt to be due to inappropriate contractions. By using a selective M3 receptor, it is felt that there will be fewer side effects. Participants will be placed on the standard 15 mg oral daily dosage for 3 days prior to the stent being placed, day 3 being the am of the surgery.
45795045|NCT03024164|Other|Treatment following current guidelines|Treatment following current guidelines
45795046|NCT05065346|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
45921620|NCT00115648|Drug|NVP+AZT|Oral NVP daily plus oral AZT daly to age 14 weeks
45795047|NCT03770091|Drug|Theraworx|Theraworx foam applied to skin and/or compression wrap
45921621|NCT00008294|Drug|FOLFOX regimen|
45921622|NCT00008294|Drug|dexamethasone|
45921623|NCT00008294|Drug|floxuridine|
45921624|NCT00008294|Drug|fluorouracil|
45921625|NCT00008294|Drug|leucovorin calcium|
45921626|NCT00008294|Drug|oxaliplatin|
45921627|NCT00115687|Drug|placebo|
46071731|NCT05878873|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS is a form of nerve stimulation that stimulates at a frequency below motor threshold, targeting activation of sensory receptors, such as muscle spindles. Electrodes that create this stimulation will be placed on the skin superficial to the muscle bellies of the tibialis anterior and biceps femoris.
45921628|NCT00115687|Drug|2 mg nicotine polacrilex|
45921629|NCT00115726|Drug|furosemide|for patients on chronic furosemide therapy, patients are randomized to furosemide (at their previous dose) or placebo (given in identical form to ensure masking)
45921630|NCT00115726|Drug|placebo|patients will be given placebo capsules (identical to experimental arm in color) at the equivalent dose as to their chronic furosemide therapy.
45921631|NCT00401869|Drug|Epoetin alfa|
45648580|NCT05117125|Diagnostic Test|Proteome|Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.
45648581|NCT05117047|Procedure|liver resection|After adequate periods of follow-up, the long-term oncological outcomes of the three different surgical approaches were compared, providing a higher level of evidence using a non-randomized comparative study based on propensity score matching (PSM) analysis.
45648582|NCT05121961|Procedure|Sacroiliac intra-articular injection|CT guided injection of platelet-rich plasma versus steroid/anesthetic into the sacroiliac joint
45648583|NCT05116969|Drug|PTX-35|PTX-35 is a humanized, affinity matured, IgG2 monoclonal antibody
45921632|NCT00008333|Drug|vinorelbine tartrate|
45921633|NCT00115843|Device|Mobile Cardiac Outpatient Telemetry|
45921634|NCT00115882|Behavioral|MI + CBST|The HS Study intervention consisted of proactive identification and recruitment of eligible smokers (and selected nonsmokers) within the target population, and a protocol-guided series of counselor-initiated, personally-tailored telephone calls (from 1 to 10, depending on participant's interest) to eligible high school senior smokers and nonsmokers in experimental high schools. The telephone-delivered behavioral intervention integrated Motivational Interviewing and Cognitive Behavioral Skills building. Content and dose were tailored to the individual.
45921635|NCT00008372|Drug|chloroquinoxaline sulfonamide|
45921636|NCT00115921|Behavioral|Provision of antimalarial treatment at home|
46071732|NCT05878860|Biological|ATSN-201|AAV.SPR-hGRK1-hRS1syn
46071733|NCT05878847|Dietary Supplement|Q-actin|idoBR1 is an iminosugar amino acid isolated from fruits of certain cucumbers, Cucumis sativus (Cucurbitaceae), which has been shown to have anti-inflammatory activity. IminoTech Inc in the USA has produced a quality-controlled cucumber extract containing measured idoBR1 (Q-actin™) that has given good results in osteo-arthritis from oral use.
45449902|NCT02164552|Other|Placebo pills|Placebo pills similar in appearance and shape but without vitamin D
45449903|NCT03518073|Drug|Zagotenemab|Administered IV
45449904|NCT03518073|Drug|Placebo|Administered IV
45449905|NCT02759692|Device|TEST Contact Lens|
45449906|NCT02759692|Device|CONTROL Contact Lens|
45648584|NCT00232999|Drug|Nebulized IVX-0142|
45795048|NCT03770091|Drug|Placebo|Placebo foam
45795049|NCT02515851|Drug|Exparel|
45921637|NCT00115960|Biological|HIV-1 gag DNA|DNA vaccine containing the HIV gene gag
45921638|NCT00115960|Biological|IL-15 DNA adjuvant|Cytokine injection
45921639|NCT00115960|Biological|IL-12 DNA adjuvant|Cytokine injection
45921640|NCT00115999|Drug|alfimeprase|
45921641|NCT00008411|Drug|Docetaxel|Every 3 weeks at a starting dose of 75 mg/m2 IV over 1 hour on day 1, repeated every 21 days.
45921642|NCT00008411|Drug|Docetaxel|35 mg/m2 IV over 30 minutes on days 1, 8, and 15, for 3 weeks followed by one week of rest repeated every 28 days.
45921643|NCT04728373|Procedure|surgery|the need for surgery after aircraft accidents
46071734|NCT05878847|Dietary Supplement|Placebo|Placebo
45795050|NCT02515851|Drug|Placebo|
45795051|NCT02282930|Drug|ACTH (Acthar) Gel|Injected dose of 80 units subcutaneously twice weekly for 6 months.
45921644|NCT04727671|Drug|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
45921645|NCT04727671|Drug|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
45921646|NCT04727671|Drug|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
46071735|NCT05878821|Device|Shockwave|Shockwave therapy session once a week for month 1000shock per session
45795052|NCT01151553|Device|CRT Therapy|Screen for enrollment criteria, consented, echocardiogram and electrocardiogram performed, demographics reviewed, obtain blood sample, pre-operative QOL questionnaire and 6 minute hall walk
45921647|NCT04727671|Drug|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
45921648|NCT00116038|Device|Femoral implant (Versys Fiber Metal Taper®)|
45795053|NCT02492295|Drug|Propofol|"Propofol will be administered as a 0.5mg/kg (at a concentration of 10mg/mL, rounded to the nearest 0.5mL) initial bolus, followed by repeat 0.25mg/kg boluses (same rounding) every three to five minutes as needed to maintain RASS target -2 (light sedation - awakens to voice <10 seconds) to RASS target of -3 (moderate sedation - movement or eye opening without eye contact) for 15 minutes. No more than 1.5mg/kg of propofol will be administered over this time period. After the sedation session is complete, patients will be allowed to wake up and will be monitored in the ED for at least another hour prior to discharge."
45795054|NCT02468583|Drug|FX006 32 mg|Experimental
45921649|NCT00008450|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
45795055|NCT02468583|Drug|TCA IR 40 mg|Comparator
45921650|NCT00008450|Drug|Cyclosporine|Given PO or IV
45921651|NCT00008450|Other|Laboratory Biomarker Analysis|Correlative studies
45921652|NCT00008450|Drug|Mycophenolate Mofetil|Given PO or IV
45921653|NCT00008450|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic hematopoietic stem cell transplant
45921654|NCT00008450|Radiation|Total-Body Irradiation|Undergo TBI
45921655|NCT00116155|Biological|CV787 (CG7870)|
45921656|NCT00116194|Behavioral|Physical Activity|
45648585|NCT05116657|Diagnostic Test|Nasal Lavage and Oral Wash|"Nasal Lavage: The nasal lavage will be performed using a spray technique. Using a disposable metered-dose inhaler (100 µl per spray), room temperature saline will be sprayed in one nostril while the other nostril is closed. After 5 sprays, the subject will gently exhale through the lavaged nostril and the fluid will be collected in a specimen cup. The procedure will be repeated a minimum of 8 times and a maximum of 15 times in each nostril. After collection, the sample will be placed on ice and processed within 2 hours.~Oral Rinse: Oral samples will be collected using a standardized procedure in accordance with the Manual of Procedures for Human Microbiome Project.Study participants will rinse their mouth (swish/gargle) with 15 mL sterile normal saline for 1 min, and will expectorate the contents of the mouth into a 50 mL centrifuge tube. Sample should be kept cold on ice until processing."
45921657|NCT00116233|Device|REPEL-CV|
45921658|NCT00008489|Drug|Didanosine|
45648586|NCT05116501|Diagnostic Test|Whole-exome sequencing|Whole Exome Sequencing (WES), as a comprehensive genetic test, will be used to identify changes in a patient's DNA that are causative or related to patient's low VWF levels.
45648587|NCT05116345|Drug|DEXTENZA|Intracanalicular Dexamethasone ophthalmic insert (0.4mg)
45648588|NCT05116345|Drug|Topical Dexamethasone|topical dexamethasone drops
45648589|NCT05120401|Device|presbyopia glasses|fogging for glasses for far and intermediate
45795056|NCT02280122|Other|no intervention provided|No Intervention was rendered but the aMMP-8 test was made
45921659|NCT00116311|Behavioral|allergen inhalation|
45648590|NCT05121181|Other|delphi project|delphy study
45648591|NCT05120167|Diagnostic Test|Endocervical liquid-base cytology|Endocervical sample collected by brushing and preserved in a liquid-base.
45648592|NCT05120167|Diagnostic Test|Endocervical cell block|"Endocervical sample collected by endocervical brush and preserved in a buffered formalin base for obtaining a cell block and evaluated as histology."
45648593|NCT05120167|Diagnostic Test|Endocervical curettage|Endocervical sample obtained by curettage, preserved in buffered formalin, and evaluated as histology.
45648594|NCT05096689|Other|MRI|Magnetic Resonance Imaging
45795057|NCT02296476|Drug|Birabresib|Administered orally in a fasted state once daily.
45795058|NCT02987504|Drug|Samalizumab|Samalizumab is a humanized, anti CD200 monoclonal antibody provided as a sterile 5 mg/milliliters (mL) solution for IV administration.
45795059|NCT03763929|Drug|Trans-Sodium Crocetinate|In the study drug kit containing the experimental drug (TSC), TSC will be reconstituted with the Sterile Water for Injection (USP) supplied in the same kit. There will be an unblinded paramedic who will reconstitute and inject the TSC on the ambulance.
45795060|NCT03763929|Other|Placebo|The study drug kit containing placebo (sterile saline for Injection) will be prepared and injected by the unblinded paramedic on the ambulance.
45921660|NCT00116311|Behavioral|withdrawal of medication|
45921661|NCT00116311|Procedure|sputum induction|
45921662|NCT00116350|Drug|Misoprostol|800 mcg sublingual misoprostol
45921663|NCT00116350|Drug|Oxytocin|40 IU Oxytocin IV
45921664|NCT00116389|Drug|talabostat mesylate tablets|
45921665|NCT00116389|Drug|gemcitabine|
45921666|NCT00116467|Biological|GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)|
45921667|NCT00008528|Drug|Enfuvirtide|
45921668|NCT02986386|Procedure|Dental occlusion restoration|Placement of dental implants by surgical intervention followed, after a healing period of 2 months, by fabrication and installation of implant supported dental prosthesis
45921669|NCT02986386|Procedure|Orthodontic treatment of malocclusion|Orthodontic therapy to treat malocclusion
45921670|NCT00116506|Drug|erlotinib|
45921671|NCT00116506|Drug|FOLFOX|
45921672|NCT00116506|Drug|bevacizumab|
45921673|NCT00116545|Drug|troglitazone|
45921674|NCT00116623|Drug|Indomethacin|
45921675|NCT00116623|Drug|Magnesium sulfate|
45921676|NCT00116662|Drug|Resiquimod|
45921677|NCT02909322|Procedure|Bupivacaine and Hydromorphone|Patients receive bupivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
45921678|NCT02909322|Procedure|Ropivacaine and Hydromorphone|Patients receive ropivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
45921679|NCT00116701|Drug|Aranesp®|
45921680|NCT00116740|Drug|APD356|
45921681|NCT00116818|Drug|GW685698X aqueous nasal spray|
45921682|NCT00008801|Drug|hOKT3gamma1 (Ala-ala)|
45921683|NCT04727905|Dietary Supplement|energy drink|The explosive force and muscle endurance of the lower limbs were tested first, and then the special training intervention for fire rescue was performed. Solution supplementation was carried out. The experiment group was divided into the control group and only drank 1 liter of pure water, and the sports drink group supplemented with commercially available sports drinks (using commercially available treasures). Mineral water powder configuration), mint-flavored sports drink group supplemented with mint-flavored commercially available sports drinks (using commercially available treasure mineral water powder configuration plus edible flavor 0.01% menthol)
45921684|NCT00116896|Drug|OSI-7904L|
45921685|NCT00116896|Drug|Cisplatin|
45921686|NCT02752815|Drug|Rituximab|
45648595|NCT05076097|Drug|Orelabrutinib in in combination of rituximab and lenalidomide(OLR)|Induction treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: Cycle 1: 15mg QD D1-21, if no dose-limiting toxicity occurred in Cycle 1, cycle 2-6: 20mg QD D1-21; Cycle 1: 375 mg/m2 d1, 8,15,22; Cycle 3, 5: 375 mg/m2 D1 Maintenance treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: cycle 7-24: 15mg QD D1-21; Cycle 7, 9, 11, 13, 15, 17, 19, 21, 23: 375 mg/m2 D1. 28 days for a cycle.
45648596|NCT05059717|Procedure|Magnetic Resonance Imaging|Undergo standard of care MRI
45921687|NCT02752815|Drug|Cyclophosphamide|
45921688|NCT02752815|Drug|Epirubicin|
45921689|NCT02752815|Drug|Vincristine|
45921690|NCT02752815|Drug|Prednisone|
45921691|NCT00116935|Drug|imatinib mesylate|imatinib 400 mg/day orally qd for 12 months
45921692|NCT00116935|Drug|imatinib|imatinib 400 mg/d orally qd for 36 months
45921693|NCT00116935|Drug|imatinib|imatinib 400 mg/d orally qd for 36 months
45648597|NCT05059717|Procedure|Magnetic Resonance Imaging|Undergo MR DENSE imaging
45921694|NCT00388388|Drug|losartan, hydrochlorothiazide|Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
45648598|NCT04413019|Other|Clinical follow up|"Patients recruited in this study commenced antibiotic treatment according to the recent guidelines :~Erythromycin 250 mg 4 times daily for 10 days following the diagnosis of PPROM, or until the women is established labor (whichever sooner)~Penicillin may be used in patients who can't tolerate erythromycin~In cases of penicillin allergy: Cefazolin 1 g intravenously every 8 hours for 48 hours, followed by cephalexin 500 mg orally four times daily for five days. These drugs provide coverage for both GBS and Escherichia coli, the two major causes of neonatal infection."
45648599|NCT05119933|Drug|YL-15293|After a screening period of approximately 28 days, eligible patients will receive oral YL-15293 once daily until documented disease progression, unacceptable AEs, intercurrent illness prevents further administrations of study treatment, investigator's decision to withdraw the patient, the patient withdraws consent, pregnancy of the patient, or for administrative reasons (see Section 7.1). Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
45754372|NCT03586622|Dietary Supplement|Low FODMAP diet (LFD)|The Low FODMAP diet (LFD) is an acronym for Fermentable Oligo-, Di-, and Monosaccharides And Polyols - all of which are small osmotic active carbohydrates or sugar alcohols that are poorly absorbed in the small intestine and therefore easily fermented by the gut microbiota. The fact that they are fermented rapidly and osmotic active makes them potential and likely candidates for causing luminal distension due to accumulation of gas and water in the intestine.
45795061|NCT00378885|Behavioral|Cognitive-behavioral tailored intervention|
45795062|NCT03762993|Behavioral|Vocal rest and Controlled Phonation|Voice rest and semi occluded vocal tract voice exercises
45921695|NCT00116974|Procedure|Scaling and root planing|Scaling and root planing
45921696|NCT00117013|Drug|Fluorine-19-Fluoroded Xyglucose|
45921697|NCT00117013|Drug|Topotecan|
45921698|NCT02743455|Drug|ISA-720|The vaccine adjuvant ISA 720 will be used with Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) as vaccine adjuvant with a depot effect. This comprises slow release of antigen at the injection site, protection of antigen against degradation and strong stimulation of the immune response.
45921699|NCT02743455|Biological|MVA Smallpox Vaccine|Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine (MVA BN(R)) is a purified live vaccine will be used as an active comparator.
45449907|NCT02164630|Behavioral|Hope Therapy|Hope therapy is designed to address key components of hope theory through augmentation of hopeful thinking and enhancement of goal-directed activities. Training focuses on effective goal setting, mobilization of internal resources to reach goals, identification of resilience factors to formulate hopeful thinking, and enhancing maintenance of future goal development.
45795063|NCT03762213|Device|Oculus GO VR HMD, application Happy Place (© Mimerse)|The Entertainment Software Rating Board (ESRB) has rated Happy Place as 'E' ('Everyone' or content suitable for all ages).
45795064|NCT03762213|Device|iPad, application Happy Place (© Mimerse)|The Entertainment Software Rating Board (ESRB) has rated Happy Place as 'E' ('Everyone' or content suitable for all ages).
45795065|NCT01118013|Biological|anti-thymocyte globulin|
45795066|NCT01118013|Biological|donor lymphocytes|
45921700|NCT02743455|Biological|MVA-BN Yellow Fever Vaccine|Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) clinical trial material is manufactured in CEF cells derived from Specific Pathogen Free (SPF) eggs in a bioreactor culture using serum free medium.
45921701|NCT02743455|Other|Placebo|0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.
45921702|NCT02743455|Other|Placebo|0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.
45795067|NCT01118013|Biological|filgrastim|
45921703|NCT02743455|Biological|YF Vax 17D Strain|Yellow Fever Vaccine (YF-VAX) is a vaccine prepared by culturing the 17D-204 strain of yellow fever virus in living avian leucosis virus-free (ALV-free) chicken embryos. Will be used as an active comparator.
45921704|NCT00117052|Drug|cinacalcet|All eligible subjects were assigned to receive once daily oral doses of cinacalcet, but were randomised in a 1:1 ratio to receive the drug either with the first meal after dialysis or during the dialysis visit on dialysis days.
45921705|NCT00117091|Drug|Anakinra (Kineret®)|
45795068|NCT01118013|Biological|therapeutic allogeneic lymphocytes|
45648600|NCT05085847|Other|Mindfulness meditation training|Mindfulness-based intervention encompasses different practices which intend to exercise awareness by using mindfulness meditation training moment by moment. Thus, practices such as mindful breathing, compassionate communication, loving-kindness, self-compassion, mindful listening, dealing with difficulties, the 3 step meditation, walking meditation, body scan with progressive relaxation, thoughts, emotions, gratitude, and sounds and breathing will be teaching to participants. Mindfulness training will be conduct by two instructors with more than 30 years' experience in meditation practices (Zen and Tibetan Buddhist approach to mind-training) and extensive mindfulness teaching and practices (> 5 years each) experiences.
45795069|NCT01118013|Drug|busulfan|
45795070|NCT01118013|Drug|fludarabine phosphate|
45795071|NCT01118013|Drug|methotrexate|
45795072|NCT01118013|Drug|mycophenolate mofetil|
45795073|NCT01118013|Drug|tacrolimus|
45648601|NCT05085847|Other|Active control|Participants will receive lectures that provide cognitive and sensorial stimulus which does not specifically involve awareness training (meditation). Lesson topics include science.
45648602|NCT04932577|Biological|Faecal microbiota transplantation|All participant will receive three applications of either FMT or placebo and afterwards followed for 1 year.
45648603|NCT04932577|Biological|Placebo|Placebo
45795074|NCT01118013|Other|reduced-intensity transplant conditioning procedure|
45795075|NCT01118013|Procedure|allogeneic hematopoietic stem cell transplantation|
45795076|NCT01118013|Procedure|peripheral blood stem cell transplantation|
45795077|NCT00378027|Drug|Fondaparinux|Administer Fondaparinux Risk Stratify
45795078|NCT00552032|Drug|Mometasone Furoate nasal spray|Mometasone Furoate nasal spray 1 puff (50 mcg) per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
45795079|NCT00552032|Drug|Placebo|Placebo nasal spray 1 puff per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
45795080|NCT02429583|Drug|Recombivax|Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment
45795081|NCT04935632|Behavioral|prevention training|Evaluate the impact of hypothermia prevention training on the proportion of patients hypothermic patients in the operating room
45795082|NCT02413047|Drug|Azathioprine|Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
45795083|NCT02413047|Drug|6 mercaptopurine|Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
45795084|NCT02413047|Drug|Methotrexate|Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.
45795085|NCT02277548|Drug|Lyrica 300 mg|Lyrica 300 mg per day
45795086|NCT02277548|Drug|Placebo|
45795087|NCT00378963|Device|ProAdjuster|
45795088|NCT02988596|Other|Multidimensional Active Rehabilitation|Participants will be asked to complete activities aimed at: stabilization of symptoms, impairment reduction, activity integration, recovery acceleration and sport specific application during a 20 minute session at least 4 times a week. Activities will be selected by the supervising clinician with respect to the specific impairment presentation of each participant. Session logs will be completed by each clinician and will include the following information: initial symptom checklist, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
45795089|NCT02988596|Other|Enhanced Graded Exertion|Participants will be asked to use their symptoms to guide their activity from the time of their injury until they are asymptomatic. Once they are asymptomatic they will begin the graded exertion (Zurich/Berlin Protocol). During this time clinicians will complete session logs that include the following information: initial symptom checklist, phase of graded return to play progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
45795090|NCT02411643|Drug|topical calcipotriene 0.005% ointment|Affected area will be treated twice daily for 3 months
45795091|NCT02277626|Device|Electro Flo 5000|Airway clearance device
45795092|NCT02277626|Device|Incourage Vest System|Airway Clearance Device
45795093|NCT03758157|Diagnostic Test|welloStationX|welloStationX is an automated electronic thermometer using an infrared sensor of the surface of the forehead to measure human body skin temperature to screen for fever.
45795094|NCT03758157|Diagnostic Test|SureTemp|SureTemp is an oral thermometer to measure human body skin temperature.
45795095|NCT01107795|Procedure|Transoral Robotic Surgery|Base of tongue resection with transoral robotic-assisted surgery (TORS).
45795096|NCT02280200|Device|AFO to improve outcomes|Ankle foot orthoses (AFO) are light-weight, low profile carbon fiber devices that store and release energy during ambulation. The AFO, in combination with standard of care advice to walk more, will be used to determine if there is any improvement in PAD patient outcomes.
45795097|NCT01085643|Drug|Lubiprostone|24mcg PO taken once
45795098|NCT01085643|Drug|Placebo|24mcg placebo capsule taken once
45795099|NCT03028766|Drug|AZD1775|AZD1775 is a potent, selective small molecule inhibitor of WEE1
45795100|NCT03028766|Drug|Cisplatin|Chemotherapy drug
45795101|NCT03028766|Radiation|Radiotherapy|Intensity Modulated Radiotherapy
45795102|NCT01071993|Drug|placebo|pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
45795103|NCT01071993|Drug|atorvastatin|pre-treatment with atorvastatin (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
45795104|NCT02379585|Drug|Doxorubicin|doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
45795105|NCT02379585|Drug|cyclophosphamide|doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
45795106|NCT02379585|Drug|paclitaxel|For patients with HER2 negative breast cancer: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
45795107|NCT02379585|Drug|docetaxel|For patients with HER2 positive breast cancer: docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
45795108|NCT02379585|Drug|Trastuzumab|docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
45795109|NCT02379585|Drug|Pertuzumab|docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
45795110|NCT03756818|Drug|Mivavotinib|Given PO
45795111|NCT03756818|Drug|Paclitaxel|Given IV
45921706|NCT02972450|Biological|GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine|"The vaccine is a solution of HIV MVA vectors (see section 1.3.2) in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection."
45921707|NCT02972450|Biological|GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine+ Vedolizumab|"The vaccine is a solution of HIV MVA vectors (see section 1.3.2) in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection. Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline."
45921708|NCT02972450|Drug|Vedolizumab 300 MG [Entyvio]|Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline.
45921709|NCT02972450|Other|Placebo|"Placebo for MVA it is a solution composed of S08 buffer (as for the MVA vaccine) that will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection.~Placebo for GTU-MultiHIV B-clade vaccine: Sodium Chloride (NaCl) for infusion, 0.9%.~Placebo for Vedolizumab: Sodium Chloride (NaCl) for infusion, 0.9% in 250 ml infusion bags."
45921710|NCT00117130|Drug|Aranesp®|
45921711|NCT00117169|Procedure|multi-detector helical computed tomography|
45921712|NCT00117208|Drug|mannitol|400mg BD for 12 weeks
45921713|NCT00117208|Drug|mannitol + pulmozyme|combination
45921714|NCT00117208|Drug|Dornase alpha|2.5mg daily for 2 weeks
45921715|NCT00117247|Drug|darbepoetin alfa|
46071736|NCT05878808|Diagnostic Test|Psychometric assessment|Eighty subjects diagnosed with bipolar I disorder were enrolled in this study, subjects were divided according to the presence or absence of OCD to Group A: Bipolar disorder patients with OCD (n = 26), Group B: Bipolar disorder patients without OCD (n = 54). The following scales were applied: Dimensional Yale-Brown obsessive compulsive scale (DYBOCS)- Beck scale for Suicidal ideations (BSSI) - Hamilton depression rating scale (HDRS) and Young mania rating scale (YMRS).
46071737|NCT05878782|Other|MCRO+Occupational therapy|Experimental group A will combine the assessment of occupational problems (MCRO) and an occupational therapy intervention.
45648604|NCT04882111|Behavioral|ALIGN|The ALIGN intervention was developed by the Holding Group, an independent partnership of palliative care-trained social workers. The intervention is theory driven, patient/caregiver centered, addresses palliative care and psychosocial issues, and integrates with health care teams. Working in collaboration with KPCO and Dr. Stacy Fischer (primary mentor), the Holding Group tested the ALIGN intervention in the LTAC and SNF setting (Preliminary Studies). The Holding Group will be the intervention personnel providing psychosocial care that targets communication, goal alignment, and caregiver support.
45648605|NCT05230069|Other|Interview|Patients will be interviewed post an emergency call and evaluation.
46071738|NCT05878782|Other|MCRO without intervention|Experimental group B will have only the MCRO assessment because the occupational problems assessment alone (without intervention) could improve quality of life and occupational performance outcomes, according to the Nielsen, 2019 study
45449908|NCT02164630|Other|Pain Education|Pain Education is aimed to increase understanding of TMD symptomatology and etiology, as well as provide general education on pain, lifestyle management, and effective pain communication methods.
45795112|NCT03756818|Other|Pharmacokinetic Study|Correlative studies
45795113|NCT01065051|Drug|Riociguat (Adempas, BAY63-2521)|1 mg single oral dose
45449909|NCT03723135|Drug|CC-486|Oral azacitidine administered as directed by treating physician.
45449910|NCT02167750|Other|Cherry Flavored Beverage|Intervention involves consuming one beverage at the beginning of each visit of the crossover sequence.
45449911|NCT03586167|Device|LID014341 contact lenses|Investigational monthly replacement silicone hydrogel contact lenses with water gradient coating
45795114|NCT01065051|Drug|Placebo|Single oral dose
45795115|NCT02376933|Procedure|Vertebroplasty|Under imaging guidance, a fractured vertebral body is stabilized with injected bone cement.
45648606|NCT04513639|Drug|Early treatment of relapse with carfilzomib, dexamethasone, daratumumab|Second line treatment will start at MRD reapperance
45795116|NCT02376933|Radiation|Radiotherapy|Radiotherapy of metastatic lesions to the spine.
45795117|NCT01048125|Device|Sympathetic Nerve Activity|Resting Sympathetic Nerve Activity
45795118|NCT01048125|Behavioral|Mental Stress Test (Color Word Test)|"A printed word will be shown to the subject, displayed in a color different from the color it actually names. The subject will be asked to say the color that the word is printed in as quickly as possible. For example if the word green is written in blue ink, they will say blue. This mental stress procedure will be used to cause brief changes in heart rate and blood pressure."
45795119|NCT01048125|Drug|The Modified Oxford Technique for Baroreflex Sensitivity|Sodium nitroprusside (100 µg) will be infused intravenously as a bolus, followed 60 seconds later by a bolus of phenylephrine hydrochloride (150 µg). Infusion of nitroprusside will decrease blood pressure approximately 10-15 mmHg below baseline values. Subsequent phenylephrine infusion will increase blood pressure approximately 10-15 mmHg above baseline values. Nitroprusside and phenylephrine have been used extensively to assess baroreflex sensitivity in healthy as well as heart failure populations. Additionally, the dosages being used have been shown to minimize the risk of excessive decreases or increases in blood pressure.
45795120|NCT01048125|Other|Cold Pressor Test|The subject will be asked to place their hand in ice water for 2 minutes. This procedure will be used to cause transient changes in sympathetic nerve activity, heart rate and blood pressure.
45795121|NCT01048125|Device|Echocardiographic evaluation|Transthoracic echocardiography with 2D, color and pulse Doppler will be employed in all of our subjects. Baseline left ventricular function, systolic as well as diastolic, will be quantified.
45795122|NCT01901588|Drug|Dexmedetomidine|intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes
45921716|NCT00388427|Drug|Dasatinib (BMS-354825)|100 mg, 150 mg, or 200 mg per dose escalation schedule; continuous oral dosing on Days 1-21 of each 21-day cycle until progression or unacceptable toxicity develops.
45921717|NCT00388427|Drug|Cetuximab (Erbitux, C225)|Loading dose of IV 400 mg/m^2 on Day 1 of Cycle 1; IV 250 mg/m^2 weekly thereafter each 21-day cycle until progression or unacceptable toxicity develops.
46071739|NCT05878743|Behavioral|Safety Planning a recovery-orientated mental health risk management intervention|Developing the skills to manage risks associated with mental health difficulties in ways which increase personal recovery for individuals.
46071740|NCT05878730|Diagnostic Test|urine collection|"Urine collection will be made on a 12 hours period (20h00-8h00), the night before V2~at V2 : 2 mL urinal sample for measure of 6-SMT concentration (ng/mL) and creatinin (mg/mL)~Measure of 6-SMT will be made by a validated radio-immunology assay"
45449912|NCT03586167|Device|Comfilcon A contact lenses|Silicone hydrogel contact lenses
45449913|NCT02167828|Behavioral|Social Support|
45648607|NCT04513639|Drug|Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab|Second line treatment will start at progressive disease
45648608|NCT04765735|Device|Open-loop testing, Closed-loop testing - External Spinal Cord Stimulator (SCS)|SCS therapy with an external neurostimulator using either open-loop or closed loop algorithm
45795123|NCT01901588|Other|Placebo|intraoperative dose of intravenous placebo
45795124|NCT03673124|Drug|Ribociclib|600 mg by mouth daily for 21 days followed by 7 days off treatment
45921718|NCT00117364|Drug|SACCHACHITIN patch|
45921719|NCT00117403|Drug|Vitamin E, Vitamin C, and Alpha-lipoic Acid|vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals
45648609|NCT04746001|Diagnostic Test|Genomic sequencing|Sequencing data
45648610|NCT04746001|Diagnostic Test|Histological examination|Images for deep learning
45921720|NCT00117403|Drug|Coenzyme Q|400 mg, compounded as a wafer, two wafers three times per day with meals
45921721|NCT00117403|Drug|Placebo capsules|one placebo capsule three times per day with meals
45921722|NCT00117403|Drug|Placebo wafers|two placebo wafers three times per day with meals
45921723|NCT00423410|Drug|EPC2407 (crinobulin)|IV infusion 1 to 4 hours
46071741|NCT05878730|Diagnostic Test|Level of Protein 14.3.3|"blood sample at V2 (2x7mL ACD tubes)~measured by ELISA"
46071742|NCT05878730|Diagnostic Test|Level of miR-451|"blood sample at V2 (2.5mL PAX-gene tube)~measured by quantitative RT-PCR"
46071743|NCT05878717|Biological|Belimumab|Belimumab will be administered.
46071744|NCT05878717|Other|Placebo|Placebo will be administered.
46071745|NCT05878704|Drug|GBT021601|Oral
45648611|NCT04696549|Behavioral|Virtual visual art experience guided by Visual Thinking Strategies|All study dyads (where study dyad consists of a participant with dementia and his/her care-partner) will participate in 3 scheduled virtual visual art sessions via Zoom. Each session will last about an hour and will include a guided discussion of pre-selected visual art using the Visual Thinking Strategies approach. It is anticipated that two pieces of art will be shown during each art session. The three sessions will be scheduled one month apart.
45795125|NCT03673124|Drug|Letrozole|2.5 mg by mouth daily
45795126|NCT01056315|Drug|GRT3938Y|Overencapsulated tablets of GRT3983Y, 100 to 300mg daily dose, 16 weeks treatment.
45795127|NCT01056315|Drug|Placebo|Overencapsulated tablets of placebo, 16 weeks treatment.
45795128|NCT03656354|Device|Seismocardiography|Seismocardiography recording
45795129|NCT05296785|Procedure|intramedullary nail with Limb Reconstruction System|bone transport by Limb Reconstruction System over intramedullary nail on fracture tibia
45795130|NCT01025271|Drug|Daptomycin|one dose of daptomycin (10 milligrams of the drug per kilogram of the subject's body weight
45921724|NCT00117442|Drug|carboplatin|Chemotherapy
45921725|NCT00117442|Drug|paclitaxel|chemotherapy
45921726|NCT00117442|Drug|pegfilgrastim|Growth factor for mobilization
45921727|NCT04728022|Behavioral|Education program|Mentored high school summer research program
46071746|NCT05878678|Device|Fixed positions of arm down and arm up|In order to explore the accuracy of breast cancer patients' treatment positions and its impact on dose of the new fixation device in two different fixed positions of arm up and arm down, optimize the position fixed equipment and methods of particle radiotherapy for breast cancer, and then establish the precision process of particle radiotherapy for breast cancer under the guidance of multimodal images.
45648612|NCT04675333|Drug|Evorpacept|IV Q3W
45648613|NCT04675333|Drug|Pembrolizumab|IV Q3W
45648614|NCT04675333|Drug|Cisplatin/Carboplatin; 5FU|IV Q3W
45648615|NCT05119543|Other|outdoor time|This cohort study aimed to assess the change of refractive status in Chinese school children under different outdoor time
45648616|NCT05229913|Drug|Esketamine is not added|Postoperative intravenous analgesia pump formula：Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg
45648617|NCT05229913|Drug|Esketamine 0.2mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.2mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
45795131|NCT03029858|Other|No interventions will be taken in this Observational study|TAGRISSO(osimertinib/AZD9291）
45795132|NCT02973555|Other|PRP injection|autologous intrauterine infusion of PRP
45795133|NCT01902758|Drug|ambrisentan and theophylline|
45795134|NCT01902758|Drug|placebo|placebo for comparison group
45795135|NCT02336763|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
45795136|NCT02336763|Other|Laboratory Biomarker Analysis|Correlative studies
45795137|NCT01020903|Procedure|Aprepitant|40 mg po pre-op
45795138|NCT01020903|Drug|Placebo|Orally, pre-op
45795139|NCT02318901|Drug|Pembrolizumab|
45795140|NCT02318901|Drug|Trastuzumab|
45795141|NCT02318901|Drug|ado-trastuzumab emtansine|
45795142|NCT02318901|Drug|Cetuximab|
45795143|NCT01904864|Drug|elemental iron (NovaFerrum®)|single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks
45795144|NCT01904864|Drug|elemental iron (Ferrous Sulfate)|single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, Ferrous Sulfate, for 12 weeks
45795145|NCT01016847|Drug|Montelukast|10 mg Q day
45795146|NCT01016847|Other|Sugar pill|Sugar pill that looks like Montelukast that will be given Q day
45795147|NCT00989937|Drug|Oxytocin|20 IU BID or 40 IU BID
45795148|NCT00989937|Drug|Placebo|20 IU BID or 40 IU BID
45795149|NCT00982995|Drug|Palonosetron|Palonosetron 0.25 mg as an I.V. bolus. After Palonosetron treatment, no other nausea medication will be given for 2 hours. At that point, if no relief from nausea or vomiting has occured then other anti-nausea medications may be prescribed, and patient will be taken off study. If relief from nausea and vomiting as a result of the Palonosetron occurs, patient will not receive any more anti-nausea medication unless nausea recurs. If it does recur and patient wishes to be retreated with Palonosetron. This may be repeated for a total of 3 doses, as long as it is providing relief.
45795150|NCT01905254|Device|Transient elastography (TE)|TE and minilaparoscopic guided liver biopsy were performed by physicians blinded to the results the other within a period of less than 3 months.
45795151|NCT01905254|Other|Liver biopsy|Minilaparoscopic guided liver biopsy was performed within a period of 3 months of Transient Elastography
45795152|NCT00965055|Drug|Ezetimibe|10 mg
45795153|NCT00965055|Drug|Atorvastatin|"Visit 1: (atorvastatin open label challenge): Those who complete the initial screening and washout period will receive open label atorvastatin 10 mg daily for 6 weeks to verify compliance and confirm hyporesponse to statin therapy.~Visit 2: After 6 weeks of therapy repeat baseline fasting cholesterol. Those with LDL-c reduction of 25% or less will be able to proceed to next phase. Patients with greater than 25% LDL-C reduction will be excluded. We expect to randomize 80 patients~Visit 2a: Dispensing of first randomized drug allocation- all patients receive open label atorvastatin 10 mg with additional ezetimibe 10 mg or matching placebo. No blood test during this visit.~Visit 3, 4, 5: Dose titration to atorvastatin to 20 mg, 40 mg, 80 mg, respectively, after fasting blood test~Blood collected in visits 3, 4, and 5 will be stored for additional tests regarding cholesterol metabolism and inflammation.~Visit 6: Final cholesterol panel and conclusion of study period"
45795154|NCT04331925|Behavioral|Anxiety and depression screening|At the time of consent, the participant parent will be randomized into either the control or intervention groups. The control group will complete the Hospital Anxiety and Depression Scale (HADS) questionnaire at the start of the study. After two weeks or at the time of discharge, the control group will complete the HADS questionnaire again.
45795155|NCT04331925|Behavioral|Journaling|Parents randomized into the intervention group be given verbal instructions to use a journal how/when they choose for the duration of the intervention period
45795156|NCT01905956|Dietary Supplement|IQP-AK-102|IQP-AK-102 was presented in the form of a capsule containing proprietary, patent pending combination of three soluble fibres and excipients.
45795157|NCT01905956|Dietary Supplement|Placebo|The placebo contained microcrystalline cellulose and other excepients. Both active and placebo capsules had identical physical appearance in terms of size, shape, colour and opacity.
45921728|NCT05441371|Other|Toothpaste; Paradontax|Comparison of Paradontax toothpaste anti-plaque abality versus regular toothpaste
45921729|NCT00117481|Drug|DR-2001a|DR-2001a administered vaginally each month
45921730|NCT00117481|Drug|DR-2001b|DR-2001b administered vaginally each month
45921731|NCT00117481|Other|Placebo|Placebo administered vaginally each month
45648618|NCT05229913|Drug|Esketamine 0.4mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.4mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200ml.
45648619|NCT05229913|Drug|Esketamine 0.6mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.6mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
45648620|NCT05229913|Drug|Esketamine 0.8mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.8mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
45648621|NCT05229835|Other|Time restricted eating and exercise|We apply time restricted eating, exercise alone and combined
45921732|NCT00117520|Drug|Caffeine|
45921733|NCT00000113|Other|Progressive Addition Lenses|Varilux comfort with +2.00 addition
45921734|NCT00000113|Other|single vision lenses|
45795158|NCT00378651|Procedure|Neck Auscultation|
45795159|NCT02266797|Drug|Dexamethasone|The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
45795160|NCT02266797|Other|Saline|The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.
45795161|NCT00378183|Drug|risperidone|
45795162|NCT00936585|Other|Immunologic Monitoring|blood draws and colonoscopy before and after receiving study drug
45795163|NCT00378261|Procedure|Use of an Electronic Data Capture System by patients and physicians to assess patient-physician interactions & therapeutic decisions & outcomes in RA subjects.|
46071747|NCT05878665|Diagnostic Test|Weight-adjusted low-dose contrast media paired with low-radiation dose abdomen CT|The investigators are aiming for a 10% reduction in iodine dosage at 10 kVp reduction in CT radiation. Routine iodine dosing is 0.521 g I/kg at 120 kVp. Therefore, at 90 kVp, a 30% reduction in iodine dosing is expected, which is 0.365 g I/kg. At 100 kVp, the iodine dosage is reduced to 0.417 g I/kg, which is a 20% reduction. The kVp value is automatically selected by the CT device according to the body habitus, which is a clinical routine.
45795164|NCT01906658|Drug|Repository corticotropin injection|Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks
45795165|NCT02192775|Drug|MV-NIS|one dose in conjunction with a 4 day course intravenously
45795166|NCT00935649|Device|PinPointe FootLaser|Medical laser
45795167|NCT01908062|Drug|Extended Release Naltrexone|
45795168|NCT01908062|Other|Treatment As usual|
45795169|NCT00924807|Drug|Leuprolide acetate, Bicalutamide, Sorafenib|Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg
45795170|NCT00896025|Drug|N-acetylcysteine|"Patients will be included in the trial from the onset of any hepatic coma grade and will receive NAC for the following 72 hrs.~NAC Solutions: The N-acetylcysteine will be added to 5% dextrose in defined concentrations according to the sequence of four specific doses required for the study.~i.Solution A: 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour~ii.Solution B: 50 mg/kg in 500 ml 5% dextrose over four hours~iii.Solution C: 125 mg/kg in 1000 ml 5% dextrose over 19 hours~iv.Solution D: 150 mg/kg in 1000 ml 5% dextrose per 24 hours~v.Solution E: 150 mg/kg in 1000 ml 5% dextrose per 24 hours"
45795171|NCT03325088|Procedure|Bronchial endoscopy|Bronchial endoscopy will be performed after clinical examination and pulmonary function tests
45795172|NCT03325088|Procedure|Bronchial biopsies|5 biopsies will be done and analysed at the end of recruiting to assess monomeric GTP Rac1 protein expression and activity on bronchial biopsies
45795173|NCT03325088|Procedure|Bronchial alveolar enema|For participants who had signed ancillary research consent
45795174|NCT01908530|Device|Microprobe glucose sensor|Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.
45795175|NCT02162979|Drug|sildenafil|sildenafil 50mg BID for 2 weeks
45795176|NCT02162979|Drug|Placebo|
45795177|NCT03734601|Radiation|Total body irradiation (TBI)|Administer Total body irradiation (TBI) 80 cGy on Day 1 of standard TLI ATG conditioning
45795178|NCT03734601|Drug|Anti-thymocyte globulin (ATG)|Given intravenous (IV), Dose 1.5 mg/kg x 5 days
45795179|NCT03734601|Drug|Tacrolimus|Oral, Dose 0.05 mg/kg twice daily, can be given intravenous (IV)
45795180|NCT03734601|Drug|Mycophenolate mofetil (MMF)|Given Oral, 15 mg/k every 2 hours for peripheral blood stem cells (PBSC) from matched related donors; 15 mg/kg every 8 hours for PBSC from unrelated donors (URDs) or mismatched related donors.
45795181|NCT03734601|Radiation|Total lymphoid irradiation (TLI)|9 x 120 cGy over 11 days
45795182|NCT01908842|Drug|BNX sublingual tablets|Buprenorphine/naloxone sublingual tablets
45795183|NCT01908842|Drug|BNX sublingual film|Buprenorphine/naloxone sublingual film
45449914|NCT03723057|Drug|AG-221|Oral AG-221 administered as directed by treating physician.
45795184|NCT01908842|Drug|Buprenorphine|Buprenorphine sublingual tablets
45795185|NCT05292261|Other|Recreational team handball|Two to three weekly sessions of recreational team handball training for 36 weeks. Each 60-min session started with a standardised warm-up (including running, coordination, strength, flexibility, and balance exercises) followed by three 15-min periods of recreational team handball matches, interspersed by 2-min breaks, played as small-sided games (4v4, 5v5 or 6v6). The training sessions were performed on an indoor team handball court (40x20 m) adjusted to result in 34-36 m2 per player. During the matches, the participants rotated positions every 3 min in a random order, including the goalkeeper and no exclusions or substitutions were applied.
45795186|NCT03727425|Device|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.
45795187|NCT02987816|Device|Sham tDCS|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
45795188|NCT02987816|Device|Anodal tDCS|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
45795189|NCT00833859|Drug|GTX (gemcitabine, docetaxel and capecitabine)|GTX: 21 day cycle x 2 Gemcitabine 750mg/m2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m2 on days 1-14
45795190|NCT00833859|Radiation|stereotactic body radiation therapy|stereotactic body radiation therapy (SBRT) 25
45795191|NCT00832299|Drug|FOLFOX|6 cycles of neo-adjuvant mFOLFOX6
45795192|NCT00832299|Procedure|total mesorectal excision (TME)|TME will be done 4-6 weeks after 6 cycles of neo-adjuvant FOLFOX.
45795193|NCT03723603|Device|Fibrillar collagen powder dressing|A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.
45795194|NCT03723447|Drug|Liposomal bupivacaine|Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.
45648622|NCT04667923|Diagnostic Test|Respiratory monitoring|Measurement of the tidal volume, peak inspiratory flow, inspiratory time, respiratory rate and the pressure gap during triggering on NIV and plateau pressure on mechanical ventilation
45648623|NCT04667923|Diagnostic Test|Respiratory muscles ultrasound|Measurement of the diaphragm thickening fraction, assessment of the contraction of scalene and sternocleidomastoid muscles
45795195|NCT03723447|Drug|Bupivacaine/epinephrine/dexamethasone|Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.
45795196|NCT03718455|Device|Axillary Magseed|The Magseed will replace the investigators' current clinical practice of using radioactive seeds in women receiving neoadjuvant chemotherapy.
45795197|NCT00836355|Drug|Enoxaparin|2 (or 3) intravenous doses, the first on study entry, the last 24 hours later
45795198|NCT00836355|Drug|Minocycline|200 mg orally once daily for 5 days
45795199|NCT00816777|Procedure|Chemoembolization with irinotecan Bead|Intra arterial chemoembolization using Irinotecan Bead 100mg irinotecan per procedure in combination with irinotecan monotherapy 250mg/m2 alternating on a 3 weekly schedule
45648624|NCT04667923|Diagnostic Test|Electro impedance tomography|Measurement of the lung impedance changes in 4 quadrants, measurement of regional ventilation delay in 4 quadrants
45921735|NCT04727515|Drug|fentanyl 2µg/kg intravenously and maintained with isoflurane|Anesthesia will be induced using titration of intravenous propofol till loss of verbal contact and fentanyl 2µg/kg intravenously and maintained with isoflurane (end tidal up to 1.5%), oxygen in air 50:50 via a laryngeal mask.
45648625|NCT04667923|Diagnostic Test|Capnography|Measurement of end-tidal carbon dioxide tension
45795200|NCT00816777|Drug|Irinotecan|Irinotecan monotherapy: 250mg/m2 repeated every 3 weeks
45795201|NCT00823095|Drug|Nitric Oxide|Topically applied gaseous nitric oxide at 8 to 10 parts per million, for 8 hours each night for 14 nights.
45795202|NCT03703791|Biological|AR101|AR101 powder
45795203|NCT00803283|Drug|Hydromprphone Hydrochloride (HCl) OROS|Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
45921736|NCT04727515|Procedure|Axillary nerve Block|Axillary block will be performed using ultrasound technique. Patients will receive an axillary block under ultrasound guidance using a linear 5-12 MHz probe.
45648626|NCT04667923|Diagnostic Test|Arterial blood gas|Measurement of the oxygen partial pressure and the carbon dioxide partial pressure
45648627|NCT04667923|Diagnostic Test|Quasistatic pressure-volume curve|Quasistatic pressure-volume curve
45795204|NCT00803283|Drug|Morphine Sustain Release (SR)|Participants will receive morphine SR 8 mg every24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
45648628|NCT05229757|Other|Physiotherapy and rehabilitation treatment in a special education and rehabilitation center.|Routine physiotherapy and rehabilitation practice was performed 2 days a week for 8 weeks in the special education and rehabilitation center.
45795205|NCT03701295|Drug|Azacitidine|Given IV or SC
45921737|NCT00117754|Drug|Terbinafine hydrochloride|
45449915|NCT03722979|Procedure|Cardiac surgery|The study will enroll patients having a planned cardiac surgery under extracorporeal circulation (CEC)
45648629|NCT05229757|Other|Family-based home exercise.|Home exercise was applied by the families every day of the week for 8 weeks.
45648630|NCT05229289|Other|Standard Medical Treatment|"Standard medical therapy (SMT):~Lactulose (Titrated to 2-3 soft bowel movements per day) Oral LOLA can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Oral BCAAs can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Diet Daily energy intakes of 35-40 kcal/kg ideal body weight Daily protein intake 1.2-1.5 g/kg/day Small meals or liquid nutritional supplements evenly distributed throughout the day Oral BCAA supplementation in patient's intolerant of dietary protein (to allow recommended nitrogen intake to be achieved and maintained)"
45648631|NCT05229289|Other|Fecal Microbiota Transplant|Fecal Microbiota Transplant
45648632|NCT01362517|Biological|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at 2, 3 and 4 months of age"
45795206|NCT03701295|Drug|Pinometostat|Given IV
45795207|NCT03697551|Drug|Satoreotide trizoxetan|Subjects will receive a single dose of Satoreotide trizoxetan consisting of a peptide mass up to 45 μg, with a radioactivity range of 150-200 MBq. Satoreotide trizoxetan is intended for diagnostic use as a Positron emission tomography/computed tomography (PET/CT) tracer for the imaging of tumours expressing SSTR2.
45795208|NCT00379119|Other|diagnostic laboratory biomarker analysis|
45795209|NCT00379119|Other|flow cytometry|
45795210|NCT00379119|Other|physiologic testing|
45795211|NCT00379119|Procedure|computed tomography|
45795212|NCT00799773|Drug|Rituximab|Dose of 375 mg/m2, given intravenously, repeated at 1-week intervals for a total of four doses
45795213|NCT00799773|Procedure|Plasma exchange|Target volume of 1.25 plasma volume replacement; fresh frozen plasma (FFP) is the required replacement fluid; provided daily until platelet counts are normal and signs of tissue damage have improved.
45795214|NCT00799773|Drug|Corticosteroids|1 mg/kg of prednisone (or equivalent) each day until plasma exchange is stopped
45921738|NCT00117832|Drug|Azelastine nasal spray|
45921739|NCT00117871|Drug|Resiquimod|
45921740|NCT00117910|Drug|pegfilgrastim|
45921741|NCT00118027|Drug|sulphadoxine-pyrimethamine intermittent preventive treatment|
45921742|NCT00118066|Dietary Supplement|calcitriol|Given orally
45921743|NCT00118066|Procedure|observation|No initial intervention
45921744|NCT05636150|Drug|Fruquintinib in Combination with S-1|"Cohort A: Fruquintinib 3 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort B: Fruquintinib 4 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort C: Fruquintinib 5 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Patients will be treated until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria."
45921745|NCT00118105|Biological|bevacizumab|Preoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3 Postoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3,4
45921746|NCT00118105|Drug|capecitabine|Pre & Post Operative: 1,700 mg/m^2/day, PO at 12 hr interval, Days 1-14 of cycles 1,2,3,4
45921747|NCT00118105|Drug|oxaliplatin|130 mg/m^2, IV, Day 1 of cycles 1,2,3,4
45921748|NCT00118105|Procedure|conventional surgery|Resection
45648633|NCT05229133|Device|CLEAR|FEMTO LDV Z8 Surgical Laser is intended for use in Corneal Lenticule Extraction for Advanced Refractive correction (CLEAR), also called Curved Lamellar Resection (CLR), for the reduction or elimination of myopia from -0.50 D to -10.00 D, with astigmatism of 0 D to -5.00 D or without astigmatism, and MRSE of -0.50 D to -12.50 D in the eye to be treated in patients who are 18 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude.
45795215|NCT00765765|Drug|hydroxychloroquine|Dose escalation from 200 mg po qd to 200 mg po bid.
45795216|NCT00765765|Drug|ixabepilone|Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.
45795217|NCT01975467|Device|CRx|The CRx is used to treat mid-shaft, with or without comminution clavicle fractures.
45795218|NCT00760461|Drug|Domperidone|10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily
45795219|NCT00750555|Drug|Erlotinib|150 mg per day orally until disease progression occurs, up to a maximum of 12 months
45795220|NCT00754767|Drug|L-carnitine L-tartrate|Given orally
45795221|NCT00754767|Other|placebo|Given orally
45795222|NCT00751335|Device|CPAP with ThermoSmart, then CPAP without ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
45795223|NCT00751335|Device|CPAP without ThermoSmart, then CPAP with ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
45921749|NCT00118183|Drug|docetaxel|Given IV
45921750|NCT00118183|Biological|cetuximab|Given IV
45921751|NCT00118183|Drug|bortezomib|Given IV
45921752|NCT00390975|Drug|Tegaserod|
45921753|NCT05636306|Drug|NoNO-42|A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute
45921754|NCT05636306|Drug|Placebo|A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.
45921755|NCT00118222|Drug|porfimer sodium|All patients receive porfimer sodium IV.
45921756|NCT00118222|Procedure|adjuvant therapy|All patients receive porfimer sodium IV.
45921757|NCT00118222|Procedure|conventional surgery|All patients receive porfimer sodium IV. One day later, patients undergo craniotomy and tumor resection.
45921758|NCT00118261|Biological|bevacizumab|Beginning in course 3, patients also receive bevacizumab IV over 30 minutes. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
45921759|NCT00118261|Drug|erlotinib hydrochloride|Courses 1-3: oral erlotinib once daily on days 1-14. Patients who do not develop grade 2 toxicity after the first 3 courses (6 weeks) will have their erlotinib dose escalated. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
45921760|NCT00118261|Drug|fluorouracil|Starting with course 2: fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
45921761|NCT00118261|Drug|leucovorin calcium|Starting with course 2: Leucovorin calcium IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
45648634|NCT04330261|Other|Exposure (not intervention) - SARS-CoV-2 infection|Exposure is infection with the virus. There is no intervention
45648635|NCT05108155|Procedure|Cemented THA|THA with cement fixation
45648636|NCT05108155|Procedure|Unemented THA|THA with uncemented / pressfit fixation
45795224|NCT01962675|Device|Transcranial direct current stimulation + step training|Direct current stimulation of motor cortex with low stimulation intensity
45795225|NCT01962675|Behavioral|Sham transcranial direct current stimulation + step training|Stepping over specified soft foam obstacles
45795226|NCT00706329|Device|Deflux|Patients undergo surgery using Deflux to correct umbilical hernia
45795227|NCT01941615|Drug|faldaprevir|oral doses for 10 days (period B)
45795228|NCT01941615|Drug|Microgynon®|oral doses for 23 days (period A+B)
45795229|NCT01941615|Drug|BI 207127|oral doses for 10 days (period B)
45795230|NCT01901679|Drug|Celebrex|200 mg PO BID
45795231|NCT00688935|Biological|Melatonin|0.1-3 mg, daily, up to 1 year (minimum duration of 6 weeks)
45795232|NCT01877343|Device|CVInsight(TM)|Patient will be placed on a tilt table and pulse oximetry (Nonin Medical) and blood pressure will be measured at different table positions (different angles). Four positions will be explored. A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
45795233|NCT00684255|Procedure|Reduced Intensity Allogeneic Transplant|Eeduced intensity allogeneic stem cell transplantation with a fludarabine/busulfan/alemtuzumab conditioning regimen is anticipated to result in mixed and/or complete donor chimerism and potentially alter the natural history and outcome of patients with medically refractory Systemic Lupus Erythematosus (SLE) or Systemic Sclerosis (SSc).
45795234|NCT00684255|Drug|Fludarabine|Fludarabine 30 mg/m2 Day -7, -6, -5, -4, -3, -2
45795235|NCT00684255|Drug|Busulfan|Busulfan 3.2 mg/kg Days _8, -7, -6, -5
45921762|NCT00118261|Drug|oxaliplatin|Starting with course 2: oxaliplatin IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
45921763|NCT02733081|Procedure|Simplified IUD Insertion|IUD Insertion with no bimanual pelvic exam or uterine sounding.
45921764|NCT00118300|Drug|capecitabine|Patients also receive oral capecitabine twice daily 7 days a week in weeks 1-5 and 7-8. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
45921765|NCT00118300|Radiation|brachytherapy|1 or 2 applications of low-dose rate intracavitary brachytherapy in weeks 7-8 OR 5 applications of high-dose rate (HDR)* intracavitary brachytherapy once weekly in weeks 4-8.
45795236|NCT00684255|Drug|Campath|Campath: 2 mg/m2 Day -5; 6 mg/m2 Day -4, -3; 20 mg/m2 Day -2
45795237|NCT00668265|Drug|Quetiapine|Dosage is 50 - 300 mg, once daily, at bedtime.
45795238|NCT01856361|Drug|Ramipril|Angiotensin Converting Enzyme Inhibitor
45795239|NCT01856361|Drug|Placebo|Placebo pill that will match the treatment pill
45795240|NCT00642603|Drug|capecitabine [Xeloda]|1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
45795241|NCT00642603|Drug|capecitabine [Xeloda]|1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
45795242|NCT00642603|Drug|bevacizumab [Avastin]|5 mg/kg taken intravenously on Day 1 of each 2 week cycle
45795243|NCT00642603|Drug|oxaliplatin|85 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
45795244|NCT00642603|Drug|irinotecan|135 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
45795245|NCT03689192|Biological|ARG1-18,19,20|300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide
45795246|NCT01841931|Drug|Buprenorphine/Naloxone|Sublingual buprenorphine/naloxone taken in a 3 day induction, with a final daily dose (up to 32 mg depending on the subject) taken daily, as prescribed by the study psychiatrist. Subjects will continue buprenorphine for study duration (6 months).
45795247|NCT05313087|Biological|COVID-19 vaccine|assess response to vaccine
45795248|NCT00633087|Drug|2-deoxyglucose|30 mg/kg of 2-deoxyglucose administered orally on a daily schedule for two weeks (Days 1-14) of a three week (21 Day) cycle.
45795249|NCT00610467|Device|Disease Group|Participants will received the following agents before their imaging are taken MRI contrast agent (0.1 mmol/kg) optical contrast agent ICG (0.5 mg/kg)
45795250|NCT00610467|Device|Control Group|Participants will received the following agents before their imaging are taken MRI contrast agent (0.1 mmol/kg) optical contrast agent ICG (0.5 mg/kg)
45795251|NCT05312931|Other|OSCE|Students undergo OSCE (objective structured clinical exams). It means students will perform CPR for 2 min and their success rate will be monitored.
45795252|NCT04713891|Drug|KF-0210 tablets, 120 mg|KF-0210 tablet will be orally administered as a single agent at 120 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
45795253|NCT04713891|Drug|KF-0210 tablets, 240 mg|KF-0210 tablet will be orally administered as a single agent at 240 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
45795254|NCT04713891|Drug|KF-0210 tablets, 450 mg|KF-0210 tablet will be orally administered as a single agent at 450 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
45795255|NCT04713891|Drug|KF-0210 tablets, 600 mg|KF-0210 tablet will be orally administered as a single agent at 600 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
45795256|NCT04713891|Drug|KF-0210 (dosage RP2D-2) + Atezolizumab|KF-0210 tablet will be orally administered at dosage RP2D-2 once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
45795257|NCT04713891|Drug|KF-0210 (dosage RP2D-1) + Atezolizumab|KF-0210 tablet will be orally administered at dosage RP2D-1 once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
45795258|NCT04713891|Drug|KF-0210 (dosage RP2D) + Atezolizumab|KF-0210 tablet will be orally administered at dosage RP2D once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
45795259|NCT00379509|Drug|lapatinib ditosylate|Patients will be assigned in cohorts of 3. Dose levels of GW572106 will include 500mg, 1000mg,1500 mg (additional levels at 750 mg and 1250 mg will be added if needed). Lapatinib is an oral drug. It is taken every day.
45795260|NCT00379509|Genetic|TdT-mediated dUTP nick end labeling assay|Genetic analysis of tumor tissue
45795261|NCT00379509|Genetic|gene expression analysis|Genetic analysis of tumor tissue.
45795262|NCT00379509|Genetic|microarray analysis|Genetic analysis of tumor tissue.
45795263|NCT00379509|Other|immunohistochemistry staining method|Laboratory analysis of tumor tissue.
45921766|NCT00118300|Radiation|radiation therapy|Patients undergo external beam radiotherapy to the whole pelvis once daily 5 days a week in weeks 1-5.
45921767|NCT05636384|Other|Home-based care|"Home-based medical care is based on a specialized home-based medical team approach, including following:~Specialized Home-Based Medical Team Approach~Initial Assessment and Education~Initial Home Visits and Education~Multidisciplinary Team Meeting~Regular Assessment After the Initial Visit"
45921768|NCT00118339|Drug|chemoprotection|
45921769|NCT00118339|Procedure|complementary or alternative medicine procedure|
45921770|NCT00118339|Procedure|management of therapy complications|
45795264|NCT00379509|Procedure|biopsy|Serial biopsies by skin punch or core biopsy or fine needle aspiration.
45795265|NCT00379509|Radiation|radiation therapy|Radiotherapy will be delivered at standard dose and fractionation. For patients who have not received previous locoregional radiotherapy, 50-56 Gy will be delivered to the regional lymph nodes and/or chest wall at a dose of 2 Gy per fraction, 5 days per week followed by a boost to the sites of gross involvement to a total dose of 60-70 Gy over a course of 6-7 weeks. For patients who have received adjuvant radiotherapy, a dose of 35-45 Gy will be delivered to sites of chest wall involvement at a dose of 1.8 Gy per fraction over 4-5 weeks. In either de novo or reirradiated settings, the total dose to the brachial plexus will not exceed 60 Gy.
45921771|NCT00118456|Drug|AEE788|
45921772|NCT02723409|Procedure|Round Procedure Umbilicoplasty|"Umbilicoplasty surgery (belly button reshaping) is performed using the Round Procedure"
45921773|NCT02723409|Procedure|"Scarless round procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Scarless round procedure"
45795266|NCT04706247|Other|thoracic combined spinal epidural anesthesia|A combined spinal-epidural anesthesia set will be used for the block. Using the loss of resistance to saline technique, an 18 G Tuohy needle will be advanced to the T2-3 vertebral interspace with the mid-line approach. After confirming the epidural space, a 26 G pencil point spinal needle will be inserted slowly through the Tuohy needle to puncture the dura. After free flow of cerebrospinal fluid will be observed, local anesthetic wil be injected into the subarachnoid space over 15 secs. Then, an epidural catheter will be inserted into the epidural space.
45795267|NCT00597909|Drug|sodium phenylacetate and sodium benzoate injection 10% / 10%|5.5 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
45795268|NCT00597909|Drug|sodium phenylacetate and sodium benzoate injection 10% / 10%|2.75 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
45795269|NCT00597909|Drug|placebo solution (10% dextrose)|Placebo solution (10% dextrose), IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
45795270|NCT00422955|Drug|rosiglitazone|
45921774|NCT02723409|Procedure|"Inverted U Procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted U Procedure"
45921775|NCT02723409|Procedure|"Inverted VProcedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted V Procedure"
45921776|NCT02723409|Procedure|"Y deepithelialized Procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Y deepithelialized procedure"
45921777|NCT00118495|Drug|Non-prescription Zestra(TM): patented formulation|
46071748|NCT05878652|Device|3D printed knee extender device|Participants will receive the standard of prehabilitation education at Sanford as well as a 3D printed knee extension device with sealed water bottles and a home prehabilitation program designed to be used with the 3D printed knee extension device.
45648637|NCT05228821|Drug|Voxelotor Oral Tablet|During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor once daily (administered as tablets) or matching placebo for 12 weeks in addition to ongoing current standard of care (SOC) treatment.
45648638|NCT05228821|Drug|Placebo|During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor once daily (administered as tablets) or matching placebo for 12 weeks in addition to ongoing current standard of care (SOC) treatment.
45648639|NCT04375735|Drug|Bovine Lipid Extract Surfactant|BLES will be administered in doses of 50mg/kg ideal bodyweight, at a concentration of 27mg/ml so a total volume of approximately 2ml/kg will be administered. The material will be instilled via the suction catheter through the ET tube so that the ventilation circuit is not broken. Half of the material will be instilled with the patient positioned on their left and right sides, with a pause to allow 5 min of MV between. The procedure will be repeated at, 24 and 48 hours while intubated, so the patient will receive up to 3 doses. To minimize aerosol generation, all patients will be paralyzed during surfactant administration and the ventilator will be paused. The proposed administration technique, surfactant concentration, volume and dosing schedule is based on previous studies, and has shown to be safe in patients with ARDS.
45648640|NCT01362439|Drug|Paliperidone ER|Participants will be administered paliperidone extended release (ER) tablets orally (taken by mouth; to be swallowed) once daily in the dose range of 3 to 12 milligram (mg) for 13 weeks. Dose will be increased or decreased as per Investigator's discretion.
45648641|NCT05228743|Procedure|Comparing Hyperthermic Intraperitoneal Chemotherapy|After laparoscopic exploration, HIPEC was started immediately: the temperature was 43 ℃ and the duration was 60 min. paclitaxel (PTX) was used with a dose of 50mg / m2. The second HIPEC was completed 24-48 hrs after the first HIPEC, and at least 4 HIPEC was completed.
45795271|NCT00586209|Drug|L-Glutamine|L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (>66.7 kg)
45795272|NCT00586209|Drug|Placebo|Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine
45795273|NCT00588471|Drug|Simvastatin|Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
45795274|NCT00588471|Drug|Placebo|Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
45795275|NCT05600673|Drug|Bimatoprost 0.03% solution|Topical Bimatoprost 0.03% solution
45795276|NCT05600673|Device|CO2 fractional laser|CO2 fractional laser treatment
45795277|NCT01784991|Drug|Hydromorphone|1mg of Hydromorphone at timepoint 0 and 1 mg of hydromorphone at 15 min timepoint.
45795278|NCT01784991|Drug|Usual care group|Patient will have pain treated at timepoint 0 as per usual care based on physician discretion. At 15 min timepoint, patients will be asked for pain level, and then subsequently treated as per physician discretion.
45795279|NCT01760889|Drug|SPD489 low dose range (40mg, 80mg, and 100mg)|"Capsule, dose titration,~40 mg capsule once-daily for 1 week; then~80 mg capsule once-daily for 4 weeks; then,~100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;~if able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks"
45921778|NCT00118573|Procedure|EVAR (Endovascular repair of Abdominal Aortic aneurysm)|AAA repair with endografting
45921779|NCT00118573|Procedure|Surveillance|Surveillance of AAA without any repair until AAA will reach 5.5cm, become tender or rapidly grow
45921780|NCT00118612|Biological|Tree MATA MPL - Therapeutic Regimen|600, 1600, 4000, 4000 SU/0.5 mL
45921781|NCT00118612|Biological|Tree MATA MPL - Intermediate dose|300, 600, 1600, 1600 SU/0.5 mL
45921782|NCT00118612|Biological|Tree MATA MPL - Low dose|300, 300, 300, 300 SU/0.5 mL
45921783|NCT00118612|Biological|Placebo|L-tyrosine 2% w/v , 4 injections
45921784|NCT02710734|Drug|Methotrexate|Administered Day 1 of each 14 day cycle for 3 cycles
45921785|NCT02710734|Drug|Vinblastine|Administered Day 1 of each 14 day cycle for 3 cycles
45921786|NCT02710734|Drug|Doxorubicin|Administered Day 1 of each 14 day cycle for 3 cycles
45921787|NCT02710734|Drug|Cisplatin|Administered Day 1 of each 14 day cycle for 3 cycles
45921788|NCT02710734|Radiation|Intensity modulated radiation therapy (IMRT)|2.0 Gy per fraction to the whole bladder plus a margin for a total of 32 fractions (64.0 Gy). Radiation will be administered from Monday to Friday
45921789|NCT02710734|Procedure|Transurethral Resection of Bladder tumor|Performed at before and after AMVAC and after chemoradiation and intravesicle therapy
45921790|NCT02710734|Drug|5-FU|Continuous 24hr Intravenous infusion days 1-5 and 16-20 with radiation treatment
45921791|NCT02710734|Drug|Mitomycin C|Intravenous on day 1 with radiation treatment
45795280|NCT01760889|Drug|SPD489 high dose range (120mg, 140mg and 160mg)|"Capsule, dose titration,~40 mg capsule once-daily for 1 week; then~80 mg capsule once daily for 1 week; then~120 mg capsule once-daily for 1 week, then,~140 mg capsule once-daily for 2 weeks, then~160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;~if able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks"
45795281|NCT01760889|Drug|Placebo|One capsule a day for 26 weeks
45648642|NCT05228743|Drug|Paclitaxel|A natural anticancer drug that has been widely used in the treatment of breast, ovarian and some head and neck and lung cancers.Three to six weeks after HIPEC was completed, chemotherapy was started:: PTX: 50mg / m2 IV, D1, D8; PTX: 20mg / m2 IP, D1, D8; q3w; S-1: 60mg / m2, bid, d1-14, repeated every 3 weeks.
45795282|NCT05600517|Other|Fluoride|a patient-centered education on diet, oral hygiene and fluoridated toothpaste 5000ppm with check up´s and topical fluoride application (varnish) every second month.
45795283|NCT01745913|Device|CliniMACS® CD34 Reagent System|If a subject is randomized to the haplo-cord transplant group, their family member will undergo a stem cell collection. The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
45795284|NCT01745913|Drug|Fludarabine|Fludarabine: 30 mg/m2 /day intravenously x 5 days total dose 150 mg/m2. Fludarabine will be dosed according to actual body weight
45648643|NCT05228743|Drug|S1|S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which degrades 5-FU), and oteracil (which inhibits the phosphorylation of 5-FU in the gastrointestinal tract, thereby reducing the toxic effects of 5-FU in the intestinum).Three to six weeks after HIPEC was completed, chemotherapy was started:: PTX: 50mg / m2 IV, D1, D8; PTX: 20mg / m2 IP, D1, D8; q3w; S-1: 60mg / m2, bid, d1-14, repeated every 3 weeks.
45648644|NCT05228665|Behavioral|Heart Rate Variability Biofeedback (HRV-B)|Breathing technique twice every day (10 min each) to increase HRV
45648645|NCT03321019|Drug|Capsaicin|Participants will inhale aerosolized capsaicin with the goal of this inducing cough and an urge-to-cough.
45648646|NCT03321019|Device|Resistive respiratory loads|Participants will breath through a mouthpiece. Every 3-5 breaths in, a respiratory load will be applied. Participants will be asked to rate the magnitude of the load.
45648647|NCT03321019|Other|Event-related evoked potential using electroencephalography (EEG).|The study team will use EEG time-locked to a respiratory occlusion to measure the brain's response to respiratory sensation.
45648648|NCT03321019|Procedure|Fluoroscopic swallow evaluation|Participants will swallow various consistencies of barium under fluoroscopy (moving-picture x-ray) in order to assess swallowing safety and efficiency.
45648649|NCT05228587|Drug|Indocyanine green|Indocyanine green will be injected in all donor
45795285|NCT01745913|Drug|Melphalan|Melphalan: 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis.
45795286|NCT01745913|Drug|Rabbit ATG|Rabbit ATG (rATG): 1.5 mg/kg/day intravenously x 4 days, total 6 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
45795287|NCT01745913|Procedure|Double Umbilical Cord Blood Transplantation|All subjects will receive an UCB dose of > 3 x107/kg nucleated blood cells. It is expected that this will require co-infusion of two UCB in the large majority of cases. If two UCB are required, they will be at least 4/5 matched to the recipient.
45795288|NCT01745913|Procedure|Haplo-Identical Cord Transplantation|"If randomized to the haplo-cord group, a family member will undergo a stem cell collection. In both arms, subjects will receive a conditioning regimen prior to transplantation. The conditioning regimen utilized in this study incorporates fludarabine-Melphalan and antithymocyte globulin (ATG). This regimen has the advantage of being nearly identical to the regimen utilized for our haplo-cord regimen is based on the experience of the Dana-Farber/Mass-General regimen."
45795289|NCT05600439|Behavioral|CareME|"CareME program was planned to integrate 12 group session (90 minutes), implemented fortnightly during a 6-month period, and facilitated by two psychologists and expert researchers on attachment framework. Components included psychoeducation (description of core concepts such as attachment, secure base, safe haven, emotion regulation, mentalization, trauma, and discussion of research on professional caregiving in YRC); experiential and relational exercises (roleplay; cases discussion, film script discussion).~The program has 7 moduli: (i) adolescents' pain-based behaviors and attachment theoretical lens; (ii) adolescence and main developmental challenges (iii) setting rules and limits; (iv) trust & secure base (figures and environment); (v) professionals' stories of attachment & caregiving (vi) personal and structural characteristics that prevent a secure caregiving environment and (vii) professional impairment and strategies promoting healthy secure base provision."
45921792|NCT00118690|Drug|Fluticasone propionate/salmeterol|
45648650|NCT03307915|Biological|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5*10^10 vp as 0.5 mL IM injection at Weeks 0, 12 in Group 1 and at Weeks 0, 12, 24, 36 in Group 2.
45648651|NCT03307915|Biological|MVA-Mosaic|Participants will receive MVA-Mosaic 10^8 pfu as IM injection at Weeks 24 and 36.
45648652|NCT03307915|Biological|Clade C gp140 + Mosaic gp140|Participants will receive both Clade C gp140 125 mcg plus Mosaic gp140 125 mcg (250 mcg coformulated with Aluminum phosphate adjuvant) OR an equivalent dose of a bivalent vaccine that includes both Clade C gp140 and Mosaic gp140, and aluminum phosphate adjuvant in a single vial, via IM injection at Weeks 24 and 36.
45648653|NCT03307915|Drug|Placebo|Participants will receive matching placebo as IM injection at Weeks 24, 36 in Group 1 and at Weeks 0, 12, 24, 36 in Group 3.
45648654|NCT04154059|Other|Intervention Group|Patients will receive a physical therapy intervention for strengthening, stretching and functional training of ankle and foot.
45648655|NCT05227963|Other|soft tissue mobilization|In this group, each participants received 45-minutes long session that includes 25-minutes of soft tissue mobilization and 20-minutes of neck isometric strengthening exercises. In each session, patient was seated on chair and sustained pressure, direct oscillation, perpendicular mobilization, parallel mobilization, and friction massage was applied on the neck musculature for a minute followed by a release for 30 seconds. This protocol was repeated three times in each session. Each session was repeated four-times a week for two-weeks (a total eight sessions).
45795290|NCT05600361|Drug|hyperpolarized 13C-labeled pyruvate from dynamic nuclear polarization (DNP) magnetic resonance spectroscopy|In stage 1, we expected to enroll 8 first-time diagnosed lymphoma patients referred from clinicians for 13C-pyruvate DNP MRS. In stage 2, another 8 patients with proven relapse will be referred from clinicians for 13C-pyruvate DNP MRS. We will collect related clinical information, patient follow up information, including treatment outcome, and imaging parameters from MRI and PET/CT.
45795291|NCT05600127|Drug|Avelumab|3 cycles of avelumab (800mg, every 2 weeks)
45795292|NCT05600595|Procedure|Operation for snoring in children|Tonsillectomy and/or adenoidectomy
45795293|NCT01693653|Drug|Tocilizumab|Intravenous infusions every 4 weeks for 3 doses.
45795294|NCT01691079|Drug|ipratropium bromide|Inhaled ipratropium bromide administered before exercise.
45795295|NCT01691079|Drug|Placebo|Inhaled placebo administered before exercise.
45795296|NCT05599737|Radiation|Integrated boost|Integrated boost based on the dominant intra-prostatic lesion delineated on multi-parametric Magnetic Resonance Imaging and 68Ga-Prostate Specific Membrane Antigen Positron Emission Tomography
45795297|NCT05599659|Behavioral|Palliative care|"It is a pilot model of outpatient clinical care for patients in advanced stages of PDRD that will allow earlier access to PC in this population. PC visits will be in person or by telemedicine every three months and complemented with phone calls by different team members when needed as defined by the PC team.~The typical visit duration will be 2 to 2.5 hours and address nonmotor symptoms, goals of care, anticipatory guidance, difficult emotions, and carepartner support. Providers will communicate in-person or via notes during the clinic visit to increase interdisciplinary coordination and meet at the end of the day for discussion including follow-up plans.~The team will consist of a neurologist, a registered nurse with palliative care experience and training, a psychology counselor, a social worker, spiritual counselor and a research assistant."
45795298|NCT01673061|Drug|Lidocaine|See associated Arm Description
45795299|NCT01673061|Drug|Vapocoolant|See associated Arm Description
45795300|NCT05599425|Behavioral|Enhanced Healthy Living Education|24-session healthy living education program, with enhanced content about health beliefs and mechanisms of behavior change
45795301|NCT05599425|Behavioral|Basic Healthy Living Education|24-session healthy living education program
45795302|NCT05599347|Drug|Azithromycin Pill|Tablet - 500 mg azithromycin (as dihydrate)
45795303|NCT05599347|Other|Placebo|Placebo tablet identical in shape and appearance to the azithromycin tablet used in the treatment arm
45795304|NCT01602471|Drug|[F-18]RDG-K5|Approximately fifteen (15) patients with carotid artery stenosis > 69% will undergo an endarterectomy and will be imaged under PET/CT with [F-18]RGD-K5
45795305|NCT05599269|Device|Examination of dentures with SR Phonares II teeth|The intraoral situation will be examined similar to a standard dental examination. The dentures are then removed, cleaned and examined extraoral. Pictures and an impression of the dentures are taken.
45795306|NCT05599113|Device|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is an expedient remedy that is used in various joint and non-invasive muscle pain treatments
45795307|NCT01621737|Drug|Oxytocin|42 IU BID for six weeks
45795308|NCT01621737|Drug|Oxytocin|84 IU BID for six weeks
45795309|NCT01621737|Drug|Placebo|Vehicle placebo
45795310|NCT05598801|Device|VersaWrap|VersaWrap is applied to the affected tendon to allow post-operative gliding.
45795311|NCT04706169|Device|Surface Electromyography|SEMG was used to measure the amplitude and onset of five shoulder muscle electrical signal, performing glenohumeral abduction. In this movement, the middle deltoid muscle was selected because it is a main motor. The infraspinatus muscle represented the rotator cuff muscle group. The middle deltoid muscle was selected as the representative of shoulder abduction because it is a main motor in this movement. The trapezius muscle and the serratus anterior muscle were chosen as representative established of the ascending scapular rotator muscles.
45795312|NCT04706325|Other|ACUTE KIDNEY INJURY|KDIGO LEVELS
45795313|NCT00379665|Drug|Cisplatin|1 mg/ml at a dosage of approximately 2 mg per cubic cm of tumor. Weekly up to 6 injections.
45795314|NCT00379743|Behavioral|Health coordinator (or patient navigator)|Individuals randomized to receive the less intensive intervention receive educational materials only. Those randomized to the more intensive intervention are assigned a health coordinator (patient navigator) who delivers an enhanced, tailored educational intervention after review of the participant's screening history and knowledge gaps about cancer. The health coordinator also facilitate adherence to cancer screening and/or treatment services, by assisting in scheduling and keeping of appointments for cancer-related screening and/or treatment services.
45795315|NCT00379743|Behavioral|Educational materials only|A brochure is provided to the participant with information about preventive services covered by Medicare, and the frequency with which those services should be obtained.
45795316|NCT02056769|Radiation|CT Perfusion|Quantitative CT Perfusion imaging
45795317|NCT00357383|Drug|Azithromycin (T1225)|
45921793|NCT00402142|Biological|Dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
45921794|NCT00402142|Biological|non pulsed dendritic cell untreated patients|107 DC subcutaneous 3 doses every 2 weeks
45921795|NCT00402142|Biological|pulsed dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
45921796|NCT00402142|Biological|dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
45921797|NCT00402142|Biological|non pulsed dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
45921798|NCT00118729|Drug|GW685698X Aqueous Nasal Spray|
45921799|NCT00118768|Drug|valopicitabine|
45921800|NCT00118768|Drug|Pegylated Interferon Alfa|
45921801|NCT02706873|Drug|Placebo to Upadacitinib|Tablet; Oral
45921802|NCT02706873|Drug|Methotrexate|Capsule or Tablet; Oral
45795318|NCT02010983|Other|chromoendoscopy|chromoendoscopy (lugol stain and virtual chromoendoscopy)
45795319|NCT01598025|Radiation|total-body irradiation (TBI)|
45795320|NCT01598025|Drug|thiotepa|
45795321|NCT01598025|Drug|fludarabine phosphate|
45648656|NCT05227963|Other|neck isometric strengthening exercises|In this group, each participant received 20-minutes long session. Each session started in seated position and participants were asked to perform flexion, extension, side bending and rotation against resistance. During flexion movement, therapist placed hand on forehead and asked patient to move the neck forward, while in extension, therapist hand was placed at back of the head and patient had to move neck in backward direction. However, in side bending and rotation- therapist hand was placed at lateral side of the head and asked patient to side bend the neck and look at shoulder in the same direction respectively. Each session was repeated four-times a week for two-weeks (a total eight sessions).
45795322|NCT01598025|Drug|melphalan|
45795323|NCT01598025|Biological|anti-thymocyte globulin|
45795324|NCT01598025|Procedure|allogeneic hematopoietic stem cell transplantation|
45795325|NCT01598025|Biological|peripheral blood stem cell transplantation|
45795326|NCT01598025|Other|laboratory biomarker analysis|
45795327|NCT01912313|Procedure|Rectal biopsies from IBS patients or healthy subjects will be taken during proctoscopy|
45795328|NCT01587963|Drug|Ascorbic Acid|66mg/kg/hour of peripheral intravenous Vitamin C infusion for 24 hour duration, maximum total of 200 grams
45795329|NCT01587963|Other|Ringers Lactate or Normal Saline|Fluid resuscitation will be given with NS or LR to achieve a same mean urine output of 0.5cc/kg/hour.
46071749|NCT05878652|Other|Standard Prehabilitation Education|Participants in the control group will receive the standard prehabilitation education at Sanford and provided exercises to do at home.
45449916|NCT02164708|Behavioral|Mindfulness Meditation|"The program progressively trained students in mindfulness of breathing, a form of meditation frequently employed secularly. The tutorials were held on campus five times weekly, led by a faculty member and a graduate student who were trained, experienced MM practitioners. The tutorials were one hour in duration and typically involved 40-45 minutes of guided MM followed by a question-answer period that addressed recent research findings. Program participation required attendance at one tutorial per week, and participants were encouraged to maintain autonomous MM practice."
45449917|NCT03730233|Procedure|Hiatal hernia repair by tension-free mesh closure|
45648657|NCT05010343|Radiation|carbon ion irradation|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle
45795330|NCT01648751|Drug|Vaginal estrogen|1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
45795331|NCT01648751|Drug|Placebo|1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
45795332|NCT05550519|Other|Entecavir (ETV)|ETV will continue throughout screening and will be stopped at baseline.
45795333|NCT05550519|Other|Tenofovir Disoproxil Fumarate (TDF)|TDF will continue throughout screening and will be stopped at baseline.
45795334|NCT05550519|Other|Tenofovir Alafenamide (TAF)|TAF will continue throughout screening and will be stopped at baseline.
45795335|NCT01203371|Drug|Naftopidil|0,25 mg (2weeks) and 0,50 mg (10 weeks)
45449918|NCT03730233|Procedure|Hiatal hernia repair by simple suturing|
45449919|NCT03639597|Device|VytronUS Ablation System|
45795336|NCT01203371|Drug|Tamsulosin|0,4 mg/day
45795337|NCT05722691|Drug|Double-Stranded RNA sodium salt|Once intramuscular injection 5 mg (1 vial)
45795338|NCT05722691|Drug|Placebo|Once intramuscular injection (1 vial)
45795339|NCT01549977|Drug|Febuxostat|Febuxostat tablets
45795340|NCT01549977|Drug|Placebo|Febuxostat placebo-matching tablets
45795341|NCT05523843|Other|Tulsa Life Chart (TLC)|The TLC is a self-administered, interactive assessment of patient history. Participants are asked to provide information from birth to their current age in developmental epochs (i.e., ages 0 to 5; 6 to 10; 11 to 14; 15 to 18; 19 to 25; 26 to 35; and so on in 10-year increments). Participants are first asked to rate their average mood during the epoch. They are then asked about locations lived, schools attended, people they were close to, hobbies, medical conditions, medications, hospitalizations, direct and indirect substance use exposure, mental health symptoms, mental health treatment, and important life events. The information is then displayed in an interactive, graphic of the individual's life that is reviewable by the patient and the healthcare providers enrolled in the study that the patient consents to having access.
45795342|NCT00357617|Drug|celecoxib|
45795343|NCT00357617|Genetic|microarray analysis|
45795344|NCT00357617|Genetic|protein expression analysis|
45795345|NCT00357617|Other|immunoenzyme technique|
45795346|NCT00357617|Other|immunohistochemistry staining method|
45795347|NCT00357617|Other|laboratory biomarker analysis|
45795348|NCT00357617|Procedure|biopsy|
45795349|NCT00357617|Procedure|conventional surgery|
45795350|NCT00357617|Procedure|neoadjuvant therapy|
45804094|NCT05717881|Dietary Supplement|Placebo|"Placebo powder capsules (maltodextrin, fatty acids, magnesium salts and silicon dioxide) are presented in the same packaging to have an identical appearance and taste. Patients in the propolis group were dosed with propolis to reach 6 mg total polyphenols/kg body weight, based on the results of a previous preclinical study in mice.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed."
45921803|NCT02706873|Drug|Placebo to Methotrexate|Capsule or Tablet; Oral
45921804|NCT02706873|Drug|Upadacitinib|Tablet; Oral
45921805|NCT05636579|Biological|EO2002|Intracameral injection of magnetic human corneal endothelial cells (EO2002)
45921806|NCT05636579|Drug|Ripasudil|Daily use of Ripasudil drops
45921807|NCT00118807|Drug|Amodiaquine plus artesunate (AQ/AS)|
45921808|NCT00118807|Drug|Sulfadoxine-pyrimethamine plus chloroquine (SP/CQ)|
45921809|NCT00118807|Drug|Sulfadoxine-pyrimethamine plus amodiaquine (SP/AQ)|
45921810|NCT00118885|Behavioral|Tai Chi Chih|
45795351|NCT01548651|Drug|Saxagliptin|Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and C Reactive Protein (CRP), Intracellular Adhesion Molecule (ICAM), vascular cell adhesion molecule (VCAM), plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
45921811|NCT00118924|Biological|LGT(TP21)/DEN4|Live attenuated LGT(TP21)/DEN4 vaccine (one of two doses)
45795352|NCT01548651|Drug|Placebo|Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and CRP, ICAM, VCAM, plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 month treatment period.
45795353|NCT05722457|Other|external focus task focus in addition to physiotherapy and rehabilitation exercises|"The first study on the external focus was made in 1998 by Wulf, Ho ¨ß, & Prinz, (1998). Focusing on the inside of the body while performing a movement is called internal (internal focus), focusing on the outside of the body is called external (external focus). Previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement."
45795354|NCT05722457|Other|internal focus task focus in addition to physiotherapy and rehabilitation exercises|"he first study on the external focus was made in 1998 by Wulf, Ho ¨ß, & Prinz, (1998). Focusing on the inside of the body while performing a movement is called internal (internal focus), focusing on the outside of the body is called external (external focus). Previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement."
45795355|NCT00695981|Procedure|Rotator cuff repair|Rotator cuff repair + physical therapy according to a standardized protocol
45795356|NCT00695981|Procedure|Conservative treatment|Physiotherapy according to a standardized protocol
45795357|NCT05453877|Other|No intervention will be applied.|This is an observational study.
45795358|NCT00637013|Procedure|Acromioplasty|Arthroscopic or open acromioplasty
45921812|NCT00118924|Biological|Placebo|Placebo for LGT(TP21)/DEN4 vaccine
45921813|NCT00118963|Drug|Metformin|Tablets of 500 mg; 1000 mg two times daily.
45921814|NCT00118963|Drug|Insulin BIAsp30 (Novolog 70/30)|Subcutaneous injection. Starting dose 6 units. Titration according to glycaemic targets during the entire intervention period.
45921815|NCT00118963|Drug|Repaglinide|Tablets of 1 mg; Dosage: 2 mg three times daily.
45921816|NCT00118963|Drug|Placebo-Metformin|Tablets corresponding to 500 mg; two tablets two times daily.
45921817|NCT00118963|Drug|Placebo-Repaglinide|Tablet corresponding to 1 mg; two tablets three times daily.
45648658|NCT05010343|Radiation|Carbon Ion Irradiation With SIB|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle, and with simultaneous integrated boost (SIB) to the gross tumor in the PSMA PET/CT and mpMRI
45648659|NCT04990921|Combination Product|Palliative Radiation and Pembrolizumab|Stereotactic radiation therapy will be administered as clinically indicated.
45921818|NCT00119002|Drug|dexamethasone|1mg/kg dexamethasone
45921819|NCT00119002|Drug|Placebo|1mg/kg placebo
45921820|NCT00119080|Biological|meningococcal conjugate vaccine (Menactra)|
45449920|NCT04662190|Device|3D printing model/guide.|Orbital decompression surgery will be previously planned and simulated using 3D-printed individualized models. In the operating room, surgery will be assisted with 3D-printed individualized guides.
45449921|NCT04662190|Procedure|Standard surgery|Orbital decompression surgery will be previously planned and simulated using the actual standard methods.
45921821|NCT00119119|Drug|pentoxyphilline|
45921822|NCT00119119|Drug|tocopherol|
45921823|NCT00119197|Biological|killed whole cell oral cholera vaccine|"Bivalent oral killed cholera vaccine: each dose of this vaccine contains:~Inactivated V.Cholerae Inaba (569B), Classical biotype - 25.109 cells~Inactivated V.Cholerae Ogawa (Cairo 50) Classical biotype - 25.109 cells~Inactivated V.Cholerae Inaba (Phil 6973) El Tor biotype - 50.109 cells~Inactivated V.Cholerae O139 - 50.109 cells~each 1.5 mL dose given orally, two doses given 14 days apart"
45921824|NCT00119197|Biological|Heat Killed E. coli|"Escherichia coli K12 strain placebo: each dose of placebo contains heat-killed E. coli K12 strain in an amount whose optical turbidity is identical to that for the cholera vaccine.~Each 1.5 mL dose given orally, two doses given 14 days apart"
46071750|NCT05878639|Drug|3 bottles of Lactulose oral solution|Patients will take lactulose for bowel preparation.
46071751|NCT05878639|Drug|3L-polyethylene glycol|Patients will take 3L-polyethylene glycol for bowel preparation.
45449922|NCT03721731|Device|Obesity treatment with a Plication device|Plicating the stomach to treat obesity
45648660|NCT02824237|Device|Improved cook stove|The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
45648661|NCT02673385|Other|Brazelton scale|
45648662|NCT02628535|Biological|MGD009|B7-H3 x CD3 DART protein
45921825|NCT00119236|Drug|tanespimycin|
45921826|NCT00119236|Drug|irinotecan hydrochloride|
46071752|NCT05878626|Other|Transcranial Direct Current Stimulation|The intensity of TDCS will be 2.5 mA and the duration will be 20 mints. The intervention will be applied twice a day with a time difference of 30 minutes between the two sessions.
45795359|NCT00637013|Procedure|Physiotherapy|Physiotherapy according to a standardized protocol
45795360|NCT05414565|Device|Vivity IOL|Commercially available extended vision IOL
45795361|NCT05414565|Device|Aspheric monofocal IOL|Commercially available aspheric IOL
45795362|NCT05722379|Procedure|left bundle branch pacing (LBBP)|After recording the His potential, the 3830-69 lead (Medtronic Inc., Minneapolis, MN USA) was sent 1-2 cm forward and downward to find the insertion point of the right side of intra-ventricular septum combined with the pre-rotation impedance and ECG changes. Ultimately, the tip was perpendicularly straightforward posited against the septum to the left septal side .
45795363|NCT05722379|Procedure|Right ventricular pacing (RVP)|Right ventricular pacing (RVP) is the standard treatment for patients with continuous ventricular pacing needs.
45795364|NCT01533753|Drug|Gabapentin|Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
45795365|NCT01533753|Drug|Venlafaxine|Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.
45795366|NCT05722301|Drug|Testosterone Therapy|The testosterone pellet implantation will be performed 2 weeks before surgery. The dose is determined by baseline levels of sex hormone binding globulin (SHBG) in the following manner: If SHBG > 60nmol/L implant 5 Testosterone Compounded 200mg (total 1000mgs testosterone). If SHBG 41-59 nmol/L implant 4 Testosterone Compounded 200mg (total 800mgs testosterone). If SHBG <40 nmol/L implant 3 Testosterone Compounded 200mg (total 600mgs testosterone).
45795367|NCT05722301|Other|No Testosterone Therapy|For the sham procedure no pellets will be implanted.
45795368|NCT05413005|Combination Product|ECP regular-intensity arm|"Weeks 1-8: Once every 2 weeks: weeks 1, 3, 5, 7 (cryo-ECP bags infused twice-a-week)~Weeks 9-16: Once per month: weeks 9, 13 (cryo-ECP bags infused once-a-week)~Weeks 17-24: One: week 17 (cryo-ECP bags infused every two weeks)"
45795369|NCT05413005|Combination Product|ECP accelerated-intensity arm|"Weeks 1-8: Once every week: weeks 1- 7 (cryo-ECP bags infused twice-a-week)~Weeks 9-16: Cryo-ECP bags infused once-a-week~Weeks 17-24: Cryo-ECP bags infused every two weeks"
45795370|NCT05413005|Biological|T1DM standard of care|"The standard of care is defined as per the DOH Standards for diagnosis, management and data reporting for diabetes in combination with the DOH recommended NICE guidelines Type 1 diabetes in adults: diagnosis and management (NG17)"
45795371|NCT04344509|Other|Bacterial species isolated|in the respiratory specimen
45795372|NCT01534143|Other|pharmacological study|Correlative studies
45795373|NCT01534143|Drug|tacrolimus|Given IV
45795374|NCT01534143|Drug|sirolimus|Given PO
45795375|NCT01534143|Biological|anti-thymocyte globulin|Given IV
45795376|NCT01534143|Drug|fludarabine phosphate|Given IV
45795377|NCT01534143|Drug|busulfan|Given IV
45795378|NCT01534143|Drug|bortezomib|Given IV
45795379|NCT01534143|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
45795380|NCT01534143|Other|laboratory biomarker analysis|Correlative studies
45795381|NCT02978729|Other|Two-way videoconference remote genetic counseling|
45795382|NCT02978729|Other|Telephone remote genetic counseling|
45795383|NCT05722223|Combination Product|Trimodal prehabilitation|Pancreatic cancer patients (not stage 4) will undergo trimodal prehabilitation: nutrition, psychological, and exercise support.
45921827|NCT00119314|Drug|capecitabine|
45921828|NCT00119314|Drug|docetaxel|
45921829|NCT00119314|Drug|gemcitabine hydrochloride|
45449923|NCT02162836|Drug|JNJ-56021927|Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.
45795384|NCT05381961|Device|Bioimpedance spectroscopy (BIS) measurement, SOZO device|All patients enrolled in this study will undergo BIS measurement before and after 12 hemodialysis sessions (pre-dialysis and post-dialysis BIS measurements for each session). Measurements are not provided to treating physicians and are not used to guide clinical decisions; i.e., BIS measurements are collected for observational purposes only.
45921830|NCT00119314|Procedure|positron emission tomography|
45795385|NCT01528293|Device|ActiVAC System|The ActiV.A.C. System will be applied in a customary manner per manufacturer's recommendations. Acticoat Flex 7™ will be applied as contact layer on the wound surface. Open cell foam is then applied over the top of the Acticoat Flex 7™. Adherent transparent occlusive material will be applied over the open cell foam. The tubing is then attached after cutting a small aperture through the occlusive material. Negative pressure will be set at 125mmHg on continuous suction. Sponge and canister will be replaced 2 time a week.
45921831|NCT00119431|Drug|C1 inhibitor concentrate|
45921832|NCT00119470|Procedure|EUS-FNA|
45921833|NCT00119470|Procedure|Conventional Surgical Technique|
45921834|NCT00119509|Procedure|HPV DNA testing|
45921835|NCT00119509|Procedure|Conventional management (repeat Pap smear at 6 months)|
45921836|NCT00119509|Procedure|Decision aid with choice of management|
45795386|NCT01528293|Other|Compression therapy|Compression Therapy Profore™ multi-layered compression bandaging system will be utilized. This includes the application of a contact layer dressing using Acticoat Flex 7™. The compression bandage will be applied per manufacturer's recommendations.
45795387|NCT05722067|Other|calcium ionophore|The intervention group will be treated with a ready-to-use ionophore medium (GM508 CultActive, Gynemed) within 15 min after ICSI (or 18 min in IVF) based on the situation of sperm. After 15 min of incubation in GM508 CultActive and a thorough washing process, the oocytes will be cultured in the same protocol as the control group.
45795388|NCT05290077|Diagnostic Test|NGAL|Serum NGAL in blood for early detection of CVR
45449924|NCT02162914|Drug|Regorafenib/active|Subjects randomized to be treated with Regorafenib/active will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
45449925|NCT02162914|Drug|Regorafenib/placebo|Subjects randomized to be treated with Regorafenib/placebo will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
45648663|NCT03923101|Diagnostic Test|Topographic, tomographic and biomechanical analysis.|"The study is based upon data obtained during routine medical follow-ups using~the Pentacam high resolution (Oculus, Wetzlar, Germany)~the Corvis ST (Oculus, Wetzlar, Germany)~the Anterior-Segment Optical Coherence Tomograph (AS-OCT) Casia 2 (Tomey, Nagoya, Japan)~the Ocular Response Analyzer (Reichert Technologies, New York, USA)."
45648664|NCT04984603|Procedure|PLR in patients under VA-ECMO|After securing the VA-ECMO tubing, PLR is realized using an automatic bed elevation technique. The lower limbs are raised to a 45° angle while the patient's trunk is lowered in supine position
45795389|NCT03831347|Behavioral|Hatha Yoga|12 weeks of Hatha Yoga
45795390|NCT01692171|Drug|Heparin, Low-Molecular-Weight|single intravenous administration of 3mg/Kg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
45795391|NCT05723471|Other|Adaptative Physical Activity|12 weeks of a collaborative program of customized, adaptative and supervised physical activity by sports instructor
45795392|NCT05723315|Drug|recombinant human B-type natriuretic peptide|The recombinant human B-type natriuretic peptide produces physiological effects by imitating endogenous B-type natriuretic peptide
45795393|NCT00490503|Procedure|Magnetic Resonance Imaging (MRI)|3 Scans performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
45795394|NCT00490503|Procedure|Magnetic Resonance Spectroscopy (MRS)|3 MRI Scans with MRS performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
45795395|NCT05721833|Device|Non-invasive high-frequency oscillatory|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
45795396|NCT05721833|Device|Noninvasive Bilevel Positive Pressure Ventilation|Noninvasive Bilevel Positive Pressure Ventilation.
45795397|NCT05715749|Other|In-home body weight support harness system|A portable, adjustable body weight support harness system that occupies roughly 9 feet x 9 feet space in the home. The system allows 360 degrees of mobility anywhere within the footprint of the frame. The amount of body weight support is adjustable.
45795398|NCT05715593|Other|health education intervention|health education intervention
45795399|NCT00570531|Drug|Bevacizumab|Pre-Operative Treatment: Bevacizumab will be given over 60-90 minutes through an I.V. catheter on days # 2 and 16. Post-Operative Treatment:Bevacizumab given over 60-90 minutes through an I.V. catheter every 21 days for 12 months, starting 6-8 weeks after surgery.
45795400|NCT00570531|Drug|Paclitaxel|Pre-Operative Chemotherapy treatment: Paclitaxel 45 mg/m2 will be administered as a 1-hour intravenous infusion on days #2, 9, 16, 23, and 30. It will be given before cisplatin administration.
45795401|NCT00570531|Drug|Cisplatin|Pre-Operative Chemotherapy Treatment: Cisplatin 30 mg/m2 over 1 hour on days #2, 9, 16, 23, and 30. It will be given after paclitaxel.
45795402|NCT00570531|Drug|5-Fluorouracil|Pre-Operative Chemotherapy Treatment: 5-Fluorouracil at 200 mg/m2/day will be given as a continuous intravenous infusion on days #2-33.
45795403|NCT00570531|Radiation|Radiation Therapy|Pre-Operative Treatment: Radiotherapy will be given Monday through Friday five days a week on days 1-5, 8-12, 15-19, 22-26, and 29-33. Radiotherapy will be administered using MV x-rays. CT scans, the barium swallow, the endoscopy and endoscopic ultrasound reports and PET scans should be used for tumor definition. Post-Operative Radiotherapy: In the event that gross residual disease is left behind at the time of surgery or the patient is found to have a microscopic positive deep or gastric margin following surgery, additional treatment with radiation therapy will be considered.
45795404|NCT00570531|Procedure|Esophagectomy|Transhiatal esophagectomy performed on approximately Day #57 (6 weeks after last dose of bevacizumab.)
45795405|NCT05721599|Behavioral|Integrated care with nutrition and lifestyle counselling|The structured care includes specialist care, integrated assessment, group health education, one-on-one nutrition and lifestyle guidance, online and face-to-face support group and case management.
45795406|NCT05258565|Drug|IV tPA (Activase)|Any patients eligible came with acute ischemic stroke with or without COVID-19 infection within the time window for thrombolytic therapy (within 4 hours of onset)
45449926|NCT03540940|Other|PEEP|7cmH2O positive end expiratory pressure
45449927|NCT03540940|Other|ZEEP|0 cmH2O positive end expiratory pressure
45449928|NCT03540862|Device|maintenance negative pressure ventilation (Philips Respironics Lifecare NEV-100)|hospital-based NPV once every week as the maintenance program
45648665|NCT04853407|Drug|LY03005 extended-release tablet|orally once a day
45795407|NCT04344743|Device|Cryoballoon ablation without contrast|Cryoballoon ablation without contrast
45804095|NCT00355303|Drug|Misoprostol|Vaginal application of Misoprostol tablets at 4 hrly interval with maximumof five doses
45804096|NCT00355303|Drug|PGE2 gel|PGE2 gel will be applied in poaterior fornix at six hrly interval with maximum of 2 doses
45648666|NCT04853407|Drug|Placebo|orally once a day
45804097|NCT05717725|Procedure|Pulsed-field ablation|Patients will receive catheter ablation, i.e. pulmonary vein isolation by means of pulsed-field energy
45804098|NCT05717725|Procedure|Sham procedure|Patients will receive sham procedure, no ablation.
45648667|NCT02653495|Biological|Influenza vaccine|Influenza vaccine administered intramuscularly (IM), 1 time only, on visit 3
45648668|NCT02495311|Procedure|myomectomy or adenomyomectomy|
45648669|NCT04218487|Drug|Xuefu-Zhuyu Capsule|treatment with 2.4g (6 capsules) of XFZY three times daily for 12 weeks.
45648670|NCT04218487|Drug|placebo|treatment with 2.4g (6 capsules) of placebo three times daily for 12 weeks.
45795408|NCT05715515|Diagnostic Test|Panbio™|"The Panbio™ COVID-19/Flu A&B Rapid Panel Professional use device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in nasopharyngeal swabs, collected by a trained health worker.~The Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in self-collected mid-turbinate nasal swabs. The test is designed to be used by lay users"
45795409|NCT05216991|Other|TetraGraph on dominant hand|Using standard of care TetraGraph device on dominant hand
45795410|NCT05216991|Other|TetraGraph on non-dominant hand|Using standard of care TetraGraph device on non-dominant hand
45795411|NCT05715437|Drug|Bupivacaine plus Normal Saline|Effect of Bupivacain and ketamine and is superior to Bupivacaine and Normal Saline in terms of providing better pain control for 48 hours postoperatively after TKA.
45795412|NCT05715437|Drug|Bupivacain and ketamine|Effect of Bupivacain and ketamine and is superior to Bupivacaine and Normal Saline in terms of providing better pain control for 48 hours postoperatively after TKA.
45795413|NCT05216367|Drug|Fruquintinib|Fruquintinib will be administered as a single oral dose on the morning of day 1 under fasting conditions
45795414|NCT05721521|Other|Spin Bike Exercise|30 minute spin bike class led by a qualified instructor.
45795415|NCT05721521|Other|Control|30 minute completing seated activities (e.g., wordsearches)
45795416|NCT05721443|Drug|Dalpiciclib+cetuximab|"The dosing regimen for cetuximab combined with dalpiciclib is: the starting dose of cetuximab is 400 mg/m2, titrated over 120 minutes, and the titration rate should be limited to 5 ml/min. A maintenance dose of 250 mg/m2, titrated over not less than 60 minutes, with pretreatment with H1 receptor blocker desensitization prior to dosing, administered once weekly.~The recommended dose of dalpiciclib is 150 mg once daily for 21 days, followed by 7 days of discontinuation (3/1 dosing regimen) for a 28-day treatment cycle. Take the drug at approximately the same time each day. If the patient vomits or misses a dose, the dose should not be made up that day. The next dose should be taken as usual.~Subjects will continue treatment with cetuximab in combination with dalpiciclib until termination criteria are met."
45795417|NCT00540969|Procedure|cryosurgery|Patients undergo cryosurgery using guidance from CT scan or ultrasound
45795418|NCT00540969|Radiation|radiation therapy|Patients undergo radiotherapy for 1 week
45795419|NCT02978807|Procedure|Point of care and venous screening|
45795420|NCT00524511|Device|Surgical skin staples|Standard method to close abdominal surgical wounds
45795421|NCT00524511|Device|Dermabond|Alternative method (superglue) to close abdominal surgical wounds
45795422|NCT05097807|Behavioral|smartphone related behaviors|Participants are required to watch specific contents on their own smartphones.
45795423|NCT02988817|Biological|Enapotamab vedotin (HuMax-AXL-ADC)|Enapotamab vedotin (HuMax-AXL-ADC) will be administered intravenously.
45795424|NCT00358085|Procedure|Endovascular Repair of Abdominal Aortic Aneurysm|
45795425|NCT00358085|Procedure|Conventional open repair of Abdominal Aortic Aneurysm|
45795426|NCT00523809|Drug|Bevacizumab|10 mg/kg IV Daily Over 30 Minutes for 1 Day
45795427|NCT00523809|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Stem Cell Transplantation on Day 8.
45795428|NCT00523809|Drug|Fludarabine|25 mg/m^2 IV Daily Over 30 Minutes for 5 Days
45795429|NCT00523809|Drug|Melphalan|70 mg/m^2 IV Daily Over 30 Minutes for 2 Days
45795430|NCT00523809|Drug|Thymoglobulin|0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1.
45449929|NCT02762578|Drug|insulin degludec/insulin aspart|Twice daily subcutaneous (sc, under the skin) injection.
45449930|NCT02762578|Drug|biphasic insulin aspart|Twice daily subcutaneous (sc, under the skin) injection.
45648671|NCT04218487|Other|conventional therapy|conventional therapy will be given according to the suffering diseases including stable coronary heart disease, chronic insomnia, headache, endometriosis.
45648672|NCT04507477|Biological|Rituximab|For EBV seropositive lungs meant for an EBV seronegative recipient, one dose of rituximab (500mg) will be added to the EVLP perfusate and be allowed to circulate for 3-4 hours.
45648673|NCT02472925|Behavioral|MedSignals Pill Box|Pill box will provide feedback to the study team regarding subjects' compliance and provide reminders depending on Arm.
45795431|NCT03838211|Device|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)
45795432|NCT03838211|Behavioral|Intensive cognitive training|Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
45795433|NCT05065281|Other|Education|Training for health care professionals on how to identify and manage cases of elder abuse among their patients
45795434|NCT00511329|Drug|somatropin [rDNA origin] for injection|Genotropin will be started at 0.3 mg/kg/week administered by daily subcutaneous injection. Doses will be increased by weight at each visit. Additionally, we will monitor IGF-1 levels at month 3, and 6 and adjust the Genotropin dose to maintain IGF-1 levels in the 50th -75th percentile for ages.
45795435|NCT03838055|Procedure|Injection of tracer ( ICG) and detection of sentinel lymph nodes|Pelvic SLN's defined by ICG injected cervically
45795436|NCT05714501|Device|Millipede System|Mechanical thrombectomy
45795437|NCT00501345|Drug|Aspirin|325 mg by mouth on Day 1 only, followed by 160 mg by mouth daily
45795438|NCT00357773|Drug|Azithromycin (T1225)|
45795439|NCT05721287|Drug|SBS-1000|SBS-1000 administered as a single continuous IV infusion over 60 minutes
45795440|NCT05721287|Drug|Placebo|Normal saline (0.9% sodium chloride [NaCl]) administered as a single dose IV infusion over 60 minutes
45795441|NCT00487461|Drug|Simvastatin 40 mg|Comparing two doses of Simvastatin to placebo
45795442|NCT00487461|Drug|Placebo|Placebo tablet
45795443|NCT00487461|Drug|Simvastatin 80 mg|Comparing two doses of Simvastatin to placebo
45795444|NCT02978651|Drug|Pitolisant (BF2.649)|
45648674|NCT01391143|Biological|MGA271|"Up to 9 dose escalation cohorts will be enrolled to determine the maximum tolerated dose of MGA271. Patients with evidence of clinical benefit will be allowed to continue therapy at the same dose once per week for 3 weeks out of every 4-week cycle until documented progression.~Patients treated in the Expansion Segment at the maximum administered dose will receive weekly, uninterrupted infusions of MGA271 in 8 week cycles for up to 12 cycles."
45648675|NCT01675141|Drug|Lenalidomide|10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
45648676|NCT04825561|Drug|AD-208|PO, Once daily(QD), 24weeks
45648677|NCT04825561|Drug|AD-2081|PO, Once daily(QD), 24weeks
45795445|NCT02978651|Drug|Placebo Oral Tablet|
45795446|NCT05712629|Other|Bread and vla dadiah|Consumption bread and vla dadiah to pregnant women 1 Pieces a day during 12 weeks.
45795447|NCT05712629|Other|Bread and vla without dadiah|Consumption bread and vla without dadiah to pregnant women 1 Pieces a day during 12 weeks.
45795448|NCT04972383|Combination Product|Platelet Rich Plasma|In the Platelet Rich Plasma group, 4mL Platelet Rich Plasma was given.
45795449|NCT04972383|Combination Product|Hyaluronic Acid|In the Hyaluronic group, 3mLHYAJOINT Plus was given.
45795450|NCT04962321|Behavioral|Wellness Education|Psychoeducation on relationships between mood, anxiety, eating, and exercise behaviors. One one-hour session each week for 8 weeks.
45795451|NCT05721131|Device|NC° Thermometer (Gen 3)|The NC° Thermometer (Gen3) is used orally for the intermittent measurement and monitoring of human body temperature. The device can be used by adults and children over the age of 5 years old.
45795452|NCT05243485|Diagnostic Test|PreHEART|"The PreHEART score is validated for use in the pre-hospital setting.The score can be calculated based on five different elements: history, ECG, age, gender, and a Point-of-Care (POC)-Troponin. A minimum of 0 points and a maximum of 2 points can be scored in each element, the total PreHEART can contain a maximum of 10 points. The score of the history is based on the symptoms of the patient in accordance with the symptoms of a myocardial infarction. Based on the suspicion of ischemia on the ECG. Age will be based on the date of birth. Compared to the female gender, the male gender has higher risk of developing myocardial infarction and will be scored higher. The biomarker Troponin will be collected via intravenous access and measured using a POC-analyzer I-Stat from Abbott industries. In total 17 µl of blood is required to fill a cardiac Troponin I (cTnI) cartridge. Analyzing the blood will take approximately 10 minutes."
45795453|NCT04954443|Procedure|Removing urinary catheter|Removing urinary catheter after vaginal surgery of pelvic organ prolapse
45795454|NCT05207761|Drug|D565|Q.D. in both eye
45795455|NCT05207761|Drug|D930|T.I.D in both eye
45795456|NCT05720975|Device|iNstroke|Patients to undergo thromboaspiration with iNstroke.
45795457|NCT05459935|Device|PBM Tonsil Arm|exposure of hypertrophic tonsils to photobiomodulation
45795458|NCT05459935|Device|Sham PBM Tonsil Arm|non-powered exposure of hypertrophic tonsils to photobiomodulation
45795459|NCT05720897|Other|Auditory Alone|Participants randomized to this arm will receive earphones to listen to an 8 minute guided brief relaxation recording, focusing on breathing and a body scan. Participants will listen to the recording prior to their dental procedure.
45795460|NCT05720897|Device|Relaxation Virtual Reality|Participants randomized to this arm will receive will receive virtual reality goggles and choose a scene of their liking to experience. Participants will choose from 11 different themed environments (such as savannah, beach, meadow, or space), and will experience the chosen virtual reality environment for 8 minutes. Participants will complete the virtual reality intervention prior to their dental procedure.
45795461|NCT05178979|Behavioral|Training|This training program integrates evidence-based strategies to reduce provider bias, adapted to address gender bias in the context of HIV care in Uganda. The content aims to increase providers' knowledge, motivation, skills, and empathy to equitably deliver Ugandan Ministry of Health ART program guidelines to male and female patients (e.g., increasing awareness of HIV gender disparities, increasing empathy/skills to counsel men and women's gendered barriers to care, promoting shared decision-making). The intervention is delivered in a series of group training sessions with HIV providers.
45795462|NCT00370695|Device|Precision Spinal Cord Stimulation System|Stimulation turned on from implant throughout the Study
45795463|NCT00358241|Procedure|Nerve block|
45804099|NCT05717647|Other|Observational study: neuromonitoring|collection of multimodality neuromonitoring data including ICP, brain tissue oxygen tension, cerebral microdialysis data
45921837|NCT05636735|Other|data collection|evaluation of self -confidence
45921838|NCT00119548|Other|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
45921839|NCT00119548|Other|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
45449931|NCT03540628|Dietary Supplement|Thiamine and Vitamin C|Supplementary vitamins for the patient in septic shock
45449932|NCT02168218|Other|7-day overfeeding|7-day overfeeding with an excess sucrose intake corresponding to 40% total energy requirements
45648678|NCT04825561|Drug|placebo of AD-208|PO, Once daily(QD), 24weeks
45648679|NCT04825561|Drug|placebo of AD-2081|PO, Once daily(QD), 24weeks
45648680|NCT05122897|Device|Rings made of PA (test)|Rings made of PA (test) 0.2mm in thickness are pushed on the conical titanium base (abutment) of implant crowns and are removed and replaced after 48h, 2 weeks and 3 months for quantification of the bacterial biofilm. Test rings are applied in a split-mouth design provided that 2 implants are present (total of 4 months study period), or one after the other when only 1 implant is present (total of 8 months study period).
45648681|NCT05122897|Device|Rings made of TAN (control)|Rings made of TAN (control) 0.2mm in thickness are pushed on the conical titanium base (abutment) of implant crowns and are removed and replaced after 48h, 2 weeks and 3 months for quantification of the bacterial biofilm. Control rings are applied in a split-mouth design provided that 2 implants are present (total of 4 months study period), or one after the other when only 1 implant is present (total of 8 months study period).
45648682|NCT04505293|Device|InfraScanner 2000™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
45648683|NCT03915223|Procedure|leg fracture|Surgical leg fracture with injection of solumedrol (steroidal anti-inflammatory drug) or physiological serum
45648684|NCT05102149|Drug|PB-201|PB-201: 100 mg each time, orally in the morning and evening respectively;
45648685|NCT05102149|Drug|Vildagliptin|Vildagliptin: 50 mg each time, orally in the morning and evening respectively;
45648686|NCT05102149|Drug|PB-201 matched placebo|PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;
45648687|NCT05102149|Drug|Vildagliptin matched placebo|One tablet each time, orally in the morning and evening respectively;
45795464|NCT05720819|Device|Combined biofeedback-virtual reality device|The study's biofeedback-VR device was developed in collaboration with students and faculty at the University of Washington Global Innovation Exchange program. The system included an Oculus Go mobile VR headset (wireless, portable, head-mounted display, with screen providing a 101° field of view with 2560 x 1440 resolution at a 60-72 Hz frame rate; Oculus VR, LLC, Menlo Park, CA/USA) and with built-in speaker, in addition to a Polar H10 heart rate monitor (electrocardiogram, or ECG, to measure heart rate; Polar Electro Inc., Bethpage, NY/USA), with customized software programmed for the study using the Unity3D game engine (Unity Technologies, Bellevue, WA/USA). Individuals in the experimental arm are asked to use this device for 10 minutes daily, on at least 3 days per week.
45795465|NCT00356187|Drug|Propranolol|
45795466|NCT02973399|Drug|SNX-5422 plus ibrutinib|SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
45648688|NCT04019431|Dietary Supplement|Whey protein, vegetable protein or animal protein|meal replacements or animal protein
45648689|NCT04922749|Behavioral|MULTI+|MULTI+ is a multidisciplinary, multicomponent treatment which aims to improve lifestyle factors through a holistic lifestyle approach, by focusing on 10 core components. The MULTI+ will be integrated into daily treatment to promote uptake and sustainability.
45795467|NCT04879563|Other|ASCAPE-based follow-up strategy|"Follow-up through ASCAPE platform including AI-based predictions for health-related QoL issues and suggestions for personalized interventions depending on the type of QoL issue that needs to be tackled.~The ASCAPE-based follow-up strategy includes follow-up through validated QoL questionnaires, wearables for capturing active monitoring data, and mobile apps for answering the questionnaires and capturing potential health-related issues."
45795468|NCT05708885|Device|Concurrent manometry/impedance and fluoroscopy with and without laryngeal restriction|To reduce the laryngeal movement and St.Eso excursion we will use a device constructed in our laboratory which can induce an adjustable resistance to excursion of the larynx. This handmade device that is worn around the neck consists of a band and a concave plastic disk which serves as a support structure for an inflatable polyethylene bag which is connected to a hand pump and pressure gauge. When worn around the neck the inflatable bag rests in position on the thyroid cartilage with a portion of it hung over above the cartilage creating resistance to its superior excursion when fixed by closure straps. A known external force may be applied to the thyroid by partially inflating the bag to a specific pressure reading on the gauge. The soft and compliant bag conforms to the larynx while applying a resistive force to anterior and superior distraction of the hyolaryngeal complex during swallowing.
45795469|NCT05708885|Device|Concurrent manometry/impedance and fluoroscopy before and after six weeks of using swallow muscle exercising device|Use the previously mentioned wearable device (sRED) and exercise regimen described previously for studying the effect of increase in anterosuperior excursion of the larynx/St.Eso on St.Eso peristaltic function.
45795470|NCT04680117|Other|Blood collection|"Blood collection with samples of 15ml max by subject (case or control) at J0, M6 and M12:~subject less than 5 kg : 1.8 to 4.5 ml max~subject 5 kg to 10 kg : 4.5 to 9 ml max~subject 10 kg to 15 kg : 9 to 13.5 ml~subject 15 kg to 20 kg : 13.5 to 15 ml max"
45795471|NCT04680117|Other|Saliva sample|Saliva sample by subject at J0
45795472|NCT04680117|Other|Nasal|Nasal brushing by subject at J0
45795473|NCT02224729|Drug|Bendamustine hydrochloride|Given IV
45795474|NCT02224729|Drug|Bortezomib|Given SC
45795475|NCT02224729|Drug|Dexamethasone|Given PO
45648690|NCT04870099|Behavioral|Doing What Matters in Times of Stress: An Illustrated Guide|"From the WHO's website: Doing What Matters in Times of Stress: An Illustrated Guide is a stress management guide for coping with adversity. The guide aims to equip people with practical skills to help cope with stress. A few minutes each day are enough to practice the self-help techniques. The guide can be used alone or with the accompanying audio exercises.~Informed by evidence and extensive field testing, the guide is for anyone who experiences stress, wherever they live and whatever their circumstances."
45795476|NCT00320931|Device|Hybrid PET/CT|Rest and vasodilation stress rubidium PET and coronary angiography with CT were performed using standard doses for clinically indicated studies.
45648691|NCT04412395|Dietary Supplement|Lactoferrin (Apolactoferrin)|Apolactoferrin is an iron-free Lactoferrin (with very low iron saturation). Lactoferrin (Lf) is a natural glycoprotein that is found predominantly in milk. Lf represents a known component of the innate immune system present in neutrophil-specific granules and broadly distributed within the body fluids and exocrine secretions.
45648692|NCT04412395|Drug|Placebo of excipient(s) will be administered|Placebo of the equivalent excipient will be administered to placebo group
45795477|NCT03004495|Drug|CHF5259 and CHF6001|b.i.d. for 14 days
45795478|NCT03004495|Drug|CHF5259 + placebo|b.i.d. for 14 days
45795479|NCT03004495|Drug|CHF6001 + placebo|b.i.d. for 14 days
45795480|NCT03004495|Other|Placebo|b.i.d. for 14 days
45795481|NCT05720585|Other|Intervention of mobile health application|According to the contents of the Subjective Memory Complaint (SMC) application intervention program for the older adults previously formulated, the intervention time and the frequency (30min / time, once a week) of each training module and other contents were determined. The application will be implemented and lasted for a total of 1 month.
45795482|NCT03004417|Drug|CHF 6001 Dose1|CHF 6001 plus placebo
45795483|NCT03004417|Drug|CHF 6001 Dose2|CHF 6001 only (high dose)
45795484|NCT03004417|Other|Placebo|Placebo only
45648693|NCT04016935|Other|Observational|Observational
45795485|NCT00305643|Drug|Capecitabine|Initial dose of 750-1500 mg/m^2 orally twice a day for each 21 day cycle.
45795486|NCT00305643|Drug|Celecoxib|200 mg given orally twice a day for each 21 day cycle.
45795487|NCT00305643|Procedure|Radiation Therapy|Some patients may undergo radiation therapy 5 days a week for 5-6 weeks, and receive oral capecitabine twice daily 5 days a week. Following completion of radiotherapy, patients may continue oral capecitabine once daily on days 1-14.
45795488|NCT00305643|Drug|Placebo|Oral placebo twice daily on days 1-21
45795489|NCT05702801|Device|Stochastic Vibratory Stimulation (SVS)|Investigators implement stochastic vibratory stimulation (SVS) to alter proprioceptive performance by increasing excitement of type Ia afferents in muscle spindles. Based on previous preliminary data, vibration frequencies around 40Hz may provide adequate noise for enhancing aging-related proprioceptive deficits. To make a subsensory noise investigators set it to 90% of the sensory threshold amplitude, which has been effectively used previously for influencing mechanoreceptor sensation in older adults. Stimulation will be imposed bilaterally on: 1) distal ankle (tibialis anterior, peroneus longus, soleus, gastrocnemius); and 2) proximal hip (quadriceps, gluteus medius, and paraspinals). Investigators use Gaussian noise to reduce the anticipative and preemptive adjustments of muscle spindles to the vibration. For SVS investigators use a magnetic actuator system and a Universal Controller (C-2HDLF Tactor/TDK), to provide programmable frequency ranges.
45795490|NCT04874623|Other|Collection of peripheral blood mononuclear cells|Analysis of specific memory B cells in CDI patients
45449933|NCT02168296|Dietary Supplement|Plant-based ingredient added to starchy meal|
45795491|NCT05702255|Other|Active acupressure|Participants will receive training (2 sessions, 2 days a part) by a training researcher. Patients will be taught on the acupoints location and the acupressure technique. Participants will be verified for the correct location of the acupoints, acupressure technique and strength. Participants will be instructed to use thumb or middle finger to self- press each acupoint using circular movements. The force of pressing must be sufficiently strong but still within a comfortable range. A lubricant will be uses to decrease friction between the acupoints and the finger. Follow up evaluation will be at the end of the week 2 and week 4 .The training researcher will make weekly calls to remind participants to perform acupressure and to answer questions
45795492|NCT05702255|Other|Sham acuptressure|The same protocol as the active acupressure group.
45795493|NCT03004105|Drug|Selumetinib|"Safety Run-In - Beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle~Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off.~Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in."
45795494|NCT03004105|Drug|Durvalumab|Safety Run-In, Intermittent Arm, Continuous Arm - Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
45795495|NCT03004105|Behavioral|Phone Calls|About every 6 months, participant called by a member of the study staff to ask how participant is doing and if participant has started any new treatments outside of the study. These calls should last about 10 minutes each time.
45795496|NCT02959385|Radiation|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
45795497|NCT02959385|Procedure|Neoadjuvant Radiochemotherapy|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
45795498|NCT00271011|Drug|Mitomycin C|Patients will receive mitomycin C 7 mg/m2 as a bolus infusion on day -1 of each 28 day cycle.
45795499|NCT00271011|Drug|Cetuximab|Patients will receive cetuximab 400 mg/m2 loading dose over 90 minutes cycle 1, day 1. All subsequent weekly cetuximab treatments will be 250 mg/m2 as a 60 minute infusion days 1, 8, 15, and 22 of each 28 day cycle.
46071753|NCT05878613|Device|treadmill training with KT group (TTKT group)|The area to be taped will be cleaned with an alcohol swab, and the I-shaped elastic KT was applied to the four trunk muscles from their insertion to their origin. Patients will then undergo treadmill walking with easy speed control for 20 minutes. The training will be immediately stopped if the subject complain of fatigue during treadmill training; training will be resumed after sufficient rest.
45449934|NCT02168296|Dietary Supplement|Plant-based ingredient added to liquid|
45449935|NCT02168296|Dietary Supplement|No Plant-based ingredient|
45648694|NCT05048173|Procedure|Sentinel lymph node mapping and biopsy|Sentinel lymph node mapping with indocyanine green dye followed by biopsy if positive
45648695|NCT05048173|Procedure|Lymphadenectomy|Conventional lymphadenectomy
45648696|NCT04754269|Behavioral|Beverage Intervention|Parents will watch a video that promotes optimal beverage practices for young children including discouraging consumption of sugar-sweetened beverages and fruit juice and encouraging consumption of water and unsweetened milk. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
45921840|NCT00119548|Other|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
45921841|NCT00119548|Other|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
45648697|NCT04754269|Behavioral|Reading Intervention|Parents will watch a video that promotes reading to children and includes specific ideas and techniques for how to make reading interactive and engaging. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
45795500|NCT00271011|Drug|Irinotecan.|Patients will receive irinotecan 140 mg/m2 as a 90 minute infusion on days 1 and 15 of each 28 day cycle after cetuximab infusion. Patients found to be homozygous for UGT1A1*28 allele will receive irinotecan 110 mg/m2.
45795501|NCT05720429|Other|Psychoeducational program|"A psychoeducational program consisting of 11 one-hour sessions, with a weekly or biweekly frequency, each one regarding specific tools and skills to promote emotional well-being, self-care, and the ability to deal with stressful situations. They are conducted by community psychologists, who will give a brief theoretical introduction and then conduct practical group exercises that apply the concepts introduced. Every session ends with a relaxation exercise and some habits that the participants can incorporate into their daily life.~Session Index: (1) Emotional management;(2) Thought management; (3) Stress management; (4) Communication skills, active listening, and empathy; (5) Self-care; (6) Individual/group self-esteem; (7) Anxiety/coping with panic. Mindfulness; (8) Activating motivation; (9) Problem-Solving; (10) Positive psychology and emotional intelligence; (11) Emotional expression through art."
45795502|NCT00214149|Radiation|brachytherapy|breast brachytherapy to 34 Gy
45795503|NCT03312530|Drug|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm.
45795504|NCT03312530|Drug|Venetoclax|Venetoclax will be administered as per the schedule specified in the respective arm.
45795505|NCT03312530|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
45795506|NCT05720351|Procedure|Lachmann maneuver|Patients undergone the Lachmann recruitment maneuver (30 CmH2O PEEP for 30 seconds)
45795507|NCT05720351|Procedure|Staircase maneuver|Patients undergone Undergone staircase recruitment maneuver (stepped increase in PEEP by 2 CmH2O every five breaths until reach upper deflection point
45795508|NCT05697965|Drug|Vancomycin|applying 1 gm of vancomycin powder intracapsularly during primary total knee and hip arthroplasty to prevent periprosthetic joint infection
45795509|NCT05697965|Procedure|Total knee or total hip arthroplasty|Primary total knee or total hip arthroplasty without using local vancomycin
45795510|NCT00179127|Drug|glargine|0.3u/kg of glargine, subcutaneously, once
45921842|NCT00119548|Other|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
45921843|NCT00119548|Other|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
45648698|NCT04987099|Dietary Supplement|550 mg/day Choline|Choline chloride (550 mg) is a water soluble choline salt that will be provided in a grape juice cocktail solution to participants for daily consumption.
45648699|NCT04987099|Dietary Supplement|25 mg/day Choline|Choline chloride (25 mg) is a water soluble choline salt that will be provided in a grape juice cocktail solution to participants for daily consumption.
45648700|NCT03906721|Drug|Placebo|Sugar pill used to condition patients.
45795511|NCT00179127|Drug|saline|0.3u/kg of saline, subcutaneously, once
45795512|NCT05720273|Drug|palicalcitol|This study does not interfere with the clinical medication of the researchers, and the usage and dosage of the drugs will be recorded according to the actual use. The recommended starting dose of palicalcitol may be based on body weight, baseline iPTH, or combined with prior medication. Dose adjustment should be determined according to pre-dialysis iPTH, Ca and P. iPTH levels should be maintained at 150-300pg/ml, while Ca and P levels should be closely monitored. If hypercalcemia occurs, the dose should be reduced or medication should be discontinued until these parameters return to normal; Subsequently, the dose of palicalcitol should be restarted at a lower dose. If PTH levels decrease as a result of treatment, the dose of medication may need to be reduced accordingly. The dose adjustment interval is 2-4 weeks, and the dose can be adjusted immediately for safety reasons.
45795513|NCT05696249|Device|OhmTrak device.|All probands will undergo six-week outpatient therapy once a week. The intervention group will be equipped with an OhmTrak device for home self-therapy and instructed in its correct use at least 5 times a week.
45795514|NCT05696249|Other|Outpatient Physiotherapy|All probands will undergo six-week outpatient therapy once a week for an hour
45795515|NCT00183963|Drug|Tamoxifen|20mg
45795516|NCT00183963|Drug|Fulvestrant|250mg
45795517|NCT00183963|Drug|Fulvestrant|500 mg IM
45795518|NCT05720195|Diagnostic Test|ALBI|Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades for prognosis of HCC
45795519|NCT01930058|Drug|MK-8876|MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.
45921844|NCT02702310|Other|Quality-of-Life Assessment|At initial visit (day 1) - for determination of a baseline quality of life, patients will be given a self-reported questionnaire called the Skindex-29. Following standard of care radiation treatments, at weeks 6 & 12, and every 3 months thereafter, patients will complete the Skindex-29 questionnaire.
45921845|NCT02702310|Other|Objective Grading of Skin Findings|At initial visit (day 1) , using mSWAT the radiation oncologist can follow the patient's treatment response by accurately grading the severity of the patient's skin findings. Following standard of care radiation treatments, at weeks 6 & 12, and every 3 months thereafter, mSWAT will again be determined by physician. Follow-up visits will continue until patient has a change in disease.
45921846|NCT00119587|Drug|darbepoetin alfa|
45921847|NCT00119626|Drug|NXY-059|
45921848|NCT00119665|Drug|MF101|
45921849|NCT05636813|Other|Training|Patients are trained to use AT (2 sessions of 4 hours). Written langage skills, autonomy, the use are evaluated before and after training.
45921850|NCT00119704|Drug|Botulinum toxin A injection or normal saline|
45921851|NCT02621151|Biological|Pembrolizumab|
45648701|NCT03906721|Drug|Oxycodone|An opioid used for analgesia.
45648702|NCT03906721|Other|Essential Oil|An aromatic oil used for conditioning.
45648703|NCT04668001|Device|Near-Infrared Transcranial Photobiomodulation|tPBM-NIR involves the use of a device that administers near-infrared light over the scalp. The light activates target brain regions.
45921852|NCT02621151|Procedure|Transurethral Resection of Bladder Tumor|
45921853|NCT02621151|Drug|Gemcitabine|
45921854|NCT02621151|Radiation|External Beam Radiation Therapy|
45921855|NCT00119743|Biological|undecavalent pneumococcal-protein D conjugate vaccine|
45921856|NCT00119782|Behavioral|Diet|A dietary intervention that will promote lower calorie intake
45921857|NCT00119782|Behavioral|Exercise|A physical activity intervention combining increased daily physical activity and regular, structured exercise
45921858|NCT00119782|Behavioral|Environment|Increase worksite access to both healthy foods and physical activity
45921859|NCT05636891|Biological|Stimus|"NNG-DEPO (Darbepoetin alfa 10 mcg/0.4 mL, 20 mcg/0.5 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL) is available as a prefilled syringe in a sterile, colorless, glass tube.~Aranesp® (Darbepoetin alfa 10 mcg/ 0.4 mL, 20 mcg/ 0.5 mL, 40 mcg/ 0.4 mL, 60 mcg/ 0.3 mL) is manufactured by Amgen, as a pre-filled syringe in a sterile, glass tube, colourless.~Storage: 2-8ºC, not frozen. The process of transporting and storing the drug must ensure the temperature in the range of 2-8ºC.~NNG-DEPO/Aranesp is administered subcutaneously (or intravenously for patients with PK-PD in the previous IV group), at a dose of 0.75 g/kg initially, every 2 weeks at the second visit.~IPs will be prepared according to standard procedure (SOP). Dosage adjustment guideline:~Patients will have hemoglobin levels monitored every 2 weeks. The investigators will evaluate and adjust the dose of Darbepoetin alfa to maintain the Hb levels within the target range (10 - 12 g/dL)"
45648704|NCT04668001|Device|Sham Transcranial Photobiomodulation|tPBM-Sham involves the use of an identical device to tPBM-NIR but does not administer near-infrared light. It mimics the sensation by applying heat but does not actually activate target regions of the brain
45648705|NCT03994081|Device|tACS|XCSITE100
45795520|NCT04659213|Device|esolution catheter|esolution is a catheter-based therapy designed to displace the esophagus away from the source of ablation energy during ablation of AF and to eliminate the risk of esophageal injury
45795521|NCT02978261|Drug|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
45795522|NCT04526769|Diagnostic Test|Tear Collection|"A microcapillary tube will be placed at the corner of the eyelid so tears can be absorbed to the tube without causing any trauma. The tube will be placed in a transfer tube. Standard virus sampling swabs will be used to collect samples from the same patient's nasopharynx. RT-PCR will be run to determine virus yield in each sample.~For the second part of the study, IHC staining will be done on the existing ocular tissue pathology slides to detect the expression of ACE2 and other cell surface and intracellular receptors. The investigators will use existing UMN ocular pathology lab and Lion's Eye Bank tissue samples. These are banked tissue samples that were collected and examined previously and then the remaining tissue samples were stored."
45795523|NCT01909154|Biological|Mesenchymal stromal cell therapy|Stem cells administration locally
45795524|NCT00176631|Dietary Supplement|licorice root extract|Licorice root is started on Day 1 and is given at a dose of 6.75 g each day (five 450 mg capsules tid) for a total of 21 days in each cycle.
45795525|NCT00176631|Drug|docetaxel|All the patients will be treated with docetaxel at a dose of 60 mg/m2 every 21 days on Day 1 of the treatment cycle.
46071754|NCT05878613|Device|treadmill training without KT group (TT group)|General treadmill training without taping will be carried out for the same time as the gait training of the experimental group, and the treadmill speed will also be a comfortable speed in the same manner as in the experimental group.
46071755|NCT05878600|Other|kendall's exercise|comparative effect of targeted cervical spine strengthening versus kendalls exercise will be analyzed
46071756|NCT05878600|Other|cervical spine strengthening|sole effect of cervical spine strengthening will be analyzed
46071757|NCT05878587|Other|thermotherapy+ TENS+ low intensity high repetition exercises and Buerger Allen|Patient will be asked to lie down flat on the plinth with legs elevated from 45 degrees until the skin turns pale, it will take approximately 2 minutes to occur. Then the patient turns to sit at the edge of the plinth with feet hanging and doing the following exercises; dorsiflexion, plantar flexion, inversion, eversion, and flexion the extension of toes, this phase may also be maintained for 2 minutes. Finally, the patient lies flat with his leg rested in a horizontal position and covered with a warm blanket for about 5 minutes
46071758|NCT05878587|Other|thermotherapy+ TENS+ low intensity high repetition exercises|The intervention will be repeated 3 times per day and the posttest will be conducted 5th day using KOOS, NPRS and goniometer.
46071759|NCT05878574|Drug|Low molecular weight heparin|Continuous use of LMWH for more than 3 months during pregnancy preparation and through pregnancy
46071760|NCT05878561|Drug|Fimasartan + Indapamide|a fixed dose combination
45648706|NCT03994081|Device|Sham tACS|XCSITE100
45795526|NCT05684081|Behavioral|Digital payment|The proposed intervention is designed to support the implementation of polio campaigns through digital payments
45795527|NCT05719961|Drug|INS062 injection|Part I: A single dose of 1.2noml/kg is administered.
46071761|NCT05878561|Drug|Fimasartan + Indapamide placebo|a fixed dose combination
46071762|NCT05878548|Procedure|corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture|corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture
46071763|NCT05878522|Drug|sisunatovir|6 capsules administered Q12 hours for 5 doses
45795528|NCT05719961|Drug|Insulin Aspart|Part I: A single dose of 0.2U/kg is administered.
45795529|NCT05719961|Drug|HR20014 injection|Part II: Ascending single doses at three dose levels
45795530|NCT05719961|Drug|Insulin Aspart 30 Injection|Part II: A single dosewas administered
45648707|NCT04663711|Behavioral|degree of adherence of pre-anesthetic tests at kasr Alaini hospital to the NICE-Uk guidelines|"The anesthesiologist, whom is in charge of preoperative assessment at each unit, will assess patients who are scheduled for elective surgery, and will inform senior anesthesiologists with a minimum 3 years of experience.~preoperative investigations will be divided into: First part will be on patient's gender, ASA classification, medical history and examination.~Second part will be on Grade of surgery - Minor/ Intermediate/ Major or complex.~Third part is requested investigation(s), its rationale, the hierarchy of anesthesiologist requested, and the planned date for surgery.~Fourth part is about whether that investigation(s) is adherent with NICE-UK guidelines or not."
45648708|NCT04096573|Drug|LC51-0255|LC51-0255
45648709|NCT04096573|Drug|Placebo|Placebo
45921860|NCT02598219|Drug|Pre-operative SN mapping with radionucleide|"Preparation : four 1ml syringe (Nanocis, or Nanocoll, or Rotop-nanoHSA) are prepared per patient, each containing a total activity 10 MBq if the injection is planned the same day of surgery and in the operative theater OR each containing a total activity 30MBq if the injection is performed the day before the surgery.~Intracervical injection is performed by the surgeon, no more than 3-24 hours before surgery : 4 submucous injections with the filtered radiocolloid at 3, 6, 9 and 12 o'clock positions. Each injection if performed at 2 mm of depth for a total activity of 40 MBq or a total activity of 120 MBq is the surgery is planned the day after the injection.~Sentinel Node detection by planar scintigraphy at 1 and 3h (if no detection at 1 hour), or by SPECT-CT imaging if available."
45921861|NCT02598219|Drug|Intra-operative SN mapping with patent V blue dye|"Patent blue V dye are diluted with saline sterile solution to obtain 4ml of 50%. Four 1ml syringe, each containing a 50% patent blue dye solution, are prepared per patient.~Intracervical injection is performed by the surgeon. after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible.~SN are detected by direct visualization of blue colored lymphatics and node"
45648710|NCT04919083|Other|Program of Therapeutic Exercise and Functional Recovery|"Specific hip fracture recovery programme,restoring the mobility, strength and balance of the operated patient, in order to facilitate the return to a functional state as close as possible to the state prior to surgery and in the shortest possible time, as detailed in Annex VIII. This programme is part of the standard treatment protocol implemented since January 2021 by the Orthogeriatrics Unit of the San Juan de Dios Hospital.~This programme is divided into 5 phases, each of these phases coincides with a level of the gait assessment scale. Each individual will start at the level assigned by the doctor and will only have access to the videos of the indicated level and the levels below it. As the patient meets the recovery goals, the physician will provide access to the higher level videos.The functional recovery plan begins the day after the hip fracture and continues after the patient has been discharged for a total of 16 weeks."
45648711|NCT04919083|Other|Standardised nursing care plan|Consisting of postural changes described in the standardised nursing care plan. Within this plan, the patient was moved to a sitting position prematurely (within the first 24 hours) and started to ambulate within the following 48 hours, provided that the patient's general condition allowed it. This group did not receive any specific functional recovery plan.
45921862|NCT02598219|Drug|Intra-operative SN mapping with indocyanin green|"1: Infracyanine powder is diluted in aqueous sterile water to obtain 4ml with a concentration of 1.25 mg/mL. Four 1ml syringe, each containing a 1.25 mg/mL Infracyanine dye solution, are prepared per patient.~2- Intracervical injection is performed by the surgeon, after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible~3- SN detection by near-infrared fluorescence imaging"
45921863|NCT02598219|Procedure|Full bilateral laparoscopic lymphadenectomy and Hysterectomy|"Bilateral pelvic lymphadenectomy (intermediate risk endometrioid)~Or Ilio-infrarenal paraaortic lymphadenectomy (high risk endometrioid)~Or Pelvic + paraaortic lymphadenectomies (high risk non endometrioid)"
45921864|NCT02598219|Procedure|Current initial staging protocols|Current French initial staging protocols
45795531|NCT01910636|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
45648712|NCT04529863|Drug|Tocilizumab|Tocilizumab claim is used as the reference group.
45648713|NCT04529863|Drug|Abatacept|Abatacept claim is used as the exposure group.
45795532|NCT01910636|Drug|RBV|Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing according to the approved Copegus labeling in Japan (< 60 kg = 600 mg , > 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
45795533|NCT04317807|Drug|Levetiracetam Pill|Levetiracetam is an anticonvulsant that is frequently used to treat epilepsy in children and adults due to its superior tolerability, ease of use and excellent safety profile. It is rapidly absorbed and rapidly crosses the blood-brain barrier. Levetiracetam does not affect metabolism of antipsychotic drugs and may normalize hippocampal hyperactivity by decreasing excessive glutamatergic and dopaminergic transmission, thereby making it an ideal agent to test the hypothesis that reducing excessive hippocampal activity may enhance treatment of early psychosis and prevent antipsychotic toxicity. Levetiracetam will be administered in 500 mg capsules twice a day.
45795534|NCT04317807|Other|Placebo|The placebo pill (sugar pill) will look just like the levetiracetam pill but does not contain levetiracetam. Placebo will be taken along with optimal antipsychotic medication selected by either the outpatient provider or the hospital staff responsible for the participant's care. Participants will be instructed to take the placebo pill twice daily for 12 weeks.
45795535|NCT01932164|Procedure|maxillary alveolar graft by tissue engineering|Extraction of deciduous teeth of cleft lip and palate patients to obtain mesenchymal stem cells;
45795536|NCT01932164|Procedure|Bone tissue engineering using mesenchymal stem cells|Secondary alveolar graft in patients with cleft lip and palate using using mesenchymal stem cell obtained from dental pulp of deciduous teeth (autogenous) associated with a biomaterial composed of collagen and hydroxyapatite.
45795537|NCT00118053|Biological|herceptin|
45795538|NCT00118053|Drug|carboplatin|
45795539|NCT00118053|Drug|docetaxel|
45795540|NCT00118053|Procedure|conventional surgery|Modified radical mastectomy or lumpectomy and axillary node dissection
45795541|NCT00118053|Procedure|radiation therapy|Whole breast or chest wall irradiation (as determined by radiologist)
45795542|NCT04266717|Behavioral|Baby Play Intervention|Baby Play Intervention involves teaching parents targeted ways they can handle, position, and play with young infants that aim to provide infants enhanced early opportunities to learn to control their bodies and interact with objects. These abilities are associated with future motor, cognitive, and language outcomes. Parents will be asked to perform the intervention activities 20 minutes daily and to log their activity performance weekly.
45795543|NCT04266717|Behavioral|Milestone Education|Parents in the Milestone Education Intervention group will receive information regarding milestones expected based on infants' CA. This information is based on forms from the Centers for Disease Control and Prevention (CDC) and The American Academy of Pediatrics (AAP). This will help parents understand the milestones typically observed at the their child's CA and reflects the education parents receive from healthcare providers. Parents will be asked to provide their infants opportunities to perform these milestone behaviors 20 minutes daily and to log their activity performance weekly.
45795544|NCT05719727|Diagnostic Test|colonoscopy|lower colonoscopy
45795545|NCT04225611|Drug|Dexamethasone|The investigators have developed a topically-applied corticosteroid-delivery system that has the potential to treat recurrent cystoid macular edema with fewer risks to patient, and more dose control. The system is comprised of a drug-polymer film that is completely encapsulated within the periphery of a hydrogel that is commonly used to make contact lenses.
45795546|NCT05677061|Device|Dynamic Hip Screw with HA-coating (Hiploc)|During surgery for pertrochanteric hip fracture a lag screw with hydroxyapatite coating on the screw thread was used to fix the fracture
45795547|NCT05677061|Device|Dynamic Hip Screw without coating (Hiploc)|During surgery for pertrochanteric hip fracture a lag screw with no coating on the screw thread was used to fix the fracture
45795548|NCT00379977|Biological|diphtheria, tetanus, pertussis & Hib vaccine|
45648714|NCT04456933|Procedure|Extracorporeal left hemicolectomy anastomosis|"Standard surgical technique protocolized in the unit for laparoscopic surgery of the left colon, sigma and high rectum for the last 10 years.~After sectioning the distal colon using a mechanical stapler (60mm blue load), a pfannestiel-type suprapubic accessory incision is made, with externalization of the tumor under wound protection with a ringed retraction device. Both the resection of the left mesocolon or mesosigma, and the placement of the head of the circular stapler are performed extracorporeally by proximal section of the colon with a pursetring® self-suturing device, removal of the piece, placement of the head, and reconnection of the pneumoperitoneum for colorectal anastomosis with Circular Stapler Curved B. Braun®"
45648715|NCT04456933|Procedure|Intracorporeal left hemicolectomy anastomosis|"o Intracorporeal resection of the left mesocolon~The mesocolon resection will be performed totally intracorporeally to its proximal end. The distal colon section will be performed using a mechanical stapler (blue charge 60mm)~o Preparation of Intracorporeal Anastomosis~The anastomosis will be performed in a mechanical end-to-end manner using a Circular Stapler Curved B. Braun®.~The Insertion of the stapler head into the proximal colon will be placed intracorporeally with an incision distal to the staple section. Once the head has been exteriorized at the terminal end of the proximal colon, a circular purse-type suture with prolene 2.0 will be made.~Once the mechanical colorectal anastomosis is performed, 4-6 stitches of anastomotic reinforcement with silk 2.0 will be placed.~The extraction of the piece will be carried out with endobag protection and with an accessory incision (pfannestiel or other location depending on the patient)"
45795549|NCT04007601|Device|Active tDCS|Participants will receive active 1mA direct current stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.
45795550|NCT04007601|Device|Sham tDCS|Participants will receive sham (no direct current) stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.
45795551|NCT02978573|Device|Cartiva|Cartiva Synthetic Cartilage Implant
45795552|NCT05717855|Diagnostic Test|Displaying optic chiasm for screening septooptic dysplasia|Displaying and measuring the width and length of the optic chiasm for screening septooptic dysplasia with ultrasound between 16-20 weeks of gestation
45795553|NCT01996371|Device|Pedicle Screw|
45921865|NCT00119821|Behavioral|Weight Reducing Diet|Behavioral intervention
45921866|NCT00119821|Behavioral|Exercise|Moderate exercise implemented plus behavioral intervention.
45795554|NCT05719493|Other|multicomponent treatment|The intervention to be evaluated consists of 4 group sessions carried out in two weeks, 6 hours per week divided in 2 days (a total of 12 hours), of active education in nutrition, chronobiology and physical exercise in people diagnosed with Chronic Fatigue Syndrome and Fibromyalgia.
45795555|NCT05669885|Drug|Sildenafil|Study participants will be allocated to receive oral administration of 100 mg sildenafil.
45795556|NCT05669885|Drug|Placebo|Study participants will be allocated to receive oral administration of placebo.
46071764|NCT05878522|Drug|placebo|6 capsules administered Q12 hours for 5 doses
46071765|NCT05878522|Drug|moxifloxacin|6 capsules of placebo administered Q12 hours for 4 doses, followed by a single tablet of moxifloxacin
46071766|NCT05878496|Procedure|fixation by plate and screws|reduction and fixation of pediatric fracture neck femur by plate and screws
45921867|NCT00119821|Behavioral|Smoking Cessation|"Nicotine Patch in dosages given based on number of cigarettes per day smoked. 21 mg patch, 14 mg patch, 7 mg patch for total of 6 weeks duration of therapy.~NRT gum is being provided to assist with relapse prevention. At the randomization visit the participant is given one (1) box of 2mg NRT gum, which consists of (110) pieces. The participant may request up to two (2) more boxes, for a maximum of three (3) boxes per participant."
45795557|NCT00955929|Drug|Placebo QHS and sildenafil and questionnaires|Pts will be offered sildenafil 100 mg to be used before intercourse on an as-required basis. They will be given six 100 mg doses, per month, for a 12-month duration. Each patient in this group will use a placebo pill (blinded) each night, except on a nights that 100mg is taken for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
45795558|NCT00955929|Drug|Sildenafil and questionnaire|Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window
45921868|NCT00119899|Procedure|FDG-PET scan|
45648716|NCT04441957|Device|Endovenous Mechano- Chemical Ablation|The Flebogrif™ catheter (Balton® Sp. z o.o., Warsaw, Poland) represents endoluminal Non Thermal Non Tumescent devices designed to cause occlusion (fibrosis) of the target vein through the combined mechanical and chemical damage to its endothelial lining with retractable cutters and foamed sclerosant.
45921869|NCT00119938|Behavioral|Access to online patient portal|
45921870|NCT00119977|Procedure|1 Periacetabular osteotomy|pelvic osteotomy to increase acetabular coverage
45921871|NCT00120016|Behavioral|dietary counseling|telephone counseling
45648717|NCT04594603|Other|Phacoemulsification for cataract|Phacoemulsification for removal of cataract
45921872|NCT05636930|Other|Test the accuracy of the wearable device|No intervention was done for the subjects
45921873|NCT00120055|Drug|Atorvastatin (Lipitor)|
45921874|NCT00120133|Drug|Atorvastatin|
45921875|NCT00120172|Drug|oxaliplatin, capecitabine, bevacizumab|
45921876|NCT05636969|Behavioral|Multimodal prehabilitation|Multimodal prehabilitation including i) exercise training and physical activity promotion; ii) nutritional counselling and supplementation if needed; iii) psychological support
45921877|NCT02470728|Other|New Clinical Pathway|
45648718|NCT04432441|Other|Therapeutic physical exercise program for scapulo-humeral stabilitation|This group realize a therapeutic physical exercise program for scapulo-humeral stabilitation during a month
45648719|NCT04432441|Other|Therapeutic physical exercise program for scapulo-humeral stabilitation + electrostimulation|This group realize a therapeutic physical exercise program for scapulo-humeral stabilitation added electrostimulation during a month
45921878|NCT00402181|Biological|Siltuximab|Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days.
45648720|NCT03883945|Drug|AIV001|intradermal injection
45648721|NCT03883945|Drug|Vehicle|intradermal injection
45648722|NCT04582591|Drug|Cannabidiol 100 MG/ML|Patients receive cannabidiol before and after treatment with chemotherapy
45648723|NCT04217239|Procedure|MIE Ivor- Lewis|minimally invasive esophagectomy (MIE) with intrathoracic anastomosis
45648724|NCT04217239|Procedure|MIE McKeown|minimally invasive esophagectomy (MIE) with cervical anastomosis
45648725|NCT04212481|Procedure|uniport video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery for NSCLC using single port or two ports or three ports
45648726|NCT04212481|Procedure|two ports video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery for NSCLC using two ports
45921879|NCT00402181|Drug|Dexamethasone|Dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles and duration of each cycle is 28 days.
45921880|NCT04727437|Other|No treatment|Withholding anticoagulation for at least 3 months.
45921881|NCT04727437|Drug|Warfarin|anticoagulation drug given for at least 3 months.
45921882|NCT04727437|Drug|direct oral anticoagulants|anticoagulation drug given for at least 3 months.
45921883|NCT04727437|Drug|Low molecular weight heparin|anticoagulation drug, subcutaneous injection given for at least 3 months.
45921884|NCT00120211|Radiation|Accelerated Radiotherapy Fractionation|Radiation Therapy 6 fractions per week
45921885|NCT00120211|Radiation|Accelerated Radiotherapy Fractionation|Radiotherapy 5 fractions per week
45921886|NCT00120328|Drug|SPP301|
45921887|NCT00120367|Drug|Enfuvirtide|
45921888|NCT00120367|Drug|Tenofovir-Emtricitabine|
45921889|NCT04727320|Drug|Tauroursodeoxycholic acid|Oral TUDCA, once a day, one tablet (250mg) at a time for 6 months
45648727|NCT04212481|Procedure|three ports video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery for NSCLC using three ports
45648728|NCT04007575|Diagnostic Test|Magnetic Resonance CholangioPancreatography|The imaging data will be collected from the hospital records and image archiving system of the radiology departments of the University Hospitals
45648729|NCT03997669|Other|Collection of pleural effusion|Detection of pleural effusion
45921890|NCT04727320|Drug|Placebo|Oral placebo, once a day, one tablet at a time for 6 months
45921891|NCT05637125|Other|aerobic exercise for upper limb|aerobic exercise for upper limb in the form of arm ergometer 3 session/week for 12 weeks. Patient started with warming up for 5 minutes in form of stretching. Patients used arm ergometer without resistance for upper limb aerobic exercise for 20 minutes and instructed to take rest if they feel tired or fatigue. The intensity was according to rate of perceive exertion, after 20 minutes, patients were asked to cool down for 5 minutes in the form of stretching at the end of an exercise session.
45795559|NCT00955929|Drug|Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires|Intracavernous injections of a trimix combination (Papaverine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL) will be injected three times a week, and sildenafil 50mg taken on the other four (non-injection) nights. Injection therapy can be used for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
45795560|NCT05719415|Other|Measurement of pulmonary functional capillary surface area|Measurement of transpulmonary metabolism of trace injected doses of benzoyl-Phe-Ala-Pro
45795561|NCT03987789|Other|Driving-pressure-guided group|Patients will receive PEEP levels individually set at the highest possible value (up to 15 cmH2O) providing a driving pressure (airway plateau pressure minus PEEP) lower than 13 cmH2O, in addition to recruitment maneuvers.
45648730|NCT04497883|Drug|Maribavir (400 mg)|Non-Hispanic, Caucasian group and Japanese descent group participants will receive 400 mg maribavir tablets orally once on Day 1 during treatment period 1.
45648731|NCT04497883|Drug|Maribavir (200 mg)|Japanese descent group participants will receive 200 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
45795562|NCT03987789|Other|Low PEEP|Patients will receive a PEEP level ≤5 cmH2O without recruitment maneuvers
45795563|NCT00357851|Drug|Aprotinin|
45795564|NCT05664659|Drug|Oxytocin + misoprostol|600 micrograms misoprostol rectally 20 IU Oxytocin IV infusion on 1000 ml of normal saline solution
45795565|NCT05664659|Drug|Carbetocin|100 micrograms carbetocin
45921892|NCT05637125|Other|aerobic exercise for lower limb|received aerobic exercise for lower limb in the form of cycling 3session/week for 12 weeks. Patient started with warming up for 5 minutes. Patients used bicycle for lower limb aerobic exercise for 20 minutes and instructed to take rest if they feel tired or fatigue. The intensity was according to rate of perceive exertion. After 20 minutes, patients were asked to cool down for 5 minutes in the form of stretching at the end of an exercise session.
45921893|NCT00120445|Procedure|air|0.3 ml of filtered air
45921894|NCT00120445|Procedure|expansile gas|0.3 ml of perfluoropropane gas
45921895|NCT00120484|Drug|Vitamin B12|
45921896|NCT00391014|Drug|liposomal Amphotericine B|"AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.~If patient required ALO-TPH, the prophylaxis should be followed."
45921897|NCT00120562|Procedure|Gastric Bypass Surgery|
45795566|NCT03482505|Device|INVSENSOR00004|The INVSENSOR00004 will be placed on the subject's neck or chest to provide acoustic respiration rate.
45795567|NCT05719337|Device|Echocardiography|Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software.
45795568|NCT03985839|Device|MICRORAPTOR™ REGENESORB™ Suture Anchor|Smith & Nephew MICRORAPTOR™ REGENESORB™ Suture Anchor is a fixation device intended to provide secure attachment of soft tissue to bone.
45795569|NCT03985839|Device|MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor|MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor is fixation device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (REGENESORB™), and a non-absorbable PEEK (Polyether ether ketone) distal anchor tip.
45921898|NCT00120601|Drug|Naltrexone|
45921899|NCT00120601|Drug|Acamprosate|
45648732|NCT04497883|Drug|Maribavir (800 mg)|Japanese descent group participants will receive 800 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
45648733|NCT03756103|Drug|SPH3127 tablet Dose 1|Oral SPH3127 tablet, a kind of renion inhibitor, 50 mg, once daily for 8 weeks.
45648734|NCT03756103|Drug|SPH3127 tablet Dose 2|Oral SPH3127 tablet, a kind of renion inhibitor, 100 mg, once daily for 8 weeks.
45921900|NCT00120640|Drug|17 hydroxyprogesterone caproate intramuscular injections|
45648735|NCT03756103|Drug|SPH3127 tablet Dose 3|Oral SPH3127 tablet, a kind of renion inhibitor, 200 mg, once daily for 8 weeks.
45648736|NCT03756103|Drug|SPH3127 tablet Placebo|Oral SPH3127 tablet placebo, once daily for 8 weeks.
45648737|NCT04347655|Procedure|handgrip test|The patient will be supine for at least 5 minutes to collect baseline data before being handed a dynamometer device. The subject will then be asked to squeeze the dynamometer with maximum force for a minimum of 2 minutes while only engaging their forearm and remaining relaxed in the rest of their body. The subject will then release the dynamometer and remain supine, in recovery, for a minimum of 5 minutes.
45648738|NCT03688633|Drug|Candesartan|Candesartan treatment with dose adjustments (8-16mg/day) during 6 months in accordance with adverse effects
45648739|NCT03688633|Other|Usual care|patients will be followed as usual
45648740|NCT04436029|Biological|Descartes 11|Car T-cells
45648741|NCT03743935|Other|Gadolinium-enhanced cardiac MRI|Gadolinium-enhanced cardiac MRI during the 1st days post-STEMI with specific sequences including extra-cellular volume measurement
45921901|NCT00120679|Drug|darbepoetin alfa|
45921902|NCT00120679|Drug|recombinant human erythropoietin (rHuEPO)|
45921903|NCT00120718|Drug|fasudil|
45921904|NCT05637203|Behavioral|THRIVE (Toward Hope, Recovery, Interpersonal Growth, Values, and Engagement)|"THRIVE is an interpersonally focused recovery and care transition program. THRIVE (previously called RELATE in our SAMHSA grants) involves engaging a person during and following acute suicidal crisis in a sequence of interpersonally focused therapeutic tasks. The purpose of THRIVE is to help CSC guests re-build connections and contribute to the world in ways they find personally meaningful, while also transitioning safely to outpatient, community-based care. THRIVE involves a Belonging and Giving Reflections Group while at the CSC, followed by a 4-week, phone-based, recovery and care transition series of coaching calls."
45648742|NCT03963895|Drug|AB002 Dose 1|AB002 (E-WE thrombin) 1.5 mcg/kg administered on Day 1 as a single intravenous infusion
45648743|NCT03963895|Drug|AB002 Dose 2|AB002 (E-WE thrombin) 3.0 mcg/kg administered on Day 1 as a single intravenous infusion
45795570|NCT03985839|Device|MICRORAPTOR™ Knotless PEEK Suture Anchor|The MICRORAPTOR™ Knotless PEEK Suture Anchor is a class IIb device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (PEEK), and a non-absorbable PEEK distal anchor tip.
45921905|NCT05637203|Behavioral|Discharge / Safety Planning|"A written safety plan completed with the person~Mental health appointment scheduled within seven days~One phone follow-up call within 30 days"
46071767|NCT05878483|Device|Venipuncture Device (VD)|"The Venipuncture Device is a pre-market medical device that fully automates the blood drawing procedure (also called phlebotomy or venipuncture). It automatically detects a vein using near-infrared and ultrasound imaging technology, robotically inserts a needle, automatically connects blood tubes and applies pressure to the puncture site.~During the ADOPT Study, the technology is further improved over time; for example features are released (such as: automated tourniquet). Initially, several manual steps are required to be performed by a device supervisor and operator. At the final stage of the ADOPT Study, Phase C2, the device has full functionality and only limited manual steps are required to be performed by a device supervisor."
46071768|NCT05878470|Behavioral|video|A brief (119 seconds) social contact-based video. The video presented a young Black man in his early twenties, a professional actor, sharing his scripted personal story of struggles with psychotic illness and raising themes of recovery and hope.
45648744|NCT03963895|Drug|placebo|placebo administered on Day 1 as a single intravenous infusion
45648745|NCT03736759|Behavioral|Exercise|10 sets of 5 repetitions of 80% of calculated one-repetition maximum weight of lateral side arm raise and biceps curls, alternating
45648746|NCT03662815|Biological|iNeo-Vac-P01|Neoantigen peptides
45795571|NCT00358319|Drug|Karenitecin|
45648747|NCT03662815|Other|GM-CSF|immune adjuvant
45648748|NCT03509467|Behavioral|Personalized Information|Personalized information about ways that participants can protect themselves and their child from developing melanoma.
45648749|NCT03509467|Behavioral|Standard Information|Standard information about ways that participants can protect themselves and their child from developing melanoma.
45795572|NCT00358319|Drug|Valproic Acid|
45795573|NCT03981783|Behavioral|Best available care (BAC)|Eligible patients are assigned to a standard pulmonary rehabilitation program
45795574|NCT03981783|Behavioral|Telerehabilitation (TH)|Eligible patients are assigned to a pulmonary telerehabilitation program
45795575|NCT03833765|Procedure|CAF+XCM|After flap elevation according to the Coronally Advanced Flap procedure for multiple recession defects, a Xenogeneic Collagen Matrix was applied and then covered by the flap.
45648750|NCT03509467|Other|DNA Extraction Determination of MC1R Genotypes|After signing informed consent, a biologic sample (saliva) will be collected for the purpose of DNA extraction determination of MC1R genotypes. All participants who carry high risk MC1R genotypes and a proportion of those who carry low risk or no MC1R variants will be randomized to the control or intervention arm.
45795576|NCT03833765|Procedure|CAF alone|Coronally Advanced Flap procedure alone was performed to treat multiple recession defects
45795577|NCT05717699|Biological|Ad-TD-nsIL12|This is a novel adenovirus 5-based Ad-TD, which had three gene deletions (E1ACR2, E1B19K and E3gp19K) but retains the E3B gene. This new mutant oncolytic adenovirus exhibited strong anti-tumor efficacy in vivo. On the basis of Ad-TD, Ad-TD-nsIL12 is armed with human non-secretory interleukin-12 (nsIL12, deletion of the signal peptide).
45648751|NCT03490903|Device|Virtual Reality|Subjects undergoing the Virtual Reality Intervention will be fitted with a VR headset and headphones, and undergo an immersive meditation experience provided by AppliedVR, Inc. The headphones will not be noise-cancelling, and the subject will be able to communicate with the physician or circulating nurse if needed.
45648752|NCT03490903|Drug|Fentanyl Injection|Fentanyl is commonly administered to treat pain during invasive procedures such as coronary angiography. Intravenous fentanyl injection dosages are determined by the physician operator, and administered by the circulating nurse.
45648753|NCT03490903|Drug|Midazolam injection|Midazolam is commonly administered to treat anxiety during invasive procedures such as coronary angiography. Intravenous midazolam injection dosages are determined by the physician operator, and administered by the circulating nurse.
45648754|NCT03438721|Behavioral|Infant obesity prevention|Parents will receive education on infant feeding, sleep, and screen time practices just after well-child visits in the first year of life. The education will be provided by a lay health educator. Parents will also receive text messages to reinforce the intervention content
45795578|NCT00380055|Behavioral|Navigation Services|Navigators (community health workers) identify and assist in overcoming barriers to appropriate cancer care.
45795579|NCT00380055|Behavioral|Cancer education|Community health workers provide cancer education appropriate for Medicare participants.
45921906|NCT00120757|Drug|Alendronate|
45921907|NCT00120796|Drug|Lamivudine|
45921908|NCT00120796|Biological|Recombinant hepatitis B surface antigen|
45648755|NCT03438721|Behavioral|Financial coaching|Parents randomized to the financial coaching arm will receive basic education on financial topics including budgeting, savings, and managing debt as well as coaching on these topics just after well-child visits in the first year of life. Coaching will be provided by lay health educators trained in financial coaching. Parents will also receive text messages reinforcing the information learned.
45648756|NCT04435951|Other|Evaluation|No attempt was made to the individuals in Group 1 and Group 2. Individuals were only evaluated.
45648757|NCT04253509|Diagnostic Test|Circulating Tumor DNA Methylation Sequencing|Whole blood (21mL) collection through venipuncture. Analysis of tumor markers and ctDNA methylation sequencing.
45921909|NCT00120835|Drug|valopicitabine|
45921910|NCT00120835|Drug|pegylated interferon|
45921911|NCT02398734|Device|sonolysis|Continual transcranial Doppler monitoring of ipsilateral middle cerebral artery using a transcranial Doppler systems (e.g. DWL Multi-Dop T1, DWL, Sipplingen, Germany) with a diagnostic 2-MHz probe.
45921912|NCT00120913|Drug|Birth control pills|
45921913|NCT00120991|Procedure|Coronary artery bypass grafting|
45921914|NCT04727164|Drug|HBM4003 and Triprilimab|Subjects will be treated with HBM4003 on Day 1 Cycle 1 and be treated with HBM4003 and Triprilimab during each 21-day cycles from Cycle 2 in part 1.Subjects will be treated with HBM4003 and Triprilimab on Day 1 during each 21-day cycle in part 2.
45921915|NCT00121030|Drug|darbepoetin alfa|
45921916|NCT00121030|Drug|recombinant human erythropoietin (rHuEPO)|
45648758|NCT03712579|Dietary Supplement|SFA-Rich Meal|Saturated fatty acid-rich test meal, containing 75g test fat
45449936|NCT02168374|Other|Indirect pulp treatment|Carious dentine was sampled from the mesial portion of the cavity floor and the pulpal wall was entirely covered with one of the randomly selected materials: GIC containing 4.5% DOX; GIC containing 1.25% CHX or GIC as a control group. The antimicrobial concentrations were chosen based in the previous in vitro results obtained in this study. The cavities were then temporarily restored using a conventional GIC. Within 3 months after the initial treatment,the materials were carefully and completely removed, a new dentine sample was collected, and the teeth were then restored with a light-cured composite resin using a bonding system, after a new placement of the initial liner material.
45921917|NCT02377830|Device|In-bed cycle ergometer (Restorative Therapies RT300 Supine)|
45795580|NCT01444209|Radiation|Iodine Implants|Interstitial Radioactive Iodine Implants
45921918|NCT02377830|Other|Routine physiotherapy|activities to assist with optimizing airway clearance and respiratory function, and, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out of bed mobility, and ambulation
45921919|NCT00121069|Drug|Escitalopram|
45921920|NCT05637320|Behavioral|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems|The intervention arm will consist of a transdiagnostic psychotherapy program: The Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC). MATCH draws from various domains of evidence-based treatment and consists of 33 treatment modules. There are several core module sequences for problem areas such as depression, anxiety, trauma, and disruptive behavior, and a clinician can utilize these sequences based on the primary concern of the presenting child. If an individual reports additional stressors or comorbid conditions, the clinician can modify the sequence of the modules to address these comorbidities. MATCH treatment is flexible and is tailored for each individual client.
45921921|NCT00121147|Drug|Travatan|
45449937|NCT02168452|Procedure|sentinel lymph node biopsy(SLNB)|"incision will be made over the skin site that had fluorescence lymphatic flow which visualized using fluorescence imaging camera and gamma probe.~double check after removal of the sentinel lymph node~sending frozen biopsy"
45921922|NCT00121147|Drug|Azopt|
45648759|NCT03712579|Dietary Supplement|MUFA-Rich Meal|Monounsaturated fatty acid-rich test meal, containing 75g test fat
45648760|NCT04248985|Other|Pre-Imaging - an ultrasound technique of acquiring images|Technique involves finding low quality images of the heart during CPR prior to pausing CPR to acquire high quality images once CPR is paused.
45795581|NCT05663801|Drug|Use of Bupivacaine in pectoral nerve block in mastectomy|Pectoral nerve block will be performed and patients will be given 30 mL of 0.25% bupivacaine hydrochloride and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
45795582|NCT05663801|Drug|use of Ketamine as adjuvants to bupivacaine in pectoral nerve block in mastectomy|Pectoral nerve block will be performed and Patients will be given 30 mL of 0.25% bupivacaine hydrochloride plus ketamine hydrochloride (1 mg/kg) and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
45795583|NCT05663801|Drug|Use of Magnesium Sulfate as adjuvants to bupivacaine in pectoral nerve block in mastectomy|Pectoral nerve block will be performed and Patients will be given 30 mL 0.25% Bupivacaine hydrochloride plus Magnesium Sulfate ( 28 ml Bupivacaine 0.25% plus 2ml magnesium sulfate 50%) and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
45795584|NCT03866499|Drug|BPI-7711|180 mg, oral, QD
45795585|NCT03866499|Drug|Gefitinib|250 mg, oral, QD
45795586|NCT03866499|Drug|Placebo Tablet|250 mg gefitinib placebo tablet, QD
45921923|NCT00121147|Drug|Alphagan P|
45921924|NCT00121264|Drug|sorafenib tosylate|Given orally
45449938|NCT02170948|Drug|Dexmedetomidine|An anesthetic concoction of 2% Lidocaine, 1% Ropivacaine, and Dexmedetomidine diluted solution will be provided via a series of anesthetic injections related to the ankle block procedure
45795587|NCT03866499|Drug|Placebo capsule|180 mg BPI-7711 placebo capsule, QD
45795588|NCT02296320|Drug|MEDI4893|Participants will receive a single IV dose of MEDI4893 2000 or 5000 mg on Day 1 of the study.
45449939|NCT03540550|Other|Diet based on inulin-rich vegetables|During two weeks, healthy subjects were instructed to adhere to a controlled diet based on ITF-rich vegetables (±15 g ITF/day).
45795589|NCT02296320|Other|Placebo|Participants will receive a single IV dose of placebo matched to MEDI4893 on Day 1 of the study.
45795590|NCT05717465|Other|Anatomy diagrams|"The visual aids used included:~An anatomical diagram illustrating how a lumbar puncture is carried out~Paling palette, diagram illustrating the number of individuals affected by a particular condition~Paling perspective scale, diagram comparing the risk of an event occurring in comparison to other 'everyday' risks"
45795591|NCT05717465|Other|Standard informed consent|Audio narration of a video containing text information relating to the lumbar puncture procedure (including risks) and an image of a consent form
45921925|NCT00121264|Drug|tanespimycin|Given IV
45921926|NCT00121264|Other|laboratory biomarker analysis|Correlative studies
45921927|NCT00121264|Other|pharmacological study|Correlative studies
45921928|NCT00121264|Procedure|magnetic resonance imaging|Correlative studies
45921929|NCT00121303|Drug|cytarabine|
45921930|NCT00121303|Drug|daunorubicin hydrochloride|
45921931|NCT00121303|Drug|gemtuzumab ozogamicin|
45921932|NCT05637359|Device|Tracked ultrasound measurement|"Participation in the study will not involve additional visits to the hospital or additional CT scans for the included patients. For this experiment, 2D ultrasound images are obtained using an ultrasound transducer linked to the electromagnetic navigation system, which is already in place for the navigation at the operating room. After anesthesia and in parallel to the final preparations of the patient, two percutaneous ultrasound measurements of the pelvic bone are performed and recorded. The first measurements are performed in Trendelenburg patient position and the second measurements in supine patient position. When preparations are finished, normal workflow is continued, including the standard Cone Beam CT acquisition required for the navigation and sterile draping of the patient.~The acquired ultrasound scans will be analyzed post-operatively and offline. This measurement has no impact on the (navigated) surgical procedure itself."
45921933|NCT00121381|Drug|Pimecrolimus plus topical corticosteroid (TCS)|Pimecrolimus 1 % cream plus topical corticosteroid (TCS) twice daily
45921934|NCT00121381|Drug|Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)|twice daily administration
45921935|NCT00121420|Drug|Motexafin gadolinium|
45921936|NCT00391131|Drug|IgNextGen 16%|IgNextGen 16% administered subcutaneously on a weekly basis from visit 1 to 12
45921937|NCT00121459|Device|Ortho All-Flex diaphragm and Replens lubricant gel|
45921938|NCT00121498|Drug|Lidocaine (local anesthetics) 20 ml of 1 % subcutaneously|
45921939|NCT00121537|Device|Wound Care -Wound Vacuum Assisted Closure (VAC)|
45648761|NCT04169191|Drug|Sildenafil Citrate|Cohort 1 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, and subsequent doses of 2.5mg/kg/dose q12h (= 5 mg/kg/day from dose #2) Cohort 2 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, 3rd dose of 3mg/kg/dose, and subsequent doses of 3mg/kg/dose q12h (= 6 mg/kg/day from dose #3) dose expansion phase in up to 5-15 asphyxiated neonates
45648762|NCT03954613|Combination Product|Ebicomb|Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
45795592|NCT03780153|Other|No intervention|Observation study. No intervention
45795593|NCT05717231|Behavioral|laughter yoga|laughter yoga
45795594|NCT00000105|Biological|Intracel KLH Vaccine|Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly.
45795595|NCT00000105|Biological|Biosyn KLH|Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly.
45795596|NCT00000105|Drug|Montanide ISA51|Emulsify the KLH with Montanide ISA-51. The KLH 1 mg vial will be reconstituted in 0.5 mL sterile water. Once solubilized, add 0.6 mL of Montanide ISA to the vial and administered contents subcutaneously.
45921940|NCT00121537|Procedure|Wound Care - Wet to Dry Dressing Changes|
45921941|NCT00121615|Drug|etanercept|
45921942|NCT00391248|Drug|Erlotinib|150 mg in a single daily dose, starting Day 1 through Day 22
45921943|NCT05637437|Behavioral|Peer supported diabetes self-care intervention|"Participants in the intervention group will attend a multi-faceted 8 weeks peer supported diabetes self-care intervention through digital communication.~Weekly group video telephony meeting facilitated by trained peer supporters.~Support and assistance through instant messaging services between peer supporters and participants."
45921944|NCT05637437|Other|Usual care|Participants in the control group will receive the usual care of the hospital.
45921945|NCT04727398|Device|Wide-field optical coherence tomography (Optovue®)|Merged 4 images for wide-filed OCT-based PVD classification, 2 vertical line images and 2 horizontal line images
45449940|NCT02171026|Drug|Dabigatran etexilate|
45449941|NCT02171026|Drug|Amiodarone|
45648763|NCT04504201|Other|Focus Group|Breast cancer patients and oncology clinicians will participate in separate focus groups discussing patient-centered communication about healthy weight.
45795597|NCT00000105|Biological|Tetanus toxoid|Tetanus Toxoid Adsorbed, Aluminum Phosphate Adsorbed, PUROGENATED® (TT), is a sterile preparation of refined tetanus toxoid for intramuscular use only.
45795598|NCT00000111|Procedure|Oral mucosal graft|
45795599|NCT02959151|Drug|CAR-T cell|CAR-T cells are generated by T cells from the patients or a suitable donor transfected by CAR-lentivirus vectors. There are three options for CAR-targets: GPC3 for hepatocellular carcinoma;mesothelin for pancreatic cancer metastatic; CEA for colorectal cancer metastatic.
45795600|NCT00000117|Drug|Immunoglobulin|
45795601|NCT05646017|Device|Intermittenly scanned continuous glucose monitoring|Use of Intermittenly scanned continuous glucose monitoring (FreeStyle Libre)
45449942|NCT02261194|Behavioral|Self-Care Tools|
45449943|NCT02168530|Drug|placebo|matching placebo administered daily orally
45449944|NCT02168530|Drug|vismodegib|vismodegib 150 mg administered daily orally
45795602|NCT03597399|Biological|AAV2-hRPE65v2,voretigene neparvovec-rzyl|Subretinal administration of gene therapy vector AAV2-hRPE65v2 (voretigene neparvovec-rzyl) to both eyes via surgical procedures on separate days.
45795603|NCT05711303|Dietary Supplement|Superba Boost|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of intervention using a TEWAMetre.
45795604|NCT00000123|Device|Polymethyl Methacrylate-Silicone Contact Lenses|
45795605|NCT00000123|Device|Polymethyl Methacrylate Contact Lenses|
45795606|NCT03505203|Behavioral|Sleep Soothe|An intervention in which parents are given information on how to respond to their baby's cues related to sleeping and fussiness.
45795607|NCT03505203|Behavioral|Sleep Safe|An intervention in which parents are given information on a safe sleep environment, as well as other strategies to keep baby safe.
45795608|NCT03364647|Other|Arm A - blood flow restriction training|Group receive standard of care plus blood flow restriction training
45795609|NCT03364647|Other|Arm B - standard of care|Group will receive standard of care plus a sham version of blood flow restriction training
45795610|NCT05716919|Drug|Ivaltinostat|Ivaltinostat capsule
45795611|NCT05716919|Other|Placebo|Placebo capsule
45795612|NCT00380133|Drug|SB681323|5 mg and 2.5 mg tablets - The tablets will be round (9.0 mm in diameter) and white and provided in labelled bottles
45795613|NCT00380133|Drug|Prednisolone|5 mg size DB AA capsule shell (Swedish orange) with a powder backfill (lactose Anhydrous)
45795614|NCT00380133|Drug|Placebo|Tablets matched to SB681323 or prednisolone
45754373|NCT03586622|Dietary Supplement|VSL#3®|VSL#3® is a dietary supplement that helps maintain the balance of the intestinal flora. VSL#3® has been recognized and classified as GRAS (Generally Regarded as Safe) by a panel of experts in the USA for both adult and pediatric IBD and IBS patients. VSL#3® is a probiotic food containing 450 billion freeze-dried live lactic acid bacteria and bifidobacteria from 8 different strains per bag/sachet: Streptococcus thermophilus BT01, Bifidobacteria (B. breve BB02, B. longum* BL03, B. infantis* BI04), Lactobacillus acidophilus BA05, Lactobacillus plantarum BP06, Lactobacillus paracasei BP07, Lactobacillus delbrueckii subsp. bulgaricus** BD08; *Recently reclassified as B. animalis subsp. lactis ** Recently reclassified as L. helveticus. The recommended daily dose is 1-2 bags.
45795615|NCT05716841|Other|Ballistic exercises|stretching and then strengthening of the upper limb through ballistic six exercises from a moderate to intense manner with 3 sets of 10 repetitions with a 30sec gap between sets, 3 Sets of 15 repetitions with a 30sec gap between sets, and 3 sets of 20 repetitions with a 30sec gap between sets for 3 to 4 days per week for six weeks.
45921946|NCT04711096|Procedure|Ultrasound-guided transversus abdominis plane (TAP) block 0.25% bupivacaine.|After preparing the skin with antiseptic solution, a linear high frequency ultrasound probe will be placed abdominal wall between the iliac crest and the costal margin. A Spinal needle 22g attached with flexible tubing to a syringe filled with saline will be used to perform the block then introduced through the skin anteriorly in the plane between the internal oblique and transversus abdominis muscles with its tip lying in the mid axillary line. To assist with identifying these structures, The final position of the probe will to be no further anterior than the anterior axillary line. If satisfactory views are not obtained, the TAP block will not be performed. Hydro dissection with saline (2-5 ml) will be used to separate the fascial layers. After aspiration to exclude inadvertent vascular puncture, 20 ml of the 0.25% bupivacaine will be injected . TAP block will be performed in a similar fashion on the opposite side.
45921947|NCT04705948|Drug|Magnesium sulfate versus ketamine|Magnesium sulfate versus ketamine for of post-operative sore throat after endotracheal intubation
45795616|NCT05642351|Other|Autobiographical reminder|"The analysis of the specificity of Autobiographical Recall will be done through the following scale, developed for the study:~6 points for a recall involving a single personal event located in space AND time (e.g.,I remember when my parents took me to the sea for the first time..in 1962..in Dunkerque)~5 points for a recall involving a single personal event located in space OR time (I remember when my parents first took me to the sea...in 1962)~4 points for a recall involving a single personal event but without spatial/temporal details (I remember when my parents took me to the sea for the first time)~3 points for a recall involving a general personal event but located in space AND time (we used to go to Dunkerque in the summer)~2 points for a recall involving a general personal event but located in space OR time (we used to go to Dunkerque)~1 point for a recall involving a general personal event without spatial/temporal details (we used to go on vacation)"
45921948|NCT00121654|Device|Spinal cord stimulation|Under sterile conditions and local anesthesia, the epidural space is punctured at the level of T5-T6 and a quadripolar electrode catheter is introduced and advanced under X-ray control into the epidural space. A suitable position for the electrode catheter is sought for, corresponding to the site where a prickling sensation (paresthesia) is felt and covers the area of radiation of angina pain under neurostimulation. The electrode catheter is connected to an internal pulse generator placed in a subcutaneous abdominal or gluteal pocket through an extension lead connected to the electrode by subcutaneous tunneling.
45795617|NCT03306615|Drug|Hyaluronidase|HYLENEX recombinant, diluted with 0.9% Sodium Chloride Injection
45795618|NCT03306615|Drug|Placebo|0.9% Sodium Chloride Injection
45921949|NCT00121693|Behavioral|Music therapy (listening to specific music)|Listening to Music
45921950|NCT00121732|Drug|E7974|Maximum tolerated dose = 0.15 mg/m^2 administered on Days 1, 8, 15 of 28-day cycle.
45921951|NCT00121732|Drug|E7974|Maximum tolerated dose = 0.37 mg/m^2 administered on Days 1 and 8 of 21-day cycle.
45921952|NCT05637749|Other|Medical serious game intervention (educational)|Medical serious game designed to facilitate the rehearsal of diabetes management knowledge. Players are presented with a colony of individuals, all of whom have some form of diabetes, and are tasked to manage food, insulin, and medication intake throughout the day. The intervention may be played with a facilitator.
45921953|NCT05637749|Other|Medical serious game intervention (educational)|Medical serious game designed to facilitate the rehearsal of diabetes management knowledge. Players are presented with a colony of individuals, all of whom have some form of diabetes, and are tasked to manage food, insulin, and medication intake throughout the day. The intervention may be played alone.
45921954|NCT00121771|Biological|FP9 CS|
45921955|NCT00121771|Biological|MVA CS|
45921956|NCT00121849|Biological|Leish-111f + MPL-SE vaccine|
45921957|NCT00121888|Behavioral|Prolonged Exposure Therapy|
45449945|NCT02168608|Other|Remote ischemia precondition|Three cycles of 5-min ischemia/5-min reperfusion induced by a blood pressure cuff placed on the right upper arm served as RIPC stimulus.
45449946|NCT02168608|Other|None remote ischemia precondition|Placed an uninflated cuff on the right upper arm for 30 min.
45795619|NCT05641805|Other|PAQ-C (Physical activitiy questionare for children), MoCA (Montreal Cognitive Assessment), PBS (Pediatric Balance Scale), Modified Mini Mental State Examination, BMI (Body Mass Index)|"PAQ-C will use to evaluate physical activity level of participants. MoCA and Modified Mini Mental State Examination will use to evaluate cognitive functions of participants.~PBS will use to evaluate participants' balance responses."
45921958|NCT00121888|Drug|Paroxetine-CR|
45921959|NCT00121927|Behavioral|Atkins diet (15 grams/day carbohydrates)|
45921960|NCT05637788|Diagnostic Test|CT Scan Radiomics Features Extraction|Extraction of CT radiomics data through AI
45921961|NCT00121966|Drug|Insulin Aspart|
45921962|NCT00121966|Drug|Insulin NPH|
45449947|NCT02165020|Device|Hyaluronic acid (Macrolane VRF 30®, Q-MED)|"One injection of 3 to 10 cc of hyaluronic acid (Macrolane VRF 30®, Q-MED) introduced in the perirectal fat between the rectum and the prostate in connection with an ultrasound.~The injection is performed under local anesthesia (with Lidocaine) and ultrasound guidance, using a 16 gauge needle."
45921963|NCT00121966|Drug|Metformin|
45795620|NCT00000159|Drug|Sorbinil|
45795621|NCT02959229|Drug|Lactoferrin|
45795622|NCT02959229|Drug|Placebo (for Lactoferrin)|placebo in form of distilled water
45921964|NCT00121966|Drug|Rosiglitazone|
45921965|NCT00122005|Biological|GM-CSF gene transduced allogeneic vaccine GVAX|
45921966|NCT00122044|Drug|trihexyphenidyl|
45921967|NCT05637827|Other|No intervention|There was no intervention in each group, and only the natural development was observed
45795623|NCT02953665|Drug|Liraglutide|Liraglutide 6 mg/ml once daily at a maximum dose of 1.8 mg
45921968|NCT02013492|Drug|propranolol hydrochloride|Given PO
45648764|NCT04052893|Procedure|Expanded Mckissock surgery|Expanded Mckissock surgery: (1) According to patient's preoperative imaging results and subjective expectations of their own breast morphology, the incision design and breast surface marking will be performed under the standing position. (2) After general anesthesia, the upper limbs will be abducted, and the upper body will be tilted by 15°-20° to dermatize the labeled skin around and below the areola. (3) The medial and lateral flaps will be dissociated to remove the total gland with nipple and areola preserved. (4) The cutting-edge of nipple-areola complex will be sent for cancer screening. The axillary lymph node biopsy or cleaning will be performed along the outer edge of the pectoralis major muscle. (5) The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
45648765|NCT04052893|Procedure|Modified radical mastectomy|The patients will be placed in the supine position. After intravenous anesthesia, the tumor boundary will be marked and the breast will be removed. The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
45648766|NCT03367819|Drug|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45648767|NCT03367819|Drug|Cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45921969|NCT02013492|Other|Correlative Studies|"Correlative studies will be conducted using the following materials:~Plasma derived from peripheral blood.~Peripheral blood mononuclear cells (PBMC) derived from patient blood~Tumor tissue obtained at the time of core needle biopsy at the 2 month time point.~Paraffin-embedded tumor tissue obtained pre-therapy to make the diagnosis of metastatic disease."
45795624|NCT02953665|Drug|Placebo|Placebo (for Liraglutide) 6 mg/ml once daily at a maximum dose of 1.8 mg
45795625|NCT05707013|Device|HP Arize 3D-Printed Orthotics|Custom 3D-printed orthotics manufactured by HP.
45795626|NCT05707013|Device|Traditional Orthotics|Traditionally fabricated custom orthotics manufactured by a local supplier.
45795627|NCT00000189|Drug|Gepirone|
45449948|NCT03514641|Drug|Bexagliflozin|Bexagliflozin tablet, 20 mg
45795628|NCT05716685|Other|Health coaching|The intervention consisted of transferring the knowledge acquired on health coaching by the nurses of the cardiology unit to their care activity with CHF patients. To this end, all the nurses in the cardiology unit received two training packages: 1) five theoretical and practical sessions on health coaching competencies, emotional intelligence, communication and support for CHF patients in the hospital setting; and 2) training sessions 7 months after the first training package to reinforce the theoretical and practical knowledge acquired in health coaching. During this period, debriefing was carried out to provide feedback on the health coaching process with patients.
45921970|NCT00122083|Device|Health education information|
45921971|NCT00122122|Behavioral|Enhanced Pharmacy Care|
45921972|NCT00122161|Behavioral|ATHENA Decision Support System, An Automated Clinical Decision Support System for Health Care Providers|
45921973|NCT00122161|Behavioral|Profiling performance|
45921974|NCT00122356|Drug|Alendronate sodium|70mg tablets, once weekly
45921975|NCT01931709|Radiation|fludeoxyglucose F 18|Undergo FDG PET
45449949|NCT03514641|Drug|Placebo|Placebo (inactive) tablet to match the active drug
45648768|NCT04051333|Device|ALS Nutrition App (MyDataHelps platform)|We have designed a mobile health app to provide nutritional counseling and to measure disease outcomes both through self-reported questionnaires and through passive data collection.
45648769|NCT04023253|Drug|Mirabegron|Mirabegron 25 mg
45648770|NCT04023253|Drug|Solifenacin|Solifenacin 5 mg
45795629|NCT02681211|Other|Auricular Acupuncture|ASP (acupuncture semi-permanent) gold needles will be placed in the efficacious ear points with a maximum of 3 needles in each ear.
45795630|NCT02681211|Drug|Ketorolac 0.5mg/kg, max 30mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
45921976|NCT01931709|Device|positron emission tomography|Undergo FDG PET
45921977|NCT01931709|Device|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
45921978|NCT01931709|Other|laboratory biomarker analysis|Correlative studies
45921979|NCT00122395|Behavioral|Screening via pen and paper|
45921980|NCT00122395|Behavioral|Screening via audiotape|
45921981|NCT00122434|Drug|BEA 2180 BR|
45921982|NCT00122434|Drug|tiotropium|
45921983|NCT05637944|Procedure|oro tracheal intubation|chest trauma requiring oro tracheal intubation
45795631|NCT02681211|Drug|Metoclopramide 0.1 mg/kg, max 10mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
45795632|NCT02681211|Drug|Diphenhydramine 1mg/kg, max 50mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
45795633|NCT02681211|Drug|Normal saline fluid bolus 20mL/kg, max 1000mL|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
45795634|NCT00000195|Drug|Naltrexone|
45795635|NCT03632655|Procedure|prostate biopsy|Men will be randomized to receiving either TPM or TRUS targeted biopsy
45795636|NCT02276157|Device|Direct peroral cholangioscopy|"The multibending (MB) or conventional ultra-slim endoscope was inserted through the mouth. After facing the papillary orifice, the endoscope was inserted directly, without any accessories, into the distal bile duct. The second bending of the MB ultra-slim endoscope was kept in an upward angled position to achieve a more acute angle of the endoscope tip for entering the distal CBD. Then, the endoscope was pushed by steering the first bend into an upward angle (α shape) or the endoscope was pulled by steering the first bend into an upward angle and torqueing it counter-clockwise (u shape) for insertion into the distal CBD. If the distal bile duct was visualized on an endoscopic view, carbon dioxide insufflation was stopped. The endoscope was advanced into the hilum or the obstructed segment of the extrahepatic bile duct under fluoroscopic and endoscopic control. Then, the diagnostic and therapeutic interventions were performed during direct POC as necessary."
45795637|NCT05688371|Drug|standard dose morphine|Receiving 0.05 mg morphine /kg as a bolus dose followed by 0.05 mg/kg/hr morphine continous infusion dissolved in 100 ml normal saline with lockout interval of 15 min.PCA bolus dose 0.5mg morphine.
45795638|NCT05688371|Drug|low dose morphine plus dexmedetomidine|Receiving 0.05 mg morphine /kg bolus dose followed by 0.02mg/kg/hr plus 0.2 µg/kg dexmedetomidine continous infusion in 100 ml normal saline with lockout interval of 15 min.PCA bolus dose 0.2mg morphine + 2 microgram dexmedetomidine.
45795639|NCT03621657|Drug|Low Dose FMT Capsule DE|5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.
45795640|NCT03621657|Drug|Single Dose FMT Capsule DE|30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.
45795641|NCT03621657|Drug|Placebo oral capsule|Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.
45795642|NCT05683769|Genetic|miRNA|Assessment of miRNA, as potential biomarkers to discriminate erosive hand osteoarthritis from psoriatic arthritis
45795643|NCT05634083|Dietary Supplement|Uremic pateints with itching|Activated charcoal
45795644|NCT00000201|Drug|Selegiline|
45795645|NCT05716529|Other|rehabilitation protocol|It's a four phases rehabilitation protocol mainly based on the remodeling process of the graft., emphasizing full passive knee extension, immediate weight bearing as tolerated and functional exercises
45795646|NCT05440695|Device|Continuous non-invasive arterial pressure (Infinity® CNAPTM, Dräger)|The basic working principle of CNAP is to keep the blood volume of the finger arteries constant by applying an exterior pressure to the vessel wall, that is done by an electronic system controlling the pressure inside a cuff around the finger. The pressure in the cuff, which is needed to keep the volume constant during arterial pulsation, corresponds to the AP.
45795647|NCT05716451|Device|Device-assisted mobilisation with the sit/stand stabilizer Liana|Non-invasive device-assisted mobilisation with LIANA
45795648|NCT02199015|Device|Lateral spinal cord surgical implant of electrodes|"The procedure is based on the classic approaches to posterior cervical region for herniated discs, actually not longer employed for that aim A unilateral hemilaminectomy will be performed at C3-C4 level, starting from 4th cervical spinous process.~A multicontact electrode will be placed on the lateral surface of the spinal cord that will be subcutaneusly connected to an implanted pulse generator (IPG)."
45795649|NCT02978105|Other|self-conditioning techniques|Self-hypnosis to increase self-control before meals and every food compulsion episode
45795650|NCT02978105|Other|standard care (diet, exercise and behavioral therapy)|dietary recommendations, exercise recommendations, and behavioral recommendations
45795651|NCT00000207|Drug|Buprenorphine|
45795652|NCT01952223|Drug|Cabazitaxel|Cabazitaxel administered at 25 mg/m² as a 1 hour intravenous infusion every 3 weeks (1 cycle = 21 days) for 4 cycles
45795653|NCT01952223|Radiation|Pelvic radiotherapy|"Prostate+pelvic RT (2 Gy fractions, 5 times per week):~Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
45795654|NCT01952223|Radiation|prostate radiotherapy|"Prostate-only RT (2 Gy fractions, 5 times per week):~Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
45795655|NCT05677607|Diagnostic Test|Magnetic resonance imaging|Imaging diagnostics mainly based on Magnetic resonance imaging.
45795656|NCT02296242|Drug|BVD-523|Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
45921984|NCT00122473|Drug|Imatinib (Glivec)|
45795657|NCT05716373|Behavioral|pain|reiki
45795658|NCT00357929|Procedure|Permissive hypercarbia|
45795659|NCT02295774|Procedure|standard white light colonoscopy-equivalent to placebo|standard white light colonoscopy
45795660|NCT02295774|Drug|Methylene Blue MMX tablets|8x25mg methylene blue MMX tablets administered before a colonoscopy
45921985|NCT00122512|Drug|Tenofovir Disoproxil Fumarate|
45921986|NCT01720407|Drug|Imiquimod cream + surgery|Imiquimod (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks (i.e. a total of 20 applications), followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision at 5mm will be performed within a few days (equivalent to 2-stage surgery).
45921987|NCT01720407|Drug|Placebo + surgery|Placebo (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks, followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision of 5mm of clinically healthy tissue will be performed within a few days (equivalent to 2-stage surgery).
45795661|NCT01807611|Radiation|Total Lymphoid Irradiation|Participants receive total lymphoid irradiation over four doses.
45449950|NCT02168764|Device|ATI Neurostimulation System|All subjects will be implanted with the ATI Neurostimulator which, along with the ATI Remote Controller, provides electrical stimulation.
45449951|NCT03539224|Drug|Dolutegravir (DTG)|DTG 50 mg tablet will be orally administered once daily with or without food upto 48 weeks
45921988|NCT00122551|Procedure|Intermittent antiretroviral therapy|
45921989|NCT00122590|Drug|nelfinavir|
45921990|NCT00122590|Drug|lopinavir/r|
45921991|NCT00122590|Drug|indinavir|
45921992|NCT00122590|Drug|ritonavir|
45921993|NCT00122629|Drug|peg-interferon alfa-2b|
45921994|NCT00122629|Drug|ribavirin|
45648771|NCT03947515|Procedure|prostate biopsy|All patients included, will report to the urology department on the date previously agreed with the surgeon. The patient will be seen by the nurse and urologist on duty as part of outpatient care or, more rarely, in ambulatory care. After verification of the patient's identity, the signature of informed consent, the absence of immediate contraindications to biopsy (haemorrhagic and infectious) and the patient's proper preparation (antibiotic prophylaxis and possible enema), the patient will be installed for the taking of samples covered by the protocol (rectal swabbing and prostate biopsies, see paragraph IX). If the patient has not taken the antibiotic prophylaxis or performed the enema, he or she will be reconvened at a later date for the biopsies. After the prostatic biopsies have been performed, the patient's participation in the study ends and his follow-up resumes according to the recommendations adapted to his pathology.
45648772|NCT03947515|Other|Urinary sampling|It will be collected after the prostate massage performed by the surgeon in charge of the patient during his clinical examination for prostate cancer screening. After elimination of the first draft, the urine will be collected in 2 tubes with borated preservative
45648773|NCT03947515|Other|Rectal swabbing before biopsies are performed|A rectal swab will then be taken by the urologist on the day the prostate biopsies are taken. The analysis of the digestive microbiota will eliminate contamination of prostate biopsies by bacteria from the faecal flora during transrectal sampling
45449952|NCT03539224|Drug|Lamivudine (3TC)|Lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets. It will be orally administered once daily with or without food upto 48 weeks.
45795662|NCT01807611|Drug|Fludarabine|Given IV.
45795663|NCT01807611|Drug|Cyclophosphamide|Given IV.
45795664|NCT01807611|Drug|Thiotepa|Given IV.
45795665|NCT01807611|Drug|Melphalan|Given IV.
45795666|NCT01807611|Biological|HPC,A Infusion|Participants received infusions of HPC,A (CD34+ selected) and HPC,A (CD45RA depleted).
45795667|NCT01807611|Biological|TC-NK Infusion|Participants receive infusions of TC-NK.
45795668|NCT01807611|Biological|G-CSF|"Participants receive G-CSF subcutaneously or intravenously.~Donors receive G-CSF subcutaneously during cell mobilization."
45795669|NCT01807611|Drug|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
45921995|NCT00122629|Drug|amantadine|
45921996|NCT05637983|Procedure|US-guided femoral puncture vs Fluoroscopy-guided puncture|US-guided femoral puncture and Perclose ProGlide®/Prostyle implantation compared to Fluoroscopy-guided puncture and Perclose ProGlide®/Prostyle in TAVR
45921997|NCT00122668|Drug|non-nucleoside reverse transcriptase inhibitors|
45921998|NCT00122668|Drug|nucleoside reverse transcriptase inhibitors|
45921999|NCT00122668|Drug|protease inhibitor|
45922000|NCT00122707|Device|catheters|
45922001|NCT00402220|Drug|TMS|Active Transcranial Magnetic Stimulation
45922002|NCT00402220|Device|Sham TMS|Sham Transcranial Magnetic Stimulation
45922003|NCT05638022|Diagnostic Test|Total cholesterol (TC) level test and direct Low density lipoprotein cholesterol (LDL-C) level test|Total cholesterol (TC) level testing and direct Low density lipoprotein cholesterol (LDL-C) level testing will be performed in all 10,000 newborns enrolled in the project.
45922004|NCT05638022|Diagnostic Test|DNA testing|DNA testing (NGS analysis of DNA mutations in 9 genes: LDLR, APOB, APOE, PCSK9, LDLRAP1, STAP1, ABCG5, ABCG8, LIPA and polygenic markers) will be performed in the subcohort of 1,500 newborns with highest level of Low density lipoprotein cholesterol (LDL-C).
45922005|NCT00129610|Behavioral|Virtual Reality Therapy|
45922006|NCT00129610|Behavioral|Cognitive Behavior Therapy|
45922007|NCT05637164|Drug|norepinephrine bitartrate|The treatment group will receive a continuous infusion of norepinephrine at the beginning of anesthesia induction until 15 minutes after intubation. The dosage of norepinephrine was decided by the up-and-down sequential allocation method with an initial dose of 0.05 µg/kg/min and a 0.005 µg/kg/min gradient.
45922008|NCT00129571|Drug|XL820|
45922009|NCT00129532|Drug|1.0% C31G SAVVY vaginal gel|
46073694|NCT00849589|Behavioral|Computerized SBA with technological extenders|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors. In addition, the provider sends them a brief email or text message at 4 months and 9 months after study entry to reinforce the brief advice.
45648774|NCT03044509|Diagnostic Test|Secreted cytokine assay|Blood collected in a sodium-heparin tube will be used for the assay using novel TB-specific antigens. After incubation the supernatant will be harvested and cryopreserved at -80 °C for further testing of cytokines. Cytokines will be measured using a bead-based multiplex assay reader (MAGPIX, Luminex Crop., Austin, USA).
45648775|NCT03044509|Diagnostic Test|Intracellular cytokine assay|Blood will be stimulated with recombinant MTB-specific antigens, ESAT-6, CFP-10, positive control or left unstimulated. Following an initial duration of stimulation, Brefeldin-A will be added and the blood incubated for a further 5 hours. White cells will be fixed and cryopreserved at - 80°. Batched analysis within 6 months of cryopreservation will be done using multi-colour flow cytometry.
45648776|NCT03969199|Behavioral|Intervention|Dietary intervention in coordination with MANNA, who will deliver low sodium meals to patients for 90 days
45648777|NCT03066739|Drug|Remifentanil|0.1 micrograms/kg/mL
45449953|NCT02171182|Drug|Qutenza|capsaicin patch
45449954|NCT00100828|Drug|irinotecan hydrochloride|
45449955|NCT02165098|Drug|Cariprazine prolonged release tablet A|Cariprazine prolonged release tablet A - fasted
45449956|NCT02165098|Drug|Cariprazine prolonged release tablet B|Cariprazine prolonged release tablet B - fasted
45648778|NCT03066739|Drug|Remifentanil+ Placebo|high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)
45648779|NCT03066739|Drug|Remifentanil +ultra-low dose naloxone|high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone
45449957|NCT02165098|Drug|Cariprazine capsule|Cariprazine capsule - fasted
45648780|NCT04875871|Radiation|Particle radiotherapy|Partial radiotherapy targeting the hypoxic tumor segment
45795670|NCT01807611|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
45795671|NCT01807611|Drug|Mycophenolate mofetil|Given intravenously or orally.
45795672|NCT05661695|Device|RT Assistant|RRT's will be given the RT Assistant to use during a regular ICU shift to make patient care decisions.
45795673|NCT05653583|Device|Wrist Device|peripheral nerve stimulation via wrist-worn device
45795674|NCT05653583|Device|Ear Device|peripheral nerve stimulation via ear-worn device
45795675|NCT05653583|Device|Sham Device|Wrist-worn device that does not actually deliver stimulation
45795676|NCT01798407|Device|Activa Tremor Control Sys (DBS Implant)|DBS system consists of the Activa RC 37612 System (Implantable Pulse Generator with Model 37085 Extensions (40 to 95cm), Activa Patient Programmer, and Medtronic Model 3389 DBS Lead). This system is commercially approved for the treatment of chronic, intractable Parkinson's Disease. It will be used with the Model SP-10344 Memory Mod Software which enables the physician to program the Implantable Pulse Generator to a higher frequency.
45795677|NCT01798407|Other|Randomized, staggered withdrawal phase|For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.
45795678|NCT02977949|Drug|Raloxifene|
45795679|NCT02294682|Drug|GSK2140944|Immediate release capsules (pink hard gelatin size 00 capsule, with no external marking, filled with slightly agglomerated pale yellowish to grayish yellow powder) containing GSK2140944 500 mg and inactive formulation excipients. GSK2140944 will be administered orally once 1500 mg (3 capsules) or 3000 mg (6 capsules).
45795680|NCT01692717|Drug|Atorvastatin|10 mg
45648781|NCT04875871|Diagnostic Test|Magnetic resonance imaging|For treatment planning as well as for follow-up radiological tumor assessment.
45648782|NCT04875871|Diagnostic Test|Computertomography|For treatment planning as well as for follow-up radiological tumor assessment.
45795681|NCT01692717|Drug|Hydrochlorothiazide + Losartan|12.5 mg + 50 mg
46073695|NCT00706251|Device|Silicone tube|Silicone tube which is inserted into the tear duct through the punctum in the eyelid, then passed through the tear duct till it enters the nose and secured in place using a surgical knot. The tube remains in place for 3-6 months, than take out by the surgeon.
46073696|NCT02546791|Drug|Dasatinib|
46073697|NCT00842101|Device|Quick Pressure Monitor|The monitor measures actively the actual pressure inside the compartment affected.
46073698|NCT00966875|Biological|LY2439821|Subcutaneous
46073699|NCT00966875|Drug|Placebo|Subcutaneous
46073700|NCT04201080|Drug|Part A: TRV250-20mg/ml|TRV250 SC Injections
46073701|NCT04201080|Drug|Placebo|Placebo SC injections
45648783|NCT04875871|Diagnostic Test|Copper-64-Diacetyl-bis (N4-methylthiosemicarbazone) Positron Emission Tomography-Computer Tomography (64Cu-ATSM-PET-CT)|For the definition of the hypoxic tumor segment in treatment planning.
45648784|NCT04875871|Diagnostic Test|18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)|For follow-up radiological tumor assessment.
45449958|NCT02165098|Drug|Cariprazine PR tablet A|Cariprazine Prolonged Release tablet A - fed
45648785|NCT04875871|Diagnostic Test|Blood sampling|Evaluation before treatment-start, during treatment and follow-up period.
45754374|NCT03586466|Device|BupreCare|"Subjects will receive their medication in a MedicaSafe device. Medication will be dispensed in accordance with the programmed treatment plan for each subject. Subjects will complete a Check-In remotely each week with their device."
46073702|NCT04201080|Drug|Part B: TRV250 Dose 1|Dose 1of3 TRV250
46073703|NCT04201080|Drug|Part B: TRV250 Dose 2|Dose 2of3 TRV250 SC injections
46073704|NCT04201080|Drug|Part B: TRV250 Dose 3|Dose 3of3 TRV250 SC injections
46073705|NCT04201080|Drug|Placebo|Placebo SC injections
46073706|NCT02820792|Procedure|function tests|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
46073707|NCT02820792|Device|LMA ProtectorTM|
45795682|NCT01692717|Drug|Hydrochlorothiazide + Losartan + Atorvastatin|12.5 mg + 50 mg + 10 mg
45795683|NCT00355277|Drug|Amitriptyline|
45795684|NCT00000735|Drug|Ampligen|
45795685|NCT00000213|Drug|Fluoxetine|
45795686|NCT00000219|Drug|Buprenorphine|
45648786|NCT03598387|Other|Automated peritoneal dialysis|"The prescription of automated peritoneal dialysis:~The first 48-72 hours dose: 0.8-2.0 liter exchange with 1-2 hour-cycle (8-36 liters per day); After initial 48-72 hours, 1.0-2.5L exchange with 2-6 hour-cycle (at least 8 liters per day), if the acidosis, hyperkalemia and pulmonary edema are corrected.~The minimal target weekly Kt/V is 2.1-3.5/W."
45648787|NCT03598387|Other|Intermittent hemodialysis|Intermittent hemodialysis will be performed 3-4h of each session and 2-5 times per week. The prescription will be adjusted based on patients' conditions to ensure spKT/V≥1.3.
45795687|NCT05640869|Behavioral|Modified Diabetes Prevention Program Curriculum|The modified DPP curriculum will be an exact copy of the current DPP curriculum except that references to the prevention of diabetes will be modified to prevention of health outcomes associated with overweight/obesity and/or management of overweight/obesity.
45795688|NCT00000225|Drug|Buprenorphine|
45648788|NCT04781725|Drug|INT230-6|INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also known as SHAO-FA or SHAO as a sodium salt at 10mg/mL).
45922010|NCT01345578|Drug|human hepatocyte transplantation|"Transplantation of hepatocytes into the liver will be through the portal vein. The portal vein will be accessed transhepatically, by umbilical vein, or surgically by a peripheral mesenteric vein.~The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant. Even if the subject receives the hepatocyte transplant and it does not work, they will be evaluated for orthotopic liver transplantation as if they never received the hepatocyte transplant.~If at 6 months we see an improvement in disease, we will recommend a re-transplantation with a goal of complete correction of disease and until the subject is no longer required to be a candidate for organ transplantation. Subjects will be re-evaluated every 6 months for re-transplantation. Subjects will remain on the waiting list for organ transplantation. Further radiation therapy will not be needed prior to re-transplantation."
45922011|NCT01345578|Radiation|Preparative Radiation Therapy|Just prior to the hepatocyte transplant, a portion of the right hepatic lobe comprising between 35-50% of the entire liver volume will be irradiated to a dose of 7.5-10 Gy in a single fraction using a linear accelerator-based stereotactic radiosurgery system with intensity-modulated radiation therapy planning (IMRT).
46073708|NCT02820792|Device|Ambu AuraGainTM|
46073709|NCT00849745|Procedure|Nonmyeloablative allogeneic stem cell transplant|Prior to receiving Campath-1H, patients will be premedicated with Benadryl 50 mg IV or PO, and acetaminophen 650 mg orally. Hydrocortisone 100 mg IV is given on the first day of Campath. The preparative regimen will begin on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours. The mixed dosage of chemotherapy may be rounded off to within +/- 5% of the calculated dose, and doses of fludarabine and cyclophosphamide will be based on adjusted ideal body weight. IV hydration and diuretics will be used to maintain adequate urine output during and after administration of cyclophosphamide.
45449959|NCT02165098|Drug|Cariprazine PR tablet B|Cariprazine Prolonged Release tablet B - fed
45449960|NCT02171338|Other|PCT-level|PCT-level is available to the treating doctor.
45449961|NCT02171338|Behavioral|Antibiotic treatment based on PCT-level|"PCT-level is available to the treating doctor and the decision whether or not to treat with antibiotic is based on the level of PCT.~The type of antibiotic chosen to treat is based on the existing antibiotic treatment guidelines of Holbaek Hospital and includes the antibiotics listed above."
45449962|NCT02171416|Drug|Rilonacept|
45795689|NCT02294604|Device|ethyl alcochol, chlorhexidine and moisturizers|
45449963|NCT02171416|Drug|Placebo|
45795690|NCT02294604|Device|chlorhexidine|
45795691|NCT02294604|Device|povidone-iodine|
45795692|NCT03483051|Drug|Potassium Nitrate|Potassium nitrate capsules will consist of potassium nitrate (KNO3-) crystals [610 mg, corresponding to 6.03 mmoles of NO3-] with 190mg of lactose monohydrate, spray dried, NF. The dose for this trial will be 18 mmoles of NO3-per day, given as one capsule (6 mmoles) three times a day.
45795693|NCT03483051|Drug|Potassium Chloride|Potassium chloride capsules will consist of potassium chloride (KCl), granular, USP (450mg) plus lactose monohydrate, spray dried, NF (300mg). The dose for this trial will be 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day.
45795694|NCT01645176|Drug|Hydroxychloroquine/Atorvastatin|Hydroxychloroquine 200-600 mg /day Atorvastatin 40 mg/day
45795695|NCT05615207|Other|Motor Imagery as compared to physical practice for balance tasks|We will investigate if using motor imagery (mentally imagining and practicing a task) as a means of balance training is as effective as physical practice
45795696|NCT04888416|Behavioral|I-STROM|I-STROM is a combination of the following implementation strategies: (a) initial and ongoing training, (b) learning collaboratives/knowledge sharing meetings, and (c) outcome measure champions
45795697|NCT05715983|Procedure|Bascom II procedure|Buttocks are strapped apart with wide adhesive tape. The area is prepared using antiseptic solution twice. Solution of brilliant green with 3% hydrogen peroxide was injected in all orifices to visualize all tracts and sinuses. The proposal area of incision is marked nearby sinus tract openings and the skin with lateralization on one side of the cleft. A vertical-orientated incision of the skin and subcutaneous fat around the primary and secondary orifices is made using a scalpel or a monopolar electrocautery. The sinus tract is excised in en-block till unchanged subcutaneous tissue. The wound is irrigated with antiseptic solution. If postoperative wound is larger than 5 cm then a silicone draining tube is placed through the contraperature in the upper corner. The wound is closed by interrupted sutures Vicryl/Polysorb 2/0 3/0 layer by layer. Aseptic dressing is applied to the closed wound.
45795698|NCT05715983|Procedure|SiLaC|Buttocks are strapped apart with wide adhesive tape. The area is prepared using antiseptic solution twice. Solution of brilliant green with 3% hydrogen peroxide is injected in all orifices to visualize all tracts and sinuses. All visible orifices are excised with a scalpel or dermo punch. After that hairs are removed from the sinus by Volkmann curette. A metallic stylet is used to determine the length and direction of the different tracts. Then laser destruction of the sinus is performed with FiberLase VT laser, wavelength 1460 or 1520 nm, the laser energy 10-12 Watts. The fiber delivers energy homogeneously in a continuous way. Hemostasis by electrocautery. The wound is washed with povidone-iodine solution. Aseptic dressing is applied.
45795699|NCT03465735|Combination Product|Vascular Boot|The Vascular Boot is one size fits all, insulated fleece padding, and cell foam to enhance and maintain lower limb warmth while maintaining no pressure points on the lower extremity.
45922012|NCT00129493|Behavioral|Group medical visits|Our intervention aims to develop and implement a model of group medical visits in iterative steps, to evaluate whether group medical visits improve patient adherence to prescribed antihypertensive medications and improve BP control, and to assess patient, physician, and health care system factors involved in successfully making organizational changes to encompass group medical visits.
45922013|NCT00129454|Behavioral|Cognitive Behavioral Therapy|"The investigators adapted two previously validated CBT manuals for use in both Telephone and In-Person groups (the Personal Health Improvement Program and Dr. Charles Engel's group treatment for GWI). Treatment included the following standard components of CBT: Didactic or educational material about the causes of GWI and an explanation of how thinking can cause stress (ABC model); Assessment of psychological distress and behavioral problems that may be targets of therapeutic intervention (e.g. symptom-related anxiety); Assessment of thinking errors that lead to psychological distress and trigger behavioral problems (e.g. catastrophizing); Cognitive restructuring to teach disputing skills or how to correct thinking errors; Cognitive and behavioral homework assignments (e.g. written self-disclosure); Didactic homework assignments (e.g. listen to previous treatment session)."
46071769|NCT05878457|Device|MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System|Treatment will consist 12 approximately-three-minute sessions on each of three treatment days within a seven-day period. To promote participant adherence and retention, treatment days will not need to be contiguous. A single session consists of 600 pulses delivered to the dmPFC at an intensity of 120% resting motor threshold (rMT). 50 hz triphasic bursts will be delivered for two seconds, followed by an 8 second inter-train interval. Trains will be repeated every 10 seconds, 10 times total, for a total of 190 seconds per session. An intersession interval of at least 15 minutes will be employed between each of the 12 sessions. Each treatment day will thus last approximately 3-4 hours in duration.
45795700|NCT03465735|Drug|Standard of Care|Anticoagulant therapy will be decided by physician and patient.
45795701|NCT04197960|Procedure|Microwave ablation|Use thermal energy to destroy tumor
46071770|NCT05878444|Dietary Supplement|Probiotic|Resistant gastrointestinal capsules will be provided daily to the participants.
46073710|NCT02821884|Device|Combination of tDCS and NMES|Both tDCS and NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. The NMES electrodes are placed over the following muscle: extensor digitorum communis, extensor carpi radialis to produce wrist and hand extension. The settings for the NMES is frequency at 50 Hz, pulse width of 200μs,duty cycle of 10 seconds on and 10 seconds off,current amplitude is adjusted to patients comfort (10-20mA).
45449964|NCT03540082|Other|Tuck and Roll Group|An instructor will explicitly verbally and visually demonstrate the falling technique and provide feedback on participant performance. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
45648789|NCT04781725|Other|Saline injection|Standard 0.9 % NaCl Normal Saline
45795702|NCT04197960|Procedure|Surgical resection|Resect tumors
45795703|NCT05637671|Drug|oxybutynin ER|One study group will receive 10 mg of oxybutynin ER orally once daily for 12 weeks.
45648790|NCT04761835|Biological|Peanut powder or peanut butter|Commercially available peanut powder or peanut butter.
45648791|NCT02550769|Procedure|TRANSANAL TOTAL MESORECTAL EXCISION|The technique begins with the TEO equipment and a purse string 1 cm distal to the tumor. The dissection progresses in the posterior part until the laparoscopic TME field is reached. After the section of the rectum and TME transanal dissection, the anvil of the circular mechanical stapler is introduced through the TEO rectoscope. In the laparoscopic field, the mesosigma is sectioned at the point where the colon section is to be performed. The TEO rectoscope is withdrawn, and the bag containing the specimen is removed through the anus. The stapler is inserted. From the laparoscopic field, the strings of the purse are tightened and the purse is closed around the rectal stump with a clip. Then the stapler are joined to perform the anastomosis and a loop ileostomy is placed in the right flank.
45795704|NCT05637671|Drug|Paroxetine CR|the other group will receive 12.5 mg of paroxetine CR orally once daily for 12 weeks.
45795705|NCT02322216|Drug|Olopatadine Hydrochloride Ophthalmic Solution 0.2%|
45795706|NCT02322216|Drug|Olopatadine Hydrochloride Ophthalmic Solution 0.1%|
45795707|NCT02322216|Drug|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
45795708|NCT03447639|Drug|Povidone-iodine irrigation|Single dose, 60 cc of 2% povidone-iodine indwelling for 10 minutes prior to catheter removal using aseptic technique
45795709|NCT05610215|Procedure|hybrid ablation|simultaneous thoracoscopic epicardial and catheter endocardial ablation
45795710|NCT05610215|Procedure|catheter ablation|catheter endocardial ablation
45795711|NCT03425799|Drug|Sodium Chloride 0.9% Inj|Inactive ingredient mixture for injection without drug, intravenous infusion bags containing normal saline, manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
45795712|NCT03425799|Drug|Tranexamic Acid|Tranexamic Acid Intravenous Infusion Bags (10 mg/mL), manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
45795713|NCT05576285|Diagnostic Test|ophthalmoscopy and fundus photography through dilated pupills|ophthalmoscopy and fundus photography through dilated pupills
45795714|NCT03363633|Drug|sodium tetradecyl sulfate|Ultrasound-guided injection with sodium tetradecyl sulfate foam of refluxing perforating veins
45922014|NCT00129454|Behavioral|Cognitive Behavioral Therapy|This description is the same as the experimental treatment only disseminated in person rather than over the telephone.
45795715|NCT03363633|Device|Compression|20-30 mmHg compression stockings
45922015|NCT05638061|Other|Soy protein|Soy foods or isolated soy protein
45795716|NCT05614193|Diagnostic Test|Deep learning imaging enhancement|Conventional imaging or down-sampling imaging from CT or MR are enhanced by approved deep learning method.
45795717|NCT03360903|Drug|Placebo|"Anesthetized volunteers will be allowed to wake after injection of saline (placebo control).~Other Names:~Saline"
45922016|NCT00129415|Procedure|UVA1 Irradiation|The affected areas on the body will be treated with UVA1 (Sellemed UVA1 light source) for up to 5 times per week for 16 weeks. The UVA1 dose will be up to 130 J/cm2.
45922017|NCT00129415|Procedure|UVB Irradiation|The affected areas on the body will be treated with UVB light for up to 5 times per week for 16 weeks. The maximum UVB dose will be 4000 mJ/cm2.
45922018|NCT00129337|Drug|Bavituximab|Bavituximab is a sterile drug solution supplied in glass bottles. Bavituximab will be intravenously administered over approximately 90 minutes on days 0, 7, 14 and 21 (dosage determined based on dose cohort and body weight).
45922019|NCT00129298|Drug|Tiagabine|The tiagabine group will start receiving tiagabine 4mg in the evening of the first day on week 2. The dose will be titrated every third day, until the target dose of 32mg/day is achieved by week 5. The study medication must be titrated to 32 mg/day or to the subject's maximum tolerated dose (MTD).
45922020|NCT00388466|Device|GALILEO|
45922021|NCT00129181|Drug|cabergoline|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
45795718|NCT03360903|Drug|Caffeine|"Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg).~Other Names:~Caffeine citrate"
45795719|NCT05607563|Drug|PM1009 injection|Participants receive PM1009 intravenously, every 2 weeks
45922022|NCT00129181|Drug|carbidopa/levodopa|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
45922023|NCT00129181|Procedure|DATscan and SPECT imaging|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
45922024|NCT00129142|Drug|Toremifene Citrate|
45922025|NCT00129064|Behavioral|Electronic referral system|
45922026|NCT00129025|Procedure|Hypofractionated radiotherapy|
45449965|NCT03540082|Other|Fall Exposure|An instructor will implicitly be exposed to the falling technique. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
45648792|NCT02550769|Procedure|Laparoscopic-LAR|Standard laparoscopic low anterior resection of the rectum with total mesorectal excision and colorectal anastomosis
45648793|NCT02320279|Device|Fetal Heart Rate Monitor|Use of a system that monitors fetal heart rate through use of fetal EKG read using abdominal electrodes
45922027|NCT00128986|Procedure|Tomotherapy|3T MRS scans (3T magnetic resonance spectroscopy)
45922028|NCT00128947|Drug|Mycophenolic Acid|
45922029|NCT00128947|Drug|Mycophenolate 7-O-Phenolic Glucuronide|
45922030|NCT00819780|Drug|Panitumumab|Panitumumab is a fully human immunoglobulin G (IgG)2 monoclonal antibody antagonist directed against human Epidermal Growth Factor receptor (EGFr).
45922031|NCT00819780|Drug|Bevacizumab|Bevacizumab is a humanized monoclonal IgG1 antibody that is directed against Vascular Endothelial Growth Factor (VEGF).
46073711|NCT02821884|Device|Combination of tDCS and sham NMES|Both tDCS and sham NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
45648794|NCT03580525|Drug|Nicotine saline infusion 0.00mcg/kg/s|saline 0.00mcg/kg/s
45648795|NCT03580525|Drug|Nicotine infusion 0.24mcg/kg/s|nicotine 0.24mcg/kg/s
45648796|NCT03580525|Drug|Nicotine infusion 0.096mcg/kg/s|nicotine 0.096mcg/kg/s
45648797|NCT03580525|Drug|Nicotine infusion 0.048 mcg/kg/s|nicotine 0.048mcg/kg/s
45795720|NCT00000231|Drug|Buprenorphine|
45795721|NCT05601635|Dietary Supplement|ButyraGen™|ButyraGen™ contains tributyrin as the primary active as well as Sunfiber®, a partially hydrolyzed guar fiber, and acacia fiber.
45795722|NCT00000237|Drug|Buprenorphine|
45795723|NCT00000765|Drug|Zidovudine|
45795724|NCT05564429|Drug|18F-SF12051|Injected IV followed by PET scanning
45795725|NCT05196789|Diagnostic Test|whole genome and transcriptome sequencing|To perform whole genome/transcriptome analysis of patients in a cohort of up to 350 Australian patients with IBMFS-RD
45795726|NCT05594927|Drug|Icaritin|600 mg (6 x 100 mg capsules) icaritin administered orally twice daily (30 minutes after breakfast and dinner, respectively) until treatment discontinuation criteria are met.
45795727|NCT05594927|Drug|Huachansu|1200 mg (4 x 300 mg tablets) huachansu administered orally three times a day (30 minutes after breakfast, lunch and dinner, respectively) until treatment discontinuation criteria are met.
45795728|NCT00000243|Drug|Buprenorphine|
45795729|NCT05584085|Behavioral|ACT-DE|Acceptance and Commitment Therapy is a third-wave psychological therapy to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the ACT hexagonal model, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.
45795730|NCT00000771|Drug|Paromomycin sulfate|
45922032|NCT00819780|Drug|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m^2) via ambulatory pump administered for a period of 46 to 48 hours.
45922033|NCT00128908|Drug|Standard Continuous Highly Active Antiretroviral Therapy (HAART)|
45922034|NCT00128908|Drug|Rapidly Cycled HAART|
46071771|NCT05878431|Other|Foot Reflexology|"The patients in the experimental group underwent 12 sessions of foot reflexology in a quiet room, twice a week, for 6 weeks. No application was made to the patients in the control group.~FOOT REFLEXOLOGY APPLICATION STAGES~Application of heating methods such as Achilles tendon stretching, wrist loosening, walking the thumbs of both hands on the soles of the feet and wringing the laundry, which lasts about 3 minutes,~Pressure on the brain, cervical region, solar plexus (the projection of the central nervous system on the sole of the foot), lymph system, adrenal glands, urinary system, digestive system, sciatic nerve, hips, knees and reflex points on the soles of the legs for about 10-15 minutes. implementation (Figure 3.4),~Ending the application by applying heating methods such as Achilles tendon stretching, wrist loosening, walking the thumbs of both hands on the soles of the feet and wringing the laundry, which lasts approximately 3 minutes after the application."
45449966|NCT03540004|Device|MolecuLight i:X Imaging Device|The i:X Imaging Device uses built-in light-emitting diodes (LEDs) emitting 405 nm violet excitation light to illuminate the wound during fluorescence imaging in (FL-Mode). The light excites biological components of the wound and surrounding tissues. Non-biological components may also fluoresce although their presence in wounds is less common, provided the wound has been cleaned following standard care protocols. The resulting wound fluorescence wavelengths emitted are typically between 420 - 700 nm in the visible wavelength spectrum. In FL-mode, a customized fluorescence emission filter, which is mechanically placed in front of the built in imaging sensor and allows real-time capture of wound, limits the visualization of fluorescence to wavelengths between 500-545 nm, which typically appears green in color, and 600-665 nm, which typically appears red in color.
45449967|NCT02165176|Drug|Oral cannabis|
45648798|NCT03580525|Drug|Nicotine infusion 0.024mcg/kg/s|nicotine 0.024mcg/kg/s
45648799|NCT03554707|Genetic|SGT-53|2.1 mg DNA/m2 or 2.8 mg DNA/m2 twice weekly
45648800|NCT03554707|Radiation|Radiation|Standard radiation plan
45648801|NCT03554707|Drug|Irinotecan|50mg/m2/dose IV daily for five days in a 4-week cycle
45648802|NCT03554707|Drug|Temozolomide|100mg/m2 PO daily for five days in a 4-week cycle
45648803|NCT03554707|Drug|Bevacizumab|10mg/kg IV every two weeks in a 4-week cycle
45648804|NCT02179333|Other|Ataxia rating scale|Administer new rating scale for ataxia. This will be administered by two different raters on two separate occassions, 4 to 6 weeks apart.
45648805|NCT03502759|Behavioral|CHICA SUDEP module|CHICA reminds physicians to counsel patients/families about the risk of SUDEP.
45648806|NCT04349605|Behavioral|Meditation|Meditation involves guided breathing and mindfulness training.
45795731|NCT00000777|Biological|gp160 Vaccine (MicroGeneSys)|
45795732|NCT05575505|Drug|Pentoxifylline 400 MG|Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics
45795733|NCT00000249|Drug|20% N2O|20% inhaled N2O
45795734|NCT00000249|Drug|30% N2O|30% inhaled N2O
45795735|NCT00000249|Drug|40% N2O|40% inhaled N2O
45795736|NCT00378339|Device|gold berlocks|
45795737|NCT00000261|Drug|30% Nitrous oxide|
45795738|NCT00000261|Other|Placebo|No drug (100% oxygen)
45795739|NCT00000261|Drug|0.2% sevoflurane|
45795740|NCT00000261|Drug|0.4% sevoflurane|
45922035|NCT05638178|Other|No intervention|No intervention, cohort study.
45922036|NCT00128869|Procedure|spine mobilizations|
45922037|NCT00128869|Procedure|spine manipulations|
45922038|NCT00128791|Drug|Nitroprusside|
45922039|NCT00128752|Behavioral|absorption and conversion of beta-carotene in human gastrointestinal (GI) tract|
45922040|NCT05638256|Drug|68Ga-NY104|Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY104
45922041|NCT05638295|Procedure|Biopsy|Undergo tumor biopsy
45922042|NCT05638295|Procedure|Biospecimen Collection|Undergo collection of blood
45922043|NCT05638295|Procedure|Computed Tomography|Undergo CT scan
45922044|NCT05638295|Procedure|Magnetic Resonance Imaging|Undergo MRI
45922045|NCT05638295|Biological|Panitumumab|Given IV
45922046|NCT05638295|Drug|Sotorasib|Given PO
45922047|NCT00063414|Drug|Alicaforsen|
45922048|NCT00048321|Drug|ISIS 104838|
45922049|NCT05638451|Drug|Sintilimab plus Bevacizumab and Temozolomide|200mg Sintilimab plus 10mg/kg Bevacizumab very 3 weeks 200 mg/m2/day Temozolomide on days 1-5 out of a 28 days schedule
45795741|NCT00000261|Drug|0.6% sevoflurane|
45795742|NCT05592587|Behavioral|Evaluation of the effectiveness of eye massage device producing both vibrations and nature sounds distraction in the management of anxious pediatric patients during inferior alveolar nerve.|"The child will be provided inferior alveolar nerve during eye massage device producing both vibrations and nature sounds. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale"
45795743|NCT05592587|Behavioral|Evaluation of the effectiveness of eye massage device producing vibratory stimulations distraction in the management of anxious pediatric patients during inferior alveolar nerve.|"The child will be provided inferior alveolar nerve during eye massage device producing vibratory stimulations. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale"
45795744|NCT05592587|Behavioral|Evaluation of the effectiveness of basic behavior guidance techniques without using any type of distraction aids in the management of anxious pediatric patients during inferior alveolar nerve.|"The child will be provided inferior alveolar nerve during eye massage device producing vibratory stimulations. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale"
45795745|NCT05592353|Other|Brace|Brace following hip arthroscopy
45922050|NCT05638490|Other||no intervention
45922051|NCT00008853|Biological|GBS III-TT-SSI|
46071772|NCT05878418|Device|Thoracolumbosacral Spinal Orthosis (TLSO)|In the PR-PC + spinal orthosis group, in addition to the control group program, a thoracolumbosacral spinal orthosis (TLSO) designed specifically for the child will be used for 8 hours a day for 8 weeks, every day of the week.
46071773|NCT05878418|Other|Pulmonary Rehabilitation(PR) and Pulmonary Care (PC)|The active control group will receive a PR and PC program in the outpatient clinic once a week for 8 weeks, 7 days a week, once a day, 40-60 minutes per session, for 8 weeks.
46071774|NCT05878392|Other|bone filling materials|the buccal jumping gap was packed using PRF in group 1 the buccal jumping gap was packed using xenograft in group 2 the buccal jumping gap was packed using Alloplastic β-tricalcium phosphate in group 3
45795746|NCT00000801|Drug|Filgrastim|
45795747|NCT00000801|Drug|Vincristine sulfate|
45795748|NCT00000801|Drug|Doxorubicin hydrochloride|
45795749|NCT00000801|Drug|Cyclophosphamide|
46073712|NCT02821884|Device|Combination of sham tDCS and sham NMES|Both sham tDCS and sham NMES conduct simultaneously for 30 minutes. Sham tDCS electrodes are placed in the same position on patients receiving the sham stimulation. Just like during real tDCS, stimulation is started in a ramp-like fashion but fade out slowly after 30 seconds. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
46073713|NCT00835627|Drug|sertraline|flexible dose sertraline
46073714|NCT00835627|Behavioral|CBT-ip|cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual 1 hour therapy sessions
45795750|NCT00000801|Drug|Cytarabine|
45795751|NCT00000801|Drug|Dexamethasone|
45795752|NCT00000267|Drug|Risperidone|
45795753|NCT00000807|Drug|Etoposide|
45795754|NCT02978027|Behavioral|Brief Advice|
45795755|NCT02978027|Behavioral|NIAAA Clinician's Guide|
45795756|NCT02978027|Behavioral|Motivational Interviewing (MI)|
45795757|NCT00001677|Drug|Methotrexate|
45795758|NCT00001677|Drug|Fludarabine|
45795759|NCT00358397|Drug|Clostridium novyi-NT spores|
45795760|NCT00001689|Drug|Vincristine|
45795761|NCT02977871|Procedure|Bladder flap|Performing uterine incision and cesarean section with a bladder flap.
45795762|NCT00001713|Drug|Recombinant Tissue Plasminogen Activator|
45795763|NCT00001713|Drug|Heparin|
45795764|NCT00001713|Drug|Warfarin|
45795765|NCT00000273|Drug|opiates|prescription opioids
45795766|NCT00000819|Drug|Prednisone|
45795767|NCT05371847|Other|assessment for upper limb dysfunction|clinical assessments and questionnaires
45795768|NCT05371847|Other|retest assessment|For the test-retest reliability testing, participants will be invited to have an additional appointment approximately 1 week after the main assessment.
45795769|NCT00000279|Drug|Clonidine|
45795770|NCT00000825|Drug|Aldesleukin|
45795771|NCT00000285|Drug|Phenytoin|
45795772|NCT00001737|Drug|Cyclosporin A Implant|
45795773|NCT00001761|Drug|Interleukin-10|
45795774|NCT03835325|Dietary Supplement|Cogmax®|Research participants will receive 2 capsules of Cogmax® per day (after lunch) for 12 weeks.
45795775|NCT00000843|Drug|Adefovir dipivoxil|
45795776|NCT05362487|Device|Spiriva® Respimat®|Spiriva® Respimat®
45795777|NCT05362487|Device|Spiriva® HandiHaler®|Spiriva® HandiHaler®
45795778|NCT05362487|Drug|Tiotropium bromide|Tiotropium bromide
45922052|NCT00008853|Biological|GBS III-TT-MPHL|
45922053|NCT05638685|Other|Questionnaire|The questionnaire comprises demographics, job or school related questions, screen work questions, the International Physical Activity Questionnaire (IPAQ) and questions about the participant's health.
45922054|NCT00128713|Procedure|Medium Dose Prophylactic Platelet Transfusions|2.2 x 10^11 platelets per m^2 BSA
45922055|NCT00128713|Procedure|Lower Dose Prophylactic Platelet Transfusions|1.1 x 10^11 platelets per m^2 BSA
45922056|NCT00128713|Procedure|Higher Dose Prophylactic Platelet Transfusions|4.4 * 10^11 platelets per m^2 BSA
45922057|NCT00009009|Drug|immunosuppressive regimen designed to complement HAART|
45922058|NCT05638763|Drug|Dasatinib Pill|Patients will receive half pill of dasatinib 50mg (25mg/day, orally) for one year
45648807|NCT04349605|Behavioral|Kundalini Yoga|Kundalini Yoga involves stretching, guided breathing and meditation
45648808|NCT04299451|Other|Open dialogue about CAM|1-hour dialogue about CAM with a nurse specialist as an integrated part of conventional oncology care
45648809|NCT04503265|Drug|AMXI-5001:Dose Escalation Phase I|Phase I will enroll up to 30 participants to identify the Recommended Phase II daily dose in the treatment of various cancers and to characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, without food. AMXI-5001 is administered weekly on a 4-day ON, 3-day OFF schedule. Each cycle is 28 days.
45648810|NCT04503265|Drug|AMXI-5001:Dose Expansion Phase II|Phase II will enroll up to 52 study participants to further characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, without food. AMXI-5001 is administered weekly on a 4-day ON, 3-day OFF schedule. Each cycle is 28 days.
45648811|NCT04264663|Drug|Furazolidone|Furazolidone-tetracycline-containing quadruple regimens
45648812|NCT04264663|Drug|Tinidazole|tinidazole-tetracycline-containing quadruple regimens
45795779|NCT00000291|Drug|Labetalol|
45795780|NCT05362331|Other|Web Application|Internet based application
45795781|NCT00000861|Drug|Indinavir sulfate|
45795782|NCT05139797|Other|EchoNet-LVH screening for cardiac amyloidosis|An AI algorithm identifies LVH, low voltage, and high suspicion for cardiac amyloidosis. The intervention is the suspicion score. Patients with high suspicion score will be referred to specialty clinic for standard of care evaluation, screening, and treatment as determined by physicians.
45795783|NCT00000297|Drug|Labetalol|
45795784|NCT00359879|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day (before lunch and dinner)
45795785|NCT00359879|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day (before breakfast and dinner)
45648813|NCT04264585|Behavioral|Internet-delivered cognitive behaviour therapy|All clients will receive the same materials, namely the UniWellbeing Course, which was developed at Macquarie University, Australia. The UniWellbeing Course is a transdiagnostic intervention targeting symptoms of depression and anxiety, that has been tailored for use in post-secondary students. It comprises 4 online lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model; thought monitoring and challenging; de-arousal strategies and pleasant activity scheduling; graduated exposure; and relapse prevention. Seven supplementary lessons can also be accessed at any time (e.g., sleep, communication). Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) with 4 lesson summaries and homework assignments that facilitate skill acquisition. Therapists will spend ~15 mins. per week/per client.
45795786|NCT00000303|Drug|Baclofen|
45795787|NCT00001785|Drug|Recombinant human interferon beta-1a|
45795788|NCT05357963|Procedure|Sternotomy application|The chronic pain findings of the patients who underwent sternotomy will be questioned at the postoperative 3rd month.
45795789|NCT04331613|Biological|CAStem|CAStem will be administered intravenously.
45795790|NCT00001827|Biological|aldesleukin|
45795791|NCT00001827|Biological|incomplete Freund's adjuvant|
45795792|NCT00001827|Biological|p53 peptide vaccine|
45795793|NCT00001827|Biological|sargramostim|
45795794|NCT00001827|Biological|therapeutic autologous dendritic cells|
45795795|NCT00001827|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45795796|NCT05355077|Drug|JT001 200mg Bid|JT001 (VV116):200 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
45795797|NCT05355077|Drug|JT001 400mg Bid|JT001 (VV116):400 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
45795798|NCT05355077|Drug|JT001 600mg Bid|JT001 (VV116):600 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
45795799|NCT01647516|Drug|Ozanimod|Ozanimod capsules by mouth daily.
45795800|NCT01647516|Drug|Placebo|
45795801|NCT02959073|Other|Symptom Recording|Subjects muss record their allergic symptoms after contact with their cats
45795802|NCT00000873|Drug|Infant Formula|
45795803|NCT05133323|Drug|Lu AG09222|Lu AG09222 will be administered per schedule specified in the arm.
45795804|NCT05133323|Drug|Placebo|Placebo matching to Lu AG09222 will be administered per schedule specified in the arm.
45795805|NCT00358475|Drug|GW685698|
45795806|NCT00001839|Drug|Antithymocyte globulin|
45795807|NCT00001839|Drug|Cyclosporine|
45795808|NCT00000885|Drug|Indinavir sulfate|
45795809|NCT00000885|Drug|Abacavir sulfate|
45795810|NCT00000885|Drug|Nelfinavir mesylate|
45795811|NCT00000885|Drug|Efavirenz|
45795812|NCT00000885|Drug|Levocarnitine|
45795813|NCT00000885|Drug|Adefovir dipivoxil|
45795814|NCT00000885|Drug|Lamivudine|
45795815|NCT00000885|Drug|Stavudine|
45795816|NCT00000885|Drug|Zidovudine|
45795817|NCT00000885|Drug|Didanosine|
45795818|NCT05127551|Device|iStent Infinite|Implantation of the iStent Infinite
45795819|NCT05127551|Device|Competitor Device|Implantation of competitor device
45795820|NCT01647282|Drug|locally-applied minocycline HCl (1 mg)|
45795821|NCT01647282|Procedure|scaling and root planing (Sc/RP)|
45795822|NCT05348759|Diagnostic Test|Pulmonary function test|Spirometry was performed by trained nurse at division of pulmonology, Vajira hospital. The forced vital capacity (FVC), forced expiratory volume in first second of exhalation (FEV1), forced mid-expiratory flow (FEF25-75%), and the FEV1/FVC ratio before and after bronchodilators (2 puffs of salbutamol via spacer) were collected in all cases. Total lung capacity (TLC) using the spirometry (Masterscreen PFT, Jaeger, Germany) and diffusion capacity of carbon monoxide was performed in selected case with abnormalities of lung parenchyma found from computed tomography of the chest.
45922059|NCT05638763|Drug|Ketoconazole Pill|Patients will receive ketoconazole 200mg two times a day, orally, for one year.
45922060|NCT00128635|Radiation|iodine I 131 monoclonal antibody TNT-1/B|
45922061|NCT00394420|Behavioral|Telephone Quitline|
45922062|NCT00009048|Drug|EMD 128130|
45922063|NCT00009048|Drug|IV Levodopa|
45922064|NCT00128596|Drug|arsenic trioxide|
45795823|NCT05348759|Diagnostic Test|Chest computer scan|High-resolution computed tomography (HRCT) was performed in a single breath-hold on a 128 slice multidetector computed tomography (MDCT) scanner (Philips Healthcare Nederland B.V, Ingenuity 128, Netherlands). HRCT was performed with the patient in the supine position during end-inspiration, supine position during end-expiration, and prone position during end-inspiration with 1 millimeter (mm) slice thickness.
46073715|NCT00835627|Other|Combined (sertraline + CBT-ip)|flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12, individual 1 hour therapy sessions
46073716|NCT00835627|Other|Standard Care|community care, treatment as usual: routine follow up with existing providers
45648814|NCT04264585|Behavioral|Motivational Interviewing|Clients assigned to the ICBT with Motivational Interviewing condition will receive access to the Planning for Change lesson before accessing Lesson 1. They will be presented with five interactive online exercises based on motivational interviewing principles (i.e. values clarification, importance ruler, looking back, confidence ruler, and looking forward). As clients complete the exercises, they are prompted to answer open-ended questions and are provided with written feedback.
45648815|NCT04264585|Behavioral|Booster Session|"Clients assigned to the ICBT with Booster condition will receive access to a booster session one month after the end of the ICBT course. The booster session will include information about maintaining motivation, a review of the ICBT course content and skills, and information about structured problem solving. Clients will also have access to a Do-It-Yourself guide that summarizes the information in the booster session and includes worksheets for clients to practice the problem-solving skills described in the booster.~This booster session will be self-guided (ie. no therapist support is offered)."
45795824|NCT00000897|Drug|Zidovudine|
45795825|NCT05347979|Drug|Dabigatran Etexilate|Dabigatran will be administered orally as a 75 mg capsule on Day 1 and Day 12.
45795826|NCT05347979|Drug|Relacorilant|Relacorilant will be administered orally as 4 X 100 mg capsules (400 mg) on Days 3 through 13.
45795827|NCT00001857|Drug|BG9588|
45795828|NCT00000909|Drug|Aldesleukin|
45795829|NCT05444699|Drug|Prednisolone Sodium Phosphate|Oral suspension administered 1 mg/kg once a day for three days
45795830|NCT05444699|Drug|Sugar syrup|Oral suspension administered the same amount in milliliters as experimental product once a day for three days
45795831|NCT00001863|Drug|Leflunomide|
45795832|NCT05120531|Other|Monitoring patients undergoing surgery to look for association between ANS activity and bradycardia|Use of an Ambulatory Monitoring System from Vuije University (VU-AMS) to record autonomic and cardiovascular activity of patients undergoing otolaryngologic surgery with anesthesia. This monitoring device will provide data of ANS activity and normoxic bradycardia among patients with Down Syndrome. This data will be compared to data from patients without Down Syndrome.
45795833|NCT00000915|Behavioral|Vaccine preparedness|
45795834|NCT05530655|Drug|Lisinopril Tablets|This is a dose escalation study of 5 mg, 10 mg and 20 mg doses given once a day.
45795835|NCT00000921|Drug|Prednisone|
45795836|NCT05118035|Other|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which shows the risk prediction results for each patients. Moreover, the clinicians will recieve a short message when patients with a high risk ECG identified by AI.
45795837|NCT02321436|Biological|Botulinum toxin type A|Subjects to receive Dysport® 500U administered intramuscularly in the targeted upper limb.
45795838|NCT02321436|Drug|Placebo|Placebo administered intramuscularly in the targeted upper limb.
45795839|NCT05325515|Drug|Conventional alendronate|Conventional alendronate 70mg weekly
45795840|NCT05325515|Drug|Effervescent and buffered alendronate|Effervescent and buffered alendronate 70mg weekly
45795841|NCT00000939|Drug|Hydroxyurea|
45795842|NCT00000939|Drug|Efavirenz|
45795843|NCT00000939|Drug|Stavudine|
45795844|NCT00000939|Drug|Didanosine|
45795845|NCT00000837|Biological|Varicella Virus Vaccine (Live)|
45795846|NCT05527691|Behavioral|SupportGroove|"An app-delivered program consisting of positive psychology-based activities, such as expressing gratitude, finding meaning, savoring, and fostering connections. Participants complete daily quests suggested through the app, some of which are completed on their own, and some with their partner."
45795847|NCT00000945|Drug|Cidofovir|
45795848|NCT00000945|Drug|Probenecid|
45795849|NCT04344041|Drug|cholecalciferol 200,000 IU|Patients receive a vitamin D supplementation of 400,000 IU in a single oral dose.
45795850|NCT04344041|Drug|cholecalciferol 50,000 IU|Patients receive a vitamin D supplementation of 50,000 IU in a single oral dose
45795851|NCT00000963|Drug|Didanosine|
45795852|NCT05322707|Drug|Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg|Inhalation aerosol, 2 actuations orally inhaled twice daily
45795853|NCT05322707|Drug|Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol|Inhalation aerosol, 2 actuations orally inhaled twice daily
45795854|NCT05322707|Drug|Placebo|Inhalation aerosol, 2 actuations orally inhaled twice daily
45795855|NCT02319642|Drug|Certolizumab Pegol|Active Substance: Certolizumab Pegol Pharmaceutical form: Prefilled syringes Concentration: 200 mg/ ml Route of Administration: Subcutaneous injection
45795856|NCT05110937|Other|Blood sampling|Blood sampling
45795857|NCT00001893|Drug|TNFR:Fc|
45795858|NCT02977793|Device|Tomey EM-4000 Specular Microscope|
45795859|NCT02977793|Device|Konan CellChek XL Specular Microscope|
45795860|NCT00000981|Drug|Fiacitabine|
45922065|NCT05638841|Other|After radiofrequency ablation of atrial fibrillation|This study imposed an intervention. Clinical data were obtained by telephone or outpatient follow-up.
45648816|NCT05403307|Biological|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
45648817|NCT05403307|Biological|CoronaVac COVID-19 vaccine|CoronaVac COVID-19 vaccine
45795861|NCT04713423|Diagnostic Test|Diagnosis and treatment of the case|The infant was transferred to a hospital for better management of her infection. She was immediately started on intravenous acyclovir (20 mg/kg/6 h/5 d) while acetaminophen suppositories (80 mg/8 h/5 d) were given to lower her body temperature. In addition, other palliative drugs, such as diphenhydramine syrup (12.5 mg/5 mL, 2.5 mL orally) once-a-night for five days, were given to ease the effort of drinking and to aid in achieving good sleep. Upon completion of five days of therapy, the patient showed complete recovery and was subsequently discharged from the hospital free from symptoms.
45795862|NCT02280096|Drug|4-aminopyridine|Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
45795863|NCT02280096|Drug|Placebo|The placebo arm will include Microcrystalline Cellulose placebo
45795864|NCT00001905|Drug|Interferon gamma|
45795865|NCT00000987|Drug|Bleomycin sulfate|
45795866|NCT00000987|Drug|Vincristine sulfate|
45795867|NCT00000987|Drug|Doxorubicin hydrochloride|
45795868|NCT00000987|Drug|Zidovudine|
45795869|NCT05320289|Device|AblaCare System|"The intervention includes the short-term use of the AblaCare System, which is comprised of three elements: (1) the AblaCare Needle-Catheter Ablation Device (NCAD) (the Device) a 16G echogenic needle including a bipolar temperature-controlled RF ablation catheter which is clipped and secure onto a vaginal ultrasound probe; (2) the AblaCare Adapter which is clipped onto the ultrasound probe; and (3) the AblaCare Generator: a bipolar radiofrequency (RF) ablation platform utilizing the single use AblaCare NCAD for ovarian tissue ablation.~Once th patient is under conscious sedation, the physician guides the AblaCare system transvaginally with the use of a transvaginal ultrasound. Once the AblaCare device is safely and securely positioned, the physician will deliver radio frequency energy inside the ovary in order to ablate the tissue."
45795870|NCT00001911|Drug|Interleukin-12|
45795871|NCT04877574|Procedure|ANI-guided intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil to maintain 50-70 of ANI.
45795872|NCT04877574|Procedure|Conventional intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil at the discretion of attending anesthesiologists based on hemodynamic parameters.
45795873|NCT00001917|Drug|O15|
45795874|NCT00001917|Drug|[F-18] FP-TZTP|
45795875|NCT00001923|Procedure|Transcranial magnetic stimulation|
45795876|NCT00001929|Drug|Eliprodil|
45795877|NCT05096429|Behavioral|PROVIDENT|Each of the state's 39 municipalities will be randomised to the intervention (PROVIDENT) or comparator condition. An interactive, web-based tool will be developed to visualize the PROVIDENT model predictions. Municipalities assigned to the treatment arm will receive neighborhood risk predictions from the PROVIDENT model, and state agencies and community-based organizations will direct resources to neighborhoods identified as high risk. Municipalities assigned to the control arm will continue to receive surveillance information and overdose prevention resources, but they will not receive neighborhood risk predictions from this study.
45795878|NCT00358553|Drug|Insulin|
45795879|NCT00000993|Drug|Zidovudine|
45795880|NCT00359177|Drug|GW679769|GW679769 will be available in dose strength of 50 mg tablets. Subjects will receive two tablets of 50 mg orally once daily in the morning
45795881|NCT00001017|Drug|Fluconazole|
45795882|NCT00001017|Drug|Amphotericin B|
45648818|NCT02827045|Device|Vestibular test|
45648819|NCT02765737|Other|Dehydrated Human Amnion/Chorion Membrane|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA).
45648820|NCT02765737|Device|Mepilex Ag|
45795883|NCT00359255|Behavioral|Education manual|The control arm was given education on stroke, the affected arm post strooke, bone health, and healthy living. This information was given in a booklet format and administered once weekly by the site coordinator.
45795884|NCT00359255|Behavioral|An inpatient homework based exercise program for the upper limb post stroke|"The experimental arm was given arm exercises graded based on motor impairment and administered by the site coordinator. The exercises were given in a booklet with written and photographic instructions. These exercises were monitored on a twice-weekly basis.~The intervention was to be completed once daily for 45 minutes, 5 days per week, and supervised by the site coordinator. Exercises consisted of range of motion, strengthening, and use of the arm in daily activites such as buttoning, pouring and throwing."
45795885|NCT02279862|Drug|Ipilimumab|
45795886|NCT00001965|Drug|Cyclosporine A|
45795887|NCT00001023|Drug|Clarithromycin|
45795888|NCT00001023|Drug|Azithromycin|
45795889|NCT00001023|Drug|Rifabutin|
45795890|NCT05550233|Device|drug-coated balloon|drug-coated balloon in big de novo coronary disease
45795891|NCT00359957|Behavioral|Pediatric Obesity Intervention (STANDARD)|14 weekly behavioral intervention visits with parent and child; individual family sessions (25-30 minutes) and separate parent and child groups (40 minutes)
45795892|NCT00359957|Behavioral|Pediatric Obesity Intervention + High Activity (ADDED)|14 weekly behavioral intervention visits with parent and child; individual family sessions (25-30 minutes) and separate parent and child groups (40 minutes)
45795893|NCT00001035|Drug|Interferon alfa-2b|
45795894|NCT00001035|Drug|Zidovudine|
45795895|NCT00001035|Drug|Zalcitabine|
45795896|NCT00001035|Drug|Didanosine|
45795897|NCT02318940|Device|central venous catheter|installation of Central venous catheter ultrasound guided
45795898|NCT02318940|Device|central venous catheter|installation of Central venous catheter landmark guided
45648821|NCT04599751|Device|Hair removal treatment|Axilla and bikini line hair removal treatments using the Trio Laser Module (Alma Lasers).
45922066|NCT00128557|Dietary Supplement|vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU)|Single dose of 15,000 ug retinol equivalents at or near birth vs a placebo
45922067|NCT00128518|Drug|Indapamide (T2)|1.5 mg/day during 4 weeks
45922068|NCT00128518|Drug|Perindopril (T1)|4 mg/day during 1 week then 8 mg/day during 3 weeks
45922069|NCT00128518|Drug|Placebo of Perindopril (P1)|1 pill/day during 1 week then 2 pills/day during 3 weeks
45922070|NCT00128518|Drug|Placebo of Indapamide (P2)|1 pill/day during 4 weeks
45795899|NCT05503901|Drug|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks
45922071|NCT00009204|Drug|Citalopram [Celexa]|
45922072|NCT00009204|Drug|Perphenazine [Trilafon]|
45922073|NCT00394459|Device|Perifix Epidural Anaesthesia Catheter|Epidural Catheter
45922074|NCT00394459|Device|Perifix Standard|Perifix Standard
45922075|NCT00394459|Device|Perifix New|Perifix New
45922076|NCT00394498|Drug|Granulocyte Colony Stimulating Factor|
45795900|NCT05503901|Drug|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks
45795901|NCT05503901|Drug|STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks and 1 drop Timolol ophthalmic solution 0.5% twice daily for 52 weeks
45795902|NCT05083091|Behavioral|Mindfulness and Attention Training|Guided mindfulness meditation with attention monitoring and acceptance skills training
45795903|NCT05083091|Behavioral|Mindfulness training|Guided mindfulness meditation, no attention monitoring or acceptance skills training
45795904|NCT05083091|Behavioral|Coping Condition|Guided training focused on coping effectiveness strategies, no monitoring or acceptance instruction
45795905|NCT00001053|Biological|HIV p17/p24:Ty-VLP|
45795906|NCT00001053|Biological|Aluminum hydroxide|
45795907|NCT00001989|Drug|Trichosanthin|
45795908|NCT00001989|Drug|Zidovudine|
45922077|NCT00394537|Drug|Labetalol 10mg iv|
45922078|NCT00009555|Drug|Testosterone|
45922079|NCT00128479|Drug|mifepristone|mifepristone 300 mg daily for 7 dats
45922080|NCT00128479|Drug|mifepristone matched placebo|daily for 7 days
45922081|NCT00128479|Drug|mifepristone 600 mg|mifepristone 600 mg daily for 7 days
45922082|NCT00128479|Drug|mifepristone 1200 mg|mifepristone 1200 mg daily for 7 days
45922083|NCT05638958|Device|Immediate post-extractive Implant placement|Teeth scheduled for extraction will be used to study the effect of a customized healing abutment. All patients should receive prophylactic antibiotic therapy of 2g of amoxicillin (or clindamycin 600mg if allergic to penicillin) 1 hour before the surgery. Implant placed along the lingual/palatal bone plate and the implant platform should be placed at the level of the buccal bone plate. GUIDOR easy-graft CRYSTAL will be used to fill the defect between implant and buccal bone plate, subsequently, a standard healing abutment or a customized healing abutment will be screw-retained on the implants.
45922084|NCT00128440|Drug|BEA 2180 BR|
45922085|NCT00128440|Drug|tiotropium|
45922086|NCT00009594|Procedure|Naturopathic Medicine|
45922087|NCT00009594|Procedure|Traditional Chinese Medicine|
45922088|NCT05638997|Other|Instrument assisted manipulation + Core exercises|The effect of Instrument assisted manipulation on chronic non-spesific low back pain
45648822|NCT04563559|Drug|Dextenza 0.4Mg Ophthalmic Insert|The eye will have a sustained release device of Dexamethasone 0.4 mg placed in the inferior nasal lacrimal system.
45648823|NCT04563559|Drug|Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]|The eye will be randomized to receive topical treatment with prednisolone acetate 1% on a tapering dose schedule
45795909|NCT05079815|Diagnostic Test|CBC and serum ferritin|take blood sample for CBC and serum ferritin
45922089|NCT05638997|Other|Mulligan mobilization with movement + Core exercises|The effect of Mulligan mobilization with movement on chronic non-spesific low back pain
45648824|NCT02124187|Device|Ecig 24 mg nicotine|eCig 24 mg nicotine for 12 weeks
45648825|NCT02124187|Device|Ecig 0 mg nicotine|eCig 0 mg nicotine for 12 weeks
45795910|NCT00001059|Drug|Doxorubicin hydrochloride (liposomal)|
45795911|NCT00001059|Drug|Filgrastim|
45795912|NCT00001059|Drug|Bleomycin sulfate|
45795913|NCT00001059|Drug|Vincristine sulfate|
45795914|NCT05079425|Drug|NXC736|Oral administration
45795915|NCT05079425|Drug|Placebo|Oral administration
45795916|NCT00001065|Drug|Amphotericin B|
45795917|NCT05310461|Procedure|Transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement|Early transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement.
45922090|NCT05638997|Other|Core exercises|The effect of core exercises on chronic non-spesific low back pain
45922091|NCT00128401|Drug|D-Cycloserine|
45922092|NCT00128401|Drug|Placebo|
45922093|NCT00128362|Procedure|Radio-guided sentinel node biopsy|
45922094|NCT00128362|Procedure|Axillary sampling|
45922095|NCT00128323|Drug|Gentian violet 1% solution|
45922096|NCT00128323|Drug|Gentian violet 0.00165% solution|
45922097|NCT00128323|Drug|Nystatin solution|
45922098|NCT00394576|Behavioral|Internet-based nutrition module along with usual care|usual care plus Internet-based nutrition module
45922099|NCT00394576|Behavioral|usual care|usual care
45922100|NCT05639075|Other|Peripheral vision|A gait analysis test will be performed in each patient after cataract surgery to test peripheral vision
45922101|NCT00018616|Behavioral|MEMS caps|
45922102|NCT00009672|Drug|Nortriptyline|
45648826|NCT02124187|Device|Nicotine free inhalator|eCig 24 mg nicotine for 12 weeks
45922103|NCT00009672|Drug|Morphine|
45922104|NCT00018655|Behavioral|Twelve Step Facilitation|Twelve Step Facilitation Therapy involves focusing on topics from 12-Step programs which support sobriety goals and personal growth.
45922105|NCT00018655|Behavioral|Integrated Cognitive Behavioral Treatment|Integrated Cognitive Behavioral Treatment involves focusing on thoughts, activities, and interactions with people related to depressive symptoms and/or substance use.
45922106|NCT00018694|Drug|Chenodeoxycholic Acid|
45922107|NCT00018733|Drug|paroxetine|
45795918|NCT05310461|Procedure|Deferred treatment, with intervention once AVA is ≤1.0 cm2 or if concomitant mitral regurgitation meets an indication for intervention|Deferred transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement.
45795919|NCT02977637|Procedure|Feraheme MRI/MRA|
45449968|NCT02165254|Behavioral|PLUS|1 hour tai chi session 3 times a week (weeks 1-12), to twice a week (week 13-16), and every other week (week 17-26) for a total of 24 weeks
45648827|NCT05403073|Procedure|Ultrasound guided Suprainguinal Iliac Fascia Nerve Block.|Pain management at ER Department will be as usually with iv drugs and ultrasound guided Suprainguinal Iliac Fascia Nerve Block.
45648828|NCT02002819|Drug|levetiracetam|
45795920|NCT00001995|Drug|Rifabutin|
45795921|NCT05501483|Drug|Pioglitazone 45 mg|Starts with 45 mg
45795922|NCT05501483|Drug|Empagliflozin 25 MG|Starts with 25 mg
45795923|NCT05501483|Drug|Semaglutide 7 MG|Starts with 3 mg daily for the first 2 weeks
45795924|NCT05501093|Other|sample collection|Blood, plaque, and other oral samples
45795925|NCT00002001|Drug|Zidovudine|
45922108|NCT00018733|Drug|Desipramine|
45922109|NCT00009711|Procedure|management of therapy complications|
45922110|NCT00018811|Behavioral|Relaxation training & thermal biofeedback|
45922111|NCT00018811|Behavioral|Surface EMG biofeedback|
45922112|NCT00018850|Drug|ondansetron|
45922113|NCT00018850|Behavioral|neuropsychological testing|
45922114|NCT00018850|Drug|nicotine|
45922115|NCT00018850|Drug|haloperidol|
45922116|NCT00018967|Drug|glucarpidase|
45922117|NCT05639153|Drug|DR30303|DR30303 dose level of escalation IV every 3 weeks (Q3W) Day 1, as well as dose expansion with recommended dose level from dose escalation.
45648829|NCT05399017|Device|EZVent|EZVent Ventilator System is designed for respiratory support in hospitalized mechanical ventilated patients. The Ventilator is designed to be used for adults patients. It is designed to be a stationary product suitable for service in hospitals, critical care situations to provide continuous positive pres- sure respiratory support to the patient. The ventilator met EDA, ISO 80601-2-12 requirements on essential performance of critical care ventilator and other applicable international standards.
45648830|NCT01915615|Other|None - this is an observational study|None - this is an observational study
45648831|NCT05123833|Procedure|Hypospadias repair|surgical repair of hypospadias
45648832|NCT05123677|Diagnostic Test|Non-invasive haemodynamic assessment|Maternal non-invasive haemodynamic assessment: a pressure cuff (similar to the one used to measure blood pressure) is applied to the arm and thigh, and a further neck sensor applied. Information about the function of heart and major blood vessels are recorded
45795926|NCT00002001|Drug|Zalcitabine|
45795927|NCT00002001|Drug|Didanosine|
45795928|NCT05292131|Drug|bimekizumab|Study participants will receive a single dose of bimekizumab (BKZ) administered subcutaneously in the Treatment Period.
45795929|NCT00002007|Drug|Zidovudine|
45795930|NCT00002007|Drug|Sargramostim|
45922118|NCT00009750|Biological|filgrastim|
45922119|NCT00009750|Biological|monoclonal antibody m170|
45922120|NCT00009750|Drug|cyclosporine|
45922121|NCT00009750|Drug|paclitaxel|
45922122|NCT00009750|Procedure|peripheral blood stem cell transplantation|
45922123|NCT00009750|Radiation|indium In 111 monoclonal antibody m170|
45922124|NCT00009750|Radiation|yttrium Y 90 monoclonal antibody m170|
45922125|NCT00019006|Drug|Detox-B adjuvant|
45922126|NCT00019006|Drug|ras peptide cancer vaccine|
45922127|NCT00019084|Biological|aldesleukin|
45922128|NCT00019084|Biological|mutant p53 peptide pulsed dendritic cell vaccine|
45922129|NCT00019084|Biological|ras peptide cancer vaccine|
45922130|NCT00019084|Biological|sargramostim|
45922131|NCT00019084|Biological|therapeutic autologous lymphocytes|
45922132|NCT00019084|Biological|therapeutic tumor infiltrating lymphocytes|
45922133|NCT05639348|Other|Data collection on POD for calculation of the PIPRA score|"Data collection for presence of POD as diagnosed by the 4 A Tests (4AT) or the Intensive Care Delirium Screening Checklist (ICDSC). The collected data will be used to validate the existing PIPRA algorithm and to improve the algorithm and evaluate it in a cross-validation setting. For the model validation the area under the receiver operating characteristics (ROC) curve (AUC) will be computed."
45922134|NCT00019123|Drug|thalidomide|
45922135|NCT00009789|Radiation|accelerated conformational radiotherapy|
45922136|NCT00019201|Other|cytology specimen collection procedure|
45922137|NCT00019201|Other|immunohistochemistry staining method|
45922138|NCT00019201|Other|sputum cytology|
45922139|NCT00019201|Procedure|bronchoscopic and lung imaging studies|
45922140|NCT00019201|Procedure|bronchoscopy|
45922141|NCT00019201|Procedure|comparison of screening methods|
45922142|NCT00019201|Procedure|endoscopic biopsy|
45922143|NCT00019240|Drug|cidofovir|
45922144|NCT05639387|Procedure|actual tVNS|Active tVNS (stimulation on cymba conchae --> nervus vagus stimulation)
45922145|NCT05639387|Procedure|sham tVNS|Sham tVNS (stimulation on earlobe --> no nervus vagus stimulation)
45922146|NCT00019357|Biological|aldesleukin|
45922147|NCT00019357|Biological|therapeutic autologous lymphocytes|
45922148|NCT00019357|Biological|therapeutic tumor infiltrating lymphocytes|
45922149|NCT00019396|Drug|flt3 ligand|
45648833|NCT05123677|Diagnostic Test|Maternal ophthalmic artery doppler|Maternal ophthalmic artery doppler: an ultrasound probe is applied gently over the eyelid for a few seconds to study the blood flow of the main artery to the eye
45648834|NCT05123521|Diagnostic Test|urine analysis|Urine was then tested for evidence of substance abuse using the multi-drug screen panel dip steak ABONtm (Abon Biopharm (Hangzhou) CO., Ltd) which is a lateral flow chromatographic immunoassay . It allowed for qualitative detection of multiple drugs in a single run. This kit was chosen for its ability to detect the most commonly abused substances in Egypt, namely: opioids, benzodiazepines, hashish, and tramadol. A single coloured line at region C for of a specific drug indicated a positive result, whilst two coloured lines at both regions C and T indicated a negative result. The absence of coloured lines was an indication of the invalidity of the particular kit, and the kit was discarded.
45648835|NCT05123443|Biological|Blood sample provided|Individuals who consent to provide a blood sample will be included in the cross-sectional genetics study.
45648836|NCT05123443|Diagnostic Test|7-T MRI scan|Individuals who consent to receive an additional 7-T MRI scan will be invited to the Sir Peter Mansfield Imaging Centre. This current MRI will be compared against the baseline 7-T scan performed between 2008 - 2012.
45648837|NCT01597193|Drug|enzalutamide|80 mg (2 capsules) or 160 mg (4 capsules) taken orally daily.
45648838|NCT01597193|Drug|anastrozole|1 mg/day
45648839|NCT01597193|Drug|exemestane|The exemestane dose is 25mg daily.
45648840|NCT01597193|Drug|fulvestrant|500 mg every 28 days
45648841|NCT01597193|Drug|enzalutamide|160 mg (4 capsules) taken orally daily.
45648842|NCT01597193|Drug|exemestane|The exemestane dose is 50 mg daily.
45648843|NCT04920461|Device|Additional MRI sequences|Additional MRI sequences (3D T2 SPACE sequence, 4/5 minutes approximatively)
45648844|NCT04920461|Other|Neuropsychological assessment|Neurovisual function assessed with neuropsychological tests
45648845|NCT04920305|Dietary Supplement|Phosphatidylserine|subjects in the treatment group oral the PS (600mg/d, q.d.) for 6 months.
45648846|NCT04920305|Dietary Supplement|Bean powder|Subjects in the control group were given a placebo, which was the same shape of bean powder(600mg/d, q.d.).
45648847|NCT04930133|Drug|Gilotrif|This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.
45648848|NCT02649439|Biological|PROSTVAC -V|Recombinant Vaccinia Virus Vector Vaccine of the Genus Orthopoxvirus
45795931|NCT00001095|Drug|Indinavir sulfate|
45922150|NCT00019396|Drug|gp100 antigen|
45922151|NCT00019396|Drug|MART-1 antigen|
45449969|NCT02165254|Behavioral|LITE|1 hour tai chi session 3 times a week (weeks 1-12)
45449970|NCT02168920|Drug|2 mg/day|Once daily for 10 weeks
45648849|NCT02649439|Biological|PROSTVAC-F|Recombinant Fowlpox Virus Vector Vaccine of the Genus Avipoxvirus
45648850|NCT04911647|Device|ERCP using plastic stent|Insertion of plastic stent (plastic stent with inner diameter 1.8mm or more) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
45795932|NCT00001095|Drug|Amprenavir|
45795933|NCT00001095|Drug|Nevirapine|
45648851|NCT04911647|Device|ERCP using metal stent|Insertion of metal stent (full covered self-expandable metal stent) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
45648852|NCT03057041|Drug|Fentanyl|100 mcg of intranasal fentanyl, 50 mcg/ mL in each nostril via mucosal atomizer 15 minutes prior to procedure start
45795934|NCT00001095|Drug|Lamivudine|
45795935|NCT00001095|Drug|Stavudine|
45795936|NCT00001095|Drug|Zidovudine|
45795937|NCT02294058|Drug|Ozanimod|Capsules for oral administration once a day
45795938|NCT02294058|Drug|Interferon beta-1a|Administered by intramuscular injection once a week
45922152|NCT00019396|Drug|Montanide ISA-51|
45922153|NCT00019396|Drug|tyrosinase peptide|
45922154|NCT00009828|Drug|leucovorin calcium|
45922155|NCT00009828|Drug|paclitaxel|
45795939|NCT02294058|Drug|Placebo to ozanimod|Matching placebo capsules administered orally once a day
45795940|NCT02294058|Drug|Placebo to interferon beta-1a|Placebo intramuscular injection once a week
45922156|NCT00009828|Drug|tegafur-uracil|
45922157|NCT00019435|Biological|LMB-9 immunotoxin|
45922158|NCT00019474|Biological|filgrastim|
45922159|NCT00019474|Biological|recombinant interferon alfa|
45922160|NCT00019474|Drug|fluorouracil|
45922161|NCT00019474|Drug|hydroxyurea|
45922162|NCT00019513|Drug|fluorouracil|
45922163|NCT00019513|Drug|gemcitabine hydrochloride|
45922164|NCT00019513|Drug|leucovorin calcium|
45922165|NCT05639465|Behavioral|JoH-C19|Journey of Hope- COVID 19 (JoH-C19) includes eight, 1-hour consecutive sessions delivered in groups of 8 children during the school day and in after school settings. The 1.5 hour JoH-C19 caregiver workshop is delivered with groups of 8 parents prior to the child JoH-C19 curriculum
45922166|NCT05639465|Behavioral|Switch off Get Active|Switch off Get Active covers 4 topics, and its eight, 1- hour sessions are delivered in groups of 8 children. The 1.5 hour Switch Off Get Active caregiver workshop is delivered with groups of 8 parents prior to the Switch off Get Active child curriculum
45795941|NCT00002013|Drug|Zidovudine|
45795942|NCT00002013|Drug|AS-101|
45449971|NCT02168920|Drug|3 mg/day|Once daily for 10 weeks
45795943|NCT00380991|Drug|lactoserum|
45449972|NCT02168920|Drug|6 mg/day|Once daily for 10 weeks
45449973|NCT02168920|Drug|Placebo (0 mg/day)|Once daily for 10 weeks
45795944|NCT00359333|Drug|Gemcitabine , Docetaxel|Gemcitabine 800 mg/m2 IV over 80 minutes on day 1 and day 8, and Docetaxel 60 mg/m2 IV over 60 minutes on day 1 of a 21-day cycle
45795945|NCT00001101|Drug|ceftriaxone|
45795946|NCT00001101|Drug|doxycycline|
45795947|NCT04344275|Other|-Scapular endurance test|The resistance of the trapezius and serratus anterior muscles to fatigue was assessed using the scapular muscle endurance test.
45795948|NCT04344275|Other|-Muscle strength test|Upper trapezius (UT), middle trapezius (MT), lower trapezius (LT), and serratus anterior (SA) muscle strengths were tested using a hand-held digital dynamometer (Lafayette Manual Muscle Tester, Model 01165).
45795949|NCT00001107|Drug|Fluconazole|
45795950|NCT00001107|Drug|AmBisome|
45795951|NCT00002019|Drug|Amphotericin B, Lipid-based|
45795952|NCT00002019|Drug|Amphotericin B|
45449974|NCT02171494|Drug|IVAX Warfarin|
45449975|NCT02171494|Drug|BMS Coumadin|
45449976|NCT02165332|Drug|Part 1: SAD RO7033877|Single dose
45449977|NCT02165332|Drug|Part 1: SAD placebo|Single dose
45449978|NCT02165332|Drug|Part 2: Treatment A, RO7033877|Single dose RO7033877 and moxifloxacin placebo
45449979|NCT02165332|Drug|Part 2: Treatment B, RO7033877|Single dose RO7033877 and moxifloxacin placebo
45449980|NCT02165332|Drug|Part 2: Treatment C, moxifloxacin|Single dose moxifloxacin and RO7033877 placebo
45449981|NCT02165332|Drug|Part 2: Treatment D, RO7033877 and moxifloxacin placebo|Single dose moxifloxacin placebo and RO7033877 placebo
45795953|NCT05065619|Biological|MT-2766 High dose (3.75 µg)|Subjects will receive two doses of MT-2766 high dose (3.75 µg) given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
45922167|NCT00019552|Drug|irofulven|
45922168|NCT00009867|Drug|arsenic trioxide|Given IV
45922169|NCT00019591|Biological|aldesleukin|
45449982|NCT02171572|Drug|Dabigatran etexilate low|
45449983|NCT02171572|Drug|Dabigatran etexilate high|
45449984|NCT02168998|Behavioral|Clown|Comparison of routine venipuncture with a distraction technique by a medical clown
45648853|NCT03057041|Drug|placebo|1 mL of sterile saline in each nostril via mucosal atomizer 15 minutes prior to procedure start
45648854|NCT05123287|Drug|PD-1 immune checkpoint blockades|intravenous injection; frequency: 2-3 weeks/cycle; duration: 3 months
45648855|NCT04911569|Device|Cryoneurolysis|Cryoneurolysis
45648856|NCT05123209|Biological|IM83 CAR-T cells|3×10^9 CAR-T cells
45648857|NCT05123209|Combination Product|The second-line treatment of liver cancer|approved by NMPA
45648858|NCT03056807|Other|25° head-up position|Angle person is positioned for procedure.
45648859|NCT03056807|Other|55° head-up position|Angle person is positioned for procedure.
45648860|NCT04377685|Other|CT-Scan|Chest CT scan on admission to the hospital
45795954|NCT05065619|Drug|Placebo|Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
45922170|NCT00019591|Biological|ras peptide cancer vaccine|
45922171|NCT00019591|Procedure|adjuvant therapy|
45922172|NCT00019630|Drug|doxorubicin HCl liposome|
45922173|NCT00019669|Biological|aldesleukin|
45922174|NCT00019669|Biological|fowlpox virus vaccine vector|
45922175|NCT00019669|Biological|gp100 antigen|
45795955|NCT05065619|Biological|MT-2766 Low dose|Subjects will receive two doses of MT-2766 low dose given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
45922176|NCT05639504|Diagnostic Test|IMX-BVN-4 and IMX-SEV-4|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection
45922177|NCT00019708|Drug|tanespimycin|Given IV
45922178|NCT00009906|Drug|Imatinib Mesylate|Given orally
45922179|NCT00019786|Drug|isolated perfusion|
45922180|NCT00019786|Drug|melphalan|
45922181|NCT00019786|Procedure|conventional surgery|
45922182|NCT00019825|Drug|decitabine|
45922183|NCT00019864|Biological|filgrastim|
45922184|NCT00019864|Drug|cisplatin|
45922185|NCT00019864|Drug|dexrazoxane hydrochloride|
45922186|NCT00019864|Drug|doxorubicin hydrochloride|
45648861|NCT03056885|Other|Conventional One-Lung Ventilation|Vt 10 ml/kg
45648862|NCT03056885|Other|Protective One-lung ventilation|Vt 5 ml/kg
45648863|NCT03056105|Other|Residential Insight Meditation Retreat|"Retreats at Spirit Rock Meditation Center were led by teams of 6 experienced teachers. Participants practiced noble silence-refraining from eye contact as well as verbal and written communication-except during meetings with teachers. Teachers lead guided Insight meditation practices, as well as meditations on loving-kindness, compassion, empathetic joy, and equanimity. The daily schedule consisted of sitting and walking meditation sessions (30-45 mins) totaling 8-10 hours/day, meals, and short work meditations (sweeping, dishes, etc.). Seated meditation was practiced as a group in a meditation hall with approximately 80 participants. Walking meditation took place in adjoining halls or on the grounds. Participants lived on-site during the retreat and were provided with a vegetarian diet."
45795956|NCT00001125|Biological|Varicella Virus Vaccine (Live)|
45922187|NCT00019864|Drug|leucovorin calcium|
45922188|NCT00019864|Drug|methotrexate|
45922189|NCT00019864|Procedure|adjuvant therapy|
45922190|NCT00019864|Procedure|conventional surgery|
45922191|NCT00019864|Procedure|neoadjuvant therapy|
45922192|NCT05639621|Procedure|Accompaniment|presence of a person freely chosen by the patient, who will escort in a visual and tactile way during the endoscopic procedure
45922193|NCT00020098|Procedure|evaluation of cancer risk factors|
45922194|NCT00020176|Biological|filgrastim|
45795957|NCT05477381|Diagnostic Test|Measurement of cervical stiffness by Pregnolia Device|"The Pregnolia® System is designed to provide information about the mechanical properties of the cervical tissue by assessing the CSI (Cervical Stiffness Index) through a probe that will create a weak vacuum to retract tissue. The Pregnolia® System is designed with the purpose to provide an alternative diagnostic marker to identify women at risk of spontaneous PTB.~The Pregnolia® System is a CE-marked device developed for quantitative assessment of softening of the uterine cervix.~The Pregnolia® System will be applied within its intended use."
45795958|NCT00002025|Drug|Ganciclovir|
45795959|NCT00001131|Drug|Aldesleukin|Subcutaneous injection of IL-2 in the amount of 2.0 X 10^6 mIU per day for the entire duration of therapy
45795960|NCT00001131|Drug|HAART|Current HAART regimen to be continued for duration of therapy or until certain criteria specified by the study is met
45795961|NCT04331457|Radiation|Brain magnetic resonance imaging (MRI) , computed tomography (CT)|imaging
45449985|NCT04662112|Drug|NASOX|Oxalipatin 60 mg/m2 IV (2 h infusion) on Day 1, every 2 weeks Nal-IRI 50-60 mg/m2 IV (FBE, 90 min infusion) on Day 1, every 2 weeks S-1 40mg/m2 oral twice daily on Day 1-7, every 2 weeks
45449986|NCT03539146|Other|Dietary fiber|Intake of yogurt containing cascara with 0%, 3%, 7%,13% dietary fiber in a crossover design.
45795962|NCT00002031|Drug|Dinitrochlorobenzene|
45922195|NCT00020176|Biological|therapeutic allogeneic lymphocytes|
45922196|NCT00020176|Drug|cyclophosphamide|
45922197|NCT00020176|Drug|cyclosporine|
45922198|NCT00020176|Drug|fludarabine phosphate|
45449987|NCT03539146|Other|Control yogurt|Control yogurt
45648864|NCT03949777|Device|Aer-O-Scope Colonoscopy|resection or biopsy of colonic abnormalities for histopathalogical evaluation
45922199|NCT00020176|Procedure|peripheral blood stem cell transplantation|
45922200|NCT00020254|Biological|aldesleukin|
45922201|NCT00020254|Biological|recombinant fowlpox-prostate specific antigen vaccine|
45922202|NCT00020254|Biological|recombinant vaccinia prostate-specific antigen vaccine|
45922203|NCT00020254|Biological|recombinant vaccinia-B7.1 vaccine|
45922204|NCT00020254|Biological|sargramostim|
45922205|NCT00020254|Drug|nilutamide|
45922206|NCT00009984|Drug|fludarabine phosphate|Given IV
45922207|NCT00009984|Drug|thalidomide|Given orally
45922208|NCT05639660|Other|non-interventional|The treatment guideline recommends the 3+Q2m regimen for Aflibercept, but this study is an observational study, no intervention is made in the subjects' treatment regimen. There is no prescribed visit plan. According to the decision of the doctor and the patient according to the treatment plan, the patient needs to come to the clinic within the prescribed time window (3, 6, and 12 months) to facilitate the recording of data.
45922209|NCT00020332|Drug|alvocidib|
45922210|NCT00020332|Drug|docetaxel|
45922211|NCT00020371|Drug|BMS-247550|
45922212|NCT00020371|Drug|filgrastim|
45922213|NCT00020410|Biological|filgrastim|
45922214|NCT00020410|Procedure|peripheral blood stem cell transplantation|
45922215|NCT00020410|Radiation|yttrium Y 90 monoclonal antibody B3|
45922216|NCT00020449|Biological|recombinant interleukin-12|
45922217|NCT00020449|Drug|paclitaxel|
45922218|NCT00020449|Drug|pegylated liposomal doxorubicin hydrochloride|
45922219|NCT00010023|Drug|capecitabine|
45922220|NCT00010023|Drug|cisplatin|
45922221|NCT00020488|Drug|FOLFIRI regimen|
45922222|NCT00020488|Drug|fluorouracil|
45922223|NCT00020488|Drug|irinotecan hydrochloride|
45922224|NCT00020488|Drug|leucovorin calcium|
45922225|NCT00020527|Drug|caspofungin acetate|
45922226|NCT00020566|Biological|dactinomycin|Given IV
45922227|NCT00020566|Drug|busulfan|Given orally and IV
45922228|NCT00020566|Drug|doxorubicin hydrochloride|Given IV
45922229|NCT00020566|Drug|etoposide|Given IV
45922230|NCT00020566|Drug|ifosfamide|Given IV
45922231|NCT00020566|Drug|melphalan|Given orally and IV
45922232|NCT00020566|Drug|vincristine sulfate|Given IV
45922233|NCT00020566|Procedure|autologous hematopoietic stem cell transplantation|Given IV
45922234|NCT00020566|Procedure|conventional surgery|Given to patients deemed to require it
45648865|NCT03056963|Behavioral|Positive Self-Reference Training|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on positive self-referent material.
45795963|NCT00001155|Drug|cyclophosphamide|
45922235|NCT00020566|Radiation|radiation therapy|Given to patients deemed to require it
45922236|NCT00010062|Drug|fluorouracil|
45922237|NCT00010062|Radiation|radiation therapy|
45922238|NCT00020605|Drug|naloxone hydrochloride|
45922239|NCT00020644|Drug|gemcitabine hydrochloride|
45922240|NCT00020683|Drug|incyclinide|High dose given orally
45922241|NCT00020683|Drug|incyclinide|Low dose given orally
45922242|NCT00020683|Other|laboratory biomarker analysis|Correlative studies
45449988|NCT02169076|Device|Cardiac Resynchronization Therapy|The cardiac resynchronization therapy of the ICD/Pacemaker device of the patients enrolled in the study will be programed under a standardized protocol and enabled or disabled in a crossover fashion during the study.
45449989|NCT02255578|Device|Endobarrier treatment in PCOS|the effect of an EndoBarrier device on fertility and metabolic parameters in obese insulin resistant (IR) PCOS women
45648866|NCT03056963|Behavioral|Neutral Training Control|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on neutral, non-self-referent material.
45922243|NCT05639738|Other|Clinical and instrumental measurements|"Clinical evaluations~Non-invasive instrumental measurements~Subject's evaluations"
45922244|NCT00020761|Drug|irinotecan hydrochloride|"The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks."
45922245|NCT00020761|Drug|paclitaxel|"The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
45922246|NCT00020800|Biological|rituximab|
45922247|NCT00020800|Drug|fludarabine phosphate|
45449990|NCT02255578|Drug|clomiphene citrate treatment|
45449991|NCT02169154|Drug|1% Diclofenac Sodium|1% diclofenac sodium
45449992|NCT02169154|Drug|3% Menthol|3% Menthol
45795964|NCT00002037|Drug|Trifluridine|
45795965|NCT05280587|Device|Technological Rehabilitation|Specific rehabilitation for balance disorder using the robotic platform
45795966|NCT00358631|Drug|SSR149415|
45795967|NCT04714983|Biological|DNX-2440|DNX-2440 is a replication competent oncolytic adenovirus expressing human OX40 ligand.
45795968|NCT05271617|Diagnostic Test|VIDAS® NEPHROCLEAR™ CCL14|Measurement of CCL14 in sample aliquots after being subjected to different testing conditions
45795969|NCT00001197|Drug|Hydroxyurea|
45795970|NCT05270057|Drug|Etoposide|Dose level -2=50 mg/m^2; dose level -1=50 mg/m^2; dose level 1=50 mg/m^2; dose level 2=60 mg/m^2; dose level 3=72 mg/m^2; dose level 4=86.4 mg/m^2; dose level 5=103.7 mg/m^2; dose level 6=124.4 mg/m^2; dose level 7=149.3 mg/m^2
45922248|NCT00020839|Drug|temozolomide|
45922249|NCT00020839|Radiation|radiation therapy|
45922250|NCT05639816|Procedure|Saline irrigation group|Normal saline irrigation of common bile duct after complete stone removal
45922251|NCT00010140|Drug|docetaxel|
45922252|NCT00010140|Drug|epirubicin hydrochloride|
45922253|NCT00010140|Drug|tamoxifen citrate|
45922254|NCT00010140|Procedure|adjuvant therapy|
45922255|NCT00020878|Drug|celecoxib|Dosing will occur for a total of 6 months. 400 mg by mouth twice daily.
45922256|NCT00020917|Biological|cetuximab|
45922257|NCT00020917|Drug|fluorouracil|
45922258|NCT00020917|Drug|irinotecan hydrochloride|
45922259|NCT00020917|Drug|leucovorin calcium|
45922260|NCT00020995|Procedure|therapeutic dietary intervention|
45922261|NCT05639855|Other|Mental Health Literacy Programme|Mental Health Literacy Program. This program is part of the training of third-year students of the occupational therapy degree at the University of A Coruña. We will follow a mixed method following a sequential explanatory design. The quantitative part corresponds to a quasi-experimental study, where a comparison will be made between the phase before and after the students take the program. The qualitative part will comprise a phenomenological study to collect the knowledge acquired by the students after taking the program.
45922262|NCT00021034|Drug|chemotherapy|
45922263|NCT00021034|Drug|taurolidine|
45922264|NCT00010179|Drug|lurtotecan liposome|
45922265|NCT00021073|Drug|alvocidib|Given IV
45922266|NCT00021073|Drug|leucovorin calcium|Given IV
45922267|NCT00021073|Drug|fluorouracil|Given IV
45922268|NCT00021073|Drug|irinotecan hydrochloride|Given IV
45922269|NCT00021112|Drug|cisplatin|
45922270|NCT00021112|Drug|etoposide|
45922271|NCT00021112|Procedure|conventional surgery|
45922272|NCT00021112|Radiation|radiation therapy|
45922273|NCT00000122|Drug|5-Fluorouracil|
45922274|NCT00021151|Biological|alemtuzumab|
45922275|NCT00010218|Drug|karenitecin|
45922276|NCT00021268|Drug|tocladesine|
45922277|NCT00021307|Drug|carboplatin|
45922278|NCT00021307|Drug|temozolomide|
45922279|NCT00000131|Procedure|Photocoagulation Therapy|
45922280|NCT00021346|Drug|carboplatin|
45922281|NCT00021346|Drug|gemcitabine hydrochloride|
45795971|NCT05270057|Drug|Doxorubicin|Dose level -2=10 mg/m^2; dose level -1; dose level -1=10 mg/m^2; dose level 1=10 mg/m^2; dose level 2=12 mg/m^2; dose level 3=14.4 mg/m^17.3 mg/m^2; dose level 4=17.3 mg/m^2; dose level 5=20.7 mg/m^2; dose level 6=24.8 mg/m^2; dose level 7=29.8 mg/m^2.
45922282|NCT00021385|Drug|carboplatin|
45922283|NCT00021385|Drug|squalamine lactate|
45922284|NCT00021424|Biological|recombinant fowlpox-TRICOM vaccine|
45922285|NCT00010335|Procedure|Stem Cell Transplantation|Participants will receive a stem cell transplantation along with irradiation and the drugs anti-thymocyte globulin, cyclophosphamide, and filgrastim as noted in the text of this record.
45648867|NCT04184323|Drug|EX-527 (Selisistat)|EX-527 is a specific inhibitor of the histone deacetylase Sirtuin-1 (SirT1). It is being given to reverse the effects of endometriosis, namely progesterone resistance, that is thought to interfere with the establishment of pregnancy in women with endometriosis
45922286|NCT00010335|Device|CD34 selection|CD34+ cells are separated from the rest of the peripheral blood stem cells.
45648868|NCT04184323|Drug|Placebo|We will use the same vehicle for producing the active drug such as maltose without any hormones or active components
45795972|NCT05270057|Drug|Cyclophosphamide|Dose level -2=480 mg/m^2; dose -1=600 mg/m^2; dose level 1=750 mg/m^2; level 2=900 mg/m^2; level 3=1080 mg/m^2; level 4=1296 mg/m^2; level 5=1555 mg/m^2; level 6=1866 mg/m^2; level 7=2239 mg/m^2.
45922287|NCT00021463|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
45648869|NCT03056027|Diagnostic Test|Ecocolordoppler ultrasound testicular evaluation|Ecocolordoppler ultrasound testicular evaluation
45648870|NCT04165993|Drug|Concurrent chemotherapy and KN026|30 mg/kg Q3W KN026 75 mg/m2 docetaxol
45648871|NCT04165993|Drug|KN026 monotherapy|30 mg/kg Q3W KN026
45648872|NCT04165993|Drug|KN026 combination|30 mg/kg Q3W KN026 5 mg/kg Q3W KN046
45648873|NCT03055949|Behavioral|Early rehabilitation program|The investigators evaluated patients who were admitted SICU for more than 3 days for an early rehabilitation program and delivered one of 5-stepped rehabilitation program if the patient was eligible.
45795973|NCT05270057|Drug|Rituximab|Level -2 through level 7: 375 mg/m^2
45795974|NCT05270057|Drug|Vincristine|Level -2 through level 7: 0.4 mg/m^2/day
45648874|NCT04202107|Other|Food Frequency Questionnaire|Food frequency questionnaires (FFQs) are a common method for measuring dietary intake in large epidemiological studies, in particular in low literacy settings were diaries and food history would not be viable.
45648875|NCT04202107|Other|24 Hour food recall|Standardized and validated approach of collecting all foods, beverages, and supplements consumed during the past 24 hours
45648876|NCT04911413|Drug|Tranexamic acid|The drug used in this RCT is tranexamic acid. We used three different doses of TXA in three groups.
45795975|NCT05270057|Drug|Prednisone|Level -2 through level 7: 60 mg/m^2/twice daily (BID)
45922288|NCT00021463|Drug|Abacavir sulfate|
45922289|NCT00021463|Drug|Efavirenz|
45922290|NCT00021463|Drug|Nevirapine|
45922291|NCT00021502|Drug|pyridoxalated hemoglobin polyoxyethylene conjugate (PHP)|
45922292|NCT00000134|Drug|Ganciclovir|intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
45922293|NCT00000134|Drug|Foscarnet|intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
45922294|NCT00021580|Procedure|human cadaveric islet cell transplantation|
45449993|NCT02169154|Drug|0.09% Menthol|0.09% Menthol
45795976|NCT05270057|Drug|Loncastuximab Tesirine 0.075 mg/kg by IV|Cohort 1: 0.075 mg/kg by IV. The dose-expansion phase will use the maximum-tolerated dose.
45795977|NCT05270057|Drug|Loncastuximab tesirine 0.12 mg/kg by IV|Cohort 2: 0.12 mg/kg by IV. The dose-expansion phase will use the maximum-tolerated dose.
45795978|NCT05270057|Drug|Loncastuximab tesirine 0.15 mg/kg by IV|Cohort 3: 0.15 mg/kg by IV The dose-expansion phase will use the maximum-tolerated dose.
45795979|NCT00002043|Drug|Dapsone|
45922295|NCT00010413|Drug|cyclophosphamide|
45922296|NCT00010413|Drug|filgrastim|
45449994|NCT02169154|Drug|0.2% Sodium Lauryl Sulfate|0.2% Sodium Lauryl Sulfate
45449995|NCT02169154|Drug|0.9% Saline|0.9% Saline
45922297|NCT00021658|Procedure|Pesticide application procedures|
45922298|NCT00021697|Drug|AVP-923|
45922299|NCT00394615|Procedure|Metabolic Imaging|
45922300|NCT00000137|Procedure|Histocompatibility Matching|
45922301|NCT00010452|Drug|picibanil|Up to .2 mg per injection, given intralesionally every 6-8 weeks
45922302|NCT00394693|Genetic|Adenovirus Interferon gamma|intra-tumoral injections, 1 dose per lesion, up to 6 simultaneous lesions.
45922303|NCT00394732|Device|Total Disc Prosthesis|
45922304|NCT00394732|Behavioral|Multidisciplinary rehabilitation program|
45922305|NCT00394810|Drug|Panzem® NCD|suspension, 100 mg/mL, four times daily continuous dosing
45922306|NCT00000140|Drug|Perfluoropropane|
45922307|NCT00000140|Drug|Sulfur Hexafluoride|
45922308|NCT00000140|Drug|Silicone Oil|
45922309|NCT00021736|Drug|EYE001 anti-VEGF aptamer|
45922310|NCT00010491|Procedure|Acupuncture|
45922311|NCT00010491|Procedure|Moxibustion|
45922312|NCT00388544|Behavioral|Activity matched to interest|Recreational activities are tailored to subject's style of interest
45922313|NCT00388544|Behavioral|Activity matched to function|Recreational activities are tailored to subjects physical and cognitive functioning
45922314|NCT00388544|Behavioral|Activity matched to both interest and function|Recreational activities are tailored to both style of interest and physical and cognitive functioning.
45922315|NCT00021814|Drug|Doxazosin|
45922316|NCT00021814|Drug|Finasteride|
45922317|NCT00021814|Drug|Doxazosin placebo|
45922318|NCT00021814|Drug|Finasteride placebo|
45922319|NCT00019318|Drug|romidepsin|
45922320|NCT00021853|Behavioral|constraint-induced movement therapy|
45922321|NCT00388622|Behavioral|Pharmacist intervention|
45922322|NCT00022009|Drug|gemcitabine hydrochloride|
45922323|NCT00388661|Drug|Melatonin tablet 3 mg once daily|Melatonin tablet 3 mg once daily
45922324|NCT00388661|Drug|Placebo comparator|Placebo comparator
45922325|NCT00022048|Biological|bevacizumab|
45922326|NCT00022087|Dietary Supplement|calcium salts|1000 mg PO per day
45922327|NCT00022087|Dietary Supplement|cholecalciferol|400 IU PO per day
45449996|NCT02169232|Device|Videolaryngoscope|
45449997|NCT02169232|Device|Fiberoptic|
45449998|NCT05142670|Procedure|experimental group: task-oriented training individualized by the gravity perception|All participants received 50 minutes of physical therapy per session for 5 days per week for 8 weeks. Subjects in the experimental group underwent 20 minutes of task-oriented training individualized by the gravity perception following 30 minutes of regular physical therapy. All outcome measurements were evaluated on the day before intervention (pretraining), 4 weeks and 8 weeks after training by the same physical therapist (who was blinded to the group of the subjects). These regular protocols including preparatory techniques, mat activity, sitting, standing, and walking training.
45922328|NCT00022087|Drug|zoledronic acid|4 mg IV infusion q 3 months, months 1-24 in Zoledronic acid initial tx arm and months 13-36 in calcium + vit D initial tx arm
45922329|NCT00388700|Drug|GM-CT-01|On Day 1 and 2 of each cycle, GM-CT-01 280 mg/m2 administered IV over 30 minutes with 5-FU (400 mg/m2), followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) with 5-FU (600 mg/m2 .)
45795980|NCT00001209|Drug|vincristine, adriamycin and cytoxan, alternating with ifosfamide VP-16|
46071775|NCT05878379|Behavioral|Dietary Iron Program|"Teachers Lesson 1: Discuss about causes, prevention and effects of anemia and ID, dietary iron, dietary enhancers and inhibitors of iron absorption, and school lunch menu Lesson 2: Participate in and observe how to teach children in an iron curriculum~Caregivers Lesson 1: Presentation and group talk about causes, prevention, and effects of anemia and ID, dietary iron, and dietary enhancers and inhibitors of iron absorption Lesson 2: Discuss benefits and barriers of changing to an iron-rich meal at home Lesson 3: Cooking class for preparing an iron-rich meal at home (2 times) Lesson 4: Home visit~Children Lesson 1: Group talk about causes and effects of anemia and ID Games: Where are you from? Lesson 2: Presentation and group talk about dietary iron, and dietary enhancers and inhibitors of iron absorption, and iron-rich food Games: What is the winner? Assignment: Market assignment Lesson 3: Cooking class (2 times)"
46071776|NCT05878366|Other|Seasonal Malaria Chemoprophylaxis (under 5 year old) implemented by the MoH without DOT|Standard approach for SMC strategy used by the Ministry of Health (without directly-observed therapy) and without any interference of the study team. Implemented over 4 rounds, carried out in June-October 2023 with ~30 days between rounds.
45449999|NCT05142670|Procedure|control group: visual feedback treatment|Subjects in the control group underwent 20 minutes of visual feedback (VF) treatment. The regular physical therapy protocols for the control group were the same as those used for the experimental group. These regular protocols including preparatory techniques, mat activity, sitting, standing, and walking training.
45795981|NCT00001239|Drug|FLAC with GM-CSF|
45795982|NCT00002049|Drug|Thymopentin|
45795983|NCT05044637|Drug|Primaquine|7 days of unsupervised primaquine (3.5 mg/kg total dose) administered once per day (0.5 mg/kg OD).
45922330|NCT00388700|Drug|5-Fluorouracil, Leukovorin, bevacizumab|On Day 1 and 2 of each cycle, LV (200 mg/m2) will be administered IV over 2 hours, followed by 5-FU 400 mg/m2 in solution with GM-CT-01 280 mg/m2 administered over 30 minutes, followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) and 5-FU (600 mg/m2 ). on Day 3 Avastin® (5 mg/kg)will be given IV over 30 to 90 minutes per the package insert.
45450000|NCT00100048|Drug|Comparator: MK0518 monotherapy|MK0518 twice daily for 10 days
45450001|NCT00100048|Drug|Comparator: MK0518 combination therapy|MK0518 twice daily for 48 weeks
45450002|NCT00100048|Drug|Comparator: efavirenz|efavirenz 600 mg every night at bedtime for 48 weeks
45648877|NCT04911725|Device|Elastic Compression Prototype|Elastic Compression device - No medical, surgical or laboratory procedure is implied in the use of the IMD.
45648878|NCT04929665|Procedure|Two different block and combination of these two blocks|Thoracic paravertebral block, erector spina block, and a combination of paravertebral block and erector spinae block will be applied to the patients under real-time ultrasound guidance.
45754375|NCT03586466|Drug|Buprenorphine/naloxone|Subjects will be given buprenorphine/naloxone as a component of Medication Assisted Treatment (MAT).
45754376|NCT03586466|Other|MEMS|Subjects will receive their medication in a MEMS pill bottle.
45754377|NCT00570349|Drug|Nitric Oxide for Inhalation|Nitric oxide will be administered at 20 ppm via nasal cannula over a 44 hour period.
45795984|NCT05044637|Drug|Primaquine|7 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (1.0 mg/kg OD).
45795985|NCT05044637|Drug|Primaquine|14 days of unsupervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
45795986|NCT05043077|Drug|Microdrop administration of phenylephrine 1.67% and tropicamide 0.33%|1 drop (6.5 μL) for 3 doses with 5-minute intervals
45795987|NCT05043077|Drug|Standard drop administration of phenylephrine 1.67% and tropicamide 0.33%|1 drop (28-34 μL) for 3 doses with 5-minute intervals
45795988|NCT00002055|Drug|Pentamidine isethionate|
45795989|NCT00001269|Drug|IL-3|
45922331|NCT00022126|Drug|asparaginase|
45922332|NCT00022126|Drug|cyclophosphamide|
45922333|NCT00022126|Drug|cyclosporine|
45922334|NCT00022126|Drug|cytarabine|
45922335|NCT00022126|Drug|daunorubicin hydrochloride|
45922336|NCT00022126|Drug|dexamethasone|
45922337|NCT00022126|Drug|doxorubicin hydrochloride|
45922338|NCT00022126|Drug|mercaptopurine|
45922339|NCT00022126|Drug|methotrexate|
45922340|NCT00022126|Drug|methylprednisolone|
45922341|NCT00022126|Drug|pegaspargase|
45922342|NCT00022126|Drug|thioguanine|
45922343|NCT00022126|Drug|vincristine sulfate|
45922344|NCT00022126|Procedure|allogeneic bone marrow transplantation|
45922345|NCT00022126|Radiation|radiation therapy|
45922346|NCT00010530|Procedure|Meditation|
45922347|NCT00022165|Dietary Supplement|selenium|
45922348|NCT00022204|Dietary Supplement|vitamin E|
45922349|NCT00022204|Drug|pentoxifylline|
45922350|NCT00022204|Procedure|quality-of-life assessment|
45922351|NCT00388739|Drug|Intervention: Budesonide|Patients 1-5 years of age who are randomly assigned to the treatment arm will be given a one month supply as well as a prescription (for a 6 month supply) for Pulmicort respules (children with mild persistent disease will receive 0.25 mg bid whereas children with moderate or severe persistent disease will receive 0.5 mg bid).
45922352|NCT00388739|Drug|Usual care: albuterol + systemic steroids|All children (control and treatment arm) will be given a burst dose of steroids (4 days of prednisone, 1mg/kg/dose to a maximum of 40 mg/dose to be given twice a day) at discharge from the ED. All children 1-5 years of age will also receive standardized discharge medication instructions for using albuterol nebulizer treatments: they will receive a prescription for 2.5mg of albuterol in 3cc Normal Saline for aerosol use via compressor every 3 times a day as a chronic care regimen if they are either in the treatment arm and 1-5 years of age or if they are in the control group and already own a nebulization compressor.
45922353|NCT00022243|Drug|batabulin sodium|
45922354|NCT00010608|Behavioral|Transcendental Meditation|a mantra meditation technique which originated from the Vedic tradition of India. It is practiced from 20 minutes twice a day sitting comfortably in a chair with eyes closed.
45922355|NCT00010608|Behavioral|Health Education|didactic education classes for lifestyle modification through diet, exercise, substance use control, and salt intake
45922356|NCT00022282|Drug|shark cartilage extract AE-941|
45450003|NCT00100048|Drug|Comparator: tenofovir|tenofovir 300 mg daily for 48 weeks
45648879|NCT04911179|Other|Vivfrail-Cog combined multicomponent physical exercise and cognitive stimulation.|"The areas to be worked on are: Attentional system: selective attention and concentration; alternating attention / dual attention; Processing speed; perceptual organization; working memory and cognitive flexibility; comprehension, abstraction and verbal reasoning, planning, execution, and problem solving.~Four programs have been developed stimulation different difficulty levels to adapt to the capabilities of each participant."
45648880|NCT04095559|Diagnostic Test|multipolar mapping catheter|mapping of the left atrium will be performed in sinus rhythm using the IntellaMap Orion multipolar mapping catheter (Boston Scientific).
45648881|NCT04095559|Diagnostic Test|multielectrode circular catheter|mapping of the left atrium will be performed using the multielectrode circular catheter (Lasso, spacing 2-6-2 mm, Biosense Webster)
45795990|NCT05465369|Other|giomer|injectable flowable Giomer composites is a material used for direct filling techniques has been developed over the past years. It has the property of Giomer technology that able to release and recharge fluoride and other beneficial ions for the life of the restoration and induce remineralization of the underlying hard dental tissues . Injectable flowable Giomer composite (Beautifil flow plus x) has a long-term clinical performance like conventional composite., it also aids in decrease acid production and formation of antiacid resistant layer, help in reduction of tooth mineral solubility also it has high survival rate and wear resistance in high stress bearing areas in posterior teeth Beautifil Flow Plus X also helps to remineralise the tooth structure for sustainable caries prevention and easily polishes for long-lasting luster
45804100|NCT05717569|Drug|Vitamin D|o Fibroscan: as a non-invasive imaging study for measuring liver cirrhosis by transducer probe-induced elastic share wave that propagates through liver tissue to measure its velocity. It is a promising non-invasive method for detection of cirrhosis in patients with chronic liver disease. Therefore, fibroscan can be used regarding the decision of treatment and follow-up of patients with cirrhosis for screening and detection of the complications . In our study the investigators will assess liver fibrosis before and after vitamin D therapy using fibroscan.
45922357|NCT00022321|Drug|gemtuzumab ozogamicin|
45922358|NCT00022360|Drug|taurolidine|
45922359|NCT00010647|Procedure|Acupuncture|
45922360|NCT00022399|Drug|celecoxib|400mg PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
45922361|NCT00022399|Drug|Placebos|Placebo PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
45922362|NCT00000143|Device|Ganciclovir implant and oral ganciclovir|oral ganciclovir, 1 gm three times daily
45922363|NCT00000143|Drug|Cidofovir intravenous|intravenous, 5 mg/kg once weekly for two doses, followed by 5 mg/kg every other week
45922364|NCT00022438|Biological|aldesleukin|
46071777|NCT05878366|Other|Seasonal Malaria Chemoprophylaxis (under 5 years old) with DOT|SMC will be implemented with the same number of rounds and the same timing as in active comparator arm but village health workers will visit the participants at home to administer each dose of study treatment (with DOT-directly-observed therapy)
45648882|NCT04095559|Diagnostic Test|irrigated ablation catheter|mapping of the left atrium will be performed using the irrigated ablation catheter (IntellaNav Mifi OI)
45648883|NCT04919915|Device|HEPA air cleaner|Participants in the intervention group received two HEPA air cleaners per household. They were informed to place the HEPA air cleaners in the child's bedroom and the living room. Field staff provided and discuss how to use the air cleaner which promoted continuous operation of both air cleaners, keeping the child's bedroom door closed, and selected the highest fan speed. Typical use of the HEPA cleaners were questioned during the mid-study and final visits.
45648884|NCT03830203|Drug|BAT1806|8 mg/kg
45922365|NCT00022438|Biological|incomplete Freund's adjuvant|
45922366|NCT00022438|Biological|recombinant tyrosinase-related protein-2|
45450004|NCT00100048|Drug|Comparator: lamivudine|lamivudine 300 mg daily for 48 weeks
45450005|NCT00100048|Drug|Placebo monotherapy|Placebo to MK0518 twice daily
46071778|NCT05878366|Other|Seasonal Malaria Chemoprophylaxis (under 10 years old) with DOT|SMC will be implemented as in arm 2 but age of participants is extended up to 10 years: each dose of study treatment (with DOT-directly-observed therapy) distributed at home by village health workers.
45648885|NCT03830203|Drug|Actemra(EU-licensed)|8 mg/kg
45922367|NCT00022477|Drug|BMS-247550|
45922368|NCT00010686|Drug|Dietary Phytoestrogens|
45450006|NCT02171650|Drug|BIBW 2992|
45648886|NCT03668587|Other|Troponin Protocol|Feasibility and security of a rapid rule-out and rule-in troponin protocol in the management of NSTEMI in an Emergency Departement.
45795991|NCT05465369|Other|high viscosity glass ionomer|High viscous glass ionomer, the most suitable restorative material for ART procedure and can be used outside the dental clinic, which increases the opportunity for dental care , using a high-viscosity glass-ionomer as an ART sealant in both primary and permanent posterior teeth have a high caries preventive effect High viscosity glass ionomer (EQUIA Fil) has new technology involves ultrafine, and highly reactive glass diffused within the glass-ionomer fillers to increase and enhance matrix formation. This system allows ion availability and builds a stronger matrix structure with greater physical properties, wear resistance and fluoride release. Mechanical properties and fluoride release is the most important features to evaluate glass ionomer restorative material and it's proven that EQUIA Fil fulfilled all these requirement
45922369|NCT00022555|Drug|bryostatin 1|Given IV
45922370|NCT00022555|Drug|vincristine sulfate|Given IV
45922371|NCT04733287|Other|High Intensity Interval Training of the Knee Extensors|"Subjects will perform intense, single leg knee extension exercise 3 times a week for 6 weeks. Specifically, subjects will be seated in a custom knee extension ergometer and perform single leg, dynamic knee extension (similar to single leg cycling) as they perform the exercise. After a 6 minute warm-up at ~20% of that leg's maximum aerobic power (determined during a graded exercise test of single leg knee extension), subjects will perform 4 bouts of 4 minutes at ~80% of maximum aerobic power. Recovery of 4 minutes at ~40% will occur between each bout of exercise. A cool down will be provided at the end of exercise. In total, subjects will perform 40 minutes of single leg knee extension exercise, 3 times a week for 6 weeks.~Maximum aerobic power (determined by a graded exercise test) will be determined again at 3 weeks to appropriately adjust the training intensity."
45795992|NCT05031455|Drug|Aspirin Challenge|"Dupilumab is a fully human monoclonal antibody that blocks the receptor component for IL-4 and IL-13, which are key drivers of type 2 inflammation. All subjects will be prescribed this at standard 300mg subcutaneous dosing every 2 weeks. The intervention will be the response to aspirin challenge.~8 of 16 subjects will randomly receive dupilumab. All subjects will undergo an aspirin challenge/desensitization procedure. To achieve adequate steady state levels of dupilumab, the dosing regimen will be a 600mg loading dose of dupilumab followed by 300mg subcutaneous at 1 week, 3 weeks and 5 weeks. Aspirin challenge/desensitization will take place at week 6 after dupilumab loading dose."
45795993|NCT00380601|Drug|MRA(Tocilizumab)|8mg/kg/4 weeks
45795994|NCT05029973|Drug|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
45922372|NCT04733287|Other|Muscle Heat Therapy|Subjects will receive muscle heat therapy on the knee extensor muscles (short-wave diathermy) for 120 minutes for each visit. Specifically, subjects will lie supine while short-wave diathermy units (Megapulse II) will be placed on the quadriceps femoris and turned on to 800 pulses per second with a pulse duration of 400 microseconds. Our previous research (e.g. Hafen et al 2018- Repeated exposure to heat stress...) has indicated that this treatment raises muscle temperature to ~39C, a similar temperature induced by exercise.
45795995|NCT05029973|Drug|Sintilimab|200mg IV d1,Q3W
46071779|NCT05878353|Procedure|Decontamination of the pocket with local doxycycline|Gentle debridement will be performed under local anesthesia (mepivacain 2% 1:1000) for a time of 5 minutes by mean of ultrasonic devices by the same experienced clinician. Great attention will be made to avoid marginal and interproximal soft tissue damage. Local doxycycline was administered according to the manufacturer's instruction. Briefly, the plastic needle of the syringe will be inserted into the sulcus and the product will be progressively released in the periodontal pocket up to the gingival margin. The syringe will be then removed and a cotton pellet used to compact the gel into the sulcus. Patients will be then instructed not to floss or use interdental brushes in that area for the following 10 days.
45795996|NCT05029973|Drug|Bevacizumab Biosimilar|7.5mg/kg IV d1,Q3W
45795997|NCT00002061|Drug|Inosine pranobex|
45795998|NCT00380679|Biological|Influenza vaccination|
45795999|NCT00380679|Biological|Pneumococcal polysaccharide vaccination|
45796000|NCT05443451|Device|3D-Ultrasound-Guided Transperineal Microwave needle ablation of BPH|The procedure will consist of a focal, transperineal, targeted microwave ablation of prostate adenoma. Surgical planning using 3D transrectal ultrasound and real-time monitoring of the ablation would preserve key anatomical landmarks such as the bladder neck, prostatic urethra and verumontanum. The Organ-Based Tracking (OBT®) patented technology would provide a 3D prostate model to facilitate real-time navigation-guided ablation and accurate mapping of treatment zone. The procedure will be conducted under general anaesthesia, spinal anaesthesia, or monitored anaesthetic care / sedation. An average number of one to three microwave ablations per lobe is expected, depending on the size and shape of each prostate. The microwave ablation parameters will be chosen intraoperatively. A urinary catheter may be necessary immediately after the procedure. Patients are planned to be discharged on the same day or the day after when they are fit for discharge.
45648887|NCT03889795|Drug|Metformin|Metformin oral pill will be taken daily at breakfast (cohort 1) and breakfast and dinner (cohort 2 and 3).
45648888|NCT03889795|Drug|Simvastatin|Simvastatin oral pill will be taken daily in the evening.
45648889|NCT03889795|Drug|Digoxin|Digoxin oral pill will be taken daily in the morning.
45648890|NCT02622113|Drug|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 36 weeks
45796001|NCT00002067|Drug|Megestrol acetate|
45796002|NCT05442983|Drug|PanCytoVir™ (probenecid)|Active drug
45796003|NCT05442983|Drug|Placebo|Matching placebo
45648891|NCT02622113|Drug|Insulin|
45648892|NCT04920227|Procedure|phacoemulsification;|Group A: class combined with phacoemulsification
45754378|NCT00570349|Drug|Nitric Oxide for Inhalation|Nitric oxide will be administered at 40 ppm via nasal cannula over a 44 hours period.
45796004|NCT00380757|Procedure|bystander CPR using 30:2 ratio vs 15:2 ratio|Participants will use 2 CPR techniques with different chest compression to ventilation ratios
45796005|NCT05020535|Drug|MW189|MW189 (0.25 mg/kg) is administered within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
45796006|NCT05020535|Other|Saline|Administration of saline within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
45796007|NCT00380835|Drug|Amrubicin|
45648893|NCT03860155|Biological|allo-APZ2-ACLF|Administration of 2 x 10e6 allogeneic ABCB5-positive stem cells/kg bodyweight, each at Day 0, Day 5 (±1) and Day 13 (±1) into peripheral vein (arm) intravenously with a flow rate of 1-2 ml/min. Infusion of the product via a central venous catheter (CVC), a Port-a-Cath (Port) or a similar catheter is also possible. Allo-APZ2-ACLF will be in a concentration of 1 x 10e7 cells/mL in Human Serum Albumin/Ringer-Lactate/Glucose (HRG)-solution.
45648894|NCT04430777|Drug|Tranexamic acid|Administration of tranexamic acid 1 gr either intravenously or subcutaneously
45648895|NCT04929587|Other|This is a observational research, there is no intervention|This is a observational research, there is no intervention
45922373|NCT04733287|Other|Muscle Disuse|Subjects will undergo 2 weeks of limb immobilization (a model of muscle disuse). Specifically, a knee brace will be placed on one of the subjects' legs and bent to a flexion of 60 degrees to prevent the foot from touching the ground while standing. Subjects will given a pair of crutches and asked to ambulate on crutches for 2 weeks, avoiding bearing any weight with the immobilized leg.
45922374|NCT04733287|Other|Sham Heat Therapy|Specifically, subjects randomly assigned to the sham group will receive the same treatment as the heat group (same number of visits and set up with the heating units applied to leg for 2 hours each visit) except, unbeknownst to either group, the heating units will never be turned on for the sham group.
45648896|NCT04910789|Procedure|transhiatal/transabdominal approach|Radical surgery should be finished via transhiatal/transabdominal approach
45648897|NCT04910789|Procedure|thoracoabdominal approach|Radical surgery should be finished via thoracoabdominal approach
45796008|NCT00001311|Device|heparin-surface modified intraocular lens|
45648898|NCT02651467|Other|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|1.5% w/w KOX, 0ppm F, pH 7.0
45648899|NCT02651467|Other|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|2.0% w/w KOX, 45ppm F, pH 4.5
45648900|NCT02651467|Other|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|0% w/w KOX 0ppm F, pH 4.5
45648901|NCT04910477|Drug|Dexmedetomidine|ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.
45648902|NCT04910477|Drug|Neostigmine/atropine|nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.
45648903|NCT04910477|Other|Saline placebo|nebulization of saline placebo in 4 ml) twice daily for three days.
45796009|NCT05016713|Combination Product|Chlorhexidine mouthwash|"Chlorhexidine mouthwash is added to the oral hygiene protocol being used beside fluoride-based toothpaste and interdental brushes. CHX mouthwash is used by patients according to the manufacturer's instructions 15 min after tooth-brushing: 5 mL of 0.2% CHX was applied for 60s in the morning and at bedtime. The patients will be instructed not to consume any liquid or food at least 30 min after using the prescribed mouthwash. All patients are asked to bring the mouthwash bottle, so we could determine patient compliance based on how much liquid was left.~If any participant shows any signs of CHX hypersensitivity, the intervention will be discontinued."
45796010|NCT05016713|Device|Interdental brush|Fluoride-based toothpaste is used for tooth-brushing beside using interdental brushes.
45796011|NCT05016713|Other|Fluoride-based toothpaste|Regular tooth-brushing is carried out using fluoride-based toothpaste supplied only.
45648904|NCT03487705|Other|electromyographic essential tremor|"Making a recording electromyographic recording of the essential tremors in each child included at prospective.~Collect an electromyographic recording of essential tremors already made in each child included at retrospective."
45648905|NCT04431089|Drug|SHC014748M|Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
45648906|NCT02468245|Behavioral|weekly telephone follow up|For the study group, at the initial education visit, a time for each phone call that is convenient for the patient will be scheduled. At each phone call, the OCN will get a pill count and discuss reasons for missed doses if applicable; grade any AE's experienced and interventions for those side effects; and answer any questions or concerns that they patient may be having. Patients will then return for the standard 4 week clinic visit.
45648907|NCT02468245|Behavioral|usual care|The control group will receive the standard chemotherapy education and will return for the standard 4 week follow up clinic visit.
45648908|NCT04910555|Other|strong desire to void - cognitive task|Strong desire to void - cognitive task (verbal fluency)
45796012|NCT00002073|Drug|Epoetin alfa|
45796013|NCT00001317|Drug|interferon-gamma|
45796014|NCT00001335|Drug|ADR-529|
45796015|NCT00001335|Drug|Topotecan|
45796016|NCT00001335|Drug|G-CSF|
45796017|NCT05443529|Other|Adaptive sports|Participation in community adaptive sports programs
45796018|NCT00001353|Drug|Genetically Marked Syngeneic T Lymphocytes|
45922375|NCT00000146|Drug|Methylprednisolone|
45922376|NCT00000146|Drug|Prednisone|
45922377|NCT00010725|Drug|MAK|
45922378|NCT00010725|Drug|Vitamin Supplements|
45922379|NCT00022594|Drug|liposomal lurtotecan|
45922380|NCT00000149|Drug|Beta Blocker|
45922381|NCT00000149|Procedure|Trabeculectomy|
45922382|NCT00000149|Procedure|Argon Laser Trabeculoplasty|
45922383|NCT00394849|Procedure|suture one tonsillar fossa|one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
45922384|NCT00010764|Procedure|Acupuncture|
45922385|NCT00022711|Drug|temozolomide|150 mg/m2/day Repeat cycles every 28 days following first daily dose of each cycle until toxicity or disease progression for a maximum of six months
45922386|NCT00010842|Drug|Ginkgo biloba|
45922387|NCT00010842|Drug|Alpha-lipoic acid|
45648909|NCT03104569|Procedure|Injection of 37℃ contrast agent|Nonionic contrast agent is heated to 37℃ in a incubator when injection of contrast agent
45648910|NCT04910633|Other|COCA is an observational study based on retrospective data issued from patient medial file.|"The following parameters will be collected from the medical files of the patients involved in this study:~Age~Gender~Cancer type~Cancer Stage~Cancer Treatment~COVID-19 severity (based on chest X-Ray damage. Low ≤25%, Middle: between 25-50%, High above 50%)~Living Status~Attribution of Mortality to COVID status~Comorbidities"
45922388|NCT00010842|Drug|Vitamin E/Selenium|
45922389|NCT00010842|Drug|Essential fatty acids|
45922390|NCT00000152|Drug|Aspirin|
45922391|NCT00000152|Drug|Beta-Carotene|
45922392|NCT00022750|Behavioral|Nurse Case Manager and Community Health Worker Team|
45648911|NCT05099419|Device|Repetitive Transcranial Magnetic Stimulation|"rTMS uses pulses of magnetic energy to non-invasively stimulate the brain. The rTMS device to be used in this study is the Magstim Rapid2 Plus1. The rTMS device is connected to an active figure-of-eight coil which rests against the scalp and delivers the magnetic energy to the brain. The rTMS protocol is specified by the parameters of pulse frequency, duration of continuous pulse delivery, intensity, and stimulation location.~Each participant will receive two different standard rTMS protocols that have been used in past research studies for modulation of pelvic floor tone delivered over the motor cortex in an area that is known to control pelvic floor muscles."
45648912|NCT04919603|Behavioral|Enhanced physical activity intervention|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
45648913|NCT04919603|Behavioral|Standard education|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on diabetes prevention according to < Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition)
45796019|NCT00002079|Drug|Butyldeoxynojirimycin|
45796020|NCT00002079|Drug|Zidovudine|
45796021|NCT05240339|Other|Observation of minor phenomena|observation twice a year over 3 years
45796022|NCT00002085|Drug|Azithromycin|
45796023|NCT05430269|Other|Faecal bacteriotherapy (FBT)|Enema of 350 ml of standardised mixed transplantate prepared from faeces of 7 healthy donors.
45796024|NCT05430269|Other|standard-of-care protocolised treatment of postantibiotic diarhea|standard-of-care protocolised treatment of postantibiotic diarhea
45796025|NCT00001383|Drug|PSC 833|
45796026|NCT00001383|Drug|paclitaxel|
45922393|NCT00022828|Device|3-D Laser Imaging Device|
45922394|NCT00010881|Drug|antioxidants|
45796027|NCT05231369|Biological|ChulaCov19 BNA159 mRNA vaccine|ChulaCov19 BNA159 mRNA vaccine is the lipid nanoparticles (LNPs)-encapsulated mRNA-based ChulaCov19 vaccine
45796028|NCT00359489|Device|cardiac echosonography|
45796029|NCT00002091|Drug|Pentoxifylline|
45804101|NCT05717491|Other|Biological analysis, Physical examination and Questionnaires|Biological analysis, Physical examination and questionnaires will be performed for all patients of the main group.
45804102|NCT05717491|Other|Physical examination and Questionnaires|In addition to exams for the main group, there will be 2 additional examinations (bone densitometry and arterial stiffness) for the patients of the subgroup and others questionnaires.
45922395|NCT00010881|Behavioral|stress reduction|
45922396|NCT00022867|Drug|Nondigestible oligosaccharide (NDO)|
45922397|NCT00022906|Drug|Iodine-131 Anti-B1 Antibody|
45922398|NCT00022945|Drug|Iodine-131 Anti-B1 Antibody|
45922399|NCT00022945|Drug|Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)|
45922400|NCT00010920|Drug|Ginkgo Biloba Extract|
45922401|NCT00000158|Procedure|Argon Blue-Green Laser Photocoagulation|
45922402|NCT00023218|Drug|Lopinavir/Ritonavir|
45922403|NCT00023218|Drug|Efavirenz|
45922404|NCT00394966|Drug|SCH 619734 Dose 1|SCH 619734 10 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
45922405|NCT00394966|Drug|SCH 619734 Dose 2|SCH 619734 25 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
45922406|NCT00394966|Drug|SCH 619734 Dose 3|SCH 619734 100 mg (2 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
45922407|NCT00394966|Drug|SCH 619734 Dose 4|SCH 619734 200 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
45922408|NCT00394966|Drug|Placebo|Matching placebo x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
45922409|NCT00000170|Drug|Atropine|Atropine
45922410|NCT00000170|Device|Eye Patch|Patching
45922411|NCT00395122|Device|Retinal nerve fiber layer and macular thickness measurements|
45922412|NCT02024607|Drug|BBI608|
45922413|NCT02024607|Drug|Fluorouracil|
45922414|NCT02024607|Drug|Oxaliplatin|
45922415|NCT02024607|Drug|Leucovorin|
45922416|NCT02024607|Drug|Irinotecan|
45922417|NCT02024607|Drug|Bevacizumab|
45922418|NCT02024607|Drug|Capecitabine|
45922419|NCT02024607|Drug|Regorafenib|
45922420|NCT00023296|Drug|Nitric Oxide|
45922421|NCT00023296|Device|INO Pulse - NO Delivery System|
45922422|NCT00023335|Drug|Rifapentine|
45922423|NCT00023335|Drug|Isoniazid|
45922424|NCT00000173|Drug|Donepezil|
45922425|NCT00000173|Drug|Vitamin E|
45922426|NCT00023374|Drug|Rifampin|6mos REZ intermittent
45922427|NCT00023374|Drug|Pyrazinamide|6mos REZ intermittent
45922428|NCT00023374|Drug|Ethambutol|6mos REZ intermittent
45922429|NCT00023374|Drug|REZ|Rif+PZA+EMB given 2 or 3 times weekly for 6 months
45922430|NCT00023413|Drug|Rifabutin|
45922431|NCT00023413|Drug|Efavirenz|
46071780|NCT05878353|Procedure|Decontamination of the pocket with mechanical instrumentation|Gentle debridement will be performed under local anesthesia (mepivacain 2% 1:1000) for a time of 5 minutes by mean of ultrasonic devices by the same experienced clinician. Great attention will be made to avoid marginal and interproximal soft tissue damage.
45450007|NCT02165566|Drug|Regular-insulin|patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
45450008|NCT02165566|Drug|Lispro-insulin|patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
45648914|NCT05092633|Device|Miniscrew|Application of laser on miniscrew
45648915|NCT04929275|Procedure|Enhanced recovery program|12 items of program (preoperative, peroperative postoperative) according to the enhanced recovery after surgery society
45648916|NCT04929353|Other|Systematic symptom assessment|"Systematic symptom assessment~Conventional symptom assessment"
45804103|NCT05716633|Diagnostic Test|MRI|Serial MRI scans will be performed starting at day 15 from date of pain. Subsequent scans will be performed at 5 days interval till the clinically significant encapsulation (for all the collections in an individual patient) is seen.
45804104|NCT02385097|Drug|Chloroprocaine HCl 2%|Single Administration (20mL) by Axillary Nerve Route
45922432|NCT00010959|Drug|Cimicifuga racemosa|
45922433|NCT00010959|Drug|Trifolium pratense|
45922434|NCT00023530|Drug|fluconazole|
45922435|NCT00023530|Drug|voriconazole|
45922436|NCT00023530|Procedure|bone marrow transplant|
45922437|NCT00023530|Drug|thalidomide|
45922438|NCT00023530|Drug|dexamethasone|
45450009|NCT02171728|Drug|BIBW 2992|
45450010|NCT02169388|Drug|Probiotic|Microbial composition using probiotic
45450011|NCT02169388|Drug|placebo（for probiotic）|microbiota modulation using placebo
45450012|NCT02165644|Drug|Acetazolamide|"Acetazolamide 250 mg QID oral for 4 days along with standard of care which includes Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.~If the drug can't be given orally, then feeding tube (NG Tube or DHT) will be used for drug administration."
45648917|NCT03843151|Drug|BI 1358894|tablet
45804105|NCT02385097|Drug|Ropivacaine 0.75%|Single Administration (20mL) by Axillary Nerve Route
45804106|NCT02387359|Drug|Plecanatide|
45804107|NCT02387359|Drug|Placebo|
45450013|NCT02165644|Drug|Nimodipine|Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days
45450014|NCT02171806|Drug|BI 1744 CL|
45450015|NCT02171806|Drug|Placebo|
45804108|NCT02387749|Genetic|mesenchymal stem cells|collection of stem cells by bone marrow biopsy from iliac crest, then culture for 1 month , then IV transfusion on 2 sessions to the same patient
45450016|NCT02165800|Procedure|L-PANP-TME|
45648918|NCT03843151|Drug|Itraconazole|oral solution
45648919|NCT04919759|Behavioral|R-Basic|Participants in the R-Basic arm received access to a static website that contained educational materials on healthier eating and physical activity and the study questionnaires. The R-Basic intervention was implemented in the University of Sharjah.
45922439|NCT00000176|Drug|Estrogen|
45922440|NCT00000176|Drug|Estrogen and Progesterone|
45922441|NCT00023647|Biological|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
45922442|NCT00023647|Biological|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
45922443|NCT00023647|Biological|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
45922444|NCT00023686|Procedure|surgery|
45922445|NCT00023686|Radiation|radiation|
45922446|NCT00010998|Procedure|Yoga|
45922447|NCT00000179|Drug|Trazodone|
45922448|NCT00000179|Drug|Haloperidol|
45922449|NCT00023725|Drug|semaxanib|
45922450|NCT00023725|Procedure|conventional surgery|
45922451|NCT00023725|Radiation|radiation therapy|
45922452|NCT00391404|Drug|Alendronate|Alendronate 70 mg weekly (oral)
45922453|NCT00391404|Drug|Placebo|Placebo
45922454|NCT00000191|Drug|Carbamazepine|
45922455|NCT00023842|Biological|BCG vaccine|
45922456|NCT00023842|Drug|mitomycin C|
45922457|NCT00023842|Procedure|adjuvant therapy|
45922458|NCT00023842|Procedure|conventional surgery|
45922459|NCT00011037|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|1 x 10^ 7 TCID50 administered intramuscularly
45922460|NCT00011037|Biological|MN rgp120/HIV-1|0.6 mg administered intramuscularly
45922461|NCT00011037|Biological|ALVAC(2)120(B,MN)GNP (vCP1452) placebo|ALVAC placebo administered intramuscularly
45922462|NCT00011037|Biological|MN rgp120/HIV-1 placebo|Alum placebo administered intramuscularly
45922463|NCT00000221|Drug|Buprenorphine|
45922464|NCT00023881|Drug|bortezomib|
45922465|NCT00023920|Biological|bevacizumab|Given IV
45922466|NCT00023920|Drug|idarubicin|Given IV
45922467|NCT00023920|Drug|cytarabine|Given SC
45922468|NCT00023959|Drug|hydroxyurea|Given orally
45922469|NCT00023959|Drug|fluorouracil|Given IV
45922470|NCT00023959|Biological|bevacizumab|Given IV
45922471|NCT00023959|Radiation|radiation therapy|Undergo radiotherapy
46071781|NCT05878340|Behavioral|Miffy|A method to stimulate children to try different fruits and vegetables using reward and role modelling
46071782|NCT05878340|Behavioral|Reward|Reference method to stimulate children to try fruits and vegetables using reward alone
46071783|NCT05878327|Other|Thrombophilia screening|No intervention. Blood is drawn for analysis.
46071784|NCT05878288|Drug|Cemiplimab|Cemiplimab 50 mg/mL supplied as a sterile liquid in single-use glass vials.
45922472|NCT00023959|Biological|filgrastim|Given subcutaneously
45922473|NCT00023959|Other|laboratory biomarker analysis|Correlative studies
45922474|NCT00023998|Drug|doxorubicin hydrochloride|Given IV
45648920|NCT04919759|Behavioral|R-Enhanced|The R-Enhanced intervention was guided by the Social Cognitive Theory and employed a variety of behavior modification strategies, including self-monitoring, goal setting, self-efficacy, and social support to facilitate changes in diet and physical activity. In addition, participants in the R-Enhanced intervention had online access to a nutritionist. The R-Enhanced intervention was implemented in the United Arab Emirates University.
45648921|NCT03711019|Device|Magnetic Seizure Therapy (MST)|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
45922475|NCT00023998|Drug|cisplatin|Given IV
45450017|NCT02165800|Procedure|O-PANP-TME|
45648922|NCT03711019|Device|RUL-UB ECT|"In the RUL-UB ECT arm treatment, the MECTA spectrum 5000Q machine will be used, which is an FDA approved device used for providing standard-of-care clinical ECT treatments. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
45648923|NCT03711019|Device|Bitemporal ECT|"Bitemporal ECT treatments will be administered using the MECTA spECTrum 5000Q, which is an FDA approved device used for providing standard-of-care clinical ECT treatments. Bitemporal ECT will be administered at 1.5 times seizure threshold according to standard clinical practice. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
45648924|NCT04919837|Other|Low vision aids|the assisting devices fitting for low-vision patients
45648925|NCT02918305|Device|PRDS-001 Renal Denervation Ultrasound System|
45648926|NCT02918305|Procedure|Sham Procedure|
45648927|NCT04929509|Other|self-assembling peptide|each Curodont Repair applicator unit contains both Curolox technology for guided enamel regeneration and water for activation of the device, each box contains 10 applicators
45796030|NCT04997681|Behavioral|Combined Aerobic Exercise and Resistance Training (AE + RT)|AE + RT will be conducted via a video-conferencing platform under the direct supervision and coaching of a certified exercise physiologist with certification from the Canadian Society for Exercise Physiology (CSEP; or equivalent certification). These certified trainers will administer the exercise interventions in a one trainer to one participant ratio. AE + RT includes a set of warm up exercises, which will be completed in approximately 5 minutes, followed by a break. Next, 6 strength training exercises (that progressively increase in resistance intensity over time) will be completed followed by a break. Aerobic exercises that safely increase the participant's heart rate will follow for 30 minutes followed by a break and a set of cool down exercises for 5 minutes. In total the AE + RT exercise session is approximately 65 minutes.
45922476|NCT00023998|Drug|methotrexate|Given IV
45922477|NCT00023998|Drug|leucovorin calcium|Given IV or orally
45922478|NCT00023998|Biological|filgrastim|Given IV
45922479|NCT00023998|Procedure|therapeutic conventional surgery|Undergo resection
45922480|NCT00023998|Radiation|radiation therapy|Undergo radiotherapy
45922481|NCT00023998|Drug|etoposide|Given IV
45922482|NCT00023998|Drug|ifosfamide|Given IV
45922483|NCT00023998|Biological|trastuzumab|Given IV
45922484|NCT00023998|Other|laboratory biomarker analysis|Correlative studies
45922485|NCT00024037|Procedure|management of therapy complications|
46071785|NCT05878262|Drug|ibuprofen suppository|After the induction of anesthesia was performed, the nurse delivered the ibuprofen suppository at the dose of 5-10 mg/Kg for the pre-emptive analgesia group children.
46071786|NCT05878249|Procedure|wound lavage with normal saline|After removing caries and achieving hemostasis after removing caries and achieving hemostasis, wound lavage of the exposed pulp will be done with 5 ml of Normal saline for 30 seconds
46071787|NCT05878249|Procedure|wound lavage with sodium hypochlorite|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5% sodium hypochlorite (NaOCl) for 30 seconds,Subsequently the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets
45922486|NCT00024076|Procedure|radiofrequency ablation|
45922487|NCT00024115|Drug|BL22 immunotoxin|
45922488|NCT00024115|Procedure|antibody therapy|
45922489|NCT00024115|Procedure|biological response modifier therapy|
45922490|NCT00024115|Procedure|immunotoxin therapy|
45922491|NCT00024154|Biological|trastuzumab|Given IV
45922492|NCT00024154|Drug|gefitinib|Given orally
45922493|NCT00024154|Other|laboratory biomarker analysis|Correlative studies
45922494|NCT00011076|Drug|Pirfenidone|
45922495|NCT00000248|Drug|Pergolide|
45922496|NCT00024193|Biological|filgrastim|
45922497|NCT00024193|Drug|busulfan|
45922498|NCT00024193|Drug|cisplatin|
45922499|NCT00024193|Drug|cyclophosphamide|
45922500|NCT00024193|Drug|doxorubicin hydrochloride|
45922501|NCT00024193|Drug|etoposide|
45922502|NCT00024193|Drug|melphalan|
45922503|NCT00024193|Drug|vincristine sulfate|
45922504|NCT00024193|Procedure|conventional surgery|
45922505|NCT00024193|Procedure|peripheral blood stem cell transplantation|
45922506|NCT00024232|Biological|monoclonal antibody huJ591|
45922507|NCT00024271|Biological|recombinant interferon gamma|
45922508|NCT00024271|Drug|cisplatin|
45922509|NCT00024271|Drug|doxorubicin hydrochloride|
45796031|NCT04997681|Behavioral|Cognitive Training (NeuropeakTM)|NeuropeakTM is a program which will be completed by participants remotely using a tablet or computer. It consists of cognitive training including dual-task training that requires participants to maintain and prepare for many response alternatives (working memory) and to share attention between two concurrent tasks (divided attention). Difficulty of cognitive training is tailored to their individual functioning level. During each session, participants perform one of two different visuo-motor tasks, which include sets of visual stimuli (e.g., letters, numbers, animals, vehicles, fruits, celestial bodies) and respective hand-button correspondences (i.e., keys that are to be tapped on either the right or the left side of the screen). Participants are instructed to perform these tasks as fast as possible, while maintaining accuracy. Training also includes online feedback and a histogram of daily performance to encourage improvement. NeuropeakTM takes approximately 30 minutes to complete.
45922510|NCT00024271|Drug|gemcitabine hydrochloride|
45922511|NCT00024271|Drug|mitomycin C|
45922512|NCT00024271|Procedure|conventional surgery|
45922513|NCT00024271|Procedure|hyperthermia treatment|
45922514|NCT00024271|Radiation|radiation therapy|
45922515|NCT00024310|Dietary Supplement|folic acid|
45922516|NCT00024310|Drug|lometrexol|
45922517|NCT00024310|Drug|paclitaxel|
45922518|NCT00011115|Behavioral|Weight loss motivations|
45922519|NCT00024349|Drug|fluorouracil|
45922520|NCT00024349|Drug|mitomycin C|
45648928|NCT04929509|Other|nanosilver fluoride varnish|The synthesis of aqueous solution of silver nanoparticles will be carried out via the chemical reduction of silver nitrate (1 mL, 0.11 M) with sodium borohydride (0.3 mL, 0.8 M) and chitosan biopolymer (28.7 mL, 2.5 mg/mL) as a stabilizing agent. Sodium fluoride (10,147 ppm of fluorine) will be incorporated at the end of the experiment.
45648929|NCT04929509|Other|sodium fluoride varnish|5% sodium fluoride varnish; One ml of fluoride varnish contains 50 mg of sodium fluoride in an alcohol-based suspension of resins.
45450018|NCT02171962|Device|Zilver® PTX® Drug-Eluting Peripheral Stent|Zilver® PTX® Drug-Eluting Peripheral Stent for treatment of lesions of the above-the-knee femoropopliteal artery
45922521|NCT00024349|Radiation|radiation therapy|
45922522|NCT00000251|Drug|30% N2O|
45922523|NCT00000251|Drug|0.2% isoflurane|
45648930|NCT02798107|Drug|idarucizumab|drug
45450019|NCT03539926|Device|Lit-control®pH Meter|Alkalinization products will be used as standard clinical practice together with the pH monitoring through the Lit-control®pH Meter.
45450020|NCT03539926|Diagnostic Test|Reactive strips|Alkalinization products will be used as standard clinical practice together with the pH monitoring through the reactive strips.
45450021|NCT02169544|Drug|Abatacept|
45450022|NCT02165956|Dietary Supplement|New Infant Cereal|New Infant Cereal
45450023|NCT02165956|Dietary Supplement|Standard Infant Cereal|Standard Infant Cereal
45450024|NCT03539770|Procedure|Posterior spinal fusion|Surgical procedure that involves placement of spinal rods to correct spinal curvature
45648931|NCT04403867|Procedure|Sentinel lymph node (SLN) biosy +/- lymphadenectomy|Evaluation of type and volume of lymph nodal disease
45922524|NCT00000251|Drug|0.4% isoflurane|
45922525|NCT00000251|Other|100% oxygen|Placebo
45648932|NCT01865539|Device|Custom Foot Orthotic|Custom foot orthotic with custom design pads
45922526|NCT00024388|Drug|DHA-paclitaxel|
45922527|NCT00024427|Drug|fluorouracil|High dose 5-FU
45922528|NCT00024427|Drug|gemcitabine hydrochloride|Normal dose to treat pancreatic cancer
45922529|NCT00024427|Drug|triacetyluridine|6 grams (12 tablets)
45922530|NCT00000257|Drug|0% N2O and 10% N2O|
45922531|NCT00000257|Drug|0% N2O and 20% N2O|
45922532|NCT00000257|Drug|0% N2O and 30% N2O|
45450025|NCT02166034|Behavioral|garden intervention|The intervention includes raised bed garden kits for participating classes as well as access to garden-based curriculum.
45450026|NCT02172118|Drug|BI 1774 CL|
45922533|NCT00000257|Drug|0% N2O and 40% N2O|
45922534|NCT00024466|Biological|GVAX|
45922535|NCT00024466|Procedure|Autologous transplant|
45922536|NCT04733131|Drug|Conversion to a belatacept regimen|belatacept intravenous on Days 1, 15, 29, 43, 57 then every 28 days.
45922537|NCT00024544|Drug|anti-IL-4 monoclonal antibody (pascolizumab)|
45922538|NCT00024661|Drug|LErafAON|
45922539|NCT00000359|Behavioral|Canalith repositioning maneuver (Epley maneuver)|Standard passive motion of the head: Dix-Hallpike maneuver, turn head to opposite side, roll over, sit up.
45922540|NCT00000359|Behavioral|Semont maneuver|Sidelying maneuver, flip over 180 deg, sit up.
45922541|NCT00000359|Behavioral|Brandt-Daroff exercises|Active exercise. Sidelying to involved side, sidelying to uninvolved side, sit up.
45922542|NCT00000359|Behavioral|Vestibular habituation exercises|Head shaking exercises in pitch, roll, yaw and circumduction. Titrating from 2 repetitions per exercise to 20 repetitions per exercise, as tolerated.
45922543|NCT00000359|Behavioral|ShamManeuver|Passive movement of the head
45922544|NCT00024934|Drug|B-Lymphocyte Stimulator (BLyS)|
45922545|NCT00395200|Procedure|MSC Treatment|Intravenous administration of up to 2x10^6 autologous MSCs per kg
45922546|NCT00395239|Drug|inhaled corticosteroid|Fluticasone; Budesonide; Ciclesonide Dosage and frequency is patient dependant.
45922547|NCT00000362|Behavioral|Chin-down position|
45922548|NCT00000362|Behavioral|Thickened liquid administration|
45922549|NCT00395356|Behavioral|calorie controlled diet|
45922550|NCT00025012|Drug|isotretinoin|
45922551|NCT00025051|Drug|celecoxib|
45922552|NCT00025051|Procedure|anti-cytokine therapy|
45922553|NCT00025051|Procedure|antiangiogenesis therapy|
45922554|NCT00025051|Procedure|biological therapy|
45922555|NCT00025051|Procedure|cancer prevention intervention|
45922556|NCT00025051|Procedure|chemoprevention of cancer|
45922557|NCT00025051|Procedure|growth factor antagonist therapy|
45796032|NCT04997681|Behavioral|Control Cognitive Training of Website Searching and Video Watching (WS+V)|During the WS + V task, participants alternate between 2 different tasks (touristic searching using internet and video watching). For the touristic searching using internet, participants are required to find 3 hotels, 3 touristic places, and 3 restaurants of their own preference in a city assigned by the instructor (a new city will be selected each session). They will also need to include the respective addresses of those places on their log sheet. For the video watching task, participants watch a National Geographic video on YouTube selected by the instructor with a different video selected for each session. They will watch the video for 20 minutes and during the remaining 5 minutes they will answer the following questions on their log sheet: 1) What is the video about? 2) What is the most important information in your opinion? 3) Create a question based on the video and answer your own question. WS + V sessions take approximately 30 minutes to complete.
45922558|NCT00025090|Drug|cisplatin|
45922559|NCT00025090|Drug|fluorouracil|
45922560|NCT00025090|Drug|mitomycin C|
45922561|NCT00025090|Radiation|radiation therapy|
45922562|NCT00000368|Behavioral|Cognitive behavior therapy|
45922563|NCT00000368|Drug|Paroxetine or other medication - algorithm used|
45922564|NCT00025129|Drug|laromustine|
45922565|NCT00011505|Drug|G-CSF|
46071788|NCT05878249|Procedure|wound lavage with Ethylenediaminetetraacetic acid(EDTA)|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 12% Ethylenediaminetetraacetic acid for 5minutes ,Subsequently, the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets.
46071789|NCT05878249|Procedure|wound lavage with sodium hypochlorite followed by Ethylenediaminetetraacetic acid|fter removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5%sodium hypochlorite (NaOCl) for 30 seconds followed by 12%Ethylenediaminetetraacetic acid(EDTA) for 5 minutes.Subsequently, the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets.
45648933|NCT01865539|Device|Sham Orthotic|Leather insert without the custom design pads
45648934|NCT03054467|Drug|Caduet 10Mg-20Mg Tablet|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
45648935|NCT03054467|Drug|NorvasC® 10 mg Tablets|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
45648936|NCT05009485|Device|Current Health platform|A remote patient monitoring system which includes a small footprint device and tablet, combined with an AI-powered, cloud-based system driving advanced real-time and predictive analytics related to a patient's clinical condition. The wearable records heart rate, respiratory rate, oxygen saturation, skin temperature and step count.
45648937|NCT04910165|Drug|Exparel|Exparel used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
45648938|NCT04910165|Drug|Ropivacaine|Ropivacaine used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
45648939|NCT02730325|Other|Serum-derived bovine immunoglobulin/protein isolate (SBI)|
45648940|NCT02730325|Other|Placebo|
45648941|NCT03054233|Procedure|Crossed leg sitting position|Spinal anesthesia done in crossed leg sitting position
45648942|NCT04500769|Behavioral|Acute Resistance Exercise|Participants will perform three sets of eight repetitions, with a 90-120 second rest between sets, with a fourth set performed to failure. All resistance exercise will be performed on pneumatic resistance devices (Keiser Sports Health Equipment, Fresno, CA).
45648943|NCT04928495|Drug|Vitamin C|Vitamin C 500 mg / day for ten days
45648944|NCT04928495|Drug|N-acetylcysteine (NAC)|N-acetylcysteine 1800 mg / day for ten days.
45648945|NCT04928495|Drug|NAC + Bromhexine (BMX)|NAC + Bromhexine (BMX) 32 mg / day for ten days.
45922566|NCT00011505|Procedure|Leukapheresis|
45922567|NCT00025168|Drug|gemcitabine hydrochloride|
45450027|NCT02166112|Procedure|Permacol mesh placement|All patients were treated for a complex abdominal wall hernia by implantation of Permacol mesh. This intervention took place before patients were included in the cohort.
45450028|NCT02261272|Behavioral|CBT for insomnia SHUTi|SHUTi
45648946|NCT03053921|Procedure|recession coverage|recession coverage done using Zuchellis technique
45648947|NCT03053921|Procedure|recession coverage and membrane|recession coverage done using Zuchellis technique with placental membrane
45922568|NCT00025168|Drug|irinotecan hydrochloride|
45922569|NCT00025168|Radiation|radiation therapy|
45648948|NCT05015413|Device|Shockwave|Shock wave master 500 Germany
45922570|NCT00000380|Drug|GHRH|
45922571|NCT00025207|Drug|gefitinib|Given orally
45922572|NCT00025207|Other|laboratory biomarker analysis|Correlative studies
45922573|NCT00025246|Drug|imatinib mesylate|Given orally
45922574|NCT00025246|Other|laboratory biomarker analysis|Correlative studies
45922575|NCT00025285|Drug|carboplatin|
45922576|NCT00025285|Drug|irinotecan hydrochloride|
45922577|NCT00025285|Drug|thalidomide|
45922578|NCT00000383|Behavioral|Trauma-Focused CBT|Structured skills, exposure, trauma-specific interventions
45922579|NCT00000383|Behavioral|Child-Centered Therapy|Client-directed supportive interventions
45922580|NCT00025324|Biological|filgrastim|
45922581|NCT00025324|Drug|carboplatin|
45922582|NCT00025324|Drug|cyclophosphamide|
45922583|NCT00025324|Drug|etoposide|
45922584|NCT00025324|Drug|thiotepa|
45922585|NCT00025324|Procedure|autologous bone marrow transplantation|
45922586|NCT00025324|Procedure|bone marrow ablation with stem cell support|
45922587|NCT00025324|Procedure|conventional surgery|
45922588|NCT00025324|Procedure|peripheral blood stem cell transplantation|
45922589|NCT00025324|Radiation|radiation therapy|
45796033|NCT04997681|Behavioral|Control Balance and Toning Exercise Training (BAT)|BAT exercises will be conducted via a video-conferencing platform under the direct supervision and coaching of a certified exercise physiologist with certification from the Canadian Society for Exercise Physiology (CSEP; or equivalent certification). These certified trainers will administer the exercise interventions in a one trainer to one participant ratio. BAT includes a set of warm up exercises, which will be completed in approximately 5 minutes, followed by a break. Next, 6 balance and toning exercises will be completed followed by a break. Stretching exercises will follow for 30 minutes followed by a break and a set of cool down exercises for 5 minutes. In total the BAT exercise session is approximately 65 minutes.
45922590|NCT00011544|Procedure|Performance Measure|
45922591|NCT00025363|Drug|vincristine sulfate|Given IV
45922592|NCT00025363|Drug|irinotecan hydrochloride|Given IV
45922593|NCT00025363|Drug|cyclophosphamide|Given IV
45922594|NCT00025363|Drug|doxorubicin hydrochloride|Given IV
45648949|NCT01573429|Other|deuterated-Bisphenol A (d-BPA)|The primary endpoints are key pharmacokinetic measurements of d-BPA and d-BPA conjugates in blood and urine over 6 days after a single dose of oral and/or ethanol solution dermal application and/or a carboxymethylcellulose suspension dermal application of a dose of 100 micro g/kg bw of d-BPA.
45796034|NCT00001407|Drug|Interferon Gamma|
45922595|NCT00025363|Drug|ifosfamide|Given IV
45922596|NCT00025363|Drug|etoposide|Given IV
45922597|NCT00025363|Drug|tirapazamine|Given IV
45922598|NCT00025363|Biological|filgrastim|Given SC
45922599|NCT00025363|Biological|sargramostim|Given SC
45922600|NCT00025363|Other|pharmacological study|Correlative studies
45922601|NCT00025363|Other|pharmacogenomic studies|Correlative studies
45922602|NCT00025363|Other|laboratory biomarker analysis|Correlative studies
45922603|NCT00025402|Biological|filgrastim|
45648950|NCT03055559|Dietary Supplement|Globifer Forte|
45648951|NCT04910009|Other|Four sessions of practical privacy education|Two sessions of theoretical, four sessions of practical privacy education
46071790|NCT05878236|Diagnostic Test|CyTOF Analysis|CyTOF laboratory testing for cytokine levels to correlate with severity of acute pancreatitis
46071791|NCT05878197|Behavioral|Straw phonation|"The two experimental groups will receive either straw phonation therapy or resonant voice therapy. The hierarchical structure of the therapy sessions will be equal for the three programs. In each session, vocal rest pauses will be foreseen by playing games, performing drawing assignments, etc. This will make the therapy more pleasant and less intensive. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations, straw phonation on vowel and syllable level, pitch variations Day 3: breathing exercises, vocal hygiene recommendations, straw phonation on word and sentence level, pitch variations Day 4: straw phonation in spontaneous speech, combination exercises"
45648952|NCT01518673|Procedure|Blood test|Analysing X-ray induced genetic effects in pediatric patients directly after a computer tomography scan.
45648953|NCT04909931|Drug|Vitamin D 2|Randomized allocation first arm : add on vitamin D supplementation 40,000 iu/week for 12 weeks
45648954|NCT04909931|Drug|Placebo|Second arm : add on placebo for 12 weeks
45796035|NCT00002097|Drug|Nystatin|
45796036|NCT00001431|Drug|gemcitabine|
45922604|NCT00025402|Biological|recombinant interferon alfa|
45922605|NCT00025402|Drug|busulfan|
45922606|NCT00025402|Drug|cyclophosphamide|
45922607|NCT00025402|Drug|cytarabine|
45922608|NCT00025402|Drug|etoposide|
45922609|NCT00025402|Drug|hydroxyurea|
45922610|NCT00025402|Drug|idarubicin|
45922611|NCT00025402|Procedure|allogeneic bone marrow transplantation|
45922612|NCT00025402|Procedure|peripheral blood stem cell transplantation|
45922613|NCT00025402|Radiation|radiation therapy|
45922614|NCT00000392|Drug|Peptide T|
45922615|NCT00000392|Drug|Placebo|
45922616|NCT00011583|Device|Robot-assisted therapy|1 hour/day of mechanically-assisted upper limb therapy
45922617|NCT00011583|Device|Traditional therapy|1 hour/day of upper limb therapy that includes exposure to, but no manipulation by the robot
45922618|NCT00011622|Device|Continuous ambulatory subcutaneous glucose monitor|
45922619|NCT00025441|Biological|dactinomycin|
45922620|NCT00025441|Biological|filgrastim|
45922621|NCT00025441|Drug|carboplatin|
45922622|NCT00025441|Drug|cyclophosphamide|
45922623|NCT00025441|Drug|doxorubicin hydrochloride|
45922624|NCT00025441|Drug|epirubicin hydrochloride|
45922625|NCT00025441|Drug|etoposide|
45922626|NCT00025441|Drug|ifosfamide|
45922627|NCT00025441|Drug|vincristine sulfate|
45922628|NCT00025441|Procedure|peripheral blood stem cell transplantation|
45922629|NCT00025441|Radiation|radiation therapy|
45922630|NCT00000395|Drug|Methotrexate|
45922631|NCT00000395|Dietary Supplement|Folinic acid|
45922632|NCT00000395|Dietary Supplement|Folic acid|
45922633|NCT02971579|Procedure|ERCP|Endoscopic procedure used to manage biliary and pancreatic diseases
45922634|NCT00025480|Drug|carboplatin|
45922635|NCT00025480|Drug|paclitaxel|
45922636|NCT00025480|Drug|tipifarnib|
45922637|NCT00025480|Radiation|radiation therapy|
45922638|NCT00011661|Behavioral|Education on behaviors to reduce lead exposure|
45922639|NCT00025519|Biological|therapeutic allogeneic lymphocytes|
45922640|NCT00025519|Drug|fludarabine phosphate|
45922641|NCT00025519|Drug|mycophenolate mofetil|
45922642|NCT00025519|Drug|tacrolimus|
45922643|NCT00025519|Drug|thalidomide|
45922644|NCT00025519|Procedure|peripheral blood stem cell transplantation|
45922645|NCT00025519|Radiation|radiation therapy|
45922646|NCT00000410|Procedure|Diskectomy|The surgeon will leave the nerve root freely mobile and undamaged following the procedure. During the procedure, the surgeon may consider using loop magnification or a microscope. The surgical incision will be midline and, after reflecting the paraspinous muscles, the interlaminar level will be identified and entered. The nerve root will be clearly identified and mobilized and then gently retracted to prepare for the discectomy. Removal of the medial border of the superior facet may, in some cases, be necessary in order to have a clear view of the lateral border of the involved nerve root. Following the clear view of the nerve root and mobilization, the IDH will be approached by making a small annular incision if necessary, the fragment of disc will then be removed (i.e., limited disc excision). A search of the canal will follow removal of the fragment, along with probing of the intervertebral-foramen for residual disc or bony pathology.
45922647|NCT00000410|Procedure|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
45922648|NCT00025558|Biological|filgrastim|
45922649|NCT00025558|Drug|carboplatin|
45922650|NCT00025558|Drug|temozolomide|
46071792|NCT05878197|Behavioral|Resonant voice therapy|"The two experimental groups will receive either straw phonation therapy or resonant voice therapy. The hierarchical structure of the therapy sessions will be equal for the three programs. In each session, vocal rest pauses will be foreseen by playing games, performing drawing assignments, etc. This will make the therapy more pleasant and less intensive. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations, resonant voice therapy on vowel and syllable level, pitch variations Day 3: breathing exercises, vocal hygiene recommendations, resonant voice therapy on word and sentence level, pitch variations Day 4: resonant voice therapy in spontaneous speech, combination exercises"
45796037|NCT05428007|Drug|Sarilumab|Injectable solutions of sarilumab are formulated in 2 mL of aqueous solution in a 5 mL vial containing 175 mg/ml of sarilumab arginine (8.94 mg), histidine (3.71 mg), polysorbate 20 (2.28 mg), sucrose (57 mg) and Water for Injection USP.Patients will be administered sarilumab at a dose of 150 mg subcutaneously in combination with ipilimumab, nivolumab and relatlimab given intravenously, with nivolumab/relatlimab given intravenously, or sarilumab at a dose of 150 mg subcutaneously given alone.
45796038|NCT05428007|Drug|Ipilimumab Injection|Ipilimumab injection is a sterile, nonpyrogenic, clear to slightly opalescent, colorless to pale yellow solution, single-use, preservative-free, isotonic aqueous solution that may contain particles. It is formulated at a concentration of 5 mg/mL ipilimumab in TRIS hydrochloride (also known as 2-amino-2-hydroxymethyl-1,3-propanediol hydrochloride), sodium chloride, mannitol, pentetic acid (also known as diethylenetriaminepentaacetic acid or DTPA), polysorbate 80, and water at pH 7.0. Sodium hydroxide and/or hydrochloric acid may be used to adjust the pH of the solution. Ipilimumab Injection 200 mg/40 mL (5 mg/mL) is packaged in a 50-cc Type I flint molded glass vials.
45796039|NCT05428007|Drug|Nivolumab/Relatlimab|The FDC drug product, referred to as nivolumab/relatlimab, contains relatlimab and nivolumab in a single vial in a kit of 2 vials. The product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution for IV infusion. It is formulated at a total protein concentration of 16 mg/mL (4 mg/mL relatlimab and 12 mg/mL nivolumab) and is packaged in a 20-cc glass vial in a kit of two vials. Each vial contains 80 mg of relatlimab and 240 mg of nivolumab.
45796040|NCT00002103|Drug|Trimetrexate glucuronate|
45796041|NCT00002103|Drug|Leucovorin calcium|
45796042|NCT00001437|Drug|pentoxifylline|
45648955|NCT04928807|Combination Product|Short course radiotherapy sequential camrelizumab and chemotherapy|Short course radiotherapy, 5 * 5Gy, once a day, 5Gy each time, for 5 days, continuous irradiation, three-dimensional 3D-CRT or IMRT technology is recommended camrelizumab 200 mg , D1, intravenous drip, q3w, 2 cycles before operation, postoperative adjuvant treatment, the longest medication time of camrelizumab was less than 1 year during the whole study period; Capecitabine 1000 mg / m2, twice a day, oral, 1-14 days, then rest for 7 days, q3w, 2 cycles before operation and 6 cycles after operation; Oxaliplatin 130 mg / m2, D1, intravenous infusion 2 hours, q3w, 2 cycles before operation, 6 cycles after operation
45648956|NCT02360839|Device|EUS-guided fine needle biopsy sampling (EUS-FNB)|Dual sampling with EUS-FNA and EUS-FNB in a randomized order.
45648957|NCT04919291|Device|Topoguided LASIK|Topoguided ablation profile on dominant eye
45922651|NCT00025558|Drug|thiotepa|
45922652|NCT00025558|Procedure|autologous bone marrow transplantation|
45922653|NCT00025558|Procedure|peripheral blood stem cell transplantation|
45922654|NCT00025597|Drug|carboplatin|
45922655|NCT00025597|Drug|cyclophosphamide|
45922656|NCT00025597|Drug|doxorubicin hydrochloride|
45922657|NCT00025597|Drug|etoposide|
45922658|NCT00025597|Drug|vincristine sulfate|
45922659|NCT00025597|Procedure|conventional surgery|
45922660|NCT00025636|Biological|filgrastim|
45922661|NCT00025636|Drug|carmustine|
45922662|NCT00025636|Drug|cisplatin|
45922663|NCT00025636|Drug|cyclophosphamide|
45922664|NCT00025636|Drug|cytarabine|
45922665|NCT00025636|Drug|dexamethasone|
45922666|NCT00025636|Drug|etoposide|
45922667|NCT00025636|Drug|melphalan|
45922668|NCT00025636|Drug|methotrexate|
45922669|NCT00025636|Drug|vincristine sulfate|
45922670|NCT00025636|Procedure|bone marrow ablation with stem cell support|
45922671|NCT00025636|Procedure|peripheral blood stem cell transplantation|
45922672|NCT00000413|Behavioral|Psychoeducational program|
45922673|NCT00025675|Drug|gefitinib|
45922674|NCT00025753|Drug|rosiglitazone (Avandia)|
45922675|NCT00025753|Behavioral|Aerobic and weight lifting exercise training|
45796043|NCT00360191|Drug|Buspirone|
45796044|NCT00360191|Procedure|Motivational enhancement therapy|
45796045|NCT00001443|Drug|indinavir (MK-0639)|
45922676|NCT00025792|Drug|Pramipexole|
45922677|NCT00000416|Other|Rehabilitation counseling|Provided in 2 in-person meetings and in follow-up phone calls
45922678|NCT00025909|Procedure|Leukapheresis|
45922679|NCT00025987|Device|Head and Neck Cooling System|
45922680|NCT00025987|Device|Thermometer Pill|
46071793|NCT05878197|Behavioral|Vocal Hygiene|"Participants of the control group will receive a sham treatment, including the exact same games, drawing assignments, etc. as in the experimental groups. However, no SOVT or other active vocal techniques will be practiced. Vocal hygiene guidelines (e.g. avoid screaming, imitating voices, sufficient hydration etc.) will be kept equally in the four groups. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations Day 3: breathing exercises, vocal hygiene recommendations Day 4: combination exercises"
46071794|NCT05878158|Drug|Simvastatin|pulpotomy of immature permanent teeth
45648958|NCT04919291|Device|Wavefront optimized LASIK|Wavefront optimized ablation profile on non-dominant eye
45648959|NCT04918589|Drug|Tranexamic acid|3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline
45648960|NCT04918589|Drug|Normal Saline|40 mL topical of 0.9% normal saline
45796046|NCT05229341|Procedure|Diagnostic Procedure|Analysis via DDMS-2
45796047|NCT05229341|Other|Electronic Health Record Review|Review of medical records
45796048|NCT05229341|Procedure|Needle Biopsy|Undergo needle biopsy
45450029|NCT02261272|Behavioral|passive patient education/sleep hygiene|
45648961|NCT04928651|Drug|Clonidine|"Clonidine will be administered to preterm infants in need of analgesia and sedation; either as the primary drug for comfort and light sedation or as an add-on drug to opioids according to an algorithm based on pain and sedative scoring results. Opioids are mostly given to postoperative patients. These drugs (morphine or fentanyl) will not be studied, but a baseline PK sample will be taken to correlate to the baseline aEEG."
45648962|NCT05128981|Behavioral|MI-CBT|Education of MI and common reactions, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention
45648963|NCT04101643|Drug|evolocumab|Eligible patients receive subcutaneous injections of evolocumab 420 mg
45648964|NCT02620787|Drug|Tedizolid|
45648965|NCT02620787|Procedure|Microdialysis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
45648966|NCT04082455|Radiation|carbon ion radiotherapy|carbon ion radiotherapy
45648967|NCT04062799|Other|no intervention|It is an observationa study. There is no intervention.
45796049|NCT00001449|Drug|gemcitabine|
45796050|NCT00001449|Drug|fluorodeoxyuridine|
45796051|NCT00001449|Drug|leucovorin|
45922681|NCT00000419|Drug|Premarin and Provera|
45922682|NCT00026065|Behavioral|Biofeedback|
45922683|NCT00026104|Drug|gemcitabine hydrochloride|Given IV
45922684|NCT00026104|Drug|paclitaxel|Given IV
45922685|NCT00026104|Drug|tipifarnib|Given orally
45922686|NCT00026104|Radiation|radiation therapy|Undergo radiation therapy
45922687|NCT00026143|Biological|recombinant interleukin-12|Given IV
45922688|NCT00026143|Biological|recombinant interferon alfa|Given SC
45922689|NCT00026143|Other|laboratory biomarker analysis|Correlative studies
45922690|NCT00000422|Behavioral|Cognitive-behavioral psychotherapy and physical exercise|
45922691|NCT00026182|Biological|rituximab|Given IV
45922692|NCT00026182|Biological|recombinant interleukin-12|Given SC
45922693|NCT00026182|Other|laboratory biomarker analysis|Correlative studies
45922694|NCT00026182|Other|questionnaire administration|Ancillary studies
45922695|NCT00026182|Procedure|quality-of-life assessment|Ancillary studies
45922696|NCT00026260|Drug|semaxanib|
45922697|NCT00026299|Drug|ZD1839|
45922698|NCT00026299|Drug|oxaliplatin|
45922699|NCT00026338|Drug|erlotinib hydrochloride|150 mg po daily
45922700|NCT00026338|Drug|gemcitabine hydrochloride|1000 mg/m2 IV weekly (Cycle 1 -Day 1, 8, 15, 22, 29, 36, 43 of an 8 week cycle, Cycle 2 and subsequent cycles -Day 1,8 and 15 of a 4 week cycle)
45922701|NCT00026377|Drug|bicalutamide|50 mg daily for 1 month
45922702|NCT00026377|Drug|flutamide|250 mg 3 times daily for 1 month
45922703|NCT00026377|Drug|goserelin acetate|3.6 mg once a month for 4 months
45922704|NCT00026377|Drug|leuprolide acetate|7.5 mg once a month for 4 months
45922705|NCT00026377|Drug|SU5416|IV infusion at assigned dose
45922706|NCT00026377|Radiation|radiation therapy|daily for 5 days each week
45922707|NCT00026416|Biological|recombinant interferon alfa|
45922708|NCT00026416|Drug|thalidomide|
45922709|NCT00026416|Procedure|adjuvant therapy|
45922710|NCT00026533|Drug|thalidomide|
45922711|NCT00026611|Biological|Dryvax vaccine|
45922712|NCT00026923|Procedure|Laparoscopic surgery|
45922713|NCT00026962|Procedure|measuring estradiol and progesterone levels in saliva|
45922714|NCT00027001|Behavioral|Aerobic and Resistance Exercises|
45922715|NCT00027001|Behavioral|Qigong|
45922716|NCT04732858|Other|Cross sectional e-Survey on surgeons exposed to any educational intervention|"Educational intervention was considered as any procedure or program to facilitate the acquisition of basic skills about the disease, its ramifications and treatment2,6,7:~Education in infectious disease, including~pandemic training for health personnel~Personal protective equipment (PPE) and protection.~Specific speed-training focusing on environmental control (decontamination area, dressing...), personal protection, hand hygiene, sample management, risky gestures, control measures.~Intensive care education:~mechanical ventilation~airways management~emergencies and cardiovascular drugs~Intensive care monitoring systems~Basic nurse skills~COVID-specific clinical management"
45922717|NCT04733209|Other|TENS, US, exercise|Physiotherapy
45922718|NCT00027040|Drug|Selegiline hydrochloride|
45922719|NCT00027079|Drug|ondansetron (Zofran)|
45922720|NCT00027079|Drug|naltrexone (ReVia)|
45922721|NCT00027079|Behavioral|Cognitive Behavioral Therapy|
46071795|NCT05878145|Behavioral|Structured rehabilitation exercise program|Stretching (10 mins): neck, shoulder, wrist, back; Aerobic exercise (20 mins): cycle ergometer, wheelchair run; Strengthening exercise (15 mins): shoulder press, chest press, front raise, biceps curl, lateral raise, bent over rowing or rowing, bent over lateral raise, triceps extension; Balance training (5 mins); Stretching exercise (10 mins)
45796052|NCT05422625|Device|PTNS Treatment|Patients will be placed in a comfortable position, sitting or supine. The treatment leg will be propped up comfortably on a footrest but draped and out of view from the patient. A 34-gauge needle electrode will be inserted at a 60-degree angle 5 cm cephalad to the medial malleolus and slightly posterior to the tibia. A PTNS surface electrode will be placed on the ipsilateral calcaneus as well as 2 inactive sham surface electrodes, 1 under the little toe and 1 on the top of the foot. When the PTNS lead set is connected to the Urgent PC stimulator, a current level of 0.5 to 9 mA at 20 Hz is selected based on each patient's foot and plantar motor and sensory responses. Treatment lasts 30 minutes and given once weekly for 12 consecutive weeks.
45922722|NCT00011778|Drug|bortezomib|
45922723|NCT00011778|Radiation|radiation therapy|
45450030|NCT02261350|Dietary Supplement|Food fortification|
45922724|NCT00000425|Drug|Nonsteroidal anti-inflammatory drugs (NSAIDs)|
45922725|NCT00000425|Drug|Acetaminophen|
46071796|NCT05878132|Device|Wearable device -'Smart Reminder'|The wearable device, a wristwatch, has a Bluetooth function to link to mobile devices for the participants to view the prescribed videos and engage in telerehabilitation. It has sensors to monitor arm movements and provides multiple feedbacks (auditory, visual and tactile). Participants were instructed to practice the prescribed exercises -tailored according to the severity of UL paresis for the recommended therapy dose. The device recorded the angles of arm movement and the number of repetitions completed and data collected is uploaded to an encrypted cloud server for remote monitoring. Weekly, the participants will receive a 30-minute consultation session to review their progress and modify prescribed exercises based on the wearable device data.
45450031|NCT02261350|Dietary Supplement|Oral Nutritional Supplements|
45450032|NCT02166190|Procedure|Radiofrequency Ablation using EndoHPB Probe|Radiofrequency Ablation using EndoHPB Probe
45648968|NCT04909619|Procedure|Ultrasound-guided bilateral suprazygomatic maxillary nerve block|The maxillary nerve, V2, is purely a sensory branch of the trigeminal nerve. V2 exits the skull through the foramen rotundum and courses through the pterygopalatine fossa, a small pyramid-shaped depression located posterior to the maxilla. As the maxillary nerve exits the pterygopalatine fossa, it divides into numerous branches that supply sensation to the posterior nasal cavity, palate, sinuses, and maxilla. It is within the pterygopalatine fossa that the maxillary nerve is targeted and anesthetized during the block. With the patient in the supine position after nasotracheal intubation, a needle is inserted perpendicularly between the upper border of the zygomatic arch and posterior orbital rim until it reaches the greater wing of the sphenoid, where the needle is then retracted by a few millimeters and redirected toward the nasolabial fold until it hits the pterygopalatine fossa.
45648969|NCT04909619|Procedure|Local anesthetic infiltration of the palate|Local anesthetic infiltration of the palate during cleft palate repair is universally practiced. The benefits of local anesthetic infiltration are twofold: to provide anesthesia to the terminal branches of the nasopalatine and greater palatine nerves that are in the immediate area of the injection sites and to achieve hemostasis during closure when the medication is mixed with epinephrine. To administer local anesthetic infiltration of the palate, a 25 gauge needle is inserted next to the incision into the soft tissue. The tissue is first aspirated to determine safety of injection at that site. The medication is then injected parallel to the incision on both sides.
45648970|NCT04061941|Behavioral|Cognitive Assessment|Assessment on cognitive dysfunction using standardised cognitive tests
45648971|NCT05128747|Other|DASH diet|it will be face to face about the role of nutritional program to control dyslipidemia
45648972|NCT03056729|Drug|BIIB076|Administered as single intravenous (IV) infusion
45450033|NCT02166190|Procedure|Stenting only|Stenting only
45648973|NCT03056729|Drug|Placebo|Administered as single IV infusion
45754379|NCT00570349|Drug|Nitrogen|100% nitrogen (placebo) will be administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.
45922726|NCT00000428|Drug|Amitriptyline|Amitriptyline 25 mg po
45922727|NCT00000428|Drug|Amitriptyline plus Fluoxitine|Amitriptyline 25 mg po plus Fluoxitine 20 mg po
45922728|NCT00027391|Drug|Albuterol|
45922729|NCT00027391|Drug|Oxandrolone|
45922730|NCT00027430|Drug|TheraDerm|
45922731|NCT00027469|Procedure|MRI|
45922732|NCT00000461|Drug|pravastatin|
45922733|NCT00000461|Drug|niacin|
45922734|NCT00000461|Drug|cholestyramine|
45922735|NCT00000461|Drug|gemfibrozil|
45922736|NCT00000461|Drug|fatty acids, omega-3|
45922737|NCT00027508|Drug|trabectedin|
45922738|NCT00027547|Biological|therapeutic allogeneic lymphocytes|
45922739|NCT00027547|Drug|cyclosporine|
45922740|NCT00027547|Drug|cytarabine|
45922741|NCT00027547|Drug|fludarabine phosphate|
45648974|NCT03053999|Other|Genome Sequencing|Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.
45922742|NCT00027547|Drug|methotrexate|
45922743|NCT00027547|Drug|mycophenolate mofetil|
46071797|NCT05878132|Other|Conventional therapy|The participants in the control group received similar in-home upper limb exercises as the wearable device group, with the prescribed exercises presented in the form of a pictorial handout rather than an in-app video. They were instructed to perform the exercises for the recommended therapy dose and received a weekly therapy consultation as well. To monitor the participant's exercise compliance, they were instructed to record their daily exercise progress in the exercise log.
45648975|NCT03053999|Other|Data Review|Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels).
45796053|NCT05422625|Device|Sham PTNS Treatment|"Patients will be positioned similarly as PTNS patients. A Streitberger needle will be used at the tibial nerve insertion site as described above to simulate needle placement. Three electrodes will be placed on the patient's foot, two active TENS electrodes and one inactive TENS electrode. The TENS grounding pad will be a gel electrode pad from a TENS unit device that is placed on the bottom of the foot just below the smallest toe. Another gel electrode will be placed on the top of the foot just above the small toe for conduction. These two electrodes will be connected to the TENS unit lead wires for sham stimulation. A third, inactive, gel electrode, will be placed near the medial aspect of the calcaneus to mimic the PTNS treatment. The TENS electrode will be connected by lead wires to the TENS unit set at 20 HZ. The TENS unit will be turned on and stimulation slowly increased to the patient's first sensory level and then turned off."
45796054|NCT00002109|Drug|Thymopentin|
45796055|NCT00002109|Drug|Stavudine|
45796056|NCT00002109|Drug|Zidovudine|
45796057|NCT00002109|Drug|Zalcitabine|
45796058|NCT00002109|Drug|Didanosine|
45796059|NCT05226533|Drug|DWRX2003|Intramuscular injection of DWRX2003
45796060|NCT05226533|Drug|Placebo|Intramuscular injection of placebo
45796061|NCT00359567|Drug|palonosetron|intravenous injections of 0.75 mg palonosetron (5 mL) and then granisetron placebo before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
45796062|NCT00359567|Drug|granisetron hydrochloride|intravenous injections of palonosetron placebo and then 40μg/kg granisetron hydrochloride before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
45648976|NCT03843073|Device|Connected Urinary Catheter|Patients will use the Connected Catheter to empty the bladder during the course of treatment.
45648977|NCT03053843|Dietary Supplement|Mediterranean diet plus extra virgin olive oil|The patients in the intervention group will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months. Dietary intervention will be carried out by nutritionists with previous experience in the PREDIMED study. All of them were registered, trained and certified for developing the PREDIMED intervention protocol that is similar to the one to be carried out in this study. The theoretical sessions with patients about dietary education shall be conducted in telephone form, using the internet and sending comprehensive written material to their homes that includes recipes, shopping lists, menus and explanations of typical food in the Mediterranean diet
45796063|NCT05217641|Biological|BG505 MD39.3 mRNA|Administered by IM injection
45796064|NCT05217641|Biological|BG505 MD39.3 gp151 mRNA|Administered by IM injection
45796065|NCT05217641|Biological|BG505 MD39.3 gp151 CD4KO mRNA|Administered by IM injection
45796066|NCT00381069|Behavioral|Family & Community Recreation Center Intervention|The two year intervention involves changing the environment and policies in community recreation centers to promote physical activity and healthy eating choices. The Recreation Specialist will meet with recreation center staff monthly to create action plans that work towards this goal. Family Health Coaches will be in contact with intervention families twice a month either through a phone consultation, workshop at the recreation center,or home visit. Intervention families will receive a monthly mailing highlighting tips for healthy eating and physical activity. MOVE families will be encouraged to utilize the recreation center as a resource in supporting their child's physical activity and healthy eating behaviors.
45922744|NCT00027547|Procedure|allogeneic bone marrow transplantation|
45922745|NCT00027547|Procedure|peripheral blood stem cell transplantation|
45922746|NCT00027547|Radiation|radiation therapy|
45922747|NCT00011895|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
45922748|NCT00011895|Drug|Efavirenz|
45922749|NCT00027586|Drug|Imatinib mesylate (STI571)|400 mg twice a day orally
45922750|NCT00000464|Drug|amiodarone|
45922751|NCT00000464|Drug|imipramine|
45922752|NCT00000464|Drug|mexiletine|
45922753|NCT00000464|Drug|procainamide|
45922754|NCT00000464|Drug|propafenone|
45922755|NCT00000464|Drug|quinidine|
45922756|NCT00000464|Drug|sotalol|
45922757|NCT00027625|Drug|gefitinib|
45922758|NCT00027625|Drug|temozolomide|
45922759|NCT00027664|Biological|recombinant interferon alfa|
45922760|NCT00027664|Drug|thalidomide|
45922761|NCT00027703|Drug|gemcitabine hydrochloride|Given IV
45922762|NCT00027703|Drug|cisplatin|Given IV
45922763|NCT00027703|Biological|bevacizumab|Given IV
45922764|NCT00027703|Other|placebo|Given IV
45922765|NCT00027703|Other|laboratory biomarker analysis|Correlative studies
45922766|NCT00011934|Biological|recombinant interferon alfa|
45922767|NCT00011934|Biological|sargramostim|
45922768|NCT00011934|Procedure|autologous bone marrow transplantation|
45922769|NCT00027742|Biological|pegylated interferon alfa|
45922770|NCT00027742|Drug|temozolomide|
45922771|NCT00000467|Behavioral|diet|
45922772|NCT00000467|Behavioral|exercise|
45648978|NCT05128435|Diagnostic Test|Blood sample|Blood sample taken 3 to 5 months after the infection
45922773|NCT00000467|Behavioral|smoking cessation|
45922774|NCT00027781|Drug|sabarubicin|
45922775|NCT00027820|Drug|Fludarabine Phosphate|Given IV
45922776|NCT00027820|Radiation|Total-Body Irradiation|Undergo TBI
45922777|NCT00027820|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo nonmyeloablative PBSCT
45922778|NCT00027820|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative PBSCT
45922779|NCT00027820|Drug|Cyclosporine|Given PO
45922780|NCT00027820|Drug|Mycophenolate Mofetil|Given PO
45922781|NCT00011973|Drug|fenretinide|
45648979|NCT03055637|Procedure|Furlow double opposing z-plasty|* Furlow, (1986) has described a technique for palatoplasty combining the principles of mucosal lengthening with creation of an intact muscular sling in the palate with double opposing Z-plasty. On the soft palate, mirror image Z-plasties are drawn, one for the nasal musoca and the other oral flaps, the nasal flaps are developed and closed first .The oral flaps are then approximated. The defect created usually closes readily. The closure lines of the two soft plate layers do not overlap, minimizing the potential for contracture. Also, this repair permits closure of the hard palate without lateral incisions
45648980|NCT03055637|Procedure|Two flap palatoplasty|design the 2-flap palatoplasty, with a 2-layer closure in the hard palate and 3-layer closure in the soft palate,
45648981|NCT03559855|Behavioral|Real Essentials|The REAL Essentials curriculum is a healthy relationship education program for youth developed by the Center for Relationship Education.
45648982|NCT04918901|Combination Product|NO Severe COVID-19|Non-severe and critically ill patients with COVID-19
45648983|NCT03520231|Drug|Denosumab|RANK Ligand Inhibitor
45648984|NCT03520231|Other|Denosumab Placebo|Placebo
45796067|NCT00381147|Drug|Clarithromycin|
45796068|NCT05210465|Other|speckle tracking mode of the stress ECHO test with dobutamine|speckle tracking mode of the stress ECHO test with dobutamine
45796069|NCT05199857|Behavioral|WE BEAT Group Wellness Education program - phase 1|Participants will be assigned into a small group with 3-6 other participants and will participate in a weekly, 45-50 minute intervention session for 5 weeks, delivered by a licensed clinical psychologist or limited licensed clinical psychology fellow using University of Michigan (UM) Zoom. Each session will focus on a particular skill related to wellness and resiliency. There will also be a short battery of questionnaires to complete.
45922782|NCT00000476|Drug|digitalis|
45922783|NCT00027898|Drug|bortezomib|Given IV
45922784|NCT00027898|Drug|carboplatin|Given IV
45922785|NCT00027898|Drug|etoposide|Given IV
45922786|NCT00027898|Other|laboratory biomarker analysis|Correlative studies
45648985|NCT03520231|Drug|Gemcitabine|Antineoplastic Agent
45648986|NCT03520231|Drug|Carboplatin|Antineoplastic Agent
45648987|NCT03520231|Drug|Cisplatin|Antineoplastic Agent
45648988|NCT03520231|Dietary Supplement|Calcium|Calcium Supplement
45648989|NCT03520231|Dietary Supplement|Vitamin D|Vitamin D Supplement
45648990|NCT04927481|Drug|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
45648991|NCT05128357|Other|the study is observational, no intervention foreseen|the study does not foresees any intervention, since it is a multi step observational study.
45648992|NCT05117749|Drug|Saffron 100|to Mild and Moderate UC patients
45922787|NCT00027898|Other|pharmacological study|Correlative studies
45922788|NCT00027937|Biological|aldesleukin|
45922789|NCT00027937|Biological|filgrastim|
45922790|NCT00027937|Biological|sargramostim|
45922791|NCT00027937|Drug|busulfan|
46071798|NCT05878119|Drug|Investigational Product - MIB 626|The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.
46071799|NCT05878119|Drug|Placebo|Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC
45648993|NCT05117749|Drug|Saffron 50|to Mild and Moderate UC patients
45922792|NCT00027937|Drug|cyclophosphamide|
45922793|NCT00027937|Drug|melphalan|
45922794|NCT00027937|Drug|paclitaxel|
45922795|NCT00027937|Drug|thiotepa|
45922796|NCT00027937|Procedure|bone marrow ablation with stem cell support|
45922797|NCT00027937|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45922798|NCT00012051|Biological|filgrastim|
45922799|NCT00012051|Biological|rituximab|
45922800|NCT00012051|Drug|carmustine|
45922801|NCT00012051|Drug|cisplatin|
45922802|NCT00012051|Drug|cytarabine|
45922803|NCT00012051|Drug|dexamethasone|
45922804|NCT00012051|Drug|etoposide|
45922805|NCT00012051|Drug|ifosfamide|
45922806|NCT00012051|Drug|melphalan|
45922807|NCT00012051|Drug|methotrexate|
45922808|NCT00012051|Procedure|bone marrow ablation with stem cell support|
45922809|NCT00012051|Procedure|peripheral blood stem cell transplantation|
45922810|NCT00012051|Radiation|radiation therapy|
45922811|NCT00027976|Drug|celecoxib|
45922812|NCT00027976|Drug|Placebo|
45922813|NCT00000479|Drug|Aspirin|Participants will receive 100 mg of aspirin every other day.
45922814|NCT00000479|Drug|Vitamin E|Participants will receive 600 IU of vitamin E every other day.
45922815|NCT00000479|Behavioral|Placebo|Participants will receive placebo.
45922816|NCT00028015|Drug|SarCNU|
45922817|NCT00028132|Drug|Tenofovir|
45922818|NCT00028171|Drug|Tacrolimus|
45922819|NCT00012090|Drug|bicalutamide|
45922820|NCT00012090|Drug|goserelin acetate|
45922821|NCT00395395|Drug|Oral salmon calcitonin, salmon calcitonin nasal spray|
45922822|NCT00395434|Drug|Combretastatin A4 Phosphate (CA4P)|
45922823|NCT00395434|Drug|Bevacizumab (Avastin)|
45922824|NCT00395551|Drug|ranibizumab|0.5mg intravitreal injection
45922825|NCT00012129|Drug|liposomal annamycin|
45922826|NCT00028288|Drug|Daclizumab|
45450034|NCT02169700|Procedure|Ischemic compression. Dry Needling|Ischemic compression was carried out after dry needling. Dry needling was performed with a solid filament needle. Subjects were asked to lie in a prone position. The MTrP was held firmly in a pincer grasp. Before inserting the needle, the patient was advised about the possible sharp pain and muscle twitching. The needle was inserted perpendicular to the skin. Then, the muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needles from the MTrP until two local twitch responses were elicited from the muscle. On removal of the needle, the area was compressed firmly with a cotton bud for two minutes. Immediately after the needling, subjects were randomly assigned to one of three groups (IC, sham and control).
45450035|NCT02169778|Behavioral|Intermittent energy restricted diet|
45648994|NCT05117749|Drug|Placebo|to Mild and Moderate UC patients
45648995|NCT04918667|Combination Product|Berberine incorporated in gamma cyclodextrin|Experimental modified product. One capsule contains 250 mg of Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract incorporated in gamma-cyclodextrin
45648996|NCT04918667|Dietary Supplement|Berberine|Active comparator. One capsule contains 500 mg of Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract
45796070|NCT05199857|Behavioral|HEART Club Home Exercise program - phase 2|This is an individualized home exercise program adapted from the exercise programs used in traditional, hospital-based cardiac rehabilitation. A complete cardiopulmonary exercise test (CPET) may be completed if needed for a baseline and one will be done at the last visit. The exercise physiology team will discuss participants exercise goals, interests, and available resources to help develop the exercise plan for the research study. Once the program is designed, participants will complete the exercise activities in the plan. Over time, participants will advance through various stages in the program and then will be gradually introduced to the principles of exercise rehabilitation and more intense physical exercise. Participants will be asked to wear a wearable activity tracker and have scheduled video check-ins with the exercise physiology team. Throughout the program participants will complete a short battery of surveys.
45922827|NCT00012168|Drug|isosulfan blue|
45922828|NCT00012168|Genetic|polymerase chain reaction|
45450036|NCT02169778|Behavioral|Continuous energy restricted diet|
45922829|NCT00012168|Other|immunohistochemistry staining method|
45922830|NCT00012168|Procedure|lymphangiography|
45922831|NCT00012168|Procedure|radionuclide imaging|
45922832|NCT00012168|Procedure|sentinel lymph node biopsy|
45450037|NCT02169856|Behavioral|EFTs (emotional freedom techniques)|The Emotional Freedom Techniques (EFTs) which has been pioneered by Gary Craig is a form of alternate medicine which works by tapping on body energy meridian points. Unlike drugs the EFTs has no side effects too
45922833|NCT00012168|Radiation|technetium Tc 99m sulfur colloid|
45922834|NCT00000482|Drug|estrogen|
45648997|NCT03456193|Procedure|LA transplant|"The proposed study treatment will include three central components:~Harvest of the left atrium and pulmonary veins from a suitable donor~Excision of the left atrium and portions of stenotic pulmonary veins from the patient with pulmonary vein stenosis~Implantation of the donor posterior left atrium and portions of pulmonary veins into the patient."
45648998|NCT03056495|Drug|N-hydroxy-N'-phenyl-octanediamide (Vorinostat)|N-hydroxy-N'-phenyl-octanediamide capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
45922835|NCT00000482|Drug|clofibrate clofibrate|
45922836|NCT00000482|Drug|dextrothyroxine sodium|
45922837|NCT00000482|Drug|niacin|
45922838|NCT00028327|Drug|Lamivudine/Zidovudine|
45922839|NCT00028327|Drug|Nelfinavir mesylate|
45922840|NCT00028327|Drug|Efavirenz|
45922841|NCT00028327|Drug|Lamivudine|
45922842|NCT00028327|Drug|Zidovudine|
45922843|NCT00028366|Drug|Fosamprenavir|
45922844|NCT00028366|Drug|Lopinavir/Ritonavir|
45922845|NCT00028366|Drug|Ritonavir|
45922846|NCT00028366|Drug|Tenofovir disoproxil fumarate|
45922847|NCT00395668|Device|TETRA (at lowest carrier freq, std TDMA pulse at 17,6 Hz).|
45922848|NCT00028405|Drug|LS 11(Taporfin Sodium)|
45922849|NCT00028405|Device|Lumaflex Light Delivery Catheter|
45922850|NCT00012207|Biological|aldesleukin|
45922851|NCT00012207|Biological|therapeutic autologous lymphocytes|
45922852|NCT00012207|Drug|cyclophosphamide|
45922853|NCT00012207|Drug|prednisone|
45922854|NCT00012207|Drug|vincristine sulfate|
45922855|NCT00012207|Procedure|adjuvant therapy|
45922856|NCT00028483|Drug|cBR96-doxorubicin immunoconjugate|
45922857|NCT00028483|Drug|docetaxel|
45922858|NCT00000485|Drug|diuretics|
45922859|NCT00000485|Drug|antihypertensive agents|
45922860|NCT00028522|Drug|R(+)XK469|Given IV
45922861|NCT00028561|Drug|ixabepilone|Given IV
45922862|NCT00028561|Drug|carboplatin|Given IV
45922863|NCT00028561|Other|laboratory biomarker analysis|Correlative studies
45922864|NCT00028561|Other|pharmacological study|Correlative studies
45922865|NCT00028600|Biological|filgrastim|PBSC collection: 10 ug/kg/d subQ inj D 5 until completion of collection Auto transpl: 5 ug/kg/d subQ inj D 5 until ANC >= 1500/uL for 2d or 5000/uL for 1 d Allo transpl: 5ug/kg/d subQ inj D 7 until ANC > 1000/uL for 3 days Donor pheresis: 10ug/kg/d subQ inj d -5 thru -2
45922866|NCT00028600|Biological|CD34+ cells|2-8,000,000/kg IV infusion allogeneic transplant 2,000,000/kg IV infusion autologous transplant
45648999|NCT03171805|Drug|Propranolol|Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
45922867|NCT00028600|Drug|cyclophosphamide|4g/sq m IV infusion over 1-2 hrs D 1 for auto, and 1g/sq m/d IV infusion over 1 hr on D -4 thru -3 for allo, transplant prep
45922868|NCT00028600|Drug|fludarabine phosphate|30mg/sq m/d IVPB over 30 min d -7 thru -3 allo transpl
45796071|NCT00001545|Device|Magstim Super Rapid Magnetic Stimulator|
45796072|NCT00001545|Device|Cadwell MES-10|
45922869|NCT00028600|Drug|melphalan|200mg/sq m IV infusion over 15-30 min D 2 auto transpl
45922870|NCT00028600|Drug|methotrexate|5mg/sq m/d IV infusion D 1,3,& 6: allo transpl
45922871|NCT00028600|Drug|tacrolimus|0.03mg/kg PO bid starting dose, D -1 thru +90, then taper thru D +150
45922872|NCT04732741|Diagnostic Test|Salivary Gamma-synuclein|Gamma-synuclein salivary levels measured using ELISA assay
45922873|NCT04732741|Diagnostic Test|Incisional biopsy|"A) Biopsy (reference standard): biopsy for group 1 will be performed by specialists in the national cancer institute.~B) Biopsy for oral potentially malignant lesions will be performed by the candidate from the most representative region."
45649000|NCT03098329|Other|Ct/GC screening|Men aged 15-26 years old will be tested for chlamydia and gonorrhea at community based venues; positive men and their sexual partners will be offered expedited treatment at participating pharmacies; positive men will be asked to be rescreened for Ct/GC at 3 months post treatment.
45796073|NCT00002115|Drug|Adefovir|
45796074|NCT00360347|Drug|C.E.R.A.|
45922874|NCT04732741|Diagnostic Test|Conventional visual and tactile examination|Conventional visual and tactile examination using light and mirror
45922875|NCT00388778|Drug|Doxycycline|
45796075|NCT00002121|Drug|Diethylhomospermine|
45649001|NCT03053531|Device|"PockeTalker Hearing Assistive Device (HAD)"|Investigators will test impacts of the provision of the HAD on hearing and understanding, and preparation for discharge. Just prior to going home, consented subjects will answer a set of survey questions, using an electronic tablet to support impaired hearing.
45649002|NCT05117593|Drug|FBL-MTX|FBL-MTX is available as sterile liposomal dispersion for injection at nominal dose strength of 1 mg/mL of methotrexate free base. The dose of 0.1 mg was selected as starting dose in the present study. Three subsequent FBL-MTX dose levels are pre-planned: 0.33 mg, 1 mg and 2.5 mg.
45649003|NCT05117593|Drug|Placebo|Placebo will consist of sterile saline 0.9% NaCl solution.
45796076|NCT04983407|Drug|batiraxcept|Batiraxcept is experimental drug
45796077|NCT04983407|Drug|Nab paclitaxel|Nab paclitaxel is active comparator
45796078|NCT04983407|Drug|Gemcitabine|Gemcitabine is active comparator
45796079|NCT00001569|Drug|Cisplatin|
45796080|NCT00001569|Drug|Paclitaxel|
45796081|NCT00001569|Drug|5-FU|
45922876|NCT00012246|Biological|carcinoembryonic antigen peptide 1-6D|
45922877|NCT00012246|Biological|incomplete Freund's adjuvant|
45922878|NCT00012246|Biological|sargramostim|
45922879|NCT00028717|Biological|filgrastim|
45922880|NCT00028717|Biological|rituximab|
45922881|NCT00028717|Drug|cyclophosphamide|
45922882|NCT00028717|Drug|doxorubicin hydrochloride|
45922883|NCT00028717|Drug|prednisone|
45922884|NCT00028717|Drug|vincristine sulfate|
45796082|NCT00001587|Procedure|Isolated hepatic portal and arterial perfusion|
45796083|NCT00001587|Drug|Melphalan|
45796084|NCT04978571|Device|percutaneous electrical nerve-field stimulation, PENFS|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
45796085|NCT04978571|Device|percutaneous electrical nerve-field stimulation, PENFS (sham device)|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear. The sham device will not deliver field stimulation to the ear.
45796086|NCT00002127|Drug|Thalidomide|
45796087|NCT05421923|Drug|SR1375 capsules|Ascending single and multiple doses of SR1375 orally
45796088|NCT05421923|Other|Placebo|Ascending single and multiple doses of Placebo orally
45796089|NCT00001599|Drug|Thalidomide|
45796090|NCT00380913|Drug|Cesamet™ (nabilone)|
45796091|NCT00002133|Drug|Itraconazole|
45796092|NCT00001629|Drug|Angiotensin II type 1 receptor antagonists|
45796093|NCT05194631|Other|Quadriceps microbiopsy using a Tru-Cut biopsy needle|During surgery for a benign or malignant tumor of the liver a quadriceps microbiopsy will be performed. A 1 cm incision of the skin and fat planes will be made using a scalpel until contact with the quadriceps aponeurosis. The biopsy needle will be inserted superficially into the muscular part allowing, through a suction system, a micro biopsy of the quadriceps of approximately 25 mg.
45796094|NCT00002139|Drug|Azithromycin|
45796095|NCT05418023|Other|Salivary Collection|Collection of saliva via swab for miRNA processing
45796096|NCT05418023|Other|Adaptive Assessment|Includes Vineland Adaptive Behavior Scale or equivalent
45922885|NCT00388817|Behavioral|Pharmacist intervention|
45922886|NCT00028756|Drug|doxorubicin hydrochloride|Given IV
45922887|NCT00028756|Drug|gemcitabine hydrochloride|Given IV
45922888|NCT00028756|Drug|vinblastine sulfate|Given IV
45922889|NCT00028756|Drug|methotrexate|Given IV
45922890|NCT00028756|Drug|cisplatin|Given IV
45922891|NCT00028756|Biological|filgrastim|Given SC
45922892|NCT00012324|Drug|doxorubicin hydrochloride|
45922893|NCT00012324|Drug|nolatrexed dihydrochloride|
45922894|NCT00028795|Drug|temozolomide|
45922895|NCT00028795|Procedure|adjuvant therapy|
45922896|NCT00028795|Radiation|radiation therapy|
45922897|NCT00388856|Drug|Vitamin C 1000mg and E 400IU|
45922898|NCT00012363|Drug|gemcitabine hydrochloride|1,000mg/m2, IV over 30 min, days 1 & 8, q 21 days
45922899|NCT00012363|Drug|irinotecan hydrochloride|100 mg/m2, IV over 90 min, days 1 & 8, q 21days
45922900|NCT00388895|Drug|chemotherapy|
45922901|NCT00388895|Drug|Glivec|
45922902|NCT00028834|Drug|gemcitabine hydrochloride|Given IV
45796097|NCT05418023|Other|Medical and Demographic questionnaire|Survey that collects basic medical and demographic information
45922903|NCT00028834|Biological|bevacizumab|Given IV
46071800|NCT05878119|Other|Standardized, progressive, high intensity, multidimensional exercise|Participants will be asked to perform high intensity, standardized, progressive, multidimensional exercise.
45653181|NCT05111925|Other|PREPARE Initial Clinical Assessment - Pre-Injury (one iteration)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~Two-Minute Walk~Gait~Double Leg Squat~Single Leg Squat~Jump-Landing~Single Leg Triple Hop~Closed Kinetic Chain Upper Extremity Stability Test~Functional Movement Screening Shoulder Clearing Test~Prone Plank~Active Hip Abduction~Joint range of motion assessments:~Knee Extension~Hip Abduction~Hip Internal Rotation~Hip External Rotation~Ankle Dorsiflexion~Psychosocial assessments:~NIH PROMIS Physical Function, Pain Interference, Depression, & Anxiety~Tampa Scale of Kinesiophobia"
45796098|NCT05418023|Other|Autism Assessment|Includes Autism Diagnostic Observation Schedule (ADOS), Childhood Autism Rating Scale (CARS), Gilliam Autism Rating Scale (GARS), Autism Diagnostic Interview - Revised (ADIR) or an equivalent
45796099|NCT05418023|Other|Intellectual Development Assessment|Includes Mullens Scales of Early Learning, Stanford Binet Intelligence Scales, Wechsler Preschool and Primary Scale of Intelligence (WPPSI), Bayley Scales of Infant Development or an equivalent
45796100|NCT00002295|Drug|Inosine pranobex|
45796101|NCT00002145|Drug|Foscarnet sodium|
45796102|NCT05417555|Device|Low-Intensity Focused Ultrasound Pulsation (LIFUP)|Focused ultrasound is a re-emerging neuromodulation technology. Ultrasound uses high-frequency longitudinal pressure waves to generate clinical images via refraction. At high intensities, ultrasound can be used to cause ablations (e.g. for neurosurgical pallidotomy). Low intensity tFUS can penetrate the skull and dura, thereby affecting neuron populations in the brain, likely through cellular modulation. By changing the parameters of the ultrasound such as pulse repetition frequency and duty cycle, it is possible to create potentiating or disruptive effects at the network level, without also causing tissue damage via the heating effects seen at higher intensities.
45796103|NCT00002301|Drug|Foscarnet sodium|
45796104|NCT05416541|Behavioral|social media|ASA I-II, who speaks and writes Turkish and do not have psychiatric illness patients will attend the study.
45796105|NCT00002151|Drug|Celgosivir hydrochloride|
45796106|NCT00002307|Drug|Stavudine|
45796107|NCT00002307|Drug|Zidovudine|
45796108|NCT00002313|Drug|Nystatin|
45796109|NCT00002313|Drug|Didanosine|
45796110|NCT05188235|Device|Acoustical Resonance Device|"Infants will be studied for 15 min using an electronic tuning fork to transmit sound through the hip from a point on the skin while transmitted sounds FDA-approved stethoscope"
45796111|NCT00002157|Drug|Thalidomide|
45796112|NCT00002319|Drug|Doxorubicin hydrochloride (liposomal)|
46071801|NCT05878119|Other|Usual Physical Activity|Participants will be asked to perform usual physical activity per listed in the protocol
46071802|NCT05878106|Dietary Supplement|Creatine supplementation|"5 g/day supplementation of creatine for the duration of the exercise the 16-week intervention.~The RG and the RCG will receive a supplement of soluble protein powder (20-30 g) daily."
46071803|NCT05878106|Other|Resistance training|They will do resistance training. Resistance training will be a 16-week supervised workout that will consist of a series of resistance exercises (leg press, knee extension, knee bends, chest press, sit-ups, back extensions, pull-ups, and shoulder press) that involved the largest muscle groups of the body and will be performed three times a week on non-consecutive days.
45922904|NCT00028834|Other|laboratory biomarker analysis|Correlative studies
45922905|NCT00028873|Drug|docetaxel|
46071804|NCT05878080|Device|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
45922906|NCT00028873|Drug|laniquidar|
45922907|NCT00028873|Drug|paclitaxel|
45922908|NCT00028912|Drug|bortezomib|
45922909|NCT00028912|Drug|carboplatin|
45922910|NCT00028951|Drug|fibrin sealant|
45922911|NCT00028951|Procedure|surgical wound closure|
45922912|NCT00388934|Device|Drug eluting stent|percutaneous intervention with implantation of drug eluting coronary stent
45922913|NCT01803555|Drug|Budesonide/Formoterol SPIROMAX®|BF Spiromax will be administered per dose and schedule specified in the arm.
45922914|NCT01803555|Drug|SYMBICORT® TURBOHALER®|Symbicort Turbohaler will be administered per dose and schedule specified in the arm.
45922915|NCT01803555|Drug|SYMBICORT placebo|SYMBICORT placebo multi-dose dry powder inhaler (DPI) identical in appearance to SYMBICORT TURBOHALER will be administered per dose and schedule specified in the arm.
45796113|NCT00358709|Behavioral|Cognitive-Behavioral therapy and Symptom Management|A group cognitive-behavioral therapy approach to lessening psychotic symptoms of individuals with a first episode of psychosis, and comparison its effects to a known skills training approach and a control group.
45796114|NCT00002163|Drug|Abacavir sulfate|
45922916|NCT01803555|Drug|SPIROMAX Placebo|SPIROMAX Placebo multi-dose dry powder inhaler (DPI) identical in appearance to BF SPIROMAX will be administered per dose and schedule specified in the arm.
45922917|NCT00029029|Procedure|pain therapy|
45922918|NCT00029029|Procedure|radiofrequency ablation|
45649004|NCT04927013|Behavioral|Message-based Outreach Intervention for Survivors|The Georgia Cancer Registry will mail the initial recruitment containing messages intended to persuade the survivor to visit the study website as well as a unique login to access the website. In addition to the components of the standard website, an expanded website for the Message-based group will include Guidance for Talking with Close Relatives about Their Cancer Risk, and the request to enumerate each close relative and choose from a menu of options about how the survivor would prefer for their relatives to be contacted. Survivors also can select the option that they prefer a relative not be contacted. In this case, no invitation letter will be generated for these relatives. Survivors who provide mobile phone numbers will receive two SMS thanking them for accessing the website, and encouraging them to revisit the website to review information and contact relatives. The messages will occur at 3-week intervals over a 6-week time period.
45796115|NCT05406947|Other|Prospective observational study, no intervention|Prospective observational study, no intervention
45922919|NCT00000488|Drug|cholestyramine|
45922920|NCT00000488|Behavioral|diet, fat-restricted|
45796116|NCT05440539|Other|Written Handouts|The written materials were generated using the collaboration of healthcare communication specialists to generate content that is tailored to a younger age demographic of childbearing age regarding their risk of developing a pelvic floor disorder and what can be done to prevent or treat them in the future.
45796117|NCT05440539|Other|Interactive Workshop|Participants logged onto a virtual meeting platform and listened to a live 20 minute presentation by a pelvic floor physical therapist followed by time for questions, which were answered live. Participants anonymity was maintained by not allowing participants to view each other's name and disabling sharing of video feeds.
45796118|NCT05180591|Biological|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
45922921|NCT00029185|Drug|Dehydrex|
45922922|NCT00029224|Drug|zoledronic acid|
45922923|NCT00012441|Procedure|hemodialysis|
45922924|NCT00029263|Drug|herbals|
45922925|NCT00029341|Behavioral|Treatment Interruption|
46071805|NCT05878054|Other|Proactive, integrated and personalised care|During the intervention patients receive proactive, integrated and personalised care. An intake consultation using Positive Health tool, or a similar method, the needs of each patient is assessed. In a multidisciplinary meeting with the GP, mental health care practice nurse, a social worker and the patient, a personalised care plan is made. The personal is executed and a care coordinator maintains proactive contact with the patient. Clinical follow-up will be done via a second multidisciplinary meeting.
46071806|NCT05878041|Diagnostic Test|Molecular and genetic screening|Molecular and genetic screening
46071807|NCT05878028|Combination Product|L-TIL, Tislelizumab, Docetaxel|PD1 positive lymphocytes were collect, isolated, and expanded from peripheral blood, then infused back into the patient's body. Besides this, Tislelizumab and Docetaxel were used as combination therapy.
46071808|NCT05878015|Drug|Acetaminophen|1000mg intravenous every 6 hours on day 1 and day 2. 1000mg intravenous every 8 hours on day 3 as needed.
46071809|NCT05878002|Device|polysomnography|Sleep study through polysomnographic examination
45922926|NCT00000491|Drug|aspirin|
45922927|NCT00029380|Drug|Sangstat|
46071810|NCT05877989|Drug|Amino Acid|Amino acid enteral and/or parenteral nutrition either enteral or parenteral to target a total protein delivery of 2.0g/kg/day.
46071811|NCT05877989|Procedure|Physical exercise|The physical exercise intervention will be delivered by trained nursing staff, and started as close to the time of randomization as feasible (within 24hours of randomization). The intervention group will receive exercise sessions, for up to 20 min duration (as tolerated by patient).The implementation of physical exercise intervention will be protocolized to provide passive exercise early before weaning and shift to active exercise after weaning and also graduated resistance during each session and between daily sessions.
45796119|NCT05180591|Biological|Saline Injection|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
45796120|NCT00002325|Drug|Fluconazole|
45796121|NCT04745429|Other|breathing exercises, cold exposure and meditation|It is a combination of exercises that include breathing exercises, cold exposure and meditation
45796122|NCT00002331|Drug|Ethambutol hydrochloride|
45922928|NCT00029380|Drug|Cyclophosphamide|
45922929|NCT00029380|Drug|Busulfan|
45922930|NCT00029380|Drug|Mycophenolate Mofetil|
45922931|NCT00029380|Drug|Cyclosporine|
45922932|NCT00029380|Procedure|Cord Blood Transplantation|
45922933|NCT00029458|Drug|Clozapine|
45922934|NCT00029497|Procedure|Acupuncture|
45922935|NCT00029497|Drug|Amitriptyline|
45922936|NCT00000494|Drug|indomethacin|
45922937|NCT00000494|Procedure|surgery, cardiovascular|
45922938|NCT00029575|Device|Surgi-Vision Guidewire Coil|
45922939|NCT00012519|Drug|indinavir sulfate|
45922940|NCT00012519|Drug|ritonavir|
45922941|NCT00029614|Drug|Atomoxetine|
45922942|NCT00029692|Drug|Ginseng|
45922943|NCT00029692|Drug|Ginkgo|
45922944|NCT00029731|Drug|Arginine hydrochloride|
45922945|NCT00000497|Behavioral|diet, sodium-restricted|
45922946|NCT00000497|Behavioral|diet, reducing|
45922947|NCT00029770|Procedure|Chiropractic spinal manipulation|
45922948|NCT00029770|Drug|Acetaminophen|
45922949|NCT00029770|Behavioral|Self-care|
45922950|NCT00029770|Drug|Non-Steroidal anti-inflammatory drugs (NSAIDS)|
45922951|NCT00029770|Drug|Tylenol with codeine|
45922952|NCT00012558|Drug|lithium|
46071812|NCT05877976|Behavioral|Visual Arts Immersion|Museum educators from The Metropolitan Museum of Art (MET) will provide a curriculum including an art immersion program that will select specific works/art in the museum as well as virtually that will help to stimulate self-reflection and prompt connection to their nursing practice. Participants will be asked to sign up for 2 art immersion classes. The first class will be an in-person class at The MET and the second class will be virtual via WebEx. Each class will last 60 minutes.
45649005|NCT04927013|Behavioral|Standard Outreach for Survivors|The Georgia Cancer Registry will mail survivors an introductory letter modeled on the Registry's general outreach letters that will include log-in information. Survivors will have access to a condensed version of the website that includes Information about Ovarian Cancer, Information about Who in Your Family is at Increased Risk, and the offer of Free Genetic Counseling with the option to schedule an appointment.
46071813|NCT05877950|Device|Smartphone-based speech therapy|Participants will be instructed to use the speech therapy app for 1 hour per day (5 days for 1 week) over a 4-week period.
46071814|NCT05877950|Other|Home-based speech therapy|Participants will receive treatment maintaining the same frequency as the intervention group.
45922953|NCT00012558|Drug|valproate|
45922954|NCT00012558|Drug|bupropion|
45922955|NCT00012558|Drug|paroxetine|
45922956|NCT00012558|Drug|lamotrigine|
45796123|NCT00002331|Drug|Clarithromycin|
45796124|NCT00002331|Drug|Clofazimine|
45796125|NCT05172479|Diagnostic Test|Measurement of qSOFA score|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's qSOFA score.
45922957|NCT00012558|Drug|risperidone|
46071815|NCT05877937|Other|Supportive care (Watching a comedy movie)|A 10.1 inch Android tablet (2 pieces) and disposable earplugs for each patient were used in the study. A comic film archive was created in line with the recommendation and consultancy of department of state conservatory and performing arts. In this regard, the officials of the Conservatory stated that they had no standardized comedy films specific to society and emphasized that the standardization of art limits art activities. Therefore, there should be no limitations for art. In the film archive cre-ated according to their suggestions, there were a total of five comedy movies, including three Turkish comedies, one foreign romantic comedy, and one foreign Turkish-dubbed family comedy. The original/licensed versions of the movies in this archive were ob-tained and uploaded to the tablet. The movies lasted 90-120 minutes (as long as the av-erage duration of IV treatment). The patients selected the movie that they would watch during the treatment.
46071816|NCT05877924|Drug|NBL-020 for Injection|NBL-020 for Injection, Q3W, i.v.
45450038|NCT02169856|Drug|Tab. Midazolam 7.5 mg|Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
45450039|NCT02169856|Drug|Inj. Midazolam 0.7mg/kg|Inj . Midazolam 0.7 mg/kg given as premedication 45 min before surgery.
45649006|NCT04927013|Behavioral|Message-based Outreach Intervention for Close Relatives|Relatives will receive a unique website login linked to the survivor that enables access to the website. The website content will be identical to the survivor content with the exception of the addition of the Breast Cancer Genetics Referral Screening Tool (B-RST) risk assessment tool. This brief risk assessment is a validated screening tools that is clinically useful for estimating the probability of breast cancer (BRCA1/2) gene mutation and identifying women for referral to genetic counseling. Although all 1st or 2nd degree relatives of ovarian cancer survivors will screen positive on B-RST, asking relatives to complete the screener aims to raise their awareness of the factors that contribute to hereditary risk of ovarian cancer and will reinforce the salience of seeking genetic counseling. Additionally, relatives for who provide cell phone numbers will receive 3 SMS reminders over 9 weeks.
45796126|NCT05172479|Diagnostic Test|Measurement of SIRS criteria|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's SIRS criteria.
45450040|NCT02169856|Drug|Inj. Propofol 2.5mg/kg|It was given to induce anesthesia after 3 min of pre oxygenation.
45450041|NCT02169856|Drug|Inj. Atracurium 0.5 mg/kg|It was given to induce muscle relaxation during anesthesia
45450042|NCT02169856|Drug|Sevoflurane 2.5 vol %|It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
45450043|NCT02169856|Drug|Inj. Cefuroxime 1.5 g IV|It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
45649007|NCT04927013|Behavioral|Standard Outreach for Close Relatives|The invitation letter shared by the survivor will provide a unique login code for each relative to visit the standard website with sections specifically for relatives that include information about genetic risk, the value of completing an online short validated risk screener, and the offer of free genetic counseling with the option to schedule an appointment.
45796127|NCT05172479|Diagnostic Test|Measurement of NEWS|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS.
45922958|NCT00012558|Drug|inositol|
45922959|NCT00012558|Drug|tranylcypromine|
45922960|NCT00012558|Behavioral|Cognitive Behavioral Therapy|
45922961|NCT00012558|Behavioral|Family-focused Therapy|
45922962|NCT00012558|Behavioral|Interpersonal and Social Rhythms Therapy|
45922963|NCT00029809|Behavioral|Chinese exercise modalities|
45922964|NCT00395707|Drug|Lucentis|0.3mg/0.05 ml or 0.5mg/0.05 ml
45922965|NCT00395707|Drug|Ranibizumab|0.3mg/0.05 ml or 0.5mg/0.05 ml
45922966|NCT00395707|Drug|Ranibizumab (Lucentis)|0.3mg/0.05 ml intravitreally
45922967|NCT00395707|Drug|Ranibizumab (Lucentis)|0.5mg/0.05 ml
45922968|NCT00395785|Device|Carotid Stent Implantation|
45922969|NCT00395785|Device|Embolic Protection|
45922970|NCT00000500|Drug|aspirin|
45922971|NCT00000500|Drug|carotene|
45922972|NCT00395824|Procedure|anticoagulation procedure|
45922973|NCT00012597|Procedure|Web-based telemedicine system for assessment of status of pressure ulcers|
45922974|NCT00395902|Drug|Sensipar after Post Transplant|
45922975|NCT00029848|Drug|Rimonabant (SR141716)|
45922976|NCT00000503|Drug|nitroglycerin|
45922977|NCT00000503|Drug|streptokinase|
45649008|NCT02787187|Procedure|Pancreaticoduodenectomy with Standard lymphadenectomy|Pancreaticoduodenectomy：child's digestive reconstruction standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
45796128|NCT05172479|Diagnostic Test|Measurement of NEWS2|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS2.
45450044|NCT02169856|Drug|Drug: Inj. Ketorolac 30 mg IV|3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period
45922978|NCT00000503|Procedure|heart catheterization|
45922979|NCT00012636|Procedure|Computer generated statements about guideline concordance of drug therapy deliver to clinicians|
45922980|NCT00029926|Drug|2-deoxy-2 [F-18] fluoro-2-d-glucose|
45922981|NCT00030004|Procedure|spinal manipulation|
46071817|NCT05877911|Drug|Sodium Sulfate|Sodium thiosulfate has previously been reported to reduce the incidence of acute kidney injury after HIPEC with cisplatin, but this finding has not been confirmed in a high-level study.
46071818|NCT05877911|Other|Hydration|On the day of surgery, the day of HIPEC, and 24 hours after HIPEC, daily intravenous rehydration should be performed using natrium chloride, glucose chloride or potassium chloride. The amount of fluid to be replenished should not be less than 3000 milliliters.
45450045|NCT02169856|Drug|Inj. Zantac 50mg IV|2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
45450046|NCT02169934|Drug|Radiolabeled TRV130|A single 2 mg IV dose administered as a 10 mL manual IV push over 2 minutes
45649009|NCT02787187|Procedure|Pancreaticoduodenectomy with Extended lymphadenectomy|Pancreaticoduodenectomy：child's digestive reconstruction extended lymphadenectomy: No8p 12a 12p 14c 14d 16
45649010|NCT03053375|Device|MDCure|Battery powered portable pulsed electromagnetic therapy device
45796129|NCT05172479|Diagnostic Test|Measurement of MEWS|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's MEWS.
45796130|NCT00002337|Drug|Vesnarinone|
45796131|NCT00002169|Drug|Nelfinavir mesylate|
45796132|NCT02293902|Drug|Sarilumab SAR153191 (REGN88)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
45796133|NCT02293902|Other|Placebo (for sarilumab)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
45796134|NCT02293902|Drug|Methotrexate|Dispensed according to local practice.
45922982|NCT00030004|Drug|midazolam|
45922983|NCT00030043|Device|Penetrating auditory brainstem implant|
45796135|NCT02293902|Drug|Folic acid|Dispensed according to local practice.
45796136|NCT05400629|Other|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises will be perform between 6 and 8 maximal repetitions.
45796137|NCT00002343|Drug|Ethambutol hydrochloride|
45922984|NCT00030082|Drug|isolated perfusion|
45922985|NCT00030082|Drug|melphalan|
45922986|NCT00000518|Procedure|electrophysiology|
45450047|NCT02170012|Drug|PF-06743649|20 mg tablet once daily dosing for 14 days
45450048|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
45450049|NCT02170012|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
45649011|NCT05405023|Other|Concentric exercises with wrist mobilization|Participants will receive concentric exercise including wrist flexion, extension, and abduction, adduction, supination and pronation plus wrist mobilizations with movements.
45649012|NCT05405023|Other|Concentric exercises without wrist mobilization|Participants will receive concentric exercises only.
45649013|NCT04918277|Device|Assessment of gastric volume|Measuring the cross-sectional area of stomach in supine and right lateral decubitus
45796138|NCT00002343|Drug|Rifabutin|
45796139|NCT00002175|Drug|Dinitrochlorobenzene|
45796140|NCT05168735|Drug|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
45796141|NCT05168735|Behavioral|Brief Mindfulness Exercises|30min guided training in mindfulness meditation immediately prior to infusion
45922987|NCT00000518|Procedure|electrocardiography, ambulatory|
45922988|NCT00000518|Drug|imipramine|
45922989|NCT00000518|Drug|mexiletine|
45922990|NCT00000518|Drug|procainamide|
45922991|NCT00000518|Drug|quinidine|
45922992|NCT00000518|Drug|sotalol|
45922993|NCT00030121|Drug|recombinant human atrial natriuretic polypeptide|
45922994|NCT00030160|Behavioral|Strength Training|
45922995|NCT00030238|Drug|Calcium supplement|Calcium Carbonate capsules prepared by NIH PDS
45922996|NCT00030238|Drug|Placebo|Placebo capsules prepared by the NIH PDS to be identical to Calcium Carbonate capsules
45922997|NCT00012714|Behavioral|Case management services|
45922998|NCT00000521|Behavioral|diet, sodium-restricted|
45922999|NCT00000521|Behavioral|diet, potassium-supplemented|
45923000|NCT00030277|Procedure|high-intensity focused ultrasound ablation|
45923001|NCT00030355|Drug|homoharringtonine|
45923002|NCT00030355|Procedure|chemotherapy|
45923003|NCT00030394|Drug|imatinib mesylate|Given orally
45923004|NCT00030394|Other|laboratory biomarker analysis|Correlative studies
45923005|NCT00030394|Other|pharmacological study|Correlative studies
45923006|NCT00395941|Drug|Pioglitazone|
45923007|NCT00395941|Drug|Acitretin|Acitretin
45923008|NCT00030433|Drug|gemcitabine hydrochloride|
45923009|NCT00030433|Drug|irinotecan hydrochloride|
45923010|NCT00012753|Procedure|Automated telephone health status assessments with nurse follow-up.|
45923011|NCT00030472|Drug|pegylated liposomal doxorubicin hydrochloride|
45923012|NCT00000527|Drug|aspirin|
45923013|NCT00000527|Drug|dipyridamole|
45923014|NCT00030511|Drug|fluorouracil|
45923015|NCT00030511|Procedure|conventional surgery|
45796142|NCT05168735|Behavioral|Academic Exercises|30min of mental math and other academic cognitive puzzles completed silently/mentally
45796143|NCT00002349|Drug|Stavudine|
45923016|NCT00030511|Radiation|radiation therapy|
45796144|NCT04706013|Drug|Pyridoxal Phosphate|Oral tablets 50 mg
45923017|NCT00012792|Behavioral|Exercise Training|
45923018|NCT00030550|Drug|thalidomide|
45923019|NCT00030589|Drug|bexarotene|
45923020|NCT00030589|Drug|methoxsalen|
45796145|NCT00002355|Drug|Fomivirsen sodium|
45923021|NCT00030589|Procedure|UV light therapy|
45923022|NCT00000530|Drug|nifedipine|
46071819|NCT05877911|Drug|Cisplatin|Infuse cisplatin (75mg/m^2) at 43℃ through the two drainage tubes placed in the upper abdomen, using the two drainage tubes placed in the lower abdomen as the effluent tubes, with an infusion time of 60-90 minutes and an infusion rate of 500-600 mL/min. The first HIPEC should be performed within 24-48 hours after cytoreductive surgery. The second HIPEC should be performed 24 hours after the completion of the first HIPEC. Intravenous sedatives such as dexmedetomidine or propofol at 2-6 ml/h should be administered during HIPEC treatment with continuous intravenous infusion by a pump，or intramuscular injection of 50 mg of pethidine.
46071820|NCT05877898|Behavioral|CHW Education|Participants will be invited to meet with the CHW to learn about eating healthier to reduce blood pressure and enhance quantity and quality of life.
45649014|NCT04918433|Procedure|Regional anaesthesia|Regional anaesthesia for sternotomy incision for congenital cardiac surgery
45649015|NCT05093803|Behavioral|CONTROL GROUP|Intervention based on measurements of health parameters before and after providing participants with personalized dietary and physical activity recommendations.
45649016|NCT05093803|Behavioral|HEALTH APP GROUP|"Use of a mobile application based on machine learning with the aim of improving health parameters and body composition.~Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators."
45796146|NCT00358787|Procedure|Crossed K-wiring of supracondylar fracture of the humerus|Closed reduction of the fracture followed by crossed K wire percutaneous pinning.
45796147|NCT00358787|Procedure|Lateral K-wiring of supracondylar fracture of the humerus|Closed reduction of the fracture followed by lateral K wire percutaneous pinning.
45796148|NCT02278614|Drug|T2347|T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.
45796149|NCT02278614|Drug|Xalacom|Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.
45796150|NCT00002361|Drug|Indinavir sulfate|
45796151|NCT00002361|Drug|Ritonavir|
45796152|NCT00002181|Drug|Cidofovir|
45796153|NCT04880772|Other|Prehabilitation|exercise & multivitamin (nutritional/dietary advice)
45796154|NCT00002367|Drug|Saquinavir|
45796155|NCT00002367|Drug|Lamivudine|
45796156|NCT00002367|Drug|Zidovudine|
45796157|NCT04880382|Drug|ICI treatment discontinuation|After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be discontinued. Patients will be followed as per standard mangement thereafter
45796158|NCT04880382|Drug|ICI treatment continuation|After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be continued until disease progreession or unacceptable toxicity
45796159|NCT00002187|Drug|Fomivirsen sodium|
45796160|NCT00359645|Procedure|Screening by head and neck clinical examination with a fiberoptic nasolaryngoscopy and an oesopharyngeal brush biopsy annually during 3 years|
45796161|NCT00002373|Drug|Maribavir|
45796162|NCT00002379|Drug|Indinavir sulfate|
45796163|NCT00002379|Drug|Levocarnitine|
45796164|NCT00002379|Drug|Adefovir dipivoxil|
45796165|NCT00002379|Drug|Lamivudine|
45796166|NCT00002379|Drug|Stavudine|
45796167|NCT00002379|Drug|Zidovudine|
45923023|NCT00000530|Behavioral|biofeedback (psychology)|
45923024|NCT00000530|Procedure|electromyography|
45923025|NCT00030628|Radiation|radiation therapy|
45923026|NCT00030628|Procedure|surgery|
45923027|NCT00030628|Radiation|WBRT|
45923028|NCT00030667|Drug|imatinib mesylate|Given orally
45923029|NCT00030667|Other|laboratory biomarker analysis|Correlative studies
45923030|NCT00030667|Other|pharmacological study|Correlative studies
45923031|NCT00030706|Drug|ixabepilone|
45923032|NCT00000533|Behavioral|social support|
45923033|NCT00030745|Drug|cisplatin|
45923034|NCT00030745|Drug|gemcitabine hydrochloride|
45923035|NCT00030745|Procedure|conventional surgery|
45923036|NCT00030784|Drug|ifosfamide|
45923037|NCT00030784|Drug|pegylated liposomal doxorubicin hydrochloride|
45923038|NCT00030862|Drug|cisplatin|
45923039|NCT00030862|Drug|irinotecan hydrochloride|
45923040|NCT00000539|Drug|niacin|
45923041|NCT00000539|Drug|pravastatin|
45923042|NCT00000539|Drug|beta-carotene|
45923043|NCT00000539|Drug|vitamin E|
45923044|NCT00000539|Behavioral|dietary supplements|
45923045|NCT00000539|Drug|vitamin C|
45923046|NCT00000539|Drug|warfarin|
45923047|NCT00030979|Drug|Donepezil|
45923048|NCT00031018|Drug|Aricept|
45923049|NCT00031018|Drug|IFN-alpha2A|
45923050|NCT00012870|Behavioral|Behavioral Management|
45923051|NCT00031057|Drug|Thiamine hydrochloride|
45923052|NCT00031057|Drug|Riboflavin|
45923053|NCT00000554|Procedure|Angiography, MRI, Dobutamine-Stress Echocardiography, PET,|
45923054|NCT00000554|Procedure|Myocardial Contrast Echo, Coronary Flow and Vasomotor Testing|
45923055|NCT04711720|Device|"VTS surgical navigation system"|"TheVTS surgical navigation system can accurately match the preoperative and intraoperative image data with the patient's anatomical structure on the operating table, track the surgical instruments during the operation, and update the position of the surgical instruments on the patient's image in real time, so that the doctor can clearly understand the position of the surgical instruments relative to the patient's anatomical structure, and make the operation procedure more accurate and safer."
45796168|NCT00359723|Drug|methylphenidate|
45923056|NCT00012909|Behavioral|Hormone Replacement Therapy Decision-Aid|
45923057|NCT00031096|Drug|Azelaic Acid Gel 15% (Finacea, BAY39-6251)|Azelaic Acid 15% gel (SH H 655 BA) applied topically two times per day.
45923058|NCT00031096|Drug|Vehicle gel (SH H 655 PBA)|Vehicle gel (SH H 655 PBA) applied topically two times per day.
45923059|NCT00031135|Drug|Choline Chloride|
45923060|NCT00000557|Behavioral|social support|
45923061|NCT00012948|Procedure|Telephone Care|
45649017|NCT04926467|Drug|Anakinra|"Pre-operative treatment: Nab-paclitaxel (125 mg/m2), gemcitabine (1000 mg/m2), and cisplatin (25 mg/m2) will be given on Day 1 and 8 of a 21-day cycle. Patients will receive anakinra 100 mg injection twice a day starting on day 1 of chemotherapy. Anakinra will be self-administered by the patients and will be discontinued 2 days prior to surgery. Total number of cycles = 4.~Post-operative treatment: 5-Fluorouracil (2400 mg/m2 CI for 48 hours), oxaliplatin (85 mg/m2), and irinotecan (150 mg/m2) will be given once every 2 weeks (1 cycle =14 days). Patients will receive anakinra 100 mg injection subcutaneously twice a day starting on day 1 of chemotherapy (initiated within 4-8 weeks after surgery). Anakinra will be self-administered by the patient throughout the treatment without any break. Total number of cycles = 8."
45923062|NCT00031291|Drug|Anthrax Immune Globulin|
45923063|NCT00000560|Drug|adrenergic beta antagonists|
45923064|NCT00395980|Device|surgical table pressure mat|
45649018|NCT02302105|Radiation|IGRT|Image Guided RT to the prostate
45649019|NCT05128045|Behavioral|NEW-R|Eight session class on nutrition, physical activity, diet, and weight management
45923065|NCT00012987|Behavioral|Quality Improvement|
45923066|NCT00396058|Drug|Methylphenidate|
45923067|NCT00396214|Drug|Bifeprunox|52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 1 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
45923068|NCT00396214|Drug|Quetiapine|Fixed oral dose of quetiapine at 400 mg/day to be administered in divided doses (BID) utilizing a 5-day upward titration from 50 mg/day.
45649020|NCT03053297|Other|Patient Reported Outcomes|"HRQoL will be assessed using questionnaire EORTC QLQ-C30 and the questionnaire EORTC QLQ-LC 13.~These two questionnaires are validated instruments, translated in various languages and are not used as an intervention but rather to track patient quality of life and symptom reduction in real-life settings. Data for these patient reported outcomes will be collected prospectively from the time of enrolment until the end of follow-up. The two questionnaires will be self-administered by the patients in both cohorts at the enrolment visit and subsequently every 3 months (±1 month) at routine standard of care scheduled visits. The questionnaires are expected to take about 15 minutes to complete"
45796169|NCT00002193|Drug|Amprenavir|
45796170|NCT02977559|Device|Laryngeal Tube Suction Disposable|Device for ventilation
45796171|NCT02977559|Device|Laryngeal Mask Airway AuraGain|Ventilation device
45796172|NCT00002385|Drug|Fozivudine tidoxil|
45796173|NCT00002391|Drug|Abacavir sulfate|
45796174|NCT00002391|Drug|Lamivudine|
45796175|NCT00002391|Drug|Zidovudine|
45796176|NCT00002199|Drug|Indinavir sulfate|
45796177|NCT00002199|Drug|Lamivudine/Zidovudine|
45796178|NCT00002199|Drug|Abacavir sulfate|
45796179|NCT04973267|Behavioral|Game Plan for PrEP|See arm description.
45796180|NCT04973267|Behavioral|Attention-Matched Control Lifestyle Habits Videos|Web-based videos providing information on sleep hygiene and proper diet.
45796181|NCT00002397|Drug|Nelfinavir mesylate|
45796182|NCT00002397|Drug|Saquinavir|
45796183|NCT00002397|Drug|Lamivudine|
45796184|NCT00002397|Drug|Stavudine|
45796185|NCT00002205|Drug|Abacavir sulfate|
45796186|NCT00002205|Drug|Amprenavir|
45796187|NCT02977169|Radiation|PORT|3-dimensional conformal or intensity-modulated radiotherapy, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks, following the standard and consistent PORT CTV delineation guideline
45923069|NCT00396214|Drug|Bifeprunox|52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 2 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
45923070|NCT00000563|Drug|dexamethasone|
45923071|NCT00013026|Behavioral|CHF Self-management Education (Web-based Education)|
45923072|NCT00031564|Biological|Interleukin-2|
45923073|NCT00031564|Biological|B7-1|
45923074|NCT00000566|Procedure|ventilation-perfusion ratio|
45923075|NCT00000566|Procedure|angiography|
45923076|NCT00031642|Biological|rituximab|
45923077|NCT00031642|Radiation|yttrium Y 90 ibritumomab tiuxetan|
45923078|NCT00031681|Drug|7-hydroxystaurosporine|Given IV
45923079|NCT00031681|Drug|irinotecan hydrochloride|Given IV
45923080|NCT00031681|Other|diagnostic laboratory biomarker analysis|Correlative studies
45923081|NCT00031720|Dietary Supplement|soy protein|Given orally
45923082|NCT00031720|Dietary Supplement|isoflavones|Given orally
45923083|NCT00031720|Drug|Tamoxifen|
45923084|NCT00031720|Other|Placebo|Oral
45923085|NCT00000569|Drug|triamcinolone|1200 micrograms of triamcinolone in daily divided doses
45923086|NCT00000569|Other|Placebo|Placebo
45923087|NCT00031759|Drug|imiquimod|
45923088|NCT00031759|Procedure|Ablative or excisional therapy|
45923089|NCT01791816|Drug|Phenylephrine|"Phenylephrine dose-response comprises infusion of 0.5, 1, 2, 3, 4 micrograms/kg/min for 10 min at each dose.~If bloods pressure increases by 30% or if heart rate decreases below 40 beats per minute we will stop infusion."
45796188|NCT02977169|Drug|Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)|Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
45923090|NCT01791816|Drug|L-Ng-monomethyl Arginine (L-NMMA)|Systemic L-NMMA is infused as a 500μg/kg/min loading dose for 15 min followed by a 50μg/kg/min maintenance dose for the remainder of the experiment.
45923091|NCT00031798|Drug|methylphenidate hydrochloride|
45923092|NCT00031798|Procedure|quality-of-life assessment|
45649021|NCT05127889|Drug|curodont|"To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide.~The varnish will be mixed with the brush to avoid separation of the material during storage~However, to guarantee the best results suction will be used during application of the varnish.~A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush~The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles.~After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs."
45923093|NCT00031798|Radiation|radiation therapy|
45923094|NCT00031837|Drug|dalteparin|
46071821|NCT05877898|Behavioral|CHW Education and Navigation|Participants will be invited to complete all the CHW education arm material and be offered a menu of optional services for personalization including: (1) transportation to the grocery store (weekly for 4 weeks), (2) culturally adapted hypertension-tailored cooking recipes, (3) a virtual cooking class with food delivered to their door led by community partner, (4) access to UF IFAS's online library of healthy food cooking videos, and (5) in-store education on food labels, grocery shopping, and food resource management skills through the Cooking Matters at the Store curricula.
45649022|NCT05127655|Procedure|full mouth rehabilitation|full mouth rehabilitation under general anesthesia
45649023|NCT04926935|Diagnostic Test|Microbiological analysis of blood samples.|Microbiological analysis of blood samples collected from the patients with clinically suspected infection.
45649024|NCT03053219|Drug|AC0010|Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours
45923095|NCT00031837|Drug|gemcitabine hydrochloride|
45923096|NCT00031837|Procedure|quality-of-life assessment|
45923097|NCT00000572|Procedure|positive-pressure ventilation|Detailed computer protocol controlled positive pressure ventilation
45923098|NCT00000572|Procedure|extracorporeal membrane oxygenation (CO2 removal)|Detailed computer protocol controlled Extracorporeal CO2 Removal with reduced positive pressure ventilation
45923099|NCT00031876|Drug|capecitabine|
45923100|NCT00031876|Drug|paclitaxel|
45923101|NCT00031915|Drug|imatinib mesylate|
45450050|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
45450051|NCT02170012|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
45450052|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
45450053|NCT02170012|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
45796189|NCT00002403|Drug|Zintevir|
45796190|NCT05152823|Biological|Gene Therapy|AAV9 carrying the IGHMBP2 gene.
45796191|NCT00002409|Drug|Lamivudine/Zidovudine|
45796192|NCT00002409|Drug|Abacavir sulfate|
45923102|NCT00031954|Drug|carboplatin|
45923103|NCT00031954|Drug|gemcitabine hydrochloride|
45923104|NCT00031954|Drug|paclitaxel|
45923105|NCT00013143|Behavioral|Patient risk profiling (potential ADEs) w/provider feedback|
45923106|NCT00031993|Drug|erlotinib hydrochloride|Given PO
45923107|NCT00031993|Other|laboratory biomarker analysis|Correlative studies
45923108|NCT00000575|Drug|Placebo|Two 100 Og puffs budesonide placebo bid + two 90 Og puffs albuterol prn OR four 2 mg puffs nedocromil placebo bid + two 90 Og puffs albuterol prn.
45923109|NCT00000575|Drug|Nedocromil|Four 2 mg puffs bid + two 90 Og puffs albuterol prn
45923110|NCT00000575|Drug|Budesonide|Two 100 Og puffs bid + two 90 Og puffs albuterol prn.
45923111|NCT00032032|Drug|carboplatin|
45923112|NCT00032032|Drug|paclitaxel|
45923113|NCT00032032|Radiation|radiation therapy|
45923114|NCT00032110|Drug|erlotinib hydrochloride|Given orally
45923115|NCT00032110|Other|pharmacological study|Correlative studies
45923116|NCT00032110|Other|laboratory biomarker analysis|Correlative studies
45923117|NCT00013182|Behavioral|social activity|
45923118|NCT00032149|Biological|bleomycin sulfate|
45923119|NCT00032149|Biological|filgrastim|
45923120|NCT00032149|Drug|cyclophosphamide|
45923121|NCT00032149|Drug|etoposide|
45923122|NCT00032149|Drug|mitoxantrone hydrochloride|
45923123|NCT00032149|Drug|prednisolone|
45923124|NCT00032149|Drug|vincristine sulfate|
45923125|NCT00000593|Procedure|blood transfusion|
45923126|NCT00032188|Biological|aldesleukin|Given subcutaneously
45796193|NCT05151185|Other|Case Management Service Program|The dementia case manager in experiment group will undergo training (Competency-based Dementia Case Management Train-the-trainer Program; CDCMTP); The family caregiver in experiment group will receive competency-based Dementia Case Management Service Program: Needs Assessment, Intervention, evaluation and follow up, etc. The case management program is provided by a trained case manager in a dementia clinic, as well as telephone consultations and follow-up are provided.
45796194|NCT00002211|Drug|Nelfinavir mesylate|
45796195|NCT00002211|Drug|Delavirdine mesylate|
45796196|NCT00002211|Drug|Stavudine|
45796197|NCT00002211|Drug|Didanosine|
45796198|NCT04744805|Other|face mask or not|long term face mask wear
45796199|NCT00002415|Drug|Tenofovir disoproxil fumarate|
45796200|NCT05148533|Drug|TJ1133 Injection|TJ011133 (30 mg/kg, 45 mg/kg,QW) in combination with toripalimab injection (240 mg, Q3W)
45923127|NCT00032188|Drug|bryostatin 1|Given IV
45923128|NCT00032188|Other|laboratory biomarker analysis|Correlative studies
45923129|NCT00032227|Procedure|Early Carpal Tunnel Release for Mild or Moderate CTS|Either open or endoscopic surgery
45923130|NCT00032227|Other|MR Nerve Imaging for CTS|New diagnostic test for CTS to directly image the median nerve
45796201|NCT00381537|Drug|phenobarbitone|
45923131|NCT00013221|Behavioral|Exercise|
45796202|NCT00381537|Drug|carbamazepine|
45923132|NCT00032305|Drug|Visilizumab|
45923133|NCT00000596|Drug|prednisone|
45923134|NCT00000596|Drug|cyclophosphamide|
45923135|NCT00000596|Drug|dapsone|
45923136|NCT00032344|Procedure|Colonoscopy|Phase I - Cross-sectional; Phase II - 5 year follow-up; Phase III - 10 year follow-up
45796203|NCT00381225|Procedure|Ultra-sound guided radio-frequency ablation|
45796204|NCT00002427|Drug|Hydroxyurea|
45796205|NCT00002427|Drug|Stavudine|
45796206|NCT00002427|Drug|Didanosine|
45796207|NCT00002223|Drug|Indinavir sulfate|
45796208|NCT00002223|Drug|Ritonavir|
45796209|NCT00002433|Drug|Interferon gamma-1b|
45796210|NCT00002439|Drug|Alitretinoin|
45796211|NCT04967339|Device|Foot deformity correcting insoles|Foot deformity correcting insoles (e.g. insoles with medial arch support for plano-valgus deformity)
45796212|NCT04967339|Device|Lateral wedge insoles|Lateral wedge insoles
45796213|NCT00002229|Drug|Saquinavir|
45796214|NCT04963673|Other|calcineurin inhibitor dosage|The dosage of calcineurin inhibitors will be done as usual by the toxicology pharmacology laboratory of the CHU Amiens-Picardie. If the patient does not object, the determination of protein-bound uremic toxins from the rest of the collected blood tube will be performed using high performance liquid chromatography.
45796215|NCT04962815|Device|Electroencephalogram (EEG) Test|EEG test and delirium assessments will be performed on subjects experiencing delirium in the ICU.
45796216|NCT00002445|Drug|IM862|
45796217|NCT05381909|Drug|BGB-24714|administered orally
45796218|NCT05381909|Drug|Paclitaxel|administered intravenously
45796219|NCT00002451|Drug|Indinavir sulfate|
45796220|NCT00002451|Drug|Ritonavir|
45796221|NCT00002451|Drug|Lamivudine|
45796222|NCT00002451|Drug|Stavudine|
45796223|NCT00002235|Drug|Indinavir sulfate|
45796224|NCT00002235|Drug|Nelfinavir mesylate|
45796225|NCT00002235|Drug|Efavirenz|
45796226|NCT04959695|Behavioral|PE Coach|PE Coach is a treatment companion mobile application designed with features to support the tasks of prolonged exposure psychotherapy and the homework between sessions.
45796227|NCT04959695|Behavioral|Prolonged exposure without PE Coach|Standard PE treatment protocol without PE Coach
45923137|NCT00032383|Behavioral|Tai Chi|
45923138|NCT00013260|Procedure|Integrated model of primary care|
45923139|NCT00032422|Procedure|Acupuncture|
45923140|NCT00000599|Drug|colestipol|
45923141|NCT00000599|Drug|niacin|
45923142|NCT00000599|Behavioral|diet, fat-restricted|
45923143|NCT00032500|Drug|Echinacea|
45923144|NCT00391482|Behavioral|Peer Mentoring Intervention for HCV-Infected IDUs|
45923145|NCT00032617|Procedure|Prolonged Exposure|trauma-focused exposure therapy
45923146|NCT00032617|Procedure|Present Centered Therapy|therapy that focuses on current problems
45923147|NCT00000602|Drug|hydroxyurea|
45923148|NCT00032695|Drug|methionine|
45923149|NCT00032734|Drug|satavaptan (SR121463B)|
45923150|NCT00000608|Behavioral|diet, fat-restricted|
45923151|NCT00000608|Behavioral|diet, sodium-restricted|
45923152|NCT00032773|Drug|pentostatin for injection|
45923153|NCT00032812|Drug|Raclopride|
45923154|NCT00032890|Drug|glucosamine|
45923155|NCT00032890|Drug|chondroitin sulfate|
45923156|NCT00032890|Drug|glucosamine and chondroitin sulfate combined|
45923157|NCT00032890|Drug|celecoxib|
45923158|NCT00013338|Procedure|Ambulation Training|
45923159|NCT00032929|Drug|Selegiline|
45923160|NCT00000611|Drug|hormone replacement therapy|
45923161|NCT00000611|Drug|estrogens|
45923162|NCT00000611|Drug|progestins|
45923163|NCT00000611|Drug|estrogen replacement therapy|
45923164|NCT00000611|Behavioral|diet, fat-restricted|
45923165|NCT00000611|Drug|calcium|
45923166|NCT00000611|Drug|vitamin D|
45923167|NCT00000611|Behavioral|dietary supplements|
45923168|NCT00396370|Biological|BCG strain Connaught|Connaught strain Bacillus Calmette-Guerin (BCG), 8-32 x 10^5 CFU vaccine for intradermal administration.
45923169|NCT00396370|Biological|BCG strain Danish|Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 1.2 X 10^8 colony-forming units (CFU) oral (PO) in 60 mililiters phosphate buffered saline (PBS).
45923170|NCT00396370|Biological|BCG strain Danish|Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 2-8 X 10^5 colony-forming units (CFU) intradermal in 100 microliters diluent.
45923171|NCT00396370|Other|Placebo|0.1 mL of sterile Sauton medium for intradermal administration.
45923172|NCT00396370|Other|Placebo|60 mL of sterile phosphate buffered saline (PBS) for oral administration.
45923173|NCT00013377|Procedure|Low vision|
45796228|NCT00002241|Drug|Indinavir sulfate|
46071822|NCT05877885|Behavioral|Targeted Cognitive Training Intervention|In this intervention, participants will complete 25-30 minutes of cognitive training per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform, and includes tasks that emphasize training of sustained attention, salience detection, and dimensions of cognitive control. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.
45649025|NCT04764019|Diagnostic Test|High resolution intestinal manometry|Evaluation of intestinal manometry by the use a high resolution intestinal manometry catheter with 34 closely spaced sensors.
45450054|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
45450055|NCT02170012|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
45450056|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
45796229|NCT00002241|Drug|Ritonavir|
45796230|NCT00002241|Drug|Lamivudine|
45450057|NCT02170246|Drug|Telmisartan|
45649026|NCT03055793|Other|budesonide formoterol fixed combination|Asthmatic patients who will be on budesonide formoterol fixed combination treatment administered by Elpenhaler device.
45796231|NCT00002241|Drug|Stavudine|
45649027|NCT04583761|Behavioral|questionnaire|Mailed structured regarding current and former tobacco consumption and use of alternative nicotine delivery systems
45796232|NCT04957277|Other|load modulation|Adding body weight (BW) up to 20% BW and subtracting body weight down to -20% BW
45796233|NCT00002463|Drug|MOPP Regimen|Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP)
45796234|NCT00002463|Drug|Leucovorin Calcium|
46071823|NCT05877885|Behavioral|General Cognitive Training Intervention|In this intervention, participants will complete 25-30 minutes of cognitive activities per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform. The intervention protocol will include computerized cognitive activities designed to provide general cognitive stimulation. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.
45450058|NCT02170324|Drug|Exenatide|
45450059|NCT02170324|Drug|Placebo|
45450060|NCT02170402|Biological|Octocog alfa (recombinant human coagulation factor VIII)|"Part 1: Pharmacokinetic (PK) analysis - Subset of 24 participants~Part 2: On-demand treatment regimen~Part 3: Prophylaxis treatment regimen"
45450061|NCT03538990|Other|DASH Eating Pattern|The DASH diet is a heart-healthy eating pattern that is focused on adequate consumption of fruits, vegetables, whole grains, low-fat dairy, fish, poultry, beans, nuts, and vegetables oils while emphasizing limited intake of foods containing saturated fat, such as fatty red meats, full-fat dairy products, and tropical oils, such as coconut, palm kernel, and palm oils, as well as sugar-sweetened beverages and sweets.
45450062|NCT02172196|Drug|BI 10773|
45450063|NCT02172196|Drug|Sitagliptin|
45796235|NCT00002463|Drug|Mechlorethamine Hydrochloride|
45796236|NCT00002463|Drug|Methotrexate|
45796237|NCT00002463|Drug|Prednisone|
45450064|NCT02255968|Drug|EDP-788|EDP-788 Capsules. All interventions are given as multiple doses.
45796238|NCT00002463|Drug|Procarbazine Hydrochloride|
45796239|NCT00002463|Drug|Vincristine Sulfate|
45450065|NCT02255968|Drug|Placebo|Matching placebo capsules. All interventions are given as multiple doses
45450066|NCT02172274|Drug|[14C]-BI 10773 - oral solution|
45450067|NCT02172352|Drug|Ba 679 BR low dose|
45450068|NCT02172352|Drug|Ba 679 BR middle dose|
45450069|NCT02172352|Drug|Ba 679 BR high dose|
45450070|NCT02172352|Drug|Placebo inhalation powder|
45450071|NCT02757430|Procedure|Cardiac Ablation|
45450072|NCT02166268|Drug|AVANZ Phleum pratense 15,000 SQ+|
45649028|NCT04531891|Other|Fatigue protocol|During the fatigue protocol, participants will sprint forward 5 m, cut at a 90° angle, sprint forward another 5 m, and backpedal 5 m. This activity will be repeated 4 times before participants will complete a series of hurdle activities. First, they will perform 2-legged jumps over 5 hurdles that are 30 cm high, turn, and repeat the jumps. Second, they will perform side-stepping exercises over the 5 hurdles. Third, they will complete four 5-m lateral shuffles.
45796240|NCT00002463|Procedure|Conventional Surgery|
45796241|NCT04500899|Drug|Mydfrin|A test dose of 20 mcg of Mydfrin will be administered through the peripheral intravenous line. Subsequent Mydfrin injections will then be administered in 40 mcg aliquots every 10-15 minutes, until the mean arterial blood pressure (MAP) increases by ≥ 20 mm Hg from the baseline MAP, however making sure not to exceed a MAP of 100 mmHg. Once a desired blood pressure has been achieved and maintained, echocardiographic evaluation of mitral regurgitation would be performed.
45796242|NCT00002247|Drug|Ganciclovir|
45796243|NCT04950803|Dietary Supplement|Microbiome immunity formula|Microbiome immunity formula contains probiotics blend (3Bifidobacteria, 10 billion CFU per sachet)
45796244|NCT04950803|Dietary Supplement|Active placebo|Active placebo contains active vitamin
45796245|NCT00002475|Biological|allogeneic tumor cell vaccine|
45796246|NCT00002475|Biological|autologous tumor cell vaccine|
45796247|NCT00002475|Biological|recombinant interferon alfa|
45796248|NCT00002475|Biological|recombinant interferon gamma|
45796249|NCT00002475|Biological|sargramostim|
45796250|NCT00002475|Drug|cyclophosphamide|
45796251|NCT04873661|Behavioral|Hypnosis group intervention|See arm description
45796252|NCT04873661|Behavioral|Cognitive trance group intervention|See arm description
45796253|NCT04873661|Behavioral|Meditation group intervention|See arm description
45796254|NCT00002481|Drug|cisplatin|
45796255|NCT00002481|Drug|cyclophosphamide|
45796256|NCT00002481|Drug|cytarabine|
45796257|NCT00002481|Drug|dexamethasone|
45796258|NCT00002481|Drug|etoposide|
45796259|NCT00002481|Procedure|autologous bone marrow transplantation|
45796260|NCT00002481|Radiation|radiation therapy|
45796261|NCT02318706|Drug|DS-5565|
45796262|NCT02318706|Drug|placebo|
45649029|NCT04926389|Other|low-level laser therapy applied on days 0, 3,7,14 & every 2 weeks|one side of the maxillary arch will randomly receive LLLT on days 0, 3, 7, 14, and every 2 weeks thereafter and the contralateral side will serve as the controls.
45923174|NCT00032968|Drug|Buprenorphine/naloxone|
45923175|NCT00033007|Behavioral|Behavior Therapy|
45923176|NCT00033046|Drug|Modafinil|
45796263|NCT04476797|Drug|GC4711|15 minute IV Infusion prior to SBRT
45923177|NCT00013416|Procedure|Hearing|
45923178|NCT00033085|Drug|Ondansetron|
45923179|NCT00033124|Behavioral|Behavior Therapy|
45923180|NCT00033163|Drug|Adefovir dipivoxil|
45923181|NCT00033163|Drug|Tenofovir disoproxil fumarate|
45923182|NCT00013455|Device|Hearing|
45923183|NCT00033202|Drug|Gimatecan® (ST-1481)|
45923184|NCT00033241|Drug|erlotinib hydrochloride|
45923185|NCT00033241|Drug|gemcitabine hydrochloride|
45923186|NCT00000620|Drug|Anti-hyperglycemic Agents|Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control <6%; standard control 7.0-7.9%).
45923187|NCT00000620|Drug|Anti-hypertensive Agents|Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control <120 mm Hg; standard control <140 mm Hg).
45923188|NCT00000620|Drug|Blinded fenofibrate or placebo plus simvastatin|Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR <50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.
45923189|NCT00033280|Drug|temozolomide|
45923190|NCT00033280|Procedure|neoadjuvant therapy|
45923191|NCT00033280|Radiation|radiation therapy|
45450073|NCT02166268|Drug|Placebo|
45450074|NCT02757352|Drug|Ixekizumab|Administered SC
45450075|NCT02757352|Drug|Placebo|Administered SC
45450076|NCT02172430|Drug|Tiotropium powder inhalation capsules|Powder inhalation via the HandiHaler® once daily
45450077|NCT02172430|Drug|Tersigan®|2 puffs of oxitropium three times daily via MDI
45649030|NCT04926389|Other|low-level laser therapy applied every 3 weeks|one side will also be randomly chosen to receive LLLT every 3 weeks and the contralateral side will serve as the controls.
45649031|NCT04926155|Drug|Metformin|The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
45649032|NCT05133583|Other|Laughter yoga|"The experimental group was interviewed in an online meeting prepared by a certified LY trainer.~She received LY exercises once a week (40 minutes per session) for 6 weeks (6 sessions). Each The meeting was organized with a maximum of 12 people."
45649033|NCT04917965|Other|Laboratory clotting studies|Cord blood will be utilized to perform lab test including PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s
45649034|NCT04909775|Drug|Tislelizumab|200 mg per cycle, IV on day 1 of 3-week
45796264|NCT04476797|Drug|Placebo|15 minute IV infusion prior to SBRT
45796265|NCT00002253|Drug|Octreotide|
45923192|NCT00013494|Procedure|Stroke Rehabilitation|
45923193|NCT00033319|Dietary Supplement|folic acid|
45796266|NCT04862585|Drug|Cimetidine|Given IV and/or PO
45796267|NCT04862585|Drug|Dexamethasone|Given IV and/or PO
45796268|NCT04862585|Drug|Diphenhydramine|Given IV and/or PO
45796269|NCT04862585|Drug|Famotidine|Given IV and/or PO
45796270|NCT04862585|Drug|Paclitaxel|Weekly or every 14 day dosing
45796271|NCT04862585|Other|Quality-of-Life Assessment|Ancillary studies
45796272|NCT04862585|Drug|Ranitidine|Given IV and/or PO
45796273|NCT00002487|Drug|dipyridamole|
45796274|NCT00002487|Drug|methotrexate|
45796275|NCT00002493|Drug|cisplatin|
45796276|NCT00002493|Drug|doxorubicin hydrochloride|
45796277|NCT00002493|Radiation|low-LET photon therapy|
45796278|NCT04860947|Diagnostic Test|Brain MRI|"Axial DWI with ADC card~Axial 2D TSE T2/DP or 3DT2~Gadolinium injection (0.1 mmol/kg)~3D Fluid-attenuated inversion recovery~3D T1 with Gadolinium injection."
45796279|NCT04860947|Diagnostic Test|Spinal Cord MRI|Sagittal T2 Sagittal T1 with Gadolinium injection
45796280|NCT04860947|Diagnostic Test|Retinal imaging|spectral-domain high definition optical coherence tomography
45796281|NCT04858607|Diagnostic Test|Blood sample|Serology, immune status, T cell immunity, and T cell aging.
45796282|NCT04858607|Diagnostic Test|Saliva sample|Antibody tests
45796283|NCT00002259|Drug|Mitoxantrone hydrochloride|
45796284|NCT00002499|Drug|asparaginase|
45796285|NCT00002499|Drug|cytarabine|
45796286|NCT00002499|Drug|daunorubicin hydrochloride|
45796287|NCT00002499|Drug|dexamethasone|
45796288|NCT00002499|Drug|methotrexate|
45796289|NCT00002499|Drug|prednisone|
45796290|NCT00002499|Drug|vincristine sulfate|
45796291|NCT00002499|Radiation|radiation therapy|
45796292|NCT00002505|Biological|filgrastim|
45796293|NCT00002505|Biological|recombinant interferon gamma|
45796294|NCT00002505|Biological|tumor cell lysate vaccine therapy|
45796295|NCT00002265|Drug|Zalcitabine|
45796296|NCT04933331|Drug|Curodont Repair Fluoride Plus|Self-assembling peptide that integrates calcium and phosphate ions into the same hydroxyapatite that the enamel is made of through biomimetic re-mineralization. Amino acid sequence: CH3,COQQRFEWEFEQQ,NH2.
45923194|NCT00033319|Drug|acetylsalicylic acid|
45923195|NCT00033358|Drug|medroxyprogesterone|Given intramuscularly
45923196|NCT00033358|Drug|ethinyl estradiol|Given orally
45923197|NCT00033358|Drug|norgestrel|Given orally
45923198|NCT00033358|Other|laboratory biomarker analysis|Correlative studies
45923199|NCT00013533|Procedure|Stem cell transplantation|>3 x 106/kg CD34+ stem cells by IV infusion
45923200|NCT00033397|Procedure|biopsy|
45923201|NCT00033397|Procedure|magnetic resonance imaging|
45923202|NCT00033397|Procedure|radiomammography|
45923203|NCT00033397|Procedure|ultrasound imaging|
45923204|NCT00033397|Radiation|gadopentetate dimeglumine|
45923205|NCT00033397|Drug|chemotherapy|
45649035|NCT04909775|Drug|Cisplatin|70mg/m2 IV on Day 1 of 3-week, for 4 cycles. Dose fractionation is permissible.
45796297|NCT04933331|Device|Silver Diamine Fluoride|Silver diamine fluoride 38% is indicated for the treatment of dentinal hypersensitivity. SDF works by killing pathogenic organisms and hardens softened dentin making it more acid and abrasion resistant. The ADA recommends the use of SDF in treating early lesions.
45796298|NCT04933331|Device|Glass Ionomer Sealant|A hydrophilic type of sealant material made with water, polymeric acid, and glass power. These sealants release fluoride over time which also helps protect against and repair initial caries lesions. The ADA recommends the use of sealants in treating occlusal early lesions.
45796299|NCT04933331|Device|Fluoride varnish|2.5% Sodium Fluoride Varnish which reduces dentinal hypersensitivity by occluding dentinal tubules.
45923206|NCT00000632|Biological|Env 2-3|
45923207|NCT02971696|Drug|Sorafenib|Sorafenib will be administrated at a dose of 400 mg twice daily (consisting of two 200-mg tablets).Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) will permitted for drug- related adverse effects. If further dose reductions will required, patients will withdraw from the study
45796300|NCT04933331|Drug|Fluoride toothpaste|Prescription sodium fluoride toothpaste medicament used in place of regular toothpaste. It works by making the teeth stronger and more resistant to caries.
45796301|NCT00002511|Radiation|low-LET photon therapy|
45923208|NCT02971696|Drug|Best Supportive care|Liver Support, pain management
45923209|NCT00033436|Dietary Supplement|niacinamide|
45923210|NCT00033436|Drug|carbogen|
45923211|NCT00033436|Radiation|radiation therapy|
45923212|NCT00013572|Biological|ALVAC-HIV MN120TMG (vCP205)|
45923213|NCT00033475|Biological|therapeutic allogeneic lymphocytes|
45649036|NCT04909775|Drug|Gemcitabine|1000mg/m2, Day 1 and Day 8 of 3-week, for 4 cycles
45649037|NCT05133349|Drug|Anlotinib|Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
45649038|NCT04925141|Drug|Dasatinib Tablets|Tyrosine Kinase Inhibitor (TKI)
45796302|NCT00002271|Drug|Alovudine|
45450078|NCT02166424|Dietary Supplement|Omega-3 polyunsaturated fatty acids|
45796303|NCT04933097|Device|Microfet2®|"Conducting a day hospitalization including analyses:~Quantitative muscular analysis by measuring the DEXA of the whole body, the reference method for measuring body compartments and allowing the diagnosis of sarcopenia (IMMA<7 in men and 5.5 in women)~Qualitative muscular analysis:~isokinetic measurement of muscular strength carried out on 3 muscle groups using a manual measurement sensor such as Microfet2 ® : quadriceps, triceps brachii, biceps~measurement of grip strength using Jamar® equipment validated as recommended by the EWGSOP~a walking test to assess the functional impact of sarcopenia and its severity"
45649039|NCT04209517|Other|Filming|Behavioural markers selection from video-recordings of the interview
45649040|NCT04908917|Device|Portable Air Cleaner with a HEPA Filter|A novel intervention using a portable air cleaner with HEPA filter to treat mildly high BP to potentially reduce the cardiovascular effects of PM2.5. Leave the PAC running with the HEPA filter installed on the highest setting during sleeping periods in the room in which the participant sleeps.
45796304|NCT00002517|Drug|cytarabine|
45796305|NCT00002517|Drug|daunorubicin hydrochloride|
45796306|NCT00002517|Drug|dexamethasone|
45796307|NCT00002517|Drug|etoposide|
45796308|NCT00002517|Drug|idarubicin|
45796309|NCT00002517|Drug|mitoxantrone hydrochloride|
45796310|NCT00002517|Drug|thioguanine|
45796311|NCT00002517|Procedure|allogeneic bone marrow transplantation|
45796312|NCT00002517|Radiation|radiation therapy|
45796313|NCT04931459|Drug|ACU193|Intravenous ACU193
45923214|NCT00000635|Drug|Trifluridine|
45796314|NCT04931459|Drug|Placebo|Intravenous Placebo
45796315|NCT04673409|Diagnostic Test|Novel Cardiac MRI sequences|Novel CMR sequences that allow accurate multiparametric evaluation of the whole myocardium with 3D high spatial resolution and in a patient-friendly free-breathing approach in a predictable amount of scanning time (3D T2 mapping and 3D anatomical and LGE imaging). This will be compared to the data acquired with conventional/2D sequences.
45923215|NCT00000635|Drug|Bacitracin zinc/Polymyxin B sulfate|
45923216|NCT00033553|Drug|carboplatin|Arm A: AUC=6 IV over 30 min for 2 cycles then AUC=2 IV over 30 min q wk for 7 wks Arm B: AUC=5 IV over 30 min for 2 cycles
45923217|NCT00033553|Drug|gemcitabine hydrochloride|1000 mg/sq m IV over 30 min days 1 & 8 repeat q 21 days for 2 cycles; then 35 mg/sq m IV over 30 min 2X wk for 7 wks
45923218|NCT00033553|Drug|paclitaxel|225 mg/sq m IV over 3 hrs q 21 days for 2 cycles, then 45 mg/sq m IV over 1 hr q wk for 7 wks
45923219|NCT00033553|Radiation|radiation therapy|3-D XRT 7400 cGy total after induction (during cycles 3-9)
45923220|NCT00013650|Drug|Cyclophosphamate|
45923221|NCT00033592|Other|placebo|
45923222|NCT00033592|Drug|bupropion hydrochloride|
45923223|NCT00033592|Drug|nicotine|
45923224|NCT00389012|Procedure|exercise therapy|
45923225|NCT00389012|Procedure|walking rehabilitation|
45923226|NCT00013689|Drug|Fansidar (pyrimethamine and sulfadoxine)|
45923227|NCT00033709|Drug|temozolomide|
45923228|NCT00033709|Drug|thalidomide|
45923229|NCT00013299|Device|Prevention of Diabetic Ulcers|
45923230|NCT00033748|Biological|monoclonal antibody 11D10 anti-idiotype|2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
46071824|NCT05877872|Procedure|Reduced-target resection|Patients receive surgery according to pSTV-post-IC.
45923231|NCT00033748|Biological|monoclonal antibody 3H1 Alu Gel|2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
45649041|NCT04908917|Device|Portable Air Cleaner without a HEPA Filter|Leave the PAC running without a HEPA filter installed on the highest setting during sleeping periods in the room in which the participant sleeps.
45649042|NCT04908995|Drug|EC5026 oral tablet|"12 subjects will receive a single oral 8 mg dose of EC5026 in two Dosing Periods (one in fed state and one in fasted state) separated by a Washout Period. Subjects in this group will be randomized 1:1 to one of 2 sequences:~Dosing Sequence A: Subjects will be dosed in a fed state in Dosing Period 1 and in a fasted state in Dosing Period 2, or~Dosing Sequence B: subjects will be dosed in a fasted state in Dosing Period 1 and in a fed state in Dosing Period 2."
45923232|NCT00000641|Drug|Ciprofloxacin hydrochloride|
45923233|NCT00000641|Drug|Ethambutol hydrochloride|
45649043|NCT04908995|Other|Placebo oral tablet|"6 subjects will receive an oral dose of matching placebo in one single Dosing Period. Subjects in this group will be randomized 1:1 to receive placebo under fed or fasted conditions.~Note: Subjects assigned to the placebo arm will not return for a second Dosing Period."
45649044|NCT02651155|Drug|Lubiprostone|Lubiprostone capsules
45796316|NCT02977091|Other|change in fitness level|fitness level assessed by the Euro-fit tests for school age children.including 1.body fat 2. single leg balance test 3.Plate Tapping -for speed of limb movement 4.Sit-and-Reach flexibility test 5. Standing Broad Jump - measures explosive leg power. 6.Handgrip Test - measures static arm strength 7.Sit-Ups in 30 seconds - measures trunk strength 8.Bent Arm Hang - muscular endurance/functional strength 9.20 m endurance shuttle-run - cardiorespiratory endurance Wingate anaerobic test which is a 30 seconds maximum pedaling against resistance on bike for evaluating the anaerobic fitness
45796317|NCT00002277|Drug|Fluconazole|
45649045|NCT02651155|Drug|Placebo|Lubiprostone placebo-matching capsules
46071825|NCT05877872|Procedure|Full-target resection|Patients receive surgery according to pSTV-pre-IC.
45649046|NCT04925063|Drug|Metformin|The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
45649047|NCT04909151|Device|Robot-assisted gait training (walking speed: 0.5km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
45796318|NCT00002277|Drug|Amphotericin B|
46071826|NCT05877872|Drug|Adjuvant immunotherapy|Toripalimab(240 mg d1) continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
46071827|NCT05877846|Dietary Supplement|Beta-hydroxymethyl butyrate supplement|Beta-hydroxymethyl butyrate (750 mg) - Vitamin D3 (200 IU) capsules. The formulation is 750 mg of Beta-hydroxymethyl butyrate with 200 IU of vitamin D3 per capsule. Frequency is 2 capsules twice daily (morning, evening)
46071828|NCT05877846|Dietary Supplement|Vitamin D supplement|Beta-hydroxymethyl butyrate (750 mg) - Vitamin D3 (200 IU) capsules. The formulation is 750 mg of Beta-hydroxymethyl butyrate with 200 IU of vitamin D3 per capsule. Frequency is 2 capsules twice daily (morning, evening)
45649048|NCT04909151|Device|Robot-assisted gait training (walking speed: 0.8km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
45649049|NCT04909151|Device|Robot-assisted gait training (walking speed: 1.1km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
45649050|NCT05127343|Procedure|Sealing deep pits and fissures|Application of the pit and fissure sealant
45796319|NCT04469075|Drug|Clindamycin Phosphate|phosphate 1% solution triamcinolone 0.01% at every array change (or approved equivalent)
45923234|NCT00000641|Drug|Amikacin sulfate|
45923235|NCT00000641|Drug|Azithromycin|
45923236|NCT00000641|Drug|Rifampin|
45923237|NCT00000641|Drug|Clofazimine|
45923238|NCT02971462|Device|ischemic conditioning|In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
45923239|NCT00000644|Drug|Clarithromycin|
45923240|NCT00013767|Behavioral|Individual and Community education|
45923241|NCT02971423|Drug|ETX2514|
45923242|NCT02971423|Drug|Placebo|matching placebo infusion
45923243|NCT02971423|Drug|Sulbactam|
45923244|NCT02971423|Drug|Imipenem/Cilastatin|
45923245|NCT00033865|Behavioral|Yoga, Relaxation Exercises, Sleep Hygiene|Sleep hygiene and relaxation exercises, with additional yoga
45923246|NCT00013806|Drug|131I-MIBG|
45923247|NCT00389051|Drug|bendamustine hydrochloride|1 cycle; 120 mg/m2/day,2 days concecutively, followed by 19days of oveservation period. (3 to 6 cycles)
45923248|NCT00033904|Drug|autologous human tumor-derived HSPPC-96|
45923249|NCT00033943|Drug|deligoparin|
45923250|NCT00389090|Drug|Temozolomide and O6-Benzylguanine|O6BG + Temozolomide
45923251|NCT02971384|Drug|Echinaforce|
45796320|NCT04469075|Drug|Triamcinolone Acetonide|triamcinolone acetonide 0.01% lotion triamcinolone 0.01% at every array change
45796321|NCT00002523|Drug|fluorouracil|
45796322|NCT00002523|Drug|leucovorin calcium|
45796323|NCT00002523|Procedure|conventional surgery|
45796324|NCT00002523|Radiation|radiation therapy|
45796325|NCT02977325|Other|water cure|
45796326|NCT00002529|Drug|cyclophosphamide|cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days
45796327|NCT00002529|Drug|doxorubicin hydrochloride|doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.
45796328|NCT00002529|Drug|epirubicin hydrochloride|epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.
45923252|NCT00033982|Drug|Posaconazole|
45923253|NCT00034021|Drug|Ginkgo Biloba|
45649051|NCT03055481|Other|High irradiance level of phototherapy|High irradiance level of phototherapy: the target irradiance level is 30-35uW per square centimeter per nanometer of wavelength.
45649052|NCT03055481|Other|Low irradiance level of phototherapy|Low irradiance level of phototherapy: the target irradiance level is 12-15uW per square centimeter per nanometer of wavelength
45649053|NCT05132959|Diagnostic Test|magnetic resonance imaging|The MRI images of patients who had undergone to shoulder magnetic resonance imaging because of shoulder pain or another pathology were studied
45649054|NCT04925297|Other|No intervention|No intervention will be given
45649055|NCT04495777|Other|Fonseca Anamnestic Index|"Fonseca Anamnestic Index was developed to assess the severity of temporomandibular disorders, based on its signs and symptoms. It has been proposed as a low cost and easy to apply alternative and has been used in screening for TMD in a non-patient population5. It was created with 10 items with 3 options of answers (specific scores): yes (10 points), sometimes (5 points) and no (0 points). The final score of the instrument is determined by the sum of the scores of all items, allowing the following classifications: the absence of signs and symptoms of TMD (0-15 points), mild TMD (20-45 points), moderate TMD (50-65 points), and severe TMD (70-100 points) (19)."
46071829|NCT05877846|Dietary Supplement|Matching Beta-hydroxymethyl butyrate supplement without Vitamin D|Beta-hydroxymethyl butyrate (750 mg) capsules. The formulation is 750 mg of Beta-hydroxymethyl butyrate per capsule. Frequency is 2 capsules twice daily (morning, evening)
45796329|NCT00002529|Drug|tamoxifen citrate|Tamoxifen 20 mg daily.
45796330|NCT00002529|Drug|toremifene|Toremifene 60 mg daily.
45796331|NCT04832087|Drug|Teduglutide|Standard of care Teduglutide dosing
45796332|NCT00002217|Drug|Lamivudine/Zidovudine|
45649056|NCT03055169|Genetic|genetic analysis|
45649057|NCT03055169|Biological|blood and stools samples|
45796333|NCT00002217|Drug|Abacavir sulfate|
45649058|NCT03055325|Other|Observational study of patients undergoing surgery|Cognitive testing, testing of heart rate variability and collection of blood samples
45649059|NCT05132725|Behavioral|diet therapy|Adjusting the quantity and quality of food intake to improve glycemic control, growth rate and quality of life among children with type 1 diabetes and celiac disease.
45796334|NCT00002217|Drug|Amprenavir|
45796335|NCT00002283|Drug|Trimethoprim|
46071830|NCT05877820|Biological|Tislelizumab|Intravenous infusion
46071831|NCT05877820|Drug|Lenvatinib|Oral tablet
46071832|NCT05877807|Drug|Baclofen|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
45796336|NCT00002283|Drug|Sulfamethoxazole|
45796337|NCT00002283|Drug|Dapsone|
45796338|NCT04826237|Drug|Statin|Oral dose to be taken with methylprednisolone
45923254|NCT00034021|Behavioral|Sex Therapy (genital focus)|
45923255|NCT00034060|Drug|Etanercept|
45649060|NCT04908527|Behavioral|Walking to OR|Patients, after being prepared for the OR, walk to the operating room
45649061|NCT04924829|Drug|Tocilizumab|Tocilizumab received as a single intravenous infusion over the period of 60 minutes. Dose of 8 mg/kg, maximum dose of 800 mg.
45649062|NCT05132413|Drug|SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab|SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab
45649063|NCT05132413|Drug|Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin|Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin
45649064|NCT05132413|Drug|Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin|Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin
45649065|NCT04924751|Diagnostic Test|Endoscopic ultrasound-guided fine needle biopsy|Under endoscopic ultrasound guidance, fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions.
45923256|NCT00013884|Drug|T-20|
45923257|NCT02972567|Dietary Supplement|Lactobacillus spp|9 log10 cfu/capsule. 1 capsule/day for 12 weeks
45923258|NCT02972567|Dietary Supplement|Control|Maltodextrin
45923259|NCT00034138|Drug|oregovomab|
45923260|NCT00034177|Drug|S-8184 Paclitaxel Injectable Emulsion|
45649066|NCT05126953|Device|samfilcon A Lenses with EPG01 Packaging Solution|samfilcon A Lenses with EPG01 Packaging Solution
45796339|NCT04826237|Drug|methylprednisolone|oral dose, standard of care
45796340|NCT04826237|Drug|dexamethasone|Drug for intratympanic administration
45796341|NCT04826237|Drug|Placebo|Capsule the same as for statins but without statin
45796342|NCT00002535|Biological|aldesleukin|
45796343|NCT00002535|Biological|lymphokine-activated killer cells|
45796344|NCT00002535|Biological|therapeutic tumor infiltrating lymphocytes|
45796345|NCT00002535|Drug|cyclophosphamide|
45796346|NCT00002535|Drug|indomethacin|
45796347|NCT00002547|Drug|busulfan|
45796348|NCT00002547|Drug|cyclophosphamide|
45796349|NCT00002547|Drug|cyclosporine|
45796350|NCT00002547|Drug|cytarabine|
45796351|NCT00002547|Drug|methotrexate|
45796352|NCT00002547|Procedure|allogeneic bone marrow transplantation|
45796353|NCT00002547|Procedure|syngeneic bone marrow transplantation|
45796354|NCT00002289|Drug|Thymopentin|
45796355|NCT00002553|Drug|cyclophosphamide|
45796356|NCT00002553|Procedure|allogeneic bone marrow transplantation|
45796357|NCT00002553|Radiation|low-LET cobalt-60 gamma ray therapy|
45796358|NCT00002559|Biological|filgrastim|
45923261|NCT00034177|Drug|Experimental Arm: TOCOSOL Paclitaxel|Doses of 80, 100 and 120mg/m2
45923262|NCT00034255|Drug|INGAP Peptide|
45923263|NCT00013923|Drug|Nutritional Supplement|
45923264|NCT00034294|Drug|GT160-246|
45923265|NCT00389129|Drug|acetylsalicylic acid|
45450079|NCT02166424|Dietary Supplement|Olive oil|
45649067|NCT05126953|Device|B+L Ultra Lenses|Commercially available Biotrue ONEday lenses
45649068|NCT03052829|Behavioral|Physical activity counseling|Subjects in this arm will receive counseling on how to increase their physical activity level.
45450080|NCT02170558|Device|TM- Ardis implant and Metal Reduction CT software|TM- Ardis implant and Metal Reduction CT software
45649069|NCT03052829|Behavioral|Usual care|Subjects will undergo their usual care without intervention
45649070|NCT04924595|Behavioral|Personalised exercise|Personalised exercise intervention including aerobic and resistance training
45649071|NCT03052907|Behavioral|BSPAN|"Identify readiness assessment criteria (RAC) essential in determining a rural county's capacity to support comprehensive mammography and appropriate follow-up services.~Using the RAC, we will determine which of the five BSPAN1 counties have capacity to manage and sustain the Outreach & Health Promotion and Delivery & Navigation components of the program (High Capacity), and which have the capacity to manage and sustain only the Outreach & Health Promotion component (Medium Capacity).~Expand BSPAN to 12 new rural and underserved counties according to RAC score and evaluate each county's ability to implement program components and increase comprehensive mammography and appropriate follow-up."
45649072|NCT04133935|Procedure|Laparoscopic Obturator Urethropexy|Suspending the periurethral vaginal tissue to the obturator internus fascia bilaterally via sutures, creating a support for the bladder neck compartment.
45649073|NCT04133935|Procedure|Burch Urethropexy|Suspending the periurethral vaginal tissue to Cooper's ligament bilaterally via sutures, creating a support for the bladder neck compartment
45649074|NCT04924049|Other|Video-assisted education|Prior the study, the content and comprehensibility of the VE were evaluated by an orthopedic surgeon, two orthopedic nurses, and a physiotherapist who were not involved in the study and relevant amendments were made based on their suggestions. The preview of the final version of the VE was shown to four patients (10% of the sample) and these patients were excluded from the study. The patients were interviewed by phone calls on a weekly basis and watching VE at home, the frequency of watching VE, and doing home-based exercises were questioned.
45649075|NCT04435717|Drug|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1|Tocilizumab 20 MG/ML Intravenous (one dose)
45649076|NCT04435717|Drug|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses)|Tocilizumab 20 MG/ML Intravenous ( two doses)
45796359|NCT00002559|Drug|cisplatin|
45796360|NCT00002559|Drug|ifosfamide|
45649077|NCT04907981|Diagnostic Test|Novel coronavirus infection|Using eye examination to judge whether novel coronavirus is infected or not.
45649078|NCT05124223|Diagnostic Test|Cardiac MRI|Cardiac MRI was performed as clinically indicated to assess cardiac pathology.
45796361|NCT00002559|Drug|paclitaxel|
45450081|NCT02172508|Drug|Tiotropium Inhalation Capsule|
45796362|NCT00002565|Biological|bleomycin sulfate|
45796363|NCT00002565|Drug|CHOP regimen|
45796364|NCT00002565|Drug|cisplatin|
45796365|NCT00002565|Drug|cyclophosphamide|
45450082|NCT02172508|Drug|Placebo Lactose Capsule|
45450083|NCT02174692|Other|Exercise|"One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum~2 mins rest between sets"
45450084|NCT02172586|Drug|Telmisartan|
45450085|NCT02172586|Drug|Losartan|
45649079|NCT04075981|Drug|Botulinum Toxin Type A Injection [Xeomin]|Before the main stage of the surgery, botulinum toxin will be injected into the entire visible area of the 4 major epicardial fat pads, during extra corporal circulation and before aortic cross clamping in order to reduce the time of ischemia.
45649080|NCT04075981|Other|Drug placebo|All patients from the control group will receive placebo. Before the main stage of the surgery, during extra corporal circulation and before aortic cross clamping, the placebo will be injected into the entire visible area of the 4 major epicardial fat pads as follows (1 mL at each fat pad).
45649081|NCT05122195|Other|Compression therapy|Graduated elastic compression promote venous flow which is impaired by hormonal changes in the venous system during the gestational period and minimize the blocking effect of the gravid uterus.
45649082|NCT04917497|Drug|Levosimendan|Levosimendan was administered according to a standardized treatment protocol. A total dose of 12.5mg or 25mg (corresponding to one or two ampoules) was given at an infusion rate of 0.05 μg/kg/min to 0.2μg/kg/min with or without a loading dose (6 μg/kg or 3 μg/kg over 10 minutes). The decision about total dose, infusion rate and loading dose was at the discretion of the treating physician.
45649083|NCT03933007|Drug|Colchicine,|"the day of phenotyping assay~Colchicine : 1.5 mg over 1 hour (1 mg + 0.5 mg 1 hour later)"
45649084|NCT03933007|Drug|midazolam,|Midazolam 1 mg
45796366|NCT00002565|Drug|cytarabine|
45796367|NCT00002565|Drug|doxorubicin hydrochloride|
45796368|NCT00002565|Drug|etoposide|
45796369|NCT00002565|Drug|idarubicin|
45796370|NCT00002565|Drug|ifosfamide|
45796371|NCT00002565|Drug|mesna|
45796372|NCT00002565|Drug|methylprednisolone|
45450086|NCT02172586|Drug|Hydrochlorothiazide|
45450087|NCT03538522|Drug|N-831(Traneurocin) 10 mg QD|Oral administration of 10 mg capsule of NA-831 QD for 24 weeks
45450088|NCT03538522|Drug|NA-831 (Traneurocin) 20 mg QD|Oral administration of 20 mg capsule of NA-831 QD for 24 weeks
45450089|NCT03538522|Drug|NA-831 (Traneurocin) 40 mg QD|Oral administration of 40 mg capsule of NA-831 QD or for 24 weeks
45450090|NCT03538522|Drug|Placebo oral capsule QD|Oral administration of oral placebo capsule QD or 24 weeks
45450091|NCT02170636|Drug|BIBR 1048 MS Capsule E|50 mg BIBR 1048 MS
45796373|NCT00002565|Drug|mitoxantrone hydrochloride|
45796374|NCT00002565|Drug|prednisone|
45796375|NCT00002565|Drug|vincristine sulfate|
45796376|NCT00002571|Biological|bleomycin sulfate|5u/m2 IV Q21days x 6 cycles
45796377|NCT00002571|Biological|filgrastim|5ug/kg SC, Days 9-20, Q 21 days x 6 cycles
45796378|NCT00002571|Drug|cyclophosphamide|490 mg/m2 IV Q 21 days x 6 cycles
45796379|NCT00002571|Drug|cytarabine|225 mg/m2 IV Q 21 days x 6 cycles
45796380|NCT00002571|Drug|doxorubicin hydrochloride|19 mg/m2 IV Q 21 days x 6 cycles
45649085|NCT03933007|Drug|fexofenadine|Fexofenadine 120 mg
45649086|NCT04924439|Other|foot reflexology|Foot reflexology was applied to the experimental group for 40 minutes once a week for postpartum 8 weeks. The control group was only watched.
45649087|NCT05126875|Radiation|Repeated stereotactic radiosurgery|Repeated stereotactic radiosurgery to recurring brain metastases
45796381|NCT00002571|Drug|etoposide|90 mg/m2 IV Q 21 days x 6 cycles
45796382|NCT00002571|Drug|leucovorin calcium|25 mg/m2 po 24 hours after methotrexate Q 6 hours x 4 doses for 6 cycles.
45796383|NCT00002571|Drug|methotrexate|90 mg/m2 IV, Q 21 days x 6 cycles.
45796384|NCT00002571|Drug|prednisone|60 mg/m2 po QD x 14days for 6 cycles
45796385|NCT00002571|Drug|trimethoprim-sulfamethoxazole|1 double throughout strength treatment tablet po on Monday, Wednesday, and Friday x 6, 21 day cycles
45796386|NCT00002571|Drug|vincristine sulfate|1.4 mg/m2 IV Q 21 Days x 6 cycles
45796387|NCT00002571|Radiation|radiation therapy|All patients achieving a CR or PR following systemic therapy and IT Ara-C, will receive 2,400 cGy in two hundred cGy fractions to the whole brain. Fields should adequately encompass all meningeal surfaces.
45796388|NCT00002571|Drug|Intrathecal cytarabine|"If initial bone marrow positive:~Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first two cycles of therapy. Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle.~If initial CSF cytology positive:~Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first cycle of therapy. If CSF negative after above, Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle. If CSF positive after initial five doses of Ara-C, IT MTX 12 mg per dose x 5 doses should be given spaced evenly during the second cycle of therapy.~If initial bone marrow and CSF negative:~Ara-C 30 mg/m2 IT per dose x 5 doses to be given spaced evenly within 1 month of completion of systemic therapy."
45796389|NCT04896515|Dietary Supplement|Supplemental parenteral nutrition|Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)
45796390|NCT00002577|Radiation|radiation therapy|
45796391|NCT04417907|Drug|Perampanel 1 week titration|Healthy adults will take 2mg perampanel PO QD for one week followed 4mg perampanel PO QD for five weeks.
45796392|NCT04417907|Drug|Perampanel 2 week titration|Healthy adults will take 2mg perampanel PO QD for two weeks followed 4mg perampanel PO QD for four weeks.
45796393|NCT04417907|Drug|Perampanel 4mg|Healthy adults will take 4mg perampanel PO QD for six weeks
45796394|NCT04417907|Drug|Placebo|Healthy adults will take 2mg placebo PO QD for six weeks
45649088|NCT03056651|Other|treatment in day-care heart failure unit|
45649089|NCT04917263|Diagnostic Test|Immunohistochemistry, Flow citometry, Trascriptome analysis|we will perform immunohistochemistry, flow cytometry, transcriptomic analysis, mRNA microarray and mutational profiling
45649090|NCT04907435|Procedure|simultaneous operations|simultaneous operations
45649091|NCT05404399|Behavioral|"Free From Pain Exercise Book"|"Participants in Group 1 will be provided with the Free From Pain Exercise Book."
45649092|NCT05404399|Behavioral|Physiotherapy|Participants in Group 2 would be referred to Physiotherapy (usual care)
45649093|NCT04923503|Behavioral|diurnal fasting|subject conduct fasting in Ramadan for 30 days
45796395|NCT04798547|Procedure|Short Myotomy|Evaluation of short length myotomy
45796396|NCT04798547|Procedure|Standard Length Myotomy|Standard Length Myotomy
45450092|NCT02170636|Drug|BIBR 1048 MS Capsule F|50 mg BIBR 1048 MS
45450093|NCT02170636|Drug|BIBR 1048 MS Capsule G|50 mg BIBR 1048 MS
45450094|NCT02170636|Drug|BIBR 1048 MS Tablet H|50 mg BIBR 1048 MS
45796397|NCT00360815|Behavioral|Insulin|
45796398|NCT00002583|Drug|cisplatin|50 mg/m2 IV
45796399|NCT00002583|Drug|vinorelbine ditartrate|25 mg/m2 IV
45796400|NCT02191111|Behavioral|Task-focused facilitation|An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia.
45796401|NCT02977247|Other|Non-Interventional|Only standard care procedures will be performed for clinical intervention and diagnostic purposes.
45796402|NCT02977247|Device|Automated Whole Breast Ultrasound|Bilateral breast ultrasound images will be captured, but not clinically evaluated for diagnostic purposes by a physician.
45796403|NCT02157493|Behavioral|Arrowhead Business Group Curriculum|Arrowhead Business Group (ABG) is a culturally tailored entrepreneurship/life-skills intervention, which features instruction from American Indian paraprofessionals in an effort to decrease drug use, depressive symptoms, hopelessness and other high-risk behaviors among youth while improving their school performance and college/career aspirations.
45796404|NCT02157493|Behavioral|Recreational League Control Condition|The control condition will consist of a recreational sports league that will be led by local American Indian study staff who are experienced with Johns Hopkins camps and community-based Apache sports programs. Activities will be conducted on 3 Saturdays during the academic year to mixed gender groups of approximately 50 participants.
45796405|NCT00002589|Biological|aldesleukin|
45796406|NCT00002589|Biological|muromonab-CD3|
45796407|NCT00002589|Biological|therapeutic autologous lymphocytes|
45796408|NCT00002589|Procedure|adjuvant therapy|
45450095|NCT02170636|Drug|BIBR 1048 MS Drinking solution|50 mg BIBR 1048 MS tartaric acid solution
45796409|NCT02223871|Drug|ACT-451840:|ACT-451840 500 mg was provided in 100 mL amber glass bottles formulated as a powder for oral suspension. The ACT-451840 suspension was prepared extemporaneously by addition of 25 mL of water and administered orally under fed condition.
45649094|NCT03862729|Procedure|Minimally invasive surgery|Intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided endoscopic surgery, or surgical aspiration followed by alteplase clot irrigation (1·0 mg every 8 h for up to nine doses). CTA will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset.
45796410|NCT02223871|Other|Plasmodium falciparum-infected human erythrocytes:|Each participant was inoculated on Day 0 with approximately 1,800 viable Plasmodium falciparum-infected human erythrocytes administered intravenously.
45796411|NCT02223871|Drug|Artemether 20 mg and lumefantrine 120mg combination tablet:|Rescue treatment to ensure clearance of Plasmodium falciparum comprising six doses of four tablets (total course of 24 tablets) given over a period of 60 hours. Each dose of tablets administered orally was immediately followed by food or drinks rich in fat (e.g., milk).
45649095|NCT03862729|Procedure|conventional treatment|Conventional treatment includes medical treatment and conventional craniotomy.
45649096|NCT04907747|Drug|Vonoprazan|Potassium-competitive acid blocker
45796412|NCT02223871|Drug|Primaquine:|Rescue treatment to ensure clearance of Plasmodium falciparum, to be taken as a single oral 45 mg dose with food only if gametocytes were identified after administration of Riamet® rescue medication.
45649097|NCT04907747|Drug|Esomeprazole|Proton pump inhibitor
45649098|NCT04907747|Drug|Colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
45796413|NCT00002595|Drug|toremifene|
45796414|NCT00002595|Procedure|conventional surgery|
45796415|NCT03004339|Drug|SOR007 Ointment 2.0%|
45796416|NCT03004339|Drug|SOR007 Ointment 1.0%|
45796417|NCT03004339|Drug|SOR007 Ointment 0.3%|
45796418|NCT03004339|Drug|SOR007 Ointment 0.15%|
45796419|NCT03004339|Drug|SOR007 Ointment Placebo|
45796420|NCT03004339|Drug|Taclonex® Ointment|
45796421|NCT00360581|Behavioral|Yoga|
45796422|NCT00360581|Behavioral|Yoga and Cognitive Behavioral Therapy|
45796423|NCT00002619|Biological|filgrastim|
45796424|NCT00002619|Drug|carboplatin|
45796425|NCT00002619|Drug|thiotepa|
45796426|NCT00002619|Procedure|autologous bone marrow transplantation|
46071833|NCT05877807|Other|Placebo|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
45450096|NCT02170636|Drug|Pantoprazole|40 mg Pantoprazole
45450097|NCT02255734|Drug|Acyclovir|
45649099|NCT04907747|Drug|Amoxicillin|Antibiotic for H. pylori eradication
45649100|NCT04907747|Drug|Furazolidone|Antibiotic for H. pylori eradication
45649101|NCT03812263|Biological|RP-L201|CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
45649102|NCT03052673|Drug|Fentanyl|Fentanyl 1mcg/kg will be given at induction of anaesthesia followed by intraoperative infusion of 0.5 mcg/kg/hr in both the arms . Postoperatively IV-PCA pump containing fentanyl will be attached to patients in both the arms
45796427|NCT00002619|Procedure|peripheral blood stem cell transplantation|
45796428|NCT00360659|Device|Continuous Positive Airway Pressure|
45796429|NCT00002625|Drug|topotecan hydrochloride|
45796430|NCT00002625|Radiation|low-LET electron therapy|
45796431|NCT00002625|Radiation|low-LET photon therapy|
45796432|NCT00360737|Biological|Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)|Biological/Vaccine NP-018 Experimental with 8 Cohorts of 5 Subjects each evaluating 2 Dosage levels of 1 or 2 vials of NP-018 administered intravenously.
45796433|NCT02249221|Biological|Quadrivalent cell-culture based influenza vaccin|GC3106, 0.5ml, intramuscular, a single dosing at Day 1
45796434|NCT02249221|Biological|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
45796435|NCT05752305|Drug|Dexamethasone 4 Mg/mL Injectable Solution|Preoperative submucosal administration of 8mg of dexamethasone or 40mg of methylprednisolone.
45796436|NCT05752305|Drug|MethylPREDNISolone 40 Mg/mL Injectable Suspension|Preoperative submucosal administration of 8mg of dexamethasone or 40mg of methylprednisolone.
45796437|NCT04343729|Drug|Methylprednisolone Sodium Succinate|injectable solution at a dose of 0.5mg/kg
45796438|NCT04343729|Drug|Placebo solution|injectable saline solution
45796439|NCT02043691|Device|Cook Custom Aortic Endograft|The Cook Custom Aortic Endograft has a variable design such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
45796440|NCT02043691|Device|Zenith t-Branch Endovascular Graft|The Zenith t-Branch Endovascular Graft is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for proximal fixation of the device. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents.
45796441|NCT02043691|Device|Surgeon-Modified Endograft|The Surgeon-Modified Endografts are created in the operating room by modifying a commercially-available Cook Alpha Thoracic Endograft or Cook Zenith Infrarenal Aortic Device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
45796442|NCT00002631|Drug|chemotherapy|
45796443|NCT00002631|Drug|cisplatin|
45796444|NCT00002631|Drug|fluorouracil|
45796445|NCT00002631|Radiation|low-LET electron therapy|
45796446|NCT00002631|Radiation|low-LET photon therapy|
45923266|NCT00034333|Drug|MTC-DOX for Injection|
45923267|NCT00013962|Drug|Vitamin D|
45923268|NCT00000665|Drug|Foscarnet sodium|
45923269|NCT00000665|Drug|Ganciclovir|
45796447|NCT02008045|Device|Magnetic Resonance Imaging|Brain MRI without Contrast
45796448|NCT02008045|Behavioral|Neurodevelopmental Testing|Validated battery of neurodevelopmental and psychological tests.
45796449|NCT00002637|Biological|aldesleukin|
45796450|NCT00002637|Biological|gene-modified tumor cell vaccine therapy|
45923270|NCT04711876|Biological|Cytokine level in blood and CSF|Measure of cytokine level
45923271|NCT00034372|Drug|oregovomab|
45796451|NCT00002637|Biological|recombinant interferon gamma|
45923272|NCT00034450|Drug|L-carnitine|
45923273|NCT00014001|Drug|perphenazine|
45923274|NCT00014001|Drug|olanzapine|
45923275|NCT00014001|Drug|quetiapine|
45923276|NCT00014001|Drug|risperidone|
45923277|NCT00014001|Drug|ziprasidone|
45923278|NCT00014001|Drug|clozapine|
45923279|NCT00014001|Drug|fluphenazine decanoate|
45450098|NCT02170714|Other|Clinical and laboratory assessment|Clinical assessment through PUCAI and laboratory data (Erythrocyte Sedimentation Rate, C-Reactive Protein, hemoglobin, albumin, hematocrit, ferritin) were recorded at admission and at day 3 and 5. All patients were treated according to the 2011 ECCO-ESPGHAN guidelines for ASC: all patients received intravenous (iv) corticosteroids (methylprednisolone 1.5-2 mg/Kg/day) for 5 days. Patients not responding to corticosteroids (i.e. PUCAI>65 at day 5) started Infliximab (IFX, 5 mg/Kg 0,2,6 then every 8 weeks) as second-line therapy. All therapies were decided at the discretion of the referral gastroenterologist and recorded on standardized case report forms
45649103|NCT03052673|Drug|ketamine|Ketamine 0.5 mg/kg will be given post-induction of anaesthesia followed by infusion of 0.5 mcg/kg /hr in the Ketamine + Fentanyl group arm
45649104|NCT05049421|Diagnostic Test|Echocardiography|Full 2D and 3D echocardiography with special focus on right ventricular function
45796452|NCT02977013|Diagnostic Test|Anti-Xa assay|Correlation between anti-Xa assay and the efficacy and safety of enoxaparin in the treatment of pulmonary embolism
45923280|NCT00000671|Drug|Zidovudine|
45796453|NCT04823611|Drug|Part A:Placebo|Placebo solution
45796454|NCT04823611|Drug|Part A:AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
45796455|NCT04823611|Drug|Part B:Placebo|Placebo solution
45796456|NCT04823611|Drug|Part B:AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
45796457|NCT04823611|Drug|Part C: Placebo|Placebo solution
45923281|NCT00000671|Drug|Didanosine|
45923282|NCT02971540|Drug|Metamizol|in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram with following intravenous infusion of 5 grams per day.
45923283|NCT02971540|Drug|Tramadol|in group A patients will receive pre-emptive analgesia using intravenous infusion of tramadol in a single dose of 2 mg per hg of body weight with following intravenous infusion of 400 mg per day.
45923284|NCT02971540|Drug|Bupivacaine|patients in group BF will receive local wound infiltration with a solution of 0,2% bupivacaine in a volume of 10 ml per segment of vertrebral columne.
45923285|NCT02971540|Drug|Ropivacaine|patients in group RF will receive local wound infiltration with a solution of 0,2% ropivacaine in a volume of 10 ml per segment of vertrebral columne.
45923286|NCT02971540|Other|control group|patients will receive no pre-emptive analgesia. intraoperatively standard dose of fentanyl will be used.
45923287|NCT00034489|Drug|pemetrexed|
45649105|NCT04907123|Other|Intensive sodiuria-guided diuretic treatment|Intensive stepwise diuretic treatment based on combined diuresis and urinary sodium assessment
45649106|NCT04907123|Other|Standard diuretic treatment|Stepwise diuretic therapy based on diuresis assessment
45649107|NCT05030857|Drug|GLPG4716|From Day 3 to Day 14, participants will receive GLPG4716 tablets once daily in fasted state. On Day 8 GLPG4716 will be administered in fed state.
45796458|NCT04823611|Drug|Part C: AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
45796459|NCT05752227|Procedure|Transthoracic biopsy|Us guided transthoracic biopsy
45796460|NCT05752227|Radiation|CT chest|Computed tomography
45796461|NCT04665999|Device|Continuous Glucose Monitor|Data collection only
45796462|NCT05807022|Procedure|Percutaneous or transbronchial argon-helium cryoablation|The participants would undergo Percutaneous or transbronchial argon-helium cryoablation.
45923288|NCT00034489|Drug|gemcitabine|
45923289|NCT04711681|Behavioral|Positive Behavior Supports in Middle Schools|"2-4 days SWPBS training for school team and 1-2 days for whole staff training (SW and Classroom Management). Use staff release days for whole staff training.~Schedule up to four meetings with the PBS team~1K/School is to fund part or whole day training meeting with PBS team Schedule whole staff training per school year staff release days Enhanced Intervention Family Support Universal -- parent education and invitation Selective -- Family Check up School Intervention ACT for teachers PBS Calendar Kernel Recipes (Treatment) Reminder Emails Brochures Weekly phone contact (Treatment)"
45923290|NCT04711681|Behavioral|Positive Behavior Supports in Middle Schools|1 days PBS training for school team and informational presentation to whole staff Attend 2-3 PBS team meetings (coaching) Data-based feedback (limited)
45923291|NCT00396487|Drug|Capecitabine, Irinotecan, 5-Fluorouracil+Calciumfolinat|
45923292|NCT00000674|Drug|Pyrimethamine|
45923293|NCT00000674|Drug|Leucovorin calcium|
45923294|NCT00000674|Drug|Clindamycin|
45923295|NCT00014040|Drug|Nitric Oxide and INOpulse Delivery System|
45923296|NCT00034528|Drug|Busulfan|0.8 mg/kg/d administered as a single intravenous infusion over 3 hours for 4 days. All infusions are anticipated to be given in the outpatient clinic.
45923297|NCT00034528|Drug|Fludarabine|30 mg/m^2/d administered as a bolus infusion over 30 minutes for 4 days. All infusions are anticipated to be given in the outpatient clinic.
45923298|NCT00034528|Drug|FK506|0.15 mg/kg taken orally daily for 12 to 14 weeks
45649108|NCT05030857|Drug|Midazolam|On Days 1, 3 and 13, participants will receive a single oral dose of MDZ as an oral solution in fasted state.
45649109|NCT04917341|Diagnostic Test|re-evaluation of endometrial biopsy samples by a gynecopathologist working at a university hospital|The endometrial biopsy samples taken at the second stage state hospital were re-evaluated by the gynecopathologist working at the university hospital and / or the repeated endometrial biopsy sampling was examined and the evaluation process was carried out in two steps.
45649110|NCT03810859|Biological|Blood sample|Adults : 7 to 10 mL Childs : 2 to 4 mL
45450099|NCT02174770|Other|Blood Flow Restriction (BFR) Training|This is a modality of physical therapy where during low-load resistance activity, the venous return of blood from an extremity is limited only during the duration of the exercise. This can be accomplished through multiple means. For the purposes of our study, we will use an inflatable tourniquet.
45923299|NCT00034528|Drug|Prednisone|0.5 mg/kg taken orally four times daily on Day 7 and increase to 1 mg/kg taken orally four times daily on Day 14. Participants will continue regimen until Day 30 before a 20-25% taper per week.
45450100|NCT02174770|Other|Standard ACSM-guided strength training|This is the standard protocol to be used for post-operative and other physical therapy patients for rehabilitation. It includes the use of American College of Sports Medicine-guidelines for how much weight to use during the strength training portion of the rehabilitation.
45450101|NCT02170792|Drug|BIBR 1048 MS|Low, medium or high dose
45649111|NCT04917185|Other|Electro-Acupuncture|Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
45450102|NCT02170792|Drug|Ranitidine|150mg
45649112|NCT03319459|Drug|FATE-NK100|FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity
45649113|NCT03319459|Drug|Cetuximab|Epidermal growth factor receptor inhibitor antineoplastic agent
45649114|NCT03319459|Drug|Trastuzumab|HER2/neu receptor inhibitor
45649115|NCT04998799|Behavioral|Current clinical practices of participating physicians|Current clinical practice of participating physicians on management of antithrombotics for COVID-19 during hospitalisation and post-discharge
45649116|NCT04916951|Drug|Amoxicillin|oral one-time dose of amoxicillin
45649117|NCT04916951|Drug|Cephalexin|oral one-time dose of cephalexin
45649118|NCT04430933|Drug|NC318|NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle
45649119|NCT04430933|Drug|Pemetrexed/Carboplatin|Pemetrexed/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
45649120|NCT04430933|Drug|Nab paclitaxel/Carboplatin|Nab-paclitaxel/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
45649121|NCT04430933|Drug|Docetaxel|Docetaxel will be administered per the approved product label following the infusion of NC318 on the first day of each 21 day cycle
45450103|NCT02174926|Procedure|Elective laparoscopic sigmoid resection|
45450104|NCT02174926|Dietary Supplement|Conservative treatment|Written lifestyle guidance and fiber supplements
45450105|NCT02172976|Drug|Gemcitabine|
45649122|NCT04839133|Device|MyoSuitFeasibility|Participants will absolve feasibility tests with and without wearing a MyoSuit.
45649123|NCT03056417|Behavioral|The Complete Health Improvement Program|The Complete Health Improvement Program is a nationally recognized program that encourages a diet of whole plant based foods, moderate exercise, stress reduction, and social support.
45649124|NCT04815343|Device|Naída CI M90 Sound Processor (hearing aid and cochlea implant sound processor)|Speech perception measures, Hearing thresholds, Enjoyment rating, Sound identification, Subjective feedback
45649125|NCT04906733|Procedure|Tumor biopsy|Patients with RAS/RAF wild-type metastatic right colon cancer will receive biopsy before the standard treatment of chemotherapy or target therapy.
45649126|NCT03176095|Dietary Supplement|Probiotic|
45649127|NCT03176095|Dietary Supplement|Placebo|
45649128|NCT04906655|Drug|Glycopyrronium 2.4 % Medicated Cloth|The investigational product (glycopyrronium cloth, 2.4%) is a pre-moistened, medicated cloth towelette that comes in individually wrapped packets. Subjects will receive marketed Qbrexza, one box, containing 30 pouches.
45649129|NCT03130699|Behavioral|Dulce Digital|One-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
45649130|NCT03130699|Behavioral|Dulce Digital-Me (Automated Delivery)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
45649131|NCT03130699|Behavioral|Dulce Digital-Me (Medical Assistant)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
45923300|NCT00000677|Drug|SCH 39304|
45923301|NCT04711642|Drug|The study will include three arms, one non interventional and 2 interventions. The intervention arms will include two commercially available sodium hyaluronate 0.1% (Systane ultra plus and Hylo-comod)|All groups will receive a topical steroid-antibiotic for 3 weeks. The study groups will be also prescribed eye drops containing sodium hyaluronate 0.1% from the postoperative day 7 for 4 weeks.
45923302|NCT00014079|Genetic|DNA stability analysis|
45450106|NCT02172976|Drug|Oxaliplatin|
45450107|NCT02172976|Drug|5-Fluorouracil|
45450108|NCT02172976|Drug|Irinotecan|
45450109|NCT02172976|Drug|Natriumfolinate|
45450110|NCT02178202|Behavioral|McKenzie exercise|First to sixth McKenzie exercises were performed for 5 times/week and 10 treatment sessions totally.
45450111|NCT02178202|Device|Harmonic technique|Lower limb suspension exercise was performed for 5 times/week and 10 treatment sessions totally
45796463|NCT05807009|Other|core exercise|the patients will receive seven exercises performed in crook lying and side lying position on exercise mats. Cushions were used to allow the participants to be comfortable in all positions. The exercises in the crook lying position were core activation with breathing, single-leg lift with knees bent, single-leg slides, bridging and knee drop sideways. The exercises completed in side lying included hip external rotation with knees bent and hip abduction with knees straight.
45923303|NCT00014079|Genetic|loss of heterozygosity analysis|
45796464|NCT05807009|Other|traditional therapy|the patients will receive : an active warm-up including low intensity movements and dynamic stretching; choreographed aerobic training, progressing gradually from low to moderate intensity; and a cool-down involving low intensity movements, and dynamic and static stretching
45796465|NCT05806983|Other|Technology Based Psychosocial Program|A technology-based model-based psychosocial empowerment program will be implemented for parents and children in the control group.
45796466|NCT05806970|Other|Email Nudge|An email to UCLA Health Cardiology clinic managers with a list of MRA-eligible HFrEF patients and a request to schedule or change cardiology appointments.
45796467|NCT05806957|Device|Fundus Photography|Subjects will undergo Fundus Photography using FDA approved non-mydriatic fundus cameras and mydriatic camera with OCT
45796468|NCT05806918|Drug|Recombinant Human Interferon α-2b Gel (After the Alteration)|Recombinant human interferon α-2b gel (after the alteration of the active ingredient manufacturer) will be applied to the lesions as a thin layer, at the frequency of four times a day, together with the therapy of valaciclovir hydrochloride.
45923304|NCT00014079|Genetic|microsatellite instability analysis|
45923305|NCT00034606|Drug|Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)|
45923306|NCT00034645|Drug|Posaconazole oral suspension|
45450112|NCT04588480|Biological|BNT162b2|BNT162b2 (intramuscular injection)
45450113|NCT04588480|Other|Placebo|Placebo (intramuscular injection)
45450114|NCT02178280|Other|liver transplantation combined with neoadjuvant therapy|liver transplantation combined with neoadjuvant radiochemotherapy
45450115|NCT02178514|Other|Formula fed with BabyNes Nutrition System|
45450116|NCT02173132|Drug|Acetyl-L-carnitine|
45450117|NCT02173132|Other|Placebo|
45450118|NCT02175082|Other|Cycling at Forced rate|
45450119|NCT02175082|Other|Cycling at self-selected rate|
45450120|NCT03538366|Other|Donor FMT|Fecal transplant from unrelated, healthy donors using enemas
45450121|NCT02175160|Other|Braking and functionality|
45450122|NCT03538288|Device|rTMS|rTMS will be applied at 10 Hz to the DLPFC
45450123|NCT02756650|Drug|Canakinumab|150 mg or 300 mg of canakinumab was administered monthly. IV (SC after month 6)
45450124|NCT02173288|Drug|Standard medical therapy|
45450125|NCT02173288|Drug|Tolvaptan|
45450126|NCT02173288|Drug|Midodrine|
45450127|NCT02173366|Behavioral|Change Club Intervention|
45450128|NCT02173444|Other|Blood test|
45450129|NCT02178670|Biological|CSC-DC|
45450130|NCT02178748|Biological|MVA85A|Single dose of 1x10^8pfu MVA85A intramuscular vaccination
45450131|NCT02178826|Device|Rapid Maxillary Expansion|The Rapid Maxillary Expander will over 10-14 days create a palatal expansion of about 5mm.
45450132|NCT02178826|Device|Placebo Appliance|The Placebo Appliance looks exactly like the Rapid maxillary Expander but the expansion screw does not work. When the expansion screw is activated it does not create a palatal expansion.
45450133|NCT02175238|Drug|BI 691751 fasted|single dose BI 691751 in fasted state
45450134|NCT02175238|Drug|BI 691751 after high fat breakfast|single dose BI 691751 after a standardised high fat breakfast
45450135|NCT02175316|Device|Enhanced External Counterpulsation|Enhanced External Counterpulsation
45450136|NCT02175394|Drug|Microgynon®|
45450137|NCT02175394|Drug|BI 1356|
45450138|NCT02173600|Behavioral|Group-level Intensive dietary Counselling|
45450139|NCT02173600|Behavioral|Individual-level Intensive Dietary Counselling|
45796469|NCT05806918|Drug|Recombinant Human Interferon α-2b Gel (Before the Alteration)|Recombinant human interferon α-2b gel (before the alteration of the active ingredient manufacturer) will be applied to the lesions as a thin layer, at the frequency of four times a day, together with the therapy of valaciclovir hydrochloride.
45796470|NCT05806892|Other|Thera Pearl|"You can apply Thera°Pearl warm breast therapy before breastfeeding or during milking. You should do this application 4 times a day, in the morning, at noon, in the evening and at night before going to bed. Each application should be done on both breasts and should last at least 20 minutes.~Thera°Pearl Warm Breast Therapy has been developed to open milk ducts and accelerate milk flow.~Thermogel packs for Thera°Pearl hot therapy can be heated inside the fabric covers in the microwave for a maximum of 15 seconds or in hot water by removing the fabric covers. Packages that have been removed from the cover should be kept in boiling water for 1-2 minutes and then applied by putting them into the sheath."
45923307|NCT00034684|Drug|Farnesyl Protein Transferase Inhibitor|
45796471|NCT05806879|Other|Maternity Napkin|"Use of maternity napkin with the following specifications (followed for 4.5 months)~Length is 230-240mm, to be able to provide adequate coverage.~Width is 150-155mm with wings.~Thickness is 3-5mm.~The maternity napkin is curved to prevent leakage on the sides, has wings for secure attachment to the underwear and able to absorb 30-40 ml per minute."
45796472|NCT05806866|Behavioral|Cognition scores, cognitive instrumental activities of daily living scores|A detailed neuropsychological test battery will be applied. The Functional Activitites Questionnaire (FAQ) subscores will be used to define cognitive and motor instrumental activities of daily living function
45649132|NCT03056183|Behavioral|Depression Care Transitions (DCT)|DCT Intervention group - Patients in the DCT intervention will have a Transitional Care Social Worker (TCSW) who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
45649133|NCT03055091|Other|Xylitol syrup|Each dose will be 5 mL of 400 g/L and subjects will receive Three to 5 doses will be given each day.
45649134|NCT03055091|Other|Placebo|Each dose looks and tastes like the xylitol syrup but it is not microbial. Each dose will be 5 mL of 300 g/L of sorbitol. Three to 5 doses will be given each day.
45649135|NCT02648581|Drug|Subcutaneous Ustekinumab|Injections of ustekinumab at 90 mg at week 0, week 4 and week 16. Patients in treatment failure at week 24 will terminate the study. Responder patients at week 24 will receive additional 2 injections of ustekinumab at week 28 and week 40 with a final evaluation at week 52.
45649136|NCT04916717|Other|Counseling|Face-to-face and telephone counseling were applied to individuals in the intervention group.
45649137|NCT02609815|Drug|gemigliptin/metformin|zemimet-SR 50/1000 mg x 1 tablet
45649138|NCT02609815|Drug|glimepiride/metformin|amaryl-Mex 1/500 mg x 2 tablets
45649139|NCT04923581|Behavioral|Oral Health Behavioral Interventions|The study will use a factorial design to evaluate the efficacy of three distinct intervention components: Motivational interviewing, storytelling videos and oral health promotion messages, in enhancing mothers' brushing of their preschool children's teeth using fluoridated toothpaste.
45649140|NCT01315639|Biological|biomarkers, MRI and CSF|MRI at Day 0 and month 24 (or conversion) Biomarkers at Day 0 et month 24 (or conversion) CSF at D0
45649141|NCT04916639|Device|Device: Physiomer undiluted seawater nasal spray|"In this study, subjects are asked to adhere to the following dosage during the 3 weeks of the study:~Nasal wash four times every day~These washes are to be carried out in each nostril~By continuously pressing the spray for 3 seconds in each nostril~Subjects are recommended to distribute the 4 nasal washes as follows:~1st : morning~2nd : midday~3rd : afternoon~4th : evening Subjects will be instructed to maintain daily nasal wash over the 3 weeks study period even in case of earlier nasal symptoms resolution, in order to assess the impact of nasal wash on viral load and other COVID-19 symptoms."
45796473|NCT05806853|Drug|68Ga-PSMA|Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)] (68Ga-PSMA)
45796474|NCT05806853|Drug|68Ga-RM2|Bombesin receptor antagonist (68Ga-RM2)
45649142|NCT04662463|Behavioral|Cognitive Bias Modification for Interpretation (CBM-I)|Patients will receive CBM-I training by reading and imaging themselves in a series of emotionally ambiguous scenarios. Each scenario ends with an incomplete final word. Patients need to complete the final word to resolve the scenario in a positive direction.
45649143|NCT04662463|Behavioral|Placebo|Patients will receive placebo task which uses neutral rather than emotional material.
45649144|NCT04916561|Diagnostic Test|RT-PCR|Detection of Covid-19 in bone, articular fluid and muscle samples using RT-PCR
45649145|NCT04906967|Procedure|flaps|coverage of soft tissue defect around ankle
45649146|NCT04585399|Behavioral|Contingency management|Financial incentives for attending bup appointments and demonstrating opioid abstinence. Rides will also be provided for up to two clinic visits per week.
45649147|NCT01118767|Other|Cell phone intervention|Participant receives short text messages, including: antiretroviral reminders, clinic appointment reminders, and preventive/educational messages
45796475|NCT05806840|Behavioral|Rapid Adaptation to Prevent Drug Use (RAPD)|RAPD will include a novel bundle of implementation strategies to support rapid responses to urgent drug use events. The strategies deployed will be based on the first step of the After Action Review: critical analysis and reflection.
45796476|NCT05806840|Behavioral|Standard Implementation|Standard implementation of the Michigan Model for Health (MMH) includes curriculum materials and as-needed technical assistance provided by a school health coordinator.
45796477|NCT05806827|Diagnostic Test|Virological screening|The preoperative viral screening protocol will start with a self-assessment questionnaire that will be provided to all the enrolled patients, where they will be asked to indicate previously SARS-CoV-2, HPV, EBV, CMV infections. Collection of peripheral blood mononuclear cells (PBMCs) from blood samples and serum specimens for the virological screening (HPV, EBV, CMV, SARS-CoV-2). Preoperative MoCA assessment, follow-up 5 days, 3 months and 6 months after the surgery.
45796478|NCT05806814|Biological|Sipuleucel-T|Three doses of Sipuleucel-T, each containing a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, given at week 0, 2, and 12-14.
45796479|NCT05806762|Device|BioIntellisense|Enrolled patients will have a BioIntellisense patch applied to their chest. There is no comparator group enrolled.
45450140|NCT02178904|Procedure|CT and stress test|Coronary computed tomographic angiography (CCTA) plus computed tomography stress myocardial perfusion imaging (CTP)
45450141|NCT02173678|Drug|COMBIVENT® HFA-MDI|
45450142|NCT02173678|Drug|COMBIVENT® CFC-MDI|
45450143|NCT02173678|Drug|Placebo HFA-MDI|
45649148|NCT04922879|Behavioral|Individualized lung rehabilitation|Early respiratory function training, reasonable oxygen therapy to prevent hypoxemia, Positive pressure vibration training to promote coughing ability recovery, early exercise, Health education and psychological support.
45923308|NCT04732819|Behavioral|High touch multi-pronged behavioral intervention|"In this intervention, facilities will work with our research team to accomplish the following:~Identify and engage a Facility Opinion Leader.~Employ Consenting Specialists to facilitate the clinical consent for vaccination process.~Engage well respected persons in the community who are willing to provide messages that promote trust in the vaccine and that will be distributed widely within a facility by email, website, text and/or social media.~Distribute buttons, T-shirts, and masks that promote awareness about vaccination (e.g., Ask me about the COVID-19 vaccine!) through facility leadership.~Acquire additional COVID-19 testing kits using funds provided by our research team."
45796480|NCT05806749|Combination Product|Donor CD34+, CD3+. and belumosudil|"Immediately after living donor kidney transplantation, subjects will begin a conditioning regimen of rATG and total lymphoid irradiation. An infusion of at least 8 X106 donor CD34 cells/kg recipient weight and of at least 10 X106 donor CD3 cells/kg recipient weight will then be given. A triple immunosuppressive regimen of tacrolimus, corticosteroids, and mycophenolate will be utilized.~Corticosteroids will be given on a tapering schedule from day 0 through the first four months. Tacrolimus will be given on a tapering schedule from day 1 through month 18. Mycophenolate will be given at a fixed dose from day 11 through month 12.~Subjects will receive belumosudil 200 mg by mouth daily from day 28 following the kidney transplant through month 24."
45923309|NCT00000683|Biological|HIVAC-1e|
45796481|NCT05806736|Device|Transcutaneous auricular vagus nerve stimulation (real stimulation)|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs, twice a day, 30 minutes each time.
45796482|NCT05806736|Device|Transcutaneous auricular vagus nerve stimulation (sham stimulation)|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the left earlobe. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs, twice a day, 30 minutes each time.
45796483|NCT05806723|Drug|Atorvastatin 40 Mg Oral Tablet|daily drug intake during six months
45796484|NCT05806710|Dietary Supplement|GourMed© meal|patients receive GourMed© meal as lunch for 7 consecutive days
45649149|NCT04906343|Procedure|Colonoscopy|Colonoscopy surveillance in SPS patient after 3 years of the last colonoscopy.
45649150|NCT05132023|Drug|Empagliflozin & Metformin (Test)|one tablet administrated according to a randomization scheme with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing.
45796485|NCT05806697|Procedure|Electroencephalogram (EEG)|The EEG will be uniquely performed during for the whole study if a given subject converts to symptomatic AD or in the occurrence of significant cognitive decline.
45796486|NCT05806697|Procedure|Oculomotor tests|All participants in the INSIGHT-2 study are invited to perform the oculomotor test, excepting subjects reporting oculomotor disorders.
45923310|NCT00000683|Biological|gp160 Vaccine (MicroGeneSys)|
45649151|NCT05132023|Drug|Empagliflozin & Metformin (Reference)|one tablet administrated according to a randomization scheme with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing.
45796487|NCT05806697|Procedure|MRI|All INSIGHT-2 participants will undergo a baseline MRI (structural and resting state fMRI) a follow-up MRI at M12, M36 and M60.
45923311|NCT00034762|Drug|risperidone|
45923312|NCT00000686|Drug|Stavudine|
45923313|NCT00034801|Drug|olanzapine|
45923314|NCT00034801|Drug|ziprasidone|
45923315|NCT00014196|Drug|cisplatin|
45923316|NCT00014196|Drug|docetaxel|
45923317|NCT00014196|Radiation|radiation therapy|
45923318|NCT00034840|Drug|telmisartan, valsartan|
45923319|NCT00000689|Drug|Bleomycin sulfate|
45923320|NCT00000689|Drug|Vincristine sulfate|
45450144|NCT02256124|Drug|Lamotrigine|
45450145|NCT02256124|Drug|Placebo|
45649152|NCT04916405|Other|Standardized management of pregnancy weight of twin pregnancy|Standardized management of pregnancy weight of twin pregnancy
45649153|NCT05404087|Device|Dedicated breast CT|Administration of contrast agent and scanning of the breast in order to evaluate the enhancement of the tumor
45649154|NCT04904159|Procedure|Thyroidectomy|total thyroidectomy
45649155|NCT04904159|Procedure|Lobectomy|Lobectomy
45649156|NCT04498663|Behavioral|Emotion- and Relationship-Focused Therapeutic Interview|In this study, the therapeutic interview will be one-session lasting 90 minutes. Participants will explore prior and ongoing stressful life experiences. Participants will be educated about the role of stress in pain and will be encouraged to identify links between stressors, psychological and emotional conflicts related to the stressors, and their pain symptoms. The interview will encourage the experience and expression of previously avoided emotions related to interpersonal stressors.
45923321|NCT00000689|Drug|Doxorubicin hydrochloride|
45923322|NCT00000689|Drug|Cyclophosphamide|
45923323|NCT00000689|Drug|Methotrexate|
45923324|NCT00000689|Drug|Cytarabine|
45923325|NCT00000689|Drug|Leucovorin calcium|
45923326|NCT00000689|Drug|Sargramostim|
45923327|NCT00000689|Drug|Dexamethasone|
45923328|NCT00034879|Drug|ZD1839 (Gefitinib)|
45923329|NCT00000707|Drug|Pentamidine isethionate|
45923330|NCT00014235|Drug|fludarabine phosphate|Given IV
45923331|NCT00014235|Radiation|total-body irradiation|Undergo TBI
45923332|NCT00014235|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
45649157|NCT04916483|Other|group cognitive stimulation therapy|The experimental group will receive totally 7 weeks,14 sessions, twice a week, and 60 minute group cognitive stimulation therapy (GCST).
45649158|NCT04916483|Other|usual care|The control group maintains the unit routine treatment.
45923333|NCT00014235|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo PBSCT
45923334|NCT00014235|Drug|cyclosporine|Given PO or IV
45649159|NCT05131711|Combination Product|Combined stereotactic radiosurgery and enhanced immunotherapy|Patients will be administrated immunal adjuvants intratumorally and systemically with concurrent stereotactic radiosurgery.
45923335|NCT00014235|Drug|mycophenolate mofetil|Given IV or PO
45923336|NCT00014235|Other|laboratory biomarker analysis|Correlative studies
45649160|NCT02619617|Drug|SOM230|The study evaluated SOM230 vs Placebo
45923337|NCT00000710|Drug|Didanosine|
45923338|NCT02972151|Drug|Comprehensive treatment of TCM|Subjects were treated with comprehensive treatment of TCM including Oral medicine: 1 dose daily by our hospital pharmacy medicine room Decoction decoction, each agent 200ml, and the 2 ton service. 10 days for a course of treatment, continuous treatment of 3 courses; retention enema with traditional Chinese medicine oral drugs according to different types of concentrated decoction enema, each dose of medicine decocting 2 times, 2 days of external application of Chinese medicine: Chinese medicine enema; break into powder, into the bag, steam for 45 minutes, and so the temperature dropped to appropriate, will be installed a Chinese medicine bag used on patients with lower abdomen for 20 minutes. Above method, a course of treatment for 10 days, continuous treatment of 3 courses.
45923339|NCT02972151|Other|Expectant treatment|Expectant treatment group patients were not treated during the observation period.（3 months after the start of the trial and 1 months after the end of the trial.）From the point of view of medical ethics, the expectant treatment group of patients at the end of the observation period, given the treatment of traditional Chinese medicine treatment group.
45649161|NCT02619617|Drug|Placebo|The study evaluated SOM230 vs Placebo
45649162|NCT04012957|Drug|Desidustat Oral Tablet|Desidustat tablet
45450146|NCT02173756|Drug|morphine gel|1 mg / ml ofmorphine hydrochloride, presented in a 5 mL sterile syringe (single dose), raspberry aroma, 30% glucose
45450147|NCT02173756|Drug|placebo gel|Sterile placebo gel with raspberry aroma, 30% glucose presented in 5 mL syringe (single dose) of the same appearance and the same packaging as morphine gel to maintain the blind
45450148|NCT00102466|Drug|vildagliptin|
45649163|NCT04012957|Drug|Darbepoetin Alfa|Darbepoetin injection
45649164|NCT05125705|Biological|Platelet rich plasma injection|The PRP is prepared by RegenLab's RegenKit-THT, in accordance with operating instructions supplied with the kit. The device allows automated blood collection (8 mL) and blood component separation in closed circuit. After centrifugation at room temperature for 9 minutes at centrifugal force of 1500g, the RegenTHT tube is then inverted several times before re-suspension, allowing 4mL of PRP to be obtained for each tube. 2.5mL will be injected into patients
45649165|NCT05125705|Other|Saline injection|Saline injection
45649166|NCT04906031|Drug|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on d1-5 and d15-19. 28 days per cycle.
45649167|NCT05131243|Procedure|Chemotherapy time|6 months of chemotherapy
45649168|NCT05131243|Procedure|Chemotherapy time|3 months of chemotherapy
45649169|NCT05125627|Drug|"Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)"|Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
45649170|NCT05125627|Drug|Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)|Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
45649171|NCT04399265|Dietary Supplement|Trehalose|A disaccharide sugar usually used as food preservative, but for this study it is given at a higher dose
45649172|NCT04399265|Dietary Supplement|Maltose|Maltose power
45796488|NCT05806697|Radiation|18-F amyloid PET Scan|The primary endpoint is conversion to the symptomatic stage in subjects at risk, identified by positive amyloid staining (A+) on florbetapir PET imaging. Participants will receive an injection of 18F-Florbetapir prior to undergoing amyloid PET scanning. Florbetapir (18F) is an experimental imaging compound labeled with [18F] fluorine that decays by positron (β+) emission and has a half-life of 109.77 min. This procedure will be done at baseline.
45796489|NCT05806697|Radiation|18F-fluorodeoxyglucose (FDG) PET Scan|Participants will receive an injection of Fludeoxyglucose 18F prior to undergoing FDG-PET. The [18F]FDG is the most well-known radiopharmaceutical positron emitter, in both clinical and preclinical fields.
45923340|NCT00000716|Drug|Zidovudine|
45923341|NCT00034918|Drug|ZD6474|
45923342|NCT00014274|Drug|carboplatin|
45923343|NCT00014274|Drug|gemcitabine hydrochloride|
45649173|NCT05125549|Drug|Сlopidogrel bisulfate film-coated tablets, 75 mg (JSC Farmak, Ukraine)|One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
45923344|NCT00014274|Drug|methotrexate|
45796490|NCT05806697|Biological|Blood sampling|A total of 80 ml of whole blood will be collected for each participant in the INSIGHT-2 study for routine laboratory assessment and biobank sampling.
45923345|NCT00014274|Drug|vinblastine sulfate|
45923346|NCT00034957|Drug|Investigational drug|
45923347|NCT00035035|Drug|GEMZAR|
45923348|NCT00035035|Drug|ALIMTA|
45796491|NCT05806697|Biological|Lumbar puncture|A lumbar puncture for cerebrospinal fluid (CSF) collection is proposed to all participants.
45796492|NCT05806671|Drug|Dalpiciclib|Dalpiciclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off
45923349|NCT00000719|Drug|Zidovudine|
45923350|NCT00000719|Drug|Zalcitabine|
45923351|NCT00014313|Drug|cisplatin|
45923352|NCT00014313|Drug|etoposide|
45923353|NCT00035074|Drug|Methotrexate|
45923354|NCT00035113|Drug|epothilone b|
45649174|NCT05125549|Drug|Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie, France)|One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
45450149|NCT00102466|Drug|Gliclazide|
45450150|NCT00102466|Drug|Metformin|
45649175|NCT04398719|Radiation|[11C]PBR28|The radiotracer, [11C]PBR28, will be administered at the beginning of each PET scan
45649176|NCT04398719|Drug|Low-dose lipopolysaccharide|Subjects will receive intravenous lipopolysaccharide.
45649177|NCT04398719|Drug|Intradermal Capsaicin|A small dose of capsaicin will be administered by intradermal injection.
45649178|NCT04906577|Other|photography+odour|Daily from D0 to D5: a square of cotton cloth will be placed against the child's scalp by the childcare worker in charge of the child, then removed and placed in a sealed box containing a photograph of the child, which will then be given to the mother.
45649179|NCT04906577|Other|photography|A neutral smelling cloth will be placed with the child's photograph which will then be given to the mother.
45796493|NCT05806671|Drug|Pyrotinib|Pyrotinib 320mg/day orally continuously
45796494|NCT05806671|Drug|Fulvestrant|Fulvestrant 500mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle
45649180|NCT04903847|Drug|Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]|Two-drug therapy
45649181|NCT04903847|Drug|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]|Three-drug therapy
45649182|NCT05130697|Other|eMPowEr App|A mobile app to support participants in the management of malignant pleural effusions at home
45649183|NCT04905953|Drug|Neostigmine|Intrathecal injection of two doses of neostigmine (10 & 20 mic) during spinal anesthesia for cesarean section.
45796495|NCT05806645|Other|Risk-guided transition of care intervention delivered through an integrated digital health strategy|The proposed experimental intervention will incorporate our risk prediction model which will be used to guide the hospital to home transition of care for medium and high-risk groups of patients. Patients will receive transition of care plans that are tailored to their risk and embedded within standardized discharge pathways within the electronic health record
45796496|NCT05806632|Other|Prognostic model|Risk assessment and risk stratification
45796497|NCT05806619|Other|histopathological analysis; morphological and non-morphological magnetic resonance|The surgical material removed during surgery was subjected to histological analysis. Morphological and non-morphological magnetic resonance examination before the neurosurgical surgery, according to clinical practice.
45796498|NCT05806528|Other|Ultrasound|Use ultrasound to make placental invasion index
45796499|NCT05806515|Procedure|Biospecimen Collection|Undergo collection of blood samples
45796500|NCT05806515|Drug|Carboplatin|Given IV
45796501|NCT05806515|Procedure|Chest Radiography|Undergo chest X-ray
45796502|NCT05806515|Procedure|Computed Tomography|Undergo CT
45796503|NCT05806515|Procedure|Magnetic Resonance Imaging|Undergo MRI
45796504|NCT05806515|Procedure|PSMA PET Scan|Undergo PSMA PET
45796505|NCT05806515|Procedure|Surgical Procedure|Undergo surgery
45923355|NCT00000722|Drug|Pentamidine isethionate|
45923356|NCT00035152|Drug|Paclitaxel and carboplatin|
45923357|NCT00014352|Drug|docetaxel|
45923358|NCT00014352|Drug|doxorubicin hydrochloride|
45923359|NCT00014352|Drug|estramustine phosphate sodium|
45923360|NCT00014352|Drug|ketoconazole|
45923361|NCT00014352|Drug|warfarin|
45923362|NCT00035191|Drug|galantamine|
45923363|NCT00035230|Drug|Topiramate|
45923364|NCT00000740|Drug|Sitamaquine|
45923365|NCT00035269|Drug|Antibiotic|
45923366|NCT00014391|Biological|palivizumab|
45923367|NCT00014391|Drug|ribavirin|
45923368|NCT00035308|Drug|Abetimus sodium (LJP 394)|
45923369|NCT00000746|Biological|rgp120/HIV-1 SF-2|
45923370|NCT00000746|Biological|Env 2-3|
45923371|NCT00000746|Biological|HIVAC-1e|
45923372|NCT00000746|Biological|gp160 Vaccine (MicroGeneSys)|
45923373|NCT00035347|Drug|IV azithromycin|500 mg once daily
45923374|NCT00035347|Drug|ceftriaxone|1 gram once daily for 2 to 5 days
45923375|NCT00035347|Drug|oral azithromycin|2 x 250 mg once daily
45923376|NCT00035347|Drug|IV levofloxacin|500 mg once daily
45923377|NCT00035347|Drug|oral levofloxacin|500 mg once daily
45923378|NCT00014430|Biological|trastuzumab|"Trastuzumab (INN; trade name Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers.~The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell to inside the cell, and turn genes on and off. The HER proteins regulate cell growth, survival, adhesion, migration, and differentiation-functions that are amplified or weakened in cancer cells. In some cancers, notably some breast cancers, HER2 is over-expressed, and causes breast cells to reproduce uncontrollably."
45923379|NCT00014430|Drug|vinorelbine ditartrate|Vinorelbine (trade name Navelbine) is an anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer.
45923380|NCT00035386|Procedure|trans-right ventricular alcohol septal ablation (TRVASA)|
45923381|NCT00035425|Drug|linezolid|600mg every 12 hours
45450151|NCT02173834|Other|18F- fluorodeoxyglucose-positron emission tomography Computed Tomography scan and 123I-metaiodobenzylguanidine-single-photon emission computed tomography scan|
45649184|NCT03647917|Biological|Platelet Rich Plasma|"Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands."
45649185|NCT03647917|Biological|Platelet Rich Plasma|"Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands."
45923382|NCT00035425|Drug|vancomycin|1gm every 12 hours. The dose of vancomycin intravenously may be adjusted for renal function, but the patient must be able to receive a 300 mL volume of intravenous fluid at the assigned dosing times of every 12 hours.
45923383|NCT00000752|Drug|Pseudoephedrine hydrochloride|
45649186|NCT04905875|Procedure|Prone Position|Every center will prescribe PP in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
45649187|NCT03637309|Behavioral|BeReady2Smile Video and App|BeReady2Smile is a coordinated oral health prevention intervention program that includes video content that features demonstrations/content on encouraging brushing, proper loading of toothbrush, brushing duration and frequency, fluoride myths, and limiting sugar sweetened beverages and milk in baby bottles while in bed. BeReady2Smile will also include a mobile application built within a web-based infrastructure, so parents can participate in multi-media educational activities, develop dental health behavior plans, tailor features and receive feedback from the system on a secure website.
45649188|NCT04905719|Diagnostic Test|Ultrasound|Each patient included to the study will undergo Point-of-Care ultrasound testing specific for the area defined in the Groups section.
45923384|NCT00000752|Drug|Guaifenesin|
45923385|NCT00000752|Drug|Cefuroxime axetil|
45923386|NCT00000752|Drug|Beclomethasone dipropionate|
45923387|NCT00035464|Drug|Azimilide Dihydrochloride|125 mg azimilide tablets, twice a day for 6 months
45923388|NCT00035464|Drug|Placebo|placebo tablets, twice a day for 6 months
45923389|NCT00014469|Drug|busulfan|
45796506|NCT05806489|Other|Intermittent Fasting|Participants received a 3-day individualized diet plan consisting of 3 meals per day. Meals needed to be consumed during 6 hours (while fasting for the remaining 18 hours). Diet plans were matched for energy and macronutrients.
45796507|NCT05806489|Other|Control Diet|Participants received a 3-day individualized diet plan consisting of 3 meals per day. Meals needed to be consumed during 12 hours (while fasting for the remaining 12 hours). Diet plans were matched for energy and macronutrients.
45796508|NCT05806476|Dietary Supplement|caffeine|1.75mg / kg body mass of caffeine x 3 times a day during the run-in days and 3mg / body mass of caffeine once on the experimental days
45923390|NCT00014469|Drug|melphalan|
45923391|NCT00014469|Drug|methotrexate|
45923392|NCT00014469|Drug|tacrolimus|
45923393|NCT00014469|Procedure|allogeneic bone marrow transplantation|
45923394|NCT00000755|Biological|rgp120/HIV-1MN|
45923395|NCT00000755|Drug|Zidovudine|
45923396|NCT02971267|Other|Observational|None, observational only
45923397|NCT00035581|Drug|poly I-poly C12U|200-400 mg IV infusions 2x/week for 24 weeks
45450152|NCT02175550|Device|NR CC|
45923398|NCT04733170|Diagnostic Test|KnowNow SARS-CoV-2 Rapid Antigen Test|KnowNow SARS-CoV-2 Rapid Antigen Test for the detection of Covid-19 in saliva, as compared to high sensitivity reverse transcription polymerase chain reaction (RT-PCR) of nasopharyngeal swabs as the reference test method
45923399|NCT00000758|Drug|Fluorouracil|
45450153|NCT04620928|Behavioral|Concepts|Images and sounds that are characteristic of various common objects.
45450154|NCT02256046|Device|Esophagogastroduodenoscope|Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
45450155|NCT02175706|Device|Resolute Integrity®|Biolinx-zotarolimus coating on a chobalt-cromium alloy stent platform that has a novel sinusoidal design.
45923400|NCT00035620|Drug|pegfilgrastim|pegfilgrastim
45923401|NCT00035620|Drug|filgrastim|filgrastim
45923402|NCT00014547|Drug|BBR 3464|
45450156|NCT02175706|Device|Promus Element®|fluoropolymer-everolimus coating on a novel stent platform made from a platinum-chromium alloy
45450157|NCT02173912|Drug|Candesartan cilexetil 16 mg and Amlodipine besylate 10mg (Reference)|"Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between."
45923403|NCT02971306|Drug|standard medical therapy|Standard medical therapy involves primary treatment with pentoxifylline at a dose of 400 mg three times a day and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
45796509|NCT05806476|Dietary Supplement|placebo|1.75mg / kg body mass of microcrystalline cellulose x 3 times a day during the run-in days and 3mg / body mass of microcrystalline cellulose once on the experimental days
45923404|NCT02971306|Drug|G-CSF|G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
45923405|NCT02971306|Drug|n-Acetylcysteine|n-Acetylcysteine at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution
45649189|NCT03619681|Drug|KN026|Patient will be intravenously administrated with one dose of KN026. dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.
45923406|NCT00000761|Drug|Interferon gamma-1b|
45923407|NCT00014586|Drug|bicalutamide|
45923408|NCT00014586|Drug|goserelin acetate|
45923409|NCT00014586|Procedure|orchiectomy|
45923410|NCT04732390|Procedure|erector spinae block with bupivacaine|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5
45923411|NCT04732390|Procedure|erector spinae block with bupivacaine and magnesium sulphate|Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5.
45923412|NCT00035854|Drug|Zyvox® / Linezolid|
45923413|NCT00000779|Biological|Aluminum hydroxide|
45923414|NCT00000779|Biological|MF59|
45923415|NCT00000779|Biological|rgp120/HIV-1IIIB|
45923416|NCT00000779|Biological|rgp120/HIV-1MN|
45450158|NCT02173912|Drug|CJ-30059 (Test)|"Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between."
45923417|NCT00000779|Biological|rgp120/HIV-1 SF-2|
45923418|NCT00000779|Biological|Env 2-3|
45649190|NCT04905641|Procedure|Bilateral intermediate cervical plexus block|Bilateral intermediate cervical plexus block was performed under ultrasound guidance.
45649191|NCT03609073|Device|Endomina|Suturing system then cutting the bridge between the diverticulum and the esophagus.
45923419|NCT00035893|Drug|poly I-poly C12U|200-400 mg IV infusions 2x/week for 64 weeks
45923420|NCT00035971|Drug|raloxifene HCI and alendronate Na|
45923421|NCT00014625|Drug|indisulam|
45923422|NCT02971345|Procedure|Stent and Iodine-125 seed strand implantation|The patent second-order branch of the intrahepatic portal vein was punctured with a 22-gauge Chiba needle under ultrasound guidance.Stent and Iodine-125 seed strand are implanted by two 0.035-inch,150-cm-long wire.
45923423|NCT02971345|Device|Stent|Bare stent should be placed through a 7-F, 23-cm-long sheath over the wire.
45649192|NCT04916093|Drug|Vildagliptin 50 MG|Galvus 50 mg oral tablets
45649193|NCT04916093|Drug|Sitagliptin 100mg|Januvia 100mg oral tablets
45649194|NCT04916093|Drug|MetFORMIN 1000 Mg Oral Tablet|Glucophage 1000 mg oral tablets
45923424|NCT02971345|Device|Iodine-125 seed|The number of Iodine-125 seeds planned to be implanted was calculated by the following formula: N = length of obstructed main portal vein (mm)/4.5 + 4. These seeds were arranged linearly and sealed into a 4-F catheter continuously to construct a Iodine-125 seed strand.
45450159|NCT02173990|Drug|Aflibercept-FOLFIRI|"Aflibercept : 4 mg/kg, IV over 1 h on Day 1~FOLFIRI :~Irinotecan 180 mg/m² IV infusion in 500 mL D5W (5% Dextrose in Water solution) over 90 minutes and dl leucovorin* 400 mg/m² IV infusion over 2 hours, at the same time, in bags using a Y-line, followed by :~5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by :~5-FU 2400 mg/m² continuous IV infusion in 500 mL over 46-hours.~*400 mg/m² of leucovorin expressed in dl racemic. When the l-isomer form is used the dose should be divided by 2, i.e. 200 mg/m²"
45649195|NCT05130619|Dietary Supplement|Ethanol|Crossover meal study
45649196|NCT03052205|Drug|IMO-2125|IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle.
45649197|NCT03512119|Drug|Lumacaftor-Ivacaftor treatment|Lumacaftor-Ivacaftor treatment during one year
45649198|NCT04903769|Behavioral|Stress Management and Resiliency Training Program for Parkinson's Disease (SMART-PD)|SMART-PD is a manualized intervention that teaches cognitive-behavioral techniques and relaxation skills to help participants learn to elicit the relaxation response, alter cognitive appraisals, improve healthy lifestyle behaviors (i.e., sleep, nutrition, physical activity) and access social support.
45796510|NCT05806437|Dietary Supplement|sideremil vita cp|assunzione per 30 giorni dell'integratore
45796511|NCT05806385|Device|Cryoablation|Tumor ablation before neoadjuvant chemotherapy
45796512|NCT05806385|Combination Product|Cryoablation combined with PD1 Inhibitor|Combination of cryoablation with PD1 inhibitor before neoadjuvant chemotherapy
45796513|NCT05806333|Diagnostic Test|FAPI PET|Drug: 18F-FAPI 18F-FAPI were injected into the patients before the PET/CT scans
45923425|NCT02971345|Drug|Epirubicin|Epirubicin is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: Epirubicin 30-60 mg per patient,depending on the situation of the patient.
45923426|NCT02971345|Drug|Ultra-fluid lipiodol|Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .
45923427|NCT02971345|Other|Gelatin sponge articles|Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.
45923428|NCT00036088|Drug|Olanzapine|
45923429|NCT00014664|Biological|apolizumab|
45923430|NCT00036127|Drug|aripiprazole|
45923431|NCT00000788|Drug|Methadone hydrochloride|
45923432|NCT00000788|Drug|Fluconazole|
45923433|NCT00036166|Drug|FK463|
45923434|NCT00014742|Drug|collagenase|
45923435|NCT00036205|Drug|sumanirole|
45923436|NCT00000794|Drug|Sulfadiazine|
45923437|NCT00000794|Drug|Clarithromycin|
45923438|NCT00000794|Drug|Atovaquone|
45804109|NCT00355381|Behavioral|Information Services (IRx)|Information services tailored to the needs of individual patients. The information prescription (IRx)or service is defined for this study as a combination of: 1)An evidence-based web site for use by patients and their families; 2) A reference interview and assistance in locating relevant general information in response to patient information needs; 3) Documentation of the questions and the information service provided in response to these in the patient's Electronic Patient Record for review by providers as needed; and, 4) Triage of patient's/parents clinical questions to providers.
45923439|NCT00000794|Drug|Pyrimethamine|
45923440|NCT00000794|Drug|Leucovorin calcium|
45923441|NCT00036244|Drug|RG1068 (Synthetic Human Secretin)|
45923442|NCT00391521|Drug|AS703569|Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle
45923443|NCT00391521|Drug|AS703569|Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle
45923444|NCT00391521|Drug|AS703569|Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
45923445|NCT00036283|Drug|Celecoxib|
45923446|NCT04732585|Procedure|Physiotherapy or Surgery|"Physiotherapy: Guidelines suggest a tailored and progressive exercise program to improve muscle strength and control, joint mobility, and patient understanding of the problem and how to manage it. Additional interventions like tape or manual treatment can also be implemented but should not be exclusive~Surgery: ACL surgical reconstruction"
45649199|NCT05130541|Behavioral|Proning|Rotating on long axis 90 degrees every 30 minutes
45923447|NCT00391638|Drug|TRUVADA (EMTRICITABINE + TENOFOVIR DF)|Truvada ® (200 mg tablet of 300 mg of emtricitabine + tenofovir DF) Dosage 1 tablet taken orally once a day
45923448|NCT00391638|Biological|PEGASYS 180μg (Interféron pégylé alpha -2a)|Pegasys ® injection 180μg Dosage: A subcutaneous injection per week
45923449|NCT00036361|Drug|Aripiprazole|
45923450|NCT00036400|Drug|epoetin alfa|
45923451|NCT00036439|Drug|Infliximab|
45649200|NCT05130541|Other|Supportive Care|Usual Care
45649201|NCT04903613|Drug|Ligelizumab|Ligelizumab 120 mg s.c every 4 weeks
45923452|NCT02971189|Device|Librata Endometrial Ablation|The treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
45923453|NCT00000821|Drug|Aldesleukin|
45923454|NCT00036517|Drug|PHY906|
45923455|NCT00036556|Drug|Atrasentan|
45923456|NCT00000827|Drug|Anti-HIV Immune Serum Globulin (Human)|
45923457|NCT00036634|Drug|Tenofovir DF|Tenofovir DF tablet administered orally once daily
45923458|NCT00036634|Drug|Tenofovir alafenamide|Tenofovir alafenamide tablet(s) administered orally once daily
45923459|NCT00000851|Drug|Stavudine|
45923460|NCT00000851|Drug|Didanosine|
45923461|NCT00036712|Procedure|management of therapy complications|
45923462|NCT00036712|Procedure|pain therapy|
45923463|NCT00036751|Drug|imatinib mesylate|Given orally
45923464|NCT00036751|Other|laboratory biomarker analysis|Correlative studies
45923465|NCT00036790|Drug|doxorubicin hydrochloride|
45450160|NCT02255812|Dietary Supplement|Single intragastric instillation of 200 mL tap water via nasogastric tube|
45450161|NCT02255812|Dietary Supplement|Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube|
45923466|NCT00036790|Drug|motexafin gadolinium|
45649202|NCT04905485|Behavioral|VIOME Precision Nutrition Program|Precision diet and supplement recommendations based on participants' microbiome results.
45649203|NCT03052439|Other|FODMAP|After 2 weeks on a low FODMAP diet, subject will undergo a reintroduction period. 5 different FODMAPs will be reintroduced (1 week at a time, followed by 1 week washout) in a blinded, randomized fashion.
45649204|NCT04905329|Drug|Empegfilgrastim|Extimia®
45649205|NCT02767921|Other|Cytology Specimen Collection Procedure|Correlative studies
45649206|NCT02767921|Other|Laboratory Biomarker Analysis|Correlative studies
45649207|NCT02767921|Procedure|Radical Cystectomy|Undergo robotic-assisted radical cystectomy
45649208|NCT02767921|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
45649209|NCT02767921|Procedure|Therapeutic Conventional Surgery|Undergo robotic-assisted radical or partial nephrectomy
45649210|NCT04903379|Other|Education|An explanation of contemporary pain science and a description of effective treatment strategies used by people with a history of persistent pain.
45649211|NCT02642809|Drug|Pembrolizumab|
45649212|NCT02642809|Radiation|Brachytherapy|
45923467|NCT00000857|Drug|Interleukin-12|
45923468|NCT00036829|Procedure|pain therapy|
45923469|NCT00036868|Biological|trastuzumab|
45923470|NCT00036868|Drug|CMF regimen|
45923471|NCT00036868|Drug|cyclophosphamide|
45923472|NCT00036868|Drug|fluorouracil|
45923473|NCT00036868|Drug|methotrexate|
45923474|NCT00036946|Biological|ziv-aflibercept|
45923475|NCT00000863|Drug|Sitamaquine|
45923476|NCT00036985|Drug|cyclophosphamide|
45923477|NCT00036985|Drug|doxorubicin hydrochloride|
45923478|NCT00036985|Procedure|conventional surgery|
45923479|NCT00036985|Procedure|neoadjuvant therapy|
45923480|NCT00036985|Procedure|thermal ablation therapy|
45923481|NCT00037024|Procedure|fatigue assessment and management|
45923482|NCT00037024|Procedure|nutritional support|
45923483|NCT00037024|Procedure|physical therapy|
45923484|NCT00037024|Procedure|psychosocial assessment and care|
45923485|NCT00037024|Procedure|quality-of-life assessment|
45923486|NCT00037063|Drug|Thiamine hydrochloride|
45923487|NCT00037063|Drug|Riboflavin|
46071834|NCT05877794|Device|central venous catheter insertion|All patients were under trendlenburg position (10 degrees) and disinfected for CVC catheterization. After attaching 2 suture wings of 18G single catheter set to the insertion needle in the 7 Fr or 8 Fr central catheter set, check the IJV to be punctured with an ultrasonic probe. The IJV is punctured using a cross sectional image confirmed at the cricoid cartilage level. After confirming the needle tip on the ultrasound image and blood coming out, the guide wire is mounted on the IJV and then a CVC catheter (arrow international INC) ., USA) is inserted. All actions are performed by a specialist who has more than 30 CVC catheterization experiences using ultrasound, and the occurrence of side effects and the time from puncture to guide wire entry are recorded by another researcher. After the procedure, the researcher who directly performed the procedure records the difficulty or difference compared to when using a conventional needle that does not have a suture wing installed.
46071835|NCT05877781|Dietary Supplement|Palmitoylethanolamide|8-week treatment 3x400 mg per day
45450162|NCT02255812|Dietary Supplement|Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube|
45450163|NCT02255812|Dietary Supplement|Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube|
45450164|NCT02255812|Dietary Supplement|Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube|
45450165|NCT02255812|Dietary Supplement|Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube|
45649213|NCT02642809|Procedure|Endoscopic biopsy|
46071836|NCT05877768|Diagnostic Test|Photon Counting Detector Coronary Computed Tomography Angiography|Clinically indicated Photon Counting Detector Coronary Computed Tomography Angiography for the suspicion of coronary artery disease or the progression thereof.
45450166|NCT02179138|Drug|TFV 1% gel|
45450167|NCT02175784|Drug|ipragliflozin|oral
45450168|NCT02175784|Drug|placebo|oral
45450169|NCT02256280|Drug|Sugammadex|"Sugammadex will be diluted in a saline water solution in a 10 mL syringe.~Administration will be according to the neuromuscular blockade:~If Post tetanic count = 1-15: 4 mg/kg~If at least 1 twitch at the Train-of-four stimulation: 2 mg/kg"
45649214|NCT02642809|Procedure|Computed tomography-guided biopsy|
45649215|NCT02642809|Procedure|Peripheral blood collection|
45649216|NCT03052361|Drug|Ondansetron|Patients allocated to this arm will receive ondansetron in the ED triage.
45649217|NCT03052361|Drug|Placebos|similar looking and tasting liquid placebo
45923488|NCT00037063|Drug|Ascorbic acid|
45923489|NCT00037063|Drug|Vitamin E|
45923490|NCT00000869|Drug|Nevirapine|
45923491|NCT00037102|Drug|interferon beta 1a|
45923492|NCT00037102|Drug|methotrexate|
45923493|NCT00037141|Drug|dehydrated alcohol|
45923494|NCT00037180|Drug|Celecoxib|
45923495|NCT00037180|Drug|Irinotecan|
45923496|NCT00037180|Drug|5-fluorouracil|
45923497|NCT00037180|Drug|Leucovorin|
45923498|NCT00037219|Drug|Anidulafungin, VER002|
45923499|NCT00000893|Drug|Nelfinavir mesylate|
45923500|NCT00000893|Drug|Efavirenz|
45923501|NCT00396526|Drug|Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.|
45923502|NCT00037492|Procedure|home-based sessions/family meetings with trained clinician|
45923503|NCT00037531|Drug|Sirolimus (RAPAMUNE)|
45923504|NCT00037570|Drug|Pantoprazole|
45923505|NCT00000899|Drug|Nelfinavir mesylate|
45923506|NCT00000899|Drug|Lamivudine|
45923507|NCT00000899|Drug|Filgrastim|
45923508|NCT00000899|Drug|Stavudine|
45923509|NCT00000899|Drug|Cyclophosphamide|
45923510|NCT00037609|Drug|Capecitabine|1000 mg/m^2 taken by mouth twice daily.
45923511|NCT00037609|Drug|Exisulind|125 mg taken by mouth twice daily.
45923512|NCT00037648|Drug|Anakinra|anakinra
45923513|NCT00037648|Drug|Placebo|placebo
45923514|NCT00037687|Drug|rPAF-AH|
45923515|NCT00389246|Behavioral|Consultation without genetic information|
45923516|NCT00389246|Behavioral|Consultation with genetic information|
45923517|NCT00037804|Drug|Irinotecan|
45923518|NCT00037843|Drug|I-131 Iodocholesterol|
45923519|NCT00037882|Drug|PEG-Intron|Once weekly injection.
45923520|NCT00037921|Procedure|Bacterial colonization|
45923521|NCT00037960|Procedure|Constrained Induced Therapy|
45923522|NCT00037999|Procedure|Testosterone supplement|
45923523|NCT00038038|Drug|18F-fluoromisonidazole|Small amount of radioactive traces drug given by intravenous injection prior to PET Scan
45923524|NCT00038038|Procedure|PET scan|Series of pictures using 20 minute scan performed 2 hours after an 18F-fluoromisonidazole injection
45923525|NCT00038077|Drug|Seloken ZOK/Toprol-XL|50 mg
45923526|NCT00038077|Drug|Seloken ZOK/Toprol-XL|200 mg
45923527|NCT00038077|Drug|Placebo|
45923528|NCT00038116|Procedure|embryonic dopamine cell implant surgery|Half of the participants received the cell implant surgery, while the other half received the placebo. After the double-blind phase of the study, patients in the placebo group had the option of receiving tissue implants. Fourteen of these patients eventually had transplants.
45923529|NCT00038116|Procedure|placebo|sham surgery
45796514|NCT05806320|Other|Intrauterine Sound Listening Group 1|This group consisted of 15 infants with 26-32,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. The babies were listened to the sound obtained in 3 time periods. If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. Before the procedure, the baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00. During the baby procedure, uterine sound was listened to the baby in the prone position monitored with a monitor device and recorded on video between 11:00-11.30/13.45-14.15/17.00-17.30 hours. After the procedure, the baby was watched with a monitor device and recorded on video between 11.30-11.45/14.15 and 14.30/17.30-17.45.
45804110|NCT05713825|Procedure|Endovascular embolization or surgery|"Endovascular embolization may be done with coils, remodeling technique (coils and balloon), stent and coils, flow-diverter, endosaccular devices. The access is through the femoral or radial artery.~Surgery is considered the standard neurosurgical procedure of aneurysm clipping."
45923530|NCT00038155|Procedure|Ambulation training|Recruitment of eligible subjects, ambulatory and resistance training in hospital and post-discharge
45923531|NCT00038194|Drug|imatinib mesylate|
45923532|NCT00038194|Drug|docetaxel|
45923533|NCT00391677|Behavioral|Social skills training with attention shaping procedures|Social skills training with attention shaping procedures includes behavioral procedures to increase the frequency, intensity, and duration of attentive behaviors and to reduce the frequency of inattentive behaviors.
45923534|NCT00391677|Behavioral|Social skills training without attention shaping|Social skills training without attention shaping is based on the UCLA Basic Conversation Skills Training Module, used without attention shaping procedures.
45923535|NCT00038233|Drug|Thalidomide|200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)
45923536|NCT00000926|Drug|Nonoxynol-9|
45649218|NCT05125393|Procedure|Laparoscopic linear stapler|The ileocecal or ascending colon tumors were resected using a combined cephalic caudal approach. When the accessory right colonic vein is separated from the head and then turned to the caudal side for upward dissociation. After no metastasis of 203 groups of lymph nodes is confirmed according to ICG development during the operation, the Henle stem and its root tissue were resected with a linear stapler.
45923537|NCT00038272|Drug|Mycophenolate mofetil|
45923538|NCT00038272|Drug|Amdoxovir|
45649219|NCT04905095|Diagnostic Test|EWS|Early Warning Score will be implemented in the computer system of the nursing station. When the nurses enter the vital signs of the patients into the system, the EWS will be automatically calculated and an alarm will be displayed if an intervention is necessary, which is protocolized.
45649220|NCT05125159|Procedure|angioplasty guidewire-assisted transseptal puncture or Standard conventional transseptal puncture|"Patients randomized to the angioplasty guidewire-assisted transseptal puncture (GW-TSP) group will undergo transseptal puncture with angioplasty guidewire-assistance.~Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with BRK needle (St. Jude Medical)."
45649221|NCT04902833|Procedure|Blood Draw|Blood specimen 2-4 teaspoons
45649222|NCT02532127|Other|Saliva sampling|Cells will be collected from consenting participants just before and after (30 min and 24 hr) exposure to CBCT, by brushing a swab against the inner cheek, which can be done by the patients themselves. Swab kits are provided together with an envelope for sending the swabs back.
45804111|NCT05712655|Other|Measurement of bilateral electromyographic activity of Masseter and Anterior Temporalis muscles.|Assessment was done by surface electromyography (sEMG) device.
45923539|NCT00038311|Drug|PN-152,243)/PN-196,444|
45923540|NCT05434273|Behavioral|HE programme|Participants will receive a 12-week integrated exercise and cardiovascular health education programme (HE programme) which is constructed based on self-efficacy theory. A booster intervention in the form of SMS messaging will be given from Week 1 to Week 12.
45923541|NCT05434273|Behavioral|Usual care|Participants will receive usual care which primarily includes an education talk on basic health issues. A governmental health education leaflet and a lecture video will be provided for reference.
45923542|NCT05434195|Dietary Supplement|Arcofolin® 5-Methyltetrahydrofolate|5-methyltetrahydrofolate (5-MTHF) is the biologically active form of reduced folate, which can increase BH4 availability. 5-MTHF is available as a nutritional vitamin (Merck & Cie) for human use including during pregnancy. Two out of three preeclamptic study groups will receive 5-MTHF - one at a low dose and the other at a high dose.
45923543|NCT05434195|Dietary Supplement|Arcofolin® Placebo|The placebo, this consists of the same excipients as 5-MTHF, microcrystalline cellulose and silica with no active ingredient.
45450170|NCT02256280|Drug|Neostigmine|"Neostigmine will be diluted with atropine in a saline water solution in a 10 mL syringe.~Administration will be according to the neuromuscular blockade:~If Post tetanic count = 1-15: 0.07 mg/kg~If at least 1 twitch at the Train-of-four stimulation: 0.05 mg/kg Atropine will be administered at a 0.02 mg/kg dosage."
45923544|NCT05434000|Drug|Hydroxyurea|Children at risk of developing stroke (TCD values>200cm/s) will be given 20mg/kg of Hydroxyurea
45923545|NCT05433922|Drug|Avatrombopag|cyclosporine in combination with Avatrombopag to treat
45923546|NCT05433883|Procedure|sleep surgery|Thirty severe OSA patients (AHI>30, treatment group) receive comprehensive upper airway surgery with/without bariatric surgery and repeat postoperative assessment in polysomnography and aforementioned examinations 1 year later.
45923547|NCT00000941|Drug|Pravastatin sodium|
45923548|NCT00000941|Drug|Simvastatin|
45923549|NCT00000941|Drug|Atorvastatin calcium|
45923550|NCT00000941|Drug|Ritonavir|
45923551|NCT00000941|Drug|Nelfinavir mesylate|
45923552|NCT00000941|Drug|Saquinavir|
45796515|NCT05806320|Other|Intrauterine Sound Listening Group 2|This group consisted of 15 infants with 33-36,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. The babies were listened to the sound obtained in 3 time periods. If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. Before the procedure, the baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00. During the baby procedure, uterine sound was listened to the baby in the prone position monitored with a monitor device and recorded on video between 11:00-11.30/13.45-14.15/17.00-17.30 hours. After the procedure, the baby was watched with a monitor device and recorded on video between 11.30-11.45/14.15 and 14.30/17.30-17.45.
45649223|NCT04915547|Other|Group-Based Exercise|"Each group session will consist of 10 to 18 participants and each exercise session will last 60 minutes and consist of four stages: (1) five minutes warm up (i.e. self-regulated walk); (2) twenty minutes of moderate intensity walking (3) thirty minutes of resistance training for the major muscles of the leg, trunk and arm and balance exercises that progress in difficulty; (4) five-minute cool down period (i.e. self-regulated walk). The exercise intensity will be assessed by one of the following criteria: 1) Resistance training - Point of volitional fatigue. Walking - Somewhat difficult (Borg at 3 to 4). The intensity will be increased according to the ACSM guideline.~The exercise was set up based on changes in instruments of evaluation of the older peoples as, Berg Balance Scale; Dynamic Gait Index and Timed Up and Go. In addition, exercises commonly used in primary health care groups. The protocol will take place in a gymnasium and will be supervised by a trained instructor."
45796516|NCT05806307|Drug|Misoprostol|(15 patient): who will receive 800 microgram (tablet 200mcg X 4) misoprostol (Misotac 200 mcg, SIGMA pharmaceutical, Egypt) rectally one and half hour before operation.
45796517|NCT05806307|Device|Tourniquet|(15 patient): The operation will be performed with the use of Foleys catheter as an improvised tourniquet applied at the base of the uterus then infiltration myometrium overlying the leiomyoma with a solution composed of Bupivacaine Hcl 0.25% and 0.5 mg of epinephrine
45796518|NCT05806307|Drug|Carbetocin|(15 patients): intramural; preparation of 100 μg of carbetocin ((Pabal, Ampoule 100 mcg in 1 ml, Carbetocin; FERRING, North York, Canada) diluted within 10 cm of saline (0.9%) in sterile syringe then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
45923553|NCT05433844|Drug|Reference Drug or Test Drug|"Test Drug: single administration of JW0301 Reference Drug: single administration of C2105~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration"
45923554|NCT05433805|Other|Fasting-mimicking diet (FMD) and physiotherapy|"FMD is a diet held monthly during five days with the restriction of calories to less than 1000 kcal, glucose and proteins.~Physiotherapy will be organized as home-based exercises explained by the physiotherapeutist at the beginning of the study."
45923555|NCT02971150|Behavioral|Brief Behavioral Treatment for Insomnia|
45923556|NCT05433376|Device|Shockwave Coronary Intravascular Lithotripsy (IVL) System C2|lithotripsy-enabled, low-pressure dilatation balloon to modify severely calcified lesions
45923557|NCT00014937|Drug|lopinavir/ritonavir|
45923558|NCT00014937|Drug|lamivudine/zidovudine|
45923559|NCT00014937|Drug|efavirenz|
45923560|NCT00014937|Drug|lamivudine|
45923561|NCT00014937|Drug|stavudine|
45923562|NCT00014937|Drug|zidovudine|
45923563|NCT00014937|Drug|didanosine|
45923564|NCT00000959|Drug|Isoniazid|
45923565|NCT00000959|Drug|Pyridoxine hydrochloride|
45923566|NCT05433025|Device|Cervigard Neck Collar|A device used to treat neck pain caused by forward head posture
45923567|NCT00396643|Drug|Omega 3 fatty acids|The active treatment is a supplement of yellow gelatin 0.5 g fish oil capsules. The daily dose of 4 (2x2) capsules provides 700 mg of eicosapentaenoic acid and 500 mg of docosahexaenoic acid, and 10 mg of Vitamin E. Placebo treatment comprises coconut oil capsules, carefully matched with the active treatment with respect to both appearance and flavor, also containing 10 mg Vitamin E, and 10 mg of fish oil to mimic taste. Coconut oil was chosen as placebo because it does not contain polyunsaturated fatty acids and has no impact on n-3 fatty acid metabolism. The intervention period is 12 weeks.
45923568|NCT00000962|Drug|Nevirapine|
45923569|NCT04732468|Biological|hAd5-S-Fusion+N-ETSD (Suspension for injection)|The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
45923570|NCT04732468|Drug|hAd5-SFusion+ N-ETSD (Oral capsule)|The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
45923571|NCT00396682|Drug|Cyclophosphamide|150 - 250 - 350 mg
45923572|NCT00396721|Drug|ACE inhibitor + statin|sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d
45923573|NCT00396721|Drug|Sirolimus (study drug)+ACE inhibitor + statin|enalapril starting at 5 mg/d in order to control blood pressure. Atorvastatin starting at 10 mg/d
45923574|NCT00015015|Drug|Dichloroacetate|
45923575|NCT05432908|Behavioral|Orofacial exercises and oropharyngeal functions|Oropharyngeal exercises (derived from speech-language pathology) to the tongue and facial muscles exercises as well stomatognathic functions.
45923576|NCT00000965|Drug|Zidovudine|
45923577|NCT02970838|Other|Structured weight-loss program|"During the fasting phase, daily consumption consists of five sachets fully replacing normal food and corresponded to an energy content of 800 kcal. This fasting phase is followed by a four-week refeeding phase, during which regular food will be reintroduced and formula diet is gradually replaced until a daily total intake of 1200 kcal is reached. During the last five weeks of the program, energy intake is gradually increased to an individual level between 1200 kcal and 1500 kcal that allowed subjects to keep their weight stable.~Once a week participants visit the study center to monitor health status and taking part in supervised exercises and a nutritional and behavioral counseling."
45796519|NCT05806307|Drug|Oxytocin|(15 patients): who will receive oxytocin 40 I.U. intramyometrially (Syntocinon, Ampule 10 I.U. in 1 ml, Oxytocin; NOVARTIS, Basel, Switzerland) then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
45796520|NCT05806307|Drug|combined TXA and ethamsylate|(Patient 15): will receive 1 g tranexamic acid (2 ampoules of kapron 500 mg, kapron®, Amoun, Egypt) and 500 mg ethamsylate (2 ampoule of ethamsylate 250 mg, Dicynone, OM pharma, Geneva, Switzerland) IV 10 minutes before skin incision by slowly intravenous injection Then infusion was applied continuously for 24 hours within 1 liter of saline as 1 mg/kg/hour.
45796521|NCT05806307|Drug|Vasopressin|15 patient intramyometrial injection of one ampoule of vasopressin containing 20 units in1 ml after dilution in 19 ml of normal saline during myomectomy.
45796522|NCT05806307|Drug|Bupivacaine Hydrochloride 0.5 % Injectable Solution epinephrine|15 patient infiltration of the serosa and / or myometrium overlying the leiomyoma before uterine incision with a solution composed of 50 ml Bupivacaine Hcl 0.25% (Bucain® Weimer pharma, for Actavis Group PTC) and 0.5 mg of epinephrine Hcl (2 vials of Epinephrine® 0.25mg/1ml Misr Co. for Pharmaceutical Industries).
45649224|NCT05079607|Other|Mitopure Topical Formula 1|topical skin cream containing the low dose mitophagy activator Mitopure
45649225|NCT05079607|Other|Mitopure Topical Formula 2|topical skin cream containing the high dose mitophagy activator Mitopure
45923578|NCT05432869|Other|ES and lifestyle advices|"The lifestyle advices include fluid consumption, diet, weight control, constipation, smoking, etc.~External electrical stimulation will be applied for 30 minutes 3 days a week during 4 weeks. Electrodes were placed on the thighs."
45923579|NCT05432869|Other|Lifestyle advices|The lifestyle advices include fluid consumption, diet, weight control, constipation, smoking, etc.
45796523|NCT05806294|Behavioral|Digital Metabolic Rehab|The Digital Metabolic Rehab combines two programs: The Canadian Health Advanced by Nutrition and Graded Exercise protocol (CHANGE) and My Viva Plan (MVP). All participants receive free access to MVP and attend group video conferencing sessions with health professionals. After the 60-minute initial assessments with the dietitian and the kinesiologist, each participant has an individualized diet and exercise plan based on the intervention protocol built in MVP. Participants are split into groups of 10 based on physical ability and stage of COPD. Intervention starts in phase 1. During phase 1 (first three months), participants have weekly videoconference group sections with the kinesiologist and the dietitian and monthly with the psychologist and the respiratory therapist. Phase 2 starts from month 4 to month 12, and the video conference group sessions with health professionals are transitioned to monthly sessions.
45923580|NCT00015054|Drug|Methylphenidate|
45923581|NCT05432440|Behavioral|The digital asthma education program|The intervention group receives the digital asthma education program (MIRACLE program). It consists of an asthma interactive narrative, a serious game, and an asthma action plan. It mainly covers asthma self-management and asthma attack prevention, such as asthma definition, asthma triggers and how to prevent asthma triggers exposures, asthma medications, proper inhaler technique, and asthma written action plan.
45923582|NCT05432401|Biological|T cell injection targeting FLT3 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 1.0 × 10^8, 2.0 × 10^8 and 4.0 × 10^8 CAR-T groups in order of sequence. And the subjects will be administered once.
45923583|NCT00000968|Biological|gp160 Vaccine (Immuno-AG)|
45923584|NCT00015132|Drug|Sertraline|
45923585|NCT05422300|Behavioral|Fed|Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.25g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with [13C]-leucine.
45923586|NCT05422300|Behavioral|Ex-Fed|"Participants will be subjected to a full-body resistance exercise protocol, consisting of an upper and lower body circuit. The upper body circuit will be a chest press and dumbbell row superset, whereas the lower body circuit will be leg press and leg extension (4 sets of 10 repetitions @ 75% of their 1 repetition max, respectively). The inter-set rest period will be 90 seconds.~Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.25g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with [13C]-leucine."
45923587|NCT00000971|Drug|Clarithromycin|
45923588|NCT00000971|Drug|Zidovudine|
45923589|NCT00000971|Drug|Didanosine|
45923590|NCT00015171|Drug|Buprenorphine/naloxone|
45923591|NCT05403112|Procedure|Bone ring with open sinus lifting|All patients involved in this study will be divided in to two group each group will receive a different technique of sinus lifting use autogenous bone ring technique with study group and autogenous sticky bone with control group.
45649226|NCT02370589|Biological|Base Dose EBOV GP Vaccine|
45649227|NCT02370589|Biological|2x Base Dose EBOV GP Vaccine|
45923592|NCT05363254|Other|Marlboro Gold Box|A combustible cigarette
45450171|NCT02174068|Drug|paracetamol 1000 mg per os, nefopam 60mg per os, paracetamol 1000 mg + nefopam 60 mg per os|
45450172|NCT00101608|Drug|vinflunine|solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
45649228|NCT02370589|Biological|4x Base Dose EBOV GP Vaccine|
45649229|NCT02370589|Biological|8x Base Dose EBOV GP Vaccine|
45649230|NCT02370589|Biological|Placebo|
45649231|NCT02370589|Biological|Matrix-M Adjuvant|
45649232|NCT04903145|Diagnostic Test|REOM|To compare data generated by the REOM device with data from the tremoflo C-100 device
45649233|NCT01752049|Drug|Topical timolol maleate|"Topical timolol maleate 0.5% drops~Applied twice daily for 12 weeks (84 days) or until disappearance of lesions~Study drops will be applied to 4 cutaneous telangiectasias per patient (timolol drops for 3 telangiectasia per patient and placebo drops to 1 telangiectasia per patient)."
45923593|NCT05363254|Other|Newport Box|A combustible cigarette
45923594|NCT05363254|Other|Non-combusted cigarette variant 42001401|A menthol flavor variant of a non-combusted cigarette (42001401)
45923595|NCT05363254|Other|Non-combusted cigarette variant 42001399|A menthol flavor variant of a non-combusted cigarette (42001399)
45923596|NCT05363254|Other|Non-combusted cigarette variant 40007386|A menthol flavor variant of a non-combusted cigarette (40007386)
45923597|NCT05363254|Other|Non-combusted cigarette variant 42001402|A non-menthol flavor variant of a non-combusted cigarette (42001402)
45649234|NCT01752049|Drug|placebo saline drops|Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to one cutaneous telangiectasias per patient.
45796524|NCT05806255|Device|The RELIEF App|"RELIEF is a virtual app designed for the remote self-reporting of symptoms in patients with palliative care needs. The patient/caregiver securely logs into the site and self-reports symptoms, distress, and pain using the validated clinical tools ESAS-r, Distress Thermometer (DT), and Brief Pain Inventory (BPI) currently in daily use by healthcare providers across Canada.~This data is reported to the healthcare providers via RELIEF. Any increases in symptom burden, distress, or pain are flagged for clinical review as RELIEF alerts. Healthcare providers received alerts via secure email for any sudden changes in symptom status, or if the patient's symptoms, distress, or pain severity increases by set amounts over a period of time. Following review of the RELIEF alert by the healthcare providers, patients receive (1) earlier intervention; (2) mobilization of auxiliary services; and (3) recommendation for urgent clinic/home visit or emergency department visit."
45796525|NCT05806229|Procedure|Mid transverse process to pleura block (MTP)|After marking the level of the incision by surgeon (commonly T11 -T12) The patient will be situated in modified lateral position with flank region over kidney elevated to wide the space between iliac crest and subcostal margin, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally lateral to the spinous process of T11 or T 12 and scanning till appearance of transverse process, 100-mm short bevel echogenic needle (Vygon) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura.After negative aspiration to avoid intravascular injection levobupivacaine 0.5% and dexamethazone 4mg total volume 21ml will be injected
45923598|NCT00000977|Biological|gp160 Vaccine (MicroGeneSys)|
45923599|NCT05319652|Behavioral|Pain self-management program|Each week for eight weeks, participants are invited to complete self-directed lessons on particular themes. The program covers goal setting, stress management through relaxation, breathing and mindfulness, pacing, physical activity, thoughts and emotions, sleep, nutrition, flare-up management, and planning. Through pain education, positive testimonials from individuals with CNCP applying the suggested strategies, reflective activities, goal setting and monitoring, and the gradual development of a personal plan, the program supports self-efficacy building to manage CNCP.
45923600|NCT00015210|Drug|Nefazodone|
45923601|NCT00015210|Behavioral|Psychosocial Treatment|All subjects attended a weekly 1-hour therapy session during the 8 week treatment period.
45923602|NCT05280691|Other|Family Support Intervention (FSI)|In addition to usual care, families in the intervention group will receive (1) specialist nurse support along the patient pathway at defined time-points, from admission to discharge including follow-up care, and (2) nurse-coordinated liaison and structured, interprofessional communication by the ICU team. The intervention is grounded in a family systems approach and guideline-based strategies for family engagement in the ICU and has been pilot-tested in one ICU.
45923603|NCT00000986|Drug|Zidovudine|
45923604|NCT00000986|Drug|Aldesleukin|
45649235|NCT04904939|Procedure|Bronchoscopic mucosal biopsy|Endobronchial forceps biopsy using flexible bronchoscope
45649236|NCT05067673|Other|Dry needling|The dry needling will be performed using disposable stainless steel needles (AGU-PUNT needles of size 0.30x50mm or 0.30x60mm depending on the patient) that will be inserted perpendicularly at the point of major hyperalgesia using the Hong technique. The patient will be in the prone position with a pillow placed in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. After this time, the needle will be inserted at the point indicated by the evaluator before reaching the lumbar multifidus by means of echolocation. Once it is assured that it is in the right place, a total of 10 repetitions are performed. The needle will be removed by depositing it in a needle container and a compression will be removed in the treated area until hemostasis is achieved.
45649237|NCT05067673|Other|Placebo dry needling|Placebo dry needling will be performed with DongBang DB100 Acupuncture Needles which, upon contact with the patient, retract, hiding in the needle handle. The patient will be in the prone position with a pillow in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. At the point indicated by the evaluator, the placebo needle will be placed initially and the introduction of the needle and its location will be simulated with the ultrasound system. 10 repetitions will be performed. The needle will be removed by depositing it in a needle container and a compression will be made in the treated area.
45649238|NCT04966507|Drug|Listerine Antiseptic Mouthwash Product|COOL MINT LISTERINE® Antiseptic Mouthwash will be used as the 'active' study drug condition. This is a commercially available, over the counter mouthwash product. Active ingredients for this product include Eucalyptol 0.092%, Menthol 0.042%, Methyl salicylate 0.060%, Thymol 0.064%. This product also contains 21% alcohol. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
45923605|NCT00015249|Drug|Amantadine|
45923606|NCT05216809|Behavioral|Habitual Physical Activity|Participants will maintain habitual levels of physical activity (inclusive of structured physical activity). Participants will be required to maintain >7,000 steps/day.
45923607|NCT05216809|Behavioral|Step-Reduction|Participants will be required to reduce their daily step-counts to <2,000 steps/day. Further, they will be required to refrain from structured physical activity.
45923608|NCT05195242|Drug|Dexamethasone|ATC code H02AB02
45923609|NCT05147077|Procedure|Acupuncture|"Acupuncture:~Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees.~Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Tongli (HT5), Xingjian (LR2).~Traditional Chinese medicine Danzhixiaoyao Power: Danpi 10g, fried Zhizi 10g, Danggui 12g, Baishao 12g, fried Chaihu 6g, Fuling 10g, fried Baishu 10, roasted Gancao 3g.~Repetitive transcranial magnetic stimulation The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 1Hz.~Standard care The same as the standard care group."
45923610|NCT00015288|Drug|Buprenorphine/naloxone|
45923611|NCT05146882|Drug|Belcesiran|Belcesiran will be administered subcutaneously (SC) in the treatment arm.
45450173|NCT02174146|Procedure|non-surgical periodontal therapy|supra and subgingival debridement
45649239|NCT04966507|Drug|Biotene Mouthwash|Biotène Rinse is designed with a moisturizing formula to help relieve dry mouth symptoms and is specifically designed to have a pH similar to saliva. This is a commercially available, over the counter mouthwash product. Biotène Mouthwash Ingredients include: Purified Water, Propylene Glycol, Hydrogenated Starch Hydrolysate, Poloxamer 407, Hydroxyethylcellulose, Sodium Benzoate, Flavor (Peppermint Oil), Benzoic Acid, Disodium Phosphate, Zinc Gluconate, Lactoferrin, Lysozyme, Lactoperoxidase, Potassium Thiocyanate, Aloe Vera Gel, Calcium Lactate, Glucose Oxidase. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
45649240|NCT05049265|Biological|JS007|JS007 only
45796526|NCT05806229|Procedure|Mid transverse process to pleura Sham block|After marking the level of the incision by surgeon (commonly T11 -T12) The patient will be situated in modified lateral position with flank region over kidney elevated to wide the space between iliac crest and subcostal margin, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally lateral to the spinous process of T11 or T 12 and scanning till appearance of transverse process, 100-mm short bevel echogenic needle (Vygon) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura. with 2ml normal saline subcutaneously will be injected
45923612|NCT05118139|Other|P1211216|Flavor variant P1211216 of a 1.5% nicotine ENDS product
45923613|NCT05118139|Other|P1213416|Flavor variant P1213416 of a 1.5% nicotine ENDS product
45923614|NCT05118139|Other|P1213716|Flavor variant P1213716 of a 1.5% nicotine ENDS product
45923615|NCT05118139|Other|P1213616|Flavor variant P1213616 of a 1.5% nicotine ENDS product
45649241|NCT04902989|Other|pollutants and pollen|Pollutants (ozone, SO3, NO3, PM2.5, diesel exhaust particles)
45923616|NCT05118139|Other|P1213816|Flavor variant P1213816 of a 1.5% nicotine ENDS product
45923617|NCT05118139|Other|P1211916|Flavor variant P1211916 of a 1.5% nicotine ENDS product
45923618|NCT05118139|Other|P1210016|Flavor variant P1210016 of a 1.5% nicotine ENDS product
45923619|NCT05118139|Other|P1211217|Flavor variant P1211217 of a 2.4% nicotine ENDS product
45923620|NCT05118139|Other|P1213417|Flavor variant P1213417 of a 2.4% nicotine ENDS product
45649242|NCT05013619|Other|Circumstances of pain|It will be questioned in which situations the pain occurred in the previous week (at rest from spasms, at rest from splints, on feeding, on moving, on dressing, at night, on exercise, on other treatments, on botulinum toxin application) and record as yes/no.
45796527|NCT05806203|Device|Low intensity shockwave treatment to pelvic floor region plus typical physical therapy|Treatment dose: 1,000 - 1,500 shocks, 2.5-3.0 Hz, 0.06-0.10 mJ/mm2 (Intensity of 6-8), 8 to 12 minutes
45796528|NCT05806203|Device|Sham shockwave treatment plus typical physical therapy|Inactive dose of shockwave treatment
45923621|NCT05118139|Other|P1211222|Flavor variant P1211222 of a 5% nicotine ENDS product
45923622|NCT05118139|Other|P1213422|Flavor variant P1213422 of a 5% nicotine ENDS product
45923623|NCT05118139|Other|P1213722|Flavor variant P1213722 of a 5% nicotine ENDS product
45923624|NCT05118139|Other|P1213622|Flavor variant P1213622 of a 5% nicotine ENDS product
45923625|NCT05118139|Other|P1213822|Flavor variant P1213822 of a 5% nicotine ENDS product
45923626|NCT05118139|Other|P1211922|Flavor variant P1211922 of a 5% nicotine ENDS product
45923627|NCT05118139|Other|P1210022|Flavor variant P1210022 of a 5% nicotine ENDS product
45923628|NCT05114863|Other|Product A1|Usual Brand (UB) filtered, non-menthol cigarette
45923629|NCT05114863|Other|Product B|40007388, A Non-Combusted Cigarette Variant and product use Mode A
45450174|NCT02179216|Other|Hydration|Hydratation the first day in the arm 1 Hydration the second day in the arm 2
45923630|NCT05114863|Other|Product C|40007388, A Non-Combusted Cigarette Variant and product use Mode B
45923631|NCT05114863|Other|Product D|40007386, A Non-Combusted Cigarette Variant and product use Mode B
45923632|NCT05114863|Other|Product A2|Usual Brand (UB) filtered, menthol cigarette
45923633|NCT05114863|Other|Product E|40007385, A Non-Combusted Cigarette Variant and product use Mode A
45923634|NCT05114863|Other|Product F|40007385, A Non-Combusted Cigarette Variant and product use Mode B
45923635|NCT05114863|Other|Product G|40007387, A Non-Combusted Cigarette Variant and product use Mode B
45923636|NCT05114863|Other|Product H|40007386, A Non-Combusted Cigarette Variant and product use Mode B
45923637|NCT05114863|Other|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
45923638|NCT05101915|Drug|RESP301|Inhaled IMP delivered via nebulisation
45923639|NCT05089903|Behavioral|Bulk Order|A mammogram order will be placed using bulk order technology in the EHR in advance of outreach for all patients.
45923640|NCT05089903|Behavioral|Texting|In addition to outreach, patients will receive text messaging with information regarding the importance of screening, how to schedule a mammogram, and locations available for mammography.
45923641|NCT05089903|Behavioral|Clinician Endorsement|Outreach informing patients that they are overdue for a mammogram will be signed by the patient's primary care provider.
45923642|NCT05089903|Behavioral|No Bulk Order|The outreach will ask patients to contact their PCP's office in order to have a mammogram order placed on their behalf.
45649243|NCT05013619|Other|Pain Questionnaire|"Participants will be asked to respond to the initial question Over the past month, have you experienced physical pain? (yes or no). Those responding yes will be asked Please indicate how severe your pain was over the past month, on average, with response options from 1 (very little pain) to 10 (extremely painful). They will be also asked to indicate How much the pain gets in the way of your daily activities over the past month from a low of 1 (does not get in the way at all) to 10 (unable to carry out activities because of the pain). Finally, they will be asked to indicate the body regions in which they experienced pain."
45923643|NCT05089903|Behavioral|Standard Endorsement|Patient's will receive outreach from the practice informing them that they are overdue for a mammogram.
45923644|NCT05083975|Device|Buzzy System|Vibrating Device
45923645|NCT05083975|Drug|Topical anesthetic|20% benzocaine gel (Opahl Topical Gel)
45450175|NCT02179216|Other|Venous contention|Venous contention the second day in the arm 1 Venous contention the first day in the arm 2
45649244|NCT05013619|Other|Gross Motor Functional Classification System|Severity of CP will be determined based on the Gross Motor Functional Classification System (GMFCS). GMFCS is a standardised measure that classifies gross motor functions in children with CP. Children in level I are very independent in motor functions while those in level V are the least independent
45649245|NCT05013619|Other|The subtypes of Cerebral palsy|The subtypes of CP will be classified, using the Swedish classification, into spastic (tetraplegia, diplegia and hemiplegia), ataxic, dyskinetic and mixed
45649246|NCT04904783|Radiation|Low dose radiotherapy|Patients in study group will receive LDRT to both lungs by two parallel opposed fields, antero-posterior (AP) and postero-anterior (PA) to deliver a midplane dose of 0.5 Gy in a single fraction. As this dose is very less, doses to the critical structures including heart and lungs would be very low. All the patients will be treated on Telecobalt unit (Theratronics Phoenix, Canada) and not on the linear accelerator to avoid risks to cancer patients on treatment with linear accelerator. CT based plan will not be undertaken for logistic issues and is also not felt to be mandatory for this LDRT. Dose computation would be carried out by manual dose calculation for the Telecobalt unit.
45649247|NCT05136079|Procedure|Prophylactic lymphaticonvenous anastomosis|Prophylactic lymphaticovenous anastomosis is an immediate prophylactic approach whereby the lymphaticovenous anastomosis is performed at the time of nodal dissection utilizing fluorescing indocynanine green (ICG) and an operating microscope.
45796529|NCT05806177|Drug|AD16 30mg、40mg|AD16 was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
45796530|NCT05806177|Drug|AD16 Placebo 30mg、40mg|AD16 placebo was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
45796531|NCT05806151|Diagnostic Test|Genetic and immunologic assessments|Definitive Local Therapies including surgery, radiotherapy, radio-frequency ablation of metastases.
45923646|NCT05083975|Drug|Mepecaine - L 1.8 ml carpule|Local dental anesthetic agent
45923647|NCT00000998|Drug|Trimetrexate glucuronate|
45923648|NCT00000998|Drug|Leucovorin calcium|
45796532|NCT05806112|Behavioral|Resiliency Training|"The Stress Management and Resiliency Training: Relaxation Response Resiliency Program (SMART-3RP) has been shown to be effective in improving resilience and reducing distress among individuals across different populations and settings. The SMART-3RP enhances resilience by 1) teaching tools to elicit the relaxation response (RR) to offset negative effects of chronic stress; 2) improving stress management and awareness; and 3) promoting growth enhancement and agency to effect positive change. It blends stress coping principles from mind-body, cognitive-behavioral, and positive psychology theory to teach skills to advance each of these resiliency processes. The training will be delivered in six 50-minute virtual group sessions with 2 optional booster sessions available for those who desire additional sessions to further consolidate the core resiliency skills."
45796533|NCT05806112|Behavioral|Task Sharing|"Task Sharing is a process involving health care workers in partnership with others in which workers retain many of their primary tasks, but some tasks are completed collaboratively or by other workers or volunteers in a shared effort. Study coaches will work with the group home directors and RCWs to identify shared tasks that may be conducted by peers or resident volunteers by task co-assignment with supervision and support. Task co-assignments will be discussed in routine house meetings occurring on a weekly basis and incorporated into a jointly developed house plan. The house plan will engage staff and residents to identify shared activities to reduce the burden on RCWs through task co-assignment and team-based efforts aimed at tasks that create unnecessary burden and stress for RCWs, yet do not require RCWs to complete them."
45923649|NCT05078437|Behavioral|Medication therapy management|The proposed deprescribing intervention is using a patient-centered framework by: (1) balancing the risks and benefits, and addressing the specific needs of each individual patient, (2) considering the individual patient and the caregiver's preferences and values, and (3) empowering the patient and the caregiver to take responsibility and fully participate in the decision-making process as equal team players.
45923650|NCT05078047|Drug|Reduced dose intensity of IO|After 6 months of treatment with standard IO, IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision
45923651|NCT00001001|Drug|Zidovudine|
45923652|NCT05076877|Drug|Lazertinib|Lazertinib tablets will be administered orally, alone or in combination with probe substrates.
45923653|NCT05076877|Drug|Midazolam|Midazolam (cytochrome P450 3A4 [CYP3A4] substrate) will be administered orally as a syrup as a part of probe substrates.
45923654|NCT05076877|Drug|Rosuvastatin|Rosuvastatin (breast cancer resistant protein [BCRP] substrate) tablet will be administered orally as a part of probe substrates.
45450176|NCT02174224|Behavioral|Brief Intervention|Goals of the bedside intervention will be to help the patient understand their risky behaviors that resulted in the injury and to assess and deescalate any threat of retaliatory violence by the patient. The outreach worker will: (1) develop a rapport with the patient by introducing themselves and describing their (outreach worker's) background and reason for the bedside visit; (2) assess the emotional response to the current injury; (3) ensure the patient and/or family understand the nature of the injury and ED course; (4) address any immediate concerns of the patient; and (5) develop a plan for staying safe following discharge.
45649248|NCT04915469|Other|Standardized enhanced adherence counseling package|A standardized package was developed to support the adherence counsellor and other cadres to ensure provision of quality EAC sessions for children, adolescents and their caregivers. The package included; 1) Orientation and on job mentorship on EAC processes to clinicians, nurses, peer educators and mentor mothers. 2) Using a communication's training curriculum, providers were trained on psychosocial support and communication skills for children and their caregivers. 3) Appointment management was done using appointment dairies or a digital platform that sends patients short message services (SMS) reminders 3 days and 1 day before a scheduled clinic day. 4)Home visits. - All home visits were done according to the EGPAF standard operation procedures (SOPs) drawn from the Kenya National guidelines. 5) Individualized case management -Each EAC client was allocated a case manager who ensured that the barriers to adherence were identified and tackled both at individual and community level.
45649249|NCT04959877|Behavioral|health education|data collect / Telemedicine
45923655|NCT05076877|Drug|Metformin|Metformin (organic cation transporter 1 [OCT1] substrate) will be administered orally as a syrup as a part of probe substrates.
45923656|NCT04996654|Behavioral|Exergame|According to the training concept, each participant is instructed to train 5x/week for 21 min per session resulting in a weekly exercise volume of 105 min. All training sessions are planned to take place at participant's homes using the exergame training system Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification).
45923657|NCT04996654|Behavioral|Usual Care|An active control group will proceed with usual care as provided by the memory clinics where the patients are recruited.
45923658|NCT04976023|Drug|Yupingfeng Powder granules|14.5 5 g twice daily for 8 weeks
45923659|NCT04976023|Other|Placebo|14.5 5 g twice daily for 8 weeks
45923660|NCT00015600|Behavioral|Behavior modification through social marketing|
45923661|NCT04970836|Biological|recombinant hepatitis B vaccine|Hepatitis B vaccine (Engerix-B) will be administered to the eligible participants by 4 groups. Each case will be tracked for 12 months, at 0, 7-10 days, 28 days, 24-28 weeks, 48-52 weeks anti-HBs titer concentration and 4 follow-up questionnaires.
45923662|NCT00001004|Drug|Tumor Necrosis Factor|
45923663|NCT00001004|Drug|Interferon gamma-1b|
45923664|NCT04915378|Other|hypoxia altitude simulation test (HAST) at 760m|Normobaric hypoxia at a FiO2 of 15.1% will be generated by the Everest Summit II altitude generator (Hypoxico Altitude Training Systems, Bickenbach, Germany) and delivered to the patients face via tubes and a tightly fitted mask. Patients will be seated comfortably in a chair and fitted with a full-face mask equipped with a one-way valve. After a baseline period of quiet rest of 5-10 min with ambient air breathing and installation of equipment, patients will breath the hypoxic air mixture via a tightly fitted facial mask. They will be monitored with a finger-tip pulseoximetry to continuously assess SpO2 and heart rate. After at least 15' and steady-state values of the SpO2 (±1%) for at least 5' arterial blood gases will be drawn from a radial artery and immediately analyzed (RapidPoint 500, Siemens, Zürich, Switzerland).
45450177|NCT02174224|Behavioral|Case Management|Case management based on needs-assessment. Resource connection and mentoring.
45450178|NCT02174224|Behavioral|Standard Medical Care|This will include physician discretion for medical treatment and potentially a social worker visit as the physician sees fit for the patient. This will also include a list of resources that are typically needed and used for violently injured youth.
45804112|NCT05711953|Other|Egyfil Pain Lotion|"Egyfil is a cosmetic product to be applied to intact skin, useful to attenuate muscolar pain and stiffness, with a novel topical formulation containing hyaluronic acid, SH-Polypeptide-6 and SH-Oligopeptide-1.~The presence of sodium hyaluronate and peptides mixture promotes the pain alleviating activity and soothing properties of the product."
45450179|NCT03537430|Procedure|TNT uniportal VATS mediastinal tumor resection|TNT uniportal video-assisted thoracoscopic surgery refers to the use of conventional uniportal video-assisted thoracoscopic surgery, the use of laryngeal mask anesthesia instead of tracheal intubation anesthesia, intraoperative catheter was not retained, postoperative chest catheter placement.
45450180|NCT03537430|Procedure|Traditional uniportal VATS mediastinal tumor resection|The surgical procedures followed principles of mediastinal tumor resection，uniportal video-assisted thoracoscopic surgery in mediastinal tumor resection.
45450181|NCT02176096|Dietary Supplement|Glycosade|
45450182|NCT02179294|Drug|Pethidine|100mg by intramuscular injection, up to 4 hourly in frequency (up to a maximum of 4 doses). The maximum dose being 400mg in 24 hours.
45649250|NCT04915235|Behavioral|Algorithm|Algorithm
45649251|NCT05124145|Other|No intervention (surveillance system)|The surveillance network will collect data on all consecutive COVID-19 cases
45649252|NCT04902755|Other|Questionnaire|validation of the French linguistic version and the cross-cultural adaptation of the NBSS-SF.
45649253|NCT05136625|Drug|Sphenopalatine ganglion block|A cotton swab soaked in levobupivacaine 7,5% in inserted into the nose to block sphenopalatine ganglion, with the classic technique previously described
45649254|NCT05136625|Drug|Standard Preparation|Troncular scalp blockade. Local site infiltration
45804113|NCT00355459|Drug|Tetracycline: Doxycycline analog|
45804114|NCT02390791|Other|enhanced myADHDportal.com|Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
45804115|NCT02390791|Other|treatment as usual standard portal|Standard version of myADHDportal.com web software
45923665|NCT04915378|Procedure|High Altitude (3100m)|High Altitude (3100m) exposure for 2 days
45923666|NCT00396604|Drug|indacaterol maleate|
45923667|NCT04896541|Biological|AZD7442 300 mg IM(male)|Single dose of 300 mg of AZD7442 or saline placebo on Day 1.
45923668|NCT04896541|Biological|AZD7442 600 mg IM (male)|Single dose of 600 mg of AZD7442 or saline placebo on Day 1.
45923669|NCT04896541|Biological|AZD7442 300 mg IV (male and female)|Single dose of 300 mg of AZD7442 or saline placebo on Day 1.
45923670|NCT04896541|Biological|AZD7442 1000 mg IV (male)|Single dose 1000 mg of AZD7442 or saline placebo on Day 1.
45923671|NCT04892407|Device|Algeness® DF 3.5%|dermal filler CE Mark approved for treatment of cheek and midface volume loss
45649255|NCT04402697|Other|Dietary and physical activity intervention|"OW-OB group: 6-month program of weight loss consisting in a low-calorie food plan (30% reduction in the individual energy requirements) with dietary sessions and exercise counselling.~MONW group: 6-month program to improve eating habits (Mediterranean diet) with dietary sessions and exercise counselling."
45649256|NCT05124847|Behavioral|Standard Care|Participants will receive nutritional education sessions and will be instructed to maintain an intake window of at least 13 hours a day, preferably every day of the week and in any case at least 6 days a week.
45923672|NCT04892407|Device|Juvéderm Voluma|dermal filler CE Mark approved for treatment of cheek and midface volume loss
45923673|NCT00396760|Drug|aprotinin or tranexamic acid|
45923674|NCT00001007|Drug|Zidovudine|
45923675|NCT00396799|Drug|bazedoxifene/conjugated estrogens|
45923676|NCT01786434|Drug|Routine medication arm|50 micrograms of fentanyl given before the procedure
45923677|NCT01786434|Drug|Fentanyl on-demand arm|Fentanyl 50 microgram is provided on-demand, that is, if the patient has pain during the procedure.
45649257|NCT05124847|Behavioral|Time restricted eating|A personalized progression will be established to progressively reduce the intake window during the first 10 days of intervention. After these first 10 days, the participants will be prescribed to limit food intake to a maximum of 10 hours a day, at least 5 days a week. Participant can freely select the time of day to place the intake window. However, it will be recommended to avoid making the last intake in the 3 hours before going to bed. After 4 weeks of intervention, the dietitian will invite them to reduce the intake window to 9 or 8 hours, if they consider it feasible, maintaining this new intake window during the last 4 weeks of intervention. The intake window can be maintained at 10 hours until the end of the study.
45923678|NCT00396916|Device|PET/CT imaging|
45649258|NCT04402619|Behavioral|Cognitive behavior therapy|"The ten modules cover:~Psychoeducation about sleep, sleep problems, and associations with alcohol~How to keep and use a sleep diary~Sleep hygiene~Sleep compression~Cognitive restructuring~Emotional regulation~Preparing for the future"
45450183|NCT02179294|Drug|Remifentanil|"Dedicated intravenous cannula for remifentanil administration PCA protocol~PCA bolus remifentanil 40 μg~Lockout interval 2 minutes~In the event of excess sedation being recorded by regular observation of respiratory function, the regimen will be altered by reduction of the remifentanil bolus dose to 30 μg with a lock-out interval of 2 minutes."
45649259|NCT04902001|Behavioral|Multidisciplinary weight loss|The adolescents will follow a 12-week intervention combining nutritional education, physical activity 3 times per week and psychological supports.
45796534|NCT05806112|Behavioral|Workplace Improvement Learning Collaborative|The Workplace Improvement Learning Collaborative (WILC) consists of identifying major sources of RCW burnout across the system and then instituting an organizational (agency-wide) measure to address the identified sources of burnout by restructuring tasks (e.g., reducing administrative burdens, increasing workflow efficiencies) through a virtual earning collaborative with group home leaders. Learning collaboratives commonly use a structured framework within which teams learn about research and best practices, apply quality-improvement methods, and exchange their experiences in making improvements with the widespread use of such collaboratives. Program Directors will participate in a learning collaborative facilitated by trained and certified study coaches to identify and collaboratively develop and implement effective strategies to address root causes of RCW burnout across group homes and program directors assigned to the WILC intervention.
45923679|NCT00001010|Drug|Zidovudine|
45923680|NCT00001010|Drug|Acyclovir|
45923681|NCT04815382|Other|Dynamic Upper Limb Orthosis|"The dynamic upper limb orthosis extends from subdeltoid level to 10 mm distal to the metacarpal-phalangeal joints. The orthosis will be tailored to include 20 degrees of wrist extension and to abduct the thumb. They made from nylon and lycra.~The orthosis will be used throughout the day, being removed when the patient lies down.~The orthosis will be used during 3 months"
45923682|NCT04796155|Diagnostic Test|Intrapartum ultrasound|Intrapartum ultrasound will be performed by suprapubic and transperineal approach for 30 seconds.
45923683|NCT04759807|Drug|Placebo Comparator|The placebo designed for administration in the proposed clinical study consists of a dry powder composed of the same excipients as the active (sodium sulfate, mannitol and polysorbate 80), pre-metered into HPMC capsules at the same 5 mg powder fill weight as the active formulations. Subjects will receive 14 doses administered once daily in the morning.
45923684|NCT04759807|Drug|PUR1800 250 ug|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to a 250 μg nominal dose strength of RV1162. Subjects will receive 14 doses administered once daily in the morning.
45923685|NCT04759807|Drug|PUR1800 500 ug|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to a 500 μg nominal dose strength of RV1162. Subjects will receive 14 doses administered once daily in the morning.
45923686|NCT04693585|Behavioral|MESSSSAGE - live|mHealth education and social support intervention, synchronous via call
45923687|NCT04693585|Behavioral|MESSSSAGE - asynchronous|mHealth education and social support intervention, asynchronous via text
45923688|NCT00001013|Drug|Trimetrexate glucuronate|
45923689|NCT00001013|Drug|Pentamidine isethionate|
45923690|NCT00001013|Drug|Sulfamethoxazole-Trimethoprim|
45923691|NCT00001013|Drug|Leucovorin calcium|
45923692|NCT04680442|Drug|Trastuzumab|Trastuzumab is a HER-2 targeting monoclonal antibody that improves overall survival and reduces the risk of recurrent disease in early stage HER-2 positive breast cancer.
45923693|NCT04680442|Drug|Pertuzumab|Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer
45923694|NCT04680442|Drug|Trastuzumab emtansine|Ado-trastuzumab emtansine is approved to treat: Breast cancer that is HER2 positive and has already been treated with a taxane and trastuzumab.
45923695|NCT04529551|Other|1601A|A filtered, king size cigarette with a menthol capsule in the filter.
45923696|NCT04529551|Other|1601B|A filtered, king size cigarette with a menthol capsule in the filter.
45649260|NCT04904315|Other|Mindera Kit|The entire duration of the study, including the screening period, will be approximately 16 weeks. Mindera Kit will be applied with applicator and left on the skin for 5 minutes, and once removed, the investigational product (IP) will be placed in a buffer solution, sealed, labeled and sent to Mindera for processing.
45649261|NCT05124613|Other|Survey|"Information collected and stored in Survey:~Type of knee surgery the patient is waitlisted for~Demographics: age, sex, recent weight gain~Validated and bespoke questions:~EQ-5D survey (a validated questionnaire on health)~Bespoke questions on knee pain today~Bespoke questions on knee function today~Bespoke questions on change in knee pain since being waitlisted for surgery~Bespoke questions on change in knee function since being waitlisted for surgery~Bespoke questions on coping mechanisms patients use to manage symptoms~Bespoke questions on what support they would find beneficial whilst they wait for their surgery~Three bespoke questions about COVID-19 (Have they ever tested positive/Has the pandemic changed their mind about wanting surgery/Has the perception of their knee pain and function changed since the first lockdown was introduced?)"
45923697|NCT04511065|Other|Newsletter using a virtual mode of delivery|Newsletter creation where topics in the newsletter are chosen by participants in the intervention group.
45923698|NCT03476135|Biological|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
45923699|NCT04390867|Device|TOPS1 DBS|TOPS1 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
45923700|NCT04390867|Device|TOPS2 DBS|TOPS2 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
45923701|NCT04390867|Device|TOPS3 DBS|TOPS3 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
45923702|NCT04390867|Device|Standard DBS|Standard is the pattern of stimulation that is usually delivered clinically by a DBS system
45923703|NCT04219618|Device|Off-Pump|After a standard median sternotomy, pericardium will be divided to expose the heart and major vessels, and the aortic cannulation sutures will be placed. Pyramid positioner will be applied to the apex of the heart, and the heart will be manually elevated upward. The inflow cannula placement location and placement of the sewing ring will be done with pledged sutures. The LV diaphragmatic site coring will be completed, and immediate LV digital exploration will be accomplished. The LVAD inflow cannula will be inserted through the sewing ring into the LV cavity. Upon completing proper LVAD inflow cannula placement into the LV and securing it in position, the heart will be dropped into the pericardial cavity with the outflow graft elevated for LVAD and outflow graft de-airing and to prevent potential later air embolization. A partial occlusion clamp will be placed on the ascending aorta and appropriately trimmed outflow graft will be sewn to the aorta.
45923704|NCT04219618|Device|On-Pump|A standard median sternotomy incision will be performed and pericardium divided to expose the heart and major vessels. Cannulation will be done through the aorta and the right atrium and the patient will be put on cardiopulmonary bypass (CPB). The patient's heart will be freed from the surrounding tissues. With a cylindrical blade, the surgeon will excise a core of myocardium from the apex. The LVAD sewing ring will then be sutured to the margins of the apical hole. The LVAD will be inserted into the LV cavity through the sewing ring. The outflow graft will be measured for the anastomosis into the aortic root. Partial occlusion clamp will be placed on the aortic root and the anastomosis will be performed. De-airing will be performed and the LVAD will be started. The patient will then be weaned from CPB and decannulated.
45923705|NCT00015795|Device|airway interruption test|
45923706|NCT04185922|Device|Hemopatch|As stated in Hemopatch arm description
45649262|NCT04904393|Device|Implant of the device for Cardiac Contractility Modulation (CCM) Therapy|The intervention is an implant of CCM therapy devices and it is similar to conventional dual chamber cardiac devices with only difference of to insert n 2 leads fixed in right ventricular septum
45649263|NCT04904237|Drug|Aza-Ven-allo-HSCT|aaa-ven treatment followed by allo-HCTS with reduced toxicity conditioning (RTC) of Fludarabine, Busulifan and Melphalan
45649264|NCT05136469|Other|NEURAL GLIDING|with Sciatic nerve gliding which is done by applying force on the proximal point and releasing the force distally and then reversing the process. This process was achieved for 30 seconds, 6 times on each leg for a total time of 3 minutes (360 seconds).
45649265|NCT05136469|Other|DYNAMIC STRETCH|The stretch force was applied on the ankle in downward direction which was held for 30 seconds and was repeated 5 times total of 2.5 minutes (150 seconds). Stretch was given on both legs one at a time. Treatment was given for 3 weeks with 2 sessions per week
45649266|NCT04894487|Behavioral|THE USE OF BABY MOBILE ACCOMPANIED WITH BRAHMS LULLABY|Using of baby mobile and listening Brahms Lullaby during sternum dressing process
45796535|NCT05806099|Drug|MBS303|"Phase I: The patients confirming to the eligibility criteria will be assigned to one of the 7 dose groups (0.05/0.15/0.45 mg ~ 1.5/6/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS303 as per the schedule specified in the respective arms. Based on the safety data of the previous dose groups, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subject should be given an IV infusion of MIL62 1000 mg single dose on the D-7.~Phase Ⅱ: One or two recommended doses will be selected based on the results of Phase I. Each patient will receive one of the two recommended doses MBS303 as step-up doses on D1 (low dose) and D8 (intermediate dose) of C1 and at the target dose on D1 of C2-17 (21-day cycles). Based on the previous safety data, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subjects should be given an IV infusion of MIL62 1000 mg single dose on the D-7"
45649267|NCT05136235|Diagnostic Test|Echocardiography|There will be screened for pulmonary hypertension by means of serial echocardiographies during the study period
45796536|NCT05806086|Drug|Panfoshu+Conventional Treatment（program-A）|On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken orally once a day on an empty stomach, one capsule at a time. 1 course of treatment was 6mon, which was taken 10 days a month, stopped for 20 days for 3 months, and observed for another 3 months(unmedicated). Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
45923707|NCT04171999|Other|Community Rx-Hunger (CRx-H)|"The CRx-H Intervention provides dosages of health content that offer assistance for food insecurity and other health-related social needs. A caregiver randomized to the intervention will receive a hard-copy print-out of their tailored list of resources to address food insecurity. A member of our research team will deliver this list and provide a brief educational component which includes: a brief, structured script about the common problem of food insecurity in households with children and co-occuring HRSNs, review of the resource list which includes nearby, vetted resources to address these needs and coaching on how to activate resources on the list. Prior to discharge, the caregiver will receive a duplicate copy of the list of resources. After discharge, the caregiver will receive text messages at a frequency based on the Critical Time Intervention (CTI) Model, from baseline to 3 months post discharge, in order to receive ongoing support by a research team member."
45796537|NCT05806086|Drug|Panfoshu+Conventional Treatment（program-B）|On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken for 30 days in the first month, stopped in the second month, taken for 10 days and stopped for 20 days in a row for 3 months, and finally observed for 1 month. Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
45796538|NCT05806086|Other|Conventional Treatment|Patients in this group were treated with only the conventional treatment.
45923708|NCT00001037|Biological|gp160 Vaccine (Immuno-AG)|
45923709|NCT00015834|Drug|imatinib mesylate|Given PO
45923710|NCT00015834|Drug|cytarabine|Given IV
45796539|NCT05806047|Drug|chidamide combined with fulvestrant|chidamide combined with fulvestrant
45923711|NCT04141423|Drug|Tregopil|Insulin Tregopil is recombinant human insulin modified by a single amphiphilic oligomer covalently linked via an amide bond to lysine at position 29 of the B-chain. This alters the physicochemical characteristics of the molecule, leading to enhanced stability and resistance to intestinal degradation following oral administration.
45923712|NCT04732702|Other|no intervention|There will be no intervention.
45450184|NCT02179372|Dietary Supplement|Eicosapentaenoic acid|30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value >150 μg/g will recive 2 g/day of Eicosapentaenoic acid for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured. The effect of Eicosapentaenoic acid on fecal calprotectin level will be monitored. Clinical relapses will be considered during the study.
45450185|NCT02179372|Dietary Supplement|Medium chain fatty acid (placebo)|30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value >150 μg/g will recive 2 g/day of medium chain fatty acids for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured.
45450186|NCT02174380|Other|Active Household Contact Evaluation|Active evaluation of TB household contacts will be introducted as a new intervention in the district. The intervention will be undertaken by routine public health staff under routine conditions, however the assignment, training, monitoring and supervision of this intervention will occur in a stepped wedge roll out.
45450187|NCT02176252|Drug|AZD1722|
45450188|NCT02176252|Drug|Placebo|
45450189|NCT02174458|Procedure|Body Contouring Surgery|Patients after bariatric surgery (BS) and patients with no history of BS but after natural weight loss and some degree of skin laxity who underwent Body contouring will be included after written informed consent is obtained.
45649268|NCT05136235|Diagnostic Test|NT-proBNP|At 36 weeks postmenstrual age there will be screened for pulmonary hypertension by means of an NT-proBNP measurement in a blood sample
45649269|NCT04902209|Procedure|postural stability measurements|"Static balance assessment on bi-module stabilometric platform CQStab2P. It registers the movement of centre of foot pressure (COP).~Harris hip score- disability assesment"
45796540|NCT05806034|Other|tractography MRI sequence protocol|tractography MRI sequence protocol does not require injection of contrast agent.
45796541|NCT05805995|Procedure|vertebral derotation|"Incentive spirometer (Mediciser): Used for breathing exercises.~Cycle ergometer ( Mijnhardt , St. Paul, MN): Used for lower limb exercise."
45796542|NCT05805982|Behavioral|Educational Video|Pre-recorded educational video including hereditary cancer information, genetic cancer testing candidates, types of testing, type of results, benefits and risks, recommendations according to results, inheritance and common questions.
45796543|NCT05805982|Behavioral|In person genetic cancer counseling|"Includes:~Family history of cancer (3-generation family tree) Personal Cancer Risk Assessment Education on inheritance and expression of disease Types of tests Preparation on possible outcomes according to results Obtaining consent for test Opportunity to solve doubts"
45923713|NCT04081246|Device|Bipolar transurethral modified en bloc resection of bladder tumour|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
45923714|NCT00001040|Drug|Saquinavir|
45923715|NCT00001040|Drug|Zidovudine|
45923716|NCT00001040|Drug|Zalcitabine|
45923717|NCT04042402|Drug|DCR-PHXC|Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
45923718|NCT00015873|Drug|asparaginase|
45923719|NCT00015873|Drug|cytarabine|
45923720|NCT00015873|Drug|mercaptopurine|
45923721|NCT00015873|Drug|methotrexate|
45923722|NCT00015873|Drug|prednisolone|
45923723|NCT00015873|Drug|vincristine sulfate|
45923724|NCT00001043|Biological|gp160 Vaccine (Immuno-AG)|
45923725|NCT03772210|Device|tDCS|Current will be administered to subject groups as specified in arm descriptions.
45923726|NCT03772210|Other|Sham|Apparent Stimulation administered
45923727|NCT00015912|Biological|recombinant interferon alfa|Given IV
45923728|NCT00015912|Drug|thalidomide|Given orally
45649270|NCT04957537|Behavioral|semantic therapy and semantic re-education|"Patients will be followed over two periods Phase A (randomized, 6 to 8 weeks) - Phase B (5 weeks).~Phase A : Baseline Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 6 to 8 weeks (i.e. 18 to 24 sessions) depending on the randomisation, at the rate of 3 speech therapy sessions of 45 minutes per week.~Phase B : Semantic re-education The sessions will consist of training based on the analysis of semantic traits (Coustaut, 2019). This phase will last 5 weeks (i.e. 15 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week.~In accordance with the application of the SCED methodology, repeated measurements will be carried out every second session during phases A and B. They will consist of proposing the oral naming task (lasting 10 minutes)."
45923729|NCT00015912|Other|laboratory biomarker analysis|Correlative studies
45923730|NCT03668431|Drug|Dabrafenib|"Dabrafenib will be taken twice a day for 28 consecutive days~."
45923731|NCT03668431|Drug|Trametinib|Trametinib will be taken once a day for 28 consecutive days
45450190|NCT02174536|Biological|Decidual stromal cells|Decidual stromal cells (approximately 1x10^6 cells/kg) will be infused intravenously.
45649271|NCT04894409|Device|Mouthwash and nose rinse with the AgNPs solution|"The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution for the prevention of SARS-CoV-2 infection in health workers"
45649272|NCT04894409|Device|Mouthwashes and nose rinse in a conventional way|The control group was instructed to do mouthwashes and nose rinse in a conventional way
45649273|NCT04949113|Drug|Neoadjuvant ipilimumab + nivolumab|2 cycles ipilimumab (80mg) + nivolumab (240mg) every 3 weeks followed by total lymph node dissection
45649274|NCT04949113|Drug|Adjuvant nivolumab|Upfront total lymph node dissection followed by 12 cycles of nivolumab (480mg) every 4 weeks.
45796544|NCT05805969|Other|Accommodating variable-resistance training|"The training was conducted twice weekly for six successive weeks under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.~The training protocol included maximum voluntary concentric knee flexor/extensor actions. Three sets of five to 10 repetitions of maximum-effort concentric action at angular speeds of 240, 180, and 120 degrees/second.~The training started with a 10-minute warm-up exercise and ended up with a 5-minute cool-down exercise."
45649275|NCT05115955|Drug|DS group|In DS group, subjects will receive intramuscular single dose of NALDEBAIN® at least 12 hours before surgery.
45796545|NCT05805969|Other|Standard physical therapy|The program encompassed the standard exercises for patients with juvenile idiopathic arthritis (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 45 minutes, two times a week for six successive weeks.
45796546|NCT05805956|Drug|IMM2902|a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47
45796547|NCT05805943|Drug|IMM0306|IMM0306 is an bi-specific antibody
45923732|NCT03668431|Drug|PDR001|PDR001 will be administered IV every 28 days
45923733|NCT00001073|Drug|Isotretinoin|
45923734|NCT02970721|Drug|Antipsychotic|Antipsychotic monotherapy
45923735|NCT02970721|Drug|Antidepressant|Antidepressant monotherapy
45923736|NCT02970721|Drug|Antipsychotic and Antidepressant|Polytherapy
45450191|NCT02174536|Biological|Placebo|
45450192|NCT02174614|Behavioral|Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.
45649276|NCT05115955|Drug|Control group|In Control group, subjects will receive intramuscular 2 ml sesame oil at least 12 hours before surgery.
45649277|NCT04901897|Device|kalifilcon A|kalifilcon A daily disposable contact lens
45649278|NCT04901897|Device|delefilcon A|DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses
45649279|NCT04901897|Device|senofilcon A|Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens
45796548|NCT05805930|Drug|Anakinra|: Patients will continue daily treatment with anakinra up to week 12. Treatment will be then progressively tapered through the reduction of an administration of the drug per week. Reductions will be performed every 2 weeks up to discontinuation. Therefore, if a relapse does not occur, the treatment will be withdrawn at week 24.
45923737|NCT03636958|Drug|Perampanel|Perampanel is an antiepileptic with a novel mechanism of action as it targets post-synaptic AMPA receptors. It has been shown to be effective as adjunctive therapy (dual therapy) for partial / focal epilepsy seizures and generalized in patients over 12 years of age.
45923738|NCT03636958|Drug|conventional antiepileptic treatment|choice of the molecule is left to the discretion of the clinician excluding the following benzodiazepines: clobazam, clonazepam, diazepam. Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin, topiramate, phenytoin, phenobarbital, zonisamide, vigabatrin.
45923739|NCT00015951|Biological|bevacizumab|
45923740|NCT00015951|Drug|cytarabine|
45450193|NCT02174614|Behavioral|TAU plus Rapid Abstinence Initiation (RAI)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment followed by 8 weeks of CBT4CBT computerized therapy.
45923741|NCT00015951|Drug|mitoxantrone hydrochloride|
45923742|NCT03531853|Device|hand-held swept source optical coherence tomography|images the eye
45923743|NCT03509896|Other|Non-Interventional|Non-Interventional
45923744|NCT00001076|Biological|ALVAC-HIV MN120TMG (vCP205)|
45923745|NCT00001076|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
45923746|NCT00001076|Biological|rgp120/HIV-1 SF-2|
45923747|NCT00015990|Drug|thalidomide|Given orally
45923748|NCT00015990|Other|laboratory biomarker analysis|Correlative studies
45923749|NCT03206476|Behavioral|Nutritional intervention based on the SCT and the TM|Nutritional workshop based on the Cognitive Social Theory and the Transtheorical Model: twelve group sessions (one per week) lasting 40 minutes each, aimed at adolescents; With delivery of printed material to work at home (workbook); And two sessions (every month and a half) addressed to parents.
45923750|NCT03206476|Behavioral|Nutritional information|Three informative sessions of 25 minutes (one each month) on healthy eating habits and delivery of educational material to adolescents.
45923751|NCT00001085|Drug|Amprenavir|
45923752|NCT00001085|Drug|Lamivudine|
45923753|NCT00001085|Drug|Zidovudine|
45923754|NCT04732312|Other|Home help|Setting up of a formal home help
45923755|NCT00016029|Other|screening questionnaire administration|
45796549|NCT05805930|Drug|Prednisone|Steroids will be progressively tapered with a reduction of 0,1-0,15 mg/kg/day of prednisone (or 5 mg in patients in treatment with the maximum dosage of 50 mg/day) from the ongoing treatment every week up to discontinuation. If a relapse does not occur, the treatment will be withdrawn in a period of time of 10 weeks.
45796550|NCT05805917|Device|Neoviderm Skin Emulsion medical device|Neoviderm Skin Emulsion will be applied twice daily, to cover the entire cutaneous surface interested by burns, followed by a gentle massage to spread the product evenly of all the affected skin.
45796551|NCT05805917|Drug|Connettivina 0.2% Cream|Connettivina 0.2% Cream will be applied twice daily, to cover the entire cutaneous surface interested by burns, followed by a gentle massage to spread the product evenly of all the affected skin.
45796552|NCT05805904|Drug|BMS-986278|Specified dose on specified days.
45796553|NCT05805904|Drug|Placebo|Specified dose on specified days
45796554|NCT05805891|Drug|bortezomib|bortezomib 2mg/week subcutaneous injection
45796555|NCT05805865|Device|Toothpaste Tablet|Colgate Anywhere Toothpaste Tablets
45796556|NCT05805865|Device|Conventional Toothpaste|Colgate Cavity Protection
45796557|NCT05805839|Drug|C-11 ER176 Radiotracer|Administered at a single time IV prior to the PET imaging. The injected dose of C-11 ER176 will be 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi).
45796558|NCT05805839|Drug|C11 Pittsburgh Compound B|Administered at a single time IV prior to the PET imaging. The injected dose of C-11 PiB will be 555 MBq (range 370 - 629 MBq).
45796559|NCT05805839|Diagnostic Test|PET/CT scan|Imaging of entire brain
45796560|NCT05805839|Diagnostic Test|MRI|Magnetic Resonance Imaging of the Brain
45796561|NCT05805800|Drug|5HT3RA+Olanzapine|"Using one of the 5-HT3 receptor antagonists within 30 minutes before cisplatin/adriamycin/cyclophosphamide.~On day 1-4, Olanzapine is delivered orally after dinner."
45923756|NCT00016029|Procedure|barium enema injection|
45923757|NCT00016029|Procedure|computed tomography|
45923758|NCT00016029|Procedure|computed tomography colonography|
45923759|NCT00016029|Procedure|diagnostic colonoscopy|
45649280|NCT04895371|Other|Tele-physiotherapy group|Allocated participants to this group will receive 18 physiotherapy sessions (three sessions per week) during six weeks. in these sessions, physiotherapist will prescribe aerobic, resistive, breathing and functional exercises and airway clearance techniques (if needed) based on result of assessment of patients at the discharge phase. the physiotherapist will use some educational contents for the patient and call him/her to guide the patient about how exercises should be performed (determining frequency, time, intensity and type of exercise). the patient should do exercises until next session and provide a feedback. The patient will be assessed weekly using a pre-designed questionnaire remotely. the progression of interventions will be based on the results of weekly assessment.
45796562|NCT05805800|Drug|5HT3RA+Olanzapine+Dexamethasone|"Using one of the 5-HT3 receptor antagonists within 30 minutes before cisplatin/adriamycin/cyclophosphamide.~On day 1-4, Olanzapine is delivered orally after dinner. On first day, dexamethasone is given orally within 30 minutes before cisplatin/adriamycin/cyclophosphamide administered.~Other Names:~Acidocont; Deronil; Dexacortal; Desameton; Fluprednisolone; (11β，16α-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione"
45923760|NCT00016029|Procedure|screening colonoscopy|
45923761|NCT02970916|Drug|FOLFIRI+aflibercept|"Aflibercept: 4 mg/kg administered intravenous infusion on day 1~FOLFIRI regimen immediately after aflibercept:~Irinotecan:180 mg/m2 intravenous infusion, folinic acid (dl racemic): 400 mg/m2 intravenous infusion, followed by 5-fluorouracil (5-FU): 400 mg/m2 intravenous bolus, followed by 5-FU: 2400 mg/m2 continuous intravenous infusion over 46 hours.~* folinic acid: 400 mg/m² (racémic) or 200 mg/m² (L-form)"
45923762|NCT00016068|Drug|ganciclovir|
45923763|NCT00016068|Drug|valganciclovir|
45923764|NCT00016107|Drug|estramustine phosphate sodium|Given orally
45796563|NCT05805774|Procedure|Distal Femur Replacement|Knee surgery to remove the lower part of the femur and knee joint (where the broken bones are) and will replace them with an artificial knee joint (prosthesis).
45796564|NCT05805774|Procedure|Surgical fixation|Knee surgery to fix the fracture, that can use wires, nails, screws, pins or plates to health and fix the bones together.
45796565|NCT05805761|Procedure|Conventional Treatment|A bicarbonate jet will be used to remove the biofilm from the surface of the teeth.
45796566|NCT05805761|Procedure|Antimicrobial Photodynamic Therapy|aPDT will be performed before each cleaning/prophylaxis session, only in one of the groups. Participants will swish with the photosensitizer erythrosine for 1 min of pre-irradiation time, so that the drug can stain all the bacterial biofilm. The D-2000 LED (DMC) will be applied, emitting at a wavelength of ʎ = 430-490 nm and 900-1100 mW/cm2. Irradiation will be performed until the biofilm of the cervical region is illuminated for 2 min per point. Each irradiation point will be approximately 0.4 cm2.
45804116|NCT02392351|Device|Renal Denervation (Vessix)|Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator
45923765|NCT00016107|Drug|docetaxel|Given IV
45923766|NCT00016107|Biological|bevacizumab|Given IV
45923767|NCT00016107|Other|laboratory biomarker analysis|Correlative studies
45923768|NCT00001118|Drug|Enfuvirtide|
45923769|NCT00016146|Biological|GPI-0100|
45923770|NCT00016146|Biological|MUC-2-Globo H-KLH conjugate vaccine|
45923771|NCT00001145|Drug|Bacteriophage|
45923772|NCT00001145|Drug|rhuCD40L|
45923773|NCT00001145|Drug|KLH|
45923774|NCT00016185|Drug|alvocidib|
45923775|NCT00016185|Drug|docetaxel|
45923776|NCT00001151|Drug|1,25-Dihydroxycholecalciferol|Usual doses of 1,25-dihydroycholecalciferol are 0.25-1 ug per day. All patients in this study received very high doses or 5-20 ug per day.
45923777|NCT00016224|Drug|thalidomide|
45923778|NCT00016263|Biological|oblimersen sodium|
45923779|NCT00016263|Drug|dacarbazine|
45923780|NCT00016302|Drug|prednisone|Given orally
45923781|NCT00016302|Drug|vincristine sulfate|Given IV
45649281|NCT04895371|Other|Control group|Allocated participants to control group will receive one consultation session by the physiotherapist. At this session, patients will be educated about how to perform their daily activities, breathing exercises, walking, using oxygen cylinder and dietary.
45649282|NCT05135221|Biological|dual biological therapy|Simultaneous use of two biologicals.
45649283|NCT05135065|Other|Artificial Intelligence-Assisted Supervision Protocol|Measurement-based supervision protocol that incorporates fidelity measurement from a machine learning tool and feedback reports from this tool into a standardized supervision protocol for behavior therapy to task-shift burdensome supervision tasks to a machine, reducing costs and improving precision of fidelity measurement for agencies.
45649284|NCT04894331|Other|Dietary intervention|"Each patient receives one of 5 dietary plans, different only for energy intake (1400-1600-1800-2000-2100 Kcal/day). The choice depends on the personalized energy needs. The energy requirement is calculated on basal metabolic rate (BMR) of the patient according to Harris & Benedict's and Schofield's formulas.~All dietary plans include foods with low-Ni content. Finally, each patient completes 30-day personalized diet."
45649285|NCT04894331|Other|Video call|Each patient receives a follow-up remote visit through video call 15 and 30 days after the start of the dietary intervention.
45649286|NCT05134909|Device|Customized contact lens|The customized lenses are designed to correct the eye's optical aberrations.
45649287|NCT04893941|Drug|CM310|IL-4Rα monoclonal antibody
45923782|NCT00016302|Drug|daunorubicin hydrochloride|Given IV
45796567|NCT05805748|Behavioral|serious game rehabilitation|The SG rehabilitation was proposed to be played four times per week for three weeks, for a total of 12 sessions, with 15 min per session (= 60 minutes per week). Conventional rehabilitation comprised five sessions of 45 min of neuropsychological rehabilitation using classical exploration training (= 225 minutes per week).
45796568|NCT05805696|Behavioral|Impostor tasks|Tasks to do every week
45923783|NCT00016302|Drug|asparaginase|Given IM
45923784|NCT00016302|Drug|methotrexate|Given IT and orally
45923785|NCT00016302|Drug|cyclophosphamide|Given IV
45923786|NCT00016302|Drug|cytarabine|Given IV or SC
45923787|NCT00016302|Drug|mercaptopurine|Given orally
45649288|NCT04893941|Drug|Placebo|Placebo
45923788|NCT00016302|Drug|leucovorin calcium|Given IV or orally
45450194|NCT02174614|Behavioral|TAU plus RAI plus Cognitive Control Training (CCT)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment PLUS sessions of computerized cognitive control training (CCT) 3 times per week for the first 4 weeks followed by 8 weeks of CBT4CBT computerized therapy.
45450195|NCT02179528|Drug|Etoposide|
45649289|NCT05057845|Drug|Tislelizumab|Tislelizumab will be initiated on day 14 after cryoablation. Tislelizumab will be administered at 200 mg i.v. every 3 weeks
45649290|NCT05057845|Drug|lenvatinib|Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
45649291|NCT05057845|Combination Product|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
45649292|NCT04901585|Procedure|Totally intracorporeal distal gastrectomy|Minimally invasive distal gastrectomy with intracorporeal anastomosis and handsewn enterotomy closure
45649293|NCT05109949|Drug|Dapagliflozin 10Mg Tab|Daily morning dose per oral of Dapagliflozin 10 mg for 7 days
45649294|NCT05109949|Drug|Empagliflozin 25 MG|Daily morning dose per oral of Empagliflozine 25 mg for 7 days
45796569|NCT05805644|Device|Robot mediated upper limb therapy|"The OR is classified as a Class A device with the Health Sciences Authority. The OR is capable of delivering RMIT as well as RMTT. It can provide zero, partial or full assistance to the patient to complete the movement or task. Its teach-and-follow mode allows a movement to be performed by the therapist, with the device then replaying the movement at either zero, partial or full assistance for the patient.~Impairment oriented training will focus on the following movements:~Diagonal movement~Shoulder abduction~Shoulder adduction~Shoulder flexion~Shoulder extension~Elbow flexion~Elbow extension~Task-specific training will focus on the following activities:~Picking up a cup/glass by the side and drink~Brushing hair~Cleaning unaffected upper limb (hand to arm)~Wiping table~Wiping wall~Sliding card on table to a designated location~Clipping a clothe peg"
45796570|NCT05805631|Drug|Pemetrexed|Intrathecal Pemetrexed
45796571|NCT05805592|Behavioral|Screen-to-Move-Program (STEP)|"It is planned as 6 sessions, 1 session per week for children and parents. The program will be introduced to children and parents under the call with Screen-to-Move-Program (STEP)."
45923789|NCT00016302|Drug|dexamethasone|Given orally
45923790|NCT00016302|Drug|doxorubicin hydrochloride|Given IV
45923791|NCT00016302|Drug|thioguanine|Given orally
45923792|NCT00016302|Radiation|radiation therapy|Undergo cranial irradiation
45923793|NCT00016302|Drug|nelarabine|Given IV
45923794|NCT00016302|Drug|pegaspargase|Given IM
45923795|NCT00016302|Radiation|radiation therapy|Undergo craniocervical radiotherapy
45923796|NCT00016302|Other|pharmacological study|Correlative studies
45923797|NCT00016302|Other|laboratory biomarker analysis|Correlative studies
45923798|NCT00389285|Drug|rIL-21 only|Part 1: rIL-21, IV, Day 1-5 and 15-19 of each 6-week treatment course
45923799|NCT00389285|Drug|rIL-21 + sorafenib|Part 2: rIL-21 IV, Day 1-5 and 15-19 of each 6-week treatment course + sorafenib (up to 400 mg taken orally twice daily)
45923800|NCT00389363|Drug|ALK HDM tablet|
45923801|NCT00016341|Biological|filgrastim|
45923802|NCT00016341|Drug|cisplatin|
45923803|NCT00016341|Drug|doxorubicin hydrochloride|
45923804|NCT00016341|Drug|megestrol acetate|
45923805|NCT00016341|Drug|paclitaxel|
45923806|NCT00016341|Drug|tamoxifen citrate|
45923807|NCT00001181|Drug|Testolactone|
45923808|NCT00016380|Drug|dexamethasone|
45923809|NCT00016380|Drug|ondansetron|
45923810|NCT00016380|Procedure|quality-of-life assessment|
45923811|NCT00001190|Drug|Deslorelin|
45923812|NCT00001202|Drug|Spironolactone|
45923813|NCT00001202|Drug|Testolactone|
45923814|NCT00001202|Drug|Deslorelin|
45923815|NCT00016419|Biological|anti-thymocyte globulin|3.5 mg/kg/d IV over 12 hrs day 1
45923816|NCT00016419|Drug|cyclosporine|3 mg/kg bid days 5-94 then taper to 0 at day 124 PO
45923817|NCT00016458|Drug|anti-thymocyte globulin|
45923818|NCT00016458|Drug|cyclophosphamide|
45923819|NCT00001217|Drug|pre-surgical chemotherapy|
45923820|NCT01156545|Drug|BIBW 2992|BIBW 2992 40mg, once a day, oral intake, every day
45649295|NCT05109949|Other|Placebo|Daily morning dose per oral of Calcined magnesite 500 mg for 7 days
45796572|NCT05805579|Diagnostic Test|Diaphragmatic echography|Diaphragmatic echography
45796573|NCT05805566|Other|Blood collection|Blood samples will be collected from the patient at baseline. This blood will be collected during the standard of care blood drawing in extra.
45796574|NCT05805553|Drug|Propranolol|2mg/kg/day in 3-4 dividd doses
45796575|NCT05805553|Drug|Nandrolone Decanoate|1mg/kg weekly
45796576|NCT05805540|Procedure|Cold-water immersion|Subjects were immersed, in a sitting position where legs were always covered, in cold water at 11ºC in periods of 2 minutes submerged and 2 minutes out of the water at room temperature (25ºC), repeating this process 5 times
45923821|NCT01156545|Drug|simvastatin|simvastatin 40mg, once a day, oral intake, every day.
45450196|NCT02176330|Other|ePAQ-PF followed by a telephone consultation.|All women randomised to this arm of the study were entered onto the hospital electronic patient record system under the ePAQ clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. The research nurse (HJW) then arranged their telephone consultation. Women in this group who felt unable to complete the questionnaire online would use this telephone call with the research nurse to make arrangements to attend and complete the questionnaire at the hospital.
45450197|NCT02176330|Other|ePAQ-PF followed by a face to face consultation|All women randomised to this arm of the study were posted an appointment to attend the urogynaecology clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. Women then attended for their face to face clinic consultation as normal. Women in this group who felt unable to complete the questionnaire online were given the opportunity to complete the questionnaire at the hospital when they attended for their consultation.
45450198|NCT02179606|Device|Dermalax Implant Plus|Dermalax implant plus injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
45450199|NCT02179606|Device|Restylane Sub-Q|Restylane Sub-Q injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
45450200|NCT02176564|Drug|inhaled bronchodilator|
45649296|NCT04893473|Device|IscAlert|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and carbon dioxide is measured continuously.
45649297|NCT04901429|Procedure|Truncal vagotomy|Truncal vagotomy will be performed in 50% of patients during other routine procedure.
45923822|NCT00016497|Procedure|bilateral myringotomy|
45649298|NCT04926259|Drug|18F-T807|Intravenous injection of one dose of 10mCi (370MBq, ±5%) 18F-T807. Each subject receive a single intravenous injection of 18F-T807, and undergo PET/CT imaging within the specificed time.
45923823|NCT00016497|Procedure|bilateral myringotomy and tubes|
45923824|NCT00016497|Procedure|adenoidectomy|
45923825|NCT03031873|Device|MRI perfusion imaging|Evaluate the evolution of progressive obliteration of the AVM nidus
45923826|NCT02892955|Device|HeartMate 3 LVAS|Implantation of HeartMate 3 LVAD to evaluate safety and clinical performance of the HM3 LVAS for the treatment of advanced, refractory, left ventricular heart failure following completion of enrollment in the MOMENTUM 3 IDE Study.
45923827|NCT01140516|Drug|Trimethoprim|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
45923828|NCT01140516|Other|Simple Syrup|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
45923829|NCT02754544|Procedure|Direct Electrocortical Stimulation|Undergo direct electrocortical stimulation
45796577|NCT05805540|Procedure|Protein-carbohydrates supplementation|Subjects consumed a mixed carbohydrate and protein beverage, composed of 0.3gr/kg of maltodextrin and 0.2gr/kg of neutral whey protein in 0.5 litres of water. Subject sat for 25 minutes until all recovery methods were completed.
45796578|NCT05805540|Procedure|Active recovery|Subjects was carried out using a bicycle ergometer. The subjects pedaled for 25 minutes at 50% of the maximum heart rate (HRmax)
45923830|NCT02754544|Other|Electrocorticography|Undergo electrocorticography
45923831|NCT00016536|Drug|Naphthalene 2-sulfonate polymer|
45923832|NCT00016536|Drug|Carbopol polymer|
45923833|NCT02734771|Drug|Brentuximab vedotin|
45923834|NCT02734771|Drug|Rituximab|
45923835|NCT02734771|Drug|Cyclophosphamide|
45923836|NCT02734771|Drug|Doxorubicin|
45923837|NCT02734771|Drug|Prednisone|
45923838|NCT02347111|Drug|Flecainide|flecainide up to 150mg twice daily for the control of atrial fibrillation
45923839|NCT02347111|Drug|Sotalol|sotalol up to 120mg twice daily for the control of atrial fibrillation
45923840|NCT00001250|Drug|preoperative dose intense chemotherapy (FLAC/G-CSF)|
45923841|NCT02323945|Other|AIH|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FiO2) = 0.10±0.02 (hypoxia). Participants will receive treatment on 5 consecutive days.
45796579|NCT05805540|Procedure|Placebo|Subjects drank a water-based drink and sweetener. Subject sat for 25 minutes until all recovery methods were completed.
45796580|NCT05805527|Diagnostic Test|mobile health application named KANOPEE|Volunteers will undergo two clinical interviews, an in person clinician-led interview and a fully-automated interview administered via mobile phone
45796581|NCT05805514|Other|Animal source of food and psychosocial stimulation|209 mother-child pair will receive the animal source of food and psychosocial stimulation for 12 months. Child will be recruited within 6-12 months.
45796582|NCT05805514|Other|Animal source of food|209 mother-child pair will receive the animal source of food for 12 months. Child will be recruited within 6-12 months.
45923842|NCT02323945|Other|Walk|30 minutes of walking practice consisting of 5 repetitions of 6-minute walks
45796583|NCT05805514|Other|Control|209 mother-child pair will receive the control package for 12 months. Child will be recruited within 6-12 months.
45923843|NCT02323945|Other|Strength|30 minutes of isometric ankle plantar flexion torque practice broken into 3 sets of 10 repetitions
45923844|NCT02307253|Device|Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)|EUS-guided fine needle biopsy performed through the duodenum with the Expect™ 19 Flex needle
45796584|NCT05805488|Dietary Supplement|Placebo sachet|consume 1 sachet per day
45796585|NCT05805488|Dietary Supplement|TCI904 sachet|consume 1 sachet per day
45796586|NCT05805475|Other|Endotracheal suctioning with expiratory pause|Perform closed endotracheal suctioning with an expiratory pause of 5 seconds
45796587|NCT05805475|Other|Endotracheal suctioning without expiratory pause|Perform closed endotracheal suctioning without expiratory pause
45923845|NCT00001253|Behavioral|cognitive tests and scales|
45923846|NCT04732039|Other|Measurement of peak oxygen uptake|Oxygen uptake measured on bike (pVO2) and during the conduction of specific daily life activities (ADL-VO2).
45923847|NCT00016653|Drug|Creatine Monohydrate|
45450201|NCT02182102|Drug|BIBF 1120|
45923848|NCT00016653|Drug|Glutamine|
45450202|NCT02182102|Drug|Pemetrexed|
45450203|NCT02176720|Drug|FDOPA PET|[18F]FDOPA radiopharmaceutical will be intravenousely injected for PET-CT scanning of the brain.
45796588|NCT05805449|Procedure|Surgery|Control patients will receive usual standard of care surgical repair of their complex fistula by LIFT or advancement flap technique without any biologic adjunct.
45923849|NCT02179489|Procedure|Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC|HIPEC with MMC: Mitomycin C (MMC) (30 mg/m2 of body surface area). Closed technique, as preferred. Duration: 60 minutes. Mean Intra-abdominal Temperature: 43°C.
45923850|NCT00001262|Drug|Copper Histidine|
45923851|NCT00016692|Drug|Z-100|
45923852|NCT02170363|Device|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
45923853|NCT00396955|Drug|PLA-695|
45450204|NCT04373434|Behavioral|Health Homes/Healthy Families (HH/HF) Intervention|The HH/HF Intervention involves coaching calls, text messages and intervention materials that are designed to increase behavioral capability, self-efficacy and behavioral intention to improve the home food environment for healthy eating and weight gain prevention. The intervention is delivered over a 12 week period.
45450205|NCT04373434|Behavioral|Control|"Participants in the control condition will receive two mailings on healthy eating, the first from the Dietary Guidelines For Americans 2015-2020, 8th Edition and the second from Choose MyPlate. Additionally, both mailings will include a food diary from the Centers for Disease Control and Prevention. Mailings will be sent to participants one and six-weeks post-baseline. These materials focus on the same dietary outcomes being targeted in the HH/HF intervention, but without the home environment emphasis. Control group participants will receive their home environment profile with a list of healthy actions upon completion of the study."
45796589|NCT05805449|Other|Platelet-rich plasma (PRP)|Participants will have 40-50cc of peripheral whole blood drawn into a syringe pre-loaded with acid citrate dextrose (ACD) anticoagulant and concentrated PRP harvested by double centrifugation technique using the manufacturer's kit and benchtop centrifuge. This typically yields 5-8cc of PRP that is 18-times more concentrated than baseline.
45796590|NCT05805449|Device|Matrix|"Participants will receive 200g of paste matrix and 200g injected at the following sites: the internal opening closure site at level of the sphincter muscle, within the walls of the fistula tract along its length, and within the tissue of an advancement flap particularly at areas of tissue apposition."
45796591|NCT05805410|Behavioral|robotic hippotherapy|A custom designed cable-driven robotic system that mimics horseback movement during walking was used in this study.
45923854|NCT00001277|Drug|68Ga-Dotatate|68Ga-Dotatate PET/CT will be administered prior to a PET/CT scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.
45923855|NCT00001277|Drug|18F-DOPA|18F-DOPA PET/CT will be administered prior to a whole-body scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.
45923856|NCT02088190|Procedure|Sleeve gastrectomy|Type of bariatric surgery
45796592|NCT05805410|Behavioral|Conventional physical therapy|Stretching of trunk and leg muscles, followed by sitting and standing balance training, and conventional treadmill walking.
45804117|NCT02392351|Device|Renal Angiography|Percutaneous renal angiography
45649299|NCT04901663|Drug|Omeprazole 20 MG Capsule; Amoxicillin 1000 MG; Clarithromycin 500 MG|Orally twice daily for 2 weeks
45923857|NCT02069743|Other|ePAL Mobile Application|A mobile application designed to help cancer patients better self-manage cancer pain.
45923858|NCT00001280|Drug|itraconazole|
45796593|NCT05805397|Behavioral|Motivation Skills Training|Participants will complete a baseline assessment, receive weekly MST sessions in a group format for a duration of 12 weeks, and will then repeat the assessment battery from baseline immediately following treatment completion and 2-months after.
45796594|NCT05805397|Behavioral|Healthy Behaviors Control Group|Participants will complete a baseline assessment, receive weekly HBC sessions in a group format for a duration of 12 weeks, and will repeat the assessment battery from baseline immediately following treatment completion and 2-months after.
45796595|NCT05805384|Device|SEDA|Speech Enhancement using Dynamic thresholding Approach (SEDA) is a software algorithm that removes background noise.
45923859|NCT00016887|Biological|filgrastim|
45923860|NCT00016887|Biological|recombinant interferon alfa|
45923861|NCT00016887|Drug|carmustine|
45796596|NCT05805358|Drug|Hyperpolarized 13C-Pyruvate injection|DNP-MRI for splenic immune function evaluation through hyperpolarized 13C-Pyruvate injection
45923862|NCT00016887|Drug|cyclophosphamide|
45923863|NCT00016887|Drug|cytarabine|
45923864|NCT00016887|Drug|dexamethasone|
45923865|NCT00016887|Drug|etoposide|
45796597|NCT05805332|Other|pulmonary rehabilitation|The participants would undergo pulmonary rehabilitation.
45450206|NCT04494568|Device|HIFU treatment|HIFU Treatment of rectal endometriosis
45796598|NCT05805319|Other|increasing total fiber intake|Patients in the intervention arm will complete a dietary survey and be counselled on increasing their total fiber intake.
45796599|NCT05805306|Behavioral|Entre Herman@s|The intervention unfolds as follows: (Week 1) the research team, Latino MSM, & sibling will all engage in a PrEP Conversation followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
45923866|NCT00016887|Drug|melphalan|
45923867|NCT00016887|Procedure|bone marrow ablation with stem cell support|
45923868|NCT00016887|Procedure|peripheral blood stem cell transplantation|
45923869|NCT00016887|Radiation|radiation therapy|
45923870|NCT00819793|Device|CentriMag Ventricular Assist System|All eligible subjects will receive the CentriMag Ventricular Assist System. The system is comprised of a single-use centrifugal blood pump, a motor, a primary drive console, a back up drive console and cannulae. Blood from the failing heart is directed from the ventricle or the atrium to the inlet of the pump via an inlet cannula. Blood exits through the outlet port of the pump through the outlet cannula ultimately to the pulmonary or systemic circulation. The system can be used in either a right, left or biventricular configuration.
45923871|NCT00038350|Behavioral|Lingual Strengthening|8 week lingual strengthening exercise protocol
45450207|NCT02176876|Drug|GS-5745|GS-5745 400 mg administered intravenously
45450208|NCT02176876|Drug|Placebo to match GS-5745|Placebo to match GS-5745 administered intravenously
45450209|NCT02179684|Procedure|Baby-sitter surgery N. fascialis|
45649300|NCT04901663|Drug|Vonoprazan 20 MG; Amoxicillin 1000 MG|Orally twice daily for 2 weeks
45754380|NCT03586388|Other|Oral immunotherapy protocol|"In hospital setting: three increasing doses every 30 minutes of 1ml, 5ml and 10ml of cow milk (CM). Oral food challenge (OFC) stopped at 10ml even if no clinical reactions occurred.~At home: every child will take the dose tolerated in hospital, starting the day after the OFC, for 3-4 weeks.Once reached the dose of 40ml of CM without reactions for at least 2 weeks, families increment the dose of 5 ml every week, till the tolerance of 50 ml, then of 10 ml every week, till the tolerance of 100ml and then, of 10 ml every 3 days till the tolerance of 150 ml of milk."
45923872|NCT00038389|Drug|Vioxx|Starting dose for patients age 3-14 years 10.0 mg/1.73 m2 and for patients above 14 years of age 12.5 mg for 5 days per week for 6 weeks during radiation treatment, and 7 days per week for 6 months after radiation treatment.
45450210|NCT02179684|Other|Conventional treatment and follow-up|Patient´s with Bells´palasy are treated with conventional treatment and follow-up
45923873|NCT00038428|Drug|TLK286|
45923874|NCT00038506|Drug|abacavir/lamivudine/zidovudine|
45923875|NCT00038506|Drug|tenofovir|
45923876|NCT00016926|Drug|capecitabine|
45923877|NCT00038545|Drug|Filgrastim SD/01|
45923878|NCT00038545|Drug|Paclitaxel|
45450211|NCT03537196|Drug|Sofosbuvir 400 mg and Daclatasvir 60 mg|All patients will receive sofosbuvir 400-mg and daclatasvir 60-mg (1 tablet each per day) during 12 weeks.
45754381|NCT04141826|Dietary Supplement|Hydrolysed whey|500 mL solution of 25 gram hydrolysed whey per day during 4 weeks
45923879|NCT00038545|Drug|Topotecan|
45923880|NCT00038584|Drug|SCH66336|
45923881|NCT00038623|Drug|Yttrium-ibritumomab (Zevalin)|After Rituximab infusion, 111^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.
45923882|NCT00038623|Drug|Rituximab|250 mg/m^2 in the vein over 6 to 8 hours on Day 1.
45923883|NCT00016965|Drug|ixabepilone|
45923884|NCT00038662|Drug|Atrasentan|
45923885|NCT00038701|Drug|TNP-470|
45923886|NCT00038779|Procedure|Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation|
45923887|NCT00038818|Biological|CD8 Depleted Donor Lymphocyte|
45923888|NCT00038896|Drug|Venlafaxine ER|
45923889|NCT00038935|Drug|ReFacto AF|
45923890|NCT00017004|Radiation|External Beam Radiation Therapy|Undergo radiation
45923891|NCT00017004|Drug|Cisplatin|Given IV
45649301|NCT05134597|Genetic|Genetic assessment|Blood samples will be collected in 3-mL K3 EDTA vacutainer tubes. Peripheral blood mononuclear cells will be isolated via density gradient centrifugation within 2 hours of sample collection. Primary CD4+ T cells will be purified from the peripheral blood lymphocytes using a magnetic cell sorting CD4+ T cell isolation kit, according to the manufacturer's instructions. RNA extraction will be performed. Total RNA will be quantified, and the quality of RNA will be assayed using formaldehyde agarose gel electrophoresis and by determining the 260/280 absorbance ratio. One microgram of total RNA from each sample will be subjected to reverse transcription. One microliter of cDNA will be amplified via real-time PCR and 10 pmol of primers specific to IL23R, IL17, SGK1, RANBP1, TFGB. Real-time PCR assays will be performed in triplicate The specificity of the PCR products will be determined via melting curve analysis.
45450212|NCT03537196|Drug|Sofosbuvir 400 mg and Daclatasvir 90 mg|For HIV/HCV co-infected patients receiving efavirenz or nevirapine, daclatasvir dose will be increased to 90-mg per day.
45450213|NCT03537196|Drug|Ribavirin|"In case of cirrhosis:~Ribavirin will be added to sofosbuvir/daclatasvir during the 12 weeks of treatment. The dose will be adapted to the patient weight although the vast majority of patients (weight < 75 kg) will receive 500 mg x 2/day.~In case of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks."
45796600|NCT05805306|Behavioral|Vaccines for Health|The intervention unfolds as follows: (Week 1) the research team, Latino MSM, & sibling will all engage in a Health Conversation about vaccines for COVID, Hep A/B, or MPOX, followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
45796601|NCT05804747|Drug|Edoxaban|This is observational, non-interventional study. No study drug will be administered during this study.
45450214|NCT03537196|Drug|Sofosbuvir and Daclatasvir for 24 weeks|In case of cirrhose and of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks.
45450215|NCT02179762|Behavioral|moderate exercise intervention|Perform moderate exercise therapy
45796602|NCT05803109|Other|AVIVA-PURE-CocoPull-Organic-made in USA|virgin cold pressed coconut oil with Peppermint essential oil
45923892|NCT00017004|Radiation|Internal Radiation Therapy|Undergo radiation
45796603|NCT05802784|Procedure|Hysteroscopic septoplasty with scissors|In hysteroscopic septoplasty with scissors arm, incision of the septum was done by continuous flow hysteroscopy and scissors using saline as distension media.
45923893|NCT00017004|Biological|Epoetin Alfa|Given SC
45450216|NCT02179762|Behavioral|vigorous exercise intervention - standard|Perform HIIT exercise therapy on a standard stationary bike
45450217|NCT02179762|Other|questionnaire administration|Ancillary studies: Functional Assessment of Cancer Therapy-General (FACT-G), Godin Leisure-Time Exercise questionnaire, 24-hour diet recalls, USDA 5 Step Multiple Pass Method, Memorial Anxiety Scale for Prostate Cancer, Pittsburgh Sleep Quality Index (PSQI)
45649302|NCT05134519|Drug|Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC)|Regimen: RC48-ADC: 2.0 mg/kg, intravenous drip, once every 2 weeks,4-6 cycles
45754382|NCT04141826|Dietary Supplement|Intact whey|500 mL solution of 25 gram intact whey per day during 4 weeks
45796604|NCT05802784|Procedure|Hysteroscopic septoplasty with resectoscope|In hysteroscopic septoplasty with resectoscope arm, incision of the septum was done by 26 Fr monopolar resectoscope with collin's knife using glycine1.5% as distension media.
45450218|NCT02179762|Other|laboratory biomarker analysis|Correlative studies
45450219|NCT02179762|Behavioral|vigorous exercise intervention - cybercycling|perform HIIT exercise on cybercycles aided by electronic racing and other games
45796605|NCT05802199|Diagnostic Test|Hepatic fat fraction and hepatic fibrosis|"All patients underwent measurement of UDFF for hepatic fat fraction and auto-pSWE for hepatic fibrosis.~All patients underwent measurement of MRI-PDFF for hepatic fat fraction and MRE for hepatic fibrosis as reference standard."
45450220|NCT02179762|Behavioral|Exercise Logs|The exercise physiologists will keep exercise logs and tracking sheets that log the date, start and stop time (duration) of exercise sessions as well as time in the THR and RPE for each exercise session.
45804118|NCT02393677|Drug|Ropivacaine|Ropivacaine 0.5% 30 ml was used to block brachial plexus
45804119|NCT02393677|Drug|Ropivacaine with Dexmedetomidine|Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus
45923894|NCT00396994|Device|Low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a vibrating platform set at 0.3 g and 30 Hz
45923895|NCT00396994|Device|Sham low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a sham vibrating platform
45923896|NCT00038974|Drug|peginterferon alfa-2a|
45923897|NCT00038974|Drug|Ribavirin|
45923898|NCT00001298|Drug|carboxypeptidase-G2|
45796606|NCT05802095|Device|Supplemental Feeding Tube Device|One end of the catheter is in such a way that milk comes into the bottle. The tip of the feeding catheter can be fixed to the mother's breast with a plaster so that it is in the baby's mouth. The tip of the catheter is placed inside the baby's mouth while the baby is sucking on its mother. While the mother is breastfeeding, milk is supplied to the baby from both the mother and the bottle. The baby will continue to suckle as he feels that plenty of milk is coming. To increase the flow of milk from the bottle, the mother hangs the bottle around her neck with the teat side down. The higher the bottle or milk container is held, the greater the flow of milk. It is an easy and safe method.
45796607|NCT05800938|Drug|Isosorbid mononitrate|Imdur tablets were given twice daily for 4 weeks
45796608|NCT05800938|Drug|Placebo|Placebo tablets were given twice daily for 4 weeks
45796609|NCT05797935|Drug|Dapagliflozin 10mg Tab|Dapagliflozin was given at a dose of 10 mg/day in one group and its effect was observed on the pancreatic fat content
45796610|NCT05796921|Dietary Supplement|Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain|Patients allocated to the probiotic arm will take the dietary supplement, containing 15 billion of the Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain, once a day for 10 consecutive days.
45923899|NCT00039013|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
45923900|NCT00039013|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
45796611|NCT05796921|Dietary Supplement|placebo|Patients allocated to placebo arm will take placebo capsules once a day for 10 consecutive days.
45796612|NCT05796518|Other|PREVENT Cardiovascular Health Assessment Tool|Participants will access a heart health information visualization tool online using a personal device or a study tablet computer using their e-mail address to log-in. Investigators will review participant lab results specifically related to their cardiovascular health (e.g. blood pressure, cholesterol) in order to personalize the heart health tool for participants. A brief survey before and after use of the tool will also be completed by participants.
45796613|NCT05796518|Other|Survey|A brief survey before and after use of the tool will also be completed by participants.
45450221|NCT02179762|Behavioral|Adherence|We will assess barriers to adhering to the exercise protocol by asking an open-ended question to solicit barriers. If the patient calls to cancel an exercise session, he will be called and probed for reasons
45649303|NCT04394663|Drug|High-dose oral omeprazole|Local made oral omeprazole 40 mg twice daily will be prescribed for 72 hours after randomization.
45649304|NCT04394663|Drug|Standard IV PPI|Pantoprazole 8mg/hour IV continuous drip will be prescribed for 72 hours after randomization
45796614|NCT05796518|Other|Interview Regarding Heart Health|Participants will be asked questions related to their heart health.
45796615|NCT05795361|Drug|Idursulfase-IT|Participants will continue to receive the same dose of idursulfase-IT, once monthly, that was administered during the HGT-HIT-046 [NCT01506141] or SHP609-302 [NCT02412787] study [10mg or 30mg] along with intravenous (IV) infusions of standard-of-care therapy Elaprase via intrathecal drug delivery device (IDDD) or lumbar punctures.
45796616|NCT05794802|Dietary Supplement|BHB supplement|Oral consumption of 0.5 g/kg of a BHB supplement (KE4; Ketoneaid®, Falls Church, Virginia, USA)
45796617|NCT05794802|Other|Placebo solution|80 to 120 ml of a placebo solution, depending on the participant's body weight, with the addition of stevia and bitter agent solution (Bitrex, Scotland, UK) as well as the same flavouring as the ketone supplement drink (provided by Ketoneaid)
45796618|NCT05794386|Procedure|LVA-guided LA substrate modification|The LVA-guided additional LA ablation is included linear ablation or LVA zone border modification/isolation/ homogenization. The additional ablation strategies are finally selected at the physicians' discretion, considering LVA location and distribution.
45804120|NCT02394457|Drug|Cosyntropin|Intravenous Drug Infusion over 1 hour and a half
45804121|NCT02394457|Procedure|Epidural Blood Patch|Blood drawn from subject and then same Blood placed into Epidural space by anesthesia personnel.
45649305|NCT05133193|Drug|three kinds of antibiotics|All patients were educated carefully about the medical instructions, including the duration of treatment, possible side effect, the necessity of completing the full 14-day course.
45649306|NCT04901117|Drug|Amoxicillin|Use according to the drug combination options selected by each center.
45649307|NCT04901117|Drug|Clarithromycin|Use according to the drug combination options selected by each center.
45649308|NCT04901117|Drug|Tetracycline|Use according to the drug combination options selected by each center.
45804122|NCT05504395|Drug|CSTI-500|Single 10 mg capsule
45923901|NCT00039013|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
45923902|NCT00039013|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
45923903|NCT00017043|Drug|ixabepilone|
45923904|NCT00039052|Biological|interleukin-4 PE38KDEL cytotoxin|
45923905|NCT00017082|Drug|oxaliplatin|
45923906|NCT00039091|Biological|ipilimumab|Given IV
45923907|NCT00039169|Drug|ortataxel|
45923908|NCT00001304|Drug|Synthetic Human Parathyroid Hormone 1-34|twice daily subcutaneous injections
45649309|NCT04901117|Drug|Metronidazole|Use according to the drug combination options selected by each center.
45649310|NCT04901117|Drug|Bismuth Potassium Citrate|Use according to the drug combination options selected by each center.
45923909|NCT00001304|Drug|Calcitriol & Calcium|Twice daily oral calcitriol with 1000 mg Calcium carbonate supplementation
45796619|NCT05789940|Procedure|hysteroscopy|The procedure is performed by a gynecologic surgeon under general or spinal anesthesia, depending on the standard practice of the center involved, with the patient in the gynecologic position. Antibiotic prophylaxis may be administered according to the standard practice of the center. The equipment available at each center will be used for operative hysteroscopy. The use of energy is usually unnecessary and saline will be preferred. Before the operation, the appearance of the uterine cavity will be described. The selected design product will be resected from top to bottom using the surgical resector, without electrical energy, as this method is known to be the most protective of the endometrium in previous studies. Electric current should be used only as a last resort, in cases where the selected design cannot be removed without it. If there is active bleeding after the procedure, elective coagulation via the hysteroscope may be performed to stop intrauterine bleeding.
45796620|NCT05789940|Procedure|Aspiration|The aspiration will be performed by a gynecological surgeon, according to the center's standard protocol. A flexible or rigid cannula can be used. Antibiotic prophylaxis, the diameter of the cannula used, the cervical preparation required, and the use of intraoperative ultrasound guidance will be left to the discretion of the operator and the standard practice of the center. In most centers, the cervix is dilated with a Hegar dilator of up to 9 mm in size.
45796621|NCT05786794|Behavioral|Patient Navigation Program for Hearing Health Care|Patients presenting for routine office visits will be invited to participate in the study and informed consent procedures and study enrollment will be conducted by a research assistant. Participants will then undergo baseline assessment. Approximately one week later, patients will be contacted by the Patient Navigator (PN) and begin the intervention. The navigator will contact patients every 2 weeks to focus on addressing key aspects of Hearing Health Care (HHC): education, screening, diagnosis, and treatment. PNs will guide the patient through a free smartphone enabled app-based Mimi© hearing screening testing. Based on those results, PNs will assist the patient to undergo a formal audiogram with the 12 months following enrollment. Each PN session will likely last between 10-30 minutes. Post-intervention data collection also administered by a trained interviewer, will occur following a diagnostic audiogram with an audiologist or at 12 months following enrollment.
45796622|NCT05786586|Device|650 nm low-level red-light|650 nm low-level red-light is a kind of laser, concentrated into a beam, to repeatedly irradiate the retina
45796623|NCT05784948|Other|Virtual Reality Mindfulness Treatment|once a week for 30 minutes, over 8 weeks
45923910|NCT00039208|Drug|fluorouracil|
45796624|NCT05784948|Other|Experience relaxing scenery and music|once a week for 30 minutes, over 8 weeks
45923911|NCT00039208|Drug|irinotecan hydrochloride|
45796625|NCT05781893|Other|Data collection|Data collection on sociodemography, clinical data (retrieved from regular care for PCC in the UHB medical outpatient clinic), biomarkers derived from blood samples, neurocognitive testing, psychometric questionnaires, and measures of physical performance.
45649311|NCT04901117|Drug|Colloidal Bismuth Pectin|Use according to the drug combination options selected by each center.
45796626|NCT05775237|Dietary Supplement|Curcumin Gummies|Chew gummies thoroughly and completely before swallowing.
45796627|NCT05775237|Dietary Supplement|Vitamin C Gummies|Chew gummies thoroughly and completely before swallowing.
45796628|NCT05775237|Dietary Supplement|Multivitamin Gummies|Chew gummies thoroughly and completely before swallowing.
45796629|NCT05773365|Other|PENG block with or without local anaesthetic infiltration|As mentioned.
45796630|NCT05773196|Other|Biospecimen Collection|"Cohort 1-Huntington's Disease:~The target blood volume of each phlebotomy visit will be 20 mL. The minimum accepted volume (in the event of tough venipuncture attempts or difficulty obtaining the blood) will be 5 mL. The maximum amount that can be drawn in a 6-week period will be 100 mL (whole blood 6-week maximum).~Sample Collection:~10 mL EDTA Vial (Box 1; Frozen)~o Whole blood will be collected into 1 x 10 ml EDTA tube (no in-home/laboratory processing), shipped frozen (on dry ice) FedEx priority overnight (by 10:30 am) to Labcorp after each collection in box 1.~10 mL EDTA Vial (Box 2; Ambient)~Whole blood will be collected into 1 x 10 ml EDTA tube (no in-home/laboratory processing), shipped ambient FedEx priority overnight (by 10:30 am) to Labcorp after each collection in box 2."
45649312|NCT04901117|Drug|Vonoprazan fumarate|Use according to the drug combination options selected by each center.
45649313|NCT05121571|Procedure|HAIC|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
45649314|NCT05121571|Drug|Sorafenib|sorafenib 400mg bid
45649315|NCT03051269|Drug|Calcium chloride|Tumour site is injected with a solution of 9 mg/ml calcium chloride and afterwards the tumour site is given electroporation to facilitate calcium to enter the cell cytosol.
45649316|NCT03051269|Device|Electroporation|"Performed by single use electrodes attaches to a device called Cliniporator provided from IGEA, ITALY."
45923912|NCT00039208|Drug|leucovorin calcium|
45923913|NCT00039208|Drug|oxaliplatin|
45923914|NCT00017121|Biological|sargramostim|
45923915|NCT00039286|Procedure|positron emission tomography|
45923916|NCT00039286|Procedure|radionuclide imaging|
45923917|NCT00039286|Radiation|fludeoxyglucose F 18|
45923918|NCT00039325|Biological|dendritic cell-MART-1 peptide vaccine|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^6 (for arm A) or 10^7 (for arms B-E). Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
45923919|NCT00039364|Drug|imatinib mesylate|
45923920|NCT00039403|Drug|7-hydroxystaurosporine|Given IV
45923921|NCT00039403|Drug|gemcitabine hydrochloride|Given IV
45923922|NCT00039403|Other|pharmacological study|Correlative studies
45649317|NCT05088733|Drug|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
45796631|NCT05772442|Diagnostic Test|Extra blood samples (5-10 mL) drawn|Extra blood samples will be sent for metabolomics analysis.
45796632|NCT05770830|Device|Esophageal temperature|Temperature data measured by esophageal temperature probe (disposable probe, Ace-medical, Seoul, Korea)
45796633|NCT05770830|Device|Skin core temperature|Temperature data measured by skin core temperature device measured by 3M™ Bair Hugger™
45923923|NCT00039403|Other|laboratory biomarker analysis|Correlative studies
45923924|NCT00039442|Drug|Capecitabine|Given orally
45923925|NCT00039442|Other|Laboratory Biomarker Analysis|Correlative studies
45923926|NCT00039481|Biological|oblimersen sodium|Given IV
45923927|NCT00039481|Drug|dexrazoxane hydrochloride|Given IV
45923928|NCT00039481|Drug|doxorubicin hydrochloride|Given IV
45923929|NCT00039481|Drug|cyclophosphamide|Given IV
45923930|NCT00039481|Biological|filgrastim|Given SC
45923931|NCT00039481|Other|laboratory biomarker analysis|Correlative studies
45923932|NCT00039481|Other|pharmacological study|Correlative studies
45923933|NCT00001322|Drug|Leuprolide Acetate 3.75|Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly
45923934|NCT00001322|Drug|Estradiol|Transdermal Estradiol, 100mcg/day by skin patch
45923935|NCT00001322|Drug|Progesterone|Progesterone suppository, 200mg vaginally twice/day
45923936|NCT00001322|Drug|Placebo suppository|Placebo suppository twice daily
45923937|NCT00001322|Drug|Placebo patch|Placebo by skin patch
45923938|NCT00039520|Drug|docetaxel|
45923939|NCT00039520|Drug|sulindac|
45923940|NCT00039559|Other|Early detection|CA125 is measured in blood and the longitudinal results interpreted with a statistical algorithm to determine if there has been a significant increase from baseline.
45923941|NCT04731961|Procedure|Standard of care (15 Botox injections)|The controls will be given the standard of care of 15 Botox injections.
45649318|NCT05088733|Other|Routine medical care|Routine medical care
45649319|NCT04924777|Other|Brisk Walk|1-Brisk walk for 30 minutes 2-5 days a week 3-3months
45649320|NCT04924777|Other|Strength training|1-Strength Training Exercises for 30 minutes. 2-5 days a week 3-3 months
45649321|NCT04924777|Other|Aerobic Exercises|1-Aerobic exercises for 30 minutes 2-5 Days a week 3-3months
45649322|NCT04861285|Device|RACESTYPTINE Solution with cord|The dentist inserts a non-medicated gingival retraction cord into the sulcus and then impregnates the cord in situ with a few drops of RACESTYPTINE Solution. The impregnated cord is left in place a few minutes and then removed. The gingival sulcus is washed and gently air-dried before taking impression.
45649323|NCT04861285|Device|RACEGEL with cord|The dentist applies a sufficient amount of RACEGEL directly into the sulcus, following the contour of the prepared tooth, and then inserts a non-medicated gingival retraction cord into the sulcus. The impregnated cord is left in place a few minutes and then removed. The sulcus is washed and gently air-dried before taking impression.
45649324|NCT04861285|Device|RACEGEL without cord|The dentist applies a sufficient amount of RACEGEL directly into the sulcus, following the contour of the prepared tooth. The gel is left in place a few minutes and then removed. The sulcus is washed and gently air-dried before taking impression.
45649325|NCT05115331|Radiation|Experimental Radiation Dose|16 Gy in 2 fractions
45796634|NCT05769764|Other|Archival tissue specimen and immunohistochemistry staining|This is a non-interventional study and no intervention will be administered.
45923942|NCT04731961|Procedure|Experimental Arm (5 Botox injections)|5 Botox injections will be given, with each injection containing three times the amount of Botox than each of the 15 injections given in the standard of care arm.
45923943|NCT00039754|Drug|Holmium-166-DOTMP|
45923944|NCT00001328|Drug|Cytovene (Ganciclovir Sodium)|
45923945|NCT00001328|Device|G1TKSVNa.53 Producer Cell Line|
45923946|NCT00017160|Drug|doxorubicin|
45923947|NCT00017160|Drug|filgrastim|
45923948|NCT00017160|Drug|ifosfamide|
45923949|NCT00017160|Procedure|biological response modifier therapy|
45923950|NCT00017160|Procedure|brachytherapy|
45923951|NCT00017160|Procedure|chemotherapy|
45923952|NCT00017160|Procedure|colony-stimulating factor therapy|
45923953|NCT00017160|Procedure|conventional surgery|
45923954|NCT00017160|Procedure|cytokine therapy|
45923955|NCT00017160|Procedure|intraoperative radiotherapy|
45923956|NCT00017160|Procedure|radiation therapy|
45923957|NCT00017160|Procedure|surgery|
45923958|NCT00039793|Procedure|Moderate-intensity and low-intensity bodywork therapy|
45923959|NCT00039832|Drug|Abciximab (ReoPro) and Reteplase (Retavase)|
45923960|NCT00039910|Drug|(PN-152,243)/ PN-196,444|
45923961|NCT00039988|Drug|Glatiramer acetate|20 mg administered subcutaneously daily
45923962|NCT00039988|Drug|Albuterol|2 mg or 4 mg oral capsules taken daily
45923963|NCT00039988|Drug|Albuterol placebo|Oral placebo capsules will be taken daily
45923964|NCT00040027|Drug|thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a|
45923965|NCT00040027|Drug|placebo + PEGinterferon alfa-2a|
45923966|NCT00001343|Drug|Humatrope|
45923967|NCT00001343|Drug|Oxandrolone|
45923968|NCT00040066|Procedure|Cocaine (IV)|
45923969|NCT00040105|Drug|Zarnestra (R115777)|"Starting Dose:~300 mg by mouth (PO) Twice daily"
45923970|NCT00040105|Drug|Gleevec (Imatinib mesylate)|"Starting Dose:~300 mg By Mouth (PO) daily"
45923971|NCT04734249|Drug|Surufatinib(HMPL-012)|"Cohort 1:Surufatinib(250mg ,qd,po)+mFOLFOX6/FOLFIRI,14 days for a cycle.The curative effect was evaluated every 4 cycles.~Cohort 2:Surufatinib(250mg ,qd,po)+FOLFOXIRI,14 days for a cycle.The curative effect was evaluated every 4 cycles.~if the first-line chemotherapy was used FoLFOX ,the second-line is FOLFIRI,or the first-line chemotherapy was used FOLFIRI ,the second-line is FoLFOX.~Second-line Surufatinib Combined With Chemotherapy in Advanced CRC."
45923972|NCT00040144|Drug|ACH126, 433|
45923973|NCT00040183|Drug|Tarceva (erlotinib HCl, OSI-774)|
45923974|NCT04734171|Behavioral|Digital social activity video intervention|A 150 seconds video aimed at encouraging the use of a digital device (i.e. not in person contact) to meet with friends during the COVID-19 pandemic. Two friends meet via zoom instead of in person and share their experiencing supporting each other.
45923975|NCT04734171|Behavioral|Informational sheet|An informational sheet to learn about the COVID-19 outbreak (standard).
45923976|NCT04734171|Behavioral|Stigma awareness video intervention|A video aimed at sensitizing participants to COVID-19 related stigma. A COVID-19 + individual share their experience.
45796635|NCT05765370|Procedure|Achieving a Target LDL-C level of 25mg/dL≤ LDL-C<70mg/dL|"Investigators initiated or adjusted lipid-lowering agents (drug and dosage) to achieve the target of 25mg/dL≤ LDL-C<70mg/dL. The protocol encouraged, but did not mandate, the initiation of moderate-intensity statin therapy for secondary prevention with the evaluation of the potential for ASCVD risk reduction, adverse effects, and drug-drug interactions, as well as patient frailty and patient preferences. Statin monotherapy or in combination with ezetimibe, PCSK9 inhibitor or other drugs were adjusted on the basis of LDL-C levels.~At each follow-up visit, the investigators should verify whether the target LDL-C has been obtained. If the target level of LDL cholesterol was achieved, it is reasonable to continue to monitor adherence to lifestyle modiﬁcations, medication, and ongoing LDL-C response to therapy. If the target level of LDL cholesterol was not achieved, adjustment of the type and dose regimen of statin, or the additional of a nonstatin agent should be considered."
45796636|NCT05765370|Procedure|Achieving a Target LDL-C level of 70mg/dL≤ LDL-C<100mg/dL|"Investigators initiated or adjusted lipid-lowering agents (drug and dosage) to achieve the target of 70mg/dL≤ LDL-C<100mg/dL. The protocol encouraged, but did not mandate, the initiation of moderate-intensity statin therapy for secondary prevention with the evaluation of the potential for ASCVD risk reduction, adverse effects, and drug-drug interactions, as well as patient frailty and patient preferences. Statin monotherapy or in combination with ezetimibe, PCSK9 inhibitor or other drugs were adjusted on the basis of LDL-C levels.~At each follow-up visit, the investigators should verify whether the target LDL-C has been obtained. If the target level of LDL cholesterol was achieved, it is reasonable to continue to monitor adherence to lifestyle modiﬁcations, medication, and ongoing LDL-C response to therapy. If the target level of LDL cholesterol was not achieved, adjustment of the type and dose regimen of statin, or the additional of a nonstatin agent should be considered."
45796637|NCT05763043|Drug|Ferric derisomaltose|Participants between the gestational ages of 14 to 42 weeks with iron deficiency will receive IV Ferric derisomaltose at a routine prenatal visit.
45796638|NCT05756946|Procedure|periodontal dressing (coe-pak)|Guided tissue regeneration and periodontal dressing
45796639|NCT05756946|Procedure|Guided Tissue Regeneration|Regeneration of lost periodontal tissues
45796640|NCT05753319|Other|Physiotherapy in the emergency department after a fall|Realization of a physiotherapy assessment.
45450222|NCT02179762|Behavioral|Exercise and body composition test|Height will be measured to the nearest 0.1 cm and weight will be measured to the nearest 0.1 kg. Waist and hip circumference will be measured to the nearest 1/8 inch. Whole body dual-energy X-ray absorptiometry scans will be conducted at baseline and end of treatment to quantify total body fat.
45923977|NCT00040261|Drug|Memantine HCL|
45923978|NCT00040300|Drug|Racivir|
45923979|NCT04734093|Diagnostic Test|Evaluation of sonographic signs of gouty arthritis|the EULAR scanning protocol for the knee and 1st MTP will be considered [2]. Further, scanning of the double contour sign over the femur condyles anteriorly and posteriorly in sagittal planes will be assessed. Examination of erosions, tophus, double contour, effusion, and echogenic foci will be recorded.
45450223|NCT02179840|Procedure|Mechanical ventilation adjustment|Mechanical ventilation adjustment and study procedure: This is a validation study of the CHS method in assessing cerebral microvascular hemodynamic changes. Cyclical physiological events such as respiration are essential in CHS methodology. The previous study shows that the robust measurement of the CHS method occurs at a respiratory rate of about 4-10 breaths per minute. Therefore, we propose the following respiration adjustment in this study with the consideration that CO2 is a powerful regulator of cerebral blood flow. Blood gas analysis will be performed during the 1st and 2nd rounds of ventilation adjustment.
45450224|NCT02182258|Drug|BIBF 1120 soft gelatine capsule|
45450225|NCT02182258|Drug|BIBF 1120 intravenous solution|
45796641|NCT05751044|Drug|Dasatinib|Oral
45450226|NCT02182258|Drug|Placebo ampoule|
45450227|NCT02182336|Drug|BI 201335 NA|"480 mg BI 201335 NA in the morning, 240 mg BI 201335 NA in the evening of day 10~240 mg BI 201335 NA bid from day 11 to 23"
45450228|NCT02182336|Drug|Caffeine|days 1, 10 and 19
45796642|NCT05751044|Drug|Venetoclax|oral
45796643|NCT05751044|Drug|Dexamethasone|oral/intervenous
45796644|NCT05751044|Drug|Cyclophosphamide|intravenous
45450229|NCT02182336|Drug|Warfarin sodium|days 1, 10 and 19
45923980|NCT00040339|Procedure|hypothermia (body temperature lowered to 33°C or 91.4°F)|
45923981|NCT00040378|Drug|alphatocopherol|400 IU daily
45450230|NCT02182336|Drug|Vitamin K|days 1, 10 and 19
45450231|NCT02182336|Drug|Omeprazole|days 1, 10 and 19
45450232|NCT02182336|Drug|Dextromethorphan hydrobromide|days 1, 10 and 19
45450233|NCT02182336|Drug|Midazolam HCl solution|Days 3 and 21
45450234|NCT02182336|Drug|Midazolam HCl oral syrup|days 1, 10 and 19
45450235|NCT02182336|Drug|Digoxin|Days 2 and 20
45450236|NCT02176954|Device|Test A|Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
45796645|NCT05751044|Drug|Cytarabine|intravenous
45796646|NCT05751044|Drug|intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
45923982|NCT00040378|Drug|Selenium|200mcg daily
45923983|NCT00040378|Drug|Placebo replacement for vitamin E|1 placebo pill daily
45923984|NCT00040378|Drug|Placebo replacement for Selenium|1 placebo pill daily
45923985|NCT00017199|Drug|bortezomib|
45923986|NCT00040417|Drug|FLUDARABINE|
45923987|NCT00040417|Drug|CAMPATH-IH|
45923988|NCT00040417|Procedure|Total Body Irradiation|
45923989|NCT00040417|Drug|FK506|
45923990|NCT00040417|Drug|G-SCF (Granulocyte-colony stimulating factor)|
45923991|NCT00040456|Drug|Mg Pidolate|Mag 2 will be used (magnesium pidolate, a granular powder, containing 0.184 g of Mg/packet, equal to 7.6 mmol or 15.2 meq Mg), since this preparation has less side effects such as diarrhea than other Mg preparations. The study medication will be a liquid containing 0.6 meq Mg pidolate/kg body weight per day, divided into 2 daily doses. The Mg pidolate (45 g) will be distributed as a pre-mixed powder containing Koolaid Tropical Punch powder (9 gm), and sucrose (67 gm).
45796647|NCT05744921|Drug|Pozelimab|Administered subcutaneously (SC) every 4 weeks (Q4W)
45923992|NCT00040456|Drug|Placebo|The study medication will be a liquid containing an equivalent amount of placebo to the study medication, divided into 2 daily doses.The placebo will have the same amount of sucrose and Tropical Punch powder as the study drug, MG Pidolate, as well as 45 g of lactose. Subjects will continue with the same assignment for 6 months and then switch to the other arm (after a 2-month wash-out period).
45923993|NCT00040495|Drug|Pantoprazole|
45923994|NCT00040534|Drug|Farnesyl Protein Transferase Inhibitor|
45923995|NCT04734132|Dietary Supplement|Moringa|Leaves of Moringa oleifera from an organic Iberian peninsula cultivar. A single lot was prepared from the same crop. Leaves were dried and ground and encapsulated as a organic dietary supplement. No other changes in diet or physical activity were included although a general healthy lifestyle pattern was recommended.
45796648|NCT05744921|Drug|Cemdisiran|Administered SC Q4W
45796649|NCT05741125|Behavioral|DSME + ASE intervention (Centering Appetite)|The intervention will enable participants to relearn their stomach's hunger and fullness signals and monitor their appetite. Participants will also learn strategies for glucose monitoring and carbohydrate management. Monthly booster sessions will be devoted to problem-solving, addressing barriers to emotion management, and self-monitoring type 2 diabetes mellitus symptoms. Participants will also receive weekly lessons with interactive activities delivered via a digital app.
45796650|NCT05736042|Device|Lens fragmentation|Lens fragmentation with the microinterventional microfilament loop device (miLOOP)
45923996|NCT04734132|Dietary Supplement|Placebo|Placebo capsules were indistinguishable from the experimental capsules in material and color (opaque white). Same number of capsules were consumed as in the experimental arm and no other changes in diet or physical activity were included although a general healthy lifestyle pattern was recommended.
45923997|NCT00040573|Drug|131I-TM-601|
45923998|NCT00040651|Drug|Fludarabine|
45923999|NCT00040651|Drug|Cyclophosphamide|
45924000|NCT00040651|Drug|Thymoglobulin|
45649326|NCT05115331|Radiation|Conventional Radiation Dose|8 Gy in a single fraction
45649327|NCT04832815|Behavioral|Equine Therapy|Aim 1: Six session equine interventions. Intervention will be provided one day per week for four weeks. During the first two weeks, each intervention day with consist of two sessions with a lunch break in between. Weeks four and five consist of one trail riding session per intervention day followed by lunch. Each session will be approximately 1.5 hours in length. Sessions 1-4 will occur at the USU Equine Education Center, and session 5-6 will occur on local trails. Optional transportation for participants will be provided from the VA to the intervention site.
45924001|NCT00040651|Procedure|Leukapheresis|
46071837|NCT05877755|Device|Cardiac MRI acquisition|All patients will have additional images collected during the magnetic resonance imaging (MRI) examination. These are high-resolution multi-contrast cardiac MRI sequences in gradient echo or in balanced steady state free precession with synchronization on the electrocardiogram. The acquisitions last between 1 minute and 10 minutes. This duration depends on the patient's heart rate and breathing rate. The imaging protocol will last approximately 50 minutes. MRI examinations will be performed on a 1.5 Tesla clinical system with specific cardiac imaging coils.
46071838|NCT05877742|Other|AA group|Participants will individually receive a 5-minute AA education delivered verbally at his/her respective clinic by a trained nursing student interventionist in addition to the usual scheduled follow-ups and activities at clinics.
46071839|NCT05877742|Other|Control group|To mimic the time and attention spent, the control group will individually receive a 5-minute seminar delivered by an RA.
45450237|NCT02176954|Device|Test B|Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
45649328|NCT04832815|Behavioral|Therapeutic Horsemanship Program|Aim 2: Therapeutic Horsemanship program utilizes the USU Pathways to Horsemanship model and covers levels of equestrian training from basic groundwork to more advanced riding techniques. Training occurs in a three or six-session format with once weekly sessions over three or six weeks. Mindfulness and mindful self-compassion training may be included.
45754383|NCT04141826|Dietary Supplement|Caseinate|500 mL solution of 25 gram casein ate per day during 4 weeks
45796651|NCT05727202|Diagnostic Test|The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel|A multiplex real-time PCR IVD test for the qualitative detection and identification of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus (RSV).
45924002|NCT00040651|Procedure|Self bone marrow transplant|
45924003|NCT00040690|Biological|filgrastim|
45924004|NCT00040690|Drug|cyclophosphamide|
45924005|NCT00040690|Drug|cytarabine|
45924006|NCT00040690|Drug|doxorubicin hydrochloride|
45924007|NCT00040690|Drug|etoposide|
45924008|NCT00040690|Drug|ifosfamide|
45924009|NCT00040690|Drug|leucovorin calcium|
45924010|NCT00040690|Drug|methotrexate|
45924011|NCT00040690|Drug|vincristine sulfate|
45924012|NCT00040690|Radiation|radiation therapy|
45924013|NCT00040729|Genetic|mutation analysis|
45924014|NCT00040768|Drug|bortezomib|Given IV
45924015|NCT00017238|Drug|KRN5500|Given IV
45924016|NCT00017238|Other|pharmacological study|Correlative studies
45924017|NCT00040885|Biological|infliximab|
45924018|NCT00040885|Drug|docetaxel|
45924019|NCT00040885|Other|placebo|
45924020|NCT00001421|Drug|methimazole|
45924021|NCT00017277|Biological|epoetin alfa|
45924022|NCT00017277|Radiation|radiation therapy|
45924023|NCT00041041|Drug|imatinib mesylate|Given PO
45924024|NCT00041041|Other|laboratory biomarker analysis|Correlative studies
45924025|NCT00041197|Drug|imatinib mesylate|Given orally (PO)
45924026|NCT00041197|Other|placebo|Given PO
45924027|NCT00041197|Other|laboratory biomarker analysis|Correlative studies
45649329|NCT04725955|Other|Enriched wheat bread|Either 50g of glucose dissolved in 250mL water or white wheat bread or wheat bread enriched with 5mg a-cyclodextrin or wheat bread enriched with a 5mg mixture of a-cyclodextrin and encapsulated hydroxytyrosol (per 50g of available carbohydrates).
45649330|NCT04674007|Other|3D analysis of landing task|Landing tasks (anticipated, unanticipated and cognitive dual task) are investigated with 3D analysis by using an opto-electronic system
45796652|NCT05709093|Drug|Lemzoparlimab+Azacitidine (AZA)|"Lemzoparlimab is administered by intravenous (IV) infusion once a week at a dose of 30 mg/kg in 28-day treatment cycles~Azacitidine (AZA): AZA is administered by subcutaneous injection once a day at a dose of 75 mg/m2 on D1 to D7 of each treatment cycle in 28-day treatment cycles."
45796653|NCT05709093|Drug|Azacitidine (AZA)|AZA is administered by subcutaneous injection once a day at a dose of 75 mg/m2 on D1 to D7 of each treatment cycle in 28-day treatment cycles.
45924028|NCT00001427|Drug|9-aminocamptothecin|
45924029|NCT00041236|Drug|exatecan mesylate|
45924030|NCT00017316|Drug|semaxanib|
45924031|NCT00017316|Drug|thalidomide|
45924032|NCT00041275|Drug|megestrol acetate|
45924033|NCT00017355|Biological|filgrastim|
45924034|NCT00017355|Biological|therapeutic autologous dendritic cells|
45924035|NCT00041353|Other|cytology specimen collection procedure|
45796654|NCT05704530|Other|Blood sample|Retrospective collection of leftover tissue from standard of care biopsies or resection specimens and prospective collection of additional blood samples for study-specific analyses at specific timepoints, at the same time as routine labs are foreseen. No additional venipunctures are expected.
45796655|NCT05701566|Device|virtual reality headset|use of virtual reality headset during colonoscopy as a substitute to sedation.
45796656|NCT05701566|Other|colonoscopy with standard sedation.|use of standard sedation during colonoscopy.
45924036|NCT00041353|Procedure|comparison of screening methods|
45924037|NCT00041353|Procedure|study of high risk factors|
45924038|NCT00397072|Drug|ZK 219477|
45649331|NCT05005585|Procedure|immediate implant|immediate implant placement with VST technique versus early implant placement with contour augmentation technique
45649332|NCT04646239|Diagnostic Test|Heterologous stimuli|In vitro exposure of peripheral blood mononuclear cells to heterologous stimuli
45796657|NCT05690646|Drug|Nirmatrelvir/ritonavir|nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days
45796658|NCT05690646|Drug|Ursodeoxycholic acid|ursodeoxycholic acid 15mg/kg/day bid for5 days
45649333|NCT04646239|Diagnostic Test|Neutralization assay|In vitro measurement of neutralizing antibody activity to wild-type SARS-CoV-2
45796659|NCT05690165|Behavioral|Walking Exercise|Heart rate controlled walking exercise
45796660|NCT05687708|Other|Non-Nutritive Sucking|NNS is stimulated by giving stimulus into the baby's mouth with the help of a finger wearing gloves.
45796661|NCT05672628|Device|Oculus VR|During the first visit, the Oculus headset will be placed on the stroke survivor's head and demonstrate how to use the headset. participant will be then allowed to play a game using the hand controllers for up to 30 minutes. Finally, a copy of exercises for their home rehabilitation program will be provided. During the next rehabilitation visits, a trained research assistant will guide the stroke survivor with using the gaming headset. The session will be stopped every 20 minutes to make sure that the stroke survivor is feeling well and to give them a break. The stroke survivor may stop the session at any time. This session will last for an hour.
45796662|NCT05668624|Other|Clean household energy|LPG stoves/fuel for cooking and solar electricity for lighting
45924039|NCT02972372|Procedure|CRT|"Drug: Capecitabine(Aibin) capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total~Other Names:~Aibin Drug: Oxaliplatin(Aiheng) Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.~Other Names:~Aiheng cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85. 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88.~Radiation: Radiotherapy concurrent radiotherapy：IMRT radiotherapy 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity"
45924040|NCT02972372|Procedure|surgery|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
45924041|NCT00397267|Drug|inhalation of corticosteroids|
45924042|NCT00397306|Device|Bioimpedance Analysis|
45924043|NCT00017394|Biological|bevacizumab|Given IV
45924044|NCT00017394|Drug|vinorelbine tartrate|Given IV
45924045|NCT00017394|Other|laboratory biomarker analysis|Correlative studies
45924046|NCT00041431|Drug|Hormone Replacement Therapy|
45924047|NCT00041509|Drug|SB-424323|500 mg, oral, BID for 28 days or 125 mg, oral, BID for 28 days
45924048|NCT00041509|Drug|Placebo|matching placebo, oral, BID for 28 days
45924049|NCT00001436|Drug|OncoLAR® (Registered Trademark)|
45924050|NCT00001436|Drug|tamoxifen|
45924051|NCT00041548|Drug|nitric oxide for inhalation|given at 20 ppm for 1 hour then weaned off over 4 hours
45924052|NCT00041548|Drug|Oxygen|given at 20 ppm for one hour, then weaned off over four hours
45924053|NCT00041587|Drug|IL13-PE38QQR|
45924054|NCT00041587|Procedure|targeted fusion protein therapy|
45924055|NCT00041587|Procedure|surgery|
45924056|NCT00017433|Drug|arsenic trioxide|
45924057|NCT00041626|Genetic|INGN 201|
45924058|NCT00001445|Biological|HIV-1 Immunogen|
45924059|NCT00041665|Drug|Recombinant Human Keratinocyte Growth Factor|
45924060|NCT00041704|Drug|Anidulafungin, VER002|
45924061|NCT00017472|Biological|apolizumab|Given IV
45924062|NCT00017472|Other|laboratory biomarker analysis|Correlative studies
45924063|NCT00017472|Other|pharmacological study|Correlative studies
45924064|NCT00041743|Behavioral|Group Cognitive Behavioral Therapy|
45924065|NCT00041782|Drug|Dalteparin (Fragmin)|200 IU/kg subcutaneously daily (based on actual body weight with a maximum dose of 18,000 IU).
45924066|NCT00041821|Procedure|Nasal irritation thresholds and irritant provocation|
45796663|NCT05658913|Drug|AV-1451|This is a cross-sectional study using the radiotracer AV-1451 to determine the relationship of tau pathology to other biomarker data of MPC participants.
45924067|NCT00041860|Procedure|Controlled Exposure to Environmental Contaminant|
45924068|NCT00017511|Drug|cevimeline hydrochloride|
45649334|NCT04934527|Drug|Cytotect|"The inclusion visit is conducted by the investigating nephrologist and the patient will receive their first infusion of anti-CMV Ig.~Patients with positive CMV serology at transplantation will receive 6 infusions of 100 units per kilogram of body weight every 15 days with the first injection on the day of transplantation, i.e. at visits D0, S2, S4, S6, S8 and S10. CMV infection will be monitored by quantitative PCR on whole blood every week during 3 months and then every 2 weeks until 4 months and then at months 5 and 6, 9 and 12."
45796664|NCT05658627|Other|active release technique|Hamstring active release technique-
45796665|NCT05658627|Other|conventional therapy|ultrasound therapy - stretching Exercise - Strengthening Exercise -
45796666|NCT05648201|Drug|Doravirine 100Mg Tab|1 single dose of 100mg taken orally
45796667|NCT05648201|Drug|Raltegravir 600Mg Tab|1 single dose of 1200mg taken orally
45796668|NCT05648201|Drug|Biktarvy 50/200/25 Tab|1 single dose of 50/200/25 taken orally
45924069|NCT00041899|Drug|CDB-2914|
45924070|NCT00041899|Drug|COB-2914|
45924071|NCT00041977|Drug|doxycycline hyclate 20 mg twice daily|
45924072|NCT00042016|Drug|decitabine (5-aza-2'deoxycytidine)|
45924073|NCT00042055|Drug|CP-461|
45924074|NCT00042094|Biological|Cell-Cultured Smallpox Vaccine compared to Dryvax®|
45924075|NCT00017550|Biological|anti-thymocyte globulin|
45924076|NCT00001457|Drug|Lamivudine|
45924077|NCT00042172|Drug|Donepezil|
45924078|NCT00042172|Drug|Ginkgo Biloba Extract|
45924079|NCT00042211|Behavioral|Problem Solving Treatment|Brief Cognitive Behavioral Therapy
45924080|NCT00042211|Behavioral|Control|No treatment control
45924081|NCT00042250|Drug|Chemotherapy for hematologic malignancy|
45924082|NCT00017589|Biological|oblimersen sodium|
45924083|NCT00017589|Drug|gemtuzumab ozogamicin|
45924084|NCT00001475|Drug|IL-2 plus Anti-TNF or Thalidomide|
45924085|NCT00042328|Drug|Valacyclovir|
45649335|NCT05288647|Procedure|TMJ injection|four sodium hyaluronate injections in superior TMJ space
45649336|NCT05287009|Procedure|ILM nonpeeling|ILM is not peeled after ERM removal
45649337|NCT05287009|Procedure|ILM peeling|ILM is peeled after ERM removal
45649338|NCT04584619|Device|Spine fusion surgery with Clariance Idys TLIF 3DTi|Posterior fusion of the lumbar spine with Clariance Idys TLIF 3DTi interbody fusion device used in conjunction with a posterior fixation system (pedicle screws and rod).
45649339|NCT04576663|Drug|Normal saline|Normal saline infusion simultaneous with subarachnoid block
45649340|NCT04576663|Drug|Phenylephrine|Different infusion dose of phenylephrine simultaneous with subarachnoid block
45649341|NCT04789369|Behavioral|Questionnaires|Assessing the behavioral metrics (quality of life, functionality and fear of movement) with appropriate measurement tools
45796669|NCT05641493|Combination Product|HLX208+HLX10|HLX208 is a BRAF V600E inhibitor ,and HLX10 is an anti-PD-1 monoclonal antibody.
45796670|NCT05635448|Behavioral|Better Together Physician Coaching Program|thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies. BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
45796671|NCT05635448|Behavioral|No intervention - waitlist control|No intervention - waitlist control
45796672|NCT05627635|Biological|Balstilimab|Given IV
45796673|NCT05627635|Biological|Bevacizumab|Given IV
45796674|NCT05627635|Procedure|Biospecimen Collection|Undergo a blood sample collection
45796675|NCT05627635|Biological|Botensilimab|Given IV
45924086|NCT00042367|Drug|Induction therapy (Regimen 1, Course 1, Cycle A1|"2-8 hrs: Cisplatin 3.5 mg/kg + mannitol 0.4 g/kg in D5 NS (1000 ml/m2) over 6 hrs at approximately 167ml/m2/hr. 8-12 hrs: D5 NS (665 ml/m2) + KCl (2 mEq/100 ml) +MgSO4 (0.5 mEq/100 ml) at approximately 167ml/m2/hr.~12-24 hrs: D5 NS + KCl (2 mEq/100 ml) + MgSO4 (0.5mEq/100 ml) at approximately 65 ml/m2/hr.~Days 2,3: 0 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg of IVF over 15 min 15 min: Cyclophosphamide 30 mg/kg IV over 30 min 45 min: Post-chemotherapy hydration - D5 1/2 NS + KCl(1 mEq/100 ml) at approximately 130 ml/m2/hr for at least 24 hours.~3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 4 G-CSF 5 µg/kg subcutaneously, daily until ANC ≥ 2000 on two consecutive days, post ANC nadir.~Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg)"
45924087|NCT00042367|Drug|Regimen 1, Course 1, Cycle A2 (Days 22 - 42)|Drugs and doses are same as in Cycle A1. Cycle A2 begins following recovery from Cycle A1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modifications
45924088|NCT00042367|Drug|Cycle B|"Days 43 - 63) Etoposide, 1.7 mg/kg p.o. qd x 21 days. The dose will be diluted immediately prior to administration in juice flavored syrup to a final concentration of 0.4 Each dose should be aken 1 hour before or 2 hours after a meal.~Cycle B begins following recovery from Cycle A2; however, it begin no sooner than 21 days after the start of Cycle A2.~Monitor weekly CBC/diff/plt. If ANC < 500/mm3 or platelets (unsupported) < 50,000/mm3 then discontinue etoposide. A 25% reduction should be made for the next cycle of oral etoposide.~Interim Response Evaluation (Days 64 - 70) Interim Response Evaluation should be performed the week following the completion of Course 1."
45924089|NCT00042367|Drug|Regimen 1, Course 2|6.3.3 Regimen 1, Course 2 Repeat systemic therapy as per Course 1 (Cycle A1, Cycle A2, and Cycle B) in patients with SD or better at the interim response evaluation (see Figure 2 for IT mafosfamide guidelines). Course 2 should not begin any sooner than 7 days after the completion of Course 1.
45924090|NCT00042367|Drug|Intrathecal Mafosfamide|Regimen 1, Course 1 Mafosfamide, 14 mg, is given two times/week during Cycle A1 and Cycle A2 of Course 1, for 12 total doses during days 1-41. The first dose of Cycles A1 and A2 should be given, if possible, on the same day as the first I.V. cyclophosphamide dose and the second dose 3 to 4 days later. The assigned dose is given one time/week during Cycle B, Course 1 for 3 total doses during days 43 - 63.
45924091|NCT00042367|Drug|Regimen 1 Course 2, IT mafosfamide|"Regimen 1, Course 2 The assigned dose is administered once with IV cyclophosphamide during each of Cycle A1 and Cycle A2, and day 1 of Cycle B for a total of 3 doses during Course 2.~Patients with an initially abnormal flow study, who show no evidence of obstructive hydrocephalus or compartmentalization on the repeat study, may begin intrathecal mafosfamide administration with the initiation of Regimen 1, Course 2. The frequency of intrathecal mafosfamide administration, for such patients, will be as outlined in Regimen 1, Course~1."
46071840|NCT05877729|Other|Standard of Care|The SOC arm will include the current care delivery model: regularly scheduled visits with a healthcare provider and lab testing every 3-6 months or more/less frequently depending on the individual's HIV health outcomes (e.g., VL suppression). At each assessment, the investigators will review 149 SOC participant responses to examine acute need for referral for medical, psychological, or substance use services. In between assessments, the investigators will also do monthly check-ins to improve retention and check contact information.
45796676|NCT05627635|Procedure|Computed Tomography|Undergo a CT scan
46071841|NCT05877729|Behavioral|Video-counseling+app|"The intervention tailors the telehealth counseling according to the individual's needs. Tailoring occurs based on the participant's baseline MH, SU, and HIV knowledge/outcomes and assessment responses inform the sessions on these topics. Participants choose from a list identified in the menu sessions: HIV care, MH, SU, lifestyle, health, social support, family of origin, romantic and sexual relationships, self-identity and disclosure, subsistence needs, education and vocation, and a wildcard session.~WYZ contains 3 main features: My Health, My Team, and My Community. Tailoring is achieved based on the individual's needs at a given time (e.g., My Community may be used more if social isolation is a barrier)."
46071842|NCT05877703|Other|close kinetic chain exercises|CKC include mini squats, leg press, step-up and step-down, wall slides etc along with their respective modality as quadriceps drill and static cycle ergometer respectively on grade-3 knee OA patients
45649342|NCT04491409|Other|Best Practice|Undergo standard of care
46071843|NCT05877703|Other|open kinetic chain exercises|The distal segment of the body components can move freely during OKC exercise.OKC exercises include quadriceps setting, knee extension in sitting and straight leg raise in lying position; it also includes quadriceps drills as part of OKC exercises
46071844|NCT05877690|Drug|Bupivacaine 0.5% Injectable Solution|Patient will be received the drug intrathecal
46071845|NCT05877690|Drug|Prilocaine Hydrochloride 2% Injection|Patient will be received the drug intrathecal
46071846|NCT05878509|Other|conducting questionnaires|The patients were administered TSK, Pain Catastrophizing Scale (PCS), Beck Anxiety Inventory (BAI) by face to face interview technique.
45649343|NCT04491409|Other|Medical Chart Review|Medical charts reviewed
46071847|NCT05878509|Other|assesment of the severity and pain|The Modified Hand Injury Scoring System (MHISS) to determine the severity of the injury, and Visual Analog Scale (VAS) to evaluate perceived pain levels were used.
46071848|NCT05877677|Dietary Supplement|Placebo drink|consume 1 bottle per day
46071849|NCT05877677|Dietary Supplement|Polygonatum kingianum extract drink|consume 1 bottle per day
46071850|NCT05877638|Device|SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel|(FDA) 510(k) cleared wound care medical devices formulated with a novel biocompatible chitosan derivative, poly (acetyl, arginyl) glucosamine. SynePure is optimized for the cleansing and debridement of wounds and thermal injuries, and Catasyn serves as a protective gel dressing.
45649344|NCT04905199|Procedure|Temporary transvenous cardiac pacing|Transvenous temporary pacemaker insertion by modified IC-ECG monitoring.
45649345|NCT04763005|Behavioral|HIIT exercise intervention|The exercise intervention will be eight weeks of high-intensity interval training (HIIT) started by one warm-up week with an intensity of 75% maximum heart rate (HRmax). In the following seven weeks, the participants will perform a HIIT based on the following protocol and with a total duration of 45 minutes per session: warm-up for 10 minutes at 60-70% HRmax followed by a high-intensity interval consisting of 4x4 minutes at 80-90% HRmax with 3 minutes of active recovery at 60-70% HRmax and a 10 minutes cool-down at 60-70% HRmax. HR will be monitored during training by Polar® H7 heart rate sensors combined with Polar® M400 watches.
45649346|NCT04763005|Behavioral|Physical activity recommendations|The control group will get physical activity recommendations based on actual guidelines from the European Association of Preventive Cardiology.
45649347|NCT05281549|Drug|Alteplase|Alteplase 0.9mg/kg are being used.
45649348|NCT05281549|Drug|Tenecteplase|Tenecteplase 0.25mg/kg are being used.
45649349|NCT05281549|Drug|Tenecteplase|Tenecteplase 0.4mg/kg are being used.
45649350|NCT04494295|Device|Aurora Surgiscope System|MIS evacuation of hematoma using the Aurora Surgiscope System
45796677|NCT05627635|Drug|Fluorouracil|Given IV
45796678|NCT05627635|Drug|Leucovorin Calcium|Given IV
45796679|NCT05627635|Procedure|Magnetic Resonance Imaging|Undergo MRI
46071851|NCT05877638|Drug|SILVADENE Cream 1% (silver sulfadiazine)|SILVADENE Cream 1% (silver sulfadiazine) is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.
45649351|NCT05276479|Other|Anonymous online survey on dietary habits and mental health|Assessment of regular feeding behavior and mental health
45649352|NCT04400695|Drug|RC48-ADC|RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
45796680|NCT05627635|Drug|Oxaliplatin|Given IV
45796681|NCT05627635|Procedure|Positron Emission Tomography|Undergo a PET scan
45796682|NCT05627635|Procedure|X-Ray Imaging|Undergo an x-ray
45796683|NCT05626712|Biological|CELZ-201 Administration|Participants in this group will receive a single dose of CELZ-201, in addition to standard of care for Type 1 Diabetes treatment. Perinatal tissue derived cells will be administered at a dose of 1x10^6 cells/kg via an intra-arterial infusion into the dorsal pancreatic artery.
45796684|NCT05626712|Other|Control Group|Enhanced standard of care for Type 1 Diabetes treatment only.
45796685|NCT05610644|Other|isocaloric, isonitrogenous meals|Participants will eat prepared study meals for 3 days that have either the RDA of protein per day or twice the RDA of protein per day.
45924092|NCT00042367|Drug|Regimen 2, Course 1|"Cycle C1 (Days 1 - 21) Day 1: Prehydrate with D5W 1/2 NS + KCl 2 mEq/100 ml) at 2 times the hourly maintenance rate until the urine specific gravity is < 1.012.~0 hrs: Mesna 6 mg/kg IV over 15 min. Dilute in 0.65 ml/kg IVF. 15 min: Vincristine 0.05 mg/kg IV push (Day 1 only)(max dose = 2 mg) 20 min: Cyclophosphamide 30 mg/kg IV over 30 min. 50 min: Post-chemotherapy hydration - D5 1/2 NS + KCl~(1 mEq/100 ml) at twice the hourly maintenance rate for at least 24 hours. 3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 2: Repeat day 1, but omit vincristine. Day 3: G-CSF 5 µg/kg/day subcutaneously, daily, until ANC is > 2000 on two consecutive days, post ANC nadir."
45924093|NCT00042367|Drug|Regimen 2, Course, 1, Cycle C1|"Cycle C1, Weeks 2 and 3 Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Cycle C2 (Days 22-42) Drugs and doses are same as in Cycle C1. Cycle C2 begins following recovery from Cycle C1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modificationsCycle D (Days 43 - 63) Etoposide 1.7 mg/kg, po qd x 21 days The dose will be diluted immediately prior to administration in juice or flavored syrup as per section 3.4.3. Each dose should be taken 1 hour before or 2 hours after a meal.~Cycle D should begin following recovery from Cycle C2; however, it should begin no sooner than 21 days after the start of Cycle C2."
45924094|NCT00042367|Drug|Regimen 2, Course 2|Repeat Course 1 (Cycle C1, Cycle C2, and Cycle D) in patients with SD or better at the interim response evaluation. Chemotherapy should begin as soon as the patient has recovered from the toxicities of oral etoposide in cycle D, course 1. However, it should not begin any sooner than 7 days after the completion of Course 1.
45924095|NCT00042367|Radiation|radiation therapy|"Conformal Irradiation Patients who are initially M0 with a CR, PR, or SD to Regimen 1 induction chemotherapy (with or without second surgery) will receive local irradiation using conformal techniques. Treatment will commence within 2 weeks of completing Regimen 1 or second surgery. Treatment planning and technique may involve 3D conformal,IMRT, or proton planning and delivery, provided the guidelines regarding volume, dose,and normal tissue restrictions are honored.~8.3.1 Fraction Size 180 cGy fractions will be used for all target volumes. 8.3.2 Fractionation Conventional fractionation will be used. Treatments will be given once daily, 5 days/week except for necessary interruptions secondary to medical or administrative reasons."
45924096|NCT02970643|Drug|Olanzapine|Moderate risk chemotherapy induced nausea group in all cancer. D1 Olanzapine 10mg PO D2-3 Olanzapine 10mg PO
45924097|NCT02970643|Drug|Palonosetron|Moderate risk chemotherapy induced nausea group in all cancer. D1 Palonosetron 0.25mg IV
45924098|NCT00017628|Drug|cyclophosphamide|
45924099|NCT00017628|Drug|filgrastim|
45924100|NCT00017628|Drug|methylprednisolone|
45649353|NCT04400695|Drug|Paclitaxel Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
45796686|NCT05607004|Drug|Z-endoxifen|(Z)-endoxifen capsules. Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).
45924101|NCT00017628|Procedure|Autologous Stem Cell Transplantation|
45924102|NCT00042484|Procedure|Community-level intervention & policy change|
45924103|NCT00017706|Behavioral|physician-delivered weight control|
45924104|NCT00042562|Drug|duloxetine|
45924105|NCT00001487|Drug|Dehydroepiandrosterone|
45924106|NCT00042601|Drug|Pramlintide acetate|Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
45924107|NCT00042601|Drug|Placebo|placebo injection will be supplied in 5-mL multidose glass vials with a rubber stopper
45924108|NCT00042679|Drug|Gemcitabine|
45924109|NCT00042679|Drug|Carboplatin|
45924110|NCT00042679|Drug|LY900003|
45924111|NCT00042718|Drug|levofloxacin, azithromycin, amoxicillin/clavulanate|
45796687|NCT05607004|Drug|exemestane|exemestane tablets 25 mg
45796688|NCT05607004|Drug|goserelin|goserelin 3.6 mg subcutaneous implant
45924112|NCT00042796|Drug|decitabine|Given IV
45924113|NCT00042796|Other|pharmacological study|Correlative studies
45796689|NCT05604300|Dietary Supplement|Vitamin E incorporated oat supplement|A twice daily supplementation of Vitamin E incorporated oat for 12 weeks
45796690|NCT05604300|Dietary Supplement|Oat supplement|A twice daily supplementation of oat for 12 weeks
45796691|NCT05599932|Drug|Siremadlin|HDM201 capsule
45924114|NCT00042796|Other|laboratory biomarker analysis|Correlative studies
45924115|NCT00042835|Drug|cisplatin|Given IV
45924116|NCT00042835|Drug|etoposide|Given IV
45924117|NCT00042835|Drug|erlotinib hydrochloride|Given orally
45924118|NCT00042835|Radiation|radiation therapy|Undergo radiotherapy
45924119|NCT00042835|Drug|docetaxel|Given IV
45649354|NCT04400695|Drug|Docetaxel Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
45649355|NCT04400695|Drug|Vinorelbine Tartrate Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
45649356|NCT04400695|Drug|Capecitabine Tablets|Administered according to label, as one option for Physician's Choice (determined before randomization)
45649357|NCT04284475|Diagnostic Test|Quadriceps strength|Using a handheld dynamometer, in supine position in a standardized position of the dominant leg Measurement of the maximal isometric voluntary quadriceps contraction Measure expressed as Newton and Newton/kg
45796692|NCT05597514|Other|3D printed educational model|Slide-based presention plus 3D printed airway suction model
45796693|NCT05597514|Other|Tranditional model education|Slide-based presention plus tranditional model
45924120|NCT00042835|Drug|paclitaxel|Given IV
45924121|NCT00042835|Drug|carboplatin|Given IV
46071852|NCT05877599|Biological|Autologous, engineered T Cells targeting TP53 R175H|"Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide~Single infusion TCR T cells~Post-infusion recombinant interleukin-2 (rIL-2)"
45924122|NCT00042835|Other|laboratory biomarker analysis|Correlative studies
45924123|NCT00017784|Drug|Valganciclovir|
45796694|NCT05596877|Behavioral|Music therapy|Performing music therapy during a course of pulmonary rehabilitation (25 mins)
45924124|NCT00042874|Drug|alvocidib|Given IV
45924125|NCT00042874|Drug|irinotecan hydrochloride|Given IV
45924126|NCT00042874|Drug|fluorouracil|Given IV
45649358|NCT04284475|Diagnostic Test|Grip strength|Testing of dominant hand using a handgrip Measurement of the maximal isometric voluntary grip contraction Measure is expressed as kg
45796695|NCT05593497|Drug|Capivasertib|400 mg (2 tablets) BID given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week (4 days on, 3 days off). Treatment will be given in combination with abiraterone for 16 weeks duration (+/- 1 week for surgery window).
45796696|NCT05593497|Drug|abiraterone acetate|"Administered orally as tablets at a dosage of 1000 mg daily. To be administered with prednisone 5mg po daily.~Subjects will be on concurrent GNRH agonist therapy (leuprolide, administered as standard of care). Intensified androgen deprivation (iADT) consisting of abiraterone and leuprolide will be administered for a 4 week run-in prior to addition of capivasertib."
45796697|NCT05579275|Biological|JCXH-212 Injection|Based on the development principle of NCV, a community-type tumor neoantigen mRNA vaccine, JCXH-212 injection, has been developed that can be applied to patients with advanced malignant solid tumors. NCVs activate tumor-specific CD4+ T cells and CD8+ T cells through active immunity, and these T cells can inhibit and kill tumor cells in cancer patients, thus prolonging the survival of cancer patients.
45796698|NCT05556824|Drug|MHS-1031|Study medication will be supplied as a syrup in individual sachets containing 1g (1.5 mL) of MHS-1031. Subjects will be randomized in 2:1 fashion to either study drug (2) or placebo (1)
45924127|NCT00042874|Drug|leucovorin calcium|Given IV
45924128|NCT00042874|Other|laboratory biomarker analysis|Correlative studies
45649359|NCT04284475|Diagnostic Test|ICU mobility scale|Scoring the physical capacity of the patient on a 10-points validated scale: the ICU mobility scale
45649360|NCT05255809|Other|Alexander Technique + Routine Physical Therapy|Verbal Instructions in Trunk stabilizing exercises. The time duration will be 15 minutes. Verbal instructions in Stance Phase Time duration 15 minutes.Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Lessons would be two days a week for 16 weeks.
45649361|NCT05255809|Other|Routine Physical Therapy|Trunk stabilising exercises time duration will be 15 minutes. Stance Phase time duration will be 15 minutes. Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Two days a week for 16 weeks.
45649362|NCT05239351|Device|Jalucomplex|Device: Jalucomplex Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
45796699|NCT05556824|Other|Placebo|Matching placebo is an oral solution formulated to have a degree of sweetness and acidity similar to the study medication and will be provided in equivalent sachets containing 1.5g (1.5 mL) of the oral placebo solution.
45924129|NCT00042913|Biological|epratuzumab|
45924130|NCT00042952|Drug|imatinib mesylate|Given orally
45924131|NCT00042952|Procedure|therapeutic conventional surgery|Undergo surgical resection
45924132|NCT00042952|Other|laboratory biomarker analysis|Correlative studies
45924133|NCT00017823|Procedure|Acupressure|
45924134|NCT00043030|Procedure|psychosocial assessment and care|
45924135|NCT00043069|Dietary Supplement|calcium carbonate|
45924136|NCT00043069|Dietary Supplement|cholecalciferol|
45924137|NCT00043069|Drug|Estrogen Antagonists|
45924138|NCT00043069|Drug|risedronate sodium|
45924139|NCT00043069|Other|placebo|
45924140|NCT00001550|Drug|IVIg|
45924141|NCT04732234|Procedure|Superior Hypogastric Plexus Block|Pre operative ultrasound guided superior hypogastric plexus block in pelvic surgeries using a curvilinear probe below umbalicus with needle in plane technique to reach the plexus in front of L5 vertebra
45924142|NCT00043147|Drug|beclomethasone dipropionate|
45924143|NCT00043147|Drug|methylprednisolone|
45924144|NCT00043147|Drug|prednisone|
45924145|NCT00017862|Drug|SCH55700|
45924146|NCT00043264|Drug|Rifampin|
45924147|NCT00043264|Drug|Azithromycin|
45924148|NCT00043303|Drug|interferon gamma-1b|100 or 200 mcg, SQ, 3x per week
45924149|NCT00017940|Genetic|Human Nerve Growth Factor|
45924150|NCT02970604|Drug|Aspirin|Non enteric coated aspirin
45924151|NCT00043342|Drug|interferon gamma-1b|100 or 200 mcg, SQ, 3x per week
45924152|NCT00043381|Drug|decitabine (5-aza-2'deoxycytidine)|
45924153|NCT00001568|Drug|2-Fluoro-2-deoxyglucose|
45924154|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.08mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
45924155|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.16mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
45924156|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.24mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
45924157|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.28mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
45924158|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.32mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
45924159|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.36mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
45924160|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 10 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
45924161|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
45924162|NCT00043459|Drug|intravenous T900607-sodium|
45796700|NCT05550753|Behavioral|Better Together Physician Coaching Program|thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies.4 BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
45649363|NCT04182061|Behavioral|The AMTE protocol|The AMTE program is an adaptation of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A; Ehrenreich-May et al., 2018) to be applied as an internet-based protocol. Like the UP-A, the program AMTE implements a set of core principles to address common factors underling youth anxiety and depressive symptoms. It includes the following 10 modules: (1) Understanding emotional problems and disorders, (2) Getting to know your emotions and behaviors, (3) Enjoy your positive activities, (4) Mindful emotion awareness, (5) Being flexible in your thinking, (6) Confronting physical sensations, (7) Situational emotion exposure, (8) How to regulate the emotional avoidance, (9) Respiratory relaxation training, and (10) Relapse prevention.
45649364|NCT05230147|Procedure|Spinal cord stimulation|Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation with modulated current via skin patches captures posterior horns of the spinal cord.
45796701|NCT05550753|Behavioral|No intervention - placebo control|No intervention - placebo control
45796702|NCT05515497|Device|BMT4me 2.0 app|The BMT4me app was designed by AWRI RISI developers and has been through multiple phases of stakeholder testing. The app is a virtual assistant for caregivers, allowing for medication record keeping, medication and refill reminders, symptom tracking, and a word and picture journal. All data is secured on the individuals password protected phone.
45796703|NCT05511870|Drug|Etripamil Nasal Spray 70mg|Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
45924163|NCT00043537|Behavioral|Social Effectiveness Therapy for Children (SET-C)|
45796704|NCT05511870|Drug|Placebo|Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
45796705|NCT05506891|Behavioral|Physical therapy group|Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.
45924164|NCT00043537|Drug|Fluoxetine|
45924165|NCT00043537|Drug|Pill Placebo|
45924166|NCT00043576|Drug|calcitriol|
45924167|NCT00043576|Drug|docetaxel|
45924168|NCT00043654|Drug|Mifepristone|
45924169|NCT00043693|Behavioral|Family Intervention for Dual Diagnosis|The family intervention for dual diagnosis program lasts for up to 3 years and includes both single and multiple-family group formats.
45924170|NCT00043693|Behavioral|Family psychoeducation program|The family psychoeducation program consists of 6 weekly sessions.
45649365|NCT05230147|Procedure|Sham stimulation|Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation is not delivered.
45649366|NCT04227301|Other|blood sampling|blood sampling for measurement of bone markers after a fasting period of at least 6 hours
45796706|NCT05506891|Drug|Astragalus|After a 2-week washout period, astragalus granules 15g, drunk with warm water, once a day, will be taken for 3 months.
45796707|NCT05493891|Other|Visual analogue scale (VAS)|The Visual analogue scale (VAS) is a reliable and valid scale for the assessment of low back pain (LBP) intensity
45796708|NCT05493891|Device|Pressure Biofeedback Unit|The pressure biofeedback unit (PBU) s a reliable and valid device for measuring the strength of transversus abdominis and lumbar multifidus muscles
45796709|NCT05492851|Drug|Zilretta|Intra-articular injection to treat knee osteoarthritis
45924171|NCT00043732|Drug|SCIO-469|
45924172|NCT00043771|Drug|Tolvaptan|
45924173|NCT04734327|Procedure|Orthokine periradicular injection|Ultrasound guided injections
45924174|NCT04734327|Procedure|Orthokine epidural injection|Ultrasound guided injections
45450238|NCT02176954|Device|Comparator|"Two comparators will be used: Moderma Flex (Hollister) or Confidence Natural drainable (Salts).These product are commercially available.~Subjects will be randomized into one of twelwe arms. Data will be analyzed by pooling the two comparators, Moderma Flex and Confidence Natural, Drainable, why six arms are displayed."
45924175|NCT00043810|Procedure|Gelonin|Gelonin-AntiCD33 purging, 3 purging concentrations (fixed dose of 5 x 10^6 CD34+ cells/kg to be infused) with 3 dose levels of 1 nanomolar, 5.0 nanomolar and 10.0 nanomolar.
45924176|NCT00043810|Drug|Busulfan|130 mg/m2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -6 to -3).
45924177|NCT00043810|Drug|Fludarabine|40 mg/m2 in 100 ml of saline over one (1) hour on each of four (4) consecutive days (days - 6 to -3).
45924178|NCT00043849|Drug|Quetiapine|
45924179|NCT00001586|Biological|Rituximab|Rituxan
45924180|NCT00001586|Drug|Fludarabine phosphate|Fludara
45924181|NCT00001586|Other|Leukemic or stroma cells|Patients are eligible to donate cells for the purpose of analyzing leukemic cells. Cells can be donated by apheresis (e.g. 60-90 minute intravenous technique), lymph node biopsy (e.g. 3 biopsy/excision of lymph nodes)bone marrow biopsy (e.g. 2-4 separate bone marrow biopsies), and bone marrow aspiration (e.g. 3 to 5cc of marrow per aspirate).
45450239|NCT03538132|Other|dental regenerative techniques|dental regenerative techniques
45649367|NCT05214547|Device|Radial Extracorporeal Shock-wave Therapy|Radial Extracorporeal Shock Wave Therapy, also called radial pulse therapy. In contrast to regular focused shock wave therapy,Radial Extracorporeal Shock Wave Therapy creates a diverging pressure field, which reaches a maximal pressure already at the source, and therefore has a more superficial, but broader, effect than focused shock wave therapy. This treatment is increasingly used for calcific and non-calcific tendinopathy, probably because it is easier to apply and more affordable than focused shock wave therapy. The proposed mechanisms for the effect of Radial Extracorporeal Shock Wave Therapy include pain relief, tissue regeneration and destruction of calcification.
45649368|NCT05207059|Behavioral|HELMS Lifestyle Intervention|The HELMS life-course Interventions, namely 4S ('Screening', 'Size', 'Supplementation' and 'Specific case management'), are developed to deliver care throughout the journey from preconception to postpartum periods. Screening involves health and risk assessments through physical and biomarker measurements, as well as emotion and sleep evaluations for mother, and developmental assessment for children. Body Size management encompasses education on weight status awareness and mother-child health implications, both mother-child weight tracking, healthy eating and physical activity guidance. Supplementation includes multi-micronutrient, vitamin D, calcium and/or Docosahexaenoic acid (DHA) supplements, which is phase-specific for mother, and vitamin D drops supplement for child. Specific case management comprises preconception sexual health and function management, pregnancy symptoms management, postpartum recovery management, infant growth monitoring and feeding management.
45649369|NCT05205499|Device|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System|Subjects in this arm will be treated with IBS
45649370|NCT03965611|Procedure|Oropharyngeal swab|Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.
45450240|NCT02182414|Drug|BI 207127 NA (TF-I)|200 mg tablet
45450241|NCT02182414|Drug|BI 207127 NA (TF-II)|400 mg tablet
45450242|NCT02182414|Drug|BI 207127 NA delayed release|400 mg tablet
45649371|NCT03965611|Procedure|Rectal swab|Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.
45649372|NCT03965611|Procedure|Disability rating scale (DRS-F)|Will be assessed at day 90 +/- 7 days.
45649373|NCT05191225|Drug|RiTUXimab Injection [Truxima]|375 (mg/m2) / 60 minutes
45649374|NCT05191225|Drug|RiTUXimab Injection [Truxima]|375 (mg/m2) / 30 minutes
45796710|NCT05492851|Drug|Synvisc-One 48 MG in 6 ML Prefilled Syringe|Intra-articular injection to treat knee osteoarthritis
45796711|NCT05492851|Drug|Monovisc 88 MG Per 4 ML Prefilled Syringe|Intra-articular injection to treat knee osteoarthritis
45796712|NCT05492578|Drug|Amlitelimab|Solution for injection Subcutaneous
45796713|NCT05488288|Procedure|Mesh repair|Abdominal ventral hernia (VH) repair with mesh during bariatric surgery. the repair technique and the type of mesh are left to the choice of the center, as there are no strong data to demonstrate which technique is the best for VH repair in this population.
45796714|NCT05488288|Procedure|Suture repair|The hernia sack is resected through an open approach, and the fascial defect is systematically closed with a slowly absorbable monofilament suture.
45796715|NCT05486104|Drug|Hemay005 tablets|Hemay005 tablets (15mg/tablet）will be orally administered twice daily.
45796716|NCT05486104|Drug|Hemay005 placebo tablets|Hemay005 placebo tablets will be orally administered twice daily.
45924182|NCT00043888|Drug|fosamprenavir|
45924183|NCT00043888|Drug|COMBIVIR|
45450243|NCT02182414|Drug|BI 207127 NA extended release (10% HPMC)|400 mg tablet
45649375|NCT05189275|Dietary Supplement|Daily Beverage Intervention|Individuals will consume one of 4 beverages, daily for 8 weeks.
45649376|NCT05187325|Other|no intervention|there is no intervention
45796717|NCT05483998|Drug|TLC-2716|TLC-2716
45796718|NCT05483998|Other|Placebo|Placebo to match
45796719|NCT05479305|Device|The Valiant Captivia Stent Graft|Aortic arch/Descending aorta Repair
45796720|NCT05478525|Drug|GLY-200|0.5 g GLY-200 (1 x 0.5 g capsule) BID for 14 days (n=12)
45796721|NCT05478525|Drug|GLY-200|1.0 g GLY-200 (2 x 0.5 g capsules) BID for 14 days (n=12)
45924184|NCT00043888|Drug|ritonavir|
45450244|NCT02182414|Drug|BI 207127 NA extended release (15% PEO)|400 mg tablet
45450245|NCT02182414|Drug|BI 207127 NA extended release (20% HPMC)|400 mg tablet
45450246|NCT02182570|Drug|WAL 801 CL dry syrup|
45450247|NCT02182648|Drug|etomidate|"intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~infusion of etomidate at 2 minutes before anesthesia induction"
45450248|NCT02182648|Drug|propofol|"intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~infusion of propofol at 2 minutes before anesthesia induction"
45450249|NCT02182648|Drug|sevoflurane|"intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~inhale sevoflurane for anesthesia induction and maintenance"
45796722|NCT05478525|Drug|GLY-200|2.0 g GLY-200 (4 x 0.5 g capsules) BID for 14 days (n=12)
45796723|NCT05478525|Drug|Placebo|1 placebo capsule BID for 14 days (n=4)
45796724|NCT05478525|Drug|Placebo|2 placebo capsules BID for 14 days (n=4)
45796725|NCT05478525|Drug|Placebo|4 placebo capsules BID for 14 days (n=4)
45796726|NCT05472935|Behavioral|Mindfulness Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) is an evidenced based intervention utilized to reduce stress.
45924185|NCT00043888|Drug|TRIZIVIR|
45924186|NCT00018018|Drug|CD34+ cells transduced with ADA retrovir|
45924187|NCT00043927|Drug|topotecan/cisplatin|
45924188|NCT00043927|Drug|etoposide/cisplatin|
45924189|NCT00391755|Drug|ramelteon|"ramelteon 8mg po qhs with sleep and headache diary~placebo 1 po qhs with sleep and headache diary"
45924190|NCT00043966|Drug|Lopinavir/ritonavir|
45924191|NCT00043966|Drug|Tenofovir DF|
45924192|NCT00043966|Drug|Emtricitabine|
45924193|NCT00001598|Drug|Dehydroepiandrosterone|
45924194|NCT04731727|Drug|Riboflavin|Corneal cross linking achieved by combination of Riboflavin and ultraviolet light
45796727|NCT05460845|Behavioral|Low-Carbohydrate Diet|Using a meal delivery service and a list of prepared meals and recipes, foods/meals will be delivered to participants weekly to maintain daily net carbohydrate intake to less than 40 grams.
45924195|NCT00391794|Behavioral|Early Stage Memory Loss Support Group|8 week support group led by trained facilitators
45924196|NCT00391794|Behavioral|Educational Seminar|4 hour education session led by trained facilitators
46071853|NCT05877586|Other|CLARE app|"CLARE will contain materials on hospital discharge preparation, Covid care, and caregiver self-care, all of which have already been vetted by the DUHS Patient and Family Education department. Existing CLARE teaching on Covid covers isolation; quarantine; home sanitization; and monitoring for Covid symptoms such as cough, fever, fatigue, and shortness of breath. All will be reviewed and amended to reflect the latest CDC guidelines for Covid care at the time of pilot implementation. CLARE will also include reminders on examining the After-Visit-Summary to determine home medications and information on follow-up care.~CLARE will have two sessions of training and support to caregivers that can be delivered before hospital discharge and daily for seven days after discharge."
46071854|NCT05877573|Drug|Toripalimab|Toripalimab 240mg,d1,q3w
46071855|NCT05877573|Radiation|short-term radiotherapy|25Gy/5Fx
46071856|NCT05877573|Drug|Oxaliplatin|135mg/m2 d1 q3w
46071857|NCT05877573|Drug|Capecitabine|1200mg/m2 d1-14 q3w
45450250|NCT02182726|Drug|MOBEC|
45649377|NCT05185921|Behavioral|Trial-based Cognitive therapy|The virtual CBT will be provided by 02 psychotherapists, who will follow a protocol developed for this study. The number of sessions will be eight, which will be held weekly, projecting an intervention time of 2 to 3 months considering the possibility of rescheduling any of the sessions for reasons derived from the participant People with relevant cognitive impairment that prevents them from answering the questionnaire questions or providing informed consent are excluded.
45649378|NCT03914833|Other|Inclusion Questionnaires|During the inclusion visit, neuropsychologist tests the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Scale) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
45754384|NCT05582486|Behavioral|obstetric violence prevention education intervention|While the training program for the prevention of obstetric violence consisting of 16 sessions was applied by the researcher to the midwives and nurses in the experimental group, no intervention was applied to the midwives and nurses in the control group.
45796728|NCT05434663|Drug|SUSTOL|SUSTOL 10 mg Subcutaneous (SC) on Day 1 of up to 4 cycles.
45796729|NCT05429762|Drug|Tusamitamab ravtansine|Pharmaceutical form: Concentrated solution for intravenous (IV) administration; Route of administration: IV infusion
45796730|NCT05426460|Behavioral|Approach/Avoidance Task|The Approach/avoidance task (AAT) training is done using a joystick. The AAT tasks involves having participants push away pictures of smoking stimuli that appear on the screen by pushing the joystick forward, and pulling in pictures of nonsmoking stimuli that appear on the screen by pulling the joystick towards themselves. Pushing smoking-related pictures away causes the picture to shrink in size, whereas pulling a picture closer causes the picture to increase in size. This task consists of 4 blocks of 24 pictures, taking 30 minutes.
45796731|NCT05426460|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation active (2.0 mA) (tDCS) will be used to temporarily increase cortical excitability of the dorsolateral prefrontal cortex (dlPFC) in healthy daily smokers. Participants assigned to active tDCS conditions will receive active (2.0 mA) tDCS, with anode electrode placement over the right dlPFC and cathode electrode placement over the left bicep. tDCS will be administered the first 20 minutes of each of the five 30 minute AAT training sessions.
45796732|NCT05426460|Behavioral|AC|During Active Control (AC) participants press a button on the left of right of the joystick to indicate the position the picture on a screen. Position of pictures will be balanced across the 4 blocks of 24 pictures, taking 30 minutes.
45796733|NCT05426460|Device|Sham tDCS|Sham transcranial Direct Current Stimulation (0.1 mA) (sham tDCS) will be used as a control for active tDCS with anode electrode placement over the right dlPFC and cathode electrode placement over the left bicep. Sham tDCS will be administered during the first 20 minutes of each of the four blocks of 24 pictures, taking 30 minutes, across the 5 training sessions.
45924197|NCT00044278|Drug|lamotrigine|
45924198|NCT00391833|Drug|Panax Ginseng|
45924199|NCT00001601|Procedure|Electrocardiogram|
45924200|NCT00001601|Procedure|Biopsies|
45924201|NCT00001601|Procedure|Diagnostic imaging|
45924202|NCT00044356|Genetic|Allovectin-7®|
45924203|NCT00044395|Drug|Ruboxistaurin mesylate|
45924204|NCT00018096|Biological|LPS endotoxin, saline, HDM|instillation of interventional products during bronchoscopy each down a different airway, each subject acts as their own control.
45450251|NCT02179996|Biological|Three vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections at two, three, four months after birth
45450252|NCT02179996|Biological|Two vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections are administered at two and four months after birth
45924205|NCT00044434|Drug|bupropion (Wellbutrin)|
45924206|NCT00044473|Drug|levofloxacin|
45924207|NCT00044551|Drug|Taxane (Cytotoxic, BAY59-8862)|Daily 1 h infusion every 3 weeks
46071858|NCT05877521|Behavioral|MORE treatments|MORE participants will also be asked to engage in 15 minutes/day of skill practice at home, and complete daily diaries of mindfulness practice time
46071859|NCT05877521|Other|Standard of Care for Pain Management|Participants in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers.
46071860|NCT05877508|Drug|AER002|Intravenous infusion of AER002
46071861|NCT05877508|Other|Placebo|Placebo infusion
45450253|NCT04466098|Biological|Mesenchymal stromal cells|Thawed product containing MSC(300x10^6) in DMSO resuspended 1:1 with Dextran 40 + 5% human serum albumin [total volume 60 mL]
45924208|NCT00018135|Drug|calcium acetate|
45924209|NCT00018135|Drug|aluminum hydroxide|
45924210|NCT00018135|Drug|Sevelamer|
45924211|NCT00397384|Drug|cetuximab|Given IV
45924212|NCT00397384|Drug|erlotinib hydrochloride|Given PO
45924213|NCT00397384|Other|laboratory biomarker analysis|Correlative studies
45796734|NCT05423535|Device|test group: collagen matrix (Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland)|Following tooth extraction and wound debridement, the alveolar socket was filled with collagen-enriched deproteinized bovine bone mineral (C-DBBM, Bio-Oss Collagen® 100 mg or 250 mg, Geistlich Pharma AG, Wolhusen, Switzerland) up to the level of the oral bone crest. Subsequently, a collagen matrix (Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland) or gelatin spons (Spongostan Dental® 1x1x1 cm, Ethicon, Johnson & Johnson, New Brunswick, VS) was sutured on top with 4 to 6 single sutures (Seralon 6/0, Serag Weissner, Naila, Germany) to protect the underlying C-DBBM.
45796735|NCT05423145|Behavioral|self-administered acupressure|The acupressure intervention is self-administered. The intervention group receives an app that instructs them on how to perform a stimulating acupressure protocol, consisting of six acupoints with four of the acupoints performed on both the left and the right sides of the body for a total of ten points. Each of the ten acupoints is to be stimulated for 3 minutes per point for a total treatment time of 30 minutes daily for 6 weeks.
45924214|NCT00397423|Drug|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor,5ug/kg/day iH Qd*5 days,3 months interval for 4 times
45924215|NCT00397423|Drug|NS|NS 1ml iH Qd*5 days, 3 months interval for 4 times
45924216|NCT00397501|Biological|trastuzumab|"Trastuzamab, 6mg/kg, within 48 hrs before BBBD~Then, Trastuzumab, 2mg/kg, weekly until next BBBD Then continue for 12 cycles"
45924217|NCT00397501|Drug|carboplatin|200mg/m2/day x 2 days; total dose 400mg/m2 Infused i.a. over 10 mins in 200ml of normal saline after MTX infusion
45649379|NCT03914833|Other|Questionnaires at inclusion, M1 and M3|During the inclusion visit, the 1-month visit and the 3-month visit; neuropsychologist grading of the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Index) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
45924218|NCT00397501|Drug|methotrexate|2500 mg/day x 2 days; total dose 5000mg Infused over 10mins in 200ml saline beginning immediately after mannitol infusion
45924219|NCT00397501|Drug|sodium thiosulfate|STS dose admin i.v. over 15mins @ 4hrs post carboplatin = 20gm/m2; STS dose admin i.v. over 15mins @ 8hrs post carboplatin = 16gm/m2
45796736|NCT05420064|Behavioral|Intervention Arm At-risk Relative/ARR Contacts|Probands will give contact info for their ARR in the eDGP and indicate a date by which they will discuss the familial pathogenic variant with their ARR (can request a delay/halt to outreach). After this date the team will contact the ARR to invite them to review education and e-consent to the study. The study team will facilitate ARR cascade testing through telegenetics pre- and post-test counseling and saliva-based at home testing through MSK or a reference laboratory.
45796737|NCT05417451|Other|Acupuncture|All participants will receive a semi-standardized acupuncture protocol (standardized points for pain, fatigue, depression, anxiety, sleep disturbance, with additional points for patient's particular pain location)
45924220|NCT00018174|Drug|Fluoxetine|
45924221|NCT00018174|Behavioral|Behavioral group smoking cessation treatment|
45924222|NCT00018174|Drug|Placebo|
45924223|NCT00044629|Behavioral|Cognitive-Behavioral Therapy for Insomnia|
45924224|NCT00044629|Drug|zolpidem tartrate (Ambien)|
45924225|NCT00044629|Drug|Placebo|
45924226|NCT00044668|Drug|AC2993|Subjects will receive 5 μg AC2993, subcutaneously injected twice daily, for 4 weeks followed by 10 μg AC2993, subcutaneously injected twice daily, during a maintenance period that is expected to continue for at least 11 months.
45924227|NCT00001622|Procedure|investigate the relationship between in vivo and in vitro vascular responses|
45924228|NCT04734054|Device|Modified Hyrax Palatal Expander|The rapid maxillary expansion will be performed. The expansion should be accomplished between 10 to 15 days at most. The screw is going to be turned in a rapid manner.
45450254|NCT04466098|Other|Placebo|Dextran 40 + 5% human serum albumin [total volume 60 mL]
45649380|NCT05173051|Other|Solid Medication intake vs. crushed medication intake|The swallowing ability for solid and crushed medications in stroke patients is evaluated.
45796738|NCT05414409|Drug|Metformin|Metformin is an oral medication that improves insulin sensitivity.
45796739|NCT05411575|Drug|Plerixafor 20 MG/ML [Mozobil]|Plerixafor (Mozobil®) continuous intravenous infusion for 7 days
45796740|NCT05411575|Other|Placebo|Placebo continuous intravenous infusion for 7 days
45924229|NCT04734054|Device|Removable Palatal Expander|The slow maxillary expansion will be performed. The expansion will be performed in a slow manner. Patients may need between 6 to 8 months to achieve the required expansion.
45924230|NCT00044707|Drug|Pramlintide acetate|Clear, colorless, sterile solution for SC injection.
45924231|NCT00044746|Drug|Piperacillin/Tazobactam|
45924232|NCT00044785|Drug|triacetyluridine|
45924233|NCT00044785|Drug|fluorouracil|
45924234|NCT00044785|Drug|leucovorin|
45924235|NCT00044785|Drug|camptosar|
45924236|NCT00044824|Drug|Fexofenadine|
45924237|NCT00018213|Drug|Naltrexone Hydrochloride|
45924238|NCT00018213|Drug|Transdermal Nicotine|
45924239|NCT00044863|Biological|Erbitux (Cetuximab)|400 mg/m2 initial dose, 250 mg/m2 weekly
45924240|NCT04731805|Behavioral|Moving On After Breast Cancer|Patient education intervention that is evidence-based, physical therapy, patient & family centered through the use of face to face instruction, a booklet, and therapeutic exercise DVD. The education materials are designed to deliver information on short term, long term, and late physical and functional effects of breast cancer treatment and given to breast cancer survivors before beginning cancer treatment. The education materials are designed to be used before, during, and after breast cancer treatment.
45924241|NCT00044902|Drug|epratuzumab|
45924242|NCT00044980|Procedure|nutritional support|
45924243|NCT00044980|Procedure|quality-of-life assessment|
45924244|NCT00001631|Procedure|Magnetic resonance imaging|
45924245|NCT00018252|Behavioral|exercise|
45924246|NCT00045019|Other|quality-of-life assessment|QLQ-C30 SAT32
45924247|NCT00045097|Drug|ixabepilone|
45924248|NCT00045136|Drug|melphalan|
45649381|NCT03909217|Procedure|TECAS Procedure|"Location:~Cranial electrical stimulation acupoints: Baihui (DU20) and Yintang (DU29).~Auricular electrical stimulation zone: the distribution area of auricular branch of the vagus nerve.~Two electrodes electric stimulation at a frequency of 4/20 Hz will be employed on the cranial acupoints and the auricular zone respectively. The TECAS treatment will consistent of two sessions per day (30 minutes) for 8 consecutive weeks."
45649382|NCT03909217|Drug|Escitalopram|Each subject shall receive oral administration Escitalopram (10-20mg/day, q.d.), as prescribed by clinical psychiatrist with respect to patients' conditions for 8 consecutive weeks.
45924249|NCT00045136|Procedure|peripheral blood stem cell transplantation|
45450255|NCT02180152|Behavioral|Postprandial walks|Obese pregnant women will be target to carry out walks lasting 10' after the main meals (breakfast, lunch and dinner), Monday to Friday, during 8 weeks. Adherence to the program will be determined by daily readings of pedometers previously provided to pregnant women; minimum of 1500 steps per day from Monday to Friday.
45796741|NCT05407025|Procedure|Biospecimen Collection|Undergo collection of blood, urine, and tissue samples
45649383|NCT03909217|Drug|Insomnia medication|For patients with severe insomnia, stabilizers and benzodiazepines could be prescribed and must be recorded in the case report form.
45649384|NCT04914533|Device|Luminance RED Low Level Laser Therapy Device|Low Level Laser Therapy (LLLT) sometimes known as Low Level Light Therapy or Photobiomodulation (PBM) is a low-intensity light therapy. The effect is photochemical not thermal. The Luminance RED Device is specifically designed to make it easy to issue LLLT to canker sores.
45796742|NCT05407025|Other|Questionnaire Administration|Complete risk factor questionnaire
45796743|NCT05406115|Drug|AMG 786|Oral tablet
45796744|NCT05406115|Other|Placebo|Oral tablet
45924250|NCT00045136|Radiation|holmium Ho 166 DOTMP|
45924251|NCT00001649|Drug|Valaciclovir|
46071862|NCT05877495|Behavioral|Nutritional Education Intervention|A 14-session training created by the researchers by examining the literature and various guides. This training includes about, prevention food waste with kitchen activities, food safety, food security and waste control. The content of the intervention will be loaded soon.
45649385|NCT04914065|Other|Regular care in the surgery intensive care unit|"Part 1: Two arms(muscle thickness observation):~Inspiratory muscles: diaphragm~Anti-gravity muscles: rectus femoris and the vastus intermedius~Part 2: Predictors of short-term and long-term goals in the ICU~Short-term goal: successful ventilator weaning in the ICU- pass weaning profile without re-intubation in the hospital~Long-term goal- Quality of life after hospital discharge: SF-36 (Taiwan version)"
45649386|NCT02650921|Device|Restylane Lyft with Lidocaine|An injectable gel of Hyaluronic Acid and Lidocaine
45649387|NCT04914143|Other|broken Ganoderma lucidum spore powder|The experimental group was treated with broken Ganoderma lucidum spore powder after chemotherapy
45649388|NCT04914143|Other|placebo|the control group was treated with placebo after chemotherapy
45649389|NCT04913987|Device|Stryker Triathlon total knee replacement|Knee arthroplasty using a standard care total knee.
45649390|NCT04913987|Device|Zimmer Biomet Persona Partial Knee unicondylar knee replacement|Knee arthroplasty using the Zimmer Biomet Persona Partial Knee (PPK).
45649391|NCT03054935|Other|Indirect Calorimetry|Measurement of resting energy expenditure
45649392|NCT05139589|Other|None, observational|Patients with infective endocarditis who do and do not undergo valve surgery compared with patientswithout endocarditis, who are operated on with similar valve surgery
45450256|NCT02177188|Device|LBNP Lower Bodi Negative Pressure Chamber|
45649393|NCT04914299|Behavioral|"App-based positive intelligence intervention"|"A 6 weeks App-guided and support-group based positive intelligence cognitive behavioral intervention in addition to standard prenatal and postnatal care"
45649394|NCT04914299|Behavioral|Standard of care|Standard prenatal and postnatal care(Providing psychoeducation and referral to psychotherapy or pharmacotherapy based on participant's symptoms).
45796745|NCT05401994|Procedure|screw retained arch bar|maxillomandibular fixation with bone screwed arch bar
45796746|NCT05401994|Procedure|conventional Erich's Arch Bar|maxillomandibular fixation with conventional arch bar fixed to the teeth
45796747|NCT05367401|Drug|Sabatolimab|Solution for intravenous infusion
45796748|NCT05367401|Drug|Magrolimab|Solution for intravenous infusion
45796749|NCT05367401|Drug|Azacitidine|Solution for subcutaneous injection or intravenous infusion
45796750|NCT05351164|Drug|Metreleptin|Study drug for injection is supplied in a carton containing 30 vials for reconstitution. Each vial contains 11.3 mg of the study drug as a sterile, white, solid, lyophilized cake or powder to deliver 5 mg/mL of the study drug when reconstituted with 2.2 mL of water for injection (WFI).
45796751|NCT05344183|Device|Low-level laser|A laser will be used in the quadriceps and gluteus medius muscles with the following parameters described for muscle recovery: dose of 40 J for the gluteus medius muscle, 180 J for the quadriceps muscle; power from 50 to 200 mW per diode (for single probes), 10 to 35 mW per diode (for cluster probes). The full power of the device cannot lead to thermal effects; Wavelengths of 950 nm (infrared).
45796752|NCT05334342|Dietary Supplement|Low-GI Diet|Participants will be given a low glycemic index diet
45796753|NCT05334342|Dietary Supplement|High-GI Diet|Participants will be given a high glycemic index diet
45796754|NCT05323461|Biological|SCTV01C|intramuscular injection
45924252|NCT00018291|Drug|Risperidone|
45924253|NCT00018291|Drug|Gabapentin|
45924254|NCT00045175|Drug|7-hydroxystaurosporine|
45924255|NCT00045175|Drug|topotecan hydrochloride|
45924256|NCT00045292|Drug|acyclovir|
45924257|NCT00045292|Drug|acyclovir sodium|
45924258|NCT00045292|Drug|valacyclovir|
45924259|NCT00045331|Genetic|proteomic profiling|
45924260|NCT00018330|Behavioral|Weight Loss|
45924261|NCT00045370|Biological|recombinant interferon alfa|
45796755|NCT05323461|Biological|SCTV01E|intramuscular injection
45924262|NCT00045370|Drug|temsirolimus|
45924263|NCT02970682|Drug|SFX-01|Stabilised Sulforaphane
45924264|NCT02970682|Drug|Fulvestrant|Fulvestrant
45796756|NCT05323461|Biological|Sinopharm inactivated COVID-19 vaccine|intramuscular injection
45796757|NCT05323461|Biological|Comirnaty|intramuscular injection
45924265|NCT02970682|Drug|Tamoxifen|Tamoxifen
45796758|NCT05322928|Behavioral|Engagement in daily occupations|"The 12-week occupational therapy individual person-centered intervention will be delivered by an occupational therapist according to the individual intervention plan, with a 1-hour video appointment (Region Zealand VDX-connection) a week in four weeks and a maintenance phase of similar session format every second week in two months.~The intervention will include identification of occupational problems that limit compliance with the PA recommendations, setting tailored occupational goals to enhance physically active lifestyle, supervised goal work and goal evaluation. Through active involvement in value-based prioritizing, planning and performance of meaningful everyday activities, the participants will reduce their sedentary time. Changing health behaviour in a stepwise manner, the participants will become prepared for continuous lifestyle goal work as self-management which will allow for sustainable lifestyle changes, and thus, improved long-term health and quality of life."
45796759|NCT05313607|Other|Designed physical therapy|Attention is given to improve motor function, conducted for 30 minutes
45796760|NCT05313607|Other|Occupational therapy|included exercises facilitating hand skills, conducted for 30 minutes
45796761|NCT05313607|Other|Conventional Therapy|aimed to improve the affected upper extremity function, conducted for 30 minutes
45796762|NCT05313607|Other|Plyometric training|basically focuses on upper extremity strength training conducted for 30 minutes
45924266|NCT02970682|Drug|Aromatase Inhibitors|
45924267|NCT00045448|Drug|alvocidib|
45796763|NCT05309980|Other|standard of care|retrospective study : standard of care
45924268|NCT00045448|Drug|docetaxel|
45924269|NCT00045526|Drug|erlotinib hydrochloride|Given PO
45924270|NCT00045526|Other|laboratory biomarker analysis|Correlative studies
45450257|NCT02256202|Other|Interview|Monitoring interviews to show medical and economic advantages of given therapy
45649395|NCT03801109|Other|Hyperbaric group|Participants in this group performed 5 sessions per week for 8 weeks (40 sessions in total) . The time of each session is 90 minutes and the chamber pressure is 1.4 ATA with a 100% oxygen mask.
45649396|NCT03801109|Other|Magnetic group|There will be 5 sessions per week for 2 consecutive weeks (10 sessions in total), stimulating the left motor cortex at high frequencies, 10 Hz, for 30 minutes.
45649397|NCT03801109|Other|Physical group|A protocol of low-impact physical exercise will be performed twice a week for 8 weeks, with a total of 16 sessions.
45649398|NCT03801109|Other|Baseline group|This group will be the control group that did not take any action, perform the activities of daily life
45924271|NCT00045565|Drug|arsenic trioxide|Given IV
45924272|NCT00045565|Radiation|radiation therapy|Undergo radiation therapy
45924273|NCT00045604|Drug|cisplatin|
45924274|NCT00045604|Drug|imatinib mesylate|
45924275|NCT00045604|Drug|irinotecan hydrochloride|
45924276|NCT00045682|Drug|Paclitaxel Poliglumex|Given IV
45924277|NCT00045721|Drug|O6-benzylguanine|
45924278|NCT00045721|Drug|polifeprosan 20 with carmustine implant|
45924279|NCT00045721|Procedure|adjuvant therapy|
45924280|NCT00045721|Procedure|conventional surgery|
45924281|NCT00045721|Procedure|neoadjuvant therapy|
45924282|NCT04731766|Behavioral|Citrine 5 % sodium fluoride|Citrine varnish is a 5% sodium fluoride varnish, It was developed to prolong the contact between the tooth surface and fluoride to increase the resistance against caries attack and manage tooth hypersensitivity; the active ingredient of fluoride varnish is mostly 5% sodium fluoride.
45924283|NCT04731766|Behavioral|concocted nano-silver fluoride|Nano-silver fluoride (NSF) is a solution which has been introduced as an experimental formulation in which it's stability for three years has been proved by Santos et al. The laboratory synthesis of concocted NSF was carried out in a nano-technology center; Several trials were done until we have reached a successful end product.
45924284|NCT00045760|Drug|Drotrecogin alfa (activated)|
45924285|NCT00018447|Drug|PTH 1-34|
45924286|NCT00018447|Drug|MFPSR-fluoride|
45924287|NCT00001688|Drug|Ritonavir|
45924288|NCT00001688|Drug|Nevirapine|
45924289|NCT00001688|Drug|Stavudine|
45924290|NCT00389402|Drug|saquinavir/ritonavir|
45924291|NCT00389402|Drug|atazanavir/ritonavir|
45924292|NCT00018525|Procedure|Lung Volume Reduction Surgery|
45924293|NCT00001703|Biological|incomplete Freund's adjuvant|0.7 ml of ISA-51 (Montanide ISA-51 adjuvant, incomplete Freund's adjuvant) will be mixed with peptide alone and injected subcutaneously every four weeks for a total of four vaccinations.
45924294|NCT00001703|Biological|von Hippel-Lindau peptide vaccine|1000 micrograms administered subcutaneously every four weeks for a total of four vaccinations.
45924295|NCT00045799|Drug|Omeprazole sodium bicarbonate immediate release PWD/FS|
45924296|NCT00045799|Drug|Cimetidine IV|
45924297|NCT00045838|Drug|VCR-HIVDNA006-00-VP|
45924298|NCT04394130|Drug|ropivacaine 0.2%|continuous peripheral nerve local anesthetic infusion (ropivacaïne 0.2 %) for 48 hours postoperative.
45796764|NCT05309668|Drug|Selumetinib granule formulation|"Selumetinib granule formulation will be administered using BSA-based dosing. The granule formulation dose schema to be used in the study will be established in the dose finding phase.~At enrolment participants must have a BSA within the range 0.40 to 1.09 m2; once participants attain a BSA between 1.10 and 1.29 m2 they will be encouraged to transition to the capsule formulation, if feasible, although all participants must remain on the granule formulation until after they have completed their third cycle of treatment."
45649399|NCT04914221|Drug|JLP-2002|administration of JLP-2002
45924299|NCT00045877|Drug|Recombinant Human Interleukin-2 and Rituximab|
45649400|NCT04914221|Drug|Comparator|administration of comparator
45924300|NCT00045916|Procedure|High dosage electroconvulsive therapy|Participants will receive high dosage right unilateral ECT at six times the seizure threshold.
45924301|NCT00045916|Drug|Nortriptyline|Participants will receive nortriptyline.
45924302|NCT00045916|Drug|Venlafaxine|Participants will receive venlafaxine.
45924303|NCT00045916|Drug|Lithium|Participants will receive lithium.
45924304|NCT00045916|Procedure|Low dosage electroconvulsive therapy|Participants will receive low dosage bilateral ECT at one and a half times the seizure threshold.
45924305|NCT04380207|Drug|QPX7728|antibiotic
45924306|NCT04380207|Drug|Placebo|Placebo comparator
45924307|NCT04380207|Drug|QPX2014|antibiotic
45924308|NCT00045955|Drug|Fexofenadine, Comparator = Montelukast|
45450258|NCT03536650|Device|DMR|"Procedure: DMR Procedure The Fractyl DMR procedure using the Revita System utilizes an over the wire endoscopic approach to ablate the duodenum. The procedure may be completed in an endoscopic suite or in an operating room depending on the facilities and support at each investigative site. All subjects are monitored and anesthetized by conscious sedation per each facility's standard protocol. A full DMR procedure is defined as 5 complete ablations or 9 axial centimeters of circumferentially ablated tissue in the duodenum. Subjects who do not receive any ablations during the DMR procedure will be followed for safety through the 4 week visit and then discontinued from the study.~Other Names:~DMR Revita"
45450259|NCT02177344|Drug|Low dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
45924309|NCT00001718|Device|Electropalatography|
45924310|NCT00045994|Drug|ALT-711|
45924311|NCT00046033|Drug|Lopinavir/ritonavir|
45924312|NCT00046033|Drug|Ritonavir|
45924313|NCT00046033|Drug|Saquinavir|
45924314|NCT00046033|Drug|Tenofovir disoproxil fumarate|
45924315|NCT00046033|Drug|Amprenavir|
45924316|NCT00046072|Drug|E5564|
45924317|NCT04369560|Diagnostic Test|Magnetic Resonance Imaging|60-cm wide bore 3T scanner (Siemens AG, Erlangen, Germany) with a 32-channel pelvic phased-array coil placed over the bladder.
45924318|NCT04369560|Drug|Gadobutrol intravesical administration (4mM)|A paramagnetic macrocyclic gadolinium-based contrast agent administered intravenously for use in magnetic resonance imaging. Contrast-enhancement is a result of the neutral complex of gadolinium and dihydroxy-hydroxymethylpropyl- tetraazacyclododecane-triacetic acid (butrol).
45924319|NCT04369560|Drug|Ferumoxytol intravesical administration (5 mM)|An iron preparation (Fe3O4) approved for intravenous treatment of anemia in the setting of renal failure, comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution.
45924320|NCT00046111|Drug|topotecan|A topoisomerase I inhibitor used for ovarian and lung cancer treatment
45924321|NCT00001724|Drug|Flurbiprofen|
45924322|NCT04731493|Other|Therapeutic Education Program|"needs assessment~educational group workshop~specialized workshops by age group: child / adolescent / transition / adult / entourage / separated parents and in parallel~socio-administrative workshop~individual summary (accompanied or not by his entourage / family)~satisfaction questionnaire"
45924323|NCT00046150|Drug|Insulin glulisine (HMR1964)|
45924324|NCT02970487|Device|Intraocular implant of the Precisight|Precisight ismplanted in place of the natural cloudy lens, inside the capsular bag.
45450260|NCT02177344|Drug|High dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
45649401|NCT04739449|Behavioral|Coaching, Cleaning, Communication, Collaboration|"Coaching staff~Cleaning protocols, standardized~Communication with staff and leadership~Collaboration with local expertise"
45649402|NCT03711877|Device|Scalp cooling system|Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3°C (37°F) throughout chemotherapy and for 90 minutes to 120 minutes afterward. Temperature of scalp cooling system can be controlled constantly, the effect of reducing scalp temperature maybe better and patient tolerance maybe better. Meanwhile, there is a higher likelihood of hair retention due to a tight fit in scalp cooling system.
45924325|NCT04364880|Device|TBS|Theta-burst stimulation (TBS) is a novel repetitive transcranial magnetic stimulation (rTMS)
45924326|NCT04364880|Device|Sham|The sham-TBS coil produced a similar sound without a magnetic pulse.
45924327|NCT00046267|Drug|Niacin|
45924328|NCT00001730|Drug|Thyrogen|
45924329|NCT00046306|Drug|Antioxidants|
45924330|NCT00046345|Drug|Atazanavir (BMS-232632)|
45924331|NCT04318041|Drug|Artrodar|"Diacerein (Artrodar):~D1-D28 (1 month): Artrodar (50 mg) 1 x 1 with evening meal D29-end of study (23 months): Artrodar (50 mg) 1 x 2 with meal"
45924332|NCT04318041|Drug|Placebos|"Placebo:~D1-D28 (1 month): Placebo 1 x 1 with evening meal D29-end of study (23 months) Placebo 1 x 2 with meal"
45924333|NCT00397657|Drug|extended release niacin|Extended release niacin will be started at 1000mg and titrated to 2000mg once a day
45924334|NCT00397657|Drug|ezetimibe|Ezetimibe 10mg once daily
45924335|NCT00001763|Drug|Interleukin-12|
45924336|NCT00397735|Procedure|amniocentesis|Amniotic fluid will be retrieved for routine amniocentesis to rule-out or confirm intra-amniotic infection and /or inflammation. The amniocentesis procedure will be clinically indicated and the patient will undergo the procedure independent of our study.
45924337|NCT00397735|Drug|N-acetylcysteine or placebo|Only women with amniocentesis results consistent with infection/inflammation will be randomized
45924338|NCT00046384|Drug|aripiprazole|
45924339|NCT00046423|Drug|ABI-007|
45924340|NCT04258410|Drug|Placebo oral soft chew|placebo identical to experimental drug contained in soft chew
45924341|NCT04258410|Drug|Quercetin|experimental drug contained in soft chew
45649403|NCT03711877|Device|Cold cap|The operation of chemical cold cap is convenient and the price was low, and the economic burden of patients was not increased. But it is necessary to replace the cold cap periodically during chemotherapy, and the temperature during chemotherapy is difficult to keep constant.
45649404|NCT03054701|Other|Hip specific resistance exercise|Hip specific resistance exercise
45649405|NCT03054701|Other|Knee specific resistance exercise|Knee specific resistance exercise
45796765|NCT05309668|Drug|Selumetinib capsule formulation|Selumetinib capsule formulation will be administered using BSA-based dosing. Once participants attain a BSA between 1.10 and 1.29 m2 they will be encouraged to transition to the capsule formulation, if feasible, although all participants must remain on the granule formulation until after they have completed their third cycle of treatment.
45796766|NCT05305352|Other|Very low carbohydrate dietary intervention|The experimental group will be counseled about very low carbohydrate diet i.e., <10% carbohydrate,40-50% protein and lipid in diet).
45649406|NCT05124379|Device|Hemoclin Gel|Non sterile gel for intra-rectal use
45649407|NCT03344263|Diagnostic Test|tests of attentional performance|tests of attentional performance before and after 6 months of continuous positive airways pressure
45796767|NCT05297448|Drug|Rifaximin SSD|Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily
45796768|NCT05297448|Drug|Placebo|Placebo Twice Daily
45796769|NCT05285618|Device|Argus II|In response to the stimulation/image on the monitor subjects will be asked to make perceptual judgments and complete simple behavioral tasks. Examples include detecting a stimulus ('did you see a light on that trial'), reporting size by drawing on a touch screen, reporting shape by selecting a tactile object of similar shape, or locating a target by moving around, rotating the head, and pointing. Sighted control subjects will perform similar tasks in virtual reality.
45796770|NCT05280964|Behavioral|Better Together Physician Coaching|6 month, online group coaching program
45796771|NCT05273268|Other|Personalized nutrition|Personalized nutrition based on individual traits delivered through mobile device app.
45796772|NCT05273268|Other|Generalized nutrition|General nutrition guidelines currently used by USDA.
45649408|NCT04892615|Device|drainage tube was removed on 5th days after surgery.|drainage tube was removed on 5th days after surgery.
45796773|NCT05256160|Other|TMS Paired-Pulse assessment of cortical excitability|Using the paired-pulse TMS paradigm, intracortical inhibition and facilitation of cortical circuitry will be assessed by stimulating the motor cortex and using the electromyographic (EMG) response of a target muscle as readout. In such studies, a conditioning stimulus modulates the amplitude of the motor-evoked potential (MEP) produced by the test stimulus. Depending on the inter-stimulus interval, effects can be attributed to different aspects of cortical processing. Brief intervals (1-5 ms) will be used to assess short-interval intracortical inhibition (SICI) and short-interval intracortical facilitation (SICF), intermediate intervals (7-20 ms) to assess intracortical facilitation (ICF) and long intervals (50-200 ms) to assess long-interval intracortical inhibition (LICI).
45796774|NCT05256160|Other|Autonomic activity|Autonomic function will be determined using continuously recorded EKG and used as covariates to investigate any systematic impact on cortical excitability measures collected with the paired-pulse protocols.
45796775|NCT05248204|Device|Scotchbond™ Universal Plus Adhesive|Eligible tooth with Class I or Class II carious lesion randomized to the SBU+ treatment group will undergo restoration with Scotchbond™ Universal Plus Adhesive using self-etch mode and Filtek Universal Restorative
45796776|NCT05248204|Device|Scotchbond™ Universal Adhesive|Eligible tooth with Class I or Class II carious lesion randomized to the SBU control group will undergo restoration with Scotchbond™ Universal Adhesive using self-etch mode and Filtek Universal Restorative
45796777|NCT05241834|Drug|LOXO-260|Oral
45796778|NCT05241444|Biological|CD4^LVFOXP3|"Infusion of autologous CD4+ T cells that have undergone lentiviral-mediated gene transfer of:~i) healthy human FOXP3 gene leading to persistent high FOXP3 expression and acquisition of Treg-like cell function; and ii) human CD271 surface marker gene that allows tracking and quantification of the CD4^LVFOXP3 in the blood."
45796779|NCT05207748|Diagnostic Test|Bone mineral density|Bone mineral density (BMD) will be measured on the lumbar spine (L1-L4) and femoral neck by dual X-ray absorptiometry (DXA) method.
45796780|NCT05205655|Behavioral|collection of odour samples|Odours will be collected by participants by putting sterile compresses under the armpits for at least 4 h.
45796781|NCT05201287|Other|VIA Disc NP|VIA Disc NP is processed from donated cadaveric disc tissue, lyophilized, and micronized to particles.
45796782|NCT05192174|Biological|NIB101|NIB101
45796783|NCT05161156|Combination Product|Test Product (tiotropium bromide inhalation powder)|A single dose of test product
45796784|NCT05161156|Combination Product|18 mcg of Spiriva (Reference Product)|A single dose of reference product (Spiriva)
45796785|NCT05161156|Combination Product|Placebo|A single dose of placebo
45796786|NCT05155150|Behavioral|Providing patient-reported outcome|Patients receive personalized information on expected quality of life one year after ICU during ICU admission (during a family meeting)
45796787|NCT05132101|Drug|Patients who received Palbociclib as first line therapy in MBC setting|Patients who received Palbociclib as first line therapy in MBC setting
45796788|NCT05131672|Procedure|open reduction and internal fixation (ORIF)|open reduction and internal fixation with pin or screw fixation
45796789|NCT05131672|Procedure|cast immobilization|immobilization in a cast without reduction
45796790|NCT05129202|Drug|immune therapy|The patient receives immunotherapy
45924342|NCT00046462|Drug|Lantus (insulin glargine [rDNA origin] injection)|
45924343|NCT00046462|Drug|Metformin|
45924344|NCT00046462|Drug|Glyburide|
45924345|NCT00046462|Drug|Thiazolidinedione|
45450261|NCT02177344|Drug|Atrovent|Two puffs, 4 times daily by oral inhalation
45450262|NCT02177344|Drug|Placebo|
45649409|NCT04892615|Device|drainage tube was removed on 7th days after surgery.|drainage tube was removed on 7th days after surgery.
45754385|NCT04211649|Drug|3 days of antibiotherapy|Reduce at 3 days of antibiotherapy for the treatment of mild leptospirosis
45924346|NCT00001766|Drug|Amprenavir, Efavirenz, Abacavir, Nelfinavir, Ritonavir|
45924347|NCT00046501|Drug|Lantus (insulin glargine [rDNA origin] injection)|
45924348|NCT00046501|Drug|Humulin N|
45924349|NCT00046501|Drug|Humulin L|
45924350|NCT00046501|Drug|Lispro|
45796791|NCT05100641|Biological|AV-GBM-1|Therapeutic autologous dendritic cell vaccine
45796792|NCT05100641|Biological|Autologous monocytes|Autologous monocyte control
45796793|NCT05093972|Drug|Ulonivirine|Four ulonivirine 100 mg tablets (total dose 400 mg) taken by mouth.
45796794|NCT05089929|Device|Endoflip 2.0|FLIP topography (Endoflip 2.0) analysis will be performed on all patients undergoing routine evaluation for gastroesophageal reflux disease at the time of their pre-operative EGD.
45924351|NCT00046540|Drug|Liposome-encapsulated SN38|
45924352|NCT04222959|Behavioral|Girls Invest Mobile App Intervention|"Gender and life skills training:~App-based trainings culturally tailored and adapted to this population using our formative work and based on elements from life skills trainings used in previous effective pregnancy prevention interventions among youth. We added sessions focused specifically on financial skill-building. Trainings included app features such as gaming dynamics, and quizzes. Each module estimates 25 minutes to complete.~Training modules:~The first 3 modules cover gender and cultural norms related to girls' social and economic opportunities, increasing girls' recognition of the importance of financial literacy, independence, and power in decision-making. The last 3 modules cover finance, educational loans, and employment."
45924353|NCT04222959|Other|Savings Account Subsidies|Girls Invest builds upon two broadly accepted economic empowerment strategies: a) savings and b) cash transfers. The most promising economic empowerment interventions for girls have incorporated concrete economic resources along with training on life skills and gender.1-3 Trainings encourage girls to save additional funds (e.g. from family). Participants have online access and can withdraw savings anytime, however, we will assess savings behaviors to consider other account features (e.g. commitment-based savings). In the future, subsidies could be supported via ads in the app and financial support from banks.
45924354|NCT00046696|Drug|NM-3|
45924355|NCT00046735|Drug|Lenalidomide|The planned doses for investigation are as follows: 5, 10, and 25 mg/day. Lenalidomide will be administered as a single daily dose for 4 weeks followed by a 2-week rest period. Dosing will be in the morning at approximately the same time each day, at least 1 hour before the morning meal. Patients will be assigned to dose level in the order of study entry. No dose adjustments or suspensions are allowed during the first cycle, except discontinuation for DLT
45924356|NCT00046774|Drug|MRA 003 US|
45924357|NCT00001784|Drug|Mexiletine|
45924358|NCT00046813|Drug|Nicotine patch|
45924359|NCT00046852|Biological|filgrastim|
45924360|NCT00046852|Biological|pneumococcal polyvalent vaccine|
45924361|NCT00046852|Biological|therapeutic autologous lymphocytes|
45796795|NCT05089929|Procedure|High Resolution Manometry|All patients undergoing routine evaluation for gastroesophageal reflux disease will undergo high resolution manometry (HRM) testing.
45796796|NCT05081752|Device|OTSC Stentfix|Stent placement with fixation of the esophageal stent using OTSC Stentfix.
45796797|NCT05081752|Procedure|Stent Suturing / Endoscopic Clips|Stent placement with fixation of the esophageal stent using sutures / endoscopic clips.
45796798|NCT05076552|Drug|TACH101|Orally via capsules
45796799|NCT05062395|Procedure|Computed Tomography|Undergo FDG PET CT
45796800|NCT05062395|Other|Fludeoxyglucose F-18|Undergo FDG PET CT
45796801|NCT05062395|Other|Low Carbohydrate High Fat Diet|low carbohydrate and high fat diet for 48-72 hours
45796802|NCT05062395|Procedure|Positron Emission Tomography|Undergo FDG PET CT
45796803|NCT05045950|Drug|Memantine -Twice Daily or Extended Release|"Both extended release memantine and twice daily memantine dosing will be allowed.~Twice daily dosing:~The target dose for memantine is 20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg each week to a target of 10 mg twice daily (i.e., 5 mg a day on week 1, then 5 mg twice daily (BID) on week 2, then 10 mg in AM plus 5 mg in PM on week 3, followed by 10 mg in AM plus 10 mg in PM by week 4).~Extended Release Memantine:~The target dose for extended release memantine is 28 mg. Dose will be escalated by 7 mg per week to a target of 28 mg daily (i.e., 7 mg a day on week 1, then 14 mg a day on week 2, then 21 mg a day on week 3, followed by 28 mg a day by week 4)."
45796804|NCT05045950|Radiation|WBRT utilizing the PRDR technique|The total dose of 3000 cGy (30 Gy) will be divided 10 fractions of 300 cGy (3 Gy); each fraction will be delivered as a series of 20 cGy (0.2Gy) pulses separated by 3 min time intervals. 20 cGy / 3 min = 6.67 cGy/min (or 0.0667 Gy/min). Total time is determined by the fractionated series and time intervals, meaning 300cGy/20cGy = 15 division x 3 minutes = 45 minutes. Including time to set up, approximate total time per treatment session will be 60 minutes.
45796805|NCT05023317|Behavioral|Strengths-based linkage to alcohol care|SLAC is a behavioral intervention designed to link persons with substance use/misuse to care
45796806|NCT05023317|Behavioral|Usual care|Usual care consists of brief screening and intervention and/or standard referral to alcohol care
45649410|NCT04892381|Diagnostic Test|Skin Biopsy|"Skin biopsy will be taken under local anesthesia :~From each normal control; a 3 mm punch skin biopsy from a sun protected area will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study.~From each LP patient; two punch skin biopsies will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study:~i. The first biopsy will be a 3 mm punch biopsy from the center of LP lesional skin of sun protected area ii. The second biopsy will be a 3 mm punch biopsy from non lesional skin at least 15 cm away from the edge of any existing LP lesion of sun protected area~The level of PD1 and PD-L1 will be detected using ELISA technique.~The lesional biopsy will be assessed by routine hematoxylin and eosin (H&E) to confirm the diagnosis of LP"
45796807|NCT04998201|Drug|ARO-APOC3|ARO-APOC3 Injection
45796808|NCT04998201|Drug|Placebo|Sterile Normal Saline (0.9% NaCl)
45924362|NCT00046852|Biological|therapeutic tumor infiltrating lymphocytes|
45924363|NCT00046852|Drug|carmustine|
45924364|NCT00046852|Drug|cyclophosphamide|
45924365|NCT00046852|Drug|melphalan|
45924366|NCT00046852|Procedure|bone marrow ablation with stem cell support|
45924367|NCT00046852|Procedure|peripheral blood stem cell transplantation|
45924368|NCT00046969|Biological|epoetin beta|
45924369|NCT00046969|Drug|cisplatin|
45924370|NCT00046969|Radiation|brachytherapy|
45924371|NCT00046969|Radiation|radiation therapy|
45924372|NCT00001805|Drug|Rituximab|
45924373|NCT00047047|Drug|gemcitabine hydrochloride|Given IV
45924374|NCT00047047|Drug|tanespimycin|Given IV
45796809|NCT04997733|Drug|Fecal Microbiota Transplantation (FMT)|"The colonoscopy for FMT will be planned between 7 and 14 days after the last adalimumab or sub-cutaneous infliximab administration and 6 weeks +/- 7 days after the last intravenous infliximab administration. After colon cleansing using polyethylene glycol, the patient will have a colonoscopy under general anesthesia. The patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of saline (NaCl 0.9%), (FMT vehicle in the terminal ileum or the colon.~At W12 and W24 after first colonoscopy, the patient receives treatment by capsule (15 capsules contain 0.8g of stools by visit)."
45924375|NCT00047047|Drug|cisplatin|Given IV
45924376|NCT00047047|Other|laboratory biomarker analysis|Correlative studies
45924377|NCT00047125|Radiation|radiation therapy|
45924378|NCT04733781|Drug|Tumescent Lidocaine and Epinephrine|Subcutaneous injection of a relatively large volume (125ml to 250ml) of a relatively dilute solution of lidocaine (1gm/L) and epinephrine (1mg/L or 2mg/L).
45924379|NCT04198311|Behavioral|CBT-I|CBT-I will be delivered individually, in five weekly sessions. Intervention components include sleep hygiene, sleep restriction, stimulus control, relaxation, cognitive therapy.
45924380|NCT00047164|Biological|ipilimumab|
45924381|NCT05641571|Behavioral|The home-based extremity exercise program|Participants have to perform a total of 50 minutes of exercise including the Ten Skilled Hand exercise fourth a day, 5 minutes each time and Buerger Allen exercise twice a day, 15 minutes each time before chemotherapy to the completion of chemotherapy.
45924382|NCT00047203|Drug|alvocidib|Given IV
45924383|NCT04163874|Drug|Fiasp|Fiasp Insulin delivered in a basal-bolus manner.
45924384|NCT04163874|Drug|Pramlintide Acetate|Pramlintide delivered in a basal-bolus manner with a fixed ratio with insulin.
45924385|NCT04163874|Drug|Placebo|Placebo delivered in a basal-bolus manner with a fixed ratio with insulin.
45924386|NCT04163874|Device|Artificial Pancreas|Tandem insulin pump, dexcom G5 sensor, Nexus 5 cellphone running the iMAP algorithm.
45924387|NCT00047242|Drug|7-hydroxystaurosporine|
45924388|NCT00047242|Drug|irinotecan hydrochloride|
45924389|NCT00047281|Drug|celecoxib|
45924390|NCT00047281|Drug|cyclophosphamide|
45450263|NCT03536494|Behavioral|Review the use of mirabegron and its discontinuation|"A structured intervention was designed consisting of four major sections:~General practitioners: information and training with written material and patient-centred prescribing.~Specialized hospital care: information regarding the intervention for urologists and gynaecologists.~Management support with the definition of a structured strategy.~Monthly monitoring of the intervention."
45450264|NCT02180308|Device|PET/MRI|Simultaneous PET/MRI (3T system)
45450265|NCT02177422|Drug|Telmisartan|telmisartan 80 mg once daily
45924391|NCT00047281|Drug|etoposide|
45924392|NCT00047281|Drug|thalidomide|
45924393|NCT00047437|Behavioral|Supervised Exercise Training Program|Exercise 30 minutes minimum three times per week.
45924394|NCT00047476|Drug|dexmethylphenidate(d-mph)|
45924395|NCT00047515|Drug|Alcon Investigational Agent|
45924396|NCT00047554|Drug|Travoprost, 0.004% ophthalmic solution|
45450266|NCT02177422|Drug|Hydrochlorothiazide|12.5 mg or 25 mg Hydrochlorothiazide in addition to telmisartan in case that the goal response (mean sitting diastolic blood pressure < 90 mmHg) is not met after at least 4 weeks of treatment with telmisartan
45649411|NCT05100121|Device|Interactive app|In the app, the patients will report frequency and distress on commons concerns regarding urine dysfunction, bowel dysfunction, emotional distress, sleep, pain, loss of appetite, hot flashes/sweating, edema, and sexual dysfunction. Free text comments will also be possible to make to cover the patients' other potential needs. Questions regarding symptoms of acute character that might need to be treated quickly like severe pain, blood in stool and urine, and involuntary weight loss will also be asked for to timely detect and treat signs of for example cancer relapse. Information about the concerns will be included in the app containing; a) general information of why they have the side effect and what it means b) evidence-based advice about self-management; c) when they should contact health care providers, and d) further information linked to reliable documents and web pages.
45924397|NCT00047593|Drug|IOP Lowering Medications|
45924398|NCT00047632|Drug|Interferon gamma-1b|100 mcg, SQ, 3x per week
45924399|NCT04153890|Behavioral|FamPALcare|"Intervention participants will receive standard care plus five weekly coaching sessions with telephone follow-up to reinforce HF palliative home care. FamPALcare intervention will be delivered by community-based nurses. FamPALcare intervention involves coaching patients and family caregivers in advanced HF home care and supporting EOLPC discussions.~The standard care group will receive routine HF care and instruction at university hospital or at clinic appointments. All patients can be referred for supportive care and heart failure care per national HF guidelines."
45924400|NCT00047671|Drug|Citalopram|PDA Approved antidepressant
45924401|NCT00047710|Drug|Bevacizumab|Beginning 2 weeks prior to radiotherapy, dose of 5 mg/kg by vein then of 2.5 mg/kg during radiotherapy for four weeks every 2 weeks (three doses).
45649412|NCT05100121|Other|Survivor-ship care|At coaching session with the district nurse, patient reported assessments will be used to discuss the individual's current situation and to plan eventual additional actions needed such as support from a physiotherapist, social worker, dietitian or if a visit to the physician if needed. This is documented in a survivorship care plan which contain e.g., risk of symptoms, late effects, healthy lifestyle information, prevention tips and support of psychosocial concerns. The intervention incorporates coaching encounters using motivational interviewing techniques to engage patients in the patient-owned survivor-ship care plan that include health goals and strategies related to cancer follow-up, surveillance, symptom management, and health behavior.
45649413|NCT03054779|Other|Canola Oil|Regular canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.
45649414|NCT03054779|Other|High oleic acid canola oil|High oleic acid canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.
45796810|NCT04997733|Drug|Sham-transplantation (placebo)|"The colonoscopy for sham-transplantation will be planned between 7 and 14 days after the last adalimumab or sub-cutaneous infliximab administration and 6 weeks +/- 7 days after the last intravenous infliximab administration. After colon cleansing using polyethylene glycol, the patient will have a colonoscopy under general anesthesia. The patient will then receive either sham transplantation (frozen preparation of NaCl 0.9% with 10% glycerol) in the terminal ileum or the colon.~At S12 and S24 after first colonoscopy, the patient receives treatment by capsule (15 capsules contain placebo)."
45796811|NCT04991077|Biological|analyse of angiogenic, vasoactive and VEGF systems|the angiogenic, vasoactive and VEGF systems will be analysed through blood and urine sampling. These samples will be collected at the time of malignant hypertension diagnosis and repeated one month later, in 30 patients (patients group). The same tests will be performed once in 15 patients with severe non-malignant hypertension, constituting the control group.
45796812|NCT04969146|Behavioral|Dyadic Intervention|The patient and caregiver dyads will complete and return baseline questionnaires and then be randomized to Modified CBTi Dyadic Intervention. The patient and caregiver in the dyadic intervention will have 5 sessions of Modified CBTi. Upon completion of the intervention, the patient and caregiver will complete the follow up assessments at approximately 3 months and 6 months after the baseline questionnaires.
45796813|NCT04969146|Behavioral|Patient Only Intervention|The patient and caregiver dyads will complete and return baseline questionnaires and then be randomized to Modified CBTi Patient Only Intervention. The patient in the Patient Only Intervention will have 5 sessions of Modified CBTi. Upon completion of the intervention, the patient and caregiver will complete the follow up assessments at approximately 3 months and 6 months after the baseline questionnaires.
45796814|NCT04949711|Behavioral|ridesharing voucher|Ridesharing vouchers will be given for completing each of the online surveys, for a possible total of $80 if you complete all three surveys. You will be paid with electronic vouchers that will be sent to your cell phone.
45796815|NCT04949711|Behavioral|online shopping voucher|Online shopping vouchers will be given for completing each of the online surveys, for a possible total of $80 if you complete all three surveys. You will be paid with electronic vouchers that will be sent to your cell phone.
45796816|NCT04948827|Drug|SBP-9330|SBP-9330 oral capsules
45796817|NCT04948827|Drug|Placebo|Placebo oral capsules
45649415|NCT03054779|Other|Western diet oil combination|"A typical Western diet fat intake as a control treatment, comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA, will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily"
45796818|NCT04947514|Drug|Tranexamic acid|Topical tranexamic acid (1000mg) will be administered to the raw surface of the breast prior to closure of the incisions.
45796819|NCT04947514|Other|Placebo (topical saline)|The untreated breast will receive topical saline.
45796820|NCT04939324|Biological|Blood samples at 2 sites: peripheral vein and tumor-draining vein|"D0: surgery (inclusion): oncological lung resection~Blood samples at 2 sites: peripheral vein and tumor-draining vein~Resected tumor analysis Standard clinical and radiological follow-up during 2 years (medical consultation or phone call)"
45924402|NCT00047710|Drug|Capecitabine|650mg/m^2 taken by mouth twice a day 15-52 during the radiotherapy.
45796821|NCT04937972|Drug|SHR-1701 Combined With Fluazopalil|SHR-1701 +fluzoparib
45796822|NCT04931797|Behavioral|video decision aid|advance care planning video decision aid
45796823|NCT04931797|Behavioral|control arm ACP information sheet|control arm ACP information sheet
45796824|NCT04924101|Biological|Pembrolizumab|IV infusion
45796825|NCT04924101|Biological|MK-4830|IV infusion
45796826|NCT04924101|Biological|Boserolimab|IV infusion
45796827|NCT04924101|Drug|Lenvatinib|Oral capsule
45796828|NCT04924101|Drug|Etoposide|IV infusion
45796829|NCT04924101|Drug|Cisplatin|IV infusion
45796830|NCT04924101|Drug|Carboplatin|IV infusion
45796831|NCT04921631|Behavioral|Early Integration of Specialty Palliative Care with Critical Care|The PC team will visit the patient within 24 hours of randomization and the consultation will address the following domains of PC: illness understanding and goals of care conversations with patients/surrogates; symptom assessment and management; spiritual needs; patient and family coping and support; and care coordination and transitions. The initial family meeting will be scheduled to occur within two days of randomization. Follow-up visits will be conducted by the PC MD/APP every weekday. During this time, the ICU and PC team will be in daily communication. The PC team will continue to follow the patient in the hospital once discharged from ICU. Prior to discharge, the PC team will document patient goals and preferences for future treatment, coordinate appropriate PC services in the home and/or outpatient clinic settings and contact the patient's primary physician to provide an update on the patient's hospital stay.
45924403|NCT00047710|Radiation|Radiotherapy|Radiography given once a day for 5 days at 50.4 Gy in 28 fractions over 5.5 weeks.
45924404|NCT00047749|Drug|Prialt (ziconotide)|
45924405|NCT03416816|Drug|DSP-0337|DSP-0337 will be administered at the following doses in dose-escalation cohorts, maximum tolerated dose (MTD) for food effect, and recommended phase 2 dose (RP2D) for dose-expansion cohort. Dose 1: 200 mg once daily, Dose 2: 200 mg twice daily, Dose 3: 400 mg twice daily, Dose 4: 600 mg twice daily, Dose 5: 800 mg twice daily, Dose 6: 1000 mg twice daily.
45924406|NCT00047788|Drug|ZD6474|
45924407|NCT00047788|Drug|VEGF-receptor tyrosine kinase (KDR)|
45924408|NCT00047827|Drug|Micafungin|IV
45924409|NCT00047827|Drug|Liposomal Amphotericin B|IV
45796832|NCT04919109|Biological|CodaVax-RSV|live attenuated vaccine against RSV
45649416|NCT04900961|Other|Resistance Exercise|The exercise regimens are generic and designed not to require expert physiotherapy input, therefore, the availability of NHS physiotherapists, which may be at times limited, will not be a barrier to implementation
45796833|NCT04919109|Biological|Normal Saline|Placebo comparator
45796834|NCT04917094|Device|Compression stocking|"A below-the-knee compression stock will be worn daily for 2 weeks from waking up to before sleep.~Bioelectrical impedance will be performed before and 2 weeks after wearing the stocking to assess the total body water content.~Measuring the calf and neck circumference will be done before and after wearing the compression stocking. After 2 weeks, the patient will return back to the clinic for calf and neck circumference measurement.~Sleep test will be done the night before and 2 weeks after wearing the compression stocking. Oxygen Desaturation Index(ODI) will be assessed through a level 4 home sleep apnea testing device.~Patients recruited will have mild excessive to severe excessive daytime sleepiness and/or STOP-Bang score of 3 or more, with underlying conditions such as type II diabetes and hypertensive patients using the Epworth sleepiness scale. Epworth sleepiness scale will be assessed again 2 weeks after to assess for increase sleep efficiency."
45796835|NCT04912089|Behavioral|COGENT|COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.
45796836|NCT04910139|Device|Soniflow System|Treatment using acoustic vibrational headband worn circumferentially at the level of the forehead paired with a Smartphone App.
45796837|NCT04906265|Other|Intervention|The intervention comprises of standard rehabilitation and continuous measures of body positions and movements 24 hour a day with an IMU. Standard rehabilitation comprises of home-visits by a PT, where an individualized rehabilitation plan is outlined together with the patient. The plan includes individually tailored functional exercises. The plan also includes individually tailored walking exercises, indoor and outdoor when possible. At each home visit, the PT provides feedback to the participant based on the data from the IMU, i.e. body positions (time spent in sitting, standing, lying down) and body movements (steps per day, step length, walking speed, sideway deviation during walking)
45924410|NCT03389711|Combination Product|DMARD´s and multidisciplinary treatment|"At study enrollment, medical history, disease-specific autoantibodies, ACR 1987 classification criteria for RA were applied. Medical evaluations were standardized and included at least 66 swollen and 68 tender joint counts, acute reactant-phase determinations , patient and physician reported outcomes, comorbidity established by record review, and treatment assessments (name, dose and schedule of all drug they were taking) along with an evaluation of persistence, at six-month intervals.~Patients were evaluated by a single rheumatologist every two months during the first two years of follow-up, and every two, four or six months thereafter.~Also the following scores: Michigan Hand Outcome Questionnaire (MHQ), Disabilities of the Arm, Shoulder and Hand Outcome Measure (DASH),Mayor Depressive Episodes (MDE) was defined using the Mini International Neuropsychiatric Interview and the severity of depressive symptoms was assessed with the Beck Depression Inventory (BDI-II)."
45924411|NCT00047905|Behavioral|examine the process of prenatal genetic counseling|
45924412|NCT00047983|Dietary Supplement|Canola oil|
45924413|NCT00047983|Dietary Supplement|Arginine|
45924414|NCT00047983|Dietary Supplement|Fish oil emulsion|
45450267|NCT02180386|Behavioral|Patients will play a video game with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.|videogame can be considered as a method of distraction.
45450268|NCT02182882|Drug|GINSANA|
45450269|NCT02182882|Drug|Placebo|
45924415|NCT00389480|Drug|AR-67 (formerly DB-67)|infusion daily x 5 days, every 21 days
45450270|NCT02182960|Drug|Ibuprofen syrup|
45796838|NCT04906265|Other|Control|Standard rehabiliation
45796839|NCT04878614|Drug|Levothyroxine Tablet|Standard clinical management
45450271|NCT02182960|Drug|Brufen syrup|
45450272|NCT05141968|Dietary Supplement|vitamin D supplements (2000 IU/day)|The interventional (experimental) group received vitamin D supplements (2000 IU/day). According to previous studies and after the direct supervision from the treating pediatrician and endocrinologist, the best preparation and dosage of vitamin D was used (According to FDA the recommended dose for children age 1 year and older is 2,000 IU/day).
45796840|NCT04878614|Drug|Levothyroxine Sodium|Liquid levothyroxine through enteral feeding tube
45450273|NCT00110357|Drug|Cetuximab + Irinotecan|Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 16 or 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
45649417|NCT03054623|Procedure|DRIL procedure|The DRIL procedure involves creation of a bypass from an arterial inflow site (usually mid brachial artery) proximal to the fistula inflow, to the bifurcation of the brachial artery distal to the fistula, with ligation of the intervening native vessel, thus restoring distal flow while preserving flow through the fistula.
45796841|NCT04870658|Procedure|Dental implant treatment|Patients who receive one o more dental implant treatment to restore oral function.
45924416|NCT00048022|Drug|Dual Integrin Antagonist|
45924417|NCT00291447|Biological|ch806|ch806 is a chimeric (part human, part mouse) antibody which recognizes and attaches to a protein called the 806 antigen (a type of EGFR), which is found on the surface of some cancer cells.
45924418|NCT00048100|Procedure|Apheresis|Apheresis for T-Cell collection
45924419|NCT00048100|Biological|Stem Cell Transplant|Stem cell or marrow infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL).
45924420|NCT00048139|Drug|Irinotecan|250mg/m2 iv on day 1 of each 3 week cycle
45924421|NCT00048139|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-15 of each 3 week cycle
45649418|NCT04900883|Other|survey|anonymous survey
45796842|NCT04860011|Drug|Dapagliflozin 10 MG Oral Tablet|Dapagliflozin 10mg once daily
45796843|NCT04860011|Drug|Metolazone Tablets|Metolazone 5MG or 10MG once daily
45796844|NCT04842500|Behavioral|Demand Informed Moderator Analysis|This analysis is designed to determine the degree to which relative price, and the timing of extinction, interact to increase or abate responding during extinction (thereby highlighting mechanisms of control).
45796845|NCT04837014|Other|prescription for regular acetaminophen and naproxen|Patient allocated to the intervention arm will be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then prn for one week's duration. No narcotic will be prescribed at discharge post-operatively.
45796846|NCT04837014|Other|prescription for regular acetaminophen , naproxen and dilaudid|prescription for regular acetaminophen , naproxen and dilaudid
45796847|NCT04827745|Drug|BLINCYTO (Blinatumomab)|Blinatumomab (BLINCYTO , AMG 103, formerly also known as MT103 or bscCD19xCD3) is a novel single chain antibody construct in the class of the bispecific T-cell engager (BiTE®). Blinatumomab directs CD-3 positive effector memory T cells to CD19-positive target cells (Hoffmann et al, 2005; Dreier et al, 2002). The targeted CD19 antigen is constitutively expressed on normal B cells throughout a person's lifetime (Smet et al, 2011) and is highly conserved in B-cell malignancies (Tedder, 2009; Wang et al, 2012).
45796848|NCT04777084|Drug|IBI318|IBI318, 300 mg, administered by intravenous infusion on the first day of each cycle, 1 cycle every 2 weeks (Q2W), continuous medication; lenvatinib 20 mg, orally, continued medication until disease progression, death, toxicity is intolerable, Withdrawal of informed consent, start a new anti-tumor treatment or terminate the treatment for other reasons specified in the plan, the maximum use time is 2 years.
45796849|NCT04747275|Drug|Liquid stable levothyroxine (L-T4) Tirosint-SOL|Investigation of tolerability, palatability, and adherence of liquid levothyroxine (L-T4) for 8 weeks.
45649419|NCT04892225|Behavioral|Technology-supported behavioral intervention (text message)|A simple text message regarding the salt and fluid restriction in order to reduce the inter-dialytic weight gain will be send on daily basis to all the individuals in the intervention group.
45649420|NCT04147559|Device|Total Hip Arthroplasty Implant|Single study group either newly or previously implanted with the PROFEMUR® Preserve Classic Femoral Stem combined with other Wright Medical Technology (WMT) or MicroPort Orthopedics Inc (MPO) THA components including acetabular shells, liners and femoral heads.
45649421|NCT04900649|Other|chest resistance exercise|lung function.
45649422|NCT04900649|Other|chest expansion exercises|thoracic excursion
45649423|NCT04913909|Dietary Supplement|Effects of an oral probiotic or placebo use on oral microbiota and glycemic index in Type 2 diabetic patients|"The participants were randomized to the interventional groups, probiotic or placebo, by the diabetes nurse. During the intervention period of 30 nights, the participants were asked to let one Dentoblis™ or placebo lozenge slowly melt in their mouth for one minute before going to bed and after tooth brushing. Dentoblis™, as a test lozenge, contains 4x109 CFU/g S. salivarius M18 strain isolated from a healthy oral microbiota and has been utilized as oral probiotic inhibiting dental caries-causing pathogens.~The placebo is indistinguishable in form, size, color, and taste from the probiotic lozenge, but contains no bacteria. Placebo and probiotic lozenges were equivalent to 810 mg each and containing same amount of xylitol. Both were provided by the manufacturer, Bluestone Pharma GmbH, Baar, Switzerland, in equal white containers boxes, separated by production code. Neither the investigators nor the subjects were aware of the contents of the lozenges except for the research nurse."
45649424|NCT04891601|Procedure|polypropelene mesh|compare use mesh alone or combined mesh and darn repair
45649425|NCT01596335|Drug|TA-650|TA-650 at 5 mg per kg body weight on the day of TA-650 administration (day 0) is administered by intravenous infusion slowly over at least 2 hours.
45649426|NCT01596335|Drug|Polyethylene Glycol-treated Human Immunoglobulin (VGIH)|VGIH at 2 g per kg body weight on the day of VGIH administration (day 0) is administered by intravenous infusion slowly over at least 20 hours.
45796850|NCT04747275|Drug|Oral tablet levothyroxine (L-T4)|Investigation of tolerability, palatability, and adherence of maintained oral tablet levothyroxine (L-T4) for 8 weeks
45796851|NCT04744324|Behavioral|Self-supporting Care|Individualized self-supporting care with four principals (i.e., drinking water, exercise, excretion, and nutrition)
45796852|NCT04744324|Behavioral|Home health education|Individualized home health education
45796853|NCT04744285|Other|Cigarette packaging|receive normal packet cigarette
45796854|NCT04744285|Other|Data capture|Attend video sessions
45649427|NCT04891679|Drug|Oral misoprostol solution (OMS)|"Based on the WHO labor induction recommendation, and for the purpose of achieving precise oral misoprostol dosage, one misoprostol tablet (200 mcg) was pulverized and dissolved into 200 ml water.90 Thus 1ml of solution had 1mcg of misoprostol. This misoprostol solution could be preserved at room temperature and remained active for 24 hours.~Hourly titrated oral misoprostol solution was given to group A as described by Wang X et al, 2016 as described below.~0 hour= 20ml~hour= 20ml~hour= 30ml~hour= 30ml~hour= 30ml~hour= 40ml 6.5 hour= 50ml 8.5 hour= 60ml 10.5 hour=60ml~Group B received 25 mcg (25 ml) oral misoprostol solution every 2 hours for a maximum of 12 doses or until the onset of regular uterine activity."
45796855|NCT04744285|Other|Questionnaire administration|Ancillary studies
45796856|NCT04735978|Biological|RP3|Genetically modified HSV-1
45796857|NCT04735978|Biological|Nivolumab|anti-PD1 monoclonal antibody
45796858|NCT04720534|Drug|ARO-APOC3|2 doses of ARO-APOC3 by subcutaneous (sc) injection
45796859|NCT04720534|Drug|Placebo|calculated volume to match active treatment by sc injection
45796860|NCT04715581|Dietary Supplement|Preoperative nutritional optimization|"Indication for oral nutritional supplementation: Patients at risk of malnutrition (MNA-SF 8-11) or with malnutrition (MNA-SF 0-7).~Protocol of nutritional optimization: Enteral nutritional powder (Ensure for patients without diabetes and Glucerna for patients with diabetes) twice a day. The target protein intake is 1.5-1.8 g/kg/d. Patients with iron deficient anemia (hemoglobin <130 g/L for men and <120 g/L for women) will be given oral iron therapy.~The duration of nutritional optimization: Two weeks prior to the surgery to one day prior to the surgery."
45804123|NCT05686213|Behavioral|combined aerobic exercise + resistance exercise intervention (AE + RE)|The AE + RE intervention group will be offered a supervised exercise program which includes both aerobic and resistance exercise. Exercise sessions will take place twice a week with a duration of 60 minutes. The training load will be tailored to a patient's individual fitness level throughout the intervention. Patient will be asked to be physically active on an additional day in the week on their own (for at least 30 minutes at moderate intensity) according to the ACSM guidelines for patients with cancer.
45649428|NCT04913831|Drug|Cerebrolysin|Cerebrolysin 20ml + physiological saline 80ml, 8-35 days, once/day, intravenous administration
45649429|NCT04913831|Drug|Placebo|physiological saline 100ml, 8-35 days, once/day, intravenous administration
45796861|NCT04715581|Other|Preoperative exercise training|"Exercise training includes aerobic exercise and respiratory training.~A home-based aerobic exercise will be performed for at least 1-2 times per day. The respiratory training will be performed for at least 2-3 times per day. Every training should be last for 45 minutes to 1 hour. If the patient can not tolerate, the training time should be reduce to 30 minutes.~Aerobic exercise includes jogging, walking or climbing stairs. Exercise intensity will be based on patients' tolerance. The goal of the training is to complete the training plan as far as possible.~Respiratory training include thoracic breathing exercise and cough training."
45796862|NCT04704050|Drug|dronedarone 400 mg Oral Tablet|"Dronedarone is an anti-arrhythmic drug with properties belonging to Vaughan-Williams class I-IV.~Participants will receive dronedarone 400 mg tablet, to be taken orally and twice daily for 52 weeks."
45796863|NCT04704050|Drug|Placebo|Participants will receive a placebo tablet matching the physical appearance of dronedarone, to be taken orally and twice daily for 52 weeks.
45796864|NCT04696146|Drug|Berinert|Intrarenal dose of 500 U of Berinert
45796865|NCT04696146|Drug|Placebo|Normal Saline placebo
45796866|NCT04684225|Other|Hand Therapy via Telerehabilitation|Hand Therapy via Telerehabilitation
45796867|NCT04684225|Other|Hand Therapy via home-exercises|Hand Therapy via home-exercises
45796868|NCT04674761|Drug|Odevixibat|Odevixibat is a small molecule and selective inhibitor of IBAT.
45796869|NCT04674761|Drug|Placebo|Placebo identical in appearance to experimental drug (odevixibat).
45796870|NCT04669210|Drug|Ruxolitinib|Ruxolitinib administered during conditioning 5 mg tid before allogeneic hematopoietic stem cell transplantation, 5 mg tid days 5-21 and 5 mg bid days 22-150 after transplantation instead of tacrolimus and MMF.
45796871|NCT04669210|Drug|Tacrolimus|Tacrolimus 0.03 mg/kg adjusted to concentrations 5-15 ng/ml from day+5 to +100
45796872|NCT04669210|Drug|Mycophenolate Mofetil|Mycophenolate mofetil 30 mg/kg from day +5 to +35
45796873|NCT04655157|Drug|encorafenib|A small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway.
45796874|NCT04655157|Drug|nivolumab|A programmed death receptor-1 (PD-1) blocking monoclonal antibody that works by helping the immune system to slow or stop the growth of cancer cells.
45796875|NCT04655157|Drug|ipilimumab|A monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
45796876|NCT04655157|Drug|binimetinib|A small molecule, selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
45796877|NCT04654910|Behavioral|PROMIS Score Explanation|The surgeon completing the clinical visit with the participant will explain what the PROMIS tool is, the purpose of the tool and what the participant's scores mean using a script.
45796878|NCT04654910|Behavioral|Placebo|Subjects will complete the PROMIS assessment but will not receive an explanation of the tool.
45796879|NCT04650269|Drug|Biktarvy 50Mg-200Mg-25Mg Tablet|Daily Biktarvy (50/200/25mg) combination ART by mouth for 6 months
45924422|NCT03346109|Radiation|medial group retropharyngeal node（MRLN） sparing|Patients in MRLN sparing group will not routinely receive MRLN irradiation; while patients in MRLN prophylactic irradiation group will always receive MRLN irradiation to 56Gy/33Fr.
45649430|NCT04900415|Drug|Vitamin A|Metabolic supplement for neurogenesis at the olfactory apparatus
45649431|NCT04900415|Device|Electronic portable aromatic rehabilitation (EPAR) diffuser|Handheld essential oil ultrasonication diffuser technology
45796880|NCT04650269|Other|HIV care|HIV primary care (including Biktarvy delivery) will be conducted outside of a clinical setting by a community-based harm reduction program for 6 months.
45796881|NCT04643652|Behavioral|Noise Reduction Bundle|"Implementation of a bundle of noise reducing interventions. This concerns among other things:~reduction of alarms, phone calls/pagers/ bleepers, introduction of a defined period in which there is a reduction of controllable sound (quiet time), etc"
45796882|NCT04629196|Drug|Ustekinumab|A second IV weight-based induction dose of Stelara at week 8
45796883|NCT04629196|Drug|Ustekinumab|A standard 90mg subcutaneous dose of Stelara at week 8
45796884|NCT04629196|Drug|Ustekinumab|All patients will receive IV ustekinumab weight-based dose at 260mg (55kg or less), 390mg (more than 55kg to 85kg), or 520mg (more than 85kg) at time point 0
45796885|NCT04628936|Drug|KZR-616|KZR-616 subcutaneous injection
45796886|NCT04628338|Drug|IFN-γ (interferon gamma-1b) injection|Dosage form: 100 mcg (2 million International Units) per 0.5 mL solution, administered subcutaneously Dose regimen: three times weekly (Weeks 0-7), once weekly (Weeks 8-12)
45796887|NCT04617002|Drug|ONC201|ONC201 is a ClpP agonist and DRD2 antagonist.
45796888|NCT04591808|Drug|Atorvastatin/Perindopril|1 over-encapsulated S05167 capsule, fixed dose combination of Atorvastatin/Perindopril Arginine 40/10 mg, will be administered once daily each day before breakfast during 8 weeks.
45649432|NCT03051035|Drug|KO-947|Intravenous administration
45649433|NCT04900571|Drug|Nitrofurantoin 100 MG|Comparison of alleviating post-operative pain between nitrofurantoin and calcium hydroxide
45649434|NCT04900337|Drug|AMOR 18 Powder & Inhalation|AMOR Inhalation x 3 times a day, via Circulaire® II AMOR Powder x 4 times a day, sublingual
45649435|NCT04900337|Drug|Placebo|Placebo Inhalation x 3 times a day, via Circulaire® II Placebo Powder x 4 times a day, sublingual
45649436|NCT04900727|Other|No intervention|No intervention
45649437|NCT04900181|Procedure|the same-day discharge surgery|the same-day discharge surgery is the procedure in which the patient is admitted, operated and discharged within 24 hours.
45649438|NCT04891211|Dietary Supplement|Vitamin D deficiency|Ocular significance of vitamin D deficiency in pediatric cases
45924423|NCT00048217|Drug|T-1249|
45924424|NCT00048334|Drug|Depsipeptide, FR901228, FK228|
45924425|NCT00048373|Drug|Etanercept|
45924426|NCT05641337|Drug|Insulin Degludec and Insulin Aspart|The hypoglycemic scheme of the experimental group was that the initial dose of Insulin Degludec and Insulin Aspart was 0.3U/kg multiplied by the patient's weight, plus 5 mg of linagliptin and 0.5 g of metformin three times a day. The control group was treated with traditional four needle insulin.
45649439|NCT04817189|Drug|NEPA (300mg netupitant/0.5mg palonosetron)|Oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.
45649440|NCT04817189|Drug|Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV)|Standard of care will be administered on Day 1 of each cycle.
45649441|NCT04817189|Drug|Dexamethasone, 8 mg (oral) or equivalent IV dose|Dexamethasone (8 mg) will be administered on Day 1 of each cycle.
45649442|NCT03050957|Dietary Supplement|menthol|Alimentary bolus supplemented with menthol
45649443|NCT04885049|Drug|Racecadotril|Anti secretary
45796889|NCT04591808|Drug|Atorvastatin|1 over-encapsulated atorvastatin 40 mg tablet will be administered once daily each day before breakfast during 8 weeks.
45796890|NCT04591808|Drug|Perindopril|1 over-encapsulated perindopril 10 mg tablet will be administered once daily each day before breakfast during 8 weeks.
45796891|NCT04587687|Drug|Bendamustine Hydrochloride|Given IV
45796892|NCT04587687|Drug|Brentuximab Vedotin|Given IV
45796893|NCT04585750|Drug|PC14586|First-in-class, oral, small molecule p53 reactivator selective for the p53 Y220C mutation.
45796894|NCT04585750|Drug|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.
45796895|NCT04583995|Biological|SARS-CoV-2 rS/Matrix M1-Adjuvant|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.
45796896|NCT04583995|Other|Placebo|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.
45796897|NCT04583995|Biological|Licensed seasonal influenza vaccine|Single intramuscular injection of licensed seasonal flu vaccine, administered ideally in opposite deltoid to SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo injection on Day 0.
45796898|NCT04583280|Drug|Rilematovir|Participants of age group greater than or equal to (>=) 28 days to less than (<) 3 months (age group 1) or >= 3 months to < 6 months (age group 2) or >= 6 months to less than or equal to (<=) 5 years (age group 3) will receive rilematovir orally twice a day (BID) from Days 1 to Day 7 or Day 8.
45796899|NCT04583280|Drug|Rilematovir X mg/kg|Participants of age group birth at term (after at least 37 weeks of gestation) to < 28 days (age group 4) will receive rilematovir orally BID from Days 1 to Day 7 or Day 8. The dose is dependent on outcome of the substudy in neonates and following independent data monitoring (IDMC) review and recommendation.
45796900|NCT04583280|Drug|Placebo|Participant of age group 1, 2, 3 and 4 will receive matching placebo of rilematovir BID from Days 1 to Day 7 or Day 8 as per assigned age group.
45796901|NCT04578600|Drug|Lenalidomide|Given PO
45796902|NCT04578600|Biological|Obinutuzumab|Given IV
45796903|NCT04578600|Drug|Oral Azacitidine|Given PO
45796904|NCT04557930|Behavioral|Hopewell Hospitalist Video Game|Hopewell Hospitalist is a customized theory-based adventure video game that uses narrative engagement to educate physician players on advance care planning to increase physicians' likelihood of engaging in and billing for ACP conversations.
45796905|NCT04554212|Device|Blood Flow Restriction Training|Participants will undergo 8 weeks of blood flow restriction training with cuff inflated to 60% occlusion.
45796906|NCT04554212|Device|Sham Blood Flow Restriction Training|Participants will undergo 8 weeks of sham blood flow restriction training with cuff inflated to less than 10% occlusion.
45796907|NCT04538352|Drug|Semaglutide|Medication for type 2 diabetes management
45796908|NCT04538352|Drug|Insulin Degludec|Medication for type 2 diabetes management
45796909|NCT04538352|Drug|Insulin aspart|Medication for type 2 diabetes management (rapid-acting)
45796910|NCT04534985|Behavioral|Dietary|Dietary intake behavioral intervention via time restricted feeding and normal healthy eating recommendations vs. normal healthy eating recommendations without restricted
45796911|NCT04510792|Other|No intervention|No intervention
45796912|NCT04501796|Drug|Double-Blind NT-I7|Administered by intramuscular (IM) injection
45796913|NCT04501796|Drug|Double-Blind Placebo|Placebo
45796914|NCT04500600|Other|Quality-of-Life Assessment|Ancillary studies
45796915|NCT04500600|Other|Questionnaire Administration|Complete questionnaire
45796916|NCT04489940|Drug|Bintrafusp alfa|Participants received an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death.
45796917|NCT04471987|Drug|IL12-L19L19|"Part I - The dose escalation is designed with an initial accelerated phase followed by a standard 3+3 design. Cohorts contain one patient until first instance of moderate toxicity or a DLT in the DLT observation period (28 days). With the second occurrence of moderate toxicity or occurrence of a DLT the accelerated phase will be terminated and the dose escalation will continue with a 3+3 dose escalation. Initiation of the study treatment for an individual subject will occur not less than 7 days after initiation of the study treatment for the previous patient. Not more than 2 patients are to be treated simultaneously within their DLT observation period (i.e., Day 1 to Day 28).~Part II - Dose expansion: Once the dose escalation is completed, additional 40 patients will be enrolled at the RD to better understand the safety profile and to explore early signs of efficacy in different disease indications."
45924427|NCT00048412|Drug|FLUDARABINE|
45924428|NCT00048412|Drug|CAMPATH 1H|
45924429|NCT00048412|Drug|FK50|
45924430|NCT00048412|Procedure|Stem Cell Collection and Infusion|
45649444|NCT04885049|Drug|DiaResQ Children's Powder for Suspension|oral immunoglobulins
45649445|NCT04884581|Device|GI Genius CADx device|GI Genius System is an Intelligent Endoscopy Module designed to be an adjunct to video colonoscopy with the purpose of supporting the operating physician with artificial intelligence during colonoscopy. GI Genius CADx is the AI software that provides a histology prediction of framed polyps during real-time colonoscopy, with each polyp being classified as adenoma or non-adenoma.
45754386|NCT03902366|Diagnostic Test|Neuropsychological assessment|Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later).
45924431|NCT04712370|Procedure|Conventional caudal block|Patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected in the caudal epidural space) by the conventional method (blind technique without ultrasound).
45924432|NCT04712370|Procedure|Ultrasound-guided caudal block|Using ultrasound, patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected in the caudal epidural space).
45796918|NCT04471987|Drug|IL12-L19L19|Patients initially receive 8 consecutive administrations of IL12-L19L19 every week. At the end of this eight weeks treatment window, a tumor assessment is performed and those patients who achieve a clinical benefit (SD, PR, CR) may continue treatment with IL12-L19L19 as a biweekly maintenance therapy until disease progression, unacceptable toxicity, withdrawal of consent, at the discretion of the investigator or up to 1 year from study treatment start.
45796919|NCT04455386|Diagnostic Test|Stress radiography,Anterior drawer test,Stress ultrasound,Computed tomography, Magnetic resonance imaging,Arthroscopy|All patients suspected chronic ankle instability, will perform an anterior drawer test, stress ultrasound, computed tomography, magnetic resonance imaging of ankle. Patients with chronic ankle instability will be recommended to perform an arthroscopic repair if non-operative treatment failed.
45796920|NCT04447768|Drug|Obinutuzumab|"Cycle 1, Day 1- 100 mg~Cycle 1, Day 2 - 900 mg~Cycle 1, Day 8 - 1000 mg~Cycle 1, Day 15 -1000 mg~Cycle 2, Day 1 to Cycle 6, Day 1- 1000 mg"
45924433|NCT04712370|Procedure|Ultrasound guided erector spinae plane Block|Under ultrasound guidance, patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the transverse process of the second lumbar vertebrae(L2).
45924434|NCT00048451|Drug|paricalcitol|
45796921|NCT04447768|Drug|Venetoclax|"Cycle 1, Day 22 to 28 -20 mg daily~Cycle 2, Day 1 to Day 7 -50 mg daily~Cycle 2, Day 8 to Day 14- 100 mg daily~Cycle 2, Day 15 to Day 21- 200 mg daily~Cycle 2, Day 22 to Day 28 - 400 mg daily~Cycle 3, Day 1 to end of Cycle 12-24 - 400 mg daily"
45924435|NCT00048490|Device|transcranial magnetic stimulation (TMS)|
45924436|NCT02970526|Drug|Oxaliplatin|Intensity of neuropathy induced by oxaliplatin evaluated by the QLQ-CIPN20 Questionnaire (EORTC).
45924437|NCT00048529|Drug|T900607-sodium intravenous|
45796922|NCT04408599|Drug|NC410|NC410 is an experimental antibody drug that may make the immune response more active against cancer
45796923|NCT04405037|Drug|Alvimopan|Alvimopan will be given to patients who are diagnosed with postoperative ileus after surgery
45796924|NCT04389177|Drug|Pembrolizumab Injection [Keytruda]|"Neoadjuvant period:preoperative therapy with three cycles: Pembrolizumab 200mg D1; Paclitaxel 135mg/m2 D2; Cisplatin 20mg/m2 D2-D4; repeated every 3 weeks.~Da Vinci robot radical surgery: Before surgery, head/abdomen/chest CT scan, type B ultrasonic, upper gastrointestinal contrast, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 4-6 weeks after last neoadjuvant treatment finished.~Adjuvant period: Adjuvant treatment with pembrolizumab 200mg every 3 weeks (6 cycles) should be performed within 3-6 weeks after surgery if the surgical pathology result is not pCR. abdomen/chest CT scan will be performed every 3 month after surgery."
45796925|NCT04368988|Biological|SARS-CoV-2 rS - Phase 1|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS (0.6 mL) on Days 0 and 21.
45450274|NCT00110357|Drug|Cetuximab + Irinotecan|Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
45924438|NCT00048607|Drug|aprepitant|
45450275|NCT03537976|Other|Static Images and Facial Videos|2D and 3D still and video images obtained from each patient before surgery.
45450276|NCT02183038|Drug|Meloxicam low|
45450277|NCT02183038|Drug|Meloxicam high|
45450278|NCT02183038|Drug|Naproxen sodium|
45450279|NCT02183038|Drug|Meloxicam placebo low|
45450280|NCT02183038|Drug|Meloxicam placebo high|
45796926|NCT04368988|Biological|SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Days 0 and 21.
45450281|NCT02183038|Drug|Naproxen sodium placebo|
45450282|NCT01067807|Drug|25 mg Proellex|25 mg - given as one 25 mg capsule (252 mg of Gelucire and 88 mg of PEG400, original formulation) [Original], single dose
45450283|NCT01067807|Drug|25 mg Proellex|25 mg - given as one 25 mg capsule (coated with microcrystalline cellulose, new formulation) (coated), single dose
45450284|NCT01067807|Drug|25 mg Proellex|25 mg - given as one 25 mg capsule (blended with microcrystalline cellulose, new formulation) [Blended], single dose
45450285|NCT01067807|Drug|50 mg Proellex|50 mg - given as two 25 mg capsules (blended with microcrystalline cellulose, new formulation) [Blended], single dose
45450286|NCT01067885|Device|MARIS-stent (Invatec)|stenting of SFA with Maris nitinol stent/s
45924439|NCT00048607|Drug|Comparator: paroxetine HCL|
45924440|NCT00048607|Drug|Comparator: Placebo (Unspecified)|
45924441|NCT00048646|Drug|IV Progesterone|
45924442|NCT00048763|Drug|Pletal|
45924443|NCT05641181|Drug|CRB4101|"After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo."
45924444|NCT05641181|Drug|Placebo|"After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo."
45924445|NCT05576298|Biological|Insulin degludec injection, RD15003|single dose, s.c. injection
45924446|NCT05576298|Biological|Insulin degludec, Tresiba|single dose, s.c. injection
45924447|NCT00048802|Drug|Lithium|
45924448|NCT00048802|Drug|Olanzapine|
45924449|NCT00048802|Drug|Divalproex|
45924450|NCT00048802|Drug|Risperidone|
45924451|NCT00048802|Drug|Quetiapine|
45924452|NCT00048802|Drug|Ziprasidone|
45924453|NCT00048802|Drug|Aripriprazole|
45796927|NCT04368988|Other|Normal saline solution (NSS), Placebo - Phase 1|Alternating intramuscular (deltoid) injections of placebo (0.6 mL) on Days 0 and 21.
45924454|NCT00048841|Drug|alendronate|
45450287|NCT02752906|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular
45450288|NCT02752906|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
45450289|NCT01067963|Behavioral|Computer assisted education and motivational interviewing.|9 study contact points. 3-week intervention using computer-assisted learning modules and telephone counseling using motivational interviewing.
45649446|NCT04056533|Biological|CMV CTLs|The donor derived cytomegalovirus specific T lymphocytes (CMV-CTL) will be transfused to the patients. The patients will receive CMV-CTL cells when their donors are sero-positive for CMV-DNA 21 days after transplant. The CMV-DNA levels will be monitored weekly for at least 100 days after the HAPLO. If after the initial dose of CMV-CTL cells the patient develops a viral infection, then they may be eligible to receive a CMV specific antiviral drug.
45924455|NCT00048880|Drug|HeFi-1 Monoclonal Antibody|
45924456|NCT00048958|Genetic|cytogenetic analysis|
45924457|NCT05576259|Other|oVRcome phone app with headset|The intervention oVRcome is self-help VRET for social anxiety, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
45924458|NCT00049075|Drug|fludarabine phosphate|
45924459|NCT00049114|Drug|doxorubicin hydrochloride|
45924460|NCT00049114|Drug|cyclophosphamide|Given IV
45924461|NCT00049114|Drug|tipifarnib|Given orally
45649447|NCT04890899|Procedure|Cystic enculation of spleen hydatid|Preoperative preparation did according to the general condition of the patient and fitness for anaesthesia. Laparotomy did under general anaesthesia, supine position, the abdomen opened either by midline or left subcostal incision. Identification of splenic hydatid cyst. Exploration of the peritoneal cavity for undetected hepatic or peritoneal hydatid preoperatively. Isolation of operative field by packs socked with hypertonic solution (20 -30 % hypertonic saline). Aspiration of the cyst fluid. Injection of suitable amount about 5 ml of (1 % of cetramid) solution and waiting for at least 5 minutes and then re-aspiration. The spleen is not needed to mobilize. Extraction of the endocyst and washing of the cavity with normal saline. Occupying the cystic cavity intracystic drain. Perioperative and postoperative close observation of the patient for an anaphylactic reaction or any other complication. Follow-up of the patient until discharge from hospital on (3th - 5th) days.
45649448|NCT04890587|Drug|AL8326 tablets|Tablet:10mg/tablet; administered orally once daily in part 1 and part 2, administered orally twice daily for continuous 28-Day cycles in part 3.
45754387|NCT03902366|Behavioral|Neuroimaging|Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
45754388|NCT05582330|Other|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of Telephone Based ABILOCO-Stroke
45754389|NCT04947579|Drug|CC-99677|Oral
45796928|NCT04368988|Other|Normal saline solution (NSS), Placebo - Phase 2|Intramuscular (deltoid) injections of placebo (0.5 mL).
45796929|NCT04368988|Biological|SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1|Intramuscular (deltoid) injection of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Day 0.
45796930|NCT04368988|Other|Normal saline solution (NSS), Placebo, Day 21 - Phase 1|Intramuscular injection of placebo (0.6 mL) in alternate deltoid on Day 21.
45796931|NCT04368988|Biological|SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2|Intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL).
45924462|NCT00049114|Biological|filgrastim|Given subcutaneously
45924463|NCT00049114|Procedure|therapeutic conventional surgery|Undergo complete resection
45924464|NCT00049114|Other|laboratory biomarker analysis|Correlative studies
45924465|NCT00049192|Biological|oblimersen sodium|Given IV
45924466|NCT00049192|Drug|imatinib mesylate|Given PO
45924467|NCT00049192|Other|laboratory biomarker analysis|Correlative studies
45924468|NCT05576181|Drug|ThisCART19A|ThisCART19A is a new type CAR-T therapy for patients with r/r B-ALL.
45924469|NCT05576181|Drug|Fludarabine Oral Tablet|Fludarabine is used for lymphodepletion.
45924470|NCT05576181|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
45924471|NCT05576181|Drug|VP-16|VP-16 is used for lymphodepletion.
45924472|NCT05576181|Procedure|HSCT|Hematological stem cell transplantation
45924473|NCT00049231|Drug|EF5|
45924474|NCT00049231|Other|immunohistochemistry staining method|
45924475|NCT00049231|Procedure|biopsy|
45924476|NCT00049309|Dietary Supplement|dietary intervention|
45924477|NCT00049309|Dietary Supplement|flaxseed|
45924478|NCT05576142|Diagnostic Test|Oral examination|Patients underwent oral examination with the recording of DMFT, PSR, PI and presence/absence of mouth breathing.
45924479|NCT00049387|Drug|tipifarnib|Given PO
45924480|NCT00049387|Drug|temozolomide|Given PO
45924481|NCT00049387|Radiation|radiation therapy|Undergo partial brain radiation therapy
45924482|NCT05640791|Drug|Cisplatin|25mg/m2；d1, 8, 21 d cycle
45924483|NCT05640791|Drug|Gemcitabine|1000mg/m2；d1, 8, 21 d cycle
45924484|NCT05640791|Drug|Nab-paclitaxel|100mg/m2；d1, 8, 21 d cycle
45924485|NCT05640791|Drug|Durvalumab|1000mg；d1, 21 d cycle
45924486|NCT00391911|Drug|N-Acetylcysteine|Patients are assigned to either N-Acetylcysteine or placebo. Dose is weight based Placebo is normal saline or D5W
45924487|NCT00391911|Other|N-Acetylcystine and Non CRRT|Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind
45649449|NCT04890665|Behavioral|Online psychological intervention for healthcare workers|"The intervention is based on Cognitive Behavioral Therapy, Mindfulness, Behavioral Activation Therapy, Acceptance and Commitment Therapy and Positive Psychology, aimed at the Psychoeducation regarding the manifestations of anxiety, depression, burnout, fatigue compassion, posttraumatic stress disorder, and affectations in sleep quality and perception of life quality in healthcare workers.~And 3 complementary modules that according to the scientific literature could affect the mental health of healthcare workers related to how to deliver bad health news, Psychological first aid and how beliefs could influence physical and emotional self-care in the face of the COVID-19 pandemic."
45649450|NCT04890353|Drug|Dimethyl fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
45796932|NCT04365257|Drug|Prazosin|Participants in this arm will receive the study drug as outlined in the arm description.
45796933|NCT04365257|Other|Standard of care|Participants in this arm will receive standard of care.
45796934|NCT04341545|Other|Placebos|Placebo 4 tablets a day for one week.
45796935|NCT04341545|Drug|Letrozole tablets|Letrozole 10mg daily for one week.
45649451|NCT04890353|Drug|Placebo|Placebo 240mg orally twice daily for 3 consecutive days
45796936|NCT04331769|Device|AccuCinch Ventricular Restoration System|AccuCinch Ventricular Restoration System
45796937|NCT04331769|Drug|Guideline-Directed Medical Therapy|Guideline-Directed Medical Therapy
45649452|NCT04899713|Other|Survival survey|To assess the effect of adding ZOMETA® to neoadjuvant chemotherapy on event-free survival.
45649453|NCT04430621|Drug|Follicle Stimulating Hormone|FSH will be administered s.c. in the morning to male healthy subjects
45649454|NCT04393649|Other|ESOGER|Questionnaire
45649455|NCT04900259|Behavioral|COVID-19 pandemic|Patients diagnosed with primary bladder cancer by transurethral resection in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.
45649456|NCT04884503|Drug|Clonazepam tablets|Dosing of clonazepam was as follows: in the first week, 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning), in the second week, 1 mg to be sucked for 2 minutes, and then swallowed (twice a day in the morning and one hour before falling asleep), in the third week, 1 mg to be sucked for 2 minutes and in the fourth week 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning)
45649457|NCT04884503|Device|tongue pads|wearing a tongue pad 3 times a day for 20 minutes for 4 weeks
45796938|NCT04320186|Behavioral|Entertainment education|
45796939|NCT04320186|Other|video|video
45796940|NCT04297384|Other|Informational Intervention|Receive standard chemotherapy educational materials
45796941|NCT04297384|Other|Informational Intervention|Receive personalized information about cancer, treatment, and side effects
45796942|NCT04297384|Other|Quality-of-Life Assessment|Ancillary studies
45796943|NCT04297384|Other|Survey Administration|Complete surveys
45796944|NCT04296994|Biological|QL1706|QL1706（PSB205） is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
45796945|NCT04258709|Behavioral|AME|Participants receive education on AME and feedback on technique with a remotely-based IBCLC via live streaming video.
45649458|NCT04884425|Device|Pulsed Electromagnetic Frequency Device (Energy5)|A pulsed electromagnetic frequency (PEMF) device which is recommended to be used for 30 minutes a day
45796946|NCT04258709|Behavioral|Video-based infant care education|Participants view a standard set of web-based streamed videos addressing evidence-based infant care, unrelated to feeding/breastfeeding.
45796947|NCT04220021|Drug|Metformin|Metformin is a widely used, well-tolerated drug that has been used for decades as a first-line defense for treating type 2 diabetes. Its safety has been well established. Subjects will begin treatment with Metformin at a dosage of 500mg with an escalation of dosage by 500mg every week to a maximal dosage of 2000mg. Dosing will be twice daily.
45796948|NCT04219722|Device|Injection of DESIRIAL®|"DESIRIAL® is a hyaluronic acid injectable gel intended to treat symptoms associated with vulvovaginal atrophy in postmenopausal women by vaginal mucosa rehydration in this study.~1 mL of DESIRIAL® will be injected in the vestibule and on the posterior and lateral walls of the vagina, 2 to 3 cm after the introitus."
45796949|NCT04219722|Other|Injection of placebo|"Placebo is an isotonic saline solution (0.9% NaCl).~1 mL of placebo will be injected in the vestibule and on the posterior and lateral walls of the vagina, 2 to 3 cm after the introitus."
45649459|NCT03051893|Drug|Chronocort|Modified formulation of hydrocortisone
45649460|NCT04890197|Dietary Supplement|tahini|48 grams tahini
45649461|NCT04890197|Other|control|no intervention
45754390|NCT04947579|Other|Placebo|Oral
45796950|NCT04191304|Biological|Benralizumab|Benralizumab solution for injection in an accessorised prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks
45796951|NCT04191304|Biological|Placebo|Matching placebo solution for injection in an APFS will be administered SC every 4 weeks
45796952|NCT04187131|Behavioral|augmented reality|The participants will be wearing an EEG cap and Augmented Reality headset (AR-based EEG-guided system) for 10 sessions with a licensed occupational therapist, provided in addition to usual rehabilitation care (either in inpatient rehabilitation or at home). These sessions will focus on activities of daily living that the participants want to practice. All sessions will last approximately 1 hour. These sessions will be scheduled around the existing therapy schedule to cause the least amount of interference with planned clinical activities.
45796953|NCT04186299|Drug|Clonidine|Each patient will receive a buccal infiltration of 1.7mL of 1:100,000 clonidine.
45796954|NCT04186299|Drug|Articaine Hydrochloride + Epinephrine|Each patient will receive a buccal infiltration of 1.7mL of 4% articaine with 1:100,000 epinephrine.
45796955|NCT04170244|Other|Skin swab, TEWL with tape stripping, and serum (adults)|Skin will be swabbed to collect samples for bacterial analysis. Transepidermal water loss (TEWL) will be measured at 4 time points: before tape stripping, after application of 5 D-squame tapestrips, after application of 10 D-squame tapestrips, and after application of 15 D-squame tapestrips (total tapestrips per site = 15).
45924488|NCT00391911|Other|Placebo and CRRT|Patients are assigned to Placebo and CRRT. The N-Acetylcysteine/Placebo is blinded to everyone except pharmacy. The CRRT is open label
45924489|NCT00391911|Other|Placebo and Non CRRT|Patients are assigned to Placebo and non-CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
45924490|NCT02970409|Device|saline|catheter lock using saline
45450290|NCT01067963|Behavioral|Group talks/social chat|9 study contact points. 3 group talk session on general topics about healthy lifestyle, printed power point handouts, telephone calls comprised of social conversation to discuss the handout content.
45924491|NCT02970409|Device|Heparin|catheter lock using Heparin
45924492|NCT00049465|Procedure|fatigue assessment and management|
45924493|NCT00049465|Procedure|management of therapy complications|
45924494|NCT00049465|Procedure|psychosocial assessment and care|
45796956|NCT04168580|Other|Exercise Training Intervention|Older sedentary participants will undergo 8 weeks of exercise training. The exercise program will be supervised by a certified exercise physiologist and will take place at the AdventHealth Translational Research Institute (TRI) exercise training facility. Exercise compliance will be monitored for exercise training 4 days per week (32 total sessions). Aerobic training will be 30 minutes of brisk walking, jogging, cycle ergometry. Walking will be the primary mode of aerobic exercise given its widespread popularity and ease of administration across a broad segment of the older adult population. Walking will be at a moderate intensity and determined based on Heart Rate (50-70% of Maximal Heart Rate from most recent VO2max) and rating of perceived exertion using Borg's scale (ranges from 6 to 20).
45924495|NCT00049582|Drug|decitabine|Given IV
46071863|NCT05877482|Other|Short foot exercises|A total of 26 participants with pes planus were assigned to the short-foot exercises group (n = 13) and the control group (n = 13). Both groups will be informed about pes planus, usual foot care, and appropriate footwear with foot insoles. In experimental group Short foot exercises (SFE) and internal shoe modification will be performed by placing a medial longitudinal arch support insoles inside the shoe. Exercises will be performed daily for six weeks.
46071864|NCT05877482|Other|Insoles|In control group only internal shoe modification will be performed by placing medial longitudinal arch support insoles inside the shoe. Group assignment and SFE training will be conducted by the second physical therapist to provide blindness.
45649462|NCT04889963|Biological|adypose mesenchymal conditioned medium and ligament derived conditioned medium|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture and ligament derived conditioned medium
45649463|NCT04412213|Other|Stuttering severity instrument for school-age children (SSI-3 Arabic version)|Stuttering severity instrument for school-age children (SSI-3 Arabic version) for measuring stuttering severity Stanford Binet test version 4 to evaluate the mentality (IQ)
45796957|NCT04551872|Behavioral|Digital weight loss intervention|Participants with obesity enter into a proven 6 month weight loss program that utilizes health coaching and goal-setting. It is a remote intervention that is delivered entirely over their phones. Participants will also receive a FitBit and electronic scale.
45796958|NCT04165096|Biological|Pembrolizumab|IV infusion
45796959|NCT04165096|Biological|Boserolimab|IV infusion
45924496|NCT00049582|Other|laboratory biomarker analysis|Correlative studies
45924497|NCT00049582|Other|pharmacological study|Correlative studies
45924498|NCT00049660|Drug|capecitabine|
45924499|NCT00049660|Drug|vinorelbine tartrate|
45924500|NCT05640713|Drug|ThisCART19A|ThisCART19A is a new type CAR-T therapy for patients with r/r B Cell Malignancy .
46071865|NCT05877469|Other|Mat pilates Training|In this group 22 patients will perform mat pilates training. Patients will be asked to stay comfortable while performing mat pilates exercies that involve different types of movements of whole body like leg lifts, toe taps, Single leg stretch, one leg circle, side bend preparation, side kicks, side leg lifts, roll down and crisscross to improve the core strength. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
45924501|NCT05640713|Drug|Fludarabine Pill|Fludarabine is used for lymphodepletion.
45924502|NCT05640713|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
45924503|NCT05640713|Drug|VP-16 Protocol|VP-16 is used for lymphodepletion.
45924504|NCT00391950|Drug|Zoledronic acid|
45924505|NCT00049699|Drug|laromustine|
45924506|NCT00049777|Drug|Drotrecogin Alfa (Activated)|
45924507|NCT00049777|Drug|Unfractionated heparin|
45450291|NCT01068041|Drug|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.
45450292|NCT02180464|Drug|LAS41004|
45450293|NCT02180464|Drug|control|
45450294|NCT02756338|Device|BioMonitor 2 Insertable Cardiac Monitor|
45450295|NCT02180620|Other|No exercise|During the no exercise trial (NoEX), the participants will remain sedentary during testing.
45649464|NCT04889885|Device|High-intensity laser therapy (HILT)|"HILT was done by Multiwave Locked System (MLS) laser therapy combining 2 laser wavelengths (808 and 905 nm) in order to strengthen the effects of HILT. The laser was applied on medial, lateral and posterior parts around the knee joint. The total energy per session was 562.5 Joules (J) which was done 2-3 times a week for a total of 10 sessions.~Additionally, the participants received conservative treatment for knee OA such as education about the disease, proper activities, and exercise."
45924508|NCT00049777|Drug|Low molecular weight heparin|
45924509|NCT00392028|Drug|ertapenem|
45924510|NCT05640635|Procedure|Ventilator weaning first|Ventilator weaning initiated and completed before start of ECMO weaning.
45924511|NCT05640635|Procedure|ECMO weaning first|ECMO weaning initiated and completed before start of ventilator weaning.
45924512|NCT00049816|Behavioral|Walking exercise|30 minutes/day, 3 times/week for 52 weeks
45924513|NCT00049816|Behavioral|Cycling Exercise|30 minutes/day, 3 times/week for 52 weeks
45924514|NCT00392067|Drug|Calcipotriol and LEO80122 (LEO19123 cream)|
45924515|NCT00397852|Procedure|Kirschner-wires or not|
45924516|NCT00389558|Procedure|disinfection efficacy using Biseptine|Detersion and antiseptic application when changing catheter dressing
45924517|NCT00389558|Procedure|disinfection efficacy using Amukin|Detersion and antiseptic application when changing catheter dressing
45450296|NCT02180620|Other|Meal then exercise|During the post-meal exercise trial (M→EX), 45 min of resistance training will be performed
45450297|NCT02180620|Other|exercise then meal|During the exercise prior to the meal trial (EX→M), 45 min of resistance training will be performed
45450298|NCT02180698|Other|Laboratory Biomarker Analysis|Correlative studies
45796960|NCT04165096|Biological|MK-4830|IV infusion
45450299|NCT02180698|Radiation|Radiation Therapy|Undergo radiation therapy
45450300|NCT02180698|Drug|TLR4 Agonist GLA-SE|Given intratumorally
45649465|NCT04889885|Device|Sham laser|The control group received a sham laser (2-3 times a week for a total of 10 sessions) plus conservative treatment as in the intervention group. The laser machine was the same as in the intervention group; however, the laser was applied without releasing laser energy to the knee joint.
45649466|NCT04899401|Dietary Supplement|Standard of care + PediaFlù®|Standard of care: Standard of care for acute tonsillitis / rhinopharyngitis is focused on symptomatic treatment. PediaFlù®: During the 6 days of the clinical investigation, the subjects will administer PediaFlù® 5ml x3 times per day for children below 6 years and 10mlx3 times per day for children above 6 years.
45649467|NCT04899401|Other|Standard of care|Standard of care for acute tonsillitis / rhinopharyngitis is focused on symptomatic treatment. Standard of care Nasopharyngeal liberation through hydration with drinking fluids to support body fluid excretion, aspiration of secretions, NaCl solution for nasal irrigation, Nasal sprays with sea water, nasal spray with active compound (to be used only at special indication of the medical doctor) Throat spray with Benzydamine hydrochloride (Tantum Verde®), Pediatric use: children over 6 and below 12: 4 sprays 2 - 6 times a day. Children (under 6 years): 1 spray per 4 kg of body weight, a maximum of 4 sprays at once, 2-6 times a day according to the leaflet. Each spray equals 0.17 ml of solution. Acetaminophen (Paracetamol) per os: at need, as antipyretic (>38,5C), 10 mg/kg/dose, per need every 6-8 hours or according to the leaflet, maximum dosage 80 mg / kg / day. A dosage of over 30 mg/Kg/dose will result in an IP failure;
45796961|NCT04165096|Drug|diphenhydramine|PO
45796962|NCT04165096|Drug|acetaminophen|PO
45796963|NCT04165096|Biological|MK-0482|IV infusion
45796964|NCT04150874|Diagnostic Test|Lumason®|Hepatic artery embolization using standard of care radioembolization and assessment of tumor and hepatic parenchymal perfusion kinetics before, during and after treatment with standard of care iodinated contrast (at the time of Y90 radioembolization treatment) and standard of care follow-up with multiphase CT or MRI with the addition of study agent Lumason microbubbles for contrast-enhanced ultrasound (which will be performed concurrently with standard evaluation).
45796965|NCT04145700|Drug|Ramucirumab|Ramucirumab given IV
45796966|NCT04145700|Drug|Gemcitabine|Gemcitabine given IV
45796967|NCT04145700|Drug|Docetaxel|Docetaxel given IV
45796968|NCT04144608|Drug|Toripalimab combination with platinum-containing dual-drug chemotherapy|Nab-paclitaxel/pem +cisplatin +PD-1(Nab-paclitaxel260mg/m2 D1 Cisplatin 75mg/m2 D1 or carboplatin,determined by the investigator AUC)PD-1 200mg D1
45796969|NCT04126395|Diagnostic Test|Movement Assessment Battery for Children 2(M-ABC-2)|The M-ABC-2 is a motor performance test for children aged 3 trough 16 years of age. We will use Dutch-Flemish norms.
45796970|NCT04126395|Diagnostic Test|Developmental Coordination Disorder - Questionnaire (DCD-Q)|The DCD-Q is a brief parent questionnaire designed to screen for the presence of DCD in children aged 5 trough 15 years of age. We will use Dutch norms.
45796971|NCT04126395|Diagnostic Test|Social Responsiveness Scale 2 (SRS-2)|The SRS-2 is a parent questionnaire designed to identify social impairments associated with ASD in children 4 trough 18 years of age. We will used Dutch norms.
45796972|NCT04126395|Other|Retrospective Video Analysis|Retrospective video analysis will be used to explore motor development in children with DCD, DCD+ASD and controls.
45796973|NCT04118569|Behavioral|Narrative Intervention|Research staff conducts an open-ended, audio-recorded interview with the patient about their illness and how this illness has affected their psycho-social-spiritual well-being. The investigators will use the interview transcription to create a meta-narrative, which is then uploaded to the electronic medical record and the patient's primary nurse is notified that it is available to read.
45796974|NCT04115280|Diagnostic Test|Primary Hyperaldosteronism diagnostic|blood sample to obtain the aldosterone to renin ratio
45796975|NCT04110249|Procedure|Photoacoustic Imaging|Undergo PAI
45796976|NCT04110249|Procedure|Transcutaneous Acupoint Electrical Stimulation|Undergo ALTENS
45796977|NCT04101253|Procedure|new screening procedure with small variations in electrode positioning|"Every ICD patient will undergo the standard screening process. Initial screening will be performed as usually performed by physician or Boston Scientific technical support. In case of one or more vector satisfying screening criteria, patient will be assigned in screening success group. In case of failure, a pre-determined electrode positioning protocol will be done with variation of para-sternal and axillary electrodes. Positioning variations will be left to the discretion of the operator cardiologist."
45796978|NCT04088058|Drug|GXHPC1|autologous ADSCs
45796979|NCT04077996|Device|Peritonitis treatment placed in APD|Antibiotic treatment of peritontiis placed in bags of Automated peritoneal dialysis.
45796980|NCT04077996|Device|Peritonitis treatment with one exchange in CAPD|Antibiotic treatment of peritontiis placed in one bag of Continuos ambulatory peritoneal dialysis per 6 hours each day.
45796981|NCT04068753|Drug|Niraparib|Niraparib: 200 mg, oral, once daily, days 1-21
45796982|NCT04068753|Drug|dostarlimab|dostarlimab: 500 mg IV, every three weeks for 4 cycles followed by 1000 mg every six weeks for up to two years
45796983|NCT04005690|Drug|Cobimetinib|Given PO
45796984|NCT04005690|Drug|Olaparib|Given PO
45796985|NCT04005690|Drug|Onvansertib|Given PO
45796986|NCT04005690|Drug|Temuterkib|Given PO
45796987|NCT03973268|Device|Arm 1, 2, 3 device interventions|MagPro 100 TMS Therapy System
45796988|NCT03973268|Other|Arm 2 Interventions|Placebo
45796989|NCT03973268|Drug|Arm 1, 2, 3 drug Interventions|Ketamine
45796990|NCT03973268|Drug|Arm 1 and 2 Interventions|Perampanel
45796991|NCT03931941|Drug|RBX2660|RBX2660 is a microbiota suspension administered as an enema
45796992|NCT03927222|Biological|Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF|2x10^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
45796993|NCT03927222|Drug|Temozolomide|Temozolomide is a chemotherapy drug given to all enrolled patients at the post-RT clinic visit as dose-intensified TMZ (100 mg/m2/day for 21 days).
45450301|NCT00293033|Drug|BEMA™|BioDelivery Sciences International, Inc. (BDSI) has developed BioErodible MucoAdhesive (BEMA) Fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small soluble film that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the film readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the film are water soluble, so the entire dosage form dissolves within 30 minutes of application.
45450302|NCT00293033|Drug|Placebo|
45450303|NCT02180776|Other|Summit 456 TLSO|Thoracolumbarsacral orthosis
45649468|NCT04889651|Drug|BR9004|BR9004: Abiraterone acetate 200mg, Boryung Pharmaceutical Co., Ltd.
45796994|NCT03927222|Biological|Tetanus-Diphtheria Toxoid (Td)|Before the first DC vaccination, patients will receive 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Prior to pp65 DC vaccination #4,(3±1) weeks after leukapheresis 2 the vaccine site will receive a pre-conditioning intradermal injection of Td (1 flocculation unit (Lf), in 0.3 mL of saline for a total of 0.4 mL).
45796995|NCT03927222|Biological|GM-CSF|Granulocyte macrophage-colony stimulating factor (GM-CSF) is a sterile, white, preservative-free lyophilized powder in a vial containing 250 mcg that will be reconstituted in 0.5 mL of sterile water for injection and used as an adjuvant with the DC vaccine.
45796996|NCT03927222|Biological|111-Indium-labeling of Cells for in vivo Trafficking Studies|111-In-labeled DCs are 2 x 10^7 pp65-LAMP mRNA loaded mature DCs labeled with 111-In (50 μCi / 5 x 10^7 DCs) and given i.d. as the fourth vaccine. In up to 16 patients, the fourth vaccine will be labeled with 111-In (50 μCi / 5 x 10^7 DCs) prior to injection.
45796997|NCT03869892|Drug|Trifluridine/tipiracil hydrochloride (S95005)|Film-coated tablets of S 95005 (35 mg/m²/dose) will be administered orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest; This treatment cycle will be repeated every 4 weeks.
45796998|NCT03869892|Drug|Capecitabine|Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks.
45796999|NCT03869892|Biological|Bevacizumab experimental|Concentrate for solution for infusion, Bevacizumab (5 mg/kg, IV) administered every 2 weeks (Day 1 and Day 15). This treatment cycle will be repeated every 4 weeks.
45797000|NCT03869892|Biological|Bevacizumab control|Concentrate for solution for infusion, Bevacizumab (7.5 mg/kg, IV) will be administered on Day 1 of each cycle.This treatment cycle will be repeated every 3 weeks.
45797001|NCT03858998|Other|Case Management Intervention|A 90-day case management intervention to link hospitalized HIV-infected participants with local HIV clinics.
45797002|NCT03858998|Other|Control|Current routine HIV care in Tanzania.
45797003|NCT03847285|Other|solid organ transplantation|solid organ transplantation: kidney, heart, pancreas, lung and liver transplantation
45450304|NCT02183116|Drug|Meloxicam|
45797004|NCT03845088|Procedure|temporomandibular jont reconstruction with costochondral transplantation|temporomandibular jont reconstruction with costochondral transplantation guided by virtual mandibular position
45797005|NCT03844789|Device|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Eligible participants will be use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM technology for 16 weeks during the main study. All participants will be provided the option of continue using the t:slim X2 with Control-IQ system in a 12 week Extension Phase. This arm to be uset:slim X2 with Control-IQ Technology & Dexcom G6 CGM
45797006|NCT03844789|Device|Control Group|Eligible participants will be use the study Dexcom G6 CGM for 16 weeks during the main study. All participants will be provided the option of using the t:slim X2 with Control-IQ system in a 12 week Extension Phase.
45924518|NCT00049972|Drug|paroxetine CR|
45924519|NCT02970370|Other|no intervention|
45924520|NCT00389636|Device|TheraGauze|TheraGauze
45450305|NCT02183194|Device|Lutonix Paclitaxel Drug Coated Balloon|
45450306|NCT02756182|Device|TDOC air-charged catheter|Urodynamic study utilizing a single catheter technique to measure WP & AC measurements
45450307|NCT02183272|Drug|Intranasal Ketamine|Ketamine in liquid form to be distributed nasally by a board-certified physician while the subject is already in the hospital for suicidal ideation.
45450308|NCT02183272|Drug|Intranasal Saline Placebo|Intranasal Saline to be distributed by a board-certified physician while the patient is already hospitalized for suicidal ideation.
45450309|NCT02177500|Drug|Telmisartan + hydrochlorothiazide|
45450310|NCT02177500|Drug|Telmisartan|
45450311|NCT02177500|Drug|Placebo|
45450312|NCT02183350|Drug|BI 1356 BS - single rising dose|
45450313|NCT02183350|Drug|Placebo|
45450314|NCT04289597|Diagnostic Test|Distance between hyoid bone-skin (DSHB)|Distance between hyoid bone-skin
45450315|NCT04289597|Diagnostic Test|Vocal cord anterior commissura-skin distance (DSAC)|Vocal cord anterior commissura-skin distance
45649469|NCT04889651|Drug|BR9004-1|BR9004-1: Zytiga Tab. 500mg (Abiraterone acetate 500mg), Janssen Korea
45649470|NCT04898933|Procedure|eyelid lesion excision|eyelid lesion excision was done under local anesthesia
45649471|NCT04898777|Procedure|Biliary drainage|Biliary decompression in cases of distal malignant obstruction by stent placement either using ERCP or EUS.
45649472|NCT04889339|Device|Test brace versus control brace: Immediate correction|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
45924521|NCT00389636|Drug|Regranex|Regranex + TheraGauze
45924522|NCT00050050|Behavioral|Cognitive behavioral therapy|
45924523|NCT00050050|Drug|Drug therapy|
45924524|NCT00050128|Device|rTMS, Magstim|
45924525|NCT04731337|Device|Digital Caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)|Measuring the vertical distance between the tip of the upper and lower canine teeth.
45797007|NCT03832686|Other|Virtual Coach|The smartphone application, tailored to patients with HNC, will monitor patient progress while also providing a direct line to health care providers should any questions or concerns arise concerning their treatment. The mobile application will also feature instructional videos that describe the swallowing exercises in detail, providing patients with another resource to help improve their overall rehabilitation experience. Finally, home practice reminders and prompts will be used to help patients integrate the exercises into their daily routine.
45924526|NCT05576064|Diagnostic Test|Gait analysis|Analysis of gait profile and measures by gait laboratory on patients with suspected lower limb rotational deformities and anterior knee pain
45924527|NCT05640440|Diagnostic Test|Executive function testing|Assessment of executive function subdivision
45924528|NCT00050206|Drug|Olanzapine|
45924529|NCT00050206|Drug|Placebo|
45924530|NCT00050245|Drug|Rituximab|
45797008|NCT03822663|Dietary Supplement|Caffeine supplementation|The experimental procedure for each athlete includes an acute CAF supplementation in a different-dose crossover regimen in order to assess whether the dose affects the actual physical capacity and discipline-specific exercise performance (doses: 3.0-, 6.0- and 9.0 mg/kg of body mass, respectively). CAF (pure pharmaceutical caffeine) will be administered in the dissolved form. On testing days, the supplements will be taken 45 min before physical and exercise capacity test session. Between the CAF and PLA or a PLA and CAF treatments, a minimum 7-day washout period will be introduced.
46071866|NCT05877469|Other|Functional Training|In this group 22 patients will perform functional training. Patients will be instructed to perform their daily living movements like squatting, reaching, or even carrying a heavy object. These exercises typically use the whole body and emphasize core strength and stability. Functional training typically uses weight-bearing activities that work the core muscles in the torso. the functional movements include involve glute bridge, squats, pushups, lateral lunge, step up to shoulder press, goblet and squats. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
46071867|NCT05877417|Dietary Supplement|Creatine Monohydrate|Creatine supplementation for 8 weeks, 5g daily. A 5 day loading phase will be implemented with 20g daily for 5 days.
46071868|NCT05877417|Device|Blood Flow Restriction|Blood Flow Restriction Cuffs applied during exercise
45924531|NCT00050323|Drug|Allogeneic DCs and Autologous RCC Tumor Derived Cells|
45924532|NCT05574660|Dietary Supplement|High-Fat/High-Sugar (HF/HS) Diet|
46071869|NCT05877417|Other|Exercise|Participants will exercise
46071870|NCT05877378|Device|Single-use negative pressure therapy (PICO)|PICO system will be applied to patients in the intervention group with diabetic foot ulcers, venous leg ulcers or pressure ulcers. This device will be changed every 7 days, until the wound is closed, or until a set period of study duration, approximately 12 weeks.
46071871|NCT05877365|Dietary Supplement|Standard Process 21-Day Purification Program|Purification, also known as detoxification, may help remove natural toxins from the body, while maintaining a healthy weight. The toxin load humans are exposed to daily may take a toll on physical and emotional well-being. Internally, human bodies produce waste byproducts because of normal metabolic function. Although the body is designed to rid itself of these toxins naturally, it can become overburdened. Purification may offer the body additional support to expel these toxins and manage weight, which is important to maintaining health and vitality.
45924533|NCT05574660|Dietary Supplement|Low-Fat/Low-Sugar (LF/LS) Diet|
45924534|NCT00050362|Drug|Rofecoxib and Bupivacaine|
45924535|NCT00050401|Drug|MERREM I.V. 2g as a 3 hour infusion every 8 hours|
45924536|NCT00050401|Drug|vancomycin I.V. 1 g every 12 hours|
45924537|NCT00050401|Drug|tobramycin I.V. 5 mg/kg every 24 hours|
46071872|NCT05877352|Radiation|Intraoperative Electron Radiotherapy (IOERT)|IOERT can be defined as the direct application of high-energy electron beam irradiation to a tumour bed during an operative procedure. This approach permits precise delivery of a single large fraction of radiation directly and specifically to high recurrence risk anatomical target areas, which the treating clinicians (surgeon and attending clinical oncologist) predict will be a close or involved margin, while simultaneously displacing and shielding dose-limiting radiosensitive structures such as the small bowel or ureter or any anastomoses, if not involved by tumour.
46071873|NCT05877352|Procedure|Extended Margin Surgery|Surgery intended to remove both a tumour and any metastases
46071874|NCT05877339|Diagnostic Test|Survey|Survey
46071875|NCT05877313|Other|Sterile water foot bath|Participants will use the same foot bath and sterile water used in the treatment arm minus the active ingredients.
46071876|NCT05877313|Drug|Nitric Oxide|Participants will use a foot bath filled with 500mL of NORS for 15 min. The solution's two components are mixed 1:1 to 500mL in the foot bath immediately before treatment. The solution contains NO at 68.9ppm*hrs and 203.2ppm*hrs for 1X and 2X solutions respectively, and it acts as a virucidal agent. Instructions for storage, handling, and use will be provided to site staff and participants.
45924538|NCT00050401|Drug|MERREM I.V. 1g as a 30 minute infusion every 8 hours|
45924539|NCT00050401|Drug|MERREM I.V. 500 mg as a 3 hour infusion every 8 hours|
45924540|NCT05640362|Other|Natural enzymes mouthwash|Natural enzymes mouthwash contains numerous natural protein-enzymes, including lactoferrin, lysozyme, lactoperoxidase, glucose oxidase. These active ingredients were proposed to render this mouthwash to act as salivary substitutes by reinforcing the functions of available saliva, hence reinforcing the immune system in the oral cavity. It was expected to relieve the symptoms in xerostomia patients, and even more if the patients have salivary flow reduction by improving the functions of the limited amount of saliva. The potential mechanisms of action of the mouthwash to treat xerostomia may be related to: (1) lubrication effects to wet the oral mucosal surfaces; (2) antimicrobial properties that will reduce risks of mucosal irritation by infections; (3) absence of alcohol in the mouthwash Subjects were instructed to rinse with the mouthwash 4 times per day at a specific period, for 2 weeks.
45924541|NCT05640362|Other|Benzydamine mouthwash|Subjects were instructed to rinse with the mouthwash 4 times per day at a specific period, for 2 weeks.
45924542|NCT02970214|Other|no intervention, only observational|no intervention, only observational
45924543|NCT00050440|Drug|Trabectedin|Trabectedin 1.3 mg/m2 administered intravenously every 21 days.
45797009|NCT03822663|Dietary Supplement|Placebo treatment|The experimental procedure for each athlete will include PLA supplementation. Placebo will be administered in the dissolved form. On testing days, the PLA will be taken 45 min before physical and exercise capacity test session. Between the PLA and CAF or a CAF and PLA treatments, a minimum 7-day washout period will be introduced.
45649473|NCT04889339|Device|Test brace versus control brace: Long-term correction|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
45797010|NCT03801525|Drug|Ublituximab|"recombinant chimeric anti-CD20 (cluster of differentiation 20) monoclonal antibody~administered as an intravenous (IV) infusion"
45797011|NCT03801525|Drug|Umbralisib|"inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase 1 epsilon (CK1e)~Tablet form"
45797012|NCT03801525|Drug|Venetoclax|"B-cell lymphoma 2 (BCL-2) inhibitor~Tablet form, to be taken orally"
45797013|NCT03778957|Drug|Durvalumab|Durvalumab IV (intravenous)
45797014|NCT03778957|Drug|Bevacizumab|Bevacizumab IV (intravenous)
45797015|NCT03778957|Other|Placebo|Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous)
45797016|NCT03778957|Procedure|Transarterial Chemoembolization (TACE)|TACE (chemo and embolic agent injection into the hepatic artery)
45797017|NCT03767933|Drug|Ibuprofen|10mg/kg, maximum 600mg; Oral liquid
45797018|NCT03767933|Drug|Acetaminophen|15mg/kg, maximum 1000mg; Oral liquid
45797019|NCT03767933|Drug|Hydromorphone|0.05mg/kg, maximum 5 mg; Oral liquid
45797020|NCT03767933|Drug|Acetaminophen placebo|Oral liquid
45797021|NCT03767933|Drug|Hydromorphone placebo|Oral liquid
45797022|NCT03743298|Drug|AV-MEL-1|AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
45797023|NCT03728257|Behavioral|LTGO-Home Based Exercise|The LTGO intervention consists of two phases: Phase 1. Intensive home-based exercise training and behavioral coaching via a telerehabilitation platform, VISYTER (Versatile and Integrated System for Tele-Rehabilitation)/two-way video communication system. Interactive intervention sessions will be delivered to the home via real time video conferencing (up to 12 sessions and a behavioral contract plan to prepare for phase 2); and Phase 2. Transition to self-management. Three telephone sessions (3 monthly counseling sessions) will be delivered over 12 weeks to provide behavioral coaching and exercise reinforcement
45797024|NCT03728257|Behavioral|Enhanced Usual Care|Enhanced Usual Care (EUC) will involve delivery of monthly newsletters (6 newsletters) on the topics of post-lung transplant management, including food safety, environmental health, flu, mental health, etc. and the provision of a self-monitoring device.
45797025|NCT03713905|Drug|GLS-010|Recombinant Human Anti-PD-1 Monoclonal Antibody
45797026|NCT03701919|Drug|Botulinum toxin pyloroplasty|Intraoperative laparoscopic injection of Botulinum toxin into the pylorus immediately following sleeve gastrectomy
45797027|NCT03701919|Drug|Normal saline pyloric injection|Intraoperative laparoscopic injection of normal saline into the pylorus immediately following sleeve gastrectomy
45797028|NCT03690843|Other|Test Battery|All toddlers (DCD children + TD children) included in the study will be tested at three points in time, that is at the age of 3y, 4y and 5y with an extensive test battery. Questionnaires will be filled in by parents and teachers. Children will be tested using different instruments.
45797029|NCT03688503|Dietary Supplement|magnesium glycinate supplement|magnesium glycinate (480 mg/day)
45649474|NCT04884347|Dietary Supplement|Alline proMEN|1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months
45649475|NCT04884347|Dietary Supplement|Placebo|1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months
45797030|NCT03688503|Dietary Supplement|placebo|placebo
45797031|NCT03636152|Procedure|MRI carotid|To assess the carotid atherosclerotic plaques
45797032|NCT03636152|Procedure|APWV|Doppler measurement of the APWV
45797033|NCT03636152|Drug|Hydroxychloroquine|Active Drug
45797034|NCT03636152|Drug|Matching Placebo|Matching Placebo for the control group.
45797035|NCT03633604|Biological|HBOC-201|Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.
45797036|NCT03582371|Procedure|Stand-Up Paddle Rehabilitation|Patients in the Aqua SUP group will benefit from a 1 hour Aqua SUP session, twice a week, for 8 weeks in a therapeutic pool.
45797037|NCT03582371|Procedure|Physiotherapy Rehabilitation|Patients in the control group will receive a conventional physiotherapy session of 1 hour, twice a week, for 8 weeks.
45797038|NCT03555916|Drug|BOTOX®, Allergan|50 U BTX-A (BOTOX®, Allergan) powder diluted in 2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
45797039|NCT03555916|Drug|Placebo|2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
45797040|NCT03490201|Device|Market Approved RF Ablation System|Subjects receive ablation using an FDA approved ablation system.
45797041|NCT03490201|Device|FlexAbility SE Ablation Catheter|Subjects receive ablation treatment using an ablation system that is not FDA approved.
45797042|NCT03487120|Procedure|facet joint denervation|Bipolar electrocautery
45924544|NCT00050440|Drug|Dexamethasone|Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose
45924545|NCT00050479|Drug|Celecoxib (Celebrex)|
45649476|NCT04883723|Device|Shotblocker|Shotblocker is a small, flat, horseshoe-shaped plastic tool that can be used to reduce pain due to intramuscular injection, suitable for all age groups, without drug properties. It is used by keeping it on the skin surface during injection and has no side effects. Shotblocker has short, non-pointed blunt protrusions on one side that connect with the skin, there is a hole in the middle of the vehicle to expose the injection site. The protruding surface of the vehicle is placed in the area to be applied just before injection. The protrusions on the surface of the Shotblocker do not pierce the skin and provide a warning for the Door Control Theory, which is thought to exist regarding pain
45450316|NCT04289597|Diagnostic Test|minimum distance of the trachea to the skin at the level of suprasternal notch|Distance of the trachea to the skin at the level of suprasternal notch
45450317|NCT04289597|Diagnostic Test|Thyroid isthmus-skin distance (DSI)|Thyroid isthmus-skin distance
45649477|NCT04883723|Other|Manual Pressure|The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Pressure was applied to the determined injection area with the thumb of the active hand for 10 seconds. Immediately after the application of pressure was terminated, the injection site was cleaned with an alcohol cotton pad with circular movements of 5 cm diameter from inside to outside, and the alcohol was allowed to dry. With a single movement at a 90 ° angle, the compression area was entered quickly and the injection was performed. Manual pressure reduces pain within the framework of the gate control theory. According to the gate control theory, when pressure is applied to an area, a fiber transmits the feeling of pressure instead of pain and ultimately the pain sensation is alleviated. There are many studies in the literature that prove the effectiveness of this method.
45649478|NCT04898699|Device|UrSure Rapid Urine Tenofovir Test|A point of care urine immunoassay to measure PrEP drug levels for adherence in participant urine samples over the preceding seven days will be done at all follow-up visits. At enrollment, study staff will explain the use of this experimental measurement of PrEP drug level in urine samples. Participants will receive results of the test at the same study visit during which it is performed.
45797043|NCT03474497|Drug|IL-2|• A total of four interleukin-2 treatments will be delivered into the treatment lesion by intralesional injection biweekly (at least 48 hours apart) starting 24-96 hours after the completion of radiotherapy and to be completed during the second on-trial cycle of Pembrolizumab. Intralesional injections will be performed by direct visualization and/or palpation of the lesion or under ultrasound or CT guidance as indicated.
45450318|NCT04289597|Diagnostic Test|Skin-epiglottic distance (DSE)|Skin-epiglottic distance
45450319|NCT02180854|Other|Control group|
45754391|NCT00608491|Drug|Stepped pharmacologic care|Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.
45754392|NCT00608491|Device|Ultrafiltration|All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
45754393|NCT02985086|Drug|Cefoxitin|
45754394|NCT02985086|Drug|oxytocin/misoprostol|
45797044|NCT03474497|Drug|Pembrolizumab|Pembrolizumab will be delivered at 200 mg in three week cycles per standard protocol.
45797045|NCT03474497|Radiation|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the second cycle of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1-2 of cycle 2 and will not be repeated in future cycles.
45797046|NCT03463824|Behavioral|Experimental Group 1|Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
45450320|NCT02180854|Other|Increased monitoring frequency|
45754395|NCT04143542|Procedure|trunk blocks|Comparison of trunks blocks and control groups for Postoperative Analgesia in Abdominal Surgery
45754396|NCT03586310|Device|ear-EEG|soft silicone electrode array placed in each ear (outer ear-canal and concha), connected to a battery powered EEG amplifier.
45754397|NCT03586232|Dietary Supplement|Arnica Montana|Arnica Montana is from the Asteraceae plant family and is native to the mountain areas in Europe and western North America. It is reported to have anti-inflammatory, antiseptic, and vasodilatory properties and is often used in plastic surgery to help reduce pain, edema, and ecchymosis postoperatively.
45754398|NCT03586232|Dietary Supplement|Bromelain|Bromelain is a protease enzyme derived from the pineapple plant, Ananas comosus, which has been used to reduce swelling, inflammation, and pain and may help to reduce wound healing time.
45797047|NCT03463824|Behavioral|Experimental Group 2|Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
45797048|NCT03395223|Drug|Methylene Blue|Administration of Methylene Blue to treat acquired methaemoglobinaemia
45797049|NCT03347877|Procedure|autologous osteo-periosteal cylinder graft transplantation|Autologous osteo-periosteal cylinder graft transplantation is a novel treatment for Hepple V osteochondral lesions of the talus.
45797050|NCT03347877|Procedure|autologous osteochondral graft transplantation|Autologous osteochondral graft transplantation is the most common treatment for Hepple V osteochondral lesions of the talus.
45797051|NCT03347877|Device|autologous osteo-periosteal cylinder graft|Autologous osteo-periosteal cylinder graft is taken from ilium.
45797052|NCT03329469|Device|Toshiba CT-FFR|Patients receiving CCTA to diagnose acute chest pain or unstable angina will receive CT-FFR to estimate rate of blood flow through the coronary arteries. The rate of flow will be compared to the rate found on Invasive FFR (the gold standard) if the subject receives invasive FFR.
45797053|NCT03289650|Drug|Tacrolimus|immunosuppressive agent tacrolimus, given twice-daily
45649479|NCT04898699|Device|OraQuick Rapid HIV Self-test kit|Participants will be provided with HIV self-testing kits to use at their discretion and, in case of multi-month dispensing, prior to start of new bottle of PrEP medication, in between study visits. HIV self-testing kits will be provided to confirm their HIV-negative status and make a connection between PrEP use and protection against HIV. Participants will receive detailed, interactive training on HIVST with pictorial elements, including instructions to contact study staff immediately in event of a reactive test for confirmation as per Kenya guidelines.
45649480|NCT04898699|Drug|Tenofovir (300mg)/Emtricitabine(200mg) [Truvada®]|Information will be provided regarding dosing of PrEP medications, importance of daily adherence, importance of frequent HIV testing, and signs and symptoms of drug toxicity, acute HIV infection and STIs. An initial one-month supply (30 pills) of FTC/TDF will be given to all PrEP study participants. At the one-month study assessment, a two-month supply of daily oral FTC/TDF will be given to each participant, after HIV testing, assessment for acute HIV infection and review of side effects and adherence, following national guidelines and procedures for PrEP services. At Month 3 assessment, a three-month supply of oral FTC/TDF will be given.
45797054|NCT03289650|Drug|Tacrolimus Extended Release Oral Tablet [Envarsus]|immunosuppressive agent extended-release tacrolimus, given once daily
45797055|NCT03255070|Drug|ARX788|An antibody drug conjugate
45797056|NCT03192397|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplant
45754399|NCT03586232|Other|Placebo|A pharmacologically inert preparation
45797057|NCT03192397|Drug|Cyclophosphamide|Given IV
45797058|NCT03192397|Drug|Fludarabine Phosphate|Given IV
45797059|NCT03192397|Other|Laboratory Biomarker Analysis|Correlative studies
45797060|NCT03192397|Drug|Melphalan Hydrochloride|Given IV
45797061|NCT03192397|Drug|Mycophenolate Mofetil|Given IV
45797062|NCT03192397|Drug|Sirolimus|Given IV and PO
45797063|NCT03192397|Radiation|Total-Body Irradiation|Undergo TBI
45797064|NCT03015402|Drug|Sodium Nitrite|40 mg PO (by mouth) TID (three times each day) for 10 weeks
45797065|NCT03015402|Drug|Placebo Oral Capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) TID (three times each day) for 10 weeks
45797066|NCT02982096|Device|Cellutome Device|Use of FDA approved Cellutome treatment on burn wounds
45797067|NCT02982096|Other|Standard of Care|Acellular burn wound management
45797068|NCT02978183|Biological|ST266|One (1) drop of 1X ST266 ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
45797069|NCT02978183|Drug|Saline (0.9% NaCl)|One (1) drop of saline ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
45797070|NCT02976792|Procedure|Renal Resistive Index/NephroCheck™test|Renal Resistive Index and NephroCheck™ test before TAVI and after TAVI
45797071|NCT02975492|Drug|Cholecalciferol sequential dose|sequential dose administration of the treatment
45797072|NCT02975492|Drug|Cholecalciferol daily dose|daily dose administration of the treatment
45797073|NCT02937818|Drug|Durvalumab and Tremelimumab|Durvalumab + tremelimumab via intravenous (IV) infusion every 4 weeks (q4w), starting on Week 0, for up to a total of 4 months (4 cycles) followed by durvalumab monotherapy via IV infusion q4w, starting on Week 16 until PD, or for other discontinuation criteria.
45797074|NCT02937818|Drug|AZD1775 and carboplatin (CBPT)|AZD1775 twice daily (oral) for 2.5 days from Day 1 + CBDP area under the curve 5 (Day1) (IV); every 3 weeks.
45797075|NCT02937818|Drug|AZD6738 and olaparib|AZD6738 once a day (oral) for 7 days from Day 1 + olaparib twice a day(oral) for 28 days from Day 1, every 4 weeks
45797076|NCT02920788|Behavioral|Goal-Oriented Attentional Self-Regulation (GOALS)|GOALS is a manualized, therapist-administered cognitive training program that targets executive control functions of applied mindfulness-based attention regulation and goal management strategies and links them to participant-defined real-life goals. In contrast to training via practice on isolated tasks, this training protocol involves application of attention regulation skills and strategies to participant-defined goals in real life, ecologically valid settings. One of the main training aims is to improve self-regulatory control mechanisms as they contribute to goal attainment.
45797077|NCT02920788|Other|Brain Health Education (BHE)|BHE group is a formal in-person, active, psycho-educational, control intervention closely matched to GOALS for length, intensity, and contact with a therapist/facilitator. Topics include brain structure, function, sleep, stress, emotion and the brain.
45797078|NCT02920788|Device|fMRI|Functional Magnetic Resonance Imaging of the Brain
45797079|NCT02867267|Drug|Thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
45797080|NCT02867267|Other|Placebo|Subcutaneous injections of placebo every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
45797081|NCT02864940|Device|Lumosity|A web-based cognitive training platform that includes games designed with the purpose of improving the user's cognitive abilities
45797082|NCT02864940|Device|Crossword puzzle|This game offers a choice between three puzzle sizes, three levels of complexity, and varying font sizes. It also includes optional help features such as filling in an unknown letter or word.
45797083|NCT02863107|Procedure|Biospecimen Collection|Undergo collection of blood or saliva samples
45797084|NCT02863107|Other|Medical Chart Review|Review of medical charts
45797085|NCT02863107|Other|Quality-of-Life Assessment|Ancillary studies
45797086|NCT02863107|Other|Questionnaire Administration|Complete questionnaires
45797087|NCT02821832|Procedure|Saliva collection|For biomarker assessments
45797088|NCT02821832|Procedure|Urine collection|For biomarker assessments
45797089|NCT02821832|Procedure|Sputum collection|For primary endpoint assessments and other biomarker assessments
45797090|NCT02821832|Procedure|Blood Collection|For biomarker and eligibility assessments
45797091|NCT02821832|Radiation|PET/CT Scan|Imaging of the lungs to establish disease extent and severity
45797092|NCT02821832|Drug|Isoniazid, Rifampicin, Pyrazinamide and Ethambutol|Treatment-standard of care
45797093|NCT02813148|Drug|Naloxegol|Non-interventional study of drug utilization
45924546|NCT05640167|Behavioral|Interdisciplinary Clinic|Interdisciplinary Clinic - assessment and recommendations by Nutrition, Pharmacy, Physical Therapy, and Speech Therapy and Educational Seminar - Parkinson's specific education and resources in group format
45924547|NCT00050518|Biological|Aventis Pasteur Smallpox Vaccine|
45797094|NCT02756611|Drug|Venetoclax|Tablets for oral administration
45797095|NCT02673359|Drug|Progesterone|Vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) will be given in a dose of 400 mg/day
45797096|NCT02673359|Procedure|Cervical cerclage|Cervical cerclage will be performed by transvaginal placement of purse-string stitch suture at the cervicovaginal junction, without mobilization of the urinary bladder (McDonald cervical cerclage)
45797097|NCT02662933|Other|Bedside assessment|"The study intervention consists of a bedside functional assessment to be administered to eligible, consented subjects who are hospitalized with a new diagnosis of AML or are undergoing workup for suspected AML diagnosis. All subjects will be enrolled within 5 days of admission to the hospital for known or suspected AML or within 5 days of new confirmed diagnosis of AML obtained during a hospitalization for other indications. All measures will be performed by a trained examiner during a face to face interview.~Bedside assessment measures will be repeated once for subjects who complete induction chemotherapy within 2-8 weeks post discharge from initial hospitalization."
45797098|NCT02629809|Drug|Cyclophosphamide|Given IV
45924548|NCT05574543|Drug|AGA111|AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
45924549|NCT05574543|Drug|Placebo|Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
45924550|NCT00050557|Behavioral|Multifamily Psychoeducation Group (MFPG)|MFPG will include 8 weekly 90-minute group therapy sessions.
45924551|NCT00050557|Behavioral|Treatment as usual (TAU)|Participants will receive standard care for mood disorders.
45649481|NCT04898699|Behavioral|2-way text message reminders|"All participants will receive weekly SMS visit reminders to support PrEP adherence. Participants will be asked at study enrollment for a primary contact telephone number and an alternate number for contact. Participants without cell phones will be provided an inexpensive cell phone (although cell phone ownership is very high in Kenya). Participants will receive a discrete weekly SMS text (or voice message if participant is illiterate) to encourage healthy behaviors, use of HIV self-test kit, study engagement and PrEP adherence. Messages will be a general message that the participant has selected and will not have any information identifying the participant as part of the study or describing the purpose of the study. An example text is Remember to look after yourself today, See you tomorrow. Participants will be requested to respond to the message with any questions, concerns or messages that they have for the study staff."
45797099|NCT02629809|Drug|Fludarabine Phosphate|Given IV
45649482|NCT04898699|Behavioral|HIV risk-reduction counseling|All study participants will be provided with brief interactive counseling at each study visit, tailored to the results of their urine assay.
45649483|NCT04883801|Diagnostic Test|Reviewed clinical records and laboratory results|Retrospectively reviewed clinical records and laboratory results
45649484|NCT02618759|Drug|DSXS|active treatment
45649485|NCT02618759|Drug|Placebo|placebo treatment
45649486|NCT04899011|Other|Questionnaire|"Questionnaire about taste and salivary disturbance before surgery, 10 days, 4 months and 1 year after surgery.~Questionnaires include characteristics of taste disturbance, and specific impact on quality of life."
45649487|NCT04888715|Drug|DWN12088|Prolyl-tRNA synthetase (PRS) inhibitor
45649488|NCT04888715|Drug|Pirfenidone|Pirfenidone
45649489|NCT04888715|Drug|Nintedanib|Nintedanib
45649490|NCT04888559|Other|Breakfast product: Whole grain|This intervention is a whole grain-based breakfast product containing oats and barley.
45649491|NCT04888559|Other|Breakfast product: Reference|This intervention is a rice-based breakfast product.
45797100|NCT02629809|Drug|Ibrutinib|Given PO
45797101|NCT02629809|Biological|Obinutuzumab|Given IV
45797102|NCT02624518|Drug|68Ga-RM2|Imaging with PET/MRI
45797103|NCT02624518|Procedure|Magnetic Resonance Imaging|Imaging with 68Ga-RM2 PET/MRI
45797104|NCT02624518|Procedure|Positron Emission Tomography|Imaging with 68Ga-RM2 PET/MRI
45797105|NCT02603146|Drug|Hydroxychloroquine|As described. Dosing will be based upon Screening IBW.
45797106|NCT02603146|Drug|HCQ Placebo|As described. Dosing will be based upon Screening IBW.
45797107|NCT02542657|Drug|Clarithromycin|Given PO
45797108|NCT02542657|Drug|Dexamethasone|Given PO
45797109|NCT02542657|Drug|Ixazomib Citrate|Given PO
45797110|NCT02542657|Drug|Pomalidomide|Given PO
45797111|NCT02445222|Genetic|Previously treated CAR-T patients|Lentiviral-based CAR-T cell therapy
45804124|NCT05686213|Behavioral|Aerobic exercise prior to daily radiotherapy sessions (ExPR)|Patients in the ExPR in-hospital exercise intervention group will be offered an aerobic exercise program at moderate intensity. The exercise sessions will take place 5 days a week (only weekdays), and will have a duration of 30 minutes including a warming-up (5 min) and cooling-down (5 min). Total exercise volume will be aimed at 150 min per week. The sessions will take place within an hour before the daily radiotherapy session.
45924552|NCT00050596|Drug|MDX-010 / MDX-010 + Docetaxel|
45924553|NCT00050635|Drug|Sandostatin LAR Depot|
45924554|NCT05574465|Device|High resolution solid state manometry|The use of esophageal manometry device during removal of endotracheal tube by anesthesia
45924555|NCT05640128|Other|Aldosterone in HPLC-MS/MS|Aldosterone in HPLC-MS/MS
45924556|NCT00397774|Behavioral|Physical exercise|Physical exercise twice a week for 8 weeks, and best supportive care
45924557|NCT00397774|Other|best supportive care|
45924558|NCT00050674|Drug|Filgrastim-SD/01|6 mg SC on Day 9 (24 hours after the end of the chemotherapy infusion)
45924559|NCT00050713|Drug|Sirolimus|
45924560|NCT00050791|Drug|Leptin|Leptin is an adipocyte hormone that functions as an afferent signal in a feedback loop regulating body weight
45450321|NCT01068119|Procedure|Same-day discharge|Patients identified as clinically stable are discharged home the same day as the PCI procedure with telephone follow-up at 12 hr, 24 hr, 3, 30, 180 and 365 days post procedure.
45797112|NCT02415816|Procedure|Diffusion Weighted Magnetic Resonance Imaging|Diffusion weighted magnetic resonance imaging (DWI MRI) is a method that does not involve radiation and can be used to assess the primary tumor as well as to image the entire patient, from head to toe. Diffusion weighted MRI uses a strong motion probing gradient to detect the movement of water in tissue. Tissues that are composed of tightly packed cells, such as tumors, allow less water movement than tissues with loosely packed cells. As tumors respond to therapy they become necrotic and cells are less tightly packed. This change in water diffusivity can be quantitated using DWI. Therefore, DWI provides a non-invasive, non-ionizing, and quantitative method of assessing tumor response at a cellular level and does not depend on a change in tumor size
45797113|NCT02303171|Drug|Enoxaparin|Women will be given Enoxaparin throughout pregnancy in a dose of 40 mg/day subcutaneously (SC)
45797114|NCT02303171|Drug|Warfarin|Women will be given Enoxaparin (40 mg/day SC) in the first trimester then Warfarin (3-5 mg/day) after the first trimester until termination of pregnancy
45450322|NCT03537898|Other|Lactated Ringer's|Lactated Ringer's will be used whenever an isotonic crystalloid is ordered
45450323|NCT03537898|Other|Normosol|Normosol-R pH 7.4 will be used whenever an isotonic crystalloid is ordered
45797115|NCT02287623|Drug|liposomal bupivacaine|patients will receive a tap with liposomal bupivacaine
45450324|NCT01080833|Device|ERCP mechanical simulator practice|Trainees will receive ERCP mechanical simulator practice in addition to routine ERCP training
45450325|NCT02183428|Drug|BI 1356|
45450326|NCT02183428|Drug|Glyburide|
45797116|NCT02287623|Drug|bupivacaine|patients will receive a tap with bupivacaine
45797117|NCT02266329|Drug|prazosin hydrochloride|Prazosin as oral capsules titrated to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
45797118|NCT02266329|Drug|placebo|Oral capsules of placebo identical in appearance to prazosin capsules titrated in the same manner as prazosin.
45797119|NCT02195310|Device|Prevena™ Incision Management System|Prevena™ Incision Management System is used after sternotomy on the closed incision
45797120|NCT02195310|Device|Conventional sterile wound dressings|Conventional sterile wound dressings are placed after sternotomy on the closed incision
45797121|NCT02174159|Drug|Ulonivirine|MK-8507 administered as a single oral dose
45797122|NCT01794520|Drug|Venetoclax|Each dose of venetoclax was to be taken with approximately 240 mL of water. On days that pre-dose pharmacokinetic (PK) sampling was required, dosing was to occur in the morning at the clinic at approximately 0900 (± 1 hour) to facilitate PK sampling. Dose Escalation cohort participants were to take venetoclax within 30 minutes after the completion of a standard low-fat breakfast with approximately 240 mL of water on Cycle 2 Day 1. On all other dosing days, participants were instructed to take venetoclax orally QD within 30 minutes after the completion of a low-fat breakfast. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed.
45797123|NCT01794520|Drug|Dexamethasone|Tablets were administered by mouth per the dexamethasone prescribing information.
45797124|NCT01774019|Device|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|
45797125|NCT01668953|Other|Platelet Rich Plasma (PRP) Injection|"The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.~For the PRP preparation, the Arthrex ACP system will be used. This is a closed, double syringe system which uses 16 mL of whole blood drawn from the patient's contralateral arm, using a 19G butterfly needle. The blood is centrifuged at 1500 rpm for 5 minutes and extracts 4-7 ml of PRP. No anticoagulant will be used.~Fenestration of the tendon will continue as 3mL of PRP is injected into the common extensor tendon.~The remaining PRP will be sent for analysis of platelet, WBC, and RBC concentrations."
45797126|NCT01668953|Other|Whole Blood Injection|"The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.~6mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle.~Fenestration of the tendon will continue as 3mL of whole blood biologic agent is injected into the common extensor tendon.~The remaining 3mL will be sent for analysis of platelet, WBC, and RBC concentrations."
45804125|NCT00355225|Procedure|ITN distribution channel|
45804126|NCT00355771|Drug|Levocetirizine|Intake of 1 tablet of Levocetirizine 5mg OD for 8 weeks
45804127|NCT00355771|Drug|Placebo|1 tablet OD in the morning for 8 weeks
45450327|NCT02183428|Drug|BI 1356 + Glyburide|
45450328|NCT01080911|Drug|Morphine|spinal morphine 0.05 mg
45450329|NCT01080911|Drug|Morphine|spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
45649492|NCT04897997|Procedure|coronarography and angioplasty|selective angiography of the coronaries and angioplasty of significant culprit lesion(s)
45450330|NCT02183506|Drug|Metformin|
45450331|NCT02183506|Drug|BI 1356 BS|
45649493|NCT04888325|Other|Oral glucose|Oral glucose consumption (1.25 grams/kg in 200 ml water at time 0 and the same amount again at 3 hours). During the 6-hour observation period infusion of normal saline (NaCL 0,9%) at a rate of 0.83 plus Heparin, 800 IU/h with a priming dose of 1000 IU.
45649494|NCT04888325|Other|Intravenous glucose|10% intravenous glucose infusion at a rate of 3.6 ml/kg/h plus Heparin 800 IU/h with a priming dose of 1000 IU will be administrated for 6 hours. Consumption of 300 ml of water at 0 and 3 hours
45649495|NCT04888091|Procedure|Cotton swab|Removal of the cervical mucus with a cotton swab before embryo transfer.
45649496|NCT04888091|Procedure|Cannula|Removal of the cervical mucus with a cannula before embryo transfer.
45649497|NCT03050723|Device|Princess® FILLER|Princess® FILLER injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
46071877|NCT05877300|Combination Product|Cellspan™ Esophageal Implant-Adult (CEI)|The CEI is a combination product consisting of an engineered synthetic scaffold (device constituent) seeded and cultured with the patient's adipose derived mesenchymal stromal cells (biologic constituent), intended to stimulate regeneration of a structurally intact, living biologic esophageal conduit, in patients requiring full circumferential esophageal reconstruction up to 6 cm segment in length.
46071878|NCT05877287|Other|mindfulness-based stress reduction program|The FTSA program will be carried out once a week for 60 minutes, for 8 weeks, in a total of 8 sessions. The program will be conducted in face-to-face groups. Sessions will be held in a suitable area in the practice area. In each 60-minute session, it is planned to be 20 minutes of narration on the subject of the session, accompanied by a power point presentation, and the remaining 40 minutes of exercise, meditation practices and sharing experiences.
46071879|NCT05877274|Other|Sodium channel mutation|Mutation of the genes SCN9A and SCN10A, which encode for Sodium channel 1.7 and 1.8.
45649498|NCT04888403|Drug|Toripalimab+Nedaplatin+Albumin Paclitaxel|"Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 1 cycles.~Other Names:Toripalimab+Nedaplatin+Albumin Paclitaxel Neoadjuvant radiotherapy after 2W: The radiotherapy dose is 41.4Gy, completed in 23 times, 5 times a week, using intensity-modulated radiotherapy (IMRT) or volume-modulated radiotherapy (VMAT); In the same period, albumin paclitaxel combined with nedaplatin chemotherapy: albumin paclitaxel 60mg/m2 + nedaplatin 25mg/m2, performed once a week, 5 times in total; Simultaneous immunotherapy: 240 mg of Toripalimab (PD-1 antibody), once every 3 weeks, 4 times in total; Received radical resection of esophageal cancer within 7 weeks after radiotherapy and chemotherapy.~Other Names:Toripalimab+Nedaplatin+Albumin Paclitaxel"
45649499|NCT04883567|Diagnostic Test|The use of artificial intelligence system Cerebro|The artificial intelligence system Cerebro would be used during OGD
45797127|NCT01668953|Other|Dry Needle Fenestration|"The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.~A 22-gauge needle will then be placed into the tendon.~15-25 strokes or as many strokes required until tendon is softened of dry needling will be performed in which the needle pierces the tendon at multiple sites. No blood will be injected into the tendon."
46071880|NCT05877261|Device|Cementless Total Knee Replacement|Artificial knee implant inserted by cementless fixation.
46071881|NCT05877235|Dietary Supplement|Quercetin|Trans-quercetin, 1000 mg daily for 60 days
45649500|NCT03050177|Drug|Gefitinib Tablet 250mg of Hunan Kelun|Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered under fed conditions after a 10-hour overnight fast.
45797128|NCT01668953|Other|Sham Injection|"The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine (no epinephrine) for local anesthetic.~3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.~The superficial subcutaneous soft tissues will be re-entered however, the tendon itself will not be entered and nothing will be injected."
45797129|NCT01653678|Dietary Supplement|Vitamin D-3 (cholecalciferol), 2000 IU|
45797130|NCT01653678|Drug|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
46071882|NCT05877235|Dietary Supplement|Placebo|Starch, 1000 mg daily for 60 days
45797131|NCT01653678|Dietary Supplement|Vitamin D placebo|
45797132|NCT01653678|Drug|Fish oil placebo|
46071883|NCT05877196|Behavioral|Moderate Intensity Continuous Training (MICT)|Aerobic cycling at a moderate intensity (50-75% of heart rate reserve) for 30-50 minutes, 3 times per week for 3-6 months.
45797133|NCT01370811|Drug|oxybutynin and clonidine oral solution treatment A|
45797134|NCT01370811|Drug|oxybutynin and clonidine oral solution treatment B|
45797135|NCT01370811|Drug|oxybutynin and clonidine oral solution treatment C|
45797136|NCT01370811|Drug|oxybutynin and clonidine oral solution treatment D|Placebo
45797137|NCT01323569|Drug|Sativex|Sativex dose level 1: 10.8 mg THC/10 mg CBD (4 sprays) + 12 placebo sprays + 4 placebo capsules.
45797138|NCT01323569|Drug|Sativex|Sativex dose level 2: 21.6 mg THC/20 mg CBD (8 sprays) + 8 placebo sprays + 4 placebo capsules
45797139|NCT01323569|Drug|Sativex|Sativex dose level 3: 43.2 mg THC/40 mg CBD (16 sprays) + 4 placebo capsules
46071884|NCT05877196|Behavioral|Chair-based Stretch|Stretching while seated for 30-50 minutes, 3 times per week for 6 months.
46071885|NCT05877196|Behavioral|High-Intensity Interval Training (HIIT)|Aerobic cycling at a vigorous intensity (80-90% of heart rate reserve 4-minute bouts with 4-minute recovery intervals) for 40 minutes, 3 times per week for 3 months.
45797140|NCT01323569|Drug|Placebo|16 placebo sprays and 4 placebo capsules
45797141|NCT01323569|Drug|Marinol|Marinol dose level 1: 20 mg THC (2 marinol capsules) + 2 placebo capsules + 16 placebo sprays
45797142|NCT01323569|Drug|Marinol|Marinol dose level 2: 40 mg THC (4 marinol capsules) + 16 placebo sprays
45797143|NCT01323465|Drug|Sativex and rifampicin|Single dose of 4 sprays Sativex on Day 1, Rifampicin 2 x 300 mg capsules on Days 2-10, Sativex dose of 4 sprays and rifampicin 2 x 300 mg capsules on Day 11.
45797144|NCT01323465|Drug|Sativex and rifampicin|Rifampicin 2 x 300 mg capsules on Days 1-9, Sativex x 4 sprays and rifampicin 2 x 300 mg capsules on Day 10, Single dose of Sativex 4 sprays on Day 18.
45797145|NCT01323465|Drug|Sativex and ketoconazole|Single dose of 4 sprays Sativex on Day 1, ketoconazole 2 x 200 mg tablets on Days 2-5, Sativex x 4 sprays and ketoconazole 2 x 200mg on Day 6.
45797146|NCT01323465|Drug|Sativex and ketoconazole|Ketoconazole 2 x 200 mg tablets on Days 1-4, Sativex x 4 sprays and ketoconazole 2 x 200 mg tablets on Day 5, Single dose of 4 sprays Sativex on Day 9.
45797147|NCT01323465|Drug|Sativex and omeprazole|Single dose of 4 sprays of Sativex on Day 1 Omeprazole 2 x 20 mg on Days 2-6. Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 9.
46071886|NCT05877196|Behavioral|Combined Aerobic Resistance Exercise (CARE)|6 full-body strength-building exercises followed by 30 minutes of MICT cycling (described above). Total duration is 60 minutes, 3 times per week for 3 months.
45649501|NCT03050177|Drug|Iressa® Tablet 250mg of AZN|Single dose of Iressa® Tablet 250mg of AZN was administered under fed conditions after a 10-hour overnight fast.
45797148|NCT01323465|Drug|Sativex and omeprazole|Omeprazole 2 x 20 mg on Days 1-5, Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 6, Single dose of 4 sprays Sativex on Day 9.
45924561|NCT00050791|Behavioral|Very Low Calorie Diet|placebo injections
45450332|NCT01068197|Behavioral|Low Glycemic Load Diet versus Low Fat Diet|"We propose a randomized controlled clinical trial to evaluate the effectiveness of a low-glycemic load diet versus low-fat diet on insulin sensitivity, body composition, and other hormonal and biochemical measures. The culturally competent and family-based Intervention program has a dietary experimental component (low-glycemic load versus low-fat diet), as well as elements of physical activity, reduction in sedentary behavior and behavior modification. The nutrition training sessions are divided into 12 modules taught over a 12-week course. Care has been taken to make the content and intensity of the low-fat and low-glycemic load programs comparable. Both treatments include 12 weekly sessions, followed by nine monthly, and four 3-monthly sessions.~Participants are obese (BMI ≥95th percentile for age and sex) Hispanic American children ages 7-14 years."
45924562|NCT00050830|Drug|CI 1033|
45924563|NCT05640050|Other|Audit Implementation|The feasibility of establishing and implementing an acceptable and robust audit system with community representation at secondary health facilities to improve maternal and perinatal outcomes. The implementation phases follow the standard World Health Organization (WHO) audit system.
45924564|NCT00050947|Drug|oxcarbazepine|
45924565|NCT05574348|Other|PO2 osteopathic protocol|"PO2 works on the principle that there is a concordance between the author's Pre-existing Torsion Pattern (PTP) and the rotatory direction of osteopathic dysfunctions in osteopathic hinges and pivots.~The PO2 consists of two sessions of 30 minutes each, one week apart. A 13-item clinical examination is performed at the first session. It focuses on caused pain tests, and classifies patients in left or right PTP. During the first session 14 normalizations of joint, muscular, ligament and visceral dysfunctions are performed systematically. During the second session 10 normalizations of joint, muscular, ligament and visceral dysfunctions are performed .~PO2 is an innovative osteopathic protocol for back pain."
45797149|NCT01322464|Drug|Sativex|4 sprays Sativex in fasted state on Day 1. 4 sprays Sativex in fed state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.
45924566|NCT00051103|Drug|Investigational Cancer Drug|
45797150|NCT01322464|Drug|Sativex|4 sprays Sativex in fed state on Day 1. 4 sprays Sativex in fasted state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.
45797151|NCT01322464|Drug|Sativex|2 sprays Sativex daily in fasted state Days 4-13.
46071887|NCT05877183|Device|Wearable device -'Smart Reminder'|The wearable device, a wristwatch, has a Bluetooth function to link to mobile devices for the participants to view the prescribed videos and engage in telerehabilitation. It has sensors to monitor arm movements and provides multiple feedbacks (auditory, visual and tactile). Participants were instructed to practice the prescribed exercises -tailored according to the severity of UL paresis for the recommended therapy dose. The device recorded the angles of arm movement and the number of repetitions completed and data collected is uploaded to an encrypted cloud server for remote monitoring. Weekly, the participants will receive a 45-minute consultation session to review their progress and modify prescribed exercises based on the wearable device data.
45450333|NCT02177656|Behavioral|Motivational Interviewing tailored intervention|MI is grounded in client-centered counseling, cognitive-behavioral therapy, and social cognitive therapy. MI integrates the concepts of relationship building from humanistic therapy with active strategies oriented towards stages of change.The main characteristics of motivational interviewing are: expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. The interviewer maintains a nonjudgmental approach and allows the patient to determine the need for behavioral change, rather than offering unsolicited advice on the need for change. The interviewer only explores ways to implement change once the patient expresses the desire and confidence to change. The goal of MI is to help individuals work through inherent ambivalence present in problematic or unhealthy behaviors and to help them verbally express reasons for or against change using a nonjudgmental, empathetic and encouraging tone.
45450334|NCT02177734|Biological|Investigational H7N9 vaccine GSK3277510A|One dose of GSK3277510A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277510A H7N9 vaccine administered IM in the deltoid region of dominant arm at Day 21
45649502|NCT04882787|Device|BTE hearing aid|Amplification
45797152|NCT01322464|Drug|Sativex|8 sprays Sativex daily in fasted state Days 4-13.
45797153|NCT01322139|Drug|Placebo spray and oral moxifloxacin placebo|24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
45797154|NCT01322139|Drug|Sativex spray and oral moxifloxacin placebo|8 Sativex sprays (4 sprays twice daily every 12 hours) + 16 or 28 placebo sprays (8 or 14 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
45924567|NCT00051142|Drug|Travoprost|
45797155|NCT01322139|Drug|Sativex spray and oral moxifloxacin placebo|24 or 36 Sativex sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
45797156|NCT01322139|Drug|Placebo spray and moxifloxacin|24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin 400 mg tablet on Day 5.
45797157|NCT01182623|Other|Observation of surface patterns of polyps|examination of the surface patterns of polyps using FICE and indigo carmine dye spray
45797158|NCT01169259|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
45797159|NCT01169259|Drug|omega-3 fatty acids (fish oil)|Omacor, one 1-gram capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
45924568|NCT00051142|Drug|Latanoprost|
45924569|NCT00051181|Drug|Travoprost (0.004%)|
45924570|NCT00051181|Drug|Latanoprost (0.005%)|
46071888|NCT05877183|Device|Sham device|The sham device is also a wristwatch, which consists of an accelerometer, a gyroscope sensor, and a rechargeable battery that supports up to 72 hours of continuous use. The device will monitor the participant's arm activity, but it will not emit any reminders or be connected to a telerehabilitation system. The participants were instructed to perform the exercises from the pictorial handout for the recommended therapy dose and received a weekly therapy consultation as well.
45797160|NCT01169259|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
45924571|NCT05574231|Procedure|Periodontal treatment|It includes surgical and non-surgical procedures depending on patient as well as tooth level.
45924572|NCT00051220|Behavioral|One-Session Treatment for Specific Phobias|
45797161|NCT01169259|Dietary Supplement|Fish oil placebo|Fish oil placebo
45924573|NCT00051259|Drug|Extended-Release Bupropion Hydrochloride|
45797162|NCT01165632|Procedure|biopsy|Correlative studies
45797163|NCT01165632|Procedure|computed tomography|Undergo computed tomography
45924574|NCT05639777|Drug|Dexmedetomidine group|That will receive intranasal dexmedetomidine (1.5mcg/kg)
45797164|NCT01165632|Procedure|therapeutic conventional surgery|Undergo stereotactic craniotomy
45924575|NCT05639777|Other|control group|That will receive the same volume of 2 ml of intranasal normal saline
45924576|NCT00051298|Drug|Olanzapine|
45924577|NCT00051298|Drug|Placebo|
45797165|NCT01165632|Radiation|radiation therapy treatment planning/simulation|Undergo radiation therapy treatment planning/simulation
45797166|NCT01165632|Radiation|radiation therapy|Undergo radiation therapy
45797167|NCT01165632|Procedure|magnetic resonance imaging|Undergo magnetic resonance imaging
45797168|NCT01165632|Procedure|positron emission tomography|Undergo positron emission tomography
45924578|NCT05574192|Behavioral|Social Engagement Intervention|"The intervention includes social visiting with women affected by violence. Social visiting is carried out by trained peer-workers. Peers are women who share life histories with the target study population. Peer-workers will establish a visiting schedule (day/time) and provide a detailed list of activities in two categories:~arts-based activities.~physical activities.~The peer will meet with the participant at the scheduled place and times to accompany the participant and engage in the activities with the participant.~Participation in scheduled social activities that target the interest and ability of women affected by violence is considered to improve social connectedness by increasing the quality and quantity of a woman's social interactions with a supportive, trained person who shares life experiences. Shared, consistent and reliable social activities also are hypothesized to reduce loneliness by contributing to a sense of belonging and sense of being cared for."
45924579|NCT00051376|Drug|L-Arginine|
45924580|NCT00051415|Behavioral|Flaxseed-supplemented diet|
45924581|NCT05636774|Drug|Heart failure medication|Combination of Sacubitril/valsartan, Ivabradine, Ferric carboxymaltose and/or Empagliflozin.
45924582|NCT05636774|Drug|Placebo|Placebo tables / infusion
45924583|NCT00051454|Biological|HIV DNA plasmid vaccine plus recombinant fowlpox vector|
45924584|NCT00397969|Other|counseling intervention|
46071889|NCT05877170|Dietary Supplement|Palmitoyletinolamide|Taking a once-daily supplement containing PEA in an oral formulation (tablets), to be taken away from meals
46071890|NCT05877170|Drug|Placebo|Taking a placebo in an oral formulation (tablets), to be taken away from meals
46071891|NCT05877144|Procedure|Nerve-Sparing Prostatectomy|Undergo nerve-sparing prostatectomy per standard of care
46071892|NCT05877144|Other|Medical Device Usage and Evaluation|Receive LiSWT
45797169|NCT01165632|Drug|fluorine F 18 fluorodopa|Given IV
45797170|NCT01019850|Drug|Vorinostat|Patients on study will receive vorinostat orally once daily on days 1 to 14 of treatment.This is a single course treatment. The study has a planned dose escalation schedule, the starting dose level is 180 mg/M2.The maximum absolute dose of vorinostat is 400 mg.
45797171|NCT01019850|Radiation|131- I Metaiodobenzylguanidine|Patients will receive 131-I MIBG on day 3 , one hour after vorinostat dosing.Patients will initially receive 8 mCi/kg 131-I MIBG with 180 mg/m2/dose vorinostat. The dose of 131-I MIBG will be escalated in subsequent cohorts to 15 mCi/kg and then to 18 mCi/kg.If the starting dose exceeds the maximum tolerated dose, patients will be treated with a lowering of vorinostat dose initially (150 mg/m2/day . Dose level -1). If this combination still exceeds the maximum tolerated dose, then a dose level using reduced dose 131-I MIBG will be studied (6 mCi/kg. Dose level -2).
45924585|NCT00397969|Procedure|screening colonoscopy|
45924586|NCT00398008|Drug|Buprenorphine/Subutex|Opioid agonist medication to treat opiate dependence
45924587|NCT00398008|Drug|Naltrexone|Opioid antagonist medication to treat opiate dependence
46071893|NCT05877144|Procedure|Duplex Ultrasound|Undergo DDUS
45797172|NCT01019850|Procedure|Peripheral Blood Stem Cell Infusion|Stem cell infusion is planned for 2 weeks after MIBG infusion (day 17). However, stem cells may be infused on day 18 or day 19 to avoid weekend or holiday stem cell infusions.The dose for Purged PBSC is a minimum of 2 x 106 viable CD34+ cells/kg and for Unpurged PBSC: a minimum of 2 x 106 viable CD34+ cells/kg must be available. Stem cells must be infused over 15-30 minutes and within 1.5 hours of thawing.Stem cells will be infused following institutional guidelines for prophylaxis of hypersensitivity reactions and monitoring.
45797173|NCT01019850|Drug|Filgrastim|All patients will receive filgrastim following hematopoietic stem cell infusion according to institutional guidelines (section 4.2.3 of protocol).
45804128|NCT05502679|Other|Weight bearing as tolerated|Bearing weight on lower limb extremity
45924588|NCT00398008|Behavioral|Drug counseling|DC-HIV: Drug Counseling that provides education about HIV, drug abuse and dependence; encourages medication adherence; uses motivational enhancement techniques; encourages life style changes; and teaches cognitive and behavioral coping skills to prevent relapse
45924589|NCT05636189|Procedure|warming during induction of anesthesia|Warming group patients are applied air-forced warming device (bair-hugger 43'C) with blanket (warm touch, COVIDIEN, full body blanket) during induction of anesthesia in the operation room.
45924590|NCT05636189|Procedure|Prewarmed intravenous fluid administration|Prewarmed intravenous fluid is connected.
45924591|NCT00051493|Drug|ALIMTA|
45924592|NCT00051493|Drug|Carboplatin|
45924593|NCT05574075|Diagnostic Test|Diffusion tensor imaging|white matter imaging markers
46071894|NCT05877144|Other|Survey Administration|Ancillary studies
46071895|NCT05877144|Procedure|Nerve-Sparing Prostatectomy|Undergo nerve-sparing prostatectomy per standard of care
46071896|NCT05877144|Procedure|Sham Intervention|Receive sham LiSWT
46071897|NCT05877144|Procedure|Duplex Ultrasound|Undergo DDUS
46071898|NCT05877144|Other|Survey Administration|Ancillary studies
45797174|NCT00885326|Drug|Bevacizumab|Every course will be 28 days. Bevacizumab 10 mg/kg/dose , will be administered intravenously every 14 days beginning on day 0 of the second course.
45797175|NCT00885326|Drug|cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).
45797176|NCT00885326|Drug|zoledronic acid|Administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first.
45797177|NCT00704626|Other|Blood Draw|A 5cc sample of serum will be drawn from each subject. Only one blood draw is required, but up to 8 additional blood draws can be obtained.
45797178|NCT00704626|Other|Cheek swab|A swab will be swished around the inside of the mouth to collect mouth (buccal) cells. This will be done with each blood draw.
45797179|NCT00685243|Procedure|Laser treatment|Fraxel and pulsed dye laser
45797180|NCT00606138|Drug|ranibizumab|One 0.5 mg intravitreal injection
45924594|NCT04731532|Procedure|classical respiratory physiotherapy with thoracic vibration|Classical respiratory physiotherapy application: Patient is positioned, postural drainage application is operated by tapping and trifled .
45797181|NCT00606138|Procedure|Laser photocoagulation|panretinal photocoagulation (up to 500 300-500 um laser spots)
45924595|NCT00051532|Drug|Seocalcitol|
45797182|NCT00390793|Drug|Cyclophosphamide|Given IV
45797183|NCT00390793|Drug|Cytarabine|Given IV or IT
45797184|NCT00390793|Drug|Dasatinib|Given PO
45797185|NCT00390793|Drug|Dexamethasone|Given IV or PO
46071899|NCT05877131|Drug|Levobupivacaine|To evaluate the efficacy of low-dose levobupivacaine (0.125%) (0.2) in avoiding hemodynamic changes after performing regional analgesia in pregnant women in labor and preventing changes in fetal heart rate and cardiotocographic recording.
45450335|NCT02177734|Biological|Investigational H7N9 vaccine GSK3277509A|One dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of dominant arm at Day 21
46071900|NCT05877131|Drug|Ropivacaine|To evaluate the efficacy of low-dose ropivacaine (0.2) in avoiding hemodynamic changes after performing regional analgesia in pregnant women in labor and preventing changes in fetal heart rate and cardiotocographic recording.
46071901|NCT05877118|Behavioral|Enhanced Overdose Education (EOE)|"EOE was adapted by Co-I Dr. Monique Miley at HHC's premier addiction hospital-The Rushford Center. It follows the guidelines set by Co-PI Jonathan Craig Allen when working with opioid patients reluctant to obtain naloxone:~Express confidence in naloxone~Provide a clear statement about suitability (You are an excellent candidate for naloxone)~Begin discussion using presumptive language (You must be ready for an overdose)"
46071902|NCT05877118|Behavioral|Standard education|Written instructions that accompany a kit prescription in many EDs throughout the country.
45450336|NCT02177734|Biological|Placebo|One dose of placebo administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of placebo administered IM at the deltoid region of dominant arm at Day 21
45450337|NCT02183584|Drug|Rifampicin|
45450338|NCT02183584|Drug|Linagliptin|
45450339|NCT02180932|Biological|periodontal pocket samples|
45450340|NCT03537040|Other|Method of Levels|Talking Therapy
45649503|NCT03051581|Device|18F-FDG PET/ CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
45797186|NCT00390793|Drug|Doxorubicin|Given IV
45797187|NCT00390793|Drug|Methotrexate|Given IV or IT
45797188|NCT00390793|Drug|Prednisone|Given PO
45797189|NCT00390793|Drug|Vincristine|Given IV
45924596|NCT00051571|Drug|SGN-15|
46071903|NCT05877092|Device|implants with overdentures|two implants with bar attachment placed in interforaminal of the mandible mandible of the participants, the patients were delivered conventional upper complete denture constructed from heat cured acrylic rein, but in implanted mandibular arch they were received complete overdenture constructed from heat cured acrylic resin for Group I, and complete thermoplastic denture was constructed for Group II.
45649504|NCT04882865|Device|assist|A custom designed patient wrap will envelope the patient. This will be coupled to a mechanical lift system to facilitate repositioning of the patient (AMMP) Commercially available repositioning sheets will be used for the general care of some study patients
45797190|NCT00084422|Drug|lestaurtinib|Given orally twice daily x 5 consecutive days followed by a two day rest. 28 days = 1 treatment course. Courses repeated indefinitely without gap provided patient has recovered course from toxicities and no DLTs. Dose level assigned according to the planned dose escalation schedule.
45797191|NCT00005835|Drug|buthionine sulfoximine|Dose fixed at a bolus of 3 gm/M2 given over 30 minutes followed by a continuous infusion of 1 gm/M2/hour for 72 hours (total 72.5 hours).Total daily infusion dose (minus the initial bolus)will be 24 gm/m2/day.
45797192|NCT00005835|Drug|melphalan|The dose level of melphalan will be assigned at study entry onto protocol. There will be 6 dose levels ranging from 20mg/m2/day x 2 days (dose level 1a) to 62.5 mg/m2/day x 2 days (dose level 6a). The starting dose level will be 1a, with a decrease to level 0a (15mg/m2/day x2 days) if there is unacceptable toxicity.
45797193|NCT00005835|Procedure|Peripheral blood stem cell infusion|Stem cells will be infused intravenously on day 0 , 24 hours after BSO continuous infusion is completed.Infused within 1.5 hours of thawing via a central venous catheter over 15-30 minutes.
45804129|NCT05502679|Other|Pragmatic Exercise protocol|Designed exercise prescriptions according to the patients' needs
45924597|NCT00051571|Drug|Docetaxel|
45924598|NCT05636072|Behavioral|WISER|Participants will engage in one or more positive psychology well-being tool(s).
45797194|NCT00005835|Other|Filgrastim|5 microgram/kg/day , subcutaneous or intravenous, given daily beginning day 0. First dose to begin 4 hours after completion of stem cell infusion and then to continue till ANC >/= 1500 mm3 for three consecutive days.
45924599|NCT04731415|Device|Optical coherence tomography and optical coherence tomography angiography (Optovue®)|"Optical coherence tomography and optical coherence tomography angiography (Optovue®) were performed in each trimesters and at 6 weeks after childbirth.~st trimester : gestational age 8-12 weeks~nd trimester : gestational age 24-28 weeks~rd trimester : gestational age 34-38 weeks"
45924600|NCT05573958|Drug|Rivaroxaban 2.5 Mg Oral Tablet|Rivaroxaban 2.5 mg oral tablet will be administered twice daily
45924601|NCT05573958|Drug|Clopidogrel tablet|Clopidogrel 75 mg once daily orally
45924602|NCT05573958|Drug|Aspirin tablet|Aspirin 81 mg tablet once daily
45450341|NCT02181010|Behavioral|Intervention|Intervention components will occur at the policy level (working within Baltimore City policy makers to sustain intervention components, and develop virtual simulations of the Baltimore food environment); food wholesaler level (working with wholesalers to stock healthier food items and provide pricing incentives to storeowners on healthier foods); small food retail outlet level (working with corner store and carry-out owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with Baltimore college students to deliver nutrition intervention sessions to younger youth in recreation centers in intervention neighborhoods); household level (providing a text messaging and social media program that provides parents and caregivers tips for healthier eating in their respective neighborhoods).
45797195|NCT04802473|Procedure|Mucogingival surgery|In brief description, Tunnel+acellular dermal matrix treatment will be performed by starting initial sulcular incisions, tunneling knives will be used to elevate the buccal gingiva by means of a full-thickness flap elevation. Flap preparation will be extended beyond the MGJ. The exposed root surfaces will be treated with pre-conditioning EDTA (Straumann PrefGel®) for 2 minutes. ADM (OrACELL, LifeNet Helth, Virginia Beach, VA, USA) of 1.25-1.75mm in thickness will be cut to the exact size of the defect, and will be inserted into the tunnel, and subsequently covered advancing the flap by means of sling sutures to stabilize the flap in a coronal position (6-0 Polypropylene, Prolene, Ethicon, Johnson and Johnson, New Brunswick, NJ, USA). Sutures will be removed after 14 days. Two weeks after surgery, patients will resume mechanical tooth cleaning with a soft toothbrush. Patients will be recalled at 1, 3 and 6 months for professional oral hygiene procedures.
45797196|NCT04401995|Drug|Vidutolimod (CMP-001)|A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).
45797197|NCT04401995|Biological|Nivolumab|a fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.
45797198|NCT04401995|Other|[18F]F-AraG PET/CT|[18F]F-AraG is an 18F-labeled analog of arabinofuranosylguanine (AraG), a compound that has shown remarkably selective accumulation in T cells. It has several advantages over conventional [18F] and existing small molecule PET agents being investigated for immuno-monitoring. [18F]F-AraG has lower accumulation and more efficient efflux from cancer cells than a dCK agent.
45450342|NCT03823703|Drug|Miricorilant|Tablets taken orally
45450343|NCT03823703|Drug|Placebo|Placebo tablets
45450344|NCT02181088|Biological|ChAd63 RH5 low dose|ChAd63 RH5 at 5 x 10^9 vp
45649505|NCT04883021|Device|Dual Target Theta Burst Stimulation|"TMS treatment will be provided daily for 5 days, then daily for 5 days in week 2, and three times per week (Monday, Wednesday, Friday) in weeks 3 and 4.~Treatment targeting will occur at the Beam F3 and FP1 scalp regions as defined by the 10-20 EEG system and previous publications. A Magventure MagPro X100 figure-8 coil with theta burst capabilities will be used to deliver the stimulus, including intermittent theta burst stimulation to the DLPFC (2 seconds of 50-Hz triplets delivered at 5 Hz, 8 seconds intertrain interval, 600 total pulses) and continuous theta burst to the MPFC (continuous 50-Hz stimulation triplets, 600 pulses). Stimulation will be delivered at 110% of the resting motor threshold."
45649506|NCT04897685|Behavioral|Flow with Nature|Nature-based intervention was facilitated by a health care professional and included 12 x 90 mins sessions within 12 weeks.
45649507|NCT03050411|Drug|Apatinib Mesylate Tablets|250mg, 500mg, 750mg, q.d., p.o.
45797199|NCT00002643|Biological|filgrastim|
45797200|NCT00002643|Drug|amifostine trihydrate|
45797201|NCT00002643|Drug|cyclophosphamide|
45924603|NCT00051688|Drug|tezacitabine|
45924604|NCT00051688|Drug|oxaliplatin|
45924605|NCT00051727|Behavioral|Bridges to High School Project|
45924606|NCT00051766|Behavioral|Computer-based Intervention|
45924607|NCT00051805|Behavioral|Promotion of adherence to ARV medications|
45924608|NCT02971917|Radiation|Chest x-ray image acquisition|Obtain a digital X-ray chest image of the patient
45924609|NCT02971917|Radiation|Creation of TRUVIEW ART applied image|"Application of TRUVIEW ART to the original chest x-ray image to create a new set of TRUVIEW ART applied image.~Outcome: 2 versions of chest image~Original Chest X-ray (w/o TRUVIEW ART)~TRUVIEW ART applied image"
45924610|NCT02971917|Radiation|Comparison of TRUVIEW ART image with original image|Comparison of 2 versions of chest image side by side Performance evaluation may consist of detailed categories such as expression of chest structure, visibility level of pulmonary vascular system, etc. For all categories visibility and preference will be scored and each category will be analyzed to point out any statistical difference
45924611|NCT00051844|Drug|Capravirine|
45924612|NCT05635136|Other|Dynamic full-field optical coherence tomography analysis of kidney transplant biopsy|Dynamic full-field optical coherence tomography analysis of kidney transplant biopsy before conventional histopathological analysis
45924613|NCT05573880|Device|Galileo Med35|whole-body vibration training on the platform
45924614|NCT00051922|Biological|PolyEnv1|Recombinant vaccinia virus vaccine
45924615|NCT00052000|Drug|MLN2704 (DM1 conjugated monoclonal antibody MLN591)|
45797202|NCT00002643|Drug|doxorubicin hydrochloride|
45924616|NCT05635058|Other|The Reminisence Therapy|Reminiscence sessions were held in a meeting room in the nursing home and arranged in accordance with the interviews. In the reminiscence sessions, mnemonic materials selected specifically for the determined interview topic were used. The materials to be used in the reminiscence sessions were determined in accordance with the education level and cultural characteristics of the participants. In the sessions, topics such as childhood life, work life, religious holidays, national holidays, old songs, military ceremonies, wedding ceremonies, gardening and field work were shared. In the reminiscence sessions, the participants were encouraged to verbally express the feelings and thoughts they remembered about the mnemonics. The interviews were recorded by the researcher and each session lasted 45-60 minutes. At the end of the reminiscence session, the topics addressed in the session were summarized by the researcher, the following weeks topic was determined and the interview was concluded.
45924617|NCT00052039|Drug|interferon-gamma 1b|This study was terminated prior to enrollment.
45797203|NCT00002643|Drug|etoposide|
45797204|NCT00002643|Drug|ifosfamide|
45797205|NCT00002643|Drug|topotecan hydrochloride|
45797206|NCT00002643|Drug|vincristine sulfate|
45797207|NCT00002643|Procedure|conventional surgery|
45924618|NCT00052039|Drug|azathioprine|This study was terminated prior to enrollment.
45924619|NCT05573763|Device|F&P Toffee|Nasal pillows mask
45924620|NCT00052117|Drug|capravirine|
45924621|NCT00052117|Drug|Kaletra|
45450345|NCT02181088|Biological|ChAd63 RH5 full dose|ChAd63 RH5 at 5 x 10^10 vp
45450346|NCT02181088|Biological|MVA RH5 low dose|MVA RH5 at 1 x 10^8 pfu
45924622|NCT00052117|Drug|2 NRTIs|
45450347|NCT02181088|Biological|MVA RH5 full dose|MVA RH5 at 2 x 10^8 pfu
45450348|NCT01080989|Other|diagnosis, treatment and education|"Drug:~anti-intestinal parasitic drugs:~mebendazole 500mg one dose (For Hook worm infections, Ascariasis, Trichuriasis)~albendazole(400 mg bid * 7days) or Ivermectin(200 mcg/kg/day * 2 days) (For Strongyloidiasis).~Behavior:~Education capacity building (for local health personals): promote their ability of diagnosis and education to the community and patients for the associated diseases in this study.~Assist the trained local health personals to educate the patients and the community from the design of teaching materials and the contents."
45797208|NCT00002643|Radiation|low-LET cobalt-60 gamma ray therapy|
45450349|NCT01068275|Procedure|lumbar plexus catheter|lumbar plexus catheter with 0.2% ropivacaine at 0.15 ml/kg/hr (max 10 ml/hr)
45450350|NCT01068275|Procedure|femoral nerve catheter|femoral nerve catheter with 0.2% ropivacaine at 0.15 ml/kg/hr (max 10 ml/hr)
45450351|NCT01068275|Procedure|single-shot femoral block|single-shot femoral block with 0.2% ropivacaine 0.3 ml/kg (max 20 ml)
45797209|NCT00002643|Radiation|low-LET electron therapy|
45797210|NCT00002643|Radiation|low-LET photon therapy|
45924623|NCT00052156|Biological|CancerVax vaccine (CANVAXIN)|
46071904|NCT05877079|Drug|Menthol|Patients will wear hand and foot wraps with 8% w/w menthol lotion (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.
45450352|NCT02181166|Other|Kinesiotherapy|
45450353|NCT02181166|Other|Isquemic compression|
45797211|NCT04342559|Other|Belamy (vaginal moisturizer)|"The conformity of the product use by the research participants will be verified through the filling of the product use diary by the research participants and also by the accounting of the tubes not used in T22.~Interdiction and Restriction~Keep the test product tightly closed, protected from heat, moisture and out of the reach of children;~Do not apply any other product to the genital area. Only the use of soap normally used for hygiene will be allowed;~Do not change genital / vaginal hygiene habits;~Not having sexual intercourse in the 48 hours (2 days) before the research visits;~Do not perform a hygienic shower in the genital region within 24 hours (1 day) prior to the research visits;~Do not perform gynecological / intimate showers during the study period"
45797212|NCT04779437|Behavioral|Imagery Cognitive Bias Modification|"The imagery cognitive bias modification intervention is derived from that developed via experimental psychopathology research (e.g. Holmes et al., 2009) and adapted for clinical applications in the context of depression (e.g. Blackwell & Holmes, 2010; Blackwell et al., 2015). The intervention is a series of training sessions in which participants listen to training scenarios consisting of descriptions of everyday situations, structured so that they start ambiguously but always end positively. Participants are instructed to imagine themselves in the situations described as the scenarios unfold. The training aims to train a bias to automatically imagine positive resolutions for ambiguous situations encountered in daily life.~Participants will complete one introductory session of the training with the researcher present (in the outpatient center, or via videoconferencing software), then 8 sessions over two weeks completed from home via the study website."
45797213|NCT04779437|Behavioral|Cognitive Control Training|The cognitive control training is an adaptive Paced Auditory Serial Addition Task (PASAT), adapted from that applied in previous studies (e.g. Siegle et al., 2007; Hoorelbeke et al., 2015; Blackwell et al., 2018). Participants will complete one introductory session of the training with the researcher present (in the outpatient center, or via videoconferencing software), then 8 sessions over two weeks completed from home via the study website.
45924624|NCT00052195|Biological|SRL-172|5 doses of 0.1mL vaccine or placebo given intradermally over 12-months
45924625|NCT00052273|Drug|capecitabine|
45924626|NCT00052273|Drug|enzastaurin hydrochloride|
45924627|NCT05634551|Behavioral|Questionnaires|Participants will complete 5 questionnaires about any symptoms participants may be having, any anxiety and/or depression participants may be having, your preference in decision-making, and your expectations about your treatment. It should take about 30 minutes to complete all 5 questionnaires
45924628|NCT05634551|Behavioral|Interview|The interview will last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom or FaceTime (based on your preference)
45924629|NCT00052312|Drug|cisplatin|
45797214|NCT00002649|Biological|aldesleukin|Given IV
45924630|NCT00052312|Drug|doxorubicin hydrochloride|
45924631|NCT00052312|Drug|paclitaxel|
46071905|NCT05877079|Drug|Placebo|Patients will wear hand and foot wraps with lotion without menthol (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.
45797215|NCT00002649|Biological|filgrastim|Given SC or IV
45797216|NCT00002649|Drug|cyclophosphamide|Given IV
45797217|NCT00002649|Drug|etoposide|Given IV
45797218|NCT00002649|Radiation|radiation therapy|Undergo radiation therapy
46071906|NCT05877053|Drug|CK-4021586|CK-4021586
46071907|NCT05877053|Drug|Placebo for CK-4021586|Placebo for CK-4021586
46071908|NCT05877040|Drug|Rituximab|Open label proof-of-concept study with intravenous Rituximab, given at the dose of 1g in one day, followed by the same dose after two weeks
45649508|NCT03050411|Drug|EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)|EGFR-TKIs include but are not limited erlotinib, gefitinib and osimertinib
45797219|NCT00002649|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
45797220|NCT00002649|Procedure|bone marrow ablation with stem cell support|Undergo bone marrow ablation with stem cell support
45924632|NCT05573451|Diagnostic Test|ultrasound - transvaginal/transrectal + transabdominal|Each patient undergoes at least ultrasound examination and PET-CT.
45924633|NCT04731454|Other|Control Diet (CD)|All food was provided to participants for the duration of the intervention (8 days), including prepared lunches and dinners and ingredients for breakfasts and snacks. A sugar-sweetened juice drink was provided for consumption of one portion per day. Water, milk, coffee, tea and alcohol were consumed as usual.
45924634|NCT04731454|Other|Healthy Nordic Diet (ND)|All food was provided to participants for the duration of the intervention (8 days), including prepared lunches and dinners and ingredients for breakfasts and snacks. Water, milk, coffee, tea and alcohol were consumed as usual.
46071909|NCT05877014|Other|questionnaires|EQ-5D-5L and SF-12
46071910|NCT05877014|Other|scanner|CT scan at M9 and then at M12 if the humerus is not consolidated at M6
45450354|NCT02181166|Other|High voltage electrical stimulation|
45450355|NCT02183662|Drug|BI 224436|
45450356|NCT02183662|Drug|Placebo to BI 224436|
45797221|NCT03004027|Other|Self help leaflet|Self help leaflet entitled 'Building confidence in social situations: A guide for people living with a visible skin differences'
45797222|NCT02976857|Biological|C-CAR-011|lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene.
45797223|NCT01170559|Device|Implantable Loop Recorder|
45797224|NCT04342637|Other|Practice details|Physicians will report details of their endoscopy practice through answering the questions of the questionnaire
45797225|NCT01151605|Drug|insulin|insulin to be infused at three different rates (2, 3.5 and 5 units/hour)
45797226|NCT01151605|Drug|insulin|insulin to be infused at three different rates (2, 3.5 and 5 units/hour)
45797227|NCT01151605|Drug|insulin|insulin to be infused at three different rates (2, 3.5 and 5 units/hour)
45797228|NCT00002655|Procedure|cryosurgery|
45797229|NCT03003871|Device|Powered toothbrush|Oral-B® AdvancePowerTM 400 series
45797230|NCT03003871|Device|Manual toothbrush|Oral-B® Pro-Health All-In-One
45797231|NCT03003871|Other|Toothpaste|Colgate Maximum Cavity Protection®
45797232|NCT03003871|Other|0.2% chlorhexidine gluconate mouth rinse|CorsodylPTMP
45924635|NCT00052351|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
45924636|NCT00052351|Biological|recombinant vaccinia-CEA(6D)-TRICOM vaccine|
45924637|NCT00052351|Biological|sargramostim|
45924638|NCT00052351|Drug|cyclophosphamide|
45924639|NCT00052351|Drug|doxorubicin hydrochloride|
45924640|NCT00052351|Drug|paclitaxel|
45924641|NCT00052351|Radiation|radiation therapy|
45924642|NCT05634122|Behavioral|Acceptance and Commitment Therapy (ACT)|Group treatment protocol of 8 weeks of 90 minutes sessions Session 1: Presentation of the general ACT therapy concept. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis third Session 5: Values and feelings. Session 6: Drink one direction. Session 7: Dare and change. Session 8: Ready to act with ACT. Treatment as usual (TAU) Standard pharmacological treatment for patients with chronic pain.
45924643|NCT05634122|Behavioral|Treatment as Usual (TAU)|Standard pharmacological treatment for patients with chronic pain
45924644|NCT00052390|Biological|bevacizumab|
45924645|NCT00052390|Drug|doxorubicin hydrochloride|
45797233|NCT04768127|Other|early aftercare|This group begins the aftercare program immediately after their bariatric surgery.
45924646|NCT00052468|Drug|TCG|
45924647|NCT00052468|Drug|TC|
45797234|NCT04768127|Other|mid-term to late aftercare|This group begins the aftercare program 18 months post surgery.
45924648|NCT05573412|Other|Cellular analysis|Previously cryopreserved samples will be analyzed for total nucleated cell count (TNC), cell viability and proliferative potential
45797235|NCT00381771|Behavioral|Conservative management for xerostomia|Active hydration (drinking more than 10 cups of water per day), Humidification, Oral gargle with a diluted (0.05% to 0.1%) chlorhexidine solution, Sugarless chewing gum, Saliva-stimulating sour juice (sugarless orange juice), Commercial artificial saliva, Nasal saline spray 3 to 4 times a day, Warm massage of the 4 major salivary glands.
45797236|NCT00995059|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo transplantation
45924649|NCT00052507|Drug|bortezomib|
45924650|NCT05633927|Biological|SARS-CoV-2 Vaccine|Analyse humoral and cellular response to SARS-CoV-2 Vaccine.
45653182|NCT05111925|Other|PREPARE Initial Clinical Assessment - Post-Injury (up to three iterations)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report thee most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~Two-Minute Walk~Gait~Double Leg Squat~Single Leg Squat~Jump-Landing~Single Leg Triple Hop~Closed Kinetic Chain Upper Extremity Stability Test~Functional Movement Screening Shoulder Clearing Test~Prone Plank~Active Hip Abduction~Joint range of motion assessments:~Knee Extension~Hip Abduction~Hip Internal Rotation~Hip External Rotation~Ankle Dorsiflexion~Psychosocial assessments:~NIH PROMIS Physical Function, Pain Interference, Depression, & Anxiety~Tampa Scale of Kinesiophobia"
45924651|NCT00052585|Drug|irinotecan hydrochloride|Given IV
45924652|NCT00052585|Drug|gefitinib|Given orally
45797237|NCT00995059|Procedure|allogeneic bone marrow transplantation|Undergo transplantation
45797238|NCT00995059|Drug|bortezomib|Given IV
45797239|NCT00995059|Drug|melphalan|Given IV
45797240|NCT00995059|Drug|anti-thymocyte globulin|Given IV
45797241|NCT00995059|Drug|sirolimus|Given orally
45924653|NCT00052585|Drug|leucovorin calcium|Given IV
45924654|NCT00052585|Drug|fluorouracil|Given IV
45924655|NCT00052624|Biological|transferrin-CRM107|
45924656|NCT00052780|Drug|O6-benzylguanine|Given IV
45924657|NCT00052780|Drug|temozolomide|Given PO
45797242|NCT00995059|Drug|tacrolimus|Given oral or IV
45797243|NCT00995059|Radiation|total-body irradiation|Undergo total-body irradiation
45797244|NCT05752071|Device|Gastric electric pacemaker|Mounting of a temporary gastric pacemaker
45797245|NCT04372823|Behavioral|Policy/program|Policy/program to improve nutrition and increase physical activity
45797246|NCT00002673|Procedure|infection prophylaxis and management|
45797247|NCT04759157|Behavioral|Couples-based treatment|Couples will attend 3, video based sessions for couples-based treatment
45924658|NCT00052780|Biological|filgrastim|Given SC or IV
45797248|NCT04759157|Other|Standardized education|Patients will receive standardized educational materials
45797249|NCT02249299|Drug|Sativex Oromucosal Spray|Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).
45797250|NCT02249299|Drug|Placebo|
45924659|NCT00052780|Other|pharmacological study|Correlative studies
45804130|NCT05500885|Device|PEMF device, Quantum Tx, Singapore|The options of the appliance will be adjusted to 1.5mT, 10Hz on the diseased leg for 10 minutes.
45804131|NCT05500885|Other|Standard rehabilitation for CAI/Ankle Sprain|Balance training and muscle strengthening
45804132|NCT05500885|Other|Foot exercise for Hallux Valgus|Toe spread out exercise, short foot exercise and heel raise exercise
45924660|NCT00052780|Other|laboratory biomarker analysis|Correlative studies
45924661|NCT05633888|Device|CATAMARAN SI Joint Fusion System|Placement of the Catamaran Fixation Device
45924662|NCT00052897|Biological|HspE7|
45924663|NCT00052936|Biological|filgrastim|
45924664|NCT00052936|Biological|rituximab|
45924665|NCT00052936|Drug|CHOP regimen|
45924666|NCT00052936|Drug|cyclophosphamide|
45924667|NCT00052936|Drug|doxorubicin hydrochloride|
45924668|NCT00052936|Drug|prednisone|
45924669|NCT00052936|Drug|vincristine sulfate|
45924670|NCT00052936|Radiation|radiation therapy|36Gy on BULK and extranodal involvement
45924671|NCT05573178|Procedure|cardiac ganglion plexus ablation(cardioneuroablation)|Under the guidance of three-dimensional system, the located ganglion plexus was ablated with saline irrigating electrode. The upper limit of power was 40W, the upper limit of temperature was 43 ℃, and the washing rate of saline was 17ml/min. The site of vagal reaction during ablation was defined as the effective ablation site. The surgical end point of denervated interventional therapy is defined as the disappearance of vagal response at the effective ablation site or the ablation of each effective point discharge for at least 30 seconds.
45924672|NCT05633849|Dietary Supplement|SMP group|Participants were instructed to take two 500 mg softgels of LIPINOVA(SPM group) after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
46071911|NCT05877001|Drug|Tislelizumab|200mg, IV, Q3W
46071912|NCT05877001|Drug|Regorafenib|80 mg once daily for the first 3 weeks of each 4-week cycle
45450357|NCT03964493|Drug|TNP-2092|TNP-2092 100mg/vial
45450358|NCT03964493|Drug|Vancomycin|Vancomycin 1g/vial
45797251|NCT05751915|Device|CardioFlux|CardioFlux MCG is a process that observes incremental changes in the heart's electrical activity by the magnetic fields generated by these currents. These magnetic fields have been used for decades via electrocardiogram to help diagnose and treat both acute and chronic cardiac pathology. The CardioFlux device reaches the potential of this phenomenon by sensing a complete magnetic field map. It is equipped with a magnetic shielding chamber and can attenuate magnetic field noise by a factor of nearly 1500 which maximizes signal to noise ratio. CardioFlux is an easy to operate, noninvasive modality that can detect the presence of ischemic cardiac tissue in symptomatic patients in a less than 5-minute scan. The device uses the proprietary software called Faraday which processes MCG scans, create diagnostic functional images, and run analytics.
45797252|NCT04627441|Device|Transcutaneous spinal cord stimulator|DS8R Electrical Stimulator For Human Research
45797253|NCT04627441|Device|Epidural spinal cord stimulator system|Spectra WaveWriter Epidural Spinal Cord Stimulator System with CoverEdge 32 Electrode Surgical Lead
45797254|NCT00002679|Biological|filgrastim|
45797255|NCT00002679|Drug|cyclophosphamide|
45797256|NCT00002679|Drug|doxorubicin hydrochloride|
45924673|NCT05633849|Dietary Supplement|Placebo group|Participants were instructed to take two 500 mg softgels of olive oil placebo after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
45450359|NCT02183740|Behavioral|Multifaceted educational program|
45649509|NCT03050567|Diagnostic Test|Transcranial Doppler Ultrasound|Transcranial Doppler will be performed on the symptomatic (ipsilateral to an index event) middle cerebral artery in a quiet temperature controlled room. The middle cerebral artery will be identified through the temporal window in a supine position with a flow direction towards the probe. The subject will have a head frame (Marc 600 Spencer Technologies, USA) fitted to reduce motion and to secure a constant angle of the middle cerebral artery insonation depth at 50-60 mm from the skull surface. All recordings will be made using the ST3 Transcranial Doppler Ultrasound System (Spencer Technologies, USA) with a 2-MHz transducer for 1 hour. Emboli will be detected by listening for their characteristic short audible sound (range 10-100 ms, intensity threshold above 7 dB) and spectral appearance using the International Consensus Group microembolus identification criteria and an automated Embolus Detection Software (Spencer Technologies, USA).
45797257|NCT00002679|Drug|paclitaxel|
45797258|NCT00002679|Drug|tamoxifen citrate|
45797259|NCT00002679|Radiation|radiation therapy|
45797260|NCT03003715|Procedure|PET Scans|Two 90 minute scans whose maximum radiological dose is 15 mCi [11 C] carfentanil, a selective and specific mu-opioid receptor radioligand. The first one provided baseline data, and the second occurred with the sequence of sham tDCS and tDCS as described in each arm description.
45797261|NCT03003715|Procedure|transcranial direct current stimulation (tDCS)|In active tDCS, a 2 milli-amp transcranial direct current stimulation is for 20 minutes.
45797262|NCT03003715|Procedure|MRI|No radiotracer is used; 3 tesla scanner; all participants have MRI prior to PET scans.
45797263|NCT03003715|Other|sham tDCS (prior to real tDCS)|For sham tDCS, current is applied only for 30 seconds, as sensations arising from tDCS treatment occur only at the beginning of application; however the equipment will be on the participant for 20 minutes to match that of the active tDCS application.
45649510|NCT04882943|Other|questionnaires|Quality of life questionnaires
45924674|NCT02970253|Procedure|Capsular resection|Capsular resection
45924675|NCT02970253|Procedure|Capsular retention|Capsular retention
45924676|NCT05573139|Diagnostic Test|Assessment of muscle strength by manual dynamometry|The reliability and validation of a new manual dynamometer was verified, compared to one already used, in the muscle groups: knee extensors and flexors; hip extensors, flexors, abductors, adductors, internal and external rotators.
45649511|NCT04887545|Diagnostic Test|Proteomics analysis of pleural effusion|Pleural effusion removed as part of standard care is fractionized and analyzed by mass spectrometry
45649512|NCT03049943|Device|low level laser|
45649513|NCT04896905|Other|Rehabilitation|Rehabilitative procedures in isolation ward
45649514|NCT04887233|Other|Longan nasal spray|The patients will be received 2 puff of Longan nasal spray 2 times/day for 3 days.
45649515|NCT04887233|Other|Placebo|The patients will be received 2 puff of placebo nasal spray 2 times/day for 3 days.
46071913|NCT05877001|Other|HAIC|OXA 85mg/m2 IA 0-4h +5-Fu 2000mg/m2 IA 4-48h，CF 200mg/m2 IV 2-4h， Q3W
45450360|NCT01068353|Biological|Etanercept|50 mg given as a once weekly subcutaneous injection
45649516|NCT04887311|Drug|MBM-01|Patients will be administered study drug daily for 9 months QD via premarked medicine cups.
45797264|NCT00002691|Biological|filgrastim|
45797265|NCT00002691|Drug|asparaginase|
45797266|NCT00002691|Drug|cyclophosphamide|
45450361|NCT01068353|Other|Placebo|Placebo injection given once weekly
45450362|NCT02177890|Device|Transcutaneous vagal nerve stimulation|
45450363|NCT02177890|Device|Sham vagal nerve stimulation|
45797267|NCT00002691|Drug|cytarabine|
45797268|NCT00002691|Drug|daunorubicin hydrochloride|
45797269|NCT00002691|Drug|dexamethasone|
45797270|NCT00002691|Drug|etoposide|
45797271|NCT00002691|Drug|leucovorin calcium|
45797272|NCT00002691|Drug|mesna|
45797273|NCT00002691|Drug|methotrexate|
45797274|NCT00002691|Drug|vincristine sulfate|
45797275|NCT03003637|Drug|Nivolumab|Nivolumab (240 mg flat dose, week 1 and week 3, twice in total) monotherapy, neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
45797276|NCT03003637|Drug|Ipilimumab|Ipilimumab (1 mg/kg) only in week 1, in combination with nivolumab (240 mg flat dose, week 1 and week 3, twice in total), neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
45804133|NCT05500885|Device|SHAM PEMF device, Quantum Tx, Singapore|PEMF 0mT, 0Hz, 10 minutes
45924677|NCT05633498|Other|Book|Self-help book describing advice to cope with shift work
45924678|NCT05633498|Other|Sleep hygiene|Basic sleep hygiene advice on a piece of paper
45924679|NCT00053053|Dietary Supplement|Juven|
45924680|NCT00053053|Dietary Supplement|Non-Juven Supplement|
45797277|NCT04054115|Drug|Alprostadil 5 MCG Injection|During the MRI, Alprostadil infusion will be started and titrated to the target dose, ensuring there is a less than 20% drop in blood pressure from baseline. Repeat pressure and MRI flow measurements once Alprostadil reaches 0.1mcg/kg/min.
45797278|NCT04051151|Behavioral|Gameficiation|Participants and partners that have randomized to the gamification group will receive instructions and help in setting up a game platform via Way to Health. This game will include wearing a Fit Bit device, setting a daily step goal, and point deductions for failure to meet this step goal throughout the following 4 weeks. Participants will move up or down specified levels each week depending on how many days they met their step goal.
45797279|NCT04570267|Biological|CSL324|Sterile solution of recombinant anti G-CSF receptor monoclonal antibody for injection
45450364|NCT01083095|Biological|Sporozoite Challenge Model for Plasmodium vivax in Humans|Eighteen naïve volunteers were exposed to the bite of carrying P. vivax sporozoites. Volunteers were randomly allocated to 1 of 6 groups and exposed to different numbers of mosquito biting, for 10 min. After feeding, dissection of all mosquitoes exposed in the cage was performed, to confirm the presence of a blood meal in their midguts and sporozoites in their salivary glands. If a volunteer did not get the number of infective bites assigned for his/her group, he/she was allowed to be bitten for a new group of mosquitoes until a total of 3±1, 6±1, or 9±1 mosquito bites were achieved.
45924681|NCT03290651|Dietary Supplement|Probiotic Natural Health Product - RepHresh Pro-B|Participants will take the probiotic or placebo daily for 90 days.
45924682|NCT03290651|Dietary Supplement|Placebo|Participants will take the probiotic or placebo daily for 90 days.
45924683|NCT05572983|Drug|Chidamide combined with CHOP|A)Chidamide: 20mg, D1, 4,8,11, po; B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip; C) Doxorubicin: 50 mg/ m2, D1, iv.drip (or epirubicin 70 mg/ m2, D1, iv.drip); D) Vincristine: 1.4 mg/ m2, D1 (maximum dose 2mg, maximum dose 1.5mg for age over 70 years), iv; E) Prednisone: 40mg/m2, D1-5,po
45924684|NCT05572983|Drug|Chidamide|Chidamide: 20mg，qw（d1,d4）,po
45924685|NCT00053092|Biological|rituximab|
45924686|NCT00053092|Drug|cyclophosphamide|
45924687|NCT00053092|Drug|fludarabine phosphate|
45924688|NCT00053131|Biological|filgrastim|
45924689|NCT00053131|Biological|sargramostim|
45649517|NCT03050255|Other|Medical air|
45924690|NCT00053131|Drug|cytarabine|
45924691|NCT00053131|Drug|mitoxantrone hydrochloride|
45797280|NCT04570267|Drug|Placebo|Sterile solution of CSL324 formulation buffer for injection
45797281|NCT04047719|Diagnostic Test|Karius Test|Karius Test for detection of microbial cell free DNA (mcfDNA) in plasma
45924692|NCT05633225|Other|Submax exercise test on a bicycle ergometer|"To achieve exertion and not exhaustion, cycling will be stopped at 75% of the expected maximum heart rate (maximum heart rate of 220 beats per minute minus age) as a target value.~If the participant then indicated that they do not feel strained, the cycling will continue until the participant experienced an effort on Borg Rating of Perceived Exertion Scale scale of 15 (hard)."
45450365|NCT02183896|Biological|Platelet-rich plasma (PRP)|
45924693|NCT00398125|Drug|GSK364735|
45924694|NCT05572905|Other|Exercise|Patients after overnight fast will cycle on ergo-meter for 60 minutes. No per-oral food intake will be allowed during the test. Level of the intensity of exercise will be determined as individual range of heart frequency (HF), oxygen consumption (VO2) and respiratory quotient (RQ) just bellow the aerobic threshold of the given participant (close to anticipated fatmax). These values will be obtained during maximal capacity stress test on cyclo-ergo-meter. This maximum stress test will be performed at least one week prior to the 60 minutes exercise to eliminate potential carry-over effect. Power output will be modulated during the 60 minutes of exercise to ensure keeping participants values of HF, RQ and VO2 in the given range. Blood will be sampled at 5 time points with interval of 30 minutes during the exercise (0, 30, 60, 90, 120) and 24 hours post-exercise.
45924695|NCT05572905|Other|Fasting control|The same participants will be monitored while resting for 120 minutes in calm environment. No peroral food intake will be allowed during the test. Fasting control will take place at least one week apart of the exercise. Blood will be sampled at 5 timepoints with interval of 30 minutes during the exercise (0, 30, 60, 90, 120) and 24 hours post-control.
45924696|NCT05633069|Other|Datas analysed by medical records|"Datas analysed by medical records : pupillary parameters: pupillary diameter and pupillary diameter variation. heart rate, the blood pressure, the Behavioral Pain Scale (BPS) pain score before and during painful procedures.~The pupillary parameters were recorded with the AlgiScan® pupillometer (iDMed, Marseille, France), which allows the recording of Pupillary Diameter (PD) variations at the patient's bed at a sampling frequency of 67 hertz."
45450366|NCT02183896|Drug|Saline|
45924697|NCT05572866|Other|COVID-19 pandemic|To retrospectively review the surgical volume across 2019-2022 to see the impact of the COVID-19 pandemic.
45924698|NCT00053248|Drug|arsenic trioxide|
45924699|NCT00053248|Drug|imatinib mesylate|
45450367|NCT05141734|Diagnostic Test|The relationship between the vestibulo-ocular reflex (VOR) gains and the slow phase velocity (SPV)|The vestibulo-ocular reflex (VOR) gains were measured by video Head Impulse Test (vHIT) in both the study group and the control group. The slow phase velocity (SPV) values of the nystagmus observed during the Dix-Hallpike maneuver in the study group were recorded by Videonystagmography (VNG) and compared with the VOR gains.
45450368|NCT00109577|Drug|MCN36 (nutritional supplement)|nutritional supplement
45649518|NCT03050255|Other|Oxygen (2Liter/min)|
45649519|NCT03050255|Other|Oxygen (4Liter/min)|
45649520|NCT04898387|Combination Product|Bimatoprost Timolol (T4030)|Eye drop
45649521|NCT04898387|Combination Product|Bimatoprost Timolol (Ganfort)|Eye drop
45649522|NCT04897139|Drug|Flu-Bu-Mel-E|fludarabine 150mg/m2, busulfan 9.6mg/kg, melphalan 100mg/m2 and etoposide 800mg/m2
45797282|NCT00002697|Biological|filgrastim|
45797283|NCT00002697|Biological|sargramostim|
45924700|NCT00053287|Drug|carboplatin|Carboplatin IV over 24 hours on days 1-5
45924701|NCT00053287|Drug|fludarabine phosphate|Fludarabine IV over 5-10 minutes on days 1-5.
45924702|NCT00053287|Drug|thalidomide|Oral thalidomide daily beginning within days 1-3 and continuing in the absence of disease progression or unacceptable toxicity.
45924703|NCT00053287|Drug|topotecan hydrochloride|Topotecan IV continuously over 72 hours.
45797284|NCT00002697|Drug|carboplatin|
45924704|NCT05632055|Other|blood draw|Blood test for miRNA and FGF21. However, the laboratory result is not reported and not involved in management
45797285|NCT00002697|Drug|etoposide|
45924705|NCT00053326|Drug|fenretinide|Given orally
45924706|NCT00053326|Other|pharmacological study|Optional correlative studies
45924707|NCT05572788|Procedure|EUS-guided fine needle aspiration of pancreatic cysts|Patients with pancreatic cysts requiring fine needle aspiration will be enrolled in this randomized trial
45450369|NCT00109577|Drug|Placebo|nutritional supplement
45797286|NCT00002697|Drug|ifosfamide|
45797287|NCT00002697|Procedure|autologous bone marrow transplantation|
45649523|NCT04886921|Behavioral|Abdominal muscle training|Participants will receive 12-week, 60 minutes, 36-session abdominal muscle training in the TRAM women. Aimed to evaluate the effects on abdominal muscle functions after 12 weeks abdominal muscle training in the TRAM women. Outcome measures were the clinical tests for trunk muscle strength, endurance and one-leg standing was also used to exam the abdominal muscle function.
45649524|NCT04886843|Other|Cold pack|Five minutes cold pack was applied on the affected side dorsiflexor muscle skin, a five-minute break was given and a further 5-minute cold application was repeated
45797288|NCT00002697|Procedure|bone marrow ablation with stem cell support|
45797289|NCT00002697|Procedure|peripheral blood stem cell transplantation|
45924708|NCT00053443|Device|Medication Reminder System/Adherence Tracker|
45797290|NCT00002697|Radiation|radiation therapy|
45797291|NCT04488601|Drug|Rapamycin|Rapamycin in 2 different dosage forms.
45924709|NCT00053560|Drug|Prasterone (GL701)|
45924710|NCT02970058|Other|Platelet-rich Plasma|The active group will receive Platelet-rich Plasma following spinal injection
45924711|NCT02970058|Other|Control|The control group will receive saline as a placebo
45924712|NCT00053599|Drug|Simvastatin|
45649525|NCT04886843|Device|NMES|NMES was applied to the nonaffected side ankle dorsiflexors
45649526|NCT03049631|Dietary Supplement|Raspberry and fructooligosaccharide|Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
45649527|NCT03049631|Dietary Supplement|Raspberry|Red raspberries (1 cup equivalent)
45649528|NCT04886765|Drug|ALMB-0168|ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
45924713|NCT02970019|Drug|K0706|Once a day administration after fast
45924714|NCT02970019|Drug|Placebo|Once a day administration after fast
45924715|NCT05626790|Other|Exercise|All participants will join an exercise program that will last 20-30 minutes, 5 days a week for 4 weeks, especially targeting proximal stabilization. The exercise program is expected to take 20-30 minutes. Each exercise will be done in 3 sets. Each set will include 10 repetitions. In weight-bearing exercises, the participant will be asked to hold the position for 10 seconds.
45924716|NCT05626790|Other|PNF Stretching|"In addition to the exercises, three different PNF stretching will be applied to the participants in the PNF stretching group for 4 weeks, 5 days a week.~Biceps: Flex-Add-ER repositioned half pattern~Brachioradialis: Flex-Abd-ER repositioned half pattern~Brachialis: Ext-Add-IR half pattern In the supine position, the physiotherapist will move the forearm to the end of the passive range of motion according to the direction of limitation. Secondly, participants will be asked to perform a submaximal isometric contraction of the target muscle with an emphasis on rotation for 10 seconds. After this contraction, participants will be asked to relax for 5 seconds. In the third phase, the elbow joint will be actively repositioned to the new range of motion, and the physical therapist will help to the patient to keep this position for an additional 10 seconds. This procedure will be repeated 10 times with a 10 secs resting period between two consecutive stretches."
45450370|NCT02183974|Procedure|Peptest|
45450371|NCT02177968|Other|descriptive analysis of characteristics|comparison between elderly fallers and non-fallers
45649529|NCT04896671|Behavioral|Physical exercise (running on a treadmill)|Participants in the intervention group join a total of 12 treadmill running sessions, two sessions per week and each session for 30 minutes. In each session, every participant will be trained to run for 30 minutes on a treadmill. According to Exercise and Sports Science Australia (ESSA) exercise intensity guidelines, the intensity of running is suggested to be moderate and vigorous (alternating between the two) in this study.
45797292|NCT04488601|Drug|Placebo|Placebo capsules
45797293|NCT00002703|Radiation|high-LET heavy ion therapy|
45797294|NCT00002703|Radiation|low-LET photon therapy|
45797295|NCT05032807|Drug|Cannabidiol standard formulation|Cannabidiol 1000mg standard formulation, single dose, oral
45797296|NCT05032807|Drug|Cannabidiol novel formulation|Cannabidiol 1000mg with lipid encapsulation, single dose, oral
45797297|NCT04040387|Device|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
45797298|NCT04040387|Device|Sham NightWare|NightWare device not providing interventions
45797299|NCT00002715|Biological|Bleomycin sulfate|A component of the Stanford V regimen.
45797300|NCT00002715|Drug|Stanford V regimen|
45797301|NCT00002715|Drug|Doxorubicin hydrochloride|A component of the Stanford V regimen.
45797302|NCT00002715|Drug|Etoposide|A component of the Stanford V regimen.
45797303|NCT00002715|Drug|Mechlorethamine hydrochloride|A component of the Stanford V regimen.
45797304|NCT00002715|Drug|Prednisone|A component of the Stanford V regimen.
45797305|NCT00002715|Drug|Vinblastine|A component of the Stanford V regimen.
45797306|NCT00002715|Drug|Vincristine sulfate|A component of the Stanford V regimen.
45797307|NCT04972513|Procedure|Biospecimen Collection|Undergo collection of blood
45797308|NCT04972513|Procedure|Nitric Oxide Breath Test|Undergo nitric oxide breath testing
45797309|NCT04972513|Procedure|Oscillometry|Undergo airwave oscillometry
45797310|NCT04972513|Procedure|Spirometry|Undergo spirometry
45797311|NCT04972513|Other|Survey Administration|Complete survey
45649530|NCT04396847|Drug|Lorcaserin Oral Tablet|Lorcasering 10mg Oral Tablet (BID)
45649531|NCT04396847|Drug|Placebo oral tablet|Placebo Oral Tablet (BID)
45797312|NCT04972513|Procedure|Endothelial function|Endothelial function will be assessed with the EndoPAT device, which measures changes in pressure from sensors placed on the fingertip
45797313|NCT02976467|Drug|Fulacimstat (BAY1142524)|25 mg BAY 1142524 are given twice daily over a treatment period of 6 months
45797314|NCT02976467|Drug|Placebo|Matching placebo tablets are given twice daily over a treatment period of 6 months
45797315|NCT02981095|Procedure|Thyroidectomy|Thyroidectomy performed by the same surgical and anesthesia team
45797316|NCT02981095|Drug|Bupivacaine|bupivacaine 0.5%, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
45797317|NCT02981095|Drug|Saline Solution|%0.9 sodium chloride solution, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
45649532|NCT03051503|Drug|The Transdermal Therapeutic System-Fentanyl (TTS-F)|(TTS-F) group (n=30) 50ug/h patch, placed 12 hours preoperatively
45797318|NCT00002721|Drug|doxorubicin hydrochloride|
45797319|NCT00002721|Drug|estramustine phosphate sodium|
45797320|NCT00002721|Procedure|drug resistance inhibition treatment|
45797321|NCT04739345|Drug|Pentoxifylline|400 mg of pentoxifylline orally TID with the standard COVID-19 protocol of the Egyptian Ministry of Health
45797322|NCT00002727|Radiation|radiation therapy|
45797323|NCT01623739|Procedure|Placement of a dental implant|Type 1 implant placement Type 2 implant placement
45797324|NCT04039529|Device|SCENERGY-guided Biopsy|Use of SCENERGY during a lung, liver or kidney biopsy
45649533|NCT03051503|Device|Intravenous patient-controlled analgesia (PCA) morphine|IV PCA morphine for pain in the postoperative period.
45649534|NCT04896437|Procedure|non-centrifuge fat graft application to the wounds|Autologous fat grafts were harvested from abdominal or gluteal regions of the patients and injected into the wound bed and wound environment. Clinical observation and photograph records were used to follow the wounds.
45649535|NCT04886687|Procedure|mechanical thrombectomy|mechanical thrombectomy
45649536|NCT04886375|Procedure|erector spina plane block|The investigators performed erector spina plane block to that patient group for postoperative analgesia
45649537|NCT04886375|Procedure|modified pectoral nerve block|The investigators performed modified pectoral block to that patient group for postoperative analgesia
45649538|NCT04882709|Device|Receiver-in-canal hearing aid 1 default|A receiver-in-canal hearing aid developed by the Study Sponsor used with the default settings as specified in the Study Sponsor's fitting software.
45649539|NCT04882709|Device|Receiver-in-canal hearing aid 2|A receiver-in-canal hearing aid developed by another hearing aid manufacturer used with the default settings as specified in the manufacturer's fitting software.
45797325|NCT01625221|Device|Magnetic Anal Sphincter|The implantable single-use Magnetic Anal Sphincter (FENIX) device consists of a series of titanium beads with magnetic cores that are linked together with independent titanium wires forming an annular shape. The device is supplied sterile and is placed through an open incision.
45797326|NCT02976311|Procedure|cesarean section(C/S) via the modified Misgav-Ladach technique|the first consecutive 44 patients underwent C/S via the modified Misgav-Ladach technique
45797327|NCT02976311|Procedure|cesarean section via the Pfannenstiel-Kerr technique|the second consecutive 44 patients underwent C/S via the Pfannenstiel-Kerr technique
45797328|NCT04036097|Other|MS-adapted AWIS questionnaire (MS-AWIS)|The predefined questionnaire-based infection score of the Airway Infection Susceptibility (AWIS) study is predictive for the occurrence of respiratory tract infections (RTI). In addition several MS-specific items (e.g. bladder dysfunction and urinary tract infections) are included into the AWIS questionnaire (MS-AWIS).
45797329|NCT04036097|Other|infection diary (MS-AWIS diary)|MS patients prospectively fill out monthly infection diaries for 24 months. Infection diaries will either be sent back (with pre-franked envelopes) or handed back to the InRIMS-study team during regular clinical visits (usually every 6 or 12 months).
45797330|NCT01625455|Drug|Aprepitant|Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days.
45797331|NCT01625455|Drug|Placebo|Placebo will be given orally for a total of 7 days.
45797332|NCT05751681|Other|progestin primed ovarian stimulation protocol|progestin primed ovarian stimulation protocol
45797333|NCT05751681|Drug|dydrogesterone (Duphaston, Abbott)|20 mg oral dose of dydrogesterone (Duphaston, Abbott)
45797334|NCT05751681|Drug|Cetrotide|0.25 mg of Cetrotide (gonadotropin releasing hormone (GnRH) antagonist)
45797335|NCT02976623|Other|metric-based feedback training|Structured feedback; a trained investigator will give feedback according to a set of metrics and errors previously developed and validated. Trainees will undergo deliberate practice on the volunteer until they demonstrate adequate and objective performance as assessed by the set of metrics and errors provided.
45797336|NCT00002733|Biological|aldesleukin|
45797337|NCT00002733|Biological|recombinant interferon alfa|
45797338|NCT00002733|Biological|therapeutic tumor infiltrating lymphocytes|
45797339|NCT00002733|Drug|cimetidine|
45797340|NCT01625923|Drug|Olanzapine|Subjects will initially start on olanzapine 2.5 mg per mouth daily. Subjects will return on days 7 and 14 to determine response to medication and medication dose can be increased to 5 mg and 10 mg, respectively, based on incomplete symptom response (mean change GCSI-DD < 0.5). The total dose of olanzapine will not exceed 10 mg daily during this study and subjects will continue on treatment for a total of 8 weeks.
45797341|NCT00002745|Drug|aminocamptothecin|850 micrograms/square meter/day (total dose 2550 micrograms/square meter) via central venous catheter using infusion pump over 72 hours + one cycle Cycle repeated every 14 days for minimum of 6 cycles if partial or complete response
45649540|NCT04882709|Device|Receiver-in-canal hearing aid 1 strategy 1|A receiver-in-canal hearing aid developed by the Study Sponsor used with a modified compression strategy that is expected to improve the sound quality.
45649541|NCT04882709|Device|Receiver-in-canal hearing aid 1 strategy 2|A receiver-in-canal hearing aid developed by the Study Sponsor used with a modified compression strategy that is expected to improve the sound quality.
45649542|NCT04896359|Dietary Supplement|Vitamin C|12.5 grams of ascorbic acid
45649543|NCT04896359|Other|Placebo|vehicle
45649544|NCT04886609|Device|ORISE gel|To establish if ORISE Gel an effective and feasible submucosal injecting solution during endoscopic resection of large colorectal polyps
45649545|NCT04896047|Procedure|Meal test and muscle biopsies|"The FGF19 parameters will be assessed in fasting and in postprandial period after the consumption of a hyper-carbohydrate and hyper-lipidic test meal called Flexmeal.~A muscle biopsies by a needle will be performed before and after the Flexmeal."
45649546|NCT04896203|Procedure|rotational thromboelastometry|Viscoelastometric method useful to study the kinetics of clot formation and fibrinolysis, providing a global information of both the cellular component and the pro and anticoagulant proteins, as well as the interactions between both components.
45649547|NCT04895891|Device|EOS hand imaging|For each patient, EOS images are compared with CT images
45649548|NCT04896125|Drug|Lumigan PF; Xalatan|Lumigan PF: 0.03% bimatoprost (preservative-free) Xalatan: 0.005% latanoprost (containing 0.02% BAK as a preservative) All patients were instructed to use only the given study medication during the study period.
45649549|NCT03049319|Device|Psoriashield in the presence of a non-UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a non-UV absorbing block.
45649550|NCT03049319|Device|Psoriashield in the presence of a UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a UV absorbing block.
45649551|NCT03049319|Device|Psoriashield|The psoriashield will be applied to patient's back.
45649552|NCT03049319|Device|Xtrac laser in the presence of a non-UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a UV absorbing block.
45649553|NCT03049319|Device|Xtrac in the presence of a UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a non-UV absorbing block.
45649554|NCT03049319|Device|Xtrac laser|The Xtrac laser will be applied to patient's back.
45797342|NCT04722185|Diagnostic Test|Veriton SPECT/CT|The Veriton system represents an FDA approved (510k cleared) new generation of SPECT/CT systems. It consists of 12 small gamma cameras arrayed in a circle around the patient, and is coupled to a 64-slice CT system.
45797343|NCT00002751|Biological|monoclonal antibody Me1-14 F(ab')2|
45797344|NCT04721639|Other|Sphinx Yoga Therapy|Sphinx Pose Yoga is among the best beginner Yoga Poses that relieve Lower Back Pain. It extends the back gently and activates muscles along the spine. The subject will be asked to lay down on their stomach with feet set hip-width apart, the elbows positioned under the shoulders, and the legs held together. The chin should be pointing towards the floor. Next, the subject is required to pull up the kneecaps, squeezing the thighs and buttocks, pressing the pubic bone into the floor and dropping shoulders back away from the neck and pushing the chest forward. In this position, the subject is asked to breathe and hold the pose for two to six breaths. By the end, the subject will be required to exhale, bringing the elbows to the sides and slowly lowering the chest and head to the floor.
45797345|NCT05751603|Drug|sugammadex|sugammadex is administered just after extubation
45797346|NCT00002757|Biological|filgrastim|
45797347|NCT00002757|Drug|cyclophosphamide|
45797348|NCT00002757|Drug|cytarabine|
45797349|NCT00002757|Drug|doxorubicin hydrochloride|
45797350|NCT00002757|Drug|etoposide|
45797351|NCT00002757|Drug|methotrexate|
45797352|NCT00002757|Drug|prednisolone|
45797353|NCT00002757|Drug|prednisone|
45797354|NCT00002757|Drug|therapeutic hydrocortisone|
45797355|NCT00002757|Drug|vincristine sulfate|
45649555|NCT04895657|Drug|Piperacillin/Tazobactam Continuous infusion|Continuous infusion
45797356|NCT02976779|Drug|OWC MGC cream|Topical cream containing 3% CBD and 3% THC for Psoriasis treatment
45797357|NCT02976779|Drug|OWC Control Cream|Topical Cream without active ingredients
45797358|NCT04713449|Other|Empowered Survivor Online|Informational online intervention for head and neck cancer survivors
45797359|NCT04713449|Other|Springboard Beyond Cancer|Informational online intervention for all cancer survivors
45797360|NCT04713449|Other|Survey Administration|Survey measures administered at BL, two and 6 months post-baseline
45797361|NCT05751525|Drug|Sulfonylurea|Glibenlclamide / glyburide
45797362|NCT02230579|Drug|MMV390048 5mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
45797363|NCT02230579|Drug|MMV390048 20mg|"Supplied as powder in bottle formulation for reconstitution pre-dose."
45797364|NCT02230579|Drug|MMV390048 40mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
45797365|NCT02230579|Drug|MMV390048 80mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
45797366|NCT02230579|Drug|MMV390048 120mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
45797367|NCT02230579|Drug|Placebo to match MMV390048|"Supplied as powder in bottle formulation for reconstitution pre-dose"
45797368|NCT00002763|Biological|recombinant interferon alfa|
45649556|NCT04895657|Drug|Piperacillin/Tazobactam Intermittent infusion|Intermittent infusion
45649557|NCT04885673|Device|Vapotherm|flow rate 50 L/min with 100% humidified oxygen and the temperature adjusted to be 38℃
45649558|NCT04885673|Device|Apneic oxygenation|Standard apneic oxygenation through the side port of rigid bronchoscope during the procedure
45649559|NCT04895423|Drug|Methotrexate therapy|Methotrexate subcutaneously 10-15 mg/m2 once every 7 days within 12 months
45649560|NCT04895423|Drug|Mycophenolate mofetil therapy|Mycophenolate mofetil per os 500-700 mg/m2 2 times a day within 12 months
45649561|NCT04895423|Drug|Cyclosporine therapy|Cyclosporine per os 3 mg/m2 2 times a day within 12 months
45649562|NCT04895423|Drug|Dupilumab therapy|Patients weighing <30 kg received an initial dose of 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 4 weeks. Patients weighing 30 to <60 kg received an initial dose of 400 mg (2 injections of 200 mg subcutaneously), then 200 mg every 2 weeks; Patients weighing 60 kg or more, the initial dose is 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 2 weeks.
45924717|NCT05626790|Other|Prolonged Stretching|"In addition to the exercises given to both of the groups, static stretching will be applied to the elbow flexors in 2 different positions for 4 weeks, 5 days a week. Participants will need to complete 5 sets of 1.5-minute stretching and 30-second rest periods for both of the two stretching positions listed below. The total duration of the stretches to be performed together with the rest periods will be 20 minutes.~In supine position, the shoulder will be positioned in 90° abduction and internal rotation, the forearm will be positioned in pronation, then the shoulder will be slowly extended. In this way, especially the Biceps Brachii and Brachioradialis muscles are expected to be stretched.~In supine position, the shoulder will be positioned in 90° abduction and maximum external rotation, and the forearm will be positioned in full supination. In this way, especially the brachialis muscle is expected to be stretched."
45924718|NCT00398203|Device|NaviAid™ BGE Device|NaviAid™ Balloon Guided Endoscopy Device
45450372|NCT01083251|Drug|Peginterferon + Vitamin D|180 mcg/week + 400 IUX2/day
45450373|NCT01083251|Drug|Peginterferon|180 mcg/week
45450374|NCT01083251|Drug|Sebivo|Telbivudine 600 mg daily
45797369|NCT04032587|Behavioral|Modified training version of the Approach / Avoidance Task (AAT, see Wiers et al., 2011)|First, a modified training version of the Approach Avoidance Task, (see Wiers et al. 2011) with arbitrary Pavlovian cues will be developed and the effectiveness of this manipulation will be assessed. In detail, positive as well as negative Pavlovian cues (derived from a Pavlovian-to-Instrumental transfer Task, see Garbusow et al. 2014, Garbusow et al. 2016) will be modified according to their approach/ avoidance propensities by 1) approaching negative stimuli (pulling joystick), 2) approaching positive stimuli (pulling joystick), 3) avoiding negative stimuli (pushing joystick) and 4) avoiding positive stimuli (pushing joystick). Thus, we aim at reversing the PIT effect (pushing positive cues/ pulling negative cues) or enhancing the PIT effect (pulling positive cues/ pushing negative cues).
45924719|NCT00053638|Drug|efavirenz|
45924720|NCT00053638|Drug|tenofovir|
45924721|NCT00053638|Drug|abacavir/lamivudine|
45649563|NCT03051425|Dietary Supplement|Probiotic yogurt|120 mL of Yogurt containing Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, Lactobacillus casei, Bifidobacterium animalis ssp. lactis, and Lactobacillus plantarum
45450375|NCT01083251|Drug|entecavir+ vitamin d|entecavir 1 mg daily+ vitamin d
45450376|NCT02184052|Drug|Meloxicam|7.5 mg or 15 mg
45450377|NCT01083329|Behavioral|training|the last 8 weeks, the subjects will follow a training program calculated to optimize use of lipid
45450378|NCT01083329|Drug|nicotinic acid|Obese subjects will receive nicotinic acid or placebo for 16 weeks
45450379|NCT01083329|Drug|Placebo|Obese subjects will receive nicotinic acid or placebo for 16 weeks
45450380|NCT03537820|Other|questionnaire|questionnaire EVAN-G
45450381|NCT02181244|Other|Egg, one a day, for breakfast|One egg per day as breakfast for 5 weeks followed by a 3 week washout period and 5 additional weeks on oatmeal. This is a randomized crossover design. Half of subjects started with the eggs and the other half with oatmeal. Blood lipids, glucose and inflammatory measurements will be finished 24. weeks after completion of the study. Data will be reported 1 year after the completion of the study.
45649564|NCT03051425|Dietary Supplement|Placebo|120 mL of low-fat milk
45797370|NCT04032587|Behavioral|Mindfulness-based interventions (e.g. body scan)|Acute stress reduction will be applied in a standardized way using audio files with an anticipated duration of 20-30 minutes.
45797371|NCT00002775|Drug|docetaxel|
45797372|NCT00002775|Drug|estramustine phosphate sodium|
45797373|NCT01631071|Biological|Virosomal influenza vaccine|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL virosomal influenza vaccine
45797374|NCT00002781|Drug|boronophenylalanine-fructose complex|
45797375|NCT01631149|Drug|Surgical block (rocuronium; atracurium/mivacurium)|The surgical block will be varied by either induction of a deep block (via rocuronium infusion) or a moderate/normal block (using atracurium/mivacurium infusion)
45797376|NCT01631149|Drug|Surgical block (rocuronium; atracurium/mivacurium)|A surgical block will be induced by infusion of either rocuronium (deep block) or atracurium/mivacurium (normal/moderate block)
45797377|NCT05751447|Diagnostic Test|Lymph node puncture, bronchoscopy|Included patients will undergo an extra lympn node punction through oesophagus and/ or an extra bronchoscopy.
45797378|NCT00002787|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|Given SC
45797379|NCT00002787|Biological|sargramostim|Given SC
45797380|NCT00002787|Biological|aldesleukin|Given SC
45797381|NCT00002787|Other|laboratory biomarker analysis|Correlative studies
45797382|NCT01631929|Other|One bag|Infusion of dextrose and electrolytes using one bag
45924722|NCT05572554|Other|Foot Bath Group|The elderly were asked to soak their feet in the water in a marked plastic container with a depth of 10 centimeters and a temperature of 41-42°C for 20 minutes up to their ankles 50 minutes before normal sleeping hours every night for 8 weeks.
45924723|NCT00053716|Drug|Liprostin [liposomal Prostaglandin E1]|
45649565|NCT03050099|Other|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
45797383|NCT01631929|Other|Two bags|Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.
45797384|NCT02975453|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by the treating physician
45797385|NCT00002793|Drug|fluorouracil|
45797386|NCT00002793|Drug|leucovorin calcium|
45797387|NCT01632709|Drug|Bupivacaine|one injection of 10ml of .25%
45797388|NCT01632709|Drug|Placebo|Dry needling
46071914|NCT05876988|Device|Chinese acupuncture|"Disposable acupuncture needles(0.30mm in diameter and 25-40mm in length) will be inserted at a depth of 10-30mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation was additionally delivered on the 6 pairs of the frontal acupoints. The output peak current and voltage of the machine would be 6V and 48mA, respectively, with constant wave at frequency of 2Hz and phase duration of 100µs for 30min. Electrical stimulation lasted 30min. The needles on body acupoints will be also retained for 30min.~Acupuncture intervention will be conducted for 2 sessions per week over 8 consecutive weeks. The determination of 8 weeks of the treatment duration will be based on the fact that the robust eﬀects of acupuncture in cancer patients will be generally observed within 8 weeks of treatment."
45797389|NCT04701671|Behavioral|Observational (not including MRI scanning)|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.
46071915|NCT05876975|Procedure|laparoscopic pectopexy|Women with pelvic organ prolapse and suitable indications underwent laparoscopic pectopexy.
46071916|NCT05876949|Biological|Denosumab|AVT03 (denosumab) or Xgeva (denosumab) will be given as 1 time subcutaneous injection)
46071917|NCT05876936|Device|contact lens sensor (CLS) SENSIMED Triggerfish®|contact lens sensor CLS placing and fitting evaluation, 24h recording
45450382|NCT02181244|Other|Oatmeal, one cup a day|Subjects will be fed oatmeal for a period of 5 weeks. After 3 weeks they will be switched to the alternate diet. This is a randomized control trail in which plasma glucose, plasma lipids and inflammatory markers will be measured. All these measurements will be finished 24 weeks after completion of the study. Data will be reported after 1 year of the completion of the study.
45450383|NCT01083407|Drug|0.12% Chlorhexidine Digluconate|Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
45797390|NCT04701671|Behavioral|Observational (including MRI scanning)|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, fMRI imaging, and a semi-structured interview.
45797391|NCT00381927|Behavioral|Physician Counseling|
45797392|NCT05729217|Other|SBQ-LC survey|Symptom burden questionnaires of Long COVID
45797393|NCT04299425|Device|NIRAF Detection Technology|"Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio > 1.2 is interpreted by device as the suspect tissue being positive for parathyroid."
46071918|NCT05876910|Behavioral|Speech Production Tasks|View visual cues and undergo speech production for 30 minutes. Electrical stimulation of speech related brain regions in the middle of speech production.
46071919|NCT05876871|Diagnostic Test|Pelvic Binder Radiography|One series of radiographic exposures
46071920|NCT05876858|Drug|18F-FDG|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
46071921|NCT05876858|Drug|11C-butanol|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
45649566|NCT04882163|Drug|CC-220|CC-220
45649567|NCT04882163|Drug|Polatuzumab vedotin|Polatuzumab vedotin
45797394|NCT05751291|Drug|Bupivacaine Hydrochloride|"Pericapsular Nerve Group (PENG) Block: 20 mL of 0.25% bupivacaine will be injected in increments while observing for an adequate fluid spread in this plane. Fascia Iliaca Compartment (FIC) Block: 20 mL of 0.25% bupivacaine will be injected until it spreads.~laterally toward the iliac spine and medially toward the femoral nerve."
45924724|NCT05626595|Behavioral|Project Group - PRO-ECO Project|The PRO-ECO project will be tailored to individual sites. Through collection of focus group and baseline data, the project will be further refined to provide site-specific adjustments, such as specific materials in the built environment design modification or targeted training. Identified features of effective projects outlined in the literature have informed the development of the project foundation and potential tailoring.
45649568|NCT04882163|Drug|Rituximab|Rituximab
45649569|NCT04882163|Drug|Tafasitamab|Tafasitamab
45649570|NCT04882163|Drug|Gemcitabine|Gemcitabine
45649571|NCT04882163|Drug|Cisplatin|Cisplatin
45649572|NCT04882163|Drug|Dexamethasone|Dexamethasone
45649573|NCT04882163|Drug|Bendamustine|Bendamustine
45649574|NCT04882163|Drug|Lenalidomide|Lenalidomide
45797395|NCT04691843|Drug|Iron Sulfate|Early, high dose, iron supplementation
45450384|NCT01083407|Other|Toothbrushing|Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto-anterior movements.
45797396|NCT04684901|Other|AlloWrap® Amniotic Membrane|AlloWrap is a human amniotic membrane designed to provide a biologic barrier following surgical repair.
45797397|NCT04010123|Device|Atherectomy/Thrombectomy|Percutaneous transluminal removal of thrombotic, thromboembolic and atherothrombotic material from fresh, subacute and chronic occlusions of blood vessels in native blood vessels or vessels fitted with stents, stent grafts or native or artificial bypasses.
45797398|NCT00382161|Drug|Fluvastatin-sodium|
45797399|NCT01634191|Drug|Apremilast|One oral 30 mg dose of apremilast
45797400|NCT04005443|Other|radiopharmaceutical|his study will consist of a monthly intra-ocular injection of antiangiogenic and a follow-up ophthalmological consultation with OCT and visual acuity score
45797401|NCT05751213|Other|knack technique.|"It consists of 11 patients who will receive pelvic floor muscle exercise and knack technique at outpatient clinic and at home. 8 maximum voluntary contractions of pelvic floor muscles in supine sustained for 6s with a resting interval twice as long between contractions, followed by 3 fast contractions. 3 times per day. 3 days per week at home for 3 months. 3 exercises in supine position. 8 repetitions of each exercise 3times per day , 3 days per week. .~Orientation to perform the knack during activities of daily life. The knack consists of voluntary pelvic floor muscles contraction before and during activities that increase abdominal pressure.~The exercise will be performed in the supine (first month), sitting (second month), and standing (third month) positions twice a month for 3 months at outpatient clinic. (6 outpatient sessions)"
45797402|NCT05751213|Other|pelvic floor muscle exercises|It consists of 11 patients who will receive pelvic floor muscle exercises at the outpatient and at home. 8 maximum voluntary contractions of pelvic floor muscles in supine position sustained for 6s with a resting interval twice as long between contractions followed by 3 fast contractions. 3 times per day , 3 days per week at home for 3 months. Two sessions per month at outpatient clinic for 3 months
45797403|NCT04003649|Biological|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given ITV/ITC
45450385|NCT01068431|Other|bandaging with trico as active controller|In general non-elastic bandaging is the compression treatment in lymphedema
45797404|NCT04003649|Biological|Ipilimumab|Given IV
45797405|NCT04003649|Biological|Nivolumab|Given IV
45797406|NCT04003649|Other|Quality-of-Life Assessment|Ancillary studies
45797407|NCT04003649|Other|Questionnaire Administration|Ancillary studies
45797408|NCT05713851|Drug|Dapagliflozin|dapagliflozin is given for 21 days vs standard of care
45797409|NCT05751057|Diagnostic Test|Cardiovascular Magnetic Resonance|All NSTEMI patients will undergo to CMR before invasive coronary intervention.
45797410|NCT00361907|Procedure|Effect of Pulsatile IV insulin on diabetic pt blood markers|Diabetic patients are given pulsatile intravenous insulin on a weekly basis determined by weekly physician order based on pt response and insulin resistance.
45797411|NCT00361907|Procedure|Effect of Pulsatile IV Insulin on blood markers|Circulating blood markers are performed at baseline and every twelve months to compare and measure against diabetic patients receiving pulsatile intravenous insulin.
45797412|NCT00361907|Procedure|Effect of Pulsatile IV insulin on diabetic pt blood markers|Blood markers will be performed on diabetic patients enrolled as control patients at baseline and every twelve months to measure and compare against diabetic patients treated with Pulsatile intravenous insulin therapy
45797413|NCT05710185|Drug|Deucravacitinib|See arm/group description
45797414|NCT05710107|Other|PENG + LFC Block|Subjects assigned to this group will receive PENG + LFC Block
45797415|NCT05710107|Other|QL Block|Subjects randomized to this group will receive a QL Block
45797416|NCT05700981|Diagnostic Test|colon capsule endoscopy|Patient allocated for the intervention arm will have a CCE using the PillCam Colon 2 (Medtronic, Minneapolis, Minnesota, USA). Upon inclusion and allocation to the intervention arm patients are contacted by a dedicated CCE nurse. The course of the CCE procedure and preparations are explained thoroughly. In case of additional questions patients can contact the nurses by telephone during office hours (Monday-Friday, 8am-3pm). Before the CCE participants will have to undergo a bowel preparation procedure. The bowel preparation kit will be distributed by mail and is to be completed at home, beginning 72 hours before the CCE. The kit contains polyethylene glycol (PEG) sachets (Movicol, Norgine Danmark A/S, Herlev, Denmark), PEG solutions (MoviPrep, Norgine Danmark A/S, Herlev Denmark) and instructions on how to properly perform the preparation procedures.
45797417|NCT04287959|Device|High flow nasal cannula support|airvo2 highflow devices will be used.
45797418|NCT05750901|Device|Fractional ablative laser|Fractional ablative laser used for treatment for skin laxity and tightening
45797419|NCT03995069|Behavioral|3D|Practice generating grip force to the target shown on the computer screen in 3 dimensions.
45797420|NCT03995069|Behavioral|1D|Practice generating grip force to the target shown on the computer screen in 1 dimension.
45797421|NCT05698875|Other|High glycaemic load breakfast meal|Breakfast meal
45450386|NCT05141656|Other|No intervention will be considered in this study.|No intervention will be considered in this study.
45450387|NCT03977051|Behavioral|Focus group|Kidneys transplant patients will discuss their attitudes and beliefs towards immunosuppressant medication adherence
45450388|NCT02181322|Drug|Meloxicam - low dose|
45797422|NCT05698875|Other|High glycaemic load breakfast meal with additional 10g protein|Breakfast meal
45797423|NCT05698875|Other|Medium glycaemic load breakfast meal|Breakfast meal
45797424|NCT05698485|Other|Cleansing Balm|DermResults Cleansing Balm w/ Avocado Oil twice daily
45797425|NCT05698485|Other|Facial Serum|DermResults Advanced Serum w/ Hyaluronic Acid twice daily
45797426|NCT05698485|Other|Moisturizer|DermResults Advanced Moisturizer w/ Hyaluronic Acid twice daily
45797427|NCT04287647|Device|Transpyloric stent|See arm/group descriptions
45797428|NCT04287647|Other|Sham|Sham
46071922|NCT05876845|Other|Combined pre-, pro-, and post-biotic supplement|Participants will take 2 capsules daily with water, with their first meal of the day.
46071923|NCT05876832|Drug|XY0206|Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,37.5mg at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until the subjects meet the withdrawal criteria.
45649575|NCT04882007|Drug|OSE-127|mAb antagonist to CD127 receptor (or IL-7Rα)
45797429|NCT02975375|Procedure|Preoperative geriatric consult or assessment|A preoperative geriatric consult or assessment will be considered to be present if such a consult or assessment is billed by a geriatrician for a patient in the cohort within 4 months preceding surgery. For the primary analysis we will collapse both geriatric consultations and comprehensive geriatric assessments into a single exposure level.
45797430|NCT02975375|Procedure|No Preoperative geriatric consult or assessment|No assessment or consult billed in the 4 months before surgery
46071924|NCT05876832|Drug|Salvage Chemotherapy|Low-dose Cytarabine (LoDAC) or azacitidine, fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) or mitoxantrone, etoposide, cytarabine (MEC)will be administered by subcutaneous (SC) and/or intravenous (IV) injections.
45797431|NCT05693025|Behavioral|Group Exercise|The study evaluates two different approaches for group exercise. Participants in the Standard Implementation (SI) group complete the standard Walk with Ease intervention as recommended by the Arthritis Foundation. Participants are guided to learn and perform a series of stretching and strengthening exercises recommended in the base WWE program. Primary BCTs include instruction on how to perform behavior (#4.1) and Graded tasks (#8.7). Participants in the Enhanced Implementation (SI) group complete the standard Walk with Ease intervention as recommended by the Arthritis Foundation. They may perform some of the same exercises as those in the SI group but they are also guided to learn and perform specific exercises prescribed by a physical therapist to improve balance and reduce risks of falling. The primary BCTs include instruction on how to perform behavior (#4.1), Graded tasks (#8.7) from the base program as well as Information on health consequences (#5.1) and Credible source (#9.1).
45797432|NCT05693025|Behavioral|Behavioral Training|The study evaluates two different approaches for promoting behavior change. Participants in the Standard Training (ST) model follow the standardized Walk with Ease training to support behavior change. Participants are provided with goal setting tools and an online tracker to monitor their progress. Weekly video-based lessons, resource links and eBook content support behavior change. Primary BCTs include Goal Setting (BCT #1.1) and self-monitoring (BCT#2.3). Participants in the Enhanced Training (ET) model access the same basic content as the ST model, but the weekly education-based videos are replaced with lessons focus on habit-formation training. Student coaches are also assigned to individual participants to support behavior change efforts using motivational interviewing strategies. Thus, participants in the ET model also receive two additional theory- and evidence-based BCTs: (1) habit formation training (BCT#1.2, #1.4, #8.3) and (2 health coaching (BCT# 3.3).
45797433|NCT04668521|Other|OVA360|Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection
45924725|NCT05626595|Behavioral|Wait List Group - Normal Daily Practice|ELCCs that are randomly assigned to the waitlist group will participate in their normal daily practice, including standard curriculum and outdoor play time. Once post-data collection is complete, wait list sites will be given the PRO-ECO project.
45450389|NCT02181322|Drug|Meloxicam - medium dose|
45450390|NCT02181322|Drug|Meloxicam - high dose|
45649576|NCT04882007|Drug|Placebo|Normal saline
45450391|NCT03976817|Procedure|aortic valve replacement|After median sternotomy, cardiopulmonary bypass (CPB) was established between the ascending aorta and the right atrium. The aorta was cross-clamped and a high potassium warm cardioplegia was infused and repeated every 15 minutes. The aortotomy was made above the sinuses and the aortic valve was removed. The prosthesis was chosen one size larger than the maximal sizer that could be inserted, which was also used to determine the appropriate height for insertion of the sutures along the wall of the non-coronary sinus.
45450392|NCT03536962|Other|no intervention|no intervention
45450393|NCT02184130|Other|transcranial magnetic stimulation and motion stimuli|
45924726|NCT04731259|Drug|ATR-04|ATR-04 is a proprietary formulated product containing lyophilized SEΔΔΔ, a Staphylococcus epidermidis genetically modified to be auxotrophic to D-alanine as the active ingredient.
45924727|NCT04731259|Other|Placebo|Placebo
45924728|NCT02969941|Other|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
45649577|NCT04885751|Drug|Eupatilin|take eupatilin to prevent NSAID induced gastroenteropathy
45649578|NCT04885751|Drug|Rebamipide|take rebamipide to prevent NSAID induced gastroenteropathy
45649579|NCT03051347|Other|Itch Questionnaire and Interview|
45649580|NCT03051347|Other|Stigma Questionnaire and Interview|
45450394|NCT02184286|Drug|Nevirapine|200 mg q.d. days 1-14 followed by 200 mg b.i.d. days 15-28
45649581|NCT03051347|Other|Cognitive Interview and PROMIS Itch Questionnaire|
45649582|NCT04885517|Device|Esophageal catheter|Patients are equipped with an esophageal catheter: positioning is performed after accurate nasopharyngeal anesthesia with lidocaine
45649583|NCT03051191|Diagnostic Test|micro RNA|micro RNA, cell free DNA and 16S rRNA genes will be explored cross-sectionally at enrollment.
45649584|NCT04400981|Procedure|Remote ischemic conditioning|Remote ischemic conditioning will be applied immediately after randomization in the Emergency Department, through a standard blood pressure cuff placed around the non-paretic arm. The protocol includes 4 cycles of intermittent manually induced upper limb ischemia, alternating 5 minutes of inflation (20mmHg above systolic blood pressure) and 5 minutes of deflation.
45924729|NCT00053794|Drug|perifosine|
45450395|NCT02184286|Drug|Saquinavir-sgc|1600 mg b.i.d. from pre trial to day 28
45450396|NCT02178124|Drug|Donepezil|
45450397|NCT02178124|Drug|placebo|
45450398|NCT02030314|Drug|Chlorthalidone|treatment of resistant hypertension in kidney transplant patients
45924730|NCT05626478|Drug|Dextenza 0.4Mg Ophthalmic Insert|"DEXTENZA 0.4Mg Ophthalmic Insert is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.~Omni (yellow top) Prednisolone Phosphate 1%/Moxifloxacin 0.5%/Bromfenac 0.075%"
45924731|NCT05626478|Drug|Prednisolone Acetate 1% Oph Susp|Prednisolone Acetate 1% is a corticosteroid (to decrease inflammation) and being used as a topical drop after cataract surgery per Standard Of Care.
45924732|NCT05626478|Drug|Moxifloxacin 0.5% Ophthalmic Solution|Moxifloxacin 0.5% is an Antibiotic (to prevent infection) and is being used as a topical drop after cataract surgery per Standard Of Care.
45924733|NCT05626478|Drug|Prolensa 0.07% Ophthalmic Solution|Prolensa 0.07% is a NSAID (to decrease inflammation, swelling and pain) and is being used as a topical drop after cataract surgery per Standard Of Care.
45797434|NCT04281875|Device|NIRAF Detection Technology|"Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio > 1.2 is interpreted by device as the suspect tissue being positive for parathyroid."
45797435|NCT04276493|Biological|ZW25|Administered as specified in the treatment arm
45797436|NCT04276493|Drug|Docetaxel|Administered as specified in the treatment arm
45797437|NCT04276493|Biological|Tislelizumab|Administered as specified in the treatment arm
45924734|NCT02970175|Drug|Terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
45924735|NCT02970175|Procedure|bronchoscopy under local anesthesia|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
45797438|NCT04276493|Drug|Capecitabine|Administered as specified in the treatment arm
45797439|NCT04276493|Drug|Oxaliplatin|Administered as specified in the treatment arm
45797440|NCT00361049|Biological|graft versus host disease prophylaxis/therapy|Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
45797441|NCT00361049|Genetic|fluorescence in situ hybridization|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
45450399|NCT02184364|Drug|Low dose of Klimadynon®|
45450400|NCT02184364|Drug|Medium dose of Klimadynon®|
45924736|NCT02970175|Procedure|Biopsy sampling|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
45924737|NCT00053833|Drug|irinotecan|
45924738|NCT05570682|Procedure|TCI|General anesthesia will be induced with a TCI pump
45924739|NCT05570682|Procedure|Manual induction|General anestehsia will be induced and maintained using a pro kilo regimen.
45450401|NCT02184364|Drug|High dose of Klimadynon®|
45924740|NCT00053872|Drug|cisplatin|
45924741|NCT00053872|Drug|lomustine|
45450402|NCT02184364|Drug|Oestrofeminal®|
45450403|NCT02184364|Drug|Placebo|
45924742|NCT00053872|Drug|vincristine sulfate|
45924743|NCT00053872|Procedure|adjuvant therapy|
45924744|NCT00053872|Radiation|radiation therapy|
45924745|NCT05624918|Drug|Nab paclitaxel|125 mg/m^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
45924746|NCT05624918|Drug|Gemcitabine|1000 mg/m^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
45924747|NCT05624918|Device|NovoTTF-200T|Worn > 18 hr /day starting C1D1 until completion of cycle 3
45924748|NCT00053911|Drug|anastrozole|
45924749|NCT00053911|Drug|cyclophosphamide|
45924750|NCT00053911|Drug|docetaxel|
45450404|NCT02181478|Drug|cyclophosphamide|All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6
45450405|NCT02181478|Drug|fludarabine phosphate|Given by IV during prep at 40mg/m2 for 5 days
45450406|NCT02181478|Radiation|total-body irradiation|Undergo single fraction of reduced intensity conditioning (RIC) regimen of 200 cGy TBI without shielding on day -1
45450407|NCT02181478|Drug|cyclosporine|Initiated in patients on the day -5. Cyclosporine will be administered orally or intravenously at 2 mg/kg/dose every 12 hours for 2-hour period. Cyclosporine will continue until day +100
45797442|NCT00361049|Other|immunoenzyme technique|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
45797443|NCT00361049|Other|immunohistochemistry staining method|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
45797444|NCT00361049|Other|laboratory biomarker analysis|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
45924751|NCT00053911|Drug|epirubicin hydrochloride|
45924752|NCT00053911|Drug|fluorouracil|
45924753|NCT00053911|Drug|goserelin acetate|
45924754|NCT00053911|Drug|tamoxifen citrate|
45924755|NCT00053911|Procedure|adjuvant therapy|
45924756|NCT05569902|Device|active tACS|transcranial alternating current stimulation is a non-invasive method of entraining specific frequency bands in the brain by applying weak intensities of electric current in a desired shape and phase to the desired brain regions.
45924757|NCT05569902|Device|sham tACS|transcranial alternating current stimulation is a non-invasive method of entraining specific frequency bands in the brain by applying weak intensities of electric current in a desired shape and phase to the desired brain regions.
45924758|NCT00053950|Drug|pyrazoloacridine|Given IV
45924759|NCT00053950|Biological|filgrastim|Given IV or SC
45924760|NCT00053950|Procedure|autologous bone marrow transplantation|Undergo autologous bone marrow transplantation
45924761|NCT00053950|Procedure|peripheral blood stem cell transplantation|Undergo peripheral blood stem cell transplantation
45797445|NCT00361049|Procedure|in vitro-treated bone marrow transplantation|Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
45797446|NCT00361049|Procedure|management of therapy complications|Patients will be evaluated for clinical signs and symptoms of GVHD weekly for up to 28 days.
45924762|NCT00053950|Other|laboratory biomarker analysis|Correlative studies
45924763|NCT00053950|Other|pharmacological study|Correlative studies
45924764|NCT00054067|Drug|cisplatin|
45649585|NCT04400981|Other|standard medical therapy|"Standard medical therapy comprises single antiplatelet therapy, either aspirin given in a total dose ranging between 100 to 300 mg per day on days 1-5 and followed by aspirin 100mg/day on days 1-5 followed by aspirin 100mg/day, or Clopidogrel 75mg/day (at the discretion of the patient's attending physician), unless an indication for early anticoagulation (e.g. atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state) or dual antiplatelet therapy (e.g. early carotid stenting) is present.~All patients will receive standard deep venous thrombosis (DVT) prevention therapy together with appropriate treatment for blood pressure control, glycemic control and cholesterol reduction."
45924765|NCT00054067|Procedure|adjuvant therapy|
45924766|NCT00054067|Procedure|conventional surgery|
45924767|NCT00054067|Radiation|brachytherapy|
45649586|NCT04895345|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
45797447|NCT04342949|Behavioral|quality of life|To observe the difference of quality of life
45797448|NCT05670795|Drug|Recombinant Follicle Stimulating Hormone|clinical pregnancy rates
45797449|NCT05670795|Drug|Recombinant Follicle Stimulating Hormone and Clomiphene Citrate|clinical pregnancy rates
45924768|NCT00054067|Radiation|radiation therapy|
45924769|NCT05568069|Device|Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronisation Therapy Defibrillator (CRTD)|An ICD is a device that is implanted under the skin under a local anesthetic. It has a battery/generator component and leads which are fixed into the heart chambers. It has the ability to detect dangerous heart rhythms if they occur, and deliver a shock to treat this to help prevent sudden cardiac death. A CRTD is a pacemaker with a defibrillator function.
45450408|NCT02181478|Drug|mycophenolate mofetil|Given at 1g intravenously or orally twice daily from day -5 to +100, or as clinically indicated.
45450409|NCT02181478|Procedure|umbilical cord blood transplantation|Following RIC, on day T+0, dimethylsulphoxide will be removed from the cord blood cells and given as transplant.
45797450|NCT04266197|Combination Product|Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)|RT234 capsules of a dry powder formulation containing vardenafil administered via oral inhalation with a non-invasive AOS DPI.
45797451|NCT05750511|Diagnostic Test|molecular tissue analysis|
45797452|NCT02975531|Other|Simulator's construction|Model to build the mold for the simulator
45450410|NCT02181478|Procedure|mesenchymal stem cell transplantation|The total dosage of hMSC will be 2x10^6cells/kg (+/-20%).
45649587|NCT04895345|Radiation|Intensity modulated radiotherapy|Intensity-modulated conformal radiotherapy (IMRT) is a kind of three dimensional conformal radiotherapy, which requires the dose intensity in the radiation field to be adjusted according to certain requirements.
45797453|NCT02975531|Other|Model Features|Volunteers to determine the elasticity of the skin and cirtometry neck to compare with the simulator.
45797454|NCT02975531|Other|Parameterization technique|Evaluation of the simulator features and parameterization of the Pompage technique in the simulator.
45797455|NCT02975531|Other|Simulator training|Training of pompage technique using the simulator.
45924770|NCT00054106|Drug|buserelin|
45924771|NCT00054106|Drug|custirsen sodium|
45924772|NCT00054106|Drug|flutamide|
45924773|NCT00054106|Procedure|conventional surgery|
45924774|NCT00054106|Procedure|neoadjuvant therapy|
45924775|NCT00054145|Drug|perifosine|
45924776|NCT00054184|Drug|docetaxel|
45924777|NCT00054184|Drug|paclitaxel poliglumex|
45924778|NCT05621525|Drug|BBP-398|BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK -MAPK signal transduction pathway. Key components of the MAPK pathway include the small GTPase RAS, the serine/threonine-protein kinase RAF, mitogen-activated protein kinase (MEK) and ERK. In cells, SHP2 binds to phosphorylated tyrosine residues in the intracellular domain of RTKs such as the EGFR, leading to activation of the downstream MAPK signaling pathway.
45924779|NCT00054223|Procedure|psychosocial assessment and care|
45924780|NCT00054262|Drug|T900607|
45924781|NCT00054301|Procedure|adjuvant therapy|
45924782|NCT00054301|Procedure|conventional surgery|Patients undergo excisional biopsy or surgery.
45924783|NCT00054301|Radiation|intraoperative radiation therapy|Patients undergo excisional biopsy or surgery followed by an intraoperative dose of radiation to the tumor cavity.
45450411|NCT02181712|Biological|Mesenchymal stem cell 0.5|0.5 million MSC per Kg will be infused intravenously. Product will be infused at the rate of 2 - 3 ml/minute during the first 15 minutes and may be adjusted up to 5ml/minutes if tolerable. It is anticipated that the infusion will be completed within approximately 3 hours.
45924784|NCT00054340|Biological|anti-thymocyte globulin|
45924785|NCT00054340|Drug|busulfan|
45924786|NCT00054340|Drug|cyclophosphamide|
45924787|NCT00054340|Drug|cyclosporine|
45924788|NCT00054340|Drug|methotrexate|
45924789|NCT00054340|Procedure|allogeneic bone marrow transplantation|
45924790|NCT00054340|Procedure|peripheral blood stem cell transplantation|
45924791|NCT05619458|Behavioral|Mindfulness Intervention|6-week mindfulness intervention
45797456|NCT02975531|Other|Training Evaluation|Evaluation of volunteers from GE group before and after training with the simulator.
45924792|NCT05567250|Behavioral|Behavioral: Telephone-based ACEs care coordination|The 211LA care coordinator will use the agency's extensive resource directory to identify and provide appropriate referral recommendations to each family. In addition, they will develop a care coordination plan, noting these recommendations and plans for follow-up, to be provided to the family's clinical care provider. The coordinator will routinely follow-up with the family until 1) children begin receiving services, 2) families refuse services, or 3) children are deemed ineligible by service providers.
45924793|NCT00054418|Dietary Supplement|calcium carbonate|calcium 600 mg daily administered orally for one year
45924794|NCT00054418|Dietary Supplement|vitamin D|vitamin D 400 U daily administered orally for one year
45649588|NCT04885361|Biological|CoVepiT (OSE13E)|Study will be open label and will be randomized 1:1 in two parallel study arms receiving either one single dose or two doses separated by 21 days.
45924795|NCT00054418|Drug|risedronate sodium|risedronate 35 mg weekly administered orally
45924796|NCT00054418|Other|placebo|placebo tablet weekly administered orally for one year
45924797|NCT05560230|Drug|Clonidine|A single dose of intraoperatively administered intravenous clonidine 150 μg will be infused over 5-10 min., immediately after intubation
45924798|NCT05560230|Drug|Isotonic saline|A single dose of administered intravenous isotonic saline will be infused over 5-10 min., immediately after intubation
45797457|NCT05669313|Drug|Rivaroxaban 15 MG|Rivaroxaban 15 mg after inclusion and on the morning after inclusion, i.e., before blood sampling
45924799|NCT05616338|Other|Blood sample|"A blood sample and a nasal brush for each participant. The nasal brushing will allow the isolation of epithelial cells that will serve as a comparison for the bronchial tissue produced from blood-derived iPS.~A blood sample of approximately 14 ml will be taken for isolation and freezing of the blood mononuclear cells allowing the generation of iPS."
45924800|NCT00054457|Drug|capecitabine|
45924801|NCT00054457|Drug|docetaxel|
45924802|NCT00054496|Drug|erlotinib hydrochloride|
45924803|NCT05615519|Diagnostic Test|A new technology based on 3D reconstruction and deep learning algorithm to achieve an automatic diagnosis of strabismus based on patient-sourced videos of programmatic cover tests.|Digital ruler of strabismus
45924804|NCT00054535|Biological|aldesleukin|
45924805|NCT00054535|Biological|recombinant fowlpox-tyrosinase vaccine|
45924806|NCT00054535|Biological|vaccinia-tyrosinase vaccine|
45450412|NCT02181712|Biological|Mesenchymal stem cell 1.0|1 million MSC per Kg will be infused intravenously. Product will be infused at the rate of 2 - 3 ml/minute during the first 15 minutes and may be adjusted up to 5ml/minutes if tolerable. It is anticipated that the infusion will be completed within approximately 3 hours.
45797458|NCT04665635|Procedure|Rectosigmoid resection|Most of the colorectal involvements are observed in the seromuscular layer. In seromuscular infiltration, resection of the rectosigmoid colon or shaving of tumoral implants without resection can be performed.
45797459|NCT04262609|Radiation|hypofractionated radiotherapy|volumetric modulated moderately fractionated arc therapy
45924807|NCT00054574|Biological|panitumumab|
45924808|NCT00054613|Drug|Methoxsalen|
45924809|NCT00054613|Procedure|Extracorporeal Photopheresis|
45924810|NCT05612243|Other|Consumption of a meal with yogurt enriched with probiotics immobilized on oat flakes and polyphenols|Participants will consume a meal including 200g of yogurt enriched with Lacticaseibacillus rhamnosus probiotics (3*10^9 cfu/g) immobilized on oat flakes (1g) and polyphenol-rich lyophilized extract (250mg) of Cistus Albidus (77,3 mg GAE/g), as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of functional yogurt on postprandial glycemia and lipemia
45797460|NCT05669157|Procedure|Radiography request by nurse|Intervention group with radiography requested by the IRN instead of the physician. The radiography will be interpreted by the physician afterwards, according to current practice
45924811|NCT05612243|Other|Consumption of a meal with yogurt enriched with probiotics immobilized on oat flakes|Participants will consume a meal including 200g of yogurt with Lacticaseibacillus rhamnosus probiotics (3*10^9 cfu/g) immobilized on oat flakes (1g), as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of probiotic-enriched yogurt on postprandial glycemia and lipemia.
45924812|NCT05612243|Other|Consumption of a meal with plain Yogurt with oat flakes|Participants will consume a meal including 200g of plain yogurt containing 1g of oat flakes, as a placebo, as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of probiotic-enriched yogurt on postprandial glycemia and lipemia.
45924813|NCT00054730|Drug|CX516 (Ampalex®)|
45649589|NCT03049163|Drug|vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]|to observe the anesthesia effect of topical anesthesia of 27-gauge vitrectomy for vitreous floaters
45797461|NCT05669157|Procedure|Radiography request by physician|The physician prescribed the X-ray, the X-ray technician carries out the imagery and the physician interprets it afterwards
45797462|NCT00361127|Drug|isotonic saline infusion|
45797463|NCT04343963|Drug|Pyridostigmine Bromide|One 60mg tablet P.O. once per day for 14 days
45797464|NCT04343963|Drug|Placebo|One tablet P.O. once per day for 14 days
45924814|NCT00054808|Drug|gallium nitrate|
45924815|NCT00054886|Drug|SU-011,248|
45924816|NCT05609591|Dietary Supplement|Liquid diet group|Fluid diet including juice, rice soup, filtered vegetable juice/broth, lotus root powder and milk and egg soup were given to children for bowel preparation.
45924817|NCT05609591|Dietary Supplement|Enteral nutrition group|100% short peptide enteral nutrition are given to children for bowel preparation
46071925|NCT05875805|Behavioral|Telehealth Serious Illness Care Program|The adapted telehealth Serious Illness Care Program is a multilevel intervention engaging the patient, caregiver, clinician, and system. It consists of tools, training, and system change. Tools include: 1) The Serious Illness Conversation Guide for clinicians; and 2) Education materials for patients on the importance of Serious Illness Conversations (Patient Preparation Pamphlet) and of the involvement of caregivers (Family Communication Guide).
45797465|NCT05750199|Other|Immunotherapy Special Training Course (ISTC)|16 weeks and includes 8 hours of digital media training and 2 days of workshop training.
45797466|NCT05750199|Other|Advanced Oncology Nurse Training Course (AONTC)|4 weeks and includes 8 days of Advanced Oncology Nurse Training Course
45797467|NCT04248179|Drug|Ropivacaine injection|Ropivacaine 5mg/ml
45797468|NCT04248179|Drug|Saline 0.9%|Saline 0.9%
45797469|NCT04248179|Drug|Sufentanil and PONV prophylaxis|30 minutes prior to emergence 0.2 μg/kg total body weight Sufentanil IV and 1 gram of paracetamol IV (if 6hrs since preoperative medicine) and 4 mg ondansetron IV (PONV prophylaxis) will be administered.
45797470|NCT05750121|Behavioral|E-health enhanced motor-cognitive training|The intervention group will implement physical activity (aerobic exercise and resistance training) and cognitive training (CogniFit) intervention with the e-health components (persuasive technology). The intervention period will last for 12 weeks, with three 90 minutes sessions (60 minutes of physical activity and 30 minutes of cognitive training) per week.
45797471|NCT00361517|Behavioral|Galactomannan antigen monitoring, Aspergillus PCR|There will be blood draws twice weekly for monitoring GM antigen and once a week for Aspergillus PCR.
45797472|NCT00361517|Other|blood draws|Blood is drawn for monitoring of Galactomannan antigen in the blood
45797473|NCT00361517|Other|blood draws for GM monitoring|blood samples will be taken twice weekly for monitoring of GM antigen levels in the blood and once a week for Aspergillus PCR.
45797474|NCT00361517|Drug|Amphotericin-B deoxycholate|1-1.5mg/kg, i.v, once a day
45797475|NCT00361517|Other|blood test|Blood will be tested twice a week for the presence of Galactomannan.
45797476|NCT00361517|Other|Blood test|Blood will be drawn twice a week and it will be tested for the presence of GM(a component of the cell wall of the mold Aspergillus which is released during growth)
45797477|NCT02976545|Device|fMRI (functional Magnetic Resonance Imaging)|fMRI examination
45797478|NCT02976545|Behavioral|psychiatric evaluation|psychiatric evaluation
45797479|NCT05657691|Drug|Xanamem™|Xanamem™ is formulated in green and cream-colored size 3, Coni-Snap-shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains the active pharmaceutical ingredient of UE2343.
45797480|NCT05657691|Drug|Placebo|Matching placebo which is identical in appearance to the test product (10 mg Xanamem™ QD) except that it contains no active ingredient.
45797481|NCT03920267|Drug|BMS-986165|Specified dose on specified days
45797482|NCT05749965|Procedure|Unicompartmental knee arthroplasty|medial unicompartmental knee arthroplasty
45797483|NCT05447507|Drug|Remimazolam|0.075 mg/kg Remimazolam bolus infusion for 1 min, then 0.5~1.0 mg/kg/h continuous infusion
45797484|NCT05447507|Drug|Dexmedetomidine|1 mcg/kg Dexmedetomidine infusion for 10 min, then 0.2~0.7 mcg/kg/h continuous infusion
45797485|NCT05749887|Procedure|salvage surgery|"Open/minimally invasive salvage surgery performed when cervical biopsy and/or PET/CT scan ( SUVmax ≥2.5 ) indicate patients with residual tumor intrapelvic 4-12 weeks after standard CCRT.~Surgery type:~No parametrial involvement, extrafascial hysterectomy;~There is parametrial involvement, extensive hysterectomy(Q-MC);~Only bladder invasion, anterior pelvic exenteration;~Only rectal invasion, posterior pelvic exenteration or total pelvic exenteration;~Invasion of bladder and rectum, total exenteration.~The pelvic lymph nodes are removed at the same time when 18F -FDG PET /CT indicates that the SUVmax is ≥ 2.5."
45797486|NCT01634269|Device|MDT-2111 TAVI 23 mm|Device: 23 mm MDT-2111 System for Transcatheter Aortic Valve Implantation (TAVI) Transcatheter Aortic Valve Implantation (TAVI) using the 23 mm MDT-2111 system.
45797487|NCT05644821|Other|complex intervention|"The intervention has several elements:~Regular symptom monitoring via ePROMs~Alarm when defined thresholds of EPIC-26 or PHQ-4 are reached or exceeded, 3.) In case of alarm, standardized telephone contact by a study nurse at the treating center with the offer to coordinate a urological consultation at the center, 4.) if requested by the patient: a urological consultation at the treating prostate cancer center by urologists trained in the PRO-P study,~4) content of the consultation: if necessary, the guideline-compliant initiation of further diagnostics and therapy including in this context necessary follow-up contacts and 5) postal communication of the ePROM results in case of an alarm as well as postal dispatch of a report of the findings in case of a urological consultation at the treating prostate cancer center to the practicing, treating urologist."
45797488|NCT05644821|Other|current clinical practice|current clinical practice
45797489|NCT05643105|Procedure|Any kind of colectomy|This is a registry of surgical patients with colon cancer that are managed following current clinical practice in each participating center. The aim of this research is studying anastomotic leak rates and posible risk factors.
45924818|NCT05609591|Dietary Supplement|Low residual diet group|Low residua diet included gruel with grain only, peeled carrot, white gourd, powdered skin, tofu, vegetable, mud and fruit. were given to children for bowel preparation
45924819|NCT00054925|Behavioral|Personal contact (PC)|This arm uses brief, individual contacts on a monthly basis which emphasize core elements of weight maintenance. Monthly contacts with an interventionist occur for 30 months after the end of Phase I. Face-to-face contacts occur approximately every four months (e.g., three annually), with telephone contacts occurring every month between FTF contacts.
46071926|NCT05875805|Other|Education Control|"Education materials developed by the NCI on Communication in Cancer Care (PDQ®) - Patient Version"
46071927|NCT05875623|Other|MALPIP criteria|In the intervention group, the clinical pharmacist will apply the MALPIP criteria on all the admission and discharge medications. The intervention will consist of 4 steps: i) pharmacist review using MALPIP criteria to detect PIM, ii) discussion with doctors for deprescribing decision iii) discussion with patients and documentation of shared decision iv) follow up patients
45649590|NCT04894955|Device|MARIA|After consent has been given, the participant's breast will be fitted by the operator using a clear plastic cup to ascertain their corresponding MARIA® cup insert size. Once this has been determined, participants will be required to lie prone with their breast pendent through an aperture in the MARIA® participant bed. The cup insert will contain a layer of coupling fluid. The hemispherical cup inserts and array are brought into contact with the breast. A scan sequence comprising of two complete scan rotations will then be performed, which takes around 5 minutes. The participant will then be assisted to adjust their positioning, and the scan sequence performed on the other breast.
45797490|NCT01635439|Drug|Propess|The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour, the rupture of the membranes, or at the occurrence of hyperstimulation.
45797491|NCT01635439|Drug|Prostin E2|3 mg tab is placed in the posterior vaginal fornix. dose can be repeated every 6 hours till onset of active labour, the rupture of the membranes, or the occurrence of hyper-stimulation.
45450413|NCT02755090|Drug|Nitrous Oxide|Participants in the nitrous oxide group will receive a scented face mask through which nitrous oxide will be administered. The nitrous content of the gas will be titrated up by 20% every 5 breaths with a goal of 70% N2O/ 30% O2 as tolerated by the participant. This group will also receive saline through an IV. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
45450414|NCT02755090|Drug|IV Saline|
45450415|NCT00109343|Biological|Comparator: ProQuad™ (V221)|0.5-mL subcutaneous injection of measles, mumps, rubella, varicella virus vaccine live (MMRV)
45649591|NCT04881695|Other|Questionary patients|"The patients will answer 1 questionnaire consisting of 5 parts :~General (demographic information)~Desire for a child~Hospital Anxiety and Depression scale~Sexual life~Additional questions regarding medical care"
45649592|NCT04881695|Other|Questionary controls|"Witnesses will complete 1 survey containing 4 parts:~General (demographic information)~Desire to have a child~Hospital Anxiety and Depression scale~Sexual life"
45797492|NCT01636063|Drug|Mifepristone|Mifepristone 200 mg capsulized orally once 24-48 hours prior to abortion procedure
45797493|NCT01636063|Drug|Misoprostol|Misoprostol 400 mcg buccally once 3 hours prior to abortion procedure
45797494|NCT05635305|Drug|Zoliflodacin Patheon|"Zoliflodacin Patheon formulation to be compared with Zoliflodacin Dr Reddy's formulation during BE study (cohort 1).~Itraconazole will be administered with Zoliflodacin Patheon formulation during DDI study (cohort 2)"
45797495|NCT01636297|Behavioral|Forced exercise|Exercise on a stationary cycle that was controlled by a motor, to augment voluntary cycling rate by 35%. Intervention was administered 3 times per week for 8 weeks
45797496|NCT01636297|Behavioral|Voluntary exercise|Exercise on a stationary cycle without motor assistance. Intervention was administered 3 times per week for 8 weeks
45797497|NCT05749653|Drug|Bi-annual CDTI|Bi-annual CDTI
45797498|NCT05630703|Behavioral|Mindfulness-based Attention Training in IBS|The MB-IBS-EAT is an 8-week intervention with weekly 1-hour sessions in a web-based group format.
45797499|NCT05630703|Other|Low FODMAP Diet|Subjects in the FODMAP group will be provided dietary instructions by a registered dietician during weekly 1-hour sessions in a web-based group format
45797500|NCT01636453|Device|Stent assisted coiling with the Liberty Stent|Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months
45797501|NCT05749575|Drug|Chidamide Plus Toripalimab Plus Paclitaxel|Each participant receives chidamide plus toripalimab plus paclitaxel
45797502|NCT05628987|Other|no intervention|Observational studies, no intervention
45797503|NCT04387201|Drug|Cyanocobalamin|Cyanocobalamin (vitamin B12) 1000 mcg subcutaneous weekly for 6 weeks.
45797504|NCT04387201|Drug|Dulaglutide|Dulaglutide 0.75 mg subcutaneous weekly for 2 weeks, followed by 1.5 mg subcutaneous weekly for 4 weeks
45797505|NCT04370587|Biological|T3011|T3011 will be administered up to 4mL as an intratumoral injection given Q2W.
45797506|NCT04370587|Combination Product|T3011 + pembrolizumab|T3011 will be administered up to 4mL as an intratumoral injection in combination with intravenous pembrolizumab given Q3W.
45797507|NCT04178005|Drug|Cladribine|All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI
45797508|NCT05749497|Other|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
45797509|NCT05623761|Drug|BUCCOTHERM® Sensitive Gums with Fluoride|Toothbrushing using standardised technique and pear-sized amount of toothpaste BUCCOTHERM® Sensitive Gums with Fluoride twice daily for 1 month.
45450416|NCT00109343|Biological|Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)|0.5-mL intramuscular injection of pneumococcal 7-valent conjugate vaccine
45649593|NCT04885439|Behavioral|NextSteps|Intervention sessions are delivered by a Masters level trained interventionist. During sessions, the interventionist will: conduct the weekly symptom screen, review content, answer questions, ensure skills mastery through homework review, and work with participants to develop action plans and identify/overcome barriers to self-care/caregiving. Patients and caregivers will receive individual calls from the interventionist for sessions 1, 2, and 3, and participate together for sessions 4, 5, and 6 via speakerphone.
45649594|NCT04410809|Biological|TA-46|Decoy protein of the fibroblast growth factor receptor 3, 50 mg/mL (Parts A, B and C) and 120 mg/mL (Part C and Part D), sc solution for injection/infusion
45797510|NCT05623761|Drug|BUCCOTHERM® Sensitive Gums Fluoride-Free|Toothbrushing using standardised technique and pear-sized amount of toothpaste BUCCOTHERM® Sensitive Gums Fluoride-Free twice daily for 1 month.
45924820|NCT00054925|Behavioral|Interactive technology (IT)|The website utilizes collaborative goal setting and problem-solving strategies to identify contingent action plans for perceived obstacles to success. In order to tailor the intervention to the needs of the participant, the action plan can be updated anytime and as frequently as desired by the individual. Participants are encouraged to input data on weight, food records, physical activity, and goals on a weekly basis. Participants are not restricted to logging on to the website only once a week. Rather, participants have the option of logging on to the website to enter data, communicate with other participants, or to seek other information, as frequently as they wish.
45649595|NCT04410809|Other|Placebo|The same composition as the active medication but without the active substance TA-46
45450417|NCT02185690|Drug|Binimetinib|"Continuous MEK162 with dose escalation until the Recommended Phase 2 dose (RP2D) one dose level below the Maximum administered dose (MAD) or progression of disease.~MEK162 tablets 15 mg strength will be taken orally on a BID dose schedule."
45450418|NCT02185690|Drug|Pemetrexed|4-6 cycles given intravenously in combination with carboplatin as per standard therapy.
45649596|NCT04894565|Procedure|rehabilitation|physical therapy 24 hrs after surgery
45649597|NCT04881851|Dietary Supplement|Inositol + alpha lipoic acid|Inositol 1000 mg + alpha lipoic acid 400 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
45797511|NCT05621109|Behavioral|Weight loss intervention|"Subjects will receive very low-calorie diet for 8-10 weeks to introduce a rapid weight loss of at least 10%. Once target weight is achieved, participants will be reintroduced to foods to introduce weight stability.~The male will follow the maternal randomization, i.e. weight loss if BMI ≥25 until a BMI of 23 or a weight loss of at least 10% is obtained.~During weight loss maintenance, subjects will receive dietary counseling to follow a diet high in protein (corresponding to 22-25E%), high fiber and wholegrain while fulfilling the requirements for essential fatty acids, micronutrients and trace elements in accordance with Nordic Nutrition Recommendations (NNR) 2012.~Throughout the study period participants will be encouraged to follow the official recommendations for physical activity as recommended by the Danish health authorities 2022."
45797512|NCT05749185|Device|radiofrequency ablation|radiofrequency ablation
45797513|NCT05749107|Diagnostic Test|Echocardiography|Identify AF patients at risk of developing moderate/severe STR and those who will benefit from restoring the normal sinus rhythm
45797514|NCT05749107|Combination Product|Proteomic analyses|To identify the mechanisms leading to moderate/severe STR during AF.
45797515|NCT02975609|Radiation|Conventional Fractionated Radiotherapy|5Fx/W,3Gy/Fx,Dt:PTV-G:30Gy/10F/2W for metastatic sites, Dt:60Gy/30F for primary tumor and metastatic lymph node.
45450419|NCT02185690|Drug|Carboplatin|4-6 cycles of intravenous Carboplatin in combination with Pemetrexed as per standard therapy.
45450420|NCT02181868|Other|Biodegradable and titanium fixation used in mandibular fractures.|
45797516|NCT02975609|Radiation|Stereotactic Body Radiation Therapy|30Gy/3-5F for the primary and the metastases.
45797517|NCT05748951|Device|Canalicular occlusion device|Occlusive device is inserted into the tear duct to block tear drainage
45797518|NCT02227693|Drug|avatrombopag|E5501 (avatrombopag) 20-mg tablets
45797519|NCT02227693|Drug|Placebo|Placebo matching 20-mg tablets
45797520|NCT04231331|Drug|Ertugliflozin|Ertugliflozin 5mg qd for 12 months
45797521|NCT04231331|Drug|Placebo|Placebo qd for 12 months
45797522|NCT04221581|Device|Knee prosthesis - FHK ASYMETRIQUE total knee prosthesis|FHK ASYMETRIQUE prosthesis are intended to be implanted in the tibial and femoral regions during total knee arthroplasty in order to restore joint function.
45797523|NCT05583981|Other|Interview|Participate in interview
45797524|NCT00361985|Drug|Esomeprazole|Esomeprazole 40mg once daily orally.
45797525|NCT00361985|Drug|Esomeprazole|Esomeprazole 40mg once daily orally
45797526|NCT00362063|Drug|growth hormone (Nutropin)|growth hormone (Nutropin), 0.3mg/kg/week administered subcutaneously daily.
45797527|NCT00382239|Drug|exenatide (LY2148568)|subcutaneous injection twice daily, 5 mcg for 4 weeks, then 10 mcg for 8 weeks
45797528|NCT00382239|Drug|exenatide (LY2148568)|subcutaneous injection twice daily, 5 mcg for 4 weeks, then 5 mcg for 8 weeks
45797529|NCT00382239|Drug|exenatide (LY2148568)|subcutaneous injection twice daily, 2.5 mcg for 4 weeks, then 2.5 mcg for 8 weeks
45797530|NCT00382239|Drug|Placebo|subcutaneous injection twice daily, 0.02 mL to 0.04 mL
45797531|NCT04004845|Drug|Cytotec|Misoprostol 25mcg vaginal
45450421|NCT03536806|Drug|Saline 0.9%|Patients assigned to control group will be administered saline 0.9% in bolus of 10 cm3 within 2-3 minutes. BP will be measured before injection.
45649598|NCT04881851|Dietary Supplement|Inositol|Inositol 1000 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
45649599|NCT04881851|Dietary Supplement|Folic acid (placebo comparator)|Folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
45797532|NCT04004845|Drug|oxytocin|Oxytocin 10 IU/ml Solution for infusion
45797533|NCT04004845|Device|Cervical Foley Balloon|Cervical Foley will be inflated to 80cc
45797534|NCT04634201|Dietary Supplement|Oral probiotics (L. reuteri)|administration of probiotic containing tablets twice daily after tooth brushing for 3 months
45797535|NCT04634201|Dietary Supplement|Placebo|administration of a placebo twice daily after tooth brushing for 3 months
45797536|NCT03968419|Drug|canakinumab|Administered subcutaneously
45797537|NCT03968419|Drug|pembrolizumab|200mg administered intravenously every 3 weeks
45797538|NCT01636765|Drug|No Intervention|No intervention.
45797539|NCT01637935|Drug|Pioglitazone|Pioglitazone tablets.
45797540|NCT05748639|Other|Mobile health application|Participants randomized to receive the QG-A (Experimental) intervention will receive monthly appointments with a medical provider, access to naltrexone, and weekly and bi-weekly appointments with a licensed clinical counselor through an integrated digital health application.
45797541|NCT05748639|Other|Medical Management|Participants randomized to receive the MM (Control) intervention will receive monthly appointments with a medical provider and access to naltrexone.
45797542|NCT04218617|Device|Diagnostic MRI|Diagnostic MRI
45797543|NCT04218617|Device|Planning MRI|Planning MRI: high definition (HD) MRI of the region of interest (1 vertebral level above and below the level(s) being treated)
45797544|NCT04218617|Other|Simulation CT|Simulation CT is obtained (1.5 mm slice thickness)
45797545|NCT04218617|Other|QOL assessment|QOL assessment
45797546|NCT04218617|Other|Brief pain inventory (BPI)|Brief pain inventory (BPI), including narcotic assessment
45797547|NCT04218617|Radiation|sSRS in 1 fraction|sSRS 18 Gy in 1 fraction
45797548|NCT04218617|Radiation|sSRS in 2 fraction|sSRS 24 Gy in 2 fractions to be delivered either on consecutive days or one day apart.
45649600|NCT04872335|Other|Gong's Mobilization|Group A received Gong's mobilization and common treatnent (TENs,Hot pack and cervical stretches). Gong's mobilization which is concurrent application of Apophyseal joint gliding and end range passive physiological movements while the subject's cervical postures are passively Neutral in order to induce Normal Cervical Extension. The Subjects in Group A were treated three times in a week for 4 weeks.
45649601|NCT04872335|Other|Gradually Graded Exercise Therapy|"The Subjects in Group B were received Exercise Therapy and common treatment (TENs, Hot pack and cervical stretches) three times in a week continue for 4 weeks . Each exercise session will take 30 min. It will be consisted of 5 min warm-up exercises, 20 min stabilization exercises, 5 min cool-down, and stretching exercises including neck and shoulder girdle muscles.~The aim of Exercise program was to create a neutral spine and activate deep muscles of the cervical spine. The patients were educated to maintain neutral spine during the exercises and throughout the day as much as possible.~Scapulothoracic stabilization exercises were included_ specific exercises for the muscles affecting scapular orientation related to neck pain. The subjects were educated to maintain the positions and contractions during the exercises including scapular retraction, eccentric scapular retraction, and combined scapular retraction with shoulder lateral rotation, forward punch, and dynamic hug."
45450422|NCT03536806|Drug|Canrenone|Patients assigned to canrenone group will be administered canrenone in bolus of 200 mg diluted to 10 cm3 within 2-3 minutes in one dose. Drug administration will be stopped in case of serious adverse event. Further treatment of the patient will depend on clinical condition and will follow appropriate clinical guidelines.
45797549|NCT02981017|Device|Porcine Intestinal submucosal xenograft|Cook Biodesign ENT repair graft will be used in the experimental group to cover exposed bone in the sinonasal cavity as a result of the Draf III/endoscopic modified lothrop procedure.
45797550|NCT05551377|Other|Head-up tilt sleeping|Whole-body head-up tilt sleeping (HUTS) will be carried out in three different angles, each for the duration of two weeks. Prior to the first angle the participant will sleep in a horizontal position for 1 week. The different angles will be installed using a wedge between the mattress and bed frame.
45797551|NCT03003559|Device|High flow nasal cannula|High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
45797552|NCT04214561|Diagnostic Test|Polysomnography|Each of the patients will undergo polysomnography
45924821|NCT05545878|Device|Super enhanced single vision lens 01 for spectacles|This is a spectacle lens designed to have a small amount of positive power towards the bottom of the lens as this is the area that is in line with the eye when downwards for near tasks such as looking at a digital device.
45797553|NCT05746533|Procedure|Hip Arthroscopy|Hip Preservation surgeries
45797554|NCT03875729|Biological|teplizumab|Treatment
45797555|NCT03875729|Biological|Placebo|Control
45797556|NCT00382083|Drug|1000 mg acetaminophen|
45797557|NCT00382083|Drug|800 mg ibuprofen|
45797558|NCT00382083|Drug|1 oz 4% lidocaine gel|
45797559|NCT01640197|Dietary Supplement|Resveratrol|Transmax (Biotivia). 500mg (1 capsule) per day for 28 days.
45797560|NCT01640197|Other|Placebo|Methyl Cellulose. 1 capsule taken once daily for 28 days.
45797561|NCT00382317|Drug|Iobitridol|
45797562|NCT04207151|Behavioral|SNAPS intervention|"The intervention is multi-level yet, targets the weakest chains in the link of PrEP initiation at safety-net hospitals designed for scalability, sustainability, and implementability across a wide range of settings. It consists of Surveillance by STI testing, Navigation by unannounced patient navigators to the Sexual Health Clinic (SHC), Accelerated follow-up with providers with PrEP expertise, Point-of-care PrEP counseling and laboratory testing, and Seamless, consistent, longitudinal, comprehensive care (SNAPS). SNAPS will selectively target those care settings where PrEP prescribing is particularly rare or absent (eg, OB/GYN). Study team will utilize a quasi- experimental design to compare rates of PrEP uptake overall, PrEP initiation in disproportionately-impacted groups, and PrEP retention pre-versus post-initiation of SNAPS, controlling for secular trends."
45797563|NCT03003091|Other|Needs-based patient education|
45797564|NCT03003091|Other|Traditional patient education|
45797565|NCT02975687|Biological|CD19 CAR T cells|CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.
45797566|NCT04610411|Device|surgical navigation|surgical navigation for pedicle screw placement and rod beinding using AR-glasses and a specially developed software
45797567|NCT04610411|Other|standard surgical method|standard surgical method established at the institution
45797568|NCT05742399|Drug|Hyaluronic acid NanoGel|Hyaluronic acid nanoparticles (2%)
45450423|NCT00108485|Drug|Extended release niacin|Extended release niacin 1500-2000mg once daily
45450424|NCT00108485|Other|Placebo|Placebo tablets
45450425|NCT02256514|Biological|Daily oral dose of hepcortespenlisimut-L|Oral therapeutic vaccine, hepcortespenlisimut-L (V5) to be given once-per-day with monthly check-up
45797569|NCT05742399|Drug|Placebo gel|conventional gel having the same color, form and packaging
45797570|NCT04607915|Behavioral|Intervention for TECC Model|The Care Coordinator (CC) will provide brief coaching sessions (15 to 20 minutes) to each participant once per week for 8 weeks. Participants can identify topics for discussion and the CC and participant can decide if a video session via WebEx is required versus a phone call. Also, participants will be given peer support and will be indirectly monitored by a virtual care team of experts.
45797571|NCT01641445|Drug|Topiramate|Topiramate (200 mg daily)
45797572|NCT01641445|Drug|Placebo|"Matching placebo capusules (sugar pills"
45924822|NCT00398242|Device|above or below elbow cast for the last 3 weeks of treatment|
45924823|NCT02970097|Drug|20ml bolus of 0.5% ropivicaine|local anesthetic
45924824|NCT02970097|Drug|10 ml of 0.5% ropivicaine|local anesthetic
45924825|NCT02970097|Drug|Midazolam|1-2 mg of medication given intravenously before nerve block
45450426|NCT05123339|Other|Questionnaire|Questionnaire
45450427|NCT02256592|Drug|Fecal Microbiota|300 mL of fecal suspension from a healthy donor will be delivered during colonoscopy
45450428|NCT01068587|Drug|MET/VEGFR2 inhibitor Foretinib|"PhaseI and Phase II Arm A:~Foretinib PO daily dosing starting cycle 1 day 15 and erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I."
45797573|NCT04204187|Behavioral|service learning|service learning for university students
45797574|NCT05741151|Diagnostic Test|PET-Neck Parkinsonian patients|Brain and neck PET-CT scan with 68Ga-PSMA to detect metabolism in the Superior Cervical Ganglion of both sides.
45797575|NCT04200209|Other|Implementation of a quality indicator feedback mechanism|"Audit and feedback: A summary of clinical performance and hospital safety culture over a specified period of time.~Benchmarking Achievable: benchmarks are calculated from the performance of all members of a peer group and represents a realistic standard of excellence attained by the top performers in that group (i.e. comparing to the top 10% of peers).~Educational outreach: A trained independent person or investigator will meet with health professionals or managers in their practice setting to provide information (e.g. feedback of quality indicators).~Action planning: The purpose of action planning is to support quality improvement efforts by identifying opportunities for improvement, strategies and steps to accomplish the work."
45797576|NCT04185311|Biological|Ipilimumab|Given IV
45797577|NCT04185311|Biological|Nivolumab|Given IV
45797578|NCT04185311|Biological|Talimogene Laherparepvec|Given intratumorally
45797579|NCT05513937|Drug|Nebivolol|Tablets administered orally once daily according instructions provided by Principal Investigator.
45797580|NCT05513937|Drug|Amlodipine|Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
45797581|NCT01642147|Device|Transcranial Doppler (TCD)|A 2-MHz Transcranial Doppler probe (MULTI-DOP P2.2C; DWL, Elektronische Systeme GmbH, Germany) will be used to measure both sides of Vmca of both patients undergoing craniotomy and patients undergoing abdominal surgery. The signal will be range-gated to a depth of 45 to 60 mm at temporal bone window to achieve the optimal signal according to standard techniques. The measures will be recorded in the operation room before anesthesia, in the recovery room at extubation, 30, 60, 90, and 120 min after extubation.
45797582|NCT01642147|Procedure|jugular venous bulb catheterization|After local anesthesia, a jugular venous bulb catheter(16G, manufactured by Arrow International Inc. USA) will be placed in the dominant side. The proper placement of the tip of the catheter in the jugular bulb will be confirmed later by a postoperative lateral skull X-ray. SjvO2 (blood sample will be drawn slowly at a speed of 2ml per minute) will be measured before anesthesia, at extubation, 30, 60, 90, and 120 min after extubation.
45797583|NCT01642147|Procedure|Tumor removal surgery under general anesthesia|Surgery types include total or subtotal removal of tumors.For all surgical procedures, general anesthesia will be maintained with isoflurane (0.5-1.0 minimal alveolar concentration (MAC) expired), repeated boluses of fentanyl (1~2 µg/kg IV), and continuous vecuronium 50～70 IV. All patients will be mechanical ventilated with oxygen. During anesthesia, blood pressure and heart rate will be kept stable, within ±10% of the preoperative levels. Hematocrit (Hct) will be maintained higher than 30%. After surgery, tracheal extubation will be performed when patients regain full muscle strength, breathe spontaneously with acceptable oxygenation and normocapnia.
45797584|NCT01642147|Procedure|Radial artery catheterization|After local anesthesia, an intra-arterial pressure line(I.V. catheter and pressure line kit are both manufactured by Smiths Medical International Ltd. USA) will be inserted in radial artery. Sample blood will be drawn from the line before anesthesia, at tracheal extubation, and 30, 60, 90, 120 min after tracheal extubation.
45797585|NCT01642147|Procedure|Abdominal surgery under general anesthesia|For all surgical procedures, general anesthesia will be maintained with isoflurane (0.5-1.0 minimal alveolar concentration (MAC) expired), repeated boluses of fentanyl (1~2 µg/kg IV), and continuous vecuronium 50～70 IV. All patients will be mechanical ventilated with oxygen. During anesthesia, blood pressure and heart rate will be kept stable, within ±10% of the preoperative levels. Hematocrit (Hct) will be maintained higher than 30%. After surgery, tracheal extubation will be performed when patients regain full muscle strength, breathe spontaneously with acceptable oxygenation and normocapnia.
45450429|NCT01068587|Drug|erlotinib hydrochloride|erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I.
45450430|NCT01068587|Other|laboratory biomarker analysis|Tumour markers alone cannot be used to assess objective tumour response. If markers are initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response
45450431|NCT02181946|Drug|Fluconazole|
45450432|NCT02181946|Drug|Nevirapine|
45797586|NCT04584749|Drug|Lidocaine Iv|"2% lidocaine or 0.9% physiological saline will be used as placebo, and it will be administered as a bolus during anesthetic induction equivalent to 1.5 mg / kg of lidocaine. After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine.~20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing 2% Lidocaine ."
45797587|NCT01643707|Behavioral|Evidence based guidelines and tools|Education, guidelines, tools
45797588|NCT04581629|Drug|CLTX-305|"Period 1: Once daily, followed by twice daily of CLTX-305 for 5 days~Period 2: Twice daily doses of CLTX-305 for 5 days~Period 3: Individualized dose titration of CLTX-305 for up to 24 weeks~LTE: Individualized dose titration of CLTX-305 for up to 25 months"
45797589|NCT05512611|Diagnostic Test|Finger photoplethysmography|Finger photoplethysmography in tested hand, noninvasive blood pressure and heart rate during blood donation.
45797590|NCT04579991|Other|Visnadin, ethyl ximeninate, coleus barbatus and millet in emulgel|Topical product, apply small amount on mucosal surface of vulva included clitoris once daily
45797591|NCT04579991|Other|Emulgel-only|Topical placebo product, apply small amount on mucosal surface of vulva included clitoris once daily
45924826|NCT02970097|Drug|Fentanyl|50-100 mcg of medication given intravenously before nerve block
45924827|NCT05539287|Drug|Lactobacillus-Based Capsule|25 patients will receive Lactobacillus species 5 billion colonies forming unit (CFU) 2 capsules daily together with their standard antiepileptic drug for 6 months.
45924828|NCT00398281|Drug|dutasteride|Given orally
45924829|NCT00398281|Other|placebo|Given orally
45924830|NCT00398359|Behavioral|Motivational Interviewing (physicians)|Identifying and referring children with BMI >93%.
45797592|NCT03827057|Behavioral|Reconsolidation of Traumatic Memories (RTM)|"RTM is a trauma-focused, but not cognitive behavioral, therapy: it involves brief exposure to the trauma memory, but does rely on conscious responses to correct the symptoms of PTSD. RTM was first used to treat phobias in the 1970s, and has more recently been refined to focus on reconsolidation to update long-term memories, reconfiguring the salience structure of the original memory, and incorporating those changes into the overall memory structure. Reconsolidation is a neural mechanism for updating long-term memory, inserting new information that contradicts an essential element of the memory, which makes it possible to change the emotional tone and salience of the memory. It is hypothesized that RTM can thereby achieve quicker, greater, and more durable responses than with traditional exposure therapies."
45924831|NCT00398359|Behavioral|Behavior Modification (families)|Group meetings and individual family meetings based on behavior modification for healthy lifestyle changes.
45924832|NCT05531643|Device|Active Cefaly Dual (R)|Transcutaneous electrical nerve stimulation (TENS) device with electrode placement at the forehead. A biphasic rectangular wave will be delivered for a maximum of 20 minutes at a maximum amplitude of 16mA. Participant may halt amplitude before it reaches maximum amplitude. The device has previously been cleared by the FDA for use in migraine patients.
45924833|NCT05531643|Device|Sham Cefaly Dual (R)|Transcutaneous electrical nerve stimulation (TENS) device with electrode placement at the forehead. A 1Hz wave will be delivered for 20 minutes at 1mA.
45924834|NCT00055042|Drug|Vitamin E|
45924835|NCT00055081|Behavioral|Critical Time Intervention|
45797593|NCT03827057|Behavioral|Prolonged Exposure (PE)|PE is a trauma-focused cognitive behavioral therapy (TFCBT) that depends on exposure to the feared stimulus as a central effector of change, utilizing extinction, which theorizes that if a trigger that previously elicited a fear response is presented enough times without reinforcement, the response fades. Previous researchers have shown that extinction involves the creation of a new blocking memory which prevents expression of the original fear memory. While PE has more evidence to support its efficacy in PTSD than other approaches, and a majority achieve a clinical response (e.g., decrease in CAPS score of 10 or more), many do not achieve complete remission of symptoms, and the blocking memory may be fragile, so subsequent triggers may result in relapse.
45797594|NCT02976155|Other|A standard enteral nutrition protocol|Patients in the experimental arm, the practice of enteral nutrition will based on a standard protocol. The core content of this protocol includes five step：1. Whether the participants need nutrition therapy? 2. The choice of nutrition way? 3. Nasogastric tube or nasointestinal tube? 4. The choice of enteral nutrition type? 5. The target calorie and protein of the participants? And how to achieve these target？(In this study, the practice of the above protocol is the only intervention).
45924836|NCT00055120|Drug|Emtricitabine/tenofovir disoproxil fumarate|
45924837|NCT00055120|Drug|Lopinavir/ritonavir|
45924838|NCT00055120|Drug|Stavudine|
45924839|NCT05527704|Drug|salbutamol|Patients assigned to the active group will be treated with 0.15 mg/kg body weight (diluted in 3 mL 0.9% NaCl) nebulized salbutamol (Ventolin®, GlaxoSmithKline, Dublin, Ireland) for 30 min.
45797595|NCT01644331|Drug|Tolvaptan|IV furosemide plusTolvaptan (given at 0, 24 and 48 hours)
45797596|NCT01644331|Drug|Placebo|IV furosemide plus oral placebo (given at 0, 24 and 48 hours)
45924840|NCT05527704|Drug|0,9% Chloride Sodium|3 mL nebulized 0.9% NaCl administered for 30 min.
45450433|NCT02184598|Behavioral|Cognitive training|12 weeks of cognitive training; 4 sessions/week; duration 30 min
45924841|NCT00055159|Procedure|Pulse-sprayed injection of recombinant tissue plasminogen activator (rtPA)|
45924842|NCT00055198|Drug|daptomycin|
45924843|NCT05604482|Diagnostic Test|CXCR4-PET|New imaging modality using CXCR4 for imaging in GCA
45924844|NCT05525325|Procedure|General Anesthesia|Patients randomized to the GA arm are intubated after anesthetic induction. For this purpose, they are pre-oxygenated with an oxygen mask and non-invasive monitoring is established. After sufficient pre-oxygenation has been applied, analgesic and sedative medication are administered. If the patient is sufficiently long nil by mouth they are manually ventilated before a muscle relaxant is administered. A rapid-sequence induction is performed with administration of an opioid, sedative and muscle relaxant in rapid succession and without intermediate manual ventilation in non-nil by mouth patients. To secure the airway, an endotracheal tube is inserted into the trachea with the aid of a laryngoscope. After insertion of the endotracheal tube, its endotracheal position is confirmed with auscultation and capnography. GA maintenance therapy with opioids, sedatives and catecholamines, if needed, will then be started.
45924845|NCT00055315|Behavioral|Systems Training for Emotional Predictability and Problem Solving (STEPPS)|STEPPS is a 20-week, manual-based, psychoeducational group treatment that combines skills training with cognitive-behavioral techniques. It includes a systems component to train family members, friends, and significant others.
45924846|NCT00055315|Behavioral|Treatment As Usual (TAU)|
45924847|NCT00055354|Procedure|Acupuncture|
45924848|NCT00055354|Behavioral|Cognitive Behavioral Therapy|
45924849|NCT00055393|Drug|Bupropion|18 subjects in this randomly controlled double blind study received bupropion.
45924850|NCT00055393|Drug|Placebo|21 subjects received Placebo.
45924851|NCT00055432|Drug|Gemzar and Alimta|
45924852|NCT00055510|Drug|BO-653|
45924853|NCT00055549|Drug|Dextromethorphan|
45924854|NCT00055549|Drug|Lorazepam|
45924855|NCT00055588|Procedure|Locomotor training|
45924856|NCT00055666|Drug|beclomethasone dipropionate|
45924857|NCT00055705|Biological|PV701|
45924858|NCT00055783|Biological|apolizumab|
45924859|NCT00055822|Biological|oblimersen sodium|
45924860|NCT00055822|Drug|fluorouracil|
45924861|NCT00055822|Drug|leucovorin calcium|
45924862|NCT00055822|Drug|oxaliplatin|
45924863|NCT00055861|Biological|bevacizumab|Given IV
45924864|NCT00055861|Drug|docetaxel|Given IV
45924865|NCT00055861|Other|laboratory biomarker analysis|Correlative studies
45450434|NCT02184598|Behavioral|Placebo cognitive training|In the control group, we will use a placebo training that will consist of the same exposure time of the active training but not related to any element of cognitive training. To this end, we will set up an online platform with quiz and educational videos - being the most related to school content - without any component of executive function or working memory.
45450435|NCT00107783|Drug|Nitisinone (NTBC)|Treatment
45924866|NCT05596292|Device|Immersive Virtual Reality glasses|The immersive virtual reality glasses support a smartphone device, allowing videos to be used with 360º rotation and earpods headphones with bluetooth for sound. Video options will be offered to participants according to the exercise performed, ie: a cycling video for activities with a cycle ergometer; video with people walking for ambulation; and videos of the patient's choice, such as forest, beach or city scenarios, for other moments.
45924867|NCT05596292|Other|early mobilization protocol|Three days of an early mobilization protocol. The exercises will be progressed every day, starting in the first day with active movements of lower and upper limbs with cycle ergometer; in the second day repeat the first day exercise and do orthostasis training; and in the last day training ambulation.
45924868|NCT00392106|Drug|propafenone|Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
45924869|NCT00392106|Drug|flecainide|Anti-arrhythmic drug prescribed for the treatment of Atrial fibrillation
45924870|NCT00392106|Drug|dofetilide|Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
45797597|NCT05734755|Behavioral|The Individualized Dietary Behavioural Change Programme (IDBC)|The first three weekly face-to-face sessions will be during the 'goal initiation' and 'planning' phases. The remaining seven face-to-face sessions will be offered once to twice per month between weeks 4 and 24 during the program at the 'action execution' phase. Family members will be encouraged to join the dietary consultations. Strategies will be discussed with the family members to facilitate the participant's adherence to the recommended diet regimen.Phase I Goal Initiation is aimed at motivating the participants to actively manage their sarcopenic obesity. Phase II Plan Formulation is aimed at guiding the participants in transforming their (sub-) goals into detailed individualized action plans.Phase III Action Execution is aimed at encouraging the participants to continually execute the action plan. The IDBC guidebook will be given to the participants to guide them on how to gradually adopt our dietary recommendations in their daily life.
45924871|NCT00392106|Drug|sotolol|Anti-arrhythmic Drug prescribed for treatment of Atrial Fibrillation
45924872|NCT00392106|Device|Pulmonary vein ablation|Electrical isolation of pulmonary vein with high-intensity focused ultrasound
45924873|NCT00392106|Drug|Amiodarone|Anti-arrhythmic Drug prescribed for the treatment of Atrial Fibrillation
45797598|NCT05734755|Behavioral|The Exercise Training|The group size will be < 10. They will be used in the resistance exercise in this study to improve muscle strength (20 mins). Brisk walking (20 mins) will be employed in the aerobic exercise in this study. Each session will include 10 minutes of warm-up and cool-down exercises at the beginning and at the end. A YouTube video and a pamphlet describing the different types of exercises used in this programme will be disseminated to all participants to encourage them to continually practise their exercises at home for 30 minutes at least 5 times per week.
45924874|NCT00055939|Drug|exatecan mesylate|
45924875|NCT00055978|Drug|celecoxib|Given orally. 400mg twice daily for 6 months.
45924876|NCT00055978|Other|placebo|Given orally
45924877|NCT05590754|Device|Hyper-buoyancy Floatation (HBF)|Participants remained on a waterbed encased within a wooden frame partially (≈50%) filled with water super-saturated with magnesium sulphate at a temperature between 34-36°C regulated by an ultra-thin underbed heater. Participants remained supine and motionless when lay on the HBF except for temporary passive re-orientation to/and back from the prone position for vertebral compliance assessment
45924878|NCT05590754|Device|Axial Load after 4h of HBF|Participants from observational sat upright in a chair without back support for 15 min before post testing (1G), whilst experimental group participants performed a 30s seated squat with 50% of their body weight (BW) before returning to the upright seated position.
45450436|NCT05127694|Other|Vestibular Rehabilitation|Vestibular Rehabilitation which is consist of repetitive exercises and canalit repositioning maneuvers
45797599|NCT04165733|Diagnostic Test|Online questionnaire|Clinical psychologists in Germany currently working with patients with mental disorders
45797600|NCT00362141|Drug|levetiracetam (add-on)|
45797601|NCT05733897|Drug|hydroxychloroquine|Using hydroxychloroquine to treat nonalcoholic steatohepatitis
45797602|NCT04558151|Behavioral|preoperative inspiratory muscle training|Physiotherapists will measure the maximal inspiration pressure (MIP) with the POWER®breathe device of each single patient. Patients will then be instructed to perform inspiratory muscle training at the level of 60% of their individual MIP. Patients are instructed to perform the training containing of 30 breaths twice a day for 14-18 days before surgery. The devices are able to register the performance of each single training session and training results are monitored.
45924879|NCT00056056|Drug|bexarotene|The recommended initial dosage of Bexarotene (75 mg Bexarotene capsules to be administered according to body surface area) for patients entered in this trial is 300 mg/m2 /once a day, taken orally, till CCR, PD, unacceptable toxicity, 16 weeks of treatment, whichever comes first
45797603|NCT02975765|Procedure|Piezosurgery|The surgical tip is going to be used to make small cuts into the cortex of the alveolar bone between the crowded teeth.
45924880|NCT00056056|Drug|methoxypsoralen|The dose of methoxypsoralen, as conventional capsules or liquid-filled capsules, is based on the patient's weight. The standard dose of 0.6 mg/kg will be given to all patients three times weekly - Increasing dose of PUVA according to a set protocol after a Minimal Phototoxic Dose (MPD) testing.
45924881|NCT00056056|Procedure|UV light therapy|Initial UVA light exposure times should be based on the minimal phototoxic dose (MPD) for the specific light source being used. MPD can be determined by irradiating several skin areas 2 cm in diameter with varying light exposure times and determining the exposure time that produces erythema at 72 hours. The initial dose of UVA administered will be 70% of the MPD. The dose of UVA for the subsequent UVA sessions will be increased according to a standard protocol consisting of 20% increments with each successive treatment session depending on the presence of erythema.
45924882|NCT00056095|Biological|therapeutic allogeneic lymphocytes|
45924883|NCT00056095|Drug|cyclophosphamide|
45924884|NCT00056095|Drug|cyclosporine|
45924885|NCT00056095|Drug|fludarabine phosphate|
45924886|NCT00056095|Procedure|allogeneic bone marrow transplantation|
45450437|NCT02184676|Biological|Analysis of early immune modifications|"blood and stool sampling in parents during pregnancy (at enrollment, i.e. 7th-8th month of pregnancy)~cord blood sampling~stool sampling in mothers and newborns at birth (day 7)~blood and stool sampling in children at the age of 8, 18, 30 and 42 months"
45797604|NCT01646671|Drug|LCZ696|LCZ696 200 mg tablet once daily
45797605|NCT01646671|Drug|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
45797606|NCT01646671|Drug|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
45797607|NCT05731713|Behavioral|Journey of Transformation-Native Youth Health Leadership Program curriculum|Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.
45797608|NCT05448339|Combination Product|PVHA or TACE|PVHA or TACE
45797609|NCT04556201|Device|SOLTIVE™ Premium SuperPulsed Laser Fiber System|SOLTIVE™ SuperPulsed Laser Fiber System and SOLTIVE™ Laser Fibers for single-use only
45797610|NCT03561259|Drug|131I-MIBG|Subjects will receive 18 mCi/kg of 131I-MIBG administered over 1.5 to 2 hours on Day 1 either a central line or a peripheral intravenous catheter. The maximum absolute dose of 131I-MIBG is determined by institution therapeutic limits and will not exceed 1,000 mCi. Subjects with an overall response of stable disease or better as assessed by the Investigator, and who meet certain protocol predefined criteria, may receive a second 18 mCi/kg 131I-MIBG treatment no sooner than 6 weeks following the first treatment.
45450438|NCT02184676|Other|Collection of clinical and socio-demographic data|"Questionnaire filled in by clinicians at enrollment and at birth~Self-administered questionnaire filled by parents at enrollment, at birth, and then at month 8, 18, 30 and 42"
45450439|NCT02030392|Behavioral|Intervention group|Cognitive-behavioral intervention
45450440|NCT02030392|Behavioral|Active control group|Education and information
45649602|NCT03048929|Biological|Typhoid Vi Polysaccharide Vaccine|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
45450441|NCT01083719|Procedure|FDG-PET|Fluoro-deoxy gluocose-Positron emission tomography for delineating volumes in Glioblastoma
45797611|NCT03561259|Drug|131-MIBG + Vorinostat|Subjects will receive vorinostat 180 mg/m2/dose (maximum dose 400 mg) once daily by mouth, NG, or G-tube on days -1 to +12 (14 total doses) for 14 days continuously. The 131I-MIBG treatment will be administered on day 1 via either a central line or a peripheral intravenous catheter over 1.5 to 2 hours. On day 1 of therapy, vorinostat should be taken 1 hour prior to the start of the 131I-MIBG infusion. Subjects with an overall response of stable disease or better, as assessed by the Investigator and who meet certain predefined criteria, may receive a second course of 18 mCi/kg 131I-MIBG combined with vorinostat (180 mg/m2) no sooner than 6 weeks following the first therapeutic 131I-MIBG treatment.
45450442|NCT02185768|Drug|idarubicin|
45797612|NCT05492409|Biological|GNR-069|Once a week as a subcutaneous injection.
45450443|NCT02185768|Device|Dc- Beads 300-500µm|
45450444|NCT02958202|Drug|BMN 044 IV 6 mg/kg|
45450445|NCT02958202|Drug|BMN 044 IV 9 mg/kg|
45450446|NCT02958202|Drug|BMN 044 SC 6 mg/kg|
45450447|NCT02182024|Drug|Dabigatran etexilate high dose|
45450448|NCT02182024|Drug|Dabigatran etexilate low dose|
45450449|NCT00095303|Behavioral|Brief Strategic Family Therapy (BSFT)|"BSFT is a family therapy approach that consists of 12 to 16 sessions (each 1 to 1.5 hours long) over a 4-month period during the Main Study, and up to 8 booster sessions. Interventions are delivered to adolescents and relevant family members in non-restrictive community settings (e.g., clinics, homes, school)."
45450450|NCT00095303|Behavioral|Treatment as Usual|TAU varies depending on site, however each will offer services that include at least 1 therapy session (individual or group therapy) per week during the Main Study, as well as participation in ancillary services (e.g., case management, self help groups, etc.) over a four month period.
45450451|NCT03536260|Device|Implant with NanoBone graft|Using of NanoBone graft to fill the gap in the socket after immediate implant placement
45924887|NCT00056095|Procedure|peripheral blood stem cell transplantation|
45450452|NCT03536260|Device|Implant with Xenograft|Using of Xenograft to fill the gap in the socket after immediate implant placement
45450453|NCT02190136|Other|Protein whole foods|Protein-rich whole foods consumed at 20-30 grams of protein at each of 4-6 meals per day
45450454|NCT02190136|Other|Protein Resistance Exercise Training|Protein rich whole foods diet and resistance training 3 times per week for 11 weeks
45924888|NCT00056134|Biological|Dendritic cell vaccine plus denileukin difitox|
45924889|NCT05587127|Behavioral|Cognitive Behavioral Therapy|Eight 1-hour sessions delivered weekly via the MGH-approved secure video platform Enterprise Zoom. Skills include: education about gut-brain regulation and weight loss, and regularizing eating to improve hunger and satiety cues; techniques to facilitate weight gain with targets of increased food volume and variety; and plan for maintenance of treatment gains.
45924890|NCT00056173|Drug|GTI-2040|
45450455|NCT02190136|Other|Protein Stretching/Yoga Training|Protein-rich whole foods diet of 20-30 grams of protein at each of 4-6 meals per day with stretching/yoga training 3 times per week for 11 weeks
45450456|NCT02184754|Procedure|Magnetic endoscope imaging (MEI)|
45450457|NCT02185846|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
45450458|NCT02185846|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
45450459|NCT02184832|Drug|Metformin|2 doses of 500 mg metformin given approximately 12 hrs apart
45450460|NCT02184832|Other|Low tryptophan diet|
45450461|NCT02184832|Other|High tryptophan diet|
45450462|NCT02256670|Behavioral|Text Message Application|Two-way text messaging application addressing adherence with adjuvant endocrine therapy
45450463|NCT03537352|Procedure|Any appropriate surgical treatment|Any appropriate surgical treatment for the management of patient's current disorder
45649603|NCT03048929|Biological|Placebo|The placebo injection will consist of 0.5mL of saline.
45649604|NCT04871789|Diagnostic Test|Laboratory and instrumental examination|All patients will undergo a comprehensive examination to identify the consequences of COVID-19
45797613|NCT04449393|Device|Emdogain® FL|Emdogain® FL is an enamel matrix derivative intended for subgingival and topical application in conjunction with scaling and root planing procedures to provide regeneration of tooth support lost due to periodontal disease. Emdogain® FL has been shown to be effective in residual pockets with probing depths from 5mm to 9mm with no furcation involvement in patients with adequate plaque control. Emdogain® FL has also been shown to enhance the early healing of periodontal soft tissue wounds resulting from the instrumentation of periodontal pockets.
45649605|NCT04881305|Diagnostic Test|questionnaires and neuropsychological assessment|Participants will undergo: (1) An evaluation of COVID-19-related symptoms such as fatigue, post-exertional malaise, dizziness, etc. (2) A comprehensive evaluation of behavioral measures (e.g., hearing, vision, olfaction, sleep, social engagement) (3) A short validated neuropsychological evaluation, of multiple cognitive domains, with an emphasis on the memory domain; motivational factors will also be taken into account using performance validity tests (4) A thorough well-being and emotional state assessment, including the evaluation of mood disturbance and quality of life. The assessment will involve both self-report and cognitive tasks, previously associated with psychopathology. In addition to the above-mentioned evaluations, a subgroup of participants will undergo either MRI examination or FDG PET-CT, with the aim of clarifying the neural mechanisms underlying the neurologically-related symptoms.
45797614|NCT04449393|Other|Scaling and root planing|Scaling and root planing procedures as part of non-surgical periodontal therapy involves mechanical removal of dental plaque and calculus using curettes and sonic scalers.
45649606|NCT04871633|Drug|Remdesivir|Remdesivir is an intravenous (IV) loading dose of 200 mg on day 1 followed by daily IV maintenance doses of 100 mg for 5-10 days
45649607|NCT04871633|Drug|Conventional|IV Steroids Antibiotics
45924891|NCT05499000|Behavioral|Emotional freedom technique|"Emotional freedom technique will be applied online with the researcher in 2 sessions, 3 days apart.~KBF, SUE, PMSS tests will be applied before the intervention, SUE will be applied before and after each session, At the end of the 2nd session, post-test data will be taken with SUE, PMSS."
45924892|NCT00056212|Behavioral|Yoga|
45924893|NCT00056212|Behavioral|Exercise|
45924894|NCT00056251|Procedure|H&P; ECG; Blood tests; voiding diary; Cystoscopy|
45924895|NCT00056290|Biological|VEGF|3 sets of injections, at 2 week intervals
45649608|NCT04881071|Device|Scarf|Scarf specifically designed to facilitate mother-neonate skin-to-skin contact
45797615|NCT00361205|Device|Electronic Monitoring cap|
45924896|NCT00056290|Biological|VEGF|3 sets of injections, at 2 week intervals
45797616|NCT03002857|Device|LMA-C|LMA-C will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.
45797617|NCT03002857|Device|Baska Mask|Baska Mask will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.
45797618|NCT03002857|Device|I-gel|I-gel LMA placement will be done as suggested in supine position with a standard gel pillow under patients head.
45924897|NCT00056329|Drug|Vitamin E|1,000 international units twice daily for three years
45924898|NCT00056329|Drug|multivitamin|once daily for three years
45924899|NCT00056329|Drug|Placebo|Placebo twice daily for three years
45924900|NCT00056368|Drug|Anidulafungin|
45924901|NCT00056368|Drug|Fluconazole|
45924902|NCT05540678|Dietary Supplement|FibreGum|To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
45924903|NCT05540678|Dietary Supplement|Placebo|To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
45924904|NCT00056446|Drug|Vatalanib|
45924905|NCT05463081|Device|Laser treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
45924906|NCT05463081|Diagnostic Test|Blood test|Taking blood from a vein for Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study) and clinical blood analysis (to include the participant in the study and evaluate procedure efficiency)
45450464|NCT03537352|Drug|Any appropriate drug or non-drug treatment excluding surgery|Any appropriate drug or non-drug treatment excluding surgery for the management of patient's current disorder
45450465|NCT00105521|Drug|Sarizotan|Sarizotan will be administered twice daily.
45450466|NCT00105521|Drug|Placebo|Placebo matching to sarizotan will be administered twice daily.
45924907|NCT05463081|Diagnostic Test|Clinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
45924908|NCT05463081|Diagnostic Test|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study and evaluate procedure efficiency)
45924909|NCT05463081|Diagnostic Test|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
45924910|NCT05463081|Other|Female Sexual Function Index|Female Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
45924911|NCT05463081|Other|International Consultation on Incontinence Questionnaire - Short Form|International Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
45649609|NCT04880915|Other|surgical smoke affects|The study, experimental type, was conducted to investigate the effects of five different methods on surgical smoke protection.
45797619|NCT00361361|Device|Excimer Laser Therapy|excimer laser is a UV 308nm laser. repeated sessions (10 sessions) needed. once per week.
45924912|NCT05463081|Other|The Short Form Health Survey|The Short Form Health Survey will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
45924913|NCT05463081|Diagnostic Test|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
45924914|NCT05463081|Diagnostic Test|Vital signs determination|Vital signs determination (respiration rate, blood pressure, pulse rate, body temperature).
45924915|NCT05463081|Diagnostic Test|pH of vagina determination|Potential of hydrogen (pH) of vagina will be investigated by test-lines paper (to evaluate procedure efficiency).
46071928|NCT05874635|Device|Continuous Glucose Monitor Device|Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.
46071929|NCT05873868|Other|Six minutes walk test|Six minutes walk test and Kansas City questionnaire just before first intake of treatment and after a year
46071930|NCT05873855|Behavioral|Para ti, para mi, para nosotros (P3)|From day 1 to day 180 (i.e., entire 6-month duration, post baseline) of the pilot trial, participants randomized to the intervention arm will have access to use the five modules as directed. The P3 intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
45649610|NCT04880993|Drug|Dapagliflozin 10 mg tablets|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd
46071931|NCT05873855|Behavioral|Waitlist Control Para ti, para mi, para nosotros (P3)|From day 91 to day 180 (i.e., starting after 3-month assessment) of the pilot trial, participants randomized to the waitlist control condition will have access to use the five modules as directed. The P3 intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
45649611|NCT04880993|Drug|Farxiga® 10 mg tablets|Manufactured by AstraZeneca Pharmaceuticals LP
45649612|NCT05183243|Drug|GH21 Capsule|GH21 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.
45649613|NCT04871555|Other|MRI|structural imaging
45649614|NCT04430231|Other|Wait list time|
45649615|NCT04936997|Biological|SARS-COV2 Pfizer Vaccine|Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
45649616|NCT04880525|Other|Dietary intervention|In accordance with Turkey Dietary Guidelines, these diet plans were designed to provide 45-60% of energy from carbohydrates, 10-20% from protein, and 20-35 percent from fat.
45649617|NCT04880369|Dietary Supplement|Soy isoflavones|Commercially available dietary supplement (capsule) containing 60 mg isoflavones (genistein, daidzein and glycitein).
45797620|NCT03003013|Procedure|Biphasic Bone Graft Material (BGM) in Combination With Autologous Platelet-rich Fibrin (PRF)|
45797621|NCT03002935|Drug|BPM31510 Oral Nanosuspension 4%|Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
45797622|NCT01647217|Drug|Terpinen-4-ol|Lid scrub once or twice per day for one month.
45797623|NCT01647217|Other|Placebo|Lid scrub once or twice per day for one month
45797624|NCT05490225|Device|Ark Implantation|"The Ark is a two-piece, porous, 3D-printed, titanium device that surrounds a segment of the access vein arising from an arterio-venous fistula. The top of the Ark has an opening designed for easy needle insertion using a standard dialysis needle. These novel features of the Ark venous access port are designed to:~Create a palpable target for easier cannulation of the access vein;~Provide protection of the side and back walls of the access vein from unintended puncture;~Reinforce the access vein by acting as an external support; Provide a porous structure designed to integrate with surrounding tissues and reduce the chance of foreign body reaction for long-term use."
45924916|NCT05463081|Diagnostic Test|Physical parameters determination|Physical parameters determination (body weight, age, height, body mass index).
45924917|NCT05539469|Device|Ortodontika app|parents will download and use Ortodontika smartphone application for all the duration of the study. It will be an aid during orthopedic treatment. During the activations, a notification will be set to remind the daily activation of RME. After the end of the activation protocol, parents will receive a notification every 2 weeks to instruct their children to proper oral hygiene maneuvers. Parents will have to show their children the videos for oral hygiene maintenance every 2 weeks until the end of the study.
45924918|NCT05539469|Other|Verbal instructions|verbal instructions will be given chairside to patients and parents regarding RME activation and its cleaning, together with instructions for daily oral hygiene manoeuvres.
45924919|NCT00056485|Behavioral|Pleasant Events-Based Behavioral Intervention|
45649618|NCT04880369|Dietary Supplement|Lignans|Commercially available dietary supplement (capsule) containing 63 mg lignans (secoisolaricirecinol)
45649619|NCT04880369|Dietary Supplement|Placebo|The placebo capsules are supplied and packaged by Region Hovedstadens Apotek (Denmark) and will contain lactose monohydrate, potato starch, gelatin, magnesium stearate and talc.
45649620|NCT04870931|Procedure|TEM / TEM-ESD|Transanal local excision of a rectal tumour as a conventional, full-thickness TEM or submucosal dissection as TEM-ESD
45649621|NCT04879901|Diagnostic Test|surface EMG|surface EMG estimation with Carrying backpacks forward or backward
45649622|NCT04738175|Biological|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
45649623|NCT04738175|Drug|Placebo|Diluent solution
45924920|NCT05437692|Drug|zimberelimab combined With concurrent radiotherapy and chemotherapy|zimberelimab: 240 mg Q2W Intravenous drip，The maximum duration of medication shall not exceed one years; chemotherapy: Starting from the first week of radiotherapy and chemotherapy, cisplatin 40mg/m2 and paclitaxel 35mg/m2 were given intravenously for 30-60min; Radiotherapy: intensity modulated radiation therapy (IMRT) was used for external irradiation. The total dose of pelvic cavity and lymph drainage planning target area (PTV) was 45-50 gy/25-28f. The metastatic lymph nodes should be able to supplement or synchronously push 10-15 Gy; The internal irradiation was started within 2 weeks after the end of external irradiation treatment. The image-guided three-dimensional brachytherapy was used, and 30-40gy was added to make the total dose of point a reach 80-85 Gy, twice a week, 5-6gy each time. All radiotherapy was completed within 8 weeks.
45797625|NCT03002779|Drug|JNJ-53718678|Participants will receive a single 500 milligram (mg) dose of 14C-JNJ-53718678 as an oral liquid solution containing 14C-labeled and unlabeled JNJ-53718678 corresponding to a radioactivity dose.
45924921|NCT00056524|Drug|AVP-923|
45797626|NCT03788291|Drug|Acalabrutinib|100 mg by mouth twice a day starting on day 8 of cycle 1
45924922|NCT00056641|Drug|tipranavir|
46071932|NCT05873829|Other|Hand-foot exercises|Hand-foot exercise program consists of 5 hand and 5 foot exercises, and a total of 15 minutes of simple hand-foot exercises. The exercise program is applied 3 times a day, 3 days a week. The tennis ball and the towel that used in the exercise program, the booklet which containing the exercise explanations and the video link showing the implementation of the exercises were provided by the researcher.
45649624|NCT03046979|Drug|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
45649625|NCT04711187|Drug|AT-527 Formulation 1|AT-527 Formulation 1 (R07496998)
45649626|NCT04711187|Other|Placebo Comparator|Placebo Comparator
45649627|NCT04711187|Drug|AT-527 Formulation 2|AT-527 Formulation 2 (R07496998)
45797627|NCT03788291|Drug|Rituximab|Administered 2 times weekly for 6 cycles. Initial dose day 1: 50 mg IV, then 50 mg SQ thereafter.
45450467|NCT04238260|Behavioral|Enhancing Physical Therapy Usual Care|The protocol is focused on the completion of a minimum of 30 minutes of weight-bearing, walking-related activities that progressively increase in intensity informed by heart rate and step counters over 4 weeks.
45797628|NCT05488977|Behavioral|Exercise training|8 weeks of supervised high-intensity interval training (HIIT).
45649628|NCT04676399|Drug|Hydrochlorothiazide 12.5mg|2 pills/day (1 pill every morning and 1 pill every evening) for 14 days.
45797629|NCT03002467|Other|PESI score|
45797630|NCT03784625|Drug|[131I]ICF01012 (therapeutic dose level 1)|"1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)~1 therapeutic injection (D11) at a dose of 800 MBq/m²"
45797631|NCT03784625|Drug|[131I]ICF01012 (therapeutic dose level 2)|"1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)~1 therapeutic injection (D11) at a dose of 1600 MBq/m²"
45797632|NCT03784625|Drug|[131I]ICF01012 (therapeutic dose level 3)|"1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)~1 therapeutic injection (D11) at a dose of 2700 MBq/m²"
45797633|NCT03784625|Drug|[131I]ICF01012 (therapeutic dose level 4)|"1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)~1 therapeutic injection (D11) at a dose of 4000 MBq/m²"
45450468|NCT04238260|Behavioral|Physical Therapy Usual Care|Usual physical therapy
45649629|NCT04676399|Drug|Placebo|2 pills/day (1 pill every morning and 1 pill every evening) for 14 days
45797634|NCT04593459|Dietary Supplement|Probiotic|See Arm description
45797635|NCT04593459|Drug|Metformin Hydrochloride|See Arm description
45797636|NCT04593459|Dietary Supplement|Probiotic Placebo|See Arm description
45924923|NCT00056641|Drug|ritonavir|
45924924|NCT00056641|Drug|saquinavir|
45924925|NCT00056641|Drug|amprenavir|
45649630|NCT04880213|Drug|M5049|Participants will receive single oral dose of film-coated tablet M5049 at low dose on Day 1 under fasted condition.
45649631|NCT04880213|Drug|M5049|Participants will receive single oral dose of film-coated tablet M5049 at medium dose on Day 1 under fasted condition.
45649632|NCT04880213|Drug|M5049|Participants will receive single oral dose of film-coated tablet M5049 at high dose on Day 1 under fasted condition.
45649633|NCT03047057|Drug|Lidocaine|IV Lidocaine infusion
45649634|NCT03047057|Drug|IV normal saline|IV normal saline infusion
45649635|NCT04630847|Biological|Fecal Microbiota Transplant|FMT utilizing stool from first degree relatives
45649636|NCT04430309|Behavioral|Baduanjin exercise program|The sessions includes 10-minute warm-up, 40-minute Baduanjin exercise and 10-minute cool down.
45649637|NCT04430309|Behavioral|Brisk walking program|The sessions includes 10-minute warm-up, 40-minute brisk walking and 10-minute cool down.
45649638|NCT04880135|Other|Supervised stretching and strengthening exercise|The structure of the supervised exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
45924926|NCT00056641|Drug|lopinavir|
45924927|NCT05509283|Behavioral|Risk Reduction|Letter, patient portal, SMS and/or another modality
45924928|NCT05433714|Other|Assesment|The figure of walk test, Berg Balance scale, Timed 25-Foot Walk, Timed up and go test, Foursquare walk test
45924929|NCT00056680|Behavioral|Psychoeducational video|
45924930|NCT00056680|Behavioral|Infant massage|
45924931|NCT00056680|Behavioral|Brazelton Neonatal Behavioral Assessment Scale|
45924932|NCT00398437|Biological|trastuzumab|
45924933|NCT00398437|Drug|chemotherapy|
45797637|NCT04120883|Drug|Hydroxychloroquine lower dose|The participants weight will be measured and converted to kilograms. The participants will receive 4 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily.
45924934|NCT00398437|Procedure|magnetic resonance imaging|
45924935|NCT05503862|Device|YoSperm|The purpose of the app is for at-home semen analysis including sperm motility concentration and sperm quality (YO Score) and compares the results to laboratory standards. We will be utilizing the YoSperm® technology in order for patients to send their semen analysis results directly from their device to their provider via secure email.
45924936|NCT05433675|Drug|Macitentan|Macitentan dispersible and film-coated tablets will be administered orally as per assigned treatment sequence.
45924937|NCT00423631|Behavioral|Standard care and web|A static web site containing cognitive and behavioral self management instructions.
45924938|NCT00423631|Behavioral|Standard Care|Standard care delivered by the primary care provider.
45649639|NCT04880135|Other|Home-based stretching and strengthening exercise|The structure of the home based exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
45924939|NCT00423709|Procedure|Allogeneic Blood Stem Cell Transplantation|
45797638|NCT04120883|Drug|Hydroxychloroquine higher dose|"The start of intervention for treatment arm 2 of the study will be delayed until preliminary safety of the drug is established with the 6 patients in treatment arm 1 at the first follow-up visit (4 months).~The participants in this group will receive 5 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily."
45797639|NCT01651195|Dietary Supplement|Probiotic|
45797640|NCT01651195|Other|Placebo|
45797641|NCT04744961|Other|SCAR-Q survey|Telephone survey
45924940|NCT00423709|Drug|Fludarabine|
45924941|NCT00423709|Drug|Melphalan|
45924942|NCT05499143|Other|Online questionnaire|Online questionnaire impact for DCD - Belgian version
45924943|NCT00056758|Biological|Autologous Dendritic Cell HIV Vaccination|
45924944|NCT05433636|Behavioral|Body Scan|Patients will listen to a 5-minute, audio-recorded body scan practice.
45924945|NCT05433636|Behavioral|Mindful Breathing|Patients will listen to a 5-minute, audio-recorded mindful breathing practice.
45924946|NCT05433636|Behavioral|Mindfulness of Discomfort|Patients will listen to a 5-minute, audio-recorded mindfulness of discomfort practice.
45924947|NCT05433636|Behavioral|Mindful Savoring|Patients will listen to a 5-minute, audio-recorded mindful savoring practice.
45924948|NCT05433636|Behavioral|Integrative Health Recording|Patients will listen to a 5-minute, audio-recorded description of integrative health.
45924949|NCT00056797|Biological|ALVAC HIV vaccine (vCP1452)|
45924950|NCT00056797|Drug|Interleukin-2|
45924951|NCT00056836|Drug|rhuFab V2 (ranibizumab)|
45924952|NCT05495321|Drug|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10~6 IU once every other day, for 6 months.
45924953|NCT00056875|Drug|recombinant human keratinocyte growth factor|
45924954|NCT00056953|Behavioral|Peer mentoring program|
45924955|NCT00056992|Drug|ADI-PEG 20|
45924956|NCT02969902|Device|Buzzy® device|
45924957|NCT02969902|Device|Hand-held computer|
45924958|NCT05410197|Drug|Envofolimab|400mg by subcutaneous injection every 3 weeks
45924959|NCT05410197|Drug|Lenvatinib|8 mg orally once a day
45924960|NCT05410197|Drug|Gemcitabine|1000mg/m2 by intravenous infusions on day 1 and 8 every 3 weeks for up to 24 weeks
45924961|NCT05410197|Drug|Cisplatin|25mg/m2 by intravenous infusions on day 1 and 8 every 3 weeks for up to 24 weeks
45924962|NCT03262454|Drug|Atezolizumab|Patients undergo hypofractionated radiation therapy with 24 Gy over 4 fractions in days 1-4 of 1st cycle of atezolimumab and receive Atezolizumab 1200 mg fixed dose via intravenous on day 1 of each 3-week cycle until disease progression or unacceptable toxicity occurs.
45924963|NCT00057031|Drug|DN-101 (calcitriol)|
45924964|NCT00057070|Procedure|Smoking cessation information, collection, and dissemination|
46071933|NCT05873777|Diagnostic Test|18F-FDG PET/CT, 68Ga-FAPI-LM3 PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-LM3, and undergo PET/CT imaging within the specified time. A part of participants will undergo additional 68Ga-FAPI-46 PET/CT for comparison.
45924965|NCT00057148|Procedure|massage treatment|
45924966|NCT05487170|Drug|RNK05047|RNK05047 is a chaperone-mediated protein degrader administered as IV infusion once weekly for 3 consecutive weeks in a 4-week cycle (no treatment in the fourth week).
45924967|NCT05407038|Other|Exercise Counseling|Receive call from health coach
45924968|NCT05407038|Other|Exercise Intervention|Undergo routine exercise
45924969|NCT05407038|Other|Internet-Based Intervention|Receive Android tablet
45924970|NCT05407038|Other|Interview|Complete a qualitative interview
45924971|NCT05407038|Other|Medical Device Usage and Evaluation|Wear Garmin Vivofit and Nonin 3150 WristOx2 pulse oximeter
45924972|NCT05407038|Other|Questionnaire Administration|Ancillary studies
45649640|NCT04870619|Other|High Intensity Gait Training|The intervention provided in this project is routinely delivered as a standard of care at the participating sites for patients after stroke that have a goal of walking improvement. The intervention consists of 45-60 minute, physical therapy sessions that occur five days per week (not weekends), focusing on prioritizing stepping practice at higher aerobic intensities during scheduled treatments (target training zone of 70-85% heart rate max (HRmax). Stepping is performed on treadmills and over ground, with safety harness systems and body weight support only as needed to ensure successful stepping. Tasks are progressed by increasing task difficulty as determined by the therapist. Accordingly, practice of non-walking tasks performed during physiotherapy, including bed mobility, transfers, and standing balance/ pre-gait activities, is limited.
45924973|NCT00057187|Behavioral|Contracting, Prompting and Reinforcing|
45924974|NCT00057226|Drug|Radafaxine|
45649641|NCT04879667|Procedure|endoscopic management of gastrocutaneous fistula after laparoscopic sleeve gastrectomy|we performed upper GI endoscopy to all cases first to assess the site , size and cause of fistula . we used stents , clips , sutures and ballon dilatation to close the fistula according to size , site and cause of fistula.if the fistula had no track that was proved by CT with oral & I.V contrast , we used the endoscopic stent. if the fistula had track that was proved by CT with oral & I.V contrast , we used the OVASCO clip , endo suturing or ballon. Combined maneuvers may be used like ballon dilation and clipping or ballon dilatation and suturing if there was distal narrowing.
45649642|NCT04550195|Drug|BMS-986337|Specified Dose on Specified Days
45924975|NCT02969980|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg/day i.v. daily on days 3 and 4 of hematopoietic cell transplantation
45924976|NCT05486897|Other|None, pure observational study|None, pure observational study
45924977|NCT05388864|Behavioral|Three-Tier Model|Families in the intervention will be counseled by a pediatric provider about ACEs, resilience, stress management, and healthy relationships. Families will also be referred to community health workers and parenting educators.
45924978|NCT00057265|Drug|telbivudine or lamivudine|
45924979|NCT00057343|Drug|Zevalin (ibritumomab tiuxetan)|
45924980|NCT00057343|Drug|Rituxan (rituximab)|
45924981|NCT05452811|Procedure|Burch colposuspension|Anti-incontinence surgery for stress urinary incontinence
45924982|NCT00057382|Drug|T138067 intravenous|
45924983|NCT00057382|Drug|doxorubicin intravenous|
45924984|NCT05447741|Diagnostic Test|Quantitative Ultrasound|Shear Wave Elastography acquisition. RF data acquisition (for HDK parameters calculation).
45924985|NCT04733859|Dietary Supplement|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
45924986|NCT04733859|Dietary Supplement|red djulis drinks|subjects drank 50 ml , 1 bottle a day for 8 week
45924987|NCT00057421|Drug|prednisolone|
45924988|NCT00057460|Drug|Talampanel|
45924989|NCT00057499|Biological|IBC-VS01|IBC-VS01
45924990|NCT00057499|Biological|IBC-VS01 placebo|IBC-VS01 placebo
45924991|NCT00057538|Behavioral|Mantram Repetition|
45924992|NCT00057616|Drug|CC-5013|
45924993|NCT05349864|Drug|PF-07284890 Treatment A|PF-07284890 tablet by mouth while fasting
45924994|NCT05349864|Drug|PF-07284890 Treatment B|PF-07284890 tablet after low fat meal
45924995|NCT05349864|Drug|PF-07284890 Treatment C|PF-07284890 tablet after high fat meal
45924996|NCT02969746|Drug|Activated Charcoal|"Patients will take oral activated charcoal after randomization in the intervention arm.~A blood sample(TO) will be collected after patient enrollment and before charcoal administration and 4 blood samples will be collected on a 8h length period (T1 to T4)"
45924997|NCT00389714|Device|dental restoration|
45924998|NCT05310747|Behavioral|Artwork present|A virtual museum exhibit with a curated selection of artworks
46071934|NCT05873556|Behavioral|Lab-based Cue Reactivity Personalized Feedback Intervention (PFI)|This is an online personalized feedback intervention that contains information summarizing participants' desire to drink, mood, willingness to drink, and alcohol demand as reported before and after alcohol exposure.
46071935|NCT05873491|Other|Music therapy|The music therapy sessions will offer sensory workshops of immersive musical listening, digital and acoustic music creation and shared improvised music.
46071936|NCT05872958|Drug|AZD3152|AZD3152 will be administered via IM injection or IV infusion, as per the assigned arms.
45797642|NCT04593303|Procedure|Internal iliac artery ligation with cervicoisthmic compression suture|Retroperitoneal approach will be performed to ligate both internal iliac arteries before bladder dissection followed by cervicoisthmic compression suture application at placental bed
45924999|NCT05310747|Behavioral|Artwork absent|The same virtual museum exhibit space as the 'Artwork present' condition but with all of the artworks removed from the walls
45925000|NCT05310747|Behavioral|Social connection high|Participants will identify a person from their life that makes them feel socially connected and then write (1) about that person and (2) an experience they had with that person that made them feel socially connected.
45925001|NCT05310747|Behavioral|Social connection low|Participants will identify a person from their life that makes them feel socially disconnected and then write (1) about that person and (2) an experience they had with that person that made them feel socially disconnected.
45925002|NCT00057733|Procedure|psychosocial assessment and care|
45925003|NCT00057733|Procedure|quality-of-life assessment|
45649643|NCT04550195|Other|BMS-986337 Placebo|Specified Dose on Specified Days
45649644|NCT04550195|Biological|Famotidine|Specified Dose on Specified Days
45797643|NCT04593303|Procedure|Cervicoisthmic compression suture without Internal iliac artery ligation|Bladder dissection followed by cervicoisthmic compression suture application at placental bed without Internal iliac artery ligation
45925004|NCT00057850|Drug|cisplatin|
45925005|NCT00057850|Drug|ixabepilone|
45649645|NCT04525391|Drug|Durvalumab+AZD2811 to SCLC patients|AZD2811 must NOT be infused through a 0.2-µm or 0.22-µm filter and therefore durvalumab and AZD2811 MUST be infused through different infusion lines. In order not to exceed the endotoxin limit, durvalumab and AZD2811 mustbe administered consecutively. Durvalumab is administered first over 1 hour, followed by AZD2811 administered over 2 hours. AZD2811 should be administered at 30 minutes after the end of the durvalumab infusion, as long as there are no acute infusion reactions to durvalumab.
45797644|NCT03775109|Drug|Canakinumab 150mg/ml solution for injection|Canakinumab 150mg/ml solution for injection
45925006|NCT00057889|Biological|ipilimumab|
45925007|NCT05436314|Other|Manual Lymphatic Drainage|Manual Lymphatic Drainage (MLD) is applied towards the flow direction of lymph vessels with special hand movements. MLD is made with very light, completely painless and rhythmic translational movements of the skin. MLD, by expert and trained physiotherapists (G.K, H.K) in this field. It will be applied with the techniques defined by Dr. Vodder. MLD ( to the neck region, abdominal region, axillary and inguinal lymph nodes) will be applied by following the lymphatic pathways specific to the anterior and posterior trunk, respectively. The treatment session will take approximately 45 minutes. It will be applied 5 days a week during 3 weeks.
45925008|NCT05436314|Drug|Medical treatment|The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
45797645|NCT03775109|Drug|Placebo|100ml 5% Dextrose
45797646|NCT03251924|Drug|BMS-986226|specified dose on specified days
45797647|NCT03251924|Biological|Nivolumab|specified dose on specified days
45797648|NCT03251924|Biological|Ipilimumab|specified dose on specified days
45797649|NCT03251924|Biological|Tetanus Vaccine|specified dose on specified days
45797650|NCT04591119|Procedure|Transversus Thoracic Muscle Plane Block|40 ml %0.375 bupivacaine divided into 4 equal doses will be injected by the surgeon between internal intercostal muscle and transversus thoracis muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space
45797651|NCT04591119|Procedure|Parasternal Intercostal Plane Block|40 ml %0.375 bupivacaine injection will be performed by ultrasound guidance after completion of surgery between psoas major muscle and external intercostal muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space bilaterally by anesthesiologist.
45797652|NCT01651351|Biological|Alpha1-proteinase inhibitor|GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.
45797653|NCT01651351|Biological|Placebo: Human albumin 2.5%|Intravenous administration
45925009|NCT05436314|Other|Sham Manual Lymphatic Drainage|Sham MLD will be administered by MLD-trained physiotherapists (G.K, H.K) with a protocol that is far from techniques that reveal the physiological effects of MLD. Sham application consists of applications that do not follow the lymphatic pathways from distal to proximal to the trunk, neck, and abdominal region, and superficial breathing. The session will take approximately 45 minutes.
45925010|NCT00057928|Drug|cisplatin|
45925011|NCT00057928|Drug|gemcitabine hydrochloride|
45925012|NCT00057928|Drug|paclitaxel|
45925013|NCT05309304|Drug|Cefazolin|Cefazolin Injection - 2 g/100 mL or 3 g/150 mL
45925014|NCT05436041|Behavioral|Collaborative Diet Goal Setting Clinical Decision Support|Receives Nutri
45925015|NCT00057967|Biological|alemtuzumab|Will be administered as a two-hour IV infusion with a target dose of 30 milligrams three times a week for a maximum of 12 weeks.
45925016|NCT00058006|Drug|celecoxib|
45925017|NCT00058006|Procedure|adjuvant therapy|
45925018|NCT00058045|Biological|aldesleukin|
45925019|NCT00058045|Biological|recombinant human stem cell factor|
45925020|NCT00058084|Drug|ixabepilone|Given IV
45925021|NCT00058084|Drug|mitoxantrone hydrochloride|Given IV
45925022|NCT00058084|Drug|prednisone|Given orally
45925023|NCT05273892|Behavioral|Diet + Activity + Sleep|Personalized lifestyle behavior change counselling
45925024|NCT05273892|Behavioral|Diet + Activity|Personalized lifestyle behavior change counselling
45925025|NCT02969629|Drug|Apomorphine|
45925026|NCT02969629|Drug|Normal Saline|
45925027|NCT00058201|Drug|fluorouracil|Given IV
45925028|NCT00058201|Drug|gemcitabine hydrochloride|Given IV
45925029|NCT00058201|Drug|leucovorin calcium|Given IV
45925030|NCT00058201|Other|clinical observation|No intervention
45925031|NCT00058279|Biological|aldesleukin|
45925032|NCT00058279|Biological|ipilimumab|
45925033|NCT05272332|Diagnostic Test|Gastric ultrasound|Gastric ultrasound upon fasting, after 4 hours, and after nasogastric aspiration, to estimate gastric volume
45925034|NCT00058318|Drug|capecitabine|Capecitabine will be given 625 mg/m^2 (1250 mg/m^2/day) by mouth twice a day on day 1-21 for every cycle (1 cycle =28 days) until disease progression
45925035|NCT00058318|Drug|gemcitabine hydrochloride|Gemcitabine will be given 900 mg/m^2 by intravenous infusion over 30 minutes on day 1, 8, and 15 for every cycle (1 cycle = 28 days) until disease progression.
45649646|NCT04870697|Behavioral|ACT intervention|"The components of ACT intervention will include six processes to foster parental PF according to the ACT framework.~Session one - Generate creative hopelessness and build acceptance. The objective is to help parents know about the ACT intervention and realize the experiential avoidance or emotional control strategies do not work, finally turn attention to more useful strategies.~Session two - Create space for your thought. The objective is to help parents create a distance from their thoughts and facilitate parents' ability of not being trapped by thoughts.~Session three - Focus on here and now. The objectives to facilitate parents' experiences of observing self and contact with the present moment but not trapped in the past or future.~Session four - Commit actions in line with the value. The objectives to help parents identify their inner value and take value-based actions even facing the challenges in current difficulties of their children with cancer."
45649647|NCT04870697|Other|Usual care|Usual care in this study setting includes providing general information, education, psychological support, and consultation.
45649648|NCT04505423|Procedure|Blind CSF Drain Placement|CSF Drain placement without fluoroscopic image guidance.
45649649|NCT04505423|Procedure|Fluoroscopy-guided Drain Placement|CSF Drain placement utilizing fluoroscopic image guidance.
45797654|NCT03774329|Other|Usual care|Patients included in the control group will not benefit from the intervention in adapted physical activity. However, this will not affect their support. Patients will be seen by their specialist doctor as part of the usual management of their IBD.
45797655|NCT03774329|Other|adapted physical activity|Patients in the experimental group will have, in addition to their usual follow-up with their specialist doctor, an intervention in adapted physical activity at home, at the rate of 3 sessions (of a duration of 10 to 20 minutes) per week during 9 consecutive months.
45797656|NCT04580511|Device|CELLIS (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in abdominal reconstruction
45925036|NCT00058357|Drug|lidocaine|
45925037|NCT00058357|Other|placebo|
45925038|NCT00389753|Drug|Application of Aruba Aloë formula F-BC-096 or control|
45925039|NCT00392145|Drug|Standard IV rehydration|A 20 mL/kg 0.9% normal saline bolus (maximum 999 mL) will be administered over 1 hour. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
45925040|NCT00392145|Drug|Rapid intravenous rehydration (RIVR)|A 60 mL/kg 0.9% normal saline bolus (maximum 999 mL) over 1 hour will be administered. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
45925041|NCT00058396|Biological|lumiliximab|
45925042|NCT05413460|Device|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given during surgery.
45450469|NCT01083797|Drug|Dexmedetomidine|1 μg kg-1 infused in 10 min, and thereafter maintained from 0.2 to 0.7 μg kg-1 h- 1
45649650|NCT04879511|Drug|metformin|Oral hypoglycemic drug metformin
45797657|NCT03172195|Procedure|rectosigmoidoscopy|A rectosigmoidoscopy will be realized and two fragments will be collected.
45797658|NCT03172195|Biological|biopsies|For this study, two biopsies in healthy area and two biopsies in ulcer will be collected.
45450470|NCT01083797|Drug|Chloral Hydrate|Initial dose=50 mg/kg
45797659|NCT03172195|Biological|blood sample|Blood sample will be collected in more.
45797660|NCT03762317|Drug|Clonidine|clonidine will be given at 12 mcg/kg/d to the experimental arm in addition to oral morphine
45797661|NCT03762317|Drug|Placebo|Placebo with volume similar to clonidine at 12 mcg/kg/d will be given to this arm in addition to oral morphine
45450471|NCT01083875|Drug|amlexanox|0.5% amlexanox oral rinse; use 5 ml every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid was be swirled around the mouth then to be swallowed. Repeated daily until completion of radiation therapy: approximately 7-8 weeks.
45450472|NCT01083875|Drug|Vehicle rinse|use 5 ml of the vehicle rinse every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid is be swirled around the mouth then swallowed.
45450473|NCT04325464|Device|PEAR-003A|PEAR-003A delivers CBT-I through a decentralized clinical trial open to participants with chronic insomnia
45649651|NCT04879511|Drug|Basal/bolus insulin|Basal/bolus insulin
45797662|NCT04383639|Other|No product (A)/mixture of coca and carob together with breakfast (B)/mixture of coca and carob 10 h before breakfast (C)|The subjects will receive, after overnight fasting, a high-fat high-sugar breakfast. In treatment A, they will not receive any additional product; in treatment B, they will receive at the same time a mixture of coca and carob; in treatment C, they will receive the mixture of coca and carob 10 h before breakfast. A total of 6 blood samples will be collected during each visit: 0-30-60-120-180-240-270 min. Urine samples will be collected during the permanence of the subjects in the Unit of Human Nutrition. Feces will be collected the first time they are generated after treatments A and C. Both interventions will be separated by two weeks. Subjects will be instructed not to modify their dietary habits during the development of the study, but during the 72 h before each visit they will have to restrict the intake of polyphenol-rich foods (a detailed list will be provided).
45797663|NCT03083431|Drug|Propranolol|Oral propranolol (1.6 mg propranolol-hydrochloride/kg/d in 4 divided dosages)
45925043|NCT00058435|Biological|abagovomab|
45925044|NCT00392184|Procedure|Accelerated partial breast irradiation|
45925045|NCT00058474|Drug|capecitabine|825 mg/m2 oral daily 5 days a week on days of planned RT
45925046|NCT00058474|Drug|fluorouracil|225 mg/m2 IV daily continuous infusion
45925047|NCT00058474|Drug|oxaliplatin|50 mg/m2 IV 5 days a week on days of planned RT
45925048|NCT00058474|Radiation|radiation therapy|Given 5 days a week for 5-6 weeks
46071937|NCT05872958|Other|Placebo|Placebo is a matching volume of 0.9% sodium chloride, will be administered via IM injection or IV infusion, as per the assigned arms.
45797664|NCT03083431|Drug|Placebo|Oral solution containing the same excipients as propranolol solution
45925049|NCT00058591|Biological|Intravenous injection of EBV specific CTLS|"The dose levels for this study are as follows:~Level Dose~2 x 107 CTLs/m2~5 x 107 CTLs/m2~1 x 108 CTLs/m2~If patients have a clinical response to the first infusion defined by an improvement in the fatigue score or resolution of clinical abnormalities such as lymphadenopathy or an improvement in laboratory parameters such as a decrease in VCA titer or reduction in free EBV DNA they will be eligible to receive up to 3 additional injections of CTLs at the original dose at 3 monthly intervals."
45925050|NCT00392262|Drug|valsartan + amlodipine|
45925051|NCT00058747|Drug|Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™.|
46071938|NCT05872802|Other|eccentric exercises and electrical stimulation|Eccentric exercises and strengthening currents to improve ankle dorsiflexion in professional padel players.
46071939|NCT05872802|Other|proprioceptive neuromuscular facilitation|proprioceptive neuromuscular facilitation to improve ankle dorsiflexion in professional padel players.
46071940|NCT05870865|Drug|ASN008|ASN008 topical gel applied twice daily.
46071941|NCT05870865|Other|ASN008 Matching Vehicle|The ASN008 matching vehicle formulation matches the formulation of each ASN008 topical gel dose, but contains no ASN008.
46071942|NCT05864391|Drug|AZD7503|Each participant is expected to be in the study for approximately 24 weeks, including a screening period of up to 28 days, a 12-week study intervention period, and a follow-up visit at week 18 (10 weeks following the final dose). Participants will be randomly assigned in a 3:1 ratio to receive AZD7503 or placebo. Study intervention will be administered via subcutaneous injection.
46071943|NCT05862727|Behavioral|Telehealth Intervention|Telehealth intervention that teaches caregivers evidence-based skills and provides practice opportunities to manage their children's ADHD-related behaviors according to their assigned intervention.
45797665|NCT04535999|Drug|Secukinumab Auto-Injector|300 mg- Every 4 weeks after loading dose (Loading Dose-300 mg once weekly for 5 weeks)
46071944|NCT05861076|Other|Moringa Powder - Low Dose|1 teaspoon Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
45797666|NCT01910792|Device|Sperti Lamp|UV light exposure 3 times per week for 12 weeks
45797667|NCT04330911|Procedure|Aerobic Exercise|Exercise loading is determined by increasing the heart rate. This loading calculated by Karvonen formulas (maximum %80 of Heart Rate)
46071945|NCT05861076|Other|Moringa Powder - Medium Dose|2 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
45450474|NCT01068977|Drug|bevacizumab|Repeating intravenous dose
45450475|NCT01068977|Drug|MetMAb|Repeating escalating intravenous dose
45450476|NCT01068977|Drug|MetMAb|Repeating intravenous dose
45450477|NCT02190370|Behavioral|Resources activation|
45450478|NCT03964103|Dietary Supplement|gQ-lab daily|probiotics
45450479|NCT03964103|Dietary Supplement|Placebo|powdered skim milk, lactose
45450480|NCT02184910|Drug|pepsinogen and gastrin|
45450481|NCT00291551|Device|Placement of the PVSS Implant|Implant is placed on epicardial surface of the heart surrounding both the right and left ventricles, to provide mechanical support to the ventricular walls.
45450482|NCT02185924|Drug|Parecoxib|
45797668|NCT03038269|Behavioral|Upper Extremity Robotics, tDCS|Participant will receive 20 minutes of non-invasive brain stimulation followed by one hour of shoulder/wrist robotic training.
45797669|NCT02975921|Drug|Povidone-Iodine|Intrapleural administration of Povidone-Iodine
45797670|NCT05452785|Drug|DFD-29 (Minocycline) Fasting|In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
45450483|NCT02185924|Drug|CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%|
45450484|NCT02185924|Drug|N/S 0.9%|
45797671|NCT05452785|Drug|DFD-29 (Minocycline) Fed|In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast and 30 minutes after the start of a high-fat, high-calorie breakfast.
45797672|NCT05452785|Drug|Solodyn (Minocycline) Fasting|In each study period, a single 105 mg dose of SOLODYN® Tablets will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
45797673|NCT03002545|Dietary Supplement|Magnesium citrate|
45797674|NCT03002545|Dietary Supplement|Placebo|
45797675|NCT05217849|Behavioral|Tai Chi|Tai Chi is an ancient Chinese form of exercise/martial art that involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
46071946|NCT05861076|Other|Moringa Powder - High Dose|3 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
46071947|NCT05859958|Other|No Intervention|Difference in outcomes in patients with COVID-19 diagnosis and ABO blood groups
46071948|NCT05859880|Behavioral|Expressive writing intervention|4 videoconference-delivered group-based expressive writing sessions
46071949|NCT05859737|Behavioral|Disaster Preparedness Education Program|The SIMAH Program includes interactive group training for three months, public education materials prepared by AFAD, and reminder phone messages will apply.
46071950|NCT05859737|Other|Disaster and Emergency Management Presidency Education|Public education materials prepared by the Disaster and Emergency Management Presidency (AFAD) will give.
46071951|NCT05859009|Procedure|EUS-Guided Therapy of Glue and Coil|This clinical trial aims to evaluate the effectiveness and safety of endoscopic ultrasound (EUS)-guided therapy of glue and coil in the management of gastrointestinal bleeding due to varices. The procedure involves the insertion of a catheter through an endoscope to deliver glue and/or coils to the bleeding site, under EUS guidance. Patients who meet the inclusion criteria will undergo EUS-guided therapy of glue and coil, followed by follow-up assessments to evaluate the outcomes of the procedure, including bleeding recurrence and adverse events.
46071952|NCT05859009|Drug|Non-Selective Beta Blockers (Propanolol)|Participants in this arm will receive a daily oral dose of a non-selective beta blocker (such as propranolol) for the duration of the study. Participants will be monitored for side effects and efficacy of the medication.
45925052|NCT00058786|Biological|Injection of IL-2-secreting CD40L-expressing autologous B-CLL cells|Patients may be treated with a minimum of three up to six injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window, i.e. in the absence of concurrent cytotoxic therapy. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol (see Section 5.8), determined by previous studies in acute leukemia and in neuroblastoma, in which this level of IL-2 production has been safe. The dose escalation of CD40L-expressing cells is designed to reach the IL2/CD40L ratio shown to be effective in our preclinical models of neuroblastoma and lymphoma.
45925053|NCT00058864|Device|Energy absorbing and distributing trochanteric pad|
45925054|NCT02969551|Device|Manometry and possibly DISE|A Manometry is performed on all patients. After it in some Patient DISE is followed
45925055|NCT05393141|Behavioral|diet and biopsychosocial exercise intervention|dietary intervention: biopsychosocial exercise intervention:
45797676|NCT05217849|Behavioral|Preventing Loss of Independence through Exercise (PLIE)|PLIE is a gentle, mindful movement exercise program that integrates elements of Eastern and Western exercise modalities to develop mindful body awareness and enhance social connection.
45925056|NCT00058903|Drug|sertraline|
45925057|NCT00058942|Device|home drinking water treatment device|
45925058|NCT00058981|Drug|DiaPep277|
45925059|NCT02969473|Drug|Docetaxel|"Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the DP group received two cycles of DP regimen (docetaxel 60 mg/m2 delivered on day 1 and cisplatin 80 mg/m2 delivered on day 1) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle."
45925060|NCT02969473|Drug|Fluorouracil|"Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the PF group received two cycles of PF regimen (cisplatin 80 mg/m2 delivered on day 1 and 5-FU 1000 mg/m2 continuous infusion over 24 hours daily on days 1-4) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle."
45925061|NCT03254264|Behavioral|Early Start Denver Model|"ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM at minimum 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery."
45925062|NCT03254264|Behavioral|'as-usual' intervention|a control group receiving typical heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period.
45925063|NCT00059254|Dietary Supplement|Oleic acid (OA)|OA-enriched (HI OA; fat, 40%; PA, 1.7%; OA, 31.4%)
45797677|NCT05217849|Behavioral|Health and Wellness Education|This on-line class will consist of hour-long lectures/talks about various topics related to healthy aging and wellness.
45925064|NCT00059254|Dietary Supplement|Palmitic Acid (PA)|PA-enriched (HI PA; fat, 40% of energy; PA, 16.8%; OA, 16.4%)
45925065|NCT00059371|Procedure|male circumcision|
45925066|NCT01349907|Drug|Asenapine|One flavored asenapine sublingual tablet (containing either 2.5, 5 or 10 mg asenapine) twice daily (BID), starting at 2.5 mg on Day 1 for three consecutive days. Normally on Day 4, the dose will increase to 5 mg BID beginning with the evening dose. Normally on Day 7, the dose will increase to 10 mg BID beginning with the evening dose. The dose may be up-titrated earlier than Days 4 and 7 at the investigator's discretion. Beginning on Day 8 (or after at least 1 day on 10 mg BID), asenapine dosing will be flexible (2.5, 5, or 10 mg BID) until up to Week 50.
45925067|NCT01349907|Drug|Rescue medication|For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines (i.e., lorazepam [up to 4 mg/day] or an equivalent dose of short-acting benzodiazepines) and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
45925068|NCT05368025|Device|Mobili-T/Noona|Use of two mobile health systems over a period of 6 months
45925069|NCT02969434|Other|Sleep assessment tools|Interventions are 3 tools to assess sleep: Verran Snyder Halpern sleep scale, the Pain and Sleep Questionnaire 3 Item Index (PSQ-3) and the Pittsburg Sleep Quality Index (PSQI).
45925070|NCT00059527|Behavioral|Healthy Youth Places: a behavior change model|
45797678|NCT03002701|Behavioral|UNDERPIN-ICU program|UNDERPIN-ICU consists of standardized protocols focusing on several modifiable risk factors for delirium, including cognitive impairment, sleep deprivation, immobility and visual and hearing impairment.
45797679|NCT04527185|Drug|Endotoxin|Endotoxin 0.4ng/kg i.v.
45797680|NCT01932242|Biological|ETI-204|Monoclonal Antibody
45925071|NCT02969278|Procedure|18FDG-PET/TC|Nuclear medicine exam (18FDG-PET/TC) to assess the status of the regional groin and pelvic lymphnodes
45925072|NCT02969278|Procedure|Sentinel node biopsy|Intradermal injection of 0.2 ml 37-148 MBq of radiocolloid and a blue dye near the tumor to locate the position of the sentinel lymph node. Intraoperatively, sentinel node localization is guided by a gamma probe and by the eyes of the surgeon who detects the lymph nodes that are stained with the blue dye.
45925073|NCT05364476|Behavioral|16 weeks digital intervention|"Participants will be enrolled into a 16-week program which consist of an online and offline support from health coaches and dietitian. Participants will be given diet and exercise recommendations and lesson plans on a weekly basis by the health coaches, and supported by the dietitian.~Participants will be required to log in their blood sugar levels, weight and steps daily using connected device, including glucometer, smart band and body fat weighing scale provided into the daily report card. They will also be required to manually record their meals and exercise daily in the daily report card provided upon enrollment into study. Reviews of log will be done on a weekly/biweekly interval by the health coaches."
45925074|NCT00059605|Genetic|DOTAP:Chol-fus1|Infusion of DOTAP:Chol-fus1 by vein once every 3 weeks.
45925075|NCT05228262|Other|Cohort follow-up|"Inclusion medical consultation,~Inclusion clinical examination,~Collection of biological samples (bone biomarkers, epigenetic biomarkers (microRNA)) and analysis of microbiota and genotyping,~Calculation of the Kauppila score on profile spine radiographs by the rheumatologist,~Cardiovascular investigations (FMD, Flow-Mediated Dilation); measurement of digital volume increase (RHI, Reactive hyperhemia index); measurement of microcirculatory perfusion of the skin at the hand (FLD, Flow Laser Doppler) ; measurement of the stiffness of the main arteries (aorta) by the Pulse Wave Velocity (PWV),~Exploration of sarcopenia: questionnaires and tests: SARC-F, SPPB, muscle strength,~Quality of life component questionnaires Pittsburgh Sleep (PSQI), Numerical Scale (NS), Brief Pain Inventory (BPI), Hospital Anxiety and Depression scale (HADs), and 36-Item Short Form Survey (SF-36) Quality of Life Questionnaire."
45925076|NCT00059644|Drug|Ecraprost in lipid emulsion|
45925077|NCT00059683|Procedure|cervical cerclage|Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix
45649652|NCT04361825|Drug|Durvalumab|Durvalumab 1500mg via IV administered for every 4weeks(fixed dosing for subjects > 30 kg body weight) in Day 1 of each cycle and AZD 6738 240mg bid per os administered in each cycle days 15 and 28. One cycle is consisted of 28 days.
45797681|NCT01932242|Other|Placebo|Placebo for ETI-204
45649653|NCT03048695|Behavioral|GMT|Metacognitive strategy training where the primary objective is to stop ongoing behavior to define goal hierarchies and monitor performance
45649654|NCT03046901|Drug|Vancomycin|Vancomycin belongs to the family of medicines called antibiotics.When taken by mouth, is used to treat Clostridium difficile-associated diarrhea (also called C diff). C diff is a type of bacteria that causes severe diarrhea. Oral Vancomycin is also used to treat enterocolitis caused by a certain bacteria (e.g., Staphylococcus aureus). Subjects enrolled in the study will take 500 mg capsule, 3 times per day for 3-12 weeks.
45797682|NCT02358811|Device|Magnetic resonance imaging (MRI)|"The acquisition of the image will last 45 minutes with 6 sequences.~Before any examination, the manipulator will check the absence of contraindication to MRI.~During the fifth sequence, Gadolinium (Gadovist®) will be injected intravenously to the concentration 0.1 mmol / kg. For this, a venous catheter will be placed before the first sequence and then removed after the examination. This injection will be carried out according to the usual practice of MRI.~Throughout the examination, a physician will always be present."
45649655|NCT03048539|Procedure|Transoral endoscopic thyroidectomy|This procedure will remove thyroid lobe through oral vestibule. Aim to avoid scar at anterior neck.
45649656|NCT04181801|Procedure|Subtotal cholecystectomy|a surgical procedure in which more than the top half of the gallbladder is removed
45925078|NCT05364047|Biological|Low-dose of LVRNA009|25μg/person
45925079|NCT05364047|Biological|Middle-dose of LVRNA009|50μg/person
45925080|NCT05364047|Biological|High-dose of LVRNA009|100μg/person
45925081|NCT05364047|Other|Placebo|0.5ml/person
45925082|NCT02969200|Drug|Enzyme replacement therapy|All patients included in the study have received enzyme replacement therapy with either agalsidase alfa and/or agalsidase beta
45649657|NCT04879277|Biological|Blood samples|Plasmatic cytokine and plasmatic CRP assay will be realised using luminex in both arms. IL2, IL10,INF gamma, IL, IL6, ILB, TNF alpha will be analysed.
45797683|NCT02358811|Behavioral|Cognitive assessment|"This cognitive assessment will include the following executive tests :~test of Stroop~left Trail Making Test A and B~verbal fluence test~test of memory of figures direct and inverse in order~completion of matrices~Paced Auditory Serial Addition Test (PASAT)"
45797684|NCT04518215|Procedure|Erector Spinae Plain Block|Patients will receive erector spinae plane block (ESP) at the level of T 9-10. Following skin sterilization, high-frequency linear ultrasound probe will be placed 1-2 cm lateral to the midline at the T 9 level. After identification of the erector spinae muscle (ESM) and the transverse process; a 22 G needle will be inserted, in a cranio-caudal direction, deep into the ESM in an in-plane technique. Correct needle placement will be verified with the administration of 0.5-1 ml Normal Saline to view the hydrodissection between the transverse process and the ESM. 0.25% Bupivacaine in a calculated volume of 0.5 ml/kg (with a maximum dose of 20 ml) will be injected deep to the erector spinae muscle for unilateral ESPB.
45925083|NCT05223582|Drug|Abiraterone acetate|Patients would be treated with 1000mg abiraterone qd.
45925084|NCT05223582|Drug|Fluzoparib|Patients would be treated with 150mg fluzoparib bid.
45925085|NCT05223582|Drug|Prednisone|Patients would be treated with 5mg prednisone bid.
45925086|NCT05223582|Drug|Androgen deprivation therapy|Patients would get medical castration.
45925087|NCT05223582|Procedure|Radical Prostatectomy|Patients would get radical prostatectomy after the neoadjuvant treatment.
45925088|NCT00059722|Drug|ZD6474|
45925089|NCT00059722|Drug|Placebo|
45925090|NCT00059722|Drug|ZD1839|
45450485|NCT02185066|Drug|Atorvastatin 20mg and Metformin XR 500mg (Reference)|"Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between."
45925091|NCT05359133|Drug|Tetrodotoxin|TTX for Injection, 30 µg/mL, is a sterile, nonpyrogenic, white, lyophilized powder provided in a 5 mL glass single-use vial with a rubber stopper and aluminum overseal. Upon reconstitution of the lyophilized product with 1.1 mL of sterile water for injection, each vial delivers 1 mL of fluid containing 30 µg of TTX with a pH of 4.0 to 5.5
45649658|NCT04879199|Diagnostic Test|Static stability measurement|"The child stands barefoot on dual force platforms in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). Each condition is recorded three times each lasting for 30s, and 30s rest between them. Both conditions are recorded with and without wearing a headset. The order of conditions (within each Virtual Reality (VR)-condition) is randomized. For each condition, the child rests in a comfortable position for 20s with the heels on the same level and arms hanging at their sides. Between both VR-conditions, the child rests for 120 s."
45797685|NCT04518215|Procedure|Intra-Venous Analgesia|Post-operative rescue analgesic plan will consist of 15 mg/kg Paracetamol IV if the FLACC [Face, Leg, Activity, Cry, Consolability] score is 2-4 and 1 mg/kg Tramadol IV if FLACC score > 4.
45925092|NCT05359133|Drug|Placebo|"Placebo for injection is a sterile 0.9% sodium chloride injection or normal saline for injection. To ensure blinding, subjects receiving placebo will receive the same volume (1.0 mL) for injection to match the volume used for the cohorts assigned to receive active trial drug.~Route and frequency: 1.0 mL of placebo, SC injection in the thigh or abdomen, twice daily for 4 Days in each treatment Cycle."
45925093|NCT05174559|Other|PreKUnil® LNAA Medical Food for PKU|PreKUnil® LNAA Medical Food for PKU is a commercially available active LNAA treatment product for PKU. PreKUnil® inactive LNAA is a customized placebo for this research.
45797686|NCT05213559|Other|wheat biscuit enriched with plant proteins|Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a biscuit enriched with plant proteins
45797687|NCT05213559|Other|common wheat biscuit|Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a common wheat biscuit
45797688|NCT04517747|Drug|Ramucirumab|chemotherapy i.v.
45797689|NCT04517747|Drug|TAS 102|p.o. twice daily
45925094|NCT02969239|Drug|Norepinephrine|bolus administered norepinephrine 5mcg intravenously, if SBP <90mmHg or 20% decrease from baseline
45450486|NCT02185066|Drug|CJ-30056 20/500mg (Test)|"Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between."
45450487|NCT01081223|Biological|Cancer vaccine plus immune adjuvant|Tumor tissue is used for cancer vaccine. Following vaccinations, white blood cells are collected, stimulated and expanded, and are then reinfused. The infusion is followed by a course of low-dose IL-2.
45450488|NCT02186002|Drug|ACT-451840 10 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
45450489|NCT02186002|Drug|ACT-451840 50 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
45450490|NCT02186002|Drug|ACT-451840 200 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
45450491|NCT02186002|Drug|ACT-451840 500 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
45925095|NCT02969239|Drug|Phenylephrine|bolus administered phenylephrine 100mcg intravenously, if SBP <90mmHg or 20% decrease from baseline
45925096|NCT02969122|Procedure|standard gastrectomy with D2 lymphadenectomy|standard distal or total gastrectomy and accorded D2 lymphadenectomy
45450492|NCT02186002|Drug|ACT-451840 1000 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
45797690|NCT02219581|Drug|Dexamethasone 10 mg|Two doses of dexamethasone 10 mg will be given intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
45797691|NCT02219581|Drug|Dexamethasone 20 mg|Two doses of dexamethasone 20 mg will be given intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
45925097|NCT02969122|Procedure|hyperthermic intraperitoneal chemotherapy|Intraperitoneal docetaxel of 100mg/m2 at 42℃ for 30 minutes
45925098|NCT02969122|Procedure|Extensive intraperitoneal lavage|Lavage of peritoneal cavity with 1000ml saline for 10 times
45925099|NCT02969122|Other|Preoperative chemotherapy|Oxaliplatin 130mg/m2 D1 S-1 40-60mg Bid D1-14 Repeated every 3 weeks.
45925100|NCT02969122|Other|Postoperative chemotherapy|SOX regimen postoperative chemotherapy (Oxaliplatin 130mg/m2 D1, S-1 40-60mg Bid D1-14, Repeated every 3 weeks) for surgery-first arm. Regimen for chemotherapy-first arm is determined according to the postoperative pathologic evaluation of response.
45925101|NCT00059761|Drug|cisplatin|
45797692|NCT02219581|Drug|Standard multimodal pain management regimen|"The standard multimodal postoperative pain management regimen typically used for total knee arthroplasty consists of the following:~Preoperative:~Decadron: 10 or 20mg IV x 1 2 doses, 8 hours apart (if randomized to study group)~Intraoperative:~Ropivacaine: Given intraoperatively. Capsule, subcutaneous tissue/skin. Administered in standard fashion. (300mg)~Toradol: 30mg q 6hr for 6 total doses. 1st dose given intraoperatively at incision. The dose is 15 mg for older patients or if creatinine clearance (CrCl) is low.~Postoperative~Tylenol: 1000mg po q 8hr (scheduled)~Oxycodone: 5mg or 10mg q 3-4hr prn pain, If intolerant to Oxycodone: second agent line is Hydrocodone or Oral Dilaudid~IV Morphine (or Dilaudid): 1 or 2 mg q 2hr prn breakthrough pain~Morphine patient-controlled analgesia (PCA): only for failure of the above~Morphine Sulfate (MS) Contin: Use as backup prn pain"
45925102|NCT00059761|Drug|irinotecan hydrochloride|
45925103|NCT00059761|Radiation|radiation therapy|
45925104|NCT00059800|Radiation|boron neutron capture therapy|
45925105|NCT03216083|Drug|Tranexamic Acid Injectable Solution|1g IV tranexamic acid mixed in normal saline (67mL)
45925106|NCT03216083|Other|Placebo|67mL IV normal saline
45925107|NCT04730752|Diagnostic Test|Appendicitis Inflammatory Response|A scoring system used to diagnose acute appendicitis. It consists of clinical findings and laboratory parameters
45925108|NCT04730752|Diagnostic Test|Adult Appendicitis Score|A scoring system used to diagnose acute appendicitis. It consists of clinical findings and laboratory parameters
45925109|NCT02969005|Radiation|surgical treatment|Use of a radiopaque localizer grid and methylene blue staining as an aid to resect the lesions
46071953|NCT05850585|Drug|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10^12 Colony-Forming Units(CFU)/capsule) in addition to their usual antipsychotics treatment. Subjects will continue to receive FMT capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
45649659|NCT04879199|Diagnostic Test|Dynamic stability measurement|"The child walks at their normal walking speed on a 10-m walkway in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). For each condition, at least six error-free trials are recorded. Errors in data may occur due to hidden or lost markers during walking or software interruptions. Both conditions are recorded with and without wearing a headset. The order of conditions (within each VR-condition) is randomized."
45925110|NCT05158257|Device|balloon and Stent|balloon dilatation combined stent angioplasty
45925111|NCT05158257|Device|endovascular debulking and DCB|endovascular debulking combined drug-coated balloon
45925112|NCT02968966|Other|Therapy regime|Patient will receive Phenytoin, if no success is obtained, Vimpat is given. In case of success after one of the treatments, the endpoint is reached. Success is defined as reduction of seizures to 50% compared to baseline.
45925113|NCT00059878|Biological|recombinant interferon gamma|
46071954|NCT05850585|Other|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antipsychotics treatment. Placebo capsules contained the food probiotic Lactobacillus (10^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
45649660|NCT03046667|Dietary Supplement|Barley β-glucan|The test beverages with Barley β-glucan is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks consumed for 5 weeks. In total was the test drinks consumed for 6 weeks.
45649661|NCT03046667|Dietary Supplement|Control|The control beverages is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks
45649662|NCT03046589|Drug|DP13|dose escalation
45649663|NCT03046589|Drug|placebo|control to dose-escalation
45797693|NCT02219581|Drug|Placebo|Participants in the placebo arm will receive two doses of saline intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
45797694|NCT05212077|Other|Advanced Care at Home (ACH)|Inpatient hospitalization offered in the home setting.
45797695|NCT05212077|Other|Traditional Brick-and-Mortar Hospitalization|Inpatient hospitalization offered in the hospital setting.
45797696|NCT04516109|Device|Modified hip capsule side fixed slotted cannula|Modified hip capsule side fixed slotted cannula used during surgery to allow for continued access to the hip joint.
45925114|NCT00059878|Drug|voriconazole|
45925115|NCT00059917|Drug|polyglutamate camptothecin|
45925116|NCT00059995|Biological|iratumumab|
45925117|NCT05155020|Biological|AK120|AK120 regimen 1-subcutaneous injection every two weeks up to week 24, and follow up to week 32.
45925118|NCT05155020|Biological|AK120|AK120 regimen 2(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.
45925119|NCT05155020|Biological|AK120|AK120 regimen 3(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.
45925120|NCT05155020|Biological|Placebo|Placebo subcutaneous injection every two weeks up to week 24, and follow up to week 32.
45925121|NCT00060112|Biological|oblimersen sodium|Given IV
45925122|NCT00060112|Drug|gemcitabine hydrochloride|Given IV
45925123|NCT00060112|Other|pharmacological study|Correlative studies
45925124|NCT00060112|Other|laboratory biomarker analysis|Correlative studies
45925125|NCT05344157|Biological|XSTEM-OA|XSTEM-OA is an allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cell (MSC) product for the treatment of osteoarthritis.
45925126|NCT00060151|Drug|pazopanib hydrochloride|
45925127|NCT00060268|Drug|HPPH|iv
45925128|NCT00060307|Drug|erlotinib hydrochloride|Given orally
45925129|NCT00060307|Other|laboratory biomarker analysis|Correlative studies
45797697|NCT04516109|Device|Modified bone graft delivery tool set|Modified bone graft delivery tool set for grafting subchrondral cysts arthroscopically during hip arthroscopy procedure.
45797698|NCT05442957|Behavioral|BRIGHT|BRIGHT is a manualized theory-based tele-CBT intervention consisting of 6 weekly 60-minute sessions. BRIGHT is delivered one-on-one by a licensed clinical psychologist at each site via standard video tele-CBT platform. BRIGHT session topics include (1) psychoeducation about the cognitive model of body image, (2) self-monitoring about thoughts, feelings, and body image behaviors, (3) cognitive restructuring to identify and challenge unhelpful automatic HNC body image thoughts, (4) positive body image coping strategies, (5) social support and identifying personal value, and (6) thinking ahead and planning for setbacks.
45925130|NCT05134662|Drug|ALT-801|Injected subcutaneously (SC)
45925131|NCT05134662|Other|Placebo|Injected subcutaneously (SC)
45925132|NCT02968927|Drug|Everolimus 0.5 MG|
45925133|NCT02968927|Drug|Auranofin 6 MG|
45925134|NCT02968927|Drug|Vitamin D3|
45925135|NCT02968927|Drug|CC-11050|
45450493|NCT02186002|Drug|ACT-451840 (Dose to be determined)|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
45649664|NCT04037813|Procedure|Laparoscopic and hysteroscopic tubal occlusion for hydrosalpinx|"For hysteroscopic tubal occlusion group it will be done under general anesthesia using standard, rigid 4-mm hysteroscopy with a 30° forward-oblique lens and a 5.5-mm diagnostic sheath (Karl Storz , Germany). Uterine distension allowed a panoramic view of the uterine cavity and identification of the tubal ostia.The roller ball (Ball Electrode, unipolar, 5 Fr) will be used for the coagulation of the interstitial part of the tube and the uterine cornu area.~For laparoscopic tubal occlusion group it will be done under general anesthesia using bipolar coagulation and a proximal tubal cut."
45649665|NCT02614079|Device|DSSEP|Collision testing after the placement of SCS leads
45649666|NCT03871049|Drug|Bupivacaine with dexamethasone|bupivacaine with dexamethasone
45649667|NCT03871049|Drug|Bupivacaine|bupivacaine
45649668|NCT04878809|Other|Escola L'Horitzó|Diagnosis of SARS-CoV-2 infection by rapid antigen detection tests in nasal and nasopharyngeal swabs, in asymptomatic and symptomatic subjects who attend regularly to L'Horitzó school .
45797699|NCT05442957|Behavioral|Attention Control|AC is a manualized video-tele-supportive care intervention that addresses non-body image aspects of HNC survivorship. Identical to BRIGHT, AC consists of 6 weekly 60-minute sessions delivered by a trained empathic interventionist via standard video-telemedicine platform. AC session topics include (1) Introduction to HNC survivorship, (2) Post-Treatment Side Effects (3) Psychosocial Aspects of HNC, (4) Health Promotion and Nutritional Challenges, (5) Financial Distress and Return to Work, and (6) Cancer Recurrence. AC controls for professional attention (i.e., ensuring that findings are not driven by simply interacting with an empathic interventionist), common factors, dose, and delivery method while not providing the active, behavior change mechanism in BRIGHT.
45925136|NCT02968927|Drug|2HRbZE/4HRb|
45925137|NCT05344040|Behavioral|Remotely Delivered and Supported Aerobic Walking Exercise Training|"This condition will include 16-weeks of remotely-delivered and supported aerobic walking exercise training based on guidelines for physical activity in persons with MS for general health benefits. Exercise intensities will be prescribed based on steps per exercise sessions from a waist-worn FitBit One™ (FitBit, Inc., San Francisco, CA).~The exercise program involves one-on-one semi-structured sessions with an MS exercise specialist (i.e., behavior coach) throughout the program. These sessions focus on exercise training guidance and oversight, discussion of the behavioral strategies of action planning and self-monitoring, and presentation and discussion of newsletters for optimizing exercise compliance."
46071955|NCT05849623|Procedure|Endoscopic Mucosal Resection (EMR)|EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
46071956|NCT05849623|Procedure|Cold Endoscopic Mucosal Resection (C-EMR)|C-EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
45649669|NCT04878809|Other|Escola John Talabot|John Talabot School will provide the incidence of infection by SARS-CoV-2 in order to compare the incidence of infection from L'Horitzó School.
45649670|NCT04430465|Dietary Supplement|Grain products high in wholegrains from oat and rye|A selection of grainproducts high in wholegrain from oat and rye, including cereals, bread, rolls, and pasta is replacing habitual grain products
45649671|NCT04430465|Dietary Supplement|Grain products low in wholegrains|A selection of grainproducts low in wholegrain, including cereals, bread, rolls, and pasta is replacing habitual grain products
45649672|NCT04878653|Device|BACtrack S80 Breathalyzer|The breathalyzer, BACtrack S80 Breathalyzer, will be calibrated per manufacturer's recommendations before each reading will be taken. Participants will administer the breathalyzer test on themselves. They will be instructed on how to hold and blow into the breathalyzer machine.
45649673|NCT04870541|Drug|Ondansetron 8mg|Patients receiving 8 mg of ondansetron diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater(75 patients).
46071957|NCT05849623|Procedure|Underwater Endoscopic Mucosal Resection (U-EMR)|U-EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
46071958|NCT05848440|Drug|AZD9550|Participants will be administered AZD9550 subcutaneously.
45450494|NCT02186002|Drug|Placebo|
45450495|NCT01069055|Other|Sterile Saline|Group I: 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.
45450496|NCT01069055|Drug|Intravenous lornoxicam|Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.
45649674|NCT04870541|Drug|Nefopam Injectable Solution|Patients receiving 20 mg of nefopam diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater (75 patients)
45649675|NCT04870385|Behavioral|5-week prevention program|Online modular psychological prevention program featuring integrated elements of Islamic spirituality and Acceptance and Commitment Therapy (ACT).
45649676|NCT04870385|Behavioral|Control|Control group waitlisted to receive prevention program after completion of final data collection.
45649677|NCT04870073|Procedure|Retrograde autologous priming|Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.
45797700|NCT01437709|Biological|Ofatumumab (This arm is closed)|Ofatumumab Day 1 Week 1: 1000 mg, Day 2 week 1: 1000mg. Patients who exhibit a baseline leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose Ofatumumab Day 1, Weeks 2-4: 1000 mg Will reassess 8-10 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
45649678|NCT04870073|Drug|Mannitol|Mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
45649679|NCT04870073|Procedure|Conventional Priming|The conventional priming procedure will be used in the standardized cardiopulmonary machine used at the Hamilton General Hospital.
45797701|NCT01437709|Other|Ofatumumab + Bendamustine|Ofatumumab day 1 + Bendamustine 90 mg/m2 days 1 & 2 x 6 cycles q 28 days Cycle 1, day 1: Ofatumumab 1000 mg followed by Bendamustine 90 mg/m2. Patients who exhibit a leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose. Cycle 1, day 2: Ofatumumab 1000mg followed by Bendamustine 90 mg/m2 Cycles 2-6: Ofatumumab 1000 mg day 1, Bendamustine 90 mg/m2 days 1 and 2 Will reassess 4-6 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
45797702|NCT03740165|Biological|Pembrolizumab|IV infusion
45450497|NCT01069055|Drug|Intravenous paracetamol|Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
45649680|NCT04878731|Biological|PF-06741086|single dose SC injection of 300 mg PF-06741086
45797703|NCT03740165|Drug|Placebo for pembrolizumab|IV infusion
45797704|NCT03740165|Drug|Carboplatin|IV infusion
45797705|NCT03740165|Drug|Paclitaxel|IV infusion
45797706|NCT03740165|Drug|Olaparib|Oral tablet
45797707|NCT03740165|Drug|Placebo for olaparib|Oral tablet
45797708|NCT03740165|Biological|Bevacizumab|IV infusion
45797709|NCT03740165|Drug|Docetaxel|IV infusion
45797710|NCT01393483|Other|serum and tissue mesothelin|"Tissue mesothelin staining at the time of the initial endoscopy, and of any subsequent biopsy specimen during the endoscopic screening period.~Serum mesothelin level at the time of initial endoscopy, and at each subsequent endoscopy for two years or until disease recurs."
45797711|NCT01393483|Other|serum and tissue mesothelin|Tissue mesothelin staining on the surgically resected esophageal specimen. Serum mesothelin level at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
45797712|NCT01393483|Other|serum and tissue mesothelin|Tissue mesothelin staining on the initial endoscopic specimen (typically obtained when an EUS is done) and on the surgically resected esophageal specimen Serum mesothelin level prior to initiation of induction chemotherapy, at the time of the post-induction PET, at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
45797713|NCT01912274|Drug|Pracinostat|Elderly newly diagnosed patients will all receive pracinostat
45797714|NCT01912274|Drug|Azacitidine|Elderly newly diagnosed patients will all receive azacitadine
45797715|NCT01654861|Drug|Gemcitabine, Intravenous and oral Ascorbic Acid (Vitamin C)|Weeks 1,2,3: IV Gemcitabine 1000 mg / m² over 30 minutes followed by HDIVC 1.2 g / kg: 1.2 g/kg over 90 minutes for a dose ≤90 g and over 120 minutes for a dose >90g followed by 0.3 g / kg over 120 minutes; Week 4: no treatment.
45797716|NCT01934582|Drug|UT-15C SR|
45797717|NCT01934582|Drug|treprostinil diethanolamine|Open label study drug.
45797718|NCT05436717|Behavioral|MINDxYOU|The online program MINDxYOU is based on the principles of 'third wave' psychotherapies and it is an online program particularly addressed at healthcare providers which will both monitor and support the individual's mental health. The program is self-administered and will be delivered via the Internet and available via smartphone, tablet, and personal computer.
45797719|NCT03723707|Behavioral|EQUIPED-ADRD Intervention|(10 clinic sites and ~500 patients) which includes practice guidelines for clinicians, provider education, electronic health record support for quality DM-ADRD care, information about community/clinical resources, ongoing targeted provider feedback, and a panel manager (PM)
45797720|NCT03723707|Behavioral|Control (CON)|Will use current guidelines for primary care treatment with Diabetes and Dementia
45797721|NCT04565691|Procedure|Non-surgical periodontal treatment|Non-surgical periodontal treatment that is accepted to cause bacteremia in about 50% of the cases.
45797722|NCT05735834|Drug|Rituximab|Truxima concentrate for solution for infusion 500 mg/50 ml
45797723|NCT05735834|Drug|Zanubrutinib|Zanubrutinib 80 mg hard capsules
45797724|NCT05184777|Diagnostic Test|Determination of progesterone and oestradiol|Blood and saliva samples will be taken for determination of progesterone and oestradiol hormones.
45797725|NCT03721367|Other|Diagnostic Ultrasound|All individuals will undergo a blood draw for measurement of biomarkers of liver disease and an ultrasound with shear-wave elastography.
45797726|NCT05429307|Other|Population|Turkish Validity and Reliability of The Exercise Sensitivity Questionnair Scale to Turkish society and to make its validity and reliability in Turkish.
45797727|NCT01912352|Drug|Methylphenidate|
46071959|NCT05848440|Drug|AZD9550|Participants will be administered AZD9550 intravenously.
45649681|NCT04869839|Other|oral examination|examination done by dentist
45649682|NCT02616029|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
45925138|NCT05344040|Behavioral|Remotely Delivered and Supported Stretching and Toning Exercise Training|The active, non-aerobic exercise condition will involve stretching-and-toning activities. These activities will be based on a manual provided by the National Multiple Sclerosis Society. Participants will be provided with necessary exercise equipment (e.g., yoga mat, FitBit), an instructional DVD, and a manual, log-book, calendar, and prescription for the stretching program. This program will be supplemented with periodic newsletters delivered electronically that highlight principles of behavior change, and video-chats with a behavior coach that provide motivation and social accountability. These occur on the same timeline and frequency as in the walking condition, but focus on constructs for stretching.
45925139|NCT02968888|Other|Strength training|
45925140|NCT02968888|Dietary Supplement|Milk 1%|
45925141|NCT02968888|Dietary Supplement|Whey protein concentrate 80|
45925142|NCT02968888|Dietary Supplement|Native whey|
45797728|NCT02975843|Drug|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium|single inhalation of 99mTc radiolabelled CHF 5993 pMDI (4 puffs for a total dose of: Beclometasone diproprionate (BDP) 400 μg, Formoterol fumarate (FF) 24 μg, Glycopirronium bromide (GB) 50 μg)
45797729|NCT01655563|Drug|Tacrolimus|Tacrolimus, a calcineurin inhibitor, is the commonest immunosuppressive agent used for maintenance immunosuppression after solid organ transplantation. The mechanism of action involves binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the generation of nuclear factor of activated T-cells, a nuclear component, resulting in inhibition of transcription of lymphokines (interleukin-2, γ-interferon). The net result is the inhibition of T-lymphocyte activation.Tacrolimus is metabolized primarily by the CYP3A enzymes in the liver particularly the CYP3A5.
45925143|NCT00398515|Drug|lenalidomide|Given orally
45925144|NCT00398515|Drug|temsirolimus|Given IV
45925145|NCT00398515|Other|pharmacological study|Correlative studies
45925146|NCT00398515|Other|laboratory biomarker analysis|Correlative studies
45925147|NCT05105685|Drug|recombinant human growth hormone|RhGH treatment was started at 0.1 IU/kg once daily
45925148|NCT05105685|Drug|Saline|Saline was started at 0.1 IU/kg once daily as the placebo
45925149|NCT05325164|Drug|Methadone|Methadone
45925150|NCT05325164|Drug|Morphine|Morphine
45925151|NCT00060385|Drug|CHOP regimen|
45925152|NCT00060385|Drug|EPOCH regimen|
45925153|NCT00060385|Drug|cyclophosphamide|
45649683|NCT04878341|Other|Erector Spinae Plane Block|The ESP is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
45797730|NCT05180019|Device|SMD ( Self Monitoring Device)|Automated 3D ultrasound based follicullometry with SMD self-performed by the patient.
45925154|NCT00060385|Drug|doxorubicin hydrochloride|
45925155|NCT00060385|Drug|etoposide|
45925156|NCT00060385|Drug|prednisone|
45925157|NCT00060385|Drug|vincristine sulfate|
45925158|NCT00060385|Radiation|radiation therapy|
45925159|NCT00060463|Behavioral|Increased access to emergency contraceptive pills|
46071960|NCT05848440|Drug|Placebo|Participants will be administered matching volumes of placebo subcutaneously or intravenously.
45925160|NCT02968771|Other|Non intervention|
45925161|NCT05055921|Device|Multi Pulse Therapy as delivered from the Cardialen External Stimulation System|"The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen MultiPulse Therapy (MPT). The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.~Other Names:~Unpinning Termination Therapy~Multi-stage therapy~Multi-stage electrotherapy~MultiPulse Therapy"
45925162|NCT04730908|Other|DENTIFRICE|GEL -DENTIFRICE FOR BRUSHING TEETH
45925163|NCT05319197|Other|No Interventions|No Interventions
45925164|NCT02968693|Device|antibiotic-loaded calcium sulfate|To obtain a paste suitable for pellets, the following steps should be used: 1. Empty 10 cc Stimulan® calcium sulfate powder (Stimulan; Biocomposites Ltd; United Kingdom) into a sterile mixing bowl. 2. The calcium sulfate powder was mixed with 2,000 mg of vancomycin powder. 3. Add approximately 5 ml mixing solution into the above mixture. Mix thoroughly until a smooth paste is formed (approximately 30 seconds). 4. The resultant paste is uniformly smooth into the mould provided to form pellets with diameters of 4.8 mm and height of 3.3 mm. 5. Allow paste to cure undisturbed for at least 15 minutes after mixing. Flex mould to release pellets.
45925165|NCT02968693|Device|antibiotic-loaded polymethyl methacrylate|One sachet of 40g PALACOSR®+G power containing 33.6g PMMA and with the addition of 0.5g gentamicin sulphate (Heraeus Medical Gesellschaft mit beschränkter Haftung,Germany) was mixed with 4,000 mg of vancomycin powder in a sterile bowl. The liquid provided was poured into the resultant mixture above. Then, the mixture was stirred carefully for 30 sec. If the dough-like mass no longer sticked to the rubber gloves, it can be progressed. If the required consistency was obtained, the cement can be applied to the bony defect until it hardened completely.
45649684|NCT04878497|Drug|Warfarin|Initiation of warfarin, identified using prescription fill in pharmacy claims
45649685|NCT04878497|Drug|Dabigatran|Initiation of dabigatran, identified using prescription fill in pharmacy claims
45649686|NCT04878497|Drug|Rivaroxaban|Initiation of rivaroxaban, identified using prescription fill in pharmacy claims
45925166|NCT02968693|Drug|Vancomycin|Vancomycin powder was added into the combination therapy group and PMMA groups
46071961|NCT05840549|Procedure|TURP|TURP is an operation which can be performed under a general / regional anaesthetic. A cystoscope is passed into the urethra meatus, along the length of the urethra to the level of the prostate. The obstructing prostate lobes are resected using mono polar or bipolar energy to create a channel for improved urinary flow. Haemostasis is achieved by coagulation followed by insertion of a catheter for irrigation post procedure. Generally, patients stay for 1-2 nights post operatively. On the day of discharge the catheter is removed.
45925167|NCT04731181|Behavioral|mobile application (little lovely dentist).|mobile application
45925168|NCT00060502|Drug|Infliximab; Gemcitabine|
46071962|NCT05840549|Procedure|UroLift|UroLift (Neotract) is a NICE-approved alternative to TURP that can be performed under local anaesthetic, sedation or general anaesthetic. The system comprises of two single-use components, a delivery device and an implant. The implant is made of a nitinol capsular tab, a polyethylene terephthalate monofilament and a stainless-steel end-piece. Again, a modified cystoscope is passed into the urethral meatus, along the length of the urethra to the level of the prostate. The delivery device deploys the implants into the prostate to 'pin' back the lobes of the prostate to create a channel for improved flow. Typically, 2-4 implants are used per procedure. Nine out of ten patients do not require a catheter post procedure
46071963|NCT05838586|Behavioral|prolonged SB|4 hours of prolonged SB
46071964|NCT05838586|Behavioral|SB broken 1|4 hours of SB broken up by 5 minutes of self-paced walking every hour
46071965|NCT05838586|Behavioral|SB broken 2|4 hours of SB with one 20-minute bout of self-paced walking
45649687|NCT04878497|Drug|Apixaban|Initiation of apixaban, identified using prescription fill in pharmacy claims
46071966|NCT05838560|Drug|Dasatinib + quercetin|dasatinib 100mg / quercetin 1250mg The intervention will involve the participant taking both dasatinib and quercetin combined.
45649688|NCT04878497|Drug|Edoxaban|Initiation of edoxaban, identified using prescription fill in pharmacy claims
45649689|NCT03277703|Biological|Influenza vaccine|"The primary aim of this study is to assess the immunogenicity of booster dose influenza vaccine strategy in patients with rheumatologic diseases and IBD who are receiving immunosuppressive therapies.~Secondary aims of this study include assessment of the safety and clinical efficacy, of booster dose influenza vaccine in the prevention of influenza-like illnesses (ILI) in this patient population"
45649690|NCT03257033|Drug|Gemcitabine|Chemotherapy
45649691|NCT03257033|Drug|nab-paclitaxel|Chemotherapy
45649692|NCT03257033|Device|RenovoCath|Intra-arterial catheter
45649693|NCT03250169|Drug|Alemtuzumab|Licensed dose
45649694|NCT04429841|Procedure|Radical gastrectomy with D1 lymphadenectomy|
45649695|NCT04429841|Procedure|Radical gastrectomy with D2 lymphadenectomy|
45649696|NCT02614859|Drug|Observation and Bicalutamide|Cycles 1 - 2: Observation without treatment Cycles 3 - 8: Bicalutamide 50 mg daily, orally, continuously to the end of study (week 32).
45797731|NCT05172141|Biological|IBI314(low dose)|intravenously, once, on Day 1
45797732|NCT05172141|Biological|IBI314(high dose)|intravenously, once, on Day 1
45797733|NCT05172141|Biological|IBI314(medium dose)|intravenously, once, on Day 1
45797734|NCT05172141|Other|Placebo|intravenously, once, on Day 1
45797735|NCT01655719|Drug|Pioglitazone|
45797736|NCT01913600|Device|Resolute Integrity Stent|Drug eluting stent (DES)
45925169|NCT05055336|Other|Gastric emptying breath test|The gastric emptying breath test is used to diagnose gastroparesis. Participants ingest spirulina in a meal and samples are taken every 45 minutes for 4 hours.
45925170|NCT05055336|Other|Stomach ultrasound|Ultrasound of the fundus of the stomach will be done immediately after ingestion of the test meal, at 15 minutes, and at 30 minutes.
46071967|NCT05838430|Drug|Solriamfetol 75 MG|Solriamfetol (trade name Sunosi), is a norepinephrine-dopamine reuptake inhibitor available in 75mg and 150mg tablets for oral administration during the day. Solriamfetol's primary indication is to treat excessive daytime sleepiness (EDS) in patients diagnosed with obstructive sleep apnea or Narcolepsy. It binds to the dopamine and the norepinephrine transporters with affinities (Ki) of 14.2 μM and 3.7 μM, respectively),does not undergo significant metabolism in humans, and has a Tmax of ~2 hours (range 1.25-3.0 hours) and a T1/2 of ~7.1 hours.
45797737|NCT05735756|Drug|Citalopram 20mg|Citalopram 20mg once a day for 12 weeks
45797738|NCT05735756|Drug|Placebo|Placebo once a day for 12 weeks
45797739|NCT01936844|Drug|Anakinra (high dose)|Anakinra 100 mg daily twice daily for days 1, 2, and 3
45797740|NCT01936844|Drug|Anakinra (standard dose)|Anakinra 100 mg daily for days 4-14
45797741|NCT01936844|Drug|Placebo|Placebo twice daily for days 1, 2, and 3
45797742|NCT01936844|Drug|Placebo|Placebo daily for days 4-14
45797743|NCT01917188|Behavioral|Full simulation and education|
45797744|NCT01917188|Behavioral|See simulation room, usual education|
45797745|NCT01937624|Device|Diagnostic Ultrasound|
45649697|NCT02614859|Drug|Metformin and Bicalutamide|Cycles 1-2: Metformin 1000mg BID Cycles 3-8: Bicalutamide 50 mg daily and Metformin 1000 mg BID
45649698|NCT04384445|Biological|Zofin|Biological: Zofin will be administered intravenously with 1ml, containing 2-5 x 10^11 particles/mL in addition to the Standard Care. The Zofin dose will be diluted in 100 mL of sterile saline at subject's bedside.
45649699|NCT04384445|Other|Placebo|Other: Placebo Placebo (saline) will be administered intravenously with 1ml in addition to the Standard Care. The Placebo dose will be diluted in 100 mL of sterile saline at subject's bedside.
45649700|NCT01495637|Drug|GM-CSF|GM-CSF is to be administered IV at one of four possible dosing regimens (three days at a dose of 30, 62, or 125 mcg/m2 per day, or an extended dosing regimen of 125 mcg/m2/day through post-trauma 6) if severe innate immune suppression is identified on post-trauma days 1, 2, or 3.
45797746|NCT01937624|Radiation|X-ray imaging|
45797747|NCT01938170|Biological|FluMist|Subjects receiving Flumist vaccine
45797748|NCT02987348|Drug|exenatide once weekly|patients received exenatide once weekly treatment under their standard care, no intervention was given by the study investigator
45797749|NCT02987348|Drug|exenatide twice daily|patients with exenatide twice daily treatment under their standard care, no intervention was given by the study investigator.
45797750|NCT02987348|Drug|basal insulin|patients with basal insulin treatment under their standard care, no intervention was given by the study investigator
45925171|NCT05312372|Drug|Combination (S095033 + paclitaxel)|"Phase 1- dose escalation S095033 ; paclitaxel started at 80 mg/m²,(IV)~Phase 2 - S095033 at RP2D; paclitaxel started at 80 mg/m²,(IV)"
45925172|NCT00060580|Procedure|Raman scattering spectroscopy|
45925173|NCT00060619|Behavioral|thermal biofeedback|
45925174|NCT00060619|Behavioral|relaxation training|
45925175|NCT00060619|Behavioral|cognitive coping skills|
45925176|NCT00060619|Behavioral|parent education|
45450498|NCT02185144|Behavioral|PATH For Triples|In addition to providing weekly home-health nursing focused psycho-education aimed at insuring adherence to drug treatment regimen, the nurse health navigator model provided in PFT combines continuous and integrated care across mental health, substance abuse, and infectious disease provides. The nurses will accompany the patient to appointments, or make collateral contacts with other care providers. Often the nurses serve as intermediaries and ensure accurate and timely information exchange. Their specialized training also allows them to monitor side effects of medications and advocate for the patients with their various specialty providers. A treatment cascade approach is utilized when the patient is non-adherent to treatment allowing for increased patient monitoring.
45797751|NCT05735522|Device|Extracorporeal magnetic stimulation|Extracorporeal magnetic stimulation is a technique based on Faraday's law of magnetic induction, approved by the United States Food and Drug Administration in 1998, for conservative treatment of urinary incontinence. It generates electrical activity, which induces controlled depolarization of the nerves, resulting in pelvic muscle contraction and sacral S2-S4 roots neuromodulation. The patient seats in the chair fully clothed.
45797752|NCT05735522|Other|Sham|The same chair as is used in the active group with the magnetic field density at the lower 2% resulting in negligible efficacy.
45925177|NCT04730713|Device|The morphology and parameters of cranial ultrasound spectrum based on cerebral artery|Subjects who meet the standards will undergo a full-body examination and basic life after entering the ICU Sign evaluation and monitoring, mainly including nervous system specialist physical examination, multi-modal brain function testing, Respiratory system monitoring and management, hemodynamic monitoring, APACHE Ⅱ score, GCS score, and routine general circulation, respiratory management, sedation and analgesia management, temperature management, infiltration Pressure management, lumbar pressure measurement The included subjects were monitored for optic nerve sheath diameter, TCD/TCCD before and after lumbar puncture, and recorded spectrum morphology: normal, high resistance state, ischemic topic, congestion state, spasticity, nail wave/oscillating wave state, S1S2 fusion high point state, and recording at the same time Parameters: systolic flow rate (Vs) Shu Tensile blood flow velocity (Vd), average blood flow velocity (Vm), pulsatility index (PI), impedance Index (RI)
45925178|NCT05038410|Drug|Wobenzym®|Wobenzym®
45649701|NCT04877795|Diagnostic Test|Blood sampling|Blood will be sampled from enrolled patients and analyzed for levels of troponin, copeptin and heart-type fatty acid binding protein (HFABP).
45649702|NCT03046355|Procedure|Labor induction at 37.0 to 37.6 weeks of gestation|Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
45797753|NCT01656031|Drug|clofarabine|
45797754|NCT01656031|Drug|cytarabine|
45925179|NCT05038410|Other|Placebo|Microcrystalline cellulose
45925180|NCT00060697|Behavioral|Adolescent sexual activity education for mothers|
45649703|NCT03046355|Procedure|Expectant monitoring until delivery|Diagnosis of FGR managed with expectant monitoring and delivery as indicated
45649704|NCT04877717|Drug|SHR-A1904|SHR-A1904
45649705|NCT04877951|Behavioral|LSVT BIG|LSVT BIG is a 4-week program that focuses on movement recalibration for people with a diagnosis of Parkinson's disease.
45797755|NCT01917812|Device|Digital Activity Tracker|
45797756|NCT01917812|Other|Smart Text Messaging|
45797757|NCT05735444|Device|Continuous positive airway pressure|Continuous positive airway pressure (CPAP) is one of the standard medical treatments for patients with OSAS. The mechanism of CPAP probably involves maintenance of a positive pharyngeal transmural pressure so that the intraluminal pressure exceeds the surrounding pressure. CPAP also increases end-expiratory lung volume, which stabilises the upper airway through caudal traction.
45797758|NCT01656187|Drug|Memantine 10 mg capsule|"Memantine oral capsule was initiated at 5 mg/day at Randomization (Week 0), then titrated to 5 mg twice a day at Week 2, then increased to 10 mg in the morning and 5 mg in the evening at Week 3, and then to 10 mg twice a day (intervention dose) at Weeks 4-24. For the participants in the Placebo, then Memantine arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52)."
45797759|NCT01656187|Drug|Memantine-matched Placebo capsule|"Memantine-matched oral Placebo capsule was initiated at Randomization (Week 0) and maintained Weeks 0-24 in a manner consistent with the active drug titration schedule. The number of placebo capsules matched the number of active drug capsules at each titration checkpoint. For the participants in the Memantine, then Placebo arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52)."
45925181|NCT05303831|Other|Mechanical ventilator|patients on a mechanical ventilators in ICU will be followed for 28-days for clinical outcomes
45925182|NCT00060814|Other|Combined intervention|300 mg bupropion plus 4mg nicotine gum ad lib plus motivational interviewing counseling
45925183|NCT05037513|Behavioral|SBCM-PrEP|Multi-session SBCM intervention adapted for PrEP initiation focus
45797760|NCT01658059|Other|Homeopathic remedy|drops of the homeopathic remedy will be taken twice a day before the treatment and once on the morning of the treatment day.
45797761|NCT01658059|Other|Placebo|drops of the placebo will be taken twice a day before the treatment and once on the morning of the treatment day.
45797762|NCT01658839|Drug|Travoprost ophthalmic solution, 0.004% (new formulation)|Travoprost ophthalmic solution, 0.004%, new formulation
45450499|NCT02185144|Behavioral|Treatment as Usual|Control subjects receive enhanced TAU care which will consist of the opportunity to complete the full complement of baseline instruments that will then be shared with their outpatient mental health case manager to facilitate linkage with needed MH, SA, and ID care
45450500|NCT02190448|Dietary Supplement|study herbal tea|3-5 cups, 8oz tea daily for 4 weeks
45649706|NCT04877171|Other|telemedicine neurology consultation|consultations via phone-only at 12-14-day post-discharge. Consultations via phone both audio and video at 1, 3 and 6 months
45649707|NCT04877171|Other|in-person neurology consultation|consultation in-person at Hospital Internacional de Colombia
45797763|NCT01658995|Drug|Doxycycline|Doxycycline 100 mg oral capsules twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.
45797764|NCT01658995|Drug|Placebo|Placebo, one capsule orally twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.
45450501|NCT02190448|Dietary Supplement|herbal placebo tea|3-5 cups, 8oz each daily for 4 weeks
45797765|NCT01350141|Other|Placebo|An infusion lasting approximately 60 minutes
45797766|NCT01350141|Drug|PF-04950615 (RN316)|An infusion lasting approximately 60 minutes
45450502|NCT01083953|Drug|Sevoflurane|Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
45450503|NCT01083953|Drug|Desflurane|Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
45450504|NCT02190526|Drug|Mesalazine(asacol 800 mg)|
45450505|NCT02190526|Drug|Amitriptyline|
45797767|NCT01350141|Drug|PF-04950615 (RN316)|An infusion lasting approximately 60 minutes
45450506|NCT02190526|Drug|placebo like asacol|
45450507|NCT02190526|Drug|placebo like amitriptyline|
45450508|NCT01084031|Drug|propofol|intravenous propofol with sevoflurane inhalation induction
45450509|NCT02186080|Drug|Gemigliptin|
45450510|NCT02186080|Drug|Placebo|
45450511|NCT01084109|Other|Lyophilized meat|Daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo)
45797768|NCT01660321|Drug|spinosad|A sufficient amount of Natroba Topical Suspension was applied to completely cover the scalp, worked out to the ends of the hair, and left in place for 10 minutes (±30 seconds), followed by a complete rinse and shampoo.
45797769|NCT00471601|Behavioral|counseling intervention|
45797770|NCT00471601|Behavioral|questionnaire administration|
45797771|NCT00471601|Behavioral|psychosocial assessment and care|
45797772|NCT00471601|Behavioral|quality-of-life assessment|
45797773|NCT01597141|Behavioral|Family-aided Assertive Community Treatment|The experimental treatment is a combination of family psychoeducation, assertive community treatment, supported education/employment and psychotropic medication.
45797774|NCT01597141|Behavioral|Enhanced standard treatment|In this arm, the subjects will receive the same psychotropic drugs, but will receive individual case management, family education and crisis intervention
45797775|NCT05164107|Device|Globe Mapping and Ablation System (Globe System)|During the procedure, the Globe Catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the left atrium (LA) will be followed by PFA to achieve pulmonary vein isolation (PVI). Additional PFA or radiofrequency (RF) ablation lesions may be created as deemed appropriate by the Investigator. Intracardiac electrogram mapping with the Globe System will be used to confirm PVI.
45797776|NCT00382551|Behavioral|Moderate daily consumption of Red wine|
45797777|NCT00382551|Behavioral|Moderate daily consumption of beer|
45450512|NCT01084109|Other|Cereal|Daily intake of an equi-caloric fortified cereal as complementary feed from 6 to 18 months.
45450513|NCT02185222|Drug|Cholecalciferol 100 000 UI|Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
45450514|NCT02185222|Drug|Placebo|Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
45450515|NCT01084187|Drug|Vardenafil|vardenafil 20 mg on demand or vardenafil daily or placebo
45649708|NCT03046277|Other|No intervention|No intervention
45649709|NCT04876859|Procedure|CRF of anterior sensitive branches to the hip|Steroid and anesthetic extra articular injection followed by denervation using CRF at 90 celsius degree during a period 90 minutes at the sensitive branches of obturator and femoral nerve, separately.
45649710|NCT04876859|Procedure|Anesthetic block with steroid injection of anterior sensitive branches to the hip|Corticosteroid and anesthetic extra articular injection at the sensitive branches of obturator and femoral nerve, only
45649711|NCT03049241|Other|neuromuscular fatigue|The main aim of the present protocol is to compare the effect of knee extensors and ankle plantarflexors length on the development and aetiology of neuromuscular fatigue, in children and adults
45797778|NCT00382551|Behavioral|Moderate consumption of fruit juice rich in polyphenolics|
45797779|NCT01597687|Procedure|Blood collection|1 blood sample will be collected from each subject.
45797780|NCT01597687|Other|Data collection|Quality of Life and HE questionnaires.
45797781|NCT05154513|Other|Cohort 1|No intervention provided in this study
45797782|NCT01597843|Other|Education|Series of training sessions, in person and on line, to educate post superusers who will in turn educate post members on the utility and mechanics of use of MHV.
45925184|NCT05037513|Behavioral|CDC-PrEP|1 session PrEP education following CDC guidelines
45925185|NCT00060892|Genetic|HGF plasmid|Intramuscular injections into index leg on Days 0, 14, and 28
45925186|NCT05300945|Combination Product|HIPEC|HIPEC after gastrectomy with D2 local lymph node dissection.
45649712|NCT03046043|Procedure|pulmonary vein isolation|pulmonary vein isolation is conducted on the junction between the left atrium and pulmonary vein
45925187|NCT02968615|Behavioral|Dietary Intervention|Participants were instructed to increase both their dietary fiber intake to 35 g/day and protein intake to 0.8 g per kilogram/day of their ideal body weight. Patients in both conditions will receive intensive dietary instruction for 6 weeks, followed by a 6 weeks maintenance phase. Participants received dietary instructions via individual and group sessions led by registered dietitians.
45797783|NCT03001999|Behavioral|PP-MI health behavior intervention|"The positive psychology exercises include 3 modules:~Gratitude-based activities, Strength-based activities, and Meaning-based activities. Various goal setting exercises will appear in each of the 14 study sessions."
45649713|NCT03046043|Procedure|Low-Voltage & CFAE guided ablation|In CFAE guided ablation,. Within low voltage zone, CFAE areas defined by shortest SCI and high ICL are identified.-Areas with the shortest SCI and high ICL within low voltage areas should be targeted first, followed by longer SCI regions (up to 120ms). Radiofrequency energy is delivered at target sites for 30-60 sec until the local electrogram is completely eliminated.
45649714|NCT05257889|Diagnostic Test|blood and CSF studies + neuroimaging studies|blood and CSF studies + neuroimaging studies
45649715|NCT03047915|Other|Music|The intervention consists of listening to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones.
45797784|NCT01662115|Drug|Nicotine gum|Patients will chew nicotine gum 3 times a day until discharge or 7 days, whichever comes first
45925188|NCT05030493|Drug|mFOLFOX6 + panitumumab combination therapy|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
45450516|NCT03536182|Radiation|Carbon Ion Radiation Therapy (CIRT)|Patient will receive CIRT daily, 4 days a week for a total of 12 fractions/treatments plus concurrent chemotherapy (gemcitabine) weekly for 3 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic. Within 6 weeks of completing radiotherapy, patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
45925189|NCT05030493|Drug|mFOLFOX6 + bevacizumab combination therapy|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
45925190|NCT02968498|Dietary Supplement|Lactulose crystals 10 g|White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
45925191|NCT02968498|Dietary Supplement|Lactulose crystals 20 g|White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
45925192|NCT02968498|Dietary Supplement|Lactulose liquid 10 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
45925193|NCT02968498|Dietary Supplement|Lactulose liquid 20 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
45925194|NCT02968498|Dietary Supplement|Oral glucose 20 g|White crystalline powder used as food ingredient. To standardise for 20 g glucose, 22 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
45925195|NCT02968498|Dietary Supplement|Still water|Still water will be used. Water from the same source will be also used to dissolve investigational and control products.
45925196|NCT00060931|Drug|carvedilol|
45925197|NCT00060931|Drug|metoprolol|
45925198|NCT05292794|Device|CereGate Software; BSN cDBS Programmer; BSN Burst Programmer|"CereGate's objective is to, with a single DBS system implanted in the standard STN location for PD:~(i) deliver conventional tonic DBS stimulation of STN-to mitigate dopamine-responsive symptoms; and concurrently (ii) deliver bursting DBS-induced cueing stimulation-to mitigate FOG.~The sole function of CereGate Software is to guide the clinician through a systematic investigation of the stimulation parameter space to thereby configure / tune CereGate Therapy for each participant. CereGate Software proposes parameters for the clinician to evaluate and assists in documenting the response. It does not send commands to, nor control the output of, the DBS System."
45797785|NCT01662115|Other|Regular chewing gum|Patients will chew regular sugar-free gum 3 times a day until discharge or 7 days, whichever comes first
45925199|NCT00060970|Procedure|Physical Therapy|
45925200|NCT00061087|Drug|Methylphenidate|Methylphenidate 80mg/day
45649716|NCT04876313|Drug|Nivolumab + Nab-paclitaxel|4x3 weekly cycles of 360 mg nivolumab + 125 mg/m^2 nab-paclitaxel IV on days 1 and 8
45649717|NCT04876313|Drug|Nivolumab|360 mg IV Q3W x 13 cycles
45925201|NCT00061087|Drug|Bupropion|Bupropion 400mg/day
45649718|NCT04876469|Procedure|Pulsed Radiofrequency treatment of the lumbar dorsal root ganglion|Using radiocontrast media or not for the pulsed radiofrequency treatment of the lumbar dorsal root ganglion
45797786|NCT01662583|Other|Text Message|
45797787|NCT01662583|Other|Written reminder|
45797788|NCT03002233|Drug|TRK-820|
45797789|NCT01598545|Drug|Hydromorphone|Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
45797790|NCT01598701|Drug|Acetaminophen|Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.
45797791|NCT01598701|Drug|Placebo|100 mL 0.9% Sodium Chloride
45797792|NCT05139303|Device|Orthoapnea NOA®|The efficacy of the appliance for the management of OSA will be stablished based on two criteria. Criterion I: > 50% reduction of AHI/RDI. Criterion II: AHI/RDI < 5 events/hour or <15 events/hour with a significative reduction of OSA associates symptoms as defined before. Therapeutic failure will be established when at 100% of advancement of the device, there is less than 50% of reduction of the AHI/RDI with a residual AHI/RDI >5 events/hour with OSA associates symptoms.
45797793|NCT00000309|Drug|Risperidone|
45797794|NCT00000315|Drug|Cocaine|
45797795|NCT00000321|Drug|Desipramine|
45925202|NCT00061087|Other|Placebo|Placebo
45797796|NCT01694563|Device|Synergy Ablation System|"Patient will undergo an elective open cardiac surgical procedure to be performed on cardiopulmonary bypass for one or more of the following:~Coronary Artery Bypass Grafting (CABG)~Mitral valve repair or replacement~Aortic valve repair or replacement~Tricuspid valve repair or replacement The aim of the treatment is a complete bi-atrial Maze IV procedure which includes pulmonary vein isolation coupled with lesions made on both the left and right atria."
45649719|NCT02615249|Biological|Metal Allergen Epicutaneous Patch|48 hour application of metal allergen patch to diagnose contact dermatitis
45649720|NCT05257811|Device|NextSense EEG-enabled earbuds|Each NextSense EEGBud device includes custom-fit earbuds with biometric sensors to detect EEG, motion (via tri-axial accelerometers), and heart rate. A ring laser scanner is used to capture the unique geometry of each participant's ear and external auditory canal. Digital models of the individual ear scans are generated and used to create custom fit, 3D-printed earbuds. This design process allows for consistent contact with the inner surface of the ear canal, providing high quality signal capture of brain activity, cardiac activity, and eye movements.
45925203|NCT00061126|Drug|ABX-EGF|
45925204|NCT05282225|Behavioral|MI- Safety Plan|"The MI-enhanced safety plan (MI-SP) component is delivered during hospitalization and includes an individual and family meetings. The goal of the individual meeting with the adolescent is to develop an individualized safety plan for use during a suicidal crisis. This best practices approach of safety planning is augmented with Motivational Interviewing (MI) as a core strategy to explicitly elicit adolescents' motivation and commitment to behavior change (i.e. use safety plan; adaptive coping), address barriers or ambivalence, and strengthen self-efficacy. The focus of the family meeting, which is similarly guided by MI, is to prepare parents/guardians, with input from the adolescent, for how they may support the adolescent in implementing the individualized safety plan after discharge and on strengthening parents' commitment and self-efficacy"
45797797|NCT05373381|Dietary Supplement|Supplemental High Fat Low Carbohydrate (sHFLC) + KetoPhyt|Following a screening period, subjects will adhere to the sHFLC + KetoPhyt diet for six 4-week cycles. Patients will receive dietary advice from a Registered Dietitian (RD) to allow for the design of personalized meal plans maintaining carbohydrates up to 33% of total caloric intake, and be asked to maintain a daily dietary log. To assist patients in understanding, monitoring and controlling their dietary choices to maintain a low carbohydrate diet, they will be trained and receive assistance on the use of an online tool for tracking nutrition [Healthtrac].
45797798|NCT05125029|Drug|Botulinum toxin|Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum that prevents the release of the neurotransmitter acetylcholine from the neuromuscular junction, thereby preventing muscular contraction. Eligible subjects will be randomized 1:1:1 into three different groups: 1) placebo 2) 10 Units of BT injected per digit and 3) 20 units of BT injected per digit.
45797799|NCT01940276|Drug|Abiraterone acetate|
45797800|NCT01940276|Drug|Prednisone|
45925205|NCT05282225|Behavioral|Texts messages|For participants randomized to receive supportive text messages (Texts), text messages will be sent daily for 4 weeks. The messages will be tailored to encourage use of individualized coping strategies identified as part of safety planning at hospitalization and will include additional adaptive coping tools and resources. The text message content and tone will be consistent with principles of MI.
45925206|NCT05282225|Behavioral|Monitoring|Adolescent participants will complete daily surveys for 4 weeks (including assessment of suicidal ideation, behavior, and other relevant risk and protective factors) and these will be monitored daily to identify presence of heightened suicidal ideation and presence of suicidal behavior. In addition, daily surveys will be used to determine if adolescents are sufficient responders to Phase 1 intervention.
46071968|NCT05838430|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"Treatment will be conducted via a HIPAA compliant video link (Zoom). Sessions 1-8 will follow our published protocol (published in 2005 by Springer).~Each session will be conducted individually and have a singular focus per session.~All sessions following the delivery of sleep restriction therapy & stimulus control instructions (post Session 2) will include, as needed, management of non-adherence and/or time-in-bed titration."
45797801|NCT01600495|Other|Experimental TENS|Use of Transcutaneous Nerve Electrical Stimulation in the lumbosacral region for 30 continuous minutes in the active phase of labor (4-5 cm).
45797802|NCT00382395|Device|SOLX Gold Shunt GMS-plus|Single use implant
45797803|NCT00382395|Device|Ahmed FP7 Glaucoma Valve|Single use implant
45797804|NCT00000327|Drug|Heroin Dependence|
45797805|NCT01919216|Drug|Citalopram|
45797806|NCT01600729|Drug|No Intervention|No intervention.
45797807|NCT04527237|Other|acupressure|"The person will be given 2 applications a day at 12-hour intervals and 6 applications in 72 hours in total. The session duration of an individual will be approximately 25 minutes.~Physiological measurements will be made before and after the acupressure application. Physiological measurements 10-15 min. From acupressure application. will be taken before and the same measurements after acupressure 20-30. Will be taken again in the min interval. In addition, the Continuous Anxiety Scale will be applied once before application, the State Anxiety Scale will be applied once before the application and 3 times in total after the application at the end of every 24 hours. Sleep Scale will be applied 3 times in total before the next day after application."
45797808|NCT04527237|Other|Placebo|Unlike acupressure, it will only be in contact with gloves, to reduce the electrical effect of touch, away from the actual acupressure points.
46071969|NCT05838430|Other|Monitoring|No CBT-I will be administered, however, the tracking system used for CBT-I will be used for all subject conditions. This includes a sleep disorder symptoms screener, the administration of several questionnaires on a weekly basis, and the administration of daily sleep diaries online or via iPhone. Note: it is a common effect that regular monitoring of this type produces perceived clinical benefit.
46071970|NCT05838430|Other|Placebo|Placebo, identical in appearance to the active drug.
46071971|NCT05835154|Behavioral|Assessment|Complete checklist
45797809|NCT02993185|Behavioral|Your Move|"Your Move (YM) is an interactive sex education intervention. Groups of girls are randomly assigned to YM or Eat Smart (ES), a control interactive nutrition education intervention. Each program consist of seven 75-minute sessions, and each session contains 60 minutes of facilitator-led discussion, video clips, activities, and games as well as 15 minutes of personal reflection time during which girls practice the decision making skills they have learned. Participants complete online surveys about their attitudes, knowledge, and behavior related to food and nutrition and relationships and sex at baseline and also 3 months after the program ends."
45797810|NCT02993185|Behavioral|Eat Smart|"Eat Smart (ES) is an interactive nutrition education intervention. Groups of girls are randomly assigned to ES or Your Move, an interactive sex education intervention. Each program consist of seven 75-minute sessions, and each session contains 60 minutes of facilitator-led discussion, video clips, activities, and games as well as 15 minutes of personal reflection time during which girls practice the decision making skills they have learned. Participants complete online surveys about their attitudes, knowledge, and behavior related to food and nutrition and relationships and sex at baseline and also 3 months after the program ends."
45925207|NCT05282225|Behavioral|Portal follow-up|This will be part of Phase 2. The portal follow-up will similarly address content offered in the booster call. For the adolescent, the focus will be on revisiting and adjusting the safety plan, addressing barriers to safety plan adherence, as well as enhancing motivation and self-efficacy to use healthy coping. For the parent, portal communication will focus on revisiting safety recommendations provided as part of MI-SP, addressing barriers in implementing safety recommendations and in supporting the adolescent's safety plan use, as well as enhancing parents' motivation and self-efficacy in these areas. The portal will enable additional asynchronous contacts up to 3 weeks to provide added support and problem solving, based on identified barriers and concerns, to promote post-discharge behavior change. Counselors will initiate approximately 6 contacts with adolescents and, separately, with parents over 3 weeks as soon as non-response is detected.
45649721|NCT02615171|Behavioral|Comprehensive Dietary Self-Monitoring; Device: smartphone; Other: physical activity|The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.
45797811|NCT01940510|Drug|RO5424802|Single dose without (Day 1) and with (Day 17) co-administration of rifampin
45925208|NCT05282225|Behavioral|Booster call|The focus of the post-discharge booster phone call with adolescent and with parent, each conducted separately, is to further adjust the safety plan to better meet post-discharge needs, to further enhance adolescents' motivation and commitment to use coping strategies, and to further support adolescents' and parents' self-efficacy to manage suicidal crises.
45925209|NCT02968225|Behavioral|Computer Game|The game involves viewing subtle nonverbal behaviors of game characters for the purpose of executing their own goal-directed behavior in the game related to solving various crimes. The learning involves interpreting nonverbal cues on the animated characters, such as pointing, head turns, eye gaze cues.
45925210|NCT00061165|Behavioral|School + family changes promoting healthy eating + activity|
45925211|NCT02968186|Behavioral|Implementation program|Health professionals in the intervention arm will receive up to four training sessions in the first three months of the implementation period. Practice support will be continuously available throughout the project. Posters specifically designed for this project will be added to the primary health care units aiming to facilitate eliciting alcohol issues during the consultations, and to help professionals remembering to conduct alcohol screening and brief intervention. Leaflets to be handed-in to patients were also specifically produced for this project, aiming to aid professionals in advising at-risk drinkers to cut down. The research team will schedule with each primary health care unit regular visits for feedback on the progress of the program.
45925212|NCT00061243|Biological|HIV-1 DNA vaccine with protein vaccine boost|Three doses of DNA vaccination will be administered at weeks 0, 4, and 12, and 2 doses of protein vaccination at weeks 20 and 28
45797812|NCT01940510|Drug|rifampin|Multiple doses Days 8-16 and Days 17-20
45925213|NCT04711564|Other|Olive oil-based intravenous fat emulsions|Parenteral nutrition planned according to the requirements of the patients is given for ten days.
46071972|NCT05835154|Other|Questionnaire Administration|Complete questionnaires
46071973|NCT05835154|Other|Interview|Undergo semi-structured feedback interview
46071974|NCT05835154|Other|Electronic Health Record Review|Review of medical records
46071975|NCT05834842|Behavioral|Unisalud|"The UNISALUD intervention will be made up of 42 videos, made using the visual collage technique, where illustration, video fragments and visual interactions are mixed and in some there will be a presenter to achieve captivating visual material. to the participant. Likewise, it will be accompanied by digital infographics that will help reinforce the information proposed by the intervention."
46071976|NCT05832918|Other|exercise therapy|Exercise therapy is one of the rehabilitation methods that is defined as a regimen or plan of physical activities designed and prescribed to facilitate the patient's recovery from diseases and any conditions which disturb their movement and activity of daily life or maintain a state of well-being through neuro re-education, gait training, and therapeutic exercises.
45797813|NCT00380211|Biological|Influenza vaccine (A/H3N2, A/H1N1, and B strains)|
45797814|NCT00380211|Biological|Fluarix|
45797815|NCT01601431|Device|Cap Assisted Colonoscopy|Plastic transparent cap added to the distal end of the colonoscope which can increase adenoma detection rate
45797816|NCT01601431|Device|Conventional colonoscopy|Regular colonoscopy as per standard clinical guidelines
45797817|NCT00380289|Drug|Thiazide and beta blocker|
45797818|NCT01601977|Device|AVAPS-AE|Novel ventilation mode (Omnilab - AVAPS AE algorithm)
45797819|NCT01601977|Device|Usual care|Non-invasive ventilation with standard ventilator
45797820|NCT05364645|Drug|Carboplatin|Given IV
45797821|NCT05364645|Drug|Pemetrexed|Given IV
45797822|NCT05364645|Drug|Selpercatinib|Given PO
45925214|NCT04711564|Other|Soybean-based intravenous fat emulsions|Parenteral nutrition planned according to the requirements of the patients is given for ten days.
45649722|NCT02615171|Behavioral|Simple Dietary Self-Monitoring; Device: smartphone; Other: physical activity|Arm: Active Comparator: Simple Dietary Self-Monitoring he intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
46071977|NCT05831670|Drug|KSP-0243|Oral administration
46071978|NCT05831670|Drug|Placebo|Oral administration
45649723|NCT03049085|Drug|Aspirin|preoperative uncoated 75 mg Aspirin is administered 2 hours prior OPCAB
45649724|NCT03049085|Drug|vitamin C|preoperative 75 mg Vit. C (Placebo) is administered 2 hours prior OPCAB
45649725|NCT04876547|Procedure|appendectomy|appendectomy performance
45649726|NCT04876001|Behavioral|Brief Behavior Therapy for Insomnia|"The BBTI consists of two in-person sessions on week 1 and 3 and two sessions on week 2 and 4 as the booster delivered by phone call."
45649727|NCT04875845|Behavioral|Fasting for elective surgery|6-hours and 8-hours fasting before elective surgery
45649728|NCT04869293|Device|Hypnosis 3D virtual reality headset|3D experience to journey through a natural and therapeutic environment. Immersion is amplified by the realism of 3D environment, a soothing sound atmosphere and specific medical hypnosis.
45797823|NCT01919450|Drug|Regadenoson|Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
45649729|NCT04875611|Drug|Opdivo|Dose of Nivolumab is constant and is 240 mg .All patients will undergo maximum of 12 cycles of investigation product's infusion ( around 6 month of treatment).Each cycle will be done in intervals of 14 day (no less than 12 days after previous infusion and no longer than 42 day/6 weeks after previous infusion).
45649730|NCT04875689|Other|Group A (Experimental|"Laser therapy is performed on patients in supine lying position. Treatments will be delivered with a diode laser (wavelength 830 nm, continuous wave, power 50 mW) in skin contact at a dose of 6 J/point. Treatment times per point are in the range of 30 seconds to 1 minute. eight points were irradiated per session.~Conventional therapy will include:~TENS for 15 minutes~Hot pack for 15 minutes~Hamstrings muscle stretching and calf muscle stretching. Strengthening exercises ,straight leg raising exercise in crook lying position~Joint mobilizations"
45797824|NCT01919450|Radiation|Rubidium-82|Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
45797825|NCT01602679|Drug|oral micronized progesterone suspension|oral micronized progesterone (100 mg p.o.) suspension
45797826|NCT01602679|Drug|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
45797827|NCT01919606|Drug|EXPAREL|Single-dose EXPAREL diluted with 20 mL or 40 mL saline to a volume of 40 mL or 60 mL, respectively.
45797828|NCT01663363|Device|LASIK correction of myopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
45797829|NCT01919996|Drug|Azithromycin|Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
45797830|NCT02234713|Behavioral|Motivational Interview|
45797831|NCT02234713|Other|Video Attention Control|
45797832|NCT01921322|Device|Pump|722 Paradigm Real-Time System
45797833|NCT01921322|Other|CGMS Gold|Device used to collect retrospective sensor data, blinded to the subjects, to compare to the treatment arm
45797834|NCT05735210|Device|Polso™ Watch blood pressure measurement compared to a reference blood pressure measurement|The referenced blood pressure measurements are taken by dual auscultators.
45797835|NCT01665157|Dietary Supplement|Enimaclin®|"Enimaclin Colomil ® (Glico Co., Japan Osaka)，a low-residue diet package for each meal.~The duration of study is one day before colonoscopy."
45797836|NCT01665157|Other|Self-controlled diet|Self-controlled low residue diet.
45797837|NCT01665157|Drug|2L PEG-ELS|Normal volume of PEG-ELS
45797838|NCT01665157|Drug|low volume 1.5L PEG-ELS|Low volume PEG-ELS
45797839|NCT05735132|Procedure|Conventional Line-blocking|Participants will receive a 2 cm subcutaneous 1% lidocaine local infiltration injection parallel to the arm at the puncture site.
45797840|NCT05735132|Procedure|Bar-blocking|Participants will receive a bar-shaped subcutaneous 1% lidocaine local infiltration injection in the vertical arm, 2 cm away from the puncture site.
45797841|NCT05735132|Procedure|V-blocking|Participants will receive a V-shaped subcutaneous 1% lidocaine local infiltration injection at a 90-degree angle 2 cm away from the puncture site.
45797842|NCT01943474|Device|AccuCath IV Catheter Device|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
45797843|NCT01943474|Device|Conventional IV Catheter Device|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples.
45797844|NCT01667029|Drug|Sulfasalazine|
45797845|NCT01667029|Drug|placebo|
45797846|NCT01694641|Other|time-lapse morphokinetic evaluation|embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse
45797847|NCT05118633|Behavioral|Device and app system designed for participant to self-administer Habit Reversal Training and Stimulus Control|Participants will receive an awareness bracelet and an app that work together to implement key features of Habit Reversal Training and Stimulus Control. The participant will take part in psychoeducation, awareness training, and competing response training related to trichotillomania, as well as receive stimulus control reminders.
46071979|NCT05826418|Dietary Supplement|MEND diet|Participants will be asked to adhere to their randomized MEND diet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
46071980|NCT05826418|Dietary Supplement|mNICE diet|Participants will be asked to adhere to their randomized mNICEdiet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
45925215|NCT00061321|Drug|Nevirapine and mulitvitamins|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum Infants (Arm 2 Only): Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
45925216|NCT00061360|Drug|ATG+Rapamune+cyclosporine|ATG+Rapamune+cyclosporine
45925217|NCT00061360|Drug|ATG+cyclosporine|ATG+cyclosporine
45925218|NCT00061438|Drug|meropenem|
45925219|NCT05001009|Behavioral|Clinician Implementation Strategy Stage 1|"A booster of the established LSTDI implementation strategy. Clinicians will be presented with summary written/electronic materials on the LSTDI developed for the study. Online training options and when and how to complete goals of care conversations and documentation will be highlighted."
45925220|NCT05001009|Behavioral|Clinician Implementation Strategy Stage 2|"This includes two components:~Team facilitation to help the primary care team (advance practice provider, nurse, social worker) work together to create roles and responsibilities for accomplishing goals of care conversations with patients~A patient list trigger of patients potentially eligible for goals of care conversations (the patient study population) will be sent to the primary care clinicians."
45925221|NCT05001009|Behavioral|Low patient engagement|Patients will be sent information about goals of care conversations, including the PREPARE website.
45925222|NCT05001009|Behavioral|High patient engagement|Patients will be sent information about goals of care conversations, including the PREPARE website. Follow-up phone calls to discuss goals of care conversations and the PREPARE website will be made.
45925223|NCT00061477|Drug|Pemetrexed|
45925224|NCT00061477|Drug|Gemcitabine|
45925225|NCT02968342|Device|Vaginal progesterone 8%|vaginal self application
45925226|NCT05243732|Behavioral|Mindful Music Listening|"Participants will be instructed to self-administer this intervention daily, five days a week, for four weeks, 20 to 60 minutes per day at any time that is convenient for them.~During the intervention period, participants will be recommended to listen to music in a private setting that is quiet, where they will not be disturbed or distracted so they can fully focus on the music.~Participants in the mindful listening group will be given specific instructions on how to listen and follow mindfulness."
45925227|NCT05243732|Behavioral|Music Listening|"Participants will be instructed to self-administer this intervention daily, five days a week, for four weeks, 20 to 60 minutes per day at any time that is convenient for them.~During the intervention period, participants will be recommended to listen to music in a private setting that is quiet, where they will not be disturbed or distracted so they can fully focus on the music. No other specific music listening instructions will be given"
46071981|NCT05818397|Behavioral|Self-Compassion for Children and Caregivers (SCCC)|A standardized, manualized adaptation of the mindful self-compassion curriculum for adults, designed for online delivery. Dyads join a group video conference call along with other caregiver-child dyads and an experienced SCCC facilitator. Sessions occur 1-hour per week for 6 weeks at a time convenient for the group.
46071982|NCT05808127|Behavioral|PainTracker|The PainTracker tool reframes the patient visit around improving functional status and obtaining functional goals, understanding psychological concerns that may exacerbate pain such as traumatic stress, anxiety, and depression. This approach may promote an increase in referrals for physical therapy, mental health counseling, and psychiatric follow-up.
45649731|NCT04875689|Diagnostic Test|Group B (Control)|"1. Participants of this group will receive only conventional therapy which will include;~TENS for 15 minutes~Hot pack for 15 minutes~Hamstrings muscle stretching and calf muscle stretching.Each stretch was sustained for 30 seconds, with 10-second rest intervals.~Strengthening exercises include quadricep drills(full knee extension maintained for 5 seconds, followed by a 5-second rest) 20 repetitions per session,straight leg raising exercise in crook lying position(the patients were asked to tense the quadriceps muscle, elevate the limb to 45° and maintain it for 6 seconds, and lower the limb slowly and then relax for 6 seconds; the exercise was performed for three sets of 10 repetitions per session).~Joint mobilizations (tibiofemoral extension and flexion; patellofemoral medial-lateral and inferior glide)."
45649732|NCT04386317|Drug|Terazosin|Fifteen patients with defined pre-motor PD risk and abnormal baseline 123I-MIBG uptake, with or without 123I-Ioflupane uptake abnormality or PD motor symptoms, will be recruited to receive daily oral doses of terazosin 5 mg or 10 mg. The dosage of terazosin will be gradually increased from the initial recommended starting dose of 1 mg daily at bedtime and titrated stepwise to 2mg, 5mg or 10 mg weekly, according to patient tolerability, as measured by subjective complaints, arterial blood pressure and heart rate. The target dose will be 5 mg or 10 mg daily based on subject's tolerability. Development of incompatibility will be addressed by individually adjusting the dose of terazosin.
45797848|NCT05118633|Behavioral|Reminder bracelet and journaling app control condition|Participants will receive a bracelet programmed to vibrate randomly several times per hour during waking hours. They will be instructed this is a reminder not to pull. They will also be instructed to journal in an app on their phone several times per day.
45797849|NCT05362305|Behavioral|Essential Coaching for Every Mother|Daily text messages for the first six-weeks postpartum.
45797850|NCT02992093|Other|all the indicators|BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites
45797851|NCT05358951|Behavioral|STEP-YA with Coaching|Online instruction on behavioral changes to improve sleep with 2 additional individually coached session
45797852|NCT05358951|Behavioral|STEP-YA without Coaching|Online instruction on behavioral changes to improve sleep without additional individually coached session
45797853|NCT01669603|Dietary Supplement|Bifidobacterium lactis Bl-04|The study product will be a 2*109 cfus of probiotic Bifidobacterium lactis Bl-04 mixed with 1g of sucrose as a carrier.
45649733|NCT04369625|Behavioral|CHIMPS-T|CHIMPS-T (Children of mentally ill parents) is a family-oriented lowfrequency brief therapy for diagnosis and treatment of mental disorders in children and adolescents.
45649734|NCT04369625|Behavioral|CHIMPS-P|CHIMPS-P is a family-oriented prevention for children and adolescents without signs of mental disorders in the initial screening. These families will receive the 3 family sessions from the modular CHIMPS intervention.
45649735|NCT04369625|Behavioral|CHIMPS-MFT-group|The CHIMPS-MFT-group is a prevention with a multi-family setting based on the CHIMPS approach. The multi-family intervention comprises 8 sessions for children and adolescents without psychiatric disorders and their families.
45649736|NCT04369625|Behavioral|iCHIMPS|iCHIMPS is an online intervention. In terms of content, iCHIMPS is based on the CHIMPS program as well as on other evidence-based interventions of the study group. iCHIMPS will also be comprised of one module for children and adolescents as well as one module for parents; moreover; modules for the family system will be included.
45649737|NCT04366895|Other|conventional single implant overdenture|conventional manufactured implant overdenture
45649738|NCT04366895|Other|3d printed single implant overdenture|CAD-CAM manufactured implant overdenture.
45649739|NCT05257187|Device|Transcervical foley catheter|The foley catheter is inserted manually by an obstetric provider through the cervix and inflated with 60cc of saline. Once in the correct position, the catheter is inflated, which puts pressure on the cervix, allowing it to release hormones that soften the cervix and help the cervix to open. The foley catheter can be left in place up to 12 hours but typically will fall out when the cervix is dilated to 3-4 centimeters.
45797854|NCT01669603|Dietary Supplement|Placebo|Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.
45797855|NCT01669603|Biological|Rhinovirus|rhinovirus for experimental challenge
45797856|NCT01606735|Drug|IBI-10090|dexamethasone
45649740|NCT04429763|Biological|Umbilical cord derived mesenchymal stem cells|One dosis of 1*10^6 cells/Kg
45797857|NCT01943864|Drug|Trametinib (single tablet)|The drug substance is blended with inert
45797858|NCT01943864|Drug|Trametinib (Multiple tablet)|The drug substance is blended with inert
45797859|NCT05100459|Dietary Supplement|Pasture-raised whey protein|25 grams of protein delivered 3 times daily
45797860|NCT05100459|Dietary Supplement|Conventional whey protein|25 grams of protein delivered 3 times daily
45797861|NCT05100459|Dietary Supplement|Placebo|Iso-caloric placebo taken 3 times daily like the protein supplementation
45797862|NCT01607203|Drug|Decapeptyl Daily|Decapeptyl 0.2 mg SC once 1day
45797863|NCT01607203|Drug|pregnyl|5000 IU SC
45797864|NCT00000333|Drug|Benztropine|
45797865|NCT00000339|Drug|Risperidone|
45797866|NCT00000345|Drug|Lofexidine|
45797867|NCT01921634|Other|Modified Pathologic Analysis|
45797868|NCT00000357|Drug|Buprenorphine|
45797869|NCT01922024|Device|LRT55 Testing|Testing on the Unyvero LRT55
45797870|NCT00000387|Behavioral|Self-management therapy|Behavioral
45797871|NCT00000387|Behavioral|Self-management therapy|
45797872|NCT00000393|Drug|Peptide T|
45797873|NCT05095311|Drug|Nedocromil Sodium|Eight participants will be administered 4 mg of nedocromil sodium to examine whether this drug can improve their oxyhemoglobin saturation during exercise.
45797874|NCT05095311|Drug|Cetirizine HCl|Eight participants will be administered 10 mg of cetirizine HCl to examine whether this drug can improve their oxyhemoglobin saturation during exercise.
45797875|NCT05095311|Other|Placebo|The placebo pill is a sugar-free gelatin pill casing. The placebo inhaler contains isotonic saline.
45797876|NCT01922336|Biological|SB2|IV infusion
45797877|NCT01922336|Biological|EU Remicade|IV infusion
45797878|NCT01922336|Biological|US Remicade|IV infusion
45797879|NCT01608061|Device|DBS-f on|deep brain stimulation of the fornix
45797880|NCT01608061|Device|DBS-f off|deep brain stimulation of the fornix turned off
45797881|NCT01696357|Device|Automated Device for Asthma Monitoring (ADAM)|Both groups of adolescents (asthma/non-asthma)wore a prototype ADAM device for 7 days as they went about their usual daily activities. At night, the device continued to monitor symptoms as it was placed in close proximity to the adolescent's head during sleep. The asthma group answered survey questions about the status of their symptoms and their usage of asthma medication every morning and every evening- entering their answers directly onto the monitoring device.
45797882|NCT04330755|Drug|Saline Solution|Placebo
45797883|NCT04330755|Drug|Levosimendan|Levosimendan
45797884|NCT04330755|Drug|Magnesium Sulfate|Magnesium Sulfate
45797885|NCT04366323|Drug|ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS|Two doses of 80 million adipose-tissue derived mesenchymal stem cells
45797886|NCT01944644|Device|Active Low Field Magnetic Stimulation|Active Low Field Magnetic Stimulation treatments will be delivered with a prototype LFMS device manufactured by Tal Medical. LFMS sessions consist of proton echo-planar magnetic resonance spectroscopic imaging (EP-MRSI) and will be 20min in duration. LFMS exposes subjects to magnetic fields of the same magnitude and frequency used in clinical MR-Spectroscopic imaging of the brain.
45797887|NCT01944644|Device|Sham Low Field Magnetic Stimulation|Sham Low Field Magnetic Stimulation will consist of a three-dimensional spoiled gradient echo sequence of the same duration as active LFMS and which provides auditory stimulation indistinguishable from active treatment.
45925228|NCT02968303|Drug|Vemurafenib and Cobimetinib|Combination of Vemurafenib with Cobimetinib in BRAF V600E/K mutated melanoma patients to normalize LDH and optimize immunotherapy with Nivolumab and Ipilimumab
45925229|NCT00061516|Drug|BETAXON (levobetaxolol HCl)|levobetaxolol suspension, 0.5%
45925230|NCT00061516|Drug|AZOPT (brinzolamide)|brinzolamide suspension, 1%
45450517|NCT03536182|Radiation|Intensity Modulated Radiation Therapy (IMRT)|Patient will receive IMRT daily, 5 days a week for a total of 28 fractions/treatments plus concurrent chemotherapy (gemcitabine or capecitabine) weekly for 5 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic,within 6 weeks of completing radiotherapy,patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
45649741|NCT04429763|Biological|Placebo|Placebo
45925231|NCT00061594|Drug|rhuFab V2 (ranibizumab)|
45925232|NCT04977180|Drug|Cardioprotection|Preventive beta blocker (metoprolol or carvedilol) and an ACE inhibitor (lisinopril)
45925233|NCT02968147|Device|High frequency jet ventilation|General anaesthesia and ventilation with the Acutronic Monsoon III Jet ventilator system
45925234|NCT02968147|Device|Conventional ventilation|General anaesthesia and ventilation with a conventional Phillips intermittent positive pressure ventilator system
45925235|NCT00061672|Drug|ABT-510 - Thrombospondin-1 Mimetic|
45925236|NCT00389792|Drug|ATI-2042|no intervention
45925237|NCT00389792|Drug|ATI-2042 200 mg|To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.
45925238|NCT02968069|Device|NBI|Endoscopic factors under white light view and simplified narrow band imaging classification assisting in diagnosing cancerous lesions will be recorded.
45925239|NCT00061711|Drug|Hormone Replacement Therapy|
45925240|NCT00061711|Drug|Cimicifuga racemosa (Black Cohosh)|
45925241|NCT00061711|Drug|Multibotanical phytoestrogen formula|
45925242|NCT00061750|Drug|ICL670|
45925243|NCT00061750|Drug|deferoxamine|
45925244|NCT00061789|Drug|SPECT Imaging of Nicotinic Acetylcholine Receptors in Brain|
45925245|NCT02968030|Other|Muscle strength|"Strength training The strength training for lower limbs muscles occurred twice a week, 40 minutes per session for eight consecutive weeks.~n the first two weeks of training, each elderly performed the exercises with 50% of its load defined in 8RM test, increasing to 60 and 70% of the load in the third and fourth subsequent weeks, respectively. After this period, a new evaluation by 8RM strength test was conducted, adopting the fifth and sixth weeks of training 50% of value of the new load defined in 8RM test and to finalize the program in seventh and eighth weeks applied, respectively, 60% and 70% of the new charge. The exercises were performed for the quadriceps, hamstrings, muscles adductor and abductor hip."
45450518|NCT03964025|Device|Wearing Cardioskin™ for 14 days|The current standard of care for diagnosing AF is through the use of a 24 hour Holter device. In this study, in addition to wearing the 3-lead Holter recorder for 24 hours, the subject will be wearing the Cardioskin™ for a period of 24 hours as well, after which the subject will continue wearing the Cardioskin™ alone for an additional period of 13 days.
45925246|NCT04939584|Device|MultiPulse Therapy|Electrical Stimulation
45925247|NCT05221346|Dietary Supplement|Plant food supplement|Food supplements are consumed during 3 weeks by hypercholesterolemic volunteers
45450519|NCT02185300|Drug|Dolutegravir Pediatric Granules|Dolutegravir pediatric granules are supplied as 40 grams bulk bottles containing 0.4% weight by weight of dolutegravir to be reconstituted with 73 mL of purified water to yield a dolutegravir concentration of 1.6 milligram / millilitre. 12.5 mL of reconstituted granules contain 20 mg DTG
45649742|NCT05257031|Drug|SmofKabiven extra Nitrogen|SmofKabiven extra Nitrogen contains amino acids (Aminoven®), glucose, lipids (SMOFlipid®: 30% soybean oil, 30% medium-chain triglycerides, 25% olive oil, 15% fish oil), and electrolytes.
45797888|NCT01608295|Drug|Vilazodone; Viibryd|Subjects randomized to receive vilazodone blindly will have incremental dose titration of 10mg per day for the 1st week; 20mg per day the 2nd week; 40mg per day for the 3rd-12th week. Doses of the drugs will be adjusted according to individual tolerability and safety.
45797889|NCT01608295|Drug|Paroxetine; Paxil|Subjects randomized to receive paroxetine blindly will have incremental dose titration of paroxetine 10mg per day for the 1st week; 20mg per day for the 2nd week; and 30mg per day for the 3rd-12 week. Doses of the drugs will be adjusted according to individual tolerability and safety.
45925248|NCT05221346|Dietary Supplement|Maltodextrin|Food supplements are consumed during 3 weeks by hypercholesterolemic volunteers
45925249|NCT00061867|Drug|pegylated liposomal doxorubicin hydrochloride|
45925250|NCT00061867|Procedure|hyperthermia treatment|
45925251|NCT00061906|Drug|celecoxib|Treatment will be administered on an outpatient basis. Oral celecoxib will be given at the dose of 400 mg BID for total of 12 months. Patients will be advised to take this medication with food to improve absorption.
45925252|NCT02967913|Procedure|Bladder flap|bladder is separated from the lower uterine segment prior to making the uterine incision at time of cesarean delivery
45925253|NCT02967835|Behavioral|Tele-psychiatry consult|tele-psychiatry consult for evaluation and treatment recommendations
45925254|NCT04936776|Behavioral|Text messaging|Text parents of children (age 0-2yrs) who are due and due soon for a vaccine across the entire NYU-Brooklyn FHC network to increase vaccination rates.
45925255|NCT05219825|Behavioral|Breathwork workshop|Participants will complete 1.5 hours of breathwork session in addition to a total of 6 hours of brief psychotherapeutic intervention in a span of 1 week. The therapy sessions will occur both before and after the breathing session.
45925256|NCT00398554|Drug|cyclophosphamide|1250 mg/m2 i.v. 60 Min.-Inf. day 1 and 21
45925257|NCT00398554|Drug|doxorubicin hydrochloride|25mg/m²/day, 2 hours i.v.infusion on day 21
45925258|NCT00398554|Drug|etoposide|150 mg/m²/day, 2 hours i.v.infusion (intravenous drip) on days 1 - 3
45925259|NCT00398554|Drug|prednisone|40 mg/m2/day p.o. (intake by mouth)divided in 3 single doses daily from day 1 - 14 and day 21 - 34
45925260|NCT00398554|Drug|vinblastine sulfate|6 mg/m² i.v. bolus on day 1 and day 21
45925261|NCT00398554|Drug|vincristine sulfate|1,5 mg/m2 i.v. bolus max. single dose 2 mg (cap dose at 2 mg) on day 8 and day 29
45925262|NCT00398554|Radiation|radiation therapy|involved field irradiation, single daily fractions 1,5 Gy to max. 1,8 Gy standard dose 20 Gy, max dose 30 Gy (boost irradiation if required)
45925263|NCT00398593|Behavioral|Range of electronic pill dispensers with alarms|Patients will be offered 1. Counselling with education and/or 2. Electronic reminders
45925264|NCT04917900|Drug|Pyrotinib combined with albumin-bound paclitaxel and trastuzumab|Pyrotinib: 400mg, po,qd,with warm water within 30 minutes after breakfast, q3weeks, 6 cycles in total. Albumin-bound paclitaxel: 260mg/m2, iv, Day1, q3weeks, 6 cycles in total. Trastuzumab: The first cycle dose is 8mg/kg, and each subsequent cycle is 6mg/kg, iv, Day 1, q3weeks, a total of 6 cycles.
45797890|NCT04713111|Behavioral|Lifestyle (Meditation)|Those in the meditation arm (exercisers) were instructed to complete meditation sessions from the smartphone app, Headspace 2 or more times a week for a duration of 4 weeks.
45925265|NCT05219435|Drug|Nivolumab|Nivolumab at 1 mg/kg by intravenous (IV) infusion on D1 of each cycle. Nivolumab at a fixed dose of 480 mg by intravenous (IV) infusion on D1 of each cycle. The maximum duration of treatment with nivolumab will be 2 years, and patients will discontinue treatment at any time in case of unacceptable toxicity, disease progression (PD), investigator ́s decision, patient's consent withdrawal or death by any cause, whichever occurs first.
45649743|NCT05256953|Procedure|Erector spina plane block + general anesthesia|"Bilateral-injection ultrasound-guided bilateral erector spinae plane block~Pre-operatively, with the patient in the sitting position, 20ml 0.25% bupivacaine will be administered between the T9 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane. The same procedure was applied bilaterally.~Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied.~Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.~Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score >3, (max doses 300 mg/day)."
45797891|NCT04713111|Behavioral|Lifestyle (Exercise)|Those in the physical activity arm (meditators) were instructed to complete 30 minutes to 1 hour of physical activity for 2 or more sessions per week for 4 weeks.
45925266|NCT05219435|Drug|Ipilimumab|Ipilimumab at 3 mg/kg by intravenous (IV) infusion on D1 of each cycle.
45649744|NCT05256953|Procedure|Only general anesthesia|"Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied.~Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.~Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score >3, (max doses 300 mg/day)."
45649745|NCT04875299|Other|The study is observational|The study is observational
45649746|NCT04875143|Dietary Supplement|Citrus aurantium L.|In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention.
45450520|NCT02185300|Drug|Dolutegravir Dispersible Tablet|Dolutegravir is available as 5mg dispersible tablets and can be administered as 4 tablets dispersed in 12.5 mL LMC water and consumed immediately or 4 tablets dispersed in 12.5 mL CONTREX mineral water and consumed immediately or 4 tablets dispersed in 12.5 mL LMC water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed or 4 tablets dispersed in 12.5 mL CONTREX mineral water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed
45649747|NCT04874753|Other|change in kidney function and proteinuria|change in eGFR nad proteinuria in patients with chronic kidney disease
45649748|NCT05256719|Biological|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg , i.v. single dose usage.
45450521|NCT02185378|Procedure|I:E ratio 1:2|We plan to evaluate the improvement on respiratory function with different ventilation I:E ratios (1:2 vs. 1:1) during the one-lung ventilation in an obese patients.
45450522|NCT02185378|Procedure|I:E ratio 1:1|The purpose of our study is to compare the effects of minimal prolonged 1:1 IE ratioventilation on respiratory mechanics and oxygenation with conventional 1:2 IE ratio ventilation during OLV in obese patients.
45450523|NCT02190760|Drug|Dexamethasone|
45450524|NCT02190760|Drug|Bupivacaine|
45450525|NCT02190838|Drug|Metformin|per os 850 mg BID
45649749|NCT05256719|Biological|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg , i.v. single dose usage.
45649750|NCT05256719|Biological|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg , i.v. single dose usage.
45797892|NCT04713189|Drug|Inhaled fentanyl aerosol|Participants in the stage I were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhale fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
45797893|NCT04713189|Drug|Placebo|Participants in the stage Ⅰ were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence. I
45450526|NCT02190838|Drug|Melatonin|per os 3 mg daily
45925267|NCT04730323|Drug|Tocilizumab|"Participants received an initial dose calculated as per the body weight (8mg/kg) maximum 800mg/dose) over 1 hour, followed by up to three additional doses if required as per the response after the first dose with 8 hours intervals. Predefined Parameters of disease severity were assessed 12 to 24 hourly. Injection Paracetamol 1g was administered before infusion. The response of the participants after Tocilizumab administration was recorded based on clinical parameters (Oxygen requirement, Fever, Need for invasive positive pressure ventilation), biochemical parameters (D-dimers, C-reactive protein (CRP), Ferritin, Lactate dehydrogenase (LDH) levels), Chest X-ray findings, and Repeated PCR test for COVID-19. Any side effects noted after administration of TOCILIZUMAB were recorded.~Any side effects noted after administration of TCZ/ Corticosteroid were recorded."
45925268|NCT00061984|Biological|pegfilgrastim|
45797894|NCT01610011|Dietary Supplement|Glycine administration|Glycine will be administered once as a 250 cc lemon-flavored beverage based on each subject's body weight. The drink concentration will be 0.4 g/kg glycine (not to exceed 30 grams). Subjects will have 10 minutes to consume the beverage.
45797895|NCT04712955|Other|Bloodflow restricted exercise|Low-intensity bloodflow restricted resistance exercise is conducted as traditional knee extension exercise with a load corresponding to 30% of 1 repetition maximum (RM), with concurrent partial occlusion of the circulation by means of inflatable pneumatic cuffs wrapped around the proximal part of the thighs. Cuffs are inflated to a pressure corresponding to 50% of the arterial occlusion pressure, which only compromises venous but not arterial blood flow.
45797896|NCT01945112|Device|Paper Tape|Applied to blister prone areas of the foot
45797897|NCT00000399|Drug|Hormone replacement therapy|
45925269|NCT00061984|Drug|doxorubicin hydrochloride|
45450527|NCT02190838|Drug|Dacarbazine|IV 1 hour 1000 mg/m^2 once in 28 days
45649751|NCT05256719|Biological|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg , i.v. single dose usage.
45649752|NCT05256719|Biological|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg , i.v. single dose usage.
45797898|NCT00000399|Procedure|Strength training|
45450528|NCT02185456|Drug|750 mg metronidazole/ 200 mg miconazole vaginal suppository|The higher dose 750 mg metronidazole/ 200 mg miconazole vaginal suppository will be given to patients who were refractory to the standard of care therapy, oral metronidazole 500 mg twice a day for 7 days, and to asymptomatic patients in a randomized arm, who show poor responses based on the qPCR test result.
45649753|NCT05256719|Biological|Placebo-1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg
45649754|NCT05256719|Biological|Placebo-2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg
45450529|NCT02185456|Drug|Standard of care|oral metronidazole 500 mg twice a day for 7 days
45450530|NCT02186158|Drug|Vitamin C|
45450531|NCT02186158|Drug|Placebo|
45797899|NCT02237989|Drug|paracetamol|1500 mg
45797900|NCT02237989|Drug|paracetamol+native collagen type 2|paracetamol (1500 mg) + native collagen type 2 (10mg)
45797901|NCT00382473|Behavioral|Aerobic exercise program - 8 weeks|No drugs. Regular aerobic exercise in structured prescription format
45925270|NCT00061984|Drug|ifosfamide|
45925271|NCT00061984|Procedure|multimodality therapy|
45450532|NCT02186314|Device|Pacemaker Biotronik: apical stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in apical stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( bifocal stimulation) and patients will be kept in the new pacing mode for two months when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
45649755|NCT05256719|Biological|Placebo-5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg
45649756|NCT05256719|Biological|Placebo-7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg
45649757|NCT05256719|Biological|Placebo-10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg
45797902|NCT05326893|Other|Femoral nerve neurodynamic mobilization|The mobilization was carried out with the patient lying on the non-dominant side in a total flexion position, and the therapist performed the hip extension movement with the knee joint kept in flexion till the patient felt soreness or pain. This position was held for three seconds and then released. This tensioning maneuver was repeated in three sets of ten repetitions at each session and an interval of 2 min between series were performed. A total of nine sessions were performed within three weeks.
45649758|NCT05256485|Behavioral|cognitive behavioral therapy,mindfulness based relapse prevention,twelve-step therapy|"In cognitive-behavioral therapy, participants learned that thoughts and emotions contribute to behavior, and responses to thoughts and emotions can be controlled.~in mindfulness-based relapse prevention, participants learned to focus on the present moment experience including craving with an attitude of acceptance and non-judging.~In twelve-step therapy, participants learned principles of acceptance, gratitude, forgiveness, tolerance, patience, humility, and honesty together with participation in different healthy ways to enrich life."
45797903|NCT05326893|Other|Femoral nerve placebo neurodynamic mobilization|The individual was asked to lie on his non-dominant side and keep his head in the midline. In this position, while the pelvis was stabilized, the upper leg, which was in full knee extension, was grasped and the hip was abducted for 3 seconds. This maneuver was repeated in three sets of ten repetitions at each session and an interval of 2 min between series were performed. A total of nine sessions were performed within three weeks.
45797904|NCT05439681|Device|Theranova 400|medium cut off (MCO) membrane
45925272|NCT02967796|Dietary Supplement|Proteochoc|
45925273|NCT04900272|Behavioral|VIPA and companion booklet|Participants will be asked to use the VIPA and accompanying second iteration of the instructional booklet focused on social-isolation. These participants will be surveyed over the phone for 16 weeks (baseline, 2 weeks, 4 weeks, 8 weeks, and 16 weeks) with outcomes measured at each time point.
45925274|NCT00062023|Drug|Acetylsalicylic acid (Aspirin)|Patients receive oral aspirin once daily for 12 months.
45925275|NCT00062023|Drug|Sulindac|Patients receive oral sulindac twice daily for 12 months.
45649759|NCT04874987|Other|Simulation based learning with Advocacy inquiry and ladder of influence|Simulation scenarios based on identified gender and equity gaps. We will explore experiences of male and female participants, and inter-professional simulation participants (e.g nurses and doctors, medical and nursing students) post intervention exposure on their role and experiences in simulated sessions and clinical care experiences
45797905|NCT05439681|Device|FX 10|low-flux membrane
45797906|NCT05439681|Device|FX CorDiax 800|high-flux membrane
45797907|NCT05439681|Device|HDF|hemodiafiltration
45797908|NCT01945970|Other|Black tea extract|Black tea extract
45797909|NCT01945970|Other|Positive control|Positive control
45797910|NCT01945970|Other|Placebo|Placebo
45925276|NCT00062023|Drug|Ursodiol|Patients receive oral ursodiol three times daily for 12 months.
45925277|NCT00062023|Other|Sulindac Placebo|Oral sulindac placebo twice daily.
45925278|NCT05215808|Drug|RBN-3143|Oral Administration of tablets
45925279|NCT00062062|Drug|carboplatin|
45649760|NCT04874675|Drug|diclofenac / acetaminophen /codeine|routine pain medication used post extraction of third molars
45797911|NCT00000417|Procedure|Counseling intervention|
45797912|NCT00000417|Device|Informational film|
45925280|NCT00062062|Drug|gefitinib|
45925281|NCT00062062|Drug|paclitaxel|
45925282|NCT00392340|Biological|filgrastim|
45925283|NCT00392340|Drug|doxorubicin hydrochloride|
45450533|NCT02186314|Device|Pacemaker Biotronik: bifocal stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in bifocal stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( apical stimulation) and patients will be kept in the new pacing mode for two months, when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
45649761|NCT04874675|Drug|ibuprofen/acetaminophen/codeine|routine pain medication used post extraction of third molars
45649762|NCT04874363|Other|no intervention|no intervention
45797913|NCT02229487|Other|Oral glucose tolerance|
45797914|NCT00000423|Behavioral|Social support group|
45797915|NCT00000423|Behavioral|Social support and education group|
45797916|NCT02992561|Behavioral|FORNET (adapted version)|
45797917|NCT00000429|Drug|Calcium carbonate|
45450534|NCT02185612|Behavioral|Savings program|The intervention is a web-based centralized savings account, which is a secure online account without fees. The account offers eligible savers nominal financial rewards for each deposit they make, as a financial incentive for savings.
45797918|NCT01946126|Other|No Intervention|There is no intervention in this study.
45797919|NCT01673113|Device|Zeltiq CoolSculpting device|"This is an FDA approved cooling device used for non-invasive and selective reduction of fat around the flanks, an area commonly referred to as the love handles."
45797920|NCT05322135|Drug|18F-FSPG|Given by vein (IV)
45797921|NCT05322135|Drug|11C-Glutamine|Given by vein (IV)
45797922|NCT01924988|Device|Prostatic Embolization with Embosphere Micropsheres|"Each patient will have a selective internal iliac arteriogram, and as necessary, an arteriogram of the anterior division of the internal iliac artery performed to identify the prostatic arterial supply. This typically arises from the inferior vesicle artery (also known as the prostatic artery), but may have supply from the superior vesicle, the internal pudendal or obturator branches as well.~The prostatic arteries will be selected using standard micro-catheter technique. Embolization of the prostate will be performed with 300 to 500 um sized TAGM (Embosphere® Microspheres, Merit Medical, South Jordan, UT). The embolization endpoint will be absence of the normal blush of the prostate on post embolization angiography and stasis of flow in the prostate arteries."
45925284|NCT00392340|Drug|topotecan hydrochloride|
45925285|NCT00392340|Drug|vincristine sulfate|
45925286|NCT05195684|Other|imaginal probe|trauma and nightmare imaginal probe/challenge for which psychophysiological and CNS responses are recorded
45925287|NCT00062101|Drug|erlotinib hydrochloride|Given orally (PO)
45925288|NCT00062101|Drug|celecoxib|Given PO
45925289|NCT00062101|Other|laboratory biomarker analysis|Correlative studies
45925290|NCT00062140|Drug|cyclophosphamide|
45925291|NCT00062140|Procedure|allogeneic bone marrow transplantation|
45925292|NCT00062140|Procedure|peripheral blood stem cell transplantation|
45925293|NCT00062140|Radiation|radiation therapy|
45925294|NCT04870476|Behavioral|"Internet-delivered treatment: One step at the time"|The guided internet treatment program consists of 11 modules (+ 1 module for relatives) activated consecutively over a period of 14 weeks. The content is written psychoeducation, patient videos, audio exercises and exposure exercises. The program is therapist-guided; hence all patients will receive support primarily from a specific therapist during the 14 weeks.
45925295|NCT00062179|Drug|carboplatin|Carboplatin: dosed at an AUC of 6 by the Calvert Formula 3 cycles of carboplatin 21 days apart
45925296|NCT00062179|Drug|celecoxib|Celecoxib: 400 mg po BID celecoxib 3-7 days before first dose of chemotherapy
45925297|NCT00062179|Drug|paclitaxel|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion 3 cycles of paclitaxel 21 days apart
45925298|NCT00062179|Other|Placebo|placebo 3-7 days before first dose of chemotherapy
45925299|NCT00062257|Drug|irofulven|
45925300|NCT00062296|Biological|rituximab|
45925301|NCT00062296|Drug|epirubicin hydrochloride|
45925302|NCT00062335|Radiation|radiation therapy|
45925303|NCT04865874|Other|PPV-GDT|fluid-therapy based on PPV monitoring
45925304|NCT04865874|Other|Zero-balance|fluid-therapy based on urinary output balance
45925305|NCT05183984|Drug|Chemotherapy|Chemotherapy (carboplatin + paclitaxel) will be administred by intravenous infusion, AUC 5-6 q3w - 5 cycles during the treatment period
45797923|NCT05320263|Procedure|Contact aspiration Thrombectomy|"The contact aspiration approach is performed, as in standard care, using a long sheath positioned in the distal cervical vasculature using an exchange technique.~A large bore balloon guide catheter as to be placed into the cervical ICA. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control superselective angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. through the long sheath positioned in the cervical vasculature."
45797924|NCT05320263|Procedure|Stent retriever thrombectomy|The technique used should be in accordance with the device IFU. A large bore access guide catheter possible is recommended. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE-marked stent retriever device is then deployed across the occlusion. A minimum of 3 attempts with SR should be performed. A revascularization score will be recorded after each device attempt.
45925306|NCT05183984|Drug|Bevacizumab-Awwb|"MVASI (bevacizumab biosimilar) will be administrated by intravenous infusion at the second chemotherapy cycle for 5 cycles.~the administration will continue during maintenance phase. Total bevacizumab duration therapy is 15 months."
45797925|NCT01673191|Drug|Dexamethasone intravitreal implant|
45797926|NCT01673191|Drug|Steroid plus NSAID eye drop combination therapy|
45797927|NCT05734742|Other|Educational video|"There were two videos including the first video Sleep apnea Syndrome Driving Safety Picture Scroll and the second video Sleep apnea Syndrome and Traffic Accidents. The first video was approximately 3 minutes long. This video was suitable for all ages. It was an easy-to-understand video explaining the characteristics of OSA and its relationship with traffic accidents. The second video was the detailed video, which is approximately 20 minutes in duration. This video was suitable for those who desire to learn more about OSA. It can be used in various educational settings, including internal training and traffic safety workshops. Participants must watch at least the first video."
45797928|NCT01925144|Drug|Baricitinib|Administered orally
45925307|NCT05183984|Drug|Niraparib|niraparib will be administered orally once daily continuously after chemotherapy (+/- bevacizumab) cycles (maintenance treatment period). Total niraparib duration mainance treatment period is 2 years.
45925308|NCT02967874|Procedure|Intra-articular auto-SVFs injection|Liposuction under local anesthesia followed by single intra-articular injection of auto-SVFs under the ultrasound navigation
45925309|NCT02967874|Drug|Hyaluronic Acid|Single intra-articular injection of Synocrom Forte 2% under the ultrasound navigation
45649763|NCT04868669|Behavioral|In-home, intensive nutrition counseling|"Individualized sessions will be conducted by trained health workers following a standard document (counseling booklet)~The messages to be provided through the counseling will be contextualized~Sessions will start from the early second trimester and repeat monthly until 36 weeks of gestation~Counseling sessions will be conducted at the participant's place~Sessions will involve influential family members such as the husband, mother-in-law, mother, and the household head along with the pregnant women~Women will receive personalized feedback on their dietary intake pattern (dietary diversity) and the rate of weight gain in each session~Sessions will be tailored according to each participant's need and progress"
45649764|NCT04874285|Dietary Supplement|HA|hyaluronic acid, alpha-lipoic acid, vitamin D and vitamin B6
45649765|NCT03048851|Device|Low dosage SES group|The participants were randomly assigned to one of the five intervention groups. Low dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 45 minutes and arm with wrap for 45 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
45797929|NCT01925144|Drug|Omeprazole|Administered orally
45797930|NCT01673893|Device|ClearWay™ Rx catheter|
45450535|NCT02186392|Device|Circadian Light luminaries|The light is programmed to have the desired light intensity (lux), color temperature (Kelvin) and wavelength (nm) according to the knowledge about the phase-response curve.
45450536|NCT02190994|Drug|Hydrocortisone|used intravenously
45450537|NCT02190994|Drug|Prednisone|used as tablet form
45797931|NCT00000435|Drug|dnaJ peptide|dnaJP1 was taken in pill form at 25mg/day for 6 months
45925310|NCT02967952|Device|supraglottic airway (SGA) V.S. endotracheal intubation (ETI)|already being described above
45925311|NCT00062491|Drug|Karenitecin (BNP1350)|Karenitecn (1.0 mg/m2) administered as a single daily 60-minute intravenous infusion for 5 consecutive days repeated every 21 days (1 treatment cycle). Patients who respond (CR< PR, SD) can continue treatment for 6 cycles, unless unacceptable toxicity develops. Treatment will be discontinued if progressive disease or unacceptable toxicity develops.
45925312|NCT00062530|Biological|SCBaL/M9|Oral recombinant Salmonella typhi HIV-1 gp120 vaccine
45649766|NCT03048851|Device|High dosage SES group|The participants were randomly assigned to one of the five intervention groups. High dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 90 minutes and arm with wrap for 90 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
45797932|NCT00000435|Drug|None-placebo|placebo was taken in pill form at 25mg/day for 6 months
45925313|NCT04733625|Drug|Cholecalciferol|single injection of Vitamin D (200000 I.U
45925314|NCT04733625|Drug|Placebo|placebo medication
45925315|NCT05181293|Behavioral|Mobile Gaming App for Nutrition Intervention|A mobile gaming app (BabyThrive) will be disseminated to teenage mothers to help them learn about exclusive breastfeeding, introduction to solid/semi-solid foods, meal frequency and dietary diversity. BabyThrive will also demonstrate how to prepare 30 nutritious recipes for complementary feeding; create a calendar and set reminders to prompt mothers to access child health services; and plot growth patterns of the baby to facilitate growth monitoring.
45925316|NCT00062569|Behavioral|Bathing Support Intervention (BSI)|Bathing Support Intervention - Review of caregiver current practices and perceptions and care recipient behavioral symptoms associated with bathing with pattern analysis based on observation; skill building for bathing and communication techniques; coaching for implementation
45797933|NCT00000441|Drug|lorazepam (Ativan)|
45925317|NCT00062569|Behavioral|Caregiver reminiscence with coaching|"BSI plus Reminiscence - BSI as above plus caregiver interview to ascertain pleasant long-term memories (e.g. stories, pictures, music) developed into a crib sheet for caregiver use conversationally prior to and during the bath"
45925318|NCT00062608|Behavioral|Written self-disclosure|
45925319|NCT00062686|Drug|GW572016|
45925320|NCT05178914|Procedure|Treatment adaptation|Patients will benefit from intensified treatment or de escalation treatment according to the result of the index of microcirculatory resistance
45925321|NCT00062803|Drug|SR34006|
45925322|NCT00062803|Drug|(LMW)heparin|
45925323|NCT00062803|Drug|Warfarin VKA|
45925324|NCT00062803|Drug|Acenocoumarol VKA|
45450538|NCT03536338|Other|Spinal Stimulation|transcutaneous electrical stimulation of the lumbar spinal cord during rehabilitation.
45925325|NCT00062842|Drug|Irinotecan|
45925326|NCT05178563|Procedure|IPT+PDT|The experimental arm consist of performing IPT in randomly assigning patients to receive local use of photodynamic therapy (PDT).
45925327|NCT05178563|Procedure|IPT+Placebo|IPT+Placebo
45925328|NCT02967445|Device|Arabin Pessary|Arabin silicon pessary
45797934|NCT00000441|Drug|carbamazepine (Tegretol)|
45925329|NCT02967445|Device|Cervical cerclage|
45925330|NCT00062881|Drug|Intrathecal Mafosfamide|
45797935|NCT01675063|Device|Retia Non-Invasive Sensors|Three adhesive sensor patches (similar to ECG patches) will be placed on the chest and a sensor similar to a pulse oximeter will be placed on the toe. The sensors will be connected to an electrical amplifier that produces a waveform.
45797936|NCT00000447|Drug|naltrexone (Revia)|
45925331|NCT00062959|Behavioral|Going Places: School program to prevent problem behavior|
45925332|NCT00063037|Behavioral|Behavioral modification - nutrition education|
45925333|NCT00389909|Drug|Doxapram|"Dosing comparison between fixed scheduled and sex related dosage.~Dosing related to weight only versus chart taking into account weight, age and gender."
45925334|NCT00063076|Drug|Targretin Gel 1%|Alopecia lesions on one-half of the head including facial hair treated, and other half on head serves as control (untreated). Starting dose once every day till Week 3 then escalate to twice a day.
45925335|NCT04744662|Drug|ONL1204 Ophthalmic solution|Liquid formulation administered by intravitreal (IVT) injection
45450539|NCT03536338|Other|Sit-to-stand Training|Rehabilitation of standing from a chair using the Keiser Rack
45450540|NCT02193568|Procedure|Arm I (light sedation)|If patients experience excessive preoperative anxiety they will receive light sedation of midazolam 1 mg IV.In our standard practice, it is very rare that patients receive anxiolytic premedication for craniotomies, so it is unlikely that many will require midazolam. Two IVs will be placed, one for infusion of meds and one for possible resuscitation.
45450541|NCT02193568|Procedure|Arm II (intubated general anesthesia)|Receive intubated general anesthesia
45450542|NCT02193568|Procedure|Arm II (intubated general anesthesia)|Undergo craniotomy
45797937|NCT00000447|Drug|nicotine replacement patch|
45797938|NCT01927718|Drug|Thalidomide|100 mg by mouth daily for 28 days in a 28 day cycle.
45925336|NCT04744662|Procedure|sham injection|sham injection is done by touching the eye surface with a syringe without a needle
45925337|NCT00063193|Drug|minocycline|
45925338|NCT00063193|Drug|creatine|
45925339|NCT02967484|Device|acupuncture|"Huo Xue San Feng acupuncture method: Patients will recieve the acupuncture treatment,choose the bilateral point:Renying(ST9),Hegu(L14),Taichong(LR3),Quchi(LI11),Zusanli(ST36).~Routine care for ischemic stroke :patients will recieve the acupuncture treatment,choose the point:Neiguan(PC6),Renzhong(10),Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).~Drugs: Antihypertensive drugs.Patients will be treated 1 of 5 type of antihypertensive drugs,include ARB、ACEI、βreceptor blocker,CCB,Diuretic.~The time of therapy will consist of 6 times per week in Continuous treatment phase(1st-6th week after enrollment) and 3 times per week(once every other day) in Consolidation treatment phase(7th-tewlve week after enrollment)"
45925340|NCT05167019|Behavioral|CODE intervention|The CODE intervention consists of 1) One interactive session of 2 to 3 hrs focusing on the concepts of medical-ethical decision-making, the psychological challenge of dealing with ethically sensitive medical topics, and empowering leadership. 2) Observation and debrief of the interdisciplinary meeting to enhance self-reflection on empowering leadership and managing group dynamics. 3) Individual coaching on the spot in self-reflective and empowering leadership and in managing groups dynamics with regard to ethical decision-making about patients who are perceived to receive excessive treatment during the intervention period, and in absence of such patients, every item with regard to ethical decision-making that is important for the coachee. 4) During the intervention coaches and doctors in charge will be informed of the presence of a patient potentially receiving excessive treatment in their ward by an electronic alert.
45925341|NCT05167019|Other|Usual care|The control group will receive usual care in which the quality of the ethical decision-making is determined by the clinical team according to their usual practice. Except from a treatment-limitation-decisions guideline which focuses on the legal and deontological framework, no other guideline with regard to ethical decision-making has been implemented at the Ghent University Hospital. In one ward (geriatrics), there is a ongoing project in which a clinical nurse specialist stimulates and performes advance care planning conversations with patient and/or relatives at request of the team and who organizes debriefings when needed based on the ethical concerns of the nurses.
45925342|NCT02967523|Device|DEB-TACE with Surefire Precision Infusion System|Subjects have undergone/will undergo DEB-TACE using the Surefire Precision Infusion System.
46071983|NCT05796427|Behavioral|SupporT for ADHD and Related Treatment|Intervention will include 6 modules typically taught over 6-7 weeks. Participants will have up to 3 months to complete the intervention. Modules will provide more knowledge on ADHD, discuss stigma around ADHD, address barriers in receiving care, encourage communication with physician and child, and empower caregivers. Overall, the goal being to improve engagement in ADHD treatment for newly diagnosed or unengaged families. This intervention is mostly targeted towards primary caregivers. However, the last module explicitly includes the child.
45450543|NCT02193568|Other|Arm II (intubated general anesthesia)|Ancillary studies
45797939|NCT01927718|Drug|Lenalidomide|Lenalidomide continued by mouth at the previous dose of 5 mg daily for 21 days on a 28 day cycle, 5 mg daily for 28 days on a 28 day cycle, 10 mg daily for 28 days on a 28 day cycle, or 15 mg daily for 28 days on a 28 day cycle.
45797940|NCT01927718|Behavioral|Questionnaires|Questionnaire completion at screening, once a month for the first 6 months, then every other month while on study.
45797941|NCT05069961|Procedure|ESPB|Ropivacaine is injected near the nerves in the back
45797942|NCT05069961|Procedure|TEA|Bupivacaine is injected into the space around the spinal cord.
45797943|NCT05734664|Device|Pulsify sensor|A positioning system will move the 1X1 cm Pulsify sensor step-by-step over a marked area of 10x10 cm on the subjects' chest to record a complete 3D data set of the heart. For accurate 3D reconstruction, the ECG and breathing cycle are also recorded during the acquisition using commercially available devices (Bitalino HeartBIT + Respiration Sensor). From the 3D dataset of the heart, the end-systolic and end-diastolic volumes will be extracted automatically to calculate the cardiac output.
45797944|NCT05734664|Device|State-of-the-art ultrasound equipment|A complete 2D and 3D ultrasound data set using a GE Vivid E95 ultrasound machine, version 203 (General Electric Healthcare, Chicago, IL, United States) will be recorded. All data will be processed offline with a specialized software packet (EchoPAC, version 203, General Electric Healthcare, Chicago, IL, United States
45797945|NCT02238847|Device|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|Reintervention can occur in Arm 1 or Arm 2 with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System
45797946|NCT05734586|Other|EAT-10 (Eating assessment Tool) screening questionnaire|After inclusion, issuance of the EAT-10 screening questionnaire for swallowing disorders by the healthcare team
45797947|NCT05734586|Procedure|Protective measures for the upper airways|"In the event of an EAT ≥2 score, immediate implementation or within three days by the healthcare team of protective measures for the upper airways in 3 sectors:~1: Postural maneuvers; 2: Hygienodietetic rules; 3: Food textures"
45450544|NCT02193568|Procedure|Arm I (light sedation)|Undergo craniotomy
45649767|NCT03048851|Device|VRCIT group|The participants were randomly assigned to one of the five intervention groups. VRCIT group received the VRCIT training plus traditional rehabilitation, conducted twice per week for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, plus home program, and restraint of the less affected UE for 1.5 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training. The VRCIT combined CIT and commercially available VR-based systems including Sony Playstation EyeToy and Nintendo Wii.
45649768|NCT03048851|Device|VRCIT+SES group|The participants were randomly assigned to one of the five intervention groups. VRCIT+SES group executed VR programs by affected UE in Mesh-gloves (Electro-Mesh Glove-Sleeve Electrode Kit) with the optimal SES (Micro-Z Mini, Prizm Medical Inc., USA) protocol formulated from the 1st phase study. The VRCIT program was conducted 1.5 hours/time, twice/week for 12 weeks. The VRCIT combined CIT and commercially available VR-based systems. Some commercially programs, such as Sony Playstation EyeToy (Sony Computer Entertainment America, Foster City, Calif., USA), and Nintendo Wii (Nintendo Domestic Distributor, College Point, N.Y., USA).
45797948|NCT05066607|Drug|Isatuximab|Patient will receive the association of Isatuximab, Pomalidomide and Dexamethasone during 9 or 12 cycles.
45797949|NCT01948310|Drug|Ranolazine|Comparison of Ranolazine 1000mg twice per day versus placebo twice per day
46071984|NCT05795309|Device|Hybrid Automated Insulin Delivery|Consists of an insulin pump and real-time continuous glucose monitoring (CGM)
45450545|NCT02193568|Other|Arm I (light sedation)|Ancillary studies
45450546|NCT02191072|Drug|omalizumab|a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE)
45450547|NCT02186548|Procedure|Closed surgical technique|"Surgically uncovering of the impacted canine with a mucoperiosteal flap dissected off the bone~The bone covering the canine is being removed~Attachment with a chain is bonded to the exposed tooth~The palatal flap is repositioned and sutured back with the chain above the mucosa. Shortly after the surgery~The canine is orthodontically moved beneath the palatal mucosa"
45649769|NCT03048851|Procedure|traditional rehabilitation program|The participants were randomly assigned to one of the five intervention groups. The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
45649770|NCT04868513|Drug|Pregnant women to whom applied silane fluoride|Pregnant women who received 0.1% silane fluoride applied as varnish in the teeth.
45649771|NCT04868513|Drug|Pregnant women to whom applied silane fluoride + 1% chlorhexidine|Pregnant women who received silane fluoride + 1% chlorhexidine applied as varnish in the teeth.
45797950|NCT01948310|Behavioral|Aerobic Exercise|Aerobic exercise 3 times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold (heart rate at which angina symptoms began on the stress test)
45797951|NCT01948310|Drug|Placebo|Comparison of placebo twice per day vs. Ranolazine 1000mg twice per day
45797952|NCT04499547|Behavioral|YouTube-delivered aerobic and muscle-strengthening physical activity intervention|Participants in the intervention group will receive two YouTube-delivered videos each week, for 8 weeks. In detail, on Monday, participants will receive an aerobic-based physical activity video with information and a workout to complete and on Thursdays, the participants will receive a video with muscle-strengthening physical activity information and a workout to complete.
45797953|NCT01948388|Drug|corticotrophin 80 units|Comparison of different dosages of the drug. Ten patients will receive 80 units of corticotrophin weekly. Ten patients will receive 80 units bi-weekly of corticotrophin
45797954|NCT05045625|Device|HD Study Electrode|The HD Study Electrode is an array of 8 columns of stimulation contacts arranged in 8 rows with a low-volume electrode body. This array of stimulation electrodes contact patterns of bi-poles and tri-poles may be applied to the spinal cord for assessment of dermatomal selective stimulation patterns.
45797955|NCT01928030|Biological|recombinant human hyaluronidase|Given SC
45797956|NCT01675297|Drug|Risedronate/Cholecalciferol combination|Risendronate/Cholecalciferol combination once a week
45797957|NCT01675297|Drug|Risedronate|Risedronate once a week
45797958|NCT05295537|Procedure|PERCUTANEOUS LIVER BIOPSY (PLB)|Percutaneous liver biopsy using a 16 gauge (G) Trucut needle.
45797959|NCT05295537|Procedure|ENDOSCOPIC ULTRASOUND GUIDED LIVER BIOPSY (EUS-LB)|EUS-guided liver biopsy using a 19 gauge (G) Franseen core EUS needle
45797960|NCT02287376|Drug|Diclofenac Potassium for Oral Solution|NSAID
45797961|NCT05294289|Other|Alpelisib|There is no treatment allocation. Patients administered alpelisib by prescription that involved in Novartis' alpelisib managed access program will be enrolled
45797962|NCT01675453|Drug|7.2% NaCl plus 6% hydroxyethyl starch 200/0.5|
45797963|NCT01675453|Drug|0.9% NaCl|
45797964|NCT01928186|Drug|Fluorothymidine F-18|Undergo FLT PET
45797965|NCT01928186|Procedure|Positron Emission Tomography|Undergo FLT PET
45797966|NCT01928186|Other|Laboratory Biomarker Analysis|Correlative studies
45797967|NCT01928186|Drug|Run-in (short pre-surgery course) of endocrine-targeted therapy|Patients undergo run-in (short pre-surgery course) of endocrine-targeted therapy with aromatase inhibitor between the two (baseline and repeat) FLT PET scans. This is not an experimental therapy. This is a standard of care therapy that patients will continue after surgery, when the study is completed.
45797968|NCT01611571|Drug|Risedronate|weekly risedronate
45797969|NCT01611571|Drug|Teriparatide|daily teriparatide
45797970|NCT01611571|Drug|Placebo Teriparatide|daily placebo of teriparatide
45797971|NCT01611571|Drug|placebo Risedronate|weekly placebo of Risedronic Acid
45797972|NCT05505890|Other|suprainguinal fascia iliaca block|Suprainguinal fascia iliaca block will be performed after the end of surgery for postoperative analgesia.
45797973|NCT05734430|Genetic|Genetic profiling|Whole exome sequencing
45797974|NCT05734430|Other|Retrospective tissue procurement|Collection of archived fixed-formalin, paraffin-embedded (FFPE) primary appendix tumor tissues that were previously removed
45797975|NCT00000477|Drug|lovastatin|
45797976|NCT05733884|Other|soft contact lens|soft contact lens
45797977|NCT00000483|Drug|estrogen|
45797978|NCT00000483|Drug|clofibrate|
45797979|NCT00000483|Drug|dextrothyroxine sodium|
45797980|NCT00000483|Drug|niacin|
45797981|NCT05733572|Drug|CHF6467|drug eyedrops
45797982|NCT05733572|Drug|Placebo|placebo eyedrops
45797983|NCT05217225|Procedure|Simple restorative treatment|Simple Occlusal Cavity class I then followed by final restoration
45797984|NCT02238925|Drug|CPX-351|
45797985|NCT02987192|Device|pen type 27 gauge needles|minimally invasive group patients will receive pen type 27 gauge needles.
45797986|NCT02987192|Device|cutting type 22 gauge needles|traditional group patients will receive cutting type 22 gauge needles.
45797987|NCT05732636|Other|Validation study|"The whole protocol is divided into two stages: Urdu Translation and validation. Following steps are involved.~First version (Forward Translation): Forward translation from the English to Urdu by two bilingual translators (Version 1)~Second Version: Three experts compared the original FADI with urdu version of FADI.~Backward translation: Version 2 will be translated Back in English by an independent translator.~Third Version: will be finalized after tracking differences in forward and backward translation.~Final Version: of Urdu FADI will be used on Chronic Ankle Instability patients.~Foot and Ankle Disability Index(FADI) Urdu version will be introduced and the patients will be asked to fill FADI Urdu version. The questionnaire will be filled again by the same participants after one week to assess the test retest reliability."
45925343|NCT02967406|Behavioral|4 x 4 lifestyle modification|Participants in the intervention group will be given 4x4 lifestyle modification intervention, which will address four health behaviors (diet, physical activity, alcohol drinking and smoking) at four different levels: individual, household, knowledge management and community levels. A new computer program called 'iActive' adapted from the GPAQ with add-on functions to allow real-time assessment and presentation of the energy expenditure along with recommendations specific to each individual will be used. Dietary counseling will be given individually following assessment using a new dietary assessment program called Dietary Assessment Scanning Calculator. Home visit will be done every 3 months by responsible nurses and village health volunteers. Knowledge management will be done through meetings between participants and villages with support from trained nurses. Situation analysis and community action will be encouraged to address four health behaviors.
45925344|NCT02967601|Behavioral|STAI (State Trait Anxiety Inventory) questionaire|Each patient would fill the STAI questionaire before Cesarean Section (on the same day, in the morning)
45925345|NCT05165576|Behavioral|Child-centered communication|The child is asked for ideas, fears and concerns regarding the magnetic resonance imaging exam and responses are tailored to these individual needs
45925346|NCT00063310|Drug|Leuprolide acetate|
45450548|NCT02186548|Procedure|Open surgical technique|"Surgically uncovering of the impacted canine, removing a window of tissue from around the tooth~Pack/filling material is applied on the tooth~Spontaneous eruption of the palatally impacted canine is allowed expected~The canine is orthodontically moved above the mucosa"
45797988|NCT00000507|Drug|streptokinase|
45450549|NCT02186626|Biological|WN/DEN4Δ30 Vaccine|WN/DEN4Δ30 vaccine is a live attenuated, recombinant, chimeric virus. Dose: 10^4 plaque-forming units (PFUs); delivered by subcutaneous injection in the deltoid region of the upper arm.
45649772|NCT05256407|Other|Intervention, digital support|Internet based support of parents in child health care. Various options and choices includes parental education, digital meetings with child health nurse and peer groups
45450550|NCT02186626|Biological|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm.
45649773|NCT04873973|Other|Telemedical support|The nursing homes participating in the project will be equipped with telemedical equipment. This will allow teleconsultations to take place when needed. In addition, an early warning system will be introduced and, within the framework of the teleconsultation, a trained medical assistant can be sent to the care facility if necessary, who can carry out medical activities on site under a physician's delegated instructions. In addition, an electronic patient file will be introduced which can be accessed by the telemedicine physician and the general practitioner.
45649774|NCT04874129|Drug|YYC506-T and YYC506-A (phase 1)|Comparator
45797989|NCT00380445|Drug|Vildagliptin|
45925347|NCT04707690|Device|Intraurethral laser therapy|The laser will be applied according to the manufacturer's protocol. This includes a 2 step laser treatment using 2 different modes at 2 timepoints. The treatment takes about 15 minutes time.
45925348|NCT04707690|Device|Intraurethral SHAM laser therapy|The laser will be applied according to the manufacturer's protocol. This includes a 2 step laser treatment using 2 different modes at 2 timepoints. The treatment takes about 15 minutes time.
45925349|NCT00063388|Biological|Cetuximab|Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).
45925350|NCT00063427|Drug|MAC-321|
45925351|NCT00063583|Drug|Pirfenidone|Pirfenidone will be administered orally at 1200 or 2400 mg day in divided doses
45925352|NCT05157191|Other|Observational|Observational
45925353|NCT00063700|Procedure|reducing exposure to marketing pressures|
45925354|NCT00063778|Biological|AVX101|Alphavirus replicon particle vaccine expressing HIV Gag antigen
45450551|NCT02186704|Device|ICD with DX system|Implantable cardioverter defibrillator (ICD) system implantation with single lead with ventricular sensing and pacing and defibrillation combined with dedicated atrial sensing dipole.
45450552|NCT02191228|Drug|Linagliptin - single dose|
45450553|NCT02191228|Drug|Linagliptin - Multiple dose|
45450554|NCT02186782|Drug|Clomiphene citrate and Estradiol|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle)
45450555|NCT02186782|Drug|Clomiphene citrate and Placebo|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and placebo (for 5 consecutive days from day 2 of cycle)
45450556|NCT05011396|Drug|PH94B Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
45797990|NCT01950260|Drug|Levothyroxine|Early initiation of levothyroxine after radioactive iodine (to start at 4 weeks).
45797991|NCT01950260|Other|Placebo|Placebo to start at 4 weeks after RAI
45925355|NCT00063778|Other|placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
45925356|NCT04655118|Drug|TL-895|TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
45450557|NCT05011396|Drug|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
45450558|NCT02186860|Biological|CAR-T cells|Given IV
45450559|NCT02187094|Drug|TC-6499|
45450560|NCT02187094|Drug|Placebo|
45450561|NCT02187250|Drug|metformin|
45450562|NCT02187250|Drug|liraglutide|
45649775|NCT04874129|Drug|YYC506 (phase 1)|Test
45649776|NCT04874129|Drug|YYC506-T and YYC506-A (phase 2)|Comparator
45649777|NCT04874129|Drug|YYC506 (phase 2)|Test
45925357|NCT00063817|Drug|Conditioning Regimen|Cyclophosphamide 60 mg per kilogram (kg) of body weight per day intravenously (IV) on days -5 and -4 with respect to transplantation; humanized anti-CD2 monoclonal antibody (MEDI-507) 0.6 mg per kg on days -1, 0, and 1 (after test dose of 0.1 mg per kg on day -2); and cyclosporine A 5 mg per kg IV and thymic irradiation (700 cGy) on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered postoperatively, 8 to 12 mg per kg per day, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months. Protocol amendment that applied to participant 4 and 5: rituximab, 375 mg per square meter of body-surface area days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.
45797992|NCT05039307|Behavioral|Educational and motivational strategy|The intervention will focus on the following topics A) Healthy diet: food pyramid, a healthy plate distribution, type of carbohydrates and fats, healthy cooking techniques and healthy oils. B) Physical activity: definition, types of physical activity, advantages and benefits, examples, active physical activity sessions. C) Weight control: strategies, benefits and healthy weight gain during pregnancy. D) Knowledge and awareness of T2DM and GDM: definition, prevention, management and complications. These topics will be delivered through individualized education, group sessions and focus groups. Participants will be provided with printed material at baseline and also during the individual education sessions at the household containing a brief summary of the topics covered. The motivational components of goal setting and the use of a pedometer will be incorporated explained during the individual education sessions. The intervention will be primarily delivered by trained peer educators.
45925358|NCT00063856|Biological|Wetvax (APSV)|
45649778|NCT03047837|Drug|Aspirin (ASA) + Metformin (MET)|Arm D (experimental arm) Treatment: active ASA + active MET Dose: 100 mg, 1 tablet daily + 850 mg,1 tablet twice a day (BID) Duration: 12 months
45649779|NCT03047837|Drug|ASA|Arm C (experimental arm) Treatment: active ASA + placebo MET Dose: 100 mg, 1 tablet daily + 1 tablet twice a day (BID) Duration: 12 months
45649780|NCT03047837|Drug|MET|Arm B (experimental arm) Treatment: placebo ASA + active MET Dose: 1 tablet daily+ 850 mg, 1 tablet twice a day (BID) Duration: 12 months
45797993|NCT01676311|Drug|Huperzine A|Huperzine A will be administered for 12 weeks as outlined in the Arm Description
45797994|NCT01676311|Drug|Placebo|Placebo Arm (blinded randomization) for Huperzine A Intervention
45797995|NCT05036187|Behavioral|Behavioral Weight Loss Intervention|Rx Weight Loss: PRIDE is a fully automated online behavioral obesity treatment that is tailored for sexual minority women and involves viewing 12 online video lessons delivered each week, self-monitoring body weight, calorie intake, and physical activity levels, and receiving personalized automated weekly feedback on progress toward goals.
45797996|NCT05036187|Behavioral|Minority Stress Intervention|The Minority Stress Intervention is designed to help sexual minority women cope with stress and stigma (e.g., due to weight, sexual orientation, gender). In this program, participants watch online video lessons that teach cognitive and behavioral strategies for coping with minority stress so that it may have less of an influence on participants' weight and well-being.
45797997|NCT05036187|Behavioral|Negative Body Image Intervention|The Negative Body Image Intervention is designed to help participants improve their body image. In this program, participants will watch online video lessons that provide education on queer women's body image and teach cognitive and behavioral strategies for improving your body image (regardless of your weight) to reduce its influence on your health.
45797998|NCT05036187|Behavioral|Social Support Intervention|The Social Support Intervention provides online opportunities for participants to receive more social support as they work toward their weight loss goals. Participants receive education on the importance of social support for weight management, they can earn badges for completing program milestones, and they gain access to a private online forum to get support and advice from other participants.
45797999|NCT01951118|Drug|Donepezil|Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease. For patients who do not tolerate donepezil or have a history of intolerance to donepezil or cannot take donepezil for other reasons, treatment with other cholinesterase inhibitors (galantamine or rivastigmine) is permitted at any stage of the protocol. Data will be analyzed in two ways: for donepezil alone, and for any cholinesterase inhibitor (donepezil or rivastigmine or galantamine) as the intervention.
45798000|NCT01698463|Other|Identification of patients at risk, tailored exercise prescription, motivational interviewing, review of behavioural outcomes|"The intervention was delivered in two visits and two follow-up phone calls.~Physician identifies that the patient is at risk of falls or fractures~Visit one: individualized exercise prescription by a physiotherapist.~Visit two: motivational interviewing (behavioural counselling) by kinesiologist~Phone call 1 and 2: Kinesiologist reviews behavioural components (action planning, coping planning, coping self-efficacy, intentions."
45798001|NCT01951352|Other|Soap|
45798002|NCT01951820|Drug|Pliaglis|Apply 0.2mg of compounded topical anesthetic (Pliaglis) to gums for 2.5 minutes before giving patient injection of local anesthetic.
45798003|NCT01951820|Drug|Benzocaine|Apply 0.2mg of topical anesthetic (benzocaine) to gums for 2.5 minutes before giving patient injection of local anesthetic.
45798004|NCT01951820|Drug|Articaine|Injection of 0.4mg of local anesthetic in gum tissue where topical anesthetic was placed
45798005|NCT01700725|Other|Nasal Irrigation - Saline|"Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the saline solution by themselves using the study-provided kit which will include packets of salt powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 2% buffered saline solution. The solution is then delivered to the nasal cavity using neti pot."
45925359|NCT05153876|Other|Questionnaires|Headache attack descriptions, Headache related disability descriptions, Questionnaires, MIDAS, MSQv2.1, SF36
45450563|NCT02187250|Drug|roflumilast|
45450564|NCT02191384|Drug|Orcinoside|oral, twice per day
45649781|NCT03047837|Drug|Placebos|Arm A (control arm) Treatment: placebo ASA + placebo MET Doses: 1 tablet daily +1 tablet twice a day (BID) Duration: 12 months
45925360|NCT00063895|Drug|erlotinib hydrochloride|Given PO
45925361|NCT00063895|Other|pharmacological study|Correlative studies
45925362|NCT00063895|Other|pharmacogenomic studies|Correlative studies
45925363|NCT00063895|Other|laboratory biomarker analysis|Correlative studies
45925364|NCT00063973|Drug|cilengitide|Given IV
45925365|NCT00063973|Other|laboratory biomarker analysis|Correlative studies
45649782|NCT05256173|Other|Melatonin Tablets|Melatonin Tablets was given 3 tablets (6.21mg) daily at the beginning of bedtime at night for a total of 4 weeks.
45798006|NCT01700725|Drug|Nasal Irrigation - Xylitol|"Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the Xylitol solution by themselves using the study-provided kit which will include packets of Xylitol powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 5% Xylitol solution. The solution is then delivered to the nasal cavity using neti pot."
45798007|NCT01678885|Behavioral|Digital Photography of Foods|The digital photography of foods method was developed to unobtrusively measure energy intake in naturalistic settings (e.g., cafeterias). Participants will be provided with cell-phones with digital cameras and cellular network capability. Participants were trained to take pictures of their food selection and plate waste and to send these pictures to the researchers over the cellular network. The participant will collect data in free-living conditions and these data will be collected in near real time.
45925366|NCT04648683|Behavioral|Individual telehealth mindfulness|Participants who enroll and complete lumbar spine surgery will participate in a one-on-one telehealth-delivered (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight, weekly sessions lasting 75 minutes each (except the first session which lasts 90 minutes).
45925367|NCT04648683|Behavioral|Group telehealth mindfulness|Participants who enroll and complete lumbar spine surgery will participate in a group-delivered telehealth (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight, weekly sessions lasting 90 minutes each.
45925368|NCT00064012|Drug|bortezomib|
45925369|NCT00064012|Drug|docetaxel|
45925370|NCT05146700|Drug|Restrictive oxygen|Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94%
45925371|NCT05146700|Drug|Liberal oxygen|15 L O2/min flow for non-intubated trial participants or FiO2 = 1.0 for intubated trial participants in the initial phase; later in the operating room, intensive care unit, post-anesthesia care unit and ward, the flow/FiO2 can be reduced to ≥12 L O2/min or FiO2 ≥0.6 if the arterial oxygen saturation is ≥98%
45925372|NCT00064051|Drug|gemcitabine hydrochloride|
45649783|NCT05256173|Other|Lactasin Tablets|The placebo group was given at the beginning of bedtime at night for a total of 4 weeks.
45649784|NCT05256173|Device|transcutaneous vagus nerve stimulation|transcutaneous vagus nerve stimulation treatment, frequency 10Hz, stimulation site is the anterior wall of the left external auditory canal (tragus), used twice a day, each treatment for 30 minutes, a total of 4 weeks.
45798008|NCT01678885|Other|doubly labeled water|Doubly labeled water, considered the gold standard for measuring energy intake in humans, was used to measure total daily energy expenditure during free-living conditions. DLW is used to obtain an accurate measure of total daily energy expenditure, which is equal to energy intake during energy balance.
45925373|NCT00064051|Drug|triapine|
45925374|NCT02967328|Other|RP% Measurement by FCM as a Diagnostic Test for ITP|
45925375|NCT02967172|Drug|Ropivacaine|
45925376|NCT02967172|Drug|Epinephrine|
45925377|NCT02967172|Drug|Morphine|
45925378|NCT02967172|Drug|0.9% sodium chloride solution|
45925379|NCT00064090|Drug|cytarabine|
45649785|NCT05256173|Device|sham transcutaneous vagus nerve stimulation|In the sham stimulation group, the stimulation site was the left earlobe with a frequency of 10Hz, which was used twice a day for 30 minutes for a total of 4 weeks.
45649786|NCT03048071|Other|Data collection within medical files|Data collection within medical files
45649787|NCT04868825|Device|Ivory Dentin Graft|Ivory Dentin Graft is a bone graft material for the repair or augmentation of bone defects in dental procedures. It consists of sterile 300 - 900 μm porous particles or granules of hydroxyapatite and collagen which retain the natural form of the source porcine dentin and protein matrix. (Packed Vial: 1.00 gr; Packed Syringe: 1.0 gr)
45649788|NCT04868825|Device|OsteoBiol Gen-Os|Comparator control device A natural porcine origin cortico-cancellous heterologous bone mix consists of sterile 250 - 1000 μm porous particles of hydroxyapatite and collagen (Packed Vial: 1.0 gr)
45925380|NCT00064090|Drug|triapine|
45925381|NCT05141357|Drug|HBI-8000 in combination with pembrolizumab|Participants will take 30 mg of HBI-8000 by mouth every 3-4 days on a twice weekly (BIW) schedule. Pembrolizumab will be administered at 400 mg IV every 6 weeks (Q6W) or 200 mg IV every 3 weeks (Q3W) according to Prescribing Information and institution's prescribing practice for pembrolizumab.
45925382|NCT00064129|Biological|Ipilimumab|Given IV
45925383|NCT00064129|Other|Laboratory Biomarker Analysis|Correlative studies
45925384|NCT00064129|Other|Pharmacological Study|Correlative studies
45925385|NCT00064129|Biological|Sargramostim|Given SC
45925386|NCT00064207|Drug|gemcitabine hydrochloride|
45925387|NCT00064207|Procedure|adjuvant therapy|
45925388|NCT00064207|Radiation|radiation therapy|
45925389|NCT00064246|Biological|rituximab|Given IV
45925390|NCT00064246|Radiation|indium In 111 ibritumomab tiuxetan|Given IV
45925391|NCT00064246|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
45925392|NCT00064285|Drug|alvocidib|
45925393|NCT00064285|Drug|imatinib mesylate|
45925394|NCT00392418|Drug|Multiple micronutrient supplement (iron)|
45925395|NCT00064324|Drug|perifosine|Given orally
45925396|NCT00064324|Other|laboratory biomarker analysis|Correlative studies
45649789|NCT03048773|Device|shockwave therapy|Intervention with shockwave therapy
45798009|NCT01678885|Device|IDEEA|The Intelligent Device for Energy Expenditure and Activity (IDEEA) will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
45798010|NCT01678885|Behavioral|low-calorie diet|Participants will be instructed to consume five packets of Health One per day, which provides 800 kcal and 125% of Recommended Daily Intake of vitamins and minerals. Additionally participants will be instructed to consume a meal consisting of 200 kcal to 350 kcal daily, which could consist of a portion-controlled meal replacement or a home-cooked meal. Participants will meet with a Registered Dietitian at weeks 0, 2, 4, and 6 and receive instructions on adhering to the meal plan.
45798011|NCT01678885|Device|Actical|The Actical will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
45798012|NCT01678885|Device|Sensewear Armband|The Sensewear armband will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
45649790|NCT03048773|Other|PT|Physical therapy 3 times per week for 3 weeks
45798013|NCT01952444|Biological|ETI-204|A single IV infusion of 16 mg/kg ETI-204 over 90 minutes on Day 1
45649791|NCT03048773|Other|placebo|sham shockwave therapy
45649792|NCT04868201|Device|0-anxiety|0-anxiety is a self-guided app-based utilizing virtual reality establish in cognitive behavior therapy treatment.
45649793|NCT04429997|Procedure|Removal of fibrosynovial tissue|Remove of fibrosynovial tissue at the superior border of patella
45798014|NCT01952444|Drug|Ciprofloxacin|A single IV Infusion of 400 mg Ciprofloxacin over 60 minutes immediately following the infusion of ETI-204 on Day 1, followed by oral Ciprofloxacin (750 mg every 12 hours) on Days 2-8, and a final oral dose on the morning of Day 9.
45798015|NCT01679197|Drug|Metreleptin|
45798016|NCT01952678|Other|DaTscan™ - Non-Caucasian Participants|Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.
45798017|NCT01952678|Other|DaTscan™ - Caucasian Participants|Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.
45649794|NCT04429997|Procedure|Non-removal of fibrosynovial tissue|Do not remove of fibrosynovial tissue at the superior border of patella
45649795|NCT05255939|Procedure|distal TRA group|dTRA for PCI procedure to ACS patients.
45649796|NCT05255939|Procedure|conventional TRA group|Conventional TRA for PCI procedure to ACS patients
45798018|NCT01954628|Drug|AQX-1125|Synthetic SHIP1 activator
45798019|NCT01954628|Drug|Placebo|Placebo control
45798020|NCT01680835|Device|EverFlex™ Self-Expanding Peripheral Stent System|Using the EverFlex™ Self-Expanding Peripheral Stent System to treat atherosclerotic superficial femoral artery (SFA) and proximal popliteal lesions 4-18 cm long in subjects with Rutherford Clinical Categories 2-4.
45798021|NCT05495984|Behavioral|ERPs with electroencephalography (EEG)|E-Prime 2.0 software will present visual and auditory stimuli in an experimental paradigm lasting approximately 30 minutes (ERPs). Visual stimuli will include photographs of color photographs of unfamiliar infants (aged 5- 10 months) balanced for ethnicity (Black/White) and gender (male/female) displaying happy neutral, and sad affective expressions. Auditory stimuli will include 2-second audio clips of high-distress and low-distress infant cries. Experimental procedure: Trials will consist of a central fixation cross (jittered 400-600ms), stimulus presentation (500ms faces, 2000ms cries), and blank screen (1000ms). Continuous electroencephalography (EEG) will be recorded using Net Station 4.2.1. A 128 Ag/Silver Chloride (AgCl) electrode net will be soaked in a warm potassium chloride solution, and net electrodes will be spaced evenly and symmetrically on each participant's head to cover the scalp.
45798022|NCT05495984|Behavioral|MIO|A 12-week, manualized, individual parenting psychotherapy developed specifically for mothers with addictions administered by the Principal Investigator. It is designed to foster a mother's capacity for mentalization or reflective functioning (RF). MIO is offered in conjunction with standard addiction treatment.
45798023|NCT01614613|Device|Bayer G3 / Tatsu System|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
45798024|NCT01614613|Device|Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
45798025|NCT01614613|Device|Freestyle Lite® Meter and Test Strips with ZipwikTM tabs|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
45798026|NCT01614613|Device|OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips|Study staff performed Blood Glucose (BG) tested with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
45798027|NCT01614613|Device|One Touch® VerioTM Pro/One Touch® VerioTM Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
45925397|NCT00064324|Other|pharmacological study|Correlative studies
45925398|NCT00064363|Drug|talampanel|
45925399|NCT05126147|Drug|Hydroxychloroquine|Compare the effects of hydroxychloroquine 200mg twice daily for 6 months with those without treatment.
45925400|NCT00064402|Drug|arformoterol tartrate inhalation solution|arformoterol 50 mcg QD
45925401|NCT00064402|Drug|arformoterol tartrate inhalation solution|arformoterol 25 mcg BID
45925402|NCT00064402|Drug|arformoterol tartrate inhalation solution|arformoterol 15 mcg BID
45925403|NCT00064402|Drug|Salmeterol|Salmeterol MDI 42 mcg BID
45925404|NCT00064402|Drug|Placebo|Placebo BID
45925405|NCT04604847|Diagnostic Test|blood test|blood test to explore BDNF level
45925406|NCT00064441|Drug|OPC-6535 Tablets (drug)|
45925407|NCT05125211|Drug|GB001 recombinant peptide spray|administrated oral spray
45925408|NCT05125211|Drug|Placebo|administrated oral spray
45925409|NCT00423748|Drug|ambrisentan|
45925410|NCT04578873|Drug|QPX7831|capsule
45925411|NCT04578873|Drug|placebo comparator|oral matched placebo capsule
45925412|NCT05122091|Drug|Fruquintinib + SOX|Fruquintinib：5mg qd for 2 weeks on and 1 week off, q3w； SOX: Tegafur gimeracil oteracil potassium capsule: 40-60mg bid（dosage according to body surface area），d1-14，q3w； Oxaliplatin：130mg/m2，intravenous (IV) ，d1，q3w.
45925413|NCT02967211|Drug|insulin glargine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45925414|NCT02967211|Drug|insulin glargine (U100)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45925415|NCT02967211|Drug|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45925416|NCT02967211|Drug|insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45925417|NCT02967211|Drug|insulin degludec|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45925418|NCT04573452|Diagnostic Test|Galectin-3|Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R&D Systems, Minneapolis, MN, USA).
45925419|NCT04573452|Diagnostic Test|Placental Galactin-3|Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA
45925420|NCT05115656|Behavioral|Online group 1|The intervention is specifically tailored to meet particular cognitive standard and satisfy the needs of brain injury patients. For 2-3 hours weekly, participants will be immersed in mental exercises designed to help them overcome various challenges.
45925421|NCT05115656|Behavioral|Online group 2|The intervention is specifically tailored to meet particular cognitive standard and satisfy the needs of brain injury patients. For 2-3 hours weekly, participants will be immersed in mental exercises designed to help them overcome various challenges.
45450565|NCT02191462|Dietary Supplement|Niagen 100mg|
45450566|NCT02191462|Dietary Supplement|Niagen 300mg|
45450567|NCT02191462|Dietary Supplement|Niagen 1000mg|
45450568|NCT02191540|Drug|Abnoba Viscum F 20mg|intravesical instillation of five amples of AbnobaViscum® F20mg and 0.9% normal saline into the pleural space
45649797|NCT02648347|Drug|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
45798028|NCT01614613|Device|Truetrack® Meter/Truetrack® Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
45925422|NCT00064636|Drug|VELCADE TM (bortezomib) for Injection, or PS-341|
45925423|NCT00064831|Drug|Black Cohosh Extract (BCE)|
45925424|NCT05113394|Drug|HDM sublingual Immunotherapy|HDM-SLIT tablet (Odactra®/Acarizax®) is a rapidly dissolving, freeze-dried, oral lyophilizate for oromucosal treatment, which contains a 1:1 mixture of two allergen extracts derived for the cultivated house dust mites, D. pteronyssinus and D. farinae. These species are included in SLIT tablet and subcutaneous immunotherapy administered for the treatment of allergic rhinitis and asthma in the pediatric and adult populations. The tablet dissolves within seconds after contact with a wet surface such as the oral mucosa. Participants will be administered the drug sublingually for 3 years.
45450569|NCT02187328|Other|Grapefruit juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
45925425|NCT05113394|Drug|Placebo|Placebo sublingual therapy
45450570|NCT02187328|Other|Apple juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice or Apple juice ingested in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
45450571|NCT02191696|Device|IMED-4 recording|
45450572|NCT02187406|Procedure|Modified ankle athletic taping|
45450573|NCT02187406|Procedure|Traditional ankle athletic taping|
45450574|NCT03535480|Drug|G-CSF|G-CSF subcutaneously during five days
45450575|NCT03535480|Combination Product|ASCOT|G-CSF subcutaneously during five days, aphaeresis to hematopoietic stem cell collection and catheterism for ovarian artery infusion
45649798|NCT02648347|Drug|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis.
45649799|NCT05255783|Device|subcutaneous continuous glucose sensor|Dexcom G6 continuous glucose monitoring system
45798029|NCT05732324|Procedure|IVUS guided PCI optimization|PCI to long lesion will be optimized according to the IVUS.
45798030|NCT05732324|Procedure|FFR guided PCI optimization|PCI to long lesion will be optimized according to the FFR.
45925426|NCT00065026|Behavioral|Physical activity opportunities for low-income women|
45925427|NCT00065104|Drug|DHEA|
45925428|NCT04560699|Other|Physiotherapeutic treatment and medical care|Physiotherapeutic treatment twice a week for twelve weeks and medical care three times at baseline, week 13 and week 26
45925429|NCT04560699|Other|medical care|medical care three times during the study period; baseline, week 13 and week 26
45925430|NCT00065143|Drug|clofarabine|
45925431|NCT00065143|Drug|Ara-C|
45925432|NCT00389948|Drug|Lanzoprazole|
45925433|NCT00065221|Drug|Ginger|
45925434|NCT00065299|Behavioral|Restricted phenylalanine diet|
45798031|NCT05732324|Diagnostic Test|FFR measurement|Fractional flow reserve protocol will be applied for both FFR-guided and IVUS-guided PCI groups. FFR will be measured according to the standard practice using intravenous adenosine. FFR will be recorded before PCI at the distal third of the coronary artery and after PCI at the same location. In FFR optimization group more than one post PCI FFR measurements could be acquired if the operators performed additional optimization. In IVUS optimization group only one post PCI FFR measurement will be recorded after which the procedure will be considered to be finished, and no further interventions will be undertaken. The same FFR measurements will be performed at 9-12 months follow-up.
45925435|NCT00065338|Behavioral|Exercise and behavior modification|Participants will undergo 1000 kcal/day caloric restriction (relative to experimentally determined weight-maintenance caloric needs) for 8 weeks during one phase of study. Additional 11 week period consists of 8 weeks of caloric restriction with an additional daily walking program.
45925436|NCT00398671|Device|Application of cool cap after primary successful CPR|
45798032|NCT01614847|Drug|Artificial tears|At random, subjects will receive isotonic artificial tear or a control (normal saline).
45798033|NCT00382629|Drug|BHT-3009 0.5 mg|
45798034|NCT00382629|Drug|BHT-3009 1.5 mg|
45925437|NCT04527861|Procedure|Single-incision Laparoscopic Surgery|In this group，the surgery is performed through a single incision. The surgeon will adjust surgical position to expose the operative field with the help of gravity. Besides，hand over hand cross and parallel techniques are needed to achieve the SILS. All the other operative procedures are the same as conventional laparoscopic surgery.
45925438|NCT04527861|Procedure|Conventional Laparoscopic Surgery|In this group，the surgery is performed through 3-5 ports according to the surgeons habits and specific conditions.
45925439|NCT00398749|Drug|Epoetin alfa|40,000 IU once weekly, variable treatment length
46071985|NCT05791253|Other|Pain management|Check whether pain management was carried out according to the recommendations of the French Society of Anaesthesia and Intensive Care (SFAR) and the French Society of Emergency Medicine (SFMU)
45798035|NCT00382629|Drug|Placebo|
45798036|NCT00000513|Behavioral|diet, reducing|
45798037|NCT00000513|Behavioral|diet, sodium-restricted|
45925440|NCT00398788|Drug|OROS® hydromorphone HCL; Dilaudid CR (controlled release); Dilaudid IR (immediate release) as rescue medicine|
45450576|NCT02187484|Drug|BIBR 277|
45925441|NCT00398827|Drug|Dexmedetomidine|
45450577|NCT02191852|Drug|Seresis®|
45925442|NCT00398827|Drug|Placebo|
45925443|NCT02966977|Other|Conventional microbiological identification by culture plate|Conventional microbiological identification involves a step of overnight-2days growth of bacteria/fungi on culture plates prior to identification by biochemical methods or by mass spectrometry. See also information noted in arm/group description.
45450578|NCT02256748|Drug|BIRT 2584 XX|
45925444|NCT02966977|Other|Direct mass spectrometry identification from urine sample|The urine sample is concentrated and directly measured by a MALDI-TOF mass spectrometer without an intermediary microbiological culture on agar plates.
45925445|NCT00065377|Drug|Glucosamine Hydrochloride|
45925446|NCT00065416|Procedure|massage|
45925447|NCT05105048|Biological|mRNA-1647|Lyophilized product that is reconstituted with saline
45925448|NCT05105048|Biological|Placebo|0.9% sodium chloride (normal saline) injection
45450579|NCT02256748|Drug|Midazolam|
45925449|NCT00065455|Drug|Vitamin A|
46071986|NCT05790707|Procedure|Atrial fibrillation ablation + antiarrhythmic drugs|"Atrial fibrillation ablation will be performed with endovascular catheters and will be done either with radiofrequency, cryoballoon or pulsed field ablation.~Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed."
45450580|NCT02187562|Drug|Meloxicam|
45450581|NCT02187562|Drug|Aspirin|
45450582|NCT02187640|Behavioral|Self-administered acupressure|Self-administered acupressure: In order to ensure the compliance of treatment, they would apply this intervention according to the acupressure group protocol once per day in groups with one trained research nurse's instructions and supervision .
45798038|NCT00000513|Drug|chlorthalidone|
45798039|NCT00000513|Drug|atenolol|
45798040|NCT00000543|Behavioral|dietary supplements|
45798041|NCT00000543|Drug|calcium|
45798042|NCT01617421|Behavioral|Yoga|This study used Hatha yoga (influenced by Integral, Iyengar, and Kripalu yoga) which includes postures (asanas), breathing techniques (pranayama) and meditation [9]. Biweekly, 60-minute, bilingual yoga classes were offered for 8 weeks at a yoga studio in Washington, DC. Classes were kept small (3-10 participants) to allow for pose modifications as needed for each participant. Participants were given instructions, bilingual manuals, and yoga equipment to encourage home practice. Participants were asked to keep journals to document the frequency and duration of home practice and their experience while on the study. After the last class, a yoga DVD and a list of local yoga studios were given to encourage continued practice.
45925450|NCT00065572|Drug|ZD6126|
45925451|NCT00065572|Drug|Placebo|
46071987|NCT05790707|Drug|Antiarrhythmic drug|Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed.
45798043|NCT00000549|Drug|estrogen replacement therapy|
45925452|NCT05089760|Other|No intervention|This is a prospective observational cohort study. The purpose of the study was to compare the incidence of mortality, complications, and other outcomes between infants with multi-resistant bacteria sepsis and infants with sepsis caused by non-multi-resistant bacteria, and compare the incidence of complications and other outcomes between infants with sepsis-related death and infants who survive.
45925453|NCT00065650|Drug|Vedic Medicine|
45925454|NCT00065650|Behavioral|Vedic Medicine|
45925455|NCT04488081|Drug|Remdesivir|Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days. Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
45925456|NCT04488081|Drug|Imatinib Mesylate|Subjects will be administered 800 mg on Day 1 orally, in divided doses of 400 mg administered twice per day. 400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
45925457|NCT04488081|Drug|Dexamethasone|6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
45925458|NCT04488081|Drug|Cenicriviroc|Oral, loading 300 mg qAM followed by 150 mg qPM, 12 hours apart on day 1, then 150 mg BID for total of 14 to 28 days depending on date of hospital discharge.
45925459|NCT04488081|Drug|Icatibant|Subcutaneous, a safety run-in for the first 10 subjects was conducted using a regimen of 30 mg q8h × 3 days. All subsequent subjects received drug at 30 mg q8h x 6 days.
45925460|NCT04488081|Drug|Apremilast|oral, 30 mg bid × 14 days.
45925461|NCT04488081|Biological|dornase alfa|"For Non-intubated subjects: 2.5 mg BID until hospital discharge, improvement to room air (or baseline oxygen use prior to illness) for 24 hours, or total of 14 days of study drug, whichever comes first.~For intubated subjects: 5.0 mg BID in 10 mL normal saline until extubation or 14 days, whichever comes first. If intubated for less than 14 days, extubated subjects received 2.5 mg BID for a total Dornase treatment of 14 days, or until hospital discharge, whichever comes first."
45925462|NCT04488081|Drug|Celecoxib|Oral: 400 mg BID for 7 days.
45925463|NCT04488081|Drug|Famotidine|Oral: High dose 80 mg QID for 7 days followed by 40 mg BID for a course of 14 days.
45925464|NCT04488081|Biological|IC14|intravenous, 4 mg/kg on day 1, followed by 2 mg/kg on days 2, 3, 4
45925465|NCT04488081|Drug|Aviptadil|Inhalation via nebulizer, 100 µg three times (TID) daily for a maximum of 14 days
45450583|NCT02187640|Behavioral|Sham control group|Sham intervention: Patients received similar aupressure intervention on the non-acupoints.
45597892|NCT02205203|Device|Mayo Clinic Anxiety Coach|Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
45649800|NCT02614703|Drug|Chromoendoscopy using Acetic Acid 2.5%|Spraying esophageal mucosa during random biopsies for Barrett's esophagus
45925466|NCT04488081|Biological|narsoplimab|Dosed at 4 mg/kg, given as a 30-minute intravenous infusion (up to a maximum of 370 mg per infusion) twice weekly for a total of four weeks (i.e. 9 doses) or until hospital discharge whichever comes first.
45925467|NCT04488081|Drug|Cyproheptadine|4 mg tablet, with dosing regimen of 8 mg every 8 hours daily for ten (10) days. If the patient weighs less than 48 kg, the regimen is 6 mg every 8 hours daily for ten (10) days. If the participant was discharged before completion of this dosing regimen the drug was not continued.
45925468|NCT04488081|Drug|Cyclosporine|Modified CsA at an oral dose of 5mg/kg per day administered in two divided doses daily for 5-days.
45925469|NCT00065689|Device|high-intensity light therapy|
45925470|NCT00065767|Drug|Raloxifene|
45925471|NCT00065845|Procedure|Burch urethropexy at time of sacrocolpopexy|The Burch colposuspension procedure entails the retropubic placement of at least two stitches in the vaginal tissue lateral to each side of the urethra, and suspension of these stitches from Cooper's ligament (the iliopectineal line at the superior aspect of the posterior pubic bone).
45925472|NCT05085821|Device|HEART|In an augmented reality environment, the patient receives visual feedback in synchrony with their cardiac-cycle (HEART)
45925473|NCT05085821|Device|Placebo|In an augmented reality environment, the patient receives visual feedback out-of-synchrony with their cardiac cycle (Placebo)
45925474|NCT00065884|Drug|Valproate|
45925475|NCT00065923|Drug|Topiramate|
45649801|NCT02614703|Other|Standard random esophageal biopsies|Random esophageal biopsies performed as per protocol
45649802|NCT03047525|Biological|Cytokine-induced Killer Cells|Concurrent of chemotherapy plus 4 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment and 4 cycles of Cytokine-induced Killer Cells(CIK) treatment
45649803|NCT04867967|Behavioral|Iyengar Yoga|Classical Iyengar Yoga intervention, especially designed for headache patients. Note: First administered face-to-face, due to Covid-restrictions changed to online classes
45649804|NCT04867967|Behavioral|Mindfulness-based stress reduction|Standardazied Mindfulness-based stress reduction intervention Note: First administered face-to-face, due to Covid-restrictions changed to online classes
45798044|NCT00000549|Drug|hormone replacement therapy|
45798045|NCT00000549|Drug|estrogens|
45798046|NCT00000549|Drug|progestins|
45798047|NCT01617577|Drug|G-CSF; filgrastim|The drug is administered s.c. at a dose of 10 microg/kg daily for 5 days
45925476|NCT04438044|Drug|ICP-022|ICP-022 The drug product is a white, round, uncoated tablet
45925477|NCT00065962|Drug|secretin, synthetic porcine|
45925478|NCT00065962|Drug|secretin, biologically derived porcine|
45798048|NCT01617577|Drug|Placebo|vehicle (D5W or 5% dextrose solution) is administered subcutaneously daily for 5 days
45798049|NCT05258175|Other|KT|Kinesio tapping will be applied in three session and it will be changed on every fifth day in total 15 days.
45925479|NCT05083754|Drug|Retifanlimab|Anti-PD-1 Therapy
45925480|NCT05083754|Drug|Temozolomide|Anti-PD-1 Therapy
45925481|NCT05083754|Radiation|Radiation Therapy|Standard of Care
45925482|NCT00066001|Drug|metronidazole|antibiotic that is particularly effective against Gram negative bacterial species
45925483|NCT00066079|Procedure|massage|
45925484|NCT00066079|Behavioral|relaxation|
45925485|NCT00066118|Device|Dental amalgam restorations|
45925486|NCT04432779|Other|no intervention|no intervention
45925487|NCT00066157|Drug|Transdermal estradiol|50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months
45450584|NCT02192086|Other|goal directed fluid therapy|"The treatment group will initially be given a 1L bolus after induction over 20 minutes (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) followed by maintenance infusion at a rate of 5mL/kg/hr until the graft kidney is removed from ice. After removing the organ from ice, the kidney recipient will be administered supplemental crystalloid until PVI is 10 or lower. Plasmalyte will be warmed in accordance to the departmental hypothermia protocol. A PVI of 12 or lower will be maintained until emergence of anesthesia, at which time the PVI monitor will be removed and all patients will be managed by existing standards (pain control, fluid replacement, hemodynamic goals, etc).~a.At the time the treatment group begins receiving goal directed fluid therapy the anesthesia team is to wean any vasopressors aggressively with the goal of terminating infusion as quickly as is safe."
45649805|NCT05218265|Diagnostic Test|routine laboratory tests|Complete blood count (CBC), coagulation profile, serum biochemical tests (including renal and liver function, and electrolytes), laboratory investigation to assess severity of COVID-19: lactate dehydrogenase (LDH), myocardial enzymes (CPK-MB), serum ferritin, D dimer and arterial blood gases analysis
45649806|NCT01669343|Drug|Letrozole|Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period. Part B In overweight/obese participants who completed Part A, provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period.
45649807|NCT04867811|Other|conventional therapy|conventional therapy
45925488|NCT00066157|Drug|Medroxyprogesterone|2.5mg tablet daily for 12 months
45925489|NCT00066157|Drug|Placebo Patch|Transdermal placebo patch, changed every 3 days, for 12 months
45925490|NCT00066157|Drug|Placebo|Placebo tablet daily for 12 months
45925491|NCT00066196|Biological|MEDI--522|IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL.
46071988|NCT05790460|Other|Telehealth|Enhanced synchronous telehealth nurse navigation, compared to usual care nurse navigation, to increase timely molecularly-informed treatment recommendations through early integration of concurrent molecular testing.
45649808|NCT04867811|Other|cupping therapy|cupping therapy
45649809|NCT04867811|Device|TENS|transcutaneous electrical nerve stimulation
45649810|NCT04867811|Other|TENS and cupping therapy|TENS and cupping therapy
45649811|NCT05403619|Diagnostic Test|Diagnostic test|Cardiac Ultrasound in order to explore the causes of shortness of breath
45649812|NCT04678765|Procedure|Ultrasound-guided distal peripheral nerve block|"To localize the median nerve, the ultrasound transducer will be placed in a transverse orientation proximally to the wrist cease at mid-forearm level, with a slight tilt distally towards the hand. An in-plane ultrasound-guided medial-to-lateral puncture will be made and 3ml of 2% lidocaine was injected within the fascia that envelopes the median nerve.~To perform the ulnar block, an ultrasound transducer will be placed in a transverse orientation over the ulnar side of the distal forearm. An in-plane ultrasound-guided medial-to-lateral or proximal-to distal puncture will be made and 3 ml of 2% lidocaine will be infiltrated into the fascial plane to block the ulnar nerve. Finally, we will apply a circumferential subcutaneous infiltration of 4 ml 2% lidocaine at the radial side of the wrist, 2cm proximal to the styloid process of the radius to block the terminal sensory branches of the radial, musculocutaneous, and medial antebrachial cutaneous nerves that may reach the palmar crease."
45798050|NCT05258175|Other|Standardized physiotherapy protocol|3 sets with five repetitions per day for total of 15 days.
45798051|NCT05257941|Drug|IT Injection|an intrathecal (IT) injection in the back in which a small dose duramorph and bupivacaine will be placed into the spinal fluid
45798052|NCT05257941|Drug|ESP Block|an erector spinae plane (ESP) block in which bupivacaine and decadron are injected near the nerves under a muscle in the back
45798053|NCT02235493|Biological|Retrospective Case Only|
45798054|NCT01955564|Drug|NW-3509a|single dose
45798055|NCT01701037|Drug|dabrafenib|150 mg given PO
45798056|NCT01701037|Drug|trametinib|2 mg given PO
45798057|NCT01701037|Other|laboratory biomarker analysis|Correlative studies
45798058|NCT00000585|Drug|penicillin|
45798059|NCT04996797|Drug|PRA023 IV|PRA023 administered by IV infusion
45798060|NCT04996797|Device|Companion Diagnostic (CDx) Testing|PRA023 CDx Genotyping Assay
45925492|NCT00066196|Biological|Integrin + Dacarbazine|supplied in other formulations
45925493|NCT00066274|Drug|FOLFIRI regimen|
45925494|NCT00066274|Drug|FOLFOX regimen|
45798061|NCT04996797|Other|Placebo|Placebo administered by IV infusion
45798062|NCT05249205|Behavioral|REHIT1|This intervention involves a single REHIT exercise session per week. REHIT involves 10 minutes of unloaded cycling on a stationary bike interspersed with two 20-second 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass.
45649813|NCT04678765|Procedure|Ultrasound-guided quadruple-injection axillary nerve block|"The US probe will be applied in the axilla to obtain a short-axis view of the axillary artery. The following 4 nerves will be identified as hyperechoic structures: the median, ulnar, and radial nerve surrounding the axillary artery and the musculocutaneous nerve in the fascial layers between the biceps and coracobrachialis muscles.~A total volume of 20 mL lidocaine 2% will be administered divided over 4 locations. The needle is inserted in-plane from the anterior aspect of the axillary artery and directed toward the posterior aspect of the axillary artery to first anesthetize the radial nerve. The posteriorly located radial nerve is surrounded with 8 mL of local anesthetic. Afterward, the needle is withdrawn and redirected to the median and ulnar nerves, after which another 8 mL of local anesthetic is deposited. In the end, the needle is withdrawn and redirected toward the musculocutaneous nerve where another 4 mL of local anesthetic is deposited."
45798063|NCT05249205|Behavioral|REHIT2|This intervention is the same as that for the REHIT1 intervention, but with 2 sessions per week instead of 1.
45798064|NCT01955720|Drug|BI 655075|
45798065|NCT01955720|Drug|BI 655075|
45798066|NCT01955720|Drug|Placebo|
45798067|NCT01955720|Drug|BI 655075|
45798068|NCT01955720|Drug|Placebo|
45925495|NCT00066274|Drug|fluorouracil|
45925496|NCT00066274|Drug|irinotecan hydrochloride|
45925497|NCT00066274|Drug|leucovorin calcium|
45925498|NCT00066274|Drug|oxaliplatin|
45925499|NCT04401150|Drug|Vitamin C|Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-ml solution of either normal saline (0.9% NaCl) or dextrose 5% in water (D5W) during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
45925500|NCT04401150|Drug|Control|Dextrose 5% in water of normal saline (0.9% NaCL) in a volume to match vitamin C.
45925501|NCT05077280|Radiation|stereotactic body radiotherapy|Stereotactic Body radiotherapy will be given to 1-5 target metastases in 3 doses over 8 days or less. Each dose will be 15Gy for a total dose of 45GY
45925502|NCT05077280|Drug|Immunotherapy|Opdualag (nivolumab 480mg and relatlimab 160mg) will be given every 4 weeks for two years
45925503|NCT00066313|Drug|vandetanib|
45925504|NCT00066313|Procedure|adjuvant therapy|
45925505|NCT00066352|Drug|bortezomib|
46071989|NCT05789420|Other|P1R stick|Regular flavor tobacco stick
46071990|NCT05789420|Other|P1M stick|Mentholated flavor tobacco stick
46071991|NCT05789420|Other|CIG|Subjects' preferred brand of commercially available, regular or mentholated cigarettes
45649814|NCT04383743|Drug|Cisplatin|Given IV
45649815|NCT04383743|Drug|Doxorubicin|Given IV
45798069|NCT01955720|Drug|Placebo|
45798070|NCT01955720|Drug|Placebo|
45798071|NCT01955720|Drug|BI 655075|
45798072|NCT01619839|Drug|NKTR-181|
45798073|NCT01619839|Drug|Placebo|Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181
45798074|NCT01955954|Device|Canary Breathing System|The Canary Breathing System is a biofeedback device meant to assist patients in the re-training of abnormal breathing patterns.
45798075|NCT01701115|Procedure|Low Dose (20 ml) Local Anesthetic Volume for Interscalene Block|"Anesthetic volume:~Investigational group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 20 mL"
45798076|NCT01701115|Procedure|Control Dose (40 mL) Local Anesthetic Volume for Interscalene Block|"Anesthetic volume:~Control group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 40 mL"
45798077|NCT01701115|Drug|Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)|
45798078|NCT01701115|Drug|Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)|
45798079|NCT00000597|Drug|antilymphocyte serum|
45798080|NCT00000597|Drug|nandrolone|
45798081|NCT01621009|Drug|Active bupropion + counseling|"Medications-Pre-quit: 150 mg bupropion per day 7 days before quit attempt, then 150 mg twice daily for 4 days before quit attempt; then 150 mg bupropion twice daily for eight weeks.~Counseling-Pre-quit: two 10 minutes sessions before quit date; eight 10-minute sessions post quit date."
45925506|NCT00066391|Drug|cisplatin|
45925507|NCT00066391|Drug|irinotecan hydrochloride|
45925508|NCT00066391|Procedure|neoadjuvant therapy|
45925509|NCT04388475|Drug|OKN-007|Drug: OKN-007 (400 mg OKN-007/mL in a phosphate buffer) Administered via IV infusion, at a dose level of 60 mg/kg, given three times a week for 12 weeks, two times a week for a further 12 weeks and once per week until disease progression or up to two years.
45925510|NCT04388475|Drug|Temozolomide (TMZ)|Administered via oral, at a dose level of 150 mg/m2, once daily on Days 1-5 of each 28 day cycle in Cycle 1. If this dose level is tolerated, then in Cycle 2 (and subsequent cycles), at a dose level of 200 mg/m2, once daily on Days 1-5 of each 28 day cycle.
45925511|NCT00066430|Procedure|infrared photocoagulation therapy|
45925512|NCT00066430|Device|Infrared Coagulator|IRC treatment of up to 3 HGAIN lesions at baseline (study initiation). A second IRC treatment may be administered for recurrent lesions at the 3 month visit.
45925513|NCT00389987|Drug|MK0826, /Duration of Treatment : 8 Weeks|
45925514|NCT00389987|Drug|Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks|
45925515|NCT00066508|Drug|bortezomib|
45925516|NCT02966899|Dietary Supplement|Omega-3 fatty acids|
45925517|NCT00066547|Biological|monoclonal antibody HuHMFG1|
45925518|NCT00066586|Drug|exemestane|exemestane 25 mg once daily x 1 year
45925519|NCT00066586|Drug|Placebo|placebo once daily x 1 year
45450585|NCT02192086|Other|Control Group|"Control patients will be given a constant infusion of crystalloid (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) at a rate determined by the following: 70mL/kg for the duration of the surgery, 1L bolus after induction (over 20-30 minutes) followed by the remainder as a constant infusion determined by (70mL/kg * wt - 1000mL) / 160 minutes (using the local average of approximately 180 minutes of operative time).~a.A Masimo PVI monitor will be placed on the patient on an extremity not affected by an AV fistula and recorded for evaluation, but no fluid administration decisions will be made based on it (providers will not have access to its values)."
45925520|NCT00066625|Drug|oxaliplatin|Given IV
45450586|NCT02187718|Procedure|Sentinel Node Procedure under Local Anaesthesia|
45649816|NCT04383743|Drug|Methotrexate|Given IV
45649817|NCT04383743|Biological|Pegfilgrastim|Given SC
45649818|NCT04383743|Biological|Pembrolizumab|Given IV
45649819|NCT04383743|Procedure|Radical Cystectomy|Undergo standard of care radical cystectomy
45649820|NCT04383743|Drug|Vinblastine Sulfate|Given IV
45649821|NCT03126643|Biological|Nivolumab|"Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody approved by the US Food and Drug Administration (FDA) on an accelerated basis for some types of cancer. Please contact your physician for more details."
45649822|NCT02675179|Device|EOS|Pelvimetry will be performed with the new EOS technique of diagnosis to measure the diameter of the basin.
45649823|NCT02675179|Device|Spiral CT pelvimetry|Pelvimetry will be performed with the spiral CT technique. It is the technique usually used.
45649824|NCT04617067|Drug|Paricalcitol|Paricalcitol 12mcg, administered orally on every day of each 28-day cycle.
45798082|NCT01621009|Drug|Active bupropion, No counseling|"Medication - 150 mg bupropion per day starting week before quit day, then 150 mg twice daily 3 days before quit day, then 150 mg twice daily for eight weeks after quit day.~Counseling: No cessation counseling, only medication checks"
45798083|NCT01621009|Drug|Placebo medication + counseling|"Placebo bupropion once daily 7 days before quit day, then twice daily 4 days before quit attempt, then twice daily for 8 weeks after quit day.~Counseling: Two 10-minutes sessions before quit day, then eight 10-minutes sessions for eight weeks after quit day."
45798084|NCT01621009|Drug|Placebo medication, No counseling|"Pre-quit: Placebo medication once daily 7 days before quit day, then twice daily before quit day, then twice daily for 8 weeks after quit day.~Counseling: No counseling, just medication checks"
45925521|NCT00066625|Drug|bortezomib|Given IV
45925522|NCT00066625|Other|laboratory biomarker analysis|Correlative studies
45925523|NCT00066625|Other|pharmacological study|Correlative studies
45925524|NCT00066664|Genetic|proteomic profiling|
45925525|NCT00066859|Drug|Zoloft 50 mg|Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
45925526|NCT00066859|Dietary Supplement|St. John's Wort 600 mg|St. John's wort 600 mg daily for 1 week, if tolerated. Dose may be increased to 900 mg daily for 4 months.
45925527|NCT00066898|Drug|AGI-1067|
45450587|NCT02187718|Procedure|Sentinel Node Procedure under General Anaesthesia|
45450588|NCT02193724|Other|Skin Biopsy|A very small skin sample will be taken from the participant's arm. This will only be performed while the patient is under sedation for clinical purposes (e.g. exam under anesthesia, MRI, or other procedure requiring sedation).
45450589|NCT02193724|Other|Blood Draw|About 1 teaspoon of blood will be drawn from the participant's arm or from a central line catheter if present. Blood collection will be done at the same time the participant has blood drawn for routine clinical care.
45450590|NCT03535168|Drug|BAY1902607|3 different doses over the course of part 1 and 4 different doses over the course of part 2.
45649825|NCT04617067|Drug|Gemcitabine (GEM) and Nab-paclitaxel|GEM (at 1,000 mg/m2) and Nab-paclitaxel (at 125 mg/m2 of bodysurface area), administered weekly for 3 of every 4 weeks (on days 1, 8 and 15 only).
45925528|NCT04248543|Device|qMRI with Gadoteridol contrast agent|quantitative MR: MRI uses a magnet and radio waves to make medical images of the body. Gadoteridol is used as a contrast agent. Quantitative MRI involves the use of software to analyze the acquired images.
45925529|NCT04235673|Dietary Supplement|melatonin|orally administered drops
45925530|NCT04235673|Drug|placebo|orally administered drops
45925531|NCT00067015|Drug|bicalutamide|
45925532|NCT00067015|Drug|goserelin acetate|
45925533|NCT00067015|Procedure|assessment of therapy complications|
45925534|NCT00067015|Procedure|quality-of-life assessment|
45925535|NCT00067015|Radiation|radiation therapy|
45925536|NCT00067093|Drug|SanOrg34006|
45925537|NCT00067093|Drug|LMW heparin|
45925538|NCT00067093|Drug|Unfractionated heparin|
45925539|NCT00067093|Drug|Vitamin K antagonist (VKA)|
45925540|NCT04220307|Biological|AK104|Subjects will receive AK104 by intravenous administration
45925541|NCT00067132|Procedure|Juven (nutritional), HMB (nutritional)|
45925542|NCT00067171|Behavioral|Behavior Therapy|
45925543|NCT00067210|Device|Head and Neck Cooling System|
45925544|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|2,5 mg twice daily (5 mg total daily dose)
45925545|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|5 mg twice daily (10 mg total daily dose)
45798085|NCT05730530|Behavioral|Nutrition education curriculum|This intervention consists of a 6-week-long nutrition education curriculum aimed at improving fruit and vegetable acceptance and consumption. Sessions will occur within the classroom 3 times per week for 6 weeks. Each week, the sessions will consist of 2 days of teaching activities and 1 day of taste-test activities designed for children to guess various common fruits and vegetables, assemble recipes including 2-4 different fruits and vegetables, and then taste the foods. These activities will be conducted in a full-classroom group setting.
45925546|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10 mg twice daily (20 mg total daily dose)
46071992|NCT05789238|Behavioral|ANVISA|Products carrying front-of-package labels based on Brazil's Health Regulatory Agency (ANVISA's) nutrient profile model
46071993|NCT05789238|Behavioral|PAHO|Products carrying front-of-package labels based on the Pan-American Health Organization (PAHO's) nutrient profile model
46071994|NCT05788484|Drug|CDX-585|CDX-585 is administered by infusion every 2 weeks
46071995|NCT05784662|Behavioral|Social Workers Addressing Firearm Risk|Educational intervention for social workers.
45450591|NCT03535168|Drug|Matching placebo|Matching placebo for BAY1902607
45450592|NCT03535168|Drug|Midazolam|Part 1: The subjects will initially (Day -1) receive a sub-therapeutic dose of 1 mg midazolam as solution in the morning.
45450593|NCT02192242|Other|acute ischemic pain|acute ischemic pain was induced by treadmill exercise
45450594|NCT02192320|Drug|Atorvastatin|20 mg (every evening orally) for 5 weeks
45450595|NCT02192320|Drug|Atorvastatin and Dexamethasone|"Atorvastatin: 20 mg (every evening orally) for 5 weeks;~Dexamethasone:0.75mg Tid (1st-2nd week), 0.75mg Bid (3th week), 0.75mg Qd (4th week), 0.375mg Qd (5th week)"
45450596|NCT02187874|Procedure|delayed umbilical cord occlusion|
45649826|NCT04600531|Device|1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)|"tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants."
45798086|NCT04830969|Drug|Chlorhexidine gluconate oral rinse|Paroex® is a non-alcohol chlorhexidine preparation. Participants are to use 15 mL morning and evening for 3 months. With use of chlorhexidine, there is risk of reversible staining of teeth and the possibility of some alteration in taste. There is increased likeliness of staining in smokers, coffee drinkers and those who are susceptible to teeth staining in general. The cleaning of the front teeth is provided at the 3-month visit and helps to reduce any staining that may occur. If there is any alteration in taste, it should go away when use of chlorhexidine stops.
45925547|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|20 mg twice daily (40 mg total daily dose)
46071996|NCT05769283|Other|Platelet Rich Plasma|Platelet rich plasma (PRP) is autologous blood which has been centrifuged to separate the supernatant resulting in a solution with high concentration of platelets. It is then injected into the anterior vaginal wall and periclitoral area
45925548|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|30 mg twice daily (60 mg total daily dose)
45925549|NCT00398905|Drug|Enoxaparin|40 mg once daily (40 mg total daily dose)
45925550|NCT00398944|Device|Evaluation of the impact of a guideline based computerized decision support system.|
45925551|NCT05036642|Device|Compliant Passive Arm Support|The device is a mechanical device that consists of two linkages, elastic bands, a commercial posture brace, and a hook-and-loop fastener. The design of the device, with several compliant elements, ensures that one device fits many without joint alignment concerns. No motors or other actuators add energy into the system, meaning that it is stable.
46071997|NCT05769283|Other|Saline|Normal Saline to be injected into the anterior vaginal wall and periclitoral area
46071998|NCT05766202|Other|An group intervention for multiparas with fear of childbirth|The intervention consists of 4 group meetings, three during pregnancy and once after giving birth. It also includes a phone call.
45450597|NCT02187874|Procedure|early umbilical cord occlusion|
45450598|NCT02187874|Drug|Oxytocin|
45450599|NCT02193802|Device|PillCam® COLON 2 and PillCam Crohn's capsules|"Patient preparation for PillCam® COLON 2 and PillCam Crohn's capsule procedure:~Patients will drink only clear liquids beginning 12 noon the day prior to the procedure,12 hour fast prior to the procedure and 1 L of PEG on the morning two hours before the capsule ingestion.~Patients can drink clear liquids 2 hours and eat 4 hours post ingestion. Eight hours post ingestion the data recorder should be removed. Patients will confirm excretion of the capsule or as required by the investigator."
45450600|NCT02187952|Behavioral|Behavioral feeding intervention|Behavioral feeding intervention will include escape extinction.
45450601|NCT02188030|Other|Group Exercise Program|The participants allocated into the GET Group will receive a general exercise training realized in group of workers. Each training session started with a five minute swarm-up by slowly moving the neck, upper back, shoulder, arms and hands through pain-free range of motion; followed by 30 minutes of stretching and strengthening exercises for neck, upper back, shoulder, arms and hands, performed in the standing posture, sitting or lying. For resistance exercise, will be adopted 3 sets of 10 repetitions with a load of 80% of 1 repetitions maximum. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises.
46071999|NCT05764629|Diagnostic Test|blood test|Testing the peripheral blood for PPDM-C, including blood glucose, glycated hemoglobin A1c, fasting insulin and C-peptide, etc.
46072000|NCT05764629|Drug|pharmacologic approaches to glycemic treatment|documenting the change of glycemic treatment during the follow-up period
46072001|NCT05764239|Drug|SYNB1934v1|SYNB1934v1 IMP consists of powder for oral suspension packaged in sachets. During dose preparation, the powder will be resuspended in water or apple juice prior to administration.
45925552|NCT04172571|Biological|AK105|Anti-PD-1 antibody; IV infusion, 200 mg Q3W
45925553|NCT04172571|Drug|Anlotinib Hydrochloride|multi-targeted receptor TKI; oral administration; every 3 weeks as one cycle administered as 2 weeks on/1 week off
45925554|NCT00067288|Behavioral|Meaning-Centered Group Psychotherapy|
45925555|NCT00067288|Behavioral|Standard Supportive Group Psychotherapy|
45925556|NCT00067327|Drug|Inosine|
45925557|NCT00067366|Behavioral|Cognitive-Behavioral treatment|Cognitive-Behavioral skills training for chronic pain
45649827|NCT04600531|Device|4x1 Multichannel Stimulation Adapter for High Definition Transcranial Direct Current Stimulation (HD tDCS)|"HD tDCS will be delivered over M1. By connecting the conventional tDCS device (described above) to this adapter, the direct current is delivered along the 4x1 HD tDCS configuration, allowing for more specific neuromodulation. Stimulation is delivered by means of one central gel-electrode and four return-electrodes placed in plastic encasings embedded in an EEG cap.~Stimulation of left M1 (right hand = performing): delivered via the central electrode corresponding with C3 and held in place using a synthetic cap to hold the HD-tDCS electrodes on the head. Return-electrodes are positioned at Cz, F3, T7 and P3 (10-20 EEG system).~Stimulation of right M1 (left hand = performing): central electrode will be positioned at C4 with the return-electrodes at Cz, F4, T8 and P4.~Strategies for anodal and sham stimulation are identical to the ones described above (conventional tDCS)."
45798087|NCT04830969|Procedure|Scaling & Root Planing|SRP is standard treatment of periodontitis. It involves using a scaler to remover subgingival plaque and other debris in the space between teeth and gums.
45649828|NCT05023057|Behavioral|Multidomain intervention|For 24 weeks, participants will receive cognitive training using the tablet PC application twice a week, exercise 3 times a week, nutrition education 12 times, anthropometric measurements and alcohol and smoking monitoring every 4 weeks, motivation reinforcement training 4 times.
45798088|NCT04830969|Device|Soft Picks|Soft Picks are a rubber interdental bristle cleaner. Participants are to use Soft Picks morning and evening for all 12 months of the study. They may cause some bleeding of the gums at first usage, but the bleeding should lessen and stop as use is continued (as gums heal). Soft-Picks are a readily available consumer product sold in supermarkets and drug stores.
45649829|NCT04669015|Biological|Novaferon|a novel recombinant antiviral protein drug
45649830|NCT04669015|Biological|Placebo|Formulation vehicle
45798089|NCT01683331|Drug|Insulin treatment for hyperglycemia|
45798090|NCT02986880|Drug|Botulinum toxin A|
45798091|NCT02986880|Procedure|Placebo|Injection of sodium chloride (NaCl) 9/1000
45798092|NCT01701271|Other|Hair loss prevention lotion|For greatest problems 20 drops on the scalp per day for 3 months. For minor problems 10 drops on the scalp three times per week for 3 months.
45798093|NCT02290106|Drug|pitavastatin|
45798094|NCT02290106|Other|PLACEBO|
45798095|NCT00000615|Behavioral|diet, reducing|
45798096|NCT00000621|Drug|all trans retinoic acid|
45798097|NCT00000621|Drug|13 cis retinoic acid|
45798098|NCT00000621|Drug|placebo|
45925558|NCT00067366|Behavioral|Attention and lifestyle counseling|Attention and lifestyle counseling added to Standard Care
45925559|NCT00067405|Drug|Intravenous micronutrient therapy|
45925560|NCT00067444|Drug|Paroxetine CR|
45925561|NCT00399022|Drug|Duloxetine|
45925562|NCT00065533|Drug|pemetrexed|
45925563|NCT04103268|Other|sepsis|patients in the ICU with infection called sepsis
45925564|NCT02967094|Drug|Administration of mucolytic solution before upper endoscopy (Espumisan, ACC long)|
45925565|NCT02967094|Drug|Administration of water before upper endoscopy|
45925566|NCT00067522|Behavioral|User-independent contraception program|
45925567|NCT00067522|Behavioral|Future Planning Perspectives program|
45925568|NCT04096833|Other|Virtual Reality Group|Participants are from 3 to 14 years old who attend a pediatric primarey health care of the Fuensanta Health Center (Valencia) for immunization by vaccine.
45925569|NCT00067561|Drug|Alosetron|
45925570|NCT00067600|Behavioral|Diet with increased fruits, vegetables, and calcium|
45925571|NCT00067600|Behavioral|Increased high impact activity and resistance training|
45925572|NCT03113513|Procedure|fixation of the vaginal apex|In the course of vaginal hysterectomy the vaginal cuff is either fixed to the sacrospinous ligament or to the uterosacral ligament.
45925573|NCT00067639|Drug|Pegfilgrastim (Neulasta)|12 mg single injection of pegfilgrastim under the skin prior to apheresis.
45925574|NCT00067639|Procedure|Apheresis|Collection of stem cells, repeated daily until target stem cell dose reached, maximum of 5 procedures.
45925575|NCT00067678|Drug|soy protein|
45925576|NCT00067717|Behavioral|Distance healing|
45925577|NCT05010707|Drug|Transdermal patch|Participants will be prescribed the medication and dosed based on their hormonal profile. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
45925578|NCT05010707|Diagnostic Test|Pro-thrombotic markers|Once participants are started on gender affirming hormone therapy, pro-thombotic markers will be checked at baseline and every 6 months. Pro-thrombotic markers will include: Factor II, Factor IX, Factor XI, Von Willebrand factor, Protein C, Protein S, activated Protein C resistance.
45925579|NCT05010707|Diagnostic Test|Metabolic markers|Once participants are started on gender affirming hormone therapy, metabolic markers will be checked at baseline and every 6 months. Markers will include: Insulin level, fasting glucose, body mass index, waist circumference.
45798099|NCT02287688|Biological|Meningococcal quadrivalent CRM-197 conjugate vaccine|This study is strictly observational. Decisions of vaccination are made by health care providers.
45798100|NCT04818957|Dietary Supplement|Oral Thin Film (OTF) Cholecalciferol (Vitamin D3)|Study participants will receive vitamin D OTF weekly for a maximum of 12 weeks. The dose may be increased or decreased based on the dosing schema.
45925580|NCT05010707|Diagnostic Test|Hormone Profile|Once participants are started on gender affirming hormone therapy, hormonal levels will be checked every 4 weeks until estradiol and testosterone levels are within goal as established by standard of care.
45925581|NCT05010707|Drug|Sublingual Tablet|Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as once daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
45798101|NCT01621477|Drug|clofarabine|Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
45925582|NCT05010707|Drug|Sublingual Tablet|Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as twice daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
45925583|NCT05010707|Drug|Spironolactone|All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.
45798102|NCT01621477|Drug|cytarabine|Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
45649831|NCT02590783|Procedure|experimental intervention surgery|Patients are placed supine on the carbon table. Screw paths are planned on a spiral CT scan from the sacrum on transversal slices, two Kirschner-wires 2.5 mm in diameter are introduced into the iliac bone through a stab incision and advanced into the ilio-sacral joint, through the lateral part of sacrum into the first and second sacral body, through the contralateral lateral part of the sacrum and exiting the contralateral iliac bone through the sacra-iliac joint with aid of CT-guidance. Over the Kirschner-wires 7.0 mm cannulated screws are introduced and the Kirschner-wires withdrawn. Several low-dose computer tomography scans are performed to secure the correct position. Total radiation dose is 300 mille gray square centimetres (mGycm).
45798103|NCT01621477|Drug|busulfan|Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
45798104|NCT01621477|Drug|Plerixafor|Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: Hematopoietic Stem Cell Mobilizer
45798105|NCT01621477|Drug|cyclophosphamide|Given on Day -5 and Day +4 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent; immunosuppressive agent.
45798106|NCT01621477|Drug|antithymocyte globulin (rabbit)|Given on Day -4, Day -3, Day -2, and Day -1 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
45798107|NCT01621477|Biological|stem cells|Patients undergo T cell replete Hematopoietic stem cell infusion on Day 0 and Day +1. Patients undergo natural killer (NK) cell transplantation on day +6 (Day 0 is first stem cell infusion).
45798108|NCT01621477|Drug|Tacrolimus|Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
45798109|NCT01621477|Drug|mycophenolate mofetil|Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
45798110|NCT00000627|Drug|Fluconazole|
45798111|NCT02987036|Device|Aerogen|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by mesh nebulizer
45798112|NCT02987036|Device|Jet nebulizer|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Jet nebulizer
45798113|NCT04816149|Behavioral|VA Standard Suicide Intervention|Our active control condition is standardized and contains the elements of standard practice suicide-specific intervention delivered at the VA, which include: 1) suicide risk assessment using the CSSR-S, 2) VA Safety Planning Intervention, 3) timely referral to VA mental health outpatient care, including couples intervention (engagement will be tracked), and 4) Suicide Prevention Coordinator (SPC) follow-up contacts (which have been found to significantly reduce suicidal behavior).
45925584|NCT00067756|Drug|4-PBA|During the first 3 days of this phase baseline serum AAT levels will be determined. The participants will be then given increased amounts of 4-PBA orally in 6 divided doses (day 4-6, 30 g/day and day 7-9, 40/day
45925585|NCT04091880|Biological|EV71 vaccine and influenza vaccine|simultaneously administrated with EV71 vaccine and influenza vaccine
45925586|NCT04091880|Biological|EV71 vaccine|administrated with EV71 vaccine only
45925587|NCT04091880|Biological|influenza vaccine|administrated with influenza vaccine only
45925588|NCT00067834|Device|Pulsing electromagnetic field (PEMF)|
45925589|NCT00067873|Behavioral|Diet|
45925590|NCT00067873|Behavioral|Aerobic exercise|
45925591|NCT00067873|Behavioral|Resistance exercise|
45925592|NCT02966860|Drug|Oral solution OC/APAP|
45925593|NCT04999241|Combination Product|exclusive enteral nutrition|Administration of a liquid formula diet with the exclusion of all other regular food for 8 weeks, then patients can administration of regular food.
45925594|NCT04999241|Combination Product|regular food|Administration of regular food in the induction phase and the later time.
45925595|NCT00067912|Drug|Duloxetine Hydrochloride|
45925596|NCT00067912|Drug|Venlafaxine Extended Release|
45925597|NCT04074096|Radiation|Stereotaxic radiosurgery (SRS)|For patients randomised to arm B only: Upfront SRS of all lesions ≥5 mm in diameter (or ≥3 mm if other cerebral metastases >5 mm).
45925598|NCT04074096|Drug|Binimetinib Oral Tablet|All patients: binimetinib 45 mg PO BID.
45798114|NCT04816149|Behavioral|Treatment for Relationships and Safety Together (TR&ST)|TR&ST consists of eleven 90-minute sessions delivered in three phases. During phase one, couples receive a tailored cognitive-behavioral conceptualization of suicide and relationship distress based on clinical interview, as well as psychoeducation about their bidirectional influences. They also engage in behavioral activation focused on positive couple activities, emotion regulation, distress tolerance, and conflict management strategies. In phase two, couples learn communication skills and discuss suicidal thoughts and behaviors, as well as their relationship challenges that interact with suicidal thoughts and behavior. Phase three is focused on conjoint thought challenging to shift dysfunctional cognitions related to suicide and relationship problems.
45925599|NCT04074096|Drug|Encorafenib Oral Capsule|All patients: encorafenib 450 mg PO QD
45925600|NCT04074096|Drug|Pembrolizumab|All patients: pembrolizumab 200 mg IV Q3W
45925601|NCT02958475|Behavioral|Social Support Group (Facebook)|The breastfeeding social support group on Facebook will be moderated to facilitate posting of shared experiences. Short videos, photographs, and written blurbs on related topics are posted on the Facebook page to reinforce the messaging and content of the texts.
45798115|NCT00000633|Biological|gp160 Vaccine (Immuno-AG)|
45798116|NCT00000633|Biological|Hepatitis B Vaccine (Recombinant)|
45798117|NCT01621633|Drug|LCZ696|
45925602|NCT02958475|Behavioral|Breastfeeding messages|The Mother's Milk Messaging app gives participants access to text messages via push notification on the app, as well as access to videos and written material to facilitate knowledge acquisition and skills building. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.
45798118|NCT01958606|Other|High-intensity interval training (HIT)|Treadmill exercise using bursts of concentrated effort alternated with recovery periods
45925603|NCT02958475|Behavioral|Injury Prevention Messages|The Mother's Milk Messaging app will provide participants in the control group with genetic injury prevention message.
45925604|NCT00067951|Drug|rosiglitazone/metformin|
45925605|NCT00392457|Drug|ketoconazole|loading dose of 1g followed by a maintenance dose of 400 mg PO QID for 7 days
45925606|NCT00392457|Drug|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
46072002|NCT05764239|Drug|Placebo|A placebo will be manufactured using an inactive powder that is color matched to the SYNB1934v1 drug product. In order to maintain study blinding during the RWP, placebo will be packaged, labeled, stored, and administered in an identical manner to SYNB1934v1.
46072003|NCT05763914|Behavioral|Change in the incidence of hand eczema|Assessed by the self-reported cases of newly-developed hand eczema. Change between baseline and 6 months.
46072004|NCT05763914|Behavioral|Change in severity of hand eczema|Assessed by using the Hand Eczema Severity Index (HECSI). HECSI score: 0-360 points (0 best, 360 worst). Change between baseline and 6 months.
45649832|NCT02590783|Procedure|control intervention|Mobilization guided by our physiotherapists. Full weight bearing is allowed. Analgetic treatment with metamizol, ibuprofen or paracetamol to the attending physicians discretion under regular surveillance laboratory values and/ or morphine or methadone. Patients will be treated with an individually based approach, if necessary involving our anesthesiologic pain service. Thrombo-embolic prophylaxis with a low molecular weight heparin or rivaroxaban for 6 weeks unless there is an indication for oral anticoagulation. All patients will be followed up by the Geriatric Fracture Center considering osteoporosis, fall prophylaxis, malnutrition and delirium. For the duration of the study the patients will not receive Parathyroid Hormone Substitution or Phosphonates.
45649833|NCT01594931|Drug|pyronaridine/artesunate|Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1. The tablets were taken daily for 3 days.
45798119|NCT01958606|Other|Traditional Aerobic Training|Moderate intensity continuous aerobic exercise on a treadmill
45798120|NCT05479214|Drug|Metformin|1gm tablet with the 2 main meals
45798121|NCT05479214|Drug|Insulin|subcutaneous insulin daily administration
45798122|NCT04798053|Behavioral|Questionnaire|14-item Perceived Stress Scale (PSS-14), 9-item Patient Health Questionnaire (PHQ-9 questionnaire), State Trait Inventory Anxiety questionnaire (STAI questionnaire), Post-traumatic Stress Disorder Checklist Scale (PCL-S questionnaire)
45798123|NCT04798053|Biological|blood sample and salivary sample|10 ml whole blood for Peripheral blood and 2 ml saliva sample. Only for 100 cases.
45798124|NCT04794387|Biological|Amended LLS COVID-19 Registry|Do people with blood cancer who did not develop antibodies after a complete COVID-19 vaccination, develop antoibodies after a COVID-19 booster?
45798125|NCT00000657|Drug|Zidovudine|
45798126|NCT00000657|Drug|Didanosine|
45798127|NCT02330588|Behavioral|Eat It|"The SBIRT (Screening, Brief Intervention, Referral to Treatment), called RIPPLE (Resource Information Program for Parents on Lifestyle Education) was delivered on a study-designated tablet and designed to (1) screen children's weight status, (2) deliver a brief intervention*, and (3) provide parents with the opportunity select resources and services to help prevent obesity in children.~*Two brief questions about children's grain portion sizes and sugar sweetened beverage intake were presented."
45925607|NCT00068029|Drug|Pegvisomant/ Sandostatin LAR|
45925608|NCT00068029|Drug|Sandostatin LAR|
45925609|NCT00068029|Drug|Pegvisomant|
45925610|NCT00068068|Drug|Talaporfin sodium (LS11)|
45925611|NCT00068068|Device|LED-based light infusion device|
45925612|NCT00068068|Device|Light emitting diodes (LED)|
45925613|NCT00068068|Procedure|Photodynamic therapy|
45925614|NCT00068068|Procedure|Phototherapy|
45925615|NCT00068068|Procedure|Chemotherapy|
45925616|NCT04987346|Other|Walking on an instrumented treadmill|Participants will be asked to walk at different gait velocities for 1 minute. The treadmill speed will be increased incrementally at 0.1m/s intervals until just before running.
45925617|NCT00068185|Drug|Black cohosh|
45925618|NCT00392535|Radiation|conventional radiotherapy 74 Gy delivered in 37 fractions|
45925619|NCT00392535|Radiation|hypofractionated radiation therapy 60 Gy in 20 fractions|
45925620|NCT00392535|Radiation|hypofractionated radiation therapy 57 Gy in 19 fractions|
45925621|NCT00068263|Radiation|radiation therapy|
45925622|NCT04975295|Drug|LY3361237|Administered SC
45925623|NCT04975295|Drug|Placebo|Administered SC
45925624|NCT00068302|Drug|sirolimus|3-6 subjects will be enrolled into each dose level
45925625|NCT00068458|Dietary Supplement|Calcium-Rich Diet|1,200 - 2,500 mg/day. 6 month intervention
45925626|NCT00068458|Other|Arm 2: Exercise + Calcium-Rich Diet|Dietary counseling + material promoting strength training an aerobic activity + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
45925627|NCT00068458|Other|Exercise + Fruit & Vegetable, Low Fat + Calcium Diet|1,200 - 2,500 Calcium intake per day. 6 month intervention period.
45649834|NCT04981171|Procedure|Electro-thumbtack Needle Therapy|Each treatment session starts with sterilizing acupoints. Dazhui (GV14), bilateral Wangu (GB12), bilateral cervical Jiaji (at C4 and C6 level), two Ashi points and bilateral Houxi (SI3) have been selected in accordance with the principle of acupuncture prescription making and the consensus of experts on treating neck pain. Electro-thumbtack needles (0.25×2 mm) will be held by the acupuncturist between thumb and forefinger, vertically inserted into skin instantly and taped well on skin. Then assemble the gel electrodes to the surface of the conductive adhesive tape, also assemble the portable stimulation devices, adjust the current intensity from level 1 to a proper level that the participant can tolerate. Participants will receive three 30-min treatment sessions per week every other day for 4 consecutive weeks.
45649835|NCT04981171|Procedure|Sham electro-thumbtack needle therapy|Each treatment session starts with sterilizing acupoints. Sham electro-thumbtack needles (0.25×0.2 mm) will be held by the acupuncturist between thumb and forefinger, taped well on skin without penetration. The adhesive tape of needles are also produced with conductive material, after assembling the gel electrodes and the portable stimulation devices, adjust the current intensity to level 1 for a minimal stimulus which will last for only 30 seconds. By this time the acupuncturist will turn the device off to cut the current. Participants will receive three 30-min treatment sessions per week every other day for 4 consecutive weeks.
45649836|NCT04978831|Device|PEP Device|The breathing exercise device is a device that simulates pursed-lip breathing by creating positive expiratory pressure (PEP). Before starting to use the device, it will be explained that they need to put the mouthpiece on the device and put the nose clip on their nose, and the participants will be shown how it is done. The device will be used at 5 cmH2O pressure. A single exercise session consists of 3 exercise cycles, and a single exercise cycle consists of 15 breathing-exhalation activities. Participants will complete 3 cycles (a total of 45 inhales and exhales) in a single session. 1 loop lying on the left side, 1 loop lying on the right side, and 1 loop in sitting upright position. Participants held these sessions in the morning, afternoon, and evening. After completing each cycle, the participants will remove their nose clips and cough 2-3 times. Each participant will perform a total of 135 breathing exercises in one day.
45649837|NCT04978831|Other|Reading Aloud|"The patients in this group were given a book that they chose from among the book types within the scope of the study, according to their wishes. For the selection of books, opinions were taken from the experts in the education faculty of the same university and it was stated that any book separation was not important. The books that the participants wanted to read were provided by the researcher. They were asked to read this book aloud during the day, sitting upright on a chair or sofa, for 15 minutes, three times a day.~They were able to stop reading when the participant was tired or felt too short of breath to continue reading."
45649838|NCT04872725|Behavioral|Time management & participation & the leisure time activity|evaluated in terms of leisure time activities, time management and participation
45798128|NCT02330588|Behavioral|Move It|"The SBIRT (Screening, Brief Intervention, Referral to Treatment), called RIPPLE (Resource Information Program for Parents on Lifestyle Education) was delivered on a study-designated tablet and designed to (1) screen children's weight status, (2) deliver a brief intervention*, and (3) provide parents with the opportunity select resources and services to help prevent obesity in children.~*Two brief questions about children's moderate-to-vigorous physical activity (MVPA) and screen time were presented."
45798129|NCT02330588|Behavioral|eHealth Control|The eHealth Control group (1) screened children's weight status, and (2) provided parents with the opportunity select resources and services to help prevent obesity in children.
45798130|NCT01701505|Drug|400uL of Kovacaine Mist|2 unilateral intranasal sprays of 200uL each.
45798131|NCT01701505|Drug|200uL of Kovacaine Mist|2 unilateral intranasal sprays of 100uL each.
45925628|NCT02966821|Drug|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
45925629|NCT00068497|Drug|gefitinib|Given orally
45925630|NCT00068614|Biological|HER-2/neu peptide vaccine|
45925631|NCT00068653|Drug|Celecoxib|Celecoxib 400mg orally two times a day, taken with meals.
45925632|NCT00068653|Drug|ZD1839|ZD1839 250 mg po every day, taken with or without food.
45798132|NCT01701505|Drug|120uL of Kovacaine Mist|2 unilateral intranasal sprays of 60uL each.
45798133|NCT00000663|Drug|CD4-IgG|
45925633|NCT00068731|Dietary Supplement|lycopene|
45925634|NCT00068809|Procedure|Short Cycle Antiretroviral Therapy|
45925635|NCT00068848|Behavioral|Quick start oral contraceptive initiation|
45925636|NCT00399061|Drug|Systane, Optive, Restasis|Systane 30ml (in the eye) instill one drop twice a day in morning and evening Optive 15ml (in the eye) instill one drop twice a day in morning and evening Restasis 0.4ml (in the eye) instill one drop twice a day in morning and evening more frequently if needed
45925637|NCT00399100|Procedure|HBO - hyperbaric oxygen treatment|
45925638|NCT00069082|Drug|Civamide (Zucapsaicin)|Nasal Solution 0.01%
45925639|NCT00069082|Drug|Sodium Chloride|Nasal Solution 10%
45925640|NCT00069316|Drug|Omr-IgG-am|
45925641|NCT00069355|Drug|Propranolol|
45925642|NCT04963712|Drug|Zadaxin|1.6 mg subcutaneous injection, once a day in the first 2 weeks, and 1.6 mg subcutaneous injection, twice a week in the successive 22 weeks.
45925643|NCT04002219|Dietary Supplement|beverage containing mushroom-extracts|Subjects recruited from both arms will receive treatment and be followed up clinically for 8 weeks.
45925644|NCT00069433|Procedure|Social skills and symptom management training|
45925645|NCT00069511|Drug|UT-231B|
45925646|NCT00069550|Drug|dextromethorphan|
45925647|NCT00069550|Drug|donepezil hydrochloride|
45925648|NCT04960280|Device|©VoqX stethoscope|Computerized auscultation detects both infrasound and audible sounds and is capable of amplifying auscultated sounds by a factor of thirty.
45925649|NCT00069628|Device|GlucoWatch® G2™ Biographer (GW2B)|
45925650|NCT00069628|Device|Continuous Glucose Monitoring System (CGMS)|
45925651|NCT02966587|Biological|Durvalumab|Given IV
45925652|NCT02966587|Other|Laboratory Biomarker Analysis|Correlative studies
45925653|NCT04958720|Procedure|Surgery|Surgery
45925654|NCT04958720|Drug|Chemotherapy, anti-targeted agents and immunotherapy|Chemotherapy, anti-targeted agents and immunotherapy
45925655|NCT04958720|Radiation|Radiotherapy|Radiotherapy
45925656|NCT00069706|Drug|AL-12182 0.003% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
45925657|NCT00069706|Other|AL-12182 Ophthalmic Solution Vehicle|Placebo
45925658|NCT00069706|Drug|Latanoprost 0.005% Ophthalmic Solution|Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
45925659|NCT00069706|Drug|AL-12182 0.01% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
46072005|NCT05763914|Behavioral|Change in the number of self-reported days with absence from work due to having hand eczema|Self-reported total number of sick days due to having hand eczema. Change between baseline and 6 months.
46072006|NCT05763914|Behavioral|Change in the number of participants being forced to change their job due to having hand eczema|Self-reported change of job due to having hand eczema. Change between baseline and 6 months.
45649839|NCT03045185|Procedure|RET using Ciprofloxacin 100mg, and Metronidazole 100mg.|"First Treatment Visit: Tooth isolation, access, pulp extirpation and root canal irrigation with 0.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the Bi antibiotic paste (mixture of Bi antibiotic paste (Ciprofloxacin 100mg and Metronidazole 100mg with sterile water). Sealing tooth access with glass ionomer cement.~Second Treatment Visit: Tooth analgesia using plain local analgesics, isolatation and re-access as described above. Irrigation of root canal system using normal saline followed by paper point dying. Initiation of bleeding through insertion of a sterile 23-gauge needle with a length of 2 mm beyond the working length into the periapical tissues. Access sealed using Portland cement, followed by glass ionomer and then composite resin."
45798134|NCT05720780|Other|MS group|"All patients will perform the usual training by listening a piece of music of the same duration as the training. The patient will be able to choose among 4 different musical proposals corresponding to 4 different styles: rock, modern, jazz and classical. The song chosen by the patient will be the musical support for all the sessions of training on the cycle ergometer. The musical pieces will be composed with a constant rhythm (bpm=60) which, from a tonal point of view, will echo the pedaling movement. The constant rhythm will be superimposed on musical patterns in the form of loops in the styles mentioned. The musical support will assume a priming (activation) and dragging (synchronization) function, facilitating movement planning/synchronization and creating a pleasant context in which to carry out training"
45925660|NCT00069706|Drug|AL-12182 0.03% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
45925661|NCT00069862|Drug|Deferitrin (GT56-252)|
45925662|NCT00069862|Drug|desferoxamine (DFO)|
45925663|NCT03960099|Behavioral|Pictograph in Banner and Verification Alert|Patient Pictograph will be displayed in the banner at the top of the screen in the electronic health record AND patient Pictograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
45649840|NCT03045497|Drug|Perflutren Lipid Microspheres|Given IV
45925664|NCT00069901|Drug|CT-2103 (poly(L)glutamate-paclitaxel)|
45925665|NCT00069901|Drug|carboplatin|
45925666|NCT00069940|Biological|sargramostim|
45925667|NCT00069940|Biological|telomerase: 540-548 peptide vaccine|
45925668|NCT00390026|Drug|Bevacizumab (Avastin)|
45925669|NCT00390026|Drug|Verteporfin photodynamic therapy (PDT)|
45925670|NCT03960060|Biological|CCT301-59|Collect blood from the patients and isolate peripheral blood mononuclear cells for the production of CCT301-59. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion during the production of CCT301-59 and then subjects will receive one dose of CCT301-59 via intravenous injection.
45925671|NCT00070057|Drug|celecoxib|Given orally
45925672|NCT00070057|Procedure|therapeutic conventional surgery|Undergo surgery
45925673|NCT00070057|Other|pharmacological study|Correlative studies
45925674|NCT00070057|Other|laboratory biomarker analysis|Correlative studies
45925675|NCT00070096|Drug|ixabepilone|
45925676|NCT00070174|Drug|asparaginase|
45925677|NCT00070174|Drug|busulfan|
45925678|NCT00070174|Drug|cyclophosphamide|
45925679|NCT00070174|Drug|cyclosporine|
45925680|NCT00070174|Drug|cytarabine|
45925681|NCT00070174|Drug|daunorubicin hydrochloride|
45925682|NCT00070174|Drug|etoposide|
45925683|NCT00070174|Drug|gemtuzumab ozogamicin|
45925684|NCT00070174|Drug|methotrexate|
46072007|NCT05763914|Behavioral|Change in The Quality Of Life in in relation to hand eczema|Assessed by using Hand Eczema Questionnaire (QolHEQ). Change between baseline and 6 months.
46072008|NCT05763914|Behavioral|Change in the level of knowledge regarding skin care and protection.|Self-reported level of knowledge regarding skin care and protection. Change between baseline and 6 months.
46072009|NCT05762276|Drug|VXX-401|A synthetic PCSK9 peptide-based immunotherapy
46072010|NCT05762276|Biological|Placebo|Normal saline
46072011|NCT05761275|Procedure|Elective cystectomy|Adnexal cyst removal for presumed benign adnexal pathology.
45649841|NCT03045497|Device|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
45649842|NCT03045497|Device|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced Magnetic Resonance Imaging
45798135|NCT05720780|Other|C group|All patients will perform 12 to 14 supervised sessions depending on the center they belong to (5-6 sessions/week) each consisting of 30 minutes of exercise at the cycle ergometer plus 3 minutes of warm-up and 3 minutes of recovery. After a warm-up phase at 0 W, the initial workload will be set to 60% of the theoretical maximum. Intensity increases or decreases of 10 W will be made according to the criteria of Maltais et al (workload will be increased when patients will report dyspnea and/or leg fatigue as ≤3 on a Borg scale modified to 10 points of perceived effort. The training load will remain unchanged if the Borg score is 4 or 5 and will be reduced for scores ≥6). Patients will have to maintain a pedaling frequency between 55 and 60 rpm.
45798136|NCT00000669|Drug|Didanosine|
45925685|NCT00070174|Drug|mitoxantrone hydrochloride|
45925686|NCT00070174|Procedure|allogeneic bone marrow transplantation|
45925687|NCT03960021|Radiation|RFA interventions|Each patient is treated with 2 RFA interventions. Abiopsy of one metastasis is done at each RF session. Histological samples are sent to the Bio-pathology department of Institut Bergonié for tumor infiltrating lymphocytes counting. Primary outcome results from this counting (stromal TILs ≥ 20% is considered as a significant level, a comparative measurement before and after RF will be performed). In parallel blood samples are performed before and after RFA to analyze the kinetics of peripheral blood T lymphocytes subsets, tumoral circulating cells and tumoral DNA.
45925688|NCT00070213|Drug|FOLFOX regimen|
45925689|NCT00070213|Drug|capecitabine|
45925690|NCT00070213|Drug|fluorouracil|
45649843|NCT03047759|Device|water flosser|Powered
45649844|NCT03047759|Device|air floss|Powered
45649845|NCT04435639|Other|Manual lymph drainage.|"Manual Lymphatic drainage:~Patients will receive manual lymphatic drainage by massage for 40 minutes for 5 treatments over a 15 day period."
45649846|NCT04435639|Procedure|Coban compression bandage..|Coban compression bandaging: Patients will be wrapped in Coban compression bandaging which stays on until the next treatment. Patients will wear standard compression sleeves during the six month maintenance phase.
45649847|NCT04435639|Device|Adjustable Compression Sleeve|Patients wear an adjustable compression sleeve (Juzo varocare adjustable compression system) between treatments. They will be shown how to put it on and how to tighten the sleeve when needed. Patients will also wear the adjustable compression sleeve in alternation with a standard compression sleeve over a six month maintenance phase.
45649848|NCT04145531|Drug|IM JZP-458|IM JZP-458 will be administered in Part A, Cohorts 1 & 2
45649849|NCT04145531|Drug|IV JZP-458|IV JZP-458 will be administered in Part B
45649850|NCT04969237|Diagnostic Test|Vitamine D in blood samples|vitamine D values
45649851|NCT05138185|Device|Exoskeleton assisted gait on a treadmill|Subjects were instructed to walk on a treadmill at a constant speed during trials of 5 minutes. All subjects carried out four trials: (1) NoExo: subjects only wore the sensors to acquire their basal motion; (2) Free: subjects wore the exoskeleton although the actuator was mechanically decoupled, so it enabled the free movement of the knee; (3) Echo: the device provided gait assistance following the Echo-control strategy; and (4) Pattern: the device provided gait assistance following the Pattern strategy. During trials, patients wore a safety harness that did not support any weight. Previously to the execution of the trials, the gait velocity was self-selected by the subjects to a comfortable level. Subjects rested between trials for five minutes. Healthy subjects also performed a previous trial under variable gait speed. They walked over the treadmill as in the NoExo condition, although the gait speed randomly varies from 1km/h to 3km/h in 0.2km/h steps for 15 seconds at least.
45649852|NCT03045419|Procedure|gadoxetic acid-enhanced liver MRI|liver MRI using a standard dose (0.025mmol/kg) of gadoxetic acid
45649853|NCT05048251|Device|cTBS|continuous theta burst stimulation
45649854|NCT05048251|Device|iTBS|intermittent theta burst stimulation
45649855|NCT05048251|Device|sham|sham stimulation
45649856|NCT01594853|Behavioral|exercise training|The exercise program uses a local Curves® gym to provide an individualized program of strength and cardiovascular training. The program is expected to be performed for 45 minutes 4-6 days per week.
45649857|NCT05137639|Procedure|Platelet-rich fibrin (PRF)|PRF was only applied in the experimental arm to improve wound bed conditions
45649858|NCT03047681|Diagnostic Test|venous blood withdrawl|patients will be asked for a venous blood sample
45798137|NCT01622257|Device|Cavitation US|The areas with localized fat are treated 2 times per week for 3 months using Aesthetic cavitation via ultrasonic cavitation machine (Cavi SMART, South Korea, supplied with one piece cavitation probe of 40 KHz, 3-6 watt(W)/cm^2 adjustable, 60W with 20cm^2 active surface).
45649859|NCT05137561|Procedure|PSMA PET guided prostate biopsy|PSMA PET-guided prostate biopsy from PSMA avid prostatic lesion will be done.
45649860|NCT05137561|Procedure|MRI directed TRUS guided prostate biopsy|TRUS guided MR directed Cognitive fusion prostate biopsy based on the PIRADS scoring
45798138|NCT01622257|Drug|Metformin|Metformin hydrochloride (Glucophage 500 mg/tablet, Bristol-Myers Squibb, New York, USA). Medication is initiated in a step-up fashion every 5 days, from one tablet per day to three. This dose is maintained as tolerated throughout the 3 months of the study.
45798139|NCT01622257|Other|Cavitation US + Metformin|Combination of both Cavitation US + Metformin. the treatment duration lasts 3 months
45925691|NCT00070213|Drug|leucovorin calcium|
45925692|NCT00070213|Drug|oxaliplatin|
45925693|NCT00070213|Procedure|quality-of-life assessment|
45925694|NCT04949204|Procedure|Wearable sensor detection|Empatica E4 wearable wrist sensor
45925695|NCT03959943|Procedure|Sensory nerve coaptation|A recipient sensory nerve branch of the lateral cutaneous femoral nerve (LCFN) was reattached to a donor nerve in the chest area. The anterior cutaneous branch of the second or third intercostal nerve was used as the donor nerve. Direct, end-to-end nerve coaptation was performed.
45925696|NCT00070252|Drug|Capecitabine|Given PO
45925697|NCT00070252|Drug|Docetaxel|Given IV
45798140|NCT04958031|Drug|CVL-871 1.0 mg|CVL-871 1.0 mg, oral (tablet), once per day for 12 weeks (stepped up-titration of dose days 1-7)
45798141|NCT04958031|Drug|CVL-871 3.0 mg|CVL-871 3.0 mg QD oral (tablet), once per day for 12 weeks (stepped up-titration of dose days 1-21)
45925698|NCT00070252|Other|Laboratory Biomarker Analysis|Correlative studies
45649861|NCT04341467|Drug|Amisulpride|The initial dose of amisulpride group is 50mg/d, and the maximum dose is 800mg/d.
45798142|NCT04958031|Drug|Placebo|Placebo QD, oral (tablet), once per day for 12 weeks
45798143|NCT05740046|Device|INTORUS|INTERVENTION PROTOCOL WITH INTORUS
45925699|NCT00070252|Other|Pharmacological Study|Correlative studies
45925700|NCT00070252|Drug|Tipifarnib|Given orally (PO)
45925701|NCT00070447|Biological|rituximab|
45649862|NCT04341467|Drug|Olanzapine|The initial dose of olanzapine is 2.5 mg/d, and the maximum dose is 20 mg/d.
45798144|NCT04950543|Behavioral|Meditation|An online survey will be offered to participants who have enrolled in a 21-day meditation online course. The survey will be conducted using mobile website technology before and after the online course and additionally after 3 and 6 months.
45798145|NCT05739968|Other|Usual care + oncology case manager (OCM) care|Usual care + oncology case manager (OCM) care
45649863|NCT04933591|Drug|Diosmin / Hesperidin|Venoactive drugs are used for patients with varicose veins as a tool for alleviating symptoms
45798146|NCT05739968|Other|Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care|Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care
45798147|NCT04770207|Drug|Injection of drug-eluting microspheres into malignant tumors|Under the guidance of CT, puncture fine needle was used to inject drug-eluting microspheres into the tumor
45798148|NCT04942899|Drug|letrozole|concurrent capecitabine 500 mg three times daily in combination with letrozole 2.5 mg orally once daily.
45798149|NCT02290184|Behavioral|PilAm Go4Health Weight-loss Program|This is a 3-month lifestyle intervention program promoting weight loss through physical activity and health diet using a mobile health application (app), pedometer to track daily step-counts, and social networking (in-person and virtual social networking through Facebook) to reduce risks for metabolic syndrome in Filipino Americans with type 2 diabetes on metformin. Subjects will be asked: 1) to use a mobile app diary every day to input their weight, and calories (food and drink intake) and 2) wear a pedometer everyday to monitor their physical activity (step-counts).
45798150|NCT02290184|Behavioral|Active Control|This is a 3-month active control using a pedometer only without any education related to wt loss, physical activity, health eating, or tracking healthy behaviors
45798151|NCT00000693|Drug|Zidovudine|
45798152|NCT00000693|Drug|Acyclovir|
45798153|NCT05739890|Other|Embryo genome sequencing|This project proposes the testing of a cohort of research embryos to establish the key parameters for amplified trophectoderm biopsied embryos using minimum depth required for genome sequencing (>depth of 30X per base) and whole exome sequencing (>depth of 500X per base).
45798154|NCT05739890|Other|Parents genome sequencing|Analysis will be performed using multiple trio testing of each embryo in addition to the DNA from the genetic parent.
45798155|NCT04752033|Drug|Morphine|Dose titration utilizing will be done using sequential up and down design using biased coin method. All participant will receive a morphine dose that is within the range of doses currently utilized clinically and no participant will receive placebo only.
45649864|NCT04872881|Procedure|Endotracheal Tube Insertion|ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords)
45649865|NCT04872881|Procedure|Laryngeal Mask Insertion|After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted.
45798156|NCT04752033|Drug|Hydromorphone|Dose titration utilizing will be done using sequential up and down design using biased coin method. All participant will receive a hydromorphone dose that is within the range of doses currently utilized clinically and no participant will receive placebo only.
45925702|NCT00070447|Drug|cyclophosphamide|
45925703|NCT00070447|Drug|doxorubicin hydrochloride|
45925704|NCT00070447|Drug|prednisone|
45925705|NCT00070447|Drug|vincristine sulfate|
45925706|NCT00070447|Radiation|yttrium Y 90 ibritumomab tiuxetan|
45649866|NCT04872881|Procedure|Fiberoptic Bronchoscopy|"After the patients' airway is established, the trachea and the process area will be displayed by the physician.~The success rate will be increased by performing the procedure with fiberoptic bronchoscopy."
45649867|NCT04872881|Procedure|Radial Artery Monitoring|The radial artery will be cannulated. Hemodynamic monitoring and blood gas analysis will be done in this way.
45649868|NCT04872881|Diagnostic Test|Anteroposterior chest x-ray|When the tracheostomy cannula is placed and the patient is ventilated, the procedure will be terminated and confirmed with anteroposterior chest x-ray.
45649869|NCT04872881|Diagnostic Test|Arterial Blood Gas Analyses|Hypoxia, acidosis and carbon dioxide increase will be followed
45798157|NCT02987270|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine is an antimalarial in the artemisinin-based combination therapy class of drugs. It is the Kenya Ministry of Health second-line treatment for malaria in Kenya.
45798158|NCT00000699|Drug|Inosine pranobex|
45798159|NCT00000699|Drug|Ribavirin|
45798160|NCT02987114|Drug|PLT101|PTL 101 (Cannabidiol, CBD) Two piece hard capsules filled with seamless gelatin matrix green beads containing CBD (50 or 100 mg CBD per capsule) The beads should be administered following a meal, mixed with food
45798161|NCT04931979|Drug|Pembrolizumab Injection [Keytruda]|Up to 17 cycles of pembrolizumab until disease progression, toxicity, death, or withdrawal of IC (whichever occurs first)
45925707|NCT03959865|Drug|Long-acting GLP-1RA|Dulaglutide 0.75 or 1.5 mg /week or Exenatide once weekly 2 mg
45925708|NCT03959865|Drug|Short-acting GLP-1RA|Liraglutide 0.6 mg or 1.2 mg or 1.8 mg / day or exenatide 10 mcg or 20 mcg bid or lixisenatide 10 mcg or 20 mcg / day.
45925709|NCT03959865|Drug|Human-based GLP-1RA|Liraglutide 0.6 mg or 1.2 mg or 1.8 mg / day or dulaglutide 0.75 or 1.5 mg / week
45925710|NCT03959865|Drug|Exendin-based GLP-1RA|Exenatide 10 mcg or 20 mcg day or 2 mg / week or lixisenatide 10 mcg or 20 mcg / day.
45925711|NCT03959865|Drug|Fixed ratio BI/GLP-1RA combination|Insulin degludec / liraglutide (0.036/U) or insulin glargine / lixisenatide (0.5 mcg/U)
45798162|NCT04931979|Radiation|Salvage Radiation Therapy (SRT)|SRT according to standard of care (SRT with at least 66 Gy)
45798163|NCT05739812|Device|telesurgery by domestic surgical robot|telesurgery of urological diseases by domestic surgical robot
45925712|NCT03959865|Drug|Flexible BI/GLP-1RA combination|GLP-1RA (Liraglutide or dulaglutide or exenatide or lixisenatide) and basal insulin (BI, glargine, degludec, detemir, NPH insulin)
45925713|NCT00070486|Drug|carboplatin|given IV
45925714|NCT00070486|Drug|celecoxib|given PO
45925715|NCT00070486|Drug|gemcitabine hydrochloride|given IV
45925716|NCT00070486|Drug|zileuton|given PO
45925717|NCT00070525|Drug|tipifarnib|Given orally
45649870|NCT04872881|Drug|Propofol Fresenius|2mg/kg of propofol 2% injectable solution was given and propofol infusion at the dose of 6 mg/kg/hour will be started.
45925718|NCT00070642|Drug|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
45925719|NCT00070642|Drug|dacarbazine|dacarbazine 850mg/m2 in three-week cycles until disease progression
45798164|NCT04929795|Behavioral|Rhythmic auditory stimulation (RAS)|"The song named 'Sign of The Times' is played and recorded by the research personnel beforehand. The beat of the song will serve as RAS. The computer software Audacity will be used to adjust tempi of RAS. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo. For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Participants in the experimental groups are required to use their right hand to pick up beads from source bowls to the target bowl when listening to the song. The 3-week intervention program will include 21 40-minute daily training sessions."
45798165|NCT04929795|Behavioral|no RAS|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
45798166|NCT05739734|Drug|CRIS100|local application of CRIS100
45925720|NCT00070642|Drug|Chemotherapy|"Chemotherapy in three-week cycles until disease progression:~dacarbazine 850mg/m2"
45925721|NCT00070642|Drug|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 10 mg weekly.
45925722|NCT00070642|Drug|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
45925723|NCT00070681|Procedure|Polysomnography|
45925724|NCT00070720|Behavioral|Opinion Leaders, Academic Detailing, Reminders, and Feedback|
45925725|NCT00070759|Drug|Daclizumab|
45925726|NCT00070837|Drug|MLN2704 (DM1 conjugated monoclonal antibody MLN591)|
45925727|NCT00070876|Behavioral|Mental health communication skills training|
45925728|NCT00070915|Behavioral|Tai chi|
45925729|NCT00070915|Behavioral|Mindfulness-based Stress Reduction program|
45925730|NCT00070915|Procedure|Therapeutic massage|
45925731|NCT00070954|Drug|ginkgo biloba|EgB 761
45925732|NCT00070954|Other|matched placebo|Inactive look-alike placebo
45925733|NCT02966431|Behavioral|Counseling|
45925734|NCT02966431|Behavioral|No Counseling|
45925735|NCT04730440|Other|AD-TAR|Intervention description: 12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using a rehabilitation program named Training of Affect Recognition (TAR).
45925736|NCT04730440|Other|AD-Cognitive Stimulation|Intervention description: 12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using classic cognitive stimulation workshops.
45925737|NCT00070993|Drug|creatine monohydrate|
45925738|NCT03959826|Behavioral|activity contracting|Participants will complete job-related activity contracts each week with the goal of obtaining employment.
45649871|NCT04872881|Drug|Rocuronium|0.6 mg/kg of rocuronium 50mg/5ml injectable solution was given.
45649872|NCT04872881|Drug|Fentanyl|1mcg/kg fentanyl of 0.5 mg/10ml injectable solution was given.
45925739|NCT03959826|Behavioral|contingency management for activity completion|Participants will earn chances to win prizes for completing specific job-related activities.
45925740|NCT00071188|Drug|ZD6474|
45925741|NCT00071188|Drug|Paclitaxel|
45925742|NCT00071188|Drug|Carboplatin|
45925743|NCT00071227|Drug|Triamcinolone Acetonide (TAC-PF)|
45925744|NCT00071266|Drug|Niacin Extended Release and Lovastatin Tablets|
45925745|NCT03959787|Other|Educational|Educational pamphlet will be given to intervention group.
45925746|NCT00071422|Drug|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
45925747|NCT00071422|Drug|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
45925748|NCT00071422|Drug|placebo|1.5 mL, once daily, self-administered SC injection for 90 days
45925749|NCT00071500|Device|MedSignals™|An electronic device that is used to improve medication compliance among HIV patients. It allows convenient storage and transport of antiretroviral medications and functions as an aid to compliance by incorporating reminding alarms at dosing times and usage reporting functions.
45925750|NCT02966743|Drug|Midazolam|administration of midazolam during spinal anesthesia for target bispectral index 75-80
45925751|NCT02966743|Drug|Dexmedetomidine|administration of dexmedetomidine during spinal anesthesia for target bispectral index 75-80
45925752|NCT00071539|Drug|TP-38|Recombinant chimeric protein
45925753|NCT00071539|Drug|TP38|recombinant chimeric protein
46072012|NCT05761275|Procedure|Elective oophorectomy|Ovarian removal for presumed benign adnexal pathology.
46072013|NCT05761275|Procedure|Elective salpingectomy|Tubal removal for presumed benign adnexal pathology.
45925754|NCT03959709|Procedure|immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.|On the day of surgery, after the completion of the mastectomy, the vascularity of the mastectomy flaps will be evaluated, and debridement is performed where necessary. A temporary implant sizer is placed in the pocket to assess the position and shape of the prepectoral pocket. The pocket is adjusted where necessary. A sheet of ADM (DermAcell) is then selected. The DermAcell will be prepared as per the manufacture's instructions and fenestrated using size 11 blade. The DermACELL piece will be trimmed to the appropriate shape and sutured to the superior medial and lateral edges of the pectoralis major muscle. The inferior edge will be sutured to the fascia at the level of the inframammary fold. Two closed suction drains will be placed (one below the mastectomy skin flap, and one below DermACELL). The implant will be inserted to the pre-pectoral pocket and several anchor sutures will be used to secure the superior-medial edge of DermACELL to mastectomy flap.
45925755|NCT03959709|Procedure|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement|On the day of surgery, after the completion of the mastectomy, the vascularity of the mastectomy flaps will be evaluated, and debridement is performed where necessary. The reconstructive operative procedure will then proceeded with (1) elevation of the pectoralis major muscle with release of inferior attachments; (2) placement of implant subpectorally; (3) placement and suturing of DermACELL to constitute the inferolateral breast pocket; (4) placement of two closed suction drains (one superiorly between the pectoralis major and skin, and one inferiorly between the DermACELL and skin); (5) removal of sizer and placement of permanent to the pocket and (6) suture the inferior edge of DermACELL to the inferior edge of the pectoral major muscle. The skin will be closed and the dressing will be applied as standard protocol.
45798167|NCT00000723|Drug|Methotrexate|
45798168|NCT00000723|Drug|Leucovorin calcium|
45798169|NCT00000723|Drug|Zidovudine|
45798170|NCT00000723|Drug|Dexamethasone|
45925756|NCT00071578|Behavioral|Group Psychotherapy-Negative Emotion Focus|20 weekly sessions, 2 hours, group format
45925757|NCT00071578|Behavioral|Group Psychotherapy- Self-Esteem Focus|20 weekly sessions, 2 hours, group format
45925758|NCT00071617|Behavioral|Youth-Nominated Support Team|
45798171|NCT02329964|Drug|Sugammadex|Sugammadex 2mg/kg was injected to patients to R-S group, as reversal of neuromuscular blockade.
45925759|NCT00071656|Behavioral|Psychosocial (behavioral) Intervention|
45925760|NCT00071695|Drug|Duloxetine Hydrochloride|
45925761|NCT00071695|Drug|Venlafaxine Extended Release|
45798172|NCT02329964|Drug|Neostigmine|Neostigmine (pyridostigmine) 0.2 mg/kg mg was injected to patients to S-C-N group, as reversal of neuromuscular blockade.
45925762|NCT00392613|Procedure|Strict versus lenient rate control|
45925763|NCT00071773|Procedure|modified-ETDRS photocoagulation|A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
45798173|NCT04750395|Drug|Haloperidol Solution|Oral transmucosal haloperidol solution 2.5mg
45925764|NCT00071773|Procedure|Mild Macular Grid photocoagulation|A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
45925765|NCT04876040|Device|SSO2 Downstream System|60-min adjunctive reperfusion of hyperoxemic blood into target coronary artery, immediately following revascularization by means of PCI with stenting.
45925766|NCT04876040|Procedure|PCI + Impella|Standard of Care Intervention
45925767|NCT00071851|Biological|VRC-HIVDNA009-00-VP|
45925768|NCT00071929|Drug|oxaliplatin|
45798174|NCT04750395|Drug|Olanzapine Tablets|Oral transmucosal olanzapine tablet 5.0mg
45798175|NCT05739656|Procedure|CATARACT SURGERY|Approximately up to 100 subjects (100 eyes) will be successfully implanted with an enVista Toric IOL (Model MX60ET) in one or both eyes.
45925769|NCT00071968|Drug|temsirolimus|
45798176|NCT04748900|Diagnostic Test|spirometer|different values are measured on the spirometer after training in respiratory physiotherapy.
45798177|NCT05707598|Procedure|Laparoscopic surgery|The laparoscopic approach was used for the treatment of clinical T4b colorectal cancer
45798178|NCT00000729|Drug|Foscarnet sodium|
45798179|NCT04365855|Diagnostic Test|Magnetic Resonance Elastography|Combines MRI imaging with sound waves to create a visual map (elastogram) showing the stiffness of body tissues.
45798180|NCT04365855|Other|Blood draw|Clinical blood tests with a focus on liver function parameters and diabetes
45798181|NCT04365855|Procedure|Liver biopsy|If indicated per MRE results a biopsy will be taken of the liver.
45798182|NCT04365855|Procedure|Fibro Scan|If indicated per MRE results a fibroscan will be performed of the liver.
45798183|NCT04364217|Device|Luminis ultrapulse fractional ablative carbon dioxide laser|This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.
45798184|NCT04920201|Other|Over-ground walking without GEMS-H|Over-ground walking without GEMS-H (30 min per session, at least 3 times per weeks, total 10 sessions)
45798185|NCT04920201|Device|Over-ground walking with GEMS-H with resist mode|Over-ground walking with GEMS-H with resist mode (30 min per session, at least 3 times per weeks, total 10 sessions)
45798186|NCT04920201|Device|Stair ascent with GEMS-H with assist mode|Stair ascent with GEMS-H with assist mode (30 min per session, at least 3 times per weeks, total 10 sessions)
45798187|NCT04920201|Device|Incline walking with GEMS-H with assist mode|Incline walking with GEMS-H with assist mode (30 min per session, at least 3 times per weeks, total 10 sessions)
45798188|NCT03438773|Drug|Envarsus|Patients randomized into the Envarsus group will be prescribed Envarsus, mycophenolate and prednisone once daily.
45798189|NCT03438773|Drug|Tacrolimus|Patients randomized to the Tacrolimus group will be prescribed Tacrolimus twice-daily with standard of care immunosuppression, anti-proliferative and prednisone once-daily.
45798190|NCT04366245|Biological|Hyperimmune plasma|PLASMA OF CONVALESCENT COVID-19
45798191|NCT04366245|Drug|Standard of care for SARS-CoV-2 infection|Standard of care for SARS-CoV-2 infection
45925770|NCT00071968|Procedure|conventional surgery|
45925771|NCT00071968|Procedure|neoadjuvant therapy|
45925772|NCT00390065|Drug|Nitric Oxide|Early low dose (5ppm) NO inhalation Placebo
45925773|NCT02966392|Device|Tracoe cuff pressure controller|Participant will be attached to the cuff pressure controller as soon as possible after enrolment. They will remain attached during their intubated stay. If reintubated during same admission they will continue in the intervention arm. If readmitted to ICU they will be managed according to standard care.
45798192|NCT02974985|Device|injection of Restylane Lyft and Restylane L|Intervention--Injections of volumizing products to the midface, nasolabial fold, and marionette folds in female patients in two different age groups
45925774|NCT03959631|Behavioral|Virtual Communities of practice|based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.
45925775|NCT00072007|Biological|filgrastim|filgrastim
45925776|NCT00072007|Biological|rituximab|rituximab
45925777|NCT00072007|Drug|CHOP regimen|CHOP regimen
45925778|NCT00072007|Drug|cladribine|cladribine
45925779|NCT00072007|Drug|cyclophosphamide|cyclophosphamide
45798193|NCT01704781|Drug|Lenalidomide|In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A
45798194|NCT01704781|Drug|Lenalidomide placebo|Capsules are identical to the active Lenalidomide capsules used.
45798195|NCT01704781|Drug|Vacc-4X|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
46072014|NCT05761275|Procedure|Elective tubal sterilization|Tubal obstruction as a definitive contraceptive method (tubal cauterization with or without sectioning, partial or total removal of both tubes, or obstruction with small clips/ligatures).
45798196|NCT01704781|Drug|rhuGM-CSF|Granulocyte macrophage colony stimulating factor as a local adjuvant
45798197|NCT04699773|Procedure|LITT|This procedure is done under MRI guidance and employs low-powered thermal energy to achieve tumor ablation through coagulation.
45798198|NCT04699773|Radiation|Hypofractionated Radiation Therapy|Treatments will be delivered once daily on consecutive treatment days (typically 5 fractions per week). Radiation therapy simulation is to be performed within 10 days of the LITT procedure.
45798199|NCT04804761|Other|Electroacupuncture|Needle insertion on bilateral LI4 HeGu and PC6 NeiGuan and ipsilateral ST6 JiaChe and ST7 XiaGuan (as shown in Table 1), using disposable sterile acupuncture needles (length 25 mm, diameter 0.25 mm; Seirin Corporation, Shizuoka, Japan)
45798200|NCT02975063|Behavioral|A&T IYCF intervention|(1) Interpersonal communication through frontline workers/volunteers to increase mothers' knowledge and practice of optimal infant and young child feeding (IYCF) behaviors. Interpersonal communication will involve multiple contacts with mothers and an array of IYCF messages; (2) Community mobilization activities to raise awareness of the benefits of optimal IYCF practices among opinion leaders and family members, and increase their support to mother for IYCF; (3) Training of facility and community-based health workers on IYCF to improve their ability to support mothers and provide timely information on IYCF; and (4) Mass media communication on IYCF.
45798201|NCT02288156|Drug|Capsaicin|via nasal spray
45798202|NCT02288156|Drug|placebo|via nasal spray
45798203|NCT04699383|Drug|Sodium Stibogluconate with allopurinol|Routine administration of SSG/allopurinol combination treatment, from 1-5 cycles
45798204|NCT04350177|Drug|IkT-148009|Oral administration gelatin capsule
45798205|NCT04350177|Drug|Placebo|Oral administration gelatin capsule
45798206|NCT01623037|Device|The Zeltiq System|Non-invasive cooling is applied to the each flank with a defined cooling rate and duration.
45925780|NCT00072007|Drug|doxorubicin hydrochloride|doxorubicin hydrochloride
45925781|NCT00072007|Drug|prednisone|prednisone
45925782|NCT00072007|Drug|vincristine sulfate|vincristine sulfate
46072015|NCT05757141|Drug|ABBV-CLS-7262|ABBV-CLS-7262 is an eIF2B activator
46072016|NCT05746572|Drug|MDMA|Participants will receive MDMA HCl (100 mg, 84 mg MDMA) in combination with massed exposure therapy for PTSD.
45925783|NCT00072046|Biological|bevacizumab|10mg/kg IV infusion on Days 1 & 15 of each cycle
45925784|NCT00072046|Biological|recombinant interferon alfa|9 million units subQ injection 3 x/week for 4 weeks
45925785|NCT03959553|Drug|GV1001|Lyophilized peptide from hTERT
45925786|NCT03959553|Drug|Normal saline|0.9% normal saline
45925787|NCT04847141|Biological|C19-IG 20%|Anti-COVID-19 Immune Globulin (Human) 20%
45925788|NCT04847141|Drug|0.9% Sodium chloride|C19-IG 20% matching placebo
45925789|NCT03959514|Biological|NovoRapid|Rapid acting prandial insulin aspart
45925790|NCT03959514|Biological|Fiasp|Fast acting prandial insulin aspart
45925791|NCT03959514|Biological|AT247|Ultra rapid acting prandial insulin aspart
45925792|NCT04730596|Drug|Ketamine|Ketamine at a dose of 0.3 mg/kg dissolved in normal saline.
45925793|NCT04730596|Drug|Dexmedetomidine|Dexmedetomidine at a dose of 0.5 ug/kg dissolved in normal saline.
45925794|NCT04730596|Drug|Normal saline|Normal saline in a labeled syringe
45925795|NCT04846088|Other|Product A|A 4mg nicotine pouch product
45925796|NCT04846088|Other|Product B|A 7mg nicotine pouch product
45925797|NCT04846088|Other|Product C|A 7mg nicotine pouch product
45925798|NCT04846088|Other|Product D|A 7mg nicotine pouch product
45925799|NCT04846088|Other|Product E|A 7mg nicotine pouch product
45925800|NCT04846088|Other|Product F|A 7mg nicotine pouch product
45925801|NCT04846088|Other|Product G|A 7mg nicotine pouch product
45925802|NCT04846088|Other|Product H|A 7mg nicotine pouch product
45925803|NCT04846088|Other|Product I|A 7mg nicotine pouch product
46072017|NCT05746390|Behavioral|Home Alone|See Home Alone description.
46072018|NCT05745883|Drug|DISC-0974|DISC-0974 is administered subcutaneously
46072019|NCT05745883|Drug|Placebo|Placebo is administered subcutaneously
46072020|NCT05737121|Drug|VNX001|VNX001 (alkalinized lidocaine HCl and heparin sodium)
45649873|NCT04606459|Device|Coronary sinus reducer|The Reducer System comprises the Reducer device (Reducer) pre-mounted on the Reducer Balloon Catheter. The Reducer System is available in one model size. The Reducer is a sterile, single-use, implantable device designed to establish a narrowing in the coronary sinus (CS) and is intended to improve perfusion to ischemic myocardium in the presence of reversible ischemic heart disease to alleviate the symptoms of refractory angina. The device is implanted percutaneously through the right internal jugular vein into the CS. The Reducer is pre-mounted (crimped) on the Reducer Balloon Catheter which, after inflation, causes device expansion and apposition with the vessel wall. The balloon catheter is then deflated and removed from the CS, leaving the device permanently implanted.
45798207|NCT04087343|Behavioral|Meals plus exercise|Patients will receive 12 weeks of meals on wheels meal delivery consisting of 3 meals per day during the weekdays with 6 frozen meals to cover the weekends.They will also receive an exercise kit on the first visit by the meal delivery driver with 2 tennis balls,2 1-pound hand weights, and one towel.Every week,the driver will give them 3 exercises from the National Institute on Aging's Go4Life Workout-to-Go book,1 exercise from each of 3 categories:strength/endurance, balance, and flexibility. They will be asked to do the 3 exercises every day.The meal delivery drivers will ask daily questions about physical activity and any potential injuries and the participants will be asked to track their own weekly exercise and physical activity as well as their monthly progress on a standardized log. All participants will also be asked to wear a fitness activity tracker which will monitor heart rate, activity level, and sleep habits for the duration of the study.
45925804|NCT00072085|Biological|aldesleukin|
45925805|NCT00072085|Biological|gp100 antigen|
45925806|NCT00072085|Biological|incomplete Freund's adjuvant|
45925807|NCT04730674|Drug|tetracycline mixed with xylocaine|10 cc of saline containing 2 gm of tetracycline mixed with 5 ml of 2% xylocaine (as a pain relieving agent) was injected at the seroma bed.
45925808|NCT03959436|Drug|Carbetocin|Carbetocin as the primary uterotonic for all cesarean sections
45925809|NCT00072124|Drug|cisplatin|
45925810|NCT00072124|Drug|dacarbazine|
45925811|NCT00072124|Procedure|conventional surgery|
45925812|NCT00072163|Drug|temozolomide|Given orally
45925813|NCT00072163|Drug|thalidomide|Given orally
45925814|NCT00072319|Biological|filgrastim|
45925815|NCT00072319|Drug|cyclophosphamide|
45925816|NCT00072319|Drug|epirubicin hydrochloride|
45925817|NCT00072319|Drug|paclitaxel|
45925818|NCT00072319|Procedure|adjuvant therapy|
45925819|NCT00072319|Procedure|neoadjuvant therapy|
45925820|NCT03959397|Drug|nab-paclitaxel|nab-paclitaxel monotherapy or combination therapeutic regimen
45925821|NCT00072436|Drug|gemcitabine hydrochloride|Given IV
45925822|NCT00072436|Drug|alvocidib|Given IV
45925823|NCT00072436|Other|pharmacological study|Correlative studies
45925824|NCT02966158|Other|AIT Group|"The AIT Group will begin with a one-month, run-in period where patients will perform current standard of care CR programming, which will involve traditional MICE. MICE at the Cardiac Rumsey Centre will consist of either track walking/jogging or treadmill walking/jogging for approximately 30-40 minutes, performed at an intensity of 60-80% of VO2peak, in addition to a warm-up and cool down period. In the second month of the study intervention, patients will begin to perform AIT three days per week, which involves performing 4-minute intervals at greater than 90% of peak heart rate, separated by 3-minutes of active recovery, with one of those AIT exercise sessions occurring at the Rumsey Centre under supervision, and 2 sessions per week of MICE, which will again consist of the 30-40 minutes of walking/jogging at an intensity of 60-80% of VO2peak, with an allotted warm up and cool down period."
45925825|NCT02966470|Device|Obtain grip strength from a standardized gripometer|Obtain grip strength from a standardized gripometer, 3 times on each hand
45925826|NCT00072553|Drug|celecoxib|
45925827|NCT00072553|Drug|fluorouracil|
45925828|NCT00072553|Drug|leucovorin calcium|
45925829|NCT00072553|Drug|oxaliplatin|
45925830|NCT00072553|Procedure|adjuvant therapy|
45925831|NCT00072553|Procedure|conventional surgery|
45925832|NCT00072553|Procedure|neoadjuvant therapy|
45925833|NCT04733586|Procedure|Sonar guided fascia iliaca|Sonar guided fascia iliaca
45925834|NCT04733586|Procedure|Sonar guided quadratus lumborum block|Sonar guided quadratus lumborum block
45925835|NCT00072592|Drug|Rituximab|
45925836|NCT00072631|Drug|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Intrapatient dose escalation of oral single agent daily erlotinib until intolerable rash
45925837|NCT00072670|Drug|Trabectedin|Trabectedin will be administered intravenously as either 0.58 milligram per square meter (mg/m^2) weekly as 3-hour infusion or 1.5 mg/m^2 or 1.2 mg/m^2 every three weeks as 24-hour infusion until disease progression or unacceptable toxicity.
45925838|NCT03959358|Drug|Lenalidomide|Lenalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
45925839|NCT03959358|Drug|Pomalidomide|Pomalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
45925840|NCT02966704|Dietary Supplement|intrinsically labeled milk protein|
45925841|NCT00072709|Drug|TCH346|
45925842|NCT04839848|Device|Lichtenstein mesh repair|A groin hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures
45925843|NCT00399178|Drug|Transdermal delivery system|
45925844|NCT00072748|Drug|EKB-569|
45925845|NCT03959280|Other|Tailored intervention|"The exercise program consists of 2 x 1.5-hour supervised nordic walking sessions weekly during 12 weeks and 1-hour unsupervised moderate physical activity per week from week 4.~The diet intervention includes one face-to-face consultation with a dietician and one telephone-based contact monthly, i.e. 6 diet interventions for 12 weeks.~Behavioural changes techniques will be included in diet and exercise interventions."
45925846|NCT03959280|Other|Control|This intervention will include tailored instruction on CPAP use and standard advices on physical activity and nutrition at CPAP initiation.
45925847|NCT00072787|Drug|S-1|
45925848|NCT00072787|Drug|cisplatin|
45925849|NCT00072826|Drug|Oxypurinol|
45925850|NCT00072826|Drug|L-NMMA|
45925851|NCT00072826|Drug|Acetylcholine|
45925852|NCT00072865|Drug|Pemetrexed|
45925853|NCT00072865|Drug|Carboplatin|
45925854|NCT00072904|Drug|Insulin Asparte|Insulin asparte given 0.5 units per carb per meal
45925855|NCT00072904|Drug|Repaglinide|0.5mg tab with meals tid
45798208|NCT04087343|Behavioral|Meals only|Patients will receive 12 weeks of an enhanced meals on wheels (MOW) in-person meal delivery consisting of 3 meals per day (1 shelf-stable, 1 hot, and 1 frozen) during the weekdays (Monday through Friday) with 6 frozen meals at the end of the week to cover the weekends.The meal delivery drivers will ask daily questions about physical activity and any potential injuries and the participants will be asked to track their own weekly exercise and physical activity as well as their monthly progress on a standardized log. All participants will also be asked to wear a fitness activity tracker which will monitor heart rate, activity level, and sleep habits for the duration of the study.
45798209|NCT05700266|Drug|Rivaroxaban|Rivaroxaban (2.5mg orally twice a day for 90 days)
45798210|NCT05700266|Drug|Clopidogrel|Clopidogrel (300mg loading dose, then 75mg once daily for 90 days)
45925856|NCT00072943|Drug|anti-Interferon-gamma monoclonal antibody|
45649874|NCT04606459|Other|Optimal medical therapy|Guideline-directed medical therapy
45649875|NCT05137483|Other|Functional tests|We will apply upper extremity performance tests, hand grip measurements, and scales measuring fatigue and quality of life to the groups.
45649876|NCT04872647|Behavioral|Phone-Based Health Coaching Utilizing Lifestyle Action Plans|Culturally sensitive health coaches trained in motivational interviewing provide 10-20 minutes of weekly phone-based health coaching. They not only guide the patient in creating a SMART goal, but assess and build off of the previous weeks' goal and problem-solve with the patient. During the week, the coach and patient text regarding daily blood glucose monitoring with real-time feedback and coaching about the implementation of the patients' goal.
45798211|NCT05700266|Drug|Aspirin|Aspirin (100mg once a day for 1 year)
45653183|NCT05111925|Other|PREPARE Optimized Clinical Assessment|"Participants will complete an optimized set of clinical assessments that may include semi-automated field-expedient functional movement quality, joint ranges of motion, and/or psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~Two-Minute Walk~Gait~Double Leg Squat~Single Leg Squat~Jump-Landing~Single Leg Triple Hop~Closed Kinetic Chain Upper Extremity Stability Test~Functional Movement Screening Shoulder Clearing Test~Prone Plank~Active Hip Abduction~Joint range of motion assessments:~Knee Extension~Hip Abduction~Hip Internal Rotation~Hip External Rotation~Ankle Dorsiflexion~Psychosocial assessments:~NIH PROMIS Physical Function, Pain Interference, Depression, & Anxiety~Tampa Scale of Kinesiophobia"
45798212|NCT05700266|Other|Risk Factor Management in both arms|Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed
45798213|NCT03683225|Combination Product|CTC-413|pramipexole ER, given with aprepitant
45798214|NCT02249689|Other|Definitive 65|
45798215|NCT02249689|Other|Definitive 74|
45798216|NCT05423132|Drug|Ropivacaine injection|The patients will receive 15 ml of Ropivacaine 0.375 % on each side.
45798217|NCT05423132|Drug|Physiological serum injection|The patients will receive 15 ml of physiological serum (NaCl 0.9 %) on each side.
45798218|NCT03681977|Device|Zimmer MP Persona|The medial pivot Persona® knee implant with a Medial Congruent™ Bearing
46072021|NCT05737121|Drug|Placebo|Inactive placebo for VNX001
46072022|NCT05737121|Drug|Lidocaine|Alkalinized lidocaine hydrochloride
46072023|NCT05737121|Drug|Heparin|Alkalinized heparin sodium
45798219|NCT03681977|Device|Zimmer Persona Knee-PS|Persona the personalized knee system
45798220|NCT05739500|Other||no intervention, just observation
45798221|NCT02975219|Drug|Bevacizumab-800CW|4.5mg Bevacizumab-800CW will be administered intravenously three days prior to surgery
45925857|NCT02966197|Procedure|prophylactic internal iliac artery balloon catheterization|Between June 2015 and August 2016
45925858|NCT02966197|Device|Prophylactic internal iliac artery balloon|
45925859|NCT02966197|Radiation|Radiology operation|
45925860|NCT04834349|Other|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT
45925861|NCT04834349|Procedure|Intensity-Modulated Proton Therapy|Undergo IMPT
45925862|NCT04834349|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45925863|NCT04834349|Biological|Pembrolizumab|Given IV
46072024|NCT05731947|Drug|SNDX-5613|Administered either as oral tablets or oral capsule with or without food. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
45798222|NCT05688956|Dietary Supplement|Fortimel Advanced, Nutricia|Per 200 mL serving size: 300 kcal, 21 g whey protein, 3 g leucine & 10 µg Vitamin D.
45798223|NCT05688956|Other|Resistance Exercise programme|Participants will participate in the resistance-based exercise programme twice a week for 12-weeks via Zoom. Each session will last between 45-60 minutes with 2-3 sets and 8-12 reps, twice a week for the 12 weeks.
45798224|NCT05688956|Other|Dietary advice|Standard dietary advice to increase intake of protein, leucine and vitamin D using available literature designed for those at risk of malnutrition will be provided to both groups by the research nutritionist. Literature provided will include booklets containing lists of foods high in protein, leucine and vitamin D plus easy-to-prepare meal ideas. The dietary advice provided will be informed by the 24-hour dietary recall information obtained from each participant.
45798225|NCT01686451|Drug|XueZhiKang|Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
45925864|NCT04834349|Other|Quality-of-Life Assessment|Ancillary studies
45925865|NCT04834349|Other|Questionnaire Administration|Ancillary studies
45925866|NCT04834349|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45925867|NCT00072982|Drug|fish oil|The object of this intervention is to determine whether treatment of rheumatoid arthritis with a combination of fish oil and borage seed oil is superior to treatment with either oil alone. Each arm of the study will take 13 capsules daily (divided doses) for 18 months.
46072025|NCT05731947|Drug|Chemotherapy|Either Lonsurf® or Stivarga® administered per the investigator's choice at the respective drug label's dose and schedule. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
45798226|NCT01686451|Drug|simvastatin|Participants will receive 20mg of simvastatin daily for 4 weeks.
45925868|NCT00072982|Drug|borage seed oil|Borage oil 13 capsules divided doses daily for 18 months
45925869|NCT00072982|Drug|combination fish oil and borage seed oil|Fish oil and borage seed oil capsules - 13 capsules to be be taken daily (divided doses) for a period of 18 months
45798227|NCT04086953|Diagnostic Test|6-minute walk test|This test is carried out in a 30-meter long walking corridor with two cones placed at the ends of the course and representing the turning zones
45925870|NCT03959124|Device|Deep brain stimulation|Brain stimulation electrodes at parameters 2.0~4.5 V；60 μs；20 Hz
45925871|NCT03959124|Drug|Best medical treatment for Alzheimer's disease|Alzheimer's disease patients take medications including Exelon (Rivastigmine Tartrate), Witgen (Memantine) for at least 3 months without plan of dosage adjustment
45925872|NCT02966236|Drug|Tranexamic Acid|
45925873|NCT02966236|Drug|Placebos|
45925874|NCT00073138|Drug|ABT-751|
45925875|NCT00073177|Drug|Roflumilast|
45798228|NCT04086953|Diagnostic Test|Walk-Time Limit Tes|Endurance test where the patient must walk at the same speed during the whole test (time limit). The test is carried out in a corridor 10 meter long.
45925876|NCT03959046|Behavioral|GIST|The GIST intervention will train physicians in an alternative way of communicating with their patients.
45925877|NCT00073216|Biological|Clade B gag DNA/PLG and env DNA/PLG Microparticles|
45649877|NCT04591249|Behavioral|Physical activity intervention|Participants will 1) receive Fitbit, 2) be enrolled in a secure electronic platform to access Fitbit data, 3) receive 8-week remote counseling by a physical therapist that will include motivational interviewing and creating SMART goals (1 session per week) through a web-based teleconference platform, and 4) receive usual postoperative care directed by their surgeon. The first session will be 45 minutes and sessions 2-8 will be 30 minutes each. During the sessions, participant's confidence in meeting daily step goals will be assessed using a 0-10 scale. If self-reported confidence to meet their goal is <8, the physical therapist will help participants modify their goal using techniques such as problem-solving, positive statements and affirmations. Progression will be made only if daily steps goals are met for at least 4 out of 7 days a week. If this weekly step goal is not met, a physical therapist will help the participant identify solutions for realistic progression.
45649878|NCT04591249|Other|Usual care|Participants will receive postoperative care as determined by their treating surgeon. This includes lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
45798229|NCT04086953|Diagnostic Test|Incremental shuttle walk test|Incremental walking test suitable for patients with chronic respiratory diseases. To perform this test, it is necessary to have a 10-meter walking corridor. The walking speed is dictated by a sound signal previously recorded. Every minute, the time between each beep is decreased and therefore the walking speed increased. The increment is 0.17m / sec every minute. Shifting to a higher speed is indicated by a triple beep. At most, the ISWT includes 12 speed levels.
45798230|NCT04086953|Diagnostic Test|Endurance shuttle walk test|"Constant load endurance running test performed on the same 10 meter run as the ISWT.~The patient is walking at a constant speed imposed by the audio beeps as for the ISWT. The objective of this test is to maintain the imposed walking speed as long as possible. The speed is calculated from the ISWT."
45798231|NCT04086953|Diagnostic Test|Respiratory Functional Assessment|Forced vital capacity, total lung capacity, forced expiratory volume measured during the first second of forced expiration, and carbon monoxide diffusion capacity will be measured by plethysmographic examination and spirometry.
46072026|NCT05727904|Biological|Lifileucel plus Pembrolizumab|A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive Pembrolizumab followed by the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2. Patients will then continue to receive Pembrolizumab every 6 weeks until disease progression.
45798232|NCT05413616|Behavioral|FITFOOD lifestyle intervention|Lifestyle intervention with a nutritional and exercise component.
45798233|NCT04901403|Other|Education|Parents will be provided with information about Earned Income Tax Credits and budgeting
45925878|NCT00073216|Biological|Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant|
45925879|NCT04827953|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
45925880|NCT04827953|Drug|Nab paclitaxel|Nab-Paclitaxel 125 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
45925881|NCT04827953|Drug|NLM-001|NLM-001 administration during first 3 cycles.
45925882|NCT04827953|Drug|Zalifrelimab|Zalifrelimab administration each 6 weeks.
45925883|NCT04711291|Combination Product|Conversion to Envarsus-XR and use of smart phone app, TransMedAx|"Convert to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours used in combination with the smart phone application, TransMedAx.~Patients in this arm will be trained to use the app along with conversion to Envarsus-XR. Once patient scan the code on medicine bottle and the app will remind them about the time and dose of the medication in their native language."
45925884|NCT04711291|Drug|Convert to Envarsus XR once daily|Convert from tacrolimus immediate release to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours
45925885|NCT00073255|Drug|hokt3g1 (ALA-ALA)|
45925886|NCT00073294|Behavioral|diet|
45925887|NCT00073372|Drug|Abciximab|
45925888|NCT04821830|Drug|carbidopa/levodopa, as prescribed by treating physician|"There will be 4 measurement states:~at baseline prior to chronic treatment initiation (OFF-No LDR); at baseline after a standard, acute oral dose (25/250 carbidopa/L-dopa), referenced in the protocol, but prescribed and provided by their prescribing physician as standard of care initial dosage (ON-No LDR); 2 months after initiation of chronic, stable L-dopa treatment (amounts and sequences as prescribed by treating physicians) but with no L-dopa for 10-12 hours prior to evaluation (Practical OFF- LDR); and after resuming subjects' usual physician-prescribed L-dopa dose (ON-LDR)."
45925889|NCT00073411|Drug|duloxetine|
45925890|NCT00073411|Drug|escitalopram|
45925891|NCT00073411|Drug|placebo|
45649879|NCT03044873|Drug|BMS-986165|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
45649880|NCT03044873|Drug|Rosuvastatin|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
45649881|NCT03044951|Procedure|cryoballoon ablation|cryoballoon ablation：pulmonary vein isolation by cryoballoon
45925892|NCT00073450|Drug|Farnesyl Protein Transferase Inhibitor|
45925893|NCT00073489|Drug|OSI-461|
45798234|NCT04901403|Other|Home visiting|Parents as Teachers home visiting program
45925894|NCT04820855|Behavioral|Treatment|This is the treatment program devised win conjunction with a pelvic floor physical therapist. It is a daily yoga series and mindfulness with a Smartphone app.
45925895|NCT04820855|Other|Usual Cares|This is standard treatment for Interstitial cystitis with your provider.
45925896|NCT00073645|Behavioral|Peer/Group CBT|Children will be trained to be more helpful and positive toward other children through role-playing activities.
45649882|NCT03044951|Procedure|radiofrequency ablation|radiofrequency ablation: pulmonary vein isolation by radiofrequency energy
45798235|NCT00361751|Drug|fenofibrate|
45925897|NCT00073645|Behavioral|Family/Parents CBT|Parents will be trained to manage their children's anxiety and avoidant behaviors by increasing acceptance and warmth toward their children.
45925898|NCT00073684|Behavioral|Trauma focused cognitive behavioral therapy (TF-CBT)|This study aims to: (1) examine the differential effects of CBT with and without trauma narrative interventions; (2) examine the comparative efficacy of brief and extended (8 vs. 16 sessions) individual CBT; (3) make developmental comparisons between 4-7 year olds and 8-11 year olds as to the appropriateness and therapeutic necessity of exposure interventions and longer treatment; and (4) identify child and parent factors that may significantly mediate the relationships between treatment conditions and outcomes. The findings of this study will help establish clinical as well as developmental markers for the early identification of sexually abused children who may require more focused (i.e., including trauma narrative) and/or longer treatment to achieve optimal outcomes.
45925899|NCT00073684|Behavioral|Brief abuse-focused treatment|Participants will receive 8 sessions of TF-CBT with abuse-focused treatment.
45925900|NCT00073684|Behavioral|Brief coping skills treatment|Participants will receive 8 sessions of TF-CBT with brief coping skills treatment.
45925901|NCT00073684|Behavioral|Extended abuse-focused treatment|Participants will receive 16 sessions of TF-CBT with extended abuse-focused treatment.
45925902|NCT00073684|Behavioral|Extended coping skills treatment|Participants will receive 16 sessions of TF-CBT with extended coping skills treatment.
45649883|NCT05137405|Procedure|Sleeve gastrectomy|An online survey format was administered to all obese patients on the waiting list for bariatric surgery in our Department of Medical and Surgical Sciences to obtain information about the COVID- 19 pandemic's impact on patients with obesity starting March 09, 2020 until May 18, 2020.
46072027|NCT05727904|Biological|Pembrolizumab with Optional Crossover Period|"Patient will receive Pembrolizumab monotherapy every 6 weeks until disease progression. Upon verified confirmed disease progression by the blinded independent review central committee, patients may proceed to lifileucel monotherapy during an optional crossover period if they meet eligibility criteria.~Optional crossover: A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2."
45798236|NCT05682638|Biological|LVRNA009|100μg/1.0ml/dose(50 μg/0.5ml/Vial), 2 injection with 28 days apart
45798237|NCT05682638|Other|0.9%NaCl|1.0ml/dose, 2 injection with 28 days apart
45798238|NCT04899297|Other|Questionnaire|All parents of patients visited at an outpatient service dedicated to the treatment of vertebral deformities will be recruited at the end of the medical clinical evaluation. The doctor will invite all subjects to complete the questionnaire anonymously at the end of each follow-up visit.
46072028|NCT05725044|Dietary Supplement|Ginsengberry concentrate|Ginsengberry concentrate
46072029|NCT05725044|Dietary Supplement|Placebo|Placebo
46072030|NCT05724186|Device|Test myopia control lenses (CSL)|A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
46072031|NCT05721235|Drug|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
45649884|NCT03044795|Drug|Veliparib|Subjects in part A and part B will all start treatment with oral veliparib monotherapy twice a day. Patients will receive oral veliparib BID on days 1- 21, q3 weeks. All subjects will start with veliparib 300 mg, if the subject tolerates 300 mg BID for 2 weeks, veliparib may be increased to 400 mg BID at the investigator's discretion. Subjects will self-administer the morning dose and the evening dose of veliparib approximately 12 hours after the morning dose with or without food. ANC must be above 1.5 × 109/L in order to commence a new cycle.
45649885|NCT04587583|Behavioral|WeCareAdvisor|Tailored, internet-based software intended to assess, manage and track behavioral symptoms and their contributing factors and to instruct dementia caregivers in problem solving approaches (tailored strategies for in-home, medication-free behavior management) to address difficult or disruptive behaviors exhibited by the person with dementia. During the testing period participants will refer to the WeCareAdvisor when behavioral challenges occur.
45798239|NCT05681702|Drug|aspirin plus clopidogrel|After at least 30 days of DAPT [with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will continue aspirin and switch to clopidogrel 75-mg.
45925903|NCT02966041|Drug|Ondansetron|Ondansetron/Zofran is an antiemetic drug used to prevent and treat nausea and vomiting.
45925904|NCT02966041|Drug|Saline|Normal saline is salt water and is acting as a placebo in this study. A placebo is an inactive substance that looks identical to the test drug, but it contains no therapeutic ingredient.
45925905|NCT00073723|Drug|ABI-007|
45925906|NCT00073762|Drug|DVS-233 SR|
45925907|NCT00073840|Drug|levalbuterol|"Levalbuterol 90 ųg QID (manufacturing sites A or B);~Racemic Albuterol 180 ųg QID;~Placebo QID"
46072032|NCT05718921|Drug|YR001 Dose A on low body surface area|Part A: Single topical dose
46072033|NCT05718921|Drug|YR001 Dose A on middle body surface area|Part A: Single topical dose
45798240|NCT05681702|Drug|prasugrel or ticagrelor|After at least 30 days of DAPT [with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will drop aspirin and continue prasugrel or ticagrelor.
45798241|NCT04675983|Drug|Sintilimab|Administered IV
45925908|NCT03958851|Diagnostic Test|Doppler ultrasonography of renal arteries|"Ultrasound evaluation will be performed for all patients as well as healthy individuals.in patients with lupus nephritis,the ultrasound evaluation will be performed the 24 h prior to the renal biopsy . In the maximum long-axis section images, the largest diameter and width of each kidney will be measured. The participants will be scanned in a supine or decubitus position to achieve an ultrasound beam as close to parallel to the blood flow direction in the intrarenal artery as possible. RRI is measured as :~RRI = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity. the average of three measurements will be taken."
45925909|NCT03958851|Diagnostic Test|Renal biopsy|Renal biopsy is a medical procedure in which a small piece of kidney is removed from the body for examination, usually under a microscope. Microscopic examination of the tissue can provide information needed to diagnose, monitor or treat problems of the kidney.Renal biopsy will be taken according American college of Romatology guidelines 2012.The renal biopsy samples were evaluated according to the Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis 2017. the actvity index and chronicity index will be calculated.
45925910|NCT03958851|Diagnostic Test|kidney function tests|blood sample will be taken to measure blood urea nitrogen (BUN) and serum creatinine(S Cr). estimated glomerular filtration rate (eGFR) will be measured using CKD-EPI Equation.These investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .
45925911|NCT03958851|Diagnostic Test|The 24-hour urine protein test|The 24-hour urine protein test checks how much protein is being spilled into the urine.Urine samples are collected in one or more containers over a period of 24 hours. The containers are kept in a cool environment and then sent to a lab for analysis. Specialists then check the urine for protein.This investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .
46072034|NCT05718921|Drug|YR001 Dose A on high body surface area|Part A: Single topical dose
46072035|NCT05718921|Drug|YR001 Dose B on low body surface area|Part A: Single topical dose
46072036|NCT05718921|Drug|YR001 Dose B on middle body surface area|Part A: Single topical dose
45649886|NCT04341155|Drug|Dexamethasone|Patients in experimental arms will receive i.v. dexamethasone 20 mg (4 ampules = 20mL) for 7 days
45649887|NCT04341155|Drug|Placebo|Patients in placebo arms will receive 20 mL normal saline intravenously for 7 days
45649888|NCT04581811|Other|Prolonged Proned Positioning|Patients will be placed in the prone position for 24 hours followed by 8 hours supine for consecutive periods for the duration of the study period
45649889|NCT04581811|Other|Traditional Proning Arm|Patients will be placed in the prone position for 16 hours followed by 8 hours supine for consecutive periods for the duration of the study period
45649890|NCT03047603|Diagnostic Test|PIVKA-II|Serum samples are tested for tumor markers including PIVKA-II,AFP,AFP-L3% and biochemical tests.
45649891|NCT04430153|Other|"Class 1 Medical Device CE certified devices: ActiGraph wGT3X-BT accelerometer"|Accelerometers on both patients' wrists will give insight into the daily life upper limb use.
45649892|NCT03047291|Drug|Probiotic|30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
45798242|NCT04675983|Drug|Ramucirumab|Administered IV
45798243|NCT04675983|Drug|Cisplatin|Administered IV
45798244|NCT04675983|Drug|5-fluorouracil|Administered IV
45798245|NCT04675983|Drug|Oxaliplatin|Administered IV
45798246|NCT04675983|Drug|Capecitabine|Administered orally
45798247|NCT03668951|Drug|Dexmedetomidine buccal|DEX 2 mcg/kg buccal
45450602|NCT02188030|Other|Individual Exercise Program|"The participants allocated into the IET Group will receive a individual and specific strength training with seven different exercises, based in training programme describe by Andersen et al.3 and Sundstrup et al4.~During the intervention period, the training intensity were progressively increased according to the principle of periodization and progressive overload5. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises. Experienced instructors supervised every other training session."
45649893|NCT03047291|Device|Placebo Oral Tablet|30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
45653184|NCT04838405|Drug|CT-388|Synthetic Peptide
45653185|NCT04838405|Drug|Placebo|Placebo
45798248|NCT03668951|Drug|Dexmedetomidine Intranasal|DEX 3 mcg/kg intranasal
45798249|NCT03668951|Drug|Dexmedetomidine Intranasal|DEX 4 mcg/kg intranasal
45798250|NCT05739344|Behavioral|Cognitive behavioral approach based resilience development program for schizophrenic individuals|The intervention will be administered as sessions of 2 hours once a week.
45798251|NCT04890327|Other|Web-based family health history tool|Web-based tool that collects subject's family health history through a series of questions and generates a pedigree which documents a risk assessment report for the physician to use. The risk assessment report uses standard, validated risk scores including GAIL , CLAUS, BRCAPRO which measure breast cancer risk, and MMRPRO which measures endometrial cancer risk, MELAPRO which measures melanoma cancer risk, and PANCPRO which measures pancreatic cancer risk
46072037|NCT05718921|Drug|YR001 Dose B on high body surface area|Part A: Single topical dose
46072038|NCT05718921|Drug|Placebo on low body surface area|Part A: Single topical dose
46072039|NCT05718921|Drug|Placebo on middle body surface area|Part A: Single topical dose
45798252|NCT05400356|Procedure|On-pump valve surgery or CABG|On-pump valve surgery or coronary arterial bypass grafting
45798253|NCT04889703|Drug|15% Trichloroacetic acid peel|Trichloroacetic acid peel (15%) will be applied topically to the face for 2 treatments at 4 week intervals.
46072040|NCT05718921|Drug|Placebo on high body surface area|Part A: Single topical dose
46072041|NCT05718921|Drug|YR001 Dose A on high body surface area twice daily|Part B: Multiple topical dose
45798254|NCT04889703|Drug|30% Salicylic acid peel|Salicylic acid peel (30%) will be applied topically to the face for 2 treatments at 4 week intervals.
45798255|NCT05739266|Behavioral|3 minutes step test|3 minutes step test- Stair hight:20 cm, Pace: 96 steps per minute
45798256|NCT00421811|Drug|ADH-1|4 gm IV Days 1 and 8
45649894|NCT04487899|Device|Analysis of heart rate variability|The HR HRV interval of the heartbeat (variations in the time interval between beats) was used as a measure of autonomous modulation, and the Firstbeat Bodyguard monitor (Firstbeat Technologies, Jyväskylä, Finland) was used to record HRV data during the session with emergency situations in the flight simulator. Data was downloaded from the devices to a computer using Firstbeat Uploader software (Firstbeat Technologies), and all R-R interval series were imported into the Kubios software package (University of Eastern Finland, Kuopio, Finland). To calculate the autonomous equilibrium, the commonly used HRV method based on the Poincaré graph was used (Brennan et al., 2001; Mourot et al., 2004).
45798257|NCT00421811|Drug|melphalan|By Isolated Limb Infusion (ILI), Lower Extremity: 7.5 mg/L (Limb Volume), Day 1 or Upper Extremity: 10 mg/L (Limb Volume), Day 1
45798258|NCT04884477|Biological|Convalescent Plasma|Convalescent Plasma
45798259|NCT05679362|Behavioral|online brief CBT intervention|Cognitive behavioral therapy
45798260|NCT05676476|Drug|Antihypertensive treatment|Antihypertensive treatment to goal of less than 140/90 mmHg
45798261|NCT03374657|Biological|CPK850|In one of 5 dose levels administered via subretinal injection under anesthesia
45649895|NCT04865705|Drug|tislelizumab|Tilelizumab 200mg d1 Q3W Albumin Paclitaxel 260mg/m2 d1 Carboplatin/Cisplatin 75mg/m2/AUC5 d1 every 3 weeks
45798262|NCT04670523|Procedure|Early postoperative day 0 (POD 0) chest tube removal.|Chest tube removal is a standard bedside intervention after lung resections. Its time point is normally defined according a traditional standard airleak threshold. Traditionally, in our department this threshold will be respected not earlier than 1 day after the operation. The patients of the study group are getting their chest tube removed according to our current airleak protocol (Flow <20 mL/ min on digital suction device) but already in the operating room after wound closure (POD 0). If airleak is persisting than chest tube removal will be performed according to the traditional protocol not earlier than on postoperative day 1 (POD 1).
45649896|NCT04375111|Procedure|Serratus anterior plane block|•Serratus anterior plane block will be carried out with the patient lying in the lateral position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 5th and 6th ribs in the mid axillary region, for identification of the superficial latissimus dorsi muscles and deep anterior serratus muscles. Then, 25 ml of isobaric bupivacaine 0.25% will be injected above the serratus anterior muscle.
45798263|NCT04670523|Procedure|Chest tube removal according to traditional standard protocol not earlier than on postoperative day 1 (POD 1).|Chest tube removal according to traditional standard protocol not earlier than on postoperative day 1 (POD 1).
45798264|NCT03363893|Drug|CT7001|Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
45798265|NCT03363893|Drug|CT7001 in combination with fulvestrant|Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression in combination with fulvestrant given as 2 x 250mg intramuscular (IM) gluteal injections on Day 1, Day 15, Day 28 and every 28 days thereafter
46072042|NCT05718921|Drug|YR001 Dose B on high body surface area twice daily|Part B: Multiple topical dose
46072043|NCT05718921|Drug|Placebo on high body surface area twice daily|Part B: Multiple topical dose
46072044|NCT05715606|Drug|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion
46072045|NCT05703269|Radiation|single fraction stereotactic radiosurgery (SSRS)|SSRS is an advanced radiation technique that delivers high dose precision radiation in a single dose to discrete intracranial lesions.
46072046|NCT05703269|Radiation|fractionated stereotactic radiosurgery (FSRS)|FSRS is an advanced radiation technique that uses a lower dose precision radiation delivered over 3 to 5 treatments given daily or every other day to intracranial lesions.
46072047|NCT05703256|Behavioral|Amygdala real-time fMRI neurofeedback|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
45925912|NCT03958851|Diagnostic Test|complete blood counting (CBC)|A complete blood count is a blood panel that gives information about the cells in a patient's blood, such as the cell count for each blood cell type and the concentrations of hemoglobin.
45925913|NCT00073879|Biological|alemtuzumab|
45925914|NCT00073879|Biological|graft-versus-tumor induction therapy|
45925915|NCT00073879|Drug|cyclophosphamide|
45925916|NCT00073879|Drug|fludarabine phosphate|
45925917|NCT00073879|Procedure|allogeneic bone marrow transplantation|
45925918|NCT00073879|Procedure|peripheral blood stem cell transplantation|
45450603|NCT04870216|Other|Questionnaire regarding intimate protections habit.|Questionnaire regarding intimate protections habit.
45925919|NCT00074074|Biological|infliximab|
45925920|NCT00392652|Drug|oral microencapsulated diindolylmethane|Given PO
45925921|NCT00074191|Drug|cytarabine|
45925922|NCT00074191|Drug|dexamethasone|
45925923|NCT00074191|Drug|lomustine|
45925924|NCT00074191|Drug|methotrexate|
45925925|NCT00074191|Drug|procarbazine hydrochloride|
45925926|NCT00074230|Biological|Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin|Within cohort 1 patients received the vaccine intradermally; in cohort 2 the route of Administration was intravenous Infusion, half of the patients had additional loading with RNA coding for EL-Selektin; in cohort 3 the vaccines was again infused intravenously, the cells were matured not with MCM.mimic as in cohort 1 and 2 but either with TriMix or MCM-mimic plus CD40L-RNA.
45925927|NCT02965885|Drug|TAS-116|TAS-116 is an oral heat shock protein 90 (HSP90) inhibitor investigated in 3 dosing regimens (QD, QOD, 5 days on 2 days off) in patients with advanced solid tumor and then at one dose schedule in advanced breast and lung cancer.
45450604|NCT02192476|Other|conventional neuro rehabilitation programme|All the conventional group subjects were received standardized conventional neuro rehabilitation programme. The conventional neuro rehabilitation treatment includes, active, and passive range of motion exercise, bilateral activation of pectoralis major, activation of latissimus dorsa, activation of the retractors, weight bearing exercise of upper extremity, activation of supraspinatus, reaching activities, grasping, holding and release, and activity of daily living (ADL) activities. Every participant was received conventional neuro rehabilitation for 45 minutes and 5 days a week.
45649897|NCT04375111|Procedure|Transversus thoracic plane block|•Transversus thoracic plane block will be carried out with the patient lying in the supine position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, 15 ml of isobaric bupivacaine 0.25% will be injected between the transversus thoracic muscle and the internal intercosatal muscle.
45649898|NCT03044717|Other|Nutrition survey|Survey will be done prior to the initiation of the education
45649899|NCT03044717|Other|Educational Conference|A prevention educational conference will be available to attend once every 5 weeks.
45798266|NCT05663840|Behavioral|Progressive resistance exercise|Patients with predominant symptoms of cervical dystonia will receive exercise training. Patients will receive progressive resistance exercise focused cervical and shoulder training (PERFECT) plus standard-of-care (SOC) therapy. Resistance training will consist of mainly muscle-strengthening exercises for the neck, shoulder and arms and a few upper trunk muscles. Resistance training will be guided by physical therapists at twice a week schedule for 6 months. These participants will also receive SOC therapy.
45798267|NCT05663840|Behavioral|Standard of care|Subjects will receive SOC therapy only
45798268|NCT02974829|Other|follow-up|
45798269|NCT03029468|Behavioral|cognitive behavioral therapy|CBT teaches users how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation.
45798270|NCT03029468|Behavioral|eEducation|Pain and sickle cell disease education delivered through a mobile electronic device
45925928|NCT00392691|Drug|ibritumomab tiuxetan|185 MBq (5mCi) of 111In-Zevalin will be used for radioimaging. and the dose is 14.8 MBq/kg (0.4 mCi/kg) total body weight of 90Y-Zevalin (max. 1184 MBq or 32 mCi at patients > 80kg) for imaging.
45925929|NCT00392691|Drug|rituximab|250 mg/m2
45925930|NCT00392691|Drug|melphalan|"Dose level 1: 100 mg/m2~Dose level 2: 140 mg/m2~Dose level 3: 170 mg/m2~Dose level 4: 200 mg/m2"
45925931|NCT00392691|Drug|vinorelbine tartrate / G-CSF|on day 1: 35 mg/m2 day 4-8 (longer if required) G-CSF 5 μg/kg s.c. morning and 5 μg/kg s.c. evening for at least 5 days
45925932|NCT00392691|Procedure|autologous hematopoietic stem cell harvesting and transplantation|"Optimal mobilization usually takes place on day 8. A minimum of 2.5x106 CD34+ cells/kg should be collected (optimal 5x106 CD34+ cells/kg). If not enough CD34+ cells can be collected on day 8, it is recommended to continue with G-CSF until a sufficient collection (a minimum of 2.5x106 CD34+ cells/kg) can be obtained.~Stem cells will be reinfused approximately 24 hours after the melphalan administration. The infusion will be performed with a minimum of 2.5x106 CD34+ cells/kg body weight according to local guidelines. G-CSF (5 μg/kg/d) will be given from day 5 and continued until neutrophils > 0.5x109/l for at least 2 consecutive days."
45925933|NCT02966080|Drug|HEP-IV|
45925934|NCT04767776|Drug|Rivaroxaban|rivaroxaban 40 mg/day (1 day).
45925935|NCT04767776|Drug|Activated charcoal|Activated charcoal 2 hours after rivaroxaban administration (1 day).
45925936|NCT00399217|Device|Subcutaneous Implantable Defibrillator (S-ICD) system|
46072048|NCT05703256|Behavioral|Sham feedback|Participants are shown activity from another participant's left amygdala who previously completed the task and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
46072049|NCT05702983|Drug|STSA-1002 subcutaneous injection|Subjects will receive a single low dose on day 1 following protocol requirements.
46072050|NCT05702983|Drug|STSA-1002 subcutaneous injection|Subjects will receive a single high dose on day 1 following protocol requirements.
45925937|NCT00399217|Device|ICD|
45925938|NCT04730284|Other|Health supplements|tailor-made Synbiotics, 4g per day for 28 days
45925939|NCT03958812|Diagnostic Test|Circulating tumor cells, Volatile organic compounds|Alveolar exhaled breath samples and peripheral venous blood(10ml) will be collected from each patients
45925940|NCT04754321|Radiation|External Beam Radiation Therapy|Undergo EBRT
45925941|NCT04754321|Radiation|Intraoperative Radiation Therapy|Undergo IORT
45925942|NCT04754321|Biological|Pembrolizumab|Given IV
45925943|NCT04754321|Other|Quality-of-Life Assessment|Ancillary studies
45649900|NCT03044717|Other|3-hour nutrition module|Nutrition module will be provided by the Gaples Institute to participants as part of this study. This will be completed online via e-mail
45798271|NCT02974751|Procedure|Aquablation|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-velocity saline stream to resect and remove prostate tissue.
45798272|NCT04872387|Drug|BAY2586116|Nasal administration
45798273|NCT04872387|Drug|Placebo|Matching placebo
45649901|NCT04898179|Other|Telecare Group|"Home-based telehealth program: telenursing and specialist teleconsultation~Telemonitoring with a new pulse oximeter and specific App~E-health platform~Videoconference"
45798274|NCT02411357|Behavioral|Treatment as usual|General information about contraceptive options and referral to contraceptive service providers
45798275|NCT02411357|Behavioral|WHO contraception protocol|World Health Organization's contraception protocol
45798276|NCT02411357|Behavioral|Incentives|Financial incentives contingent on follow-up visit attendance
45925944|NCT04754321|Procedure|Salvage Surgery|Undergo salvage surgery
45925945|NCT00074542|Drug|Epanova™ (Omega-3 Free Fatty Acids)|
45925946|NCT04730245|Drug|sodium phosphate enema, oral rifaximin and polyethylene glycol|Patients were hospitalized for 4-5 hours to receive two saline colon enemas with sodium phosphate Fleet®, 2 to 3 hours apart, appropriate hydration was provided during the procedure. If signs of fecal impaction were observed, the stools were removed manually prior to the first enema. Patients were discharged with oral treatment consistent with rifaximin 200 mg three times a day for 7 days and polyethylene glycol-3350, 17 gr per day in water for 10 days, but it was continued if necessary. Importantly, no modifications in time and dose of dopaminergic therapy or anti-dyskinetic medication (i.e. amantadine) were done at baseline or during the study
45925947|NCT00074620|Drug|PEG-hirudin|
45925948|NCT03958773|Device|Cardiovalve transfemoral Mitral valve system|Cardiovalve System, comprised of: 1) Cardiovalve Implant; 2) Cardiovalve Delivery System (DS); 3) Cardiovalve Accessories.
45450605|NCT02192476|Other|California tri-pull taping (CTPT)|"Two types of tape was used, a self-adhesive 1.5 cotton undercover tape and a 1 rigid strapping tape. Participants placed their affected arm on a supporting surface to better approximate the humeral head back into the glenoid fossa. The three pieces of rigid tape were applied to the patient's shoulder on top of the already applied self-adhesive cotton tape."
45450606|NCT04870138|Drug|Azithromycin|Alternative antibiotic treatment failure therapy: Azithromycin 2 g orally in a single dose after treatment failure with both cephalosporin and quinolone antibiotics.
45649902|NCT04898179|Other|Control group|Usual care
45649903|NCT04867577|Diagnostic Test|CT scan of lung and spine|Dual energy CT scan of thorax and spine
45649904|NCT05137171|Drug|AK105 and anlotinib|AK105(penpulimab): 200mg, every 3 weeks, 21 days as a treatment cycle;Anlotinib: 12mg, 2 weeks on/1 week off, 21 days as a treatment cycle;Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, non-adherence to treatment or trial procedures.
45649905|NCT04384679|Device|Hydrophilic polymer and potassium ferrate powder|Application with pressure until hemostasis is achieved
45653186|NCT05111847|Device|Baseplates with two types of adhesives are tested: 3M 1522 & Nitto ST-2410WD|Baseplates with two different types of adhesives are placed behind the ears; One baseplate with one of the two types of the adhesive behind each ear
45798277|NCT01687387|Drug|IPH2102 at 0.1 mg/kg|every 3 months
45798278|NCT01687387|Drug|IPH2102 at 1 mg/kg|every 4 weeks
45798279|NCT01687387|Drug|Placebo (normal saline solution)|every 4 weeks
45798280|NCT05739110|Behavioral|tumor micronecrosis|whether HCC patients have tumor micronecrosis or not
45798281|NCT05739032|Other|Aerobic exercise and strength training|"Aerobic Exercise Training: The individuals in the study group were given aerobic exercise training at 70-80% of the 6MWT average speed. Patients performed exercise three days per week (twice under the supervision of a physiotherapist and once at home) for 30 minutes a day.~Strength Training: Lower and upper extremity strengthening training was performed three days a week, 3x10-12 repetitions per day, with the help of a resistance band suitable for muscle strength. Hip flexion, hip abduction, knee flexion, and knee extension exercises for the lower extremity, and shoulder flexion, shoulder extension, shoulder abduction, shoulder elevation, external rotation, horizontal shoulder abduction, and scapular adduction exercises for the upper extremity were performed."
45798282|NCT04638699|Other|OptiScreen training|Special psycho-oncological training for nursing staff to acquire basic knowledge about the experience of mental stress as well as diagnostics of psychosocial stress
45925949|NCT02965807|Device|Bronchial Thermoplasty|patients will be under Bronchial Thermoplasty approximately every three weeks.And totally having three surgerys will be considered as completed.
45925950|NCT00074698|Drug|FG-3019|
45925951|NCT02972333|Drug|AZD9291 80mg oral each day|All eligible patients will have access to AZD9291 regimen through the ASTRIS study as long as they continue to show clinical benefit.
45925952|NCT02972333|Radiation|Radiation therapy|Radiation therapy will be implemented according to investigator's clinical practice.Based on the guidelines provided for the interruption of ADZ9291 with brain radiation therapy, a 7-10 days washout period before radiotherapy and 1 week period after completion of brain radiothearpy before re-starting AZD9291.
45925953|NCT00074737|Drug|cenersen|cenersen with standard of care
45925954|NCT00074737|Drug|Idarubicin|standard of care for AML
45653187|NCT05111847|Device|Baseplates with two types of adhesives are tested: Amparo 130002 & 3M 2480|Baseplates with two different types of adhesives are placed behind the ears; One baseplate with one of the two types of the adhesive behind each ear
45925955|NCT00074737|Drug|Cytarabine|standard of care Ara-C and High dose Ara-C
45925956|NCT03958734|Other|High-fat meal|Participants will be given a serving of Marie Callendar's Chocolate Satin Pie to eat over a period of 20 minutes
45925957|NCT00074776|Drug|Lithium|Participants will receive lithium.
45925958|NCT00074776|Drug|Lamotrigine|Participants will receive lamotrigine.
45925959|NCT00074854|Drug|CP-547,632|
46072051|NCT05695599|Device|Whole body vibration training|3 times per week of 20 to 30 minute sessions during 16 weeks of training
45798283|NCT05738954|Other|Ultrasound|"Collect patient data, anonymize and label it. Written informed consent or verbal recorded consent (if the participant lacks the ability to write or sign) will be obtained before performing the MS. In the unlikely event that some of the participants will withdraw their consent after the ultrasound has been performed, the data collected will not be used in the project. Data for publications and dataset will be previously made anonymous following standard practices. The participants will sign a GDPR form.~The DL/SL algorithms will work in a competitive/collaborative way. Following the 'no-free-lunch' theorem, we shall use the competitive phase to establish the most suitable DL/SL technique for the identification and anomaly detection of each organ, and the collaborative phase to make all the algorithms work together in providing a 'second' opinion."
45925960|NCT00074893|Device|piezoelectric wrist brace|
45798284|NCT01706263|Drug|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
45925961|NCT00074932|Biological|Myozyme|20 mg/kg
45798285|NCT01706263|Drug|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
45798286|NCT01706263|Drug|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
45798287|NCT05738876|Procedure|CORONARY ANGIOGRAPHY|coronary angiography by femoral or radial artery access
45925962|NCT04741256|Behavioral|Education booklet & standardized discharge training|Tracheostomy education booklet and tracheostomy teaching performed by nurses during hospitalization as dictated by the booklet.
46072052|NCT05695222|Other|This is not an interventional study|This is not an interventional study
46072053|NCT05695105|Device|Electric Toothbrush-Generated Vibration|Testing electric toothbrush handle-generated vibration to treat ankylosis of teeth
46072054|NCT05695105|Device|Mini-Implant-Assisted Orthodontic Treatment|Testing mini-implant-assisted heavy force application to treat ankylosis of teeth
46072055|NCT05694494|Behavioral|internet-based Lifestyle-integrated Functional Exercise (iLiFE)|receiving internet-based LiFE training and home safety assessment
46072056|NCT05694494|Behavioral|upper limb exercise training|upper limb exercise training
45450607|NCT04870138|Drug|Ceftriaxone|Mandatory antibiotic treatment failure therapy: Ceftriaxone 250 mg intramuscular in a single dose on patient request, at the onset of symptoms, or on the 5th study day after inoculation.
45649906|NCT04866875|Behavioral|dieting|The minimum amount of caloric intake will be pre-set in 1200 kcal for the both groups, in order to avoid micronutrient deficiencies during the intervention. The diet macronutrient composition will be personalized for each participant based on the results of 2-day energy intake at preliminary session, measured with food items selected from a validated food menu. Individuals will be instructed to maintain the level of energy restriction and macronutrient composition during the diet period, however they will be able to do food exchanges, based on the Canadian Diabetes Association system . This method allows individuals to select foods they enjoy during the weight loss, however in smaller quantities.
45649907|NCT04373005|Diagnostic Test|Nasopharyngeal (NP) swab|A dry swab will be inserted through one nostril straight towards the back of the nasal passage and rotated gently before the swab is removed.
45798288|NCT05738798|Dietary Supplement|oral immunotherapy|oral immunotherapy is performed by freely available, widely used food products, regularly part of a normal infant's diet such as peanut butter or boiled egg.
45798289|NCT04858737|Behavioral|e-predictD-Work intervention|The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps worker participants to develop their own personalized plans to prevent (PPP) depression; 3) nine intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the participants. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improve sleep, expand relationships, solve problems, improve communication, assertiveness, decision making, manage thoughts and reduce work stress. Worker participants will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 6 and 12 months.
45925963|NCT00074971|Drug|Fabrazyme (agalsidase beta)|
45925964|NCT00075010|Drug|Decitabine|15 mg/m^2 by vein over 1 hour times 10 days
45925965|NCT00075010|Drug|Valproic acid|20 mg/kg given orally daily for 10 days
45925966|NCT04729595|Drug|Tempol|Tempol 800 mg capsule will be administered at 400mg (2 capsules) two times daily for fourteen (14) consecutive days.
45925967|NCT04729595|Other|Placebo|Placebo capsules will be administered orally (2 capsules) two times daily for fourteen (14) consecutive days.
45925968|NCT01349829|Biological|HAVpur Junior|"≥12 International Units (IU) hepatitis A antigen coupled to virosomes, intramuscularly (i.m.), anterolateral thigh (M. vastus lateralis) or deltoid (M. deltoideus)~Vaccination schedule: single doses at 0 and 6 months"
45925969|NCT01349829|Biological|Havrix 720 Junior|"≥720 ELISA Units (EU) hepatitis A antigen adsorbed to aluminium hydroxide, intramuscularly (i.m.), anterolateral thigh (M. vastus lateralis) or deltoid (M. deltoideus)~Vaccination schedule: single doses at 0 and 6 months"
45798290|NCT04858737|Other|Brief psychoeducational messages|The intervention consists of an App that weekly send short messages about stress and general health that will be extracted from brochures and websites of official agencies.
45925970|NCT00075049|Biological|RTS,S with AS02A/AS01B adjuvant|
45925971|NCT02965495|Drug|YYD302 2ml|YYD302 2ml
45925972|NCT02965495|Drug|YYD302 3ml|YYD302 3ml
45925973|NCT02965495|Drug|Placebo 3ml|phosphate buffered saline 3ml
45925974|NCT00075166|Procedure|Stereotactic surgery (SRS)|
45925975|NCT00075166|Procedure|Craniotomy|
45925976|NCT00075205|Drug|SR141716 (Rimonabant)|
45925977|NCT00075244|Drug|Replagal|
45450608|NCT04870138|Drug|Ciprofloxacin|Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose on patient request, at the onset of symptoms or on the 5th study day after inoculation.
45649908|NCT04858997|Drug|Palbociclib|Palbociclib,125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
45649909|NCT04858997|Drug|AI|AI, orally once daily (continuously)
45925978|NCT04716101|Other|Massage therapy technique|The massage therapy technique consists of manual deep and slow compression and shearing forces applied on the lumbar spine muscles and thoracolumbar fascia in a distal to proximal direction.
45925979|NCT04716101|Other|Sham massage technique|For the sham massage technique the massage therapist will put the right palm at the participant's right lower back along erector spinae and likewise left palm at left lower back without applying force, holding the palm during 2 minutes and half.
45925980|NCT03958617|Device|Bilateral Deep brain stimulation of the thalamus, Medtronic Device|
45649910|NCT05135143|Combination Product|Antioxidant formula|Administration of antioxidant formula 3 times a day and once daily.
45649911|NCT04865549|Procedure|SNB + TAD + Lymphadenectomy|Sentinel Node Biopsy + Targetted Axillary Dissection (Previously to surgery marked cN1 node) + Lymphadenectomy
45649912|NCT04867265|Procedure|Mout-to-mouth ventilation|we will record the visibility of chest rising
45798291|NCT01690117|Behavioral|GE-REACH-program|"The intervention program Resources to Enhance Alzheimer's Caregivers Health -second step (REACH II) is a multimodal, individualized and structured multi-component intervention program for family caregivers"
45649913|NCT04867265|Procedure|Mout-to-mouth ventilation with quantitative analysis|we will record the visibility of chest rising, review the ventilation metrics and evaluate each rescue breath in QCPR Skill Reporter
45649914|NCT04865653|Drug|Lysergic Acid Diethylamide Base oral drinking solution|A moderate dose of 0.1 mg LSD will be administered.
45649915|NCT04865653|Drug|Lysergic Acid Diethylamide Base solid orodispersible film|A moderate dose of 0.1 mg LSD will be administered.
45649916|NCT04865653|Drug|Lysergic Acid Diethylamide Tartrate oral drinking solution|A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).
45798292|NCT04286607|Drug|Topical roflumilast|Active treatment
45798293|NCT02330978|Procedure|Intravitreal transplantation of mesenchymal stem cell|
45798294|NCT02330978|Biological|Culture and isolation of autologous bone-marrow mesenchymal stem cells|
45798295|NCT02330276|Drug|(+)-Epicatechin|The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.
45798296|NCT04632303|Other|Early Palliative Care|Baseline palliative care visit Palliative care visits/calls at least every 4 weeks throughout life and additionally upon request Referral to exercise training Referral to nutritional specialist
45798297|NCT03639623|Drug|Saroglitazar|Saroglitazar magnesium 4 mg tablet once daily (OD) in the morning 60 minutes before breakfast without food
45925981|NCT00075283|Device|Lokomat (Robotic Orthosis) combined with slat belt treadmill|
45925982|NCT00075439|Drug|gefitinib|Given orally
45925983|NCT00075439|Other|laboratory biomarker analysis|Correlative studies
45925984|NCT02965417|Drug|Sym004|Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).
45925985|NCT04707443|Other|donor human milk|"Donor human milk: from our center's milk bank~Starting dose: 10-20 ml/kg/day (specific according to the amount of fistula or excrement).~Evaluate twice every 24 hours, observe for at least 24 hours before volume advancement.~Target dose: 150mL/kg/d (energy: 100 to 140 kcal/kg/d).~Duration: from the first day when the patient start enteral feeding to the 28th day, lasting for four weeks."
45925986|NCT04707443|Other|extensively hydrolyzed formula|"eHF：commercial formulation, distribution from enteral nutrition preparation room of our center~Starting dose: 10-20 ml/kg/day (specific according to the amount of fistula or excrement).~Evaluate twice every 24 hours, observe for at least 24 hours before volume advancement.~Target dose: 150mL/kg/d (energy: 100 to 140 kcal/kg/d).~Duration: from the first day when the patient start enteral feeding to the 28th day, lasting for four weeks."
45925987|NCT00075517|Drug|docetaxel|
45925988|NCT00075517|Drug|gemcitabine hydrochloride|
45925989|NCT00075556|Drug|capecitabine|
45925990|NCT00075556|Procedure|conventional surgery|
45925991|NCT00075556|Procedure|neoadjuvant therapy|
45649917|NCT04865653|Drug|Lysergic Acid Diethylamide Tartrate intravenous administration|A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).
45649918|NCT04865653|Other|LSD Placebo|Placebo for each formulation containing only the solvent or gel but no LSD.
45925992|NCT00075556|Radiation|radiation therapy|
45925993|NCT00075595|Drug|FOLFIRI regimen|
45925994|NCT00075595|Drug|fluorouracil|
45925995|NCT00075595|Drug|irinotecan hydrochloride|
45925996|NCT00075595|Drug|leucovorin calcium|
45925997|NCT03958539|Device|3D printed insoles for normal footware|"Imprints are low-cost, bespoke, 3D-printed orthotics designed to prevent diabetic foot ulceration by redistributing and lowering peak foot pressures. This is achieved by using different density zones designed specifically for the patient. The patient's foot shape and pressure zone are capture by a 3D imaging system. Once scanned the software automatically identifies the peak pressure zones, matches these with the correct material and stiffness (densities), fits the insole arch to the patient and generates the insole.~The imprints insole is divided into four pressure zones: heel, midfoot, metatarsal head region and toes. These zones are printed with different stiffness to account for the difference in loading between them. The design of the pressure zones is automatically matched to the shape of each individual foot with the help of the 3D scan."
45925998|NCT00075634|Drug|decitabine|Given IV
45925999|NCT00075634|Drug|doxorubicin hydrochloride|Given IV
45926000|NCT00075634|Drug|cyclophosphamide|Given IV
45926001|NCT00075634|Biological|filgrastim|Given SC
45798298|NCT01690273|Other|mobility exercise|30 minutes, twice a week
46072057|NCT05689541|Other|Mobile app intervention|"A mobile-based application will be developed to provide parents with a supplemental curriculum that will include games and activities focusing on motor outcomes. The focus of these games and activities will correspond with the adapted horseback riding program's weekly lesson plan. The mobile app will be created with Glide, which allows us to create a mobile application with basic spreadsheet skills.~The mobile app will aim to incorporate 10-12 games and activities designed to improve specific motor outcomes. Parents will be instructed to partake in the app-delivered activities with their children daily for at least 30-45 minutes."
45926002|NCT00075634|Biological|pegfilgrastim|Given SC
45926003|NCT00075634|Other|laboratory biomarker analysis|Correlative studies
45926004|NCT00075634|Other|pharmacological study|Correlative studies
46072058|NCT05689073|Device|chatbot|a chatbot based on NLP techniques
45649919|NCT04858763|Other|No Intervention|There will be no intervention during this study.
46072059|NCT05689073|Other|Printed educational booklet|a printed booklet
45649920|NCT04863469|Behavioral|B-POC high load intervention|aerobic exercise [heartrate range (HRR) 70-75% of max HR, on treadmill] and a computerized high-load task for 45 minutes, 3 times per week, for 6 weeks
45649921|NCT04863469|Behavioral|B-POC low load intervention|aerobic exercise [heartrate range (HRR) 70-75% of max HR, on treadmill] and a computerized low-load task for 45 minutes, 3 times per week, for 6 weeks
45649922|NCT04867109|Other|Patients with Post menopausal bleeding|"Any patient presenting post-menopausal bleeding who is to undergo hysteroscopy or hysterectomy will have an additional blood tube taken during her pre-operative blood work-up for the determination of the serum markers HE4 and CA125, after having obtained her non-opposition to participate in the study.~The blood tube collected for the research will be sent to the biochemistry laboratory of the Nantes University Hospital for a centralized analysis.~This analysis will be done sequentially and the results will not be transmitted to the investigator.~At D0, the day of surgery, the operative report will be retrieved as well as the quality of life questionnaires SF12 and PGI-I and the acceptability questionnaire completed before surgery.~At 1 month after surgery, the anatomopathological results will be retrieved as well as the value of the tumour markers CA125 and HE4."
45798299|NCT01690273|Other|mobility and elastic resistance exercise|30 minutes, twice a week each exercises group. (total 1 hour)
45798300|NCT02384993|Behavioral|Enhanced Physical Activity|This is a 26-week aerobic exercise intervention. The primary mode of training is treadmill walking, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Participants will train 3-4 days per week with the goal of attaining 150+ minutes of exercise per week by the seventh week. Exercise will be set between 50-60% of maximum heart rate reserve for weeks 1-4, 60-70% for weeks 5-8, and 70-80% for weeks 9-26. Exercise duration will be approximately 15-20 minutes per session during the first week and then increase by 5 minutes each week until a duration of approximately 38-50 minutes per session is reached. Each training session will begin with a 5-minute warm-up and end with a 5-minute recovery period.
45798301|NCT05641298|Drug|Sodium Fusidate|Tablets
46072060|NCT05688917|Dietary Supplement|Green coffee been extract|supportive treatment
46072061|NCT05688917|Other|Placebo|Placebo capsule
46072062|NCT05685602|Procedure|Biopsy|Undergo a tumor biopsy
45798302|NCT05641298|Drug|Placebo|Tablets
45798303|NCT00382707|Device|cortical magnetic stimulation provided by an eight-shaped coïl placed upon the skull.|
45798304|NCT04342247|Drug|external testosteron|external testosteron
45926005|NCT04703855|Device|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Advanced heart failure patients will be implanted with the HM3 LVAS
45926006|NCT00075673|Drug|celecoxib|Patients receive oral celecoxib twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
45926007|NCT00075673|Drug|vinorelbine ditartrate|Patients receive oral vinorelbine on days 7, 14, and 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
45926008|NCT00075712|Drug|carboplatin|
45926009|NCT00075712|Drug|paclitaxel|
45926010|NCT00075712|Procedure|adjuvant therapy|
45926011|NCT00075712|Procedure|conventional surgery|
45926012|NCT00075712|Procedure|neoadjuvant therapy|
46072063|NCT05685602|Procedure|Biospecimen Collection|Undergo blood sample collection
45926013|NCT03958500|Procedure|Indocyanine green fluorescent angiography intraluminally and intraperitoneally|The use of indocyanine green fluorescent angiography to check bowel and anastomosis viability in standard low anterior rectal anastomosis
45926014|NCT04690907|Behavioral|Dietary intervention|Written material on healthy diet during pregnancy and 2 virtual dietary counseling sessions.
45926015|NCT00075751|Drug|gemcitabine hydrochloride|Given IV
45926016|NCT00075751|Drug|carboplatin|Given IV
45926017|NCT00075751|Drug|bortezomib|Given IV
45926018|NCT02965612|Device|Injex|administration of Specific Immunotherapy (ITS) with car pressure injector without a needle
45649923|NCT04867109|Diagnostic Test|CA125 and HE4 assays|Blood was collected in a standard heparinized vial. Samples were sent to a central laboratory unit (biochemistry laboratory at the Nantes university hospital), centrifuged and plasmas were stored at -20°C until analysis. Plasma CA125 and HE4 concentrations were determined by run in single measurements using an electrochemiluminescence Elecsys immunoassay (ECLIA) on a Roche Diagnostics Cobas 8000® e602 analyser (Roche Diagnostics, Mannheim, Germany).
45649924|NCT05306119|Other|Rehabilitation method|Application of techniques of kinesiotherapy, electrotherapy, massage in comorbid patients and patients with low back pain who had undergone myocardial revascularization surgery in main group.
45926019|NCT02965612|Procedure|SCIT|administration of Specific Immunotherapy (ITS) via traditional subcutaneous
45649925|NCT05305729|Other|No intervention|No intervention
45926020|NCT00392730|Dietary Supplement|Remove Mn from PN if evidence of increased brain Mn on MRI|Withhold Mn-containing trace element cocktail and add zinc, copper and chromium individually to PN
45926021|NCT00075868|Drug|octreotide acetate|
45649926|NCT04488679|Other|direct pulp capping|teeth with exposed pulp during caries removal will be capped either with PRF followed by mta or mta alone directly on exposed pulp, in both groups restoration will be placed over mta
45926022|NCT00075868|Other|Placebo|
45926023|NCT00075907|Drug|Efavirenz + 2 NRTIs|
45926024|NCT00075907|Drug|Lopinavir/Ritonavir + 2 NRTIs|
45926025|NCT00075907|Procedure|Therapeutic Drug Monitoring|
45649927|NCT05305417|Procedure|Autologous Regenerative Endodontic Treatment|The intervention consist in achieve an access to the teeth root canal system, do a chemico-mechanical preparation each root canal for to be obturated with an autologous biological scaffold and bioactive biomaterials to maintain teeth free of signs/symptoms caused by pulp necroses and periapical lesions
45926026|NCT04650425|Behavioral|Cognitive tasks|Patients will perform the coffee-tea task and the virtual T-maze task, both in the acute and chronic phase after stroke.
45926027|NCT03958422|Drug|cardiomyopeptidin|The main component of cardiomyopeptidin is the peptide active substance extracted from the ventricular myocytes of healthy young pigs.
45926028|NCT00076063|Biological|ALVAC-HIV (vCP1452)|experimental vaccine
45926029|NCT00076063|Biological|LIPO-5|experimental vaccine
45926030|NCT00076180|Biological|Hu-MiK-Beta-1|Hu-MiK-Beta-1 administered as an intravenous infusion over 90- minutes.
45653188|NCT05111301|Device|Control-IQ technology 1.5|"All subjects wearing the t-slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor.~Outcomes will be analyzed overall and subgroup analysis will be performed by Group, and by baseline A1c level."
45798305|NCT04620369|Drug|Placebo Administration|Instill isotonic nasal saline intranasally
45798306|NCT04620369|Other|Questionnaire Administration|Ancillary studies
45798307|NCT04620369|Drug|Rose Geranium in Sesame Oil Nasal Spray|Instill intranasally
45798308|NCT05637476|Other|Functional strength training of hip abductors|"Every participant will perform three sets of fifteen repetitions, fifteen seconds rest in between, three times per week for the following exercises:~Pelvic drop.~Single leg -bridge.~Side-lying hip abduction with hip internal rotation.~Lateral step-up.~Standing hip abduction on stance or swing leg with extra resistance ."
45926031|NCT03958383|Biological|hu14.18-IL2|A recombinant fusion protein linking the monoclonal antibody (mAb) hu14.18 with interleukin-2 (IL2), administered IT
45926032|NCT03958383|Radiation|Radiation Therapy|Palliative radiation therapy
45926033|NCT03958383|Biological|Nivolumab|Human programmed death receptor (PD-1) blocking antibody, given IV
45926034|NCT03958383|Biological|Ipilimumab|Monoclinal antibody that targets cytoxic T-lymphocyte-associated protein 4 (CTLA-4), given IV
45926035|NCT00076375|Drug|Nanocrystalline silver cream (NPI)|
45926036|NCT00076414|Drug|Acetylcholine|
45926037|NCT00076414|Drug|L-NMMA|
45926038|NCT00399256|Drug|Acetylcysteine|
45926039|NCT00399256|Drug|Zinc|
45926040|NCT04608188|Behavioral|Summer Camp|The intervention camps will operate according to routine practice, with no assistance from the investigative team. The camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. All camp meals will adhere to the United States Department of Agriculture Summer Food Service Program nutrition guidelines. The camps employ 1 staff member for every 12 children - which is consistent with childcare regulations in the state of operation and operate daily (Mon-Fri) for 8 weeks during the summer. The camps open at 7am and close 6 pm daily.
45926041|NCT00399295|Drug|Hydromorphone HCL 16mg; Dilaudid SR 16mg; Naltrexone (opioid antagonist) 50mg.|
45926042|NCT03958305|Procedure|RADICAL HYSTERECTOMY|Radical hysterectomy is an operation done to treat some cancers of the cervix. The surgeon takes out the uterus and the ligaments (tissue fibers) that hold it in place. The cervix and an inch or 2 of the vagina around the cervix are also removed.
45926043|NCT00399334|Drug|antipsychotic medications|as prescribed
45926044|NCT00076453|Device|Lateral wedge orthotic shoe inserts|Customized lateral wedge orthotic shoe inserts
45926045|NCT00076453|Device|Standard orthotic shoe inserts|Neutral orthotic inserts
45926046|NCT04607993|Behavioral|Prone position ventilation technique|"Inform the children's family members of the purpose and method of prone position ventilation~Assess the fixation of various catheters~Suspend feeding before placing prone position~Confirm the time to start prone position ventilation under the joint assessment of medical staff~Place the child in a prone position with the participation of researchers, doctors and nursing staff, with the child's head tilted to one side to avoid damage to the eyes and nose due to compression, and the arms are bent upward to form a W . Bend both lower limbs downward to form an M shape, and use a soft pillow cushion to measure the knee joints to avoid compression~The whole process ensures the smooth fixation of tracheal intubation and various catheters~Proper sedation during prone position ventilation to achieve good human-machine synchronization~At least 6-8 hours in prone position every day"
45926047|NCT00076492|Drug|CoQ10|
45926048|NCT00076492|Drug|GPI 1485|
45926049|NCT03958227|Other|Manuel Therapy plus Exercise Intervention|Shoulder mobilization techniques include glenohumeral traction, anterior, posterior and inferior glide. We will also use anterior, posterior and inferior joint stretching exercises and scapular mobilization. Exercise interventions include range of motion exercises, stretching exercises, strengthening exercises, and pendulum exercises.
45926050|NCT03958227|Other|Exercise Intervention|Exercise interventions include range of motion exercises, stretching exercises, strengthening exercises, and pendulum exercises.
45926051|NCT00076531|Drug|Leuprolide Acetate for Injectable Suspension 22.5 mg|
45926052|NCT00076609|Drug|PHY906|
45926053|NCT00076609|Drug|capecitabine|
45926054|NCT00076648|Drug|Poly SFH-P Injection|
45926055|NCT00076726|Drug|Infliximab|
45926056|NCT03958188|Other|Standardized computerized tomography (CT) reading grid for preoperative planning|"Using the standardized reading grid, the following data will be collected:~Small Intestine: tumor, parietal thickening, occlusive syndrome, proximity of the tumor with the ileocecal valve.~Mesenteric mass: presence, size, shape, contours, calcifications, enhancement, superior mesenteric arterial invasion and number of non-invaded arterial arteries.~Mesentery: moniliform venous dilatations, combed appearance.~Duodenal invasion.~Lymphadenopathies (Mesenteric, Right mesocolic and Retropancreatic): presence, size, shape, enhancement~The anonymized CT exam will be reviewed by an expert radiologist and a radiology resident from imaging department of the Hospital."
45926057|NCT00076843|Drug|Hu MiK-Beta-1|
45926058|NCT04576949|Drug|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
45649928|NCT05305417|Procedure|Conventional Root Canal Treatment|The intervention consist in achieve an access to the teeth root canal system, do a chemico-mechanical preparation each root canal for to be obturated with an inert biomaterial to maintain teeth free of signs/symptoms caused by pulp necroses and periapical lesions
45649929|NCT05305339|Other|Placental and Umbilical cord biopsy|After delivery of the placenta, two tissue fragments, 1st piece about 1x1 cm from the central zone of the maternal surface of the placenta and 2nd piece about 1 x 1 cm from mid segment of umbilical cord will be cut. Each of both samples will be divided and fixed in either a 10% formalin for light microscopic examination or glutaraldehyde 2.5% for Electron microscopic examination. Paraffin-embedded placental tissue sections (4 μm thick) will be used for histological (stained with hematoxylin and eosin) and immunohistochemical examination using primary antibody markers for telocytes CD117, CD34, vimentin, SMA (smooth muscle actin), and the new telocyte marker TMEM16a (DOG-1).
45649930|NCT04794283|Other|Breast milk|Milk substitute given during the first 24h
45798309|NCT05637476|Other|A selected physical therapy exercise program|"Every participant will perform three sets of fifteen repetitions, fifteen seconds rest in between, three times per week for the following exercises:~Strength dorsiflexors of the ankle-using rubber band.~Eccentric calf exercise (calf raise) .~Balance and proprioceptive exercise using wobble boards.~Stretch planter flexors (three sets of thirty repetitions, thirty seconds rest in between, three times per week)"
45798310|NCT03628313|Other|Transthoracic ultrasound|Patients are prospectively identified during echocardiography performed in the echocardiography laboratory of the two participating centers when a diagnosis of aortic stenosis is made.
45926059|NCT04576949|Drug|Placebo|film-coated oral tablets containing matched placebo
45926060|NCT04576949|Behavioral|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
45926061|NCT00076960|Drug|Stanate (TM) [stannsoporfin, tin-mesoporphyrin]|Treatment with 4.5 mg/kg
45926062|NCT03958110|Diagnostic Test|OCT A|OCT (Optical Coherence Tomography) and Retinophotography made at the beginning and end of the Rugby season.
45926063|NCT00077077|Drug|DJ-927|
45926064|NCT00077077|Drug|capecitabine|
45926065|NCT00077116|Drug|busulfan|
45926066|NCT00077116|Drug|cyclophosphamide|
45926067|NCT00077116|Drug|cytarabine|
45926068|NCT00077116|Drug|gemtuzumab ozogamicin|
45926069|NCT00077116|Drug|idarubicin|
45926070|NCT00077116|Procedure|allogeneic bone marrow transplantation|
45926071|NCT00077116|Procedure|peripheral blood stem cell transplantation|
45926072|NCT00077116|Radiation|radiation therapy|
45926073|NCT02958436|Drug|REGN3500|
45926074|NCT02958436|Drug|Placebo|
45926075|NCT04572074|Other|Guided imagery|10 minutes of guided imagery experience
45926076|NCT04572074|Other|Virtual reality|10 minutes of virtual reality experience
45926077|NCT03951207|Drug|Rosuampin 10/5mg|Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
45926078|NCT03951207|Drug|Rosuampin 20/5mg|Rosuampin 20/5mg qd for 8 weeks
45926079|NCT03951207|Drug|Amlodipine/Atorvastatin 5/20mg|Amlodipine/Atorvastatin 5/20mg qd for 8 weeks
45926080|NCT00077155|Drug|cilengitide|
45926081|NCT00077194|Drug|romidepsin|
45926082|NCT00077233|Drug|cetuximab|IV
45926083|NCT00077233|Drug|5-FU|IV
45649931|NCT05305183|Drug|Minodronate Tablets and Alendronate Sodium Tablets-matching placebo;Alendronate Sodium Tablets and Minodronate Tablets -matching placebo|all subjects will receive Calcium Carbonate and Vitamin D3 Tablets as basic medication.
45926084|NCT00077233|Drug|irinotecan|IV
45926085|NCT00077233|Drug|leucovorin|IV
45926086|NCT00077233|Drug|oxaliplatin|IV
45649932|NCT04782271|Drug|SYL18001 sodium Low dose q.d|1 drop in the randomized eye once daily
45926087|NCT04566848|Diagnostic Test|Flow cytometric analysis|Measuring the sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9 levels with flow cytometry
45926088|NCT03939429|Drug|QPX2015|antibiotic
46072064|NCT05685602|Procedure|Computed Tomography|Undergo a CT scan
46072065|NCT05685602|Biological|Emavusertib|Given PO
45649933|NCT04782271|Drug|SYL18001 sodium Middle dose q.d|1 drop in the randomized eye once daily
45649934|NCT04782271|Drug|SYL18001 sodium High dose q.d|1 drop in the randomized eye once daily
45649935|NCT04782271|Drug|SYL18001 sodium High dose b.i.d|1 drop in the randomized eye twice daily
45649936|NCT04781179|Behavioral|CM-II|It is an intervention of 4 two-hour sessions with a psychologist, MC-II technique
45649937|NCT04781179|Behavioral|Psychoeducation|It is an intervention of 4 two-hour sessions with a psychologist, psychoeducation
45649938|NCT01668797|Drug|Brexpiprazole|Brexpiprazole tablets 1 to 4 mg /day
45649939|NCT01668797|Drug|Placebo|Placebo comparator for 52 weeks
45798311|NCT05738642|Drug|4 factor Prothrombin Complex Concentrates|Cluster 4 f - PCC by intravenous infusion (boya 4 f - PCC, a bottle of 400 IU) : 25 IU/kg dose infusion time: as soon as possible after admission infusion, at the latest within 2 hours after admission to infusion infusion method: Sodium chloride injection 5% glucose injection was diluted into 50 ml per bottle, and then intravenous infusion was carried out with a blood transfusion device with a mesh device. The infusion was finished in 60-120 minutes
45798312|NCT01690663|Drug|Bupivacaine 0.25%|
45798313|NCT01690663|Drug|Dexamethasone|
45798314|NCT01690663|Drug|normal saline|placebo
45798315|NCT05360186|Device|MateRegen® gel (BioRegen)|Modification of Hyaluronic acid structure to 3-dimensional self-cross-linked network structure enables all-dimensional coverage of tissue surface to enhance better healing process. Self-cross-linked HA hydrogels can maintain the biocompatibility and biodegradability that characterize the unmodified material. Moreover, high dynamic viscosity enables continuous indwelling in the uterine cavity. The gel could provide precise regulation, and degradation and absorption time prolonged to 7-14 days post operatively, which completely cover key postoperative healing period (5-7 days), at the highest time of intrauterine adhesion formation.
45798316|NCT02290574|Radiation|Hyperthermia with concurrent chemo-radiation therapy|
45926089|NCT03939429|Drug|Placebo oral capsule|Placebo comparator
45926090|NCT02958631|Drug|Fimasartan|
45926091|NCT02958631|Drug|Losartan|
45649940|NCT04570891|Procedure|Ultrasound-guided fascia iliaca compartment block|Ultrasound-guided fascia iliaca compartment block (0.25% ropivacaine 1mL/kg, Max 30mL) will be provided at the end of surgery.
45649941|NCT04570891|Procedure|Control|No regional block is provided at the end of surgery.
45649942|NCT05305027|Behavioral|Prompt diagnois pregnancy outcome|
45649943|NCT05304793|Other|Best Practice|Receive usual management of dyspnea
45649944|NCT05304793|Behavioral|Cognitive Behavior Therapy|Receive TAB treatment
45649945|NCT05304793|Other|Questionnaire Administration|Ancillary studies
45649946|NCT04759027|Other|subacromial distance measurement|distance between acromion and humerus
45649947|NCT05304637|Device|iTEAR100 treatment|Vibratory energy to the external nasal nerve
45649948|NCT04511767|Other|Do not take any interventions|Do not take any interventions
45926092|NCT04729894|Other|Medication Lockbox|Participants will receive a medication lockbox to store medications in their home.
45926093|NCT04729894|Behavioral|Education|Participants will receive information on safe medication storage practices.
45649949|NCT05304559|Drug|S-Ketamine|S-Ketamine0.1mg/kg was injected intravenously during anesthesia induction and S-Ketamine0.1mg/ (kg.h) was injected intravenously during anesthesia maintenance.S-Ketamine was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
45798317|NCT01706497|Device|Cerebral tissue oxygen saturation monitoring, blinded|
45798318|NCT05356052|Combination Product|INOpulse|Patients will be treated by means of an INOpulse device using an INOpulse nasal cannula
45926094|NCT00077311|Biological|darbepoetin alfa|200 mcg sub Q on day 1 of each cycle if HgB < or = 11 g/dL
45926095|NCT00077311|Biological|pegfilgrastim|6 mg sub Q day 2 of each cycle
45926096|NCT00077311|Drug|cisplatin|75 mg/sq m IV over 1 hr Day 1 of each cycle
45926097|NCT00077311|Drug|docetaxel|75 mg/sq m IV over 1 hr Day 1 of each cycle
45926098|NCT00077311|Drug|BNP7787|40 g IV over 30 min Day 1 of each cycle
46072066|NCT05685602|Drug|Gemcitabine Hydrochloride|Given IV
46072067|NCT05685602|Procedure|Magnetic Resonance Imaging|Undergo MRI
46072068|NCT05685602|Drug|Nab-paclitaxel|Given IV
46072069|NCT05685602|Procedure|Positron Emission Tomography|Undergo a PET scan
46072070|NCT05685602|Procedure|X-Ray Imaging|Undergo an x-ray
46072071|NCT05683977|Drug|durvalumab|Visits will be completed at W0 (durvalumab in combination with chemotherapy initiation) and at regular visits approximately every 6 weeks during the induction period (durvalumab + PE) (W6 and W12), then every two months during the maintenance period (durvalumab alone) for the first year and every three months up to the end of follow-up or the final visit at M36.
46072072|NCT05682443|Drug|ONC-392|ONC-392 will be given at 10 mg/kg IV infusion, once every 28 days, for up to 13 doses.
46072073|NCT05682443|Drug|lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV infusion, Q6W for up to 6 doses.|lutetium Lu 177 vipivotide tetraxetan will be given 7.4 GBq (200 mCi), IV infusion, once every 6 weeks, for up to 6 doses.
45450609|NCT04870138|Biological|Neisseria gonorrhoeae strain FA1090 A26|0.4 mL of a suspension containing 10^5 - 10^6 CFU of wild-type (WT) Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
45926099|NCT04561388|Procedure|Electrocochleography|"Electrocochleographic responses will be evoked using different pure tone sounds delivered through an insert placed in the external auditory duct. The responses will be recorded with the electrodes of the cochlear implant connected to a dedicated interface.~Electrocochleographic responses will be collected continuously during the electrode-array insertion at the implantation surgery using 500Hz pure tone and after suturing with 250, 500, 750 and 1000Hz pure tones. Then, electrocochleographic responses to pure tones from 125 to 8000HZ (according to the subject residual hearing) will be recorded 2 weeks, 1 month, 2 months and 4 months after implantation."
45926100|NCT04561388|Other|Pure Tone Audiometry|"The perception thresholds to 125, 250, 500, 750, 1000, 2000, 4000 and 8000 Hz pure tones will be measured within the month preceding the implantation using the same insert t.~Pure tone audiometry with the same frequencies will be done 2 weeks, 1, 2 and 4 months after the implantation."
45798319|NCT05738564|Drug|Epinephrine Inhalation Solution|epinephrine prepared solution mixed with lidocaine (EL) Otrivin adult nasal drops 0.1Otrivin adult nasal drops 0.1%, 10 ml of 1 mg/ml; Novartis Consumer Health, UK Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK) in each nostril in the pre-induction room just before the induction of anesthesia
45798320|NCT05629364|Drug|KIO-101|Randomized, Controlled
45926101|NCT04561388|Other|Speech audiometry|The speech perception will be assessed in silence and in noise in free field 1 and 4 months after implantation. The speech perception in silence will be assessed using monosyllabic words 60 dB SPL. Speech in noise will be assessed using an adaptative test with fixed noise level (60 dB SPL).
45926102|NCT00077350|Drug|triapine|Given IV
45926103|NCT00077350|Drug|gemcitabine hydrochloride|Given IV
45926104|NCT00077350|Other|laboratory biomarker analysis|Correlative studies
45926105|NCT00077389|Drug|carboplatin|
45926106|NCT00077389|Drug|cisplatin|
45926107|NCT00077389|Drug|doxorubicin hydrochloride|
45926108|NCT00077389|Procedure|adjuvant therapy|
45926109|NCT00077389|Procedure|conventional surgery|
46072074|NCT05681806|Dietary Supplement|Carnipure AAS|A combination of a low dose of Carnipure crystalline (L-carnitine tartrate) and lipid multi-particulate (LMP) creatine monohydrate
45649950|NCT05304559|Device|Continuous iliac fascia space block|After admission, the iliac fascia space block and catheterization were performed under the guidance of ultrasound, and the analgesia was continued until two days after operation.
45649951|NCT05304559|Drug|Normal saline|Normal saline0.1ml/kg was injected intravenously during anesthesia induction and Normal saline0.1ml/ (kg.h) was injected intravenously during anesthesia maintenance.Normal saline was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
45649952|NCT03045263|Behavioral|Pivotal Response Treatment|Behavioral intervention for autism
45798321|NCT05343572|Drug|Plerixafor|A 20mg single dose of PLERIXAFOR is administered subcutaneously the evening prior to scheduled standard of care surgery for women with AS, AE or RIF for peripheral mobilization of stem cells. For subjects weighing >83 kilogram, the dosing is a single dose of 0.24 milligram per kilogram.
45926110|NCT00077389|Procedure|neoadjuvant therapy|
45926111|NCT00077428|Drug|bortezomib|Given IV
45926112|NCT00077428|Drug|doxorubicin hydrochloride|Given IV
45926113|NCT00077428|Other|laboratory biomarker analysis|Correlative studies
45450610|NCT04870138|Biological|Neisseria gonorrhoeae strain FA7527|0.4 mL of a suspension containing 10^5 - 10^6 CFU of isogenic LptA mutant Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
45450611|NCT03536026|Procedure|Conventional bronchoscopy|-Standard of care
45649953|NCT04478851|Behavioral|Group Exercise Classes|The exercise program to be implemented for rural cancer survivors will combine aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format, twice weekly for a 12-week period. If public health restrictions require closure of fitness facilities due to COVID-19, the program will be delivered online. If facilities are open, the sessions will be integrated in the community, delivered in-person. Whether delivered in-class or remotely, the program follows exercise progression principles (ie, frequency, intensity, time, type, overload and progression) over the 12-weeks, with tailoring of any exercise to meet individual participant needs as required, in order to promote fitness and wellness benefits. The exercise intervention is based on the Alberta Cancer Exercise (ACE) program.
45926114|NCT00077467|Drug|bortezomib|Given IV
45926115|NCT00077467|Other|pharmacological study|Correlative studies
45926116|NCT00077467|Other|laboratory biomarker analysis|Correlative studies
45926117|NCT03832569|Drug|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.
45926118|NCT04551482|Drug|Oxytocin nasal spray|24 IU nasal spray, 4 times per day for 12 weeks
45926119|NCT04551482|Drug|Placebo|24 IU nasal spray, 4 times per day for 12 weeks
45926120|NCT02965651|Behavioral|ECA System|"The ECA system, named Gabby, included content pertaining to stress management, nutrition and physical activity as well as dialogue scripts and media such as meditations. The scripts included motivational interviewing dialogue: dialogue to simulate shared decision making interactions and additional longitudinal interaction using techniques such as goal setting, problem solving, tips, and homework. Gabby was available on a web browser through a username and secure password login."
46072075|NCT05681806|Dietary Supplement|Creatine Monohydrate|5g creatine monohydrate
45926121|NCT00077545|Drug|triapine|Given IV
45926122|NCT00077545|Drug|cisplatin|Given IV
45926123|NCT00077584|Drug|Bosentan 62.5 mg|Oral tablets containing 62.5 mg of bosentan
45649954|NCT04866797|Other|cyclic merocyanine|long-UVA absorber
45798322|NCT01706965|Drug|Kuvan|20mg/kg using a daily dosing schedule. To increase tolerability, treatment will be initiated at 10mg/kg for the first week of the study. Given the short length of the trial, no dose adjustments will be made for changes in weight
45926124|NCT00077584|Drug|Bosentan 125 mg|Oral tablets containing 125 mg of bosentan
45926125|NCT00077584|Drug|Placebo|Oral tablets matching bosentan 62.5-mg tablets and bosentan 125-mg tablets
45926126|NCT03780972|Drug|ONL1204|Administration of ONL1204 - inhibitor of Fas(CD95) signaling by intravitreal injection
45926127|NCT03780972|Procedure|Intravitreal Injection|Injection of study drug into the eye
45926128|NCT03780972|Procedure|Collection of ocular fluids|vitreous and aqueous fluid collection by a tap and during vitrectomy
45926129|NCT04551053|Drug|parsaclisib|parsaclisib will be administered QD orally
45926130|NCT04551053|Drug|ruxolitinib|ruxolitinib will be administered BID orally
45926131|NCT04551053|Drug|placebo|placebo will be administered QD orally
46072076|NCT05677100|Device|Aortix System|Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and are resistant to diuretic therapy.
46072077|NCT05675579|Drug|Sacituzumab Govitecan|Given by IV (vein)
46072078|NCT05675579|Drug|Pembrolizumab|Given by IV (vein)
46072079|NCT05674110|Behavioral|DSMES Intervention|This study will provide participants with on-line education, plus weekly text messaging that will contain messages of support or encouragement sent to participants in the individual's preferred language (English or Spanish). Participants will be encouraged to attend monthly group support meetings to review the content and address any questions. Group meetings will occur at 3-time intervals (end of months: 1, 2, and 3). Group support meetings will be held in-person at a food pantry and moderated by peer mentors, nursing students, registered dietitian nutritionist (RDN), and/or a diabetes care and education specialist (DCES). Group support meetings will be held in Spanish and/or English, with no more than 10 participants in a group at one time, and will last approximately 50 minutes. For the duration of the study, participants will continue to receive monthly food items from the food pantry.
46072080|NCT05671055|Other|Custom study version of icompanion app|Patients complete patient-reported outcomes on cognition and covariates, as well as objective cognitive tests through a version of icompanion app customized specifically for this study. Patients complete all assessments remotely in an at-home situation.
45798323|NCT01706965|Drug|Multivitamin|Multi-vitamin will be used as an active control in this study. Will be dosed daily
45798324|NCT04350086|Drug|Treatment with Dexmedetomidine|Administration of Dexmedetomidine in continuous infusion by electric syringe pump at a dose of 0.4 µg / kg / h, with dose adjustment according to the sedation score and tolerance.
45798325|NCT05620238|Drug|Carfilzomib|Investigate the home administration of Carfilzomib IV reported by both patients and health care staff compared to the hospital setting.
45798326|NCT05738408|Behavioral|Financial Incentives (FI) and Nicotine Replacement Therapy (NRT)|: In the intervention condition, patients will receive both NRT plus a 12-week program of monetary incentives for verified smoking abstinence that will be implemented by our clinic staff
45450612|NCT03536026|Device|VIDA Pulmonary Workstation 2|-Virtual bronchoscopic navigation system
45450613|NCT03536026|Procedure|Biopsy|-Standard of care
45649955|NCT04866797|Other|Placebo|Placebo
45649956|NCT04476355|Other|Select and Tailor implementation interventions|Based on previously adapted guidelines and the assessment of innovation, adopters and practice environment for barriers and supports, the interventions mainly include patients education, practioners education and system changes.
45649957|NCT04865471|Procedure|Liver transplantation|Auxiliary liver transplantation and staged hepatectomy
45926132|NCT00077779|Drug|Adalimumab|
45926133|NCT00077818|Drug|Enoxaparin sodium|
45450614|NCT02188186|Drug|Initial triple combination|Initial triple combination arm
45450615|NCT02188186|Drug|Conventional treatment|Conventioanl treament with dose escalation
45926134|NCT00077896|Procedure|Direct Current Polarization|
45926135|NCT00077935|Drug|Civamide|Cream 0.075%, TID for 52 weeks
45926136|NCT00078013|Drug|MCC-135|
45926137|NCT00078130|Drug|Buprenorphine/naloxone|
45926138|NCT00078169|Behavioral|Behavior Therapy|
45926139|NCT00399412|Device|subcutaneous ICD|
45926140|NCT00399451|Drug|Polidocanol Sclerotherapy|
45926141|NCT02936024|Procedure|Two-Stage GSLO Technique|The patient will initially receive the first stage of the two-stage technique which involves the ligation of testicular vessels laparoscopically, or transection of these vessels using cautery. After the first stage is complete, the patient will be seen approximately 3-6 months later for the second stage. The second stage of the procedure involves free mobilization of the testis and placement/fixation of the testicle in the scrotum.
45926142|NCT02936024|Procedure|One-Stage GSLO Technique|The patient will receive only one surgical procedure during which ligation of testicular vessels is performed, as well as mobilization of the testis and placement/fixation of the testicle in the scrotum.
45926143|NCT00399607|Procedure|Rectal biopsy during colonoscopy|Biopsies of rectal tissue will be obtained during the 3 or 5 year follow-up colonoscopy. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
45926144|NCT00399607|Procedure|Rectal biopsy at randomization|Biopsies of rectal tissue will be obtained at the time of randomization. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
45926145|NCT00399607|Procedure|Rectal biopsy at 1 year|Biopsies of rectal tissue will be obtained at the time of the one year follow-up visit. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
45798327|NCT05738330|Behavioral|Symptom Monitoring on Renal Replacement Therapy - Hemodialysis (SMaRRT-HD)|Dialysis clinics randomized to the SMaRRT-HD group will use the SMaRRT-HD system to capture patient-reported symptoms and support clinician follow-up. The online system includes the patient symptom ePROM surveys, clinician real-time email alerts, clinician guidances for symptom management, and patient-facing symptom reports as well as an administrative dashboard supporting management of trial participants at clinics using SMaRRT-HD. Designated clinic personnel (i.e., patient care technicians and nurses) will receive training on how to use the system to administer the symptom ePROM surveys to patients on tablet computers. Designated clinic nurses and medical providers will receive training on how to access guidances for symptom management and patient-facing symptom reports in the SMaRRT-HD system. For trial participants in SMaRRT-HD clinics, the SMaRRT-HD system will be implemented in addition to the Usual Care approach to symptom monitoring.
45649958|NCT04117711|Drug|AT-007|AT-007 will be administered once daily before breakfast. Up to 4 different dose cohorts in part A; up to 4 dose cohorts in part B, up to 2 dose cohorts for part C, and up to 3 dose cohorts for part D will be enrolled in the study. The starting dose in Part A will be 0.5 mg/kg as a single dose. Subsequent doses in Part A and all doses in Parts B, C, and D will be based on the results of previous cohorts and/or previous parts of the study. Part B will start after all subjects in Part A have completed the study. Cohort C1 will be conducted simultaneously with Cohort B3 and using the same dose as Cohort B2. The dose for Cohort D1 will not be higher than the dose for Cohort B2. The second and third cohorts in Part D (D2 and D3) will not start until after all subjects in Cohorts B3 and B4, respectively, have completed the study and the dose levels will not be higher than those for Cohorts B3 and B4, respectively.
45926146|NCT00399607|Procedure|Rectal biopsy prior to colonoscopy|Biopsies of rectal tissue will be obtained 7-21 days prior to the 3 or 5 year colonoscopy. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
45926147|NCT00399607|Procedure|Biopsies during colonoscopy|Biopsies of the rectum, sigmoid colon and ascending colon will be obtained during the 3-5 year follow-up colonoscopy. The colonoscopy involves insertion of a flexible tube through the anus, which is then advanced the full length of the colon. Biopsies (tiny pinches of tissue less than 1/16 of an inch thick) will be taken as the colonoscopy tube is being removed. In total, 12-16 biopsies will be taken from the rectum (or lower colon about 3 - 4 inches up), sigmoid colon and ascending colon.
45926148|NCT04711447|Device|kinesio-tape|Twenty-one individuals with healthy shoulders completed 10 repetitions of an arm elevation task during three taping conditions (no-tape, experimental KT, sham KT) and 2 loading conditions (no-load and loaded).
45926149|NCT04538417|Device|Cooled Radiofrequency Ablation|RFA procedures will be performed with modification accounting for appropriate C-RFA technique. Participant will be positioned prone and skin prepped with chloroprep. Ultrasound probe will be placed on residual limb at a transverse angle in order to view the nerve and associated neuroma in long-axis. The probe will be advanced to the site of the stump neuroma. C-RFA electrode will be placed adjacent to neuroma. Needle will be connected via wire to a cooled radiofrequency generator. Motor and sensory testing will be performed to reproduce or exacerbate the RLP and / or PLP. At the site of the neuroma, 2 mL of local anesthetic will be injected through the needle. C-RFA lesions will be created by using the typical C-RFA protocol. Upon completion needle will be removed. Following ablation, 0.5 mL of 0.5% bupivacaine will be injected at the site of the ablated neuroma to provide post procedure analgesia.
45926150|NCT04711213|Drug|Dexamethasone Dose 1|Dexamethasone ophthalmic suspension dose 1
45926151|NCT04711213|Drug|Dexamethasone Dose 2|Dexamethasone ophthalmic suspension dose 2
45926152|NCT04711213|Drug|Placebo Dose 1|Placebo suspension dose 1
45926153|NCT04711213|Drug|Placebo Dose 2|Placebo suspension dose 2
45926154|NCT03697707|Biological|DCP-001|allogeneic dendritic cell vaccine
45926155|NCT00078247|Drug|Abacavir|300 mg tablet taken orally twice daily
45926156|NCT00078247|Drug|Lamivudine|300 mg tablet taken orally daily
45926157|NCT00078247|Drug|Zidovudine|300 mg tablet taken orally twice daily
45926158|NCT00078247|Drug|Tuberculosis treatment|Tuberculosis treatment
45926159|NCT04534751|Biological|Fibrinogen + PCC|"Patients randomized to the intervention group will receive 4g of Fibryga and 2000 IU Octaplex will be released as part of the first and second MHP packs, if requested.~If a third MHP pack is required, and thereafter, FC will be administered if the fibrinogen level drops below 1.5-2.0 g/L at the discretion of the clinical team or based on conventional laboratory test results or viscoelastic methods.~Patients in both groups will otherwise receive identical MHP treatment packs (4 units of red blood cells [RBC] in pack 1 and 4 units of RBC and 1 pool of platelets in pack 2 (equivalent to 4 units)."
46072081|NCT05669014|Drug|Daxdilimab|Participants will be administered daxdilimab by subcutaneous (SC) injection
46072082|NCT05669014|Drug|Placebo|Participants will be administered identically matching placebo by SC injection over a total of 24 weeks, then participants will be given active treatment for the remainder of the study.
46072083|NCT05663658|Other|Intravenous morphine patient control device|24-hour morphine consumption will be recorded
45450616|NCT02192632|Drug|Epiduo once daily with detailed instruction for how to apply it|
45450617|NCT02192632|Drug|Epiduo- once daily, simple instruction for application|
45450618|NCT02192632|Drug|BPO once daily|
45450619|NCT03535090|Drug|Methylprednisolone|
45450620|NCT02257060|Procedure|Endocardial Ablation|
45450621|NCT03535870|Drug|Fluticasone propionate/salmeterol|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the LOMI inhaler device
45798328|NCT05738330|Behavioral|Usual Care|Dialysis clinics randomized to Usual Care will not adopt SMaRRT-HD or any other trial-driven procedures. Usual Care clinics will monitor symptoms through clinical care interactions with participants and by administering a CMS-mandated Health-Related Quality of Life (HRQOL) survey that includes questions about symptoms.
45926160|NCT04534751|Biological|Frozen Plasma|"4U FP will be released as part of the first and second MHP packs.~Patients in both groups will otherwise receive identical MHP treatment packs (4 units of red blood cells [RBC] in pack 1 and 4 units of RBC and 1 pool of platelets in pack 2 (equivalent to 4 units).~Patients randomized to the control group may receive FC if the fibrinogen level drops below 1.5-2.0 g/L at the discretion of the clinical team or based on conventional laboratory test results or viscoelastic methods. FC dosing in MHP packs 3 and above will be site-specific and at the discretion of the treating clinician."
45926161|NCT00078364|Procedure|MRI|
45926162|NCT00078442|Drug|Pegylated interferon alfa-2a|Recombinant PEG-IFN alfa-2a is a synthetic version of IFN and is used in hepatitis C virus treatment
45926163|NCT03696810|Diagnostic Test|Laboratory tests|• Laboratory tests (HbA1C levels and lipids)
45926164|NCT04510454|Diagnostic Test|Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR|Nasopharyngeal and throat/oropharyngeal swabs analyzed by both RT-PCR and ddPCR
45926165|NCT00078481|Drug|Idebenone|
45926166|NCT00078520|Biological|Dose Level 1|IL-2-B-CLL 2 x 10^7; CD40L-B-CLL 0
45926167|NCT00078520|Biological|Dose Level 2|IL-2-B-CLL 2 x 10^7; CD40L-B-CLL 2 x 10^6
45926168|NCT00078520|Biological|Dose Level 2- Fixed Dose|IL-2-B-CLL 2 x 10^7; CD40L-B-CLL 2 x 10^7
45926169|NCT00078598|Drug|Rituximab or Iodine I 131 Tositumomab Therapy|
45926170|NCT03665922|Dietary Supplement|BroccoMax®|Nutraceutical neoadjuvant
45450622|NCT03535870|Drug|Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder|Advair (Fixed dose combination of fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
45450623|NCT03535870|Drug|Placebo|placebo dry powder administered via the LOMI inhaler device
45649959|NCT04117711|Drug|placebo|Matching placebo will be administered once in the morning before breakfast
45649960|NCT02613221|Drug|Panitumumab + TAS-102|panitumumab + TAS-102 combination therapy
45649961|NCT05304325|Procedure|Bariatric surgery|Sleeve gastrectomy
45649962|NCT05304325|Other|Blood sampling|Blood samples will be collected to measure glucose, insulin, albumin, uric acid, HbA1c, lipids, hepatic enzymes, TSH, hs-CRP, complete blood cell counts and persistant organic pollutants
45649963|NCT05304325|Other|Blood pressure|Systolic and diastolic blood pressure will be measured.
45798329|NCT03417739|Drug|BVD-523|ERK1 and ERK2 inhibitor
45798330|NCT05322356|Other|Interstitial Brachytherapy of the Prostate With Iodine 125 Implant With Target Dose Supplementation in the Tumor Volume Guided by the TRINITY® PERINE 3D|Target dose supplement with the TRINITY® PERINE 3D system
45798331|NCT03414229|Drug|Epacadostat|100mg bid days 1-21
45798332|NCT03414229|Drug|Pembrolizumab|200mg/dose Day 1, Q 3 weeks
45926171|NCT03665922|Other|Placebo|control
45926172|NCT00078637|Drug|E7820|
45926173|NCT00078793|Drug|Enbrel®|Etanercept alone, etanercept plus methotrexate or other DMARDs
45926174|NCT00078832|Drug|anastrozole|aromatase inhibitor
45926175|NCT00078832|Drug|placebo|Arimidex placebo
45926176|NCT03659916|Drug|A4250 (odevixibat)|A4250 is a small molecule and selective inhibitor of IBAT
45926177|NCT01350128|Drug|PT001 MDI|PT001 MDI administered as two puffs BID for 7 days
45926178|NCT01350128|Drug|Ipratropium Bromide HFA Inhalation Aerosol|Taken as 2 inhalations of the 17 µg per actuation strength MDI QID
45926179|NCT01350128|Other|Placebo MDI|Matching placebo to PT001 MDI administered as two puffs BID for 7 days
45926180|NCT00078910|Drug|exisulind|
45926181|NCT00078910|Procedure|conventional surgery|
45798333|NCT01352117|Drug|efavirenz/emtricitabine/tenofovir disoproxil fumarate|600 mg efavirenz/200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally at night
45926182|NCT00078910|Procedure|neoadjuvant therapy|
45450624|NCT02192710|Procedure|electronic tab|classic use of an electronic tab with age specific games
45450625|NCT02192710|Drug|Midazolam oral intake|
45649964|NCT05304325|Other|Anthropometric measurements|Body weight, height and waist circumference will be measured.
45649965|NCT05304325|Other|Body composition|Body composition will be evaluated by dual-energy X-ray absorptiometry.
45649966|NCT05304325|Other|Resting metabolic rate|Resting metabolic rate will be measured by indirect calorimetry.
45649967|NCT05304325|Other|Food intake|Food intake, energy intake and food quality will be evaluated using the food frequence questionnaire.
45649968|NCT05304325|Procedure|Adipose tissue biopsy|A sample of 3-5g of adipose tissue will be collected under local anesthesia by needle aspiration in the periumbilical region.
45926183|NCT00078988|Biological|filgrastim|Given IV
45926184|NCT00078988|Drug|carboplatin|Given IV
45926185|NCT00078988|Drug|etoposide|Given IV
45926186|NCT00078988|Drug|isotretinoin|Given IV
45926187|NCT00078988|Drug|thiotepa|Given IV
45926188|NCT00078988|Procedure|autologous bone marrow transplantation|Peripheral blood stem cells or bone marrow will be reinfused about 72 hours following completion of the last dose of chemotherapy (Day 0)
45926189|NCT00078988|Procedure|peripheral blood stem cell transplantation|Filgrastim is to be given daily in the afternoon for 4 days prior to the first harvest and continued until the completion of the daily harvests. The daily PBSC harvesting should be started prior to the fifth dose of filgrastim.
45926190|NCT00079027|Drug|doxorubicin hydrochloride|
45926191|NCT00079027|Procedure|hepatic artery embolization|
45926192|NCT03655002|Drug|Cyclophosphamide|Given IV
45926193|NCT03655002|Biological|Cytokine-based Biologic Agent IRX-2|Given SC
45926194|NCT03655002|Biological|Nivolumab|Given IV
45926195|NCT04478708|Biological|AMG 133|Participants will receive AMG 133 as a single dose in Part A and multiple doses in Part B and C.
45926196|NCT04478708|Drug|Placebo|Participants will receive placebo as a single dose in Part A and multiple doses in Part B.
45926197|NCT00079105|Biological|bleomycin sulfate|Treatment
45926198|NCT00079105|Drug|cyclophosphamide|Treatment
45926199|NCT00079105|Drug|etoposide|Treatment
45450626|NCT02188342|Behavioral|HIT|12 HIT exercise sessions in 31 days on a stationary cycle ergometer
45450627|NCT02188420|Device|Transcranial Magnetic Stimulation (Magstim)|
45450628|NCT02752048|Drug|TAS-205|2 groups: Low dose group, High dose group. Oral administration for 24 weeks, bis in die (BID) after meal
45450629|NCT02752048|Drug|Placebo|1 group: Placebo group. Oral administration for 24 weeks, BID after meal
45450630|NCT02188498|Procedure|Polysomnography|Polysomnography, also called a sleep study, is a test used to diagnose sleep disorders. Polysomnography records your brain waves, the oxygen level in your blood, heart rate and breathing, as well as eye and leg movements during the study.
45450631|NCT02188654|Drug|Metformin|500mg/day retarded formulation of metformin
45450632|NCT02188654|Drug|Placebo|500 mg/day of placebo tablets
45450633|NCT02192944|Drug|Chloroquine|Chloroquine base 600 mg single dose. To monitor ECG 12 lead at 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
45798334|NCT01352117|Drug|etoposide|50 mg taken orally daily from days 1-7 of each 2-week cycle. For participants without PR or CR after two cycles of therapy and no toxicity greater than Grade 2, the dose of ET was escalated to 100 mg/day orally, days 1-7, every 2 weeks. A cycle could be delayed for a maximum of 14 days. ET could not be initiated prior to 7 days after the last dose in previous cycle. ET could be administered up to a maximum of eight cycles (2 cycles during dose titration and 6 cycles at maximum dose). Participants who could not tolerate escalation of the ET dose to 100 mg/day were treated for a maximum of six cycles.
45450634|NCT02192944|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine 120/960 mg single dose To monitor ECG 12 lead at: 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
45450635|NCT02193022|Drug|Miltefosine|
45798335|NCT03379207|Other|Blood samples|Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose
45798336|NCT03379207|Other|Tracheal Aspirates|Only for mechanically ventilated participants.
45798337|NCT03379207|Other|Surplus of Broncho-alveolar lavage fluid|Only if performed for diagnosis purpose by the treating investigator : indication left at his discretion
45798338|NCT03377569|Other|Sleep, PD and DBS|Sleep, PD and DBS
45798339|NCT02987426|Behavioral|Mindfulness-oriented intervention|"The 10 minutes daily sessions every weekday, will take place at the inpatient unit in groups of 10 people. The intervention will be alternating between three forms of moving mindfulness-oriented interventions as detailed below:~Seated Tai Chi: patients will slowly move their arms in soft movements coordinated with slow breaths Gentle stretching: patients will slowly stretch their bodies coordinated with the breath and with awareness of physical sensations throughout the body4 Walking meditation: patients will walk slowly in no particular direction, focusing close attention on the act of walking"
45798340|NCT05309018|Other|Interviews|Semi-structured interview about perceptions and expectations of APN participation in AML monitoring according to patient and to care team.
45798341|NCT02974673|Procedure|Ejaculatory test|Measures of sphincter pressures during ejaculation will be registered using a sensor introduced in the urethra on patient with spinal cord injury.
45798342|NCT02974439|Drug|LANDI-Amlodipine Besylate Tablet 5mg|LANDI-Amlodipine Besylate Tablet 5mg is a generic product manufactured by YangTZE River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.
45798343|NCT02974439|Drug|Norvasc Tablets 5mg|Norvasc Tablet 5mg will be used as a comparator drug for the BE study.
45798344|NCT05275712|Other|Audiological evaluation|Questionnaire for parents about their children behavior after implantation, audiological evaluation and speech perception test .
45798345|NCT02974517|Device|EmbryoScope®|The intervention is EmbryoScope® versus conventional incubators.
45798346|NCT05736614|Behavioral|Stage 1 Strength Based Case Management (SBCM) Condition|Intervention participants will receive a trained SBCM to motivate, support, and assist in linkage to PrEP prescribers to help facilitate obtaining PrEP medication to initiate treatment.
45798347|NCT05736614|Behavioral|Stage 2 PrEPare for Work Intervention Condition|Intervention participants will receive 1-on-1 adherence counseling and personalized daily text messaging reminders to increase PrEP adherence. Intervention participants will undergo three adherence intervention sessions (once per week for 3 weeks) with interventionist.
45798348|NCT03340727|Drug|Caffeine Citrate|The study intervention is caffeine citrate given once daily at 10 mg/kg/day. It is given orally, before hospital discharge and 28 days after discharge.
45798349|NCT03340727|Drug|Placebo|The study intervention is placebo given once daily at a volume equivalent to 10 mg/kg of caffeine citrate. It is given orally, before hospital discharge and 28 days after discharge.
45798350|NCT04612179|Device|The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system|"Investigational device: SUPRAFLEX CRUZ™ Sirolimus eluting Coronary Stent System The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system consists of a balloon ex-pandable Sirolimus eluting stent, premounted on a stent delivery system. The active pharmaceutical ingredient in the SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent is Sirolimus (also known as Rapamycin).~The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system is indicated for improving coronary luminal diameter in patients with symptomatic Ischemic heart disease due to discrete de-novo stenotic lesions and in-stent restenotic lesions in native coronary arter-ies with a reference vessel diameter of 2.00 mm to 4.50 mm."
45798351|NCT05578820|Biological|Intratumoral administration of Stimotimagene copolymerplasmid|Intratumoral administration of gene therapy drug Stimotimagene copolymerplasmid
45798352|NCT05578820|Drug|Intravenous administration of Ganciclovir (Cymeven®)|Intravenous administration of prodrug Ganciclovir (Cymeven®)
45798353|NCT04843995|Procedure|Mid-urethral sling|Treatment of stress urinary incontinence with retropubic mid-urethral sling
45926200|NCT00079105|Drug|mitoxantrone hydrochloride|Treatment
45926201|NCT00079105|Drug|prednisolone|Treatment
45926202|NCT00079105|Drug|procarbazine hydrochloride|Treatment
45926203|NCT00079105|Drug|vinblastine sulfate|Treatment
45926204|NCT03647124|Drug|Lenalidomide|Specified dose on specified days
45926205|NCT00079144|Biological|NY-ESO-1 peptide vaccine|
45926206|NCT00079144|Biological|aldesleukin|
45926207|NCT00079144|Biological|filgrastim|
45926208|NCT00079144|Biological|incomplete Freund's adjuvant|
45926209|NCT00079144|Biological|therapeutic autologous lymphocytes|
45926210|NCT00079144|Drug|cyclophosphamide|
45450636|NCT02188732|Behavioral|CBHH+AT|"Community Based Health Home + Automated Telehealth (CBHH+AT):~Community-Based Health Home (CBHH) PLUS Automated Telehealth: a wireless telehealth device programmed with psychiatric content corresponding to the primary psychiatric diagnosis, and medical content tailored to the primary medical diagnosis. Daily interactive sessions last 5-10 min. Branching logic tailors questions or feedback to the user's responses (e.g., if a participant endorses medication nonadherence, a question appears asking why medications were not taken). The device automatically provides specific instructions to participants demonstrating signs of high risk."
45450637|NCT02188732|Behavioral|CBHH+SMT|Illness Management and Recovery (IMR) for psychiatric illness combines (1) psychoeducation, which improves knowledge about mental illness management, (2) behavioral tailoring, which improves medication adherence, (3) relapse prevention training, which decreases relapses and rehospitalizations, and (4) coping skills training, which reduces distress related to symptoms. Illness Management and Recovery (I-IMR) by adding chronic medical illness self-management to psychiatric illness self-management. For each psychiatric self-management skill module, there is a corresponding medical illness self-management training component using established methods in self-management of common chronic health conditions (e.g., diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease, etc.).
45926211|NCT00079144|Drug|fludarabine phosphate|
45926212|NCT00079222|Drug|itraconazole|
45926213|NCT00079222|Drug|voriconazole|
45450638|NCT02188732|Behavioral|CBHH|Community-based Health Home (CBHH): Each team has a staff-to-participant ratio of approximately 1:12, with each team serving approximately 120 participants with SMI using person-centered planning and recovery-oriented, flexible service models. Each team provides mobile outreach and includes a team leader; a peer counselor; a psychiatric nurse coordinator; a clinical care coordinator; specialists in substance abuse (dual diagnosis), community integration, rehabilitation, employment, and housing; and a medical nurse practitioner (MNP) and a health outreach worker (HOW).
45450639|NCT02188810|Biological|PAL|Single dose administered intramuscularly.
45926214|NCT00079261|Drug|CHOP regimen|
45926215|NCT00079261|Drug|cyclophosphamide|
45926216|NCT00079261|Drug|doxorubicin hydrochloride|
45926217|NCT00079261|Drug|gemcitabine hydrochloride|
45926218|NCT00079261|Drug|prednisone|
45926219|NCT00079261|Drug|vincristine sulfate|
45926220|NCT00423787|Biological|Ragweed MATA MPL|"4 injections of increasing dose strength:~300 SU/0.5 ml~700 SU/0.5 ml~2000 SU/0.5 ml~6000 SU/0.5 ml"
46072084|NCT05663658|Other|External oblique intercostal plane block|External oblique intercostal plane block will be administered before the surgery.
46072085|NCT05660135|Drug|Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca|Olomax Tab 20/5/5mg Olomax Tab 20/5/10mg Olomax Tab 40/5/10 mg
45450640|NCT02188810|Biological|TIV|Single dose administered intramuscularly .
45450641|NCT02188888|Drug|esmolol|Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm
45450642|NCT02188966|Device|Geographic Information System|"GIS data is delivered by SimaTech Enterprise System communicating via the mobile network and TETRA (in Denmark called SINE). It is developed as a Java Enterprise application and is executed on a JBOSS application platform"
45450643|NCT02194036|Behavioral|Learning Oriented Physiotherapy|Clinical practice based on a new understanding of the neurobiological basis for the interaction between body and mind, the foundation of learning and what is needed to bring about change of behavior.
45450644|NCT02194036|Behavioral|Widely Recognized Psychiatric Treatment|Standard recognized psychiatric treatment tailored to individual needs.
45649969|NCT05304169|Drug|Leuprorelin Acetate (Eligard® 45 mg).|Semiannually Leuprorelin Acetate (Eligard® 45 mg).
45649970|NCT04867031|Dietary Supplement|Milk|One portion of semi-skimmed cow's milk (approx. 450mL), providing ~140µg of iodine.
45649971|NCT04867031|Dietary Supplement|Fish|One portion of cod (approx. 130g), providing ~140µg of iodine.
45926221|NCT04467827|Diagnostic Test|examining group|Posture assessment in young healthy people depending on their level of physical activity
45926222|NCT00079300|Drug|imiquimod|
45926223|NCT00079300|Procedure|conventional surgery|
45926224|NCT00079378|Drug|decitabine|Given IV
45926225|NCT00079378|Drug|valproic acid|Given orally
45926226|NCT00079378|Other|pharmacological study|Correlative studies
45926227|NCT00079378|Other|laboratory biomarker analysis|Correlative studies
45926228|NCT00079456|Drug|temsirolimus|Given IV
45926229|NCT00079456|Other|pharmacological study|Correlative studies
45926230|NCT00079456|Other|laboratory biomarker analysis|Correlative studies
45926231|NCT04467086|Drug|Propranolol Hydrochloride|"Propranolol enterally at a starting dose of 20mg every 6h for 2-4 doses, and then re-assessed for upwards titration every 24 hours (+/- 6 hours) at 10mg dose increases depending on clinical response. Maximum dose of 60mg every 6h. Titration decision to be made by clinical team at daily rounds.~Daily titration will be guided by hemodynamic markers indicative of the expected sympatholysis from propranolol. Upward titration of propranolol should coincide with a downward titration in sedatives until a minimum level of sedative infusion is reached (propofol <0.5mg/kg/h or midazolam <1.0mg/h). Nurses will be instructed at each assessment to determine if sedative targets can be achieved with lower doses of sedatives. Daily upward titration of propranolol will be recommended if none of these conditions are met: (1)HR<70 beats/min, (2) Mean Arterial Pressure <70 mmHg or (3) norepinephrine or equivalent vasopressor dose increase to >0.15 mcg/kg/min."
45926232|NCT00079495|Drug|NBI-5788|
45926233|NCT00079534|Behavioral|Non-local/distant healing or prayer|
45926234|NCT03528681|Drug|Sodium Zirconium Cyclosilicate 5g|Suspension administered Sodium Zirconium Cyclosilicate 5g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
46072086|NCT05653713|Drug|CSL324|Single intravenous (IV) dose of CSL324
46072087|NCT05653713|Drug|Placebo|IV dose of 0.9% saline
46072088|NCT05652868|Drug|MYTX-011|MYTX-011 will be administered as an intravenous infusion every 21 days for up to two years.
46072089|NCT05651919|Biological|Blood test|During the routine blood test of the patient, 4 more tubes of 4 milliliters (mL) will be collected to make a biological collection of PBMC and plasma for further analysis.
45597893|NCT02205203|Other|Treatment as Usual|In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure).
45597894|NCT04155385|Other|Measurement|The measurement system collects information about patients' treatment progress and goals in key areas that are associated with long-term clinical outcomes (e.g., substance use, craving, coping skills, self-efficacy, life satisfaction, depression). Patients complete the measure up to once per week for up to six months.
45798354|NCT05736458|Device|Transcranial Magnetic Stimulation (TMS)|Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication.
45798355|NCT05736458|Procedure|High controllability TMS target|Administer TMS to a brain regions with high regional controllability while the subject engages in a working memory task.
45649972|NCT04867031|Dietary Supplement|Seaweed|One portion of dried seaweed sheets (approx. 6g), providing ~140µg of iodine.
45649973|NCT03045107|Procedure|Laparoscopic right colectomy with intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The antimesenteric side of the stapled ends of the transverse colon and terminal ileum are approximated by a stay suture tied intracorporeally and then held by the assistant. An antimesenteric enterotomy and an antimesenteric colotomy are made about 10 cm distal to the stapled ends of the transverse colon and terminal ileum, respectively. A side-to-side anastomosis is fashioned with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The enterotomies are then closed by two layers of reabsorbable sutures tied intracorporeally. The specimen is delivered through a small Pfannenstiel or a median incision. A big dressing covering all incisions will be applied, similar to that used for the EIA group.
45798356|NCT01707043|Drug|Taclonex|Subjects will be evaluated at baseline, Day 3 and Day 6 (or end of study).
45798357|NCT05736380|Device|Cerebellar rTMS|250 pulses at 10 Hertz over the cerebellum
45798358|NCT05736380|Device|Sham cerebellar rTMS|Sham cerebellar rTMS
45798359|NCT03294499|Other|Questionnaire|Patients will be asked to complete one off questionnaire.
45798360|NCT04350164|Drug|Romiplostim|romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.
45798361|NCT04609137|Procedure|Early drain removal|"Patients randomized to the experimental group, will have an early drain removal if DFA on POD1 is lower than 2000 U/L and/or the drain fluid does not appear sinister (i.e. varying from dark brown to greenish fluid to milky water to clear spring water pancreatic juice like appearance) according to the clinical team. If DFA is greater than 2000 U/L, the drain will be maintained in place. If the sample on POD1 DFA is not available (e.g. drainage fluid is viscous and amylase value cannot be evaluated) or the sample could not be analyzed DFA will be evaluated on POD2, and drain removal will be considered if DFA is lower than 2000 U/L. If DFA on POD 3 is lower than 300 U/L, that is 3-fold the upper limit of normal serum amylase value, and/or the drain fluid does not appear sinister according to the clinical team, the drain will be removed. Otherwise, the drain will be kept in place and the patient will then follow standard postoperative drain management."
45798362|NCT04609137|Procedure|Standard drain removal|"Patients randomized to this group will receive the current standard of care, thus the drain will be maintained at least until postoperative day 5. If DFA on POD 5 is lower than 3-fold the upper limit of normal serum amylase value, and/or the drain fluid does not appear sinister (i.e. varying from dark brown to greenish fluid to milky water to clear spring water pancreatic juice like appearance) according to the clinical team, the drain will be removed. If the drain is maintained in place beyond POD 5, it will be removed inhospital or after discharge when the daily amount is lower than 10 ml and there are no signs of ongoing infection"
45798363|NCT01708213|Device|Aline HA|Implantable dermal filler
45798364|NCT04768088|Other|Falling Training|For the falling training, participants will be instructed to initially land softly with increased knee and hip flexion and then smoothly fall to the direction of the movement while transferring the weight from the feet to the hands and subsequently to the lateral trunk and hip. The training program includes three one-hour training sessions over a week with one or two days between two sessions. Each training session will begin with a warm-up protocol. Participants will progressively increase the task difficulty and decrease the thickness of the mat. For each training session, participants will perform a minimum of one successful practice trial for each task difficulty and each landing direction on the thicker mat and then complete a minimum of three successful practice trials for each task difficulty and landing direction on the thinner mat. The last training session involves falling on a 0.5-inch mat, which is the same as the surface for the post-training and retention assessments.
45798365|NCT05314855|Device|functional MRI|Subjects will undergo functional MRI at 4 time points in 24 hours.
45798366|NCT04265625|Device|endoscopic guidance|Percutaneous tracheotomy performed by endoscopic guidance
45798367|NCT04258839|Drug|Brexpiprazole|Oral tablet; taken once daily
45798368|NCT01708525|Device|Ulthera® System Treatment|Focused ultrasound energy delivered below the surface of the skin
45798369|NCT01708525|Other|Heavy Water|A tissue labeling model via the consumption of the stable isotope, deuterated water (heavy water). Heavy water consumed over the course of the 6-week study period for a direct kinetic measure of in vivo collagen synthesis. 60 ml (about 12 teaspoons) of heavy water (also called deuterated water or 2H2O), was consumed three times a day for the first five days. Starting on Day 6, two 60 ml doses of heavy water were consumed per day for the remaining 37 days.
45597895|NCT04155385|Other|Feedback|The feedback system is a web-based dashboard that displays current and historical results in each of the outcome and goal domains that is measured; it is available to addiction treatment clinicians who are working with patients enrolled in the study.
45926235|NCT03528681|Drug|Sodium Zirconium Cyclosilicate 10g|Suspension administered Sodium Zirconium Cyclosilicate 10g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
45798370|NCT05244512|Other|Evidence-based leadership training|7-modules online training over six months mentored by tutors. Independent familiarisation of reading material, peer-group discussions, self-reflection, assignments, tutor's feedback.
45798371|NCT05244512|Other|Conventional training|7-modules online training over six months. Independent reading only.
45798372|NCT04258137|Genetic|Liquid biopsy|Liquid biopsy will be performed at cycle 1 day 1 and cycle 2 day of each line of systemic treatment, at each tumor evaluation by Imaging and at confirmation of progression
45798373|NCT04257747|Other|MRI acquisitions|MRI acquisitions will be performed on the ACHIEVA 3T TX DStream Philips® Research MRI of the GIE Faire Faces.
45798374|NCT04257747|Other|Doppler ultrasound procedure|The Doppler ultrasound procedure will be conducted in the traditional way in the Vascular Medicine Department of the Amiens-Picardie University Hospital
45649974|NCT03045107|Procedure|Laparoscopic right colectomy with extracorporeal ileocolic anastomosis (EIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. A primary ileocolic side-to-side handsewn or mechanical (with GIA stapler - Covidien Medtronic) anastomosis is fashioned and the bowel returned to the abdominal cavity. After reinduction of pneumoperitoneum, the lack of twists of the ileocolic anastomosis is checked. A big dressing covering all incisions will be applied.
45926236|NCT03528681|Drug|Placebo|Suspension administered orally placebo once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
45798375|NCT03029312|Device|Galileo M|Motorized board producing side-to-side alternating vertical sinusoidal (rotational) vibrations around a fulcrum in the mid-section of the plate. The vibration frequency can be selected by the user who stands on the board with both feet, wearing shoes. The peak-to-peak displacement to which the feet are exposed increases with the distance of the feet from the centre line of the vibrating board. Three positions marked 1, 2 and 3 are indicated on the vibrating board, corresponding to peak-to-peak displacements of 2, 4, and 6mm. The peak acceleration exerted by vibration exercise increases with higher frequencies and higher amplitudes.
45926237|NCT00079573|Behavioral|Atkins diet (extremely low carbohydrate)|
45926238|NCT00079573|Behavioral|Zone diet (low carbohydrate, high protein)|
45926239|NCT00079573|Behavioral|Ornish diet (very low fat)|
45926240|NCT04466228|Device|non-invasive transcranial electrical stimulation|Non-invasive transcranial electrical stimulation across the prefrontal cortex.
45926241|NCT00079612|Drug|Sorafenib (Nexavar, BAY43-9006)|800mg daily (2x 400mg tabs)
45926242|NCT00079612|Drug|Placebo|2x 400mg tabs daily
45926243|NCT00079651|Behavioral|Montessori-based dementia programming|
45798376|NCT03634917|Drug|Acamprosate Calcium|1 capsule with 666 mg Acamprosate
45798377|NCT03634917|Drug|Calcium Carbonate|1 capsule with 1500 mg Calcium Carbonate
45798378|NCT03634917|Drug|Placebo|1 Capsule with Placebo (lactose monohydrate, micro crystalline cellulose, magnesium stearate)
45798379|NCT03634917|Drug|Placebo lead in|1 Capsule with Placebo (lactose monohydrate, micro crystalline cellulose, magnesium stearate)
45798380|NCT05058872|Drug|Levonorgestrel/ethinyl estradiol|Levonorgestrel 0.15mg/ethinyl estradiol 0.03mg
45926244|NCT03526107|Other|CF Control|CF Control: 587 mg of cocoa flavanols, <1 mg caffeine and <1 mg theobromine
45926245|NCT03526107|Other|CF-Theobromine|CF-Theobromine: 575 mg of cocoa flavanols, 11 mg caffeine and 93 mg theobromine
45926246|NCT03526107|Other|CF-Caffeine|CF-Caffeine: 587 mg of cocoa flavanols, 112 mg caffeine and <1 mg theobromine
45926247|NCT04451720|Drug|Risankizumab|Subcutaneous (SC) injection
45926248|NCT04451720|Drug|Placebo|Subcutaneous (SC) injection
45926249|NCT00079768|Drug|Alemtuzumab (Campath)|
45926250|NCT00079807|Drug|Alpha-Lipoic Acid|
45926251|NCT00079846|Drug|Implitapide|
45926252|NCT00392847|Behavioral|Promoting Parental Skills and Enhancing Attachment|The first group will receive routine follow-up as currently provided by national community health and social services.
45926253|NCT00392847|Behavioral|had home visits by community workers during pregnancy|had home visits by community workers during pregnancy to the child's second birthday.
45926254|NCT00079885|Drug|tigecycline|
45926255|NCT00079924|Drug|teriparatide|
45926256|NCT00079924|Drug|aldrenodate|
45926257|NCT00079924|Drug|raloxifene|
45926258|NCT00079963|Dietary Supplement|Vitamin C|1000 mg/day
45926259|NCT00079963|Dietary Supplement|Vitamin E|800 IU/day
45926260|NCT00079963|Dietary Supplement|Placebo|
45926261|NCT04450901|Drug|YBL-006|Route of Administration: IV infusion; 0.5 mg/kg Q2W
45926262|NCT04450901|Drug|YBL-006|Route of Administration: IV infusion; 2 mg/kg Q2W
45926263|NCT04450901|Drug|YBL-006|Route of Administration: IV infusion; 5 mg/kg Q2W
45926264|NCT04450901|Drug|YBL-006|Route of Administration: IV infusion; 10 mg/kg Q2W
45926265|NCT04450901|Drug|YBL-006|Route of administration : IV infusion, 200 mg Q2W
45926266|NCT04450901|Drug|YBL-006|Route of administration : IV infusion, 300 mg Q3W
45926267|NCT04450901|Drug|YBL-006|Route of administration : IV infusion, 300 mg Q2W
45798381|NCT05058872|Drug|Placebo|Placebo comparator
45798382|NCT03623763|Diagnostic Test|Serologic tests of blood samples|Five milliliters of peripheral venous blood will be (after 8-12 hours of fasting) from each participant and will be collected into Human Tube Serum Gel - C/A for ELISA. All blood samples will be collected in August and January. Serum levels of 25(OH) VD and TNF-α, IFN-γ, IL-4 and IL-6 will be detected by ELISA technique
45798383|NCT05056922|Behavioral|Tele-PCIT|"Families randomized to Tele-PCIT will receive a time-limited version of PCIT via telehealth. The first 5 sessions focus on the child directed interaction (CDI) phase. The first session includes a teaching session where the parent will learn PRIDE/Do skills and Don't skills. The next 4 CDI sessions include coaching where the therapist coaches the parent on the these skills within the context of play. The first PDI session includes a teaching session where parents will be given instructions for providing commands and timeout procedures. During the 4 PDI coaching sessions, the therapist coaches the parent through timeout procedures. Handouts are emailed to families throughout therapy. The treatment period is 12 weeks to complete the 10 sessions to account for scheduling challenges. Families will be provided a Bluetooth headset for sessions. Families who do not have access to a computer, tablet, or smartphone with internet access will be provided with a tablet for therapy use."
45926268|NCT04450901|Drug|YBL-006|Route of administration : IV infusion, 200mg Q2W
45798384|NCT05056922|Behavioral|Treatment as Usual|Families randomized to Treatment-as-Usual (TAU) will receive brief feedback and psychoeducation during the baseline visit and will be provided with community resources and referrals as needed. The TAU procedures will reflect the level of care families receive after an ASD assessment or professional consultation in our own clinic. For addressing behavioral concerns specifically, families will be provided handouts on behavior management tips, given access to a webinar workshop reviewing basic behavioral parenting principles, and instructed to engage with available services. The Vanderbilt Treatment & Research Institute for ASD (TRIAD) Center offers a webinar series for managing challenging behaviors that parents will be directed to along with the Autism Speaks Challenging Behavior Toolkit handouts. The TAU period will be 12 weeks in length to match time specifications for the active treatment condition.
45798385|NCT03618771|Device|Total knee arthroplasty|Parts of the knee joint diseased by osteoarthritis are replaced by metal and plastic prostheses.
45798386|NCT05054036|Drug|MoviPrep|Split-dose MoviPrep bowel preparation
45597896|NCT02208947|Behavioral|Consumer financial incentive|Immediate financial reward upon completing self-directed ACP (e.g., completing the web-based educational modules on PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).
45597897|NCT02208947|Behavioral|PREPARE|"PREPARE for your care is 5-step on-line ACP process developed specifically for low-literacy Medi-Cal populations. PREPARE can be navigated as interactive, self-directed modules or played like a movie, at a time or a place of the subject's own choosing (e.g., home, work, public library)."
45597898|NCT03544567|Drug|Oraxol|oral paclitaxel will be supplied in capsules and oral HM30181A-US in tablets
45798387|NCT05054036|Drug|Golytely|Split-dose GoLYTELY bowel preparation
45798388|NCT04595565|Drug|Capecitabine|2000 mg/m² day 1-14 q21 day cycle for eight cycles
45798389|NCT04595565|Drug|Carboplatin|AUC 5 q3w or AUC 1.5 weekly for eight 3 weekly cycles
45798390|NCT04595565|Drug|Cisplatin|25mg/m3 weekly or 75 mg/m3 q3w
45798391|NCT04595565|Drug|Sacituzumab govitecan|10 mg/kg body weight on days 1, 8 q3w
45798392|NCT05049824|Device|Self Forming Magnetic (SFM) Anastomosis System|The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact metabolic disease indicators
45798393|NCT03028844|Other|Music therapy|The musical intervention will be played for ten minutes prior to venepuncture
45798394|NCT02284880|Drug|BIA 2-093|MF - Marketed formulation
45798395|NCT02284880|Drug|BIA 2-093|TBM - to-be-marketed
45926269|NCT00399646|Device|Metricath Gemini System|
45926270|NCT00392886|Drug|carboplatin|Given IV
45926271|NCT00392886|Drug|cisplatin|Given IV
45926272|NCT00392886|Drug|cyclophosphamide|Given IV
45926273|NCT00392886|Drug|etoposide|Given IV and orally
45926274|NCT00392886|Drug|methotrexate|Given IV
45926275|NCT00392886|Drug|temozolomide|Given orally
45926276|NCT00392886|Drug|thiotepa|Given IV
45597899|NCT02209025|Dietary Supplement|Theobromine|Theobromine a compound for cocoa
45597900|NCT02209025|Dietary Supplement|Placebo drink|
45597901|NCT03526471|Device|Omega™ Left Atrial Appendage (LAA) Occluder|catheter delivery of Omega device in the left atrial appendage
45926277|NCT00392886|Drug|vincristine sulfate|Given IV
45926278|NCT00392886|Procedure|autologous bone marrow transplantation|Given on day 0
45926279|NCT00392886|Procedure|autologous hematopoietic stem cell transplantation|Given on day 0
45798396|NCT04560621|Behavioral|Managed Problem Solving (MAPS)|MAPS is an individual-level, problem-solving intervention delivered in person and via telephone calls to HIV clinic patients. The intervention focuses on improving medication adherence through an iterative, five-step process which consists of 1) identifying barriers to adherence, 2) brainstorming to generate potential solutions, 3) decision-making and developing a plan of action, 4) implementing the plan, and 5) evaluating and modifying the plan as necessary. In-person sessions include education related to the treatment regimen and to common medication misperceptions; problem-solving to identify daily routines, cues, cognitive aids and social supports; screening to identify barriers related to depression, substance use, toxicity management and competing demands; and review of adherence data to determine where problems have occurred and to develop solutions.
46072090|NCT05651919|Behavioral|quality of life Questionnaire|"During the routine medical visit, the patient will be asked to fill in a short questionnaire about quality of life.~This is a descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. This decision results into a 1-digit number that expresses the level selected for that dimension. Each patient's health state is referred to in terms of a 5-digit code;~Levels of perceived problems are coded as follows:~Level 1 is coded as a '1' (indicating no problem)~Level 2 is coded as a '2' (indicating some problems)~Level 3 is coded as a '3' (indicating extreme problems) For example, state 11223 indicates no problems with mobility and self-care, no problems with performing usual activities, moderate pain or discomfort and extreme anxiety or depression, while state 11111 indicates no problems."
46072091|NCT05651581|Other|Online module|online module including around 5 videos and several infographics covering the topics of symptoms transmission, prevention, vaccination, and treatment of the monkeypox virus.
45798397|NCT03538899|Drug|AProArt|Participants will undergo infusion with autologous hematopoietic cells transduced with a lentiviral vector, AProArt, which contains the correct form of DCLRE1C complementary deoxyribonucleic acid DNA, after receiving sub-ablative, exposure-targeted busulfan conditioning.
45597902|NCT03524755|Other|Exercise|
45597903|NCT02209103|Dietary Supplement|Lozenge containing citrus flavonoid|
45597904|NCT02209103|Dietary Supplement|Lozenge containing citrus flavonoid formulation|
45597905|NCT02209103|Dietary Supplement|Identical looking placebo|
45597906|NCT03956095|Dietary Supplement|Ensure Surgery Immunonutrition Shake supplements|Three Ensure Surgery Immunonutrition Shake supplements per day for seven days prior to their scheduled procedure.
45798398|NCT03538899|Device|CliniMACS® CD34 Reagent System cell sorter device|Processing of hematopoietic progenitor cells to select CD34 cells, using the CliniMACS® CD34 Reagent System, prior to infusion.
45798399|NCT03538899|Drug|Busulfan|Busulfan is a cell cycle non-specific alkylating antineoplastic agent, in the class of alkyl sulfonates. Patients will receive low-dose busulfan conditioning targeted over 2 days to achieve a cumulative area under the curve (AUC) of 20 mg*hr/L.
45597907|NCT03956095|Other|Daily Food Intake form|On the day of surgery, the patient will return her Daily Supplement/Food Intake Forms and complete the Day of Surgery Intake Form can also be completed the day before surgery and the Daily Supplement/Food Intake Forms can be returned at the patient's postoperative appointment.
45649975|NCT05304091|Other|Questionnaire on a smartphone application|Each day, the smartphone application will ask the patient if he or she is having an angioedema attack. It not, the questionnaire will stop. If the patient is having an attack, a series of 5 short questions is asked about the attack characteristics and the events that preceded it.
45649976|NCT04865081|Device|VACCIN box|The VACCIN box is a translucid box that can be placed over the patient's head. It has entry holes on the front and the side of the box in which nitrile gloves can be attached. The anesthesiologist can intubate with arms and hands inside the box. Its also has the capacity to create a negative pressure environment inside the box by connecting an air suction cable from the box to the OR medical aspiration line.
45649977|NCT04865003|Other|treatment of infection|
45649978|NCT04730011|Behavioral|Short and Intensive Treatment|Intensive Treatment Week with behavioural psychotherapy
45649979|NCT04864769|Dietary Supplement|Krill protein hydrolysate|Ingestion of 35 g Krill protein hydrolysate
45649980|NCT04864769|Dietary Supplement|Soy protein isolate|Ingestion of 35 g Soy protein isolate
45649981|NCT04864769|Dietary Supplement|Whey protein isolate|Ingestion of 35 g Whey protein isolate
45649982|NCT04864769|Dietary Supplement|Water|Ingestion of water (control)
45798400|NCT04238715|Drug|E7090|E7090 tablets orally.
45926280|NCT00392886|Procedure|peripheral blood stem cell transplantation|Given on day 0
45597908|NCT02205281|Behavioral|Lifestyle Intervention|The intervention is a multi-component program designed to prevent excessive gestational weight gain in overweight and obese women and to promote weight loss in their non-pregnant overweight and obese partners through modifications of diet, exercise, and behavioral strategies during pregnancy.
45597909|NCT03524677|Diagnostic Test|Liquid Biopsy|K-RAS, CDKN2A, SMAD4 and TP53 mutation on circulating cfDNA
45798401|NCT04230681|Drug|Hydromorphone|Patients will be randomized to one of two opioids for the treatment of post-operative pain.
45926281|NCT00392886|Radiation|radiation therapy|Some patients undergo radiation therapy once daily, 5 days a week for 4-6 weeks.
45926282|NCT00080002|Drug|Pegamotecan|
45926283|NCT00080041|Drug|Motexafin Gadolinium Injection|
45926284|NCT00080080|Drug|talabostat (PT-100) tablets|
45926285|NCT00080080|Drug|Docetaxel|
45926286|NCT04437368|Drug|GT005; Low Dose|The study will test two doses of GT005: Low Dose and High Dose.
45926287|NCT04437368|Drug|GT005; High Dose|The study will test two doses of GT005: Low Dose and High Dose.
45926288|NCT00080158|Drug|fluoxetine|
45798402|NCT04230681|Drug|Fentanyl|Fentanyl
45926289|NCT00080158|Drug|sertraline|
45926290|NCT00080158|Drug|citalopram|
45798403|NCT04538625|Drug|Crofelemer 125 MG [Mytesi]|Randomized, Double-blind, Placebo-controlled, two arm trial
45926291|NCT00080158|Drug|escitalopram|
45926292|NCT00080158|Drug|bupropion|
45926293|NCT00080158|Drug|mirtazapine|
45926294|NCT00080158|Drug|venlafaxine|
45926295|NCT00080158|Drug|lithium|
45926296|NCT00080158|Behavioral|Cognitive Behavioral Therapy|
45926297|NCT00080197|Drug|E7070|
45926298|NCT00080236|Drug|IDN-6556|
45926299|NCT00080236|Drug|Placebo|
45926300|NCT00080275|Drug|Niacin Extended-Release and simvastatin Tablets|
45926301|NCT00393003|Device|Closed-loop anesthesia system|
45926302|NCT04436666|Device|motivational video production through virtual reality glasses|Music-funded, park, nature and seaside walks, submarine, museum, with virtual reality glasses (Bobo VR Z4 Binocular Glasses and 5.7 inch 1440x2560 pixel display resolution, China) for 10 minutes to diabetic patients before blood glucose measurement and insulin injection The videos that the patient wants to watch will be watched from videos such as his trip Studies have indicated that these videos are relaxing environments, and motion videos should not be watched to reduce nausea and vomiting.
45926303|NCT04436666|Other|Ice Application|Before the blood glucose measurement and insulin injection, patients with diabetes will be given ice for 5 minutes. It is planned to apply ice cubes in liquid-proof ice bags.
45926304|NCT00080314|Drug|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
45926305|NCT00080314|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
45926306|NCT00080353|Drug|IL-2|
45926307|NCT00080353|Drug|gp100:209-217|
46072092|NCT05647798|Other|Blood sugar check every 2 hours|Blood sugar check every 2 hours
46072093|NCT05647798|Other|Blood sugar check every 4 hours|Blood sugar check every 4 hours
45649983|NCT03042455|Device|Armeo and rTMS|"The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. rTMS is a magnetic method used to stimulate small regions of the brain.~The Robot and rTMS group will receive the robot-assisted upper arm training and rTMS for 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks."
45798404|NCT04538625|Drug|Placebo|Matching placebo tablets
45798405|NCT02324543|Drug|Gemcitabine|IV on days 4 and 11 of a 21 day cycle
45798406|NCT02324543|Drug|Taxotere|IV on days 4 and 11 of a 21 day cycle
45926308|NCT00080353|Drug|OKT3|
45926309|NCT00080353|Drug|rF-go 100P209|
45798407|NCT02324543|Drug|Xeloda|Twice a day orally on days 1 through 14 of a 21 day cycle
45798408|NCT02324543|Drug|Cisplatin|IV on days 4 and 11 of a 21 day cycle
45798409|NCT02324543|Drug|Irinotecan|IV on days 4 and 11 of a 21 day cycle
45798410|NCT01708603|Drug|210 mg brodalumab|210 mg brodalumab administered SC
45926310|NCT00080353|Drug|Montanide ISA 51|
45798411|NCT01708603|Drug|140 mg brodalumab|140 mg brodalumab administered SC
45798412|NCT01708603|Drug|ustekinumab|45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
45798413|NCT01708603|Drug|placebo|Placebo administered SC
45798414|NCT04187391|Device|Active tDCS|Active tDCS anode is applied over the left DLPFC with the cathode over the right supraorbital region.
45926311|NCT00080392|Drug|DNA Plasmid Vector|
45926312|NCT00080392|Drug|EW-A-401 DNA Plasmid Vector|
45926313|NCT04733391|Other|Quality of life questionnaire|"Quality of life will be evaluated using the child version of the VSP-A questionnaire, for patients aged 8-10 years and the adolescent version for those aged 11-17 years."
45926314|NCT04435496|Device|GYN-CS|placement of the GYN-CS device
45926315|NCT00080431|Drug|Daclizumab|
45926316|NCT00080509|Drug|KOS-862|
45926317|NCT03506373|Drug|Ibrutinib|Given PO
45926318|NCT03506373|Drug|Ixazomib Citrate|Given PO
45926319|NCT03506373|Other|Laboratory Biomarker Analysis|Correlative studies
45926320|NCT03506373|Other|Pharmacodynamic Study|Correlative studies
45926321|NCT03506373|Other|Pharmacokinetic Study|Correlative studies
45926322|NCT02972411|Behavioral|Voluntary ventilatory response|Training of the subjects for voluntary increase in the respiratory minute ventilation
45926323|NCT02972411|Drug|Acetazolamide|Acetazolamide 125mg. PO every 12 hours since 24 hours before ascent, until 48 hours at high altitude
45926324|NCT00080626|Biological|pegfilgrastim|6 mg injection on day 1 of each cycle
45926325|NCT00080626|Drug|docetaxel|100 mg per meter-squared, every 14 days for 4 cycles
45926326|NCT00080626|Procedure|conventional surgery|lumpectomy or mastectomy at end of treatment
45926327|NCT00080626|Procedure|neoadjuvant therapy|treatment prior to definitive breast surgery
45926328|NCT00080665|Drug|docetaxel|Docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle
45926329|NCT00080665|Drug|imatinib mesylate|Imatinib mesylate (400-600 mg, oral, once daily) each 28 day cycle
45926330|NCT00080743|Drug|gefitinib|250 mg po once daily
45798415|NCT04187391|Device|Placebo tDCS|Placebo tDCS is applied but the current is turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period.
45798416|NCT04187391|Behavioral|Language training|patients receive language training
45798417|NCT04187391|Behavioral|Unstructured cognitive training|patients receive unstructured cognitive training.
45798418|NCT03523221|Drug|Dexamethasone Oral|use of one dose of Dexamethasone orally.or placebo in addition to regular treatment of anaphylaxis
45926331|NCT00080743|Drug|tamoxifen citrate|20 mg po once daily
45798419|NCT04532541|Other|Monogenic lupus screening|This is an observational study, and there is no intervention. This study intends to obtain the incidence of monogenic lupus in childhood onset SLE through gene test and bioinformatic analysis.
45798420|NCT03329963|Behavioral|Healthy Lifestyle Intervention|Participants in the this group will receive group educational sessions that focus on diet, exercise, and social support once a month throughout the study. The sessions will provide an opportunity for participants to discuss issues related to living with obesity and aging.Participants will also attend regular scheduled clinic visits for assessment of outcomes.
45798421|NCT03329963|Behavioral|Lifestyle Intervention|"The lifestyle modification will be achieved by group behavior therapy sessions designed to have older adults acquire positive weight-control skills/attitudes, and practice weight-maintenance skills.Participants will attend weekly group sessions (10-15 persons), which will last ~75-90 minutes. Visit frequency will be decreased to every 2 wks. from 6 to 12 mos. to prevent treatment fatigue. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.~The exercise sessions are of ~90 min duration (~15 min warm-up of flexibility exercise, followed by ~30 min of aerobic exercise, and after a brief rest period, ~30 min of resistance training, and finally ~15 min balance exercise) conducted three times weekly supervised at our exercise facility for one year. Aerobic exercises consist of treadmill, stationary cycling, and stair climbing."
45798422|NCT03590171|Drug|Bortezomib|Patients randomised to the HR-B arm receive induction, consolidation with the modified ALL R3 protocol. In this arm, patients are randomized to receive Bortezomib together with the ALL R3 protocol during induction. Administration of Bortezomib: 1.3 mg/m2 as intravenous bolus or subcutaneously (SC, at the discretion of the treating physician) on days 1 and 4 of weeks 1 and 3.
45798423|NCT04526535|Diagnostic Test|Lung ultrasound|Lung ultrasound performed with a portable device with an 8 zones protocol within the first 24 hours after and ST-segment elevation acute myocardial infarction
45926332|NCT00080743|Drug|Placebo|One pill po once daily
45798424|NCT05223985|Device|Depth Coagulation Electrode|SEEG and thermocoagulation
45926333|NCT04423367|Drug|bortezomib/dexamethasone|Enrolled patients would receive the combination therapy of bortezomib and dexamethasone.
45926334|NCT00080782|Drug|Celecoxib|Oral celecoxib twice daily in the absence of disease progression.
45926335|NCT00080782|Drug|Doxorubicin Hydrochloride|By vein (IV) over 30 minutes on days 1, 8, 15, and 22
45926336|NCT00080782|Radiation|Strontium chloride Sr 89|IV on day 1
45926337|NCT03444948|Device|EUS-RFA using Habib Tm as a probe|3 EUS-RFA interventions at 1-month interval
45926338|NCT03444948|Procedure|EUS|Standard intervention
46072094|NCT05644834|Other|I'm Fully Empowered for Her (IFE4Her)|IFE4Her consists of 2 key components: 1) An awareness-raising messaging campaign with messages about PrEP that includes posters and Peer Networkers; and 2) access via a mobile medical unit outreach delivery model linking women in public housing to care from the PrEP providers of a university healthcare system and other complementary screening services (i.e., blood pressure, blood glucose monitoring, and HIV testing).
46072095|NCT05635929|Combination Product|Composition comprising olive oil, xylitol and betaine|Topical composition in the form of a gel and in the form of a water dilution as a mouthwash
45597910|NCT02323204|Behavioral|Link for Injured Kids|Psychological First Aid
45597911|NCT02323204|Other|So you've been in an accident|Educational materials
45597912|NCT02220803|Drug|Acetazolamide|Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.
45597913|NCT02220803|Device|nasal Continuous Positive Airway Pressure (nCPAP)|
45597914|NCT02258321|Drug|PPI-668 tablet|
45597915|NCT02258321|Drug|PPI-668 capsule|
45597916|NCT02258399|Behavioral|Exercise|Moderate intensity exercise
45926339|NCT00080860|Genetic|microarray analysis|
45926340|NCT00080860|Other|immunohistochemistry staining method|
45926341|NCT00080860|Procedure|conventional surgery|
46072096|NCT05632354|Drug|open-label GBT021601|open-label GBT021601
45926342|NCT00080860|Procedure|lymphangiography|
45926343|NCT00080860|Procedure|radionuclide imaging|
45926344|NCT00080860|Procedure|sentinel lymph node biopsy|
45926345|NCT00080860|Radiation|technetium Tc 99m sulfur colloid|
45926346|NCT04730089|Device|Electrical impedance tomography|A bolus of 10ml 10% NaCl was injected during a respiratory pause (≥10s) through the central venous catheter.The results of arterial blood gas analysis and the data of EIT were collected before the first prone session (time baseline), the end of prone positioning (time P).
45926347|NCT00080977|Biological|aldesleukin|
45926348|NCT04396925|Other|Point-of care Ultrasonography|GPs using POCUS and how it affects clinical judgement
45926349|NCT00081055|Biological|autologous expanded mesenchymal stem cells OTI-010|
45926350|NCT00081055|Drug|busulfan|
45926351|NCT00081055|Drug|cyclophosphamide|
45926352|NCT00081055|Drug|cyclosporine|
45926353|NCT00081055|Drug|methotrexate|
45926354|NCT00081055|Procedure|peripheral blood stem cell transplantation|
45926355|NCT00081055|Radiation|radiation therapy|
45926356|NCT03437148|Device|Innocor®|Inert gas rebreathing device: Innocor® (Innovision, Odense, Denmark)
46072097|NCT05630716|Device|NICOM|non-invasive monitor capable of measuring cardiac output (CO) and cardiac index (CI), and stroke volume (SV) and stroke volume index (SVI) based on heart rate. The NICOM technology will be implemented by the Rapid Response Team providers (Advanced Practice Providers) and ICU nurses at FSH, most of whom are already trained and familiar with its use.
45798425|NCT04330365|Behavioral|Whole Health Team (WHT) Intervention Arm, Primary Care Group Education (PC-GE) Intervention Arm, Usual Primary Care (UPC) Arm|Participants will be randomly assigned at the individual level to either WHT, PC-GE or Usual Primary Care, stratified by site, sex, and use of prescribed opioids for chronic pain. The follow-up period for the three arms will be 12 months. The primary outcome is change in pain interference. Secondary outcomes include change in pain intensity, functioning, quality of life, changes in use of pain medications, including opioids (if applicable) and changes in nonpharmacological pain self-management activities. After the baseline assessment, masked telephone assessments will be administered to participants at 3, 6, 9, and 12 months.
45798426|NCT03578237|Device|Cryoneurolysis (active)|Mastectomy (subjects 1-18): Myoscience Iovera device: full cryo cycle. Mastectomy (subjects 19-end) and all other procedures: Epimed PainBlocker device: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with an active probe which results in a decrease in temperature
45798427|NCT03578237|Device|Sham cryoneurolysis procedure|"Mastectomy (subjects 1-18): Myoscience Iovera device: simulated full cryo cycle without administering gas to the probe.~Mastectomy (subjects 19-end) and all other procedures: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with a SHAM probe that does not deliver gas to the tip or result in a drop in temperature"
45798428|NCT00362765|Drug|Fenofibrate|160 mg
45798429|NCT00362765|Drug|Metformin|2000 mg
45798430|NCT00362765|Drug|Placebo|Placebo
45450645|NCT02189044|Other|Pilates Exercise|"The training through the Pilates exercises were performed in eleven weeks. Each class consisted of five exercises lasting 40 minutes each lesson.~During the first four weeks exercises performed were: Cat, Coffee Table, Single legcircle, pelvic movements, contraction of the glutes and closure was performed with posterior chain elongation range.~In the next four weeks began a new series of exercises, which are: Bridge, Side Table, Bridge hip roll with legextension, Abdominal - halfhollup, obliques, and ultimately Stretching - Series of William's.~In the last four weeks of training proposed a new series of exercises involving: Beaststroke, Support heel Bridge - hip roll with leg extension, and Hundred Squats with bat on the wall."
45649984|NCT03042455|Device|Armeo|The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. The Robot group will receive the robot-assisted upper arm training for 30 minutes daily 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
45597917|NCT02258399|Dietary Supplement|Breakfast|Breakfast consumption
45798431|NCT03430011|Biological|JCARH125|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JCARH125 administered intravenously (IV).
45597918|NCT02209337|Device|SRS|
45798432|NCT03430011|Biological|JCARH125 + anakinra|Participants will undergo leukapheresis to isolate PBMCs for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by two doses of anakinra administered subcutaneously and one dose of JCARH125 administered IV. Subjects receive anakinra for 5 consecutive days following JCARH125 infusion.
45798433|NCT04342403|Diagnostic Test|Quality of Life|Quality of life instruments including King's Sarcoidosis Questionnaire (KSQ) and Sarcoidosis Assessment Tool (SAT)
45798434|NCT03305783|Procedure|cholecystectomy|elective cholecystectomy performed due to gallstones, cholecystitis or other non-malignant conditions and therefore done regardless of the protocol of this study.
45798435|NCT04174365|Drug|Brexpiprazole|Oral tablet; take once daily
45798436|NCT04174365|Drug|Placebo|No Intervention
45798437|NCT03301883|Drug|Tocilizumab|Tocilizumab will be administered as per the schedule specified in the arm description.
45798438|NCT03301883|Drug|NSAIDs|Participants may receive NSAIDs up to the maximum recommended stable daily dose. Study protocol does not enforce any particular NSAID.
45798439|NCT03301883|Drug|CSs|Participants may receive CSs at a stable dose of 30 milligrams per day (mg/day) or 0.5 milligrams per kilogram per day (mg/kg/day), whichever is less. Study protocol does not enforce any particular CS.
45798440|NCT03301883|Drug|MTX|Participants may receive MTX at a stable dose of less than or equal to (</=) 20 milligrams per square meter (mg/m^2).
45798441|NCT02286518|Drug|TAK-114 10 mg capsule|
45798442|NCT02286518|Drug|TAK-114 matched placebo|
45926357|NCT03437148|Device|Physioflow®|Bioimpedance cardiograph: Physioflow® (Manatec, France)
45926358|NCT00081094|Procedure|18F-Fluorodeoxyglucose-PET (FDG-PET)|
45926359|NCT00081094|Procedure|11Carbon-Acetate-PET|
45926360|NCT00081133|Drug|arsenic trioxide|
45926361|NCT00081133|Drug|imatinib mesylate|
45926362|NCT04343027|Behavioral|Review|Physicians will review patient-reported outcome measurements with their patients during office visits.
45926363|NCT00081172|Radiation|lutetium Lu 177 monoclonal antibody J591|
45926364|NCT03431064|Other|Lung Recruitment Maneuver|Lung Recruitment Maneuver by Anesthesiologist
45649985|NCT03042455|Other|Control group|The conventional group will receive occupational therapy for 30 minutes daily 5 times per week, for 4 weeks instead of Robot or rTMS. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
45649986|NCT04451785|Biological|blood sample|6 tubes of 4 milliliters (ml) maximum (total: 24 ml) will be sampled for the measurements of the different biological markers. In case of the genetic mutation is already known, only 5 tubes will be collected (total: 20 ml).
45649987|NCT04451785|Diagnostic Test|Pulse wave velocity|Non-invasive measurement of pulse wave velocity between the carotid and femoral arteries with piezo-electric sensors.
45649988|NCT03042065|Device|vibrating Mesh nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using vibrating Mesh nebulizer
45649989|NCT03042065|Device|jet nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using jet nebulizer
45649990|NCT04858685|Other|early mobilization|early mobilization was defined, on the basis of the ERAS protocol, as mobilization of a few steps or a few meters from the bed within the first 24 hours after surgery with another person's support/control and/or a walking aid.
45649991|NCT04709107|Other|Quality of life assessment - elective|"Patients will be asked to fill up both VascuQoL-6 and SF-36 questionnaires before the procedure, as well at 30-days and 1-year follow-up visit while they are sitting in the waiting room. To assess reliability and systematic shift and variation between the two assessments, elective patients will be asked to fill the VascuQoL-6 again at the admission to hospital, as well as 1 week after the 30-days follow-up vie an e-mail link for a test-retest assessment. All questionnaires will be administered on a tablet.~During the 30-days follow-up 4 extra questions concerning patient related outcomes and occurrence of major complication will be added to the VascuQoL-6 questionnaire in the App. During every visit (preoperatively, at 30-days and 1-year follow-up) the stage of the lower limb peripheral artery disease will be noted according to the WIfI-Classification."
45798443|NCT03300947|Drug|Psilocybin 100 mcg/kg|"Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms)."
45798444|NCT03300947|Drug|Psilocybin 300 mcg/kg|"Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms)."
45798445|NCT03300947|Drug|Lorazepam 1 mg|A medication used to treat anxiety belonging to a class of drugs known as benzodiazepines, which act on the central nervous system to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).
45798446|NCT02294435|Device|Visceral Manifold and Thoracic Bifurcation|Visceral Manifold and Thoracic Bifurcation Endovascular stent graft system
45798447|NCT02294435|Device|Unitary Manifold|Unitary Manifold Endovascular stent graft system
45798448|NCT05736068|Procedure|Non-surgical treatment|If allocated to non-surgical group, cast optimization in the outpatient clinic may be necessary if the cast from the emergency room is considered insufficient.
45798449|NCT05736068|Procedure|Surgical treatment|Closed reduction with or without fixation
45798450|NCT03543839|Biological|Belimumab|Subjects in this arm will receive 200mg belimumab subcutaneously weekly for 2 years
45798451|NCT03543839|Biological|Belimumab/Placebo|Subjects in this arm will receive weekly subcutaneous injections of 200mg belimumab for 1 year and then placebo subcutaneous injections for 1 year.
45798452|NCT03543839|Other|Placebo|Subjects in this arm will receive weekly subcutaneous injections of placebo for 2 years
45798453|NCT04173507|Drug|Avelumab|Given IV
45798454|NCT04173507|Drug|Talazoparib|Given PO
45798455|NCT04173507|Drug|Talazoparib Tosylate|Given PO
45798456|NCT05735990|Device|Intraocular lens|Aspheric hydrophilic acrylic IOL for implantation into the capsular bag
45798457|NCT05228522|Behavioral|Lifestyle Intervention|16-week family-focused intervention that includes nutrition education, behavioral change skills training, and physical activity.
45798458|NCT02220725|Biological|Andexanet|
45798459|NCT02220725|Other|Placebo|
45798460|NCT05033756|Drug|Pembrolizumab Injection [Keytruda]|The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumor type.
45926365|NCT03431064|Other|Fluid Administration|Administration of IV Fluid by Anesthesiologist
45926366|NCT00081211|Biological|PV701|Given intratumorally
45798461|NCT05033756|Drug|Olaparib Oral Tablet [Lynparza]|All patients will receive olaparib treatment as an addition to pembrolizumab. The dose of olaparib used in this study is 300 mg twice daily (total daily dose of 600 mg) which is the currently approved dose.
45798462|NCT02980484|Procedure|Active|Repetitive transcranial magnetic stimulation (rTMS) will be applied to the left dorsolateral prefrontal cortex (DLPFC) (4000 pulses, 10 Hz, 5-sec trains, 25-sec inter-train interval) followed by the right DLPFC (1000 pulses, 1 Hz frequency, single train). The DLPFC will be identified using individual subject-level resting-state network estimation (Hacker et al, 2013). Each treatment will be completed over the course of 1 hour, and each subject will receive a total of 20 treatments over the course of 20 consecutive weekdays.
45926367|NCT00081250|Dietary Supplement|creatine monohydrate|Given orally
45926368|NCT00081250|Other|placebo|Given orally
45926369|NCT03187080|Procedure|Paravertebral block procedure using either local anesthetic (0.25% bupivacaine) or sterile saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of 0.25% bupivacaine with 2.5 mcg/mL of epinephrine will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
45926370|NCT03187080|Other|Enhanced recovery after breast surgery (ERABS) strategies|"For comparing ERABS strategies to our current standard of care, we will utilize the following perioperative strategies [Arsalani]:~Standardized written information given preoperatively.~Allow clear liquids for up to 2 hours prior to arrival at the surgery center.~Use paravertebral block to augment postoperative pain control.~Standardized multimodal analgesic regimen~Antiemetics~Easily accessible call-in or walk-in postop care/support~The proposed strategies differ from standard of care in the following ways:~PVB is less commonly used in elective surgery.~Patients do not eat or drink after midnight.~There is no standardized preoperative information packet.~Anesthetic/intraoperative analgesic and antiemetic regimen varies between providers."
45926371|NCT03187080|Procedure|Sham paravertebral block using saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of sterile saline will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
45926372|NCT03187080|Drug|Paravertebral block using local anesthetic|Use of local anesthetic (0.25% bupivacaine) that is *NOT* an experimental drug but will be used as part of the paravertebral block to provide local anesthetic. This will not be given to those in the sham block groups.
45926373|NCT00081367|Behavioral|CBT|Participants will receive ten weekly sessions of treatment. Suicidal thoughts or attempts, hopelessness, depression, health care utilization, and overall psychological and social adaptation will be assessed.
45798463|NCT02980484|Procedure|Sham|Treatment that looks and feels similar to active rTMS will be administered as a sham treatment.
45926374|NCT00081367|Behavioral|Standard care alone|Participants will receive standard care for suicide prevention.
45926375|NCT03152292|Other|Real-world, non-interventional|N/A - non-interventional
45926376|NCT00081406|Behavioral|Individual Child CBT|
45926377|NCT00081406|Behavioral|Family CBT|
45798464|NCT03532295|Drug|Epacadostat|-All BID doses will be taken in the morning and evening, approximately 12 hours apart
45798465|NCT03532295|Drug|Bevacizumab|-The first infusion will be over the course of 90 minutes; if tolerated, the second infusion will be over the course of 60 minutes; if tolerated, all subsequent infusions will be over 30 minutes
45798466|NCT03532295|Radiation|Radiation therapy|-The gross tumor maximum diameter (to be irradiated) to be </= 6 cm in the first 6 patients. If more than 1 target is irradiated, then the sum of all the target maximum diameters should be </= 6 cm. No more than 3 separate targets for RT is allowed.
45926378|NCT00081406|Behavioral|Education/Support/Attention|
45597919|NCT04972123|Drug|CPC - Capsaicin, Phenylephrine, Caffeine|CPC is a combination of Capsaicin, Phenylephrine and Caffeine
45597920|NCT04972123|Diagnostic Test|Tilt Table Test|Participant will undergo tilt tablet testing using the Italian protocol (see reference section). The Italian protocol includes 20 minutes of passive tilt at 70 degrees (Passive Phase) followed by nitrogylcerin (NTG) administration and tilt testing for another 15 minutes (NTG Phase).
45597921|NCT04972123|Drug|Placebo|Placebo for CPC
45926379|NCT00081484|Drug|epoetin alfa or beta|iv or sc, as prescribed
45597922|NCT02220881|Device|Mold making silicone toe separator|Each subject in the controlled receives the custom-made mold making silicone toe separator made by certified orthotist and the recommendation of use the proper shoes without determination of current drug use
46072098|NCT05625659|Diagnostic Test|Dual-Energy Contrast-Enhanced Spectral Mammography (CESM)|In addition to their standard, digital breast tomosynthesis mammogram (DBT) performed at their regular screening visits, all participants will also receive a contrast-enhanced spectral mammography (CESM). These same diagnostic tests, both the DBT and CESM, with be repeated at 1 year post study entry for all participants. At year 2 post study entry, all participants will return to their usual breast screening exams and no longer received a CESM.
46072099|NCT05621668|Drug|Cyclophosphamide|Given by IV (vein)
45798467|NCT03532295|Procedure|Peripheral blood draw|"Baseline (prior to administration of any study treatment)~Before initiation of RT (up to 7 days prior to start of RT; may be on the same day as RT before RT treatment)~At the end of RT and/or Cycle 2 Day 1 prior to administration of INCMGA00012 with our without epacadostat~Cycle 3 Day 1 prior to administration of INCMGA00012 with or without epacadostat (+/- 7 days)~Cycle 5 Day 1 prior to administration of INCMGA00012 with our without epacadostat (+/- 7 days)~Time of disease progression"
45798468|NCT03532295|Drug|Retifanlimab|-Will be supplied by Incyte
45649992|NCT04709107|Other|Quality of life assessment - emergent|"Patients will be asked to fill up both VascuQoL-6 and SF-36 questionnaires before the procedure, as well at 30-days and 1-year follow-up visit while they are sitting in the waiting room. All questionnaires will be administered on a tablet.~During the 30-days follow-up 4 extra questions concerning patient related outcomes and occurrence of major complication will be added to the VascuQoL-6 questionnaire in the App. During every visit (preoperatively, at 30-days and 1-year follow-up) the stage of the lower limb peripheral artery disease will be noted according to the WIfI-Classification."
45798469|NCT05030714|Diagnostic Test|Visual Field Testing|Visual field testing using the protocol 24-2 and/or 10-2 Threshold Test
45798470|NCT05028452|Other|Internet based support|Carer eSupport is designed to prepare informal caregivers for caregiving, to decrease caregiver burden and prevent a deteriorated health.
45798471|NCT00382941|Device|Red and near infrared LED phototherapy device|
45798472|NCT03522077|Device|RadAR EasyCLik plus ®-STF hemostatic pad|Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot in conjunction with the RadAR EasyCLik compression device
45798473|NCT03522077|Device|TR BAND® Compression device plus ®-STF hemostatic pad|Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot in conjunction with the TR BAND® compression device
45798474|NCT03522077|Device|SoftSeal®-STF hemostatic pad|Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot
45798475|NCT03522077|Device|VascBand™ Hemostat|The VascBand™ Hemostat is an FDA-approved compression device designed to assist hemostasis of arterial, venous and hemodialysis percutaneous access sites.
45798476|NCT02980562|Drug|Polyethylene Glycols|(Split dose 2L PEG-Asc)
45798477|NCT02980562|Drug|Bisacodyl|(1L PEG-Asc plus bisacodyl)
45798478|NCT04476693|Other|Breakfast consumption|"Consumption of breakfast: The breakfast provided was designed based on the characteristics of an ideal breakfast outlined in Giovannini et al., (2008). The breakfast provided in the present study will include the following: all-bran cereals (Kellogg's), semi-skimmed milk (Tesco), Royal Gala Apple (Tesco) and Orange Juice from Concentrate (Tesco) containing the amount of carbohydrates usually consumed at breakfast in the UK (Reeves et al., 2013). The portion for each participant will contain 0.06 g of carbohydrate per kcal of measured RMR. As the portion size (20% of daily calorie intake) will be calculated based on individual RMR , no leftovers will be allowed."
45798479|NCT04476693|Other|Breakfast Omission|Omission of breakfast. Participants will consume water within 15 min, the individual volume of which will be calculated based on the liquid content of the breakfast [milk (ml)+ orange juice (ml)].
45798480|NCT03266393|Drug|Envarsus XR|Once daily sustained-release tacrolimus
45798481|NCT03266393|Drug|Tacrolimus|Twice daily immediate-release tacrolimus
45798482|NCT04349618|Other|PROTECTIVE VENTILATION|Protective ventilation with tidal volume 6 mL/kg of predicted body weight further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20, and PEEP set using the PEEP FiO2 table of the ARMA trial
45798483|NCT04349618|Other|ULTRAPROTECTIVE VENTILATION|Ultraprotective ventilation with tidal volume reduction down to 4 mL/kg further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20, and PEEP set using the PEEP FiO2 table of the ARMA trial
45798484|NCT04117971|Other|Questionnaire|The study will involve structured questionnaire asking questions about knowledge, attitude, and practice of child abuse diagnosis and reporting among dentists.
45798485|NCT03246347|Drug|ADT+Docetaxel+Enzalutamide|combination therapy as listed above
45798486|NCT04474509|Behavioral|FACT Module Engagement|Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
46072100|NCT05621668|Drug|attIL2-T cells|Given by IV (vein)
45798487|NCT04474509|Behavioral|FACT Module Openness|Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
45798488|NCT04474509|Behavioral|FACT Module Awareness|Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
45798489|NCT02986568|Procedure|Cervical cancer|"If tumor sized ≥ 5cm, undergo neoadjuvant chemotherapy with Cisplatin before surgery. (40mg/m2 on day 1 of each 7 day cycle for 5 cycles), then perform Fusion TMMR after neoadjuvant chemotherapy with cisplatin as above.~If tumor size < 5cm, perform Fusion Total mesometrial resection (TMMR)~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy.~If not, no adjuvant therapy."
45798490|NCT02986568|Procedure|Uterine cancer|"Perform Fusion Peritoneal mesometrial resection (PMMR).~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy.~If not, no adjuvant therapy."
45926380|NCT00081484|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|30, 50 or 90 micrograms iv or sc (starting dose) every 2 weeks
45926381|NCT04317716|Behavioral|fall prevention program|The intervention consists of the fall prevention program for ambulatory and non-ambulatory people with multiple sclerosis. The program will be group-based with 6-8 participants, led by a facilitator, and performed online. It comprises six two-hour sessions held once a week, and a booster session held eight weeks after the sixth session. In addition they will receive a brochure about falls and fall risk factors.
45798491|NCT02986568|Procedure|Cervical cancer, pelvic sidewall invasion|"Perform Fusion Laterally extended endopelvic resection (LEER).~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy. Patients with primary disease will be treated with adjvuant chemotherapy. In case of recurrent disease, bevacizumab, paclitaxel, and cisplaitn will be administered regardless of the pathologic report (bevacizumab 15mg/kg on day 1, paclitaxel 135mg/m2 on day 1, and cisplatin 50mg/m2 on day 2, of each 21 day cycle).~If not, no adjuvant therapy."
45798492|NCT02986568|Procedure|Non-cervical cancer, pelvic sidewall invasion|"Perform Fusion Laterally extended endopelvic resection (LEER).~After surgery, appropriate adjuvant chemotherapy will be administered depending on the tumor type."
45926382|NCT04317716|Other|Brochure about falls and fall risk factors|Control-group participants will receive a brochure about fall risk factors and fall prevention in addition to the standard MS care and rehabilitation.
45926383|NCT00081601|Drug|CEP-701|
46072101|NCT05619523|Behavioral|Developing Inclusive Youth (DIY)|Developing Inclusive Youth (DIY) is a web-based curriculum tool that serves as the intervention program. The animated and narrated tool displays eight peer social exclusion scenarios in a range of familiar everyday social contexts (such as the playground and school). Children enter their responses while watching the scenarios. Responses include making decisions about inclusion and exclusion, evaluating the actions as okay or not okay, attributing feelings to includers, excluders, and excluded characters, and selecting reasons that best match their justification for their decisions and evaluations. The program includes teacher-guided group discussions following use of the tool in which teachers facilitate discussions about children's interpretations of the scenarios, evaluations, reflections regarding their own experiences of exclusion, and solutions. Participants will view and discuss 8 scenarios and engage in a discussion for each one over the course of 8 weeks.
45649993|NCT04858919|Diagnostic Test|3D transabdominal ultrasound|Initially 3D pelvic ultrasound will be performed on all patients. The transabdominal probes used will be those of the ultrasound scanner using a convex probe (multiple frequency 1-6 MHz).
45798493|NCT00421967|Drug|Ropivacaine, Ketorolac, adrenaline|Infiltration: 150 ml Ropivacaine 2mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml Adrenaline 1 mg/ml Intraarticular infusion: 4 ml/h 384 mg Ropivacaine 60 mg Ketorolac
45649994|NCT04858919|Diagnostic Test|transrectal ultrasound|The vaginal probe will be covered with the customary plastic sheath and richly lubricated with lubricating gel. The probe will then be slowly advanced into the rectum. The transvaginal probes used will be those of the ultrasound scanner using a vaginal probe (multiple frequency 1-8 MHz). The scanning technique will be similar to that of Transvaginal ultrasound.
45649995|NCT04858919|Diagnostic Test|vaginoscopy|It is the final procedure in the study to reach the accurate diagnosis. A rigid hysteroscope will be used. The sheath has a 5-mm outer diameter, with 2.9 mm rod lens. A high intensity light source and fiberoptic cable will be used to illuminate the uterine cavity. A solution of 0.9% normal saline will be used as the distention medium. The pressure will be kept at 100-120 mmHg using a pressure adjustable cuff system with the aim of maintaining the lowest pressure required to distend the uterine cavity.
45798494|NCT00421967|Drug|Ropivacaine Ketorolac|Epidural infusion: 4 ml/h 384 mg Ropivacaine I.V. Ketorolac 90 mg
45798495|NCT04744337|Procedure|orthodontic treatment|fixed orthodontic treatment in adolescent females initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion.
45649996|NCT05303389|Procedure|Fixation of 2,3 or 4 column pilon fracture of the tibia|anterior to posterior screws in classic arm and posterolateral approach in new arm group
45649997|NCT04858841|Drug|Levetiracetam Oral Product|Administer levetiracetam powder once a day in eligible patients
45798496|NCT04403204|Other|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
45798497|NCT04403204|Other|DCE-MRI|Characterize the relationship between bone perfusion as quantified by ICG based DCE-FI and DCE-MRI in human patients to develop an accurate depth-sensitive fluorescence imaging model that will correct for the surface-weighted feature of fluorescence imaging
46072102|NCT05611632|Device|Multi-cancer early detection test (Galleri test)|Blood collection and multi cancer early detection testing with return of positive test results.
45926384|NCT03152253|Behavioral|Text My Quit (TMQ)|Text messages designed to aid smoking cessation
45926385|NCT03152253|Behavioral|Peer Support|A group chat room for peer support
45926386|NCT03152253|Other|Motivational Messages|Generic motivational messages not related to smoking cessation
45926387|NCT00081640|Drug|PRO 2000/5 Gel (P)|
45926388|NCT00390260|Drug|MK0966 / Duration of Treatment: 1 Days|
45926389|NCT00390260|Drug|Comparator: acetaminophen (+) hydrocodone bitartrate / Duration of Treatment: 1 Days|
45926390|NCT00390260|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 1 Days|
45926391|NCT00081757|Drug|Thalidomide|
45597923|NCT02220881|Other|Observation|The participants in this groups will be educated on how to care the hallux valgus without any intervention. The follow up will be on the 3rd, 6th, 9th and 12th month.
45597924|NCT02322892|Drug|Thiamine|200 mg thiamine in 50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
45597925|NCT02322892|Drug|Normal saline solution|50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
45926392|NCT00081796|Drug|larotaxel (RPR109881, XRP9881)|
45926393|NCT00081796|Drug|capecitabine|
46072103|NCT05606263|Drug|Caldonirimab and Nimotuzumab|Subjects will receive caldonirimab (6mg/Kg, q2w) until disease progression or for a maximum of 12 months, and Nimotuzumab (400mg/time, q2w) for a total of 8 cycles
45649998|NCT04858841|Drug|Perampanel Oral Product|Administer perampanel powder once a day in eligible patients
45649999|NCT04858841|Drug|Placebo|Administer placebo powder once a day in eligible patients
45798498|NCT03209687|Drug|human menopausal gonadotropin|Merional injections will be given to participants after ovum pickup in in-vitro fertilization cycles
45798499|NCT04997798|Drug|Trastuzumab Pyrotinib Exemestane Dalpiciclib|Early triple positive breast cancer patients receive combination regimen of Dalpiciclib in Combination With Exemestane and Trastuzumab plus pyrotinib
45798500|NCT03199469|Genetic|AT132|AT132 is an AAV8 vector containing a functional copy of the human MTM1 (hMTM1) gene.
45798501|NCT04997096|Other|Exercise|16-week, virtually supervised, technology-based, aerobic and resistance exercise program performed 3 days per week which starts at least 4 weeks after surgery
45798502|NCT04997096|Other|Attention Control|Home-based stretching program consisting of one set of 4 static stretching exercises held for 30 seconds and performed 3 days/week. Participants will be shown how to use the booklet and instructed on how to complete the stretching exercises by an exercise trainer.
45650000|NCT04858529|Drug|docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP)|docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP)
46072104|NCT05606172|Behavioral|Primary Care Intervention for PTSD (PCIP) Youth aged 6 -11|This treatment ranges from 1-4 sessions which last 50 minutes per session. The first session will cover psychoeducation about PTSD symptoms in children that can be delivered to the parent or both the parent and child. The first session will also teach the parent and child a breathing technique to combat the physiological impact of PTSD in children. The subsequent sessions will be tailored to meet the needs of the child's most distressing PTSD symptom cluster including hyper arousal, negative changes in cognition and mood, avoidance, re-experiencing. Each session contains coping skills that the parent and child can learn together. There is also material for parents to address behavior problems in youth. This treatment will be delivered via telehealth.
46072105|NCT05606172|Behavioral|Waitlist Treatment as Usual|Will receive treatment as usual at local clinic and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
46072106|NCT05599451|Other|THS Blade device|Tobacco Heating System (THS) device with Blade technology for Blade tobacco stick use
46072107|NCT05599451|Other|THS Induction Mono device|Tobacco Heating System (THS) device with Induction technology (combined Charger-Holder device for Induction tobacco stick use).
46072108|NCT05599451|Other|THS Induction Mid device|Tobacco Heating System (THS) device with Induction technology (device with Induction stick Holder for Induction tobacco stick use and separate Charger).
46072109|NCT05599451|Other|CIG|Subject's preferred brand of commercially available regular (non-mentholated) cigarettes. (Cigarettes are not provided by the study sponsor.)
45650001|NCT04858529|Drug|docetaxel/trastuzumab/pertuzumab (THP)|docetaxel/trastuzumab/pertuzumab (THP)
45650002|NCT04866407|Other|Mentha x piperita|2% solution of Mentha x piperita diluted in fractionated coconut oil for topical application will be applied to one extremity of the subjects in the 'Mentha x piperita' group.
45650003|NCT04866407|Other|Eucalyptus globulus|2% solution of Eucalyptus globulus diluted in fractionated coconut oil for topical application will be applied to one extremity of the subjects in the 'Eucalyptus globulus' group.
45650004|NCT03997747|Other|cytology specimen|Biopsy and Genetic: DNA analysis;Genetic: RNA analysis;Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymorphism analysis
45650005|NCT03970915|Device|Body warmer|The body warmer will be wrapped in a waterproof treatment field to avoid the risk of burns, 2 body warmer will be applied on the inguinal crease and 2 on the subclavicular fossa.
45650006|NCT03970915|Device|Standard warming procedure|Warming only according to the standard procedure : survival blanket and heating in the emergency vehicle.
45650007|NCT05303155|Diagnostic Test|16S rRNA sequencing|Fecal microbiome analysis using 16S rRNA sequencing
45650008|NCT03919435|Drug|Trimethoprim Sulfamethoxazole|Dosage: 160mg-800mg Frequency: 2 times a day Dosage Form: Pill (oral) Duration: 4 weeks
45650009|NCT04379089|Other|Observational study only|No Intervention
45798503|NCT00362531|Drug|tacrolimus combined with prednisone|
45798504|NCT05209646|Dietary Supplement|Bee honey|patients will receive honey for 8 weeks in a dose of 30 ml undiluted honey per day divided as 5 ml honey 30 minutes before each meal six times daily. The honey will be kept in a closed glass container and away from light until the time of use. Each patient will be provided with a well-sealed container containing 210 ml honey each week. The honey used in the study will be a raw, unprocessed Clover honey collected from AL Mahala-Gharbia governorate, Egypt. The honey will be supplied directly from a beekeeper without heating or gamma irradiation.
45798505|NCT04432311|Behavioral|Binge Focused Therapy (BFT)|The BFT group will be provided Binge Focused Therapy, a group-based, guided-self help intervention. Participants in this group will attend three online group sessions spread over six weeks (Week 1, Week 2, and Week 6) and complete homework between sessions. Following Session 3, there is a four week period where participants complete self-guided check-ins once per week to monitor continued progress and/or signs of relapse.
46072110|NCT05597722|Behavioral|Digital cognitive behavioral intervention-RxWell|RxWell is a coach enhanced digital behavioral health intervention that teaches techniques to help manage emotional distress, which may improve cognitive fog and/or depression. Participants will have access to this app for three months.
45798506|NCT04432311|Behavioral|CBT Unguided Self Help (CBT USH)|The CBT USH group will be provided with the book, Overcoming Binge Eating by C. Fairburn, which is a well-established self-help book used to help individuals understand binge eating and control binge eating behaviours. After participants receive the book, they will have 10 weeks to read it and work through the exercises provided in the book.
46072111|NCT05597722|Drug|Amphetamine-Dextroamphetamine|Participants randomized to this arm will be prescribed 10mg of amphetamine-dextroamphetamine to take as needed to help with cognitive fog. Participants in this arm will be contacted at 2 and 6 weeks to assess for any side effects from taking the medication.
46072112|NCT05592483|Other|None (Observational Study)|Not Applicable since observational study
46072113|NCT05574101|Drug|Cemiplimab|Participants will undergo baseline imaging, followed by two doses of neoadjuvant cemiplimab at a dose of 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days). Then, participants will receive concurrent cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) concurrently with RT to 70 Gy in 35 fractions over 7 weeks. Thereafter, participants will receive 38 weeks of cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) for a cumulative total of 12 months of cemiplimab.
45650010|NCT04363177|Behavioral|Web-based psychosocial peer-to-peer support|"The evidence-based eHealth peer-to-peer psychosocial intervention Thinking Healthy, will be tested in this RCT. In line with the World Health Organization's mhGAP Intervention Guide (mhGAP-IG), Thinking Healthy is used to identify and manage perinatal mental health conditions (distress, symptoms of depression, and anxiety) in non-specialized psychosocial support setting."
45650011|NCT05302921|Procedure|Cryoablation Therapy|"Cryoablation therapy is an established method of cancer treatment in adults and pediatrics with certain types of tumors and is standard of care for certain tumors in the setting of progression/relapse.~Percutaneous image-guided Cryoablation (cryosurgery, cryotherapy) is a technique that utilizes successive rapid freeze/thaw cycles to destroy tumor cells. This technique is performed by inserting specialized needles known as cryoprobes into target tumors under imaging guidance with Computed Tomography (CT) and Ultrasound (US), or Magnetic Resonance Imaging (MRI). After the cryoprobe needles are placed within the target tumor, rapid cooling of liquid gas inserted into these probes leads to temperatures reaching -20 to -40 degrees Celsius.~Cryoablation therapy of one disease site will be done starting Day 3 and prior to Day 15 of Cycle 1 only."
45798507|NCT05194202|Behavioral|ED-HEART|Behavioral intervention that assesses 1) healthy and unhealthy relationship behaviors, 2) conversation with partners around boundaries within relationships, 3) harm reduction strategies, and 4) resources for Adolescent Relationship Abuse (ARA) and related concerns, including Point of Care (POC) Reproductive and Sexual Health (RSH) harm reduction resources.
45798508|NCT04081701|Diagnostic Test|Ga68-DOTATATE-PET/MRI|"In patients with meningioma who are undergoing surgical planning, subjects will undergo a PET scan at the time of their pretreatment or preoperative standard of care MRI exam, prior to surgery performed for research purposes. Instead of the standard of care MRI exam, subjects will undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI.There will be up to two follow-up with Ga68-DOTATATE PET/MRI scans performed as standard of care.~In patients with SSTR-positive CNS tumors that are non-meningioma, MRI is often performed to assess extent of disease. Subjects may be asked to undergo a PET scan for research purposes at the time of their standard of care MRI. Instead of the standard of care MRI exam, they may be asked to undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI."
45798509|NCT04330443|Procedure|Surfactant therapy|To study if lung ultrasound allows an earlier surfactant therapy (within the first 2 hours of life) compare to FiO2 and Chest X Ray
45798510|NCT04986332|Behavioral|Physical activity program|24-weeks moderate-intensity physical activity program
45798511|NCT04986332|Other|Global therapeutic remodeling|Re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions
45798512|NCT04330677|Drug|Oxytocin nasal spray|Intranasal administration of 24 International Units, Oxytocin will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
45798513|NCT04330677|Drug|Placebo nasal spray|The placebo spray contains the identical ingredients, except for the peptide itself. It will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
45798514|NCT04330677|Drug|Estrogen Gel|Participants received a single dose of estradiol gel (Estramon 2 mg estradiol, Hexal AG, Holzkirchen, Germany), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
45798515|NCT04330677|Drug|Placebo Gel|Participants received a single dose of the placebo gel (ultrasonic gel, 2 mg), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
45798516|NCT04978766|Behavioral|Interactive Book Reading|"The intervention is a package including five children's books and information on how to practice interactive book reading. Information includes 36 audiovisual products delivered via text messaging over a 12-week period. Products include:~An introductory video about interactive book reading, along with a written list of recommendations on how to practice interactive book reading.~Two videos of child development experts explaining the benefits of interactive reading.~Thirty written text messages strengthening content provided in the videos.~Three audio messages guiding the progress of the intervention.~Based on Abraham and Michie's (2008) taxonomy of behavior change techniques, one audiovisual product prompts specific goal settings, 13 provide instruction, one provides information on consequences, 10 prompt practice, three use follow-up prompts, one prompts self-monitoring of behavior, one models or demonstrates the behavior and six prompt barrier identification."
45798517|NCT04965116|Drug|Progestin Only Contraceptive Pills|Daily pill (placebo or active tablet)
45798518|NCT02986490|Biological|Blood sample|Blood sample
45798519|NCT02986412|Other|CG428|The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
45798520|NCT04964960|Drug|Pembrolizumab|Pembrolizumab is an immunotherapy that can help fight certain cancers.
45926394|NCT03152214|Other|Vigorous Intensity Aerobic Exercise and Community Engagement|"Each veteran will be provided with an Apple watch for the duration of the study. Research staff will use the resultant data to monitor the veteran's activity level. Veterans will be asked to complete three 25-minute sessions of vigorous intensity aerobic exercise per week (either running, cycling, rowing, or elliptical workouts). Data collected will include the number of minutes exercised and the heartrate level (77-85% maximum heart rate). Any exercise session of 25 minutes at > 76% of maximum heart rate will be characterized as 1 completed session of vigorous-intensity exercise. Veterans will enter the activity, minutes exercised, average heartrate, and perceived exertion into REDCap.~Community engagement will involve attending at least one Team RWB event per week through the Austin or Killeen chapters. This could be a weekly running group, hike, or community service project-among other activities. Veterans will enter whether or not they attended a Team RWB event on REDCap."
45926395|NCT03152214|Other|Community Engagement|Veterans in the study will receive a monthly calendar of Team RWB events upon assignment. Veterans will be able to participate in any Team RWB event located in Austin or Killeen. Veterans will be asked to attend at least one Team RWB event. This could be a weekly running group, hike, or community service project- among other activities. Veterans will enter whether or not they attended a Team RWB event on the REDCap exercise adherence surveys.
45926396|NCT00390338|Biological|polarized dendritic cells|
45798521|NCT04964960|Drug|Nab paclitaxel|Nab-paclitaxel is a taxane derivative that is an albumin-bound paclitaxel nanoparticle formulation that promotes microtubule assembly.
45926397|NCT00390338|Biological|non-polarized dendritic cells|
45926398|NCT03152175|Drug|Propranolol Hydrochloride|1mg / kg of propranolol hydrochloride, oral capsule
45926399|NCT03152175|Drug|Placebo|1mg / kg of matched placebo, oral capsule
45926400|NCT00399685|Drug|Ortho Tri-Cyclen LO|Tablets, oral, OTC Lo 1 tab/daily (no dosage units), once daily, 28 days.
45798522|NCT04964960|Drug|Paclitaxel|Paclitaxel is a taxane derivative that promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication.
45926401|NCT00399685|Drug|Ortho Cyclen|Tablet, oral, Ortho Cyclen 1 tab/daily (no dosage units), once daily, 28 days.
45450646|NCT02030782|Other|Quality Improvement (QI) for depression|Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.
45650012|NCT05302921|Drug|Nivolumab|"Nivolumab (Bristol Myers Squibb) is a human monoclonal antibody (immunoglobulin G4) that targets the programmed death-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease."
45650013|NCT05302921|Drug|Ipilimumab|"Ipilimumab (Bristol Myers Squibb) is a fully human monoclonal immunoglobulin G1Κ specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4, cluster of differentiation [CD]152), which is expressed on a subset of activated T-cells.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease."
45650014|NCT05302843|Drug|BPI-28592|Characterize the pharmacokinetics (PK)，safety，antitumor activity of BPI-28592
45650015|NCT05302219|Other|Respiratory rate|The participant alternates respiratory rates of 30, 15 and 7.5 breaths/min. Breathe each frequency for 2 minutes with a one-minute break.
45926402|NCT00399685|Drug|Ortho Cyclen + Efavirenz|Tablet, oral, OC + EFV 600 mg, once daily, 14 days.
45926403|NCT00399685|Drug|Ortho Cyclen|Tablet, oral, OC 1 tab daily (no dosage units), once daily, 7 days.
45798523|NCT04964960|Drug|Pemetrexed|Pemetrexed is an antifolate agent that disrupts folate-dependent metabolic processes essential for cell replication.
45926404|NCT00081835|Drug|NP-016 Vaccine Immune Globulin (IV-VIG)|
45926405|NCT00390377|Procedure|Cutting scalp hair|
45926406|NCT00081874|Drug|RAD001|"Phase I: Starting dose 5 mg by mouth daily for 28 days.~Phase II: Maximum Tolerated Dose (MTD) from Phase I."
45926407|NCT03152136|Device|Cala ONE device|The Cala ONE device is a wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves.
45926408|NCT00081913|Genetic|Cell Therapy - Autologous CD34 Positive Cells|
46072114|NCT05574101|Radiation|Radiotherapy|Participants will receive radiotherapy to 70 Gy in 35 fractions over 7 weeks concurrently with cemiplimab
46072115|NCT05574010|Drug|Cohort 1 in Part A|Dose 1 KAN-101 Intravenous (IV) infusion
46072116|NCT05574010|Drug|Cohort 2 in Part A|Dose 2 KAN-101 Intravenous (IV) infusion
46072117|NCT05574010|Drug|Cohort 3 in Part A|Dose 3 KAN-101 Intravenous (IV) infusion
45926409|NCT00081952|Drug|L-norleucine|
45926410|NCT00082069|Biological|Shigella flexneri 2a Invaplex 50|
45926411|NCT03152097|Dietary Supplement|Commercially available Diindolylmethane|Commercially available Diindolylmethane is a compound derived from cruciferous vegetables (e.g. broccoli)
45926412|NCT03152097|Other|Placebo|A matching placebo capsule will be compounded by the UPMC Investigational Drug Service
45926413|NCT00082147|Procedure|Biopsy|Patients will then undergo endorectal coil MR imaging of the prostate gland, including conventional anatomic imaging and dynamic-contrast-enhanced MRI During MR imaging, 4 to 10 needle biopsy cores of the prostate will be obtained using a trans-rectal needle guide system (APT-MRI).
46072118|NCT05574010|Other|Placebo: Group 1 in Part B|Placebo Intravenous (IV) infusion
46072119|NCT05574010|Drug|Group 2 in Part B|Dose 4 KAN-101 Intravenous (IV) infusion
46072120|NCT05574010|Drug|Group 3 in Part B|Dose 5 KAN-101 Intravenous (IV) infusion
45450647|NCT02030782|Other|Usual Care|Usual care enhanced by provider education regarding depression evaluation and management
45450648|NCT03535402|Drug|Sarilumab|SC administration of 200 mg twice a week
45798524|NCT04964960|Drug|Carboplatin|Carboplatin is a platinum compound alkylating agent which covalently binds to DNA and interferes with the function of DNA by producing interstrand DNA cross-links.
45798525|NCT04089969|Diagnostic Test|CTA/FFRct|Computed Tomography Angiogram with Fractional Flow Reserve. A Ct scan of the heart's blood vessels.
45926414|NCT00082186|Drug|bosentan|Oral bosentan tablets 62.5 mg twice daly for 4 weeks, then 125 mg twice daily for 20 weeks.
45798526|NCT04089969|Diagnostic Test|SOC cardiovascular evaluation|Standard of care (SOC) cardiovascular evaluation i.e ECG, 2 D echocardiogram and pharmacologic stress test such as Dobutamine and Myocardial Perfusion Imaging stress test.
45926415|NCT00082225|Biological|CD45 antibodies|The antibody solution is administered by a syringe pump in incremental doses, 0.2-0.8 mg in the first hour and up to 10 mg/hr thereafter, for a maximum infusion time of 8 hrs.
45926416|NCT00082225|Biological|EBV specific T cells|"The following dose levels will be evaluated: Each patient will receive 1 injection, according to the following dosing schedules:~2 x 10e7 cells/m2 5 x 10e7 cells/m2~1 x 10e8 cells/m2"
45798527|NCT02371135|Genetic|colonic biopsies|
45926417|NCT00082303|Behavioral|Music Imagery|
45926418|NCT00082459|Biological|autologous human tumor-derived HSPPC-96|
45798528|NCT02371135|Genetic|questionnaires|
45798529|NCT05114486|Drug|Pilocarpine Ophthalmic|Pilocarpine 2% ophthalmic spray administered with the Optejet microdose dispenser
45650016|NCT05302219|Other|Tidal volume|The participant alternates tidal volumes of approx. 2, 1 and 0.5 litres. Breathe each tidal volume for 2 minutes with a one-minute break.
45798530|NCT05114486|Drug|Placebo|Vehicle ophthalmic solution administered with the Optejet microdose dispenser
45926419|NCT00390494|Procedure|Hysterectomy|
45926420|NCT00390494|Procedure|Myomectomy|
45926421|NCT00390494|Procedure|Uterine Fibroid Embolization|
46072121|NCT05574010|Drug|Group 4 in Part B|Dose 6 KAN-101 Intravenous (IV) infusion
45650017|NCT05302219|Other|Apnea|The participant simulates three apneic pauses lasting 1 minute with a two-minute break.
45650018|NCT04690465|Behavioral|Resistance training|"Participants will receive a 16-week resistance training program, with 3 times a week (a total of 48 training sessions) and 60 minutes per session intervention, which is adopted from the 12-week resistance training program introduced in the book Growing Stronger: Strength Training for Older Adults (Seguin et al., 2002), with minor modifications under the advice of Physical Fitness Association of Hong Kong, China (PFA)."
45650019|NCT04690465|Behavioral|Eight-form Yang-style Tai Chi program|The active concurrent control group will receive Eight-form Yang-style Tai Chi program which has been confirmed feasible and will be taught by the qualified coach.
45650020|NCT04689997|Behavioral|cSBI|The standard CRAFFT SU screen has additional questions about reasons to use or not use, SU expectancies of effect and embedded education. The teens of enhanced care PCPs will also complete a Strengths and Goals tool. Data from both will be used by the PCP in counseling regarding continued abstention, reduction or cessation of SU or referral. Teens will also get monthly text messages about goals.
45650021|NCT04682743|Drug|paracetamol|received intravenous one gram of paracetamol over a 15-minute period,
45650022|NCT04682743|Drug|ondansetron|received intravenous 8 mg of ondansetron over a 15-minute period.
45650023|NCT04682743|Drug|normal saline|received intravenous 0.9% normal saline over a 15-minute period.
45650024|NCT03472573|Drug|Palbociclib|Given PO
45798531|NCT02249143|Device|CPAP and room air|Stable premature infants on CPAP and room air and meeting specific stability criteria will be randomized to stay on continuous positive airway pressure and room air for an additional two weeks or will be transitioned to room air alone.
45798532|NCT04940078|Drug|Cagrilintide|Once weekly doses of cagrilintide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. for 2 weeks
45798533|NCT04940078|Drug|semaglutide|Once weekly doses of semaglutide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. over 2 weeks
45798534|NCT04940078|Drug|Cagrilintide and semaglutide|Cagrilintide and semaglutide combined and administered using the DV3384 manual syringe
45798535|NCT03200847|Drug|Pembrolizumab with All-Trans Retinoic Acid|All the patients will receive 200mg Q3W pembrolizumab treatment plus the supplemental treatment of 150 mg/m2 All-Trans Retinoic Acid orally for 3 days surrounding each of the first four infusions of pembrolizumab
45926422|NCT00082498|Drug|SCH-D (vicriviroc)|Group 2 will receive 5 mg vicriviroc daily; Group 3 will receive 10 mg vicriviroc daily; and Group 4 will receive 15 mg vicriviroc daily. If at or after Week 16 a participant's viral load has not met certain criteria, a dose increase of vicriviroc may occur and the participant will enter Step 2. As of 10/12/05, patients in Group 2 and any patients who entered Step 2 following virologic failure in Step 1 will be unblinded and offered either 15 mg vicriviroc daily through this study or the option of seeking alternative treatment.
45926423|NCT00082498|Drug|Placebo|Patients in Group 1 will receive placebo.
45926424|NCT00082537|Drug|caspofungin acetate|Duration of Treatment: 28-90 days
45926425|NCT00082537|Drug|Comparator: AmBisome|Duration of Treatment: 28-90 days
45926426|NCT03151980|Procedure|Hamam treated skin and sun exposure|Hamam is a skin treatment (soaping and scrubbing).
45926427|NCT03151980|Other|Untreated skin and sun exposure|Skin that will not receive Hamam.
45926428|NCT00082576|Drug|Azithromycin/Chloroquine|
45926429|NCT00082576|Drug|Mefloquine|
45926430|NCT04269239|Behavioral|Healthy Habits|Participants in this group will be coached during four hour-long sessions on topics such as physical activity, nutrition, pain coping skills, bladder health, diabetes, heart health, eyes/vision, hearing, and doctor-patient communication.
45650025|NCT03472573|Drug|Dexamethasone|Given PO
45650026|NCT04357717|Diagnostic Test|ExoDx Prostate|Urine-based biomarker tool to support decision to biopsy in patients with PSA between 2-10ng/ml
45650027|NCT05301985|Dietary Supplement|preoperative nutrition|The participants of experimental group consumed 400 ml of a clear carbohydrate drink (12,5 gr/100 ml carbohydrate, 50 kcal/100 ml, pH 5.0) at 10:00 pm the evening before surgery and 200 ml of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
45926431|NCT04269239|Behavioral|Sleep Habits|Participants in this group will be coached during four hour-long sessions on topics such as sleep education, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene education, and relapse prevention.
45926432|NCT00082654|Procedure|psychosocial assessment and care|
45926433|NCT00082732|Behavioral|behavioral dietary intervention|
45926434|NCT00082732|Dietary Supplement|dietary intervention|
45926435|NCT00082732|Procedure|therapeutic dietary intervention|
45926436|NCT00082927|Drug|ibandronate sodium|
45926437|NCT04259450|Drug|AFM24|intravenous infusions
45926438|NCT00082966|Drug|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|Given IV
45926439|NCT00083005|Drug|docetaxel|
45926440|NCT00083005|Drug|estramustine phosphate sodium|
45926441|NCT00083005|Drug|thalidomide|
45926442|NCT04245956|Procedure|Measure of hemodynamic indices in a stenosed coronary artery using a pressure wire|The intervention consists of measuring a series of hemodynamic indices in a stenosed coronary using a pressure wire, immediately before and after transcatheter mitral valve repair using the percutaneous edge-to-edge MitraClip system in patients with severe mitral insufficiency and concomitant intermediate coronary artery stenosis.
45926443|NCT00083083|Drug|carboplatin|
45926444|NCT00083083|Drug|cisplatin|
45926445|NCT00083083|Drug|docetaxel|
45926446|NCT00083083|Drug|etoposide|
45926447|NCT00083083|Drug|paclitaxel|
45926448|NCT00083083|Drug|vinblastine sulfate|
45926449|NCT00083083|Drug|vinorelbine tartrate|
45926450|NCT00083083|Genetic|gene expression analysis|
45650028|NCT04331509|Other|No Intervention|No Intervention
45798536|NCT02259517|Drug|Guanfacine|Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
45926451|NCT00083083|Procedure|positron emission tomography|
45926452|NCT00083083|Radiation|fludeoxyglucose F 18|
46072122|NCT05568550|Biological|Pembrolizumab|Pembrolizumab will be delivered via IV at 200mg on day 1 of each 3-week cycle for approximately 12 months. Cycle 1 begins 21 days prior to radiation therapy and cycles 2-17 are administered during and after radiation therapy.
45650029|NCT04672915|Diagnostic Test|test of HBV DNA|Real time PCR or nested PCR to check
45650030|NCT04649593|Dietary Supplement|Samarin|Half of the group with a high AFL value will have a glass of Samarin to drink
45650031|NCT04636333|Biological|Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Two doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14.
45798537|NCT02259517|Drug|Lisdexamfetamine|Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
45926453|NCT00083083|Radiation|radiation therapy|
45926454|NCT03151863|Drug|Opioids|The usual opioid treatment used for nursing care
45926455|NCT03151863|Drug|Dexmedetomidine|Dexmedetomidine is provided intranasally
45926456|NCT03151863|Drug|Placebo|Normal saline is either given subcutaneously or intranasally
45926457|NCT00083161|Drug|cisplatin|60 mg/m2 IV day 1, every 21 days for 4 cycles.
45926458|NCT00083161|Drug|cyclophosphamide|25 mg by mouth BID days 8-19 or each cycle x 4 cycles. After restaging (if no progression) maintenance cyclophosphamide alone 25 mg by mouth BID daily until disease progression
45926459|NCT00083161|Drug|etoposide|120 mg/m2 IV days 1-3 OR 120 mg/m2 IV day 1 and 120 mg/m2 by mouth BID days 2-3
45926460|NCT00083239|Drug|talabostat (PT-100) tablets|
45926461|NCT00083278|Drug|MDX-010|
45926462|NCT03151824|Other|quality of life|Quality of life which was measured by the Korean version of the 36-item short-form health survey (SF-36)
45926463|NCT00083356|Procedure|Wisdom tooth extraction|
45926464|NCT00083434|Drug|Epoetin alfa|
45926465|NCT03151785|Other|Face-to-face BLS training|Pupils will receive CPR training by standardised face-to-face BLS training only
45926466|NCT03151785|Other|Lifesaver training|Pupils will receive CPR training by Lifesaver programme only
45926467|NCT03151785|Other|Lifesaver and Face-to-Face BLS training|Pupils will receive CPR training by Lifesaver and standardised face-to-face BLS training
45926468|NCT00083473|Drug|Pivanex|
45926469|NCT00083590|Drug|Huperzine A|
45926470|NCT04729699|Other|Aerobic exercise and exercise for TMJ|Aerobic exercise
45926471|NCT04729699|Other|Aerobic exercise at home|Aerobic exercise
45926472|NCT03151746|Drug|Placebo|Placebo pill administered orally 1 hour before planned surgical procedure
45926473|NCT03151746|Drug|Gabapentin|Gabapentin pill (1200mg) administered orally 1 hour before planned surgical procedure
45926474|NCT00399724|Drug|Insulin glargine|
45926475|NCT00083629|Procedure|PET|
45926476|NCT00083668|Drug|Paliperidone ER|
45926477|NCT00083707|Drug|Thalidomide|
45926478|NCT00083785|Drug|Talaporfin sodium (LS11)|
45926479|NCT00083785|Device|LED-based light infusion device|
45926480|NCT00083785|Device|Light emitting diodes (LED)|
45926481|NCT00083785|Procedure|Photodynamic therapy|
45926482|NCT00083785|Procedure|Phototherapy|
45926483|NCT00083785|Procedure|Chemotherapy|
45926484|NCT03151707|Drug|Nicotinamide Riboside|Nicotinamide riboside 2g/day for a 2 week duration
45926485|NCT05568589|Other|Preoperative Interpectoral - Pectoserratus Plane Block|Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.
45798538|NCT04330209|Other|weight loss diets|The ketogenic diet group were instructed to consume <35g of carbohydrates per day, and <10% of total calories were from saturated fats. Daily protein intake was set at 1.2g/kg bodyweight for females, and 1.5g/kg bodyweight for males. The low-GI nutrigenetic diet group had individualised dietary instructions based on their genetic results
45798539|NCT04358588|Drug|iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System|Patients will be treated by means of an INOpulse device and cannula. The active study drug, nitric oxide for inhalation (iNO), will be provided in size 0.074 liter aluminum cartridge at a concentration of 6.0 mg/L (4880 ppm).
45926486|NCT05568589|Other|Intraoperative Interpectoral - Pectoserratus Plane Block|Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.
45926487|NCT05568589|Other|Non Block|Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.
45926488|NCT05568433|Diagnostic Test|Endoscopic ultrasound fine needle aspiration (EUS-FNA)|Patients with pancreatic cysts who underwent endoscopic ultrasound and endoscopic fine needle aspiration for diagnostic and therapeutic purpose. A sample of the cyst fluid and frozen serum was collected from the patients and stored at minus 80 degrees.
45926489|NCT05568238|Procedure|Vacuum Assisted Wound Closure and Permanent On-lay Mesh-mediated fascial traction (VAWCPOM)|Vacuum Assisted Wound Closure and Permanent On-lay Mesh-mediated fascial traction (VAWCPOM) in patients with open abdomen.
45926490|NCT03151668|Drug|Dexmedetomidine|
45926491|NCT05568082|Drug|AMG 510|Oral tablet
45926492|NCT05568082|Drug|Itraconazole|Oral capsule
45926493|NCT05567965|Other|Home care intervention|The duration of the intervention, both for the control group and the intervention group, will be 18 months or until the user's admission to the nursing home.
45926494|NCT03151590|Behavioral|exercise training|
45926495|NCT02965066|Device|Coloplast Test Catheter|Newly developed intermittent catheter
45926496|NCT02965066|Device|Coloplast Speedicath|Marketed Coloplast Speedicath catheter
45926497|NCT04729777|Procedure|Combined Cardiovascular Magnetic Resonance and Cardiopulmonary Exercise Testing|Clinical Cardiac MRI scan at rest with routine administration of gadolinium contrast agent. Participants then undergo the research component of the test which requires them to perform exercise, using a recumbent, MRI-compatible cycle ergometer, whilst their breathing is simultaneously analysed using a mask connected to a CPET machine, until they are limited by symptoms and they stop pedalling. Most participants will undergo only one scan. Some participants will be asked to have two or three such scans over 3 months to assess changes over time, and in response to standard treatment of pulmonary hypertension.
45926498|NCT05567653|Dietary Supplement|Lactobacillus helveticus Rosell-52 and Bifidobacterium longum Rosell-175 (Sanprobi Stress)|3-month, multi-strain probiotic supplementation (one a day, 3 x 10⁹ CFU)
45926499|NCT05567653|Dietary Supplement|Starch (placebo)|3-month placebo
45650032|NCT04636333|Biological|Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Three doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
45650033|NCT04636333|Biological|Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Two doses of high-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHOCell) at the schedule of day 0, 14.
45798540|NCT01379287|Drug|Iso-Fludelone|Iso-fludelone will be administered IV over 6 hours (+/- 30 mins) on Day 1 of every 3 week cycle.
45798541|NCT04351958|Behavioral|"Experimental: Augmented Reality (No Time Wasted)"|"No Time Wasted will be an innovative, immersive intervention using novel technology that will captivate the target audience with narrative and gaming elements to scaffold the educational message."
45926500|NCT05567614|Radiation|Liver Fibroscan|Patients with CHB virus will do liver fibroscan and correlat between platelets count and degree of liver fibrosis
45926501|NCT04172714|Device|SIR-Spheres microspheres|SIR-Spheres® Y-90 resin microspheres consist of biocompatible polymer resin microspheres of a median diameter of 32.5 microns (range between 20 and 60 microns) loaded with yttrium-90 (beta radiation penetrating an average of 2.5 mm in tissue to destroy tumor cells). The resin microspheres are small enough to become lodged in the arterioles within the growing rim of the tumor but are too large to pass through the capillaries and into the venous system. Since yttrium-90 has a half-life of 64.1 hours, most of the radiation (94%) is delivered to the tumor over 11 days.
46072123|NCT05568550|Drug|Olaparib|200mg Olaparib will be given twice daily for a total of 3 cycles. Cycle 1 begins 21-days prior to radiation therapy.
46072124|NCT05568550|Drug|Androgen Deprivation Therapy|Androgen Deprivation Therapy (either LHRH agonist or LHRH antagonist) as per treating physician choice will be allowed within 3 months prior to randomization. Duration is per institutional standards.
46072125|NCT05568550|Radiation|Radiation Therapy|Definitive radiation (total dose and fractions) will be dosed per institutional standards. Definitive radiation may include external beam radiation therapy with or without brachytherapy, based on NCCN risk score and as per treating physicians.
46072126|NCT05563220|Drug|Elacestrant|Elacestrant 86mg, 172mg, 258mg or 345mg QD in cycles of 28 days
46072127|NCT05563220|Drug|Alpelisib|Alpelisib 250 mg or 300 mg QD in cycles of 28 days
46072128|NCT05563220|Drug|Everolimus|Everolimus 5.0mg, 7.5mg, or 10mg QD in cycles of 28 days
46072129|NCT05563220|Drug|Ribociclib|ribociclib 400mg or 600mg once daily for 21 days followed by 7 days off in cycles of 28 days
46072130|NCT05563220|Drug|Palbociclib|palbociclib 100 mg or 125mg once a day for 21 days followed by 7 days off in cycles of 28 days
45650034|NCT04636333|Biological|Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Three doses of middle-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
45926502|NCT05567575|Behavioral|Cognitive Behavioral Therapy,|TechCare is based on the intelligent real time therapy (iRTT) conceptual model proposed by Kelly et al. iRTT relates to the use of mobile technologies to deliver interventions such as CBT, extending beyond assessment of symptoms. The intervention is based on the treatment manual developed by David G. Kingdon and Douglas Turkington. The intervention is informed by evidence based cognitive models of psychosis, where the participant is able to choose from a list of pre-selected digital self-help strategies that are personalised to each participant. For example, the App may incorporate the participant's favourite music in the form of multimedia or YouTube links, which are prompted during symptom elevation. Other examples may include psychoeducation, goal setting, problem-solving, etc., based on common self-help strategies in CBT for Psychosis (CBTp).
45926503|NCT04733508|Drug|111In-DTPA-exendin-4|Injection of 111In-DTPA-exendin-4 and localization of the tracer in excised pancreatic tissue using autoradiography
45926504|NCT04733508|Drug|IRDye800CW-exendin-4|Injection of IRDye800CW-exendin-4 and localization of the tracer in excised pancreatic tissue using fluorescence microscopy
46072131|NCT05561400|Device|tDCS|5x5 saline-soaked sponge electrodes will be used with the cathode placed over the right cerebellar hemisphere; 1cm under and 4cm lateral of the inion targeting lobule VII and the anode will be placed on the right shoulder. The electrode placement will be the same across both conditions.
46072132|NCT05561400|Other|Placebo|sham tDCS to the right cerebellum
46072133|NCT05555667|Drug|Remimazolam besylate|Sedation drug
46072134|NCT05555667|Drug|Propofol|Propofol. Sedation drug
46072135|NCT05549258|Drug|Inebilizumab|Inebilizumab administered intravenously (IV) over a total of 28 weeks.
46072136|NCT05547438|Drug|NTS-104 TRIS|Subjects will receive a single IV infusion of either 0.8, 4, 8, or 16 mg/mL NTS-104 depending on the Cohort number
46072137|NCT05547438|Drug|Placebo|Subjects will be administered an IV infusion of placebo and the same duration and volume as the subjects administered NTS-104 TRIS in the cohort
45650035|NCT04636333|Biological|Two doses of placebo at the schedule of day 0, 14 #middle-dose group#|Two doses of placebo (0.5ml) at the schedule of day 0, 14.
45650036|NCT04636333|Biological|Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#|Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
45798542|NCT05203627|Other|Best Practice|Receive standard nutritional support
45798543|NCT05203627|Other|Questionnaire Administration|Ancillary studies
46072138|NCT05544019|Drug|SGR-1505|SGR-1505 will be administered orally.
46072139|NCT05536973|Genetic|ADVM-022|A single IVT injection of 2E11 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens
46072140|NCT05536973|Genetic|ADVM-022|A single IVT injection of 6E10 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens
46072141|NCT05534568|Other|Parent-Child Assistance Program|Case managers work closely with mothers over the course of three years, meeting the mothers in their own homes when possible, to help them to set goals and take advantage of available resources.
46072142|NCT05533658|Dietary Supplement|VisionPure Dietary Supplement|Subjects will consume two softgels capsules of the Treatment (VisionPure) once daily for 60 days. At Day 0, they will come in for a Comprehensive Eye Exam, a National Eye Institute Visual Functioning Questionnaire, and a series of Cognitive Function Exams. After 60 days, subjects will return and repeat the same questionnaires and exams from Day 0.
45798544|NCT05203627|Other|Telemedicine Visit|Receive telehealth sessions
45798545|NCT03166761|Drug|Dexamethasone|Dexamethasone injection into the sacroiliac joint
45798546|NCT03166761|Drug|Triamcinolone Acetonide|Triamcinolone injection into the sacroiliac joint
46072143|NCT05533658|Dietary Supplement|Placebo|Subjects will orally consume two softgel capsules of Placebo once daily for 60 days. At Day 0, they will come in for a Comprehensive Eye Exam, a National Eye Institute Visual Functioning Questionnaire, and a series of Cognitive Function Exams. After 60 days, subjects will return and repeat the same questionnaires and exams from Day 0.
45450649|NCT04519138|Device|Endodrill Model X|The investigational device Endodrill Model X is used for biopsy sampling in the upper gastrointestinal tract
45450650|NCT04519138|Device|Fine-needle aspiration/biopsy|The standard method is used for biopsy sampling in the upper gastrointestinal tract
45650037|NCT04636333|Biological|Two doses of placebo at the schedule of day 0, 14 #High-dose group#|Two doses of placebo (0.5ml) at the schedule of day 0, 14.
45798547|NCT04323176|Other|Village Model implementation|Participate in the Village Model using a website
46072144|NCT05528744|Other|Observational Study|No intervention. This is an observational study
46072145|NCT05528744|Other|Sample collection only|Collection of blood and/or skin samples.
46072146|NCT05514873|Drug|zilucoplan (RA101495)|Subcutaneous injection
46072147|NCT05512390|Drug|ABBV-319|Intravenous (IV); Infusion
46072148|NCT05491226|Drug|Pembrolizumab|Pembrolizumab 400 mg is administered intravenously at Week 1, then every 6 weeks during the treatment period. Therapy will continue for until initiation of SOC curative-intent treatment (neoadjuvant chemo therapy or surgery).
46072149|NCT05491226|Radiation|Radiation Therapy|Radiation therapy (RT) consists of 8 Gy for 3 fractions over 3 consecutive days at Week 2.
46072150|NCT05491226|Drug|Axatilimab|Axatilimab 1 mg/kg is administered intravenously weekly starting 1 week post- RT (Week 3). Therapy will continue until initiation of SOC curative-intent treatment (neoadjuvant chemo therapy or surgery).
45650038|NCT04636333|Biological|Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#|Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
45650039|NCT04084561|Behavioral|HRHA|participants will be asked to consider a hypothetical scenario in which genetic test results reveal that: 1) they carry genotypes that place African American smokers at a particularly high (~50%-80%) risk for the development of lung cancer, and 2) their genetic profile reflects a particularly high concordance with African heritage (~90%).
45650040|NCT04084561|Behavioral|LRLA|participants will be asked to consider a scenario in which genetic test results reveal that: 1) they are at normal (~7%-10%) risk for the development of lung cancer, and 2) their genetic profile reflects a particularly low concordance with African heritage (~10%).
45798548|NCT05176093|Biological|Engensis|Lyophilized biologic to be reconstituted containing Engensis
45798549|NCT05176093|Other|Placebo|Injectable Liquid
45798550|NCT04259762|Behavioral|Breast, Colorectal, and Cervical Cancer Screening Interventions|Adult men and women will receive age- and gender-specific interventions. Women age 50-75 years will receive the interventions for breast, colorectal, and cervical cancers screening. Men age 50-75 years will receive the intervention for colorectal cancer screening. Women age 21-49 years will receive the intervention for cervical cancer screening. The 4-week interventions, delivered once a week, will consist of educational sessions that discuss cancer-specific information (i.e., breast, colorectal, and cervical cancer): breast (colorectal, cervical) cancer myths and facts, risk factors and symptoms, screening, and review/action plan. The educational sessions will be complemented by cancer-specific small media (brochure).
45798551|NCT05172661|Behavioral|Integrated physical-cognitive training|Perform a postural task and a cognitive task at the same time (dual-task model) 70 minutes/session*2 sessions/week*6 weeks
45650041|NCT04084561|Behavioral|HRLA|"participants will receive High Risk, Low Ancestry (HRLA) hypothetical"
45798552|NCT05172661|Behavioral|Consecutive physical-cognitive training|Perform a postural task and a cognitive task separately for identical durations 70 minutes/session*2 sessions/week*6 weeks
45798553|NCT04250558|Procedure|Lower Extremity Amputation|patients 18 years of age or older who will have a planned lower leg (either below knee, through knee, or above knee) amputation surgery are scheduled to undergo a lower extremity amputation (either below knee, through knee or above knee), performed by a participating surgeon or delegate. Provision of informed consent.
45798554|NCT05711017|Drug|Huashibaidu granule|Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the Huashibaidu group will receive Huashibaidu granule two times a day for five consecutive days (day 1~5).
45450651|NCT02189200|Dietary Supplement|oat bran - 40g|oat bran - 40g per day
45798555|NCT05711017|Drug|Placebo|Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the placebo group will receive placebo two times a day for five consecutive days (day 1~5).
45450652|NCT02189200|Dietary Supplement|refined rice flour- 40g|refined rice flour - 40g per day
45650042|NCT04084561|Behavioral|LRHA|"participants will receive Low Risk, High Ancestry (HRLA) hypothetical"
45798556|NCT00597805|Behavioral|questionnaires/interviews|All patients who agree to participate will be interviewed for a baseline quality of life assessment prior to surgery. A brief in hospital interview will follow in the peri-operative period. In the ensuing months, patients will be interviewed at approximately 3, 6 and 12 months post-operatively (eg: 3 month interview will be done between 8-16 weeks and 6 month interview between 20-28 months post-operatively). Annual interviews in years two through five will be employed to determine areas for future study and solicit narrative on transition toward cancer survivorship.
45798557|NCT04220294|Procedure|Subcutaneous tissue closure|Subcutaneous tissue closure with 2-0 vicryl suture.
45798558|NCT05710939|Other|exercises|
45798559|NCT04042155|Drug|dabigatran, rivaroxaban, apixaban or edoxaban|Record of all serious complications associated with any of the drugs and the clinical changes that occurred during prospective follow-up.
45798560|NCT04213196|Drug|HSK21542|Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
45798561|NCT04213196|Drug|HSK21542|Intravenous injection 0.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
45798562|NCT04213196|Drug|HSK21542|Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
45798563|NCT04213196|Drug|HSK21542|Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.
45798564|NCT04213196|Drug|HSK21542|Intravenous injection 0.75 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
45450653|NCT02194114|Other|Protein Diet|Protein diets fed for 17-19 days to each patient in random order: 0.6 g protein/kg/day, 0.8 g protein/kg/day, 1.0 g protein/kg/day, 1.15 g protein/kg/day, 1.3 g protein/kg/day.
45450654|NCT03535246|Biological|Engineered Immune Cells|Engineered immune effector cells (EIE)
45650043|NCT01362049|Other|Physical Therapy rehabilitation: Stabilization exercises.|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles and then incorporation of these isolated contractions into other exercises. The exercise protocol progresses to include trunk flexion and extension strengthening exercises as well as abdominal bracing exercises in supine and quadruped positions, and finally to exercises in more functional positions.
45798565|NCT04213196|Drug|HSK21542|Intravenous injection 1.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
45798566|NCT04213196|Drug|HSK21542|Intravenous injection 2.25 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
45798567|NCT04213196|Drug|HSK21542|Intravenous injection 3.375 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
45798568|NCT04213196|Drug|HSK21542|Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.
45798569|NCT00002895|Drug|chemotherapy|
45798570|NCT02980406|Dietary Supplement|FODMAP|Fermentable oligo-, di- and monosaccharides and polyols are poorly absorbed carbohydrates that are known to cause symptoms in IBS patients.
45798571|NCT02980406|Dietary Supplement|Glucose (control)|Glucose is not a FODMAP.
45798572|NCT04029363|Device|HighLife Transcatheter Mitral Valve Replacement|Transcatheter Mitral Valve Replacement
45926505|NCT05567536|Drug|Antiplatelet Agents|Patients who received a single antiplatelet agent will be analyzed according to the prescribed antiplatelet agent
45926506|NCT05567419|Diagnostic Test|Biological assays|PCR and NGS-WGS on stools and respiratory samples
45926507|NCT05567341|Procedure|Remote ischemic preconditioning|A blood pressure cuff is inflated to 200 mmHg for 4x5 min (5 min rest between cycles) at the right upper extremity when the vestibular schwannoma surgery is started
45798573|NCT02331992|Behavioral|Adherence program|Participants will receive supportive messages while enrolled in the program.
45653189|NCT05475275|Procedure|pancreaticojejunostomy|"The experimental group underwent intraoperative measurements (A: short distance from the center of the pancreatic duct to the edge of the pancreas) and (B: pancreatic thickness). When the ratio of the thickness of the short distance from the center of the pancreatic duct to the edge of the pancreas at the pancreatic section was ≥0.401, it was divided into the N1 group (central pancreatic duct). If the ratio was <0.401, it was divided into the N2 group (eccentric pancreatic duct). The central pancreatic duct group was given 1+1 mode pancreaticojejunostomy; the eccentric pancreatic duct group was given 1+1² mode pancreaticojejunostomy."
45798574|NCT04198454|Other|Compression bandages|Class I (20-30 mmHg) compression bandages or stocking
45798575|NCT04198454|Other|Standard wound dressings|Wound dressings alone consisting of gauze and skin tape to cover the wound
45798576|NCT04198454|Device|Fractional ablative carbon dioxide laser|Participant will have laser applied to their wound bed.
45926508|NCT05567341|Procedure|Sham-control|A blood pressure cuff is inflated to 0 mmHg for 4x5 min (5 min rest between cycles) at the right upper extremity when the vestibular schwannoma surgery is started
45926509|NCT05567146|Behavioral|Experimental group|"It is planned to use the social media platform WhatsApp application to carry out the study. technique of gamification will have content in the form of points, ranking, penalties and rewards, which are the basic principles of gamification.~Studies have shown that these contents are effective techniques to increase the interest, encouragement, motivation and purpose of the participants."
45926510|NCT04114370|Drug|18F-fluciclovine|Prior to beginning PET imaging, 18F-fluciclovine will be administered as an intravenous bolus injection followed by a 10mL saline flush. 18F-fluciclovine will be injected through a cannula (or indwelling catheter) in an antecubital vein or another vein that will provide access. The administration site will be evaluated pre- and post-administration for any reaction. Documentation of administration to a participant will be recorded or as part of the scan upload, including date, prescription number, dose activity (as measured at time of administration), total volume, and start/stop time of administration.
45926511|NCT00135265|Behavioral|smoking cessation, practice change|Providers will be trained in a brief smoking cessation intervention for teens.
45926512|NCT00135304|Drug|Sensipar®|Cinacalcet hydrochloride
45926513|NCT00135304|Drug|Vitamin D|Vitamin D administered IV
45926514|NCT00135460|Drug|nucleoside analogue sparing HAART regimen|
45798577|NCT03086655|Behavioral|Tel-me-box with reminder features|Participants will meet with a study staff member to go over their daily routines, including their pill taking schedule, and to work out a plan for tailored reminders. The participant will choose from the reminders available and convey their preferences regarding when reminders should be sent for the TMB. Preferences will be stored in an online secure database. If requested by the participant, the reminder schedule and type of reminder can be reprogrammed by study staff via an online portal. When the reminder is reprogrammed the TMB receives a new configuration SMS to update the device reminder settings.
45926515|NCT04103606|Device|GGBI: Positive Body Image (Mobile App)|Brief, game-like, training exercise for challenging body image disorder symptoms and associated psychological features
45798578|NCT03086655|Behavioral|Tel-me-box|Participants receive tel-me-box device with no reminder features added.
45926516|NCT00135499|Drug|Rituximab|375 mg/m², D1, 4 cycles
45926517|NCT00135499|Drug|Doxorubicin|75 mg/m², D1, 4 cycles
45926518|NCT00135499|Drug|Cyclophosphamide|1200 mg/m², D1, 4 cycles
45926519|NCT00135499|Drug|Vindesine|2 mg/m², D1, D5, 4 cycles
45926520|NCT00135499|Drug|Bleomycin|10 mg, D1, D5, 4 cycles
45926521|NCT00135499|Drug|Prednisone|60 mg, D1-D5, 4 cycles
45926522|NCT00135499|Drug|Prednisone|40 mg, D1-D5, 4 cycles
45926523|NCT00135499|Drug|Doxorubicin|50 mg/m², D1, 4 cycles
45926524|NCT00135499|Drug|Cyclophosphamide|750 mg/m², D1, 4 cycles
45926525|NCT00135499|Drug|Vincristine|1.4 mg/m², D1, 4 cycles
45926526|NCT03151434|Drug|US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion)|Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.
45926527|NCT03151434|Drug|US Guided Paravertebral Catheter (0.2% ropivicaine bolus)|Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.
45450655|NCT02030626|Device|active or placebo rTMS or active or placebo tDCS|
45450656|NCT02256826|Drug|BILR 355 BS|
45798579|NCT04195256|Drug|IN Ketodex (D4K2)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 4 mcg/kg (0.04 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 2 mg/kg (0.04 mL/kg) of 50 mg/mL solution, maximum of 200 mg (4 mL) (D4K2), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
45798580|NCT04195256|Drug|IN Ketodex (D3K3)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 3 mcg/kg (0.03 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 3 mg/kg (0.06 mL/kg) of 50 mg/mL solution, maximum of 300 mg (6 mL) (D3K3), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
45798581|NCT04195256|Drug|IN Ketodex (D2K4)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 2 mcg/kg (0.02 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 4 mg/kg (0.08 mL/kg) of 50 mg/mL solution, maximum of 400 mg (8 mL) (D2K4), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
45926528|NCT03151434|Drug|Thoracic Epidural (0.125% bupivicaine/hydromorphone)|Epidural catheter will be placed in the thoracic region prior to surgery.
45926529|NCT00135538|Device|Noninvasive positive pressure ventilation|
45926530|NCT00135577|Drug|alvimopan|
45926531|NCT00135577|Drug|placebo|
45926532|NCT00135616|Device|surgical placement of a suburethral sling tvt or tvt-o|
45798582|NCT04195256|Drug|IV Ketamine|Ketamine, single dose, 1.5 mg/kg (0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 100 mg (2 mL) AND two aliquots of 0.9% normal saline in 3 possible combinations: (i) 0.04 mL/kg (max 2 mL) then 0.04 mL/kg (max 4 mL) (placebo D4K2), (ii) 0.03 mL/kg (max 2 mL) then 0.06 mL/kg (max 6 mL) (placebo D3K3), (iii) 0.02 mL/kg (max 2 mL) then 0.08 mL/kg (max 8 mL) (placebo D2K4), delivered intranasally using a MAD and divided to both nares
45926533|NCT03151356|Device|Measurement of Prostate Health Index (PHI)|Use of a diagnostic tool to predict prostate biopsy outcome: measurement of total and free PSA as well as the [-2]proPSA and calculation of The Prostate Health Index according to the following formula: Prostate Health Index (PHI) = [p2PSA /fPSA] x √tPSA
45926534|NCT00135655|Drug|denufosol tetrasodium (INS37217) Intravitreal Injection|
45926535|NCT00135733|Drug|Amevive (Alefacept)|
45926536|NCT00135733|Drug|Placebo|
45926537|NCT04061798|Drug|ACT guided heparinization|"If the ACT is <180 sec., an additional dose of heparin of 60 IU/kg is administered. If the ACT is 180-200 sec., 30 IU/kg.~If the ACT is >200 sec., no extra heparin is given. 5 min. after every administration of heparin the ACT is measured. If the ACT is >200 sec, the next ACT measurement is performed every 30 min., until the end of the procedure or until new heparin administration is required. After each new dose of heparin, an ACT measurement is performed after 5 min. and the above- described protocol of ACT measurements will be repeated. After re-establishing blood flow and removing all clamps, the ACT is measured.~If the ACT at closure is 200-250 sec., 2500 IU of protamine should be administered. If >250 sec., 5000 IU protamine. If 180-200 sec., 1000 IU protamine. 5 min. after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 sec. If the ACT is still more than 200 sec., protamine should be administered again."
45926538|NCT04061798|Drug|5 000 IU of heparin|"A single dose of 5 000 IU of heparin is given 3-5 min before clamping of the aorta. No ACT measurements are performed, except for one ACT measurement after re-establishing blood flow and removing all clamps. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.~If the ACT at closure is between 200 and 250 s, 2500 IU protamine should be administered. If the ACT is higher than 250 s, 5000 IU protamine should be administered. If the ACT is between 180 and 200 s, 1000 IU protamine should be administered. Five minutes after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 s. If the ACT is still more than 200 s, protamine should be administered again."
45926539|NCT00135811|Drug|Cyclosporin|Participants assigned to this group will initiate treatment with CSA, 5-6 mg/kg per day with a 250 mg/day maximum starting dose, divided into two daily doses. The CSA dose will be adjusted based on drug levels determined at specified study visits in order to achieve a 12-hour trough concentration in the therapeutic range of 100-250 ng/ml.
45926540|NCT00135811|Drug|MMF and Dexamethasone|"MMF, 25-36 mg/kg per day with a maximum dose of 2 g/day divided into two daily doses. The dose range reflects the use of fixed size (250 mg) capsules and application of defined daily doses to specific weight ranges (see Table below). In younger children or those participants who are unable to swallow capsules, a liquid formulation will be used to provide 36 mg/kg per day to a maximum of 2 g per day. The starting MMF dose will be 0.5-0.67 of the full dose for 2 weeks before advancing to the full dose for the duration of the 12-month treatment period.~Dexamethasone, 0.9 mg/kg per dose, with a maximum dose of 40 mg"
45926541|NCT00135850|Genetic|VEGF-A165 plasmid|
45926542|NCT00135889|Drug|Femoral perineural infusion|
45926543|NCT00135928|Drug|Granulocyte Colony Stimulating Factor G-CSF (Neupogen®)|
45926544|NCT03151278|Procedure|Zero-fluoroscopy ablation|Catheter ablation will be performed under the guidance of one kind of three-dimensional navigation system and without fluoroscopic guidance.
45798583|NCT00002901|Drug|docetaxel|
45798584|NCT00002907|Drug|bryostatin 1|
45450657|NCT02256826|Drug|Ritonavir (RTV)|NORVIR®
45798585|NCT01710787|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|3 unilateral intranasal sprays per dose
45798586|NCT01710787|Drug|Tetracaine HCl 3%|3 unilateral intranasal sprays per dose
45798587|NCT01710787|Drug|Placebo|3 unilateral intranasal sprays per dose
45450658|NCT02256826|Drug|Kaletra®|(lopinavir (LPV) and ritonavir (RTV))
45798588|NCT05102864|Device|Intermittent Theta Burst Stimulation to the Left Dorsolateral Prefrontal Cortex|iTBS will be administered to the left DLPFC for 10 consecutive days
45798589|NCT01711177|Drug|placebo|Placebo
45798590|NCT01711177|Drug|travoprost|Travatan Z is administered to newly diagnosed glaucoma patient
45798591|NCT04874870|Drug|Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex]|1 injection of 0.58mg will be injected into applicable cord.
45926545|NCT03151278|Procedure|Conventional fluoroscopy ablation|Catheter ablation will be performed using fluoroscopy plus one kind of three-dimensional navigation system.
45650044|NCT01362049|Other|Physical Therapy rehabilitation. Movement System Impairment (MSI) classification based exercise|The MSI-classification based approach focuses on education and instruction for modifying movement strategies during functional activities, and on exercises that are specific to the classification category. First there is an analysis of and instruction in modifying a subject's direction-specific alignment and movement strategies during symptomatic functional activities. Second, there is education about the principles of tissue injury and healing, and how cumulative tissue stress contributes to microtrauma and LBP. Unique to the education process is the emphasis on how using one's particular movement strategies during functional activities may accelerate tissue stress accumulation because the strategies are used repetitively. Thirdly, there is exercise prescription that includes practice in performing modified versions of the direction-specific impairment tests from the physical exam, with an emphasis on impairments that can be modified to eliminate LBP symptoms.
45798592|NCT04874870|Combination Product|Xiaflex + Hand-Based Custom Orthosis|1 injection of 0.58mg will be injected into applicable cord followed by use of hand-based custom orthosis to maintain finger extension
45798593|NCT02277990|Device|TYRX™ Absorbable Antibacterial Envelope|
45798594|NCT01715233|Drug|Docetaxel|Modified Docetaxel 40mg/m2 on Day 1
45798595|NCT01715233|Drug|Leucovorin|Leucovorin 400mg/m2 on Day 1
45798596|NCT01715233|Drug|Fluorouracil|Fluorouracil 400mg/m2 on Day 1 Fluorouracil 1000mg/m2/day on Days 1 and 2
45798597|NCT01715233|Drug|Cisplatin|Cisplatin (or Carboplatin) 40mg/m2 on Day 3
45798598|NCT04868630|Device|Pulsewave Health Monitor (PAD-2A) Device|This is an observational study of the average breathing rate measurement of a non-invasive wrist cuff device. The purpose of this study is to calibrate the average breathing rate measurement of the Pulsewave Health Monitor (PAD-2A) wrist cuff device with the breathing rate measurement of a standard clinical capnography device. Additionally, we will also compare the average breathing rate measurement of the capnography device with other standard clinical respiratory devices (i.e. nasal pressure transducer, thermistor, and respiratory inductance plethysmography (RIP) belts of the chest and abdomen).
45798599|NCT01716013|Device|BondEase|topical skin adhesive
45926546|NCT00135967|Drug|mycophenolate mofetil orally 1000 mg twice a day (BID)|
45798600|NCT01716013|Procedure|CWCD|traditional closure methods of sutures, staples or adhesive strips
45798601|NCT03028922|Device|creos xenogain|GBR procedure will be performed using creors xenogain bone graft substitute in patients that need horizontal bone augmentation prior to implant placement. The defect should be located in the pre-molar and molar region of the mandible
45926547|NCT00135967|Drug|prednisone 0,5 mg/kg orally on alternate days|
45926548|NCT00135967|Drug|intravenous (i.v.) methylprednisolone 1000 mg, total 9|
45926549|NCT00136006|Behavioral|Study to determine the burden of disease|
45926550|NCT00136045|Drug|Rotigotine|
45926551|NCT00136201|Drug|tigecycline|
45926552|NCT04045340|Device|Philips QLAB Ultrasound Quantification Software|Offline processing of intraoperative transesophageal echocardiography would be performed with Global Longitudinal Strain on apical 4 chamber, apical 2 chamber and long axis views in order to analyze left ventricle and left atrium contractility and right ventricle free wall motion
45926553|NCT03151239|Dietary Supplement|NMN supplement|Intervention will last at least 8 weeks in the form of two capsules (250 mg total).
45926554|NCT03151239|Other|Placebo|Intervention will last at least 8 weeks in the form of two capsules.
45926555|NCT00136240|Behavioral|Computer Assisted Education for Behavior Change|
45926556|NCT04042025|Biological|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the cytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec-xioi administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
45926557|NCT00136279|Behavioral|Linking Lives parent-based intervention|Parent intervention consists of mothers attending two, 2.5 hour-long, face-to-face sessions at the school during which they are given an intervention manual, two homework assignments, and a manual for their adolescent. Parents also receive two booster telephone calls approximately one-month and six-months after completing the intervention. As part of the comparison condition, school-based interventions for adolescents also consist of two, 2.5 hour-long, face-to-face sessions at schools during which they complete either the Project TNT intervention for preventing tobacco use or the Making a Difference intervention for reducing sexual risk behavior.
45926558|NCT00136396|Drug|Rituximab|Given once weekly for 4 weeks followed by a 4 week observation therapy.
45926559|NCT00136474|Drug|Amifostine|Given 30-60 minutes prior to daily radiation therapy
45926560|NCT00136474|Radiation|Radiation Therapy|Daily radiation therapy
45926561|NCT00136513|Drug|SB-743921|
46072151|NCT05489237|Drug|IDRX-42|IDRX-42 will be administered at assigned doses and schedules once daily in continuous cycles of 28 days each.
45926562|NCT04026386|Behavioral|Center Based or In Home Early Intervention Program|This is a 12-week early intervention program that will include 12 weekly hours of treatment in an intensive center-based preschool environment or in home to treat social communication deficits in children with developmental disorders.
45650045|NCT04435561|Other|Standard physiotherapy rehabilitation and dry needling|The dry needling group receives 6 sessions of dry needling in the spastic muscles of the upper and lower hemiparetic limbs.
45650046|NCT04435561|Other|Standard physiotherapy rehabilitation|This group receives their traditional intervention, without dry needling.
45653190|NCT05078463|Device|Microneedle|Maltose Microneedle Patch (Patch Size: 1 cm x 1 cm, 36 microneedles per patch, microneedle's height, base width and tip radius are 400 μm, 100 μm and 3 μm, respectively) will be firmly applied for 5 seconds on the 1 cm x 1 cm site for IV cannulation on the dorsal surface of the hand for blood transfusion, prior to EMLA cream application.
45926563|NCT00136552|Drug|rituximab|
45926564|NCT00136591|Drug|Bortezomib|Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle
45926565|NCT00136591|Drug|Bortezomib|Arm B: a 35-day cycle of 1.6 mg/m2 Velcade™once weekly for 4 weeks. Days 1, 8, 15, and 22 of a 35-day cycle. Subjects in this treatment arm will receive a total of 6 cycles of treatment, approximately 30 weeks.
45926566|NCT03151161|Drug|Icotinib,Pemetrexed,Carboplatin|Pemetrexed (500mg/m2) + Carboplatin (AUC=5), every 3 weeks, maximum 4 cycles; icotinib 125mg, three times a day, d2-15 in each cycle, and icotinib 125mg,three times a day, since the last cycle until disease progression
45926567|NCT03151161|Drug|Icotinib|Single drug: Icotinib 125mg, three times a day, continuous until disease progression.
45926568|NCT03998579|Other|The CanMoRe programme|An exercise intervention in Primary Health Care
45926569|NCT03998579|Other|Home exercise|An active control group
46072152|NCT05489237|Drug|IDRX-42|IDRX-42 will be administered at RP2DS once daily in continuous cycles of 28 days each.
46072153|NCT05484596|Procedure|Measuring VA Coupling|Subjects will undergo clinically indicated investigations and tests. The research part of the study is measuring the VA coupling using high fidelity catheters. That is expected to increase the duration of the cardiac catheterization for 30 minutes.
46072154|NCT05481450|Dietary Supplement|Nutritears®|Strength: Lutein/Zeaxanthin - 20/4 mg; Curcuminoids 200 mg; Vitamin D3 600 IU (Total capsule weight ≈670 mg)
46072155|NCT05481450|Dietary Supplement|Placebo|Soybean oil capsule (Total capsule weight ≈670 mg)
45926570|NCT02964520|Behavioral|Neurofeedback training|uptraining alpha (8-11 Hz) and theta (5-7.5 Hz) frequency bands, inhibiting beta (15-30 Hz) and delta (2-4 Hz)
46072156|NCT05474846|Drug|Melatonin|Given by PO
46072157|NCT05474846|Other|Placebo for Melatonin|Given by PO
46072158|NCT05474846|Drug|Melatonin|Given by PO
46072159|NCT05474846|Drug|Methylphenidate|Given by PO
45650047|NCT04481737|Behavioral|Peer-delivered and Technology Support Integrated Illness Management and Recovery|PDTA-IIMR is delivered by a peer support specialist with the use of guided IIMR eModules and a smartphone application designed to complement in-person eModule sessions. The eModules are designed to be reviewed with a peer support specialist and consumer during one-hour, weekly, telephonic sessions in a community setting. Each eModule includes videos and experiential learning tasks on psychoeducation and coping skills training.
45926571|NCT02964520|Behavioral|Sham comparator: Sham neurofeedback training|in UNEVEN neurofeedback sessions (1,3,5,7,9): up-training lobeta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz) in EVEN neurofeedback sessions (2,4,6,8,10): down-training beta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz)
45798602|NCT05145283|Drug|Conestat alfa (Ruconest®)|In the current study, participants will receive two intravenous injections of conestat alfa (immediately during the TAVI procedure and again 3h later) at a dose of 100 U/kg (first dose) and of 50 U/kg (subsequent dose), for patients less than 84 kg; two intravenous injections (immediately during the TAVI procedure and again 4h later) of conestat at a dose of 8400 U (4 vials, first dose) and of 4200 U (2 vials, subsequent dose) for patients of 84 kg body weight or greater. The chosen regimen including repeated administration should increase and maintain serum C1INH levels above twice the serum concentration for six to eight hours in the majority of patients. The timeframe of therapeutic concentrations will cover the period of the TAVI procedure itself and the immediate postprocedural period during which reperfusion and additional ischemic events related to global hypoperfusion may occur.
45926572|NCT00404053|Drug|Clopidogrel|
45926573|NCT00136669|Procedure|Acupuncture|
45798603|NCT05145283|Drug|NaCl 0.9%)|Normal saline (NaCl 0.9%) will serve as placebo treatment. The respective amount of saline (according to patient weight matching the volume of conestat alfa that would have been used for this patient) will be withdrawn in an opaque syringe for slow IV injection.
45926574|NCT00136708|Procedure|Neonatal Resuscitation|
45798604|NCT04865744|Drug|Semaglutide 7 MG Oral Tablet|Semaglutide 7 mg oral tablet taken after an overnight fast with up to 120 ml of water.
45798605|NCT04865744|Drug|Placebo|Placebo tablet is taken after an overnight fast with up to120 ml of water.
45450659|NCT02189278|Behavioral|Psychosocial Intervention|Telephone-based psychosocial intervention involving six telephone encounters. Each encounter focuses on teaching skills for improving adherence and overcoming barriers to obtaining recommended surveillance.
45450660|NCT03535792|Drug|Fentanyl/Hyperbaric bupivacaine|Intrathecal Fentanyl/Hyperbaric bupivacaine and Tibial internal fixation.
45798606|NCT04865744|Drug|Semaglutide 14 MG Oral Tablet|Semaglutide 14 mg oral tablet taken after an overnight fast with up to 120 ml water.
45798607|NCT04841252|Device|FDA approved GE LOGIQ E9 (LE9) ultrasound|Ultrasound
45650048|NCT04481737|Behavioral|Peer support|Peer support is a non-manualized form of social support, frequently coupled with instrumental support, that is mutually offered or provided by persons having a mental health condition to others sharing a similar mental health condition to bring about a desired social or personal change. Peer support specialists are provided with 1-hour of supervision each week
45650049|NCT03103009|Drug|Pasireotide|Somatostatin analogues are a last resort for medical intervention in hyperinsulinemic hypoglycemia (HH). The hypoglycemia is very debilitating and can be even life threatening. There is limited experience with pasireotide in hyperinsulinemic hypoglycemia (only one publication); there is more experience with octreotide, both in adults and children and successful interventions with octreotide in hyperinsulinemic hypoglycemia have been published. Pasireotide via its different somatostatin receptor binding profile has clear effects on insulin, glucagon and incretin secretion and can ultimately lead to hyperglycemia. This mode of action (especially the effects on insulin and incretin secretion) could be very useful in the setting of hyperinsulinemic hypoglycemia.
45798608|NCT04841252|Device|Alpinion clinical ultrasound machine|Ultrasound
45798609|NCT05710705|Device|portable prototype of bioimpedance measurement|"The device will be installed during the patient's operation. It will be attached to the healthy skin of the flap (without wound or scar) by sterile glue. It will then be covered with a self-adhesive tegaderm type dressing. The wound will be isolated from the device with a hermetic silicone dressing of the Mepilex type, for example. There will therefore be no communication between the measuring device and the surgical wound."
45926575|NCT00393159|Device|Ear Popper|
45650050|NCT04481581|Other|Electronic Alerts|When FiO2 remains =>0.4 and SpO2 =>94% for more than 45 minutes, an electronic health record based alert will be sent to respiratory therapists to titrate oxygen per decision support tool.
45926576|NCT03991130|Drug|IL-2 and Nivolumab|Course length will be 35 days. Subjects will receive 480 mg IV of nivolumab on day 1 of the cycle. The patient will be admitted to UCSD Jacobs Medical center for standard HD IL-2 which will be administered every 8 hrs for up to 14 doses days 8-12 per institutional practice. The patient will be readmitted days 22-28 for HD IL-2 every 8 hrs for up to 14 doses. Nivolumab 480 mg IV will be administered day 35. Scans for response will occur 4 weeks after day 35 nivolumab dose and response will be determined by RECIST 1.1 to determine if the patient will receive the next course.
45926577|NCT00136747|Drug|Memantine|Two capsules of Memantine twice daily for 12 days.
45926578|NCT00136747|Drug|bupropion|
45926579|NCT00136747|Drug|placebo|
45926580|NCT00136786|Drug|Memantine|
45926581|NCT00136825|Drug|N-Acetylcysteine|
45926582|NCT00136825|Drug|Placebo|
45926583|NCT00393198|Drug|Levonorgestrel (Mirena, BAY86-5028)|Removal of first MIRENA and insertion of the second MIRENA at entry visit. Removal of MIRENA (in vitro release rate 20 microgram/24h) at year 5 visit.
45926584|NCT00393198|Drug|Cytotec|Cytotec, single, sublingual dose of 400 microgram, 3 hours prior to the MIRENA removal and insertion procedure at entry visit
45926585|NCT00393198|Drug|Placebo|Placebo, single, sublingual dose, 3 hours prior to the MIRENA removal and insertion procedure at entry visit.
45926586|NCT03968822|Drug|Lidocaine 2% Injectable Solution, Lidocaine 1% Injectable Solution, Bupivacaine 0.25% injectable solution, Bupivacaine 0.5% injectable solution, saline, no injection -- Followed by IL 20% IV Bolus|3 mL of test solution followed by 1.5 mL/kg of IL 20% IV Solution
45926587|NCT03968822|Drug|Lidocaine 2% Injectable Solution, Lidocaine 1% Injectable Solution, Bupivacaine 0.25% injectable solution, Bupivacaine 0.5% injectable solution, saline, no injection -- Followed by Saline Bolus|3 mL of test solution followed by 1.5 mL/kg of Saline IV Solution
45798610|NCT02317614|Behavioral|SteadyRx|The proposed intervention consists of four core elements. The intervention will include a Smartphone application that allows direct interaction with the SteadyRx system, as well as automatic events controlled via a central server. The CONSULT element will facilitate patient-provider communication with links to care providers and other care resources. The REMIND element will provide telephonic reminders for late doses. The OBSERVE element will feature electronically observed dosing through time-stamped video recordings made on the Smartphone and sent securely to a central server. The REWARD element will feature monetary incentives designed to reinforce short- and long-term medication adherence and promote reductions in viral load.
45650051|NCT01477957|Procedure|surgery|biliopancreatic diversion, gastric banding, gastric sleeve resection
45926588|NCT00136864|Procedure|PET Diagnostic Imaging|Patients in the PET group will undergo the standard diagnostic tests plus PET to determine those suitable for combined modality therapy
45926589|NCT00136942|Drug|Atorvastatin|
45798611|NCT05056909|Device|Kidney ACTion|AI-supported software for chronic kidney disease care
45798612|NCT05056909|Other|Standard of care|Standard of care
45926590|NCT00136981|Drug|torcetrapib/atorvastatin|
45926591|NCT00136981|Drug|atorvastatin|
45926592|NCT03947606|Behavioral|CASCADE (CAre Supporters Coached to be Adept DEcision partners)|CASCADE (CAre Supporters Coached to be Adept DEcision partners) is a multicomponent, nurse coach-led supportive care intervention designed to increase family caregivers' skills in providing decision support to individuals with advanced cancer. In a series of weekly, one-on-one, 15-20 minute, in-person or telephone sessions, family caregivers receive psychoeducation on principles of providing effective social support and decision partnering, decision support communication, and Ottawa Decision Guide training.
45926593|NCT03151122|Behavioral|Nurse-led Continuous Support|"The Nurse-Led Continuous Support was provided by a integrative care team. In-hospital support included(1) Promoting early parental-infant interaction;(2) Instruct the mother and/or father to use sensory stimulation activities to promote infant neuro-development in the NICU;(3) Parental educational support. The integrative care team will teach infant care skills, prepare them for successful transition from hospital to home setting.~After infant discharge support will consist of regular home visits by the nurses. Home visits will be offered every other week until children reaching 3 Months of corrected age."
45650052|NCT02839291|Other|quality of life questionaries|
45926594|NCT03151122|Procedure|routine follow-up care|after infant discharge, parents were usually called upon to remind the date and time of follow-up care with physicians in outpatient department. A contact number was also given to parents in case they have questions about follow-up care.
45798613|NCT04880226|Device|Magnetic Resonance Imaging (MRI)|Ongoing evaluations of magnetic resonance imaging (MRI) using the Philips Ingenua 1.5T scanner associated with MRI-guided procedures (e.g. ablations or biopsies) are essential to continued procedure improvement within the newly-built hybrid procedure suite.
45926595|NCT00137020|Drug|ziprasidone|
45926596|NCT00137059|Drug|acetaminophen sustained-release|
45926597|NCT00137098|Drug|Caffeine|
45926598|NCT03940157|Behavioral|Oh Happy Day Class - Still I Rise|one-time, 4-hour class focused on awareness of depression and healthy self-management strategies
45650053|NCT02839291|Drug|intravenous or oral bone antiresorptive treatments|
45650054|NCT04485481|Drug|ADX-914|Single dose from 0.1mg/kg to TBD
45650055|NCT04485481|Drug|Placebo|Matching single dose placebo
45798614|NCT04826588|Drug|Methylprednisolone sodium succinate 10 mg/kg intravenously|Methylprednisolone sodium succinate 10 mg/kg intravenously once daily for 3 days (max 1 g per dose)
45926599|NCT00137137|Procedure|Placement of the mini-screw|
45926600|NCT03151083|Behavioral|Internet-based Self-help Insomnia Intervention|The investigators will use the program, SHUTiTM for the treatment of insomnia. The intervention is a CBT-based 6-week, self-administered course accessed via the Internet on mobile, desk-top, and other devices. The program is split into six modules, completed weekly, which include instruction on psycho-education, stimulus control, relaxation training, sleep restriction, medication tapering, and addressing cognitive distortions. The content is delivered via text, video vignettes, case histories, interactive learning tools, interactive skills assessments, symptom assessments, and a sleep log. Homework is assigned after each module. Providers and support staff can follow treatment progress via access to a dashboard of patient information collected by the program. Such information includes progress through the modules, date of last engagement, symptom assessment outcomes, and sleep log data abstracted into commonly used sleep indices such as sleep onset latency and sleep efficiency.
45926601|NCT00137176|Drug|Rebif|Rebif 44mcg TIW
45650056|NCT04485481|Drug|ADX-914|Multiple dose from TBD to TBD
45650057|NCT04485481|Drug|Placebo|Matching multiple dose placebo
45653191|NCT05078463|Drug|1 Finger Tip Unit (FTU) EMLA Cream (30-minute application time)|1 Finger Tip Units (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
45653192|NCT05078463|Drug|1 Finger Tip Unit (FTU) EMLA (15-minute application time)|1 Finger Tip Unit (FTU) EMLA applied for 15 minutes on the dorsal surface of the IV cannulated hand
45653193|NCT05078463|Drug|0.5 Finger Tip Unit (FTU) EMLA (30-minute application time)|0.5 Finger Tip Unit (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
45926602|NCT00137215|Device|Silverlon|dressing for donor site mamagement
45926603|NCT00137254|Drug|Insulin|IV insulin
45926604|NCT00137254|Drug|Stable Isotopes|IV administration of stable isotopes
45926605|NCT00137254|Drug|Indocyanine Green|IV administration of ICG
46072160|NCT05472909|Other|Standardized Relaxation Music|Participants listen to standardized relaxation music during surgery.
46072161|NCT05472909|Other|Personal Choice of Music|Participants listen to their preferred music during surgery.
45926606|NCT03906149|Combination Product|Whole-body hyperthermia + standard medical care|Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization) in addition to standard medical care. The hyperthermia will be applied using Heckel-HT3000 MPIIb. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
45926607|NCT03906149|Combination Product|Standard medical care|Standard medical care included guideline-based anti-depressive drug treatment in combination with psychotherapy. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
45798615|NCT04826588|Biological|Human normal immunoglobulin (IVIg)|Human normal immunoglobulin (IVIg) 2g/kg intravenously as a single dose in line with guidance for dosing and administration in Kawasaki disease
45926608|NCT00137293|Drug|GAP-486 (ZP-123)|
45926609|NCT00137293|Drug|0.9% Sodium Chloride, USP|
45926610|NCT03151044|Drug|High-dose Epirubicin Combined with CVP ± Rituximab|Experimental group shall be given high-dose Epirubicin (90mg/m2) combined with standard-dose Cyclophosphamide (750mg/m2), Vincristine (1.4mg/m2) and Prednisolone (100mg/m2) ± Rituximab
45926611|NCT03151044|Drug|Standard-dose Epirubicin Combined with CVP ± Rituximab|Active comparator group shall be given standard-dose Epirubicin and standard-dose Cyclophosphamide (750mg/m2), Vincristine (1.4mg/m2) and Prednisolone (100mg/m2) ± Rituximab
45450661|NCT03535792|Drug|Nalbuphine/Hyperbaric bupivacaine|Intrathecal Nalbuphine/Hyperbaric bupivacaine and Tibial internal fixation.
45450662|NCT02189356|Behavioral|exercise programme|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group
45926612|NCT00137332|Drug|GAP-486 (ZP-123)|
45926613|NCT00137332|Drug|0.9% Sodium Chloride, USP|
45450663|NCT02189356|Behavioral|standard care|standard pregnancy follow up
45650058|NCT03996109|Behavioral|Aim2Be smartphone app system|Youth-parent dyads will receive the LiGHT program (addressing healthy eating, physical activity, screen time and sleep) via the Aim2Be smartphone app for 1 year. It provides personalization beginning with creation of an avatar and identifying user motivations, offers progressive goal-setting considering readiness, sub-tasks, milestones, self-monitoring tools with feedback and positive reinforcement. It applies behaviour change techniques, provides a knowledge centre, simulation narratives to enable decision making, and separate social exchange platforms for parents and youth to share ideas and challenges with peers. A Virtual Coach has been programmed using motivational interviewing theory. Gamification includes elements of choice, challenge, uncertainty, discovery, and kudos for achieving outcomes in the process of developing motivations, skills and mastery.
45650059|NCT03996109|Behavioral|BnLt smartphone app|Youth-parent dyads will receive a simple app called BnLt for 1 year. It provides web-links to external websites that provide information and tips on healthy eating and activity, including the Canada Food Guide, Canadian Society of Exercise Physiology recommendations for physical activity, screen time and sleep for youth, and other resources.
45650060|NCT03852511|Biological|NG-350A|NG-350A is oncolytic adenoviral vector which expresses a full length agonist anti-CD40 antibody at the site of virus replication.
45650061|NCT03787381|Device|Ultrasound|Vaginal ultrasound examination
45798616|NCT01719367|Drug|Atenolol|
45926614|NCT00137371|Drug|PVC (daily for 21 days, 7 days off)|
45926615|NCT00137371|Drug|PVC (twice weekly)|
45926616|NCT00137410|Drug|Celebrex|
45450664|NCT03535714|Behavioral|MANTR-a treatment|MANTR-a treatment
45450665|NCT02193256|Drug|Varenicline|Titrated over 1 week to a maximum dose of 2mg/day
45450666|NCT02193256|Drug|Prazosin|Titrated over 3 weeks to a maximum dose of 8mg/day
45450667|NCT02193256|Drug|Placebo|
45450668|NCT03535558|Drug|Fluoroquinolone (FQ)|Participants exposed to an oral FQ will be observed. The oral FQ included are Levofloxacin, Ciprofloxacin, Moxifloxacin, Ofloxacin, Gemifloxacin. Participants will not receive any intervention as a part of this study.
45450669|NCT03535558|Drug|Azithromycin (AZ)|Participants exposed to an oral AZ will be observed. Participants will not receive any intervention as a part of this study.
45650062|NCT03781921|Other|No intervention|There is no intervention. Each group will conduct the same tasks and questionnaires and we will compare performances between groups.
45650063|NCT03153787|Other|Probiotic|Vaginal probiotic administration according to the standard regimen: 1 tablet (via vaginal) for 5 days after menstruation during the same cycle of the next embryo transfer.
45926617|NCT00137488|Device|imaging and angiogenic profiles|Image tumor angiogenesis by DCE-MRI using 1.5- or 3-T MRI instruments (13,14,15) pre-and postoperatively (before biopsy or surgery).
45926618|NCT03151005|Drug|Metformin-GLP-1 Receptor Agonist|metformin oral with exenatide/liraglutide subcutaneous injection.
45926619|NCT03151005|Drug|Metformin-Oral Contraceptive(OC)|metformin with Diane 35 oral intake.
45926620|NCT03894215|Drug|AGEN2034|PD-1 antibody
45926621|NCT03894215|Drug|AGEN1884|CTLA-4 antibody
45798617|NCT02276040|Drug|periarticular bupivicaine and liposomal bupivicaine|Participants will receive Exparel (liposomal bupivacaine). Exparel is a FDA approved product. Exparel is an extended-release formulation of bupivacaine consisting of microscopic lipid-based particles that diffuse over an extended period. The result is pain relief that can last up to 96 hours after surgery. Extended-release liposomal bupivacaine-based analgesics were shown to provide extended pain relief and decrease opioid (pain medication) use. At the conclusion of the total joint arthroplasty procedure, Exparel is administered via injection into the joint (periarticular bupivicaine and liposomal bupivicaine).
45926622|NCT00137527|Device|Optimizing hemodynamic and anesthetic parameters to improve cerebral perfusion|
45926623|NCT00137566|Drug|acetaminophen (paracetamol)|Paracetamol tablets, 50 mg/kg/day for 3 days.
45926624|NCT00137566|Other|Placebo|
45798618|NCT05064956|Biological|Ad26.ZEBOV|"Ad26.ZEBOV is a non-replicating, monovalent vaccine expressing the full-length Mayinga glycoprotein (GP) of the Ebola virus (formerly known as Zaire ebolavirus), and is produced in human cell line.~Participants will receive a 0.5mL intramuscular injection of Ad26.ZEBOV, at a concentration of 1x10^11 vp/mL, into the anterolateral deltoid muscle."
45798619|NCT04824872|Drug|Dasiglucagon|dasiglucagon SC, low dose
45926625|NCT00137605|Biological|Pneumovax|
45926626|NCT00137605|Biological|Prevnar|
45926627|NCT03150966|Drug|Nanocurcumin|Patients will take 80 mg nanocurcumin in the form of capsules daily during the 6 month study period
45926628|NCT03150966|Drug|Placebo|Patients will take placebo in the form of capsules daily during 6 months study period
45926629|NCT00137644|Behavioral|Preventing AIDS Through Live Movement and Sound (PALMS)|
45926630|NCT00137683|Behavioral|one-on-one education, group education, small media|
45926631|NCT00137722|Behavioral|Education of providers and their staff|
46072162|NCT05471128|Procedure|Standard of Care Biopsy|Patients will be evaluated with multiparametric MRI prostate followed by ExactVu micro-ultrasound to identify target lesions all of which will be biopsied by the examiner
45650064|NCT03694249|Drug|Ifetroban Sodium|Given by mouth
45650065|NCT03694249|Other|Placebo|Given by mouth
45926632|NCT00137722|Behavioral|Case management|
45926633|NCT00137722|Behavioral|Payment for desired behaviors|
45926634|NCT00137761|Drug|ZD 1839|Taken orally once daily
45650066|NCT03621943|Procedure|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
45650067|NCT03621943|Procedure|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
45650068|NCT03043339|Other|Stool Specimen Collection|Participants will provide a stool sample at baseline (pre-operation) and 30 days after the transplant operation. Stool specimens will be self-collected by the participant.
45798620|NCT04824872|Drug|Dasiglucagon|dasiglucagon SC, high dose
45926635|NCT00137761|Drug|Docetaxel|Given intravenously once weekly for 2 out of 3 weeks
45926636|NCT00137800|Drug|OSI-774 (Tarceva)|Once daily without interruption as long as there is no disease progression or serious side effects experienced.
45926637|NCT00137878|Drug|TNFerade™|
46072163|NCT05463484|Combination Product|Test|Toothpaste including a Saliactive® that is the combination of an olive product, betaine and xylitol.
46072164|NCT05463484|Combination Product|Placebo|Toothpaste with the same composition as the test product but without Saliactive®.
46072165|NCT05463484|Combination Product|Control|Toothpaste marketed for gingivitis with zinc citrate.
46072166|NCT05462613|Other|quality of life questionnaires|EORTC QLQ-C30 questionnaire (Quality of life questionnaire- Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D3L questionnaire (EuroQol-5 Dimensions, 3 levels)
45798621|NCT04824872|Drug|Placebo|placebo for dasiglucagon
45798622|NCT02315664|Behavioral|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker called Fitbit Flex, and remote counseling by a PT. Intervention will be received immediately.
45926638|NCT00137917|Biological|Meningococcal serogroup B vaccine|
45926639|NCT02858921|Drug|Dabrafenib|Dabrafenib, a 4-(3-aminosulfonylphenyl)-5-(pyrimidine-3-yl) thiazole, is a potent and selective inhibitor of B-RAF kinase activity with a mode of action consistent with adenosine triphosphate (ATP)-competitive inhibition, and is approved as monotherapy in BRAF V600E-mutant advanced/metastatic melanoma.
45926640|NCT02858921|Drug|Trametinib|Trametinib, a pyrido - pyrimidine derivative, is a potent and highly selective allosteric non-competitive inhibitor of MEK1/MEK2 activation and kinase activity has been approved as monotherapy in BRAF (V600E)-mutant and BRAF (V600K)-mutant melanoma.
45926641|NCT02858921|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
45926642|NCT03150927|Dietary Supplement|Probiotic Microbial Composite|125mg (or 250 mg) of BiOWiSH Probiotic Microbial Composite™ is to be dosed once daily. Product will be supplied in capsule form to be administered orally. Each subject will be given a 15-day supply (30 capsules) to take with them after their initial visit. Capsules will be administered every 15 days by primary investigators at follow up visits.
45926643|NCT03150927|Dietary Supplement|Placebo|125mg (or 250 mg) of Placebo is to be dosed once daily. Product will be supplied in capsule form to be administered orally. Each subject will be given a 15-day supply (30 capsules) to take with them after their initial visit. Capsules will be administered every 15 days by primary investigators at follow up visits.
45926644|NCT00137956|Device|Emphasys Endobronchial Valve (EBV) Device and Procedure|
45926645|NCT00137995|Drug|Rituximab|375 mg/m² D-2/D1
45926646|NCT00137995|Drug|Etoposide|100 mg/m² D1-D2-D3
45926647|NCT00137995|Drug|Carboplatine|max 800mg D2
45926648|NCT00137995|Drug|Ifosfamide + Mesna|5 g/m² from D2 to D13
45926649|NCT00137995|Drug|Cisplatine|100 mg/m² from D1 to D13
45798623|NCT02315664|Behavioral|Same intervention with a 2 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 2 month delay.
45798624|NCT02250703|Drug|Midazolam|oral midazolam 0.5mg/kg upto maximum dose of 15mg
45926650|NCT00137995|Drug|Cytosine Arabinoside|2000 mg/m²/12 h D2 D3
45926651|NCT00137995|Drug|Dexamethasone|40 mg From D1 to D4
45798625|NCT02250703|Drug|Dexmedetomidine|intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg
45926652|NCT00137995|Procedure|Autologous Stem Cell Transplantation|
45926653|NCT00137995|Drug|BCNU|300mg/m² on D-6
45798626|NCT02298842|Device|Platelets stored in InterSol|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
45798627|NCT02298842|Device|Platelets stored in Plasma|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. During the collection, plasma collected from the donor will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
45798628|NCT02314728|Drug|Misoprostol|Patients who are randomized to receive misoprostol will have 25mcg placed vaginally. Repeated dosing of misoprostol is based on clinical exam and clinical judgment of the provider.
45650069|NCT03043339|Other|Anal Swab Sampling|Anal swabs will be collected prior to surgery (baseline) and at post-operation days 2, 15, and 30. Participants whose planned hospitalization duration is extended from the pre-surgical plan will have an additional, optional, anal swab collected 2 days prior to their anticipated hospital discharge date. Anal swabs will be collected by the study team, except for the standard of care post-operative appointment (30 days after the operation) for the living donors who will collect their own samples.
45798629|NCT02314728|Drug|Oxytocin|Patients who are randomized to receive oxytocin alone will receive intravenous administration of oxytocin as designated by the hospital protocol. Protocol begins with 2 milliunits of oxytocin that is then titrated over time. Titration is based on clinical exam and clinical judgment of the provider and is continued until there are adequate uterine contractions.
45798630|NCT03135860|Drug|Inhaled Nitric Oxide 30mcg/kg IBW/hr|Inhaled Nitric Oxide 30 mcg/kg IBW/hr will be administered through the INOPulse Device open label for 4 weeks
45798631|NCT04083794|Other|Laboratory based assessments|physical maneuvers to assess physiological responses in bone blood flow
45798632|NCT02326363|Behavioral|Mindfulness Based Relapse Prevention (MBRP)|Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of MM practices such as breath meditation, urge surfing, walking or movement meditation.
45926654|NCT00137995|Drug|Etoposide|200 mg/m² from D-6 to D-3
45926655|NCT00137995|Drug|Cytarabine|100 mg/m² from D-6 to D-3
45650070|NCT03043339|Other|Short Diet Assessment (SDA)|The study coordinator will administer the Short Diet Assessment (SDA) to participants prior to surgery at baseline and post-operation days 2, 15, and 30. Participants whose planned hospital length of stay is extended from the pre-surgical plan will complete the questionnaire 2 days prior to their anticipated hospital discharge date.
45926656|NCT00137995|Drug|Melphalan|140 mg/m² on D-2
45926657|NCT03150888|Drug|Antihypertensive Agents|Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.
45926658|NCT03150888|Other|Cardiovascular risk factors|Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.
45926659|NCT00138112|Drug|Empirical Vancomycin|
45926660|NCT00138112|Drug|Prophylactic Vancomycin|
45926661|NCT00138229|Biological|aldesleukin|
45926662|NCT00138229|Biological|filgrastim|
45926663|NCT00138229|Biological|therapeutic autologous lymphocytes|
45926664|NCT00138229|Drug|cyclophosphamide|
45926665|NCT00138229|Drug|fludarabine phosphate|
45926666|NCT02834780|Drug|H3B-6527|H3B-6527 by mouth once or twice daily at specified doses.
45926667|NCT00404131|Drug|diquafosol tetrasodium (INS365) Ophthalmic Solution|
45926668|NCT00404209|Procedure|Vitrectomy|pressurized 23GA vitrectomy with a 3D system
45926669|NCT03150849|Diagnostic Test|C-X-C Chemokine Receptor 4|marker assessed by flowcytometry in a blood sample
45926670|NCT02826161|Drug|Napabucasin|Napabucasin will be administered in continuous 28-day cycles. The starting dose of napabucasin is 240 mg twice daily (480 mg total daily dose) with approximately 12 hours between each dose. Napabucasin should be taken with fluids either 1 hour prior to a meal or 2 hours after a meal.
46072167|NCT05462613|Procedure|Blood sample|Blood sample for plasma collection Blood sample for ctDNA (circulating tumoral DNA) collection
45798633|NCT02326363|Behavioral|Twelve-Step Facilitation Intervention (TSF)|"The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a take home summary and homework assignment."
45798634|NCT02275338|Drug|Lanreotide Autogel|120mg administered via deep subcutaneous injection at Day 0 and Day 28.
45798635|NCT04781348|Procedure|Platelet Rich Plasma plus fat grafting|The study participants fulfilling the inclusion criteria giving consent will be randomly divided into two groups, one group will receive only fat grafting whereas another group will receive Platelet Rich Plasma plus fat grafting.
45926671|NCT02826161|Drug|Paclitaxel|Paclitaxel will be administered intravenously, once weekly, via one-hour infusion at a starting dose-level of 80 mg/m^2 body surface area. The weekly paclitaxel infusion will be given during 3 out of every 4 weeks, on days 1, 8, and 15 of each 28-day study cycle.
45650071|NCT03043339|Other|NHANES Dietary Screener Questionnaire (DSQ)|The National Health and Nutrition Examination Survey (NHANES) 2009-2010 Dietary Screener Questionnaire will be completed on Post-Operative Day 2. The questionnaire asks about foods consumed during the past 30 days. There are 25 items on the questionnaire and additional questions may be asked depending on responses provided. The questionnaire will be self-administered or administered by a study team member.
45650072|NCT04210687|Procedure|trapeziometacarpal limited excision|Narrow pseudarthrosis CMC1
45650073|NCT04210687|Procedure|Trapeziectomy|Simple trapeziectomy
45650074|NCT04196335|Device|intra-procedural intracardiac echocardiography|use of intra-procedural intracardiac echocardiography during Watchman FLX devices
45650075|NCT03357367|Device|TiVi system|"Device: TiVi system A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by TiVi system 10 minutes later.~Measurement of the value of skin blood flow (by TiVi system) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
45798636|NCT02313558|Drug|Dentifrice Containing Ilex Rotunda Thunb|Use the dentifrice to brush teeth twice a day for 12 weeks
46072168|NCT05462613|Drug|Regorafenib|"- Regorafenib will be administered 3 weeks out of 4 for two months or unacceptable toxicity.~For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~For the second cycle: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle."
46072169|NCT05462613|Drug|Metronomic chemotherapies|"Capecitabine: 625mg/m²/orally twice daily continuously during the first two months~Cyclophosphamide: 50 mg per os, daily, for two months"
46072170|NCT05462613|Drug|Aspirin|75 mg orally and daily during two months
46072171|NCT05462613|Drug|Bevacizumab|5 mg/Kg every 2 weeks according to investigator practice, until disease progression or unacceptable toxicity
46072172|NCT05462613|Drug|FOLFIRI or FOLFOX|every 2 weeks according to investigator practice
46072173|NCT05451888|Behavioral|Spa treatment|A 40 minute period of lying in the spa treatment pool
45450670|NCT03535558|Drug|Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination|Participants exposed to an oral ST will be observed. Participants will not receive any intervention as a part of this study.
45798637|NCT02313558|Drug|Control dentifrice|Use the dentifrice to brush teeth twice a day for 12 weeks
45798638|NCT01721473|Other|positron emission tomography scan|2-FA positron emission tomography scan
45798639|NCT03075254|Device|A Peltier for Sensory testing|Subjects will be trained to rate the magnitude of late sensations elicited following brief (700 msec) contact of a preheated thermode with the glabrous (palmar) skin of either hand/foot either numerically or using a visual analogue scale.
45798640|NCT03075254|Device|functional magnetic resonance imaging for Brain Neuroimaging|to evaluate baseline changes in regional cerebral blood flow to nociceptive thermal stimuli applied to the extremities of FM patients and healthy volunteers.
45926672|NCT00138385|Biological|FluMist|
45926673|NCT00138385|Biological|Fluzone|
45926674|NCT00138541|Drug|vildagliptin|
45926675|NCT00138580|Drug|vildagliptin|
45926676|NCT03150771|Drug|Aripiprazole|Injection
45926677|NCT00138619|Drug|vildagliptin|
45926678|NCT00138697|Drug|IVIG-L|
46072174|NCT05451212|Biological|MuSK-CAART|Intravenous infusion of MuSK-CAART at different doses. Subjects may also receive MuSK-CAART following pre-treatment with CY, or CY plus FLU.
46072175|NCT05450198|Biological|MK-6194|MK-6194 administered subcutaneously (SC)
45926679|NCT00138775|Drug|D-serine|
45926680|NCT03150732|Drug|Systemic nalbuphine|Patients will receive systemic nalbuphine 10 mg
46072176|NCT05450198|Biological|Placebo|Placebo comparator to MK-6194 administered SC
46072177|NCT05740280|Drug|iCP-NI|20 mg/mL iCP-NI solution for intravenous injection
46072178|NCT05740280|Drug|Placebo|Placebo solution for intravenous injection
46072179|NCT05431088|Drug|GBT021601|Tablets which contain GBT021601 drug substance
45597926|NCT03274375|Drug|IA session|10 IA sessions performed in 28 days maximum, using TherasorbTM adsorbers which contain sheep derived polyvalent antihuman-immunoglobulin coupled to SepharoseTM CL-4B.
45597927|NCT03274375|Drug|Rituximab|"Concomitantly, Rituximab will be given each week for 4 weeks (one injection by week +/- 3 days):~at least 1 day before each IA session~the last injection will occur after the last session IA (minimum one day after)"
45597928|NCT02220959|Other|walk test|patients will be encouraged to walk a 60 meter distance under 1 minute and FVC will be measured before and after the walk test
45650076|NCT04183699|Diagnostic Test|Prostate biopsy|MRI-targeted + systematic random prostate biopsy
45926681|NCT03150732|Drug|Local nalbuphine|Patients will receive local nalbuphine 10 mg
45926682|NCT03893825|Drug|TV-46000|TV-46000 will be administered per dose and schedule specified in the arm description.
45926683|NCT03893825|Drug|Placebo|Placebo matching to TV-46000 will be administered per schedule specified in the arm description.
45926684|NCT00138814|Procedure|Radiotherapy (boost versus no boost)|
45798641|NCT03075254|Device|fMRI for Spinal Cord Neuroimaging|The subjects will be positioned supine and immobilized by means of a padded head support. The spinous process of the first thoracic vertebra (T1) will be aligned with the center of surface Neuro - coil. This coil will be employed for both transmission of radio-frequency (RF) pulses and detection of the magnetic resonance (MR) signal. A modified FLASH sequence will be employed to obtain Blood Oxygen Level Dependent (BOLD)-sensitive images of the spinal cord.
45926685|NCT00138892|Procedure|Waiting time (access time to Total joint replacement)|See Detailed Description.
45798642|NCT01646268|Drug|Rotigotine|"Transdermal Patch~Content:~2 mg /24 h (10 cm^2), 4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)~For early-stage Parkinson's disease, receive Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 24 week maintenance period"
45926686|NCT00138970|Drug|Zenapax®, CellCept® and prednisolone|
45926687|NCT00138970|Drug|Sandimmun Neoral®, CellCept® and prednisolone|
45798643|NCT01646268|Drug|Placebo Patch|"Transdermal Patch~Size:~10 cm^2, 20 cm^2, 30 cm^2, 40 cm^2~Subjects randomized to placebo will receive matching placebo patches"
45926688|NCT00139009|Drug|Cyclosporine A|
45798644|NCT02275026|Procedure|Functional magnetic resonance imaging|Diffusion tensor imaging
45926689|NCT00139048|Behavioral|Decision Aid|
45926690|NCT00139087|Behavioral|Telephone Outreach for Therapy|
45926691|NCT03890666|Drug|Albuterol eMDPI DS|"Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) DS with 4 component devices:~Device 1: Albuterol eMDPI~Device 2: Albuterol eMDPI Patient-facing smart device application (App)~Device 3: DHP Cloud solution)~Device 4: Provider-facing dashboard (dashboard)"
45650077|NCT04173013|Biological|Uromune|2 sprays of solution once daily for a total of 3 months.
45926692|NCT03890666|Drug|albuterol|Standard of care albuterol-administering rescue inhaler
45650078|NCT03020875|Drug|Ofirmev|Intravenously administered acetaminophen.
45650079|NCT03020875|Drug|Per Os Acetaminophen|Orally administered acetaminophen.
45926693|NCT00139126|Behavioral|Fire safety education|Education on smoke alarm maintenance based on behavioral theories
45926694|NCT00139165|Drug|Budesonide|Capsule. Oral 6 mg o.d. for 24 weeks
45926695|NCT00139165|Procedure|sigmoidoscopy|Sigmoidoscopy performed 2 times during the study period.
45926696|NCT00139204|Procedure|C11 Methionine PET scan|
46072180|NCT05421754|Device|ANNE Sleep|ANNE Sleep system for 1 night with HST followed by 3 nights of ANNE Sleep system alone.
46072181|NCT05411887|Drug|Rosuvastatin, Olmesartan Medoxomil|Olostar Tablet
45650080|NCT03102931|Other|Reduced ROS/RNS content products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
45650081|NCT03102931|Other|Typical to high (ROS/NOS) products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
45650082|NCT02996305|Drug|OV101 Regimen 1|
45650083|NCT02996305|Drug|OV101 regimen 2|
45650084|NCT02996305|Other|Placebo|
45650085|NCT02612909|Biological|IVACFLU-A/H5N1 vaccine|Monovalent A/H5N1 influenza vaccine (MIV), whole virion inactivated, purified by sucrose gradient on ultracentrifuge. The vaccine was produced in eggs, inactivated with formaldehyde, and formulated with aluminum hydroxide 0.6 mg/0.5 mL with no preservative.
45926697|NCT00139243|Drug|Taxotere|
45926698|NCT00139243|Drug|Cisplatin|
45926699|NCT00139243|Drug|5-Fluorouracil|
45926700|NCT00139243|Drug|Leucovorin|
45926701|NCT00139282|Drug|Squalamine Lactate|
45926702|NCT03861767|Drug|Metformin ER|tablet
45926703|NCT03861767|Drug|Placebo|Matched placebo in doses of 1, 2 and 3 tablets to coincide with the 500, 1000, and 1500 mg arms.
45926704|NCT00139321|Device|Force platform and electromyography|
45926705|NCT00139360|Drug|Bevacizumab|Anti angiogenesis treatment
45926706|NCT00139438|Behavioral|Disease Management Assessment|
45926707|NCT00139516|Behavioral|self-help|
45926708|NCT00139516|Drug|nicotine replacement therapy|
45926709|NCT00139516|Behavioral|smoking cessation|
45926710|NCT03150654|Device|Laser pan-retinal photocoagulation|Green laser photocoagulator
46072182|NCT05411822|Device|Lighting Intervention Blue light|Custom made lighting fixture that will deliver the blue lighting intervention
46072183|NCT05411822|Device|Lighting Intervention Green light|Custom made lighting fixture that will deliver the green lighting intervention
46072184|NCT05409911|Drug|S-217622|Tablet for oral administration
46072185|NCT05406817|Drug|SNDX-5613|Initial radiolabeled SNDX-5613 will be administered as an oral solution. Capsules will be administered thereafter.
45650086|NCT02612909|Biological|Placebo|Includes 4.500mg sodium chloride, 0.685 mg sodium phosphate dibasic dihydrate, and 0.186 mg sodium phosphate monobasic dihydrate.
45650087|NCT02975479|Drug|ALK Diluent|
45650088|NCT02975479|Drug|ALK Alutard SQ 5-grasses or ALK Alutard Birch|Depot formulation of relevant allergen adsorbed to aluminium hydroxide in a suspension.
45650089|NCT03102853|Other|Nordic diet|
45650090|NCT03102853|Other|Control diet|
45926711|NCT00139555|Drug|amlodipine/benazepril|
45926712|NCT03844412|Drug|5% lidocaine/5 mg/ml 0.02% estradiol compound cream|Lidocaine/estradiol cream targets peripheral nerves and tissues affected in VBD. Participants will be provided with a diagram and written instructions, detailing how to apply the cream to the vaginal vestibule daily for weeks 1-16. Treatment with lidocaine/estradiol or placebo cream will be terminated at week 16 (end of month 4).
45926713|NCT03844412|Drug|Nortriptyline|Nortriptyline is a centrally-acting tricyclic antidepressant that is FDA-approved for treatment of neuropathic pain. Dosing will begin with one 10 mg pill nightly for week 1, then two 10 mg pills nightly for week 2, three 10 mg pills nightly for week 3, four 10 mg pills nightly for week 4, and five for weeks 5 -16. Treatment with nortriptyline or placebo pill will be tapered off over weeks 16-18, decreasing the dose by 10 mg every 4 days. Participants will be provided with a list of drugs to avoid that are known to interact with nortriptyline.
45926714|NCT03844412|Drug|Placebo cream|The comparison treatment will be an identical-appearing placebo Moisturel™ cream
46072186|NCT05398081|Drug|Cefuroxime (Zinnat®)|Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Cefuroxime (Zinnat®), a second generation cephalosporin will be used
46072187|NCT05398081|Drug|Ceftriaxone (Rocephin®)|Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Ceftriaxone (Rocephin®) a third generation cephalosporin will be used
46072188|NCT05394259|Drug|Piflufolastat F18|Given by vein (IV)
45798645|NCT04021082|Drug|Cerdulatinib|Small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies
45798646|NCT04010786|Drug|NNC0247-0829|Participants will receive either single or multiple doses given subcutaneously (s.c., under the skin) in a lifted fold of the stomach skin. Dose level and number of doses will depend on the cohort.
45650091|NCT04866485|Drug|HBM4003 and pembrolizumab|Subjects will be treated with HBM4003 and pembrolizumab on Day 1 during each 21-day cycles.
45650092|NCT04858373|Other|Glucose as reference food|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
45650093|NCT04858373|Other|Emmer bread from Greek emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from Greek emmer bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
45650094|NCT04858373|Other|Emmer bread from Italian emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from Italian emmer bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
45650095|NCT04858373|Other|Whole wheat commercial bread|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from whole wheat commercial bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
45798647|NCT04010786|Drug|Placebo (NNC0247-0829)|Participants will receive either single or multiple doses of placebo given s.c. in a lifted fold of the stomach skin.
45798648|NCT03988634|Drug|sacubitril/valsartan|"Sacubitril/valsartan (LCZ696) is available as 24/26 mg, 49/51 mg, and 97/103 mg in tablet form to be taken orally, twice daily, for the double-blind period.~Valsartan matching placebo is available as 40 mg, 80 mg, and 160 mg in tablet form to be taken orally, twice daily, for the double-blind period."
45798649|NCT03988634|Drug|valsartan|"Valsartan is available as 40 mg, 80 mg, and 160 mg in tablet form to be taken orally, twice daily, for the double-blind period.~Sacubitril/valsartan (LCZ696) matching placebo is available as 24/26 mg, 49/51 mg, and 97/103 mg in tablet form to be taken orally, twice daily, for the double-blind period."
45798650|NCT03981926|Other|Team-Based Connected Health (TCH)|TCH is an asynchronous, secure online platform where patients can upload images of atopic dermatitis disease and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
45798651|NCT04734626|Diagnostic Test|Creatine Chemical Exchange Saturation Transfer (CrCEST) Imaging Sequence|CrCEST be used to assess creatine distribution and concentrations in muscle (lower extremity), both at rest and after recovery from a brief foot-pedal depression exercise
45798652|NCT02294630|Drug|Surfactant|Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.
45798653|NCT03906110|Behavioral|Community Colorectal Cancer Awareness, Research, Education & Screening (C-CARES) Materials|Educational materials (photonovella +DVD) + Fecal Immunochemical Test (FIT) kit. Offers colorectal cancer screening information using a novella format. Materials describe colorectal cancer and screening tests that are available, and procedures for completing FIT kit.
45798654|NCT03906110|Behavioral|Contact Message|Card with a general message about colorectal cancer screening. This same message will be delivered at 3 time points.
45798655|NCT03906110|Behavioral|Personalized One on One Education|"Trained study coordinators will meet with participant for a brief 15 minute educational session delivered in clinic that summarizes information from the materials and demonstrates FIT collection.~Email or text reminders with brief messages in clear language will be sent that aim to remind and prompt patients to complete FIT.~For participants that are not responsive to above, trained study staff will address specific FIT specific hinderances by telephone or in clinic.~Participants will receive a one page summary of key points of salience of repeat screening GET FIT AGAIN. Another FIT kit is provided."
45798656|NCT03906110|Diagnostic Test|Fecal Immunochemical Test (FIT)|The Fecal Immunochemical Test (FIT), is a screening test that detects hemoglobin in stool samples, only requiring one stool sample.
45798657|NCT02811614|Procedure|Endoscopic Evacuation|Endoscopic surgery for treatment of supratentorial hypertensive intracerebral hemorrhage.
45798658|NCT02811614|Procedure|Stereotactic Aspiration|Using image guidance to aspirate hematoma.
45798659|NCT02811614|Procedure|Craniotomy|Craniotomy with a big bone flap to evacuate intracerebral hematoma.
45798660|NCT01722487|Drug|Ibrutinib|Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.
45798661|NCT01722487|Drug|Chlorambucil|Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle. The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
45798662|NCT02795858|Drug|Ramucirumab|
45798663|NCT02795858|Drug|Somatostatin Analog|
45798664|NCT02730962|Drug|Vancomycin|Vancomycin 3 times a day for 7 days
45798665|NCT02730962|Other|Placebo|Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic
45798666|NCT02730962|Drug|Neomycin|Neomycin 3 times a day for 1 day
45798667|NCT02730962|Drug|Clindamycin|Clindamycin 3 times a day for 5 days
46072189|NCT05382299|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
46072190|NCT05382299|Drug|Paclitaxel|Administered intravenously
46072191|NCT05382299|Drug|nab-Paclitaxel|Administered intravenously
46072192|NCT05382299|Drug|Gemcitabine|Administered intravenously
46072193|NCT05382299|Drug|Carboplatin|Administered intravenously
45798668|NCT02730962|Procedure|Fecal Microbiota Transplantation|FMT conducted via colonoscopy
45650096|NCT02888041|Drug|Dinoprostone|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
45650097|NCT02888041|Drug|Oxytocine|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.
45650098|NCT04858139|Drug|Lactate|Intravenous injection (20 min), 300 mmol/L, 1mmol/Kg body weight,
45650099|NCT04858139|Drug|Placebo|Intravenous injection (20 min)
45650100|NCT01688167|Behavioral|MC and sexual risk reduction|Four group counselling sessions focused on male circumcision and sexual risk reduction
45798669|NCT05006989|Other|Blueberry Powder|Administered 10 grams/day
45798670|NCT05006989|Other|Placebo Powder|Administered 10 grams/day
45798671|NCT04983823|Other|Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)|A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.
45798672|NCT04983823|Other|Usual care|This will be provided by participants' usual healthcare professional(s).
45798673|NCT05710549|Device|high-density electroencephalography (hdEEG)|EEG will be recorded with a 257-channel EEG system (Geodesic Sensor Net, MegStim). An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek, Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touches the participant's scalp surface directly. Net application takes about 10 min to derive impedances to <30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between 0.1-200 Hz. Vertex electrode Cz is used as an acquisition reference.
46072194|NCT05382286|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
46072195|NCT05382286|Drug|Pembrolizumab|Administered intravenously
46072196|NCT05382286|Drug|Paclitaxel|Administered intravenously
46072197|NCT05382286|Drug|nab-Paclitaxel|Administered intravenously
45650101|NCT04864691|Biological|endovascular recanalization|to recanalize the occlusion cerebral artery with intravascular intervention
45650102|NCT02838745|Drug|Pemetrexed|
45650103|NCT02838745|Drug|Cisplatin|
45650104|NCT03102541|Other|None intervention|
45650105|NCT04864847|Diagnostic Test|RENISCHEM L-FABP POC Test|Point-of-care test cassette with quantitative reader used for the measurement of L-type fatty acid binding protein (L-FABP) in human urine specimens.
45650106|NCT04143919|Diagnostic Test|NYHA assessment|The New York Heart Association (NYHA) functional classification of HF
45798674|NCT05710549|Device|Transcranial alternating current stimulation (tACS)|tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance.
45798675|NCT03871556|Diagnostic Test|LOGIQ P6 Diagnostic Ultrasound|Ultrasound measurements of subcutaneous fat thickness
45798676|NCT01722643|Behavioral|MAxIM|This new intervention, called MAxIM (MotivAtion, Incentives, Memory) uses: 1) motivation enhancement therapy (MET) (an existing evidence-based treatment for adolescent with diabetes) supplemented with cognitive behavior therapy (CBT) to enhance behavior change; 2) financial incentives for daily blood glucose testing and parental monitoring to provide frequent positive feedback; and 3) working memory training (WMT), a method for strengthening specific cognitive processes that support decision-making and future orientation. The interventions will be delivered to families at home via the internet.
45926715|NCT03844412|Drug|Placebo pill|The comparison treatment will be an identical-appearing placebo pill
45798677|NCT01722643|Behavioral|Usual Care|Usual Care reflects the standard treatment currently provided at the Children's Hospital at Dartmouth. Teens will be followed by their treating endocrinologist and receive the following standard services as part of that treatment-quarterly outpatient clinic visits, including an interval medical history and physical examination; routine laboratory assessment; review of glycemic control, medication adjustment, medical nutrition therapy, and diabetes self-management education; telephone consultations with a nurse/certified diabetes educator in their treating clinic are available as often as necessary between clinic visits.
45926716|NCT00139594|Drug|licarbazepine|
45926717|NCT00139633|Drug|carboplatin, 5FU, Taxol and radiation|
45926718|NCT00139672|Drug|PD-217,014|
45926719|NCT03150615|Other|Early enteral nutrition|"Naso-jejunal tube will be placed intraoperatively. The distal end of the feeding tube would be placed at 30 cm distal to Treitz ligament. Standard enteral diet, administered through a nasojejunal tube, is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.~After PD, enteral nutrition liquid regimen will be used step by step from postoperative day 1 to postoperative day 7.Patients are targeted to receive calories for 25 kcal/kg/day. Meanwhile, oral food intake was not restricted."
45926720|NCT03150615|Other|Saline|"Naso-jejunal tube will be placed intraoperatively. The distal end of the feeding tube would be placed at 30 cm distal to Treitz ligament.~After PPPD,Only Normal Saline were given through nasojejunal tube. Entral nutrition was not administrated. Patients intake food orally at will."
45926721|NCT03150615|Device|nasojejunal tube insertion|
45926722|NCT03150615|Other|Oral intake|Patients was encouraged to drink water on postoperative day 1, to eat liquid diet on postoperative day 2, to eat semi-solid on postoperative day 3, to eat solid food on postoperative day 4.
45926723|NCT00139711|Drug|Irinotecan|
45926724|NCT00139711|Drug|Docetaxel|
45926725|NCT03837977|Drug|Liposomal Irinotecan|Arm I
45926726|NCT03837977|Drug|Fluorouracil|Arm I
45926727|NCT03837977|Drug|Folinic Acid|Arm I
45926728|NCT03837977|Drug|Docetaxel|Arm II
45650107|NCT04143919|Procedure|Serum NT-proBNP concentration|Subjects with NYHA score ≥ II will undergo a rapid, on site serum NT-proBNP test on the same day of the visit. Roche CARDIAC proBNP+ test, using the Cobas h 232 device, is a quantitative immunological test for the determination of NT-proBNP in heparinized venous blood.
45650108|NCT04143919|Diagnostic Test|Transthoracic Ecocardiogram|Subjects with a serum NT-proBNP result of ≥ 125 pg/mL at Visit 1 will be referred to a study cardiologist for a transthoracic echocardiogram to assess LVEF and relevant structural heart disease
45798678|NCT02296346|Drug|SoluMedrol|Infusion of drug subcutaneously, once a month.
45926729|NCT00404287|Drug|Fluvastatin|
45926730|NCT00404326|Drug|Hydralazine and magnesium valproate|
45926731|NCT00404326|Procedure|Punch biopsy of the primary tumor|
45926732|NCT03150537|Biological|Fluviral influenza vaccine|Influenza vaccine (Fluviral) given via Med-Jet H4 or IM injection
45926733|NCT00139750|Drug|CP-526,555 (varenicline)|
45926734|NCT00139789|Drug|Kemstro|
45926735|NCT03803228|Drug|DUOSTIM|2 consecutive stimulations by Fertistartkit® on the same cycle
45926736|NCT03803228|Drug|Conventional stimuli|2 stimulations by Fertistartkit® performed on 2 different cycles
45926737|NCT00139828|Drug|human coagulation Factor IX|
45926738|NCT02964481|Genetic|Whole exome sequencing|DNA sequencing of protein coding sections of all genes
45926739|NCT03150498|Drug|BTD-001|BTD-001 in fed vs fasted state
45926740|NCT00139867|Drug|PARCOPA|
46072198|NCT05382286|Drug|Gemcitabine|Administered intravenously
45650109|NCT00136435|Drug|prednisone|Induction Phase: Given orally on days 1-28
45650110|NCT00136435|Drug|doxorubicin|Induction Phaese: Given intravenously on day 1 and day 2 CNS Therapy: Given intravenously on day 1 Intensification: Given day 1 of each cycle
45650111|NCT00136435|Drug|vincristine|"Induction: Given intravenously on days 1, 8, 15, and 22. If complete remission not acheived, will be given on days 29, 36 and 43.~CNS Therapy: Given intravenously on day 1. Intensification: Given intravenously on day 1 of each cycle. Continuation: Given intravenously on day 1 of each cycle"
45650112|NCT00136435|Drug|methotrexate|Induction: Given intravenously on day 3. CNS Therapy: Given intrathecally 4 times over two weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intravenously weekly and intrathecally every 18 weeks
45650113|NCT00136435|Drug|asparaginase|Induction: Given into the muscle on day 5
45650114|NCT00136435|Drug|dexamethasone|Intensification: Given orally on days 1-5 of each cycle
46072199|NCT05382286|Drug|Carboplatin|Administered intravenously
45926741|NCT00139906|Drug|Bifeprunox|
45926742|NCT03761615|Device|Dexcom G6 CGM|All women in the study will be given Dexcom G6 CGM and a study glucometer.
45926743|NCT00139945|Drug|Human acylated ghrelin|5 pmol/kg body weight per min
45926744|NCT03150459|Drug|Simvastatin 20 mg|Simvastatin 20 mg/day for 12 weeks (Group 1)
45926745|NCT03150459|Drug|Simvastatin 40mg|Simvastatin 40 mg/day for 12 weeks (Group 2)
45926746|NCT03150459|Drug|Rifaximin 400 mg|Rifaximin 400 mg/8 hours for 12 weeks (Group 1 and 2)
45926747|NCT03150459|Other|Placebo of Simvastatin|Placebo of Simvastatin for 12 weeks (Group 3)
45926748|NCT03150459|Other|Placebo of Rifaximin|Placebo of Rifaximin for 12 weeks (Group 3)
45926749|NCT00139984|Device|24 hour blood pressure measurement|
45926750|NCT00140023|Drug|Azithromycin microspheres 2.0 single dose|
45926751|NCT00140062|Drug|latanoprost 0.005% (Xalatan)|
45926752|NCT03748550|Behavioral|Aerobic exercise|All participants will receive standard of care for their cancer as well as given a 12-week, home-based progressive aerobic exercise (AE) program. A nonlinear progressive training approach will be used whereby each participant will perform two AE sessions (e.g. walking), on non-consecutive days, per week. AE sessions will vary between low (35-45% heart rate reserve (HRR)), low-moderate (46-55% HRR), high-moderate (56-70% HRR) and high (71-85% HRR) intensity.
45926753|NCT00140101|Device|ZoMaxx™ Drug-Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
45798679|NCT02296346|Device|Extracorporeal Photopheresis|This intervention is the placement of up to two IV's to extract your blood as a set volume, separate out the white cells and return the red cells to your body. Then the white cells are treated with a drug called UVADEX (methoxsalen), excited by a UV light and returned to your body. Once IV is to withdraw your blood and the other is to return your blood to your body.
45798680|NCT01726621|Device|Medtronic MiniMed 620G or 640G Insulin Pump|Subjects to use the Medtronic MiniMed 620G or 640G Insulin Pump and Guardian Link transmitter to manage their diabetes for 4 - 6 weeks.
45798681|NCT02711852|Drug|Duvelisib|Administered as oral capsules
45798682|NCT02507804|Other|Patient diary PROMs|
45798683|NCT02507804|Other|Counselling|
45798684|NCT04687046|Device|JUVÉDERM VOLUX®|JUVÉDERM VOLUX® injectable gel
45926754|NCT00140101|Device|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
45798685|NCT02296502|Other|DSM|Comparing use of DSM-IV versus DSM-5 criteria for autism spectrum disorder
45798686|NCT02501330|Drug|Bosutinib|The recommended adult dose of bosutinib is 500 mg orally once daily with food. For newly-diagnosed chronic phase CML, the recommended dose is 400 mg. The dose may be adjusted appropriately according to the patient's condition; however, the maximum dose is 600 mg once daily.
45926755|NCT03150420|Drug|Sodium Thiosulfate|Intravenous Sodium Thiosulfate Injection (25 grams sodium thiosulfate) to be administered each hemodialysis session (3 times weekly) for 3 weeks
45798687|NCT02427698|Procedure|cyrolipolysis (CoolSculpting device)|Treatment will be a cold exposure for up to 120 minutes using the CoolSculpting device with a commercially available treatment setting.
45798688|NCT02427698|Procedure|subcision|The skin will be punctured using a subcision needle to cut the septa responsible for the skin depression after cryolipolysis.
45798689|NCT03734588|Genetic|SPK-8016|adeno-associated viral vector
45798690|NCT02372630|Drug|Linagliptin|5 mg daily oral tablets of linagliptin
45798691|NCT02372630|Drug|Placebo|matching placebo giving orally daily
45798692|NCT02365454|Device|Stent Graft Placement (Nexus)|"The Nexus stent graft is introduced through a groin to the diseased location at the Aortic Arch. Depending on the patients anatomy and other medical considerations the physician may decide that blood flow to the sub-clavian artery and possibly also to the left carotid artery is required to be maintained via surgical bypass grafting, either immediately, or a few days, before the implantation. In addition to the incision for introducing the investigational stent graft, two smaller access sites are required, one at the groin on the opposite side and on into the Right Arm to the Brachial Artery.~This endovascular procedure will likely require full anesthesia. The entire procedure is assisted by an angiography imaging system."
45798693|NCT02318654|Other|Ice Pack|Subjects will have 600 grams of ice in clear plastic bag size 18 x 23 cm applied to the randomized axilla for 10 minutes. After 10 minutes, the ice pack will be removed and laser hair treatment will be performed.
45798694|NCT02318654|Drug|Topical EMLA cream|Topical EMLA will be applied approximately 2 mm thick to the randomized axilla with a wooden tongue depressor wrapped with impermeable plastic occlusion dressing for 60 minutes. After 60 minutes, the drug will be removed with regular gauze and saline and laser hair treatment will be performed.
45798695|NCT04349930|Drug|Cannabidiol vaginal suppository|Cannabidiol vaginal suppository
45798696|NCT04349930|Drug|Placebo vaginal suppository|Placebo vaginal suppository
45798697|NCT02303990|Drug|Pembrolizumab|
45798698|NCT02303990|Radiation|Radiotherapy|
45798699|NCT03029078|Drug|fecal microbiota transplant|We will perform a fecal microbiota transplant for patients harboring XDR bacteria in their digestive tract
45798700|NCT04585958|Procedure|Biopsy|Undergo biopsy
45798701|NCT04585958|Procedure|Biospecimen Collection|Undergo collection of blood samples
45798702|NCT04585958|Procedure|Computed Tomography|Undergo CT
45798703|NCT04585958|Procedure|Echocardiography|Undergo echocardiography
45798704|NCT04585958|Drug|Olaparib|Given PO
45798705|NCT04585958|Biological|Trastuzumab Deruxtecan|Given IV
45798706|NCT04579250|Biological|VRC-FLUNPF0103-00-VP (H10ssF-6473)|The vaccine is composed of the haemagglutinin (HA) stem domain from A/Jiangxi/IPB13/2013 (H10N8) influenza genetically fused to the ferritin protein from H. pylori. Purified H10ssF-6473 displays eight well-formed HA trimers that antigenically resemble the native H10 stem viral spikes.
45798707|NCT04565522|Other|Prospective observation|Prospective observation until one year follow-up
45798708|NCT03699020|Behavioral|Acceptance and Commitment Therapy (ACT)|Empirically based behavioral intervention that encourages acceptance of circumstances with commitment and behavioral change strategies to improve psychological flexibility.
45798709|NCT03699020|Other|Chronic Pain Education|Education materials about living with chronic pain developed by Weill Cornell Universitys Translational Research Institute for Pain in Later Life
45798710|NCT01727089|Biological|Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Given IV
45798711|NCT01727089|Biological|Bevacizumab|Given IV
45798712|NCT01727089|Other|Laboratory Biomarker Analysis|Correlative studies
45798713|NCT01727089|Other|Pharmacological Study|Correlative studies
45798714|NCT03175367|Drug|Evinacumab|SC or IV administration
45798715|NCT03175367|Drug|Matching placebo|SC or IV administration
45798716|NCT03175367|Other|Background Lipid Modifying Therapy (LMT)|All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.
45798717|NCT01727791|Drug|pregabalin (Lyrica)|Subjects will receive a single 150 mg dose of pregabalin in the evening of Day 1, a 150 mg dose of pregabalin in the morning and evening of Day 2 and a 150 mg dose in the morning of Day 3.
45798718|NCT01728337|Drug|Dysport|Dysport® was injected on the right side of the forehead and Xeomin® was injected on the left side of the forehead.
45798719|NCT01728337|Drug|Xeomin|Xeomin® was injected on the right side of the forehead and Dysport® was injected on the left side of the forehead
45926756|NCT03150420|Drug|Placebo-Normal Saline|Placebo: to be administered each hemodialysis session (3 times weekly) for 3 weeks
45798720|NCT02980627|Behavioral|Therapy with Mobile App Enhancement|"Treatment includes 12 weekly therapy sessions with daily RR app use between sessions. Intervention is CBT-based and specifically draws from ACT. ACT is a contextual behavior therapy that emphasizes the function of behavior (e.g., affect regulation) and helps individuals accept (or tolerate) emotional discomfort for a broader purpose (i.e., personal values). Broadly, treatment will focus on improving diabetes management by increasing patients' capacity to effectively cope with psychological barriers to self-care using acceptance and mindfulness strategies."
45798721|NCT02247193|Drug|Botulinum Toxin Type A|Injection of botulinum toxin at the time of surgery at cleft lip repair site. Botulinum toxin will be injected intraoperatively at 4 standardized sites in the cleft lip during surgical repair.
45798722|NCT02247193|Drug|Normal Saline Injection|Injection of normal saline into cleft lip at time of surgical repair. Saline will be injected intraoperatively at 4 standardized sites in the cleft lip during surgical repair.
45798723|NCT02245087|Drug|Atorvastatin|20 mg of atorvastatin daily
45798724|NCT02991703|Device|pOpmètre®|the pOpmètre® uses saturation sensors,
45926757|NCT00140179|Drug|valnoctamide|
46072200|NCT05382221|Other|Comprehensive Chronic Care|Those randomized to CCC will receive smoking treatment offers via the following routes: 1) Four Outreach Calls from a Health Counselor at 4, 8, 12, and 14 months post-study enrollment; 2) Four texts and/or mailings (depending on healthcare system preferences) over 14 months. These outreach contacts will offer cessation treatment or reduction treatment.
45650115|NCT00136435|Radiation|cranial radiation|Given in 10 daily treatments during CNS therapy phase
45798725|NCT02991703|Device|Sphygmocor|the Sphygmocor uses applanation tonometry
45798726|NCT05710159|Device|iBLAD Application to monitor symptoms and quality of life by the use of pateint-reported outcomes|Development and implementation of a national multimodality application for patients with bladder cancer that builds upon knowledge from the iBLAD study.
45798727|NCT04726969|Drug|Moxidectin 2 mg Oral Tablet|Tablets of 2 mg moxidectin
45450671|NCT02189434|Other|Serum procalcitonin lab draws|"Blood will be collected in a 4mL capacity, green top lithium heparin tube. Samples can be drawn from a port with other labs. The samples will be centrifuged and then the plasma/serum will be removed and placed into a screw-capped round bottom plastic vial. Samples will be stored at -20○C until processing. Serum samples will be batch processed for each participant at the conclusion of their study period.~These draws will be conducted for the sole purpose of this study, and whenever possible, they will be performed at the same time as routine blood draws conducted for medical monitoring to reduce the burden to the patients."
45450672|NCT02193334|Drug|KP-100IT|
45798728|NCT04726969|Drug|Albendazole 400 mg Oral Tablet|Tablets of 400 mg albendazole
45450673|NCT02193334|Drug|Placebo|
45650116|NCT00136435|Drug|leucovorin|Induction: Given intravenously or orally 36 hours after methotrexate
45650117|NCT00136435|Drug|cytarabine|Induction: Given intrathecally days 1, 15, 29 CNS Therapy: Given intrathecally 4 times over 2 weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intrathecally every 18 weeks
45650118|NCT00136435|Drug|hydrocortisone|Induction: Given intrathecally on days 15 and 29. Intensification: Given intrathecally every 18 weeks. Continuation: Given intrathecally every 18 weeks.
45650119|NCT00136435|Drug|6-mercaptopurine (6-MP)|CNS Therapy: Taken orally on days 1-14. Intensification: Taken orally on days 1-14. Continuation: Taken orally on days 1-14.
45650120|NCT00136435|Drug|e. coli L-asparaginase|Intensification: Given in to the muscle weekly.
45650121|NCT04857905|Procedure|Microsurgical resection|Depending on the patient's choice, the microsurgical resection of the brain metastases will be performed.
45798729|NCT04726969|Drug|Ivermectin 3 mg Oral Tablet|Tablets of 3 mg ivermectin
45798730|NCT03174275|Drug|Durvalumab|Subjects will receive durvalumab, 750 mg every 2 weeks by IV infusion over approximately 1 hour (± 5 minutes).
45798731|NCT03174275|Drug|Carboplatin|Carboplatin is commercially available and approved by the US FDA for use in patients with ovarian cancer.
45798732|NCT03174275|Drug|Nab-paclitaxel|Nab-paclitaxel is commercially available and approved by the US Food and Drug Administration (FDA) for use in patients with metastatic breast cancer, metastatic pancreatic cancer, and for the treatment of locally advanced or metastatic NSCLC.
45798733|NCT03174275|Drug|Cisplatin|Cisplatin is commercially available and approved by the US Food and Drug Administration (FDA) for the treatment of advanced bladder, ovarian and testicular cancer. It has been widely studied in a variety of solid tumor types.
45798734|NCT03174275|Procedure|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
45798735|NCT03174275|Radiation|IMRT|"involved field radiation will refer to areas demonstrated to harbor disease on pathology, and not elective areas"
45798736|NCT01731691|Biological|α1 Proteinase Inhibitor|Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.
45798737|NCT01731691|Drug|Placebos|Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.
45798738|NCT05317429|Other|A meal delivering 75 g of carbohydrate|"The nature of the test meal will depend upon the research question being addressed and it is anticipated that the test meals may include (but are not limited to) the following:~(i) Re-structured, enriched, and/or reformulated or non-conventionally processed food products (ii) Model food matrices with different structures or types of carbohydrate e.g. soups with different viscosity."
45798739|NCT05317351|Device|Standard Colonoscopy|Subjects randomized into arm 1 will undergo standard colonoscopy using a standard colonoscope
45798740|NCT05317351|Device|Artificial Intelligence Aided Colonoscopy (GI Genius™)|Subjects randomized into arm 2 will undergo colonoscopy using a standard colonoscope aided by Artificial Intelligence (GI Genius™)
45798741|NCT05317351|Device|Combined Artificial Intelligence Aided Colonoscopy (GI Genius™) and G-EYE® Balloon Aided Colonoscopy|"Subjects enrolled to arm 3 (AG) will undergo colonoscopy using the G-EYE® Colonoscope and Artificial Intelligence Aided Colonoscopy (GI Genius™)."
45798742|NCT04342013|Other|Electronic Clinical Decision Support Application|Robust, real-time medication-related clinical decision support application for use in the operating room. The application is fully integrated with existing clinical systems. It provides visual alerts for medication errors and adverse medication events at the point-of-care.
45798743|NCT03478553|Other|Blood draw|Blood draw
45798744|NCT03478553|Other|Questionnaire|Pulmonary Fibrosis Questionnaire
45798745|NCT02247739|Biological|Recombinant human C1 inhibitor|
45798746|NCT02247739|Other|Placebo|
45798747|NCT02975141|Drug|Afatinib 30Mg Tab|Study Drug
45798748|NCT02975141|Drug|Afatinib 40Mg Tab|Study Drug
45798749|NCT02975141|Drug|Gemzar|Chemotherapy Backbone
45798750|NCT02975141|Drug|Abraxane|Chemotherapy Backbone
45798751|NCT03452891|Other|Methylcellulose|Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
45798752|NCT03452891|Drug|Simvastatin-Methylcellulose|Simvastatin-Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
45798753|NCT04341935|Drug|Linagliptin|5 mg Linagliptin administered by mouth once daily
46072201|NCT05382221|Other|Standard Care|one offer of cessation treatment annually
46072202|NCT05372614|Procedure|Biopsy|Correlative studies
45650122|NCT04857905|Procedure|Gamma Knife radiosurgery|Depending on the patient's choice, the radiosurgical treatment of the brain metastases will be performed.
45650123|NCT04857749|Other|Standard care|As a pre-test to the patients in the group just before starting treatment; Informed Consent Form, Patient Identification Form, CTCAE v5.0 toxicity criteria, Quality of Life Scale will be applied. At the end of the seven weeks, the post-test (measurement tools included in the pre-test) will be applied.
45798754|NCT04341935|Drug|Insulin regimen|Standard of care insulin regimen as per hospital protocol
45798755|NCT04723303|Drug|Umbilical Cord Lining Stem Cells|An IV infusion of ULSCs will be administered.
45798756|NCT04693351|Drug|Troriluzole|Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten.
45798757|NCT04693351|Drug|Placebo|Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten.
45798758|NCT02440451|Device|Neurofeedback using BCI|This group will undergo five sessions of neurofeedback intervention in the fMRI scanner. Each subject will also undergo neuropsychological evaluations before the first neurofeedback session (week 0) and after the last neurofeedback session (week 7). The first four sessions are weekly while the last one is one month later. The intervention will take a total of four months. Follow up will be performed in the the first week and 6 months after the last intervention session.
45798759|NCT04744415|Other|Epidemiology of admissions|Cardiology Intensive Care Unit admission
45798760|NCT05317039|Other|silica-calcium phosphate nanocomposite SCPC|Patients will be treated with the buccal plate repositioning technique and grafted with SCPC then the grafted defect will be covered with a platelet-rich fibrin membrane.
45798761|NCT05317039|Other|freezed dried bone|Patients will be treated with the buccal plate repositioning technique and grafted using DFDBA. then the grafted defect will be covered with a platelet-rich fibrin membrane.
45798762|NCT05316961|Device|Active PEMF|PEMF 1.5mT, 10Hz, 10 minutes
45798763|NCT05316961|Device|Sham PEMF|PEMF 0mT, 0Hz, 10 minutes
45798764|NCT05316961|Other|Eccentric exercise|Eccentric exercise, 10 repetitions, 3 sets
45798765|NCT05710003|Behavioral|breathing exercises|"A-breathing exercises: 20 times per hour. While setting down, deep breathing is taken from the nose while mouth is closed, breath holding for at least ten seconds, then slow maximal exhalation for at least 10 seconds.~B-Upper Limb Endurance Exercises (low weight and high repetition) : Study participants will be educated to perform upper limb exercises every 4 hours. Three exercises will be repeated 10×3 times with 1 minute rest in between.~Breathing exercise and upper limb endurance exercises is explained in the reminder in details"
45798766|NCT05316883|Drug|Clozapine|clinical doses adjusted to sideeffects and clinical effect
46072203|NCT05372614|Drug|Neratinib Maleate|Given PO
46072204|NCT05372614|Biological|Trastuzumab Deruxtecan|Given IV
46072205|NCT05368103|Biological|Daxdilimab|Daxdilimab will be administered subcutaneously as two injections for each dose.
45798767|NCT02442869|Behavioral|Stage 1 Treatment as usual (TAU)|4-8 weeks of the treatment typically provided by that counselor with the caveat that neither DBT nor CAMS can be provided.
45798768|NCT02442869|Behavioral|Stage 1 CAMS|4-8 weeks of Collaborative Assessment and Management of Suicidality (CAMS)
45650124|NCT04857749|Other|Navigation Nursing|With the role of navigator, the nurse contributes to increase the quality of care and to positively affect the physical, psychological and social well-being of the patient. Navigator nurses address patient barriers to care that are complex and often not easily resolved. As a result of the navigation nurses participating in care in the field of oncology; Providing assistance to the side effects of cancer and its treatment, including symptom preventive measures, supporting communication between individuals participating in treatment, preventing delays in treatment, explaining the language of medical treatment, providing psychosocial support, defining and recommending resources.
45798769|NCT02442869|Behavioral|Stage 2 CAMS|4-16 weeks of Collaborative Assessment and Management of Suicidality (CAMS)
45650125|NCT05045209|Other|Virtual rehabilitation|Patient who are assigned to this group will receive virtual rehabilitation
45798770|NCT02442869|Behavioral|Stage 2 Dialectical Behavioral Therapy (DBT)|4-16 weeks of Dialectical Behavioral Therapy (DBT)
45798771|NCT05316649|Other|Measurement of external blood loss|Measurement of external blood loss
45798772|NCT05316649|Diagnostic Test|Serum Hemoglobin concentration|Serum Hemoglobin concentration
45798773|NCT02443571|Radiation|Fluciclovine (18F)|Not applicable. This is an observational study.
45798774|NCT01952873|Other|Prolonged inflation|Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with <0.3 atm drop during that period.
45798775|NCT01952873|Other|Rapid inflation|The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but <30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
45798776|NCT03990363|Drug|Verinurad|"Study treatments will be titrated in 3 steps for target low dose (3 mg), intermediate dose ( 7.5 mg) and High Dose (12 mg) Verinurad.~As per Protocol Version 5.0, Patients from 3 mg dose will be switched to 24 mg at visit 9"
45798777|NCT03990363|Drug|Allopurinol|Study treatments will be titrated in 3 steps: Low dose (100 mg), intermediate (200 mg) and High Dose ( 300 mg) Allopurinol
45798778|NCT03990363|Drug|Placebo for Verinurad|Matching Capsule
45798779|NCT03990363|Drug|Placebo for Allopurinol|Matching tablet
45798780|NCT02444663|Radiation|Clinician Valgus|Clinician performed valgus stress X-ray under fluoroscopy
45798781|NCT02444663|Radiation|Clinician Varus|Clinician performed varus stress X-ray under fluoroscopy
45798782|NCT02444663|Radiation|Device Valgus - 0 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
45798783|NCT02444663|Radiation|Device Valgus - 10 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed varus stress X-ray under fluoroscopy.
45798784|NCT02444663|Radiation|Device Valgus - 20 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
45798785|NCT02444663|Radiation|Device Valgus - 30 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
45798786|NCT02444663|Radiation|Device Varus - 0 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
45798787|NCT02444663|Radiation|Device Varus - 10 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
45798788|NCT02444663|Radiation|Device Varus - 20 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
45798789|NCT02444663|Radiation|Device Varus - 30 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
46072206|NCT05364008|Drug|Green Tea Extract|Green tea extract 1650 mg/day (45% EGCG) along with ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles.
45650126|NCT02612285|Drug|SNX-5422|Capsule(s) dosed every other day for 21 days (total 11 doses) out of a 28-day treatment cycle
45650127|NCT02737579|Procedure|XFM guidance|X-ray images and MRI roadmaps are aligned, during the medically indicated catheterization procedure, both conventional X-ray and investigational XFM images are displayed side-by-side. The operator may choose to be guided by either.
45650128|NCT02642185|Procedure|Microwave ablation|CT-guided percutaneous ablation of 1-5, <31mm in diameter, colorectal liver metastases, performed with any generic microwave ablation system cleared for clinical use
45650129|NCT02642185|Procedure|Resection|Open or laparoscopic resection of liver metastases using standard of care surgical procedures
45798790|NCT02445287|Radiation|Radiation|Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT). Human subjects will be imaged with CARESTREAM Cone Beam Computed Tomography (CBCT) 3D only.
45798791|NCT04341857|Drug|PD-1 Monoclonal Antibody(Sintilimab)|Sintilimab combined with FLOT regimen,Docetaxel#50mg/m2d1,iv infusion for 1 hour#,Oxaliplatin#80mg/m2d1#iv infusion for 2 hours#,Calcium,leucovate#200mg/m2d1#iv infusion# ,Fluorouracil#2600mg/m2,intravenous drip for 24h# Every 14 days is one cycle# Sintilimab#200mg, d1#iv infusion Every 21 days is one cycle.
45798792|NCT02974283|Other|Normobaric oxygen therapy|"In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should within 1 hour after diagnosed ischemic stroke and uninterrupted during other treatments including r-tPA thrombolytic therapy and standard clinical treatment. .~Other Names:"
45798793|NCT00002913|Drug|paclitaxel|Given IV
45798794|NCT00002913|Drug|cisplatin|Given IV
45798795|NCT00002913|Drug|topotecan hydrochloride|Given IV
45798796|NCT00002913|Biological|filgrastim|Given SC
46072207|NCT05364008|Other|Placebo|Placebo 1650 mg/day along with ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles.
46072208|NCT05360966|Drug|AR-15512 Ophthalmic Solution|Topical ocular administration of one drop in both eyes BID for 90 days.
45798797|NCT04661839|Biological|COVID-HIGIV|COVID-HIGIV is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2. COVID-HIGIV will be administered via intravenous infusion.
46072209|NCT05360966|Drug|Vehicle|Topical ocular administration of one drop in both eyes BID for 90 days.
45926758|NCT03748121|Behavioral|Pranayama assisted trauma-focused Cognitive Behavioral Therapy (TF-CBT)|The pranayama intervention is placed directly at the begin of the respective TF-CBT unit and will be repeated for 10 subsequent TF-CBT units. Pranayama contains the performance of Kapalabhati, Ujjayi, and/or Nadi Shodhana (for overall 1 minute) as well as following Kumbhaka (intentional respiratory reflex inhibition). Pranayama will be repeated 3 times before each TF-CBT unit.
45926759|NCT03748121|Behavioral|Trauma-focused Cognitive Behavioral Therapy (TF-CBT)|Trauma-focused Cognitive Behavioral Therapy (TF-CBT)
45798798|NCT04661839|Other|Placebo (saline)|The reference product is a liquid solution of normal saline (0.9% weight per unit volume (w/v) sodium chloride). Placebo will be administered via intravenous infusion.
45926760|NCT00140218|Drug|R(+) pramipexole dihydrochloride monohydrate|10 mg tid oral
45926761|NCT00140257|Drug|Escitalopram|
45926762|NCT03150381|Behavioral|Weight Loss Only|24- month weight loss program (year 1: weekly in person meetings for 6 months, followed by 2 meetings per month for 3 months, then monthly for 3 months; year 2: monthly phone calls)
45650130|NCT02609633|Device|Accu-Chek® CONNECT DMS|SMBG will be performed during the 6-month study using the Accu-Chek® Aviva CONNECT monitoring device, and corresponding Smartphone app and online tracking tool.
45798799|NCT00002919|Biological|filgrastim|
46072210|NCT05359016|Behavioral|HPV testing of women for cervical cancer screening|Women enrolled in this study will receive HPV testing for cervical cancer screening. They will be offered self-sampling. And also they will be offered voluntary Family Planning services, as appropriate.
45798800|NCT00002919|Drug|cisplatin|
46072211|NCT05357898|Biological|SQZ-eAPC-HPV|Enhanced antigen presenting cells (eAPC) cell therapy; therapeutic vaccine engineered from autologous peripheral blood mononuclear cells (PBMCs) by incorporating 5 mRNAs.
45650131|NCT02609633|Device|DMS|SMBG will be performed during the 6-month study according to usual care, using the participant's current DMS (other than Accu-Chek® CONNECT DMS).
45798801|NCT00002919|Drug|doxorubicin hydrochloride|
45798802|NCT00002919|Drug|methotrexate|
45926763|NCT03150381|Behavioral|Weight Loss Plus|Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.
45926764|NCT03150381|Behavioral|Control|Participants receive quarterly newsletters containing generic cancer prevention messages and participate in community-wide cancer awareness educational sessions.
45926765|NCT00140296|Behavioral|Contraceptive counseling|
45926766|NCT00140335|Behavioral|handwashing|
45926767|NCT03745859|Device|Fraxinus VBN system|Open source planning tool for bronchoscopy
45926768|NCT00140374|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
46072212|NCT05357898|Biological|Pembrolizumab|programmed cell death 1 (PD-1) blocking antibody
46072213|NCT05350878|Other|Implementation Intervention|Virtual and in-person implementation support
46072214|NCT05343390|Behavioral|Enhanced implementation package|Individual training with teaching and modeling (tablet-guided, ~8 hours) Small group training with practice and feedback (tablet-guided, ~16 hours) Ongoing continuous quality improvement sessions (tablet-guided, ~2 hours/month)
46072215|NCT05343390|Behavioral|Standard implementation package|Individual training with teaching (facilitator-guided, ~2 hours) Small group practice (facilitator-guided, ~1 hour) Ongoing clinic support (facilitator-guided, ~30 minutes/month)
46072216|NCT05342883|Device|Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide)|At the initiation of the surgical phase maximal safe resection will be undertaken, and after 25 + 4 from surgery participants will start the concomitant phase and receive daily temozolomide (TMZ, 75mg/m2) and 20 fractions external beam radiation (EBRT). The EBRT treatment will be to the operative bed and any residual disease identified at the time of the imaging obtained for EBRT planning. The EBRT planning will utilize the GT implant dosimetry with the intent that the dose received from the GT will be accounted for during the EBRT treatment planning process. Twenty-eight days ±7 after the completion of concomitant TMZ and EBRT, participants will enter the adjuvant phase and will be treated with TMZ (150-200mg/m2) for 5 days at the start of every 28- day cycle, for 6 cycles.
46072217|NCT05329584|Device|InSpace Subacromial Tissue Spacer|Rotator Cuff Tear Treatment
45650132|NCT04053907|Other|Community Case Management|Community Case Management (CCM), consisting of community health workers able to diagnose malaria by standard RDTs and treating positive individuals with artemether-lumefantrine (AL), according to national guidelines.
45650133|NCT04053907|Other|Weekly fever screening and treatment|Consists of weekly visits by trained VHW who will screen for fever by taking the axillary temperature. If the body temperature is ≥37.5°C, a standard RDT will be performed and, if positive, the individual will be treated with AL, according to national guidelines.
45798803|NCT00002919|Drug|vinblastine sulfate|
46072218|NCT05323045|Drug|BYON3521|BYON3521 (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
45798804|NCT00002919|Procedure|conventional surgery|
45798805|NCT03083405|Drug|Opipramol|The study group will get a drug to decrease bruxism activity. Group will be evaluated using polysomnography included rhythmic masticatory muscle activity registration before and after intervention.
45798806|NCT00383799|Drug|iv Amiodarone|
45798807|NCT00383799|Drug|iv Procainamide|
45798808|NCT04635241|Drug|Unfractionated heparin|Inhaled nebulised 6 hourly
45798809|NCT04616677|Drug|JNJ-42847922|JNJ-42847922 tablet will be administered orally.
45926769|NCT03150342|Diagnostic Test|myocardial perfusion imaging|dipyridamole-stressed MPI scan using thallium-201
46072219|NCT05318573|Drug|Pembrolizumab|Treatment at 200 mg pembrolizumab, administered intravenously (IV) on Day 1 of each 21-day cycle prior to infusion of FF-10832
45650134|NCT04053907|Other|Monthly malaria screening|CCM plus monthly screening of the whole population with high sensitive RDT (HS-RDT); positive individuals will be treated with AL regardless of symptoms (MSAT).
46072220|NCT05318573|Drug|FF-10832|Following administration of pembrolizumab, FF-10832 Gemcitabine Liposome Injection, 40 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
46072221|NCT05307783|Device|EmboCube Embolization Gelatin|EmboCube is a uniformly cut gelatin foam pre-loaded into a syringe, indicated for use in embolization of blood vessels to occlude blood flow to control bleeding/hemorrhaging in the peripheral vasculature
46072222|NCT05307770|Dietary Supplement|Immediate Release Melatonin|5 mg orally every night at 9 pm for 4 weeks
46072223|NCT05307770|Dietary Supplement|Extended Release Melatonin|5 mg orally every night at 9 pm for 4 weeks
45650135|NCT04053907|Other|MDA|CCM plus 3 monthly rounds of MDA with dihydroartemisinin-piperaquine (DP) starting during the dry season, before the malaria transmission season starts.
45650136|NCT04857125|Other|Patient interventions|"The multicomponent intervention consists of several elements regarding avoidance of specific pre-medications and optimising the patients condition before surgery (reducing fasting and fluid-fasting time).~Per-operative focus on using bispectral index (BIS) guided anaesthesia, Total intravenous anaesthesia (TIVA) as first choice, pain-and PONV (postoperative nausea and vomiting) prophylaxis and treatment.~Postoperative focus on: Reducing indwelling catheters, Fluid (p.o. or IV), Nutrition, Mobilisation, Sleep, Non-pharmacological interventions (Shielding, involving of relatives, orientation, optimizing of senses)"
45650137|NCT04857125|Other|Staff education|Staff will be educated for at least 1-2 hours. Anaesthesiologist and nurse anaesthetists will receive a brush up on the use of bispectral index (BIS) and the intervention elements that are implemented and monitored. Staff in the PACU, as well as staff in the surgery wards, will be educated in postoperative delirium, learning to identify symptoms of delirium and how to use the screening tool CAM.
46072224|NCT05307458|Drug|Buprenorphine/naloxone|Participants will receive gradually increasing doses of buprenorphine while tapering down on their methadone dose.
45798810|NCT04612075|Diagnostic Test|FDG-PET/MRI|Performed at baseline, interim and at 12-16 weeks post radiotherapy.
45798811|NCT03963453|Other|Physical Exercise|Physical exercise are prescribed to be performed three times per week for a year
45798812|NCT03954483|Drug|Buspirone 10 Mg Oral Tablet|Orally administered prior to experiments.
45798813|NCT03954483|Drug|Triazolam 0.25 MG Oral Tablet|Orally administered prior to experiments.
45798814|NCT03954483|Drug|Placebo oral tablet|Orally administered prior to experiments.
46072225|NCT05290064|Other|Ultra-processed food, high energy density|Ultra-processed diet that is high in non-beverage energy density and low in hyperpalatable foods
45650138|NCT04864379|Biological|iNeo-Vac-P01|iNeo-Vac-P01: 300 mcg per peptide
45650139|NCT04864379|Other|GM-CSF|GM-CSF: 40 mcg
45650140|NCT04864379|Drug|PD-1|PD-1: 200mg administered by intravenous infusion every 2 weeks.
45650141|NCT04864379|Procedure|RFA|Radiofrequency ablation surgery
45798815|NCT05709925|Procedure|Instrument Assisted Soft Tissue Mobilization|The Graston Technique which is the Instrument Assisted Soft Tissue Mobilization is the use of a firm instrument to break tissue adhesions and mobilize scar tissue thus improving pain, range of motion and disability.
45798816|NCT05709925|Procedure|myofascial release|myofascial release through stripping technique to the lumbar region.
45798817|NCT02997657|Behavioral|Positive Psychotherapy|Exercises designed to boost moods, positive behaviors, and positive cognitions.
45798818|NCT02997657|Behavioral|Standard smoking cessation counseling|Counseling designed to provide support and problem solving for smoking cessation
45798819|NCT04570579|Device|Vivity Extended Depth of Focus Intraocular Lens|Patients selected to have bilateral sequential cataract surgery using the Vivity (spherical and/or toric where applicable) intraocular lens implant will subsequently be offered enrollment into this observational study. Visual outcomes will be recorded at postoperative day 1, week 1, month 1 and month 3.
45798820|NCT04545541|Drug|Nebulised unfractionated heparin (UFH)|Nebulised UFH (25,000 Units in 5 mL) will be administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days.
45798821|NCT00002925|Drug|ara-C|
45798822|NCT00002925|Drug|Daunorubicin|
45798823|NCT00002925|Drug|Etoposide|
45798824|NCT00002925|Drug|PSC-833|
45798825|NCT00002925|Biological|Aldesleukin|
45798826|NCT05316415|Other|Acemaşiran Music Group|Agreeing to participate in the study Knowing Turkish and being literate Having been hospitalized for bed rest for at least 5 days. Having a gestational age of 28 to 36 weeks Being hospitalized due to at least one of the diagnoses including hypertensive diseases, diabetes mellitus, preterm labor, placenta previa, cervical insufficiency, or premature rupture of the membrane
45798827|NCT05709847|Other|Coffee|24 ounces of coffee will be consumed daily
45798828|NCT02445911|Drug|KQ-791|Capsules administered orally
45798829|NCT02445911|Drug|Placebo|Capsules administered orally
45798830|NCT02955537|Other|MI-BP|MI-BP includes the following components: 1) Home blood pressure monitoring 2) Physical activity monitoring 3) Sodium intake self-monitoring 4) Physical activity and sodium intake goal setting 5) Educational messaging via push notification and in-app messaging 6) motivational messaging 7) tailored messaging relevant to individual participants and 8) medication reminders.
45798831|NCT02446223|Drug|Inggenol Mebutate 0.015%|
45798832|NCT05709769|Other|There are no interventions.|There are no interventions.
45798833|NCT00002937|Drug|paclitaxel|
45798834|NCT00002937|Drug|valspodar|
45798835|NCT02446613|Other|Pollen allergen extract|Pollen (tree, grass or ragweed) allergen extracts will be provided by the research unit and diluted as required in normal saline. The specific pollen allergen extract that will be used for the nasal allergen challenge will be selected according to each subject's individual allergic sensitivity demonstrated in the previous study, TL7116958. If possible, extracts remaining from this study in 2014 will be used, provided they have not reached their expiry date.
45798836|NCT02922777|Drug|BGB324|75 mg/m2 every 21 days
45650142|NCT04132375|Drug|INM004|"The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses."
45650143|NCT04132375|Drug|Placebo|"The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses."
45798837|NCT02922777|Drug|Docetaxel|75 mg/m2 given IV every 21 days
45798838|NCT04483297|Drug|AK1320 MS|AK1320 MS + Local Autologous Bone + Posterior Fixation. Ascending Dose.
45798839|NCT04483297|Other|Control|Local Autologous Bone + Posterior Fixation
45926770|NCT00140452|Drug|Thalidomide|Thalidomide will start at a dose of 100mg/day, dose escalated every 2 weeks by 100mg/day to a target dose of 400mg/day.
45926771|NCT00140491|Device|Vision Restoration Therapy (NOVAVISION)|
45926772|NCT00140530|Device|Paclitaxel-eluting stent (Taxus)|patients has been implanted the Paclitaxel-eluting stent.
45798840|NCT02918955|Procedure|up-front neck dissection|
45798841|NCT02918955|Radiation|radiotherapy|70 Gy in 35 fractions to the macroscopic disease 50 Gy in 25 fractions (if sequential boost) or 56 Gy in 35 fractions (if simultaneous integrated boost) to the elective volumes 66 Gy in 35 fractions to the post-operative region with lymphatic extracapsular extension (Arm B only)
45798842|NCT02918955|Drug|Chemotherapy (Cisplatin)|"100 mg/m2 every three weeks during radiotherapy~In Arm B, chemotherapy can be omitted in case of a cT1-2 primary and a surgical downstaged pN0-1 neck without lymphatic extracapsular extension."
45926773|NCT00140530|Device|Rapamycin-eluting stent|patients has been implanted the Rapamycin-eluting stent.
45798843|NCT02918955|Procedure|Early Salvage Neck Dissection in case of less than cCR (Arm A only)|"Early salvage neck dissection in case of residual lymph node disease will be performed based on the response evaluation by MRI and PET/CT performed 3 and 4 months after the end of (chemo)radiotherapy, respectively (and additional diagnostic modalities if clinically indicated by the physician) and not more than 3 weeks after this post-radiotherapy evaluation.~In Arm A, a successful early salvage neck dissection without the operation of the primary tumor in case of less than clinical complete response (cCR) will be considered a component of the multimodality treatment and not as a failure."
46072226|NCT05290064|Other|Ultra-processed food, both low|Ultra-processed diet that is low in both non-beverage energy density and hyperpalatable foods
45926774|NCT03737825|Device|Computerized gaming rehabilitation Program 1|Brain training games displayed on a large screen paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching in place.
45926775|NCT03737825|Device|Computerized gaming rehabilitation Program 2|Brain training games displayed on a tablet device paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching.
46072227|NCT05290064|Other|Ultra-processed food, both high|Ultra-processed diet that is high in both non-beverage energy density and hyperpalatable foods
45926776|NCT00140569|Procedure|CHVP + interferon|
46072228|NCT05290064|Other|Unprocessed food diet|Unprocessed diet that is low in both non-beverage energy density and hyperpalatable foods
45798844|NCT05315869|Procedure|Appendectomy|Surgical procedure for removal of the appendix
45798845|NCT05315791|Procedure|different methods for maxillary sinus floor elevation|a: 0~3mm+ground into pieces; b: 0~3mm+replace the bone; c: 0~3mm+turn inward to hold up the membrane; d: 3~5mm+ground into pieces; e: 3~5mm+replace the bone; f: 3~5mm+turn inward to hold up the membrane
46072229|NCT05287685|Behavioral|Screen media adapted School Readiness Parenting Program|For the screen time adapted parenting intervention, screen time intervention components will be infused into the SRPP (described below) to address three primary areas shown in research to play an important role in healthy screen media use: (1) reducing and managing screen time use; (2) maximizing benefits of screen time content; and (3) promoting positive parent-child interactions during co-use of screen media. Psychoeducation and practice of these strategies will be incorporated into sessions of the SRPP in which relevant behavioral concepts are addressed.The screen time adapted parenting intervention will utilize the same format (large group, 8 weekly 1.5 hour sessions) as the SRPP.
45798846|NCT00002943|Drug|carboplatin|
45798847|NCT00002943|Drug|cyclophosphamide|
45798848|NCT00002943|Drug|etoposide|
45798849|NCT00002943|Procedure|autologous bone marrow transplantation|
45926777|NCT00140569|Drug|fludarabine|
45926778|NCT00140569|Procedure|CHOP + TBI and autotransplant|
45798850|NCT02446847|Drug|3BNC117|3BNC117 infusions
45798851|NCT02446847|Other|ART Interruption|Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.
45926779|NCT00140608|Device|Seprapack Sinus Dressing|
45926780|NCT00140647|Drug|Ramipril|
45798852|NCT04350853|Procedure|Surgical extrusion|Surgically coronal reposition of the tooth
45798853|NCT00002949|Drug|paclitaxel|Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
45798854|NCT00002949|Drug|vinorelbine tartrate|Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2),
45926781|NCT00140647|Drug|Rosiglitazone|
45926782|NCT00404365|Other|counseling intervention|
45926783|NCT00404365|Other|screening questionnaire administration|
45926784|NCT00404365|Other|study of socioeconomic and demographic variables|
45926785|NCT00404365|Procedure|psychosocial assessment and care|
45926786|NCT03735992|Behavioral|Mind-body medicine group program|The group program is mainly based on MBSR. It further integrates elements of the mind-body medicine cancer program of the Benson-Henry Mind/Body Medical Institute at Harvard Medical School which is rooted in psychoneuroendocrinology and focuses on relaxation techniques, exercise, cognitive restructuring, diet, and social support. In addition, naturopathic methods of selfregulation and self-care are incorporated.
45926787|NCT00140686|Biological|Rotavirus (vaccine)|
45798855|NCT00002949|Radiation|radiation therapy|Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy)
45798856|NCT05315557|Drug|Terlipressin|1mg/24 hour and titrate according to MAP
45798857|NCT05315557|Drug|vasopressin|0.03 U/hour and titrate according to MAP
45926788|NCT03150264|Device|PCV-VG, PEEP5cmH₂O|This is an innovative ventilation mode developed in recent years. The preset tidal volume help the machine modify inspiratory pressures and compensate the decrease of lung compliance.
45926789|NCT03150264|Device|PCV, PEEP5cmH₂O|This is a traditional ventilation mode used in obese patients in the past.
45926790|NCT00140725|Drug|Lamivudine plus Polyethylene glyco-interferon alfa-2b|
45926791|NCT00140725|Drug|Lamivudine|
45926792|NCT03730688|Device|Conventional compartment pressure measurement|Compartment pressure will be measured using the conventional compartment pressure measurement system.
45798858|NCT00002955|Drug|fluorouracil|
45650144|NCT04336241|Biological|RP2|Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation
45798859|NCT00002955|Drug|leucovorin calcium|
45926793|NCT03730688|Device|Experimental compartment pressure measurement|Compartment pressure will be measured using the newly-developed compartment pressure measurement system.
45798860|NCT00002955|Drug|trimetrexate glucuronate|
45926794|NCT03150225|Other|Concurrent training|"In this protocol the participants will perform aerobic and resistance training according to published evidence for middle-aged men; Characterized as concurrent training.~The protocol will last six months and will be divided into two quarters. In the first trimester, initial 30 minutes will be assigned to resistance training, followed by 30 minutes of aerobic training; Already in the second trimester will be 20 initial minutes for the aerobic training and later 40 minutes for the resistance training; Aiming to obtain benefits in the levels of muscular strength, aerobic capacity, body composition, besides positive results in relation to the hormonal adaptations of testosterone, as well as in the psychological well being of the participants. Classes will occur at a frequency of three times weekly, lasting 60 minutes a session."
45926795|NCT03150225|Dietary Supplement|Eurycoma longifolia|Eurycoma longifolia will be administered by supplementation with the standard aqueous-soluble extract extract (Physta ™) in single 200mg capsules daily, and placebo by starch capsules. The supplementatio will last six months.
45926796|NCT00140764|Drug|Metronidazole gel versus placebo gel|
45926797|NCT02964598|Behavioral|Gamified intervention|A new mobile application for assisting in sleep regulation, duration 4-6 weeks
45798861|NCT05709613|Device|Use of a chest compressions' feedback device|The participants will have access to a chest compressions' feedback device
45926798|NCT02964598|Behavioral|Sleep coaching|A new personalized program, duration 4-6 weeks
45926799|NCT02964598|Device|Bright light|Morning bright light 10 000 lux maximum duration 4-6 weeks
45926800|NCT02964598|Other|Control|Minimal information on sleep timing and advancing the sleep rhythm
45926801|NCT02964598|Other|Psychoeducation|An extensive information platform in the internet created for this purpose
45926802|NCT00138736|Drug|Mannan Binding Lectin (MBL)|
46073717|NCT05659446|Procedure|endoscopy management of low output colonic fistula or leak after anterior resection for rectal cancer|Patients involved in endoscopic group were firstly subjected for Interventional Radiology to drain any intra-peritoneal collection present in preoperative radiology then were subjected either to Clips application (OTSC, OVASCO Endoscopy AG. Tubingen, Germany) or Endo-suturing (Overstitch, Apollo Endo-Surgery , TX, United states) to close the low output fistula or leak after anterior resection for rectal cancer. The endoscopy was done under sedation, not general anesthesia after colonic preparation (chemical & mechanical preparation) firstly, to detect size of fistula . Clips were used in cases with fistula's size less than 10 mm, while Endo-suturing devices were used in cases with fistula's size more than 10mm till 15mm.
45650145|NCT04336241|Biological|nivolumab|Programmed death receptor (PD-1) blocking antibody
45650146|NCT00338689|Dietary Supplement|Lower protein formula; Higher protein formula|During the intervention phase of the study, which is from inclusion in the study (latest age 2 weeks) until age 12 months, two experimental infant formulae with different protein content are fed to the enrolled infants; Lower protein formula and Higher protein formula. Additional a breastfed observational group without any intervention is included.
45650147|NCT02848885|Other|Active TDCS|Participants will receive active tDCS stimulation.
45650148|NCT02848885|Other|Sham TDCS|Participants will receive sham tDCS stimulation
45650149|NCT04849559|Drug|Tradipitant|Tradipitant Capsule
45650150|NCT04849559|Drug|Placebo|Placebo Capsule
45650151|NCT03044561|Drug|Sildenafil Citrate|25 mg orally, 4 times per day for 21 days
45650152|NCT03044561|Drug|matching placebo|orally, 4 times per day for 21 days
45650153|NCT02494063|Procedure|Sentinel lymph node biopsy|Bilateral sentinel lymph node biopsy, pathologic ultrastaging
45650154|NCT02494063|Procedure|At least unilateral systematic pelvic lymph node dissection|
45650155|NCT03044405|Diagnostic Test|Fluid challenge|Fluid bolus of 500 ml of crystalloids is given over 15 minutes. Positive fluid responsiveness is defined by an increase in SV of at least 15%.
45798862|NCT04322851|Diagnostic Test|Lung ultrasound|Lung ultrasound performed at the time of extubation to evaluate B-line in patients with mechanical ventilation due to acute decompensated heart failure
45798863|NCT02991079|Other|Intervention group|"Smartphone with APP (EVIDENT) for 3 months, cardio-health rides and feeding workshop.~Counseling on physical activity and Mediterranean diet."
45798864|NCT02991079|Other|Control: Lifestyle counseling|Conseling on physical activity and nutrition (intervention)
45798865|NCT04320199|Dietary Supplement|Fermented Protaetia brevitarsis seulensis powder group|This group takes Fermented Protaetia brevitarsis seulensis powder for 8 weeks
45798866|NCT04320199|Dietary Supplement|Placebo group|This group takes placebo for 8 weeks
45798867|NCT05315245|Other|AGI|no intervention, only observation
45926803|NCT00138736|Drug|Mannan Binding Lectin|"MBL dose at a twice weekly dose interval (3 or 4 days):~0.2 mg/kg, for a 3-day interval; 0.3 mg/kg, for a 4-day interval"
45926804|NCT00140920|Drug|MK0966; rofecoxib|
45926805|NCT00140920|Drug|Comparator: diclofenac 2x 75 mg|
45926806|NCT00390650|Drug|Saredutant|
45926807|NCT03136497|Drug|ABT-199|Oral dose daily until disease progression
45926808|NCT03136497|Drug|Ibrutinib|Oral dose daily until disease progression
45926809|NCT03136497|Drug|Rituximab|Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1
46072230|NCT05287685|Behavioral|School Readiness Parenting Program|The SRPP is an 8-week parenting program for parents of preschool aged children with externalizing behavior problems. The SRPP targets child externalizing behavior problems specifically, as well as to help parents promote children's school readiness skills. The SRPP follows a group Parent-Child Interaction Therapy (PCIT) model and also uses motivational interviewing and modelling problem solving approaches. The SRPP utilizes a large group format (10-15 parents) with weekly sessions lasting 1.5 hours. The SRPP curriculum contains traditional aspects of behavioral management strategies (e.g., improving parenting skills and the parent-child relationship; discipline strategies such as time out). Specific sessions of the SRPP also directly target parental interactions during children's learning activities and setting up homework and household structure and routines. In its original form, SRPP does not address children's screen time.
45926810|NCT00140998|Drug|17 beta estradiol|
45926811|NCT00141076|Behavioral|low vs high glycemic index diet|
45926812|NCT00141154|Drug|Celecoxib|
45926813|NCT00141154|Drug|Placebo|
45798868|NCT05709535|Diagnostic Test|[18F]-PSMA-1007|[18F]PSMA-1007 is a diagnostic radiopharmaceutical for Positron Emission Tomography (PET) scan. The intervention involves single intravenous administration of [18F]PSMA-1007 for PET scan.
46072231|NCT05275634|Other|Stander treatment|Standard treatment will be (active cervical range of motion exercises, myofascial release to upper trapezius muscle and postural advices at home).
46072232|NCT05275634|Device|Interferential current with carrier frequency 2 KHz|Interferential current treatment parameters will be as following; carrier frequency 2 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
46072233|NCT05275634|Device|Interferential current with carrier frequency 4 KHz|Interferential current treatment parameters will be as following; carrier frequency 4 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
45650156|NCT03044405|Diagnostic Test|Focused transthoracic echocardiography|Focused transthoracic echocardiography is performed to assess expansion of stroke volume after fluid challenge. Also mitral E and A waves, left ventricle outflow tract velocity time integral (LVOT VTI) and its variability, inferior vena cava diameters during breathing cycles are measured.
45798869|NCT03912519|Procedure|Parallel placement of 16 gauge electrodes|Parallel technique
45926814|NCT00141154|Drug|Loxoprofen|
45650157|NCT02455141|Drug|Epirubicin plus Cyclophosphamide|Epirubicin 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4
45650158|NCT02455141|Drug|Taxanes|Paclitaxel: 80mg/m2, d1, qw*12 or Docetaxel: 80-100mg/m2,d1,q3w*4
45650159|NCT02455141|Drug|Taxanes plus Carboplatin|Paclitaxel: 80mg/m2, d1,d8,d15, q4w*4 Carboplatin AUC=2, d1,d8,d15, q4w*4 or Docetaxel: 75mg/m2,d1,q3w*4 plus Carboplatin AUC=5-6, d1, q3w*4
45650160|NCT03044639|Drug|Lipid Emulsions, Intravenous|The every day provision of lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
45650161|NCT04864301|Procedure|Tumescent Stretching Measurement Technique|"The Tumescent Stretching Measurement Technique (TSMT) group (N=12) will be administered an intracorporal injection (ICI) of 20 microgram Alprostadil. Hegar 7 dilator will be introduced through the corporotomy until reaching a bone stopping point. The tumescent penis will stretched maximally, and the proximally inserted dilator measured externally to the coronal sulcus."
45650162|NCT02439385|Drug|Avastin/FOLFIRI|Avastin: 5mg/kg iv on day1, every 14 days. Irinotecan: 180 mg /m2 iv on day1, every 14 days. Leucovorin: 200 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil infusion: 1200 mg/m2 iv on day1,2 every 14 days.
45798870|NCT03912519|Procedure|Perpendicular placement with 22 gauge electrodes|Perpendicular technique
45798871|NCT00002961|Drug|cyclophosphamide|Arms A and B Day 2 and 3: Cyclophosphamide 60 mg/kg intravenously; Administer 20 mg/ml concentration over 2 hours.
45798872|NCT00002961|Drug|cyclosporine|"graft vs. host disease (GVHD)prophylaxis: starting on day-1, cyclosporin 1.5 mg/kg IV every 12 hours or by continuous infusion.~When the patient tolerates adequate oral intake, cyclosporin therapy may be changed from IV to oral administration. Cyclosporin therapy should be continued at full dose until day +50. if the patient has less than Grade 2 GVHD, cyclosporin may be tapered by 5-10% weekly until completely off cyclosporin therapy."
45926815|NCT03709706|Drug|Lete-cel|lete-cel will be administered to eligible participants.
45926816|NCT03709706|Drug|Pembrolizumab|Pembrolizumab will be administered to eligible participants.
45926817|NCT00141193|Drug|Celecoxib|
45926818|NCT00141232|Drug|Atorvastatin and Omega-3 fatty acids|
45926819|NCT02315534|Drug|BBI608|"In arm A, BBI608 will be administered at the recommended Phase 2 dose (RP2D) twice daily for 7(±2) days prior to planned surgical resection or biopsy of recurrent GBM. Upon the clinical recovery of the patient and at a time between 15-28 days after surgery, BBI608 will be administered orally, daily, each day of a 28 day cycle in combination with temozolomide.~In arm B, patients who are not candidates for surgical resection will receive BBI608 administered orally, daily, each day of a 28 day cycle at the RP2D in combination with temozolomide."
45926820|NCT02315534|Drug|Temozolomide|Temozolomide (TMZ) will be administered orally, once daily, at a dose of 150 mg/m^2 daily on days 1 through 5 of each 28-day study cycle. The dose of temozolomide can be increased to 200 mg/m^2 as per standard TMZ dosing guidelines for patients who complete at least one cycle at 150 mg/m^2.
45926821|NCT00141310|Drug|Sildenafil citrate|
45926822|NCT03093051|Device|Unpinning Termination therapy|Electrotherapy comprised of standard biphasic and monophasic pacing pulses
45926823|NCT00141349|Drug|UK-369,003|
45926824|NCT00141388|Drug|Pregabalin|
45926825|NCT00404404|Biological|bevacizumab|
45926826|NCT00404404|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
45650163|NCT02439385|Dietary Supplement|Curcumin|Dietary supplement of nanostructured lipid curcumin particle 100mg po bid daily
45798873|NCT00002961|Drug|etoposide|Day 4 (arms A/B): 40 mg/kg over four hours intravenously
45650164|NCT04429529|Biological|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb)
45650165|NCT04429529|Other|0.9% Saline|Placebo
45650166|NCT03104959|Dietary Supplement|N-acetyl cysteine|
45798874|NCT00002961|Drug|methotrexate|"methotrexate 15 mg/m2 IV on day +1 (do not give until 24 hours after marrow infusion), and 10mg/mg2 IV on days +3 and +6.~Methotrexate may be held after two doses for bilirubin .2 mg/dL. If serum creatinine is >2x baseline, methotrexate will be omitted. If the presence of ascites or pleural effusion, methotrexate will be omitted."
45798875|NCT00002961|Procedure|allogeneic bone marrow transplantation|Bone marrow infusion given on day 0
45650167|NCT03104959|Other|placebo|
45650168|NCT03044483|Other|Measurement of sublingual microcirculatory parameters|Measurement of the sublingual microcirculatory function using the CytoCam-IDF imaging device to establish the normal range for each age group noted.
45650169|NCT04006015|Other|No intervention being delivered.|No interventions are being delivered.
45650170|NCT03044171|Device|Low Level Laser Therapy|Laser therapy: it was used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and central-medial region of the incisors, canines and premolars.
45650171|NCT03044171|Drug|1.1% Sodium Fluoride|Fluoride therapy: 1.1% sodium fluoride 5000 ppm was applied for 5 minutes on the vestibular surface of all pre-bleached dental elements.
45650172|NCT03044171|Drug|In-office dental bleaching|Both groups received the in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 4 sessions, with a 7-day interval.
45650173|NCT03102463|Dietary Supplement|Water Control|120mL water given as a control, followed by a hyperinsulinemic-euglycaemic clamp
45798876|NCT00002961|Radiation|Total Body Irradiation|Day 0: Marrow Transfusion; Day 1: rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6 and 7: Total Body Irradiation (TBI) [200 cGy twice a day (BID)].
45798877|NCT00002961|Drug|Busulfan|"Conditioning Regimen Arm B:~Day 0: Marrow infusion; Day 1: Rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6,7 and 8: Busulfan 0.8 mg/kg intravenous (IV) every 6 hours x 4 doses.~Patients </= 20kg to receive busulfan 1.0 mg/kg/dose IV**Busulfan oral preparation may be substituted: 1mg/kg/dose by mouth (po) for patients >20kg and 1.25 mg/kg/dose by mouth (po) for patients </= 20 kg."
45798878|NCT00002961|Drug|Mesna|Dosing per institutional preference for hemorrhagic cystitis. Mesna 300 mg/m2 as a 15 minute infusion prior to each dose of cyclophosphamide, then at 3,6,9,12, 18 and 21 hours after initiation of each cyclophosphamide infusion. Alternative method of Mesna administration is 10 mg/kg prior to cyclophosphamide and 100 mg/kg/24 hours by continuous infusion.
45798879|NCT00002961|Radiation|Radiation|"Central Nervous System (CNS) therapy:~a) CNS Leukemia prior to study entry: No TBI i) No prior CNS irradiation: 2340 centigray (cGy) in 13 fractions of 180 cGy to the cranial field and 600 cGy in 200 cGy fractions to the spinal field prior to conditioning. II) >/= 1800 cGy prior CNS irradiation: 1800 cGy to cranial field and 600 cGy spinal prior to conditioning. If prior radiation therapy (RT) doses >3000 cGy have been administered or CNS Leukemia prior to study entry: TBI, consult with Principal Investigator (PI). Recommend: 1) no prior CNS irradiation: 600 cGy in 3 fractions to the cranial field prior to conditioning or overlapping with TBI.~Testicular Boost Irradiation: a) overt testicular leukemia at relapse: No TBI 2400 cGy in 12 fractions prior to conditioning; b) overt testicular leukemia at relapse: TBI 1200 cGy in 6 fractions over 8-10 days prior to conditioning. c) No overt testicular leukemia: 200 cGy first and last fractions of TBI-"
45798880|NCT05303077|Dietary Supplement|Nutribén Innova® 1|Infants are fed solely with infant formula supplemented with an inactive probiotic and omega 3 fatty acids over the first 6 months of their life, from then on the infants are fed with the study formula and the usual supplementary food, recommended to the baby's
45798881|NCT05303077|Dietary Supplement|Nutribén®|Infants are fed solely with infant formula over the first 6 months of their life, from then on the infants are fed with the study formula and the usual supplementary food, recommended to the baby's age.
45798882|NCT05303077|Dietary Supplement|Breastfeed|Infants are breastfeeding solely over the first 6 months of their life, from then on the infants are fed as recommended by their caregiver, as if they are not participating in a research study.
45798883|NCT00002967|Drug|cyclophosphamide|
45798884|NCT00002967|Drug|doxorubicin hydrochloride|
45798885|NCT00002967|Drug|octreotide pamoate|
45798886|NCT00002967|Drug|tamoxifen citrate|
45798887|NCT02448641|Biological|SB623 Implant (2.5M)|2.5 million SB623 cells
45798888|NCT02448641|Biological|SB623 Implant (5.0M)|5 million SB623 cells
45798889|NCT02448641|Procedure|Sham surgery|
45798890|NCT04246177|Drug|Lenvatinib|Administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) via oral capsules once a day during each 21-day cycle.
45798891|NCT04246177|Biological|Pembrolizumab|Administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W).
46072234|NCT05275634|Device|Interferential current with carrier frequency 8 KHz|Interferential current treatment parameters will be as following; carrier frequency 8 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
46072235|NCT05275634|Device|placebo interferential current|Interferential current intensity will not be raised.
46072236|NCT05274815|Biological|Tezepelumab|Tezepelumab subcutaneous injection
45450674|NCT02189512|Other|blood sampling|cases - blood sampling controles - blood sampling
45450675|NCT04443478|Procedure|Radical gastrectomy with dissection of lower mediastinal lymph node|Radical gastrectomy for gastric cancer should be consistent with Japanese gastric cancer treatment guideline.
45650174|NCT03102463|Dietary Supplement|Milk derived hydrolysate|Milk derived hydrolysate made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
45650175|NCT03102463|Dietary Supplement|Parent Protein|Parent protein made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
45798892|NCT04246177|Drug|Oral Placebo|Lenvatinib-matching placebo administered via oral capsules once a day during each 21-day cycle.
45798893|NCT04246177|Drug|IV Placebo|Pembrolizumab-matching placebo administered via IV infusion once every 6 weeks (Q6W).
45798894|NCT04246177|Procedure|TACE|Conducted as a background procedure of chemotherapeutic and embolic agent(s).
45798895|NCT00002973|Drug|melphalan|
45650176|NCT03102463|Other|Lipid Load|100mL oral lipid load
45650177|NCT04863989|Procedure|tube thoracostomy|insertion of intercostal tube for drainage of traumatic hemothorax or pneumothorax
45650178|NCT03102385|Behavioral|Motivational Interview|A web-based computer-tailored intervention that includes open-ended questions, reflective responses, affirmations, and summarizing, as well as informing and advising. Specific topics include 1) individual motivations for giving, 2) the relationship between past donation behavior and the individual's personal goals/values, 3) donation importance and confidence rulers, 4) addressing donor concerns, and 5) summarizing.
45650179|NCT03102385|Behavioral|Knowledge Interview|A web-based interview that includes open-ended questions regarding blood donation knowledge.
45798896|NCT00002973|Procedure|hyperthermia treatment|
45798897|NCT04744259|Behavioral|Behavioural Activation|A psychological intervention which aims to increase activity and reduce depressive symptoms.
45798898|NCT02450747|Device|etafilcon A MULTIFOCAL|Subjects will wear the test lens for four weeks.
45798899|NCT00002985|Drug|daunorubicin hydrochloride|
45798900|NCT00002985|Drug|pegylated liposomal doxorubicin hydrochloride|
45798901|NCT00363233|Drug|flax lignans|
45798902|NCT02767557|Drug|Tocilizumab|Intravenous infusion
45798903|NCT02767557|Drug|Gemcitabine|Intravenous infusion
45798904|NCT02767557|Drug|nab-Paclitaxel|Intravenous infusion,
45798905|NCT04227379|Behavioral|Intervention 1- DD-TXT|Participants in this group will be signed up for an interactive, tailored self-management texting protocol (DD-TXT). The DD-TXT protocol will consist of: Core Messaging: Customizable core modules on medication management, blood sugar and blood pressure monitoring, preventive care, problem solving, appointment reminders, administrative messages; and Optional Messaging: A library of patient-selected modules (e.g. nutrition, physical activity, weight management, emotional coping, goal setting) designed to motivate and educate.
45798906|NCT04227379|Behavioral|Comparison - DSE|"The comparison condition will be signed up for a one-way education-only protocol called Diabetes Skilled Education-Only (DSE). DSE contains only one-way educational content consisting only of content from the VA educational workbook entitled Self-Care Skills for the Person with Diabetes, which was created in alignment with VA/DoD diabetes guidelines and is recommended for patients as part of usual care. Everyone in the DSE arm will receive the same daily text messages taken verbatim or almost verbatim from workbook content but shortened to fit the 160-character limit of a text message (See Appendix 3 for sample messages from workbook). There will be no customizable or interactive content for the DSE arm."
45798907|NCT00363389|Drug|misoprostol and cervical ripening|
45798908|NCT03057431|Drug|Placebo oral capsule|Once daily for 3 years
45798909|NCT03057431|Drug|12.5 mg hydrochlorothiazide|Once daily for 3 years
45798910|NCT03057431|Drug|25.0 mg hydrochlorothiazide|Once daily for 3 years
45798911|NCT03057431|Drug|50.0 mg hydrochlorothiazide|Once daily for 3 years
45798912|NCT02248285|Device|FilmArray™ Gastrointestinal (GI) Panel|BioFire Diagnostics, LLC (BioFire) has developed a polymerase chain reaction (PCR), high-resolution melting analysis instrument called the FilmArray™ and an associated reagent pouch that together are capable of simultaneously detecting multiple microorganisms in a single sample. The FilmArray™ Gastrointestinal (GI) Panel pouch contains freeze-dried reagents to perform nucleic acid purification and nested, multiplex PCR for the identification of common bacterial, viral, and parasite microorganisms responsible for infectious gastroenteritis. The test was made available for sale in the US and EU following FDA clearance and CE marking in May, 2014
45650180|NCT04863755|Behavioral|DASH|Patients receive DASH diet orientation and recommended to maintain their usual physical activity
45798913|NCT00003003|Biological|sargramostim|
45798914|NCT00003003|Drug|mitomycin C|
45798915|NCT00003003|Drug|mitoxantrone hydrochloride|
45798916|NCT05709457|Behavioral|Cash transfer in prior study|Women were offered a cash transfer conditional on attending prenatal and postnatal visits and delivering in a facility
45798917|NCT00003009|Biological|aldesleukin|
45798918|NCT04210843|Drug|Ligelizumab|liquid in vial 120 mg/mL Prefilled Syringe 120 mg/mL
45798919|NCT04330053|Other|Experimental|"Training will address issues such as: environmental security, identifying hazards that can lead to a fall, psychological support, getting up from a fall, standing techniques and calling for help.~The exercise program will last for six months and will be based on the OTAGO exercise program, which includes five exercise groups: general warm-up, muscle strengthening exercises, balance exercises, range of motion and stretching exercises. The program will be performed individually or in groups of two people at most and will be conducted once a week in one of the 5 outpatient clinics under the supervision of a specialized OTAGO trainer, while seniors should repeat the exercises twice a week alone at home and also walk twice a week for at least half an hour."
45926827|NCT03646760|Behavioral|HYCR|"This group involves a hybrid design, with the frequency of center based cardiac rehabilitation (CBCR) visits and HYCR visits individualized and modified based on the subject's personal preferences and their family, transportation and work constraints. Patients in HYCR will engage in at least one CBCR visit. Patients will have the video app loaded to their smart phone or tablet (or that of a willing to assist family member or friend). HYCR patients receive a chest strap/wrist heart rate device to document HR before, during, and/or after exercise during the TM session. Program education for patients in HYCR will be delivered using the twenty-eight, 7-15 min audio PDF's that are free to access from the Health System's web site."
45926828|NCT03646760|Behavioral|CBCR|This group will attend 2-3 sessions of cardiac rehabilitation per week at the investigator's Detroit location. Program education for patients in CBCR will be delivered during eight. 1 hour education lectures taught by staff (exercise physiologists and registered dieticians).
45926829|NCT00404443|Device|Acupuncture|Placebo-needles 17 will be used for those randomized to receive sham-acupuncture, which will be connected to the electrical current generator for the same duration and at the same acupuncture points without any current passing through, and intermittent non-specific manual twirling will also be applied. Patients are discouraged to communicate with each other before and after the treatment sessions to minimize bias.
45926830|NCT00404482|Drug|Cyclosporine A|
45798920|NCT04330053|Other|Control|"Information / Education about falls The participants in this group will receive the same information - education as the participants of the 1st group.~They will be given a leaflet with general gentle exercises (not fall prevention specific) for the home."
45798921|NCT02645487|Radiation|Stereotactic Radiosurgery|Radiation, Stereotactic Radiosurgery Size <= 1cm: 24 Gray (Gy); + 3 Gy incremental escalation up to 30 Gy >1-2cm: 21 Gy; + 3 Gy incremental escalation up to 27 Gy >2-3cm: 18 Gy; + 3 Gy incremental escalation up to 24 Gy
45798922|NCT00383253|Behavioral|caloric restriction - 10%|Subjects maintained on 10% caloric restriction (caloric intake = 90% of baseline)
45798923|NCT00383253|Behavioral|caloric restriction - 25%|Subjects maintained on 25% caloric restriction (caloric intake = 75% of baseline)
45926831|NCT00404521|Drug|PM02734|Administered every 3 weeks, intravenously, over 30 minutes
45926832|NCT03073941|Device|Persona total knee system|314 participants with knee osteoarthritis set to receive primary total knee arthroplasty will receive either Persona knee or the Nexgen
45926833|NCT03073941|Device|Nexgen total knee system|314 participants with knee osteoarthritis set to receive primary total knee arthroplasty will receive either Persona knee or the Nexgen
45926834|NCT04726696|Behavioral|ROLE-AP programme|The intervention group will be split in two groups of 7-8 primary care nurses each. These two groups will receive the ROLE-AP program over a three weeks period. Each workshop will be divided into two sessions of 90-120min. The first workshop focuses on the clarification of health promotion concepts and the discussion of the state of nursing practice in health promotion. Participants will discuss the misalignments between this description of nursing practice and the ideal one portrayed by the Ottawa Charter. The second workshop will allow the presentation of the objectives of the health care organization, showing its alignment with the Ottawa Charter areas of action. In addition, it will present a standardized instrument that reflects expectations about nurses' activities in health promotion that will serve for discussing and realigning participants' expectations on nurses' role in health promotion. The third workshop will continue with the discussion of nurses' expected activities.
46072237|NCT05269355|Drug|Unesbulin|Unesbulin will be administered as per the dose and schedule specified in the arm description.
46072238|NCT05269355|Drug|Dacarbazine|Dacarbazine will be administered as per the dose and schedule specified in the arm description.
45650181|NCT04863755|Behavioral|DASHPED|Patients receive DASH diet orientation and recommended to increase their usual activity with the use of a pedometer
45650182|NCT03102229|Other|Enhanced Supportive Care - Status Checks|Would occur everyday during treatment when a patient is deemed high-risk.
45798924|NCT00383253|Behavioral|caloric restriction - 50%|Subjects maintained on 50% caloric restriction (caloric intake = 50% of baseline)
45798925|NCT00383253|Behavioral|caloric restriction - Control|Subjects maintained on their baseline caloric intake (caloric restriction = none)
45650183|NCT03102229|Other|Enhanced Supportive Care - Referrals|On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor.
45650184|NCT04108429|Behavioral|IntelliCare for College Students|Participants will receive access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
45650185|NCT04857515|Device|Clickotine®|Clickotine is a DTx that contains behavior modification techniques that include controlled breathing, social engagement, personalized messaging, medication access and adherence, digital diversions, and financial incentives.
45798926|NCT00383097|Genetic|LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES|1 injection One of the following 4 dose levels: 2x 10^7 cells/m2, 1x 10^8 cells/m2, 3 x 10^8 cells/m2, 1 x 10^9 cells/m2
45798927|NCT00383097|Genetic|LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES|1 injection One of the following 4 dose levels: 2x 10^7 cells/m2, 1x 10^8 cells/m2, 3 x 10^8 cells/m2, 1 x 10^9 cells/m2
45798928|NCT00003015|Drug|carboplatin|
45798929|NCT00003015|Drug|vincristine sulfate|
45798930|NCT00003015|Procedure|conventional surgery|
45798931|NCT00003015|Radiation|radiation therapy|
45926835|NCT03608579|Drug|Autologous Adipose Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices
45926836|NCT00141427|Drug|Pregabalin|
45926837|NCT00141466|Behavioral|Education for professionals|
45798932|NCT04204837|Drug|Nivolumab|Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.
45650186|NCT04857047|Drug|BR9003 2mg|After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003 tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it.
45650187|NCT04857047|Drug|BR9003A 1mg|After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003A tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it. Another BR9003A tablet will be administered orally with water 150mL around 20:30 after dinner between 18-19:00.
45926838|NCT00141466|Behavioral|Distribution of educational materials|
45798933|NCT04204837|Drug|Nivolumab plus Relatlimab|Patients wil receive a fixed-dose combination of nivolumab 480 mg and relatlimab 160 mg by intravenous infusion every four weeks (Q4W) (Group 2) for up to two years after initial dosing or until PD - or absence of investigator-assessed clinical benefit
45926839|NCT00141466|Behavioral|Feedback for professionals|
45650188|NCT04856969|Drug|Olmesartan|First stage: ATB-1011 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
45650189|NCT04856969|Drug|Dapagliflozin|First stage: ATB-1012 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
45650190|NCT04856735|Other|Intraperİtoneal local anaesthesİc İn cesarean sectİon|After the birth of the newborn and placenta, the uterus is closed and the blood accumulated in the pelvis is carefully wiped with surgical towels, after hemostasis is fully achieved, a total of 20 ml solution containing 10 cc of 0.5% bupivacaine +10 cc 2% lidocaine and 2 injectors containing 20ml saline and the 20ml solution were given to the surgeon area.
45650191|NCT04856735|Other|Local wound infiltrasyon|A solution containing 20 ml of saline was added to all four quadrants of the uterus in 5 ml volume and 20 ml solution containing lidocaine and bupivacaine were subcutaneously in the form of LWI before the skin was closed
45798934|NCT00003021|Drug|bizelesin|
45798935|NCT05709379|Behavioral|Sedentary behavior|Interrupting sitting with walking/jogging at either high -or low physical activity intensity.
45798936|NCT02240485|Behavioral|Integrative Couple Treatment for Pathological Gambling (ICT-PG)|"The experimental couple treatment is offered over 8 to 12 sessions of 90 minutes. The couple treatment called (Integrative Couple Therapy for Pathological Gambling - ICT-PG) is inspired by the Alcohol Behavior Couple Therapy from Epstein and McCrady, to which the team added diverse components to adjust to gamblers. During the sessions, the focus is on a) reducing/stopping gambling behaviors, b) helping the partner to stop behaviors facilitating gambling habits and rise the frequency of behaviors incompatible with gambling habits and c) improve marital components (communication, sharing positive moments, negotiation, mutual support)."
45798937|NCT02240485|Behavioral|Usual individual/group treatment|The control group receive individual or group treatment as already offered by the specialized centers in addiction.Their partner can receive individual intervention if desired.
45798938|NCT00003039|Drug|alvocidib|
45798939|NCT04246203|Other|Liquid Biopsy|17-20 ml of blood will be collected prior of surgery and within 14 days before start of adjuvant chemotherapy.
45798940|NCT02637687|Drug|Larotrectinib (Vitrakvi, BAY2757556)|BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
45798941|NCT00383877|Drug|insulin detemir|
45798942|NCT00383877|Drug|insulin NPH|
45798943|NCT02534649|Procedure|Newly obtained biopsy and Blood samples collection|"For each patient:~Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~Four blood samples will be obtained for genetic profiling and assessment of markers The results of each tumor profile will be discussed within a multidisciplinary tumor board which aims at discussing the genomic profiles and at providing a therapeutic decision for each patient.~Patients for whom no molecular aberration has been identified will be treated at the discretion of the investigator and followed until death or study termination whichever occurs first.~All the patients carrying a molecular aberration will be proposed to enter in a clinical trial depending on the possibility of inclusion at the time of molecular report."
45798944|NCT00003045|Device|Hyperthermia|Hyperthermia is delivered by the transrectal ultrasound applicator just prior to XRT, at least one week apart, during the first 4 weeks of XRT. The goal of hyperthermia is CEM T 90 43 greater than or equal to 10 minutes. The maximum applied power duration will be 120 minutes per treatment session
45798945|NCT00003045|Radiation|XRT|external beam radiation to a dose of 4500 cGy to a small pelvic field, followed by a boost to a reduced volume for an additional 2160 cGy. XRT is given daily, 5 days a week for 180 cGy per day. Total radiation dose=6660cGy
45926840|NCT00141466|Behavioral|Reminders for professionals|
45926841|NCT02972073|Other|Exercise intervention|Physical therapist will provide exercise for patients with low back pain for 60 minutes per day, 2-3 days per week for the total of 8 weeks.
45926842|NCT00141505|Drug|Bifeprunox|
45926843|NCT00141544|Drug|esterified estrogens 1.25 mg and methyltestosterone 2.5 mg|ESTRATEST® administered orally QD
45926844|NCT00141544|Drug|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
45926845|NCT00141583|Drug|Enalapril 20 mg bd|
45450676|NCT02189590|Device|i-gel|Patients randomized to this intervention will have the i-gel placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
45926846|NCT00141583|Drug|Candesartan 8 mg bd|
45926847|NCT03584594|Diagnostic Test|Presepsin measurement|Presepsin measurements are performed with PathFast immunoassay analytical system on the ICU, bedside method. (Mitsubishi Chemical, Japan).
46072239|NCT05269355|Other|Placebo|Placebo will be administered as per the schedule specified in the arm description.
45926848|NCT00141622|Drug|Slow sodium|
45650192|NCT04856735|Other|Control group|One of the two sterile injectors containing 20 ml of saline was applied to the uterine peritoneal region and the other was applied to the incision area as a local subcutaneous wound infiltration.
45798946|NCT02490813|Dietary Supplement|Treatment - Chinese Herbal Formula - X|Wu Mei (Fructus Pruni Mume), Ling Zhi (Gonoderma), Huang Bai (Cortex Phellodendron), and Zhi Su (Perilla frutescens).
45798947|NCT02490813|Dietary Supplement|Placebo|Placebo will be starch with colorings
45926849|NCT00141661|Drug|PF-04494700 - Low Dose Arm|30 mg loading dose for 6 days, followed by 10 mg daily
45926850|NCT00141661|Drug|PF-04494700 - High Dose Arm|60 mg loading dose for 6 days, followed by 20 mg daily
45650193|NCT04856501|Behavioral|PALS intervention condition|The Play and Learning Strategies (PALS) intervention provides parents with behaviors that, collectively, are known as a responsive parenting style. Four constructs make up this responsive parenting style: 1) contingent responsiveness, (responses are conditionally linked to the child's signals) 2) warm sensitivity (high levels of affection and understanding of child states), 3) maintaining vs. redirecting attention, and 4) verbal scaffolding (providing child appropriate language supports). Parents assigned to this intervention will be paired with a coach who will guide them through the program over the course of 9 weekly sessions. The intervention (ePALS) will be implemented via an internet adaptation through the Children's Learning Institute's ENGAGE platform. However, ePALS could easily be adapted for other platforms and accessed with any web-enabled device.
45650194|NCT04856501|Behavioral|Control condition|Families assigned to the control condition will be provided with a website with information corresponding to milestones of toddler development. Control families will be asked to review that week's materials before the each of the 9 weekly coach calls. The active control condition serves three important purposes: 1) Maintains an active line of communication and accurate contact records for Post-test 1 and Post-test 2 session scheduling; 2) Masks participant's awareness of intervention vs. control assignment; and 3) Approximates communication with intervention staff such that results showing ePALS effects are attributable to intervention rather than regular communication with an interventionist.
45653194|NCT05078463|Device|Sham Patch|A Polyvinyl Alcohol (PVA)-containing Polyethylene Terephthalate (PET) Sham Patch of a size of 1cm x 1cm will be applied for 5 seconds against the pre-specified 1 cm x 1 cm grid on the dorsal surface of the IV cannulated hand for blood transfusion.
45653195|NCT05077137|Biological|Tetanus Diptheria Vaccine|tetanus and diphtheria toxoids
45653196|NCT05077137|Biological|Polio Boost Immunization|trivalent inactivated polio vaccine
45926851|NCT00141661|Drug|Placebo Comparator|Matching placebo.
45926852|NCT00141700|Drug|Rituximab|
45653197|NCT04786769|Drug|Ferric carboxymaltose|Intravenous ferric carboxymaltose according to baseline weight and hemoglobin
45926853|NCT00141856|Behavioral|Telephone care|
45926854|NCT03555149|Drug|Regorafenib|Regorafenib will be administered orally on Days 1-21 of each 28-day cycle.
45926855|NCT03555149|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of 21-day cycles, with the exception of the Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Idasanutlin, Atezolizumab + Regorafenib and Atezolizumab + Regorafenib + AB928 arms where the Atezolizumab will be administered by IV infusion every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.
45926856|NCT03555149|Drug|Imprime PGG|Imprime PGG will be administered by IV infusion weekly on Days 1, 8, and 15 of each 21-day cycle.
46072240|NCT05267626|Drug|AU-007|Monoclonal Antibody Targeting IL-2
45450677|NCT02189590|Device|air-Q|Patients randomized to this intervention will have the air-Q placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
45798948|NCT00003063|Biological|recombinant interferon alfa|
45798949|NCT00003063|Drug|fluorouracil|
45798950|NCT00003063|Drug|leucovorin calcium|
45798951|NCT00003063|Drug|levamisole hydrochloride|
45798952|NCT03793881|Behavioral|Nutritional Strategy|Counseling based on dietary goals and mindfulness techniques.
45798953|NCT03793881|Behavioral|Dietary Prescription|Dietary prescription according to guidelines.
45798954|NCT00003075|Drug|Fenretinide|Oral Fenretinide daily for 6 months with 3 days of rest every month.
45798955|NCT00003075|Other|Placebo|Oral placebo daily for 6 months with 3 days of rest every month.
45798956|NCT00383175|Other|Autorefractor, standard clinical instrument|Autorefractor, standard clinical instrument was used to assess the children's focusing power at near.
45798957|NCT00003081|Biological|filgrastim|
45798958|NCT00003081|Drug|busulfan|
45798959|NCT00003081|Drug|melphalan|
45798960|NCT00003081|Drug|thiotepa|
45798961|NCT00003081|Procedure|peripheral blood stem cell transplantation|
45798962|NCT00003081|Radiation|radiation therapy|
45798963|NCT02348385|Drug|Amphetamine|Subjects will have 2 PET scans on the same day. Up to 3 hours before the second PET Scan, amphetamine (0.4mg/kg, orally) will be administered.
45798964|NCT00003087|Drug|cisplatin|
45798965|NCT00003087|Drug|paclitaxel|
45798966|NCT00003087|Procedure|surgical procedure|
45926857|NCT03555149|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion on Day 1 of each 21-day cycle for the Atezolizumab + Imprime PGG + Bevacizumab arm, and on Day 1 and Day 15 of each 28-day cycle for the Atezolizumab + Selicrelumab + Bevacizumab arm.
45926858|NCT03555149|Drug|Isatuximab|Isatuximab will be administered on Day 1, 8 and 15 of cycle 1 and on day 1 of all subsequent cycles. Cycles will be 21 days long.
45798967|NCT00003087|Radiation|radiation therapy|
45798968|NCT00003093|Biological|filgrastim|
45798969|NCT00003093|Biological|sargramostim|
45926859|NCT03555149|Drug|Selicrelumab|Selicrelumab will be administered by subcutaneous (SC) injection on Day 1 of cycles 1-4 and every third cycle thereafter. Cycles will be 28 days long.
45926860|NCT03555149|Drug|Idasanutlin|Idasanutlin will be administered orally on Days 1-5 of each 28-day cycle.
46072241|NCT05267626|Drug|Aldesleukin|IL-2
45798970|NCT00003093|Drug|carboplatin|
45650195|NCT05037175|Behavioral|CPT-Text|CPT is a 12-session, trauma-focused, cognitive therapy that teaches clients to examine and change problematic beliefs about themselves and the world that were altered as a result of trauma. Each session includes psychoeducation and introduction of a new skill or module, which builds on the previous information and skills. Participants will receive psychoeducation video links via Talkspace and an electronic workbook with handouts, written explanations of the concepts and activities, and CPT worksheets, which will be embedded in the platform and sent by the therapist at the appropriate point in the protocol. Therapists encourage the client to complete each module using the provided materials and assist clients in reflecting on their beliefs through Socratic questions and feedback on their worksheets [5,6]. Clients work at their own pace, with therapists sending the skill or module after the client has practiced the previous one.
45926861|NCT03555149|Drug|AB928|AB928 will be administered orally once daily on Days 1-28 of each 28-day cycle.
45653198|NCT05611541|Behavioral|Diet therapy, Progressive Muscle Relaxation training, Progressive Muscle Relaxation group|The group that received Progressive Muscle Relaxation training and applied progressive muscle relaxation for 8 weeks.
45798971|NCT00003093|Drug|cyclophosphamide|
45798972|NCT00003093|Drug|doxorubicin hydrochloride|
45926862|NCT03555149|Genetic|LOAd703|LOAd703 will be administered by intratumoral injection on Day 1 of each 21-day cycle.
45926863|NCT00141895|Drug|Misoprostol|2 tablets 200 micrograms Vaginal route
45926864|NCT00141895|Drug|Misoprostol|2 tablets of 200 micrograms Sublingual route
45926865|NCT00141934|Drug|AD 452|
45926866|NCT00142012|Behavioral|Nutrition Intervention|
45926867|NCT00142051|Drug|nitric oxide|80 ppm 8 hrs, 40 ppm 8 hrs, 20 ppm 4 hrs, 10 ppm 4 hrs
45926868|NCT00142051|Drug|oxygen|oxygen fi02 21% (room air)
45798973|NCT00003093|Drug|etoposide|
45798974|NCT00003093|Procedure|conventional surgery|
45798975|NCT00003093|Procedure|neoadjuvant therapy|
45798976|NCT04149535|Device|Sentinel® Cerebral Protection System|cerebral embolic protection system
45798977|NCT00003099|Drug|Fenretinide|Daily for 14-28 days.
45798978|NCT00003099|Drug|Tamoxifen Citrate|Daily for 14-28 days.
45798979|NCT00003099|Other|Placebo|Daily for 14-28 days
45798980|NCT04137445|Other|Baby Foods|Commercially available baby foods
45798981|NCT04137445|Other|Foods from the home|Caregiver will provide participant with usual foods from the home
45798982|NCT02294799|Other|Intervention Group|Grade 1, Nonspecific Mandibular Mobilization
45798983|NCT02294799|Other|Placebo group|Nonspecific Mandibular Movement.
45798984|NCT00003105|Biological|filgrastim|
45798985|NCT00003105|Drug|cisplatin|
45798986|NCT00003105|Drug|doxorubicin hydrochloride|
45798987|NCT00003105|Drug|gemcitabine hydrochloride|
45798988|NCT00003105|Drug|ifosfamide|
45798989|NCT00003105|Drug|paclitaxel|
45926869|NCT00142090|Drug|3% Hypertonic saline|
45926870|NCT00142090|Drug|Placebo|Normal saline
45926871|NCT00142129|Drug|Bortezomib (Velcade)|
45926872|NCT02825979|Procedure|Cryoballoon-based PVI|Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.
45926873|NCT02825979|Drug|Anti-Arrhythmic Drug Therapy|Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
45926874|NCT00142207|Drug|Intermittent preventive treatment:sulphadoxine-pyrimethamine|Two doses given twice during pregnancy (once in the second trimester, and once in the third trimester). Oral medication in tablet form: single daily dose given on each occasion
45926875|NCT00142207|Device|Insecticide-treated mosquito bed net|Insecticide-treated mosquito bed net
45926876|NCT02290886|Other|Intravenous administration of placebo|
45926877|NCT02290886|Drug|Intravenous administration of 1 million of MSC|
45926878|NCT02290886|Drug|Intravenous administration of 2 million of MSC|
45926879|NCT02290886|Drug|Intravenous administration of 4 million of MSC|
45926880|NCT00142246|Drug|Intermittent preventive treatment (SP and amodiaquine)|Oral medication. SP: single dose given over one day; amodiaquine: 3 daily doses over 3 days. Dosage has given according to age.
45926881|NCT00142246|Other|Placebo|Three doses given over three days (Day 1: placebo SP + placebo AQ; Days 2 and 3: placebo AQ). Dosage given according to age
45926882|NCT00142324|Drug|Donepezil|
45926883|NCT00142402|Drug|Modafinil|
45926884|NCT03532256|Behavioral|Observation|Patients will be contacted postoperatively via an automated text-message to assess pain, functional status, and opioid consumption.
45926885|NCT03532256|Behavioral|Text to online survey|Subset of surgical patients will receive an automated text message with a link to a secure online survey with questions that assess pain, functional status, and opioid consumption.
45926886|NCT03532256|Behavioral|Bi-directional text script|Subset of surgical patients will receive an automated bi-directional text message script with questions that assess pain, functional status, and opioid consumption.
45926887|NCT00142441|Device|Pulsed dye laser|
45926888|NCT00142480|Drug|Capecitabine|Given orally for 14 consecutive days (days 1-14) followed by a week of no capecitabine then another week of 14 consecutive days (days 21-28).
45926889|NCT00142480|Drug|Oxaliplatin|Given intravenously once weekly during weeks 1, 2, 4 and 5 on days 1, 8, 22 and 29
45926890|NCT00142480|Drug|Bevacizumab|Given intravenously every two weeks during weeks 1, 3 and 5 on days 1, 15 and 29.
45926891|NCT00142480|Procedure|Radiation therapy|Once daily for 5 days (Monday through Friday) for a total of 28 treatments.
45926892|NCT02806050|Drug|Palbociclib|all patients will be treated with palbociclib, on a 3 weeks on, 1 week off cycle until progression
45926893|NCT02806050|Device|FES PET|all patients will have a FES PET at baseline
45926894|NCT02806050|Drug|Letrozole|all patients will be treated with Letrozole daily until progression
45926895|NCT00142675|Behavioral|Physical Activity|
45926896|NCT00142714|Procedure|Sympathetic manipulation on sexual arousal in women|
45798990|NCT05237401|Procedure|Non-Surgical Periodontal treatment (NSPT)|participants will receive local anaesthesia, then thorough debridement of the root surface will be completed to the depth of the periodontal pocket and of the furcation lesion, by using sonic scaler (KaVo Sonicflex, KaVo, Germany), piezo-electric/ultrasonic devices with specific thin and delicate tips (such as Cavitron, Dentsply Sirona, US) and/or curettes.
45926897|NCT00142753|Biological|Engerix B|Standard adult dose for A1; increased adult dose for A2. Doses at Entry, Weeks 4 and 24. Non-responders (<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at Week 48.
45926898|NCT00142753|Biological|Twinrix for ATN 024|Standard adult dosage, taken at Entry, Weeks 4 and 24. Non-responders (<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at week 48.
45926899|NCT00142753|Biological|Recombivax|Dosage at entry and week 24; non-responders ((<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive 3rd dose of Recombivax during weeks 48-72.
45926900|NCT00142753|Biological|Twinrix for ATN 025|Doses at Entry and Week 24. Non-responders (<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive a dose of Recombivax during week 48-72.
45926901|NCT02781792|Drug|Temozolomide|-Given standard of care
45926902|NCT02781792|Other|Functional Assessment of Cancer Therapy - Brain|"23-item questionnaire that can be completed in 5 to 10 minutes with little or no assistance in patients who are not neurologically incapacitated. This brain subscale is usually used along with the core (general) questionnaire [2] that includes 27 items.~Patients rate all 5 items using a five-point Likert scale ranging from 0 not at all to 4 very much. Overall, higher ratings suggest higher QOL. Items are totaled to produce the following subscales, along with an overall QOL score: physical well-being (7 items); social/family well-being (7 items); emotional well-being (6 items); functional well-being (7 items); and concerns relevant to patients with brain tumors (23 items)~The sleep portion of this questionnaire consists of 17 questions about sleeping patterns and the ability to rate severity of insomnia."
45926903|NCT02781792|Other|ActTrust Condor Instrument Watch|-Will be required to wear 24 hours per day and will only be removed at specified data collection time points
45926904|NCT00142831|Drug|Pharmacotherapies for Smoking Cessation|Bupropion-SR or Identical Placebo
45926905|NCT00142870|Drug|Bupropion|150 mg, twice a day
45450678|NCT02189746|Other|Continuous Kangaroo Mother Care to 1 hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
45650196|NCT05037175|Behavioral|Culturally Informed Trauma Treatment (CITT)|CITT will be conducted by Talkspace therapists with a specialty in PTSD treatment. Based on previous research and Talkspace's analysis of TAU and the therapists' training in culturally informed trauma treatment, it is likely CITT will include culturally informed, supportive and client-centered interventions, problem solving, and elements from EBTs such as cognitive-behavioral therapy [5].
45653199|NCT05611541|Behavioral|The group who received diet therapy and practiced their daily activities.|The group who received diet therapy and practiced their daily activities.
45653200|NCT05170113|Dietary Supplement|Alpinia galanga formulation|Alpinia galanga formulation capsule- 1 capsule daily
45653201|NCT05170113|Dietary Supplement|Theacrine formulation|Theacrine formulation capsule- 1 capsule daily
45926906|NCT00142948|Drug|Naltrexone|naltrexone
45926907|NCT00142948|Drug|Placebo|placebo
45926908|NCT02780427|Drug|intranasal dexmedetomidine|"Phase 1, Children received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for TEE study. The first child received 2.5 mcg/kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose varied by 0.1 mcg/kg according to the up-and-down method Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.25 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD)."
45926909|NCT00142987|Drug|Tegaserod|
45926910|NCT00143026|Drug|carbidopa, levodopa, entacapone|
45926911|NCT03487913|Drug|Lixivaptan|Oral vasopressin V2 receptor antagonist
45926912|NCT00404599|Drug|atrorvastatin 10mg|Atorvastatin 10 mg once a day
45926913|NCT00404599|Drug|simvastatin 40mg|simvastatin 40mg once a day
45926914|NCT02756247|Drug|Buparlisib|
45926915|NCT02756247|Drug|Ibrutinib|
45926916|NCT00404638|Drug|Desmopresin|
45926917|NCT00404638|Behavioral|Paula Method of Circular Muscle Exercise|
45926918|NCT00404677|Other|deep inhalation|deep inhalation is comprised of an inhalation manoeuver from FRC to TLC
45926919|NCT00143065|Drug|Fludarabine|25 mg/m2/day for 5 days every 28 days (Week 2,6,10,14, 18,and 22) will be administered by IV over 10-30 minutes. (Fludarabine should be given AFTER rituximab on all days on which both drugs will be administered.)
45926920|NCT00143065|Drug|Rituximab|"Day 1, week 2 of cycle 1 rituximab 100 mg will be administered by IV, without dose escalation, over 4 hours (rate: 25 mg/hr). Day 3, week 2 of cycle 1 rituximab 375 mg/m2 will be administered by IV. Rituximab can be administered at 50 mg/hr. If hypersensitivity or infusion related events do not occur, the infusion rate will be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.~On Day 5, week 2 of cycle 1 rituximab 375 mg/m2 will be administered by IV. Rituximab can be administered at 100 mg/hr. If hypersensitivity or infusion related events do not occur, the infusion rate will be escalated in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.~Rituximab 375 mg/m2 will be repeated on Day 1 of Week 6, 10, 14, 18, and 22. During these treatments, acetaminophen and diphenhydramine prophylactic treatment is left to the discretion of the treating physician."
45926921|NCT00143065|Drug|Alemtuzumab|The dose of alemtuzumab will be escalated during Week 1 of therapy. On Day 1 of Week 1, a dose of 3 mg should be administered IV over 2-hours. If this dose is well tolerated(grade 2 or less infusion or skin related toxicity), then the dose on Day 2 can be increased to 10 mg IV over 2 hours. If this dose is well tolerated, then the dose on Day 3 will be increased to 30 mg IV over 2-hours, and if tolerated, then day 5 and all subsequent alemtuzumab doses will be 30 mg. Vital signs (blood pressure, pulse, respiration rate,temperature, and O2 saturation) and skin assessment should be assessed at baseline, 1-hour, and 1-hour post administration during week 1 and 2. Following successful escalation to 30 mg of alemtuzumab, all subsequent doses of alemtuzumab will be 30 mg administered on the second day of fludarabine therapy (week 2,6,10,14,18,and 22).
45926922|NCT00143104|Drug|Inhaled insulin|
45926923|NCT00143143|Drug|Pregabalin|
45798991|NCT05237401|Procedure|Surgical Periodontal treatment/ Open Flap Debridement (OFD)|Patients will receive local anaesthesia and intrasulcular incisions will be made on the buccal and lingual/palatal aspects in order to reflect full-thickness flaps. After reflection of the flaps, the granulation tissue around the tooth will be removed with the non-cutting edge of a suitable scaling instrument such as a curette, taking care not to damage the root surfaces. Thorough debridement of the furcation area will be carried out by using diamond coated inserts, sonic scaler (KaVo Sonicflex, KaVo, Germany), piezo-electric/ultrasonic devices with specific thin and delicate tips (such as Cavitron, Dentsply Sirona, US) and/or curettes. Osteoplasty (removal of non-supporting bone) may be carried out, as judged by the operator. The surgical site will be closed with resorbable or non-resorbable sutures.
45798992|NCT05228197|Diagnostic Test|Biopsy & Imaging|H&E stained prostate biopsy slides from standard of care treatment
45926924|NCT00143221|Drug|Viagra|
45926925|NCT00143221|Drug|Placebo|
45926926|NCT00143260|Drug|Viagra (Sildenafil Citrate) 100 mg|
45926927|NCT03446417|Drug|ZN-e4|Oral dose, tablet, daily dosing
45926928|NCT00143299|Drug|varenicline (CP-526,555)|
45926929|NCT00143338|Drug|Inhaled insulin|
45926930|NCT00143377|Drug|tolterodine SR, overactive bladder|
45926931|NCT03387878|Device|Intermittent Catheter|Intermittent urinary catheter for bladder drainage
45450679|NCT02189746|Other|Standard Kangaroo Mother Care to 1 hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
45926932|NCT00143416|Drug|Pegvisomant|
45926933|NCT04726267|Device|Wide-field optical coherence tomography|Merged 4 images of wide-field optical coherence tomography, 2 images of vertical scan and 2 images of horizontal scan.
45926934|NCT02972216|Drug|Nolbaxol|
45926935|NCT02972216|Drug|Taxotere|
45653202|NCT05170113|Dietary Supplement|Caffeine formulation|Caffeine formulation capsule- I capsule daily
45653203|NCT05170113|Dietary Supplement|Placebo|Placebo capsule- 1 capsule daily
45653204|NCT05475119|Device|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure (CPAP) is a form of positive airway pressure ventilation in which a constant level of pressure greater than atmospheric pressure is continuously applied to the upper respiratory tract of an individual.
45653205|NCT05475119|Device|High Flow Nasal Cannula (HFNC)|High Flow Nasal Cannula (HFNC) is an oxygen supply system capable of delivering up to 100% humidified and heated oxygen at a flow rate of up to 60 liters per minute
45798993|NCT00003111|Drug|carboplatin|
45798994|NCT00003111|Drug|cisplatin|
45926936|NCT02972216|Drug|cisplatin|
45926937|NCT00143494|Procedure|measurement of abdominal pressure|measurement of abdominal pressure with different volume and saline temperature
45926938|NCT04726345|Drug|Fexofenadine Hcl 180Mg Tab|Fexofenadine 180mg tablet to be taken orally once a day until stent removal.
45926939|NCT04726345|Drug|Placebo|Placebo tablet to be taken orally once a day until stent removal.
45926940|NCT00393276|Biological|Twinrix|Combined hepatitis A and hepatitis B immunization
45926941|NCT00393276|Biological|Decavac|Diphtheria and tetanus toxoid vaccine
45926942|NCT00143533|Drug|Irinotecan, Cefpodoxime|See Detailed description section for treatment details.
45926943|NCT00143572|Drug|Magnesium Pidolate, Hydroxyurea|Intervention Description: Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months. Mg pidolate will be given at an initial dose of 0.6 mEq/kg/day divided into 2 daily doses for the first cohort of patients. This dose will be escalated for the subsequent patient cohorts as defined by a classic Phase I design (according to toxicity).
45926944|NCT03327467|Biological|Cord Blood Infusion|IV infusion of umbilical cord infusion (sibling or autologous)
45926945|NCT00143611|Drug|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.05 mg/kg/h (1.2 mg/kg/day), injection, subcutaneously over 96 hours.
45926946|NCT00143611|Drug|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.1 mg/kg/h (2.4 mg/kg/day), injection, subcutaneously over 96 hours.
45798995|NCT00003111|Drug|irinotecan hydrochloride|
45798996|NCT00003111|Drug|paclitaxel|
45926947|NCT00143611|Drug|Placebo|Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours.
45926948|NCT00393315|Device|paclitaxel coated balloon catheter|
45926949|NCT02247752|Other|inactive carrier|"Yearly demographic, clinic, biologic and ultrasonic data collection realized during usual follow-up as recommended.~Yearly centralisation of a complementary biological analysis in Paul Brousse Hospital laboratory of virology."
45926950|NCT00143650|Behavioral|House dust|
45926951|NCT00143689|Drug|lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine|See Detailed Description.
45926952|NCT00143728|Drug|Lamivudine|See Detailed Description.
45926953|NCT00140803|Drug|Visudyne|
45926954|NCT00140803|Drug|Kenalog|
45926955|NCT00143806|Drug|Transitioning patients from cyclosporine to alefacept|
45926956|NCT00390728|Drug|Insulin Glargine|
45926957|NCT00143884|Procedure|Reduced intensity conditioning|
45926958|NCT00143884|Procedure|Prophylactic donor leukocyte infusions|
45926959|NCT00143962|Behavioral|Low Carbohydrate Diet|
45926960|NCT00390767|Biological|MultiGeneAngio|Escalating doses of MultiGeneAngio, one dose per patient administered as one treatment, infused intra-arterially
45926961|NCT00144040|Behavioral|Physician & patient education on appropriate antibiotic use|
45926962|NCT00144040|Procedure|Rapid C-reactive protein testing to guide antibiotic treatment|
45926963|NCT00144079|Procedure|external beam radiotherapy|
45926964|NCT00144118|Drug|sevoflurane or isoflurane|
45926965|NCT00144157|Drug|Nevirapine|
45650197|NCT05037175|Behavioral|Retention Incentive|Participants will be told at baseline that they can earn discounts for other individuals with PTSD who are in need of financial assistance if they remain consistently engaged in treatment. If client participants do not re-engage after 24 hours from the RAU (3 days without engagement), they will receive an automated text-message reminding them to message their therapist regularly (on average, every other business day) in order to get a discount donated it to a fund that will offer free or discounted therapy to individuals with PTSD who require financial assistance. Throughout treatment, participants will be sent reminders every other week of what the incentive is and how it can be acquired, in addition to feedback about whether they are on or off track to earn the discount.
45798997|NCT00003111|Procedure|neoadjuvant therapy|
45798998|NCT00003111|Procedure|surgical procedure|
45798999|NCT00003111|Radiation|radiation therapy|
45926966|NCT00144157|Drug|Zidovudine|
45799000|NCT05709301|Drug|Donepezil Hydrochloride|Donepezil 10mg once daily
45799001|NCT05709301|Drug|Placebo|Matching placebo
45799002|NCT04329897|Behavioral|Software Messaging|Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
45799003|NCT04047433|Genetic|screening for single nucleotide polymorphism|samples from both arms will be tested for a set of single nucleotide polymorphism
45799004|NCT04047433|Genetic|whole exome sequencing|samples from arm #1 (women with external anal sphincter) will be tested for identifying specific genetic mutation
45799005|NCT00003117|Drug|carboplatin|
45799006|NCT00003117|Drug|paclitaxel|
45926967|NCT00144157|Drug|3TC|
45926968|NCT00144196|Drug|tiotropium (Spiriva)|
45926969|NCT03276572|Drug|225Ac-J591|225Ac-J591 (13.3 KBq/Kg - 93.3 KBq/Kg or 0.36 uCi/Kg - 2.52 uCi/Kg) on day 1
45926970|NCT00144235|Drug|Pharmaton PHL 00749|
45926971|NCT00144235|Drug|Placebo|
45926972|NCT00144274|Drug|Ambroxol Lozenge|
45926973|NCT00144313|Biological|hepatitis B vaccine|
45926974|NCT00144352|Drug|sulfadoxine-pyrimethamine|
45926975|NCT00144430|Drug|Pentostatin|The drug, Pentostatin, is given every 2 weeks. This drug will be given by intravenous (IV) infusion.
45926976|NCT02143128|Other|Efficacy Safety Score|Evaluation using the score for postoperative patients
45926977|NCT02143128|Other|Verbal Numeric Rating Scale|Patients assessed for postoperative pain using VNRS (0-10)
45926978|NCT00144469|Drug|peginterferon alfa-2a|
45926979|NCT00144469|Drug|rivavirin|
45926980|NCT05595343|Procedure|Laparoscopic distal pancreatectomy|Comparison of performed laparoscopic distal pancreas surgery in two different surgeon groups
45926981|NCT05595304|Procedure|prosthetic refunctioning|Active treatment followed by regular interventions
45926982|NCT05595304|Procedure|conventional prosthetic treatment|new prosthesis
45926983|NCT05595265|Diagnostic Test|immunohistochemical|Immunohistochemical Evaluation: Corresponding sections of 4µm thickness from each Formalin-fixed paraffin blocks will be immunohistochemically stained by anti- PD-L1 antibody according to the recommended protocol.
45926984|NCT04726540|Other|Patient Satisfaction|Patients were then asked to grade their overdentures/dentures on a visual analog scale and written questionnaire to evaluate their overall satisfaction.
45926985|NCT05595187|Device|Tricuspid repair|Tricuspid repair included suture placement and the type of prosthetic annuloplasty.
45926986|NCT00404716|Drug|Cilostazol|
45926987|NCT00404794|Drug|prednisolone and mycophenolate mofetil|
45926988|NCT00404794|Drug|prednisolone and tacrolimus|
45926989|NCT01950351|Other|Laboratory Biomarker Analysis|Correlative studies
45926990|NCT01950351|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
45926991|NCT01950351|Other|Quality-of-Life Assessment|Ancillary studies
45926992|NCT00404833|Drug|prednisolone and mycophenolate mofetil|
45926993|NCT00404833|Drug|prednisolone and chlorambucil|
46072242|NCT05263648|Other|Virtual Reality Session|"VR-based education sessions will be used to influence patients' perceived emotional and social distress while undergoing radiation therapy (RT).~Emotional and social distress levels will be evaluated using questionnaires at baseline (prior to the first VR experience), at completion of RT, and at 30-60 days post RT."
46072243|NCT05249530|Other|Chiropractic spinal adjustment|Chiropractic spinal adjustment
45799007|NCT02240329|Behavioral|Neuropsychological Testing and Measures of TBI severity|A brief cognitive assessment will be given to each participant when he or she presents for this project.
45926994|NCT05595109|Drug|Silymarin|"Silymarin administration prevent the neuro-degeneration through inhibiting the activation of microglia, silymarin attenuates the activation of glial cell activation in cellular models possibly through inhibition of inducible nitric oxide synthase (iNOS) production, also reported to protect both microglia and astroglia from oxidative insults induced by peroxide in ex vivo system .~It also significantly reduces doxorubicin-pro-oxidative activity and decreases histological changes in liver and heart tissue . The hepato-protective and cardio-protective effects of silymarin may be attributed to its antioxidant capacity, its ability to prevent lipid peroxidation and its ability to increase glutathione concentration.~silymarin was reported to improve cognitive impairment in mice."
45799008|NCT02240329|Behavioral|Respiratory measures|We will collect measures of cough airflow and breathing strength.
45799009|NCT02240329|Drug|Capsaicin cough sensitivity testing|Subjects will inhale a saline vapor mixed with various concentrations of capsaicin powder in order to determine how sensitive his or her cough response is.
45799010|NCT04329741|Behavioral|6-week basic dog obedience training course|The class focused on teaching owners how to better communicate with their dog and covered basic commands (e.g., sit, down, watch), loose leash walking, and polite greetings, among other skills. The importance of dog walking was implied, but not specifically emphasized. Classes were held once per week for 45 minutes, with 5-8 students per class.
45799011|NCT03751605|Procedure|unipulmonary ventilation|observational study based on the computation of respiratory quotient in patient cohort treated by unipulmonary ventilation in routine thoracic surgery
45799012|NCT02241811|Drug|3% Sodium Pentaborate Pentahydrate|For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
45926995|NCT05595109|Drug|Placebo|which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle was given every 21 day) followed by 12 cycles of paclitaxel (each cycle was given in a weekly basis) plus placebo tablets once daily.
45926996|NCT05595070|Procedure|Haematopoietic stem cell transplantation|Haematopoietic stem cell transplantation (HSCT) is widely used in the treatment of malignant and non-malignant conditions to reconstitute the immune system secondary to cytotoxic conditioning regimens. These regimens, consisting of chemotherapy with or without total body irradiation, cause severe immunosuppression prior to, during and after HSCT. Immune reconstitution takes place by infusion of stem cells either harvested from the patient (autologous HSCT) or from a donor (allogeneic HSCT).
45799013|NCT02241811|Drug|Placebo|Hydrogel without 3% Sodium Pentaborate Pentahydrate
45926997|NCT03128021|Drug|Escitalopram Pill|Double-blinded, randomly assigned
45926998|NCT03128021|Other|Placebo|Double-blinded, randomly assigned
45926999|NCT03128021|Drug|Levomilnacipran Pill|Double-blinded, randomly assigned
45927000|NCT05594992|Drug|JR-141|IV infusion, 2.0 mg/kg/week
45927001|NCT05594914|Drug|AK104|AK104 plus TC regimen(paclitaxel liposome , carboplatin), once every 3 weeks (Q3W), induction treatment for 2 cycles; Subsequently, AK104 plus TC regimen is combined with radiotherapy for 2 cycles.
45450680|NCT02189746|Other|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
45650198|NCT05037175|Behavioral|Reminder as Usual|As per Talkspace guidelines, therapists are available to client participants twice per day, five days per week. In the event a client participant has not engaged or messaged in 48 hours, therapists send a personalized message to the client participant to encourage them to re-engage.
45799014|NCT00003123|Drug|amifostine trihydrate|
45927002|NCT01919619|Biological|Ipilimumab|Given IV
45927003|NCT01919619|Drug|Lenalidomide|Given PO
45927004|NCT05594836|Behavioral|Infant Calming Training|Perception of Maternal Role, Maternal Attachment and Breastfeeding Self-Efficacy during Infant Calming Training
45650199|NCT03041987|Other|Demographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc|
45650200|NCT03981211|Drug|Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet|8 weeks of 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily or 4 weeks of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily
45650201|NCT03981211|Drug|Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet|4 weeks of 1 x sofosbuvir (400mg) tablet and 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily
45650202|NCT04856579|Procedure|Varicocelectomy|Subinguinal varicocelectomy under general anesthesia and complete aseptic condition
45799015|NCT03739905|Device|Blood Brain Barrier (BBB) Disruption|Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
45799016|NCT03981523|Drug|Benznidazole|50 mg and 100 mg tablet taken orally
45799017|NCT03981523|Drug|Nifurtimox|120 mg tablet taken orally
45799018|NCT03965923|Drug|Dapivirine (DPV) Vaginal Ring (VR)|Vaginal ring containing 25 mg of DPV
45799019|NCT03965923|Drug|Truvada Tablet|Tablet taken orally
45799020|NCT03962725|Drug|Neuromuscular Blocking Agents|Use of non depolarizing neuromuscular blocking agents for maintenance of general anesthesia.
45799021|NCT03962725|Drug|Anesthetic Adjuncts|Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine for maintenance of general anesthesia.
45799022|NCT03820219|Device|Prevena™ system|The Prevena™ System acts by removing exudate from a clean, closed incision. It helps hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment.
45799023|NCT03820219|Other|Standard sterile wound dressing|Standard wound care involves the application of an occlusive dressing in the operating room.
45799024|NCT03775837|Dietary Supplement|Panax Ginseng C.A. Mey Extract group|This group takes Panax Ginseng C.A. Mey Extract for 8 weeks
45799025|NCT03775837|Dietary Supplement|Placebo group|This group takes placebo for 8 weeks
45799026|NCT02251561|Device|FID 109182|Investigational multipurpose contact lens cleaning and disinfecting solution
45799027|NCT02251561|Device|Opti-Free Plus|Commercially available multipurpose contact lens cleaning and disinfecting solution
45927005|NCT05594719|Device|Shorter-wavelength dominant light|Shorter-wavelength dominant light
45927006|NCT05594719|Device|Light similar to the solar spectrum proportion|Light similar to the solar spectrum proportion with no specific wavelength dominant
45799028|NCT02251561|Device|Senofilcon A contact lens|Commercially available silicone hydrogel contact lens
45799029|NCT05699473|Dietary Supplement|5-MTHF glucosamine salt|Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) glucosamine salt
45927007|NCT05594719|Device|Longer-wavelength dominant light|Longer-wavelength dominant light
45927008|NCT00404911|Behavioral|MFG therapy|MFG includes 16 weekly group therapy sessions for families with children who have ODD or CD. Sessions will include adult caregivers and all children over age 6. Each session will follow the same procedures, and will proceed through the following stages: creating social networks; information exchange; group discussions; individual family practice; and homework assignment.
45927009|NCT00404911|Behavioral|Standard of Care|Participants assigned to standard care will receive treatment that is traditionally offered to outpatients. Participants in the MFG program will also receive standard care.
45450681|NCT02189746|Other|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
45799030|NCT05699473|Dietary Supplement|5-MTHF calcium salt 1|Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) calcium salt, crystal form 1
45799031|NCT05699473|Dietary Supplement|5-MTHF calcium salt 2|Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) calcium salt, crystal form 2
45799032|NCT02210559|Drug|FG-3019|FG-3019 will be administered per dose and schedule specified in the arm group description.
45799033|NCT02210559|Drug|Gemcitabine|Gemcitabine will be administered per dose and schedule specified in the arm group description.
45799034|NCT02210559|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered per dose and schedule specified in the arm group description.
45799035|NCT02991001|Procedure|Ultrasound-guided hydrodissection|Ultrasound-guided hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
45799036|NCT02991001|Procedure|Placebo ultrasound-guided injection|Ultrasound-guided injection with 5cc normal saline at subcutaneous layer beyond carpal tunnel
45799037|NCT02991001|Device|Ultrasound|
45799038|NCT02991001|Drug|Normal Saline|
45799039|NCT03724357|Drug|Vaxchora|One dose. Approximately 100 mL of cold or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.
45799040|NCT00003135|Drug|fluorouracil|
45799041|NCT00003135|Drug|pegylated liposomal doxorubicin hydrochloride|
45799042|NCT00003135|Procedure|hyperthermia treatment|
45799043|NCT02135679|Radiation|Radiotherapy|
45799044|NCT03669133|Drug|Vitamin E|Vitamin E 800 IU/daily
45799045|NCT03669133|Drug|Placebos|Matching placebo daily
45799046|NCT03546205|Drug|JNJ-64565111|All participants will receive a single SC dose of JNJ-64565111 solution on Day 1.
45799047|NCT03731559|Drug|DTG 50 mg OD with food|Dolutegravir 50 mg once daily with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy
45927010|NCT01891695|Radiation|39.6 Gy radiation|
45927011|NCT05594368|Device|Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT)|Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT) refractory to conventional antiarrhythmic and catheter ablation-based therapy. First patients will be treated with a dose from 25 Gy prescribed to the 65-90% target volume encompassing isodose escalating to a maximum of 32.5 Gy prescribed to the 65-90% isodose.
45927012|NCT01807494|Device|Total hip replacement components|All patients will receive the same implants
46072244|NCT05249530|Other|Non-force simulation|Non-force simulation
45799048|NCT03731559|Drug|DTG 50 mg BID|Dolutegravir 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
45799049|NCT03728127|Dietary Supplement|Brazilian cardioprotective diet|Brazilian cardioprotective diet prescription
45799050|NCT03728127|Dietary Supplement|Brazilian cardioprotective diet plus 30g/day of mixed nuts|Brazilian cardioprotective diet plus 30g/day of nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)
45799051|NCT03507673|Diagnostic Test|Blood samples and microbiological swaps|Blood analysis and analysis of vaginal microbiota.
45927013|NCT05594212|Behavioral|Abdominal breathing training|In the sleep center, it is carried out in a one-on-one manner by the trainer. At home, self-training through abdominal breathing training videos (10 minutes per day, you can accumulate up to 10 minutes in divided doses)
45927014|NCT01807455|Device|Restylane Vital Lidocaine|
45927015|NCT02964169|Behavioral|Family Planning Support|
45927016|NCT05594017|Drug|Scopolamine (5ug/kg)|Patient receives a dose of scopolamine (5ug/kg) via IV fifteen minutes prior to spatial or episodic memory task/completion.
45927017|NCT05594017|Drug|Placebo|Patient receives a dose of saline via IV fifteen minutes prior to spatial or episodic memory task/completion.
45927018|NCT01807416|Procedure|implant insertion and abutment connection|After implant insertion (standard platform or switching platform) the titanium abutment (standard or flat) will be connected
45927019|NCT03092453|Biological|Mature dendritic cell (DC) vaccine|Mature DC 7.5-15 million/peptide followed by 2 booster every six weeks of 1-5 million/peptide followed by standard of care anti PD-1 therapy.
45927020|NCT03092453|Drug|Cyclophosphamide 300mg/m^2|administered prior to subject's first DC dose
45799052|NCT02114229|Drug|alisertib|Alisertib will be administered orally at 80 mg/m^2 per day for enteric coated tablet formulation and 60 mg/m^2 per day for oral solution formulation.
45927021|NCT03092453|Drug|Pembrolizumab|administered 7-8 weeks after subject's last DC dose
45927022|NCT05572489|Diagnostic Test|visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale|evaluation of pain, fatigue, mood, quality of life, cognitive status
45927023|NCT04726384|Device|Assessment of physical activity level|Physical activity was assessed using the Sensewear Armband device. Patients received the device on Thursday mornings, prior to exercise and treatments. The device was placed on the right arm throughout the study. Patients in whom the device monitored a minimum of 95% of the time of the study day were analyzed. Prior to the study, the devices were programmed to record a minimum level of intense (>3MET) and moderate ( >6MET) exercise.
45927024|NCT01807377|Drug|PF-05175157|200 mg tablet administered twice per day for 14 days
46072245|NCT05243836|Device|S.T.O.P® F2|Ocufilcon D, 55% water
45927025|NCT01807377|Drug|Midazolam|2mg administered as single doses on Days 0 and 11
45927026|NCT01807377|Other|Placebo|Placebo administered twice per day for 14 days
45927027|NCT01807377|Drug|Midazolam|2mg administered as single doses on Days 0 and 11
45927028|NCT05552911|Procedure|Pretreatment strategies before drug balloon therapy|Preconditioning strategies for the treatment of in de novo coronary lesions using drug-coated balloons.
45799053|NCT02114229|Drug|methotrexate|Methotrexate will be given at a dose of 5 g/m^2/dose as an intravenous infusion over 24 hours on day 1 of each induction cycle except in patients ≤ 31 days of age at enrollment. These young infants will receive methotrexate at a reduced dose of 2.5g/m^2/dose.
45799054|NCT02114229|Drug|cisplatin|Cisplatin will be given intravenously (IV): 75 mg/m^2 IV infusion.
45927029|NCT05552911|Procedure|Different types of in-stent restenosis were treated with drug-coated balloons|A new classification method of ISR lesions was proposed to observe the clinical prognosis of different ISR lesions treated with drug-coated balloon.
45927030|NCT05551663|Other|Isometric exercise training|Participants randomised to the intervention will perform a 4-week programme of isometric exercise training.
45927031|NCT03090737|Biological|Nivolumab|Specified Dose on Specified Days
45927032|NCT05550103|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
45927033|NCT05550103|Procedure|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
45927034|NCT05550103|Other|Standard medical treatment|Standard medical treatment
45927035|NCT05545657|Behavioral|Cognitive assessments|Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Rey Auditory Verbal Learning Test (RAVLT), Boston Naming Test (BNT), Digit Span Test (DST), Trail Making Test (TMT).
45927036|NCT05545657|Other|Simultaneous EEG-fMRI scan|EEG recordings were conducted with a 64-channel MR-compatible EEG system (Electrical Geodesics Inc., Eugene, OR, USA) and an MR-compatible EEG cap (HydroCel Geodesic Sensor Nets), using ring-type sintered silver chloride electrodes with iron-free copper leads.
46072246|NCT05243836|Device|S.T.O.P® DT|Ocufilcon D, 55% water
46072247|NCT05243836|Device|MiSight®|Omafilcon A (60% water)
46072248|NCT05235204|Procedure|Removal of Foley Catheter 2 to 3 days post Colovesical Fistula (CVF) repair surgery|According to review of internal clinical practices, the average duration of catheterization after Colovesical Fistula (CVF) repair is 10.8 days after CVF repair. The intervention in this study removes the Foley Catheter at 2 to 3 days post CVF repair.
45650203|NCT03104803|Device|long-term paired associative stimulation|Paired associative stimulation (PAS) administered several times per week for 6 weeks to one hand. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
45927037|NCT05545657|Other|Multimodal magnetic resonance imaging|3D T1-weighted imaging, Resting-state fMRI, Diffusion tensor imaging, Arterial spin labeling.
45927038|NCT05545657|Other|Peripheral blood neuropathology biomarkers assay|Detecting the peripheral blood neuropathology biomarkers using single molecule array (Simoa) technique, including Aβ40, Aβ42, P-tau 181, P-tau 231, GFAP and NfL.
45927039|NCT05519800|Dietary Supplement|Isomaltulose|Diet will be supplemented with a beverage containing Isomaltulose as a carbohydrate source.
45927040|NCT05519800|Dietary Supplement|Maltodextrin|Diet will be supplemented using a beverage containing Maltodextrin.
45927041|NCT05504941|Diagnostic Test|Diagnostic, cerebral Digital Subtraction Angiography (DSA)|The DSA is the goldstandard for the visualization of brain vessels. For performing a diagnostic cerebral DSA, the femoral artery of the patient will be punctured in the groin. Over this arterial access a catheter will be advanced under fluoroscopy guidance to the target vessel in the brain. After navigation to the targeted brain vessel, contrast media will be injected over the catheter into the vessel. The efflux of the contrast media will be monitored and visualized with fluoroscopy. The additional radiation to the patient due to the DSA will be approx. 1.1 mSv. The duration of the DSA will be 15 to 20 minutes.
45927042|NCT01807260|Procedure|Shock wave lithotripsy|All procedures were performed under continuous intravenous sedo-analgesia (using a combination of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave lithotrpisy was poerformed with a Dornier Compact Delta lithotripter (Dornier Medtech, Germany). Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiplying the largest length and width of the individual stones measured from the abdominal plain X-ray.
45927043|NCT02972255|Drug|RO7079901|RO7079901 will be administered as per schedule described in individual arm.
45927044|NCT02972255|Drug|Meropenem|Meropenem will be administered as per schedule described in individual arm.
45927045|NCT02972255|Other|RO7049389 Placebo|Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
45927046|NCT02972255|Other|Meropenem Placebo|Placebo matching to meropenem will be administered as per schedule described in individual arm.
45927047|NCT05488015|Other|Global Postural Re-education (GPR)|GPR intervention lasted 8 weeks. Each week the postures had to be performed on 4 or 5 days.
45927048|NCT05488015|Other|Lifestyle habits|No change in lifestyle habits during the 8-week trial.
46072249|NCT05231954|Diagnostic Test|Passive Digital Marker for screening for ADRD|Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
46072250|NCT05228834|Drug|Voxelotor Only Product in Oral Dose Form|During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants < 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
46072251|NCT05228834|Drug|Placebo|During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants < 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
46072252|NCT05223036|Procedure|Biopsy|Undergo biopsy
46072253|NCT05223036|Procedure|Biospecimen Collection|Undergo collection of blood samples
45650204|NCT03041519|Procedure|Zero-fluoroscopy ablation|Catheter ablation will be performed under the guidance of Ensite NavX and without fluoroscopy.
45650205|NCT03041519|Procedure|Conventional fluoroscopy ablation|Catheter ablation will be performed under the guidance of fluoroscopy pllus Ensite NavX.
45799055|NCT02114229|Drug|carboplatin|Carboplatin may be substituted for cisplatin during induction for patients having Grade 4 ototoxicity or bi-lateral hearing loss after having prior cisplatin dose reduction. Route of administration is IV.
45799056|NCT02114229|Drug|cyclophosphamide|Cyclophosphamide will be given 1.5 g/m^2 IV infusion during induction and consolidation.
45799057|NCT02114229|Drug|etoposide|"Etoposide will be given 100 mg/m^2 IV infusion.~In case of etoposide reactions, etoposide phosphate will be given 40 mg/kg/day."
45799058|NCT02114229|Drug|topotecan|Topotecan will be administered by intravenous infusion over 4 hours on days 1-5 of each consolidation cycle for Stratum B2 and B3 patients not receiving craniospinal irradiation. The initial dose of Topotecan will be based on patient's age with subsequent doses adjusted, if necessary, to achieve a topotecan lactone area under the curve (AUC) of 140 ± 20 ng/mL*hr.
45927049|NCT01807143|Other|laboratory biomarker analysis|Correlative studies
45927050|NCT05482165|Behavioral|Multi-faceted health promotion programme|"This intervention programme will target the influencing factors of childhood obesity to influence the knowledge, attitude and behaviours of school children. Students in the intervention group will receive the following interventions:~Develop and implement school policies related to weight loss~Distribute health education materials on diet and exercise to students~Carry out student health education courses"
45927051|NCT03088943|Other|TTE Apical 4 Chamber View|We will measure a number of echocardiography parameters by TTE (apical 4 Chamber View) prior to and after induction
45927052|NCT03088943|Other|TEE dTG View|We will measure a number of echocardiography parameters by TEE (dTG View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
45927053|NCT03088943|Other|TEE ME 4C View|We will measure a number of echocardiography parameters by TEE (ME 4C View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
45927054|NCT05468671|Drug|Remimazolam|Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil. It acts on GABA receptors like midazolam and has organ-independent metabolism like remifentanil.
45799059|NCT02114229|Drug|vincristine|Vincristine will be given 1 mg/m^2 IV via 25 mL normal saline (NS) mini-bag (maximum 2 mg for all patients) or administration per local institutional standards for participating sites.
45927055|NCT05468671|Drug|Propofol|Propofol is used to put you to sleep and keep you asleep during general anesthesia for surgery or other medical procedures.
45927056|NCT05468671|Drug|Rocuronium|Rocuronium is a non-depolarizing neuromuscular blocker
45927057|NCT05468671|Drug|Remifentanil|Remifentanil is an esterase-metabolized opioid
45927058|NCT05468671|Drug|oxycodone|Oxycodone is an opiate painkiller.
46072254|NCT05223036|Procedure|Gastrointestinal Endoscopy|Undergo GI endoscopy
46072255|NCT05223036|Biological|Obeticholic Acid|Given PO
45450682|NCT04247542|Drug|Ibezapolstat|Investigational antibacterial agent
45799060|NCT02114229|Procedure|Surgical resection|"For patients with localized AT/RT, gross total resection results in a significant survival benefit. Maximal resection that can be achieved without undue risk to the patient should be attempted prior to trial enrollment. Decisions about initial resectability will be at the discretion of the local neurosurgeon. In rare instances, the feasibility of completely resecting residual tumor may change as a result of induction chemotherapy; in these cases a second-look operation is encouraged if and may be performed prior to consolidation therapy."
45650206|NCT03938311|Other|early rehabilitation|"The three study groups share a same intervention protocol in addition to the initiation timing of intervention from the stroke onset. The frequency and intensity of the intervention is titrated according to functional activity baseline and monitored daily and adjusted with recovery. Encourage patients to move out of bed as soon as possible.~Definition of bed movement: Encourage and help patients to perform functional actions, focusing on activities such as sitting, standing, walking out of the bed."
45799061|NCT02114229|Radiation|Radiation therapy|The guidelines for this protocol were developed to maximize the curative potential of radiation therapy and minimize the risk of treatment complications for children with newly diagnosed CNS AT/RT. Focal irradiation is indicated for children < 36 months with no evidence of metastatic disease. Craniospinal irradiation is indicated for children age > 36 months.
45799062|NCT03439891|Biological|Nivolumab|Given IV
45799063|NCT03439891|Drug|Sorafenib|Given PO
45799064|NCT04943575|Dietary Supplement|EZC Pak|After the onset of common cold symptoms, participants will take one pill (EZC Pak) each day for a period of 5 days.
45799065|NCT04943575|Dietary Supplement|EZC Pak +D|After the onset of common cold symptoms, participants will take one pill (EZC Pak +D) each day for a period of 5 days.
45799066|NCT04943575|Dietary Supplement|Placebo|After the onset of common cold symptoms, participants will take one pill (Placebo) each day for a period of 5 days.
45799067|NCT00003141|Biological|filgrastim|Given IV
45799068|NCT00003141|Drug|carboplatin|Given IV
45799069|NCT00003141|Drug|cisplatin|Given IV
45799070|NCT00003141|Drug|cyclophosphamide|Given IV
45799071|NCT00003141|Drug|etoposide|Given IV
45927059|NCT05468671|Drug|Sugammadex Sodium|Sugammadex sodium is an organic sodium salt that is the octasodium salt of sugammadex. Used for reversal of neuromuscular blockade induced by rocuronium and vecuronium in adults undergoing surgery
45927060|NCT05468671|Drug|Flumazenil|Flumazenil is used to reverse the effects of a benzodiazepine
45927061|NCT05463991|Device|Bioengineered collagen implant|Urethral stricture repair
45927062|NCT01807104|Procedure|Anterior Approach / Posterior Approach|compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
45927063|NCT01807104|Procedure|Anterior versus Posterior Approach for total hip replacement|Compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
45650207|NCT03041597|Procedure|placement of implants|surgical procedure and placement of implants
45650208|NCT03041597|Procedure|immediate loading|cone-anchored implant supported removable dental prostheses placement
45650209|NCT03041597|Procedure|conventional loading|cone-anchored implant supported removable dental prostheses placement in 3mo
45650210|NCT03041597|Device|Ankylos implant|
45799072|NCT00003141|Drug|thiotepa|Given IV
45799073|NCT00003141|Drug|vincristine sulfate|Given IV
46072256|NCT05223036|Drug|Placebo Administration|Given PO
46072257|NCT05223036|Other|Questionnaire Administration|Ancillary studies
46072258|NCT05217628|Drug|Basimglurant|"Period 1: Basimglurant 1.5 to 3.5 mg QD titrated on individual tolerability.~Period 2: Patients randomized to receive either double blind Basimglurant at the tolerated dose from Period 1 or Placebo.~OLE: Open label Basimglurant at the dose tolerated from Period 2, patients previously assigned placebo in period to be titrated to the Period 1."
46072259|NCT05217628|Other|Placebo|Participant randomized to receive matching placebo once daily.
46072260|NCT05202210|Biological|blood and urine sampling|extra sample of blood and urine will be collected
46072261|NCT05199662|Drug|Intravenous tenecteplase|Intravenous tenecteplase (TNK). Patients will receive intravenous TNK (0.25mg/kg, maximum 25mg, administered as a bolus over 5 seconds).
46072262|NCT05199662|Drug|Placebo|Placebo matching IV TNK
46072263|NCT05198934|Drug|Sotorasib|Sotorasib will be administered orally
46072264|NCT05198934|Drug|Panitumumab|Panitumumab will be administered as intravenous (IV) infusion
45650211|NCT04435171|Procedure|Renal transplantation|Open or robot assisted renal transplantation
45650212|NCT04856345|Other|Walking with music with synchronisation|Walking with music than one can synch to
45650213|NCT04856345|Other|Walking with music without synchronisation|Walking with music than one cannot synch to
45650214|NCT04856345|Other|walking without music|Walking without music
45650215|NCT04856267|Device|"LINQ device - implantable cardiac monitor - referred to in the application as implantable loop recorder or ILR)"|Implantation of an implantable cardiac monitor device (brand name LINQ device, Medtronic) will be performed under local anaesthetic using an aseptic sterile technique. They will undergo frequent follow-up and monitoring for arrhythmias through remote monitoring of the device
46072265|NCT05198934|Drug|Trifluridine and Tipiracil|Trifluridine and Tipiracil will be administered orally
45650216|NCT03919045|Drug|Saline injection|Half of the patients will be randomized to saline injections into the neck and head muscles
45650217|NCT03919045|Procedure|Placebo|Half of the group will be treated with needle stings without injections
45650218|NCT04856111|Drug|Pirfenidone|Same as arm description
45650219|NCT04856111|Drug|Nintedanib|Same as arm description
45927064|NCT05461885|Behavioral|Supervised exercise|The exercise sessions start with warm-up exercises, followed by 10-20 minutes resistance training (Part A), 10-20 minutes High Intensity Functional Training (HIFT) (Part B) and cool down. Instructors are allowed to make local adjustments as the delivery of the intervention is considered pragmatic. The participants can either perform the exercise together as one group, in pairs or one-by-one depending on individual needs and requests.
45927065|NCT05461807|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data
46072266|NCT05198934|Drug|Regorafenib|Regorafenib will be administered orally
45799074|NCT00003141|Procedure|conventional surgery|
45799075|NCT00003141|Procedure|peripheral blood stem cell transplantation|
45927066|NCT05461807|Drug|Apixaban|Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data
45450683|NCT04247542|Drug|Vancomycin|Active comparator
46072267|NCT05166161|Drug|PTC923|PTC923 powder for oral use will be suspended in water or apple juice prior to administration.
45650220|NCT02053051|Device|ABC4D|Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) to calculate pre-meal insulin boluses
45650221|NCT02053051|Drug|Novorapid|Multiple daily injections(MDI) of insulin
45927067|NCT05437900|Procedure|Pressure Microcatheter guided strategy - PIOS MC|Use of Pressure Microcatheter during PCI. After the PCI, the patient will receive treatment according to the incremental optimization strategy (PIOS) .
45927068|NCT05437900|Procedure|Pressure Wire guided strategy - PIOS - PW|Use of Pressure Wire during PCI. After the PCI, the patient will receive treatment according to the incremental optimization strategy (PIOS) .
45927069|NCT05437900|Procedure|Pressure Microcatheter guided strategy - Standard of care|Use of Pressure Microcatheter during PCI. After the PCI, the patient will receive standard of care treatment.
46072268|NCT05161169|Genetic|Genome Sequencing|20 times read depth (20x) next-generation whole genome sequencing with comprehensive analysis.
45650222|NCT04856423|Diagnostic Test|The us-qFIT and colonoscopy with pathological examination|Detect fecal hemoglobin concentration by us-qFIT before colonoscopy, detect colon lesions using colonoscopy and pathological examination.
45650223|NCT03881683|Diagnostic Test|HRD and BRCA mutations|Compare BRCA1/2 and HRD genes mutation detected from blood sample (20 ml) and biopsy
45799076|NCT00003147|Biological|Ad5CMV-p53 gene|
45927070|NCT05437900|Procedure|Pressure Wire guided strategy - Standard of care|Use of Pressure Wire during PCI. After the PCI, the patient will receive standard of care treatment.
45927071|NCT03079427|Drug|Gemcitabine plus cisplatin|Gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 Day 1 and 8, every 3 weeks
45927072|NCT03079427|Drug|Capecitabine|Capecitabine 1,250 mg/m2 Day 1 to 14, every 3 weeks
45927073|NCT05433649|Behavioral|Therapeutic exercise|The therapeutic exercise intervention with the help of elastic bands was carried out for 8 weeks with a frequency of two sessions per week, for a total of 16 sessions of 45 minutes duration.
46072269|NCT05154526|Other|Manual Therapy|Manual Therapy: High velocity-low amplitude technique
46072270|NCT05154526|Other|Exercise Program|Exercise program
46072271|NCT05147571|Device|Responsive stimulation|The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
46072272|NCT05147571|Device|Sham stimulation|For those in the Sham Stimulation group, the RNS System will be set to detect abnormal activity but will not have responsive stimulation enabled. Both Sham and Active groups will undergo therapy testing at each appointment in order to maintain the blind.
45450684|NCT02193412|Procedure|noxious stimulus|standardized noxious stimulus with tetanic stimulation
45450685|NCT02193412|Procedure|change in operating table slope: head-down tilt position|-30°
45450686|NCT02193412|Procedure|change in operating table slope: head-up tilt position|+30°
45650224|NCT04856033|Behavioral|TM|Transcendental Meditation instruction, 12-sessions over 3-4 months with monthly follow-up
45650225|NCT04856033|Behavioral|PCT|Present Centered Therapy, 12-sessions over 3-4 months with monthly follow-up
45650226|NCT04077541|Behavioral|internet platform|The trauma care bundles combined with the internet platform.
45650227|NCT04855565|Drug|ALY688-SR|single dose subcutaneous injection
45650228|NCT03864289|Behavioral|Parent skills training|Parents of children with autism spectrum disorder attend the parental training course once a week, and there was a total of eight courses with each course lasting 3 hours
45653206|NCT05110521|Behavioral|PROMPTS|PROMPTS is a two-way Short Message Service (SMS) digital health platform that connects mothers with information, advice and referrals to care during the prenatal and postnatal period. The platform also collects information from women on care experience that is reported back to maternity facilities.
45799077|NCT04867135|Drug|Amikacin Sulfate Injection|The dose and frequency of amikacin was defined by each hospital.
45799078|NCT04860661|Drug|Esketamine|After delivery, the parturient was given a loading dose of esketamine, and then a small dose of esketamine was added into PCIA analgesia pump
45799079|NCT04860661|Drug|Normal saline|10 ml normal saline
45799080|NCT02249455|Device|Acapella|Treatment time for 20 min twice daily
45799081|NCT02249455|Other|ELTGOL|ELTGOL technique 20 min twice daily
45799082|NCT02249455|Other|conventional physiotherapy|Conventional physiotherapy was given twice daily for 20 min
46072273|NCT05136417|Device|intra-procedural intracardiac echocardiography (ICE) probe|placing the WATCHMAN FLX device using the intra-procedural intracardiac echocardiography (ICE) probe.
46072274|NCT05127226|Drug|ION582|ION582 will be administered by IT injection.
46072275|NCT05124821|Device|Central venous catheter intended to be used for children during routine clinical practice|Device will applied according to instruction for use (IFU) and respective indication during routine clinical practice.
46072276|NCT05123053|Drug|Amifampridine|10mg tablet
46072277|NCT05117619|Behavioral|HOME for Us|HOME is an in-home, family inclusive, rehabilitation intervention in 8 sessions. Six of the sessions will be in-home and 2 will be over the phone. The in-home sessions will be about 1 ½ hrs. each, and the phone sessions will be about 15 minutes each. The sessions are delivered by an occupational therapist (OT).
46072278|NCT05117619|Behavioral|Attention-control condition|The Attention-control condition consists of educational materials presented over 8 contacts. Two of the contacts are by video conferences or phone calls and last 1 to 2 hours each. Two of the contacts are mailings of educational materials for discussion during the longer sessions. Three of the contacts are phone calls lasting about 10-15 minutes each to check for general updates, health care utilization/access, and study reminders.
46072279|NCT05112601|Procedure|Biospecimen Collection|Undergo collection of blood samples
46072280|NCT05112601|Procedure|Computed Tomography|Undergo CT
46072281|NCT05112601|Biological|Ipilimumab|Given IV
46072282|NCT05112601|Procedure|Magnetic Resonance Imaging|Undergo MRI
46072283|NCT05112601|Biological|Nivolumab|Given IV
45650229|NCT04863911|Radiation|combined CT and MRI|"1 mL of gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) will be diluted with 100 mL of saline; 8 mL of this will be mixed with 7 mL of iodine solution (340 mg/cc) and 3 mL of lidocaine 2% and injected under ultrasonographic guidance.~The fixed US-guided technique, the needle will be inserted into the needle guide hole and directed toward the hip joint, targeting the femoral head-neck junction. The volume injected varies from 10 to 20 mL, with a mean of 15 mL.~Ideally CT should be performed immediately after the injection and MR should be performed within 90 minutes after the initial injection."
46072284|NCT05109702|Drug|0.25% HL036 Ophthalmic Solution|HL036 ophthalmic solution.
46072285|NCT05109702|Drug|Placebo|Placebo vehicle solution.
46072286|NCT05104125|Drug|ASC40 25mg|25mg of ASC40 orally once daily for 12 weeks.
45799083|NCT01738321|Other|Cuff pressure|Measuring endotracheal tube (ETT) cuff pressure
45927074|NCT01807026|Drug|LY2886721|
45927075|NCT01807026|Drug|Placebo|
45927076|NCT05428540|Dietary Supplement|Polyphenol-rich supplement|Polyphenol-rich capsules containing 1,200 mg of a combination of plant extracts rich in polyphenols. Frequency: 3 capsules a day. Duration: 12 weeks.
45927077|NCT05428540|Other|Placebo|Placebo
46072287|NCT05104125|Drug|ASC40 50mg|50mg of ASC40 orally once daily for 12 weeks.
46072288|NCT05104125|Drug|ASC40 75mg|75mg of ASC40 orally once daily for 12 weeks.
46072289|NCT05104125|Drug|Placebo|Placebo orally once daily for 12 weeks.
46072290|NCT05102084|Device|Listening to music with a bluetooth headset to patients receiving CPAP support|Listening to music with a bluetooth headset during the CPAP application to the patients and checking the compatibility on the CPAP device.
45450687|NCT02189824|Biological|Partially HLA-matched unrelated donor cells|
45450688|NCT02189902|Dietary Supplement|4000 IU/d D3 over 12 weeks|
46072291|NCT05100862|Drug|Zanubrutinib|Zanubrutinib will be administered orally as two 80-milligram (mg) capsules twice a day (160 mg twice a day or 320 mg once a day) continuously in repeated 28-day cycles.
46072292|NCT05100862|Drug|Rituximab|Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.
46072293|NCT05100862|Drug|Lenalidomide|Lenalidomide will be administered orally as 20-mg capsules once a day on Days 1 to 21 of each 28-day cycle for a total of 12 cycles.
46072294|NCT05100862|Drug|Obinutuzumab|Obinutuzumab will be administered at a dose of 1000 mg on Cycle 1 Days 1, 8, 15 and then on Cycles 2 to 6 Day 1.
46072295|NCT05100368|Other|patients|Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis
45450689|NCT02189902|Dietary Supplement|7000 IU/d D3 over 12 weeks|
45450690|NCT02194192|Drug|Placebo|Normal saline 10 ml
45450691|NCT02194192|Drug|Ondansetron|Ondasetron 8 mg IV after spinal anesthesia
45450692|NCT02194192|Drug|Ephedrine|Ephedrine 10 mg IV after spinal anesthesia
45450693|NCT02194270|Drug|Ambroxol hydrochloride - soft pastille|
45650230|NCT02798341|Other|Biospecimen Collection|
45650231|NCT02051257|Biological|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
45650232|NCT02051257|Biological|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
45650233|NCT02051257|Other|Laboratory Biomarker Analysis|Correlative studies
45650234|NCT04855877|Drug|Oral tablet|Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration
45650235|NCT04855877|Drug|Placebo|Oral administration of lactose tablet (placebo)
45799084|NCT01740817|Drug|Intralipid 20%|30 ml/h for 48 h
45799085|NCT01740817|Drug|Saline|30 ml/h for 48 h
45799086|NCT01742065|Other|Auto Plus|Clinics randomized to the Auto-Plus arm will engage in all activities in the Auto arm (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to one other outreach effort.
45799087|NCT04806295|Other|any/all treatments for blood cancer|Following people undergoing any/all treatments for blood cancer.
45927078|NCT00390923|Drug|Selegiline + nicotine replacement therapy|Participants will begin selegiline once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
45799088|NCT04728217|Drug|Efmoroctocog Alfa Injection [Eloctate]|Efmoroctocog alfa should be administered according to Summary of Product Characteristics (SmPC)/ Instruction on Medical Use approved by Russian Ministry of Health ЛП-006034 (13.01.2020).
45799089|NCT05656807|Behavioral|Go NAPSACC Enhanced|Centers will receive the Go NAPSACC program as well as an online weight management intervention that focuses on personal weight management strategies. Participants will have access to materials that will support their adoption of evidence-based strategies for their weight management or loss goal. Behavior change strategies used are meant to increase intervention adherence and improve weight loss.
45799090|NCT05656807|Behavioral|Go NAPSACC|Go NAPSACC is an online evidence-based behavioral intervention that supports centers as they adopt center-wide healthy weight practices. It anticipates producing change in the child care environment through fostering best practices in center provisions, practices, policies, and professional development around child nutrition and physical activity and in turn foster healthier habits in the children in their care.
45450694|NCT02194270|Drug|Ambroxol hydrochloride - syrup - low dose|
45799091|NCT04702711|Other|No intervention|No intervention
45799092|NCT05642065|Other|Hip muscle activation home exercise program|Participants will perform a home exercise program consisting of five hip muscle activation exercises with the use of a resistance band. The program will be eight weeks in duration, and participants will perform the exercises twice weekly.
45799093|NCT04655365|Drug|Enzalutamide capsule|160 mg po id
45799094|NCT04633993|Behavioral|PCSMP|This study divided the patient-centered self-management manual for patients with hypertensive nephropathy into 4 units, including: Unit 1: hypertensive nephropathy brief introduction and complications. Unit 2: dietary precautions for patients with hypertensive nephropathy. Unit 3: medication treatments for patients with hypertensive nephropathy. Unit 4: the content included stress management (emotional control, spiritual support). This program was implemented in small groups with 5-10 patients. This study used patient-centered self-management group activity manual as the tool. The group activities with 4 units lasting for 400 minutes were expected to be designed. The group activities were expected to last for 4 weeks and be implemented once per week and 100 minutes per time (including: 90 minutes of group discussion and 5-10 minutes of video-waring).
45799095|NCT04581343|Drug|Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine|Canakinumab 250 mg s.c. injection; Spartalizumab 400 mg IV infusion, nab-paclitaxel 125 mg/m2 IV infusion, gemcitabine 1000 mg/m2 IV infusion
45799096|NCT04565743|Behavioral|Support on dentification and treatment of patients with high risk of osteoporotic fractures|Education for primary care health care professionals and referral of patients with recent osteoporotic fracture.
45799097|NCT01743859|Drug|Azacitidine|Enrolled patients will receive 75 mg/m2 of azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 alone.
45799098|NCT01743859|Drug|Lenalidomide|Beginning on day 8, patients will receive 50 mg of lenalidomide PO, and will take this daily from day 8 through 28.
45799099|NCT01743859|Other|Off Therapy|2 weeks off therapy, then begin sequence again for 12 weeks.
45799100|NCT01746043|Drug|Armodafinil|150 mg by mouth once a day for 6 weeks.
45799101|NCT01746043|Other|Placebo|1 capsule by mouth 2 times a day for 6 weeks.
45799102|NCT01746043|Drug|Minocycline|100 mg by mouth 2 times a day for 6 weeks.
45799103|NCT01746043|Behavioral|Questionnaires|Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
45799104|NCT05635903|Procedure|Continuous nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser|Continuous nebulisation of 0.9% saline using the Aerogen Solo vibrating mesh nebuliser
45799105|NCT05635903|Procedure|Intermittent nebulisation 0.9% saline Aerogen vibrating mesh Solo Nebuliser|Intermittent nebulisation of 0.9% saline using the Aerogen Solo vibrating mesh nebuliser
45799106|NCT05635903|Procedure|Intermittent standard intermittent nebulisation of 0.9% saline Intersurgical Cirrus 2 self sealing Jet Nebuliser|standard intermittent nebulisation of 0.9% saline using the Intersurgical Cirrus 2 self-sealing Jet Nebuliser
45799107|NCT01746511|Procedure|Phototherapy|Light therapy is used to treat cases of neonatal jaundice through the isomerization of the bilirubin and consequently transformation into compounds that the newborn can excrete via urine and stools.
45799108|NCT01746511|Drug|glycerin suppository|Promotes stooling through rectal stimulation and softening of stool. Given every 8 hours rectally. A pediatric glycerin suppository is 1.2 grams. All infants in this study arm will receive our standard dose of glycerin suppository which is 0.25 of the pediatric suppository or 0.3 grams.
45799109|NCT01746745|Drug|[^14C]-LY2940680|Administered as solution by mouth
45799110|NCT01746979|Drug|TH-302|TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
45799111|NCT01746979|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 1000 (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
45450695|NCT02194270|Drug|Ambroxol hydrochloride - syrup - high dose|
45799112|NCT01746979|Drug|Placebo (5 percent dextrose - D5W)|TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
45450696|NCT02189980|Other|Aromatherapy blend|A blend of 45% ginger, 25% peppermint, 5% spearmint, and 25% cardamom essential oils
45927079|NCT00390923|Drug|placebo + nicotine replacement therapy|Participants will begin placebo once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
45927080|NCT02972112|Behavioral|CBT|novel cognitive behavioral protocol for the treatment of tokophobia
45799113|NCT04552171|Behavioral|Access to Game Plan app and 24-hour helpline|Game Plan is a web-based application that helps users reflect on their risk for HIV and level of alcohol use, and if interested, make a plan for reducing their sexual risk or drinking.
45927081|NCT02972112|Other|Sham|standard birth preparation sessions.
45927082|NCT05397847|Behavioral|Education|"Rational Drug Use in Elderly Individuals~Training: Through home visits, an average of 30 minutes of training will be given to elderly individuals (drugs, rational drug use, the importance of rational drug use, and what the elderly should do for rational drug use). Question-answer method and visual materials will be used in the training.~Training: An average of 20 minutes of training will be given, including a brief repetition of the topics covered in the first training, via a home visit. Visual materials will be used in the training."
45927083|NCT05397847|Other|Rational Drug Use Guide|At the end of the first training, a rational drug use guide will be given to elderly individuals, including the topics explained.
45799114|NCT05631535|Other|Intensive lifestyle change program with a very-low-energy diet|The intervention will consist of two phases. In the first phase, the participants receive weekly visits for two months. During these visits, a nutritionist will take the participants' weight and abdominal circumference measurements, and each one will receive a meal plan with a very low-energy diet (800 kcal/d). The second phase will implement in the third and fourth months, and nutritional counseling will continue to be provided every week in the third and biweekly in the fourth month. In this second phase, a gradual reintroduction to low-energy dietary meal plans (1200-1800 kcal/d) will perform. In addition, a specially adapted Diabetes Prevention Program for a very low-energy diet will implement.
45799115|NCT05631535|Other|Intensive lifestyle change program with a low-energy diet|The structure (frequency of nutritional counseling, number of sessions, time of sessions, etc.) in this group will be the same as that of the intervention group, and a modified Diabetes Prevention Program will also provide. From the beginning of the study will recommend meal plans with a low-energy diet (1200-1800 kcal).
45799116|NCT01748227|Behavioral|Peer-Delivered Pain Self-Management|Patients (n=20) were assigned a peer coach to meet with for 4 months to discuss pain self-management.
46072296|NCT05098405|Drug|MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen)|"The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).~Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.~Study treatment will be administered every 3 weeks (q3w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)."
45799117|NCT01748695|Drug|V158866|
46073718|NCT00849823|Behavioral|Male Sexual Health Program|"An attention equivalent control condition entailing a 60-minute one-to-one session that will didactically teach teens about several aspects of male sexual health. The content and objectives are related only to knowledge acquisition. In addition to this program, teens randomized to the control condition will receive standard-of-care services from the clinic. This involves the provision of free condoms (one size fits all condoms) and a brief (nurse-delivered) counseling message to practice safer sex."
45450697|NCT02189980|Other|Duration of effectiveness of the essential oil blend|Evidence of effectiveness of tested aromatherapy blend in reducing symptoms of post-operative nausea as measured by patient self-report using Likert-type scale measure immediately to one-day post-operative.
45450698|NCT02189980|Other|Participant comfort using the nasal clip delivery system|Comfort of participants using nasal clip delivery system for aromatherapy will be measured by self-report using Likert-type scale immediately to one-day post-operative.
45450699|NCT02190058|Drug|DS-1971a|suspension
45799118|NCT01748695|Drug|Placebo|
45799119|NCT05617495|Other|fMRI Neurofeedback|Participants will receive mindfulness-based fMRI neurofeedback targeting the default mode network and central executive network.
45799120|NCT05614453|Drug|Tislelizumab|Tislelizumab is an investigational, humanised-IgG4 monoclonal antibody with high affinity/binding specificity for PD-1. It is engineered to minimise binding to FcγR on macrophages to abrogate antibody-dependent cellular phagocytosis.
45799121|NCT05614453|Drug|Sitravatinib|Sitravatinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential anti-neoplastic activity.
45927084|NCT05397847|Other|Medicine Box|Elderly individuals will be given a medicine box large enough to be carried in the pocket when appropriate, so that the elderly people do not forget their medicines and use them regularly, with a 7-day medicine compartment that organizes their medicines and a daily (morning, noon, evening and night) medicine box.
45927085|NCT05397847|Behavioral|Counseling|After the training, counseling services will be given to elderly individuals regarding rational drug use. Within the scope of the counseling service, it will be ensured that the drugs used by the elderly person are regulated and their questions about rational drug use will be answered.
45450700|NCT02190058|Drug|placebo|placebo matching DS-1971a
45450701|NCT02194348|Drug|BIBN 4096 BS - in single rising doses|
45450702|NCT02194348|Drug|Placebo|
45450703|NCT02257216|Other|Vayarin®|Medical Food
45450704|NCT02257216|Other|Placebo|Cellulose
45450705|NCT02194426|Drug|MP0250|Intravenous application by infusion of MP0250 at up to six dose levels, every other week for up to 24 infusions.
45450706|NCT02195908|Other|single point Neiguan(PC6) plus antiemetic drug|
45450707|NCT02195908|Other|single point Zhongwan(CV12) plus antiemetic drug|
45450708|NCT02195908|Other|matching points Neiguan(PC6) and Zhongwan(CV12) plus antiemetic drug|
45450709|NCT02195908|Drug|only antiemetic drug|
45927086|NCT05394610|Device|Sana Device|Audio Visual Stimulation patterns intended to produce a therapeutic benefit.
46072297|NCT05098405|Drug|MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)|"The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).~Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.~Study treatment will be administered every week (q1w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)."
46072298|NCT05087641|Device|IAB System|Bronchoscopic implantation of one or multiple IABs
46072299|NCT05083481|Drug|ASP1570|Oral tablet
45450710|NCT02197000|Dietary Supplement|DIM-Avail 100mg|DIM 100 mg*1 daily for 2 years
45450711|NCT02197312|Device|NobelProcera Bridge Shaded Zirconia|
45799122|NCT01750255|Other|Pharmaceutical Care|Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy; Depression and Mania Rating Scale, Clinical Global Assessment Scale, Quality of life and adherence to treatment
45450712|NCT02194504|Other|Dietary advice, Western|Dietary advice, guided by professional dieticians. Caloric restricted (-30en%) diet with Western type nutrient composition (SFA, carbohydrates, sugars, fruit juice, meat, dairy)
45799123|NCT01750255|Other|Education|The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life (Sf - 36 test), adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.
45799124|NCT04339933|Diagnostic Test|FGFR test|Detection of FGFR gene mutations in the tumor tissue and urine of patients
45799125|NCT05605015|Behavioral|ACTIVE-CR|The ACTIVE-CR intervention comprises three key components: a wrist-worn physical activity monitor, a web-based platform providing physical activity feedback, and three autonomy supportive online trainer sessions. Each component is grounded by multiple established behaviour change techniques consistent with the behaviour change taxonomy developed by Michie et al. (2013). The barriers to physical activity were identified in our previous work and are consistent with previous literature
45799126|NCT01751971|Drug|Inspired oxygen (40%)|Supplemental oxygen at 40% inspired via venturi mask (15 L/min). Equivalent to 5 L/min via nasal cannula.
45799127|NCT01751971|Other|Sham|Medical air with 21% oxygen via venturi mask (15 L/min).
45799128|NCT01754389|Drug|Tacrolimus|
45799129|NCT01754389|Drug|Methotrexate|
45799130|NCT01754389|Drug|Bortezomib|
45799131|NCT01754389|Drug|Sirolimus|
45799132|NCT04288453|Behavioral|Engagement in a 8-week community-based activity program|"Participants engage in a 8-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 8 weeks - the actual intervention phase.~Other Names:~• Pathways and Resources for Engagement and Participation"
45799133|NCT01754623|Drug|Capecitabine|Treatment will begin with the first round of chemotherapy. Each round of chemotherapy will take 21 days. Each round or cycle will start with participants taking capecitabine pills. Participants will take tablets of capecitabine (Xeloda®) twice per day for 14 days followed by 7 days without capecitabine.
45927087|NCT05394610|Drug|Sana Device (Control)|A control device that mimics the physcial appearance of the Sana device.
45927088|NCT05388955|Other|None, transplantation recipients|None, observational
45927089|NCT05387629|Behavioral|Education|Nursing students will be trained through social media.
45450713|NCT02194504|Other|Dietary advice, Targeted|Dietary advice, guided by professional dieticians. Caloric restricted (-30en%) diet with nutrient composition aiming at an improvement in organ health and a reduction in liver fat (PUFA, fish, soy protein, whole grain)
45450714|NCT02197390|Behavioral|Family wellness workshops|Nine family wellness workshops and eight family physical activity sessions facilitated by community health workers.
45450715|NCT02197390|Behavioral|Obesity chronic care model|
46072300|NCT05083481|Drug|Pembrolizumab|Intravenous Infusion
46072301|NCT05061550|Drug|Durvalumab|Participants will receive Durvalumab via intravenous route.
46072302|NCT05061550|Drug|Oleclumab|Participants will receive Oleclumab via intravenous route.
45450716|NCT02197390|Behavioral|Physical activity, healthy eating, water drinking, healthy sleep promotion|
45450717|NCT02197390|Behavioral|Environment, policy, systems changes in clinic setting only|
45450718|NCT02197390|Behavioral|No intervention|No intervention.
45450719|NCT02197390|Behavioral|Environment, policy, and systems changes in schools, early child care education & recreation|
45450720|NCT02196142|Drug|Cortisol 20mg|Drug: Cortisol 20mg
45450721|NCT02196142|Drug|Placebo Mannitol|Drug: Placebo Mannitol
45799134|NCT01754623|Drug|Gemcitabine|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. First, this will consist of placing gemcitabine (Gemzar®) in a bag of fluid and giving it by vein over 30 minutes.
45799135|NCT01754623|Drug|Docetaxel|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. After the gemcitabine, participants will receive docetaxel (Taxotere®) in a bag of fluid over 1 hour.
45799136|NCT01754623|Radiation|Stereotactic body radiation therapy (SBRT)|30/40 Gy to pancreatic tumor/area of borderline resectability
45799137|NCT01754623|Other|Restaging review after radiation|After radiation, participants will be re-evaluated for surgery. Patients who have Complete Response (CR), Partial Response (PR) or stable disease (SD) will proceed with surgical exploration and resection provided they are suitable fit for surgery in the judgment of the surgical oncologist. Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT). If no surgery: then chemotherapy. If surgery: chemotherapy will be given based on response.
45799138|NCT01754623|Procedure|Surgery|Non-metastatic patients who are deemed resectable after neoadjuvant therapy will be taken to surgery. After surgery, chemotherapy will be given based on response.
45799139|NCT01754623|Drug|5-Fluorouracil|Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT).
45927090|NCT01806987|Behavioral|KITS Program|The KITS Program is a 4-month psychosocial intervention for children at high risk for school difficulties and their caregivers. The intervention begins in the summer before kindergarten and continues across the first two months of kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 time per week in the fall); and (b) a 12 session psychoeducational workshop to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques (once per week in summer, bi-weekly in the fall).
45799140|NCT01755169|Drug|Ketamine|Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).
45799141|NCT01755169|Drug|Placebo|
45799142|NCT02073279|Drug|Satralizumab|Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
45799143|NCT02073279|Drug|Placebo|Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
45799144|NCT01755949|Drug|Colchicine, 0.6 mg PO BID|Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo
45799145|NCT01755949|Drug|Matching placebo|Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug
45799146|NCT01756885|Drug|Varenicline|Varenicline was used in accordance with FDA approved labeling: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
45799147|NCT01756885|Drug|Placebo|On Day 85, participants randomized to standard therapy will be given placebo pills (resembling the 1.0mg pills),
45927091|NCT05378776|Dietary Supplement|sucrose|The experimental arm will receive 1.5 ml/kg of the sucrose solution at triage (once). The composition of the homemade sucrose solution used in our emergency department is 3.5 g of table sugar (sucrose) mixed with 10 ml of water. For this double-blind study, we replaced water with diluted juice (see standard arm description) to obtain a solution with the same appearance as the standard arm. With the idea of correcting ketosis, we chose to provide the same amount of sugar as we do in hypoglycemia (0.4-0.5 g/kg of dextrose) to participants in the intervention group, which represents 1.5 ml/kg of the sucrose solution containing 0.4 g of sucrose/mL for a total of 0.6 g/kg of sucrose.
45927092|NCT05378776|Dietary Supplement|Standard rehydration solution|This group will receive 1.5 mL/kg of diluted juice composed of juice (apple or orange) and water in equal proportion once at triage. This solution contains 0.05 g/ml of sucrose for a total of 0.075 g/kg of sucrose (eight times less than the intervention arm).
45450722|NCT03534856|Behavioral|Mindfulness meditation|Short guided mindfulness meditations were provided on an MP3 player.
45927093|NCT00425425|Biological|cetuximab|
45927094|NCT00425425|Drug|fluorouracil|
45927095|NCT00425425|Drug|oxaliplatin|
45927096|NCT00425425|Procedure|conventional surgery|
45927097|NCT00425425|Procedure|neoadjuvant therapy|
45927098|NCT00425425|Radiation|radiation therapy|
46072303|NCT05061550|Drug|Monalizumab|Participants will receive Monalizumab via intravenous route.
45450723|NCT02257294|Drug|Alteplase|Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
45450724|NCT02257294|Other|Placebo|Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
45450725|NCT03534388|Other|Sodium Hypochlorite Cleanser|Cleansing with CLn BodyWash
45653207|NCT05110521|Behavioral|MENTORS|MENTORS is a program in which in facility nurse-mentors are trained and supported to offer training to nurses, midwives and other maternity facility staff on aspects of basic and emergency obstetric and newborn care.
45653208|NCT01295723|Radiation|Hypofractionated Whole Breast Radiation Therapy|"Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days postoperatively (week 2-8 post-op)~Single reference dose per fraction: 2.7 Gy (ICRU)~Number of fractions: 15~Number of fractions per week: 5~Regular Radiation Therapy breaks: Weekend/ Holidays (not exceeding 7 days break)~Total dose: 50.5 Gy (40.5 WBRT + 10 Gy boost) Radiation: Intraoperative Electron Radiation Therapy"
45927099|NCT01806948|Drug|Ramosetron|
45927100|NCT05374525|Drug|APRETUDE|Available as intramuscular injection.
45927101|NCT05374525|Drug|Cabotegravir OLI|Available as marketed orally administered tablets.
46072304|NCT05061550|Drug|MEDI5752|Participants will receive MEDI5752 via intravenous route.
45799148|NCT01756885|Behavioral|Smoking Cessation Counseling|"Behavioral Counseling (from Week 0 - Week 18)~The counseling protocol was based on PHS guidelines for smoking cessation treatment (Fiore et al., 2008), used in our past studies with cancer patients (Schnoll et al., 2010a) and in our ongoing cessation trial at NU (R01 DA025078). Counseling is included given its efficacy at helping smokers quit (Fiore et al., 2008) and to increase study retention. Counseling is provided to both treatment arms through Week 18 to equate for time and attention across arms and since this method was used in varenicline clinical trials (Gonzales et al., 2006) and in our extended therapy trial (Schnoll et al., 2010b). In-person counseling was selected for most sessions to ensure adequate monitoring of participant safety and adherence throughout the trial."
45650236|NCT03102073|Diagnostic Test|Radner test|"The A5 reading booklet is held by the subject~The subject is instructed to read sentence by sentence, by turning consecutively the pages of the booklet (on the first side is the number of sentence and the backward side contains the sentence)~The subject is instructed to read the sentences aloud as quickly and accurately as possible to the end, and to not correct reading errors.~One assessor is writing the reading time and records any reading errors on the scoring sheet while the second assessor is audio recording the operation~Stop criterion: reading time longer than 20 seconds or severe errors."
45927102|NCT03004976|Biological|Umbilical Cord Blood|Umbilical cord blood will be infused intravenously through a peripheral IV line after premedication with diphenhydramine, hydrocortisone, and acetaminophen. Units will be from a public cord blood bank with selection based on blood type, race, and the number of cells in the pre cryopreservation product, targeting a dose range of 0.5 to 5 x 10^7 TNCC/kg.
45927103|NCT03004976|Other|Placebo|The placebo product will be acellular and will consist of tissue culture medium 199 (TC-199 [pink]) with 1% dimethyl sulfoxide (DMSO), which are standard components in cellular products. The volume of placebo product will be 50 mL, which is in the range of a typical UCB unit that has been washed and thawed after cryopreservation. Infusion and premedication procedures will be the same as those conducted for the umbilical cord blood arm.
45799149|NCT04209907|Other|retrolaminar block tecnique|By using ultrasound probe, the needle with in-plane , after seeing vertebral lamina, the local anesthetic will injectate
45927104|NCT05360329|Procedure|Transarterial geniculate artery embolization|The procedure will be performed in local anaesthesia. An antegrade percutaneous transfemoral approach with super-selective catheterisation of geniculate neovesselswill be performed and subsequently the target will be pruned with microspherical embolic material.
45927105|NCT02958163|Procedure|Trans-arterial Chemo-Embolization|Trans-Arterial Chemo-Embolization will be performed with Doxorubicin-Eluting-Beads (DEB-TACE). It will be performed in each arm of treatment.
45927106|NCT02958163|Drug|Doxorubicin|Drug-eluting Bead for Trans Arterial Chemo-Embolization will be loaded with Doxorubicin.
45927107|NCT02958163|Radiation|Stereotactic Ablative Radiotherapy|"SABR schemes will be adapted according to the CP score and the vicinity of surrounding organs at risk. These are the different schemes proposed in this trial:~48Gy = 3x16Gy BED 124.8Gy ( α/β=10) 50Gy = 5x10Gy BED 100Gy ( α/β=10) 48Gy = 6x8Gy BED 86.4Gy ( α/β=10) 40Gy = 5x8Gy BED 72Gy ( α/β=10)~For patients with Child-Pugh (CP) A cirrhosis : the choice of the scheme will be left to each physician. The highest BED should be favored if dose constraints to the organs at risk are respected.~For patients with CP B cirrhosis : only the latter scheme will be allowed: 40Gy = 5x8Gy."
45927108|NCT01806909|Biological|Ad4-H5-Vtn|
45927109|NCT00424138|Radiation|FDG|
45927110|NCT05336032|Other|Food (rice)|Cooked rice with 75 gm carbohydrate
45927111|NCT05329831|Behavioral|Structured training using telehealth|The intervention is based on self-care activities. Self-care states that people have an innate ability to take care of themselves.
45927112|NCT01806870|Dietary Supplement|Zinc and SAMe|If a subject has side effects their dose of Zinc will be reduced. SAMe will remain the same dose.
45927113|NCT02985866|Device|Artificial Pancreas|Use of CTR at home for 3 months
45927114|NCT02985866|Other|Sensor Augmented Therapy|Use of personal pump with study CGM & glucometer at home for 3 months
45650237|NCT01371981|Drug|Asparaginase|Given IM
45650238|NCT01371981|Drug|Bortezomib|Given IV
45650239|NCT01371981|Drug|Cytarabine|Given IT or IV
45927115|NCT05310955|Other|daily rehabilitation interventions|including Naikan therapy, Morita therapy, group art therapy, group painting therapy
45927116|NCT05310955|Other|shen-based Qigong exercise|a 12-week intervention of shen-based Qigong exercise : exercise 5 days a week, about 30 minutes a day
45927117|NCT01806831|Device|"Biocellulose Mask, Farhorm®"|
45927118|NCT05275933|Other|TCM intervention|Lian Hua Qing Wen Capsules (LH) are provided in addition to Standard Care medications which include Symptomatic therapies include Paracetamol, antihistamines (eg. Cetirizine, loratadine or chlorpheniramine) and etc pro re nata (PRN) basis accordingly to the patient's condition.
46072305|NCT05061550|Drug|Dato-DXd|Participants will receive datopotamab deruxtecan (Dato-DXd) via intravenous route.
46072306|NCT05061550|Drug|AZD0171|Participants will receive AZD0171 via intravenous route.
45650240|NCT01371981|Drug|Daunorubicin Hydrochloride|Given IV
45650241|NCT01371981|Drug|Etoposide|Given IV
45650242|NCT01371981|Other|Laboratory Biomarker Analysis|Correlative studies
45650243|NCT01371981|Drug|Mitoxantrone Hydrochloride|Given IV
45650244|NCT01371981|Other|Pharmacological Study|Correlative studies
45927119|NCT05275933|Other|Placebo intervention|Placebo Capsules (PC) are provided in addition to Standard Care medications which include Symptomatic therapies include Paracetamol, antihistamines (eg. Cetirizine, loratadine or chlorpheniramine) and etc pro re nata (PRN) basis accordingly to the patient's condition.
45927120|NCT02942108|Procedure|piezo surgery|
45927121|NCT02942108|Procedure|conventional surgery|
45650245|NCT01371981|Other|Quality-of-Life Assessment|Ancillary studies
45799150|NCT04172701|Drug|Long-acting Muscarinic Antagonists (LAMA)|drug
45927122|NCT05240989|Procedure|pulmonary rehabilitation|one-year regular lung rehabilitation treatment and control the intensive monitoring of hemodynamic parameters
45927123|NCT01806792|Drug|risedronate combine|
45927124|NCT01806792|Drug|Risedronate|
45927125|NCT01806792|Drug|Placebo(for Risedronate)|
45927126|NCT01806792|Drug|Placebo(for risedronate combine)|
45927127|NCT05228431|Drug|XELOX|Starting from the first day of radiotherapy (set as day 0), the patient received a total of 4 courses of XELOX chemotherapy on days -42, -21, 42, and 63, including oxaliplatin 130 mg/m2, intravenous administration, d1, repeat every 3 weeks; and capecitabine 1000mg/m2, twice daily, d1-d14, repeat every 3 weeks.
45927128|NCT05228431|Drug|Capecitabine monotherapy|During radiotherapy (Monday to Friday), capecitabine was administered at 1650 mg/m2/d, twice a day.
45927129|NCT05228431|Radiation|Radiation|The TV is expanded by 6-7mm to form PTV1, and the CTV is expanded by 6-7mm to form PTV2. The dose of PTV1 was 50Gy/25 times/35 days, and the dose of PTV2 was 45Gy/25 times/35 days, 5 times/week for a total of 5 weeks.
45650246|NCT01371981|Other|Questionnaire Administration|Ancillary studies
45927130|NCT05227456|Drug|Etonogestrel 68mg implant|Implant will be inserted
45927131|NCT05227456|Device|Etonogestrel 68mg implant|Implant will be inserted
45927132|NCT05216146|Other|Strength and Conditioning|A specially designed strength and conditioning program will be delivered for a period of 6 months from the experienced strength and conditioning coaches. The program will consist of the basic aerobic and anaerobic exercises that could be practiced without additional equipment and with own body weight.
45650247|NCT01371981|Drug|Sorafenib Tosylate|Given PO
45650248|NCT03041675|Device|Laser Acupuncture group|47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
45650249|NCT03041675|Device|Sham Laser Acupuncture group|The investigators apply the Laser Acupuncture pen (without pressing the Laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
45650250|NCT04849247|Drug|68Ga-DOTA-FAPI, 177Lu-DOTA-FAPI|PET imaging using 68Ga-DOTA-FAPI will be used to diagnose patients who are eligible for treatment with the 177Lu-DOTA-FAPI.
45650251|NCT02845453|Drug|Quetiapine|Participants will be randomly assigned Quetiapine and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
45799151|NCT04172701|Drug|Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)|drug
45799152|NCT04151875|Device|Extraction orthodontic treatment|orthodontic treatment with teeth extraction
45799153|NCT04151875|Device|Non-extraction orthodontic treatment|Non-extraction orthodontic treatment
45799154|NCT04113421|Diagnostic Test|Contrast-enhanced chest CT|A single follow-up contrast-enhanced chest CT to compare off-line with the contrast-enhanced chest CT done at baseline for the diagnosis of PE.
45927133|NCT01806753|Procedure|Intermittent midazolam/propofol injection controlled by endoscopist|"In this arm1, sedation during endoscopic submucosal dissection is controlled by endoscopists.~First, pethidine 50 mg with midazolam 0.05 mg/kg are injected in a bolus fashion.~When the patient seems to be discomfort or the patient's movements were observed, endoscopists should check the Modified Observer Assessment of Alertness/Sedation (MOAAS).~If MOAAS is 5 or 6, propofol 0.25 mg/kg will be injected. Otherwise, pethidine 12.5 mg will be injected."
45927134|NCT01806753|Procedure|Continuous propofol infusion with opioid administration|"In this arm2, sedation during endoscopic submucosal dissection is controlled by anesthesiologists.~First, remifentanil 0.5 ug/kg with propofol 0.5 mg/kg are injected in a bolus fashion.~Then, remifentanil 0.08 ug/kg/min and propofol 2 mg/kg/h are infused continuously.~When the patient seems to be discomfort or the patient's movements were observed, anesthesiologists should check the MOAAS.~If MOAAS is 5 or 6, infusion rate of propofol will be increased by 0.5 mg/kg/h. Otherwise, infusion rate of remifentanil will be increased by 0.02 ug/kg/min."
45927135|NCT05211661|Diagnostic Test|Respiratory Muscle Testing|Comprehensive assessment of respiratory muscle function. Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
45927136|NCT05208424|Diagnostic Test|Coronary angiography|Invasive coronary angiography
45927137|NCT05197075|Drug|DRV/COBI FDC|DRV/COBI FDC tablet dispersed in water will be administered orally.
45927138|NCT05175430|Drug|Paroxetine|Paroxetine (per os) will be used as pharmacological tool to downregulate 5-HT1/2 receptors.
45927139|NCT05175430|Drug|Lysergic Acid Diethylamide|LSD (per os) will be used to see if 5-HT 1/2 receptors were downregulated by paroxetine.
45927140|NCT05175430|Drug|Placebo|Placebo (per os) for the Paroxetine condition will be used to compare the data from the study day with LSD between both arms.
45927141|NCT01806675|Drug|18F-fludeoxyglucose (18F-FDG)|18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan
45927142|NCT01806675|Drug|18F-FPPRGD2|18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.
45927143|NCT05173519|Device|Omnibond Topical Skin Adhesive|Application of Omnibond topical skin adhesive to close incision following surgery
45927144|NCT05173519|Device|Dermabond Advanced Topical Skin Adhesive|Application of Dermabond topical skin adhesive to close incision following surgery
45927145|NCT02762981|Drug|Relacorilant with nab-paclitaxel|Relacorilant is supplied as capsules for oral dosing. Nab-paclitaxel administered as an IV infusion.
45927146|NCT00405184|Drug|IntragamP|IntragamP - dosage based on previous dose of IntragamP prior to study entry. One cycle (Cycle 0)only administered, with dosage calculation based on body weight on Day 1 of the study and must be between 0.2-0.8 g/kg body weight. IntragamP to be administered intravenously.
45927147|NCT00405184|Drug|Ig NextGen 10%|Ig NextGen 10% - dosage based on previous dose of IntragamP in Cycle 0. Dosage calculation to use body weight on Day 1 of Cycle 1 of the study and must be between 0.2-0.8 g/kg body weight. 7 cycles administered, and patients to be dosed at 3 to 4 week intervals (in accordance with previous dosage schedule with IntragamP). Ig NextGen 10% to be administered intravenously.
45650252|NCT02845453|Other|Placebo|Participants will be randomly assigned to placebo and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
45927148|NCT01806636|Device|PneumRx Coil System|
45927149|NCT05148052|Device|Virtual reality exergames|Twelve sessions of virtual reality exergames involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
45927150|NCT05148052|Behavioral|Conventional occupational therapy|Conventional occupational therapy involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
45650253|NCT01799629|Drug|Glycerin suppositories|
45927151|NCT05065567|Drug|Droperidol|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 2.5mg droperidol IV
45927152|NCT05065567|Drug|Haloperidol|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 5mg haloperidol IM
45927153|NCT05065567|Drug|Ondansetron 8mg|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to ondansetron
45927154|NCT02762825|Behavioral|HIIT|HIIT will consist of 4 min of higher intensity work set at 90% of heart rate reserve, based on peak heart rate from CPX test. Recovery intervals will be 3-4 min in duration and set at 60-70% of heart rate reserve. Resistance training will be performed once per week.
45927155|NCT02762825|Behavioral|MCT|MCT will consist of aerobic exercise performed 3 times per week for 30 min each session, at an intensity of 60-80% of heart rate reserve, based on peak heart rate from CPX test.
45927156|NCT01806558|Procedure|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
45927157|NCT05016700|Diagnostic Test|blood sample|we want to identify a diagnostic option to identify patients, who have a neuropathological distraction of their ganglia cells in the bowel
45927158|NCT02739035|Drug|Dexamethasone|8 mg of IV dexamethasone immediately before MUA.
45927159|NCT02739035|Drug|Celecoxib|2 weeks per mouth of celecoxib (200 mg daily)
45927160|NCT01806519|Behavioral|Motor control intervention of head posture|"The tailored motor control intervention used for motor learning-procedure described by Fitts and Posner, further developed and adapted to rehabilitation of the spine by O´Sullivan.~The stages involved in the process was the Cognitive stage, Associative stage and the Autonomous stage"
45927161|NCT05015920|Genetic|BD211 Drug Product|Transplantation of Autologous CD34+Stem Cells Transduced to BD211 finished Product with a Lentiviral Vector coding βA-T87Q-Globin.
45927162|NCT04997473|Behavioral|W8L2G mobile health (mHealth) app|Weight loss phone app based on addiction principles. This intervention has been validated in two prior studies. Participants will also interact with coaches throughout the intervention
45650254|NCT04849403|Procedure|CTSP|In all patients Carter Thomasson Suture Passer (CTSP) were used for closing fascial defect peroperatively
45650255|NCT04848701|Other|latent phase duration|latent phase duration in post term pregnancies
45650256|NCT04848701|Other|uterocervical angle (UCA)|uterocervical angle is the angle between lower segment of uterus and cervix
45650257|NCT04428827|Procedure|Unilateral adrenalectomy in patients with unilateral disease|Unilateral adrenalectomy in patients with unilateral disease
45650258|NCT03041129|Diagnostic Test|oral glucose tolerance test|6 hours OGTT
45650259|NCT03041129|Diagnostic Test|MRI of liver|MRI of the liver and use of DIXON method
45650260|NCT01597375|Drug|Placebo Oral Tablet|Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh >60kg or 5 mg by mouth daily if they weigh <60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
45650261|NCT01597375|Drug|Prasugrel Oral Tablet|Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh >60kg or 5 mg by mouth daily if they weigh <60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
45927163|NCT01806480|Behavioral|Person-centred proactive breastfeeding telephone support|Person-centred care is a model of care, which comprise components such as: building mutual trust and understanding; treating the person as an individual; respect the rights for the person, sharing decision-making, providing holistic care and developing therapeutic relationships. Furthermore, the care provider should have a sympathetic presence and show an engagement
45927164|NCT02964130|Other|No name|
45927165|NCT04958044|Drug|Calcium Gluconate|Calcium electroporation
45927166|NCT01806441|Other|3-days high fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).
45927167|NCT01806441|Other|3-days low fat diet|During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
45927168|NCT04951453|Other|None (observational)|None (observational)
45927169|NCT04923412|Procedure|Pulmonary branch of vagus nerve preserved|During the mediastinal lymph node dissection using minimally invasive surgery, efforts to preserve the pulmonary branch of vagus nerve is made.
45927170|NCT04923412|Procedure|Pulmonary branch of vagus nerve not preserved|During the mediastinal lymph node dissection using minimally invasive surgery, efforts to preserve the pulmonary branch of vagus nerve is not made/ can be severed.
45927171|NCT04912336|Diagnostic Test|Standard coagulation profile|prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), the fibrinogen level, plateletcount
45927172|NCT04912336|Diagnostic Test|Specific coagulation tests|AT III, anti Xa, ACT, ROTEM
45927173|NCT04912336|Other|Bleeding Scores|Global Utilization of Streptokinase and Tpa for Occluded arteries definition of bleeding (GUSTO) AND Bleeding Academic Research Consortium Definition for Bleeding (BARC)
45927174|NCT04871308|Drug|Dexmedetomidine|"Anesthesia is induced using midazolam or etomidate, and sufentanil. A target-controlled infusion of propofol and remifentanil is used for anesthesia maintenance.~From anesthesia induction before the initiation of cardiopulmonary bypass, dexmedetomidine is infused intravenously at a rate of 0.5 mcg/kg/hr after a loading dose infusion of 0.75 mcg/kg for 10 mins."
45927175|NCT04871308|Drug|Control|During the same time window for dexmedetomidine, normal saline is infused at the same rate calculated for dexmedetomidine.
45927176|NCT04861051|Drug|Ketamine|Study participants will receive 0.5mg/kg of ketamine - one single infusion
45927177|NCT01806363|Drug|Telmisartan 80mg|
45927178|NCT01806363|Drug|Chlorthalidone 25mg|
45927179|NCT04846855|Drug|local anaesthetic injection|Realization by the anesthesiologist of the local anesthesia by single dose of ropivacaine 0.35% in perinervous under ultrasound with distraction by a tablette.
45927180|NCT04829227|Device|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
45927181|NCT02709161|Behavioral|real-time fMRI neurofeedback: Amygdala|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
45927182|NCT02709161|Behavioral|real-time fMRI neurofeedback: HIPS|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
45927183|NCT04828096|Other|Orthodontic retention|The stability of the mandibular anterior teeth after two resp. 5 years of retention
45927184|NCT04816201|Other|Electroacupuncture|Electroacupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36).
45927185|NCT04815304|Diagnostic Test|peripheral lymphocytes subsets|The data were collected during the first and the second wave of epidemic in COVID-19 patients with acute respiratory distress syndrome. At the moment of hospitalization, at the moment of intensive care unit admission and during the in intensive care unit staying, the following data were collected: peripheral lymphocyte subsets were measured by multiple-color flow cytometry, chest computed tomography and ultrasonography scans (lung ultrasound score, diaphragmatic thickness and motion), arterial blood gas analysis parameters (pH, partial pressure of carbon dioxide, partial pressure of oxygen, concentration of hydrogen carbonate, base excess, and arterial oxygen saturation ), and pain assessed by using numeric rating scale. Macroscopic and microscopic hypopharynx and larynx damages were also evaluated by video-laryngoscopy and light miscoscopy.
45650262|NCT03044093|Drug|Mifepristone|The group that will get in addition to Misoprostol also Mifepristone
45650263|NCT03044093|Drug|Placebo|The group that will only get Misoprostol
45650264|NCT03044093|Drug|Misoprostol|Both groups will get think drug
45650265|NCT04848545|Other|Observational|Prenatal maternal exposure to endocrine disrupting chemicals
45650266|NCT01553071|Drug|Fenretinide (4-HPR) plus Intravenous Safingol|"A course for this study is defined as the 5 days of treatment with Fenretinide (4-HPR) plus Safingol followed by 16 days of rest. A course is repeated every 21 days if there is no clinical evidence of disease progression for a maximum of six 5-day infusions.~Days 1-5 of every cycle: Day 1 Fenretinide (4-HPR) intravenous emulsion: 600 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Day 2 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Days 3-5 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 continuously for 3 days Days 8 and 15 : Weekly blood draw to monitor side effects requires a clinic visit for approximately 1 hour Days 6,7,9-14, 16-21 Rest and monitor side effects."
45650267|NCT03044327|Procedure|LPS challenge|LPS inhalation and bronchial instillation
45650268|NCT01506973|Drug|Hydroxychloroquine (HCQ)|
45650269|NCT01506973|Drug|Gemcitabine|
45799155|NCT01760239|Behavioral|Clinical Decision Support (CDS)|The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR. The CDS tool includes six key features: (i) prompts regarding the need for height data to classify the BP by percentile (ii) prompts to repeat any BP that is ≥90% or ≥120/80 mm Hg (iii) classification of BPs by percentile, including classification of those in pre-HT, stage 1 HT and stage 2 HT range (iv) review of previous HT diagnoses and BPs in order to classify elevated BPs as incident (first or second elevated BP) or persistent (third or greater elevated BP) (v) tailored CDS based on HT category and previous diagnoses (vi) graphical representation of current and historical BP data by age and BP percentile.
45799156|NCT01760473|Drug|Intranasal challenge drug|Each of the experimental challenge drugs were administered intranasally to all participants in random order.
45927186|NCT04803331|Diagnostic Test|SPIO-enhanced MRI|SPIO is peritumorally injected. A T2*-weighted iron sensitive MRI scan is performed 1 hour later to localize and assess the sentinel lymph nodes.
46072307|NCT05061550|Drug|Carboplatin|Carboplatin as chemotherapy
46072308|NCT05061550|Drug|Cisplatin|Cisplatin as chemotherapy
46072309|NCT05061550|Drug|Pemetrexed/Cisplatin|Pemetrexed/Cisplatin as chemotherapy
46072310|NCT05061550|Drug|Pemetrexed/Carboplatin|Pemetrexed/Carboplatin as chemotherapy
46072311|NCT05061550|Drug|Carboplatin/Paclitaxel|Carboplatin/Paclitaxel, as chemotherapy
46072312|NCT05060744|Device|Antacid|The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.
46072313|NCT05060744|Other|Control|The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.
45799157|NCT01760785|Drug|divalproex sodium|Doses will be given in 250mg increments and titrated over the first four days of study until a starting dose of 750 mg is reached. The Study Oversight Team, who is not involved in any clinical visits, will be un-blinded to study drug assignment and will have plasma concentration results and adverse event reports available to them. If a subject has no adverse events and is not at therapeutic level as indicated by the blood levels, the Study Oversight Team may inform the research pharmacy to increase the dose by 1 tablet of 250 mg to 1000 mg per day. The Study Oversight Team may also inform the research pharmacy to reduce the daily dosage back down to 750 mg per day if plasma concentrations or adverse events become intolerable. The maximum dose for the purpose of this study will be 1250 mg daily and the minimum dose will be 750 mg daily. Subjects who cannot tolerate the minimum dose will be excluded from any further study participation.
45799158|NCT01760785|Drug|Placebo|Doses will be titrated over the first four days of study in the same manner as the active study drug. After titration, the research pharmacy may increase the dose by 1 tablet per day, in the same fashion that the active drug may be adjusted, so that the participant and clinical team remain blinded to the drug assignment. The research pharmacy may also reduce the daily dosage back down by one tablet per day for the same reason.
45927187|NCT04799860|Behavioral|health promotive work-way|"Clinical intervention: The patient is asked to fill in a screening form with life-style related questions. The caregiver takes adequate measures according to the recommendations of the national guideline and the filled in screeing form. The caregiver documents the measures taken.~Implementation intervention as described previously: using tailored strategies to support implementation of the gudieline-based recommendations"
45799159|NCT01761019|Drug|Taclonex Topical Suspension|topical medication for psoriasis
45799160|NCT01761175|Procedure|Ultrasound-guided infraclavicular block|Ultrasound-guided single injection infraclavicular block: using an in-plane technique, 30 mL of mepivacaine 1.5% is injected at the posterior aspect of the artery.
45927188|NCT04794907|Other|Observation|Patient data will be collected from eye exams, surveys and medical record review.
45927189|NCT04787029|Device|Medical compression stocking (medical device name: mediven Harmony 734 (compression class1 AG armsleeve or with wide(735))|Compression stockings worn on the arm or partial swelling of the hand after trauma or surgery.
45927190|NCT01806246|Behavioral|integrative rehabilitation program|
45450726|NCT04308694|Drug|Pharmacy-based methadone administration and dispensing|Eligible participants receiving between 6- and 13-days of methadone take-home doses will have methadone administration and dispensing transferred from the opioid treatment program to the partnered community pharmacy. Each participant will be assessed monthly for 3 months (at 1, 2, and 3 months following intake/baseline) to explore the feasibility of transferring their methadone administration and dispensing to the select community pharmacy.
45450727|NCT03534778|Diagnostic Test|Lymph Node Yield (LNY) and Lymph Node Ratio (LNR)|LNY and LNR will be examined after neck dissection
45650270|NCT01506973|Drug|Abraxane|
45650271|NCT03041207|Behavioral|Development and implementation of an antibiotic guideline|A consensus conference will develop and then implement a guideline for stopping vs. continuing antibiotics in infants with suspected ventilator-associated infection
45650272|NCT03101995|Drug|Gemcitabine|"Gemcitabine 300 mg/m2, prepared in 0.5 liters of sodium chloride 0.9%, IV administered in 30 minutes weekly for a maximum of 6 weeks.~Radiotherapy will start the first week, or as soon as the blood count is normal or the patient has recovered after blood transfusion. Radiotherapy will be applied, using an external beam releasing 40-50.4 Gy in 20-28 fractions: 1.8 Gy/day for 5 days/week, during 4 to 6 weeks.~Intracavitary brachytherapy will be added to reach a total EQD2 dosage (α/β=10) of 78-86 Gy."
45650273|NCT04848467|Biological|SARS-CoV-2 mRNA Vaccine (CVnCoV)|Two intramuscular injections administered 28 days apart at a dose level of 12 μg mRNA.
45450728|NCT04306432|Other|Cognitive tests and Patient Reported Outcomes|Each patient will undergo cognitive tests and questionnaires
45450729|NCT02196298|Device|Lokomat|16 sessions in total, 30 minutes each plus set-up time followed by 5 minutes of overground walking. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
45450730|NCT02196298|Other|Physiotherapy|16 sessions, 35 minutes. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
45799161|NCT01761175|Procedure|Ultrasound-guided axillary block|Ultrasound-guided double injection axillary block: using an in-plane technique, 25 mL of mepivacaine 1.5% is injected postero-medial to the artery. During needle withdrawal, 5 mL of the same solution is injected close to the musculocutaneous nerve.
45927191|NCT04774198|Diagnostic Test|blood sample|Blood samples are collected within 24 hours before the surgical procedure, on postoperative day two and seven. Samples collected are as following: TruCulture, flow cytometry, markers of systemic inflammation (Plasma level of pro- and anti-inflammatory molecules assed by Olink inflammation panel, leucocytes, differential count, hemoglobin, thrombocytes and CRP)
45927192|NCT02964403|Drug|Cox-2|
45927193|NCT02964403|Drug|Indomethacin|
46072314|NCT05057117|Device|Microwave thermolysis|Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization
45450731|NCT03534310|Drug|LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)|
45450732|NCT03534310|Other|lifestyle modification|
45450733|NCT03534310|Other|sleeve gastrectomy|
45450734|NCT02194894|Drug|Acetaminophen|acetaminophen will be given for patient for both arms for 14 days
45799162|NCT04769089|Procedure|Treatment with Pulse Dye Laser|Pulse Dye laser treatment will be applied to one randomized area with the 10mm hand piece, duration of 0.45ms, and fluence of 5.25J/s.
45450735|NCT02196454|Other|Educational Video with Male or Female Narrator|Participants will watch an educational video about the quadrivalent HPV vaccine (Gardasil) narrated by either a male or female.
45927194|NCT04749043|Device|Oculus Quest 2 Virtual Reality Device|30 min VR experience exposure for labor analgesia. VR experiences include swimming in the ocean, walking through forests, engaging in 3D puzzles, exploring virtual lands, or interacting with musical objects
45927195|NCT04749043|Drug|Nitrous oxide|30 min exposure for labor analgesia
45799163|NCT04769089|Procedure|Treatment with CO2 Laser|CO2 laser treatment will be applied to one randomized area with the deep Fx hand piece, 300Hz, 15mJ, 15% density.
45927196|NCT00393393|Drug|intra-articular injection of Hylan G-F 20|
45927197|NCT02687360|Device|Active rTMS treatment|In the active treatment, magnetic power output will be delivered to the participants through the coils.
45450736|NCT03534622|Drug|Delafloxacin|In this study, thirty subjects who meet the entry criteria will be assigned to 1 of 5 groups (A, B,C, D, or E) to receive 300 mg delafloxacin IV every 12 hours for a total of 7 doses over 4 days
45450737|NCT02194972|Drug|Pectin|pectin （Andeli Ltd. Yantai, China）, 24g/d for 4weeks
45450738|NCT02197546|Other|Acupuncture & acupressure|Bilateral acupuncture with indwelling fixed needles 1.5 mm length with subsequent acupressure by the parents
45450739|NCT02197702|Dietary Supplement|vitamin D|Two doses of cholecalciferol 100,000 unit (2 mL) given 3.5 months apart, once in the fall, once in the winter
45450740|NCT02197702|Dietary Supplement|placebo|Two doses of identical placebo (2 mL) given 3.5 months part, once in the fall, once in the winter
45650274|NCT04848467|Biological|Quadrivalent influenza vaccine (QIV)|One intramuscular injection as 0.5 mL. Each 0.5 mL dose will contain 15 μg haemagglutinin (HA) from each of the four influenza strains.
45650275|NCT04848467|Other|Placebo|One intramuscular injection as normal saline [0.9% NaCl].
45650276|NCT03102307|Other|Not suitable for TAD|Registry of the rate of patients not suitable for TAD as initial CNB with clip placement of axillary lymph nodes is not possible and underlying medical contraindications, technical obstacles or miscellaneous reasons why needle biopsy and/or clip labeling of clinically affected lymph nodes cannot be done
45650277|NCT03102307|Procedure|Suitable for TAD|Registry of surgical outcome measures of targeted resection of the clipped node with optional sentinel node biopsy or axillary lymph node dissection with or without preceding neoadjuvant chemotherapy
45927198|NCT02687360|Device|Sham rTMS treatment|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
45927199|NCT00405262|Drug|Ketorolac|0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter
45927200|NCT00405262|Drug|Bupivacaine|0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.
45927201|NCT00405262|Drug|ketorolac + bupivacaine|"0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.~For ketorolac, patients will receive 0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter"
45927202|NCT00405301|Drug|Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)|Patients who develop ATT drug induced hepatotoxicity will be divided into 3 arms .Arm 1,2,3 will be given drugs as described in detailed description of the title.
46072315|NCT05057117|Drug|Botulinum toxin A|Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization
46072316|NCT05051358|Procedure|Therapeutic Endoscopic Ultrasound|Therapeutic Endoscopic Ultrasound or Interventional Endoscopy for Gastrointestinal Indications
45450741|NCT03533920|Device|UNI-DEB|Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient
45650278|NCT02527161|Device|ShapeMatch Cutting Guides with Triathlon|All participants will undergo medical imaging assessment using Magnetic Resonance Imaging (MRI) of the affected lower limb.These images will be used to manufacture the patient-specific cutting guides for preparation of the bones prior to implantation of the total knee replacement (Pre-operatively). Patients will undergo primary total knee arthroplasty with the Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA) using the Shapematch cutting guides to guide the bone resection. Patients will follow the standard postoperative rehabilitation program established by the investigator at each site.
45799164|NCT04769089|Procedure|Treatment with combination of pulse dye laser and CO2 laser.|Pulse Dye laser and CO2 treatment will be applied to one randomized area. Pulse Dye will be applied with the 10mm hand piece, duration of 0.45ms, and fluence of 5.25J/s followed by the CO2 laser treatment with the deep Fx hand piece, 300Hz, 15mJ, 15% density.
45799165|NCT04769089|Other|Control|One area will be randomized to receive no laser treatment.
45450742|NCT04213300|Other|Low carbohydrate diet|"Study duration: 13 weeks (run in phase = 1 week; low carbohydrate diet phase = 12 weeks).~Each participant will be provided with an individualised meal plans to meet their energy needs as per the Schofield formula and a macronutrient distribution of 20% for carbohydrate, 25% for protein and 55% for fat.~Participants will self-report quality of life using a validated diabetes specific quality of life questionnaire for Australian adults and HbA1c (pre and post intervention phase of 13 weeks duration) ."
45450743|NCT02196532|Device|Device: Optical coherence tomography|
45927203|NCT00405340|Drug|Rituximab|Patients will received rituximab 4 weekly doses of rituximab 375 mg/m2 at baseline. Patients will be retreated at 6 months.
45927204|NCT00405379|Device|Trabecular Metal Mesh Tibial Monoblock Knee Arthroplasty|new porous metal tibial component with potential to result in improved bone in-growth and implant integration with proximal tibia
45927205|NCT00391001|Drug|Taurine|double-blind, placebo-controlled, adjunctive medication
45927206|NCT04740541|Other|Dietary Intakes (Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies)|Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies to meet nutritional requirements, 5 levels of threonine intakes
45927207|NCT04713826|Drug|BAY2586116|160 µg, nasal spray administration.
45799166|NCT04062097|Drug|Dabigatran Etexilate Oral Capsule [Pradaxa]|Dabigatran is the most frequently used direct thrombin inhibitor in secondary stroke prevention in patients with atrial fibrillation.
45450744|NCT02031016|Drug|Fentanyl|"fentanyl bolus injections on an as needed base, NEXT TO the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium."
45927208|NCT04713826|Drug|Placebo|Placebo matching BAY2586116, nasal spray administration.
45927209|NCT04713319|Drug|Panavital|In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.
45927210|NCT04713319|Other|Placebo|In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.
45927211|NCT00393471|Drug|Etanercept|
45927212|NCT04669093|Behavioral|"Placebo cream- promotion suggestion"|"Over-the-counter hand cream will be applied to participants' skin, but they will be told that they are given a highly efficient topical analgesic cream. The suggestion will be based on a promotion approach (promoting good feelings)."
45927213|NCT04669093|Behavioral|"Placebo cream- prevention suggestion"|"Over-the-counter hand cream will be applied to participants' skin, but they will be told that they are given a highly efficient topical analgesic cream. The suggestion will be based on a prevention approach (preventing pain)."
45927214|NCT04669093|Behavioral|Control cream|In a control condition, with the same cream as in the placebo interventions, participants will be instructed that the cream is a control cream with no effects.
45927215|NCT02669576|Behavioral|Mind body medicine day care clinic|Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
45927216|NCT02669576|Other|Usual care|Patients continue usual care by their practitioner
45927217|NCT04635904|Behavioral|Imaginal exposure one-session|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a future distressing anxiety provoking scenarios multiple times while honing in on the most negative aspects.
45927218|NCT04635904|Behavioral|Imagery rescriptinf one-session|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) o imagine a script based on a future distressing anxiety provoking scenarios one time while honing in on the most negative aspects. Afterwards they will insert changes into the script that try to help them cope in the imagery.
45650279|NCT04848311|Procedure|lymph nodes dissection at 253 station assisted by ICG|In ICG group :All patients will be subjected to laparoscopic radical resection with station 253 lymph nodes dissection by fluorescence laparoscopic.
45650280|NCT05431231|Diagnostic Test|Outcome Questionnaire-45|a questionnaire that evaluates the patient's level of distress. The questionnaire was developed by Lambert et al. in 1996 and was translated to Hebrew by Gross, Glasser, Elisha et al. in 2015. The questionnaire is composed of 45 statements that describe emotional states, assessing three main components: subjective discomfort, interpersonal relationships and performance of social roles. The participants are asked to rate how often they have felt the states described by each statement using a five-level Likert scale (0 - never, 4 - almost always). This questionnaire has been used extensively and has showed good internal consistence of 0.93 for its English version and 0.91 for its Hebrew version.
45653209|NCT01295723|Radiation|Intraoperative Electron Radiation Therapy|Intraoperative Electron Radiation Therapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on mobile or fixed linac with variable electron energies in the range of 4-12 MeV
45927219|NCT02647892|Drug|lidocaine|local anesthesia
45927220|NCT02647892|Drug|sodium bicarbonate|additional drug added to lidocaine
45799167|NCT04062097|Drug|Idarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND]|Idarucizumab is the current standard therapy in patients with intracranial bleeding under anticoagulation with dabigatran.
45799168|NCT04062097|Drug|Vitamin K antagonist|This drug group includes the active substances phenprocoumon and warfarin.
45799169|NCT02241655|Device|a pragmatic EEG-guided anesthetic protocol|
45927221|NCT04602091|Other|no intervention|no intervention
45927222|NCT00393549|Device|NeuroPath|
45927223|NCT04594564|Procedure|Total hip arthroplasty with Delta TT cup|Total hip arthroplasty using Delta TT cup and ceramic bearings
45927224|NCT04585087|Other|Dietary Intakes|6 levels of threonine intake will be provided by the protein liquid drink
45927225|NCT02624804|Biological|Stem Cell Educator Therapy|"Patients will receive apheresis and then have their own blood returned to them with the educated lymphocytes"
45927226|NCT04528810|Other|not applicable (Observational Study)|This is an observational study and does not include interventions.
45927227|NCT00393627|Behavioral|Sleep Education Program|The Sleep Education Program (SEP) is conducted by a licensed MS- or PhD-level mental health professional experienced in working with persons with dementia and their caregivers. The therapist meets with the AFH owner/operator and staff for four weekly sessions at the AFH. The SEP content includes information about the causes of sleep problems in dementia, and provides staff with assistance in developing customized resident behavioral sleep plans focused on environmental (light and noise), dietary (eliminating caffeine and excessive nighttime fluids), and sleep scheduling (reducing afternoon/ evening napping; consistent, appropriate bed and rising times) factors that are commonly associated with resident nighttime awakenings. A written manual is used.
45650281|NCT05431231|Diagnostic Test|Hopkins symptoms checklist - short form|a questionnaire for assessing symptomatic distress. The questionnaire was developed by Lutz, Tholen, Schürch, and Berking in 2006. It is a short version of the SCL-90-R, that was developed by Derogatis in 1992. The checklist includes 11 items that describe negative feelings and thoughts. Participants are asked to rate the extent to which a given feeling or thought has troubled them in the past week using a four-level Likert scale (1 - not at all, 4 - very much). This tool is highly correlated with the Global Severity Index (r=.91) and has shown high internal consistency.
45927228|NCT04516408|Biological|Recombinant zoster vaccine|Recombinant zoster vaccine (RZV) is indicated for prevention of herpes zoster in adults aged ≥ 50 years old. RZV contains a varicella zoster virus glycoprotein E antigen and the AS01B adjuvant system.
45927229|NCT04516408|Biological|Placebo|Sterilized water
45927230|NCT02593175|Drug|Carboplatin|Given IV
45927231|NCT02593175|Drug|Paclitaxel|Given IV
45799170|NCT04005079|Drug|Pilocarpine|2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin)
45650282|NCT05431231|Diagnostic Test|Prodromal Questionnaire - Brief Version|a patient questionnaire that assesses the existence of a prodromal state or fully developed psychosis. It was developed by Ising et al. in 2012 and was translated to Hebrew by Koren et al. in 2016. The tool is based on a more extensive questionnaire - PQ-92 - that was developed by Loewy et al. in 2005 - and constitutes an attempt to create an improved shorter version. The PQ-16 includes 16 items that refer to thoughts, feelings and experiences that describe various symptoms, including abnormal perception (9 items), unconventional thinking and paranoia (5 items) and negative symptoms (2 items). For each item, first, the participant is asked to indicate whether he had experienced that phenomenon in the past month, and if he had, he is asked to describe the extent to which the phenomenon had caused him distress, using a four-level Likert scale (0 - no distress, 3 - severe distress). Ising et al. found that Kronbach's α was 0.774 for the whole questionnaire.
45799171|NCT04005079|Drug|Ofloxacin|Standard of care
45799172|NCT04005079|Drug|Prednisolone|Standard of Care
45799173|NCT01761643|Device|SoC + iTab|Text messaging reminders to improve adherence to PrEP
45799174|NCT01762501|Drug|Azilsartan|Azilsartan 20mg/day
45450745|NCT02031016|Drug|Remifentanil|starting with 0.15 ug/IBW(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
45927232|NCT02593175|Biological|Panitumumab|Given IV
45927233|NCT01806207|Device|Durolane injection|
45927234|NCT01806207|Other|Saline injection|
45450746|NCT02031016|Drug|Fentanyl|fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
45799175|NCT01762501|Drug|Amlodipine|Amlodipine 5mg/day
45799176|NCT02990221|Drug|Ingenol mebutate|150 mcg / g per day, to be applied on a predetermined area of 25 cm2 of skin of the face or scalp, for 3 days consecutive
45799177|NCT02990221|Procedure|cryotherapy|application with 5 seconds of freezing time of each lesion located in a predetermined skin area of 25 cm2 of the face or scalp
45927235|NCT04453969|Other|COVID-19|Exposure of interest for this observational study is current COVID-19 positive status or COVID-19 positive status during pregnancy
45450747|NCT02196610|Other|Applanation tonometry|Two consecutive sets of carotid-femoral Pulse Wave Velocity (PWV) measurements by Applanation tonometry with a time-interval of 1 week will be obtained (1 week ± 2 days). Two research assistants will each perform a carotid-femoral-PWV measurement at each time point with the testing order randomized.
45450748|NCT02031094|Other|Observational study: Sense Wear armband and indirect calorimetry used to measure resting energy expenditure|Observational methods of measuring resting energy expenditure
45450749|NCT02195284|Device|ELLIPTA|Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate
45450750|NCT02195284|Device|DISKUS/ACCUHALER|Placebo inhaler with one blister strip containing lactose monohydrate.
45450751|NCT02195284|Device|MDI|Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane)
45799178|NCT01764607|Drug|Sirolimus|Patients randomized to this arm of the study will receive sirolimus from the time of randomization at least until 5 weeks or the removal of the skin tumor. Nephrology will determine/manage the immunosuppressant therapy.
45799179|NCT01764685|Drug|Topiramate|Max therapeutic dose of 150mg/day
45799180|NCT01764685|Behavioral|Medical Management|Medical Management (MM; Pettinati, 2004) will support patients' efforts to reduce their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The patient is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the patient's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 2 drinks/day and 8 drinks/week; women will be advised to consume no more than 1 drink/day and 4 drinks/week.
45799181|NCT01764685|Drug|Placebo|Placebo
45799182|NCT01764919|Radiation|[124I]FIAU|A single intravenous injection of 5 mCi[124I]FIAU in patients with diabetic foot infection who will undergo 2 PET-CT scanning.
45799183|NCT01765465|Drug|Rowachol|
45799184|NCT01765465|Drug|Placebo|
45799185|NCT02989831|Device|Vibrating insoles 'on'|Duration: 30-60 seconds
45450752|NCT02195284|Device|TURBUHALER|Placebo inhaler containing lactose monohydrate.
45650283|NCT05431231|Diagnostic Test|Manchester Short Assessment of Quality|a patient questionnaire that assesses quality of life. This questionnaire was developed by Priebe, Huxley, Knight and Evans in 1999. It is based on a longer questionnaire - Lancashire Quality of Life Profile (LQLP) - and was created as an attempt to form an improved shorter version. The questionnaire is composed of two parts: personal details that can change over time and 16 questions that assess objective and subjective quality of life. The objective items are presented as yes or no questions, while regarding the subjective items, participants are asked to describe, using a 7-level Likert scale, the extent to which they are satisfied with their lives. Priebe et al. reported an alpha internal consistency of 0.74.
45799186|NCT02989909|Device|CATS tonometer prism|demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
45799187|NCT02989909|Device|Goldmann tonometer prism|demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
45799188|NCT05115409|Drug|Anti-PD-1 Antibody Plus Chidamide and Rituximab|Anti-PD-1 Antibody 200mg, ivd, D1, every 3 weeks Chidamide 30mg, po,D-1, 4, 8, 11, 15, 18, every 3 weeks Rituximab 375mg/m2, ivd, D1, every 3 weeks
45799189|NCT02249533|Other|Spot Light Concussion App|Certified Athletic Trainers will report football injuries using High School RIO and will report possible concussions using the Spot Light concussion app.
45799190|NCT01766713|Drug|Ezetimibe|10mg daily oral dose of ezetimibe
45799191|NCT03821467|Device|Dual beam Doppler Fourier-domain OCT (DOCT)|Retinal blood flow will be assessed using DOCT.
45799192|NCT03821467|Device|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
45799193|NCT03821467|Device|Optical coherence tomography (OCT)|Retinal morphology will be imaged using OCT.
45799194|NCT01767103|Drug|Ferriprox®|
45799195|NCT02243449|Procedure|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, continuous positive airway pressure (CPAP) less than or equal to 5 cm H2O or PS less than or equal to 8 cm H2O with PEEP less than or equal to 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for patients enrolled at their centre.
45799196|NCT02243449|Procedure|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be conducted in the same manner as in the once daily screening arm. The subsequent SBTs will be 30 -120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP < to 5 cm H2 O or PS < 8 cm H2 O with PEEP < 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and with the use of different humidification strategies. Each centre will be asked to choose one technique for all patients enrolled at their centre.
45799197|NCT01767415|Drug|Indigo carmine|During resection, a small quantity of a special dye called indigo carmine will be infused at the margins of the tumor using computer-guided stereotactic navigation equipment. This dye will be visible during the tumor resection and it can potentially serve as an additional marker of the tumor margins. A post-operative MRI scan -which is part of the standard care- will accurately measure the extent of tumor resection.
45653210|NCT05169957|Drug|Ipilimumab|Ipilimumab administered IV over 85-100 minutes at 3 mg/kg (combined with nivolumab administered IV over 30-60 minutes at 1 mg/kg) every 3 weeks for a total of 4 doses or until progression or unacceptable toxicity.
45799198|NCT01769209|Drug|Bortezomib|Administered subcutaneously (SC) at 1.3 mg/m², on Days 1, 4, 8, and 11.
45927236|NCT04437355|Diagnostic Test|Specific provocation test|To compare the results the investigators invite a healthy control group matching in age and gender with the intervention cohort. The control group is informed about the study and asked to participate in the outpatient clinic. In case of informed consent, the participants are invited to the study site. The participants undergo the same provocation test of the ankle, and are asked to complete the specific provocation test. In case of substantial underachievement in the provocation test (<60% of maximum) an X-Ray of both ankles in a.p. and lateral projection is performed. The aim is to radiologically analyse the ankles, and to rule out any morphological reasons for the above mentioned underperformance.
45927237|NCT01806090|Drug|clopidogrel|Clopidogrel 7 days prior to the endoscopic procedure (Colonoscopy)
45927238|NCT01806090|Other|Placebo|Placebo for 7 days prior to the endoscopic procedure (Colonoscopy)
45927239|NCT02505893|Biological|Human pancreatic islet|One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver.
45799199|NCT01769209|Drug|Doxorubicin hydrochloride (HCl)|Administered intravenously (IV) over 15 min at 60mg/m², on Day 1.
45927240|NCT02505893|Drug|ATG|ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant
45927241|NCT02505893|Drug|Pegylated G-CSF|Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion
45799200|NCT01769209|Drug|PEG-Asparaginase|Administered intravenously (IV) or intramuscularly (IM) 2500 U/m² (maximum 3750 U), on Days 5 and 22.
45799201|NCT01769209|Drug|Vincristine sulfate|Administered by intravenous (IV) push at 1.5 mg/m² (maximum 2 mg), on Days 1, 8, 15, and 22.
45799202|NCT01769209|Drug|Dexamethasone|Administered orally (PO) at 10 mg/m², daily on Days 1 to 14.
45799203|NCT01769209|Drug|Cytarabine|Administered intrathecally (IT) at 100 mg, on Day 1
45799204|NCT01769209|Drug|Methotrexate|Administered intrathecally (IT) at 15 mg, on Day 15.
45799205|NCT01769365|Drug|7-day quadruple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days
45927242|NCT02505893|Drug|Rapamycin|Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
45927243|NCT04414150|Drug|SHR-1802|This study will evaluate the preliminary safety, tolerability, pharmacokinetic characteristics and initial efficacy of SHR-1802 The goal is to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of SHR-1802 when administered to patients with locally advanced/ unresectable or metastatic malignant tumours that are refractory to available therapy or for which no standard therapy is available.
45927244|NCT04396444|Combination Product|Aromastick|Vascular surgery patients will be randomized to either the intervention group and receive a lavender infused aromastick to use as an adjunct to their inpatient pain management plan, or to the control group, given a blank aromastick. Subjects will be blinded to their group.
45927245|NCT01806012|Device|Sealing tissue with the Enseal device|
45927246|NCT01806012|Procedure|Conventional supracervical hysterectomy|
45927247|NCT02496416|Behavioral|Aquatic Exercise Program|The aquatic exercise program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be led by an aquatic fitness instructor certified to teach individuals with MS at the YMCA in Scotch Plains-Fanwood. The exercises will focus on improving flexibility, balance and strength. Equipment such as water mitts, paddles, noodles and bands will be used to increase the level of difficulty as needed.
45927248|NCT02496416|Behavioral|Stretching Program|The stretching program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be conducted online via a secure video-conferencing website.
46072317|NCT05051033|Procedure|Mitral valve repair|Patients who are randomized to the surgical arm will undergo mitral surgery. Mitral surgery will be conducted using general anesthesia and cardiopulmonary bypass. Mitral surgery may be performed via a sternotomy or a right thoracotomy approach with or without robotic assistance. Standard techniques commonly include a ring or band annuloplasty to correct and prevent annular dilatation; leaflet prolapse and redundancy may be corrected by leaflet resection techniques and / or chordal reconstruction.
45450753|NCT00095147|Drug|Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)|Abatacept, intravenous (IV) Solution, Infusion, Depends on participant weight, Monthly, 12 months.
45650284|NCT05431231|Diagnostic Test|Self-Stigma of Mental Illness Scale|a patient questionnaire that assesses internalized self-stigma. It was developed by Corrigan, Watson, and Barr in 2006. The questionnaire is composed of four dimensions. The questionnaire includes 40 items, 10 items for each dimension. The participant is asked to rate the extent to which he agrees with each item using a 9-level Likert scale. The questionnaire yields four separate scores for each dimension, and each dimension can be administered separately and independently. In the current study, only one 10-item dimension will be administered - the extent to which the participant has internalized stereotypes concerning mental illness. Corrigan et al (2006) reported an internal consistency alpha of 0.81 and a test-retest reliability ratio of 0.82 for this dimension.
45799206|NCT01769365|Drug|10-day sequential therapy|pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days
45799207|NCT01769365|Drug|7-day standard triple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
45799208|NCT02327143|Drug|LY2835219|Administered orally
45799209|NCT02327143|Drug|¹³C₈-LY2835219|Administered IV
45799210|NCT01770691|Device|TIPI vaginal pessary|TIPI vaginal pessary G3 model, and TIPI SMD's
45799211|NCT01771627|Drug|varenicline|Given PO
45799212|NCT01771627|Drug|nicotine patch|
45799213|NCT01773187|Drug|Pacritinib|
45799214|NCT01773187|Drug|Best Available Therapy|
45799215|NCT01774045|Drug|PDC-1421|
45799216|NCT01774045|Drug|Placebo|
45799217|NCT01775371|Device|Patient controlled analgesia (PCA)|Loading dose 0.1 mg/kg morphine and demand dose of 1 mg morphine available every 6 minutes
45799218|NCT01775371|Other|Usual Care|Usual opioid analgesia determined by the provider
45799219|NCT03749629|Other|GeneSight Psychotropic test|GeneSight® Psychotropic powered by CPGx® technology, the only test for depression reimbursable by Medicaid and Medicare. GeneSight® is a neuropsychiatric, combinatorial, PGx test that provides recommendations for psychotropic medications (antidepressants, mood stabilizers, hypnotics for insomnia, and antipsychotics) based on a patient's individual genetic profile.
45799220|NCT03749629|Other|Canadian Network for Mood and Anxiety Treatment (CANMAT) Best Practice Guidelines|Guidelines for treatment
45799221|NCT03723811|Drug|SJP002 BID|1 drop b.i.d for 12 weeks
45799222|NCT03723811|Drug|SJP002 QID|1 drop q.i.d for 12 weeks
45799223|NCT03723811|Drug|SJP002 Placebo 1|1 drop q.i.d for 12 weeks
45799224|NCT03723811|Drug|SJP002 Placebo 2|1 drop q.i.d for 12 weeks
45450754|NCT00095147|Drug|Infliximab (INF) + MTX, DB|Infliximab, IV Solution, Infusion, Depends on participant weight, Every 2 Months, 12 months.
45650285|NCT05431231|Diagnostic Test|Session Alliance Inventory - for patient|this questionnaire has two versions, one for patients and one for the main therapist in the therapeutic team, and its goal is to evaluate the therapist-patient relationship (therapeutic alliance). It is composed of 6 statements that relate to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). In the current study, patients will define who their main therapist is. Falkenstrom et al. reported that in their three tested samples, the alpha coefficients ranged from 0.89 to 0.94.
45799225|NCT03719755|Procedure|50% dextrose|maximum injection of 40 cc of 50% dextrose plus 300 cc of normal saline washout versus normal saline after hysterectomy for benign indications.
45650286|NCT05431231|Other|Quality of service/satisfaction questionnaire|measured by the quality of service department at Sheba Medical Health Center (or - PROMS, to be decided). Here customer's experience of the online services would be measured as well.
45799226|NCT03719755|Procedure|Normal Saline|Cystoscopic distention media of normal saline
45799227|NCT03717103|Drug|IBI188|Part A: 0.1 mg/kg IV QW, 0.3 mg/kg IV QW, 1 mg/kg IV QW. Part B: 1mg/kg IV D1+3, 10, 20, 30 mg/kg IV D8 QW or 45mg/kg D8 IV Q3W.
45799228|NCT03682393|Drug|Hydrocortisone|100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
45799229|NCT03682393|Drug|Placebos|100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
45799230|NCT03499483|Drug|bictegravir|Single One Pill Formulation of bictegravir, emtricitabine/tenofovir alafenamide (Bictarvy) to be taken once daily orally for a period of 28 days.
45799231|NCT04350931|Biological|intradermal injection of BCG Vaccine|0.10 mL intradermal injection of BCG Vaccine over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds
45799232|NCT04350931|Other|placebo|placebo 0.10 mL intradermal normal saline (0.9% NaCl) over the distal insertion of the deltoid muscle onto the humerus
45799233|NCT03406429|Device|Active rTMS|All study participants will receive one block of active rTMS. Each block will consist of daily sessions of 20Hz active rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
45799234|NCT03406429|Device|SHAM rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of 20Hz SHAM rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
45799235|NCT02243215|Other|Access to a portable trainer for laparoscopic skills|Participants will have a portable trainer available to allow training at their convenience, and will be able practice on-site at Center of Clinical Education and at their local hospital.
45799236|NCT03403153|Behavioral|SAHP|"Aim 1: To obtain and incorporate expert clinician and Veteran feedback on credibility, acceptability, and satisfaction with the intervention to ensure Veteran-friendly intervention manual, materials, and processes. Aim 1 will be accomplished through two rounds of expert panel review of treatment/MIA manual and two rounds of pilot testing of the treatment for Veteran Feedback in 16 female and 16 male Veterans.~Aim 2: To evaluate feasibility of study recruitment, retention, assessment procedures and proposed methods of the intervention. Preliminary examination of whether the intervention results in improvements to parenting behaviors, parenting satisfaction and overall family functioning."
45799237|NCT03377647|Behavioral|Asthma Care Provider Training|In this intervention, asthma care providers will be trained in current, evidence-based guidelines for care of children with asthma, and will be provided with tools that their practice may use to facilitate care improvements.
45799238|NCT03377647|Behavioral|School Staff Asthma Education|In this intervention, teachers and other school staff will be provided current, evidence-based training in understanding asthma and will be provided tools to help schools address the special needs of children with asthma.
45799239|NCT05490979|Behavioral|Contemplative dyad meditation|Participants take part in a 3-hour group meditation training led by a professional meditation teacher. They receive detailed instructions and also practice contemplative dyad meditation for at least 30 minutes with another participant. During the 2 weeks following the training, participants meet in supervised group settings to practice the meditation method with alternating partners for up to 6 times.
45799240|NCT05490979|Behavioral|Fast friends|During 2 weeks, participants meet in supervised group settings to practice the 'fast friends' exercise with alternating partners for up to 6 times.
45799241|NCT01673867|Biological|Nivolumab|
45799242|NCT01673867|Drug|Docetaxel|
45799243|NCT03005977|Procedure|Urodynamics|UDS is to be performed with prolapse reduced by a speculum. The patient will be asked to valsalva three times then cough while seated after 150 ml of fluid is instilled in the bladder and then again at 300 ml. The same provocative measures will be performed at capacity, with the catheter in place and without the catheter if no leak is identified. If the patient leaks at any volume or if the patient leaks during the cough pressure profile (CPP), the test will be considered positive. If the patient does not leak during filling nor during the CPP then the test will be considered negative.
45799244|NCT03003169|Other|Medical questionnaire|"quality of life questionnaire (EORTC QLQ-C30 and QLQ-BR23)~Hospital Anxiety and Depression scale~satisfaction care questionnaire (IN-PATSAT32)"
45799245|NCT01777945|Drug|capecitabine|Participants received capecitabine according to individualized physician-prescribed regimen.
45799246|NCT01777945|Drug|docetaxel|Participants received docetaxel according to individualized physician-prescribed regimens.
45799247|NCT03012581|Drug|Nivolumab|Treatment
46073719|NCT00849823|Behavioral|Focus on the Future Program|A 60-minute, theory-guided program designed to increase the quality and frequency of teens' condom use within the context of making safer choices regarding partners and sexual behaviors. The program is explicitly designed to increase the quality and frequency of teen's condom use.
45450755|NCT00095147|Drug|Placebo (PLA) + MTX, DB|Placebo, IV Solution, Infusion, Depends on participant weight, Monthly, 6 months.
45450756|NCT00095147|Drug|PLA + MTX switched to ABA+ MTX, DB|Placebo=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months. Abatacept=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months
45799248|NCT01778179|Drug|Tri-luma|"Pre-procedure phase (From Baseline up to Week 2) treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) for 2 weeks.~Post-procedure phase (From week 2 up to Week 13 - Visit )~- Tri-Luma® cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5):The investigational drug (Tri-Luma® cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
45799249|NCT01778179|Procedure|Cryotherapy (CRY-AC3® device)|Procedure performed at week 2.
45650287|NCT05431231|Diagnostic Test|Clinical decision-making style|a questionnaire with two - patient and therapist - versions, meant to evaluate decision making style. It was developed by Puschner, Neumann, Jordan, et al. in 2013. The questionnaire constitutes a modified version of the Autonomy Preference Index (API), which was developed by Ende, Kazis, Ash, & Moskowitz in 1989 for mental health patients. In the current study, only the therapist/psychiatrist version would be administered. The questionnaire is composed of 21 items and yields two components related to clinical decision making: preferences in decision making style and information seeking during decision making. Puschner et al (2013) reported that Kronbach's α coefficient ranged from 0.87 to 0.89.
45650288|NCT05431231|Diagnostic Test|Global Assessment of Functioning Scale|a questionnaire meant to assess the patient's global functioning. It was developed by Jones, Thornicroft, Coffey, & Dunn in 1996. The GAF was used in DSM-IV as the fifth axis of psychiatric evaluation. The therapist is asked to determine for each patient a general score ranging from 10 to 100 to describe his everyday functioning in psychological, social and occupational fields. A score of 10 refers to a state of persistent danger of severely hurting the self or others, and a score of 100 refers to superior functioning in all areas of life. Jones et al. reported that Kronbach's α ranged from 0.74 to 0.76.
45799250|NCT05490043|Drug|ATG-101|ATG-101 will be administered intravenously once every 28 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.
45799251|NCT02999009|Device|Trident II Tritanium Acetabular Shell|A hemispherical acetabular shell indicated for cementless application.
45799252|NCT02994017|Other|cardiopulmonary exercise testing|The Cardiopulmonary exercise testing (CPET) was performed at the beginning of the study, the same at each center. Each patient underwent a symptom-limited incremental exercise test on an ergometric bicycle (Ergoline-Ergometrics 800®). The protocol included a warm-up period of 3 min at 20 W followed by a progressively increasing work rate (WR) in a ramp fashion and then 3 min recovery. The ramped WR increment was individualized (range,8-30 W/min). during exercise, heart rate (HR) was monitored continuously by 12-lead ECG, and arterial oxygen saturation (SpO2) was measured by pulse oximetry (Nellcor N-395). The expired gases were analyzed with an Ergocard®, focusing on oxygen consumption(VO2), carbon dioxide production (VCO2), minute ventilation (VE), and tidal volume (VT).
45799253|NCT02917915|Other|Canadian Standardized PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the New Canadian Standardized PR educational approach (experimental).
45799254|NCT02917915|Other|Traditional PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the Traditional PR education approach (active comparator).
45799255|NCT05473273|Drug|Endometrin 100Mg Vaginal Insert|Endometrin will start once endometrial thickness is equal or higher to 7 mm with a trilaminar appearance, after at least 10 days and always less than 16 days of estradiol administration. First day of supplementation a dose of 100mg will be administered at of at 1.pm and 9 pm. From the second day and onwards administration will be increased to three times daily, at 6 am, 2 pm and 10 pm
45799256|NCT05473273|Drug|Estradiol Valerate|Estradiol valerate dose will be reduced to 4mg daily at 7 pm during the first two days of vaginal natural micronized progesterone supplementation and increased afterwards to 6 mg daily (2 mg at 10 am and 4 mg at 7 pm).
45799257|NCT05451043|Biological|Durvalumab|It is a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of programmed cell death ligand 1 with the PD-1. Durvalumab is known as a checkpoint inhibitor drug
45799258|NCT05451043|Drug|Gemcitabine|Gemcitabine is a nucleoside analog and a chemotherapeutic agent. As a prodrug, gemcitabine is transformed into its active metabolites that work by replacing the building blocks of nucleic acids during DNA elongation, arresting tumour growth and promoting apoptosis of malignant cells
45799259|NCT05451043|Drug|Nab paclitaxel|Nanoparticle albumin-bound (nab) paclitaxel is a form of paclitaxel which works as an antimicrotubule agent. Paclitaxel, the active ingredient in nab-paclitaxel promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This interferes with the normal dynamic reorganization of the microtubule network required for interphase and mitotic functions
46073720|NCT02822820|Device|Ligasure-Covidien|Vessel sealing device Ligasure-Covidien used during laparoscopic hysterectomy and pelvic lymphadenectomy
45450757|NCT00095147|Drug|ABA, open-label (OL)|Abatacept, IV solution, Infusion. Depends on participant weight, Monthly, 12+ months
45597929|NCT03526393|Device|Survey training equipment|The survey was checking the equipment designed to assist the lifter training survey with greater precision, in aspects of average height of contact of the ball by striker and maximum perimeter of contact with the ball, for the execution of the attack.
45597930|NCT03526393|Device|Attack and serve training equipment|The attack and serve training equipment was designed to assist the athlete in their body positioning for the execution of the fundamentals of the attack and serve, and the correct extension execution of the of trunk, upper limbs and reaction time of contact with the ball.
45650289|NCT05431231|Diagnostic Test|Session Alliance Inventory - for therapist|a questionnaire that has two - patient and therapist - versions, meant to assess the therapist-patient relationship (therapeutic alliance). It was developed by Falkenstrom, Hatcher, Skjulsvik, Larsson, & Holmqvist in 2014. Each questionnaire (patient/therapist) is composed of 6 statements that refer to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). Falkenstrom et al reported that Kronbach's α coefficient ranged from 0.89 to 0.94 for their three tested samples. In the current study, patients will define who their main therapist is.
45927249|NCT04341181|Drug|Alectinib|Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile.
45927250|NCT04341181|Drug|Atezolizumab|Atezolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab might be expected based on their molecular tumor profile.
45927251|NCT04341181|Drug|Avelumab|Avelumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Avelumab might be expected based on their molecular tumor profile.
45927252|NCT04341181|Drug|Axitinib|Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile.
45927253|NCT04341181|Drug|Erlotinib|Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Erlotinib might be expected based on their molecular tumor profile.
45927254|NCT04341181|Drug|Vemurafenib plus Cobimetinib (combination)|Vemurafenib plus Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib plus Cobimetinib might be expected based on their molecular tumor profile.
45927255|NCT04341181|Drug|Trastuzumab plus Pertuzumab (combination)|Trastuzumab plus Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab plus Pertuzumab might be expected based on their molecular tumor profile.
45927256|NCT04341181|Drug|Trastuzumab emtansine|Trastuzumab emtansine treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab emtansine might be expected based on their molecular tumor profile.
46072318|NCT05051033|Device|Transcatheter edge-to-edge repair|Patients will be treated with a commercially-approved edge-to-edge mitral repair device. The steerable guide catheter (guide) is inserted into the femoral vein and advanced across the inter-atrial septum using image guided puncture. Fluoroscopic and echocardiographic guidance will be used to visualize the devices and assess the repair. The guide is positioned over the MV and the clip/clasp delivery system is inserted into the guide and positioned over the MV in accordance with the manufacturer's instructions. The delivery catheter is advanced until the clip/clasp emerges from the tip of the guide into the left atrium. The catheter is manipulated using the control handle until the clip/clasp is correctly oriented with respect to the line of coaptation of the mitral valve. The clip/clasp is opened, and advanced across the mitral valve into the left ventricle then pulled back to grasp the leaflets.
46072319|NCT05050799|Device|Central Venous Access|The Surfacer® Inside-Out® Access Catheter System is intended to obtain central venous access to facilitate catheter insertion into the central venous system for patients with upper body venous occlusions or other conditions that preclude central venous access by conventional methods.
45799260|NCT05451043|Biological|Tremelimumab|Tremelimumab is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker.
46072320|NCT05047965|Procedure|Dixon MRI|Undergo Dixon MRI
46072321|NCT05047965|Procedure|Magnetic Resonance Imaging|Undergo standard MRI
45597931|NCT03526393|Device|Pass training equipment|The equipment for the training of the pass, it was designed to represent the serve forced and technical, variables height, circumference and average speed of the ball. This equipment has been adapted from the conventional volleyball serve equipment, respecting the limits of the sitting volleyball court.
45650290|NCT03040583|Other|No intervention|Patients data will be collected during their disease follow-up
45650291|NCT03104335|Drug|Apatinib|750 mg daily once oral administration of apatinib for body surface area (BSA) > 1.5 and 500mg daily for BSA <1.5. Half an hour after meal and everyday at the same time is usually advised.
45799261|NCT05451043|Drug|Propranolol|Competitively blocks both β1 and β2 adrenergic receptors.
45799262|NCT05451043|Drug|Cisplatin|cisplatin has been associated with ability to crosslink with the urine bases on the DNA to form DNA adducts, preventing repair of the DNA leading to DNA damage and subsequently induces apoptosis within cancer cells.
45799263|NCT02713399|Device|Optical Coherence Tomography|
45799264|NCT02700295|Device|Orthokeratology lens|
46073721|NCT02822820|Device|RoBi forceps-Karl Storz|Vessel sealing device RoBi forceps-Karl Storz used during laparoscopic hysterectomy and pelvic lymphadenectomy
45597932|NCT04466839|Other|Questionnaire and interview|The questionnaires are Parkinson Disease Questionnaire-8 Items (PDQ-8) Visual Analog Scale (VAS) is visual analog scale visual numeric from 0 to 100, Neuropsychiatric Inventory-Questionnaire-Reduced (NPI-R) and Clinical Global Impression-Impairment (CGI-I).
45799265|NCT02652169|Drug|PRF mixed with amikacin and teicoplanin|PRF, mixed with amikacin and teicoplanin is applied to the chronic ulcer
45799266|NCT02652169|Drug|PRF mixed with PHMB plus Macrogolol|PRF, mixed with Lavasorb is applied to the chronic ulcer
45799267|NCT02652169|Drug|PRF plus normal saline|PRF as a monosubstance plus sodium chloride 0.9% is applied to the chronic ulcer
45799268|NCT02652169|Other|Silver gauze|Acticoat 7 silver wound dressing is applied to the chronic ulcer
45799269|NCT02478775|Drug|Degarelix (GnRH antagonist)|Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist degarelix will be given subcutaneously.
45927257|NCT04341181|Drug|Vismodegib|Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vismodegib might be expected based on their molecular tumor profile.
45927258|NCT04341181|Drug|Niraparib|Niraparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Niraparib might be expected based on their molecular tumor profile.
45927259|NCT01806324|Drug|HL040XC|single dose
45799270|NCT02478775|Drug|recombinant FSH|Day-2: Blood samples will again be obtained every 10 minutes for 10 hours. Repeated boluses of exogenous recombinant FSH (rFSH) will be given by IV during this 10 hour visit.
45927260|NCT01806324|Drug|Losartan + Atorvastatin|Single dose
45927261|NCT04380064|Procedure|ILM Peeling|ILM peeling performed during primary PPV for PDR
45927262|NCT04380064|Procedure|No ILM Peeling|ILM peeling not performed during primary PPV for PDR
45927263|NCT02482376|Radiation|Stereotactic body radiotherapy ( SBRT)|Single fraction of 21 Gy stereotactic radiotherapy (SBRT)delivered pre-operatively to subjects with early stage breast cancer
45450758|NCT02198014|Other|Manual Therapy|"5 minutes. Thermotherapy shallow to 50 cm away from the knee. 15 minutes. Joint traction, grade I-II. Fixation of distal femur with cinch and manual fixation of proximal tibia. Patient in prone position and the traction is carried out in the submaximal ranges of flexion and extension.~10 minutes. Passive muscle stretching of quadriceps (within the limits of mobility), through compression muscle, passive muscle stretching and relaxation of muscle.~10 minutes. Isometric and resisted exercises of quadriceps, in submaximal ranges, of flexion and extension.~10 minutes. Proprioception exercises with unipodal support, with and without visual support, and posterior destabilization.~10 minutes. Local cryotherapy with ice pack."
45650292|NCT04863365|Drug|Placebo ophthalmic solution|A matching placebo ophthalmic solution, 3 drops daily, 28 days
45650293|NCT04863365|Drug|PHP-201 ophthalmic solution|PHP-201 0.5% ophthalmic solution, 3 drops daily, 28 days
45650294|NCT04847765|Device|VIPUN Gastric Monitoring System prototype|"The VIPUN Balloon Catheter prototype is a nasogastric feeding tube with integrated balloon that can be inflated with a preset volume of air. Intraballoon pressure changes are recorded outside the body. Gastric contractions can be detected in the pressure profile.~The recording lasts 30 minutes and is combined with simultaneous cine magnetic resonance imaging."
45650295|NCT03104179|Device|Cytosorb Adsorber|Cytokine adsorption during CPB
45650296|NCT04855175|Device|Synthetic Bone Allograft (ClearFit)|Patients in this arm will receive ClearFit (synthetic bone allograft)
45650297|NCT04855175|Other|Autograft|Patients in this arm will use patient's own bone
45799271|NCT02478775|Drug|Cetrorelix|Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist Cetrorelix will be given subcutaneously.
45799272|NCT02451995|Device|Ripple Mapping guided AT ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of Ripple Mapping
45799273|NCT02451995|Device|Local activation Time Mapping AT Ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of local activation time mapping
45799274|NCT01783561|Drug|Caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. They will receive a blinded dose of the opposite of what they received in the DR (placebo or caffeine) at 6 hours of life. Therefore, the intervention is timing of initial caffeine dose.
45927264|NCT01805973|Behavioral|Exercise Training|Patients will participate in a supervised exercise training programme for 18 weeks. Patients will participate in a 50 minute exercise regime three times a week.
45927265|NCT04304677|Device|Percutaneous coronary intervention|"Pre-PCI FFR pullback recording was done with conventional system~Automated algorithm to calculate delta FFR per unit time was developed~PCI was performed using 2nd generation DES"
45927266|NCT02423876|Drug|Epidural analgesia|"Receive epidural placement. Standard epidural medications and dosage are as follows:~0.1% ropivicaine + 10 mcg/mL hydromorphone at 6 mL/hr continuous rate~3 mL/hr RN bolus, to be used as needed based on pain ratings~3 mL/30 minutes patient bolus, which is available on patient demand."
45927267|NCT02423876|Other|Intraoperative Complication Management and Prevention|Undergo ERP
45927268|NCT02423876|Procedure|Pain Therapy|Undergo ERP
45927269|NCT01805934|Drug|RBLF|The patients in Group RBLF will receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).
45927270|NCT01805934|Drug|RA|The patients in Group RA will be sent to a penicillin skin test before treatment except they were given penicillin before. They will receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).
46072322|NCT05047939|Drug|remimazolam-based TIVA|In the remimazolam-based TIVA group, general anesthesia is induced and maintained with a continuous infusion of remimazolam using an infusion pump. In the remimazolam group, its antagonist, flumazenil, is administered at the end of surgery.
46072323|NCT05047939|Drug|propofol-based TIVA|In the propofol-based TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using an infusion pump (Orchestra®; Fresenius Vial, France).
45650298|NCT05430997|Device|IOB Warming Unit (WU505) + Inflatable Warming Blanket|The inflatable warming method (Inflatable Warming Unit (IOB Warming Unit, WU505) + Inflatable Warming Blanket (IOB Warming Blanket)) is a common clinical warming technique in anesthesiology, which is well tolerated by patients and safe and effective. The anesthesiology department has established standard operating procedures for the above-mentioned non-invasive operations.
45799275|NCT02452931|Drug|Leuprolide Acetate 45 mg|Subcutaneous injection
45799276|NCT01783639|Procedure|Carotid Artery Stent|Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices
45799277|NCT04744727|Drug|paracetamol-pethidine|100 ml containing 1000 mg paracetamol -50 mg pethidine HCL
45799278|NCT02243527|Other|Inspiratory Muscle Training|6-weeks of inspiratory muscle training
45799279|NCT02243527|Other|Sham Inspiratory Muscle Training|A sham training procedure that is meant to elicit no physiologic changes
45799280|NCT02454179|Drug|pembrolizumab|
45799281|NCT02454179|Drug|Acalabrutinib|
45799282|NCT01395641|Drug|gene therapy|AAV2-hAADC viral vector will be injected into bilateral putamen by stereotactic surgery.
45799283|NCT02041533|Biological|Nivolumab|
45799284|NCT02041533|Drug|Gemcitabine|
45927271|NCT04302259|Device|Intelligent Spine Interface|"ISI-C is a bi-directional, two anatomical location Epidural Electrical Stimulation (EES) system to bridge the lesion core in patients with chronic complete and incomplete spinal cord injury (SCI). This Intelligent Spine Interface, or ISI will interpret recorded neural information from above a spinal cord lesion and transfer that information, via deep neural network-based interpreters (i.e. models), to stimulation sites (electrodes) below the lesion with the aim of restoring volitional control of the lower limb."
45927272|NCT04298242|Device|ExAblate 2100|A non-invasive thermal ablation device fully integrated with an MR imaging system
46072324|NCT05045963|Other|Electronic Health Record Review|Medical record reviewed
46073722|NCT00849979|Behavioral|Questionnaire|Day 1 MDASI-GI Questionnaire
45650299|NCT05430997|Device|cover with a quilt from the neck to both feet|The patient was covered with a quilt from the neck to both feet after entering the operating room.
45650300|NCT05376423|Biological|OBI-833/OBI-821|OBI-833 and OBI-821 are individually formulated into separate glass vials. The articles are mixed prior to subcutaneous administration at the clinic.
45799285|NCT02041533|Drug|Cisplatin|
45799286|NCT02041533|Drug|Carboplatin|
45799287|NCT02041533|Drug|Paclitaxel|
45799288|NCT02041533|Drug|Pemetrexed|
45799289|NCT02907203|Device|Drug Coated Balloon|Prospective, multi-center, single-arm study characterizing outcomes in subjects with Peripheral Artery Disease (PAD) lesions treated with percutaneous transluminal angioplasty (PTA) using the GORE® DCB Catheter.
45799290|NCT02887157|Device|Swept Source OCT|The swept source optical coherence tomography device was developed at Duke University as the result of collaboration between the Departments of Ophthalmology and Biomedical Engineering. The SSOCT system has a 100kHz repetition rate, 1050nm-centered swept-source light source (Axsun Technologies). This swept-source system allows near real-time OCT imaging during movement while imaging and it provides better OCT imaging of the choroid. The SSOCT system is a non-contact device and therefore does not touch the eye.
45799291|NCT02887157|Other|Magnetic Resonance Imaging|Non-sedated research brain MRI: Magnetic resonance imaging (MRI) is a minimal risk procedure that uses a magnet and radio waves to make diagnostic medical images of the body. There have been no ill effects reported from exposure to the magnetism or radio waves used in this test. However, it is possible that harmful effects could be recognized in the future. A known risk is that the magnet could attract certain kinds of metal. Therefore, we will carefully ask about metal within the body. If there is any question about potentially hazardous metal within the body, MRI imaging will not be performed. We will also keep the examining room locked so that no one carrying metal objects can enter while the child is in the scanner.
45799292|NCT02887157|Other|Scavenged blood collection|Serum/plasma (residual in the laboratory) collected as part of clinically indicated care will be shipped to the University of Florida for neuroinflammatory biomarker testing to identify central nervous system cellular injury.
45799293|NCT02883335|Other|Observational registry|
45799294|NCT04743869|Device|Kyphos FS™ Bone Substitute|Dorsal instrumentation via Longitude II (Medtronic Austria GmbH/Vienna) and balloon kyphoplasty are performed. KyphOs FS™ bone cement will be introduced in the fractured vertebral body.
45799295|NCT04743869|Device|KYPHON ActivOs® Bone Cement with Hydroxyapatite|Dorsal instrumentation via Longitude II (Medtronic Austria GmbH/Vienna) and balloon kyphoplasty are performed. KYPHON ActivOs® Bone Cement with Hydroxyapatite will be introduced in the fractured vertebral body.
46073723|NCT00849979|Other|Interview|Open-ended, audiotaped interviews
45650301|NCT00484471|Drug|aripiprazole|15-30 mg/day aripiprazole, 22 weeks
45650302|NCT00484471|Drug|valproate|sufficient dose as determined by investigator to maintain the therapeutic level.
45650303|NCT00484471|Drug|placebo|placebo to aripiprazole, 22 weeks
45650304|NCT03041051|Biological|PCV13|
45650305|NCT03041051|Biological|PPV23|
45799296|NCT02260531|Drug|Cabozantinib|
45799297|NCT02260531|Drug|Trastuzumab|
45799298|NCT02458235|Drug|azacitidine|40mg/m2 IV/SC daily x 4 days, maximum of 7 cycles at 6 weekly intervals
45799299|NCT02458235|Biological|donor lymphocyte infusion|For patients with cells available for DLI who are in the high risk group and do not have graft-versus-host disease (GVHD), DLI will be adminstered on day 5 of each cycle.
45799300|NCT04744103|Drug|TCA|Patients will receive a TCA peel as a treatment for their actinic cheilitis.
45799301|NCT02140723|Radiation|preoperative short course radiation|
45799302|NCT02115997|Drug|Methylprednisolone|Methyprednisolone will be administered 1 to 3 pulses at a dose of 1000 milligram (mg) IV at the discretion of the investigator.
45799303|NCT02115997|Drug|Prednisone|Prednisone will be administered orally at tapered dose (start at 1 milligrams per kilogram per day [mg/kg/day]) at the discretion of investigator given daily until participants are off the drug.
45799304|NCT02115997|Drug|Rituximab|Rituximab will be administered at 375 milligrams per meter square (mg/m^2) of body surface area given by IV infusion once weekly from Week 1 to 4.
45799305|NCT01302197|Other|No intervention|longitudinal follow-up after stroke
45927273|NCT04288258|Behavioral|Telehealth-Based Health and Wellness Program (POWERS-TBI)|The treatment program is interactive and will be delivered via the internet, along with ongoing telephone health coaching calls designed to motivate, problem-solve challenges, reinforce skills learned, and prevent relapse.
45799306|NCT01805323|Drug|Dexamethasone Intravitreal Implant|Dexamethasone Intravitreal Implant (OZURDEX®) previously administered according to general clinical practice.
45927274|NCT02316002|Drug|Pembrolizumab|
45927275|NCT01805895|Drug|Minocycline|This arm will receive a total of 5 doses of minocycline. Dose 1 will be 400mg IV within 12-hours of onset of symptoms. Dose 2 will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
45927276|NCT04278274|Procedure|artificial intelligence prediction system|The tumor ROI in the post- neoadjuvant treatment MRI images will be manually delineated, and further subjected to the AI prediction system arm to verify the predictive accuracy of this AI prediction system in identifying the pCR individuals from non-pCR patients with LARC.
45927277|NCT04278274|Procedure|the radiologists|The enrolled patients will be assigned to the trained experienced radiologists to evaluate their predictive accuracy in identifying the pCR individuals from non-pCR patients
45927278|NCT04265443|Device|Percutaneous coronary intervention|PCI was performed using 2nd generation DES
45927279|NCT04255030|Behavioral|Coping Together Booklets and Workbook|Dyads in this group will complete Coping-Together, a 6-week, booklet-based, self-directed coping and self-management skills training intervention. This intervention addresses key psychosocial challenges by offering evidence-based practical skills to: (a) manage symptoms, (b) cope with anxiety, (c) collaborate with the health care team, (d) engage in shared decision-making, (e) communicate with partner and family, and/or (f) obtain the community resources needed. A relaxation CD is also included, in addition to a workbook that accompanies the Coping-Together booklet-based intervention. The workbook aims at helping dyads choose a booklet relevant to their cancer-related challenges faced, find coping skills that best meet these challenges, and make a plan to use one of the coping skills successfully.
45927280|NCT04255030|Behavioral|Lay telephone coaching|Dyads will receive Coping-Together support via weekly telephone calls from a lay coach. Sessions will range between 10-15 minutes. The goal of coaching will be to provide information on how to use the workbook and booklets. Although no formal therapy will be provided, the coach will maintain a positive and encouraging attitude when interacting with participants regardless of their adherence to the intervention recommendations. The sessions will start with the coach setting a predetermined agenda based on the section of the workbook to review that week that week. Then, coaches will ask about the use of the booklets over the previous week, and ask participants about any required support or clarification in using the booklets. Sessions conclude with setting a goal related to the workbook, booklets and/or coping technique to focus on over the coming week.
45799307|NCT01647763|Procedure|Hemorrhoidal artery ligation with rectoanal repair|"Hemorrhoidal arteries will be detected using an ultrasound Doppler probe. The arteries will be sutured with at least 4 Z-sutures.~In the area with the 3 largest knots a purse string suture will be placed."
45799308|NCT01647763|Procedure|Stapled hemorrhoidopexy|A purse string suture will be placed just below the hemorrhoidal cushion. Fixing the suture around the shaft of a circular PPH 03 stapler (Ethicon Endo-Surgery). Hemorrhoids will be removed by firing the stapler. Sufficiency of the stapler line will be examined through a proctoscope. Eventual sources of bleeding will be sutured.
45799309|NCT01641055|Dietary Supplement|Salmon protein hydrolysate|2.5g salmon protein hydrolysate per day for 8wk.
45799310|NCT01641055|Dietary Supplement|Herring protein hydrolysate|2.5g herring protein hydrolysate per day for 8wk.
45799311|NCT01641055|Dietary Supplement|Cod protein|2.5g cod protein per day for 8wk.
45799312|NCT01641055|Dietary Supplement|Milk protein|2.5g milk protein per day for 8wk.
45927281|NCT04255030|Behavioral|Motivational Interviewing|Six, 45-60 minute weekly telephone-based sessions with a trained Motivational Interviewing Specialist to progress toward goals. Here, dyads are given one-on-one guidance from a HCP Motivational Interviewing Specialist to practice the skills they need. Calls will focus on problem-solving principles and core components of self-management (70), including: (a) identifying dyads' concerns, (b) reviewing management efforts, (c) identifying goals, (d) identifying skills needed to achieve goals, and (e) addressing barriers to applying skills to current situations, including level of self-efficacy. At each meeting, progress, subsequent goals, and corresponding plans will be discussed.
45927282|NCT01805856|Drug|PIPC piperacillin sodium|
45927283|NCT01805856|Drug|CEZ, cefazolin sodium|
45927284|NCT04253080|Biological|Blood sample|Blood sample before treatment, 3 months after treatment and after 1 year or relapse or resumption of disease progression.
45450759|NCT02198014|Other|Educational Physiotherapy|"Theory. Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of knee; Anatomy of ankle musculature; Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~Practice: exercises in favor of gravity; active exercises for mobility and pain management; knee proprioception exercises; isometric and isotonic exercises of quadriceps; swimming and cycling technique."
45650306|NCT05401929|Device|iTBS|Six trains of active intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
45650307|NCT05401929|Device|iTBS|Six trains of sham intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
45650308|NCT03835273|Other|3D motion capture system|Small reflective markers and inertia measurement units will be placed on the chest of the patients using hypoallergenic adhesive and a motion capture system will pick up a 3D image via these markers non-invasively.
45799313|NCT02459795|Drug|Ingenol Mebutate (Perrigo)|
45799314|NCT02459795|Drug|Ingenol Mebutate (Reference)|
45799315|NCT02459795|Drug|Placebo gel|
45799316|NCT01247207|Drug|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
45799317|NCT01787383|Drug|Ingenol mebutate gel 0.05 %|Ingenol mebutate gel 0.05 % (Picato®) on trunk/extremities either applied simultaneously or sequentially
45799318|NCT01787383|Drug|Ingenol mebutate gel 0.015 %|Ingenol mebutate gel 0.015 % (Picato®) on face/scalp either applied simultaneously or sequentially
45799319|NCT02461433|Device|Prevena|Prevena Incision Management system
45799320|NCT02461433|Device|Standard Dressing|This involves standard of care dressing including but not limited to gauze.
45650309|NCT03835273|Other|Incentive spirometry|Incentive spirometry is a non-invasive device for assessment of pulmonary function.
45799321|NCT02462291|Other|Ecological Environmental therapy|The program of EET consist of the physical interaction (visual, tactile, olfactory) between natural ecological elements such as flowers, trees, grass, and the patients with AD.
45799322|NCT02463227|Biological|VRC01|"40 mg/kg of VRC01 administered IV in 100 mL of 0.9% sodium chloride for injection, USP.~Administered over about 30 to 60 minutes using a volumetric pump."
45650310|NCT03835273|Other|Questionnaires|Two validated, European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) and Oesophago-Gastric Module 25 (EORTC QLQ-OG25) and one non-validated satisfaction questionnaire regarding the usability and acceptability of the 3D motion capture system [7,8]
45650311|NCT03103945|Device|CDS box connection of the Niobe™ Remote Magnetic Navigation System|For all subjects included in the study, the ablation procedure will be started per standard of care. First mapping, pacing and electrocardiograms of the right atrium will be evaluated without the CDS box connected. Second the CDS box will be connected to the catheter and mapping, pacing and electrocardiograms will be recorded again. Next, ablation will be conducted per standard of care.
45650312|NCT05591547|Radiation|IMRT/VMAT-Based Accelerated Partial Breast Irradiation|The lumpectomy bed will receive a total of 26 Gy in 5 fractions, with 1 fraction delivered per day. Ideally, the course of radiation therapy would be completed over 5 consecutive treatment days. Treatment must begin within 12 weeks of lumpectomy or re-excision of surgical margins and must be completed within 10 calendar days.
45799323|NCT00984269|Procedure|Tourniquet Use|Patients undergoing hand/wrist surgery with or without a tourniquet
45799324|NCT00937001|Procedure|Biopsy/Ultrasound|obtain muscle biopsies at approximately 14 days of ICU, muscle ultrasound at 3-4 timepoints
45799325|NCT01788631|Drug|Regadenoson|Regadenoson is an A2AR agonist that is a coronary vasodilator. It is chemically described as adenosine, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]-, monohydrate. Its molecular formula is C15H18N8O5. Regadenoson has an FDA indication for use in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. It has lower affinity for non-A2A adenosine receptor subtypes thought to be associated with some of the adverse effects associated with non-selective adenosine receptor agonists, which increase extracellular adenosine by blocking its uptake into cells. The maximal plasma concentration of regadenoson is achieved within 1 to 4 minutes after injection and parallels the onset of the pharmacodynamic response. Its half-life is approximately 2 to 4 minutes.
45650313|NCT04847999|Dietary Supplement|Dark chocolate|Dark chocolate
45799326|NCT01788631|Drug|Placebo|This study uses 0.9% Normal Saline (NS) as placebo. This is a sterile sodium chloride solution usually used to replenish fluids and electrolytes. It contains no additives, and is a standard solution used as placebo in clinical trials where the study drug is administration intravenously. NS will be prepared by investigational pharmacy.
45799327|NCT00907283|Drug|Deferiprone|15 mg/Kg/twice for 1 year
45799328|NCT01789255|Drug|vorinostat|Given PO
45799329|NCT01789255|Drug|tacrolimus|Given IV or PO
45799330|NCT01789255|Drug|cyclosporine|Given IV or PO
45799331|NCT01789255|Drug|methotrexate|Given IV
45799332|NCT01789255|Other|laboratory biomarker analysis|Correlative studies
45799333|NCT01789255|Other|pharmacological study|Correlative studies
45799334|NCT02464163|Biological|Panblok|Intramuscular injection
45799335|NCT02464163|Biological|rHA adjuvant|Intramuscular injection
45799336|NCT02465099|Device|Ultrasonic Dissection (UD)|Ultrasonic energy will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (>=6) PSF
45799337|NCT02465099|Device|Electrocautery Dissection (ED)|Electrocautery dissection will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (>=6) PSF
45799338|NCT01807585|Device|VenaSeal SCS|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
45799339|NCT01807585|Device|ClosureFast Radiofrequency Ablation (RFA)|Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.
45799340|NCT01807585|Device|Roll-in (VenaSeal SCS)|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
45799341|NCT00582257|Behavioral|questionnaires|Participation in the registry will consist of adequately completing the family history questionnaire (one per family) the gastric cancer risk factor questionnaire and providing a blood sample for future correlative studies. Registry participants (both Patient/Relative and Control cohorts) will be required to submit tissue (both normal and/or tumor) to create a Tissue and DNA repository. Select participants will be invited to undergo Genetic Counseling, eg. those participants who meet clinical criteria for HDGC.
45799342|NCT01808755|Dietary Supplement|D Mannose|1 gr. every 8 hours
45799343|NCT01808755|Drug|trimethoprim/sulfamethoxazole|one cp b.i.d. for 5 days. Then one week of antibiotic every 4 weeks for the following 23 weeks
45799344|NCT02694809|Drug|Conjugated Estrogens/Bazedoxifene|Given PO
45799345|NCT02694809|Other|Laboratory Biomarker Analysis|Correlative studies
45799346|NCT02694809|Other|Pharmacological Study|Correlative studies
45799347|NCT02694809|Other|Placebo|Given PO
45799348|NCT02694809|Procedure|Quality-of-Life Assessment|Ancillary studies
45799349|NCT02694809|Other|Questionnaire Administration|Ancillary studies
45927285|NCT04253080|Biological|Cutaneous melanoma biopsy|Cutaneous melanoma biopsy before treatment, 3 months after treatment and relapse or resumption of disease progression.
45927286|NCT01805817|Drug|YASMIN® (Drospirenone/Ethinyl Estradiol)|oral contraceptive pills
45927287|NCT01805817|Device|The Copper-T is an intrauterine device (IUD)|intrauterine device for contraception
46073724|NCT02546869|Drug|Lebrikizumab|Lebrikizumab will be administered SC using PFS, q4w up to Week 12.
46073725|NCT02546869|Device|Prefilled Syringes|
45927288|NCT01805817|Device|levonorgestrel-releasing system|intrauterine device
45927289|NCT04220320|Diagnostic Test|Vaginal examination.|Cervical properties as evaluated by a vaginal examination.
45927290|NCT04220320|Diagnostic Test|Transvaginal sonography.|Cervical length as evaluated by a transvaginal sonography.
45799350|NCT01790581|Behavioral|Balance Training|This is a 4-week supervised balance training program that has been previously validated in those with CAI by improving subjective and objective measures of function. During the 4-week program, subjects will complete three 20-25 minute sessions a week for a total of twelve supervised training sessions. The specific exercises and repetitions that will be performed per training session will include: 1) hop to stabilization (10 repetitions per direction), 2) hop to stabilization and reach (5 repetitions per direction), 3) unanticipated hop to stabilization (3 repetitions), 4) progressive single limb stance balance activities (3 repetitions), and 5) progressive single limb stance activities with eyes closed (3 repetitions).
45799351|NCT01790581|Behavioral|STARS|The STARS intervention will consist of 4 unique sensory-targeted interventions: calf stretching, ankle joint traction, anterior/posterior ankle joint mobilizations, and plantar massage. These four techniques target 3 types of sensory pathways (musculotendinous, articular, and plantar cutaneous, respectively) and will be applied in the same order for all treatment sessions: 1) 60-second calf stretch, 2) 30-second ankle traction, 3) 30-second mobilization, 4) 2-minute plantar massage, 5) 30-second ankle traction, and 6) 30-second mobilization.
45799352|NCT00568997|Drug|Pimecrolimus|Pimecrolimus 1% cream
45927291|NCT02255435|Drug|Omaveloxolone Capsules, 2.5 mg|
45927292|NCT02255435|Drug|Omaveloxolone Capsules, 5 mg|
45927293|NCT02255435|Drug|Omaveloxolone Capsules, 10 mg|
45927294|NCT02255435|Drug|Placebo|
45650314|NCT05430841|Diagnostic Test|18F-FDG, 18F-AlF-FAPI PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 18F-AlF-FAPI, and undergo PET/CT imaging within the specified time.
45650315|NCT05375721|Procedure|ST36 acupoint injection|"ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed)."
45799353|NCT02648165|Behavioral|Attention Bias Modification|Computer based Attention Bias Modification
45799354|NCT02648165|Behavioral|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
45799355|NCT02648165|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy delivered in a group therapy setting
45799356|NCT00362687|Drug|Truvada (TDF+FTC) alone|tenofovir DF 300 mg and emtricitabine 200 mg in a fixed dose tablet formulation
45927295|NCT02255435|Drug|Omaveloxolone Capsules, 20 mg|
45927296|NCT02255435|Drug|Omaveloxolone Capsules, 40 mg|
45927297|NCT02255435|Drug|Omaveloxolone Capsules, 80 mg|
45927298|NCT02255435|Drug|Omaveloxolone Capsules, 160 mg|
45650316|NCT04863053|Other|Blood samples will be taken to assess platelet function. There is no change in treatment.|
45650317|NCT03040505|Other|questionnary|Participant's verbalization will be audio recorded and then transcribed by investigators. The investigators will use predefined categories to score the strategies mentioned by participants during the think aloud task.
45799357|NCT00362687|Drug|FTC alone|emtricitabine 200 mg
45799358|NCT00362687|Procedure|No HAART|No HAART
45799359|NCT02469389|Behavioral|Engaging in Community Roles and Experiences (ENCoRE)|Engaging in Community Roles and Experiences (ENCoRE) includes evidence-based psychosocial treatment strategies to target the affective-motivational deficits, negative expectancies, and behavioral skills deficits that are central to the maintenance of negative symptoms. Behavioral strategies include motivational enhancement, psychoeducation, cognitive therapy, and social skills training.
45927299|NCT02255435|Drug|Omaveloxolone Capsules, 300 mg|
45927300|NCT02255435|Drug|Omaveloxolone Capsules, 150 mg|
45650318|NCT01746849|Biological|Palifermin|
45650319|NCT01746849|Biological|Lupron|
45927301|NCT04206046|Procedure|Spinal anaesthesia|Patients will receive a spinal anaesthetic
45927302|NCT04206046|Procedure|General anaesthesia|patients will receive a general anaesthetic and a femoral nerve block
45927303|NCT04188652|Other|Detailed symptomregistration|Information on symptoms, specialized ultrasound in accordance to IOTA, and HE4 is registered in women with ovarian cysts. Participation in the study including symptom registration, description of the cyst using IOTA terminology, and HE4 determination will not affect further diagnostics or treatment. HE4 will not be informed to the patient or clinician.
45927304|NCT00405418|Drug|Insulin glargine|Subcutaneous injection, once a day in the evening
45927305|NCT00405418|Drug|Insulin Detemir|Subcutaneous injection, twice a day at breakfast and before dinner
45927306|NCT04102852|Dietary Supplement|Lactobacillus rhamnosus GG ATCC 53103|probiotic administration at two different doses for 1 month
45927307|NCT04084054|Diagnostic Test|Ultrasound|Ultrasonic measurement of the optic nerve sheath diameter
45927308|NCT04083001|Device|OTR4132MD|"According to Regulation (EU) 2017/745(MDR), OTR4132-MD is an implantable medical device, for short term use which is specifically intended for use in direct contact with systemic circulation system.~OTR4132-MD is by definition intended to come into contact with the patient when being injected. It is administered through intra-arterial injection, in an one-shot dose and the majority of the product is eliminated within 24 hours."
45927309|NCT04078321|Other|Mollii ®|The garment claims to have a 48 hours lasting effect of an hour of treatment. The garment should be worn for at least 1 hour every other day. All participants receive individually tailored garments and individually tailored appropriate training towards specific goals set in connection to study start. The garment is used in the home environment and the family is responsible for documentation of use in a diary. Measurements is performed following an ABAB design for four weeks. Measurement performed at 12 occasions during the four weeks are; spasticity, physical function, pain, sleep and adherence. Standardized protocols for the intervention are provided to involved physical therapists.
45650320|NCT01746849|Procedure|peripheral blood stem cell transplantation|
45650321|NCT01746849|Radiation|Total-Body Irradiation (TBI)|
45650322|NCT01746849|Drug|Thiotepa|
45650323|NCT01746849|Drug|Cyclophosphamide|
45650324|NCT01746849|Drug|Degarelix|
45927310|NCT02157077|Drug|Aflibercept|Intravitreal Injection
45927311|NCT01805700|Other|Caffeine enhanced energy drink|Comparison of different energy drinks
45799360|NCT02469389|Behavioral|Health & Wellness (H&W)|"Health & Wellness (H&W) will focus on health and wellness issues and education on ways to better manage health-related concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application.~Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions), 8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1session)."
45799361|NCT01790659|Drug|WR 279,396|WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%
45799362|NCT01790659|Drug|Paromomycin|Paromomycin alone
45650325|NCT03104101|Combination Product|TPTNS+Drug|one tablet Trospium Chloride 20 mg once daily Plus TPTNS
45650326|NCT03104101|Device|TPTNS|Surface adhesive electrodes placed on the skin above medial malleolus
45650327|NCT04847921|Drug|Dalbavancin|long-acting lipoglycopeptide antibacterial agent
45650328|NCT05400525|Dietary Supplement|YMETA|1 sachet containg a total of 3g i.e. 2.5g Galacto-oligosaccharides, 0.5g Bifidobacterium polysaccharides (daily)
45650329|NCT05400525|Other|Placebo control|3g Maltodextrin (i.e. DE 10) daily
45650330|NCT03104023|Procedure|Staple line inversion|A staple line inversion will be performed with a running suture of Polypropylene 2/0
45799363|NCT00681655|Other|Alcohol|Alcohol (6% in saline vehicle) infused for 2.8 hour long clamping session (Breath alcohol level maintained at 60 mg/dL throughout).
45799364|NCT00681655|Other|Placebo|Placebo (saline vehicle) infused for 2.8 hour long session.
45799365|NCT01811875|Biological|Optivate 500IU|
45799366|NCT02469701|Drug|nivolumab and ablation|
45799367|NCT01733407|Drug|L-serine|400mg/kg/d L-serine or placebo divided TID for year 1, then crossover of placebo arm so that all patients on 400mg/kg/d L-serine divided TID for year 2.
45799368|NCT01733407|Drug|placebo|400mg/kg/d divided TID for year 1 only.
45799369|NCT04749511|Behavioral|Extrambulatory digital PROMs detection|The aim of the study is to investigate the validity of an alternative method of evaluating PROMs in which the questionnaire will be administered to the patient digitally (Google Forms) in an out-of-patient setting.
45799370|NCT00422045|Device|Low Level Laser Therapy|Low Level Laser Therapy done after surgery.
45799371|NCT01733953|Drug|Atorvastatin|6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.
45799372|NCT01733953|Drug|Sugar Pill (Placebo)|6-Months of placebo (sugar) pill; oral, once daily
45799373|NCT00362921|Drug|Gliadel wafers in combination with O6-benzylguanine|
45927312|NCT01805700|Other|Glucose drink|Glucose drink (containing 84mg glucose alone)
45927313|NCT04057378|Device|Electroconvulsive therapy|Electrically induced convulsion under anesthesia
45927314|NCT04038580|Device|Laminated Socket|This is the currently prescribed socket the participant normally wears.
45650331|NCT03104023|Combination Product|Staple line buttressing|The gastric section will be performed with a stapler with preloaded buttress material
45650332|NCT04847687|Drug|methylprednisolone|Patients who are hospitalized with a pre-diagnosis of severe COVID-19 pneumonia and who are started on methylprednisolone will be divided into two groups according to the drug dose. Groups will be compared in terms of length of hospital stay, intensive care needs and prognosis.
45650333|NCT05430685|Dietary Supplement|Ashwagandha|Intervention and placebo group each received a bottle of 60 capsules. Subjects were instructed to take one capsule in the morning and 1 capsule in the evening. Intervention group was getting 350 mg ashwagandha root extract per capsule (or 700 mg per day). Each intervention capsule delivered 2.5 mg withanolides with equivalence of 2,700 mg dry herb.
45799374|NCT01734889|Drug|Nitisinone|Oral suspension
45799375|NCT01735981|Other|Video game exercise using Dance Dance Revolution|use of the video-game, Dance, Dance Revolution as an exercise to improve gait and balance
45799376|NCT01735981|Other|hand-held video game|hand-held video games
45799377|NCT01736527|Drug|LE Gel|Single drop of LE Gel 0.5% administered to the study eye on visit 2
45799378|NCT01796665|Drug|Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%|
45799379|NCT01796665|Drug|Acanya Gel|
45799380|NCT01796665|Drug|Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product|
45799381|NCT01796977|Device|OxyGenesys Dissolved Oxygen Dressing|
45799382|NCT01796977|Device|Standard Gauze Dressing|
45799383|NCT02989987|Behavioral|Narrative Exposure Therapy|
45927315|NCT04038580|Device|Quatro|The Quatro (Quorum) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
45799384|NCT02989987|Behavioral|Social Support|A local counselors provides social support on demand.
45927316|NCT04038580|Device|Infinite Socket|The Infinite Socket (LiM Innovations) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
45927317|NCT04038580|Device|CJ Socket|The CJ Socket (CJ Socket Technologies) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
45927318|NCT04033276|Drug|Rituximab|IV rituximab
45799385|NCT01798225|Drug|Placebo|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo pills.
45799386|NCT01798225|Drug|Doxycycline|Participants received mechanical periodontal therapy, oral hygiene instructions and Doxycycline 100mg x 14 pills (to be taken one a day for 14 days)
45927319|NCT04033276|Drug|intravenous immune globulin|iv intravenous immune globulin
45927320|NCT00391040|Behavioral|SGS education|
45927321|NCT03969823|Drug|Tagrisso|Osimertinib 80mg once daily until disease progression
45927322|NCT01805661|Procedure|Canal Block and Capsular Injection|Continuous Adductor canal block with 15-30ml of ropivacaine 0.1% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30 ml ropivacaine 0.1% with epinephrine 1:400,000.
45650334|NCT05430685|Other|Placebo|The Placebo group received the same type of bottle with similar looking capsules. Each person in the placebo group was instructed to take 1 capsule twice a day (2 capsules total). Capsules were filled with glycerin to the same weight as ashwagandha. Capsules were indistinguishable from each other.
45650335|NCT01729455|Biological|BENLYSTA|"As prescribed.~Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus."
45799387|NCT02581085|Drug|Tocotrienol (TCT)|TCT is a natural vitamin E supplement with a long history of safe dietary consumption in humans. The objective of the current trial is to validate the outcome observed in an earlier trial that oral TCT attenuates the rise in MELD score over time in patients with end stage liver disease/cirrhosis.
45799388|NCT02581085|Other|Placebo|Control study capsule that includes no study product (Vitamin E - Tocotrienol)
45799389|NCT01800877|Drug|Vasopressors|
45799390|NCT00363623|Device|Silicone hydrogel contact lens|
45799391|NCT02470949|Behavioral|Low Social Status|The participants will be randomized to the Low Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
45799392|NCT02470949|Behavioral|High Social Status|The participants will be randomized to the High Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
45927323|NCT01805661|Procedure|Femoral with Tibial Nerve Block|Continuous femoral nerve block with 15 ml of ropivacaine 0.1% followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.1% up to 15 ml.
45650336|NCT01729455|Other|SLE treatment|"As prescribed.~At baseline, SLE treatment must include an immunosuppressant. During the registry, SLE treatment may include any of the following (alone or in combination): immunosuppressants, corticosteroids, antimalarials, other biologics, investigational agents for SLE, as clinically indicated."
45927324|NCT00391157|Drug|Velcade/Dexamethasone|Velcade 1,3 mg/m2 on days 1, 4, 8 and 11
45927325|NCT04726072|Behavioral|Kundalini Yoga|Participants met once a week for two hours for 12 weeks total. The Kundalini yoga intervention is a mixture of basic yoga, breathing exercises, and meditation. Participants were also asked to do at-home practice for half an hour daily.
45927326|NCT04726072|Behavioral|Psychoeducation|Participants met once a week for two hours for 10 weeks total. The psychoeducation group acted as our control group and consisted of teaching participants about healthy aging. Participants were asked to do at-home practice for half an hour daily.
45927327|NCT04725604|Device|pH probe|"Patients who agree to take part will have a pH probe inserted into their injured limb. The pH probe will be attached to a pH monitor which will record pH data for up to a maximum of 72 hours (24 hours per probe). The surgical team will not have access to the pH data. During the time they are considered at risk for ACS, patients will be monitored in the routine way (using regular clinical assessment and pressure monitoring). If ACS is diagnosed in the routine way, then treatment (fasciotomy) will be offered as appropriate."
45927328|NCT01805622|Behavioral|Active Arm #1, #2, Passive Arm #1, #2|This four-arm cluster randomized trial (five community coalitions plus 1,800 African Americans, 50-74 years of age, who are not current on CRC screening per arm) compares the following implementation strategies: (1) web access to facilitator training materials and toolkits without technical assistance (TA); (2) web access, but with technical assistance (TA); (3) in-person access to facilitator training materials and toolkits without TA and (4) in-person access with TA.
45927329|NCT03871309|Device|Tigertriever|Mechanical Thrombectomy
45927330|NCT01805583|Other|Acceptance and Commitment Therapy (ACT)|
45799393|NCT02471651|Drug|Dexamethasone intravitreal implant (0.7 mg)|Subjects with persistent DME who are randomized to this arm may get up to 3 treatments with the implant (0.7 mg dexamethasone).
45799394|NCT02471651|Drug|Intravitreal anti-VEGF injection|This injection may be ranibizumab, bevacizumab, or aflibercept.
45799395|NCT02473991|Radiation|ultrasound|The placental thickness was measured by placing the ultrasound transducer perpendicularly to the plane of the placenta, in the area of the cord insertion, near the mid-placental portion
45927331|NCT01805583|Other|workplace intervention (WPI)|
45799396|NCT02476565|Device|LMA-Supreme supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
46072325|NCT05041608|Procedure|Endoscopic Surgery|These procedures include: POEM (Peroral Endoscopic Myotomy) for Achalasia, G-POEM (Gastric Peroral Endoscopic Myotomy) for gastric outlet obstruction, Z-POEM (Peroral endoscopic myotomy for Zenker's Diverticulum), EMR (Endoscopic Mucosal Resection), ESD (Endoscopic submucosal dissection), STER (Submucosal tunneling endoscopic resection), NOTES (Natural Orifice Translumenal Endoscopic Surgery), TIF (Transoral Incisionless Fundoplication), Endoscopic Fistula Closure, Endoscopic Suturing, Capsule Endoscopy and EFTR (Endoscopic full-thickness resection).
45653211|NCT05169957|Drug|Nivolumab|Nivolumab administered IV over 30-60 minutes at 1 mg/kg (combined with ipilimumab administered IV over 85-100 minutes at 3 mg/kg) every 3 weeks for a total of 4 doses of the combination therapy or until progression or unacceptable toxicity. Subjects may receive maintenance dosing of nivolumab alone administered IV over 30-60 minutes at 240 mg every 2 weeks or 480 mg every 4 weeks for a maximum of 52 weeks or until progression or unacceptable toxicity.
45799397|NCT02476565|Device|I-gel supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
45927332|NCT03791788|Diagnostic Test|QFR assessment|QFR measurement in order to evaluate functional significance of epicardial stenosis and to compare the response of QFR for worsening stenosis severity, FFR value as reference standard
45927333|NCT01981148|Device|Fluorescence lifetime ophthalmoscope|All patients and healthy subjects will be imaged with the fluorescence lifetime ophthalmoscope
45927334|NCT03781063|Drug|Lasofoxifene|Estrogen receptor antagonist antineoplastic agent
45927335|NCT03781063|Drug|Fulvestrant|Estrogen receptor antagonist antineoplastic agent
45927336|NCT01805544|Drug|Rivaroxaban (Xarelto, BAY59-7939)|20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
45927337|NCT03773419|Behavioral|Texting Intervention (T-WRITE)|Computer-based intervention, guided by a virtual therapist, that involves repeated listening, reading and writing sentences using a cellular phone
45927338|NCT03773419|Behavioral|HandWriting Intervention (ORLA+WTG)|Computer-based intervention, guided by a virtual therapist, that involves repeated listening, reading and writing sentences using pen and paper
45799398|NCT02477423|Drug|Ampicillin|Ampicillin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
45799399|NCT02477423|Drug|Gentamicins|Gentamicin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
45927339|NCT01903421|Drug|Spinal anesthesia group: bupivacaine 10-15mg|
45927340|NCT01903421|Drug|General anesthesia group: induction propofol 1.5-2mg/kg and fentanyl 1-3g/kg, maintained with isoflurane or sevoflurane|
45927341|NCT01903421|Genetic|Blood test|DNA will be tested for the presence of ε4 allele of the apolipoprotein E gene
45927342|NCT01903421|Other|Lumbar spinal tap|1ml of cerebrospinal fluid (CSF) removed and stored for further analysis of amyloid tau protein after completion of the study
45927343|NCT01903421|Behavioral|Montreal Cognitive Assessment (MOCA) and MMSE|
45927344|NCT03748888|Behavioral|Exercise group|"An antenatal physical activity (APA) programme will be designed for participants in the exercise group.~The APA will last for 20-24 weeks. Participants in the EG must enrol in the APA between their 12-16 weeks of gestation.~The APA programme has a frequency of three times a week, which involves aerobic, strength and stretching exercises. The intensity of the APA programme is individually calculated for each participant based on their pre-pregnancy fitness level. Single sessions of the APA programme last 50-60min."
45927345|NCT01805505|Procedure|Transvaginal ultrasound-guided embryo transfer|Embryo transfer of two day-3 embryos performed with the Kitazato Long ET catheter (Kitazato Medical Co. Ltd., Tokyo, Japan), guided by transvaginal ultrasound
45927346|NCT01805505|Procedure|Transabdominal ultrasound-guided embryo transfer|Embryo transfer of two day-3 embryos performed with the Cook Soft-Trans ET catheter (Cook Medical Inc., Bloomington, IN, USA), guided by transabdominal ultrasound
46072326|NCT05041127|Biological|Cetuximab|Given IV
45653212|NCT05169957|Procedure|Stereotactic Body Radiation Therapy|24-45 Gy delivered in three fractions to up to 4 liver metastases
45927347|NCT03744286|Device|Slip Training|-On a separate day (visit 2), using the identified optimal distance, a training session that involves 24 passes on the device where 1-2 planks move will be performed.
45927348|NCT03734731|Device|Monochromatic Infrared Photo Energy (MIRE)|Apply Monochromatic Infrared Photo Energy (MIRE) to the affected nerve
45927349|NCT03734731|Device|Transcutaneous Electrical Nerve Stimulation|Apply Transcutaneous Electrical Nerve Stimulation (TENS) to the affected nerve
45927350|NCT03734731|Drug|Opioids|Prescribe Opioids to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator
45927351|NCT03734731|Drug|Cannabis|Prescribe Cannabis to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator. Comparing Opioid results to Cannabis results with objective nerve testing
45927352|NCT03663907|Procedure|Telemonitoring|"The system (the home tele-healthcare platform) designed jointly by engineers and clinical personal to be able daily automated selfreported symptom and weight, blood pressure and heart rate monitoring. The system allow weekly follow up through videoconferences.~Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians and nurses daily."
46072327|NCT05041127|Other|Questionnaire Administration|Ancillary studies
46072328|NCT05037578|Behavioral|Project Grace|A multilevel church-based intervention to encourage cognitive screens and brain health.
46072329|NCT05036512|Drug|GBT021601|Administered orally with water as a single dose in the morning.
46072330|NCT05035420|Device|Fitbit|Performance of the NIRS biosensor will be explored in comparison to this commercial wearable.
46072331|NCT05035420|Device|Douglas Bag|The Douglas Bag will be used for inducing hypercapnia.
46072332|NCT05035420|Device|Periflux 6000 EPOS|Tissue oxygen saturation measured by the Periflux 6000 will be compared with peripheral tissue saturation measured with the NIRS biosensor both at rest and during the induced hypercapnia, paced breathing and breath holding.
45927353|NCT03645226|Diagnostic Test|Colonoscopy|All subjects will undergo standard mechanical bowel preparation with 4 liters of polyethylene glycol (Klean-Prep, Norgine Ltd., Middlesex, UK). Total colonoscopy will be performed by experienced endoscopists under conscious sedation with intravenous benzodiazepines and narcotics. A conventional intermediate-length colonoscope (Olympus Corporation, Tokyo, Japan) will be used. One mucosal biopsy will be taken in the descending colon. Biopsies will be performed using standard biopsy forces without needle (Olympus Corporation, Tokyo, Japan). Half of the samples will be immersed in 4 oC normal saline solution. All samples will be immediately sent to pathology department and will be stored in a -80 oC freeze for processing of microbiota analyses.
45927354|NCT03626857|Device|Neuromuscular Electrical Stimulation (NMES)|The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of at least 40& of the contralateral MVIC.
45927355|NCT03626857|Other|Eccentric Exercise (ECC)|4 sets of 10 repetitions of an eccentric leg press exercise performed at 70-90% of the 1 repetition maximum
45927356|NCT03626857|Device|Neuromuscular Electrical Stimulation (NMES) placebo|The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of 10-20% of the contralateral MVIC.
45927357|NCT03626857|Other|Eccentric Exercise (ECC) placebo|4 sets of 10 repetitions of an eccentric leg press exercise performed at 10-20% of the 1 repetition maximum
45927358|NCT01723839|Drug|Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide|19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity.
45927359|NCT03468868|Behavioral|Exercise program for people with MS|The intervention consists of 30 minutes of resistance training and 30 minutes of cardio three times per week for 16 weeks.
45927360|NCT03421483|Dietary Supplement|Folic Acid supplementation|Participants receive a 400 microgram Folic Acid supplement
45927361|NCT03421483|Dietary Supplement|Adult Multivitamin|Participants will receive an adult multivitamin supplement
45927362|NCT03410407|Other|Observation of CNS involvement|AML patients with CNS involvement defined by the confirmation of leukemic blast cells in the centrifuged cerebrospinal fluid (CSF) with the presence of more than five WBCs in the CSF or the detection of a CNS granulocytic sarcoma using computed tomography or magnetic resonance imaging.
45927363|NCT03363217|Drug|Trametinib|Daily administration of oral trametinib at a unique dose of 0.025 mg/kg.
45927364|NCT03341143|Drug|Fecal Microbiota Transplant with Pembrolizumab|"FMT is a procedure in which fecal matter or stool is collected from a tested donor, mixed with a saline or other solution, strained and infused into the colon by doing a colonoscopy. The FMT consists of introducing normal bacterial flora contained in stool collected from a donor into your small intestine. In this case, the donor is patient with advanced melanoma who has been treated with a PD-1 inhibitor (nivolumab or pembrolizumab) and has been rendered disease-free as a result. The FMT will be performed on Cycle 1 Day 1.~Pembrolizumab, 200mg, through an IV over 30 minutes on Cycle 1 Day 1 (same day as the FMT, and then again on Day 1 of each 21-day cycle for an additional 3 cycles (Cycles 2 - 4)."
45927365|NCT03205696|Drug|Antiretrovirals|The antiretroviral (ARV) regimen provided by the clinician must follow DHHS guidelines for antiretroviral naïve adolescents and adults
45927366|NCT00405496|Drug|Difluprednate Ophthalmic Emulsion|
46072333|NCT05035420|Device|BIOPAC|The BIOPAC system will be used to record the PPG signal, cardiovascular hemodynamics, and respiratory parameters in order to noninvasively monitor the heart rate, heart rate variability, respiratory rate, respiratory effort index, and arterial oxygen saturation.
46072334|NCT05035420|Device|Flowmet|Flowmet will be used for a measurement of arterial blood flow within the finger or toe. Flowmet outputs a PPG waveform that will be compared with the NIRS biosensor.
46072335|NCT05035420|Device|NIRS|a. Each subject will be monitored with the multimodal system for 10 minutes while sitting quiescent on a chair in resting position. All screening index parameters will be collected and recorded. b. Each subject will be studied for approximately 60-80 minutes while being exposed to a mild Hypercapnia (5% CO2), paced breathing and breath holding followed by a 10-minute recovery time after each task.
45650337|NCT04854473|Device|Exero Medical Leak Detection System|"the Exero Leak Detection System components used in this study are:~Smart drain - a surgical drain with added sensing electrodes~Transceiver /Recording Unit (TRU) - a wearable placed outside the body on intact skin and is connected to the implanted electrodes. The unit also acts as a wireless connection to the Monitoring Subsystem.~Monitoring Subsystem - a tablet or a computer connected wirelessly to the transceiver providing logging, applying analysis algorithms on the logged signals and providing indication/alerts to the medical staff derived from the signals recorded by the electrodes."
45650338|NCT03101839|Drug|AZD4785|KRAS Antisense Oligonucleotide
45650339|NCT04428983|Dietary Supplement|Hericium erinaceus mycelium|Hericium erinaceus capsules 3 tables per day for 24 months
45650340|NCT04376255|Other|Augmented Reality (AR)|AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
45650341|NCT03103867|Device|CGM augmented pump with PLGS ,|5 weeks treatment CGM augmented pump with PLGS compared with 5 weeks treatment with insulin pump with CGM , without integration
45650342|NCT03103867|Device|Insulin pump with CGM|5 weeks treatment continuous subcutaneous insulin infusion pump with CGM without data integration,
45650343|NCT04847375|Drug|exogenous surfactant|Nebulized Surfactant would be administered by face mask which has a nebulizer
45799400|NCT02477423|Drug|Placebo|Normal saline will be given as placebo for those in the placebo comparator group.
45799401|NCT02478671|Device|TR Band|The radial artery will be compressed using a Terumo TR Band and artery diameter and perfusion will be measured
45799402|NCT02479763|Procedure|Waveform-confirmed loss-of-resistance|Using waveform analysis to confirm thoracic epidural space
45799403|NCT00363701|Drug|esomeprazole|
45799404|NCT04744493|Device|ExaBlate 4000|The Exablate 4000, an advanced, non-invasive technique for performing ablation of the Thalamus for treating Essential Tremor, received FDA PMA (P150038) approval for unilateral treatment of Essential Tremor in 2016.
45799405|NCT04744571|Drug|aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate- limiting medication (i.e. Beta- blocker or rate-limiting calcium antagonist) where appropriate. Anti- anginal therapy should be used if the patients have symptom.
45927367|NCT04710823|Procedure|Thoracic paravertebral block|A bolus dose of 0.25% bupivacaine (0.3 ml/kg) will be injected slowly over 3-5 minutes. At 30 minutes after injection of the loading dose, the dermatomal loss of sensation to pinprick was tested. Patients who reported pain to pinprick will be considered to have a failed block and were excluded from the study. The block will be maintained by continuous infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h via a syringe pump. The infusion will be continued for 4 days.
45927368|NCT04710823|Procedure|Serratus anterior plane block|A bolus of 30 ml of 0.25% bupivacaine will be injected slowly over 3-5 minutes between latissmus dorsi muscle and serratus anterior muscle (Figure 15). Then a catheter was inserted through the Tuohy needle and advanced 3cm into the space and secured in place. At 30 minutes after injection of a loading dose, the dermatomal loss of sensation to pinprick will be tested. Patients who reported pain to pinprick will be considered to have a failed block and were excluded from the study. The block will be maintained by continuous infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h via a syringe pump. The infusion was continued for 4 days.
45799406|NCT04744571|Device|coronary wires. or coronary balloons|all species of coronary wires, or plain balloons
45927369|NCT00405535|Drug|glycine|
45927370|NCT00405535|Other|placebo|
45927371|NCT01457183|Device|Pulsed lavage (Stryker Pulsavac Plus)|Healthy subjects with intact skin will be lavaged through the device for 1 minute on 3 different sites. The stryker pulsavac plus will be used for the lavage.
45927372|NCT00405574|Drug|ATN-224|ATN-224 high dose: 300mg ATN-224 low dose: 30mg
45927373|NCT02993029|Drug|99Tc-MDP|99Tc-MDP 15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.
45927374|NCT02993029|Drug|Celecoxib|Celecoxib capsule 200mg qd by mouth.
45927375|NCT01667952|Genetic|Family History Questionnaire (FHQ)|"Consented subjects will be given the Family History Questionnaire (FHQ) to complete either in clinic or at home. Subjects who chose to complete the FHQ at home will be given a stamped envelope with a label. For participants who are children and cannot fill out the questionnaire on their own, the clinic RSA will instruct the parent, guardian, or legally authorized representative (LAR) present to fill out the questionnaire, reminding them that the You in the questionnaire refers to their child."
45927376|NCT01667952|Genetic|Salvia sample|The saliva samples will be collected in Oragene DNA Self-Collection Kits or a similar product. Patients will be instructed to donate about 2ml of saliva into a vial, which contains 2ml of product. Oragene or similar solution.
45927377|NCT01667952|Other|Blood sample|Subjects will be offered the option of a blood collection instead of saliva. For adult subjects who opt for blood collection, two tubes of blood (approximately 20cc) will be drawn from the utilizing a sterile technique. For subjects under the age of 18 who opt for blood collection, approximately 3-5cc of blood will be collected utilizing a sterile technique.
45799407|NCT04744571|Other|drug-coated balloon|Drug-coated balloon including all sizes and all brands
45650344|NCT03103711|Behavioral|Virtual Reality Intervention|"Participants receive two sessions oriented to joy and two focused on relax. In the first 2 sessions patients can choose the environment (Emotional Parks or Walk through Nature) and in the following ones participants visit the alternate environments."
45927378|NCT02825641|Drug|Oxytocin|"Labor induction and cervical ripening by oxytocin in women with premature rupture of membranes in 2 types of women:~Induction of labor on presentation at the delivery room.~Induction of labor after 24 hours of rupture of membranes."
45927379|NCT02825641|Drug|Dinoprostone|"Labor induction and cervical ripening by dinoprostone in women with premature rupture of membranes in 2 types of women:~Induction of labor on presentation at the delivery room.~Induction of labor after 24 hours of rupture of membranes."
45927380|NCT02777047|Other|Anticoagulation Coordinated Care|see above
45927381|NCT01646034|Drug|carboplatin, thiotepa, and cyclophosphamide|tandem intermediate-dose alkylating therapy: carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
46072336|NCT05030298|Radiation|Radiation Therapy|Undergo radiation therapy
46072337|NCT05030298|Radiation|Radiosurgery|Undergo radiosurgery
46072338|NCT05030298|Procedure|Stereotactic Biopsy|Undergo MRI-guided stereotactic biopsy
45650345|NCT03044015|Behavioral|community based integrated strategy for secondary prevention of OF|Educational programme on pharmacological treatment, diet recommendations, physical activity programme on OF prevention in primary care
45650346|NCT03044015|Behavioral|as usual|
45650347|NCT05430607|Behavioral|Running therapy|A 9-week running program.
45650348|NCT04847219|Device|Professional flash glucose mornitoring|Subjects will use Professional flash glucose mornitoring once a month for 3 months.
45799408|NCT04744571|Device|drug-eluting stent|Drug-eluting stent including all sizes and all brands
45799409|NCT00363155|Drug|KRN7000|
45799410|NCT02518997|Other|Parental Reading Aloud|Infants will be exposed to parental reading aloud or to a recording of the parent's voice reading during times of cardio-respiratory monitoring.
45799411|NCT02519387|Drug|Buprenorphine Transdermal Patch|
45799412|NCT02519621|Device|NPWT PRO without irrigation|NPWT PRO without irrigation.
45799413|NCT02519621|Device|NPWT PRO with irrigation|NPWT PRO with irrigation (saline)
46072339|NCT05030298|Drug|Temozolomide|Drug
46072340|NCT05030298|Procedure|Therapeutic Conventional Surgery|Undergo surgery
46072341|NCT05030298|Procedure|Tumor Treating Fields Therapy|Undergo TTF
45650349|NCT04847219|Device|Personal flash glucose mornitoring|Subjects will use Personal flash glucose mornitoring once a month for 3 months.
45799414|NCT02519621|Device|KCI Ulta|KCI Ulta NPWT without irrigation
45799415|NCT02521181|Drug|Lower Dose Sodium Bicarbonate|Lower dose oral Sodium Bicarbonate (0.5 milliequivalents (mEq)/kg-LBW/day)
45799416|NCT02521181|Drug|Higher Dose Sodium Bicarbonate|Higher dose oral Sodium Bicarbonate (0.8 mEq/kg-LBW/day)
45799417|NCT02521181|Drug|Placebo|Oral placebo equivalent to either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of Sodium Bicarbonate
45927382|NCT01646034|Drug|chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)|"chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclofosfamide~chemotherapy naïve;1 cycle of dose-dense Adriamycin and cyclophosphamide followed by 4 cycles of carboplatin and paclitaxel~previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel~previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine"
45927383|NCT04711057|Other|Community-based PA program|After completing the PR program, the experimental group (EG) will enroll in a 6-month personalized community-based PA program, which should be attended twice-weekly, minimum. During the first month the physiotherapist will guide patients through all available physical activities; afterwards, patients will be asked to choose one or two activities, according to their preference, which they'll attend for five more months. Physiotherapists' support will gradually decrease over time.
45927384|NCT04711057|Other|Pulmonary Rehabilitation|Exercise training, twice a week, and education and psychosocial support once every other week during 12 weeks.
45927385|NCT02720302|Behavioral|SOFT|SOFT is based on systemic and solution-focused theories to change lifestyle and has shown positive effects on children with respect to the degree of obesity, physical fitness, self-esteem and family functioning.
45927386|NCT02720302|Behavioral|TeleSOFT|The therapists communicate with the overweight child and his/her family by the SOFT method on distance by use of video.
45799418|NCT02521259|Device|BIS|BIS monitoring provides the patient's depth of consciousness, enables us to monitor safe, optimal anesthesia for each patient.
45799419|NCT02257177|Drug|Inhaled TD139|DPI Galectin-3 inhibitor
45799420|NCT02257177|Drug|Placebo|DPI placebo
45799421|NCT02257957|Drug|PRP injection|
45799422|NCT02257957|Drug|Standard care Hyaluronic acid eye drops|: 15 patients with diagnosis of severe dry eye will receive standard of care treatment ( Hyaluronic acid eye drops 5 times per day). Objective measurements as corneal staining, Shirmer , BUT, and VA, will be determinate as subjective measurements as OSDI and treatment compliance will be evaluated at day 0-30,60 and 90
45799423|NCT02524769|Drug|conjugated estrogen|0.625 mg conjugated estrogen/gram and instructions to use 0.5 grams twice weekly with the applicator.
45799424|NCT01815229|Procedure|tracheal lavages|tracheal lavages obtained during endotracheal intubation.
45927387|NCT02708368|Other|blood withdrawal|3 times
45927388|NCT01628640|Other|Laboratory Biomarker Analysis|Correlative studies
45927389|NCT01628640|Other|Pharmacological Study|Correlative studies
45927390|NCT01628640|Biological|Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta|Given intratumorally
45927391|NCT00982982|Drug|THC and Iomazenil|"Iomazenil: 3.7 μg/kg intravenously over 10 minutes~Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. It is administered intravenously for 10 minutes."
45927392|NCT00982982|Drug|Placebo (control)|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
45927393|NCT01496313|Drug|300mg vandetanib|"Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment~Dosing with unblinded study treatment can continue until 24 months after patient was randomised.~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (200mg/day). Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur."
45927394|NCT01496313|Drug|150mg vandetanib|"Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment. Patients who have not dose reduced at the time of unblinding may have their dose increased to 300mg~Dosing with unblinded study treatment can continue until 24 months after patient was randomised~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (100mg/day) [OR 300 reduced to 200mg/day if dose was increased at unblinding.] Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur."
45927395|NCT00391313|Drug|Chloroquine|
45927396|NCT01466556|Other|Routine laboratory tests|Laboratory tests to determine metabolic syndrome
45927397|NCT00330200|Drug|ISIS 113715|
45927398|NCT01466517|Drug|Alivium®|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
45927399|NCT01466517|Drug|Ibuprofen|400mg of Ibuprofen equivalent to 10mL (40mg/mL) oral suspension of the Test Drug
45650350|NCT03799861|Other|Epoch 2: HBB with NeoBeat|At the beginning of Epoch 2, all birth attendants in each of the 3 maternity units will participate in a 2 day workshop in Kinshasa in French that will include instructions regarding use of NeoBeat and training in HBB 2.0. Participants will be introduced to NeoBeat, which will include practice with NeoBeat using the NeoNatalie newborn simulator. This training will be conducted in French using typical adapted training materials for this program that incorporate placement of NeoBeat at appropriate times in the algorithm, including a flipchart and NeoNatalie. Participants will complete the pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs) with the incorporation of use of NeoBeat into the OSCEs.
45799425|NCT01877161|Device|Repetitive magnetic stimulation to superior temporal gyrus|Repetitive magnetic stimulation to superior temporal gyrus
45799426|NCT01877161|Device|Repetitive magnetic stimulation to middle temporal gyrus|Repetitive magnetic stimulation to middle temporal gyrus
45799427|NCT01877161|Device|Repetitive magnetic stimulation (Sham)|Repetitive magnetic stimulation (Sham)
45927400|NCT00327626|Drug|ISIS 113715|
45927401|NCT01466478|Drug|Ointment A: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
45927402|NCT01466478|Drug|Ointment B: LEO 29102 2.5 mg/g ointment|once daily application, 4 weeks
45927403|NCT01466478|Drug|Ointment C: Calcipotriol 50 µg/g ointment|once daily application, 4 weeks
45927404|NCT01466478|Drug|Ointment D: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
45927405|NCT01466478|Drug|Ointment G: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
45799428|NCT02525549|Drug|Adapalene and Benzoyl Peroxide Gel|
45927406|NCT01466478|Drug|Daivonex® ointment|once daily application, 4 weeks
45927407|NCT01466478|Drug|Diprosone® ointment|once daily application, 4 weeks
45927408|NCT00063830|Drug|Alicaforsen|
45927409|NCT01466439|Procedure|high-frequency of repetitive transcranial magnetic stimulation (rTMS)|frequency of stimulation of 20 Hz
45650351|NCT03799861|Other|Epoch 3: HR-guided HBB|At the beginning of Epoch 3, all birth attendants in each of the 3 maternity units will participate in a 1 day workshop in Kinshasa in French that will instruct them in an adapted, HR-guided HBB algorithm. This training will include simulation with NeoNatalie and NeoBeat. Participants will complete a pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs).
45650352|NCT04847297|Procedure|Preoperative drainage and pancreatoduodenectomy|Preoperative biliary drainage before surgical removal of the tumor
45799429|NCT02525549|Drug|Adapalene and Benzoyl Peroxide Gel (Reference)|
45799430|NCT02525549|Drug|Placebo gel|
45799431|NCT01877941|Device|Pulmonary Artery Catheter (PAC)|A catheter is inserted into the pulmonary artery, through the internal jugular vein; cardiac output is indicated by the speed that a temperature gradient dissipates.
45650353|NCT04847297|Procedure|Pancreatoduodenectomy|Pancreatic tumor resection without previous preoperative biliary drainage
45799432|NCT01877941|Device|Endotracheal Cardiac Output Monitor (ECOM)|An FDA-approved medical device is inserted into the patient's throat; cardiac output is calculated by measuring how electricity moves through the chest.
45799433|NCT01877941|Device|Estimated Continuous Cardiac Output (esCCO)|Sensors are placed on the arm, finger and leg to calculate Pulse Wave Transit Time (PWTT); the time it takes for the pulse of the heartbeat to travel through the body.
45799434|NCT01878799|Drug|GS-7977/GS- 5885 FDC|The GS-7977/GS-5885 FDC product combines a potent HCV nucleotide inhibitor and a potent HCV NS5A inhibitor and will be given for 12 weeks.
45799435|NCT02527265|Biological|Afrezza|"Pharmaceutical form: powder~Route of administration: inhalation"
45927410|NCT01466439|Procedure|low frequency of repetitive transcranial magnetic stimulation (rTMS)|frequency of stimulation of 1 Hz
45927411|NCT00062816|Drug|ISIS 14803, peginterferon alfa, ribavirin|
45927412|NCT00048113|Drug|Alicaforsen|
45650354|NCT04737343|Drug|Leflunomide|Patient will be treated with Leflunomide(Tuoshu, the commericial name) 30mg QD for 18 months
45650355|NCT04737343|Drug|Azathioprine Tablets|Patients included into this study will be treated with Azathioprine tablets 100mg QD for 18 months.
45650356|NCT05579769|Drug|Ruxolitinib|Day +40 Dosage and Route of Administration-Ruxolitinib tablets should be administered orally BID, approximately every 12 hours, continuously, Oral
45799436|NCT01879345|Drug|BIA 2-093 - 1800 mg (Group 1)|3 tablets of BIA 2-093
45799437|NCT01879345|Drug|BIA 2-093 - 2400 mg (Group 2)|4 tablets of BIA 2-093 600 mg
45799438|NCT01879345|Drug|Placebo|placebo tablets
45799439|NCT05329207|Behavioral|Experimental group|Web Based Adolescent Health Promotion Education Program
45927413|NCT01466361|Drug|Nicotine lower dose|lower dose nicotine lozenge
45927414|NCT01466361|Drug|Nicotine higher dose|higher dose nicotine lozenge
45927415|NCT01466361|Drug|Placebo|placebo
45927416|NCT00035945|Drug|ISIS 14803|
45927417|NCT01466322|Drug|GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state|Four single dosing sessions where each regimen A,B C or D will be administered orally in a randomised, cross-over manner. At each dosing session, pharmacokinetic sampling time-points will be the same.
45927418|NCT01466283|Genetic|DNA methylation analysis|
45927419|NCT01466283|Genetic|fluorescence in situ hybridization|
45927420|NCT01466283|Genetic|gene expression analysis|
45927421|NCT01466283|Genetic|reverse transcriptase-polymerase chain reaction|
45927422|NCT01466283|Other|laboratory biomarker analysis|
45927423|NCT00001832|Drug|gp100:209-217 (210M)|"gp100 = gp100:209-217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209-217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.~MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections."
45927424|NCT00001832|Drug|Montanide ISA-51|MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
45927425|NCT00001832|Drug|IL-2|"125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.~720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses."
45799440|NCT05329051|Biological|SCTV01E|intramuscular injection
45799441|NCT05329051|Biological|Comirnaty|intramuscular injection
45799442|NCT01804075|Drug|Methadone|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
45799443|NCT01804075|Drug|Morphine|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
45799444|NCT02416193|Drug|Cholecalciferol|Participants will take randomly assigned high dose cholecalciferol once weekly for three months
45799445|NCT02416193|Drug|Cholecalciferol|Participants will take randomly assigned active comparator cholecalciferol once weekly for three months
45799446|NCT02530151|Drug|Morphine with clonidine|see arm description
45799447|NCT02530151|Other|Normal saline|see arm description
45799448|NCT02530541|Drug|CHG|Varied application times
45799449|NCT02416973|Device|Provant|
45927426|NCT00001832|Drug|MART-1:26-35(27L)|MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
45927427|NCT00001832|Biological|Abl cells|Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
45927428|NCT00001832|Drug|Fludarabine|5x25 mg/m^2 intravenous
45927429|NCT00001832|Drug|Cyclophosphamide|2x30 mg/kg, 2x60 mg/kg intravenous
45650357|NCT05579769|Drug|Mesna|Days -3 and -2 Dosage and Route of Administration-Mesna is dosed based on the cyclophosphamide dose and generally administered in fractionated doses at approximately 20% of the total cyclophosphamide dose, Intravenous.
45927430|NCT00001832|Biological|GCSF (Growth colony stimulating factor)|Beginning on day 1 or 2, GCSF will be administered subcutaneously at a dose of 5mcg/kg/day (not to exceed 300 mcg/day. Filgrastim administration will continue daily until neutrophil count > 1.0 x10^9/L x 3 days or > 5.0 x10^9/L.
45927431|NCT00001832|Procedure|Apheresis|
45927432|NCT01466244|Biological|cetuximab|
45927433|NCT01466244|Drug|cisplatin|
45927434|NCT01466244|Genetic|gene expression analysis|
45927435|NCT01466244|Genetic|microarray analysis|
45927436|NCT01466244|Other|immunohistochemistry staining method|
45927437|NCT01466244|Other|laboratory biomarker analysis|
45927438|NCT01466205|Drug|DAR-0100A|DAR-0100A will be administered intravenously in a dose of 15mg in 150mls of saline over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
45927439|NCT01466205|Drug|Placebo|150mls of saline is administered over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
46072342|NCT05013073|Other|ASTHMAXcel ED Application|A mobile application designed to assist patients in asthma symptom recognition, treatment best practices, and trigger identification.
45450760|NCT02198092|Other|Epi proColon Testing|"Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.~For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C."
45450761|NCT02198170|Drug|ketoconazole-placebo|Treatment Period 1: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period. Treatment Period 2: Placebo orally once daily + single oral dose of 5 mg lenvatinib of fifth day on 19-day treatment period.
45650358|NCT05579769|Drug|Anti-thymocyte globulin (ATG)|Days -3, -2 and -1 Dosage and Route of Administration-(7 mg/kg total dose); intravenous.
45650359|NCT05579769|Drug|Cyclosporine|Day -1 Dosage and Route of Administration-3 mg/kg; dose will be adjusted to maintain a steady concentration between 250-350 ng/mL or trough concentration between 175-250 ng/mL when transitioned to intermittent dosing.
45650360|NCT05579769|Drug|Cyclophosphamide|Days -3 and -2 Dosage and Route of Administration-60 mg/kg for 2 consecutive days, (120 mg/kg total dose); intravenous.
45650361|NCT05579769|Drug|Fludarabine|Days -4, -3 and -2 Dosage and Route of Administration-50 mg/m2 daily for 3 consecutive days (150 mg/m2 total dose) intravenous
45927440|NCT01466127|Drug|Oxytocin|Liquid metered-dose nasal spray, 30 IUs, administered once.
45927441|NCT01466127|Drug|Placebo|Matched nasal spray placebo
45927442|NCT00009191|Drug|Sertraline [Zoloft]|
45927443|NCT01466088|Drug|Donepezil|Subjects taking donepezil will take 1-2 capsules of 5 mg donepezil and a placebo for AZD3480 (to maintain blind) orally once a day.
45927444|NCT01466088|Drug|AZD3480|Subjects taking 30 mg AZD3480 will take one capsule of AZD3480 and two capsules of placebo for donepezil (to maintain blind) orally once a day.
45927445|NCT00009230|Drug|Celecoxib|
45927446|NCT00009542|Drug|kava (Piper methysticum)|
45927447|NCT00009581|Drug|L-NMMA|
45927448|NCT00009581|Drug|Acetylcholine|
46072343|NCT05007925|Device|Intravascular Lithotripsy|Localized peripheral intravascular lithotripsy
45927449|NCT01466010|Procedure|surgical removal of osteoid osteoma|surgery for osteoid osteoma: this may include curettage or en-bloc resection of the lesion
45927450|NCT00009620|Drug|Phenobarbital|10 mg of phenobarbital per kilogram of body weight intravenously over a period of 20 to 40 minutes (maximal dose, 1000 mg)
45927451|NCT00009620|Drug|Saline|Infusion of normal sal
45927452|NCT00009659|Drug|CDB 2914|
45927453|NCT01465932|Other|Control, no Proprioception|The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 1 (control group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff and cryotherapy.
46072344|NCT04994795|Other|Predictive models (data collection)|Machine learning predictive models
46073726|NCT02820480|Device|Rehab in a Crate System|"The therapy gym is Rehab in a Crate with 4 stations for upper and lower limb assessment/therapy. Each station will allow adaptive game-based therapy.~Note: The device is not being used at this moment for diagnostic or evaluation. Users will be asked to explore the device, try the systems, and provide feedback about use."
45927454|NCT01465932|Other|Experimental, Proprioceptive exercises|The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 2 (experimental group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff exercises and cryotherapy as well as proprioceptive sensory-motor
45927455|NCT00009698|Biological|aldesleukin|Given SQ and IV
45927456|NCT01465893|Drug|Vitamin D|vitamin D ,50000 unit /week
45927457|NCT01465893|Drug|Vitamin D withheld|do not receive anything
45927458|NCT00009776|Biological|monoclonal antibody Lym-1|
45927459|NCT00009776|Drug|cyclosporine|
45927460|NCT00009776|Drug|paclitaxel|
45927461|NCT00009776|Radiation|indium In 111 monoclonal antibody Lym-1|
45927462|NCT00009776|Radiation|yttrium Y 90 monoclonal antibody Lym-1|
45927463|NCT00009815|Drug|etoposide|
45927464|NCT00009815|Drug|leucovorin calcium|
45927465|NCT00009815|Drug|tegafur-uracil|
45927466|NCT01465815|Drug|erlotinib hydrochloride|Given PO
45450762|NCT02198170|Drug|placebo-ketoconazole|Treatment Period 1: Placebo orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period
45650362|NCT05579769|Drug|Methotrexate|Days +1, +3, +6 and +11 Dosage and Route of Administration-10 mg/m2/dose, intravenous
45650363|NCT05579769|Radiation|Total Body Irradiation (radiation treatment)|"Days -7, -6, -5 and -4 6.2.3 Target Dose 1200 cGy total dose delivered 150 cGy per treatment fraction delivered BID over 4 days with 6 MV photons.~Dose rate should be < 10 cGy/min in patients treated at extended SSD (450-500 cm) in the TBI couch and will be less than 15 cGy/min in young children and infants treated at extended SSD (200-220 cm) on the floor.~Intra-fraction interval should be 6 hours. Custom posteriorly placed (PA only) partial transmission lung shields (blocks) will be used to reduce the average dose to the lung to approximately 1000 cGy total dose.~An additional 400 cGy supplemental testicular radiation delivered in 2 fractions of 200 cGy delivered for males with lymphoid lineage leukemia."
45650364|NCT05579769|Drug|Bone marrow infusion|Day 0
45799450|NCT01804465|Drug|SipT Treatment|"All patients will receive standard of care SipT treatment every two weeks for a total of 3 treatments. The three treatments usually take about 30 days to complete.~SipT treatment is given in three 1 hour infusions. Each SipT treatment is generated from a standard blood cell-collection procedure (called leukapheresis) performed 2-3 days prior to the infusion."
45799451|NCT01804465|Drug|Ipilimumab|Ipilimumab will be given by IV over 90 minutes every 3 weeks. Patients will be monitored during the infusion and up to 1 hour post-infusion.
45450763|NCT02198248|Drug|Rituximab|Patients will be administered rituximab (375mg/m2/w x4 infusions) for reducing glucocorticoid dose in remission induction phase.
45650365|NCT05579769|Drug|Busulfan|Days -4, -3 and -2 Dosage and Route of Administration-3.2 mg/kg/day; intravenous.
45799452|NCT02531321|Drug|Levonorgestrel and Ethinyl Estradiol|All participants will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days. Pharmacokinetics and pharmacodynamics will be compared between participants using antiretroviral regimens including ritonavir-boosted protease inhibitors and those using regimens that do not interact with oral contraceptives.
45799453|NCT02531867|Biological|Asfotase Alfa|
45927467|NCT01465815|Drug|linsitinib|Given PO
45927468|NCT01465815|Drug|placebo|Given PO
45927469|NCT01465815|Radiation|radiation therapy|Undergo radiation therapy
45927470|NCT01465815|Procedure|therapeutic conventional surgery|Undergo planned surgery
45927471|NCT01465815|Other|laboratory biomarker analysis|Correlative studies
45927472|NCT00009854|Drug|carmustine in ethanol|
45927473|NCT00009854|Procedure|conventional surgery|
45927474|NCT01465776|Other|laboratory biomarker analysis|Correlative studies
45927475|NCT01465776|Other|preventative dietary intervention|lyophilized black raspberries(LBR) administration: 3 LBR troche lozenges (dissolved in mouth), 4 times/day beginning at minimum of 24 hrs following biopsy until night before surgery
45927476|NCT00009893|Drug|fluorouracil|
45927477|NCT00009893|Drug|gemcitabine hydrochloride|
45927478|NCT00009893|Drug|leucovorin calcium|
45927479|NCT01465737|Other|Histologic types|evaluate survival among different histologic types
45927480|NCT01465698|Behavioral|Exercise|"The main target for exercise intervention is to restore impairments in movement control. First, the participants need to learn the proper technique of each exercise, second to achieve movement control of lumbar neutral zone in each exercise, and finally to increase the challenge of exercises for balance, coordination, muscular endurance and strength. Target dose for exercise is twice a week, 60 minutes per session for six months.~The neuromuscular exercise program is progressive including three different performance levels. During the first eight weeks, the supervised exercise sessions will take place twice a week. The next 16 weeks the participants have one instructed weekly session, and they exercise once a week at home with help of a DVD or booklet produced for the study"
45927481|NCT01465698|Behavioral|Counseling|Counseling is conducted according cognitive-behavioral principles. Fear-avoidance model is implemented using problem based learning. The objective is to change participants' understanding of LBP towards less fearful and negative beliefs, and to provide encouragement for usual daily activities, including physical activity. Advice on nursing tasks that are strenuous for low back is aimed to improve awareness of injury risk and provide examples of proper postures and movements. The target is that participants in counseling groups attend 10 sessions each lasting 45 minutes. During the first four weeks the groups meet every second week, and after that once a month up to six months. Participants will receive workbooks to enhance problem-based learning.
45927482|NCT01465698|Behavioral|Exercise and counseling|Participants take part in both exercise and counseling as described in the separate interventions.
45799454|NCT01805089|Drug|Melatonin 3 mg|Melatonin vs. Placebo
45799455|NCT01409629|Behavioral|Computer game|Participants will play a computer game
45927483|NCT01465698|Other|Control group|Participants in the control group take part only in measurements of NURSE-RCT.
45927484|NCT00009971|Drug|fenretinide|
45927485|NCT01465620|Behavioral|hygienic-dietetic measures|Therapeutic education about hygienic-dietetic measures followed by a 5 minutes phone call per week during 3 months
45927486|NCT01465620|Behavioral|hygienic-dietetic measures|Therapeutic education about hygienic-dietetic measures followed by only one phone call
45927487|NCT00010010|Drug|exemestane|
45650366|NCT05579769|Drug|Thiotepa|Days -6 and -5 Dosage and Route of Administration-(10 mg/kg total dose); intravenous
45650367|NCT04480723|Other|Blood Sample|Blood samples will be taken and analyzed to evaluate the presence of PH.
45927488|NCT00010010|Drug|goserelin acetate|
45650368|NCT04480723|Diagnostic Test|Cardiac MRI|Cardiac MRI will be performed to evaluate the presence of PH.
45799456|NCT02417129|Drug|Rituximab|BI 695500 375 mg/M2
45927489|NCT01465581|Procedure|Division of the filum terminal|Division of the filum is performed through a 6cm incision over the lumbosacral junction that can be oriented either longitudinally or transversely - to be hidden beneath underclothes or swim wear. A single level laminectomy provides sufficient exposure. The dural opening can be as short as 1cm. Under the microscope the filum is identified visually and separated from lower sacral rootlets with the aid of microelectrode stimulation. When a segment of the filum has been excised and sent for laboratory examination, the dura is closed and reinforced with fibrin glue. The wound is closed in layers, and the patient is kept at bed rest horizontal for 2 nights to discourage CSF fistulization of the wound.
45927490|NCT00010049|Drug|imatinib mesylate|
45927491|NCT00010088|Drug|fluorouracil|
45927492|NCT00010088|Drug|gemcitabine hydrochloride|
45927493|NCT00010088|Drug|leucovorin calcium|
45650369|NCT04862819|Drug|new local drug delivery|In the first group, on one side of the dental arch, the drug under evaluation will be used, and on the other side srp
45650370|NCT04862819|Procedure|scaling root planing|In the second group, on one side of the dental arch srp will be performed
45650371|NCT03776149|Dietary Supplement|Beetroot juice|Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
45650372|NCT03776149|Dietary Supplement|Black currant juice|Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
45927494|NCT00010088|Procedure|conventional surgery|
45927495|NCT00010088|Radiation|radiation therapy|
45927496|NCT01465503|Drug|Bivalirudin|Patients randomized to Bivalirudin group will be treated by bivalirudin before and during the procedure. Bivalirudin will be given as bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.The infusion will be lowered to 1.0 mg/kg per hour in patients with eGFR <30 ml/min/1.73 m2.
45927497|NCT01465503|Drug|Unfractionated Heparin|Patients randomized to the Control group will receive unfractionated heparn (UFH) before and during the procedure. UFH bolus will be of 70 UI/kg. If the activated clotting time measured 5 minutes after the study drug administration is lower than 270 seconds, an additional bolus of the randomised drug (UFH 20 U/kg) will be given.
45927498|NCT00010127|Biological|therapeutic autologous dendritic cells|
45927499|NCT00010166|Drug|gemcitabine hydrochloride|
46073727|NCT02822430|Other|Pain scales|"Visual analogic scale of pain~Pain behaviour scale~Short-FormHealth Survey (SF-36)~Clinical Global impression~Mini International Neuropsychiatric Interview (MINI)"
46073728|NCT02546635|Drug|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
45650373|NCT04854239|Procedure|Half-guided implant placement|The surgery was performed under local anaesthesia in both groups, half-guided implant placement was carried out based on randomization.
45650374|NCT04161157|Behavioral|Pathways|Goal-setting intervention to help patients identify personal values, value-consistent goals, and ways to pursue goals and address goal obstacles. Although potential refinements may occur based on aim 1 (refining procedures and content with 6 patients), Pathways is designed to consist primarily of 2 in-person sessions (~30-60 minutes) delivered when patients are in clinic for cancer treatment, with supporting phone calls and contact in between sessions.
45799457|NCT02417129|Drug|BI 695500|BI 695500 375 mg/M2
45799458|NCT01879735|Drug|11C-CSar|PET/CT recording with bile acid tracer 11C-cholylsarcosine used to evaluate the transport of bile acids.
45799459|NCT01879735|Drug|ICG|Infusion of indocyanine green prior and during the PET/CT scanning with the bile tracer 11C-CSar.
45799460|NCT02417831|Drug|tamsulosin capsules|
45799461|NCT02417831|Drug|tamsulosin HCl|
45799462|NCT02271451|Device|Q collar|collar worn around neck
45799463|NCT02419547|Drug|Versed|Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
45799464|NCT02419547|Drug|Fentanyl|Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
45799465|NCT02419547|Drug|Propofol|Phase 2: Standard induction of GETA with intravenous agent then programed stimulation to induce ventricular tachycardia
45799466|NCT02419547|Drug|Sevoflurane|Phase 3: Standard induction of GETA with inhalent agent then programed stimulation to induce ventricular tachycardia
45799467|NCT02273323|Other|Tea|Single dose of black tea infusion containing approximately 400 mg flavonoids (expressed as gallic acid equivalents) with added sugar.
45799468|NCT02273323|Other|Placebo|Placebo: tea flavour, colouring and sugar
45799469|NCT02274649|Behavioral|one-to-one peer mentoring|Each patient received one-to-one peer mentoring each week during rehabilitation and for 90 days post discharge
45927500|NCT00010166|Procedure|adjuvant therapy|
45927501|NCT00010166|Radiation|radiation therapy|
45927502|NCT01465308|Dietary Supplement|Honey mouthwash|The patients in the intervention group will receive honey mouthwash 15 minutes before the radiotherapy session, 15 minutes after and 6 hours after the radiotherapy session
45927503|NCT01465308|Other|Normal Saline|Saline rinses 15 minutes before radiotherapy, 15 minutes after, and 6 hours after radiotherapy
45927504|NCT00391352|Drug|IFN-β-1a (Rebif®)|44 mcg Three times a week, subcutaneous injection
45927505|NCT01465269|Behavioral|Group Interactive Structured Treatment|GIST groups consist of 8 group participants and two group therapists. Group members receive the workbook and are asked to bring it to each session. During each of the 13, 1.5 hour sessions, key concepts from the previous session are reviewed, a new topic is discussed, strategies and skills are practiced interactively, and real-life social problems are addressed. Previously covered topics are integrated into each session through discussion and problem solving to provide repetition and reinforcement of information.
45927506|NCT01465269|Behavioral|Alternative Intervention|Participants in the alternative treatment will attend 13 weekly classroom sessions, where they will view video presentations of the same curriculum topics covered in the GIST workbook. The group therapists will serve as moderators and will meet with participants individually. Group interaction will not be encouraged. Homework exercises will be offered but participants will not be asked to return their homework and will not receive any feedback.
45927507|NCT00010205|Drug|benzoylphenylurea|Given orally
45927508|NCT00010205|Other|pharmacological study|Correlative studies
45927509|NCT01465152|Drug|metformin|Adminstered orally during the three main meals for 24 weeks
45450764|NCT02198248|Drug|Glucocorticoids|"Low-dose group commenced 0.5mg/kg/day, then taper and stop within 6 months following pre-defined schedule.~High-dose group commenced 1.0mg/kg/day, then taper to 10mg/day within 6 months following pre-defined schedule."
45650375|NCT05578911|Other|"medical students group"|medical student in general practice or in specialty medicine
45650376|NCT02724631|Device|TubeClear® intervention|The TubeClear® device is deemed by the Food and Drug Administration (FDA) to be non-significant risk (NSR) for use in this study. It is a control box and a single use clearing stem used to resolve the clog in an enteral access device within five minutes following the intervention.
45927510|NCT01465152|Drug|repaglinide|Administered orally before the three main meals for 24 weeks
45927511|NCT01465113|Drug|Omeprazole|28-day run-in phase during which subjects are treated with a proton pump inhibitor (omeprazole 20 mg po q day or an equivalent dose of another proton pump inhibitor).
45927512|NCT01465113|Drug|Vitamin D3|These patients (indefinite for dysplasia, LGD, or no dysplasia) will take vitamin D3 50,000 IU once a week for 12 weeks following the upper endoscopy.
45927513|NCT01465113|Drug|Vitamin D3|Due to the risk of progression, subjects with Barrett's esophagus with high grade dysplasia will take vitamin D3 50,000 IU once a week for 2 weeks.
45927514|NCT01465113|Procedure|upper endoscopy|After the run-in phase subjects will undergo an upper endoscopy for Barrett's surveillance or Barrett's mapping as part of routine clinical care. At the time of endoscopy, in addition to large cup forceps biopsies obtained for surveillance or mapping as part of standard care, research biopsies will be obtained for the study. Following vitamin D3 supplementation, all subjects will undergo a repeat upper endoscopy for additional large cup forceps biopsies for measurement of post-treatment mucosal levels.
45927515|NCT01465113|Drug|Metformin|500mg for the first week, 1000mg during the second week, 1500mg during the third week, maximum dose of 2000mg in the fourth week
45927516|NCT00010244|Radiation|radiation therapy|
45927517|NCT01465074|Drug|Nicotine polacrilex|4 mg
45927518|NCT01465074|Drug|Regular chewing gum; Dentyne Ice, Wrigely´s Mint Gum|30 min chewing, one dose
45927519|NCT00010283|Drug|beclomethasone dipropionate|
45927520|NCT00010322|Drug|atamestane|
45927521|NCT00010322|Drug|toremifene|
46073729|NCT02546635|Drug|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
45650377|NCT03760783|Other|Parabolic flight|Sperm analysis (total motility M/ml; grade a+b sperm M/ml, vitality, DNA Frag and apoptosis) will be measured on ground at 1g before the flight and after flight were sperm samples have been exposed to simulated microgravity
45799470|NCT02274649|Behavioral|general peer support|General (traditional) peer support includes introduction and provision of support services upon request
45799471|NCT02533427|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily
45799472|NCT02533427|Drug|VOX|100 mg tablet administered orally once daily
45799473|NCT02533427|Drug|Norgestimate/ethinyl estradiol|Norgestimate 0.180 mg/0.215 mg/0.25 mg/ethinyl estradiol 0.025 mg tablet administered orally once daily according to the package insert
45799474|NCT05328817|Drug|Antibiotics|In the absence of labor, broad-spectrum antibiotics (often called latency antibiotics) are recommended for women with PPROM less than 34 weeks to reduce chorioamnionitis, prolong latency, and decrease neonatal sepsis (12,13).
45799475|NCT05328739|Other|home care|home care program
45927522|NCT01465035|Biological|TIV and MVA-NP+M1|1.5 x 108 pfu MVA-NP+M1, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
45927523|NCT01465035|Biological|Saline placebo and seasonal influenza vaccine TIV|Saline placebo, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
45927524|NCT00010361|Drug|cyclosporine|
45927525|NCT00010361|Drug|fludarabine|
45927526|NCT00010361|Drug|mycophenolate mofetil|
45927527|NCT01464996|Procedure|Adhesive: OptiBond XTR; Composite: Herculite Ultra|The intervention in Arm 1 (Adhesive: OptiBond XTR; Composite: Herculite Ultra) is a 2-step, self-etching adhesive.
45927528|NCT01464996|Procedure|Adhesive: OptiBond FL; Composite: Herculite Ultra|Arm 2 (Adhesive: OptiBond FL; Composite: Herculite Ultra) is a 3-step, etch-and-rinse adhesive.
45927529|NCT00010400|Drug|Cyclophosphamide|
45927530|NCT00010400|Drug|filgrastim|
45927531|NCT01464957|Behavioral|Semi-tailored newsletter|Delivered over 3 consecutive years, in the spring
46073730|NCT02821494|Biological|Hespecta|A dose escalation of Amplivant® conjugated peptide
46073731|NCT00842491|Drug|endostar, cisplatin, capecitabine|"Product 1: endostar~Dosing schedule: 15mg daily dose, d1-14~Mode of administration: intravenously"
45927532|NCT02061605|Device|Laser Tissue Welding Device|Laparoscopic partial nephrectomy will be robotically assisted using the second generation da Vinci® Surgical System. Once the tumor is resected with laparoscopic scissors with a margin of healthy tissue, the solder will be dripped onto the cut surface of the parenchyma. A laparoscopic rigid 5mm spot-size laser hand-piece will be passed through the 10-mm port. The diode laser will be then used to weld a thin layer of solder onto the cut parenchymal surface. The 60 Watt 810-nm diode laser will be set to deliver continuous energy. During soldering, the tip of the laparoscopic laser hand-piece will be maintained 1 to 2 cm from the renal surface to generate a spot size of approximately 5 mm. Each spot will be treated with the laser until the color of the solder changes from green to white. The renal pedicle clamp will be removed to allow renal blood supply to be restored and the surgical site inspected for evidence of bleeding for 10 minutes prior to completing the surgical procedure.
45927533|NCT01464918|Device|Endoscopic submucosal dissection (ESD) using device, MASTER|Performing endoscopic submucosal dissection (ESD)of the gastric/colon cancer using the device, MASTER
45927534|NCT00010478|Procedure|Acupuncture|
45927535|NCT01464840|Drug|Azithromycin|500 mg intravenous infused over 1 hour
45927536|NCT01464801|Dietary Supplement|Resveratrol|Tablet Resveratrol 500 mg 3 times daily for 6 months
45927537|NCT01464801|Dietary Supplement|Placebo|Tablet Placebo 3 times daily for 6 months
45927538|NCT00010517|Procedure|Acupuncture|
45650378|NCT05373849|Dietary Supplement|essentiel oil mixtures in inhaler sticks (step 1) - no intervention (step 2)|The participant will receive the study treatment (essential oils mixture in inhaler sticks for 2 months) and the control (no intervention for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed
45927539|NCT00010634|Drug|Connective Tissue Nutrient Formula|
45927540|NCT00010634|Drug|Adaptogenic herbs|
45927541|NCT00010634|Drug|glutamine|
45927542|NCT01464762|Drug|TMC207|400mg once daily by mouth for 2 weeks followed by 200mg by mouth three times per week for 22 weeks + individualized background of antibacterial drugs
45927543|NCT02035358|Biological|HyperAcute®-Renal (HAR) Immunotherapy|"HyperAcute®-Renal Immunotherapy consisting of equal cell doses of each of two allogeneic renal cell cancer cell lines (HAR1 and HAR2) engineered to express the murine α(1,3)GT gene.~Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization."
45927544|NCT00010712|Drug|Black Cohosh|
45927545|NCT01464723|Drug|Ranibizumab|Intravitreal injections of 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
45927546|NCT00010829|Behavioral|American Heart Association Step 1 diet|
45650379|NCT05373849|Dietary Supplement|no intervention (step 1) - essential oils mixture in inhaler sticks (step 2)|The participant will receive the control (no intervention for 2 months) and the study treatment (essential oils mixture in inhaler sticks for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed.
45650380|NCT03754231|Other|Heart rate monitoring|"The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing"
45650381|NCT03754231|Other|Respiratory rate monitoring|"The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing"
45650382|NCT05400213|Device|Vallos|Demineralized freeze-dried bone allograft (DFBA) in a small particle form
45650383|NCT05400213|Device|Vallomix|A combination of cow-derived xenograft and human-derived DFDBA particulate
45799476|NCT05328661|Diagnostic Test|Blink reflex|The stimulator is directly connected to the right side of the frontal board. The sponge must be soaked in water or saline before being inserted into the stimulator. Dry them a bit to avoid leaking on the stimulator (it could create a bridge between the two poles). We want to stimulate the supraorbital nerve at its emergence from the eyebrow arch (the supraorbital foramen in the supra-orbital margin bone is easy to palpate 1 cm laterally to the root of the nose). We place the stimulator above the emergence of the supraorbital nerve, with the distal pole placed below. The final intensity of stimulation is generally between 5 to 10 mA, but higher intensities sometime are required.
45927547|NCT00010829|Behavioral|American Heart Association Step 2 diet + 10 g/day flax seed|
45927548|NCT00010829|Behavioral|Macrobiotic dietary intervention|
45927549|NCT01464645|Device|Modular Revision Hip System|Hip System that is indicated for patients whose bone stock is of poor quality or inadequate for other reconstruction techniques as indicated by deficiencies of the femoral head, neck or portions of the proximal femur.
45650384|NCT05400213|Device|Vallos-F|Demineralized freeze-dried bone allograft (DFDBA) in a fiber form
45650385|NCT05400213|Device|Vallomix-F|A combination of cow-derived xenograft and human-derived DFDBA fibers
45650386|NCT02609399|Drug|Oseltamivir|Oral
45650387|NCT02609399|Drug|Peramivir|"IV~Note: Subjects admitted to the hospital directly from the ED Enrollment Visit may receive more doses at the discretion of the treating physician."
45650388|NCT05430217|Drug|Buspirone|1 tablet (15 mg) once per day for 28 days
45650389|NCT05430217|Drug|Placebo|1 placebo tablet once per day for 28 days
45650390|NCT05430061|Dietary Supplement|slowly digestible carbohydrate|carbohydrates with slow digestion rate have the capacity to induce slow gastric emptying time and potentially modify metabolic response and modulate postprandial glycemia.
45927550|NCT00010868|Drug|Omega-3 Fatty Acids|
45927551|NCT01464606|Drug|Vincristine|≥ 3 years: 1.5 mg/m2 IV x 1 (maximum dose 2 mg)
45927552|NCT01464606|Drug|Dactinomycin|≥ 3 years: 0.045 mg/kg (maximum dose 2.5 mg) IV X 1
45927553|NCT01464606|Drug|Cyclophosphamide|≥ 3 year: 1.2 gm/m2/dose IV as 1 hr infusion with IV fluids
45927554|NCT01464606|Drug|Ifosfamide|≥ 3 years: 3 g/m2/dose IV over 3 hours on Days 1, 2, (6 g/m2/cycle)
45927555|NCT01464606|Drug|Doxorubicin|≥ 3 years: 30 mg/m2/dose IV over 30 min, Days 1, 2 (60 mg/m2/cycle)
45927556|NCT00010907|Drug|NPI-028|
45927557|NCT01464567|Procedure|"T Tube Spontaneous Breathing Trial"|"T Tube ventilation for 30 minutes"
45927558|NCT01464567|Procedure|Pressure Support Ventilation|Pressure-Support Ventilation for 30 minutes
45927559|NCT00010946|Procedure|Acupuncture|
45927560|NCT00010985|Procedure|Acupuncture|
45927561|NCT00010985|Procedure|Chiropractic|
45927562|NCT00010985|Procedure|massage|
45927563|NCT01464528|Drug|Hyaluronan|single use of 10 mL of the hyalobarrier gel intrauterine immediately following hysteroscopic surgery
45927564|NCT00011024|Procedure|Self Hypnosis|
45927565|NCT00011024|Procedure|Acupuncture|
45927566|NCT00011024|Procedure|Osteopathic Manipulation|
45927567|NCT00393744|Drug|pristinamycin|50 mg/kg/d in 2 doses for children, and 1g twice daily in adults for 4 days
45650391|NCT05373771|Other|Care pathway|Implementation of care pathway as part of hybrid type 2 implementation effectiveness study
45650392|NCT04853927|Drug|Proxalutamide|Proxalutamide 300mg q.d suspension
45799477|NCT05328583|Drug|HRS5685；Placebo|"Drug1: HRS5685 Single dose in group A-F and multiple doses in group G-H~Drug2: Placebo Single dose in group A-F and multiple doses in group G-H"
45799478|NCT05328427|Other|Stopping|Discontinuation of nucleoside analogue
45799479|NCT05748535|Device|Auricular Vagus Nerve Stimulation|First of all, the application will be explained to the participants and a signed consent form for the application will be obtained from the individuals. Groups; It will be in the form of Right Ear Stimulation, Left Ear Stimulation and Bilateral Ear Stimulation group. Non-invasive auricular vagus nerve stimulation will be applied to all participants with a VAGUSTIM device, biphasic, frequency 10 Hz, pulse width 300 μs in Modulation mode, and current intensity for 20 minutes for 10 sessions, keeping the current constant at the point where the participant feels the current comfortably. Before and after each application, pulse variability (rmssd, LF/HF, pNN50, LF, HF) and blood pressure measurements will be taken from both the right index finger and left index finger. Before the first session and after the 10th session, pain level will be evaluated with the Numerical Pain Rating Scale, and disability level related to headache will be evaluated with the Headache Impact Test.
45799480|NCT01816945|Behavioral|MOMBA web-based application|Web-based, interactive, social network application.
45799481|NCT02533505|Drug|Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol|Subjects will receive a single dose (2 inhalations) of Symbicort pMDI 160/4.5 μg (2 inhalations; total dosage 320/9.0 μg) or placebo (with a spacer) in a cross-over design (a total of 2 doses of Symbicort and 2 doses of placebo over the duration of the study), and assessments will be made before and after dosing at specified timepoints
45799482|NCT02533505|Drug|Matching Placebo pMDI 160/4.5 μg|Placebo will be given according at the same dose and schedule as the active comparator - cross-over design.
45799483|NCT01817491|Other|American Heart Association Diet|
45799484|NCT01817491|Other|Reduced Fat Vegan Diet|
45799485|NCT05328271|Dietary Supplement|Beta-Aminoisobutyric Acid|All supplements provided to all research participants containing BAIBA, L-Valine or placebo will be procured and prepared in a similar manner. Briefly, beta-amino isobutyric acid (BAIBA), L-Valine (an amino acid), and a resistant starch commonly consumed in various foods will be used as test agents for this study protcol. All supplements (both BAIBA and Valine) as well as placebo are produced and provided by NNB Nutrition. A certificate of analysis is provided in the attachments for the BAIBA. All supplements (BAIBA, L-Valine, and placebo) will be administered in gelatin capsules and consumed with a specified amount of cold tap water. The same number of capsules will be administered each time. All doses will be capsulated by manufacturer prior to use in the study protocol.
45927568|NCT00393744|Drug|amoxicillin|50 mg/kg/d in 2 doses in children and 1 g twice daily in adults for 6 days
45927569|NCT00011063|Drug|Ginkgo Biloba|
46072345|NCT04987034|Device|EchoTip® Insight™|Patients will undergo procedure where HVPG is obtained under mild sedation, next the patients will undergo anesthesia and mechanical intubation where HVPG measurements will be obtained simultaneously with the EchoTip Insight measurement. For patients receiving a transjugular intrahepatic portosystemic shunt (TIPS), direct portal vein pressure measurements will be obtained by the EchoTip® Insight™ and compared to the transjugular direct portal vein measurement obtained during the interventional radiology (IR) procedure.
45650393|NCT04853927|Drug|Placebo|Proxalutamide 300mg q.d placebo
45650394|NCT03103555|Drug|Bortezomib|Bortezomib will be subcutaneously administered in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
45650395|NCT03103555|Drug|Cyclophosphamide|Low dose cyclophosphamide will be given orally for 4 month after completion 2 cycles of bortezomib
45799486|NCT02481557|Device|Oxalate Salt Solution|Applied by dentist
45927570|NCT04711980|Drug|Mudan granule|"Mudan granule,a traditional Chinese medicine formula,consists of nine Chinese herbs.~Other: Standard medical care.Standard medical care is in accordance with China Guideline for type 2 diabetes (2013)."
45927571|NCT04711980|Drug|Placebo|"Granule(Placebo) is in accordance with Mudan granule in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013)."
45927572|NCT00011102|Behavioral|Weight Gain Prevention for Women Project|
45927573|NCT00393822|Drug|palifermin|dose of 120 μg/kg, intravenous (IV) on day -3 for each cycle, for up to 6 chemotherapy cycles
45650396|NCT04846751|Behavioral|TYPE OF EXERCISE (OR REST)|continous exercise in normal temperature, continous exercise in hot environment, intervallic exercise in normal temperature.
45927574|NCT00393822|Drug|placebo|one bolus IV injection at 120 μg/kg/day of matched placebo
45927575|NCT00011141|Drug|Oral lactobacillus administration|
45927576|NCT00011258|Drug|Paraoxonase|
45927577|NCT00011297|Drug|gabapentin (Neurontin)|
45927578|NCT00011297|Drug|lorazepam (Ativan)|
45927579|NCT00847977|Drug|use of a non balced fluid and of a macromolecular fluid|Physiological serum: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Heafusine: boli 10 ml/kg on 20 minutes
45927580|NCT00847977|Drug|use of balanced crystalloids fluid and macromolecular fluid|Isofundine: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Tetraspan: boli 10 ml/kg on 20 minutes
45927581|NCT00011375|Drug|Rolipram|
45927582|NCT00847938|Drug|neostigmine|0.04 mg/kg IV bolus, injection when the of train of four is > or = to 40 %
45927583|NCT00847938|Drug|neostigmine|0.02 mg/kg IV bolus, injection when the of train of four is > or = to 40 %
45927584|NCT00847938|Drug|neostigmine|0.01 mg/kg IV bolus, injection when the of train of four is > or = to 40 %
45927585|NCT00011414|Drug|Tariquidar|IV alone for 1 dose (Day -1), then in combo for rest of cycle (Day 1, etc). Given in combo with one of the following: Doxorubicin (50 mg/m2 IV over 15 min on day 1), Vinorelbine (20 mg/m2 IV over 10 min on days 1 and 8), or Docetaxel (75 mg/m2 IV over 60 min on day 1).
45927586|NCT00847899|Drug|AR9281|AR9281 taken in BID dosing regimen for 28 days
45927587|NCT00847899|Drug|AR9281|AR9281 taken in TID dosing regimen for 28 days
45927588|NCT00847899|Drug|Placebo|Placebo taken in BID dosing regimen for 28 days
45927589|NCT00847899|Drug|Placebo|Placebo taken in TID dosing regimen for 28 days
45927590|NCT00847860|Drug|Cilostazol|Cilostazol 100 mg bid for 12 months
45799487|NCT01818427|Biological|infusion of 2 units of plasma|infusion of 2 units of plasma
45799488|NCT05328193|Behavioral|Healthier Families, COVID Edition|Families randomized to this arm with receive12-weekly health coaching calls virtually with their family with topics such as nutrition, physical activity, sleep, and media use.
45799489|NCT05328193|Behavioral|Teaching Kitchen Outreach|Families receiving this intervention will recipe 11-weekly video recipes and groceries delivered to their door.
45927591|NCT00847860|Drug|Aspirin|Aspirin 100 mg qd for 12 months
45927592|NCT00847821|Drug|Bazedoxifene 10 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
45927593|NCT00847821|Drug|Bazedoxifene 20 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
45650397|NCT05417685|Device|Acute and post-acute|These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
45650398|NCT05417685|Device|Chronic|These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
45650399|NCT05417685|Device|Post-surgical|These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
45650400|NCT04853771|Behavioral|progressive muscle relaxation exercise training|Progressive muscle relaxation exercises (PKGE); 16 large muscles (right hand and forearm, right upper arm, left hand and forearm of left arm, left upper arm, forehead, upper cheek and nose, chin, neck, abdomen, upper right arm, which people can do on their own after learning) leg, right calf, right foot, left upper leg, left thigh and left foot), followed by the contraction and then relaxation and accompanied by deep breathing, is a preferred method for reducing pain, anxiety and depression in individuals.The relaxation will be required to take 10-20 before stretching the next muscle group. In this way, the muscle groups in the hands, arms, neck, shoulder, chest, abdomen, hips, feet and fingers, face and the whole body will be voluntarily stretched and relaxed, and pregnant women will be relieved.
45650401|NCT02720185|Drug|Dasatinib|100mg oral once daily dasatinib taken for 7-10 days up to the day prior to planned surgery or research biopsy (neoadjuvant chemotherapy group)
45650402|NCT02720185|Procedure|Conventional Surgery|Undergo surgery
45650403|NCT02720185|Other|Laboratory Biomarker Analysis|Correlative studies
45927594|NCT00847821|Drug|Bazedoxifene 40 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
45927595|NCT00847821|Drug|Bazedoxifene 10 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
45927596|NCT00847821|Drug|Bazedoxifene 20 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
45927597|NCT00847821|Drug|Bazedoxifene 40 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
45927598|NCT00847821|Drug|Raloxifene 60 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as raloxifene tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
46072346|NCT04983264|Drug|GBT021601|Tablets and capsules which contain GBT021601 drug substance
46072347|NCT04981756|Other|observation|This observational study does not have any intervention.
46072348|NCT04975516|Drug|Chemotherapy|Given chemotherapy
46072349|NCT04975516|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
46072350|NCT04943900|Drug|BMS-986416|Specified dose on specified days
46072351|NCT04943900|Drug|Nivolumab|Specified dose on specified days
45650404|NCT04846673|Drug|Pregabalin 150mg + Alpha-lipoic acid 480mg|Pregabalin qd + alpha-lipoic acid qd
45927599|NCT00847821|Drug|Placebo|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as placebo capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
45927600|NCT00011531|Procedure|Prevention of Pressure Ulcers|
45927601|NCT00009932|Drug|cisplatin|
45927602|NCT00009932|Drug|fenretinide|
45927603|NCT00009932|Drug|paclitaxel|
45799490|NCT05327881|Diagnostic Test|Plasma renin concentrations will be measured at enrollment and at 24, 48, and 72 hours. Whole blood lactate measurements will be performed according to normal standard of care.|"Measurement of Whole Blood Lactate Concentrations:~Whole blood lactate concentrations were measured using ABL 800 series analyzers. The IRB (Institutional Review Board) protocol specified that lactate concentrations could be obtained as part of routine care, but lactate concentrations were not measured independently for research purposes.~Measurement of Plasma Renin Concentrations:~Discarded whole blood samples (waste blood samples) in EDTA (ethylenediaminetetraacetic acid) (BD Vacutainer, 4 mL) tubes were prospectively collected from each patient at the time of study enrollment and at 24, 48, and 72 hours.~Plasma active renin levels were measured using the active renin enzyme-linked immunosorbent assay kit (DRG International, Township, NJ)"
46072352|NCT04928235|Diagnostic Test|Thermal Imaging as Diagnostic Adjunct|Thermal images of the participants lower extremities will be taken and skin surface temperature values will be provided to the healthcare provider for review during the emergency department encounter.
45927604|NCT00010751|Procedure|Reiki|
45927605|NCT00011570|Device|Bladder & Bowel Control|
46072353|NCT04921956|Drug|Concizumab|Injected under the skin (subcutaneous, sc) once daily, individual dose adjustment.
45799491|NCT02420015|Drug|Nicotine replacement therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
45927606|NCT00847782|Procedure|Blood draw|1 day
45799492|NCT02420015|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up
46072354|NCT04913675|Biological|sotrovimab|Sotrovimab 500 mg given by intravenous infusion over 15 min
45650405|NCT04846673|Drug|Pregabalin 150mg|pregabalin qd
45799493|NCT02420015|Behavioral|cognitive-behavioral smoking cessation counseling|Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
45799494|NCT02420015|Behavioral|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
45927607|NCT00011609|Device|Robotic Arm|
45650406|NCT04846673|Drug|Alpha-Lipoic Acid 480mg|alpha-lipoic acid qd
45650407|NCT04846283|Procedure|Elective or emergency colorectal surgery for cancer, diverticular disease, inflammatory bowel-disease or reversal of Hartmann's procedure|We considered all the procedures that required an intestinal anastomosis in colo-rectal surgery
45927608|NCT00847743|Dietary Supplement|Tart Cherry Juice|8 fl.oz. twice per day
45927609|NCT00847587|Drug|Etonogestrel contraceptive implant|Implant insertion postpartum prior to hospital discharge
45927610|NCT00847587|Drug|Etonogestrel contraceptive implant|Standard insertion at 4-8 weeks postpartum
45927611|NCT00847548|Behavioral|substance abuse/domestic violence treatment|This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse.
45927612|NCT00847548|Behavioral|CBT addressing partner violence|This treatment is comprised of 16 sessions of cognitive behavioral therapy addressing partner violence.
45927613|NCT00011765|Drug|Fluoxetine|
46072355|NCT04913675|Biological|sotrovimab|Sotrovimab 500 mg given by intramuscular injection
46072356|NCT04913675|Biological|sotrovimab|Sotrovimab 250 mg given by intramuscular injection
46072357|NCT04913675|Biological|sotrovimab|Sotrovimab 2000 mg given by intravenous infusion over 60 min
46072358|NCT04913675|Biological|Sotrovimab|Sotrovimab 2000 mg given by intravenous infusion over 30 min
45650408|NCT05398497|Device|Cryoablation|Cryoablation will be performed under ultrasound guidance.
45650409|NCT03040739|Other|use of O'ARM imaging system|use of O'ARM imaging system
45653213|NCT05611463|Drug|Camrelizumab Plus Docetaxel and Cisplatin|Camrelizumab (200 mg) was administered once on day 1 every 3 weeks until disease progression, intolerable toxicity, physician or participant decision or 35 cycles, whichever occurred first. Chemotherapy was received docetaxel (75 mg/m2) and cisplatin (75 mg/m²) on day 2 every 3 weeks for six cycles.
45927614|NCT00847509|Drug|[F-18]FLT|The individual doses of [F-18]FLT contain a maximum of 10 mCi. The single IP dose is administered to the study subject approximately 30 to 60 minutes prior to the start of PET imaging.
45927615|NCT00011804|Drug|Topiramate|
45927616|NCT00011921|Biological|filgrastim|
45927617|NCT00011921|Drug|carboplatin|
45927618|NCT00011921|Drug|epirubicin hydrochloride|
45927619|NCT00011921|Drug|etoposide|
45927620|NCT00011921|Drug|etoposide phosphate|
45927621|NCT00011921|Drug|ifosfamide|
45927622|NCT00011921|Drug|paclitaxel|
45927623|NCT00011921|Procedure|autologous bone marrow transplantation|
45927624|NCT00011921|Procedure|bone marrow ablation with stem cell support|
45927625|NCT00011921|Procedure|peripheral blood stem cell transplantation|
45927626|NCT00011921|Radiation|radiation therapy|
45927627|NCT00847392|Procedure|Ultrasound prior to bladder catheterization|Bedside ultrasound to estimated volume of urine in bladder
45927628|NCT00011960|Drug|cisplatin|
45927629|NCT00011960|Drug|paclitaxel|
45927630|NCT00011960|Procedure|adjuvant therapy|
45927631|NCT00011960|Radiation|radiation therapy|
45799495|NCT02420015|Behavioral|Stay Quit Coach|Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
45927632|NCT00847314|Drug|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients > 35yrs in medical practices fulfilling all criteria for documentation.
45927633|NCT00011999|Drug|cisplatin|
45799496|NCT02420015|Behavioral|SMS text messaging|Patients assigned to this condition will receive text messages relevant to their current status in their smoking quit attempt, including messages reminding participants to take their smoking cessation medication.
45799497|NCT05748457|Behavioral|Non-manualised family therapy.|Family therapy provided by qualified therapists without reference to a specific therapy manual.
45927634|NCT00011999|Drug|paclitaxel|
45927635|NCT00011999|Procedure|conventional surgery|
45927636|NCT00011999|Radiation|radiation therapy|
45927637|NCT00847275|Other|Exclusive nephrology follow-up|"250 patients will be included and randomized in the exclusive nephrology follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring."
45927638|NCT00847275|Other|Geriatric follow-up|"250 patients will be included and randomized in geriatric follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. Patients randomized in the geriatric follow-up arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status."
45799498|NCT05748457|Behavioral|Family Based Treatment|"Family therapy implemented according to the published Treatment manual for anorexia nervosa: A family-based approach by Lock & Le Grange (2nd edition, 2015)."
45799499|NCT05748379|Procedure|Kompozite closure|Immediate implant placement and temporary closure of tapered implants with a custom-made composite shaper.
45927639|NCT00012038|Drug|irofulven|
45927640|NCT00847158|Procedure|phacoemulsification alone|phacoemulsification alone
45927641|NCT00847158|Device|iStent Trabecular Micro-Bypass Stent|phacoemulsification and implantation of the iStent® trabecular micro-bypass stent
45650410|NCT04498273|Drug|Apixaban 2.5 MG|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 2.5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
45799500|NCT05748379|Procedure|Individual abutment|Immediate implant placement and temporary closure of tapered implant with a custom-made zirconium oxide abutment.
45799501|NCT05748301|Other|AI Clinician|N/A - Study is observational study testing the feasibility of running the AI Clinician in real time.
45799502|NCT02481713|Behavioral|motivational interviewing|motivational interviewing
45799503|NCT02481713|Behavioral|learning style interviews|interview and feedback about learning style
45927642|NCT00012116|Drug|temozolomide|Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.
45927643|NCT00847119|Biological|Bevacizumab|Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.
45927644|NCT00847119|Drug|capecitabine (Xeloda)|Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period
45927645|NCT00847119|Radiation|Rectal Radiotherapy|Radiotherapy in rectum 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.
45927646|NCT00012155|Biological|NV1020|
45927647|NCT00847080|Drug|Sitagliptin phosphate|Sitagliptin phosphate 100 mg per day per 2 weeks
45927648|NCT00847080|Drug|Placebo|Placebo 1 tablet per day per 2 weeks
45927649|NCT00012194|Drug|7-hydroxystaurosporine|Given IV
45927650|NCT00012194|Drug|cisplatin|Given IV
45927651|NCT00012194|Other|laboratory biomarker analysis|Correlative studies
45927652|NCT01818323|Other|Intra-tumoral T4 immunotherapy|Intra-tumoral administration of a single dose of T4-positive patient-derived T-cells (at five escalating dose levels) contained within 1-4 mL. Cohort 6 patients receive CAR T-cells (dose level 3) after lymphodepletion with fludarabine and cyclophosphamide
45927653|NCT00012311|Biological|filgrastim|
45927654|NCT00012311|Drug|CMF regimen|
45927655|NCT00012311|Drug|carboplatin|
45927656|NCT00012311|Drug|cyclophosphamide|
45927657|NCT00012311|Drug|docetaxel|
45927658|NCT00012311|Drug|doxorubicin hydrochloride|
45927659|NCT00012311|Drug|etoposide|
45927660|NCT00012311|Drug|fluorouracil|
45927661|NCT00012311|Drug|ifosfamide|
45927662|NCT00012311|Drug|methotrexate|
45927663|NCT00012311|Drug|thiotepa|
45927664|NCT00012311|Procedure|peripheral blood stem cell transplantation|
45927665|NCT00847002|Device|Standard Wound Care|
45653214|NCT05110365|Other|Proprioceptive Neuromuscular Facilitation|"The patient will be provided with mild to moderate resistance PNF pattern which is a type of Endurance training which decreases BP through a reduction in systemic vascular resistance(15).In a regimen as follow with the frequency of 3 days a week, a repetition of 3 sets for one hour and a total duration of 3 months(16). The PNF patterns will be diagonal 1 (D1) and diagonal 2 (D2) patterns. Both patterns are subdivided into: A) Moving into Flexion: the toes start flexed and ends extended. Ankle and foot start plantar flexed; everted and ends dorsiflexed inverted. Tibia starts externally rotated and ends internally rotated. Knee starts extended, and ends flexed. The hip starts extended, abducted, internally rotated and ends flexed, adducted, externally rotated.B) Moving into Extension: The start and end are reversed to D1 Moving into Flexion"
45927666|NCT00847002|Device|Flexitouch System with Standard Wound Care|
45927667|NCT00012350|Drug|FTI|
45927668|NCT00846963|Drug|Ursodiol|"Ursodiol is given by mouth, three times a day from second value of elevated conjugated bilirubin (>33mmol/L) to the resolution of cholestasis (conjugated bilirubin <34mmol/L) If Nil per os, 3,3mg/kg/dose is given. If Nil per os is required (e.g. pre-surgery, or necrotizing enterocolitis), none is given.~If enteral feeding is under 100mL/kg/day, 6,7 mg/kg/day is given. If enteral feeding exceeds 100mL/kg/day, 10 mg/kg/day is given."
45799504|NCT01819597|Procedure|Encephaloduroarteriosynangiosis (EDAS)|The operation is a form of indirect revascularization or EC-IC bypass, performed under general endotracheal anesthesia, with intraoperative electroencephalographic monitoring. The surgery consists in the dissection and relocation of the superficial temporal artery (STA) and middle meningeal artery (MMA) branches, which are separated from their surrounding tissues under microscopic visualization and re-routed through a craniotomy to be placed intracranially in close proximity to the branches of the middle cerebral artery (MCA). The MCA branches are dissected in the arachnoid space and the STA and MMA are kept in position with microsutures to the arachnoid or MMA dural cuffs, maintaining close contact between the EC and MCA branches.
45927669|NCT00846963|Drug|placebo|Placebo given in the same amount that ursodiol would be given, depending on enteral feeding and weight. It is also given three times a day, until cholestasis resolution.
45927670|NCT00012389|Drug|irinotecan hydrochloride|
45927671|NCT00012389|Drug|oxaliplatin|
45927672|NCT00846924|Device|a 30-day ambulatory cardiac event monitor|Patients will be fitted with dry electrode belt (including cardiac event monitor)and instructed to wear the device for as many hours(waking and sleeping) each day as possible, for a total of 30 days.
45927673|NCT00846924|Device|24-hour Holter|Repeat standard 24-hour Holter Monitor
45927674|NCT00846885|Drug|Sumatriptan Succinate|100 mg Tablet
45799505|NCT02482025|Other|SMMRT|Includes My HealtheVet registration and enrollment
45799506|NCT05748223|Other|Mindfulness Meditation|Mindfulness meditation has been reported to produce beneficial effects on a number of psychiatric, functional somatic, and stress-related symptoms and has therefore increasingly been incorporated into psychotherapeutic programs
45799507|NCT05327179|Other|Action Observation Treatment|Action Observation Treatment program will be applied to the group 1 for 3 weeks, 5 days a week, 30 minutes a day. In the videos prepared, activities including daily life activities for the wrist, elbow and shoulder (emptying water from the glass, throwing sugar into the glass, painting, using clothespins, spoons, etc.) will be included.
45927675|NCT00846885|Drug|Imitrex®|100 mg Tablet
45927676|NCT00012467|Drug|Itraconazole|
45927677|NCT00012467|Drug|Flucytosine|
45927678|NCT00012467|Drug|Fluconazole|
45927679|NCT00012467|Drug|Amphotericin B|
45927680|NCT00012467|Drug|Interferon gamma-1b|
45927681|NCT00846729|Procedure|CT angiogram of the remaining kidney.|
45927682|NCT00846729|Procedure|Kidney Function study using Iothalamate & PAH as clearance markers|
45927683|NCT00012506|Drug|TNFR:Fc|
45927684|NCT00012584|Drug|methylphenidate|
45927685|NCT00012584|Drug|fluvoxamine|
45927686|NCT00846690|Drug|benzocaine|20% benzocaine., topical placement onto site, minimal amount, for 1 minute
45927687|NCT00846690|Drug|TAC alternate gel|use 1 pump, place topically onto site, leave for 1-3 minutes
45927688|NCT00846651|Other|Colloid administration|The patients received 0.5 L colloid solution (hydroxyethylstarch 6%) or 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.
46072359|NCT04913675|Biological|Sotrovimab|Sotrovimab 2000 mg given by intravenous infusion over 15 min
46072360|NCT04913675|Biological|Sotrovimab|Sotrovimab up to 3000 mg given by intravenous infusion over 90 min
45799508|NCT05327179|Other|Virtual Rehabilitation|Virtual Rehabilitation program will be applied to the group 2 for 3 weeks, 5 days a week, 30 minutes a day. Among the games, games that will improve daily life activities for the wrist, elbow and shoulder (steering wheel, popping balloons, touching the aquarium, etc.) will be selected.
45927689|NCT00846651|Other|Crystalloid administration|The patients received 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.
45927690|NCT00846651|Drug|phenylephrine infusion|A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
45927691|NCT00012662|Behavioral|Diabetes Self Management Education|
45927692|NCT00846612|Drug|Doxil|1 cycle: 3 weeks; 30 mg/m^2, IV, every cycle
45927693|NCT00846612|Drug|Bevacizumab (Avastin)|1 cycle: every 3 weeks; 15 mg/kg, IV, beginning on cycle 2 and every cycle 20-24 hours following Doxil administration
45927694|NCT00846573|Drug|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
45927695|NCT00012740|Behavioral|Casefinding and Referral System|
45927696|NCT00012779|Behavioral|Health Education Program|
45927697|NCT00394017|Behavioral|Reminder letters|3 mailed reminder letters
45927698|NCT00012818|Behavioral|relaxation technique|
45927699|NCT00012818|Behavioral|educational program|
45927700|NCT00012857|Drug|acetaminophen 650 mg qid and placebo qid PRN. The other arm was placebo qid and acetaminophen 650 mg qid PRN|
45927701|NCT00394056|Drug|Vestipitant|NK1 receptor antagonist
45927702|NCT00394056|Drug|Vestipitant + Paroxetine|NK1 receptor antagonist and SSRI
45927703|NCT00394056|Other|Placebo|Placebo
45927704|NCT00012896|Behavioral|Telephone Care + Educational (AV Materials)|
45927705|NCT00846456|Biological|Dendritic cell vaccine with mRNA from tumor stem cells|Intradermal injection of transfected dendritic cells
45927706|NCT00012935|Behavioral|Help with decision making on prostate cancer treatment|
45650411|NCT04498273|Drug|Apixaban 5MG|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
45799509|NCT02420639|Device|Esophageal Cooling Device (ECD), manufactured by Advanced Cooling Therapy, Inc.|Use of the Esophageal Cooling Device for control of patient temperature.
45799510|NCT02989753|Dietary Supplement|VAL070-A|After randomization (V1 visit), 8 capsules per day of VAL070-A during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
45927707|NCT00846378|Procedure|Post conditioning|after 30 seconds of re-established coronary flow following the therapeutic balloon dilatation and deflation, the same balloon will be re-inflated for 30 seconds and then again deflated for 30 seconds. This procedure of balloon inflation/deflation will be performed a total of 3 to 4 times.
45653215|NCT05613257|Device|Distal targeting jig|Patients in this arm will have an assistive targeting device used for interlocking screw placement. The targeting device is attached to the nail proximally or distally (for antegrade or retrograde nailing, respectively) to guide screw placement through the other end of the intramedullary device.
45927708|NCT00846378|Procedure|Usual Care for STEMI|Usual care for treatment of TIMI 0 to TIMI 1 flow in occluded infarct related artery. Usual care includes reperfusion of the artery per operator discretion, i.e. primary stenting, thrombectomy, balloon inflation/deflation without timed intervals.
46072361|NCT04926285|Drug|Omacetaxine|Escalating doses of Omacetaxine 0.625 mg/m2 q12h, 1.25 mg/m2 q12h, 2.0 mg/m2 q12h, and 2.5 mg/m2 q12h
46072362|NCT04926285|Drug|Venetoclax|Venetoclax at 400mg
46072363|NCT04899284|Other|Early Intensive Bimanual Stimulation|Early intensive bimanual stimulation program for infants showing early signs of UCP, delivered by the family environment, in the child's familiar surroundings, under the guidance of a therapist, over a period of 2 months.
46072364|NCT04895033|Behavioral|Responsibility condition|During the fMRI scan, participants will complete alcohol purchase task paradigm for hypothetical alcohol rewards under two conditions. In the next-day responsibility condition, we will present a vignette describing a drinking scenario in which participants have a significant activity the next day (e.g., a work, family, or academic obligation the next morning) and participants are asked to imagine they are deciding how much they want to drink in this situation. The control condition will use a vignette describing a typical drinking scenario with no explicit responsibilities the next day
46072365|NCT04894370|Biological|Sample collection|"PBMC collection at baseline, after radiotherapy 8 Gy (gray), at 6 months and at 12 months from inclusion: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell [PBMC] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection at baseline, after radiotherapy 8 Gy, at 6 months and at 12 months from inclusion: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection at baseline, at 2, 6 and 12 months from inclusion: two EDTA tube of 4 ml should be frozen in each investigation center for ctDNA collection."
45799511|NCT02989753|Dietary Supplement|VAL070-B|After randomization (V1 visit), 8 capsules per day of VAL070-B during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
45927709|NCT00012974|Behavioral|GTelephone-administered Cognitive-Behavioral Therapy (T-CBT)|
45927710|NCT00012974|Procedure|Provider education, computer reminders, nurse case management|
45927711|NCT00846339|Drug|Bupropion|bupropion
45927712|NCT00013013|Procedure|Systems Support|
45927713|NCT00846300|Behavioral|Physician counseling for health behavior change|Physician counseling for health behavior change, compared to a no-counseling comparison group
45927714|NCT00013052|Behavioral|Peer led classes. Led by trained veterans with a chronic disease.|
46072366|NCT04867369|Drug|Pecs II block|Patients will receive an interscalene nerve block with 15 mL 0.5% bupivacaine + a Pecs II fascial plane block with 20 mL 0.25% bupivacaine
46072367|NCT04867369|Drug|Surgical infiltration|Patients will receive an interscalene nerve block with 20 mL 0.5% bupivacaine + local infiltration of 0.25% bupivacaine by the surgeon, up to 15 mL
45799512|NCT02989753|Dietary Supplement|Placebo|After randomization (V1 visit), 8 capsules per day of placebo during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
45927715|NCT00846261|Device|Use it to treatment bone nonunion (Ilzarov)|Detect the variation of limb lengthening
45927716|NCT00013091|Behavioral|Self-management therapy; Psychoeducational group therapy|
45927717|NCT04733352|Other|acupuncture|to conduct acupuncture on different acupoints
45799513|NCT05326867|Device|Infiltration of 2% Lidocaine with Needle|Infiltration of 2% Lidocaine with Needle
45927718|NCT00013130|Behavioral|Provision of health status information to patients provider|
45927719|NCT00846222|Procedure|Hypothermia|Mild therapeutic hypothermia, 33-34 celsius, for 12 hours
45927720|NCT00013169|Behavioral|Strong Patient Focus|
45927721|NCT00846183|Procedure|local injury|In one group, on the day of oocyte retrieval, local injury to endometrium with a Novak curet to anterior and posterior wall of endometrium are performed
45927722|NCT00013208|Behavioral|Case Management|
45799514|NCT05326867|Device|Infiltration of 2% Lidocaine without Needle|Free needle infiltration of lidocaine can be an alternative to reduce epidural needle insertion pain. The study of Gozdemir et al. found that 10% lidocaine infiltration without needle was less painful than 2% lidocaine infiltration with a 27G needle with no significant difference in analgesia effect during epidural needle insertion. This study aimed to compare infiltration of lidocaine with and without needle for epidural needle insertion
45927723|NCT00846144|Dietary Supplement|copper sulfate|copper sulfate 3mg/d for a period of 6 months
45927724|NCT01790360|Behavioral|Patient Navigation (PN) Intervention|Patient Navigation is defined as an individual relationship between a navigator and participant to promote retention in the continuum of HIV care . For this study, three experienced navigators will be hired. Their primary role will be to ensure that participants are linked to an HIV primary care provider, that they attend at least one scheduled visit within three months of receiving a confirmed HIV diagnosis, and that they are retained in care (as defined by attending three HIV visits within nine months of diagnosis). To promote linkage to HIV care, navigators will help participants identify material and other barriers to accessing care and will work with participants to overcome those barriers.
45927725|NCT01790360|Behavioral|Financial Incentives (FI) Intervention|After confirmation that they have completed their first HIV primary care visit, Financial Incentive participants will receive a gift card. Additionally, the coordinator will flip a coin and give participants a bonus gift card if the coin flip comes up heads. Participants who attend the second HIV primary care visit will receive a gift card. Patients who attend a third HIV primary care visit will receive a gift card. Study staff will be responsible for confirming participants' attendance at appointments.
45927726|NCT00846105|Other|Rapid MRSA PCR test for screening carriers|In the rapid test intervention arm, all patients admitted to study wards will be sampled within 24 h after admission. To ensure comparison of like with like, sample taking will include: (1) a swab from the anterior nares for PCR testing according to the test manufacturer's instructions; (2) the swab of anterior nares, and swabs from throat, perineum and of any wounds, bladder catheter or intravenous catheter exit site will be processed by conventional testing.
45927727|NCT00013247|Behavioral|Prostate Cancer Screening Education|
45927728|NCT00846066|Other|Hands on training|Hands on training by a pediatric dentist on preventive oral health
45927729|NCT00846066|Other|Web based training|Web based training alone
45927730|NCT00013286|Device|Prevention Diabetic Foot Ulcer|
45927731|NCT00845988|Drug|aripiprazole|dosage form : po recommended dosage : more than 10mg/day duration : 28 weeks
45927732|NCT00013325|Procedure|Cardiac Disease|
45927733|NCT00013364|Behavioral|Talker variability|
45927734|NCT00845910|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of every 3 week cycle
45927735|NCT00845910|Drug|capecitabine [Xeloda]|900mg/m2 po on days 1-14 of every 3 week cycle
45927736|NCT00845910|Drug|docetaxel|60mg/m2 iv on day 1 of every 3 week cycle
45927737|NCT00013403|Procedure|Blindness|
45927738|NCT00778206|Drug|Kuvan|-Recommended post-partum Assessments include: collection of baby's plasma at Birth, 1 Month and 6 months, and collection of mother's plasma and expressed breast milk sample at 1 Month.
45927739|NCT00013442|Procedure|Auditory Evoked Response|
45927740|NCT00013481|Procedure|Stroke Rehabilitation|
45927741|NCT00680628|Drug|Tenecteplase + Enoxaparin|"Enoxaparin: 1 mg/kg within 12 hours before receiving tenecteplase.Subsequently, patients will receive 1 mg/kg enoxaparin SQ Q12 hours until discontinuation is clinically indicated.~Tenecteplase:will be administered using a tiered-dosing schedule according to patient weight: <60Kg=30mg; ≥60Kg to <70Kg=35mg; ≥70Kg to <80Kg=40mg; ≥80Kg to <90Kg=45mg; ≥90Kg=50mg"
45927742|NCT00680628|Drug|0.9% Saline + Enoxaparin|Enoxaparin: 1 mg/kg within 12 hours before receiving saline.
45927743|NCT00013520|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
45927744|NCT00013520|Drug|Atazanavir|
45927745|NCT00013520|Drug|Lamivudine/Zidovudine|
46072368|NCT04858854|Other|Sulforaphane, administered as Broccoli sprout extract|Patients will randomized to BSE or Control Group. The group BSE will receive the sulforaphane, administered as broccoli sprout extract for 12 weeks. The dose will increase every four weeks if no side-effects are reported (50 µmmol/day; 100 µmmol/day and 150 µmmol/day, respectivelly). The Control group will receive a placebo (maltodextrin sprayed with copper-chlorophyllin) for the same period (12 weeks). The BSE/placebo will be administered as powder provided in 10 ml of water in the morning in a double-blind manner as dry mixtures in sealed portion size bags of similar shape and size.
45799515|NCT05326789|Device|REBOA catheter|balloon occlusion of the aorta during cardiac arrest to optimize coronary and cerebral perfusion.
45927746|NCT00013520|Drug|Abacavir sulfate|
45927747|NCT00013520|Drug|Efavirenz|
45799516|NCT05324995|Drug|Multimodal Drug|The Multimodal Drug group received morphine, epinephrine, and ketorolac (n=48), The epinephrine group (placebo group) (n=49) received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary,and the celecoxib group(control group)(n=49) recieved 400mg celecoxib orally
45927748|NCT00013520|Drug|Nevirapine|
45927749|NCT00013520|Drug|Lamivudine|
45927750|NCT00013520|Drug|Stavudine|
45927751|NCT00013520|Drug|Zidovudine|
45927752|NCT00013520|Drug|Didanosine|
45927753|NCT00394134|Behavioral|Interview|Interviews to describe the sun exposure and sun protection practices of patients and their children.
45927754|NCT00013598|Drug|Pioglitazone|
45927755|NCT04711746|Biological|blood sample|Blood sample withdrawal in order to perform DNA sequencing
45927756|NCT00277017|Drug|5-Flourouracil, Interferon-a, IL-2 and Thalidomide|"Patients will receive oral dosages of Thalidomide at 200mg/day to start, with dosage gradually increasing up to a max of 1200mg/day. This will be taken in combination with:5-fluorouracil, given by continuous IV infusion over 24 hours (Day 1) every week for 4 weeks.~Interferon-α, given subcutaneously on Day 1, 3 and 5 of every week for 4 weeks. Interleukin-2, given by continuous IV infusion Days 2-5, every week for 4 weeks.~Treatment will be followed by 2 weeks of rest then repeated."
45927757|NCT02972177|Procedure|Radiofrequency ablation|Transbronchial radiofrequency ablation will be performed under the guidance of navigation bronchoscopy.
45927758|NCT02972177|Procedure|Microwave ablation|Transbronchial microwave ablation will be performed under the guidance of navigation bronchoscopy.
45650412|NCT04498273|Drug|Aspirin|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Aspirin twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
45799517|NCT05324995|Drug|epinephrine|The second group received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary
45799518|NCT05324995|Drug|celecoxib|The third group administered celecoxib (200 mg) orally immediately before the surgery
45799519|NCT05318521|Drug|Placebo|The 800mg ibuprofen sustained-release tablet is the same as the next generation of ibuprofen sustained-release tablets developed by foreign pharmaceutical companies, but does not contain a placebo that the active ingredient of ibuprofen
45927759|NCT00276978|Drug|Aripiprazole|Addition of Aripiprazole 10 mg to concurrent medication
45927760|NCT00276939|Behavioral|Low-fat, low-Glycemic Index, vegan diet|
45927761|NCT00013793|Behavioral|Motivational enhancement and ultrasound|
45927762|NCT00276900|Drug|Sertraline|
45927763|NCT00276861|Drug|gemcitabine hydrochloride|
45927764|NCT00276861|Drug|oxaliplatin|
45927765|NCT00013871|Biological|Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed|
46072369|NCT04856566|Drug|Low Marijuana, Hash, THC, or Grass|Cannabis with low amount of THC
46072370|NCT04856566|Drug|High Marijuana, Hash, THC, or Grass|Cannabis with high amount of THC
45927766|NCT00013871|Biological|Measles-Mumps-Rubella Vaccine (Live)|
45927767|NCT00013871|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|
45927768|NCT00013871|Biological|Pneumococcal Conjugate Vaccine, Heptavalent|
45927769|NCT00013871|Biological|Hepatitis B Vaccine (Recombinant)|
45927770|NCT00276822|Other|communication intervention|Patient Education Programs to include surveys, questionnaires, interviews, and videos.
46072371|NCT04856566|Drug|Placebo|Placebo drug with no THC
46072372|NCT04856566|Drug|0.05 BAC Alcohol|Amount of alcohol when consumed leads to BAC of 0.05
46072373|NCT04856566|Drug|0.08 BAC Alcohol|Amount of alcohol when consumed leads to BAC of 0.08
46073732|NCT00842491|Drug|capecitabine|"Product 2: capecitabine~Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks~Mode of administration: orally"
45927771|NCT00013910|Drug|NNC 90-1170|
45927772|NCT00276783|Drug|pemetrexed|Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
45927773|NCT00276705|Drug|cisplatin|
45927774|NCT00276705|Drug|cyclophosphamide|
45927775|NCT00276705|Drug|doxorubicin hydrochloride|
45927776|NCT00276705|Drug|thalidomide|
45927777|NCT00276705|Procedure|adjuvant therapy|
45927778|NCT00276705|Procedure|conventional surgery|
45927779|NCT00276705|Procedure|neoadjuvant therapy|
45927780|NCT00014027|Drug|Docosahexaenoic acid (DHA)|
45927781|NCT00014027|Drug|Eicosapentaenoic acid|
45927782|NCT00276666|Drug|cisplatin|
45927783|NCT00276666|Drug|lomustine|
45927784|NCT00276666|Drug|vincristine sulfate|
45927785|NCT00276666|Procedure|adjuvant therapy|
45927786|NCT00276666|Radiation|radiation therapy|
45927787|NCT00014066|Drug|hematoporphyrin derivative|
45927788|NCT00014066|Radiation|brachytherapy|
45927789|NCT00014105|Drug|carboplatin|
45927790|NCT00014105|Drug|temozolomide|
45927791|NCT00276627|Behavioral|communication lecture|lecture on communication skills with oncology patients
45927792|NCT00276627|Behavioral|lecture plus CD-ROM|Interactive CD-ROM about responding to patients' negative emotions. The CD-ROM included tailored feedback on the oncologists' own recorded conversations.
45927793|NCT00014144|Drug|gefitinib|
45927794|NCT00276588|Drug|carboplatin|
45927795|NCT00276588|Drug|gemcitabine hydrochloride|
45927796|NCT00276588|Drug|paclitaxel|
45927797|NCT00276549|Drug|docetaxel|docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
45927798|NCT00276549|Drug|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8 followed by docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
45927799|NCT00014183|Drug|gefitinib|
45927800|NCT00014261|Biological|PEG-interferon alfa-2b|
45927801|NCT00014261|Drug|temozolomide|
45927802|NCT00276510|Drug|EGb 761® (Tanakan®)|120 mg, 1 tablet twice a day, oral route, during 5 years.
45927803|NCT00276510|Other|Placebo|1 tablet twice a day, oral route, during 5 years.
45927804|NCT00014300|Drug|glufosfamide|
45927805|NCT00014339|Drug|Wobe-Mugos E|
45927806|NCT00014339|Drug|melphalan|
45927807|NCT00014339|Drug|prednisone|
45927808|NCT00014339|Procedure|quality-of-life assessment|
45927809|NCT00014378|Drug|Chinese Herb Huanglian (Coptis chinesis)|Patients will receive capsules of the powdered extract of the huanglian root, which will take by mouth 4 times a day (qid).
45927810|NCT00276471|Device|Implantable pulse generator and electrodes|
45927811|NCT00014456|Biological|filgrastim|
45927812|NCT00014456|Drug|docetaxel|
45927813|NCT00014456|Drug|gemcitabine hydrochloride|
45927814|NCT00276432|Device|iSTAT point of care analyzer|
45927815|NCT00276393|Drug|Basal insulin|
45927816|NCT00014534|Biological|filgrastim|6 mg sub Q
45927817|NCT00014534|Drug|cisplatin|60 mg/sq m IV
45650413|NCT04498273|Drug|Placebo|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study placebo will be shipped to subjects home. Subjects will take placebo twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
45927818|NCT00014534|Drug|doxorubicin hydrochloride|50 mg/ sq m IV
45927819|NCT00014534|Drug|gemcitabine hydrochloride|1000 mg/ sq m IV for Gem + cis arm and 2000 mg/sq m IV for gem + dox + peg arm
45927820|NCT00276354|Drug|PEG 4000 (Forlax ®)|
45927821|NCT00014573|Biological|aldesleukin|
45799520|NCT05318521|Drug|Ibuprofen modified release tablet 800 mg|Medication: ibuprofen modified sustained release tablets 800 mg Ibuprofen sustained Release Tablet 800mg is a new generation of ibuprofen developed by overseas pharmaceutical companies. It works fast and lasts for up to 12 hours. The dosing regimen was twice daily, 12 hours apart. Ibuprofen :2-[4-(2-methylpropyl) phenyl] propionic acid, nonselective nonsteroidal anti-inflammatory drug (NSAID).
45799521|NCT05312905|Other|Mirror Therapy|Mirror Therapy applied alone
45650414|NCT01660971|Drug|Dasatinib|Given PO
45650415|NCT01660971|Drug|Erlotinib Hydrochloride|Given PO
45650416|NCT01660971|Drug|Gemcitabine Hydrochloride|Given IV
45799522|NCT05312905|Other|Mirror Therapy + Cognitive Therapy|Mirror Therapy supported with Cognitive Exercises
45650417|NCT04853615|Drug|Empagliflozin 25 MG|PAtient will receive empagliflozin 25 mg daily
45650418|NCT04853537|Dietary Supplement|intermittent fasting diet|intermittent fasting diet to obese pregnant women >30 BMI and incidence of gestational diabetes
45799523|NCT02420873|Drug|Lorvotuzumab Mertansine (IMGN901)|100 mg/m2 by vein on Day 1 and 8 of a 21-day cycle.
45927822|NCT00014573|Biological|autologous tumor cell vaccine|
45927823|NCT00014573|Biological|filgrastim|
45650419|NCT02526693|Diagnostic Test|Pupillometer|The Konan RAPDx (relative afferent pupillary defect) (Konan Medical USA, Irvine, CA) pupillometer utilizes digital, high-definition, infrared machine-vision with eye-tracking and automated blink detection technology to analyze and quantify pupillary response to light.
45650420|NCT04440475|Procedure|TAP block|"Tap block description:~The skin is prepped and draped in a sterile fashion for a lateral to posterior/lateral approach to the Transverse Abdominis Plane (TAP). The Anesthesiologists use ultrasound guidance for all TAP blocks and pre mix 60cc of 0.2% ropivicaine with 10mg of preservative free dexamethasone. After the plane is identified in approximately the mid axillary line, a 17g Tuohy needle is used under ultrasound guidance to enter the potential space from an anterior approach. The needle is visualized in-plane with the ultrasound probe, traversing the exterior and interior oblique muscles and penetrating through the posterior fascia of internal oblique into the transverse abdominal plane. Once the Tuohy is in place, the needle is aspirated and the plane is hydro-dissected using 0.2% Ropivicaine with 10mg of dexamethasone. The anesthesiologist will use 30ml of 0.2% Ropivicaine on each side."
45650421|NCT04862273|Diagnostic Test|Native T1 CMR|Observed method
45650422|NCT04862273|Diagnostic Test|Web-based ATTR probability estimator (Pfizer, New York)|Observed method
45650423|NCT04862273|Diagnostic Test|99mTc-DPD scintigraphy|Reference method
45799524|NCT02534129|Drug|Difinsa53|Difinsa53 cream is applied to one half of radiation field
45799525|NCT02534129|Drug|Aquaphor|Aquaphor is applied to one half of radiation field
45799526|NCT02420951|Drug|Bupivacaine|Injection of local anesthetic immediately prior to catheter removal, 24 hours postop.
45799527|NCT02420951|Other|No Intervention|No injection of local anesthetic immediately prior to catheter removal, 24 hours postop.
45799528|NCT02267083|Drug|GPX-150 for Injection|GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.
45927824|NCT00014573|Biological|sargramostim|
45927825|NCT00014573|Biological|therapeutic autologous lymphocytes|
45927826|NCT00014573|Drug|carmustine|
45927827|NCT00014573|Drug|cisplatin|
45927828|NCT00014573|Drug|cyclophosphamide|
45927829|NCT00014573|Drug|paclitaxel|
45927830|NCT00014573|Procedure|autologous bone marrow transplantation|
45927831|NCT00014573|Procedure|conventional surgery|
46073733|NCT00842491|Drug|cisplatin|"Product 3: cisplatin~Dosing schedule: 80mg/m2, day 1 of every 3 weeks~Mode of administration: intravenously"
45799529|NCT02534285|Device|hearing protection|Attenuation of hearing during surgery
45799530|NCT05748145|Drug|Metronidazole Oral|Metronidazole will be administered per os at 500 mg x 3/day, for 10 days prior to surgery.
45927832|NCT00014573|Procedure|peripheral blood stem cell transplantation|
45927833|NCT00276315|Biological|Botulinum toxin type A|
45927834|NCT00014612|Procedure|axillary lymph node dissection|
45927835|NCT00014612|Procedure|lymphoscintigraphy|
45927836|NCT00014612|Procedure|therapeutic conventional surgery|
45927837|NCT00014612|Radiation|radiation therapy|
45927838|NCT00276276|Drug|topotecan|
45927839|NCT00014651|Drug|vapreotide|
45927840|NCT00014651|Procedure|conventional surgery|
45927841|NCT00394173|Drug|DNK333|DNK333 25mg b.i.d. given orally for 4 weeks
45927842|NCT00394173|Drug|Placebo|Matching placebo
45927843|NCT02971904|Other|human milk collection|
45927844|NCT00394290|Device|Continuous Positive Pressure|Nighttime continuous positive pressure device, to be used every day
45927845|NCT00014690|Drug|plevitrexed|
45927846|NCT00014690|Drug|topotecan hydrochloride|
45927847|NCT00014729|Drug|isotretinoin|
45927848|NCT00391547|Drug|Frio Oral Rinse|
45927849|NCT00391664|Behavioral|Psychosocial|
45927850|NCT00276198|Dietary Supplement|Sprinkles|Daily dosage of fat coated iron (desote fumarate) 12.5 mg, zinc 5mg, vitamin A 300 micrograms, folic acid 150 micrograms, ascorbic acid 50 mg.
45927851|NCT00276198|Dietary Supplement|Ferripel-3, Vitamins A&D drops|Daily dosage of Iron tonic 15mg, vitamins A 300 micrograms, vitamin D 10 micrograms once a day from age 6 months up to age 12 months
45927852|NCT00391703|Behavioral|Electrostimulation programme: using a cycloergometer|Quadriceps electrostimulation programme performed prior to an endurance retraining program using a cycloergometer, for 6 weeks, 60 to 90 minutes by session, 5 to 6 sessions per week
45927853|NCT00391703|Behavioral|Usual sport activity|Usual sport activity performed prior to an endurance retraining program using a cycloergometer
45927854|NCT00276081|Drug|Gabapentin, Estrogen and placebo administration|
45927855|NCT00014768|Drug|glucose|
45927856|NCT00014768|Drug|insulin|
45927857|NCT00014768|Drug|leucine|
45927858|NCT00276042|Drug|Faropenem Medoxomil|
45927859|NCT00014807|Behavioral|Reducing Pesticide Exposure in Minority Families|
45927860|NCT00276003|Drug|Gemcitabine, Irinotecan, Allopurinol.|Gemcitabine - 1000mg/m2; IV; d1, 8; q 21 days Irinotecan - 100mg/m2; IV; d1, 8; q 21 days Allopurinol - 300 mg; PO; day 1-5; 1st cycle
45927861|NCT00275964|Drug|TMN-1|
45927862|NCT00275925|Drug|Oxcarbazepine|
45927863|NCT00015041|Drug|Buprenorphine|
45927864|NCT00015080|Drug|Naltrexone|
45927865|NCT00275769|Device|Pacemaker|
45927866|NCT00015236|Behavioral|Amantadine|
45650424|NCT04862273|Diagnostic Test|Laboratory screening for multiple myeloma / AL amyloidosis|Reference method
45799531|NCT05747989|Procedure|two-component skin adhesive, Glubran Tiss 2|After subcutaneous stitches a two-component skin adhesive, Glubran Tiss 2®, will be applied. G Each subject will receive 0.35 mL of Glubran Tiss® in the open wound, and before bandaging, subjects rested for 20 minutes for a polymerization process.
45799532|NCT05747989|Procedure|skin is stitched with transcutaneous nylon sutures|The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0
45799533|NCT05747911|Other||Groups will not be intervened. Only observational data will be used.
45927867|NCT00015275|Behavioral|Cocaine-Related Disorders|
45927868|NCT00275730|Drug|indometacine (drug) effect on ocular blood flow|
45927869|NCT00275652|Drug|LdT (Telbivudine) and lamivudine|
45927870|NCT00275613|Drug|Rituximab|The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15)
45927871|NCT00015548|Drug|Olanzapine|
45927872|NCT00015548|Drug|Quetiapine|
45650425|NCT04862273|Procedure|Cardiac biopsy|If non-invasive tests for CA (99mTc-DPD scintigraphy, biochemistry) are inconclusive
45927873|NCT00015548|Drug|Risperidone|
45650426|NCT05573607|Dietary Supplement|Placebo|Maltodextrin tablet
45650427|NCT05573607|Dietary Supplement|Chromium|A tablet consisting of a blend of Crominex® 3+, Capros® Amla Extract (Fruit), PrimaVie® Shilajit), and MetaviveTM complex (Salacia Chinensis Extract (Fruit) and a Citrus Bioflavonoids)
45650428|NCT04435483|Drug|Acalabrutinib Treatment A|Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions. A single dose of 20 mg rabeprazole will be administered with 240 mL water, 2 hours prior to administration of acalabrutinib suspension. Treatment with rabeprazole 20 mg twice daily (with meals) will be started 3 days prior to the receiving the first dose of acalabrutinib suspension.
45650429|NCT04435483|Drug|Acalabrutinib Treatment B|Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions.
45927874|NCT00015548|Drug|Citalopram|
45927875|NCT00275574|Procedure|acupuncture|acupuncture
45927876|NCT00275535|Drug|Anti-thymocyte globulin|Thymoglobulin 1.5 mg/kg/d (days 0,1,2,4,6)
45927877|NCT00275535|Drug|Mycophenolate mofetil|Mycophenolate mofetil 750 mg p.o. b.i.d.- maintenance
45927878|NCT00275535|Drug|Prednisone|Prednisone 500 mg/day initially, tapered to 5 mg/day by day 92
45927879|NCT00275535|Drug|Tacrolimus|Tacrolimus - maintain trough levels of 6-8 ng/ml (whole blood Imx assay)
45927880|NCT00275535|Drug|Sirolimus|Rapamycin 3 to 5 mg/day; adjust to the high-performance liquid chromatography (HPLC) blood level 15 to 20 ng ml
45927881|NCT00015626|Drug|Metformin|
45927882|NCT00015626|Procedure|skin biopsy|
45927883|NCT00015626|Behavioral|diet and exercise|
45927884|NCT00015626|Drug|pioglitazone|
45927885|NCT00015626|Drug|rosiglitazone|
45927886|NCT00275496|Procedure|Sentinel Lymph Node Dissection|Subject has wide excision and sentinel lymph node dissection for primary melanoma.
45927887|NCT00275496|Procedure|Complete Lymph Node Dissection|Subject has wide excision, sentinel lymph node dissection, and complete lymph node dissection (if positive sentinel node found) for primary melanoma.
45927888|NCT00275496|Procedure|Wide Excision|Subject has wide excision only for primary melanoma.
45927889|NCT00015665|Drug|Voriconazole|
45927890|NCT00275457|Drug|pramipexole|
45927891|NCT00015704|Drug|Aldesleukin|
45927892|NCT00275418|Drug|beta carotene from Dunaliella algae|
45927893|NCT01784159|Drug|Aspirin|Aspirin administration for 7 days
45927894|NCT00275379|Drug|ERB-041|
45927895|NCT00015821|Drug|thalidomide|Given PO
45927896|NCT00015821|Other|laboratory biomarker analysis|Correlative studies
45927897|NCT00275184|Drug|Senna|
45927898|NCT00275184|Drug|Citramag powder|
45927899|NCT00275184|Drug|Metoclopramide|
45927900|NCT00015860|Drug|daunorubicin hydrochloride|
45927901|NCT00015860|Drug|imatinib mesylate|
45799534|NCT02422511|Genetic|Genomic sequencing|Both sick and healthy infants randomized to receive genomic sequencing will receive a 'Genomic Newborn Sequencing Report' (GNSR) which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
45927902|NCT00015860|Drug|prednisone|
45927903|NCT00015860|Drug|vincristine sulfate|
45927904|NCT00275145|Behavioral|Resistance Training|Lifting weights 3 times per week; 8 different exercise each time; for each exercise, do three sets = lifting an appropriate weight between 8-12 for each set; rest 45 seconds (at least) between sets
45927905|NCT00275145|Behavioral|Aerobic Exercise|Exercise at 75% of maximal capacity for approximately 2 hours per week
45927906|NCT00275145|Behavioral|Combo|Lift weights (as described in RT group) and do aerobic exercise (as described in Aerobic group
45927907|NCT00275145|Behavioral|Continued Sedentary lifestyle|No changes
45927908|NCT00015899|Drug|lonafarnib|
45927909|NCT01745783|Other|Bone marrow mesenchymal stem cells autologous|Infusion of mesenchymal cells from autologous bone marrow in a dose of 1-2x106 cells / kg
45927910|NCT01745783|Other|Placebo comparator|Lactated Ringer's solution, 2.5% glucose and 1% human albumin.
46072374|NCT04854122|Behavioral|Combined exercise intervention|The exercise intervention will last 12 weeks and will consist of a supervised combined aerobic and resistance training program with a frequency of 3 days/week. Aerobic exercise will be part of all three sessions, with resistance exercise during two out of three sessions. Training sessions will be supervised by personal trainers to ensure the safe use of the equipment and the correct form when performing each exercise. The first 3 weeks of the intervention will be familiarization with the exercises and the program. After a warm-up, the participant will perform 30 min of aerobic exercise at a heart rate of 65% of the participant's maximum heart rate [43], which increases to 65-85% during weeks 4-12 of the intervention. The resistance exercise part will include all major muscle groups, both upper and lower body.
46072375|NCT04854122|Behavioral|Usual care / Sham intervention|The control condition consists of usual activities.
45450765|NCT02195596|Other|High intensity aerobic exercise+strength|"The program consist in a Continuous High aerobic exercise and moderate intensity intervals (ShoshanaB et al, 2012) combined with muscular strength exercises and joint mobility. Patients come three times a week for six months to the primary health center and will be supervised by an expert nurse."
45650430|NCT04435483|Drug|Acalabrutinib Treatment C|Participants will receive a single dose of 100-mg acalabrutinib capsule, under fasted conditions. The acalabrutinib capsule will be administered with 240 mL of water.
45650431|NCT05372445|Behavioral|Non-intensive intervention|"After an evaluation of 7 day initial food-recall, subjects will receive counseling in order to improve their dietary habits, according to the American Diabetes Association 2019 Guidelines. The goals of this intervention are (i) achieve a caloric restriction of 500 kcal from their habitual energy intake, (ii) prioritize natural, minimally processed foods with a low glycemic index and glycemic load, (iii) eat lean protein sources, both from plant and animal origin and (iv) gradual increments of fiber intake, to achieve at least the minimum recommendations for the general population.~The frequency of the follow-up appointments will be every 4 weeks, alternating between a clinical control and nutritional one. Therefore, the planned nutritional follow-up frequency will be every 2 months. In these appointments, the objective will be to achieve the mentioned energy intake reduction of 500 kcal, aiming to the nutritional goals previously mentioned, with the aid of the food-recalls."
45799535|NCT02422511|Other|Family history report|Participants from all arms of the study will have a family history taken by a study genetic counselor. Information collected through the family history will be summarized in a family history report that will be reviewed with all participants.
45927911|NCT00275106|Drug|asparaginase|
45927912|NCT00275106|Drug|cyclophosphamide|
45927913|NCT00275106|Drug|cytarabine|
46072376|NCT04849273|Drug|TPX-0131|Oral TPX-0131 tablets
46072377|NCT04837742|Drug|ESPB group|ESPB injection at T10 region with Chirocaine 100mg(20 cc)+ Omnipaque 10cc
45799536|NCT05747833|Other|Children Preparation With a Toy IV Catheter Before Peripheral Cannula application|THE EFFECT OF PROCESSING PREPARATION WITH A TOY IV CATHETER BEFORE PERIPHERAL CANNULA APPLICATION ON CHILDREN'S PAIN, FEAR and EMOTIONAL INDICATORS
45799537|NCT02989675|Drug|10% dextrose|Bolus of 10% dextrose 5mls/kg
45927914|NCT00275106|Drug|daunorubicin hydrochloride|
46072378|NCT04837742|Drug|Control group|ESPB injection at T10 region with Normal saline 20cc + Omnipaque 10cc
46072379|NCT04827732|Radiation|Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy|When feasible it is strongly recommended that radiotherapy begin on a Monday
46072380|NCT04827732|Device|MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine|-The device that will administer the IMPT
45799538|NCT05747677|Drug|HH-120 Nasal Spray|HH-120 nasal spray, 1 spray to each nostril of the participant each time,8-10 times per day, until the discharge of the SARS-CoV-2 infected patients or confirmed infection of the participant, whichever occurs first.
45927915|NCT00275106|Drug|dexamethasone|
45927916|NCT00275106|Drug|doxorubicin hydrochloride|
45927917|NCT00275106|Drug|leucovorin calcium|
45927918|NCT00275106|Drug|mercaptopurine|
45927919|NCT00275106|Drug|methotrexate|
45927920|NCT00275106|Drug|prednisolone|
45927921|NCT00275106|Drug|thioguanine|
45927922|NCT00275106|Drug|vincristine sulfate|
45927923|NCT00275106|Procedure|radiation therapy|
45927924|NCT00015938|Biological|filgrastim|
45927925|NCT00015938|Drug|docetaxel|
45927926|NCT00015938|Drug|vinorelbine|
45927927|NCT00275067|Drug|arsenic trioxide|Arsenic trioxide administered intravenously at a dose of 0.20mg/kg Daily x 5 week then twice per week
45927928|NCT00275067|Drug|temozolomide|Temozolomide administered orally once per day 1 hour prior to radiation therapy at a dose of 75 mg/m2 x 42 days; at a dose of 200mg/m2 for 5 days every cycle (1 cycle = 28 days) after radiation therapy
45927929|NCT00275067|Radiation|radiation therapy|All patients will receive 5940-6120 cGy of radiation therapy as 28-33 treatments/fractions (180-200 cGy/treatment) depending on whether they receive standard 3-D conformal radiation therapy or intensity modulated radiation therapy.
45927930|NCT00274989|Drug|Bendamustine|"First-Line Therapy: Bendamustine i.v. 90 mg/m² day 1-2, q4wks, cycle 1 to 6~2nd to 4th -Line Therapy: Bendamustine i.v. 70 mg/m² day 1-2 q4wks, cycle 1 to 6"
45927931|NCT00274989|Biological|Rituximab|"First-Line Therapy: Rituximab i.v. 375 mg/m² day 0, q4wks, cycle 1; Rituximab i.v. 500 mg/m² day 1, q4wks, cycle 2-6~2nd to 4th -Line Therapy: Rituximab i.v. 375 mg/m² day 0, q4wks, cycle 1; Rituximab i.v. 500 mg/m² day 1, q4wks, cycle 2-6"
45927932|NCT00015977|Biological|PSA prostate cancer vaccine|
45927933|NCT00015977|Biological|recombinant interleukin-12|
45927934|NCT01678586|Other|Acupuncture|In true acupuncture the needles penetrate the skin.
45927935|NCT01678586|Other|Sham Acupuncture|In sham acupuncture the needles do not penetrate the skin.
45927936|NCT01678586|Drug|Gabapentin|Gabapentin is a commonly prescribed drug used to treat neuropathic pain.
45650432|NCT05372445|Behavioral|Intensive intervention|"People will have virtual education with food and nutrition coaching workshops, as well as weekly meetings in small groups as a support and follow-up groups. The frequency of the face-to-face follow-up appointments will be every 3 weeks.~The nutritional intervention will emphasize the consumption of mainly minimally processed food from plant origin. A vitamin b12 supplement per week will be provided. This intervention group will have 2 stages. First stage will have a duration of 3 months setting the nutritional bases going to a plant-based diet with basic considerations regarding fiber intake reducing meat consumption, and incorporating protein from vegetable sources, among other considerations. Second stage will progress to higher levels of fiber and others nutritional requeriments in order to intensify the nutritional plant-based intervention."
45650433|NCT05425849|Other|rose oil aromatherapy|Aromatherapy refers to the medicinal or therapeutic use of essential oils absorbed through the skin or the olfactory system. The positive effects of social support, such as hand-holding, on anxiety and pain have been described
45650434|NCT04846205|Diagnostic Test|systematic etiological|"Theses following tests are made as usual practice :~Ventilator polygraphy, or polysomnography between 1 month and 1 year after cryptogenic ischemic stroke.~Transoesophageal ultrasound"
45650435|NCT03103633|Procedure|mean artery pressure|mean artery pressure declined with less than 20% of baseline
45650436|NCT03103633|Procedure|bispectral index|BIS 45-60 before and after CPB; and BIS 40-45 during CPB
45650437|NCT03103633|Procedure|Brain oxygen saturation|Brain oxygen saturation declined with less than 20% of baseline
45650438|NCT03103633|Other|Controlled|receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr.
45650439|NCT04862039|Device|Virtual Reality (VR) devices|Virtual Reality (VR) devices. Subjects receiving the experimental treatment will be given a VR headset, headphones and wristband and the Philips wireless fetal-maternal monitoring system, after the necessary preparation of the abdominal skin.
45650440|NCT04862117|Device|SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System|Active Implantable Vagus Nerve Stimulation device.
45650441|NCT03691909|Biological|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
45650442|NCT04861649|Biological|fecal microbiota transplantation|"The nasointestinal tube was placed and the fecal bacteria of healthy people were transplanted with liquid fecal bacteria (three transplants per course of treatment).~200ml of bacterial liquid was transplanted for each course, containing 40g of bacterial volume, transplanted consecutively for 3 times, once a day)"
45650443|NCT03040817|Procedure|Gastric peroral endoscopic pyloromyotomy (G-POEM)|"G-POEM procedure:~A. Premixed methylene blue/normal saline were injected into gastric antrum submucosa at greater curvature, 5 cm proximal to the pylorus.~B. Submucosal tunnel was created via endoscopic submucosal dissection. C. A white thick pyloric band, was in contrast to a thin-walled submucosal space of the duodenum observed distally.~D. Pyloromyotomy starts with dissection of the pyloric ring exposing muscular layer underneath.~E. Circular and longitudinal myotomy for 2-3 cm. F. Serosa indicates appropriate depth of myotomy. G. Reevaluation of the mucosotomy site. H. Mucosal entry was closed with clips from distal mucosal incision point."
45650444|NCT03040817|Drug|Esomeprazole + Mosapride|Each participant receive Esomeprazole （Nexium） 40mg bid + Mosapride （Mosapride Citrate Tablets） 5mg tid.
45799539|NCT02535611|Drug|Placebo|Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.
45799540|NCT02535611|Drug|Memantine|Beside the usual treatment for ischemic stroke this group will be treated by memantine.
45799541|NCT01823497|Drug|Morphine|Morphine will be used to control pain post-surgery.
45799542|NCT00363935|Drug|Dexmedetomidine|
45799543|NCT02423447|Device|Electro-Flo Intervention|An assigned respiratory therapist performed airway clearance on each participant with the Electro-Flo device following the 2012 CFF therapy guidelines
45799544|NCT02423447|Device|G5 Intervention|An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines
45927937|NCT01678586|Drug|Sham Gabapentin|Benadryl or diphenhydramine is used as a placebo as it could mimic some common side effects of gabapentin (i.e. sedation, drowsiness, lightheadedness)
45927938|NCT00274950|Biological|bleomycin sulfate|
45927939|NCT00274950|Drug|carboplatin|
45927940|NCT00274950|Drug|cisplatin|
45927941|NCT00274950|Drug|etoposide|
45927942|NCT00274950|Drug|ifosfamide|
45927943|NCT00274950|Drug|vinblastine sulfate|
45927944|NCT00274950|Procedure|adjuvant therapy|
45927945|NCT00274950|Procedure|conventional surgery|
45927946|NCT00016016|Drug|cytarabine|Given IV
45927947|NCT00016016|Drug|mitoxantrone hydrochloride|Given IV
45927948|NCT00016016|Drug|alvocidib|Given IV
45927949|NCT00016016|Other|pharmacological study|Correlative studies
45927950|NCT00016016|Other|laboratory procedure|Correlative studies
45927951|NCT00130455|Drug|escitalopram|
45927952|NCT00016055|Biological|lymphokine-activated killer cells|
45927953|NCT00016055|Drug|temozolomide|
45927954|NCT00130416|Behavioral|E-mail coaching to improve patient communication with doctor|
45927955|NCT00016094|Biological|bevacizumab|Given IV
45927956|NCT00016094|Other|laboratory biomarker analysis|Correlative studies
45927957|NCT00130377|Biological|cell therapy|autologous or allogeneic cells
45927958|NCT00130338|Drug|Rivastigmine|
45927959|NCT00016133|Biological|BCG vaccine|
45650445|NCT05416749|Drug|8MW2311|All subjects will receive a single intravenous (IV) infusion of 8MW2311 every 21 days (q21d), other dosing frequencies may be used.
45650446|NCT05423431|Other|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with a hydrogel spacer.
45650447|NCT04853303|Device|Hypnosis VR|Children will be required to wear a VR gadget for hypnosis when they are experiencing chemotherapy-induced nausea and vomiting, sleep quality or pain. The duration is 15 minutes.
45650448|NCT05416437|Device|PneumoCool|Device to channel medical air to the patient to alleviate dyspnea
45650449|NCT05416437|Other|Current supportive measures that are used in the hospital for standard of care|a room fan, or any other currently used supportive measures can be used for patients in the control arm
45650450|NCT05412355|Procedure|ERAS protocol|ERAS protocol is a series of procedures that enhance the recovery of surgical patients. Patients were grouped according to whether the procedure was attempted.
45650451|NCT04853069|Drug|Transdermal estradiol gel|Patients will receive standard care +/- (randomsed 1:1) transdermal 17ß-estradiol gel (3 mg; applied to forearm, upper arm and shoulder) for ten days.
45650452|NCT04259853|Procedure|PCI|Revascularization on non culprit vessel
45650453|NCT05245279|Diagnostic Test|3 dimensional ultrasound investigation|Images that contributed to the determination of placental volume and 3-DPD indices were obtained at the time of visit. All 3-D scans ultrasound measurements were performed by a Voluson 730 Expert ultrasound machine equipped with a multifrequency probe (2-5 MHz) to acquire images. Each sample was examined using 3-D rendering mode, in which the colour and gray value information was processed and combined to supply 3-D image. For laterally located placentas, the investigator positioned the transducer on a slight lateral inclination to obtain proper images. Power Doppler window was placed over the placenta to map the vascular tree from basal to chorionic plates. The 3-D static volume box was placed over the entire placenta volume. The sweep angle was set at maximum 70°. Each image was recovered from the disk in succession for processing. During gestation, the investigator recorded one sample from each patient.
45799545|NCT05747521|Drug|Anrotinib hydrochloride combined with adriamycin|To evaluate the efficacy of anrotinib hydrochloride combined with doxorubicin in the neoadjuvant treatment of high-grade soft tissue sarcoma
45799546|NCT02537717|Device|Sapphire Lens|Each subject randomized to wear either the test or control in either the left of right eye.
45799547|NCT02537717|Device|enfilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
45799548|NCT05234047|Procedure|MDCT (multidetector computed tomography)|MDCT will be performed at inclusion and after 2 years
45799549|NCT05234047|Procedure|Dual-energy X-ray absorptiometry|DXA will be performed at inclusion, 1 and 2 years after inclusion
45799550|NCT05226559|Procedure|Multimodal Physical therapy approach plus usual care|HVLA spinal manipulation, mobilization, soft tissue treatment, therapeutic exercise, education, plus standard pharmacological treatment.
45799551|NCT05226559|Drug|Usual care|Standard pharmacological treatment alone.
45927960|NCT00016133|Biological|autologous tumor cell vaccine|
45927961|NCT00016133|Drug|fluorouracil|
45927962|NCT00016133|Drug|leucovorin calcium|
45927963|NCT00016133|Procedure|adjuvant therapy|
45650454|NCT05245279|Diagnostic Test|2 dimensional ultrasound investigation|The two-dimensional (2-D) transabdominal conventional study provided data about fetal position, biometry, body movements and fetal heart rate as well as placental localization. The factorial default setting 'Obstetrics' was applied in 2-D mode.
45799552|NCT02537873|Drug|Lorcaserin|Lorcaserin HCL 10mg tablets (Belviq, Arena Pharmaceuticals)
45799553|NCT02537873|Drug|Cocaine Intravenous (IV)|Cocaine IV administered at doses of 10, 20 and 40 mg during 4 dosing sessions
45799554|NCT02537873|Drug|Placebo comparator|Dextrose in gelatin capsule
45799555|NCT01823653|Device|Liposonix System (Model 2)|Treatment of Subcutaneous Adipose Tissue in the thighs using High Intensity Focused Ultrasound
45799556|NCT05118763|Drug|INNA-051|Liquid for intranasal administration
45799557|NCT05118763|Other|Placebo|Liquid for intranasal administration
45799558|NCT02537951|Device|AFI microscope|measurement of AFI intensities following increasing nociceptive stimulus intensities
45927964|NCT00130299|Behavioral|low glycemic load diet|
45799559|NCT02537951|Device|negative control 1: lidocaine/prilocaine|measurement of AFI intensities following lidocaine/prilocaine cream
45927965|NCT00130299|Behavioral|low fat diet|
45927966|NCT00016172|Drug|pegylated liposomal doxorubicin hydrochloride|
45927967|NCT00016172|Drug|picoplatin|
45927968|NCT00130260|Biological|Staph aureus types 5 and 8 conjugate vaccine|each IM dose contains 200 mc total conjugate
45927969|NCT00130260|Biological|placebo|placebo to match StaphVAX
45927970|NCT00016211|Radiation|radiation therapy|
45927971|NCT00130182|Drug|denufosol tetrasodium (INS37217)|
45927972|NCT01470716|Drug|Erlotinib|Neo-adjuvant Erlotinib treatment during maximum 8 weeks.
45450766|NCT02195596|Other|Low intensity aerobic exercise+strength|"Low intensity aerobic exercise+strength program is similar to the other intervention but differs in the intensity of the exercise as it works with intensities below 40% of heart rate reserve.~--------------------------------------------------------------------------------"
45927973|NCT00394368|Drug|beclomethasone dipropionate plus formoterol fumarate combination|
45927974|NCT00394368|Drug|fluticasone propionate plus salmeterol xinafoate combination|
45927975|NCT01441349|Drug|IP chemotherapy|"Irinotecan/cisplatin (IP) chemotherapy~Cisplatin(30 mg/m2) diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 &8.~Irinotecan(65mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1 & 8~Every 21 days"
45927976|NCT01441349|Drug|IP chemotherapy plus simvastatin|"Cisplatin(30mg/m2)diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 &8~Irinotecan( 65 mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1& 8.~Every 21days.~Simvastatin 40 mg per day orally D1of cycle 1"
45927977|NCT00394407|Drug|sliding scale regular insulin|SSRI acqhs
45927978|NCT00394407|Drug|glargine basal insulin and glulisine prandial insulin|glargine insulin once a day and glulisine insulin three times a day as long as patient eating
45799560|NCT02537951|Device|negative control 2: 8% capsaicin|measurement of AFI intensities following 8% capsaicin patch
45927979|NCT00016250|Drug|MKC-1|
45927980|NCT00130143|Drug|Ethyol (Amifostine)|
45799561|NCT01824589|Device|-7 cm H2O ITPR|Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -7 cmH2O between periods of positive pressure ventilations.
45927981|NCT01394900|Behavioral|CNU Intervention|Notions that strengthen the closeness with one's partner, connect with similar couples, and visibly strengthen a community as key to combating dynamics that cause poor communication, isolation, fragmentation of the Black MSM community.
45927982|NCT01394900|Behavioral|WP Intervention|Attention control condition - WP focuses on nutrition, fitness, healthcare, and stress management. Given the prevalence of health problems among the target population, WP emphasizes adherence to medical guidance and medication regimens.
45927983|NCT00130104|Procedure|Transthecal Metacarpal Block|
45927984|NCT00016289|Biological|recombinant interleukin-12|Given intraperitoneally
45927985|NCT00130065|Drug|Sulfadoxine-pyrimethamine/folic acid|
45927986|NCT00130065|Drug|Sulfadoxine-pyrimethamine/placebo|
45927987|NCT00016328|Drug|temsirolimus|Given IV
45927988|NCT00016328|Other|laboratory biomarker analysis|Correlative studies
45799562|NCT01824589|Device|-12cm H2O ITPR|Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -12 cmH2O between periods of positive pressure ventilations.
45927989|NCT00016328|Other|pharmacological study|Correlative studies
45927990|NCT00130026|Drug|Caffeine|500 mg IV
45927991|NCT00016367|Biological|Trastuzumab|"Regimen A: Trastuzumab IV over 90 minutes on days 2 and 8.~Regimen B: Trastuzumab IV over 30-90 minutes on days 1, 8 and 15."
45927992|NCT00016367|Drug|Cisplatin|"Regimen A: Cisplatin IV over 2 hours on day 1 following gemcitabine.~Regimen B: Cisplatin IV over 2 hours on day 1."
45927993|NCT00016367|Drug|Gemcitabine Hydrochloride|"Regimen A: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.~Regimen B: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab."
45927994|NCT00129948|Drug|Troxatyl™ (troxacitabine)|
45927995|NCT00016406|Biological|filgrastim|
45927996|NCT00016406|Drug|cyclophosphamide|
45927997|NCT00016406|Drug|doxorubicin|
45927998|NCT00016406|Drug|paclitaxel|
45927999|NCT00016406|Procedure|surgery|
45450767|NCT02031328|Radiation|Stereotactic Ablative Radiation|
45450768|NCT01084343|Biological|MYM-V101|"Panel 1: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 10 microgram or placebo each, every 8 weeks.~Panel 2: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 50 microgram or placebo each, every 8 weeks."
45450769|NCT02198560|Device|RS-3000 Lite|
45928000|NCT00129909|Drug|fixed dose combination therapy|
45928001|NCT00129870|Drug|oxaliplatin|
45928002|NCT00129831|Drug|QAB149|
45928003|NCT00016445|Drug|growth hormone|
45928004|NCT00391742|Behavioral|Brief intervention|
45928005|NCT00129792|Drug|Dietary supplement for weight loss|The dietary supplement being investigated in this study is a natural product designed to reduce metabolic syndrome by decreasing hunger, increasing energy, and improving insulin function.
45928006|NCT00129792|Behavioral|Education and counseling for weight loss|Hour and a half weight loss education session weekly for 12 weeks.
45928007|NCT00129753|Drug|Alemtuzumab (Campath-1H)|Escalating dose 3mg, 10 mg, 30 mg on three consecutive days, then 30 mg three times per week by subcutaneous injections for 12 weeks. Each 30 mg dose will be divided in 2 injections to be administered in each thigh.
45928008|NCT00016523|Drug|Inhaled nitric oxide|Started at 5 ppm and could be increased to 10 ppm
45928009|NCT00016523|Drug|Placebo|Started at 5 ppm and could be increased to 10 ppm
45928010|NCT00129714|Other|cervical collar|
45928011|NCT00129714|Other|physiotherapy|
45928012|NCT00129675|Drug|[123I]ß CIT|"Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI."
45928013|NCT01119365|Other|Bright light|Light is administered through a custom designed mask with LED lights.
45928014|NCT00129636|Procedure|Additional specific letter written to patient|
45928015|NCT00129597|Drug|ketalar|
45650455|NCT04852913|Other|Bowen's Technique|The thumb of the therapist was placed on the top of the targeted muscle (upper trapezius, levator scapulae, tight pectoralis and sternocleidomastoid, longissimus capitis, splenius capitis cervical multifidus). The skin was carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb was flattened in the medial direction, when this happened the muscle would plop or 15 respond in some way. Heating pad + TENS will be given The session lasted for 20 minutes 3sessions/week for 6th week
45799563|NCT05747287|Device|microcatheter|supports the insertion of the guide wire，exchange of the guide wire and the delivery of contrast media
45928016|NCT00016601|Drug|Indinavir sulfate|
45799564|NCT02486939|Drug|CHS-0214|Open label
45928017|NCT00016601|Drug|Ritonavir|
45928018|NCT00016601|Drug|Nelfinavir mesylate|
45928019|NCT00016601|Drug|Efavirenz|
45450770|NCT02195752|Other|Compounded Pain Cream|All patients will have been prescribed a topical pain cream prepared by a qualified compounding pharmacy
45799565|NCT02487485|Drug|Ketamine|. Subjects will receive an infusion of ketamine (0.5 mg/kg infusion over approximately 40 minutes). All subjects will receive two ketamine infusions-once with a placebo and once with a single dose of sirolimus (6 mg, oral administration).
45928020|NCT00016601|Drug|Nevirapine|
45928021|NCT00016601|Drug|Medroxyprogesterone acetate|
45928022|NCT00129558|Drug|PT-523 for Injection|
45928023|NCT00957086|Drug|Nimotuzumab|Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
45928024|NCT00957086|Drug|Placebo|Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
45928025|NCT00016679|Drug|1-Octanol|
45928026|NCT00129519|Drug|Imiquimod 5% cream|Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
45928027|NCT00129480|Behavioral|Assistance with Pain treatment|Care management intervention including assessment, decision support, patient activation, education and followup, provider education, feedback to providers. Intervention delivered for 12 months.
45928028|NCT00016835|Procedure|Supra-gingival scaling and placebo|Included in arm/group description.
45928029|NCT00016835|Procedure|Subgingival scaling and metronidazole|Included in arm/group description.
46072381|NCT04798482|Drug|Dexmedetomidine|Patients will undergo the usual anal manometry study, with no adjuvant medications, per routine practice currently in the gastrointestinal unit. Following completion of manometry, 0.5 mcg/kg DEX will be administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Manometry measurements will be followed for 15 minutes in response to DEX.
45450771|NCT01084421|Behavioral|Computer-based parent-adolescent HIV communication|The parental intervention consists of a 60 minute computer-based program delivered in two sessions (one per week). The DVD ROM provides information about adolescent sexual risk and HIV prevention, strategies to support sexual specific communication and parent-adolescent communication in general. The computer based education program is provided in Spanish.
45450772|NCT01069133|Drug|Rifaximin|550mg BID open-label
45450773|NCT01069133|Drug|rifaximin|550mg PO BID
45450774|NCT02198638|Biological|A nasal swab|A nasal swab was performed by a research assistant and influenza virus infection was confirmed by enzyme-linked immunosorbent assay and reverse transcription-polymerase chain reaction on viral cultures
45450775|NCT02198716|Procedure|Percutaneous Coronary Intervention using drug eluting stents|Percutaneous Coronary Intervention using drug eluting stents
45450776|NCT02198716|Procedure|Percutaneous Coronary Intervention using bare metal stents|Percutaneous Coronary Intervention using bare metal stents
45450777|NCT03976583|Drug|Cpp-Acp|Remineralising agent
45450778|NCT03976583|Other|Pearl powder|Natural product
45450779|NCT02198326|Drug|BIBN 4096 BS- in single rising doses|
45450780|NCT02198326|Drug|Placebo|
45799566|NCT02487485|Drug|sirolimus|Subjects will receive a single 6 mg oral dose via oral solution of sirolimus or a dose of placebo approximately two hours prior to the infusions. As above, the order of placebo and sirolimus is randomized. The sirolimus dose as well as the placebo solution will be given in 6 ounces of orange juice.
45799567|NCT02487485|Drug|Placebo|Placebo oral dose
45799568|NCT02487563|Drug|Decitabine|Decitabine
45799569|NCT02487563|Drug|rhTPO|rhTPO
45799570|NCT02487563|Other|Conventional Treatment|immunoglobulin, glucocorticoid etc
45928030|NCT00016835|Procedure|Subgingival scaling and doxycycline|Included in arm/group description.
45928031|NCT00016874|Drug|cisplatin|
45928032|NCT00016874|Drug|paclitaxel|
45928033|NCT00016874|Drug|triapine|
45928034|NCT00129441|Drug|Merck L-830982|The initial dose of L-830982 was 3.0 mg twice daily (b.i.d.) the dosage increased to 5.0 mg b.i.d. at the end of week 1 and 8.0 mg b.i.d. at the end of week 2, which was continued for the remaining 2 weeks of the trial. Medications were dispensed weekly in blister packs by the hospital pharmacy.
45928035|NCT00129441|Drug|Placebo|Medications were dispensed weekly in blister packs by the hospital pharmacy, using the same number of pills as those on active drug.
45928036|NCT00016952|Drug|fluorouracil|
45928037|NCT00016952|Drug|irinotecan hydrochloride|
45928038|NCT00016952|Drug|leucovorin calcium|
45928039|NCT00129363|Drug|Carvedilol|
45928040|NCT00016991|Drug|gefitinib|
45928041|NCT00017030|Drug|trabectedin|
45928042|NCT00129324|Procedure|Lead Hazard Control Intervention|Prior to their child's birth, participants randomized to Lead Reduction Group received lead hazard reduction controls to reduce residential exposure to lead.
45928043|NCT00129324|Procedure|Injury Hazard Control Intervention|Between 3 and 6 months of age, participants randomized to Injury Reduction Arm received injury hazard controls to reduce the number of residential injuries.
45928044|NCT00017069|Drug|arsenic trioxide|
45928045|NCT00017069|Drug|dexamethasone|
45928046|NCT00129285|Drug|Low Dose Modafinil|modafinil 200 mg/day
45928047|NCT00129285|Drug|High Dose Modafinil|modafinil 400 mg/day
45928048|NCT00129285|Drug|Placebo|placebo 400 mg/day
45650456|NCT04852913|Other|Convention Physical Therapy|"Myofascial Release + Active Range of Motion Deep transverse friction was given for 10 minutes followed by myofascial stretching of muscle for 3 times, each holding for 90 seconds. Then myofascial release was given using ulnar border of both palms of the therapist.~Active range of motion exercises will be given 10 reps with 5 seconds hold. Heating pad + Transcutaneous Electrical Nerve Stimulator (TENS) will be given The session lasted for 20 minutes 3sessions/week for 6th week"
45928049|NCT00017108|Drug|chlorambucil|
45799571|NCT02423993|Behavioral|Education by structured programme|"Thе structured programme was developed in Endocrinology Research Centre. It is based on the following principles: education in group setting, using structured program; intensive insulin treatment using insulin pumps; self-adjustment of insulin dose and pump settings; intensive self-monitoring of blood glucose, including continuous glucose monitoring in real-time (CGM-RT); flexible physical activities and meals regimen (liberal diet, based on carbohydrates account using bread units; possible shifts of meals schedule and volume supported by appropriate treatment adjustment). Duration of education course - 8 days (35-37 hours); planned group volume is 7-10 patients."
45928050|NCT00017108|Drug|cyclophosphamide|
45928051|NCT00017108|Drug|fludarabine phosphate|
45928052|NCT00129246|Drug|Naltrexone|Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.
45928053|NCT00129246|Drug|Bupropion|Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period.
45928054|NCT00017147|Drug|carmustine|"40 mg/m^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose for experimental arm with O6=BG.~200 mg/m^2 IV over 1 hour on day 2 of each cycle for the active comparator arm."
45928055|NCT00017147|Radiation|radiation therapy|5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
45928056|NCT00017147|Drug|O6-Benzylguanine|120 mg/m^2 IV over 1 hour on day 1 of each cycle
45928057|NCT00129207|Drug|bortezomib|
45928058|NCT00129168|Drug|Zosuquidar|
45928059|NCT00129168|Drug|Daunorubicin|
45928060|NCT00129168|Drug|Cytarabine|
45928061|NCT04734236|Diagnostic Test|New technique vs Xpert|New technique vs Xpert
45928062|NCT00129051|Procedure|Tomotherapy|
45928063|NCT00017186|Drug|epirubicin hydrochloride|
45928064|NCT00017186|Drug|gemcitabine hydrochloride|
45928065|NCT00129012|Procedure|Tomotherapy|
45928066|NCT00017225|Biological|filgrastim|
45928067|NCT00017225|Drug|carboplatin|
45928068|NCT00017225|Drug|cisplatin|
45928069|NCT00017225|Drug|cyclophosphamide|
45928070|NCT00017225|Drug|dacarbazine|
45799572|NCT02423993|Device|CSII|The intensified insulin therapy by means of continuous subcutaneous insulin infusion will be provide by Medtronic insulin pumps: Paradigm MMT-712/715, Paradigm Real-Time MMT-722, Paradigm VEO MMT-754.
45928071|NCT00017225|Drug|doxorubicin hydrochloride|
45928072|NCT00017225|Drug|etoposide|
45928073|NCT00017225|Drug|ifosfamide|
45928074|NCT00017225|Drug|melphalan|
45928075|NCT00017225|Drug|tretinoin|
45928076|NCT00017225|Drug|vincristine sulfate|
45928077|NCT00017225|Drug|vindesine|
45928078|NCT00017225|Procedure|autologous bone marrow transplantation|
45928079|NCT00017225|Procedure|conventional surgery|
45928080|NCT00017225|Procedure|peripheral blood stem cell transplantation|
45928081|NCT00017225|Radiation|radiation therapy|
45928082|NCT00128934|Drug|levonorgestrel/ethinyl estradiol|
45928083|NCT00017264|Drug|atrasentan hydrochloride|
45928084|NCT00128895|Drug|azathioprine|azathioprine 2 mg/kg oral once daily, duration according to arm
45928085|NCT00017303|Drug|carboplatin|
45928086|NCT00017303|Drug|oglufanide disodium|
45928087|NCT00017303|Drug|paclitaxel|
45928088|NCT00017303|Procedure|conventional surgery|
45928089|NCT00128817|Radiation|Concurrent Chemoradiation|60-70 Gy at 2Gy/5days a week for 6 to 7 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
45928090|NCT00128817|Procedure|Laryngectomy + adjuvant radiotherapy/chemoradiotherapy|Surgery: Total Laryngectomy with or without partial pharyngectomy or Near-Total Laryngectomy with or wothout partial pharyngectomy Adjuvant Radiation 2- 3 weeks following surgery: 50-60Gy at 2Gy/5days a week for 5 to 6 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
45928091|NCT00017342|Drug|bryostatin 1|
45928092|NCT00017342|Drug|cytarabine|
45928093|NCT00128739|Drug|Budesonide|
45928094|NCT00017381|Biological|rituximab|Given IV
45928095|NCT00017381|Drug|cyclophosphamide|Given IV
45928096|NCT00017381|Biological|filgrastim|Given SC
45928097|NCT00017381|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
45928098|NCT00017381|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
45928099|NCT00128700|Drug|temozolomide|
45928100|NCT00128700|Drug|vatalanib|
45928101|NCT00128700|Procedure|adjuvant therapy|
45928102|NCT00128700|Radiation|radiation therapy|
45928103|NCT00017459|Drug|cisplatin|
45928104|NCT00017459|Drug|tirapazamine|
45928105|NCT00017459|Drug|vinorelbine tartrate|
45928106|NCT00128622|Biological|denileukin diftitox|
45928107|NCT00128622|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
45928108|NCT00128622|Biological|therapeutic autologous dendritic cells|
45928109|NCT00017498|Drug|gemcitabine hydrochloride|
45928110|NCT00128583|Biological|polyvalent melanoma vaccine|
45928111|NCT00128544|Drug|telbivudine|
45928112|NCT00128544|Drug|valtorcitabine|
45928113|NCT00017537|Biological|MVF-HER-2(628-647)-CRL 1005 vaccine|
45928114|NCT00128505|Drug|Mifepristone|
45799573|NCT02423993|Device|CGM-RT|"Continuous glucose monitoring (CGM) will be provide by means of Paradigm Real-Time MMT-722 and Paradigm VEO MMT-754 Medtronic sensor-augmented insulin pumps. For monitoring the Sof-Sensor and MiniLink transmitter (Medtronic) will be use. Each sensor will be use for 6 days. CGM will be use for self-monitoring of blood glucose on permanent basis (more than 6 days per week) within 4 month."
45799574|NCT02423993|Procedure|Screening for Complications|To assess diabetic retinopathy a fundoscopy will be held. Diabetic nephropathy will be assessed by microalbuminuria screening, serum creatinine evaluation and calculation of CKD-EPI glomerular filtration rate. Diabetic neuropathy will be assessed by all kinds of sensitivity evaluation (vibrating, tactile, temperature).
45928115|NCT00017576|Dietary Supplement|calcitriol|
45928116|NCT00017576|Drug|carboplatin|
45928117|NCT00394446|Drug|MPC-6827|2-hour intravenous infusion given once weekly for 3 consecutive weeks on a 28 day cycle
45928118|NCT00017654|Drug|anti-thymocyte globulin|
45928119|NCT00017654|Drug|cyclophosphamide|
45928120|NCT00017654|Drug|cyclosporine|
45928121|NCT00017654|Drug|methylprednisolone|
45928122|NCT00017654|Procedure|Allogeneic Bone Marrow Transplantation|
45928123|NCT00394485|Drug|Procaterol|
45928124|NCT00394485|Drug|Tiotropium|
45928125|NCT00017693|Biological|Recombinant human soluble IL-4 receptor|Subjects were randomized to twelve once weekly nebulizations of 0.75, 1.5, or 3.0 mg dose of recombinant human soluble IL-4 receptor (rsIL-4R)
45928126|NCT00017693|Biological|Placebo for Recombinant human soluble IL-4 receptor|Subjects were randomized to twelve once weekly nebulizations of placebo for recombinant human soluble IL-4 receptor (rsIL-4R). Identically prepared (to the recombinant human soluble IL-4 receptor) in the same volume
45450781|NCT03976427|Behavioral|Guided Imagery|The guided imagery exercise asks participants to think about positive associations with healthy foods and imagine their future healthy selves.
45799575|NCT02423993|Procedure|Glycaemic control assessment|Glycemic control effectiveness changes will be assessed by measure of glycated hemoglobin (HbA1c). The frequency of blood glucose self-monitoring will be estimated by patient's diaries evaluation, individual glucometer data evaluation and insulin pump reports. Bolus calculator use and hypoglycemia nonsevere frequency will be assessed by reports received from insulin pumps.
45799576|NCT02423993|Procedure|QoL assessment|"For Quality of Life (QoL) assessment will be used the following validated questionnaires (in Russian):~The Medical Outcomes Study 36-Item Short Form Health Survey - SF-36.~The Audit of the Diabetes-Dependent Quality of Life - ADDQoL (С. Bradley et al, 1999, adjusted by Starostina E.G., 2003)."
45799577|NCT02423993|Procedure|Knowledge assessment|For the knowledge assessment of disease management the standard Questionnaire for patients with type 1 diabetes will be used. Maximum score equals 37 grades; the satisfactory level of knowledge is scored 27.
45799578|NCT02427737|Behavioral|Comfort Talk® Training|Personnel of MRI units is trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This entails 16 hrs classroom work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
46072382|NCT04774250|Drug|Zonisamide 100Mg Cap|ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.
46072383|NCT04774250|Drug|Placebo|The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
45799579|NCT02489123|Drug|Enzalutamide|Given PO
45799580|NCT02489123|Other|Laboratory Biomarker Analysis|Correlative studies
45799581|NCT02489357|Procedure|Cryosurgery|Undergo whole gland cryoablation
45799582|NCT02489357|Drug|Degarelix|Given SC
45928127|NCT00128466|Drug|gentamicin|
45928128|NCT00128466|Drug|streptomycin|
45928129|NCT00128427|Drug|Colchicine (for 1 month)|
45928130|NCT00017810|Behavioral|Dietary intervention|"The dietary intervention focused on diarrhea management using skill-building techniques that provided subjects with knowledge and a sense of confidence about making food choices.~Behavioral dietary intervention (Condition 1: treatment) - a low-fat, lactose-free, low insoluble fiber, high soluble fiber, and caffeine-free diet based on normal foods"
45928131|NCT00017810|Behavioral|HIV Self-Care|Standard information regarding self-care and healthy living with HIV - focused on healthy living with HIV and did not include dietary restrictions or dietary information that could affect bowel movements.
45928132|NCT00128388|Other|PFPP|Psychoanalytic Psychotherapy for panic disorder
45928133|NCT00128388|Other|ART|Applied Relaxation Training
45928134|NCT00017927|Drug|Pegvisomant|
45928135|NCT00018005|Behavioral|Self-Management|18 in-person group sessions providing self-management training.
45928136|NCT00018005|Other|attention control|18 educational mailings follow by a a telephone call.
45928137|NCT00006099|Biological|Monoclonal antibody hu3S193|Hu3S193 was to be administered intraperitoneally or intravenously at a dose of 5mg. Doses of hu3S193 were radiolabeled with 5 mCi of 111In.
45928138|NCT00391781|Procedure|Temperature of contrast medium|
45928139|NCT00018564|Drug|treatments for essential tremor|
45928140|NCT00391820|Drug|TD-5108|
45928141|NCT00018603|Drug|guanfacine|
45928142|NCT00391859|Procedure|Pharmacist-Initiated Intervention in OsteoArthritis (PhIT-OA)|See Detailed Description.
45928143|NCT00018642|Drug|quetiapine|
45928144|NCT00018642|Drug|haloperidol decanoate|
45928145|NCT00018083|Drug|rifabutin|
45928146|NCT00018083|Drug|isoniazid|
45928147|NCT00018083|Drug|efavirenz|
45928148|NCT00018200|Drug|Desipramine|Low exposure (40-70 ng/mL), Middle exposure (70-130 ng/mL), High exposure (130-200 ng/mL)
45928149|NCT00018200|Drug|Fluoxetine|Low exposure (200-399 ng/mL), Middle exposure (400-499 ng/mL), High exposure (500-700ng/mL)
45928150|NCT00018200|Drug|Benztropine|Daily dose 0.125 to 0.5mg
45928151|NCT00018759|Drug|paroxetine|
45928152|NCT00018759|Behavioral|ongoing psychological screening|
45928153|NCT04734353|Drug|Prasugrel 5mg|Prasugrel 20 mg loading, followed by prasugrel 5 mg/day for 12 months
45928154|NCT04734353|Drug|Ticagrelor 60mg|Ticagrelor 120 mg loading, followed by ticagrelor 60 mg bid for 12 months
45928155|NCT00018837|Behavioral|Community Re-Entry Program: What is Schizophrenia|
45799583|NCT02489357|Other|Laboratory Biomarker Analysis|Correlative studies
45799584|NCT02489357|Biological|Pembrolizumab|Given IV
45928156|NCT04734314|Other|conventional physical therapy|conventional physical therapy in the form of transcutaneous electrical stimulation (TENS) for 20 min and hot pack for 10 min Each patient received 12 sessions three session per week.
45799585|NCT02490293|Drug|Cephalosporin|"During the hospitalization, intake of pacetin, 2nd generation cephalosporin. 3 g per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days."
45928157|NCT04734314|Other|vojta therapy|"Vojta Dynamic Neuromuscular Stabilization (DNS) is a therapy used to manage neurological and musculoskeletal conditions each patient in the study group (group B) was instructed to lie prone on an examination table with the participant's shoulders abducted, elbows flexed approximately 80-90°, and the forearms hanging off the edge of the table. Pressure-like stimulation of the calcaneus and ASIS were performed in the postural position named by Vojta as reflex creeping.~Each patient received 12 sessions three session per week."
45928158|NCT00018876|Procedure|Lumbar nerve root decompression|
45928159|NCT00018876|Procedure|Preoperative low-dose external beam radiation|
45928160|NCT00018239|Procedure|Exercise|
46072384|NCT04773054|Diagnostic Test|Microbiological analysis of periprosthetic tissue|Microbiological culture of tissue samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone.
46072385|NCT04773054|Diagnostic Test|Histological analysis of periprosthetic tissue|Histological assessment of cellular reactivity associated with the infection on tissue samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone.
45799586|NCT02490293|Drug|Placebo|"During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days."
46072386|NCT04773054|Other|Characterization of tissue microbiota|"Assessment of tissue microbiome composition using the next-generation sequencing of DNA extracted from samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone."
46072387|NCT04773054|Other|Characterization of gut microbiota|"Assessment of gut microbiome composition using the next-generation sequencing of DNA extracted from stool samples."
46072388|NCT04773054|Other|Characterization of oral microbiota|"Assessment of oral microbiome composition using the next-generation sequencing of DNA extracted from a buccal swab obtained by rubbing the mucosa of cheeks, gingivae, and palate."
46072389|NCT04768569|Drug|Zonisamide 100Mg Cap|ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.
45650457|NCT05397561|Other|Turkish Translation of Physical Activity Barriers and Facilitators Scale|Participants to be included in the study will be listed under a special code (traffic code of their city of birth, date of birth and order of participation). The socio-demographic characteristics, age, gender, body weight, height and Body Mass Index (BMI) of the participants will be evaluated and recorded with a specially prepared evaluation form. All participants in the study will complete the Turkish version of the PABFS, the Physical Activity Disability Scale (PADS), the Motivation for Participation in Physical Activity Scale (MPPAS), and the International Physical Activity Questionnaire (IPAQ) at their first visit. Participants will complete the BFYPA again after 7 days.
45799587|NCT02538419|Behavioral|CPAP + Peer Support|
45799588|NCT02538419|Behavioral|CPAP + Individual Education|
45799589|NCT02539511|Drug|CI-581a|
46072390|NCT04768569|Drug|Placebo|The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
45799590|NCT02539511|Drug|CI-581b|
45799591|NCT02539511|Behavioral|Motivational Enhancement Therapy (MET)|
45799592|NCT02540447|Procedure|Purge|In the recipient before portal declamping, the graft preservative solution and the mesenteric blood is washed out of the circulation into the abdominal cavity and sucked by external sucker through the incompletely anastomosed hepatic vein prior to portal declamping
45799593|NCT02428595|Device|Eclipse™ System|"The Eclipse System is a vaginal bowel control (VBC) therapy intended to provide bowel control for women with fecal incontinence. It is comprised of a non-surgical device placed in the vagina (referred to as the Eclipse Insert) and a pressure-regulated pump which is used to inflate and deflate the Insert. A Sizing Kit, for use during the fitting process, and an evaluation Insert (referred to as the Trial Insert) are also part of the Eclipse System."
45799594|NCT02493257|Drug|Capsaicin|
45799595|NCT02493257|Drug|Placebo|
45928161|NCT00018954|Drug|asparaginase|
45928162|NCT00018954|Drug|cyclophosphamide|
45928163|NCT00018954|Drug|cytarabine|
45928164|NCT00018954|Drug|daunorubicin hydrochloride|
45928165|NCT00018954|Drug|doxorubicin hydrochloride|
45928166|NCT00018954|Drug|etoposide|
45928167|NCT00018954|Drug|ifosfamide|
45928168|NCT00018954|Drug|mercaptopurine|
45928169|NCT00018954|Drug|methotrexate|
45928170|NCT00018954|Drug|prednisone|
45928171|NCT00018954|Drug|vincristine sulfate|
45928172|NCT00018954|Procedure|conventional surgery|
45928173|NCT00018954|Radiation|radiation therapy|
45928174|NCT00018278|Drug|Aricept|
45928175|NCT00018278|Drug|Exelon|
45928176|NCT00018278|Drug|Nicoderm Patch|
45928177|NCT00019032|Biological|monoclonal antibody Mik-beta-1|
45928178|NCT00018317|Behavioral|low protein diet|
45928179|NCT00018317|Behavioral|resistance training|
45928180|NCT00018317|Behavioral|combination of diet control and exercise|
45928181|NCT00019071|Drug|chemotherapy|
45928182|NCT00019071|Drug|cladribine|
45928183|NCT00019071|Radiation|radiation therapy|
45799596|NCT02430389|Drug|Remifentanil|Ninety seconds before pinning, an IV bolus of 10 mL of remifentanil (0.7 µg•kg-1 based on ideal body weight) will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
45799597|NCT02430389|Drug|Normal Saline|Ninety seconds before pinning, an IV bolus of 10 mL of normal saline will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
45928184|NCT04734119|Other|Pre operative evaluation and anesthesia administration by the same anesthesiologist|Pre operative evaluation and anesthesia administration by the same anesthesiologist (instead of two different anesthesiologists, as routinely performed in our medical center)
45928185|NCT00019110|Biological|human papillomavirus 16 E7 peptide|
45928186|NCT00019110|Biological|synthetic human papillomavirus 16 E6 peptide|
46072391|NCT04746976|Drug|Diroximel Fumarate|As described in the arm.
45799598|NCT02431637|Biological|Administration of the malaria inoculum|Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. The threshold for commencement of treatment will be when PCR quantification of all participants is ≥ 5,000 parasites/mL.
45799599|NCT02431637|Drug|Piperaquine Phosphate 480 mg|When PCR quantification of all participants is ≥ 5,000 parasites/mL, participants will receive a single dose of 480 mg Piperaquine Phosphate
45450782|NCT02198404|Drug|sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
45450783|NCT02198482|Drug|Volasertib|
45450784|NCT02198482|Drug|Cytarabine|
45450785|NCT02198482|Drug|Daunorubicin|
45450786|NCT02198482|Drug|Mitoxantrone|
45450787|NCT03961841|Radiation|chemoradiation with weekly 5Fu and oxaliplatin|5Fu 225 mg/m2 IV daily continuous infusion；oxaliplatin 40 mg/m2/week
45450788|NCT03961841|Drug|Perioperative mFLOT|Perioperative docetaxel 50mg/m2；oxaliplatin 85 mg/m2; 5Fu 2.4g/m2 civ 48 hours; repeated every 2 weeks; total of 8 cycles
45450789|NCT03961841|Drug|Perioperative FOLFOX|Perioperative oxaliplatin 85 mg/m2; 5Fu 2.8g/m2 civ 48 hours; repeated every 2 weeks; total of 12 cycles
45450790|NCT01086917|Biological|PfSPZ Challenge|each volunteer to receive a single dose
45450791|NCT02195830|Other|Ultrasound of the inferior vena cava|B mode ultrasound of the inferior vena cava Measurements taken 2cm from the hepatic vein IVC junction or 3cm from the right atrium IVC junction
45450792|NCT02206360|Procedure|Endoscopic Ultrasound|
45450793|NCT02206360|Procedure|Magnetic Resonance Imaging (MRI)|
45799600|NCT02494817|Behavioral|Male Couples Agreement Project|Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
45799601|NCT02543723|Behavioral|Nurse Coach Intervention|Participants randomized to the intervention 2 group a tailored nurse coach component. Participants will receive an initial session conducted by the nurse coach, via phone or in-person. Participants will receive weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period (whichever occurs first). The nurse coach will modify the intervention plan to address identified barriers to adherence at this time.
45799602|NCT02545907|Drug|Carfilzomib|Lyophilized carfilzomib for injection reconstituted with water to a final concentration of 2 mg/mL.
45799603|NCT02545907|Drug|Thalidomide|50mg capsule.
45799604|NCT02545907|Drug|Dexamethasone|2mg tablet.
45799605|NCT02546375|Drug|Bosutinib|Bosutinib 100mg film-coated tablets; Bosutinib 500mg film-coated tablets Dosage as prescribed at treating institution; (observational study)
45799606|NCT04340999|Diagnostic Test|Nerve conduction studies and Quantitative EMG ( MUNE and IPA)|"Nerve Conduction Studies: Electrophysiological method that tests the presence/absence of peripheral neuropathy.~MUNE: Electrophysiological technique that assess number of motor units. IPA: Electrophysiological method that assess interference pattern and hence, borderline cases of neuropathy/ myopathy"
45799607|NCT02495831|Drug|Diclofenac sodium|Diclofenac sodium 50 mg single dose
45799608|NCT02495831|Drug|Diclofenac sodium and safinamide|Diclofenac 50 mg single dose and safinamide 200 mg single dose
45450794|NCT02201134|Drug|sevoflurane|
45799609|NCT02497235|Drug|TAK-935|TAK-935 oral solution.
45799610|NCT02497235|Drug|[18F]MNI-792 (tracer)|[18F]MNI-792 injection.
45799611|NCT02497937|Drug|GSK2798745|GSK2798745 will be supplied as granule filled capsule with unit dose strength of 2.4 mg to be administered orally with 240 mL water.
45799612|NCT02497937|Drug|Placebo|Placebo will be supplied as blend filled capsule to be administered orally with 240 mL water.
45799613|NCT02498483|Drug|Acetaminophen|Infants will receive 15 mg/kg of acetaminophen.
45799614|NCT02547623|Drug|Dexamethasone|depot intracameral
45799615|NCT02547623|Drug|Prednisolone|Prednisolone eye drops 1%
45799616|NCT02433665|Drug|Iopamidol|Iopamidol is the contrast material being used for this study. 100 subjects will receive a fixed dose and rate (150 mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of 3 mL/sec for a total dose of 45 grams of iodine) and 400 subjects will be administered a customized dose and rate (X mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of X mL/sec for a total dose of X grams of iodine).
45799617|NCT02433665|Device|Mydose|400 subjects will receive a customized dose of contrast material (iopamidol) based on the experimental algorithm Mydose using a combination of subject parameters.
45928187|NCT00018356|Procedure|exercise|
45928188|NCT00018356|Drug|testosterone|
45799618|NCT02547779|Other|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
45799619|NCT02547779|Other|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
45928189|NCT00019188|Drug|interleukin-12|
46072392|NCT04740671|Drug|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody, developed by Shanghai Henlius Biotech, Inc.
45799620|NCT02433977|Dietary Supplement|Conjugated Linolenic Acid|CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day
45799621|NCT02433977|Drug|Sodium Nitrite|Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)
45799622|NCT02433977|Drug|Sodium Nitrate|Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)
45799623|NCT00559585|Drug|Subcutaneous (SC) Abatacept|Participants received 125 mg weekly SC abatacept injections (with an intravenous [IV] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
45450795|NCT02206438|Device|Insertion of C-LMA|After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
45450796|NCT02206438|Device|Insertion of air-Q according|After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
45799624|NCT00559585|Drug|Intravenous (IV) Abatacept|"Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).~500mg (for body weight up to 60 kg)~750 mg (body weight between 61 and 100 kg)~1g (body weight above 100 kg)infusions"
45799625|NCT01824901|Drug|docetaxel|Given IV
45799626|NCT01824901|Drug|AZD4547|Given PO
45799627|NCT01825057|Behavioral|See One|A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances.
45799628|NCT01825057|Behavioral|Do One|A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances. Following the workshop training, providers conduct two motivational interviews bedside with patients under the supervision of one of the MI-trained CL clinicians, who subsequently give them performance feedback and coaching. Providers receive one more supervised practice case mid-trial. In addition, they can request additional supervision at any point during the trial.
45799629|NCT01825057|Behavioral|Order One|"A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances. Following the workshop, providers have the option to conduct MI with patients themselves or to order a MI for delivery by one of the MI-trained CL clinicians."
45799630|NCT05747209|Other|Observation of Exercise Program Adherence|Observation of a monitored group exercise regimen utilizing standard of care high-load resistance training and functional exercises with compound movements under close supervision and with the goal of improving functional mobility, body composition, and strength after cancer treatment to study adherence and attendance to the exercise program.
45799631|NCT00559507|Drug|saracatinib|
45799632|NCT00559507|Other|laboratory biomarker analysis|Correlative studies
45799633|NCT05027113|Behavioral|Mindfulness meditation|Participants use the meditation app 10% Happier to practice mindfulness meditation (see detailed description in arm/group section)
45799634|NCT04993651|Device|CPAP|CPAP is a form of noninvasive positive pressure ventilation (NPPV). CPAP works to maintain adequate levels of PO2 and PCO2 through improved alveolar ventilation and maintenance of upper-airway patency.
45799635|NCT01826227|Procedure|Positron Emission Tomography|
45799636|NCT01826227|Radiation|18F-Fluoro-2-deoxy-D-lucose|
45799637|NCT01826227|Procedure|Cytoreductive surgery|
45799638|NCT04970563|Other|Body odor samples|Participants will provide six body odor samples (mask and sweat samples) at inclusion
45799639|NCT04970563|Other|Body odor samples|Participants will provide six body odor samples (masks and compresses) at inclusion. A 7-day follow-up will be carried out to check, respectively, the absence of symptoms and the persistence of negativity on the SARS-COV-2 PCR test
45799640|NCT04969627|Drug|Metformin|Use Metformin for 3 months to treat PCOS
45799641|NCT04969627|Drug|Exenatide|Use Exenatide for 3 months to treat PCOS
45799642|NCT04953325|Biological|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
45799643|NCT04953325|Biological|23-valent pneumococcal polysaccharide vaccine|25μg each of the following serotypes/each dose (0.5ml): 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F
45928190|NCT00019227|Drug|pentetic acid calcium|
45928191|NCT00019227|Radiation|yttrium Y 90 daclizumab|
45928192|NCT04734041|Behavioral|Anti-inflammatory (Mediterranean-style) diet|Prescription of an anti-inflammatory diet, which encourages increasing whole fruits, vegetables, and grains, as well as balancing macronutrients (proteins, carbohydrates, and fat) for every meal.
45928193|NCT04734041|Behavioral|Behavioral and psychosocial support|Capture a complete and detailed medical history and background. Discuss familial and social support, provide psychosocial support, assess the patient's current self-management strategies for self-care, and assess the patient's current self-management strategies for mental health. Recommendations will be made in accordance with the needs of the participant.
45928194|NCT00019344|Drug|alvocidib|
45928195|NCT00019383|Biological|aldesleukin|
45928196|NCT00019383|Biological|incomplete Freund's adjuvant|
45928197|NCT00019383|Biological|sargramostim|
45928198|NCT00019383|Biological|tyrosinase peptide|
45928199|NCT00019383|Biological|tyrosinase-related protein-1|
45928200|NCT00019422|Drug|carboplatin|
45450797|NCT05261932|Procedure|AI-assisted guided biopsy|The surface of the adenoma was classified and identified by the AI system, and different areas of the adenoma were marked by distribution to guide the endoscopist for biopsy to obtain the poorly differentiated portion of the lesion.
45799644|NCT04953325|Biological|Inactivated Hepatitis A Vaccine|500SU inactivated Hepatitis A virus in 1 mL of aluminium hydroxide solution per injection.
45928201|NCT00019422|Drug|lobradimil|
45928202|NCT00018512|Procedure|Implant-supported denture|
45928203|NCT00018551|Drug|Folic Acid|
45928204|NCT00019461|Drug|carboxyamidotriazole|
45928205|NCT00019461|Drug|chemotherapy|
45928206|NCT00019500|Drug|raloxifene|
45928207|NCT00019500|Procedure|evaluation of cancer risk factors|
45928208|NCT04312919|Behavioral|Family Based Activity Intervention|Providing youth and their families with access to the knowledge and resources to increase their physical activity will allow them to lead more healthy lifestyles will provide them with the foundation for a healthier life, and future ahead.
45928209|NCT00019539|Drug|bevacizumab|
45928210|NCT00019539|Drug|thalidomide|
45928211|NCT04312802|Diagnostic Test|Cardiopulmonary exercise test (CPET)|"The participant will undergo a cardio-pulmonary exercise test (CPET) on a cycle ergometer (Ergoline) connected to a 12-lead electrocardiogram, oxygen saturation monitor and continuous non-invasive blood pressure cuff. Respiratory gas exchanged will be measured from a tight fitting facemask. An initial 2-min period of baseline data will be collected at rest before a 180-s period of unloaded cycling. A ramp protocol will then be applied and the participant will be instructed to continue cycling at a constant cadence of 60 rpm as long as they can. The test will be terminated if the participant indicates that:~they cannot continue~cadence falls to <55 rpm due to fatigue or dyspnoea~they develop abnormal cardiac signs or symptoms, such as ischaemia and arrhythmia."
45928212|NCT00019578|Procedure|Sterotactic radiosurgery|
45799645|NCT05747053|Diagnostic Test|AlloSure|AlloSure blood-draw at Post-operation day one and four, as well as one month, 2 months, 3, 9, 12, 15,18 and 24 months operation.
45928213|NCT00019656|Drug|perifosine|
45450798|NCT02257606|Other|I-TRAVLE training|
45450799|NCT03967912|Behavioral|MOVE UP|Each of the 12 group sessions will focus on incremental behavioral strategies for maintaining healthy eating, activity, and weight loss.behaviors. Body weight will be measured in-person session and participants will also to measure their body weight on their in Session 3, participants are given physical activity goal of 10 minutes/day, 50 minutes/week. The goal is raised by 5 minutes/day, 25 minutes/week every other session, the final goal being 30 minutes/day, 150 minutes/week. All subjects will be recommended to engage in an energy restricted dietary intervention that evidence demonstrates has effectively reduced body weight by 5-7% within the initial 4 months of the intervention. This will include reducing energy intake to 1200 to 1800 kcal/d based on initial body weight (<200 pounds = 1200 kcal/d; 200 to 250 pounds = 1500 kcal/d; >250 pounds = 1800 kcal/d).
45799646|NCT05747053|Diagnostic Test|PAXGene|1 PAXgene tube will be collected with every biopsy performed and sent with the AlloSure test for the second 100 patients (patients 101-200). 21 gene markers will be sequenced by collecting 3 ml of blood.
45799647|NCT04928131|Other|No intervention - retrospective observational cohort study|
45799648|NCT01826851|Drug|Exparel|"Patients in this group will receive 266 mg Exparel diluted with 0.9% normal saline to a total volume of 50 mL and administered via parasternal intercostal nerve block prior to sternal closure.~Post-operatively, patients will receive IV fentanyl as needed in the ICU while still intubated. A fentanyl PCA pump will be set up post-extubation as soon as possible and prior to the patient leaving the ICU."
45928214|NCT00019695|Drug|alendronate sodium|
45799649|NCT01826851|Drug|Placebo|"Patients in this group will receive 50 mL of 0.9% normal saline as a parasternal intercostal nerve block prior to sternal closure.~Post-surgical pain management will be the same as for the Exparel group."
45928215|NCT00019695|Drug|ketoconazole|
45928216|NCT04280783|Behavioral|The Physical Activity for The Heart (PATH) intervention|The web-based Physical Activity for The Heart (PATH) intervention leverages openly accessible platforms, such as YouTube, to proffer workout videos that match the participants preferences. Currently, PATH includes over 90 workout videos vetted by a team of experts and curated on the PATH website in 3 controlled levels of intensity (beginner, intermediate, proficient) to foster gradual progression from low to high intensity PA in accordance with the FITT-VP (frequency, intensity, time, type, volume, progression) principle.
45928217|NCT04280783|Behavioral|Be Active Your Way Booklet|Be Active Your Way booklet was developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives. It simply encourages individuals to increase their PA gradually and gives them examples of things that they can do.
45928218|NCT04208984|Device|Study|After consent and assent the child and parent will be introduced the Lullabreath in pre-op. The purpose of Lullabreath will be explained and the Lullabreath will be taught (15 minutes). The parent will complete the PROMIS Proxy Anxiety short form. The children are then taken to the operating room (leave parents) with the Lullabreath. The anesthesiologist will hook the device up to the anesthesia circuit and start the Lullabreath. The child will then undergo induction of anesthesia while playing the Lullabreath.
46072393|NCT04740671|Drug|ranibizumab|Biologic anti-VEGF recombinant humanized monoclonal antibody fragment
46072394|NCT04736056|Behavioral|Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills|Mindfulness-based sleep strategies and cognitive-behavioral symptom coping skills.
45928219|NCT04208984|Other|Music Video|After consent and assent the child and parent will be introduced to the game in pre-op. The purpose of the game will be explained and the game will be taught (15 minutes). The parent will complete the PROMIS Proxy Anxiety short form. The children are then taken to the operating room (leave parents) with the game. The anesthesiologist will hook the device up to the anesthesia circuit and start the game. The child will then undergo induction of anesthesia while playing the game. The child can choose to watch one of two music videos (Frozen, Lion King)
45928220|NCT04205513|Device|Medly|Medly is a mobile phone-based telemonitoring system that enables patients with heart failure to take clinically relevant physiological measurements with wireless home medical devices and answer symptom questions on the mobile phone. The measurements are automatically and wirelessly transmitted to the mobile phone and then to a data server.
45928221|NCT00019734|Biological|aldesleukin|
45928222|NCT00019734|Biological|fowlpox virus vaccine vector|
45928223|NCT00019734|Biological|vaccinia-tyrosinase vaccine|
45928224|NCT04146935|Drug|Burosumab Injection [Crysvita]|Burosumab/Crysvita SC injection monthly
45928225|NCT00019773|Drug|capecitabine|
45928226|NCT00019773|Drug|oxaliplatin|
45928227|NCT03370406|Drug|5-fluorouracil|Intralesional injections of 50mg/ml over a 3 week period.
45928228|NCT03370406|Drug|Imiquimod 5% cream|Topical application of 5% cream over a 3 week period.
45928229|NCT00019812|Biological|trastuzumab|
45928230|NCT00019812|Drug|paclitaxel|
45928231|NCT03326063|Drug|Ifetroban|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
45650458|NCT04846049|Other|Comprehensive Care|"Comprehensive Geriatric Assessment (3 visits with a geriatrician alternating with 3 primary provider visits over 6 months)~Care Planning with Interdisciplinary Team~Care coordination~Co-management with Primary care~Social work needs assessment~Patient-centered telehealth using phone, home telehealth, patient portal, Video~Transportation provided for all visits~Referral to Geriatric primary care clinic and mental health per Veteran need~Goals of Care and Veteran preferences conversation~Educate primary care providers about HNHR population, home and community based services, collaboration"
45650459|NCT04846049|Other|Standard Care|No intervention or treatment will be provided.
45650460|NCT05396001|Behavioral|LowSalt4Life Application|LowSalt4Life is a dietary sodium intervention mobile application that promotes lower sodium intake.
45650461|NCT05396001|Behavioral|Just-In-time Adaptive Intervention (JITAI)|LowSalt4Life is a dietary sodium application with a just-in-time adaptive intervention (JITAI) component enabled.
45799650|NCT04893967|Device|Magnetic Tape|Magnetic tape® is applied without creating any tension over low back
45799651|NCT04893967|Device|kinesiology tape|Kinesiology Tape is applied without creating any tension over low back
45799652|NCT02499497|Drug|LY2452473|LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.
45799653|NCT02499497|Drug|Placebo|The participants will receive pills containing no active drug.
45799654|NCT01827475|Drug|Ibuprofen|single dose
45799655|NCT01827475|Drug|Acetaminophen|single dose
45928232|NCT03326063|Drug|Placebo|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
45650462|NCT03685045|Procedure|Campaign days|Participants who consent will complete study procedures (Hep C test, fibroscan, questionnaire, clinical assessment) and followed up through medical record review.
45799656|NCT01827475|Drug|Ibuprofen-acetaminophen combination|single dose
45928233|NCT00019890|Drug|dendritic cell-gp100-MART-1 antigen vaccine|
45928234|NCT00019890|Drug|sargramostim|
45928235|NCT03229811|Other|ESRD education + conservative kidney management and ACP education|Targeted conservative kidney management and advance care planning education delivered in person by trained healthcare providers
45928236|NCT00019929|Biological|mutant p53 peptide pulsed dendritic cell vaccine|
45928237|NCT00019929|Procedure|adjuvant therapy|
46072395|NCT04732962|Device|AposHealth|"AposHealth is comprised of a unique footwear (Apos device) and uses two convex pods called Pertupods, which are screwed into the plantar surface of the sole so that a person walks on these pods. A trained Apos therapist calibrates the devices. The location of the pods is adjusted according to the treatment methodology, depending on the needed effect on unloading the knee and with the purpose of potentially alleviating pain immediately."
45799657|NCT02434523|Drug|Amitriptyline|Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
45799658|NCT02434523|Other|Placebo|Subjects in this arm will receive pills composed of only Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
45799659|NCT05746741|Behavioral|Telehealth solution|Video conferencing
45799660|NCT02501135|Procedure|Femoral nerve block with ropivacaine or bupivacaine|
45928238|NCT03174314|Behavioral|Standard object battery and training sequence|Used to examine human localization and identification performance. Object battery will include: trip hazards ('pucks' with various height/width combinations to represent children's toys, street debris, rocks, pets, etc.), furniture (chairs, desks, couches, benches), people, walls, and corridors. Objects will be recorded by placing them to the right or left on the path-of-travel. Raw sensor outputs for single obstacles and walls in isolation (trip-hazard pucks with 8 heights, chair, desk, person, wall) and the same set of single obstacles against a wall. This set of 23 raw sensor traces can be used in various combinations (e.g., encountering a curb and then a person, or a chair) to create a training sequence that will help experimentally naïve subjects to understand the correspondence between tactile stimulation and the real-world scenario it is intended to depict.
45799661|NCT04828837|Device|bubble PEP|Using the bubble positive expiratory pressure (Bubble PEP) for breathing training of inpatients with COPD. The training course for one day of three times. Every time needs about 20 mins. Huff and cough after the breathing training the end.
45928239|NCT03174314|Behavioral|Assistive Mode|The participants will navigate campus while receiving navigation assistance (acquiring data and simultaneously providing assistance/audio feedback).
45928240|NCT03174314|Behavioral|Passive Mode|The participants will navigate campus while wearing a backpack without receiving navigation assistance.
45928241|NCT00394602|Behavioral|Interview|Interview regarding perceptions of side effects that are related to chemoradiation treatment.
45928242|NCT00394602|Other|Questionnaire|3 Questionnaires regarding quality of life given during and after treatment, each taking about 20 minutes to complete.
45650463|NCT04845971|Dietary Supplement|Saisei Maf capsules|Dietary supplement name: Colostrum MAF, Saisei MAF immunomodulator. Formulation: 148 mg acid-resistant coated capsules, containing 2.3 mg of enzymatically treated bovine colostrum powder and supplementary ingredients The dietary supplement substances: Active ingredien: Enzymatically treated bovine colostrum powder 2.3 mg 1.6 % Supplementary ingredients: Lactase (Derived from yeast) 0,15 mg 0.1 % HPMC (Hydroxypropyl Methylcellulose) acid-resistant capsule 47 mg 31.8 % Microcrystalline cellulose (Derived from pulp) 98,4 mg 66.5 % Dosage for adults: 2 - 10 capsules daily (stronger version 9 capsules daily) Route of administration: oral Contraindication: allergy to dairy product components Precaution: pregnancy and lactation Storage: Can be stored in at + 5 to +25°C, on dry place for up to two years Manufacturer: Saisei Pharma, Osaka, MORIGUCHI city, OKUBO-cho, 3-34-8. Japan
45650464|NCT05245045|Procedure|Shengtaibufen Photodynamic Therapy(STBF-PDT)|Shengtaibufen Photodynamic Therapy(STBF-PDT)
45650465|NCT05245045|Procedure|Red light|Red light
45650466|NCT05416281|Other|Robotic Vacuum|Participants will be provided with a Roomba iRobot vacuum and will be asked to use the vacuum in their home for 8 weeks. Exposure to environmental exposures will be evaluated before and after the intervention using silicone wristbands.
45650467|NCT03663595|Other|Model 1|Model 1 will be composed of exercises focusing on local (knee) and proximal (hip) factors.
45928243|NCT00019968|Drug|melphalan|
45450800|NCT02206516|Device|Transcranial Direct Current Stimulation|
45450801|NCT02206594|Procedure|Descemetorhexis|
45450802|NCT02201368|Drug|Triheptanoin (SpezialölÒ 107®)|"Randomization: Treatment with Triheptanoin for 6 months~Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~Crossover: Treatment with MCT(Medium-Chain Triglycerides)for 6 months"
45650468|NCT03663595|Other|Model 2|Model 2 will be composed of exercises focused on the local (knee) and distal (ankle and foot) factors.
45650469|NCT05416203|Behavioral|Brief Enhanced Anxiety Sensitivity Treatment|BEAST is a CBT-based intervention that includes psychoeducation, identifying and challenging maladaptive thoughts, and interoceptive exposure. The intervention is delivered through a single virtual face-to-face session supplemented with a mobile app for two weeks after the face to face session.
45650470|NCT04852523|Drug|18F-fluciclovine|18F-Fluciclovine is a synthetic L-leucine amino acid used clinically for PET imaging in patients with biochemical recurrence of prostate cancer following definitive therapy. The pancreas accumulates striking amounts of Axumin, where it is considered a normal finding. Pancreatic beta-cell function may be slow to recover following pancreatic transplantation and may vary as a function of perioperative steroid administration, acute rejection, inadequate islet cell transplantation, allograft pancreatitis or compromised blood supply. Viability of the allograft is a common clinical concern and is difficult to assess based on insulin, C-peptide, and blood sugar levels. Rapid identification of compromised allograft viability is critical in the management of these patients.
45650471|NCT04846361|Other|Vaginal hygiene wash|vaginal hygiene wash containing Propylene Glycol, Ethylhexylglycerin, Lactic Acid, Sodium Pyrrolidone Carboxylic Acid, Alpha-Glucan Oligosaccharide, Lactococcus Ferment Lysate, Octenidine Hydrochloride plus all other ingredients in placebo wash
45799662|NCT04809493|Procedure|Conventional dialysis treatment|Conventional dialysis treatment
45799663|NCT04809493|Procedure|Isonatremic dialysis treatment|Isonatremic dialysis treatment
45799664|NCT02550743|Drug|BYL719|
45799665|NCT02550743|Drug|Capecitabine|
45799666|NCT02550743|Radiation|Radiation|
45799667|NCT02502461|Procedure|cuff palpation|Inflated endotracheal tube cuff palpated through anterior extra-thoracic trachea while tube is gently moved to place the cuff midway between cricoid and sternal notch.
45928244|NCT00019968|Drug|tumor necrosis factor|
45928245|NCT00020007|Drug|isolated perfusion|
45799668|NCT02437253|Drug|Adalimumab|Subjects will be treated with adalimumab (20 mg [weight 15-<30 kg] or 40 mg [weight ≥30 kg] administered subcutaneously [subQ] every other week) or placebo for 16 weeks, then cross-over to the other group for 16 weeks.
45799669|NCT02437253|Other|Placebo|Saline placebo
45928246|NCT00020007|Drug|paclitaxel|
45928247|NCT00020007|Procedure|hyperthermia treatment|
45928248|NCT00142454|Drug|Imiquimod|Patients applied imiquimod cream at bedtime every day for 5 consecutive days (for the first 5 days of Cycles 1-3 and for the first 4 days of Cycle 4) at a dose of 250 mg as supplied in single-use packets to a 4 x 5 cm area of healthy skin, alternating among the extremities (upper inner arms and inner thighs) in each cycle. The cream was to be rubbed into the skin until it was no longer visible. Patients were encouraged to wash their hands before and after applying cream. The application site was not occluded. The next morning, 6 to 10 hours after initial application, the treated area was washed with mild soap and water to remove any residual cream.
45928249|NCT00142454|Biological|NY-ESO-1 protein|NY-ESO-1 protein was injected intradermally by a study physician or nurse at a dose of 100 μg into the imiquimod-pretreated area on Day 3 of each cycle for 4 consecutive 21-day cycles.
45928250|NCT00020046|Drug|docetaxel|
45928251|NCT00020046|Drug|thalidomide|
45928252|NCT00020124|Drug|doxorubicin hydrochloride|
45928253|NCT00020202|Drug|FR901228|
45928254|NCT05576675|Drug|sufentanil + nalbuphine|sufentanil 100 μ g + nalbuphine 40 mg
45928255|NCT05576675|Drug|Sufentanil|sufentanil 200 μ g
45928256|NCT05576675|Drug|hydromorphone + nalbuphine|hydromorphone 10 mg+ nalbuphine 40 mg
45928257|NCT00020358|Biological|aldesleukin|
45928258|NCT00020358|Biological|gp100 antigen|
45928259|NCT00020358|Biological|incomplete Freund's adjuvant|
45799670|NCT02551757|Device|Auto-titrating CPAP|Auto-titrating CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with active-CPAP included patient education, desensitization of CPAP through brief periods of daytime use, adjustments of humidity and mask (including addition of a chin strap), decreasing CPAP maximum pressure and use of expiratory pressure relief (CFlex) for patients treated with active-CPAP.
45928260|NCT00020358|Biological|tyrosinase peptide|
45928261|NCT05576636|Behavioral|Simulation training|"Expectations regarding the scenario were explained to the participants before the implementation. They were given information about the standard patient. Roles were distributed, and the implementation time of the scenario was announced. Written permission was obtained from students involved in the scenario. The intervention group was given scenario-based education appropriate for the approach to a standard patient with COVID-19. During the implementation of the scenario, the instructor did not interfere with students, and after the feedback, the show-do method was used to improve the incorrect skill steps. Two instructors evaluated students' performance on the standard patient simulation as achieved-failed and the application was recorded as a pre-test."
45928262|NCT05576636|Other|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
45928263|NCT00020397|Biological|NY-ESO-1 peptide vaccine|
45928264|NCT00020397|Biological|aldesleukin|
45799671|NCT02551757|Device|Sham-CPAP|Sham-CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with sham-CPAP included patient education, desensitization of CPAP through brief periods of daytime use and adjustments of humidity and mask, including addition of a chin strap.
45799672|NCT02437487|Drug|SER-109|SER 109 is a rationally designed ecology of bacterial spores enriched from stool donations obtained from healthy, screened donors.
45799673|NCT02437487|Drug|Placebo|Placebo will be identical to the investigator product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
45799674|NCT01827787|Drug|Eribulin|
45450803|NCT02201368|Dietary Supplement|MCT (Medium-Chain Triglycerides)|"Randomization: Treatment with MCT(Medium-Chain Triglycerides)for 6 months~Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~Crossover: Treatment with Triheptanoin for 6 months"
45450804|NCT02206672|Other|Micro reinjection of autologus adipose tissue|
45450805|NCT02198872|Other|Exercise, Aerobic (Water based)|Patients of this group will be submitted to an aerobic water based physical training
45450806|NCT02198872|Other|Land Group|Patients of this group perform physical training on bicycle.
45450807|NCT02206750|Other|Clean Air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
45799675|NCT01828255|Device|SENSIMED Triggerfish®|
45799676|NCT04747249|Other|Psychological support|Psychological care will be based on a monthly interview lasting approximately 45 minutes for 6 months.
45928265|NCT00020475|Drug|gp100 antigen|
45928266|NCT00020475|Drug|interleukin-2|
45928267|NCT00020475|Drug|MART-1 antigen|
45928268|NCT00020475|Drug|Montanide ISA-51|
45928269|NCT00020553|Procedure|psychosocial assessment and care|
45928270|NCT05576480|Radiation|Short-course radiotherapy|5×5Gy in Week 1
45928271|NCT05576480|Drug|Penpulimab|Apply once in the first week, then every 3 weeks from the third week for four cycles
45928272|NCT05576480|Drug|CAPEOX|Apply every 3 weeks from week 3 for 4 cycles
45928273|NCT05576480|Procedure|TME surgery|Patient will receive radical rectal cancer surgery
45928274|NCT00020631|Drug|pirfenidone|
45928275|NCT05576324|Drug|Elexacaftor / Ivacaftor / Tezacaftor|Elexacaftor / Ivacaftor / Tezacaftor is a triple drug therapy that modulates CFTR availability at (apical) cell membranes and increases opening probability.
45928276|NCT00020709|Drug|cisplatin|Given IV
45928277|NCT00020709|Drug|docetaxel|Given IV
45928278|NCT00020709|Drug|etoposide|Given IV
45928279|NCT00020709|Drug|gefitinib|Given orally
45928280|NCT00020709|Radiation|radiation therapy|Undergo radiation therapy
45928281|NCT00020709|Other|placebo|Given orally
45928282|NCT04733690|Dietary Supplement|Common bean product|"Healthy volunteers Healthy volunteers in the GI and FII studies will participate in the study during 3 test days for each of the studies. The reference food will be tested 2 times and the test food 1 time in each participant.~T2DM patients T2DM patients will participate in the study for one test day for the assessment of postprandial glycemic, insulinemic and satiety responses.~For both healthy volunteers and T2DM patients, the following will be assessed during study days: 24-hour of dietary recall; weight, height, waist and hip circumferences; blood pressure; and body composition using bioelectrical impedance analysis (BIA). Participants will be fed with a portion of the test or reference food and 250ml water. Two fasting blood samples (-5 and 0 min) and postprandial blood samples (15, 30, 45, 60, 90 and 120 min) will be collected"
46072396|NCT04732962|Procedure|Total Knee Replacement (TKR)|A total knee replacement occurs when a diseased or damaged knee joint is totally replaced with an artificial joint called an implant. The implant consists of high-grade metal and plastic components that fuse to the resurfaced bone. It is designed to move like a healthy human joint.
45928283|NCT00020748|Drug|epirubicin hydrochloride|
45450808|NCT02206750|Other|Ozone|Each subject will be exposed up to 0.3ppm ozone for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
45650472|NCT04846361|Other|placebo wash|placebo wash containing water, disodium cocoamphodiacetate, sodium chloride, sodium glycolate, acrylates copolymer, potassium laureate phosphate, tripotassium phosphate, laurel glucoside, lauramidopropyl hydroxysultaine, disulfonate de sodium, Polyethylene glycol (PEG)-120 Methyl Glucose Trioleate, Propanediol, Glycol distearate, Laureth-4, Cocamidopropyl betaine, Potassium Lactate, Caprylyl Glycol, Disodium ethylenediaminetetraacetic acid (EDTA), Potassium Hydroxide, and Perfume
45650473|NCT05244967|Other|vaginal swab|self-sampling, vaginal swab
45650474|NCT05416125|Drug|Lisdexamfetamine Dimesylate|Vyvanse treatment
45650475|NCT05416125|Behavioral|Lifestyle therapy|Lifestyle treatment
46072397|NCT04724421|Drug|Voxelotor|synthetic small molecule
45928284|NCT00020748|Drug|irinotecan hydrochloride|
45650476|NCT04429373|Procedure|Implant installation with PRF membrane|Platelet-rich fibrin membrane over the buccal aspect of implant site after dental implant installation
45650477|NCT04429373|Procedure|Implant installation without PRF membrane|Implant installation contralateral to the experimental side without PRF membrane
45799677|NCT02247427|Device|Cardiac Resynchronization Therapy Device|Cardiac Resynchronization Therapy Device pacing activity, on or off
45799678|NCT02438423|Biological|Inactivated influenza vaccine|Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season
45799679|NCT02438423|Other|Placebo|
45799680|NCT02553395|Device|Phenacite (Test) contact lens|
45799681|NCT02553395|Device|comfilcon A contact lens|
46072398|NCT04721132|Biological|Atezolizumab|Given IV
46072399|NCT04721132|Biological|Bevacizumab|Given IV
46072400|NCT04721132|Procedure|Therapeutic Conventional Surgery|Undergo surgery
46072401|NCT04719988|Biological|Blood sample collection|"A total of 9 EDTA (ethylenediaminetetraacetic acid) tubes will be collected at each time point to perform:~PBMC collection: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell [PBMC] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection: Two 4 ml EDTA tube should be frozen in each investigation center for ctDNA collection."
46072402|NCT04719988|Procedure|Biopsy|A tumor biopsy will be performed at 2 months after enrollment.
46072403|NCT04711837|Drug|HSK3486|HSK3486 for induction of general anesthesia.
45450809|NCT02201602|Drug|Gliclazide|
45450810|NCT02201602|Drug|Glibenclamide|
45450811|NCT02201758|Dietary Supplement|Flaxseed lignan-enriched complex (FLC)|Subjects will undergo treatment with FLC for an 8-week period; participants will take 300 mg flaxseed lignan-enriched complex (FLC) taken orally twice daily
45450812|NCT02201758|Other|Placebo|Placebo will consist of unflavored whey protein (manufactured by Natural Factors®)
45799682|NCT01829503|Drug|decitabine and cytarabine|
45450813|NCT02257996|Behavioral|Online Systematic Brief Psychodynamic Psychotherapy|Systematic Adaptative Diagnosis System will be applied in both groups at two different times: pre-treatment and post-treatment
45450814|NCT02201836|Other|One time music therapy|
45799683|NCT01829503|Other|Supportive Care|blood product transfusions, antiemetic medications, antiviral and antifungal medications, empiric antibiotics
45799684|NCT04691167|Device|repetitive trans magnetic stimulation|Repetitive Trans-cranial Magnetic Stimulation (rTMS) is a relatively safe and non-invasive method to modulate neuronal activity; rTMS uses alternating magnetic fields in a certain frequency to induce an electric current in the underlying brain tissue.
45799685|NCT04675957|Other|cardiac rehabilitation|stationary or ambulatory cardiac rehabilitation
45799686|NCT04654507|Drug|Dexamethasone Oral|Drug: Dexamethasone 0.3mg/kg/dose twice daily for 3 days
45450815|NCT02201836|Other|Group music therapy|
45650478|NCT05371977|Procedure|Trabeculectomy|trabeculectomy glaucoma surgery
45650479|NCT05371977|Procedure|Deep Sclerectomy|deep sclerectomy glaucoma surgery
45650480|NCT05244811|Drug|Combined Oral Contraceptive|effect of cocs in treatment of ovarian cysts
45650481|NCT05244811|Drug|Progestin|effect of progestin in treatment of ovarian cystn
45650482|NCT05564403|Drug|Binimetinib|Given PO
45799687|NCT04654507|Drug|Placebo|Placebo
45799688|NCT02504645|Drug|IPP-201101|
45799689|NCT02504645|Drug|Placebo|
45650483|NCT05564403|Procedure|Biopsy|Undergo biopsy
45799690|NCT02504645|Other|Standard of Care|
45799691|NCT02267629|Drug|Rapastinel (formerly GLYX-13)|10 mg/kg IV Rapastinel (formerly GLYX-13)
45799692|NCT05744089|Device|PCA pump|simple hydromorphone PCA pump model, which is a rapid titration followed by a convenient maintenance technique, to treat home cancer patients with severe or critical cancer pain or refractory cancer pain.
45799693|NCT05742763|Combination Product|Ibuprofen and PRP|The primary research purpose is to determine if the use of ibuprofen [arm #1] vs acetaminophen [arm #2] vs a placebo control group [arm #3] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
45799694|NCT05742763|Combination Product|Acetaminophen and PRP|The primary research purpose is to determine if the use of ibuprofen [arm #1] vs acetaminophen [arm #2] vs a placebo control group [arm #3] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
45928285|NCT02971865|Behavioral|CBT/CMT|Cognitive Behavioral Therapy (CBT - training to change nutritional thoughts and behaviors) and Chiropractic Manipulative Therapy (CMT - High Velocity, low amplitude chiropractic manipulation) were delivered in average total 8 visits in a year. The interventions were comparable in format (individual visit), duration (30 minute visits), frequency (monthly), and number of participants per group (see intervention details). Each intervention was delivered according to a protocol in which all instructors were trained. (Figure 3: Chiropractic/Behavioral health and Primary care Integration Protocol.) Routine care varied with patient complaints at the time of visit.
45928286|NCT02971865|Other|Control group traditional primary care|No change in care usually given
45928287|NCT00020787|Biological|G17DT Immunogen|Dose: 500 micrograms in 0.2mL Route: Deep intramuscular Schedule: Days 8, 36, and 64; an additional dose at week 2, cycle 7 will be administered
45928288|NCT00020787|Drug|cisplatin|dose: 100 mg/m2 Route: i.v. infusion in 500 mL in 0.9% NaCl administered up to 3 hours Schedule: day 1, and then every 4 weeks.
45928289|NCT00020787|Drug|fluorouracil|Dose: 1000mg/m2/day Route: 24-hour continuous infusion in 0.9% NaCl over 5 days Schedule: Day 1 to Day 5 (5-day infusion) and then every 4 weeks
45928290|NCT05576168|Biological|overexpression STRA6/miRNA3|RBP4 express in patients with T2DM or not
45928291|NCT00020826|Other|quality-of-life assessment|QLQ-C30 questionnaire administered. STO22 questionnaire administered.
45928292|NCT00391937|Device|Articular Surface Replacement (ASR) hip prosthesis|a DePuy ASR™ primary resurfacing femoral and acetabular component (DePuy International Ltd, Leeds, UK). The cement that will be used is one dose of DePuy SmartSet® GHV 40 gram, a high-viscosity cement with gentamycin (DePuy CMW, Blackpool, UK). Instrumentation includes standard ASR™ instruments and Ci™ Software for DePuy ASR™ System1.0.
45928293|NCT00020865|Drug|cefepime hydrochloride|
45928294|NCT00020865|Drug|levofloxacin|
45928295|NCT00020904|Drug|ixabepilone|
45928296|NCT05574725|Device|Smartphone|review of the smartphone video on patients phone by general neurologist and epileptogist each separately with comment on onquality of video using videoquality scale(10), semiology, seizure diagnosis
45928297|NCT05574647|Diagnostic Test|bpMRI|biparametric MRI takes 30-40 minutes and requires a contrast injection called gadolinium (like a dye). This is also called long MRI and is most commonly used in the NHS.
45928298|NCT05574647|Diagnostic Test|Image-Fusion targeted and systematic Biopsy|During image fusion targeted biopsy, the biopsy operator uses the MRI scans that were taken beforehand but laid on top of the live ultrasound images during the biopsy. This uses software and takes a few minutes longer to perform. Once the MRI images and ultrasound images are 'fused', the actual biopsies are taken as normal.
45928299|NCT00020943|Biological|filgrastim|5 ug/kg subQ daily day 4 until ANC >10,000 (or ANC> 5000 2X)Tx 1, 2, 4 10 ug/kg subQ daily day 14 until completion of PBSC collection Tx 3
45928300|NCT00020943|Biological|rituximab|375 mg/sq m IV infusion at , or = 400 mg/hr day 1 Tx 1, 2, days 5 & 12 Tx 3, and weekly for 2 doses Tx 5
45928301|NCT00020943|Drug|carmustine|15 mg/kg IV infusion over 2 hours Day 6, Tx 4
45928302|NCT00020943|Drug|cyclophosphamide|2000 mg/sq m IV infusion over 2 hours Day 3, Tx 1 & 2 100 mg/kg IV infusion over 2 hours Day 2, Tx 4
45928303|NCT00020943|Drug|cytarabine|2000 mg/sq m IV infusion BID over 2 hours x 8 doses Days 1-4, Tx 3
45928304|NCT00020943|Drug|doxorubicin hydrochloride|50 mg/sq m IVP Day 3, Tx 1& 2
45928305|NCT00020943|Drug|etoposide|40 mg/kg total dose continuous IV infusion over 96 hours Days 1-4, Tx 3
45650484|NCT05564403|Procedure|Biospecimen Collection|Undergo collection of blood
45650485|NCT05564403|Procedure|Bone Scan|Undergo bone scan
45650486|NCT05564403|Procedure|Computed Tomography|Undergo CT
45650487|NCT05564403|Procedure|Echocardiography|Undergo ECHO
45650488|NCT05564403|Drug|Fluorouracil|Given IV
45650489|NCT05564403|Drug|Leucovorin Calcium|Given IV
45650490|NCT05564403|Procedure|Magnetic Resonance Imaging|Undergo MRI
45650491|NCT05564403|Procedure|Multigated Acquisition Scan|Undergo MUGA
45650492|NCT05564403|Drug|Oxaliplatin|Given IV
45650493|NCT04845659|Drug|Doptelet Pill|40 mg or 60 mg Doptelet orally 10-13 days before planned procedure.
45650494|NCT03614611|Device|Contiform pessary|"Patients will be asked to use the device for 12 weeks and to become comfortable with self-insertion and self-removal. The device can be worn continuously for 1 month. When placed in the vagina it retains its shape and supports the urethra during episodes of varied intraabdominal pressure. During the assessment test (24 hours pad test), patients will be encouraged to undertake any activity that would normally induce stress leakage.~The contiform device is approved by Health Canada since 2017-04-10 (Licence No.: 98950, Company ID: 134089, Device identifier: SKU 184)"
45928306|NCT00020943|Drug|leucovorin calcium|50 mg/sq m IV infusion q 6 hours x 3 doses after MTX, then 10 mg/sq m IV/PO q 6 hrs until MTX levels <0.05 uM, Tx 1 & 2
45928307|NCT00020943|Drug|methotrexate|300 mg/sq m IV infusion over 4 hrs Day 2 Tx 1 & 2
45650495|NCT04845581|Procedure|Diagnostic tests: Determination of the gingival phenotype, measure gingival thickness and width of keratinized tissue|Gingival thickness was measured using UGTM method and CBCT/ CAD with PDIP technology at upper incisors and canines in three points localized midbucally : Free gingival thickness (FGT), supracrestal ( SGT) and crestal (CGT). Width of keratinized tissue was measured using periodontal probe calibrated for 1 mm. The gingival phenotype was determined by both methods according to the following criteria: GT ≤ 0,7 mm - thin gingival phenotype, GT &gt; 0,7 mm ≤ 1,0 mm - medium gingival phenotype, GT &gt; 1,0 mm - thick gingival phenotype. Toincrease the repeatability of the results, two researchers tested the same values twice on 2days interval between sessions.
45928308|NCT00020943|Drug|prednisone|100 mg/sq m PO Days 3-7, Tx 1 & 2
45928309|NCT00020943|Drug|vincristine sulfate|1.4 mg/sq m IVP Day 3, Tx 1 & 2
45928310|NCT00020943|Procedure|peripheral blood stem cell transplantation|Stem cells collected during Tx 3 will be transfused follwing chemotx in Tx 4
45799695|NCT05742763|Combination Product|Placebo and PRP|The primary research purpose is to determine if the use of ibuprofen [arm #1] vs acetaminophen [arm #2] vs a placebo control group [arm #3] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
45928311|NCT00021021|Biological|anti-FLT-1 ribozyme|
45928312|NCT05574569|Behavioral|Group 1: Play Therapy|Play therapy will be given to children having emotional and behavioral problems.
45928313|NCT05574569|Behavioral|Group 2: Mindful Parenting|Culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.
45799696|NCT02504723|Drug|carvedilol|Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure >90 mm Hg.
45799697|NCT02504723|Drug|cyanoacrylate|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
45799698|NCT05738941|Procedure|radiofrequency ablation|17-G length-adjustable electrode (RITA RF Electrode;) a 200-W RF generator is going to be used,under CT fluoroscopic guidance. The type of the electrode and the length of the active tip will be selected according to the size, location, and shape of the tumor, as well as the operator preference.ablation will be performed with 100 W energy for 30 seconds. The number of electrodes placed, ablation time per electrode, total ablation time, and total energy delivered to targets, as well as the temperature of the lesions, will be recorded. For lesions less than 3 cm, surgery was performed with one electrode , and for lesions of 3 cm or more, two or more electrodes were used . The procedure may be followed by injection of bone cement through the same working cannula, and a long working time will be delivered (STABILIT, Merit Medical Systems, Inc.) for the optimal filling of the bone lesion
45928314|NCT05574569|Behavioral|Group 3: (Combined Interventions of both Group 1 & 2)|Play therapy will be given to children and in addition, culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.
45928315|NCT00021060|Drug|paclitaxel|Given IV
45928316|NCT00021060|Drug|carboplatin|Given IV
45928317|NCT00021060|Biological|bevacizumab|Given IV
45928318|NCT00021060|Other|laboratory biomarker analysis|Correlative studies
45928319|NCT05574413|Other|Moderate intensity continuous exercise|Participants will perform an acute bout of continuous cycling at 70% of the power output at lactate threshold until an energy expenditure of 350 kcal is achieved. Blood samples will be obtained immediately before and immediately, 30, and 90 minutes after exercise.
45928320|NCT05574413|Other|High intensity continuous exercise|Participants will perform an acute bout of continuous cycling at 10% of the difference between lactate threshold and VO2peak until an energy expenditure of 350 kcal is achieved. Blood samples will be obtained immediately before and immediately, 30, and 90 minutes after exercise.
45928321|NCT05574413|Other|High intensity interval exercise|Participants will perform an acute bout of interval cycling at at 10% of the difference between lactate threshold and VO2peak until an energy expenditure of 350 kcal is achieved. Blood samples will be obtained immediately before and immediately, 30, and 90 minutes after exercise.
45928322|NCT05574413|Other|Resting (no exercise) control|Participants will remain in a rested state (i.e., no exercise) for the entire session. Blood samples will be obtained at the same time-points as the exercise sessions.
45928323|NCT00021099|Drug|ixabepilone|Given IV
45928324|NCT05574257|Drug|Propofol|Propofol is injected at 25-100ug/kg/min (immediately after spinal anesthesia to the end of surgery) to maintain the BIS at 70-80.
45928325|NCT05574257|Drug|Remimazolam|Remimazolam is injected at 1-20ug/kg/min (immediately after spinal anesthesia to the end of surgery) to maintain the BIS at 70-80.
45928326|NCT05574218|Procedure|Glycine air powder|Every 3 months, ultrasonic instrumentation was carried out with an specific implant tip coated with Polyether Ether Ketone (PEEK), activated subgingivally and circumferentially around the implant. Then, the implants were treated with glycine powder air-polishing.
45928327|NCT05574218|Procedure|Rubber cup polishing|Every 3 months, ultrasonic instrumentation was carried out with an specific implant tip coated with Polyether Ether Ketone (PEEK), activated subgingivally and circumferentially around the implant. Then, the implants were treated with rubber cup and a polishing paste.
45928328|NCT00021138|Behavioral|smoking cessation intervention|
45928329|NCT00021138|Drug|nicotine|
45928330|NCT00020670|Biological|CD 40|
45928331|NCT05574179|Drug|Dexmedetomidine injection|Inj precedex 200mcg in 1ml given in stat doses
45928332|NCT05574179|Drug|Midazolam|Inj.midazolam 5mg/5ml given in stat doses
45928333|NCT00021216|Drug|bortezomib|Given IV
45928334|NCT00021216|Other|laboratory biomarker analysis|Correlative studies
45928335|NCT00021216|Other|pharmacological study|Correlative studies
45928336|NCT00021294|Drug|eflornithine|
45928337|NCT00021294|Drug|triamcinolone|
45928338|NCT00021333|Biological|filgrastim|
45928339|NCT00021333|Drug|cisplatin|
45928340|NCT00021333|Drug|paclitaxel|
45928341|NCT00021333|Radiation|radiation therapy|
45928342|NCT05574023|Device|Use of Predictive Alarm for hypoglycaemia or hyperglycaemia|"Patients use CGM sensor with Predictive Alarm set at 70 mg/dl in 20 minutes for hypoglycemia and at 250 mg/dl in 20 minutes for hyperglycemia.~in case of alarm from the hypoglycemia predictive algorithm, the indicated treatment was 0.1g of sugar/kg of body weight;~in case of alarm from the hyperglycemia predictive algorithm, the indication was to give an extra shot of rapid-acting insulin. The dose will be calculated on the basis of personal insulin sensitivity factor (ISF), considering as target a blood glucose of 120 mg/dl and 250 mg/dl as the projected blood glucose level that will be reached in 20 minutes. This could be done only if there is no active insulin on-board, after at least 3 hours from the last rapid-acting insulin injection."
45928343|NCT05574023|Device|Use of Alarm on Threshold for hypoglycaemia or hyperglycaemia|"in case of alarm of hypoglycemia, the indicated treatment was 0.3g of sugar/kg of body weight, max 15g.~in case of alarm of hyperglycemia, the indication will be to give an extra shot of rapid-acting insulin. The dose will be calculated on the basis of personal insulin sensitivity factor (ISF), considering as target a blood glucose of 120 mg/dl and 250 mg/dl as blood glucose level to correct. This could be done only if there is no active insulin on-board, after at least 3 hours from the last rapid-acting insulin injection."
45928344|NCT00021372|Drug|estramustine phosphate sodium|
45928345|NCT00021372|Drug|paclitaxel|
45928346|NCT05573945|Behavioral|Family Education and Active Listening|Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator. In addition, weekly meetings of parent/s with a psychologist in a private location for an active listening counselling session.
45928347|NCT05573945|Behavioral|Family Education|Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator.
45928348|NCT00392093|Drug|Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d|
45928349|NCT00018161|Drug|Mecamylamine|
45928350|NCT00018161|Drug|Nicotine Patch|
45928351|NCT00018161|Behavioral|Cigarette brand switching|
45928352|NCT00021450|Drug|bicalutamide|
45650496|NCT05244421|Other|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula, 4 hours of Healthy Relationships workshops, and 4 hours of Economic Stability workshops over the course of 8 weeks. Participants also receive ongoing job readiness support and post-employment support.
45928353|NCT00021450|Drug|goserelin acetate|
45650497|NCT05404555|Other|two-dimensional speckle tracking echocardiography|Two-dimensional speckle tracking echocardiography is used to assess cardiac function in all enrolled patients
45650498|NCT03043859|Behavioral|Pure Prairie Living Program|Education session (n=5) on healthy eating, menu planning and skill building for effective diabetes management
45928354|NCT00021450|Procedure|adjuvant therapy|
45928355|NCT00021450|Radiation|radiation therapy|
45928356|NCT00021489|Drug|Abacavir sulfate|
46072404|NCT04711837|Drug|Propofol|Propofol for induction of general anesthesia.
45928357|NCT00021489|Drug|Mycophenolate mofetil|
45928358|NCT05573867|Other|Physical activity on prescription|"All participants, regardless of group affiliation, receive routine written and verbal information about PSF and information about recommended level of physical activity. Intervention group receive as add on individualized, digital coaching twice a week for 12 weeks with Physical activity on prescription (FaR) to increase physical activity and reduce PSF after stroke."
45928359|NCT00021528|Drug|citalopram|
45928360|NCT00021528|Drug|BuproprionSR|
45928361|NCT00021528|Drug|buspirone|
45928362|NCT00021528|Drug|Lithium|
45928363|NCT00021528|Drug|mirtazapine|
45928364|NCT00021528|Drug|nortriptyline|
45928365|NCT00021528|Drug|sertraline|
45650499|NCT05395065|Device|Silver Diamine Fluoride/Sodium Fluoride Varnish|Application of dental caries arresting topical medication
45650500|NCT02710669|Drug|(R)-propafenone|
45928366|NCT00021528|Drug|tranylcypromine|
45928367|NCT00021528|Drug|VenlafaxineXR|
45928368|NCT00021528|Behavioral|Cognitive Therapy|
45928369|NCT00021528|Drug|T3 (Triiodothyronine)|
45928370|NCT05573711|Other|assessments|Assessments, no specific intervention
45928371|NCT00021567|Drug|Interferon Gamma for Aerosol|
45928372|NCT00021645|Drug|Vitamin E|
45928373|NCT00021723|Biological|AN-1792 also known as AIP-001|
45928374|NCT05573633|Procedure|ECG|the POAF will be diagnosed using a 12-lead ECG and according to the usual monitoring protocols for patients in the cardiac surgery department of Amiens University Hospital.
45928375|NCT05573633|Procedure|scanwatch|POAF will be diagnosed with a Withings SM (ScanWatch). FAPO diagnosed by the SW will have to be confirmed by a 12-lead ECG.
45928376|NCT00394641|Behavioral|listening to music / stories via stereophonic headphones|
46072405|NCT04703192|Drug|Valemetostat Tosylate|Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity
46072406|NCT04696653|Other|Comprehensive Unit Based Safety Program (CUSP)|CUSP is a quality improvement strategy developed by the Johns Hopkins University Armstrong Institute for Patient Safety and Quality that is used to improve care delivery.
46072407|NCT04669457|Drug|Intra-nasal Dexmedetomidine|Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.
46072408|NCT04669457|Drug|Oral Midazolam|Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.
46072409|NCT04666649|Drug|Venetoclax and pegcrisantaspase|Therapeutic
45799699|NCT05738941|Procedure|angioembolization|"Use a 4- or 5-French diagnostic catheter for the initial angiogram and either continue to use this catheter for embolization where the feeding vessel is large or add a standard 2.3- to 2.5-French microcatheter as a coaxial technique .~- Injection of embolizing material in the feeding vessels using gel foam , PVA or histoacryl according to the nature of the bony lesion"
45799700|NCT02439281|Drug|Clonidine|Only the Ropivacaine /clonidine group will receive clonidine (2mcg/kg) injected with ropivacaine.
45799701|NCT02439281|Drug|Ropivacaine|One hundred pediatric patients (10-17 years old) scheduled for laparoscopic appendectomy will be randomized to the two treatment groups: the Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilateral in Both groups will receive ropivacaine 0.5% (10 ml) injected bilaterally for the rectus sheath block
45928377|NCT05573594|Other|Muscle Energy Technique|"The Janda method (Post isometric relaxation PIR Technique), one of the Muscle Energy Techniques, was used on m.piriformis, m.quadratus lumborum, m.hamstring, m.psoas major muscles in the study group. First, the dysfunctional muscle was stretched passively by the physiotherapist up to the movement barrier, and 5-7 seconds of isometric muscle contraction in the opposite direction was requested from the patient at the barrier. This practice was continued until muscle tension or joint dysfunction disappeared.~All participants performed standard home exercises consisting of stretching and strengthening. These exercises were taught to the participants by the physiotherapist in the first treatment session, and when they came to each treatment session, it was questioned whether they did it or not, and a control chart was created for exercise follow-up."
45928378|NCT05573594|Other|conventional physical therapy and rehabilitation|In the content of conventional physiotherapy program for both groups; Hot Pack (20 min), Ultrasound (ITO brand 1 MHz and 1.5 W/cm2, 5 min), Transcutaneous Electrical Nerve Stimulation (TENS, 50-100 Hz, 20 min) and standard home exercises were included. The program went 5 times a week, 10 consecutive sessions. Each session lasted an average of 45 minutes.
45928379|NCT05573516|Procedure|Open reduction and internal fixation|unicortical fully threaded 4mm screws will be used as positional screws after completely reducing the fracture
45928380|NCT00394797|Procedure|mitral valve annuloplasty|
45928381|NCT05573438|Other|Group fructose|Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with fructose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of fructose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
46072410|NCT04647851|Other|Remote exercise intervention Down syndrome|See arm description
46072411|NCT04644276|Device|Mask with Mask Adhesive/Arm 1|Patients will be randomized to Arm1 if they receive the mask adhesive and mask on the first study night then the mask without the mask adhesive on the second study night.
45650501|NCT02710669|Drug|(S)-Propafenone|
45650502|NCT02710669|Drug|Placebo|
45650503|NCT01649661|Behavioral|questionnaire|
45650504|NCT04844645|Other|mini program|To design, construct, and test the mini program in patients managing cancer pain
45799702|NCT01830205|Drug|Daclatasvir|
45799703|NCT02505269|Drug|Brentuximab Vedotin|
45799704|NCT02505269|Drug|Adriamycin|
45799705|NCT02505269|Drug|Dacarbazine|
45799706|NCT02440139|Device|ClearRead CT Insight|During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed and the vessel suppressed same slice with the vessel suppressed view as the intervention. The second image, vessel suppressed, will be grayed out until the radiologist move the mouse to the second panel. The radiologist will mark locations. These may or may not correspond to the locations of the CAD markers. As before, the radiologist will assign a level of suspicious to each mark and indicate the need, if any, of an additional diagnostic action (CT Follow-up, Contrast CT, PET-CT, or Biopsy).
45799707|NCT02554799|Drug|MMV390048 formulation A|MMV390048 formulation A, tablet
45799708|NCT02554799|Drug|MMV390048 formulation B|MMV390048 formulation B, tablet
46072412|NCT04644276|Device|Mask without Mask Adhesive / Arm 2|Patients will be randomized to Arm 2 if they receive the mask without mask adhesive on the first study night then the mask adhesive with the mask on the second study night.
46072413|NCT04642365|Drug|RO7296682|RO7296682 will be administered as per the schedules specified in the respective arms.
45650505|NCT04844645|Other|conventional pharmaceutical care|conventional pharmaceutical care
45650506|NCT04259229|Other|Mediterranean Diet -- Mushrooms|During the 2-week baseline period all participants will consume their usual, unrestricted self-chosen diets. During intervention weeks 1-8, all participants will consume the same Mediterranean-style diet, rich in fruits and seafoods and lower in dairy, designed to meet their estimated energy needs. The mushroom group will consume 0.5 cups/day of cooked mushrooms (white button mushrooms and yellow oyster mushrooms on 4 and 3 days/week, respectively). All foods will be provided to subjects during the intervention to achieve the desired eating pattern.
45799709|NCT00422123|Drug|Quetiapine fumarate (Seroquel) SR|
45799710|NCT04743713|Other|UWRI-Tr|Questionnaire
45799711|NCT00559273|Drug|Methoxy polyethylene glycol-epoetin beta|1.2 mcg/kg SC monthly, starting dose
45799712|NCT00559273|Drug|Darbepoetin alfa|0.45 mcg/kg SC weekly or 0.75 mcg/kg every 2 weeks, starting dose
45799713|NCT05131607|Procedure|Supine MRI|After completion of the standard prone MRI sequences the patient will be positioned supine, coils will be placed and baseline images will be obtained. Then a second dose of contrast equal to the first dose will be given, and additional images will be obtained
45799714|NCT02506673|Device|Zeiss, Cinema ProMED (audiovisual equipment)|
45799715|NCT02506673|Drug|Midazolam|
45799716|NCT02506673|Device|Skin Conductance Monitor|
45799717|NCT05734729|Device|EFFIDRAIN|. Effidrain is a progammable, light-weight, portable drain regulator that can control the rate and volume of body fluid being drained, while empowering the user with information on dynamic changes of pressure within the body cavity being drainged. It is able to adapt to existing drainage systems via a standard medical luer taper connector, and comes with a failsafe system to alert users of drainage irregularities.
45928382|NCT05573438|Other|Group Sucrose|Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with sucrose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of sucrose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
45928383|NCT05573438|Other|Group Glucose|Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with glucose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of glucose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
45928384|NCT00021762|Biological|HIV-1 Immunogen|
45799718|NCT05734729|Device|Manual drainage system|drainage systems required manual control and are unautomated; consequent unintended rapid intravascular and extravascular fluid shifts may result in clinical instability.
45928385|NCT00021762|Procedure|Structured Treatment Interruption|
45928386|NCT00021801|Procedure|Islet Cell Transplantation|
45928387|NCT05573204|Drug|Obeticholic Acid Oral Tablet|Obeticholic acid used as 10 mg tablet once daily for 6 months
45928388|NCT05573204|Drug|Vit E|Vitamin E used as 400 mg soft gelatin capsules twice daily for 6 months
45928389|NCT05573087|Other|Aquatic Based Exercise|10 minutes of exercise with two 20 second sprints three days per week for 8 consecutive weeks
45928390|NCT05573087|Other|Land Based Exercise|10 minutes of exercise with two 20 second sprints three days per week for 8 consecutive weeks
45650507|NCT04259229|Other|Mediterranean Diet -- Control|During the 2-week baseline period all participants will consume their usual, unrestricted self-chosen diets. During intervention weeks 1-8, all participants will consume the same Mediterranean-style diet, rich in fruits and seafoods and lower in dairy, designed to meet their estimated energy needs. The control group will not consume mushrooms at any point. All foods will be provided to subjects during the intervention to achieve the desired eating pattern.
45799719|NCT02508077|Drug|Fluorouracil|Given IV
45928391|NCT05572970|Drug|Balstilimab|An anti-programmed death 1 (PD-1) monoclonal antibody.
45928392|NCT05572970|Drug|Zalifrelimab|An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
45928393|NCT02972021|Device|High-flow nasal cannula|
45928394|NCT00021996|Drug|valdecoxib|
45928395|NCT00022035|Biological|trivalent influenza vaccine|
46072414|NCT04642365|Drug|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
46072415|NCT04633980|Drug|Mixture 3,6% H2 in N2 (96.4%)|Route of administration: intra-nasal Debit 1L/min, 24h/24h (3 hours withdrawal tolerated) duration of treatment: 24 hours, 3 days and 6 days
46072416|NCT04626635|Drug|REGN7075|Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W)
45650508|NCT02693041|Drug|probiotic|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with LGG during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
45650509|NCT02693041|Drug|placebo|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with placebo during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
45650510|NCT04851743|Other|Dry needling|The experimental extremity will received a single treatment session of TrP dry needling as follows: the therapist will located the TrP and will applied manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrPs for 60 seconds.
45650511|NCT05392959|Drug|Dapagliflozin 10 mg Tab|Dapagliflozin 10 mg per day
45650512|NCT05392959|Drug|Placebo|Placebo for dapagliflozin film-coated tablets 10 mg
46072417|NCT04626635|Drug|cemiplimab|administered concomitantly Q3W by IV infusion or SC injection
45799720|NCT02508077|Drug|Irinotecan Hydrochloride|Given IV
45799721|NCT02508077|Other|Laboratory Biomarker Analysis|Correlative studies
45799722|NCT02508077|Drug|Leucovorin Calcium|Given PO
46072418|NCT04590547|Drug|GLS-1027|GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity.
45799723|NCT02508077|Biological|Panitumumab|Given IV
45799724|NCT02268877|Other|Emergency Medicine Physician Ultrasound|An ultrasound will be performed by an emergency medicine resident or attending physician
45928396|NCT00022074|Drug|gabapentin|
45928397|NCT00022074|Procedure|quality-of-life assessment|
45799725|NCT02268877|Device|Ultrasound|An ultrasound will be performed by a radiology department technician
45928398|NCT04733807|Biological|BNT162b2 mRNA Covid-19 Vaccine|Hospital employers vaccinated with BNT162b2 mRNA against Sars-Cov2 are studied for serum antibody response.
45928399|NCT00022113|Drug|cilengitide|Given IV
45928400|NCT00022113|Other|pharmacological study|Correlative studies
45928401|NCT00022113|Other|laboratory biomarker analysis|Correlative studies
45928402|NCT05572931|Device|Fu's Subcutaneous Needling(FSN)|"Insertion points are both sides of 1) inferior edge of the scapula; 2)the midpoint of inferior edge of the posterior superior iliac spine and the ischial tuberosity.~FSN (Trocar Acupuncture Needle, Nanjing FSN Medical Co. , Ltd, China.) ) is a solid needle with plastic cannula tube on the outside. Add on swaying movement (SM) and reperfusion approach (RA) after the needle inserting into the subcutaneous layer. The SM is a horizontal fan sway movement with the base of the needle for the fulcrum, The SM speed is 200 times in 2 minutes. Apply RA when performing SM. RA movement is hip extension in prone position with resistance by physician's hand for 10 seconds. And then rest for 10 seconds. Repeat 3 cycles. The same RA is performed over the other three insertion point."
45928403|NCT05572931|Device|fine acupuncture needle|(36G, 0.5 inch, Wujiang city cloud & dragon medical device Co.,Ltd.) Only inserted to skin, not into the subcutaneous layer. No SM and RA.
45928404|NCT00022152|Drug|vinorelbine tartrate|
45928405|NCT05572814|Behavioral|Decision Support|Prompts will be provided to clinicians signaling gaps in guideline-directed care
45928406|NCT05572814|Behavioral|Referral|Patients will be referred to an interdisciplinary, expert guideline-directed medical therapy team
45928407|NCT00022191|Drug|cisplatin|
45650513|NCT04851977|Biological|Respiratory Syncytial Vaccine|BARS13 low dose (one dose of 10 μg rRSV-G protein/10 μg CsA by IM injection to the deltoid region of one arm, and one dose of placebo [saline/mannitol] by IM injection to the deltoid region of the other arm, given sequentially).
45650514|NCT04851977|Biological|Respiratory Syncytial Vaccine|BARS13 high dose (IM injection of 10 μg rRSV-G protein/10 μg CsA administered to the deltoid region of each arm [one injection of 10 μg rRSV-G protein/10 μg CsA per arm], given sequentially). The high dose is twice the strength of the low dose.
45928408|NCT00022191|Drug|gemcitabine hydrochloride|
45928409|NCT00022191|Drug|paclitaxel|
45799726|NCT04580095|Other|AI algorithm for apical foreshortening in echocardiography|The algorithm is based on artificial intelligence, giving the sonographer performing the echocardiographic exam real-time feedback on left ventricular apical foreshortening.The algorithm is developed using deep learning techniques by technologists at the Department of Circulation and Medical Imaging, NTNU.
45928410|NCT05571956|Other|Pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts establishment group|Pancreatic masses were sampled using a 22-gauge FNB needle. If a sufficient visible core was obtained on macroscopic inspection, the tissue materials from the following one needle pass were placed into the transfer medium for organoid generation. Using a tiny portion (about 20%) of the FNB sample, we isolated CAFs
45928411|NCT00022230|Biological|aldesleukin|
45928412|NCT00022230|Biological|filgrastim|
45650515|NCT04851977|Biological|Placebo|Placebo (IM injection of saline/mannitol administered to the deltoid region of each arm [one injection per arm], given sequentially).
45928413|NCT00022230|Biological|sargramostim|
45928414|NCT00022230|Biological|therapeutic autologous lymphocytes|
45928415|NCT00022230|Drug|cyclophosphamide|
45650516|NCT04851431|Behavioral|one-to-one peer mentoring|Weekly meetings with a peer family caregiver
45650517|NCT05370495|Drug|SY-201 Ophthalmic Solution 2.0%|SY-201 Ophthalmic Solution 2.0%
45650518|NCT05370495|Drug|SY-201 Ophthalmic Solution 1.0%|SY-201 Ophthalmic Solution 1.0%
45650519|NCT05370495|Drug|SY-201 Ophthalmic Solution 0.5%|SY-201 Ophthalmic Solution 0.5%
45928416|NCT00022230|Drug|doxorubicin hydrochloride|
45650520|NCT05370495|Drug|SY-201 Ophthalmic Solution Vehicle|SY-201 Ophthalmic Solution Vehicle
45650521|NCT04851665|Other|No Intervention - this was a qualitative analysis|No Intervention - this was a qualitative analysis
45650522|NCT05370417|Other|Use of fluoride toothpaste|All participants will receive brushing instruction and will be provided with toothpaste with a concentration equal to or greater than 1000ppm of fluoride, indicating three daily brushings. With this generalized measure, all of them receive basic treatment for hypersensitivity.
45799727|NCT04561297|Diagnostic Test|TDC differential value|TDC measurements in all patients agreeing to participate who are scheduled for a biopsy of a breast tumor or mass
45928417|NCT00022230|Drug|paclitaxel|
45928418|NCT05571020|Other|mat pilates|Both groups adapted for their rides by not participating in a different exercise and meal. In the study, they were not found in any store in the control groups. In the Mat-Pates Group, information about the 5 key elements of the study and pilates team, perspective (-neck-shoulder-waist-abdominal placement), lumbopel stabilization, scapular stabilization, review and information was covered. Then, in the study groups, it was purchased from groups of 5-6 people at most for one hour a day. In order to participate in all these application activities, he continues his life without participating in any evaluation.
45928419|NCT00022308|Drug|cisplatin|
45928420|NCT00022308|Drug|irinotecan hydrochloride|
45928421|NCT00022308|Radiation|radiation therapy|
46072419|NCT04590547|Drug|Placebo|Placebo looks like GLS-1027
45650523|NCT05370417|Radiation|Laser Therapy|"For laser application, the following dosimetric parameters will be used:~Low level laser diode (infra red) wavelength 808nm with a power of 100mW. Applied in three perpendicular points and in contact with the surface. One in the vestibular, mesial and distal cervical third and the third in the center of the lesion. (6) Applied 10 seconds per point with an energy of 1 J."
45650524|NCT05370417|Procedure|Simulated Laser Therapy|The same application described in the laser therapy group will be simulated, with the device turned off.
45928422|NCT00022347|Drug|canfosfamide hydrochloride|
45928423|NCT05569928|Other|Administration of deuterated compounds for kinetic study|Participants will be submitted to a standardized oral-fat load and kinetic study will be performed
45928424|NCT00022386|Biological|epoetin alfa|
46072420|NCT04579952|Device|transcranial Direct Current Stimulation|The current stimulation will be applied using 35 squares cm wide sponge electrodes
45650525|NCT05370417|Procedure|Sealant application|A glass ionomer sealant will be applied to the occlusal surface of the first permanent molar.
45650526|NCT03043781|Other|Continuous epidural infusion|Continuous infusion, 5 ml/h
45650527|NCT03043781|Other|Intermittent epidural bolus|Intermittent bolus 5 ml every hour
45650528|NCT03043937|Other|registry|
45928425|NCT00022386|Procedure|quality-of-life assessment|
45928426|NCT05569889|Procedure|Anterior Cruciate Ligament reconstruction (ACLR)|A comparison between the two groups were done regarding the three following stages: (a) the preparation time of the trolley, which is the time taken by the CNOR to recover from the reserves all the single-packed sterile instruments (SPSI) necessary for the intervention or to recover the CST (b) the opening time of the instruments by the circulating nurse who opens the packages and gives them to the surgical nurse while respecting the sterility of the items, and by the surgical nurse who prepares the table for the intervention, and (c) the sorting time of the waste between plastic and paper at the end of the intervention.
45928427|NCT00022425|Drug|perillyl alcohol|
45928428|NCT05569265|Procedure|Intraoperative hemodynamic management|Goal directed Hemodynamic therapy
45928429|NCT00022464|Drug|temsirolimus|
45928430|NCT04733885|Device|Experimental|Current application will be made in the frequency range of 20-50 Hz. The Chattanooga (Intelect Neo) device with interfering current will be used for treatment, vacuum electrodes will be made in the form of 4 pole application. Two electrodes to the outside of the inguinal ligament, the other two electrodes will be placed on the upper inner part of the thigh.ES applications will be performed in the supine position with head and knee pillow supported.
45799728|NCT05006963|Other|manual therapy and therapy by exercise|In general, patients will receive extra-oral massage and intraoral massage, myofascial release in the cranio-cervical musculature, mobilization of the hyoid bone and may also receive unspecific joint mobilization. Will bemouth opening exercise was also performed with the tongue on the palate, proprioceptive lateralization and protrusion exercises with hyperboloid and exercises with combinations of movements of laterality and opening, or protrusion and opening.
45799729|NCT04479085|Other|nursing intervention|"It includes individual trainings for the regulation of the home environment,~give a booklet~to reinforce education and to give anti-allergic bedding sets."
45928431|NCT04733885|Device|Control|The Chattanooga (Intelect Neo) device with interfering current will be used for treatment, vacuum electrodes will be made in the form of 4 pole application. Two electrodes to the outside of the inguinal ligament, the other two electrodes will be placed on the upper inner part of the thigh. The same device used in ES application to the sham group will be attached to the patients, however, active ES will not be issued from the device and only vacuum will turn on. ES applications will be performed in the supine position with head and knee pillow supported.
45928432|NCT00022542|Drug|ixabepilone|Given IV
45799730|NCT05726851|Drug|E2025|E2025 IV infusion.
45799731|NCT05726851|Drug|Placebo|E2025 matched placebo IV infusion.
45928433|NCT00022581|Drug|thalidomide|Given orally
45928434|NCT00022581|Other|laboratory biomarker analysis|Correlative studies
45928435|NCT04733313|Procedure|ultrasound guıded quadratus lumborum block|Administering local aneshtetic agent with a block needle using the in-plane technique, bilaterally. Lumbar interfascial triangle, where the middle lumbar fascia joins the deep lamina of the posterior layer on the lateral border of the erector spinae was targeted as the optimal point of injection.
45928436|NCT05553275|Procedure|Usual Care|"Blood sugar evaluation (accuchecks) every four hours in latent labor and every 2 hours in active labor.Participants will be routinely managed with maintenance fluids of lactated ringers during latent labor and lactated ringers with dextrose 5% in active labor. Blood sugars of more than 110 mg/dl at any time point in labor will be treated with an insulin drip as follows:~Regular insulin (100 units) in 100cc of normal saline, with Lactated Ringers with 5% dextrose at 125cc/hour. If blood sugar 111-140, insulin drip at 1 unit/hour will be given and continued if blood sugar is 111-140.If blood sugar is 141-180, then drip will be changed to to 1.5 unit/hour and if blood sugar is 181-220, drip will be changed to 2.0 units/hour and MD will be called if blood sugar is more than 221 mg/dl"
46072421|NCT04566432|Other|Observation|observe the association of ctDNA with efficacy of treatment
46072422|NCT04562870|Drug|Selinexor|Unit Dose Strength: 20 mg; Dose Formulation: Tablet; Dosage Level: 60 or 80 mg, QW; Route of Administration: Oral
45650529|NCT05369949|Drug|DEX group|Participants will receive a dexmedetomidine infusion in addition to low dose sevoflurane anesthesia.
45650530|NCT05369949|Other|Control group|Participants will receive general anesthesia based on institutional's practice with commonly used doses of sevoflurane.
45650531|NCT03043703|Device|AirSense 10 AutoSet for Her|Positive airway pressure
45650532|NCT05369793|Drug|Alpha lipoic acid|Administration of alpha-lipoic acid 600mg plus vildagliptin/metformin combination (50/1000mg) orally once daily for 3 months.
45650533|NCT05369793|Drug|Roflumilast|Administration of 500 mcg plus vildagliptin/metformin combination(50/1000mg) orally once daily for 3 months.
45799732|NCT01831921|Behavioral|Lifestyle Weight Loss|Changing diet, physical activity, and self-regulatory behaviors to promote weight loss.
45799733|NCT01831921|Behavioral|Counseling|Individual nutrition counseling will be delivered by a registered dietitian.
45799734|NCT00558259|Drug|dabigatran etexilate 150 mg twice daily (BID)|dabigatran etexilate capsules 150 mg BID
45799735|NCT00558259|Drug|matching placebo twice daily (BID)|Matching placebo BID
45799736|NCT02508389|Drug|Low Dose GC4419: 30mg/day|Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
45799737|NCT02508389|Drug|High Dose GC4419: 90mg/day|High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
46072423|NCT04562870|Other|Physician's Choice Treatment|Physician's choice treatment may include ruxolitinib retreatment, fedratinib, chemotherapy (e.g., hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulatory agent, androgen, interferon (all as per clinical practice) and may include supportive care only with no MF treatment; no investigational therapies are allowed.
46072424|NCT04553471|Radiation|Stereotactic body radiotherapy|Treatment will take approximately 2 weeks.
45650534|NCT04861337|Drug|Remimazolam|Remimazolam is infused at a rate of 0.25 mg/kg/h from end of anesthesia induction until 15 minutes before the end of surgery.
45650535|NCT04861337|Drug|Placebo|Normal saline is infused at a rate same as in the remimazolam group from end of anesthesia induction until 15 minutes before the end of surgery.
45799738|NCT02508389|Drug|Placebo|Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
45799739|NCT02508389|Radiation|Intensity-Modulated Radiation Therapy|Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks
45799740|NCT02508389|Drug|Cisplatin|"Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.~Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor"
45799741|NCT02509481|Drug|Ivermectin|
45799742|NCT02509481|Drug|Albendazole|
45650536|NCT04844333|Other|Extubation under deep anesthesia|When the patient in sedation or anesthesia state, no body movement, bispectral index 60-70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 < 45mmhg, regular waveform, stable circulation, the patient is in deep anesthesia state, and the endotracheal tube is removed.
45650537|NCT03043625|Other|Visceral manipulation|Participants will be instructed to lie down comfortably on a stretcher in the supine position, with lower limbs flexed and abdomen exposed, and the physiotherapist positioned to the right side of the patient. The therapeutic intervention will be began with the left hand of the physiotherapist in contact with the lower region of the stomach, to which a force will be applied so that the organ was moved in an upper and lateral left direction while the right hand controlled and directed the knees of the patient to the right side until the moment when the physiotherapist notice an increase in tension in the stomach region. For the liver manipulation, the same procedures will be followed, however, with contact in the right epigastric region and the knees directed to the left side. The same position will be maintained for each organ treated until the physiotherapist could feel, through touch, a decrease in the tension of the viscera. The mean treatment time will 5 minutes.
45650538|NCT03043625|Other|Control group (CG)|The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
45928437|NCT05553275|Procedure|Permissive intrapartum glucose control|"Blood sugar evaluation (accuchecks) every four hours in latent labor and every 2 hours in active labor.Participants will be routinely management with maintenance fluids of lactated ringers during latent labor and lactated ringers with dextrose 5% in active labor.Blood sugars of more than 180 mg/dl at any time point in labor will be treated with an insulin drip as follows:~Regular insulin (100 units) in 100cc of normal saline, with Lactated Ringers with 5% dextrose at 125cc/hour.If blood sugar is 181-200, insulin drip at 1 unit/hour will be given. If blood sugar is 201-220, then drip will be changed to 1.5 units/hour. If blood sugar is 221 - 250, then drip will be changed to 2.0 units/hour and if blood sugar is more than 251 MD will be called."
45928438|NCT05551871|Drug|Simvastatin|the patient will receive Simvastatin for 7 days
45928439|NCT05551871|Drug|Placebo drug|the patient will receive Placebo drug for 7 days
45928440|NCT00022620|Drug|paclitaxel|
45650539|NCT04423185|Drug|Almonertinib 110 MG|Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Almonertinib.
45928441|NCT00022737|Biological|filgrastim|Given SC
45928442|NCT00022737|Drug|asparaginase|Given IM
45928443|NCT00022737|Drug|cyclophosphamide|Given IV
45450816|NCT02199106|Device|Left temporal verum cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session)~Arms: Left temporal verum cTBS"
45650540|NCT04423185|Drug|Dacomitinib 45 MG|Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Dacomitinib.
45650541|NCT04423185|Drug|Alectinib 150 MG|Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion will be administrated with Alectinib.
45650542|NCT04423185|Drug|Crizotinib 250 MG|Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation will be administrated with Crizotinib.
45799743|NCT02511587|Biological|FSME-Immune vaccination|booster vaccination with FSME-Immune
45799744|NCT02560493|Behavioral|Exergaming Condition|Participants are encouraged to meet the MVPA goal of 60 minutes/day, which will be gradually achieved beginning with 10 minutes/day in Week 1 and reaching 60 minutes/day in Week 6. Three hours each week will be devoted to exergame play, following prescribed exergame routines.
45799745|NCT04950881|Procedure|Ultrasound guided vagus nerve block|Before the operation starts, patients received the ultrasound guided vagus nerve block. A 50mm Braun nerve stimulation needle is guided by the ultrasonic beam to insert into the carotid sheath and 10ml of lidocaine or ropivacaine is injected.
45799746|NCT04950881|Drug|Bradycardia Treatment|If the OVR happens because the surgical stimulation, the operation suspends and atropine (0.01-0.02mg/kg) or isoproterenol (1-2 μg/per time)is given intravenously to increase the heart rate.
45799747|NCT04341077|Drug|SHR3162|A single oral dose of fluzoparib on Day 1
45799748|NCT04914767|Drug|Nigella|"The patient will receive a study treatment containing 100 capsules:~One capsule every two hours for the first three days.~From the fourth day, the patient will take one capsule, three times a day for 12 days."
45799749|NCT04914767|Drug|Placebo|"The patient will receive a study treatment containing 100 capsules:~One capsule every two hours for the first three days.~From the fourth day, the patient will take one capsule, three times a day for 12 days."
45799750|NCT02561585|Drug|LEO 124249|
45799751|NCT02561585|Other|Vehicle|
45928444|NCT00022737|Drug|cyclosporine|Given IV
45928445|NCT00022737|Drug|cytarabine|Given IT and IV
45928446|NCT00022737|Drug|daunorubicin hydrochloride|Given IV
45928447|NCT00022737|Drug|dexamethasone|Given orally
45928448|NCT00022737|Drug|etoposide|Given IV
45799752|NCT02561897|Drug|Edoxaban|
45799753|NCT02561897|Drug|Warfarin|
45928449|NCT00022737|Drug|ifosfamide|Given IV
45928450|NCT00022737|Drug|imatinib mesylate|Given orally
45928451|NCT00022737|Drug|leucovorin calcium|Given IV or orally
45928452|NCT00022737|Drug|mercaptopurine tablet|Given orally
45928453|NCT00022737|Drug|methotrexate|Given IT, IV, and orally
45928454|NCT00022737|Drug|pegaspargase|Given IM
45928455|NCT00022737|Drug|vincristine sulfate|Given IV
45928456|NCT00022737|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
45928457|NCT00022737|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
45928458|NCT00022737|Procedure|umbilical cord blood transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
46072425|NCT04553471|Procedure|Research blood draw|-Baseline, immediately after radiotherapy completion (fraction 5), 14 days after radiotherapy, and 30 day follow-up
45650543|NCT04423185|Drug|Pyrotinib 160/80 MG|Patients with advanced rare tumors who failed to standardized treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib.
45928459|NCT00022737|Radiation|radiation therapy|Undergo radiation therapy
45928460|NCT00022776|Procedure|Surgical decompression|Simple decompression not requiring fusion.
45928461|NCT00022776|Procedure|Physical therapy|2 physical therapy sessions per week for 6 weeks Followed by home program.
45928462|NCT05530694|Behavioral|Clinician communication training|The clinician training is a generic, skills- and attitude-based approach for clinicians to acknowledge their decision making conversations with patients that 1) there is more than one option, and 2) patient's views matter in deciding what to do next. This tools-free approach can be used on the spot when needed and is termed fostering choice awareness (FCA). The one-hour training consists of 4 parts: 1) a knowledge session on evidence and guidelines on effective conversations and SDM, 2) video-review of behaviors which foster or hinder choice awareness, 3) clinical simulations in which clinicians practice fostering choice awareness behaviors, and 4) a reminder card for use in future clinic visits. Video clips will be of patient-clinician conversations around treatment decision making to prompt and probe clinicians' experiences, improve understanding, and improve practice.
45650544|NCT04423185|Drug|Imatinib 400 MG|Patients with advanced rare tumors who failed to standardized treatment carrying CKIT mutation will be administrated with Imatinib.
45650545|NCT04423185|Drug|Niraparib 200/300 MG|Patients with advanced rare tumors who failed to standardized treatment carrying BRCA1/2 mutation will be administrated with Olaparib.
45650546|NCT04423185|Drug|Palbociclib 125mg|Patients with advanced rare tumors who failed to standardized treatment carrying CDKN2A mutation will be administrated with palbociclib.
45650547|NCT04423185|Drug|Vemurafenib 240 MG|Patients with advanced rare tumors who failed to standardized treatment carrying BRAF mutation will be administrated with Vemurafenib.
45650548|NCT04423185|Drug|Sintilimab 100MG|Patients with advanced rare tumors who failed to standardized treatment carrying no targeted alterations will be administrated with Sintilimab.
45650549|NCT04423185|Drug|Atezolizumab 1680 MG|Patients with BRAF mutation treated with vemurafenib, after acquired resistance, will combine vemurafenib with atezolizumab.
45799754|NCT02512679|Drug|Cyclophosphamide Dose Level 1|given by IV at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level. After ten patients the de-escalation will begin if the stopping rule is not met.
45799755|NCT02512679|Drug|Cyclophosphamide Dose Level 2|Level 2 will be 70mg/kg in 2 divided given once a day for 2 days;
45799756|NCT02512679|Drug|Cyclophosphamide Dose Level 3|Level 3 will be 35mg/kg as a one-time dose.
45928463|NCT05530694|Behavioral|Patient activation|"The patient activation component consists of three questions patients can ask their clinician to help them become more involved: 1. What are my options?; 2. What are the possible benefits and harms of those options?; 3. How likely are each of those benefits and harms to happen to me? These questions have been used in studies to promote improved communication in a number of conditions including cardiovascular disease, cancer, and women's health."
46072426|NCT04537715|Drug|Tazemetostat|A single, oral, 400 mg dose of tazemetostat on Day 1, Day 15, and Day 36; and tazemetostat (oral 400 mg) tablets twice daily on Days 3 - 14 and Days 21 - 35.
46072427|NCT04537715|Drug|Itraconazole|Oral 200 mg itraconazole once daily on Days 18 - 38
46072428|NCT04537715|Drug|Tazemetostat|A single, oral, 800 mg dose of tazemetostat on Days 1, 15, and Day 24 ; and tazemetostat (oral 800 mg) twice daily on Days 3 - 14 and on Days 17 - 23.
46072429|NCT04537715|Drug|Rifampin|Oral 600 mg rifampin once daily on Days 17 - 25.
46072430|NCT04532528|Drug|Dabigatran|Dabigatran
45650550|NCT04851275|Behavioral|Physicians trained in shared decision making|Physicians in this group were trained in shared decision making
45650551|NCT04851275|Behavioral|Physicians were not trained in shared decision making|Physicians did not receive training in shared decision making
45650552|NCT05392179|Drug|ADX-2191|Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of three injections. Evaluation through week 16.
45650553|NCT05392179|Drug|ADX-2191|Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of six injections. Evaluation through week 16.
45650554|NCT04851041|Other|Potato|Controlled human intervention trial to evaluate the impact of boiled potato intake as part of a healthy dietary patterns on cardiometabolic health
45799757|NCT02512679|Drug|Cyclophosphamide Dose Level 4|Level 4 will be no cytoxan.
45799758|NCT02562521|Behavioral|Contingency management|Participants in the intervention group will receive a tailored intervention that utilizes contingency management in which they receive monetary rewards for reducing or quitting smoking.
45799759|NCT02562521|Drug|Nicotine replacement therapy|Participants have the option of using nicotine patch in combination with nicotine gum or lozenge
45799760|NCT02562521|Drug|Varenicline|Individuals who do not respond initially to Nicotine Replacement Therapy will be offered varenicline as an alternative
45799761|NCT02562521|Behavioral|Additional behavioral support|Based on interest, participants can be referred to a telephone quitline or receive access to mobile text messaging programs or app based smoking cessation support
45799762|NCT04887779|Behavioral|Pathologist intervention|viewing explanted organ and microscopy
45928464|NCT05530694|Behavioral|RA Medication summary guide and RA Choice|RA Choice presents information on FDA-approved RA treatments in a set of cards, which can be used alone or in combination based on a patient's preference, values, and the clinician's experience. The RA medication summary guide describes options for medication, physical therapy, occupational therapy, and ways to stay healthy with diet and exercise. Tool development followed key principles of creating low literacy materials that featured icons, short phrases written in plain language, and included topics of interest to RA patients faced with a medication decision. For the proposed study, we will include a paper-based version of the tool, or a web-based version available for telephone or VA Video Connect (VVC) visits. The tools will be updated to include new FDA-approved therapies (e.g., JAK inhibitors).
45928465|NCT00022815|Device|Tissue ultrafiltration|
45799763|NCT02562755|Biological|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells.
45799764|NCT02562755|Drug|Sorafenib|"Sorafenib belongs to the pharmacotherapeutic group of antineoplastic agents, protein kinase inhibitors, ATC code: L01XE05.~Sorafenib is a multi-kinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo.~Sorafenib is approved for the treatment of advanced HCC and is the Standard Of Care for this disease."
45799765|NCT04796129|Other|the patients with hip osteoarthritis and their inflammatory status|The participants in the experimental group will be evaluated for the hip osteoarthritis. They will take and X-ray for hip joints and also hemogram for the excluding the inflammatory diseases.
45799766|NCT02562989|Drug|[18F]MK-6240, ~185 MBq|IV dose of ~185 MBq [18F]MK-6240
45928466|NCT05521646|Other|Quality Improvement Collaborative|Explore if a Quality Improvement Collaborative can increase the proportion of immigrant women who choose an effective postpartum contraceptive method
45928467|NCT00022854|Procedure|Single-injection femoral nerve block|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
45650555|NCT04851041|Other|Pasta/rice|Since potatoes, white rice and white pasta are all products with a high glycemic index and concomitant relatively steep glucose excursions after intake, this intervention group helps to compare the effect of potato vs another high glucemic index food.
45928468|NCT00022854|Procedure|Femoral nerve block 60-hour continuous injection|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous infusion (5 mL/hr for 50 hours) of 0.25% levobupivacaine
45928469|NCT00022854|Procedure|Saline (control) injection into femoral nerve envelope|Nerve block bolus with 30 mL saline, followed by continuous saline infusion
45928470|NCT05521412|Drug|[ 161 Tb]Tb PSMA I&T|During dose escalation, doses of [161 Tb]Tb PSMA I&T will range between 4.4 GBq to 7.4 GBq. The recommended phase 2 dose of [161 Tb]Tb PSMA I&T will be used during dose expansion. [161Tb]Tb-PSMA-I&T dose will be reduced by 0.4 GBq for each subsequent cycles (2 to 6).
45650556|NCT04851197|Other|Flipped Learning Model|Students in the intervention group will be given training on testicular cancer and testicular self-examination in accordance with the Flipped Learning Model. The students in the control group will receive the same training with the traditional method. It was aimed to examine the effect of the training given with the Flipped Learning Model on the students' knowledge levels and health beliefs about testicular cancer and self-testicular examination.
45650557|NCT05414877|Drug|Ephedrine|vasopressor
45650558|NCT05414877|Drug|Phenylephrine|vasopressor
45799767|NCT02562989|Drug|[18F]MK-6240, ~160 MBq|IV dose of ~160 MBq [18F]MK-6240
45450817|NCT02199106|Device|Left temporal placebo cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session); coil tilted by 45° over both wings~Arms: Left temporal placebo cTBS"
45650559|NCT05414877|Drug|Norepinephrine|vasopressor
45650560|NCT03040271|Other|Health-E-PALS-|Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
45799768|NCT05446883|Drug|QL1706|Intravenous Infusion
45799769|NCT05446883|Drug|Placebo|Intravenous Infusion
45799770|NCT05446883|Drug|Paclitaxel injection|Intravenous Infusion
45799771|NCT05446883|Drug|Cisplatin/Carboplatin|Intravenous Infusion
45799772|NCT02565485|Drug|Lactated Ringer's|1500 cc of IV Fluid (crystalloid) used for preload prior to epidural administration in the treatment arm. Control arm receives 500 cc.
45799773|NCT00363857|Drug|Ropinirole|
45799774|NCT05445167|Drug|KLH-2109|Oral administration
45799775|NCT05445167|Drug|Placebo|Oral administration
45799776|NCT02515253|Other|Bra prescription|
45799777|NCT02515253|Other|Standard Care|
45799778|NCT02566265|Biological|Fluzone High Dose Vaccine|
45799779|NCT02566265|Biological|Standard of care/Placebo|
45799780|NCT04563923|Drug|Avdoralimab (IPH5401)|Preparation of avdoralimab and preparation of the syringes are to be performed aseptically by site pharmacy qualified personnel.
45799781|NCT04563923|Other|Control|"Superpotent topical steroids are the gold standard treatment for BP. All patients will receive 0.05% Clobetasol propionate cream as follows:~Patients of less than 45kg of body weight: 2 tubes of 10g/d~Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesion"
45928471|NCT00022893|Drug|Iodine-131 Anti-B1 Antibody|
45799782|NCT04561973|Behavioral|numerical rating scale|Patients seen for routine planned visits complete a self-administered retrospective questionnaire about pain during the last 3 months, and a prospective diary during the two weeks following the visit.
45799783|NCT02516579|Drug|Siklos|
45650561|NCT04423419|Procedure|PENG block|The US probe placed in a transverse plane over the AIIS . the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 80-mm needle was inserted from lateral to medial to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic drug was injected while observing for adequate fluid spread for a total volume of 20 mL of Bupivacain 0.25%
45650562|NCT04423419|Procedure|fascia iliaca block|ultrasound guidance landmarks are the anterior superior iliac spine and the pubic tubercle (inguinal ligament). The injection site along the lateral one-third of aline joining the anterior superior iliac spine (ASIS) and pubic tubercle (PT) targeting the compartment between fascia iliaca and fascia lata ,the total volume of injection is 20ml of Bupivacain 0.25%
45928472|NCT05514860|Procedure|Cryoballoon-based PVI|Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.
45928473|NCT05514860|Drug|Anti-Arrhythmic Drug Therapy|Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
45928474|NCT00022932|Drug|Iodine-131 Anti-B1 Antibody|
45928475|NCT00022971|Biological|Apolizumab|Apolizumab IV on Day 1. Administer weekly for 4 weeks
45650563|NCT04423419|Other|IV analgesia|IV analgesia
45650564|NCT04850885|Drug|inj dexamethasone 4mg/ml and inj lignocaine 20mg/ml|The modified technique of classical IANB was to be selected to avoid failure as described by Clark and Homes (1959). The patients were requested to keep their mouth wide open and an occlusal plane parallel to the floor. Palpation of anatomical landmarks was done properly and the guide finger was positioned at the retromolar fossa. A 5 ml syringe equipped with a 24 gauge needle length of 3.6 cm was used, it was been advanced from premolar on the opposite side into the tissue just above the fingernail until hitting the bone. The body of the syringe was redirected over the lower central incisors and kept parallel to the molars in a horizontal plane at the same time. The needle was inserted another 2 cm deep into the tissue and 3.5 ml of solution X was deposited 1 cm higher than the usual after multiple aspirations (90 degrees two planes). Further, 1 ml solution X was deposited after the withdrawn needle in pterygomandibular space.
45650565|NCT05390385|Dietary Supplement|KE1 5g|5g of KE1 (KetoneAid, Falls Church, VA), diluted to 4 ounces
45650566|NCT05390385|Dietary Supplement|KE1 10g|10g of KE1 (KetoneAid, Falls Church, VA), equal to 4 ounces
45650567|NCT05390385|Dietary Supplement|KE4 5g|5g of KE4 (KetoneAid, Falls Church, VA), diluted to 4 ounces
45650568|NCT05390385|Dietary Supplement|KE 10g|10g of KE4 (KetoneAid, Falls Church, VA), diluted to 4 ounces
45650569|NCT05390385|Other|Placebo drink|Flavor-matched control placebo drink (KetoneAid, Falls Church, VA), 4 ounces
45650570|NCT04851353|Behavioral|GT+VC|Gentle touch and verbal comfort,
45650571|NCT04851353|Behavioral|Smell|Smell breast milk
45799784|NCT02517047|Device|CareTRx|CareTRx is a novel device that can be applied to most MDI (meter dose inhaler) device and leverages mobile and cloud computing to objectively assess and provide real-visualize feedback to patients and providers around medication adherence and disease control in pediatric asthma.
45799785|NCT04768933|Dietary Supplement|Toddler Milk|At least three 130 mL servings daily of study formula are recommended for a total daily intake of 390 mL. Study participants will continue this feeding regimen Days 4 to 28 (approximately 4 weeks).
45799786|NCT00558103|Drug|lapatinib|Oral administration
45799787|NCT00558103|Drug|Pazopanib|Oral administration
45799788|NCT02974361|Drug|Ibuprofen|
45928476|NCT00022971|Biological|Rituximab|Rituximab IV 24-36 hours after Apolizumab ends. Administer weekly for 4 weeks
45928477|NCT05512754|Drug|Ibuprofen 400 mg|400 mg tablet
45928478|NCT05507840|Device|Valeda machine|Photobiomodulation treatment with Valeda machine will be applied every six months for 2 years in patients with dry age related macula degeneration.
45928479|NCT02971878|Biological|Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)|Human embryos will be cultured in media that contains 3 antioxidants (Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)) that can be found in the in vivo Environment.
45928480|NCT00023127|Procedure|Integrated Pest Management|
45928481|NCT05502575|Behavioral|Self-monitoring and personalized stress management|Self-monitoring and personalized stress management education and materials.
45928482|NCT05502575|Behavioral|Self-monitoring and general stress management|Self-monitoring and general stress management education and materials.
45928483|NCT00023166|Drug|PEG-paclitaxel|
45650572|NCT04851353|Behavioral|Taste|Taste breast milk
45799789|NCT02974361|Drug|Ibuprofen Lysine|
45799790|NCT02974361|Drug|Ibuprofen-LDH|
45799791|NCT05690815|Drug|Descovy|Descovy is a once-daily prescription medicine for adults and adolescents at risk of HIV. It helps lower the chances of getting HIV through sex. In this study, patients at risk of acquiring HIV will be screened for HIV and those that are HIV-negative will be initiated on PrEP within 24 hours.
45928484|NCT05486312|Device|CT-155 smartphone app|The CT-155 study app is designed to provide treatment monitoring and educational components of a full treatment cycle with CT-155. This design allows inferences to be made about the usability and acceptability of CT-155. Eligible participants will be enrolled during an in-person clinic visit on Day 1. Participants will then be directed to access the study app and perform tasks each day for the 49-day engagement period.
45928485|NCT00023205|Behavioral|11th grade reading level arthritis materials|
45928486|NCT00023205|Behavioral|Interactive in-person arthritis education|
45928487|NCT05481671|Other|Questionnaires|Participants will be asked to respond to the Demographic Information Sheet, Tampa Scale for Kinesiophobia, Numeric Rating Scale, Pain Catastrophizing Scale, Hospital Anxiety and Depression Scale, Resilience Scale , Pain Self-efficacy Questionnaires and Functional Exercise Compliance Scale for Orthopaedic Patients.
45928488|NCT00394875|Procedure|Treated and educated by nurses specialized in diabetes.|
45928489|NCT05478980|Dietary Supplement|Night Time Tea|Night-time Tea
45928490|NCT05478980|Dietary Supplement|Control Tea|Feel New Tea
45928491|NCT00394992|Drug|oxaliplatin+capecitabine|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
45650573|NCT03043391|Biological|Polio/Rhinovirus Recombinant (PVSRIPO)|PVSRIPO will be delivered intratumorally by convection-enhanced delivery (CED) using an intracerebral catheter placed within the enhancing portion of the tumor. A stereotactic biopsy will be performed prior to virus administration. Immediately following the stereotactically-guided tumor biopsy, a catheter will be implanted in the operating room at a site the same or different from that used for the biopsy using sterile techniques under general anesthesia. The entire volume of PVSRIPO to be delivered will be pre-loaded into a syringe by the investigational pharmacist and connected to the catheter under sterile conditions in the Pediatric Intensive Care Unit (PICU) just prior to beginning of infusion.
45928492|NCT00394992|Drug|Oxaliplatin+capecitabine+bevacizumab|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
45928493|NCT00395031|Drug|Ziprasidone|Ziprasidone dose of between 40 mg po bid to 160 mg po bid for 8 weeks
45928494|NCT05471375|Other|Database Entry|Database entries will contain wearable sensor, audio, and video data collected during rehabilitation-related movement assessments
45928495|NCT05460806|Other|Aerobic Exercise|Participants assigned to aerobic exercise training will walk on a treadmill (RodbyTM, RL 1600E, Enhorna, Sweden) for 40 minutes at an intensity of 60-75% of maximum heart rate (220-age formula) three times per week for 8 weeks. The heart rate of the participants will be measured with an electric heart rate monitor throughout the session.
45928496|NCT00395070|Biological|Allovectin-7®|Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.
45928497|NCT00395070|Drug|Dacarbazine (DTIC)|1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR
45928498|NCT00395070|Drug|Temozolomide (TMZ)|150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
45928499|NCT05447624|Procedure|Radiofrequency ablation of genicular nerves|The RF cannula will be placed near the nerve with an in-plane technique from proximal to distal. Sensory stimulation will be performed at 50 Hz to ensure localization. The sensory threshold should be less than 0.6 V. To prevent ablation of the motor nerves, when the nerve is stimulated with 2.0 V at 2 Hz, it will be seen that there is no fasciculation in the relevant region of the lower extremity. Before starting the ablation procedure, 2 mL of 1% lidocaine solution will be injected around the nerve, after vascularity control, in order to reduce the pain and the risk of neuritis during the procedure. Then the temperature will be adjusted to 80° degrees and applied for 90 seconds and the process will be terminated.
45928500|NCT00395109|Device|PET/CT|All study participates will be scanned with PET/CT scan before surgery.
45928501|NCT00023244|Drug|Basiliximab|Administered as a bolus intravenous injection. The first dose is given pre-operatively, the second dose is given on post-transplant day four. Dosage is determined by individual weight.
46072431|NCT04528992|Other|Blood Flow Restriction Therapy|BFR is a rehabilitation method that involves wearing a tight band around the exercising extremity to briefly limit blood flow while doing light weight exercises. The response is similar to heavy weight training or lifting but without the stress on the extremity that is still healing from surgery. Will be given after 2 weeks standard postoperative physical therapy per surgeon's ACL reconstruction protocol following surgery.
45650574|NCT05388981|Biological|SBT115301|Experimental treatment
45650575|NCT05388981|Biological|Placebo|Matched placebo
45650576|NCT04844177|Other|conditioning with TLI|"Total lymphoid irradiation 4 Gy (days -7, -6) in combination with:~Fludarabine 150 mg/m2 (days-6, -5, -4, -3, -2)~Cyclophosphamide 120 mg/kg (days -5, -4, -3)~Thymoglogulin (Genzyme) 5 mg/kg (days -5, -4)~Melphalan 180 mg/m2 (day -2)~Rituximab 100 mg/m2 (day -1)~Hematopoietic stem cell graft infusion after TCRab/CD19 depletion - day 0"
45650577|NCT04844255|Dietary Supplement|dietary salt|2 grams of dietary salt
45650578|NCT04843865|Dietary Supplement|Chinese Herbs|Chinese Herbs
45650579|NCT02610725|Other|Hatha yoga|Participants will be shown a 30 minute video of a yoga class that they will be invited to follow along with.
45650580|NCT04850417|Drug|Beta blocker, aspirin, clopidogrel|Pragmatic design. Beta-blockers and Antiplatelets drugs selected by the investigators. Asprin and Clopidogrel recomended for patients allocated to prologed DAPT. Aspirin Alone recomended for patients allocated to short antiplatelet therapy
45650581|NCT04843943|Drug|Sintilimab|Sintilimab: 200mg IV Q3W D1
45650582|NCT04843943|Drug|Bevacizumab Biosimilar|Bevacizumab biosimilar: 15mg/kg, IV, Q3W, D1
45799792|NCT04282603|Combination Product|Weight Loss and Weight Maintenance|Participants will consume a 1,200 kcal/day diet for twelve weeks. This is the amount of calories most commonly provided in medical weight loss programs, and considered the maximum allowable caloric intake to induce a physiologically significant weight loss. Following the weight loss portion of the trial, participants will enter the twelve week maintenance period, during which time they will consume one serving per day in place of lunch of the same meal replacement beverage used during medical weight loss.
45799793|NCT02569541|Drug|sodium fusidate|
45799794|NCT04198675|Behavioral|Supervised EMG Biofeedback Exercise Training Group|Posture training and ergonomic arrangements in the workplace. EMG biofeedback training will be carried out with electromyography-controlled video game combined with PNF exercises. Each game sessions comprising the work-rest cycle covers performing the upper trapezius muscle contraction simultaneously the upper extremity PNF patterns.
46072432|NCT04528992|Other|Standard Postoperative Physical Therapy|This is the surgeon's standard postoperative physical therapy protocol after ACL reconstruction.
46072433|NCT04477603|Device|Impella ECP|Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
45650583|NCT04850261|Drug|hCG Injection|Ovulation will be induced by subcutaneous hCG injection
45650584|NCT04850261|Drug|Nafarelin nasal spray|Ovulation will be induced by nasal application of Nafarelin
45799795|NCT04198675|Behavioral|Home-Based Exercise Training Group|Posture training and ergonomic arrangements in the workplace. Posture correction exercises, contains strengthening, stretching, mobility and relaxation exercises, will be given as a home exercises program. Exercise diary and weekly calls will be use to maintain the exercise adherence
45928502|NCT00023244|Drug|Cyclosporine|Participants receiving cyclosporine microemulsion formula (in lieu of tacrolimus) will have the dose adjusted to maintain a whole blood trough Abbott TDx assay monoclonal level of 175-400 ng/mL (or an equivalent high pressure liquid chromatography (HPLC) level) for the first 2 weeks after transplant. The dose will subsequently be tapered to maintain a trough level of 175-300 ng/mL from week 3 to month 3, and 50-250 ng/mL from month 3 through the end of the study at month 36 (year 3).
45928503|NCT00023244|Drug|Tacrolimus|Participants receiving tacrolimus (in lieu of Cyclosporine) will have the dose adjusted to maintain a whole blood trough level between 10 and 15 ng/mL for the first 4weeks after transplant. Trough levels will be maintained between 5 and 10 ng/mL thereafter throughout the duration of the study.
45928504|NCT00023244|Drug|Sirolimus|Participants take daily (orally, either as tablets or as liquid) starting on postoperative day 1 at a dose of 6 mg/m2 and will be adjusted to maintain a trough level of 10-20 ng/mL throughout the study.
45928505|NCT00023244|Drug|Methylprednisolone|Administered at 10 mg/kg intravenously perioperatively and on postoperative day 1.
45928506|NCT00023244|Drug|Prednisone|Administered orally beginning on Post-Op Day 2 and maintained for all participants until day 180. Randomization will determine whether patients will maintain this treatment following day 180.
45928507|NCT00023244|Drug|Bactrim|All subjects will receive TMP SMX (Bactrim), pneumocystis jiroveci (carinii) prophylaxis, beginning on postoperative day 1 and continuing for 6 months following transplant. Dosage: 10 mg/kg taken orally three times weekly (maximum dose 160 mg).
46072434|NCT04463225|Other|Internet-Delivered Brief Intervention|The internet-delivered brief intervention developed for the study can be accessed via computers and mobile devices.. The intervention will employ assessment data to give study participants feedback on their drinking behavior and offer strategies to avoid risky behavior.
45650585|NCT04850027|Procedure|TME+Lateral lymph node dissection.|TME and lateral lymph node dissection is performed in rectal cancer patients with lateral lymph node short diameter ≥ 5 mm.
45650586|NCT04850183|Behavioral|Education on disease management on the quality of life, and anxiety and depression about Rheumatoid Arthritis|The patients in the intervention group participated in a one-to-one training program consisting of a 30-min onset session.
45650587|NCT04849949|Other|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
45650588|NCT04849949|Other|Black walnut|Participants in this group received a muffin in which part of the butter was substituted out for black walnuts.
45799796|NCT04198675|Behavioral|Posture Training/Ergonomic Regulations Group|Posture training and ergonomic arrangements in the workplace.
45650589|NCT04849949|Other|English walnut|Participants in this group received a muffin in which part of the butter was substituted out for English walnuts.
45650590|NCT04843553|Drug|Oral Nicotinamide|
45799797|NCT04093297|Procedure|Tricuspid Annuloplasty|Patients will undergo repair of tricuspid regurgitation
45799798|NCT04477733|Drug|Butorphanol Injection|Inject 10 μg/kg of butorphanol, then propofol is injected until the patient's eyelash reflex disappears before performing colonoscopy
45650591|NCT02684461|Drug|Pembrolizumab|"Receive Pembrolizumab 200 mg on day 1 every 21 days for four cycles.~Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles."
45650592|NCT04843475|Diagnostic Test|Echocardiography|Trans-thoracic Echocardiography
45650593|NCT03040193|Drug|Lignocaine Nebulization|4% Lignocaine delivered via Nebulization
45650594|NCT03040193|Drug|Saline Nebulization|Normal Saline Delivered via Nebulization
45799799|NCT04477733|Drug|Saline|Inject saline and propofol until the patient's eyelash reflex disappears before performing colonoscopy
45799800|NCT01833403|Other|Hyperinsulinemic-euglycemic clamp|"Subject will received 6,6 2H2 Glucose prior and during a 4 hr hyperinsulinemic-euglycemic clamp to characterize hepatic insulin resistance prior to bariatric surgery~--------------------------------------------------------------------------------"
45799801|NCT01833481|Radiation|Fluoroscopy surveillance of patients while walking|While each subject performs a gait activity (normal walking) under fluoroscopic surveillance on a level treadmill, a data acquisition (DAQ) system will be used to determine the vibrations/sounds occurring during walking.
45799802|NCT00558025|Drug|Pramipexole Extended Release|
45799803|NCT00558025|Drug|Pramipexole Immediate Release|
45799804|NCT03899753|Device|2-Octyl Cyanoacrylate and Mesh|2-Octyl Cyanoacrylate and a mesh will be applied to final closure of wounds after undergoing a Total Shoulder Arthroplasty
45799805|NCT03899753|Device|2-Octyl Cyanoacrylate|Incisions will be closed with 2-Octyl Cyanoacrylate after undergoing a Total shoulder arthroplasty
45799806|NCT04125251|Behavioral|Life Skills Building Training|The Life Skills Building intervention is a curriculum based on 10-12 sessions. The sessions will include the skills essential for family harmony and improving overall mental health of the participants
45799807|NCT01834027|Behavioral|Jazz music|Jazz music from artists including Miles Davis, Ella Fitzgerald, Nat King Cole, Dave Brubeck, etc. will be played through headphones for post-surgical hysterectomy patients while they are in the post anesthesia care unit.
45799808|NCT01834027|Behavioral|No music|In this group no music will be played in PACU
45928508|NCT00023283|Drug|Buprenorphine|"Experimental Standard Medical Management with once-weekly medication dispensing~Experimental Standard Medical Management with thrice-weekly medication dispensing~Experimental Enhanced Medical Management with thrice-weekly medication dispensing"
45928509|NCT05418335|Other|Clinical examination, functional status evaluation|Barthel Index, Oral Health Impact Profile 14, Beck Depression Inventory, Stroke Impact Scale 3, Plaque Index, Calculus Index, Periodontal Disease Index, Simplified Oral Hygiene Index assesment, DMFT Index
45928510|NCT00023361|Drug|Rifabutin|
45928511|NCT05408117|Device|5-0 Polypropylene epidermal suture|Split-wound, intra-individual comparison - half of wound will receive 5-0 polypropylene epidermal suture and half of wound will receive 5-0 fast gut epidermal suture
45928512|NCT05408117|Device|5-0 Fast gut epidermal suture|Split-wound, intra-individual comparison - half of wound will receive 5-0 polypropylene epidermal suture and half of wound will receive 5-0 fast gut epidermal suture
45928513|NCT05367323|Device|Pressure algometry (Baseline 2.2-Pound Dolorimeter) and Myoton PRO device (MyotonPRO; Myoton AS, Tallinn, Estonia)|Both instruments are used for the assessment of the L4-5 interspinous space pain pressure threshold and the biomechanical-viscoelastic properties of L4-5 supraspinous ligament respectively
45928514|NCT00023400|Drug|Nelfinavir|
45450818|NCT02206906|Behavioral|Incentive intervention model|All participants will receive a real-time electronic medication monitor to monitor daily pill-taking behavior. Participants with qualifying levels of adherence will receive a weekly incentive during the intervention period. At all clinic visits participants will participate in a lottery incentive to reinforce clinic attendance and negative STI screening tests.
45650595|NCT05373199|Drug|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
45799809|NCT02576249|Drug|Ropivacaine|4cc 0.5% ropivacaine
45799810|NCT02576249|Drug|Normal saline|4cc of sterile normal saline (0.9%)
45799811|NCT02576249|Drug|Methylprednisolone|1cc 40mg methylprednisolone
45799812|NCT03868657|Drug|Moxifloxacin|Moxifloxacin is solely used to cause a known and for the drug well documented effect, namely blockade of the Kv11.1 channel.
45799813|NCT03868657|Drug|Placebo|Placebo
45799814|NCT01834261|Drug|Syntocinon Nasal Spray, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
45799815|NCT01834261|Drug|Syntocinon Placebo Formulation, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
45799816|NCT05670925|Drug|Camrelizumab plus Famitinib with/without nab-Palitaxel|After enrollment confirmed, the regimen of Camrelizumab Combined with Famitinib will be conducted for 2 cycles (8 weeks). Patients of CR or PR after 2 cycles (8 weeks) will enter dual-therapy maintenance phase until disease progression and will be recorded as PFS-1α. Patients of PD after 2 cycles (8 weeks) will be recorded as PFS-1β. Patients of SD with 2 cycles of dual therapy wlii receive triple therapy regimen: Camrelizumab and Famitinib with nab-Paclitaxel.
45799817|NCT04707989|Other|Ketone- Promoting Food Ingredient #1|Novel proprietary food ingredient (#1) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
45928515|NCT00023400|Drug|Rifabutin|
45928516|NCT00023439|Other|Nucleic Acid Amplification Methods for diagnosis|no intervention
45928517|NCT05359172|Drug|Tranexamic acid|preoperative intravenous infusion
45928518|NCT05351879|Biological|GAD-alum (Diamyd) 40 μg/mL|Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) adsorbed to Alhydrogel at a concentration of 40 μg/mL and is given as a sterile solution for intralymphatic injection
45928519|NCT00023634|Biological|KLH|100 mcg w/EGFRvIII
45928520|NCT00023634|Biological|GMCSF|arm 1: 100 mcg w/EGFRvIII
45928521|NCT05345951|Behavioral|e-PBI+|The e-PBI+ is a preventive parent-based intervention emphasizing parent-teen communication on drinking/risks of alcohol abuse, with the addition of data-driven cannabis content to guide parent communications with their students (e.g., cannabis content focusing on the endocannabinoid system; acute and chronic cannabis use effects on the brain, cognition, and development; THC potency in present-day cannabis; cannabis use effects on mental and physical health, including psychosis, depression, and anxiety; respiratory/cardiovascular/sleep problems; cannabidiol (CBD) content, myths; and cannabis effects on psychosocial function). Together the goals are to reduce alcohol and cannabis use in college students.
45650596|NCT05373199|Drug|Euglycemic clamp with Lantus®|Administration of a single dose of Lantus® during an euglycemic clamp procedure.
45650597|NCT05373199|Drug|Euglycemic clamp with Humalog®|Administration of a single dose of Humalog® during an euglycemic clamp procedure.
45650598|NCT03039101|Procedure|Nasal lavage|determine frequency of CD49d expressing neutrophils in the nasal lavage by flow cytometry
45650599|NCT03039101|Procedure|Nasal allergen challenge|A small amount of allergen extract will be applied to one naris.
45650600|NCT03039101|Procedure|Epicutaneous skin testing|Skin testing (prick) to determine allergies.
45650601|NCT03039101|Procedure|Peripheral blood|Peripheral blood draw
45650602|NCT03039101|Drug|Montelukast 10Mg Tablet|one pill orally, daily, for 1 week
45650603|NCT03039101|Drug|Placebo Oral Tablet|one pill orally, daily, for 1 week
46072435|NCT04427956|Procedure|Corneal crosslinking: CXL (UVA 9mW/cm2)|CXL treatment with UVA-radiation (9mW/cm2) with a 10 minute irradiation protocol.
46072436|NCT04427956|Drug|Isotonic riboflavin|CXL protocol with isotonic riboflavin
46072437|NCT04427956|Drug|Hypotonic riboflavin|CXL protocol with hypotonic riboflavin
46072438|NCT04427956|Procedure|Iontophoresis|CXL protocol with iontophoresis and ricrolin
45928522|NCT05345951|Behavioral|e-PBI|"The e-PBI is currently a model prevention resource at NIAAA's College Alcohol Intervention Matrix and the research was discussed in the most recent Surgeon General's Report as one of two prevention approaches that met the rigorous criteria to be considered efficacious. The first section of the e-PBI provides an introduction to the problem of substance use. The second section focuses on specific skill building strategies that parents can use to improve communication channels with their teen. Third is a section that addresses peer influence and provides strategies for developing assertiveness. The fourth section is an in-depth discussion of underage drinking, physiological and psychological effects, mixing alcohol with other drugs, motives for why students drink and don't drink, warning signs, risky binge-type drinking, impaired driving, riding with impaired drivers, alcohol and sexual assault, and how to communicate about parents' experiences when they were young."
45928523|NCT00023751|Drug|fluorouracil|
45928524|NCT00023751|Drug|leucovorin calcium|
45928525|NCT00023751|Procedure|conventional surgery|
45928526|NCT00023751|Radiation|radiation therapy|
45928527|NCT05338424|Other|Sprint Interval Training (SIT)|Active arm-- exercise dictated by protocol
45928528|NCT00023790|Drug|silicon phthalocyanine 4|Patients receive silicon phthalocyanine 4 (Pc 4) IV over 2 hours on day 1 followed by light therapy over 30-60 minutes on day 2. Treatment repeats in 6 weeks for a total of 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of Pc 4.
45928529|NCT02971982|Drug|rituximab /Dexamethasone/cyclophosphamide|rituximab:375mg/m2 ,Dexamethasone 20mg q12h,cyclophosphamide 750mg
45928530|NCT02971982|Drug|Velcade/Dexamethasone/cyclophosphamide|Velcade:1.3mg/m2,Dexamethasone 10mg q12h,cyclophosphamide 750mg
45928531|NCT00023829|Drug|bicalutamide|
45928532|NCT00023829|Drug|flutamide|
45928533|NCT00023829|Drug|releasing hormone agonist therapy|
45650604|NCT03604393|Behavioral|Practice facilitation|For this intervention, ORPRN Practice Facilitators will: 1) Build practice QI capacity by addressing the five Change Concepts; 2) Train practice clinicians and staff to generate reminder lists and notices in ALERT Immunization Information System (state immunization registry); 3) Develop an HPV immunization improvement plan for each practice using PDSA cycles and workflow mapping; and 4) Facilitate community engagement surrounding HPV vaccination messaging.
45650605|NCT03043469|Other|Short-form survey instrument|Questionnaire with questions about quality of life. Takes about 5 minutes to be completed.
45650606|NCT03043469|Other|Demographic data|height, weight, age, gender, list of comorbidities, health history, level of physical activity, medicines in use. Takes about 10 minutes to be completed.
45650607|NCT03043469|Other|Hospital Anxiety and Depression Scale|Questionnaire with questions about anxiety and depression. Takes about 5 minutes to be completed.
45799818|NCT04707989|Other|Ketone- Promoting Food Ingredient #2|Previously characterized proprietary food ingredient (#2) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
45799819|NCT04707989|Other|Ketone Free Placebo|Beverage that is matched to ketone-promoting food ingredient #1 beverage for appearance, taste, texture and volume. Does not contain ketones or ketone precursors.
45799820|NCT03868787|Device|TENS|TENS units are small, inexpensive, portable, battery-powered devices which deliver mild, alternating electrical currents via electrodes positioned on the skin near the anticipated dermatomal distribution of pain.
45450819|NCT02201914|Drug|Clomiphene citrate|patients receive clomiphene citrate 100 mg daily starting on day 2 for 5 days and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 5; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection
45928534|NCT00023829|Procedure|adjuvant therapy|
45928535|NCT00023829|Radiation|radiation therapy|
45928536|NCT05326880|Device|Ceramic Dental Implant|The ceramic implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading with definitive prosthesis after 6 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
45650608|NCT03043469|Other|Nijmegen questionnaire|Answering questions about symptoms related to breathing. Takes about 5 minutes to be completed.
45650609|NCT03043469|Other|The Self-evaluation of breathing questionnaire|Answering questions about self-evaluation of breathing. Takes about 5 minutes to be completed
45650610|NCT03043469|Other|six-minute exercise test|Cycling against certain load in a bicycle for 6 minutes. Takes about 16 minutes to be completed together with indirect calorimetry, oxygen saturation monitoring, heart rate variability analysis and continuous monitoring of arterial blood pressure).
45799821|NCT03868787|Device|Sham TENS|Non-active TENS unit
45928537|NCT05326880|Device|Titanium Dental Implant|The titanium implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading with definitive prosthesis after 6 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
46072439|NCT04427241|Drug|Cerebrolysin|30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously
46072440|NCT04427241|Drug|Control|100 ml normal saline, days 4-17, once/day, IV
45799822|NCT04707833|Diagnostic Test|Serological testing for COVID-19 infection|"The tests used will be the following:~EUROIMMUN SARS-CoV-2(IgA) ELISA ELISA SARS-CoV-2 (IgG) EUROIMMUN WANTAI SARS-CoV-2 Ab ELISA WANTAI SARS-CoV-2 IgM ELISA Abbott Architect SARS-CoV-2 IgG Diasorin SARS LINK CoV-2 S1/S2 IgG Roche ECL anti-SARS-Cov-2 (combined IgG IgM IgA)"
45928538|NCT00023868|Drug|FOLFIRI regimen|
45928539|NCT00023868|Drug|cisplatin|
45928540|NCT00023868|Drug|doxorubicin hydrochloride|
45928541|NCT00023868|Drug|fluorouracil|
45928542|NCT00023868|Drug|irinotecan hydrochloride|
45928543|NCT00023868|Drug|leucovorin calcium|
45928544|NCT00023868|Drug|mitomycin C|
45928545|NCT00023907|Drug|paclitaxel|
45928546|NCT05304221|Other|Shamir Resistance Calculator|"An on-line calculator which is free and accessible from all devices, which may predict the risk of MDRO infection upon admission, and the risk of nosocomial XDRO infection during the hospitalization.~The calculator contains only parameters that could be extracted bedside, at the first presentation of a septic patient, including the ability to conduct a complete assessment also among patients with reduced consciousness and/or cognition."
45928547|NCT05292911|Drug|ALT-801|Injected subcutaneously (SC)
45928548|NCT05292911|Other|Placebo|Injected subcutaneously (SC)
45928549|NCT00023946|Drug|ixabepilone|Given IV
45928550|NCT00023946|Other|laboratory biomarker analysis|Correlative studies
45928551|NCT05268185|Behavioral|Moderna Booster Vaccine|Participants assigned to this intervention will be given the recommendation to receive the Moderna vaccine for their Covid-19 booster shot. The study team will not be administering vaccines to the participants; participants must have equal access to both the Pfizer and Moderna booster vaccines to be eligible for this study. According to current FDA recommendations, Moderna booster (0.25 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.
45928552|NCT05268185|Behavioral|Pfizer Booster Vaccine|Participants assigned to this intervention will be given the recommendation to receive the Pfizer vaccine for their Covid-19 booster shot. The study team will not be administering vaccines to the participants; participants must have equal access to both the Pfizer and Moderna booster vaccines to be eligible for this study. According to current FDA recommendations, the Pfizer booster (0.30 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.
45650611|NCT03043469|Other|Indirect calorimetry|Breathing through a mask that measures levels of oxygen, carbon dioxide, breathing frequency and others (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
45650612|NCT03043469|Other|Oxygen saturation monitoring|The measurement of the amount of oxygen which is attached to haemoglobin molecules (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
45650613|NCT03043469|Other|Heart rate variability analysis|Measurement of the variation in the beat-to-beat interval (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
45650614|NCT03043469|Other|Continuous measurement of arterial blood pressure|Measurement of blood pressure based on the peripheral pulse using a finger cuff (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
45650615|NCT03043469|Diagnostic Test|Lung function test|Breathing through a mouth-piece in many different ways in order to measure the function of the lungs (non-invasively).
45799823|NCT02578199|Behavioral|motivational interviewing and nutrition|Motivational Interviewing and Nutritional Counseling
45799824|NCT02578745|Device|Prophylactic NPWT (PICO system)|The PICO NPWT system is a small, lightweight (~126 grams), portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary super-absorbent adhesive dressing. It is supplied as a pump with two sterile dressing kits and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 10 to 40 cm. The PICO pump maintains negative pressure of -80 mmHg (+/-20 mmHg) to the wound surface.
45799825|NCT02578745|Other|Standard Dressing|Standard wound dressing consists of routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
45928553|NCT00023985|Biological|autologous tumor cell vaccine|
45928554|NCT00023985|Biological|therapeutic autologous dendritic cells|
45799826|NCT01834651|Drug|Cabozantinib|Cabozantinib 60 mg daily (oral). Subjects may continue to receive study treatment until they experience unacceptable drug-related toxicity or disease progression.
45799827|NCT00557323|Drug|Lanthanum carbonate|
45799828|NCT02578901|Drug|Tranexamic Acid|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, TXA 1.0 gram will be administered. When given PO, TXA 1.3 grams will be administered
45799829|NCT02578901|Drug|Placebo|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, Normal Saline will be administered. When given PO, placebo pills will be administered
45799830|NCT03832439|Dietary Supplement|Probiotic|Lactobacillus rhamnosus GG 10 billion cells and microcrystalline cellulose
45799831|NCT03832439|Dietary Supplement|microcrystalline cellulose|Placebo
45928555|NCT00023985|Procedure|conventional surgery|
45928556|NCT00024024|Drug|rebimastat|
45928557|NCT00392249|Behavioral|Supervised Treatment of Schizophrenia by a family member|
46072441|NCT04410731|Drug|Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy|Single bilateral intra-articular injection of manufactured cell cultured expanded allogeneic BM-MSCs for painful lumbar facet joint arthropathy
46072442|NCT04385498|Behavioral|BREATHE Intervention|5 session program focusing on breathing retraining, psychoeducation, and positive coping.
46072443|NCT04385498|Behavioral|Waitlist Treatment as Usual|Typical primary care treatment which will include medication management and follow-up at the health facilities, at at least the same frequency as treatment arm. At the end of the trial Participants will be able to receive the BREATHE Ethiopia treatment.
45799832|NCT02579057|Drug|Furosemide Injection Solution (SCP-101)|
45928558|NCT05258864|Behavioral|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
45928559|NCT00024063|Drug|orantinib|
45928560|NCT00024141|Drug|fluorouracil|
45928561|NCT00024141|Drug|irinotecan hydrochloride|
45928562|NCT05240924|Behavioral|Exposure and Response Prevention|ERP is a specialized cognitive behavioral intervention conducted over the course of 8-16 therapy sessions. ERP is based upon exposure principles and the idea that people can habituate to the distress caused by OCD triggers and learn to cope with anxiety about feared consequences without engaging in compulsive behaviors to 'neutralize' the obsession. ERP begins with psychoeducation about OCD and exposure, followed by construction of a hierarchy, or list, of situations that are feared, avoided, or trigger OCD rituals such as washing or checking. Then, the therapist and client begin in-session exposures to hierarchy items utilizing response or ritual prevention techniques to avoid reinforcing the ritual. Exposures can be in vivo, such as touching a contaminated item, or imaginal, such as visualizing a feared consequence happening.
45928563|NCT05240924|Other|Stress Management Training|The stress management training intervention will be based on that delivered by Simpson in an ERP trial. It will be delivered by PhD and Master's level therapists from each site's clinics. The stress management training intervention will begin with an introductory session providing psychoeducation about OCD, followed by 15 sessions covering stress management skills such as deep breathing progressive muscle relaxation, positive imagery, assertiveness training, and problem solving. Each session will contain an extended practice of the selected skill and will end with homework assignments to practice the stress management skills and monitor symptoms.
45928564|NCT02971995|Device|PET Scan ou TEP-TDM|Performance of the PET/CT using Flurocholine in order to detect the localization of the pathological fixation of the tracer and to determine the place where to take the biopsy
45799833|NCT02579057|Drug|Furosemide Injection Solution, USP|
45928565|NCT02971995|Device|mpMRI|Performance of the mpMRI in order to determine the place where to take the biopsy
45928566|NCT05239286|Procedure|General anaesthesia|"All patients in supine position will receive breathing 100% oxygen, induction of anaesthesia will be achieved using propofol (2 mg/Kg), 1-2 mcg/kg of fentanyl and atracurium (0.5 mg/Kg). Endotracheal tube will be inserted after 3 minutes of mask ventilation. Patients who will experience prolonged airway instrumentation due to a difficult intubation will be excluded from further data analysis because of excessive stimulation. Then mechanical ventilation will be performed using a tidal volume of 6-8 mL/kg of ideal body weight at an inspiratory to expiratory ratio of 1:2 without positive end-expiratory pressure. The ventilatory frequency will be adjusted to maintain an end-tidal carbon dioxide tension of 35-40 mmHg.~Anaesthesia will be maintained by isoflurane (1-1.5%), atracurium 10 mg intravenous increments every 20 minutes and morphine 0.1 mg/kg intravenous will be given as a long acting analgesia."
46073734|NCT02821728|Dietary Supplement|Dietary intervention|Participants in this group will consume three portions of broccoli and stilton soup per week for a minimum of four weeks before their scheduled template prostate biopsy. The soup will be made with a specially cultivated broccoli known as Beneforte, which contains an enhanced dose of a substance called glucoraphanin.
45650616|NCT03043469|Other|Respiratory muscle function|Breathing through a mouth-piece in many different ways in order to measure the function of the respiratory muscles (non-invasively).
45650617|NCT03043469|Other|Manual assessment of respiratory motion|Measure of the movements of the thorax while the participant is breathing (non-invasively).
45650618|NCT03043469|Other|Breath-hold test|Holding the breath a few times for as long as possible.
45650619|NCT03043469|Other|Physical Activity monitoring|Wearing a light-weight activity monitor to be wore on the hip for 7 consecutive days during, at least, 8 hours per day.
45650620|NCT03043469|Other|Asthma Control Questionnaire|Only for asthmatics: answering questions about the control the participant has over this respiratory condition/symptoms.
45650621|NCT03594175|Drug|CUSA-081|Participants will receive 1 or 2 doses of CUSA-081 0.7 mg/2 mL directly into the catheter lumen
45650622|NCT03594175|Drug|Placebo|Participants will receive 1 or 2 doses of placebo (normal saline) directly into the catheter lumen
45650623|NCT03594175|Drug|Alteplase|Participants will receive 1 or 2 doses of alteplase, 2 mg/2 mL, directly into the catheter lumen
45650624|NCT03103399|Drug|Comtan®|200 mg entacapone were to be taken concomitantly with each levodopa/DDCI dose.
45650625|NCT03103399|Drug|Nebicapone|50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose.
45650626|NCT03103399|Drug|Levodopa/DDCI|"Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients."
45650627|NCT03103399|Drug|Placebo|Administered orally as encapsulated tablets, which were identical in appearance to the study drugs
45650628|NCT03040115|Other|Non-Interventional Study|
45650629|NCT03038945|Other|2/0 barbed suture|Close vaginal vault 2 planes with 2/0 barbed suture in patients with total laparoscopic hysterectomy in benign pathology
45799834|NCT00364325|Other|Acute Decompensated Heart Failure|Standard of Care
45650630|NCT03038945|Other|0/0 Vicryl suture|Close vaginal vault 2 planes with 0/0 Vicryl suture in patients with total laparoscopic hysterectomy in benign pathology
45650631|NCT05357833|Drug|Ferumoxytol infusion|Subjects will receive a single, weighted dose of intravenous ferumoxytol (4 mg/kg) diluted in 50 mL of saline.
45650632|NCT05357833|Drug|Gadoteridol|Subjects will receive a single, weighted dose of intravenous gadoteridol (0.2 mL/kg).
45650633|NCT05357833|Diagnostic Test|MRI Brain and Cervical Spine|3T MR imaging of the brain and cervical spine pre- and post-administration of gadolinium, then pre- and 96 hours (±24 hours) post-administration of ferumoxytol
45650634|NCT03043157|Drug|rocuronium|intravenous rocuronium infusion
45799835|NCT02579135|Behavioral|Safer Sex|Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.
45799836|NCT02579135|Behavioral|Growth Mindsets|Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
45799837|NCT00557245|Drug|Tenofovir Disoproxil Fumarate (TDF)|TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
45799838|NCT00557245|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
45928567|NCT05239286|Drug|Conventional fluid managment|Ringer solution at the dose of 5 ml/kg/h infused throughout the surgical procedure by taking the parameters such as Heart rate (HR), mean arterial pressure (MAP) and urine output, Hypotension was defined as a condition in which the MAP was below 30% of the baseline MAP of the patient. In this case, bolus of 250 ml crystalloids (0.9% NaCl) was given and in case of hypotension persistence, 5 mg I.V. ephedrine administered and repeated every 5 min till the MAP increased over 70% of baseline.
45928568|NCT05239286|Drug|PVI dependant goal directed fluid therapy|"After the induction of anesthesia, Ringer solution infused at the dose of 2 ml/kg/h started as a basal rate of infusion. If the PVI was higher than 13% for more than 5 min, a 250-ml bolus of crystalloids administrated. If the PVI was still higher than 13% after the bolus, it was repeated every 5 min until the PVI was less than 13% and if MAP was below 30% of the baseline MAP of the patient 5 mg iv ephedrine was applied and repeated every 5 min to keep the MAP increased over 70% of baseline.~In the cases where PVI was less than < 13% and if MAP was below 30% of the baseline MAP of the patient 5 mg iv ephedrine was applied and repeated every 5 min to keep the MAP increased over 70% of baseline.~Then the patient was turned to prone position and the same steps according to Massimo readings were repeated."
45928569|NCT00024180|Drug|romidepsin|
45650635|NCT05339113|Diagnostic Test|68Ga-FAPI-46 PET/CT|Patients are scanned 10 minute, 30 minute and 1 hour after 68Ga-FAPI-46 as well as one hour 18-FDG injection within 2-3 days interval.
45928570|NCT05217134|Procedure|DPEA|Dural puncture with 27 G Whitacre needle
45928571|NCT00024297|Drug|warfarin|
45928572|NCT05158283|Device|chocolate balloon|chocolate balloon dilatation
45928573|NCT05158283|Device|plain balloon|plain balloon dilatation
45928574|NCT00024336|Drug|tamoxifen citrate|
45450820|NCT02201914|Drug|Daily FSH and LH plus Cetrorelix|Women receive an initial daily dose of 450 IU recombinant FSH and 225 IU recombinant LH starting on day 3; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection.
45653216|NCT05613257|Procedure|Free-hand/perfect circles technique|"Patients in this arm will have no assistive targeting device use and the surgeon will use a free-hand technique for the placement of interlocking screws. With this technique, fluoroscopic images are taken such that the interlocking holes of the intramedullary device are perfect circles and indicate that a screw introduced in the same plane that the fluoroscopic image was taken would seat perpendicularly to the intramedullary device. This is the most commonly employed technique for interlocking screw placement through intramedullary devices."
45799839|NCT00557245|Drug|Placebo|Placebo TDF & Placebo FTC/TDF, 1 tablet each daily.
45799840|NCT00364091|Drug|R89674 0.025% ophthalmic solution|
45799841|NCT03583541|Behavioral|HIV Risk Reduction|This is an intervention comprised of 4 sessions provided twice per week for 2 weeks of an evidence-based, HIV/STI risk reduction intervention.
45450821|NCT02201914|Drug|Triptorelin plus daily FSH anh LH|women receive short-acting Triptorelin 0,05 mg daily starting on day 1 until the hCG injection and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 2.
45928575|NCT00024336|Radiation|radiation therapy|
45928576|NCT05142449|Drug|Amoxilan|Patients receive 8 capsules Amoxilan perioperatively and for the next 3 days 6 capsules per day
45928577|NCT05142449|Other|Placebo|Patients receive 8 capsules placebo perioperatively and for the next 3 days 6 capsules per day
45928578|NCT00024375|Drug|DHA-paclitaxel|
45928579|NCT00024414|Drug|DHA-paclitaxel|
45928580|NCT05138003|Diagnostic Test|cardiac MRI|"T1 and T2 relaxation times will be evaluated on basal and mid-cavity SA maps; a single ROI measurement in the septum will be manually drawn sufficiently far from tissue interfaces to avoid the impact of susceptibility artifacts from adjacent tissues. The differences in T1 and T2 relaxation times between rest and post-exercise will be analyzed.~Cardiac ventricular volumes, function and LV mass will also be quantified."
45928581|NCT05138003|Diagnostic Test|Echocardiography|Measurements of mass, volumes and function will be obtained of both the left and right ventricles enabling comparisons with cardiac MRI and traditional echo measures.
45450822|NCT02202070|Drug|onabotulinumtoxinA|
45450823|NCT05261698|Other|Home-based Exercise Manual|in the experimental group we will provide moist heating pads along with TENS on the neck for 10 minutes and then neck isometrics and strengthening exercises shall be performed. Patients in the experimental group will also receive a home-based exercise manual.
45928582|NCT05138003|Diagnostic Test|RootiRx for the ECG monitoring during the cycling ride|The final report will include the amount of recorded beats, the average heart rate, the maximum and minimum heart rate, the amount of cardiac pauses defined as an interruption in the ventricular rate > 2 seconds. Reported atrial events include atrial ectopic beats and supraventricular tachycardia and ventricular events include ventricular ectopic beats, doublets, triplets, bigeminy, trigeminy and ventricular tachycardia.
45928583|NCT05138003|Diagnostic Test|Blood sample|Blood sample will be performed 3 to 6 hours after the stage to analyze high-sensitivity cardiac Troponin T (high-sensitivity) levels, Creatine Phosphokinase (CPK) to eliminate the hypothesis of Troponin elevation induced by rhabdomyolysis and C-reactive Protein to corroborate the inflammatory aspect if there is any.
45928584|NCT00024453|Biological|teicoplanin|
46073735|NCT02821728|Other|Normal diet|Participants in this group will continue with their normal diet up until the day of their scheduled template prostate biopsy.
46073736|NCT00850057|Biological|Intranodal injection of Ad-ISF35|Ad-ISF35, a replication-defective recombinant type V adenovirus encoding a recombinant humanized CD154 homolog (ISF35).
46073737|NCT02821572|Biological|blood sample|
46073738|NCT02821572|Procedure|spleen sample|
45450824|NCT05261698|Other|Conventional PT|In this group patients will receive routine physical therapy including hot pack for 10 minutes, stretching, strengthening exercise and TENS at the end of each session.
45928585|NCT05135195|Other|In-House Developed VR Platform - AMD, DR, Glaucoma|Participants will conduct experiments using commercial VR headsets and controllers. Visual impairments will be systematically simulated in VR. There are three visual impairment simulations (AMD, DR, and glaucoma) at three levels of severity (mild, moderate, or severe). Symptoms' simulation tools include a gaussian blur shader, distortion shader, and a culling mask with a gray spot in the middle.
45928586|NCT05135195|Other|In-House Developed VR Platform - Glaucoma|In the second set of experiments, a multidimensional visual impairment simulation of a single pathology (glaucoma) will be used at three levels of severity (mild, moderate, or severe). The post-processing package to simulate includes glare, difficulty in light, change adaptation, ambient occlusion, visual clutter, and overall blurred effect. The shader graph package will be used to create a distortion localized on assets surfaces only.
45928587|NCT00024492|Drug|Liposome Encapsulated Mitoxantrone (LEM)|
45928588|NCT00024531|Drug|Atorvastatin calcium|
45928589|NCT05093894|Device|Group 1|Microlyte will be cut into strips and placed on the subcutaneous space
45928590|NCT00024570|Drug|IL13-PE38QQR|
46072444|NCT04385290|Drug|MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO|"Midostaurin (IMP) induction: 25 mg or 50 mg peroral BID, days 8 to 21 depending on assigned dose level~GO (IMP) induction: 3 mg/m^2 i.v. max 4.5 mg, on day1, or on days 1, 4, or days 1, 4, 7 depending on assigned dose level~Daunorubicin (DNR, non-IMP) induction: 60 mg/m^2/day i.v., days 1 to 3~Cytarabine (AraC, non-IMP) induction: 200 mg/m^2/day cont. infusion, days 1 to 7"
46072445|NCT04385290|Drug|MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO|"Midostaurin (IMP):~RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21 induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles;~GO (IMP): 3 mg/m^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only~Daunorubicin (DNR, non-IMP):~60 mg/m^2 i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
45450825|NCT02202226|Drug|Lu AF35700|
45650636|NCT04843163|Behavioral|NAMI Basics|NAMI Basics is a peer service program for caregivers of children with mental health needs. It was created by the National Alliance on Mental Illness (NAMI) and was adapted from their empirically supported model for caregivers of adult children with mental illness (Family-to-Family). The child-focused intervention, NAMI Basics, is a six-class curriculum focused on increasing caregiver knowledge about mental illness, empowering parents to advocate for their children across service systems, and introducing skills that assist in family problem-solving and communication (Brister et al., 2012). The program is currently available widely throughout the U.S. through certified trainers who volunteer with local NAMI affiliates and is provided free of charge to caregivers in a non-stigmatizing community setting (e.g., local school, church, community center). It is open to all caregivers, regardless of mental health diagnosis or time within a treatment system.
45650637|NCT03103477|Other|Urine stability|This study is proposing to assess PAF and PAF-AH activity in urine after using various handling methods of the urine specimen. Better understanding of PAF stability will allow for better design of future experiments involving PAF in interstitial cystitis patients.
45650638|NCT04840433|Device|MACE|Using magnetically assisted capsule endoscopy to examine oesophagus and stomach
45650639|NCT05332795|Drug|Metformin|gouty patients, will receive metformin tablets (1000 mg) once daily for about 3 months.
45650640|NCT05332795|Drug|Placebo|gouty patients, will receive placebo tablets once daily for about 3 months.
45450826|NCT02202226|Drug|Placebo|
45450827|NCT02751580|Other|Telemedicine|Attend a virtual visit via the JeffConnect telehealth app
45450828|NCT02751580|Other|Questionnaire Administration|Ancillary studies
45450829|NCT02207140|Dietary Supplement|HOWARU Restore|
45799842|NCT03583541|Behavioral|Financial Literacy|This evidence-based Financial Education Core Curriculum addresses the importance of savings, banking services, budgeting debt management. Undarga adaptation for FSWs included shortening and simplifying sessions while retaining core elements; adding weekly check-ins due to safety concerns FSWs share related to intervention participation, and safety planning as needed. We will further adapt sessions in months 1-6 to assure language and illustrative examples are culturally consonant, and to infuse BE principles consistent with HIVRR. During sessions 1 & 2 we will include information on delay discounting, for example, learning to understand the tendency to prefer small immediate rewards over larger available at a later time; sessions 3 & 4 will include details on economic utility; sessions 5 will contain information on salience (e.g. understanding occasions when women may minimize triggers to unsafe sex); and session 6 will address loss aversion.
45650641|NCT04370483|Drug|Leflunomide|Gievn PO
45650642|NCT04370483|Other|Quality-of-Life Assessment|Ancillary studies
45650643|NCT03571789|Device|Vine™|"The Vine™ is made of a super-elastic nitinol wire comprises a helix that resides within the CCA lumen and a linear stem that traverses the CCA wall. The helix includes three segments: supporting coils, filter, and leading coils.~The device is available in sizes of 6.0mm - 10.0mm (in 0.5mm intervals) to accommodate individual CCA diameters"
45650644|NCT03040349|Behavioral|Training|The training program consists of a one-day core session addressing tobacco use with patients in the context of a busy primary care practice setting.The curriculum design was designed to be 2/3 theory and 1/3 practical. The program employs teaching techniques including role-play and case-study approaches known to enhance practice change.
45653217|NCT05110131|Device|Device for performing biopsy via electromagnetic navigation bronchoscopy|Device for performing biopsy via electromagnetic navigation bronchoscopy (needle and forceps)
45653218|NCT05611385|Other|Difference in development of Acute Lung Injury in Amphetamine positive and negative patients|No Intervention
45928591|NCT00024570|Procedure|targeted fusion protein therapy|
45928592|NCT00024570|Procedure|surgery|
45928593|NCT00024648|Drug|LErafAON|
45928594|NCT05080049|Drug|Erythropoietin|"Patients receive a subcutaneous injection of 40,000 IU of erythropoietin alfa or zêta, repeated weekly until Day 28 (if the hemoglobin level is <12 g/dl and the patient remains hospitalized).~The study treatments are administered by an open-label nurse. In both groups, before each injection, iron deficiency (defined as reticulocyte Hb <29 pg, or hepcidin <41 µg/L, or ferritin <100 µg/L, or ferritin <300 µg/L with transferrin saturation <20%) is treated with intravenous iron infusion (depending on the product available at the center). A restrictive transfusion strategy is recommended as long as the patient remains in the ICU, according to recent recommendations.~Six visits are scheduled: V1 for inclusion and the first injection, V2 at Day 7(±2 days) for the second injection, V3 at Day 14(±2 days) for the third injection, V4 at Day 21(±2 days) for the fourth injection, V5 at Day 28(±2 days) for the fifth injection."
45928595|NCT05080049|Drug|Placebo|"In the control arm, patients receive a subcutaneous injection of placebo (0.9% NaCl) according to the same schedule.~The study treatments are administered by an open-label nurse. In both groups, before each injection, iron deficiency (defined as reticulocyte Hb <29 pg, or hepcidin <41 µg/L, or ferritin <100 µg/L, or ferritin <300 µg/L with transferrin saturation <20%) is treated with intravenous iron infusion (depending on the product available at the center). A restrictive transfusion strategy is recommended as long as the patient remains in the ICU, according to recent recommendations.~Six visits are scheduled: V1 for inclusion and the first injection, V2 at Day 7(±2 days) for the second injection, V3 at Day 14(±2 days) for the third injection, V4 at Day 21(±2 days) for the fourth injection, V5 at Day 28(±2 days) for the fifth injection."
45928596|NCT00024687|Drug|SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin|
45928597|NCT05079581|Other|Pelvic floor exercises|"The participants in the intervention group will be taught exercises involving strengthening the muscles around the pelvic floor in sitting, standing and lying positions by a physiotherapist who has been trained in women's health for 4 years and will be asked to perform them as home exercises every day for 8 weeks. The exercises are as follows:~They will be asked to tighten the muscles around the urethra, vagina and rectum as hard as possible, upwards and inwards (from the bottom up) and hold it in this way for 8-10 seconds. It will be applied in different positions as in the table."
45928598|NCT05073419|Other|Standard of Care|Routine monitoring of post AMI patient with clinic visits
45928599|NCT05073419|Device|ICM Implantation|Implantation of ICM through small incision (2 mm) under the skin
45928600|NCT00395148|Drug|rHDL|
45928601|NCT05072444|Drug|QPX7728|beta lactamase inhibitor
45928602|NCT05072444|Drug|QPX2014|antibiotic
45928603|NCT00395187|Procedure|Photodynamic Therapy|
45928604|NCT05068739|Procedure|PA-EMR|Standard oval-shaped, braided wire polypectomy snare with 10 mm or 20 mm loop diameter will be used. With the duodenoscope in a semi-long position, the tip of the snare will be anchored just below the transverse fold of the ampulla and opened above-downwards fashion until the orifice will be seen. The orifice will be strictly preserved to avoid the risk of PEP and approximately the upper two-thirds of the ampullary mound will be grabbed by the snare. The direction and the depth will be controlled by combined movements of the elevator and wheels of the duodenoscope. After removal of the mucosa, the wall of choledochus will be seen clearly and standard wire-guided cannulation (WGC) will be performed. If cannulation can not be achieved with WGC, an additional incision will be performed to the wall of the choledochus with a needle knife.
45928605|NCT05068739|Procedure|NKF|The needle knife will be placed at the junction of the upper one-third and lower two-thirds of the papillary roof (bulging portion). Minimal, superficial incisions will be made in the 11-12 o'clock direction. The length of the fistulotomy will be at the endoscopist's discretion, depending on the shape of the papilla. The cut will be extended until bile juice, the pinkish bile duct mucosa, and/or the bulging of the white sphincter of the Oddi's muscle is visible.
45928606|NCT05056688|Diagnostic Test|Testicular Model BSE/TSE Training Set|The investigators will use the Testicular Model BSE/TSE Trainer to transform individuals' routine testicular self-examination into behavior.
45928607|NCT02971722|Drug|JY09|2mg/1ml/bottle
45928608|NCT02971722|Drug|Placebo|1ml/bottle
45928609|NCT00025038|Drug|tipifarnib|Given orally
45928610|NCT00025038|Drug|isotretinoin|Given orally
45928611|NCT00025038|Drug|fludarabine phosphate|Given IV
45928612|NCT00025038|Drug|cytarabine|Given IV
45928613|NCT00025038|Radiation|radiation therapy|Undergo total body irradiation
45928614|NCT00025038|Drug|cyclophosphamide|Given IV
46072446|NCT04385290|Drug|MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO|"GO (IMP): 3 mg/m^2 i.v. max 4.5 mg on days 1, 4, 7; 1 induction cycle only~Daunorubicin (DNR, non-IMP):~60 mg/m^2/day i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
46072447|NCT04385290|Drug|MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin|"Midostaurin (IMP):~RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21, induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles;~GO (IMP): 3 mg/m^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only~Daunorubicin (DNR, non-IMP):~60 mg/m^2/day i.v., days 1 to 3 of induction cycles 1-2 in good and moderate responders; 50 mg/m^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
45928615|NCT00025038|Biological|anti-thymocyte globulin|Given IV
45928616|NCT00025038|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplant
45928617|NCT00025038|Procedure|double-unit umbilical cord blood transplantation|
45928618|NCT00025038|Procedure|umbilical cord blood transplantation|Undergo allogeneic cord blood transplant
45928619|NCT00025038|Other|laboratory biomarker analysis|Correlative studies
45928620|NCT05055830|Drug|The OPTIC study is collecting PK data on children prescribed understudied drugs of interest per standard of care.|The goal of this study is to characterize the pharmacokinetics of understudied drugs for which specific dosing recommendations and safety data are lacking. The prescribing of drugs to children will not be part of this protocol. Taking advantage of procedures done as part of routine medical care (i.e. blood draws), this study will serve as a tool to better understand drug exposure in children receiving these drugs per standard of care.
45928621|NCT00025077|Biological|filgrastim|
45928622|NCT00025077|Drug|carboplatin|
45928623|NCT00025077|Drug|cyclophosphamide|
45928624|NCT00025077|Drug|thiotepa|
45928625|NCT00025077|Procedure|conventional surgery|
45928626|NCT00025077|Procedure|peripheral blood stem cell transplantation|
45928627|NCT00025077|Radiation|radiation therapy|
45928628|NCT05051891|Drug|Orelabrutinib and R-CHOP|Orelabrutinib in Combinaion with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
45928629|NCT05051891|Drug|R-CHOP|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
45928630|NCT05042414|Behavioral|High intensity interval training|Four times four minutes treadmill interval training
45928631|NCT05042414|Behavioral|Moderate intensity training|Moderate intensity treadmill training
45928632|NCT05042414|Behavioral|Resting|No training
45928633|NCT00025194|Drug|estramustine phosphate sodium|
45650645|NCT03040349|Behavioral|Provider and Patient Tools|Provider and patient tools were translated and adapted for use in primary care settings in Greece. A tool kit of resources will be distributed to providers which includes: patient tobacco use survey; provider consult form; provider medication reference sheet; patient quit plan booklet; and, waiting room posters. The provider consult form uses a checklist style set-up and provides real-time reminders for conducting an initial smoking cessation visit and follow-up appointments. The TiTAN Crete tools are available online at www.titan.uoc.gr
45650646|NCT03040349|Behavioral|E-blast and Webinars|In order to develop the network and continue to provide training opportunities for skills development we will develop a communication platform via an email list-serv to proactively communicate with providers who participate in the TiTAN program. A quarterly e-blast will be sent to all health care professionals involved in the TiTAN program. The e-blast will address the latest evidence-base practice, and skill development. Links to videos will also be provided. A webinar series will be scheduled to cover topics identified as interest by the primary health care providers. The webinar series will also be linked the Global Bridges EPACTT project.
45650647|NCT05224453|Other|Physical training and high protein diet|In addition to the integrated physical training exercises, group A received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (>1 g/kg aBW/d)
45799843|NCT03583541|Behavioral|Mentorship|Mentorship. Mentorship to bridge the transition from FL and savings to a vocational change is a critical component of this intervention. These sessions are intended to support the transition -equipped with financial literacy and savings -to vocational, educational, employment or small business development training using matched savings. The mentorship sessions are adapted from the pilot study and integrate components (e.g., referral and linkage, coaching, exchange visits to model farmers) from income-generating activities provided by our collaborating partner, RTY. All sessions include check-in and individual attention. The first 4 sessions focus on identifying options for vocational, educational, employment or business development training. The second 4 sessions include invited experts in identified areas of interest by group members for more intensive time and attention to individualized needs to make the transition.
45650648|NCT05224453|Other|Physical training and low protein diet|In addition to the integrated physical training exercises, group B received low protein diet in the range of 0.7 - 0.9 g/kg protein/ ideal body weight/day (<1 g/kg aBW/d)
45928634|NCT00025194|Drug|ixabepilone|
45928635|NCT00025272|Drug|carboplatin|
45928636|NCT00025272|Drug|etoposide|
45928637|NCT00025272|Drug|topotecan hydrochloride|
45928638|NCT00025272|Radiation|radiation therapy|
45928639|NCT05023382|Drug|Teduglutide|Teduglutide 0.05 mg/kg SC injection
45928640|NCT00025311|Drug|topotecan hydrochloride|
45928641|NCT05019131|Behavioral|Training|trainings to reduce conscious bias and stress
45928642|NCT05019131|Behavioral|Peer support and mentorship|facilitated peer and mentorship opportunities
45928643|NCT05019131|Behavioral|Leadership engagement|Engaged leadership at the county and facility levels
45928644|NCT05019131|Behavioral|Embedded champions|Facilitate local champions to promote intervention
45928645|NCT00025116|Drug|gefitinib|
45928646|NCT00025350|Drug|gefitinib|
45928647|NCT05006300|Other|Topialyse Baume Barrière|Evaluation of the efficacy of the cosmetic product SVR TOPIALYSE Baume Barrière on the reduction of topical corticosteroid consumption in children from 3 months to 17 years old presenting mild to moderate atopic dermatitis after 28 and 56 days of use, at one or two apllications /day.
45928648|NCT00025389|Biological|bevacizumab|
45928649|NCT00025389|Drug|carboplatin|
45928650|NCT00025389|Drug|paclitaxel|
45928651|NCT00025389|Procedure|conventional surgery|
46073739|NCT00828711|Drug|MVI 100|Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
45928652|NCT00025389|Procedure|neoadjuvant therapy|
45928653|NCT04994366|Other|Thank you card|A card thanking the patient for choosing NYU and entrusting us with their care. The card notifies the patient that they may receive a patient satisfaction survey after discharge.
45928654|NCT00025428|Drug|carboplatin|
45928655|NCT00025428|Drug|cyclophosphamide|
45928656|NCT00025428|Drug|doxorubicin hydrochloride|
45928657|NCT00025428|Drug|etoposide|
45928658|NCT00025428|Drug|vincristine sulfate|
45928659|NCT00025428|Procedure|adjuvant therapy|
45928660|NCT00025428|Procedure|conventional surgery|
45928661|NCT00025428|Procedure|neoadjuvant therapy|
45650649|NCT05218837|Other|Vaginal birth|Obstetric anal sphincter injury occurs at the final stage of vaginal delivery.
45650650|NCT05211193|Device|eTNM delivered by URIS I nerve stimulation device|eTNM delivered by URIS I nerve stimulation device, self administered in the subject's home for 30 minutes per day, for a minimum of 34 therapy session between day 1-42.
45650651|NCT03042923|Drug|lactulose:mannitol (L:M) oral challenge|
45799844|NCT03583541|Behavioral|Matched savings individual development account|A matched savings individual development account (hereafter IDA) is a savings account held at a local bank whereby deposits made by the woman are matched by the intervention to encourage savings and investment in skills and asset development. The accounts introduce women to financial management skills, introduce them to formal financial institutions, and by matching their deposits, incentivize women to save small amounts. Each woman will receive an IDA held in her own name. Women will be allowed and indeed encouraged to contribute up to 50,000 shillings (~15 USD) per month towards their IDAs. The maximum amount of women's contribution to be matched will be an equivalent of US$15 per month for 10 months. During the intervention, monthly account statements will be generated for women to note their accumulated savings. During the intervention, women will have direct access to both their personal savings deposited in the accounts and the match provided by the study.
45928662|NCT04975178|Biological|MTBVAC|MTBVAC is a novel TB vaccine candidate based on an attenuated M. tuberculosis clinical isolate of the Euro-American lineage. Attenuation is based on two independent, stable genetic deletions of the genes phoP and fadD26 coding for two major virulence factors, the transcription factor PhoP and the cell-wall lipids PDIM, respectively. We hypothesize that MTBVAC will provide improved protection, as individuals latently infected with live M.tuberculosis have an 80% lower chance of developing TB, and as MTBVAC contains most of the genes deleted from BCG and presents a wider collection of antigens to the host immune system. Preclinical studies in different animal models indicated that MTBVAC is safe and is able to induce an improved protection compared to BCG.
45928663|NCT04975178|Biological|BCG|BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis. It is administered at birth.
45928664|NCT00025467|Drug|thalidomide|Given orally
45928665|NCT00025467|Other|laboratory biomarker analysis|Correlative studies
45928666|NCT04964414|Other|Smell Retraining|Smell practice with household scented items
45928667|NCT04964414|Drug|Budesonide|Nasal irrigation with liquid steroid
45928668|NCT00025545|Drug|cyclophosphamide|
45928669|NCT00025545|Drug|methotrexate|
45928670|NCT00025545|Procedure|peripheral blood stem cell transplantation|
45928671|NCT00025545|Radiation|radiation therapy|
45928672|NCT00025584|Drug|bortezomib|Given IV
45928673|NCT00025584|Other|laboratory biomarker analysis|Correlative studies
45928674|NCT00025623|Drug|carboplatin|
46073740|NCT00828711|Drug|MVI 150|Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
45450830|NCT03533140|Device|DUCEST Neurostimulator V Group A|The DUCEST Neurostimulator V needle-electrodes are applied post-operatively to stimulate the R.auricularis of the vagus nerve located at the Fossa triangularis. Connecting the needle-electrode cables to the Neurostimulator V activates the device. (The stimulation intensity can be adjusted from 0,05mA to 1,2mA, default value is 0,4mA). The starting stimulation intensity will be adjusted to 1mA and takes place at 1Hz continuously for 40 minutes, followed by a 20 minute break. The built-in 3V battery lasts for approx. 14 days. After 7 days the electrodes are replaced and applied to the other ear of the patient. A plaster with a plastic mounting clip is attached on the shoulder of the patient. The Neurostimulator is connected to the mounting clip. After 14 days or at hospital discharge of the patient, the device is unmounted and the needle-electrodes are removed.
45450831|NCT03533140|Device|DUCEST Neurostimulator V Group B|The DUCEST Neurostimulator V needle-electrodes are applied post-operatively at the Fossa triangularis. Connecting the needle-electrode cables to the Neurostimulator V activates only the signal lamp but not the device.
45650652|NCT05178355|Drug|KVD824|Active
45650653|NCT05178355|Drug|Placebo to KVD824|Placebo
45650654|NCT04429295|Biological|DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
45650655|NCT04429295|Biological|DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b)|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
45650656|NCT04429295|Biological|Inactivated Poliomyelitis Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
45650657|NCT04429295|Biological|Poliomyelitis Vaccine bivalent types 1 and 3|Pharmaceutical form:Oral suspension Route of administration: Oral
45928675|NCT00025623|Drug|cyclophosphamide|
45928676|NCT00025623|Drug|doxorubicin hydrochloride|
45928677|NCT00025623|Drug|etoposide|
45928678|NCT00025623|Drug|vincristine sulfate|
45928679|NCT00025623|Procedure|conventional surgery|
45928680|NCT04946318|Drug|CSJ117|CSJ117 (0.5 mg, 1mg, 2mg, 4 mg and 8 mg) capsules for inhalation once daily delivered via Concept1 inhalation device for 12 or 24 weeks.
45928681|NCT04946318|Drug|Placebo|Placebo inhaled once daily for 12 or 24 weeks. Delivered via Concept1 device.
45928682|NCT00025740|Drug|clonazepam and paroxetine|
45928683|NCT00025779|Drug|methylphenidate|
45928684|NCT00025779|Drug|guanfacine|
45928685|NCT04922255|Device|Reusable Underwear|Reusable Underwear are similarly available for purchase online and are absorbent underwear for bladder leak protection
45450832|NCT05261542|Diagnostic Test|flow cytometry|evaluation of intraoperative flow cytometry in detecting cancer cells in colorectal epithelium
45450833|NCT02199262|Other|music intervention|reminder+ 20 minutes in the morning and 20 minutes in the afternoon of music listening(classical or soft background music), delivered by compact disc players with headphones with disposable ear pads.
45450834|NCT02199262|Other|reflexology|reminder + 20 minutes per day feet reflexology massage provided by certified specialist in reflexology massages
45450835|NCT02199262|Other|reminder|Implementation of a reminder of guidelines of agitation diagnosis and management
45799845|NCT04743011|Drug|Heparin sodium|Nebulized inhalation of 5 mL of a solution containing high molecular weight heparin - enriched heparin - 2.5mg/mL and 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)
45450836|NCT02207296|Device|Plethysmographic variability index|
45650658|NCT04429295|Biological|Human Rotavirus, live attenuated|Pharmaceutical form:Oral suspension Route of administration: Oral
45650659|NCT04429295|Biological|Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
45799846|NCT04743011|Drug|Placebo|Nebulized inhalation of 5 mL of 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)
45799847|NCT03528941|Drug|Lamivudine|Patients who received lamivudine to prevent hepatitis B
45799848|NCT03528941|Other|No prophylaxis|Patients who did not receive any prophylaxis to prevent hepatitis B
45799849|NCT02989363|Procedure|Device O-Arm in DBS|Deep brain stimulation surgeries with device O-Arm
45799850|NCT02989363|Procedure|Device O-Arm in RAQUIS|Complex back surgeries with the device O-Arm
45450837|NCT02202304|Drug|Chlorhexidine/Thymol varnish|This will be applied on abutment teeth on partial denture wearers every 3 months during a period of 2 years.
45450838|NCT02207452|Device|He-3 MRI|Hyperpolarised helium-3 Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
45650660|NCT05258851|Drug|Ceftazidime-avibactam|Experimental
45650661|NCT05258851|Drug|Colistin|Control
45650662|NCT04843085|Other|Proteomic analysis|: Proteomic analysis in the 3 subgroups of oligodendrogliomas (O1, O2 and O3) and in the comparator groups of IDH-mutant astrocytomas, IDH-wildtype glioblastomas and normal brain samples
45650663|NCT03103243|Behavioral|Mindfulness Based Group Sessions|In-person group intervention sessions conducted with a combination of meditation, group exercise (yoga), group discussions, deep breathing and other mindfulness based practices.
45650664|NCT03043001|Drug|Memantine|All the subjects will receive add-on memantine for 12 week
45650665|NCT03496285|Radiation|Multimodal MRI with diffusion sequence for anorexia nervosa patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
45650666|NCT03496285|Radiation|Multimodal MRI with diffusion sequence for obsessional compulsive disorder patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
46073741|NCT00828711|Drug|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
46073742|NCT05659212|Drug|Dexmedetomidine|Patients will receive IV dexmedetomidine 0.5 μg /kg diluted up to 10 ml with normal saline infused over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
46073743|NCT05659212|Drug|Magnesium sulphate|Patients will receive IV magnesium sulphate 50 mg/kg diluted up to 10 ml with normal saline infused slowly over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
45450839|NCT02207452|Drug|Salbutamol|Salbutamol 5mg nebulised single dose
45450840|NCT02207452|Drug|Ipratropium|Ipratropium 500mcg nebulised single dose
45450841|NCT02207452|Device|MRI|Proton Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
45450842|NCT02202382|Drug|Korean Red Ginseng, Varicocelectomy|
45450843|NCT02202382|Drug|Placebo|Placebo were provided by Korean Ginseng Corporation (Daejeon, Korea). The placebo capsules were identical in shape, color, and taste.
45799851|NCT02989363|Procedure|Not device O-Arm in DBS|Deep brain stimulation surgeries without the device O-Arm
45799852|NCT02989363|Procedure|Not device O-Arm in RAQUIS|Complex back surgeries without the device O-Arm
45799853|NCT00364403|Behavioral|Low glycemic load|Provision of foods and dietary counseling to promote a low glycemic load diet
45799854|NCT00364403|Behavioral|Low fat diet|Provision of foods and dietary counseling to promote a low fat diet
45799855|NCT01835743|Device|Erchonia HPS Laser|The Erchonia HPS Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
45799856|NCT01835743|Device|Placebo Laser|The Placebo Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
45799857|NCT02579915|Behavioral|FaceAnxiety|Computerized treatment targeting mental habits and primary care linkage.
45799858|NCT02579915|Behavioral|Symptom Tracking|Weekly self-assessment with validated questionnaires and primary care linkage
45799859|NCT03580031|Drug|hCG|A booster dose (10,000 IU of hCG) was given IM 48 hours after first triggering dose
45799860|NCT03580031|Drug|Saline Solution|2 ml of normal saline will be injected 48 hours after first triggering dose
45799861|NCT02581475|Procedure|Extending withdrawal time in the proximal colon|
45928686|NCT04922255|Device|Disposable urethral support|The disposable urethral support is a tampon-like device that is available over the counter to help women with urinary incontinence (UI)
45928687|NCT04922255|Behavioral|Pelvic floor physical therapy|Experienced pelvic health physical therapists (at University of Pittsburgh) will complete two visits one week apart.
45928688|NCT04920422|Other|No intervention|Retrospective analysis using database without any intervention assigned in the study.
45928689|NCT00025818|Drug|Ophthalmic Emulsion|
45928690|NCT04898153|Device|aXess|Patients will be implanted with one Xeltis hemodialysis access device (aXess) in the arm
45650667|NCT03496285|Radiation|Multimodal MRI with diffusion sequence for healthy volunteer|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
45650668|NCT04843007|Drug|Pemetrexed|Alvopem® was administered every 3 weeks with a dose of 500 mg/m2
45928691|NCT00025896|Drug|recombinant human acid alpha-glucosidase (rhGAA)|
45928692|NCT04876079|Other|Test to induce a decline in plasma glucose|Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to bring plasma glucose to the glycemic threshold. Oral carbohydrates (16g) will be given when plasma glucose levels are at the target threshold. Sixty minutes after carbohydrates consumption, a standardized meal will be provided and participants will be discharged 90 minutes after the meal.
45650669|NCT05186233|Behavioral|Phototherapy|Light exposure recommendations provided by SHIFT mobile application
45928693|NCT04876079|Device|Dexcom G6|Participants will have to wear a Dexcom G6 during study interventions
45928694|NCT04876079|Other|Dex4|When the glycemic threshold is reach, participants will be given 16g of Dex4
45928695|NCT04876079|Drug|Insulin|A subcutaneous insulin bolus will be given to induce a decline in plasma glucose and reach the glycemic threshold.
46073744|NCT05659212|Drug|Lidocaine|Patients will receive IV lidocaine 1.5 mg/ kg diluted up to 10 ml with normal saline immediately before induction of anesthesia and 10 ml of normal saline infused over 10 min before induction of anesthesia.
46073745|NCT05659134|Other|Alfredson protocol|Alfredson eccentric therapeutical protocol.
45650670|NCT04840745|Drug|CKD-841 A-1 3.75mg|Single injection, subcutaneous injection
46073746|NCT05659134|Other|Silbernagel protocol|Silbernagel concentric-eccentric protocol.
45450844|NCT02202382|Procedure|Varicocelectomy|Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
45650671|NCT04840745|Drug|CKD-841 A-1 1.88mg|Single injection, subcutaneous injection
45799862|NCT02581475|Procedure|Segmental examination twice of the proximal colon|
45799863|NCT03607357|Device|High Flow Nasal Oxygen|The initial flow speed is set at 30L/min and increases at 5L/min in titrated type until the patient feels uncomfortable. The temperature is set at 37℃. The fraction of inspiration O2 is set in accordance with specific condition of patient to insure oxygen saturation more than 95%.
45650672|NCT04840745|Drug|CKD-841 D 2.92mg|Single injection, subcutaneous injection
45650673|NCT04840745|Drug|Leuplin Inj. 3.75 mg|Single injection, subcutaneous injection
45650674|NCT04842851|Device|cardiac resynchronization therapy|Cardiac resynchronization therapy in patients with systemic right ventricle
45650675|NCT05073757|Device|Personalized guides and plates|Patients will be included in the study and then followed clinically according to the routine care of orthognathic surgery with personalized guides and plates. The only specific act this study is the completion of an OQLQ quality of life questionnaire by patients preoperatively and between 8 to 12 months postoperatively.
45650676|NCT04840355|Drug|Sintilimab Injection|The recommended dose for intravenous infusion is 200 mg on day 1.Courses repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity.
45799864|NCT03607357|Device|Non-invasive Ventilation|The values of initial pressure are set at a lower level (inspiratory pressure: 6-8cmH2O, expiratory pressure: 4cmH2O) and adjusted to a suitable level in 10-20min. The fraction of inspiration O2 is set in accordance with specific condition of patient to insure oxygen saturation more than 95%.
45799865|NCT05665621|Other|Eight-week in-school strength and balance training program|Training program consisting of two 1-hour strength and balance training sessions per week.
45928696|NCT04733820|Drug|Adjuvant chemotherapy|Drug: Paclitaxel or docetaxel + Cisplatin or carboplatin Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
45650677|NCT04435405|Other|Observational|video footage analysis of group and individual behavioral processes.
45928697|NCT00026013|Drug|hypericum perforatum|
45928698|NCT00026052|Drug|riluzole|
45928699|NCT00392366|Device|MR-guided Laser Interstitial Thermal Therapy System|
45928700|NCT00026091|Drug|fenretinide|Given orally
45928701|NCT00026091|Other|laboratory biomarker analysis|Correlative studies
45928702|NCT00026091|Other|pharmacological study|Correlative studies
45928703|NCT00392405|Drug|3 amps of sodium bicarbonate mixed in one liter of D5W|
45928704|NCT04733651|Drug|Hospital standard of care for COVID-19|Standard care for COVID-19 as per the hospital guidelines
45928705|NCT04733651|Drug|Isoquercetin|Daily 1000 mg Isoquercetin as 4 capsules
45928706|NCT04733001|Drug|HSG4112|Once-daily oral administration
45928707|NCT00026130|Drug|fluorouracil|200mg/sq m/d CIVI 5/7 days during radiation therapy (wks 1-6)
45928708|NCT00026130|Drug|gemcitabine hydrochloride|200mg/sq m IV infusion over 30 min wkly (on d 1, 2, OR 3) during radiation tx (wks 1-6) 1000mg/sq m IV infusion over 30 min wkly for 3 weeks during ea chemotherapy cycle
45928709|NCT00026130|Radiation|radiation therapy|4500cGy total in 25 fractions M-F followed by 540cGy in 3 fractions (Total dose 5040cGy)during radiation tx (wks 1-6)
45928710|NCT00026169|Drug|imatinib mesylate|Given orally
45928711|NCT00026169|Other|laboratory biomarker analysis|Correlative studies
45928712|NCT00026169|Other|pharmacological study|Correlative studies
45928713|NCT00026247|Procedure|pain therapy|
45928714|NCT00026247|Procedure|radiofrequency ablation|
45928715|NCT04808414|Drug|QPX9003 for IV Infusion|antibiotic
45928716|NCT04808414|Drug|Placebo for IV infusion|Placebo comparator
45928717|NCT00026364|Drug|fluorouracil|
45650678|NCT04842695|Device|electroacupuncture group|compare the effectiveness of electroacupuncture on point B7 plus pelvic floor exercises versus pelvic floor exercises alone in women with urinary incontinence (UI) .
45650679|NCT05073289|Behavioral|Sandplay activity|The sandplay in psychiatric care, with a creative and fun approach, makes it easier for patients to verbally express their personal life stories and feelings in a safe environment, individually or as a group.
45799866|NCT05665309|Procedure|3D anatomical model of aneurysm|Surgery prepared with 3D anatomical model of aneurysm
45799867|NCT01836133|Drug|Erlotinib 150 mg|
45799868|NCT02989051|Other|Restrictive fluid regimen|In this treatment arm, patients will receive a maximal daily fluid intake of 70% of normal requirements (for a healthy child).
45799869|NCT02989051|Other|Liberal fluid regimen|This is considered current standard clinical treatment, wherein patients will receive a fluid regimen of >85% of normal fluid recommendations (for a healthy child).
45799870|NCT02581865|Drug|NBI-98854|
45799871|NCT02581865|Drug|Placebo|
45799872|NCT00365027|Procedure|Delayed embryo transfer|
45799873|NCT00365183|Drug|Motexafin gadolinium and pemetrexed|1 dose of MGd 15 mg/kg and pemetrexed 500 mg/m2 once during the first week of every 3-week treatment cycle for a maximum of 12 cycles
45799874|NCT00556075|Drug|Proellex 25 mg|1 capsule daily for 4 months
45799875|NCT00556075|Drug|Placebo|1 capsule daily for 4 months
45799876|NCT00556075|Drug|Proellex 50 mg|2 capsules daily for 4 months
45799877|NCT03441503|Other|Child HCAHPS: Automated day-of-discharge survey|Child HCAHPS surveys will be administered on the day of discharge via an electronic interactive patient care system on inpatient televisions.
45799878|NCT03376451|Other|Assessment of endometrium and blood biomarkers for endometriosis diagnosis|Biological samples will be collected from patients, sent to Endodiag, Paris, in France and be processed through IHC and molecular biology techniques to assess the ability of the identified biomarkers signature to diagnose and prognose endometriosis.
45799879|NCT01837069|Drug|Metoprolol|25mg PO BID if the HR is elevated at preadmission testing
45799880|NCT01837069|Drug|Lisinopril|2.5mg PO QD if the HR is elevated at preadmission testing
45799881|NCT01837069|Drug|Atorvastatin|80mg PO QD at preadmission testing
45799882|NCT01837069|Behavioral|Lifestyle counseling|Diet, exercise, medication adherance and smoking counseling
45799883|NCT03323489|Radiation|Celiac Plexus Radiosurgery|patients will receive a single radiation treatment of 25 Gy directed towards the celiac surgery, and at the physician's discretion also abutting tumor
45799884|NCT03193619|Device|PTA (UltraScore Focused Force PTA Balloon)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The UltraScore Focused Force PTA balloon through the blood vessel to the narrowed area to be treated."
45799885|NCT02289690|Drug|Veliparib|Capsules administered orally twice a day according to the dosing schedule.
45799886|NCT02289690|Drug|Carboplatin|Administered by intravenous infusion on Day 1 of each 21-day cycle over approximately 30 minutes at a target area under the curve (AUC) 5 mg/mL*minute.
45799887|NCT02289690|Drug|Etoposide|Administered by intravenous infusion on Days 1 to 3 of every 21-day cycle over approximately 60 minutes at 100 mg/m².
45650680|NCT05073289|Other|Routine Care|Routine care is the care given to the control group by the nurse to the patients in the psychiatry clinic.
45799888|NCT02289690|Drug|Placebo|Placebo to veliparib administered orally twice a day according to the dosing schedule.
45799889|NCT02584673|Device|Computer Assisted Instrument Guidance (CAIG), which supplements existing ultrasound capabilities.|The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
45799890|NCT02268955|Drug|IV Ibuprofen|Intravenous ibuprofen will be administered for treatment of pain in adults presenting to the ED with biliary colic
45799891|NCT02268955|Drug|Saline|Saline will be administered to the placebo group
45799892|NCT02585843|Drug|Spironolactone 100mg|2 capsules of study medication consist of 100mg, PO (oral) for 7 days
45799893|NCT02585843|Drug|Spironolactone 25mg|25mg/day of spironolactone
45799894|NCT04350385|Other|Agility training|In experimental group, 30 meter sprint test will be used as intervention with complexity in different stages. Test 1 was a straight sprint and tests 2-7 involved multiple changes of direction. Tests 2-7 were designed to involve progressively greater change-of-direction complexity by increasing either the angle of directional change and/or the number of changes of direction. In experimental group, 6 weeks of intervention will be done on alternate days and assessment will be done on 1st, 3rd & 6th week.
45799895|NCT04350385|Other|Conventional|In group B, Conventional intervention was given to the players under the supervision of Physical Therapist that includes warm-up, strength training, agility training and cool down. In control group, 6 weeks of intervention will be done on alternate days and assessment will be done on 1st, 3rd & 6th week
45799896|NCT02463305|Drug|Creatine monohydrate|21 grams creatine monohydrate total per day
45799897|NCT02463305|Other|Placebo|7 grams of dextrose dissolved in 500mL water, taken three times daily
45799898|NCT03032471|Other|There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.|There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.
45799899|NCT01838317|Drug|Pioglitazone|
45799900|NCT05249231|Drug|Silver diamine fluoride|Previous studies have recommended silver diamine fluoride (SDF) to exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. The result is useful in arresting early childhood caries (ECC)
45928718|NCT00026364|Drug|gefitinib|
45928719|NCT00026364|Drug|irinotecan hydrochloride|
45928720|NCT00026364|Drug|leucovorin calcium|
45928721|NCT00026403|Drug|cisplatin|
46073747|NCT04043169|Diagnostic Test|Clearblue pregnancy test|Urine pregnancy test
45450845|NCT03533062|Drug|botulinum toxin A|botox A injection trigonal or trigonal sparing with trial of anticholinergics 6 months post operative for 3 months
45799901|NCT05249231|Device|Hall technique|The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method
45799902|NCT05249153|Drug|low dose of dexmedetomidine with sufentanil|low dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.05ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.05ug/kg dexmedetomidine bolus)
45799903|NCT05249153|Drug|high dose of dexmedetomidine with sufentanil|high dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.1ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.1ug/kg dexmedetomidine bolus)
45799904|NCT05248685|Biological|Dual CD33/CLL1 CAR T|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion chemotherapy (fludarabine at 30 mg/m^2/day and cyclophosphamide at 250 mg/m^2/day) will be administrated for 3 days. Then this study will be using BOIN1/2 approach from starting dose 1: 1×10^6 (±20%) to dose 2: 5×10^6 (±20%). If the manufactured cells were not sufficient to meet the preassigned standard dose criteria, patients are given infusion at a low dose of 5×10^5 (±20%)
45450846|NCT02751502|Device|m2 Bimanual Arm Trainer (BAT)|Patients in the device group will be asked to train specific movements repeatedly with the device for 45 minutes five days a week for 6 weeks and compliance will be monitored through training logs and remotely
45799905|NCT02961257|Drug|cabazitaxel|"Arm A : cabazitaxel 25 mg/m² on Day 1 of a 3-week cycle plus daily prednisone or~Arm B: cabazitaxel 16 mg/m² on Day 1 and Day 15 of a 4-week cycle plus daily prednisone.~Treatment will be continued for a maximum of 10 cycles unless there is documented disease progression or unacceptable toxicity.~Standard cabazitaxel premedication will be used"
45799906|NCT02961257|Drug|Prednisone|Arm A:plus prednisone 10 mg orally given daily for a maximum of 10 cycles Arm B: plus prednisone 10 mg orally given per day up to 10 cycles
45650681|NCT04840043|Other|Osteopathic sympathic harmonization|Treatments that harmonize at the sympathetic nerves or plexus, e.g., sympathetic trunk stimulation by means of the rib-raise technique or stimulation of the prevertebral ganglia.
45799907|NCT02961257|Drug|Granulocyte colony-stimulating factor (G-CSF)|Primary prophylaxis with Granulocyte Colony-Stimulating Factor (G-CSF) will be injected from Day 3 to Day 7 after every administration of cabazitaxel
45799908|NCT02271217|Drug|Placebo|
45450847|NCT02202694|Behavioral|Culturally Adapted Cognitive behavior therapy|This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
45450848|NCT02207764|Behavioral|Reiki|Each study participant in the intervention group will receive one Reiki intervention by a registered nurse trained in Advanced Level Reiki through the Usui Shiki Ryoho method.
45450849|NCT02199340|Other|iStep exercise test|newly developed submaximal exercise test
45450850|NCT02199340|Other|CPET exercise test|maximal gold standard exercise test
45450851|NCT02202928|Biological|DC-CIK|8×10^9 autologous tumor lysate pulsed DC-CIK cells for each infusion, IV (in the vein) for four cycles, each cycle received four infusions with a 1 day interval.
45450852|NCT02202928|Radiation|Radiotherapy|45~50 Gy in 25-28 fractions.
45450853|NCT02202928|Drug|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
45450854|NCT02207920|Biological|AIDSVAX B/E Vaccine|600 mcg/mL to be administered as 1 mL intramuscular (IM) injection
45450855|NCT02207920|Biological|DNA-HIV-PT123 Vaccine|4 mg/mL to be administered as 1 mL IM injection
45450856|NCT02207920|Biological|Placebo for DNA-HIV-PT123|Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
45650682|NCT04840043|Other|Sham intervention|Different location, size and time of the rib-raise technique or stimulation of the prevertebral ganglia.
45650683|NCT04534933|Device|Evone|Airway ventilation device
45650684|NCT04534933|Device|Primus|Airway ventilation device
45799909|NCT02271217|Drug|dalfampridine-ER 7.5mg|
45799910|NCT02271217|Drug|dalfampridine-ER 10mg|
45799911|NCT02989519|Drug|dydrogesterone|
45650685|NCT04842617|Drug|SHR6390|SHR6390 combined with endocrine therapy
45650686|NCT04842617|Drug|placebo|placebo combined with endocrine therapy
45650687|NCT04860557|Other|cognitive skill, dual task and physical activity assessment|Montreal Cognitive Assessment Test, Trail Making Test (TMT) A & B sections and Stroop test for cognitive ability assessment, 10 meter walking test (single-double task) for dual task, Time up and Go test (single-double task), physical International Physical Activity Questionnaire was used for activity and The Exercise Benefit / Barriers Scale was used for exercise perception.
45653219|NCT05076279|Procedure|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection
45799912|NCT02989519|Drug|Micronized progesterone|
45799913|NCT02429375|Drug|Mocetinostat Plus Brentuximab Vedotin|All patients will receive a 1-week lead-in with mocetinostat alone (administered days 1, 3, and 5). Patients with palpable peripheral lymph nodes will undergo FNA before and after this 1 week treatment. Cycle 1 will then begin 15 days (+/-3 days) following initiation of the lead-in.
45799914|NCT02289456|Drug|nab-Paclitaxel|
45799915|NCT02289456|Drug|Carboplatin|
45799916|NCT02588573|Device|etafilcon A (control)|contact lens
45799917|NCT02588573|Device|somofilcon A (test)|contact lens
45928722|NCT00026403|Drug|gemcitabine hydrochloride|
45928723|NCT00026403|Radiation|radiation therapy|
45928724|NCT04730882|Dietary Supplement|Mixed Meal|the meal will be 40% of each subject's daily estimated caloric need, with 50%, 30%, 20% from carbohydrates, fat and protein, respectively
45928725|NCT00026442|Drug|capecitabine|
45928726|NCT04726280|Drug|Ropivacaine 0.75% Injectable Solution|10 ml extrafascial interscalene brachial plexus block
45928727|NCT04726280|Drug|Ropivacaine 0.75% Injectable Solution|20 ml extrafascial interscalene brachial plexus block
45650688|NCT05073211|Procedure|PDT|A 630 nm red light and a 520 nm green light of the light-emitting diode (LED) device (Nouvo-GB®) with an intensity of 35 mW⁄cm2 was simultaneously illuminated for 10 minutes (a total light dose of 21 J/cm2). Participants received a total of four treatments at 1-week intervals and were followed up 1 and 4 weeks after the last treatment.
45650689|NCT04842539|Other|Fecal Microbiota Transplantation|In the Fecal Microbiota Transplantation procedure 100 ml volume of strained and filtered stool will be delivered through a nasojejunal tube.The recipient patient will be kept nil per oral for at least 4 hours prior to the stool instillation. 100 mL of freshly prepared stool suspension will be given.
45650690|NCT04842539|Other|Standard of care|Nutritional supplementation and other supportive measures as per standard guidelines
45928728|NCT00026520|Biological|recombinant interferon alfa|
45928729|NCT00026520|Drug|thalidomide|
45799918|NCT01838785|Drug|18F-DTBZ AV-133|
45928730|NCT04707716|Other|conometric concept Acuris system|implant crown retention type using friction only
45928731|NCT04707716|Other|screw retention|screw retained implant crown
45928732|NCT04707716|Other|cementation|cement retained implant crown
45928733|NCT04704791|Procedure|PA-LAA shunt|At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device. The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.
45928734|NCT04699487|Device|Photobiomodulation|"Oral pads will be applied on irradiated areas presenting a risk of radiotherapy-related OM. In addition, a derma pad will be applied on the anterior face of the neck to protect the oropharynx from OM.~The dose to be delivered, at each session and each applied area, has been set at 3 J/cm². In case a lesion appears, the dose will be increased to 6J/cm² for curative treatment.~Treatment with CareMin650 must start on the first day of radiotherapy and will be administered during the whole radiotherapy period, ideally 5 days/week, at least 3 days/week, ideally before the radiotherapy session."
45928735|NCT00026637|Drug|sertraline|Sertraline: 25-200mg PO (orally); Subjects begin at 25mg for week 1 and increase to 50mg at the beginning of week 2. Sertraline is increased in 50mg increments when subjects score in the depressed range on the CES-D, a questionnaire that is administered every 2 weeks over the 16 week intervention period. Subjects may reduce dosage if toxicity occurs.
45928736|NCT00026637|Behavioral|cognitive behavior therapy|CBT (Cognitive Behavior Therapy) - CBT is a psychotherapy based on modifying cognitions, assumptions, beliefs and behaviors, with the aim of influencing disturbed emotions. Subjects will meet with a trained CBT therapist for 1 hour each week over the 16 week intervention period and will be given assignments to work on each week.
45928737|NCT04678115|Device|Magnetic Levator Prosthesis (MLP)|Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin.
46072448|NCT04385290|Drug|MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin|"Midostaurin (IMP):~RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21 induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles~Daunorubicin (DNR, non-IMP):~60 mg/m^2/day i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
45450857|NCT02207920|Biological|Placebo for AIDSVAX B/E|Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
45450858|NCT02203084|Other|Social Determinants Questionnaire|The questionnaire contains a general background information section common to all medical conditions. It then contains separate sections with medical condition specific questions.
45650691|NCT05072899|Procedure|platelet rich plasm|local injection of shoulder joint by platelet rich plasm
46072449|NCT04380116|Device|Soberlink|Soberlink is a comprehensive alcohol monitoring system designed to remotely monitor a person's Blood Alcohol Concentration (BAC). Combining a professional grade handheld breathalyzer with wireless connectivity, the technology includes real-time facial recognition, robust tamper detection and real-time alerting.
45799919|NCT02589977|Drug|regadenoson|evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants
45799920|NCT02274948|Drug|Metformin|Metformin in the form of 500mg tablets were administer to the Metformin group
45799921|NCT02274948|Drug|Placebo|A Placebo tablet physically and chemically similar to Metformin tablets except for the absence of the active ingredient was used
45799922|NCT01838863|Biological|Type AB plasma|The plasma is thawed and administered to subjects in the experimental (plasma) arm.
45450859|NCT02207998|Drug|Homeopathic complex and physiotherapy|Homoeopathic complex (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of medicated lactose tablets.
45450860|NCT02207998|Drug|Placebo and physiotherapy|Unmedicated lactose tablets. Physiotherapy: lower back classic massage, lumber joint manipulation and the application of a hot pack
45799923|NCT01838863|Drug|Crystalloid fluid (standard of care for resuscitation)|Normal saline will be give to subjects in the standard arm as the current standard of care for an initial resuscitation fluid
45799924|NCT05248451|Other|Not an Interventional Study|Not an Interventional Study
45799925|NCT02274792|Drug|Etanercept|Etanercept produced using the serum free process (SFP)2 was supplied in a single-use 1 mL prefilled syringe for subcutaneous injection.
45799926|NCT05248217|Behavioral|healthcare workers|healthcare
45799927|NCT02591537|Device|OxyGenesys Dissolved Oxygen Dressing|1/2 of the abdominal wounds will be covered with Oxygenesys Dissolved Dressing.
45799928|NCT05649930|Other|Functional power training|The training consists of weighted running and walking exercises performed at high-velocity and is given three times a week for 12 weeks.
45799929|NCT05432466|Drug|ACER-002 (celiprolol) 200 mg BID|ACER-002 (celiprolol) 200 mg BID
45799930|NCT05432466|Drug|Placebo BID|placebo for ACER-002
45799931|NCT02592629|Drug|lidocaine|used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
45799932|NCT02592629|Drug|ethyl chloride|topical spray
45450861|NCT03532984|Diagnostic Test|Beam test to predict falls|Dynamic balance will be determined in all participants during beam walking. The beams are 4m long, 2cm high, and 4, 8, and 12cm wide. After a practice trial, participants will perform three trials on each width with and without a calculation task. Trials will be block-randomized based on beam width then on task. Instructions: 'Traverse the entire length of the beam safely at your preferred speed without stepping off, facing forward, with your arms folded in front of your chest. Trials end when you step off, walk sideways, or unfold the arms.' Outcomes are the sum of length traversed, average velocity, number of steps, and average step length determined from video recordings made at 90° relative to the walking direction with full beam length in view using off-the-shelf video cameras.
45650692|NCT05072899|Procedure|Hyaluronic acid|local injection of shoulder joint by Hyaluronic acid
45650693|NCT04860479|Device|ultrasound|ultrasonography to inguinal region
45799933|NCT02592629|Drug|Kenalog|used with lidocaine in shoulder injection
45650694|NCT02647645|Device|Transcranial direct current stimulation|Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of 20 minutes each for 6 sessions over two weeks simultaneously with cognitive training.
45650695|NCT02647645|Procedure|Cognitive training|Computer delivered intervention designed to improve cognitive speed and executive functioning for a period of 20 minutes each for 6 sessions over two weeks.
45450862|NCT02208076|Device|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
45650696|NCT02647645|Device|Sham transcranial direct current stimulation|Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of one minute to simulate active treatment applied in 6 sessions over two weeks.
45650697|NCT04842305|Diagnostic Test|Blood- and saliva tests|Measurement of SARS-CoV-2 spike glycoprotein RBD antibodies in plasma and saliva
45799934|NCT05247983|Procedure|"Tension-free repair of inguinal hernia with Undissociate Spermatic cord"|"patient undergoing Tension-free repair of inguinal hernia with Undissociate Spermatic cord"
45650698|NCT04839653|Drug|Oral Paste(0,5 g) containing 10 mg of polymyxin B, 10 mg of gentamycin and 150 mg of amphotericine B or 500 000 U of nistatin q6h|The oral paste will be applied topically on the oropharyngeal mucosa q6h.
45799935|NCT05372471|Other|mHealth|ClouDi is a telemedicine platform that was developed for the remote monitoring of patients with diabetes in Colombia. It incorporated the recommendations that were published in a usability pilot study that was conducted previously with an open-source cloud platform. The platform consists of a web version, a version for mobile devices and a desktop application, which is installed on the patient's personal computer, thereby allowing glucose measurements taken through the Optium Neo glucometer (Abbott Diabetes Care, Alameda, CA, USA) to be uploaded automatically to the cloud. In this trial, the glucose measurements that were uploaded to the ClouDi website, were reviewed weekly by the members of the research group who were responsible for adjusting the therapy to the insulin titration scheme prescribed for the patient. The patients were informed about these adjustments by text messages sent from the web version of ClouDi to the patient's mobile phone via pop-up notifications.
45799936|NCT05372471|Other|Usual Care|They will have a regular visit after 3 months where the capillary glucose data will be evaluated in person by the clinical team, the insulin dose will be titrated according to the type of insulin and the presence of hypoglycemia.
45650699|NCT04839653|Drug|Suspension (10 ml) containing 100 mg of polymyxin B, 80 mg of gentamycin, 350 mg of amphotericine B or 8000000 U of nistation and 500 mg of vancomycin q6h|The suspension will be administered through the nasogastric tube q6h.
45650700|NCT04839653|Drug|Intravenous Antibacterial Agent - a 3-day course of systemic cefotaxime 1 g q6h or ceftriaxone 1 g qd|Patients who do not receive systemic antibiotics for other reasons will get a short course of systemic antibiotic
45799937|NCT02274558|Drug|NBI-98854|NBI-98854 40 mg capsules
45799938|NCT02274558|Drug|Placebo|NBI-98854 placebo capsules
45799939|NCT05247749|Device|CONVIVO Confocal Endomicroscopy System|Confocal Laser Endomicroscopy (CEM) system intended for viewing intra-operative blood flow in the cerebral vascular area. Manufacturer - Zeiss
45799940|NCT05247671|Genetic|ERCC1|ERCC1 is a rate-limiting enzyme in the nucleotide excision repair pathway that is known to repair cisplatin-induced DNA damage. Polymorphisms in ERCC1 are known to affect response to cisplatin treatment. A mechanism explaining the effect of the ERCC1 polymorphism on the kidney may be that the homozygous carriers of this rs3212986 allele might have a greater capacity to repair cisplatin-induced DNA damage in their kidney epithelia, and thus would be more resistant to cisplatin-induced nephrotoxicity
45799941|NCT05247671|Genetic|OCT2|OCT2 is expressed on the basolateral membrane of Proximal Tubular Epithelial Cell (PTEC) and plays a central role in cisplatin uptake into tubular cells. Genetic variants in the cisplatin uptake transporter OCT2 showed association with the preservation of kidney function. Patients with the CT genotype in OCT2 polymorphism rs596881 exhibited positive changes in eGFR compared to individuals with the wild type CC genotype
45799942|NCT05247515|Device|Endoscopic mucosal resection with nexpowder|At the end of the EMR procedure, the patient will be randomized. In the treated group, Nexpowder will be sprayed thanks to a catheter inserted through the operating channel of the endoscope.
46072450|NCT04360005|Drug|Asciminib|Asciminib 20 or 40 mg strength tablets will be administered orally twice-daily, without food
45650701|NCT05072587|Behavioral|Plant-based diet with no oxysterols|This group will be given 3 prepared plant-based meals a day with macronutrient content: 60% of calories from carbohydrates, 15% protein, and 25% fat. Calories: 25 kcal/kg ideal body weight (IBW). The goal is weight maintenance, but weight loss may occur. 1-5% weight loss will be acceptable and not deemed a potential confounder. Participants will be screened for food allergies and intolerances prior to receiving their research diets. All meals will include culturally familiar foods to enhance adherence. The dietary intervention will be conducted over 4 3-month periods (12 months). Meals will be packaged labeled and distributed to participants once per week. Participants will consume their meals at home.
45799943|NCT00311909|Device|Thalamic deep brain stimulation|
45799944|NCT03193567|Biological|HEKT cell|3 cycles of HEKT cell treatment
45799945|NCT00284063|Procedure|Low back adjustment and MRI|Subjects received a 15 minutes MRI in neutral position, a chiropractic low back spinal manipulation, and a second 15 minute MRI in neutral position.
45928738|NCT04678115|Device|Kinesiotape Frontalis Sling (KTFS)|Kineso Tape is FDA registered as a 510K exempt class 1 device, typically used by physical and occupational therapist to support muscular healing and movement. It is sometimes used on the face in cases of facial palsy or on the eye lid to support the lid in cases of severe blepharoptosis. In such cases it may be attached near the lid margin above the lashes extending up to the forehead skin overlying the frontalis muscle. Alternatively it may be a very short piece attached only along the lid skin. The tape is easily removed.
45650702|NCT05072587|Behavioral|Standard ADA Diet (SADA)|This group will be given 3 prepared meals a day with macronutrient content: 60% of calories from carbohydrates, 15% protein, and 25% fat. Calories: 25 kcal/kg ideal body weight (IBW). The goal is weight maintenance, but weight loss may occur. 1-5% weight loss will be acceptable and not deemed a potential confounder. Participants will be screened for food allergies and intolerances prior to receiving their research diets. All meals will include culturally familiar foods to enhance adherence. The dietary intervention will be conducted over 4 3-month periods (12 months). Meals will be packaged labeled and distributed to participants once per week. Participants will consume their meals at home.
45650703|NCT04842149|Dietary Supplement|Bif195 capsules|1 capsule daily for 8 weeks
45650704|NCT04842149|Dietary Supplement|Placebo capsules|1 capsule daily for 8 weeks
45650705|NCT04919941|Other|A Guide to Conservative Care|The intervention is receipt of a patient decision aid on conservative care, entitled A Guide to Conservative Care. This is 12-page printed handout that provides an overview of conservative care. Participants assigned to the intervention group are mailed a copy of the Guide after their initial baseline visit (T1). Participants keep the Guide throughout the duration of the study.
45799946|NCT00284063|Procedure|Low back adjustment and MRI|Subjects received a 15 minutes MRI in neutral position, a chiropractic spinal manipulation to the low back, and a second 15 minute MRI in a side posture position.
45450863|NCT02208154|Drug|Chlorhexidine oral care (CHX-Oro)|Oromucosal gel consisting of chlorhexidine 1%, administered 4 times daily.
45653220|NCT05475041|Procedure|Major liver resection|Major liver resection (3 or more contiguous segments)
45928739|NCT04669067|Drug|TL-895|TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
45928740|NCT04669067|Drug|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
45653221|NCT05475041|Procedure|Technically major liver resection|Minor liver resection (<3 contiguous segments) in the posterosuperior segments (segment 1,4a,7,8)
45799947|NCT00284063|Procedure|MRI|Subjects received a 15 minute MRI in neutral position and a second 15 minute MRI in neutral position.
45928741|NCT04657094|Drug|Acalabrutinib|Given PO
45928742|NCT00026871|Procedure|Radiotherapy|
45928743|NCT00026988|Drug|Creatine|
46072451|NCT04349514|Other|Natural history|Longitudinal observation of neuroimaging, clinical, and blood markers.
46072452|NCT04335643|Behavioral|TEACH|TEACH is a remotely delivered psychological intervention. It consists of six one-hour weekly sessions that are HIPAA compliant and conducted over video conferencing.
46072453|NCT04324463|Drug|Colchicine|oral medication
45450864|NCT02208154|Drug|Selective oropharyngeal decontamination (SOD)|SOD consists of application of a paste containing colistin, tobramycin in a 2% concentration and nystatin 1 x 10^5 units. SOD will be applied to the mouth 4 times daily until extubation.
45450865|NCT02208154|Drug|Selective Digestive Decontamination (SDD)|"SDD consists of both:~SOD (described elsewhere)~AND 10 ml of an enteric suspension containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10^6 i.u, to be administered via the nasogastric tube.~The combination is administered 4 times daily (Unlike in previous studies, systemic antibiotics are not a part of SDD)"
45450866|NCT03532906|Drug|TAP Block|Injection of Bupivacaine 0.5% 20 ml into the thickness of the right abdominal wall and of Bupivacaine 0.5% 10 ml into the surgical wounds.
46072454|NCT04324463|Drug|Interferon-Beta|subcutaneous injection
45450867|NCT03532906|Drug|Control|Injection of Bupivacaine 0.5% 10 ml into the surgical wounds
45450868|NCT02208232|Procedure|cataract surgery|cataract surgery with implantation of intraocular lens
45450869|NCT03533530|Diagnostic Test|Low-density ESI (LD ESI)|Electrical source imaging using low density EEG
45450870|NCT03533530|Diagnostic Test|High-density ESI (HD ESI)|Electrical source imaging using high density EEG
45450871|NCT03533530|Diagnostic Test|No electrical source imaging (ESI)|For all patients: MRI, semiology, visual interpretation of EEG. When needed: PET, SPECT.
45450872|NCT02208622|Dietary Supplement|Study 1: Whey Supplement Day 1|Whey supplement was given on day 1, control diet on day 2
45450873|NCT02208622|Dietary Supplement|Study 1: Whey Supplement Day 2|Control diet was given day 1, whey supplement was given day 2
45450874|NCT02208622|Dietary Supplement|Study 2: Whey Supplement|Whey supplement was given as part of diet for both day 1 and 2 of study
45450875|NCT02257762|Dietary Supplement|LNS|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients
45450876|NCT02257762|Dietary Supplement|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
45450877|NCT02257762|Dietary Supplement|Sprinkles|Multiple micronutrient powder packaged in sachet.
45450878|NCT02199418|Drug|Paclitaxel|
45450879|NCT02199418|Drug|Cisplatin|
45450880|NCT02208700|Other|Oxepa|Therapeutic nutrition with EPA, GLA< and antioxidants
45799948|NCT02595983|Drug|Revusiran|500mg Revusiran by subcutaneous (sc) injection
45799949|NCT02287896|Drug|ROLEDUMAB|See Arm description
45799950|NCT02596451|Drug|Diclofenac Sodium gel, 1%|
45450881|NCT02208700|Other|Jevity 1.5|Complete balanced nutrition with a unique fiber blend
45450882|NCT02208778|Drug|Duloxetine|54 participants will be allocated for duloxetine treatment
45450883|NCT02208778|Drug|Remifentanil|27 participants will be allocated to Remifentanil infusion
45799951|NCT02596451|Drug|Voltaren® Gel|
45799952|NCT02596451|Drug|Placebo|
45799953|NCT01839799|Drug|Gemcitabine|1000mg/m2 IV over 30 to 100 minutes, day 1, 8, 15
45799954|NCT01839799|Drug|Abraxane|125 mg/m2 IV over 30 minutes, day 1, 8, 15
45928744|NCT04610684|Drug|Carboplatin|Carboplatin 5-6 mg/mL/min AUC will be delivered over 30 - 60 minutes intravenously on Day 1 of each 21 day Cycle after completion of atezolizumab. For 4 cycles.
46072455|NCT04324463|Drug|Aspirin|oral medication
45650706|NCT04839263|Procedure|"FAST TRACK protocol"|"Preoperative evaluation and information~Patient general health state optimization proposal prior to hospitalization:~Preoperative strategy:~Hospitalization on surgery day~No prolonged fasting~Perioperative strategy:~Pain control based on limited systemic opioid therapy use~Anti-nausea prophylaxis~Anaesthesia via IV propofol / remifentanyl~Bladder catheter removal postoperative~Postoperative strategy:~Pain control using balanced analgesia~Gum chewing~Early oral refeeding and rapid mobilization~Venflon removal 6 hours post-op"
45799955|NCT01839799|Drug|FOLFIRINOX|Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated
45799956|NCT01839799|Radiation|Chemoradiation|
45799957|NCT03062059|Drug|Intravesical 2000mg/52.6ml gemcitabine instillation|Intravesical 2000mg/52.6ml gemcitabine instillation during operation to prevent intravesical recurrence after radical nephroureterectomy in upper urinary tract urothelial carcinoma
45799958|NCT03062059|Other|Normal saline|Intravesical 52.6ml normal saline instillation after radical nephroureterectomy in upper urinary tract urothelial carcinoma
45799959|NCT02597543|Drug|Regadenoson|For use in stress myocardial perfusion imaging.
45650707|NCT04353895|Device|Guidance for pedicle screw insertion (Mazor Stealth)|Using imaging devices and navigation for guidance, we perform a posterior vertebral fusion with pedicle screw insertion
45650708|NCT04353895|Device|Guidance for pedicle screw insertion (O-arm Navigation)|Using imaging devices and navigation for guidance, we perform a posterior vertebral fusion with pedicle screw insertion
45650709|NCT04842383|Drug|Hemp Oil|Hemp oil extract rich in varins (THCV and CBDV) as well as cannabidiol (CBD) in combination with 3% peppermint oil extract
45650710|NCT05072353|Device|SEFFICARE|"The SEFFI is a 5-step technique:~Preparation: the lower/lateral abdomen is chosen as the donor site.~Anesthesia: the donor site is injected with a local anesthetic.~Harvesting: a 0.8 mm or 0.5 mm cannula connected to a 10-ml VacLok® syringe is used to harvest the adipose tissue. The total amount of the harvested tissue could vary from 10 to 30 mL.~Washing: The syringe containing the lipoaspirate tissue is immediately filled with sterile physiological solution. After some minutes the syringes in the decanting stand will show a separation by the gravity of the tissue (top) from the physiological solution (bottom).~Fluidification: the syringe containing the adipose tissue should be connected to an empty 10 ml syringe. After pushing the tissue about 3 times from one syringe to the other, a good fluidification of the tissue is obtained.~The resulting tissue (2.5 mL per syringe) is ready for grafting the amputation wound."
45799960|NCT02597543|Drug|Gadolinium|For use in both perfusion imaging and late gadolinium enhancement.
45799961|NCT02597543|Procedure|Cardiac MRI|Cardiac MRI will be the imaging modality for perfusion imaging, late gadolinium enhancement and obtaining mean T1 segmental values of the heart.
45799962|NCT00364169|Procedure|Degree of constipation|
45799963|NCT02598089|Biological|Trivalent Seasonal Influenza Vaccine|
45799964|NCT02598089|Other|Placebo|0.5 mL of phosphate buffered saline
45799965|NCT05371769|Other|chronic pain management education program|The chronic pain management training program will be applied for 2 weeks. The training consists of 15 videos about theory and practice topics in chronic pain management. There are evaluation questions at the end of each video.
45799966|NCT05371769|Other|No intervention|No intervention will be made.
45799967|NCT00553501|Biological|epratuzumab|Days 1, 8, 15, 22 and weeks 12, 20, 28, & 36: 360mg/sq m IV
45799968|NCT00553501|Biological|rituximab|Day 3, 8, 15, 22 and weeks 12, 20, 28, & 36: 375mg/sq m IV
45799969|NCT02599649|Drug|Lirilumab|3 mg/kg by vein every 4 weeks.
45799970|NCT02599649|Drug|Nivolumab|3 mg/kg by vein on Days 7 and 21 of a 28 day cycle.
45799971|NCT02599649|Drug|Azacitidine|75 mg/m^2 by vein for 7 days of a 28 day cycle.
45799972|NCT01840345|Drug|N-acetyl-l-cysteine|1200 mg BID x 4 weeks
45799973|NCT02287584|Drug|DSP-5423P Placebo|DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily
45799974|NCT02287584|Drug|DSP-5423P 40mg|DSP-5423P 40mg was applied to the subject's back, chest, or abdomen once daily
45928745|NCT04610684|Drug|Etoposide|Etoposide 80-100 mg/m2 will be delivered over 60 minutes intravenously on Days 1-3 of each 21 day Cycle after completion of carboplatin (Day 1 only). For 4 cycles.
45928746|NCT04610684|Drug|Atezolizumab|Atezolizumab 1200 mg will be delivered over 60 (± 15) minutes intravenously on Day 1 of each 21 day Cycle for 4 cycles then continue as monotherapy maintenance with the same schedule.
45928747|NCT00027066|Drug|Active Aspirin|325mg tablet daily
45799975|NCT02287584|Drug|DSP-5423P 80mg|DSP-5423P 80mg was applied to the subject's back, chest, or abdomen once daily
45799976|NCT02287584|Drug|DSP-5423P Placebo-to-Flex|"DSP-5423P Placebo:~DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily"
45928748|NCT00027066|Drug|Active Warfarin|2mg scored tablet daily
45928749|NCT00027066|Drug|Aspirin placebo|325mg aspirin placebo pill
45928750|NCT00027066|Drug|Warfarin placebo|2mg scored placebo tablet
45650711|NCT04884139|Drug|Dolutegravir/Lamivudine as a single pill|- Dose: Dolutegravir 50mg/ Lamivudine 300 mg -Route of adminstration: oral -Schedule of administration: once a day for 96 weeks.
45650712|NCT04884139|Drug|Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill.|"Dose: Bictegravir 50 mg/Emtricitabine 200 mg /Tenofovir alafenamide 25 mg~Route of adminstration: oral~Schedule of administration: once a day for 96 weeks."
45650713|NCT04860167|Drug|Propofol|Injection propofol was given to keep the BIS value 60-80 during the ERCP procedure
45650714|NCT04860167|Drug|Diclofenac Sodium and Lignocaine 10 % spray|Injection Diclofenac sodium was given in the preoperative area 30 minutes before the procedure and four squirts of 10% lignocaine were given 5 minutes prior to the start of the procedure
45650715|NCT04841993|Drug|Cannabis decoction|A single 100 mL dose of cannabis decoction is administered containing 1.8 mg THC and 2.7 mg CBD.
45650716|NCT04841993|Drug|Cannabis oil|A single administration of 15 drops (045 mL) of cannabis oil containing 1.8 mg THC and 3.8 mg CBD.
45450884|NCT02208778|Drug|Placebo (for Remifentanil)|Placebo comparator to Remifentanil treatment. 27 participants will be allocated to this arm
45928751|NCT04733261|Other|Diaphragmatic mobility|Therapist will manually make contact with Pisiform Hypothenar region and last three fingers among the underneath the costal cartilage of the 7th in the direction of 10 ribs. For the duration of participant's inhalation, the counselor drag softly within a upward course accompany the increase motion of the ribs. For the period of expiration, the counselor will deepens make contact with in the direction of the internal costal border. Taking place consequent breathing, the counselor wanted on the way to expand traction as well as slickly make deeper the contact.
45799977|NCT02287584|Drug|DSP-5423P Active-to-Flex|"DSP-5423P Active:~DSP-5423P 40mg or 80mg was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily"
45928752|NCT04733261|Other|Chest Physiotherapy|Patients allocated to the control group and interventional group received pulmonary rehabilitation two times a day beginning happening the day of entrance on the way to the intensive care unit. It consists of side-lying positioning with the head of the bed horizontal for at least 20 min with the most affected lung on chest x-ray positioned uppermost is also known as postural drainage, 4 sets of 6 cycles of expiratory chest wall vibrations , and airway suctioning at least three times through the endotracheal and tracheotomy tube disperse in the course of the management
45928753|NCT04567940|Behavioral|ENRED@TE: Behavioural multicomponent intervention|Information and awareness activities; activities for the acquisition of skills; activities that help the elderly to attend spaces for leisure, participation and maintenance and/or improvement of their personal relationships.
45650717|NCT04841993|Drug|Vaporized cannabis|100mg of vaporized cannabis is administered by Volcano vaporizer, wich containing 0.6-2 mg THC and 0.8-3 mg CBD
45799978|NCT05654909|Procedure|Prehospital assessment unit|The prehospital assessment unit was developed to provide a paramedic responding by car to 1-1-2 calls in the area of Region Zealand. Further details are mentioned in the description.
45928754|NCT04473950|Drug|Naloxone Hydrochloride|An intramuscular (IM) injection of naloxone will be given.
45928755|NCT04473950|Drug|Placebo|An IM injection of 0.9% normal saline will be given.
45928756|NCT00027144|Biological|Heat Shock Protein 70 HSP70|
45928757|NCT00027222|Procedure|retinal ablation|
45928758|NCT04473482|Behavioral|Michigan Alcohol Improvement Network-Alcohol Reduction and Treatment tool|The intervention corrects misconceptions about alcohol use, liver disease, and alcohol treatment and matches patients to their top three choices of treatment while providing them with brief explanations of each treatment option.
45928759|NCT04464434|Procedure|Upfront autologous HSCT|"HSCT comprises the following consecutive steps:~Mobilisation~Infusions of CYC 2g/m2 on 1 day.~Hyperhydration, alkalinisation of urine and mesna to prevent haemorrhagic cystitis.~Filgrastim (G-CSF) 5-10 μg/kg/day subcutaneously for 5 days (or more when necessary).~Leukapheresis Prompt start of leukapheresis is required at a CD34+ cell count of ≥10-20/μL. Goal: at least 2 x 10^6 CD34+ cells per kilogram body weight.~Conditioning~CYC 50 mg/kg/day intravenously for 4 consecutive days (total 200 mg/kg)~Rabbit Antithymocyte Globulin (rbATG), a total dose of 7.5 mg/kg i.v., from Genzyme.~Hyperhydration, alkalinisation of the urine and mesna will be given to prevent haemorrhagic cystitis.~I.v. methylprednisolone 2 mg/kg will be administered on the days ATG, to improve tolerability of the ATG.~Peripheral stem cell infusion The number of CD34+ cells to be reinfused should be ≥ 2.0 x 10^6/kg."
45928760|NCT00027261|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
45928761|NCT00027300|Drug|Natalizumab|Natalizumab 300 mg IV infusion, every 4 weeks, for up to 116 weeks.
46072456|NCT04324463|Drug|Rivaroxaban|oral medication
46072457|NCT04315701|Biological|Cemiplimab|Given IV
45450885|NCT02208778|Drug|Placebo (for Duloxetine)|Sugar pill manufactured to mimic Duloxetine 30mg. 27 participants will be allocated to this intervention
45450886|NCT02203396|Drug|rabbit ATG, Cyclosporine, Levamisole|rATG is administered at a dose of 1.97 mg/kg/day for 9 days CSA is administered orally at a dose of 3 mg/kg qod Levamisole is administered orally at a dose of 2.5 mg/kg qod. The CSA and LMS is designed to alternately every other day.
45450887|NCT02208856|Drug|BIBR 796 BS|
45450888|NCT02208856|Drug|Placebo|
45450889|NCT02208856|Other|high fat standardized breakfast|
45650718|NCT05072431|Other|SVVR training program|The SVVR training program is consisted of five scenarios with tasks. Before the SVVR training implementation, the research team provided 10-minute orientation session to introduce the purpose of the training. The 3D VR professional taught the participants how to wear the 3D VR helmets and select the VR scenes, so that the participants could practice multiple times.
45650719|NCT04839341|Drug|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
45799979|NCT00364481|Drug|omeprazole|
45799980|NCT00364481|Behavioral|Tongue exercises|
45928762|NCT00027300|Drug|Placebo|Placebo, IV infusion, every 4 weeks, for up to 116 weeks.
45928763|NCT00395382|Drug|Alendronate|70mg weekly orally
46072458|NCT04315701|Procedure|Resection|Undergo surgical resection
46072459|NCT04305431|Behavioral|Cooking Intervention|90-minute culinary education sessions.
45450890|NCT02208934|Drug|PBF-999|5, 10, 20 and 40 mg of PBF-999
45799981|NCT04741529|Behavioral|Healthy Minds Program app|"The HMP app was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on the work of Drs. Richard Davidson and Cortland Dahl. HMP is designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of high-quality guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). HMP has >100 guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.~Participants in this study will receive 2 weeks of training in the Connection module of HMP."
45928764|NCT00395382|Drug|Placebo|weekly orally
45928765|NCT04227353|Behavioral|HEAL ABC|Participants will be assigned their first booklet based on the one they perceive to be the easiest for setting an incremental goal and achieving it. After the participant achieves successful behaviour change, he or she can move more confidently to the next booklet. Support will be provided every two weeks over the phone for 12 weeks. During the follow-up period, participants will use the follow-up booklet which helps them to continue with changes they have made and encourage them to set new goals.
46072460|NCT04305054|Biological|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
45799982|NCT01841047|Radiation|Radiotherapy|Evaluation of the efficacy of the combination with radio-surgery helical tomotherapy irradiation to a dose of radiation of 54 Gy in patients with retroperitoneal liposarcoma of operable
46072461|NCT04305054|Biological|Vibostolimab|Administered via IV infusion at a specified dose on specified days
46072462|NCT04305054|Biological|Pembrolizumab/Quavonlimab|Administered via IV infusion at a specified dose on specified days
45799983|NCT02601833|Device|Silver Diamine Fluoride|No caries removal will take place. The tooth will be dried and Silver Diamine Fluoride will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet.
45650720|NCT05071885|Other|games based exercise|Range of motion and strengthening exercises
45650721|NCT04841915|Dietary Supplement|High-Protein Diet|Diet consisting of 25E% from assigned protein during eucaloric diet and 35E% from assigned protein during hypocaloric diet
45650722|NCT04841915|Behavioral|Clinical dietician|Counselling from a clinical dietician bi-weekly until weight loss of 5% is achieved.
46072463|NCT04305054|Drug|Lenvatinib|Administered via oral capsule at a specified dose on specified days
45450891|NCT02208934|Drug|Placebo|Placebo for all dosis of PBF-999
45799984|NCT02601833|Procedure|Conventional Caries Management|These children will receive restorative dental care in alignment with the American Academy of Pediatric Dentistry guidelines, within the confines of the Mott Children's Health Center clinic. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
45799985|NCT00553267|Drug|fixed dose combination of telmisartan+amlodipine|
45799986|NCT00553267|Drug|amlodipine|
45450892|NCT02203552|Drug|minocycline hydrochloride|100 mg bid given by mouth for 9 weeks
45450893|NCT02203552|Other|placebo|Placebo given by mouth for 9 weeks
45450894|NCT02203552|Other|laboratory biomarker analysis|Correlative blood levels for cortisol, high sensitivity c-reactive protein (hs-CRP) and inflammatory factors including but not limited to IL-6, TNF-α, IL-1β, and MCP-1 will also be obtained weekly on protocol.
45799987|NCT02602223|Device|Placing Amnion chorion membrane over grafted site|Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol ACM (BioXclude, Snoasis Medical, Colorado, U.S.A were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed
45928766|NCT00027339|Drug|lopinavir/ritonavir|
45928767|NCT00027339|Drug|indinavir sulfate|
45928768|NCT00027339|Drug|tenofovir disoproxil fumarate|
45928769|NCT00027339|Drug|ritonavir|
45928770|NCT00027339|Drug|fosamprenavir|
45928771|NCT04206488|Drug|JNJ-70033093|Participants will receive JNJ-70033093 orally.
45928772|NCT04206488|Drug|Digoxin|Participants will receive digoxin orally.
46072464|NCT04305054|Biological|Favezelimab/Pembrolizumab|Administered via IV infusion at a specified dose on specified days
46072465|NCT04305054|Drug|ATRA|Administered via oral capsule at a specified dose on specified days
45450895|NCT02203552|Other|Questionnaire administration|The CES-D and STAI will be administrated weekly.
45928773|NCT00027417|Drug|Liothyronine sodium/triiodothyronine|
46072466|NCT04301089|Device|Pico G2 4K Headset with Applied VR software|headset worn at time points defined in study
46072467|NCT04295538|Drug|Elezanumab|Solution for infusion; Intravenous (IV)
46072468|NCT04295538|Drug|Placebo|Solution for infusion; Intravenous (IV)
46072469|NCT04268823|Drug|QBW251|Capsule 300mg
46072470|NCT04268823|Drug|Placebo|Capsule 300mg
46072471|NCT04262596|Other|A chatbot for patient decision aid|Potential participants use the chatbot on a mobile application with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks.
45650723|NCT04841915|Behavioral|Weight loss|4 weeks eucaloric diet ~13 MJ/day followed by, 20 weeks hypocaloric diet ~9 MJ/day until 5% weight loss is achieved.
45650724|NCT02514031|Drug|ARQ-761|"Dose Level 1:~ARQ761 195 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1, 8, 15 Nab paclitaxel 125 mg/m2 D1, 8, 15~Dose Level 2:~ARQ761 290 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15~Dose Level 3:~ARQ761 390 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-paclitaxel 125 mg/m2 D1,8,15~Expansion Dose Level:~ARQ761 390 IV mg or as tolerated D1, 15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-Paclitaxel 125 mg/m2 D1,8,15"
45650725|NCT02514031|Drug|Gemcitabine|"Therapy after lead in Phase:~You will receive Gemcitabine (1000mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression."
45799988|NCT02602223|Device|Placing d-PTFE membrane over grafted site|Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol d-PTFE membranes (Cytoplast, Osteogenics Medical, Texas, U.S.A) were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed
45799989|NCT00365963|Device|Comprehensive Health Enhancement Support System|computer based support and education
45799990|NCT00364559|Drug|Rosuvastatin|20 mg 10 days daily
45650726|NCT02514031|Drug|nab-paclitaxel|"Therapy after lead in phase:~You will receive nab-paclitaxel (125 mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression."
45650727|NCT04841603|Device|Mindshift CBT|A tablet with the Mindshift CBT app installed. Mindshift CBT is a free, evidence based app developed by Anxiety Canada, designed to help users reduce symptoms of anxiety and distress.
45799991|NCT02271984|Drug|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each intervention period.
45928774|NCT00027417|Procedure|Cardiopulmonary bypass and cardiac surgery|
45928775|NCT04197011|Device|prosthetic device|Individuals with TFA will use a combination of prosthetic devices.
46072472|NCT04262596|Other|A traditional patient decision aid booklet|Potential participants receive a traditional patient decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks.
46072473|NCT04256421|Drug|Tiragolumab|Tiragolumab 600 milligrams (mg) administered by IV infusion on Day 1 of each 21-day cycle.
45650728|NCT04841603|Device|Treatment as Usual|Treatment as usual. A tablet identical to the intervention group, but without the Mindshift CBT app is available for patients to use during their inpatient stay.
46072474|NCT04256421|Drug|Atezolizumab|Atezolizumab 1200 mg administered by IV infusion on Day 1 of each 21-day cycle.
45799992|NCT02271984|Drug|Cysticide|Subjects will receive a single oral dose of current PZQ formulation (Cysticide®) at 40 mg/kg with water, under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
45799993|NCT02271984|Drug|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 10 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
46072475|NCT04256421|Drug|Carboplatin|Carboplatin was administered by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
45450896|NCT02203708|Other|Supportive Program for Mother with BPD (SuPMother-B).|"The development of the program is based on several principles: group process, groupware, mentalization, parental values, behavioral strategies and information on the child's needs, knowledge of the BPD and the strategies of get better. The program will last 10 sessions of group of about 2h.~Minimal intervention. All study participants receive an individual interview about 45 minutes with a psychiatrist for three objectives: information on the diagnosis of BPD, information on resources for health care and educational aids."
45928776|NCT00027456|Drug|Leptin A-100|
45928777|NCT04166864|Device|Transcranial magnetic Stimulation|Transcranial magnetic stimulation delivered at the Subject's SCC-determined frequency. Each Subject will receive 40 pulses every 26 seconds, over 75 trains.
45450897|NCT02209012|Drug|Aminolevulinic Acid (ALA)|Levulan PDT given in CP0108
45450898|NCT02209012|Drug|Topical Solution Vehicle|Vehicle PDT given in CP0108
45450899|NCT02209012|Device|BLU-U Blue Light Photodynamic Therapy Illuminator|PDT given in CP0108
45450900|NCT02031406|Other|Post-discharge counseling on medication adherence & literacy|
45650729|NCT04823533|Dietary Supplement|Probiotic-placebo supplement|A probiotic formulation containing two well-documented probiotic strains. The finished product is a lyophilized powder packaged in single-dose sticks sachets Excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
45928778|NCT00027495|Dietary Supplement|curcumin|
45928779|NCT04163003|Behavioral|Targeted Approaches for Promoting Adolescent Sleep (TAPAS)|The targeted intervention is a three part sleep program, involving a 2- minute psychoeducation video, an in-person session with a clinician focusing on sleep, and web-based goal setting related to sleep behaviors. Intervention approaches to promoting adolescent sleep and reducing insufficient sleep use a motivational interviewing style, rooted in cognitive-behavioral strategies for improving sleep.
45928780|NCT04163003|Behavioral|Sleep Monitoring Only|Participants will monitor sleep with sleep diary, but they will not receive feedback or any other information on to sleep.
45928781|NCT00027534|Biological|TRICOM-CEA(6D)|dendritic cells loaded with TRICOM-CEA(6D)
46072476|NCT04256421|Drug|Etoposide|Etoposide 100 mg/m^2 administered by IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles.
46072477|NCT04256421|Drug|Placebo|Placebo administered by IV infusion on Day 1 of each 21-day cycle.
46072478|NCT04246346|Other|An interactive chatbot for patient decision aid|A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
45928782|NCT00027573|Biological|filgrastim|
46072479|NCT04240093|Behavioral|Behavioral Activation (BA) Therapy|8 sessions of behavioral activation therapy
45928783|NCT00027573|Biological|therapeutic allogeneic lymphocytes|
45928784|NCT00027573|Drug|cyclophosphamide|
45928785|NCT00027573|Drug|fludarabine phosphate|
45650730|NCT03042845|Device|Tiger cardiac catheter|Tiger cardiac catheter
45650731|NCT03042845|Device|Judkins 3.5L/4R cardiac catheters|Judkins 3.5L/4R cardiac catheters
45928786|NCT00027573|Drug|methotrexate|
45928787|NCT00027573|Drug|tacrolimus|
45928788|NCT00027573|Procedure|peripheral blood stem cell transplantation|
45799994|NCT02271984|Drug|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 30 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
45799995|NCT02271984|Drug|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water in fasted condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
45928789|NCT04144790|Dietary Supplement|ferrous sulfate|Although established guidelines do not currently exist for iron supplementation for children, studies have demonstrated effectiveness of a 3-month treatment regimen of 5mg/kg per day of orally-administered ferrous sulfate in reducing PLMS and subjective RLS symptoms and in increasing serum ferritin levels. Ferrous sulfate 80 mg/day resulted in improvement of ADHD symptoms in iron-deficient children.
45928790|NCT00027612|Drug|carmustine|IV
45928791|NCT00027612|Drug|irinotecan hydrochloride|IV
45928792|NCT00027612|Radiation|radiation therapy|
45650732|NCT02473549|Device|Sham TDCS|Placebo stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
45799996|NCT02271984|Drug|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg directly disintegrated in the mouth without water under fed conditions in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
45799997|NCT03833011|Procedure|Osteopathic Manipulation|Osteopathic manipulation
45799998|NCT00366041|Drug|Dermal substrate cellularised LG002 (10x10cm)|application depending on burn injury surface
45928793|NCT00027690|Drug|Gefitinib|Given orally
45928794|NCT00027690|Other|Laboratory Biomarker Analysis|Correlative studies
45928795|NCT00027729|Biological|etaracizumab|
45928796|NCT04110626|Other|Questionnaires|The questionnaires are completed at the 3 survey times (T0, T1 and T2) by all pupils involved. Collected data are quantitative
45928797|NCT04110626|Other|Non-directive Interviews|The interviews are conducted with 80 pupils/year randomly selected (i.e. 2 per class and 8 per establishment/year). Collected data are qualitative
45928798|NCT00027768|Procedure|adjuvant therapy|
45928799|NCT00027768|Radiation|iodine I 131 ethiodized oil|
45928800|NCT00027807|Biological|Aldesleukin|Subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion.
45928801|NCT00027807|Biological|Sargramostim|GM-CSF Injections will be given SQ GM-CSF (250 μg/m2/twice weekly), to start 3 days before the first ATC infusion and ending 1 week after the last ATC infusion.
45928802|NCT00027807|Biological|therapeutic autologous lymphocytes|The time for armed-ATC infusions will vary from patient to patient, but the dose of armed-ATC (up to 40 billion) will be given over 30 min.
45928803|NCT00392522|Drug|50% Nitrous Oxide and 50% Oxygen (MEOPA)|
45928804|NCT00027885|Biological|bevacizumab|Patients receive bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.
45650733|NCT02473549|Device|Anodal TDCS|Excitatory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
46072480|NCT04240093|Behavioral|Substance Abuse and Health Navigation Counseling|2 standard substance abuse and health navigation counseling
46072481|NCT04240093|Other|Medications for Opioid Use Disorder|Medications for opioid use disorder (i.e., buprenorphine and methadone) as prescribed by a community provider (not provided as part of the study).
46072482|NCT04225871|Drug|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
46072483|NCT04213794|Drug|Cisplatin|Undergo HIPEC with doxorubicin and cisplatin
46072484|NCT04213794|Procedure|Cytoreductive Surgery|Undergo cytoreduction
45650734|NCT02473549|Device|Cathodal TDCS|Inhibitory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
45650735|NCT02473549|Device|Magnetic Resonance Imaging (MRI)|Participants will receive a MRI of their brain to allow the research investigators to determine how the stroke has affected regions of the brain processing movements.
46072485|NCT04213794|Drug|Doxorubicin|Undergo HIPEC with doxorubicin and cisplatin
45650736|NCT04841681|Behavioral|Video-based Psychotherapy|"Participants in the group watched three short videos. Therapeutic elements in the three consecutive short videos included relaxation therapy, managing thoughts and feelings, and mindfulness. Each video has a duration of just over 10 minutes.~In the first video, the participants were introduced to the purpose and benefits of relaxation techniques. These included rhythmic breathing techniques, progressive muscle relaxation, imagining a comforting and quiet place, and positive self-talk. In the second video about managing thoughts and feelings, the participants were introduced to the notion of acceptance of their condition. They were invited to recognize the emergence of negative feelings and thoughts related to acceptance. In the last video about mindfulness, patients were introduced to three basic mindfulness skills: observation, elaboration, and participation."
45928805|NCT00027885|Drug|cyclophosphamide|Approximately 4 weeks after the completion of radiotherapy, patients receive cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
45928806|NCT00027885|Drug|docetaxel|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.
45650739|NCT03042533|Device|Conventional Compression|Method of Nail fitting
45928807|NCT00027885|Drug|doxorubicin hydrochloride|Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
45928808|NCT00027885|Procedure|adjuvant therapy|"After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery. Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.~Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity."
45928809|NCT00027885|Procedure|conventional surgery|After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery.
45928810|NCT00027885|Procedure|neoadjuvant therapy|"Arm I: Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.~Arm II: Patients receive docetaxel as in arm I. Treatment in both arms repeats every 8 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
45799999|NCT00366041|Device|Dermal substrate uncellularised LG002 (10x10 cm)|depending on burn injury surface
46072486|NCT04213794|Drug|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC with doxorubicin and cisplatin
46072487|NCT04213794|Drug|Sodium Thiosulfate|Given IV
45928811|NCT00027885|Radiation|radiation therapy|Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.
45800000|NCT05371535|Device|MatrixOssTM Bone Graft plus Bio-Gide membrane|To verify the efficacy and safety of MatrixOssTM Bone Graft developed and manufactured by Collagen Matrix, Inc. for bone defect repair caused by tooth extraction.
45800001|NCT02604173|Drug|Budesonide|Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
45800002|NCT02604173|Drug|Acetazolamide|Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
45800003|NCT02604173|Drug|Placebo|Placebo pill and sham inhaler
45800004|NCT01841281|Drug|L-Arginine|L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
45800005|NCT01841281|Drug|Placebo|Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.
46072488|NCT04206319|Drug|Radium-223|an alpha particle-emitting drug, dose consists of 55 kBq/kg (1.49 microcurie/kg); administered every 4 days
46072489|NCT04206319|Drug|18F Sodium Fluoride|18F-NaF (Sodium Fluoride) is a radio-pharmaceutical used to image skeletal pathology with positron emission tomography (PET) imaging
46073748|NCT00966719|Other|Lactation Consultant support|Meeting with lactation consultant once while in hospital and up to 3 times after discharge, in addition to current standard of care for jaundice.
46073749|NCT02821650|Other|TEJ (Traditional stove to Efficient stove in Jhuggi)|TEJ (means 'Bright' in Hindi) is an improved cook stove, locally designed and manufactured, aimed at reducing the indoor air emissions and improving health outcomes. 'Jhuggi' is a Hindi word which stands for a 'slum dwelling'
45450901|NCT02209090|Procedure|maternal modified sims position|Maternal Modified Sims position during at least 40 minutes for each 60 minutes
45800006|NCT02287038|Drug|Atomoxetine 80 MG|Subjects will be randomized and assigned by the study investigator into crossover group 1 (Atomoxetine 80mg at Phase I, then placebo at Phase II) or group 2 (placebo at Phase I, then Atomoxetine at Phase II) with both placebo and medication administered through pharmacy. There was a 1-week interval between the two phases.
45800007|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir|Cap/Cap/Tablet, Oral, 300/100/300 mg, QAM/QAM/QAM, 10 days.
45800008|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 coadmin, 7 days.
45800009|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 2 hr post, 7 days.
45800010|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/QPM 12 hr post, 7 days.
45800011|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/Q12 2 hr post,7 days.
45928812|NCT00027924|Drug|busulfan|
45450902|NCT02209090|Procedure|maternal free positions|At least 40 minutes each hour during labour
45450903|NCT02199886|Drug|BIBH 1|labeled with eight to ten millicurie of 131I
45450904|NCT02209246|Other|PROMIS CAT Pain Interference|
45450905|NCT02209246|Other|PROMIS CAT Pain Behavior|
45450906|NCT02209246|Other|PROMIS CAT Physical Function|
45450907|NCT02209246|Other|MISS-21|
45650740|NCT03042533|Device|Standard Backslapping|Method of Nail fitting
45650741|NCT03042533|Device|Dynamic Locking with Backslapping|Method of Nail fitting
45650742|NCT04751461|Other|Product A|P0213420, a 1.8% nicotine ENDS product
45650743|NCT04751461|Other|Product B|P0213520, a 1.8% nicotine ENDS product
45650744|NCT04751461|Other|Product C|P0211220, a 1.8% nicotine ENDS product
45650745|NCT04751461|Other|Product D|P0211820, a 1.8% nicotine ENDS product
45650746|NCT04751461|Other|Product E|P0213417, a 2.4% nicotine ENDS product
45650747|NCT03038711|Drug|BMS-986166|Specified dose on specified days
45650748|NCT03038711|Other|Placebo matching BMS-986166|Specified dose on specified days
45650749|NCT03038633|Other|Novel Medical Food|This medical food takes advantage of the stability and high level of solubility of the human H-ferritin protein to be absorbed by the body as an iron source; indeed H-ferritin is enriched in breast milk as the mechanism for transferring iron from mother to infants. Once the ferritin has been absorbed from the gut, uptake into each organ is regulated by a specific extracellular receptor pathway to deliver iron in the body's preferred bioavailable form.
45650750|NCT04622917|Drug|MethylPREDNISolone 40 Mg/mL Injectable Suspension|intramuscular injection
45650751|NCT04622917|Drug|NaCl 9 MG/ML Injectable Solution|Intramuscular injection
45650752|NCT03039803|Procedure|uterine closure during cesarean section|
45650753|NCT04113499|Procedure|Direct Endoscopic Intervention|"The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~For endoscopic necrosectomy, in patients allocated to direct endoscopic necrosectomy group, endoscopic necrosectomy is performed during the same session as the index endoscopic drainage. It is performed using a therapeutic gastroscope and various accessories (see below for further details) for 90 to 120 minutes."
45800012|NCT02815033|Drug|Enzalutamide|
45800013|NCT02815033|Procedure|11C or 18F-Choline PET/CT|
45800014|NCT02815033|Procedure|Whole body MRI|
45800015|NCT02815033|Procedure|Bone scan|
45928813|NCT00027924|Drug|cyclosporine|
45928814|NCT00027924|Drug|fludarabine phosphate|
45928815|NCT00027924|Drug|methotrexate|
45928816|NCT00027924|Procedure|peripheral blood stem cell transplantation|
45928817|NCT04022876|Drug|ALRN-6924|ALRN-6924 administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
45928818|NCT04022876|Drug|Carboplatin|Carboplatin administered IV on Day 1 of every 21-day cycle.
45800016|NCT04340687|Device|Pancreatic duct stenting|A stent placed in the pancreatic duct to reduce PEP possibly by relieving pancreatic ductal hypertension that develops because of transient procedure-induced edema and stenosis of the pancreatic orifice
45650754|NCT04113499|Procedure|Step-up Endoscopic Intervention|"The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~In patients allocated to the step-up endoscopic interventions group, endoscopic necrosectomy is not performed at the time of the index intervention, however it is performed when clinically indicated during the follow-up period (6 months from index intervention)."
45650755|NCT03038477|Drug|Durvalumab|1500mg of Durvalumab will be given every 4 weeks (Q4W) for 12 months in patients enrolled in Arm A.
45928819|NCT04022876|Drug|Pemetrexed|Pemetrexed administered IV on Day 1 of every 21-day cycle.
45928820|NCT04022876|Drug|Placebo|Placebo administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
45928821|NCT04022876|Drug|ALRN-6924|ALRN-6924 administered IV on Days 0-4 prior to topotecan administered IV on Days 1-5 of every 21-day cycle.
45928822|NCT04022876|Drug|Topotecan|Topotecan administered IV on Days 1-5 of every 21-day cycle.
45928823|NCT00027963|Drug|gabapentin|
45928824|NCT00027963|Other|placebo|
45928825|NCT04001114|Combination Product|Sampling Research Cigarettes|Participants sample two research cigarettes, which differ in typical tobacco smoke constituents such as tar, nicotine, carbon monoxide, etc. In the Cigarette Discrimination Session, participants sample both types of cigarettes repeatedly, guess their identity (A or B) with regard to reference cigarettes, and rate their subjective effects. In the Ad Libitum Smoking Session, participants can smoke one of these cigarette types as much or as little as they like for eight hours.
46073750|NCT00835939|Drug|25% Dextrose and 1% Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
45650756|NCT04103593|Behavioral|exercise training|12-weeks of high-intensity functional circuit exercise that will be broadcasted from the Salem VAMC to older Veterans living with HIV in the Atlanta and Baltimore VAMCs
45650757|NCT04004533|Procedure|Endoscopic retrograde cholangiopancreatography (ERCP)|At the time of each ERCP procedure, information on procedure indication, technical performance of the duodenoscope and adverse events will be collected using a newly designed duodenoscope assessment tool. The duodenoscope assessment tool was developed to measure the technical performance of the duodenoscopes based on three components: passage and positioning at the papilla, performing requisite technical maneuvers and technical features. Each performance component is graded on a scale ranging from 1 to 5 (1 for easy maneuverability, 5 for most difficult maneuverability). Duodenoscope assessment tool also captures data on procedural indications, cannulation success rates and adverse events.
45650758|NCT03038243|Biological|Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT)|2.25 x 10^11 Sf2aWC cells +10 µg dmLT administered orally on Days 0, 28, and 56
45650759|NCT03038243|Biological|Shigella flexneri 2a whole cell (Sf2aWC) vaccine|2.25 x 10^11 Sf2WC cells administered orally on Days 0, 28, and 56
45650760|NCT03038243|Other|Placebo|2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
45650761|NCT03101449|Other|Finnish tube|Practice the exercise with Finnish tube before choir practice once a week for a period of 14 weeks.
45650762|NCT03101449|Other|Staw phonation|Practice the exercise straw phonation before choir practice once a week for a period of 14 weeks.
45650763|NCT03038321|Drug|sofenacin|solifenacin 10 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation
45650764|NCT03038321|Drug|Tavanic|levofloxacin 500 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
45650765|NCT03038321|Drug|Xefo|lornoxicam 8 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
45650766|NCT02531373|Biological|V114 Medium Dose|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
45800017|NCT02286960|Drug|Steroid|A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.
45800018|NCT02286960|Dietary Supplement|Lactose Pills|4 day course 2 x 20mg per da
45800019|NCT01842061|Behavioral|Active Living Program|
45800020|NCT01842061|Behavioral|Education|
45800021|NCT00365495|Procedure|Physical training (aerobic training)|
45800022|NCT05371379|Biological|CM338 Injection|A humanized monoclonal antibody.
45800023|NCT02286102|Device|OrthoPAT|OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively
45800024|NCT02286102|Device|Constavac|Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively
45928826|NCT00028158|Drug|G207, an oncolytic virus|
45928827|NCT03999476|Device|ambu ascope|nasal route intubation by the device in fixed cancer tongue patients
45928828|NCT03999476|Device|fibreroptic bronchoscope|nasal route intubation by the device in fixed cancer tongue patients
45928829|NCT00395421|Drug|NM283 plus Peg-IFNα-2a|200 mg QD 180 µg QW
45928830|NCT02972099|Device|TcPRF|Transcutaneous Pulsed Radiofrequency is a method that is widely used for control of pain. There are no known complications. In this study a Radiofrequency generator will be used that has a separate outlet for transcutaneous use. It is used in the daily clinical practice in the Pain Center of the Swiss Paraplegic Center.
45928831|NCT02972099|Device|Placebo|In the Placebo Treatment, no current will be delivered. Since no sensations are produced by TcPRF treatment the patients won't recognize the difference.
45928832|NCT00395499|Drug|Risperidone|
45928833|NCT00395577|Drug|VX-702|
45928834|NCT03960164|Combination Product|Dermal regeneration photosynthetic matrix (DRPM)|"Primary Procedure: DRPM implantation~Wound bed preparation and cleaning.~DRPM implantation.~Illumination with LED device.~Secondary Procedure: Autologous partial skin graft"
45928835|NCT00395616|Drug|Botox (drug)|
46073751|NCT00835939|Drug|Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
45800025|NCT00366119|Drug|Ramipril|
45800026|NCT05371301|Drug|Paclitaxel, Carboplatin|Paclitaxel 175mg/m2 iv d1 followed by Carboplatin(AUC=5) iv d1
45650767|NCT02531373|Biological|V114 High Dose|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) in each 0.5 mL dose
45928836|NCT03960125|Device|Photodynamic Therapy|Blue Light Therapy Exposure
45650768|NCT02531373|Biological|V114 Medium Dose with Alternative Carrier Protein|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg), and Merck Aluminum Phosphate Adjuvant (125 mcg) with alternative carrier protein in each 0.5 mL dose
45650769|NCT02531373|Biological|V114 High Dose with Alternative Carrier Protein|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) with alternative carrier protein in each 0.5 mL dose
45800027|NCT05371301|Procedure|debulking surgery|"Remove all visible tumors and any other tissues or organs where tumor may have spread, which may include:~Uterus Fallopian tubes Omentum (tissue that covers the stomach, large intestine and other abdominal organs) Lymph nodes Diaphragm Part of the large bowel Spleen Parts of the liver"
45800028|NCT02285166|Drug|Omega-3 fatty acid ethyl esters|Omega-3 fatty acid ethyl esters granular capsules
45928837|NCT03960125|Drug|4% Imipramine|A tricyclic antidepressant (TCA) medication. Though it is usually taken orally, topical preparations (4%) has use in topical anesthetics and anti-pain medicaments.
45928838|NCT03960125|Drug|Base Cream|Control to 4% Imipramine
45928839|NCT00395655|Drug|Hydralazine and magnesium valproate administration|
45928840|NCT00395655|Procedure|Core-needle biopsy of the breast|
45800029|NCT02285166|Drug|Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).|
45800030|NCT01842841|Drug|velaglucerase alfa|15-60 U/kg, EOW
45928841|NCT00392561|Dietary Supplement|Selenium|200 ug Selenium daily
45928842|NCT00392561|Dietary Supplement|vitamin E|100 mg Vitamin E daily
45800031|NCT02605187|Other|No choice given|Patients are randomized to getting a choice or not getting a choice. If they do not get a choice, they receive standard dose.
45928843|NCT03960086|Other|Podoactiva cutom-made foot orthoses|Children had to use the orthotics daily during the intervention period
45928844|NCT03960086|Other|Podoactiva heel lifts|Children had to use the orthotics daily during the intervention period
45928845|NCT00028236|Drug|Gene-Transduced Autologous CD34+ Stem Cells|
45650770|NCT02531373|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
45650771|NCT03101683|Radiation|Partial chest wall radiation therapy|A dose of 40 Gy in 16 fractions (2.5 Gy per fraction) is delivered in the area at risk of local recurrence (skin and the pectoralis muscles) delineated by surgical clips and 3D-MRI reconstruction for a precise localization of the tumor excised
45800032|NCT02605187|Other|Choice given|Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.
45800033|NCT02605187|Drug|Ibuprofen|Ibuprofen 600mg po q6h
45800034|NCT02605187|Drug|Acetaminophen|Acetaminophen 650mg po q6h
45800035|NCT02605187|Drug|Gabapentin|Gabapentin 600mg po one time within 1 hour of delivery
45800036|NCT02605187|Drug|Morphine (low)|Intrathecal morphine dose 50mcg
45800037|NCT02605187|Drug|Morphine (med)|Intrathecal morphine dose 150mcg
45800038|NCT02605187|Drug|Morphine (high)|Intrathecal morphine 300mcg
45800039|NCT05371067|Other|Fructose respiratory test|Healthy volunteers will performed a fructose respiratory test in order to evaluate if they are or not fructose malabsorbing. The two population will be compared about their feelings and their micriobiote.
45800040|NCT02606903|Drug|BI 695501 prefilled syringe|
45800041|NCT02606903|Drug|BI 695501 autoinjector|
45800042|NCT04350619|Other|Genetic screening. No therapeutic intervention|Genetic screening using NGS technique. No therapeutic intervention
45800043|NCT05592197|Drug|Lenvatinib|Lenvatinib will be initially provided to patients first (dose: 8 mg qd for patients < 60 kg, and 12 mg qd for patients ≥ 60 kg)
45800044|NCT05592197|Procedure|TACE|TACE will be performed one day after oral administration of lenvatinib. Either cTACE or DEB-TACE can be used, depending on the condition of each center.
45800045|NCT05592197|Radiation|External beam radiation (RT)|RT will be given within 4 weeks after the first TACE with linear accelerator-based photon beams. Gross tumor volume is defined as intrahepatic tumor and vascular invasion including a 1-cm margin into the contiguous HCC. Prescription dose will be 4500-6000 cGy in 25 fractions.
45928846|NCT03960047|Behavioral|Virtual Reality Training|This group gets trained to cross streets using virtual reality
45928847|NCT03960047|Behavioral|Streetside Training|This group is trained to cross streets based on streetside experiences
45928848|NCT00028275|Drug|Gamma Interferon 1b|
45928849|NCT03959969|Other|Educational video|An educational video on pain management after cesarean section. The educational video was put together by two general obstetrician-gynecologists, two maternal fetal medicine specialists, and a palliative care physician.
45928850|NCT03959969|Other|Standard of care|The standard of care discharge instructions for postoperative patients after cesarean section that are provided at the institution.
45928851|NCT03959969|Drug|Ibuprofen|Prescription given for forty tablets of ibuprofen 600 mg every 6 hours as needed for pain.
45928852|NCT03959969|Drug|Oxycodone|Prescription given for twenty tablets of oxycodone 5 mg every 4 hours as needed for pain.
45928853|NCT00028314|Drug|Abacavir sulfate|
45928854|NCT00028314|Drug|Atazanavir/Ritonavir|
45928855|NCT00028314|Drug|Lopinavir/Ritonavir|
45928856|NCT00028314|Drug|Nevirapine|
45928857|NCT00028353|Drug|GTX-006 (Acapodene)|
45928858|NCT03959852|Drug|Fentanyl|1 mg/kg of Fentanyl IV administered over at least 1 minute
46073752|NCT00835939|Procedure|sclerotherapy|
45928859|NCT03959852|Combination Product|Fentanyl and Ketamine|Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute.
45928860|NCT03959852|Drug|Ketamine|0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute
45928861|NCT00028431|Biological|MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine|
45928862|NCT03959813|Other|Psychomotricity by touching and passive mobilizations|"The patient will have a first psychomotricity session. It will be carried out remotely from the drug catches to avoid bias induced by their administration having effects on the symptoms studied.~Before and after the session, two evaluations will be offered to the patient and performed by a nurse:~A questionnaire, based on the physical experience,~The ESAS scale will be administered to the patient to assess the importance of symptoms (pain, depression, anxiety, discomfort) During the session, a touch treatment will be offered to promote awareness of the body. Passive mobilizations at the level of the members and the axis will then be proposed, to promote the pleasure of being in motion. A touch treatment will be done again to promote relaxation.~A questionnaire can be offered to the patient after 4 sessions to assess his perception of psychomotricity."
45928863|NCT00028509|Procedure|management of therapy complications|
45928864|NCT03959774|Device|IPC NET|a digital pack with connected bracelet and connected balance will be given to the patient. IPC NET and Nokia Health applications will be downloaded. Pairing between connected objects and the smartphone will be done during the inclusion visit
45928865|NCT00028548|Drug|R(+)XK469|
45928866|NCT03959735|Other|High Intensity Interval Training (HIIT)|HIIT is a type of exercise involving alternating short bursts of high intensity exercise with recovery periods of rest or light exercise.
45928867|NCT00028587|Drug|bortezomib|Given IV
45928868|NCT00028587|Drug|paclitaxel|Given IV
45800046|NCT02989207|Procedure|Trabeculectomy|The current standard surgical treatment for glaucoma remains trabeculectomy. Wound healing modulation with antifibrotic agents, like MMC and 5-fluorouracil (5-FU), has been shown to increase the success of glaucoma filtering surgery in high-risk eyes
45928869|NCT00028587|Drug|carboplatin|Given IV
45800047|NCT02989207|Device|Baerveldt tube surgery|All glaucoma drainage devices consist of a tube which is inserted into the anterior chamber of the eye, draining aqueous humour to a plate which maintains a minimum bleb size and allows the collection of aqueous humour to be absorbed into the surrounding tissue.
45800048|NCT02989207|Drug|mitomycin-C|This is an anti scarring agent whcih is an standard adjunctive treatment in glaucoma surgery
45928870|NCT00028587|Other|laboratory biomarker analysis|Optional correlative studies
45800049|NCT05591729|Other|Pilates exercises|Each Pilates session will last for one hour. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centering which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the craniocervical junction). A pilates exercise program will consist of 11 levels of treatment program.
45928871|NCT03959696|Behavioral|Notification|Clinicians will be notified of their patients aged 76-85 with an upcoming, non urgent visit who are due for colorectal cancer screening.
45928872|NCT03959696|Behavioral|Training|The 2-hour continuing medical education course in shared decision making, simulated patient interaction to practice skills, and monthly calls for a year to review difficult cases with clinical and shared decision making experts.
45928873|NCT04733196|Drug|Essential oils|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
45928874|NCT04733196|Drug|Essential oils in combination with chlorhexidine 0,12%|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
45928875|NCT04733196|Drug|Placebo mouthwash|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
45928876|NCT04733196|Drug|Chlorhexidine 0,20 % in combination with aroma oils|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
45928877|NCT04733196|Drug|Prebiotic|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
45928878|NCT04733196|Drug|Hydrogen peroxide 0,8 %|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
45650772|NCT03042377|Other|Single-Visit Retreatment|The teeth in this group were treated according to the guidelines for root canal retreatment in single-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were obturated with gutta percha and coronal restoration was made using composite and/or fully crown if necessary.
45650773|NCT03042377|Drug|"Multiple-Visit-Calcium Hydroxide"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with calcium hydroxide and the cavity was filled with temporary restorative material.
45928879|NCT03959657|Other|No intervention performed by authors|Observational and retrospective study, no intervention performed
45928880|NCT00028626|Drug|embolization therapy|
45928881|NCT03959618|Other|dietary supplements questionary|Patient Questionary Patient to be carried out at the last cure
45928882|NCT00028665|Biological|filgrastim|Beginning 36-48 hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover. Patients receive G-CSF SC daily beginning 4 hours after completion of PBSC infusion and continuing until neutrophil engraftment.
45928883|NCT00028665|Biological|rituximab|rituximab IV over 2-5 hours on days 1, 8, and 15
45928884|NCT00028665|Drug|carmustine|After completion of PBSC collection, patients receive high-dose chemotherapy comprising carmustine IV on days -7 to -3
45928885|NCT00028665|Drug|cisplatin|After completion of PBSC collection, cisplatin IV for 3 days during days -7 to -3.
45928886|NCT00028665|Drug|cyclophosphamide|cyclophosphamide IV over 3-6 hours on day 16.
45928887|NCT00028665|Drug|etoposide|After completion of PBSC collection, etoposide IV for 3 days during days -7 to -3.
45928888|NCT00028665|Procedure|bone marrow ablation with stem cell support|Patients then undergo peripheral blood stem cell (PBSC) collection.
45928889|NCT00028665|Procedure|peripheral blood stem cell transplantation|Arm I: Patients receive unmanipulated PBSCs on day 0. Arm II: Patients receive CD34 cell-enriched PBSC on day 0.
45928890|NCT00028665|Radiation|radiation therapy|Patients may undergo involved-field radiotherapy to active or previously bulky (more than 5 cm) tumors daily for 7-10 days.
45650774|NCT03042377|Drug|"Multiple-Visit-Corticosteroid Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with corticosteroid & antibiotic paste and the cavity was filled with temporary restorative material.
45800050|NCT05591729|Other|postural correction exercise|the patients will receive postural correction exercises, stretches, and exercises to the pectoralis major, elevator scapulae, upper trapezius, serratus anterior, rhomboids, and deep neck flexors. The stretches included sitting chair stretches, Brugger's, wall angels, and doorway stretches. The exercises included push-up-plus, head-neck-retraction, and Kibler squeeze
45650775|NCT03042377|Drug|"Multiple-Visit-Antibiotic Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with an antibiotic paste and the cavity was filled with temporary restorative material.
45650776|NCT05071573|Other|Optimised electronic patient records|Viral load champions trained in the monitoring of patient on antiretroviral therapy to aid prompt identification of virological failure and institution of appropriate clinical management
45800051|NCT04340219|Other|Survey administration|Covid-19 Peritraumatic Distress Index, Depression Anxiety Stress Scale-21, WHO Quality of Life-BREF
45800052|NCT02647099|Drug|Acetylsalicylic acid|
45800053|NCT02647099|Drug|Placebo|
45800054|NCT02409589|Device|ECG|The ECG-guided PICC tip detection method will be used to identify catheter tip location during the procedural placement of the catheter. This method involves an ECG monitor which will be connected to the guidewire used for catheter placement. The changes in the ECG p-wave will guide correct PICC placement. An X-ray radiograph will be conducted to confirm the tip location after PICC placement.
45800055|NCT02409589|Procedure|Surface prediction length method|The method will estimate the length of the catheter from puncture site to the junction of superior vena cava / right atrium (SVC-RA) . Tip location is placed according to the estimated length but later on will be determinated by chest X-ray performed after the placement procedure. If the tip location is not at an ideal place, additional procedures and X-ray radiograph would be required in order to ensure proper tip location.
45800056|NCT01843465|Other|Maneuvers for documenting the disconnection|
45800057|NCT01843621|Biological|DEN vaccine F17|The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).
45800058|NCT02608229|Drug|BVD-523|
45800059|NCT02608229|Drug|Nab-paclitaxel|
45800060|NCT02608229|Drug|Gemcitabine|
45800061|NCT02608229|Procedure|Tumor biopsy|
45800062|NCT00555061|Drug|Retapamulin Ointment, 1%|1% Ointment
45800063|NCT01844479|Device|diabetic foot orthotic|The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.
45800064|NCT01844479|Other|Standard innersole|
45800065|NCT05547373|Behavioral|Infection prevention and control (IPC)|The intervention will be developed by matching behavioral change components identified in the gap analysis stage with the intervention components extracted from a systematic review. The investigators will use the Behavior Change Wheel (BCW) model as a guide to design this infection control prevention and control intervention. In brief, the intervention development processes will follow eight steps based on the BCW. The steps will include defining the problem in behavioral terms, selecting the target behaviors, specifying the target behaviors, identifying what needs to change, identifying intervention functions, identifying policy categories, identifying behavior change techniques, and identifying the mode of delivery.
45800066|NCT01642212|Drug|Oral Budesonide Suspension (MB-9)|OBS suspension to be taken bid over a 16 week course of double blind therapy and OBS suspension to be taken qd to bid during a 24 week optional open label extension period
45800067|NCT01642212|Drug|Placebo|
45800068|NCT02608463|Behavioral|painDETECT Questionnaire|This self-report questionnaire consists of 7 questions that address the quality of neuropathic pain syndromes. The first 5 questions ask about the gradation of pain, question 6 asks about the pain course pattern and question 7 asks about radiating pain. There are 4 additional questions (not counted in the total score) which asks the subject to rate their pain now and over the last 4 weeks and to mark on a body chart if there is pain radiating into other parts of the body.
45928891|NCT03959579|Diagnostic Test|systematic endomyocardial biopsy.|"We sought to compare the long term survival of HTx recipients followed with or without systematic endomyocardial biopsy. Second, the sensibility and specificity of cardiac echo to diagnose acute allograft rejection will be analyzed.~To show the safety of non-invasively monitoring HTx recipients without systematic endomyocardial biopsy"
45650777|NCT05071417|Drug|Semaglutide|Usual treatment with semaglutide. Dose 0.5 - 1mg weekly, subcutaneous, weekly
45800069|NCT02608463|Behavioral|Pain Catastrophizing Scale|The PCS is a 13-item self-report scale. It asks subjects to reflect on past painful experiences, and to indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain, on 5-point scales with the end points (0) not at all and (4) all the time. The PCS yields a total score and three subscale scores assessing rumination, magnification, and helplessness.
45928892|NCT00028704|Procedure|conventional surgery|
45928893|NCT00028704|Radiation|radiation therapy|
45928894|NCT03959540|Drug|Opicapone|Capsules, oral use - 50 mg Use of opicapone is only driven by the physician's decision.
45800070|NCT02608463|Behavioral|Pain Intensity Scale, Pain Interference Scale, Pain Behavior Scale|"The 3-item, self-report Pain Intensity assesses how much a person hurts. The first 2 items assess pain intensity over the past 7 days; the last item asks subject to rate pain intensity right now. The 4-item, self-report Pain Interference measures the consequences of pain on relevant aspects of subject's life. It includes impairment in subject's social, cognitive, emotional, physical, & recreational activities. It also incorporates items about sleep and enjoyment of life. It assesses pain interference over the past 7 days.~The 7-item, self-report Pain Behavior measures behaviors that typically indicate to others that an individual is experiencing pain. Measures include observations (sighing, crying), behaviors (resting, guarding, facial expressions, asking for help), & verbal reports of pain. It assesses pain interference over the past 7 days.~All three scales, derived from the Patient Reported Outcomes Measurement Information System (PROMIS), are not disease specific."
45928895|NCT03959540|Drug|Levodopa (L-DOPA) + Standard care|Levodopa (immediate- or controlled-release) + Standard care. Use of Levodopa and standard of care are only driven by the physician's decision.
45928896|NCT00028743|Drug|carboplatin|Arm 1 = 4 cycles vs Arm 2 = 8 cycles AUC5 (30 mins) day 1 of 21 day cycle
45928897|NCT00028743|Drug|cisplatin|4 cycles 50mg/m2 (60 mins) day 1 of 21 day cycle
45928898|NCT00028743|Drug|paclitaxel|Arm 1 = 4 cycles vs Arm 2 = 8 cycles 175mg/m2 (3 hours) day 1 of 21 day cycle
45928899|NCT00028743|Drug|topotecan hydrochloride|"4 cycles~.75mg/m2 (30 mins) days 1-5 of 21 day cycle"
45928900|NCT03959501|Drug|Dapagliflozin 10 mg|Dapagliflozin 10mg daily for 24 weeks
45928901|NCT03959501|Drug|Sitagliptin 100mg|Sitagliptin 100mg daily for 24 weeks
45650778|NCT03039881|Device|Non-Invasive Respiratory Volume Monitor|The device requires the application of a monitoring PadSets to the patient's skin similar to EKG electrodes and, as such, poses minimal risk.
45650779|NCT04859777|Drug|MPT-0118|MPT-0118 is an inhibitor of MALT1 protease
45928902|NCT00028782|Drug|etanidazole|Given IV
45928903|NCT00028782|Procedure|therapeutic conventional surgery|Undergo surgery
45928904|NCT00028782|Other|laboratory biomarker analysis|Correlative studies
45928905|NCT00028821|Drug|2-methoxyestradiol|Given orally
45928906|NCT00028821|Other|pharmacological study|Correlative studies
45928907|NCT00028821|Other|laboratory biomarker analysis|Correlative studies
45928908|NCT03959384|Drug|Curosurf 80Mg/Ml Intratracheal Suspension|CUROSURF is a natural surfactant obtained from swine lungs containing almost exclusively phospholipids, in particular phosphatidylcholine (about 70% of the total phospholipid content) and about 1% of low molecular weight hydrophobic proteins, specific for surfactant, SP-B and SP -C. CUROSURF will be administered via endotracheopulmunary.
45928909|NCT03959384|Other|Ambient Air|Ambient air aspirated in sterile syringes
45928910|NCT00028860|Biological|filgrastim|
45928911|NCT00028860|Drug|carboplatin|
45650780|NCT04859777|Drug|MPT-0118 + pembrolizumab|MPT-0118 is an inhibitor of MALT1 protease; pembrolizumab is a PD-1 inhibitor
45650781|NCT05563779|Other|Volume Control mode|Volume Control mode for mechanical ventilation
45928912|NCT00028860|Drug|gemcitabine hydrochloride|
45928913|NCT00028860|Drug|ifosfamide|
45928914|NCT00028860|Drug|paclitaxel|
45928915|NCT00028860|Procedure|adjuvant therapy|
45928916|NCT03959345|Drug|Combination therapy group|Adult patients with MSSA bacteraemia will be randomized to Combination therapy group: patients will receive intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
45928917|NCT03959345|Drug|Standard therapy group|Adult patients with MSSA bacteraemia will be randomized to Standard therapy group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
45928918|NCT00028899|Drug|asparaginase|
45928919|NCT00028899|Drug|cytarabine|
45928920|NCT00028899|Drug|gemtuzumab ozogamicin|
45928921|NCT00028899|Drug|mitoxantrone hydrochloride|
45928922|NCT03959306|Dietary Supplement|Black Seed Oil|Black seed oil soft gelatin capsule
45928923|NCT03959306|Drug|Anti-Diabetics|standard anti-diabetic treatment prescribed for the patient
45928924|NCT00028938|Biological|epoetin alfa|
45928925|NCT00028938|Drug|carboplatin|
45928926|NCT00028938|Drug|paclitaxel|
45928927|NCT00028938|Radiation|radiation therapy|
45928928|NCT00028977|Drug|herba scutellaria barbata|
45928929|NCT00028977|Other|herba scutellaria Barbatae (HSB)|
45928930|NCT04733612|Other|Informative messages|"In addition to their standard treatments, an informative SMS (text message) on diabetes was sent to the intervention group three to four times a week for six months.~The short messages were in the form of a short sentence for the subject and the predicate. The messages sent have been prepared in such a way that they do not exceed 1 SMS quota and are less than 160 characters on mobile phones."
45928931|NCT00029133|Procedure|mild intraoperative hypothermia (33 degrees Celsius)|
45650782|NCT05563779|Other|Pressure Control mode|Pressure Control mode for mechanical ventilation
45650783|NCT05563779|Other|Adaptive Pressure Control mode|Adaptive Pressure Control mode for mechanical ventilation
45928932|NCT03959228|Drug|keto-analogs|The patients that will be included in the experimental arm will have additional keto-analogs (1 pill/5 kg).
45928933|NCT00029211|Drug|Echinacea|
45928934|NCT03959189|Drug|ERX-963|Active medicine
45928935|NCT03959189|Drug|Placebo|Comparator
45928936|NCT00029250|Drug|Garlic powder standardized to allicin|
45928937|NCT00029289|Drug|Lutein (10 or 30 mg/day) capsules|
45928938|NCT03959150|Drug|Capecitabine|Oral fluorouracil
45928939|NCT00029328|Drug|etanercept|
45928940|NCT00029484|Behavioral|Tai chi chih|
45928941|NCT00029523|Drug|Intrathecal (injected into the spinal fluid) DepoCyt|
45928942|NCT00029523|Drug|Intrathecal methotrexate|
45928943|NCT00029523|Drug|Intrathecal cytarabine (also known as ara-C)|
45650784|NCT03039725|Other|Observational|Retrospective chart review on vaccine compliance
45650785|NCT05071261|Diagnostic Test|Hepatitis C Virus Screening|1-2 Blood Screenings for Hepatitis C Virus
45650786|NCT05562609|Drug|Tranexamic acid|Ampoules and packaging for all arms will be identical in appearance.
45800071|NCT02608463|Behavioral|Beck Depression Inventory|The BDI is a widely used instrument that has been used in both clinical and non-clinical setting measuring depressive symptoms. It is a 21 item questionnaire with 4-5 responses for each question. Responses are coded 0-3 for the 4 point scales. The 5 point scales include an additional 2a and 2b response code. The symptom categories reflect overt behavioral manifestations of depression. The instrument has both a high degree of reliability and validity (Beck, Ward, Mendelson, Mock & Erbaugh, 1961).
45800072|NCT02608463|Behavioral|Visual Analogue Scale|100 mm line scale that is subject administered to subjectively rate current pain symptoms. The subject will be instructed to draw a single vertical line that best describes current state.
45928944|NCT00392639|Procedure|Comparison of 2 cooling procedures|Comparison of 2 cooling procedures
45928945|NCT00392717|Drug|Atorvastatin|
45928946|NCT00392717|Drug|Fish oils|
45928947|NCT03958838|Behavioral|Peer Support Integrated with Primary Care|Peer leaders will deliver support that address the four key functions of peer support, providing 1) assistance in daily self-management, 2) linkages to clinical care and community resources, 3) social and emotional support, and 4) ongoing, flexible support over time.
45928948|NCT00029679|Drug|Gingko biloba|
45928949|NCT00029679|Drug|Borage oil|
45928950|NCT03958799|Biological|Investigational Tdap vaccine Formulation B|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
45928951|NCT03958799|Biological|Investigational Tdap vaccine Formulation C|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
45928952|NCT03958799|Biological|Investigational Tdap vaccine Formulation A|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
45928953|NCT03958799|Biological|Investigational Tdap vaccine Formulation D|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
45928954|NCT03958799|Biological|Licensed Tdap vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
45928955|NCT00029757|Drug|Estrogen|
45928956|NCT00029796|Drug|soy isoflavones|
45928957|NCT03958721|Drug|Capecitabine|1,000 mg/m2 twice daily taken by mouth every other week
45928958|NCT03958721|Radiation|Radiotherapy|Once daily (Monday through Friday) for six weeks
45928959|NCT00029835|Drug|Rimonabant (SR141716)|
45928960|NCT03958682|Device|AR smart wearing equipment combined with 4G + satellite information transmission system|"We are going to add a pair of wearable smart glasses with AR function to the original flight helmet .During the rescue, the doctor is asked to wear the special helmet , through the device's camera system and headset, we can obtain graphics and sound of the helicopter cabin .At the same time, it also receives the historical data of patients and real-time diagnosis as well as rescue guidance from the ground medical institutions.~It can not only transmit the patient's information in the cabin to the ground medical institutions in real time, but also transmit the rescue plan of the ground medical experts to the rescue helicopter in real time to ensure the safety of patients in transit ,which will save the time for medical staff to hand over after landing and reduce errors."
45928961|NCT03958604|Procedure|Neurostimulation|Spinal cord stimulation with burst modality for discogenic low back pain
45800073|NCT02608463|Behavioral|Patient's Global Impression of Change Scale & Clinical Global Impression-Global Improvement Scale|"The PGIC gives a global rating of change in symptoms, activities, emotion, and overall quality of life related to the subject's pain condition. This is a self-rated scale.~The CGI-I gives a global rating of the improvement/change in the symptoms since the last study visit. This is administered by the MD."
45928962|NCT00395772|Drug|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 20 mg once daily (od) for 12 weeks
45928963|NCT00395772|Drug|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 30 mg od for 12 weeks
45928964|NCT00395772|Drug|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 40 mg od for 12 weeks
45928965|NCT00395772|Drug|(LMW) Heparin + Vitamin K Antagonist|Low Molecular Weight (LMW) Heparin + Vitamin K Antagonist (VKA) for 5 days, then VKA only for the rest of 12 weeks
45928966|NCT00395811|Procedure|Bone Marrow Stem Cell Therapy combined CABG|Bone Marrow Stem Cell inject into myocardium
45928967|NCT00395889|Procedure|Rehabilitation including structured exercise training|Rehabilitation of at least 8 weeks, for at least twice/week. This group will also receive the exercise counseling as a part of the rehabilitation program.
45928968|NCT00395889|Procedure|Physical Activity Counseling|Six exercise counseling sessions will be carried out during a 6-month period. This group will only receive the counseling and no formal structured exercise training sessions.
45928969|NCT03958526|Device|active tDCS|Patients in active group will receive 10 sessions of anodal tDCS delivered over primary motor cortex (M1) contralateral to the most painful side with a constant current of 2 miliAmpers for 20 minutes.
45650787|NCT05562609|Other|Placebo|Ampoules and packaging for all arms will be identical in appearance.
45650788|NCT04370873|Drug|MK-5475|MK-5475 32 µg, 100 µg, 195 µg, 360 µg or 380 µg administered as dry powder inhalation according to randomization
45650789|NCT04370873|Drug|Placebo|Placebo administered as dry powder inhalation according to randomization
45650790|NCT05388201|Other|N95|3M N95 Respirator
45650791|NCT05388201|Other|KN95|KN95 Mask (with and without clip)
45650792|NCT05388201|Other|KF94|KF94 Mask (with and without clip)
45650793|NCT05388201|Other|Surgical|Surgical Mask (with and without clip)
45650794|NCT03632707|Radiation|Magnetic Resonance Imaging of the knee|After clinical assessment, all the patients will examined by Magnetic Resonance Imaging to diagnose the medial meniscal posterior root tear,and the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing
45928970|NCT03958526|Device|sham tDCS|Same protocol (electrode montage,session duration) will be used for sham stimulation. But the device won't be active for full 20 minutes.
45928971|NCT03958448|Procedure|Placement of extra short implants|placement of an extra short implant in the posterior edentulous ridge
45650795|NCT03632707|Procedure|Knee Arthroscopy|Correlate all the magnetic resonance imaging results with the Knee Arthroscopy
45800074|NCT02608463|Device|Transcranial Magnetic Stimulation|Subjects will undergo daily repetitive transcranial magnetic stimulation (rTMS), defined as Monday through Friday, for a total of 10 consecutive sessions. rTMS will be applied using the NeuroStar TMS Therapy System through a figure-8 coil connected to a magnetic stimulator, which provides a biphasic pulse. The coil is applied to the primary motor cortex, M1, contralateral to the painful side. The optimal stimulus site, motor hot spot, will be determined according to visual detection of muscle twitches, and a resting motor threshold is defined as the minimal intensity necessary to induce at least one visible muscle twitch. An rTMS session consists of 10 trains at 90% intensity of resting motor threshold (one train, 100 pulses at 10 Hz; intertrain interval, 50s).
45928972|NCT03958448|Procedure|maxillary sinus lift, maxillary sinus elevation, maxillary sinus augmentation|
45928973|NCT03958448|Procedure|placement of standard implant|placement of standard implant in the posterior edentulous ridge after maxillary sinus augmentation
45928974|NCT00029874|Drug|Minocycline|
45928975|NCT03958370|Other|Fitbit|Fitbit use during physical therapy session
45928976|NCT00029913|Other|Observation|Observation of participants who received HIV preventive vaccine and became infected.
45928977|NCT03958292|Device|IODIM|Eye drops containing polyvinylpyrrolidone-Iodine (PVP-Iodine), hyaluronic acid and triglycerides
45928978|NCT03958253|Other|Toolbox for Lung Cancer Screening|"-Toolbox of evidence-based elements that a primary care or referral site could implement to address known barriers to screening and referral, as well as required elements for screening. These elements will be designed to be adaptable to the unique needs and screening processes of the participating practices.~Patient education materials~Primary care practice educational materials~Pack-years/eligibility calculator~Local referral process guide~Smoking cessation materials and support~Shared decision-making guide~LDCT best practice guidelines"
45928979|NCT00029991|Drug|Gingko Biloba (Herb)|
45928980|NCT00030030|Drug|Silymarin (milk thistle)|
45928981|NCT03958214|Behavioral|Recipe 4 Success|Home visitors teach parents about children's self-regulation skills and healthy eating habits. The home visitors then teach parents how to sensitively scaffold the development of their toddlers' self-regulation skills in the context of cooking and snack preparation lessons. Prior research shows that self-regulation skills in early childhood predict long-term health indicators, such as BMI. Prior research also shows that children who are involved in the preparation of healthier foods are more likely to eat them.
45928982|NCT03958214|Behavioral|Usual practice Early Head Start|Home visitors will continue to deliver usual practice Early Head Start home visits that follow a standard curriculum and are tailored on an ongoing basis to meet individual family needs.
45928983|NCT00030069|Drug|Calcitriol|
45928984|NCT00030069|Drug|Dexamethasone|
45928985|NCT03958175|Other|Alouette test (reading test)|The alouette test was assessed at a fixed distance of 40 centimeters on a fixed surface to avoid errors related to hand tremors.
45928986|NCT03958136|Procedure|Metastasis biopsy|Metastasis biopsy will be performed for multi-omic analysis
45928987|NCT03958136|Biological|Biomarkers blood, urine and microbiota samples|Biomarkers blood, urine and microbiota samples for multi-omic analysis
45928988|NCT03958136|Behavioral|Patient Reported Outcome (PRO)|Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.
45928989|NCT00030108|Drug|ixabepilone|
45928990|NCT03958097|Combination Product|NK cell and PD-1 antibody|Each patient enrolled the study will received both NK cell and PD-1 antibody.
45928991|NCT00030225|Biological|ELAD|
45928992|NCT00030225|Other|Standard of care (Control)|
45450908|NCT03533296|Procedure|Positive end expiratory pressure (PEEP)|The different levels of PEEP, 5 cmH2O, 8 cmH2O and 12 cmH2O, are applied serially. Mean respiratory compliance and intratidal compliance-volume profile are evaluated.
45450909|NCT02203864|Biological|BIBW2 component A|BIBW2 without IL-2 secreting cell line
45450910|NCT02203864|Biological|BIBW2 component B|BIBW2 with IL-2 secreting cell line
45450911|NCT02209324|Drug|ASP2151|
45450912|NCT02209402|Behavioral|Exercise Training|Home-based training programme consisting of daily 4x10 minutes physical exercise on a magnetically braked bicycle at a heart rate corresponding to 80-90% of the heart rate achieved at the anaerobic threshold.
45450913|NCT02203942|Other|NAAT testing|comparison of NAAT testing for BV, VVC and trich to Amsel criteria, Nugent score, yeast culture and TV culture.
45650796|NCT04429451|Biological|4SCAR-PSMA T cells|Infusion of 4SCAR-PSMA T cells at 10^6 cells/kg body weight via IV
45650797|NCT03101527|Drug|Omega-3 PUFA supplementation|Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g docosahexaenoic daily for the duration of the study
45650798|NCT05367219|Device|Air sterilizer|The invesitigators will try to remove the smoke with an air sterilizer during the endoscopic gastrointestinal surgery in the Air sterilizer group.
45650799|NCT04838873|Procedure|Open radical cystectomy|Standard open radical cystectomy and urinary diversion
45650800|NCT04838873|Procedure|Laparoscopic-assisted radical cystectomy|Laparoscopic-assisted radical cystectomy and extracorporeal urinary diversion
45650801|NCT04582825|Other|N/A - Observational Study|N/A - Observational Study
45650802|NCT05413941|Behavioral|Internet-based Cognitive Behavioral Therapy|Cognitive behavioral therapy (CBT) is a form of psychotherapy in which individuals are taught to identify and modify maladaptive thinking and behavior to improve their psychological status and coping skills. CBT in this trial will be delivered digitally (internet-based).
45928993|NCT03934229|Dietary Supplement|Daily intake of study product|Daily intake of Bifidobacterium animalis ssp. lactis 420 or placebo for a 6-month period
45928994|NCT00030303|Biological|recombinant 70-kD heat-shock protein|
45928995|NCT03933059|Other|Psychotherapy|Cognitive Processing Therapy is a primarily cognitive form of Cognitive Behavioral Therapy, which has been shown to be effective at reducing symptoms of PTSD.
45928996|NCT00030342|Biological|recombinant interferon alfa|
45928997|NCT00030342|Biological|sargramostim|
45928998|NCT00030342|Biological|therapeutic autologous lymphocytes|
45928999|NCT00030342|Drug|fluorouracil|
45929000|NCT03959930|Device|Transdermal Fluid Removal|"The Transdermal Fluid Removal (TFR) device is designed for use on the lower limbs of patients with Chronic Heart Failure and treatment resistant peripheral oedema.~The TFR device is intended to be applied on oedematous skin of eligible patients, for periods of up to 10 hours at a time, to gently remove excess fluid through the skin, over a period of a few days during exacerbations, thereby avoiding hospitalisation for intravenous diuretics.~The TFR device is designed to be used in conjunction with standard Negative Pressure Wound Therapy (NPWT) devices which are currently CE Marked and approved for use in both acute and homecare environment."
45929001|NCT00030381|Drug|4'-iodo-4'-deoxydoxorubicin|Given IV
45800075|NCT05649618|Biological|Tumor Infiltrating Lymphocytes|On day 0 patients will be intravenous infusion of TILs
45650803|NCT03039959|Diagnostic Test|No intervention|No intervention
45929002|NCT00030381|Other|pharmacological study|Correlative studies
45929003|NCT01349816|Drug|PT003|PT003 MDI administered as two puffs BID for 7 days
45929004|NCT01349816|Drug|PT001|PT001 MDI administered as two puffs BID for 7 days
45929005|NCT01349816|Drug|PT005|PT005 MDI administered as two puffs BID for 7 days
45450914|NCT02200198|Other|Expiratory muscle training|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold with Positive Expiratory Pressure with a load of 30% of maximal expiratory pressure assessed by digital peak respiratory pressure monitor
45450915|NCT02200198|Other|Inspiratory muscle training|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold for Inspiratory Muscle Training with a load of 30% of maximal inspiratory pressure assessed by digital peak respiratory pressure monitor
45450916|NCT02200198|Other|Sham group|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold without load
45450917|NCT03532672|Other|Acute Fasting|The volunteers will fast overnight (10 hours) and breakfast will be offered (bread, butter, ham and industrialized fruit juice) and the participants will fast for more 10 hours during daily activities.
45650804|NCT04544839|Device|ADLC attachment system with PEEK inserts|"Each patient will receive 2 implants in the canine region using a guided-surgery protocol and a pre-prepared surgical stent. A healing abutment of an adequate size will be placed on the implant for transmucosal healing. The flaps will be subsequently sutured around the healing abutments. Patients' existing prostheses will be adjusted. Suture removal will be performed one week post implant placement.~Three months later, implant level impressions will be made using the open tray technique. Each patient will be then be randomized using eCRF (electronic Case Report Form) to either ADLC group or LOC group. A final cast of the patients will be obtained and the attachments will be installed using an in-direct technique by a calibrated prosthodontists."
45650805|NCT05071339|Drug|Ganirelix Acetate, Cetrolix Acetate|3-6 days of 0.25mg GnRH antagonist starting day 2-3 of the menstrual cycle prior to the administration of the original protocol.
45650806|NCT04838483|Device|Indirect adhesive restoration of posterior teeth|Indirect restoration of significant loss of dental hard tissue
45800076|NCT05649618|Drug|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen
45800077|NCT05649618|Drug|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
45929006|NCT00030420|Drug|Celecoxib|400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.
45929007|NCT00030420|Drug|Docetaxel|On day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days
45929008|NCT00030459|Drug|cisplatin|
45929009|NCT00030459|Drug|mitomycin C|
45929010|NCT00030459|Drug|vinblastine sulfate|
45450918|NCT02209480|Behavioral|Alexander Technique|
45450919|NCT02209480|Device|Heat pad application|
45450920|NCT02209480|Behavioral|guided imagery|
45450921|NCT02200354|Drug|pemetrexed with bevacizumab|
45450922|NCT02209558|Behavioral|Visual Sternal Precautions|"Visual depiction of SPs in addition to standard of care written precautions"
45800078|NCT05649618|Drug|IL-2|Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance.
45800079|NCT00552175|Drug|Duloxetine hydrochloride - 40 mg|duloxetine 40 mg taken orally every day
45800080|NCT00552175|Drug|placebo|placebo taken orally every day
45800081|NCT00552175|Drug|Duloxetine hydrochloride - 60 mg|duloxetine 60 mg taken orally every day
45800082|NCT05357183|Drug|PEG-IFN|PEG-IFN 180 or 135 micrograms, subcutaneously injected once a week, with a personalized treatment course of 24 weeks
45929011|NCT00030459|Drug|vinorelbine tartrate|
45929012|NCT00030498|Drug|erlotinib hydrochloride|Given orally
45929013|NCT00030498|Other|laboratory biomarker analysis|Correlative studies
45929014|NCT03873857|Drug|Venetoclax|tablet;oral
45929015|NCT02971527|Device|Oste-scan 500A|The investigators will detect the same calcaneus of each subject by experimental ultrasound bone strength device. Experimental ultrasound bone strength device's model number is Oste-scan 500A and report number is Z-Y-2009-2014, Z-E-0530-2014(G).
45929016|NCT02971527|Device|SONOST3000|The investigators will detect the same calcaneus of each subject by control ultrasound bone strength device. Control ultrasound bone strength device's model number is SONOST3000.
45929017|NCT03866408|Behavioral|Immediate weight loss|Upper body obese subjects will undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
45929018|NCT03866408|Drug|Pioglitazone|Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
45929019|NCT03866408|Behavioral|Deferred weight loss|Upper body obese subjects will complete a weight-stable period of 4 months and subsequently undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
45650807|NCT04521829|Other|Walking with different optic flow speeds with 2 different VR devices|Participants will perform 2 sessions of VR-enhanced treadmill walking. One session with the GRAIL system (semi-immersive) and the other session with a fully immersive head-mounted display (Oculus Rift S). In both sessions, the speed of the optic flow will be manipulated: equal to, 2 times faster and 2 times slower than the participant's comfortable walking speed.
45650808|NCT05386485|Other|None intervation|Observational Study
45929020|NCT03866408|Drug|Placebo|Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
45929021|NCT00030537|Drug|erlotinib hydrochloride|
45929022|NCT00030576|Drug|cisplatin|
45929023|NCT00030576|Drug|erlotinib hydrochloride|
45929024|NCT03857945|Other|Preoperative mobility device(s) training|Patients in Group 1 (the intervention, that is the mobility device training group group) will receive training on the mobility device(s) with the physical therapy visit during their standard pre-operative care.
45929025|NCT00030615|Drug|decitabine|Given IV
45929026|NCT00030615|Other|pharmacological study|Correlative studies
45929027|NCT00030615|Other|laboratory biomarker analysis|Correlative studies
45650809|NCT02606279|Drug|valsartan|Valsartan will be given in increasing doses (from 40 mg to 80 mg) to those in the valsartan arm.
45650810|NCT02606279|Other|Placebo|
45650811|NCT03037697|Other|TheraTogs Arm|TheraTogs Arm Received Soft Orthotic undergarments
45650812|NCT03037697|Other|Traditional Treatment|"Traditional treatment to Dyskinetic CP~1- Trunk control exercises 2- Core stability training 3- Proximal dynamic stability for the shoulder and pelvic girdles components. 4- Back and abdominal strengthening exercises 5- Standing exercises : - Standing alone gradually increase time. - Stride standing alone. - Step standing alone (other limb supported on wooden step then soft step and finally on small ball). - Standing on balance board"
45800083|NCT05649384|Diagnostic Test|European Society of Cardiology hs-cTnT/I 0 h/1 h algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 1 hour later in the emergency department.
45800084|NCT05649384|Diagnostic Test|European Society of Cardiology hs-cTnT/I 0 h/3 h algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 3 hours later in the emergency department.
45800085|NCT04741763|Dietary Supplement|EyePromise Visual Edge|A dietary eye supplement containing 8 mg zeaxanthin and 4 mg lutein and additional proprietary nutrients
45800086|NCT04743089|Device|ERCP using SpyGlass™ DS Direct Visualization System|Lithotripsy and stone removal will be performed using ERCP and Spyglass system to patients with IHD/EHD stone, which is difficult to remove through conventional ERCP. The SpyGlass™ DS Direct Visualization System will be applied directly into the bile duct via the working channel of the duodenoscope. Under the high-resolution digital imaging, lithotripsy such as EHL could be done.
45800087|NCT04743089|Other|PTCS|A historical cohort of patients who underwent PTCS to remove bile duct stones which is difficult to treat by ERCP.
45800088|NCT02974205|Procedure|Jack brace|Rehabilitation after acute isolated PCL rupture with orthosis
45800089|NCT02974205|Device|Rehabilitation|Rehabilitation after acute isolated PCL rupture without orthosis
45929028|NCT03857087|Drug|Gallium Ga 68-labeled PSMA-11|Given IV
45650813|NCT05412927|Device|PMA P150009 AngelMed Guardian® System|"The AngelMed Guardian® System is an implantable cardiac monitor with patient alerting capability and an additional external alarm device. The Guardian® System is indicated for use in patients who have had prior ACS events and who remain at high risk for recurrent ACS events. The Guardian® System is indicated as an adjunct to patient recognized symptoms. The Guardian® System detects potential ongoing ACS events, characterized by sustained ST segment changes, and alerts the patient to seek medical attention for those potential ACS events.~A Guardian® System alert is a more accurate predictor of ACS events when compared to patient recognized symptoms alone and demonstrates a reduced rate over time of patient presentations without ACS events (false positives) when compared to patient recognized symptoms alone. In the absence of symptoms, the Guardian® System may identify asymptomatic ACS events and prompt the patient to seek medical attention."
45650814|NCT04859855|Procedure|Restrictive transfusional strategy|Transfusion of Red Blood Concentrates (RBCs) if Hb ≤7,0g/dL with the aim of maintaining Hb levels between 7,0-9,0g/dL.
45650815|NCT04859855|Procedure|Liberal transfusional strategy|Transfusion of RBC if Hb ≤9,0g/dL, with the aim of maintaining Hb levels between 9,0-10,0g/dL
45800090|NCT02974205|Device|össur brace|Rehabilitation after acute isolated PCL rupture
45800091|NCT01644474|Drug|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
45800092|NCT01644474|Drug|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
45800093|NCT01644474|Drug|Placebo (for Alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self--injection or by another designated person using the autoinjector.
45929029|NCT03857087|Procedure|Magnetic Resonance Imaging (MRI)|Given PET/MRI
45929030|NCT03857087|Procedure|Positron Emission Tomography (PET)|Undergo PET/MRI
45929031|NCT00030654|Drug|bicalutamide|
45929032|NCT00030654|Drug|docetaxel|
45929033|NCT00030654|Drug|doxorubicin hydrochloride|
45929034|NCT00030654|Drug|estramustine phosphate sodium|
45929035|NCT00030654|Drug|flutamide|
45929036|NCT00030654|Drug|ketoconazole|
45929037|NCT00030654|Drug|paclitaxel|
45929038|NCT00030654|Drug|releasing hormone agonist therapy|
45929039|NCT00030654|Drug|vinblastine sulfate|
45929040|NCT03852407|Drug|Thymoglobulin|ATG: 2.5 mg /kg/day on day -2 and -1 (day 0 is allogenic transplantation)
45929041|NCT03852407|Drug|Melphalan|100mg/m² on day -2
45929042|NCT03852407|Drug|Fludarabine|30mg/m² on days -6, -5, -4, -3, and -2
45929043|NCT03852407|Drug|Cyclophosphamid|50 mg/kg on days +3 and +4.
45650816|NCT04859621|Drug|Vitamin D3 4000 IU|Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
45929044|NCT00030693|Biological|recombinant fowlpox-B7.1 vaccine|Given intratumorally
45929045|NCT00030693|Biological|recombinant fowlpox-TRICOM vaccine|Given intratumorally
45929046|NCT00030693|Other|laboratory biomarker analysis|Correlative studies
46072490|NCT04198272|Behavioral|CyberRwanda|The CyberRwanda intervention consists of three primary components: 1. Guide to Teen Success: The CyberRwanda curriculum empowers youth to learn about FPRH and employment skills and to set goals for their futures through age-appropriate, interactive, digital and printed stories and activities. 2. Ask Mutoni / Ask Ntwali: The Q&A platform answers questions and provides referrals to local youth-friendly services through 'Mutoni' and 'Ntwali,' virtual peer educators who provide evidence-based, teen-friendly information and signposting to clinics. 3. Youth can directly purchase health products, including menstrual hygiene and contraceptive products (emergency contraception, condoms, and oral contraceptive pills) online and via SMS. The online and SMS clinic finder tool links youth clients to clinics for longer-acting methods. All participating pharmacies will be trained using the custom digital training game that supports them to give unbiased, nonjudgmental information and services.
45650817|NCT04859621|Drug|Vitamin D3 2000 IU|Oral administration, 1 tablet of each per time, qd, oral administration with the first meal, continuous use for 48 weeks
45800094|NCT01644474|Drug|Placebo (for Ezetimibe)|One capsule orally once daily at approximately the same time of the day with or without food..
45800095|NCT02614469|Drug|Inosine|Inosine, 1000 mg
46072491|NCT04196972|Other|Communication Intervention|Receive ECHO telementoring intervention
45929047|NCT00030693|Procedure|quality-of-life assessment|Ancillary studies
45929048|NCT03823274|Drug|Aspirin, Clopidogrel|to evaluate the relationship of stroke recurrence and anti-platelet resistance in ischemic stroke patients receiving aspirin and clopidogrel
45929049|NCT00030732|Drug|Gemcitabine + Capecitabine|Gemcitabine + Capecitabine
46072492|NCT04196972|Other|Questionnaire Administration|Ancillary studies
45450923|NCT02200432|Other|PERSPeCT Recommender System|"PERSPeCT will use data to predict messages that would be most influential to the participant in health behavioral change.~Patient Experience Recommender System for Persuasive Communication Tailoring. PERSPeCT is an adaptive computer system that will assess a patient's individual perspective, understand the patient's preferences for health messages, and provide personalized, persuasive health communication relevant to the individual patient."
45650818|NCT04859621|Drug|Placebo|Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
45800096|NCT02989129|Behavioral|Questionnaires|Questionnaires regarding quality of life, pain level, and related symptoms completed at Baseline and at End of Study Visit.. It should take less than 1 hour to complete these questionnaires.
45650819|NCT04859621|Other|standard antibiotic therapy|standard antibiotic therapy
45800097|NCT02989129|Drug|Quercetin|500 mg by mouth twice daily (after breakfast and dinner) for 12 weeks during study.
45800098|NCT02615717|Behavioral|Attention Bias Modification|comparison of treatment versus control
45800099|NCT04823299|Procedure|Cryoballoon ablation|Cryoballoon pulmonary vein isolation ablation
45800100|NCT04823299|Procedure|Radiofrequency catheter ablation +EPS guided trigger and substrate ablation|RF based WACA ± electrophysiological testing guided ablation of non-PV triggers of AF and low voltage area ablation
45800101|NCT04879524|Procedure|Percutaneous infracoccygeal Botulinum toxin injection to puborectalis|"The intervention is an injection of 200 units of Botulinum toxin type A in to the puborectalis muscle under ultrasound guidance.~In the prone position, the puborectalis muscle will be identified below the coccyx using ultrasound. After skin preparation using 70% Isopropyl Alcohol Pad, and up to 5ml of local anaesthetic (1% lidocaine), an electromyography (EMG) needle will be inserted and the puborectalis muscle stimulated using a current to confirm correct needle position. 200 units of BTXA (Botox, Allergan, Ireland) prepared in 2 ml of saline solution and drawn up using a 2ml syringe. 1ml (100 units) of BTXA solution is injected through the EMG needle into the puborectalis muscle to each side of the midline, achieving a total of 200 units. The needle is withdrawn, and the procedure is complete."
45800102|NCT05302115|Device|S-ICD|Implantation of an S-ICD
45929050|NCT00030732|Drug|Gemcitabine alone|Gemcitabine alone
45929051|NCT00030810|Radiation|Hyperfractionated|Hyperfractionated radiotherapy
45929052|NCT00030810|Drug|Taxotere/Cisplatin|Taxotere/Cisplatin
45929053|NCT00030810|Procedure|conventional surgery|conventional surgery
45929054|NCT03797456|Drug|ICP-022|ICP-022 (tablets, 50 mg) is given orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.
45929055|NCT00030849|Biological|recombinant interferon alfa|
45929056|NCT00030849|Drug|bexarotene|
45929057|NCT00030888|Drug|7-hydroxystaurosporine|
45929058|NCT03736343|Drug|Alcohol|Participants will complete two drinking sessions.
45929059|NCT00030966|Drug|Natalizumab|Natalizumab, 300 mg, monthly IV infusion for up to 116 weeks.
45450924|NCT02209714|Drug|BIIF 1149 BS|
45450925|NCT02209714|Drug|Placebo|
45650820|NCT04859387|Other|set of pragmatic shoulder technique|Group A received pragmatic intervention which includes Pectoralis major and minor stretch, AC joint mobilization, rotator cuff facilitation for subscapularis and infraspinatus, serratus anterior stretch, thoracic manipulation and posterior capsular stretch.
45650821|NCT04859387|Other|traditional physical therapy|Group B received traditional interventions which includes modalities such as TENS and hot pack, soft tissue mobilization, joint mobilization, stretching and strengthening etc. other than pragmatic intervention
45650822|NCT03039491|Biological|Pneumococcal polysaccharide vaccine 23 valent|This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae
45650823|NCT03039491|Biological|13 valent conjugated pneumococcal vaccine|This is the pneumococcal vaccine consisting of the capsular polysaccharides of 13 serotypes of Streptococcus pneumoniae conjugated to non-toxic diphtheria carrier protein 197
45650824|NCT03037853|Other|Healthy volunteers|MRI scanner
45650825|NCT03037775|Other|Baseline|measurement of baseline hemodynamic parameters
45929060|NCT00030966|Drug|Placebo|Placebo monthly infusion for up to 116 weeks.
45650826|NCT03037775|Device|e-cigarette without nicotine|measurement hemodynamic parameters during smoking e-cigarette without nicotine
45650827|NCT03037775|Device|e-cigarette with nicotine|measurement hemodynamic parameters smoking e-cigarette with nicotine
45650828|NCT03037775|Device|traditional cigarette|measurement hemodynamic parameters smoking traditional cigarette
45650829|NCT03039257|Dietary Supplement|Vitamin A|Dose administration will start with 2500 IU/kg with maximum dose of 250,000 IU orally.
45929061|NCT03733886|Device|Burst SCS (Abbott Proclaim IPG and single lead Abbott Octrode at level Th9/10)|Burst SCS implies high frequency SCS treatment in intermittent packets with stimulation below detection level. Abbott BurstDR at default setting: Pulse width 1000 microseconds, frequency 500 Hz/40 Hz, continuous stimulation (no cycling). Pulse amplitude at maximum 60% of sensory threshold
45929062|NCT00031005|Procedure|modified stem cell transplant|
45929063|NCT03959267|Behavioral|Telephone Genetic Counseling|A genetic counselor fluent in Spanish (see letter of support) will conduct the TGC. The TGC intervention consists of two sessions. Prior to the sessions the investigators will mail participants the education materials with information to be reviewed prior to the genetic counseling session and a set of visual aids that the counselor will refer to during the session to facilitate the understanding of the information conveyed in the session.
45929064|NCT03715205|Drug|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
45929065|NCT00031044|Drug|Enfuvirtide|
45929066|NCT00031044|Drug|Amdoxovir|
45929067|NCT03698006|Drug|Ropivacaine 0.5% Injectable Solution|Tibial nerve block with 10ml of Ropivacaine 0.5%
45929068|NCT03698006|Drug|Ropivacaine 0.2% Injectable Solution|Infiltration with 25ml of Ropivacaine 0.2% in the posterior knee capsule
45800103|NCT01847131|Drug|oxymetazoline|0.05% Oxymetazoline nasal sprays were commercially available.
45929069|NCT00031083|Genetic|Interferon-beta|
45929070|NCT03559985|Drug|paracetamol|"Period 1 (D1 to D7): 500 mg (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.~Wash-out period (D8 to D14): patients should not take paracetamol during this week.~Period 2 (D15 to D21): 500 mg per dose (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day."
45929071|NCT03559985|Other|Placebo comparator|"Period 1 (D1 to D7): 500 mg (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.~Wash-out period (D8 to D14): patients should not take paracetamol during this week.~Period 2 (D15 to D21): 500 mg per dose (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day."
45929072|NCT04711707|Other|Community navigator|All patients who consent to participate in the study will complete a pediatric social history tool to identify social needs. The intervention group will receive support through a community navigator to guide and understand appropriate services for their specific needs. This arm will receive guidance and bimonthly check-ins.
45929073|NCT04711707|Other|Self-Navigation|The control group will receive an electronic or paper copy of community resources that address the identified social needs.
45650830|NCT04838093|Diagnostic Test|PCR|"Nasal or pharyngeal respiratory swabs were routinely taken of each patient admitted at our departments and repeated regularly at 48 h intervals during the inpatient stay.~In the HCP cohort testing for SARS-CoV-2 RNA was performed, on a weekly basis, at the Department of Laboratory Medicine, Medical University of Vienna, Austria, using real-time polymerase chain reaction (RT-PCR). Comparability of the results of all test methods used was confirmed by participation in international quality control ring trials."
45650831|NCT04859309|Behavioral|ActiveHip+ mobile application|The mobile application with the educational and multidisciplinary tele-rehabilitation program.
45800104|NCT01847131|Drug|Placebo nasal spray|Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.
45800105|NCT02285010|Drug|placebo|Placebo in capsule is prescribed to the patient 60 min prior to the surgery. Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed.
45929074|NCT03553394|Drug|Ringer's Acetate|Will receive a fluid bolus immediately (Ringer's Acetate 5 mls/kg bw) if oliguric/anuric for two consecutive hours
45929075|NCT04712448|Diagnostic Test|Anti-COVID test|No intervention is foreseen by the protocol
45929076|NCT00392873|Behavioral|EAMD+Calories|During the 12 month intervention, volunteers in the Increased calorie intake group will follow a modified dietary plan designed to achieve and maintain a target level of 20-30% above their previously determined baseline, in an effort to achieve a chronic energy surplus of +20-30% over their baseline energy requirements.
45929077|NCT04711863|Drug|Fluvoxamine|Up to 200 mg per day as tolerated until discharge from community treatment center or for approximately 10 days
45929078|NCT04711863|Drug|Placebo|Up to 200 mg per day as tolerated until discharge from community treatment center or for approximately 10 days
45929079|NCT00392912|Drug|AndroGel (Solvay Pharmaceuticals)|Testosterone Replacement Therapy: AndroGel 1% 5g packets (Solvay Pharmaceuticals). Initial dosage: 5g daily (1 packet). Patients who do not achieve eugonadal levels of 400-600 mg/dL within 2 weeks will be raised to 10g daily.
46072493|NCT04196972|Other|Waiting List|Placed on wait-list
46072494|NCT04180696|Device|aCRT ON|CRT device with AdaptivCRT enabled
45650832|NCT04859309|Procedure|Standard care in a hip fracture|The participants of this group will receive the standard treatment for a hip fracture in the Andalusian healthcare system.
45650833|NCT04859543|Device|FoundationOneHeme|Tumor tissue obtained during standard surgery will be subsequently examined histopathologically and the content of cancer cells will be determined. Broad molecular profiling of the tumor; with potential results finding such molecular changes, for which the specific targeted anti-tumor treatment will be performed.
45929080|NCT04712058|Drug|Bictegravir / Emtricitabine / Tenofovir Alafenamide Oral Tablet [Biktarvy]|Biktarvy will be administered on the same day of diagnosis. The daily dosing will be continued for 48 weeks.
45929081|NCT00393107|Drug|rituximab|
45800106|NCT02285010|Drug|Pregabalin|"Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.~Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed."
45929082|NCT00393107|Drug|rituximab,fludarabine, cyclophosphamide|
45929083|NCT04711668|Drug|Ketamine|intraoperative ketamine bolus and infusion
45929084|NCT04711668|Drug|Lidocain|intraoperative lidocain bolus and infusion
45929085|NCT04711668|Drug|Saline|intraoperative saline bolus and infusion
45800107|NCT02617667|Drug|Cyclosporine A|topical ocular, eye drops
45929086|NCT03526094|Other|Flavanols-capsules|Capsules containing 456 mg cocoa flavanols and 315 g of milk (1% fat)
45929087|NCT03526094|Other|Flavanol-banana blend|Fruit blend prepared by mixing 177 g ripe, frozen bananas, 240 g almond milk and a chocolate flavored powder containing 626 mg cocoa flavanols
45650834|NCT04789967|Behavioral|Guided Imagery|Individualized Guided Imagery (GI) technique, an alternative type of relaxation therapy. The content of GI usually includes scenery, places or any image projected to the mind. By using information generated, participants are guided to create a place in their mind using their senses of touch, sound, smell, sight and taste.
45650835|NCT04789967|Behavioral|Progressive Muscle Relaxation|Progressive muscle relaxation (PMR) therapy works by progressively relaxing and tensing the muscle groups throughout the entire body. Each muscle group will be tensed for about 5 seconds. If there's any pain or discomfort at any of the targeted areas, participants were told to omit that particular step. Constant purposeful deep breathing was instructed throughout the session especially in between changes of muscle.
45650836|NCT04789967|Other|Educational Audiobook|Participants in the control group will receive an audiobook that targets to educate patients regarding gut-brain disorders, functional gastrointestinal disorders, causes of functional abdominal bloating, and treatment modalities available. Relaxing musical background will be added to facilitate the delivery.
45650837|NCT04833569|Biological|ICG-PDT|An 810 nm diode laser (A.R.C. laser GmbH, Nurnberg, Germany) with a power of 200 mW (continuous mode) and total energy of 4 J was used to excite the ICG by starting from the papilla for 30 s followed by the insertion inside the peri-implant pocket depth for 10 s from both buccal and lingual side moving to coronal direction. The treatment was applied according to the manufacturer's recommendation. The PDT was performed by a single operator in all test patients
45650838|NCT04833569|Device|peri-implant mechanical debridement|The peri-implant mechanical debridement was done with the help of ultrasonic carbon tip (Vector, Durr Dental, Bietigheim-Bissingen, Germany).
45650839|NCT04837781|Procedure|Micro-osteoperforation|Micro-osteoperforation Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental side before canine retraction. Three MOPs were placed distal to canine on experimental sides in all group.
45800108|NCT02617667|Drug|Placebo|topical ocular, eye drops
45800109|NCT05154773|Behavioral|Kidney donation and transplant information made easy|Same as arm description
45800110|NCT03023449|Drug|Nitric Oxide|Inhaled Nitric Oxide gas
45800111|NCT05533411|Drug|Donanemab|Administered IV.
45800112|NCT05533411|Drug|Placebo|Administered IV.
45800113|NCT05513053|Biological|Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH|Pharmaceutical form: Solution for injection Route of administration: intramuscular
45800114|NCT05525195|Procedure|Congenital cardiac surgery|All children who underwent congenital cardiac surgery with cardiopulmonary bypass between 2008 and 2018
45800115|NCT04742855|Dietary Supplement|Probiotics|Study product is packaged as powders in a sachet. Participants and their parents will be instructed to dissolve the powder in water or milk, and to drink it in the morning and/or evening.
45800116|NCT01848067|Drug|Alisertib|Given PO
45929088|NCT03526094|Other|Flavanol-high protein drink|Drink prepared by mixing 225 mL of a chocolate flavored high protein dairy drink with a CF powder containing 533 mg cocoa flavanols
45929089|NCT03526094|Other|Flavanol-berry blend|Flavanol-berry blend prepared by mixing 120 g almond milk, 70 g water, 95 g yogurt, 50 g each strawberries, blueberries, blackberries, raspberries, 105 g crushed ice and a fruit-flavored powder containing 561 mg cocoa flavanols
45929090|NCT03526094|Other|Flavanol-sports drink|Drink prepared by mixing 488 g of a sports drink with a CF powder containing 533 mg cocoa flavanols
45929091|NCT03526094|Other|Flavanol-peanut butter toast|Prepared by mixing 32 g peanut butter with a chocolate flavored powder containing 602 mg cocoa flavanols and spread on 1 slice toasted bread (50 g) and 50 g sliced strawberries
45929092|NCT03526094|Other|Flavanol-oats|Prepared by mixing 40 g quick oats with 237 g boiling water and combined with a chocolate flavored powder containing 602 mg cocoa flavanols
45929093|NCT03526094|Other|Flavanol-yogurt|Prepared by 227 g yogurt (0% fat) mixed with a fruit-flavored powder containing 561 mg cocoa flavanols
45929094|NCT03526094|Other|II- Flavanol drink|Drink prepared by mixing 240 g almond milk with a chocolate flavored powder containing 626 mg cocoa flavanols
45929095|NCT03526094|Other|II- Flavanol drink + banana blend|Drink 1 (Flavanol drink): prepared by mixing 120 g almond milk with 626 mg cocoa flavanols Drink 2 (Fruit blend): prepared by mixing 120 g almond milk blended with 177 g ripe, frozen bananas
45800117|NCT01848067|Drug|Abiraterone acetate|Given PO
45929096|NCT00031122|Other|No Intervention|There is no intervention in this study
45929097|NCT03509909|Behavioral|Hatha yoga|Manualized hatha yoga
45929098|NCT03509909|Behavioral|Supportive physical activity|Manualized stretching and strengthening
45929099|NCT00031161|Drug|Nitisinone (NTBC)|
45929100|NCT00031161|Drug|Dichloroacetate|
45929101|NCT00031161|Behavioral|Low-tyrosin diet|
45929102|NCT03465449|Behavioral|CKD-EDU|Palliative Care based coaching intervention for support with dialysis-related decision making.
45929103|NCT03465449|Other|usual care|Nephrologist based usual care
45929104|NCT03430973|Behavioral|Videos|Videos depicting various aggressive driving and road rage behaviors.
46072495|NCT04180696|Device|aCRT OFF|CRT device with AdaptivCRT disabled
45800118|NCT01848067|Drug|Prednisone|Given PO
45800119|NCT05731973|Procedure|Intercostal nerve cryoablation|Intercostal nerve cryoablation is applied during Nuss procedure.
45929105|NCT03430973|Behavioral|Bumper stickers|Bumper stickers hypothesized to increase or decrease aggressive driving.
45929106|NCT03430973|Behavioral|Alcohol-related cues|Case of beer or water on passenger seat.
45800120|NCT05731973|Drug|Thoracic epidural analgesia (continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml))|Thoracic epidural is placed prior to Nuss procedure
45929107|NCT03430973|Behavioral|Music|Lyrics and tempo of music will be manipulated to increase or decrease aggressive driving.
45650840|NCT03038009|Drug|Pantoprazole|Pantoprazole (40mg qd) will be concomitant used with DAPT
45650841|NCT04334057|Drug|Turoctocog alfa pegol|Patients will be treated with commercially available Esperoct® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Esperoct® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
45929108|NCT03430973|Behavioral|Roadside vegetation|The roadside will contain trash to increase aggressive driving, or vegetation to decrease aggressive driving. There is also a control group.
45929109|NCT03430973|Behavioral|Video game|Participants will play a racing or neutral video game before driving in the simulator.
45929110|NCT00031278|Drug|CPG 7909|Each 0.01 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
45929111|NCT00031278|Drug|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
45929112|NCT00031278|Drug|CPG 7909|Each 0.04 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
45929113|NCT00031278|Drug|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
45929114|NCT00031278|Drug|CPG 7909|Each 0.16 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
45929115|NCT00031278|Drug|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
45929116|NCT00031278|Drug|CPG 7909|Each 0.32 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
45929117|NCT00031278|Drug|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
45929118|NCT03271814|Biological|LPS|0.6 by/kg LPS single dose iv
45929119|NCT03271814|Other|Placebo|Sterile Water
45650842|NCT03466801|Drug|Prednisone|Prednisone was taken for oral administration with dosage of 1mg/kg/d (maximum 60mg/d) by 8 weeks to start.Then reduced Gradually until the end of the experiment.
45650843|NCT03466801|Drug|MP and CTX|Methylprednisolone(MP) was injected for 3 day(if weight >60kg ,500mg/d<60kg,300mg/d ), methylprednisolone was 0.4mg/kg/d for 27 day.Cyclophosphamide(CTX) orally was 100mg/ d for 1 month.And repeated for six months.
45650844|NCT04833725|Device|wearable devices|All patients use wearable devices and IoT technology for information collection and data management. Specifically, we build standards from the analysis of sleep monitoring information, and we form an OSA screening model by applying machine learning algorithms.
45650845|NCT03101605|Other|e-learning teaching module|As described
45929120|NCT03228953|Other|Pharmacogenomic testing|Pharmacogenomic testing is delivered to treating providers of patients with major depressive disorder
45929121|NCT00031317|Drug|Paroxetine|
45929122|NCT00031317|Drug|Clozapine|
46072496|NCT04157335|Biological|Benralizumab 30 mg|"Benralizumab is 30 mg/ml solution for injection in accessorized pre-filled syringe, 1 ml fill volume.~Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48)."
45650846|NCT03101605|Other|Standard teaching method|As described
45650847|NCT04824677|Other|Hospital treatment of COVID disease|Hospital treatment of COVID disease
45650848|NCT05069779|Drug|Diazepam|Oral administration of 10 mg of diazepam
45650849|NCT04837469|Procedure|fissure sealant application|fissure sealants were placed after differnt adhesive strategies used
45800121|NCT05731973|Drug|Intercostal nerve block (single shot bupivacaine (1.25 mg/ml))|Single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks are placed just anterior to the side of the cryoablation.
45800122|NCT05731973|Drug|Opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours, as needed)|Opioids
45800123|NCT05502367|Drug|ABI-2280|Vaginal Tablet
45800124|NCT05068349|Drug|Butylphthalide|Butylphthalide sodium chloride injection 25mg, 2 times a day, 7-14 days, followed by 0.2g butylphthalide soft capsules, 3 times a day, 76-83 days, a total of 90 days.
45800125|NCT05515445|Drug|Chiglitazar|Oral single dose 48 mg
45800126|NCT05066789|Device|Type of stent|1:1 randomization to biodegradable polymer DES (Orsiro Mission) and polymer-free DCS (Biofreedom)
45800127|NCT05066789|Drug|Duration of DAPT|1:1 randomization to 1-month DAPT thereafter prasugrel monotherapy and 12-month DAPT (aspirin + prasugrel)
45929123|NCT03152279|Diagnostic Test|Mucosal Impedance Catheter|During routine endoscopy, consented study participants will have a mucosal impedance catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant.
45929124|NCT03152279|Diagnostic Test|Blood sample|At time of endoscopy, subjects with initial positive CeD serology will have a blood sample taken for any missing CeD serologies and intestinal fatty acid-binding protein (IFABP). This will be done at time of IV initiation as to avoid any additional venipuncture.
45929125|NCT00396045|Drug|Revlimid (CC-5013)|
45929126|NCT03152240|Other|Non intervention|Non intervention
45929127|NCT00396240|Drug|Rosuvastatin|
45929128|NCT00396240|Procedure|Initiatives to improve compliance|
45929129|NCT03152201|Diagnostic Test|electrophysiological signal|trasmit the electrophysiological signals to the neurosurgeon through the hardware
45929130|NCT00031395|Drug|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults.
46072497|NCT04157335|Biological|Matched placebo|"Matching placebo solution for injection in accessorized pre-filled syringe. 1 ml fill volume.~Matching placebo subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48)."
45800128|NCT04984421|Behavioral|Healthy School Start|The Healthy School Start program is a universal 4-component family support program for children starting school (5-7 years of age) promoting healthy dietary habits and physical activity in the home environment to prevent childhood obesity and parents' risk of developing type 2 diabetes. It is targeting both children and parents.
45800129|NCT01848847|Procedure|Hysteroscopy|
46072498|NCT04119804|Diagnostic Test|cellular neural networks-genetic algorithm|Cellular neural networks-genetic algorithm applied to conventional radiographs of hip implants with a well-established diagnosis of loosening. The study is not intended to use a software without a CE mark as a medical device, or to use the software as a tool to diagnose or prevent human disease, according to Directive 93/42 / European Economic Community. The study will evaluate if the software, properly calibrated, is able to recognize with adequate accuracy infections already diagnosed with validated methods.
46072499|NCT04115774|Drug|bisphosphonates|Since this is an observational study, the investigators collect general information on bisphosphonates treatment/impact
46072500|NCT04105699|Device|Blood sampling|Daily blood sample which will be taken for the PSP measurement using the abioSCOPE as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein [CRP] and Procalcitonin [PCT]).
46072501|NCT04093557|Other|Orton Score|Significant a priori predictors of poor prep included: male gender, COPD, diabetes with end-organ damage, severe neurologic disease, constipation medication use, and tricyclic antidepressant use. Proprietary web-based weighted scoring model allows screening clinician to predict which bowel prep would be best for patient depending on which risk factors patients have.
45650850|NCT04837625|Other|no interventions|no interventions
46072502|NCT04093557|Other|Typical Standard of Care|Clinician usual practice of prescribing bowel preps to patient
45650851|NCT03251911|Drug|Ivacaftor (VX-770)|of Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction
45650852|NCT04824755|Procedure|Yune Zhao|Yune Zhao did congenital cataract surgeries
45650853|NCT04837391|Device|Near Infrared Spectroscopy (NIRS)|Patients are monitored by near infrared spectroscopy before anesthesia induction until end of the operation. Graphical presentation of cerebral oxygenation during surgery evaluated by INVOS Analytics Tool Version 1.2.
45650854|NCT04837391|Diagnostic Test|Blood sample|Blood samples are obtained before and after surgery. S-100, Neuron specific enolase (NSE), Interleukin-6 (IL-6), High Mobility Group Box Protein (HMGB-1) are going to be studied by ELISA method after data collection process end.
45650855|NCT04837391|Diagnostic Test|Addenbrooke Cognitive Examination III (ACE-III)|ACE-III is administered to study participants one day before surgery, 1 week after surgery, and three months after surgery to diagnose postoperative cognitive dysfunction.
45650856|NCT04837391|Diagnostic Test|Confusion Assessment Method|Confusion Assessment Method is administered to study participants in postoperative recovery room to diagnose postoperative delirium.
45650857|NCT02643355|Drug|Olanzapine|
45650858|NCT02643355|Drug|Clonidine|
45650859|NCT03036527|Procedure|Activity-based locomotor training|The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stepping (IRB 07.0066).
45650860|NCT03036527|Procedure|Activity-based stand training|The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stand only program (07.0268). The stand only intervention may also be provided as part of this study.
45650861|NCT03036527|Procedure|Activity-based upper arm ergometry|The non-weight bearing activity-based upper arm ergometry intervention will be provided via a standardized arm crank therapy provided within this study.
45650862|NCT02604017|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
45650863|NCT03036605|Drug|Bupivacaine|%0.5 bupivacaine
45650864|NCT03036605|Drug|Dexamethasone|8 mg Dexamethasone
45800130|NCT05731661|Other|Day hospitalization in support care with meeting with support care professionals and coordination of actions by the advanced practice nurse|During this day hospitalization, patients will meet with different specialized professionals depending on the support care needs identified.
45800131|NCT05731661|Other|Delivery of useful information according to support care needs, concerning support care professionals in the city|Delivery of useful information according to support care needs, concerning support care professionals in the city
45800132|NCT05731661|Other|Delivery of a personalized post-cancer plan|Delivery of a personalized post-cancer plan
46072503|NCT04083170|Drug|Fludarabine|Given IV
45650865|NCT04837079|Other|Clinical observational study|Clinical observational study
45650866|NCT03099967|Device|Transcatheter closure of an atrial septal defect or patent foramen ovale.|In a prospective study in adults troponin T (TnT) serum concentrations were determined before and the day after transcatheter closure of an atrial septal defect (ASD) or patent foramen ovale (PFO).
45650867|NCT03098875|Drug|Sevoflurane|General anesthesia using sevoflurane as a hypnotic agent
45650868|NCT03098875|Drug|Propofol|General anesthesia using propofol as a hypnotic agent
45650869|NCT03098875|Drug|Remifentanil|General anesthesia using remifentanil as an analgesic.
45650870|NCT04837157|Device|Exoskeleton rehabilitation|The participants will perform physical therapy with the ATLSA2030 device, for 90 minutes per session.
45650871|NCT03099031|Drug|Tinzaparin|Subcutaneous injection of 175 IU/kg once daily for 6 months
45650872|NCT03037151|Drug|Grazaoprevir/Elbasavir|treatment naive
45650873|NCT03037151|Drug|Grazaoprevir/Elbasavir/RBV|treatment experienced
45653222|NCT05076123|Other|Modified Constraint Induced Therapy and Threshold Electrical Stimulation|M-CIMT emphasizes massed practice with the affected upper limb with restraining unaffected limb by a mitt. Threshold electrical stimulation is based on low-intensity (<100 Hz) and long-duration current and is applied with superficial electrodes.
45800133|NCT05464199|Other|Neurofeedback training|"Self-administered neurofeedback treatment using headset and tablet-based application, designed with the purpose of alleviating chronic pain by providing the user with feedback of, and allowing them to modulate, their own brain EEG signals associated with activity in brain networks related to pain perception and pain modulation.~Visual feedback will be provided onscreen representing the participant's real time EEG activity measured by the headset. Each session will be split into five blocks of five minutes each, with a one-minute rest period in between, in order to avoid fatigue and allow the participant to move around and adjust their position. After each rest block, participants will be asked if they are ready to proceed and when ready, the next block can be started. After the end of the session (5 blocks) the participant will then be asked to perform a post-session eyes-open EEG recording, similar to the eyes-open baseline taken at the start of the session."
45929131|NCT00031395|Drug|methylphenidate|MPH is FDA-approved for the treatment of ADHD symptoms in children.
45929132|NCT00031395|Other|placebo|an inactive substance
45929133|NCT03152162|Device|iTotal PS KRS|Total knee arthroplasty for treatment of osteoarthritis
45929134|NCT00031434|Drug|Valganciclovir|Valganciclovir is a mono-valyl ester pro-drug of ganciclovir, which is rapidly converted to ganciclovir on absorption. Valganciclovir oral syrup formulation for administration will be provided as a 15g powder blend containing 3g valganciclovir base, for constitution in 120 mL amber glass bottles. The beginning oral valganciclovir dose under investigation is 14 mg/kg. The dose of oral valganciclovir syrup will be adjusted for the baby's weight and renal function. Weights upon which dosage will be adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35.
45929135|NCT00031434|Drug|Ganciclovir|Ganciclovir for intravenous infusion will be provided as sterile, lyophilized powder in sealed vials containing 500 mg ganciclovir for re-constitution. The dose of intravenous ganciclovir is 6 mg/kg. Intravenous ganciclovir will be adjusted for the baby's weight and renal function. Weights upon which dosage adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35. Each dose of intravenous ganciclovir should be given over 1 hour using an intravenous pump.
45929136|NCT03152123|Drug|Pitolisant|Pitolisant 40 mg or 240 mg (tablets over-capsuled)
45929137|NCT03152123|Drug|Placebos|tablets over-capsuled
45929138|NCT03152123|Drug|Phentermine|Phentermine 60 mg (capsule over-capsuled)
46072504|NCT04083170|Drug|Cyclophosphamide|Given IV
46072505|NCT04083170|Drug|Thiotepa|Given IV
46072506|NCT04083170|Radiation|Total-Body Irradiation|Undergo TBI
45800134|NCT04621279|Procedure|Normothermia|Usual care for first 72 hours for neonates with mild encephalopathy maintaining core temperature (36.5°C ± 1 C).
45800135|NCT04621279|Procedure|Whole body therapeutic hypothermia|Whole-body therapeutic hypothermia (33.5°C ± 0.5°C) for 72 hours began by 6 hours of age for neonates with mild encephalopathy per site standard of care practice.
46072507|NCT04083170|Procedure|Umbilical Cord Blood Transplantation|Undergo UCBT
45650874|NCT03101059|Procedure|Non invasive ventilation - Continuous Positive Airway Pressure|To identify, through bronchoscopy, the prevalence of collapse and whether it is possible to counteract an optimum pressure generated by NIV with CPAP that reduces tracheal and bronchial collapse in patients with SMK; To study the frequency of OSAS in patients with MKS ; Record reversal of collapse with CPAP using chest tomography; To identify the impact of CPAP on the distribution of pulmonary ventilation through the analysis of electrical impedance tomography.
45650875|NCT03037229|Device|Smartphone ECG|
45650876|NCT03037229|Device|Standard 12-lead ECG|
46072508|NCT04083170|Biological|Dilanubicel|Given IV
45929139|NCT00031473|Drug|Virazole (Ribavirin) Inhalation Solution|
46072509|NCT04066374|Device|Peripheral Nerve Stimulation|Medtronic Intellis Spinal Cord Stimulation Device to be implanted in thoracic cavity to treat postoperative acute pain.
46072510|NCT04054154|Device|Shear Wave Elastography|Undergo shear wave elastography
46072511|NCT04054154|Procedure|Tumor Interstitial Fluid Pressure Measurement|Undergo tumor pressure measurement
45650877|NCT03100981|Behavioral|Internet-delivered Mindfulness-Based Cognitive Therapy|"Internet-delivered Mindfulness-Based Cognitive Therapy is a trainer-assisted course based on the manual for Mindfulness-Based Cognitive Therapy for depression. The course consists of 8 modules, one per week, for 8 weeks and one additional week for flexibility for the participants. In total 9 weeks with weekly written contact to the personal instructor.~Each module has an overall theme with written theory, approximately 45 minutes of daily mindfulness practice and other daily assignments with the purpose of strengthening awareness in the everyday life."
45650878|NCT03100981|Behavioral|Waitlist control|"Participants in the control arm of the study will receive treatment as usual, which means that they are not offered interventions targeting psycho-social distress but also not prevented from participating in or seeking other psycho-social treatment during the course of the study.~After the 6-months follow-up time has passed participants will get the opportunity to participate in 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy, if the intervention is found efficient."
45650879|NCT04785287|Biological|Anti-CTLA4 Monoclonal Antibody BMS-986218|Given IV
45929140|NCT00031629|Drug|Docetaxel|Given IV
45929141|NCT00031629|Biological|Filgrastim|Given SC
45929142|NCT00031629|Drug|Gemcitabine Hydrochloride|Given IV
45929143|NCT00031629|Biological|Pegfilgrastim|Given IV
45929144|NCT03152084|Drug|Dapagliflozin|The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.
45929145|NCT02971449|Device|Amazon Fire Tablet|A generic amazon fire tablet with pre-loaded instructional videos
45929146|NCT02971449|Other|ICCM Traditional Trainins|Standard, Didactic VHT Training intervention as an active comparator
46072512|NCT04025359|Drug|Dronabinol|Dronabinol 2.5 mg
46072513|NCT04025359|Drug|Dronabinol|Dronabinol 5 mg
46072514|NCT04025359|Drug|Placebo|Placebo
46072515|NCT04009499|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
45650880|NCT04785287|Biological|Nivolumab|Given IV
45650881|NCT04785287|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45650882|NCT03036371|Behavioral|High Intensity Interval Exercise|6 week at-home aerobic exercise protocol
45800136|NCT05452577|Drug|Suanzaoren Decoction and Huanglian Wendan Decoction|Twice daily. Chinese herbal medicine includes: includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.
45929147|NCT03152045|Behavioral|Communication Intervention|In this study, Investigators are testing the feasibility, acceptability, and preliminary efficacy of a systems intervention that asks adolescents to report their risk behaviors before their encounter. Both clinicians and patients will receive a Feedback Guide that gives them tips on effective ways to communicate about these behaviors.
45929148|NCT03152006|Other|ACT|Coordinated, graduated transition which includes an early introduction to the adult clinician during the PAPA pre-transfer period, a peer-facilitated organized support group aimed at improving transition readiness and addressing critical psychosocial skills including self-efficacy and locus of control and a case management team including a patient advocate who coordinates the transfer between pediatric and adult care teams.
45929149|NCT00031668|Radiation|radiation therapy|
45929150|NCT03151928|Diagnostic Test|BDMax Vaginal Panel|The tests will be used to compare results between clinician diagnosis/routine care testing and the above interventions
45929151|NCT00031707|Dietary Supplement|eicosapentaenoic acid|
45929152|NCT00031707|Drug|megestrol acetate|
45929153|NCT00031707|Other|placebo|
45450926|NCT05263414|Device|tVNS|tVNS allows the non-invasive activation of the Vagus Nerve by delivering electrical pulses to the sensory afferent fibers of the auricular, thick-myelinated, branch of the vagus nerve in the outer ear. TVNS seems to engage the same neural pathways of invasive VNS methods and may provide a novel, bottom-up NIBS method to promote GABA release. tVNS will be performed by using a CE marked tVNS device. It consists in a programmable stimulation unit connected to two titan ear electrodes that are mounted on a gel frame, allowing to generate and transfer electric impulses from the stimulation unit to the surface of the skin, where the electrodes are applied.
45650883|NCT03101215|Dietary Supplement|phosphorus|adding of phosphorus to high carbohydrate meal
45650884|NCT04824287|Other|pelvic floor muscle exercise|pelvic floor muscle exercises training from the researcher using the Roy Adaptation Model in addition to routine discharge training Face-to-face training was given to the individuals in the experimental group on the day before the operation, on the second and third postoperative days, and on the day of discharge. The training continued with phone calls at the first, second and third weeks and the first, second, third, and sixth months after the surgery Patients practiced exercises 6 month after surgery
45653223|NCT05611307|Diagnostic Test|Lipid profile|Advanced lipid profile
45653224|NCT05611307|Diagnostic Test|Coronary artery assessment|Coronary artery assessment via CT scans
45653225|NCT05611307|Diagnostic Test|Hormone levels for hypogonadism|Hormone levels for hypogonadism
45800137|NCT05452577|Drug|Estazolam 1Mg Tab|1mg tablet once daily
45800138|NCT04591717|Biological|hAd5-S-Fusion+N-ETSD vaccine|The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
45800139|NCT05464615|Drug|Amoxicillin|We will initially administer 1/5th (50 mg) of the goal dose of amoxicillin (250 mg) by oral route following the procedure outlined below. The total goal dose to be administered is amoxicillin 250 mg (5 ml of 250 mg/5 ml). These were numbers that came about for significance in relabeling penicillin allergies in patients in previous studies.
45800140|NCT05731583|Device|Home pulse oximetry monitoring|A digital application and a wireless oximeter were provided to both groups. Oxygen saturation, heart rate and (optional) body temperature were monitored at least twice a day.
45929154|NCT03151889|Device|TENS|TENS Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux); TENS treatments (50Hz / pulse duration of 250 ms / high intensities tolerated / continuously for 20 minutes / 2 sessions a week / 4 weeks / total of the 8 TENS sessions) and Post-test evaluations.
45929155|NCT00031746|Dietary Supplement|soy protein isolate|25 mg daily
45929156|NCT00031746|Dietary Supplement|casein proteins|25 mg daily
45929157|NCT03151850|Other|ulcerative colitis|We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.
45653226|NCT05473533|Drug|Placebo|Placebo; formulated as solution for inhalation without active substance.
45929158|NCT03151850|Other|Control|We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.
45929159|NCT00031785|Drug|megestrol acetate|
45929160|NCT00031785|Radiation|radiation therapy|
45929161|NCT03151772|Drug|Disulfiram|200 mg disulfiram two times daily and 2,5 mg copper once daily taken preoperatively
45929162|NCT03151772|Drug|Metformin|Metformin 850 mg x 3 taken preoperatively
45929163|NCT02971644|Device|cobalt alloy pedicle screw implantation|The patients with severe kyphosis deformity undergo cobalt alloy pedicle screw implantation.
45929164|NCT03151733|Procedure|single incision laparoscopic surgery|Patients undergo single incision laparoscopic surgery
45929165|NCT03151733|Procedure|conventional laparoscopic surgery|Patients undergo conventional laparoscopic surgery
45929166|NCT00031824|Drug|cyclosporine|
45929167|NCT00031824|Drug|hydroxychloroquine|
45653227|NCT05473533|Drug|PRS-220|PRS-220; formulated as solution for inhalation.
45929168|NCT00031824|Drug|prednisone|
45929169|NCT00031824|Drug|tacrolimus|
45929170|NCT03151655|Behavioral|MATTeRS Video|Narrative-based video intervention and accompanying workbook
45929171|NCT03151655|Behavioral|Didactic Video|Education only video
45929172|NCT00031863|Drug|rofecoxib|
45929173|NCT00031863|Procedure|adjuvant therapy|
45929174|NCT03151616|Other|anticholinergic risk scale|Risk summation scale for grading and studying anticholinergic medication exposure
45929175|NCT00031902|Biological|bleomycin sulfate|
45929176|NCT00031902|Biological|rituximab|
45653228|NCT01656759|Drug|Evicel Fibrin Spray|10cc syringe dose, once at the end of TKA
45653229|NCT04234737|Behavioral|Hypnotherapy|Hypnotherapy
45929177|NCT00031902|Drug|prednisolone|
45929178|NCT00031902|Drug|vincristine sulfate|
45800141|NCT05460793|Device|Minimally invasive endoscopy-guided surgery|The devices allowed into the trial, are minimally invasive neuronavigation integrated endoscopy-guided devices that are CE approved and admissible by the steering committee. Currently, only the Artemis Neuro Evacuation Device (Penumbra Inc, Alameda, California, USA) is available and CE approved.
45929179|NCT03151577|Procedure|XEN® Gel Stent implantation|Minimally invasive glaucoma surgery (MIGS) which consists of implanting a XEN® Gel Stent in the irido-corneal angle of the eye to drain the aqueous humour in the sub-conjunctival space to lower the IOP.
45929180|NCT00031941|Drug|lenalidomide|
45929181|NCT03151538|Behavioral|Exercise Training Mixed With Play|To assess effects of training program which includes mixed exercises with playing.Study included 90 pre-school children who suffer from pes planus and increased femoral anteversion angle. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak Index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used. CSI measurements were positive correlation with severity of pes planus.
45800142|NCT05731427|Other|Pseudomonas aeruginosa colonization infection|With or without airway Pseudomonas aeruginosa colonization infection
45929182|NCT03151538|Other|Controlled|First and last measurements will be done. There will be no intervention. Study will include 30 healthy pre-school children. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used.
45650885|NCT03101137|Drug|Caudal block with dexmedetomedine|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexmedetomidine 1 μg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
45650886|NCT03101137|Drug|Caudal dexamethasone|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexamethasone 0.1mg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
45653230|NCT05053815|Other|Pharmacogenomic Testing|Pharmacogenomic testing is done via buccal swab. As this study is retrospective, data from PGx testing has already been collected as a part of routine care.
45800143|NCT05731427|Drug|Macrolides|Before or after 6 months of treatment with macrolides for patients with bronchiectasis
45800144|NCT01850485|Device|microcirculation by SDF and NIRS, in 33 and 36 degrees|at baseline, after 12 and 24 hours in both arms
45800145|NCT00365651|Procedure|Youth Soccer|
45653231|NCT04998747|Drug|AMG 701|AMG 701 will be administered as SC or intravenous injection.
45653232|NCT04998747|Drug|AMG 701|AMG 701 will be administered as SC injection.
45800146|NCT00364871|Drug|naltrexone and bupropion SR|naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
45800147|NCT00551161|Drug|memantine|24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 10 mg orally b.i.d., in addition to their ongoing stable cholinesterase inhibitor treatment
45800148|NCT05438849|Behavioral|Mobile Health Application focused on behavioral treatments to treat urinary incontinence|Mobile health application for cell phones and computers that delivers evidence-based behavioral treatment for urinary incontinence, specifically tailored to women Veterans
45929183|NCT00031980|Drug|cyclosporine|
45929184|NCT03151499|Drug|BI 409306|Reference and Test Treatment
45800149|NCT05438849|Combination Product|Practice Facilitation|The toolkit has 4 components: (1) Practice Facilitation Visits, (2) Mobile-health or mHealth Application Training (MAT) training, (3) Access and education on the Data Dashboard, and (4) Health information technology (HIT) assistance.
45800150|NCT04660019|Other|the scalp and ear acupuncture|Some stimulation areas with outstanding effects on certain symptoms are selected for acupuncture
45800151|NCT04660019|Other|sham acupuncture|Some stimulation areas with outstanding effects on certain symptoms are selected for acupuncture, and change acupuncture to auricular points sticker.
45800152|NCT05429177|Drug|QY101 ointment or vehicle|QY101 ointment or vehicl topical applied to skin
45800153|NCT02277925|Other|Polytetrafluoroethylene|Suture used to attach mesh during sacral colpopexy surgery
45800154|NCT02277925|Other|Polydioxanone|Suture used to attach mesh during sacral colpopexy surgery
45800155|NCT02988037|Behavioral|A-DBT-A|Adapted Dialectical Behaviour Therapy for Adolescents
45800156|NCT01851655|Behavioral|Plyometric Exercise|Treatment sessions include a combination of running, jumping and agility activities (plyometric exercise). Each rehabilitation session will also include an abbreviated, standardized program of lower extremity strengthening (leg press, machine squats, knee extensions; 3 sets x 10 repetitions each), flexibility (standing gastrocnemius and quadriceps stretch, hamstrings stretch in long-sitting; 2 x 30 seconds each) and proprioception (standing on foam and a tilt board; 3 x 30 seconds each).
45800157|NCT05408663|Drug|EXT608|EXT608 is an investigational drug administered via subcutaneous injection
45800158|NCT05408663|Other|Placebo|matching placebo administered via subcutaneous injection
45800159|NCT05442151|Drug|PET/CT ([F-18]FAPI-74)|PET/CT using [18F] FAPI-74 injection
45800160|NCT00365729|Behavioral|Smear and biopsy testing for HPV-types and viral load|Smear and biopsy testing for HPV-types and viral load
45800161|NCT00365807|Behavioral|Positively Fit|12-week group intervention for children with obesity and their parents/caregivers
45650887|NCT03101137|Drug|Control (bupivacaine)|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge hypodermic needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg the control (bupivacaine) 0.25% is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
45800162|NCT00365807|Other|Brief Family Intervention (Primarily education)|3 hours of contact with registered dietician for education and nutritional counseling.
45800163|NCT00365885|Other|Computer-based clinical decision support.|computer decision support system that generates notifications about sentinel health events and communicates this information via electronic mail to care managers, feedback reports to clinical managers, and letters to patients
45929185|NCT03151499|Drug|Rifampicin|Test Treatment
45929186|NCT00032019|Biological|filgrastim|Cycle 1: 300 ug (BW < = 70 kg) or 480ug (BW >70 kg) sub Q injection Day 6 until ANC > 5000/uL after nadir counts Subsequent cycle dosages based on previous cycle toxicity or Day 1 Tx toxicity
45800164|NCT04741373|Dietary Supplement|oral nutritional supplements|oral nutritional supplements, 400-600kcal/day;
45929187|NCT00032019|Biological|rituximab|375 mg/sq m IV infusion Day 1 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 of tx toxicities
46072516|NCT04008368|Device|CliniMACS CD34 Reagent|Haploidentical recipients will receive CD34-selected cells using Miltenyi CliniMACS CD34+ cell selection kits. The target CD34+ cell dose is at least 10 x 106/kg, and the minimum CD34+ cell dose is 5 x 106/kg. All of the cells collected during the apheresis procedure will be given. The cells will be cryopreserved and stored until the day of transplant.
46072517|NCT04007848|Drug|Cobimetinib|Cobimetinib will be given at the dose of 40 milligrams once a day (21 days/28). Cobimetinib is available as 20 milligrams film-coated tablets
46072518|NCT04007848|Drug|Placebo oral tablet|Placebo will be given at the dose of 40 milligrams once a day (21 days/28). Placebo is available as 20 milligrams film-coated tablets
46072519|NCT04005716|Drug|Tislelizumab, Carboplatin /Cisplatin, Etoposide|Tislelizumab (200 mg IV Q3W) in combination with chemotherapy consisting of etoposide (100 mg/m² IV Days 1-3 of each 21-day cycle) and platinum (cisplatin 75 mg/m² IV Q3W or carboplatin area under the plasma or serum concentration-time curve (AUC) 5 IV Q3W) for 4 cycles. Then maintenance consists of Tislelizumab Q3W and will continue until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of informed consent.
46072520|NCT04005716|Drug|Carboplatin / Cisplatin, Etoposide|Placebo Q3W in combination with chemotherapy consisting of etoposide (100 mg/m² IV Days 1-3 of each 21-day cycle) and platinum (cisplatin 75 mg/m² IV Q3W or carboplatin AUC 5 IV Q3W) for 4 cycles. Then maintenance consists of Placebo Q3W and will continue until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of informed consent.
45650888|NCT04774523|Procedure|Echo-based assessment of the acute hemodynamic effect of the CRT AutoAdapt feature.|"Patients in the AutoAdapt group undergo the echo-based assessment of the acute hemodynamic effect of the CRT AutoAdapt feature.~Three steps must be followed:~Standard AV programming: perform echo for AoVTI assessment.~Echo-optimized AV programming: perform standard echo-based AV-optimization (Ritter method or iterative method, according to routine at investigational site); measure AoVTI at optimized setting.~AutoAdapt optimized programming: The system allows different programming options for the parameter 'Adaptive AV reduction'. The nominal value is 0.7, but it can be modified to different values ranging from 0.5 to 0.9. The AoVTI shall be measured at standard setting of the Adaptive Av reduction parameter, 0.7."
45650889|NCT04774523|Procedure|Echocardiography AV optimization|Patient in the control group undergo the routine echo-based AV-optimization that is usually performed at the investigational site (Ritter method or iterative method). Performance of an additional VV-delay optimization is left to the investigator discretion
45650890|NCT04774523|Procedure|Echocardiography|Echocardiography must be performed at baseline and 12 month Follow Up to collect the LVEF/LVESD(V)/LVEDD(V)
45650891|NCT04774523|Other|Self Assessment Score|Patient must complete the self assessment score at 6 and 12 month Follow Up, that will be use for the Packer Clinical Composite Score
45650892|NCT01881451|Drug|18F-EF5 PET/CT scan|Patients will undergo an investigations 18F-EF5 PET/CT scan.
45650893|NCT01881451|Procedure|Optional biopsy|Patients who choose to participate, will undergo a tissue biopsy.
45800165|NCT04741373|Behavioral|rehabilitation exercise|Aerobic exercise: fixed cycling in rehabilitation center or walking at home, 3-5 times/week, Resistance exercise: lift dumbbell by upper limb, raise legs tying sandbags, 2-3 times/week
45800166|NCT04741373|Other|health education|Establish WeChat group or QQ group or telephone contact, and regularly distribute electronic science pictures or small videos
45800167|NCT01852201|Device|Endovascular Mechanical Thrombectomy|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
45800168|NCT04433195|Diagnostic Test|Xpert MTB/RIF test|Xpert MTB/RIF performed as the initial diagnostic test for the diagnosis of pulmonary TB
45929188|NCT00032019|Drug|cyclophosphamide|750 mg/sq m IV infusion on Day 5 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 treatment toxicities
45929189|NCT00032019|Drug|doxorubicin hydrochloride|10 mg/sq m/day continuous IV infusion on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and Day 1 treatment toxicities
45800169|NCT05363813|Device|M/L-10 Multi-Fire Clip Applier and M/L-10 Clip Cartridge (Multi-Fire Clip System)|Permanent ligation of vessels and ducts as part of minimally invasive laparoscopic surgery.
45929190|NCT00032019|Drug|etoposide|50 mg/sq m/day continuous IV infusion Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
45800170|NCT05731349|Other|2018 Surviving Sepsis Campaign Hour-1 Bundle|"Measure lactate~Obtain blood cultures before administering antibiotics~Administer broad-spectrum antibiotics based on local guidelines~Begin fluid resuscitation with up to 30 mL/kg crystalloid for hypotension or lactate level ≥ 4 mmol/L.~Apply vasopressors if hypotensive during or after fluid resuscitation to maintain the MAP ≥ 65 mm Hg"
45929191|NCT00032019|Drug|prednisone|60 mg/sq m PO bid days 1-5 of ea cycle
45929192|NCT00032019|Drug|vincristine sulfate|0.4 mg/sq m/day continuous IV infusion uncapped on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
45929193|NCT03151460|Drug|Dopamine Agent|"Patients were assessed in two experimental conditions that were performed on different days, with an intersession interval of about one month. In the off condition PD subjects performed the experimental tasks in the morning after 12/18 hours of Dopamine Agent withdrawal. In the on condition they were examined 90-120 minutes after they had taken their first morning dose of levodopa and/or dopamine agonists."
45929194|NCT00032058|Procedure|magnetic resonance imaging|
45800171|NCT05731115|Biological|Experimental 23-valent Pneumococcal|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F,18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride mixture per injection.
45800172|NCT05730959|Device|Sacral nerve modulation|Implant of nerve stimulator
46072521|NCT03995628|Drug|Dexamethasone|One dose of dexamethasone (0.5 mg/kg) on post-operative day 3 after tonsillectomy
45450927|NCT02204020|Drug|5-azacytidine (5-aza) maintenance therapy after transplant|The planned initial dose of 5-aza is 32mg/m2 (Level 0) administered either subcutaneously or intravenously for days 1 through 5 of a 28-day cycle, which will be initiated between day+30 and day+100 after HCT. Patients who tolerate this dose based on hematologic parameters and with no SAEs for two consecutive cycles will be eligible for a dose escalation to 50mg/m2 (Level +1). Patients who tolerate this dose based on the same criteria as above for two consecutive cycles will be eligible for a dose escalation to 75mg/m² (Level +2). Patients will continue at dose Level +2 for the remainder of the study provided there are no toxicities that require dose reduction. Patients requiring a dose reduction are not eligible for re-escalation.
46072522|NCT03995173|Device|repetitive transcranial magnetic stimulation|rTMS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P). The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
45450928|NCT02200822|Drug|beta blockers|
45450929|NCT02200822|Drug|RAAS blockers|RAAS blockers (combination of ACE-I/ARB and a mineralocorticoid receptor antagonist)
45450930|NCT05252962|Dietary Supplement|Collagen Peptides|Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.
45450931|NCT02200900|Other|Pharyngeal pressure|Babies will have pharyngeal pressures measured during the CPAP and HFNC respiratory support.
45450932|NCT02200900|Other|Transcutaneous carbon dioxide|Babies will have transcutaneous carbon dioxide measured during CPAP and HFNC respiratory support.
45800173|NCT05730881|Procedure|ECMO|VA-ECMO is a life support measures, we need to estimate the survival by different techniques to allocate therapeutic interventions properly
45800174|NCT00550771|Drug|doxorubicin, cyclophosphamide, paclitaxel, trastuzumab|doxorubicin 60 mg/m^2 IV push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)
45450933|NCT02200900|Other|Pharyngeal gas concentrations|Measurement of pharyngeal oxygen and carbon dioxide concentration will be done during CPAP and HFNC respiratory support.
45450934|NCT02200900|Other|Tidal volume|Tidal breathing indices including tidal volume and FRC base line changes will be recorded during CPAP and HFNC respiratory support.
45800175|NCT00550771|Drug|PLD, cyclophosphamide, trastuzumab, paclitaxel|PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)
45800176|NCT04340765|Drug|18F-fluorocholine|Dual phase 18F-fluorocholine PET/CT
45800177|NCT05298449|Drug|HU-045|"HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~White powder"
45450935|NCT05240872|Biological|PRP injection|Plantar fascia injection therapy with PRP
45450936|NCT05240872|Biological|ABI injection|ABI injection
45929195|NCT00032058|Procedure|magnetic resonance spectroscopic imaging|
45929196|NCT03151421|Behavioral|Home air quality monitoring and feedback|Two-hundred smokers (50 in each country) will be recruited and offered low-cost, simple to operate particle counting instruments to measure and log SHS levels in their home for a period of 30 days. During this time near real-time, personalised feedback will be provided to, and discussed with, the smoker along with target-setting and exploration of suitable methods of behaviour-change. Feedback will be given via text message to mobile phones, emails and personal voicecalls. A final visit will gather data on changes made while a proportion of participants (10-20%) in each country will take part in a further qualitative interview by phone to gather data on their experience of the intervention.
45929197|NCT00032097|Drug|motexafin gadolinium|
45929198|NCT00032097|Radiation|radiation therapy|
45929199|NCT03151382|Drug|Tandospirone Citrate|Tandospirone, 30-60 mg/d
45929200|NCT03151382|Drug|Donepezil Hydrochloride|Donepezil, 10 mg/d
45929201|NCT00032136|Drug|exemestane|
45929202|NCT00032136|Drug|tamoxifen citrate|
45929203|NCT00032136|Procedure|adjuvant therapy|
45929204|NCT03151343|Drug|Empagliflozin|Empagliflozin tablet
45800178|NCT05298449|Drug|Xeomin®|Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.
45800179|NCT02278237|Behavioral|VME Group|Received inhaler education through VME (virtual education module)
45800180|NCT05730803|Other|dietary intervention|During the iodine balance period of pregnant women, seaweed was added to lunch on the 4-6 days of the experiment, and the iodine content was about 200 μg.
45800181|NCT01852513|Drug|QNASL|
45650894|NCT04429139|Drug|photodynamic therapy|PDT with Visudyne® was performed under general anesthesia according to the standard TAP study with some modifications: Verteporfin (6 mg/m2, Visudyne®; Novartis International AG, Basel, Switzerland) was injected intravenously with a standard 10-min infusion followed by followed by application of diode laser (Opal Photoactivator; Coherent Medical Group, Santa Clara, USA) (689 nm, 50 J/cm2, 600 mW/cm2) for 200 seconds to generate 120 J/cm2.
45800182|NCT01852513|Drug|Placebo nasal spray|
45800183|NCT04153643|Procedure|Arthroscopic Partial Meniscectomy|Surgical treatment for meniscus tear
45800184|NCT01852669|Procedure|Inversion|Patients inverted 30 degree head down in Trendelenburg position
45650895|NCT01654159|Procedure|Monofocal IOL|Monofocal Intraocular lens will be implanted
45650896|NCT01654159|Procedure|Multifocal IOL|Multifocal IOL will be implanted
45800185|NCT01852669|Procedure|Shock Wave Lithotripsy|Shock wave lithotripsy
45650897|NCT01654159|Procedure|Toric IOL|Toric IOLS will be implanted
45650898|NCT04428125|Diagnostic Test|Magnetic Resonance Scan of Thoracic outlet region|Both groups will undergo Magnetic Resonance Scan of cervicothoracobrachial region in order to study the anatomy of this region.
45650899|NCT04428125|Diagnostic Test|Duplex Ultrasound assessment of Upper limbs|Both groups will undergo Duplex Ultrasound assessment of Upper limbs, in order to study diameters and flow of the vascular system of the upper limbs.
45800186|NCT01852669|Drug|Hydration|Hydration of patient with 0.5L NaCl and 20mg frusemide IV
45800187|NCT05730647|Other|None intervention (observational study)|None intervention (observational study)
45800188|NCT05271383|Device|Orthognathic surgery using Global D's implants.|Major or minor participants who will be treated by an orthognathic surgery with ORTRAUTEK® or MINITEK® implant(s).
45800189|NCT01853215|Device|T.A.L.O.N. Intraosseous System|intraosseous catheter for use in the sternum
45800190|NCT04741295|Drug|Low molecular weight heparin|Patients with adenomyosis were treated with low molecular weight heparin after frozen embryo transfer in addition to routine luteal support.
45800191|NCT05729867|Procedure|Endoscpic biliary drainage using fully covered metal stent|"After selective cannulation of the bile duct, cholangiography is obtained using contrast agent.~A guide wire is passed through the stricture, and then fully-covered metal stent is inserted under fluoroscopy guidance during ERCP."
45800192|NCT05729321|Combination Product|neutrox|Each ECC, after discontinuing the Parental Nutrition (NP) infusion, will be flushed with 0.3 ml saline. Subsequently, Saline will be infused at a rate of 2 ml/h for 10 minutes. The ECC will then be closed for 1 hour. At the end of the hour the ECC will be once again flushed with 0.3 ml Saline and infused with SF at the rate of 2 cc/h for 10 minutes. The difference in pressure of the two infusions, before and after catheter closure, will be evaluated.
45650900|NCT05069077|Other|Music|In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
45650901|NCT05069077|Other|No music|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
45800193|NCT05729165|Device|Novafon® Pro|Local vibration therapy. The target muscles were: the orbicularis muscles of the upper and lower lips, the masticatory muscles (masseter, temporalis, pterygoidis) and lingual muscles.
45800194|NCT05729165|Other|Conventional Therapy|maneuvers were performed for passive extra-oral and intra-oral thermal stimulation, passive extra-oral and intra-oral tactile stimulation, and elicitation of active movements of the bucco-lingual and pharyngo-laryngeal muscles.
45800195|NCT04828577|Behavioral|Real Time Neurofeedback|Participants receive feedback from own brain activity.
45800196|NCT04828577|Behavioral|"Idealized/Sham Neurofeedback"|Participants receive idealized feedback not related to their own brain activity.
46072523|NCT03992430|Drug|Eteplirsen|Solution for intravenous (IV) infusion.
46072524|NCT03972280|Biological|Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody|Recombinant anti-G-CSF receptor monoclonal antibody is a preservative-free, sterile liquid formulation that is suitable for intravenous infusion
46072525|NCT03969134|Biological|ChAd63-KH|The vaccine will be injected intramuscularly into the arm.
46072526|NCT03969134|Other|Placebo|The placebo will be injected intramuscularly into the arm.
46072527|NCT03961568|Drug|Cenobamate|active drug
45650902|NCT04833257|Drug|GP combine with Tislelizumab neoadjuvant therapy+CCRT|chemotherapy combine with anti-PD-1 targeted immunotherapy+concurrent chemotherapy
45650903|NCT03098953|Drug|Loteprednol Etabonate|one drop per eye for each eye
45650904|NCT03099889|Behavioral|Physical Activity|Physical activity intervention based upon stage of change and social cognitive theory based interventions
45800197|NCT00550537|Drug|bevacizumab|15 mg/m2 given through a vein for every 3 weeks
45800198|NCT00550537|Drug|carboplatin|AUC = 6 given through a vein on day 1 of each cycle.
45800199|NCT00550537|Drug|erlotinib hydrochloride|150 mg taken by mouth daily
45800200|NCT00550537|Drug|paclitaxel|200 mg/m2 given through a vein on day 1 of each cycle.
45800201|NCT00550537|Genetic|gene expression analysis|Blood and tissue collection.
45800202|NCT00550537|Genetic|protein expression analysis|Blood and tissue collection.
45800203|NCT00550537|Genetic|proteomic profiling|Blood and tissue collection.
45800204|NCT00550537|Other|laboratory biomarker analysis|Blood and tissue collection.
45800205|NCT04801043|Drug|XNW4107|XNW4107 250mg IV over 60 minutes as a single dose
45800206|NCT04801043|Drug|Imipenem/Cilastatin|500mg/500mg IV over 60 minutes as a single dose
45800207|NCT04801043|Drug|placebo|"Matching placebo to XNW4107 containing the same inactive ingredients IV over 60 minutes as a single dose~Matching placebo to Imipenem/Cilastatin 0.9% sodium chloride IV over 60 minutes as a single dose"
45650905|NCT04823507|Device|BIOFLEX DUO+|"Data scores will be collected for patients who initially underwent the Workplace Post-Injury 1 test of the ImPACT® test system prior to PBM treatment.~Patients were treated with photobiomodulation using the BIOFLEX® DUO+ system that utilized a 180 bulb Light Emitting Diode (LED) array followed by laser probes. Both delivery methods were applied to the cervical spine and the cranium, and both entailed the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided three times per week on alternating days with weekends off for 4 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for treatment of the cervical spine.~Data scores will be collected for a second ImPACT® test using the Workplace Post-Injury 2 test.~Results of the Post-Injury 1 test and the Post-Injury 2 test will be compared."
45800208|NCT04425577|Diagnostic Test|Transabdominal Ultrasound|Transabdominal Ultrasound
45650906|NCT03099577|Radiation|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 60 Gy at 2 Gy/Fx/d, then 4.8 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
45650907|NCT03099577|Radiation|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 2: 60 Gy at 2 Gy/Fx/d, then 9.6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
45800209|NCT05706701|Other|Nicotine vaping visit 1 (free-base nicotine)|Participants will receive the free-base form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at one of their two visits. Participants will use the ENDS device with free-base nicotine and four fluxes in random order.
45800210|NCT05706701|Other|Nicotine vaping visit 1 (protonated nicotine)|Participants will receive the protonated form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at the other study visit. Participants will use the ENDS device with protonated nicotine and four fluxes in random order.
45929205|NCT03151343|Drug|Placebo Oral Tablet|Sugar pill, visually identical to active comparator
45929206|NCT00032175|Drug|capecitabine|
45929207|NCT00032175|Drug|gemcitabine hydrochloride|
45929208|NCT04712279|Drug|Ivermectin 0.6mg/kg/day|Use of ivermectin 0.6m/kg/day q.d.for 05 days
45929209|NCT04712279|Drug|Ivermectin 1.0mg/kg/day|Ivermectin 1.0mg/kg/day q.d. for 05 days
45929210|NCT04712279|Drug|Placebo|Placebo q.d.for 05 days
46072528|NCT03941886|Other|Low-dose aspirin in women with high risk of preeclampsia|Low-dose aspirin 150-162 mg/night or 100 mg/night if body weight <40 Kg, from <15 weeks till 36 weeks or, in the event of early delivery, at the onset of labor
46072529|NCT03921008|Drug|Paclitaxel|-Commercial supply
45650908|NCT03099577|Radiation|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 3: 60 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
45650909|NCT03099577|Radiation|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 4: 60 Gy at 2 Gy/Fx/d, then 19.2 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
45650910|NCT03099577|Radiation|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 5: 60 Gy at 2 Gy/Fx/d, then 4.8x5 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
45650911|NCT03099577|Radiation|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 6: 60 Gy at 2 Gy/Fx/d, then 4.8x6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
45800211|NCT05706701|Other|Nicotine vaping visit 2 (free-base nicotine)|Participants who received protonated nicotine during visit 1 will now receive free-base nicotine fluxes for visit 2: 9, 18, 27, 35 μg/sec.
45800212|NCT05706701|Other|Nicotine vaping visit 2 (protonated nicotine)|Participants who received free-base nicotine during visit 1 will now receive protonated nicotine fluxes for visit 2: 9, 18, 27, 35 μg/sec.
45800213|NCT04795505|Behavioral|Intervention|The subsequent visit was through WeChat-based online consultations. Follow-up, assessments and feedback were done at each visit. After follow-up, medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided.
45800214|NCT04795505|Behavioral|Control|The subsequent visit was through an offline outpatient clinic at 4 different community hospitals. Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention
45929211|NCT04712279|Drug|Hydroxychloroquine|Hydroxychloroquine 200mg/day q.d. for 05 days
45929212|NCT00032292|Drug|Visilizumab|
45929213|NCT03151265|Device|ThermaCare Low Back Heat Wrap|The ThermaCare Low Back Heat Wrap, is a continuous, low-level, direct heat therapy. It comes in the form of a heat-pack that is strapped to the low back. Heat is provided for approximately 8-hours.
45929214|NCT00032331|Procedure|PET Imaging|
45929215|NCT00032331|Procedure|CT scan|
45929216|NCT03151187|Other|Teaching intervention|Two two hour teaching modules on the diagnosis and treatment of disruptive behaviour disorders in children and youth
45929217|NCT00032370|Procedure|Vascular surgery with best medical treatment|Patients undergo scheduled vascular surgery
45929218|NCT00032370|Procedure|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting prior to vascular surgery
45929219|NCT00032370|Procedure|Percutaneous transluminal coronary angioplasty (PTCA)|Cardiac revascularization via PTCA prior to vascular surgery
45929220|NCT00393146|Drug|GW856553|Study drug
45929221|NCT00032409|Behavioral|Music therapy-based relaxation/stress reduction|
45929222|NCT00393185|Biological|Non-myeloablative Hematopoietic Stem Cell Transplantation|autologous Hematopoietic Stem Cell Transplantation
45929223|NCT00032448|Procedure|Standardized tension-free herniorrhaphy with prosthesis|Compare the effect of two typs of operative treatment of inguinal hernia.
45929224|NCT00032526|Drug|Corticosteroids|
45929225|NCT00032526|Behavioral|Classical conditioning to corticosteroid|
45929226|NCT03151109|Diagnostic Test|CT Scan|CT scan at minimum 1 year post op
45800215|NCT01853371|Procedure|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin. In this study, the wet cupping procedure was not done on certain days of the lunar month.
45929227|NCT03151070|Other|QVLM Intervention package|"QVLM intervention package consists of 3 simultaneous interventions:~Social marketing to promote insitutional deliveries.~PRONTO training to public health personnel~Improve interaction with traditional birth attendants"
45450937|NCT03533218|Device|Point of care Ultrasound machine|"POCUS methods of assessing ETT location offer an alternative that is time saving and thereby of critical importance in the neonatal time-is-brain scenario. Recently the government of Pakistan began upgrading health facilities and ensuring placement of essential equipment required to provide competent medical care, which may include provision of ultrasound machines to areas where there is established benefits to their use. Presence of trained staff and provision of portable ultrasound machine with short start-up time can save newborn lives(12).POCUS method empowers health care providers to read and interpret images in real time thereby saving critical time and need for specialized human resources (radiologists)."
45650912|NCT03099577|Radiation|radiochemotherapy 7|concurrent radiochemotherapy: radiotherapy dose level 7: 60 Gy at 2 Gy/Fx/d, then 4.8x7 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
45800216|NCT01853371|Other|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
45800217|NCT04734197|Drug|SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)|combination of a topical immunosuppressant and a topical corticosteroid solution
45929228|NCT04711941|Behavioral|Rehabilitation training|Rehabilitation with behavioural stimuli
45800218|NCT04734197|Drug|Mycophenolic Acid 0.1%|topical immunosuppressant
45650913|NCT04833179|Biological|fecal transplant|"Healthy donors will be selected by the fecal transplant unit, in Tel-Aviv medical center. All donors will undergo a screening process that will include a detailed medical history, blood work and fecal tests. Only after passing the screening, the donor will be added to the groups of donors that will participant in this study.~The treatment will be givenin the form of fecal capsule. Each capsule will contain a double capsule with 2 layers to ensure that the fecal material will be contained. The treatments will include 30 capsules for the first treatment, that will be taken in two consecutive days, each day 15 capsules. The second, third and fourth treatments will all include 15 fecal capsules. There will be 2 weeks intervals between each treatment."
45800219|NCT04734197|Drug|Mycophenolic Acid 0.3%|topical immunosuppressant
45800220|NCT04734197|Drug|Betamethasone Sodium Phosphate 0.01%|topical corticosteroid solution
45800221|NCT04734197|Drug|Placebo Comparator: Vehicle|topical vehicle solution
45800222|NCT04734197|Drug|Cyclosporine 0.05% Ophthalmic Emulsion|topical ophthalmic emulsion
45800223|NCT04734197|Drug|Lifitegrast 5% Ophthalmic Solution|topical ophthalmic solution
45800224|NCT00550147|Drug|Oros Methylphenidate|"Oros methylphenidate will be titrated over 3 visits according to the following schedule:~Visit 2 dose of 18 mg QAM~Visit 3 dose of 36mg QAM~Visit 4 dose of 54mg QAM."
45800225|NCT00550147|Drug|quetiapine|"Quetiapine will be titrated according to the following schedule as determined by efficacy and safety assessments (See Table 1).~Table 1: Quetiapine Dosing Schedule (subject's required weight = 30-80 kg)~Visit 5 dose of 25mg BID~Visit 6 dose of 50mg BID~Visit 7 dose of 100mg BID~Visit 8 dose of 200mg BID~Visit 9 dose of 300mg BID~Efficacy: For any visit following Visit 5, dosage will remain stable if clinically significant improvement criteria are met.If subjects subsequently fail to meet clinically significant improvement criteria, dose increases will resume at the next level of the dosing schedule."
45929229|NCT03151031|Procedure|Cryotherapy|The cooling procedure for the knee joint will be initiated by using a cryopack or cold-pack. On completion of the initial SEBT, the participant will lie supine and the investigator will apply the cryotherapy for 10 minutes. After the 10 minute period of cryotherapy, the cryopack will be removed, and the participants will perform SEBT for the second time.
45929230|NCT00032643|Drug|DITPA|
45450938|NCT02204332|Drug|Cabazitaxel|
45450939|NCT02204332|Other|Best Supportive Care|
45800226|NCT05688215|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
45800227|NCT05688215|Procedure|Computed Tomography|Undergo a CT scan
45800228|NCT05688215|Procedure|Core Biopsy|Undergo core biopsy
45800229|NCT05688215|Drug|Fluorouracil|Given IV
45800230|NCT05688215|Drug|Irinotecan|Given IV
45450940|NCT02209792|Drug|Placebo|
45650914|NCT04833179|Other|placebo|placebo
45800231|NCT05688215|Drug|Leucovorin|Given IV
45800232|NCT05688215|Drug|Leucovorin Calcium|Given IV
45929231|NCT03150992|Dietary Supplement|Elemental 028 Extra Liquid|A nutritionally complete, liquid elemental diet consisting of a mixture of essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, trace elements and flavourings with sugars & sweeteners.
45929232|NCT03150953|Device|MRI-safe bore covering|
45929233|NCT00032721|Procedure|Reiki; Subtle energy therapy|
46072530|NCT03921008|Radiation|Radiation therapy|-Patients may be treated with electrons, 3D conformal photon radiotherapy, intensity modulated photon radiotherapy (IMRT), proton radiation therapy, or a combination of these.
45450941|NCT02209792|Drug|BIBR 796 BS, 5 mg|
45450942|NCT02209792|Drug|BIBR 796 BS, 20 mg|
45800233|NCT05688215|Drug|Oxaliplatin|Given IV
45929234|NCT00032760|Behavioral|Meditation|
45929235|NCT03150914|Drug|Sirolimus|mTOR inhibitor or placebo
45929236|NCT00032799|Drug|natalizumab|
45929237|NCT03150836|Drug|Durvalumab|All participants will receive durvalumab 1500 mg via IV infusion every 4 weeks for up to 13 doses.
45929238|NCT03150836|Drug|Tremelimumab|Participants receiving Regimen B (safety lead-in or expansion cohort) will be administered tremelimumab 75 mg via IV infusion every 4 weeks for 1 cycle or 2 cycles.
45450943|NCT05263180|Biological|EMB-09|EMB-09 is a FIT-Ig® bispecific antibody against PD-L1 and OX40.
45650915|NCT03036137|Device|Transcranial Direct Current Stimulation|Anodal stimulation of the temporoparietal left area with an cathode over the right dorsolateral prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
45929239|NCT03150836|Radiation|Radiation Therapy|In all arms of the study, participants will receive 5 fractions of radiation. The radiation dose will either be 6.6 Gy for a total dose of 33 Gy, or 6.0 Gy for a total dose of 30 Gy.
45929240|NCT00032838|Drug|Yohimbine|
45800234|NCT05688215|Drug|Quemliclustat|Given intravenously (IV)
45800235|NCT05688215|Drug|Zimberelimab|Given IV
45800236|NCT01853605|Device|Anatomically shaped silicone gel-filled breast implants|Surgical implant
45800237|NCT04741685|Device|TTSX2|Treatment with Tandem T Slim X2 with Basal IQ
45929241|NCT03150797|Drug|Melatonin|Melatonin
46072531|NCT03921008|Procedure|Research blood draw|-Within 1 week (prior to cycle 1 of paclitaxel preferred but not required), pre-radiation therapy (any time weeks 5-7 as long as radiation therapy has not started), post-radiation therapy (day of last fraction), 14 days post-radiation therapy, and within 2 weeks post-surgery
46072532|NCT03900286|Dietary Supplement|Total Dietary Replacement|Total Dietary Replacement
46072533|NCT03898843|Other|Animal assisted therapy|Patients of AAT group will leave their hospital bedroom to go in the session room, where they will meet a dog, who has come with his veterinary student master. Animal assisted therapy session will last at most 20 minutes, in which the patient is going to interact with the dog, pet him, play with him, etc.
46072534|NCT03898843|Biological|Nasal swab sampling|All patients will have nasal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria
46072535|NCT03898843|Behavioral|STAI-Y and POMS Questionnaires|Before and after AAT or sham session, patients will answer State-Trait Anxiety Inventory Y (STAI-Y), Profile of Mood States (POMS) questionnaires.
45450944|NCT05238454|Biological|SCTV01C|intramuscular injection
45450945|NCT05238454|Biological|Sinopharm inactivated COVID-19 vaccine|intramuscular injection
45450946|NCT05238454|Biological|Comirnaty|intramuscular injection
45450947|NCT02204488|Procedure|Total Joint Arthroplasty|Total Joint Arthroplasty with device: Maïa® trapezio-metacarpal joint prosthesis, Groupe Lépine, Genay, France
45650916|NCT03036137|Device|Sham Transcranial Direct Current Stimulation|Sham tDCS sessions will last 20 minutes
45650917|NCT05069233|Other|UGI+SB|Patients who underwent combined upper digestive tract and small intestine examination under MCE.
45650918|NCT04833101|Biological|recombinant Ad5 vectored COVID-19 vaccine|This vaccine contains 5×10^10 virus particles of recombinant replication defective human type-5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
45650919|NCT04833101|Biological|RBD-based protein subunit vaccine (ZF2001) against COVID-19|This is a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19, made by using CHO cell, 25μg/dose, produced by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.
45450948|NCT02204488|Procedure|Trapeziectomy|Trapeziectomy
45450949|NCT02220556|Procedure|Blood sampling|
45650920|NCT04833101|Biological|trivalent split influenza vaccine|This vaccine contains 15 μ g H1NI, 15 μ g H3N2 and 15 μ g B-series hemagglutinin, produced by Dalian Aleph Biomedical Co., Ltd.It is a liquid dosage form, 0.5 ml / bottle.
45650921|NCT03100903|Drug|BI 655130|single dose
45800238|NCT04741685|Device|MM640G|Treatment with Medtronic Minimed 640G with Smartguard
45800239|NCT05211869|Behavioral|T1D-CATCH|"As defined by the CDC, a CHW is a frontline public health worker who is a trusted member of a community or who has a thorough understanding of the community being served, and leverages this unique position to link health systems, social services, and communities. CHWs engender trust with patients by having direct community and lived experience, offering specific support and empathy that may be difficult for other diabetes care professionals to provide. In addition, CHWs have firsthand understanding of cultural barriers to traditional western healthcare and can promote patient-centered culturally-relevant care. They enhance team-based care by helping providers with extra outreach, social needs management, time-consuming tasks, and aligning patient-provider priorities.~CHWs in this project will provide social needs assessment and management, introduction to diabetes technologies, and support for onboarding to technology."
45800240|NCT04740983|Other|Heliotherapy (a sole sun-bathing)|16-week heliotherapy regimen based on the predicted anti psoriasis effective irradiance values.
45800241|NCT01856491|Device|RELIANCE 4-FRONT™ Passive Fixation lead implantation|Implantation of transvenous defibrillation lead with passive fixation mechanism.
45800242|NCT00366353|Other|Sedation during SBT|
45800243|NCT00366353|Other|No sedation|
45929242|NCT03150797|Drug|Placebo oral capsule|Placebo
45929243|NCT03150758|Device|10Hz + 100 micro-seconds|10Hz Electrical Stimulation with a pulse width of 100 micro-seconds
45929244|NCT03150758|Device|10Hz + 200 micro-seconds|10Hz Electrical Stimulation with a pulse width of 200 micro-seconds
45929245|NCT03150758|Device|7Hz + 100 micro-seconds|7Hz Electrical Stimulation with a pulse width of 100 micro-seconds
45929246|NCT03150758|Device|7Hz + 200 micro-seconds|7Hz Electrical Stimulation with a pulse width of 200 micro-seconds
45929247|NCT00032916|Drug|NS2359|
45929248|NCT03150680|Genetic|SNPs associated with CAD, SNPs associated with pharmacological response to clopidogrel and statins|Genotyping will be carried out by Next-Generation Sequencing (NGS)
45929249|NCT03150641|Procedure|Umbilical cord clamping|The umbilical cord will be clamped and cut after delivery, with timing as specified in each arm
45929250|NCT00396396|Drug|Acetylcysteine|
45929251|NCT03150602|Drug|Pralatrexate|This is a single arm study. Pralatrexate will be administered via IV over 3-5 minutes into a IV line containing normal saline (0.9% sodium chloride, NaCl) with the initial dose of 30 mg/m2/week on days 1, 8, 15, 22, 29, and 36 for 6 weeks in a 7-week cycle. The scheduled date can be done within a window time of plus or minus 1 day. The pralatrexate dose may be reduced to 20 mg/m2/week or omit if a patient experiences adverse events. Pralatrexate administration can be up to 5 cycles or until subject meets withdrawal criteria.
45929252|NCT00396435|Drug|Neorecormon|Administration SC one a week in patients randomized in group A Administration SC if Hb below 10.5 g/dl in group B
45800244|NCT05350969|Drug|CDR132L|CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.
45929253|NCT03150563|Other|Passive static stretch|Each experimental group will be submitted to 10 (ten) sessions, with three (3) weekly sessions of static passive stretching, with a 48 h interval between them. Each session will be performed 3 (three) maneuvers containing a duration of 30 seconds, this being the same rest time, performed in all experimental groups.
45929254|NCT00032955|Drug|Buprenorphine/naloxone|
45800245|NCT05350969|Drug|Placebo to CDR132L|Placebo to CDR132L
45450950|NCT02209870|Behavioral|E-checklist Group|The patient group after E-checklist system deployed
45800246|NCT00366431|Drug|MOA-728|
45450951|NCT05222542|Other|Sampling of plasma and cerebrospinal fluid at specified time points|Samples (plasma, and in patients with in-dwelling cerebrospinal fluid drainages also cerebrospinal fluid) will be taken within 72 hours of subarachnoid hemorrhage and 7, 14 and 21 days following initial bleeding. Another plasma sample will be obtained if an antihypertensive therapy with a RAS modifying drug has been started.
45800247|NCT00557401|Drug|XP19986 SR3, 20 mg QD|XP19986 Sustained Release (SR) 20 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
45929255|NCT03150524|Diagnostic Test|TCD- cerebral blood flow velocities|Participants will undergo daily TCD for monitoring of cerebral blood flow.
45929256|NCT03150524|Behavioral|Headache pain score|Participants will be evaluated by nurses for headache frequency and severity every shift.
45929257|NCT03150524|Other|Neurological examination|Patients will be examined routinely for evidence of neurological improvement/decline and/or evidence of a complication such as stroke or hemorrhage.
45929258|NCT03150524|Diagnostic Test|Repeat Neuroimaging|All patients will also be seen at 90 days (+/- 30 days) and administered a headache diary, repeat neuroimaging, and neurological examination.
45929259|NCT03150524|Drug|Nimodipine|Participants will be administered nimodipine every 4 hours.
45929260|NCT03150524|Drug|Verapamil ER|Participants will be administered long acting verapamil every 12 hours.
45929261|NCT00032994|Behavioral|Behavior Therapy|
45929262|NCT03150446|Device|flexible cystoscopy|After intracorporeal insertion of the double-J catheter, additional endoscopic monitoring with flexible cystoscopy was performed. The surgeon manipulating the double-J catheter used monitor A, while an assistant inserted a flexible cystoscope into the bladder through the urethral route and determined whether the double-J stent was correctly placed in the bladder using monitor B before suturing the site of ureterotomy. If the stent was well-placed, the flexible cystoscope was withdrawn. If the double-J stent was not visualized in the bladder, the surgeon pushed the stent inferiorly using a laparoscopic instrument and monitor A until the stent came out through the ureteral orifice on monitor B.
45450952|NCT02220634|Drug|Regadenoson|Injection for intravenous administration
45450953|NCT02204644|Drug|Flumatinib 600mg qd|
45450954|NCT02204644|Drug|Imatinib 400mg qd|
45450955|NCT02204722|Drug|600mg/day of Imatinib|
45450956|NCT02204722|Drug|400mg/day of Imatinib|
45650922|NCT04837313|Procedure|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
45650923|NCT05068765|Other|Communication skills psychoeducation|Intervention explanations are explained in the groups section.
45650924|NCT05068765|Other|General psychoeducation|İntervention descriptions are explained in the intervention groups section.
45650925|NCT00794599|Drug|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
45650926|NCT00794599|Drug|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
45650927|NCT04836611|Procedure|1 blood sample|2 groups of subjects (group 1 : with diagnosis of CHS - group 2 : no diagnosis of CHS) will have 2 blood and 1 urine samples + 1 questionnaire
45650928|NCT00783133|Drug|Desloratadine 5 mg|Clarinex 5 mg daily x 7 days
45800248|NCT00557401|Drug|XP19986 SR3, 40 mg QD|XP19986 Sustained Release (SR) 40 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
45800249|NCT00557401|Drug|XP19986 SR3, 60 mg QD|XP19986 Sustained Release (SR) 60 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
45929263|NCT00033033|Drug|Reserpine|
45929264|NCT03150368|Drug|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
45650929|NCT00783133|Drug|fexofenadine|Allegra 180 mg daily x 7 days
45650930|NCT04823819|Device|Magnetic Stimulator DuoMag|Stimulation of the left dorsolateral prefrontal cortex
45800250|NCT00557401|Drug|XP19986 SR3, 30 mg BID|XP19986 Sustained Release (SR) 30 mg tablet taken orally, twice daily (BID) for approximately 32 days with titration and taper periods.
45929265|NCT00033072|Drug|Selegiline|
45929266|NCT03150290|Other|Indirect Calorimetry.|REE measurement
45929267|NCT03150290|Device|18-FDG-PET|18-FDG-PET
45929268|NCT00033111|Drug|Cabergoline|
45450957|NCT02210572|Dietary Supplement|Bimuno Galacto-oligosaccharide 1.37 g/d|Prebiotic versus low-FODMAPs diet
45450958|NCT02210572|Dietary Supplement|Low- FODMAPs diet|
45450959|NCT02204878|Drug|Parecoxib Sodium|Dynastat 40mg was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. Dynastat 40mg Q12h will be given within 72 hours after surgery
45450960|NCT05263024|Device|atrial appendage clip|During cardiac surgery, atrial fibrillation patients were treated with atrial appendage clipping
45650931|NCT04823819|Device|neuroConn DC-STIMULATOR|One electrode (anode) will be placed on the left dorsolateral prefrontal cortex, the other (cathode) on the right temporal lobe.
45650932|NCT03098719|Behavioral|Active Mobility|see detailed discription
45650933|NCT04823429|Behavioral|High intensity-interval training (HIIT)|"Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.~Without any exercise training"
45929269|NCT00033111|Drug|Placebo|sugar pill manufactured to mimic cabergoline 05mg tablet
45800251|NCT00557401|Drug|Placebo|Placebo tablet taken orally for approximately 32 days with titration and taper periods.
45800252|NCT02617901|Radiation|Left hand DXA|"All recruited children will have a left hand DXA scan which will be anonymised and from which 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.~Radiographs and DXA will be read in random and varied order."
45800253|NCT05349643|Biological|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
45800254|NCT05344261|Procedure|Targeted Muscle Re-innervation|Targeted Muscle Re-innervation involves re-routing transected nerve ends to functional motor nerves proximal to the site of amputation.
45800255|NCT05344261|Procedure|Regenerative Peripheral Nerve Interface|Regenerative Peripheral Nerve Interface involves placing transected nerve ends in harvested muscle grafts.
45800256|NCT05344261|Procedure|Standard Post-Amputation Surgical Care|Standard post-amputation surgical care involves placing transected nerve ends into muscle/soft tissue proximal to the site of amputation.
45929270|NCT03150251|Other|Cereal - oats|Consumption of one cereal in the beginning of each visit
45929271|NCT03150251|Other|Cereal - cream of rice|Consumption of one cereal in the beginning of each visit
45929272|NCT00033150|Behavioral|Fast ForWord|
45929273|NCT00033150|Behavioral|Computer Assisted Language Intervention|
45929274|NCT00033150|Behavioral|Individual Language Intervention|
45929275|NCT00033150|Behavioral|Academic enrichment|
45929276|NCT03150212|Dietary Supplement|Saccharomyces cerevisiae CNCM I-3856|2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.
45650934|NCT04823429|Behavioral|Moderate intensity-continuous (MICT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
45929277|NCT03150212|Dietary Supplement|Placebo|2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.
45929278|NCT00033189|Drug|Coenzyme Q10|
45929279|NCT00033228|Biological|MKC1106-MT|Cancer Vaccine, Immunotherapy, 500 ug
46072536|NCT03898843|Procedure|physiological parameters measure|Before and after AAT or sham session, blood pressure, heart rate dans respiratory rate will be measured.
45650935|NCT03098407|Drug|Buprenorphine|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
45800257|NCT04685213|Device|Electrical Stimulation|Subjects will receive an active electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
45800258|NCT04685213|Device|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
45929280|NCT00033228|Biological|MKC1106-MT|Cancer Vaccine, Immunotherapy, 1000 ug
45929281|NCT00033228|Biological|MKC1106-MT|Cancer Vaccine, Immunotherapy, 1500 ug
45929282|NCT00033267|Drug|temsirolimus|Given IV
46072537|NCT03898843|Other|Visual Analog Scale (VAS)|Before and after AAT or sham session, pain will be evaluated thanks to VAS
46072538|NCT03898843|Behavioral|Impact of Event Scale - Revised (IES-R)|Patients will answer IES-R questionnaire 3 months after AAT or sham session
46072539|NCT03898843|Behavioral|satisfaction questionnaire|Patients of the AAT group will answer satisfaction questionnaire at the end of the AAT session and 3 months after AAT
45800259|NCT03832777|Device|Repetitive Transcranial Magnetic Stimulation|Subjects will receive both active and placebo rTMS, in a crossover modality.
45800260|NCT02278783|Drug|regorafenib|Patients will be treated with Regorafenib 160 mg (4 x 40 mg tablets) daily for 21 days of a 28 day cycle (three weeks on drug, one week off) until disease progression or adverse effects prohibit further treatment
45800261|NCT02618915|Genetic|DTX101|solution for IV infusion
45800262|NCT04768699|Drug|TQG203|TQG203,30µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
45800263|NCT04768699|Drug|TQG203/NovoSeven®|In each of the two study periods (separated by a washout about two days),a single dose of TQG203 or NovoSeven® will be administered.TQG203 or NovoSeven®,90µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1.
45929283|NCT00033306|Drug|ixabepilone|
45929284|NCT00033306|Drug|Fluoropyrimidine|
45929285|NCT00033306|Drug|Irinotecan|
45929286|NCT02984384|Drug|Acetylsalicylic acid|The Aspirin intervention will be 81 mg enteral (by mouth, feeding tube or rectal) twice a day with no variation in dosing allowed.
45929287|NCT02984384|Drug|Low Molecular Weight Heparin (LMWH)|The LMWH intervention will be 30 mg enoxaparin subcutaneous (under the skin) twice a day with variations in dosing allowed, per the standard of care at sites, as needed for patients who are very obese or exhibit renal dysfunction.
45929288|NCT00033345|Drug|Indole-3-carbinol|400 mg pill taken daily
45929289|NCT00033345|Drug|Indole-3-carbinol|800 mg pill taken daily
46072540|NCT03898843|Biological|Rectal swab sampling|All patients will have rectal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria
46072541|NCT03868579|Procedure|Biopsy|Undergo biopsy
46072542|NCT03868579|Other|Medical Chart Review|Review medical chart
46072543|NCT03868579|Procedure|Thoracoscopy|Undergo pleuroscopy
45650936|NCT03098407|Drug|Methadone|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
45650937|NCT04836143|Drug|Intravitreal anti-vascular endothelial growth factor injection|Intravitreal injection of either ranibizumab or aflibercept
45653233|NCT02631577|Drug|Atezolizumab (MPDL3280A) [TECENTRIQ]|Atezolizumab will be administered at a flat dose of 840 mg on Days 1 and 15 of Cycles 2 to 6, given in 28-day cycles as induction treatment and 840 mg on Days 1 and 2 of each month, given as maintenance treatment.
45929290|NCT00033345|Other|Placebo|Placebo pill taken daily during run-in period
45929291|NCT02823821|Other|Default dialysate sodium concentration of 137mmol/l|Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
45800264|NCT04768699|Drug|TQG203|TQG203,180µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
45800265|NCT04749277|Other|CAD EYE® (Fujifilm, Europe, Gesellschaft mit beschränkter Haftung, Dusseldorf, Germany)|"Methods plan~Phase 1. Brief virtual chromoendoscopy training on the characterization of colorectal polyps (WLI, LCI and BLI)~Phase 2. CAD EYE® system applied during colonoscopy retrieval:~2.1. CAD EYE® system OFF: Virtual chromoendoscopy (BLI) - independently characterization of a suspected polyp in WLI and BLI by the first endoscopist and by the second endoscopist (iconographic record) 2.2. CAD EYE® system ON: Characterization mode (BLI): Characterization of a suspected polyp by CAD EYE® and respectively level of characterization (1 to 3) (iconographic record) Phase 3. Histopathological evaluation (pathologist with gastrointestinal expertise): Resection and recovery of a suspected polyp for anatomopathological characterization"
45800266|NCT04749199|Behavioral|Enhanced mirror therapy|Participants of the enhanced mirror therapy group will perform complex, randomized, finger opposition and reposition movements, using the thumb, index, middle, ring, and little fingers, and will be shown a 35% blurred visual feedback through the computerized mirror therapy device. Each participant will receive a mirror training session for 60 minutes each day, three times per week for four consecutive weeks.
45929292|NCT02823821|Other|Default dialysate sodium concentration of 140mmol/l|Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
45800267|NCT04749199|Behavioral|Standard mirror therapy|Participants allocated to this group will perform simple, sequential finger opposition and reposition movements, using the thumb, index, middle, ring, and little fingers, and will be shown a clear image of the exercising hand. Each participant will receive a mirror training session for 60 minutes each day, three times per week for four consecutive weeks.
45929293|NCT00033384|Drug|CI-1040|
45929294|NCT00033423|Biological|rituximab|
45929295|NCT00033423|Radiation|yttrium Y 90 ibritumomab tiuxetan|
45929296|NCT02809235|Dietary Supplement|coconut oil|3 tablespoons per day of supplemental coconut oil
45929297|NCT02804087|Device|MobiusHD|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
45929298|NCT02804087|Other|Sham Implantation|Sham Implantation
45929299|NCT00033462|Drug|erlotinib hydrochloride|Given orally
45929300|NCT00033462|Other|laboratory biomarker analysis|Correlative studies
45929301|NCT00393263|Drug|pimecrolimus and clobetasol|
45929302|NCT00393263|Drug|clobetasol 0.05% cream|twice daily for three months
45929303|NCT00033618|Drug|ixabepilone|Given IV
45650938|NCT05068843|Procedure|arthroscopic partial meniscectomy|In the surgery group, the orthopaedic surgeon performed an arthroscopic partial meniscectomy within 4 weeks after allocation. The surgeon removed the damaged part of the meniscus, until a stable and solid meniscus remained. All patients received written post-operative instructions. Eight weeks after surgery, patients received a consult in the outpatient orthopaedic clinic. In agreement with the Dutch Orthopaedic Association Guidelines, patients were referred to physical therapy when signs of abnormal recovery were present.
45650939|NCT05068843|Other|Physical therapy|The treatment protocol consisted of a physical therapist-led incremental exercise program over a period of eight weeks, containing 16 sessions of 30 minutes each.
45929304|NCT00033618|Other|laboratory biomarker analysis|Correlative studies
46072544|NCT03845296|Drug|Rucaparib|Given PO
46072545|NCT03837704|Other|IQOS|AAA patients will switch from cigarette smoking to ad libitum IQOS use, with no flavor variant restrictions.
45929305|NCT02723708|Other|Real-Time functional Magnetic Resonance Imaging Feedback (RTFF)|During the Activate trials, the thermometer will display the weighted average of VTA BOLD activation, dynamically updated every second. This continuously updated thermometer is the primary feedback mechanism.
45929306|NCT00033696|Biological|filgrastim|
45929307|NCT00033696|Drug|carboplatin|
45929308|NCT00033696|Drug|etoposide|
45929309|NCT00033696|Drug|paclitaxel|
45929310|NCT00033696|Drug|topotecan hydrochloride|
45929311|NCT00033696|Radiation|radiation therapy|
45929312|NCT02548559|Drug|Full-Spectrum Cannabidiol|Full-Spectrum Cannabidiol; total daily dose of 30 mg.
45929313|NCT02548559|Drug|Single-Compound Cannabidiol|Single-Compound Cannabidiol; total daily dose of 30 mg.
45929314|NCT02548559|Drug|Placebo|Placebo solution.
45929315|NCT00033735|Drug|fluorouracil|5-fluorouracil will be administered via central venous catheter or PICC beginning at 250mg/m2/ day as continous infusion for a 28 day period.
45929316|NCT00033735|Drug|Irofulven|Irofulven will be given at 0.55 mg/kg per infusion on Day 1 and and Day 15 every 28 days as a 30 minute iv infusion.
45929317|NCT00033813|Drug|Oxatomide (tinset)|
45929318|NCT00393302|Procedure|HIV screening in pregnancy|
45929319|NCT00033852|Procedure|Massage Therapy|
46072546|NCT03837704|Other|Cigarette|AAA patients will continue to smoke their cigarettes ad libitum, with no brand restrictions.
46072547|NCT03837704|Other|Smoking Cessation|AAA patients who have completely quit smoking will continue to remain abstinent from smoking cigarettes or using any tobacco or nicotine-containing product(s)
46072548|NCT03813108|Biological|CPS-immunization|Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes while taking mefloquine prophylaxis.
45929320|NCT02306174|Behavioral|Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding|"The group sessions consists of 20 classes, each lasting approximately 90 minutes and may consist of some or all of the following:~A group agreement and a confidentiality contract~Homework assignments~Viewing informational videos about hoarding~Behavioral experiments including sorting and discarding exercises~Non-acquisition exposures~This course is based on the Manual Cognitive Rehabilitation and Exposure/Sorting Therapy for Compulsive Hoarding (Ayers et al., 2014)."
45929321|NCT00033891|Drug|Infliximab|
45929322|NCT02271893|Drug|Dextromethorphan|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
45929323|NCT02235623|Procedure|Single-stage Fowler-Stephens orchidopexy (FSO)|
45650940|NCT01595555|Behavioral|Stress Free Now|8 week mindfulness online program with the following content: 8 Weekly lesson of the week (audio), 8 Weekly mindfulness practice (audio), Daily articles on concepts and information about stress, relaxation and mindfulness, Daily motivational quotes and tips, Biweekly email reminder to participate in the program.
45800268|NCT04749121|Device|UVC Irradiation|We used the Porcine epidemic diarrhea virus (PEDV) as the indicator virus .An N99 mask was contaminated by spraying or applying with the virus on the exterior and interior surface of each silicone mask. Also, 100 μl of the viral suspension was spotted onto the filter part of N99 masks. Following 20-30 minutes of drying, the silicone masks underwent each of the decontamination procedures which are ultraviolet-C (UV-C) irradiation and 70% alcohol treatment. For UV irradiation, N99 masks were placed in an UV-C incubator ) and were exposed for different times at 1, 10 and 20 minutes, respectively.Untreated control and treated N99 masks were analyzed for viral infectivity in VERO cell cultures. At 48 hours post-infection, cells were examined for evaluation the viral infectivity via observation of cytopathic effect. Results for each treatment express mean ± standard deviations of 3 biological replicates.
45800269|NCT04749121|Drug|UVC Irradiation|Bacterial and fungal sampling were obtained from the inside and outside surface areas likely to the frequently touched and close contact with the face of hospital personnel. The cultures were then isolated onto the blood agars and Mac Conkey agars, respectively. After incubation, the total number of bacterial and fungal colonies were counted, recorded, and selected different colonies.
45800270|NCT04749121|Device|Fit test|All the participants had to pass the initial fit test.After decontamination with UVC irradiation for 60 minutes, fit testing was conducted using qualitative fit test (Bittrex Solution aerosol),
45800271|NCT04749121|Device|Tensile strength|We measured the tensile strength of the strap of the Silicone mask before and after the UVC irradiation to study the strength and reliliency of the strap
45800272|NCT02264353|Drug|Donepezil|Donepezil 10mg before sleep
45929324|NCT02235623|Procedure|Two-stage Fowler-Stephens orchidopexy (FSO)|
45650941|NCT05068453|Drug|Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)|OH2：less than 8mL/time，Q2W，i.t.；
45650942|NCT05068453|Drug|Recombinant humanized anti-PD-1 monoclonal antibody for injection|HX-008：200mg/time，Q3W，i.v.；
45650943|NCT05068453|Radiation|RT|3 times radiation，totally 24-30 Gy for each lession.
45650944|NCT00751075|Drug|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
45650945|NCT00751075|Drug|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
45800273|NCT02264353|Drug|placebo|One piece of placebo before sleep
45800274|NCT04657679|Drug|Ribociclib|Patients will receive ribociclib 600 mg oral (PO) daily for 21 consecutive days of 28-day cycles and endocrine therapy with either letrozole or fulvestrant. Fulvestrant 500 mg intramuscular (IM) will be administered on days 1, 15, 29 of cycle one, and then monthly. Letrozole 2.5 mg oral daily continuously. If premenopausal women have not undergone bilateral salpingo- oophorectomy, they will receive a luteinizing hormone-releasing hormone (LHRH) agonist (e.g., goserelin leuprolide) for ovarian suppression in combination with fulvestrant or letrozole and ribociclib.
45800275|NCT05130593|Dietary Supplement|Nutrasorb bar|250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings
45800276|NCT04768621|Other|Questionary|Questions about patient health after wintering in Southern and Antarctic French Lands about social and demographics items, psychologic and psychiatric items, sleep disorders, immunological disorders,and endocrinologic disorders, sociological consequences of wintering
45800277|NCT05299099|Drug|IN-C006 inj.|IN-C006 will be injected continuously for 3 days.
45800278|NCT05299099|Drug|RCN301|RCN301 will be injected continuously for 3 days.
45800279|NCT02622191|Device|Spectral domain Optical Coherence Tomography|Undilated peripapillary circular optic nerve scans and horizontal and vertical SD-OCT B-scan images centered on the fovea were acquired using Spectralis Heidelberg Retinal Angiography (HRA)+OCT (Heidelberg Engineering GmbH, Heidelberg, Germany).
46072549|NCT03813108|Biological|malaria challenge infection, P. falciparum NF135.C10|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
45650946|NCT00751075|Drug|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
45650947|NCT00751075|Drug|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
45650948|NCT04823741|Genetic|PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA|All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).
45650949|NCT00731185|Drug|Mometasone Furoate Nasal Spray|MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning for up to 24 weeks or until relapse
45650950|NCT00731185|Drug|Placebo|
45650951|NCT04836299|Drug|Ivermectin|Participants will be randomly assigned to receive a single 600 µg / kg dose of ivermectin or placebo.
45650952|NCT04836299|Drug|Placebo|Participants will be randomly assigned to receive a single of placebo.
45800280|NCT02265913|Drug|Acyclovir 5 percent (Perrigo)|
45800281|NCT02265913|Drug|Acyclovir 5 percent (Reference)|
45800282|NCT02265913|Drug|Placebo cream|
45929325|NCT00034008|Behavioral|Healing Touch|
45929326|NCT02149823|Drug|Syntocinon 24 Intranasal Units (IU)|
45800283|NCT02624375|Drug|Zoster Vaccine Live|
45800284|NCT01858753|Biological|Autologous fibroblasts|
45800285|NCT01858753|Biological|placebo sterile saline|
45929327|NCT02149823|Drug|Syntocinon 40 Intranasal Units (IU)|
45929328|NCT02149823|Drug|Intranasal Placebo|
45929329|NCT02971410|Other|Laboratory Biomarker Analysis|Correlative studies
45800286|NCT02624843|Drug|Benzyl Alcohol Lotion 5%|White topical lotion
45800287|NCT02624843|Drug|Ulesfia (benzyl alcohol lotion) 5%|White topical lotion
45650953|NCT00651391|Drug|Ezetimibe + Simvastatin|oral tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily in the evening for 12 weeks
45650954|NCT00651391|Drug|Simvastatin|oral simvastatin 20 mg once daily in the evening for 12 weeks
45929330|NCT02971410|Other|Quality-of-Life Assessment|Ancillary studies
45929331|NCT02971410|Drug|Simvastatin|Given PO
45650955|NCT00651391|Drug|Placebo|oral placebo once daily in the evening for 12 weeks
45650956|NCT05067751|Device|hearing aid with directionality|Hearing directionality allows users the ability to focus on voices and other signals of interest, reducing background noises that are unimportant.
45800288|NCT02624843|Drug|Placebo|White topical lotion
45929332|NCT02035397|Drug|Botulinum Toxin Type A|
45929333|NCT02035397|Drug|Saline solution|
45929334|NCT00034047|Procedure|Acupuncture|
45929335|NCT00034047|Drug|Chinese Products|
45929336|NCT00034047|Drug|Nafarelin|
46072550|NCT03813108|Biological|malaria challenge infection, P. falciparum NF54|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
45650957|NCT04823351|Behavioral|Surgical Mask|The randomized wards will be wearing either FFP2 masks or surgical masks for 8 weeks. Then a cross-over will occur for another 8 weeks.
45650958|NCT04434859|Other|No intervention|No intervention
45650959|NCT04823117|Other|music therapy|music includes nature sounds recommended by the Turkish Psychological Association
45650960|NCT00650689|Drug|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
45650961|NCT00650689|Drug|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
45650962|NCT04835831|Other|adapted physical activity + Dietetic advice|adapted physical activity during 24 weeks
45650963|NCT05067517|Drug|Nintedanib|Randomized in a 1:1 ratio to either oral nintedanib 150 mg (n=80) or matching placebo (n=80) twice daily.
45650964|NCT05067517|Drug|Placebo|Randomized in a 1:1 ratio to either oral nintedanib 150 mg (n=80) or matching placebo (n=80) twice daily.
45800289|NCT00422357|Drug|Urtica Dioica (Tea bag)|
45800290|NCT05106101|Drug|L-glutamine|L-glutamine oral powder in 5 gram packet
45800291|NCT04741217|Other|Not an interventional study|No interventions are implemented. This is an observational study of respiratory droplet aerosolisation during respiratory procedures.
45800292|NCT04600973|Behavioral|Technical assistance or team-based coaching|Main comparison in delivering peri-operative preventive strategies against transmission and infection is one on one technical assistance or team-based coaching.
45800293|NCT02625545|Device|UroLift System procedure|Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH
45800294|NCT02279641|Drug|RDEA3170 10 mg|
45800295|NCT02279641|Drug|allopurinol 300 mg|
45929337|NCT00034086|Drug|Lopinavir/Ritonavir|
45929338|NCT00034086|Drug|Lamivudine/Zidovudine|
45929339|NCT00034086|Drug|Tenofovir disoproxil fumarate|
45929340|NCT00034086|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|
45929341|NCT00034086|Drug|Lamivudine|
45929342|NCT00034086|Drug|Stavudine|
45929343|NCT00034086|Drug|Zidovudine|
45929344|NCT00034086|Drug|Didanosine|
45929345|NCT00034086|Biological|Lyme Disease Vaccine Recombinant OspA|
45929346|NCT00034086|Biological|Haemophilus B Conjugate Vaccine|
45929347|NCT00034125|Drug|LY353381|
45929348|NCT00034125|Drug|tamoxifen|
45929349|NCT01807481|Drug|Mircera|Once Monthly Mircera
45929350|NCT00034164|Drug|S-8184 Paclitaxel Injectable Emulsion|
45929351|NCT01807442|Other|Qualitative Interview and Adherence|All participants receive the same intervention. The intervention involves two qualitative interviews per participant. The first interview occurs in the hospital, and the second interview occurs at 12 weeks. Participants also receive a pill bottle that tracks when they take their aspirin. They will also receive a step counter to use for two weeks at the end of the study.
45929352|NCT00034203|Drug|efalizumab|
45800296|NCT04566731|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. The current, 1.5 mA, is approximately of the same intensity as the current provided by a 9-volt battery. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp.
45800297|NCT04566731|Device|Sham tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 1.5 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
45800298|NCT04566731|Behavioral|Modified Contraint-Induced Language Therapy (mCILT)|Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
45800299|NCT02988505|Other|Standard care|
45929353|NCT01807403|Procedure|Deep brain stimulation|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.
45450961|NCT02204956|Behavioral|Sustained Care|The Sustained Care intervention includes four main components: 1. a 40-minute individual session about quitting smoking during the hospital stay; 2. a 90-day telephone-based and text messaging program that provides support regarding smoking and nicotine patch use; 3. the opportunity, during the automated calls and texts to be transferred to quit smoking resources, including live telephone quit coaching counseling, web and text-based quit coaching resources; and 4. an 8-week supply of nicotine patches, provided at no cost.
45650965|NCT05067361|Procedure|Aerobic Exercise|Jogging was performed for 20 minutes. Jogging was performed by experimental group for 3 weeks and 4 sessions per week.
45650966|NCT05067361|Procedure|Ball Exercises|Ball exercises like stability ball roll, stability ball hug, stability ball catching, ball throwing and ball tapping exercises were for 10 minutes. Ball exercises was performed by both groups for 3 weeks and 4 times per week .
45650967|NCT03100669|Procedure|Pectus surgery|Patients undergoing surgical repair of pectus excavatum or carinatum
45650968|NCT03100513|Drug|Lactulose|(lactulose) (20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate
45650969|NCT03100513|Drug|Polyethylene Glycol|PEG as single dose of (3sachets if patient <75Kg over 3 hours or 4 sachets if patient >75Kg over 4 hours) dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water).
45650970|NCT05059561|Radiation|X-ray radiograghy|Cobb angles of the patient and control groups were determined by using X-Ray radiography used in the radiological examination routinely applied to the individuals who applied for the health board examination.
45800300|NCT04339985|Drug|ATx201|Topical
45800301|NCT04339985|Drug|ATx201 OINTMENT vehicle|ATx201 OINTMENT vehicle
45929354|NCT00034242|Drug|high-dose intravenous immunoglobulin (IVIG)|
45450962|NCT02204956|Behavioral|Usual Care|Usual Care includes a brief, 5 - 10 minute education session about quitting smoking, delivered by a hospital nurse during the hospital stay. Written handouts to reinforce the educational session will also be provided.
45450963|NCT02258230|Device|3D mode of the 3D Laparoscopic Video System|Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
45800302|NCT01859611|Device|TriActive+ RF|"Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts."
45450964|NCT02258230|Device|2D mode of the 3D Laparoscopic Video System|Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
45450965|NCT02258308|Behavioral|CHW intervention|Home education and support for asthma self management
45650971|NCT02530905|Drug|SRP-4045|SRP-4045 solution for IV infusion.
45800303|NCT04135807|Combination Product|Microdevice|"Placement of 1-3 microdevices (depending on the size of the tumor) before tumor resection is started.~The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs (Temozolomide, Lomustine, Irinotecan, Carboplatin, Lapatinib, Osimertinib, Abenaciclib, and Everolimus) released by the microdevice reservoirs. The drugs used in this study will only include drugs already used systemically for the treatment of gliomas."
45800304|NCT05215093|Other|Direct access physiotherapy for acute low back pain|Interventions include physiotherapeutic treatment, without prescription of the general practitioner, for low back pain according to current biopsychosocial national (KCE - Belgium) and international (NICE) guidelines.
45929355|NCT02971371|Device|Lokomat|"Both the groups performed 40 45min Lokomat sessions, five times a week, between 9am and 11am. The RAGTand VR group received a visual feedback showing a VR run game where the patient had to collect or avoid objects, to motivate him/her to walk actively. Each avatar's leg movement corresponded to that performed by the patient. On the other hand, the RAGT without VR group was not provided an avatar, and a smile indicating the goodness of each leg movement. The biofeedback of the Lokomat gait orthosis is based on the interaction torques between the participant and the orthosis"
45650972|NCT02530905|Drug|Placebo|SRP-4045 placebo-matching solution for IV infusion.
45650973|NCT00552097|Drug|ezetimibe (plus simvastatin)|oral tablets; ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
45650974|NCT00552097|Drug|placebo (plus simvastatin)|tablets; placebo to match ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
45800305|NCT05215093|Other|Usual care for acute low back pain|Interventions include standard of care by the general practitioner for low back pain according to current biopsychosocial national (KCE - Belgium) and international (NICE) guidelines.
45800306|NCT01862419|Other|Alert|
45800307|NCT00553813|Drug|TPI 287|Intravenous dose of 125 mg/m2 TPI 287 on Day 1, Day 8, and Day 15 in a repeating 28 day cycle.
45800308|NCT02629991|Drug|Intranasal Oxytocin (IN-OXT)|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
45929356|NCT01807325|Procedure|pancreas biopsy|patients who are already having a pancreas biopsy will be invited to enroll. After obtaining enough tissue for usual medical care, we will divert some tissue for the study.
45929357|NCT00034281|Drug|TAK-165|Starting dose of TAK-165 10 mg, tablets, orally, once daily with dose escalation to tolerability for 56 days.
45929358|NCT01807286|Drug|Pomalidomide|"Phase I: Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21 of a 28 day cycle.~Phase II: Starting dose of Pomalidomide maximum tolerated dose from Phase I."
45929359|NCT01807286|Drug|Melphalan|Phase I and II: 9 mg/m2 by mouth on days 1-4 of a 28-day cycle.
45650975|NCT05067049|Device|Connected application arm|"patients have to respond different questionnaires about their quality of life on the mobile app.~And follow-up visits with the physicians as usual"
45929360|NCT01807286|Drug|Dexamethasone|Phase I and II: 40 mg/day by mouth on days 1-4 of a 28 day cycle.
45929361|NCT01807286|Behavioral|Questionnaires|Questionnaires about the feeling in hands and quality of life completed at different time points during the study.
45929362|NCT00034359|Drug|ACH-126,443|
45650976|NCT05067049|Device|Unconnected arm|Follow-up visits with the pysicians as usual
45650977|NCT00396175|Drug|MK0906, finasteride / Duration of Treatment : 48 Weeks|
45650978|NCT00396175|Drug|Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks|
45650979|NCT02530671|Device|Toothbrushing with manual toothbrush|
45650980|NCT02530671|Device|Toothbrushing with power toothbrush|
45650981|NCT02603393|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI
45650982|NCT02603393|Drug|Tiotropium|Tiotropium will be supplied as commercially available blisters, delivered via HandiHaler®
45650983|NCT02603393|Drug|Salmeterol/fluticasone|Salmeterol/fluticasone propionate dry inhalation powder delivered via Accuhaler™
45650984|NCT05365269|Behavioral|Proactive Automatized Lifestyle intervention|Multi-behavioral; including individually-tailored, theory-based, repetitive, ipsative and normative feedback.
45650985|NCT04832945|Drug|Ivermectin 6 Mg Oral Tablet|Ivermectin weekly oral dose 0.2 mg/kg equivalent for 4 weeks
45800309|NCT02629991|Other|Matched Placebo|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
45800310|NCT00553657|Drug|DETROL LA (drug)|
45800311|NCT05157529|Device|AQUABEAM Robotic System|"The AQUABEAM Robotic System is developed and manufactured by PROCEPT BioRobotics, Corp. It is intended for use in patients suffering from lower urinary tract (LUTS) resulting from benign prostatic hyperplasia (BPH). The AQUABEAM Robotic System is designed for cutting of prostate tissue during minimally invasive surgical procedure and shall be inserted via transurethral approach and is advanced through the urethra and into the prostatic urethra.~The system is designed to utilize a high-velocity sterile saline stream as the cutting medium which is projected through a nozzle positioned within the prostatic urethra. The nozzle assembly motion is driven by a motor system, controlled by the user. The pressure is generated by a high-velocity pump system controlled by the AQUABEAM Console. The user is allowed to adjust the desired flow rates manually. All functions are displayed on a medical panel computer. Pre-condition parameters are set on the console before operation."
45800312|NCT05157529|Device|Apogee 2300 digital color doppler ultrasound imaging system|"The SIUI Apogee 2300 is a digital ultrasound imaging system capable of the following operating modes: B-Mode (B, 2B, 4B), M-Mode, CFM, CPA, PWD, CWD, Combined (B, M, CFM, CPA, PWD, CWD, XBeam, Panoscope), others (3D, 4D, Trapezoidal /Extended Sector Imaging, Elastography, Anatomical M-mode, TDI, MFI, ECG, VS Flow, Color M, DICOM).~The system is designed for use in linear, convex, phased array and 3D scanning modes and supports linear, convex, phased array, 3D and endocavity (trans-vaginal and trans-rectal) transducers. The system has cine review, image zoom, measurements and calculations, image storage and review, printing and recording capabilities."
45800313|NCT05154955|Drug|10XB-101 Solution for Injection|One of the three concentrations of 10XB-101 will be evaluated against placebo for submental fat reduction.
45800314|NCT05154955|Drug|10XB-101 Vehicle Solution for Injection|This is the placebo control
45800315|NCT02633735|Other|Appy CDS|See description under arm/group section
45800316|NCT05142709|Drug|Anti-PD-1 Immune Checkpoint Inhibitors|used as 1st line treatment for metastatic ESCC.
45800317|NCT05018663|Other|Artificial Intelligence software ROSE|Rapid on-site evaluation (ROSE) of Endoscopic Ultrasound (EUS) guided FNA/FNB (Fine Needle Aspirate/Fine Needle Biopsy) of pancreatic solid lesions (PSLs) has been shown in improve diagnostic yield. The availability and performance of ROSE at EUS performing centers is variable. With strides in Artificial Intelligence (AI) capabilities over the years, the University of Texas at Health Sciences Center at Houston in collaboration with Haystac is developing an artificial intelligence based proprietary system to analyze slides from EUS FNA/FNB samples at bedside.
45929363|NCT00034359|Drug|Lamivudine|
45929364|NCT00034359|Drug|Placebo|
45929365|NCT01807247|Procedure|Intensive lower limbs muscles strengthening|
45800318|NCT03949231|Drug|PD1/PDL1 inhibitor|Infusion of PD1/PDL1 inhibitor through peripheral vein or hepatic artery.
45800319|NCT03897205|Drug|Imlifidase|Imlifidase is an IgG degrading enzyme of Streptococcus pyrogenes that cleaves all 4 human subclasses of IgG with strict specificity.
45650986|NCT05618327|Drug|JS203 for Injection|"2-steps:JS203 for Injection is administered on the first and eighth day of the first cycle and every 3 weeks thereafter.~3-steps:JS203 for Injection is administered on the first, eighth and fifteenth day of the first cycle and every 3 weeks thereafter.~4-steps:JS203 for Injection is administered on the first, eighth, fifteenth and twenty-second day of the first cycle and every 3 weeks thereafter."
45800320|NCT03897205|Other|Plasma Exchange|The subject's plasma is removed and discarded and the subject receives replacement donor plasma, albumin, or a combination of albumin and saline. IA may be used instead of PE to the discretion of the investigator. IA is achieved by passing a subject's plasma over columns that bind immunoglobulins (Igs) and then the plasma is passed back to the subject.
45800321|NCT04992143|Procedure|TACE|TACE first ,and more TACE could be performed when it is necessary.
45929366|NCT01807208|Other|Educational Tool|"A personalized health goal education and reminder tool, with 3 parts: report card showing the status of secondary prevention domains during hospitalization; questions to help prepare the patient for the follow-up visit; and potential questions for the physician."
45929367|NCT04712045|Other|New PPE|The use of a new protocol of level 2 PPE which involves wearing a short-sleeve gown and a single pair of gloves
45929368|NCT04712045|Other|Old PPE|The use of a standard protocol of level 2 PPE which involves wearing a long-sleeve gown and double pairs of gloves
46072551|NCT03813108|Biological|CPS-immunization (A/L)|Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes and receive presumptive treatment with artemether/lumefantrine initiated on day 7 after each immunization.
45450966|NCT02205034|Drug|oxytocin|Intranasal administration
45450967|NCT02210728|Drug|methylphenidate or amphetamine product|Medication is titrated over a 4-week period with stepwise increments each week. Patients and significant others complete ADHD symptom scales at baseline and before each medication visit. Patients also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the subjects remain on this dose for the remainder of the study.
45650987|NCT02642653|Drug|Lovastatin|Once per day dosing
45650988|NCT02642653|Other|Placebo|Once per day dosing
45650989|NCT01659567|Drug|Pegylated Interferon Alfa-2a|Pegylated interferon alfa-2a will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
45650990|NCT01659567|Drug|Ribavirin|Ribavirin will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
45650991|NCT04364087|Diagnostic Test|Oral glucose tolerance test|Oral glucose tolerance test with 75 g glucose (75 g OGTT) will be performed to those with normal fasting glucose and HbA1C levels. Women will be recommended to have normal diet for 3 days and overnight fasting for at least 8 hours. The blood withdrawal will be performed twice: (i) fasting and (2i) 2 hours after solution administration. The volume of blood for each test is 2 ml. Impaired glucose tolerance will be diagnosed when two-hour glucose levels of 140 to 199 mg/dL (7.8 to 11.0 mmol/l) (American Diabetes Association, 2018).
45650992|NCT04832633|Diagnostic Test|Different contrast media injection methods|Different contrast media injection methods
45650993|NCT04835909|Behavioral|Modern board and card games group|Modern board and card games group
45650994|NCT04835909|Behavioral|Paper and pencil tasks group|Paper and pencil tasks group
45800322|NCT04992143|Drug|Tilelizumab|Tilelizumab 240mg per 3weeks ivgtt within 1 week after the first TACE
45800323|NCT04992143|Drug|Sorafenib|Sorafenib should be administered 400 mg twice /day orally within 1 week after the first TACE
45800324|NCT01866163|Drug|LEO 90100|
45800325|NCT01866163|Drug|Vehicle|
45800326|NCT04485065|Drug|IBI188+azacitidine|"Escalating and maintenance dose of IBI188 will be administered 30mg/kg, IV(intravenous infusion),Q4W~Drug:Azacitidine Azacitidine will be administered daily for 7 days, IH, Q4W"
45929369|NCT00034476|Drug|sPLA2 Inhibitor|
46072552|NCT03813108|Drug|Atovaquone / Proguanil Oral Tablet [Malarone]|All participants will be treated with atovaquone/proguanil (1000/400 mg (= 4 tablets) 1×/day during 3 consecutive days) when they develop a malaria infection or on day 28 after malaria challenge infection.
45800327|NCT04969289|Behavioral|Dr. Eric Digital Health Intervention|Dr. Eric is a user-informed, theory-based, digital health intervention that aims to improve adolescent male SRH. This ED-based intervention consists of two parts-an interactive, tailored app and 3 months of personalized, two-way text messaging. It is based on an evidence-based sexual health curriculum we developed using established behavioral theories, prior literature, input from key stakeholders, qualitative patient interviews, and our prior ED-based work.
45800328|NCT03769129|Drug|Pembrolizumab|Pembrolizumab
46072553|NCT03797807|Procedure|MINST|A non-surgical minimally invasive treatment protocol, named MINST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential
45650995|NCT05363631|Drug|Selenomethionine (SLM)|Selenium (Se) is a natural element present in the earth's crust often in association with sulfur-containing compounds. Humans get their dietary requirements mainly from food. In this study Selenium will be administered in the chemical composition of selenomethionine (SLM)
45650996|NCT05363631|Drug|Axitinib|Axitinib is a small molecule tyrosine kinase inhibitor.
45800329|NCT03769129|Procedure|microwave ablation|microwave ablation
45800330|NCT04957589|Dietary Supplement|Very Low Calorie Diet|"A dietary intervention consisting of four meals (provided by LighterLife®), totaling approximately 600kcal/day (each meal comprising approximately 150kcal/day). Participants are provided with a choice of one of six meal protocols, which consist of a pre-set combination of meals that arrive at approximately 52g protein, more than 15g fibre and less than 20g sugar per day."
45929370|NCT01807169|Procedure|Colonic polypectomy or endoscopic mucosal resection (EMR).|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
45650997|NCT05363631|Drug|Pembrolizumab|Pembrolizumab is a type of immunotherapy
45800331|NCT04957589|Other|High Intensity Interval Training|The HIIT training will consist of a five-exercise approach across three movements (star jumps, standing squats, on-the-spot-sprinting, standing squats and star jumps), which are collectively described as a cycle in this context. Each exercise is performed for 60 seconds with a 90 seconds recovery period. Each training session will begin with a two minute warm-up and cooldown (on-the-spot-jogging) followed by five minutes of static stretching. Volunteers would aim to exceed the initial number of star jumps and standing squats in the subsequent attempt per cycle. A total of three training sessions per week are to be completed, preferably non-consecutive but may be consecutive on no more than two training sessions per week. Progression is through a gradual increase in volume (repetitions of star jumps and standing squats) on a per-session basis.
45929371|NCT01807130|Other|Automated HF/EP Referral|Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology (EP) with recommendations to consider those therapies that are not in compliance with guidelines.
45929372|NCT01807130|Other|Placebo (Registry Arm)|Patients assigned to the registry will receive referral to specialists in HF or EP as deemed necessary by the patients physicians.
45929373|NCT00396474|Other|post GH treatment observational study|Intravenous glucose tolerance test (IVGTT)
45800332|NCT03759847|Other|Fluid intake app|Use of fluid app to monitor intake of fluids
45650998|NCT05032729|Other|Trypophan, Theanine and 5'AMP|250 ml beverage consumed at 21:00 hours
45650999|NCT05032729|Other|Placebo|250 ml beverage consumed at 21:00 hours, matched in appearance and taste to the active beverages
45800333|NCT03759847|Other|Survey|A survey will be used to assess the usability of the app (ease of use in general, ease of capturing fluid intake data, including the choice of pre-selected volumes for fluid containers, reasons for not using the app more frequently, the usefulness of the app notifications, ease of sending data to the study coordinator for review) as well as to collect recommendations for changes to the app itself.
45800334|NCT04482569|Drug|XNW4107|Single or multiple dose ascending study for XNW4107 alone or multiple dose study of XNW4107 in combination with imipenem/cilastatin
45800335|NCT00367367|Procedure|Hysteroscopy and Curettage|
45800336|NCT05075551|Device|Acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used.SP6 is on the tibial aspect of the leg, posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus; BL23 is in the sacral region, in the second posterior sacral foramen; BL54 is in the fourth posterior sacral foramen, 3 cun beside the median sacral crest; BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
45651000|NCT04835753|Device|shock wave|true radial ESWT.A rESW pneumatic device (SHOCK MED, Italy) was used to provide one session per week (for a total of 12-week)
45651001|NCT04835753|Other|traditional physical therapy program|lower limbs muscles stretch and strength in addition to balance and gait training
45651002|NCT05059171|Device|OneSahpe single file|The rotary motion of OneShape single file
45651003|NCT05059171|Device|WaveOne Gold single file|reciprocation motions of WaveOne Gold single file
45651004|NCT04822805|Drug|Anlotinib hydrochloride|Patients with recurrent high-grade gliomas are being enrolled , treated with anlotinib 12mg once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity.The dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
45929374|NCT00034515|Drug|denufosol tetrasodium (INS37217) Inhalation Solution|
45929375|NCT01807091|Drug|Chemotherapy|Receive outpatient induction chemotherapy
46072554|NCT03797807|Procedure|MIST|A minimally invasive surgical treatment protocol, named MIST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential
46072555|NCT03797807|Diagnostic Test|GTI subgroup (Geometrical/Thermal Imaging)|Geometrical/Thermal Imaging
45651005|NCT05059249|Procedure|Hot Pack|Superficial Heating
45651006|NCT05059249|Procedure|Manual Traction|Manual Traction for 10 minutes
45651007|NCT05059249|Procedure|Mechanical Traction|Mechanical Traction for 10 minutes
45651008|NCT05059249|Procedure|Joint Mobilization|3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions
45651009|NCT05059249|Procedure|TENS|TENS for 10 minutes with hot pack
45651010|NCT04835285|Diagnostic Test|Npf.|3T MRI and 1,5 T MRI scanners. For myocardium, pancreas and pituitary gland iron overload
45651011|NCT04095637|Device|Medial knee arthroplasty|Surgical intervention where the medial portion of the knee is replaced by an artificial metal and polyethylene implant
45651012|NCT04835207|Other|"1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"|"Blood samples were obtained before PCI, and the following parameters will be measured: 1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"
45651013|NCT05058937|Diagnostic Test|Comprehensive genomic profiling|TSO500 (523 genes + MTB + MSI)
45800337|NCT05075551|Device|Sham acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used.These volunteers will receive relatively shallow needling at bilateral sham SP6, BL54, BL23 and BL35. This treatment gets involved in the same duration and frequency of sessions, but the treatment was delivered superficially at non-acupuncture points 10 mm to the lateral of corresponding acupuncture and not above a meridian line (10mm to SP6, BL54, BL23 and BL35).The same equipment of fMRI scanner will be used.
45651014|NCT04832555|Radiation|Non elective radiotherapy|Simultaneous integrated boost on CTV volumes, delineated as per guidelines, with the exception of intermediate-low risk, where the CTVs are experimental.
45651015|NCT04832789|Device|Venovenous ECMO|Venovenous ECMO
45651016|NCT05066893|Other|telehealth visits|intensive visits with doctor
45651017|NCT04435093|Other|MFM-Play|Neuromuscular patients will complete five items of the MFM (items 18 to 22) either conventionally or using the MFM-Play with 2 different therapists, on the same day. The order of the MFM type completion will be determined by randomization. Both therapists will rate items 18 to 22 blindly.
46072556|NCT03741374|Procedure|Minimally-invasive non-surgical therapy (MINST)|A non-surgical minimally-invasive treatment protocol, named MINST, has been proposed (Ribeiro et al. 2011) for the treatment of periodontitis, in order to minimise patient discomfort and maximise the healing potential. This technique usually involve the use of magnification lenses or microscopes and small instruments which would reduce the risk of tissue trauma compared with traditional instruments.
45800338|NCT05075551|Other|fMRI scan|Both two group will get fMRI scan week 0 (before treatment), week 12 (after treatment) and week 36 (following up). The resting-state fMRI data will be obtained by using a 3.0T GE MR 750 MRI scanner with an eight-channel phase array head coil at the Huashan Hospital, Shanghai. The high resolution T1-weighted magnetic resonance images will be collected by a three-dimensional fast spoiled gradient-echo dual-echo sequence [repetition time (TR) = 8100 ms; echo time (TE) = 3.1 ms; FA = 8 deg; matrix=256 × 256; field of view (FOV)=25.6× 25.6 cm2; slice thickness=1 mm; no gap and 156 slices]. The whole resting state fMRI data will be acquired by using a gradient-recalled echo-planar imaging pulse sequence (TR/TE = 2,000/30 ms; FA = 90°; acquisition matrix = 64×64; FOV = 22×22 cm2; slice thickness= 4 mm; 43 slices and total 240 time points; no gap).
45800339|NCT04470011|Other|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
45800340|NCT04470011|Other|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
45800341|NCT02988739|Biological|seasonal influenza vaccine|influenza vaccine containing 15 µg haemagglutinin of three seasonal influenza virus strains recommended by WHO
45800342|NCT02988739|Device|fractional Er:Yag laser|Fraction laser device to apply micorpores of defined depth and density into skin.
45800343|NCT00367445|Drug|Inhaled Human Insulin (Exubera)|
45800344|NCT00367445|Drug|Insulin Glargine (Lantus)|
45800345|NCT05044585|Other|Remote Automated Monitoring System|The subject will be monitored with conventional monitoring devices as well as the MultiSense patch.
45800346|NCT04467593|Device|Whole body hyperthermia|Whole body hyperthermia to treat stage IV cancer patients
45651018|NCT03100435|Device|Er:YAG Laser|Titanium disks will be decontaminated ex-vivo with the Er:YAG laser.
45800347|NCT04467593|Drug|Standard of Care (SOC) chemotherapy according to the NCCN guidelines.|Whole body hyperthermia to treat stage IV pancreatic cancer patients combined with standard of care chemotherapy
45800348|NCT01866943|Drug|Tranexamic Acid|Tranexamic Acid 1.5 g (100 mg/mL)in 100cc normal saline is applied topically to the wound for 5 minutes time then suctioned and the skin closed. The control group receives just normal saline and no drug.
45800349|NCT01866943|Drug|Normal Saline Solution|
45800350|NCT04436081|Drug|THC-free CBD Oil|Hemp-based CBD oil Gelcaps
45800351|NCT04436081|Drug|Placebo|Placebo Gelcaps
45800352|NCT05003557|Other|Questionnaire administration|"3 different questionnaires are going to be administered to each participant,~concerning the current health situation~the SF 36~the IPQ-R questionnaire"
45651019|NCT03100435|Other|Carbon Fiber Curette|Titanium disks will be decontaminated ex-vivo with carbon fiber curettes
45800353|NCT01868425|Drug|multimodal:acetaminophen, gabapentin, ketamine, bupivacaine|acetaminophen, gabapentin, ketamine, bupivacaine and standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
45800354|NCT01868425|Drug|placebo pills and injectables|receives standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane plus placebos of intervention arm meds
45800355|NCT01869439|Device|"gold standard LxW manual ruler measurement technique"|"Currently, the gold standard LxW manual ruler measurement technique is used for measuring the area of an external wound. The LxW is measured by measuring the longest length (head to toe) times the widest width (perpendicular to the length)."
45651020|NCT03036995|Drug|Apremilast|Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.
45651021|NCT03036995|Other|Placebo|Patient will receive narrow UVB treatment and placebo (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and placebo during 24 weeks.
45800356|NCT01869439|Device|WMMS ImageReview software's LxW measurement technique|This software measurement technique is part of tthe WMMS and also measures the external wound LxW by the longest length (head to toe) times the widest width (perpendicular to the longest length).
45800357|NCT01869439|Device|WMMS ImageReview software's Visual External Wound Trace|This is a measurement technique of the ImageReview software that enables the user to trace the perimeter edge of the wound's visual image.
45800358|NCT01869439|Device|WMMS ImageReview software's External Wound Trace Overlay|This measurement technique is a feature of the WMMS, utilizing the visual external wound trace and overlaying it onto the thermal wound site. From the thermal overlay, variation data such as the differences in the thermal intensities (gradient), mean, and the mode of the thermal wound bed can be measured.
45800359|NCT00550459|Drug|Tolvaptan|15-60 mg oral tablet given once a day for 21 days.
45651022|NCT03100279|Behavioral|Coping Cat/CAT Project|"The Coping Cat program, developed by Kendall and colleagues (Kendall, 1994; Kendall, 2000; Kendall, Kane, Howard, & Siqueland, 1989; Kendall, Flannery-Schroeder et al., 1997), involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward. The therapist uses modeling (e.g., revealing therapist's own anxiety and sharing successful coping experiences), in vivo exposure tasks, role-playing (e.g., to prepare for exposure tasks), relaxation training, and contingent reinforcement (e.g., for trying and for succeeding at exposure tasks), in developing these four themes."
45651023|NCT03100279|Behavioral|Primary and Secondary Coping Enhancement Therapy|PASCET is a brief (11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, & Snyder, 1982; Weisz et al., 1984a,b). In this model, primary control involves efforts to cope by making objective conditions (e.g., one's activities, one's peer status) conform to one's wishes. In contrast, secondary control involves coping by adjusting oneself (e.g., one's expectations, interpretations) to fit objective conditions, so as to influence their subjective impact without altering the actual conditions. The goal is for youngsters to build their skills in primary and secondary control coping, and apply those skills to events and conditions that can trigger depression. Therapists are guided by a Therapist's Manual and use a youth workbook.
45651024|NCT04835051|Behavioral|Breastfeeding promotion|The intervention included training of health workers in private health facilities to provide in-person breastfeeding counseling to pregnant women and women with a child <6 months during clinic visits. The health workers also offered a mobile phone support component for appointment reminders, breastfeeding SMS and WhatsApp messages, WhatsApp breastfeeding support groups, informational materials (posters and foldable pocket-sized cards), and family engagement activities. Breastfeeding-related mass media through television and radio spots was available state-wide, including to women in intervention and comparison facilities.
45651025|NCT04001101|Combination Product|RT and Anti-PD-1|limited metastatic site radiation
45651026|NCT04001101|Drug|Anti-PD-1|anti-PD-1 therapy alone
45651027|NCT04299893|Drug|Ozone|Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
45651028|NCT04299893|Drug|Oxygen|Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
45800360|NCT00550459|Drug|Placebo|Placebo tablet given once daily for 21 days
45800361|NCT04916587|Other|Implementation Strategy of ACEs Screenings|We will use implementation mapping, guided by the EPIS framework, to promote a co-created process and refine the strategy comprised of online training videos, a customized ACEs algorithm and use of technology to improve workflow efficiency, implementation technical assistance/coaching, and written implementation protocols.
45800362|NCT04916587|Other|Usual Care|"The ACEs Aware policy goal is to equip providers with training and clinical protocols to screen children and adults for ACEs, detect ACEs early, and connect patients to interventions, resources, and other support to improve patient health and well-being. ACEs screenings are comprised of: a) a 2-hour on-line provider training; b) the Pediatric ACEs and Related Life-events Screener or PEARLS tool; c) an ACEs associated health conditions checklist; and d) complete a wellness exam. The primary care provider uses multiple sources of information to identify a child's need for follow-up services."
45800363|NCT04901611|Behavioral|Parental touch|Parental touch in the form of stroking at 3cm/s for 10 seconds on the posterior lower limb where the heel lance will be/has been administered
45800364|NCT03545971|Drug|IBI310|IBI310 is anti CTLA-4 antibody
45800365|NCT03545971|Drug|Sintilimab|PD-1 monoclonal antibody
45800366|NCT01871077|Drug|PRO-156|Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
45800367|NCT03436069|Other|Conventional treatment protocols of breast cancer|
45800368|NCT03426709|Behavioral|Low intensity Internet-delivered psychotherapy|The online intervention will be individual and interactive, which will be supported by multimedia material (videos, sound recordings, etc.) and will have internet support. The estimated duration of the program is 8 weeks. Low Intensity Internet-delivered psychotherapy: Psychoeducation, Healthy living habits, Behavioral activation, Positive Psychology, Mindfulness and Compassion
45800369|NCT02988583|Device|Surgery using low viscosity silicone oil|Pars plans vitrectomy using low viscosity silicone oil
45800370|NCT02988583|Device|Surgery using high viscosity silicone oil|Pars plans vitrectomy using high viscosity silicone oil
45800371|NCT04896073|Drug|Minnelide|Administered orally (2 mg) once daily for 21 days of 28-day cycles for 12 cycles.
45800372|NCT04894045|Other|Personalized management|Intraoperative MAP will be maintained at least at the mean nighttime MAP (assessed using preoperative automated blood pressure monitoring). If the mean nighttime MAP is below 65 mmHg, intraoperative MAP will be maintained at least at 65 mmHg.
45800373|NCT01872325|Behavioral|Education|An education program will be developed using behaviour change techniques specifically mapped to address modifiable factors identified in a previous study. These techniques will include: information about the significance of agonal breathing, modeling/demonstration of desired behavioural skills, rehearsal of desired skills, and monitoring/reinforcement and feedback.
45800374|NCT01874119|Drug|Fosaprepitant|During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
45800375|NCT02280655|Biological|Storage-aged red blood cells (saRBCs) units|Packed RBCs units stored for greater than 21 days, with a mean storage duration of 29.6 ± 4.9 days (mean ± SD)
45800376|NCT02280655|Biological|Fresh red blood cells units|Packed RBCs units stored for less than 14 days, with a mean storage duration of 9.6 ± 3.9 days (mean ± SD)
45800377|NCT02987881|Behavioral|Home-based aerobic exercise and nutritional counseling|Moderate walking and running with nutritional counseling at study visits.
45800378|NCT02823145|Drug|ZX008 (Fenfluramine Hydrochloride)|
45800379|NCT02721589|Biological|SHR-1210|A fully human monoclonal immunoglobulin (IgG4 subtype)
45651029|NCT04834895|Other|mhealth exercise group|Participants were asked to perform 18 exercises specially prepared for neck pain in the M.ü Neck Exercises application according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks
45800380|NCT02657707|Device|Roadsaver™ Carotid Artery Stent Device|The Roadsaver™ carotid artery stent system is indicated for use in patients with significant atherosclerotic disease of the carotid arteries.
45800381|NCT02657707|Device|Nanoparasol® Embolic Protection System|The Nanoparasol® embolic protection system is indicated for use with a guidewire to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in carotid arteries.
45800382|NCT02280811|Drug|Fludarabine|Patients will receive Fludarabine 25 mg/m^2/day for 5 days.
45800383|NCT02280811|Drug|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days
45800384|NCT02280811|Biological|E6 TCR|On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)
45651030|NCT04834895|Other|brochure exercise group|Participants were asked to perform 18 exercises specially prepared for neck pain in the brochure according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks
45651031|NCT05066425|Dietary Supplement|Soluble Corn Fiber|Participants will be asked to consume a packet of 22g Soluble Corn Fiber/day for 4 weeks
45800385|NCT02280811|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
45800386|NCT02263963|Drug|Exparel|In this arm as described above the intervention will be TAP block injection under ultrasound guidance using Exparel.
45800387|NCT02263963|Procedure|TAP Block|no intervention will be done to this arm.
45800388|NCT03029923|Behavioral|Experimental: Behavioral Activation Treatment for Cardiac Smokers (BAT-CS)|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.
45800389|NCT03029923|Behavioral|Smoking cessation plus Health and Wellness|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
45800390|NCT01930435|Device|Sterile Humidification Device|This is a personal humidification device. It is hand held and produces sterile warm vapor.
45800391|NCT01930747|Drug|rocuronium|measure effect on laparoscopic workspace
45800392|NCT01930747|Drug|Sevoflurane|1 MAC sevoflurane inhalation is given
45800393|NCT01930747|Drug|remifentanyl|remifentanyl is given in infusion
45800394|NCT01931527|Drug|Rasburicase|one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
45800395|NCT01933243|Drug|Fish oil|Participants will take 4 capsules daily
45800396|NCT01933243|Drug|Placebo pill|Participants will take 4 capsules daily
46072557|NCT03737149|Other|mymobility with Apple Watch|The mymobility mobile application is a mobile software platform designed to facilitate remote episode of care management and asynchronous communication between the provider care team and their patient via provider-approved care plans and engagement communications. Current care pathways have been developed for: Total Hip Replacement, Total Knee Replacement and Partial Knee Replacement. Designed for the orthopedic population, mymobility also integrates wearable data from the Apple Watch into provider dashboards, providing enhanced understanding and monitoring of patients throughout the episode of care.
45651032|NCT05066425|Dietary Supplement|Maltodextrin|Participants will be asked to consume a packet of 22g Maltodextrin/day for 4 weeks
45651033|NCT04832243|Other|Survey questionnaire|Each version of the questionnaire includes a different number of true-false statements that study participants are asked to identify.
45651034|NCT04832321|Other|Survey questionnaire|Each version of the questionnaire portrays a young Ugandan man with different profiles of illness severity, treatment, and treatment response.
45651035|NCT04296071|Other|Research study|Blood and tracheal aspirates will be collected
45800397|NCT01933399|Other|Inextensible LSO (stiff back support)|Cotton/nylon canvas back support with velcro fasteners.
45800398|NCT01933399|Other|Extensible LSO, a back support that is flexible|Back support is constructed from lycra and neoprene with velcro fasteners.
45800399|NCT01933399|Other|Standard of Care|Physician visit, physician advice, medications as determined by physician, over the counter medications, and physical therapy.
45800400|NCT02639351|Biological|Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R|Intramuscular (IM) vaccination of 1 dose of 0.5 mL
45800401|NCT02639351|Biological|Investigational MenC-CRM adjuavnted with 25 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
45800402|NCT02639351|Biological|Investigational MenC-CRM adjuavnted with 50 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
45800403|NCT02639351|Biological|Investigational MenC-CRM adjuavnted with 100 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
45800404|NCT02639351|Biological|Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)|IM vaccination of 1 dose of 0.5 mL
45800405|NCT02639429|Drug|Vaginal Misoprostol|
45800406|NCT02639429|Device|Foley Balloon + Vaginal Misoprostol|
45929376|NCT00034554|Biological|gp75 DNA vaccine|6 patients will be enrolled in each of the 5 vaccination groups. Patients in vaccination groups 1-3 will receive a total of 5(1 mL) vaccinations. Patients assigned to vaccination group 4 will receive a total of 5 (2.0 mL) vaccinations administered as 2 1 mL injections. Patients assigned to vaccination group 5 will receive a total of 5 (4.0 mL or 8.0 mg)vaccinations administered as 4 1 mL injections per vaccination treatment Patients will receive gp75 DNA vaccinations every 3 weeks for 5 vaccinations. Injection sites will be given intramuscularly and rotated for each dose using all 4 limbs with the exception of a site that had the removal of lymph nodes. Progression to next higher dose level will be based on the 5* patient safely completing the 2nd vaccination at the lower dose level.
45651036|NCT02694679|Behavioral|CBNH|The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.
45651037|NCT04831931|Other|Exercise Program Applied by Telerehabilitation|"Patients will be evaluated 3 times for 4 weeks throughout the study; before the study commences, at the end of 2th and 4th week~Exercises will be planned to last for 15 minutes a day, and will be progressed and changed weekly throughout the study period. To the exercise program; It will be created as a progressive program by including stretching, normal range of motion movements, neck, core and scapular stabilization and strengthening exercises and the same program will be given to both groups."
45651038|NCT05066035|Drug|Neostigmine|"The study investigators administer neostigmine at the end of operation to reverse neuromuscular blockade, and the routine dose of the intravenous neostigmine is 0.05 mg/kg and atropine 0.02 mg/kg. The dose is given in a single syringe, and later they administer this reversal medication before extubation.~In the case of a residual block, the neostigmine group of patients receives a rescue dose of neostigmine at a dose of 0.03 mg/kg in the operating room fifteen minutes before discharge."
45800407|NCT01936363|Drug|Pimasertib once daily|Pimasertib administered as oral capsule at a dose of 60 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
45800408|NCT01936363|Drug|Pimasertib placebo|Placebo matching Pimasertib administered once daily in evening until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
45800409|NCT01936363|Drug|SAR245409 placebo|Placebo matching SAR245409 administered once daily in morning until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
45800410|NCT01936363|Drug|SAR245409|SAR245409 administered as oral capsule at a dose of 70 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
45800411|NCT01936363|Drug|Pimasertib twice daily|Pimasertib administered as oral capsule at a dose of 60 milligram (mg) twice daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
45800412|NCT04894097|Device|radial extracorpeal shock wave|Swiss DolorClast® Master - Shockwave Therapy System will be used to apply the radial extracorporeal shock wave. It consists of master console, Evo Blue hand-piece, 15mm and 36mm interchangeable contact heads (applicators), contact gel, cart, and external compressor
46072558|NCT03733626|Combination Product|ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle screw system|ViviGen® is manufactured by LifeNet Health. ViviGen® Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10 and will be used with the FDA approved DePuy Synthes Spinal pedicle screw system for fusion.
45651039|NCT05066035|Drug|Sugammadex|The study investigators administer the routine full-dose neostigmine reversal medication and three minutes later, they administer an intravenous bolus dose of 1 mg/kg sugammadex in a different syringe prepared earlier as a reversal agent. The anesthesia team considers using an intravenous rescue dose of 1 mg/kg sugammadex for this group of patients in the recovery room if patients do not show a complete recovery of TOF ratio equal to >0.9 in the recovery room before discharge to the ward.
45651040|NCT04428593|Drug|Treamid 5 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
45651041|NCT04428593|Drug|Treamid 15 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
45651042|NCT04428593|Drug|Treamid 50 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
45651043|NCT04428593|Drug|Placebo|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
45800413|NCT04893629|Biological|mono nuclear cells injection|trans endocardium injection of autologous mono nuclear cells for the intervention group and classic treatment for the control group
45450968|NCT02210728|Behavioral|Cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy. Participants also receive individual coaching 3 times a week (twice over telephone and once in person). Coaching sessions are 15 minutes each in duration and are aimed at implementation, practice, and generalization of skills acquired in therapy.
45800414|NCT04893629|Drug|Digoxin+furosemide+captopril|classical heart failure medical treatment
45450969|NCT02220868|Drug|Sofosbuvir, Ribavirin, and Stribild|
45450970|NCT02210962|Dietary Supplement|essential fatty acids|Yellow capsules containing eicosapentaenoic acid, docosahexaenoic acid (active)
45800415|NCT04892849|Other|Conventional Therapy acc. to prevailing clincal approved schemes|The study is observational. The treatment-plan of the underlying disease remains unchanged. The treatment of the patient is according to the prevailing clinical approved schemes at the respective entities. Blood will be drawn from patients at several time points during and after RT and ICI for detailed immunomonitoring of the patients.
45651044|NCT03852667|Behavioral|Pain Neuroscience Education|The PNE intervention consisted of 2 sessions of 30 minutes. In the first session, the main goal is to explain the patient why pain is important and why people can't live without it. Besides it is explained why objective findings such as x-rays, MRI, CT scans, etc. often lack significant findings despite the pain that the patient experiences. This first session of pain education might help the patient understand that pain is necessarily a result from tissue damage. Furthermore, the session explains the right approach to conquer pain and to avoid going down in this vicious circle of low back pain. The second session of PNE, is a revision of the first session, continuing on what was unclear from the first session.
45800416|NCT04891991|Drug|Intravitreal infliximab|1 mg/0.05 mL of infliximab will be injected intravitreally at the end of pars plana vitrectomy.
45800417|NCT04891991|Procedure|Pars plana vitrectomy|Standard pars plana vitrectomy
45800418|NCT00366587|Device|Cataract surgery and IOL implantation|
45651045|NCT03852667|Other|Exercise therapy|The exercise therapy varies form analytical exercises in the first sessions, to functional and sports related exercises near the following sessions. The first session focuses on the lumbar neuromuscular control of the patients: first a voluntary contraction of the Transversus Abdominis muscle, the Multifidus muscle and the pelvic floor muscles is learned. When the subject is able to maintain the combined contraction for 10 times, the exercises evolve to more complicated tasks. In the final stage, more functional and sport specific tasks will be exercised.
45653234|NCT02631577|Drug|Lenalidomide|Lenalidomide will be administered orally once daily on Days 1 to 21 of Cycles 1 to 6 (28-day cycles) during induction treatment and on Days 1 to 21 of each month during maintenance treatment. Lenalidomide will be administered at a dose of 15 or 20 mg (dose may be de-escalated to 10 mg) during induction treatment and at 10 mg during maintenance treatment. During the expansion phase, lenalidomide will be administered at the RP2D during induction treatment and at 10 mg during maintenance treatment.
45800419|NCT00366665|Device|Legacy 20000|
45800420|NCT00366665|Device|Infinit system|
45800421|NCT01936519|Drug|Arm A: Everolimus|Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
45800422|NCT01936519|Drug|Calcineurin Inhibitor|Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).
45800423|NCT00366743|Procedure|Conventional LASIK|
45929377|NCT01807052|Other|laboratory biomarker analysis|Correlative studies
45929378|NCT00034593|Drug|ALIMTA|
45800424|NCT00366743|Procedure|Wavefront-guided LASIK|
45929379|NCT00034593|Drug|gemcitabine|
45929380|NCT01807013|Procedure|ultrasound, liver elastometry, minilaparoscopy|"conventional high-end ultrasound technique,~small access laparoscopy with fine laparoscopes~Acoustic radiation force impulse (ARFI): ARFI technology uses short-duration acoustic radiation forces (approximately 100 microseconds) to generate a localized tissue displacement which results in a lateral shear-wave propagation. ARFI shear wave velocity (SWV) measured in m/sec tracked with ultrasonic correlation-based methods is proportional to the square root of tissue elasticity."
45929381|NCT00393341|Procedure|Blood Draw|Blood sample will be drawn from a vein in the arm.
45800425|NCT04509557|Drug|[177Lu]Ludotadipep|Dose is sequentially elevated starting from a low dose to a high dose (50±5 mCi, 75±8 mCi, 100±10 mCi, 125±13 mCi, 150±15 mCi). If DLT is observed in 2 or less of 6 subjects at each level, advance to the next step. If DLT is observed in 3 or more participants, no further subject will participate in the study at the relevant dose. Appropriateness of the dose elevation is evaluated 8-9 weeks after drug administration.
45800426|NCT04507841|Drug|Niraparib|Niraparib was used as 100mg capsules once a day since cycle 1 / day 1. The daily dose (e.g. 200 mg is 2 capsules of 100 mg) should be strictly controlled according to the experimental design. Patients should take medicine regularly every day under the guidance of doctors (the best in the morning). The patient must swallow all the capsules completely and do not chew the capsules. You may drink water or eat when taking medicine.
45800427|NCT04475783|Combination Product|Percutaneous Transluminal Angioplasty (PTA)|PTA with an drug-coated balloon catheter (DCB) in the femoropopliteal artery
45800428|NCT01936909|Drug|Anakinra (weeks 1-2)|Anakinra 100 mg daily for weeks 1 and 2
45800429|NCT01936909|Drug|Anakinra (weeks 3-12)|
45800430|NCT01936909|Drug|Placebo|
45800431|NCT04389203|Procedure|Unilateral tubal disconnection + Spontaneous follow up for pregnancy|Unilateral tubal disconnection + Spontaneous follow up for pregnancy
45929382|NCT01806974|Other|oral exam and|The study will be conducted with patient presenting a rheumatoid arthritis and for which an anti IL6 biotherapy treatment is planned. Each patient will benefit a record oral exam that will evaluate his periodontal status and on a possible periodontitis associated. Bacterial samples and cytokine will be realized (in defined periodontal pocket or in the most affected periodontal pocket depending of the periodontal status of patients) before the IL6 biotherapy and 6 month after. A periodontal charting will be realized at the same time.
45800432|NCT04389203|Procedure|Unilateral tubal disconnection + ICSI|Unilateral tubal disconnection + ICSI
45929383|NCT01806935|Device|DC086|
45929384|NCT01806935|Device|Placebo|
45929385|NCT00034632|Drug|Posaconazole oral suspension|
45929386|NCT00034671|Drug|Posaconazole oral suspension|
45929387|NCT01806857|Drug|Nuedexta|Nuedexta PO (by mouth) for 28 ± 3 days
45929388|NCT01806857|Drug|Matching Placebo|matching placebo PO (by mouth) for 28 ± 3 days
45929389|NCT00034710|Drug|Capsaicin Patch|
45929390|NCT01806818|Drug|Epirisone 50mg or placebo TID|3 times a day after meals for 1 week
45929391|NCT00034749|Drug|Risperidone|
45800433|NCT04386941|Procedure|Xpeeda Fibre Laser Vaporesection of the Prostate|"Both interventions are currently used standard of care treatments for the Holmium laser enucleation of the prostate (HoLEP) for patients with bothersome lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).~Holmium Xpeeda side firing fibre was introduced and it stands apart from other available technologies as a combination of power and efficiency, which minimizes vaporization time. This technology seems to revolutionize utilization of the Holmium power and delivering more energy directly to the tissue, due to its capability of being in contact with the tissue."
45929392|NCT01806701|Behavioral|Trauma-focused cognitive behavioral therapy|the 'gold-standard' behavioral treatment for children/adolescents with posttraumatic stress disorder
45800434|NCT04386941|Procedure|Greenlight XPS Vaporization of the Prostate|The introduction of the Xcelerated Performance System (XPS) 180W in 2010 with the MoXy fibers represents the highest-powered system currently in use for this type of laser.11 It encourages the adoption of the enucleation principle, making it a real contender to HoLEP in treating large adenomas. Despite the fact that large prostates often require more energy and longer operative time, the XPS system has reduced the operative time and number of fibers required in these situations.
45800435|NCT01938079|Drug|Ketamine|Ketamine will be initiated as a one-time 40 mg bolus of ketamine followed by a continuous intravenous infusion of 5 micrograms/kg/min at the start of ECMO.
45800436|NCT01938079|Other|Sedative drug regimen|(Standard of Care) Fentanyl or hydromorphone and midazolam infusions will be administered to all patients and titrated at the discretion of the attending physician to maintain the desired level of sedation.
45800437|NCT02641067|Drug|Doravirine|Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally
45800438|NCT01939405|Behavioral|built environment use counseling|
45800439|NCT02329015|Behavioral|Yoga-informed Health and Wellness Program|The HWP will be comprised of physical postures, breathing exercises, a period of sitting in stillness (meditation) and relaxation provided two times per week, 45 minutes per session, for the entire school year (Sept. - June).
45800440|NCT02329015|Behavioral|Physical Education Class|Standard physical education
45800441|NCT02641691|Radiation|Radiation|
45800442|NCT02641691|Drug|Oxaliplatin|
45800443|NCT02641691|Drug|Leucovorin|
45800444|NCT02641691|Drug|Fluorouracil|
45800445|NCT02642237|Biological|Fluenz|intranasal inoculation with Fluenz
45800446|NCT02642237|Other|placebo|
45800447|NCT02642237|Other|LPS|
45929393|NCT00034788|Drug|Becaplermin|
45929394|NCT00034827|Drug|CI-1040|
45929395|NCT00034866|Drug|Protease inhibitor tipranavir|
45800448|NCT01941745|Drug|Half normal saline|2 ml/kg
45929396|NCT00034905|Drug|quetiapine fumarate vs risperidone|
45929397|NCT01806350|Other|questionnaire administration|Ancillary studies
45651046|NCT04822649|Diagnostic Test|Adenosine stress echocardiography with the evaluation of coronary artery blood flow|"The color Doppler flow of distal left anterior descending artery will be examined from the modified apical four-chamber view in the anterior interventricular groove.~In regard to body composition analysis, Using InBody S10, impedance is measured in 6 frequency bands (1kHz, 5kHz, 50kHz, 250kHz, 500kHz, 1000kHz) for each of 5 parts (right plate, left arm, torso, right leg, left leg). Reactance is measured in 3 frequency bands (5kHz, 50kHz, 250kHz for each of 5 parts (right arm, left arm, torso, right leg, left leg).~By treadmill exercise test with modified Bruce protocol or bicycle ergometer for patients with orthopedic problems, maximal oxygen consumption (VO2 max) will be measured using the exhalation gas analysis."
45651047|NCT03753373|Other|Acupuncture|Acupuncture treatments will be utilizing the KB-2 points with manual manipulation accomplished by vigorously running the acupuncturists thumb nail up and down the handle until a perceived sensation change is noted in the subject's posteromedial tibia. A single, sterile 100mm needle will be inserted into the upper third of the medial tibiofibular ligament, followed by a second needle approximately 2-4 cm below the second needle. The needles will be manipulated as detailed above to achieve the sensation change along the posteromedial tibia. The needles will then be irregularly stimulated over the course of 5-7 minutes. The needles will be removed after the treatment is complete, which will last approximately 5-10 minutes (standard care).
45800449|NCT01941745|Drug|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)
45800450|NCT01941745|Drug|High dose rhCC10|5 mg/kg in 2 ml/kg
45800451|NCT01943227|Other|controlled positive pressure ventilation 9ml/kg tidal volume|controlled positive pressure ventilation 9ml/kg tidal volume
45800452|NCT01943227|Other|controlled positive pressure ventilation 6ml/kg tidal volume|controlled positive pressure ventilation 6ml/kg tidal volume
45800453|NCT02642393|Drug|Inosine|capsules containing 500 mg of inosine
45800454|NCT02642393|Drug|Placebo|capsules containing ~500 mg of lactose and appearing indistinguishable from inosine capsules
45800455|NCT02642627|Device|Bellafill|
45800456|NCT02643095|Device|scleral contact lens|Scleral contact lens
45800457|NCT04272593|Device|EMG-Pattern Recognition Controller|Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device.
45800458|NCT04740749|Device|Compress Compliant Pre-Stress System|Treatment of malignant femor tumors with the Compress Compliant Pre-Stress System
45800459|NCT04741061|Biological|Sputnik Light|"Sputnik-Light vector vaccine:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 1011 particles per dose."
45800460|NCT04741061|Other|Placebo|Placebo
45800461|NCT04221737|Device|APRV. General Electric Healthcare Engstrom ventilator system|APRV consist of an extended time at plateau pressure (a continuous positive airway pressure phase) comprising about 90% of the respiratory cycle, while providing very brief releases to enhance carbon dioxide removal. Time-controlled adaptive method requires interpretation of the expiratory flow curve to assess changes in lung elastance and, therefore, set the Time low to optimize carbon dioxide removal, but not at the expense of alveolar derecruitment and instability.
45800462|NCT04221737|Device|Conventional. General Electric Healthcare Engstrom ventilator system|Lung protective ventilation consist of delivery of low tidal volumes (4-6 ml/kg PBW), high PEEP enough to avoid de-recruitment, titrated according to ARDSNet PEEP/fraction of inspired oxygen (FiO2) table, while avoiding excessive transpulmonary pressure.
45929398|NCT01806350|Procedure|standard follow-up care|Receive usual care
45929399|NCT01806350|Other|educational intervention|Undergo PFMT
45929400|NCT01806311|Drug|Candesartan32mg|
45929401|NCT01806311|Drug|Amlodipine10mg|
45800463|NCT00367757|Procedure|Ablate AF triggers via PVI|Trigger-based ablation guided by pulmonary vein antrum isolation
45651048|NCT03753373|Other|Home Exercise Program|Subjects will be given a study diary to document the number of times they performed the standard of care prescribed home exercise program. Subjects will be advised to complete the stretching exercises daily and the strengthening exercises every other day.
45800464|NCT00367757|Procedure|Substrate via CFAEs|Substrate-based ablation using an approach targeting CFAEs
45800465|NCT00367757|Procedure|Combined approach for AF ablation|Combined trigger and substrate based approach
45800466|NCT04047251|Drug|FF-10850 Topotecan Liposome Injection|FF-10850 to be diluted and infused over 60 minutes.
45651049|NCT04831853|Other|nasopharyngeal swabbing procedure (self swabbing first)|Patient realises the nasal swabbing himself first, then undergoes conventionnal swabbing
45800467|NCT04045613|Drug|Derazantinib dose level 1 (300mg once daily) monotherapy|Derazantinib will be administered orally at a dose of 300 mg once per day.
45800468|NCT04045613|Drug|Derazantinib various dose levels in combination with atezolizumab|Derazantinib was administered orally at various dose levels and the RP2D of derazantinib in combination with atezolizumab was determined to be 300 mg once per day derazantinib plus 1200 mg atezolizumab every three weeks.
45800469|NCT04045613|Drug|Derazantinib dose level 2 (200 mg twice daily) monotherapy|Derazantinib will be administered orally at a dose of 200 mg twice daily.
45800470|NCT04045613|Drug|Derazantinib dose level 1 in combination with atezolizumab|Derazantinib will be administered orally at a dose of 300 mg once per day in combination with atezolizumab 1200 mg every three weeks.
45929402|NCT00034944|Drug|MK0869, aprepitant|
45929403|NCT00034944|Drug|Comparator: placebo|
45929404|NCT01806272|Drug|rhGM-CSF|The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.
45929405|NCT01806272|Drug|Compound Vitamin B12|Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
45929406|NCT00034983|Drug|aprepitant|
45929407|NCT00034983|Drug|Comparator: paroxetine HCL|
45929408|NCT00035022|Drug|BCX-1777|
45929409|NCT01806233|Procedure|Acupuncture|The treatment group：60 patients receive Acupuncture ，selecting acupoint on:Shenting（DU24), Baihui（DU20）, Fengchi（GB20), Hanyan（GB4）, Jianyu（LI15）, Quchi（LI11）,Waiguan（SJ5）, Zusanli（ST36）, Fenglong（ST40）, Xingjian(LV2), Yongquan（KI1）, 20minutes each time，ten times / treatment course，two treatment courses in total.
45800471|NCT04045613|Drug|Derazantinib dose level 2 in combination with atezolizumab|Derazantinib will be administered orally at a dose of 200 mg twice daily in combination with atezolizumab 1200 mg every three weeks.
46072559|NCT03733626|Combination Product|Local Bone Autologous Bone Graft with DePuy Synthes Spinal pedicle screw system|Patient's own bone harvested during spinal surgery will be used with the FDA approved DePuy Synthes spinal pedicle screw system to create the fusion.
46072560|NCT03718767|Drug|Nivolumab|IV Nivolumab
45651050|NCT04831853|Other|nasopharyngeal swabbing procedure (conventionnal swabbing first)|patient undergoes conventionnal swabbing first then realises the nasal swabbing himself
45800472|NCT05588999|Procedure|Cryotherapy Alone|"Patients in Group A were subjected to Cryotherapy Alone with liquid nitrogen and received maximum of four treatments given two to three weeks apart .~The liquid nitrogen was applied with a spray or a probe"
45800473|NCT05588999|Combination Product|Cryotherapy plus Salicylic Acid|Patients in Group B were subjected to cryotherapy plus with 50% salicylic acid to be properly applied for a maximum of eight weeks The liquid nitrogen was applied with a spray or a probe
45651051|NCT05058625|Device|Dry Needling plus normal volleyball training|Once the trigger point has been identified, we will use the Hong tecnique looking for a local spasm response
45651052|NCT05058625|Other|Control Group|Normal volleyball training
45800474|NCT04288115|Drug|Levothyroxine|Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
45800475|NCT04288115|Other|Placebo|Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
45800476|NCT04339283|Dietary Supplement|Standardized Hibiscus sabdariffa tea|Daily consumption of Standardized Hibiscus sabdariffa tea
45800477|NCT03783689|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
45800478|NCT04254575|Other|None, observational study only (no interventions)|None, observational study only (no interventions)
45929410|NCT01806233|Procedure|Rehabilitation|The matched group：60 patients receive rehabilitation treatment，45 minutes each once，ten time as a period of treatment，two periods of treatment in all.
45929411|NCT00035061|Drug|pemetrexed|
45929412|NCT00393419|Behavioral|Comprehensive pharmacy care program|
45929413|NCT00393497|Drug|bevacizumab|Bevacizumab 15 mg/kg IV every 21 days
45929414|NCT00035100|Drug|epothilone b|
45929415|NCT00393536|Behavioral|Educational outreach visiting|
45929416|NCT00035139|Drug|methylphenidate|
45929417|NCT00035178|Drug|Argatroban|
45929418|NCT00393575|Behavioral|Community Mobilization|The intervention will consist of guiding C2P coalitions through a strategic planning process that will result in the development and implementation of a local action plan. The action plan will focus on changing structural elements of the affected communities that are believed to be associated with youth HIV acquisition and transmission. Each coalition's plan will include: (1) identification of potential community structural changes and specific steps for how to effect such changes; and (2) the selection of a community-level Centers for Disease Control and Prevention (CDC)-endorsed HIV prevention program.
45929419|NCT00393614|Drug|levetiracetam|20 mg pr. kg a day
45929420|NCT00035256|Drug|teriparatide|
45929421|NCT00035256|Drug|raloxifene HCl|
45929422|NCT00035256|Drug|placebo|
45929423|NCT01806194|Behavioral|Lifestyle Counseling|Small changes behavioral counseling and social support, delivered in 16 sessions by community health workers
45929424|NCT01806194|Behavioral|Educational Control Arm|16 mailings of diabetes educational materials but no regular contact with community health workers
45929425|NCT00035295|Drug|MK0869, aprepitant|
45929426|NCT00035295|Drug|Comparator: placebo|
45800479|NCT01643928|Biological|Rituximab-Pfizer (PF-05280586) x 3 courses|1000 mg intravenous infusion [IV] on Days 1 and 15 of each 24 week treatment course for up to 3 treatment courses
45800480|NCT01643928|Biological|Rituximab-EU+ Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-EU on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
45800481|NCT01643928|Biological|Rituximab-US + Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-US on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
45800482|NCT04234997|Drug|Suvorexant 20 mg|Participants will be advised to take the medication at 10PM for 7 days.Participants will be instructed to stop smoking by 10 pm the day before, in order to ensure they meet the breath CO criterion (CO ≤ 4 ppm) indicating overnight abstinence.
45800483|NCT04234997|Drug|Suvorexant 0mg|Participants will be advised to take the medication at 10PM for 7 days.Participants will be instructed to stop smoking by 10 pm the day before, in order to ensure they meet the breath CO criterion (CO ≤ 4 ppm) indicating overnight abstinence.
45800484|NCT03750071|Biological|VXM01|Ty21a transformed with a eukaryotic VEGFR-2 Expression Plasmid
45800485|NCT03750071|Biological|Avelumab|Monoclonal anti-PD-L1 Antibody
45800486|NCT03635567|Biological|Pembrolizumab|IV infusion
45929427|NCT00035334|Drug|NC-503 (Anti-amyloidotic (AA) Agent)|
45929428|NCT01806116|Drug|decitabine|
45929429|NCT00035412|Drug|St. John's Wort|
45929430|NCT01806077|Drug|PZ-128|Sequential single-dose escalation; 1 to 2 hour continuous intravenous infusion
45929431|NCT00035451|Drug|Azimilide Dihydrochloride|125 mg azimilide tablets, twice a day for 6 months
45929432|NCT00035451|Drug|Placebo|tablets, twice daily for 6 months
45929433|NCT00035451|Drug|Sotalol|160 mg sot twice daily for 6 months
45651053|NCT04831463|Behavioral|Increasising Health Awareness Program for Immigrant Men|The IHAPIM program is a health promotion intervention. The aim of intervention improve health perception and responsibilitiy
45651054|NCT03099811|Behavioral|Incentive plan|The caregiver and designated social network member can each receive monthly financial incentives over the 6 month time interval. Additional monthly incentives will be received at 3- and 6-months if the participant's previous two monthly biomarker levels were below the lower-limit cutoff.
45651055|NCT03099811|Behavioral|Smoking cessation|Participants who wish to quit smoking will be referred upon study recruitment to the smoking cessation program that is provided at no-cost by the Maryland Department of Health and Mental Hygiene (DMMH). The DMMH provides standard counseling and nicotine replacement pharmacotherapies for clients and is offered online or at six health centers throughout Baltimore City.
45929434|NCT01806038|Other|RPh Counseling + Outpatient Med Dispensing at Discharge|On the day of discharge, a pharmacist will perform a chart review and medication reconciliation on all patients' discharge medications (for patients randomized to the intervention arm). Any medication discrepancies will be addressed with the patient's primary care team. At the time of discharge, the patient will receive his/her discharge medications dispensed from the Duke Outpatient Pharmacy, along with medication counseling by a licensed pharmacist
45929435|NCT01806038|Other|Discharge Med Dispensing Plus Counseling - Current Practice|At hospital discharge, patients will receive standard discharge procedures and obtain discharge medications per their usual process
45929436|NCT01805999|Dietary Supplement|7 g Ispaghula|
45929437|NCT01805999|Dietary Supplement|7 g placebo|
45929438|NCT01805999|Dietary Supplement|3.5g Ispaghula + 3.5 g placebo|
45651056|NCT04822571|Other|Reliability of 3D motion analysis protocol|The intrinsic and extrinsic reliability of the designed 3D motion analysis protocol is measured in cases of high velocity dynamic movement such as kicking a soccer ball.
45651057|NCT03722095|Device|active tDCS|A current of 2 milliampère (mA) through electrodes of 5x5cm.
45800487|NCT03635567|Drug|Paclitaxel|IV infusion
45800488|NCT03635567|Drug|Cisplatin|IV infusion
45800489|NCT03635567|Drug|Carboplatin|IV infusion
45800490|NCT03635567|Biological|Bevacizumab|IV infusion
45800491|NCT03635567|Drug|Placebo to pembrolizumab|IV infusion
45929439|NCT00035490|Drug|Azimilide Dihydrochloride|125 mg azimilide, once a day for one year
45929440|NCT00035490|Drug|placebo|placebo tablet, once daily for one year
45929441|NCT00035490|Drug|Azimilide Dihydrochloride|75 mg azimilide, once a day for one year
45929442|NCT00035607|Drug|Darbepoetin alfa SC|Subcutaneous (SC) injection of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
45929443|NCT00035607|Drug|Darbepoetin alfa IV|Intravenous administration of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
45929444|NCT01805960|Biological|Canakinumab|
45929445|NCT01805960|Biological|Placebo|
45929446|NCT01805921|Biological|PanAd3-RSV given intra-nasally (high dose)|High dose = 5x10^10 vp
45929447|NCT01805921|Biological|MVA-RSV given by intra-muscular injection (high dose)|High dose = 1x10^8 pfu
45929448|NCT01805921|Biological|PanAd3-RSV given by intra-muscular injection (high dose)|High dose = 5x10^10 vp
46072561|NCT03712618|Other|Platelet Transfusion - LONG Platelet Transfusion|Platelets Transfused over 4-HOURS
45929449|NCT01805921|Biological|PanAd3-RSV given intranasally (low dose)|Low dose = 5x10^9 vp
45929450|NCT01805921|Biological|MVA-RSV given by intra-muscular injection (low dose)|Low dose = 1x10^7 pfu
45929451|NCT01805921|Biological|PanAd3-RSV given by intra-muscular injection (low dose)|Low dose = 5x10^9 vp
45929452|NCT02971254|Drug|Sevoflurane|
45929453|NCT02971254|Drug|Desflurane|
45929454|NCT01805882|Drug|Sofosbuvir|
45929455|NCT01805882|Drug|Ledipasvir|
45651058|NCT03722095|Device|sham tDCS|Similar set-up as in the active tDCS, but stimulation is too short to cause any effects.
45800492|NCT03631979|Other|Intestinal lavage with normal saline|Specially trained pediatric surgeon will administer 10ml/kg pre-warmed (37oC) normal saline via a single-use rectal tube of size 6FR twice per day, aiming at a depth of maximum 10 cm/kg, starting after randomization and not later than 24 hours of age, and continued until full enteral nutrition of 170ml/kg/day is achieved or NEC diagnosis (Bell stage II or more) is established, which one comes first. However, the intervention will be applied at a maximum of 2 weeks from birth.
45800493|NCT05588765|Other|Neck stretching exercises|Neck stretching exercises towards lateral flexion, ipsilateral flexion and rotation and towards flexion each for 30 sec and repeated 2-3 times
45800494|NCT04339829|Drug|Dacomitinib|Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg QD
45651059|NCT03722095|Device|iTBS|54 cycles with 10 bursts of 3 pulses, train duration of 2 seconds and intertrain intervals of 6 seconds, results in 1620 pulses at 110% resting motor threshold.
45929456|NCT01805882|Drug|GS-9669|
45929457|NCT01805882|Drug|GS-9451|
45651060|NCT04822415|Drug|Mepivacaine|IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.
45800495|NCT04167917|Drug|NTX-301|oral hypomethylating agent
45929458|NCT00035802|Drug|Topiramate|"Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.~OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months."
45929459|NCT00035802|Drug|Placebo|Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
46072562|NCT03712618|Other|Platelet Transfusion - SHORT Platelet Transfusion|Platelets Transfused within 60-minutes
45651061|NCT04822415|Drug|Articaine|IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.
45651062|NCT04822727|Device|1 or more AndraTec devices (see description for list of devices)|1 or more AndraTec devices (Lokum L-Quest guidewire, Lokum Amplatz guidewire, Slider Hydrophilic Nitinol Guidewire, AltoSa-XL PTA Balloon, Alto-Sa-XL Gemini Balloon, Optimus-CoCr stent, Optimus-CVS PTFE covered stent)
45800496|NCT04740281|Behavioral|Footwear|Assessment of footwear
45800497|NCT05588531|Drug|Group 1:YK-1169|YK-1169 0.5g (containing cefepime 0.4g, avibactam 0.1g) single intravenous infusion for 2 hours
45800498|NCT05588531|Drug|Group 2:YK-1169/Placebo Injection|YK-1169 1.25g (containing cefepime 1.0g, avibactam 0.25g) / placebo single intravenous infusion for 2 hours
45800499|NCT05588531|Drug|Group 3:YK-1169/Placebo|On the first day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenously infused for 2 h. On the third day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
45929460|NCT00035841|Drug|TLK286|
45929461|NCT01805843|Other|Echo, exercise echo, and if indicated, right heart catheter|routine echocardiography and special measurements of the right heart are performed at rest and during exercise
46072563|NCT03711032|Biological|Pembrolizumab|Pembrolizumab IV infusion of 200 mg Q3W for BCG Post-Induction Cohort (Cohort A), or IV infusion of 400 mg Q6W for BCG Naïve Cohort (Cohort B), according to randomization
46072564|NCT03711032|Biological|BCG|BCG (intravesical instillation): powder for instillation fluid for intravesical use, administered during Induction and Maintenance therapy
46072565|NCT03698370|Drug|Gallium Ga 68 DOTA-NeoBOMB1|Administered intravenously (IV)
45929462|NCT00035880|Drug|ABX-CBL|
45929463|NCT04732377|Procedure|erector spinae block with bupivacaine|"Group (A) (control group):~Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5."
45929464|NCT04732377|Procedure|erector spinae block with bupivacaine and dexmedetomidine|Patient will receive 20ml 0.25% levobupivacaine above + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5.
45929465|NCT01805765|Drug|Qing'E pills|composed of eucommia, psoralen, walnuts and garlic
45929466|NCT01805765|Drug|Placebo|Containing 2% of Qing'E pills
45929467|NCT00035919|Genetic|Mx-dnG1 Retroviral Vector|
45929468|NCT01805726|Drug|xylocain|Xylocain: (C): Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum
45929469|NCT01805726|Drug|Alfentanil|(A) Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum (slow perfusion for 10 minutes) + alfentanil 10 mcg / kg (slow injection in 5 seconds)
45800500|NCT05588531|Drug|Group 4:YK-1169/Placebo|On the first day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenously infused for 2 h. On the third day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
45800501|NCT05588531|Drug|Group 5:YK-1169/Placebo Injection|YK-1169 5.0g (containing cefepime 4.0g, avibactam 1.0g) / placebo single intravenous infusion for 2 hours
45929470|NCT01805726|Drug|Dexmedetomidine|(D) Local anesthesia 1% 25 ml in total (bronchoscopy) + dexmedetomidine 0.5 mcg / kg (slow perfusion for 10 minutes) + 2 ml saline (slow injection for 5 seconds)
45929471|NCT00035958|Drug|Prednisone|
45929472|NCT00035958|Drug|Methotrexate|
45929473|NCT00035958|Drug|Etanercept|
45929474|NCT01805687|Drug|Zileuton extended release|
45929475|NCT00035997|Drug|Zometa|
45929476|NCT01805648|Drug|rhTPO|Subcutaneously dosing of rhTPO is based on screening weight. Subjects will be given rhTPO 300 IU/Kg once daily up to 14 days in the pre-treatment period . When two consecutive platelet counts is above 50×10^9/L, the subjects will be begin to receive maintenance treatment of rhTPO 300 IU/Kg. In the period of maintenance treatment, starting dosing interval of rhTPO is every other day followed by the interval adjustments for keeping platelet counts between 30×10^9/L～100×10^9/L.
45929477|NCT00036036|Drug|CP-461|
45929478|NCT01805570|Drug|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI. The loading dose of Prasugrel will be 60 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
45929479|NCT01805570|Drug|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI. The loading dose of Ticagrelor will be 360 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
45929480|NCT00036075|Drug|CP-461|
45929481|NCT01805531|Drug|Rivaroxaban (Xarelto, BAY59-7939)|20 mg po once daily, which is also the recommended maximum dose. In subjects with moderate creatinine clearance (30-49 ml/min), the dose 15 mg once daily is recommended.
45929482|NCT00036114|Drug|aripiprazole|
45929483|NCT01805492|Behavioral|Dr. Dean Ornish Program for Reversing Heart Disease|Prospective, nonrandomized clinical intervention to stabilize or reverse progression of heart disease through changes in lifestyle. Lifestyle intervention consisted of four components: 1) a very low fat vegetarian diet (<10% of calories from fat); 2) 180 minutes/week of moderate aerobic exercise; 3) one hour of stress management each day; and 4) weekly group support sessions.
45929484|NCT04732611|Other|Pilates exercises|Pilates group participants will perform 3 weekly Pilates sessions lasting approximately 50 minutes for 20 weeks.
45929485|NCT04732611|Other|Walking protocol|Walking group participants will perform 3 weekly walking sessions lasting approximately 50 minutes for 20 weeks.
45929486|NCT01805453|Drug|Losartan|Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan or placebo (Arm A or B) 50mg*2/day until the halting for any reason
45929487|NCT01805453|Drug|Placebo|Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason
45651063|NCT03661333|Behavioral|Dialectical behavioral therapy|DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly family meetings and individual therapy conducted in 60 minute biweekly sessions. Family skills training proceeds as follows: psychoeducation about DBT and bipolar disorder, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the adolescent in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants and their participating family members by cell phone for in-vivo skills coaching between sessions.
45651064|NCT04834817|Device|Celluma POD|A blue and near infrared handheld LED device
45800502|NCT05588531|Drug|Group 6:YK-1169/Cefepime hydrochloride for injection/Avibactam for injection|YK-1169 2.5g (containing cefepime 2.0g, avibactam 0.5g)/cefepime hydrochloride for injection 2.0g/avibactam for injection 0.5g, three-cycle three-cross single intravenous infusion for 2 hours
45929488|NCT00036153|Drug|Tacrolimus (Prograf®)|
45929489|NCT00036153|Drug|Methotrexate|
45929490|NCT01788917|Dietary Supplement|Linseed oil|Dietary supplement: 10 mL linseed oil per day
45929491|NCT00036192|Drug|FK614|
45929492|NCT00036231|Drug|RG1068 (Synthetic Human Secretin)|
45929493|NCT00036309|Drug|Duloxetine Hydrochloride|
46072566|NCT03698370|Device|Gallium Ga 68 PSMA-R2|Administered intravenously (IV)
46072567|NCT03694652|Behavioral|PACE|Patient-centered Assessment and Counseling for Exercise [PACE] program
46072568|NCT03694652|Behavioral|Diet|Motivating healthy dietary habits
46072569|NCT03694652|Other|App|Using an app to deliver communication to the participant.
45450971|NCT02210962|Dietary Supplement|olive oil|Yellow capsules containing olive oil (placebo)
45651065|NCT05065177|Biological|Investigational live attenuated mumps vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
45929494|NCT01761305|Procedure|Hypercorrective night-time brace|Hypercorrective night-time brace worn 8 hours per night. Patients are encouraged to also continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
45929495|NCT01761305|Behavioral|Scoliosis specific exercises.|The intervention will be delivered in 3 x 90 minute sessions, once per month during the first 3 months. Goals are directed towards active self-correction and postural control, spinal stability, aerobic functioning and development of a positive body image. Additional postural specific exercises including self-mediated hyper-corrective exercises are to be performed with moderate intensity at least for 30 minutes at least 2-3 times per week. Other physical activities to fulfill the general recommended quota of more than 60 minutes moderate intensity physical activity per day are recommended. Reinforcement of the intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
45800503|NCT04158089|Behavioral|Babies and Moms connected through Love, Openness, and Opportunity (BLOOM)|"Participants will be randomly assigned into one of two groups for the BLOOM intervention; the control group will receive treatment as usual. Participants assigned to the treatment group will receive texted attachment exercises to complete from home. The intervention will take place over a 2-week period. Participants in the Attachment Exercises group will receive a text every day with an activity designed to increase feelings of attachment (e.g., read a children's book; sign a nursery rhyme; picture giving your baby a baby; tell your baby a story, etc.)."
45800504|NCT05588375|Behavioral|home-based physical activity telemonitoring program|The home telehealth physical activity training program is a telemedicine physical activity training that uses Google Meet software to communicate and supervise through webcams.
45800505|NCT05588297|Drug|CapOx(Capecitabine+ Oxaliplatin)|CapOx: Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3 weeks for 4 cycles and Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 4 cycles
45929496|NCT01761305|Other|Self-mediated physical activity.|Instructions for self-mediated physical activity will be delivered during a 1 hour session. Patients are encouraged to perform self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
45800506|NCT05588297|Drug|Bevacizumab|Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 4 cycles
45651066|NCT05065177|Biological|control live attenuated mumps vaccine|The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
45651067|NCT04821947|Other|Rhomboid intercostal plane block or Local anesthetic infiltration of 0.25% Bupivacaine|"for RIB GroupThe following structures will be identified from superficial to deep: trapezius muscle, rhomboid major muscle, intercostal muscles between ribs, pleura, and lung. The tissue plane between the rhomboid major and intercostal muscles will be identified. A 18 gauge Tuohy needle will be advanced in plane from a superomedial-to-inferolateral direction, through the trapezius and rhomboid major muscles. The skin entry point for the first injection will be the T5-T6 level just medial to the scapula.~After the location is confirmed through hydrodissection of 3 ml on the upper intercostal muscles under the rhomboid major muscle, 20ml of bupivacaine (concentration 0.25%) is injected under rhomboid major muscle LA group will receive wound infiltration of VATS incision single-incision with 10mL 0.25% bupivacaine double-incision with 15 mL (10mL+5mL) 0.25% bupivacaine three-port strategy with 17 mL (10mL+5mL+2mL) 0.25% bupivacaine"
45800507|NCT05588297|Drug|Nivolumab|Nivolumab is given intravenously at 360 mg on day 1 every 3 weeks for 4 cycles
45800508|NCT05588219|Drug|Tislelizumab|Tislelizumab injection[10ml:100mg] will be used beginning with radiotherapy: 200mg/3W for 1 year or disease progression or intolerable toxicity, whichever occurs first.
45800509|NCT05588219|Drug|DDP synchronous with radiotherapy|DDP 40mg/m2/W, synchronous with radiotherapy, complete at least 4 cycles.
45800510|NCT04339673|Procedure|masseteric nerve block|regional bloc of masseter
45929497|NCT00036348|Drug|Aripiprazole|
45929498|NCT01665326|Other|Observational|This is a longitudinal study focused on the emerging natural history of Infantile Pompe disease, response to ERT using alglucosidase alfa (Myozyme) and response to Immune Tolerance Induction (ITI).
45929499|NCT00036387|Drug|Infliximab|
45929500|NCT00036426|Biological|FavId (Id-KLH) active immunotherapy|
45800511|NCT04339673|Procedure|trigger point injection|trigger point injection with local anesthetic
45800512|NCT04339673|Procedure|dry needling|needling with acupuncture needles of trigger points in masseter
45800513|NCT00366977|Behavioral|Multi-session telephone counseling|
45800514|NCT00366977|Drug|NRT patches|
45800515|NCT03899831|Behavioral|Function-Based Elopement Treatment (FBET)|"The Function-Based Elopement Treatment (FBET) includes 12 appointments over 16 weeks. FBET focuses on parent-training, with the parent implementing procedures with therapist support. The goals of FBET are:~to create a safer environment~teach adaptive skills to replace elopement~arrange the environment and rewards to reduce elopement~and teach caregivers how to respond if elopement occurs Psychoeducation is emphasized, including discussions of elopement as a learned behavior, reinforcement, functions of elopement, extinction, and descriptions of treatment components. The FBET manual includes scripted text, examples, caregiver completed activities, and checks for understanding."
45800516|NCT03899831|Behavioral|Parent Education Program (PEP)|The Parent Education Program (PEP) will include 12 appointments over 16 weeks, focused on general education about autism spectrum disorder and resources about elopement prevention. PEP will be administered by a Board Certified Behavior Analyst (BCBA). Participants randomized to the PEP study arm can receive the FBET intervention after completing the 16 week study period.
45800517|NCT02303405|Drug|Hydroxychloroquine|Anti-inflammatory and anti-malarial agent
45800518|NCT02303405|Drug|Pioglitazone|Anti-hyperglycemic agent
45800519|NCT02164955|Drug|IMNOVID|IMNOVID (pomalidomide) as prescribed in routine clinical practice
45800520|NCT01836497|Device|SD01 ICD lead|
45800521|NCT05587907|Device|FitLight Trainer|Evaluation of the reaction time before and after special training program using visual stimuli.
45651068|NCT03617263|Drug|Saroglitazar Magnesium 4 mg Tablet|Patients randomly assigned to this group will receive Saroglitazar Magnesium orally once daily for 24 weeks.
45651069|NCT03617263|Drug|Placebo|Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
45651070|NCT03037073|Drug|Duloxetine|35 patients will receive duloxetine (Cymbalta; Eli Lilly & Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
45651071|NCT03037073|Drug|Placebo oral capsule|35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
45651072|NCT03099421|Procedure|Prostatic Artery Embolization|The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
45651073|NCT04834739|Other|6 minute walk test|The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. 30 m long corridor is used for this test .
45929501|NCT01466543|Drug|Zydena (Udenafil)|Zydena (Udenafil) 100 mg, one time
45929502|NCT01466543|Drug|Placebo|Placebo
45651074|NCT04834739|Other|1 minute Sit to Stand Test|The 1-minute STS test is performed with a chair of standard height of 46 cm without arm rests. The patient should be ensured to be seated upright on the chair positioned against a wall. The patient sat with the knees and hips flexed to 90°, feet placed flat on the floor hip-width apart, and the hands placed on the hips.The number of repetitions is measured.
45651075|NCT04834739|Other|Fatigue Severity Scale|The Fatigue Severity Scale is a 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders
45800522|NCT05587829|Other|• Diaphragmatic breathing technique|In supine position, the participant inhales through the mouth for 5 s to expand the abdomen to the maximal level, minimizing movement of the thorax, and performs a long exhalation to maintain a lower abdominal contraction and retroversion of the pelvis
45929503|NCT00036465|Behavioral|Treatment regimen change|
45800523|NCT05587829|Other|basic breathing technique|Deep Breathing for 15 minutes
45929504|NCT01466504|Procedure|skin punch biopsy|Skin biopsy prior to sorafenib or regorafenib treatment and when rash appears or 12 weeks into treatment.
45929505|NCT02971332|Procedure|Stapled Transanal Rectal Resection|"The prolapsed tissue is pulled out through the CAD using e gauze pad and Allis forceps; this allows us to identify the extent of the prolapse to be resected. Four to five parachute stitches are then apposed circumferentially, like parachute cords, at the apex of the prolapse, in order to control the tissue during resection. The prolapse is then opened longitudinally at 3 o'clock with the electric scalpel between two Kocher clamps. Two traction stitches are applied at the deep vertex of the prolapse, one for each Kocher apex.~The longitudinal opening then allows the surgeon to begin circumferential resection of the rectum by pulling on the parachute stitches. This maneuver is performed counterclockwise using an average of 4-6 recharges, with care to always place the stapler at the base of the prolapse. The resected specimen was always inspected before the end of the procedure."
45929506|NCT01466465|Drug|Cholecalciferol|given orally, once daily, before grass pollen season
45651076|NCT04834739|Other|Medical Research Council (MRC) dyspnea scale|"The MRC dyspnea scale is a questionnaire that consists of five statements about perceived breathlessness: grade 1, I only get breathless with strenuous exercise; grade 2, I get short of breath when hurrying on the level or up a slight hill; grade 3, I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking at my own pace on the level; grade 4, I stop for breath after walking 100 yards or after a few minutes on the level; grade 5,  I am too breathless to leave the house."
45651077|NCT04834739|Other|SF-12|The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
45800524|NCT03796559|Device|Magseed Marker|Implantable Magseed marker for marking lesions in soft tissue, detected using the Sentimag handheld probe.
45800525|NCT05587361|Drug|Propranolol|Propranolol Capsule; 40 mg IR
45800526|NCT05587361|Drug|Nicotine Patch|Nicotine Patch; 14 mg
45800527|NCT05587361|Drug|Placebo Propranolol|Placebo Capsule, no active ingredients
45800528|NCT05587361|Drug|Placebo Patch|Placebo Patch, no active ingredients
45800529|NCT04740203|Drug|CAR-T cells targeting CD19 and CD22|Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion
45800530|NCT01943461|Drug|Avelumab 3 mg/kg|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 3 milligrams per kilogram (mg/kg) once every 2 weeks in the dose- escalation cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
45929507|NCT01466465|Other|middle-chain fatty acids (carrier)|given orally, once daily, before grass pollen season
45929508|NCT00036504|Drug|Insulin Lispro low mixture|
45929509|NCT00036543|Drug|Atrasentan|
45929510|NCT01466309|Device|Somnoguard oral appliances|wearing somnogaurd daily at bedtime
45651078|NCT04834739|Other|Beck Depression Inventory|The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression
45651079|NCT04834739|Other|Beck Anxiety Inventory|Beck Anxiety Scale is a 21-item, internationally valid, self-report rating inventory that measures the anxiety level.
45651080|NCT04834739|Other|5 times sit to stand test|The 5XSST scoring is based on the amount of time (to the nearest decimal in seconds) a patient is able to transfer from a seated to a standing position and back to sitting five times. The equipment need in performing 5XSST test includes: Stopwatch and standard height chair with straight back (43-45 cm, 17-18 inches high). Then the instruction is given by asking the test taker to sit on the chair by resting their back. Also, the test taker is instructed to fold their arms across their chest. Then the test taker should be instructed to do sit-to-stand five times, as quickly as possible, at the count of go and without their back or leg resting on the chair between the interval of repetition.
45651081|NCT04834739|Other|6 point Likert Scale|"Job performance was assessed by asking How do you evaluate your job performance? on 6-point Likert scale.A 6 point likert scale forces choice and gives better data.The 6 point Likert scale offers options for ''Excellent, very good, good, fair, poor and very poor''. 6 point scale anges from 1(very poor) to 5 (excellent)."
45651082|NCT03100357|Other|Thyroidectomy|Thyroid surgery for benign nodular goiter
45651083|NCT05058235|Other|Active Release Technique|"Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Active release Technique 5 reps/ 1 set/ (6 days/ week)~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins."
45651084|NCT05058235|Other|Bent leg raise|"Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Bent leg raise 5 sec hold/ 5 sec stretch/ 3 reps/ 1 min rest interval/ 1 set/ (6 days/ week).~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins."
45651085|NCT04831541|Drug|68Ga-PSMA-11|Each subject receive a single intravenous injection of 68Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
45651086|NCT03100201|Other|Intervention Armeo®Spring|The robotic-assisted training will be performed using the clinically evaluated Armeo®Spring medical device (Hocoma AG, Zurich, Switzerland). By means of a sensory orthosis, arm movements will be supported and transmitted to a computer system and visually shown on a screen.
45651087|NCT03100201|Other|Control Group|The control group will receive conventional occupational- and physiotherapy over 3 weeks
45651088|NCT03099343|Behavioral|Location-based Tailored Messaging|The mobile application works by providing tailored messages targeted to participant locations that can help individuals to choose lower sodium foods.
45651089|NCT05028205|Behavioral|Prevention Plus|Families will receive a behavioral intervention for childhood obesity provided by a BHC. This will consist of three, in-person meetings (months 1, 3, and 5), and three, 20-minute phone calls (months 2,4, and 6). During in-person visits, child height and weight will be taken, and BMI will be plotted on the BMI-for-age growth chart. During these sessions, families will receive feedback on child growth and weight status. Prevention Plus materials and child and caregiver energy balance behavior goals will be reviewed. The phone calls will be with the caregiver, where caregivers will be asked to measure the height and weight of their child, calculate BMI, and plot on the BMI-for-age growth chart. The BHC will discuss the family's progress on achieving child and caregiver goals and implementation of behavioral parenting strategies. Families will receive a fruit and vegetable prescription (FVx) in addition to the standard Prevention Plus family-based behavioral weight loss treatment.
45651090|NCT05058079|Behavioral|Intraoperative Hand Held|Intraoperative hand holding
45651091|NCT04987879|Behavioral|Exercise|Aerobic exercise can be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking (30-40% target HR for 5-min) and dynamic exercises (knee-to-chest, 10-yd lateral shuffle, bent over twist, calf sweeps, leg swings). A 5-min walking cool down will end the session (30-40% target HR).
45651092|NCT04986865|Drug|ATG-101|ATG-101 will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.
45651093|NCT04982575|Drug|Semaglutide 2.4 mg|Semaglutide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
45651094|NCT04982575|Drug|Cagrilintide 2.4 mg|Cagrilintide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
45651095|NCT04982575|Drug|Placebo (semaglutide)|"Placebo (semaglutide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks"
45651096|NCT04982575|Drug|Placebo (cagrilintide)|"Placebo (cagrilintide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks"
45651097|NCT03423589|Dietary Supplement|VSL#3|VSL#3 is a commercially available probiotic supplement manufactured and distributed by Alfasigma USA, Inc of Covington, Louisiana, USA. As with other probiotics, VSL#3 is considered a supplement and is not FDA-approved or regulated. VSL#3 contains eight probiotic strains: bifidobacteria (B. longum, B. infantis, and B. breve), lactobacilli (L. acidophilus, L. casei, L. bulgaricus, and L. plantarum) and Strepococcus thermophiles.
45800531|NCT01943461|Drug|Avelumab 10 mg/kg|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg once every 2 weeks in the dose- escalation cohort and expansion cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
46072570|NCT03694652|Other|Face-to-face|Using in person meetings and/or phone communication with the participant.
45450972|NCT02220946|Device|Vaginal Electrical Stimulation|A vaginal probe inserted, and a medium frequency (50 Hz) alternating current was administered for 5 seconds on, 5 seconds off. the intensity of the current was started at 0 mA, and gradually increased until pelvic muscle contractions was observed, then increased according to patient tolerance. each patient received a 20 minute session once a week for total 8 session
45651098|NCT05064475|Diagnostic Test|PET/CT|Patients with previous breast cancer, already treated and with clinical or biochemical suspicion of disease relapse. All patients will underwent 18F-fluorodeoxyglucose (FDG) PET/CT. In all patients, the value of CA 15.3 was compared to PET/CT. The final diagnosis of relapse will be derived from histopathological sampling As much as possible or radiological follow up for at least 6 months will be compared with PET/CT results.
45800532|NCT01943461|Drug|Avelumab 20 mg/kg|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 20 mg/kg once every 2 weeks in the dose- escalation cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
45800533|NCT01397669|Procedure|Colon biopsy, lymph node biopsy, lumbar puncture|Eligible subjects will undergo a flexible sigmoidoscopy and biopsy, lumbar puncture, lymph node biopsy at Chulalongkorn University Hospital.
45800534|NCT00786539|Device|Diffuse Optical Spectroscopy|mitochondria
45800535|NCT00422435|Device|CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter|Paclitaxel-Eluting Coronary Stent
45800536|NCT03679247|Other|Intervention|"The intervention will be a clinical decision support (CDS) system that contains three main features: 1) methods to synthesize electronic health record (EHR) data in order to identify under-diagnosed chronic conditions (synthesize existing medical data to increase recognition of CKD and uncontrolled HTN in CKD patients and deliver management recommendations based on this evidence), 2) improve the design and content of the CDS using human factors methods, specifically usability testing, and 3) the use of two behavioral nudges (pre-checked default orders and an email to obtain commitment from PCPs to obtain their commitment to follow the CDS recommendations)."
45800537|NCT03679247|Other|Control|Usual Care, PCP will receive an email with general information about CKD guidelines
45929511|NCT01466231|Drug|Everolimus|Tablets p.o. 10 mg daily until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.
45929512|NCT00036582|Drug|Clozapine|
45929513|NCT01466114|Drug|estriol|4 capsules of 2 mg (total of 8 mg) PO QD
45929514|NCT01466114|Other|Placebo|4 capsules PO QD
46072571|NCT03675737|Biological|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
46072572|NCT03675737|Drug|Cisplatin|Administered as an IV infusion on Day 1 Q3W
45651099|NCT05057299|Other|retrospective data analysis|chart review, analysis and reporting outcomes
45651100|NCT05057455|Procedure|cytokine hemadsorption|the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.
45651101|NCT05057533|Other|a questionnaire based on Rome IV Diagnostic criteria of IBS|"The Rome IV criteria for the diagnosis of IBS require that patients have had recurrent abdominal pain on average at least 1 day per week during the previous 3 months that is associated with two or more of the following~Related to defecation (may be increased or unchanged by defecation)~Associated with a change in stool frequency~Associated with a change in stool form or appearance The Rome IV criteria (May 2016) only require abdominal pain in defining this condition; discomfort is no longer a requirement owing to its nonspecificity, and the recurrent abdominal pain. [2] Supporting symptoms include the following:Altered stool frequency Altered stool form Altered stool passage (straining and/or urgency) Mucorrhea Abdominal bloating or subjective distention."
45651102|NCT05063773|Device|Mixed reality heads up display|Physician will use a mixed reality headset for image guidance of the procedure
45800538|NCT00540683|Device|Diffuse Optical Spectroscopy|Muscle properties
45800539|NCT01222351|Drug|BAY 94-9172 (Florbetaben)|Measure of brain amyloid load using BAY 94-9172 PET/CT
45800540|NCT00540371|Other|Port wine stain Birthmark|Port wine stain Birthmark
45800541|NCT03029767|Other|Aerobic exercise .|The aerobic exercise group will perform brisk walking. Intensity of the aerobic exercise program will be progressively increased throughout the 16-week program. Intensity of aerobic exercise will be 40-65% of maximum heart rate , which is low to moderate.Duration of each session will be 45 minutes. Aerobic exercise will be performed 3 days per week.
45800542|NCT03029767|Other|Resistance exercise|"The resistance exercise group will perform 8 different exercises. Frequency of exercises per week is 3 days and duration of each exercise session is 45minutes. Interval rest among different exercises is 1minute.The intensity and repetition of resistance exercises is progressive. Participants will be exercised at 30% intensity (low intensity) for upper body and 50% intensity (moderate intensity) repetition voluntary maximum for lower body.~Progressive, dynamic and rhythmical, alternative to upper-body and lower-body works and circuit resistance training of low to moderate intensity exercises will be executed."
45800543|NCT03029767|Other|Aerobic and resistance exercise|The aerobic and resistance exercise group will perform 23 minutes aerobic exercises and 22 minutes resistance exercises. The exercises will be performed three days per week . Intensity of aerobic and resistance exercise group for aerobic and resistance exercises are similar with intensity of aerobic group and resistance group exercises respectively.
45800544|NCT03676283|Other|Web-based psycho-educational support for family caregivers|A website including potentially modifiable topics shown to be associated with preparedness. The topics cover areas such as knowledge about medical issues including symptoms and symptom relief, communication within the couple, how to spend the time before death, being partner or caregiver, planning of the moment of death and considerations of the partner's future, including psychological issues, logistical issues, economy, and the care for children.
45800545|NCT03642821|Device|intracranial aneurysm coiling|endovascular treatment of intracranial aneurysm by coiling procedure using OPTIMA coils system
45929515|NCT01466114|Drug|Norethindrone|Starting at month 6, and at Months 9 and 12: subjects who are on estriol (Group A) take 0.7 mg PO QD for 2 weeks.
45929516|NCT01466114|Other|Progestin Placebo|Starting at Month 6 and at Months 9 and 12: subjects who are on placebo (Group B) take a second progestin placebo pill PO QD for 2 weeks.
45929517|NCT00036660|Drug|SarCNU|
45929518|NCT00036777|Drug|carboplatin|Given IV
45929519|NCT00036777|Drug|7-hydroxystaurosporine|Given IV
45929520|NCT00036777|Other|pharmacological study|Correlative studies
46072573|NCT03675737|Drug|5-fluorouracil|Administered as a continuous IV infusion on Days 1-5 Q3W
46072574|NCT03675737|Drug|oxaliplatin|Administered as an IV infusion on Day 1 Q3W
46072575|NCT03675737|Drug|capecitabine|Administered orally BID on Days 1 to 14 Q3W
46072576|NCT03675737|Drug|Placebo for Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
45651103|NCT02897479|Drug|Savolitinib|Enrolled patients will be treated with Savolitinib 600mg or 400mg once per day(QD), till disease progression, death or unacceptable toxicity, whichever comes first. A cycle of study treatment will be defined as 21 days of continuous dosing.
45800546|NCT00702481|Drug|Nimotuzumab|Patients will receive nimotuzumab 200 mg weekly for 8 weeks. Nimotuzumab will be started together with concurrent chemoradiation, and continued 1 week after the completion of chemoradiation.
45800547|NCT00702481|Drug|Cisplatin|Concurrent chemotherapy with cisplatin 100 mg/m2 will be given on week 1, 4, and 7 of radiotherapy.
45800548|NCT00702481|Radiation|Radiation|Concurrent radiotherapy will be given to the primary tumor and upper neck at 2 Gy per fraction, once a day, five days a week to a total of 70 Gy in 35 fractions in seven weeks.
45651104|NCT05046925|Procedure|postoperatively transferral to PACU|patients undergoing major thoracic and abdominal surgery will be transferred to PACU for postoperative care.
45651105|NCT05046925|Procedure|postoperatively transferral to ICU|patients undergoing major thoracic and abdominal surgery will be transferred to ICU for postoperative care.
45651106|NCT04470973|Drug|Cefuroxime|Patients receive cefuroxime as part of standard care.
45651107|NCT04470973|Drug|Amikacin|Patients receive amikacin as part of standard care.
45651108|NCT05046457|Dietary Supplement|Beta-cryptoxanthin (BCX)|Subjects will be randomised into one of the three study treatment arms.
45651109|NCT05056675|Procedure|PENG block|All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the test item (20 mL of ropivacaine 0.5%, Naropin). The anesthesiologist and the surgeon are blinded to the product injected.
45651110|NCT05056675|Procedure|Placebo|ll patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the placebo (20 mL of NaCL 0.9%). The anesthesiologist and the surgeon are blinded to the product injected.
45651111|NCT05063071|Drug|Tenofovir Alafenamide 25 MG|After orthotopic liver transplant, all patients will receive Tenofovir Alafenamide monotherapy without HBIG for HBV Prophylaxis.
45651112|NCT05045911|Procedure|Endoscopic Barbed-clips Suturing|Endoscopic Barbed-clips Suturing
45651113|NCT05045989|Behavioral|Residence-based testing participation pilot (SARS-CoV-2 testing with relaxed social distancing restrictions)|SARS-CoV-2 asymptomatic saliva testing (as available to all students at staff at the participating university) delivered with relaxed social distancing (behavioural element) in two halls of residence.
45651114|NCT05045599|Behavioral|Capacity Building of Health care workers and providers to deliver integrated Family Planning and Maternal, Newborn and Child Health|Community engagement to improve awareness, and use of family planning products and services
45800549|NCT03559049|Drug|Pembrolizumab|200mg IV every 21 days
45800550|NCT03559049|Drug|Pemetrexed|500mg/m^2 IV every 21 days
45800551|NCT03559049|Drug|Carboplatin|AUC 5 IV every 21 days
45800552|NCT03559049|Drug|Rucaparib|600mg PO, BID days 1-21 of each 21 day cycle
45800553|NCT05559437|Drug|Levo-bupivacaine 0.25|The blockade of ilioinguinal/iliohypogastric nerves in the anterior abdominal wall has improved postoperative analgesia after open inguinal hernia repair. Other new blocks needs to be investigated
45651115|NCT05062681|Drug|Dexamethasone|Patients will receive dexamethasone 8 mg q12hours
45651116|NCT05062681|Drug|Methylprednisolone|Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes
45651117|NCT05045521|Other|plyometric warm up group|"participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~During the plyometric intervention, subjects will perform the 2 * 8 squat jumps, 2 * 8 scissor jumps, and 2 * 8 double leg bounds (2 sets of 8 repetitions) as a part of warm-up, and will have 60 s to recover between each set. Prior to the intervention, participants will be shown the technique to be used during jumping through use of three videos."
45651118|NCT05045521|Other|resistance warm up|"participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~After the jog participants will perform the 6*10s strides with the 15% of the weight. Velocity of the strides will be controlled by the participants.~Warmup will be followed by the 10minutes rest"
45653235|NCT02631577|Drug|Obinutuzumab|Obinutuzumab will be administered by intravenous infusion at an absolute (flat) dose of 1000 mg on Days 1, 8, and 15 of the first cycle and on Day 1 of each subsequent cycle during induction treatment, and on Day 1 of every other month (i.e., every 2 months) during maintenance treatment.
45800554|NCT02643875|Device|Orthokeratology|It is a kind of rigid permeable lens.
45800555|NCT02645123|Device|TENS|Enraf-Nonius Sonopuls 692
45800556|NCT02645123|Procedure|spinal mobilization|passive physiological intervertebral movements and passive accessory posteroanterior mobilization
45800557|NCT02645123|Procedure|swedish type massage|petrissage, effleurage, tapotement
45800558|NCT02645123|Procedure|static hamstring stretch|static hamstring stretching
45800559|NCT02645123|Procedure|sham treatment|touching of the skin overlying the lumbar area
45800560|NCT00367211|Drug|PN 200 tablets (500 mg naproxen and 20 mg omeprazole)|
45800561|NCT00367211|Drug|Naproxen 500 mg tablets (PN 200 minus omeprazole)|
45800562|NCT02646371|Biological|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
45800563|NCT02646371|Biological|Placebo|2 doses of TBS solution will be injected intramuscularly 4 weeks apart
45597933|NCT04467073|Behavioral|Online RIT|"Online RIT presents RIT techniques in four sequential learning modules: (1) Setting Up For Success (2) Imitating your Child (3) Describing Play (4) Teaching Object Imitation. Each learning module includes an instructional video, quiz, interactive exercises, and at-home planning and reflection. The website also includes a video library, Frequently Asked Questions, downloadable visual aids, links to relevant external resources, and a customizable dashboard that allows users to track their individualized goals and the amount of time they have spent working on their goals (e.g., practice log)."
45651119|NCT05045521|Other|control warm up group|"participants will be asked to do 10 minutes self-paced jog on a motorized treadmill.~After the jog participants will perform the 6*10s strides without the weight. Velocity of the strides will be controlled by the participants. Warmup will be followed by the 10minutes rest The total amount of time spended in each of the three warm-up protocols will be recorded. Participants will be instructed to wear the same pair of running shoes during the three tests."
45651120|NCT05056519|Biological|Live Attenuated Influenza Vaccine|Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
45651121|NCT05056519|Biological|Live Attenuated Influenza Vaccine placebo|Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.
45651122|NCT05045443|Drug|Curcumin|Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement
45651123|NCT05045443|Dietary Supplement|Standard of Care|As per institution protocol for Standard of nutritional Care
45651124|NCT05045287|Radiation|hypofractionated radiotherapy|Undergo hypofractionated RT，obeserve reconstruction failure，cosmetic result and recurrence rate
45651125|NCT05045131|Procedure|Left atrial combined pulmonary vein isolation and posterior wall isolation|
45651126|NCT04473469|Device|Medtronic Interstim II Model 3058 Neurostimulator|Patients will undergo stimulation of the pudendal nerve. All stimulation parameters used will be within the normal hard-coded limits of the implantable pulse generator (IPG).
45651127|NCT05045053|Drug|Xiidra 5% Ophthalmic Solution|lifitegrast 0.5% ia applied twice daily after corneal collagen cross linking
45651128|NCT05044741|Procedure|Emergency surgical enterostomy|Emergency surgical enterostomy
45651129|NCT03097627|Drug|ICG Intervention|The intervention to be administered is the drug indocyanine green.
45651130|NCT03097627|Device|Near Infrared Camera|The intervention to detect the administered drug, indocyanine green.
45651131|NCT05055739|Device|Rigid plate X steel wires|Compare the sternal alignment between the fixation with rigid plate X steel wires.
45651132|NCT05055895|Drug|Anticholinergic burden|"The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale.~Higher ACB was described as equal or higher than 1."
45651133|NCT05055583|Drug|Toripalimab in Combination With Platinum-based Chemotherapy|Toripalimab will be administered at a fixed dose of 80 mg (2ml)/vial, IV, D1, with a full dose of 240 mg at one time, every 3 weeks for 3-4 cycles. Squamous cell carcinoma will be combined with cisplatin/carboplatin and Nab-paclitaxel: carboplatin, AUC=5, D1, IV, q3w, or cisplatin, 75 mg/m2, IV, q3w, and Nab-paclitaxel, 130 mg/m2, D1, IV, q3w, for 3-4 cycles. Non-squamous cell carcinoma will be combined with cisplatin/carboplatin and Pemetrexed, cisplatin/carboplatin is the same as above, Pemetrexed will be given at 500 mg/m2, D1, IV, q3w, for 3-4 cycles.
45651134|NCT05055583|Procedure|Surgical treatment stage|After the last treatment (Day 21 of Cycle 4), surgery was performed within 4-6 weeks.
45800564|NCT02646449|Drug|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
45800565|NCT02646449|Drug|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
45800566|NCT02646761|Device|InterACTION|InterACTION guided home exercise program paired with standard of care physical therapy
45597934|NCT04466605|Other|Tele-yoga therapy|Each session included combinations of different yoga exercises, postures, yoga breathing, yoga relaxation techniques, yoga counselling and meditative practices based on individualisation.
45800567|NCT02646761|Other|Standard of Care Physical Therapy|Physical therapy rehabilitation program
45800568|NCT02646917|Procedure|Aesthetic Microneedling Treatment|Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.
45597935|NCT04466605|Other|Primary care|Patients will follow standard care provided by primary care physicians including analgesics and self care management.
45597936|NCT03916081|Drug|Roflumilast Cream 0.05%|Roflumilast 0.05% cream for topical application
45597937|NCT03916081|Drug|Roflumilast Cream 0.15%|Roflumilast 0.15% cream for topical application
45597938|NCT03916081|Drug|Vehicle Cream|Inactive vehicle cream matched to roflumilast cream for topical application.
45651135|NCT05055583|Drug|Adjuvant treatment stage|Postoperatively, a comprehensive evaluation will be conducted by the investigator, and the intention will receive maintenance therapy within 6-12 weeks of the MDT assessment. Toripalimab: a fixed dose of 80 mg (2ml)/vial, IV, D1, a full dose of 240 mg at one time, every 3 weeks administered until PD or intolerable toxicity, for a maximum duration of 1 year.
45651136|NCT05061589|Procedure|permanent colostomy|An operation that creates an opening for the colon through the abdomen
45800569|NCT02650193|Drug|HSP-130|Dosage will vary per each cohort: (Five independent cohorts) Cycle 0 Regimen A - 3 mg Cycle 0 Regimen B - 6 mg Cycles 1-4 Regimen B - 6 mg Cycles 1-4 Regimen A (Potential)- 3 mg Cycles 1-4 Regimen C (Conditional)- 12 mg
45800570|NCT04339361|Drug|lidocaine spray|four puffs (50 ml, 10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
45800571|NCT04339361|Drug|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
45800572|NCT04339361|Drug|placebo|vaginal placebo will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
45800573|NCT05397197|Other|Electroencephalography|experimental task, neuropsychological evaluation, clinical exam
45800574|NCT05369351|Drug|mirabegron|In addition to standard treatment, mirabegron 50 mg/d will be given as the first dose within 24 hours of symptom onset for 14 consecutive days.
45800575|NCT05369351|Other|usual care|usual care
45800576|NCT02652221|Device|Acoustic Radiation Force Imaging|ARFI US is a novel technique, recently FDA approved for use in children and adults, which provides an alternative method for quantifying liver stiffness.
45800577|NCT03293381|Device|additional biopsies|additional biopsies
45800578|NCT04340297|Drug|Tongjiang series prescription(Tongjiang granules, Jianpi Qinghua granules and Wenpi Qingwei granules)|According to the syndrome differentiation of TCM, Tongjiang granules are taken orally by patients with liver-stomach depression-heat syndrome, Jianpi Qinghua granules are taken orally by patients with spleen deficiency damp-heat syndrome, Wenpi Qingwei granules are taken orally by patients with cold-heat complicated syndrome, 1 bag per time, 3 times a day and 1 hour after a meal.
45800579|NCT04340297|Drug|Acid inhibitors|In the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
45800580|NCT04340297|Drug|Placebo|Tongjiang granules placebo , Jianpi Qinghua granules placebo and Wenpi Qingwei granules placebo. The above three kinds of granulated placebo are respectively made of the simulation containing the low dose original prescription. Taking method is the same as Tongjiang series prescription.
45800581|NCT02653391|Drug|Part A Elamipretide 1.0% Ophthalmic Solution|Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye.
45929521|NCT01466075|Device|Apollo Evolution Investigational BG Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and Alternative Site Testing (AST) of the palm using the Apollo Evolution meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects complete basic tasks using the User Guide and provide feedback.
45929522|NCT02971059|Dietary Supplement|Phenylalanine intake|Phenylalanine will be provided as graded intakes ranging from 7-40 mg/kg/day
45929523|NCT01466036|Drug|Cabozantinib|60 mg QD orally in cycles of 28 days
45929524|NCT00036816|Biological|MART-1 antigen|
45929525|NCT00036816|Biological|NA17-A antigen|
45929526|NCT00036816|Biological|gp100 antigen|
45651137|NCT03097705|Diagnostic Test|OCT (Optical coherence tomography)|RNFL AND IOP MEASUREMNTS
45651138|NCT05060809|Drug|oral vitamin k1 (phylloquinone)|The enrolled patients received 5 mg of oral vitamin K1 (phylloquinone) three times /week for 6 months at the end of HD session to ensure compliance. We measured the serum dephosphorylated- uncarboxylated matrix Gla protein (dp-ucMGP) before and 6 months after vitamin K1 supplementation. In addition, plain lateral abdominal x-ray was conducted prior to and after 6 months of vitamin K supplementation to assess lumbar aorta calcification. The extent of aortic calcification score (AAC) was assessed by a semi-quantitative grading system developed by Kauppila.
45651139|NCT03097549|Device|Tät®II Information app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence.
45929527|NCT00036816|Biological|tyrosinase peptide|
45929528|NCT01465919|Drug|Mirtazapine|Mirtazapine will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week, dosing between 7.5mg/day and 45mg/day, in patients with interferon induced depression.
45653236|NCT05074953|Other|Exposed to a SARS-CoV-2 infection|The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
45800582|NCT02653391|Drug|Part B Elamipretide 3.0% Ophthalmic Solution|Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both eyes.
45800583|NCT02653391|Drug|Part A Placebo|Part A Each subject will receive one drop of vehicle ophthalmic solution BID in the paired eye of the randomly selected study eye.
45800584|NCT02653391|Drug|Part B Placebo|Part B: Each subject will receive one drop of vehicle ophthalmic solution BID in both eyes.
45800585|NCT05303987|Drug|Propofol sedation|"After induction with sevoflurane then Propofol will be initiated.~If adequate sedation cannot be attained then a ketamine rescue can be given."
45800586|NCT05303987|Drug|Dexmedetomidine sedation|"After induction with sevoflurane then Dexmedetomidine will be given.~If adequate sedation cannot be attained then a ketamine rescue can be given."
45929529|NCT01465919|Other|Supportive psychotherapy|Supportive psychotherapy will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week in patients with interferon induced depression.
45929530|NCT00396513|Drug|Simvastatin|
45929531|NCT00396513|Drug|Simvastatin and Metformin|
45929532|NCT00396513|Drug|Metformin|
45929533|NCT01465880|Other|Part A|Smoking abstinence, smoking 2 and 4 cigarettes
45929534|NCT00036855|Biological|rituximab|Given IV
45929535|NCT00036855|Radiation|indium In 111 ibritumomab tiuxetan|Given IV
45929536|NCT00036855|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
45929537|NCT00036855|Procedure|peripheral blood stem cell transplantation|Undergo PBSC transplantation
45929538|NCT00036855|Biological|filgrastim|Given subcutaneously
45929539|NCT00036855|Other|laboratory biomarker analysis|Correlative studies
45929540|NCT01465841|Device|PC 400 coils (Penumbra )|The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in ± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.
45929541|NCT00036894|Drug|lenalidomide|
45800587|NCT05288309|Other|RAINSTİCK|When the child, who was taken to Experimental Group 1, sat on the patient's chair, the sound of the rain stick was started to be played 1 minute before the blood draw. At that time, the nurse began to prepare the child for the blood draw. The tourniquet insertion procedure and the determination of the vein from which blood will be drawn from the antecubital region were performed by the nurse. Blood collection was taken from the antecubital region in one go by the same nurse by means of a vacuum blood collection tube, and blood flowed to the vacuum within 5 seconds, showing that the procedure was successful. This process took about 2-3 minutes and the children listened to the sound of rain sticks throughout the process.
45800588|NCT05288309|Other|KALEİDOSCOPE|The child, who was taken into Experimental Group 2, was started to watch the kaleidoscope 1 minute before the blood draw, as he sat on the patient's chair. At that time, the nurse began to prepare the child for the blood draw. The tourniquet insertion procedure and the determination of the vein from which blood will be drawn from the antecubital region were performed by the nurse. Blood collection was taken from the antecubital region in one go by the same nurse by means of a vacuum blood collection tube, and blood flow to the vacuum within 5 seconds showed that the procedure was successful. This process took about 2-3 minutes and children were watched with kaleidoscope throughout the process.
45929542|NCT01465724|Procedure|Renal denervation|percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system.
45929543|NCT00036933|Biological|MUC-2-Globo H-KLH conjugate vaccine|
45929544|NCT00036933|Biological|QS21|
45929545|NCT01465685|Drug|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
45929546|NCT01465685|Drug|Methylphenidate|1 hour before MDMA/placebo 60 mg methylphenidate per os, single dose
45929547|NCT01465685|Drug|Placebo|capsules identical to MDMA or methylphenidate
45929548|NCT01465646|Drug|levothyroxine|
45929549|NCT01465646|Drug|levothyroxine|
45929550|NCT00036972|Biological|cintredekin besudotox|
45929551|NCT00036972|Procedure|adjuvant therapy|
45929552|NCT00036972|Procedure|conventional surgery|
45929553|NCT00036972|Procedure|neoadjuvant therapy|
45929554|NCT00393653|Procedure|N-of-1 prescription method|
45929555|NCT01805414|Other|Modified Carbohydrate Breakfast|
45929556|NCT01805414|Other|Control Breakfast|
45929557|NCT00037011|Biological|beta-glucan|
45929558|NCT00037011|Biological|monoclonal antibody 3F8|
45929559|NCT01465607|Behavioral|Mujer Segura|Brief (35-minute) counseling intervention using techniques from Motivational Interviewing and principles of social cognitive theory (SCT) and theory of reasoned action (TRA).
45929560|NCT01465607|Behavioral|CENSIDA counseling program|Didactic HIV and STI counseling involving some personal risk assessment and presenting appropriate information on methods of transmission and for avoiding or reducing the risk of infection. Based on a counseling manual disseminated by CENSIDA, Mexico's federal HIV-AIDS prevention agency.
45651140|NCT03097549|Device|Tät®II Treatment app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence .Exercises for the pelvic floor muscles, for bladder training, and for behaviours of avoidance due to fear of leakage, a statistic function and possibility to set reminders. Individual advices regarding life style factors and training based on findings from the bladder diary and answers in the questionnaires.
45929561|NCT00037050|Drug|Linezolid|
45929562|NCT00037050|Drug|Vancomycin|
45929563|NCT00037050|Drug|Oxacillin|
45929564|NCT00037050|Drug|Dicloxacillin|
45929565|NCT00037089|Drug|UFT (Tegafur/Uracil)|
45929566|NCT01465568|Drug|Denosumab|60mg subcutaneous injection 6 monthly for 2 doses
45929567|NCT01465568|Drug|bisphosphonates|continue present bisphosphonate treatment
45929568|NCT00037128|Drug|GL701|
45929569|NCT01465529|Drug|OligoG CF-5/20|6% OligoG CF-5/20 in water
45929570|NCT01465529|Drug|Saline|0.9% NaCl in water
45929571|NCT00037167|Device|Exercise poles|
45651141|NCT03097471|Device|BPK-S Integration (Ceramic)|primary total knee endoprosthesis
45929572|NCT01465490|Behavioral|Monitoring and Feedback Intervention|Clients participate in standard treatment and complete the MMI weekly with their counselors at the beginning of each individual counseling session. Counselors have been trained to administer the MMI and will have access to the data to use during sessions.
45929573|NCT02971176|Radiation|Low-dose protocol computed tomography|Radiation dose under the low-dose protocol computed tomography (120 kilovolt, 15 milliampere seconds)
45929574|NCT02971176|Radiation|Standard-dose protocol computed tomography|Radiation dose under the standard-dose protocol computed tomography (120 kilovolt, 150 milliampere seconds)
45929575|NCT01465451|Procedure|curative resection for colorectal cancer|right hemicolectomy for right colon cancer, transverse colectomy for transverse colon cancer, left hemicolectomy for left colon cancer, sigmoid colectomy for sigmoid colon cancer, and anterior resection or abdominal-perineal resection for rectal cancer.
45929576|NCT01465451|Drug|intra-operative 5-FU chemotherapy|"5-FU, 1000 mg/m2, injection into bowel lumen at the beginning of resection 5-FU, 200 mg/m2, injection into portal vein via mesentery vein at the end of tumor removal and bowel reconstruction.~5-FU, 300 mg/m2, left in abdominal cavity before incision closure. surgical procedures will be the same as described in ARM A."
45929577|NCT00037206|Drug|Anidulafungin, VER002|
45929578|NCT01465412|Drug|Preladenant|After at least an 8 hours overnight fast, one 5-mg preladenant tablet, is administered orally, on Day 1.
45929579|NCT01465373|Drug|Endometrin|100 mg per vagina TID
45929580|NCT01465373|Drug|Progesterone in Oil|50 mg IM injection daily
45929581|NCT01465295|Device|Mechanical hemiepiphysiodesis using the HemiBridge System|Surgical application of mechanical hemiepiphysiodesis using the HemiBridge device.
45929582|NCT01465256|Drug|Aspirin|Aspirin hold for a certain period of time in the patients who take aspirin for the primary prevention of vascular disease,
45929583|NCT01465217|Behavioral|text message medication reminders|daily medication reminders for one month
45929584|NCT00037440|Genetic|Polymorphisms measured|
45800589|NCT04339205|Other|Analysis of every MRI at presentation of the symptoms and then over a period of 3 to 24 months if available.|"The radiologist will analyze the MRI of patients with proved auto-immune encephalitis realized at presentation of the symptoms. If available, the following-up MRIs will also be analyzed.~At each assessment, four MRI sequences will be studied : diffusion, T2-weighted, susceptibility sensitive sequences, and T1 weighted after contrast enhanced with gadolinium.~The radiologist will analyse the signal abnormalities, their localisation and the trophicity of the brain.~We will then correlate the following clinical data collected for patients : age, sex, clinical presentation, clinical evolution, and tumor associated or not."
45800590|NCT02654483|Drug|VPD-737|VPD-737 inhibits the receptor neurokinin-1.
45800591|NCT02654483|Other|Placebo|Matching tablets to VPD-737 tablets without active drug
45929585|NCT01465139|Drug|CDX-301|"CDX-301, administered in multiple dosages and frequencies depending on arm:~n=3-6 at between 1-75 μg/kg over 5 days~n=3-6 at 25 μg/kg over 7 days~n=3-6 at 25 μg/kg over 10 days"
45929586|NCT00396552|Device|refractory transcranial magnetic stimulation (rTMS)|Bilateral rTMS will be delivered according to the following protocol: high frequency left (HFL) stimulation will initially be applied at 20 Hz, in 25 trains of 1.5 second duration with a 30 second interval between trains and at 100% of the RMT for a total of 25 minutes of stimulation. Following this HFR stimulation will be applied at the same parameters. Therefore a total of 50 minutes of stimulation will be delivered.
45929587|NCT00396552|Device|Sham condition|Sham stimulation will be made at the site of active treatment but with only the side edge resting on the scalp. It will be administered as HFL and HFR for 50 minutes but with the coil angled 45-90 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those with active stimulation but with minimal direct brain effects. Participants will be unable to see the stimulating coil and therefore will remain blind to the treatment condition.
45929588|NCT01465061|Behavioral|Online support group|Joining online support group
45929589|NCT00037479|Drug|ceftriaxone|
45929590|NCT01464983|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Ibuprofen
45929591|NCT01464983|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Ibuprofen
45929592|NCT01464983|Drug|Ibuprofen|Ibuprofen 200 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Ibuprofen, and 2 Placebo tablets of Acetylsalicylic Acid
45929593|NCT01464983|Drug|Ibuprofen|Ibuprofen 2 x 200 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
45929594|NCT01464983|Drug|Placebo|2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Ibuprofen, orally, single dose
45929595|NCT00037518|Drug|AMG 073|
45929596|NCT01464944|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Paracetamol
45929597|NCT01464944|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Paracetamol
45929598|NCT01464944|Drug|Paracetamol|Paracetamol 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Paracetamol, and 2 Placebo tablets of Acetylsalicylic Acid
45929599|NCT01464944|Drug|Paracetamol|Paracetamol 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
45929600|NCT01464944|Drug|Placebo|2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Paracetamol, orally, single dose
45929601|NCT00037557|Drug|BeneFIX|
45929602|NCT01464905|Biological|NU100|0.25 mg SQ, every other day for 12 months
45929603|NCT01464905|Biological|Placebo|1 mL SQ, every other day for 4 months
45929604|NCT01464905|Biological|rhIFN beta-1b|0.25 mg SQ, every other day for 12 months
45929605|NCT00037596|Drug|Gemtuzumab Ozogamicin|
45597939|NCT04961827|Behavioral|Self-efficacy based images through instant messaging|A total of 6 images will be sent to participants via instant messaging. Images will utilize concepts in the Theory of self-efficacy to increase dietary self-efficacy among participants and hence improve dietary quality beyond that of conventional nutrition counseling.
45651142|NCT05055115|Procedure|Balloon Eustachian Tuboplasty|Balloon Eustachian Tuboplasty of the cartilaginous part of ET. The procedure is performed endonasally under general anesthesia. It is believed that BET leads to micro-bleeding in the mucosa with subsequent scarring and expansion of ET.
45651143|NCT05055349|Other|corneal ring segments|ring hard segments inserted within corneal stroma using femtolaser
46072577|NCT03664362|Behavioral|The BSHAPE Intervention|The BSHAPE intervention program key elements include strengths based assessments, individualized plans and support based on priorities and needs, motivational interviewing strategies, psychoeducation (education with skill building exercises), mindfulness activities, danger assessment, safety planning, behavioral activation and linkage to community resources
45651144|NCT03098095|Behavioral|Physical Activity|Moderate physical activity
45800592|NCT03237845|Drug|Rimegepant|75 mg tablet QD
45800593|NCT03237845|Drug|Placebo|Placebo tablet to match rimegepant dose QD
45800594|NCT02655653|Drug|Epsilon-aminocaproic acid administered|Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
45929606|NCT00037596|Drug|cytarabine.|
45929607|NCT00037635|Drug|AMG 073|30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
45929608|NCT00037635|Drug|Placebo|30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
45929609|NCT01464866|Other|Nutritional Supplement|Liquid, pediatric nutritional supplement. 1-2 bottles/day for up to 28 days.
45929610|NCT01464866|Other|Hospital food|Typical hospital food given daily at meals
45929611|NCT00037674|Drug|Topiramate|
45800595|NCT02655653|Drug|Tranexamic Acid administered|Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
45651145|NCT05061043|Other|Routine physical therapy treatment|Control group will receive the routine physical therapy treatment that will include EMS, Infrared and Intermittent stretching of facial muscles for 36 sessions on alternate days, each session comprise 30 minutes for 5 days a week
45651146|NCT05061043|Other|Routine physical therapy along with orofacial therapy|Experimental group will receive routine physical therapy along with orofacial therapy (36 sessions on alternate days, each session comprise 45 minutes)
45929612|NCT01464749|Behavioral|Task-oriented circuit class training|5 sessions/week over 2 weeks (10 sessions) 120 minutes/each
45929613|NCT01464749|Behavioral|usual care|no specific rehabilitation
45929614|NCT00037713|Biological|BEC2 Vaccine|5 vaccinations of BEC2 (2.5 mg) + BCG given day 1 of weeks 0,2,4,6 & 10.
45929615|NCT00037752|Drug|Sibutramine|At the baseline study visit, participants in Group 1 will be given a one month supply of 5 mg/d of sibutramine and a 1-month follow-up visit will be scheduled. After a safety evaluation at the 1-month follow-up visit, participants will have their dose of sibutramine titrated to 10 mg/d, a 1 month supply of the medication will be given to participants, and a 2-month follow-up visit will be scheduled. After a safety evaluation at the 2-month follow-up visit, participants will receive a 1 month supply of sibutramine 10 mg/d and a 3-month follow-up visit will be scheduled. At the 3-month follow-up visit, the sibutramine will be discontinued and participants will be scheduled for 4- and 5-month follow-up visits.
45929616|NCT00037752|Behavioral|Behavioral Smoking Cessation Program|Both groups of participants will take part in a behavioral smoking cessation program.
45929617|NCT01464671|Drug|Bivalirudin|Anticoagulation during percutaneous coronary intervention
45929618|NCT01464671|Drug|Heparin|Anticoagulation during percutaneous coronary intervention
45929619|NCT00037791|Drug|(PN-152,243)/PN-196,444|
45929620|NCT01464632|Device|EPIK™ uni-compartmental knee|This device is intended for partial replacement of the articulating surfaces of the knee when only one side of the joint is affected due to compartmental primary degenerative or post-traumatic degenerative disease, previous tibial condyle or plateau fractures, deformity, or revision of previous arthroplasty.
45929621|NCT00037869|Drug|I-131 Metaiodobenzylguanidine|
45929622|NCT01464554|Behavioral|Usual care|alcohol and drug education
45929623|NCT01464554|Behavioral|Project Free Talk|motivational interviewing alcohol and drug program
45929624|NCT00037908|Procedure|Strength training|
45929625|NCT01464515|Device|H-Coil Deep TMS|this group will receive high frequency treatment of deep TMS with 10Hz
45929626|NCT01464515|Device|SHAM Coil TMS|this group will receive SHAM treatment of deep TMS
45929627|NCT00037947|Procedure|Hearing in Multiple Sclerosis|
45929628|NCT00037986|Device|Hearing Aids|Hearing aid use
45929629|NCT00393731|Drug|Misoprostol|
45929630|NCT00393731|Drug|oxytocin|
45597940|NCT04961827|Behavioral|Knowledge based images through instant messaging|A total of 6 images will be sent to participants via instant messaging. Images will consist of information covered in nutrition counseling sessions, such as those related to serving sizes.
45929631|NCT00038025|Drug|Deoxycoformycin (DCF)|Patients received Deoxycoformycin (DCF)/Pentostatin administered by intravenous bolus daily over a consecutive 3-day period. This course was repeated at 3-week intervals.
45929632|NCT00393770|Drug|L-acetylcarnitine|250-500 mg/kg/die.
45929633|NCT00038064|Drug|Darbepoetin alfa|Darbepoetin alfa will be administered 4.5 mcg/kg QW until hemoglobin correction is achieved. Subjects meeting hemoglobin criteria for correction will receive a maintenance dose of darbepoetin alfa of 4.5 mcg/kg Q3W.
45929634|NCT00038064|Drug|rHuEPO|150 IU/kg TIW
45929635|NCT00393809|Drug|DTA-H19|
45929636|NCT00038181|Drug|Thalidomide|
45929637|NCT00393926|Device|TheraDrive Assistive Device|
45929638|NCT00393926|Procedure|Rote Therapy versus Fun Therapy|
45929639|NCT00038220|Drug|Lopinavir/ritonavir|
45597941|NCT04942405|Biological|TURCOVAC|Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,28
45597942|NCT04942405|Biological|CoronaVac|Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) vaccine at the schedule of day 0, 28
45597943|NCT04933513|Behavioral|pre DBS patients responding to the DBS-PS scale|we propose to parkinson's disease patients selected for subthalamic deep brain stimulation to complete the DBS-PS scale preoperatively
45597944|NCT04865263|Device|Digital Pain-Management Tool|Self management digital tool for chronic pain
45597945|NCT03524599|Other|Intervention municipality|In intervention municipalities, primary health care centres and the providers working within them will receive training and a range of community support mechanisms.
45651147|NCT05054959|Other|consolidation chemotherapy|6 cycles CAPOX after chemoradiotherapy
45651148|NCT05054959|Other|induction chemotherapy|4 cycles CAPOX before and 2 cycles CAPOX after chemoradiotherapy
45651149|NCT03097393|Diagnostic Test|measure Serum procalcitonin level|measuring procalcitonin level
45651150|NCT03097237|Other|Wholegrain rye|Cereal products based on wholegrain rye
45651151|NCT03097237|Other|Refined wheat|Cereal products based on refined wheat
45929640|NCT00038220|Drug|Efavirenz|
45929641|NCT00038220|Drug|Lamivudine|
45929642|NCT00038220|Drug|Tenofovir DF|
45929643|NCT01307384|Device|Continuum Metal on Polyethylene Acetabular System|Used in primary hip arthroplasty
45929644|NCT00038259|Drug|Aldesleukin|
45929645|NCT00848003|Drug|Bifidobacterium animalis subsp. lactis strain BB-12|Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
45929646|NCT00848003|Drug|Placebo|Strawberry flavored yogurt
45800596|NCT02656745|Device|Mobile Smoking Cessation Solution|"The intervention regimen is almost entirely user-directed; users will download the application on their iPhones & engage with it throughout their quit journey. They will be asked to complete missions, daily activities to help prepare them to quit and keep them off cigarettes. When they have a craving, a series of options are available to ease the craving and resist the urge to smoke. Daily and Weekly Check-Ins are scheduled by the user to gather information about their smoking habits, help them learn about their addiction, and ultimately to overcome it. Ideally, the user will open and use the program several times a day. Participants who continue with the study through its completion will spend a total of 8 weeks using this smoking cessation mobile program."
45800597|NCT03170453|Behavioral|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
45800598|NCT03170453|Behavioral|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
45597946|NCT04467229|Behavioral|Focus group|5 to 10 adolescents will participate in a discussion group lead by a paediatrician and a psychologist from the Centre de la Douleur de Trousseau. Two groups will be organized, the length of the group discussion being one hour. These focus groups will explore the adolescents' perception of the questionnaire and of different elements of the screening. The group will undergo full transcription. The verbatim will be anonymous and will be analysed through qualitative methods.
45929647|NCT00038298|Drug|Placebo|Placebo given 3 times weekly
45597947|NCT03524521|Behavioral|Interval Training|Interval training is prescribed 3 days per week using 5 body weight exercises in a progressive fashion.
45929648|NCT00038298|Drug|AMG 719|50 mg 3 times weekly
45929649|NCT00038298|Drug|AGM 719|200 mg 3 times weekly
45929650|NCT00038298|Drug|AMG 719|400 mg 3 times weekly
45929651|NCT00038298|Drug|placebo to AMG 719|Placebo dose given 3 times weekly
45929652|NCT00847964|Device|Algisyl-LVR|method of left ventricular restoration in patients with dilated cardiomyopathy
45929653|NCT00038337|Procedure|Health Literacy|
45929654|NCT05434260|Device|Surgiphor Irrigation Solution|use of Surgiphor wound irrigation solution during surgery
45929655|NCT05434260|Device|Sterile saline|Use of sterile saline as a irrigation solution during surgery
45929656|NCT00847925|Drug|Avotermin (RN1001)|100ul/linear cm of wound. Dosed before surgery and 24h later
45929657|NCT05434221|Other|COPE|"The experimental group receives the COPE during their internships. The COPE consists of two part: (1) communication skills teaching and simulation practice; (2) clinical communication teaching: record the clinical treatment process of the interns and turn them into verbatim drafts. Experts then complied the strengths and weaknesses of the interns' communication skills based on the verbatim manuscripts and gave feedback on the interns' communication skills.~The interns in the experimental group will participate 1 time of the communication skills teaching and simulation practice, and 3 times of the clinical communication teaching in three months."
45929658|NCT00847847|Procedure|Anconeus Muscle biopsy|Anconeus muscle specimens will be surgically removed. The biopsy will be performed under regional anaesthesia and will require an about 5 cm incision of the skin and muscle fascia from the lateral condyle to over the ridge of the proximal ulna, 3 or 4 cm distal to the tip of the olecranon. A triangular muscle flap will be removed, and then the fascia and skin will be closed with running dissolving suture.
45929659|NCT00847769|Other|High velocity, low amplitude stretch|This group (n=9) will receive talocrural traction manipulation. With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
45929660|NCT00847769|Other|Slow, mobilization stretch|This group (n=9) will receive talocrural traction mobilization. With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating investigator's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
46072578|NCT03621748|Procedure|Awake Anesthesia Protocol|Awake is defined as the patient being awake with electrical brain stimulation mapping during the critical portions of the procedure.
46072579|NCT03621748|Procedure|Non-awake Anesthesia Protocol|Non-awake is general anesthesia as per convention with intubation.
46072580|NCT03604991|Drug|Carboplatin|Given IV
46072581|NCT03604991|Procedure|Computed Tomography|Undergo CT scan
46072582|NCT03604991|Biological|Ipilimumab|Given IV
45597948|NCT03524521|Behavioral|Standard of Care|Walking prescribed to meet current exercise guidelines; 150 minutes per week.
45597949|NCT03116113|Biological|BIIB112|Administered as specified in the treatment arm
45597950|NCT04468009|Biological|Convalescent plasma|Convalescent plasma from patients recovering from Covid-19 and which had anti-SARS-Cov-2 antibodies
45597951|NCT03088813|Drug|Irinotecan liposome injection|IV
45651152|NCT05060419|Drug|Meropenem- FL058|"Meropenem-FL058(Meropenem 1000mg plus FL058 1000mg)q8h~Meropenem-FL058(Meropenem 2000mg plus FL058 1000mg)q8h"
45651153|NCT05060419|Drug|Piperacillin -tazobactam|Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g)q8h
45651154|NCT05060419|Drug|Saline|180min
45651155|NCT05060419|Drug|Saline|30min
45651156|NCT05055193|Drug|Evaluation at 24 months corrected age: respiratory outcome, Neurodevelopmental outcome, Growth outcome|Data concerning the 24 months corrected age outcomes were collected from the medical records of the ECL'AUR preterm infants follow-up network.
45653237|NCT01667081|Drug|Grazoprevir|Participants previously received study treatment with grazoprevir at the dose and frequency specified in the study protocol. Grazoprevir was not administered to participants in the course of this follow-up study.
45800599|NCT03081143|Drug|FOLFIRI|Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin* 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle
45800600|NCT03081143|Drug|Ramucirumab|8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle
45800601|NCT03081143|Drug|Paclitaxel|80 mg/m2 on day 1, 8, 15
45800602|NCT02657915|Drug|Placebo|Administered as specified in the treatment arm.
45929661|NCT00847769|Other|Passive Positioning|This group (n=9) will receive the manual therapy control intervention. This will consist of the same patient and clinician preparation for the mobilization/manipulation techniques. However, a single standardized treating investigator will simply maintain passive ankle positioning for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force characteristic of the intervention received by the other 2 comparison groups.
45929662|NCT04711772|Other|whole-genome sequencing|Whole-genome sequencing will be preformed for each participate to explore the potential disease-causing genes of DOR.
45929663|NCT04732299|Other|MRI examination|Magnetic resonance thrombography is used to determine the location of thrombus, quantify the thrombus and determine its stage.
45929664|NCT00847574|Behavioral|Moderate-fat|35% of calories from fat
45929665|NCT00847574|Behavioral|Lower-fat|20% of calories from fat
45800603|NCT02657915|Drug|BIIB033 100mg/Kg|Administered as specified in the treatment arm.
45929666|NCT00847496|Device|AWBAT|One-time application of dressing over partial-thickness burns
45929667|NCT00847496|Device|Biobrane|One-time application over partial-thickness burns
45929668|NCT04733339|Behavioral|Secondary Prevention|behavioral changes in dieting and exercising up to one year after clinical discharge
45929669|NCT02971020|Other|Observational/Cognitive Assessment|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
45929670|NCT00847457|Behavioral|Aerobic exercise|Aerobic exercises completed three to four times per week for 20 to 30 minutes per session
45450973|NCT02211430|Behavioral|Cognitive-Behavioral Counseling (CBC)|Participants of CBC were educated about the effects of smoking on their personal health and their pregnancy during session 1 (45 minutes counseling), and were encouraged to explore their risk perceptions and emotions, for themselves and their unborn child. During session 2, the 15-minute counseling segment highlighted the cognitive and emotion barriers undermining the participant's motivation to quit and the self-regulatory techniques for resisting personal smoking triggers. Session 3 (45 minutes counseling) involved reviewing smoking status and smoking history over the course of the pregnancy, as well as the effects of smoking on both their health and the health of their infant. Booster session was held by phone for 15 min.
45450974|NCT02211430|Behavioral|Best Practice (BC) Control|"For ethical considerations, and consistent with practice guidelines for treating tobacco addiction (Fiore et al., 2000) which mandates that every pregnant smoker be offered smoking cessation treatment, the control group has been designed to be comparable to the current best practice guidelines for smoking cessation treatments. This condition, devised from a review of the current literature, will include one brief (5-15 minutes) prenatal individual session (session 1) consisting of smoking cessation education and advice, on-site brochure pick up (session 2), and a second brief postpartum individual session (session 3) followed by receipt of a newsletter (session 4)."
45450975|NCT02221024|Procedure|Flushing with positive pressure|Placement of a sterile plug (MicroClave ICU Medica, a neutral displacement connector) on the needle cannula and flushing with positive pressure with saline solution (BD PosiFlush XS Syringes, filled with 3 ml of saline)
45450976|NCT02221024|Drug|Normal saline|
45800604|NCT02658461|Drug|Trastuzumab|Trastuzumab will be given on Day 1 of each 3-week cycle for a total of 18 cycles. Dosage will be according to the local labeling: 600 milligrams (mg) SC or 6 milligrams per kilogram (mg/kg) via IV infusion. For those assigned to the IV arm or if IV treatment is delayed >1 week, an initial loading/reloading dose of 8 mg/kg will be given instead. Due to the observational nature of this study, trastuzumab is not an investigational product but will be supplied in the MO22982 trial. Each route/device (SC single-use injection device, SC vial/syringe, IV infusion) will be observed in at least 12 episodes of care.
45800605|NCT02658851|Device|J-Plasma|Bovie Medical Corporation's J-Plasma® helium based plasma technology is a hemostatic tool for the cutting, coagulation, and ablation of soft tissue.
45800606|NCT00367913|Drug|Addition of clarithromycin to rifampicin and ethambutol|
45800607|NCT00367913|Drug|Addition of Ciprofloxacin to rifampicin and ethambutol|
45800608|NCT00367913|Biological|Vaccination with M.vaccae|
45800609|NCT03069521|Device|EndoArt® Artificial Endothelial Layer|device is intended for use as an endothelial kearatoprosthesis
45800610|NCT02974127|Radiation|Radiotherapy|Multisession radiosurgery
45800611|NCT02653079|Other|Blood Draw and Questionaire|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw from patients at several time points during and after low dose radiation therapy.
45800612|NCT04739501|Procedure|TACE|Trans-arterial chemoembolization in patients with hepatocellular carcinoma
45929671|NCT00847457|Behavioral|Stretching|Easy to moderate stretching routines completed three times per week, with a new set of routines given each week
45929672|NCT02971137|Behavioral|Smoking Cessation plus CBI|proactive tele-health intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain
45929673|NCT02971137|Behavioral|Smoking Cessation Standard|standard telephone-based smoking cessation intervention
45929674|NCT00847418|Drug|esketamine hydrochloride|
46072583|NCT03604991|Biological|Nivolumab|Given IV
46072584|NCT03604991|Drug|Paclitaxel|Given IV
46072585|NCT03604991|Procedure|Positron Emission Tomography|Undergo PET scan
45800613|NCT02659709|Device|Interest in medical education through social media|Measuring interest in social media technology designed to educate glaucoma patients about disease, testing, and treatments with reminders for taking medications.
45800614|NCT02659787|Drug|0.2mg Buprenorphine|Sublingual buprenorphine tablets (0.2mg)
45800615|NCT02659787|Drug|Placebo|Placebo
45800616|NCT02660801|Procedure|Spinal manipulation|A high-velocity and low-amplitude thrust delivered posteroanteriorly to a thoracic vertebra
46072586|NCT03604991|Radiation|Radiation Therapy|Undergo radiation therapy
45651157|NCT05060185|Device|the Flow Diverter|Those who meet the inclusion criteria but do not meet the exclusion criteria will be enrolled through the electronic central registration system. The investigator log in to the central registration system, fill in the subject information and submit it who enroll in the study. The investigator complete the surgery and conduct relevant evaluation according to the protocol.
45929675|NCT02971943|Procedure|internal fixation for ankle fractures|The patients with ankle injury underwent internal fixation for ankle fractures and ligament repair. Ankle was observed with X-ray and magnetic resonance imaging.
45929676|NCT05433597|Drug|5-fu|5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.
45929677|NCT05433597|Drug|Cisplatin|Cisplatin: 80mg/m2, used on the 1st and 28th day of each cycle.
45929678|NCT05433597|Radiation|Radiotherapy|Radiotherapy: Radiotherapy was initiated on day 15 of the first cycle of chemotherapy . GTV: 6810cGy (227 cGy/30f) Or 6996 cGy (212 cGy/ 33F); CTV: 5400-6000 cGy (180-200 cGy/f); Radiotherapy once a day, 5 times a week, a total of 30-33 times, a total of about 6 weeks.
45800617|NCT02660801|Procedure|Spinal mobilization|Three repetitions of a low-velocity and low-amplitude nonthrust movement delivered posteroanteriorly to a thoracic vertebra
45800618|NCT02661737|Device|YVOIRE volume s|
45929679|NCT05433597|Drug|TNF|TNF (recombinant human tumor necrosis factor for injection) : 1 million IU (BSA<2.0m2) or 1.5 million IU (BSA≥2.0m2), dissolved in normal saline 1-2mL, intramuscular, QD, 30 days in the first and third months, once a day.
45450977|NCT02221024|Device|MicroClave ICU Medica|
45800619|NCT05044871|Drug|Pamiparib|40mg PO. bid.
45651158|NCT05044351|Device|Fluobeam LX|See arm description
45800620|NCT05044871|Drug|Bevacizumab|7.5mg/kg IV. D1 (q3w.)
45800621|NCT05044871|Drug|Tislelizumab|200mg IV. D1
46072587|NCT03586453|Drug|Osimertinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive Osimertinib.~After the screening procedures confirm participation in the research study:~Osimertinib: Oral, Daily 28 day cycle.~Radiographic assessment: every 2 cycles for first 6 months and then every 3 cycles until disease progression.~Tumor biopsy between C4 and C8 and at disease progression"
46072588|NCT03576547|Drug|Dexamethasone|Given PO or IV
46072589|NCT03576547|Drug|Ponatinib Hydrochloride|Given PO
46072590|NCT03576547|Biological|Rituximab|Given IV
45450978|NCT02212522|Other|Collect of environmental data on T1D patients before diagnosis|Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
45800622|NCT05044871|Drug|Nab paclitaxel|125mg / m2 IV. D1, 8 (q3w).
45800623|NCT05044871|Drug|Bevacizumab + Nab paclitaxel (intense dose-dense)|Bevacizumab 7.5mg/kg IV. D1, 15 (Q4w). + Nab paclitaxel 100mg / m2 IV. D1, 8, 15 (Q4w).
45929680|NCT05433597|Drug|Placebo|Placebo: 1-2ml normal saline, intramuscular injection, QD, once a day, 30 days in the first and third months.
45929681|NCT00847340|Procedure|Biopsy Excisional|Biopsied from genital warts will be taken through an excisional procedure. Homeostasis will be obtained by using apply of Monsel solution. Biopsied sample will be splinted in order to obtain two pieces, one of them will be frozen (liquid Nitrogen) and designated to the HPV DNA PCR test (GP5, GP6) to be performed at the immunology lab at the National Cancer Institute in Bogotá. The other one will be kept in Formalin solution (10%) and sent to the pathology laboratory for haematoxiline - eosine paint and lecture.
45597952|NCT03088813|Drug|Topotecan|IV
45597953|NCT03766555|Procedure|Microwave ablation|Microwave ablation will be performed in operation theatre under general anesthesia via laparoscopic or open approach according to the tumors' locations. In case of open approach, it will be done via a right subcostal incision with possible upper midline extension was necessary. After diagnostic laparoscopy in laparoscopic approach and exploratory laparotomy in open approach to exclude the presence of extra-hepatic disease, operative ultrasound (Aloka, Tokyo, Japan) will be performed to exclude preoperatively undetected lesion; guide insertion of the microwave applicator; and monitor the whole ablation process. Surrounding organs were cooled by constant irrigation of ice-cold saline to prevent thermal injury. The ablation will be carried out according to the standard protocol with the aim to create a 1cm ablation margin around the tumor. The insertion track will be burnt after ablation in order to prevent bleeding and tumor seeding.
45651159|NCT05044351|Other|Conventional surgery without NIRAF assistance|Patients undergoing conventional thyroid lobectomy without NIRAF-assistance
46072591|NCT03576547|Drug|Venetoclax|Given PO
46072592|NCT03552796|Other|Pharmacokinetic Study|Correlative studies
46072593|NCT03552796|Biological|Recombinant EphB4-HSA Fusion Protein|Given intravesically
46072594|NCT03496402|Other|Sampling on blood, bone marrow and cerebrospinal fluid|biological sampling during treatment and follow-up
46072595|NCT03469505|Behavioral|COPES|Cooperative Pain Education and Self-Management for chronic pain therapy.
46072596|NCT03469505|Behavioral|CBT-CP|Cognitive Behavioral Therapy for Chronic Pain
46072597|NCT03467373|Drug|Glofitamab|Glofitamab will be administered intravenously (IV) as a step-up dose for Cycle 2 on Days 8 and 15, and as a single dose from Cycle 3 onwards.
46072598|NCT03467373|Drug|Obinutuzumab (G)|Obinutuzumab 1000 mg single dose IV infusion on Day 1 of Cycle 1 only
46072599|NCT03467373|Drug|Rituximab (R)|Rituximab will be administered as an IV infusion at a dose of 375 mg/m^2 on Day 1 of each 21-day cycle starting from Cycle 1 to Cycle 6 (Part 1) or from Cycles 1-6 (up to 8) (Part 2: DLBCL R-CHOP).
45651160|NCT05060107|Biological|Exosomes (sEVs)|Exosomes 3-5x10e11 particles/dose
45651161|NCT05060263|Drug|HOT-1030|HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection
45651162|NCT05036551|Diagnostic Test|Kellgren Lawrence classification|The Kellgren Lawrence classification was used in the radiological evaluation. It is a classification method used in the staging of knee osteoarthritis. Five stages were defined according to the anteroposterior X-ray.(Stage 0-5)
45929682|NCT05433480|Drug|BPI-16350|BPI-16350 400 mg, orally once daily
45929683|NCT05433480|Drug|placebo|Placebo 400 mg, orally once daily
45929684|NCT05433480|Drug|Fulvestrant|Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
45929685|NCT00847262|Drug|Temisartan|Temisartan, initial dose: 40 mg per day, Max dose: 160 mg per day
45800624|NCT05009849|Other|Yoga Exercises|The exercises in the Exercise I arm (Yoga and conventional exercises) will be upgraded to Phase II. Patients will be allowed to attend a minimum of four out of seven days in Phase I and II. Patients will be assessed at 6-9 months for compliance to phase II exercises. Only if patients are fulfilling the criteria for accuracy, sequence and duration of phase II exercises, will they be taught phase III exercises. Patients who are unable to do phase II exercises accurately or demonstrate non compliance to the exercise routine at first follow up visit/ 6-9 months will be re taught phase II exercises. These patients will be upgraded to phase III only if able to perform phase II adequately at assessment. Six months after completion of phase III exercises, patients will be assessed for compliance to phase III exercises. These women's will be assessed at the subsequent 6-9 month follow up and compliance will be evaluated.
45929686|NCT00847262|Drug|Amlodipine|Amlodipine, initial dose: 5 mg per day, Max dose: 10 mg per day
45929687|NCT00847223|Drug|ZARNESTRA (Tipifarnib)|
45929688|NCT05433207|Drug|Eldecalcitol soft capsules|0.75 μg orally once a day during the intensive monitoring period. (The dose can be appropriately reduced to 0.5 μg according to symptoms, once a day.)
45929689|NCT00847184|Device|Intubation|Intubation using the standard MacIntosh blade
45929690|NCT00847184|Device|Airtraq|Intubation with the use of the Airtraq technique
45800625|NCT01643850|Drug|MCS110|Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.
45450979|NCT02212522|Genetic|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
45929691|NCT00847106|Drug|Daclizumab|
45929692|NCT00847106|Biological|Dendritic cells|
45929693|NCT05432973|Procedure|Percutaneous Electrical Nerve Stimulation|In the PENS treatment, a biphasic continuous waveform current with a frequency of 2 Hz, a pulse width of 50 microseconds and an intensity that produces visible motor responses of the innervated muscles was used, below the patient's pain threshold. The NT6021 Percutaneous Neuromodulation equipment of the Nutek® brand distributed by Fisiolab Ibérica® was used. This equipment has the CE marking, which denotes compliance with the requirements of the legislation of Royal Decree 414/1996 of March 1, which regulates medical devices. B.O.E. of April 24, 1996
45929694|NCT05432973|Procedure|Neurodynamic and manual therapy|"The manual therapy consisted of passive-assisted mobilization and massage therapy of the muscular and fascial tissue, beginning with the cervical area, kneading while asking the patient to rotate the neck and then in the same way along the muscles and soft tissues innervated by the target nerve.~Neurodynamic was performed in a passive-assisted manner, combining the patient's cervical mobilizations with the mobility of the upper limbs adapted to each case."
46072600|NCT03467373|Drug|Tocilizumab|Tocilizumab will be administered as an IV infusion as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents. Tocilizumab will be given as rescue medication.
46072601|NCT03467373|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m^2 administered IV on Day 1 of each 21-day cycle
45651163|NCT03096925|Behavioral|Guided self-help|Web-based guided self-help intervention
45651164|NCT03097159|Procedure|Costoclavicular block|Group C for costoclavicular block Group S for supraclavicular block
45651165|NCT03097003|Drug|Apremilast|Psoriasis patients treated with Otezla® (Apremilast) in Belgium
45651166|NCT03098251|Procedure|3D typing|typing the patient with 3D typing system and give specific treatment
45651167|NCT03098251|Procedure|routine typing|typing the patient with routine typing system and give specific treatment
45653238|NCT04998045|Behavioral|Screening and brief intervention for substance use|Screening will be done using the WHO Alcohol Smoking and Substance Involvement Screening Test (ASSIST). The brief intervention will be delivered based on ASSIST risk scores: low risk - verbal positive reinforcement and brief advice on harmful consequences of substance use (ii) moderate risk - brief motivational interviewing (BMI) (iii) high risk - BMI and referral to child psychiatry out-patient clinic. The BMI will be delivered in a single session (approximately 15 minutes) using Feedback Listen Options model (15): (i) providing feedback on screening results (ii) exploring pros and cons of substance use, enquiring about importance of change (iii) exploring options for change.
45929695|NCT04733456|Behavioral|Quality of life questionnaires|Mayo Clinic Score (UC) or HBI score (CD), short IBDQ73, *EQ5D-5L, *GAD-774, *PHQ-975, *PROMIS (Gastrointestinal Belly Pain), Multidimensional Assessment of Interoceptive Awareness (MAIA)77, *Pain Catastrophizing Scale, Pittsburg Sleep Quality Index (PSQI) and Fatigue Severity Scale (FSS) at baseline and 16 weeks after the start of anti-TNF therapy
45929696|NCT04733456|Device|NIRS|A TechEn NIRSOptix continuous-wave fNIRS system will be used to record changes in cerebral oxygenation, at a sampling rate of 25 Hz
45929697|NCT04733456|Other|Stool Collection|For assessment of the known biomarker fecal calprotectin, in addition to fecal bacterial and fungal microbiome
45929698|NCT04733456|Other|Blood and urine collection|for inflammatory markers and metabolomic [IMC] analysis
45929699|NCT02971215|Device|iLux Laser|"Treatment during 15 sessions. It is divided in two phases: 1. 12W. 50 Hz 20% duty cycle. 50 J/cm² in painful zone. 2. 15 W. Burst (10 pulses-900 msec each train) 250 J/cm² in painful zone. Trough the iLux Laser (Mectronic Medicale, Italy)~+ Physical Therapy protocol."
45929700|NCT02971215|Device|Sham ilux Laser|Sham treatment during 15 sessions trough the iLux Laser (Mectronic Medicale, Italy), It is applies the same time than experimental one but with 0 W + Physical Therapy protocol.
46072602|NCT03467373|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 administered IV on Day 1 of each 21-day cycle
46072603|NCT03467373|Drug|Vincristine|Vincristine 1.4 mg/m^2 administered by IV push on Day 1 of each 21-day cycle with a recommended cap of 2 mg
46072604|NCT03467373|Drug|Prednisone|Prednisone 100 mg/day orally on Days 1-5 (prednisone on Day 1 may be administered IV, with the remaining doses on Days 2-5 to be administered orally) of each 21-day cycle
46072605|NCT03467373|Drug|Polatuzumab vedotin|Polatuzumab vedotin 1.8 mg/kg administered IV on Day 1 of each 21-day cycle
46072606|NCT03454997|Other|training including in-person and online|training, motivational interviewing practice
45800626|NCT01643850|Drug|Placebo|Participants will receive a single dose of NaCl on day 1 through intravenous infusion.
45800627|NCT04931693|Drug|paracetamol|iv post operative analgesia
45800628|NCT04931693|Procedure|modifiedPECs block|sonar guided pectoral nerve block
45800629|NCT03662633|Diagnostic Test|Breast cancer group|All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
45800630|NCT03662633|Diagnostic Test|Benign breast tumor group|All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
46072607|NCT03454997|Other|organizational strategy meetings|meetings with leadership to optimize implementation of evidence-based practices
45929701|NCT00847067|Procedure|Paravertebral block|3ml 1% Ropivacaine at each level T1 - T5
45929702|NCT00847067|Procedure|Sham injections|Sham injections with Normal Saline
45929703|NCT00396669|Drug|Bupropion|We measure dopamine release at the striatum using 11 C Raclopride at baseline and after smoking a cigarette
45651168|NCT05055037|Other|Neurofeedback|In neurofeedback (NF), the brainwave activity is measured by an electro-encephalography and fed back to the person as an auditory or visual signal, rewarding the person each time progress is made toward normalizing dysregulated neural activity. The learning mechanism is at its base considered to be operant conditioning, where the behavior of the participant-in this case, neurological activity-is gradually changed through repeated reinforcement. In neurofeedback, this simple learning mechanism is accelerated by continuous and instant feedback, with rewards occurring as often as every second. The NF intervention included 12 NF training sessions, one session per week, off approximately 12-20 min. The protocol was a replicate of the setup of recent NF studies investigating NF as a treatment for chronic PTSD. The feedback was based on a single channel recording, rewarding brainwave frequencies associated with a calm and relaxed state and inhibiting drowsiness and hyperarousal.
45651169|NCT05036239|Other|Eccentric biceps curls|10 x 5 repetitions of eccentric biceps curls, interspaced by 30 seconds of rest.
45929704|NCT00396669|Drug|Bupropion|Brain imaging after treatment with Bupropion
45929705|NCT00396708|Device|myomo e100 neurorobotic elbow brace|
45929706|NCT00847028|Other|glucose 10%|2 minutes prior to the venipuncture, a 10% glucose concentration was administered orally
45929707|NCT00847028|Other|20% glucose|2 minutes prior to the venipuncture, a 20% glucose concentration was administered orally
46072608|NCT03454997|Other|performance coaching|to enhance ability to deliver the weight management intervention
45804134|NCT05664139|Drug|Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel|"Recombinant Human Adenovirus Type 5 Injection:①the longest diameter of the lesion≥10mm and≤40mm, inject 1ml into the tumor each time;②the longest diameter of the lesion≥40mm and≤80mm, inject 2ml into the tumor each time. planned injections at D1. Every 3 weeks is a period, a total of 4 cycles; if there are visceral and superficial lesions at the same time, the injection lesions will be selected by the investigator based on possible benefits.~Camrelizumab:200mg/time.Intravenous within 48 hours after injection of recombinant human adenovirus type 5 injection. Every 3 weeks is a period, and the treatment is continued until the subject has disease progression or unacceptable toxicity or death.~Nab-paclitaxel:260mg/m2, D1, every 3 weeks as a period, a total of 4-6 cycles (determined by the investigator), or continue treatment until the subject has disease progression or Intolerable toxicity or death."
45929708|NCT00847028|Other|glucose 30%|2 minutes prior to the venipuncture, a 30% glucose concentration was administered orally
45929709|NCT00847028|Other|sterile water|2 minutes prior to the venipuncture, sterile water was administered orally
45929710|NCT02970903|Device|VitalPAD|VitalPAD prototype device
45929711|NCT02970903|Device|Traditional tools|Paper based records, screenshots of monitors and therapy devices
45929712|NCT00846989|Drug|RKI983A|RKI983 0.05 % twice daily
45929713|NCT00846989|Drug|RKI983A|RKI983 0.1 % twice daily
45929714|NCT00846989|Drug|Latanoprost|Latanoprost 0.005 % once a day
46072609|NCT03447912|Behavioral|Intervention Condition|The intervention approach will be informed by the Community Coalition Action Theory (CCAT) developed by Butterfoss and Kegler. CCAT posits that coalitions form due to a threat, opportunity, or mandate. Public health center staff will form a coalition by recruiting partner organizations from civil society and other government sectors (e.g., health care, education), conduct situational assessment, and develop and implement action plans to promote the adoption and enforcement of smoke-free policies in worksites and restaurants.
46072610|NCT03440450|Drug|FF-10832 Gemcitabine Liposome Injection|FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes
45929715|NCT00396747|Drug|Infliximab, methylprednisolone, methotrexate|
45929716|NCT00396747|Drug|Methotrexate|
45929717|NCT00396747|Drug|Methotrexate + Methylprednisolone|
45929718|NCT00396747|Drug|Methotrexate + Infliximab|
45929719|NCT00846950|Drug|dexchlorpheniramine, lorazepam|
45929720|NCT05432934|Drug|Dexamethasone|Dexamethasone will be added to local anesthetic solution and injected at 4 site for for laparoscopically placed TAP blocks.
45929721|NCT00846911|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients with acute exacerbation of chronic bronchitis for whom the physician decided to prescribe moxifloxacin
45929722|NCT05432895|Device|Dynamic splint|Device treats plantar fasciitis and replacing boot immobilization which is quite benign
45929723|NCT00846872|Drug|GHRP-3 low dose|0.1 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
46073753|NCT04708704|Dietary Supplement|Erythrosine, prepared in drinking water (0.69 mg/kg bw/day)|Erythrosine will be obtained from Roxy & Rich Inc. (Intense Water-Soluble Food Colorant - Pink), which is certified to be edible and complies with US FDA, Health Canada, and European food safety standards. The erythrosine will be prepared in 500 mL of drinking water and participants will received single daily doses for 14 days. We will use a targeted dose of 0.69 mg/kg bw.
45929724|NCT00846872|Drug|GHRP-3 high dose|0.5 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
45929725|NCT00846872|Drug|Saline|5% mannitol will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
45929726|NCT05432778|Drug|Letermovir Pill|Patients in the Study Group will receive virostatic prophylaxis with letermovir 480 mg qd (We will be utilizing Letermovir oral formulation of 240 mg or 480 mg as available). n all patients the virostatic prophylaxis will be initiated between days 4 and 7 after heart transplantation and the duration of virostatic prophylaxis will be determined by the Quantiferon-CMV assay.
45929727|NCT05432661|Device|HİGH-FLOW NASAL OXYGEN USE (HFNO)|It is aimed to show that the use of HFNO can improve oxygenation compared to the use of nasal cannula in ERCP procedures performed under sedation in the prone position.
45929728|NCT00846833|Biological|Haploidentical NK cell|"Collection of PBMCs by leukapheresis~CD3+ depletion of apheresis product using CliniMACS®"
45929729|NCT05432544|Drug|SHR-1918|Ascending dose
45929730|NCT05432544|Drug|SHR-1918 placebo|Ascending dose
45929731|NCT00846755|Drug|Levothyroxine, Propylthiouracile|Drugs were titrated to render euthyroid pregnant patients with thyroid disease
45929732|NCT05432505|Other|ligamentum teres tenodesis|Identification of ligamentum teres ligamentum teres tenodesis
45929733|NCT00846716|Drug|Pioglitazone add on to SU or biguanide|As an initial dosing, 15mg/day of pioglitazone is administered to the patients for 2 years, who are taking SU or biguanide.
46072611|NCT03431493|Behavioral|Behavioral Activation - Rehabilitation|"Participants will first receive a home visit from a physical therapist (PT) who will evaluate home safety and establish/verify the participant's exercise prescription. Within 1 week, an occupational therapist (OT) will visit the home to: 1) explain the purpose of behavioral activation (BA); 2) help the participant identify long-term recovery goals regarding valued activities; and 3) then, using the principles of BA, identify short-term goals for the next week and an action plan. The OT will then call the participant weekly (weeks 2-5) to review the status of the prior week's goals and use BA to set new goals for the upcoming week. The PT and OT will repeat home visits at week 6 to assess the participant's progress, and the OT will conduct phone calls every 2 weeks for weeks 8-12."
45450980|NCT02212522|Other|Collect of clinical data on the disease and its evolution|Collect of clinical data on the disease and its evolution every 6 months after enrollment
45651170|NCT05043727|Combination Product|Exer gaming|exer gaming treatment plan will include perfect ten balance, wii skiing, wiicycling. Each Patient will receive twenty four sessions. Each treatment session was of 50 minutes with two minutes rest between each exercise.
45450981|NCT02212522|Other|Collect of environmental data on French controls (age-matched for T1D patients)|Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
45651171|NCT05043727|Combination Product|conventional treatment plan|it will receive conventional treatment plan which includes balance training, gait training, stretching and strengthening exercises.Each patient will receive twenty four sessions of conventional physical therapy. Treatment session will be of 50 minutes with 2 minutes rest period between each exercise.
45651172|NCT02605967|Drug|Spartalizumab|Spartalizumab was administered via intravenous infusion at a dose of 400 mg every 4 weeks (Q4W). Spartalizumab is a humanized anti-PD-1 IgG4 antibody which blocks the binding of PD1 to its ligands PD-L1 and PD-L2.
45651173|NCT02605967|Drug|Investigator choice of chemotherapy|Commonly used chemotherapy as per investigator's choice. The dose and route of administration was the one described in each drug's label.
45800631|NCT04340453|Other|Exercise with Blood Flow restriction training|3 times a week for 4 weeks to a total of 12 sessions. BFR cuff (Sports Rehab Tourniquet©) will be used, with a width of 10cm and a length of 116cm or 84cm depending on the diameter of the participants thigh. Therapy sessions will be supervised and in groups. Exercises focus on strengthening the hip extensors and abductors, as well as the quadriceps both in open and closed kinetic chain. Exercises will be carried out using will be set at a load of 30% of 1RM with a limb occlusion pressure (LOP) of 70%. The first set will consist of 30reps. followed by 3 sets of 15reps. at 2:2 (con/ecc) at 60bpm by Metronome app. with auditory cue. Rest between sets will be 30sec and between exercises 2min. Cuffs will be deflated during the resting period between exercises and re-inflated at the beginning of the next exercise. Exercise progression will be individualized based on assessments at the beginning of each week. The duration has been estimated to be approximately 60min. including LOP estimation.
45800632|NCT04340453|Other|Hip and Knee Exercise Program|A supervised hip and knee strengthening exercise protocol with a combination of stretching, 3 times a week for 4 weeks to a total of 12 sessions. Exercises focus on hip extensors, abductors, as well as the quadriceps and hamstrings strength. Open Kinetic Chain (OKC) exercises will be executed first followed by CKC exercises. Exercises using weights or mechanical resistance will be set at a load of 70% of 1RM and 3 sets of 10 rep. for each exercise. Elastic band exercises will be set at 10RM for 3 sets. Tempo will be set by the Metronome app installed on a Smartphone at 1:2 (con/ecc) at 60bpm with auditory cue. Rest between sets will be 30sec and between exercises 2min. Exercise progression will be individualized based on assessments at the beginning of each week. The duration of each session is estimated to be approximately 45min, with the exception of the first session of each week which is estimated to be 80min due to the addition of strength testing
45929734|NCT00846716|Drug|SU or Biguanide|As an initial dose,a common dose of SU or biguanide is administered to the patients for 2 years.
45929735|NCT05432427|Radiation|64Cu-DOTATATE and 18F-FDG|All participants will get a 64Cu-DOTATATE-PET and 18F-FDG-PET/CT.
45929736|NCT00846677|Dietary Supplement|Vitamin D, cholecalciferol|Oral Quick Dissolve Strip, 400 IU once per day for 21 days
45929737|NCT00846677|Dietary Supplement|Vitamin D, cholecalciferol|Oral Syrup, 400IU per day for 21 days
45929738|NCT00846638|Behavioral|Brief Intervention|Diagnostic assessment followed by a single session Brief Intervention with 3, 6, and 12 month follow-up
45651174|NCT05043571|Biological|CAR T-cell therapy|This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk T-ALL, refractory or relapsed T-ALL.
45651175|NCT04473079|Dietary Supplement|Lacidofil|Investigational product intake daily for 6 weeks. Co-administration of H. pylori treatment with investigational product the first two weeks only.
45651176|NCT04473079|Dietary Supplement|Placebo|Investigational product intake daily for 6 weeks. Co-administration of H. pylori treatment with investigational product the first two weeks only.
45651177|NCT05036161|Other|Nasal high flow|Newborns with respiratory distress treated with NHF.
45929739|NCT00846638|Behavioral|Diagnostic assessment|Single session diagnostic assessment with 12 month followup
45800633|NCT04340453|Other|stretching|Both groups will receive stretching of the hamstrings, plantar flexors, quadriceps and Iliotibial Band (ITB) in the same manor at the end of each session. Passive stretching will be executed by the physiotherapist with 3x30sec stretch for each muscle group
45929740|NCT00846599|Other|Omega-3 study meal|Participant will eat a study meal high in omega-3 fatty acids.
45929741|NCT00846599|Other|Saturated fat study meal|Participant will eat a study meal high in saturated fat.
45929742|NCT05431647|Other|Sensory integration therapy|The individuals were divided into two as randomized controlled. Both physiotherapy and sensory integration therapy were applied to the intervention group. Each treatment was applied as 2 sessions per week, 2 days a week for 8 weeks. In the control group, only physiotherapy treatment was applied for 8 weeks, 2 days a week, 2 sessions per week.
45929743|NCT00846482|Drug|Oxaliplatin|Oxaliplatin will be administered once every 2 or 3 weeks
45929744|NCT00393965|Drug|MPC-6827|2-hour IV infusion given once weekly for 3 consecutive weeks on a 28-day cycle.
45929745|NCT05428683|Drug|intra-vitreal triamcinolone-moxifloxacin injection after cataract surgery as a prophylactic measures against post-operative endophthalmitis|At the end of surgery, 4mg triamcinolone acetonide and 0.2mg moxifloxacin from 0.5 moxifloxacin preservative-free eye drop) were injected once inferotemporally 3.5 mm posterior to the limbus via pars plana into the vitreous cavity by using 30 G needle.
45800634|NCT04866641|Drug|T-1201 Injection 100 mg Kit|T-1201 Injection 100 mg Kit contains lyophilized powder with a sterile aqueous solution formulated for intravenous administration.
45800635|NCT02271594|Behavioral|Intensive Training on Best Insulin Injection Technique|The intervention consists of instructing patients in whom LH is detected and who are currently injecting into it to move injections to non-LH areas; reducing insulin doses initially by 10-20% to avoid hypoglycaemia and then titrating to target control; instructing these patients to correctly rotate sites (leaving 1 cm between injection punctures and allowing used sites to heal for 2-4 weeks before injecting in them again); instructing these patients to forego needle reuse; and instructing these patients to switch to 4 mmx32G needles. A battery of tools (described below) will be used to deliver and reinforce this training, including frequent contact by phone or other electronic means after the initial training.
45929746|NCT05425953|Other|No intervention other than obtaining biopsies|Biopsies will be obtained.
45929747|NCT00394043|Procedure|Osteopathic Manipulative Treatment|A protocol of specific Osteopathic manipulative techniques was used.
45929748|NCT00394043|Procedure|Placebo Sub-Therapeutic Ultrasound|Sub-therapeutic ultrasound was applied in a standardized method.
45651178|NCT05036161|Other|Continuous Positive Airway Pressure|Newborns with respiratory distress treated with CPAP.
45929749|NCT05424549|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed six times over two consecutive days
45651179|NCT03036059|Drug|400 μg/kg Ivermectin + 400 mg Albendazole|400ug/Kg, tablet, given orally once or twice a year.
45651180|NCT03096769|Other|Ergonomist|The intervention consists of each surgeon meeting with an ergonomist where the ergonomist will adjust the console settings and chair height to an ergonomically optimal position.
45651181|NCT04834427|Drug|Conventional therapy + S (+)-Ketamine|"In principle, there are no specific restrictions on the dosage, mode of administration, timing, and compatibility of S-ketamine hydrochloride injection, but the recommended dosage is given, which is lower than the dosage specified in the instructions.~Recommended use and dosage of S (+)-Ketamine:~Intravenous injection：Bolus intravenous injection before skin incision, the dose is 0.1~0.25 mg/kg; Bolus intravenous injection (dose 0.1~0.25 mg/kg) before skin incision + continuous intravenous infusion (dose of 0.1~0.25 mg/kg/h) during operation; Continuous intravenous infusion after surgery with a dose of 0.02~0.1 mg/kg/h for 24~48 h.~Intramuscular injection：The dose is 2~4 mg/kg."
45800636|NCT02271594|Behavioral|Standard education on injection technique|Usual and customary education and training normally provided injecting patients at the center
45929750|NCT05424549|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed six times over two consecutive days
45929751|NCT00846443|Other|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:400 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
45929752|NCT00846443|Other|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
45929753|NCT00846443|Other|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:70 Gy in 35 fractions
45929754|NCT00846443|Other|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:74 Gy in 37 fractions
45929755|NCT05424432|Drug|Neoadjuvant Chemotherapy|Paclitaxel (135 mg /m2) and carboplatin (AUC=5) every 3 weeks for two cycles (D1,D22)
45450982|NCT02212522|Genetic|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
45450983|NCT02221102|Drug|Aspirin|non-steroidal anti-inflammatory drugs
45651182|NCT04834427|Drug|Conventional therapy|Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
45929756|NCT05424432|Drug|Neoadjuvant Toripalimab|Toripalimab 240mg every 3 weeks for two cycles (D2,D23)
45929757|NCT05424432|Radiation|Short Course Neoadjuvant Radiotherapy|30 Gy in 12 fractions, 1 fraction per day, 5 days per week, D3-D18
45929758|NCT05364255|Drug|[14C]AZD9833 Oral Solution, 75 mg|Oral Solution, 75 mg (NMT 0.67 MBq) - oral, fasted
45929759|NCT00846326|Drug|oxymetazoline-fluticasone propionate|Oxymetazoline 0.05% w/v Fluticasone propionate 0.05% w/w 2 squirts in each nostril twice daily
45929760|NCT00846326|Drug|Oxymetazoline|oxymetazoline 0.05% w/v and placebo nasal spray 2 squirts in each nostril twice daily
45929761|NCT05330013|Drug|Dapagliflozin|Subjects will be instructed to take dapagliflozin 10 mg once daily for 6 months (with or without food).
45651183|NCT05035849|Drug|sitagliptin and acarbose|One group used first sitagliptin and metformin, then used acarbose and metformin. Another group used first acarbose and metformin, then used sitagliptin andmetformin.
45651184|NCT04428437|Drug|Lenvatinib|Prescribed by physician.
45929762|NCT05330013|Device|MRI scan|For subjects, depending on the subject's heart rate, base, mild, or apex short-axis slices will be acquired during the first pass of the contract (60 measurements).
45800637|NCT04817969|Device|Zimmer Biomet Persona Ti-Nidium Total Knee System|Primary Knee Total Arthroplasty
45929763|NCT05330013|Device|CMR imaging|Enrolled subjects will undergo stress vasodilator and rest perfusion CMR
45800638|NCT04879212|Other|PCIA +Acupuncture group:|Acupuncturing bilateral Zusanli (ST36) and Sanyinjiao (SP6)
45800639|NCT05649228|Drug|Capsaicin 0.025% Cream|A small amount of cream about the size of a U.S. half dollar containing 0.25% non-palmitated capsaicin will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
45929764|NCT05325567|Procedure|Mini open incision CTR|two techniques commonly used for carpal tunnel release are being compared to determine if one vs. the other provides superior patient outcomes.
45929765|NCT00846287|Drug|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the intervention (drug or placebo) will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
45929766|NCT00846287|Drug|Placebo|Subject will inhale a placebo (nebulized saline) with no drug.
45929767|NCT00846287|Drug|Aformoterol|Subjects will receive the drug arformoterol prior to scanning
45929768|NCT05284188|Procedure|Open or arthroscopic Modified Broström operation|Patients with CLAI and GJL were randomly allocated to accept the open or arthroscopic Modified Broström operation.
45929769|NCT00846248|Dietary Supplement|Chromium|We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.
45929770|NCT00846248|Dietary Supplement|placebo|We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.
45929771|NCT05227170|Other|Lactobacillus Plantarum 299v Freeze Dried Capsule|The intervention is a probiotic lactobacillus that is contained in food products in the US
46072612|NCT03425643|Biological|Pembrolizumab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
45651185|NCT03095443|Other|Music Therapy - Personalized Playlist|Participant receives personalized playlist.
46072613|NCT03425643|Drug|Placebo|Normal saline by IV infusion Q3W, given on cycle day 1.
46072614|NCT03425643|Drug|Cisplatin|75 mg/m^2 by IV infusion Q3W, given on cycle day 1.
46072615|NCT03425643|Drug|Gemcitabine|1000 mg/m^2 by IV infusion Q3W, given on cycle days 1 and 8. Given only to participants with squamous NSCLC.
46072616|NCT03425643|Drug|Pemetrexed|500 mg/m^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.
45651186|NCT03095443|Other|Music Therapy - Standard Playlist|Participant receives a standard low beats per minute playlist.
45651187|NCT03095443|Other|Attention Control|Participant receives an audio-book.
45651188|NCT04821479|Biological|Mesenchymal stem cells (MSC)|Intrathecal injections of autologous bone marrow derived mesenchymal stem cells
45800640|NCT05649228|Drug|Capsaicin Palmitate|A small amount of cream about the size of a U.S. half dollar containing 0.25% capsaicin palmitate will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
45800641|NCT05649228|Drug|Placebo Cream|A small amount of topical cream about the size of a U.S. half dollar will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
45800642|NCT02664311|Device|Jet Ventilation|Patients are randomized to receive either jet or conventional ventilation during this study
45800643|NCT02664311|Device|Conventional ventilation|Conventional ventilator - control arm
45929772|NCT05227170|Other|Freeze Dried Potato Starch Capsule|The intervention is potato starch that is freeze dried designed to mimic the lp299v capsule.
45929773|NCT00846209|Other|Enhanced drug labeling|use of clear concise text and icons on drug warning labels
46072617|NCT03423459|Device|TAVR|Transcatheter Aortic Valve Replacement
46072618|NCT03421704|Device|DreamStation BiPAP autoSV|Philips Respironics DreamStation BiPAP autoSV (PR DS-autoSV) is designed to deliver pressure support for patient ventilatory assistance
46072619|NCT03417154|Drug|Nivolumab|3mg/kg IV (or if prior alloHSCT, 1 mg/kg) over 30 minutes every 14 days on Days 1 and 15 for up to four 28-day courses.
45651189|NCT05043493|Procedure|Injection in the intraarticular space of glenohumeral joint|U/S guided injection of platelet rich plasma (PRP) or normal saline (NS)
45800644|NCT02535923|Behavioral|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
45804135|NCT05463211|Device|Trexo Plus Pediatric Exoskeleton|Wearable pediatric robotic walker for the lower extremities
45804136|NCT03224351|Drug|VX-659|Tablet for oral administration.
45929774|NCT00846170|Drug|co-biotic|give probiotic 2 t/day
45929775|NCT00846170|Drug|placebo 2T/day|cross over of patients from study arm to placebo arm
45929776|NCT05185050|Diagnostic Test|physical examination and measurement of spinal alignment|physical examination for scoliosis and myofascial pain syndrome, measurement of spinal coronal and sagittal alignment in X-ray, and pain intensity (with Visual analog scale) if necessary (for MPS group)
45651190|NCT04821635|Device|Rower assisted by electrostimulation (FES-ROW)|"Pre-inclusion visit~Inclusion visit~Phase 1 Rower-FES with lower limbs (Month 0 to Month 3: M0-M3):~Training on a rower with solicitation of the electrostimulated lower limbs only for a period of 3 months at the rate of 3 sessions of 30 minutes per week~Interim assessment visit at Month 3 (M3)~Phase 2 Rower-FES with lower limbs + upper limbs (Month 3 to Month 6: M0-M6):~Training on with solicitation of the electrostimulated lower and upper limbs for a period of 3 months at the rate of 3 sessions of 30 minutes per week~Final assessment visit at Month 6 (M6)~End of clinical research visit, 3 months after the end of training (Month 9, M9)"
45929777|NCT00846131|Drug|Sorafenib|Randomized to Y-90 ± Sorafenib
45929778|NCT00846131|Drug|Yttrium-90 (Y-90)|Patients undergo radioembolization with Yttrium 90 microspheres by hepatic artery infusion
46072620|NCT03417154|Drug|Low dose Cyclophosphamide (CTX) Daily|Oral cyclophosphamide 50mg + nivolumab 3 mg/kg IV every 2 weeks for up to 4 courses of treatment
46072621|NCT03417154|Drug|Low dose Cyclophosphamide (CTX) Every 7 Days|Oral cyclophosphamide 350 mg every 7 days + nivolumab 3mg/kg IV every 2 weeks for up to 4 courses of treatment
46072622|NCT03396315|Drug|Alendronate|oral alendronate 70 mg weekly for 12 months will be given for the prevention of osteoporosis
46072623|NCT03396315|Drug|Zoledronic Acid|single intravenous dose of zoledronic acid 5 mg will be given for the prevention of osteoporosis
45651191|NCT05043181|Biological|Low Density Lipoprotein Receptor mRNA Exosomes|"The study consists of two phases: dose escalation phase and extension phase. Dose escalation phase：For the intervention of low-density lipoprotein receptor mRNA (LDLR mRNA) exosomes. A total of six dose groups are planned, with single dose of 0.044 mg/kg, 0.088 mg/kg, 0.145 mg/kg, 0.220 mg/kg, 0.295 mg/kg and 0.394 mg/kg, respectively. About 3 subjects are enrolled in each dose group. In the 0.044 mg/kg group, the second and third subjects are required to start exosome infusion treatment after the treatment of the previous subjects, and the other dose groups are not required to do this. There are three treatments in total, and the interval between each exosome treatment is 7±1 d.~Extension phase: About 12 subjects are further enrolled. The subjects will receive 3 intravenous/peritoneal infusion treatment of LDLR mRNA exosomes once a week for three weeks, whose single dose is determined in the dose escalation phase."
45651192|NCT03035981|Other|White rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
45651193|NCT03035981|Other|White rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
46072624|NCT03389347|Procedure|Biospecimen Collection|Undergo collection of bone marrow aspirate and blood
45651194|NCT03035981|Other|White rice, slow|White and brown rice were tested for differences in gastric emptying rate and appetitive response
45651195|NCT03035981|Other|White rice, resistant|White and brown rice were tested for differences in gastric emptying rate and appetitive response
45651196|NCT03035981|Other|Brown rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
45651197|NCT03035981|Other|Brown rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
45651198|NCT03035981|Other|Fructooligosaccharide (FOS)|White and brown rice were tested for differences in gastric emptying rate and appetitive response
45651199|NCT05035381|Drug|Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen|MSI-H colorectal cancer, recurrence and metastasis within 1 year after surgery, or failure of first-line oxaliplatin and fluorouracil chemotherapy for advanced colorectal cancer, PD-1 inhibitors combined with bevacizumab and FOLFIRI regimen
45800645|NCT02535923|Behavioral|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
45804137|NCT03224351|Drug|TEZ/IVA|TEZ/IVA fixed-dose combination tablet for oral administration.
45929779|NCT05116059|Drug|Amphotericin B colloidal dispersion（ABCD）|The dosage and course of ABCD were determined by clinicians, and this study was registered according to clinical practice
45929780|NCT00846092|Device|Warp 10 LED Device|Study Subjects will take the Warp 10 (LED) home and treat twice per day for three months
45929781|NCT00846092|Device|Near-infrared light (NIR)|"Subjects will be exposed to light emitted from LED's at wavelengths of 670 nm (+/-15nm) with a minimum exposure of 4 J/cm2 (4.0 - 7.68J/cm2). This is accomplished by applying the 50 mW/cm2 (50 - 80 mw/cm2) LED-generated light to the study eye.~Treatments involve application of the LED-generated light for 80 seconds, twice daily."
45929782|NCT05081154|Other|Product A|P1012915, a nicotine pouch with 8 mg nicotine
45929783|NCT05081154|Other|Product B|P1013018, a nicotine pouch with 10 mg nicotine
46072625|NCT03389347|Device|High Throughput Screening|Anti-tumor drugs are tested against myeloma cells in the laboratory, in a high-throughput drug sensitivity assay
46072626|NCT03389347|Other|Laboratory Biomarker Analysis|Correlative studies
46072627|NCT03332017|Drug|Zanubrutinib|BGB-3111 will be administered as two 80-mg capsules by mouth twice a day (160 mg twice a day)
46072628|NCT03332017|Drug|Obinutuzumab|Obinutuzumab will be administered 1,000 mg intravenously on days 1, 8, and 15 of cycle 1, then 1,000 mg on day 1 of cycles 2 to 6, then 1,000 mg every 8 weeks. 1 cycle = 28 days.
46072629|NCT03331796|Device|Active rTMS (Bilateral DLPFC)|TMS Stimulation Parameters for the active DLPFC rTMS intervention group will be: 10 Hz, 4-second train duration and 11-second inter-train interval. During each session, 2,000 pulses will be applied for each hemisphere (for a total of 4,000 pulses per session). Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
45929784|NCT05081154|Other|Product C|P1013015, a nicotine pouch with 8 mg nicotine
45929785|NCT05081154|Other|Product D|P1012815, a nicotine pouch with 8 mg nicotine
45651200|NCT03035903|Device|Not holding, then holding the MedGem®|Subjects will have a RMR measurement taken first while not holding the MedGem®, and then while holding the MedGem®
45929786|NCT05081154|Other|Product E|P1013315, a nicotine pouch with 8 mg nicotine
45800646|NCT04769921|Device|dental implants and abutments from Nobel Biocare|The implants will be inserted in an All-on-4 configuration; Abutments will be connected to the implants and serve as support for a full-arch implant-supported restoration.
46072630|NCT03331796|Device|Active rTMS (Bilateral LPC)|TMS Stimulation Parameters for the active LPC rTMS intervention group will be: 10 Hz, 4-second train duration and 11-second inter-train interval. During each session, 2,000 pulses will be applied for each hemisphere (for a total of 4,000 pulses per session). Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
45651201|NCT03035903|Device|Holding, then not holding the MedGem®|Subjects will have a RMR measurement taken first while holding the MedGem®, and then while not holding the MedGem®
45651202|NCT05043025|Other|Identification of the cricothyroid membrane|The cricothyroid membrane is identified using a laryngeal handshake technique in different patient positions.
45800647|NCT04697225|Behavioral|weight loss strategies|Participants will receive recommendations on how to increase physical activity, decrease caloric intake, monitor their weight, and track the related behaviors and progress.
45800648|NCT04697225|Behavioral|weight loss coaching sessions and email support|Participants will receive weekly coaching sessions and tailored support emails.
45651203|NCT04153747|Other|High-power and short-duration radiofrequency ablatio (70 W / 9-10 s)|Pulmonary veins electrical isolation: high-power and short-duration ablation
45651204|NCT04153747|Other|Low-power (25-40 W) radiofrequency ablation guided by lesion size index (LSI) and ablation index (AI) values|Pulmonary veins electrical isolation: low-power ablation.
45651205|NCT04153747|Other|Esophageal endoscopy|Esophageal endoscopy to detect postablation esophageal thermal lesions.
45800649|NCT02350517|Drug|Paclitaxel+Nedaplatin+Endostar|Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14
45800650|NCT02270736|Drug|NT 201 Placebo|NT 201 placebo matching injection.
45651206|NCT04153747|Diagnostic Test|Daily 30-seconds ECG|Transtelephonic daily 30-seconds single lead electrocardiogram
45800651|NCT02270736|Drug|NT 201|NT 201 injection.
45800652|NCT04672031|Other|Glycemic Targets|The intervention is glycemic targets that are lower than those currently recommended by ADA and ACOG: fasting ≤80 mg/dL, pre-prandial ≤80 mg/dL, and 1-hour postprandial ≤110 mg/dL instead of fasting ≤95 mg/dL, pre-prandial ≤95 mg/dL, and 1-hour postprandial ≤140 mg/dL.
45800653|NCT02205047|Drug|Cisplatin|
45800654|NCT02205047|Drug|5-fluorouracil or Capecitabine|
46072631|NCT03331796|Device|Placebo rTMS (Inactive)|For the Placebo rTMS (Inactive) group, the participant will wear scalp electrodes through which a low voltage, low electric current (2-20mA at no more than 100V) is passed to mimic the sensation of receiving actual rTMS. Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
46072632|NCT03288844|Procedure|Ophthalmologic examinations|epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; ocular tonometry; slit lamp examination; conjunctival (both bulbar and limbal) inflammation assessment; corneal sensitivity; central cornea involvement (for opacity or central CNV); Best-Corrected Visual Acuity; evaluation of symptoms.
45651207|NCT04152187|Other|Inspiratory muscle training|The treatment group will receive inspiratory muscle training.
46072633|NCT03288844|Other|Digital pictures|Digital pictures 2D to be taken at each visit
46072634|NCT03288844|Other|QoL Questionnaires|Quality of Life (NEI VFQ 25 and EQ-5D-3L/Y) questionnaires will be submitted at each visit
46072635|NCT03245437|Drug|Oxytocin nasal spray|nasal spray
45651208|NCT04821323|Drug|Indomethacin|Indomethacin capsules will be administered orally.
45651209|NCT04821323|Diagnostic Test|Lactulose-mannitol|Lactulose-mannitol solution will be administered orally.
45651210|NCT04821557|Dietary Supplement|Protease + Protein|Participant will consume a microbial protease supplement (31,875 Hemoglobin Unit Tyrosine base (HUT); protease activity) combined with a pea protein beverage (25 g pea protein; Roquette Nutralys® S85F)
45651211|NCT04821557|Dietary Supplement|Placebo + Protein|Participant will consume a placebo supplement (250 mg maltodextrin) combined with a pea protein beverage (25 g pea protein; Roquette Nutralys® S85F)
45651212|NCT04434703|Procedure|Platelet rich fibrin (PRF)|following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 3000 rpm for 10 minutes then criss horizontal mattress suture will be applied to close the extraction wound
45800655|NCT02205047|Drug|Trastuzumab|
45800656|NCT02205047|Drug|Pertuzumab|
45800657|NCT02205047|Procedure|gastrectomy|D2 gastrectomy
45800658|NCT01585805|Procedure|Biopsy|Undergo biopsy
45800659|NCT01585805|Drug|Cisplatin|Given IV
45800660|NCT01585805|Drug|Gemcitabine|Given IV
45800661|NCT01585805|Drug|Gemcitabine Hydrochloride|Given IV
45800662|NCT01585805|Drug|Veliparib|Given PO
45804138|NCT03224351|Drug|IVA|Tablet for oral administration.
45804139|NCT03224351|Drug|Placebo (matched to VX-659/TEZ/IVA)|Placebo matched to VX-659 and TEZ/IVA.
45804140|NCT03224351|Drug|TEZ|Tablet for oral administration.
45804141|NCT03224351|Drug|VX-561|Tablet for oral administration.
45804142|NCT03224351|Drug|Placebo (matched to VX-659/TEZ/VX-561)|Placebo matched to VX-659, TEZ and VX-561.
45929787|NCT05081154|Other|Product F|P1013115, a nicotine pouch with 8 mg nicotine
45929788|NCT05081154|Other|Product G|P1013215, a nicotine pouch with 8 mg nicotine
45929789|NCT00846014|Drug|Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the drug aformoterol will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
45929790|NCT05051553|Drug|Fedratinib|Specified dose on specified days
45929791|NCT00845975|Device|Erchonia Hearing Lasers #1 & #2|"Two treatments with Erchonia Hearing Laser #1 administered by the investigator at the test site, each treatment seven days apart.~Seven treatments with the Erchonia Hearing Laser #2 administered by the subject at home, one time each day for seven consecutive days, the first administration on the same day as the first administration with the Erchonia Hearing Laser #1 at the test site."
45800663|NCT04878198|Behavioral|Jogging program|This intervention consists of 50 sessions of morning jogging sessions at moderate intensity level. Each intervention session will be administered by a trained research assistant assisted by student helpers. All the research staff (i.e. student helpers and research assistant) will be required to attend a workshop (see educational plan) to standardize the procedure on implementing the intervention, as well as handling and motivating their ASD partners. Motivation techniques in previous protocol will be used to enhance the compliance rate.
45800664|NCT04878198|Drug|Melatonin supplement intervention|This intervention is a 10-week melatonin supplement intervention where melatonin supplement will be provided 30 minutes before bedtime.
45651213|NCT04434703|Procedure|Advanced platelet rich fibrin (A-PRF)|following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 1300 rpm for 8 minutes then criss horizontal mattress suture will be applied to close the extraction wound
45651214|NCT04434703|Procedure|blood clot|following atraumatic extraction of the tooth using periotomes, no bio-addative will be added and criss horizontal mattress suture will be applied to close the extraction wound
45804143|NCT05663281|Diagnostic Test|thrombus imaging appearance|Imaging appearance of intracranial and/or extracranial arterial thrombus
45929792|NCT00845975|Device|Placebo Lasers|The same test site and at-home treatment administration protocols are followed, but the laser devices do not emit any therapeutic light.
45929793|NCT00845936|Drug|Metformin|Metformin 850 mg bid
45929794|NCT04941378|Drug|OTL38|One time infusion of OTL38
45929795|NCT04941378|Device|intraoperative imaging camera system|intraoperative imaging camera system
45929796|NCT00277082|Drug|9-NC in aerosol reservoir|Samples will be minced or centrifuged and L9NC extracted by chromatography. L9NC will be measured by HPLC or mass spectrometry
45929797|NCT04888377|Drug|Aspirin|Participant's mothers were administered 81mg of Aspirin throughout their pregnancy with the participant.
45929798|NCT04888377|Drug|Placebo|Participant's mothers were administered placebo throughout their pregnancy with the participant.
45929799|NCT00277043|Drug|paclitaxel, docetaxel, taxane|1 mg paclitaxel or docetaxel test dose is prepared in 3 ml of normal saline and administered over two to five minutes IV push at least 30 minutes after prescribed IV and PO pre-medications. If no discernable adverse reaction ensues, the balance of the taxane dose is prepared and administered as per standard or specific chemotherapy protocol.
45929800|NCT00277043|Drug|taxane|The full taxane dose is prepared and administered as per standard or specific chemotherapy protocol, at least 30 minutes after prescribed IV and PO pre-medications.
45929801|NCT04858035|Behavioral|Perceptual training|"Perceptual training involves self-paced presentation of auditory stimuli via a computerized software program.~Stimuli are organized into three separate tasks:~Tasks 1 and 3 will train category goodness judgment: Participants will hear 75 naturally produced speech tokens containing /r/ from various speakers, with a balance of correct and incorrect productions. They will classify each /r/ as correct or incorrect and receive feedback on the accuracy of their classification. Tasks 1 and 3 differ in that task 1 will feature a subset of items designed to provide focused practice on a specific context (e.g., initial /r/ as in red; /r/ as syllable nucleus as in sir), with increasing difficulty over time, whereas task 3 will feature randomly selected items representing all contexts and difficulty levels.~Task 2: Participants will hear 75 items drawn from the synthetic rake-wake continuum used in the identification task administered at baseline."
45929802|NCT04858035|Behavioral|Production training|"Instruction: Discuss tongue shapes for /r/. Pre-practice: relatively unstructured, highly interactive elicitation; provide models and placement cue and KP on every trial.~Structured syllable practice: Practice will occur in blocks of 10 consecutive trials on the same syllable (e.g., 10 /ra/), after which a new syllable will be addressed (e.g., 10 /re/--but note that in the fully blocked condition, the same syllable should occur in two consecutive blocks of 10)."
45929803|NCT04732572|Behavioral|Sleep and healthy lifestyle education|Participants in both groups will receive age-appropriate standardized educational material for both Optimal Sleep Hygiene and Healthy Habits. Educational play will also be encouraged by providing take-home materials. Participant and parent/legal guardian (s) will be given verbal and written directions on the use of these materials at the time of the visit. Research Coordinators will encourage and track utilization of the sleep hygiene educational tools during the trial.
46072636|NCT03245437|Behavioral|Social Cognition Skills Training|Group based training in social cognition skills
46072637|NCT03245437|Behavioral|Health Management|Group-based training in mental health management
46072638|NCT03245437|Drug|Placebo nasal spray|placebo condition
45651215|NCT03035825|Dietary Supplement|Oral moisturizing jelly|Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth
45651216|NCT03035825|Other|Artificial saliva|A non-edible oral lubricating gel for dry mouth patients
45651217|NCT04469881|Behavioral|VR|"Participants will be asked to do the following things:~Wear VR goggles for the duration of the surgery~Answer questions about their experience with the VR goggles~Give permission for the researchers to collect information about the anesthesia medications used, pain medications used, and reported pain scores during the surgery and during recovery in the hospital"
45651218|NCT04834037|Behavioral|Behavioral|The provision of information and supportive nursing care is recommended to alleviate anxiety, stress and agitation in COPD patients treated with NIV.
45651219|NCT05035069|Drug|Ciprofol|Ciprofol infusion, starting with 0.8 ~ 1mg/kg/h until BIS value below 60 (including 60), and then 0.2 ~ 0.6mg/kg/h until the end of the operation, ciprofol infusion was adjusted to keep the BIS value between 40-60.
45651220|NCT05035069|Drug|Propofol|Propofol infusion, starting with 4 ~ 5mg/kg/h until BIS value below 60 (including 60), and then 1 ~ 3mg/kg/h until the end of the operation, propofol infusion was adjusted to keep the BIS value between 40-60.
45804144|NCT05658055|Drug|Vonoprazan|Potassium-competitive acid blocker
45804145|NCT05658055|Drug|Amoxicillin|Antibiotic for H. pylori eradication
46072639|NCT03221036|Drug|Vedolizumab IV|Vedolizumab IV infusion
45450984|NCT02221102|Drug|edoxaban|orally active direct factor Xa inhibitor
45651221|NCT05035147|Drug|albumin-bound paclitaxel|Experimental:Albumin-bound paclitaxel combined with gemcitabine was administered on the first and eighth day, a cycle of three weeks Active Comparator: Albumin-bound paclitaxel combined with gemcitabine was administered on the first, eighth, and fifteenth days, with a four-week cycle
45800665|NCT02269098|Other|Diabetes medication management|As above plus- Follow-up intervention visits were at 24-72 hrs, 2 and 4 weeks. During each, further DSME was provided, BG logs reviewed, and diabetes medications adjusted as needed by the CDE. Meter and insulin injections skills were reinforced as needed. Outpatient navigation included securing a primary care appointment no later than 4 weeks after study completion. Final contact was via telephone at 90 days. The MMS© (Morisky Medication Adherence Survey) was taken at 2 and 4 weeks and during the final telephone visit. Interim return visits to the ED or admissions to the hospital were queried at each visit. A follow up HbA1C was obtained at week 4 using the POC A1CNow+ ®, and a venous HbA1C was drawn if the POC result was above 13% .
45929804|NCT04732572|Other|Other supportive care|Throughout the course of the trial participants identified by the principal investigator as having suboptimal asthma or rhinitis will be referred to their primary care physician for management and further treatment of these problems. All participants will receive a generic brand of an over-the-counter saline nasal spray to use as needed for nasal dryness and crusting. Proper use of the spray will be reviewed and demonstrated by the research coordinator at the baseline visit.
45929805|NCT04732572|Procedure|Adenotonsillectomy|Surgery will be performed by board-certified otolaryngologists with or without the assistance of resident physicians in accredited otolaryngology training programs. Prior to the surgical procedure, tonsillar size will be graded using a standardized scale of 0-4. Extent of adenoid tissue will also be graded as mild (0-33%), moderate (34-66%) or severely (67-100%) obstructing the posterior choanae. Complete bilateral tonsillectomy and removal of obstructing adenoid tissue will be performed by cold dissection, monopolar electrocautery or plasma knife-assisted surgical technique under general anesthesia. All procedures will be performed using inpatient facility for 3-4 days.
45929806|NCT00276965|Drug|Sertraline|Sertraline or placebo for sertraline starting at 25 mg per day, up to maximum of 200 mg per day
45929807|NCT00276965|Drug|Lithium carbonate|Lithium or placebo for lithium starting at 150 mg per day; target dose of 900mg per day. Maximum dose based on clinical response and serum levels (maximum serum level of 1.2 mEq/L).
45929808|NCT00276926|Drug|STI571|
45929809|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 5 mg once daily plus placebo enoxaparin syringe
45929810|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 10 mg once daily plus placebo enoxaparin syringe
45929811|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg once daily plus placebo enoxaparin syringe
45929812|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 30 mg once daily plus placebo enoxaparin syringe
45929813|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 40 mg once daily plus placebo enoxaparin syringe
45929814|NCT00396786|Drug|Enoxaparin|Enoxaparin 40 mg once daily plus Rivaroxaban placebo tablets
45929815|NCT00276887|Behavioral|Cognitive Behavior Therapy|
45929816|NCT00276887|Behavioral|Psychiatric Consultation Letter|
46072640|NCT03221036|Drug|Placebo|Matching-placebo IV infusion
45651222|NCT01668173|Drug|AUY922|AUY922 will be administered as an intravenous infusion over 60 minutes, on a once weekly schedule. A cycle on study will be defined as 28 days. The dose to be studied are 70 mg/m2 and 55 mg/m2 if DLTs are identified in the first 3-6 patients. The same schedule of administration will be used for all patients in this trial.
45800666|NCT04651595|Procedure|Caudal block|caudal block with low dose bupivicaine 0.25% to preserve tone
46072641|NCT03206450|Procedure|Biospecimen Collection|Undergo collection of blood and provide saliva and semen samples
46072642|NCT03206450|Other|Laboratory Biomarker Analysis|Correlative studies
46072643|NCT03206450|Other|Questionnaire Administration|Ancillary studies
46072644|NCT03189576|Diagnostic Test|blood draw|
46072645|NCT03163511|Combination Product|VC-02 Combination Product|PEC-01 cells loaded into a Delivery Device
46072646|NCT03157635|Drug|Crovalimab|Crovalimab will be administered as per schedule described in individual arm.
45450985|NCT02221102|Drug|placebo|
45450986|NCT02213302|Drug|placebo administration|
45450987|NCT02213302|Drug|midazolam intravenous administration|
45800667|NCT04651595|Drug|Morphine|morphine to control pain and avoid using muscle relaxant
45804146|NCT05658055|Drug|probiotics|Medilac-S; Enterococcus faecium 4.5*10^8 and Bacillus subtilis 5.0*10^7, Hanmi,Beijing, China
46072647|NCT03157635|Drug|Placebo|Placebo will be administered as per schedule described in Part 1 placebo arm.
45450988|NCT02221180|Drug|Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]|Participants will receive 1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed or fasted condition in each treatment period as per treatment sequence.
45450989|NCT02221180|Drug|Canagliflozin|Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablet) under fed or fasted condition in each treatment period as per treatment sequence.
45929817|NCT00396825|Behavioral|Video-based coping skills training with telephone coaching|Subjects will view the 10 modules of Williams LifeSkills Caregiver Video, do Workbook exercises for each module, and receive telephone coaching to enhance their ability to apply the skills taught in each module to caregiver situations.
45929818|NCT00276848|Drug|Fludarabine plus Cyclophosphamide|fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, plus cyclophosphamide dosed at 250 mg/m2, administered intravenously daily over 30 minutes for 3 days, repeated every 28 days for a maximum of 6 courses
45929819|NCT00276848|Drug|Fludarabine|fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, , repeated every 28 days for a maximum of 6 courses
45800668|NCT04645511|Procedure|Balloon sinuplasty of maxillary sinuses|A shapeable tip of the balloon dilatation device (Entellus XprESS LoProfile; Stryker Corporation, Kalamazoo, Michigan, U.S.A.), with maxillary bending, is inserted into the maxillary sinus ostium. Then guided with the tip, a flexible balloon (6 mm x 20 mm) is gently inserted into the ostium and inflated up to 12 atm for 15 seconds. The dilatation is repeated one more time. The same procedure is performed for both maxillary sinuses.
45929820|NCT00396864|Drug|NPI-0052|NPI-0052 IV injection at doses ranging from 0.0125 to 0.8 mg/m2 over 1 to 10 minutes on Day 1, Day 8, Day 15 of each 28-day Cycle; 11 dose cohorts during dose-escalation
45929821|NCT00276809|Biological|alemtuzumab|
45929822|NCT00276809|Biological|filgrastim|
45929823|NCT00276809|Drug|carmustine|
45450990|NCT02221180|Drug|Metformin|Participants will receive metformin 500 mg tablet orally under fed or fasted condition in each treatment period as per treatment sequence.
45450991|NCT02221258|Biological|FURESTEM-RA Inj.|Patients will be treated FURESTEM-RA Inj.+DMARDs(Disease-Modifying antirheumatic drugs)
45450992|NCT02205112|Drug|Nemonoxacin|
45800669|NCT04645511|Procedure|Sham surgery|"The middle meatus is gently palpated with a curved suction tip (the tip is not connected to a suction unit). The curved suction tip is placed medial to the uncinate process. In order to create a better placebo effect, the operating doctor says: Now inflate the balloon up to 12 atm for 15 seconds. After 15 seconds the doctor says: Deflate the balloon. This is repeated one more time. Similar procedure is carried out on both sides."
45800670|NCT04630067|Drug|AZD3427|Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.
45800671|NCT04630067|Drug|Placebo|Participants will receive SC or IV dose of placebo matched to AZD3427 as per the arm they are randomized.
45800672|NCT04586387|Device|intermittent theta burst stimulation (iTBS)|repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head
45800673|NCT02667821|Other|Head positions and spinal manipulation|Each participant will undergo three separate test maneuvers. Neutral (0° rotation) neck position (condition 1) will be followed by block randomization between maximum voluntary rotation (condition 2) and a high-velocity-low-amplitude cervical manipulation targeted at C1-C2 (condition 3). Conditions 1 and 2 will be held for 1 minute before returning to neutral alignment. For the manipulation, the head will be repositioned at neutrality immediate. An experienced practitioner will perform the manipulation on the adjustable and pivotal MRI bed. After each condition, MRI of the upper neck and cerebrum for perfusion and blood flow will ensue.
45929824|NCT00276809|Drug|cyclophosphamide|
45929825|NCT00276809|Drug|cytarabine|
45929826|NCT00276809|Drug|dexamethasone|
45450993|NCT02205112|Drug|Levofloxacin|
45450994|NCT02205190|Drug|Fimasartan|
45800674|NCT02669615|Drug|Melphalan HCl for injection (propylene glycol free)|During the study period, patients will receive 200 mg/m^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.
45929827|NCT00276809|Drug|etoposide|
45929828|NCT00276809|Drug|fludarabine phosphate|
45929829|NCT00276809|Drug|melphalan|
45450995|NCT02205190|Drug|Rosuvastatin|
45929830|NCT00276809|Procedure|autologous bone marrow transplantation|
45929831|NCT00276809|Procedure|peripheral blood stem cell transplantation|
45929832|NCT00276809|Radiation|radiation therapy|
45929833|NCT00396903|Device|catheter|
45929834|NCT00276770|Other|fluorine F 18 fluorothymidine|
45929835|NCT00276770|Procedure|positron emission tomography|
45929836|NCT04845165|Other|Biopsy|Biopsy of subcutaneous adipose tissue
45929837|NCT00276731|Drug|carboplatin|
45929838|NCT00276731|Drug|cisplatin|
45450996|NCT02205190|Drug|Fimasartan/Rosuvastatin combination|
45450997|NCT02221336|Device|The MONARCA II system|Daily electronic monitoring of subjective and objective smartphone measures including a feedback loop
45450998|NCT02221336|Device|Non-MONARCA II system|Daily use of smartphone for normal communicative purposes. No self-monitoring in the MONARCA II system.
45450999|NCT05236816|Other|Fatigue (physical exercise)|Subjects were evaluated before and after a fatiguing exercise of hip abductor muscles that consisted to repeat hip abduction with rate and range of motion until a target decrease of force is attempt
45451000|NCT02257918|Drug|AZD0914|AZD0914 is an antimicrobial amorphous nonsterile powder. Group 1 receive 2000 mg; Group 2 receive 3000 mg. The drug name is also known as ETX0914.
45451001|NCT02257918|Drug|Ceftriaxone|Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. A white to yellowish orange crystalline powder. Group 3 receives 500 mg reconstituted with 1 ml Lidocaine HCL 1%, intramuscularly.
45451002|NCT02216578|Drug|cabozantinib|Oral
45451003|NCT05262868|Device|rTMS|The stimulus intensity will be 80% of the motor threshold and the frequency will be 20 Hz for all patients. The total number of pulses will be 1200 for a single treatment session. We plan a total of 15 sessions distributed over 5 days a week for 3 consecutive weeks.
45929839|NCT00276731|Drug|cyclophosphamide|
45929840|NCT00276731|Drug|etoposide|
45929841|NCT00276731|Drug|vincristine sulfate|
45929842|NCT00276731|Procedure|conventional surgery|
45929843|NCT00276731|Procedure|neoadjuvant therapy|
45929844|NCT00276731|Radiation|radiation therapy|
45929845|NCT04810689|Drug|Xuanfei Baidu Granules|Xuanfei Baidu granules is a prescription of 13 herbal medicinals made into dissolvable granules for oral intake
45929846|NCT04810689|Other|Placebo|Placebo for Xuanfei Baidu granule made into dissolvable granules for oral intake
45929847|NCT04805346|Device|autoRIC®|With the patient sitting upright in bed or a chair, the remote ischemic conditioning intervention will consist of 4 automatic cycles of upper arm blood pressure cuff inflation to 200 mm Hg for 5 minutes to induce transient, noninjurious, limb ischemia, followed by cuff deflation for 5 minutes, for a total of 35 minutes (autoRIC®, Cellaegis Devices, Mississauga, ON, Canada).17 The remote ischemic preconditioning cycles will be performed by trained research personnel prior to each cycle of chemotherapy (total treatments variable based on chemotherapy protocol
45929848|NCT00276692|Drug|irinotecan hydrochloride|
45800675|NCT04739579|Diagnostic Test|C-Reactive Protein|C-Reactive Protein trend in post-operative course
45929849|NCT04434885|Other|Clinical and imaging examination of symptoms and signs suggestive of axial involvement|Clinical and imaging examination including X-rays and magnetic resonance imaging of sacroiliac joints and spine
45929850|NCT04434222|Device|Compressive stockings|Compressive stockings with built in Orthotimer Sensor
45929851|NCT00276575|Biological|bevacizumab|
45929852|NCT00276575|Drug|erlotinib hydrochloride|
45929853|NCT00276575|Drug|everolimus|
45929854|NCT04433949|Other|Best Practice|Receive standard of care
45929855|NCT04433949|Radiation|Low Dose Radiation Therapy|Undergo LDRT
45651223|NCT05042713|Other|WaveOne Gold, One Curve, OneFlare|During the endodontic treatment of molar teeth diagnosed with irreversible pulpitis, the effect on postoperative pain when single file systems with rotational (OneCurve) and reciprocal (WaveOne Gold) kinematics are used with and without coronal flaring instrument (OneFlare) will be compared.
45929856|NCT00276536|Biological|recombinant interferon alpha-1b|interferon
45929857|NCT00276536|Drug|IFN|IFN daily
45929858|NCT00276497|Drug|Pioglitazone|
45651224|NCT03036761|Procedure|Auriculotherapy|3 sessions of auriculotherapy at one month intervals.
45651225|NCT04821167|Procedure|laparoscopic orchiopexy for intra-canalicular testis|laparoscopic orchiolysis of abnormal fibrous attachments and then lap assisted transcrotal fixation of the testis in subdartos pouch for intra-canalicular testis
45651226|NCT05054101|Other|Real-time assessment using the VieCovid2020 smartphone application|a real-time assessment using the VieCovid2020 smartphone application during the first 3 months in add-on to usual psychiatric intervention
45651227|NCT03036449|Behavioral|Education program for NICU caregivers.|"Intervention includes a main initial educational program, maintenance education programs and tools supply~- Main educational program will include 9 hours of courses into NICU (1 hour each week) and @ learning modules validation.~Topics: Main causes of medication errors, How to analyse retrospectively medication errors, Strategies to reduce medication errors, How to improve communication between health professional; Task interruption; Standardisation of preparation…..~Maintenance education program will return on specific topics of main program and will be fitted to each NICU needs.~Examples of Tools: check lists, medication neonatal formulary, Sound alike and Look alike drug lists…"
45651228|NCT05034757|Other|HA only|HA injection only
45651229|NCT05034757|Other|ESWT once|ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder
45651230|NCT05034757|Other|ESWT twice|ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder
45929859|NCT04430790|Drug|Doxapram|Loading dose and continuous doxapram infusion.
45929860|NCT04430790|Drug|Placebo|Loading dose and continuous placebo infusion.
45929861|NCT00276341|Drug|EGb 761® (Tanakan®)|
45929862|NCT00276302|Drug|IPI-504|"IV administration of IPI-504 for 21-day cycles. Two different schedules of treatment will be tested. On Schedule A, doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration. On Schedule B, doses occur on Days 1, 4, 8, 11, 15, and 18, or twice weekly for 3 weeks continuously.~For both Schedule A and B doses will be administered ≥ 72 hours apart."
45929863|NCT04304079|Device|ARssist system|As stated in ARssist system arm description
45929864|NCT00276263|Drug|Sarcosine (N-methylglycine)|Randomization to two treatment groups. One group treated with sarcosine 2 g/day for 16 weeks, the other group treated with placebo 2 g/day for 16 weeks.
45929865|NCT00394238|Procedure|Ultrasonographic imaging|
45929866|NCT00041340|Drug|imatinib mesylate|Given orally
45929867|NCT00041340|Other|laboratory biomarker analysis|Correlative studies
45929868|NCT00276224|Drug|ferrous sulphate (drug)|
45929869|NCT00276185|Drug|Time delay treatment of botulinum toxin|
45929870|NCT00276146|Drug|oral dipyridamole, oral magnesium, or a combination of both|
45929871|NCT00276107|Biological|Prevenar|
45929872|NCT04201665|Drug|Carbetocin|Patients will receive a single dose of carbetocin 100 mcg (Pabal ®) at admission to high dependency obstetric unit after cesarean section.
45929873|NCT04201665|Drug|Oxytocin|Patients will receive 5 units of oxytocin ( Syntocinon ®) as a 250 ml 0.9% NaCl infusion at admission to high dependency obstetric unit after cesarean section.
45929874|NCT00276068|Drug|topical lidocaine + oral desipramine, and/or placebo|
45929875|NCT00041379|Drug|beta alethine|
45800676|NCT02670629|Procedure|Partial reduction with overriding position|The patient was subjected to an alignment instead of an anatomic reduction; this means that the fracture was left in an overriding position, after this, the patient was placed in a short arm cast for 6 weeks.
45800677|NCT02670629|Procedure|Closed anatomic reduction|The patient was subjected to an anatomic reduction; this means that the fracture was completely reduced, after this, the patient was placed in a short arm cast for 6 weeks.
45800678|NCT02672111|Drug|CAM2038 q1w or q4w exposure to SL BPN/NX|
45800679|NCT02672111|Drug|CAM2038 q1w or q4w new to BPN treatment|
45800680|NCT01456013|Device|RenalGuard Therapy|Induced Diuresis with matched replacement
45929876|NCT00276029|Drug|Etanercept|
45929877|NCT00397059|Drug|Escitalopram|
45929878|NCT00275990|Device|rheolytic thrombectomy with direct stenting|
45929879|NCT00275990|Device|direct stenting|
45929880|NCT04149210|Drug|Fluorometholone 0.1% Oph Susp|fluorometholone 0.1% one drop twice daily for four weeks, beginning with one drop just before trachomatous trichiasis surgery on the upper lid.
45929881|NCT04149210|Drug|Artificial Tears|Artificial tears (placebo) given one drop twice daily for four weeks, beginning with one drop just prior to trachomatous trichiasis surgery on the upper lid.
45929882|NCT00275951|Drug|Cetuximab Plus P-HDFL|Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
45929883|NCT00275912|Drug|Oxcarbazepine|
45929884|NCT00397098|Drug|SR58611A|
45929885|NCT00397137|Procedure|Circular stapled anopexy|Patients receiving stapled anopexy to treat haemorrhoids
45800681|NCT01456013|Drug|Standard Therapy|Standard of care for patients at risk of CIN
45929886|NCT00397137|Procedure|Closed diathermy haemorrhoidectomy|Conventional haemorrhoidectomy as described by Ferguson method
45929887|NCT00275834|Drug|Zonisamide|zonisamide 400 mg, 200 mg, or placebo
45929888|NCT00397176|Drug|desvenlafaxine succinate sustained release (DVS SR)|
45929889|NCT00275795|Procedure|NAET Procedures|
45800682|NCT02675543|Device|Vitreous Tamponade with Silicone Oil|
45929890|NCT00275756|Drug|Timolol (drug)|Timolol (0.5%, non-selective beta-blocker, Timoptic®, Merck Sharp & Dohme, Haarlem, Netherlands), dose 1 drop in one eye twice daily for two weeks
45651231|NCT05034523|Radiation|MRI Voxel based morphometry|Voxel based morphometry through analysis of 3D T1 weighted sequence to assess total intracranial volume. All participants were scanned on the 1.5Tesla MR scanner (Achieva, Philips Medical Systems, Best, NL) with a 16-channel head coil at the diagnostic radiology department.
45929891|NCT00275756|Drug|dorzolamide (drug)|Dorzolamide (2%, carbonic anhydrase inhibitor, Trusopt®, Laboratoires Merck Sharp & Dohme - Chibret, France), dose: 1 drop in one eye twice daily for two weeks
45929892|NCT00275756|Drug|brimonidine (drug)|Brimonidine (0.2%. alpha-2 adrenergic agonist, Alphagan®, Allergan Pharmaceuticals, Westport, Ireland), dose: 1 drop in one eye twice daily for two weeks
45651232|NCT04427813|Behavioral|questionaire to husband and wife|a form of questions will be asked to every partner
45651233|NCT04834115|Drug|Ivermectin Tablets|Oral ivermectin at a one time dose
45800683|NCT02684435|Drug|Perflutren lipid microsphere|Dosing per approved package label
45451004|NCT02205268|Procedure|Near infrared spectroscopy neurofeedback training|
45451005|NCT05262790|Other|This is not an intervention study|
45800684|NCT02684591|Drug|Aramchol|Aramchol, a conjugate of Cholic acid and Arachidic acid, is a first in class member of a novel family of synthetic Fatty-Acid / Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds, orally administrated with potentially good safety and tolerability parameters
45929893|NCT00275756|Device|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head, in total 4x 9 minutes on 2 study days
45929894|NCT00275756|Device|Goldmann applanation tonometer|intraocular pressure measurements, in total 2x 5 measurements on two study days
45929895|NCT00275756|Procedure|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus; 4x 8 minutes on 2 study days
45929896|NCT00275678|Procedure|Blood stem cell versus bone marrow transplant|"Cyclophosphamide and Total Body Irradiation (CY-TBI)-based regimens that include at least 120 mg/kg cyclophosphamide and at least 1200 cGy of fractionated TBI.~Busulfan and cyclophosphamide (BU-CY)-based regimens that include at least 14 mg/kg busulfan orally or 11.2 mg/kg busulfan intravenously (14 x 0.8 correction factor) or a targeted busulfan dosing strategy aimed at a serum concentration greater than 600 ng/mL at steady state and at least 120 mg/kg cyclophosphamide.~Fludarabine and melphalan (Flu-Mel)-based regimens that include a fludarabine dose of least 120 mg per m2 and a melphalan dose of at least 140 mg per m2.~Fludarabine, busulfan, and ATG (Flu-Bu-ATG)-based regimens that include a fludarabine dose of at least 120 mg/m2, at least 8 mg/kg busulfan orally or 250 mg/m2 busulfan intravenously, and at least 40 mg/kg equine ATG or 4 mg/kg rabbit ATG. Institutional standards should be followed for targeting plasma levels."
45929897|NCT00275639|Drug|Cozaar|
45800685|NCT02684591|Drug|Placebo|Placebo
45929898|NCT03957057|Drug|Iron Carboxymaltose|Intravenous iron carboxymaltose application
45929899|NCT03957057|Drug|Iron Isomaltoside|Inravenous iron isomaltoside application
45929900|NCT03957057|Drug|Ferrous sulphate|Oral ferrous sulphate application
45929901|NCT00275600|Drug|Vitamin E, Evening Oil of Primrose, and Placebo|
45929902|NCT03953157|Dietary Supplement|Dietary Intervention|Receive dietary intervention
45929903|NCT03953157|Behavioral|Exercise Intervention|Receive exercise intervention
45451006|NCT05262790|Other|This is not an intervention study|
45451007|NCT05262790|Other|This is not an intervention study|
45451008|NCT02221414|Drug|Linagliptin/Metformin FDC|
45451009|NCT02221414|Drug|Linagliptin|
45651234|NCT04834115|Other|Placebo|Oral placebo at a one time dose
45651235|NCT04820777|Other|perturbation training|external or internal postural perturbations. External perturbations occur by forces outside the patient' control (e.g., a push or pull from the physiotherapist). Internal perturbations caused when the patient is unable to control the centre of mass and the base of support relationship during voluntary movement; 'agility' tasks, such as kicking a soccer ball,
45651236|NCT04820777|Other|Conventional' balance training|Starting from a situated position, expand your left leg until it's corresponding to the floor. Try not to bolt your knee. At that point, gradually bring your foot down to the floor. Rehash with your correct leg, exchanging to and fro between legs for a s
45800686|NCT02685293|Drug|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
45800687|NCT02685293|Drug|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
45929904|NCT03953157|Other|Questionnaire Administration|Ancillary studies
45929905|NCT00275522|Drug|Sirolimus|
45929906|NCT03891732|Diagnostic Test|MRI prostate|plain biparametric MRI prostate
45929907|NCT00275483|Device|Vital-band (R)|
45929908|NCT00275444|Drug|Tipranavir|
45929909|NCT00275405|Drug|Garlic Oil Macerate|
45929910|NCT00275366|Device|Robotic Therapy|
45929911|NCT00275249|Drug|levorphanol|
45929912|NCT00041496|Drug|SB-207266|White, oval, biconvex tablets containing either 10mg, 25mg or 40mg
45929913|NCT00041496|Other|Placebo|Placebo to match SB-207266
45929914|NCT00275210|Drug|Oxaliplatin (SR96669)|
45929915|NCT00041535|Drug|OGT 918|
45929916|NCT00041574|Drug|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
45800688|NCT00782249|Procedure|Vagus nerve stimulation paradigm #1|Vagus nerve stimulation parameters #1
45929917|NCT00275171|Drug|Recombinant human thyrotropin (Thyrogen)|0.1 mg rhTSH administered intramuscularly
45651237|NCT04821011|Device|electronic stethoscope|Record of maternal heart sounds (heartbeats) with an electronic stethoscope during 10 minutes.
45651238|NCT04821011|Device|acoustic listening of mother's heartbeats|Each newborn included will have 20 minutes of an acoustic listening of their mother heartbeats previously recorded.
45451010|NCT02221414|Drug|Metformin|
45800689|NCT00782249|Procedure|Vagus nerve stimulation paradigm #2|Vagus nerve stimulation parameters #2
45929918|NCT00275171|Drug|recombinant human TSH|0.1 mg rhTSH administered intramuscularly
45800690|NCT00782249|Procedure|Vagus nerve stimulation paradigm #3|Vagus nerve stimulation parameters #3
45929919|NCT00275171|Other|isotonic saline = placebo|0.1 mg isotonic saline injected intramuscularly
45929920|NCT00041613|Genetic|INGN 201|
45800691|NCT00586391|Genetic|CD19CAR-28-zeta T cells|"Intravenous injection~Dose Level 1:~CD19CAR-28zeta - 2x10^7 cells/m^2~Dose Level 2:~CD19CAR-28zeta - 1 x10^8 cells/m^2~Dose Level 3:~CD19CAR-28zeta - 2x10^8 cells/m^2"
45800692|NCT00586391|Drug|Ipilimumab|For patients with intermediate or low grade leukemia/lymphoma, patients may receive ipilimumab once during the week 2 visit after the T cell infusion.
45800693|NCT04339127|Other|Description and analysis|Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
45929921|NCT00275132|Drug|erlotinib hydrochloride|Tarceva (OSI-774, erlotinib) PO 150 mg daily
45929922|NCT00275132|Drug|Matched placebo|Matched placebo PO daily
45451011|NCT02221492|Drug|plerixafor GZ316455|Pharmaceutical form:vial Route of administration: subcutaneous injection
45451012|NCT02221492|Drug|Filgrastim|Pharmaceutical form:vial Route of administration: subcutaneous injection
45800694|NCT04340375|Dietary Supplement|AP green tea extracts|AP green tea extracts
45800695|NCT05436275|Biological|CM310|300 mg every two weeks
45800696|NCT05436275|Biological|Placebo|once every two weeks
45800697|NCT04707755|Other|Motor imagery technique|"The patient will sit on chair in a quiet room. The patients will be observing motor performance in video, motor performance video will consist of (1) knee flexion and extension movement, (2) sitting to standing movement, (3) stepping movement, (4) walking, (5) climbing and descending stairs.~Addition to motor imagery, the patients will be provided the passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs."
45800698|NCT04707755|Other|Conventional Physical Therapy|It includes passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs.
45800699|NCT05432843|Drug|Pregabalin|Patients receive for one week Pregabalin 75 mg and 7 weeks Pregabalin 150 mg
45451013|NCT05164978|Drug|DEP combine with PD-1 antibody|Doxorubicin hydrochloride liposome injection 25 mg/m2 day 1 Etoposide 100 mg/m2 day1 Methylprednisolone 1.5 mg/kg days 1 to day 3, 0.25mg/kg days 4 to 14 Sintilimab Injection 200mg d4
45451014|NCT02751424|Drug|GSK3342830|A pyrogen free lyophilized formulation, white to yellowish brown powder containing 1000 mg of GSK3342830A (as free base) per vial. The reconstituted solution looks like a clear, colorless to yellow or brownish yellow liquid, free from visible particulate matter will be administered as IV infusion over 1 hour.
45651239|NCT04821011|Device|Recording of the newborn's heart rate|"Recording of the newborn's heart rate: one hour before the acoustic listening, during the acoustic listening and one hour after the acoustic listening .~The variations of the autonomic nervous system will be analyzed.~An coupled Heart rate variability recording (ECG signal obtained from a Philips® IntelliVue MX700 monitor) and NIPΣ index of comfort (MDMS® NIPΣ monitor) will be used."
45800700|NCT05432843|Drug|Placebo|Patients receive a treatment with placebo for 8 weeks
45800701|NCT05411471|Biological|COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain|The COVID-19 vaccine (Vero cell), Inactivated, Omicron Strain was developed by Sinovac Life Science Ltd.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The antigen content is 1200 SOU/0.5 mL (6 µg/0.5 mL).
45800702|NCT02677493|Biological|IL-YANG Quadrivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
45800703|NCT02677493|Biological|IL-YANG Flu Vaccine Prefilled Syringe|A single 0.5mL dose administrated as an intramuscular injection.
45800704|NCT02677493|Biological|IL-YANG Trivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
45804147|NCT05654857|Diagnostic Test|PCR test in the stool|Patients will receive a prescription for a stool self-collection kit . Only the result of the PCR test in the stool will be considered for this arm. A positive test will determine Hp infection and the indication for treatment.
45804148|NCT04745533|Diagnostic Test|Antigen detection test|To compare the results of the antigen detection test against the polymerase chain reaction in the study of contacts of COVID-19 patients during quarantine.
45929923|NCT03502200|Device|JUUL|Participants randomized to the JUUL group will receive either tobacco or menthol flavored JUUL with 5% nicotine. Will also receive counseling.
45929924|NCT03502200|Other|Treatment As Usual|Nicotine Replacement Therapy consisting of nicotine patches and lozenge along with standard quitline counseling.
45929925|NCT00275093|Drug|temsirolimus|Given IV
45929926|NCT00275093|Other|laboratory biomarker analysis|Correlative studies
45929927|NCT00275093|Other|pharmacological study|Correlative studies
45929928|NCT00041652|Drug|hMN14 (labetuzumab)|
45929929|NCT03430596|Drug|Pramipexole|The dose of pramipexole range from 0.375mg/d to 0.75mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .
45929930|NCT03430596|Drug|Trihexyphenidyl hydrochloride|he dose of Antan range from 2 mg/d to 4 mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .
45929931|NCT00275054|Drug|Fludarabine|cycles 1-6: 25 mg/m² i.v., d2-4, q28d
45929932|NCT00275054|Drug|Cyclophosphamide|cycles 1-6: 250 mg/m² i.v., d2-4, q28d
45929933|NCT00275054|Biological|Rituximab|"cycle1: 375 mg/m² i.v., d1, q28d~cycles 2-6: 500 mg/m² i.v., d1, q28d"
45929934|NCT03208179|Drug|dihydroartemisinin-piperaquine|Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin placebo
45800705|NCT02678039|Device|Fluoroscopy|Device: Fluoroscopy Patients lie prone on X-ray compatible operating table and an X-ray device obtains X-ray images of epidural catheter placement. An epidural catheter is placed with local anesthesia as a needle that is advanced into the epidural space. A catheter is then placed through the needle to the desired location and the needle is removed. After the catheter is placed, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr
45929935|NCT03208179|Drug|sulphadoxine-pyrimethamine|Women randomised to this intervention will receive stat dose of 3 tablets of 500 mg sulphadoxine and 25 mg of pyrimethamine each (total dose of 1,500mg sulphadoxine and 75mg pyrimethamine) on a single day of clinic visit
45929936|NCT03208179|Drug|dihydroartemisinin-piperaquine plus azithromycin|Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin (500mg)
45651240|NCT01505465|Drug|Melatonin|5mg of melatonin will be taken by the subject for 3 nights prior and continuing 3 nights after surgery as tolerated.
45929937|NCT00275015|Biological|filgrastim|
45651241|NCT01505465|Drug|Placebo|5mg of placebo will be taken by the subject 3 nights prior to surgery and continuing 3 nights after surgery
45800706|NCT02678039|Procedure|Traditional|An epidural catheter is placed before surgery with the patient sitting at bedside. The catheter is placed with local anesthesia using indirect indicators of proper placement: depth of needle insertion and ability to inject solution through the needle ('loss of resistance'). After needle placement in the epidural space, an epidural catheter is threaded through the needle 3-4 cm and the needle removed. After catheter is placement, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr.
45929938|NCT00275015|Drug|carmustine|
45929939|NCT00275015|Drug|cyclophosphamide|
45929940|NCT00275015|Drug|cytarabine|
45929941|NCT00275015|Drug|dexamethasone|
45929942|NCT00275015|Drug|etoposide|
46072648|NCT03142009|Other|Intergenerational culturally adapted curriculum|"Each session starts with a collective dinner with families eating together. Then practice their Indian and clan names. The sessions are led by facilitators in their own language or bilingually. The facilitators then divide the families into children and adult groups to address the theme of the session, and they then return together at the end of the session to share their learnings. The sessions always end with the children and adults writing in their journals which are individual pages that they then put in their curriculum binders. Families are then given their home practice, which is a task that the families do together during the intervening week. The facilitators collect the curriculum binders after each session to bring back to the families the next week."
46072649|NCT03120624|Procedure|Biopsy|Undergo image-guided biopsy
46072650|NCT03120624|Procedure|Computed Tomography|Undergo SPECT/CT
46072651|NCT03120624|Other|Fluorine F 18 Tetrafluoroborate|Given IV
46072652|NCT03120624|Other|Laboratory Biomarker Analysis|Correlative studies
45451015|NCT02751424|Drug|Placebo|A clear and colorless solution containing 0.9% sodium chloride. It will administered as IV infusion over 1 hour.
45651242|NCT05618015|Procedure|Supervised progressive resistance training|Exercises were performed with cable resistance training machine
45800707|NCT02679911|Drug|Loceryl NL|Topical over the entire toenail plate of all affected toenails, once weekly in the evening (at bed time) after filing down the affected toenails.
45929943|NCT00275015|Drug|fludarabine phosphate|
45929944|NCT00275015|Drug|melphalan|
45929945|NCT00275015|Procedure|bone marrow ablation with stem cell support|
45929946|NCT00275015|Procedure|peripheral blood stem cell transplantation|
45929947|NCT00275015|Radiation|radiation therapy|
45929948|NCT00274976|Biological|alemtuzumab|
45929949|NCT00130403|Drug|risedronate sodium|
45929950|NCT03062826|Drug|dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel)|Patients who met the inclusion criteria will be treated with dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel).
45929951|NCT00130364|Drug|Pimecrolimus|Pimecrolimus 1 % cream
46072653|NCT03120624|Other|Pharmacological Study|Correlative studies
46072654|NCT03120624|Procedure|Planar Imaging|Undergo whole body planar imaging
45651243|NCT05618015|Procedure|Home-based progressive resistance training|In the first session, with the help of a physiotherapist, strengthening exercises were shown and taught to the patients. Two weeks after the beginning of the home-based PRT program, patients were called to check whether they were doing the exercises in the home program correctly. After the checking for exercise training, the patients were called by phone every two weeks for follow-up.
45651244|NCT04833881|Other||
45651245|NCT04833803|Behavioral|eBLISS|a novel instrument -Eating Behaviour Lapse Inventory Survey Singapore (eBLISS)- will be developed
45929952|NCT00130364|Drug|Placebo|Pimecrolimus vehicle cream (placebo)
45929953|NCT02950428|Device|ACURATE neo™TA Delivery System|ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™TA Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
45929954|NCT00130325|Drug|Isoniazid|Isoniazid 900mg, tablets, twice a week for 6 months
45929955|NCT00130325|Drug|Isoniazid|INH 900mg twice weekly for 6 months
45929956|NCT00130325|Drug|Placebo of Isoniazid tablets 300mg|Isoniazid BP 0mg twice weekly for 6 months
45929957|NCT00041691|Drug|hMN14 (labetuzumab)|
45929958|NCT00394316|Drug|Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells|
45929959|NCT00041730|Biological|Id-KLH|
46072655|NCT03120624|Procedure|Positron Emission Tomography|Undergo TFB-PET
46072656|NCT03120624|Biological|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Given IV
45651246|NCT04833647|Diagnostic Test|Cardio-Pulmonary-Exercise-Testing (CPET)|Cardio-Pulmonary-Exercise-Testing (CPET) . During the exercise testing, serial saturation, heart rate and blood pressure measurements were obtained. The peak oxygen consumption (VO2max) was measured and served as the primary endpoint of the study
45451016|NCT02221570|Drug|Baclofen|Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
45451017|NCT02217358|Device|NBI endoscopy|"see in detail description of the study part of the protocol"
45451018|NCT05163652|Biological|SARS-CoV-2 Vaccine, Inactivated (Vero Cell)|the third dose immunization schedule of SARS-CoV-2 inactivated vaccine
45651247|NCT04830449|Drug|HCP1904-2|Take it once daily for 8 weeks orally.
45651248|NCT04830449|Drug|RLD2001-2|Take it once daily for 8 weeks orally.
45651249|NCT05617937|Other|Massage|The connective tissue massage was started from the lumbosacral region (baseline) and was applied to the lower thoracic, scapular, inter-scapular and cervico-occipital region according to the vascular response of the connective tissue.
45651250|NCT04820543|Drug|injection of Botulinum type A|The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.
45651251|NCT04816487|Drug|Potassium Iodide or Glutathione|Patient will receive either Glutathione or Potassium iodide
45651252|NCT04360577|Procedure|acupuncture|Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combing with electro-acupuncture at Baihui(GV20), Yintang(GV29), Neiguan(PC6), Zusanli(ST36), and Gongsun(SP4).
45651253|NCT04831229|Other|Children will perform activities on interactive tablet|AIMG will actively perform activities with user interaction with the equipment through touch or verbal response. Both groups will have a total of 48 intervention sessions.
45651254|NCT04831229|Other|Children will perform passive on interactive tablet|"The PIMG is just a spectator, having contact with the equipment only when switching on / off, play / pause . Both groups will have a total of 48 intervention sessions."
45651255|NCT04358315|Behavioral|Behavioral Intervention|Smell or puff e-liquids
45651256|NCT04358315|Other|Questionnaire Administration|Ancillary studies
45651257|NCT04830371|Biological|EuTCV (Vi-CRM Typhoid conjugate vaccine)|Single dose, Intramuscular administration
45651258|NCT04830371|Biological|Typbar-TCV|Single dose, Intramuscular administration
45651259|NCT04820699|Other|post isometric relaxation and muligan bent leg raise|6 week intervention
45651260|NCT04820699|Other|muligan bent leg raise|muligan bent leg raise
45651261|NCT04830293|Procedure|Carotis Doppler Ultrasound|Neck was rotated about 30-45 ° to the opposite side of the image. The common carotid artery and internal jugular vein were viewed transversely on the B Mode USG image. Then, the probe was rotated approximately 90 ° and the carotid artery was visualized in the longitudinal plane. The probe and guide line were adjusted so that the Doppler angle was 60 °. The image was created with the guiding line parallel to the blood flow. After imaging of the carotid artery bifurcation, measurements were made 1 cm distal to this level.
45651262|NCT04816409|Other|conventional therapy|"Range of motion and Resistance training Linear actions are used to regularize extensor muscle tone (Neck extensors, back extensors hip extensors, knee extensors).(49) Postural control exercises Bouncing on gym ball in sitting, kneeling, or standing~- Linear swinging using a platform and swing, glider, hammock, and barrel; swinging in the kneeling, standing, sitting,"
45651263|NCT04816409|Other|Neurodevelopmental therapy|"Starting Posture~Start and evaluate the supreme effective posture to move from(usually straight)~Reassemble to mid plane (head/trunk)~Neutral position of body (47) Identify the Missing Components Detect starting posture and compare to normal.(47)~Neurodevelopmental therapy application :~Tonic postural extensor muscle strengthening:~Push-pull scooter board games contrary to resistive tubing strips.(48) 2. Developmental movement patterns training: Obstacle crawl, hold swing's ropes in kneeling and half kneeling position, throw balls to aim kneeling and standing position. Manual Cues .Use hands on key points of control to assist normal posture, movement and prevent abnormal posture and movement. Balance and corrective reactions was established by means of ball and tilt board after the development of the skill of~li"
45651264|NCT04820465|Other|Non available due to cross-sectional study design|Non available since this study (survey) has a cross-sectional design
45800708|NCT02679911|Drug|Ciclopirox NL|Topical over the entire toenail plate of all affected toenails and surrounding skin, once daily in the evening (at bed time) after removing the free toenail edge and diseased toenails if needed
45800709|NCT02680145|Device|Preoperative Pessary Use|Pessary use for 1-4 weeks prior to surgical prolapse repair
45800710|NCT02680301|Drug|0.1% triamcinolone CREAM|Patients will be asked to apply a topical steroid in a cream formulation to one extremity using the wet wrap technique.
45800711|NCT02680301|Drug|0.1% triamcinolone OINTMENT|Patients will be asked to apply a topical steroid in a ointment formulation to one extremity using the wet wrap technique.
45800712|NCT02680457|Drug|Insulin Degludec|Insulin Degludec 10 IU SC every 24 hours for 6 days
45800713|NCT02680457|Drug|Insulin Glargine|Insulin Glargine 10 IU SC every 24 hours for 6 days
45929960|NCT00394394|Drug|Amiloride 2,5/d or Enalapril/d 10 mg|
45929961|NCT00041769|Procedure|Therapeutic Drug Monitoring (TDM)|
45929962|NCT00130169|Drug|E7974|Maximum Tolerated Dose defined as 0.35 mg/m^2 administered on Days 1 and 15 only of a 28-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
45929963|NCT02970708|Device|EFG group|88 anisometropic amblyopia will be recruited to receive Eyetronix Flicker Glasses treatment.
45929964|NCT02970708|Device|Patching group|88 anisometropic amblyopia will be recruited to receive patching treatment.
45451019|NCT02205502|Drug|Lidocaine|Normal saline will be injected subcutaneously as a placebo for lidocaine in study group of children.
45451020|NCT02205502|Drug|Normal saline|
45929965|NCT00041808|Drug|MTC-DOX for Injection|
45929966|NCT00041808|Procedure|Chemotherapy|
45929967|NCT00130091|Drug|clonidine|2 mcg clonidine added to local anesthetic
45800714|NCT02689973|Behavioral|Self-Efficacy|"The introductory part included an abbreviated version of the education materials used in the control group. The self-efficacy materials and forms had four sections: (a) definitions of self-efficacy beliefs, (b) information on the importance of self-efficacy for goal pursuit, (c) recollecting a mastery experience, (d) persuasive statements evoking self-persuasive statements about self-efficacy beliefs. The materials ended with instructions for the following 7 days to recollect self-efficacy enhancing statements every morning. The procedures are based on a self-efficacy intervention by Luszczynska, Tryburcy et al. (2007).~Group and individual components were included. Setting: secondary and high schools."
45800715|NCT02689973|Behavioral|Planning|"The introductory part included an abbreviated version of the education materials used in the control group. The planning materials and forms had four sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. The materials ended with instructions for the following 7 days to recollect/redo plans every morning.The procedures are based on a planning intervention by Luszczynska, Sobczyk, et al. (2007).~Group and individual components were included. Setting: secondary and high schools."
45800716|NCT02689973|Behavioral|Education|"Participants received a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, myths about PA, strength and endurance training, stretching, and general healthy nutrition guidelines. The materials excluded planning and self-efficacy statements.~The materials ended with instructions for the following 7 days to recollect forms of MVPA every morning.~Group and individual components were included. Setting: secondary and high schools."
45929968|NCT02729922|Device|Cardiomems|Eligible patients will undergo implantation of a pulmonary artery sensor (CardioMEMS), a wireless implantable hemodynamic monitoring system in the cardiac catheterization laboratory. This system has a passive wireless, radiofrequency sensor without batteries or leads. Patients transmit data through a device in their home that interacts wirelessly with the sensor. Clinicians retrieve this data via a web interface to use in making management decisions for patients.
45929969|NCT00130013|Drug|Oral Amoxicillin|
45651265|NCT04816331|Other|Medical records and clinical measurements|"Medical records and clinical measurements: Detailed antenatal, birth, resuscitation, oxygen requirements throughout inpatient stay and detailed neonatal intensive care management will be collected. Therapeutic Hypothermia treatment including initiation, duration and clinical examination, and investigations such as scans. In addition, clinical data will include medication, neurological (paediatric developmental psychologist assessment and Bayley Scales of Infant and Toddler Development) and multiorgan examination.~Questionnaires for caregivers to assess social-emotional and adaptive domains.~Tissue samples analysis and processing: Samples of blood, urine and saliva will be used for laboratory testing.~Biomarker correlation with Multiorgan outcomes using statistical analysis: Data collected from medical records, clinical measurements, questionnaires, and tissue processing will be analysed using SPSS software for statistical analysis and modelling."
46072657|NCT03120624|Drug|Ruxolitinib|Given PO
45929970|NCT00129857|Drug|Dexanabinol|
46072658|NCT03120624|Drug|Ruxolitinib Phosphate|Given PO
46072659|NCT03120624|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
46072660|NCT03120624|Drug|Technetium Tc-99m Sodium Pertechnetate|Given IV
45651266|NCT04830059|Behavioral|Exercise|Two types of exercise intervention and control group
45929971|NCT00129818|Drug|Famciclovir|
45929972|NCT00129779|Behavioral|Intermediate care package|
45929973|NCT00129740|Drug|Nilotinib|400 mg orally twice daily
45929974|NCT00041925|Drug|CGT003 (E2F Duplex Decoy)|
45929975|NCT00129662|Behavioral|Pictorial action plan|
45929976|NCT00129584|Procedure|Emphasys Endobronchial Valve and procedure|
45929977|NCT00129506|Drug|methotrexate + misoprostol|
45929978|NCT00129506|Drug|misoprostol|
45929979|NCT00129428|Procedure|UVB Irradiation|A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
45929980|NCT00129350|Procedure|Pulmonary rehabilitation programme|
45929981|NCT01909167|Behavioral|Online Cognitive Behavioral Therapy (CBT)|CBT treatment: Patients randomized to the online treatment will have, in total, 10 real time individual sessions of 40min each, starting at the 20-23rd gestational week and lasting until 6 weeks postpartum. The therapy will be delivered every two weeks, with a break from the 36th gestational week until the 4th week postpartum.
45929982|NCT01909167|Other|Treatment as usual|Patients randomized to the treatment as usual arm will be advised by their GP,perinatal psychiatric team or mental health midwife concerning treatment.
45929983|NCT00129233|Drug|Valsartan|valsartan 80 to 160 mg daily
45929984|NCT00129233|Drug|Amlodipine|Amlodipine 5 to 10 mg daily.
46072661|NCT03096743|Diagnostic Test|MR elastography|MR elastography image acquisition will be conducted on the Compact 3T MRI scanner using a modified single-shot spin-echo echo-planar imaging pulse sequence.
46072662|NCT03096743|Diagnostic Test|MRI structural brain imaging|MRI structural brain imaging will be done on the Compact 3T MRI at the same time as MR elastography.
45451021|NCT02219698|Drug|Ibuprofen|
46072663|NCT03096743|Procedure|Lumbar puncture|All patients with papilledema will get lumbar punctures with opening pressure as part of their work-up for papilledema. A small number of patients without increased intracranial pressure will receive a lumbar puncture.
46072664|NCT03096743|Diagnostic Test|Optical Coherence Tomography (OCT) imaging|Optical Coherence Tomography (OCT) imaging will measure the peripapillary retinal nerve fiber layer (RNFL) thickness measurements The images with enhanced depth imaging will be obtained to measure the Bruch's membrane orientation.
46072665|NCT03096743|Diagnostic Test|Optic nerve B-scan ultrasound|Ultrasound will be used to measure the optic nerve sheath diameter 3 mm posterior to the posterior scleral surface.
46072666|NCT03075670|Drug|N9-GP|A single dose of 50 IU/kg for intravenous (i.v.) injection
45451022|NCT02219698|Drug|Paracetamol|
45451023|NCT02205580|Drug|continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion|
45929985|NCT00129194|Drug|KP-1461|
45800717|NCT02691143|Other|TheraBand Kinesiology Tape|One approach to treating musculoskeletal conditions is a elastic therapeutic taping technique designed to target muscles and lymphatic system. Limited research on the efficacy of elastic therapeutic taping (ETT) is available for specific patient populations, including neck pain. ETT it is theorized to impact muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment. In a study by Gonzalez-Iglesias et al. the investigators reported that neck pain and range of motion significantly improved immediately and 24 hours after the application of ETT in acute whiplash patients as compared to a sham taping.
45929986|NCT01568424|Device|CentriMag RVAS placement|Patients will be treated with a CentriMag RVAS
45929987|NCT00129155|Drug|treosulfan|
45929988|NCT01547442|Device|Artisan Aphakia Intraocular Lens|Implantation of an intraocular lens
45929989|NCT00712881|Drug|Liposomal doxorubicin hydrochloride|Liposomal doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
45800718|NCT02283762|Drug|Riociguat (Adempas, BAY63-2521)|Starting dose 0.5 mg TID, increase by 0.5 mg every 2 weeks until highest possible dose of 2.5 mg TID
45800719|NCT02283762|Drug|Placebo|Sham-titration
45929990|NCT00712881|Drug|Cyclophosphamide|Cyclophosphamide will be administered per dose and schedule specified in the arm description.
45929991|NCT00712881|Drug|Trastuzumab|Trastuzumab will be administered per dose and schedule specified in the arm description.
45929992|NCT00712881|Drug|Free doxorubicin hydrochloride|Free doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
45800720|NCT02692391|Drug|Indomethacin|Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.
45800721|NCT02692391|Drug|Placebo|Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin
45800722|NCT02692859|Biological|Hib conjugate vaccine|Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 years:one dose(0 d), 0.5ml for each dose
45800723|NCT04878120|Device|Hybrid Closed Loop Control (USS Virginia) with Smart Bolus Calculator Informed by SI|Hybrid Closed Loop Control (USS Virginia) with Smart Bolus Calculator Informed by SI
45800724|NCT04878120|Device|Standard Hybrid Closed Loop Control (USS Virginia)|Standard Hybrid Closed Loop Control (USS Virginia)
45800725|NCT02694029|Device|Active Breathing Coordinator (ABC)|The ABC system has a digital spirometer that records real time breathing. This group will be administered 14 fractions with ABC-assisted DIBH, followed by 14 fractions with VRT-assisted DIBH
45929993|NCT00712881|Drug|Docetaxel|Docetaxel will be administered per dose and schedule specified in the arm description.
46072667|NCT03075670|Drug|ALPROLIX®|A single dose of 50 IU/kg for intravenous (i.v.) injection
46072668|NCT03032783|Radiation|Total-Body Irradiation|Undergo Total Body Irradiation
46072669|NCT03032783|Procedure|Donor Lymphocyte Infusion|Undergo Donor Lymphocyte Infusion
45451024|NCT02205580|Drug|continuous intravenous sufentanil 0.03μg•kg-1•h-1 infusion|
45929994|NCT00129077|Procedure|plastic wrap over eye & lubrication applied q6 hrs|
45929995|NCT00042003|Drug|decitabine (5-aza-2'deoxycytidine)|
45451025|NCT02205580|Drug|continuous intravenous sufentanil 0.04μg•kg-1•h-1 infusion|
45651267|NCT04830059|Behavioral|Air purification|Air purification in order to reduce the PM2.5 and PM10
45651268|NCT04820621|Drug|Runcaciguat (BAY1101042)|Given as 1 x 15 mg modified release [MR] tablet
45651269|NCT04816253|Drug|Normal saline|Normal saline irrigation and No other drug placed after extraction
45651270|NCT04816253|Drug|Hyaluronic acid|Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
45929996|NCT00129038|Drug|modified-release dipyridamole/aspirin|
45929997|NCT00129038|Drug|aspirin|
46072670|NCT03032783|Drug|Cyclophosphamide|Given IV
45651271|NCT04816253|Drug|Methylprednisolone|Methylprednsolone will be injected half an hour preoperatively
45651272|NCT04816253|Drug|Methylprednisolone and Hyaluronic acid|Methylprednisolone will be injected half an hour preoperatively and Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
45651273|NCT04820231|Other|intra-articular PRP injection|
45800726|NCT02694029|Device|VisionRT|A technology for implementing the deep inspiration breath-hold technique is real-time surface photogrammetry. This group will be administered 14 fractions with VRT-assisted DIBH, followed by 14 fractions with ABC-assisted DIBH.
45800727|NCT04739033|Behavioral|VIVIR MEJOR EXPERIMENTAL|"This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.~The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor."
45800728|NCT04738877|Diagnostic Test|Body fat measurement|Body fat measurement using skinfolds
45929998|NCT00470223|Drug|cisplatin|
45929999|NCT00470223|Drug|doxorubicin hydrochloride|
45930000|NCT00470223|Drug|etoposide|
45930001|NCT00470223|Drug|ifosfamide|
45930002|NCT00470223|Drug|methotrexate|
45930003|NCT00470223|Drug|zoledronic acid|
45930004|NCT00470223|Procedure|conventional surgery|
45930005|NCT00128999|Procedure|Intensity-Modulated Radiation Therapy|
45930006|NCT00042042|Behavioral|Family based educational program|
45930007|NCT00103389|Drug|PI-88|PI-88+docetaxel
45930008|NCT00103389|Drug|docetaxel|docetaxel only
46072671|NCT03032783|Drug|Tacrolimus|Given IV
46072672|NCT03032783|Drug|Mycophenolate Mofetil|Given IV
46072673|NCT03032783|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo Hematopoietic Stem Cell Transplantation
46072674|NCT03010150|Procedure|Biospecimen Collection|Provide blood samples
46072675|NCT03010150|Other|Questionnaire Administration|Ancillary studies
46072676|NCT03002272|Device|TAVR|subjects that underwent TAVR more than 3 years ago
45930009|NCT00128921|Drug|VELCADE™|"Patients will receive two cycles of VELCADE™ (1.3 mg/m2, 1.0 mg/m2 or 0.7 mg/m2) on days 1, 4, 8, and 11, on a 21 day cycle. No growth factors or bisphosphonates will be allowed during study treatment. Bone markers will be measured:~Days 1, 4, 8, 11: Pre-dose, post-dose, and every 2-4 hours for 8 hours Days 2-3, 5-7, 9-10, 12-21: every 24 hours, beginning with the immediate post-dose sample (+/- 2 hours) Other laboratory and radiologic studies will be performed as detailed in the Study Calendar.~Patients will complete the study after two cycles of VELCADE™. However, if a patient continues to receive VELCADE™ as part of his/her treatment for relapsing MM, routine bone markers may be monitored for the duration of VELCADE™ treatment as clinically indicated."
45930010|NCT00042081|Drug|CGT003 (E2F Duplex Decoy)|
45930011|NCT00128882|Drug|Anti-D|Subcutaneous injection
45930012|NCT00128804|Behavioral|absorption and conversion of beta-carotene in human gastrointestinal (GI) tract|
46072677|NCT03002272|Device|SAVR|Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
46072678|NCT02978625|Procedure|Biopsy|Undergo tissue biopsy
45651274|NCT04816097|Drug|Dexamethasone phosphate|4 doses of dexamethasone 6mg IM 48h before elective CS.
46072679|NCT02978625|Procedure|Biospecimen Collection|Undergo blood sample collection
46072680|NCT02978625|Procedure|Computed Tomography|Undergo CT
45651275|NCT04815941|Other|Soft ball tissue release exercises|"Exercise program were given to patients with low back pain secondary to hip muscle tightness using soft balls, i.e. tennis balls plus core stability exercises.~3 days a week for four weeks."
45651276|NCT04363619|Diagnostic Test|OCT and OCTA|Fundoscopy, OCT and OCTA will be performed 4 times in patients
45651277|NCT04363307|Device|AF Ablation|Adult participants undergoing standard of care AF ablation using VISITAG SURPOINT
45800729|NCT04738877|Diagnostic Test|Cardiopulmonary exercise testing|Electrocardiographic exercise testing with ergospirometer on a treadmill
45651278|NCT04363307|Device|MRI|Adult participants will undergo a late gadolinium enhancement MRI of the left atrium three months post standard of care ablation
46072681|NCT02978625|Other|Laboratory Biomarker Analysis|Correlative studies
46072682|NCT02978625|Biological|Nivolumab|Given IV
46072683|NCT02978625|Procedure|Positron Emission Mammography|Undergo PET/CT
45651279|NCT04363073|Device|Annabella Breast Pump|Milk will be expressed using Annabella breast pump for 4 consecutive days (at least 24h apart)
45651280|NCT04363073|Device|Control Breast Pump|Milk will be expressed using Control breast pump for 4 consecutive days (at least 24h apart)
45651281|NCT05617781|Behavioral|Questionnary|The primary outcome of this study is to analyze the post-traumatic stress disorder's repercussions on empathy by passing the Interpersonal Reactivity Index (IRI)
45651282|NCT04820153|Device|Physical Activity Monitoring Device|Participants will be provided a Fitbit Alta HR and wall charger. Each participant will be assigned a unique ID# at baseline and used to set-up the data acquisition. The Fitbit app will be set up on their smartphone to allow self-monitoring of activity. The Fitbit device includes both an accelerometer and heart rate monitor, capable of continuous measuring and storing data up to 5 days. Fitbit data will be passively downloaded through smartphone connection to Fitabase, a research friendly application and data management program. The Fitbit will be worn on the wrist every day during the course of the 16-week study, with instructions on self- monitoring, usage and maintenance. Participants will be monitored for Fitbit compliance by weekly phone calls; and monitoring of passively downloaded Fitbit data through Fitabase. Follow-up phone call at 3-months post-study will assess continued use of the Fitbit activity monitor.
45651283|NCT04820153|Behavioral|Lifestyle Redesign Coaching|Participants will receive individualized goal setting and a guide to increase exercise at baseline and at week four visit. The Occupational therapist (OT) will administer a well published approach for promoting PA called Lifestyle Redesign which addresses physical, psychosocial and environmental barriers to health and incorporate self-care strategies and goal setting. Coaching will be administered by a bilingual OT and in Spanish. Based on studies examining PA and brain health, the OT will guide the participant through a goal setting process for moderate to vigorous intensity of physical activity including a specific guide plan to achieve these goals of 10,000 steps per day and/or 150 minutes/week of moderate to vigorous activity. Participants will also receive weekly calls from the study coordinator (overseen by OT) to review PA and goal setting for each week over the course of the 16-week study.
45800730|NCT04738877|Diagnostic Test|Echocardiography|Transthoracic echocardiography
45800731|NCT04738877|Diagnostic Test|Blood test|Blood test for measurement of haemoglobin, serum electrolytes, iron, ferritin and vitamins
45800732|NCT05407961|Drug|LY3532226|Administered SC.
45800733|NCT05407961|Drug|Placebo|Administered SC.
45800734|NCT05407961|Drug|Dulaglutide|Administered SC.
45800735|NCT02696291|Drug|UV-4B 30 mg oral solution|UV-4B 30 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
45930013|NCT00097851|Drug|docetaxel|
45930014|NCT00097851|Drug|PI-88|
45930015|NCT00128765|Behavioral|an integrated self-management education program|disease specific self-management program 'Living Well with COPD', developed in Montreal, Canada
45800736|NCT02696291|Drug|UV-4B 75 mg oral solution|UV-4B 75 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
45800737|NCT02696291|Drug|UV-4B 150 mg oral solution|UV-4B 150 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
45800738|NCT02696291|Drug|UV-4B X mg (dose to be determined) oral solution|UV-4B X mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
45800739|NCT02696291|Drug|UV-4B Y mg (dose to be determined) oral solution|UV-4B Y mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
46072684|NCT02978625|Biological|Talimogene Laherparepvec|Given IT
46072685|NCT02971501|Biological|Bevacizumab|Given IV
46072686|NCT02971501|Procedure|Biopsy|Undergo tumor biopsy
46072687|NCT02971501|Procedure|Biospecimen Collection|Undergo blood sample collection
46072688|NCT02971501|Procedure|Computed Tomography|Undergo CT scan
46072689|NCT02971501|Procedure|Magnetic Resonance Imaging|Undergo MRI
46072690|NCT02971501|Drug|Osimertinib|Given PO
45651284|NCT04819529|Behavioral|Early and Intensive Occupational Therapy|"Occupational therapists will implement the following activities:~Polysensory stimulation: external stimulation for increasing the level of alertness. It will be implemented with SAS 1 one session each 48 h and SAS 2 one session each 24 h.~Cognitive stimulation: bundle of exercises for activating mental functions, i.e: alertness, visual perception, memory, calculus, problem solving, praxis, language. Patients with SAS 3, 4 and 5. In SAS <2, 6> environmental orientation will be considered~Basic activities of daily living (BADLs): promotion of independence that initially practice hygiene, personal grooming. Patients with SAS 3, 4 and 5~Motor function Stimulation: exercises to keep the patient's upper extremities active and functional. Patients with SAS with 3,4 and 5. Patients with SAS 1 and 2 will use adaptations to prevent edema and bedsores on vulnerable body areas~Education: daily visits by trained family members and health staff about the intervention process"
45651285|NCT04829825|Diagnostic Test|18F-GP1 PET/MR|Patients will receive 1-3 18F-GP1 PET/MR
45651286|NCT04815863|Diagnostic Test|Assessment of somatic symptom disorder with SSS-CN|SSS-CN questionnaire is used to assess the presence and severity of the somatic symptoms
45651287|NCT04815863|Diagnostic Test|Assessment of depressive symptoms disorder with PHQ-9|PHQ-9 questionnaire is used to assess the presence and severity of the depressive symptoms
45651288|NCT04815863|Diagnostic Test|Assessment of anxiety disorder with GAD-7|GAD-7 questionnaire is used to assess the presence and severity of the anxiety disorder
45651289|NCT04815629|Radiation|Radiotherapy|Radiotion therapy squamous cell carcinoma in cancer bladder
45651290|NCT03035591|Drug|ODM-207|
45651291|NCT04819685|Drug|KANG FU PEN|FU PEN: anti-radiation spray (liquid dressing) treatment which is a protective irrigation solution against rays
45651292|NCT04815785|Device|TaurusOne® transcatheter aortic valve replacement system|The TaurusOne® Transcatheter Aortic Valve System consists of an aortic valve, an associated delivery catheter and a loading system. The aortic valve consists of a self-expanding nitinol frame, a sealing skirt and valve leaflets, which are made of bovine pericardium. The delivery system is mainly composed of conical head, opacity ring, inner tube, top ring, middle tube, outer tube, booster rod, stress diffusion catheter, handle, etc. The outflow end of the aortic valve is provided with three fixing holes evenly distributed on the circumference on the top ring of the delivery catheter, so as to facilitate the installation, delivery and release of the aortic valve. Before the operation, the aortic valve needs to be installed into the sheath of the delivery catheter as required.
45651293|NCT04819607|Other|model of care|Multidisciplinary model of care for BMFS patients.
45651294|NCT02600351|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
45651295|NCT02600351|Drug|RBV|Tablets administered orally in a divided daily dose according to weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45651296|NCT02640235|Device|CELSTAT|
45651297|NCT02640235|Device|Surgicel Original|
45651298|NCT04829279|Other|CONNECT AI system group|"A. During the Intervention period, paramedics wear equipment for multi-faceted data acquisition and press the start button of the system.~B. During the Intervention period, inside the ambulance, a application that implements a function that automatically evaluates the patient's severity, displays a list of optimal transfer hospitals based on this, and shares real-time information of the hospitals, is installed so that paramedics can refer to the work.~C. ED's medical staff will receive through ER-kiosk pre-hospital patient information collected and analyzed through the CONNECT AI system before arrival."
45800740|NCT02696291|Drug|Placebo|Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days
45800741|NCT05406245|Dietary Supplement|Carbohydrate drinking|Administration of carbohydrate fluid
45800742|NCT02682563|Drug|Dapagliflozin 10mg QD|Dapagliflozin 10mg once daily for 12 weeks
45800743|NCT02682563|Drug|Gliclazide 30mg QD|Gliclazide30mg once daily for 12 weeks
45800744|NCT05394545|Device|Nu-V3|The Nu-V3 device provides a continuous flow of intermittent, low frequency electrical pulses to the ear's specific cranial nerve endings. This treatment is delivered 24 hours a day for the first 12 weeks, then is delivered two weeks on, one week off for the following 12 weeks.
45800745|NCT02697071|Drug|Ketamine|Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
45800746|NCT02697071|Drug|Normal Saline|Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
45800747|NCT02683421|Drug|Tilmanocept|
45800748|NCT02683577|Drug|telotristat etiprate|
45800749|NCT05369897|Device|VR training|The intervention group will receive cognitive training through VR headsets three times a week for 12 weeks. The intervention will be delivered in a virtual setting using images and music. The participants will be allowed to select the type of music and virtual environment during the intervention. The intervention will include four modules targeting attention and working memory through immersive VR.
45800750|NCT05369897|Device|VR activity|High-quality 360º images and videos from natural environments, such as a relaxing mountain environment. The participants in the control group will not receive cognitive training.
45800751|NCT02283294|Drug|Apixaban|
45597954|NCT03766555|Procedure|Liver resection|Liver resection will be performed as described previously. Liver parenchymal transection would be performed with CUSA (cavitron ultrasonic surgical aspirator) and TissueLink (a radiofrequency saline-linked dissecting sealer) in both arms. Vascular staplers would be used to divide major vascular pedicles. Fibrin glue (Tisseel) spray would be applied to the parenchymal cut surface of the liver before closure of abdomen.
45597955|NCT02739997|Drug|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
45800752|NCT02283294|Drug|Warfarin|
45930016|NCT00128765|Behavioral|regular practice nurse review (monitoring controls)|protocol based on existing Guidelines: Dutch College of General Practitioners (NHG) Global Initiative for Chronic Obstructive Lung Disease (GOLD)
45597956|NCT02739997|Drug|metronidazole 500 mg|metronidazole 500 mg administered as an IV infusion
45651299|NCT05053789|Device|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
45800753|NCT02700425|Device|CRT Pacemaker|Cardiac Resynchronization Therapy (CRT) is the use of a pacemaker with two endocardial leads placed in the right atrium (RA) and right ventricle (RV). The third lead is traditionally placed in a tributary of the coronary sinus (CS) overlying the epicardial surface of the left ventricle (LV). Alternatively, the third lead may be positioned based on mapping of the common His bundle and actively fixed to achieve QRS normalization via direct His bundle capture.
45800754|NCT02701049|Other|Methods to collect SO/GI information in the ED|In Mode 1, all patients presenting to the ED will have SO/GI information collected verbally by the nurse, which is standard of care. In Mode 2, all patients presenting to the ED will have SO/GI information collected in a non-verbal manner, in which the registrar will ask them to complete an electronic form.
46072691|NCT02823730|Other|PCI with Synergy Stent|500 patients who have received the Synergy stent. Data will be mined from the DES registry database for the identified Synergy patients at the following time points, in-hospital and then at 1 year, 2 years, 3 years, and 4 years after percutaneous coronary intervention (PCI).
45930017|NCT00128765|Behavioral|care at initiative of the patient (usual GP care)|care at initiative of the patient (usual GP care)
45930018|NCT00068172|Drug|PI-88|
45930019|NCT00038376|Drug|Isotretinoin (Accutane)|0.5 mg/k (1.0 mg/k total) by mouth twice a day
45930020|NCT00038376|Drug|Interferon Alpha|Starting dose of 3 MU injected under skin once a day for 12 weeks.
45930021|NCT00128687|Behavioral|risk reduction|Participants receive intensive case management for CHD risk reduction for 15 months and then a maintenance program for a minimum of 12 months. Lifestyle modification was strongly emphasized as a critical component of achieving CHD prevention goals. Dietary management was emphasized, including recommendation of a low saturated fat (less than 7% of caloric intake), low cholesterol (< 150 mg/day), mainly plant-based diet with calorie restrictions for overweight/obese persons. Stress management and coping skills were emphasized, including a regular exercise regimen (≥ 30 minutes of moderate intensity on most days). Cigarette smokers were encouraged to join a stop smoking program.
45651300|NCT05053789|Device|Hylo-Vision|Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine).
45651301|NCT04829435|Drug|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration; It is a proprietary enzyme designed to degrade urate in the intestinal tract
45651302|NCT04829435|Drug|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
45651303|NCT05042635|Drug|Ixekizumab+Jueyin Granules|"Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times."
45651304|NCT05042635|Drug|Ixekizumab+Jueyin placebo Granules|"Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin placebo Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times."
45651305|NCT04815395|Drug|Oxytocin|Administration of oxytocin (24IU) orally
45651306|NCT04815395|Drug|Oxytocin|Administration of oxytocin (24IU) intranasally
45800755|NCT05648994|Biological|TCR-T cells|patients will be administration of TCR-T cells
45800756|NCT05648994|Drug|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regime
45930022|NCT00128570|Behavioral|behavioral dietary intervention|
45930023|NCT00128570|Other|educational intervention|
46072692|NCT02784210|Drug|Methylprednisolone|3 days of corticosteroids (intravenous methylprednisolone at 1000 mg/day
45597957|NCT04467931|Drug|ACEI/ARB|Veterans will be categorized as exposed to ACEI/ARB if they have one or more pharmacy fills for an oral ACEI or an ARB in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
45651307|NCT04815395|Drug|Placebo|Administration of placebo orally
45651308|NCT04819139|Other|Active Excersises|Active thumb exercises
45651309|NCT04819139|Other|Reeducation ADL|Reeducation in the activities daily life
45651310|NCT04819139|Other|Joint protection|Used of a thumb orthosis
45651311|NCT04819139|Other|Proprioception exercises|Specific proprioception exercises
45651312|NCT05034679|Biological|Vcinated|Patients who were vacinated.
45930024|NCT00128570|Other|internet-based intervention|
45930025|NCT00128570|Other|preventative dietary intervention|
45930026|NCT00128570|Procedure|evaluation of cancer risk factors|
45800757|NCT05648994|Drug|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regime
45930027|NCT00038415|Biological|CLL vaccine using DNA plasmid vector|
45930028|NCT00128531|Drug|leuprolide acetate|
46072693|NCT02784210|Drug|Prednisone|3 days of corticosteroids (oral prednisone at 1250 mg/day
45800758|NCT05648994|Drug|Albumin-bound paclitaxel|Part of the non-myeloablative lymphocyte-depleting preparative regime
45800759|NCT05648994|Drug|IL-2|Following cell infusion, the patient will be administration high-dose IL-2.
45930029|NCT00042159|Device|repetitive transcranial magnetic stimulation|1 Hertz stimulation for 16 minutes per day at 90% motor threshold, 5 sessions each to the two primary cortical targets
45930030|NCT00394511|Procedure|low-LET photon therapy|
45930031|NCT00038454|Drug|Hemolink (hemoglobin raffimer IV solution)|
45930032|NCT00128453|Drug|Colchicine (for 3 months)|Colchicine 0.5mg BID (patients>70Kg) or 0.5mg once daily
46072694|NCT02778685|Drug|Fulvestrant|
46072695|NCT02778685|Other|Laboratory Biomarker Analysis|Correlative studies
46072696|NCT02778685|Drug|Letrozole|Given PO
46072697|NCT02778685|Drug|Palbociclib|Given PO
46072698|NCT02778685|Biological|Pembrolizumab|Given IV
45930033|NCT00128453|Drug|Placebo|placebo
45930034|NCT00042198|Behavioral|Cognitive behavior therapy|Up to 12 weekly, individual, hour-long sessions
45930035|NCT00042198|Behavioral|Supportive Stress Management|Up to 12 weekly, individual, hour-long sessions, focusing on application of relaxation and other stress management techniques to depressogenic stressors
45930036|NCT00128414|Drug|Colchicine (for 6 months)|colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 1 month in patients ≥70 kg, and halved doses for patients <70 kg or intolerant to the highest dose.
45800760|NCT04869384|Other|Reminders and feedback to improve adherence|Subjects will receive reminders and feedback to improve their adherence.
45651313|NCT03096691|Device|cervical pessary|Silicone rings known as arabin pessary are used to support the cervix in women with a sonographic short cervix.
45930037|NCT00128414|Drug|Placebo|Tablets identical in colour, shape, and taste were provided in blister packs.
45930038|NCT00038493|Drug|Temozolomide and SCH66336|
45800761|NCT04869384|Other|No reminders and feedback to improve adherence|Subjects will not receive reminders and feedback to improve their adherence.
45930039|NCT00128375|Behavioral|Financial incentives|
45930040|NCT00038532|Drug|Amprenavir/ritonavir|
45930041|NCT00038532|Drug|Saquinavir/ritonavir|
45451026|NCT05262634|Other|Data collection (laboratory and obstetric results)|"Maternal data: age, pregnancy, parity, singleton or multiple pregnancy, BMI, obstetric history data, and ethnicity.~Laboratory chemical results: hemoglobin (Hb), number of erythrocytes, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), number of hypochromic erythrocytes (HRC), erythrocyte distribution width (EBW), ferritin, C reactive protein (CRP).~Maternal pregnancy outcomes and complications: Hb before and after delivery, mode of delivery, placenta abruption, preeclampsia/eclampsia, gestational diabetes, gestational cholestasis, pregnancy-induced hypertension, bacteriuria or urinary tract infections, peripartum and postpartum hemorrhage, puerperal infections, uterine subinvolution.~Perinatal outcomes: gestational age, birth weight, intrauterine growth retardation, preterm birth, macrosomia, premature rupture of membranes, Apgar score, intrauterine fetal death, pH values, admission to neonatology"
45451027|NCT02221726|Drug|JNJ-35684-AAA-023: Size 1; small patch|Placebo (matched to Fentanyl transdermal delivery device system [TDDS]) JNJ-35685-AAA-G-023 TDDS, 5.5 centimeter square (cm^2) will be applied vertically to 1 side of the paraspinal region, replicated 3 times, and worn for 72 hours.
45651314|NCT03096535|Procedure|Cooling|Individualized cooling protocol.
45651315|NCT03096535|Procedure|Thermoneutral|Thermoneutral control day.
45651316|NCT05034445|Diagnostic Test|Next generation sequencing|Extract DNA from sputum sample, minimum DNA amount should be over 50ng.
45651317|NCT05042479|Other|Usual distraction and pain prevention techniques.|"For the first painful procedure, the child will benefit usual distraction and pain prevention techniques.Pain prevention and management techniques commonly used in the conduct of care:~Application of a patch or anaesthetic cream 1 hour before the treatment~Vigilant sedation using a premedication for lumbar punctures: Midazolam /Nalbuphine/Hydroxyzine/Morphine.~Apart from care using VR, MEOPA can be given to the child for all assessed care on prescription.~Apart from care using VR, the usual distraction techniques are left to the patient's choice (electronic tablet, smartphone, games, songs...)~The presence of the parents"
45651318|NCT05042479|Other|Virtual reality|For the 2nd painful procedure, the child will use a VR (virtual reality) headset as well as pain prevention techniques (excluding oxygen-nitrous oxide mixtures). The child will choose the application he/she wishes to use according to his/her age.
45651319|NCT05042479|Other|Choice between usual distraction or virtual reality|"For the 3rd painful procedure, the child will choose his/her favorite technique between :~Usual distraction and pain prevention techniques or virtual reality"
45651320|NCT05034211|Procedure|Programmed intermittent bolus epidural|one arm will receive programmed intermittent boluses of local anesthetic via the epidural catheter on fixed time intervals. Standard 27G Tuohy needle epidural set with epidural catheter insertion on L2-L3 site, with the patient either sitting or in the lateral decubitus position will be used. Local injection with 6 ml lidocaine 2% will be performed before the insertion of the epidural needle
45800762|NCT04869306|Device|Hyaluronic acid gel|After lower third molar removal, the test group 1 will additionally receive hyaluronic acid gel prior to wound closure.
45800763|NCT04869306|Device|Hyaluronic acid gel + carrier|After lower third molar removal, the test group 2 will additionally receive hyaluronic acid gel with a collagen carrier prior to wound closure.
45800764|NCT02702921|Device|Surgeon's 'standard of care' stapler|
45800765|NCT02702921|Device|Ethicon Powered Vascular Stapler|
45800766|NCT05648760|Behavioral|Simulation training|Participants randomized to the simulation condition received simulation training based on a standard training of how to communicate bad news to patients
45800767|NCT05648682|Other|Salin|Patients were told that they should gargle using approximately 2 tablespoons of the solution given for each use. SF solution was obtained from the medical company as 500 ml separately for each patient.
45930042|NCT00038532|Drug|Efavirenz|
45800768|NCT05648682|Other|Sodium bicarbonate|Patients were told that they should gargle using approximately two tablespoons of the solution given for each use. The 500 ml distilled water bottle to be used for the SB solution was obtained from the medical company, separately for each patient.
45800769|NCT05648682|Other|Thyme honey|Patients were told that they should gargle using approximately 2 tablespoons of the solution given for each use.
45930043|NCT00128336|Behavioral|Lifestyle: diet and exercise intervention|
45930044|NCT00038571|Drug|PS341 (Bortezomib)|1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.
45930045|NCT05770804|Behavioral|Face to face education|Face-to-face training was provided and supported by booklets.
45930046|NCT05770791|Dietary Supplement|Black Seed ( Nigella Sativa)|Intervention will be given once a day for 1 month, total 30 days Data will be collected at baseline and at the end of the intervention at 30th day
45930047|NCT05770791|Dietary Supplement|Cumin Seed (Cuminum Cyminum)|Intervention will be given once a day for 1 month, total 30 days Data will be collected at baseline and at the end of the intervention at 30th day
45930048|NCT05770778|Other|Inclined Backwalk|They will receive inclined backward treadmill gait training exercise for thirty minutes with 2 interval break for 5min every 10 minutes for three times per week over three successive months with a specifically designed physical therapy program according to child need for one hour for each child, three times weekly, over three months.
45651321|NCT05034211|Procedure|Provider administered analgesia on patient request|one arm will receive bolus of local anesthetic via the catheter upon patient request. Standard 27G Tuohy needle epidural set with epidural catheter insertion on L2-L3 site, with the patient either sitting or in the lateral decubitus position will be used. Local injection with 6 ml lidocaine 2% will be performed before the insertion of the epidural needle
45651322|NCT02599961|Drug|UX007|UX007 is a liquid intended for oral (PO) administration.
45651323|NCT03096301|Device|Low-intensity laser|Laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2
45651324|NCT03096301|Device|occlusal plates|"The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).~Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.~Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment"
45800770|NCT05648682|Other|Control|The patients continued to use the antifungal solution containing the active ingredient nystatin, which was prescribed routinely in the clinical procedure, 3 times a day.
45930049|NCT05770778|Other|Knee Walk|They will receive kneel walk exercise programme for thirty minutes with 2 interval break for 5min every 10 minutes for three times per week over three successive months with a specifically designed physical therapy program according to child need for one hour for each child , three times weekly, over three months.
45930050|NCT05770752|Procedure|Elevated pressure ventilation|Elevated pressure ventilation is defined as a raise in PIP and PEEP by 10 cmH2O from each patients original pressure setting, although never higher than a PIP of 30 cmH2O.
45930051|NCT05770739|Behavioral|Perioperative accelerated rehabilitation surgical measures|To apply accelerated rehabilitation surgery to children with biliary dilatation during perioperative period
45930052|NCT05770739|Behavioral|Traditional treatment|To provide traditional perioperative treatment for children with cholangiectasia
45930053|NCT05770687|Drug|SGLT2 inhibitor|Patients started on SGLT2 inhibitors after PCI for AMI
45930054|NCT05770674|Drug|1 Month vs. 12 Months DAPT|"Dual antiplatelet therapy with aspirin plus clopidogrel will be given for the following period after PCI according to patient allocation~1 Month following PCI, followed by clopidogrel monotherapy~12 Months following PCI"
45930055|NCT05770648|Device|Transcatheter Annuloplasty|Under the guidance of ultrasound, the transcatheter tricuspid ring forming system accurately reaches the designated position of the tricuspid valve region through the jugular vein and superior vena cava approach. The expanded tricuspid ring tissue is clammed together with the clamping parts and anchor parts, and the circumference of the tricuspid ring is reduced, thus reducing the area of the opening of the tricuspid valve that cannot be closed originally, and achieving the purpose of minimally invasive treatment of tricuspid regurgitation.
45451028|NCT02221726|Drug|JNJ-35684-AAA-023: Size 2; large patch|Placebo (matched to Fentanyl transdermal delivery device system [TDDS]) JNJ-35685-AAA-G-023 TDDS, 44 cm^2 (Size 1; small patch) will be applied vertically to other side of the paraspinal region, replicated 3 times, and worn for 72 hours.
45651325|NCT03096301|Device|Placebo|For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
45800771|NCT02702999|Device|Clinically-indicated ultrasound|Routine third trimester care with clinically-indicated ultrasound (control)
45800772|NCT02702999|Device|Serial third trimester ultrasound|Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
45451029|NCT02221804|Behavioral|14 days of voluntary step count reduction to no more than 1500 steps/day.|
45800773|NCT02268864|Drug|Simeprevir|Simeprevir 150 mg oral capsule will be administered once daily for 12 or 24 weeks.
45451030|NCT05139628|Diagnostic Test|microbiological identification of samples (skin and blood samples)|"Samples will be plated on blood culture plates and will be confirmed biochemically.~Complete Bacteriological diagnosis will be done. The TTP of each BC bottle will be recorded"
45800774|NCT02268864|Drug|Daclatasvir|Daclatasvir 60 mg oral tablet will be administered once daily for 12 or 24 weeks.
45800775|NCT02268786|Other|Preimplantation Genetic Screening by NGS|The VeriSeq PGS takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for selection of euploid embryos.
45800776|NCT04859946|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
45930056|NCT05770648|Other|The guidelines guide medication|The guidelines guide medication
45930057|NCT05770635|Device|Embosphere and chemotherapy drug|chemotherapeutic drug + embolic Embosphere;Iodide is selected according to the subject's condition
45930058|NCT05770635|Device|Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug|chemotherapy drug+Polyvinyl alcohol embolization microspheres (Huihe Medical);Iodide is selected according to the subject's condition
45930059|NCT05770557|Behavioral|survey|administration of a survey among healthcare workers
45930060|NCT05770531|Procedure|Biospecimen Collection|Undergo blood sample collection for banking
45930061|NCT05770531|Procedure|Computed Tomography|Undergo CT
45930062|NCT05770531|Procedure|Magnetic Resonance Imaging|Undergo MRI
46072699|NCT02778165|Other|MyCaRe (my cardiac recovery Android application)|Android application & Fitbit Inspire 2 activity monitor
45451031|NCT02221960|Biological|MEDI6383|Subjects will receive MEDI6383 until disease progression or adverse event.
45930063|NCT05770531|Procedure|Biospecimen Collection|Undergo blood sample collection for ctDNA evaluation
45800777|NCT04859946|Drug|Busulfan|Given IV
45651326|NCT04829513|Other|kinesio taping|In kinesiology taping with the inhibition method, an I-shaped tape of 15-20 cm in length will be applied on the sacroiliac joint on both sides without stretching the ends with 50% stretching in the middle. In addition, a 25-30 cm long I band will be applied over the right spina iliaca posterior superior, towards the left spina iliaca posterior superior. In the facia correction technique, 2 bands with no cut ends, a 10-15 cm web-shaped band divided into 4 or 5 parts with a width of 1-15 cm will be applied cross over the sacroiliac joint, without stretching the ends with 50% stretching in the middle.
45651327|NCT05033977|Other|Exercise (center-based)|Exercise therapy with a physical therapist in a clinic.
45651328|NCT05033977|Other|Exercise (home-based)|Patients did exercises at home every day and 3 times per day.
45800778|NCT04859946|Drug|Cyclophosphamide|Given IV
45800779|NCT04859946|Drug|Fludarabine|Given IV
45651329|NCT05034055|Drug|atezolizumab / tiragolumab|All patients will receive 1200mg atezolizumab administered by IV infusion on Day 1 of each 21-day cycle after completion of stereotactic body radiotherapy (SBRT) for 21(+5) days. No escalations or reductions in the dose of the investigational product will be allowed.Following the administration of atezolizumab, patients will receive 600mg tiragolumab administered by IV infusion on Day 1 of each 21-day cycle. The tiragolumab dose is fixed and is not dependent on body weight.
45651330|NCT05617703|Drug|Glass Ionomer with Advanced Glass Hybrid Technology (Equia forte HT fil, GC, Japan)|Advanced Glass Hybrid technology (AGH) was achieved through introduction of ultra-fine highly reactive glass and high-molecular weight polyacrylic acid powders within conventional glass using particles and fillers with close refractive indexes
45651331|NCT03095365|Other|Dry needling|Insertion of solid filament needles in the muscle
45800780|NCT04859946|Drug|Itacitinib|Given PO
45930064|NCT05770531|Biological|Sacituzumab Govitecan|Given by IV
45451032|NCT02221960|Biological|MEDI6383 and MEDI4736|Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event.
45451033|NCT02220010|Device|Pancreatic stent|The plastic stent is introduced in the pancreatic duct by a duodenoscope
45800781|NCT04859946|Drug|Tacrolimus|Given IV or PO
45651332|NCT03095365|Other|Pain neuroscience education|Explanation of the functioning of the central nervous system, the differences between acute pain and chronic pain and the importance of thoughts and beliefs in the processing and chronification of pain
45651333|NCT03095365|Other|Conventional treatment|Electrotherapy: Transcutaneous electrical nerve stimulation and microwaves
45651334|NCT04829201|Procedure|functional septorhinoplasty or oropharyngeal/orthognathic surgery|obtain pre- and postoperative data in order to describe the specific changes in airflow and upper soft tissue behavior that causes sleep apnea
45651335|NCT03096613|Drug|Levothyroxine|Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
45651336|NCT05042245|Drug|Ornithine aspartate granule|Ornithine aspartate granules in the experimental arm.
45800782|NCT04859946|Drug|Thiotepa|Given IV
45651337|NCT05042245|Drug|Silymarin capsule|Silymarin capsules in the active comparator arm.
45800783|NCT02703779|Drug|Bortezomib|Bortezomib will be given to Group B participants by injection under the skin 11 days and 8 days before stem cell collection.
45800784|NCT02703779|Drug|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.
45800785|NCT02703779|Drug|Mozobil|Mozobil will be given to all participants by injection under the skin only if needed per Investigator.
45800786|NCT04738955|Drug|Micafungin Sodium|micafungin sodium ≥ 100, <200mg/time, once a day, intravenous drip. Low dose group
45800787|NCT02268396|Drug|Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler|GFF MDI administered as 2 inhalations BID
45800788|NCT04182113|Device|1 Hz rTMS|Subjects will receive one session of low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of MT, for a total of 1200 pulses.
45800789|NCT04182113|Device|20 Hz rTMS|Subjects will receive one session of high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minutes.
45930065|NCT05770505|Behavioral|Exercise training using an e-health tool|Experimental: Exercise training will be guided by suing the e-health tool MIA with the possibility for communication and messages between the participant and study personnel The participants will wearables that record heart rate. Participants will be encourage to achieve at least 100 Personal Activity Intelligence (PAI) equivalents per week Control: No follow-up
45930066|NCT05770492|Diagnostic Test|anterior segment optical coherence tomography|Two different optical systems (MS-39, Costruzione Strumenti Oftalmici Italy; Anterion optical coherence tomographer, Heidelberg Engineering) will be used for acquisition of cross-sectional scans. Radial scan patterns will be used for acquisition.
46072700|NCT02740985|Drug|AZD4635|AZD4635 will be administered orally as a nanosuspension or capsule on a continuous schedule in Arms A, B, C, D, E, F, G, H, I, J, K, KD, L, AA, and EA. The AZD4635 nanoparticle drug product will be constituted extemporaneously as an oral suspension by the patient immediately prior to dosing. In Arms CA, CB, and CC AZD4635 will be administered as 75 mg or 50 mg capsules. Additionally, in Arm CA, AZD4635 will also be administered at 150 mg and 200 mg, or a lower dose of 125 mg or 100 mg may be given.
46072701|NCT02740985|Drug|Durvalumab|Durvalumab will be administered by intravenous infusion once every 4 weeks. Durvalumab should be reconstituted using aseptic techniques with sterile water for injection. The reconstituted solution will be diluted with 0.9% (w/v) saline prior to IV infusion.
46072702|NCT02740985|Drug|Abiraterone Acetate|"Abiraterone acetate 1000 mg PO QD will be given with prednisone BID. The patient must receive abiraterone/prednisone according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary abiraterone/ prednisone dose modifications may follow institutional standard practice.~Abiraterone acetate is supplied in 250 mg tablets."
45930067|NCT05770479|Behavioral|Motivationally-Enhanced Compensatory Cognitive Training (ME-CCT) Booster Modules|ME-CCT is a traditionally a manualized group-based behavioral intervention (8 weeks, 2 hours per week) designed to improve cognitive and everyday functioning in patients with MCI. Our booster modules will be shortened and distilled from ME-CCT using the IM Adapt protocol (and thus will not be new information but rather 'reminder' content) for a personalized four-session sequence of booster training targeted toward specific everyday functional needs of individual participants.
45930068|NCT05770479|Other|Treatment As Usual|Treatment for MCI is generally managed by Primary Care or Neurology. Participants will continue to receive their usual care with their current providers. With no effective pharmacological treatment known for persons with MCI, providers tend to focus on encouraging a healthy lifestyle, prevention and management of modifiable risk factors for cognitive impairment, and treatment of behavioral and psychiatric symptoms.
45930069|NCT05770466|Drug|P1101 (Ropeginterferon alfa-2b)|"Name: P1101 (Ropeginterferon alfa-2b)~Dosage form: pre-filled syringe~Strength: A single dose of 250 mcg/0.5 mL~Dosage and administration: 250 mcg per subcutaneous injection~Mechanism of action (if known): Interferon work by binding to specific membrane receptors on the cell surface which in turn induce a complex sequence of intracellular events. These events include the induction of particular enzymes, suppression of cell proliferation, inhibition of virus replication in virus infected cells and immunomodulating activities.~Pharmacological category: Antineoplastic and immunomodulating agents/ Immunostimulants/ Cytokines"
45930070|NCT05770466|Procedure|SOC|SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.
45451034|NCT05262478|Device|Alpha-D CDP|Alpha-D cervical disc prosthesis was developed jointly by the Spine Center of Koç University Faculty of Medicine and Toledo University Bioengineering Department. It was designed as a single unit to ensure user-friendly administration for surgeons, and it was designed and manufactured to reproduce the movements of the normal cervical movement segment.
45451035|NCT02220088|Procedure|TAI of FOLFOX|Retreatment with TAI: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
45451036|NCT02220088|Drug|Sorafenib|Accept sorafenib.
45451037|NCT05097040|Behavioral|acceptance and commitment therapy (ACT)|The intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 6 weeks through Zoom videoconferencing. Also, a one-time 1-hour booster session will be provided at 1-month follow-up to facilitate the maintenance of treatment effects.
45651338|NCT05042245|Drug|Silymarin capsule simulant|Silymarin capsule simulant in the experimental arm.
45651339|NCT05042245|Drug|Ornithine aspartate granule simulant|Ornithine aspartate granule simulant in the active comparator arm.
45651340|NCT04427657|Procedure|autologous microfragmented lipoaspirate tissue (Lipogems®).|patient in supine position. A double contemporary operating fields is made under sedation. During arthroscopic debridement is made an injection of local anesthetic at the dermal level with a subcutaneous infiltration of Klein solution. The plastic surgeon wait for about 5 minutes for vasoconstriction and then start with liposuction of about 60 ml of adipose tissue. Then lipoaspirate was processed with Lipogems® technique that consist in a mechanical fragmentation, physiological washing and filter passage of the lipoaspirate. A volume of 8-9 ml of microfragmented adipose tissue was injected intra-articulary after arthroscopic debridement.
45651341|NCT04427657|Procedure|arthroscopic debridment|patient in supine position. Under sedation is perform an arthroscopic debridement
45651342|NCT03035669|Behavioral|Mindfulness group|8 week program
45651343|NCT03035669|Behavioral|Reading group|8 week program
45651344|NCT03095209|Drug|Carboplatin|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
45651345|NCT03095209|Drug|Paclitaxel|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
45800790|NCT04182113|Device|Sham|Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
45451038|NCT02220166|Dietary Supplement|Triticum monococcum|
45651346|NCT03095209|Radiation|Radiation Therapy|The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer.
45800791|NCT04859400|Dietary Supplement|Whey protein supplement high in leucine and β-hydroxy-β-methylbutyrate (HMB)|The whey protein supplement high in leucine and β-hydroxy-β-methylbutyrate (HMB) is ingested once daily, preferably either in the evening before going to bed or within two hours after having finished exercising.
45800792|NCT04859400|Behavioral|Standardized nutritional program|During at least two personal counseling meetings with a dietician, the patient's diet is assessed and individual nutritional interventions - based on the personal needs and individual preferences of the patient - are developed. The overall goal is to optimize protein an energy intake.
45800793|NCT04859400|Behavioral|Standardized exercise program|In at least two personal counseling meetings with a physiotherapist, the patient's individual training plan is compiled and agreed upon (mainly including strength, endurance and balance exercises). The patient then exercises at home and records the trainings with the app.
45930071|NCT05770401|Behavioral|Internet-Behavioral Cough Suppression Therapy|Participants will access training modules to learn behavioral techniques and will implement them in daily life over a four-week period.
45930072|NCT05770401|Behavioral|Sham Treatment|Participants will access training modules to learn behavioral techniques and will implement them in daily life over a four-week period.
45451039|NCT02220244|Drug|MD1003 100mg capsule|
45451040|NCT02222038|Other|skin biopsy|
45451041|NCT02222116|Device|MGuard Prime|
45451042|NCT02222116|Device|Control BMS DES|
45451043|NCT02205736|Other|Breast Health Education|Small group breast health educational sessions for Latino women in home setting.
45451044|NCT02220400|Drug|Ketamine|
45930073|NCT05770388|Device|App Take Care of Your Mood|The app provides psychoeducational information, contains several thematic modules (mindfulness, emotional regulation, healthy lifestyle habits, safety plan for crisis management, among others), allows mood monitoring, contains motivational messages and videos aimed at promoting help-seeking in mental health, and information on available support services.
45930074|NCT05770388|Behavioral|Reminder messages and counseling|Participants receive reminder messages (by email and chat) encouraging them to use the app and to request a counseling session (via phone call, videoconference or chat) with a clinical psychologist if they think it is necessary.
45930075|NCT05770323|Diagnostic Test|Uric acid level|Uric acid will be measured for all Patients with acute coronary syndrome and result will be analysed
45930076|NCT05770310|Drug|JS015|Patient receives specific dose of JS015. The administration method of JS015 is intravenous infusion.
45651347|NCT05617547|Diagnostic Test|Pulse Oximeter (Massimo)|The Massimo LNCS (low noise cabled sensors) pulse oximeter will be used to estimate the oxygen saturation and compared to the gold standard, the arterial oxygen saturation in the blood as measured by co-oximetry. The pulse oximeters is FDA cleared for this purpose so patients will not be exposed to any interventions that are not standard of care.
45930077|NCT05770284|Other|12 weeks exercise|12 weeks exercise
45451045|NCT02205892|Drug|Lupeol|Patients are supposed to apply 2% lupeol cream to one side of their face two times per day for 4 weeks. Application side is randomly determined.
45930078|NCT05770284|Other|Standard Medical Treatment|Standard Medical Treatment
45930079|NCT05770206|Device|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|Subjects in the experimental group will receive treatment by using Hydrogen-Oxygen Generator with Nebulizer (manufactured by Shanghai Asclepius Meditec Co., Ltd., flow rate: 3L/min) combined with conventional basic supportive treatment (symptomatic support treatment determined by the investigator based on the condition of the subjects);
45800794|NCT04176575|Other|Acupuncture|Acupuncture involves inserting thin needles into precise points on the body, known as acupuncture points, for therapeutic effect. Acupuncture will be provided by a licensed acupuncturist utilizing Dr. Tan's Balancing Method.
45451046|NCT02205892|Drug|Placebo vehicle|Patients are supposed to apply their control vehicle cream two times per day to the other side of their face for 4 weeks. Application side is randomly determined.
45930080|NCT05770206|Device|OLO-1 Medical Molecular Sieve Oxygen Generator|subjects in the control group will receive treatment by using Medical Molecular Sieve Oxygen Generator (manufactured by Shanghai Ouliang Medical Devices Co., Ltd., flow rate: 3L/min, provided by the sponsor) combined with conventional basic supportive treatment (same with that in the test group).
45930081|NCT05770141|Procedure|laser hemorrhoidoplasty|A skin incision of 3 mm was made about 1 to 1.5 cm of distance from the anal verge at the base of each hemorrhoidal node. The probe was driven through the incision in the submucosal tissue until reaching the area underneath the distal rectal mucosa. Then, ten to twelve effective pulses (adjusted to respective node dimensions) were fired. Half of them were fired in the submucosal tissue, the others in the intra-nodal compartment determining the shrinkage of the hemorrhoidal piles. The anal wounds were left open. At the end of the procedure an anal tampon was positioned.
45930082|NCT05770141|Procedure|open surgical hemorrhoidectomy|The anodermal wedge was incised, eventually removing external fibrosis and/or skin tags when present. Upward dissection started at this level with en-bloc excision of mucosal and submucosal layers from the underlying internal anal sphincter up to the anorectal ring. A compressive haemostatic sponge was left in place for 12-24 hours.
45930083|NCT05770128|Procedure|laparoscope|subserosal manipulation of gallbladder with laparoscope .
45930084|NCT05770115|Procedure|Vicryl 1|Double layer closure with split thickness with vicryl 1, in continuous, non-locked, 1 cm apart sutures.
45930085|NCT05770115|Procedure|Vicryl 2/0|Double layer closure with split thickness with vicryl 2/0, in continuous, non-locked, 1 cm apart sutures.
45930086|NCT05770089|Other|Adapted Physical Activity (APA)|A 8-weeks program of APA (2x1hour per week) via videoconferencing composed of resistance training and yoga.
45930087|NCT05770063|Dietary Supplement|amino acid tablet|multiple essential amino acids supplements
45930088|NCT05770050|Other|No intervention|No intervention
45451047|NCT05228626|Drug|COVIDEX|COVIDEXTm is a prepared plant extract of Zanthoxylum and Warbugia species that is reported to have antiviral agents, one of which berberine with in vitro activity against SARS COV-2, the causative agent for COVID-19 disease. Others constituents in COVIDEX include alkaloids, sponins, reducing sugars and acidic compounds. IT is given either 2 drops nasally plus 6 drops orally or 6 oral drops only of COVIDEXTm three times daily for 7 days.
45451048|NCT02924818|Other|Clinical assessment|
45451049|NCT02924818|Behavioral|questionnaires|
45451050|NCT02924818|Other|pulmonary function test|
45800795|NCT05648526|Drug|ACTH4-10Pro8-Gly9-Pro10|ACTH4-10Pro8-Gly9-Pro10 also has neuromodulator characteristics to function as a neuroprotector in inhibiting the apoptotic process. Modulation by ACTH4-10Pro8-Gly9-Pro10 will increase the levels of BDNF thereby inhibiting the process of apoptosis
45800796|NCT05648526|Drug|Ketamine|negative-positive control (ketamine 40 mg/kg BW subcutaneously)
45800797|NCT04170725|Other|Patient and Healthy Volunteers training protocol|Patients and Healthy Volunteers will undergo a 14-day endurance training protocol. No study drugs will be administered. Patients and Healthy Volunteers will be instructed regarding their training protocol. Training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 after the first examination day. Patients and Healthy Volunteers will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.
45800798|NCT02268084|Device|Magnetic EEG/ECG-guided Resonance Therapy|A coil delivers a pulsed magnetic field to the cortex of the brain
45651348|NCT05034133|Drug|Durvalumab|Durvalumab (IV 1000mg on day 1) with chemotherapy (Etoposide and Cisplatin) for 6 cycles
45651349|NCT04828967|Other|Hypnosis|Hypnosis is added to the conventional group
45651350|NCT03096379|Diagnostic Test|Magnetic resonance imaging|Enterography performed via magnetic resonance imaging
45800799|NCT02268084|Device|Sham|Sham coil simulates behavior of the intervention magnetic coil without applying the magnetic field
45930089|NCT05770024|Other|imaging tests|X-ray radiography (RX); computer tomography (CT); magnetic resonance (MR); positron emission tomography (PET); single photon emission computed tomography (SPECT)
45930090|NCT05770011|Device|intraoral scanner of nonsplinted scan bodies|scanning of non splinted scan bodies
45930091|NCT05770011|Device|impression material|conventional recording
46072703|NCT02740985|Drug|Enzalutamide|"Enzalutamide 160 mg PO QD will be dosed per the approved package insert. The patient must receive enzalutamide according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary enzalutamide dose modifications may follow institutional standard practice.~Enzalutamide is supplied as 40 mg soft gelatin capsules."
46072704|NCT02740985|Drug|Oleclumab|Oleclumab 1500 mg will be given by IV infusion on Days 1 and 15 of each cycle.
46072705|NCT02740985|Drug|Docetaxel|"Patients in Cohort CC will receive docetaxel 75 mg/m² by IV infusion according to institutional standards of practice on Day 1 of each treatment cycle. If a patient's body surface area is greater than 2.2 m², the docetaxel dose will be adjusted to a body surface area of 2.2 m².~The patient should be pre-medicated with oral dexamethasone 8 mg (or equivalent) twice daily starting the day prior to treatment for a total of 3 days, or according to institutional standards of practice."
46072706|NCT02728531|Drug|Bendamustine|
46072707|NCT02728531|Drug|Rituximab|
45451051|NCT02924818|Biological|blood test|
45651351|NCT04814693|Device|EndoRotor® System (Interscope, Inc., Northbridge, MA USA),|The EndoRotor System is intended for use in endoscopic procedures to resect and remove necrotic debris during DEN for WON. DEN with the EndoRotor System (study device) is considered to be standard of care therapy for patients with WON and not investigational.
45451052|NCT02924818|Biological|microbiology|
45451053|NCT02924818|Biological|histology|
45451054|NCT02924818|Other|imaging|
45451055|NCT02224768|Drug|Ipilimumab|
45451056|NCT05262166|Drug|INTRATHECAL dexmedetomidine INJECTION|intrathecal bolus of 3ml bupivacaine 0.5% (15mg) plus 10 micrograms dexmedetomidine at 2-3 or 3-4 spinal level.
45651352|NCT04814693|Procedure|Conventional endoscopic devices (according to standards of care)|Endoscopic devices used to perform conventional DEN will be chosen according to standard of care and Investigator preference.
45651353|NCT03096457|Drug|Paromomycin Sulfate|topical application 2 times a day during 20 days
45651354|NCT03096457|Drug|Pentamidine Isethionate|3 Intralesional injections at days 1,3 and 5
45451057|NCT02205970|Device|TENS|In the active group there was only one application with interactive TENS (n = 42) with the final parameters of frequency between 90 and 150pps and pulse duration between 300 and 400μs and intensity level of tolerance, lasting 35 minutes.
45800800|NCT05333783|Behavioral|Augmented Reality Exposure Therapy Based on ExposXR software|The ExposXR software is developed by The Stress Trauma Anxiety Research Clinic at Wayne State University, U.S.A. When it is used inside a Augmented Reality hardware such as Hololens, it renders artificial phobic objects into what the participants see. The treatment consist of a one-session treatment for cynophobia using Augmented Reality.
45800801|NCT05561478|Device|Implantation of Synthesis Plus IOL (control device)|Synthesis Plus IOLs are indicated for primary implantation for the visual correction of aphakia in adult patients.
45930092|NCT05770011|Device|intraoral scanner of splinted scan bodies|scanning of splinted scan bodies
45451058|NCT02205970|Device|TENS (sham)|In the placebo group, there was a simulated single application, following the same procedures as the active TENS group, also for 35 minutes.
45451059|NCT02225002|Drug|CP-870,893|
45451060|NCT02206126|Behavioral|Energy Restriction|The energy restriction group was instructed to follow an energy-restricted diet (-800 kcal/day).
45651355|NCT03096457|Other|Placebo|topical application 2 times a day during 20 days
45651356|NCT03096223|Drug|KHK4083|IV administration
46072708|NCT02728531|Drug|Cytarabine|
46072709|NCT02728531|Drug|Pegfilgrastim|
46072710|NCT02728531|Procedure|Leukapheresis|
46072711|NCT02728531|Drug|Filgrastim|
45651357|NCT05617469|Other|develop and visualized a radio-clinical signatures from pretreatment oversampled CT images|develop and visualized a radio-clinical signatures from pretreatment oversampled CT images to predict the neoadjuvant chemotherapy response and prognosis
45651358|NCT03096145|Behavioral|Telephone counseling 1 session|1 call coaching session for nonsmokers that will be piloted and adapted in this study
45651359|NCT03096145|Behavioral|Mobile texting|nonsmokers will receive 3-5 text messages for 4 weeks
45651360|NCT03096145|Behavioral|Health incentive|Smokers receive a $25 gift card if they call the quitline
45651361|NCT04814303|Procedure|Intrathecal morphine|After applying standard monitoring of pulse oximetry, ECG, NIBP; while the patient in the sitting position following complete sterile aseptic condition after sterilization bovine bethidine spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral levels using a 25- gauge Whitacre needle. Intrathecal morphine 150 μg will be added to patients of both groups. Supplemental oxygen will be administered via a simple face mask.
45930093|NCT05769998|Behavioral|Acceptance and Commitment-based treatment|The ACT-based group intervention includes four 1-hour group sessions over two weeks. The treatment manual was developed by the authors of this study following the ACT framework and adapting materials and resources from ACT-based treatments developed for other settings. The focus of the intervention is to provide patients with pain education specific for patients who underwent TKA and to promote psychological flexibility. Each session employs experiential exercises, including mindfulness meditation, and metaphors addressing the core components of ACT.
46072712|NCT02728531|Procedure|Autologous stem cell transplant|
45451061|NCT02206204|Drug|selexipag|
45451062|NCT02206204|Drug|placebo for selexipag|
45451063|NCT02206204|Drug|moxifloxacin|
45451064|NCT02206204|Drug|moxifloxacin-matching placebo|
45451065|NCT02230930|Drug|Apomorphine 0.25% (2.5mg/ml)|Apomorphine 0.5% (5mg/ml) will be diluted to 0.25% (2.5mg/ml) by the addition of the same volume physiological saline (NaCl 0.9%).
45451066|NCT02230930|Device|Massage with a spiky ball|Each patient will massage skin reactions with a spiky ball 3 times a day for 2 minutes.
45451067|NCT02230930|Drug|Hydrocortisone cream 1%|Hydrocortisone cream 1% (1mg/g) will be administered on each nodule one time a day
45930094|NCT05769998|Other|Treatment as usual|Standard pharmacotherapy and physical exercise plan provided to all the patients in the rehabilitation unit.
45930095|NCT05769985|Other|Caregiver's responses and patient satisfaction|Interaction between caregivers' responses and patient satisfaction about those responses
45930096|NCT05769972|Device|Immersive Virtual Reality (Parkinson's disease)|This tool involves placing sensors in the space where it will be used, wearing virtual reality glasses, and using controllers to create realistic fictional spaces and interact with them. The program used for the study consists of an interface and a set of tasks designed specifically for the type of cognitive process deficits related to frontal function (executive functions) that are predominantly presented by patients with cognitive impairment associated with Parkinson's disease. This is due to the effect of the disease's pathophysiology on a series of brain circuits and structures that range from the basal ganglia to the frontal lobe. The affected functions correspond to the individual's ability to plan, sequence, organize, make decisions, be flexible, abstract, conceptualize, inhibit, among others.
45930097|NCT05769972|Device|Computer-based cognitive rehabilitation (Parkinson's disease)|This consists of a 24-week computerized cognitive stimulation program using the NeuronUp software. The intervention includes a limited number of tasks developed ad hoc by NeuronUp and the researchers specifically aimed at stimulating the cognitive domains typically affected in movement disorders. These are cognitive processes mostly ascribed to frontal function, as well as other less prevalent but equally disabling processes mainly associated with basal ganglia and fronto-striatal circuitry, such as executive functions, attention and working memory, language, processing speed, and social cognition. Thus, the programs are the same for PD and HD, although the parameters of the number of errors, level of difficulty, and number of correct answers required to advance to the next level have been adjusted to be more demanding in PD and less in HD, with the aim of customizing this type of intervention to the clinical characteristics of each disease.
46072713|NCT02723331|Drug|Nab-paclitaxel and gemcitabine for R-PDAC Patients|Nab-paclitaxel and gemcitabine, for R-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
45651362|NCT04814303|Procedure|Adductor Canal block|The block will be performed in the mid adductor canal to block both the saphenous and the nerve to vastus medialis. After skin infiltration with 1 to 2 mL of 2% lidocaine, an 80-mm, 22-gauge, short-bevel echogenic needle is advanced in plane with the ultrasound beam in an anterior-to-posterior direction until the tip is located within the adductor canal deep to the vastoadductor membrane. After negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection plane. The study solution will be injected within the canal adjacent to the femoral artery. Patients in group 1 received 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine and 4 mg dexamethasone.
45651363|NCT04814303|Procedure|Peri-articular Infilteration|the surgeon will perform the PAI intra-operatively; 150 mL of 0.25% bupivacaine with 1:400,000 epinephrine, 30 mg of ketorolac, and 8 mg dexamethasone. Half of the solution will be administered into the posterior capsule and posterior soft tissues of the knee under direct vision after osteotomy but before insertion of the implants. The remaining half of the solution will be administered into the anterior soft tissues after placement of the implants and before skin closure. All local infiltration will be carried out while a thigh tourniquet (used to limit surgical bleeding) was inflated at a pressure of 300 to 350 mm Hg.
45451068|NCT02230930|Drug|Subcutaneous hydrocortisone 10mg|Subcutaneous hydrocortisone 10mg will be administered previous to apomorphine infusion making use of the apomorphine infusion system
45451069|NCT05073016|Other|neuromodulation|neuromodulation: Neuromodulation is technology that acts directly upon nerves. It is the alteration-or modulation-of nerve activity by delivering electrical or magnetic stimulus/current.
45451070|NCT05073016|Other|motor learning training|motor learning training requires performing a sequential training called finger taping task
45451071|NCT02222350|Drug|10mg DS-8500a tablet|
45451072|NCT02222350|Drug|75mg DS-8500a tablet|
45651364|NCT05053477|Drug|mehylprednisolone injection|(40 mg)
45651365|NCT05053477|Device|pulsed radiofrequency (PRF)|. PRF lesion will be carried out for 120 seconds at a 2 Hz frequency and pulse width of 20 ms at 42°C
45651366|NCT05053477|Biological|platelet-rich plasma|2 ml of PRP
45451073|NCT02222350|Drug|placebo|
45451074|NCT02222428|Drug|BI 1744 CL/BI 54903 XX FDC|
45800802|NCT05561478|Device|Implantation of Synthesis Plus Toric IOL (investigational device)|Synthesis Plus Toric IOLs are indicated for primary implantation for the visual correction of aphakia in adult patients with pre-existing astigmatism.
45800803|NCT05320601|Device|Repetitive Peripheral Magnetic Stimulation|Repetitive Peripheral Magnetic Stimulation at trigger point of upper trapezius muscle
45800804|NCT05320601|Procedure|Dry needling|Dry needling at trigger point of upper trapezius muscle
45800805|NCT05300711|Procedure|Bilateral salpingectomy|Removal of both fallopian tubes.
45800806|NCT05300711|Procedure|Colorectal surgery|Colorectal surgery as indicated by attending surgeon.
45800807|NCT04420338|Biological|Blood sample|rapid serological tests carried out
45800808|NCT04420338|Biological|Serum tube collection|SARS-COV2 seroconversion assay
45451075|NCT02222428|Drug|BI 54903 XX|
45451076|NCT02222428|Drug|BI 1744 CL|
45451077|NCT02222506|Device|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 24 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for diabetic foot ulcers.
45451078|NCT02231242|Biological|Autologous Stem Cell Transplantation|"Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 3 consecutive days. Bone marrow will be harvested under sedation and, after being processed in the laboratory, the buffy coat (TNC) of 10 mL will be infused intrathecally.~Intrathecal Autologous Bone Marrow TNC"
45451079|NCT02225236|Behavioral|Classroom Intervention|
45451080|NCT02225314|Behavioral|Brain Fitness|Brain Fitness is a computer-based cognitive training programs that consists of six types of exercises that train auditory processing speed and accuracy.
45651367|NCT04814459|Other|HOP-UP-PT Program|Interventions provided to EG participants included; (1) the Otago Exercise Program (OEP) which is a well-established exercise program with evidence that it reduces falls among community-dwelling older adults, (2) motivational interviewing (MI) to optimize positive health behaviors, and (3) home and environmental modification recommendations aimed at safety. Participants were provided with and educated on the use of a wrist-worn activity tracker and an automated BP monitor unit. Finally, when follow up items were identified (e.g., orthostatic hypotension, community exercise classes), these referrals were made and documented.
45651368|NCT05033587|Drug|Anlotinib|Anlotinib a multi-target receptor tyrosine kinase inhibitor.
45651369|NCT05033587|Drug|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1.
45651370|NCT05033587|Radiation|Radiotherapy|The radiotherapy regimen delivered 2.0Gy once a day, five days a week to a total dose of 60Gy.
45800809|NCT04015817|Other|paramedical and non-pharmacological services|Paramedical and non-pharmacological services (work on positions, ventilatory education, use of a fan, pulmonary rehabilitation, stress management, mindfulness meditation, psychosocial services, possible support from the mobile palliative care team)
45451081|NCT02225314|Behavioral|InSight|InSight is a computer-based cognitive training program that consists of five types of exercises that train visual processing and working memory.
46072714|NCT02723331|Drug|Nab-paclitaxel and gemcitabine for BR-PDAC Patients|Nab-paclitaxel and gemcitabine, for BR-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
45451082|NCT02225314|Behavioral|Active Control|The Active Control arm is a computerized learning program that consists of five programs (i.e., Wright Brothers, History of Britain, Sister Wendy's American Collection, In Search of Shakespeare, and View the Cosmos) designed to improve knowledge about literature, art, and history.
45451083|NCT02231320|Drug|Berodual® Respimat® - inhaler|
45651371|NCT05053009|Drug|Brufen Retard|800 mg tablet of Brufen Retard will be adminstered orally one hour before local anesthesia
45651372|NCT03095131|Device|Heart Spectrum Blood Pressure Monitor|The Heart Spectrum Blood Pressure Monitor provides a convenient and effective filtering application compared with traditional methods that require a visit to a physician for a 12-lead ECG.
45651373|NCT05617235|Device|Kinesiology taping|"On the postoperative 0th day, kinesiology taping was applied to the patients in the study group whose hemodynamic status was stable after extubation by an expert physiotherapist. Investigators applied kinesiology taping as described below:~In order to stimulate the facilitation of the diaphragmatic function~Taping was applied to the latissimus dorsi and serratus anterior muscles, which were cut during the thoracotomy.~In addition, kinesiology taping can be performed on the trigger pain point of the patient .~After 3-4 days, the tape was renewed. Thus, taping was done twice for each patient. The bands were removed at 1 week postoperatively."
45651374|NCT03095911|Other|News items with spin|Interpretation of news items with spin
45651375|NCT03095911|Other|News items without spin|Interpretation of news items without spin
45800810|NCT05558748|Procedure|USG-guided Caudal block|USG-guided Caudal block after general anesthesia
45800811|NCT05558748|Procedure|USG-guided Ilioinguinal/Iliohypogastric block|USG-guided Ilioinguinal/Iliohypogastric block after general anesthesia
46072715|NCT02670408|Procedure|Endomyocardial biopsy|One of several endomyocardial biopsy bites taken as the standard of care. We are asking now for two endomyocardial biopsy bites, to determine tissue sampling variability.
45651376|NCT04814147|Procedure|Sleeve gastrectomy|Measure of NLRP3 inflammasome preoperative activation level by the expression of NLRP3, IL-1β, IL18 and caspase-1 mRNAs in subcutaneous and visceral adipose tissue. of the epiploon;
45651377|NCT03095989|Behavioral|Mindfulness|The structure of the protocol incorporates key features of Langer's mindfulness theory. Many of the tasks and exercises have demonstrated increased mindfulness in the general population and have been modified to incorporate ALS-specific exercises that make sense from patients and caregivers' points of view. The intervention provides easily understood multimedia (video and written) presentations of the framework of mindfulness and the aims of the planned tasks. The general structure of the protocol mixes different mindfulness elements; for every week there is a specific topic examined in depth. These topics are: Attention to variability; Positive and negative events; Unpredictability; Sense Making; and Novelty seeking / novelty producing. The overall duration of the protocol is 5 weeks.
45800812|NCT05557968|Other|Conventional Therapy|"conventional therapy will be given for stroke patients and three assessments i.e. pre, post and follow up surveys, a session of 30 minutes, 3 times weekly for a six week period.~Total 18 sessions would be performed on each patient for six weeks"
46072716|NCT02660268|Other|Clinical Pathway|Implementation of a Clinical Pathway for Medical and Surgical Management of Hip Prosthesis Infections
46072717|NCT02628899|Device|Transfemoral TAVR|
45451084|NCT02222662|Other|Parent massage tx group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
45800813|NCT05557968|Other|Action Observation Therapy (AO)|"The video consists of :~Ascending and descending the step box.~Ascending and descending the stairs in the treatment room.~Holding the handrails to climb and descend the stairs inside and outside the building.~Climbing and descending the stairs inside and outside the building without holding the handle.~Climbing and descending the sidewalk block"
45800814|NCT02705807|Drug|FLOLAN injection with currently marketed diluent|FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the currently marketed diluent (epoprostenol sodium+ powder of hydrogen [pH] 10.2 - 10.8 diluent) for Injection.
46072718|NCT02628899|Device|SAVR|
46072719|NCT02593526|Drug|Bumetanide|Diuretic
46072720|NCT02593526|Other|Cool Dialysate|Cool dialysate (35°C)
46072721|NCT02571790|Behavioral|Relaxation optimized virtual reality|
46072722|NCT02571790|Behavioral|Classical relaxation (without Virtual Reality)|
46072723|NCT02515110|Radiation|External Beam Radiation Therapy|Undergo hypofractionated RNI
46072724|NCT02515110|Other|Questionnaire Administration|Ancillary studies
45930098|NCT05769972|Device|Computer-based cognitive rehabilitation (Huntington's disease)|This consists of a 24-week computerized cognitive stimulation program using the NeuronUp software. The intervention includes a limited number of tasks developed ad hoc by NeuronUp and the researchers specifically aimed at stimulating the cognitive domains typically affected in movement disorders. These are cognitive processes mostly ascribed to frontal function, as well as other less prevalent but equally disabling processes mainly associated with basal ganglia and fronto-striatal circuitry, such as executive functions, attention and working memory, language, processing speed, and social cognition. Thus, the programs are the same for PD and HD, although the parameters of the number of errors, level of difficulty, and number of correct answers required to advance to the next level have been adjusted to be more demanding in PD and less in HD, with the aim of customizing this type of intervention to the clinical characteristics of each disease.
45800815|NCT02705807|Drug|FLOLAN injection with reformulated diluent|FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the reformulated diluent (epoprostenol sodium + pH 11.7 - 12.3 diluent) for Injection.
45800816|NCT05648370|Genetic|ctDNA testing and whole exome sequencing|Blood samples will be obtained for ctDNA testing and tumor tissue for whole exome sequencing.
45800817|NCT05648292|Behavioral|Neuropsychological tests and psychological questionnaires|"The clinical group will complete:~the BCcogSEP: a comprehensive neuropsychological examination~the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity~A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression~The control group will complete:~the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity~A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression"
45800818|NCT04868994|Diagnostic Test|Whole Body MRI and ENMG|Whole body muscle MRI lasting 30 to 45 min without injection of contrast medium an ENMG
45451085|NCT02222662|Other|Parent massage wait-list control group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
45451086|NCT04719520|Behavioral|wireless vibrating caller|using the wireless vibrating caller to notify the patient's family to the operating room
45451087|NCT02225470|Drug|E7389 (Eribulin Mesylate)|
45800819|NCT02706041|Procedure|Definitive Closure Laparotomy|Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
45800820|NCT02706041|Procedure|Damage Control Laparotomy|Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
45800821|NCT01643772|Drug|Oxycodone hydrochloride|The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.
45800822|NCT02707523|Drug|Azithromycin 10 mg|
45651378|NCT04813913|Drug|Bevacizumab in combination with chemotherapy based on fluoropyrimidine IV|Enrollement of major patient with colorectal cancer of the adenocarcinoma type, stage IV, histologically confirmed, naive in antineoplastic treatment and eligible to start a systemic carcinological treatment comprising bevacizumab in combination with chemotherapy based on fluoropyrimidine IV. The main objective is to show that there is an increase in the stiffness of the carotid artery at 4 months in patients with stage IV colorectal cancer exposed to bevacizumab.
45800823|NCT02707523|Drug|Azithromycin 20mg|
45800824|NCT02707523|Drug|Placebo|
45651379|NCT03095755|Other|Ischemic Conditioning|Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
46072725|NCT02515110|Other|Laboratory Biomarker Analysis|Correlative studies
46072726|NCT02494700|Radiation|External Beam Radiation Therapy|Undergo orbital EBRT
45651380|NCT03095755|Other|Sham|Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
45651381|NCT04828889|Device|Anal dilators|Anal sphincter training for relaxation
45800825|NCT05299853|Other|Robot assisted arm training|Patients will receive 30 minutes of robot-assisted arm training and 30 minutes of conventional arm rehabilitation training. Patients will undergo 30 sessions of combined therapy (robotic+conventional) for a total of 6 weeks (5 sessions/week).
45800826|NCT05299853|Other|Conventional rehabilitation|Patients will receive 30 sessions of conventional arm training (60 minutes/day) for a total of 6 weeks (5 sessions/week).
45800827|NCT05278715|Drug|Carboplatin|Dose of carboplatin is adjusted for age (over 1 year old, full dose, 220 mg/m^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent).
45800828|NCT05278715|Drug|Vincristine|Dose of vincristine is adjusted for age (over 1 year old, full dose, 1.5 mg/m^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent). Maximum dose is 2 mg.
45451088|NCT02225470|Drug|Vinorelbine injection|
45451089|NCT02222974|Drug|BIIR 561 CL|
45651382|NCT04828889|Procedure|lateral internal sphincterotomy|lateral internal sphincterotomy is a firmly established method for treating anal fissures.
45651383|NCT05033509|Other|supervision the Kidney fonction on ECMO|patients who benefited from ECMO, and presented an acute kidney injury afterwards
45800829|NCT05278715|Drug|Recombinant human endostatin|Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks.
45800830|NCT05233085|Drug|AZD4041|On Days 1 to 14, an oral dose of the assigned formulation will be administered to subjects using a syringe. The dose will be administered directly into the subject's mouth.
45451090|NCT02222974|Drug|Placebo|
45930099|NCT05769972|Behavioral|Music-therapy (Huntington's disease)|The process used in each session will be standardized, while the content will be flexible, administering the guidelines according to the mood of the patients and their needs at that time. The therapist's clinical experience will guide them, providing sufficient space for flexible adaptation within the treatment guideline. While the sessions will be standardized, without limiting the music therapist in their interactions, the intervention itself will be applied during the experimental period, using all of the cognitive music therapy exercises detailed below in all groups: auditive perception training, musical sensorial orientation, control of musical attention, training of musical executive function, training in musical mnemotecnia and associative training of mood and musical memory
45800831|NCT05233085|Other|Placebo|On Days 1 to 14, an oral dose of the assigned formulation will be administered to subjects using a syringe. The dose will be administered directly into the subject's mouth.
45800832|NCT04738721|Behavioral|Evaluation|"Within the scope of the course, the demographic information of the students (such as height, weight, body mass index) is recorded and the physical activity status is recorded with International Physical Activity Questionnaire Short Form (UFAA). Cardiovascular endurance with 6-Minute Walking Test, flexibility and circumference of waist, hip and neck with the Sit and Lie Test and body composition and Body Fat Ratio will be evaluated. After a full year of quarantine, the same students who were previously evaluated and accepted to participate in the current study will be evaluated with online remote video viewing methods (Teams, Zoom, etc.) and, with the same tests and measurements under supervision by the researchers."
45930100|NCT05769933|Device|Simultaneous EEG-fMRI at 7 Tesla|Scalp electroencephalography (EEG) and functional magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.
45930101|NCT05769933|Device|Structural MRI at 7 Tesla|Structural magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.
45930102|NCT05769907|Behavioral|Intervention Group|The study will consist of one session per week for 8 weeks, during which the participant will receive MI for 30-45 minutes. All participants will receive the MI intervention according to their readiness to lose weight measured by means the P-weight and S-weight at the beginning of each session.
45930103|NCT05769881|Procedure|Ultrasound guided subcostal transversus abdominis plane block|After the induction of anesthesia, before the beginning of the operation, the subcostal transversus abdominis region is going to be detected under ultrasound guidance and 25-30 ml of 0.25% bupivacaine will be administered
45930104|NCT05769881|Procedure|Wound site local anesthetic infiltration|After induction of anesthesia, before the beginning of the operation, a total of 20 ml of 0.25% bupivacaine is going to be infiltrated in equal doses to the four regions that will have trocar access
45651384|NCT04828655|Behavioral|Use of a mobile application based on machine learning with the aim of improving health and body composition parameters.|Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators.
45651385|NCT05033197|Behavioral|CBBS intervention|The CBBS intervention group received the 16-week intervention, including 16 CBBS lessons in basketball unit (two 40-minute lessons/week, 8 weeks) and 16 CBBS lessons in soccer unit (two 40-minute lessons/week, 8 weeks) during the 2018-2019 school year.
45930105|NCT05769855|Drug|HR18034|HR18034 380mg
45930106|NCT05769855|Drug|ropivacaine HCl|ropivacaine HCl 75mg.
45930107|NCT05769855|Drug|Sodium Chloride Physiological Solution|Sodium Chloride Physiological Solution 20ml
45451091|NCT02259166|Other|EHFP+|Enhanced-homestead food production program including home gardening and poultry rearing + WASH interventions + SBCC around the essential nutrition actions and WASH/malaria prevention with a gender component.
45930108|NCT05769803|Diagnostic Test|Nasal and mouth swab|"Whinin 7 days from diagnosis, the subjects will be requested to sample another two specimens i.e. nasal swab and mouth swab, that will be tested for the presence of SARS-CoV-2 RNA. Results, expressed as cycle threshold will be then compared to analyze viral loads from the two different sites.~Moreover, an aliquot will be retro-transcribed into cDNA and sequenced by Next Generation Sequencing (NGS) to obtain the virus entire genome sequence or evaluated by RT-PCR for variantdetermination."
46072727|NCT02494700|Drug|Orbital Radiation|Participants receive radiation to entire involved orbit for a total dose of 4 Gy in 2 fractions over two consecutive days with external beam radiotherapy. If there is stable disease or progressive disease, an additional 20 Gy administered to involved site. If there are two consecutive evaluations with no change in disease burden then an additional 20 Gy administered. At one year if there is persistent disease, an additional 20 Gy administered to involved site.
46072728|NCT02484677|Drug|Cisplatin|Antineoplastic cytostatic. Blood sampling for pharmacokinetic evaluation
45651386|NCT05041933|Drug|outsourcing of chemotherapy to Hospital at Home|outsourcing of chemotherapy to Hospital at Home
45651387|NCT04828499|Procedure|Progressive Cracking Technique|Performing the cataract surgery with our phaco chop-progressive cracking technique.
45651388|NCT04828499|Procedure|Conventional Chop Technique|Performing the cataract surgery with Conventional Chop Technique.
46072729|NCT02484677|Drug|Docetaxel|Taxanes. Blood sampling for pharmacokinetic evaluation
46072730|NCT02484677|Drug|5-Fluorouracile|Antineoplastic and immunomodulating agents. Blood sampling for pharmacokinetic evaluation
46072731|NCT02480699|Biological|Recurring blood sample|
45800833|NCT03886961|Device|Reflux Band|The Reflux Band is to be worn when sleeping by lung transplant patients for 4 weeks starting 8 weeks after transplant.
45800834|NCT02712047|Drug|Fluticasone furoate (FF) (100 mcg)|First blister strip contains FF blended with lactose, 100 mcg per blister
45800835|NCT02712047|Drug|Vilanterol (VI) (25 mcg)|Second blister strip contains vilanterol blended with lactose and magnesium stearate, 25 mcg per blister
45451092|NCT02225548|Drug|Selegiline|
45451093|NCT02225548|Drug|Tadalafil|
45451094|NCT02259244|Behavioral|Weight reduction program|
45651389|NCT05042089|Other|No intervention will be applied.|The preoperative imaging of the participants, who were grouped according to the postoperative pathology results, will be examined.
45930109|NCT05769790|Diagnostic Test|ddPCR|The search for cfDNA will be performed using assays available in the literature for the search for E. granulosus cfDNA developed for PCR analysis in biological samples, targeting EgG1 Hae III repeat region, cox1 and nad1 (Zhao et al 2021). Appropriate controls (synthetic sequences and Parasitic reference DNA, provided by the Echinococcosis Reference Center of the Istituto Superiore di Sanità, Rome) will be included in each experiment.
45930110|NCT05769738|Drug|Furosemide|40mg (4ml) of furosemide to be nebulized 3 times daily for 3 days
45800836|NCT02712047|Drug|Placebo|Matching placebo will have two blister strips, identical in appearance to the inhaler containing active study medication; one containing lactose and the second strip containing lactose and magnesium stearate
45800837|NCT02712359|Other|Blood sample collection|A blood sample (~5mL) will be collected from all subjects at each cross-sectional survey (Year 8 and Year 10).
45800838|NCT00368693|Device|Dermal - Living Skin Replacement (Dermal-LSR)|The only experimental procedure is the application of the study device, Dermal - Living Skin Replacement (Dermal - LSR), to the foot ulcer. All others are regular or standard procedures. Dermal - LSR is a gel containing living human skin cells. This gel is applied directly to ulcers to help repair the skin. The cells used in this study device have come from one foreskin (skin covering the tip of the penis) taken from a baby boy shortly after his birth for reasons unrelated to this study. All cells that will be used have been tested to be healthy and safe. The amount of the study device you will receive depends on the size of your ulcer at each treatment visit. You will receive less than a 1/4 teaspoon of Dermal - LSR for about every dime-size area of your ulcer as measured and calculated by the research investigator.
45930111|NCT05769738|Drug|Normal saline|4ml of normal saline to be nebulized 3 times daily for 3 days
45651390|NCT04819061|Other|tDCS Active|This group will undergo the motor training and active tDCS. Will be performed 12 sessions in three sessions per week for 30 minutes. Participants will undergo an electroencephalogram before starting the clinical trial. The duration between this baseline EEG and entry into the clinical trial that will assess the effectiveness of tDCS will be two weeks. We will determine the clinical improvement labels used for machine learning classification based on data obtained during the clinical trial (baseline and post-treatment assessments), according to procedures conducted in similar studies.
45651391|NCT04819061|Other|tDCS sham|"This group will undergo the motor training and tDCS sham. Will be performed 12 sessions in three sessions per week for 30 minutes. Participants will undergo an electroencephalogram before starting the clinical trial. The duration between this baseline EEG and entry into the clinical trial that will assess the effectiveness of tDCS will be two weeks.~We will determine the clinical improvement labels used for machine learning classification based on data obtained during the clinical trial (baseline and post-treatment assessments), according to procedures conducted in similar studies."
45651392|NCT03094663|Drug|Bupivacaine|0.5% with epinephrine 30cc
45651393|NCT03094663|Drug|Methylprednisolone|40 mg/ml, 1 ml
45651394|NCT03094663|Drug|Cefazolin|500 mg in 10 ml
45651395|NCT03094663|Device|8 MHz. Chiba needle|22G/ 4 inches
45651396|NCT03094663|Drug|15 cc of bupivacaine 0.25% with 2 mg of preservative free Dexamethasone|15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone
45651397|NCT03094663|Drug|25 cc 0.25% bupivacaine|25 cc 0.25% bupivacaine
45651398|NCT03094663|Drug|20cc 0.25% bupivacaine|20cc 0.25% bupivacaine
45651399|NCT03094663|Drug|2 mg IV dexamethasone.|2 mg IV dexamethasone.
45651400|NCT03094663|Drug|bupivacaine 0.5% with epinephrine 30cc|bupivacaine 0.5% with epinephrine 30cc
45800839|NCT02716727|Device|Aquasil Ultra Cordless, Dentsply|Cordless gingival displacement procedure
45800840|NCT02716727|Device|Ultrapak, Ultradent cord|Cordless gingival displacement procedure
45800841|NCT02717273|Drug|standard|peri-operative antibiotic regimen only
45800842|NCT02717273|Drug|extended|extended three-day course of antibiotics
45800843|NCT02717273|Other|liver transplant|orthotopic liver transplantation
45800844|NCT00369239|Drug|risperidone long acting injectable|
45800845|NCT03833921|Drug|Abiraterone Acetate|1000 mg orally daily until disease progression
45930112|NCT05769725|Drug|Serplulimab|Serplulimab, 4.5mg/kg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
45930113|NCT05769725|Drug|Docetaxel|40 mg/m^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.
45930114|NCT05769725|Drug|S1|Tegafur-gimeracil-oteracil potassium: 50mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.
45930115|NCT05769712|Diagnostic Test|Shear wave ultrasonic imaging|Shear wave ultrasonic imaging technique was used to measure the superficial and deep shear wave velocity of supraspinatus tendon at 10mm (distal end) and 15mm (proximal end) from the attachment end of the greater tubercle of the humerus on the long axis section of supraspinatus tendon.
45930116|NCT05769699|Procedure|blood sample|blood sample
45930117|NCT05769673|Procedure|Placement of dental implant|Placement of a dental implant on the edentulous ridge
45930118|NCT05769673|Procedure|Placement of stock healing abutment|Placement of stock healing abutment after implant has been placed on the edentulous ridge
46072732|NCT02480699|Other|dietary survey|A dietary survey will be performed in all patients and every 3 months (4 surveys about 1 year). This survey will be given to the patient filled for 7 consecutive days. He must record during these 7 days, all of his food intake in quality and quantity. During a dialysis session this questionnaire will be taken with the patient by a dietician to better define the food intake. This surveys requires good patient compliance as well as his involvement that his collection is well within its food intake.
46072733|NCT02476097|Drug|Esomeprazole: Nexium® 20mg, Astra Zeneca|Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.
46072734|NCT02476097|Other|CYP2C19 phenotypical analysis|All patients included will undergo an assessment of the CYP2C19 activity by the administration of omeprazole 40mg and following measurement of omeprazole metabolic ratio respectively, once during the study.
46072735|NCT02476097|Drug|Placebo|Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.
46072736|NCT02456857|Biological|Bevacizumab|Given IV
46072737|NCT02456857|Drug|Everolimus|Given PO
45930119|NCT05769673|Procedure|Placement of customized CAD/CAM healing abutment|Placement of customized CAD/CAM healing abutment after implant has been placed on the edentulous ridge
45930120|NCT05769660|Drug|BEY1107|Administer twice daily, PO, 4-week continuous dose.
45930121|NCT05769660|Combination Product|Temozolomide|Administer once daily, PO, 5-day continuous dose, followed by 23-day rest period.
46072738|NCT02456857|Other|Laboratory Biomarker Analysis|Correlative studies
46072739|NCT02456857|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
45651401|NCT04814381|Drug|Ketamine + Magnesium sulfate (drug combination)|A single infusion will be performed over 2 hours with 90 days follow-up.
45800846|NCT03833921|Drug|Prednisone|5 mg oral low dose prednisone, twice daily
46072740|NCT02434809|Procedure|Bronchoscopic Implantation|Calypso transponders
45451095|NCT02231554|Other|Feldenkrais Method|The program of Awareness Through Movement ® chosen for this study, teaches the basic movements of the column. The aim is to stimulate changes in the chronic pathological patterns and in the distorted kinesthetic perceptions that so often hinder the rehabilitation of chronic non-specific low back pain. The patients will be treated in outpatient with the Feldenkrais method. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
45800847|NCT05215925|Drug|HLX07+carboplatin+pemetrexed|HLX07 1500mg q3w+carboplatin+pemetrexed
45651402|NCT05041777|Device|Optical Coherence Tomography|OCT is an imaging technique, which is able to produce real-time, in vivo, cross-sectional images of lesions with a depth of 1,5-2 mm. OCT imaging is based on light-interferometry, calculating the interference of an optical beam reflected by the tissue with a reference. [2] In such ways, microscopic details of lesions and tissues can be visualized. This information could be used to identify a lesion as BCC, and further specify the subtype. Therefore, the use of the OCT can reduce the number of biopsies and the accompanying morbidity.
45651403|NCT04819217|Dietary Supplement|Active bamboo charcoal|During this 6 months' trial, eligible 120 patients with eGFR 15 < eGFR < 45 ml/min/1.73m2 and UACR > 100 mg/g will be enrolled and randomized into 4 groups. The patients in group 1 will receive CharXenPlus 4g (with ABC 2g) thrice daily + CharXprob 0.8 g once daily in the initial 3 months. Group 2 will receive CharXenPlus 4g thrice daily in the initial 3 months, and CharXprob 0.8 g once daily in the last 3 months. Group 3 will receive CharXprob 0.8 g once daily in the initial 3 months, and CharXenPlus 4g thrice daily in the last 3 months. Group 4 will only receive CharXprob 0.8 g once daily in the last 3 months.
45651404|NCT04819217|Dietary Supplement|Probiotics|Probiotics
45651405|NCT05041465|Other|Clay mask|Clay mask powders- French green, Rhassul and bentonite
45800848|NCT05215925|Drug|HLX07+docetaxel|HLX07 1500mg q3w+docetaxel
45800849|NCT05215925|Drug|HLX07|HLX07 1500mg q3w
45800850|NCT03815357|Other|Referral to Immunology|Screening for primary immunodeficiency including splenic dysfunction
45800851|NCT02719535|Other|Corneal reshaping therapy|Reshaping the corneal curvature from wearing specific designed rigid gas permeable lenses
45930122|NCT05769634|Behavioral|Stereoelectroencephalography|Three computer-based tasks designed to evoke changes in interoceptive attention, arousal and anticipation will be completed. The first asks patients to attend to their heartbeat to manipulate interoceptive attention. The second asks patients to judge affective pictures to manipulate states of arousals. The third engages patients in a probabilistic reward-learning task, or gambling task, and anticipate the outcomes of risky decision-making. A final task guides patients to slow their breathing to 6 breaths per minute.
45930123|NCT05769569|Biological|VRC07-523LS|VRC07-523LS is a recombinant human immunoglobulin G1 (IgG1) broadly neutralizing monoclonal antibody (bNAb) directed against the HIV-1 CD4 binding site. Intravenous infusion of 10 mg/kg VRC07-523LS will be administered on Week 0.
45930124|NCT05769569|Biological|PGDM1400LS|PGDM1400LS is a recombinant human IgG1 bNAb targeted against the HIV-1 V2 apex epitope region. Intravenous infusion of 20 mg/kg PGDM1400LS will be administered on Week 0.
46072741|NCT02434809|Device|Cone-Beam CT-Guided|
46072742|NCT02434809|Radiation|stereotactic body radiation treatments|
46072743|NCT02343042|Drug|Selinexor|Oral tablets
46072744|NCT02343042|Drug|Dexamethasone|Oral tablets
46072745|NCT02343042|Drug|Lenalidomide|Oral capsule
46072746|NCT02343042|Drug|Pomalidomide|Oral tablets
46072747|NCT02343042|Drug|Bortezomib|Subcutaneous Injection (single use vial)
46072748|NCT02343042|Drug|Daratumumab|Intravenous Infusion
46072749|NCT02343042|Drug|Carfilzomib|Intravenous infusion
45800852|NCT05159687|Drug|Atomoxetine Hydrochloride|Atomoxetine 40 mg PO BID (morning and late afternoon) Dosing will start at 40 mg daily for 3 days1 week, followed by a forced titration to 40 mg BID, as per the FDA label for atomoxetine
45800853|NCT05159687|Drug|Placebo|Placebo Comparator: Placebo Matching placebo will be identical in appearance to the active treatment pill. BID (morning and late afternoon)
45800854|NCT02720627|Drug|cortexolone 17α-propionate|CB-03-01 cream is a topical steroidal antiandrogen that is being developed for the potential treatment of acne vulgaris, an androgen-dependent skin disorder.
45800855|NCT02721017|Device|Cryoanalgesia|
45800856|NCT02721017|Drug|Thoracic epidural (ropivicaine, fentanyl)|Epidural infusion was begun with with 0.1% ropivicaine and 2 mg/cc fentanyl.
45930125|NCT05769569|Biological|N-803|N-803 is a recombinant human superagonist interleukin-15 (IL-15) complex. N-803 at 6 ug/kg will be administered via subcutaneous injection to the trunk on Weeks 1, 4, 7, 39, 42 and 45.
45930126|NCT05769569|Biological|Ad26.Mos4.HIV|Ad26.Mos4.HIV is a tetravalent vaccine comprising Ad26.Mos1.Env, Ad26.Mos2S.Env, Ad26.Mos1.Gag-Pol, and Ad26.Mos2.Gag-Pol. Ad26.Mos4.HIV at 5x1010 viral particles (per 0.5 mL dose) will be administered through intramuscular injection in the quadriceps muscle at Week 11.
46072750|NCT02343042|Drug|Ixazomib|Oral capsule
46072751|NCT02343042|Drug|Elotuzumab|Intravenous infusion
46072752|NCT02343042|Drug|Clarithromycin|Tablets
45800857|NCT02721641|Drug|Herceptin|Herceptin will be administered as either 2 milligrams per kilogram (mg/kg) once weekly (first dose as a 4-mg/kg loading dose) or 6 mg/kg every 3 weeks (first dose as an 8-mg/kg loading dose) via IV infusion over 90 minutes.
45651406|NCT04818905|Dietary Supplement|Helichrysum italicum infusion|Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
45930127|NCT05769569|Biological|MVA-BN-HIV|MVA-BN-HIV is a single vector recombinant Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) expressing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol. MVA-BN-HIV at 2x108 infectious unit (per 0.5mL dose) will be administered through intramuscular injection in the quadriceps muscle at Week 35.
45930128|NCT05769569|Biological|A244d11 gp120|A244d11 gp120, consists of the gp120 envelope glycoprotein HIV-1 subtype CRF_01AE A244 derived from the CM244 CRF_01AE strain, with an 11 amino N-terminal deletion. It is a modification of the A244 rgp120 immunogen from the AIDSVAX®B/E vaccine. A244d11 gp120 at 300 ug will be administered as an intramuscular injection in the quadriceps muscle at week 11 and week 35.
45930129|NCT05769569|Biological|ALFQ|ALFQ (Army Liposome Formulation, ALF) is a liposomal adjuvant containing a synthetic monophosphoryl lipid A (MPLA, 3D-PHAD®) with the addition of QS-21. ALFQ at 200 ug will be administered as an intramuscular injection in the quadriceps muscle at week 11 and week 35.
45930130|NCT05769569|Combination Product|Antiretroviral Therapy (ART)|This study will enroll PLWH aged 18-50 years who initiated ART during Fiebig I-V AHI and are virologically suppressed (HIV RNA <50 copies/ml for ≥48 weeks) on uninterrupted ART, who meet study inclusion criteria in Bangkok, Thailand.
45930131|NCT05769452|Device|closed IV catheter system (BD Nexiva™)|There is a high-pressure extension set and a Q-syte split septum needle-free intervention device at the tip of the catheter. It creates a closed integrated system with this apparatus, reducing the risk of catheter-related bloodstream infection.
45930132|NCT05769452|Device|open IV catheter (BD Insyte™ Autoguard™)|BD Instaflash™ needle technology improves initial entry success by confirming vascular access through the needle noch. It has flexible wings for secure cannula fixation.
45930133|NCT05769439|Other|No intervention in an observational study|This study is an observational study only.
46072753|NCT02343042|Drug|Belantamab Mafodotin|Intravenous infusion
45651407|NCT04818905|Other|Hot water|Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
45651408|NCT05052619|Drug|Preventive use of advanced antibiotics|Treat patients in this group with advanced preventive usage of antibiocs: Sulperazon 3g q8h, in postoperative days 1-5.
45651409|NCT05052619|Other|Routine|Treat patients in this group with routine preventive usage of antibiocs: Cefmetazole 1g q12h, in postoperative days 1-3.
45597958|NCT04467931|Drug|Non-ACEI/ARB|Veterans will be categorized as exposed to a non-ACEI/ARB if they have one or more pharmacy fills for an oral non-ACEI or ARB medication in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an ACEI/ARB medication in the 90 days (± 14 days) prior to each Veteran's index date. Specific drug classes include: aldosterone receptor antagonist, beta-blocker, calcium channel blocker, centrally-acting drug, direct arterial vasodilator, direct renin inhibitor, thiazide diuretic, loop diuretic, and potassium sparing diuretic.
45800858|NCT02722577|Procedure|Radio-frequency Ablation|A procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats.
45800859|NCT02724449|Device|Cavilon Advanced Barrier Film|Cavilon Advanced Barrier Fim's application applied twice a week
45800860|NCT03754127|Device|tDCS|Transcranial direct current stimulation
45800861|NCT03754127|Device|sham tDCS|Sham transcranial direct current stimulation
45800862|NCT03730883|Procedure|Central line removal at 100ml/kg/day.|In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake if well tolerated.
45800863|NCT03730883|Procedure|Central line removal at 140ml/kg/day.|In this group central line will be removed at the time the infant reaches 140 ml/kg/day of enteral intake if well tolerated.
45800864|NCT03649061|Drug|Etanercept 50 MG/ML|Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme
45800865|NCT03649061|Drug|Leflunomide 10 milligram (MG)|Leflunomide 10mg PO daily added to the COBRA-Slim scheme
45800866|NCT02265744|Drug|BMS-931699|
45800867|NCT02265744|Drug|Placebo matching BMS-931699|
45930134|NCT05769374|Device|cooperative versus competitive AVG play|The duration of the study was 8 weeks and the frequency was 60 minutes three times a week. In the first two weeks, three games, Golf, Just Dance and Tennis, will be selected to experiment on easy and normal difficulty respectively. In the three weeks from week 3 to Week 5, Bowling, Shape Boxing and Table tennis will be selected for the experiment with easy, normal and difficult difficulties respectively. In the last three weeks, Rowing, Family ski and Baseball will be selected to carry out experiments with easy, ordinary and difficult difficulty respectively.Additionally,participants in control group did not participate in any AVG intervention and maintained their daily physical activity behaviors
45930135|NCT05769361|Behavioral|UNST|Strength and balance training using different destabilizing devices
46072754|NCT02335996|Biological|Blood samples for measuring adiponectin, leptin and omentin plasma|
45597959|NCT04467931|Drug|ACEI|Veterans will be categorized as exposed to an ACEI if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ARB in the 90 days (± 14 days) prior to each Veteran's index date.
45930136|NCT05769361|Behavioral|ST|Strength and balance training over firm surfaces
45930137|NCT05769348|Device|HD-tDCS Active Protocol|non-invasive brain stimulation (active protocol)
45930138|NCT05769348|Device|HD-tDCS Sham Protocol|non-invasive brain stimulation (sham protocol)
45930139|NCT05769335|Other|eCR|Eating time window from 8:00 to 16:00
46072755|NCT02335996|Device|MRI at 3 Tesla|Evaluation by MRI at 3 Tesla of the amount of ectopic fat heart, liver and pancréas and bone marrow.
45597960|NCT04467931|Drug|ARB|Veterans will be categorized as exposed to an ARB if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
45800868|NCT03647891|Device|Continuous Positive Airway Pressure|CPAP is an FDA approved therapy machine for patients diagnosed with OSA. CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep. CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether or not CPAP can improve clinical outcomes in patients with cardiovascular disease. Therefore, our investigators plan to initiate CPAP therapy in patients hospitalized for cardiovascular disease to investigate whether there is an improvement in cardiac function and clinical outcomes (e.g. mortality).
45800869|NCT03624725|Procedure|modified BII+Braun|modified BII+Braun digestive tract reconstruction
45800870|NCT05109143|Drug|Indomethacin suppository|100mg Indomethacin Suppository administered at the time of Induction
45930140|NCT05769335|Other|dCR|Eating time window from 12:00 to 20:00
45800871|NCT05109143|Other|Standard Medical Treatment|Standard Medical Treatment
45930141|NCT05769335|Other|CR|Eating time window from 8:00 to 20:00
45930142|NCT05769309|Procedure|Erector spinae block|After induction, the patients will be administered bilateral Erector spinae block with 20 ml of 0.25 % bupivacaine
45930143|NCT05769309|Drug|Fentanyl|fentanyl boluses of 0.5-to-1 µg/kg titrated according to haemodynamic parameters.
45930144|NCT05769231|Behavioral|Cognitive Behavioral Therapy for Insomnia in Chatbot|Digital interventions can relieve the worldwide burden of mental disorders. The low set-up costs and barriers of online platforms make digital interventions very cost-effective. By using the Internet as a delivery medium, many people can enjoy unrestricted access to self-help information. Unlike traditional face-to-face intervention, the effects of digital self-help interventions are scalable. The current study attempts to extend the boundary of digital interventions from accommodating didactic and informational content to providing interactive, intelligent, and most importantly, patient-centered conversational agents. AI chatbots can provide suitable recommendations and training materials to users according to their behavioral, mental, and motivational readiness. Since existing AI chatbots are developed for Western societies, a culture-specific Chinese chatbot will fill the research and service gaps.
45930145|NCT05769205|Device|MRI|MRI with contrast
45930146|NCT05769192|Other|Classical physiotherapy and classical massage|Within the scope of classical physiotherapy, hot pack will be applied for 20 minutes to the muscles in the lumbar region in the prone position. Stretching and strengthening exercises for the abdominal, lumbar and hip muscles will be given. Classical massage, known as Swedish massage, will be applied on the lumbar region in prone position. All applications will be done 5 days a week for 3 weeks.
45930147|NCT05769192|Other|Classical physiotherapy and placebo massage|Within the scope of classical physiotherapy, hot pack will be applied for 20 minutes to the muscles in the lumbar region in the prone position. Stretching and strengthening exercises for the abdominal, lumbar and hip muscles will be given. In addition, placebo massage, applied without using any technique, will be applied to the lumbar region in the prone position. All applications will be done 5 days a week for 3 weeks.
45651410|NCT04813679|Diagnostic Test|Bed side Ultrasound Sonography|Bed side Ultrasound in Neutropenic patients within 12 h from onset of any symptom such as fever and/or abdominal pain and/or diarreha
45651411|NCT05052775|Other|Chlorhexidine Mouthwash|Patients were given chlorhexidine mouthwash 2 times per day for 15 days
45651412|NCT05052775|Other|Morus Alba 20%|Patients were given morus alba 20% concentration 2 times per day for 15 days
45651413|NCT05052775|Other|Morus Alba 30%|Patients were given morus alba 30% concentration 2 times per day for 15 days
45800872|NCT03614663|Drug|ZYN002 - Cannabidiol Transdermal Gel|Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)
45930148|NCT05769179|Other|Massage group|Massage group will be applied classic massage and cervical stabilisation exercises 3 days a week for 4 weeks
46072756|NCT02316951|Device|single-arm study group|Study participants will wear a small motion detection device and a regular Webcam will be placed near the wall facing the bed in each patient's hospital room. Study participants will be questioned about their sociodemographic, pain, and health history.
45651414|NCT04427423|Other|physical therapy treatment|the experimental group received positional distraction plus stabilization exercises and the control group received stabilization exercises only.
45651415|NCT05052463|Other|electrolyte imbalance analysis|ın this retrospective study we aimed to evaluate the relationship between the ıcu prognosis and the electrolyte imbalance
45651416|NCT04813367|Procedure|Surgery of twisted fallopian tubes|Patients diagnosed with twisted fallopian tube go through surgery.
45930149|NCT05769179|Other|Connective tissue massage group|Connective tissue massage group will be applied connective tissue massage and cervical stabilisation exercises 3 days a week for 4 weeks
45930150|NCT05769179|Other|Mobilization group|Mobilization group will be applied cervical mobilization techniques and cervical stabilisation exercises 3 days a week for 4 weeks
45651417|NCT03094741|Other|CancerLife|CancerLife is a mobile digital solution that allows patients to broadcast their health status inside a private invitation only group, text, email or publicly in Facebook or Instagram. By doing, so the patient collects his/her own patient-reported outcomes data and then share this data with their doctor or care team.
45651418|NCT04818437|Other|BALANCE TRAINING|Trunk, head, and upper limbs rotation from kneeling. 2- Upper limbs flexion and extension with simultaneous head movement from kneeling. 3-Pelvic bridging followed by raising one lower limb and extending knee. 4-Lifting opposite upper and lower limbs from Quadruped position. 6-Heel and toe raises, alternate rising of he right and left feet above the floor, and tandem standing. 7-Weight shifting forward. backward, sideward, and diagonally with eyes opened and eyes closed
45800873|NCT03614663|Other|Placebo Transdermal Gel|Placebo formulated as a clear gel (transdermal delivery)
45800874|NCT05648136|Biological|blood sample|"Blood sampling by venipuncture will be performed :~for patients and controls: between the 20th and 24th day of the menstrual cycle (implantation window) preceding the following IVF+/-ICSI cycle~for patients receiving an endometrial biopsy: on the same day as the endometrial biopsy~for patients and controls receiving follicular stimulation for ovarian puncture: the day of the oocyte puncture~for patients and controls undergoing embryo transfer: on the day of embryo implantation"
45930151|NCT05769166|Other|thired domain of nordic orofcial test-screen|its a questionnaire which the parent will answer
46072757|NCT02227251|Drug|Selinexor|Dose: 60 mg (BIW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
45930152|NCT05769114|Procedure|Surgical stabilization|Anterior-posterior stabilization (360°) with pedicle screws and an expandable cage
45930153|NCT05769101|Dietary Supplement|Ingestion of a Post-Workout Supplement|The Post-Workout Supplement is administered 15 minutes after the completion of training sessions. No supplementation is administered in non-training days. The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
45930154|NCT05769101|Dietary Supplement|Ingestion of a Maltodextrin Supplement|The Maltodextrin Supplement is administered 15 minutes after the completion of training sessions. No supplementation is administered in non-training days. The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
45930155|NCT05769088|Dietary Supplement|Ingestion of a Pre-Workout Supplement|"The Multi-Ingredient Pre-Workout Supplement is administered 15 minutes before the beginning of training sessions. No supplementation is administered in non-training days.~The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing."
45930156|NCT05769088|Dietary Supplement|Ingestion of a Maltodextrin Supplement|"The Maltodextrin Supplement is administered 15 minutes before the beginning of training sessions. No supplementation is administered in non-training days.~The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing."
45930157|NCT05769049|Biological|REC610|administered as 2 intramuscular (IM) injections in healthy adults aged 40 years and older
45930158|NCT05769049|Biological|Shingrix|Shingrix
45930159|NCT05769036|Device|Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Biventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. A horizontal incision will be performed. The cephalic and subclavian veins will be used to leads deliver. The active-fixation defibrillation lead will be placed to the apex/interventricular septum. The atrial active-fixation lead will be implanted to the right atrial appendage/interatrial septum. The implantation of the left ventricular pacing lead will be performed by cannulating one of the tributaries of the coronary sinus using delivery system. Leads will be fixated, connected with CRT-D device and placed in subcutaneous (subfascial prepectoral)/submuscular pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. Cardioverter-defibrillator with a resynchronization function will be programmed for biventricular pacing.
46072758|NCT02227251|Drug|Selinexor|Dose: 40 mg (BIW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
46072759|NCT02227251|Drug|Selinexor|Dose: 60 mg (BIW) and 60 mg (QW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
46072760|NCT02211755|Drug|Bortezomib plus Clofarabine|The proteasome inhibitor bortezomib and purine nucleoside metabolic inhibitor clofarabine demonstrated greater than additive activity in combination in preclinical xenograft models
45800875|NCT03614507|Device|FreeO2 (modèle FO2-220-00) automatic oxygen flow titration|Automatic adjustment of oxygen flow titration through the FreeO2 device. The monitor allows continuous monitoring and recording of SpO2 and Heart rate
45651419|NCT04818437|Other|CORE STABILITY EXERCISES|"Abdominal bracing while lying in supine position.~Abdominal bracing with heel slide while lying in supine position.~Abdominal bracing with Leg lifts while lying in supine position.~Abdominal bracing with bridging while lying in supine position.~Abdominal bracing while Standing.-Abdominal bracing while walking.~7-Quadra pod arm lifts with bracings while Quadra pod position. 8-Quadra pod alternate arm and leg lifts with bracing while Quadra pod position. 9-Side plank with knee flexion while side lying. 10-Side plank with knee extension while side lying"
45651420|NCT03095677|Other|Program of training with exercises including apnea|16 training session on cycle ergometry with exercises including apneas.
45651421|NCT03095677|Other|Program of training with exercises without apnea|16 training session on cycle ergometry with exercises without apnea
45800876|NCT03614507|Device|FreeO2 (modèle FO2-220-00) manual oxygen flow titration|Manual oxygen flow titration performed by the healthcare provider in charge of the patient (nurse, physician). For this group, the FreeO2 device will only monitor and record SpO2 and heart rate.
45651422|NCT04813757|Other|exercise|each group will perform 2 shoulder strength exercise at the therapy session and 3 exercise at home session-2 strength exercise and one stretching exercise. they will perform the exercises 5 times per week
45800877|NCT00085735|Drug|Cisplatin|Given IV
45651423|NCT04813757|Other|manual therapy|on each treatment session both group will receive 15 minutes of manual therapy which will include: massage,3-4 trigger point treatment posterior capsule stretch and mobilization with movement
45800878|NCT00085735|Radiation|Craniospinal Irradiation|Undergo craniospinal Irradiation
45800879|NCT00085735|Drug|Cyclophosphamide|Given IV
45930160|NCT05769036|Device|Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Left Bundle Branch Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. A horizontal incision will be performed. The cephalic and subclavian veins will be used to leads deliver. The active-fixation defibrillation lead will be placed to the apex/interventricular septum. The atrial active-fixation lead will be implanted to the right atrial appendage/interatrial septum. The implantation to the left bundle branch will be performed by using special delivery system. Leads will be fixated, connected with CRT-D device and placed in subcutaneous (subfascial prepectoral)/submuscular pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. Cardioverter-defibrillator with a resynchronization function will be programmed left bundle branch pacing.
45451096|NCT02231554|Other|Back School|The rehabilitation program of Back School is divided into two parts: one theoretical and one practical. To obtain an effective action not only in reducing pain but also in preventing relapse, the Back School acts on the typical risk factors of chronic non-specific low back pain, such as incorrect postures and movements, psychological stress, poor physical fitness, overweight, obesity, smoking, and insufficient knowledge of the spine. The patients will be treated in outpatient with a Back School program. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
45451097|NCT02223052|Drug|CC-486|Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2
45451098|NCT02223052|Drug|Vidaza|75mg/m^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles
45930161|NCT05769023|Behavioral|Intervention test|behavioral sessions to promote vaccines
45930162|NCT05768997|Drug|Ferric Derisomaltose Injection|Ferric derisomaltose/iron isomaltoside (as iron) (0 weeks): 20mg/kg, diluted in 250ml of 0.9% physiological saline and injected intravenously over 30-60 minutes
45930163|NCT05768997|Drug|Darbepoetin Alfa Injection|Darbepoietin alfa (0 weeks, 3 weeks, 6 weeks, 9 weeks): 6.75㎍/kg, subcutaneous or intravenous administration
45451099|NCT02905240|Device|nSTRIDE APS|single intra-articular injection
45451100|NCT02905240|Device|Saline|single intra-articular injection
45451101|NCT02225626|Drug|BI 1060469|tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
45451102|NCT02225626|Drug|BI 1060469|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
45451103|NCT02225626|Drug|Other: standard breakfast|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
45451104|NCT02223130|Behavioral|Cognitive Behavioral Therapy techniques|Participants attend 9 weekly group sessions. Each of the weekly sessions is led by a mental health professional and a peer facilitator who use Cognitive Behavioral Therapy techniques to work with participants in tracking their cognitions, emotions and behaviors in response to stressful/discrimination experiences.
45651424|NCT03094897|Drug|18F-Al-NOTA-MATBBN PET/CT|18F-Al-NOTA-MATBBN(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
45651425|NCT03094897|Device|PET/CT|Imaging with 18F-Al-NOTA-MATBBN PET/CT.
45651426|NCT04813523|Drug|Pembrolizumab Injection [Keytruda]|Neoadjuvant period: pembrolizumab 200mg IV, Q3W with three cycles. Adjuvant period: pembrolizumab 200 mg IV, Q3W, up to one year, which should be performed within 3-6 weeks after surgery.
45651427|NCT05032261|Drug|Circulatory shock with norepinephrine in ICU|Circulatory shock with norepinephrine in ICU
45651428|NCT04812977|Drug|Group A|Combination of intravitreal triamcinolone acetonide (Kenacort-AⓇ) (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml)
45651429|NCT05040997|Diagnostic Test|Small airways assessment|Small airways assessment
45651430|NCT05052073|Diagnostic Test|oral glucose load at rest|oral glucose load (75 g) after an 12h overnight fast at rest accompanied by blood sampling and dialysate sampling (adipose tissue and skeletal muscle), and calorimetry (canopy) over three hours.
45651431|NCT05052073|Diagnostic Test|oral glucose load and exercise|oral glucose load (75 g) after an 12h overnight fast followed by a defined (0.5 W / kg), moderate bicycle exercise i a metabolic chamber
45651432|NCT04813133|Other|Synchronized Lifestyle Modification Program|Synchronization of dietary intake with circadian rhythm of the body.
45651433|NCT04813133|Other|Synchronized Lifestyle Modification Program and Physiotherapy|Synchronization of dietary intake with circadian rhythm of the body along with Physiotherapy ( Aerobics, flexibility, resistance and balance exercises.)
45651434|NCT04813133|Other|Physiotherapy|Only Physiotherapy training which includes ( Aerobics, flexibility, resistance and balance exercises.)
45651435|NCT05032027|Other|probiotics|recieving probiotics at the first day of chemoradiotherapy daily
45930164|NCT05768984|Other|Empowerment program|It is planned to conduct the empowerment program online (zoom session). For this, to protect each individual's privacy, a quiet, bright and ventilated, spacious physical environment and technological elements such as computers, headphones, microphones and internet connection are needed. The empowerment program was planned as a total of 10 sessions, one session per week. In the program, goals and objectives have been established for each session. These aims and objectives will be shared with the participants before each session. The application time of each session is planned as an average of 90 minutes.
45800880|NCT00085735|Radiation|Involved-Field Radiation Therapy|Undergo smaller volume boost (involved-field radiation therapy)
45800881|NCT00085735|Other|Laboratory Biomarker Analysis|Correlative studies
45930165|NCT05768971|Other|Mild diet|
45651436|NCT04813211|Procedure|mobile artificial cervical vertebrae replacement|"Position: The patient is in a supine position with the neck hyperextended, ensuring his/her neck and shoulders in a stable and neutral position before surgery and the cervical spine in a physiological curvature position.~Anesthesia: General anesthesia via oral tracheal intubation.~Surgical approach: Anterior cervical spine approach through the space between the visceral sheath and the vascular sheath.~Surgical method: Two intervertebral discs with adjacent lesions and part of the vertebral body between them will be removed. A curette is used to carefully strike off the annulus fibrosus and cartilage on the surface of the adjacent upper and lower endplates. Intraoperatively, the midlines of the segment and the vertebra to be replaced should be mapped out. When decompression, the midline for decompression should not be deviated from the planned midlines."
45651437|NCT04813211|Procedure|anterior cervical corpectomy and fusion|"Position: The patient is in a supine position with the neck hyperextended.~Anesthesia: General anesthesia via oral tracheal intubation.~Surgical approach: Anterior cervical spine approach through the space between the visceral sheath and the vascular sheath.~Surgical method: Two intervertebral discs with adjacent lesions and part of the vertebrae between them will be removed. A curette will be used to carefully strike off the annulus fibrosus and cartilage on the surface of the adjacent upper and lower endplates. The removed vertebral bone will be trimmed into cancellous bone particles and filled in a cervical titanium cage with an appropriate size. The titanium cage will be implanted into the vertebral space, and fixed with adjacent vertebrae using anterior cervical titanium plates and screws."
45651438|NCT03098017|Other|Short pasta (dry)|50g available carbohydrate portion of penne (~71g uncooked) will be cooked according to package instructions and served with 500mL water
45651439|NCT03098017|Other|Long pasta (dry)|50g available carbohydrate portion of spaghetti (~71g uncooked) will be cooked according to package instructions and served with 500mL water
45651440|NCT03098017|Other|Couscous|50g available carbohydrate portion of couscous (~70g uncooked) will be cooked according to package instructions and served with 500mL water
45800882|NCT00085735|Drug|Lomustine|Given orally
45930166|NCT05768971|Other|Provocative diet|
45930167|NCT05768945|Drug|Semaglutide|Semaglutide claim is used as the exposure group.
45930168|NCT05768945|Drug|DPP-4 inhibitor|DPP4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin) claim is used as the reference group.
45930169|NCT05768919|Drug|Concurrent CRT Period|"Agent: LipoCurc Premedication/Precautions: Dexamethasone 4mg IV, Diphenhydramine 25 mg IV - Dose: per treatment assignment Route: IV over 3 hours Schedule: Weekly: Weeks 1,2, 3,4,5,6 Cycle length: 6 weeks~Agent: TMZ Premedications/Precautions No food 2 hr before and after dosing Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener PRN. Dose: 75 mg/m2 Route: Oral Schedule: Daily during term of RT Cycle Length: 6 weeks~Agent: Radiotherapy Premedications/Precautions: n/a Dose: 2 Gy Route: External beam therapy Schedule: Monday-Friday Cycle Length 6 weeks"
45930170|NCT05768919|Drug|Post-CRT Period|Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over 3 hours Schedule: Weekly: Weeks 7,8,9,10 Cycle length: 4 weeks
45930171|NCT05768919|Drug|Adjuvant Period|"Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over 3 hours Schedule: Weekly: Adjuvant Cycles 1-6: Weeks 1, 2, 3, 4 of each cycle Cycle Length: 4 weeks~Agent: TMZ Premedication/Precautions: No food 2 hr before and after dosing. Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener prn Dose: 150-200 mg/m2 (Cycles 1-6) Route: Oral Schedule: Daily Cycle Length: 4 weeks"
45930172|NCT05767645|Device|Mistral Procedure|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
45651441|NCT03098017|Other|Glucose|50g available carbohydrate portion of glucose monohydrate (~55g) will be dissolved in 500mL water
45800883|NCT00085735|Other|Quality-of-Life Assessment|Ancillary studies
45800884|NCT00085735|Radiation|Radiation Therapy|Undergo standard volume boost (whole posterior fossa radiation therapy)
45800885|NCT00085735|Drug|Vincristine Sulfate|Given IV
45800886|NCT04868370|Other|Assessment of the upper limb (VPIT + PPIT)|Assessment of the upper limb sensorimotor function (VPIT and PPIT)
45800887|NCT03578783|Drug|Placebo|"For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing."
45930173|NCT05767606|Biological|NVX|Administration of NVX
45800888|NCT03578783|Drug|PSD502|"For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing."
45930174|NCT05767606|Biological|PCV20|Administration of PCV20
45930175|NCT05767606|Biological|Placebo|No intervention
45930176|NCT05766046|Diagnostic Test|early lung cancer detection|standard treatment for early lung cancer detection with LDCT at one or two years interval
45930177|NCT05766046|Other|blood test|blood analysis for microRNA and other biomarkers detection
45930178|NCT05765305|Drug|Letrozole with chromium|Letrozole versus letrozole with chromium
45651442|NCT05619341|Dietary Supplement|psyllium|psyllium 20g
45651443|NCT05619341|Dietary Supplement|inulin|long chain fructan
45651444|NCT05040919|Other|collection of medical and socio-demographic data|collection of medical and socio-demographic data
45651445|NCT05040607|Other|Data Collection|"The first stage of the study:~Retrospective data collection of pulmonary function, respiratory muscle strength, exercise capacity, physical fitness, and activities of daily living (ADL).~The second stage of the study~Retrospective data of pulmonary function, respiratory muscle strength, functional capacity before and after supervised inspiratory muscle training with POWERbreathe K5 device and airway clearance techniques performed for 6 weeks in PCD with decreased respiratory muscle strength (Intervention Group).~Retrospective data of pulmonary function, respiratory muscle strength, and functional capacity before and after airway clearance techniques performed for 6 weeks as home-based therapy in PCD with decreased respiratory muscle strength (Control group)."
45651446|NCT05040607|Other|Data Collection|-Retrospective data collection of pulmonary function, respiratory muscle strength, exercise capacity, physical fitness, and activities of daily living (ADL)
45651447|NCT05040529|Procedure|pure laparoscopic donor hepatectomy|pure laparoscopic donor hepatectomy: patients who underwent pure laparoscopic right or right extended hepatectomy for liver donation at gangnam severance hospital
45930179|NCT05765058|Other|Group A|Application of SDF (silver diamine fluoride) solution on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
45930180|NCT05765058|Other|Group B|Application of Sodium Fluoride varnish on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
45930181|NCT05765058|Other|Group C|Application of Placebo varnish (water-based) solution on the root caries lesions twice yearly in a professional setting. Application of Biosmalto tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
45930182|NCT05765058|Other|Group D|Application of Placebo varnish (water-based) solution on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
45930183|NCT05765006|Biological|Relma-cel|CD19-targeted Chimeric AntigenReceptor (CAR) T Cells; Relma-cel be administrated at four dose level:25×106 CAR+ T cells、50×106 CAR+ T cells、100×106 CAR+ T cells/150×106 CAR+ T cells
45930184|NCT05764408|Device|traxi® Panniculus Retractor|traxi® Panniculus Retractor is a disposable adhesive medical device designed for surgical patients with a BMI of at least 30kg/m2, to retract a pannus cephalad and expose the lower abdomen. The device is like a large sticker or bandage, posing no more than minimal risk to participants. The adhesive will be applied to the abdomen according to manufacturer instructions, just prior to a participant's scheduled ultrasound. Once the ultrasound exam has ended, the adhesive will be immediately removed and discarded.
45800889|NCT05548452|Drug|Intestinal Microbiota Transplant (IMT) Capsules|Capsules containing freeze-dried intestinal microbiota from healthy human donors
45930185|NCT05763316|Other|CRIB II|Calculate Clinical Risk Index for Babies II score
45930186|NCT05763316|Other|SNAP-II|Calculate Score for Neonatal Acute Physiology II
45800890|NCT05548452|Drug|Placebo Capsules|"Capsules containing an inactive substance (sugar pill)"
45930187|NCT05763316|Other|SNAPPE-II|Calculate Score for Neonatal Acute Physiology Perinatal Extension II
45930188|NCT05763316|Other|STOPS|Calculate Sensorium, temperature, oxygenation, perfusion, skin color, and blood sugar score
45930189|NCT05763316|Other|MSNS|Calculate Modified Sick neonatal Score
45930190|NCT05763316|Other|nSOFA|Calculate neonatal sequential organ failure assessment
45930191|NCT05762159|Other|data collected|"data collected:~Morphological data of the patients~Data of the erector block realization~Pupillometric data :the variation of the pupil size on stimulation (in percentage of the base diameter)"
45930192|NCT05762146|Drug|Riociguat|Riociguat is an sGC stimulator currently approved and marketed for pulmonary arterial hypertension.
45800891|NCT03543371|Diagnostic Test|Neuropsychological assessment|Standardized neuropsychological battery consisting of the following tests and questionnaires: Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) Vocabulary, Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency, WAIS-IV Block Design, WAIS-IV Matrix Reasoning, WAIS-IV Digit Span, Wechsler Memory Scale - Third Edition (WMS-III) Spatial Span, Rey Auditory Verbal Learning Test (RAVLT), WMS-III Logical Memory, Brief Visuospatial Memory Test-Revised (BVMT-R), Trail Making Test (TMT) A & B, D-KEFS Color Word Interference Test, Behavioral Assessment of the Dysexecutive Syndrome Dysexecutive Questionnaire (BADS DEX), Multidimensional Fatigue Inventory (MFI-20), Minimal Insomnia Symptom Scale (MISS), Hospital Anxiety and Depression Scale (HADS).
45800892|NCT03538457|Drug|Paracetamol|Patients are tested for their normal prescription paracetamol medication
45800893|NCT04338737|Other|timming of feeding|post-operative oral feeding receiving water and clear fluid after surgery, followed by soft food and regular diet
45930193|NCT05762146|Drug|Propylthiouracil|Propylthiouracil, already marketed for the treatment of various subtypes of hyperthyroidism, has been identified as a new member of the class of potent and effective neuronal nitric oxide synthase (NOS1) inhibitors
45930194|NCT05762146|Drug|Perphenazine|Perphenazine, already marketed as an antiemetic and antipsychotic drug, presents the best NADPH oxidase (NOX) inhibitory characteristics compared to other compounds of the same drug class.
45930195|NCT05762120|Other|Weight Management Programme|"Weight Management Programme which consists of 4 phases:~Very low calorie diet~Low calorie diet~Maintenance phase~Continuance phase"
45930196|NCT05760612|Drug|Trastuzumab and nelatinib|Postoperative adjuvant treatment, for about 1 year
45930197|NCT05760612|Drug|Trastuzumab and Parstuzumab|Postoperative adjuvant treatment, for about 1 year
45930198|NCT05760469|Other|Screening|Clinical nurse (CN) notifies research coordinator (RC) about patients with rashes. RC assesses eligibility criteria of patient based on inclusion criteria. RC provide CN with appropriate documentation tool (DT), smart device (SD), standardized red adhesive label (SRAL), and adhesive QRcode. Intervention: With written informed consent, demographic information will be collected. QRcode adhesive will be placed in the DT to track subject documentation throughout the study. Baseline live photograph (LP) of the rash will be taken with SD at day 0. LP will be taken daily. A SRAL, and a QR adhesive code will be included in the LP. LP will be automatically saved in a secure file on the cloud server under the QR code. CN will complete the DT for all rashes included in the study. Treatment of the rash will be at the discretion of the clinical team; the treatment regimen will be recorded daily. The procedure will be repeated daily for all rashes during the patient stay to a maximum of 7 days.
45930199|NCT05760144|Drug|DMPA|The participant will receive the contraceptive injectable, Depo-Provera at the enrollment visit and at 3, 6, 9, and 12 months. Participants will have endometrial biopsies at the enrollment visits and at 3, 6, and 12 months.
45930200|NCT05760144|Drug|Etonogestrel implant|The participant will receive the contraceptive implant, Nexplanon at the enrollment visits and have endometrial biopsies at the enrollment visits and at 3, 6, and 12 months.
45930201|NCT05756023|Procedure|the pregnancy rate at IVF / ICSI cycles|To study and compare other parameters between the PCOS and non PCOS group, and inside the PCOS group itself eg ; patients with PCOS who have ovarian drilling and non drilling PCOS
45930202|NCT05755087|Procedure|Biospecimen Collection|Undergo blood sample collection
45930203|NCT05755087|Procedure|Computed Tomography|Undergo CT
46072761|NCT03946358|Biological|Blood sample collection|"Four blood samples will be collected at:~baseline~2 months from inclusion (+/- 1 week)~4 months from inclusion (+/- 1 week)~the end of vaccination visit (+/- 1 week).~A total of 8 EDTA (ethylenediaminetetraacetic acid) tubes of 6 ml will be collected at each time point to perform:~PBMC collection: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell [PBMC] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection: One 6 ml EDTA tube should be frozen in each investigation center for ctDNA collection."
45451105|NCT02231632|Biological|Live attenuated Poliomyelitis vaccine (Human Diploid Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
45451106|NCT02231632|Biological|Live attenuated Poliomyelitis vaccine (Monkey Kidney Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
45451107|NCT02223286|Diagnostic Test|Corus CAD|Age/Sex/Gene Expression Score
45451108|NCT02225782|Drug|Alteplase|Alteplase is a fibrinolytic drug widely used to restore hemodialysis catheter patency.
45451109|NCT02231788|Drug|Telminuvo®Tab. 40/2.5mg|Telminuvo®Tab. 40/2.5mg, Once daily, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
45451110|NCT02231788|Drug|Telmitrend®Tab. 80mg|Telmitrend®Tab. 80mg, Once daily, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
45451111|NCT02231866|Biological|VRC-EBOADC069-00-VP|cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire + GP Sudan
45451112|NCT02231866|Biological|VRC-EBOADC076-00-VP|cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire
45451113|NCT02231944|Biological|Replenine®-VF (High Purity Factor IX)|
45451114|NCT02226094|Device|DWT device dose A|Deep Wave Trabeculoplasty (DWT) is an investigational device intended to reduce IOP in patients with POAG or OHT. The DWT device applies focal mechanical oscillation (low amplitude, sonic frequency) to the surface of the eye proximate the limbal region and anterior to the trabecular meshwork (TM). Mechanical oscillation of the TM by the DWT device is believed to initiate a physiological cascade to restore function of the TM, increase the outflow of aqueous humor and thereby decrease the IOP. DWT involves 24 spot treatments applied around the limbal region on the ocular surface. Dose A refers to 10 second spot treatments.
45451115|NCT02226094|Device|Ellex Tango SLT machine|Laser trabeculoplasty is the application of a laser beam to burn areas of the trabecular meshwork, located near the base of the iris, to increase fluid outflow. Selective laser trabeculoplasty (SLT) uses a Nd:YAG laser to target specific cells within the trabecular meshwork and create thermal damage.
45451116|NCT02226094|Device|DWT device dose B|Same as DWT device dose A except 20 second spot treatments.
45930204|NCT05755087|Procedure|Positron Emission Tomography|Undergo PET scan
45930205|NCT05755087|Drug|Tegavivint|Given IV
45930206|NCT05752682|Diagnostic Test|Diagnostic pathway|Each included patient will undergo to the faint and fall protocol, to assess the effectiveness of a patients' flow pathways developed in accordance with the most recent guidelines on syncope of the European Society of cardiology and of guidelines on falls of the American and British Geriatrics Societies.
45930207|NCT05751928|Biological|BCD-217|BCD-217 (anti-CTLA4 agent nurulimab + anti-PD1) once every 3 weeks in the neoadjuvant setting
45930208|NCT05751928|Biological|anti-PD1|anti-PD1 agent in the adjuvant setting
45451117|NCT02226094|Device|DWT sham|Same as DWT device dose A except device not applied to ocular surface.
45930209|NCT05751928|Procedure|Excision of the primary lesion|Excision of the primary lesion will be performed per standard of care.
45930210|NCT05751928|Procedure|Regional lymphadenectomy|Regional lymphadenectomy will be performed per standard of care.
45930211|NCT05749705|Other|Fat to Lean Mass Ratio|"The study will be conducted for people who suffer from excess fat mass and their age is over 18 years.~years will be calculated with G power"
45800894|NCT05544786|Drug|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
45800895|NCT05544786|Drug|Nirmatrelvir/Ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in water under fasted condition
45930212|NCT05744674|Drug|HR18034|HR18034 228mg/342mg/456mg
45800896|NCT05544786|Drug|Nirmatrelvir/Ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in infant formula under fasted condition
45930213|NCT05744674|Drug|Ropivacaine Hydrochloride Injection|Ropivacaine Hydrochloride Injection 60mg/90mg/120mg
45930214|NCT05736978|Drug|Azacitidine|75mg/m2 d1-7
45930215|NCT05736978|Drug|Venetoclax|d1 100mg, d2 200mg, d3-28 400mg
45930216|NCT05736978|Drug|Selinexor|if MRD positive in C1D14, selinexor 60mg D15, D22
45930217|NCT05736965|Drug|Selinexor|Selinexor 60mg, PO d3,10,17
45930218|NCT05736965|Drug|Azacitidine|Azacitidine 75mg/m2, IV d1-3, 8-9, 15-16
45930219|NCT05736965|Drug|Venetoclax|Venetoclax 100mg PO on day 1 and 200mg on day 2, 400mg on day 3-14
45930220|NCT05728086|Other|Group art therapy|The intervention is a manualised programme of group art therapy based on a bio-psychosocial therapeutic model. The programme is made up of six 60 - 90-minute art therapy group sessions facilitated by an experienced HCPC (Health and Care Professions Council) registered Art Therapists trained in the intervention.
45930221|NCT05723575|Device|TMS|This paradigm uses theta-burst transcranial magnetic stimulation (tbTMS) to modulate the excitability of sensory cortices to examine the effect on sensory acuity and sensorimotor adaptation. Participants will complete three total sessions targeting primary somatosensory cortex (S1): one using intermittent theta-burst stimulation (iTBS), one using continuous theta-burst stimulation (cTBS), and one with sham stimulation.
45930222|NCT05723575|Behavioral|somatosensory acuity measurement|Somatosensory acuity will be measured through a tactile discrimination task using the corticalmetrics Brain Gauge. Participants lightly press their tongue onto two vibrating probes and report which one vibrated first or with greater amplitude.
45451118|NCT02858908|Drug|Tideglusib|Tideglusib for oral suspension,
45451119|NCT02258620|Drug|dinitrate isosorbide|dinitrate isosorbide (cedocard*) by continuous intra venous (1 to 5 mg/h) dinitrate isosorbide (cedocard*) 5 mg by intra arterial direct in the sheat
45651448|NCT05040529|Procedure|conventional open donor hepatectomy|conventional open donor hepatectomy: patients who underwent conventional right or right extended hepatectomy for liver donation at gangnam severance hospital
45651449|NCT05040139|Procedure|Malone Procedure|Surgical procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, the procedure is performed under general anesthesia. The surgeon bring the end of the appendix (or a tubulized segment of the ileum) out through the abdominal wall. The appendix is opened and sutured to the abdominal skin.
45651450|NCT05040139|Procedure|Percutaneous endoscopic caecostomy|Endoscopic procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, a coloscopy is performed to reach the caecum. The cutaneous location of the caecostomy is determined by transillumination of the caecum. A caecopexy is performed with 3 anchors at the chosen location. A specific pig-tail catheter (Chait catheter) is placed percutaneously into the caecum in the center of the 3 anchors.
45451120|NCT02258620|Drug|nitroglycerine|nitroglycerine dermal patch 15 mg/24h : 67,2 mg/21 cm2
45451121|NCT02232100|Behavioral|Attentional bias modification training (AMG)|Attentional bias modification, administered via an internet-delivered visual-probe task that trains attention away from pain-related information
45451122|NCT02232100|Behavioral|Attentional bias placebo (ACG)|Attentional bias placebo, administered via an internet-delivered visual-probe task that does not train attention either away or towards pain-related information
45451123|NCT02223598|Drug|CB-5083|
45451124|NCT02223598|Drug|Dexamethasone|
45651451|NCT05031793|Other|TCM|TCM include oral chinese herb, laser acupuncture, tuina, nasal steam inhalation.
45651452|NCT05031793|Other|Western medicine|Western medicine include nasal spray steroid, oral antihistamine
45651453|NCT05039905|Drug|99mTc-MSA-ICG|Intratumoral injection of 99mTechnetium-manosylated albumin-indocyanine green to lung cancer patients
45651454|NCT05039983|Other|EGCG|EGCG use various concentrations dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls.
45800897|NCT05544786|Drug|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fasted condition
45800898|NCT05544786|Drug|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fed condition
45800899|NCT02726789|Drug|REP 2139-Ca|the nucleic acid polymer REP 2139 formulated as a calcium chelate complex
45800900|NCT02726789|Drug|pegylated interferon|immunotherapy
45800901|NCT02726789|Drug|entecavir|local generic entecavir
45800902|NCT05544396|Other|probiotic|probiotic group give probiotics (2 packs per day) for 6 months.
45930223|NCT05723575|Behavioral|Speaking Tasks|Participants will produce four training words under a vowel centralization feedback paradigm in which auditory feedback is altered. The investigators will measure changes in produced vowels as a result of the altered feedback in concert with the different stimulation regimes described in the TMS intervention.
45930224|NCT05721664|Other|Trianing program for nurse in how to provide evidence based practices for mechanically Ventilated Patients|"Short Name: (EBNPTP) for Caring of Mechanically Ventilated Patients in terms of standardized care.~Duration: Two weeks A number of Contact Hours: 30 hrs. associated arm (interventional arm): for study group of ICU Nurses working at National Hepatology and Tropical Medicine Research Institute (NHTMRI)"
45930225|NCT05721092|Other|Pre and Post Education on practice of pneumococcal vaccination|A cross-sectional study will be conducted among 25 diabetologists in each of the four zones in India representing all directions - North, East, West and South. Diabetologists will be selected through purposive sampling. A semi-structured questionnaire (study tool) is designed based on the existing literature that addresses our objectives. An education session on Pneumococcal vaccination will be conducted for the diabetologists through webinar after completing the survey. A post assessment will be done using the same questionnaire among the study participants after the education session in order to see an increase in the knowledge of pneumococcal vaccination.
45930226|NCT05720507|Behavioral|Cafe Move|Participants will be offered the opportunity to choose from a number of physical function assessments and subsequently provided personalized reports of performance results.
45930227|NCT05717075|Behavioral|Parents Round|The intervention carried out in this study is called Family Round. The Family Round is an additional medical round, aiming to involve parents in the discussion. The basic attitude of the healthcare staff is to make decisions collaboratively with parents or other family members based on the parents' observations of their infant and parents' opinions. As our daily medical round is carried out in the morning between 8 and 10 a.m. and we offer no accommodation for parents in the NICU, the Family Round will be carried out separately in the afternoon. One neonatologist who is in charge of the infant or taking care of the infant on that day will be a facilitator and proceed with the Parent Round according to the protocol. Other healthcare staff are also encouraged to participate, although the number of participants is limited.
45930228|NCT05716282|Other|Accuracy of neuromuscular recovery estimation|"Accuracy of the estimation of neuromuscular recovery will be measured as:~Correct attribution of the patients to the groups slow, intermediate or fast recovery~Real speed of recovery falls between 95 confidence interval of the estimated speed of recovery"
45930229|NCT05713929|Other|Recruitment maneuver (RM)|performance of a recruitment maneuver of 30 cm H20 for 30 seconds and measurement of electrical impedance
45930230|NCT05713929|Other|Reverse Trend (REV TREND)|Place the patient in the reverse trendelenburg position and measuring the electrical impedance after 5 minutes
45800903|NCT04420104|Procedure|erector spinae plane block|ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
45800904|NCT04420104|Drug|iv analgesia|iv contromal
45800905|NCT02731313|Biological|Trastuzumab|Trastuzumab was not administered in this study. This study informs future trastuzumab treatment decisions.
45451125|NCT02258698|Procedure|Cardiac surgery|Blood samples for assessing Insulin resistance by HOMA, QUICKI, HbA1c, ANGPTL2, CXCL5, visfatin and irisin are drawn during induction of anesthesia, upon arrival on the intensive care unit and on postoperative day 1 and 3. Thirty days after surgery adverse outcomes covering all-cause morbidity and mortality will be assessed.
45800906|NCT02281591|Drug|BIA 2-093|Tablets containing 900 mg
45800907|NCT02281591|Drug|S-licarbazepine|capsules containing 225 mg
45800908|NCT02281591|Drug|R-licarbazepine|capsules containing 225 mg
45451126|NCT02226250|Dietary Supplement|3 Placebo Beverages|Sugar beverage 2 hr before meal, with meal and 2 hr after meal
45800909|NCT02987101|Procedure|Liposuction|Adipose tissue is harvested by liposuction from either abdomen or thighs.
45930231|NCT05712109|Other|Follow-up after Anterior cruciate ligament reconstruction|The patients were referred to the sport medicine department for the post ACL-R follow-up including isokinetic knee muscle strength evaluations at 4 months and 8.months after the surgery
45930232|NCT05707884|Other|critical care management|The different sedation methods result in considerable differences in terms of set-up costs and the management of the patient, which will be examined in a direct comparison.
45930233|NCT05706727|Drug|Intravenous bolus dose of Mephentermine and mephentermine|intravenous bolus dose of mephenteramine 6mg
45930234|NCT05706727|Drug|intravenous bolus dose of phenylephrine 50 mcg|intravenous bolus dose of phenylephrine 50 mcg
45930235|NCT05706493|Other|Non surgical periodontal treatment|Non-surgical periodontal treatment will be performed using ultrasonic scaler and subgingival curettes
45930236|NCT05705739|Procedure|retrolaminar block|curved probe will be placed 1-1.5 cm lateral to the target spinous process after identification of the lamina, the needle will be advanced caudally until it contacts the lamina
45451127|NCT00094835|Biological|Panitumumab|9.0 mg/kg on Day 1 of each 21-day cycle administered by intravenous infusion over approximately 60 minutes.
45451128|NCT00094835|Drug|Motesanib diphosphate|Dose-finding with an initial dose of 50 mg once daily and up to 125 mg once daily. 75 mg twice daily was also to be tested.
45451129|NCT00094835|Drug|Paclitaxel|Paclitaxel 200 mg/m^2 administered by IV infusion over 3 hours.
45451130|NCT00094835|Drug|Carboplatin|Carboplatin was administered IV over approximately 30 minutes. Carboplatin was dosed using the glomerular filtration rate (GFR) and Calvert formula to AUC/time curve of 6 mg/mL×min.
45451131|NCT02232256|Drug|CALPXT96|Arm 1: intervention begins with CALPXT96 Arm 2: intervention begins with placebo
45451132|NCT02226328|Drug|Propofol sedation|
45451133|NCT02226328|Drug|Midazolam and Fentanyl sedation|
45451134|NCT04485442|Other|data collection by questionnaires|psychological well-being in patients evaluated by Patient Reported Outcomes (PRO)
45451135|NCT04485442|Other|data collection (photos of the patients' tumors)|photos of the patients' tumors will be taken at baseline and at follow-up after the surgery
45451136|NCT02530931|Drug|Gadolinium|diffusion of gadolinium for a population with Meniere's disease in order to develop an imaging disease screening test
45451137|NCT02226016|Device|FG-5000A|a measuring device for the assessment of levator muscle strength
45451138|NCT02226406|Other|A: Chair - Leg Cycle ergometer|
45451139|NCT02226406|Other|B: Chair - Arm Cycle ergometer|
45451140|NCT02226406|Other|C: Walk in place|
45800910|NCT02987101|Other|Standard wound care|Patients will receive standard wound care and dressings independent of their participation in this study at the discretion of the wound nurses.
45800911|NCT02987101|Drug|Adipose-Derived Regenerative Cells|Cells isolated from adipose-derived tissue will be injected locally around and under the wound.
45804149|NCT03911375|Other|Mindfulness Based Stress Reduction (MBSR)|"Psycho-educational program of stress reduction based on mindfulness. Program of 30 hours of duration divided into 9 sessions with a weekly frequency of 2.5 h and an intensive session between week 6 and 7 of the program with a duration of 7.5 hours.~Each week the theoretical contents necessary to understand the attention development practices proposed in mindfulness-based interventions will be covered. In addition, basic concepts of the psychobiology and psychology of stress and pain are explained. The subjects will have a homework load of approximately 45 minutes per day during the duration of the intervention."
45651455|NCT05031403|Other|Telerehabilitaton|Patients will be asked to apply the rehabilitation program defined for them 3 days a week for 8 weeks. A training session will last approximately 45-60 minutes.
45651456|NCT05031403|Other|Home Exercise|Patients will be asked to apply the rehabilitation program for themselves with an exercise brochure. This therapy will last 3 days a week for 8 weeks.
45651457|NCT05039827|Other|Mobilization with movement|Heating fermentation was done for 10 minutes as baseline treatment. MWM with wrist extension was given for alternative days in a week as per 3 sessions per week for 4 weeks.
45651458|NCT05039827|Other|Soft Tissue Mobilization|Heating fermentation was done for 10 minutes as baseline treatment. Parallel and longitudinal massage was given for alternative days in a week as per 3 sessions per week for 4 weeks
45651459|NCT05040061|Behavioral|SkillJoy Intervention|The savoring treatment consisted of an ecological momentary intervention (EMI) for learning and practicing savoring skills-SkillJoy. SkillJoy prompted participants to attend to positive aspects of the present moment, plan and engage in enjoyable activities, record and reflect on positive experiences, note events that turned out well, and look forward to positive events.
45651460|NCT05040061|Behavioral|Active Self-Monitoring Control Intervention|The active self-monitoring control EMI prompted participants to notice and write current thoughts and feelings, plan the day's major activities, remember and write about their daily events, and anticipate upcoming important events.
45651461|NCT05051371|Device|Train of four monitoring|Train of four monitoring in postoperative care unit
45651462|NCT05051839|Procedure|Implant surgery and restoration|Implants with two different transmucosal neck configuration are placed.
45930237|NCT05705739|Procedure|ESPB|curved probe will be placed 2-3 cm lateral to the spine using a sagittal approach at the level of T8. After identification of erector spinae muscle and transverse processes, the needle will be inserted deeply into the erector spinae muscle.
45930238|NCT05705726|Device|ultrasound guided facia iliaca block|Patient will received ultrasound guided fascia iliaca block by 20 ml Bupivacaine 0,25% .
45930239|NCT05705726|Drug|Intravenous drug|Patient will received intravenous injection of precedex 0.25mic/Kg and ketamine 0,2 mg/kg .
45451141|NCT03962777|Other|chlorhexidine|patients used chx moutrinses for four days
45800912|NCT01880047|Drug|Eltrombopag|Eltrombopag will be administered for 8 weeks or until the platelet count exceeds 150,000; at this point dosing will stop, subject will be considered a responder and the subject will eligible for entering Part 2 (the long term treatment part of the study. The dose at which the subject achieved the primary endpoint (> 50,000 and increase by > 20,000) will be considered the dose of response. Dose escalation will continue, despite satisfaction of the primary endpoint of study (> 50,000 and > 20,000 above baseline), unless the platelet count reaches the lower limit of normal range 150,000. Subjects will stop study medication if the platelet count is within the normal range, thereby minimizing any safety risk associated with elevated platelet count.
45800913|NCT01880047|Drug|Placebo|
46072762|NCT03946358|Procedure|Tumor biopsies|A tumor biopsy will be realized and centralized at baseline and at 2 months. Collection of tumor biopsies will be guided by ultrasound or CT scan
46072763|NCT03946358|Other|CT scan|"A CT scan will be planned~at baseline~at tumor evaluation visit (8 weeks)~every 8 weeks (+/- 1 week)~at end of treatment visit."
46072764|NCT03946358|Drug|Atezolizumab|"Induction phase: Atezolizumab 1200 mg intravenous every 3 weeks since day 1~Boost phase: Atezolizumab 1200 mg intravenous every 3 weeks until disease progression or unacceptable toxicity until disease progression or unacceptable toxicity."
46072765|NCT03946358|Drug|UCPVax|"Induction phase: UCPVax (combined with Montanide ISA51 as adjuvant) at 1 mg subcutaneously in two separate sites (one site per peptide) at day 1, 8, 15, 29, 36 and 43 (induction phase).~Boost phase: UCPVax boosts vaccine every 6 weeks for the 2 first boosts (boost 1 and boost 2) and then every 9 weeks (boost 3 to boost 5)."
45451142|NCT03962777|Other|oil pulling|patients used oil pulling for four days
45451143|NCT04464538|Behavioral|WALC-R|Initial group education session and individualized coaching (remote)
45451144|NCT04464538|Other|Information leaflet|Participants in the control group will complete baseline measures, and then they will receive written information on the benefits of increasing activity levels. This advice will be given in accordance with NHS guide on physical health.
45451145|NCT02226484|Drug|Quercetin|Two 250 mg capsules of quercetin twice-a-day one hour before meals with a glass of water.
45451146|NCT04453852|Biological|COVID19 vaccine|COVID19 recombinant spike protein with Advax-SM adjuvant
45451147|NCT04453852|Biological|Saline|Saline control
46072766|NCT02118584|Drug|Etrolizumab|Participants will receive etrolizumab 105 milligrams (mg), administered subcutaneously (SC) every 4 weeks for up to 9 years or until either commercial availability or the Sponsor's decision to terminate the study.
45930240|NCT05704569|Diagnostic Test|measurement of multiple biomarkers|All patients were tested for glucose and cholesterol levels. The capillary blood glucose level was measured by an electrochemical method using an Accu-Chek Active by AkkuChek blood glucose meter. The DM was considered to be verified when there were criteria which the World Health Organization (WHO) set in 2001: glucose concentration in whole blood is >6.1 mmol/l, and glucose concentration is >11.1 mmol/l in random measurement. Plasma for the study was obtained via the standard phlebotomy technique from ethylenediaminetetraacetic acid (EDTA) anticoagulants. Plasma was aliquoted into cryovials and got frozen quickly. The samples were stored in a low-temperature refrigerator (-70°C) until the study commencement (up to 3 months). All biomarkers were measured by magnetic bead-based multiplex immunofluorescence assay through the Xmap technology using the Milliplex map Human CVD Magnetic Bead Panel 1 (Millipore)
45930241|NCT05699291|Other|Sentinel node detection technique|Patients cared for by a surgeon for histologically proven breast cancer and for whom an indication for detection of the sentinel lymph node is posed.
45930242|NCT05698238|Drug|CA9hu-1|Humanized monoclonal antibody to human carbonic anhydrase IX
45930243|NCT05697783|Drug|Administration of methadone instead of fentanyl patch|comparison of delirium rates in methadone vs fentanyl patch treated patients
45930244|NCT05695690|Device|Ultrasonography|Comparing between value of ultrasound vs MRI in uterine fibroids
45930245|NCT05690724|Dietary Supplement|Mitocholine™ or Placebo|Participants will be instructed to consume one bottle of study product daily for the duration of the trial (16 weeks). They will be instructed to consume the product in the morning with breakfast.
45800914|NCT01881373|Other|CHL program|Multiple component environmentally focused program designed with community engagement.
45800915|NCT01881373|Other|Delayed Optimized CHL program|CHL programs with fewer component and shorter duration.
45930246|NCT05686486|Other|Tai Chi inspired gymnastics|"The intervention programme will address the themes of relax and seek flexibility and contact and follow. The programme will be divided into four parts with six sessions per part. A typical session will be as follows:~Joint warm-up~A body session focused on relaxation and flexibility in different planes: sagittal/sagittal and frontal/sagittal, frontal and transversal/sagittal, frontal and transversal.~A more playful session in pairs on the theme of contact and follow. Example: put the back of your hand against the back of your partner's hand and initiate movements and the other must follow without resistance."
45930247|NCT05686408|Drug|TNX-601 ER|Patients will take 1 pill orally once daily for 6 weeks.
45451148|NCT02223676|Procedure|Clinical pharmacists conduct medication history|pharmacists conduct medication history before the physician interviews the patient and does not spend time on conducting medical history
45651463|NCT05031559|Behavioral|Episodic Future Thinking|Participants are invited to imagine themselves in a positive situation after COVID-19 public health restrictions and guidelines are lifted. They are then reminded that their actions are able to change how soon this future can be achieved.
45651464|NCT05031559|Behavioral|Compassion Training|Participants are invited to imagine themselves in someone else's situation, who is in a bad situation due to COVID-19 (e.g., ER nurse, family of someone in ICU). They are then reminded that their decisions have an impact on the occurrence of these situations.
45651465|NCT05031559|Behavioral|Sham|Participants are invited to reflect on some COVID-19 related news, and reminded that their actions have bearing on the COVID-19 situation.
45651466|NCT05039749|Device|Human Centric Lights|Bright light is emitted during the day from 06:00, then auto-dimmed light is used at night, beginning 19:00.
45800916|NCT02731469|Biological|BCD-131|
45800917|NCT02731469|Biological|Mircera®|
45930248|NCT05686408|Drug|Placebo|Patients will take 1 pill orally once daily for 6 weeks.
45930249|NCT05685511|Behavioral|Behavioral Activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
46072767|NCT02115282|Drug|Entinostat|Given PO
46072768|NCT02115282|Drug|Exemestane|Given PO
45651467|NCT05039437|Dietary Supplement|MGF-4|Participants were instructed to take 2 capsules of MGF-4 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
45651468|NCT05039437|Dietary Supplement|MGF-7|Participants were instructed to take 2 capsules of MGF-7 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
45651469|NCT05030779|Biological|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
45451149|NCT02226718|Other|Administration of questionnaire|
45800918|NCT02731469|Biological|Aranesp®|
45800919|NCT03493217|Drug|ICP-022|The drug product is a white, round, uncoated tablet.
45800920|NCT01882543|Drug|AQX-1125|Synthetic SHIP1 activator
45800921|NCT01882543|Drug|Placebo|Double blind placebo capsule
45800922|NCT03445949|Drug|short postimplantation dual antiplatelet therapy|continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer or WATCHMAN device
45800923|NCT03445949|Drug|extended postimplantation dual antiplatelet therapy|stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer or WATCHMAN device
45800924|NCT03445949|Drug|long-term treatment with a single antiplatelet agent|continuing long-term treatment with single antiplatelet agent
45800925|NCT03445949|Drug|6 months treatment with a single antiplatelet agent|continuing single antiplatelet agent up until 6 months
45800926|NCT01944319|Drug|Routine meropenem therapy|Participants in control group will accept meropenem therapy with regimen routinely decided by attending physician
45800927|NCT01944319|Drug|Meropenem therapy based on a PPK and PD model|Participants in study group will accept meropenem therapy based on a software developed from a PPK and PD model
45804150|NCT05642923|Drug|Synthetic Vitamin B1|Synthetic Vitamin B1 400 mg per day
45930250|NCT05685511|Other|Medication Optimization|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
45930251|NCT05676047|Behavioral|Cognitive Rehabilitation|A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).
45930252|NCT05676047|Other|Education|The Education group will receive information about self-management of cognitive symptoms at the time of randomization, a common alternative for adults with Long COVID cognitive symptoms who do not receive Individual Therapy.
45930253|NCT05672225|Drug|Dexmedetomidine|Dexmedetomidine 0.2mcg/kg/hr (2ml/hr) administration via continuous channel in the experimental group
45930254|NCT05672225|Drug|Control|Normal saline 2ml/hr administration via continuous channel in the experimental group
45930255|NCT05664555|Drug|Fluorescein Sodium|Patients will receive Fluorescein Sodium 3mL (300mg) or 1mL (100mg) intravenously prior to fluorescein angiography.
45930256|NCT05664295|Diagnostic Test|Jenkins Sleep Disorders scale and Epworth Sleepiness scale|Jenkins Sleep Disorders scale and Epworth Sleepiness scale
45930257|NCT05663580|Drug|Cabotegravir 600mg/3mL, Rilpivirine 900mg/3mL|Initial administration of two separate intramuscolar injection of cabotegravir 400mg/3mL and rilpivirine 600mg/3mL in opposite gluteal muscles, repeated one month later and then every two months.
45930258|NCT05662176|Other|Experimental: Supportive Care based on trauma informed care|Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care based on trauma informed care was provided to the experimental group during birth.
45930259|NCT05662176|Other|Standart care|Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
45930260|NCT05657860|Drug|Guanfacine Extended Release|Initial dose for all participants will be 1mg per day. If the medication is well tolerated, the dose can be raised to 2 mg until day 28 and increased to 3 mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed., the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8 timepoint, the study will be unblinded.and subjects will continue treatment for 8 weeks.
45930261|NCT05657860|Other|Placebo|Placebo will be administered concurrently with GXR during trials.
45930262|NCT05644626|Drug|BGB-B167|Intravenous administration
45930263|NCT05644626|Drug|Tislelizumab|Intravenous administration
45930264|NCT05642962|Drug|Pertzye|Treatment with standard dose or higher dose Pancrelipase will continue for 20 weeks from enrollment. Participants will consume assigned blinded weight based Pancrelipase dose concurrent with first bite of every meal and snack for the duration of enrollment.
46072769|NCT02115282|Drug|Goserelin|Given PO
46072770|NCT02115282|Drug|Goserelin Acetate|Given SC
45451150|NCT00094757|Drug|Comparator: sitagliptin 100 mg|sitagliptin 100 mg oral tablet once daily for 54 weeks
45451151|NCT00094757|Drug|Comparator: sitagliptin 200 mg|sitagliptin 200 mg (2- 100 mg oral tablets) once daily for 54 weeks
45451152|NCT00094757|Drug|Comparator: placebo|placebo oral tablet once daily during Phase A (Weeks 0-18)
45451153|NCT00094757|Drug|Comparator: pioglitazone|pioglitazone 30 mg oral tablet once daily during Phase B (Weeks 18-54)
45451154|NCT04388020|Device|Tabletop prototype of eSpecs: Active projection of defocused image in the peripheral visual field|For the right/test eye, a defocused image is projected onto the peripheral retina while the subject views a distant, in-focus image
45651470|NCT05031091|Other|standardised exposure questionnaire|A standardised exposure questionnaire will be conducted face to face or by telephone. The search for risk factors for leprosy and in particular direct or indirect contact with armadillos will be explored
45651471|NCT05051683|Procedure|combined endoscopic & radiologic intervention for management of acute perforated peptic ulcer|endoscopic management using stent , clipping and sewing combined with radiologic interventional drainage was used. For duodenal ulcer only metallic stent was used due to narrow space while for gastric ulcer either stent , clipping and sewing were used due to capacious space.
45651472|NCT04814069|Drug|Tislelizumab|Tislelizumab 200mg q3w
46072771|NCT02115282|Other|Placebo Administration|Given PO
46072772|NCT02115282|Other|Quality-of-Life Assessment|Ancillary studies
46072773|NCT02107976|Dietary Supplement|Vitamin C|500mg twice a day after discharge, for a minimum of 8 weeks
46072774|NCT02107963|Biological|Anti-GD2-CAR engineered T cells|Administer anti-GD2 CAR T cells 1 x 105 transduced T cells/kg; 1 x 106 transduced T cells/kg; 3 x 106 transduced T cells/kg; and 1 x 107 transduced T cells/kg
46072775|NCT02107963|Drug|AP1903|If unacceptable toxicity occurs that is possibly, probably or likely related to anti-GD2-CAR T cells, AP1903, a dimerizing agent, may be administered to mediate clearance of the genetically engineered cells and resolve toxicity
46072776|NCT02107963|Drug|Cyclophosphamide|1800mg/m2/d X 2 days as a lymphodepleting regimen
46072777|NCT02106507|Drug|apalutamide|apalutamide, 240 mg/day, oral
45930265|NCT05640401|Device|Endoscopy guided by mixed reality (HoloLens2TM) (HXtend™ software)|"Included expert gastrointestinal endoscopists performing diagnostic procedures with mixed reality guidance. All the procedures will be performed by using the HoloLens2TM (Microsoft, Redmond, WA, USA), an ergonomic self-contained holographic device.~HoloLens2TM (Microsoft, Redmond, WA, USA) uses HXtend™ developed software (mdconsgroup, Guayaquil, Ecuador) installed and running on Windows holographic OS. The monitors signals are replicated into holograms by an app developed with the unity Software package (Version 2022.1.22, Unity Technologies, San Francisco, CA, USA).~After each procedure, the researchers will evaluate the device performance along with the acceptance and experience of the endoscopists using this technology."
45800928|NCT03424499|Procedure|Single-use catheter|Each urethral catheterization will be done with a new sterile catheter in a period of 8 weeks. Frequency of urethral catheterization will depend of the conditions of each patient (from 3-5 per day). Patients and parents were instructed to use clean technique by hand washing with water and soup, and penis/vulva cleansing with antiseptic wipes. Researchers reinforced the intermittent catheterization technique before the trial.
45930266|NCT05631964|Drug|BL-M07D1|Administration by intravenous infusion
45930267|NCT05631223|Behavioral|Telemedicine|The intervention will consist of two structured telemedicine visits delivered between two routine office visits and conducted by providers (nurse practitioners and clinical nurse specialists).
45930268|NCT05626907|Other|Diet modification #1|Participants will be provided all meals for a 14-day period. For 7 of the days, meals will be 130% of estimated daily caloric needs and for the other 7 days, meals will be low in calories, consistent with recommendations for weight loss.
45930269|NCT05626907|Other|Diet modification #2|Participants will be provided all meals for a 14-day period. For 7 of the days, meals will be 150% of estimated daily caloric needs and for the other 7 days, meals will be meals will be low in calories, consistent with recommendations for weight loss.
45651473|NCT05031169|Procedure|interdental papilla surgical reconstructiion|Surgical treatment of receding interdentalpapillae
45800929|NCT03424499|Procedure|Reused catheter|Each catheter is programmed to last 1 week. Evaluation will last a period of 8 weeks. Frequency of urethral catheterization will depend of the conditions of each patient (from 3-5 per day). after catheterization. Each catheter was programmed to last a week. Patients and parents were instructed to use clean technique by hand washing with water and soup, and penis/vulva cleansing with antiseptic wipes. Researchers reinforced the intermittent catheterization technique before the trial.
45800930|NCT03424499|Diagnostic Test|Urine culture|A midstream urine sample will be obtained using sterile catheterization for urine culture performed by health provider. Urine cultures will be done in days 0, 7, 14, 28, 42 and 56.
45800931|NCT02284165|Other|retrospective analysis|Analysis of data for patients hospitalized in 2006-2008 with acute ischemic stroke, and successfully linked with Medicare claims through 2009
45930270|NCT05626907|Other|Diet modification #3|Participants will be provided all meals for a 14-day period to be approximately 100% of estimated daily caloric needs.
45651474|NCT05051137|Biological|Infliximab|Initiation of infliximab in any dose and frequency of administration. Could be discontinued for safety reasons and replaced by etanercept.
45930271|NCT05619627|Drug|Dexmedetomidine|Patients will receive oral dexmedetomidine as the sole sedative agent for undergoing MRI
45930272|NCT05619627|Drug|General anesthetic|Patients will receive inhalational anesthetic to provide general anesthesia for undergoing MRI
45930273|NCT05615818|Drug|Futibatinib|Dose 20 mg once a day (QD)
45930274|NCT05615818|Drug|Ivosidenib|Dose 500 mg QD
45930275|NCT05615818|Drug|Zanidatamab|Dose: Patients < 70 kg: 1800 mg every 3 weeks (Q3W), Patients ≥ 70 kg: 2400 mg Q3W
45800932|NCT00368303|Drug|Paroxetine CR|
45451155|NCT04388020|Device|Tabletop prototype of eSpecs: No Active projection of defocused image in the peripheral visual field|For the left/control eye, no image is projected onto the peripheral retina. The subject views a distant, in-focus image.
45800933|NCT00368303|Drug|Paroxetine IR|
45930276|NCT05615818|Drug|Trastuzumab|Loading dose 8 mg/kg, then 6 mg/kg Q3W (Combination with neratinib)
45930277|NCT05615818|Drug|Neratinib|Dose: 240 mg QD (combination with trastuzumab)
45930278|NCT05615818|Drug|Encorafenib|Dose: 450 mg QD (Combination with binimetinib)
45930279|NCT05615818|Drug|Binimetinib|Dose: 45 mg twice a day (BID) (Combination with encorafenib)
45930280|NCT05615818|Drug|Niraparib|Dose: 200 mg QD or 300 mg QD
45930281|NCT05615818|Drug|Cisplatin|Dose: 25 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
45451156|NCT02223832|Drug|ACT-128800|
45651475|NCT05051137|Drug|Sulfasalazine + Hydroxychloroquine|Initiation of sulfasalazine and hydroxychloroquine not more than 180 days apart, in any dose and frequency of administration. Any one of the two drugs could be discontinued. while continuing the other, or both could be replaced by cyclosporine, for safety reasons.
45800934|NCT00368381|Drug|Hydrocortisone|Patients randomized to this arm will receive hydrocortisone for the treatment of adrenal insufficiency secondary to sepsis.
45800935|NCT02733653|Device|Jetstream Atherectomy System|A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
45800936|NCT05020145|Biological|BNT162b2 (Tozinameran)|Covid-19 Vaccine
45800937|NCT02734355|Drug|Telmisartan 80 mg and amlodipine 5 mg|
45800938|NCT02734355|Drug|Placebo (for telmisartan and amlodipine)|Sugar pill manufactured to mimic telmisartan 80 mg and amlodipine 5 mg tablet
45800939|NCT00369395|Drug|volociximab|Volociximab, 15 mg/kg, IV infusion once a week for 8 weeks. Subjects who achieved SD or better at Day 50 ± 2 days (Week 8) were eligible to continue receiving weekly infusions of volociximab until disease progression.
45930282|NCT05615818|Drug|Gemcitabine|Dose: 1000 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
45930283|NCT05609383|Other|assessment|An exit evaluation was initiated immediately upon recovery from anesthesia
45930284|NCT05605444|Other|Single bout of exercise|isometric wall squat at a knee joint angle of 100 degrees. Instruct participant to place their back against the wall with feet positioned parallel and spaced shoulder-width apart. Lower themselves down until they reached a knee joint angle of 100 degrees. Measure knee joint angle by placing a goniometer on the lateral epicondyle of the knee, in line with the femur whilst the anchor arm was in line with the lateral malleolus.
45930285|NCT05602077|Device|POCUS|"POCUS: The ultrasound examination of the injured elbow includes seven standard settings. The probe is placed on the joint in four ventral and in three posterior positions. If hemarthrosis is detected, this is always suspicious of a possible intra-articular fracture. Even the smallest amounts of blood can be detected sonographically. The surfaces of the bones involved in the joint (humerus, ulna, radius) are accurately displayed in all seven sonography settings. Disrupted bone surface indicates a fracture.~XR: The conventional radiograph of the injured elbow consists of three standard views: ap, lateral and Norman oblique.~CBCT: The injured elbow is placed in an almost most extended position in the CBCT tube."
45930286|NCT05599503|Behavioral|Behavioral Interventions|Traditional SimpleC Wellness
45930287|NCT05599503|Behavioral|Robot Interventions|Robot interventions
45930288|NCT05595603|Procedure|4mg ZOL loaded gentamicin PMMA|During surgery, 4mg ZOL will be mixed with gentamicin (1000mg) PMMA cement (40g) by surgeon under sterile conditions to prepare ZOL loaded bone cement, and then it will be filled into the bony defects of the patient where the lesion has been removed after intralesional curettage.
45930289|NCT05595603|Procedure|gentamicin PMMA|During surgery, gentamicin (1000mg) PMMA (40g) was prepared by surgeon under sterile conditions and will be filled into the bony defects of the patient where the lesion has been removed after intralesional curettage.
45800940|NCT04984109|Procedure|Sham PENG block|The regional block will be performed with the patient in the supine position in operative area with adequate groin exposure. The probe will first be placed at the anterior superior iliac spine in transverse plane, and then will be moved caudally to identify anterior inferior iliac spine (AIIS). The probe will be then rotated to align the AIIS and iliopubic eminence (IPE). This will reveal the iliopsoas tendon and muscle together with femoral vessels superficially. A 22-G 100-mm echogenic needle will be inserted in-plane from lateral to medial, and the tip will be kept at the midpoint of AIIS and IPE deep to psoas tendon. After lifting of psoas tendon by hydrolocation, the patients in PENG group will receive 1 mL of normal saline.
45930290|NCT05593549|Drug|Trehalose|Trehalose will be given at a dose of 10g mixed in 500 mL of water to be consumed 1 time per day for 14 days
45651476|NCT05039125|Radiation|ultrasonic cavitation|"From a standing position, each participant's abdomen was divided transversally into three sections; resulting in a total of 6 abdominal segments.~Part III: 3cm above the umbilicus to 2cm below the umbilicus~After washing the skin on the anterior abdominal wall with alcohol, a conducting medium (gel) was placed to the ultrasonic instrument's cavitational head.~The gadget was turned on, a 30-minute timer was set, and the intensity was gradually increased.~The cavitation head then moved extremely gently in a small circular motion on each abdomen section for 5 minutes.~After completing the ultrasonic application to the six regions of the abdomen, the skin was cleansed with a piece of cotton.~For group (A): 40000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months.~For group (B):26000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months"
45804151|NCT03906071|Biological|Nivolumab|Nivolumab is an antibody directed at the programmed death receptor-1 (PD-1), blocking its interaction with PD-L1 and PD-L2.
45930291|NCT05593549|Drug|Placebo|Microcrystalline cellulose will be given at a dose of 10g mixed in 500 mL of water to be consumed 1 time per day for 14 days
45930292|NCT05591040|Device|Biofeedback|Each participant will attend 5 sessions per week for a total duration of 4 weeks. The duration of each session will take 1 hour, including bio-feedback preparation. At the beginning of the bio-feedback session, two surface electrodes will be applied to the mylohyoid muscle. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The experimental group will perform this training for 45 minutes, plus they will receive a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
45930293|NCT05591040|Other|Conventional|Each participant will attend 5 sessions per week for a total duration of 4 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The control group will perform this training for 45 minutes, with a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
45930294|NCT05590156|Procedure|Conventional Rehabilitation|Conventional treatment for the upper extremity will be applied according to the patient's individual needs. A physiotherapist will apply this method in the clinic for 60 minutes. The duration of treatment is 60x3x8 minutes/day/week. Other methods will be applied in addition to the conventional treatment program.
45930295|NCT05590156|Device|Robotic Rehabilitation (ExoRehab X)|Robotic Rehabilitation
45930296|NCT05590156|Procedure|Action Observation Therapy (AOT)|Action Observation Therapy (AOT)
45930297|NCT05588479|Dietary Supplement|Pomegranate extract|One capsule of pomegranate extract (500 mg) will be taken daily at any time of the day for a period of 12 weeks.
45651477|NCT05039203|Device|Indwelling urinary catheter|Removal of indwelling urinary catheter
45651478|NCT05038969|Drug|Stomopral|1 capsule contains 40 mg Esomeprazole
45651479|NCT05038969|Drug|Nexium|1 capsule contains 40 mg Esomeprazole
45651480|NCT04434547|Biological|PRP|During the mock embryo transfer on oocyte retrieval day, 1ml of PRP was infused inside the uterus
45651481|NCT04434391|Other|QF-PCR for GBS screening|QF-PCR for GBS screening in pregnant women,compared with GBS culture test.
45804152|NCT03906071|Drug|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
45930298|NCT05588479|Dietary Supplement|Control|One capsule of containing no pomegranate extract will be taken daily at any time of the day for a period of 12 weeks.
45930299|NCT05579717|Behavioral|Equine Assisted Learning|EAL is an intervention in which mental health clinicians and equine specialists work together with clients to address a learning goal via unmounted interaction with a horse. It is 16 sessions in length, at a rate of two sessions per week.
45930300|NCT05570838|Device|Functional Electrical Stimulation|Functional Electrical Stimulation consist on applying a current on the damaged muscles when the patient is doing a task that requires them. 120 repetitions will be made on the 6 first sessions and 180 repetitions will be done after the sixth session
45804153|NCT03906071|Drug|Docetaxel|Docetaxel is an anti-neoplastic agent that acts by disrupting the microtubular network in cells.
45804154|NCT05462041|Other|DBD Donor Heart Transplantation|A technique of donor heart procurement.
45800941|NCT04984109|Procedure|Real PENG block|The regional block will be performed with the patient in the supine position in operative area with adequate groin exposure. The probe will first be placed at the anterior superior iliac spine in transverse plane, and then will be moved caudally to identify anterior inferior iliac spine (AIIS). The probe will be then rotated to align the AIIS and iliopubic eminence (IPE). This will reveal the iliopsoas tendon and muscle together with femoral vessels superficially. A 22-G 100-mm echogenic needle will be inserted in-plane from lateral to medial, and the tip will be kept at the midpoint of AIIS and IPE deep to psoas tendon. After lifting of psoas tendon by hydrolocation, the patients in PENG group will receive 20 ml of (0.25%) bupivacaine with 0.2 mg/mL dexamethasone that will be injected in 5 ml aliquots after negative aspiration.
45651482|NCT05030389|Behavioral|Adapted Physical Activity (APA)|The APA program lasts 12 weeks and consists in three one-hour at-home sessions a week (total of 36 sessions), including two aerobic dominant web-based sessions and one muscle strengthening self-guided session.
45651483|NCT05030389|Behavioral|Bright Light Exposure (BLE)|Bright light exposure (BLE) consists in using lamps for light therapy during 12 weeks, at the rate of five one-hour at-home sessions a week.
45651484|NCT05030389|Behavioral|Galvanic Vestibular Stimulation (GVS)|The GVS program lasts 2 weeks and consists in five 20-minutes at-home sessions a week (total of 10 sessions), using a portable galvanic stimulator.
45930301|NCT05570838|Device|Hand Robotic-Assisted Therapy|The hand Robotic-Assisted Therapy will be applyed using the AMADEO robot for hand rehabilitation by Tyromotion. The protocol that will be used consists on 200 repetitions on the active-assisted mode with flexion and extension of all the finguers and 50 repetitions on the active mode.
45451157|NCT02223910|Procedure|Neurofeedback training of functional connectivity|
46072778|NCT02106507|Drug|Everolimus|5 mg/day of everolimus dose of everolimus will be escalated to 10 mg/day depending on the safety seen during dose escalation and steady-state trough drug levels as recommended
45451158|NCT01081457|Device|Deep brain stimulation|Comparison ON vs OFF
45451159|NCT02223988|Procedure|subglottic secretion removal|
45451160|NCT02226952|Drug|BILN 2061 W, low dose|
45451161|NCT02226952|Drug|BILN 2061 W, medium dose|
45651485|NCT05030389|Behavioral|Health Education program (HE)|The HE program lasts 14 weeks and consists in one one-hour at-home session a week (total of 14 sessions). This web-based intervention includes courses on general health (sleep habits, diet, physical activity, cardiovascular diseases, etc.).
45651486|NCT05038579|Procedure|Musiquence|The participants performed a customized cognitive stimulation program, that was implemented in an augmented reality format, using Musiquence.
45651487|NCT05038657|Drug|Atezolizumab|Treatment will consist of atezolizumab, by IV infusion, at a fixed dose of 1680 mg, every 28 days (day 1 of each cycle, +/- 3 days), for up to one year. Each participant will receive up to 13 doses in total.
45651488|NCT03094585|Other|Written and oral information|The written information (booklet) was 12 A4 pages long and took about 15 minutes to read. The oral information consisted of group sessions which focused on active feedback. Each session was lead by one of the authors who first went through the topics described in the booklet. The review of the topics was followed by a plenary discussion.
45651489|NCT03094585|Other|Written information|The written information (booklet) was 12 A4 pages long and took about 15 minutes to read.
45651490|NCT05038501|Other|To study comorbidities in patients undergoing Oncosurgeries|In the Preoperative Anaesthesia checkup we will study prevalence of comorbidities as Coronary artery Disease, Hypertension, Diabetes Mellitus , Hypothyroidism and prior Corona Virus Infection in patients undergoing Oncosurgeries
45800942|NCT01947907|Drug|ACP-001|Once weekly subcutaneous injection
45800943|NCT01947907|Drug|Human Growth Hormone|Once daily subcutaneous injection of human Growth Hormone
45930302|NCT05568940|Drug|Tibolone 2.5 Mg Oral Tablet|Tibolone oral therapy for 2-3 months: All participants will take a Tibolone 2.5 mg tablet orally daily, at the same time each day, following a scheduled, luteal-phase injection of leuprolide acetate 11.25mg intramuscular (IM).
45930303|NCT05565248|Combination Product|VCTX211|CRISPR-Cas9 genetically modified PEC211 cells loaded into a delivery device
45930304|NCT05563454|Drug|BAY2395840|Administration of dosage form 1 under diet 1 condition
45930305|NCT05562973|Drug|Psilocybin|Participants will receive three psilocybin sessions, at least two weeks apart.
46072779|NCT02085668|Device|Renal denervation (Symplicity™)|Delivery of radiofrequency through the wall of the renal artery to disrupt the surrounding renal nerves under angiography control
46072780|NCT02051218|Drug|Denosumab (reduced dosing)|3x Denosumab 120mg (XGEVA®) sc. q4w followed by Denosumab 120mg (XGEVA®) sc. q12w
46072781|NCT02051218|Drug|Denosumab (standard dosing)|Denosumab 120mg (XGEVA®) sc. q4w
45451162|NCT02226952|Drug|BILN 2061 W, high dose|
45451163|NCT02226952|Drug|Placebo|
45451164|NCT02224066|Drug|Ticagrelor 90 mg twice per day during three months following TAVI|
45451165|NCT02224066|Drug|Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI|
45930306|NCT05554120|Other|Supermarket tobacco sales ban|In 2024, a ban on the sales of tobacco for supermarkets is planned by the Dutch government. Supermarkets accounted for approximately 40% of tobacco outlets in the Netherlands in 2021.
45930307|NCT05552261|Drug|Cenegemin in the DEFENDO Study|"Cenegemin as administered in the DEFENDO Study. Long-term safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution administered in Stage 1 Neurotrophic Keratitis (NK) patients enrolled in the DEFENDO Study (NCT number NCT04485546).~No intervention was performed in this follow-up / extension trial."
45930308|NCT05551299|Drug|Photosensitizer|A photosensitizer, which is absorbed preferentially by tumour cells, is administered 24 - 48 hours prior to PDT. Light of a particular wavelength is then applied during endoscopic retrograde cholangiopancreatography (ERCP) to kill primarily cancer cells locally within the stenosis. Immediately after PDT treatment, new stents are inserted into all treated segments if needed.
45800944|NCT05735665|Diagnostic Test|bowel ultrasound|Bowel US is a non-invasive tool which is able to measure intestinal inflammation by the use of emission of US from a specific probe. It is used externally, just moving the probe on the skin of the patient along the abdominal section. It does not require any contrast. The preparation used is just a fasting period of 6 hours.
45800945|NCT05735665|Diagnostic Test|colonoscopy|Colonoscopy is an endoscopic procedure where a tube is inserted from the anus up to the ileum of the patient. It requires bowel cleansing with polyethilenglicole up to 4 liters (depending on the preparation and the desired grade of cleansing) the day before the examination. Because it may be painful, usually sedation is provided.
45930309|NCT05551299|Procedure|Radiofrequency ablation (RFA)|RFA is also carried out as part of an ERCP. The RFA-probe is placed within the tumour stenosis and electrical current is applied. New stents are inserted into all treated segments if needed.
45651491|NCT03095833|Other|Odors|"Four odors are available: milk chocolate, dark chocolate, pineapple and apricot.~In addition, a neutral odor will be used clean air, a control odor transmitted during the task by the olfactometer in the same way as the other 4 odors, the only variant being that no odor will be deposited in the U-tube containing the smells. The images corresponding to the odors will be displayed after the odor has been proposed."
45651492|NCT03095833|Other|Visual stimulation|Concerning behavioral passes, the subjects will be in front of a computer screen on which the task will be presented. For fMRI passes, the visual stimulation of the participant is done by a mirror system placed about 10 cm from the participant's eyes, allowing him to watch a translucent screen on which the visual stimuli are projected. The latter have an intensity similar to that of television images, and therefore below the maximum permitted by labor legislation. The stimuli will be projected via a video projector located at the back of the imager.
45800946|NCT02737397|Drug|JMI-001 (SJP-304 and SJP-223)|
45800947|NCT02737397|Drug|SJP-304|
45800948|NCT02737397|Drug|SJP-223|
45930310|NCT05546697|Other|Online- Yoga-based Intervetion|See arms description
45930311|NCT05546697|Behavioral|Online- BA|See arms description
45930312|NCT05543785|Drug|Ketorolac|After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 30 mg ketorolac tromethamine diluted in normal saline in a total volume of 50 ml will be injected
45930313|NCT05543785|Other|Control|After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 50 ml normal saline without drugs will be injected
45930314|NCT05532800|Drug|JS002|JS002:150mg(1mL) Q2W PFS, Placebo: 1mL Q2W PFS.
45930315|NCT05532800|Drug|Placebo|JS002:150mg(1mL) Q2W AI, Placebo: 1mL Q2W AI.
45930316|NCT05527847|Behavioral|Peers LEAD|Two group session focusing on beliefs about medicines and diabetes, discrimination/mistrust, and communication with providers, and 2 peer-based phone calls from Ambassadors to occur weekly for weeks 3-8, then bi-weekly for weeks 9-12.
45930317|NCT05527847|Behavioral|HLWD|Weekly group sessions for two months. Sessions will last up to 2.5 hours and focus on a different diabetes self-management topic.
45930318|NCT05526742|Drug|CKD-510 capsule (reference)|Single-dose of CKD-510 will be administered as oral capsule in a fasted state.
45930319|NCT05526742|Drug|CKD-510 tablet (test)|Single-dose of CKD-510 will be administered as oral tablet in a fasted state.
45930320|NCT05526742|Drug|CKD-510 tablet (test)|Single-dose of CKD-510 will be administered as oral tablet in a fed state.
45930321|NCT05525845|Other|Functional Magnetic Resonance Imaging (pCASL-MRI)|MRI's will be performed at multiple points on each visit day.
45930322|NCT05525845|Other|Intragastric Balloon|Intragastric Balloon will be placed during Visit 2 study day and inflated to maximum tolerated volume. Patient will then be scanned in the MRI.
45930323|NCT05525845|Other|Elemental Meal|Patient will ingest the tasteless elemental meal until their maximum level of fullness. Once full, the patient will be scanned in the MRI.
45800949|NCT02737397|Drug|placebo|
45800950|NCT02737631|Device|"Chameleon Personal Lubricant"|
45800951|NCT01948141|Drug|nintedanib|Given PO
45800952|NCT04938323|Drug|BCG Vaccine|.1 mL of reconstituted BCG vaccine given intradermally at baseline.
45800953|NCT04938323|Drug|Placebo|.1 mL of diluent (saline) given intradermally at baseline
45930324|NCT05525845|Other|Hedonic Meal|Patient will ingest meal of their choice from a local food delivery service and eat until they reach their maximum level of fullness. Once full, the patient will be scanned in the MRI
45930325|NCT05524012|Diagnostic Test|Blood sample|longitudinal blood samples for CTC monitoring
45930326|NCT05524012|Device|MRI scan|longitudinal MRI scans (non-contrast enhanced)
45930327|NCT05522439|Drug|SHR-1703|SHR-1703 will be administered by SC injection.
45930328|NCT05522439|Drug|SHR-1703 Placebo|Matching Placebo will be administered by the SC route.
45930329|NCT05516615|Other|4 minute breathing maneuver|The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths or more per minute) followed by a maximal breath-hold.
45930330|NCT05514717|Drug|XMT-2056|XMT-2056 will be administered through a vein in your arm or port catheter (intravenously)
45930331|NCT05511389|Other|Anterolateral electrode position|As described previously
45930332|NCT05511389|Other|Anteroposterior electrode position|As described previously
45930333|NCT05511389|Other|Manual pressure|Manual pressure applied to the anterior electrode
45930334|NCT05510908|Other|Non-Interventional|Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
45930335|NCT05510908|Other|Non-Interventional Follow-up|Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
45800954|NCT05446493|Drug|Tadalafil 5mg|"Estimate serum level of serum YKL-40, total testosterone and platelets indices in diabetic patients with erectile dysfunction treated by daily tadalafil 5mg for 3months.~Penile color Doppler ultrasound examination before and after treatment"
45930336|NCT05509439|Other|Home Transfusion Program Components|The Home Transfusion Program will include trained transfusion nurse(s) who will administer transfusions in the home setting. The transfusion nurse, who is part of the study team, will work closely with the DFCI/BWH Blood Bank and the hospice agency (Care Dimensions Inc.) that all study patients are enrolled in. The transfusion nurse will administer home transfusions using safe home transfusion practices endorsed by the AABB. The home transfusion program has 4 key aspects Initial home visit, (2) subsequent contact, (3) home transfusion assessment & administration, (4) usual elements of hospice
45930337|NCT05505201|Device|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment.
45930338|NCT05505201|Device|Sham Repetitive transcranial magnetic stimulation|Sham Repetitive transcranial magnetic stimulation
45930339|NCT05502783|Drug|fostamatinib|Participants will receive fostamatinib 100 mg BID for 4 weeks. On the 4-week evaluation, a) if cytopenia improves (hemoglobin =10 g/dL, platelets = 50 x 109/L), patients will continue the same dose for a total of 12 weeks, b) if refractory cytopenias persist (hemoglobin < 10 g/dL, platelets < 50 x 109/L), the dose will be increased to 150 mg BID. Subjects with persistent (=2 readings, 2 weeks apart) loss of hematologic response after week 5 can increase their dose to 150 mg BID until at end of the study on week 12.
45930340|NCT05500313|Behavioral|Hypno-breastfeeding Education|The hypnobreastfeeding education program consists of 4 sessions and 12 hours. It includes information about breastfeeding, mental preparation for the breastfeeding experience, emotional studies, motivational practices, awareness and self-compassion practices.
45930341|NCT05500313|Behavioral|Experimental: Standart Breastfeeding Education|The standard breastfeeding education program consists of 1 session and 3 hours. It contains only information and applications about breastfeeding.
45804155|NCT05462041|Device|DCD Donor Heart Transplantation|A technique of donor heart procurement. The TransMedics' OCS Heart technology is the only portable system available for ex-vivo maintenance of the donor heart in a metabolically active and beating state. It is currently FDA approved for procurement and transport.
45930342|NCT05499416|Drug|Bimekizumab|Self-administration of two (2-160 mg/mL [1 mL]) pre-filled syringes or autoinjectors at baseline (Day1) and at Weeks 4, 8,12, and 16
45930343|NCT05492864|Procedure|extrusion of the anterior teeth|sectional leveling and alignment of the teeth, then using of the extrusion arch as an overlay wire to treat the open bite
46072782|NCT01964261|Device|Neural Prosthetic System 2 (NPS2)|The NPS2 comprises 3 NeuroPort Arrays (SIROF). The tip of the electrodes are sputtered iridium oxide film (SIROF). Each array is comprised of 100 1.5 mm microelectrodes organized on a 4mm x 4mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Of the 100 electrodes, 96 are wire bonded using 25m gold alloy insulated wires sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
45451166|NCT02232334|Other|Global Osteopathic Manual Treatment|subtle manipulations of the body according to the methodology of osteopathic manual therapy will be the intervention on subjects in the study. The global treatments will take into consideration the past medical history of each subject as well as what is found on assessment. Focus is on the position, mobililty and quality of each subjects anatomy.
45451167|NCT04682470|Other|No intervention ; observational|No intervention; observational
45451168|NCT02232490|Biological|hepcortespenlisimut-L|hepcortespenlisimut-L (V5) is given in experimental arm
45651493|NCT03095833|Other|Experimental Task|"The olfactory sensitivity and the olfactory identification capacities of the subjects will be evaluated using the ETOC test. Subjects will have to define his state of hunger/satiety thanks to a questionnaire of hunger. Finally, subjects should assess the hedonic nature of the odor and the edibility of the odor source. The task to be performed will be the same for the behavioral study as for the imaging study. The subject will receive instruction from the following three: indulge yourself, the subject must think of the desire to eat the food that will be presented to him in olfactory and visual form; Be natural, the subject must act as naturally as possible; Or hold back, the subject must distance themselves from their desire to eat and control themselves. In a second step, an odor will be presented for 5 seconds. This will be based on the subject's inspiration, then an image associated with the odor will be presented for two seconds."
45804156|NCT05459155|Other|Synapse medicine platform|Intervention is the Synapse medicine platform for inpatient pharmacists. This software analyzes drug-related risks based on each patient's clinical characteristics
45451169|NCT02232490|Biological|Placebo|
45451170|NCT02227030|Drug|BIIB 722 CL solution|
45451171|NCT02227030|Drug|BIIB 722 CL tablet|
45451172|NCT02227030|Drug|Placebo solution|
45451173|NCT02227030|Drug|Placebo tablet|
45451174|NCT02227186|Other|School-located Influenza Vaccination Clinic|Children in the intervention arm are enrolled in schools in Monroe County, NY that are offering school-located influenza vaccination clinics during school hours
45930344|NCT05491109|Device|Venous Assistance and Contracture Management System (VACOM)|Mimic therapist-assisted on bed passive ankle exercises to preclude the development of ankle joint contracture and facilitate venous flow in lower extremities to reduce DVT risk. Using soft pneumatic extension actuators, which is capable of providing robot-assisted ankle exercises, specifically dorsiflexion-plantarflexion and inversion-eversion movements. Through these natural movements to improve blood flow and venous return and maintain ankle joint flexibility. Furthermore, it can facilitate and stimulate the neurologic recovery in walking by early mobilization.
45930345|NCT05480696|Dietary Supplement|Fructo-oligosaccharide enriched inulin supplement|Experiment
45930346|NCT05480696|Other|Maltodextrin|Placebo.
45930347|NCT05479773|Device|Standard NIV mask|The hospital standered NIV mask
45930348|NCT05479773|Device|Lumena NIV mask|aerosol-reducing mask
45930349|NCT05470920|Behavioral|Electronic Decision Aid|Decision aid followed by an appointment with an oncologist. Will complete surveys/questionnaires
45930350|NCT05470920|Behavioral|Pre-Test Genetic Counseling|Receive pretest counseling with a genetic counselor. Will complete surveys/questionnaires
45930351|NCT05470348|Drug|BL-B01D1|Administration by intravenous infusion
45930352|NCT05463666|Other|Rheumatoid arthritis|A diagnosis of rheumatoid arthritis.
45930353|NCT05461768|Drug|BL-M07D1|Administration by intravenous infusion
45930354|NCT05457465|Drug|Cannabidiol|Custom formulation of a hemp-derived, high-CBD product that contains no THC.
45930355|NCT05453955|Drug|Propofol|Anesthesia induction and maintenance with propofol 60 minutes later, change the maintenance drug to remimazolam
45930356|NCT05453955|Drug|Remimazolam Besylate|Anesthesia induction and maintenance with remimazolam 60 minutes later, change the maintenance drug to propofol
45930357|NCT05448599|Drug|6MW3211 injection with Intravenous Infusion|phaseI: 6MW3211 will be administered in 30mg/kg and 45mg/kg intravenously once every 2 weeks; phaseII: 6MW3211 will be administered in 45mg/kg intravenously in both 2 cohorts.AZA will be administered in 75mg/m2 by subcoutaneous injection in cohort 1 as well as cohort 2 from Day1-Day7 every 28-day cycle. VEN will be administered orally with dose escalation to 400mg daily every cycle.
46072783|NCT01950520|Drug|Propranolol|Propanolol 160mg, oral, by mouth (Cohort 1 only)
45800955|NCT01948375|Device|real needle- placebo needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
45800956|NCT01948375|Device|placebo needle - real needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
45804157|NCT01721876|Drug|Placebo|Placebo matching Volasertib
45930358|NCT05447559|Drug|Cefazolin|Intravenous administration of 2 g cefazolin
45930359|NCT05447559|Drug|Water for injection|Intravenous administration of 10mL sterile water for injection
45930360|NCT05442853|Device|Continuous glucose monitoring|Continuous glucose monitoring involves a wearable device that measures glucose with a sensor that is inserted subcutaneously. The sensor transmits data to receiving device that displays the glucose values.
45930361|NCT05442853|Device|Point of care glucose monitoring|Point of care glucose monitoring involves use of an external device that can provide glucose readings at a patient's bedside. These devices require a small blood sample from venous, arterial, or capillary fingerstick blood. The blood sample is analyzed by the device and reports a glucose value within 5 minutes. This method of glucose monitoring is a mainstay and standard of care for most hospitals in the United States.
45930362|NCT05435963|Behavioral|Pulmonary rehabilitation (PR)|A typical PR program will include exercise training, disease-specific and self-management strategies education, and will last 6 - 8 weeks
46072784|NCT01950520|Drug|Pindolol|Pindolol 20mg, oral, by mouth (Cohort 1 only)
46072785|NCT01950520|Drug|Dantrolene|Dantrolene 100mg, oral, by mouth (Cohort 1 only)
46072786|NCT01950520|Drug|Magnesium Sulfate|Magnesium Sulfate, infusion, 50 mg/kg bolus followed by maintenance infusion at 2g/h (Cohort 1 only)
46072787|NCT01950520|Drug|Caffeine|Caffeine 200mg, oral, by mouth (Cohort 2 only)
46072788|NCT01950520|Drug|Qysmia|Qysmia (topiramate 92mg CR, phentermine 15mg PO), oral, by mouth (Cohort 2 only)
45451175|NCT04378114|Device|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. C sensor algorithm applied retrospectively to raw sensor data.|Characterize the impact of acetaminophen ingestion on the accuracy of Guardian™ Sensor (3) when C sensor algorithm is used.
45804158|NCT01721876|Drug|Volasertib|Volasertib
45930363|NCT05427786|Drug|Nicorandil|Administer 8cc or more of the prescribed drug according to randomization into the coronary artery before starting balloon therapy. The stent treatment method follows the standard treatment method.
46072789|NCT01950520|Drug|Topiramate|Topiramate 200mg, oral, by mouth (Cohort 2 only)
46072790|NCT01950520|Behavioral|Phentermine|Phentermine 37.5mg, oral, by mouth (Cohort 2 only)
46072791|NCT01950520|Drug|Naltrexone|Naltrexone 100mg, oral, by mouth (Cohort 2 only)
46072792|NCT01950520|Drug|Mirabegron 50mg|Mirabegron 50mg, oral, by mouth (Cohort 3 only)
45930364|NCT05426343|Biological|MVC-COV1901|Approximately 125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
45930365|NCT05426343|Biological|AZD1222|Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
45930366|NCT05423665|Other|sample collection|blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth
45930367|NCT05417776|Drug|[68Ga]CBP8|An injection of up to 350 MBq of [68Ga]CBP8 will be administered intravenously followed by PET-MRI.
45930368|NCT05417776|Drug|Dotarem|Dotarem will be administered during MRI portion of study.
45930369|NCT05413707|Procedure|Fixation of the posterior malleolus fractures|Fixation of the posterior malleolus fracture with screws and or plating.
45930370|NCT05413707|Procedure|Fixation of lateral and/or medial malleolus fractures|Fixation with screws and/or plating
45930371|NCT05413707|Procedure|Syndesmotic fixation|Fixation of unstable syndesmosis with one or two 3.5 mm tricortical screws, or with a suture button.
45930372|NCT05406505|Drug|Dapagliflozin 10mg Tab|patients will receive once daily dapagliflozin 10 mg orally in addition to protocol directed loop diuretic therapy.
45930373|NCT05406505|Other|Placebo|patients will receive protocol directed loop diuretic therapy and standard care.
45930374|NCT05403593|Other|No Intervention|No intervention, prospective data collection
45930375|NCT05402553|Drug|Ondansetron|patients will receive, in addition to standard therapy, ondansetron IV bolus 8 mg BID for 3 days
45930376|NCT05402553|Drug|Placebo|patients will receive, in addition to standard therapy, normal saline IV bolus BID for 3 days
45930377|NCT05402072|Procedure|Autologous matrix-induced chondrogenesis (AMIC)|AMIC is a novel approach in which the microfracture technique has been enhanced by the use of a type I/III collagen matrix (Chondro-Gide®; Geistlich Pharma AG, Wolhusen, Switzerland). In this single-step procedure, the matrix is placed over the defect to stabilize the fragile blood clot that arises from microfracture and to provide infrastructure for repair tissue formation. Essentially, the matrix covers the defect and serves as a protective shield that contains the cells and minimizes the impact of shear forces when moving the hip on the delicate blood clot. At the same time, it functions as the roof of a biological chamber that forms over the defect. The biocompatible collagen material provides an environment for cell growth and is replaced by native tissue over time.
45930378|NCT05397730|Diagnostic Test|Mycobacterium tuberculosis (MTB) cell-free DNA (cf-DNA)|Comparing the diagnostic accuracy between MTB cfDNA and PCR on diagnosing tuberculous pleuritis
45651494|NCT03095833|Other|Blood tests|Before and after the imaging examination, a blood sample will be taken by a medical imaging manipulator affiliated with the CERMEP whose actions will be remunerated in accordance with the usual hygiene and safety rules. The samples taken will then be annotated with the subject code and kept at the CERMEP. The volume of ghrelin sampling is 5 ml (10 ml for two samples). The volume of the leptin is 5 ml (ie 10 ml for two samples).
45651495|NCT03095833|Other|Questionnaires and test administered|The proposed questionnaires respond to all ethical aspects established by international and national standards to undertake studies on human subjects. Two types of questionnaires will be used in this experiment: Inclusion of the Subjects and Exploratory Tests.
45651496|NCT03095833|Other|fMRI|The purpose of the imaging part is to determine how high-level cognitive control (the setpoint) can affect the price of a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
45804159|NCT01721876|Drug|Cytarabine|Cytarabine
45804160|NCT05635045|Drug|I 124-Evuzamitide|Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging
45804161|NCT05455411|Behavioral|Group-based Parent-implemented Training|A group-based social communication training for parents of preschoolers with autism spectrum disorder will be taught by a speech therapist online (approximately 25 hours distributed over 6 months), with up to 8 parents in a group.
45804162|NCT05455411|Behavioral|Individual-based Parent-implemented Training|An individual-based social communication training for parents of preschoolers with autism spectrum disorder will be taught by a speech therapist online in a one-on-one format (approximately 25 hours distributed over 6 months).
45930379|NCT05395663|Behavioral|Community health worker|A trained navigator (e.g. OSU Extension staff) will have 3 meetings with the participants in Arm 2. These meetings will be held in person, on the phone, or in zoom.
45930380|NCT05393934|Other|High dense nutrients formula|High dense nutrients formula: Powder based Infant formula with High Nutrients' Density with energy density of 100 kcal/100ml and for Pediatric Nutrition Care: A medical service to understand nutritional status, problems related to the feeding process and clinical diagnosis of the patient.
45930381|NCT05393934|Other|Pediatric Nutrition Care (PNC)|Pediatric Nutrition Care: A medical service to understand nutritional status, problems related to the feeding process and clinical diagnosis of the patient.
45930382|NCT05385692|Drug|BL-M02D1|Administration by intravenous infusion
46072793|NCT01950520|Drug|Mirabegron 200mg|Mirabegron 200mg, oral, by mouth (Cohort 3 only)
46072794|NCT01950520|Drug|Placebo Cohort 1|Placebo, oral, by mouth (Cohort 1 only)
46072795|NCT01950520|Drug|Placebo Cohort 2|Placebo, oral, by mouth (Cohort 2 only)
45800957|NCT05446103|Other|Blood flow restriction training|"After warming up, the load is set at 80% of the predicted 1Repetition Maximum (RM) for elbow flexors. Following each successful repetition, the load is increased by 0.5 to 1kg until patients: fail to execute the exercise through the entire range of motion; used improper form to complete the repetition; needed assistance; reported pain. We will allow a 2-3 min of rest between each attempt to ensure recovery.~The session starts by calculating the arterial occlusion pressure in the standard anatomical position. Participants rest in the standing position for 3-5 minutes before measurement to ensure restoration of blood flow circulation and a cuff is placed in the most proximal part of their dominant upper-limb. BFR application is conducted by using an automatic personalized tourniquet system (Mad-Up Pro, France). An 40% occlusion pressure is set and subjects perform 4 sets of elbow flexion (30-15-15-15 reps) using 30% of 1 RM"
45800958|NCT05446103|Other|Sham Blood flow restriction training|"After warming up, the load is set at 80% of the predicted 1Repetition Maximum (RM) for elbow flexors. Following each successful repetition, the load is increased by 0.5 to 1kg until patients: fail to execute the exercise through the entire range of motion; used improper form to complete the repetition; needed assistance; reported pain. We will allow a 2-3 min of rest between each attempt to ensure recovery.~The session starts by calculating the arterial occlusion pressure in the standard anatomical position. Participants rest in the standing position for 3-5 minutes before measurement to ensure restoration of blood flow circulation and a cuff is placed in the most proximal part of their dominant upper-limb. BFR application is conducted by using an automatic personalized tourniquet system (Mad-Up Pro, France). An <20% of occlusion pressure is set and subjects perform 4 sets of 10 reps of elbow flexion using 65% of 1 RM"
45800959|NCT04934033|Other|Neurological assessments|The participants will have a MRI, and language and cognitive assessments.
46072796|NCT01950520|Drug|Placebo for Mirabegron|Placebo for Mirabegron, oral, by mouth (Cohort 3 only)
46072797|NCT01940094|Drug|5 mg Prednisone|Subjects will remain on daily prednisone dose of 5 mg
46072798|NCT01940094|Drug|0 mg Prednisone|Subjects will taper their prednisone dose from 5 mg per day to 0 mg per day
46072799|NCT01905046|Drug|metformin hydrochloride|given PO
46072800|NCT01905046|Other|placebo|given PO
46072801|NCT01875601|Biological|Recombinant human interleukin-15 (rhIL-15)|Continuous infusion rhIL15 IV
45651497|NCT03095833|Other|Odors 2|To modify the floral character of the wine used, the investigators will use the β-ionone odorant molecule (4 (2,6,6-trimethyl-1-cyclohexenyl) -3-buten-2-one (CAS number 14901-07-6) Purity ≥97.0% (Fluka) This molecule is commonly found in wines with a violet odor.
45651498|NCT03095833|Other|Images|The visual stimulation of the subject will be done by a system of mirrors placed about 10 cm from the subject's eyes allows him to look at a translucent screen behind the MRI scanner and on which the visual stimuli are projected.
45451176|NCT04378114|Device|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. Zeus sensor algorithm applied retrospectively to raw sensor data.|Characterize the impact of acetaminophen ingestion on the accuracy of Guardian™ Sensor (3) when Zeus sensor algorithm is used.
45451177|NCT04378114|Drug|Acetominophen|One time administration of acetaminophen.
45451178|NCT04334746|Other|Balance measurement tools|Timed Up and Go Test Functional Reach Test One-leg Stance Test Berg Balance Scale
45651499|NCT03095833|Other|Experimental Task fMRI|For each test the subjects will receive at the same time an image on the screen and a sample of wine (2 ml) delivered in the mouth of the subject thanks to the system of programmable pumps.
45651500|NCT03095833|Other|Genotyping for susceptibility to β-ionone|Sampling will be done by the subject himself by scratching and firmly pressing into the oral cavity, specifically at the cheeks and tongue for one minute, being careful not to touch the teeth and gums.
45651501|NCT03095833|Other|Experimental Task 2|The investigators will determine how perceptual judgments are modulated by cross-modal stimuli, as well as metacognitive judgments (how individuals judge their own sensory performance). In addition, they will determine how perceptual judgments are modified in the context of group decisions and how language influences performance.
46072802|NCT01875601|Biological|NK Cell Infusion|Infuse expanded NK cells at Day 0 after 2 days of Cyclophosphamide lymphodepletion
46072803|NCT01786265|Drug|Abiraterone Acetate|Given PO
46072804|NCT01786265|Drug|Bicalutamide|Given PO
46072805|NCT01786265|Drug|Degarelix|Given via injection
46072806|NCT01786265|Drug|Flutamide|Given PO
46072807|NCT01786265|Drug|Goserelin Acetate|Given via injection
46072808|NCT01786265|Drug|Leuprolide Acetate|Given via injection
46072809|NCT01786265|Drug|Nilutamide|Given PO
46072810|NCT01786265|Drug|Prednisone|
45651502|NCT05038423|Behavioral|5R Shared Leadership Program|"The manualised 5RS program aims to develop the leadership qualities of peer leaders by teaching them how to create, embody, advance, and embed a collective sense of 'us' in their teams. More specifically, 5RS consists of two key components that involve (1) implementing a structure of shared leadership, and (2) strengthening the identity leadership skills of the appointed peer leaders (Fransen et al., 2020).~Fransen, K., Haslam, S. A., Steffens, N. K., Mallett, C. J., Peters, K., Mertens, N., & Boen, F. (2020). All for us and us for all: Introducing the 5R Shared Leadership Program. Psychology of Sport and Exercise, 51, 101762. https://doi.org/10.1016/j.psychsport.2020.101762 Haslam, S. A., Steffens, N. K., Peters, K., Boyce, R. A., Mallett, C. J., & Fransen, K. (2017). A social identity approach to leadership development: The 5R program. Journal of Personnel Psychology, 16(3), 113-124. https://doi.org/10.1027/1866-5888/a000176"
45800960|NCT01885117|Biological|TIVf|Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)
45930383|NCT05383118|Behavioral|Education Intervention|"Participants in the intervention group will be provided e-learning about dementia prevention and promoting brain health, consisting of following components:~One multimedia e-learning lesson on promoting brain health and preventing dementia;~A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson.~Curated resources related to dementia risk factors"
45930384|NCT05383118|Behavioral|Education Control|"Participants in the control group will be provided e-learning about mild cognitive impairment, consisting of following components:~One multimedia e-learning lesson on mild cognitive impairment;~A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson.~Curated resources related to mild cognitive impairment"
45930385|NCT05379322|Drug|Anti-TNF|Upon analysis of the sample, patients that are falling into specific phenotypes (diffuse myeloid or pauci-cellular phenotypes) will be assigned to receive anti-TNF as biologic DMARD medications.
45800961|NCT04895501|Other|running flexible shoes|21kms of running flexible shoes followed by a time-to-exhaustion run.
45930386|NCT05379322|Drug|JAK inhibitor|Upon analysis of the sample, patients that are falling into specific phenotypes (lymphoid- myeloid or pauci-cellular phenotypes) will be assigned to receive JAK inhibitors as biologic DMARD medications.
45930387|NCT05378165|Other|Music group|The study was divided into three stages; before; during; and after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete. All of the patients who participated in the study underwent the standard protocol used in the Endoscopy Unit of our institution. Colonoscopy was performed on patients in all groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. The music group listened to Acemasiran-type classical Turkish music.Acemasiran-type music affects the human brain and provides a sense of creativity to people. This musical tone has pain- relieving and antispasmodic
46072811|NCT01596621|Drug|Bendamustine hydrochloride|Bendamustine will be be administered per dose and schedule specified in the arm description.
46072812|NCT01337245|Drug|Snake (Micrurus) North American immune F(ab')2 Equine|5 vials of study drug reconstituted and diluted to 250 mL Normal Saline and administered intravenously.
45800962|NCT02905721|Procedure|Spectral cardiac CT scan|Cardiac CT scan : acquisition using the spectral mode imaging in order to identify inflammatory areas of the myocardium on the iodine map imaging.
45800963|NCT02863055|Drug|Nintedanib|Nintedanib 200 mg administered twice daily
45800964|NCT02863055|Drug|Placebo|Matching placebo administered twice daily
45800965|NCT04879355|Device|Spinal needle (25G)|Fine needle aspiration from thyroid nodules using a 25G spinal needle.
45800966|NCT04879355|Device|Conventional fine needle (25G)|Fine needle aspiration from thyroid nodules using a conventional 25G fine needle
45800967|NCT05445635|Device|Iriscope|The use of Iriscope to improve the diagnostic yield of bronchoscopy in the setting of peripheral lung nodules
45800968|NCT00368771|Behavioral|IBS Stress Management|If randomly assigned to this intervention, the session with the therapist will consist of training about IBS symptoms and their relationship to stress, as well as skills training in relaxation and ways of identifying and challenging mistaken thoughts about life events. The goal of this treatment is to lessen mental and physical stressful reactions to daily events, and therefore lessen IBS symptoms as a reaction to stress. The patient will be encouraged to apply relaxation skills to stressful situations.
45800969|NCT00368771|Behavioral|IBS Symptom Management|If assigned to this group, the therapist will discuss feelings, over-attention to IBS symptoms, and your fear of IBS symptoms. Patients will learn how to identify thoughts that may increase your IBS symptoms and will practice how to change these thoughts to ones that make them feel more comfortable. The sessions will focus on reactions to daily life that in turn result in IBS Symptoms.
45800970|NCT00368771|Behavioral|IBS Educational Training|Those assigned to this group will be given educational materials about IBS and will discuss the reading material with the therapist. The reading topics include information on gut disorders, anatomy and physiology of the gut, assessment procedures, and how to manage IBS symptoms. Sessions will also consist of weekly reviews of daily records and IBS symptoms. The goal of this intervention is to provide educational training about IBS.
45800971|NCT05445479|Drug|Doxycycline|Patient with doxycycline treatment during COVID-19 waves
45800972|NCT02711735|Biological|RUTI® Therapeutic vaccine|Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.
45800973|NCT02711735|Biological|Matching RUTI® Placebo|Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid
45804163|NCT03224585|Drug|Anakinra|"Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - anakinra 100 mg subcutaneous injections daily for 4 days"
45800974|NCT04864145|Device|Transcatheter Aortic Valve Implantation|The VitaFlow™ system (MicroPort®, Shanghai, China) was a novel TAVR system, which incorporates high-radial force and a double layer polyethylene terephthalate (PET) skirt to optimize frame geometry and minimize the risks of paravalvular leak (PVL). The VitaFlow™ transcatheter aortic valve is made of a self-expanding nitinol frame and tri-leaflet bovine pericardial valve.
45930388|NCT05378165|Other|Stress ball group|"The study was divided into three stages; before; during; and after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete. Colonoscopy was performed on patients in all groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. The stress ball group was given stress balls which was medium hard and made of high-quality silicone approximately 10 minutes before colonoscopy. The patients in stress ball group were instructed to squeeze the balls twice after counting up to five and repeat until the end of the entire procedure."
45930389|NCT05378165|Other|Video group|"The study was divided into three stages; before; during; and after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete.~All of the patients who participated in the study underwent the standard protocol used in the Endoscopy Unit of our institution. Colonoscopy was performed on patients in al groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. Video group allowed to watch a licensed virtual reality application,A walk on the beach, through an Android mobile phone placed in Cardboard Super Flex Goggles, started 10 minute before the colonoscopy until the procedure was completed."
45651503|NCT05038423|Behavioral|12-week structured walking program|Participants engaged in an evidence-based 12-week structured walking program, which aimed to enhance participants' physical activity and aerobic fitness levels based on personalised walking schedules and weekly group walks organised by the community-based meeting points.
45930390|NCT05378165|Other|Control group|"The study was divided into three stages; (1) before; (2) during; and (3) after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete.~All of the patients who participated in the study underwent the standard protocol used in the Endoscopy Unit of our institution. Colonoscopy was performed on patients in al groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. Control group, without any additional intervention."
45930391|NCT05376696|Behavioral|Set For Variability|This intervention will focus on training students to use a sound variation of grapheme correspondence rule in order to read an irregular spelling word correctly.
45451179|NCT02224300|Behavioral|Internet-based education of venous leg ulcer nursing care|Intervention is delivering the ELC (Electronic Learning of venous leg ulcer nursing care) to home health-care nurses (registered nurses, public health nurses and licensed practical nurses) . The ELC development was based on the integrative literature review about nurses' knowledge gaps on venous leg ulcer nursing care. The pedagogical basis of the ELC is constructivism and blended learning approach. The ELC comprises contact learning and distance learning. Content of ELC is evidence-based information already existing in Internet and the basis of the information is the Finnish Current Care Guidelines for Chronic leg ulcers (2014), which are evidence-based clinical practice guidelines. They are intended as basis for ulcer treatment decisions, and guidelines can be used by nurses and other healthcare professionals.
45651504|NCT05038189|Diagnostic Test|Gait parameters|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
45800975|NCT04864145|Drug|Medical therapy|Angiotensin-neprilysin inhibition (ARNI), diuretics, dihydropyridine calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or beta blockers.
45800976|NCT04738565|Dietary Supplement|Probiotic preparation|The mixture of Lactobacillus rhamnosus ŁOCK 0900, Lactobacillus rhamnosus ŁOCK 0908 and Lactobacillus casei ŁOCK 0919 administered once a day at a dose of one billion for 3 months.
45800977|NCT04738565|Dietary Supplement|Maltodextrin|Maltodextrin comparable in color, texture and taste to the probiotic mixture administered once a day for 3 months.
45800978|NCT02573753|Behavioral|Sleep restriction|
45800979|NCT02573753|Dietary Supplement|Weight gain|
45651505|NCT05038189|Diagnostic Test|Spine posture|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
45651506|NCT05038189|Diagnostic Test|Trunk position sense|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
45800980|NCT04855253|Drug|E7777|E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.
45651507|NCT05051215|Other||
45651508|NCT04973059|Device|SmartDrive Summer|The SmartDrive is a power assist accessory for a manual wheelchair
45651509|NCT04973059|Device|SmartDrive Winter|The SmartDrive is a power assist accessory for a manual wheelchair
45930392|NCT05376696|Behavioral|Current Best Practices|This active control intervention will focus on training students to use grapheme-phoneme correspondence rules and sight words in the absence of set-for-variability component
45930393|NCT05373862|Device|Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter|Participants scheduled to have a clinically-indicated catheter mapping and ablation procedure using globe-shaped, high-density, multi-electrode mapping catheter for management of atrial procedure (scar-related atrial tachycardia, persistent atrial fibrillation, paroxysmal atrial fibrillation) and Ventricular procedures (ventricular tachycardia, premature ventricular complex).
45930394|NCT05368389|Device|Healthdot attachment|"The wearable health monitoring device Healthdot 5 will be attached to the patient's skin at left lower rib and data like heart rate, respiratory rate, posture and activity will be collected for 10 days.~A questionnaire will be sent to patients to fill out at the 10th day after the device attachment."
45930395|NCT05367570|Behavioral|Cross-sectional observational study|The first work package of this project is an explanatory cross-sectional study with no intervention.
45930396|NCT05363982|Device|Transcranial Photobiomodulation (tPBM)|"Transcranial Photobiomodulation (tPBM) is a novel treatment approach based on application of an invisible, non-ionizing electromagnetic wave that results in metabolic modulation in tissues targeted. This intervention consists of exposing bilaterally the frontal brain to the electromagnetic wave that penetrates the skin and skull into brain tissue, is non-invasive and minimally dissipated as thermal energy.~Other Names:~Niraxx G1 Headband"
45930397|NCT05363982|Device|Placebo/ Sham|The sham treatment will consist of applying all the procedures for the delivery of tPBM, but will not deliver light.
45651510|NCT05038111|Drug|Dexmedetomidine|perioperative dexmedetomidine infusion
45651511|NCT05030077|Drug|Anlotinib|Anlotinib(12mg) oral daily for days 1-14, 21 days per cycle
45651512|NCT05030077|Drug|Cisplatin|Cisplatin (70 mg/m2) IV day 1
45800981|NCT05445011|Drug|Fludarabine + Cyclophosphamide + TAA05 Cell Injection|Fludarabine + Cyclophosphamide + TAA05 Cell Injection Fludarabine 25 mg/kg * 3d on day-7~-2; Cyclophosphamide 250 mg/kg *3d on day-7~-2; TAA05 Cell Injection on day 0.
45800982|NCT02380781|Behavioral|Information in the form of a video|see intervention description
45651513|NCT05030077|Drug|Carboplatin|If the patients can't tolerate cisplatin, they will be treated with carboplatin (AUC 4.5mg/mL·min) IV day 1
45651514|NCT05030077|Drug|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
45800983|NCT04782245|Drug|Dapagliflozin 10mg|The intervention group will receive, during 6 months, dapagliflozin per oral route at a dose of 10 mg once daily in addition to the optimal medical management based on current heart failure practice guidelines.
45800984|NCT04782245|Drug|Placebo|Patients randomized in the control group will receive during 6 months, placebo once daily per oral route, in addition to the optimal medical management based on current heart failure practice guidelines.
45800985|NCT02136797|Biological|CMVpp65 Specific T-cells|
45800986|NCT04770155|Dietary Supplement|Dietary Nitrates 400 mg|The nitrates in the beetroot juice will be absorbed and reduced in the plasma to nitrite and nitric oxide, increasing endothelium-independent nitric oxide bioavailability.
45800987|NCT04770155|Dietary Supplement|L-citrulline 3 g|Ingested L-citrulline becomes available in large quantities in the plasma for enzymatic conversion into L-arginine. The activity of the endothelial nitric oxide synthase converts L-arginine into nitric oxide, increasing endothelium-dependent nitric oxide bioavailability.
45800988|NCT04770155|Drug|Sildenafil 100 mg|Sildenafil inhibits phosphodiesterase 5, an enzyme that degrades cyclic guanosine monophosphate in the vascular smooth muscle cells inactivating the nitric oxide-mediated signal; thus, Sildenafil will prolong the availability of cyclic guanosine monophosphate, enhancing the nitric oxide-mediated intracellular cascade.
45800989|NCT04770155|Drug|Bosentan 125 mg|Bosentan blocks endothelin-1 receptors ETA and ETB, leading to a reduction in vasoconstrictor tone and a greater magnitude of vasodilator responses.
45930398|NCT05363618|Dietary Supplement|Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml)|Active study product
45930399|NCT05363618|Other|Placebo 1.4 ml|Placebo
45930400|NCT05349175|Device|Augmented Infant Resuscitator (AIR)|Real-time visual feedback from the AIR device regarding quality of bag-mask ventilation
45930401|NCT05346406|Device|Long Peripheral Catheter|Bard Powerglide 8 cm midline catheter
45930402|NCT05346406|Device|Peripherally Inserted Central Catheter|Bard 3fr, 4fr or 6fr; Cook 4fr; or Medcomp 1.9fr and 2.6fr
45930403|NCT05346172|Device|PanOptix or PanOptix Toric IOL|Patients who previously underwent cataract surgery with the PanOptix or PanOptix Toric IOL in both eyes.
45930404|NCT05339685|Drug|BL-M02D1|Administration by intravenous infusion
45930405|NCT05322018|Diagnostic Test|Faces Thermometer Scale (FTS)|The Faces Thermometer Scale (FTS) is a one-item measure with 11 numeric rating scale steps (0, no pain to 10, much pain). Each step is associated with different faces and colors. The app presents all information in text, sound, and picture. FTS is part of PicPecc, an application for mobile devices. The child/adolescent assesses their pain on a tablet by moving the finger on the scale and points to the color and face that represent their appraised level of pain.
45451180|NCT00082433|Drug|Ixabepilone + Capecitabine|Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle
45451181|NCT00082433|Drug|Capecitabine|Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle
46072813|NCT01264315|Drug|Lenalidomide|"Lenalidomide will be started at 6 months post-allotransplant at 10 mg/day continuously in all patients:~absolute neutrophil count >1x109/L without growth factors~platelet count >75x109/L without transfusion support~calculated/measured creatinine clearance: ≥20mL/minute~total bilirubin <2 x the upper limit of normal~AST (SGOT) and ALT (SGPT) <2.5 x upper limit of normal~<1mg/kg/day of prednisone, and no more than 2 immunosuppressive drugs other than steroid to control GVHD~Treatment will be continued without interruption, unless not tolerated, until unacceptable adverse events or progressive disease occur. In case of disease progression occurring before the start of lenalidomide, the patient will be withdrawn from study and treated according to the center preference. Lenalidomide will be discontinued in patients achieving and maintaining molecular remission for 2 consecutive controls at least 6 weeks apart."
45800990|NCT05444621|Radiation|Ultrasound and doppler|All patients are then assessed by transthoracic echocardiography to measure Left ventricle and Right ventricle function and to assess LVOT-VTI and SV. Doppler Ultrasound assessment of carotid arteries to assess corrected flow time (FTc), velocity time integral (VTI) and respirophasic variation in carotid artery blood flow peak velocity (ΔVpeak). The patient will be assessed pre- and post- passive leg raising (PLR) and after fluid challenge of 30 mL/Kg of IV crystalloid
45800991|NCT04744181|Drug|Ferric carboxymaltose|administration of a single dose of ferric carboxymaltose in those patietns who fulfill the inclusion criteria
45800992|NCT04744181|Drug|B vitamin|administration of a single dose of B vitamin in those patietns who fulfill the inclusion criteria
45800993|NCT04744181|Drug|Folic acid|administration of a single dose of folic acid in those patietns who fulfill the inclusion criteria
45930406|NCT05319106|Other|stem cell preparation combined with silver ion dressing|The dosage range of each cm2 ulcer wound is (1～5)×10^6. The dosage of human umbilical cord mesenchymal stem cells for the second treatment is determined according to the severity of the ulcer. Each patient is treated for 2 consecutive times, and the interval between each treatment is 3 days.
45800994|NCT05444543|Drug|Fluticasone Propionate|Participants will cycle topical steroid in a three-months on three-months off fashion
45930407|NCT05319106|Procedure|silver ion dressing|fter wound debridement, a silver ion dressing suitable for the size of the wound was cut and covered on the wound bed. Sterile gauze was covered on the silver ion dressing and fixed with adhesive tape.
45451182|NCT00094445|Drug|Curcumin|Starting dose 8 gm orally per day for 8 weeks. If patient experiences grade III toxicity, dose held and restarted with a 50% dose reduction after resolution of toxicity to </= Grade I. Patients with grade IV toxicity will discontinue treatments. Patients with </= grade I toxicity may have a 25% dose increase at each four-week period. Patients will continue on treatment until disease progresses, unless Grade III toxicity supervenes.
45651515|NCT05038033|Behavioral|Interpersonal Psychotherapy (IPT)|The IPT group sessions follow three phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbating disinhibited eating and anxiety symptoms. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors and warning signs for excessive weight gain, such as eating in response to negative affect as opposed to hunger, or feeling a sense of loss-of-control while eating. IPT focuses on psychoeducation and general skill-building that can be applied to different relationships within the framework of four interpersonal problem areas: interpersonal role disputes, role transitions, interpersonal deficits, and grief.
45800995|NCT05444543|Drug|Budesonide|Participants will cycle topical steroid in a three-months on three-months off fashion
45930408|NCT05317299|Other|3 different type of exercise|Group 1: Resistance Exercise Group 2: Plyometric Exercise Group 3: Hight Intensity Interval Training
45930409|NCT05314985|Other|Prehab intervention|Individual training program containing strengthening, sensori-motor, joint mobilisation and endurance exercises as well as educational inputs concerning perioperative procedure and instructions on e.g. how to walk with crutches.
45930410|NCT05314413|Procedure|Single Leg Immobilization|7-days of single leg immobilization to induce muscle atrophy
45451183|NCT03961763|Dietary Supplement|EPA+DHA|4 g/day EPA+DHA in tablets of 1g, 4 tablets daily, over 8 weeks (56 days)
45930411|NCT05313243|Drug|Brentuximab vedotin|Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL.
45930412|NCT05313243|Drug|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
45930413|NCT05308537|Behavioral|Mindful Compassion Care Program|The intervention is a proven effective mindfulness programme based on well-known scientific programmes such as mindfulness-based stress reduction mindfulness-based cognitive therapy and compassion focused therapy.
45930414|NCT05308264|Drug|R906289 Monosodium (R289 Na)|Drug: R906289 Monosodium (R289 Na) R906289 Monosodium (250mg PO qd or 500 mg PO qd)
45930415|NCT05305963|Radiation|Mammogram|mammogram
45930416|NCT05301023|Other|Individualized antibiotic therapy|Individualized antibiotic therapy is based on the duration of illness after treatment initiation, as the antibiotic therapy can be stopped three days after the participant has become healthy. The participant is classified as healthy if he/she is afebrile (<38.0 °C), has experienced significant clinical improvement, and have no flank pains or dysuria.
45930417|NCT05301023|Other|Standard antibiotic therapy|Standard antibiotic therapy is 10 days of antibiotic therapy regardless of the duration of illness after treatment initiation.
45930418|NCT05300022|Other|TeKnO T1D: Parents|app-delivered curriculum to provide psychoeducational education surrounding diabetes technology use
45930419|NCT05298696|Drug|Cilostazol|Cilostazol 100 mg twice daily
45930420|NCT05298696|Drug|Placebo|Placebo twice daily
45930421|NCT05295823|Device|Butterfly portable ultrasound device with bladder ultrasound images|Point-of-care PVR measurement using existing ultrasound technology (3 consecutive measurements during the same encounter) the Butterfly portable ultrasound device with bladder ultrasound images
45930422|NCT05295823|Device|Butterfly portable ultrasound device with abstract bladder images|Point-of-care PVR measurement using the Butterfly portable ultrasound device with abstract bladder images
45930423|NCT05293782|Other|Kinesitaping|Kinesiotaping - muscle facilitation technique
45930424|NCT05287971|Behavioral|Lifestyle advice|Patients will receive lifestyle advice regarding nutricion and exercise and will be monitored with regard to exercise and vital signs.
45930425|NCT05287425|Drug|Gentamicin Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
45800996|NCT05444387|Other|Upper limb loading|1 lb. external weight will be wrapped around both wrists during partial body weight support treadmill training. The partial body weight support treadmill training will be given for a maximum of 30 minutes and will finish earlier if the child asked to stop, or if the child stopped stepping. Body weight support will be systematically reduced, walking speed will be progressively increased over the training period, upright standing posture will be emphasized and normal kinematic components of the gait cycle will be facilitated during the training session. The training protocol for the current study will consist of 2 training sessions per weeks with at least one day in between and will last for 6 weeks.
45930426|NCT05287425|Drug|Ciprofloxacin Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
45930427|NCT05287425|Drug|Povidone Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
45930428|NCT05287425|Drug|Povidone and Benzalkonium Chloride Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
45930429|NCT05276492|Drug|Abiraterone Oral Tablet|Abiraterone is used in combination with prednisone to treat a certain type of prostate cancer that has spread to other parts of the body. Abiraterone is in a class of medications called androgen biosynthesis inhibitors. It works by decreasing the amount of certain hormones in the body.
45930430|NCT05276492|Drug|Prednisone tablet|Prednisone is a corticosteroid (cortisone-like medicine or steroid). It works on the immune system to help relieve swelling, redness, itching, and allergic reactions.
45451184|NCT03961763|Other|Placebo|4 g/day olive oil placebo in tablets of 1g, 4 tablets daily, over 8 weeks (56 days).
45651516|NCT05038033|Behavioral|Cognitive Behavioral Theory (CBT)|The CBT program will be derived from Coping Cat, a manualized intervention for children and adolescents with elevated symptoms of anxiety. The group intervention builds skills for managing anxiety, in general, but with a focus on how anxiety prompts disinhibited eating, including attention to and restructuring of negative cognitions that perpetuate anxiety and behavioral exposure, rather than avoidance, of anxiety-provoking situations.
45800997|NCT01970345|Drug|IGF-1|IGF-1 is an FDA-approved (IND exemption #113450), commercially available compound that crosses the blood-brain barrier and has beneficial effects on synaptic development by promoting neuronal cell survival, synaptic maturation, and synaptic plasticity.
45800998|NCT01970345|Drug|Placebo/saline|Placebo
45800999|NCT01887041|Procedure|Stent|Endoscopically inserted biliary tract drainage
45930431|NCT05276492|Other|Drug Dairy/Log|A drug dairy/log that will the study team will give for you to document information about the study drugs and meals you take during the study.
45930432|NCT05276492|Drug|Low-fat meal|"A low-fat meal that will be taken with abiraterone. If you have questions about what is considered a low-fat meal during the study, ask the study doctor or research staff."
45930433|NCT05276466|Diagnostic Test|Polymerase Chain Reaction and Next-Generation DNA Sequencing|"The qPCR Rapid Screening Panel is a quantitative real-time PCR test for bacteria and fungi.~Next-Generation DNA Sequencing is the Comprehensive Sequencing test will detect virtually all microbial organisms and fungal pathogens that may be present in patient specimens."
45930434|NCT05270902|Device|CytoSorb Adsorber|Polymer based adsorber system for the elimination of cytokines
45930435|NCT05266898|Biological|Human papillomavirus 9-valent vaccine, recombinant|Subunit vaccine against 9 genotypes of human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52, 58)
45451185|NCT01081535|Drug|ketorolac, fentanyl|intravenous PCA
45930436|NCT05266872|Other|Observational study with sample and data collection|Observational study with sample and data collection
45930437|NCT05262491|Drug|BL-B01D1|Administration by intravenous infusion
45930438|NCT05259657|Behavioral|Lymfit Intervention|"Participants will be allocated a pre-registered Inspire II / Charge IV model Fitbit. The research team will reach out to the participant via videoconferencing and help them to: download the Fitbit smartphone application; log-in using the anonymous study identification information; and pair their Fitbit with their smartphone application.~A kinesiologist of the study will meet with the participants for a baseline fitness assessment. The kinesiologist will examine the baseline physical activity levels, fitness level and sedentary behaviours of the participants, to design a personalized exercise prescription. Within one week after the baseline fitness assessment, the kinesiologist will contact the participants to discuss the exercise prescription. Every two weeks there-after, the kinesiologist will follow up with the participants via videoconferencing to discuss their progress and to modify or advance their exercise prescriptions as needed, plus an acceptability assessment survey."
45930439|NCT05259657|Behavioral|Wait-list control|Participants will be contacted by the study kinesiologist for a baseline fitness assessment 3 months after they consent, participants will be given a Fitbit, a personalized exercise prescription and receive bi-weekly follow-ups for 12 weeks.
45930440|NCT05258721|Drug|ClōSYS® Sensitive Fluoride Toothpaste|ClōSYS® Sensitive Fluoride Toothpaste is an over-the-counter drug product containing 0.12% stabilized chlorine dioxide (sodium chlorite in an aqueous solution) and 0.13% w/v fluoride ion.
45930441|NCT05258721|Other|ClōSYS® Sensitive Rinse|ClōSYS® Sensitive Rinse is a cosmetic product containing 0.1% stabilized chlorine dioxide.
45930442|NCT05257785|Behavioral|Lymfit exercise intervention|Participants randomized to this arm will be allocated a pre-registered Inspire II / Charge IV model Fitbit. The kinesiologist of the study will meet with the participants for a baseline fitness assessment. The kinesiologist will examine the baseline physical activity levels, fitness level and sedentary behaviours of the participants, to design a personalized exercise prescription. Within one week after the baseline fitness assessment, the kinesiologist will contact the participants to discuss the exercise prescription. Every two weeks there-after, the kinesiologist will follow up with the participants via videoconferencing to discuss their progress and to modify or advance their exercise prescriptions as needed. Participants will be followed-up at 6 months and 12 months.
45930443|NCT05257785|Behavioral|Waitlist control|Participants will be contacted by the study kinesiologist for a baseline fitness assessment 3 months after they consent, participants will be given a Fitbit, a personalized exercise prescription and receive bi-weekly follow-ups for 12 weeks.
45930444|NCT05257057|Diagnostic Test|Immunohistochemical staining|Immunohistochemistry will be performed on the endometrial tissue specimens
45930445|NCT05254496|Behavioral|Dietary Intervention Classes|Participants will attend classes once per week for 6 months and then bi-weekly for 6 months.
45930446|NCT05249608|Device|A prospective, open-label, multicenter, single-arm clinical study to evaluate the safety and performance of the Gastric Bypass Stent System as a weight loss treatment for obesity|This study includes 3 phases; screening period, procedural period, and a follow-up period. Following a 2-week screening period, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 2; Day 0). Following a 3-month treatment period, the device is removed, and subjects are followed for 6 months. In total subject participation will last for approximately 9 months.
45930447|NCT05246137|Biological|COVID-19 Vaccine 40 ug/dose|Intramuscular injection of 0,5 ml with 40 ug of recombinant PHH-1V
45651517|NCT05029531|Combination Product|the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.|two-stage stratification into risk groups: Initially and According to the results of induction therapy MRD-positive patients receive a course of blinatumomab and HSCT.
45651518|NCT05037643|Procedure|TIPS|Transjugular Intrahepatic Portosystemic Shunt is performed to prevent / treat symptomatic portal hypertension
45651519|NCT05029453|Drug|Apatinib|In experimental group, the drug used with apatinib and chemotherapy.
45651520|NCT04434625|Drug|Polyethylene glycol|Before colonoscopy, patient-related and procedure-related parameters were collected by one investigator in each center. In MI group, a procedure-based score, used for predicting inadequate bowel preparation, was calculated for each patients. Patients with score ≥3 were asked to taking another dose of PEG (1.5L) within 1-2 hours. Colonoscopy was performed in afternoon (about 4h after drinking PEG). Patients with score<3 in IM group and those in the control group underwent colonoscopy directly
45451186|NCT03741257|Drug|Hypertonic saline|resuscitation fluid
45801000|NCT01887041|Procedure|Biliodigestive anastomosis|Biliodigestive anastomosis
45451187|NCT01087229|Drug|equimolar oxygen-nitrous oxide mixture|Kinesitherapy is performed with a mask by which patient inhales an equimolar oxygen-nitrous oxide mixture.
45451188|NCT01087229|Drug|Placebo|Kinesitherapy is performed with a mask by which patient inhales a placebo.
45451189|NCT00082355|Drug|Alteplase (Activase, Genentech)|Dose of Alteplase will not exceed 10 mg/d/leg and is delivered in a concentration of 100ug/mL. The actual dose delivered is based upon the length of the thrombosed vein and 1 mL is injected directly into each centimeter of a thrombosed vein in a lower extremity. The treatment will be repeated up to 4 times over a 4 day period.
45451190|NCT01084577|Device|AQUACEL® Ag|AQUACEL® Ag dressing for four weeks followed by AQUACEL® for the remaining 4 weeks.
45451191|NCT01084577|Device|Urgotul® Silver|Urgotul® Silver for four weeks followed by Urgotul® for the remaining 4 weeks.
45451192|NCT00094055|Drug|AG013736|AG013736, tablets 5 mg BID daily until tumor progression or toxicity
45651521|NCT05029765|Dietary Supplement|Mediterranean diet|"Mediterranean diet:~22% Monounsaturated fat, 6% Polyunsaturated fat, 7% Saturated fat, 15% Protein, 50% Carbohydrates"
45651522|NCT05029765|Dietary Supplement|Healthy diet (WHO recommendations)|Recommendations according to WHO
45801001|NCT04717115|Genetic|Genetic diagnosis|No Intervention foreseen, but genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene, known to cause PCD) with typical clinical symptoms of PCD and at least one other method confirming PCD-diagnosis is needed
45451193|NCT01084811|Procedure|biopsy|One or more biopsies from nasal mucosa will be harvested during surgery
45801002|NCT00840047|Drug|Methionine|Intravenous injection
45801003|NCT00619931|Drug|APD791|APD791 or matching placebo in escalating doses
45930448|NCT05245812|Device|da Vinci SP Surgical System|This is a software-controlled, electro- mechanical system designed for surgeons to perform single port minimally invasive surgery.
45930449|NCT05234671|Other|Exercise programme|12-week exercise programme. The estimated session's duration of 55 minutes. For the prescription of high intensity interval training (HIIT) and the collection of individualised peak power output (PPO) a baseline peak oxygen uptake on an arm crank ergometer will be performed. Each session will consist of 5 minutes warm up performing light to moderate intensity arm cranking (55-65% PPO), 30-minutes' high intensity interval training (HIIT; 30s 100% PPO/ 30s passive recovery) on an arm crank ergometer. The HIIT protocol will be combined with resistance training (RT) lasting for a total of 15 min.The intensity will be at 75-80% of one repetition maximum. Following each exercise session, patients will undertake a 5 min cool-down period.
45930450|NCT05232799|Other|Care Anywhere with Community Paramedics program|Outpatient management with supportive services provided by the community paramedic team.
45651523|NCT05029765|Dietary Supplement|Placebo|Placebo
45651524|NCT05029765|Dietary Supplement|Biopolis-MIX42|Biopolis-MIX42: a capsule containing 10^9 colony forming units of Lactobacillus rhamnosus and Bifidobacterium longum.
45651525|NCT02640157|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
45651526|NCT02640157|Drug|Sofosbuvir|Tablet
45651527|NCT02640157|Drug|Daclatasvir|Tablet
45651528|NCT04471519|Biological|BBV152A - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
45651529|NCT04471519|Biological|BBV152B - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
45930451|NCT05232032|Drug|Nociceptin Receptor Antagonist|Participants in the experimental arms will receive 40 mg of the nociceptin receptor antagonist. Peak concentrations are achieved 2-4 hours post-administration.
45930452|NCT05232032|Device|Aversive stimuli|As part of the approach/avoidance task, electrotactile stimulation will be used. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model, DS71, has been safely implemented in studies within Massachusetts General Hospital (Milad et al., 2013).
45930453|NCT05222516|Drug|Broncho-Vaxom|Daily administration of Broncho-Vaxom 3.5mg capsules
45651530|NCT04471519|Biological|BBV152C - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
45930454|NCT05222516|Drug|Placebo|Daily administration of Placebo capsules
45930455|NCT05219890|Dietary Supplement|Fish oil|They will consume the fish oil equivalent to 4.8 g/day of EPA and DHA for 3 months, followed by a one-month period without treatment.
45804164|NCT03224585|Drug|Placebo|"Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - placebo 100 mg saline subcutaneous injections daily for 4 days"
45651531|NCT04471519|Biological|Placebo - Phase I|0.5 ml of the Placebo will be administered intramuscularly twice at Day 0 and Day 14
45930456|NCT05219422|Behavioral|Project ALERT|14 session drug prevention program for 7th and 8th grade youth.
46072814|NCT01108627|Drug|open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER®|• Drugs. The study drugs are open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER® and FORADIL placebo. FORADIL® AEROLIZER® consists of a capsule dosage form containing a dry powder formulation of FORADIL (formoterol fumarate) intended for oral inhalation only with the AEROLIZER Inhaler. Each clear, hard gelatin capsule contains a dry powder blend of 12 mcg of formoterol fumarate and 25 mg of lactose (which contains trace levels of milk proteins) as a carrier. Ten capsules are contained in each package, which is clearly labeled. To use the delivery system, a FORADIL capsule is placed in the well of the AEROLIZER Inhaler, and the capsule is pierced by pressing and releasing the buttons on the side of the device. The formoterol fumarate formulation is dispersed into the air stream when the patient inhales rapidly and deeply through the mouthpiece.
46072815|NCT01108627|Drug|foradil placebo|open-labeled inhaled corticosteroids (ICS); foradil placebo
46072816|NCT01108627|Drug|foradil|open-labeled inhaled corticosteroids (ICS); foradil
45651532|NCT04471519|Biological|BBV152A - Phase II|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28
45651533|NCT04471519|Biological|BBV152B - Phase II|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28
45651534|NCT05037565|Dietary Supplement|Partially hydrolyzed guar gum|Partially hydrolyzed guar gum (PHGG) is a vegetal, water soluble, non-viscous, non-gelling dietary fiber that is derived from guar gum, a water-soluble, viscous, gelling polysaccharide found in the seeds of Cyamopsis tetragonolobus. PHGG is available over the counter as a dietary supplement as fiber.
46072817|NCT01087294|Procedure|Allogeneic stem cell transplant|Allogeneic stem cell transplant
46072818|NCT01087294|Biological|Anti-CD19-chimeric-antigen-receptor-transduced T cells|"Patients receive T cells genetically engineered to express an anti-CD19 CAR. The cells are cultured in media containing IL-21, IL-7, and TWS119.~TWS119 is a glycogen synthase 3 inhibitor"
46072819|NCT01087294|Procedure|Leukapheresis|Donors will undergo leukapheresis
46072820|NCT00890149|Drug|Ondansetron|Ondansetron (4ug/kg bid),
46072821|NCT00890149|Drug|Placebo|Placebo bid
46072822|NCT00890149|Behavioral|BASICS Plus|Brief Alcohol Screening and Intervention for College Students. Brief behavioral intervention to reduce drinking.
45651535|NCT05037721|Other|gargling with green tea|experimental group using 0.5% green tea gargle, control group use clear water gargle, secondary in daily use mouthwash after breakfast and lunch after 30 minutes, 15 ml each use gargle for 30 seconds, total 7 days
45651536|NCT05037721|Other|gargling with water|using water gargle, control group use clear water gargle, secondary in daily use mouthwash after breakfast and lunch after 30 minutes, 15 ml each use gargle for 30 seconds, total 7 days
45804165|NCT05452681|Other|Educational Intervention|Receive Y-AMBIENT
45804166|NCT05452681|Other|Quality-of-Life Assessment|Ancillary studies
45804167|NCT05452681|Other|Questionnaire Administration|Ancillary studies
45804168|NCT05452681|Other|Control Intervention|Receive cookbook and socialization calls
45801004|NCT05452655|Behavioral|Multidisciplinary Intensive Rehabilitation|"The rehabilitation program will last for 6 consecutive weeks and involves the execution of 30 sessions, 5 days a week lasting 160 '/ day each (80' motor; 40 'cognitive and 40' speech therapy rehabilitation) for 3 days a week and 180'/ day (80 'motor; 60' cognitive and 40 'speech therapy rehabilitation) for 2 days a week. The EXP group will receive 18 sessions (3 times a week) of treadmill (20 min), balance exercises and functional reinforcement (20 min). The remaining motor sessions will be defined based on the patient's therapeutic needs.~The cognitive treatment will be proposed both in traditional mode (3 times a week) and through the support of semi-immersive Virtual Reality Rehabilitation System (VRRS) (2 times/week). The VRRS treatment is structured in 2 sessions per week (60 min) for 6 consecutive weeks.~The speech therapy program will include clinical and instrumental evaluations and innovative techniques will be used for the treatment (biofeedback with Vitalstim)."
45801005|NCT05452655|Behavioral|Muscle-stretching and active mobilization exercises|The control group subjects will undergo a home-based self-treatment program for 40 '/ day for 6 consecutive weeks consisting of muscle-stretching and active mobilization exercises.
45930457|NCT05219422|Behavioral|Getting to Outcomes|The Getting To Outcomes (GTO) implementation support intervention provides technical assistance, training, guides, and tools to improve community-based practitioners capacity to complete tasks associated with implementing an EBP, which in turn leads to improved implementation fidelity.
45930458|NCT05216978|Behavioral|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 9-week period. The positive psychology program exercises include three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
45930459|NCT05216601|Biological|MVC-COV1901|Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region. Group A and B
45930460|NCT05216601|Biological|MVC-COV1901(Beta)-15|Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901(Beta)-15 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region
45930461|NCT05216601|Biological|MVC-COV1901(Beta)-25|Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901(Beta)-25 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region
45930462|NCT05215730|Device|MedCu wound dressings with copper oxide (COD)|Patients whose foot wound is indicated for VAC treatment will be randomized to either treatment arm after signing informed consent.
45930463|NCT05211427|Procedure|Biopsy|Biopsy of an oropharynx tumor or of a healthy oropharynx mucosa
45930464|NCT05210556|Other|Diagnosed with Surgical Site Infection|As an observational study, this notates patients who were diagnosed with a deep organ/space surgical site infection within 30 days of surgery
45651537|NCT05037253|Drug|Vitamin D|Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week, followed by a switch to a daily intake of 5,000 IU for 3 months or low dose vitamin D (2,000 IU weekly) for 3 months.
45651538|NCT05029297|Drug|Capsaicin|
45801006|NCT04739111|Drug|Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)|In the dose-escalation phase, CDP1 400 mg/ m2 will be given in the first week, then 250 mg/m2 will be given evert week. LDP will be given every two weeks with dose climbing of 5 mg/kg, 10 mg/kg, 20 mg/kg. Dose in the dose-expansion phase according to the assesment in the dose-escalation phase.
45801007|NCT05444231|Behavioral|Strategic Memory Advanced Reasoning Training (SMART)|"Research-based strategies to more effectively process information & manage stress.~Scientific information about the importance of sleep & actionable tips on how to get better sleep.~Quick, interactive activities that reinforce information learned in online modules. These also build awareness of how our daily habits (sleep, nutrition, exercise, social interactions, etc.) may be impacting our performance for better or worse."
45804169|NCT05627869|Procedure|Transversus thoracic plane block|TTPB group will receive bilateral ultrasound-guided transversus thoracic muscle plane block using 20 ml of bupivacaine 0.25% for each side.
45804170|NCT05627869|Procedure|Pecto intercostal fascial block|PIFB group will receive bilateral ultrasound-guided Pecto-intercostal fascial plane block using 20 ml of bupivacaine 0.25% for each side.
45930465|NCT05210179|Biological|TURKOVAC-Dollvet|TURKOVAC-Dollvet vaccines produced by Dollvet Veterinary Vaccine Pharmaceutical Biological Substance Production Industry Co., Ltd.
45930466|NCT05210179|Biological|TURKOVAC-Koçak|TURKOVAC-Koçak vaccines produced by Koçak Farma Pharmaceutical and Chemical Industry Co., Ltd.
45930467|NCT05209074|Drug|Ivosidenib|Ivosidenibflat dose (250mgor 500mg) daily on day 1 of a 14 day cycle.
45930468|NCT05209074|Drug|mFOLFIRINOX|mFOLFIRINOX on days 1-3 of a 14-day cycle. Surgical resection after up to ninety (90) days of treatment.
46072823|NCT00813982|Device|Lotrafilcon A Experimental Contact Lens|Experimental spherical, silicone hydrogel soft contact lens
46072824|NCT00813982|Device|Lotrafilcon A Commercial Contact Lens|Commercially marketed spherical, silicone hydrogel soft contact lens
46072825|NCT00716066|Biological|Anti-Thymocyte Globulin|Given IV
46072826|NCT00716066|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous or syngeneic stem cell transplantation
46072827|NCT00716066|Drug|Carmustine|Given IV
46072828|NCT00716066|Drug|Cytarabine|Given IV
46072829|NCT00716066|Drug|Etoposide|Given IV
46072830|NCT00716066|Other|Laboratory Biomarker Analysis|Correlative studies
45651539|NCT05028907|Drug|5 mg chloramphenicol, 1 mg dexamethasone sodium phosphate, 0.25 mg tetryzoline hydrochloride, 2 mg Hydroxypropyl Methyl Cellulose, 10 mg α-tocopherol acetate and 8 mg macrogol 400).|The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
46072831|NCT00716066|Drug|Melphalan|Given IV
46072832|NCT00716066|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous or syngeneic stem cell transplantation
46072833|NCT00716066|Drug|Prednisone|Given PO
46072834|NCT00716066|Procedure|Syngeneic Bone Marrow Transplantation|Undergo syngeneic bone marrow transplantation
46072835|NCT00566098|Biological|MILs|
45930469|NCT05208125|Biological|ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).|Intramuscular administration of 1 x ChAdOx1.HTI (5x1010 Vp), 3 x ConM SOSIP.v7 (100μg) adjuvanted with MPLA liposomes (500μg), and 1 x MVA.HTI (2x108pfu)
45930470|NCT05208125|Other|Normal saline solution|Intramuscular administration of normal saline solution
45801008|NCT05444075|Other|a method for communication|"the Arabic alphabet (arranged in the traditional order) printed on double-sided cardboard, with one copy facing the person and one facing the doctor.~The code will be in the case of a positive selection (the desired line or letter) by looking up or one blink, but in the case of a negative selection (not the desired line or letter), it will be by looking down or two blinks.~The person will choose the letters of each word and then choose the end of the word and after selecting all the words of the sentence choose the end of the sentence.~After the strategy has been taught to the subject, he or she will be asked to communicate with the physician using this way."
45801009|NCT05443997|Behavioral|MIYCN capacity building|"MIYCN knowledge, skills, and motivation of FLWs~Supportive supervision~Decentralized programmatic decision-making using data~PRI member involvement~Availability of THR~IYCF knowledge and practices"
45801010|NCT05443841|Other|pleural lavage|pleural lavages before tumor resection and after tumor resecion, respectively
45801011|NCT04623515|Other|REDCap Questionnaires|Once consent is obtained, the participants will be routed to a REDCap secure link. Participants will complete a questionnaires regarding demographics and medical history. Participants will also complete validated questionnaires regarding their lower urinary and bowel tract function and sexual health- International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms (ICIQ-FLUTS), Modified Manchester Health Questionnaire (MMHQ), PROMIS® v2.0 Brief Profile Sexual Function and Satisfaction (Female) and SF-12 ® .
45930471|NCT05201807|Device|Dailies Total 1 (DT1)|TEST Lens
45930472|NCT05197153|Biological|Half dose of MVC-COV1901|Approximately 240 participants will receive 1 doses of half of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
45930473|NCT05197153|Biological|Full dose of MVC-COV1901|Approximately 240 participants will receive 1 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
45930474|NCT05197153|Biological|AZD1222|Approximately 240 participants will receive 1 doses of AZD1222 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
45930475|NCT05197153|Biological|Half dose of mRNA-1273|Approximately 240 participants will receive 1 doses half of mRNA-1273 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
45930476|NCT05194982|Drug|BL-B01D1|Administration by intravenous infusion
45930477|NCT05194241|Behavioral|One MORE|One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into four, 30-minute segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Mindful pain management will be the focus of the second segment and participants will be guided through a mindfulness of pain practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The third segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, and the fourth segment will focus on increasing the positive emotions that can attenuate pain with mindful savoring.
45930478|NCT05192850|Drug|Metformin use|As an observational study, this is past exposure to metformin that occurred during the study period
45930479|NCT05188963|Procedure|Intermittent catheterization|Intermittent catheterization is performed as treatment for urinary retention. Treatment is stopped when postvoid urinary retention volume is below the threshold of each group.
45930480|NCT05182034|Biological|SMUP-IA-01(low dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10^6 cells/2mL)
45930481|NCT05182034|Biological|SMUP-IA-01(mid dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10^7 cells/2mL)
45930482|NCT05182034|Drug|Active Control Group Sodium chloride|A single knee administration of Sodium chloride
45930483|NCT05179655|Behavioral|Emotion Regulation Individual Therapy for Adolescents (ERITA)|The ERITA intervention as add-on to TAU consists of 11 weeks, manualized online therapy based on the methods of Cognitive Behavioral Therapy (CBT), Dialectical Behavior Therapy (DBT), and Acceptance and Commitment Therapy (ACT) adapted for youth. The ERITA content consists of psychoeducation, emotion recognition, awareness training and theory of emotion regulation, including acceptance and validation skills.
45930484|NCT05179655|Other|Treatment as usual|Within Mental Health Services in Denmark child and adolescent psychiatrists provide specialized treatment for young psychiatric patients as outpatient services. In this trial the control intervention is treatment as usual (TAU) and consists of clinical assessment and treatment for patient's current primary psychiatric condition. TAU encounters a variety of clinical treatment and assessment offers, however, all within the field of expertise in child and adolescent psychiatry; out-patient care may consist of treatment for OCD, eating disorders, psychoses or affective disorders. TAU may consist of pharmacological treatment, Family-Based Treatment (FBT), Cognitive Behavioral Therapy (CBT), supportive counselling and/or psychoeducation.
45930485|NCT05173714|Behavioral|SLIMM|Increase in light walking activity, replacing 1 hour/day of sedentary duration with casual walking duration. Increase in sedentary breaks, from sitting/lying position to standing position, at least once every hour as independent of the total time spent on sedentary activities.
46072836|NCT00566098|Drug|Melphalan|
46072837|NCT00566098|Biological|PCV13|
46072838|NCT00248287|Drug|Irinotecan + Carboplatin|irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle
46072839|NCT00248287|Drug|irinotecan + Carboplatin + erbitux|irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2
46072840|NCT04250220|Diagnostic Test|e-Health based strategy: PPG-based screening using a smartphone and ECG patch|PPG-analysis via Smartphone-App (Preventicus Heart Beats) and ECG patch
46072841|NCT00703599|Procedure|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
46072842|NCT04249284|Drug|BMS-986165|Specified dose on specified days
46072843|NCT04249284|Drug|BMS-986165 prototype 1|Specified dose on specified days
46072844|NCT04249284|Drug|BMS-986165 prototype 2|Specified dose on specified days
45930486|NCT05173714|Behavioral|Standard Resistance Training|Participants will be provided a standard resistance training regimen to follow during the course of the study. Participants will not receive individualized instruction, guidance or modification to the resistance training regimen.
45801012|NCT01885897|Biological|ALT-803|Given weekly IV at assigned dose level, ranging from 1mcg/kg to 30mcg/kg.
45801013|NCT04621331|Drug|Roxadustat|HIF-PH inhibitor for treatment of anemia in CKD
45930487|NCT05173714|Behavioral|Guided Resistance Training|Supervised resistance training sessions are individualized for a low-resistance, high-repetition regimen of lower body major muscle groups with established guidelines. Instructions and resistance training bands will be provided for home use. Study participants will record compliance to the resistance training regimen for further guidance and potential modification.
45930488|NCT05173714|Drug|Placebo|Oral placebo tablets (matching the experimental semaglutide) will be administered from the first through ninth months of the drug intervention period.
45930489|NCT05173714|Drug|Semaglutide|Oral semaglutide 3 mg/day will be administered for the first month of study drug intervention period, if tolerated, the dose will increase to 7 mg/day for the second month and to a maximum dose of 14 mg/day from the third through ninth months of the drug intervention period.
45930490|NCT05171881|Other|Intervention for cerebral hypoxia|For cerebral oxygen saturation measures below target range (cerebral hypoxia), a treatment algorithm with the following potential clinical interventions will be applied: fluid resuscitation, initiation of vasopressor/inotrope medication, change in mechanical ventilation or respiratory support, adjustment of fractional inspired oxygen, transfusion of red blood cells, acquisition of echocardiogram or cranial ultrasound.
45930491|NCT05170243|Drug|9MW1911 Injection|Single dose intravenously on day 1
45930492|NCT05170243|Drug|9MW1911 Injection Placebo|Single dose of matching placebo intravenously on day 1
45930493|NCT05151770|Other|Measure of glycemia levels and comparison to algorithm predictions|The study aims to evaluate the efficacy of a new algorithm in predicting the evolution of glycemia levels after a full meal. Glycemia levels measured during and after a full meal will be compared to the values predicted by the algorithm. Composition of the meals will also be collected.
45801014|NCT04768231|Drug|Rifampin|The target dose of 35mg/kg will be reached supplementing fixed-dose combination tablets (standard dose) with rifampin-only tablets.
45930494|NCT05145868|Behavioral|Alcohol Skills and Emotion Regulation Intervention|The text-based intervention will provide alcohol reduction strategies and emotion regulation skills.
45930495|NCT05145868|Other|Attention Control|Text-messages will be sent that include no intervention content to serve as an attention control
45930496|NCT05130359|Dietary Supplement|Placebo|consume 2 sachet per day for 4 weeks
45930497|NCT05130359|Dietary Supplement|Banana peel extract|consume 2 sachet per day for 4 weeks
46072845|NCT04474938|Drug|Daratumumab|16mg/kg, QW Cycles 1-2 (28 days/cycle), Q2W Cycles 3-6, and Q4W thereafter for up to 1 year
45651540|NCT05028907|Drug|sodium hyaluronate, polyethylene and propylene glycol based) three times daily for three months|The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
45651541|NCT03094117|Other|News items with spin|Interpretation of news items with spin
45801015|NCT02987725|Behavioral|Hypnosis|A 30-minute Hypnosis session with a trained clinician focused on relaxation and hypnotic suggestions for pain relief and reduced stress responses.
45651542|NCT03094117|Other|News items without spin|Interpretation of news items without spin
45801016|NCT02987725|Behavioral|Attention Control|A 30-minute historical story read by a research clinician.
45930498|NCT05130034|Behavioral|Home-based pulmonary rehabilitation|Home-based tablet-assisted pulmonary rehabilitation with monitoring technology and telephonic health coach calls using motivational interviewing techniques
45930499|NCT05129605|Diagnostic Test|Prostate cancer screening|Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate
46072846|NCT04474938|Drug|Bortezomib|1.3mg/m2 of subcutaneous bortezomib on days 1, 8, 15 and 22 of a 28-day cycle for 6 cycles
46072847|NCT04474938|Drug|Dexamethasone|20mg of dexamethasone on days 1, 8, 15 and 22 of a 28-day cycle for 6 cycles
46072848|NCT00837213|Drug|Benzoyl peroxide with clindamycin|Benzoyl peroxide wash - Clindamycin foam
45451194|NCT02531165|Drug|Fentanyl|Analgesia protocol using Fentanyl (initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required).
45651543|NCT05050357|Device|Hormonal intrauterine device|insertion of hormonal IUD during menstrual period
45651544|NCT05050357|Drug|Progestins Norethindrone|oral ethisteron twice daily for three months
45651545|NCT05050201|Device|Sleepio|Digital CBT application for insomnia
45651546|NCT05026411|Diagnostic Test|T 0 Diffusion Tensor MR|Magnetic resonance images has been taken from 20 individuals with eating disorders before fixed orthodontic treatment
45651547|NCT05026411|Diagnostic Test|T 1 Diffusion Tensor MR|Magnetic resonance images will be taken from 20 individuals with eating disorders after 12 months of orthodontic treatment.
45651548|NCT05026411|Diagnostic Test|T 2 Diffusion Tensor MR|Magnetic resonance images will be taken from 20 individuals with eating disorders 6 months after orthodontic treatment finished
45651549|NCT03094351|Procedure|esophagectomy|Robot assisted esophagectomy with extended two field lymphadenectomy.
45801017|NCT05452421|Dietary Supplement|Isotonic carbohydrate beetroot juice drink|An isotonic carbohydrate beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.2 g carbohydrate per 100 ml. Osmolality 304-310 mOsm/kg.
46072849|NCT00837213|Drug|Benzoyl peroxide with clindamycin and doxycycline|Benzoyl peroxide wash - Clindamycin foam - Doxycycline capsules
46072850|NCT04249050|Dietary Supplement|Oral Impact powder|Oral nutritional supplement containing fish oil, arginine and RNA
46072851|NCT05602155|Procedure|Group 1|Even numbered patients will partial weight bearing after treatment,
45804171|NCT01457612|Dietary Supplement|Strawberry|20g twice per day (BID) in beverage
45804172|NCT01457612|Dietary Supplement|Placebo1|Placebo Beverage 1 without fiber
46072852|NCT05602155|Procedure|Group 2|patients with odd numbers will walk with full weight bearing after treatment
45930500|NCT05127577|Other|Abdominal massage|Abdominal massage will be applied to patients at least 30 minutes after morning and evening meals (8:30 in the morning, 20:30 in the evening) for 15 minutes each, similar to the literature [33,34,38]. Data of the patients will be collected again 15 minutes after the application of abdominal massage (09:00-09:15 in the morning, 21:00-21:15 in the evening). Abdominal massage will start in the evening of the day the patient is transferred to the clinic (20:30), and will be terminated when the patient defecates. In order to stimulate bowel movements, four basic movements will be used in the abdominal massage to be applied clockwise: superficial effusion, deep effusion, petrissage, and vibration.
45801018|NCT05452421|Dietary Supplement|Beetroot juice drink|A beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.1 g carbohydrate per 100 ml. Osmolality 390-410 mOsm/kg.
45801019|NCT01889563|Other|Physical Exercise Training Program Exercise|Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
45930501|NCT05123118|Behavioral|Integrated intervention of smoking cessation and breastfeeding|The intervention group will receive an integrated intervention of smoking cessation and breastfeeding: education and counseling, monitoring and feedback, and contingent financial incentives.
45930502|NCT05123118|Behavioral|Attention placebo control|Participants in the control group will receive usual prenatal care from physicians, nurses, or social workers. They will receive best standard care on smoking cessation and breastfeeding, including referral to the New York State Smokers' Quitline and the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC).
45930503|NCT05111717|Drug|Desflurane|Peripheral venous blood samplesof patients will collected at two time points as follows: before the premedication and the induction of anesthesia (T₁): 120 minutes after the beginning of anesthesia (T₂). Anesthesia maintenance will be provided with 40% O₂ and minimum alveolar concentration (MAC) in 60% air with 6% desflurane. DNA will be obtained from blood samples with the help of DNA isolation kit, and global DNA methylation analysis will performed by ELISA method.
45801020|NCT04608851|Drug|E. coli Nissle|1 ml of oral suspension containing 10 E8 CFU /ml of E. coli Nissle strain
45801021|NCT04608851|Other|Placebo control|1 ml oral syrup consisting of Saccharum 630 mg/g and Aqua purificata 370 mg/g.
45930504|NCT05105919|Drug|Aspirin 80 mg EC Tab|Participants will receive a 7 day supply of Aspirin 80 mg EC Tab and will be instructed to take the drug at the same time every day for 7 days.
45930505|NCT05104749|Drug|Homeopathic Medication|Homeopathic medicines are prepared according to standardized methods as specified by the Homeopathic Pharmacopoeia of the United States (HPUS), which was mandated by Congress to regulate the manufacture of homeopathic medicines as part of the Food, Drug, and Cosmetics Act of 1939. All homeopathic medicines prescribed in this study must be found in the HPUS. For a complete list of homeopathic medicines, contact the researchers.
45930506|NCT05104749|Other|Placebo|Inert lactose pellets
45930507|NCT05099549|Drug|AFM24|Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.
45930508|NCT05099549|Biological|SNK01|Patient-specific ex-vivo expanded autologous natural killer cells.
45930509|NCT05095909|Device|Cryo-compression|Programmable intermittent compression with integrated cryo-therapy.
45930510|NCT05095909|Other|Cryo-therapy|Subjects are fitted with gel ice packs and wraps.
45930511|NCT05092009|Other|Tissue and blood|Tissue and blood will be derived from patient during a standard of care procedure
45801022|NCT04599491|Device|Sidestream capnography using the 'Respironics LoFlo Sidestream CO2 Module'|Study patients randomized into the 'Sidestream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with sidestream etCO2 monitoring using the 'Respironics LoFlo Sidestream CO2 Module'.
45930512|NCT05081453|Device|pavlik harness|The application of a pavlik harness will be carried out in the intervention group. It will follow a protocol similar to that of the treatment of hip dysplasia in terms of follow-up and safety
45930513|NCT05077527|Biological|Axicabtagene Ciloleucel|Given IV
45930514|NCT05077527|Drug|Cyclophosphamide|Given IV
45930515|NCT05077527|Drug|Fludarabine|Given IV
45651550|NCT03094351|Procedure|esophagectomy|Conventional thoracoscopic esophagectomy with extended two field lymphadenectomy.
45801023|NCT04599491|Device|Mainstream capnography using the 'Respironics Capnostat 5 Mainstream CO2 sensor'|Study patients randomized into the 'Mainstream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with mainstream etCO2 monitoring using the 'Respironics Capnostat 5 Mainstream CO2 sensor'.
45930516|NCT05070364|Drug|Peginterferon Lambda-1a|Immunomodulator
45930517|NCT05070169|Procedure|Early Surgical Fixation vs. Delayed Surgical Fixation|Evaluation of the reduction of the peri-operative blood loss in patients undergoing early surgical fixation (within 24 hours) of an intertrochanteric fracture under DOAC therapy compared to a retrospectively enrolled group of patients who underwent delayed surgical fixation (≥48 hours) of an intertrochanteric fracture under DOAC therapy.
45930518|NCT05061238|Device|Vibrating Device|The vibrating device strapped to different parts of your leg. The device will be secured to your leg with a Velcro strap.
46072853|NCT02836392|Behavioral|Questionnaire|
46072854|NCT02833038|Drug|Magnesium Sulfate|adminstration of intravenous magnesium as bolus of 50 mg/kg, followed by continuous infusion at rate of 10 mg/kg/h
45651551|NCT03094273|Procedure|Saucerization biopsy|2 mm saucerization biopsy of dysplastic nevi
45651552|NCT05025319|Radiation|X-ray image|Bedside x-ray at intensive unit.
45651553|NCT05025553|Dietary Supplement|Gut mobilization|Polyethylene Glycol (PEG) at the Dose of 6.9 g/d Once a Day for 6 Month. Children were observed and tested at baseline (T0), 1 month (T1) and 6 months (T2) after gut mobilization.
45651554|NCT05028127|Drug|Bimekizumab|Subjects will be receiving bimekizumab at pre-specified time-points.
45651555|NCT05024695|Device|MINIject™ Implant|The MINIject™ SO627 is an integrated system for Minimally Invasive Glaucoma Surgery (MIGS) comprised of a glaucoma drainage implant, the MINIject™ SO627 and the SO Delivery System, designed to deliver the MINIject™ implant into the supraciliary space.
45930519|NCT05059054|Other|Strengthening exercise|"Strengthening exercise program Participants performed this protocol at home for 3 times per day. The participants progress their exercise based on the achievement of the previous level of each exercise protocol. The physical therapist recorded the level of each exercise for each participant during eight times of treatment. Total time for this section is approximately 30 minutes. Detail of the strengthening exercise is in the following.~Toe curl exercise (toe flexors strengthening)~Ankle evertor exercise (peroneal strengthening)~Ankle invertor exercise (tibialis posterior strengthening)~Heel raise exercise (high-load strength training)"
45930520|NCT05059054|Other|Insole (CFO) group|"The CFO insole group The participants will receive the foot assessment before making the CFO for each participant. The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC) and one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort.~The participants will be asked to use the CFO in daily life during weight-bearing activities."
45801024|NCT05452343|Biological|CM310|600 mg (first doing) + 300 mg (subsequent dosing), once every two weeks
45451195|NCT02531165|Drug|Morphine|Analgesia protocol using Morphine (initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required).
45801025|NCT05452265|Procedure|Endoscopic resection|Complete resection of gastric SETs was recommended if the tumor size was >2 cm, presence of malignant features, or if the patient was symptomatic, declined periodical surveillance, and preferred to undergo diagnostic and therapeutic resection.
45451196|NCT02531165|Drug|Ticagrelor|Pre-hospital Ticagrelor loading dose of 180 mg administered orally, followed by 90 mg bid
45451197|NCT02531165|Drug|Aspirin|500 mg loading dose orally (or intravenously), followed by 100 mg od
45930521|NCT05054439|Drug|SI-B001|Si-b001 is administered by intravenous drip once a week (QW). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.
46072855|NCT02833038|Drug|Normal saline|the same bolus and infusion volumes of normal saline
45451198|NCT02531165|Drug|Unfractioned Heparin|5'000 IU loading dose intravenously, additional doses to achieve an ACT >250 sec during PCI are allowed.
45451199|NCT02531165|Procedure|Primary PCI|Primary PCI with stent implantation according to the guidelines of the European Society of Cardiology.
45451200|NCT01084889|Device|surgical mesh implantation (TiLOOP® Total 6)|The standard procedure for the surgical repair of anterior prolapse is via the obturator membrane. The surgical mesh TiLOOP® Total 6 is placed transvaginal by the aid of TiLOOP® surgical instruments to place the mesh arms.
45451201|NCT00099983|Drug|Risperidone|Initiate treatment with a low dose (1 mg/day HS) for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day. Escalation to a maximum of 4 mg/day will be allowed after a minimum of 4 weeks at the target dose (3 mg/day). Reduction to a lower dose will be allowed at any time, based on adverse effects. Treatment will continue for 6 months. Patients who discontinue treatment will be allowed to resume treatment at any time.
45651556|NCT05049811|Behavioral|mini program|To design, construct, and test the mini program in patients managing cancer pain
45651557|NCT05049811|Behavioral|conventional pharmaceutical care|Regular education includes medication guidance from doctors, nurses and pharmacists.
45651558|NCT05028049|Drug|Sufentanil injection|Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia
45651559|NCT05028049|Drug|Remifentanil Hydrochloride|Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia
45451202|NCT00099983|Drug|Placebo|Placebo
45651560|NCT05028049|Other|plain areas|Patients should be long staying residents in plain areas (altitude level below 1,000 meters above sea level)
45651561|NCT05028049|Other|plateau areas|Patients should be long staying residents in plateau areas (altitude level>3000 meters above sea level)
45651562|NCT05024461|Diagnostic Test|Salivary test for COVID19|"Results of nasopharyngeal and salivary samples taken at the Cayenne hospital and the Caen university center,~Pre-analytical particularities and analytical particularities~Cycle threeshold~Demographic variables~Clinical variables~Clinical criteria~Questionnaire on the perception of the 2 sampling methods"
45651563|NCT03093649|Other|adverse events using patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire|The intervention was administrated through APP
45801026|NCT04594031|Biological|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|Single ECT-001-CB transplant (CD34+: 2 to 5.75x10E5/kg, CD3+ >1x10E6/kg)
45651564|NCT03093649|Other|do not report adverse events through patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire|patients receive normal care and visit
45801027|NCT05452187|Drug|Assess the effectiveness and safety of DAAs in patients with IBD.|Variables evaluated: age, gender, location, extent, phenotype, and activity of IBD, treatments, anti-HCV and viral load, DAA treatment and duration, fibrosis and hepatic decompensation and adverse effects (AE).
45801028|NCT05452187|Drug|Evaluate the interaction of DAAs with IBD drugs, particularly immunosuppressants and/or biologics.|Variables evaluated: Interactions.
45804173|NCT01457612|Dietary Supplement|Placebo2|Placebo Beverage 2 with Fiber
45930522|NCT05054439|Drug|Paclitaxel|The dosage of paclitaxel was 80mg/m2 QW. SI-B001 and paclitaxel were used on the same day. After SI-B001 infusion, paclitaxel was pretreated and injected for no less than 3 hours.
45930523|NCT05050006|Biological|ITIL-168|ITIL-168 is a cell therapy product derived from a patient's own TILs. A tumor sample is removed from each patient to make a personalized ITIL-168 product. Once ITIL-168 has been made, the patient is treated with 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.
45930524|NCT05049603|Drug|Atorvastatin 20mg|One tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks
45930525|NCT05049603|Other|Placebo|One tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks
45930526|NCT05037162|Diagnostic Test|Biochemistry blood test|preformed on days 1-14 and day 28. Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL,
45930527|NCT05037162|Diagnostic Test|Hematology blood test|preformed on days 1-14 and day 28. complete CBC.
45930528|NCT05037162|Diagnostic Test|D-Dimer test (coagulation)|performed on days 1,2,7,14 and 28.
45651565|NCT05024617|Other|conservative treatment|All patients had rehabilitation for a total of three months, including activity modification, splinting and exercises.
45451203|NCT00099359|Drug|Zidovudine|Given for 6 weeks. 12mg PO BID if birthweight (BW) > 2000 grams 8 mg PO BID if BW < 2000 grams
45451204|NCT00099359|Drug|Nevirapine (NVP)|"Standard of Care (Zidovudine) plus~NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose :~12 mg PO per dose if BW > 2000 grams, 8 mg PO per dose if BW < 2000 grams"
45930529|NCT05037162|Diagnostic Test|Inflammatory markers|performed on days 1-7, 14 and 28. IL-6, IL-1β, IL-12, TNF α, IFN-γ
45451205|NCT00099359|Drug|Epivir (3TC)|"Stand of care (Zidovudine) plus~3TC, given for 2 weeks: 6 mg po bid if BW > 2000 grams 4 mg po bid if BW < 2000 grams AND~NFV, given for 2 weeks:~200 mg po bid if BW > 3000 grams 150 mg po bid if BW > 2,000 - 3000 grams 100 mg PO BID if BW < 2000 grams"
45451206|NCT00099359|Drug|Nelfinavir (NFV)|200 mg BID if birth weight (BW) > 3000 grams for 2 weeks;150 mg BID if BW > 2000-3000 grams for 2 weeks; 100 mg BID BW </= 2000 grams for 2 weeks
45801029|NCT05452187|Other|Assessment of the impact of DAAs on the course of IBD.|Qualitative variables will be expressed as a percentage and 95% confidence interval and quantitative variables as median and interquartile range. A priori it is difficult to determine which statistical analysis should be performed. It is basically a descriptive study, and the subsequent statistical analysis will depend on the evolution that the patients have presented in relation to the DAA treatment. If the drugs have been well tolerated without adverse effects, further statistical analysis will not be necessary. Instead, if the DAAs trigger activity outbreaks, variables related to the appearance of these outbreaks will be evaluated (type of DAA, immunomodulator, ...). To compare whether there are differences between the established groups, Chi Square (in qualitative independent variables), a t-student or ANOVA or their corresponding non-parametric tests (in quantitative independent variables) will be used. Statistical significance has been set at a probability level of <0.05.
45801030|NCT01889797|Biological|Arm A: Rituximab|Rituximab 375 mg/m² IV x 4 weekly doses.
45801031|NCT01889797|Biological|Arm B: GA101|GA101 1,000 mg (flat dose) IV x 4 weekly doses.
45930530|NCT05037162|Diagnostic Test|Vital signs|performed on days 1-14 and day 28. blood pressure, pulse, weight, weight, body temperature (PO), saturation, respiratory rate.
45930531|NCT05037162|Diagnostic Test|VAS scale|performed on all study visits. score: 0-10 ; a higher score indicates a higher pain level.
45930532|NCT05037162|Diagnostic Test|WHO Ordinal Score|performed on days 1,7,14 and 28. score: 0-3 ; a higher score indicates more symptoms.
45930533|NCT05037162|Diagnostic Test|COVID-19-Related Symptoms assessment|performed on days 1,7,14,21 and 28. score: 0-3 ; a higher score indicates more symptoms.
45930534|NCT05037162|Diagnostic Test|COVID-19-Impact on Quality-of-Life Questionnaire|performed on days 1,7,14,21 and 28. score: 1-5 ; a higher score indicates a lower quality of life.
45930535|NCT05037162|Diagnostic Test|POST- COVID-19 Functional Status Scale:|performed on day 28. score: 0-3 ; a higher score indicates better recovery.
45930536|NCT05037162|Diagnostic Test|Pregnancy test|performed on days 1 and 28. women of childbearing potential must undergo a urine pregnancy test.
45930537|NCT05037162|Diagnostic Test|Physical examination|performed on days 1-14 and day 28. a full examination by a doctor.
45930538|NCT05037162|Diagnostic Test|PK parameters|"performed on day 1. will be performed only on 14 patients that will agree to participate in the PK analysis (only for Brazil,Spain).~The PK will be performed only for the first dose of drug, after patient received the first dose (5 puffs) the study staff need to follow the table below.~For each test, approximately 5 ml of blood will be drawn (equivalent to one teaspoon)"
45930539|NCT05037162|Diagnostic Test|SARS-CoV-2 test (PCR)|performed on days 1,14 and 28.
46072856|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 850 mg bid (F160-M1700)
45451207|NCT00092495|Biological|V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine|qHPV Vaccine (20, 40, 60 or 100% dose formulation) 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
45451208|NCT01085123|Drug|Rapimelt|oral tablet , 2.5 and 5 mg, single dose. 10 mg (2x5 mg) visit 3, 5 mg visit 4, 2.5 mg visit 5.
45930540|NCT05037162|Diagnostic Test|ECG|performed on days 1 and 28.
45930541|NCT05037162|Drug|Treatment administration (twice a day)|performed on days 1 and 2. twice a day, morning, and evening 1:1:1 ratio to study drug (CimetrA-1) (Arm 1) or study drug (CimetrA-2) or to Placebo (Arm 3)
45651566|NCT05049109|Behavioral|Integrated Telehealth After Stroke Care|"• 3 week and 8 week follow up visits with pharmacy through telehealth~Patients will provide home blood pressure monitoring kits at discharge for the first three months. The telemonitor that can send blood pressure readings, wirelessly or through telephone, to a secure server where study staff can look at the readings. Any blood pressure readings that are not within normal range will trigger an alert to be sent to study staff who will then follow up with the patient. A trained staff member will show the patient how to use the blood pressure monitor. Patients will be asked to take blood pressure at least 3 days per week and transmit the readings to study staff.~Patients will also be asked to wear an activity monitor starting at 4 weeks."
45451209|NCT01085123|Drug|[11C]AZ10419369|solution for iv injection. Will be injected within 2 to 5 hours after administration of ZOMIG® Rapimelt
45651567|NCT05049109|Behavioral|Usual post-stroke follow-up care|"1-2 weeks follow up visit with primary care.~4-6 week and 12 week follow up visit with stroke practitioner~At the end of the study, patients will be asked questions regarding their experience with the telehealth visits, health, medication taking and quality of life"
45801032|NCT00369551|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
45801033|NCT00369551|Drug|paclitaxel|Given IV
45801034|NCT00369551|Biological|bevacizumab|Given IV
45451210|NCT00092417|Biological|Comparator: Varicella Zoster Virus Vaccine|Single 0.65 mL subcutaneous injection of higher potency zoster vaccine (~207,000 plaque-forming units [PFU]/0.65-mL dose)
45801035|NCT00369551|Drug|carboplatin|Given IV
45801036|NCT00369551|Other|laboratory biomarker analysis|Correlative studies
45801037|NCT01890031|Other|Interactive Cholesterol Advisory Tool|using the virtual clinician computer program for cholesterol information and education.
45801038|NCT01890031|Other|Study physician visits|In-person individual visits with a study physician to give information on cholesterol
45801039|NCT05451797|Device|Implant of WiSE-CRT with intracardiac pacemaker|Implant of two cardiac devices
45930542|NCT05036122|Device|LabClasp|Non-invasive device that estimates blood [lactate] from interstitial fluid via a proprietary algorithm. The device is placed between the first and second knuckle of a finger and gently applies slight pressure to extract interstitial fluid from the skin. Sensors within the device quickly estimate blood [lactate] and return a value to the subject via an accompanying tablet within 20 seconds.
45451211|NCT00092417|Biological|Comparator: Varicella Zoster Virus Vaccine|Single 0.65 mL subcutaneous injection of lower potency zoster vaccine (~58,000 plaque-forming units [PFU]/0.65-mL dose)
45451212|NCT00091949|Drug|pioglitazone|a thiazolidinedione drug
45451213|NCT00091949|Drug|placebo|an inactive substance
45451214|NCT02258542|Biological|Benralizumab|Benralizumab administered subcutaneously
45451215|NCT02258542|Biological|Benralizumab|Benralizumab administered subcutaneously
45451216|NCT00091793|Drug|AMG 162|60 mg/mL denosumab given day 1, month 6, month 12 and month 18
45451217|NCT00091793|Drug|Placebo|Placebo given at day 1, month 6, month 12 and month 18
45801040|NCT04537793|Drug|ELX/TEZ/IVA|Fixed dose combination granules for oral administration.
45801041|NCT04537793|Drug|IVA|Granules for oral administration.
45801042|NCT01949389|Behavioral|Internet-based Cognitive Behavioral Therapy for Insomnia|This is an internet-based Cognitive Behavioral treatment for insomnia. It is accessed via a computer with an internet connection and consists of 7 modules, homework, and a daily sleep log. The intervention is self administered.
45930543|NCT05032157|Drug|LOU064 (blinded)|LOU064 (blinded) active treatment
45930544|NCT05032157|Drug|Placebo|Placebo
45930545|NCT05032157|Drug|LOU064 (open-label)|LOU064 (open -label) active treatment
45930546|NCT05025332|Drug|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
45930547|NCT05024318|Drug|Pembrolizumab|Pembrolizumab 200 mg tobe administered as a 30 minute IV infusion every 21 days for 3 cycles
45930548|NCT05024318|Radiation|Stereotactic Ablative Radiotherapy|42Gy delivered in 3 fractions
45930549|NCT05024318|Procedure|Nephrectomy|Partial or total nephrectomy performed 9-12 weeks after first dose of Pembrolizumab
45930550|NCT05022654|Drug|SI-B001|Administered by intravenous drip every 2 weeks (Q2W). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.
45930551|NCT05022654|Drug|Irinotecan|The dose of irinotecan was 180mg/m2 Q2W, the infusion method was according to the drug instructions, SI-B001 and irinotecan were used on the same day, and irinotecan was injected after SI-B001 infusion.
45930552|NCT05022472|Behavioral|COVID-19 Individual Awareness and Education.|The 2VIDA! working group has developed culturally competent COVID-19 educational and outreach materials (available printed and electronically) in English and Spanish that are written at the 8th grade level (the average reading level of adults in the United States) that peer-health educators will distributed to community members during their visits to the participating SYH community centers, door-to-door, local supermarkets, and CBO's in the selected communities. These materials have general information on COVID-19 as well as educational information and resources regarding COVID-19 prevention, symptoms, testing, contact tracing, COVID-19 vaccine (how it works, technology used, administration [2-dose series and importance of vaccine completion]), safety concerns, benefits, dispelling common misconceptions and misinformation, and other topics identified based on community needs. This information will be updated monthly to ensure the most up to date information.
45801043|NCT04529291|Other|Group with walking disorder|During the patient's hospitalization, two questionnaires will be completed, assessing the handicap of the patient in his daily activities, and the specific incapacity to carry out activities of daily living and social life (10 minutes to complete). The patient will then carry out two 20-meter round-trip walking tests during his first day and his last day of care at the hospital. Additional home visits, corresponding to intervention, performed by a member of the investigative team, will take place once a week (15-20 minutes). The team will collect his feelings about the evolution of symptoms through the two questionnaires, and quantify the evolution of his walking. Walk tests are recorded using small inertial sensors (accelerometers and gyrometers) that will be placed at his feet, belt and forehead. This examination is not painful. All the measurements are carried out in 15 minutes by a member of the team.
45930553|NCT05022472|Behavioral|COVID-19 Community Outreach & Health Promotion.|Peer-health educators will work with local CBO's and facilitate a combination of live broadcast sessions, pre-recorded webinars, social media posts, and other outreach activities in English and Spanish reaching community members with information on the above COVID-19 related topics as well as other identified needs such as what to do if a family member is infected and where you can get the COVID-19 vaccine. The goal is to reach 10,000 viewers (per session) in the various social media platforms in the three randomly selected communities.
45804174|NCT03423641|Drug|Direct Acting Antivirals|The time period during which a patient is dispensed the medication and for up to 180 days after initiation of the medication.
45930554|NCT05022472|Behavioral|COVID-19 Individual Health Education & Linkages to Medical and Supportive Services.|SYHealth will establish a COVID-19 Resource Center within the participating health centers in the three randomly selected communities (intervention sites only) providing individual COVID-19 related health education and linkages to medical and supportive services for patients and community members in need of additional education and support regarding COVID-19 disease and COVID-19 vaccine.
45930555|NCT05022472|Biological|Pop-up community vaccination sites|We will offer the COVID-19 vaccine at the participating SYHealth community health centers and pop-up vaccination stations that will be set-up in these communities (intervention sites) as part of the interventions efforts to increase access and uptake of the COVID-19 vaccine. We have identified various open spaces (e.g., public parks) in these communities to set-up the vaccination stations. Additionally, data will be collected to assess individual, social, and contextual factors related to access, acceptance, and uptake of the COVID-19 vaccine.The survey will last approximately 10-15 minutes and will be self-administered in both English and Spanish. Following the survey participants will be offered the COVID-19 vaccine and will be made an automatic appointment for the 2nd dose (4-week follow-up) and will be asked to complete a 5 min survey during the follow-up visit.
45930556|NCT05020457|Drug|SI-B001|SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended), if SI-B001 and chemotherapy are used on the same day, the infusion of chemotherapeutic drugs should be continued after the completion of SI-B001 infusion.
45930557|NCT05020457|Drug|AP or TP|AP or TP should be administered immediately after SI-B001 is completed. The administration of AP or TP should refer to the drug instructions and standard usage.
45930558|NCT05020457|Drug|Docetaxel|Docetaxel should be administered immediately after SI-B001 is completed. The administration of Docetaxel should refer to the drug instructions and standard usage.
45930559|NCT05020444|Drug|TriPRIL CAR T Cells|Intravenous infusion
45930560|NCT05020444|Drug|Cyclophosphamide|Intravenous infusion
45930561|NCT05020444|Drug|Fludarabine|Intravenous infusion
45930562|NCT05020314|Behavioral|Healthy Weight Clinic|Patients meet with a multi-disciplinary team over a 12 month period. In addition to the clinical visits, group visits, and phone calls, patients will also receive education materials, community resources, and an optional text messaging/social media library of messages.
45451218|NCT00098813|Drug|romidepsin|Given IV
45451219|NCT00098813|Other|laboratory biomarker analysis|Correlative studies
45451220|NCT00098813|Procedure|positron emission tomography|Correlative studies
45451221|NCT01081613|Other|89Zr-bevacizumab PET imaging|injection 89Zr-bevacizumab and 89 Zr-bevacizumab PET scan
46072857|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 500 mg bid (F160-M1000)
45801044|NCT04529291|Other|Group without walking disorder|"During the patient's hospitalization, two questionnaires will be completed, assessing the handicap of the patient in his daily activities, and the specific incapacity to carry out activities of daily living and social life (10 minutes to complete). The patient will then carry out two 20-meter round-trip walking tests during his first day and his last day of care at the hospital.~Additional home visits, corresponding to interventions, performed by a member of the investigative team, will take place once a week (15-20 minutes). The team will collect his feelings about the evolution of symptoms through the two questionnaires, and quantify the evolution of his walking. Walk tests are recorded using small inertial sensors (accelerometers and gyrometers) that will be placed at his feet, belt and forehead. This examination is not painful. All the measurements are carried out in 15 minutes by a member of the team."
45930563|NCT05015426|Biological|Gamma Delta T-Cell Infusion|Donor cells will be processed in a laboratory, where T-cell subtype called γδ (gamma delta) T-cells will be isolated and expanded in number. These T-cells expanded in a laboratory will be infused in participants who are otherwise at high risk of AML recurrence after alloHCT.
45930564|NCT05012189|Drug|Oseltamivir|Nursing home residents and staff 18 years and older are allocated to receive oseltamivir for treatment and chemoprophylaxis for influenza.
45930565|NCT05012189|Drug|Baloxavir|Nursing home residents and staff 18 years and older are allocated to receive baloxavir for treatment and chemoprophylaxis for influenza.
45930566|NCT05006573|Biological|Benralizumab|Benralizumab active solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
45930567|NCT05006573|Biological|Placebo to Benralizumab|Matching placebo solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
45930568|NCT04995068|Radiation|Head CT to determine presence of traumatic intracranial lesion|Head CT to determine presence of traumatic intracranial lesion
45930569|NCT04986228|Other|Digital aftercare|The intervention group will receive a digital aftercare service, consisting of video calls and an app, for a period of up to eight weeks after discharge. These enable an uncomplicated and yet intensive exchange with the clinic from the comfort of the participants' own homes. To enable to optimally plan the treatment and assess its success, all participants complete questionnaires on multiple time points about different topics.
45930570|NCT04986228|Other|TAU|The control group will receive the regular follow-up consultations in the clinic (treatment-as-usual, TAU). This includes at least one consultation with the case-leading therapist from the previous inpatient stay about 6 weeks after discharge. The assessment consisting of questionnaires at multiple time points about different topics is the same as in the intervention group.
45930571|NCT04985721|Drug|Pamiparib|40 mg orally twice a day
45930572|NCT04985721|Drug|Tislelizumab|200 mg IV every 21 days
45930573|NCT04983680|Behavioral|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) is an 8-week group intervention (1.5-hour weekly sessions) that combines cognitive-behavioral therapy and mindfulness training. In this study, MBCT has been adapted to include education about cardiac health and fear of recurrence, and the intervention is delivered remotely via synchronous group videoconference. There is 15-20 minutes of daily mindfulness practice between sessions. Participants are provided a home practice record form and asked to submit the completed form to study staff each week.
45930574|NCT04978337|Drug|Rilematovir|Rilematovir 250 mg will be administered orally.
45930575|NCT04978337|Drug|Placebo|Placebo matching to rilematovir will be administered orally.
45930576|NCT04964674|Behavioral|Behavioral Measurement|Take measurements of behavioral performance
45930577|NCT04952610|Drug|Etripamil NS 70 mg|Etripamil will be administered via the Aptar Pharma Nasal Spray Bidose System.
45930578|NCT04952610|Device|Aptar Pharma Nasal Spray Bidose System|Aptar Pharma Nasal Spray Bidose System will be supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
45930579|NCT04936607|Procedure|Personalized hydration strategy|In the experimental group, NS infusion rate will be adjusted based on LVEDP for the whole duration of the procedure (<13 mmHg: 5 ml/kg/h; 13-18 mmHg: 3 ml/kg/h; >18 mmHg: 1.5 ml/kg/h), or for one hour, whichever is the longest. After the procedure, and for a duration of 4 hours, the hydration rate will be adjusted based on the (contrast volume:estimated glomerular filtration rate (eGFR)) ratio, according to the following scheme: 1.5 ml/kg/h if contrast volume/eGFR ratio <2.0; 3 ml/kg/h for contrast volume/eGFR ratio 2.0-2.9; 5 ml/kg/h for contrast volume/eGFR ratio ≥3.0.
45801045|NCT04480307|Drug|temelimab 18 mg/kg|temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
46072858|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 850 mg bid (F80-M1700)
45801046|NCT04480307|Drug|temelimab 36 mg/kg|temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
45801047|NCT04480307|Drug|temelimab 54 mg/kg|temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
45801048|NCT04480307|Drug|Placebo|Placebo will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
45801049|NCT05451407|Drug|TQB2618 injection|Humanized IgG4 mab targeting TIM-3
45930580|NCT04936607|Procedure|Standard of care|In the control group, infusion rate will be of 1.5 ml/kg/h during the procedure, and for the 4 following hours.
45930581|NCT04933136|Device|Terry2 Band|Hemostasis protocol following radial or cubital approach catheterization using the dual artery hemostasis device Terry2Band.
45651568|NCT05027659|Other|virtual reality glasses|Virtual reality (VR) glasses have a detachable screen frame compatible with smartphones. A VR headset has earphones and sensors that track the user's head movements, giving them the impression that they are moving around in a virtual environment. The investigators used a smartphone and VR glasses to perform the intervention. They connected the phone to the VR headset via a 360 degree VR video app. Experimental participants wore the VR glasses and watched a 360 degree VR video of nature scenes with ambiance music during colonoscopy. They put on the VR glasses right before the procedure and took them off right afterward.
45651569|NCT03093571|Device|Auricular stimulation|Auricular stimulation with indwelling fixed needles
45801050|NCT05451407|Drug|Terprizumab injection|Monoclonal antibody against Programmed death factor receptor 1
45930582|NCT04921189|Drug|The combined supplement of Ascorbic acid, Thiamine, and Cortisol|"The combined administration of 3 drugs will be mixed in a 50 mL 0.9% saline bag respectively and administered through intravenous infusion over 60 min every 12 h for 3 days.~Ascorbic acid (Ascorbic acid Inj [500mg]®): 50 mg/kg, maximum single dose 3 g, daily dose 6 g~Thiamine (Thiamine hcl inj [50mg]®): 200 mg~Cortisol (Cortisolu inj [100mg]®): 100mg (The main exposure was corticosteroid therapy, defined as the use of systemic corticosteroids. But if unavailable, it could be converted to hydrocortisone-equivalent doses (methylprednisolone 1:5, dexamethasone 1:25, prednisolone 1:4).)"
45930583|NCT04921189|Drug|Placebo|An identical volume of 0.9% saline (150mL) administered through intravenous infusion over 60 min every 12 h for 3 days.
45930584|NCT04918732|Diagnostic Test|FibroScan|The FibroScan device developed by Echosens (France) measures the liver stifness and steatosis based on a pulse of sound waves that goes through the liver.
45930585|NCT04902911|Device|COVID-19 SARS-CoV IgG/IgM antibody rapid test|Needle stick point of care and 3mL vial of blood will be collected and tested for individual without history of COVID-19 and immunization as well as a second group composed of individuals with history of COVID-19
45930586|NCT04891224|Other|Pathway Platform mobile app|The pathway platform intervention involves 3 components: 1. The patient facing app which will: a) Gather health information related to depression management and patient-Provider engagement. b) Clinical data collection; PHQ-9, WHO-5, PDQ-D-5, medication adherence and side effects, goal setting and goal tracking. c) Research data; Patient Activation Measure -13[PAM-13], CollaboRATE, and Work and Social Adjustment Scale [WSAS]. 2. Electronic Medical Record Integration - a) Data collected in the app is accessible to care team in real time. b) Provide a longitudinal summary to assist in decision making and depression management. 3. Educational Scaffolding - a) Training program describing how the Pathway Platform can support care team members in clinical processes related to measurement-based care and shared-decision making. b) Includes ongoing feedback with up to three audit cycles.
45930587|NCT04877782|Device|Transcutaneous vagus verne stimulation|Non-invasive and short electrical stimulation by placing the stimulating electrode at the cymba conchae of the left ear. The reference electrode is placed near the left cymba conchae. It provides a light tingling, massaging feeling in the ear.
45930588|NCT04876339|Device|"Gait rehabilitation with sonification"|The sonification system is composed by 2 inertial sensors, a computer and a pair of bluetooth headphones connected with the computer. The sensors will be placed one per leg at the ankle and connected with Matlab software. An home-made ad-hoc software associates patient's movements with music patterns. The patient's natural rhythm is detected and used at the beginning of the intervention. The first part of each exercise is supported by a pre-recorded chord progression with a click on the background. In the second part (sonification approach) the software notices and records the contact of the heel with the ground. Each contact activates musical stimuli listened to via headphones. The steps succession will build a regular and predictable musical progression in relation to the correct sequence of steps. The exercises planned in this intervention are the same as those planned in the gait standard rehabilitation (see below).
46072859|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 500 mg bid (F80-M1000)
45801051|NCT05451173|Radiation|Stereotactic body radiotherapy|An ablative dose of radiation is delivered to the primary tumor target over 1-2 week.
46072860|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin placebo (F160-M0)
46072861|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate placebo + metformin 850 mg bid (F0-M1700)
46072862|NCT00703755|Drug|Placebo|Placebo
45801052|NCT05451173|Radiation|Hypofractionated radiotherapy|Hypofractionated radiotherapy is delivered to the primary tumor and any involved lymph node target(s) over 3 weeks.
45451222|NCT02227264|Drug|Cinacalcet|Cinacalcet, Mimpara® 30mgx1-2 for 4 weeks
45651570|NCT03093571|Behavioral|Relaxation|Progressive muscle relaxation
45651571|NCT05023915|Drug|dexamethasone|40 mg qd for 4 days
45801053|NCT05451173|Drug|Durvalumab|an anti-PD-L1 immune checkpoint inhibitor is administered concurrently and adjuvantly with radiotherapy.
45801054|NCT05450939|Diagnostic Test|Signal intensity gradient|"In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A [Xa] along the arterial contour line) and at the inner point (Φb; signal intensity at position B [Xb]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
45801055|NCT05441969|Other|No intervention/expousure|No interventions/expousure since this is an observational study.
45801056|NCT05450861|Other|SF DNA extraction composition|the composition of small fragments of DNA from fish
45801057|NCT05450861|Other|Placebo|the scalp conditioning solution without SF DNA extraction composition
45930589|NCT04876339|Other|Standard gait rehabilitation (without sonification)|"The training will be carried out without any musical support. Exercises I Phase~Load shift in anteroposterior standing in tandem position, left foot forward (3 minutes exercise with a short break in the middle)~Load shift in anteroposterior standing in tandem position, right foot forward (3 minutes exercise with a short break in the middle)~Left foot swing (3 minutes exercise with a short break in the middle)~Right foot swing (3 minutes exercise with a short break in the middle)~March in place (3 minutes exercise with a short break in the middle) Exercises II phase (15 minutes): the patient will perform 14 minutes of walking with a 1 minute of break in the middle (7 minutes of walking, 1 minute rest, 7 minutes of walking). In the second part of walking the patient will be asked to slightly increase the pace of the step up to the maximum possible speed."
45930590|NCT04872959|Other|HealthReveal|"In the Intervention arm, for each study visit, the site will receive a pre-visit assessment of GDMT accompanied by recommended adjustment(s) using information extracted weekly from the sites' EHR.~The recommended adjustment(s) will be conveyed using proprietary software from HealthReveal, with a suggested follow up plan. All reminders regarding dosing targets are based on the 2020 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment.~Additionally, during visits at baseline, 3 months, and 6 months, the KCCQ-23 will be completed.~In the Usual Care arm, during visits at baseline, 3 months, and 6 months, the KCCQ-23 will be completed."
45930591|NCT04872439|Diagnostic Test|Blood sample collection|Patients with autoimmune gastrointestinal dysmotility will provide 20 mL of blood to isolate serum, plasma and peripheral blood mononuclear cells for whole exome sequence. Antibodies to be isolated are: Antineuronal nuclear antibody type 1,Collapsing response-mediator family immunoglobulin G, Ganglionic Acetylcholine Receptor Antibody, Muscle Acetylcholine Receptor Antibody, Striational, Voltage-gated calcium channel, N- type, Voltage-gated calcium channel, P/Q- type, Voltage-gated potassium channel, Glutamic Acid Decarboxylase 65, Gastric parietal cell, Thyroperoxidase, Thyroglobulin
45801058|NCT00369005|Procedure|Red blood cell transfusion guidelines|
45801059|NCT05450783|Other|Biocollection|serum
45801060|NCT05450627|Drug|Pancreatic Enzyme|Registry of pancreatic enzyme therapy prescribed to included patients
45930592|NCT04864951|Diagnostic Test|Colli-Pee urine collection device|first-void urine is collected using Colli-Pee and subsequently analyzed using Anyplex™ II HPV HR Detection from Seegene.
45930593|NCT04864951|Other|Survey|Subjects are asked to complete a survey that includes questions about sexual orientation, hormone therapy, gender reassignment surgery, number of sexual partners, HPV vaccination, and smoking
45930594|NCT04864366|Drug|Tenofovir Alafenamide 25 MG [Vemlidy]|TAF is administered as a 25mg/tablet, taken orally with food once daily, for 48 weeks.
45930595|NCT04861688|Combination Product|Traditional Chinese Medicine (NeuroAiD II™ (MLC901)|NeuroAiD II™ (MLC901) contains the extracts of 9 botanical active ingredients blended with commonly used excipients. The 9 botanical active ingredients are traditional herbs well documented in the Pharmacopoeia of the People's Republic of China.
45930596|NCT04861688|Other|Placebo|Placebo with same appearance as active intervention
45930597|NCT04859296|Drug|Placebo|Vaporized placebo
45930598|NCT04859296|Drug|Low CBG|Vaporized CBG (5 mg)
45930599|NCT04859296|Drug|High CBG|Vaporized CBG (15 mg)
45651572|NCT05023915|Drug|diammonium glycyrrhizinate enteric-coated capsule|150mg tid for 3 months
45651573|NCT05024071|Device|Wushu athletes in the experimental group used a Swiss ball for 12 weeks of core strength training|"The experimental group was given 12 weeks of core strength training, divided into 6 types~Static action under steady state.~No load movement in steady state.~Static action under unstable state.~Movement to overcome its own resistance in an unstable state.~Free strength exercise in unstable state.~Core explosive power exercise under unstable conditions."
45801061|NCT05450471|Drug|Corticosteroid Topical|The L-lactide and trimethynele carbonate (TCM) Terpolymers polymer implant will be placed in the ethmoidal region, at the same time that the nasal endoscopic examination will be performed.
45801062|NCT05450471|Other|Placebo|Placebo
45801063|NCT05437601|Drug|Astaxanthin Oral Capsule|12 mg oral astaxanthin daily for 8 weeks
45930600|NCT04859296|Drug|Low THC|Vaporized THC (5 mg)
45930601|NCT04859296|Drug|High THC|Vaporized THC (15 mg)
45930602|NCT04859166|Procedure|Organoids|A part of the tumor of approximately 1 cm3 will be removed from the primary tumor.
45930603|NCT04857684|Drug|Atezolizumab|Intravenous Infusion
45930604|NCT04857684|Drug|Bevacizumab|Intravenous Infusion
45930605|NCT04857684|Radiation|Stereotactic Beam Radiation Therapy (SBRT)|External beam radiation
45651574|NCT05024071|Device|Wushu athletes in the experimental group used a balance board for 12 weeks of core strength training|"The experimental group was given 12 weeks of core strength training, divided into 6 types~Static action under steady state.~No load movement in steady state.~Static action under unstable state.~Movement to overcome its own resistance in an unstable state.~Free strength exercise in unstable state.~Core explosive power exercise under unstable conditions."
45651575|NCT05027581|Drug|Bone marrow mesenchymal stem cells|The bone marrow mesenchymal stem cells (BM-MSCs) in Chondrochymal® for this study was obtained from the donor recruited in Taipei Veterans General Hospital, Taiwan. Donors aged 20 to 50 and tested negative to infection of human immunodeficiency virus type 1 and 2 (HIV-1/2), hepatitis B virus (HBV), hepatitis C virus (HCV), Cytomegalovirus (CMV), Treponema pallidum (syphilis), human T-lymphotropic virus types I and II (HTLV-I/II), and Tuberculosis (TB) were enrolled. The eligible donor's bone marrow was aspirated from the iliac crest or femur. The collected BM-MSCs were then cultured, expanded and cryopreserved in a Good Tissue Practice (GTP)-complied laboratory. The qualified cells in cryopreservation meeting the release criteria will be thawed, mixed with lactated Ringer's solution, and transferred into a sterile syringe as the final product.
45801064|NCT05437601|Other|Placebo|Oral placebo identical to astaxanthin
45930606|NCT04854811|Drug|Roflumilast Oral Tablet|Once daily for 12 weeks
45930607|NCT04846348|Combination Product|Topical preparation of sodium cromolyn 5%, diphenhydramine 1% and trolamine salicylate 10% in emollient cream base.|Combination of ingredients includes 2 agents which target mast cell mediators and one agent which globally reduces mast cell degranulation combined in an emollient cream base (Vanicream).components: Vanicream: Over the counter emollient cream Diphenhydramine Antihistamine Trolamine salicylate Prostaglandin inhibitor, antiinflammatory Cromolyn Sodium Mast cell degranulation inhibitor
45930608|NCT04844918|Drug|Tirzepatide|Administered SC
45930609|NCT04844918|Other|Placebo|Administered SC
45801065|NCT05437445|Diagnostic Test|Plasma amino acid assay|Plasma amino acid analysis was performed on all the blood samples received in biogenetics lab at Aga khan university, Karachi during one year period.
45801066|NCT04339907|Other|Sampling of tears|Tears will be collected at the start of any of surgery for which the participant presents. It will be collected using a tear-wash method to allow for protein collection. 0.06 ml of saline solution 0.9% will be instilled on the ocular surface. The participants will turn their eyes with eyes closed. The tear-wash fluid will be collected from the inferior fornix of the eye using a micropipette. Tear-was fluid will be placed in codified tubes stored at -150 degrees.
45801067|NCT04339907|Other|Sampling of aqueous humor|Aqueous humor will be collected at the start of any of surgery for which the participant presents. A paracentesis of the anterior chamber is a common first step in intraocular surgeries. Aqueous humor is then commonly diluted with viscoelastic material injected inside the anterior chamber to avoid collapse of the anterior chamber. This way, the aqueous humor is commonly diluted or replaced entirely by the viscoelastic material injected during intraocular surgeries. A volume of 0.1 ml of aqueous humor will be taken by paracentesis using a 30-gauge needle connected to a 1-ml syringe. It consists of less than half of the total volume of aqueous humor in the eye. Aqueous humor will be placed in codified tubes stored at -80 degrees.
45801068|NCT05447975|Other|Tai Chi training|"As for Tai Chi training, standardized Tai Chi was taught by professional Tai Chi coaches from Sino Taiji of Fuxing International in classes: Qishi (Starting Posture), Shangsanbu (Twist Step), Yema Fenzong(Part the Wild Horse's Mane on Both Side), Jingang Daozhui (Buddha's warrior attendant pounds mortar), Shoushi (Closing Posture). Patients participated in this class were trained, twice a week, 60 min per time. PD patients whose attendance rate less than 75% were excluded."
45801069|NCT05450315|Behavioral|Stride to Survive:An Exercise Guide for Young Adult Cancer Survivors|
45801070|NCT05450315|Behavioral|Canadian Physical Activity Guidelines|
45801071|NCT05450159|Behavioral|ROADskills program|Participants in the intervention arm of the study will watch a 30-minute personalized video on their driving that uses information compiled from a GPS device that will be installed in their vehicle during their baseline visit.
45930610|NCT04837703|Drug|Eltrombopag|Eltrombopag should be taken at least two hours before or four hours after any products such as antacids, dairy products, or mineral supplements containing polyvalent cation (e.g. aluminum, calcium, iron, magnesium, selenium and zinc). Eltrombopag may be taken with food containing little (< 50 mg) or preferably no calcium.
45930611|NCT04837677|Drug|PRT1419|PRT1419 will be administered by intravenous infusion
45930612|NCT04828707|Device|Nerivio active device|Nerivio neurostimulator of conditional pain modulation (CPM)
45930613|NCT04828707|Device|Nerivio sham device|Nerivio neurostimulator with an electrical output not intended for neurostimulation
45930614|NCT04802655|Other|Video-game based exercise - Exergame|Selected Kinect compatible video games from Microsoft Xbox one will be applied in this group. Four video games will be selected for a session (each game will last 10 mins). Video games are active video games which participants have to use their body parts in order to control games.
45930615|NCT04802655|Other|Activity Based Exercise Group (AG)|Task-oriented exercises to be performed in standing and sitting positions, including upper extremity and trunk, will be applied to the activity-based exercise group in addition to routine NDT training. Examples for activities; stepping and putting stickers on the wall, treading the play dough placed on a step board within one leg stance; reach-grasp activities progressively from sitting to standing, throwing and catching balls on a balance board.
45930616|NCT04792541|Other|HY containing gel; GUM® Afta Clear Gel, Sunstar|
45930617|NCT04792541|Other|saline solution|
45801072|NCT05450159|Behavioral|Healthy Aging|Participants in active comparator arm of the study will watch a 30-min video and receive a written brochure that provide tips for maintaining a healthy lifestyle in later life, including the importance of community mobility.
45801073|NCT05449925|Procedure|Injectable PRF and Microneedling|i-PRF and Microneedling Procedure in thin gingiva followed by orthodontic treatment
45801074|NCT04307615|Combination Product|Oxygen + continuous positive airway pressure (CPAP)|Oxygen-driven CPAP (7,5 cmH2O): 20 min treatment followed by 10 min rest and assessment
45801075|NCT04307615|Drug|Oxygen|Oxygen: 20 min treatment followed by 10 min rest and assessment
45801076|NCT05449847|Biological|Blood Sampling|Blood sampling under a complete aseptic conditions
45801077|NCT05449691|Procedure|One-stage immediate breast reconstruction|One-stage mesh assisted implant breast reconstruction
45930618|NCT04777201|Drug|Faricimab|Faricimab 6 mg will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen for the duration of the study.
45930619|NCT04777201|Other|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 12 weeks of this study in order to maintain the masking of the initial faricimab PTI.
45930620|NCT04774575|Biological|biomarker-guided strategy|Patients will follow a biomarker-guided strategy based on specific non-invasive biomarkers as defined in EUTRAIN-1 study on the basis of its detection and prediction capacities for rejection at M3 to decide whether a biopsy is performed. At M12 a routine biopsy is performed
45930621|NCT04771793|Behavioral|new physical restraint protocols|new physical restraint protocols
45930622|NCT04771520|Drug|Avapritinib|Given PO
45930623|NCT04769453|Device|Canaloplasty using the iTrack microcatheter with Healon GV Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
45930624|NCT04769453|Device|Canaloplasty using the Omni surgical system with Healon GV Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
45930625|NCT04769453|Device|Canaloplasty using the iTrack microcatheter with Healon Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
45930626|NCT04769453|Device|Canaloplasty using the Omni surgical system with Healon Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
45930627|NCT04767360|Device|Bioness-300|Therapeutic treatment of foot drop with the electrical stimulation device Bioness L300.
45930628|NCT04765722|Drug|Mepolizumab|Mepolizumab subcutaneous injection administered 3 times days 0, 28, 56 and 84 during 12 week treatment period.
45930629|NCT04765722|Drug|Normal Saline|Placebo subcutaneous injection administered 3 times days 0, 28, 56 and 84 during 12 week treatment period.
45930630|NCT04765709|Combination Product|durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed)|Induction therapy: durvalumab plus histology-based chemotherapy regimen (cisplatin or carboplatin plus vinorelbine for squamous histology and pemetrexed for non-squamous histology).
45930631|NCT04765709|Combination Product|Durvalumab plus radiotherapy|Concomitant durvalumab and radiotherapy
45930632|NCT04765709|Biological|durvalumab|Consolidation treatment with durvalumab
45930633|NCT04758351|Other|Usual clinical practice|Based on European Respiratory Society guidelines on management for chronic cough.
45930634|NCT04752371|Drug|Camoteskimab (CERC-007, AVTX-007, AEVI-007)|Intravenous (IV) Infusion
45930635|NCT04743362|Diagnostic Test|Dermoscopic imaging|The skin lesion will be imaged before application of alcohol (spray/wipe) and after application of alcohol (spray/wipe). The dermatoscope/camera with dermoscopy imaging capabilities, including but not limited to VEOS® SLR (Canfield Scientific, Inc.), will be placed on/near the area(s) of interest. Images will be captured in polarized and/or nonpolarized modes and contact and/or non-contact modes.
45930636|NCT04743362|Diagnostic Test|3-dimensional total body photography|Participants will stand in the center of an imaging station consisting of 92 high-resolution cameras. Image capture by all cameras will occur simultaneously, (approx. 3 milliseconds). Within a few minutes, specialized software will process and assemble the images into a 3D avatar - a digital model of the patient's skin - showing all his or her lesions.
45930637|NCT04743362|Diagnostic Test|Confocal microscopy|CM imaging (Vivascope®, Caliber Imaging and Diagnostics, Rochester, NY) will be performed using an arm-mounted CM device (Vivascope1500, Caliber I.D., Inc.) or using a handheld CM device (Vivascope3000, Caliber I.D., Inc.).
45930638|NCT04743362|Diagnostic Test|Optical Coherence Tomography imaging|OCT subsurface imaging shows structural-level morphology (epidermal and dermal layers) in skin down to the deeper reticular dermis.
45930639|NCT04743362|Diagnostic Test|Ultrasound|US imaging allows assessment of depth, Doppler vascular imaging, and elastography features of skin lesions.
45930640|NCT04743362|Diagnostic Test|Hyperspectral imaging|Hyperspectral imaging shows biochemical information regarding the distribution of skin melanin and hemoglobin50. SkinSpect™ is a form of a hyperspectral dermatoscope.
45451223|NCT02227264|Procedure|parathyroid adenomectomy|surgical removal of pathologic parathyroid tissue
45451224|NCT00091169|Dietary Supplement|levocarnitine|Given orally
45451225|NCT00091169|Other|placebo|Given orally
45651576|NCT05027581|Drug|hyaluronic acid|(60 mg/3 mL hyaluronic acid [HA])
45451226|NCT02227342|Biological|Fecal Microbiota Transplant|serial FMT
45451227|NCT02224378|Procedure|peep induced CVP|
45651577|NCT01673347|Biological|Meniscal Allograft|Meniscal allograft
45651578|NCT05027191|Diagnostic Test|Neutrophil Gelatinase-Associated Lipocalin (NGAL)|The evaluation of inhalational anesthetics (desflurane and sevoflurane) on NGAL levels in laparoscopic cholecystectomy patients.
45651579|NCT05027191|Drug|Desflurane|Desflurane
45651580|NCT05027191|Drug|Sevoflurane|Sevoflurane
45651581|NCT03094507|Drug|Tivicay|50 mg once daily
45651582|NCT03094507|Drug|Rezolsta|darunavir 800 mg/cobicistat 150 mg once daily
45651583|NCT02528253|Biological|Placebo to Week 16; tanezumab 5mg SC|Placebo SC injection every 8 weeks for 2 injections followed by tanezumab 5 mg injection every 8 weeks for 5 injections
45801078|NCT04287101|Other|Post-operative PT and OT|Strengthening exercise, range-of-motion exercise, functional training, balance training, adjustment for assistive devices, adaptation and modiﬁcation of the home environment, and patient/caregiver education
45801079|NCT04204811|Other|Prehabilitation|A program of personalized independent home exercises are outline for participants to complete daily. Prehabilitation coaching will continue weekly until admission for surgical tumor debulking or termination of neoadjuvant treatment for any reason.
45801080|NCT05449613|Drug|acupoint application|During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
45930641|NCT04743362|Diagnostic Test|Electrical impedance spectroscopy|Electrical impedance spectroscopy (EIS) measures skin's resistance to the flow of alternating electric currents to differentiate benign and malignant lesions.
45801081|NCT05449613|Other|placebo|During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
45801082|NCT05449145|Dietary Supplement|Vitamin D|Omega-3 FA (first 4-week) plus Vitamin D (second 4-week)
45930642|NCT04743362|Diagnostic Test|Patient self-imaging|Clinical and dermoscopy self-imaging by patients can be accomplished using mobile phone technology. In the case of dermoscopy, this requires a small dermatoscope attachment for the phone.
45930643|NCT04742699|Drug|Lemborexant (LEM) 5 mg (Z-Drug-mono cohort)|"Pretreatment phase: Continue pre-registration treatment (Z-drug monotherapy) without LEM.~First treatment phase: Administer LEM 5 mg/day as a substitute for Z-Drug. Increasing LEM dose to 10 mg/day is allowed.~Maintenance phase: Succeed the treatment from the first treatment phase. Changing LEM dose is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition."
45930644|NCT04742699|Drug|Lemborexant (LEM) 5 mg (SUV-mono cohort)|"Pretreatment phase: Continue pre-registration treatment (SUV monotherapy) without LEM.~First treatment phase: Administer LEM 5 mg/day as a substitute for SUV. Increasing to LEM dose to 10 mg/day is allowed.~Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed."
45930645|NCT04742699|Drug|Lemborexant (LEM) 5 mg (SUV-combination cohort)|"Pretreatment phase: Continue pre-registration treatment (SUV and BZRA combination therapy) without LEM.~First treatment phase: Administer LEM 5 mg/day as a substitute for SUV and continue BZRA. Increasing to LEM dose to 10 mg/day is allowed.~Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed. Decreasing dose or discontinuation of BZRA is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition."
45930646|NCT04742699|Drug|Lemborexant (LEM) 5 mg (RMT-combination cohort)|"Pretreatment phase: Continue pre-registration treatment (RMT and BZRA combination therapy) without LEM.~First treatment phase: Administer LEM 5 mg/day as a substitute for RMT and continue BZRA. Increasing to LEM dose to 10 mg/day is allowed.~Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed. Decreasing dose or discontinuation of BZRA is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition."
45930647|NCT04740723|Device|iRF System Renal Denervation|The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the artery
45930648|NCT04731519|Behavioral|Continuous Identity Cognitive Therapy (CI-CT)|CI-CT was developed as a manualized treatment integrating components of CBT and Acceptance and Commitment Therapy (ACT) with self-continuity and future-self related interventions to help Veterans develop a better present-to-the-future life story as a framework for increasing hopefulness, a sense of life meaning, empowerment, and an ability to attain future self-goals. The recovery oriented CI-CT for post acute suicidal episode Veterans includes eight components: 1) constructing a CI narrative, 2) mindfulness training, 3) life values identification, 4) developing a self-growth perspective, 5) identifying possible future selves - timelines, 6) connecting with the desired future self, 7) CI as context for current problems, and 8) moving toward the future self.
46072863|NCT02836158|Drug|R-IDARAM plus intrathecal chemotherapy|R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2); methotrexate 1.5 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 20mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
46072864|NCT05600205|Behavioral|GOAL!|GOAL! is a integrated support focused on a combination of lifestyle factors for achieving a healthier lifestyle for people with severe mental illness. The intervention consists of two year of guidance from a lifestyle coach and qualified professionals.
45651584|NCT02528253|Biological|Placebo to Week 16, tanezumab 10 mg SC|Placebo SC injection every 8 weeks for 2 injections, followed by tanezumab 10 mg SC injection for 5 injections
45451228|NCT02224378|Procedure|passive leg raising(PLR)|
45451229|NCT02227420|Drug|Anakinra|Anakinra 100mg s.c. x 5
45651585|NCT02528253|Biological|Tanezumab 5 mg SC|Tanezumab 5 mg SC
45651586|NCT02528253|Biological|Tanezumab 10 mg SC|Tanezumab 10 mg SC
45651587|NCT02528253|Biological|Tramadol PR oral|Tramadol PR oral
45651588|NCT03093103|Drug|Empagliflozin 10 mg|Prescription of empagliflozin 10 mg once a day Follow-up of renal parameters including BOLD MRI
45651589|NCT03093103|Drug|Placebo|Prescription of a placebo once a day Follow-up of renal parameters including BOLD MRI
45651590|NCT03092947|Other|No intervention|
45651591|NCT03092869|Other|Feet and Ankle Mobilization|A set of manual therapy mobilization in feet and ankle joints
45651592|NCT03092869|Other|Proprioceptive Training|A set of proprioceptive exercises oriented to improve balance abilities
45801083|NCT05449145|Dietary Supplement|Non-Vitamin D|MCT oil (first 4-week) plus Omega-3 FA (second 4-week)
45801084|NCT05447429|Procedure|Transversus abdominis plane block|TAP block will be performed by a needle which is punctured at the midaxillary line between subcostal margin and iliac crest, once tip of the needle had detected just above the peritoneum the syringe pulled back.
45801085|NCT05447429|Drug|Placebo|20 ml saline solution will be injected by a needle which is punctured at the midaxillary line between subcostal margin and iliac crest, once tip of the needle had detected just above the peritoneum the syringe pulled back.
45801086|NCT00369083|Procedure|Hospital at home treatment|
45651593|NCT03094039|Procedure|Ventilatory support while attached to the cord|Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
45801087|NCT05449067|Procedure|continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD)|"CAPD involves the manual instillation of 2 liters(L) of dialysis fluid into the peritoneal cavity through an indwelling abdominal catheter, four times a day. This typically means three short dwells during the day and a long dwell overnight. The total volume of dialysate is typically 8 liters.~In APD, a mechanical device is employed to assist the delivery and drainage of dialysate. Nocturnal intermittent peritoneal dialysis (NIPD) means patients receive five automated exchanges of 2 liters of dialysate each over 10 hours during the night, with the peritoneum left dry during the day. The overall dialysate volume is 10 liters."
45801088|NCT04743557|Drug|DYN101|DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 pre-mRNA
45651594|NCT03094039|Procedure|Immediate cord clamping|Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
45801089|NCT05447039|Drug|Montelukast Sodium Tablets|intervention group received standard cough therapy+ Montelukast 10 mg/day for 14 days
45801090|NCT05446961|Dietary Supplement|LCLT : 68% elemental L-carnitine and 32 % Tartric acid|3 g orally capsules
45801091|NCT05446961|Drug|Placebo|orally capsules
45801092|NCT05446805|Drug|F 18 AV-1451 (Flortaucipir)|A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for [18F] AV-1451. A PET-certified medical professional will prepare and administer the [18F] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of [18F] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).
45801093|NCT05446805|Drug|[11C]-Pittsburgh Compound B ([11C]PiB)|A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for [11C] PIB. A PET-certified medical professional will prepare and administer the [11C] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of [11C] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.
45801094|NCT05446649|Other|dry needling|the patient will be in comfortable position .and clean the area over upper trapezius and sub occipital muscles. detect the trigger point then Perpendicular needling into the bulk of the muscle is the safest technique for this area.
45801095|NCT05446649|Other|instrumented assisted soft tissue mobilization|the patients will be in sitting position. The appropriate IASTM technique instrument will be selected to scan, and then treat the affected area for 30 to 60 seconds per treated area. The procedure will be applied to the superficial cervical fascia and investing the layers of deep cervical fascia that surround all the structures in the neck. Strokes will be applied on the sub occipital and upper fibers of trapezius muscle. The IASTM technique will be applied at a 45° angle in a direction parallel to the treated muscle fibers for 20 seconds, followed immediately by an additional 20 seconds application at a 45° angle in a perpendicular direction to the muscle fibers, resulting in a total treatment time of approximately 40 seconds. The patients will be advised that they might be sore, bruised, or have small red dots called petechiae, on the treated area. Ice will be applied for 15 to 20 min after the treatment if there will be a massive soreness.
45801096|NCT05446649|Other|conventional therapy|patients will be received traditional physiotherapy (stretching and strengthening cervical muscles and postural correction exercise)
45801097|NCT05446415|Other|Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells.|Preoperative and postoperative
45801098|NCT05448443|Drug|AD981|Oral administration of AD981 in the morning and before sleep for 14 days
45801099|NCT05448443|Other|Placebo|Oral administration of placebo in the morning and before sleep for 14 days
45801100|NCT05448365|Dietary Supplement|Epigallocatechin gallate, Vitamin D, Vitamin B6, D-chiro-inositol|The patients will take for three months two tablets per day each containing 150mg epigallocatechin gallate, 25 mg D-chiro-inositol, 5mg Vitamin B6 and 25μg Vitamin D
45801101|NCT05448365|Dietary Supplement|Placebo|Maltodextrines
45801102|NCT05448053|Procedure|Ilizarov|Ilizarov fixation in open type III pediatric and adolescent tibial shaft fractures
45801103|NCT04728347|Biological|ARCT-021|ARCT-021 single dose
45801104|NCT03183791|Behavioral|RELAXaHEAD app|The Research Volunteers (RV) will explain the rationale for PMR and load the RELAXaHEAD app onto the patients' smartphones. The RV will review the app with the subject, focusing on user knowledge, usability, and engagement. The patient will perform a 15 minute session of PMR during the study enrollment and discuss the optimal time and place to practice PMR at home. Subjects will also be taught to enter their headache log daily on the app.
45801105|NCT03183791|Behavioral|Monitored Usual Care (MUC)|"The Research Volunteers (RV) will load the app onto the patients' smartphones but the PMR component will be blocked on the version of the app that the MUC patients receive.~Subjects will be taught to enter their headache log daily on the app."
45801106|NCT04713995|Other|Dietary recommendations|Dietary recommendations based on microbiome analysis of samples will be given and expected to receive and report in ~3 months survey after following recommendations.
46072865|NCT04201314|Dietary Supplement|InnoSlim®|Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.
45651595|NCT03093805|Dietary Supplement|Calcipotriene|Topical vitamin D cream will be applied to affected areas of the skin.
45651596|NCT05026879|Biological|Inactivated COVID-19 vaccine (CoronaVac)|The adverse events due to an inactivated COVID-19 vaccine.
45651597|NCT03093883|Drug|Ferrinemia|Test product Ferrinemia will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
45930649|NCT04731519|Behavioral|General Health Education|General Health Education a structured manualized group health education intervention previously developed by VISN 2 MIRECC investigators as a control condition for group psychotherapy RCTs. It has 12 1.5-hour weekly group sessions focusing on health and wellness topics such as Sleep, Physical Activity, Impact of Stress, Relaxation Techniques, Substance Use, Nutrition, Managing Daily Activities, Medication Benefits and Side Effects. GHE was chosen for the AC because it aligns in many respects with CI-CT (e.g., group format, length of sessions, similar expectations) while diverging in specific topics and skills targeted allowing for control of common factors like attention without causing confounding due to overlap in concepts
45930650|NCT04719052|Other|Diet and behavioural intervention|Intervention will receive a specific diet designed following the characteristics of Mediterranean Diet
45930651|NCT04719052|Other|Diet and behavioural intervention|Control group will receive a specific diet designed following the characteristics of Low fat Diet.
45930652|NCT04718857|Behavioral|Online education|health education
45801107|NCT03175523|Device|quantitative coronary angiography guided Bioresorbable scaffold implantation|In the QCA-guided group, BRS size and length were chosen by both visual estimation and on-line QCA, and adjunct high-pressure dilation is routinely performed to achieve angiographic residual diameter stenosis less than 30% by QCA and absence of angiographically visible dissections.
45651598|NCT03093883|Drug|Venofer|Reference product Venofer will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
45651599|NCT05047861|Procedure|socket shield technique with autogenous dentin graft|"The crown of the hopeless tooth will be decoronated with a chamfer diamond bur and a large-head round diamond bur under copious irrigation, until the bone crest level.~The root will then be sectioned along the long axis into buccal and palatal halves with a long shank fissure bur.~The lingual root fragment will be carefully retrieved using microperiotome. The remaining buccal root fragment will be thinned and concaved slightly with a long shank fissure bur. The thickness of the buccal root fragment should be at least 1.5 mm to ensure resistance to fracture and resorption.~The coronal part of this shield will be beveled to make a lingual slope for a better emergence profile with a large head round diamond bur.~The socket shield will be checked for immobility so the implant could be inserted palatally into the socket shield.~After the final preparation of the socket shield, Graft will be placed using autogenous dentin graft from the discarded palatal part of the tooth"
45653239|NCT05052411|Other|App usage assessments and analytics|All participants will be given a brief overview of the purpose of the study followed by a survey on participant characteristics and barriers to accessing HIV testing and PrEP uptake and P/SUD support services. The participant will be observed downloading the JomPrEP app and instructed with a brief tutorial on the onboarding process. The participant will be told to keep the app for 1 month and encouraged to use all app components. At 30 days, the participant will complete a post-survey, to which the Systems Usability Scale will be added. App analytics will also be collected (e.g., the number of logins). Participants will be asked to provide feedback on functionality, performance, and errors encountered, motivation to use the app, overall experiences using the app, feedback for further refinement, and subjective impact of the app on HIV prevention.
45801108|NCT03175523|Device|imaging guided Bioresorbable scaffold implantation|In the imaging-guided group, imaging is used at any step of percutaneous coronary intervention(PCI) before, during, or after PCI. Final image examination after PCI is mandatory.
45801109|NCT04709939|Other|OPAT|Observation of patients who are discharged from the hospital on OPAT.
45930653|NCT04710784|Behavioral|Sexual health information|We will provide participants with sexual health information, that is basic, accurate, and directly contributes to health-promoting decisions and behavior, once a week at the beginning of the study.
45930654|NCT04710784|Behavioral|I-TEST branded HIVST package|The I-TEST branded HIVST package will include HIV self-testing (HIVST) kits, referral coupons, condoms, female or male hygiene products, and instructions on how to use the I-TEST photo verification App or USSD (Unstructured Supplementary Service Data) system to verify the HIVST results. Study participants will be referred to a youth-friendly health clinic for confirmatory HIV testing, STI testing (syphilis, gonorrhea, chlamydia, and hepatitis B), STI treatment and PrEP referral.
45451230|NCT04772248|Drug|Tofacitinib|First eligible prescription for treating rheumatoid arthritis (RA)
45801110|NCT04709939|Other|Focus Group|Focus group with infectious disease physicians who prescribe OPAT to patients but were not involved in the study.
45801111|NCT04705025|Behavioral|Cognitive Behavior Therapy|Undergo CBSM using the BNT001 app
46072866|NCT04201314|Dietary Supplement|Placebo|Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.
46072867|NCT00703833|Drug|MK0777|Days 1-3 3mg MK0777, Days 4-7 6 mg MK0777, Days 8-28 3, 6 or 9 mg MK0777
46072868|NCT00703833|Drug|Placebo (unspecified)|matching placebo
45451231|NCT04772248|Drug|TNF Inhibitor|First eligible prescription for treating rheumatoid arthritis (RA)
45451232|NCT00090857|Drug|Letrozole|
45451233|NCT00090857|Other|Placebo|
45451234|NCT02227498|Device|Effect of Argus II on Functional Vision|To evaluate the safety and effectiveness of the Argus II Retinal Prosthesis in subjects with AMD.
45451235|NCT01775644|Drug|Bevacizumab|Administration of treatment will be as used in normal daily routine under local labeling.
45451236|NCT02227576|Drug|Romiplostim|
45451237|NCT04259086|Drug|DaxibotulinumtoxinA for injection|Intramuscular injection
45451238|NCT04243486|Drug|UHE-105|Topical shampoo containing active drug
45451239|NCT04243486|Drug|Vehicle|Topical shampoo containing no active drug
45451240|NCT04229368|Dietary Supplement|Vitamin D3|Vitamin D will be given at doses commonly given to patients with low vitamin D levels
45451241|NCT00090779|Drug|Emtricitabine/ tenofovir disoproxil fumarate|once daily
45451242|NCT00090779|Drug|Lopinavir/Ritonavir|twice daily
45930655|NCT04710784|Other|Follow-up testing and clinic assessments|Information to encourage routine retesting for HIV every 6 months and linkage to the youth-friendly clinic for confirmatory HIV testing, STI testing (syphilis, gonorrhea, chlamydia, and hepatitis B), STI treatment, and PrEP referral. Additionally, follow-up surveys will be administered to assess HIV testing, sexual behavior history, youth participation experience, and other related outcomes will be collected from enrolled participants.
45801112|NCT04705025|Other|Interview|Complete interview
45930656|NCT04685707|Device|Visual feedback monitoring system|Participants will follow the exercise monitoring system's instructions displayed on a TV. Treadmill walking speed will be set at a comfortable walking speed.
45930657|NCT04685707|Device|Control|Participants will monitor the intensity of exercise independently using a standard heart rate monitor and control it by adjusting the treadmill speed (walking speed).
45451243|NCT01085279|Device|Fraxel Restore, Solta Medical Inc. (Non-ablative fractional laser)|1,550 nm non-ablative fractional laser Irradiance: 15 mJ/microbeam. Coverage: 14-20%. Number of treatment sessions: 4-5
45930658|NCT04685304|Genetic|Pharmacogenetic Testing|Genetic results will be reported for CYP2D6, CYP2C19, CYP2C9, CYP2B6, CYP3A4, CYP3A5, SLCO1B1, TPMT, and VKORC1.
45930659|NCT04685304|Other|Pharmacist Consultation Note|Recommendations will be based on phenotypes translated from genetic data in accordance with CPIC guidelines. Drug interactions will be incorporated into phenotype assignments when appropriate.
45451244|NCT01085279|Drug|Modified Kligman's formula (Triple topical therapy)|Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% once a day during 15 weeks
45801113|NCT04705025|Other|Quality-of-Life Assessment|Ancillary studies
45930660|NCT04685304|Other|Delayed pharmacogenetic testing|Pharmacogenetic testing and a pharmacist consultation note will be provided to participants provided to the standard care arm once 3 months have passed since their baseline visit.
45930661|NCT04684654|Biological|BMS-986325|Specified dose on specified days
45930662|NCT04684654|Other|Placebo for BMS-986325|Specified dose on specified days
45930663|NCT04682730|Behavioral|Deliberative Loop|"The investigators will give background information to the stakeholders before they engage in the Deliberative session.~Stakeholders from a given clinic will come together for a Deliberative session (i.e., facilitated conversation), enabling them to hear the full range of perspectives held by their fellow colleagues and to share their own perspective regarding how best to implement the guideline in small-group discussions.~Following the Deliberative session, each stakeholder will have the opportunity to record their opinions regarding possible implementation interventions. The investigators will share these opinions with the clinic's decision-makers to help guide their decision-making about which implementation interventions to deploy. If a stakeholder happens to be absent the day of their clinic's Deliberative session, they will still have the opportunity to complete the survey."
45930664|NCT04672889|Dietary Supplement|Placebo|consume 1 sachet per day for 1 months
45930665|NCT04672889|Dietary Supplement|Babyguard® Breast Milk Probiotics|consume 1 sachet per day for 1 months
45930666|NCT04663399|Other|Prospective patient|The immuno-inflammatory and thrombo-inflammatory profiles will be evaluated at inclusion, and at 24 hours +/- 12 hours of the reperfusion treatment.
45930667|NCT04654689|Dietary Supplement|Liposomed polyphenols resveratrol and curcumin|Combination of resveratrol (75mg) and curcumin (200mg) liposomed
45930668|NCT04654689|Other|Placebo for liposomed resveratrol and curcumin|Water with sucrose replacing the liposomed polyphenols
45930669|NCT04654689|Dietary Supplement|Isocaloric Diet|40% carbohydrates, 40% lipids and 20% proteins
45930670|NCT04654689|Drug|G04CB02|G04CB02, in a single daily dose for 4 months
45930671|NCT04654689|Other|Placebo microcrystalline methylcellulose|Placebo replacing G04CB02
45930672|NCT04653805|Other|Current clinical practice in primary care of patients with type 2 diabetes mellitus|
46072869|NCT05599893|Other|Tele physical therapy|Before commencing training, warm-up exercises involving upper and lower extremity joint movements were performed for 10 times. During the first and second weeks, the third and fourth weeks, the fifth and sixth weeks and the seventh and eighth weeks, the exercises were performed 10-15, 15-20, 20-25 and 25-30 times per session, respectively. Each session lasted for 10 minutes of warm up, 60 minutes of training and 10 minutes of cool down phase. The participants in the TPG received training four times a week, for 8 weeks, each session lasted for 60 minutes.
46072870|NCT05599893|Other|Patient educationa and Conventional exercises|They were informed to do their normal daily activities, avoid a sedentary lifestyle, perform regular physical activities such as household activities, maintain a balanced diet and have 6-8 hours of sleep per day.
46072871|NCT02838342|Drug|Metronomic cyclophosphamide|50 mg oral tablet, one tablet per day, every day for 6 months; abort if progression or intolerance
45653240|NCT04545619|Device|QDOT MICRO System|QDOT Micro Catheter with nGEN Generator
45653241|NCT05474885|Biological|BCMA-CD19 cCAR T cells|BCMA-CD19 cCAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
45801114|NCT04705025|Other|Questionnaire Administration|Ancillary studies
45801115|NCT03137771|Radiation|3-Dimensional Conformal Radiation Therapy (3D-CRT)|Undergo 3DCRT
46072872|NCT02838342|Drug|Interferon-alpha|3 months of treatment from the 4th cycle metronomic cyclophosphamide : subcutaneous injection, initial dose of 3 MIU three times a week. The dose may be adjusted as tolerated to achieve a T cell counts greater than 500 / mm3
45653242|NCT04334135|Dietary Supplement|MitoQ|Four to eight 20mg capsules (depending on body mass)
45653243|NCT05728879|Combination Product|APR-TD011 (RLF-TD011)|APR-TD011 (RLF-TD011) wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician.
45801116|NCT03137771|Drug|Docetaxel|Given IV
45451245|NCT02531243|Behavioral|CALMS|Family Therapy; Multi-user Biofeedback Videogames
45801117|NCT03137771|Drug|Gemcitabine|Given IV
45801118|NCT03137771|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
45801119|NCT03137771|Drug|Pemetrexed Disodium|Given IV
45801120|NCT03137771|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
45801121|NCT03137771|Drug|Erlotinib Hydrochloride|Given PO
45801122|NCT03137771|Drug|Pembrolizumab|Given IV
46072873|NCT05333640|Device|Sirolimus Drug Coated Balloon|AVFs treated with SDCB
45801123|NCT04687553|Diagnostic Test|Simplified Evaluation of CONsciousness Disorders (SECONDs)|All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs)
45801124|NCT03057119|Behavioral|Psycho-educational content (5 Minutes)|The interventionist will discuss substance use and misuse and the influence of substance use on self care.
45801125|NCT03057119|Behavioral|Readiness Assessment (10 minutes)|The interventionist will give the patient feedback on their ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change.
45801126|NCT03057119|Behavioral|Goal-Setting (5 minutes)|The interventionist will use motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues.
45801127|NCT03057119|Behavioral|Identifying and prioritizing needs (5 minutes)|The interventionist will use problem-solving techniques to help patients identify which services may best help them work towards their goals. Services will include (but are not limited to) emergency crisis services, counseling to deal with substance use, referral to local self-help groups (Alcoholics Anonymous, Narcotics Anonymous, etc.), legal assistance, faith-based counseling, mental health counseling or inpatient substance use treatment.
45801128|NCT03057119|Behavioral|Explanation of Peer Navigator and Session wrap (5 minutes)|The interventionist will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
46072874|NCT05333640|Device|Paclitaxel Drug Coated Balloon|AVFs treated with PDCB
45801129|NCT04687475|Other|Clinical Tool (Mobile Spirometry and Survey)|The clinical tool is a combination of home spirometry measurements and a patient survey measuring patient reported outcomes including the Cystic Fibrosis Respiratory Symptom Diary (CFRSD) and Chronic Respiratory Infection Symptom Score (CRISS©), with permission from the Seattle Quality of Life Group.
45801130|NCT03034421|Behavioral|Bed rest|Patients will undergo bed rest for 48 hours following endoscopic valve implantation.
45451246|NCT01081691|Biological|CNTO 5825|10 mg/kg single dose IV or matching placebo
45801131|NCT04600817|Drug|TJ107|QW8
45651600|NCT05047861|Procedure|socket shield technique with alloplast graft|"The crown of the hopeless tooth will be decoronated with a chamfer diamond bur and a large-head round diamond bur under copious irrigation, until the bone crest level.~The root will then be sectioned along the long axis into buccal and palatal halves with a long shank fissure bur.~The lingual root fragment will be carefully retrieved using microperiotome. The remaining buccal root fragment will be thinned and concaved slightly with a long shank fissure bur. The thickness of the buccal root fragment should be at least 1.5 mm to ensure resistance to fracture and resorption.~The coronal part of this shield will be beveled to make a lingual slope for a better emergence profile with a large head round diamond bur.~The socket shield will be checked for immobility so the implant could be inserted palatally into the socket shield.~After final preparation of socket shield, Graft will be placed Alloplast graft"
45801132|NCT04600817|Drug|TJ107 placebo|QW8
45801133|NCT03025763|Other|Craniosynostosis Network Environmental Survey|Questionnaire is administered to the mothers of affected participants regarding medical history and environmental exposures during pregnancy, delivery, and neonatal period. Optional.
46072875|NCT02838264|Drug|PF-06463922|Single oral dose of PF-06463922 50 mg on Day 1 of Period 1 and Day 5 of Period 2
46072876|NCT02838264|Drug|PF-06463922|Single oral dose of PF-06463922 75 mg on Day 1 of Period 1 and Day 5 of Period 2
45451247|NCT01081691|Biological|CNTO 5825|3 mg/kg single dose IV or matching placebo
45651601|NCT03094429|Drug|NaBen®|2000 mg/day or 1000 mg/day, twice daily
45651602|NCT03094429|Other|Placebo|0 mg total, twice daily
45651603|NCT05023759|Dietary Supplement|Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules|Formula30A Full Spectrum Hemp-Derived Cannabidiol (CBD) 25mg Capsules taken once daily for 8 weeks.
45801134|NCT03025763|Other|2D/3D Photography|Full frontal and lateral face and other parts of the body may be taken for dysmorphic assessment. There is the risk of identification and loss of confidentiality. Optional.
45801135|NCT03025763|Procedure|Buccal Swab Cell Sampling|One or more swabs, like a Q-tip (for children), or saliva collection kit (for adults) will be used to collect buccal cells. With a swab, they will brush the inside of the mouth several times. With saliva collection kit, they will collect their saliva by spitting into a container several times using a commercially available saliva collection kit. Required.
45801136|NCT03025763|Procedure|Blood sampling|Venipuncture so that one teaspoon to tablespoons (1-20 ml.) of blood is collected. The volume drawn will be dependent on the age and size of the child. Minimal amounts may be required for DNA, but to establish a lymphoblastoid or iPS cell line at least 3 to 10 ml will be required independent of age. In the case of an infant, if 3 to 10 ml cannot be obtained, then a lymphoblastoid or iPS cell line will not be created. Optional.
45801137|NCT03025763|Procedure|Skin Biopsy|For those who do not undergo surgery or the skin removal is not considered part of the surgical procedure. After proper cleaning, a piece of skin the size of a pencil eraser (about 4 mm or 1/8 inch in diameter) will be removed (using a circular blade or scalpel) from the arm (inside of arm or forearm in a spot that is as unnoticeable as possible). This area will be covered with a Band-Aid. No stitches are usually required. A crust will form and eventually fall off. Optional.
46072877|NCT02838264|Drug|PF-06463922|Single oral dose of PF-06463922 100 mg on Day 1 of Period 1 and Day 5 of Period 2
46072878|NCT02838264|Drug|PF-06463922|Highest safe single oral dose (mg) of PF-06463922 identified in the previous cohorts will be administered on Day 1 of Period 1 and Day 5 of Period 2
46072879|NCT02838264|Drug|Itraconazole|200 mg oral dose of itraconazole on Days 1 to 11 during Period 2
46072880|NCT00902486|Drug|INCB028050|4 mg capsules QD
46072881|NCT00902486|Drug|INCB028050|7 mg capsules QD
46072882|NCT00902486|Drug|INCB028050|10 mg capsule QD
45451248|NCT01081691|Biological|CNTO 5825|For atopic patient:10 mg/kg single IV dose or matching placebo
45451249|NCT01081691|Biological|CNTO 5825|For atopic patient: 3 mg/kg single dose SC or matching placebo
45451250|NCT01081691|Biological|CNTO 5825|0.3 mg/kg single dose IV or matching placebo
45451251|NCT01081691|Biological|CNTO 5825|0.1 mg/kg single dose Intravenously (IV) or matching placebo
45451252|NCT01081691|Biological|CNTO 5825|1 mg/kg single dose IV or matching placebo
45451253|NCT00098345|Drug|ZD6474 (vandetanib)|oral once daily tablet
45801138|NCT03025763|Procedure|Tissues from a Clinically Indicated Procedure|In some instances when there is discarded tissues and specimens (including skin and bone at the time of reconstructive craniofacial surgery), they will be collected by making arrangements with their physicians. Some of these tissues will be used to generate cell lines. Optional.
45801139|NCT03025763|Procedure|Pre-operative CT Scan Image Files.|Optional for those who had a previous CT scan for a prior traumatic event.
45930673|NCT04649866|Diagnostic Test|plethysmography|"Forearm blood flow (FBF) measurements in both arms will be made using venous occlusion strain-gauge plethysmography prior to the initiation of any intra-arterial infusions. All FBF measurements will be expressed as mL/min per 100-1 mL forearm volume according to prior studies and the Whitney method.1, 2 Resting baseline FBF will be measured at least 30 minutes after venous and arterial catheter placement to ensure that blood flows in the cannulated arms are stabilized. We will measure FBF during the last 2 minutes of each infusion period. Infusions of individual vasoactive medications will occur over a 15-minute interval. There will be a 25-minute washout between vasoactive medications. Cumulative dose response curves will be constructed over 5-minute incremental infusions. We will proceed in the following order:~SNP 0.8, 1.6 and 3.2 mcg/min~ACh 7.5, 15 and 30 mcg/min~Normal saline"
45801140|NCT02971787|Dietary Supplement|Probiotics|Day 1-21: 2 capsules per day
45801141|NCT02971787|Dietary Supplement|Salt|Day 8-21: 10 tablets à 600 mg per day
45930674|NCT04642963|Radiation|Cardiac Radiosurgery|Non-invasive delivery of ablative radiotherapy dose to the arrhythmia substrate.
45930675|NCT04634838|Device|MedCu Antibacterial Wound Dressings with Copper Oxide|Comparison between the efficacy of antibacterial wound dressings containing copper oxide microparticles to improve the wound healing of pressure sores and post-op wounds as compared to silver wound dressings
45930676|NCT04629534|Drug|High dose Cholecalciferol|Mothers in experimental group will receive 6,000 IU of vitamin D in addition to their prenatal vitamin, daily for 3 months. Infants in this group will receive placebo vitamin D drops
45930677|NCT04629534|Drug|Cholecalciferol|Mothers in placebo control group will receive 600 IU of vitamin D in the form of their prenatal vitamin along with placebo vitamin D. Infants of the mothers in this group will receive standard 400 IU of vitamin D
45930678|NCT04628728|Other|Survey based on questionnaire (self-designed)|Participants are handed a questionnaire to asses comprehension of medical content provided in the referral letters.
45930679|NCT04621708|Device|Repetitive transcranial magnetic stimulation|Left DLPFC iTBS rTMS
45930680|NCT04616183|Drug|Abemaciclib|Given PO
45930681|NCT04616183|Biological|Cetuximab|Given IV
45930682|NCT04616183|Drug|ERK1/2 Inhibitor LY3214996|Given PO
45930683|NCT04613648|Diagnostic Test|Imaging|Ultrasonographic imaging of the shoulder
45930684|NCT04612335|Other|Rate control|Rate control drugs are administered to obtain symptom relief and a heart rate of <110 bpm, followed by a 4-week telemonitoring period.
45651604|NCT05023447|Behavioral|BRIDGE Intervention|Intensive clinical assessment; >16 sessions of Cognitive Analytic Therapy (CAT); Development of a shared formulation
45930685|NCT04612335|Other|Pharmacological or electrical cardioversion|Pharmacological or electrical cardioversion is performed to achieve restoration of sinus rhythm, either acutely or in a wait-and-see approach, all within 48 hours, and followed by a 4-week telemonitoring period.
45651605|NCT05023447|Behavioral|Service as Usual|Likely to range from social services, mental-health services, forensic services to no intervention
45801142|NCT00370799|Drug|Caudal epidural injection|group 1: Caudal epidural injection local anesthetics only
45801143|NCT00370799|Drug|Caudal Epidural Injection with generic Celestone|Group 2. Caudal Epidural Injection local anesthetic with 6mg of non-particulate Celestone
45801144|NCT00370799|Drug|Caudal Epidural Injection with Celestone|Group 3. Caudal Epidural Injection with local anesthetic with 6 mg of brand name Celestone
45930686|NCT04610944|Behavioral|Changing Talk Online (CHATO)|Three, one-hour training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication.
45930687|NCT04607226|Other|Active transcutaneous vagus nerve stimulation|respiratory-gated non-painful electrical stimulation of the auricle for 30 minutes
45930688|NCT04607226|Other|Sham transcutaneous vagus nerve stimulation|stimulation of the auricle for 30 minutes
45930689|NCT04606433|Drug|GNC-038|Administration by intravenous infusion.
45930690|NCT04602065|Drug|IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)|IBI318, 300mg, Q2W, Intravenous influsion.
46072883|NCT00902486|Drug|Placebo|Placebo matching INCB028050 QD
46072884|NCT00633438|Other|Placebo|Matched oral capsule administered 1 hour prior to surgery and matched oral capsule administered post surgery as needed
46072885|NCT00633438|Drug|Celecoxib|400 mg oral capsule as single dose administered 1 hour prior to surgery and 200 mg oral capsule as single dose administered post surgery as needed
46072886|NCT00836745|Other|Non Interventional|Sutent capsule, once daily administered per the locally approved product information.
46072887|NCT02833116|Drug|Betamethasone|
45651606|NCT05026255|Procedure|alveolar recruitment manoeuvre by pressure step|The application of alveolar recruitment manoeuvres consists of transiently increasing alveolar pressure in order to re-open collapsed alveolar territories and to re-ventilate poorly ventilated or non-ventilated lung areas.
45651607|NCT03090607|Device|Aluvra™|Endoscopic injection of bulking agent to the lower esophageal sphincter
45651608|NCT03090607|Drug|Saline|Endoscopic injection of saline
45801145|NCT00370799|Drug|Caudal Epidural Injection with DepoMedrol|Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
45801146|NCT02850575|Device|Mpact Double Mobility cup|
45801147|NCT04593953|Procedure|TLIP|Injection of 40 ml of ropivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.
45801148|NCT04560335|Behavioral|Coach to FIt|"CoachToFit: Those randomized to CoachToFit will have the CoachToFit app downloaded to their phone by the peer coach and will work with the coach to initialize the app. Individuals will receive an activity tracker compatible with Android OS and iOS (Amazfit Bit) and a Bluetooth scale (Smart Body scale). Participants will be instructed by the peer to complete at least two CoachToFit modules per week. Modules take about~15 minutes to complete and have embedded knowledge quizzes and end with a choice of three goals to practice over the next week. They will also set up a time for the first 20-minute coaching call, which will then continue weekly."
45930691|NCT04598815|Drug|Sirolimus|"Group Sirolimus: Patients will receive a first dose of Sirolimus of one 2 mg tablet on the first day, given approximately at 10 am, followed by 0.5 mg tablet per day for 12 weeks.~Group Methylprednisolone: Methylprednisolone pulse therapy will be administered for 12 weeks as follows: 500 mg iv once weekly for 6 weeks, then 250 mg iv once weekly for a further 6 weeks, for a cumulative dose 4.5 g."
45930692|NCT04593875|Device|Active LIFUP Treatment|2 LIFUP Treatments
45930693|NCT04593875|Device|Sham LIFUP Treatment|2 sham LIFUP treatments
45930694|NCT04584112|Drug|Tiragolumab|Tiragolumab 840 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of every 28-day cycle.
45930695|NCT04584112|Drug|Atezolizumab|Atezolizumab 1680 mg administered by IV infusion on Day 1 of every 28-day cycle.
45930696|NCT04584112|Drug|Nab-paclitaxel|Nab-paclitaxel 100 milligrams per square meter (mg/m^2) administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
45930697|NCT04584112|Drug|Tiragolumab|Tiragolumab 420 mg administered by IV infusion Q2W.
45930698|NCT04584112|Drug|Atezolizumab|Atezolizumab 840 mg administered by IV infusion Q2W.
45930699|NCT04584112|Drug|Nab-paclitaxel|Nab-paclitaxel 125 mg/m^2 administered by IV infusion QW.
45930700|NCT04584112|Drug|Carboplatin|Carboplatin (area under the concentration-time curve [AUC]: 5 milligrams per milliliter per minute [mg/mL/min]) administered by IV infusion Q3W.
45930701|NCT04584112|Drug|Doxorubicin|Doxorubicin 60 mg/m^2 Q2W administered by IV infusion.
45930702|NCT04584112|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m^2 Q2W administered by IV infusion.
45930703|NCT04584112|Drug|Granulocyte colony-stimulating factor (G-CSF)|G-CSF support for four doses.
45930704|NCT04584112|Drug|Granulocyte-macrophage colony-stimulating factor (GM-CSF)|GM-CSF support for four doses.
45930705|NCT04580238|Drug|Botox 200 UNT Injection|"Treatment Protocol:~Botox 200 IU vials for 40 patients for the duration of study (4 treatment cycles); Treatment will be based on the PREEMPT study full treatment (standard of care) and follow the pain protocol to a total of 195 IU in standard injection sites"
45930706|NCT04580238|Combination Product|Non Botox based Standard of Care Treatments for Headache/Migraine|Control Group will receive normal standard of care Non-Botox based interventions.
45930707|NCT04573777|Drug|Repatha|140 MG in 1 ML Prefilled Syringe PCSK9 Inhibitor
45651609|NCT04964635|Device|TetraGrip II system|"This main aim of this whole research project is to evaluate the performance of the TetraGrip II system in improving the upper limb functions in people with C4-C7 tetraplegia i.e. people who have damaged their spinal cord in the neck resulting in loss of function in all four limbs. The Tetragrip system uses a technique called Functional Electrical Stimulation (FES) in which small electrical impulses are used to activate paralysed muscles and hence provide movement. The stimulation is controlled by sensors which measure the movement of the other shoulder and enable the person to regain the use of their hand via stimulating electrodes placed on the skin over the relevant muscles.~The feasibility of using this FES based system in restoring the upper arm functions will be evaluated by clinically trying the device on participants with C4-C7 tetraplegia."
45651610|NCT03092557|Other|Determination of local pleural strain|For each tidal volume, the local pleural strain will be determined over three consecutive respiratory cycles at four predetermined sites using lung ultrasonography.
45651611|NCT03090529|Other|Exercise Group|The 12-week exercise-training program will include three sessions of aerobic exercise per week
45651612|NCT03092167|Other|Physical exercises|Physical exercises
45801149|NCT04560335|Behavioral|Treatment as Usual|Veterans randomized to the treatment as usual arm will continue to access all services of the VA Pittsburgh, and will participate in three research interviews. After the first meeting, all participants will meet with a peer coach (peer specialists) who will discuss with them the importance of losing weight (using a structured conversation that follows a handout which is provided to the participant). The handout was developed with input from a VA dietitian as well as Veterans and is graphically appealing, with a simple layout, and provides information on diet and activity as well as the local MOVE! schedule
45801150|NCT04738253|Diagnostic Test|Ultrasonography|The ultrasound measurement s of the axillary recess capsule thickness.
45651613|NCT01672957|Drug|Mycophenolate Mofetil|Protocol does not specify any regimen for treatment. The choice of treatment will be made prior to enrollment by the treating physician.
45801151|NCT05445089|Drug|Carvacrol|Carvativir 6 mg/ml diluted for oral solution.
45930708|NCT04567004|Other|Control|Participants will be shown images of juice, bread, yogurt, cookies, and cereal without any added front-of-package labels.
45930709|NCT04567004|Other|Nutriscore Label|A front-of-package Nutriscore label will be applied to images of juice, bread, yogurt, cookies, and cereal. This label applies a score of A, B, C, D, or E based on the product's nutrition profile.
45930710|NCT04567004|Other|Adapted Peruvian Nutrient Label|A front-of-package octagonal nutrient label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label text informs consumers if a product is high in sugar, saturated fat, or salt/sodium. These labels were developed by the Peruvian government and adapted by investigators.
45930711|NCT04567004|Other|Guideline Daily Amount Label|A front-of-package Guideline Daily Amount label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label shows the amount and percent of daily value of calories, total fat, saturated fat, sugar, and sodium in one serving of a product.
45930712|NCT04564105|Behavioral|simulation education|Intubation protocol will be trained by simulation exercise.
45930713|NCT04556123|Other|Measurement of the hydration state and decongestive treatment according to bioimpedance spectroscopy|"The measurements will be performed in each center by a reference physician or nurse, using a portable whole body bioimpedance spectroscopy device, BCM (Fresenius Medical Care).~The electrodes will be attached to one hand and one foot on the ipsilateral side, after the patient has been in the supine position for at least 5 minutes."
45930714|NCT04556123|Other|Measurement of the hydration state and decongestive treatment according to clinical judgement alone|Clinical judgement will be performed in each center by a reference physician or nurse
45930715|NCT04555590|Behavioral|H-HOPE Intervention|The H-HOPE intervention (Hospital to Home: Optimizing the Preterm Infant's Environment) to promote early infant development and parental engagement. H-HOPE includes ATVV, which provides Auditory (voice), Tactile (moderate touch massage), Visual (eye to eye), and Vestibular (rocking) stimulation with a parent-directed component which provides participatory guidance and social support to engage with their infants.
45451254|NCT03962387|Other|Not applicable(observational study)|Not applicable(observational study)
45930716|NCT04521972|Device|Room light/light bulb|Room light will be ON/OFF or red light used in the room. Reducing/eliminating light in the room in the evening and night is expected to allow the natural release of melatonin, which is thought to promote uterine contractions in late pregnancy.
45930717|NCT04516135|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
45930718|NCT04516135|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45451255|NCT03963713|Radiation|Stereotactic radiotherapy|Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).
45651614|NCT01672957|Drug|Immunosuppressive Therapy|Protocol does not specify any particular immunosuppressive drug and regimen for treatment. The choice of immunosuppressive therapy will be made prior to enrollment by the treating physician.
45651615|NCT05018065|Behavioral|Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)|sexual dysfunction assesment
45651616|NCT05022979|Other|Observational only|"The investigator collected the patient's data from the medical record and interviewed the patient to complete the nutritional questionnaire.~The required biological, blood and urine samples were collected during routine blood sampling upon entry and hospitalization."
45451256|NCT03963713|Radiation|Conventionally-fractionated image- guided Intensity modulated radiotherapy|Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.
45451257|NCT03963635|Diagnostic Test|MicroB-plex Lyme Immunoassay|Subject's blood and clinical data are collected to develop a diagnostic immunoassay
45651617|NCT05023213|Behavioral|Warna-Warni Waktu|Six videos and eighteen reinforcer activities
45930719|NCT04516135|Other|Quality-of-Life Assessment|Ancillary studies
45801152|NCT05445089|Other|Control group|Placebo
45930720|NCT04516135|Other|Questionnaire Administration|Ancillary studies
45930721|NCT04516135|Radiation|Volume Modulated Arc Therapy|Undergo VMAT
45801153|NCT05444777|Drug|Ketamine Hydrochloride|Ketamine was given prior to wound closure.
45801154|NCT00370877|Drug|rFVIIa|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
45801155|NCT00370877|Procedure|Standard Care|Patients will recieve standard care for post partum hemorrhage according to current recommendations.
45930722|NCT04507711|Drug|0 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using palonosetron
45930723|NCT04507711|Drug|1 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (1 ul) using palonosetron
45930724|NCT04507711|Drug|10 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (10 ul) using palonosetron
45930725|NCT04507711|Drug|100 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (100 ul) using palonosetron
45930726|NCT04499274|Drug|0 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 nl) using ondansetron
45930727|NCT04499274|Drug|0.2 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.2 ul) using ondansetron
45930728|NCT04499274|Drug|2 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (2 ul) using ondansetron
45930729|NCT04499274|Drug|20 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (20 ul) using ondansetron
45930730|NCT04497961|Drug|Lenalidomide|dose of 10mg oral lenalidomide on days 1-21 of each 28-day cycle.
45930731|NCT04497961|Drug|Daratumumab|1800 milligrams (mg) subcutaneous (SC) injection of daratumumab as follows: days 1, 8, 15, and 22 of cycles 1 and 2; days 1 and 15 of cycles 3-6; day 1 of cycles 7-36
45930732|NCT04497961|Behavioral|Questionnaires|EORTC QLQ-C30, EORTC QLQ-MY20, PRO-CTCAE)
45451258|NCT01085669|Device|Microbiological analysis of retained VEPTR Implants|Implants have to be adapted every half a year, the retained implants during revision are analysed for biological colonization.
45653244|NCT04421469|Drug|Triprilimab(JS001)|"JS001 240mg d1, gemcitabine(1g/m²),d1,8 + nedaplatin (80-100mg/m²),d2,q3w,6cycles.The curative effect was evaluated every 2 cycles.If the therapeutic evaluation was SD,the chemotherapy scheme was changed;~Local treatment of active lesions(including radiotherapy and/or radiofrequency ablation);~JS001 maintenance treatment."
45653245|NCT03067753|Drug|Monosialoganglioside Ganglioside|Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
45801156|NCT04515953|Drug|ND-340|ND-340: Subjects will receive a single administration of ND-340 at the specified dose in each arm after TKA.
45801157|NCT04515953|Drug|IV-PCA|IV-PCA: Intravenous patient-controlled analgesia (IV-PCA), morphine, will be administered in subjects of control group after TKA for postoperative pain management as standard practice.
45801158|NCT00370955|Procedure|phacoemulsification using either high vacuum or low vacuum techniques|All surgeries were performed using Sovereign phacoemulsification system (AMO) using Whitestar technology.
45930733|NCT04497961|Other|Dietary Intervention|The intervention, consisting of fully prepared whole foods plant based (WFPBD) meals and behavioral coaching provided by the company Plantable. Patients receive self-selected WFPBD meals (lunch/dinner) for 12 weeks, along with guidance for snacks and breakfast. Behavioral counseling will be provided by health coaches and a research dietitian. The first 15 participants on each arm interested in this intervention will be enrolled on C13D1 or C25D1.
46072888|NCT02833116|Drug|Dexamethasone|
45651618|NCT05047393|Other|Current blood vitamin D level and painDetect questionairre score will be detected|PainDETECT neuropathic pain questionnaire will be used to evaluate the presence of nociceptive, mixed and neuropathic pain in patients. Patients with a total questionnaire score of 12 or less are considered nociceptive pain without a neuropathic pain component. If the total score is in the range of 13-18, the result is uncertain, but it is accepted that the neuropathic component can be found in the mixed type, and in the scores of 19 and above, it is accepted that the neuropathic pain component is present. Patients with previously obtained and finalized vitamin D levels < 20 ng/mL, 20-30 ng/mL, and ˃30 ng/mL will be grouped as deficiency, insufficiency and normal, respectively.
45930734|NCT04496895|Dietary Supplement|Placebo|consume 1 sachet per day for 2 months
45651619|NCT05047081|Behavioral|Scoring Your College Goals Workshop|A two-hour virtual college readiness workshop.
45651620|NCT05047081|Other|Placebo|Placebo Treatment-As-Usual Group which does not receive the workshop intervention
45651621|NCT05022745|Other|Multimodal, multidisciplinary approach|The patient management is adapted pre-operatively, per-operatively and post-operatively
45930735|NCT04496895|Dietary Supplement|orange peel fermentation|consume 1 sachet per day for 2 months
45930736|NCT04492605|Dietary Supplement|Placebo|consume 1 capsule per day for 2 months
45930737|NCT04492605|Dietary Supplement|TCI378 Probiotics|consume 1 capsule per day for 2 months
45930738|NCT04492605|Dietary Supplement|TCI507 Probiotics|consume 1 capsule per day for 2 months
45930739|NCT04490720|Dietary Supplement|Placebo|consume 1 sachet per day for 2 months
45930740|NCT04490720|Dietary Supplement|Buckwheat husk extract|consume 1 sachet per day for 2 months
45930741|NCT04488159|Drug|Capecitabine|Tablet
45930742|NCT04488159|Drug|Oxaliplatin|Infusion
45930743|NCT04488159|Drug|Fluorouracil|Infusion
45651622|NCT05017987|Drug|ATB-101, ATB-1011, ATB-1012|"Test drug~- Code name: ATB-101~Control drug1~Code name: ATB-1011~Active ingredient: Olmesartan~Control drug2~Code name: ATB-1012~Active ingredient: Dapagliflozin"
45651623|NCT04465435|Other|Web-based self-report questionnaires|Web-based self-report questionnaires based on well established instruments.
45651624|NCT04465435|Other|Focus Group Interviews|Group conversation with open-ended questions with 7-10 students/group on topics relevant to the aim of the study.
45930744|NCT04488159|Drug|Leucovorin|Infusion
45930745|NCT04488159|Device|Immunoscore® assay|Whole-slide tissue analysis of CD3+ and cytotoxic CD8+ T cells in the tumor and in the invasive margin
45930746|NCT04488159|Other|Physical exercise|Increasing stair walking exercise twice a week over 12 weeks total.
45930747|NCT04486768|Other|Survey Instrument|This registry contains several surveys that will be released for patient/caregiver completion at enrollment and at time points following enrollment. These surveys can be completed on any computer that is connect to the internet.
45930748|NCT04481191|Biological|RotaTeq (V260)|Live, pentavalent rotavirus vaccine administered as a 2 mL-dose oral solution
45930749|NCT04481191|Biological|IPV|0.5 mL dose IPV (Sabin strain based), administered via IM injection
45930750|NCT04449861|Drug|Durvalumab plus chemotherapy|"Drug: Durvalumab IV infusions every 3 weeks for 4-6 cycles and every 4 weeks thereafter until PD or other discontinuation criteria.~Drug: Carboplatin 4-6 cycles every 3 weeks~Drug: Cisplatin 4-6 cycles every 3 weeks~Drug: Etoposide 4-6 cycles every 3 weeks"
45930751|NCT04448327|Device|active tVNS|non-painful electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session
45651625|NCT03090217|Behavioral|Pelvic Physiotherapy|1) daily pelvic floor muscle training (PFMT).
45651626|NCT03090217|Behavioral|Standard care (SC)|1) daily vaginal dilator therapy (10 to 15 minutes) and 2) usual care management.
45651627|NCT05022277|Behavioral|Low tech health SMS messages|Weekly health-related SMS messages are provided to adolescents.
45930752|NCT04448327|Device|Sham tVNS|Sham stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session
45651628|NCT05022277|Behavioral|Low tech health Phone + SMS messages|Weekly health-related phone calls plus SMS messages are provided to adolescents.
45930753|NCT04445909|Device|VA-ECMO|Deployment of extracorporeal membrane oxygenation cardiac assist device.
45930754|NCT04435691|Drug|Azacitidine|Given SC or IV
45651629|NCT05022043|Diagnostic Test|Serum Presepsin|Estimation of Serum Presepsin at time of admission
45651630|NCT05021887|Drug|Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals|2 inhalations of Test and Reference product in each study period
45651631|NCT05021887|Drug|FLOVENT DISKUS|2 inhalations of Test and Reference product in each study period
45651632|NCT05022199|Device|SPY fluorescent angiography|This group has had SPY fluorescent angiography used intraoperatively during urinary diversion. To be compared with historic controls who did not.
45930755|NCT04435691|Biological|Magrolimab|Given IV
45930756|NCT04435691|Drug|Venetoclax|Given PO
45930757|NCT04421690|Behavioral|Cognitive Training|Participants (n=15) will complete computerized cognitive training games and activities online 3 times/week for 8 weeks.
45930758|NCT04421690|Behavioral|Trivia Training|Participants (n=15) will receive computerized trivia questions to answer and submit 3 times/week for 8 weeks.
45930759|NCT04406948|Drug|MGCND00EP1|Patients will take cannabis oil during the study
45930760|NCT04406948|Drug|Placebo|Patient will take carrier oil during the study
45930761|NCT04406948|Diagnostic Test|ECG|"A standard 12-lead ECG will be recorded using digital ECG recording equipment provided to the investigational site. The ECG has to be performed prior to laboratory samplings at time points indicated in the Schedule of Assessments.~The ECG recording will be reviewed by investigator and case of need consultation with cardiologist will be performed. The investigator has the final decision on the clinical significance of the ECG results."
45930762|NCT04406948|Diagnostic Test|EEG|An EEG is an electrophysiological monitoring method that records the electrical activity and measures voltage fluctuations resulting from ionic current within the neurons of the brain. In clinical contexts, EEG refers to the recording of the brain's spontaneous electrical activity over a period of time.
45930763|NCT04406948|Diagnostic Test|Blood and urine collection|safety blood tests - hematology\blood count and biochemistry standard blood tests urinalysis - urine test analysis
45930764|NCT04393779|Device|HARPOON Beating Heart Mitral Valve Repair System (MVRS)|Repair of the chordae tendinae in the mitral valve.
45930765|NCT04376827|Drug|Guselkumab Dose 1|Participants will receive guselkumab Dose 1 via IV administration.
45930766|NCT04376827|Drug|Placebo|Participants will receive placebo IV at Weeks 0, 4 and 8 (that is, 3 IV doses) and placebo SC q4w from Week 12 through Week 48.
45930767|NCT04376827|Drug|Guselkumab Dose 2|Participants will receive guselkumab Dose 2 via SC route.
45930768|NCT04376827|Drug|Standard-of-care treatment|Participants will receive standard of care treatment including MMF/MPA and glucocorticoids from Week 12 through Week 48.
45930769|NCT04369274|Device|Mechanical ventilation with the automated BVM compressor|Mechanical ventilation is accomplished with a device that mechanically squeezes a manual bag valve instead of by hand. The rate and volume of compression are adjustable, and the device has appropriate alarms and safety features.
45930770|NCT04351555|Drug|Osimertinib|Oral
45930771|NCT04351555|Drug|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles.
45930772|NCT04351555|Drug|Carboplatin|Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles
45930773|NCT04351555|Drug|Placebo|Oral
45930774|NCT04351555|Drug|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 3 cycles
45651633|NCT05021575|Other|Data collection on outpatient care|"Outpatient data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Outpatient data related to cardiovascular diseases (CVD) were collected as described:~data on visits were collected using ICD-10 codes I00-I99 and other CVD related codes (e.g., certain Z, Q codes, J81.0, R57.0)~data were collected from CVD prevention program~data on interventional cardiology were collected from day care facility regardless of the diagnosis.~Date of the visit, patient age, sex and municipality, service level (primary, secondary or tertiary), type of service and main diagnosis were recorded."
45651634|NCT05021575|Other|Data collection on hospitalisation|"Hospitalisation data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Data on hospitalisation were collected if any of the diagnoses (principal or secondary) were in I00-I99 range. Hospitalisation data covered hospitalisation date, patient age, sex, municipality and outcome. Data on cardiovascular procedures performed during hospitalisations included date of the procedure and ACHI (Australian Classification of Health Interventions) code."
45653246|NCT03067753|Drug|Methylprednisolone (Steroid Hormone)|Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
45930775|NCT04339504|Biological|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10^6 cells/2mL)
45930776|NCT04339504|Biological|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10^7 cells/2mL)
45930777|NCT04339504|Biological|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10^7 cells/2mL)
45930778|NCT04333433|Device|PRESERFLO® MicroShunt|Device surgically implanted
45930779|NCT04333433|Procedure|Trabeculectomy|The procedure involves removal of a small portion of the trabecular meshwork and adjacent scleral tissue. Aqueous humor then drains into the subconjunctival space, creating a bleb on the external part of the eye, where it diffuses away.
45930780|NCT04321993|Drug|Baricitinib (janus kinase inhibitor)|Baricitinib will be administered as 4 mg po daily for 14 days or until hospital discharge, whichever is sooner.
45930781|NCT04321993|Drug|Remdesivir (antiviral) + barictinib (janus kinase inhibitor)|"Remdesivir will be administered as a loading dose of 200 mg IV over one hour on day 1 followed by 100 mg IV daily over one hour on days 2-5 (with a possibility to extend to up to 10 days total).~Baricitinib will be administered as 4 mg po daily for 14 days or until hospital discharge, whichever is sooner."
45930782|NCT04321993|Drug|Remdesivir (antiviral)|Remdesivir will be administered as a loading dose of 200 mg IV over one hour on day 1 followed by 100 mg IV daily over one hour on days 2-5 (with a possibility to extend to up to 10 days total).
45930783|NCT04321993|Drug|Tocilizumab (interleukin 6 inhibitor)|Tocilizumab will be administered as a single IV infusion over one hour. Dosage will be 8 mg/kg total bodyweight up to a maximum of 800 mg.
45930784|NCT04319913|Device|analgesia nociception index|Analgesia nociception index (ANI) could objectively monitor how pain the participant is. In the experimental group, the care provider would decrease the dose of narcotics (remifentanil) if the ANI value is above 70, and increase the dose if the ANI value is under 50.
45930785|NCT04315948|Drug|Remdesivir|The lyophilized formulation of Remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 100 mg of Remdesivir to be reconstituted with 19 mL of sterile water for injection and diluted into IV infusion fluids prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL Remdesivir concentrated solution with sufficient volume to allow withdrawal of 20 mL (100 mg of remdesivir). It is supplied as a sterile product in a single-use, 30 mL, Type 1 clear glass vial.
46072889|NCT02838654|Procedure|cervical epidural injection|sensitivity, specificity, positive predictive value, negative predictive value
46072890|NCT00703989|Dietary Supplement|benfotiamine, α-lipoic acid|benfotiamine 300 mg twice a day, (Advanced Orthomolecular Research, Calgary, AB,CANADA) and slow-release α-lipoic acid (600 mg twice a day) (MRI, San Francisco, CA) for a total duration of four weeks
46072891|NCT02838186|Procedure|retroflexion|examination of the right colon with scope retroflexion
46072892|NCT02838186|Procedure|forward view|examination of the right colon in forward view
46072893|NCT02835924|Drug|Regorafenib|
46072894|NCT03823430|Diagnostic Test|Pupillometry|Pupillar diameter variation measurement
46072895|NCT00891618|Other|Acupuncture|3 acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.
46072896|NCT05335460|Drug|Envafolimab|300mg,sc,d1,Q3W
46072897|NCT03816878|Biological|H5N1 pISV|Administered as an intramuscular (IM) injection
46072898|NCT02836002|Drug|Sulfadoxine-pyrimethamine (low dose)|- subcurative regimen (500mg/25mg)
46072899|NCT02836002|Drug|Piperaquine (low dose)|- subcurative regimen (480 mg)
45651635|NCT05021575|Other|Data collection on cardiovascular mortality|Data on cardiovascular mortality were obtained from death certificates provided by Causes of Death Registry from Institute of Hygiene and covered the period from 1 January to 31 December of the analysed year. Death certificates were included in the study when cause of death was adjudicated to be in I00-I99 range. Date and place of death (hospital, home, other or unspecified), patient age and sex were recorded.
45651636|NCT05021575|Other|Data collection of patients presenting to the tertiary care centre with acute coronary syndrome|Demographic, clinical and percutaneous coronary intervention (PCI) related data were collected from 1st March to 30th June of the analysed year. The timing of the chest pain onset, call for medical help, first medical contact (FMC), arrival to PCI centre, and PCI procedure were analysed.
45930786|NCT04315948|Drug|Lopinavir/ritonavir|"The oral tablets of lopinavir/ritonavir contain 200 mg lopinavir, 50 mg ritonavir. They have a yellow colour, film-coated, ovaloid shape debossed with the a logo and the code KA. The oral solution for patients who cannot swallow is a light yellow to orange colored liquid containing 400 mg lopinavir and 100 mg ritonavir per 5 mL (80 mg lopinavir and 20 mg ritonavir per mL)."
45930787|NCT04315948|Drug|Interferon Beta-1A|IFN-ß-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe. It will be provided as a single-dose prefilled graduated syringe with 44 µg per 0.5 mL. The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe.
45930788|NCT04315948|Drug|Hydroxychloroquine|Hydroxychloroquine is supplied as film-coated 200 mg tablets. Hydroxychloroquine sulfate tablets are presented as white or whitish, peanut-shaped, oblong or round film-coated tablets containing 200 mg of hydroxychloroquine sulfate (equivalent to 155 mg base).
45930789|NCT04315948|Other|Standard of care|Standard of care
45930790|NCT04315948|Drug|AZD7442|AZD7442 will be supplied as separate vials of AZD8895 and AZD1061 containing 150 mg colorless to slightly yellow, clear to opalescent solutions for injection.
45801159|NCT02665247|Behavioral|C-SIP|In session I, information about sleep and the effects of lack of sleep will be presented. Participants will also be presented with advice and tips on how to improve sleep. Session II will focus on assisting participants overcome any barriers they faced in applying the advice they received in session I; participants will also receive additional information on sleep and sleep-related techniques.
45801160|NCT02665247|Other|Dream discussion|Participants assigned to the control group will attend sessions in which information on sleep is presented in the form of dream discussions.
45651637|NCT05021419|Other|Streamlined protocol|A streamlined drug protocol for optimizing heart failure medication
45801161|NCT02661971|Drug|Docetaxel|Docetaxel 50 mg/m², d1
45801162|NCT02661971|Drug|Oxaliplatin|Oxaliplatin 85 mg/m², d1
45801163|NCT02661971|Drug|Calciumfolinat|Leucovorin 200 mg/m², d1
45801164|NCT02661971|Drug|5-Fluorouracil|5-FU 2600 mg/m², d1
45801165|NCT02661971|Biological|Ramucirumab|Ramucirumab 8mg/kg, d1
45801166|NCT05444309|Procedure|Quadratus lumborum (QL) block group|patient will receive 0.5 mg/kg of bupivacaine 0.25% through the quadratus lumborum block approach
45801167|NCT05444309|Procedure|Pericapsular Nerve Group (PENG) block group|patient will receive 0.5 mg/kg of bupivacaine 0.25% through the Pericapsular Nerve Group (PENG) block
45930791|NCT04315948|Other|Placebo|Since April, 2021, the placebo will be a 0.9% (w/v) NaCl solution for infusion also called saline. The placebo will be supplied as a single 10-mL, clear and colorless vial.
45930792|NCT04309396|Device|Hydrogen content recording|Eligible participants will eat participants' normal, typical diets during the first week of the study. Participants will use the AIRE machine to measure exhaled H2 content before and after two meals each day - the first meal of the day and the last meal of the day. Participants will breathe into the AIRE machine before eating to obtain a baseline value. Once participants have finished eating, participants will breathe into the AIRE machine 30 minutes, 60 minutes, and 90 minutes postprandially. The participants will record participants' food intake and symptoms directly into participants' smartphone via an app that comes with the AIRE device.
45930793|NCT04308681|Other|BMS-986278 Placebo|Specified Dose on Specified Days
45930794|NCT04308681|Drug|BMS-986278|Specified Dose on Specified Days
45651638|NCT05021419|Other|Standard Protocol|Current standard optimization protocol as per NICE and ESC
45651639|NCT05021731|Drug|Rifampicin plus Isoniazid|Administration of rifampicin plus isoniazid for latent tuberculosis
45651640|NCT05021731|Drug|Rifapentine plus Isoniazid|Administration of rifapentine plus isoniazid for latent tuberculosis
45930795|NCT04302051|Diagnostic Test|Thermo-acuostic image acquisition of liver|Estimation of hepatic fat content with thermo-acoustic device
45930796|NCT04302051|Diagnostic Test|MRI-PDFF estimation of hepatic fat|Estimation of hepatic fat content with MRI
45930797|NCT04301609|Dietary Supplement|Active|Take 4 capsules daily (2 capsules on an empty stomach + 2 capsules 30 minutes before dinner).
45651641|NCT05021731|Drug|Rifampicin alone|Administration of rifampicin alone for latent tuberculosis
45651642|NCT05009953|Drug|Irinotecan Liposome Injection|Irinotecan Liposome Injection, intravenously, over 90 min on days 1 of every 14-day cycle, 43mg/10mL
45801168|NCT05443217|Diagnostic Test|questionnaire survey|All patients received lifestyle questionnaire, physical performance, and imaging evaluation before treatment.
45801169|NCT01949545|Drug|Carfilzomib|Carfilzomib was administered by IV injection over 30 minutes
45801170|NCT05442905|Drug|propofol|Anesthesia will be induced with propofol 2-3mg/kg
45930798|NCT04301609|Dietary Supplement|Placebo|Take 4 capsules daily (2 capsules on an empty stomach + 2 capsules 30 minutes before dinner).
45801171|NCT05442905|Drug|Atracurium Besylate|Atracurium 0.15mg/kg used for muscle relaxation before intubation
45801172|NCT05442905|Drug|sevoflurane|sevoflurane(1%-2%) used during anesthesia
45801173|NCT00369863|Drug|Triamcinolone acetonide|
45801174|NCT04338425|Behavioral|Voice call|Attending surgeons will contact with their patients on the day of surgery after discharge via voice call.
45801175|NCT04338425|Behavioral|Video call|Attending surgeons will contact with their patients on the day of surgery after discharge via video call (video conferencing application such as FaceTime or Skype)
45930799|NCT04300348|Device|Heel2Toe|Heel to Toe (Heel2Toe) is a device that clips on the shoe and provides an instant auditory feedback (a beep) for each correct step characterized by putting the heel first and it provides data on gait parameters
45930800|NCT04300348|Other|No-feedback control group|The control group will follow the same protocol as the Heel2Toe group but the device will not be in feedback mode just in data acquisition mode.
45930801|NCT04300127|Drug|Pioglitazone 30 mg|Patients will received 30 mg of Pioglitazone once a day for 8 weeks
45930802|NCT04300062|Procedure|Rebiopsy|Biopsy will be carry out with flexible bronchoscopy as usual practice under local anesthesia: under endobronchial ultrasound, punction under CT scan or ultrasonography, percutaneous pleural puncturing.
45801176|NCT01949779|Device|TransForm™ Occlusion Balloon Catheter|TransForm™ Occlusion Balloon Catheter
45801177|NCT01890343|Drug|florbetapir 18F|Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
45930803|NCT04296305|Drug|Hydromorphone|Given IV after
45930804|NCT04296305|Drug|Placebo Administration|Given IV after
45930805|NCT04296305|Other|Questionnaire Administration|Ancillary studies
45930806|NCT04295304|Device|Retinal surgery with implantation of epi-retinal device|Retinal surgery and implantation of epi-retinal prosthesis
45930807|NCT04292496|Procedure|Introperative leak testing|After anastomosis was completed. We test the integrity of anastomosis intraoperatively.
45930808|NCT04292067|Biological|Faecal sampling|Faecal sampling at baseline
45930809|NCT04285554|Device|iRF System Hepatic Denervation|The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the common hepatic artery (CHA).
45930810|NCT04282460|Behavioral|Baduanjin practice|Use the Baduanjin training system to practice the whole set of Baduanjin at least once a day and at least 5 days each week for 3 months.
45930811|NCT04282460|Behavioral|Regular physical exercise|Take physical exercise for at least half an hour every day in addition to regular physical activities at school.
45930812|NCT04274530|Behavioral|Cognitive Behavioural Therapy|Participants who are randomized to the CBT intervention will be encouraged to begin CBT immediately following randomization. The CBT intervention will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses to baseline questionnaires. All other aspects of post-operative care will be at the discretion of participant's surgeon.
45930813|NCT04266418|Dietary Supplement|Placebo|consume 1 sachet per day for 2 months
45930814|NCT04266418|Dietary Supplement|Banana flower stamens extract|consume 1 sachet per day for 2 months
45930815|NCT04266236|Procedure|L3 LPB|ultrasound-guided L3 lumbar plexus block
45930816|NCT04266236|Procedure|L4 LPB|ultrasound-guided L4 lumbar plexus block
45930817|NCT04266236|Procedure|T12 block|ultrasound-guided thoracic 12th segment nerve block
46072900|NCT02836002|Drug|Sulfadoxine-pyrimethamine (high dose)|- curative regimen (1000mg/50mg)
46072901|NCT02836002|Drug|Piperaquine (high dose)|- curative regimen (960 mg)
45801178|NCT01890343|Drug|18F-FDG|FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.
45801179|NCT02588027|Drug|Ibuprofen|Patients will be randomized using a computer generated number to received either ibuprofen (400mg by mouth every eight hours as needed) versus placebo for post-operative pain control in addition to opiate medication (hydrocodone/acetaminophen). Study doctors or research staff will be given randomly generated treatment allocations within sealed opaque envelopes. Once the patient is screened/qualified in surgery, the envelope will be opened and the patient randomized to the allocated treatment regimen. Patients will be given a two week supply (42 pills total) of either ibuprofen or placebo on the day of surgery upon discharge from the surgery center by a research coordinator.
45801180|NCT02588027|Drug|Placebo|Pharmacy formulated placebo
45801181|NCT05441189|Procedure|Resection|radical R0 resection of pancreatic adenocarcinoma
45801182|NCT01894087|Behavioral|TBI - Cohort 1|
45930818|NCT04266236|Procedure|L3 QLB|ultrasound-guided quadratus lumborum block at L3 level
45930819|NCT04266236|Drug|0.375%ropivacaine 25 ml (Raropin)|0.375%ropivacaine (Raropin) 25ml will be given
45930820|NCT04266236|Drug|0.375%ropivacaine 40 ml (Raropin)|0.375%ropivacaine (Raropin) 40ml will be given
45930821|NCT04266236|Procedure|General anesthesia with tracheal intubation|General anesthesia with tracheal intubation will be induced with sufentanil, propofol, vecuronium for every patient before the operation and maintained with sevoflurane during the operation
46072902|NCT02836002|Biological|malaria challenge infection, P. falciparum 3D7|malaria challenge infection by P. falciparum 3D7-infected mosquito bites
46072903|NCT02836002|Drug|Atovaquone-proguanil|- curative regimen: 1000/400 mg, for 3 days
45651643|NCT05009953|Drug|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, intravenously, over 60 min on days 1 of every 14-day cycle, 100mg/10mL
45651644|NCT05009953|Drug|Fluorouracil|5-Fluorouracil (5-Fu), intravenously, over 46 h on days 1 of every 14-day cycle
45651645|NCT05009953|Drug|Leucovorin|Leucovorin (LV), intravenously, over 30 min on days 1 of every 14-day cycle
46072904|NCT00836589|Device|ICD Therapy - ICD Lead Registry|Collecting long-term safety and efficacy data on a family of market-released ICD leads.
46072905|NCT03711812|Procedure|Serratus Anterior Plane Catheter|Insertion of a Serratus Anterior Plane Catheter to establish a continuous analgesic block with a local anaesthetic infusion
45651646|NCT05009407|Biological|Immunohistochemistry and clinical analyses on patients and corneas|Immunohistochemistry and clinical analyses on patients and corneas
45651647|NCT05009641|Dietary Supplement|L-carnitine|
46072906|NCT03711812|Procedure|Thoracic Epidural Catheter|Insertion of a Thoracic Epidural Catheter to establish a continuous analgesic block with a local anaesthetic infusion
45651648|NCT03079453|Drug|Dexamethasone|The patients in Group 1 were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly before tonsillectomy
45651649|NCT03090373|Device|UroShield|The UroShield is an externally applied acoustic actuator which generates surface acoustic waves and transmits them along the length of the catheter. The device does not come in direct contact with the subjects.
45653247|NCT03067753|Drug|Prednisolone|
45801183|NCT01894087|Behavioral|TBI - Cohort 2|
45801184|NCT04449965|Drug|Povidone-iodine|This will be performed twice daily for two weeks.
45801185|NCT04449965|Drug|Placebo|This will be performed twice daily for two weeks.
45801186|NCT01951339|Drug|Sitagliptin|100 mg sitagliptin
45801187|NCT01951339|Drug|Glimepiride|"Active Comparator~2mg glimepiride"
45801188|NCT01951339|Drug|Placebo|2 mg placebo once daily
45801189|NCT01951339|Drug|Placebo|100 mg placebo once daily for three months
45801190|NCT05433389|Behavioral|Breath Counting|Patients will listen to a 5-minute, audio-recorded breath counting practice.
45801191|NCT05433389|Behavioral|Body Scan|Patients will listen to a 5-minute, audio-recorded body scan practice.
45801192|NCT05433389|Behavioral|Mindful Breathing|Patients will listen to a 5-minute, audio-recorded mindful breathing practice.
45801193|NCT05433389|Behavioral|Mindfulness of Pain|Patients will listen to a 5-minute, audio-recorded mindfulness of pain practice.
45801194|NCT05433389|Behavioral|Mindful Savoring|Patients will listen to a 5-minute, audio-recorded mindful savoring practice.
45801195|NCT05431673|Drug|Doxycycline|Doxycycline 100mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
45801196|NCT05431673|Drug|Ciprofloxacin|Ciprofloxacin 500mg/day for 4 weeks used as single or combination treatment for Rhinoscleroma
45801197|NCT05431673|Drug|Rifampin|Rifampin 600mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
45801198|NCT01951651|Drug|Exenatide|Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
45801199|NCT01951651|Drug|Glipizide|Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
45801200|NCT02466581|Drug|Sulphasalazine + Hydroxychloroquine OR Prednisolone|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, and Iceland)
45801201|NCT02466581|Biological|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
45801202|NCT02466581|Biological|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
45801203|NCT02466581|Biological|RoActemra|Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week. Methotrexate: 25mg/week
45801204|NCT01951963|Drug|Ketamine|
45801205|NCT01951963|Drug|Morphine|
45801206|NCT02377271|Drug|bosentan|treatment by bosentan or placebo is randomized , 125 mg twice a day
45801207|NCT02377271|Drug|placebo|treatment by bosentan or placebo is randomized
45801208|NCT01894555|Drug|Aspirin|81 mg daily for 4 weeks
45651650|NCT03090451|Behavioral|Aerobic Exercise|Aerobic physical exercise on treadmill, with intensity based on prior VO2-max testing during the screening visit.
45651651|NCT03090139|Drug|Anti-TNF Therapy|Anti-TNF therapy.
45651652|NCT05610813|Drug|VER-01|Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype (cannabis leaves and - flowers), corresponding to 21 mg (-)-trans-Δ9-Tetra-hydrocannabinol (THC) per gram drug product
45653248|NCT04333745|Other|Controlled Diet|Participant will consume a controlled low oxalate diet for five days
45653249|NCT04333745|Dietary Supplement|Carbon-13 Oxalate and Sucralose Ingestion|Subjects will ingest a small amount of carbon-13 oxalate and sucralose, dissolved in water.
45801209|NCT02344355|Drug|Temozolomide|"oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy.~Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days.~For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days.~If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days."
45801210|NCT02344355|Radiation|radiation therapy|Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.
45801211|NCT02344355|Drug|Ascorbic Acid|"Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.~After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide."
45801212|NCT02330471|Procedure|Spray|surgical method to achieve intraoperative hemostasis by a superficial electrocoagulation of 80 Watt voltage
45801213|NCT02330471|Procedure|Forced|surgical method to achieve intraoperative hemostasis by a deep tissue electrocoagulation of 80 Watt voltage
45801214|NCT04421495|Drug|Delamanid|the eligible patients will be give damanid-containing regimen
45801215|NCT01895647|Device|EMS|Electric muscle stimulation with programmed warm-up, stimulation and cool-down in 32 minutes
45801216|NCT02034461|Device|Utah Slanted Electrode Array|Microelectrode slanted arrays with a large number of electrodes will be surgically implanted into peripheral nerves of patients with limb amputations or peripheral nerve trauma.
45801217|NCT01896115|Device|Vercise DBS settings|Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
45801218|NCT01953211|Drug|combined oral contraceptives|
45801219|NCT02028221|Drug|Metformin|metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the duration of he intervention period.
45801220|NCT02028221|Drug|Placebo|1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
46072907|NCT02835768|Other|Internet-based injury prevention program|"An injury prevention website serves as the Internet-based intervention providing two key topics: 1) Types of domestic injury, and 2) how to prevent different types of domestic injury. The domestic injury prevention information Home Safety Tips is divided into four subgroups according to various safety issues relevant to infants/children's age groups. Apart from a knowledge hub, the website incorporates additional functions of feedback counselling, video demonstration, online consultation, games, safety checklist and discussion forum."
45651653|NCT05610813|Drug|Opiod therapy|"The patient-specific selection of the marketed opioid (based on standard of care and provided for this study) is at the discretion of the investigator and made before randomization (at visit 1) to ensure that the outcome of the randomization does not influence the opioid selection.~Preferably oral administration~Preferably retarded release preparations~Titration and dosage according to SmPC (maximum titration phase 3 weeks)~The dosage and the chosen opioid (opioid rotation) can be adapted to the patient's specific needs in the course of the study."
45801221|NCT02987569|Behavioral|mConnect plus mobile connections to multidisciplinary professionals & peers|mConnect is the integration of evidence-based HPN interventions delivered via professionally moderated iPad visual meetings with peers, and reinforced by HPN related skill-building games (apps) and iPad music guided short naps.
45801222|NCT02987569|Behavioral|iPad use plus one mobile connections to multidisciplinary professionals & peers|iPad with a data plan and one professionally moderated iPad visual meeting with peers.
45801223|NCT05735197|Drug|Dapagliflozin 10mg Tab|Dapagliflozin which is (SGLT2 inhibitor) will be used as add on medication.
45801224|NCT05735197|Drug|Placebo|Placebo which has the same shape as Dapagliflozin but without active ingredient will be used as add on medication for control group.
45801225|NCT00370097|Drug|FLOVENT (fluticasone propionate) HFA|FLOVENT HFA consists of a white to off-white suspension of FP (micronized) in a liquefied hydrofluoroalkane propellant, 1,1,1,2-tetrafluoroethane. Subject will receive FP HFA using an Aerochamber Plus with Infant Mask.
45801226|NCT00370097|Drug|Placebo HFA|Subjects will receive FP-matched placebo using an Aerochamber Plus with Infant Mask.
45801227|NCT01897285|Device|AQUACEL® foam adhesive dressing|
45801228|NCT00370253|Drug|Terlipressin|1mg/4 h per day
45801229|NCT00370253|Drug|Noradrenalin|0,1 mcg/kg/min
45801230|NCT05391737|Diagnostic Test|Echocardiography|Echocardiography after swimming (acute) and at rest (baseline)
45801231|NCT05391737|Diagnostic Test|Electrocardiogram (ECG)|Electrocardiogram (ECG) after swimming (acute) and at rest (baseline)
45801232|NCT05391737|Diagnostic Test|Cardiac biomarkers|high sensitive (hs)-Troponin I and N-terminal pro-brain natriuretic peptide (NT-pro-BNP) after swimming (acute) and at rest (baseline)
45801233|NCT01800539|Behavioral|Provider Education Model (PEM)|Providers will be trained to use evidence-based practices for early intervention service delivery in the Autism Spectrum Disorder population.
45801234|NCT04412525|Device|vitrectomy (27G gauge or larger needle)|vitrectomy surgery for either floater removal or macular surgery, with or without combined cataract (phaco) surgery.
45801235|NCT01618565|Procedure|Hands-On Training|one-time, 30 minute hands-on training
45801236|NCT01618565|Procedure|Demonstration|30 minutes passive training
45801237|NCT01491815|Drug|Non-biological DMARD's|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, Iceland, and the Netherlands)
45801238|NCT01491815|Biological|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
45801239|NCT01491815|Biological|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
45801240|NCT01491815|Biological|RoActemra|"Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week.~Methotrexate: 25mg/week"
45801241|NCT04359953|Drug|Hydroxychloroquine|Hydroxychloroquine 2 x per day during 14 days
46072908|NCT02835456|Device|Sharklet Catheter insertion|
45651654|NCT05412615|Procedure|Meniscus Allograft Transplantation with Proximal Row Carpectomy|Supplementing the wrist reconstruction with a meniscal allograft to improve wrist function and pain scores.
45651655|NCT05412615|Procedure|Proximal Row Carpectomy|Standard proximal row carpectomy with no tissue or synthetic adjuncts
45651656|NCT03090061|Diagnostic Test|Light induced fluorescence intraoral camera|assessment of marginal integrity of resin composite restorations by light induced fluorescence intraoral camera
45801242|NCT04359953|Drug|Azithromycin|Azithromycin 2 x per day during 14 days
45801243|NCT04359953|Drug|Telmisartan|Telmisartan 2 x per day during 14 days
45801244|NCT01470677|Drug|Tachosil fibrin patch|A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group. In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
45801245|NCT05364515|Drug|PRGF|"Plasma Rich in Growth Factors (PRGF) is a mixture of proteins and growth factors obtained from the blood of the patient.~Four PRGF infiltrations (two weeks between each infiltration). Then, application of topical PRGF serum (on alternate basis)"
45801246|NCT05364515|Drug|Clobetasol Propionate|0.05 propionate clobetasol: daily (first month), alternate (second moth), twice per week (from third month)
45801247|NCT04353869|Biological|Bio collection|venous blood sampling and collection of urine
45801248|NCT01438073|Drug|kisspeptin 112-121|24-h continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg)
45801249|NCT01438073|Drug|GnRH|Single intravenous dose of GnRH (2.5-250 ng/kg)
45801250|NCT04334369|Device|Proclear Single Vision Contact Lenses manufactured by CooperVision|FDA approved single vision contact lenses.
45801251|NCT04334369|Device|Proclear Multifocal Contact Lenses manufactured by CooperVision|FDA Approved Multifocal Contact Lenses
45801252|NCT04338191|Drug|mFOLFOXIRI adjuvant chemotherapy|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
45801253|NCT04338191|Drug|mFOLFOX6 adjuvant chemotherapy|mFOLFOXIRI (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
46072909|NCT02835456|Device|Silicone Foley Catheter insertion|
45451259|NCT03962621|Radiation|Fotona 4D 1064 nm laser|The 1064 nm laser can penetrate deep into the skin to explode pigment particles, destroy blood vessels and heat the dermal collagen by targeting melanin and haemoglobin.(1) Frac3®: 30-35 J/cm2, 1.6 ms pulse width, 4mm spot size, unilaterally accumulated 2000 shots; and (2) PIANO®: 160 J/cm2, 5s pulse width, spot size 9mm, unilaterally accumulated 20000 shots, to increase and maintain facial skin temperature to 39-40oC.
45651657|NCT03090061|Diagnostic Test|Visual-tactile assessment method according to FDI criteria|assessment of marginal integrity of resin composite restorations by visual-tactile method that includes the use of mirror, FDI probe under good illumination condition,
45651658|NCT05385159|Drug|AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION|Adipose tissue removal, ADSVF production and injection of ADSVF will be done on the same day during a short hospital stay
45651659|NCT05385159|Drug|Placebo|Adipose tissue removal, ADSVF production, cryopreservation of ADSVF and injection of placebo will be done on the same day during a short hospital stay.
45651660|NCT05009563|Radiation|FDG-PET/CT|whole-body F-18-fluoro-deoxy-glucose positron emission tomography/computed tomography
45801254|NCT04317053|Behavioral|RELAY|Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education.
45801255|NCT05295095|Procedure|positive pressure during extubation procedure|positive pressure during extubation procedure
45801256|NCT05454917|Device|Measure of ventilation/perfusion (V/Q) mismatch using Beacon ALPE (Automatic Lung Paramether Estimator)|Evaluation of intraoperative V/Q mismatch using the Beacon ALPE during anesthesia.
45801257|NCT05454761|Behavioral|Group-based Lifestyle Medicine Program|Participants will receive four core modules that focus on lifestyle modifications. Core Module 1 will be Diets and Nutrition. This module aims to provide simple and evidence-based information regarding nutrition for improving and maintaining mental health. Core Module 2 will be Physical Activity. Participants will practice various types of gentle and adaptable exercises during the session and learn simple ways to incorporate exercise into their daily lives. Core Module 3 will be Sleep Management. This module will include basic facts about sleep, with a focus on psychoeducation on insomnia and how the relationship between circadian and social rhythms relate to sleep and mental health. Core Module 4 will be Stress Management. This module will include psychoeducation about stress, worry management, the cultivation of positive psychology, and relaxation techniques such as diaphragmatic breathing and progressive muscle relaxation.
45801258|NCT00371033|Drug|Pregabalin|dosage
45801259|NCT00371033|Drug|Placebo|dosage
45801260|NCT00371111|Drug|Intravitreal injection of Triamcinolone|4 mg of Triamcinolone
45801261|NCT00371111|Drug|Intravitreal injection of Avastin|Injection of 1.25 mg of Avastin and
45801262|NCT00371189|Drug|Placebo|Normal saline.
45801263|NCT00371189|Biological|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10^8 viral particles (vp)/mL, 10^9 vp/mL, 10^10 vp/mL and 10^11 vp/mL.
45801264|NCT05286203|Device|Metagenomic Deep Sequencing (MDS)|MDS is an RNA-seq based testing of ocular fluid or tissue to identify potential infectious pathogens including bacteria, fungi, parasites, and DNA and RNA viruses.
45801265|NCT05286203|Diagnostic Test|Standard of Care (SOC)|SOC includes any available diagnostic tests, such as Gram stain, cultures, PCRs, that are considered the appropriate testing based on the clinical findings.
45801266|NCT05275361|Behavioral|Social Contact Reminder|-The social contact will remind patient about screening mammogram appointment
45801267|NCT04202003|Drug|TJ011133|This is an open-label Phase 1/2a clinical study. The study will be conducted in two parts: Part I: Phase 1 dose escalation, TJ011133 is tentatively scheduled to be administered once weekly in 28-day treatment cycles;Part II: Phase 2a study TJ011133 will be administered at a dose of 30 mg/kg once weekly, and AZA will be administered at a dose of 75 mg/m2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.
45801268|NCT05242523|Other|Bergamot scent|The scent of bergamot is fruity and citrusy, with floral hints and spice notes.
45451260|NCT03962621|Radiation|Fotona 4D 2940 nm laser|Er:YAG 2940nm have been considered as a good treatment of facial aging, especially in wrinkles.(1) Smooth®: 9-10 J/cm2, 7mm spot size, which is sequentially delivered to upper and lower labial mucosa and buccal mucosa to unilaterally accumulate 5000 shots; (2) SupErficial™: 0.5-1.0 J/cm2, 7mm spot size, a single pass
45801269|NCT05242523|Other|Natural wood scent|Wood notes tend to be rich and warm, often forming the base of a scent due to their aromatic weight.
45801270|NCT05233943|Device|Spinal Mouse and Digital Inclinometer|"The spinal mouse device is non-invasive and does not have any danger. The posture is evaluated by moving from top to bottom on the spine of the person. Data on the device is transferred to the computer via Bluetooth. The person's posture is evaluated in the sagittal plane by making maximum flexion, neutral stance and maximum extension positions, and in the frontal plane by lateral flexion to the right and left.~Digital Inclinometer; It is a non-invasive measurement tool that investigators measure the position sense of the body, which has two parts, one fixed and one movable. The immobile part of the digital inclinometer is placed at the sacrum and the movable part is placed at the T4 spine level. The person is made 30 degrees of trunk flexion. Then, he is expected to perform 5 repetitions of 30 degrees of trunk flexion with his eyes closed. Deviation angles are recorded."
45801271|NCT05229887|Procedure|Nostril-Tragus-Length|"Endotracheal tube depth is determined by measuring the newborn's nasal septum-tragus length (NTL) and adding 1cm.~The NTL is described as the distance from the base of the nasal septum to the tragus of the ear."
45801272|NCT05229887|Procedure|Vocal cord marking|The endotracheal tube has markings on the tube, which are called vocal cord markings, which will be used to provide a guidance to how deep to place the ETT into the trachea.
45801273|NCT05454683|Dietary Supplement|melatonin plus zinc|One capsule with melatonin 1mg plus zinc 10 mg o.d. 30 minutes before bedtime, at least 1 hour after dinner during 4 months
45801274|NCT05454683|Other|isomaltose and magnesium stearate|One capsule with excipients o.d. 30 minutes before bedtime, at least 1 hour after dinner during 4 months
45801275|NCT04175249|Other|Pizza meal challenge|Vegetarian pizza containing 10 grams of salt
45930822|NCT04261894|Behavioral|OPTIMIZE|The study intervention is implementation of the OPTIMIZE perinatal care checklist with patient navigation support. The checklist will contain perinatal care components to be assessed for each participant. Specifically, the checklist will be built into the electronic health record as a secure digital record of: (1) the participant's adherence to the recommended prenatal and postpartum visit schedule, (2) the completion of procedures and processes in a participant's prenatal and postpartum standard care plan, and (3) the completion of processes to address social determinants of health, along with completion of referrals to appropriate support resources. The OPTIMIZE checklist will also include records of patient navigation review, engagement, and tracking of barrier status and resolution
45930823|NCT04256343|Other|Deuterium Oxide (D2O) Dose|1 of 3 differing deuterium oxide (D2O) doses will provided to each of the participants to be consumed daily to assess muscle protein synthesis.
45930824|NCT04252716|Device|OVD|Intraocular administration
45930825|NCT04243629|Drug|Rapid-Acting Insulin|Novorapid or Humalog insulin delivered in a basal-bolus manner.
45930826|NCT04243629|Drug|Placebo|Placebo (saline) delivered in a basal-bolus manner at a fixed ratio with insulin.
46072910|NCT02842658|Other|A high-intensity interval exercise group|To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
45801276|NCT05206331|Device|contrast enhanced mammography|Dual-energy contrast images; low-energy CEM images will be obtained with a kilovoltage below 35 kVp while the high-energy images will be obtained with 45-49 kVp.The average glandular dose of the CEM procedure is approximately 2.44 mGy per view
46072911|NCT02842658|Other|An Attention-Control Group|Patients will be contacted weekly to access physical activity. To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
45451261|NCT03962075|Procedure|laparoscopic paravaginal repair|Using a 10mm laparoscope, with video camera, was introduced through the umbilical trocar. Another 5 mm in suprapubic area and two 10 mm trocars in right and left lateral abdominal sides were introduced. The larger trocar was needed to accommodate the passage of needles into the abdomen. Spacing of trocars sufficiently from each other was needed to facilitate laparoscopic suturing. Transperitoneal approach to retropubic space was used. Two to four polypropylene sutures were applied on each side. Sutures were tied with intracorporeal technique
45801277|NCT05206331|Drug|Iodinated Contrast Media (ICM)|standard FDA-approved low osmolarity Iodine contrast agent with 350-370 mg/ml
45801278|NCT04146857|Other|Normoxia|Nap in hypoxia chamber at 20.9% oxygen (36 m asl)
45801279|NCT04146857|Other|Hypoxia 1|Nap in hypoxia chamber at 15.0% oxygen (simulates 2660 m asl)
45801280|NCT04146857|Other|Hypoxia 2|Nap in hypoxia chamber at 12.8% oxygen (simulates 4000 m asl)
45801281|NCT05193071|Drug|Aspirin 100mg; Clopidogrel 300mg|Aspirin 100mg plus Clopidogrel 300mg will be orally administrated after randomization
45801282|NCT05186051|Drug|ZYIL1 capsule|NLRP3 inflammasome inhibitor
45801283|NCT05180825|Drug|Trametinib|Mekinist© (Trametinib) taken orally each day with a 18-course schedule of 4 weeks each.
45801284|NCT05180825|Drug|Vinblastine|weekly intra-venous Vinblastine (Velbe©) during 18 courses of 4 weeks each
45930827|NCT04243629|Drug|Pramlintide Acetate|Pramlintide acetate delivered in a basal-bolus manner at a fixed ratio with insulin.
45930828|NCT04243629|Device|Artificial Pancreas|Tandem insulin pump, Dexcom G6 sensor, study smartphone running the iMAP algorithm.
46072912|NCT05325060|Device|Electromagnetically navigated total knee arthroplasty|The navigated group had surgery using the iNav portable EM navigation system (Zimmer GmbH, Winterthur, Switzerland and Medtronic, Minneapolis, MN, USA) and the definitive implant used was NexGen LPS implant (Zimmer Inc, Warsaw, IN, USA), a fixed-bearing bicruciate-sacrificing total condylar implant using traditional instrumentation with no patellar resurfacing
46072913|NCT05325060|Device|Conventional total knee arthroplasty|The conventional group received surgery using conventional instrumentation and jigs from the implant manufacturer (Zimmer Inc, Warsaw, IN, USA) and the definitive implant used was NexGen LPS implant (Zimmer Inc, Warsaw, IN, USA), a fixed-bearing bicruciate-sacrificing total condylar implant using traditional instrumentation with no patellar resurfacing
46072914|NCT00574795|Biological|13vPnC|"First dose during 2 to 6 months of age Second dose at least 28 days after the first dose Third dose at least 28 days after the second dose Forth dose during 12 to 15 months of age"
46072915|NCT02297516|Drug|Azzalure or Dysport|Glabellar lines
46072916|NCT02297516|Device|Restylane or Emervel filler|Facial tissue augmentation
45451262|NCT01081847|Drug|Peptides (N,R&C) formulated in Montanide ISA 720|50 ug
45451263|NCT01081847|Drug|Peptides (N,R&C) formulated in Montanide ISA 51|50 ug
45451264|NCT01081847|Drug|Peptides (N,R&C) formulated in Montanide ISA 720|100 ug
45451265|NCT01081847|Drug|Peptides (N,R&C) formulated in Montanide ISA 51|100 ug
45930829|NCT04241341|Procedure|Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction|Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction
45930830|NCT04241341|Procedure|Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction|Current standard treatment at Memorial Sloan Kettering [MSK]).
45930831|NCT04241341|Other|quality-of-life questionnaires|Four validated patient reported outcome measures (PROMs): the Upper Limb Lymphedema-27 (ULL-27), the Quality of Life Measure for Limb Lymphedema (LYMQOL), the Center for Epidemiologic Studies Depression Scale-Revised (CESD-R), and the Beck Anxiety Inventory (BAI). Study participants will undergo standard lymphedema measurements and quality-of-life questionnaires at baseline before ALND and postoperatively at 6 weeks (+/- 30 days) and at 6, 12, 18, and 24 months (+/- 30 days). If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them.
46072917|NCT02297516|Device|Restylane Skinbooster|Facial skin rejuvenation
45451266|NCT01081847|Other|Placebo|PLacebo: Isotonic saline solution
45801285|NCT04707521|Behavioral|3M tape ship-shaped combined with strap fixing method|During fixation, the endotracheal intubation and dental pad were located in the center of the mouth, and one end of one piece of medical cloth adhesive was pasted on the patient's cheek near the side. When it reached one side of the mouth, the endotracheal intubation and dental pad were wound around twice, and then the other side of the adhesive tape was pasted on the cheek opposite the side from the other side of the mouth,The other is fixed in reverse with the same sticking method, and the two pieces of adhesive tape are finally crossed and fixed at the corners of the mouth.Finally, fasten it with a lacing
46072918|NCT00830479|Procedure|Anti-reflux surgery|Open ureteroneocystostomy for correction of vesicoureteral reflux
46072919|NCT00830479|Procedure|Endoscopic injection|Endoscopic injection of dextranomer/hyaluronic acid gel (Deflux) for correction of vesicoureteral reflux
45801286|NCT04145453|Behavioral|Intervention genotype personalized nutritional recommendations|Participants will receive personalized nutritional recommendations to increase fruit and vegetables consumption. Information about genotype will be given at the beginning of study
45801287|NCT04145453|Behavioral|Control Group 1 personalized nutritional recommendations|Participants will receive genotype personalized nutritional recommendations to increase fruit and vegetables consumption. Information about genotype will be given at the end of study
45451267|NCT02224456|Drug|Tenofovir disoproxil fumarate|"White, almond-shaped, film-coated tablet containing 300 mg of TDF, debossed with GILEAD and 4331 on one side of the tablet."
45451268|NCT02224534|Drug|Ticagrelor|Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose
45451269|NCT02224534|Drug|Clopidogrel|Clopidogrel 600 mg as a loading dose and 75 mg once daily as a maintenance dose.
45451270|NCT04765696|Other|No intervention is administered|No intervention is administered, the cohort is followed in order to evaluate the impact of housing and relocation on active ageing outcomes.
45651661|NCT05021341|Dietary Supplement|Berberine|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (500 mg of berberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
45801288|NCT04145453|Behavioral|Control Group 2 general nutritional recommendations|Participants will receive general nutritional recommendations to increase fruit and vegetables consumption
45801289|NCT05454059|Procedure|Non-surgical periodontal treatment|Routine non-surgical periodontal treatment will be applied to patients with periodontitis. The main aim of non-surgical periodontal treatment is to protect, heal and maintain the existing dentition. For this purpose, using manual, sonic or ultrasonic instruments, microbial dental plaque and calculus are removed by tooth surface cleaning and root surface straightening.
45801290|NCT05454059|Diagnostic Test|ELISA Test|C1P and PGE2 levels in saliva samples obtained, and will be examined by ELISA test.
45801291|NCT05454059|Other|Periodontal Examination|All diagnostic procedures were performed with examination instruments (periodontal probe, dental mirror, x-ray device, etc.). Periodontal clinical index measurements (PI, GI, BOP, PPD, CAL) recorded from all teeth. Routine panoramic radiographs were taken from all patients to determine alveolar bone resorption. Vertical/horizontal bone losses on the radiographs were evaluated and used in the diagnosis of periodontitis.
45801292|NCT05454059|Other|Saliva Sample Collection|Saliva samples were collected from all subjects in the morning. Unstimulated saliva from each patient was collected by standard defined spitting method without stimulation.
45801293|NCT05454059|Diagnostic Test|HbA1c Level|Measurement of HbA1c levels from blood tests
45801294|NCT04110353|Other|Wound dressings: Conservative dressings|Conservative dressings to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
45801295|NCT04110353|Other|Wound dressings: Prevena dressings|Prevena dressing to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
45801296|NCT04110353|Other|Wound dressings: ciVAC dressings|Closed incision VAC dressings to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
45801297|NCT05139095|Drug|Camrelizumab plus apatinib CohortA|Cohort A: Camrelizumab (200 mg q2w iv) concomitantly with apatinib (250 mg qd po) and EMA/CO [etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine] every 2 weeks. For certain patients with high tumor burden, 1-2 cycles of low-dose chemotherapy (actinomycin D 500 ug and etoposide 100mg/m2, D1-3) will be administered, then followed by EMA/CO. The observation period is 14 days.
45801298|NCT05139095|Drug|Camrelizumab plus apatinib Cohort B|Cohort B: Camrelizumab (200 mg q3w iv) concomitantly with apatinib (250 mg qd po) and multi-drug chemotherapy. The multi-drug chemotherapy regimen will be chosen by the investigator (chemotherapy regimen: EMA/CO [etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine]; or EMA/EP [etoposide, methotrexate and actinomycin-D/etoposide, cisplatin]; or FAEV [floxuridine, actinomycin-D, etoposide, vincristine]). The observation period is 21 days.
45801299|NCT05453669|Biological|CD19-CAR-DNT cells|Lentiviral vector-transducted DNT cells to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
45801300|NCT04108247|Drug|Abiraterone+SHR3162|Participants will receive Abiraterone combined with SHR3162 orally
45801301|NCT04021355|Other|Oral sodium supplementation|Participants will receive dietary sodium supplementation in the form of tablets to be taken either with breakfast or dinner.
45801302|NCT01955473|Drug|Sym004|Part-A (dose-escalation): Sym004 will be administered intravenously either weekly at 6 to 12 milligram per kilogram (mg/kg) or biweekly at 18 mg/kg from Week 1 until unacceptable toxicity, disease progression, or consent withdrawal. Part-B (dose-expansion): After the maximum tolerated dose (MTD) is determined in Part-A, up to 30 additional subjects will continue to receive treatment in Part-B.
45801303|NCT05453435|Drug|Entecavir|All patients enrolled in the study will accept entecavir prophylaxis that initiates within 1 week before the first course of CD20 monoclonal antibody therapy, and continues until 12 months after completing CD20 monoclonal antibody therapy.
45801304|NCT05453279|Combination Product|Delcetravir dry powder inhaler|Placebo dry powder inhaler
45801305|NCT05453123|Behavioral|telerehabilitation|examine the effect of the text message platform (WhatsApp) on the adherence to home exercise programs, pain and physical function among middle age and older adults with knee OA in two public hospitals in Riyadh city, Saudi Arabia.
45801306|NCT03029845|Drug|Propranolol 1|Participants will take 20 mg propranolol twice a day for 2 weeks
45801307|NCT03029845|Drug|Propranolol 2|Participants will take 10 mg propranolol twice a day for 2 weeks
45930832|NCT04241341|Other|measured by arm volume|Bilateral arm volumes will be measured with sequential circumferential measurements with the truncated cone formula. If a patient cannot return to Manhattan for these assessments but is seen by a lymphedema therapist in a regional location or at an institution outside of MSK as part of their routine cancer treatment, this data can be used in the final analysis
45930833|NCT04214392|Biological|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)|Given via ICT delivery
45930834|NCT04214392|Biological|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)|Given via ICT/ICV dual delivery
45930835|NCT04207346|Device|TMS 1 hz|High-performance magnetic stimulator designed for clinical use or use in clinical trials. This specific device has a coil designed with one side that delivers active treatment and the other side that delivers sham (no stimulation) treatment. The sham side is externally identical to the active side, but internally it has a shield that prevents any magnetic energy from interacting with the patient. This arm will use the active side.
45930836|NCT04207346|Device|Sham TMS|High-performance magnetic stimulator designed for clinical use or use in clinical trials. This specific device has a coil designed with one side that delivers active treatment and the other side that delivers sham (no stimulation) treatment. The sham side is externally identical to the active side, but internally it has a shield that prevents any magnetic energy from interacting with the patient. This arm will use the sham side.
45801308|NCT03029845|Drug|Placebo|Participants will take placebo twice a day for 2 weeks
45930837|NCT04202835|Drug|Cyclophosphamide|Post Transplant Cyclophosphamide
45451271|NCT02227732|Device|New Indwelling Pleural Catheter|Placement of an indwelling catheter in the pleural space. Drainage of effusions until resolution.
45930838|NCT04202835|Drug|Anti-Thymocyte globulin (rabbit)|Anti-Thymocyte Globulin (rabbit, Thymoglobulin)
45930839|NCT04199026|Drug|Doxorubicin|Given via microdevice
45930840|NCT04199026|Drug|Doxorubicin Hydrochloride|Given via microdevice
45930841|NCT04199026|Device|Drug Delivery Microdevice|Undergo percutaneous implantation of drug delivery microdevice
45451272|NCT02227888|Drug|N91115|S nitrosoglutathione reductase inhibitor
45651662|NCT05021341|Dietary Supplement|Dihydroberberine 200|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (200 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
45930842|NCT04199026|Drug|Everolimus|Given via microdevice
45930843|NCT04199026|Biological|Ganitumab|Given via microdevice
45801309|NCT05451719|Drug|Fruquintinib Plus Capecitabine|Fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W). Capecitabine at the dose 850mg/m2, orally twice daily, d1-7 and d15-21, given every 4 weeks (Q4W)
45801310|NCT05451719|Drug|Capecitabine|Capecitabine at the dose 850mg/m2, orally twice daily, d1-7 and d15-21, given every 4 weeks (Q4W)
45930844|NCT04199026|Drug|Ifosfamide|Given via microdevice
45930845|NCT04199026|Drug|Irinotecan|Given via microdevice
45801311|NCT05131373|Drug|ORG101 - Experimental 1|C. acnes vaccine Injection, 25 mcg, 75 mcg, 225 mcg, 4 single i.m. injections given in monthly intervals
45801312|NCT05131373|Drug|ORG101PL - Placebo 1|Injection, sterile aqueous solution of aluminium hydroxide, 4 single i.m. injections given in monthly intervals
45930846|NCT04199026|Drug|Pazopanib|Given via microdevice
45930847|NCT04199026|Drug|Polyethylene Glycol|Given via microdevice
45930848|NCT04199026|Drug|Temozolomide|Given via microdevice
45930849|NCT04199026|Drug|Temsirolimus|Given via microdevice
45930850|NCT04199026|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
45930851|NCT04199026|Drug|Vincristine|Given via microdevice
45930852|NCT04195763|Drug|asfotase alfa|This is an observational study and no intervention will be administered. All participants will be treated by their physician in accordance with standard of care. All medications are commercially available and will be used as directed by the treating physician.
46072920|NCT02842580|Drug|5 FLUOROURACYL|"Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as a 2 hr infusion.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days. For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days."
45451273|NCT03617536|Drug|CR845 0.25 mg Oral Tablet|CR845 0.25 mg medication taken orally 1 time/day
45451274|NCT03617536|Drug|CR845 0.5 mg Oral Tablet|CR845 0.5 mg medication taken orally 1 time/day
45451275|NCT03617536|Drug|CR845 1 mg Oral Tablet|CR845 1 mg medication taken orally 1 time/day
45451276|NCT03617536|Drug|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
45451277|NCT02227966|Device|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
46072921|NCT02842580|Drug|acide folinique|200 mg/m² if Elvorine
45451278|NCT02227966|Device|Sham-Yband (YDT-201N)|tDCS 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex
45451279|NCT02258776|Dietary Supplement|Pomegranate Extract|Pomegranate extract 1000mg will be taken 1/day for 12 weeks.
45451280|NCT02258776|Dietary Supplement|Pomegranate Juice|Pomegranate juice 8oz will be consumed 1/day for 12 weeks.
45451281|NCT02258776|Dietary Supplement|Placebo|Placebo will be taken 1/day for 12 weeks.
45451282|NCT04174612|Drug|Cytarabine|100 mg/m2/bid day 1-3 100 mg/m2/die day 4-7
45451283|NCT04174612|Drug|Daunorubicin|60 mg/m2/die day 1-3
45451284|NCT04174612|Drug|Midostaurin|50 mg/bid day 8-21
46072922|NCT02842580|Drug|irinotecan|"Irinotecan is administered IV at a dose of 180 mg/m² over 90 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with irinotecan.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days."
46072923|NCT02842580|Drug|Oxaliplatin|"Oxaliplatin is administered IV at a dose of 85 mg/m² over 120 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with oxaliplatin.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days."
46072924|NCT02842580|Drug|capécitabine|For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days.
46072925|NCT02842580|Drug|bevacizumab|Bevacizumab is administered IV at a dose of 5 mg/kg over 90 min at cycle 1, then 60 min at cycle 2 and 30 min in subsequent cycles. Bevacizumab is administered every 2 weeks before the start of chemotherapy
45801313|NCT01955629|Drug|Aflibercept AVE0005|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
45451285|NCT04174612|Drug|Cytarabine HD|100 mg/m2/bid day 1-3 100 mg/m2/die day 4 1.500 mg bid day 5-7
45801314|NCT01955629|Drug|Oxaliplatin|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
45801315|NCT01955629|Drug|Capecitabine|Pharmaceutical form: Tablets; Route of administration: Oral
45801316|NCT05127317|Diagnostic Test|Mechanical power|"In our study, mechanical power (MP) will be calculated during mechanical ventilation in patients who will be operated under general anesthesia.~MP will be calculated with the simplified formula applied by Gattinoni et al. MPvcv: RR x Tv x (PIP-[(Pplat-PEEP)/2]) x 0.098(2) In pressure-controlled ventilation, the simplified MP formula of Becher et al. well be used.~MPpcv: RR x Tv x (ΔPinsp + PEEP) x 0.098 (11)~For MP calculated according to the weight of the patients; Indexed MP: MP /kg according to IBW. For the force applied to the lungs in each inspiration; Dynamic power (mJ/min): Vt x RR x [(Pplato+ tPEEP)/2]. For the driver power that provides the gas flow; Driving power (mJ/min): Vt x RR x [ (Pplat - tPEEP) / 2]. Calculating mechanical energy; Mechanical energy (mJ/kg): 0.098 x (V x kg ) x (PIP - [(P plateau- PEEP) / 2]) formulas were used"
45451286|NCT00097721|Drug|E7389|The first cohort of subjects were to receive E7389 1.4 mg/m^2 as an intravenous (IV) bolus on Days 1, 8, and 15 of a 28-day cycle. A second cohort of subjects was added and were to receive E7389 1.4 mg/m^2 as an IV bolus on Days 1 and 8 of a 21-day cycle.
45451287|NCT02228044|Behavioral|Prevention program|
45451288|NCT01082003|Drug|Trental|Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months.
45451289|NCT03963791|Other|Eggshell powder gel|Eggshell powder gel produced from chicken eggs.
45451290|NCT03963791|Other|CPP-ACP crème|A water-based, sugar-free topical cream containing Recaladent (CCP-ACP) which is derived from the milk protein.
45451291|NCT02232958|Other|Hyperbaric Oxygen Treatment|Patients are placed in a special chamber in which the pressure is gradually increased up to the desired pressure with 100% Oxygen and the patient is kept at that pressure for one hour. Then the Oxygen flow is slowly reduced until the patient has been returned to one atmosphere of pressure.
45451292|NCT01082237|Drug|Escitalopram|Start at 5mg per day, after four days increase to 10mg per day for the duration of the study. 20 mg will be administered at week 8 if not significantly better.
45451293|NCT02228122|Device|Aquacel® Ag+ Extra|Aquacel® Ag+ Extra dressing will be applied to wounds as per instructions for use, dressing to be changed at least one per week for 4 weeks.
45653250|NCT05073861|Behavioral|STEM learning|"Classes will be randomly assigned to the experimental group and to the control group. As treatment, the experimental group will be assigned to an intervention that uses a STEM blended learning app with gamified videos for content knowledge along with hands-on experiments. The videos are fictitious educational narratives related to the content knowledge and students were asked to step into the shoes of the cartoon scientist (a chipmunk) to solve various problems during the stories. The science experiments will be completed with step-by-step video guidance on the app. The control group will be assigned to read the same content on an e-book and receive an arts-and-craft kit for each lesson that is unrelated to the content knowledge."
45801317|NCT01898611|Drug|Ghrelin|Ghrelin
45801318|NCT01898611|Drug|Placebo|Saline will be used as a placebo
45801319|NCT05110703|Dietary Supplement|Supergut|Meal replacement shake
45801320|NCT05110703|Dietary Supplement|Placebo|Placebo
45801321|NCT05110703|Other|Dietary guidelines|Dietary guidelines
45801322|NCT01898689|Drug|Ropivacaine 0.1%|A sciatic catheter was inserted and ropivacaine 0.1% was administered as a basal infusion for 6 hours.
45801323|NCT01898689|Drug|Ropivacaine 0.4%|A sciatic catheter was inserted and ropivacaine 0.4% was administered as a basal infusion for 6 hours.
45801324|NCT05104697|Device|Transcranial Magnetic Stimulation|All teens will receive active TMS; they will be randomly assigned to receive active TMS at either visit 1 or visit 2 (order counterbalanced)
45801325|NCT05090267|Dietary Supplement|Probiotic Supplement|Participants will take a probiotic supplement or placebo for 90 days.
45451294|NCT01082315|Drug|Erbitux (Cetuximab)|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. Cetuximab 2mg/ml will be administered intravenously via in-line filtration with an infusion pump, gravity drip or a syringe pump. For the initial dose, the recommended infusion period is 120 minutes and for the subsequent weekly doses, the recommended infusion period is 60 minutes.
45451295|NCT03963323|Dietary Supplement|Glucosamine Sulfate/Chondroitin Sulfate Tablet|Given PO
45801326|NCT05090267|Device|Transcutaneous Vagal Nerve Stimulation (tVNS)|Participants will use a non-invasive stimulator 1 hour daily for 30 days. This stimulator is placed around the ear similar to headphones and produces a very mile electric current. This wellness device is safe to use and painless. Some describe the sensation to be a slight tingle up to a small itch.
45801327|NCT04021121|Drug|LZD|LZD 1200 mg daily
45801328|NCT04021121|Drug|High dose RIF|RIF 35 mg/kg/day
45801329|NCT04021121|Drug|Standard dose RIF|RIF 10 mg/kg/day
45451296|NCT03963323|Other|Placebo|Given PO
45801330|NCT04350697|Procedure|Aortic Surgery|Surgery for aortic and/or aortic valve diseases
45451297|NCT01082471|Drug|Morphine 6-glucuronide|
45653251|NCT05728801|Diagnostic Test|Ageing|Using comprehensive cognitive tests to quality the domain-specific cognitive changes during ageing.
45801331|NCT05086757|Behavioral|TRRP|Receive TRRP services
45801332|NCT05086757|Behavioral|Enhanced Usual Care|Participants will receive an educational flyer with service referrals
45801333|NCT00370409|Procedure|Cryotherapy|Cryotherapy of both sides of sclerotomy sites was done for 6 seconds after complition of operation.
45451298|NCT01082471|Drug|Morphine|
45451299|NCT03553498|Drug|IV acetaminophen|acetaminophen given intravenously
45451300|NCT03553498|Drug|IV placebo|given intravenously
45451301|NCT03553498|Drug|hydromorphone|hydromorphone given intravenously
45451302|NCT01589393|Drug|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses starting 36-48 hours post traumatic injury.
45451303|NCT01589393|Other|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily starting 36-48 hours post traumatic injury for six doses.
45451304|NCT02228200|Behavioral|Nurse-led care|The nurse-led care consisted of a pre-chemotherapy nursing consultation and telephone follow-up sessions during chemotherapy. The nursing consultation was on the day of the first cycle before drug administration. It included: history review, overall status evaluation, need and problem assessment, information provision, psychological support, and referral. The telephone follow-up sessions were delivered within one week after the 1st, 2nd, 4th, and 6th, and 8th cycle. A telephone follow-up session included: (i) The overall status assessment and problem triage; (ii) Care delivery based on problem severity; (iii) Evaluation of the change of the problems on the following telephone call.
45451305|NCT02228200|Behavioral|Routine care|Routine care includes: (1) Brief education on possible side-effects and coping skills before chemotherapy; (2) Care on chemotherapy day: vital sign assessment, casual communication between nurses and patients, video about chemotherapy and side effects management. (3) Care in chemotherapy intervals: hotline for patients when they have health problems at home.
45451306|NCT01589471|Drug|intra-rectal Botulinum toxin A injection|intra-colic injection of 100 U of Botulinum toxin A as a single injection distributed amongst the four quadrants, 5 cm above anastomosis
45451307|NCT00096941|Drug|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
45451308|NCT03548116|Device|Ultrasound|A specially designed ultrasound will be placed against the abdomen of an individual in order to administer low levels of insonification to the spleen.
45653252|NCT05613179|Procedure|Group1 (lever positioning manipulation)|The specific lever positioning manipulation is as follows: the patient lies prone at the mouth-open position with muscles relaxed, waist exposed, knees and hips bent, and ankle joints crossed. The practitioner uses the right elbow olecranon to point at the lumbar vertebrae, then hold the patient's two ankle joints in both hands to cause the lumbar vertebra to make hyperextension and flexion movements through the arms and pull the patient backward and upwards hard. When pulling upwards to the trigger point, the practitioner pulls wit lever quickly with a technique and then senses a clatter or looseness at the positioning point. When the practitioner pulls with lever manipulation, the patient is asked to exhale and then inhale at the end of the manipulation.
45801334|NCT05062577|Drug|ASP8062|oral
45801335|NCT05062577|Drug|Placebo ASP8062|oral
45801336|NCT05062577|Drug|buprenorphine/naloxone|sublingual
45801337|NCT01956097|Dietary Supplement|HX106 590mg|
45801338|NCT01956097|Dietary Supplement|HX106 1180mg|
45801339|NCT01956097|Dietary Supplement|Placebo|
45801340|NCT05449379|Other|Respiratory training with the use of resistance set on respiratory muscle trainer|Performing respiratory training with resistance set on respiratory trainer.
45801341|NCT05449379|Other|Respiratory training without resistance set on respiratory muscle trainer|Performing respiratory training with no resistance set on respiratory trainer
45801342|NCT05735041|Behavioral|Multi-domain cognitive digital therapy|Patients in the cognitive digital therapy group received multi-dimensional targeted cognitive function training electronically, involving attention, memory, executive function, thinking, processing speed and perception. The system will adjust the training difficulty and training plan adaptively according to the patient's current training time and performance, and train the patient's weak cognitive ability as far as possible. The patients had the same total amount of training each day.
46072926|NCT00836277|Drug|Panitumumab|9mg/kg IV Day 1 Cycle = 21 days
46072927|NCT00836277|Drug|Irinotecan|125mg/m2 IV Day 1 and Day 8
46072928|NCT00831025|Biological|Immunotherapy with modified extract of Olea europaea pollen|Subcutaneous immunotherapy with modified extract of Olea europaea. A subcutaneous monthly treatment.
45651663|NCT05021341|Dietary Supplement|Dihydroberberine 100|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (100 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
45653253|NCT05613179|Procedure|Group2 (placebo group)|The specific sham lever positioning manipulation is as follows: the patient lies prone with his mouth open, muscles relaxed, waist exposed, knees bent at the hip and ankles crossed. The practitioner points to the lumbar spine with the right elbow olecranon, and then holds the patient's two ankles in both hands, so that the lumbar spine through the arm for overextension and flexion, and forcefully pulls the patient back and up. When pulling up to the trigger point, maintain this movement for a short period of time, depending on the patient's endurance, about 1-5 minutes. After finishing, ask the patient to rest in prone position.
45451309|NCT03548116|Device|Sham Ultrasound|A specially designed ultrasound will be placed against the abdomen of an individual in order to administer sham insonification to the spleen.
45801343|NCT05735041|Behavioral|Basic cognitive therapy|The training content of the positive control group was cognitive training tasks with weak difficulty or no difficulty change. The patients underwent cognitive function training with fixed programs, including 15 training items, and the internal difficulty of the training items remained constant without change. The system presents the training content randomly according to the training scheme. The patients had the same total amount of training each day.
45801344|NCT05448989|Drug|1% atropine 5+3|A method for myopia control using high-concentration atropine
45801345|NCT05447195|Drug|CAN008|Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given CAN008 + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the CAN008+TMZ maintenance therapy period in which subjects in both groups are given CAN008+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given CAN008 IV infusion weekly until disease progression.
45801346|NCT05447195|Drug|Placebo|Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given placebo + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the placebo+TMZ maintenance therapy period in which subjects in both groups are given placebo+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given placebo IV infusion weekly until disease progression.
45801347|NCT00370565|Drug|Inhaled Human Insulin|
45801348|NCT05049161|Drug|Temelimab 18 mg/kg|temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
45801349|NCT05049161|Drug|Temelimab 36mg/kg|temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
45801350|NCT05049161|Drug|Temelimab 54 mg/kg|temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
45801351|NCT05039723|Drug|Radiesse, Xeomin, Belotero|Rejuvenation with Radiesse, Xeomin, Belotero
45801352|NCT03996005|Procedure|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue
45801353|NCT05429879|Other|Preferred Music Arm|Patients will choose their preferred music to be played during the cystoscopy procedure. No music will be played prior to or immediately after the flexible cystoscopy procedure. Music will be delivered via a speaker allowing for communication between the urologist and the patient during the procedure. Aside from addition of music, standard of care will not be impacted.
45801354|NCT05429879|Other|Classical Music Arm|A standardized playlist of copyright free classical music will be played during the cystoscopy procedure. No music will be played prior to or immediately after the flexible cystoscopy procedure. Music will be delivered via a speaker allowing for communication between the urologist and the patient during the procedure. Aside from addition of music, standard of care will not be impacted.
45801355|NCT05391191|Device|MitrAssist TRISKELE® transcatheter aortic valve system|Patients were treated with MitrAssist TRISKELE® transcatheter aortic valve system
45801356|NCT03993509|Device|rTMS to the right dlPFC|A Magventure MagPro 100X stimulator with a B65 active/placebo figure-8 coil will be used. The TMS coil will be placed on the head over the target. rTMS intensity will be 100% of the motor threshold (MT), adjusted for field strength difference at motor cortex and target cortex using the individual E-field model. Subjects will receive 3000 pulses/session.
45801357|NCT05370989|Other|Technology-Based Parent School Program|The program will be continued for 10 weeks in the intervention group and will be included five web-based modules, five online group interactions after each module, and consultation throughout the program and the follow-up period.
45801358|NCT05370989|Other|ongoing treatment|Health service of the control group will ongoing.
45801359|NCT05356247|Behavioral|Lausanne Trialogue Play Brief|The brief treatment program will consist of an LTP family assessment with video feedback to caregivers to address family interaction patterns and child mental health. Families will participate in four sessions conducted online using the Zoom for Healthcare platform. In the first session, families will engage in a family assessment in different groupings that will be recoded on zoom and used later in the treatment. In the second session, taking place one week later, families will take part in a mini assessment to learn more about the difficulties of the child. In the third session, the clinical team will share videos of the family assessment to the parents and discuss the families strengths, concerns, and goals for moving forward. In the fourth session, taking place one month after the third session, families will participate in a check-in session, debriefing the family assessment.
45801360|NCT03910751|Device|Transcatheter Aortic Valve Implantation with ACURATE Neo Aortic Bioprosthesis|Transfemoral TAVI using the Boston Scientific ACURATE Neo Aortic Bioprosthesis
45801361|NCT00370019|Drug|Estradiol/Medroxyprogesterone acetate|
45930853|NCT04190368|Other|Team Clinic Care|"Participants attend quarterly visits (1 visit every 3months). Appointments scheduled for Telehealth (TH) (1 in-person visits) as decided by provider/patient.~Selected providers will be trained in the Team Clinic Care protocol for completing medical appointments. Team Clinic Care key components:~(1) Shared decision making: Providers, AYA, parent/caregiver will mutually agree on priorities for each medical visit using a shared decision making tool (2) Autonomy supportive care: Providers will be trained in skills building, patient centered key elements, intervention bites, reviewing plans, designed to support AYA autonomy and intrinsic motivation. AYA will also direct extent of eligible family involvement. (3) Goal setting and action planning: Providers will be trained to coach AYA in setting SMART goals, developing action plans, and establishing a plan for follow-up between visits as appropriate. (4) Fidelity Review and process for self-assessment"
45930854|NCT04190368|Other|Standard Care|Participants attend quarterly visits (1 visit every 3 months) and see their diabetes care provider. They do not participate in Team Clinic group visits but if they need diabetes education or supportive services they will be referred for necessary care per usual methods.
45801362|NCT05286281|Drug|PF-07265803|PF-07265803 is a p38 inhibitor formulated for oral delivery.
45651664|NCT05021341|Dietary Supplement|Placebo|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (Maltodextrin placebo) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
45801363|NCT03904823|Drug|famitinib po|Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
45801364|NCT03904823|Drug|HS-10296 po|Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
45930855|NCT04187443|Drug|MS-553|MS-553
45930856|NCT04182997|Drug|Dexamethasone|Patients included in the treatment group will have their surgical site lavaged with dexamethasone at the end of their surgery.
45930857|NCT04182997|Drug|saline 0.9%|Patients included in the placebo group will have their surgical site lavaged with sterile saline at the end of their surgery.
45930858|NCT04178434|Behavioral|Internet-based CBT intervention|A nine step intervention including internet-based feedback by psychologists
45930859|NCT04177199|Other|TRIAGE HF Pathway|A new care pathway (Triage-HF Plus) for the remote monitoring and management of heart failure stability in a cohort of device patients at 3 hospital sites in North West England.
45930860|NCT04172441|Drug|dasiglucagon|Glucagon analogue
45930861|NCT04172441|Drug|Placebo|Placebo for dasiglucagon
45930862|NCT04171219|Biological|Pembrolizumab|Given IV
45930863|NCT04171219|Drug|Talabostat Mesylate|Given PO
45930864|NCT04171037|Procedure|Oxygen Therapy|Receive oxygen via Optiflow THRIVE
45930865|NCT04171037|Procedure|Oxygen Therapy|Receive oxygen via non-rebreather
45653254|NCT04997499|Behavioral|watch an instructional video|watch instructional video and then perform self injection of subcutaneous depot-medroxyprogesterone based on the video teaching
45653255|NCT05473975|Procedure|Placement of the EGG|Placement of the EGG before the beginning of the thrombectomy
45801365|NCT03888131|Drug|CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo|Fixed combination of beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg (BDP/FF)
45801366|NCT03888131|Drug|Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo|Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (BUD/FF)
45801367|NCT01900249|Drug|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% 1 drop per eye twice a day for 12 weeks.
45801368|NCT01900249|Drug|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 1 drop per eye twice a day for 12 weeks.
45801369|NCT01900249|Drug|Placebo|Placebo Ophthalmic Solution 1 drop per eye twice a day for 12 weeks.
45801370|NCT05276453|Device|GMove Suit|12 week, home-based programme whereby participants are encouraged to use the GMove suit daily, for at least 30 minutes a day. Recommended activities include walking, sit-to-stand and step-ups
45801371|NCT05276453|Behavioral|Normal therapy|Participants are randomized to a normal therapy (physiotherapy) only program. Participants are also advised to undertake 30 mins a day of physical activity and have active physical therapy (physiotherapy) sessions.
45801372|NCT02987647|Other|Hidrafemme|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
45801373|NCT02987647|Other|Vagidrat|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
45801374|NCT02987647|Other|Lubrinat|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
45930866|NCT04171037|Other|Questionnaire Administration|Ancillary studies
45930867|NCT04171037|Device|Optiflow THRIVE|Oxygen Administration
45930868|NCT04168385|Drug|Maralixibat|"Maralixibat chloride oral solution orally twice daily (up to 1200* mcg/kg/day), and according to indication.~*equivalent to 1140 mcg/kg/day maralixibat"
45930869|NCT04167163|Drug|Abaloparatide|18 month ABL treatment
45930870|NCT04162561|Behavioral|Patients with documented IHD|Assessment of patients' quality of life with the use of the Seattle Angina Questionnaire (SAQ), blood pressure levels (using the Korotkoff method, blood pressure is measured 3 times with 1-minute intervals on the hand with the higher blood pressure levels while sitting calm after a 5-minutes rest), laboratory methods (lipids, glycosylated hemoglobin levels), patients' adherence to treatment (original questionnaire), quality of patients' therapy taken at the time of visit, necessity of invasive coronary revascularization procedures (during all visits).
46072929|NCT00831025|Biological|Placebo|Placebo for subcutaneous monthly administration
46072930|NCT00843427|Behavioral|CIAT|Patients are to receive constraint-induced aphasia therapy for 2 weeks at 4 hours per day. Detailed description of this intervention is in Szaflarski et al., 2015 Medical Science Monitor.
45930871|NCT04139603|Other|Lumbopelvic kinesio taping|"Kinesio tapes applied to the lumbopelvic region will stay 3 days. They will be removed from the site, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
45801375|NCT02987647|Other|Antrofi|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
45801376|NCT05269745|Other|Stretching through immobilisation (IG)|The immobilization group (IG) will receive the standard treatment, a dynamic ankle-foot orthosis (AFO) for night and day use (23 hours per day)
45930872|NCT04139603|Other|Abdominal supported lumbopelvic kinesio taping|"Kinesio tapes applied to the lumbopelvic region and abdominal area will stay 3 days. They will be removed from the sites, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
45801377|NCT05269745|Other|Stretching through immobilisation and activity (IAG)|The Immobilization/Activity Group (IAG) will be treated with the same type of ankle-foot orthosis at night (8 hours) and for 6 hours during the day (altogether orthosis treatment 14 hours per day). The rest of the day (10 hours) children and adolescents will be using only the foot shell of orthoses (FS) without the lower leg shell, to secure the correct position of the foot and to allow a free motion at ankle joint with a good correction of the foot deformity (e.g. Pes equinovarus / equinovalgus, midfoot-break).
45801378|NCT05269745|Other|Control Phase|Before the intervention with the orthotic treatment starts, a control phase of 8 weeks is planned. During this time, the individual orthoses for each subject are manufactured.
45801379|NCT05267171|Other|Web access|The intervention group will have access to the website where the information is provided. The control group will not have this access.
45801380|NCT01900561|Behavioral|Interactive Voice Response Symptom Management|The Interactive Voice Response (IVR) system will provide automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach.
45801381|NCT01900561|Behavioral|Tailored Newsletters|Personally tailored newsletters will incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
45930873|NCT04139603|Other|Placebo tapng|"Placebo tapes (just like Kinesio tapes) applied to the lumbopelvic region without any tension will stay 3 days. They will be removed from the site, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
45930874|NCT04134936|Drug|Tafasitamab|Six 21-day cycles of tafasitamab (12 mg/kg intravenously, on Day 1, 8 and 15) in addition to R-CHOP
45651665|NCT05362071|Other|Remote Exercise Group|The intervention will have a weekly frequency of two sessions on non-consecutive days during the first six weeks and three sessions on non-consecutive days for the remaining six weeks. The exercise intervention will consist of four 3-week mesocycles. The session's structure will consist of a warm-up, the main part, in which a combined training program will be carried out, consisting of three distinct blocks, and at the end, stretching. Blocks 1 and 2 will consist of three strength exercises with bodyweight and alternative materials and aerobic training. Between blocks 1 and 2, and later in block 3, participants will take a free walk with displacement in the space they have available in their own home. The session will end with stretching exercises for the main muscle groups. The sessions will last 37 to 57 minutes over 12 weeks, with approximately 5 min of warm-up and stretching, and the main part ranging from 27 min to 47 min throughout the intervention.
45651666|NCT05362071|Other|Group control|"Participants allocated to the GC will receive recommendations for the practice of physical activity based on information from three specific chapters of the Physical Activity Guide for the Brazilian Population (2021). The GC will receive through Whatsapp the information that is available in chapters 1, 4, and 5, which address the following topics: Understanding Physical Activity, Physical Activity for Adults, and Physical Activity for the Elderly. If sending via Whatsapp is not possible, the booklet will be printed and delivered to the participant. At the end of the 12 weeks, the same booklet will be made available to IG participants."
45801382|NCT03789617|Biological|EBViNT Cell|"Dosage: 1 bag containing 1.4x10^9 cells/100mL~Administration: Inject intravenously over 30 minutes~Dosing schedule: Single dose"
45801383|NCT05166473|Other|Telerehabilitation group (n=21)|"This group was conducted with a physiotherapist for video conference-based vestibular rehabilitation exercises, was called the telerehabilitation group (TR). In terms of ease of Use and applicability, the WhatsApp app was preferred. Patients were individually searched for two days a week, 25-30 minutes. The exercises were performed gradually from easy to difficult, initially in a sitting position in accordance with the levels of the patients."
45801384|NCT05166473|Other|Control Group (n=21)|"After the home exercise program, which should be applied twice a day for six weeks, was shown in practice, the home exercise program was given, in which the exercises were visual and written, this group was called the control group. All participants were given a phone number to consult when there were any problems, and were phoned to decry whether they were continuing the exercises."
45801385|NCT01957657|Drug|BI 207127|oral administration
45801386|NCT01957657|Drug|faldaprevir|oral administration
45801387|NCT01957657|Drug|BI 207127|oral administration
45801388|NCT01957657|Drug|BI 207127|oral administration
45801389|NCT01957657|Drug|BI 207127|oral administration
45801390|NCT01957657|Drug|faldaprevir|oral administration
45930875|NCT04134936|Drug|Tafasitamab plus lenalidomide|Six 21-day cycles of tafasitamab (12 mg/kg intravenously, on Day 1, 8 and 15) plus lenalidomide (starting dose 25 mg orally, on Day 1-10) in addition to R-CHOP
45930876|NCT04115111|Drug|Durvalumab|Durvalumab in monotherapy as second line treatment
45801391|NCT01957657|Drug|faldaprevir|oral administration
45651667|NCT05020561|Behavioral|Group life-coaching|"Group coaching sessions will be focusing on providing material and tools that guide the participants in the transition from cancer treatment to survivorship. All activities of the group session will be following the After Cancer Passport document."
45801392|NCT01957657|Drug|faldaprevir|oral administration
45801393|NCT05734963|Genetic|DNA sequencing, RNA gene expression analysis, molecular profiling|Growth of organoids from tissue samples, collection of tissue, blood and saliva samples for DNA sequencing, RNA gene expression analysis, molecular profiling
45930877|NCT04113109|Drug|LCZ 696|Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).
45801394|NCT02987491|Behavioral|Exercise|Participants will perform 2 metabolic study days of either resting or acute bout of cycling exercise in a randomized cross-over design.
45801395|NCT04969211|Drug|VHX-896 and iloperidone|oral tablet
45651668|NCT05020561|Behavioral|Individual life-coaching|In the individual coaching sessions, the life-coach will provide guidances that help the participants to put tools into actions. All activities are outlined in the After Cancer Passport. Participants will use their Passport for each individual coaching session to outline their objectives and indicators of success. The life coach will also assign activities, such as self-reflection, for the participants to complete between each session.
45801396|NCT04969211|Drug|Iloperidone and VHX-896|oral tablet
45451310|NCT02228278|Behavioral|Group A|"Phase 1: Group A will receive the typical clinic visits plus daily text messages for 12 weeks.~Phase 2: Group A will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider and for those prescribed medication for a chronic condition, medication counseling by a healthcare provide) plus daily text messages in between visits for 3 months to support their health goals."
45651669|NCT05017909|Behavioral|Face to face education|Face to face education techniques on the acquisition of the mothering Role
45801397|NCT05734885|Other|Back and Sacral massage massage application|Massage will be applied to the pregnant woman in the position preferred by the pregnant woman. Circular movements are applied to the sacrum with the thumb. Pressure is applied to both sides of the spinal cord with the thumb. The thumb is moved towards the hip of the pregnant woman at 1.5 cm intervals, starting from the lower part of the pelvis and the sacrum. The palm is placed in direct contact with the mother's sacrum and pressure is applıed. The massage is completed by making a bunch of flowers from the sacrum upwards, towards the shoulder and around it.
45651670|NCT05017909|Behavioral|Web based education|web based education techniques on the acquisition of the mothering Role
45651671|NCT05017909|Behavioral|No education|Control group will not be educated
45651672|NCT05384535|Diagnostic Test|Bi-parametric MRI|When used for the evaluation of prostate cancer, MRI typically involves multiple sequences and typically includes typical T1 and T2 phases with the addition of diffusion weighted imaging and dynamic contrast enhanced imaging. In this study, we have decided to omit dynamic contrast enhanced imaging due to its decreased diagnostic yield relative to T2 and DWI and associated increased risk of contrast agents, this is a common approach for prostate cancer screening and is referred to as a bi-parametric MRI
45801398|NCT03779867|Behavioral|Exercise Intervention|Undergo acute exercise
45801399|NCT03779867|Other|Resting|Seated resting
45801400|NCT03779867|Other|Biomarker Analysis|Correlative studies
45801401|NCT03779867|Other|Questionnaire Administration|Ancillary studies
45801402|NCT01901575|Drug|Remifentanil|Patients with established PVC's , sedated with remifentanil IVPCA per study protocol
45801403|NCT03754049|Drug|TLC599|TLC599 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP (active ingredient).
45801404|NCT03754049|Drug|DSP|Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
45801405|NCT05049005|Behavioral|Simplified dietary tracking|Mobile-delivered nutrition program using simplified dietary monitoring with a focus on weight loss.
45801406|NCT01901809|Drug|Furosemide|
45930878|NCT04113109|Drug|Icatibant|Icatibant will be given intravenously at 100 µg/kg over one hour followed by 20 µg/kg/hr during each study day.
45801407|NCT01901809|Drug|Dopamine|
45930879|NCT04113109|Drug|placebo|Placebo (vehicle) will be given at the same rate as icatibant.
45801408|NCT04947527|Drug|Test varnish|A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
45801409|NCT04947527|Drug|Placebo|A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
45930880|NCT04113109|Drug|Para-aminohippurate|Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
45930881|NCT04113109|Drug|Iohexol|Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.
46072931|NCT02842502|Procedure|Collection of supernumerary biopsies during skin graft pellet procedure|
45651673|NCT05361759|Device|Cardiac Implantable Electronic Devices|Description of Cardiac Implantable Electronic Devices
45930882|NCT04107038|Procedure|General Endotracheal Anesthesia|Participants receive general endotracheal anesthesia for the procedure, as well as analyzing the information from their transesophageal echocardiography per routine clinical care.
45930883|NCT04107038|Procedure|Monitored anesthesia care|Participants receive monitored anesthesia care for their procedure.
45930884|NCT04098003|Drug|Rosuvastatin|rosuvastatin 20 mg daily or placebo for eight weeks
45930885|NCT04098003|Drug|Placebo|Matched placebo control
45930886|NCT04084483|Drug|K-161|K-161 alternate dosage
45930887|NCT04084483|Other|Placebo (Vehicle)|Placebo solution
45930888|NCT04079179|Drug|Cobimetinib|All groups will receive the same intervention. Cobimetinib will be given orally at a maximum dose of 60mg daily for 21 days on, then 7 days off, in a 28-day treatment cycle for a total of 12 cycles (approximately 12 months).
45930889|NCT04058431|Other|Osteopathic Manipulative Treatment|Osteopathic manipulative treatment (OMT) is defined as the therapeutic application of manually guided forces by an osteopathic physician to improve physiologic function and/or support homeostasis that has been altered by somatic dysfunction. Somatic (body framework) dysfunction or altered function of related components is observed in the skeletal, arthrodial and myofascial structures, and their related vascular, lymphatic, and neural elements. Techniques can use a direct method where the restrictive barrier is engaged and a final activating force is applied to correct the somatic dysfunction, or an indirect method where the restrictive barrier is disengaged and the dysfunctional body part is moved away from the restrictive barrier until tissue tension is equal in one or all planes and directions
45930890|NCT04058431|Other|Control- No Intervention|This group will refrain from getting OMT while in the study.
45930891|NCT04043039|Procedure|Palatal wound bandage with PRF|palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membranes
45930892|NCT04043039|Procedure|Palatal wound bandage with Gelatine Sponge|palatal wound will be protected by gelatine sponge
45930893|NCT04042233|Drug|Experimental Intraosseous vancomycin 500mg in 250 mL NS|500mg of Vancomycin in 250 mL of normal saline will be injected into a pre-specified region of the greater trochanter during primary total hip arthroplasty.
45930894|NCT04042233|Drug|Standard IV administration of vancomycin|IV antibiotics (cefepime & vancomycin) are started in pre-op approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg, generally 1000-1750mg in 500 mL NS).
46072932|NCT00835731|Drug|misoprostol|400mcg misoprostol, buccal administration, 1 time dosing 3-4 hours before abortion by D&E
45651674|NCT05020639|Drug|TQB3820 tablets|TQB3820 is a novel cereblon-modulating agent.
45801410|NCT01902901|Genetic|Whole Genome Sequencing|Participants will receive Whole Genome Sequencing
45801411|NCT01902901|Genetic|Carrier status testing|Carrier status testing
46072933|NCT00835731|Device|Dilapan-S, vitamin B-12|One Dilapan-S rod placed in the cervix 3-4 hours before abortion by D&E. Control: 1000mcg vitamin B-12, buccal administration 3-4 hours before abortion by D&E
45801412|NCT05740189|Device|C2 CryoBalloon 180° Ablation System|The C2 CryoBalloon 180° Ablation System is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal therapeutic endoscopes.
45930895|NCT04039984|Device|Prime Cup|Patients in this group will have the Prime cementless acetabular cup used during surgery.
45930896|NCT04033328|Drug|ORIC-101|ORIC-101 once daily in each 28-day cycle
45930897|NCT04033328|Drug|enzalutamide 40 MG oral capsule [Xtandi]|160 mg once daily in each 28-day cycle
46072934|NCT00843505|Behavioral|Telemedicine Smoking Cessation Program|Participants will receive four sessions of telemedicine smoking cessation counseling over an 8-week period. The telemedicine sessions will be delivered by two-way Webcams mounted on desktop computers in the doctors' offices.
46072935|NCT00843505|Behavioral|Telephone Quitline Smoking Cessation Program|Participants will receive four sessions of smoking cessation counseling delivered by telephone in their homes over an 8-week period.
46072936|NCT03721406|Drug|Ropivacaine|ropivacaine administerd via thoracic paraveretebral catheter
46072937|NCT00751166|Drug|Desloratadine|Desloratadine 5 mg, oral tablet, once daily in the morning, 28 days
46072938|NCT00751166|Drug|Cetirizine|Cetirizine 10 mg, oral tablet (over encapsulated), once daily in the morning, 28 days
46072939|NCT00751166|Drug|placebo|placebo once daily for 28 days
45651675|NCT05009017|Drug|Bevacizumab|Patients with colorectal cancer or lung cancer who use originator or biosimilar of bevacizumab
45651676|NCT05017597|Other|Rehabilitation|Exercises completed, and rate of perceived exertion (RPE) will be reviewed during & after each exercise session. Exercises will be modified by either increasing or decreasing the intensity. Decisions will be made based RPE, physical symptoms & any identified barriers or supports. Weeks 1, 3, 5, & 7, Cancer-related fatigue (CRF) education will be assigned. During weeks 2, 4, 6, & 8, CRF education will be reviewed and a plan for how to apply the information will be developed. Participant will be guided through 6 steps of problem solving to address one occupational performance problem identified by participant within Canadian Occupational Performance Measure. Goal & action plan for the week will be shared with the participant electronically. At the beginning of each session, participant will describe progress on previous week action plan. Based on participant's response, either a new goal will be developed or the current one modified..
45651677|NCT05384145|Other|COAST-AL|This combination intervention includes three CDC evidence based interventions: (1) a data-driven approach to direct Community-based HIV testing to areas with high need, (2) Project Connect to expedite linkage to care at time of diagnosis, (3) and a Rapid ART Start program, all in MCHD jurisdictions in Alabama
45801413|NCT04929743|Device|BTI Implant|Placement of dental implants of 5.5 vs >6.5 mm length
45801414|NCT04707599|Other|Reminder plus (telephone call from therapist)|Reminder plus (telephone call from therapist)
45801415|NCT02284399|Other|non-invasive prenatal testing|Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation
45801416|NCT05441423|Radiation|CBCT|CBCT Scans. conventional & ultra low dose
45801417|NCT05005403|Drug|ABBV-514|Intravenous (IV) Infusion
45801418|NCT05005403|Drug|Pembrolizumab|IV Infusion
45801419|NCT05005403|Drug|Budigalimab|IV Infusion
46072940|NCT03685448|Drug|Cabozantinib|The 20 mg cabozantinib drug product is a film-coated, white, round, immediate-release tablet. Cabozantinib should not be stored above 25°C (77°F).
46072941|NCT05560971|Dietary Supplement|Palmitoleic acid|Participants will be randomized to either POA or placebo and will be asked to take 2 capsules of the POA or placebo twice a day for 8 weeks.
46072942|NCT05560971|Other|Placebo|Medium chain fatty acids in triglyceride form in capsules with the same shape, color, size and odor of POA capsules
45801420|NCT05734651|Device|PROMIS Stem|Primary Total Hip Arthroplasty with the PROMIS Stem (Fa. Falcon Medical, Mödling, Austria)
46072943|NCT00837343|Drug|quetiapine fumarate tablet (Seroquel)|Investigational product: quetiapine fumarate tablet (Seroquel) , 25 mg, 200 mg, 300mg, manufactured by AstraZeneca.The total daily doses of quetiapine fumarate will be increased to 600mg/d on the 6th since enrolment day. At day 7 or later, the dose can be adjusted in the range of 400- 800mg/day.
45651678|NCT05008939|Drug|Sevoflurane|Patients receive 1% sevoflurane and 30% oxygen for 1 hour.
45651679|NCT05008939|Drug|Placebo|Patients received 30% oxygen for 1 hour.
45651680|NCT05361525|Procedure|modified saldhana's technique|tummy tuck with anatomic definition using liposuction
45651681|NCT05361525|Procedure|Traditional abdominoplasty|uses the traditional technique of abdominoplasty with liposuction with v-shaped dissection till the coastal margin
45801421|NCT05740111|Other|Annual surveillance|Annual surveillance includes annual MRI and/or an assessment new onset diabetes and unintended weight loss.
45801422|NCT04994327|Other|Beta-glucan bread|Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks
45801423|NCT03029533|Drug|Leuprolide Acetate|DWJ108J, SC injection, once(Day1)
45801424|NCT03029533|Drug|Leuprolide Acetate|Leuplin DPS Inj, SC injection, once(Day1)
45801425|NCT04921007|Procedure|Sacral ESP block|A high-frequency ultrasound linear probe covered with a sterile sheath will be placed longitudinally to the midline of the sacrum. The median sacral crests and erector spinae muscle will be visualized, then a 22-gauge, 50 mm needle will be advanced from cranial to caudal direction until its tip touch the sacral crest.
45801426|NCT04921007|Procedure|Caudal block|A high-frequency ultrasound linear probe covered with a sterile sheath will be placed on to the sacrococcygeal region. The dura mater, epidural space, conus medullaris, sacral cornua, and sacrococcygeal ligament will be identified. Using the in-plane technique, a 22-gauge, 50 mm needle will be introduced to reach the sacral epidural space.
45801427|NCT04921007|Drug|Bupivacaine Hydrochloride|Following negative aspiration, a precalculated dose (0.5 ml/kg) of 0.25% bupivacaine will be injected.
45801428|NCT01904071|Procedure|UFNB (Ultrasound guided femoral nerve block)|Ultrasound Guided Femoral Nerve Block
45801429|NCT01904071|Procedure|UFIB (Ultrasound Guided Fascia Iliaca Compartment Block)|
45801430|NCT01904071|Drug|IVMS (IV Morphine)|Intravenous Morphine
45801431|NCT03562637|Biological|adagloxad simolenin combined with OBI-821|In the neoadjuvant and adjuvant phases of the study for a total of 100 weeks; subcutaneously injections.
45801432|NCT03562637|Device|Globo H IHC Assay|The Globo H IHC assay will be used to identify eligible patients who may clinically benefit from the OBI-822 treatment, defined by Globo H expression.
45801433|NCT03562637|Other|Standard of care treatment|Standard of care treatment consisting of observation alone, adjuvant capecitabine or platinum monotherapy over a 100 week period.
45801434|NCT01905241|Device|Anatomic TSA using RTI|Anatomic Total Shoulder Arthroplasty (TSA) will be performed using the SmartBone and Real Time Instrumentation (RTI) to transfer the preoperative plan for glenoid implant positioning to the patient's anatomy.
45801435|NCT01905241|Procedure|Anatomic Total Shoulder Arthroplasty|Anatomic Total Shoulder Arthroplasty will be performed by the two surgeons of the study as their Standard of Care. All procedures associated with the surgery will be the same with the exception of the instrumentation used to place the guide pin for placement of the glenoid implant.
45801436|NCT04903223|Drug|Rosuvastatin 10mg|Rosuvastatin will be administered to all participants on Study Day #2
45801437|NCT04735835|Other|Dietary Intervention|To carry out a dietary intervention using standardized test meals, where the participant's postprandial response to the meal is measured and is used to predict their postprandial responses to other foods, along with input variables including metabolic profile, anthropometry, sleep and exercise.
45801438|NCT01907113|Drug|BI 10773|oral administration
45801439|NCT01907113|Drug|BI 10773|oral administration
45801440|NCT01907113|Drug|BI 10773|oral administration
45651682|NCT05361369|Drug|EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule|Fixed dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine
45801441|NCT01907113|Drug|BI 10773|oral administration
45801442|NCT01907113|Drug|BI 10773|oral administration
45801443|NCT04730921|Device|Left bundle branch area pacing|Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing. In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.
45801444|NCT04730921|Device|Right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. The pacing lead was placed in the apex or septum of right ventricle.
45801445|NCT03535337|Behavioral|CPS|Assessment of participant's medication adherence and barrier problem solving via phone conversation
45801446|NCT03535337|Behavioral|SMS|Participants will receive a text message, which will be an electronic reminder regarding medication adherence. Participants will then text back a confirmatory response.
45801447|NCT01907269|Behavioral|Video-based Intervention|Video clips delivered by DVD and Internet
45801448|NCT00370643|Drug|human regular insulin|
45801449|NCT01908127|Behavioral|tell- show- do|Children came in the operation room. Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed by the dentist for each participant to increase their familiarity with dental procedures. The duration of the appointment was about 20 minutes and constant for all children.
45930898|NCT04029597|Behavioral|Remote Patient Monitoring|Families participating in the study will receive standard medical care as well as the RPMS. The RPMS was developed in collaboration with the University of Mississippi Medical Center (UMMC) Center of Telehealth. Patients enrolled in this open trial of the RPMS will interact with the RPMS system on a daily basis and with UMMC's Center for Telehealth nurse care coordinators and research and clinical staff on an as needed basis. The RPMS will provide patients with include an electronic tablet (i.e., iPad) and the ability to receive data from the patient's weight scale and pedometer. Patients will be asked to wear the pedometer daily to track engagement in physical activity and weigh themselves weekly to track weight during the 3 month period. Educational information specific to pediatric obesity and healthy eating and engagement in physical activity will be presented daily through brief presentations and video clips.
45801450|NCT01908127|Behavioral|film modelling|the children were directed to a quiet and comfort room to watch a film presented by a dental assistant. The film showed that the same procedure consisted of Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed on a 5-years-old child model with a time of 20 minutes. The child in the film was cooperative and was reinforced by a reward at the end of the procedure.
45930899|NCT04028414|Other|Early Weight Bearing|Patients will be instruction to weight bear as tolerated while in a boot.
45930900|NCT04003857|Biological|PNEUMOSTEM®|A single intratracheal administration of PNEUMOSTEM® (1.0 x 10^7 cells/kg)
45930901|NCT04003857|Biological|normal saline|A single intratracheal administration of normal saline
45930902|NCT03984565|Drug|Cannabidiol|Cannabidiol sublingual product formulated in coconut oil
45930903|NCT03984565|Drug|Placebo|Placebo sublingual product formulated in coconut oil
45930904|NCT03982693|Drug|Edetate Disodium|The solution contains up to 3 g of edetate disodium adjusted based on creatinine clearance, 2 g of magnesium chloride, 100 mg of procaine hydrochloride, 2500 U of heparin, 7 g of ascorbate, 2 milliequivalent (mEq) potassium chloride (KCl), 840 mg sodium bicarbonate, 250 mg pantothenic acid, 100 mg of thiamine, 100 mg of pyridoxine, and sterile water to complete 500 mL.
45930905|NCT03982693|Other|Placebo|Placebo infusions consist of 500 ml normal saline.
45651683|NCT05384067|Behavioral|Mindfulness-based intervention|Participants will complete one mindfulness education module every week for 4 weeks, and to practice a 15-minute formal guided mindfulness meditation at least five times per week across the 4 weeks. Participants will also be taught evidence-based sleep improvement techniques, will be provided education for when to use the techniques, and will be encouraged to implement the techniques to improve sleep.
45930906|NCT03977038|Device|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is prescribed as first-line treatment for TRD patients (4). rTMS is safe, tolerable and non-invasive neurostimulation procedure where powerful magnetic pulses are transmitted through the skull into the underlying cortical cortex with the aim of electrical current induction within the neural tissue. This study administers a standard dose of rTMS treatment to the TRD patient sample consisting of high frequency deep TMS (HF-dTMS) stimulation over left dorsolateral prefrontal cortex (L-DLPFC), at the frequency of 18Hz, at 120% value of the individual's motor threshold, in 5 daily sessions per week, taking place each weekday, over the course of 6 weeks. The technology of dTMS, which will be used in this study, is an adaptation of the therapeutic intervention of rTMS with the advancement of possessing higher efficacy in targeting deeper brain regions of interest.
45930907|NCT03974087|Device|Transcranial Direct Current Stimulation (tDCS)|2mA stimulation for 20 minutes
45930908|NCT03973541|Behavioral|Cognitive Behavioral Therapy with Exposure therapy|Treatment will be conducted for 10 consecutive weekly 60 min sessions. In the first two treatment conditions sessions are scheduled as follows: Session one: Building a therapeutic alliance and psycho-education about social anxiety and safety and avoidance behaviors. Session two to four: Cognitive restructuring. Session five to nine: Exposure in either in vivo or VR. Session 10: Relapse prevention. Sessions one to four and ten are identical in the two of three treatment arms.
45930909|NCT03973541|Behavioral|Relaxation Therapy|Relaxation Therapy
45451311|NCT02228278|Other|Group B|"Phase 1: Group B will receive current standard care - clinic visits every three months anthropometric assessments and counseling on physical activity and nutrition goals by a healthcare provider, typically with no patient-provider communication between visits.~Phase 2: Group B will initially act as the control and will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider, and for those prescribed medication for a chronic condition, medication counseling by a healthcare provider) with typically with no patient-provider communication between visits. After a 6-month delay, Group B will then receive the intervention which includes the typical clinic visits as stated previously plus daily text messages in between visits for 3 months to support their health goals."
45451312|NCT00096785|Drug|entecavir|Tablets, Oral, ETV 0.5 mg, once daily, up to 96 weeks
45451313|NCT00096785|Drug|adefovir|Tablets, Oral, ADV 10 mg, once daily, up to 96 weeks
45651684|NCT05020093|Procedure|Injection molding|preheated bilk-fill composite, co-cured universal adhesive, David Clark cavity design
45651685|NCT05020093|Procedure|Incremental packing|Incremental packing of conventional composite; pre-cured universal adhesive, non-beveled cavity design
45801451|NCT01908127|Drug|injection of local anesthesia solution|A topical anesthesia and injection of local anesthesia solution using mandibular alveolar nerve block technique was performed by the dentist
45451314|NCT04070170|Device|Low-level Laser Therapy|Low-level laser therapy is applied on premolars that will be extracted for treatment plan reasons
45651686|NCT05360823|Other|Birth ball|Exercises for childbirth
45651687|NCT05360823|Other|Squatting|Exercises for childbirth
45801452|NCT01908127|Procedure|occlusal cavity preparation|the occlusal cavity was prepared for pulpotomy and restoration of the teeth
45801453|NCT04679831|Dietary Supplement|Ujiplus®|Ujiplus® flour, a nutritional supplement will be used to prepare porridge, and each child will be given a serving of 300 ml every school day for 90 days.
45801454|NCT04679831|Drug|Praziquantel 400mg|400mg of Praziquantel will be given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300 ml per every school day for 90 days,
45801455|NCT02980471|Device|Pulse Oximeter|Blood removal and reintroduction as measured by the plethysmograph of a pulse oximeter
45930910|NCT03965195|Biological|Recombinant Influenza Vaccine|Nursing home residents and staff 18 years and older are allocated to receive quadrivalent recombinant influenza vaccine.
45930911|NCT03965195|Biological|Standard Dose Quadrivalent Influenza Vaccine|Nursing home residents and staff 18 years and older are allocated to receive standard dose quadrivalent influenza vaccine
45930912|NCT03942653|Drug|Goserelin Acetate|Goserelin Acetate, SQ, Q4W
45930913|NCT03942653|Drug|Pembrolizumab|Pembrolizumab, IV, Q3W
45801456|NCT04601831|Radiation|Focal radiation therapy (RT)|"Radiation therapy- 2 dose levels:~Definitive 40-50 Gy EQD2 (i.e. 30 Gy in 5 fractions), or if de-escalation needed,~Palliative 20-32.5 Gy EQD2 (i.e. 20 Gy in 5 fractions)~Hypofractionated regimen (i.e. 5 fractions in 1-2 weeks) recommended, but other fractionation schemes (10-20 fractions in 2-4 weeks) allowed."
45930914|NCT03941262|Biological|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
45930915|NCT03941262|Drug|Avelumab|Avelumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death-ligand 1 (PD-L1).
45930916|NCT03941262|Drug|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death receptor-1 (PD-1).
45930917|NCT03933696|Device|Tailored Lighting Intervention|Lighting Intervention either Active or Placebo
45801457|NCT00371423|Device|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
45930918|NCT03928314|Drug|ORIC-101|ORIC-101 once daily, 5 or 7 days/week, for 21 days of each 28-day cycle
45930919|NCT03928314|Drug|Nab-paclitaxel|75 or 100 mg/m2 Days 1, 8, and 15 of each 28-day cycle
45930920|NCT03924414|Drug|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic acid 5mg/100 ml IV infusion: Zoledronic acid-5 mg (ZA) is an FDA approved therapy for men and postmenopausal women for the treatment and prevention of osteoporosis.
45801458|NCT00371423|Device|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
45930921|NCT03924414|Other|Placebo|Normal Saline 100 ml (placebo) IV infusion
45651688|NCT05017285|Procedure|HoLEP with median lobe preservation|Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum
45930922|NCT03924063|Device|Hemiverse|Implantation of the hemiverse shoulderprothesis
45801459|NCT04882397|Other|Instrument Assisted Soft Tissue Mobilization|Bilateral Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
45930923|NCT03921931|Other|White light stimulation|Stimulation of the retina with white light
45930924|NCT03915548|Behavioral|The Behavioral Activation/ Problem Solving Intervention|The interventionist presents the rationale for BA/PS, promotes a positive problem orientation, and educates about the framework for problem-solving and action planning. The interventionist then administers the Canadian Occupational Performance Measure to elicit participant priorities, motivation, and long-term goals. The interventionist then guides the participant in using the BA/PS framework to set a goal, brainstorm solutions to challenges, and create a detailed action plan for the coming week.
45930925|NCT03915548|Behavioral|Attention Control Condition|The interventionist provides education regarding nine cancer survivorship topics (i.e., healthy diets, physical activity, lymphedema management, smoking cessation, stress management, communication with providers, body image and sexuality, communication with social supports, work accommodations) during the control telephone contacts.
45930926|NCT03878082|Drug|Propacetamol 1g|pain control with IVPCA and propacetamol 1g every 6 hours for 2 days
45930927|NCT03878082|Drug|Propacetamol 2g|pain control with IVPCA and propacetamol 2g every 6 hours for 2 days
45930928|NCT03878082|Drug|IVPCA|pain control with IVPCA
46072944|NCT00732368|Drug|Mometasone furoate|Two sprays mometasone nasal spray per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
45651689|NCT05017285|Procedure|HoLEP classic|Standard HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique).
45651690|NCT05610501|Procedure|Ultrasound guided tru-cut biopsy|Tru-cut biopsies can collect tissue specimens via a needle of 18G A tru-cut biopsy can be performed under the guidance of different imaging modalities including ultrasound
45651691|NCT05008861|Procedure|Capsulized Fecal Microbiota Transplant|Capsules contained washed fecal microbiota.
45651692|NCT05008861|Drug|Anti-programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody|Standard dose of one of anti-PD-1/PD-L1 mAbs administered as a 1 hour infusion every 3 weeks.
45651693|NCT05008861|Drug|Platinum based chemotherapy|Standard dose of Platinum based Chemotherapy every 3 weeks.
45651694|NCT05016739|Device|CADISS|"The CADISS® device was procured from AuXin Surgery. It consists in three elements:~A single use disposable Remote Kit, containing a sterile cartridge, which prepares the Drug Product immediately before use, and the sterile tubing for fluid connexion. The Drug Product is a 30 ml sterile 5% mesna solution of pH 7.3+/-0.5~Reusable stainless steel non-cutting mechanical instruments similar to those used in the normal practice, except for the provision of an internal irrigation channel bringing the Drug Product at the working edge.~A pedal controlled electric motor driving the peristaltic cassette included in the disposable tubing in order to control the dispensing of the Drug Product during the procedure."
45930929|NCT03869853|Behavioral|Entrepreneurial stimulation and integrated education|one month cycle of stimulation of business with integrated education on nutrition, health, and gender empowerment
45930930|NCT03869853|Behavioral|control|no intervention
45930931|NCT03862859|Drug|Warfarin|Dose adjusted Warfarin targeting an international normalized ratio of 2-3.
45930932|NCT03862430|Drug|NanO2TM|0.1 mL/kg (2% w/vol emulsion)
45930933|NCT03862430|Drug|Placebo Saline Infusion|0.1 mL/kg Saline Infusion
45930934|NCT03848689|Other|fluoroquinolone preprescription authorization|Requires authorization from Infection Control consult prior to prescribing fluoroquinolone
45930935|NCT03848689|Other|Control|Does not require authorization from Infection Control prior to prescribing fluoroquinolone
46072945|NCT00704067|Behavioral|Supported employment plus cognitive training|Supported employment for 12 months plus cognitive training for the first 12 weeks
46072946|NCT00704067|Behavioral|Enhanced supported employment|Supported employment for 12 months plus one additional supported employment session per week for the first 12 weeks.
45801460|NCT04882397|Other|Sham|Bilateral sham Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
45801461|NCT01908751|Procedure|Sliding Hip Screw|
45801462|NCT01908751|Procedure|Cancellous Screws|
45801463|NCT01908751|Drug|Vitamin D|
45801464|NCT01908751|Drug|Vitamin D Placebo|
45801465|NCT04873115|Other|Placebo|Sialanar placebo
45801466|NCT04873115|Drug|Sialanar|Sialanar - a licensed glycopyrronium bromide product
45801467|NCT04873115|Other|Oral Rehabilitation|Standard oral rehabilitation for provided drooling
45801468|NCT00370721|Drug|bevacizumab|
46072947|NCT02547571|Drug|High volume PEG split-dose|Colyte® or PegLyte® will be provided to the subject who will be asked to drink 2L of the preparation starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes until completed. The second dose of 2L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes until completed.
45930936|NCT03846310|Drug|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist
45651695|NCT04434235|Other|axial load|With a helmet with Velcro fastener we will add additional weight to produce axial load on the cervical spine
45801469|NCT03459521|Biological|Fendrix or HBVAXPRO 40|To administer hepatitis B virus vaccines in patients with chronic liver disease that have not been previously vaccinated.
45801470|NCT01909141|Drug|induction of ovulation using letrozole-pioglitazone-metformin|induction of ovulation will be done for arm 1 for 3 consecutive cycles unless pregnancy occured.
45801471|NCT01909141|Drug|induction of ovulation using clomiphene citrate-pioglitazone-metformin|induction of ovulation for arm 2 will be done in 3 consecutive cycles unless pregnancy occured.
45801472|NCT01909141|Radiation|transvaginal ultrasound|transvaginal ultrasound will be done starting from day 10 and every 48 hours until finding a follicle of > 18 mm or till day 20 of the cycle
45451315|NCT04070170|Procedure|Orthodontic force|Mechanical loading is applied on premolars that will be extracted for treatment plan reasons and in canines for tooth movement
45451316|NCT02228356|Radiation|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy with either Dynamic Tumor Tracking/Internal Target Volume approach on the Vero machine, and/or Internal Target Volume approach on the Tomotherapy machine.
45651696|NCT05383053|Device|NeuroAI|"NeuroAI is an artificial brain diagnostic software that determines whether to perform amyloid PET tests for Alzheimer's by specialists through the detection of amyloid PET positive rates based on brain MR images (T1 weighted MRI, T2 FLAIR MRI) and clinical information (age, gender, and APOE) genotype.~When using this product, input gender, birth year, and apolipoproteinE (APOE) genotype and upload T1 MR image and T2 Flair image, input data and image analysis result data are integrated to infer the positive rate of amyloid PET by PET positive prediction model. The result report provides image analysis results and amyloid PET positive prediction results compared to normal groups."
45651697|NCT04433923|Device|Phototherapy with aluminum foil|
45651698|NCT04433923|Device|Phototherapy without aluminum foil|
45651699|NCT05360277|Drug|Tislelizumab + Capecitabine|"Tislelizumab 200mg iv every 3 weeks, for 1 year after completion of perioperative chemotherapy.~Capecitabine was given at a dose of 850 mg/m2 twice a day by mouth, 2 weeks on/ 1 week off, for 1 year after completion of perioperative chemotherapy."
45651700|NCT05360277|Other|Best supportive care|Best supportive care
45651701|NCT03091933|Biological|GLIDE|Gudide Lymphocyte by Immunopeptide Derived Expansion (GLIDE) is an anti- Minor histocompatibility (MiHA) cell line
45651702|NCT05016973|Drug|RC48-ADC|2.0mg/kg, Intravenous drip on days 1 every 21 days
45651703|NCT05016973|Drug|Triplizumab|240mg, Intravenous drip on days 1 every 21 days
45651704|NCT05382819|Drug|FRTX-02 Capsule|DYRK-1A Inhibitor
45651705|NCT05382819|Drug|Placebo|Matching Placebo
45801473|NCT01909141|Other|body mass index (BMI) calculation|BMI will be calculated for all women by dividing the weight in kilograms by the height in meters squared
45801474|NCT01909141|Other|day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone|baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) will be done for all women.
45801475|NCT01909141|Other|pretreatment blood urea and serum creatinine|blood urea and serum creatinine will be assayed before stating induction of ovulation to have baseline levels.
45801476|NCT01909141|Other|serum estradiol (E2) on day 12|serum E2 will be assayed on day 12 of the cycle for all women.
45801477|NCT01909141|Other|serum progesterone on day 21|serum progesterone will be assayed on day 21 for all women to monitor ovulation.
45801478|NCT01909141|Other|blood urea and serum creatinine every month|blood urea and serum creatinine will be assayed every month during the treatment period to find out any hazards on kidney functions
45801479|NCT04558229|Other|Additional Standardized Counseling|Research staff will follow a script designed to give unbiased, medically accurate information regarding bleeding changes that may occur with use of a contraceptive ENG implant.
45801480|NCT04515251|Diagnostic Test|Ultrasound measurements|ultrasound measurement at the level of the left renal vein on a sagittal plane according to age
45801481|NCT04486859|Drug|LMWH/Rivaroxaban|combined prevention
45801482|NCT04486859|Device|IPC|mechanical prevention
45801483|NCT01910311|Drug|Baricitinib|Administered orally
45801484|NCT01910311|Drug|Rifampicin|Administered orally
45930937|NCT03846310|Drug|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
45930938|NCT03846310|Drug|Carboplatin|Carboplatin administered as part of standard chemotherapy regimen
45930939|NCT03846310|Drug|Pemetrexed|Pemetrexed administered as part of standard chemotherapy regimen
45930940|NCT03846310|Drug|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 monoclonal antibody
45930941|NCT03831490|Diagnostic Test|history|combining these 4 interventions will great an algorithm predicting preeclampsia
45801485|NCT04404959|Other|fascia iliaca compartment block with ropivacaine|the fascia iliaca compartment block catheter will be placed with the use of ultrasound till the day of surgery. Bolus doses will be given every 12 hours (40 ml of ropivacaine 0.25%)
45801486|NCT04404959|Other|fascia iliaca compartment block with placebo|the fascia iliaca compartment block catheter will be placed with the use of ultrasound till the day of surgery. Bolus doses will be given every 12 hours (40 ml of normal saline)
45801487|NCT05739877|Drug|DA-1229_01 2.5/500mg (Before)|single dose administration (one tablet once a day)
45801488|NCT05739877|Drug|DA-1229_01 2.5/500mg (After)|single dose administration (one tablet once a day)
45801489|NCT05734573|Behavioral|Family-based treatment|FBT is carried out by a family therapist who has received FBT training. The duration of FBT is commonly 6-12 months, in most cases comprising 10-20 sessions. At the beginning of treatment, there are weekly sessions; later in treatment, the sessions are less frequent. The patient and their family meet their psychiatrist every four to six weeks, and the family therapist also takes part in these meetings. The treatment is implemented in accordance with the FBT treatment manual.
45930942|NCT03818737|Biological|Bone Marrow Derived MSCs|Autologous bone marrow concentrate (BMAC) is a standard orthobiologic injection for knee osteoarthritis.The procedure involves harvesting of bone marrow aspirate (BMA) from the posterior superior iliac spine (PSIS) and then following centrifugation in an FDA approved device (EmCyte GenesisCS Pure BMAC®-60 ml) will be injected back into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
45801490|NCT04403711|Other|local anesthetic and dexmedetomidine|in patients allocated to the dexmedetomidine group, ultrasound-guided transversus abdominis plane block will be performed with the combination of local anesthetic and dexmedetomidine
45801491|NCT04403711|Other|local anesthetic and placebo|in patients allocated to the dexmedetomidine group, ultrasound-guided transversus abdominis plane block will be performed with the combination of local anesthetic and normal saline
45801492|NCT01911169|Drug|Cholecalciferol|5,000 International units versus 400 international units as an active comparator
45930943|NCT03818737|Biological|Adipose-derived MSCs|Adipose-derived Stromal Vascular Fraction (SVF) will be obtained from a mini lipoaspirate. The lipoaspirate will then be enzymatically digested to produce a SVF that will be injected into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
45930944|NCT03818737|Biological|Umbilical Cord Tissue (UCT) MSCs|Cryopreserved doses of umbilical cord tissue MSCs will be used. These MSCs were cryopreserved at P2 culture in plasmalyte A + 5% human serum albumin in 5 finger cryobags containing 20 million cells in 4 mL and stored under liquid nitrogen until shipment. Cells will be transported in a dry shipper and thawed at the study sites. The dose of MSCs will be aspirated from the cryobag into a sterile syringe and directly injected into the knee. All injections will be made via ultrasound guidance using a standard approach.
45930945|NCT03818737|Drug|Corticosteroid injection|The corticosteroid injection is prepared by mixing 1cc of 40mg/dL depomedrol and 6cc of normal saline in a 10cc syringe will be made into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
45930946|NCT03814941|Other|paper-based anesthesia record|to evaluate the incidence of artifacts in the AIMS database by paper-based anesthesia record
45930947|NCT03814941|Other|electronic documents|to evaluate the incidence of artifacts in the AIMS database by electronic documents anesthesia record
45930948|NCT03807310|Dietary Supplement|Targeted nutrient supplementation (Long-drink)|Once daily for at least 12 months
45651706|NCT03091855|Other|Questionnaire|Alzheimer's Disease Assessment Scale (ADAS-cog11) and Disability Assessment for Dementia (DAD) Questionnaires
45651707|NCT03091855|Diagnostic Test|Magnetic Resonance Imaging|MRI at baseline and at 24 months post-enrollment for 20 sub-study participants
45651708|NCT05359575|Behavioral|Audio kit|MP3 audio files for each of 6 steps of c-collar application (totaling 1 minute, 19 seconds) and instructional flashcard with seven pictures corresponding to each of the 6 steps of c-collar application
45801493|NCT04403087|Drug|Trimebutine 100 MG|Trimebutine 100mg three times a day
45801494|NCT03374891|Other|Educational video and/or handout|The intervention includes a video and/or handout (whichever is easier for the participant) that will give information about defibrillators and about other patients' experiences with their decisions about defibrillators.
45801495|NCT01911403|Procedure|Manual compression|Closure procedure by Manual compression
45801496|NCT01911403|Device|Angio-Seal|Closure procedure by angio-Seal
45930949|NCT03807310|Dietary Supplement|Placebo supplement|Once daily for at least 12 months
45930950|NCT03807310|Behavioral|Counselling|Counselling on healthy lifestyle (in particular physical activity, smoking cessation) and weight management by motivational interviewing
45930951|NCT03804853|Other|Rehabilitiation|This study will be a non-blinded randomized controlled outcomes study evaluating outcomes at baseline, 2 weeks, 6 weeks, 3 months, 6 months, and 1 year post-operatively from a primary reverse total shoulder arthroplasty with two different post-operative physical rehabilitation protocols. There will be 2 groups, one undergoing the immediate active shoulder physical therapy protocol consisting of four quadrant stretches and full active motion of the shoulder from post op day 1 in the hospital. The second group will follow the traditional TRIA physical therapy protocol consisting of PT (standard of care) followed by a gradual return to active range of motion of the shoulder beginning by week 6, calling for 18 physical therapy visits. The physical therapy will occur where the patient is most comfortable receiving it.
45451317|NCT01326767|Drug|Paclitaxel dosing according to SmPC|Paclitaxel i.V. Up to 6 cycles Dosing according to SmPC
45651709|NCT05359575|Behavioral|Instructional flashcard (version 1)|Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application.
45801497|NCT04387253|Diagnostic Test|Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus|Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus Presence of SARS-COV-2 virus in samples taken from mother and father. Circulating anti-SARS-COV-2 antibodies in the mother.
45801498|NCT04375241|Other|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
45801499|NCT01912495|Drug|Boceprevir|
45801500|NCT04358393|Drug|APG-115|APG-115 given once daily on day 1-5 of every 28 day cycle
45801501|NCT04358393|Drug|5-azacitidine|5-AZA is given at 75 mg/m˄2/d subcutaneously daily on Day 1-7 every 28 days
45930952|NCT03799419|Behavioral|Cognitive bias modification for interpretation bias|Eight sessions of scenario-based CBM-I training for OCD will be administered, based on the widely-used paradigm of ambiguous scenario training developed by Mathews and Mackintosh (2000), in which participants are presented with scenarios that are ambiguous in whether or not they are threatening. Participants will complete a computer task consisting of a series of written scenarios designed to improve interpretation and attributional biases; these scenarios conclude with word fragments, which participants must fill in to resolve the ambiguity.
45930953|NCT03799419|Behavioral|Psychoeducation|Eight sessions of psychoeducation will be administered, which will describe symptoms of anxiety, the nature of biased thinking in anxiety, and summarize common psychosocial as well as pharmacological treatments for anxiety. The sessions will provide relevant information but will not provide training in changing thinking styles.
45651710|NCT05359575|Behavioral|In-person training|10 minute of an LFR spinal immobilization course (extracted from the current LFR Level 1 trauma course).
45930954|NCT03799419|Behavioral|Approach avoidance training|Eight sessions of this computerized training program will be used to train approach tendencies, following previously validated procedures (Najmi, Kuckertz, & Amir, 2010). During the training program, participants will view a series of these images and be prompted to push or pull a joystick according to prompts on the screen, instead of the content of the picture. Avoidance will be stimulated through both pushing away (images on the screen will decrease in size upon the joystick being pushed), and approach will be stimulated through pulling towards pictures (images will increase in size to simulate approach).
45930955|NCT03799419|Behavioral|Inactive sham approach avoidance training|Eight sessions of the approach avoidance training will be administered, however the percentage of push vs pull trials will be altered in this sham version of the training.
45930956|NCT03793673|Behavioral|CoYoT1 Care|Selected providers will be trained in the CoYoT1 Care protocol for completing medical appointments (both telehealth/standard appointments). There are three key components: (1) Shared decision making: Providers and YA will mutually agree on priorities for each medical visit using a shared decision making tool completed by both the provider and patient. (2) Autonomy supportive care: Providers will be trained in communication strategies, such as motivational interviewing, designed to support YA autonomy and intrinsic motivation. YA will also direct extent of eligible family involvement. (3) Goal setting and action planning: Providers will be trained to coach YA in setting SMART goals, developing action plans, and establishing a plan for follow-up between visits as appropriate.
45930957|NCT03793673|Other|Standard Care|"Providers selected for the Standard Care group will complete medical appointments in their usual manner, without specific training or guidelines regarding how to deliver care.~NOTE: Per COVID-19 hospital policies, current clinic appointments consist of telehealth appointments."
45930958|NCT03779009|Other|ICG-nanocoll (indocyanine green coupled to the human albumin colloidal particle nanocoll)|Under laparoscopic control, 2.0 ml of ICG-nanocoll will be injected into the subserosa at four quadrants around the tumor. Directly after injection, near infrared (NIR) fluorescence images (Olympus, Tokyo, Japan) will be acquired. SLNs will be identified and marked.
45651711|NCT05359575|Behavioral|Instructional flashcard (version 2)|Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application edited for clarity based on initial pilot feedback.
45651712|NCT03091699|Drug|Nicotine|Participants will be required to smoke a cigarette to completion in a 20 minute time frame.
45651713|NCT03091699|Behavioral|Moderate Intensity Exercise|Participants will be required to perform 20 minutes of acute moderate intensity exercise (brisk walk) on a treadmill.
45651714|NCT05610423|Other|no intervention|No intervention. Observational study only
45651715|NCT05016115|Behavioral|survey|The Turkish reworded student version of the Jefferson scale of physician empathy was used. Empathy scores were compared related to study years and gender.
45451318|NCT01326767|Drug|Individualized pharmacokinetically driven paclitaxel dosing|Paclitaxel i.V. Up to 6 cycles Dosing based on patient age, gender, severity of neutropenia and Paclitaxel plasma concentration
45451319|NCT02228434|Behavioral|Monitoring and Tailored prescription|
45451320|NCT02228434|Behavioral|Happy 10 program|
45451321|NCT02228434|Behavioral|Specified nutrition education|
45451322|NCT02228434|Behavioral|General Health Education|
45451323|NCT03963479|Combination Product|Magnesium and Vitamin B6|Magnesium and Vitamin B6 will be given to the enrolled patients for 3 months
45651716|NCT05344209|Biological|UV1|UV1 vaccine
45651717|NCT05344209|Drug|Sagramostim|for stimulation of local dendritic cell population to take up the vaccine and to mature into professional APCs
45651718|NCT05344209|Drug|Anti-PD-1/PD-L1 treatment|either pembrolizumab, atezolizumab or cemiplimab
45651719|NCT03091543|Drug|Madopar® HBS 125|1 capsule of Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) in an open label manner, concomitantly with BIA 6-512/Placebo.
45651720|NCT03091543|Drug|Placebo|2 capsules of placebo
45651721|NCT03091543|Drug|BIA 6-512 25 mg dose|1 capsule of 25 mg plus 1 capsule of placebo
45651722|NCT03091543|Drug|BIA 6-512 50 mg dose|2 capsules of 25 mg
45651723|NCT03091543|Drug|BIA 6-512 100 mg dose|1 capsule of 100 mg plus 1 capsule of placebo
45651724|NCT03091543|Drug|BIA 6-512 200 mg dose|2 capsules of 100 mg
45651725|NCT04253457|Drug|1ml of triamcinolone (40mg/1ml)|Single injection of 1ml of triamcinolone (40mg/1ml)
45801502|NCT05739799|Procedure|IPL|Patients in Group A received intense pulse light (IPL) frequency of 690. A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by patients' were recorded.
46072948|NCT02547571|Drug|Low volume PEG split-dose|Bi-PegLyte® will be provided to the subject who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure. After the first bowel movement, or if there is no bowel movement within 6 hours of taking the Bisacodyl tablets, the subject will be asked to drink 1L of the solution at a rate of 240 mL every 10 minutes until the solution is completed. The second dose of 1L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes. Use of antacids will not be permitted within one hour of taking bisacodyl.
46072949|NCT02547571|Drug|High volume PEG non split, day before|Colyte® or PegLyte® will be provided to the subject who will be asked to drink 4L of preparation starting at 6:00 PM the day before the procedure, at a rate of 240 mL every 10 minutes until completed.
46072950|NCT02547571|Drug|Low volume PEG non split, same day|Bi-PegLyte® will be provided to the subject, who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure and will drink 2L of preparation the morning of the colonoscopy starting 4 hours prior to the procedure at a rate of 240 mL every 10 minutes, until completed. Use of antacids will not be permitted within one hour of taking Bisacodyl.
46072951|NCT02547571|Other|Clear liquid diet|
46072952|NCT02547571|Other|Low residue diet|
46072953|NCT02547571|Other|Early colonoscopy (stratified)|"Early appointments: 7:30 AM to 10h30 AM"
46072954|NCT02547571|Other|Later colonoscopy (stratified)|"Later appointments: 10:30 AM to 4:30 PM."
46072955|NCT00704145|Device|Taxus Libertè™ paclitaxel drug-eluting stent|device:Taxus Libertè™ (Boston Scientific,Natick,MS)assessed at different time points after implant
46072956|NCT03508232|Drug|Placebo|Patients will receive placebo in a loading dose of two capsules initially followed by one capsule every 12 hours for 7 days.
46072957|NCT03508232|Drug|Doxycycline Hyclate|Patients will receive doxycycline hyclate in a loading dose of two 100 mg capsules (200 mg total) initially followed by one 100 mg capsule every 12 hours for 7 days.
46072958|NCT00704223|Drug|biphasic insulin aspart|Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation
46072959|NCT00704301|Drug|Rivastigmine|Rivastigmine, two times 1,5 mg a day. The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.
45451324|NCT02228512|Drug|Pomalidomide|Part A: 5 mg po daily for 21 days (full course) Part A: 5 mg po daily for 4 days (short course) Part B: 5 mg po daily for 5 days (Phase I/II dose) Part C: Phase I/II dose) po daily Day 1-21 of 28 day cycle for up to 12 cycles.
46072960|NCT00704301|Drug|Placebo|Placebo, 2 times a day
45451325|NCT02228512|Drug|Rituximab|Part A: 375 mg/m2 day 22 (full course) Part A: 375 mg/m2 day 5 (short course) Part A: 375 mg/m2 day 1 (omit pomalidomode) Part B: 375 mg/m2 day 1
45451326|NCT02228512|Drug|Prednisone|Part B: 60 mg/m2/day po x 5 days (day 1-5
45451327|NCT02228512|Drug|Etoposide|Part B: 50 mg/m2/day CIVI over 24 hrs x 4 days
45451328|NCT02228512|Drug|Doxorubicin|Part B: 10 mg/m2/day CIVI over 24 hrs x 4 days
45801503|NCT05739799|Procedure|Diode|patients in Group B received diode laser treatment system. Diode laser was employed using triple wavelength (1064, 810 and 755 mm). A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by the patients were recorded.
45801504|NCT04354727|Drug|APG-1252|infusion once weekly
45801505|NCT04354727|Drug|Ruxolitinib|taken orally twice a day
45801506|NCT05739721|Behavioral|Attractiveness|Visual attractiveness scale 0-7
45801507|NCT05739721|Behavioral|Self-Esteem|Self Esteem scale
45801508|NCT05739721|Behavioral|Trustworthiness|Trustworthiness scale 0-7
45801509|NCT05739643|Biological|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
45801510|NCT04330859|Other|NeoRehab Bundle|The NICU rehabilitation program includes six multimodal, GA appropriate, parent-administered interventions (vocal soothing, scent exchange, comforting touch, kangaroo care, infant massage and physical therapy)
45801511|NCT04330859|Other|Routine care|Routine NICU care including talking, touching and holding the participant per unit guideline as well as physical therapy, occupational therapy, and speech therapy per unit guideline
45801512|NCT04748887|Other|oxidative stess markers|markers of oxidative stress , Superoxide Dismutase (SOD) and Malondialdehyde (MDA) by ( ELISA Kit SinoGeneClon Biotech Co.,Ltd Catalog No : SG- 10188) .
45801513|NCT04748575|Dietary Supplement|Acai smoothie|Smoothie containing 150g acai pulp
45801514|NCT04748575|Dietary Supplement|Placebo smoothie|Control smoothie matched nutritionally (macronutrients) and sensorially to the acai smoothie.
45801515|NCT05739487|Procedure|selective intra-arterial thrombolysis|IAT introduces rt-PA (50mg) directly into the ophthalmic circulation by super-selective microcatheterization
45801516|NCT04785443|Drug|ICG|"During thyroidectomy surgery, the patient will received 2 or 3 injections of 5 mg as a bolus. The first one during the dissection of the first lobe, then during the dissection of the second lobe and finally if needed, a 3rd injection will be done at the end of the dissection.~Patients will then be followed during 6 months."
45801517|NCT04785443|Procedure|Control group|"During thyroidectomy surgery, patients are treated according to traditional surgery with detection of parathyroids with the naked eyes.~Patients will then be followed during 6 months."
45801518|NCT01916629|Drug|Photocil for Psoriasis|Photocil for Psoriasis
45801519|NCT01916629|Other|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
45801520|NCT01916941|Drug|Prazosin|
45801521|NCT01916941|Drug|Placebo|
45801522|NCT02987413|Biological|Autologous Mesenchymal stem cells (MSCs)|2 intrathecal autologous MSCs infusions (1x10^8 cells) will be performed, escalated from 30 days apart
45801523|NCT01918189|Behavioral|behavioral pain self-management intervention Pain EASE|10 modules describing behavioral and cognitive pain coping skills such as relaxation and stress reduction methods, exercise and structured physical activity, and activity pacing
45801524|NCT04780685|Biological|hMSC|IV administration
46072961|NCT03618446|Other|The presence of a pelvic fracture|
45801525|NCT04778501|Device|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
45801526|NCT05739409|Biological|LILRB4 STAR-T cells injection|The study population was relapsed/refractory acute myeloid leukemia and chronic myelomonocytic leukemia.Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#6E6#1E7 cells/kg
46072962|NCT00837499|Behavioral|Questionnaire|Interview and survey during visit or by phone, 30 - 40 minutes.
46072963|NCT00831103|Drug|EPB-348|Treated over seven days
45801527|NCT05739331|Device|machine learning algorithm|Machine learning algorithm run on EBUS images for real-time labelling of mediastinal lymph nodes and lymph node level
45801528|NCT04776239|Drug|100 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
45801529|NCT04776239|Other|Placebo|Placebo delivered via peripheral intravenous infusion
46072964|NCT00831103|Drug|Valacyclovir|Treated over seven days
45451329|NCT02228512|Drug|Vincristine|Part B: 0.4 mg/m2/day CIVI over 24 hrs x 4 days
45451330|NCT02228512|Drug|Cyclophosphamide|Part B: 750 mg/m2 Day 5
45451331|NCT03963245|Behavioral|Meaningful Activities and Recovery|"MA&R is a new rehabilitation program for people with psychiatric disabilities. MA&R aims to enable participation in everyday activities that are meaningful to the individual.~MA&R is based on occupational science, and the underlying premise that there is a connection between mental health, recovery and meaningful everyday activities. The goal of MA&R is that participants through the course become better at connecting daily activities with values, interests, plans and goals. When this connection is strengthened, it supports the experience of meaningfulness in everyday life.~MA&R is led by two mentors where one mentor is an occupational therapist (or similar) and the other has lived experiences of mental vulnerability and recovery."
45451332|NCT03963245|Behavioral|Standard Care and Treatment|"For community mental health centres: medicine, psychoeducation, relational support, peer-support, psychotherapy, social counselling, care manager~For psychiatric rehabilitation services in Copenhagen, Odense and Svendborg: drop in centres, relational support, skills training, peer-support"
45451333|NCT01082627|Drug|Somatostatin|250ug/h,Continuous I.V. infusion,maximal 14 days
45801530|NCT05732701|Other|Algorithm-guided DAPT duration|"PRECISE-DAPT score ≥25~Chronic Coronary Syndromes (CCS): DAPT with clopidogrel is discontinued at 1 month. Aspirin is continued until 1 year post randomization.~Acute Coronary Syndromes (ACS): DAPT with clopidogrel is discontinued at 3 months. Aspirin is continued until 1 year post randomization.~PRECISE-DAPT score <25:~Non-complex PCI: DAPT with clopidogrel is discontinued at 6 months post randomization. Aspirin is continued until 1 year post randomization.~Complex PCI: DAPT with clopidogrel, prasugrel or ticagrelor is continued until 1 year post randomization.~ACS: DAPT with prasugrel or ticagrelor is continued until 1 year post randomization."
45801531|NCT05732701|Other|Standard-of-care DAPT duration|DAPT strategy at the operators´ discretion in accordance with applicable guidelines
45801532|NCT04768985|Drug|Treatment A: Acalabrutinib tablet|Participants will receive fixed single doses of acalabrutinib tablet in 2 treatment periods, under fasted conditions.
45801533|NCT04768985|Drug|Treatment B: Acalabrutinib capsule|Participants will receive fixed single doses of acalabrutinib capsule in 2 treatment periods, under fasted conditions.
45801534|NCT05739253|Procedure|Transcatheter aortic valve replacement|All patients undergo transfemoral transcatheter aortic valve replacement for aortic stenosis
45801535|NCT04210037|Drug|APG-1252|APG-1252 (Ascentage Pharma) is a highly potent Bcl-2 family protein inhibitor with high binding affinity for Bcl-2, Bcl-xL and Bcl-w. APG-1252 possesses strong antitumor activity as a single-agent against tumor cells addicted to Bcl-2/Bcl-xL, and exhibits a much broader antitumor activity when combined with chemotherapeutic agents.
45801536|NCT04210037|Drug|Paclitaxel|80 mg/m˄2 on days 1 and 8 of a 21-day cycle
45801537|NCT05739175|Device|Mobile Application with Interactive Nurse Support|"A mobile application containing an interactive nurse support program will be applied to the patients in the experimental group and its effect on patient outcomes will be evaluated through scales.~The mobile application consists of three modules. The first part is a learning module with videos on Covid 19, breast cancer and chemotherapy related side effects management. Second part is ask the nurse/doctor. Third part is patient experiences module.~After the participants download the mobile application to their phones, they can log in to the application with a valid e-mail address and password."
45801538|NCT05739097|Diagnostic Test|iron deficiency, coagulation abnormalities|avoid transfusions, where possible
45801539|NCT01923805|Device|Vitagel|Vitagel
45801540|NCT04167605|Other|Bone metastasis|Collection of waste tissue samples during surgery and immediate immersion of the same in 10% Neutral buffered formalin. The samples will be send to the laboratory where they will be processed (decalcification, inclusion in paraffin, sectioning etc.) for subsequent analyzes.
45801541|NCT04167605|Other|Breast cancer metastatic to bone|Patients will be assisted in the recovery of samples (slides) related to surgery on primary tumor (breast cancer responsible for metastatic disease).
45801542|NCT01923961|Procedure|HDF NaCl|
45801543|NCT01923961|Procedure|Hemodialysis|
45801544|NCT01923961|Procedure|Standard Predilution Hemodiafiltration|
45801545|NCT04116281|Other|Rehabilitation after breast cancer surgery|All participants are going to receive physical therapy intervention after breast cancer surgery at least removal drenaige. After that, will be randomized in two groups: Group 1 are going to receive a physical therapy program supervised by a physiotherapist; Group 2 are going to receive some instructions about the same program to perfomr at home without supervision. Both groups are going to receive 3 and 6 months of rehabilitation program.
45801546|NCT04750733|Other|Assessment|Assessment of core strength and endurance, muscle strength, postural sway in different condition, physical capacity and fatigue
45801547|NCT03273023|Device|Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System|Promus PREMIERTM Stent System
45801548|NCT01924975|Procedure|Saphenous vein cannulation|Intravenous cannulation to saphenous vein
46072965|NCT00704444|Drug|Ezetimibe|Ezetimibe, 10-mg tablets
46072966|NCT00704444|Drug|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets + other lipid-lowering medication(s), as prescribed by attending physician
45451334|NCT01082627|Other|common daily practice|common daily practice
45801549|NCT01924975|Device|ultrasound with a linear transducer (L15-7io)|Portable, bed-side ultrasound to detect saphenous vein
45801550|NCT01924975|Device|A 22 or 24 G intravenous catheter|
45801551|NCT00371501|Drug|Rosuvastatin|10mg/day
45451335|NCT03515044|Drug|40 mg Rifaximin SSD once daily|SSD once daily (QD)
45451336|NCT03515044|Drug|40 mg Rifaximin SSD twice daily|SSD twice daily (BID)
45801552|NCT00371501|Drug|placebo|one tablet/day
45801553|NCT00371501|Drug|aspirin|80mg/day
45801554|NCT00371501|Drug|placebo|placebo
45651726|NCT05380947|Drug|BI 1810631 - trial formulation 1 (TF1)|BI 1810631 - trial formulation 1 (TF1)
45801555|NCT05730595|Procedure|lymph node dissection|The extent of lymph node dissection varies between groups
45801556|NCT03251651|Drug|Propofol|Propofol is infused continuously via the target-controlled infusion device (Orchestra®, Fresenius vial, Brezins, France), and the effect-site concentration is maintained within 0.5-2.0 μg/ml.
45801557|NCT03251651|Drug|Dexmedetomidine|Dexmedetomidine is diluted with 0.9% saline to make a concentration of 4 μg/ml. As a loading dose, 1 μg/kg dexmedetomidine is administered over a 10-min period, which is then administered continuously at 0.1-0.5 μg/kg/h.
45801558|NCT01925677|Device|da Vinci® Single-Site™|Planned single-incision laparoscopic nephrectomy performed with the assistance of the Da Vinci Robotic Surgical System.
45801559|NCT05349461|Procedure|Complete patellofemoral articular contact|The patellofemoral condition is in constant contact with the femoral trochlea when the knee is bent from 30 to 90 degrees during the No thumb test.
45801560|NCT05349461|Procedure|Incomplete patellofemoral articular contact|The patellofemoral condition is in no constant contact with the femoral trochlea when the knee is bent from 30 to 90 degrees during the No thumb test.
45801561|NCT05738863|Device|Low Frequency rTMS Protocol|"It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex 5 days a week for 3 weeks, for a total of 15 sessions.~rTMS application Magventure MagPro R30 device is planned to provide magnetic stimulation with its stimulator. The stimulation pattern was shaped according to the protocols used in previous studies.~All patients were planned to continue the neurological rehabilitation program throughout the study.~Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment they are using and the drugs started for incontinence at the same effective dose, and no new incontinence medication will be started and the dose will not be changed during the rTMS sessions."
45801562|NCT05738863|Device|Sham rTMS Protocol|"It was planned to apply the recorded beat sound to the primary motor cortex area daily 5 days a week for 3 weeks, for a total of 15 sessions by turning the TMS coil with the reverse side and in a 90-angle upright position.~All patients were planned to continue the neurological rehabilitation program throughout the study.~Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment they are using and the drugs started for incontinence at the same effective dose, and no new incontinence medication will be started and the dose will not be changed during the rTMS sessions."
45801563|NCT04048421|Procedure|hvNOTES radical colectomy|With the patient under general anesthesia, pneumoperitoneum is achieved. Three trocars are inserted, one 12 mm or 5 mm in the umbilicus and two 5 mm in the right and/or left flanks. Mobilization of the splenic flexure or the hepatic flexure is performed with an initial traditional laparoscopic approach. A single-port is inserted into the abdominal cavity transvaginally through the colpotomy. Then most of the procedures are performed transvaginally with conventional rigid laparoscopic instruments. The corresponding arteries and veins are divided. The mesocolon is mobilized. The small intestine/colon/rectum are then divided with stapler. The specimen is removed transvaginally. Intracorporeal anastomosis is performed as per the surgeon's standard of care. For sigmoidectomy, the colon is then exteriorized and the anvil is fixed in the colon. An end-to-end anastomosis is performed using a circular stapler. Drainage tubes may be used.
45451337|NCT03515044|Drug|80 mg Rifaximin SSD once daily|SSD once daily (QD)
45451338|NCT03515044|Drug|80 mg Rifaximin SSD twice daily|SSD twice daily (BID)
45451339|NCT03515044|Drug|Placebo|Administered twice daily (BID)
45451340|NCT01082705|Drug|artemether-lumefantrine|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more
45651727|NCT05380947|Drug|BI 1810631 - new formulation (NF)|BI 1810631 - new formulation (NF)
45651728|NCT05380947|Drug|Rabeprazole sodium|Rabeprazole sodium
45651729|NCT05008471|Dietary Supplement|Formula nutrition|The target energy of radiotherapy patients is recommended to be 25-30kcal/(kg·d), and the target energy of the intervention group should be increased by an additional 50% daily from the beginning of radiotherapy. Specifically, under the condition of ensuring the daily target energy 14kcal/(kg·d), formula nutrition should be added daily.
45801564|NCT04023461|Device|PVAC GOLD catheter ablation|Isolation of pulmonary veins using PVAC GOLD catheter.
45801565|NCT03917927|Device|Eztetic dental implant|narrow diameter dental implant
45801566|NCT02287675|Drug|Lymphoseek|Subjects will receive a single intradermal injection of Lymphoseek followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. Lymphoseek positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
45651730|NCT05342727|Device|transcranial direct current stimulation (tDCS)|In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
45651731|NCT05342727|Device|transcranial alternating current stimulation (tACS)|In tACS, alternating electrical currents at the frequency of interest (8 Hz for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
45651732|NCT05357781|Diagnostic Test|Laboratory test|Frequency of fatigue (defined as Fatigue Scala for Motor and Cognitive Function (FSMC) total ≥ 43 points) in MS patients with IgG-deficiency
45801567|NCT02287675|Drug|Sulfur Colloid|Subjects will receive a single intradermal injection of 99mTc-SC followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. 99mTc-SC positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
45801568|NCT02973893|Biological|Placebo|Placebo
45930959|NCT03760731|Behavioral|Acceptance and Commitment Therapy for Moral Injury (ACT-MI)|Acceptance and Commitment Therapy for Moral Injury (ACT-MI) is a novel treatment protocol detailing the application of ACT for recovery from moral injury. ACT-MI is designed to help Veterans learn to interact differently with moral emotions and engage meaningfully in their lives. The intervention is group-based and spans twelve, 90-minute sessions. The current ACT-MI protocol was developed through an iterative process in which authors generated and refined the intervention based on clinical interactions with Veterans currently reporting moral injury.
45801569|NCT02973893|Biological|VF001-DP LD|VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
45801570|NCT02973893|Biological|VF001-DP HD|VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
45651733|NCT03088969|Other|questionnaire RTWSE|The evaluation of the self-efficiency perceived of return in the work of the patients by a validated auto-questionnaire is thus an additional objective parameter determining the risk factors of unfavorable evolution of the patients with Low Back Pain. This parameter also allows highlight other levers of actions in the therapeutic education.
45651734|NCT05008315|Other|Myofascial abdominal diaphragm release|Myofascial abdominal diaphragm release
45801571|NCT05738707|Biological|Recombinant protein vaccine and adenovirus vector vaccine|Administer recombinant protein vaccine and adenovirus vector vaccine
45801572|NCT05349305|Drug|continuous renal replacement therapy|continuous renal replacement therapy
45801573|NCT05738629|Drug|Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by PSC-MSC-Exo eye drops 0.125 ml/single eye/one time, four times a day for 12 weeks. The follow-up visit will be 12 weeks since the administration of PSC-MSC-Exo eye drops.
45801574|NCT05349149|Drug|Tocilizumab/Actemra® (Roche)|The infusion of tocilizumab will antagonize IL-6 signaling for the duration of the study, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
45801575|NCT05349149|Drug|Saline 9%|The infusion of saline will serve as placebo for tocilizumab, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
45801576|NCT05738551|Other|stress ball|Applicable to group 1
45801577|NCT05738551|Other|chewing gum|Applicable to group 2
45801578|NCT04337645|Procedure|surgical treatment of peri-implantitis|resective surgical treatment of peri-implantitis
45801579|NCT01928797|Device|Cardiac output monitor data|The availability of cardiac output monitor provides additional hemodynamic indices that may help guide anesthesiologists to better select vasopressors
45801580|NCT03702413|Procedure|Endovascular treatment|Acute thrombectomy
45801581|NCT04338035|Behavioral|Expectant management|Patients did not undergo surgical treatment for endometriosis and medical consultations were done every 6 months from the beginning of the attempts to conceive
45801582|NCT05726617|Behavioral|Avatar Intervention|8 weekly sessions of 60 minutes.
45801583|NCT05349071|Drug|methylprednisolone|a single preoperative dose of 500 mg of methylprednisolone diluted in 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
45801584|NCT05349071|Drug|physiological saline|a single preoperative dose of 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
45801585|NCT01929889|Drug|Iloperidone|Patients in this study will be treated with Fanapt® (iloperidone). They will begin a standardized up-titration starting with a dose of 2 mg daily. Dose increases will continue until the subject has achieved clinical stability, has achieved the maximum dose of 24 mg/day, or until 8 weeks have elapsed. Once clinical stability has been achieved, the patient will continue into the treatment phase. If clinical stability is not achieved after 8 weeks, the patient will be excluded from the study.
45801586|NCT05738473|Drug|antibiotic|For pregnant women with GBS colonization, antibiotics are used to prevent infection
45801587|NCT04335461|Procedure|Cephalomedullary nailing of extracapsular hip fracture|All patients will undergo cephalomedullary nailing of their extracapsular hip fractures. Both short and long nails will be used based on fracture morphology.
45801588|NCT04335461|Device|cephalomedullary nail|Implants to be used will be variable, but include Stryker Gamma, Synthes Trochanteric Fixation Nail, Smith and Nephew Intertan.
45801589|NCT04335461|Drug|Regional Anesthetics|Marcaine 0.25% will be administered for the two experimental arms, as described in above protocol.
46072967|NCT02611791|Device|Radiofrequency|The application of RF was through Tecatherap-VIP unit (VIP-Eletromedicina, Argentina) with bipolar method, using a gauntlet of 2cm, and the coupling electrode, which was located in the sacral region (fig x). For the application, participants were placed in a supine position with legs in lithotomy position, it was used water soluble gel for coupling and slide of the gauntlet. The application in external labia majora was made in the caudal-cranial direction, with constant movement and electrode lightly pressed. (fig) During the session, the heat level was monitored verbally and by infrared digital thermometer. The intensity was gradually increased, and at the time when the temperature reached values between 39-41ºC, the intensity was reduced two points and the procedure was maintained for two minutes.
46072968|NCT02611791|Device|Radiofrequency - OFF|The treatment protocol for the control group was identical, differing only in relation to the RF equipment, which was turned off, but a water-soluble gel was used, heated by a resistor, preventing the patient from knowing to which group she belonged. Just the physiotherapist who performed the procedure knew which group the patient belonged to.
46072969|NCT05335382|Behavioral|Brief Interventions (BI)|'Brief Interventions' (BI) is a multitude of interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. The interventions within BI often have their foundation in CBT, ACT or Motivational Interviewing (MI), however interventions from other schools of therapy can also be used. The common theme is that they are principle-based rather than manual-based and focus on behavioural change in relation to a problem, rather than focusing on a specific diagnosis. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. A BI treatment usually consists of 1-4 appointments with several weeks apart and has an open ending, where the patient easily can schedule a new appointment. Clinicians delivering brief interventions will have had 3 days of training as well as regular supervision.
46072970|NCT05335382|Behavioral|Care As Usual (CAU)|Care As Usual includes the PCC's current routine care for patients with mental and behavioral problems. This can include a multitude of procedures and treatment, such as pharmacological treatment, supportive care, cognitive behavioural therapy (CBT) and psychodynamic therapy of varying lengths. Interviews with patients as well as medical journals will be used to categorise what type of care each individual patient has received.
45801590|NCT05738395|Diagnostic Test|Questions|Questions
46072971|NCT00704691|Drug|Lenalidomide|Lenalidomide 25 mg as a daily oral dose days 1-21 followed by a 7 day rest period (28 day cycle) for 1-6 cycles
46072972|NCT02842346|Other|ultrasonography|
46072973|NCT00704925|Drug|3, 4 DAP|Patients with clinically-confirmed LEMS will receive 3, 4 DAP by mouth in slowly increasing doses. Treatment will begin with 5 mg three times a day and will increase by 50% every two weeks to 10-15 mg three to six times a day, as clinically needed, and if tolerated.
46072974|NCT02842190|Device|NIPPV|after ekstubation
46072975|NCT00574249|Biological|adalimumab|subcutaneous injection using prefilled pen/syringe, solution containing 40 mg in 0.8 milliliters; 2 injections given at Baseline (Day 1) then once every other week from Weeks 1 though 15
45801591|NCT03452033|Drug|H-1337 Placebo|H-1337 Placebo Vehicle
46072976|NCT00574249|Drug|Calcipotriol/Betamethasone Ointment|Topical ointment (calcipotriol 50 mcg/g and betamethasone 500 mcg/g) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
46072977|NCT00574249|Drug|placebo (vehicle ointment)|Topical vehicle ointment (matching active calcipotriol/betamethasone ointment) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
45451341|NCT01082705|Drug|Dihydroartemisinin-piperaquine|once daily for 3 days as tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a total dosage of 6.4 mg/kg of dihydroartemisinin and 51.2 mg/kg of piperaquine divided equally between the three days
45451342|NCT01582997|Drug|GSK2118436|Dose escalation with GSK2118436 may proceed until the overseas recommended phase III dose.
45451343|NCT02228746|Dietary Supplement|Alpha-galacto-oligosaccharides|6g of alpha-galacto-oligosaccharides in a 100 mL flavored drink
45451344|NCT01090349|Device|Implantation of an ICD/CRT-D device|The Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT-D) device and leads are not the devices being evaluated in this investigation.
45451345|NCT01090349|Device|Merlin.NET PCN|The Merlin.Net™ PCN is a dedicated computer system that connects physicians to patients outside of the clinic setting by centralizing data from remote transmissions, implant procedures and in-clinic follow-ups into single location with easy export to Electronic Health Record (EHR) systems
45451346|NCT01090505|Drug|Drug: S-1 and oxaliplatin|Drug:S-1:80mg/m2;oxaliplatin 130mg/m2
45801592|NCT03452033|Drug|H-1337 [1]|H-1337 Ophthalmic Solution Concentration 1
45801593|NCT03452033|Drug|H-1337 [2]|H-1337 Ophthalmic Solution Concentration 2
45801594|NCT03452033|Drug|H-1337 [3]|H-1337 Ophthalmic Solution Concentration 3
45651735|NCT05008315|Other|Direct focused scar release technique|Direct focused scar release technique
45651736|NCT05008315|Other|Direct manipulations to visceral structures|Direct manipulations to visceral structures
45651737|NCT05008315|Other|pelvic anatomy education|pelvic anatomy education
45651738|NCT05008315|Other|sham|sham
45651739|NCT02525133|Drug|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
45651740|NCT02525133|Other|Placebo|Plain collagen implant (vehicle)
45651741|NCT05356299|Other|Magnetictape bandage application|The Magnetic Tape bandage will be placed by the patient's care team and will be placed in the anterior superior part of each hemithorax, matching the large vessels and lymph nodes, in the posterior part of the thorax in the paravertebral area from C3 to T9 and in the subcostal region, following the direct innervation of the thorax and shoulder girdle, as well as the dorsal levels with lateral horns that control the vascularisation of the thorax and shoulder girdle.
45801595|NCT05725135|Drug|Propofol|Propofol total intravenous anesthesia (TIVA) will be used for induction and maintenance of anesthesia. Propofol will be delivered using automated closed-loop anesthesia delivery system.
45801596|NCT05718271|Other|Explicit instructions before extinction|"Shocks will no longer be administered during the next phase."
45801597|NCT05718271|Other|Explicit instructions after extinction|"Tomorrow no shocks will be administered."
46072978|NCT00891228|Drug|Testosterone|Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.
45801598|NCT05738317|Drug|Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel|Adebrelimab is recommended to be administered with an infusion pump. The infusion pipeline is equipped with a 0.22-micron online filter membrane. Intravenous injection or bolus injection is not allowed. At the end of infusion, flush the infusion tube with sufficient 5% glucose or physiological saline, and do not share the same infusion tube with other drugs. In each treatment cycle, Adebrelimab should be given intravenously first.
45801599|NCT02284555|Drug|Mupirocin|Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.
45801600|NCT02987179|Other|Observational|Collect anthropomorphic, WatchPAT, Crit-line Monitor measurements as well as sleep questionnaires and video records
45801601|NCT02753699|Drug|Alisporivir|Intervention of interest; follow-up after ALV-active study
45801602|NCT04335617|Drug|MMPF (Micronized purified Flavonoid-Fraction)|500mg film-coated tablet, oral route, tablets should be taken at meal times. 4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily, one at midday and one in the evening
45801603|NCT04335617|Other|Placebo|4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily
45801604|NCT05717413|Device|metatarsophalangeal joint endoprosthesis|arthroplasty of 1 metatarsophalangeal joint
45801605|NCT05736601|Device|focus motion knee brace|knee brace that captures knee motion
45801606|NCT03269981|Radiation|Whole breast irradiation|Radiotherapy to the whole breast alone.
45801607|NCT03269981|Radiation|Whole breast and nodal irradiation|Radiotherapy to the whole breast and regional lymph nodes.
45801608|NCT03133247|Drug|SHR-1316|PD-L1
45801609|NCT03029689|Drug|Raltegravir|Raltegravir 1200 mg (2 tablets x 600mg) once daily plus current ART during 48 weeks from randomization
45801610|NCT03029689|Drug|Placebo|Placebo (2 tablets of placebo) once daily plus current ART during 48 weeks from randomization.
45801611|NCT03029689|Drug|Current ART|3-drug antiretroviral treatment including PI/r/c or NNRTI
45801612|NCT03085277|Dietary Supplement|Bovine Colostrum|Bovine colostrum (BC) is the first milk from cows after birth and we suggest that BC may be used to supplement MM, instead of infant formula or DM. BC is a rich source of protein (up to 150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and various growth factors, such as, IGF-I and -II, EGFs, and TGF-β. BC has repeatedly been shown to have beneficial effects in a well-established piglet model of preterm infants, using various feeding regimens, including a gradual regimen that would mimic enteral feeding for preterm infants without access to MM during the first week.
45801613|NCT03085277|Dietary Supplement|Preterm Formula|Preterm formula is a type of infant formula designed for preterm infants. It is used when mother's own milk is not available or not in sufficient amount as the enteral feeding for preterm infants in hospitals that do not have donor human milk.
45801614|NCT00372047|Device|multiphoton laser imaging|
45801615|NCT02287909|Drug|Clopidogrel|Swiching from ticagrelor to clopidogrel
45801616|NCT02287909|Drug|Ticagrelor|Continue treatment with ticagrelor
45801617|NCT04335383|Biological|Isolation of anti-Pseudomonas antibodies from type B lymphocytes|Blood sampling. Isolation of mononuclear cells from human peripheral blood by density gradient centrifugation. Identification of functional anti-Pseudomonas antibodies by ELISA and cellular infection assays.
45801618|NCT00371579|Drug|rosuvastatin|
45801619|NCT02935907|Drug|APG-115|Multiple dose cohorts, PO, every other day of a 28 day cycle
45801620|NCT02284867|Other|immunohistochemistry study|After taking informed written consent,a placental sample will be taken either the patient delivered preterm or at term (term patients will be either control term group or patients with successful treatment of preterm labor). The placental sample taken should have part of the decidua and then the sample will be fixed in 10% neutral-buffered formalin for 24-48 h, routinely processed, embedded in paraffin wax, sectioned at 3 μm thickness, and mounted on 3-aminopropyl-triethoxysilane -coated slides. Serial sections will be immunostained for CD 16 and CD56 . immunohistochemistry study will be done at Ain Shams Maternity Hospital Histopathology department.
45801621|NCT02833805|Drug|Thymoglobulin|Day -9: 0.5 mg/kg Days -8 and -7: 2 mg/kg daily
45801622|NCT02833805|Drug|Fludarabine|Days -6 through -2: 30 mg/m^2 IV daily
45801623|NCT02833805|Drug|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
46072979|NCT00891228|Drug|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg Nestorone® mL gel) by pressing two times with 2 mL dispenser head.
45801624|NCT02833805|Radiation|Total body irradiation|Day -1: 200 centigray (cGy) in a single fraction
45801625|NCT02833805|Drug|Tacrolimus|Start on Day 5 through Day 365
45801626|NCT02833805|Drug|Mycophenolate mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
45801627|NCT05736445|Behavioral|Wellness coaching plus app use|Participants will participate in wellness coaching and interact with apps on their smartphones
45801628|NCT02327195|Drug|Methylphenidate HCl|Subjects will be randomly assigned to either the Methylphenidate or the Placebo arm, and be given a 20 mg dose (of Methylphenidate or Placebo) in liquid form (4 mL)
45801629|NCT02327195|Drug|Placebo|20 mg of placebo (PO) will be given 2 hours prior to surgery
45801630|NCT04737629|Behavioral|Expectancy and Water|In the expectancy and water condition, participants will be instructed to consume the mint herb and 500mL of water before the start of the taste test. The script for this condition will inform them of research that has shown water to decrease appetite by up to 50% (attempting to create an expectancy).
45801631|NCT04737629|Behavioral|No Expectancy and Water|Participants will be instructed to consume the mint herb and 500mL of water before the start of the taste test. The script will inform them of research that has shown water to decrease appetite by up to 50%. In this condition, however, the research team will also inform them that this herb is expected to counteract the effects of water on appetite because it decreases water retention, causing water to pass through the stomach and intestines at a faster than normal rate (attempting to create no water expectancy or nullify any pre-existing expectancy).
45930960|NCT03760731|Behavioral|Present Centered Therapy (PCT)|Present Centered Therapy (PCT) will include 12 group sessions, but will focus on problem solving daily life difficulties related to moral injury rather than the experiential focus on moral emotions presented in ACT-MI. Because PCT has been established as an evidence-based active control condition, it is likely to serve as a beneficial transdiagnostic intervention in its own right.
46072980|NCT00891228|Drug|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
46072981|NCT00891228|Drug|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
46072982|NCT00896168|Drug|Infliximab|Infliximab 3 mg per kg intravenous infusion at Week 0, 2, 6, 14 and 22.
45801632|NCT04737629|Behavioral|No Water|Participants will be instructed to consume the mint herb and 50mL of water before the start of the taste test. Participants will be given 100mL of water during the taste test to aid in their ability to taste and consume food, and to avoid acute thirst interfering with food consumption. Access to fluids during a taste test has been used in control conditions in similar studies. The script for this condition will inform participants of research that has shown water to decrease appetite by up to 50% but acknowledge that they will not be receiving water (thus, they should not expect an effect on appetite).
45451347|NCT01085981|Drug|arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%|On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit. Clitoral blood flow will be accessed utilizing the 12 megahertz linear probe. With light pressure, the probe will be applied sagittally and proximal to the clitoral hood with an angle less than 20 degrees. Peak clitoral artery systolic and end diastolic velocity will be measured and resistive index values will be recorded. Then utilizing the 7.5 megahertz vaginal probe baseline uterine artery flow measurements will also be obtained and recorded. With both GRAS cream and placebo.
45801633|NCT04768465|Drug|Pyridostigmine, Prednisone, Tacrolimus|Dose of tacrolimus should be initiated based on CYP3A5*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Prednisone is administrated with an initial dose of 0.25mg/kg/d and started to tamper with the achievement of MMS or the presence of any intolerable side effects. The rate of tampering is considered by the physician, usually no more than 5mg/month. If the participants failed to maintain MMS, dose of prednisone should be increased 5mg/week to 0.25mg/kg/d and maintained until MMS reached again. After MMS sustained for 1 month, prednisone dose would be tapered again with 2.5mg/month. Calcium and potassium supplements and gastric mucosa protectors could be addressed to avoid any adverse effects of prednisone. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
45801634|NCT04768465|Drug|Pyridostigmine, Tacrolimus|Dose of tacrolimus should be initiated based on CYP3A5*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
45801635|NCT02756351|Device|CytaCoat Nasal Prong|
45801636|NCT02756351|Device|Inspiration Healthcare Inspire nCPAP Nasal Prong|
45801637|NCT05698693|Behavioral|Sleep intervention|The sleep extension intervention is a 4-week intervention consisting of weekly one-on-one contact with the goal of increasing total sleep time by 60 minutes by the end of four weeks conducted by Dr. Wu or a trained counselor.
45801638|NCT05698693|Behavioral|Contact Control|This is healthy homes intervention.The program provides education on healthy homes, provide advice on specific healthy homes problems, and recommend actions to be taken by families, landlords, and community members.
45801639|NCT05736211|Behavioral|Organization-level Youth Engagement prevention strategy|Systematically incorporating Youth Engagement into prevention efforts in a community setting
45801640|NCT01744223|Biological|BPX-501 dose 1|Subjects will receive 2x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
45801641|NCT01744223|Drug|Rimiducid|Dimerizer drug administered by intravenous infusion in those subjects who develop GVHD after infusion of BPX-501 cells.
46072983|NCT00896168|Drug|Methotrexate|MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.
45801642|NCT01744223|Biological|BPX-501 dose 2|Subjects will receive 5x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
45801643|NCT01744223|Biological|BPX-501 dose 3|Subjects will receive 1x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
45801644|NCT01744223|Biological|BPX-501 dose 4|Subjects will receive 3x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
45801645|NCT01744223|Procedure|SCT|all subjects will receive an alpha beta depleted donor transplant as part of treatment
45801646|NCT05448547|Radiation|Radiotherapy or surgery|see arm/ group description
45930961|NCT03759938|Drug|Direct oral anticoagulant (DOAC)|Any of the DOACs listed above may be used for treatment in either study arm. The DOAC will be supplied from normal hospital stock, using local hospital prescriptions.
45930962|NCT03742596|Dietary Supplement|Probiotic Formula Capsule|The Probiotic will be coded in a specific label by a researcher. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 7 weeks.
45930963|NCT03742596|Drug|Control|The Placebos will be coded in a specific label by a researcher.
46072984|NCT00833703|Drug|Clopidogrel|"Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
46072985|NCT00833703|Drug|placebo|"Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
46072986|NCT02842034|Device|Repetitive Transcranial Magnetic Stimulation|Stimulate the dorsomedial prefrontal cortex for 4 weeks.
46072987|NCT00833547|Drug|eszopiclone|3 mg of eszopiclone at bedtime on two consecutive nights
46072988|NCT00833547|Drug|placebo|Placebo capsules looking identical to eszopiclone at bedtime on two consecutive nights
45451348|NCT01085981|Drug|Topical study cream|One gram applied to clitoris by nurse then ten minutes later doppler study of clitoral blood flow
45651742|NCT05016427|Biological|VT301|VT301 is off-white suspension of regulatory T cells (Tregs) (1.7x10^5 cells/kg±15%) for injection diluted with sterile saline solution and supplied in clear, colorless, polypropylene vials.
45801647|NCT05448547|Other|initial observation|see arm/ group description
45451349|NCT01085981|Drug|GRAS cream|1 gram of active cream will be applied by nurse then 10 minutes later clitoral blood flow will be assessed by doppler studies see protocol
45451350|NCT03992872|Biological|Chikungunya|Virus Like Particle
45451351|NCT03950752|Combination Product|Optimized Bagel|Participants will eat 132g of a bagel with an optimized composition in fatty acids in only one day, representing an ingestion of 556.5 kcal and 33g of total fat, of which 4.41g are saturated fatty acids, 24.27g are monounsaturated fatty acids, and 4.28g are polyunsaturated fatty acids.
45801648|NCT05448547|Drug|Hormone therapy|androgen depression therapy (ADT) by either LHRH agonist or antagonist or androgen monotherapy
45801649|NCT01614665|Drug|Tacrolimus|Participants receive an initial total daily dose of tacrolimus depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 2 doses in the morning and the evening. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus doses are taken orally twice a day in the morning and evening and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
45801650|NCT01614665|Drug|Tacrolimus prolonged release|Participants receive an initial total daily dose of tacrolimus prolonged release depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 1 dose. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus prolonged release doses are taken orally once a day in the morning and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
45801651|NCT05443945|Device|Nasal Spray|3 sprays in each nostril 3 times per day
45801652|NCT05348447|Device|cryoanalgesia|intraoperative intercostal nerve freezing for post-operative pain control
45801653|NCT05348447|Other|Standard of Care Pain Control|Standard of Care Pain Control Post-operatively
45801654|NCT02285023|Other|CU-Q2oL|"The patients will be explained how to complete the Urticaria Activity Score (UAS7) form for evaluating their severity of chronic urticaria symptoms at home.~At the 2nd visit, collect the 1st UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 1st DLQI and CU-Q2oL questionnaire and get the 2nd UAS7 form and two-week appointment to follow up.~At the 3th visit, collect the 2nd UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 2nd DLQI and CU-Q2oL questionnaire."
45651743|NCT05602311|Drug|General anesthetic|Monitoring the changes of brain functional connectivity and assess cognition in two groups after general anesthesia
45651744|NCT05016349|Drug|All trans-retinoic acid|Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
45651745|NCT05016349|Drug|13-Cis Retinoic Acid plus Tocopherol|13-Cis Retinoic Acid (50 mg/m2/d) Tocopherol (800 mg/day) supplied orally at the total dosage of 50 mg/m2/d (two daily administrations of 25 mg/m2 each). Treatment will last 28 days
45651746|NCT05016349|Drug|Mifepristone|Mifepristone 200mg capsules daily for 28 days
45651747|NCT05016349|Drug|Cannabidiol|Liquid taken orally for daily for 28 days
45801655|NCT05348135|Other|functional strength training|children in this group received FST. Each training session started with 10 minutes dynamic warm-up period and ended with 5 minutes cool down in the form of muscle stretching and aerobics. The warm up was followed by gait training in addition to 4 functional lower limb exercises; sit to stand exercise, forward/ lateral step-up exercise, half knee rise exercise, and bridging exercise.
45801656|NCT05348135|Other|cognitive training|Children in this group received cognitive training by RehaCom cognitive rehabilitation software. Training was applied for four cognitive domains of function; attention / concentration, figural memory, reaction behavior and logical reasoning.
45801657|NCT05348135|Other|conventional physical therapy|including reinforcement of normal motor development, reflex inhibiting patterns, balance exercises, stretching exercises and gait training
45801658|NCT02330341|Dietary Supplement|Artemisia dracunculus|
45801659|NCT02330341|Other|Placebo|
45801660|NCT04337801|Other|Acupressure|The acupressure for symptom management is performed by pressing and scrubbing-like manipulations at certain points on the acupuncture meridians.
45801661|NCT04337801|Other|Placebo|The placebo intervention involves touching to the Pericardium 6 and Large Intestine 4 points without pressing.
45801662|NCT02958839|Procedure|Catheter ablation|Patients with persistent or paroxysmal atrial fibrillation will go through catheter ablation
46072989|NCT02831634|Procedure|Blood sampling|After inclusion in the protocol, a blood sample (50 mL in EDTA tubes) will be withdrawn during pre-operative consultation.
46072990|NCT00833469|Drug|Escitalopram|Once daily by mouth
46072991|NCT02831478|Drug|BAY987517|Applied liberally to the skin (Formulation: RB# Z16-071)
46072992|NCT02831478|Drug|Sunscreen Lotion (RB# T78-190B)|Applied liberally to the skin
45801663|NCT05691829|Drug|Pembrolizumab|Pembrolizumab 200mg solution administered intravenously every 3 weeks for 6 cycles followed by maintenance therapy until progression of disease or unacceptable toxicity (standard of care). Administered alongside chemotherapy.
45801664|NCT05691829|Radiation|Radiation|One-time, up-front radiation delivered at up to five metastatic subsites at a 4 Gy x 5 radiation dose fractionation schedule. Radiation will be delivered within five days before or after initiation of first cycle of pembrolizumab treatment. Radiation modality and technique will be determined at the discretion of the treating radiation oncologist.
45930964|NCT03737240|Drug|IDegLira|Participants in this study arm will discontinue all other diabetes medications, except for metformin which will be continued at prescribed dose (unless contraindicated). IDegLira will be given once daily, at the same time of the day with or without food for 26 weeks. IDegLira will be titrated until the maximum dose is reached, up to the target fasting blood glucose of 70 to 100 milligrams per deciliter (mg/dL).
45930965|NCT03737240|Drug|Insulin Degludec (U-100)|Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin Degludec (U-100) will be given once daily at the same time for 26 weeks. The dose will be titrated up to the fasting blood glucose target of 70 to 100 mg/dL, with no maximum dose.
45930966|NCT03737240|Drug|Insulin Aspart|Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin aspart will be taken before meals with a titration schedule and dose adjustment protocol to target pre-meal blood glucose level of 70 to 100 mg/dL.
45930967|NCT03732950|Biological|Pembrolizumab|Given IV
45930968|NCT03713411|Procedure|urethral catheter placement|urethral catheter placement to provide low-pressure urinary bladder by providing active drainage of the bladder
45651748|NCT05016349|Drug|9 cis retinoic acid|9 cis retinoic acid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
45930969|NCT03703609|Behavioral|Tele-yoga|Participants will get a 60 min tele-yoga session biweekly led by a certified medical yoga instructor via live videoconference link on the participants tablet. Each participant will perform a total of 20-24 yoga instructor-led sessions over a 12-week period. A session will contain 10 min breathing exercises, 40 min of yoga and 10 min relaxation/meditation. Before and at the end of each session, participants can discuss their experiences or ask questions to the instructor online. The tablet also includes an app with instructions (text, pictures, and sound files) for yoga positions, breathing and meditation. Participants are encouraged to practice yoga at home individually with one goal of one session a day for a minimum of 10 minutes.
45930970|NCT03695185|Drug|Ravagalimab 600 mg|Ravagalimab 600 mg was administered intravenously (IV).
45930971|NCT03695185|Drug|Ravagalimab 300 mg|Ravagalimab 300 mg was administered subcutaneously (SC).
45930972|NCT03685461|Other|Electrocochleography|Electrocochleography is a noninvasive method of monitoring for acoustic evoked electrophysiologic responses from the cochlea. A speaker in the external auditory canal presents a tone burst stimulus and a nearby electrode, in this case from the apical electrode of the cochlear implant, records changes in the electrical activity within the cochlea. Different functional elements within the cochlea have signature electrophysiologic responses that can be isolated and studied individually. Through the use of intracochlear electrocochleography during cochlear implant electrode insertion valuable insight can be gained about structural or physiological changes that may be occurring.
45930973|NCT03677648|Drug|SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).
45930974|NCT03677648|Drug|Placebos|Placebos
45930975|NCT03658447|Drug|Pembrolizumab|200mg Pembrolizumab given 3 weekly for upto 35 cycles
45930976|NCT03658447|Drug|177Lu-PSMA|6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.
45930977|NCT03652402|Procedure|kidney transplantation|samples additional to the standard of care' (SOC)will be taken at each visit (Day 0, Month 3, Month12, clinical indication)
45930978|NCT03647163|Biological|VSV-IFNβ-NIS|Intravenous oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and the sodium iodide symporter (NIS)
45930979|NCT03647163|Biological|Pembrolizumab|Pembrolizumab
45930980|NCT03626363|Behavioral|Stress Management|An eight week stress reduction course.
45930981|NCT03596164|Drug|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
45930982|NCT03596164|Device|Syringe|Teduglutide will be administered using syringe. Syringe is approved for use in Japan by PMDA.
45651749|NCT05016349|Drug|Tamoxifen|Patients will be given 10mg Tamoxifen twice a day. Treatment will last 28 days
45930983|NCT03596164|Device|Needle|Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.
45651750|NCT05016349|Drug|Standard therapy|Patients will receive the approved standard therapy tamoxifen
45451352|NCT03950752|Combination Product|Conventional Bagel|Participants will eat 132g of a bagel with a conventional composition in fatty acids in only one day, representing an ingestion of 589.0 kcal and 35.6g of total fat, of which 16.76g are saturated fatty acids, 13.00g are monounsaturated fatty acids, and 5.81g are polyunsaturated fatty acids
45651751|NCT05355675|Other|blood sample|collecting 15ml peripheral blood samples at -7 days before transplantation and+28 days, +100 days, +1 years, +2 years after transplantation
45930984|NCT03596164|Device|Vial Adapter for Device|Vial adapter for device is approved for use in Japan by PMDA.
45930985|NCT03585660|Procedure|Diagnostic MRI|Participants will be scanned using a standard clinical prostate MRI protocol.
45930986|NCT03585660|Procedure|Diagnostic Prostate Biopsy|Participants will undergo a prostate biopsy as their standard of care treatment. The provider performing biopsy will select areas to be biopsies as part of normal clinical judgment.
45930987|NCT03585660|Device|Risk Map DSS tool|The Risk Map DSS tool will select up to 2 additional areas to be biopsied based on analysis of MRI images. The clinical provider will make final decision on areas to be biopsied.
45930988|NCT03585049|Other|Vaginal swabs|The protocol includes the secondary use of vaginal swabs that are primarily used for routine diagnostic assessment in a vulvovaginal clinic
45930989|NCT03578887|Behavioral|Behavioral Weight Loss Program|Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program (DPP).
45930990|NCT03578887|Procedure|Roux-en-Y Gastric Bypass or Sleeve Gastrectomy|Subjects undergoing Roux-en-Y Gastric Bypass or Sleeve Gastrectomy with their own surgical team
45930991|NCT03557944|Other|Medication reduction|Systematic approach to reduction in polypharmacy.
45930992|NCT03556332|Drug|Carfilzomib|Dara-CRd Induction Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 27 mg/m2 per dose, days 8, 9, 15, and 16 Cycles 2-4: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
45930993|NCT03556332|Drug|Lenalidomide|Dara-CRd Induction Cycles 1-4: Lenalidomide 25 mg/day, days 1-21 every 28 days Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Lenalidomide 25 mg/day, days 1-21 every 28 days
45930994|NCT03556332|Drug|Dexamethasone|Dara-CRd Induction Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23
45930995|NCT03556332|Drug|Daratumumab|"Dara-CRd Induction Cycles 1 and 2: Daratumumab 16 mg/kg weekly (days 1,8, 15, 22) Dara-CRd Consolidation (60-90 days post HCT)~Cycles 3 and 4: Daratumumab 16 mg/kg every other week, days 1 and 15.~Cycles 5-6:Daratumumab 16 mg/kg every other week, days 1 and 15. Schedule together with Carfilzomib and use scheduled dexamethasone as premed.~Cycles 7-8: Daratumumab 16 mg/kg days 1 of each cycle."
45930996|NCT03556332|Procedure|autologous hematopoietic cell transplantation|High Dose Melphalan and Autologous Hematopoietic Cell Transplantation Patients will receive Melphalan 200 mg/m2 per institutional guidelines, or if over 70 years of age or creatinine >2mg/dL, they will receive 140 mg/m2.
45451353|NCT02258854|Drug|Dose 2 gevokizumab|Solution for subcutaneous injection
45451354|NCT02031562|Other|chiropractic|chiropractic
45451355|NCT02031562|Other|physical therapy|physical therapy
45651752|NCT05355675|Other|stool sample|collecting 50mg fresh stool samples at -7 days before transplantation and+28 days, +100 days, +1 years, +2 years after transplantation
45651753|NCT05016193|Device|Axem Home Prototype Device|The Axem Home prototype device is a rehabilitation system designed to be used independently by a stroke survivor to facilitate physical rehabilitation exercises in their home environment. The device uses a functional near-infrared spectroscopy (fNIRS) headband that measures the hemodynamic response to rehabilitation exercises and displays this brain activity information to the user.
45651754|NCT05016193|Behavioral|Rehabilitation Exercise Program|Individual exercise program prescribed by a therapist in the Early Supported Discharge Program.
45651755|NCT05380635|Drug|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.
45651756|NCT03091309|Other|Interactive educational video|A web-link to an educational video on IBD and pregnancy tailored to emphasize the importance of optimal disease control and medication adherence.
45651757|NCT03091309|Behavioral|Initial in-person counseling with an IBD nurse|This session will emphasize key points from the educational video and the nurse will answer any additional questions the subject may have. The nurse will assess subjects' medication adherence and specifically query any concerns subjects may have regarding specific medications and discuss their intentions to be adherent throughout pregnancy.
45651758|NCT03091309|Behavioral|Motivational interviewing|The nurse will be trained in a technique known as motivational interviewing (MI) specifically adapted for optimizing medication adherence during pregnancy.
45651759|NCT03091309|Behavioral|Telemedicine-based follow-up|The IBD nurse will arrange follow-up visits with each subject on a monthly basis with additional ad-hoc sessions as needed. The encounter will focus on monitoring disease activity adherence and applying MI communication skills to reinforce and improve the latter.
45801665|NCT05691829|Drug|Chemotherapy|Administered alongside pembrolizumab every 3 weeks for 6 cycles per institutional standard of care. For non-squamous, the standard chemotherapy option of choice is carboplatin and pemetrexed. For squamous cell carcinoma, the chemotherapy used would be carboplatin and paclitaxel or nab-paclitaxel
45801666|NCT05348057|Drug|Ivabradine|The starting dose is 5 mg twice a day. Adjust the dose according to the actual situation
45451356|NCT03938038|Diagnostic Test|Serial ultrasound assessments for GDT|routine ultrasound assessments of volume status and fluid responsiveness for goal-directed therapy (GDT)-based fluid resuscitation
45451357|NCT03938038|Diagnostic Test|Usual care|Close hemodynamic cardiac monitoring and volume responsiveness assessment on an unscheduled basis to aid physicians in resuscitation feedback
45930997|NCT03549845|Behavioral|Cardiovascular Health Awareness Program|Cardiovascular disease prevention and health promotion
45930998|NCT03547908|Drug|B/F/TAF|50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food
45930999|NCT03547908|Drug|Placebo to match DTG|Tablet administered orally once daily, without regard to food
45931000|NCT03547908|Drug|Placebo to match F/TDF|Tablet administered orally once daily, without regard to food
45931001|NCT03547908|Drug|DTG|50 mg tablet administered orally once daily, without regard to food
45931002|NCT03547908|Drug|F/TDF|200/300 mg tablet administered orally once daily, without regard to food
45931003|NCT03547908|Drug|Placebo to match B/F/TAF|Tablet administered orally once daily, without regard to food
45451358|NCT03345082|Biological|OPT-302|Intravitreal injection
45451359|NCT03345082|Biological|ranibizumab|Intravitreal injection
45931004|NCT03539900|Drug|Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination|NB medication will combine BUPROPION HYDROCHLORIDE (360 mg/day) and NALTREXONE HYDROCHLORIDE (32 mg/day). Taken daily in pill form.
45931005|NCT03539900|Other|Placebo|Placebo will be inactive and taken daily in pill form.
45451360|NCT03345082|Other|sham intravitreal injection|Sham (mock) intravitreal injection
45451364|NCT02228902|Drug|Ferrous fumarate|one group receives ferrous fumarate (12 patients) and one group (12 patients) receives ferrous gluconate
45931006|NCT03536546|Behavioral|Alcohol Peer Mentor Intervention|A Veteran Peer research assistant will have contact with a study participant once in person in the emergency department at enrollment, and up to 6 times after enrollment over the course of 2 months. Participants will receive brief advice from a peer. Brief advice content will be based on strengths-based discussions with participants regarding their drinking and personal goals and preferences. Participants will also receive a resource pamphlet on alcohol and other health issues. Follow-up contact will be made by phone. The content of the follow-up peer intervention will be based on the manual developed by the study team to address strengths-based intervention topics.
45931007|NCT03536546|Behavioral|Brief Advice|Participants will receive brief substance use advice from a non-peer research staff member in the emergency department. Brief advice content will mirror standard care practices currently provided in VHA when a patient endorses hazardous drinking behaviors. Participants will also receive a resource pamphlet on alcohol and other health issues.
45931008|NCT03533504|Other|Variability in individual PK|Multivariate hierarchical analysis will be performed on various factors (age, sex, weight, height, dose and type of factor administered (as total and IU/kg), blood group, baseline factor level, positive history of inhibitors, hematocrit, hemoglobin, and serum creatinine, laboratory methods used to measure factor VIII and factor IX) to explore sources of variability in patient outcome.
45651760|NCT03091309|Other|Monthly follow-up questionnaires|Web-based short questionnaires, administered monthly, will be used to assess medication adherence [self-reported using the 5 item Medication Adherence Report Scale (MARS-5)] and IBD related disease activated [self-reported using PRO-2 scale for Crohn's Disease related disease activity and 6-Point Mayo Score for Ulcerative Colitis related disease activity].
45801667|NCT05736133|Other|Physiotherapist-led primary care model for hip and knee pain|"Initial assessment and screening: The PT will provide a comprehensive assessment according to established clinical practice guidelines.~Brief individualized intervention at first visit: The PT intervention will be at the discretion of the PT to reflect real-world PT intervention.~Health services navigation: Participants will be provided with options available to them in their community for rehabilitation. For example, they may be referred to community PT for ongoing management or presented with group exercise options. Participants will be assessed regarding the need for specialist referrals or resources available to manage complex clinical presentations such as comorbidity or frailty. Participants may be referred to the primary care provider if no specialized services are needed or when the PT cannot provide a direct referral. All individuals may have their medications reviewed by a physician if deemed appropriate by the PT or requested by the participant."
45931009|NCT03525873|Other|Laboratory Biomarker Analysis|Correlative studies
45931010|NCT03525873|Drug|Methylphenidate|Given PO
45931011|NCT03525873|Other|Physical Activity|Participate in physical activity
45931012|NCT03525873|Other|Placebo|Given PO
45931013|NCT03525873|Other|Quality-of-Life Assessment|Ancillary studies
45931014|NCT03525873|Other|Questionnaire Administration|Ancillary studies
45931015|NCT03503929|Device|LaparoGuard System|Adjunctive safety system for laparoscopic surgery
45931016|NCT03492125|Drug|MS-553|Oral, multiple dose levels
45931017|NCT03492125|Drug|MS-553|Oral recommended phase 2 dose of MS-553
45931018|NCT03492125|Drug|acalabrutinib|Oral
46072993|NCT00837655|Drug|Sevelamer|sevelamer tablets, 800 mg (Renagel(r), Genzyme Inc). The initial daily dose of sevelamer will be 2400 mg (800 mg x 3). After the first week of treatment the dose will be increased to 4800 mg. If treatment with sevelamer is well tolerated and if a phosphate concentration of <1.8 mmol/l is not obtained, the dose may be increased further. The maximum daily dose of sevelamer will be 9600 mg. If a patient experiences side effects, the dose of sevelamer will be reduced to the highest acceptable dose, and, if a phosphate concentration of <1.8 mmol/l is not obtained, the treatment will be supplemented with calcium carbonate in a dose tolerated by the patient.
46072994|NCT00837655|Drug|Calcium carbonate|Calcium carbonate tablets, 250 mg (Kalcidon, Abigo AB). Calcium carbonate will be prescribed at the dose given prior to the washout period. The dose will be adjusted weekly to obtain a serum phosphate concentration <1.8 mmol/l.
46072995|NCT02842268|Drug|BAY987517|Test product dried for at least 15 minutes.Subjects to ride for 30 minutes on a stationary bicycle.(Formulation Number :Y73-161)
46072996|NCT02611869|Procedure|Cryoballoon|Pulmonary vein isolation by cryoablation using a 2nd generation cryoballoon catheter
45651761|NCT03091309|Other|Comprehensive questionnaires|Web-based detailed questionnaires, administered at enrolment and gestational week 34, will be used to assess medication adherence [self-reported using the Medication Adherence Report Scale (MARS-5)], patient trust in physician [self-reported using the Trust in Physician Scale (TIPS)], IBD related disease activated [self-reported using the PRO-2 or 6-Point Mayo Score], IBD-specific health related quality of life [self-reported using the Inflammatory Bowel Disease Questionnaire (IBDQ)], patient satisfaction [self-reported using the Patient Satisfaction with Healthcare in Inflammatory Bowel Disease (CACHE) questionnaire]and IBD specific knowledge [self-reported using the Crohn's and Colitis Knowledge (CCKNOW) questionnaire].
46072997|NCT02611869|Procedure|RF ablation|Pulmonary vein isolation by radiofrequency current ablation using a touch-force-sensing irrigated catheter
45801668|NCT05736133|Other|Usual physician-led primary care model for hip and knee pain|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
45931019|NCT03492125|Drug|venetoclax|Oral
45931020|NCT03492125|Drug|Rituximab|IV
45931021|NCT03492125|Drug|obinutuzumab|IV
45931022|NCT03485391|Behavioral|Prolonged Exposure|Practice guidelines have identified that trauma-focused psychotherapies have most evidence for treatment PTSD. Prolonged Exposure (PE) is one type of trauma-focused psychotherapy. PE teaches you to gradually approach trauma-related memories, feelings, and situations that you have been avoiding since your trauma. By confronting these challenges, you can decrease your PTSD symptoms. Treatment will last anywhere from 8-12 weeks for 75-90 minutes, once per week.
45451365|NCT02228902|Drug|Ferrous gluconate|One group receives ferrous fumarate and one group receives ferrous fumarate.
45451366|NCT03313882|Other|no intervention is involved|
45931023|NCT03476590|Procedure|new model of ambulatory care with use of of non-invasive vital signs assessment and telemedicine|"The report of symptoms and physical examination will be obligatory performed by the ACP nurse. Self-condition and quality of life assessment at every visit will be based on EQ-5D questionnaire and VAS 10-points scale Hemodynamic assessment - the ACP nurse will perform impedance cardiography (cardiomonitor) and bioimpedance (scale). The parameters measured by ICG and bioimpedance will be assessed with respect to individually defined target values for: heart rate (HR), systolic and diastolic blood pressure (SBP and DBP), thoracic fluid content (TFC) and its change (delta TFC), change of body mass and total body water (delta TBW).~Supervising physician will confront ICG/bioimpedance results with the patient's clinical data and give final remote recommendations."
45801669|NCT05735977|Diagnostic Test|Indocyanine Green (ICG)|Will the use of ICG delineate the margin between normal kidney parenchyma and renal tumour in children at a macroscopic level and can this be replicated at a microscopic level
45931024|NCT03459677|Behavioral|Back2School|Modular Trans-diagnostic Cognitive Behavioral Therapy treating school absenteeism in youths
45931025|NCT03459677|Other|Treatment As Usual|Aarhus municipality's treatment as usual for youths presenting school absenteeism
45931026|NCT03427463|Drug|receiving 0.1 mg IT morphine|Patients will receive the standard of care dose 0.1 mg of intrathecal morphine
45931027|NCT03427463|Drug|recieving 0.05 mg IT morphine|Patients will receive 0.05 mg of intrathecal morphine
45931028|NCT03386513|Drug|IMGN632|CD123-targeted ADC
45931029|NCT03363867|Drug|Atezolizumab|840mg every 2 weeks (i.e. Day 1 and Day 15 of each 28 day cycle) via intravenous infusion from Cycle 2 onwards.
45931030|NCT03363867|Drug|Bevacizumab|5mg/kg every 2 weeks (i.e. Day 1 and Day 15 of each 28 day cycle) via intravenous infusion.
45931031|NCT03363867|Drug|Cobimetinib|60mg per day, every day for 21 days (i.e. Day 1 to Day 21 of each 28 day cycle)
45931032|NCT03356873|Drug|Vitamin D|Vitamin D supplementation
45931033|NCT03356873|Other|Placebo|Placebo
45931034|NCT03308578|Drug|Atorvastatin|Subjects randomized to this arm will receive 40 mg capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
45931035|NCT03308578|Drug|Placebo oral capsule|Subjects randomized to this arm will receive placebo capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
45931036|NCT03305341|Biological|COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection|"Intradermic Injection, ID~COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection"
46072998|NCT02841956|Other|Electronic Screen + Education (Phase 1)|PHASE 1 Electronic Screening Arm + Targeted Education: Referral sources will receive the same standard targeted education as active comparator. In addition, the PQ-B (a 21 item screening questionnaire) will be administered to all patients at their first visit to the referral sites (e.g. intake) via an android tablet provided to the site for ease of administration and scoring. The investigators will provide multiple tablets per site so that the screening is available for more than one individual simultaneously and can be completed in any appropriate location. The investigators will allow paper-and-pencil administration for situations where it is more appropriate (e.g. emergency room).
46072999|NCT02841956|Other|Targeted Provider Education (Phase 1)|PHASE 1 Targeted Education Intervention: EDAPT standard targeted provider education1 focuses on increasing awareness about the signs of early psychosis & building collaborative relationships with community members so community members see EDAPT as a rapid, effective source of help. It consists of a 2-hour workshop describing: 1) how to identify specific early symptoms & changes associated with the onset of psychotic illness, 2) the benefits of early intervention on treatment outcomes in psychosis, 3) the structure, philosophy & treatment model of the EDAPT Clinic, and 4) procedures for expeditious referral to our program. Case-based vignettes are reviewed to ensure understanding of the key symptoms.
45451367|NCT03288454|Drug|Ciraparantag|Ciraparantag (administered over 10 minutes)
45451368|NCT03288454|Drug|Placebo|Saline for injection
45801670|NCT00371735|Drug|chlorproguanil-dapsone-artesunate|
45801671|NCT00371735|Drug|chlorproguanil-dapsone|
45651762|NCT05015959|Other|observation|quality
45651763|NCT03091387|Diagnostic Test|Spontaneous Breathing Test|subjects when ready for extubation will be given a three minute spontaneous breathing test on ET-Cpap mode of the ventilator
45801672|NCT03833245|Behavioral|Patient Navigation|The patient navigation (PN) intervention will initiate following participant recruitment. It is important to note that PN sessions do not strictly coincide with specific weeks of pregnancy since the women can be recruited up to ≤25 weeks of gestation. The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention. All contact will be reported by staff in a patient contact log developed for the study that will be used to quantify level of patient contact.
45653256|NCT04331639|Dietary Supplement|vitamin D3|Subjects will receive oral high dose interval vitamin D3, concurrently when they are receiving their biologic treatment for their inflammatory bowel disease every 4-8 weeks.
45801673|NCT04337411|Other|Follow-up assessments|Longitudinal evaluation of recovery
45801674|NCT04337333|Device|Two-in-one stent|Endoscopic placement of a Two-in-one metal stent into extrahepatic bile duct
45931037|NCT03255473|Drug|Dexamethasone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
45931038|NCT03255473|Drug|Prednisone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
45931039|NCT03253835|Diagnostic Test|Single Group Assignment|
45931040|NCT03240874|Behavioral|SweetMama Focus Groups|Focus groups will assess tool functionality, design, interpretability, and acceptability (initial reaction, attitude, and receptiveness) of SweetMama via qualitative interviewing. The group format will generate feedback on areas that may not be revealed in a one-on-one interview.
45451369|NCT03288454|Drug|Apixaban|Apixaban 10mg given twice daily (q12h)
45653257|NCT05728645|Drug|Intravenous HES130/0.4 of 5ml/kg|HES130/0.4 of 5ml/kg
45653258|NCT05728645|Drug|intravenous Lactated Ringer's solution|intravenous Lactated Ringer's solution of 5ml/kg
45931041|NCT03240874|Behavioral|SweetMama Individual Testing|"Women will be oriented to SweetMama use on their own Android- or Apple-based phones. The goals of this phase are to collect data from diverse users that will (1) confirm that the mobile apps are functioning (not crashing) across a wide range of devices and operating systems, (2) provide basic information about app usage and user satisfaction (3) inform the development of future iterations by analyzing participant characteristics and use, and (4) collect quality assurance data that will allow the research team to refine the applications. Women will use SweetMama for 2 weeks, engage in periodic check-ins with the research assistant, and participate in a semi-structured interview upon completion of SweetMama usage."
45651764|NCT04254393|Behavioral|Early Adolescent Skills for Emotions (EASE) Program|EASE has been developed to manage and reduce symptoms of depression, anxiety and distress in adolescents. EASE is designed to be delivered by non-specialists in low resource settings such as a trained school-health counsellor. The intervention comprises of 7 young adolescent group sessions, each lasting 90 minutes and involves the empirically supported components of psycho education, problem solving, stress management (slow breathing), behavioural activation, and relapse prevention and 3 caregiver group sessions, each lasting 120 minutes and involve psycho education, active listening, quality time, praise, caregiver self-care and relapse prevention.
45931042|NCT03240874|Behavioral|SweetMama Feasibility Testing - Pilot Randomized Trial|"Women will be oriented to SweetMama use on their own Android- or Apple-based phones. The goals of this phase are to collect data from diverse users that will determine acceptability, feasibility, and pilot procedures in anticipation of a fully powered randomized controlled trial. Women will use SweetMama from enrollment (early pregnancy) to up to 8 weeks postpartum, engage in periodic check-ins with the research assistant, and participate in surveys and a semi-structured interview upon completion of SweetMama usage."
45931043|NCT03956706|Radiation|Stereotactic Radiosurgery|Stereotactic radiosurgery dose escalation by either 18, 20, or 22 Gy to the subventricular zone in addition to standard of care
45801675|NCT00425399|Procedure|Shiatsu|Shiatsu treatment provided in 40-minute sessions, twice a week for 4 weeks
45931044|NCT03197363|Other|Discovering novel risk factors.|The study protocol includes multiple imaging and functional investigations (including heart, carotid, thyroid, liver ultrasound, fundoscopy, plethysmography, pulse wave velocity, ankle-brachial index, ECG, body composition measured by bioimpedance and dual energy x-ray absorptiometry, anthropometric assessment, rhinometry, hand grip test, oral glucose tolerance test, advance glycation end-products measurement, voice recording. There will be a detailed and verified questionnaires concerning various activities of the subject: physical activity, depression, sino-nasal symptoms, prostate hypertrophy, female urinary tract symptoms, quality of life, smoking and drinking addiction, hirsutism.
45651765|NCT04254393|Other|Treatment As Usual (TAU)|Evidence based health practices are not available in schools to manage the mental health problems of children. No structured programs are being implemented in school settings for at-risk children. During the study, participants in TAU showing severe psychiatric symptoms that require immediate specialist treatment and follow-up, will be referred to the Institute of psychiatry (IoP)-the tertiary mental health care facility of the region.
45801676|NCT05052307|Drug|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
45931045|NCT03176277|Drug|ONO-7475|ONO-7475 tablets
45931046|NCT03176277|Drug|ONO-7475 + venetoclax|ONO-7475 tablets + venetoclax tablets
45931047|NCT03173560|Drug|lenvatinib|lenvatinib capsules.
45931048|NCT03173560|Drug|everolimus|everolimus tablets.
45931049|NCT03172117|Biological|human umbilical cord blood derived mesenchymal stem cells|"Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals~High dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals"
45931050|NCT03172117|Other|Normal saline 2mL|Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations
45931051|NCT03098225|Radiation|Orbital radiotherapy|A high-voltage linear accelerator will be used and a cumulative radiation dose of 20 Gy will be delivered to each eye in 10 fractionated doses over a period of 2 weeks. All patients will be treated in both eyes.
45931052|NCT03098225|Drug|Methylprednisolone|Methylprednisolone pulse therapy for 12 weeks as follows: 500 mg IV once weekly for 6 weeks, then 250 mg IV once weekly for a further 6 weeks. Cumulative dose 4.5 g.
45451370|NCT03285178|Drug|IW-1701|Oral Tablet
45451371|NCT03285178|Drug|Placebo|Oral Tablet
45651766|NCT03079609|Procedure|subinguinal microscopic varicocelectomy|During the procedure approximately 1cm long fragment of varicose vein will be taken for further investigation.
45801677|NCT05052307|Drug|CoronaVac COVID-19 vaccine|CoronaVac COVID-19 vaccine
45801678|NCT05052307|Drug|ChAdOx1 nCoV-19 Covid-19 Vaccine|ChAdOx1 nCoV-19 Covid-19 Vaccine
45801679|NCT05052307|Drug|Ad26.COV2.S COVID-19 Vaccine|Ad26.COV2.S COVID-19 Vaccine
45801680|NCT04337567|Procedure|radiofrequency ablation|ablative treatment as allocated to radiofrequency ablation
45801681|NCT04337567|Procedure|ballon cryoablation|ablative treatment as allocated to ballon cryoablation
45801682|NCT05332457|Drug|Reduced dosage of beta-blocker|"Phase I:~CPET performed at trough BB concentration: participants will undergo CPET at least 30 hours after last beta-blocker usage.~CPET performed at peak BB concentration : participants will undergo CPET at 3 hours after last beta-blocker usage.~Phase II:~BB dosage will be reduced."
45801683|NCT03029377|Other|Posture Study, Autonomic Function Tests, and a Stress Test|Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function at baseline, in three postural positions, after autonomic tests, and after a stress test.
45931053|NCT03091374|Drug|Somatotropin (Human)|
45931054|NCT03071341|Drug|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
45931055|NCT03053089|Drug|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
45931056|NCT03017131|Biological|Aldesleukin|Given SC
45801684|NCT00372125|Drug|Norditropin SimpleXx|0.3-0.4 mg/day placebo or GH for 4 weeks. Thereafter 0.6-0.8 mg/day placebo or GH for 11 months. During the following 24 months open phase doses will be individually titrated.
45801685|NCT05681143|Other|Crisis Prevention Arm|The crisis prevention program involves a 3-session model. Each session lasts up to 60 minutes. They take place via telehealth with a licensed clinical therapist. Sessions involve case formulation, provision of prevention strategies, connecting with professional and lay resources, what to do if a crisis occurs, and strategies to prevent the re-occurrence of a crisis, should one occur. Each session involves use of checklists, a community resource guide, and homework. Implementation is standardized using two different manuals, one for the parent and the other for the provider.
45451372|NCT00090545|Drug|BAY 43-9006|400 mg BAY 43-9006 orally twice daily in 28 day cycles.
45451373|NCT02829814|Drug|TNX-102 SL Tablet, 2.8 mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
45451374|NCT02829814|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
45451375|NCT03916042|Drug|Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID|Reproxalap Opthalmic Solution (0.25% Novel Formulation) administered QID for four weeks, followed by BID administration for eight weeks
45651767|NCT03079609|Procedure|open hernia repair|During the procedure approximately 1cm long fragment of spermatic cord vein will be taken for further investigation.
45801686|NCT05681143|Other|Control|The control condition will involve sending families the Autism Speaks Challenging Behavior Toolkit. It offers a complimentary set of recommendations. It is freely available and can be found here: https://www.autismspeaks.org/tool-kit/challenging-behaviors-tool-kit. There is no interaction with the clinician in the controlcondition. After the study observation period, we will provide them with the crisis manual (for parents) used in the active treatment arm.
45451376|NCT03916042|Drug|Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID|Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
45801687|NCT05028439|Device|radiofrequency ablation|All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture. Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction
45451377|NCT02229058|Drug|Albumin Bound Paclitaxel|120 mg/m2, D1,D8,every 3 weeks until disease progress or intolerable toxicity.
45451378|NCT02229058|Drug|S-1|40mg QD D1-D14,every 3 weeks,for BSA<1.25 m2, 50mg QD D1-D14,every 3 weeks,for BSA=1.25～1.5m2, 60mg QD D1-D14,every 3 weeks,for BSA>1.5m2,until disease progress or intolerable toxicity.
45651768|NCT05538819|Drug|Glimepiride|Glimepiride 1-4 mg/day
45801688|NCT05028439|Drug|Chemotherapy drug|Gemcitabine 1 000 mg/m2 intravenously on day 1，8; S-1 80 mg/m2 was taken orally twice for two weeks. The curative effect was evaluated comprehensively for each 2 cycles of chemotherapy
45451379|NCT03249376|Drug|Lumateperone|Lumateperone 42 mg (ITI-007 60 mg tosylate)
45651769|NCT05015647|Dietary Supplement|LP group|LP group patients replaced pasta, bread, biscuits etc. with low protein substitutes. We allowed them to consume more animal products than NP, preferring white meat to red meat and trying to limit cold cuts as much as possible. Furthermore, they were advised to prefer fresh or frozen fish, instead of dried or smoked one as well as to prefer fresh cheeses to seasoned ones. As for legumes, we advised to combine them with bread or normal cereals, for protein complementarity.
45651770|NCT05015647|Other|NP group|NP group was given the indication to try to eat the second dish only once a day or to split the portion of the second plate between lunch and dinner, if they wanted to keep the habit of making the meal complete. It was also given the indication to prefer, among protein sources, those of plant origin. We also indicated to alternate or replace cow's milk with plant substitutes such as: rice, almonds' or oats' drinks. Furthermore, we suggested to prefer white meat and to avoid offal and processed meat. Moreover, we indicated to substitute dried or smoked fish with fresh or frozen one.
45651771|NCT05308641|Procedure|radial extracorporeal shockwave therapy_4000_20|application of radial extracorporeal shockwave therapy (rESWT) with 4000 pulses and 20 Hz
45651772|NCT05308641|Procedure|radial extracorporeal shockwave therapy_500_2|application of radial extracorporeal shockwave therapy (rESWT) with 500 pulses and 2 Hz
45801689|NCT02761967|Behavioral|Physical activity|Women from the 20th week of moderate physical exercise performed in water character designed following the guidelines in the SWEP method will end in week 37 of gestation. After the postpartum period, women begin a program based on postpartum recovery exercises Fitness Low Pressure method 12-week, 3 days a week, in sessions of 60 minutes.
45801690|NCT03029299|Device|FilmArray RP EZ|Patients in the intervention arm will be tested with the FilmArray RP EZ and the results of the test will be provided to the treating clinician
45801691|NCT05012605|Other|Observation|Observe physical function and sleep disorder symptoms following stroke
45931057|NCT03017131|Drug|Cyclophosphamide|Given IV
45931058|NCT03017131|Drug|Decitabine|Given IV
45931059|NCT03017131|Biological|Genetically Engineered NY-ESO-1-specific T Lymphocytes|Given IV and IP
45451380|NCT03249376|Other|Placebo|Placebo
45451381|NCT04607434|Drug|Ocotillol Type Ginsenoside Derivatives|Peripheral blood PMN of patients with ARDS were taken. The neutrophils isolated from peripheral blood of ARDS patients were incubated with different doses of OCT glycine derivatives (20,50,100 UM) for 20 h
45651773|NCT05308641|Procedure|standard multimodal pain therapy|standard multimodal pain therapy
45931060|NCT03017131|Other|Laboratory Biomarker Analysis|Correlative studies
45931061|NCT02990468|Drug|BMX-001|Subcutaneous injection.
45931062|NCT02990468|Radiation|Radiation Therapy|Patients will receive standard dose intensity modulated radiation therapy (IMRT).
45451382|NCT03200704|Combination Product|IC2000 and SPY-PHI|Investigational treatment to assess the effectiveness of IC2000 (Indocyanine Green (ICG) for Injection) and the SPY Portable Handheld Imaging System (SPY-PHI) as an intraoperative fluorescence visualization tool, in the visual identification of lymphatic vessels and lymph nodes (LNs) during lymphatic mapping and sentinel lymph node biopsy (SLNB) procedures in early stage breast cancer
45651774|NCT05354583|Drug|Appropriate treatment|Treatment with at least 3 antibiotics, which the pathogen is susceptible to based on in vitro drug susceptibility test, in the initial phase of the treatment
45651775|NCT03079219|Drug|Experimental drug: Aprepitant|Day 1: 125mg QD; Day 2 to Day 3: 80mg QD
45651776|NCT03079219|Drug|Experimental drug: Ondansetron|Day 1: 8mg BD, First dose 8mg, Second dose 8mg, 8 hours after first dose
45651777|NCT03079219|Drug|Experimental drug: Dexamethasone|Day 1: 12mg QD
45651778|NCT03079219|Drug|Experimental drug: Olanzapine|Day 1 to Day 5: 10mg QD
45651779|NCT03079219|Drug|Standard: Aprepitant|Day 1: 125mg QD, Day 2 to Day3: 80mg QD
45801692|NCT05009797|Procedure|atrial fibrillation catheter ablation|The ablation is performed under local anesthesia or general anesthesia. A transseptal puncture will be performed to access the left atrium. Pulmonary vein isolation will be performed as a first step. Additional lesions will be made at the discretion of the operators. Patients will receive anticoagulation for at least 3 months after the ablation. Treatment thereafter will be extended at the discretion of the treating physician.
45801693|NCT05417659|Dietary Supplement|Exercise plus carbohydrate|A high carbohydrate drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise.
45801694|NCT05417659|Dietary Supplement|Exercise plus niacin|A dose of niacin to be consumed 30 minutes prior to exercise, at onset of exercise and 30 minutes into exercise.
45801695|NCT05417659|Other|Placebo|A placebo drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise and placebo tablets to be consumed 30 minutes prior to exercise, at the onset of exercise and 30 minutes into exercise.
45801696|NCT02762513|Drug|Axitinib|
45801697|NCT04996225|Other|Aerobics exercises, Balance exercises|Aerobic exercise, or endurance exercise, is a subdivision of physical exercise that improves cardiovascular and respiratory health. Additionally, it is generally assumed to increase well-being and reduce negative mood states such as anxiety and depression.
45801698|NCT02958761|Biological|intraarticular injections of platelet lysate|
45801699|NCT02958761|Drug|hyaluronic acid|intraarticular hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) injections at the same intervals
45801700|NCT04991389|Drug|129-Xe|Inhaled contrast for MRI
45801701|NCT02764385|Other|Teachable Moment Communication Process|A clinician-focused intervention designed to guide an approach to discussing smoking cessation during routine primary care visits.
45801702|NCT02764385|Other|AAC|A system-based change to the EHR that allows for eReferral to the Quitline coupled with role and process changes for medical technical assistants
45801703|NCT05658835|Other|Thrombi and blood analyses|Thrombi and blood will be collected during thrombectomy
45801704|NCT05284487|Device|Jalosome® soothing gel|Jalosome® Soothing gel is a phospholipid based vesicular system based on hyaluronic acid (HA). HA supports the process of formation of extracellular matrix and collagen synthesis by fibroblasts, favoring the formation of a well-vascularized granulation tissue and thus accelerating the healing process. Jalosome® Soothing gel contains other active ingredients: Acetyl-L-carnitine which plays an important role as shuttle for energy production and is involved in cellular metabolism. It is an effective cytoprotective, anti-inflammatory, neuroprotective, metal chelator, anti-apoptotic and anti-oxidant agent. Allantoin is a key constituent of comfrey (Symphytum officinale L), it has moisturizing and keratolytic effect, increasing the water content of the extracellular matrix and enhancing desquamation of upper layers of dead skin cells. Hydrogenated phosphatidylcholine is a permeation enhancers, which increases the solubilization of active ingredients, improving their skin permeation ability.
45801705|NCT05284487|Device|Placebo|The placebo does not contain the active ingredients of Jalosome, only the co-formulants.
45801706|NCT05215535|Radiation|Abbreviated MRI of the liver/abdomen|"The MRI examinations of the liver/abdomen will be performed at the same time as the pelvic MRI. A 1,5 T scanner will be used together with a dedicated torso/abdominal coil. An abbreviated MRI liver protocol includes 3 different sequences as follows:~Axial T2-weighted respiratory triggered sequence with 5 mm slice thickness.~Axial diffusion weighted spin echo respiratory triggered sequence with fatsat with b-factors 50/800 s/mm2 and ADC calculation maps, 5 mm slice thickness~An axial breath-hold 3D T1-weighted gradient echo with fatsat with 4 mm slice thickness, gap 2 mm, contrast enhanced venous phase and in a 3 min equilibrium phase, using regular i.v bolus injection of gadolinium contrast medium with standard clinical dose."
45801707|NCT05215535|Radiation|Combined single venous and 3 min equilibrium phase CT of the abdomen/liver|The CT examination of the liver will be performed as a combined examination in a single venous phase starting with the thoracic region directly followed by the abdomen down to the pelvis. An additional 3 min equilibrium phase of the liver only will end the examination. Regular iodinated low-osmolar non-ionic contrast media will be used of 350 mg I/ml using a power injector, 2-4 ml/s, 100-150 ml dependent on patient weight and kidney function. Reconstructed images in axial, coronal and sagittal plane will be performed.
45801708|NCT05649397|Other|cervical manipulation|provide a high velocity, low-amplitude manipulation to each subject's cervical spine.
45801709|NCT05649397|Other|conventional therapy|15 mins moist hot pack Neck Isometric exercise hold for 5-8 seconds and repeat 10 times Cervical range of motion 10 repetitions of movement in rotation within pain free range
45801710|NCT04336709|Drug|Calcipex II|Water based intracanal medicament
45801711|NCT04336709|Drug|Metapex|Oil based intracanal medicament
45931063|NCT02990468|Drug|Cisplatin|Cisplatin will be administered per institution's standard of care practice.
45931064|NCT02952170|Other|MRI|MRI to assess hepatic steatosis
45931065|NCT02940301|Drug|Ibrutinib|Given PO
45931066|NCT02940301|Other|Laboratory Biomarker Analysis|Correlative studies
45931067|NCT02940301|Biological|Nivolumab|Given IV
45931068|NCT02927769|Biological|Nivolumab|Specified Dose on Specified Days
45931069|NCT02927769|Biological|brentuximab vedotin|Specified Dose on Specified Days
45651780|NCT03079219|Drug|Standard: Ondansetron|Day 1: 8mg BD, First dose 8mg, second dose 8mg, 8 hours after first dose
45801712|NCT04934137|Behavioral|Sensoria|The Sensoria system uses a force-sensing mat installed under the wheelchair cushion that connects via Bluetooth to a mobile app. The mobile app displays information about weight shifts, goal-setting functions, and feedback on performance/outcomes.
45801713|NCT04934137|Behavioral|AW-Shift|The AW-Shift system uses a pressure-sensing mat installed on top of the wheelchair cushion that connects via Bluetooth to a mobile app. The mobile app displays visual representation of the seating surface and can set reminders for weight shifts.
45651781|NCT03079219|Drug|Standard: Dexamethasone|Day 1: 12mg QD ; Day 2 to Day 3: 4mg BD
45651782|NCT03078985|Procedure|ablation for typical atrial flutter|Typical atrial flutter is treated by catheter ablation.
45651783|NCT03078985|Device|catheter ablation with study device|The study device is used inside the MRI environment to localize the cavotricuspid isthmus (CTI). The CTI is then treated with radiofrequency energy to achieve complete isthmus block.
45651784|NCT03078829|Drug|Treatment with a GnRh agonists|All patients will be treated with GnRH agonists
45651785|NCT05019469|Device|Rhythmic vibration cueing (lower leg)|A non-invasive wearable device worn against both gastrocnemius muscles provides rhythmic vibrations when triggered.
45651786|NCT03091153|Other|Medication Review|In depth medication review with a focus on deprescribing
45801714|NCT02767271|Drug|Luliconazole Cream 1%|Luliconazole cream will be applied topically per schedule specified in the arms.
45801715|NCT04928677|Drug|Codrituzumab|For Phase A (Dose Escalation), the starting dose (dose level 1) will be 10 mg/kg with 1 planned dose escalation to 20 mg/kg (dose level 2) if dose level 1 is determined to be safe and tolerable. Once a RP2D/MTD is identified in Phase A, then Phase B (hepatoblastoma expansion cohort) will open and allow for enrollment of up to 10 additional patients.For both phases, patients will receive codrituzumab IV once per week for a period of 21 days per cycle. Patients will be eligible for up to 25 cycles.
45801716|NCT02741297|Device|Spinal Cord Stimulation (SCS) System|Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
45801717|NCT05375071|Other|Blood Flow Restriction (BFR) Therapy|BFR Cuff will be applied to the most proximal portion of the affected arm or leg, immediately before performing exercises during physical therapy. The cuff will remain on for the entire time while an exercise is performed and will be removed in between exercises while the subject rests.
45801718|NCT05375071|Other|Physical Therapy|Standard of care physical therapy consisting of a structured program progressing from range of motion to strength training and then functional tests
45451383|NCT03200704|Combination Product|Tc-99m radioactive colloid and Gamma Probe|Comparator; standard of care for sentinel lymph node biopsy (SLNB) procedures in early stage breast cancer
45451384|NCT03887026|Drug|Norketotifen|Norketotifen oral capsule
45801719|NCT05647993|Drug|Azithromycin Injection [Zithromax]|Intervention group patient will receive standard antimicrobial prophylaxis(cefazolin intravenously weight dependent) and azithromycin 500 mg intravenously before the incision
45801720|NCT05647993|Drug|Cefazolin|All the participants will receive the cefazolin intravenously. The dosage of the cefazolin is depend on participant's weight. The participant with weight less than 80kg will receive cefazolin 1 gm and between 80-120kg will receive cefazolin 2 gm and for the participant with more than 120kg will receive cefazolin 3 gm before the incision.
45451385|NCT03887026|Drug|Placebo|Placebo oral capsule
45451386|NCT03863080|Drug|RVT-1401|Subcutaneous administration of RVT-1401
45451387|NCT03863080|Drug|Placebo|Subcutaneous administration of Placebo
45651787|NCT05015179|Procedure|mixed reality technology in laparoscopic partial nephrectomy|All patients undergo contrast-enhanced computed tomography before surgery. DICOM files are converted to a 3D model. This model is then sent to HoloLens 2 smart glasses using HLOIA software
45651788|NCT05019781|Other|Therapeutic tape|Tape was applied to sternocleidomastoid, upper trapezius, deltoid, flexor palmaris longus muscles as suggested by Kase et al. (Kase, Wallis, Kase, & Association, 2003). The tape was applied to the left side of the participants while sitting position because the violin is traditionally played by placing it on the left shoulder, balancing the neck using the left hand, and bowing with the right arm.
45651789|NCT05019781|Other|Placebo tape|The placebo tape was applied transverse to the muscle groups in two levels (a point of 10 cm above to wrist and elbow) with no tension when the participants were sitting position with the shoulder flexed at 90°, and the elbow flexed at 90°.
45651790|NCT05019391|Device|transcranial doppler|it provides an accurate, noninvasive, and simple method for the diagnosis of VBI. Through the diagnosis results, it will be clear about the blood flow status of single vessel and vascular compliance, which is helpful for accurate reflection of the subtle changes of VBI
45653259|NCT05073393|Behavioral|Sugar stress|Sucrose rinsing for 14 days (8-10 times a day) followed by 14 days without sucrose rinsing
45653260|NCT05473507|Diagnostic Test|Digital Dermoscopy|Digital Dermoscopy will be performed every 3 months.
45653261|NCT05473507|Diagnostic Test|Reflectance confocal microscopy (RCM)|Reflectance confocal microscopy (RCM) will be performed every 3 months.
45801721|NCT05647993|Drug|Sodium Chloride 0.9% Intravenous Solution|For the placebo group will receive the cefazolin intravenously and 0.9% NaCl 100ml before the incision
45801722|NCT02741687|Drug|Sitagliptin|Participants will take 100 mg/day for patients with glomerular filtration rate (GFR) > 50 and 50 mg/day for GFR 30 - 49, beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
45801723|NCT02741687|Drug|Placebo|Participants will take one pill daily beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
45931070|NCT02927769|Biological|bendamustine|Specified Dose on Specified Days
45931071|NCT02899299|Biological|Nivolumab|
45931072|NCT02899299|Biological|Ipilimumab|
45931073|NCT02899299|Drug|Pemetrexed|
45931074|NCT02899299|Drug|Cisplatin|
45931075|NCT02899299|Drug|Carboplatin|
45931076|NCT02882100|Biological|adjuvanted trivalent influenza vaccine|Nursing home residents over 65 years are allocated to receive adjuvanted trivalent vaccine. Residents under 65 years are provided standard trivalent vaccine (TIV-Fluvirin).
45931077|NCT02882100|Biological|trivalent influenza vaccine|Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
45931078|NCT02878850|Other|Augmented Blood Pressure|Subjects will have their blood pressure kept in a higher range.
45931079|NCT02855944|Drug|Chemotherapy|Chemotherapy will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.
45931080|NCT02855944|Drug|Rucaparib|Tablets of rucaparib, at a dose of 600 mg, will be taken orally twice a day
45931081|NCT02828917|Device|MedJ-01 Ridaforolimus Eluting Coronary Stent System|
45931082|NCT02733185|Drug|disodium EDTA|
45931083|NCT02733185|Dietary Supplement|Oral Multi Vitamins/Minerals (OMVM)|
46073000|NCT02841956|Other|Community Mobile Engagement (Phase 2)|PHASE 2 Community-based Mobile Engagement: Clinical assessment appointments will take place at the EDAPT clinic or within the community, wherever the individual would prefer. With patients deemed eligible for EDAPT services, the EDAPT clinician will obtain vitals and contact the EDAPT psychiatrist with a telemedicine-enabled laptop to complete the psychiatric evaluation remotely. The psychiatrist will prescribe medications and order labs, as indicated. The EDAPT clinician will follow up with the individual within 5 days to determine if the prescribed medication regimen has started.
45651791|NCT05019157|Other|Telerehabilitation group|Participants will undertake the first three training sessions in the outpatient clinic for familiarization with the training modalities, the wearable sensors and the data uploading. Afterwards, the participants will proceed with the telerehabilitation program at their homes. The participants will be lent the wearable sensors and will undergo an exercise - based program 3 times/week, comprising of 10' warm up exercises, 40' aerobic, resistance, balance exercises and 10' cool down.Training sessions will be monitored, in real time, by the study investigator. Participants should upload the recorded data to Polar Flow web platform after every training session and should visit the outpatient clinic every month to upload the accelerometry's recorded data to a secure personal computer) application. Educational and informational videoconferences will be held every week for upright training exercise sessions, physical activity counseling, diet/nutritional and smoking cessation counseling.
45653262|NCT05473507|Diagnostic Test|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) will be performed every 3 months.
45653263|NCT05473507|Diagnostic Test|Dermtech tape-stripping|Dermtech tape-stripping for genetic analysiswill be performed every 6 months.
45653264|NCT05473507|Diagnostic Test|Total Skin Examinations|Total Skin Examinations will be performed every 12 months.
45801724|NCT02741687|Drug|Supplemental insulin (insulin lispro)|"Supplemental insulin lispro will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) >240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~BG between 181-220 mg/dL; 2-4 units of insulin lispro~BG between 221-260 mg/dL; 3-5 units of insulin lispro~BG between 261-300 mg/dL; 4-6 units of insulin lispro~BG between 301-350 mg/dL; 5-7 units of insulin lispro~BG between 351-400 mg/dL; 6-8 units of insulin lispro~BG > 400 mg/dL; 7-9 units of insulin lispro"
45931084|NCT02733185|Drug|Placebo disodium EDTA|
45931085|NCT02733185|Dietary Supplement|Placebo Oral Multi Vitamins/Minerals (OMVM)|
45931086|NCT02730338|Behavioral|High intensity aerobic and resistance training|
45931087|NCT02730338|Behavioral|Psychosocial support|
45931088|NCT02688569|Behavioral|Cognitive Behavioral Therapy for Chronic Widespread Pain|CBT-CWP in this study involves 4 sessions of one-hour non-drug behavioral intervention. Session 1 involves education about pain and insomnia and the relationship between the two. Participants will also learn sleep hygiene and stimulus control skills. Session 3 involves teaching participants skills to limit non-sleep time in bed and thus increase sleep efficiency. Participants will also learn the relationship between pain and activity. Session 4 involves teaching participants cognitive restructuring and mindfulness skills to manage maladaptive thoughts related to pain and insomnia. Participants will also review the skills they learned and discuss the maintenance of treatment gains.
45931089|NCT02681055|Drug|MN-001|MN-001 is a novel, orally bioavailable small molecule compound which demonstrates anti-inflammatory activity
45931090|NCT02663518|Drug|TTI-621|Monotherapy
45931091|NCT02663518|Drug|TTI-621 plus Rituximab|Combination therapy
45931092|NCT02663518|Drug|TTI-621 plus Nivolumab|Combination therapy
45931093|NCT02603848|Drug|Ibuprofen|(10mg/kg; maximum 600 mg) every six hours as needed
45931094|NCT02603848|Drug|Morphine|0.2 mg/ kg morphine suspension (maximum 10mg) every four hours as needed
45931095|NCT02582489|Biological|Bone Marrow Aspirate Concentrate|Subjects undergoing autologous bone marrow aspirate concentrate will receive an intra-articular injection into the affected knee.
45931096|NCT02582489|Procedure|Standard Meniscectomy|All subjects will undergo either a partial or complete meniscectomy to treat the torn meniscus.
45931097|NCT02580539|Biological|Group A|Peptide-stimulated T cells 2 x 10^7/m^2
46073001|NCT02841956|Other|Clinic based Engagement (Phase 2)|PHASE 2 Clinic-based Engagement: The clinical assessment appointment will be completed within the EDAPT clinic. If deemed eligible for EDAPT services, the individual will be scheduled for a clinic-based appointment with the EDAPT psychiatrist within 5 days, who will prescribe medications and order labs as indicated. The EDAPT clinician will follow up with the individual within 5 days of the psychiatric evaluation (by phone or in the clinic) to determine if the prescribed medication regimen has started.
45801725|NCT02741687|Drug|Supplemental insulin (insulin aspart)|"Supplemental insulin aspart will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) >240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~BG between 181-220 mg/dL; 2-4 units of insulin lispro~BG between 221-260 mg/dL; 3-5 units of insulin lispro~BG between 261-300 mg/dL; 4-6 units of insulin lispro~BG between 301-350 mg/dL; 5-7 units of insulin lispro~BG between 351-400 mg/dL; 6-8 units of insulin lispro~BG > 400 mg/dL; 7-9 units of insulin lispro"
45651792|NCT05019157|Other|Centre - based rehabilitation group|Participants will attend an exercise - based cardiac rehabilitation program at the outpatient clinic's facilities under the supervision of cardiac rehabilitation specialized staff. The participants will receive an individually tailored training program on a treadmill or a cycle ergometer. Total training attendance rate will be documented by the cardiac rehabilitation centre staff. Patients will be instructed to wear a tri - axial accelerometer during the entire 12 weeks study period. Participants should upload recorded data to the local server every month. Educational videoconferences will be held every week for physical activity counseling, diet/nutritional and smoking cessation counseling.
45651793|NCT05008237|Drug|docetaxel plus Cisplatin|D1, D8 Docetaxel 35 mg/m2 + D5W 100mL MIV over 1hr D1 Cisplatin 70mg/m2 + NS 150mL MIV over 1hr every 3 weeks Treatment will be continued until disease progression or unacceptable toxic effects.
45651794|NCT05014711|Drug|Remifentanil|Before infusion, remifentanil is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT < 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.
45651795|NCT05014711|Drug|Fentanyl|Before infusion, fentanyl is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT < 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.
45801726|NCT02741687|Drug|Long acting basal insulin (insulin detemir)|"Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) >180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~Fasting and pre-meal BG between >180-240 mg/dl: increase detemir or glargine dose by 10% every day~Fasting and pre-meal BG >241 mg/dl: increase detemir or glargine dose by 20% every day~Fasting and pre-meal BG <100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight"
45801727|NCT02741687|Drug|Long acting basal insulin (insulin glargine)|"Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) >180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~Fasting and pre-meal BG between >180-240 mg/dl: increase detemir or glargine dose by 10% every day~Fasting and pre-meal BG >241 mg/dl: increase detemir or glargine dose by 20% every day~Fasting and pre-meal BG <100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight"
45801728|NCT05643469|Other|Self-determination theory-based intervention plus instant messaging|subjects will receive brief interventions using the AWARD model and they will be allowed to select their own quit schedules (quit immediately, or quit progressively) with the ultimate goal of complete cessation. Follow-up booster intervention with WhatsApp/WeChat messages to help them to adhere to their schedules and independent 1-minute videos will be delivered.
45651796|NCT03087721|Behavioral|HIIT-LV|"Supervised endurance treadmill training as walking/running uphill, 3 times/week during 12 weeks starting at 85-90% of previously determined maximum oxygen consumption (VO2 max). Warm-up 3 min at 30% of VO2 max, 3 min cool-down. Progression in intensity every 3erd week."
45801729|NCT05643469|Other|AWARD model|Subjects will receive a brief intervention using the AWARD model and all of them will advise to quit immediately. Only general health advice via WhatsApp/WeChat will be delivered.
45801730|NCT05361499|Biological|Sp_6B|Intranasal inoculation of Streptococcus pneumoniae serotype 6B, 160,000 colony forming units (CFU)
45653265|NCT04212351|Genetic|Frameshift Array blood sample test|Patient blood test samples will be collected and evaluated for frameshift peptide mutations.
45801731|NCT05361499|Drug|Amoxicillin 500 mg|Amoxicillin, 7 days, 2x 500 mg
45801732|NCT02742077|Device|Robotic-assisted peripheral vascular intervention|Remote delivery and manipulation of guidewires and rapid exchange catheters during percutaneous vascular interventions.
45801733|NCT00372203|Procedure|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy of mediastinal lymph nodes at the time of the mediastinoscopy.
45801734|NCT04900597|Other|Elecare Jr|Elecare Jr is a standard pediatric elemental formula
45801735|NCT04900597|Other|Nourish|Nourish is a commercially prepared blenderized tube feed that is formulated for pediatric use
45801736|NCT04900597|Other|Real Foods Blends|Real Foods Blends is a commercially prepared blenderized tube feed that is formulated for pediatric use
45801737|NCT02768129|Device|transcranial direct current stimulation|active stimulation: 2 milliamp (mA), 20 mins
45801738|NCT02768129|Device|sham transcranial direct current stimulation|sham stimulation
46073002|NCT00843661|Drug|ezetimibe|10 mg ezetimibe/day
45651797|NCT03087721|Behavioral|CAE|Supervised moderate intensity treadmill training, 3 times/week for 12 weeks starting at 70% of VO2 max. Warm-up 3 min at 30% of VO2 max, 3 min cool-down. Progression in intensity every 3erd week.
45651798|NCT05007457|Other|Telerehabilitation|"Patients belonging to the experimental group will receive the brochure and, weekly a telematic comparison will take place lasting about 30 minutes, with a physiotherapist to be asked questions. The physiotherapist will be able to evaluate and modify the training program based on the patient's response.~The tele-rehabilitation sessions will take place: once / week for the first month, once every 2 weeks for the second month and from the third month from the third month the patient can contact the professionals in case of doubts or questions regarding the exercises he is taking place at home."
45651799|NCT05018923|Drug|Rabeprazole|20mg bid
45651800|NCT05018923|Drug|Bismuth potassium citrate|0.6g bid
45651801|NCT05018923|Drug|Metronidazole|0.4g qid
45651802|NCT05018923|Drug|Doxycycline|0.1g bid
45651803|NCT05018923|Drug|Tetracycline|0.5g qid
45451388|NCT02229292|Drug|Tranexamic Acid|"Active group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml tranexamic acid (100mg/ml) administered iv. prior to the onset of the surgical procedure."
45801739|NCT02980549|Other|children's sleep habits questionnaire|survey of children's sleep habits completed by parent
45801740|NCT05192603|Dietary Supplement|low FODMAP or SSRD|The participants are given oral and written information about each diet. No food is delivered from the investigator to the participant
45801741|NCT04337099|Drug|MBM-02 (Tempol)|Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
45801742|NCT05637151|Other|clamp time of umbilical|The umbilical cord was clamped immediately or late for more than 30s
45801743|NCT05356117|Behavioral|Resistance Training (RT) and Protein Supplementation (PS)|Aerobic and resistance exercise with orally consumed pre-packed protein supplement
45801744|NCT05356117|Behavioral|Resistance Training (RT)|Aerobic and resistance exercise
45801745|NCT05356117|Behavioral|Attention Control (AC|Stretching
45801746|NCT02768753|Procedure|The Axillary Bilateral-breast Approach|
45931098|NCT02580539|Biological|Group B|Peptide-stimulated T cells per dose-escalation protocol
45931099|NCT02577354|Device|ReActiv8 Implantable Stimulation System (Patient Appropriate Stimulation)|ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.
45931100|NCT02577354|Device|ReActiv8 Implantable Stimulation System (Low Stimulation)|ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.
45931101|NCT02537899|Drug|NeuroAiD|
45931102|NCT02512887|Drug|Caudal Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine 1mL/kg without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
45931103|NCT02512887|Drug|Dorsal Penile Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine without epinephrine into the dorsal portion of the penis.
45931104|NCT02484261|Drug|Bortezomib|1.3 mg/m2/dose subcutaneously (SQ) daily (total 4 doses) on Days 1, 4, 8 and 11 (+/- 1 day with at least 72 hours between doses) q3 weeks. (For patients continuing to receive drug in cycles 6 or greater, at investigator discretion, the schedule may be changed to 1.3 mg/m2/dose SQ daily (total 3 doses) on Days 1, 8, and 15 (+/- 1 day with at least 72 hours between doses) every 4 weeks in an effort to decrease risk of peripheral neuropathy.)
45931105|NCT02484261|Drug|Pravastatin|10 mg for age < 8 years, 20 mg for age 8-<13 years, 40 mg for ages >14 years
45451389|NCT02229292|Drug|Saline|"Placebo group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml sodium chloride (9mg/ml) administered iv. prior to the onset of the surgical procedure."
45451390|NCT02233114|Other|Yogic exercises|Yogic exercises (YE) - 2 hours per week, 1h in each session
45651804|NCT03090919|Biological|Platelet transfusion|
45651805|NCT03090919|Other|Saline|
45651806|NCT05019079|Other|electroacupuncture|In the electroacupuncture group, acupoints of Lieque (+), Chize (-), Sanyinjiao (-), Zusanli (+), Tanzhong (+) and Yutang (-) will be selected for electrical stimulation. Density wave will be selected, and the current intensity should be tolerated by the patients. Conventional anesthesia operation could be started after the connection of electroacupuncture, and acupuncture point stimulation will be stopped 30min later.
45801747|NCT02768753|Procedure|The bilateral Axillo-breast Approach|
45931106|NCT02477696|Drug|ACP-196|acalabrutinib 100 mg BID (Arm A; N=250)
45931107|NCT02477696|Drug|ibrutinib|ibrutinib 420 mg QD (Arm B; N=250)
45801748|NCT05635513|Device|Owlet OSS V3|A wearable pulse oximeter designed for monitoring infants and children in a home environment
45801749|NCT05162807|Behavioral|Psychoeducational Video on Palliative Care|The intervention is a psychoeducational video introducing palliative care and discussing its purpose, structure, benefits, and efficacy.
45801750|NCT05162807|Behavioral|Educational Video on Nutrition|The attention control is a video on nutrition and healthy eating during cancer survivorship.
45801751|NCT05630677|Drug|AZD5055 solution for infusion|Subjects will receive a single dose intravenous infusion of AZD5055 as 20-minute infusion on Day 1 of the respective period in overnight fasted state.
45801752|NCT05630677|Drug|AZD5055 oral suspension|Subjects will receive single dose of AZD5055 oral suspension on Day 1 of the respective period in overnight fasted state.
45801753|NCT05630677|Drug|AZD5055 film-coated tablet|Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in overnight fasted state.
45801754|NCT05630677|Drug|AZD5055 film-coated tablet|Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in fed state (either a high fat meal or low-fat meal calorie standard breakfast)
45451391|NCT02233114|Other|Physiotherapy|Physiotherapy (low intensity cardiovascular training and strength training) - 2 hours per week, 1 h in each session
45651807|NCT03086863|Device|electroacupuncture|All the patients in verum electroacupuncture group will receive acupuncture on the six adjacent acupoints (LI4, LI15, TE14, SI9, SI11, and GB21) in unilateral side. Acupuncture needles (stainless steel, 0.25 mm × 40 mm, Dong Bang Acupuncture Inc., Republic of Korea) will be inserted 10-15 mm in depth and de qi sensation will be elicited. Park sham guide tubes will be used in verum group, too. Low frequency stimulate (STN-111, Stratek, Republic of Korea) will be connected to the tips of needles to provide electrical stimulation at middle frequency (30 Hz). Needles with electrical stimulation will be retained for 20 minutes. Patients should take this procedure 3 times a week for 3 weeks (9 sessions in total).
45801755|NCT05630677|Drug|Rabeprazole, Delayed-release tablet|Subjects will receive oral doses of rabeprazole twice daily 3 days prior to AZD5055 single dose and 4 days after the AZD5055 single dose including the day that AZD5055 is dosed under fasted conditions [Study Day 10 to 18].
45801756|NCT05630677|Drug|Rabeprazole, Delayed-release tablet|Subjects will receive oral doses of rabeprazole twice daily prior to AZD5055 single dose under fed conditions (low-fat standard breakfast) and then continued for 2 days.
45451392|NCT02229526|Dietary Supplement|Low dose fish oil|Four 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 2.7 g n-3 fatty acids per day.
45653266|NCT04330781|Device|Intraoral stent|Radiotherapy with intraoral stent
45801757|NCT05129735|Dietary Supplement|Meal replacement shake|Each day for the study period (12 weeks), the participants will take one meal-replacement shake per day for breakfast. The breakfast will be replaced by the shake entirely.
45801758|NCT05354323|Biological|NECVAX-NEO1|Oral Ty21a based T-cell vaccination, personalized patient-individual NECVAX-NEO1 constructs containing a eukaryotic expression plasmid encoding for a series of selected neoantigen epitopes
45801759|NCT02770625|Drug|ISU302|60 U/kg given intravenously
45801760|NCT05350657|Behavioral|Ketogenic Diet|2 week isocaloric, high protein and low carbohydrate ketogenic diet
45801761|NCT05124041|Diagnostic Test|Rotational thromboelastometry|ROTEM-guided protocol of hemostatic resuscitation
45801762|NCT05627791|Drug|Oxytocin|Oxytocin vaginal gel that have oxytocin 400IU/1ml of gel, base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0
45801763|NCT05627791|Drug|Placebo|Placebo gel that have base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0 without oxytocin
45801764|NCT02771093|Drug|Trelagliptin|Trelagliptin 100 mg tablet
45801765|NCT02771093|Drug|Alogliptin|Alogliptin 25 mg tablet
45801766|NCT05326243|Biological|CD19-targeted chimeric antigen receptor T-cell|"Drug: Fludarabine~patients will receive a lymphodepletion chemotherapy with Fludarabine 25 mg/m2/day IV for 3 days on Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3).~Drug: Cyclophosphamide~patients will receive a lymphodepletion chemotherapy with cyclophosphamide 300 mg/m2/day IV for 3 dys Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3).~Biological: CD19 CAR-T~CD19 CAR-T cells will be administered using as a single dose at 0.1-9*10^6 cells/kg on Day 0 after completion of the lymphodepletion chemotherapy. The body weight calculated for PL001 dose is the actual body weight on the day of leukapheresis."
45801767|NCT04855747|Drug|REL-1017|REL-1017 tablet
45801768|NCT04855747|Drug|Placebo|Placebo tablet
45801769|NCT00372281|Drug|Cliavist|Injection of 0,9 mL (weight < 60kg) or 1,4 mL (weight > 60kg) of Cliavist (ferucarbotran) by direct intraveinous way, 48 h following the MRI done with gadolinium.
45801770|NCT02986945|Behavioral|Resiliency App|
45801771|NCT05306587|Drug|Darzalex|Investigate the home administration of Darzalex SC reported by both patients and healthcare professionals compared to the hospital administration setting.
45801772|NCT04337879|Drug|AL2846|AL2846 is a multi-target receptor tyrosine kinase inhibitor, which has obvious selectivity for c-met.
45801773|NCT04337879|Drug|Calcium folate|Calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle
45801774|NCT04337879|Drug|5-FU|5-FU 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.
45801775|NCT04337879|Drug|Oxaliplatin|Oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle.
45801776|NCT04337879|Drug|Irinotecan|Irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle.
45451393|NCT02229526|Dietary Supplement|Low dose olive oil|Four 1 g capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
45653267|NCT04330781|Other|No intraoral stent|Radiotherapy without intraoral stent
45801777|NCT05613049|Other||If the CE is high, antibiotics will be given to the patients as usual practice in hospitals.
45801778|NCT05294419|Device|CVD Integrated Risk Test|CVD IRT (IVD regulations with a software device)
45801779|NCT04336631|Behavioral|Intervention on DCP3 based strategies for Hypertension Management and Control|Intervention on DCP3 based strategies for Hypertension Management and Control was developed after formative research findings and evidence built on desk review which was conducted prior to implementation of the multi-componnet strategy. It was tested and implemented in a tertiary care hospital of cardiology among hypertensive patients visiting out-patient department in Rawalpindi, Pakistan.
45801780|NCT05456945|Other|acupressure application|Acupressure will be applied to the UB32 point
45801781|NCT05456945|Device|Shotblocher|Shotblocher will be administered during injection
45801782|NCT02774213|Other|Questionnaires completion|
45801783|NCT02774213|Other|Clinical Pain Assessments|
45801784|NCT05456789|Device|combined catheter-thrombectomy and local fibrinolysis|combination of catheter-based thrombectomy with local pulmonary fibrinolysis plus conventional treatment
45801785|NCT05456789|Other|conventional treatment|conventional treatment of pulmonary embolism
45801786|NCT05274217|Behavioral|Journey of Transformation-Native Youth Health Leadership Program curriculum|Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.
45651808|NCT03086863|Device|sham electroacupuncture|We selected a non-penetrating sham needling, i.e., Park sham device, which has been developed and validated in preceding studies as comparison. On the exactly same 6 acupoints as verum electroacupuncture group, needles will be installed with Park sham guide tubes and the same electrical stimulators will be connected the tips of needles. Since the needles do not penetrate the skin, the stimulation is not electrically conducted. To be sure of patient blinding, the low frequency stimulate will be turned on with the same frequency (30 Hz), which makes a fake noise, resulting in letting patients believe that they are taking real electroacupuncture therapy for 20 minutes. Sham group will also 9 session for 3 weeks (3 sessions a week).
45651809|NCT05019001|Procedure|Laminoplasty|A posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
45651810|NCT05019001|Procedure|Laminectomy With Fusion|Another posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
45651811|NCT05019313|Device|Evaluation of diaphragmatic contractility by ultrasound|Lung ultrasound is performed during mechanical ventilation weaning. The diaphragmatic thickening fraction is evaluated positioning a linear probe in midaxillary line. Inspiratory and expiratory measurements are bilateral and are M-mode images. Right diaphragmatic thickening fraction has been considered as true and reproducible measurement.
45651812|NCT03086473|Drug|Caffeine Citrate|The intervention in this study is timing of the initial caffeine dose. In the Caffeine arm, participants will receive Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) within 2 hours of life, and Normal Saline (0.9% NaCl) 1ml/kg IV at 12 hours of life.
45651813|NCT03086473|Drug|Placebo (Normal Saline)|The intervention in this study is timing of the initial caffeine dose. In the Placebo arm, participants will receive Normal Saline (0.9%NaCl) 1ml/kg IV within 2 hours of life, and Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) at 12 hours of life.
45651814|NCT03086005|Drug|Metformin|
45801787|NCT02745353|Drug|naloxegol|
45801788|NCT04778839|Drug|Paclitaxel Micelles for Injection|Paclitaxel Micelles for Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
45801789|NCT04778839|Drug|Paclitaxel injection|Paclitaxel Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
45801790|NCT05456711|Diagnostic Test|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality
45801791|NCT05602207|Drug|Abrocitinib|100 mg Abrocitinib once daily (QD) for 12 weeks
45801792|NCT04765189|Dietary Supplement|Placebo|Placebo product is 100% maltodextrin. Daily dosage is 500 mg in 2 capsules.
45801793|NCT04765189|Dietary Supplement|Verum A|Verum A is 200 mg of mangosteen extract. Daily dosage is 200 mg in 2 capsules.
45801794|NCT04765189|Dietary Supplement|Verum B|Verum B is 400 mg of mangosteen extract. Daily dosage is 400 mg in 2 capsules.
45801795|NCT04765189|Dietary Supplement|Verum C|Verum C is 200 mg mangosteen extract + 300 mg grape extract. Daily dosage is 500 mg in 2 capsules.
45801796|NCT05261425|Device|Monocryl (FDA Approved) buried running|Participants randomized to this group will receive the Monocryl (FDA Approved) (suture) buried running (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
45801797|NCT05261425|Device|Monocryl buried interrupted|Participants randomized to this group will receive the Monocryl (suture) buried interrupted (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
45801798|NCT05261425|Device|Monocryl not buried interrupted|Participants randomized to this group will receive the Monocryl (suture) not buried interrupted (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
45801799|NCT05261425|Device|Monocryl not buried running|Participants randomized to this group will receive the Monocryl (suture) not buried running (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
45931108|NCT02471430|Drug|Panobinostat|Panobinostat will be administered orally.
45931109|NCT02471430|Drug|Pegylated Interferon-alpha2a|Pegylated Interferon-alpha2a will be administered subcutaneously in one shot.
45931110|NCT02459002|Behavioral|QOL Questionnaire|Participant outcomes assessed with survey
45931111|NCT02459002|Behavioral|Caregiver Satisfaction Questionnaire|Caregiver satisfaction with quality of care assessed with surveys
45931112|NCT02451943|Drug|Olaratumab|Administered IV
45931113|NCT02451943|Drug|Doxorubicin|Administered IV
45931114|NCT02451943|Drug|Placebo|Administered IV
45931115|NCT02438007|Drug|Galeterone|2550 mg galeterone tablets once daily PO
45931116|NCT02438007|Drug|Enzalutamide|160 mg enzalutamide capsules once daily PO
45931117|NCT02412696|Device|Positive Airway Pressure|Auto-titrating PAP + nasal dilator strips during sleep
45931118|NCT02412696|Other|Nasal Dilator Strips|Nasal dilator strips
45931119|NCT02409342|Drug|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab 1200 milligram (mg) will be administered as intravenous infusion every 21 days until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
46073003|NCT00843661|Drug|fenofibrate|200 mg fenofibrate/day
46073004|NCT00843661|Drug|pravastatin|40 mg pravastatin/day
45651815|NCT03079141|Drug|Eplerenone|"Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment."
45651816|NCT03079141|Other|Photodynamic therapy|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment."
45651817|NCT03085615|Other|Jevity 1.5|Jevity 1.5 is an enteral nutrition product delivering 1.5 kcals/mL and 0.06 g protein/mL.
45801800|NCT05261425|Device|Gut (FDA Approved) not buried interrupted|Participants randomized to this group will receive the Gut (FDA Approved) (suture) not buried interrupted (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
45801801|NCT05261425|Device|Nylon (FDA Approved) not buried interrupted|Participants randomized to this group will receive the Nylon (FDA Approved) (suture) not buried interrupted (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
45801802|NCT05261425|Device|Nylon not buried running|Participants randomized to this group will receive Nylon not buried running as the suture and technique. The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
45801803|NCT05598619|Dietary Supplement|Vitamin C|Colon delivered vitamin C (ascorbic acid) for 12 weeks
45801804|NCT05598619|Other|placebo|Colon delivered placebo once a day for 12 weeks
45801805|NCT02746991|Drug|Sham Injection|Placebo
45801806|NCT02746991|Drug|FAI Insert|Fluocinolone Acetonide
45801807|NCT04738357|Drug|HSK21542|HSK21542：1 µg/kg
45801808|NCT04738357|Drug|Placebo|Placebo
45801809|NCT02289157|Device|Negative pressure wound therapy|Single use negative pressure wound therapy systems are composed of a pressure pump and dressing kit. The pump creates a negative pressure of 125 mmHg (+/- 20 mgHg) and the dressing directly covers surgical incision. The system is battery-powered and designed to be used for a minimum of two days and a maximum of seven days of continuous use. The investigators hypothesize that negative pressure wound therapy will decrease the wound complications in these patients. The investigators will be using Prevena Incision Management System as the negative pressure device in our study.
45801810|NCT02747615|Other|transfused pre-operatively donated autologous blood.|Pre-operative autologous donation for minimising perioperative allogeneic blood transfusion
45801811|NCT02747615|Drug|intravenous tranexamic acid (TXA) infusion|Intravenous tranexamic acid is a safe pharmacological treatment to reduce blood loss and transfusion requirements in patients undergoing major orthopedic surgery.
45801812|NCT02747615|Other|transfused only allogeneic blood.|
45801813|NCT04336319|Biological|Fecal Microbial Transplantation|"At baseline, the fecal fluid from 3 different donors, 150 ml, will be delivered via pouchoscopy after which the patient will roll in to the right lateral position and stay in that position for at least 15 minutes. Prior to the procedure, the patient will fast for 12 hours and preform two fleet enemas as preperation.~FMT at 7 days and 4 weeks will be delivered via ingestion of 15 capsules containing 650 µL of fecal fluid from 3 different donors (the same three donors as at baseline)."
45801814|NCT02775617|Drug|Ivermectin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Ivermectin will be offered as a a single dose 200μg/kg on Day 1 and Day 8.
45801815|NCT02775617|Drug|Azithromycin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Azithromycin will be offered as single dose of 30mg/kg, max 2G.
45801816|NCT02775617|Drug|Permethrin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Individuals with a contra-indication to ivermectin will be offered Permethrin instead.
45801817|NCT05590195|Drug|Preforpro|Preforpro will be investigated to improve vaginal health in women with BV.
45801818|NCT05590195|Other|Placebo|Placebo capsules manufactured to look like Preforpro capsules
45931120|NCT02409342|Drug|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) 6 when given in combination with pemetrexed or at a dose of AUC 5 when given in combination with gemcitabine, every 21 days for 4 or 6 cycles as per local standard of care.
45451394|NCT02229526|Dietary Supplement|High dose fish oil|Nine 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 6.1 g n-3 fatty acids per day.
46073005|NCT00832377|Drug|timolol/dorzolamide combination|Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks
46073006|NCT00843739|Device|EMST - Active Treatment|Hand held device used for strengthening expiratory muscles
46073007|NCT00843739|Device|sham EMST|Four week sham device training program
46073008|NCT00705237|Procedure|Functional Endoscopic Sinus Surgery with Balloon Dilatation|Luma lightwire technology will be utilized in conjunction with fluoroscopy for patients with sinusitis undergoing functional endoscopic sinus surgery with balloon dilatation. Trans-illumination of the sinus will be compared to fluoroscopy for accuracy
45451395|NCT02229526|Dietary Supplement|High dose olive oil|Nine 1g gelatine capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
45451396|NCT02229604|Other|EA|For BL33, insert the needle to the third posterior sacral foramina to a depth of 80-100mm. For ST25, EX-CA1 and RN4, the needle will be inserted vertically and quickly through the skin, and then slowly and vertically penetrate through the layer of fatty tissue, up into the muscles of the abdominal wall (until the moment of resistance is sensed on the tip of the needle and the participant feels a sting). The electric stimulator will be put on the BL33 and EX-CA1 with a continuous wave, 20 Hz, 1.0-4.0 mA.
45801819|NCT04336007|Device|Resistive Diathermy (INDIBA® Activ Ct9)|Intervention is conducted using a 65-mm diameter Resistive (RES) electrode (movable), and a planar electrode was used as a return electrode on the abdomen. The electricity is administered in the following manner: cream was applied to the upper limbs existent area, and the electrical output is marked at 75% by moving the movable electrode and if not tolerated by the patient lowered until 35%, Therapy is conducted for 20 minutes, prior swimming time trials.
45801820|NCT04336007|Device|Resistive Diathermy OFF (INDIBA® Activ Ct9)|Placebo is conducted using a 65-mm diameter RES electrode (movable), and a planar electrode was used as a return electrode on the abdomen. The electricity IS NOT administered, the cream was applied to the upper limbs existent area and moving the movable electrode, intervention is conducted for 20 minutes, prior to swimming time trials.
45801821|NCT04336007|Other|Control|This group will warm-up as they usually do in competitions, for later time trial measuring.
45801822|NCT04719403|Other|HealthPAL|Participants who are randomly assigned to the HealthPAL arm will have immediate post- visit access to audio/video-recordings of their clinical visit through a HIPAA-compliant web-based program called HealthPAL.
45801823|NCT05456633|Device|Capri Cervical Static|When used in the cervical spine (C2-T1), CAPRI Static cages are intended for use in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture, or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in cervical degenerative disorders.
45801824|NCT05456633|Other|CAPRI Static Expandable|When used in the cervical spine (C2-T1), CAPRI Static Expandable cages are intended for use in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture, or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in cervical degenerative disorders.
45801825|NCT05456633|Device|Capri Thoracolumbar|Intended for use to replace a collapsed, damaged, or unstable vertebral body due to tumor and trauma (i.e. fracture).
45801826|NCT00371813|Drug|Varenicline tartrate|
45801827|NCT00371813|Drug|Placebo|
45801828|NCT05456009|Other|No intervention|No intervention
45931121|NCT02409342|Drug|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (mg/m^2) every 21 days for 4 or 6 cycles as per local standard of care.
45931122|NCT02409342|Drug|Gemcitabine|Gemcitabine will be administered as intravenous infusion at a dose of 1250 mg/m^2 (in combination with cisplatin) or 1000 mg/m^2 (in combination with carboplatin), on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles as per local standard of care.
45931123|NCT02409342|Drug|Pemetrexed|Pemetrexed will be administered as intravenous infusion at a dose of 500 mg/m^2 on Day 1 of each 21-day cycle as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).
45931124|NCT02399085|Drug|MOR00208|12 mg/kg
45931125|NCT02399085|Drug|Lenalidomide|25 mg
45931126|NCT02356523|Diagnostic Test|Confusion Assessment Method|Administration of Confusion Assessment Method at patent over 65 years at admission and every day until discharge
45931127|NCT02352506|Other|Blood draw for measurement of MIF|Observational study, no intervention
45931128|NCT02336503|Drug|BBI-4000 Gel, 5%|BBI-4000 Gel, 5%
45931129|NCT02336503|Drug|BBI-4000 Gel, 10%|BBI-4000 Gel, 10%
45931130|NCT02336503|Drug|BBI-4000 Gel, 15%|BBI-4000 Gel, 15%
45931131|NCT02336503|Drug|Vehicle|Placebo, BBI-4000 Gel, 0%
46073009|NCT00843895|Biological|pneumococcal conjugate vaccine(prevenar)|to see the vaccine impact on pneumococcal diseases
46073010|NCT00705315|Drug|Docetaxel|Docetaxel as an IV infusion over 1h at the dose of 75mg/m2 every 3 weeks for 6 cycles
46073011|NCT00705315|Drug|Epirubicin|Epirubicin as an IV infusion over 10 min at the dose of 75mg/m2 every 3 weeks for 6 cycles
46073012|NCT00705315|Drug|Bevacizumab|Bevacizumab as an IV infusion over 1h at the dose of 15 mg/kg every 3 weeks for 6 cycles
46073013|NCT00837733|Procedure|Endometrial biopsy|Endometrial biopsy was done at luteal phase on the day 21-26 of spontaneous menstrual cycles, when GnRH agonist uses begun. Endometrial samples were taken by a biopsy catheter
46073014|NCT00837733|Procedure|Endometrial Biopsy|Biopsy catheter
46073015|NCT00892008|Drug|Pregabalin|Pregabalin 75-150 mg BID for at least 2 weeks.
46073016|NCT02548507|Other|observational study, no intervention|
45801829|NCT05224531|Drug|CS1 Administration|CS1 delayed-release capsules will be supplied with 160 mg active pharmaceutical ingredient (sodium valproate) per capsule. Three dose levels that will be evaluated in this study; study drug will be administered as uneven, divided doses twice daily in the morning and in the evening (1/3 of the daily dose is to be administered between 7 and 9 am; 2/3 of the daily dose is to be administered between 7 and 9 pm).
45931132|NCT02255409|Biological|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)|1 dose 0.25 ml: ≥6 months to <36 months, 0.5 ml: ≥36 months to <72 months
46073017|NCT05238168|Other|ePIPARI digital follow up tool|A digital platform includes questions to parents about child wellbeing and development and parent wellbeing. A notification by email or app comes two weeks before the follow up time point. The parents respond via a link to a webpage or via an app.They also receive information (text and video) about age-appropriate child development. ePIPARI includes 8 assessment points from term age until 2 years of corrected age.
45931133|NCT02255409|Biological|non-adjuvanted Quadrivalent Influenza Vaccine (QIV)|1 dose 0.25 ml: ≥6 months to <36 months, 0.5 ml: ≥36 months to <72 months
46073018|NCT04247490|Diagnostic Test|pediatric AIH|pediatric patients with clinical, laboratory (transaminase and IgG increase), instrumental (ultrasound, liver biopsy) characteristics
46073019|NCT04201236|Other|respiratory muscle strengthening exercise|These exercises strengthen locally inspiratory muscles. IMT can be done with threshold loaded devices.
45931134|NCT02213757|Drug|Premarin vaginal estrogen cream|
45931135|NCT02213757|Drug|Placebo vaginal cream|Inactive vaginal cream manufactured to mimic Premarin vaginal cream
46073020|NCT04201236|Other|oropharyngeal muscles strengthening exercise|These exercises strengthen locally oropharyngeal muscles. Oropharyngeal exercise can be done with some facial movements .
45651818|NCT03090763|Genetic|PCR and sequencing|Blood will be subsequently added into a test tube containing RNA solution of a stabilizer, necessary for preservation of the circulating miRNAs. Subsequently, centrifugation will be performed in a cooled centrifuge and the material thus processed will be kept for the subsequent isolation. The isolation of miRNA will be performed using the High Pure miRNA Isolation Kit (Roche, Basel, CHE) according to the manufacturer's standardized procedure. Presence and quality of the miRNA isolated will be spectrophotometrically confirmed using the NanoDrop device (ThermoScientific, Wilmington, DE, USA). By means of the data available in the on-line gene data basis, primers that are necessary for amplification of miRNA through the RT-PCR method using fluorescent dyes will be suggested.
45931136|NCT02137824|Procedure|sinus floor elevation|
46073021|NCT00623233|Drug|Gemcitabine|Gemcitabine 2500 mg/m^2 IV over 30 minutes given on Day 1 q 14 days prior to bevacizumab until PD or unacceptable toxicity.
45931137|NCT02120404|Drug|Esmolol administration|"Esmolol will be administered during 24 hours, beginning with a titration period to determine the minimal dose allowing to achieve the randomized heart rate reduction of 10% or 20%, as defined by randomization.~Titration will be performed in sequences of increasing doses, beginning with 5 μg/kg/min as initial dose, and increasing by 5 μg/kg/min each 30 minutes until the target heart rate reduction is obtained. The maximum dose is 200 μg/kg/min.~The titrated dose will be maintained for a total duration of 24 hours."
45931138|NCT02102243|Drug|DEFINITY® infusion|The DEFINITY® vial contains components that upon activation yield perflutren lipid microspheres, a diagnostic drug that is intended to be used for contrast enhancement during echocardiographic procedures. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic liquid, which upon activation with agitation, provides a homogeneous, opaque, milky white injectable suspension of perflutren lipid microspheres. The suspension of activated DEFINITY® will be infused intravenously at a rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit.
46073022|NCT00623233|Drug|Bevacizumab|"Bevacizumab 10 mg/kg IV over 90 minutes at Cycle 1; infusion time may have been decreased for subsequent cycles. (For example, if the first infusion was tolerated without an infusion-associated adverse event [AE], the second infusion was delivered over 60 minutes. If the 60-minute infusion was well tolerated, all subsequent infusions were delivered over 30 minutes.)~Bevacizumab 10 mg/kg initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity."
46073023|NCT02835612|Other|Early stimulation|Intervention Group: skin-to skin care by mother ( kangaroo care ) plus massage therapy by mothers. They will receive the tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants
46073024|NCT02835612|Other|Conventional care|skin-to skin care by mother, kangaroo care. Standard care, according to the routine care of the NICU.
45801830|NCT02748785|Drug|Methotrexate|Methotrexate will be continued
45801831|NCT02748785|Biological|Seasonal Influenza vaccine|all subjects will be vaccinated with a seasonal influenza vaccine
45801832|NCT04709341|Device|TR Band 60MIN|TR-Band will be in left in place for 15 minutes before it is gradually deflated by 25% at 15 minute intervals
45651819|NCT03085849|Drug|Durvalumab|1500 mg IV on day 8 (flat dose) until progression
46073025|NCT00837889|Drug|diuretics, inotropica|
45801833|NCT04709341|Device|TR Band 120MIN|TR-Band is left in place for 60 minutes before it is gradually deflated by 25% at 15 minute intervals
45801834|NCT02750267|Device|Diabetes Assistant (DiAs) with Closed-Loop|All subjects will use DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a Research House/Hotel admission that will last up to 72 hours.
45451397|NCT02229604|Drug|HRT, DHEA and herb|HRT, dehydroepiandrosterone (DHEA) and herb decoction could be used for this group. Time frame of treatment is not fixed. Herb decoction will be given to participants based on the principle of syndrome differentiation (a diagnosing method in Traditional Chinese Medicine).
45451398|NCT00070109|Drug|trabectedin|Given IV
45801835|NCT02295553|Drug|Ketamine|
45451399|NCT00070109|Other|pharmacological study|Correlative studies
45451400|NCT00090233|Biological|Rotateq™|3 doses of 2.0 mL RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
45651820|NCT03085849|Drug|Tremelimumab|75 mg IV on day 8 (flat dose) x 4 doses
45801836|NCT02295553|Drug|Propofol|
45801837|NCT05455151|Procedure|Conservative therapy|Conservative therapy to which the patients were subjected was the effect of an electrical impulse
45801838|NCT05455151|Biological|PRP injection|This intervention consisted of injecting platelet-rich plasma (PRP) into the endometrium
46073026|NCT02832882|Procedure|No-touch RFA|No-touch RFA indicates RFA without tumor puncture. In this study, no-touch RFA is performed using Octopus electrodes.
46073027|NCT02832882|Procedure|Conventional tumor puncture RFA|Conventional tumor puncture RFA indicates routine procedure of RFA in our institution. In this study, RFA procedure is performed using Octopus electrodes.
45451401|NCT00090233|Biological|Comparator: Placebo|3 doses of 2.0 mL Placebo to RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
45931139|NCT02102243|Drug|Human Recombinant Regular Insulin infusion|The plasma insulin concentration will be acutely raised and maintained at at a steady state by a prime-continuous insulin infusion.
45931140|NCT02102243|Drug|Dextrose infusion|The plasma glucose concentration will be held constant at 90 mg/dl by a variable glucose infusion during euglycemic hyperinsulinemic clamp
45651821|NCT03085849|Drug|SGI-110|"SC daily for 5 days (days 1-5) until progression or toxicity~Dose escalation scheme:~Dose level -1 - SGI-110 20 mg/m2 SC daily; Dose level 0 - SGI-110 30 mg/m2 SC daily; Dose level 1 - SGI-110 45 mg/m2 SC daily; and SGI-110 given on days 1-5 of every 28 day cycle"
45651822|NCT03090685|Procedure|True auriculotherapy with seeds|Roasted edible mustard seeds with ~ 2mm diameter fixed with adhesive tape in 4 to 5 specific body points to control musculoskeletal pain.
45651823|NCT03090685|Procedure|Placebo Auriculotherapy with seeds|Roasted edible mustard seeds with ~ 2mm diameter fixed with adhesive tape at 4 points located in the auricular lobe not specific for musculoskeletal pain.
45651824|NCT03079063|Biological|Eptacog alfa, biosimilar|Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period. Then, in an open follow up phase of 12 months, for every bleeding episode eptacog alfa biosimilar 30 μg/kg, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
45651825|NCT03079063|Biological|Novoseven|Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period.
45651826|NCT03085303|Device|Full Body Blue Light Device|Full body blue light irradiation (phototherapy) of atopic dermatitis patients.
45651827|NCT04434079|Other|Regular critical care|Clinical demographic data, daily and cumulative FB (input minus output) with and without insensible fluid losses, and daily and total BW changes are recorded, as well as survival outcome.
45651828|NCT04958941|Behavioral|Experimental: Intervention group|During 2 months participants will be able to asses their mood and practice in real time their emotional regulation skills with an ecological momentary interventions APP.
45651829|NCT05015101|Other|Cohort observation|Cohort observation
45651830|NCT01659255|Drug|Tirabrutinib|Capsules administered orally
45651831|NCT05014633|Other|EI skills training|EI training sessions were held and managed by two experienced instructors selected from medical education specialists with sufficient experience in conducting EI training. Both instructors attended the sessions, presented the content, videos, slides, and brochures with the help of each other, and managed related scenarios in each session.
45651832|NCT05308485|Other|Events exposure questionnaire|Events exposure questionnaire that assess the occurrence of exposure to events and their severity over a limited period
45651833|NCT05341089|Drug|LY3502970|Administered orally.
45653268|NCT05050149|Drug|PTX-022|Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations
45801839|NCT05455151|Biological|Injection of PRP after conservative therapy|This intervention consisted of conducting conservative therapy with an electrical impulse and then injecting PRP inside the endometrium
45801840|NCT05455151|Biological|Injection of PRP with endometrial cells|This intervention consisted of injecting endometrial cells suspended in prp
45931141|NCT02102243|Procedure|Flow mediated vasodilation|Flow mediated vasodilation (FMD), which is a non-invasive assessment of endothelial function, will be performed on the brachial artery using ultrasound. After a clear picture of the artery has been obtained, the cuff on the same arm will be inflated until it is tight for five minutes. During and following this, the subject's arm will continue to be imaged to monitor maximal increase in the brachial artery diameter.
46073028|NCT02546557|Procedure|Coronary Artery Bypass Graft surgery|
45931142|NCT02102243|Procedure|Endothelial cell collection|We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
45931143|NCT02102243|Procedure|Microvascular perfusion assessment using Definity|Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
45931144|NCT02102243|Procedure|Microneurography|Sympathetic nerve activity from the peroneal nerve measured by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. .The recording needle will remain in position throughout the study.
45801841|NCT02296099|Drug|liposomal bupivacaine|Liposomal bupivacaine 20 mL diluted with 10 mL normal saline. Ten mL of solution to be injected into the vaginal epithelium in the mid-urethral area and 10 mL injected into each of the trocar paths through the suprapubic incisions bilaterally.
45801842|NCT02296099|Drug|Placebo|Normal saline 30 mL total injected. Ten mL injected into the vaginal epithelium in the mid-urethral area and 10 mL will be injected into each of the trocar paths through the suprapubic incisions bilaterally.
45931145|NCT02088658|Behavioral|Technology Intensified|The intervention is based on the Information-Motivation-Behavioral Skills (IMB) model and provides information, motivation, and behavioral skills training (using motivational enhancement techniques). Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse educators will have access to a secure server to which the uploaded measurements are stored in real time. The glucose and BP readings will be used to tailor and reinforce behavior change during weekly telephone-delivered diabetes education sessions.
45931146|NCT02081924|Other|Kisspeptin 0.1|"Participants will receive kisspeptin hormone at a dose rate of 0.1nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
45931147|NCT02081924|Other|Saline|"Participants will receive placebo (saline) via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
45931148|NCT02081924|Other|Kisspeptin 0.3|"Participants will receive kisspeptin hormone at a dose rate of 0.3 nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
46073029|NCT03346772|Biological|Influenza vaccination|Adults will receive one intramuscular dose of seasonal quadrivalent inactivated influenza vaccine, as indicated for standard of care.
46073030|NCT04201002|Procedure|Resection plus intraoperative radiotherapy|En-bloc resection plus intraoperative radiotherapy
46073031|NCT00843973|Procedure|iliac crest bone graft|iliac crest bone graft procedure
46073032|NCT00843973|Procedure|Reamer Irrigator Aspirator|Reamer Irrigator Aspirator (RIA) Procedure
45651834|NCT05001529|Biological|anti IL5 receptor antibodies|Subjects with severe uncontrolled asthma will be assigned to treatment with Omalizumab (anti Ig E antibodies) or Mepolizumab (anti IL-5 antibodies) according to medical advice and standardized protocols for asthma treatment.
45651835|NCT05307159|Dietary Supplement|bean protein supplement|They will have a snack with bean protein for 21 days Participants will follow their usual diet, which will be quantified and evaluated.
45651836|NCT05001061|Drug|Misoprostol Pill|sublingual versus vaginal Misoprostol in termination of first trimester missed abortion
45651837|NCT05531955|Drug|Pirfenidone Oral Capsule|pirfenidone capsules were added to patients receiving basic treatment
45651838|NCT05531955|Other|Placebo Oral Capsule|placebo oral capsules were added to patients receiving basic treatment
45651839|NCT05339529|Drug|Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-|Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead.
45651840|NCT05339529|Drug|Blank control|Blank control
45801843|NCT05455073|Dietary Supplement|Weekly Iron and Folic Acid Supplementation (WIFA)|Weekly school provision of WIFA tablets to adolescent girls
45801844|NCT05455073|Combination Product|WASH|Ensure availability (or provision) of water, sanitation, and hygiene supplies for adolescent girls and boys
45801845|NCT05455073|Combination Product|Menstrual Hygiene Management|Support for adolescent girls' menstrual hygiene
45801846|NCT05455073|Behavioral|Nutrition Behavior Change Intervention (BCI)|Changing the knowledge, attitudes, and practices of nutrition (including dietary diversity), IFA, deworming
46073033|NCT02832804|Device|transcranial Direct Current Stimulation|Experimental: anodal stimulation (2mA) for 20 minutes Active Comparator: cathodal stimulation (2mA) for 20 minutes Sham Comparator: sham stimulation (2mA) for 15 seconds
46073034|NCT02841488|Procedure|Continuous peripheral sciatic nerve block|Continuous infusion of local anesthetics through perineural sciatic nerve catheter
46073035|NCT02841488|Drug|Fentanyl|Use of patient controlled analgesia device with intravenous fentanyl
46073036|NCT02841488|Drug|Ropivacaine|
46073037|NCT02841488|Device|Perineural catheter|
46073038|NCT02832726|Dietary Supplement|Vitamin B12|
45931149|NCT02081924|Other|Kisspeptin 1.0|"Participants will receive kisspeptin hormone at a dose rate of 1.0 nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
45931150|NCT01998971|Drug|Daratumumab|Administered by either intravenous or subcutaneous infusions, in combination with the applicable backbone treatment.
46073039|NCT00831337|Dietary Supplement|VSL3|2 times daily 450 billion live bacteria (in each saschet)
46073040|NCT04201158|Diagnostic Test|Exercise Capacity|Modified Shuttle Walk Test
46073041|NCT00838045|Device|The Bausch & Lomb Akreos TL IOL (MI60) posterior chamber IOL|Surgery to implant the Bausch & Lomb Akreos TL Intraocular Lens will be performed using standard microsurgical techniques following cataract surgery.
45651841|NCT05006911|Drug|Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound|To determine the safety and efficacy of a PBOHB compound in near vision of presbyopic patients.
45651842|NCT05339295|Drug|Levofloxacin 500mg|A single dose consisting of one tablet of either test drug (Levomerc 500 mg) or reference drug (Tavanic 500mg) administered to each of the subjects in both Period.
45651843|NCT05353569|Diagnostic Test|OCT Device(s)|Results from standard-of-care examinations will be compared to research-only examination(s) (OCT device(s)).
45651844|NCT05353491|Behavioral|Technology assisted Thinking Healthy Program (THP-TA)|A technology adapted version of the Thinking Healthy Program (THP) delivered by peers using multimedia android based app.
45651845|NCT05353491|Behavioral|Standard Thinking Healthy Program|This intervention paper-based manual delivered by lady health workers ie government employed community health workers with health training background.
45651846|NCT05352009|Other|Sling exercise training|All participants will receive exercise training for 30 min/ session, 3 sessions/ week for 4 weeks (a total of 12 training sessions). The training includes 20 min of sling exercise training and 10 min treadmill training.
45651847|NCT05352009|Other|Conventional balance training|All participants will receive exercise training for 30 min/ session, 3 sessions/ week for 4 weeks (a total of 12 training sessions). The training includes 20 min of balance exercise training and 10 min treadmill training.
45651848|NCT02637037|Drug|dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)|single fixed-combination dose tablets
45651849|NCT02637037|Drug|dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)|single fixed-dose combination tablets
45651850|NCT02637037|Drug|dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)|single fixed-dose combination tablets
45651851|NCT02637037|Drug|dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)|single fixed-dose combination tablets
45651852|NCT05307081|Drug|Artificial Tears|Artificial Tears are an FDA approved intervention
45651853|NCT05306535|Procedure|Occlusal reduction|Occlusal reduction of the experimental single rooted tooth after root canal completion will be done to evaluation reduction in postoperative pain and sensitivity to percussion
45651854|NCT05000827|Device|PSMA-PET/CT|In the intervention arm patients will only undergo ePLND in addition to robot-assisted radical prostatectomy (RARP) in case of suspected LNI on PSMA PET/CT (miN1), whereas ePLND will be omitted in those without PSMA positive lymph nodes (miN0).
45651855|NCT05000827|Other|Nomogram|Current standard of care includes performing extended pelvic lymph node dissection (ePLND) in all patients with primary prostate cancer and a nomogram-based risk of LNI >5%
45651856|NCT05306067|Diagnostic Test|LDH-based malaria rapid diagnostic test|Malaria testing using an LDH-based malaria rapid diagnostic test will be added to standard routine testing of suspected cases at health facilities
45801847|NCT05455073|Behavioral|MHM & WASH Behavior Change Intervention (BCI)|Changing the knowledge, attitudes, and practices of WASH and menstrual hygiene management
45801848|NCT04334993|Drug|Blinatumomab|Patients with high risk disease features after 2 induction blocks as defined per protocol will be treated with CNS directed block followed by up to 2 cycles of blinatumomab (for B-cell ALL) followed by allogeneic stem cell transplantation.
45931151|NCT01998971|Drug|Velcade|Administered subcutaneously in accordance with product labeling and local standards.
45931152|NCT01998971|Drug|Pomalidomide|Administered orally in accordance with product labeling and local standards.
45931153|NCT01998971|Drug|Dexamethasone|Administered intravenously or orally in accordance with product labeling and local standards.
45931154|NCT01998971|Drug|Melphalan|Administered orally in accordance with product labeling and local standards.
45931155|NCT01998971|Drug|Prednisone|Administered intravenously or orally in accordance with product labeling and local standards.
46073042|NCT02548754|Device|Parasym device|
46073043|NCT02831322|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention was a nonsurgical technique for treating obstructive coronary artery disease
46073044|NCT02547259|Procedure|pain words test|"words to painful sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer will need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word."
45451402|NCT00069953|Biological|filgrastim|During induction therapy, patients ≤ 70 kg will receive 300 μg OR patients >70 kg will receive 480 μg subcutaneously on days 6-15 and 34-42.
45651857|NCT05306067|Diagnostic Test|Malaria rapid diagnostic test|All pregnant women attending their first routine antenatal visit will be tested for malaria using routine malaria rapid diagnostic tests
45651858|NCT05350995|Other|No intervention|No intervention
45931156|NCT01998971|Drug|Thalidomide|Administered orally in accordance with product labeling and local standards.
45931157|NCT01998971|Drug|Diphenhydramine|Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.
45931158|NCT01998971|Drug|Acetaminophen|Administered in prophylactic doses by mouth in accordance with product labeling and local standards.
45931159|NCT01998971|Drug|Carfilzomib|Administered intravenously in accordance with product labeling and local standards.
46073045|NCT02547259|Procedure|negative words test|"words to negative sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word."
45801849|NCT05562193|Behavioral|Physical activity intervention coupled with standard post-cancer directed treatment care|CCS will participate in a 16-week physical activity program. CCS will be instructed to start with a session duration of <15-min, three days per week at low intensity (e.g., activities expending >1.5 to 3 METs or intensity <5 on a scale of 0 to 10). Any type of physical activity will be acceptable. The program will be individualized, and activity increased according to patients' health status, results from the physical function assessment, and most recent week's achieved physical activities. The program will include support calls and texts from research staff (exercise physiologist). The program will be modified and adapted during support calls or texts, including frequency, intensity, time and type to maximize CCS' success. CCS will receive a Fitbit at the beginning of the intervention.
46073046|NCT02831244|Device|Agili-CTM|Consenting individuals will be selected from the population of patients with osteoarthritis of the great toe examined by a participating investigator. Following signing an informed consent, candidates will be evaluated by an adjudication committee for possible inclusion in the trial based on medical history and Standing Foot X-ray. Candidates that are approved or conditionally approved by the adjudication committee will undergo Agili-CTM implantation procedure
46073047|NCT02499302|Behavioral|Mental training|
46073048|NCT02831400|Behavioral|Walking test|Walking test to increase cardiac output, maximum 12 minutes
45651859|NCT05350527|Other|Consultation of a Web Platform|Patients willing to participate in this research and randomized in the experimental arm will benefit, in addition to standard preoperative medical information, an access to the EDOP internet platform via personalized and secure access codes. They will be able to watch an explanatory video about breast surgery and find all the essential, practical and useful information about their intervention and the postoperative effects for the duration of their follow-up.
45651860|NCT04462705|Procedure|Usual physiotherapeutic intervention and Abdominal Massage|Abdominal massage is not widely applied amongst general surgery team and is not part of the recommendation. This technique refers to profound manœuvrers of visceras through abdominal palpation and breathing, and has been used as part of the local protocol of Grenoble Alps University Hospital for many years with satisfactory results. No complications have been reported.
45651861|NCT05338905|Other|Palliative Therapy|Receive standard symptom management
45801850|NCT05562193|Other|Standard post-cancer directed treatment care control|CCS in the control group will not participate in a 16-week physical activity program and will not receive support calls or texts. Physical activity advice according to the Children's Oncology Group Guidelines for Diet and Physical Activity recommendations and the International Pediatric Oncology Exercise Guidelines will be offered to CCS following completion of 16-week follow-up. Moreover, CCS will receive a Fitbit following completion of 16-week follow-up
45801851|NCT04335071|Drug|Tocilizumab (TCZ)|Patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) Actemra® (active ingredient: TCZ) intravenously in 100 mL NaCl 0.9% after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.
45801852|NCT04335071|Drug|Placebo|The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.
45801853|NCT04350229|Drug|Drug omission|Drug omission. In the experimental group, dexamethasone will be omitted from the second application of paclitaxel.
45801854|NCT04350229|Other|Control group|No drug omission. In the control group, dexamethasone will not be omitted in the second application of paclitaxel.
45931160|NCT01998971|Drug|Lenalidomide|Administered orally in accordance with product labeling and local standards.
45931161|NCT01998971|Drug|Montelukast|Administered intravenously or orally only with the first daratumumab dose in accordance with product labeling and local standards.
45931162|NCT01969227|Drug|Subanesthetic ketamine|Ketamine drip at a subanesthetic infusion rate (low dose ketamine 5 - 10 mcg/kg/min)
45931163|NCT01885949|Drug|Tivozanib|Oral
45451403|NCT00069953|Biological|pegfilgrastim|During induction therapy, patients receive 6 mg subcutaneously on days 6 and 34.
45931164|NCT01885949|Drug|Enzalutamide|oral
45931165|NCT01778322|Procedure|Intracranial aneurysm embolization|Treatment of intracranial aneurysms
45931166|NCT01771536|Other|Decision Aid|
45931167|NCT01758042|Procedure|Haploidentical Bone Marrow/Kidney|Combined bone marrow and kidney transplantation using a haploidentical donor.
45931168|NCT01725763|Other|Cardiac MRI|
45931169|NCT01709734|Drug|galeterone|
45651862|NCT05338905|Other|Quality-of-Life Assessment|Complete quality of life questionnaire
45651863|NCT05338905|Other|Questionnaire Administration|Complete quality of life questionnaire
45651864|NCT05338593|Other|Outcome|Mortality rate of prolonged therapy.
45931170|NCT01662713|Device|OFDI|Imaging of skin
45931171|NCT01604135|Device|Corneal Collagen Crosslinking|Keratoconic corneas that show significant progression as specified in the inclusion criteria section will receive one single treatment with CXL if randomized to the treatment arm. A treatment protocol based on 30 minutes dropping with riboflavin/dextran solution and 10 minutes UV-illumination treatment will be used.
45651865|NCT02637895|Drug|Placebo|Placebo pill matching Vortioxetine.
45801855|NCT04704583|Behavioral|SPACE parental-guidance|The treatment will be delivered to the parents in ten 50-minute sessions. The sessions are planned to be weekly and will be completed within 13 weeks of the first session. The sessions include instruction and education, acquiring skills, role-play, and simulations. Parents will be given exercises and goals in reducing accommodation to achieve at home (in cognitive behavioral therapy this is sometimes called 'homework') in some of the sessions. For example, parents to write down one or two things that they would most like to see their child handling better.
45931172|NCT00852657|Procedure|Tendon repair with acromioplasty|Open or mini-open tendon repair in combination with an acromioplasty and eventually a tenodesis of the long head of the biceps
45931173|NCT00852657|Procedure|Physiotherapy|According to a rehabilitation program which was established prior to study start.
45931174|NCT00819208|Behavioral|exercise intervention|3 phases Phase 1: Intensive intervention for 6 months Phase 2: Reduced intervention for months 6-12 Phase 3: Minimal intervention for months 12-36
45451404|NCT00069953|Drug|cisplatin|During induction therapy, patients receive 15 mg/m^2/day by IV over 1 hour on days 1-5 and 29-33. During radiotherapy, patients receive 15 mg/m^2/day by IV over 1 hour beginning on days 57-61.
45931175|NCT00819208|Other|counseling intervention|Achieving an increase in PA from baseline of ≥ 10 MET hours/week will require a significant amount of behavioural support. The intervention will comprise a 36-month individualized PA and behavioural support program with a PAC. This will include a personalized PA prescription which takes into account the baseline fitness test results, PA history, performance status and patient's personal PA preferences and any barriers to activity. Most patients are likely to choose a walking program however any PA of at least moderate intensity level is acceptable.
45931176|NCT00819208|Other|educational intervention|Once at the beginning of the program
45931177|NCT00819208|Other|laboratory biomarker analysis|Every 12 months
45931178|NCT00819208|Other|questionnaire administration|Every 6 months
45931179|NCT00819208|Other|study of socioeconomic and demographic variables|Every 6 months
45931180|NCT00819208|Procedure|fatigue assessment and management|Every 6 months
45931181|NCT00819208|Procedure|quality-of-life assessment|Every 6 months
45451405|NCT00069953|Drug|fluorouracil|During induction therapy, patients receive 650 mg/m^2/day by IV continuously over 96 hours beginning on days 1 and 29. During radiotherapy, patients receive 300 mg/m^2/day by IV continuously over 96 hours beginning on day 57 for 5 cycles.
45451406|NCT00069953|Drug|paclitaxel|During induction therapy, patients receive 200 mg/m^2/day by IV over 2 hours on days 1 and 29.
45801856|NCT05349929|Drug|Gelofen (generic name of Ibuprofen in Iran)|Gelofen capsules, 400mg Ibuprofen, Dana pharma company, every 6hours
45931182|NCT00819208|Other|Educational Intervention|For Arm 2 just once at beginning of program.
45931183|NCT00819208|Other|Fitness testing|Objective fitness testing for both arms
45801857|NCT05349929|Drug|Anahil ( generic name of Bromelain in Iran)|Anahil capsules,200 mg Bromelain, Permon Amin Health Company,every 6hours
45801858|NCT05349929|Procedure|Root Canal Therapy|all the participants go under RCT.
45931184|NCT00644189|Drug|Clofarabine|Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
45931185|NCT00630032|Drug|cyclophosphamide|500 mg/m² every 3 weeks
45931186|NCT00630032|Drug|Docetaxel|100 mg/m² every 3 weeks
45931187|NCT00630032|Drug|epirubicin hydrochloride|100 mg/m² every 3 weeks
45931188|NCT00630032|Drug|fluorouracil|500 mg/m² every 3 weeks
45451407|NCT00069953|Procedure|conventional surgery|Patients with residual or recurrent esophageal disease 4-6 weeks after completion of chemoradiotherapy may undergo salvage esophagectomy.
45451408|NCT00069953|Radiation|radiation therapy|External beam radiotherapy with megavoltage linear accelerators (> 6 MV) will be used to deliver multiple (> 2) field techniques. Patients will be treated 5 days/week at 1.8 Gy/day for 28 days for a total dose of 50.4 Gy.
45451409|NCT01090583|Other|Specimen Collection|We will compare mediators from non-invasive samples (blood, urine, saliva, vaginal or cervical secretions) with traditional gold-standard invasive samples (amniotic fluid and placenta samples).
45931189|NCT00630032|Drug|ixabepilone|40 mg/m² every 3 weeks
45451410|NCT03118570|Drug|setrusumab|Intravenous infusion
45931190|NCT00465517|Drug|Ganaxolone|Oral suspension 200-500 mg 3x/day
45931191|NCT00465517|Other|Placebo|non-active placebo
45931192|NCT00353483|Procedure|Peripheral blood draw|
45931193|NCT00353483|Procedure|Breast tissue collection|
45931194|NCT00353483|Procedure|Bone marrow biopsy|
45931195|NCT00289952|Drug|Valproic Acid|Oral valproic acid twice daily for 16 or 32 weeks. Dosage varies based on plasma levels.
45931196|NCT00289952|Drug|HAART|As per standard of care.
46073049|NCT02831400|Behavioral|Standard Meal|After the walking test, volunteers eat a standard warm meal
46073050|NCT00202904|Drug|ezetimibe|ezetimibe 10 mg tablets, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
46073051|NCT00202904|Drug|placebo|placebo tablets matched to ezetimibe, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
46073052|NCT04248660|Other|uterine artery doppler measurement|"The effect of delivery type on changes in uterine blood flow will be investigated.~Doppler results groups will be defined according to the effect of deviations in uterine blood flow on neonatal and perinatal results."
45451411|NCT03118570|Dietary Supplement|Calcium|tablets
45451412|NCT03118570|Dietary Supplement|Vitamin D|capsules
45651866|NCT02637895|Drug|Vortioxetine|Immediate Release 10 mg. Vortioxetine Pill
45651867|NCT05013697|Drug|Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib|TQB2450 injection: 1200 mg, i.v.gtt , d1;Anlotinib 10mg, po.qd , d1-14；Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to Anlotinib (10mg, po.qd , d1-14)+TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.
45651868|NCT05013697|Drug|Paclitaxel + Cisplatin + TQB2450 injection|TQB2450 injection: 1200 mg, i.v.gtt , d1;Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.
45931197|NCT05772910|Behavioral|EDUcation|The education intervention will consist of an individualized educative program based on intrinsic capacity optimization through lifestyle changes. To develop the program, the program creation team will be multidisciplinary (psychologists, medical doctor, dietitian…) and will discuss goal setting, the education strategy, and retention of motivation. The experts are required to create the education program such that the participants can manage their health by themselves. The goal will be self-management of dietary habits and increases in physical activity levels for each individual case. The education program will be in Spanish or in English; as it will consist in personal counselling, even with a low level of the language the communication will be possible. The nutritional education program will be conducted every 2 weeks for 10 consecutive weeks, with 20-min counselling sessions by an expert.
45931198|NCT05772910|Other|EXERcise|The intervention period will have 10 weeks, in which the EXER group will carry out 2-3 sessions a week (total of 20-30 sessions). In this concurrent program, exercises of the lower extremities (leg press, abduction and plantar flexion) will be performed mainly on weight training machines. Intensity in each exercise will be individualized for each participant through a test to determine muscle power. In addition, in the last part of each session the participants will perform an endurance training type high insensitive interval training on a cycle ergometer (60-80 rpm). The intensity will be individualized to each patient through an incremental stress test until volitional exhaustion, and the subjects will alternate intervals of 30 seconds at 90% of the maximum workload, with intervals of 90 seconds at 40% of the maximum. Each session is estimated to have a total duration of 30-50 minutes.
45931199|NCT05772910|Other|EDU-EXER|This group will carry out the same two previous interventions together.
45931200|NCT05772910|Other|CONtrol|CONtrol group will continue the usual clinical treatment and their normal life
45451413|NCT03118570|Drug|zoledronic acid (optional)|Following completion of the study treatment (Month 12) participants can receive an optional single dose of zoledronic acid. Participants can receive an optional further dose of zoledronic acid at Month 18 at the discretion of their treating physician.
45451414|NCT03771040|Drug|Masitinib|
45451415|NCT03771040|Drug|Placebo|
45451416|NCT02229682|Radiation|Mild-dose IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 46.2 grays (Gy) in 22 fractions.
45451417|NCT02807428|Drug|AYX1 Injection 660 mg/6 mL|6 mL solution for intrathecal injection with 660 mg of AYX1 (Brivoligide)
45651869|NCT05509647|Drug|Unfractionated heparin|Patients are treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa levels of 0.3-0.7 iE/ml
45651870|NCT04928911|Biological|COVID-19 vaccine|Adults about to receive a COVID-19 vaccine fill out a questionnaire of potential predictors of side effect occurrence
45651871|NCT05305911|Drug|Dapagliflozin|Dapagliflozin once daily for six months
45801859|NCT04335227|Other|Structured yoga therapy program|Structured yoga therapy prepared according to traditional yoga scriptures of Patanjali yoga sutras will be administered to 32 females with PCOS. The structured yoga therapy which includes, Surya Namaskara (Sun Salutation) and asanas performed in four positions, standing, sitting, supine and prone for total duration of 60 minutes. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
45801860|NCT04335227|Other|Aerobic exercise training program|Thirty two females with PCOS in aerobic exercise (AE) group will be subjected to aerobic training of moderate intensity for 30-60 minutes six days per week for 12 weeks, in the light of guidelines framed by American College of Sports Medicine (ACSM). Aerobic exercise volume for each female recruited will be set at greater than 500 and up to 1000 MET-min/week, which will be approximately equal to 1000 kcal/week. They will be made sure that they exercise for minimum duration of 150 min/week and thereby covering 5400 to 7900 steps/day in pedometer readings. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
45801861|NCT04335227|Other|Combined yoga and aerobic training program|Thirty two females with PCOS in combined yoga therapy and aerobic exercise (cYTAE) group will be subjected to three days of structured yoga therapy and three days of aerobic training of vigorous intensity. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
45801862|NCT04335227|Other|Nutritional management|Thirty two females with PCOS will be asked to undergo only nutritional management uniquely prepared by dietitian
45451418|NCT02807428|Drug|Placebo Injection 6 mL|6 mL solution for intrathecal injection; vehicle formulation designed to mimic AYX1 Injection (with no active drug)
45931201|NCT05772871|Drug|Huaiqihuang granule|Huaiqihuang Granule, oral administration, recommended daily dose: for body weight <10 kg, 5g, twice a day; for 10 kg ≤ body weight <20 kg, 10g, twice a day; for 20 kg≤body weight <30 kg, 15g, twice a day; for 30 kg≤body weight <50 kg, 20g, twice a day; for body weight>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
45651872|NCT05305911|Drug|Placebo|Placebo once daily for six months
45651873|NCT05013775|Diagnostic Test|Computed tomography|Computed tomography to gauge response after preoperative chemotherapy cycles and excluded the development of interval metastases or irresectable disease
45651874|NCT05013775|Diagnostic Test|Diagnostic laparoscopy with peritoneal lavage|Diagnostic laparoscopy lavage to exclude (small-volume) metastases and determine local resectability
45651875|NCT05349591|Biological|cePolytreg|The treatment group will receive cePolyTregs 2 weeks after islet transplantation as immunotherapy to improve islet survival and reduce the need for immunosuppression drugs.
45651876|NCT05007067|Device|DELTA Multihole TT|Advance articular destruction generated by primary degenerative or post-traumatic arthrosis or reumatoid arthritis; fracture or avascular necrosis; congenital or acquired deformity.
45651877|NCT05349435|Drug|Fezagepras|Investigational drug
45651878|NCT05349435|Drug|Sodium phenylbutyrate|Investigational drug
45651879|NCT05007223|Drug|Doxycycline|200mg/day for 28 days(Given doxycycline to patients with Hailey-Hailey disease)
45651880|NCT05305599|Drug|ZED1227|ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).
45651881|NCT05305599|Drug|Placebo|Placebo
45651882|NCT03083587|Behavioral|Normal lifestyle|Normal lifestyle
45651883|NCT03083587|Behavioral|Exercise|Mild exercise 3 min every half hour
45651884|NCT03083587|Procedure|muscle and fat biopsy|Biopsy under local anesthesia
45651885|NCT03083587|Device|Continuous glucose monitoring|Glucose concentrations during the study period
45651886|NCT03083587|Device|Activity monitoring (ActivePal)|Objective measurements of standing and sitting time
45651887|NCT05000281|Drug|Ibuprofen|600 mg Ibuprofen 3 times a day for up to six weeks.
45651888|NCT05348889|Drug|1A46 Injection|Participants will receive IV 1A46 weekly for Cycles 1-8, then every 3 weeks (Q3W) for Cycles 9-16 (21 days/cycle).
45651889|NCT03081949|Drug|Oral Sodium Selenite 200 µg/day for 3 months|PPCM patients with selenium deficiency, who have not achieved LV reverse remodelling (LVRR) (LV end-diastolic dimension indexed to body surface area (LVEDDi) ≤33.0 mm/m2) at 6 months after diagnosis.
45801863|NCT04692103|Drug|F-18 16 Alpha-Fluoroestradiol|Undergo F-18 FES PET/CT
45801864|NCT04692103|Procedure|Positron Emission Tomography|Undergo F-18 FES PET/CT
45801865|NCT04692103|Procedure|Computed Tomography|Undergo F-18 FES PET/CT
45801866|NCT04692103|Drug|Fludeoxyglucose F-18|Undergo FDG PET/CT
45801867|NCT04692103|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
45801868|NCT04692103|Procedure|Computed Tomography|Undergo FDG PET/CT
45801869|NCT04692103|Other|Laboratory Biomarker Analysis|Correlative studies
46073053|NCT02690870|Drug|Tamoxifen|Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from day 3 of the menses for 5 days.
45651890|NCT04999579|Device|T scan|Occlusal load analysis
45651891|NCT04999813|Combination Product|Comprehensive intensive intervention|"Health education ② Medication guidance: antihypertensive therapy, hypoglycemic therapy, lipid-lowering therapy~Diet guidance: A healthy diet requires low-salt, low-oil, more fruits and vegetables, more cellulose, appropriate amount of protein, restricted fat and cholesterol foods, etc. Quit smoking, drink less alcohol, and limit alcohol intake.~Exercise guidance: Do aerobic exercises of medium and low intensity at least 5 times a week, and exercise for at least 30 minutes each time.~Weight loss guidance."
45651892|NCT05347797|Diagnostic Test|therascreen® KRAS RGQ PCR Kit|To utilize a Clinical Study assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190009), in order to identify patients with NSCLC with KRAS G12C mutation positive tumours.
45651893|NCT05347563|Procedure|Electrical impedance tomography|All change in ventilator settings (mode, tidal volume or inspiratory pressure, Peep, recruitment…)
45651894|NCT03076255|Procedure|Computed Tomography|Undergo CT simulation
45651895|NCT03076255|Device|Medical Device|Given thermoplastic mask
45651896|NCT03076255|Device|Medical Device|Given MID
45651897|NCT03076255|Procedure|Cone-Beam Computed Tomography|Undergo CBCT imaging
45651898|NCT03076177|Other|Taping application|Kinesio taping application will be applied for experimental group; non specific taping application for control
45651899|NCT05336877|Device|Aveir VR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention is required in this study.
45651900|NCT05336877|Device|Single-Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a single-chamber transvenous pacemaker as a comparator to the Aveir VR LP system study arm. No device intervention is required in this study.
45801870|NCT05349851|Other|Follow-up with blood and urine analysis|The patients will receive the preparation standards according to the usual clinical practice of each center. On the day of the colonoscopy, patient will be informed about this study and the informed consent will be requested to record the study information. Then, an analysis will be carried out. A second visit will be carried out, follow-up at 3-7 days, which will include a clinical interview and an analysis, being the unique intervention that patients receive.
45801871|NCT00371891|Procedure|Multidetector Computed Tomography Coronary Angiography|1 Multidetector Computed Tomography Coronary Angiography
46073054|NCT02690870|Drug|Clomiphene|Patients in clomiphene group will take 100 mg of CC oral tablets daily from day 3 of the menses for 5 days.
46073055|NCT02835378|Other|No intervention|
45651901|NCT03076411|Drug|Pepsin|
45651902|NCT05303649|Device|Noninvasive transcranial brain stimulation: excitatory iTBS|600 pulses (3 pulses at 50 Hz given every 200 milliseconds in 2-second trains at 10-second intervals, delivered at 80% of active motor threshold) generated by Magstim Super Rapid2 stimulator equipped with a figure-of-eight coil applied over BA 45 Device: Magstim Co., Wales, UK.
45653269|NCT05471245|Device|Magic Touch SCB by Concept Medical Inc.|PCI with drug-coated balloon
45801872|NCT05203471|Other|integrated care model|The investigators are piloting an integrated care model for rural patients with diabetic foot ulcers. The model uses two tools to promote collaboration between providers: a care algorithm and a referral checklist. The care algorithm will be used by rural primary care providers to guide integrated care addressing glycemic control, vascular disease, wound care, and infection. The referral checklist will be used by rural schedulers who place referrals to urban specialists. It prompts schedulers to fax appropriate supporting documents (e.g. notes, labs, vascular testing results) with the referral request.
45801873|NCT05455463|Behavioral|Online aphasia-adapted physical activity class|Online 50-minute physical activity sessions, two to three times weekly for 10-11 weeks. The activity instructions will be modified to be aphasia-friendly (simplified language, multimodality support).
45801874|NCT04737941|Procedure|Endothermal Ablation|Endothermal ablation is performed to suitable insufficient truncal veins (Great-, Anterior Accessory- and/or Small Saphenous Vein)
45801875|NCT04737941|Procedure|Foam Sclerotherapy|Foam sclerotherapy is performed to insufficient veins distal to the truncal superficial veins.
45801876|NCT00371969|Behavioral|Enhanced Motivational Interview|The intervention consists of a brief motivational interview, which is combined with daily alcohol monitoring through the use of an interactive voice response system IVR (automated telephone system).
45801877|NCT00371969|Behavioral|Standard Motivational Interview or viewing DVD|Brief motivational interview, viewing a DVD on HIV self-care.
45801878|NCT05455307|Device|Allium ureteral stent|observe the effficacy and safety of long-term self expanding ureteral stents for treating refractory ureteral stricture
45931202|NCT05772871|Drug|Prednisone|Prednisone, oral administration, recommended dose: 2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks. If patients have relapsed during reducing dosage or withdrawal, the patients will receive Prednisone for 8 weeks again [2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks]. If a second relapse is observed, patients will receive immunosuppressants and then withdraw from the trial.
45651903|NCT05303649|Device|Noninvasive transcranial brain stimulation: inhibitory cTBS|600 pulses (3 pulses at 50 Hz, repeated at 5 Hz, delivered at 80% of active motor threshold) generated by Magstim Super Rapid2 stimulator equipped with a figure-of-eight coil applied over BA 45 homologue Device: Magstim Co., Wales, UK.
45451419|NCT02750800|Biological|Adalimumab|Pre-filled syringe or pen, administered by subcutaneous injection
45651904|NCT05303649|Behavioral|Individual speech-language therapy (SLT)|45 minutes training tailored to every patient's deficits, abilities and needs. Exercises used during each therapeutic session include: expressions tasks (naming and sentence building), complex utterances comprehension tasks, reading and writing exercises. Training is administered using paper-and-pencil tasks and computerized aphasia therapy program AfaSystem (Harpo sp.zoo, Poznań, Poland).
45651905|NCT05303649|Device|Sham TBS simulating left hemispheric iTBS|Sham TMS coil positioned exactly like an active TMS coil resulting in a very good approximation of the auditory effects Device: Magstim Co., Wales, UK.
45651906|NCT05006755|Combination Product|Mineral Trioxide Aggregate|Mineral Trioxide Aggregate stimulates cementoblasts to produce matrix for cementum formation and is biocompatible with the periradicular tissues thus shows a superior sealing ability when used in perforation repair
45801879|NCT04335851|Other|Video based aerobic exercise|"During social isolation induced by COVID-19, physically inactive people will do exercise in company with aerobic exercises named videoswalk at home which made by American Heart Association. 3 days a week in total 4 weeks. Each sessions will last approximately 30-40 minutes."
45801880|NCT04202393|Behavioral|Integrated Treatment Adherence Program (ITAP)|Psychosocial support and treatment to improve treatment adherence, symptoms, and functioning.
45801881|NCT04202393|Behavioral|Safety Assessment and Follow-up Evaluation (SAFE)|Enhanced assessment and evaluation with clinician feedback.
45801882|NCT04334447|Other|Improved primary care HF diagnostics|Reimbursement of natriuretic peptide testing for participating general practitioners (GPs) Audit and feedback in GPs EHR
45801883|NCT04334447|Other|Heart Failure education|Reimbursement of heart failure education for patients at risk. Web-based training for participating general practitioners
45801884|NCT04334447|Other|Structured transitional protocol planning post-discharge care|Checklist-supported discharge protocol for HF patients including telephone contact with patients' general practitioners and a contact with the HF educator
45801885|NCT05182567|Drug|GLS-5310 (Group 1)|GLS-5310 DNA plasmid vaccine
45801886|NCT05182567|Drug|GLS-5310 (Group 2)|GLS-5310 DNA plasmid vaccine
45801887|NCT05182567|Drug|GLS-5310 (Group 3)|GLS-5310 DNA plasmid vaccine
45801888|NCT05182567|Drug|GLS-5310 (Group 4)|GLS-5310 DNA plasmid vaccine
45801889|NCT04336085|Procedure|caudal block|Caudal block will be performed using ultrasound guidance, the sacral hiatus will be visualized at the level of the sacral cornus by employing the linear transducer of ultrasound machine the ultrasound transducer will be rotated to 90 degree to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and will be subsequently placed between the two cornua. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament.
45801890|NCT04336085|Procedure|pericapsular nerve group block|In PENG group, the patient will be placed in supine position. The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. A 22-gauge, 50-mm needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, a total volume of 0.5 mL/kg local anesthetic solution will be injected.
45801891|NCT05559931|Drug|N,N-Dimethyltryptamine|IV infusion over 6 hours
45801892|NCT05559931|Drug|Placebo|Placebo infusion over 6 hours
45801893|NCT05349695|Device|Spinal cord stimulation|Eligible patients will undergo a SCS trial period for three weeks (as legally defined by the reimbursement authorities). The leads can be placed both surgically of percutaneously with an external trial stimulator. Surgical implantation of an implanted pulse generator (IPG) is performed if the patient achieves at least 50% pain reduction and a reduced pain medication use (reimbursement requirements) during the trial period. Subsequently, the implanted devices are programmed to the optimal parameters in collaboration with a nurse specialized in SCS treatment. The patients are educated on the use of the patient programmer.
45801894|NCT04162847|Device|SilverCloud Health Intervention|SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs for preventing and treating anxiety, depression, and eating disorders as appropriate Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.
45801895|NCT05174767|Device|AMDS|AMDS Implantation
45801896|NCT04335695|Behavioral|Vascular Rehabilitation|Vascular rehabilitation is a supervised exercise therapy program that includes healthy lifestyle changes to help patients gain strength, energy and confidence to return to daily activities. A program of supervised exercise rehabilitation is considered a primary treatment for people with Peripheral Artery Disease and Intermittent Claudication. In addition, patients will be given a wrist-worn activity tracker and be in contact with a research coordinator every 3 months after they are discharged from the Vascular Rehab program.
45451420|NCT02750800|Behavioral|AbbVie Care 2.0|Supportive services provided to participants included reminder calls, emails, text messages, nursing services, dietician, and psychological support. An adalimumab starter pack, injection guide, digital and print educational materials were also provided.
45451421|NCT05633056|Behavioral|Adherence support intevention|Compare the effects of adherence support interventions on clinical and biological endpoints using an adaptive randomized platform.
45931203|NCT05772871|Drug|Levamisole placebo|Levamisole placebo, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
45931204|NCT05772871|Drug|Levamisole|Levamisole, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
45931205|NCT05772871|Drug|Huaiqihuang Granule placebo|Huaiqihuang Granule placebo, oral administration, recommended daily dose: for body weight <10 kg, 5g, twice a day; for 10 kg ≤ body weight <20 kg, 10g, twice a day; for 20 kg≤body weight <30 kg, 15g, twice a day; for 30 kg≤body weight <50 kg, 20g, twice a day; for body weight>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
45931206|NCT05772858|Other|Training on CIFFTA competencies using Family Therapy Training and Implementation Platform (FTTIP)|An Innovative Web-based Tool to train mental health therapists in family therapy competencies with animated families and provided recorded video responses to receive feedback from trainers.
45801897|NCT05169073|Procedure|Virtual Reality training|In the Virtual Reality (VR) study arm, a VR software (Specto VRTM, version 4.0, Diffuse Ltd, Heimberg, Switzerland) will be used to display volumetric MRCP data using a tethered head-mounted display (HMD) prior to the operation. Specto uses volume rendering at 180 frames/sec to visualize the medical data in an immersive fashion in the VR environment and allows for viewing of the 3D reconstructed 3D imaging with 360° free movement. Each participant will perform a procedure with VR training and one with conventional preparation (MRCP).
45801898|NCT05169073|Procedure|Conventional training|In the conventional study arm, the participants will view the preoperative MRCP.
45931207|NCT05772858|Other|Training on CIFFTA competencies using Training and Coaching as Usual (TCAU).|Therapists receive training using the traditional face to-face training method for 2.5 days followed by coaching.
45931208|NCT05772858|Other|Culturally Informed and Flexible Family-Based Treatment for Adolescents (CIFFTA).|CIFFTA has three major components: Family Therapy, Individual Therapy, and Psycho-educational Modules, delivered over 16 weeks in a two session (60 minutes each) per week format. One session will typically be a family session which may include Family Therapy or Psychoeducational modules designed for the family or parents alone. The other session is typically with the adolescent alone which may include individual treatment or Psycho-educational modules designed for the adolescent.
46073056|NCT00844207|Drug|Fixed combination of Azithromycin and Chloroquine|Pfizer will provide the study medications, fixed combination azithromycin/chloroquine tablets (250 mg/155 mg, base), The study treatment is single dose.
45651907|NCT05006755|Combination Product|Biodentine|Biodentine has a good sealing ability, high compressive strengths, short setting time, biocompatibility, bioactivity and biomineralization properties that make it available to be used in endodontic repair procedures
46073057|NCT00844207|Drug|Azithromycin and Chloroquine|Pfizer will provide Zithromax (500 mg) and Aralen (500 mg containing 300 mg chloroquine base). The study treatment is single dose.
45451422|NCT05628688|Diagnostic Test|Insight Pro Device for Diagnosis|Insight Pro Device for Diagnosis of Lymphatic and Venous Disorders
45451423|NCT02229760|Drug|Tipranavir capsules|
45451424|NCT02229760|Drug|Ritonavir capsules|
45651908|NCT05347173|Drug|Dexmedetomidine|patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Dexmedetomidine (10 µg in 0.5 mL normal saline)
45651909|NCT05347173|Drug|Nalbuphine|patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Nalbuphine (1 mg in 0.5 mL normal saline)
45651910|NCT05006287|Drug|Non-vitamin K oral anticoagulants (NOACs)|"NOAC Group (Intervention):~Patients randomized to the NOAC group will receive a NOAC dosed according to the Canadian monograph for the respective indication. Patients receiving a NOAC before cardiac surgery will resume the same NOAC as pre-operatively, whereas patients not previously receiving a NOAC will preferentially receive apixaban according to local practice. The NOAC will be started no earlier than post-operative day 5 and based on the standard protocol depending on whether the patient has a pre-existing indication for anticoagulation or new indication (e.g. post-operative atrial fibrillation).~Patients at high risk of thrombosis and low risk of bleeding will receive a standardized bridging protocol as early as post-operative day 3 with unfractionated heparin infusion or low molecular weight heparin until the NOAC is initiated."
45451425|NCT05627908|Other|Contrast-enhanced ultrasound|Patients data monitoring with medium- and high-grade trauma to the liver, spleen, and kidney
45801899|NCT04822883|Drug|RL-007|Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
45801900|NCT04822883|Drug|RL-007 Matching Placebo|Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
46073058|NCT02835300|Behavioral|CampAir|CampAir is a dynamic e-learning intervention to help adolescents with uncontrolled asthma to manage their illness and to improve their asthma control. CampAir consists of seven online modules with one module being completed each week over seven weeks. Each module provides a brief introduction to the topics and strategies focused on in that module followed by a set of interactive exercises and games for practice and personalized feedback.
46073059|NCT02835300|Behavioral|Information and Referral|The information and referral comparator condition will provide access to existing generic asthma education websites. They will also be referred to their medical providers for asthma. After the completion of the trial, all participants will have access to CampAir.
46073060|NCT02841722|Procedure|ERIBULIN + G-CSF (Granulocyte-Colony Stimulating Factor)|8 additional blood samples
45801901|NCT02331589|Drug|KRG (Korea Red ginseng)|3 weeks of KRG capsule (3,000 mg/day)
46073061|NCT02548117|Drug|Finasteride|Subjects will take 5 mg finasteride orally every day for about 2 years.
45451426|NCT03737812|Drug|elezanumab|solution for infusion
45451427|NCT03737812|Drug|placebo|solution for infusion
45451428|NCT02229838|Drug|BIBB 1464 MS tablet|
45451429|NCT02229838|Drug|BIBB 1464 MS solution|
45451430|NCT02229838|Drug|BIBB 1464 MS placebo|
45451431|NCT02229838|Other|Standard dinner|
45801902|NCT02331589|Drug|Placebo (for KRG)|Placebos with same shape and size were manufactured and at Korea Ginseng Corporation
45931209|NCT05772858|Other|Agency Readiness Consultation- Family Therapy Training and Implementation Platform (FTTIP)|The FTTIP agency readiness work begins with a pre-recorded FTTIP introduction webinar presented separately to each agency which presents overall goals of the project and the different FTTIP components, and key decisions agencies often make when seeking to sustain a new EBT.
45801903|NCT05439083|Biological|9-valent HPV vaccine|All participants will receive the immunization schedule according to guidelines: immunosuppressed patients will receive a three-dose schedule: 0.5 mL intramuscular injection of 9vHPV at entry plus an additional dose at month 2 and month 6. Healthy controls aged 9-14 years will receive a two-dose schedule: 0 and 6 months.
45801904|NCT04669171|Biological|EO2463|Multiple dose of EO2463
45931210|NCT05772858|Other|Agency Engagement and Orientation as Usual|Work with the agency leaders will consist of the traditional engagement of the leadership so that they agree to collaboration with the study team, with the training team, and with the study procedures.
45931211|NCT05772845|Behavioral|Acute (24-hour) abstinence|Participants will be asked to abstain from all tobacco/nicotine for 24 hours prior to the visit
45931212|NCT05772845|Behavioral|Ad libitum smoking/vaping|Participants will be asked to smoke/vape as usual during the 24 hours prior to the visit
45931213|NCT05772832|Drug|Dexmedetomidine|Efficacy of dexmedetomidine on postoperative pain in patients undergoing transsphenoidal pituitary surgery
45931214|NCT05772832|Drug|Remifentanyl|Efficacy of remifentanyl on postoperative pain in patients undergoing transsphenoidal pituitary surgery
45931215|NCT05772819|Diagnostic Test|exercise MRI|All patients are subjected to two types of in-magnet exercise tests consisting of exercise cardiac magnetic resonance imaging (exCMR) and Phosphorus 31 magnetic resonance spectrography (31P MRS) of the quadriceps muscle, during exercise at various exercise intensities in a supine position using a MR-compatible ergometer (Lode MR Ergometer Pedal, Lode BV, Groningen, the Netherlands).
45931216|NCT05772806|Device|Electrocardiogram|"The electrocardiogram will help to diagnose atrial fibrillation and the electronic devices (App Fibricheck and Smart bracelet/watch) will help to detect an arrhythmic rhythm.~The echocardiography will be used for detecting criteria of atrial cardiomyopathy.~MRI may help to detect silent strokes."
45651911|NCT05006287|Drug|Warfarin|"Warfarin Group (Comparator):~Patients randomized to the warfarin group will receive warfarin titrated to achieve a target International Normalized Ratio (INR) of 2.5 (range 2.0 to 3.0). Warfarin will be started as early as post-operative day 1 and based on the standard protocol depending on whether the patient has a pre-existing indication for anticoagulation or new indication (e.g. post-operative atrial fibrillation).~Patients at high risk of thrombosis and low risk of bleeding will receive a standardized bridging protocol as early as post-operative day 3 with unfractionated heparin infusion or low molecular weight heparin until INR is 2.0 or above."
45931217|NCT05772793|Device|Telerehabilitation|The home visual telerehabilitation path using the EyeFitness software consisted of performing one visual training session per day, 5 days a week (from Monday to Friday) for a total of 6 weeks.
45931218|NCT05772780|Device|MP-3 microperimeter|Biofeedback stimulation two days a week
45931219|NCT05772780|Device|MP-3 microperimeter|Biofeedback stimulation three days a week
45931220|NCT05772767|Other|Biological sample collection|Collection of tumor tissue and blood for stem cell culture and organoids generation.
45931221|NCT05772767|Other|Dissecting ciliogenesis players|Assessment of cilium-related transcriptome in glioblastoma stem cells. Modulation of cilium-related genes and administration of cilium-targeted drugs to glioblastoma stem cells in vitro and ex vivo in glioblastoma brain organoids.
45651912|NCT05303415|Other|Neuromodulation with low-intensity focused ultrasound|Application of LIFU to induce temporary neuromodulation, effects tested with resting state and heat evoked (QST) fMRI signals
45651913|NCT05013151|Dietary Supplement|Dates|Consumption of 6 dates a days until 41 weeks of gestation
45931222|NCT05772767|Diagnostic Test|Validating ciliogenesis players|Cilium-related signature will be studied in tumor tissue to evaluate its prognostic role.
45931223|NCT05772741|Other|Biological sample collection|Collection of biological samples
45931224|NCT05772728|Drug|Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen|CAM regimen (every 21 days as a treatment cycle). Cetapenem 20 mg orally twice weekly Azacitidine 75 mg/m2 subcutaneously d1-7 Mitoxantrone liposomes 20 mg/m2 intravenous d6
46073062|NCT05263518|Procedure|Cataract surgery with AcrySof IQ IOL implantation.|Patients in this study will receive cataract surgery with AcrySof IQ IOL implantation.
45651914|NCT05013151|Dietary Supplement|Castor oil|One time consumption of 60 CC Castor oil
45651915|NCT05303337|Other|Stool sampling|Stool samples will be collected from participants at baseline and W52
45801905|NCT04669171|Drug|lenalidomide|D1-21 of 4-weekly cycles
45801906|NCT04669171|Biological|rituximab|Multiple doses of rituximab
45801907|NCT05427227|Device|EV-array detection|Collect peripheral blood sample of 500 GI patients at treatment baseline, every time point response till disease progression.Blood samples will be transferred to central lab to detect certain exosome proteins expression by EV-array.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastatic organ ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
46073063|NCT05263518|Procedure|Cataract surgery with TECNIS toric IOL implantation.|Patients in this study will receive cataract surgery with TECNIS toric IOL implantation.
45801908|NCT05421455|Drug|Group A|treat participants with biologics
45801909|NCT05421455|Procedure|Group B|treat participants with surgery
45801910|NCT05414591|Drug|DWP16001 drug A|1 tablet, Oral, once daily single dose
45801911|NCT05414591|Drug|DWP16001 drug B|3 tablet, Oral, once daily single dose
45801912|NCT05412407|Other|Questionnaire|description of analgesic self-medication in the context of acute pain using a questionnaire evaluating the drug taken, the dosage, the duration of treatment, the type of pain, its intensity, the origin of the drug, the source of information consulted and the factors that prompted the patient to self-medicate
45801913|NCT04814225|Other|Test Product 1|Pea Protein powder
46073064|NCT02841566|Other|questionnaire|
45651916|NCT05303337|Other|Blood plasma collection|Blood plasma collection to assess persistent inflammation, immune activation and HIV reservoir at baseline,W24,W52
45931225|NCT05772715|Other|orthosis + exercise therapy|The orthosis + exercise group receives the same orthosis and instructions as the orthosis group (see next section), supplemented by exercise therapy. This includes weekly 25-30-minute physical therapy sessions with a total of 12 sessions. Sessions include patient education on thumb positioning, functional training and home exercise instructions to improve CMC-1 stability during pinch in extension/abduction, as instability and degeneration occurs in flexion/adduction(17,19,28-31). The first phase (week 0 - week 6) comprises coordination exercises for the thumb intrinsics (except adductor pollicis), extensor pollicis brevis and first dorsal interosseous to support CMC-1 extension/abduction. The second phase (week 6 - month 3) comprises reduced orthosis usage and thenar muscle strengthening exercises(except adductor pollicis).
45931226|NCT05772715|Other|Orthosis|The orthosis group receives a custom-made thermoplastic orthosis immobilizing the first carpometacarpal joint (CMC-1) in extension/abduction and the metacarpophalangeal joint in flexion. Orthosis usage is 24/7 in the first two weeks, thereafter only during activities with high load until three months. Two appointments take place: one for orthosis fabrication and one for a one-week checkup.
45931227|NCT05772702|Device|Closed-loop tACS|Individual alpha tACS
45931228|NCT05772676|Drug|Aprepitant|80 or 125 mg tablet + standard antiemetic regimen, once two hours before surgery
45931229|NCT05772676|Other|Placebo|Placebo + standard antiemetic regimen, once two hours before surgery
45931230|NCT03392467|Biological|PNEUMOSTEM|human umbilical cord blood-derived mesenchymal stem cells
45801914|NCT04814225|Other|Test Product 2|Pea & Oat Protein Powder
45931231|NCT03392467|Other|Placebo|normal saline
45931232|NCT05772663|Other|Personalized program of rehabilitation|"D56: Follow-up visit (D56). Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20*20). At D119, the person returns the accelerometric writbands."
45651917|NCT05006365|Device|Transcranial Pulse Stimulation|A total of 30 participants (both TPS group and the waitlist control group) will receive six 30 minute-TPS sessions (300 pulse in each session, total: 1800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up at 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on depressive symptoms.
46073065|NCT02546947|Other|Train of four monitoring|with an end point of one or two response at orbicularis oculi to TOF stimulation
46073066|NCT02841878|Genetic|Analysis on colorectal biopsy|
46073067|NCT02841800|Device|'Intra-luminal radiofrequency ablation (Habib EndoHPB)|endobiliary radiofrequency ablation device
45651918|NCT05302089|Other|Pain management and shoulder bandage|All Patients receive standard pain management according to the local guidelines and a sling and swathe on the day of injury. After 10 to 14 days, all patients will receive a sling for optional use for one to two weeks and be randomized after oral and written informed consent.
45651919|NCT05302089|Other|One-time physiotherapy instruction|Patients are offered a one-time physiotherapy instruction about the course of pain and suggestions for quick and safe return to activities of daily living within the first three months post-injury.
45801915|NCT04814225|Other|Test Product 3|Oat Protein Powder
45801916|NCT04814225|Other|Comparator|Whey Protein Isolate
45801917|NCT05441033|Other|Group-FHB|This is the group where pregnant women and their spouses listen to the fetal heartbeat.
45651920|NCT05302089|Other|Usual rehabilitation care|At the visit 10-14 days after the injury, the orthopaedic consultant (senior author SB) will refer the patient to usual rehabilitation care with a physiotherapist in a municipality close to the patient´s home. The physiotherapist then schedules the start date, typically three weeks after the injury. The rehabilitation content and duration is planned according to the choice of the local treating physiotherapist in consultation with the patient.
45651921|NCT05006209|Other|One visit root canal treatment|
45651922|NCT05006209|Other|Two visit root canal treatment|
45653270|NCT05557799|Radiation|Photobiomodulation|The treatment group will receive four consecutive applications, using laser diode DMC (808 nm), 4J per point, 100mW of power, 510mW/cm², beam area of 0.2cm², 8 sites in the external vagina, for 40s in each site, once per week for 4 weeks.
45801918|NCT05441033|Other|Group-GIT|This is the group in which the guided imagery technique is applied to pregnant women and their spouses.
45801919|NCT05541679|Device|Right ventricular septal pacing followed by left bundle branch area pacing|All patients will undergo implantation of right ventricular septal lead, left bundle branch area lead, and atrial lead in the absence of permanent atrial fibrillation with a CRT-pacing generator. Patients will be randomized to pacing protocols based on group assignment and crossover during the study.
45801920|NCT05541679|Device|Left bundle branch area pacing followed by right ventricular septal pacing|All patients will undergo implantation of right ventricular septal lead, left bundle branch area lead, and atrial lead in the absence of permanent atrial fibrillation with a CRT-pacing generator. Patients will be randomized to pacing protocols based on group assignment and crossover during the study.
45801921|NCT00372671|Behavioral|Survey|
45801922|NCT00372671|Behavioral|Survey and videotape|
45801923|NCT02986867|Radiation|SAbR Treatment of Lesions|"SAbR will be administered as per the guidelines of UTSW with a single 24-27Gy or three 10-14 Gy/fraction fractions totaling 33-48Gy. Lesions receiving SAbR will be called radiated lesions."
45801924|NCT05146999|Biological|QM1114-DP|QM1114-DP
45651923|NCT05346003|Procedure|TCSP|In the pre-test, all students will be given a BLS information form, followed by blended e-learning with theory and video in a virtual environment. The BLS knowledge post-test will be administered immediately after class.T-shirts and standard pillows (550 g silicon fiber pillow 50x70 cm size) with a simulation of an adult human size (approximately) sternum, rib and heart drawing (printed as picture) will be given to the intervention group only after the pretest. In the study, the BLS will be simulated for adult patients only. To simulate a half-body human BLS mock-up, a pre-made simulation t-shirt will be fitted on a standard pillow to create a BLS mock-up in a home environment, and after blended e-learning, they will be able to perform BLS iteratively on a T-shirt-clad simulation pillow (TCSP) model. In this way, autonomous learning will be supported. All students will practice BLS in a real simulation model two weeks after the blended e-learning.
45651924|NCT03081013|Behavioral|Social information|Social comparison information will be provided to the study participants weekly via SMS
45931233|NCT05772663|Other|Routine program of rehabilitation|"Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20*20). At D119, the person returns the accelerometric writbands."
45931234|NCT05772650|Behavioral|e-Health Program|Lifestyle modification for health and disease management using digital solutions
45931235|NCT05772637|Procedure|Repeated cystometries with bladder sensations assessment|A second cystometry will be performed to assess bladder sensations reliability. A third cystometry with cognitive task (STROOP test) at the same time will be performed to assess the impact of distractive attentional task on bladder sensations
45931236|NCT05772624|Drug|low dose nivolumab in combination with AVD|Nivolumab as an standard dose of 40mg in combination with AVD.
45801925|NCT05146999|Biological|Placebo|Placebo
45931237|NCT05772611|Biological|Genetic and immunology tests|"This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF, cells). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes."
45931238|NCT05772585|Other|Blood collection|Blood collection (1 to 4 times for each patient) in order to perform metabolomic analyses of the plasmatic fingerprints of patients with hepatic encephalopathy
45931239|NCT05772559|Other|Collection of blood sample of bone marrow (cohort 1)|"3 additional tubes of blood sample (cohort 1), at diagnosis and upon relapse if relapse occurs~Bone marrow aspirate : 3 additional tubes (cohort 1), at diagnosis and upon relapse if relapse occurs"
45931240|NCT05772559|Other|Collection of blood sample of bone marrow (cohort 2 and 3)|"1 additional tube of blood sample (cohort 2 and 3 at inclusion)~Bone marrow aspirate: 1 additional tube (cohort 2 and 3 at inclusion)"
46073068|NCT02832336|Drug|Vivarin|Adenosine is an endogenous sleep-promoting substance with neuronal inhibitory effects. Adenosine has been proposed to be a sleep-inducing substance accumulating in the brain during prolonged wakefulness. Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakeup state. Caffeine results in the release of norepinephrine, dopamine and serotonin in the brain and the increase of circulating catecholamines, consistent with reversal of the inhibitory effect of adenosine.Vivarin Drug class :Central nervous system (CNS) stimulants.
45651925|NCT03081013|Device|Fitbit|Fitbit is a wireless pedometer that tracks steps of participants and will be offered in conjunction with a tailored website with customised information for participants.
45801926|NCT03947957|Diagnostic Test|collection of expectoration, stools and blood|collection of expectoration, stools and blood
46073069|NCT02832336|Drug|Fiber|Fiber will be used as placebo.
46073070|NCT03369236|Drug|Danicopan|Danicopan was administered as an oral tablet.
46073071|NCT03369236|Drug|Placebo|Matching placebo was administered as an oral tablet.
46073072|NCT02841410|Other|Magnetic Resonance Imaging|
45801927|NCT03029221|Other|PREP 8.0 curriculum developed by PREP|healthy marriage and relationship education
45801928|NCT03029221|Other|Within My Reach curriculum developed by PREP|healthy marriage and relationship education
46073073|NCT00621751|Drug|Carbamazepine|800 mg daily
46073074|NCT00621751|Drug|Placebo|Placebo
46073075|NCT02690792|Other|NAFLD/NASH - Placebo|Placebo capsules, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
46073076|NCT02690792|Dietary Supplement|NAFLD/NASH - Vitamin E|Vitamin E 200 IU capsule, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
45651926|NCT05335629|Drug|Dapagliflozin 10Mg Tab|Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor (SGLT2 inhibitor) which is a new class of hypoglycemic drugs, and they can block sodium-dependent glucose transporter-2 (SGLT2) located in the early proximal renal tubule to increase urinary glucose excretion and decrease the concentration of blood glucose
45801929|NCT03029221|Other|Within Our Reach 8 Hours curriculum|healthy marriage and relationship education
45801930|NCT04787939|Behavioral|Early Feeding|Subjects will be permitted to drink liquids by mouth on the first day after surgery. Outcomes related to their care, wound healing, and quality of life will be followed for 30 days after surgery.
45801931|NCT04757675|Drug|S-ketamine 0.3|0.3 μg/kg intravenous injection s-ketamin
45801932|NCT04757675|Drug|S-ketamine 0.5|0.5 μg/kg intravenous injection s-ketamin
45801933|NCT04757675|Drug|S-ketamine 2|2 μg/kg intranasal s-ketamin
45801934|NCT04757675|Drug|S-ketamine 1+Dexmedetomidine 1|1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine
45931241|NCT05772546|Drug|Avatrombopag|Thrombopoietin receptor agonist, tablet taken orally.
45931242|NCT05772546|Drug|Matching Placebo|Lactose monohydrate, tablet taken orally.
45931243|NCT05772520|Drug|TLL018 tablets|oral tablets administered BID for 12weeks
45931244|NCT05772507|Device|URGO AWC_008 dressing or URGO AWC_022 dressing|local management of acute or chronic wounds
45801935|NCT04757675|Drug|S-ketamine 0.5 +Dexmedetomidine 2|0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine
45801936|NCT04731311|Device|Usability evaluation of BrightGo computerized device for cognitive therapy of individuals with early Alzheimer's Disease|4 participants with undergo 4 usability evaluations each, inter-spaced by days when researchers will address design changes. 2 participants will be elderly healthy and 2 will have the early Alzheimer's disease. Each session will last up to 1 hour, during which participants will interact with tasks in the form of games. Games will be gradated in level of difficulty, increasing from session to session. They will be played with one game controller or with two controllers while participants wear an all-in-one head mounted display. The degree of cognitive engagement during tasks will be measured with custom biosensors and used in adjusting level of difficulty. Each participant will fill subjective evaluation form and a USE form assessing ease of use, usefulness, and perceived technology issues. Scores will be analyzed and data published, in conjunction with game performance data.
45801937|NCT04611529|Drug|Ibuprofen 400 mg|Ibuprofen 400mg
45931245|NCT05772494|Other|Assessment of activity limitations, SDO and DOA|The assessment is made with two instruments (DOA, SDO), and finally the occupational therapist includes the analysis and summary of activity limitations to the sickness certificate. For comparative reasons the participant will answer to a sociodemographic questionnaire focusing on work situation and sick leave
45931246|NCT05772494|Other|Control group|All assessments concerning activity limitations are made using usual routines, primarily by the sick-listing physician. For comparative reasons the participant will answer to a sociodemographic questionnaire focusing on work situation and sick leave
45931247|NCT05772481|Other|PET-MRI|"Each patient will have a pre-treatment PET-MRI (PET-MRI 1) within 21 days before the start of treatment.~Induction chemotherapy may be performed at another center than the investigating center.~After 3 cycles of induction chemotherapy and before the 4th cycle, a second PET MRI (PET MRI 2) will be performed. In patients who have received less than 3 cycles of induction chemotherapy, this mid-therapy PET-MRI will not be performed.~A 3rd PET-MRI will be performed prior to radiation therapy (PET-MRI 3). A final MRI PET (MRI PET 4) will take place before surgery.~A total of 4 PET MRI scans will be performed."
45931248|NCT05772468|Device|Virtual Reality ('VRelax' VR system)|The intervention group 1 will be wearing the 'VRelax' Virtual Reality system during the wound care moment in addition to the standard procedure. The VR system consists of Virtual Reality glasses, and a headphone. The VRelax Application will be used.
45931249|NCT05772455|Drug|XZB-0004|Part 1a: 100mg BID, 150mg BID, and 200mg BID of XZB-0004 are planned to be evaluated, and the possibility of exploring higher or lower doses is not ruled out. Continuous administration of XZB-0004 for 21 days is a treatment cycle. Part 1b: XZB-0004 in combination with peramprizumab in subjects with advanced NSCLC or solid tumors, starting at a dose level down from the RP2D of XZB-0004 monotherapy- cohort 1: Advanced or metastatic NSCLC with advanced disease progression after treatment with PD-1 or PD-L1 inhibitors; cohort 2: Advanced or metastatic NSCLC with advanced disease progression after platinum-containing chemotherapy without prior use of any immunocheckpoint inhibitors; cohort3: Advanced or metastatic solid tumors that cannot be radically cured by surgery or local therapy, including but not limited to urothelial carcinoma, melanoma, etc. Subjects had disease progression since last antitumor therapy, no availability or intolerance or refusal of standard therapy.
45931250|NCT05772377|Drug|Hydrochloride anlotinib|Hydrochloride anlotinib is a small molecular anti-angiogenesis drug with multiple targets. It will be taken at a starting dose of 10 mg for 14 days. Then participants will rest for 7 days and start a new cycles. At most of 3 cycles will be administrated. If intolerable toxicity happen, dosage of 8mg will be taken.
46073077|NCT05335304|Other|intervention group 1|Kinesio taping The intervention of this experimental study is therapeutic taping (kinesio tape) on the respiratory muscles of the participants.
45651927|NCT03078673|Other|training intervention, motor skill training|cross country specific motor skill strength training
45931251|NCT05772377|Drug|cis Platinum/carboplatin|Concurrent chemotherapy with cisplatin at 75mg/m2 during radiotherapy will be the most preferred regimen. For patients who cannot tolerate the toxicity of cisplatin, 75 mg/m2 nedaplatin will be used as an alternative drug.
45931252|NCT05772377|Radiation|External beam radiotherapy and brachytherapy|Radiation will be given by external beam of 40Gy total dose and 3D-brachytherapy of 30Gy/2.5F. Duration of radiotherapy will be no more than 5 weeks
46073078|NCT05335304|Other|intervention group 2|Rigid taping The intervention of this experimental study is therapeutic taping (rigid tape) on the respiratory muscles of the participants.
46073079|NCT05335304|Other|intervention group 3|Thoracic Mobilization The intervention of this experimental study is active-passive Thoracic mobilization techniques on the on the upper, middle or lower parts of the chest of the participants
45651928|NCT03078673|Other|training intervention, maximal strength training|general maximal strength training
45801938|NCT04611529|Drug|Topical diclofenac|Diclofenac 1% gel 4gm
45801939|NCT04730063|Device|VQm PHM™|Procedure: Non-invasive measurements obtained with the VQm PHM™
45801940|NCT04726163|Device|Continuous blind glucose measurement device (Free style Pro)|A continuous blind glucose measurement device (Free style Pro) will be set up on the first day and throughout the entire hospital stay
45801941|NCT05323721|Drug|Sulfadoxine pyrimethamine and amodiaquine|This is where children 3-59 months will receive SPAQ for SMC
45801942|NCT05323721|Drug|dihydroartemisinin-piperaquine|This is where children 3-59 months will receive DP for SMC
45931253|NCT05772351|Drug|micronized flavonoid fraction|"Patients of the experimental group received Detralex® 1000 mg QD for 15 days before the operation, 3000 mg starting from day 1 after the surgery for 4 days, then 2000 mg for the next 3 days and 1000 mg till day 30 after surgery.~Under spinal anesthesia appropriate surgical intervention was performed. After the surgery, the patient was given a questionnaire and a scale for assessing pain at rest and during defecation within the first 2 weeks after surgery. During the hospital stay, the nurse filled out a section on the drugs used; after discharge, the patient filled out this section for 7 days after the surgery. After 30 days, the side effects section was filled out, and the quality of life was assessed on days 7 and 30. Also, the patients indicated in a separate column on which day after the surgery they were able to return to normal living or go to work."
45931254|NCT05772286|Biological|763SIP8/MPLA-5 vaccine|763SIP8/MPLA-5 vaccine at day 0, week 8, week 24 and week 48.
45931255|NCT05772247|Diagnostic Test|Lung ultrasound|Lung ultrasound score was calculated by the results of lung ultrasound examination
45931256|NCT05772221|Other|Screening|Screening assessments to measure social determinants of health in relation to cardiovascular disease.
45651929|NCT03078673|Other|control group|regular training
45931257|NCT05772208|Drug|Camrelizumab|camrelizumab 200mg q3w
45931258|NCT05772208|Drug|Nimotuzumab|nimotuzumab 200mg qw
45931259|NCT05772208|Drug|neoadjuvant chemotherapy and CCRT|the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1，8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle definitive radiotherapy for primay lesion and lymph node region.
45931260|NCT05772182|Device|ACORYS MAPPING SYSTEM|"Diagnostic Test: ECG-Imaging~Diagnostic Test: Standard 12-lead ECG~Diagnostic Test: Endocardial mapping and/or pacing"
45931261|NCT05772143|Procedure|Percutaneous discectomies under CT|Percutaneous discectomies under CT guidance to treat lumbar disc herniations resistant to conservative treatment and nerve root infiltrations.
45931262|NCT05772130|Other|Best Practice|Receive family letter and genomic test report
45931263|NCT05772130|Other|Electronic Health Record Review|Ancillary studies
45931264|NCT05772130|Behavioral|Personal Contact|Receive family letter and genomic test report with provider-mediated contact
45931265|NCT05772130|Other|Survey Administration|Ancillary studies
45931266|NCT05772104|Drug|Shugan Jieyu Capsules|Oral, 4 Capsules, BID
46073080|NCT05335304|Other|intervention group 4|Core Stabilization The intervention of this experimental study is Core Stabilization exercises to the trunk muscles of the participants.
46073081|NCT05335304|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation respiratory rehabilitation, stretching exercises, posture correction exercises
46073082|NCT00831649|Drug|natalizumab|
46073083|NCT02841332|Drug|F-MISO|"The fluoro-misonidazole is a positron emission tomography tracer (labeled with Fluorine-18)-specific hypoxia. This compound penetrates into cells where it is reduced by a nitroreductase enzyme. It is rapidly regenerated by reoxidation when the cell is properly oxygenated. This metabolite can accumulate in viable hypoxic cells (necrotic cells that can provide initial reduction reaction of F-MISO).~Moreover, the fixing of this tracer appears to be independent of blood flow. The advantage of this technique is to provide a direct image of hypoxic cells by directly targeting under stress hypoxic."
46073084|NCT02841332|Other|Cerebral magnetic resonance imagery|"During the pre-therapeutic imagery session :~Morphological magnetic resonance imagery ( axial T1 sequence axial T1 post contrast , Flair Axial )~magnetic resonance imagery spectroscopy sequence~Perfusion magnetic resonance imagery sequence~Diffusion magnetic resonance imagery sequence"
45801943|NCT04601779|Behavioral|VIPP-PUF|The VIPP-PUF Intervention is developed as an add-on to the existing PUF-programme to address infants with major cognitive and regulatory vulnerabilities identified at age 9-10 months and adapted to the settings of community health nurses. The intervention (VIPP-PUF) will be created from an evidence-based method, the Video-based Intervention to Promote Positive Parenting (VIPP), to comprise six therapeutic sessions delivered by the community health nurse during home visits over a three months period. The VIPP -PUFbuilds on teaching the health nurses to promote parents' sensitivity to meet infants' cognitive and regulatory vulnerabilities, while taking in account the particular needs of families of psycho-social disadvantage.
45931267|NCT05772104|Drug|Shugan Jieyu Capsules+Placebo|"Drug: Shugan Jieyu Capsules, Oral，3 capsules，BID~Drug: Placebo, Oral, 1 capsule, BID"
45931268|NCT05772104|Drug|Placebo|Oral，4 capsules，BID
45931269|NCT05772078|Other|Assess compliance rate and demographics|Records to evaluate attendance rate
45931270|NCT05772039|Drug|Topical application of 38% Silver Diammine Fluoride Solution|"Application of petroleum jelly on lips and around the mouth for prevention of temporary silver tattoo.~Before SDF application, the affected area will be thoroughly dried and isolated using the cotton rolls or dri-angle.~Isolation throughout the procedure and following three minutes is considered most desirable.~The varnish should be allowed to be in place for 60 seconds. This is the most critical step in the process. Applied varnish will be dried with gentle flow of compressed air.~SDF will be applied with a microbrush to all carious lesions and to all pits and fissures on posterior (molar) teeth for 60 seconds.~To avoid gingival or mucosal irritation, contact of varnish with any oral tissue other than affected area will be avoided.~If the application time is shorter due to unforeseen reasons reapplication will be considered."
45651930|NCT03075787|Device|standard 24-h ambulatory polysomnography|A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
45651931|NCT03076099|Drug|Dexmedetomidine|1.2 μg/kg Dexmedetomidine was administered intravenously constantly after tracheal extubation.
45651932|NCT03076099|Other|normal saline|equal volume of normal saline was administered intravenously constantly after tracheal extubation.
45651933|NCT05301621|Other|Akcelerometry follow up|The patients and control group will be followed up with single accelerometer.
45651934|NCT03075709|Other|Clinical Pathway (CPW)|CPWs bring the available evidence to a range of healthcare professionals by adapting guidelines to a local context and detailing the essential steps in the assessment and care of patients.
45651935|NCT05345769|Biological|AM712(ASKG712)|AM712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
45931271|NCT05772039|Drug|Topical application of 5% Sodium Fluoride with functional Tricalcium phosphate Varnish|"According to manufacturer, Clinpro® White Varnish can be applied to tooth surfaces where plaque is present. A prophylaxis is not required.~The applicator brush provided along is used to thoroughly mix the varnish inside the single-unit dose pack, since components of all sodium fluoride varnishes are separate during storage.~Excessive contact with soft tissue should be avoided.~Only enough varnish to form a thin coating on the desired treatment area should be used.~After application, patient should be instructed to close their mouth to set the varnish.~Rinsing or suctioning immediately after application is not recommended.~The operator might appreciate the formation of a thin coating on the teeth and the patient should be informed that they may feel a thin coating when rubbing the treated area with their tongue."
45931272|NCT05772013|Drug|Azithromycin Pill|"Participants will take azithromycin according to their standard of care prescription.~If the participant is on the seasonal azithromycin treatment arm, they will only take azithromycin during the winter months (October-March) followed by matched placebo (April-September)."
45931273|NCT05772013|Drug|Placebo|The placebo tablets will be matched in appearance, taste and smell to the azithromycin tablets.
45931274|NCT05771987|Procedure|pace maker implant guided by acute hemodynamic testing|To evaluate the ability of acute hemodynamic testing to optimize pacing therapy and to predict the response of HOCM to pacing
45931275|NCT05771922|Diagnostic Test|High-resolution ultrasonography|High-resolution ultrasonography to detect fetal CNS anomalies
45931276|NCT05771896|Drug|Darolutamide|"Participants will continue treatment with darolutamide until radiological progression, withdrawal, death, termination, or study completion.~The maximum time for darolutamide dose interruption period is 28 consecutive days beyond scheduled dose (>56 days between cycles). Any participant requiring dose interruption >28 consecutive days beyond the scheduled dose may restart treatment with darolutamide if clinical benefit is anticipated and after discussion with and approval from the study Medical Monitor.~Until primary endpoint is reached, participants are not allowed to switch ARPI (Abiraterone, Apalutamide or Enzalutamide) during the study. Switching to other ARPI following radiographic progression should be considered a subsequent life prolonging therapy and documented accordingly."
45931277|NCT05771896|Drug|Radium-223|"Radium-223 should be given for 6 cycles, administered IV on Day 1 of each cycle or until radiological progression, withdrawal, death, termination, or study completion. The placebo will be administered in precisely the same fashion as the active drug.~Subsequent cycles 2-6 should be scheduled to occur every 28 ± 7 days following the previous cycle, but dosing may be delayed up to 28 days per cycle (maximum 56 days between cycles). Any participant requiring dose interruption >28 consecutive days (>56 days between cycles) may restart treatment with radium-223/placebo if clinical benefit is anticipated and after discussion with the Medical Monitor. Participants will continue with darolutamide irrespective of Radium-223 administration.~Upon radiological progression, further treatments are decided by the site investigator according to standard local practice."
45651936|NCT03075631|Other|Questionnaire|Questionnaires
45651937|NCT03075865|Device|OmniMax MMF system|OmniMax MMF system consists of arch bars and screws that work together to achieve temporary fixation of the maxilla and mandible to provide indirect or passive stabilization of fractures and maintenance of occlusion in the oral and maxillofacial region. The arch bars have hooks designed to accommodate either wires or elastic bands for temporary maxillomandibular fixation (MMF) either intraoperative or postoperative.
45801944|NCT05288075|Drug|Indacaterol/glycopyrronium|"In each period, subjects receive single dose of indacaterol/glycopyrronium consisting of 2 inhaled doses via Easyhaler or 2 capsules inhaled via Ultibro Breezhaler.~In addition to study treatments, activated charcoal will be administered on each study period before and after study drug administration."
46073085|NCT02841332|Drug|Bevacizumab|Administration of bevacizumab during 7 cycles of treatment (J1, J15, J30, J45, J60, J120 and J180)
46073086|NCT02841332|Other|Clinical examination|"During the examination, the following parameters will be checked :~Neurological examination~Corticotherapy prescribed~General status of patient (world health organization score)~Weight and height~Control of arterial pressure~Chirurgical and medical history~Concomitant treatment"
45801945|NCT04424251|Drug|Experimental: stage I：HSK21542 0.4 μg/kg|Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
45801946|NCT04424251|Drug|Experimental: stage I：HSK21542 1 μg/kg|Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
45801947|NCT04424251|Drug|Experimental: stage I：HSK21542 0.5μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
45801948|NCT04424251|Drug|Experimental: stage I：HSK21542 1μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
45801949|NCT04424251|Drug|Experimental: stage II：HSK21542 0.5μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
45801950|NCT04424251|Drug|Experimental: stage II：HSK21542 1μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
45801951|NCT04424251|Drug|Placebo|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
45801952|NCT05272787|Other|TH Facial Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
45931278|NCT05771870|Other|Peer mentoring|"Mentoring is a support network in which a more talented or experienced individual serves as a role model for a less talented individual in order to encourage professional and personal growth. Mentoring improves students' learning, abilities, and self-efficacy while decreasing stress and anxiety in nursing students through more effective communication, collaborative learning, and critical thinking.~After understanding about the study, two master's degree students from Karabük University Institute of Graduate Studies of Child Health and Diseases Nursing consented to participate on a volunteer basis and became peer mentors in the study. All postgraduate students are pediatric nurses with at least two years of clinical experience who have completed their undergraduate nursing program."
46073087|NCT00838357|Drug|Generic = Plerixafor|240µg/kg administered as an SC injection 10 to 11 hours prior to initiation of apheresis. Daily administration for 1 up to 5 consecutive days
46073088|NCT02841254|Other|Non interventional study|
45651938|NCT05301543|Behavioral|Experimental: Behavioral approach 1|Includes changing sleep habits and cognitions around sleep from a mental level
45931279|NCT05771870|Other|Nurse mentoring|"Mentoring is a support network in which a more talented or experienced individual serves as a role model for a less talented individual in order to encourage professional and personal growth. Mentoring improves students' learning, abilities, and self-efficacy while decreasing stress and anxiety in nursing students through more effective communication, collaborative learning, and critical thinking.~After providing information about the research to bachelor's degree nurses who have worked in the Children's Units of Karabuk Training and Research Hospital for at least two years, two mentors for the nurse mentoring group were chosen on a volunteer basis. Mentors were taught on the concept of mentoring, the roles of the mentor, interpersonal relationships, and communication skills prior to the study."
46073089|NCT02840942|Behavioral|Coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to teach coping skills."
46073090|NCT02840942|Behavioral|Non-coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to be distraction only."
45801953|NCT05272787|Other|TH Lip Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
46073091|NCT00156104|Drug|Asenapine|5 mg BID
45651939|NCT05301543|Behavioral|Comparator: Behavioral approach 2|Includes changing sleep habits and awarenes of sleep from a perception level
45651940|NCT05554965|Drug|Propofol|Remifentanil maintenance analgesic dose was 1.2-9 μg/kg/h. If the CPOT score ≥3 at the time of maintenance administration, dose adjustment can be considered. Propofol was used for sedation at a loading dose of 0.5mg/kg and a maintenance dose of 1.5mg/kg/h.
45651941|NCT05554965|Drug|Remimazolam besylate|Remifentanil was administered at a maintenance dose of 1.2-9 μg/kg/h for analgesia. If CPOT score ≥3 during maintenance administration, dose adjustment could be considered. For sedation, remazolam besylate was given a load of 0.1-0.2mg/kg and a maintenance dose of 0.1-0.3mg/kg/h.
45651942|NCT03078517|Device|I-gel|After the induction of anesthesia, i-gel is inserted along the palatopharyngeal curve.
45801954|NCT05272787|Other|Facial Moisturizer B (Control)|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
45801955|NCT05272787|Other|Sunscreen|Auxiliary product
45651943|NCT03078517|Device|Laryngeal mask airway protector|After the inudction of anesthesia, laryngeal mask airway protector is inserted along the palatopharyngeal curve, and the cuff is inflated.
45801956|NCT05272787|Other|Facial wash|Auxiliary product.
45801957|NCT04593277|Other|Internet Mobile Technology|Use INSPIRE mobile application
46073092|NCT00156104|Drug|Asenapine|10 mg BID
46073093|NCT00156104|Drug|Haloperidol|4 mg BID
46073094|NCT00156104|Other|Placebo arm|
46073095|NCT02841020|Procedure|Additional biopsy|• Patients in the experimental group receive the additional biopsy for non-neoplastic disease during the same procedure before the biopsy of the renal mass (with potential for direct benefit to the patient by revealing non-neoplastic renal disease).
45931280|NCT05771857|Device|Obesity|the objective of identifying the epidemiological profil of the patients, as well as, the clinical, radiological and prognosis of obese patients with covid 19
45931281|NCT05771844|Device|Transcranial Electrical Stimulation|Oscillating electrical current
45931282|NCT05771831|Biological|Thrombosomes®|The intervention with TBX® is to be administered as an intravenous infusion as hemostatic blood product as part of the Massive Transfusion Protocol (MTP).
45931283|NCT05771831|Biological|Standard platelet concentrate|The administration of standard platelets is administrated, as part of the Massive Transfusion Protocol (MTP).
45651944|NCT05300217|Other|Strategies for promoting mental health|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding strategies for promoting mental health"
45651945|NCT05300217|Other|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding general information about depression"
46073096|NCT05334602|Procedure|Addition of dermal fat graft as protection over bone graft|A barrier membrane
45801958|NCT04593277|Other|Internet-Based Intervention|Access to a study-specific control website
45801959|NCT04593277|Other|Questionnaire Administration|Ancillary studies
45801960|NCT04593277|Procedure|Supportive Care|Receive telehealth stepped care
45931284|NCT05771818|Other|Falls Prevention Program|The intervention consists of 10 sessions. One session a week consists of obstacle course training. The other session focuses on falls strategies training and walking and balance exercises. Each session lasts approximately 1.5 hours.
45801961|NCT05215145|Behavioral|Baby Navigator Bundle|The Baby Navigator Bundle includes 1) Baby Navigator, an online collection of resources: videos, growth charts, milestones, short articles, checklists, tools, and tips to help families promote early learning. Tools are customized to the child's age (in months). Baby Navigator can be found at https://babynavigator.com. 2) Social Communication (SoCo) Growth Charts is a self-guided app for parents of babies from birth to 24 months. Parents can watch video clips of early milestones and chart their child's social communication development. 3) Baby Navigator Webinars are held twice a month. Parents can learn how to support their child's growth from birth to 24 months. Content and videos focus on social communication milestones. Expert-led sessions cover a range of topics: gestures and sounds babies need to learn to talk, everyday activities that encourage learning, getting ahead of the Terrible Twos, and how Baby Navigator can help families.
45931285|NCT05771805|Other|Vagus nerve stimulation with task oriented training|VNS Group will receive non-invasive vagus nerve stimulation at left auricle of ear for 30 mins during the task-oriented training. Subjects will receive protocol 3 days per week for 12 weeks.
45931286|NCT05771805|Other|Task oriented training|Task oriented group will receive task oriented training and placebo effect with vagus nerve stimulator.
46073097|NCT00844363|Procedure|NB-UVB|UVB light will be administered to the entire body except for the genitals in men and eyelids, which will be shielded.NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.
46073098|NCT00844441|Other|medical chart review|
46073099|NCT00844441|Other|questionnaire administration|
46073100|NCT00844441|Procedure|quality-of-life assessment|
46073101|NCT00254462|Drug|Atomoxetine|Participants will receive atomoxetine for 8 weeks up to a maximum of 1.8 mg/kg/day. Dosed once daily in capsule formulation.
45801962|NCT05215145|Behavioral|Baby Navigator Bundle + Individual-ESI|Continued Baby Navigator Bundle. Addition of ESI mobile coaching. ESI program planning entails identifying goals and objectives for the child and teaching strategies and supports for parents. Each session includes the following components: 1) setting the stage to develop that session's agenda and gather updates; 2) intervention implementation that must include the following steps to coach the parent: a) review the objective, b) use modeling, guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to the parent, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and 3) summarize plans for parent implementation between sessions. Families are also invited to and guided through the Autism Navigator How-To Guide for Families online course.
45801963|NCT04349683|Drug|Jinshuibao|6 capsules at a time, 3 times a day (tid).
46073102|NCT00254462|Drug|Placebo|Participants will receive placebo for 8 weeks. Dosed once daily, capsule formulation.
45801964|NCT04349683|Drug|Placebo|6 capsules at a time, 3 times a day (tid).
45801965|NCT05145569|Drug|Carboplatin AUC 5 and paclitaxel|Carboplatin AUC 5 and paclitaxel combination chemotherapy is very well tolerated and highly effective for the treatment of ovarian cancer and thus is standard of care therapy. Both carboplatin and paclitaxel are chemotherapy agents that are designed to kill and slow the growth of cancer cells.
45801966|NCT05145569|Drug|Bintrafusp alfa (M7824)|"Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of the human TGF-β receptor II (TGF-βRII or TGF-β trap) fused via a flexible linker to the C-terminus of each heavy chain of an IgG1 antibody blocking programmed death ligand 1 (anti-PD-L1); it is designed to target tumors via colocalized, simultaneous inhibition of 2 key mechanisms of immunosuppression in the tumor microenvironment."
45931287|NCT05771779|Biological|Oral Cholera Vaccine (OCV)|Bivalent, Killed, Whole Cell Oral Cholera Vaccine
45931288|NCT05771779|Biological|Typhoid Conjugate Vaccine (TCV)|Vi-polysaccharide conjugated to tetanus toxoid, Vi-TT
45931289|NCT05771779|Biological|Measles and Rubella (MR)|Live attenuated vaccine
45931290|NCT05771766|Other|Postural Drainge and aerobic training|This will be a randomized controlled trial Patients will be divided into two groups randomly. Both groups will receive postural drainage as baseline treatment thrice a week for two weeks. The intervention group will undergo additional Aerobic Training thrice a week for two weeks as well along with postural drainage. Aerobic training will include 5-step stair-climbing and 10 step walk during each session.
46073103|NCT00254462|Behavioral|Parent Training|All children will receive parent training for the duration of the study.
46073104|NCT00831727|Behavioral|Expressive Writing|Participants will write about their experienced trauma for 20 minutes on each of three consecutive days using techniques associated with expressive writing
45651946|NCT04947475|Behavioral|SBIRT|First, the BI is designed to inform potential participants on the risks of substance misuse, abuse, and dependency by illustrating the potential hazards and adverse health consequences. Second, the BI aims to motivate potential participants to reduce risky behavior (e.g., continued drug use) and seek treatment for their substance dependence disorder. In our BI, we will provide evidence-based information on Opioid Agonist Therapy (OAT) that is available to them in the community upon release or in the community. We will inform them of the risks and benefits of OAT and explain to them how OAT can be accessed in the community. OAT is provided at no cost to Ukrainian, Moldovan, and Kyrgyz citizens with opioid dependence. The BI will last approximately 20 minutes and time will be made available for them to ask questions. The BI will not be audio recorded.
45651947|NCT05554419|Drug|Azacitidine|Given IV or SC
45651948|NCT05554419|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
45651949|NCT05554419|Drug|Cytarabine|Given IV
45651950|NCT05554419|Procedure|Echocardiography|Undergo ECHO
45931291|NCT05771766|Other|Postural Drainage|Postural Drainage
46073105|NCT00831727|Behavioral|Control|Participants will write as factually as possible about an assigned trivial topic for 20 minutes on each of three consecutive days
46073106|NCT00891930|Biological|Panitumumab|Panitumumab 6 mg/kg administered via IV infusion over 60 minutes
46073107|NCT00891930|Biological|Ganitumab|AMG 479 12 mg/kg adminstered by IV infusion over 60 minutes
46073108|NCT00891930|Drug|Irinotecan|Irinotecan starting dose of 180 mg/m² adminstered via IV infusion
46073109|NCT04248426|Drug|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth.
46073110|NCT04248426|Drug|ATI-2173 Placebo|ATI-2173 Placebo is used as an inactive comparator to ATI-2173. It will be dosed as a capsule by mouth.
45651951|NCT05554419|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
45931292|NCT05771753|Other|Stretching Exercises|6 stretching exercises 2 repetitions x1 set, 3 days/week and targeted muscles stretching (Lower Back, Lower limb)
45931293|NCT05771753|Other|Dynamic core stabilizing exercises|This group received core stabilizing exercises 2 repetitions x1 set, 3 days/week and the targeted muscles were abdominals, lower back, and lower limb.
45931294|NCT05771727|Other|survey|The 55-item survey created by the researchers was applied online to determine the psychological and physical effects of COVID-19 on neuromuscular patients and their families. This survey also included the Content of the 9-Item Caregiver COVID-19 Limitations Scale (CCLS-9).
45931295|NCT05771714|Device|CareSuperb COVID-19 Antigen Home Test Kit|At home COVID-19 antigen test kit
45801967|NCT04566991|Drug|Deferoxamine|"There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 milligram per kilogram per hour (mg/kg/hr). The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.~Patients will be randomized to 32 mg/kg or 48 mg/kg of Deferoxamine."
45801968|NCT04566991|Drug|Placebo|There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 mg/kg/hr. The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.
45931296|NCT05771688|Device|FETO therapy|placement of FETO prior to 29 weeks 6 days GA; and removal of the FETO device no later than 35 weeks and 6 days
45931297|NCT05771675|Drug|Simvastatin|40Mg Oral Tablet
45801969|NCT05143853|Procedure|non-absorbable tape fixation around AC joint|fixation around AC joint with tape in different configurations
45931298|NCT05771675|Drug|Placebo|Matching Simvastatin Placebo tablet
45931299|NCT05771610|Behavioral|Activity pattern in CVD|Only individuals who have had a cardiac event within the past twelve months upon recruitment will be included in this study.
45931300|NCT05771597|Other|Home Biofeedback therapy|"Patients will be given home biofeedback device to take home and practice biofeedback exercises at least twice a day for six weeks of therapy.~HBT for patients with constipation and dyssynergic defecation:~Patients will attend one session of training on how to use the device followed by daily sessions at home for 6 weeks. After placing a probe into rectum, the patient sits on a commode, activates the smart phone app and follow the voice-guided instructions to perform diaphragmatic breathing exercises and push maneuvers with/without balloon distension.~HBT for patients with FI:~Subject will receive training on how to use the home-trainer device and probe placement. The patient will be asked to follow a series of voice guided instructions consisting of performing short and long duration squeeze maneuvers over 25 minutes.~HBT for patients with UI:~The instructions protocol as written above for patients with FI will be followed for UI patients as well."
45931301|NCT05771597|Other|Office biofeedback therapy|"Patients will receive traditional office biofeedback, once weekly, over six weeks.~OBT for patients with constipation and dyssynergic defecation:~The patient will receive instructions on the diaphragmatic breathing techniques. Then the patient sits on a commode, coordination between push effort and the anal and pelvic floor relaxation is corrected by the therapist. The patients will receive visual and verbal feedback instructions from the therapist.~OBT for patients with FI:~Patients will be taught Kegels and abdominal muscle exercises. Visual and verbal feedback techniques are used to reinforce the maneuvers. The patient is instructed to squeeze and to maintain this squeeze for as long as possible.~OBT for patients with UI:~Biofeedback training is performed using the protocol and objectives as described above for FI training."
45931302|NCT05771584|Drug|AST-301|100 μg
45931303|NCT05771584|Drug|rhuGM-CSF|100 μg
45931304|NCT05771558|Device|Tailored Lighting Intervention (TLI)|The lighting intervention will provide high circadian stimulation produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system.
45931305|NCT05771558|Device|Actigraph|An actigraph is a wrist worn devices that measures rest and activity.
45651952|NCT05554419|Procedure|Multigated Acquisition Scan|Undergo MUGA
45801970|NCT05143853|Procedure|no fixation around AC joint|there will be no additional fixation around AC joint in this group
45801971|NCT05143853|Procedure|coracoclavicular (CC) fixation|mandatory coracoclavicular fixation with to suspensory systems, comprised of non-absorbable tapes and metal buttons
45931306|NCT05771545|Other|Telepsychiatry|Instead of coming to the hospital physically, the attending psychiatrist will evaluate the patient via a video-link.
46073111|NCT02835066|Other|Integrated Fitness Assessment|Undergo function/fitness assessment
46073112|NCT02835066|Procedure|Psychosocial Assessment and Care|Undergo psychosocial health assessments
46073113|NCT02835066|Procedure|Quality-of-Life Assessment|Complete EORTC QLQ-C30 and QLQ-LC13 questionnaires
46073114|NCT02831166|Procedure|Transradial primary percutaneous coronary intervention|Transradial coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. To achieve hemostasis in the transradial approach, a radial compression device will be applied, to maintain patent antegrade flow.
45651953|NCT05554419|Drug|Venetoclax|Given PO
45653271|NCT05557799|Radiation|Placebo Photobiomodulation|The Placebo Group will receive the same four consecutive applications, but with the laser turned off.
45653272|NCT05613101|Procedure|Erector Spinae Plane Block|After the necessary asepsis and antisepsis procedures, the linear ultrasound probe was placed parasagittally 2-3 cm lateral to the spinous process at the L3 or L4 level and the transverse process was visualized. The peripheral block needle (85 mm B Braun Stimuplex A) was advanced in plane up to the transverse process and 10 ml 0.5% bupivacaine hydrochloride 10 ml 0.9% isotonic NaCl mixture was applied on the erector spina muscle.
45801972|NCT05136833|Biological|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.
45801973|NCT05136833|Biological|Placebo|Normal saline will be used as a placebo.
45801974|NCT04547725|Other|CRS followed by IP and systemic chemotherapies|Complete cytoreductive surgery (CRS) + normothermic intraperitoneal chemotherapy (N-IPEC) + systemic chemotherapy
45931307|NCT05771532|Behavioral|Received the GS-SHEP|"The experimental group (n=33) received the GS-SHEP (a 10-15-minute individual sexual health education and a sexual health pamphlet). GS-SHEP effectiveness was examined using a self-report instrument to measure background information and three dependent variables: sexual knowledge, sexual attitudes, and sexual self-efficacy."
45931308|NCT05771506|Other|Balance Assessment|"Balance assessment will be done with the Biodex Balance System® (Biodex Medical Systems, Shirley, New York, United States). Postural stability test overall score, stability limits test overall score, and sensory integration test of balance composite score will be recorded."
45931309|NCT05771506|Other|Pulmonary function test|"Pulmonary function test will be performed with a spirometer (COSMED Pony FX (COSMED; Italy) in accordance with ATS/ERS criteria. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC, peak expiratory volume measured at 25% and 75% of forced expiratory time (FEF 25-75%), and peak expiratory volume (PEF) parameters will be measured. The results will be recorded both as a percentage of measured values and expected values."
45931310|NCT05771506|Other|Respiratory muscle strength test|Respiratory muscle strength will be measured in accordance with ATS/ERS criteria using an electronic, mobile, (MicroRPM, Micro Medical; UK) intraoral pressure measuring device. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) values will be recorded. Three measurements will be repeated for each maneuver and the highest value recorded as cmH2O.
45651954|NCT05335161|Device|Home-based leg heat therapy|The Aquilo system consists of a garment that contains an inner water-circulating pad that is compressed by air bladders. The volume of air inflating the air bladders is pressure-controlled so the garment automatically adjusts to the shape and size of all legs. The touch screen console contains pre-programmed settings for ease of use. After baseline characteristics are established, patients will be provided with the Aquilo device and will be instructed on how to operate the equipment and how to rapidly remove the system if the alarm sounds or if they have any unusual feeling. Patients in both groups will also receive a logbook to record their sessions. Patients will undergo daily home-based leg HT (90 min/day, 7 days/week) for 12 weeks. Water at 42ºC will be perfused through the water-circulating garment for 90 min, with the goal of increasing skin temperature in the calf to ~37ºC.
45931311|NCT05771506|Other|Peripheral muscle strength test|Peripheral muscle strength will be assessed by measuring M. Quadriceps muscle strength with a digital handheld dynamometer (MicroFET® Hoggan Scientific; USA). The test will be done in three measurements for the dominant side lower extremity. The average of the obtained values will be recorded in kilograms.
45651955|NCT05335083|Device|CPAP withdrawal|A negative CPAP intervention
45651956|NCT05529147|Drug|Antihypertensive Agents|Study participants receive antihypertensive drug treatment as part of regular care to induce systolic BP (SBP) reductions ≥10 mmHg within 6-8 weeks, while reaching a treatment target of ≤140 mmHg, and while preserving diastolic BP ≥70 mmHg.
45931312|NCT05771506|Other|6-minute walk test|Functional capacity will be assessed with the 6-minute walk test (6MWT). 6MWT will be performed in accordance with the criteria of the American Thoracic Society. The 6MWT distance will be recorded in meters.
45931313|NCT05771506|Other|Cognitive assessment|Cognitive function will be assessed with the Montreal Cognitive Assessment (MoCA) test. The MoCA test is a questionnaire developed to evaluate different cognitive functions and mild cognitive impairment. The maximum score that an individual can obtain from the test is 30, and a score of 21 or above is considered as mild cognitive impairment. Test; will be administered by a certified physiotherapist who has received training on practice and scoring directives
45931314|NCT05771493|Other|Measurement of baseline characteristics|Calculation of the correlation between BMI, WC and PI
45931315|NCT05771454|Procedure|Histopathological confirmation|After mastectomy, each specimen will be assessed histopathologically for the presence or absence of invasive focus of breast cancer.
45651957|NCT05268471|Device|Positional device (PD)|OSA treatment with PD for 6 months
45931316|NCT05771441|Other|neck stabilization exercise (nse)|neck stabilization exercise (nse)- exercise
45931317|NCT05771441|Other|NSE + HOT PACK THERAPY|NSE + HOT PACK THERAPY- exercise plus heat therapy
45931318|NCT05771441|Other|NSE + infrared therapy|NSE + infrared therapy- exercise plus heat therapy
45931319|NCT05771441|Other|NSE + ultrasound therapy|NSE + ultrasound therapy exercise plus heat therapy
45931320|NCT05771350|Procedure|online hemodiafiltration|20 patients on regular hemodialysis received online hemodiafiltration
45931321|NCT05771350|Procedure|high flux hemodialysis|20 patients on regular hemodialysis received high flux hemodialysis
45931322|NCT05771350|Procedure|low flux hemodialysis|20 patients on regular hemodialysis received low flux hemodialysis
45931323|NCT05771337|Diagnostic Test|blood sample|blood sample
45651958|NCT05268471|Device|Continuos Positive Airway Pressure (CPAP)|OSA treatment with CPAP for 6 months
45651959|NCT05505825|Drug|AK104 IV infusion；Chiauranib oral|AK104 IV infusion once every 3 weeks；Chiauranib once a day oral
45801975|NCT05086289|Drug|LY3526318|Administered orally
45801976|NCT05086289|Drug|Placebo|Administered orally
45801977|NCT04645823|Drug|Fentanyl Citrate|Fentanyl citrate 20 µg in 2 ml of saline injected into csf
45801978|NCT04645823|Drug|Lidocaine 1% Injectable Solution|Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
45801979|NCT04645823|Drug|Fentanyl Citrate|Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
45931324|NCT05771324|Other|Baby-Led Weaning (BLW)|BLW trainings given to mothers for 6-12 month old babies
45931325|NCT05771324|Other|Traditional Complementary Feeding (TCF)|TCF trainings given to mothers for 6-12 month old babies
45931326|NCT05771311|Device|KTP|split-side, 1 -5 sessions at intervals of 6 - 8 weeks
45931327|NCT05771311|Device|PDL|split-side, 1 -5 sessions at intervals of 6 - 8 weeks
45931328|NCT05771298|Device|532nm KTP|one to three treatment sessions
45931329|NCT05771298|Device|585nm PDL|one to three treatment sessions
45931330|NCT05771285|Other|Cold application|To evaluate the effect of cold application applied before subcutaneous low molecular weight heparin injection on post-injection pain, ecchymosis and hematoma formation.
45931331|NCT05771272|Diagnostic Test|Sit and Reach Test|To conduct the test, a box measuring 32 centimeters in height, 45 centimeters in width, and 35 cm in length, and the upper surface of the box was 15 cm longer than the area on which the feet rest. The participant is positioned on the ground with both legs fully extended, separated by shoulder width, and flat on the box. The participant positioned themselves with one hand on top of the other, knees fully extended, stretched as far forward as they could, sliding their hands across the ruler's top, and kept that posture for at least two seconds. The end location of the fingertips on or approaching the ruler was measured in centimeters to get the sit and reach score. Scores that are higher showed improved performance. The best result is recorded after the test was run three times.
45801980|NCT05088265|Device|Bigfoot Unity Diabetes Management System|The Bigfoot Unity System is a wirelessly connected set of hardware and software that is intended for use by people with diabetes mellitus who use disposable insulin pens for self-injection of insulin. Bigfoot Unity consists of the Abbott FreeStyle Libre 2 Sensor, two durable insulin pen caps (one each for specific rapid-acting and long-acting insulin pens) and an iOS-specific mobile App.
45801981|NCT04622345|Drug|VSJ-110|ophthalmic solution
45801982|NCT04622345|Drug|Placebo|ophthalmic solution
45801983|NCT04608617|Device|Viz LVO (De Novo Number DEN170073)|"Viz LVO is a notification-only, parallel workflow tool for use by hospital networks and trained clinicians to identify and communicate images of specific patients to a specialist, independent of standard of care workflow.~Viz LVO uses an artificial intelligence algorithm to analyze images for findings suggestive of a pre-specified clinical condition and to notify an appropriate medical specialist of these findings in parallel to standard of care image interpretation. Identification of suspected findings is not for diagnostic use beyond notification. Specifically, the device analyzes CT angiogram images of the brain acquired in the acute setting and sends notifications to a neurovascular specialist that a suspected large vessel occlusion has been identified and recommends review of those images. Images can be previewed through a mobile application."
45931332|NCT05771272|Diagnostic Test|Weight Bearing Lunge Test|To conduct the test, with a tape measure on the floor, measure the distance from the big toe's end to the wall. Participants make a lunging motion forward until their knee hit on the wall. The participant's foot is positioned on the floor with the big toe and heel line aligned on the tape measure. To determine how close to the wall a subject could touch the wall with their knee while still keeping their heel in contact. The tape measure is then used to calculate the distance from the big toe's tip to the wall in centimeters. Increasing the distance indicates that the participant has less ankle dorsiflexion range
45931333|NCT05771259|Other|Assessment of knowledge and behaviour|Assessment of knowledge and behaviour
45801984|NCT02292433|Drug|PF-04937319 high dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 7 days
45801985|NCT02292433|Drug|PF-04937319 low dose|tablets, 50 mg with breakfast plus 50 mg with lunch, 7 days
45931334|NCT05771233|Other|Prevention|"First, an anamnesis is performed to collect information on illnesses, previous and current injuries, medication, sports practice outside of dance, diet, sleep hours and, where appropriate, information on menstruation.~Subsequently, an individual pre-intervention assessment of each participant is carried out, where personal data is collected, motor, elasticity and flexibility, muscle strength and stability tests are performed.~After the initial assessment, group sessions are stablished, divided by classes according to the type of specialty of 6th grade dance. The first session is focused on teaching the different exercises and the importance of muscle strengthening, the subsequent sessions are focused on the correction of the exercises, the resolution of doubts and the incorporation of progressions regarding strength and stabilization.~At the end of the intervention, each participant is re-evaluated and results are compared."
45651960|NCT05333523|Radiation|Sentinel lymph node biopsy guided selective elective neck irradiation|"Patients will undergo sentinel lymph node biopsy. Based on the histopathologic status of the sentinel lymph node(s), selective elective neck irradiation is performed with standard radiation treatment of the primary tumor.~There are 3 possible treatment scenarios.~Bilateral elective neck irradiation is indicated when sentinel lymph nodes at both sides of the neck contain metastases or when sentinel lymph node detection fails.~Unilateral elective neck irradiation is indicated when sentinel lymph node(s) at one side of the neck contain metastases.~Full omission of elective neck irradiation is indicated when all sentinel lymph nodes are free of metastases."
45651961|NCT05333523|Radiation|Standard elective neck irradiation|Patients randomized to the control arm will receive the standard of care, according to (inter)national clinical practice guidelines. This will consist of (chemo)radiotherapy to the primary tumor with standard elective neck irradiation in all patients. No sentinel lymph node biopsy will be performed.
45651962|NCT05299749|Other|stg-rt-fMRI-Neurofeeback|the patients will receive real-time feedback from the brain activity of the superior temporal gyrus
46073115|NCT02831166|Procedure|Transfemoral primary percutaneous coronary intervention|Transfemoral coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. A vascular closure device will be used to achieve hemostasis in the transfemoral approach, preceded by systematic performance of femoral angiography and maintaining absolute bed rest for 60 minutes.
45651963|NCT05299749|Other|sham-rt-fMRI-Neurofeedback|the patients will receive real-time feedback from the brain activity of the somato-motor cortex
45801986|NCT02292433|Drug|Placebo|tablets, breakfast plus lunch, 7 days
45801987|NCT03907631|Other|Standard of care|care decisions driven by local physicians; this is an observational cohort
45801988|NCT03892187|Behavioral|Intervention Group|Walking prescriptions plus weekly coaching calls prior to surgery.
45801989|NCT04939805|Device|Selective CRP apheresis using the PentraSorb®-CRP system|Selective CRP apheresis as an adjunct to standard of care. Apheresis using the PentraSorb®-CRP system will be performed at day 1, 2 and 3 after PCI.
45931335|NCT05771220|Combination Product|ESWT+ traditional physical therapy treatment|"Participants will receive one session per week for 6 weeks on the affected tissue region which will be achieved by a sequence of 2000 shock wave pulses fired with a repetition frequency of 2 pulses per second. Energy level or intensity will be set at a tolerable level by patient (0.2mJ/mm2).~The usual physical therapy care consists of hot pack (10min), stretching, pendulum exercises, isometrics exercises of shoulder one per week, and for 12 weeks. home exercises program (HEP)"
45931336|NCT05771220|Combination Product|Placebo shockwave + traditional physical therapy treatment|"Participants will be treated one time a week over a six-week period. Placebo shockwave treatment (apply low intensity with low dose and frequency: intensity 0.1, freq 1, dose 200 shocks).~The usual physical therapy care consists of hot pack (10min), stretching, pendulum exercises, isometrics exercises of shoulder one per week, and for 12 weeks. home exercises program (HEP)"
45931337|NCT05771207|Dietary Supplement|soy protein|The intervention is made up of soy protein supplements (30g/d) and dietary pattern modification.
45931338|NCT05771207|Dietary Supplement|whey protein|The intervention is made up of whey protein supplements (30g/d) and dietary pattern modification.
45801990|NCT05082883|Diagnostic Test|Risk Assessment Cognitive Screening|Completion of a risk assessment cognitive screening app that includes working memory and voice-based tasks
45931339|NCT05771207|Dietary Supplement|placebo|The intervention is made up of maltodextrin (30g/d) and dietary pattern modification.
45931340|NCT05771194|Drug|Routine preoperative and postoperative anti-infection therapy|received gatifloxacin eye drops (Otsuka Pharmaceutical Co., Ltd.) 4 times daily and gatifloxacin eye ointment once every night (Shenyang Xing Qi Pharmaceutical Co., Ltd) for 3 days before surgery. Postoperatively, gatifloxacin eye drops were administered 4 times daily, 0.1% fluorometholone (San Tian Pharmaceutical Co., Ltd., China) was administered 4 times daily, and pranoprofen (Qian Su Pharmaceutical Co., Ltd., Japan) was administered 4 times daily. The doses of the above three drugs were reduced each week. The compound tropicamide was administered once a day (Shentian Pharmaceutical Co., Ltd., China). All of the above procedures were stopped 1 month after surgery.
45651964|NCT05299047|Other|Group US-guided|An ultrasound system with a 5-2 MHz curved transducer will be used. The division of the abdominal aorta into the common iliac arteries was located using oblique sonography. Then, the transducer will image the body of the fifth lumbar vertebra, at which level bilateral common iliac vessels will be seen leaving a space in the midline. a 20 cm long, 22 gauge Chiba needle will be introduced into the hypogastrium, with out-of-plane technique to access the fifth lumbar vertebral body at its anterior-most point, so that injected drug spreads equally bilaterally along the anterior curvature of the fifth lumbar vertebral body.Suction was applied to the needle to confirm that it was not within a vessel and 10 ml of 50% ethanol will be injected for neurolysis.
45801991|NCT04334213|Drug|CKD-501|QD, PO
45801992|NCT04334213|Drug|D745, D150|QD, PO
45801993|NCT04334213|Drug|CKD-501, D745, D150|QD, PO
45801994|NCT05076565|Device|Airbag Belt Fall Protection System|Both versions of Airbags features different number of IMU sensors. Participant's will be randomly assigned one of the two versions. The algorithms developed in this project will help the researcher to identify the optimal performance (sensitivity and specificity values for detecting falls). Based on this information the research team will be able to choose a version for home/community deployment portion of the study. Based on the performance of the airbags in detecting true positives (falls) and true negatives (non-falls) accurately one of the airbags will be used in community deployment phase of the study.
45801995|NCT04524013|Other|There is no intervention. It is an observational study.|There is not intervention
45801996|NCT04885595|Procedure|Forceps biopsy and cryobiopsy|Once the nodule is visualized by radial EBUS, the position of the probe in relation to the lesion is noted. Routinely, forceps biopsy and cryobiopsy are used serially in each patient within the same session.
45801997|NCT02986477|Other|Contrast Ultrasound|For diagnostic purposes, intravesicle administration of contrast ultrasound agent will be performed to study vesicoureteral reflux.
45801998|NCT04873271|Device|Medtronic Implantable Tibial Neuromodulation (TNM) System|Tibial neuromodulation (TNM) devices are implantable devices that provide stimulation to the tibial nerve.
45801999|NCT03812549|Drug|Sintilimab|Patients will receive treatment with Sintilimab 200mg every 3 weeks for a maximum of 24 months.
45802000|NCT03812549|Radiation|stereotactic body radiation therapy|Radiation treatment utilized in this trial consists of SBRT with a standard doses to 30 Gy/3f
45802001|NCT03812549|Radiation|Low Dose Radiotherapy|LDRT at dose escalation levels: 2 Gy/1f, 4 Gy/2f, 10 Gy/5f with conventional external beam radiation.
45931341|NCT05771194|Drug|artificial tear therapy|given 0.1% sodium hyaluronate eye drops 4 times daily for 3 days before surgery (Jiang Xi, Zhen Shiming Pharmaceutical Co., Ltd.) and 3 months after surgery.
45931342|NCT05771194|Procedure|Cleaning, hot compresses and massage of the meibomian gland|Group B used a steam eye mask (Your Ga Run Fang, Shang Hai Run Mu Industrial Co., Ltd.) for 20 minutes 3 days before surgery. Sterile cotton swabs were used to apply physiological saline to the eyelid for local cleaning, and the secretions and phosphorus debris on the surface of the eyelid margin were removed to fully expose the meibomian gland. Meibomian gland tweezers were used to squeeze from the root of the gland toward the opening to expel the secretions; each gland was expressed twice. After the operation, an appropriate amount of gatifloxacin cream (Shen Yang Xing Qi Pharmaceutical Co., Ltd.) was applied to the conjunctival sac to prevent infection. Hot towels (40°C) were applied to the eyes for 10 minutes every morning and evening for 3 days before the operation.
46073116|NCT04392024|Device|Triumf|Triumf is intraocular lens which offers multifocal vision by extended depth of focus and diffractive optics.
45802002|NCT03763175|Drug|SYN-010 21 mg|21 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
46073117|NCT04247568|Other|Listening to an audiotape|The participants listen to a audiofile that consists of hypnosis
46073118|NCT02832414|Behavioral|Intensive weight loss program|behavioral and dietary supplement
45651965|NCT05299047|Other|Group fluoroscopy-guided|The patient will be placed in the supine position. The L5-S1 inter-discal space was identified under fluoroscopy.After providing local cutaneous and subcutaneous anesthesia with 2% Lignocaine solution nearly 3-4 cm below the umbilicus, a 20 cm long, 22 gauges Chiba needle is advanced to the anterior portion of the 5th vertebral body under ongoing fluoroscopic guidance. Once bony resistance is reached, gently inject 2-5 ml contrast which typical reveals a characteristic triangular blob of contrast with no vascular opacification.Before injection the needle is aspirated to confirm there is no blood. A preliminary test dose of about 3 cc of 0.5% bupivacaine is then injected. If there is no change in heart rate or neurological status, rest of the 20 cc phenol 10% is injected slowly with intermittent aspiration.
45931343|NCT05771181|Drug|Vitamin E|Vitamin E: 400mg (QD), oral, once daily, continued until disease progression or intolerable toxicity.
45931344|NCT05771181|Drug|Fruquintinib|Fuquinitinib: 5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
45931345|NCT05771181|Drug|Tislelizumab|Tislelizumab: 200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
45931346|NCT05771168|Device|Artificial urinary sphincter|Implantation of peri-urethral artificial urinary sphincter
45931347|NCT05771168|Device|Male sling|Retrourethral implantation of male sling
45931348|NCT05771155|Biological|Intravenous (IV) infusions|Intravenous (IV) infusions of a dose of 300mg, on Weeks 0, 2 and 6, 14, 22, 30, 38 and 46
45931349|NCT05771142|Device|Smart t-shirt|24h ECG Monitoring with the smart t-shirt under study
45931350|NCT05771142|Device|ECG Holter|24h ECG Monitoring with ECG Holter
45931351|NCT05771142|Device|Smartwatch|24h ECG Monitoring with a smartwatch
45931352|NCT05771129|Device|Pulse electric field ablation system developed by Zhouling (Shanghai) Medical Appliance Co., Ltd.|Pulsed electric field ablation instrument is a therapeutic instrument based on the irreversible electroporation (IRE) mechanism. The high frequency short duration energy is delivered via a disposable pulse ablation catheter through the bronchoscope and act on the bronchial mucosa, through which goblet cell hyperplasia and airway mucus secretion will be alleviated. The entire treatment consists of two procedure sessions that will be performed one month apart. The first treatment procedure consists of a baseline biopsy of the airway mucosa followed by the treatment of the right lung. The second procedure consists of a biopsy of the treated airway, followed by the left-side treatment. A third bronchoscopy will be performed three months following the first treatment and mucosa-biopsy will be conducted to evaluate the histopathological change in mucus producing cells after treatment. Subjects will also be required to fill questionnaire and complete several examinations during follow-up.
45802003|NCT03763175|Drug|SYN-010 42 mg|42 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
45802004|NCT03763175|Drug|Placebo|A placebo will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
45802005|NCT05064007|Behavioral|A: 40 Hz music|The participant will listen to the 40 Hz music playlist one hour each day, 5 days a week for 4 weeks
45802006|NCT05064007|Behavioral|B: 40 Hz sound|The participant will listen to the 40 Hz sound playlist one hour each day, 5 days a week for 4 weeks
45802007|NCT05064007|Behavioral|C: Preferred music|The participant will listen to the preferred music playlist one hour each day, 5 days a week for 4 weeks
45802008|NCT04396873|Drug|11C-MC1|Injected IV followed by PET scanning
45802009|NCT04396873|Drug|11C-PS13|Injected IV followed by PET scanning
45802010|NCT04396873|Drug|18f-florbetaben|Injected IV followed by PET scanning
45802011|NCT04829045|Device|SEIRIN PYONEX Acupuncture Needles|10 press needles (PYONEX ø0.20×1.5mm made by Seirin Corporation) will be placed on abdomen area; 10 sessions over 6 weeks.
45931353|NCT05771077|Drug|Poly(Amidoamine) dendrimer|to evaluate the Remineralizing effect of Poly Amido Amine Dendrimer, Nanohydroxy apatite & Their Combination on demineralized enamel & Their Clinical Efficacy on White Spot lesion
45931354|NCT05771051|Device|Headpulse measurements|Placement of headset on subject
45931355|NCT05771038|Procedure|socket preservation using sodium alendronate gel|"sockets will be preserved by sodium alendronate gel before then Patients will be evaluated after 3 days and weekly thereafter for the first month and then once monthly for signs of soft tissue irritation.~After 3 months post-operative CBCT scans will be done to evaluate the bone density, alveolar crest bone height will be measured and core biopsy will be taken for Histomorphological study at the same visit where implant will be placed"
45931356|NCT05771038|Procedure|socket preservation using sticky bone|"sockets will be preserved by sticky bone as mentioned before then Patients will be evaluated after 3 days and weekly thereafter for the first month and then once monthly for signs of soft tissue irritation.~After 3 months post-operative CBCT scans will be done to evaluate the bone density, alveolar crest bone height will be measured and core biopsy will be taken for Histomorphological study at the same visit where implant will be placed"
45931357|NCT05771012|Drug|0.05% cyclosporin (Restasis®, Allergan Inc)|study the efficacy of topical 0.05% cyclosporin eye drops (Restasis®, Allergan Inc) in management of grade 1 and 2 acquired punctal stenosis (group A)
45931358|NCT05771012|Device|mini-monoka stent|insertion of mini-monoka stent in the lower punctum in management of grade 1 and 2 acqquired punctal stenosis (group B)
45931359|NCT05770999|Other|Lavender application|Lavender application
45802012|NCT04829045|Other|PYONEX Placebo|Subjects are given placebo on abdomen area; 10 sessions over 6 weeks.
45802013|NCT04737863|Procedure|Endodontic retreatment|Root canal retreatment in cases with secondary root canal infection
46073119|NCT02842112|Other|PBSC mobilization and leukapheresis|"Mobilization and harvest of autologous PBSCs was scheduled during the recovery phase after the consolidation course. Granulocyte colony stimulating factor (G-CSF) (150 µg/m2/day) was given by daily subcutaneous injection from day 20 of the chemotherapy course until completion of the blood stem cell collections. PBSC collections were performed on 1 - 5 consecutive days during the hematopoietic recovery phase, as soon as the leukocyte count exceeded 2x 109/L.~Collections were performed after induction or after consolidation. In cases in which the minimum number of CD34+ cells was not collected, an additional mobilization was performed in steady state.~Harvesting was performed using continuous flow blood cell separators. Cells were stored in liquid nitrogen until use, according to standard techniques."
45802014|NCT04365049|Radiation|Radiotherapy|Radiotherapy started after two cycles of chemotherapy. External beam radiation therapy was performed using an intensity modulated radiation therapy technique. The gross target volume included the gross primary tumor and positive regional lymph nodes as defined by the multiphasic imaging. A total radiation dose greater than 50 Gy without damaging organ function was the essential requirement.
45802015|NCT04365049|Drug|Nab-paclitaxel|Eight 21-day cycles of nab-paclitaxel 125 mg/m² by intravenous infusion for approximately 30-45 mins on days 1 and 8.
45802016|NCT04365049|Drug|Gemcitabine|Eight 21-day cycles of gemcitabine 1000mg/m² intravenous infusion for approximately 30 mins on days 1 and 8.
45802017|NCT04365049|Drug|Camrelizumab|Anti-PD-1 antibody (camrelizumab, Hengrui Medicine Co., Ltd) 200 mg was administered intravenously for 30 mins every three weeks. During the chemotherapy-treated period, camrelizumab was administered on day 1 of each 21-day cycle before the infusion of chemotherapy.
45802018|NCT04606901|Drug|neostigmine/glycopyrrolate|neuromuscular blockade reversal agents
45802019|NCT04606901|Drug|sugammadex|neuromuscular blockade reversal agent
45802020|NCT03092011|Drug|Clonidine|Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours Clonidine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
45802021|NCT03092011|Drug|Morphine Sulfate|Morphine at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours Morphine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
45802022|NCT04589585|Device|DiVeRt|DiVeRt - Vascular Reconstruction Device and Delivery System
45802023|NCT04573205|Drug|FSME-IMMUN Vaccine|0.5 ml intramuscular injection scheduled in the two different arms
45802024|NCT03088033|Device|IASD System II implant|The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.
45802025|NCT03088033|Other|intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)|intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.
45802026|NCT04572035|Behavioral|Behavioural Coaching|behaviour change strategies (i.e., action planning, implementation intentions, relapse prevention, and goal setting)
46073120|NCT00895622|Radiation|54 Gy radiotherapy|External beam radiation therapy (EBRT) to a total dose of 54 Gy (RBE) in 30 fractions. 1.8 Gy (RBE) daily, 5 fractions per week, excluding weekends. 3D-CRT or IMRT or Proton allowed.
46073121|NCT00895622|Radiation|60 Gy radiotherapy|External beam radiation therapy using intensity-modulated radiation therapy (IMRT) to a total dose of 60 Gy in 30 fractions. 2.0 Gy daily, 5 fractions per week, excluding weekends.
45931360|NCT05770986|Other|Group A|the patient must attain the goal repetitions (and holds when required) at one level before progressing to the next level. The principal investigator will provide extensive education to the patient while progressing through the program. Three resistance bands will be used through the exercise progression; yellow band (low resistance), green band (moderate resistance) to blue band (high resistance). The patient will progress to more advanced level if he/she can sustain the position with high resistance band (blue) for one minute with three isometric holds of each exercise on each limb. three sets for 10 repetitions will be performed) Phases 1-3 of the program are focused on GMax activation. Phases 4- 5 are focused on GMax strength, and the final three phases emphasize functional applications of the GMax during ballistic tasks.
45802027|NCT04572035|Behavioral|Self-compassion psychoeducation|self-compassion strategies (i.e., mindfulness, self-directed kindness meditations, and writing tasks)
45802028|NCT04572035|Other|Exercise|aerobic exercise program either delivered in a laboratory setting or via Zoom
45802029|NCT04554173|Procedure|surgical resection neurogenic tumors|Patient who was treated for a thoracic neurogenic tumor by minimally invasive surgery
45802030|NCT00372749|Behavioral|Aversive reaction during alcohol cue exposure|Aversive reaction during alcohol cue exposure
45651970|NCT05267769|Drug|AP707|Preparation of Cannabis flowers (Cannabis flos)
45802031|NCT02986165|Dietary Supplement|Placebo control|The placebo control is water containing a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions
45802032|NCT02986165|Dietary Supplement|Low dose pomace extract|Immediately prior to ingestion, 'drinks' containing 1 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
45802033|NCT02986165|Dietary Supplement|High dose pomace extract|Immediately prior to ingestion, 'drinks' containing 2.5 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
46073122|NCT02831088|Drug|Neu2000KWL High-does group|1st infusion of 750mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
45802034|NCT04772807|Device|Kinocardiograph|Measure with the Kinocardiograph device and the Okcardio application installed on a smartphone
45651971|NCT05267223|Other|Semi-structured interviews|Semi-structured interviews with individuals with paraplegia
45802035|NCT00372515|Drug|Gefitinib|On days 1-14 gefitinib will be taken orally daily at either 750, 1000, or 1250mg (depends upon when subject entered trial). If medication is tolerated well, subject will take 500mg daily on days 15-28 of each 28-day cycle. Cycles (higher dose followed by lower dose) will be repeated as long as subject's cancer does not worsen and they do not experience any serious side effects.
45651972|NCT05298891|Other|Usual clinical practice + hypoproteic diet|"Diet will be composed by:~energy equal to daily energy expenditure (estimated by indirect calorimetry * physical activity factor)~fats 28-35%~carbohydrates 50-60%~proteins 0,7-0,8g/kg of body weight 10-13% Diet will be given to the patient after the first visit and the study will start once the patient begins the diet."
45651973|NCT05298033|Drug|Crisaborole 2 % Topical Ointment|Twice daily crisaborole 2% topical ointment
45651974|NCT05298033|Drug|PF-07038124 0.01% topical ointment|Twice daily PF-07038124 0.01% topical ointment
45802036|NCT04333979|Other|Drainage|Using drain after operation
45802037|NCT04448119|Drug|Favipiravir|Favipiravir is the experimental drug. The dosage for favipiravir to be used in this study for prophylaxis is 1600 mg (8 x 200 mg tablets) orally twice daily on day 1 followed by 800 mg (4 x 200 mg tablets) orally twice daily on days 2-25. The dose of favipiravir for treatment is 2000 mg orally twice daily on day 1, the 1000 mg orally twice daily for 13 additional days.
45802038|NCT04448119|Drug|Favipiravir Placebo|Favipiravir Placebo is the placebo drug. For chemoprophylaxis, the dosage of favipiravir placebo is 8 tablets orally twice daily on day 1, followed by 4 tablets twice daily from days 2-25. The dosage of favipiravir placebo for treatment is 10 tablets orally twice daily on day 1, followed by tablets twice daily from days 2-14.
45802039|NCT04706507|Drug|IV Ganciclovir|For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
45802040|NCT04342429|Radiation|Proton-beam Therapy for Small Cell Lung Cancer|The goal of intensity-modulated proton therapy (IMPT) is to deliver radiation to the tumor while minimizing exposure to surrounding normal tissues.
45802041|NCT04508309|Biological|Cecolin®|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine
45802042|NCT04508309|Biological|Gardasil®|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine
45802043|NCT02986633|Other|Echocardiography|
45802044|NCT04502615|Other|Sand|sand surface
45802045|NCT04502615|Other|artificial grass|grass surface
45802046|NCT04502615|Other|firm ground|firm surface
45802047|NCT02986555|Device|Existing Biofeedback|Using relaxing assisted biofeedback approach
45802048|NCT02986555|Device|Biofeedback accompanied with virtual reality|Using relaxation approach with existing biofeedback accompanied by virtual reality relaxation
45802049|NCT00372983|Drug|NOV-205|
45802050|NCT03047473|Biological|avelumab|add on of avelumab 10mg/kg IV to standard therapy
45931361|NCT05770986|Other|Group B|Flexibility exercises of the back muscles: knee to chest stretch, bridging, stretching exercises for hip flexors, piriformis, adductors and hamstring will be performed, with a hold of position for 30 s and with repetitions (3-5 times). Static stretches will be held for 30 seconds to induce changes in flexibility and will be repeated for three sets. Three sessions of stretching per week will be performed b. Prone resisted hip extension 10 repetitions for two sets. c. Hot pack: for 10 minutes. d. TENS: The electrodes will be placed over the area of most severe pain for 15 minutes.
45931362|NCT05770973|Other|Compression dressing (build by Kompressen, gauze swabs, Nobamed Paul Danz AG, Wetter, Germany and NOBALUMENAL® - steril, eye pad, Nobamed Paul Danz AG, Wetter, Germany|Compression dressing after ptosis surgery
45651975|NCT05298033|Device|NBUVB phototherapy|Home narrow band UVB phototherapy exposure sessions 3 times per week
45651976|NCT05298033|Device|Sham phototherapy|Non-NBUVB visible light radiation exposure sessions 3 times per week
45651977|NCT05298033|Drug|Vehicle|Twice daily vehicle ointment
45653273|NCT05613101|Procedure|Adductor Canal Block|After the necessary asepsis and antisepsis procedures, the linear ultrasound probe was placed in the middle between the medial condyle and the SIAS, and the superficial femoral artery (FSA) was visualized under the sartorius muscle. By following the FSA distally, the point where the sartorius muscle crosses the adductor magnus muscle, which is the beginning of the adductor canal, was found and the saphenous nerve was visualized hyperechoic in the anterolateral aspect of the FSA. 20 cc 0.5% bupivacaine hydrochloride was applied
45653274|NCT05613023|Radiation|SBRT|Stereotactic Body Radiotherapy
45653275|NCT04746677|Device|Endovascular aortic repair with a physician-modified endovascular graft (PMEG)|Endovascular aortic repair with a physician-modified endovascular graft (PMEG)
45802051|NCT03043963|Behavioral|Sleep Extension|Lengthen the duration of sleep time.
45802052|NCT03043963|Behavioral|Sleep Timing|Regularize the timing of the sleep period.
45802053|NCT03020251|Other|preoperative chest physiotherapy|preoperative chest physiotherapy : 5 sessions per week during 3 weeks
45802054|NCT03020251|Other|preoperative rehabilitation program|exercise training at home : 5 sessions per week during 3 weeks
45802055|NCT03069131|Drug|Rifaximin|twice daily administration of 1 tablet containing 550 mg of active rifaximin
45802056|NCT03069131|Other|Placebo|twice daily administration of 1 rifaximin placebo tablet
45802057|NCT04707365|Biological|Tumor samples|for each patient: liver sampling, blood samples ( serum, plasma, PBMC, whole blood), per-endoscopic bile sampling, stool samples, and materials derived from fresh tumors
45931363|NCT05770960|Drug|Naloxegol|Oral administration of Naloxegol after waking up from the Midazolam administration during the colonoscopy.
45931364|NCT05770960|Drug|codeine phosphate|Oral administration of Codeine after waking up from the Midazolam administration during the colonoscopy.
46073123|NCT02831088|Drug|Neu2000KWL Low-does group|1st infusion of 500mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
46073124|NCT02831088|Drug|Placebo|1st infusion of the same volume of saline in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 hours
45802058|NCT02990845|Drug|Pembrolizumab/ Exemestane/ Leuprolide|Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
45802059|NCT04381559|Behavioral|Cognitive Behavioural Therapy|In sessions 1-2, the participant's sexual history and goals regarding social anxiety reduction and HIV risk reduction will be discussed, including reducing CAS, and considering use of PrEP to reduce HIV risk. In sessions 3-4, the role of social anxiety and substances in social avoidance and HIV risk will be discussed, and a fear hierarchy of the participant's social fears will be created. In sessions 5-7, cognitive restructuring and coping skills for anxiety reduction will be discussed. In sessions 8-9, participants will face their fears via exposures to feared situations using their new cognitive coping skills. In sessions 10-11, exposures are continued with a focus on (a) situations higher in the fear hierarchy and (b) the role of substance use as a barrier to personal goals. In session 12, relapse prevention and goals for progress regarding social anxiety, substance use, and HIV risk reduction beyond the end of therapy will be discussed.
45651978|NCT04422483|Other|Realist evaluation|In-depth exploration of individual service models will be carried out to determine the interrelationship of context, intervention, mechanisms and outcomes as they occur in their natural setting. Data will be gathered within case studies using mixed methods at two levels: (i) service model and (ii) individual child/ family. Methods will include semi structured realist Interviews, focus groups, and document reviews to assemble a comprehensive description of the service and model. Interviewees will include commissioners, service managers, clinicians, referrers, parents and young people. Interviews will be recorded and transcribed, proceeding to qualitative analysis based on components of the programme theory. Regular team meetings will discuss coding, address inconsistencies, and refine collective understanding of coding framework. Coded data will be collated using NVivo software.
45651979|NCT05297097|Dietary Supplement|Trulacta breastmilk supplement|one supplement daily
45651980|NCT05266053|Device|PICO 7 dressing|The PICO 7 dressing consists of a negative pressure wound therapy pump (NPWT) connected to an absorbent gentle adhesive dressing that is applied to a wound. When the pump is activated, it acts by pulling excess fluid from the wound. The dressing absorbs this fluid and helps to prevent bacteria from entering the wound. It has been shown to prevent wound infections and promote healing.
45651981|NCT05266053|Other|Standard wound dressing|Standard abdominal dressing at the time of cesarean
45651982|NCT05265195|Other|Mixed Methods study|Mixed Methods study
45802060|NCT04381559|Behavioral|Applied Relaxation|12 sessions of AR will serve as our second, control arm. In AR, patients are trained in progressive muscle relaxation, and then taught to practice using relaxation when facing feared situations, as a new coping response.86 AR involves noticing early signs of anxiety, learning relaxation skills, and applying relaxation at the first sign of anxiety.87 This therapy is chosen because it does not involve the cognitive and exposure focused techniques that are used in the experimental condition.88 Reviews of psychological treatments show that AR does not statistically differ from cognitive restructuring with exposure in its effects on social anxiety.87 However, AR is an appropriate control arm for the present study because it is credible and can be time-matched to CBT, but has no theoretical or empirical support for substance use management or HIV risk behaviour reduction, the latter of which is the primary outcome of the present study.
45802061|NCT04438213|Drug|Ertugliflozin|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
45802062|NCT04438213|Drug|Metolazone|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
45802063|NCT04438213|Drug|Placebo|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
45802064|NCT04310449|Procedure|Connective tissue graft and customized healing abutment|Immediate implant placement without flap raising using standard implant system protocol preparation will take place. Connective tissue grafts from the hard palate will be placed at the implant sites in a supraperiosteal partial dissection prepared at the buccal aspect. Sutures will be used to stabilize the graft, followed by customized healing abutment. Flowable composite will be injected at the gingival margin level to adapt to the sandblasted abutment, taking the shape of the socket at the marginal gingiva. Buccal groove will be made after the polymerization of this material for easier application. The abutments will be removed for final configurations of the apical part mimicking the emergence profile of the extracted tooth and finishing with laboratory discs and burs. The custom healing screw will be screwed to the implant.
45802065|NCT04310449|Procedure|Bone graft and customized healing abutment|Tooth extraction and immediate implant placement as mentioned, followed by particulate bone grafts are packed in the gap between the implant and the buccal plate of bone till the crest of the alveolar bone, then will be covered by a customized healing abutment that will be done as mentioned before.
45802066|NCT04310449|Procedure|Bone graft and ovate pontic|The extraction will take place and then particulate bone graft will be placed in the socket and a fixed temporary ovate pontic (PMMA) extending 3mm inside the socket, with minimal occlusal contact (38), will be placed and cemented on the adjacent teeth
45802067|NCT04480931|Behavioral|mHealth Intervention Group|Access to the mobile health application with exercise plans and education
45931365|NCT05770960|Other|Placebo|Oral administration of siripus simplex syrup after waking up from the Midazolam administration during the colonoscopy.
45931366|NCT05770947|Behavioral|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy (CBT) is a psychological treatment or talk therapy that integrates how people think, feel, and behave to create new behavior patterns that improve thinking processes and reduce distress."
45931367|NCT05770947|Behavioral|Mindfulness|"Mindfulness is a psychological treatment or talk therapy that practices different coping skills to improve thinking processes and reduce distress."
45931368|NCT05770921|Device|Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter|All subjects will be ablated using the Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the management of their Paroxysmal Supraventricular Tachycardia
45931369|NCT05770908|Other|Therapeutic exercise program|"Therapeutic exercise program based on increasing resistance with elastic bands or weights. The programmes are composed of combinations of the following exercises:~Scaption with elastic band.~External rotation at 0º of abduction with elastic band.~Internal rotation at 0º of abduction with elastic band.~Shoulder protraction in supine position with weights.~Low row with elastic band.~Horizontal adduction stretching."
45802068|NCT04480931|Behavioral|Educational Brochure|An evidence-based educational brochure with general information about the benefits of physical activity during pregnancy
45802069|NCT04465253|Other|Best Practice|Undergo standard of care occupational therapy
45802070|NCT04465253|Behavioral|Motivational Interviewing|Participate in discussions via videoconferencing
45931370|NCT05770908|Other|Multimedia animation information|Multimedia animation videos (including audio) showing the performance of the prescribed exercises.
45802071|NCT04465253|Behavioral|Motivational Interviewing|Participate in interview via videoconferencing
45931371|NCT05770908|Other|Paper-based information|Paper-based information showing the performance of the prescribed exercises, based on figures and a brief description of the exercise performance.
45931372|NCT05770869|Device|ALIBIRD mHealth platform|Use of a mHealth platform to follow-up and empower cancer patients in the self-management of their own health.
45931373|NCT05770583|Procedure|Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation|"FiO2 will be titrated by reducing 10% if Ori>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95<oxygen saturation≤%98~FiO2 will be increased by 10% if oxygen saturation <95 or PaO2<60 mmHg"
45931374|NCT05770583|Procedure|SpO2 (oxygen saturation)|Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95<oxygen saturation≤%98
45931375|NCT05770362|Other|lifestyle questionnaire|The changes in lifestyle by lifestyle questionnaire during and after home isolation
45931376|NCT05769946|Drug|Hemay005|A PDE-4 inhibitor
45931377|NCT05769465|Drug|disease modifying treatments|Patients will be enrolled if exposed to nusinersen, risdiplam, onasemnogene abeparvovec
45931378|NCT05769257|Drug|IS-001|Intravenous injection of IS-001 investigational drug
45931379|NCT05768867|Other|FRAnçaise du PEYronie's Disease QUESTionnaire|Complete an online FRAnçaise du PEYronie's Disease QUESTionnaire
45931380|NCT05768321|Drug|GEC255 tablets|"Part 1: Dose escalation After initial starting dose cohort, daily dosages in subsequent cohorts are determined by cohort review committee.~Part 2: Dose expansion Daily oral dosage RP2D based on data from Part 1"
45651983|NCT05501379|Other|No intervention - observational study only|No intervention - observational study only
45931381|NCT05768282|Drug|Oral prednisolone (30mg/day) for 28 days|Oral prednisolone was started at a dose of 30 mg/day on the third day after RFA, and continued for 4 weeks.
45651984|NCT05331573|Device|apomorphine pump|observationnal
45651985|NCT05262075|Other|Online Mindfulness Resiliency Program|An approximate 20 minute online mindfulness resiliency program offered 3/wk x 4 weeks.
45931382|NCT05768009|Procedure|Interscalene brachial plexus block (ISB)|• Group A will include 21 patients who will undergo the procedure under general anesthesia and ultrasound guided ISB using 10 ml bupivacaine 0.25%.
45931383|NCT05771740|Device|Stemoscope (bluetooth sound amplifier)|The bluetooth device will be placed in six locations on the front and six locations on the back of the chest and sound recordings stored for each location.
45931384|NCT05766800|Drug|Serplulimab|Specified dose on specified days
45931385|NCT05766800|Drug|Carboplatin|Specified dose on specified days
45931386|NCT05766800|Drug|Pemetrexed|Specified dose on specified days
45651986|NCT05261451|Other|Workshop|Participants will engage in three 1 hour workshops about trauma informed care. They will complete pre and post measure before engaging in the workshops
45651987|NCT05260359|Drug|6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation|SU E 101413 85
45651988|NCT05260359|Drug|6% Bemotrizinol (BEMT) dispersion in petrolatum|SU-E-101413-82
45651989|NCT05260359|Other|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT|SU E 101413 91
45931387|NCT05766800|Drug|Nab-paclitaxel|Specified dose on specified days
45931388|NCT05766800|Procedure|Surgery|Patients with stage IIIB-IIIC non-small cell lung cancer are treated with nab-paclitaxel/pemetrexed plus carboplatin and serplulimab for 4 cycles. Those with downstaged and resectable tumors after chemoimmunotherapy are randomised into surgical treatment arm and radiotherapy arm, and those with tumors still unresectable after chemoimmunotherapy will receive non-surgical treatment in department of medical oncology in the third arm.
45931389|NCT05766800|Radiation|Radiotherapy|Patients with stage IIIB-IIIC non-small cell lung cancer are treated with nab-paclitaxel/pemetrexed plus carboplatin and serplulimab for 4 cycles. Those with downstaged and resectable tumors after chemoimmunotherapy are randomised into surgical treatment arm and radiotherapy arm, and those with tumors still unresectable after chemoimmunotherapy will receive non-surgical treatment in department of medical oncology in the third arm.
45651990|NCT05260359|Other|Petrolatum vehicle|SU-E-101413-83
45651991|NCT05260359|Other|0.9% Saline|low irritancy control
45651992|NCT05260359|Other|Sodium Lauryl Sulfate 0.1% (SLS)|positive control
45651993|NCT05260359|Other|Undosed patch|negative control
45653276|NCT03067597|Drug|Dinoprostone|The DVI contains 10 mg dinoprostone
45653277|NCT02518971|Drug|Tamsulosin|0.4 mg daily
45653278|NCT02518971|Drug|Placebo|one capsule daily
45653279|NCT03067519|Other|Fast track surgery|early feeding and mobilization after surgery
45802072|NCT04465253|Other|Quality-of-Life Assessment|Ancillary studies
45802073|NCT04465253|Other|Questionnaire Administration|Ancillary studies
45802074|NCT04448171|Device|Active TENS|Standard TENS unit with four pads affixed to the lower back area, will be used in this arm. The TENS device will be set to an active setting.
45802075|NCT04448171|Device|Sham TENS|Standard TENS unit with four pads affixed to the lower back area, will be used in this arm. The TENS device will be set to an inactive setting.
45931390|NCT05766566|Procedure|Perianal fistula surgery|surgical treatment of the perianal fistula through curettage, closure with suture thread (vicryl 2/0) of the internal orifice and lipofilling of the passage with microfragmented autologous adipose tissue processed with the Lipogems® system.
45931391|NCT05766410|Drug|Palbociclib|CDK4, 6 inhibitor
45931392|NCT05766410|Drug|Ribociclib|CDK4, 6 inhibitor
45931393|NCT05766410|Drug|Abemaciclib|CDK4, 6 inhibitor
45651994|NCT05260047|Behavioral|IMANI|For the intervention, the study will introduce and offer Medication Assisted Treatment. Those participants wishing to receive MAT will be randomized to one of two intervention IMANI + church-based telehealth MAT or IMANI + Traditional MAT + Referral and Linkage. Those who do not wish to partake of MAT services will remain in the IMANI alone.
45931394|NCT05766410|Drug|Letrozole|Endocrine therapy
46073125|NCT02835144|Other|TIQAAM_therapy|The treatment program consists of TIQAAM therapy blocks to three priority areas: promoting change and motivation, relapse prevention and relapse management, and promote resource and euthymic activities to increase the abstinence motivation. The TIQAAM is based on behavioral approaches as well as motivational interviewing of Miller and Rollnick.
45802076|NCT01987219|Drug|Albuterol-sulphate|Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
45651995|NCT05260047|Behavioral|Telehealth MAT|Describe what is the Telehealth MAT briefly
45802077|NCT01987219|Drug|Ipratropium-bromide|Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.
45802078|NCT01987219|Other|placebo|Saline solution 3 cc NA
45802079|NCT03027245|Drug|Eribulin|
45802080|NCT04768387|Dietary Supplement|Personalized microbiome diet|The personalized nutrition model estimates the optimal micronutrient compositions for a required microbiome modulation. In this study, we computed the microbiome modulation needed for an IBS case, based on the IBS-indices generated by the machine learning models. According to that, the baseline microbiome compositions are perturbed randomly with a small probability p. Perturbed profiles are accepted with a probability proportional to the decrease in the IBS-index as suggested by Metropolis sampling. This Monte-Carlo random walk in the microbiome composition space is expected to meet a low IBS-index microbiome composition nearby the baseline microbiome composition of the patient with a minimal modulation. The personalized nutrition model, then, estimates the optimized nutritional composition needed for this individual, expecting to drive the IBS-index to lower values.
45802081|NCT02917993|Drug|Itacitinib|In Phase 1, itacitinib at a protocol-defined starting dose, with subsequent dose escalation based on protocol-specific criteria. In Phase 2, itacitinib at the recommended dose from Phase 1.
45802082|NCT02917993|Drug|Osimertinib|Osimertinib 80 mg once daily (QD)
45802083|NCT02758223|Biological|TCM allogeneic humane central memory T cells, cryopreserved|Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65*10^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
45931395|NCT05765318|Procedure|QLB|QLB is ultrasound-guided injection of 30 ml bupivacaine 0.25% into quadratus lumborum plane posterior to the end of internal oblique muscle.
45931396|NCT05763810|Other|Erector Spinae Plane Block|Erector Spinae Plane Block
45931397|NCT05763810|Other|Superficial Parasternal Intercostal Plane Block combined with Rectus Sheath Block|Superficial Parasternal Intercostal Plane Block combined with Rectus Sheath Block
46073126|NCT02835144|Other|Psychoeducation|This intervention is a psychoeducation module pertaining to substance use disorders.
45651996|NCT05260047|Behavioral|Traditional MAT plus Referral and Linkage|Describe what he traditional MAT plus referral and linkage briefly
45651997|NCT05258877|Other|Plasma samples|Up to 80ml of plasma may be collected from each participant over the 24 hour sampling period to be used for PK analysis.
45651998|NCT05258409|Behavioral|Media Advocacy (MA)|MA content generally centers on acknowledging and discussing the role the media has on shaping body image ideals. Session 1: In session 1, similar to MTM, the primary activities will include: (1) describing the ideal body for men in our culture, (2) discussing how the media impacts this ideal, with a particular focus on advertising. Following this, participants will (3) watch a video on how the media influences body image among men, and the consequences of internalizing these messages. Session 2: In session 2, content will continue by further discussion of the video showed in session 1, with participants sharing their reactions. Next, the group discusses the attainability of the ideal as well as discusses other forms of media (e.g., social media) and how it impacts body image.
45802084|NCT04405349|Biological|VB10.16|Vaccination
46073127|NCT02841098|Other|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) (Surgery and Drug)
45802085|NCT04405349|Biological|Atezolizumab|Intravenously infusion
45931398|NCT05762198|Device|Rezūm|In the REZUM arm, water vapour treatment is performed for all subjects under local anaesthesia.
46073128|NCT02841098|Drug|Optimal medical therapy alone|Optimal medical therapy alone
45931399|NCT05762198|Device|TURP|In the TURP arm, all men will receive TURP operation under general or spinal anaesthesia
46073129|NCT05334446|Behavioral|The Effect of the Mobile Application|"This study was planned to determine the Effect of Mobile Application Use on Treatment Adherence and Self-Care Management in Patients with Hypertension. The study was designed to improve individuals' knowledge about the disease, regular drug use, diet compliance, physical activity level, quitting smoking and alcohol if using, and weight control."
45653280|NCT03067519|Other|Conventional management|Management per the primary surgeon
45653281|NCT04733963|Drug|Fruquintinib Plus Capecitabine|Maintenance therapy with fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
45802086|NCT04265053|Drug|L-NMMA|L-NMMA is a modified amino acid which competitively inhibits Nitric Oxide Synthase (NOS). It is infused acutely (~5 min) via IV catheter. Metabolized via normal metabolic (amino acid) pathways in ~24 hours.
45802087|NCT04265053|Drug|Ketorolac Tromethamine|Ketorolac is an NSAID which competitively inhibits Cyclooxygenase (COX). It is infused acutely (~5 min) via IV catheter. Metabolized in <24 hours.
45931400|NCT05761873|Other|Provision of audit and feedback via email and paper|Provision of A&F reports by paper via the post (new intervention being trialled) and email (standard practice) to allocated practices depending on randomisation status.
45931401|NCT05761873|Other|Provision of audit and feedback via paper only|Provision of A&F reports by email (standard practice in the region) to allocated practices depending on randomisation status.
45651999|NCT05258409|Behavioral|More than Muscles (MTM)|"In session 1, the primary activities are: 1) define the ideal body type for men in our culture, 2) discuss the origin and perpetration of the ideal, 3) brainstorm the costs of pursuing the ideal, 4) participate in a verbal challenge during which participants counter the ideal message, and (5) are asked to complete three homework assignments (i.e., a letter to an adolescent boy, a behavioral challenge, and a mirror exposure assignment). In session 2, the primary activities are: 1) reviewing homework, 2) engage in role-plays to counter/discourage pursuit of the ideal, 3) discuss ways to challenge and avoid negative body talk statements, 4) list ways to resist the pressure to pursue this ideal both individually and as a group within the larger community (i.e., body activism), 5) discuss barriers to body activism and strategies to overcome those barriers, and 6) individually select an exit exercise to continue to actively challenge the appearance ideal."
45802088|NCT04265053|Drug|Ganirelix Acetate|"Gonadotropin-Releasing Hormone (GnRH) antagonist ganirelix acetate as a model to isolate estrogen and testosterone effects on the cerebrovascular system. Participants receive daily injections of ganirelix for 12-14 days for Aim 3 studies only. This will be overseen by clinical endocrinologists.~Both males and females receive this treatment in Aim 3."
45652000|NCT05330091|Dietary Supplement|Once Daily Women's Probiotic|Active product
45652001|NCT05330091|Other|Placebo|Placebo product
45931402|NCT05757011|Procedure|pre-sacral nerve block (bupivacaine injection into both uterosacral ligaments at the end of laparoscopic hysterectomy.|pre-sacral nerve block (bupivacaine injection into both uterosacral ligaments at the end of laparoscopic hysterectomy.
45802089|NCT04265053|Drug|Testosterone Transdermal Product|In Aim 3, males receive this for 7-9 days of the ganirelix treatment.
45802090|NCT04265053|Drug|Estradiol Topical|In Aim 3, females receive this for 7-9 days of the ganirelix treatment.
45652002|NCT05329155|Drug|Heparin Sodium Injection|Heparin Sodium Injection (100U/Kg body weight)
46073130|NCT02841176|Other|Thermography|Thermographic imaging of arthritic joints will be performed at baseline and within 5 days after the participant's 2nd and 4th doses of monthly Golimumab
45802091|NCT04332497|Other|"Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''"|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
45802092|NCT04332497|Other|"Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''"|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
45802093|NCT02840383|Other|Delayed Intervention|Schools not receiving intervention until two years after implementation.
45802094|NCT02840383|Other|Intervention|intervention at the beginning of study.
45931403|NCT05756790|Behavioral|Motivational Interviewing|Counseling
45931404|NCT05756790|Behavioral|Motivational Interviewing plus Breathalyzer|Counseling plus mobile breathalyzer/ app
46073131|NCT02841176|Biological|Golimumab|Participants will start monthly Golimumab after their baseline visit
46073132|NCT01615874|Drug|MF/F Metered Dose Inhaler (MDI) 25/5 mcg|MF/F MDI 25/5 mcg, 2 inhalations twice a day (BID)
46073133|NCT01615874|Drug|MF/F MDI 50/5 mcg|MF/F MDI 50/5 mcg, 2 inhalations BID
45653282|NCT04733963|Drug|Bevacizumab Plus Capecitabine|Maintenance therapy with bevacizumab at the dose 5mg/kg q2w (Q2W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
45802095|NCT04322981|Behavioral|Pharmacist-Led care|Rapid testing in a community pharmacy, with rapid linkage to care and treatment that is pharmacist-led
45802096|NCT04322981|Behavioral|Standard of Care (Hepatology)|Rapid testing in a community pharmacy, with standard of care referral to academic hepatology
45802097|NCT02746159|Device|Lutonix 035 Drug Coated Balloon PTA Catheter, Model 9004|
45802098|NCT04307225|Device|Zenicor|Handheld Thumb ECG monitoring device
45802099|NCT02548715|Drug|Levothyroxine|
45802100|NCT02548715|Drug|Placebo|
45802101|NCT02633137|Drug|Lenalidomide|
45802102|NCT02633137|Drug|R-CHOP|"Rituximab 375 mg/m^2 IVPB with premedications Day 1~Cyclophosphamide 750 mg/m^2 IVPB Day 1~Doxorubicin 50 mg/m^2 IVP Day 1~Vincristine 1.4 mg/m^2 IVP (capped at 2 mg) Day 1~Prednisone 100 mg PO Daily on Days 1-5 or 2-6"
45802103|NCT02633137|Drug|high-dose cytarabine (HIDAC)|
45802104|NCT02611687|Drug|pitolisant|Tablet
45802105|NCT02611687|Drug|Placebo|Tablet
45802106|NCT04258397|Drug|Pirfenidone|Pirfenidone vs. matching placebo
45802107|NCT04258397|Drug|matching placebo|matching placebo
45802108|NCT01988857|Biological|Boostrix™|Single-dose administered intramuscularly in the deltoid region of non-dominant arm.
45931405|NCT05754827|Diagnostic Test|RDW to platlet count ratio|RDW to platlet ratio will be measured for all patients and results will be compared between groups
45931406|NCT05751434|Behavioral|Exercise Therapy|The intervention will consist of exercise therapy, individualized, walking delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule, up to 5 individual treatment sessions/week to achieve a cumulative total duration of 225 to 300 mins/wk until the participant's next standard of care prostate biopsy (about 6-12 months).
45931407|NCT05750875|Drug|Loratadine|Participants were given loratadine 10mg, oral, daily, for 4 weeks
45931408|NCT05750875|Drug|Gabapentin|Participants were given gabapentin 100mg, oral, daily, for 4 weeks
46073134|NCT01615874|Drug|MF/F MDI 100/5 mcg|MF/F MDI 100/5 mcg, 2 inhalations BID
46073135|NCT01615874|Drug|BDP hydrofluoroalkane (HFA) 80 mcg|BDP HFA 80 mcg, 2 inhalations BID
45931409|NCT05744960|Behavioral|Communication training|Clinics will host an Announcement Approach Training (AAT) workshop. A trained facilitator will use a standard script and slides to deliver workshop in-person or over Zoom; clinical staff who are unavailable will take the workshop later on their own.
45931410|NCT05744960|Behavioral|financial Incentive|Clinics will host an AAT workshop, as in the other trial arm. Clinics in the intervention arm will then receive a 12-month clinic-level financial incentive program with predetermined targets for HPV vaccine initiation rates (5%, 10%, and 30% increases from baseline). Clinics will be notified of their HPV vaccination rates though a monthly, automated report. Clinic achievement will be assessed and incentives will be paid out to clinics monthly. Incentives will be tiered based on target and sized based on the number of clinic providers. For reaching the highest tier of 30%, clinics will receive an aggregate of $1000 per provider.
45931411|NCT05744843|Behavioral|exercise|cardiovascular and lower limb strengthening exercise programme
45931412|NCT05744843|Procedure|Deep venous stenting|Planned surgical intervention
45931413|NCT05734794|Drug|Rituximab|Rituximab dose: 4 doses of 375 mg/m2 rituximab at 1-week intervals( within +7 days), associated with trimethoprim-sulfamethoxazole(25-50 mg/kg/day orally twice per day, 3 days per week. If the patient is not allergic) for three months from the first rituximab dosing date(Day 1). Four doses of rituximab are necessary whether the patient achieves complete remission.
45931414|NCT05734794|Drug|Steroid|Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks. Vitamin D and calcium(adjusted according to the blood calcium level) were administered for three months.
45931415|NCT05732649|Behavioral|Auditory neurofeedback|Network interaction measured with EEG at visual areas will be coupled with the intensity of a sound.
45931416|NCT05732649|Behavioral|Tactile neurofeedback|Network interaction measured with EEG at visual areas will be coupled with the intensity of tactile stimulation (i.e., electrical or vibrotactile stimulators applied on both hands and feet).
45802109|NCT04707209|Drug|Sirolimus|"An intravitreal injection of 20 µL of drug will be given through the pars plana of the eye. The injected eye will be treated with topical antibiotic and steroid eye drops prescribed for 7 to 10 days after the injection. The first injection will only be provided into the worse eye despite both eyes showing signs of exudation. Injection into the other eye will be considered only two months after the safety of this first injection is determined.~Safety and efficacy of treatment will be determined by repeat eye examinations in the eye clinic one day, one week and one month after each injection.~Injections will be repeated every eight weeks. A total of 3-6 injections will be given per eye, over 6-12 months. The current treatment plan is for a maximum of six injections per eye, which may be amended to accommodate more in the future."
45451432|NCT02229994|Other|Cross sectional psychometric evaluation of a self-administered dyspnea questionnaire.|"Evaluation will be performed on a group of 200 patients deriving from 4 samples.~From these 200 patients, a sub-sample will be evaluated at 7 days (DYSLIM questionnaire only) for reproducibility (n = 50 patients: 10 patients with diffuse interstitial lung disease, 10 patients with cystic fibrosis, 10 patients with arterial pulmonary hypertension, 20 patients with COPD).~From these 200 patients, a sub-sample (COPD, n = 60) will be recruited among patients undergoing pulmonary rehabilitation at the beginning of the 6 months separating follow up visit and the initial assessment."
45931417|NCT05732649|Behavioral|Auditory and tactile neurofeedback|Network interaction measured with EEG at visual areas will be coupled with the intensity of a sound and tactile stimulation.
45451433|NCT03690388|Drug|Cabozantinib|Tablets containing 60-mg or 20-mg cabozantinib once daily orally.
45652003|NCT05295849|Behavioral|Building Habits Together Online Weight Loss 6-Week Usability Trial|The intervention includes: the Facebook-delivered Diabetes Prevention Program (DPP) Lifestyle Intervention, MyFitnessPal and the Habit app. The DPP will be delivered within a counselor-led private Facebook group. It uses behavioral strategies to help participants 1) achieve a program assigned calorie goal based on amount needed to lose 1-2 pounds per week, 2) develop a healthy diet, and 3) engage in 150-300 minutes per week of moderate intensity exercise. Participants will be instructed to use MyFitnessPal for the first two weeks, the Habit app slip tracker and exercise planner for two weeks, and the Habit app problem solver for two weeks.
45653283|NCT04222023|Drug|Intravenous immunoglobulins (IVIG)|"Experimental group: administration of a single dose of IVIG at:~Day 10+/- 4 days~Day 41 +/- 7 days~Day 62 +/- 7 days The dose of IVIG is defined according the donor BKV genotype: genotype I: 0.4 g/Kg/day; genotype II and IV: 1g/kg/day."
45802110|NCT04295213|Other|oligosaccharides|1 dose a day of oligosaccharides or placebo
45802111|NCT01989793|Drug|Losartan|Losartan will be given in increasing doses to those in the losartan arm.
45802112|NCT01989793|Drug|Placebo|Placebo will be given to those in placebo arm
45802113|NCT02422745|Dietary Supplement|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
45802114|NCT02422745|Dietary Supplement|Multivitamin|Multivitamin
45451434|NCT03690388|Drug|Placebo|Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.
45451435|NCT02230150|Behavioral|Adhesion-HF|The hypothesis that was investigated is whether the nursing consultation improves therapeutic strategies for membership, adherence to self-care, improved levels of NT-proBNP improves performance in 6-minute walk test, monitoring of biomarkers of laboratory tests (sodium , potassium, urea, creatinine and NT-proBNP) frequent occurrence of readmissions and mortality in patients with heart failure after 1 month.
45802115|NCT02422745|Dietary Supplement|Cocoa extract placebo|Cocoa extract placebo
45802116|NCT02422745|Dietary Supplement|Multivitamin placebo|Multivitamin placebo
45802117|NCT04254185|Procedure|Simple decompression|Surgical technique
45802118|NCT04254185|Procedure|Subcutaneous anterior transposition|Surgical technique
45451436|NCT03662542|Drug|Guselkumab Dose 1|Guselkumab Dose 1 will be administered as IV infusion.
45451437|NCT03662542|Drug|Guselkumab Dose 2|Guselkumab Dose 2 will be administered as SC injection.
45653284|NCT03066115|Drug|L-NMMA|See arm description.
45653285|NCT03066115|Drug|Ketorolac|See arm description.
45802119|NCT01991821|Drug|APD421|
45802120|NCT01991821|Drug|Placebo|
45931418|NCT05732649|Behavioral|Neurofeedback|Participants train to decrease the intensity of a sensory stimulation (defined in Experiment 1) that is coupled with the network interaction at a specific brain region.
45931419|NCT05724888|Behavioral|Peer mentorship and physical activity|Participants will be asked to participate for 12 weeks, attending 3 sessions per week (if in the intervention arm). Session 1 will be a group session that will be about 90 minutes, session 2 will be an individual session with a peer mentor for 20-30 minutes, and session 3 will be a virtual check in with the peer mentor about 15 minutes. The intervention will focus on increasing physical activity through the circle of courage.
45931420|NCT05720156|Other|Contrast-enhanced CCTA|Allows for non-invasive assessment of atherosclerotic plaque burden and morphology
45931421|NCT05720156|Other|99mTc-tilmanocept SPECT/CT scanning|99mTc-Tilmanocept SPECT/CT allows for visualization of macrophage-specific arterial infiltration
45931422|NCT05715073|Dietary Supplement|TeaCrine and Caffeine|Participants will take Teacrine and caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.
45931423|NCT05715073|Dietary Supplement|Caffeine|Participants will take caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.
45931424|NCT05715073|Other|Placebo|Participants will take the placebo cellulose pill and than an hour later perform an intense interval exercise protocol followed by cognitive tests.
45931425|NCT05712785|Device|Use of shuotong ureteroscopy|Treatment of patients with ureteral stones using the Shuotong-scopy
45931426|NCT05712317|Behavioral|Exergame Intervention|8-week exergame-based intervention 3x per week
45652004|NCT05328063|Other|Control group|"All subjects will carry out a gluteus maximus strengthening work out. The exercises should be performed at a frequency of 3 times/week and with a dosage of 3 sets of 8 repetitions.~1-4 Weeks: 1. Bilateral gluteal bridge: Supine decubitus with knees and hips bent and feet supported. To raise the pelvis until the knees are flexed to 90° and then returns to the starting position. 2.Clam shell: Lateral decubitus with knees and hips bent to 45º, working leg placed on top of the other. Separate this knee while feet remain in contact using a medium density Theraband on the distal thighs. Bilateral work. 3. Side-Step: Bipedestation with Knees and hips bent. The exercise then consists of two steps taken in one direction followed by two steps in the opposite direction to return to the starting position. The elastic band shall be placed above the knees.~4-8 Weeks: 1.Unilateral gluteal bridge. 2 Clam shell: hips bents to 60º. 3. Side-Step: placing the elastic band over the ankles"
45802121|NCT04209569|Behavioral|Nutrition Impact and Positive Practice Circle (NIPP)|GOAL's NIPP approach is a gendered, grass-roots SBC approach, tackling a package of underlying behavioral determinants of malnutrition, irrespective of the particular manifestation. The approach is multi-sectoral in nature. It also has a strong monitoring, evaluation and adaptive learning component by design. The intervention approach (based on GOAL's NIPP approach) involves the creation of community, male and female circles in each community with messaging and activities targeted towards the three groups in varying intensities. While the male and female circles meet 2-3 times per week for a maximum period of 12 weeks while the community circles will meet for approximately three hours at any one time over a period of 2-7 days. (See GOAL NIPP Implementation Guidelines)
45931427|NCT05712317|Behavioral|Moderate-intensity endurance exercise|8-week moderate-intensity endurance exercise 3x per week
45931428|NCT05711498|Other|Transcutaneous spinal direct current stimulation (tsDCS)|tsDCS will be carried out using a direct current stimulator (DC-Stimulator Plus, neuroConn, Ilmenau, Germany), with one electrode placed above the thoracic spinal cord and the other electrode placed on the right shoulder. We will employ rectangular electrodes of 7 x 5 cm size (neuroConn, Ilmenau, Germany) covered by electrode paste (Ten20 Conductive Paste, Weaver and Company, Aurora, USA). Stimulation will consist of the following phases: a fade-in period of 15 seconds, a plateau period of 20 minutes (with stimulation at 2.5mA either anodally or cathodally) and a fade-out period of 15 seconds. Sham stimulation will follow the anodal montage with 15-second fade-in and fade-out periods, but only 45 seconds of plateau stimulation at 2.5 mA. Such a combination of stimulation and electrodes results in a current density of 0.071mA/cm2, well below thermal and histological limits for current density.
45931429|NCT05702463|Drug|Aspirin 81Mg Ec Tab twice daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take EC ASA 81 mg twice daily for 7 days.
45931430|NCT05702463|Drug|Aspirin 40Mg Chew Tab twice daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take chewable ASA 40 mg twice daily for 7 days.
45931431|NCT05702463|Drug|Aspirin 162 mg EC Tab once daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take EC ASA 162 mg once daily for 7 days.
45931432|NCT05696795|Drug|Abrocitinib 200 mg|Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of sarcoidosis.
45931433|NCT05690074|Device|Spectra Wave Writer™ Spinal Cord Stimulator System|Device: 5-6-5 Specify electrode Device: Restore Advance Pulse Generator
45931434|NCT05689359|Drug|Hydroxychloroquine|Hydroxychloroquine will be administered at 600 mg po BID for 3 days prior to starting chemotherapy, continued during the course of chemotherapy, and for 7 days after chemotherapy.
45931435|NCT05680584|Drug|Melatonin 3 MG|0.1 mg/ kg melatonin in 10 ml apple juice 1 hour before induction of anesthesia
45931436|NCT05680584|Drug|Hydroxyzine Pill|1 mg/ kg hydroxyzine in 10 ml apple juice 1 hour before induction of anesthesia
45931437|NCT05680584|Other|Placebo|10 ml apple juice 1 hour before induction of anesthesia
45931438|NCT05676710|Drug|Linperlisib|"Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation."
45451438|NCT03662542|Drug|Golimumab Dose 1|Golimumab Dose 1 will be administered as SC injection.
45451439|NCT03662542|Drug|Golimumab Dose 2|Golimumab Dose 2 will be administered as SC injection.
45451440|NCT03662542|Drug|Placebo|Placebo will be administered.
45652005|NCT05328063|Other|Intervention group|"All subjects will receive a specific program of manual therapy on the hip joint. 10 sessions of manual therapy will be applied during 8 weeks, 1 session per week, except the first week when two sessions will be applied.~The protocol consists of passive manual joint therapy at low speed on the hip, applying each mobilization in 3 series of 10 repetitions. It also includes muscle stretching, performing 3 series and holding the stretch for 25 seconds.~Manual therapy includes: 1. Anteroposterior (AP) and posteroanterior (PA) displacement of the hip. 2. Lateromedial and mediolateral displacement of the hip. 3. Distraction of the long axis/traction of the hip. 4. Lower slip in internal rotation (IR) and external rotation (ER) of the hip. 5. Iliopsoas stretch. 6. Piriformis stretch.To perform the protocol, the patient shall be placed in the supine decubitus position.~In addition to the same gluteus maximus strengthening programme used for the control group."
45802122|NCT04197635|Diagnostic Test|Maximal functional capacity by cardiopulmonary exercise testing|It will be done with cycle ergometer (CORTEX Metamax3B), starting with 10W of power and increasing 10W every minute. During the test, heart rate, rhythm and blood pressure will be monitored. Gas exchange data shall be evaluated every 10 seconds and the peak oxygen consumption (peak VO2) shall be considered the maximum value obtained during the last 20 seconds of exercise. The main parameters to be determined are: maximum functional capacity, peak VO2, slope of the VE/VCO2 ratio, and chronotropic incompetence variables. It will be performed by a trained cardiologist blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
45653286|NCT03066115|Drug|Ascorbic Acid|See arm description.
45802123|NCT04197635|Diagnostic Test|Echocardiography|The following parameters will be evaluated: a)left ventricular volumes; b) left ventricular systolic function; and c)left atrial volume and E/e' ratio. It will be performed by a trained cardiologist blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
45802124|NCT04197635|Behavioral|Evaluation of health related quality of life|Assessment of the quality of life through the Minnesota Living with Heart Failure Questionnaire (MLHFQ), Spanish version. It will be completed at baseline and at 30 and 90 days after treatment initiation. The score of the questionnaire is 0 to 105 points.
45802125|NCT04197635|Diagnostic Test|Submáximal functional capacity assesment by 6 minutes walk test|It will be performed in an area equipped for cardiopulmonary resuscitation. Subjects will be asked not to perform a vigorous physical exercise in the previous 2 hours. They will be allowed to have a light meal before the test. Before the test, the vital signs will be determined in a seated position after a rest of 10 minutes. Subjects will be instructed to walk at their own pace to cover as much distance as possible in 6 minutes. It will be performed by a trained nurse blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
45802126|NCT04197635|Other|Clinical evaluation|Evaluation of signs and symptoms of heart failure
45802127|NCT01992523|Drug|Ticagrelor mashed pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.
45802128|NCT01992523|Drug|Ticagrelor integral pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).
45802129|NCT04188665|Drug|MASL|Patients treated with MASL lozenge
45802130|NCT04188665|Other|Placebo|Patients treated with placebo lozenge
45802131|NCT04186247|Drug|Azithromycin|Weeks 4-12: 7.5 mg/kg azithromycin once daily (500 mg/day maximum) for five consecutive days/ week for 4 weeks, and 3 times a week for the following 4 weeks
45802132|NCT04186247|Drug|Metronidazole|Weeks 4-12: 20 mg/kg/day of metronidazole (10 mg/kg twice daily to a maximum of 1000 mg/day) for 8 weeks
45802133|NCT04186247|Other|Standard of Care|SOC induction therapy is nutritional therapy (Crohn's disease exclusion diet + partial enteral nutrition) for up to 12 weeks. Induction therapy is as assigned by the treating gastroenterologist prior to study entry.
45802134|NCT02164019|Procedure|long-stem cemented hemiarthroplasty (LSCH)|
45802135|NCT02164019|Procedure|intramedullary nailing (IMN)|
45802136|NCT02164019|Behavioral|questionnaires|
45802137|NCT04181255|Drug|Curosurf|This arm will consist of a single dose of Curosurf (200 mg/kg) that will be given in the Pediatric Cardiothoracic Unit (PCTU) after surgery once the subject has reached a normalized body temperature.
45802138|NCT04181255|Drug|Sham|This arm will consist of a single dose of sham (air) that will be given through the endotracheal tube in the Pediatric Cardiothoracic Intensive Care Unit after surgery once the subject has reached a normalized body temperature.
45802139|NCT04258813|Behavioral|iGuide Intervention (Self-guided)|The iGuide Intervention consists of two patient-level and four PCP-level components. These components include: (1) the patient-level brief video vignettes with a written summary; and (2) patient-facing webinars. The investigators will not use any institutional branding in the videos, printed materials, or recorded webinars so that these deliverables can be used in other settings.
45931439|NCT05676697|Drug|Linperlisib|The phosphatidylinositol 3-kinase delta (PI3Kδ) signaling pathway plays a critical role in the activation, proliferation, and tissue homing of self-reactive B cells that contribute to autoimmune diseases. B cells play an essential role in immune system function and dysfunction (e.g., autoimmunity) by producing antibodies and by acting as antigen-presenting cells (APCs) for T cells. Signaling via PI3K controls many essential B cell functions and is therefore a promising target for preventing aberrant B cell activation.
46073136|NCT01615874|Drug|Montelukast tablets 5 mg (4 mg for children 5 years of age)|"Montelukast chewable tablets 5 mg once daily (QD) for children 6-11 years of age~OR~Montelukast chewable tablets 4 mg QD for children 5 years of age"
45451441|NCT05615506|Procedure|Suction Diathermy Adenoidectomy|suction diathermy adenoidectomy
45802140|NCT04258813|Behavioral|iGuide 2 Intervention (Tailored/Targeted)|"The iGuide2 patient-level intervention will use a stage-based, tailored approach to four monthly 5-minute video vignettes that incorporates a pre-video worksheet. The investigators will send the worksheets and video vignettes in the method preferred by the patient.~The targeted iGuide 2 PCP-level intervention will include a cancer specialist-facing dashboard that includes the specialists's patients who are enrolled in the study and are in the intervention arm. The HEDIS quality measures for our three CVD comorbidities will be used. The dashboard will be populated with data available in Epic for the specific patient. If some information is missing (i.e., there is no lipid profile in the laboratory tab), the dashboard will query the PCP via an e-consult, asking to supply the information. Bimonthly, starting with the second randomization, an asynchronous specialist-to-PCP e-consult will be sent to PCPs whose patient(s) do not meet all three of the HEDIS quality metrics."
45931440|NCT05673824|Drug|Huaier Granule|"Treatment period: oral administration, 10g each time, 3 times a day. Continuous medication until the end of the study, failure of treatment, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.~If the treatment of hepatobiliary malignancies needs to be changed due to disease progression, whether to continue the medication or not should be determined by the researcher."
45931441|NCT05673824|Drug|VEGFR-TKIs|Treatment period: Therapeutic agents were selected according to clinical routine, including but not limited to Sorafenib, Lenvatinib, Donafenib, Regorafenib, Apatinib and Cabozantinib. Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
45931442|NCT05663918|Behavioral|Self- determined Intensity Interval Training|Individuals will participate in 3 sessions of Self Determined Intensity Interval training, using a cycle ergometer, for 4 weeks.Ratings of Perceived exertion (RPE) will be measured using a Borg's 6-20 scale. (44). Users will be asked to exercise on a stationary bike at an intensity whereby there RPE is challenging. The cycling protocol includes five, 1-minute cycling intervals, interspersed with 1.5 minutes of recovery (cycling at a slow pace to bring the individuals heart rate down). Participants will also perform a 3-minute warm-up and a 2-minute cool-down for a total exercise duration of 17.5 minutes
46073137|NCT01615874|Drug|Rescue medication: short-acting beta-2 agonist (SABA) MDI|albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed
46073138|NCT01615874|Drug|Rescue medication: Prednisone/Prednisolone|Prednisone/Prednisolone for rescue medication, taken as directed
46073139|NCT00891462|Drug|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 12 weeks of treatment
45802141|NCT04258813|Behavioral|Control|Participants randomized to the control group (n=400) will receive current guideline-concordant cancer care. The investigators will also provide information for healthy living during and after cancer and for preparing for transition from cancer therapy to follow-up care. Monthly, patient education material on healthy living will be sent to the participants via the patient portal or by mail, based on participant preference. At the completion of therapy, they will be provided the NCI Facing Forward:Life After Cancer booklet. Note, this approach is not fully equivalent to an attention control as there will be touch points in the iGuide and iGuide2 interventions that the investigators cannot match for the control group. Also, the research team will not engage the PCPs in clinics randomized to the control group.
45931443|NCT05661435|Device|RESP Biosensor|The RESP Biosensor will be placed on the patient for periodic recording of auscultory sound.
46073140|NCT00891462|Drug|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 12 weeks of treatment
45652006|NCT05257707|Diagnostic Test|Molecular biology|"Samples will be taken as part of routine care consultations. These include~Smears taken with cytobrushes adapted to the anatomical site (cervix, vulva, vagina, penis, anus, upper aerodigestive tract...).~Blood samples taken to isolate plasma, cells or serum.~CSF and effusion samples taken with a suitable puncture needle (lumbar puncture, ascites puncture, pleural puncture, etc.).~Urine samples collected in sterile ECBU jars.~Biopsies taken according to the recommendations of good clinical practice using specific forceps adapted to the anatomical site.~Surgical parts.~Eyebrows.~Saliva samples or gargle samples."
46073141|NCT00891462|Drug|Placebo|Dose-matched placebo, oral inhalation twice per day for 12 weeks of treatment
46073142|NCT02834910|Other|collection of bacterial sample|
46073143|NCT04248348|Drug|Low Molecular Weight Heparin|Cancer patients will be protected against thrombosis using Low Molecular Weight Heparin (LMWH)
46073144|NCT02830854|Other|Molecular Hydrogen|
46073145|NCT02832024|Device|plaque excision system|
46073146|NCT02832024|Device|stent|
45652007|NCT05294835|Drug|Ketamine|ketamine infusion
46073147|NCT02832024|Device|Balloon|
46073148|NCT04247022|Other|Health care product (intimate gel)|heath care product (intimate gel) for home use, under real conditions of use, for 28 ± 2 days
45451442|NCT01329562|Drug|Treximet|Tablet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg.
45451443|NCT01329562|Drug|Placebo|A placebo tablet matching Treximet for oral administration.
45451444|NCT00069641|Biological|Iduronate-2-sulfatase enzyme replacement therapy|Patients will receive weekly infusions of idursulfase at a dose of 0.5 mg/kg.
45802142|NCT04101149|Other|No intervention|No intervention.
46073149|NCT04245774|Drug|Levobupivacaine (as Levobupivacaine Hydrochloride) 75 Mg/10 mL Solution for Injection Ampoule|7,5 mg (1.5 mL) of 0,5% hyperbaric levobupivacaine (1 mL 0.75% isobaric levobupivacaine (Chirocaine® 75 mg/10mL ampoule Abbott/Turkey, Nycomed Pharma/Norway) plus 0.24 mL 50% Dextrose (dextrose 120 mg) (Eczacıbaşı/Turkey) and 0.26 mL distilled water) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after intrathecal injection and than layed in supine position, finally they positioned in prone jack-knife.
45931444|NCT05661422|Device|RESP™ Biosensor|The RESP Biosensor will be placed on the patient for periodic recording of auscultory sound.
46073150|NCT04245774|Drug|Bupivacaine/Dextrose|7,5 mg (1.5 mL) of 0,5% hyperbaric bupivacaine (dextrose content 80 mg/mL) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after intrathecal injection and than layed in supine position, finally they positioned in prone jack-knife.
46073151|NCT04245696|Device|Dermal Handpiece / SubQ Handpiece|Bipolar radiofrequency (RF) travels from the RF generator, through the electrodes and into the dermal layers beneath the surface of the skin. The microneedles of the Dermal and SubQ cartridges coupled with thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.
45652008|NCT04422405|Procedure|One Anastomosis Gastric Bypass (OAGB)|"The procedure is performed laparoscopically. The GIA stapler divides the stomach at the junction of the body and antrum. An Ewald tube, roughly the diameter of the esophagus, is passed by the anesthetist and held against the lesser curvature. The division of the stomach against the tube is completed, with 5- 6 lines of staples. The division of the stomach is parallel to the lesser curvature and up to the angle of His. A point is selected on the small bowel about 200 cm distal to the ligament of Treitz. The jejunal loop is brought up antecolic, and the Endo-GIA stapler is used to perform the anastomosis between the stomach and the small bowel at this point. The distal end of the gastric tube is anastomosed to the side of the small bowel."
45652009|NCT02522481|Drug|Lumason|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
45652010|NCT02522403|Procedure|Rehabilitation|The investigators will be apply fake laser therapy in the patients with distal radius fracture, with the device in an off position; plus the patients will be teaching to do rehabilitation exercise in flexion, extension, pronation and supination of the wrist and forearm, and to do cubital and radial deviation exercise. The investigators delivered to all patients a graphic demonstration of the exercise
45652011|NCT02522403|Device|Low Lever Laser acupuncture|The investigators will be used a low lever laser device, to apply in ten selected acupuncture points, each point will be irradiated for 30 seconds at 8000 Hz, this therapy is useful for tissue regeneration and stimulate the acupuncture points, plus an antinociceptive effect.
45652012|NCT04243785|Drug|BTX-A51|Orally administered capsules available in strengths of 0.5 mg, 1.0 mg, and 2.0 mg.
45652013|NCT05326581|Device|mri|The people included will carry out an MRI comprising the sequence currently used in routine care and the different variants of the sequence being tested, for the optimization of the parameters. The duration of the examination (or the extension of the examination planned as part of patient care) will be from a few minutes to an hour depending on the sequences to be optimized. Subjects who agree to research for more than 30 minutes in the MRI machine will be compensated with a multi-brand gift voucher worth 30 euros.
45652014|NCT02522325|Drug|Phendimetrazine|Phendimetrazine will be administered in divided doses twice daily.
45652015|NCT02522325|Drug|Cocaine|Intranasal cocaine will be administered during experimental sessions.
45652016|NCT02522325|Drug|Placebo|Placebo capsules will contain only cornstarch.
45652017|NCT05326347|Drug|OPC-34712FUM/ Brexpiprazole fumarate|The treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation.
45652018|NCT04243551|Drug|Latiglutenase|Administered orally (daily)
45652019|NCT04243551|Other|Placebo|Administered orally (daily)
45652020|NCT04243395|Other|Pork|1 oz lean pork
45652021|NCT04243395|Other|Egg|1 large whole egg
45652022|NCT04243395|Other|Black beans|0.5 cups cooked black beans
45652023|NCT04243395|Other|Almonds|0.5 oz almonds
45652024|NCT01672879|Biological|Placebo|Placebo to match SIM intravenous infusion over 30 minutes every 2 weeks
45802143|NCT04057391|Diagnostic Test|QT Scanner|Diagnostic test that is repeatable, non-invasive imaging tool for the early and accurate detection of breast cancer, breast abnormalities, and musculoskeletal findings. Comparing with mammography, the QT Scanner uses harmless soundwaves to screen and diagnose the breast.
45802144|NCT00373373|Drug|Sorafenib|2 x 400 mg/d
45802145|NCT00373373|Drug|Placebo|Chemotherapy + Placebo
45802146|NCT00373451|Drug|Abciximab + UFH|Abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125 µg/kg/minute [maximum of 10 µg/minute] infusion for 12 hours)
45652025|NCT01672879|Biological|SIM|Intravenous infusion over 30 minutes every 2 weeks
45931445|NCT05655611|Other|first rib mobilization|To perform the first rib mobilization, the patient remained lying supine with the head in the examiner's right hand. Examiner then palpated the left first rib and passively side-bended the patient's head to the left to relieve any muscular tension on the first rib. Patient was then asked to take a deep breath in and out. During exhalation, the examiner applied pressure to depress the first rib, holding it in place at the end of the exhalation. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depressed the first rib as able during exhalation. This process was repeated three times in two sets, for a total of six first rib depression mobilizations.
45931446|NCT05655611|Other|muscle energy technique|Muscle energy technique for glenohumeral joint restricted abduction-The therapist stood in front of the patient, then placed one hand over the top of the subject's involved shoulder. The therapist cups the glenohumeral joint to palpate for motion and the subjects are directed to press the elbow towards their body. Muscle energy technique was applied for five repetitions per set, five sets per session, one session per day, three days a week for three weeks with each repetition maintained for the duration of 7-1 seconds.
45931447|NCT05650736|Drug|Abrocitinib 200 mg|Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of GA.
45931448|NCT05646992|Procedure|Uterine Allotransplantation|Temporary allogenic uterus transplantation from a living donor with the goal of achieving pregnancy and delivering viable baby.
46073152|NCT02832102|Procedure|Standard treatment of SCCHN patients|The interventions may include surgery, radiotherapy, chemotherapy or combined therapies, as recommended by best practice and international guidelines.
46073153|NCT02832180|Drug|OC containing EE and NET|
46073154|NCT02832180|Drug|BMS-986142|
46073155|NCT04247646|Dietary Supplement|Melatonin|Participants will take sublingual melatonin (or placebo) nightly for 29 doses after undergoing total knee replacement surgery.
46073156|NCT04247646|Dietary Supplement|Placebo|Participants will take sublingual melatonin (or placebo) nightly for 29 doses after undergoing total knee replacement surgery.
46073157|NCT02831868|Device|HAVAI|implantation of the HAVAI device to correct the IMA angle
46073158|NCT02831946|Device|MODIFIED VICRYL PLUS|closing the intra-cuticular layer with MODIFIED VICRYL PLUS suture
46073159|NCT02831946|Device|DERMABOND GLUE|closing the intra-cuticular layer with Dermabond glue
46073160|NCT00900146|Drug|Canakinumab|Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
46073161|NCT00900146|Drug|Metformin|Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.
46073162|NCT00900146|Drug|Placebo|Placebo lyophilized cake will be reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
45652026|NCT02601209|Drug|Pazopanib|Given PO
45652027|NCT02601209|Drug|Pazopanib Hydrochloride|Given PO
45652028|NCT02601209|Drug|Sapanisertib|Given PO
45652029|NCT05012839|Other|impact of COVID-19 on Health-Seeking Behaviors|The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Taiwan's government rapidly established diverse public actions, which helped maintain the medical supply without travel restrictions. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether acute complicated appendicitis (ACA) rates in adults were affected by the COVID-19 pandemic.
45652030|NCT01659021|Drug|Idelalisib|150 mg tablets administered orally twice daily
45802147|NCT00373451|Drug|Bivalirudin|Bivalirudin (intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure)
46073163|NCT04247724|Behavioral|Recreational handball|
46073164|NCT04247724|Behavioral|Control|
46073165|NCT02828748|Other|no intervention in patients treatment, only biopsy taken|
45802148|NCT00373451|Drug|Heparin|i.v. bolus of 70 units/kg/body weight of unfractionated heparin
45802149|NCT01387763|Drug|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
45652031|NCT01659021|Drug|Ofatumumab|Administered intravenously
45652032|NCT05012449|Procedure|Arthrography-assisted joystick technology.|Arthrography-assisted joystick technology.
45652033|NCT05012215|Procedure|Paravertebral|Ultrasound-guided paravertebral block
45802150|NCT01387763|Drug|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
45802151|NCT01387763|Drug|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
45802152|NCT01387763|Drug|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
45802153|NCT01387763|Drug|Hydrea|Capsule Hydrea 500-2000 mg orally QD or BID
45802154|NCT01719497|Drug|[C-11]OMAR|PET radioligand
45802155|NCT02514187|Drug|Cyclotron-produced 99mTc|"Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events."
45802156|NCT02514187|Drug|Generator-produced 99mTc|"Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events."
46073166|NCT02831790|Other|Fontan Education Videos|"The intervention will consist of three brief (~5 minute) professionally-developed whiteboard videos, available online. The videos will feature lay language at a grade 7 level or below and will be engaging. Topics are based on key findings of the Family Resilience Study, namely:~Stress reactions in children and parents post Fontan. This video will be supplemented with existing resources on the topic.~Anticoagulation~Prolonged pleural drainage"
46073167|NCT02828670|Biological|blood sample|
45652034|NCT05012215|Procedure|Caudal block|Caudal block
45652035|NCT05012137|Procedure|Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB) with 0.5% ropivacaine|all the patients received Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB)
46073168|NCT02828670|Procedure|spleen sample|
45931449|NCT05646992|Drug|Tacrolimus|Used as daily immunosuppression. Started at 3mg twice daily (PO) on post-operative Day 1, adjusted to achieve serum trough concentrations of 8-10ng/ml.
45931450|NCT05646992|Drug|Azathioprine|Used as daily immunosuppression posttransplant. Started on post-operative Day 1. Dose: PO 100mg/day for total body weight (TBW) <75kg, 150mg/day for TBW ≥75kg
45931451|NCT05643001|Other|In-patient and out-patient electronic health record alert|Electronic health record best practice alert which suggests measurement of LDL and HbA1c (in-patient) and referrals to sleep study and audiology (out-patient)
45931452|NCT05637606|Drug|Ephedrine|In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg). The maximal dose for the ephedrine allowed is 25 mg (10 boluses of 2.5 mg), after this threshold a continuous infusion of norepinephrine will be started
46073169|NCT03621644|Radiation|Stereotactic MRI-guided On-table Adaptive Radiation Therapy|Radiation therapy will be delivered with an integrated magnetic resonance imaging (MRI)-guided radiotherapy delivery system (ViewRay MRIdian or MRIdian Linac). The prescribed dose will be 50 Gray (Gy) in 5 fractions. Stereotactic body radiotherapy (SBRT) fractions will be delivered at least twice per week, and with at least 18 hours between fractions. Each participant will be aligned in the treatment system with MRI image-guidance. On-table adaptive re-planning will be used when clinically indicated. In all patients, real-time MRI imaging will be used throughout treatment delivery to monitor the target location and control the radiation beam as necessary.
46073170|NCT04245462|Other|No intervention|Cross-sectional
46073171|NCT00140972|Drug|MK0663; etoricoxib / Duration of Treatment:4 Weeks|
46073172|NCT00140972|Drug|Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks|
46073173|NCT02828826|Other|telephone coaching|
46073174|NCT03617198|Biological|CD4 CAR+CCR5 ZFN T-cells|A dual cohort, open-label, randomized study of the safety and tolerability of a single infusion of autologous T cells genetically modified to express a CD4 chimeric antigen receptor while also having zinc finger nuclease-mediated disruption of the CCR5 gene
46073175|NCT02830932|Biological|VXA-RSV-f Tablets (high dose)|The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the high dose.
46073176|NCT02830932|Other|VXA Placebo Tablets|The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
46073177|NCT02830932|Biological|VXA-RSV-f Tablets (low dose)|The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the low dose
45652036|NCT05012137|Drug|different volume of 0.5% ropivacaine|According to the subject's response to the injection dose, the next subject will be injected with a different volume of the drug according to the preset rules
46073178|NCT00895310|Drug|Ketoconazole|Ketoconazole is taken three times a day by mouth.
45652037|NCT05291559|Dietary Supplement|Enterade|Enterade is a glucose-free, amino acid-based medical food containing specific amino acids (aspartic acid, valine, serine, threonine and tyrosine) in addition to electrolytes and a non-sugar sweetener.
45652038|NCT05291559|Dietary Supplement|Placebo|The placebo is an identical product to Enterade except without added amino acids.
45652039|NCT04999345|Other|Rehabilitation|Progressive resistance exercise and graded aerobic exercise will be provided for those in the experimental group.
45652040|NCT04999345|Other|Health education|Health education and gross joint range of motion exercise for bilateral upper and lower extremities will be provided for those in the control group.
45802157|NCT02503423|Drug|ASTX660|described above
46073179|NCT00895310|Drug|Hydrocortisone|Hydrocortisone is taken by mouth 20 mg every morning and 10 mg every evening.
46073180|NCT02830386|Device|LVIS stent|Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
46073181|NCT02840864|Device|Sonography assisted breast surgery|
46073182|NCT04245618|Drug|neoadjuvant chemotherapy ( cisplatin - gemcitabine)|Neoadjuvant chemotherapy before TURBT
46073183|NCT00092768|Drug|MK0663, etoricoxib|
46073184|NCT00092768|Drug|Comparator: celecoxib|
46073185|NCT02831712|Dietary Supplement|Ferrous Fumarate|One tablet of a commercial iron supplement (Ferrous Fumarate 200 mg, from Drug House of Australia) will be provided to participants after overnight fast. The intervention is only one time.
45802158|NCT00373061|Drug|Xolair®|This being an observational study, the study protocol does not specify any dose regimen.
45802159|NCT03936257|Other|Breastfeeding|Infants were breastfed during 3 months minimum. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
45802160|NCT03936257|Other|Conventional BIO Infant formula|Infant were fed during 6 months with a conventional BIO infant formula. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
45931453|NCT05637606|Drug|Norepinephrine|In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg) or Etilefrine (1 mg). The continuous infusion of norepinephrine, as decided by the attending anesthetist, may be started at any point of the intraoperative period. The starting dose of norepinephrine is the lowest needed to reach the predefined MAP target.
45652041|NCT05325645|Drug|OPC-34712FUM/ Brexpiprazole fumarate|2 brexpiprazole QW tablets 24 mg (48 mg/dose) will be orally administered once weekly for 7weeks.(As an initial dose, one brexpiprazole QW tablet 24 mg and one placebo tablet will be orally administered (24 mg/dose))
45802161|NCT03936257|Other|TrueGreen BIO infant formula|Infant were fed during 6 months with the TrueGreen BIO infant formula. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
45802162|NCT02500381|Drug|SRP-4045|SRP-4045 solution for IV infusion
45931454|NCT05637606|Drug|Etilefrine Hydrochloride bolus|The maximal dose for the etilefrine allowed is 10 mg (10 boluses of 1 mg), after this threshold a continuous infusion of norepinephrine will be started
45931455|NCT05637606|Diagnostic Test|Use of pulse pressure and stroke volume variation (PPV and SVV); use of Mini Fluid Challenge (mini_FC)|PPV, SVV and mini_FC will guide fluid bolus administration during an episode of intraoperative hypotension, following two predefined algorithms for laparotomic/non laparotomic surgery
45931456|NCT05630924|Other|SI! Program-NYC|SI! Program-NYC incorporates a comprehensive and integrated vision of CV health promotion that encompasses four (4) basic and interrelated components: body and heart, physical activity healthy diet; and emotional management.
45451445|NCT00069641|Biological|iduronate-2-sulfatase enzyme replacement therapy|Patients will receive every other week infusions of idursulfase at a dose of 0.5 mg/kg.
46073186|NCT00895154|Behavioral|General Tutoring|Participants will be tutored for approximately 8-10 hours per month during the school year.
45652042|NCT05325645|Drug|Placebo|Two placebo tablets will be orally administered once weekly for 7weeks.
45652043|NCT03075319|Procedure|Received perioperative photograph|"All participants in experimental group were adviced to see periopertive knee photograph before rehabilitation everyday.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups."
45802163|NCT02500381|Drug|SRP-4053|SRP-4053 solution for IV infusion
45802164|NCT02500381|Drug|Placebo|SRP-4045 or SRP-4053 placebo-matching solution for IV infusion
45802165|NCT03871907|Behavioral|Digital technology|Lifestyle-Focused Text Messaging
45931457|NCT05630469|Other|Electroconvulsive therapy|repetitive induction of a generalized seizure under controlled conditions (muscle relaxation and sedation)
45931458|NCT05621083|Dietary Supplement|Omega- 3|In each visit, the investigators will perform a postprandial meal test (set breakfast: Butter (61 g) with jam and three slices of white bread) In the fish oil supplement period, the participants will receive concentrated fish oil which is equal to in total 2.3 g EPA+DHA per day during 6 weeks.
45931459|NCT05621083|Dietary Supplement|HOSO|In each visit, the investigators will perform a postprandial meal test (set breakfast: Butter (61 g) with jam and three slices of white bread) In the HOSO period, the participants will receive similar amount of HOSO per day during 6 weeks.
45931460|NCT05610722|Device|DreaMed Endo Digital|The DreaMed Endo.Digital uses information gathered from glucose monitoring (sensor readings or capillary blood glucose measurements), insulin dosing and meal data during daily routine home care. Following a 5-minute data collection and analysis, the algorithm learns and suggests insulin dose adjustments and behavioral tips for optimization of glucose control. The algorithm is designed as an advisory tool for health care professionals.
46073187|NCT00895154|Behavioral|Memory Training|Participants will receive memory training for approximately 8-10 hours per month during the school year.
46073188|NCT01769924|Other|Nephrectomy|Nephrectomy for the purposes of living kidney donation
45802166|NCT03865979|Device|Viz RECRUIT|Viz RECRUIT includes the following modules: Viz ICH, Viz VOLUME, Viz VIEW and Viz HUB
45451446|NCT00069641|Biological|Placebo|Patients will receive weekly infusions of placebo.
45451447|NCT02230228|Drug|ALK-001 (No generic name)|Daily, oral administration of ALK-001 capsules.
45451448|NCT01090661|Drug|mipomersen sodium|200 mg of mipomersen intravenous (IV) (single dose)
45451449|NCT01090661|Drug|mipomersen sodium|200 mg of mipomersen subcutaneous (SC) (single dose)
45451450|NCT01090661|Drug|moxifloxacin hydrochloride (Avelox®)|400 mg of moxifloxacin intravenous (IV) single dose
45802167|NCT00707213|Drug|[18F]fluoro-2-deoxy-D-glucose (FDG)|FDG-PET/CT scan-The scans that will be done with a radioactive sugar ([18F]fluoro-2-deoxy-D-glucose) and positron emission tomography (FDG-PET/CT). These scans will help to identify areas of possible infection.
45802168|NCT01993849|Drug|N-Acetylcysteine (NAC)|This is the medication N-acetylcysteine (NAC)
45802169|NCT01993849|Other|Placebo|Placebo, designed to match in appearance to NAC
45802170|NCT02308189|Behavioral|Exercise with blood flow restriction|Low load resistance exercise performed with an external pressure cuff applied over both legs or both arms during respective leg and arm exercises.
45802171|NCT02308189|Behavioral|Exercise|Low load resistance exercise performed with no external pressure cuff applied to the appendicular limbs.
46073189|NCT02843984|Drug|Lactoferrin|
46073190|NCT04281498|Drug|Ruxolitinib|Patients who are on ruxolitinib will continue their current dose. Patients who are not on ruxolitinib will receive ruxolitinib dosing based on platelet count
45451451|NCT01090661|Drug|placebo|placebo intravenous (IV) single dose
45451452|NCT01090661|Drug|placebo|placebo subcutaneous (SC) single dose
46073191|NCT04281498|Drug|Enasidenib|50mg -100mg daily
46073192|NCT02840552|Drug|18F-Fluoromethylcholine (18F-FCH)|FCH PET/CT
46073193|NCT02828280|Device|NuMask|The NuMask is a relatively new mask ventilation device that has been registered with the FDA and used in the United States since 2006.
45931461|NCT05602012|Behavioral|Mindfulness based cognitive counseling group|Intervention: The sessions were conducted by the researchers who received training in the field of Mindfulness Based Cognitive Therapy. Sessions are structured as follows; 'Awareness and autopilot, living in our minds, tidying up the dispersed mind, recognizing the unpleasant/version, allowing, ways to take care of oneself, turning to face difficulties, being stuck in the past, living in the present?'
45802172|NCT04231591|Diagnostic Test|NT-proBNP|Collect serum NT-proBNP levels in singleton ACHD patients and a comparative normotensive control group at time of admission for delivery to characterize negative predictive values for intrapartum and postpartum cardiac events.
45931462|NCT05600556|Procedure|Magnetic Resonance Imaging|Undergo MRI
45931463|NCT05600556|Procedure|Computed Tomography|Undergo CT
45931464|NCT05600556|Other|Best Practice|Review imaging on standard computer screen
45931465|NCT05600556|Other|Questionnaire Administration|Complete questionnaire
45931466|NCT05600556|Procedure|Magnetic Resonance Imaging|Undergo MRI
45931467|NCT05600556|Procedure|Computed Tomography|Undergo CT
45931468|NCT05600556|Other|Virtual Technology Intervention|Review virtual reality images
45652044|NCT03075319|Procedure|Didn't receive perioperative photograph|"All participants in active comparator group didn't receive perioperative knee photograph.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups."
45652045|NCT05325333|Behavioral|Retrieval-based word learning|"Learning sessions: Words/meanings are practiced on Day 1. The timing of retrieval trials differs for the two conditions. For the expanding spaced retrieval condition, retrieval trials occur immediately after hearing the target, after 1 intervening word and after 3 intervening words. For the standard spaced retrieval condition, retrieval trials occur immediately after hearing the target and after 3 intervening words. This practice schedule is repeated the next day (Day 2).~Testing sessions: 5 minutes after the learning session on Day 2, the child is asked to recall each word/meaning twice. One week after the first learning session, this recall test is completed again. After the one-week recall test, the child will complete a recognition task: viewing sets of 4 images from the experiment, the child will hear each novel word in turn and be asked to point to its referent."
45931469|NCT05600556|Other|Questionnaire Administration|Complete questionnaire
45931470|NCT05591599|Diagnostic Test|calponin 2|serum calponin 2 level
45931471|NCT05585619|Other|Pain treatment|Any pain treatment to include medications, procedures, or referrals
45931472|NCT05574153|Diagnostic Test|Cardiac MRI|Participants will undergo an oxygenation-sensitive cardiac MRI and, during the scan, perform a vasoactive breathing maneuver composed of a period of paced hyperventilation followed by a voluntary maximal breath hold.
45931473|NCT05574140|Diagnostic Test|Cardiac MRI|The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths per minute) followed by a maximal breath-hold. This technique is used in Oxygenation Sensitive CMR, a type of MRI, and will induce a vasoactive response visible in cardiac and cerebral MRI images
45931474|NCT05566938|Other|Tailored nutritional recommendations for each metabotype|Tailored nutritional recommendations for each metabotype detected (at the group level), that will be delivered through a mobile application. Moreover, each volunteer will recieve individualized nutritional recommendations.
45451453|NCT02230462|Other|Viewing of cancer excision defect|Patients will be invited to view their cancer excision defect, with the aid of a mirror, prior to its reconstruction.
45451454|NCT01086449|Biological|Herpes Zoster Vaccine GSK 1437173A|Investigational vaccine (GSK 1437173A) administered intramuscularly.
45802173|NCT02778113|Drug|Nasal Glucagon|Administered intranasally.
45931475|NCT05564026|Other|Questionnaire Administration|Questionnaire provide to participant's about their health and quality of life since treatment
45931476|NCT05564026|Other|Tumor Specimen Collection|Tumor DNA requested from the Biopathology Center
46073194|NCT02828280|Device|Traditional mask|A traditional air inflated facemark used to ventilate patients
46073195|NCT02840708|Drug|Sargramostim|
46073196|NCT02840786|Device|plaque excision system|
46073197|NCT02840786|Device|balloon and Stent|
46073198|NCT04245072|Procedure|Intravitreal injection|Intravitreal injection of Aflibercept 2 mg (0.05 ml) or Ranibizumab 0.5 mg (0.05 ml) to the regimen pro re nata.
46073199|NCT04245072|Diagnostic Test|Fluorescent angiography|Ophthalmic examination
46073200|NCT04245072|Diagnostic Test|Visometry|Ophthalmic examination
46073201|NCT04245072|Diagnostic Test|Refractometry|Ophthalmic examination
45652046|NCT04999033|Other|no intervention|This is a cross-sectional study, and no intervention will be included
45652047|NCT04818203|Biological|Clusters of Autologous Dermal Fibroblasts|Dose: 1 x 10^7 cells/1 mL/vial
45652048|NCT04818203|Other|Placebo|The injection solution without clusters of autologous dermal fibroblasts
45802174|NCT02778113|Drug|Glucagon|Administered SC.
45802175|NCT01994785|Diagnostic Test|Capnographic Monitoring|Capnographic Monitoring: Patients will undergo procedures with real-time capnographic monitoring
45802176|NCT04982237|Biological|AK104|IV infusion
45802177|NCT04982237|Drug|paclitaxel|IV infusion
45802178|NCT04982237|Drug|carboplatin|iv infusion
46073202|NCT04245072|Diagnostic Test|Slit lamp examination|Ophthalmic examination
46073203|NCT04245072|Diagnostic Test|Ophthalmoscopy|Ophthalmic examination
45802179|NCT04982237|Drug|cisplatin|iv infusion
45802180|NCT04982237|Drug|bevacizumab|iv infusion
45802181|NCT04982237|Drug|Placebo|iv infusion
45802182|NCT02780765|Device|heated humidifier|30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using Heated Humidifier(HH)
45802183|NCT02780765|Device|mist humidifier|30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using mist humidifier
45931477|NCT05564026|Other|Germline DNA Samples|Germline DNA specimens requested from the Biopathology Center or newly collected saliva
45931478|NCT05564026|Procedure|Blood Sample Collection|Collection and storing of serum/plasma
45931479|NCT05561075|Dietary Supplement|Pterostilbene cocrystal|One capsule with Pterostilbene cocrystal
45451455|NCT05585476|Device|C02 microablative laser|The C02 microablative laser was the first to be used in the treatment of menopausal genitourinary syndrome. Its mechanism of action is based on the emission of light at a wavelength of 10600nm that is absorbed by the water molecules contained in the vaginal mucosa, leading to local remodeling of connective tissue and neoformation of collagen, elastic fibers and other components of the extracellular matrix.
45451456|NCT05585476|Combination Product|Regenerative topical treatment|It is a moisturizing and regenerating gel whose active ingredients are olive oil, trimethylglycine and xylitol.
45451457|NCT05563480|Drug|TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection|TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
45931480|NCT05561075|Dietary Supplement|Pterostilbene free form|One capsule with Pterostilbene free form
45931481|NCT05559346|Other|Diaphragmatic exercises|Diaphragm exercises will be applied to the research group in addition to conventional rehabilitation.The content of the individualized conventional rehabilitation program consists of passive stretching exercises, strengthening exercises to antagonists of spastic muscles and exercises aimed at improving weight transfer, balance and correction reactions, and postural control. In addition to conventional rehabilitation, manual diaphragmatic relaxation exercises and diaphragmatic breathing exercises will be applied to the children in the research group two days a week.
46073204|NCT04245072|Diagnostic Test|OKT|Ophthalmic examination
45451458|NCT05563480|Drug|Penpulimab injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection|Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
45652049|NCT05252793|Behavioral|Education based on the health belief model|After the intervention, it is expected that the scores of the patients on the healthy lifestyle behaviors scale will increase.
45652050|NCT04827797|Device|balls|Birth balls to exercise
45802184|NCT01995487|Device|BioNIR|drug-eluting stent
45931482|NCT05559346|Other|conventional physiotherapy|The control group will only be taken to the conventional rehabilitation program. e content of the individualized conventional rehabilitation program consists of passive stretching exercises, strengthening exercises to antagonists of spastic muscles and exercises aimed at improving weight transfer, balance and correction reactions, and postural control.
45802185|NCT01995487|Device|Resolute|drug-eluting stent
45802186|NCT02783027|Behavioral|SleepTrackTXT2|Participants that report high levels of fatigue, sleepiness, or difficulty with concentration during shift work (intra-shift) will receive tailored text-messages promoting adoption of behaviors that can improve alertness during shift work. Participants will also receive a summary of their sleep debt once a week and suggestions for paying back sleep debt. Participants will also have access to a graphic summary of their sleep hours over previous 30-days.
45931483|NCT05558358|Device|Experimental 1 - DBS of bilateral NAc - 6 months of active stimulation -- > 6 months of sham stimulation|6 months of active stimulation -- > 6 months of sham stimulation
45931484|NCT05558358|Device|Experimental 2 - DBS of bilateral NAc - 6 months of sham stimulation -- > 6 months of active stimulation|6 months of sham stimulation -- > 6 months of active stimulation
45931485|NCT05557006|Procedure|left bundle branch pacing|In the procedure of left bundle branch pacing, various QRS morphologies are observed as penetrating the lead into the interventricular septum.
45931486|NCT05552027|Device|CCS System- Prototype|Participants will be exposed to each of the 3 scenarios with the sensor system enabled (with feedback)
45931487|NCT05552027|Device|CCS System- Control|The participants will be exposed to each of the 3 scenarios with the system disabled (no feedback).
45451459|NCT05563480|Drug|TQB2618 injection; Penpulimab injection|TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
45451460|NCT05546398|Drug|Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab|No study drug was administered during this study.
45451461|NCT05546398|Other|No study drug|No study drug was administered during this study.
45451462|NCT05509348|Behavioral|Phase 1: ADAPT Workshop|2 day workshop
45931488|NCT05549479|Behavioral|Peer Matching|Participants will be matched with a peer based on evidence informed criteria. Partners will independently communicate and support each other around exercise for the duration of the study.
46073205|NCT04208360|Device|StethoMe stethoscope|Assessing whether use of the StethoMe AI lung sounds analysis software provides clinical benefit by improving the identification of abnormal lung sounds.
46073206|NCT02828202|Other|Biological|DNA from peripheral blood mononuclear cells, RNA, plasma, serum sampled at inclusion, every 6 months and before each new systemic therapy.
46073207|NCT02828202|Other|Tissular|Primary melanoma (mostly paraffin embedded), metastatic sample (s)(paraffin embedded and frozen) from at least 1 site at inclusion and during evolution, particularly before treatment modification if clinically required.
46073208|NCT02828202|Other|Quality of life|Specific questionnaires (FACT-M, EUROQUOL) at inclusion, every 3 months and before each new systemic therapy.
46073209|NCT00817076|Drug|desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
45451463|NCT05509348|Behavioral|Phase 1: ADAPT Online|Online curriculum
45451464|NCT05509348|Behavioral|Phase 2: ADAPT Group|3 in person group sessions
45652051|NCT04999189|Other|Mobile app forDiabetes (Tessera Multimedia, 2020)|Patients will use a mobile app forDiabetes (Tessera Multimedia, 2020) to manage their disease.
45652052|NCT05290779|Procedure|selective lumbar nerve root injection|selective lumbar nerve root steroid injection for treatment of radicular pain.
45652053|NCT05252481|Device|Active tDCS|Eight sessions of transcranial current direct stimulation
45652054|NCT05252481|Device|Sham tDCS|Eight sessions of transcranial current direct stimulation (sham)
45652055|NCT04998955|Behavioral|Maximal strength training|Exercise intervention utilizing 4 x 4 repetitions heavy resistance training
45802187|NCT01996657|Drug|Warfarin|
45802188|NCT02462629|Drug|BLZ-100|
45802189|NCT01996813|Device|Thigh-high compression stockings|The intervention in this study are thigh-high compression stockings manufactured by Covidien.
45802190|NCT02784275|Drug|Cyclo-Z|
45802191|NCT02784275|Drug|Placebo|
45802192|NCT04229563|Device|AURYON™ System|"The AURYON™ System consists of two sub-units: 1) a single use catheter (AURYON™ catheter); and 2) a laser system."
45802193|NCT02784587|Procedure|Stellate Ganglion Block|After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, which typically requires about 3 minutes to perform. The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 (Chassaignac's tubercle) or C7 (3-5 cm above the clavicle). The non-operative hand will retract the muscle together with the carotid sheath prior to needle insertion. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
45652056|NCT04827641|Other|Severity Grading assessment in children with perioperative unexpected events|Systematic documentation of all unexpected events was carried out by designated team members during daily routine team conferences. Briefly, on-call team members and all other staff reported on any unexpected event that had occurred within the previous 24 hours, after weekends during the past 72 hours. Events included those that had occurred in inpatients, outpatients and in the pediatric emergency department. Data concerning each event included patient demographics, diagnoses, treatments/operations and types of events.
45652057|NCT05324631|Drug|SHR0302|SHR0302, oral, once daily
45931489|NCT05549479|Behavioral|Qualified Exercise Professional Support Sessions|Dyads will participate in weekly virtual sessions with a QEP for 10 weeks. Each session will last up to 1 hour. The QEP (i.e., registered kinesiologist) will provide a tailored exercise program, focusing on aerobic activity for both individuals in the dyad based on personal circumstances, cancer-related characteristics, side effects, current fitness level (consistent with home-based exercise strategies), and personal preferences.
45931490|NCT05549206|Biological|SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose|50μg/dose
45652058|NCT05324631|Drug|SHR0302 placebo|SHR0302 placebo, oral, once daily
45802194|NCT01997125|Device|Neural Bridge System|Implanted device
45931491|NCT05549206|Biological|SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high dose|100μg/dose
45931492|NCT05549206|Drug|Placebo|Saline solution
45931493|NCT05547204|Other|Beverage|Free from added carbohydrates (contain 1g CHO only) and electrolytes are absent.
45802195|NCT01997437|Device|Stem-cell seeded bioartificial tracheal scaffold|Seeding the synthetic scaffold with autologous stem cells; scaffold' cultivation within 48-72 hours in bioreactor, injection of growth factors into scaffold in the first and last stages of the cultivation, replacement of the damaged trachea by generated tissue-engineered organ
45931494|NCT05546645|Other|Questionnaire|Hypersecretion questionnaire
45931495|NCT05545566|Procedure|Thoracic ultrasound versus chest X-ray|"Perform un ultrasound test, in addition to Chest X-Ray (usual practice), few hours after the surgery (D0), the next day (D1) and 4 to 6 hours after drain removal.~The data are collected in the standardized protocol for the two type of imaging.~The thoracic ultrasound and the Chest X-Ray are performed, blindly each other, in the same position for the patient and the same suction level of drain."
45931496|NCT05539404|Procedure|Endovascular treatment in addition of best medical treatment.|Endovascular treatment (EVT) of acute ischemic stroke (AIS) related to an anterior large cerebral vessel occlusion (LVO)
46073210|NCT02844062|Biological|anti-EGFRvIII CAR T cells|CAR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）with a total targeted dose.
45652059|NCT05290155|Drug|anti-CD7 CAR-T cells|Administration with anti-CD7 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients
45652060|NCT05011747|Procedure|single-site rigid probe viscotrabeculotomy (VT)|single-site VT by the rigid probe trabeculotome is performed through a superonasal triangular scleral flap.
45652061|NCT05011747|Procedure|two-site rigid probe viscotrabeculotomy (VT)|Two-site VT by the rigid probe trabeculotome is performed through a superonasal and an inferotemporal triangular scleral flap.
45652062|NCT04422327|Dietary Supplement|Probiotic capsule|"Each probiotic capsule contains 5 x 10^8 CFU B. longum 35624® and 5 x 10^8 CFU B. longum 1714™ with corn starch and magnesium stearate.~The probiotic capsule will be supplied by PrecisionBiotics Ltd."
45802196|NCT02316379|Drug|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
45802197|NCT02316379|Device|MRI|
45802198|NCT03764501|Device|Image fusion system|Image fusion system for the 3D preoperative planning
45931497|NCT05533684|Drug|Gabapentin|single preoperative dose of 600 mg gabapentin
45931498|NCT05532813|Drug|Treatment taken|Treatment (Metformin or placebo) will be administered orally and titrated following the same guideline that metformin in diabetic patient: start with a daily dose of 500 mg twice a day, given during or after meals; then increase to 1000 mg twice a day after a week. If digestive tolerance is good, treatment will be increased to a maximum of 1000 mg three times a day i.e. 3000 mg/day after another week.
45931499|NCT05530382|Other|self-guided learning|video-based self-directed learning for medical device training
45931500|NCT05528107|Procedure|Lap IPOM plus|Participants will undergo Lap IPOM plus repair according to the assigned treatment arm.
45931501|NCT05528107|Procedure|eTEP|Participants will undergo eTEP repair according to the assigned treatment arm.
46073211|NCT02844062|Drug|cyclophosphamide|250 mg/m^2 d1-3
46073212|NCT02844062|Drug|Fludarabine|25mg/m^2 d1-3
45931502|NCT05523453|Behavioral|Processing of Positive Memories Technique (PPMT)|PPMT comprises of 5 sessions focused on identifying and processing positive memories. In Session 1-5, participants narrate details of one positive memory, and process the positive memory to elicit positive values, affect, strengths, and thoughts.
45931503|NCT05523453|Behavioral|Supportive Counseling (SC)|SC is a 5-session, active and non-specific treatment administered weekly, which includes a discussion of the daily monitoring diary and exploration of current issues and concerns.
45802199|NCT03701165|Device|DryMouth Shield|The DryMouth Shield provides an elastomeric, one-piece design with breath-actuated, one-way valves configured to create an air-tight seal between the teeth and lips, which effectively reduces oral venting and air leakage while also allowing air flow into the mouth by generating a high-volume, low resistance airflow during inhalation while sealing when the user exhales.
45802200|NCT02303743|Device|Smart Phone Application|Bowel preparation was evaluated using the Harefield Cleansing Scale (HCS). The scale was the primary outcome measure
45931504|NCT05520411|Dietary Supplement|HUM Flatter Me|Proprietary Enzyme Blend: Protease 3.0 Protease 4.5 Protease 6.0 Neutral Bacterial Protease Peptidase Bromelain Papain Lipase Amylase Glucoamylase Alpha-galactosidase Invertase Diastase Hemicellulase + Cellulase Beta-Glucanase Phytase Lactase Ginger Root Fennel Seed Peppermint Leaf
45931505|NCT05505747|Drug|Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. This naturally derived senolytic has few side effects and previous animal models of both osteoarthritis and rheumatoid arthritis have demonstrated that the senolytic supplement fisetin reduces inflammation and slows cartilage breakdown.
45931506|NCT05505747|Drug|Placebo oral capsule|The oral placebo will consist of corn starch and gelatin capsules
45931507|NCT05499546|Device|SCALE EYE|Polyp size measurement using the SCALE EYE functionality
45931508|NCT05496595|Drug|DCBY02|A monoclonal antibody that binds to CD93, DCBY02 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
45931509|NCT05492032|Device|Active-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
45931510|NCT05492032|Device|Sham-tDCS|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participants will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
45451465|NCT05509348|Behavioral|Phase 2: ADAPT Individual|3 sessions in person one on one
45652063|NCT03075475|Behavioral|Common Elements Treatment Approach|The Common Elements Treatment Approach (CETA), is a trans-diagnostic psychotherapy that is based on common evidence-based treatments for depression, anxiety, trauma and stress related disorders. This treatment can be used to treat individuals with any of these mental health problems and with any combination of these problems. CETA expands upon traditional treatment approaches that are designed to focus on one specific disorder and has been proven through multiple rigorous trials to reduce the burden of multiple common mental health problems and improve functionality among men and women living in low resource settings. CETA can be provided to people in their own communities by trained and supervised lay providers, for example community health workers.
45652064|NCT04827329|Other|Questionnaire|Patients will complete a questionnaire regarding their anesthesia history, course and possible complications, and Questions about their treatment for their sleep disorder.
45652065|NCT05251467|Other|Focus group|Focus group to confirm PROM conceptual framework
45802201|NCT02303743|Device|Written instructions with visual aids|written instructions with visual aids explaining the procedure and when to begin self-administration of the bowel solution (control group).
45802202|NCT04981613|Drug|Kunxian capsule|Kunxian capsule (2# tid or 2# bid) + irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
45802203|NCT04964375|Drug|ABSK043 oral capsule|ABSK043 is a novel, oral small molecule inhibitor of PD-L1
45802204|NCT02303977|Drug|Abraxane|
45931511|NCT05476783|Drug|TB006|Clear to slightly opalescent, sterile solution for injection
45451466|NCT05472766|Drug|Direct Acting Oral Anticoagulant starting at Day 30|Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP
45451467|NCT05472766|Drug|Direct Acting Oral Anticoagulant starting at Day 90|Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP
45451468|NCT05461924|Other|questionnaire survey|questionnaire survey the long term outcomes of long-segment HSCR and compared with rectosigmoid HSCR
45451469|NCT03653026|Drug|Placebo|Tablet for oral administration
45451470|NCT03653026|Drug|Upadacitinib|Tablet for oral administration
45802205|NCT02303977|Drug|Gemcitabine|
45931512|NCT05476718|Other|Kinesio taping|Patients will be informed about the study on the first day of their hospitalization and the Introductory Information Form, Visual Analogue Scale, and Oswestry Disability Index will be filled in by the patients. 24 hours after the operation, 20 minutes of training will be given to the patient and their relatives on the use of a pedometer and home care, and the first tape will be applied. After discharge, the renewal of the bands will be carried out on the postoperative 1th- 5th-10th-15th days when the patients come to the hospital for post-op evaluation. The clinical recovery of the operation area will be done by the investigative physician. In the follow-ups, evaluations will be made with the Visual Analog Scale, Medication Tracking Form, Oswestry Disability Index,Functional Low Back Pain Scale, Kinesio Tracking Form, and Gait Tracking Form.
46073213|NCT02828046|Biological|M281|
46073214|NCT02828046|Other|Placebo|
46073215|NCT02830230|Drug|Tab cefixime,Tab Azithromycin|The women with clinical cervicitis will receive treatment for cervicitis.
46073216|NCT02840396|Device|rTMS|repetitive TMS (rTMS) can lead to temporary increases or decreases (depending on the protocol used) in excitability of the targeted area. This change in excitability has been shown to last beyond the duration of the stimulation.
45451471|NCT03647098|Genetic|kras|the gene mutation
45451472|NCT02232568|Behavioral|Feedback|
45451473|NCT02232724|Device|Choline PET/CT and Dual time point FDG PET/CT|Choline PET/CT and dual time point FDG PET/CT
45802206|NCT01997515|Drug|Ketamine|Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
45931513|NCT05476718|Other|placebo taping|Patients will be informed about the study on the first day of their hospitalization and the Introductory Information Form, Visual Analogue Scale, and Oswestry Disability Index will be filled in by the patients. 24 hours after the operation, 20 minutes of training will be given to the patient and their relatives on the use of a pedometer and home care, and the first tape will be applied. After discharge, the renewal of the bands will be carried out on the postoperative 1th-5th-10th-15th days when the patients come to the hospital for post-op evaluation. The clinical recovery of the operation area will be done by the investigative physician. In the follow-ups, evaluations will be made with the Visual Analog Scale, Medication Tracking Form, Oswestry Disability Index,Functional Low Back Pain Scale, Kinesio Tracking Form, and Gait Tracking Form.
45931514|NCT05476601|Behavioral|CMAP Plus|The CMAP Plus intervention will be delivered individually, weekly over a period of 12 weeks.
45931515|NCT05474859|Drug|XT-0528|Once Daily
45931516|NCT05458479|Drug|Fluoxetine|All participants in the study will receive open-label treatment with orally administered fluoxetine for the full duration of the 16-week trial. Fluoxetine is a selective serotonin reuptake inhibitor. It is approved for the management of major depressive disorder in adults.
45931517|NCT05456477|Other|Beef|Beef entrees
45931518|NCT05456477|Other|Poultry|Poultry entrees
45931519|NCT05445284|Behavioral|Group education sessions for parents plus usual diabetes care|≥3 in person/virtual group education sessions for parents in addition to usual diabetes care, every 3 months for 12 months
45931520|NCT05445284|Other|Usual diabetes care|Usual diabetes care, every 3-month for 12 months
45451474|NCT01329328|Device|vibrating platform (Bioplate RF)|whole body vibration exercise with multiple positions, with or without localized delivery of heating radiofrequency
45931521|NCT05435027|Drug|GRT-R912, samRNA-Spikebeta-TCE11|IM injection of GRT-R912. Doses will be decided after safety review of Part A.
45931522|NCT05435027|Drug|GRT-R914, samRNA-Spikebeta-TCE9|"Part A: 3 microgram (mcg), 10 mcg, or 30 mcg intramuscular (IM) injection of GRT-R914.~Part C: IM injection of GRT-R914. Doses decided after safety review of Part A."
45931523|NCT05435027|Drug|GRT-R918, samRNA-SpikeOmicron-N-TCE11|IM injection of GRT-R918. Doses will be decided after safety review of Part A.
46073217|NCT02840396|Device|Sham rTMS|Sham rTMS (or placebo rTMS) refers to a control condition in which no physiological effect on the targeted cortical region occurs.
46073218|NCT02840240|Drug|Gabapentin enacarbil|600 mg BID 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg BID 3 days post-operative
45451475|NCT02234440|Drug|Metformin|
45451476|NCT02234440|Drug|Insulin|
45802207|NCT01997515|Drug|placebo|Group P (placebo) will receive the same amount of saline.
45802208|NCT02786771|Device|Spire|
45802209|NCT02786771|Device|Muse headband|
45802210|NCT04333823|Drug|Dapagliflozin 5mg|Dapagliflozin tablet
45802211|NCT04333823|Drug|Placebo|Sugar pill manufactured to mimic Dapagliflozin 5mg tablet
46073219|NCT02840240|Drug|Placebo|600 mg BID taken 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg 3 days post-operative
45802212|NCT01997905|Device|AtriClip LAA Exclusion Device|
45802213|NCT04938089|Other|Maintenance|Regular compliant individual is defined in the study as a subject attending 100% of his/her recall visits with a maximum interval of 6 months. Irregular compliant individual is defined as a subject who missed at least one of the recall visits but continued to appear on an irregular basis with a maximum interval of 18 months, non-smoker individual is defined as a subject who never smoked, and lastly, smoker individual is defined as a subject who is smoking > 9 cigarettes per day.
45802214|NCT04211935|Device|Use of PCA|A commercially available PCA pump will be connected to the patient's intravenous line at the end of the MIRPE operation.
46073220|NCT00888654|Drug|B-Dim|B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
46073221|NCT00888654|Procedure|Radical Prosatectomy|
46073222|NCT03238430|Drug|intrathecal morphine|A single intrathecal injection of 300 micrograms of Morphine preoperatively, just before induction.
46073223|NCT03238430|Drug|Morphine PCA|a postoperative Morphine PCA
45802215|NCT04211935|Device|Use of ESB for postoperative pain control after MIRPE|Pediatric anesthesiologists will place ESB at the time of the MIRPE operation if study participants are randomized into this group.
45802216|NCT04211935|Device|Use of INC for postoperative pain control after MIRPE|Pediatric surgeons will perform INC during the MIRPE operation if they are randomized to this group.
46073224|NCT03238430|Drug|Ropivacaine infiltration|Ropivacaine 2mg / ml at the rate of 8ml per hour via a multiperforated catheter with connector after bolus of 20 ml
46073225|NCT04246866|Biological|GEM103|GEM103
46073226|NCT02843906|Procedure|Lombar Punction|cerebrospinal fluid testing at screening and M36
46073227|NCT02843906|Radiation|Magnetic Resonance Imaging (MRI)|MRI done at screening and M36
45802217|NCT02788019|Drug|Ropivacaine|Ropivacaine is routinely used to perform localized blockade prior to surgery to improve management of postoperative pain.
45802218|NCT02788097|Procedure|Progesterone supplementation|artificial frozen embryo transfers
45931524|NCT05434299|Drug|TFX05-01|TFX05-01 for intravenous
45931525|NCT05433961|Drug|MagniXene Hyperpolarized Xenon MRI|Magnetic Resonance Imaging of lung function using Hyperpolarized Xenon as a contrast agent.
45931526|NCT05426408|Diagnostic Test|Cardiac magnetic resonance imaging to study coronary microvascular dysfunction|Myocardial perfusion mapping will be investigated after administration of adenosine
45931527|NCT05423769|Drug|Fingolimod|0.5 mg hard gelatine capsules
45931528|NCT05408247|Drug|N-acetyl cysteine|2400mg/day
45931529|NCT05408247|Drug|Placebo|Matched placebo
45931530|NCT05400694|Other|Food|Dairy products with reduced sugar content
45931531|NCT05397639|Drug|Masupirdine 50 mg|Tablet, Once Daily
45931532|NCT05397639|Drug|Masupirdine 100 mg|Tablet, Once Daily
45931533|NCT05397639|Drug|Placebo|Matching Placebo Tablet, Once Daily
45931534|NCT05397015|Other|No intervention will be done|No intervention will be done
45931535|NCT05396040|Procedure|LOLLI METHODE|WEEKLY SCREENING WITH POOLED SALIVA PCR TEST
45931536|NCT05393921|Drug|Intravesical Botox injection|Intravesical botox injection given only in experimental group.100 units of Botox will be used and diluted in 10 mL of normal saline. 0.5 cc injections will be administered in 20 injection sites (trigone sparing).
45931537|NCT05392335|Other|Myofascial stretch|Myofascial stretch will be applied at hip adductors, hamstrings and calf muscles for 10 -15 repetitions on each muscle. 2-3 sessions will be performed in a week for 8 weeks.
45802219|NCT01999231|Biological|ESAT6-CFP10|32 healthy subjects who meet the standard of protocol are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml ESAT6-CFP10、5μg/ml ESAT6-CFP10、10μg/ml ESAT6-CFP10、20μg/ml ESAT6-CFP10.Each dose group have six healthy subjects(three male and three female) , at the same time set up two people for substitute (one male and one female) . ESAT6-CFP10 administered intradermally by the mantoux injection technique. Each receives only one dosage in right or left arm .
45451477|NCT02234518|Other|High quantity fiber|The intervention type is food product
45451478|NCT02234518|Other|Low quantity fiber|The intervention type is food product
45931538|NCT05392335|Other|Functional massage along with myofacial stretch|In this group during the first 20 minutes, ten minutes FM will be applied to each lower extremity of the subject. The muscle groups to which FM would be applied were hip adductors, hamstrings and calf muscles. During the remaining period traditional physiotherapy involving myofascial strecth will be given. 2-3 session will be performed in a week for 8 weeks.
45931539|NCT05391308|Other|Pre-polysomnography mesurement|Leg fluid volume (bioelectrical impedance), neck circumference (tape measure), neck volume (3D scanner), time spent sitting down (self-reporting)
45931540|NCT05391308|Other|Polysomnography measure|Apnea-Hypopnea Index
46073228|NCT02843906|Radiation|Positron-Emission Tomography (TEP) /(FDG)|TEP/FDG done at screening and M36
46073229|NCT02843906|Other|Psychiatric tests|
45451479|NCT02234518|Other|Placebo|
46073230|NCT02843906|Other|Neuropsychological Tests|done at screening, M12, M24 and M36
46073231|NCT02843906|Genetic|Apolipoprotein (ApoE) detection|ApoE detection done at screening
46073232|NCT02829840|Drug|Ponatinib|"Part 1: Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle."
45802220|NCT04175977|Behavioral|Aliviado Dementia Care-Hospice Edition QAPI program|Multi-modal QAPI program for improving the quality of care provided to PWD and support to their informal caregivers through hospice. It has been culturally tailored for use in diverse settings and tested with multiple minority communities in New York, including multiple Hispanic groups and African-Americans and Caribbean blacks. The intervention includes mentorship, training, a toolkit, and mobile app to assist clinicians in providing evidence-based symptom management to persons with dementia.
45451480|NCT04981678|Drug|Buprenorphine|Patients randomized to this group will reduce their buprenorphine dose prior to surgery.
45802221|NCT04175977|Behavioral|Usual Care|Usual care as provided by the hospice agency
46073233|NCT02829840|Drug|5-azacytidine|"Part 2 Phase I Dose Escalation: 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
46073234|NCT02829840|Behavioral|Phone Calls|"About 30 days after end-of-study visit, study staff calls participant and asks if they have had any side effects and/or started any new treatment(s).~If disease appears to be responding to study drugs, study staff calls participant every 3-6 months for up to 5 years and asks how they are doing and about any side effects they may be having."
46073235|NCT02844296|Behavioral|Video about exercise|Video about short-bout exercise will be played for the participants.
45451481|NCT04981678|Drug|Buprenorphine|Patients randomized to this group will continue their buprenorphine at the full prescribed dose.
45451482|NCT02230618|Drug|insulin degludec/insulin aspart|Ryzodeg™ will be prescribed by the physician under normal clinical practice conditions and will be obtained/purchased from the chemist based on physician prescription. No treatment given.
45451483|NCT05419648|Biological|1 additional tube of blood|For all the patients included, a specific blood sampling will be performed in addition to the classical evaluations that are performed in routine practice
45802222|NCT02789033|Drug|Chitosan|Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
45802223|NCT02789033|Drug|Isosorbide dinitrate|Isosorbide dinitrate (ISDN), is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate
45802224|NCT02789033|Drug|Placebo|placebo
45802225|NCT01999777|Drug|USL261|
45802226|NCT01999777|Drug|Placebo|
45802227|NCT02790281|Procedure|Blood sampling|Blood sample collected at a single visit
45802228|NCT04913519|Drug|TDM-105795|TDM-105795 topical solution
45802229|NCT04913519|Drug|Placebo|Placebo for TDM-105795 topical solution
45931541|NCT05391308|Other|Post-polysomnography measurements|Leg fluid volume (bioelectrical impedance), neck circumference (tape measure), neck volume (3D scanner)
45931542|NCT05390411|Behavioral|SOCIAL HF|participate in SOCIAL HF training
45931543|NCT05385965|Behavioral|Meaning-Centered Pain Coping Skills Training|The goal of this intervention is to help participants reduce pain interference so that they can engage with what gives them a sense of meaning, purpose, and peace.
45931544|NCT05375942|Drug|Inflectra|1. To describe the characteristics of patients newly initiated on Inflectra.
45931545|NCT05375942|Drug|Inflectra|2. To describe 6-month outcomes after initiating Inflectra, among patients who have 6 months follow-up information in the CorEvitas' RA Registry.
45931546|NCT05367817|Other|Neuromuscular exercise therapy|Participants perform specific neuromuscular exercises aimed at enhancing the sensorimotor control of the wrist.
45931547|NCT05367817|Other|Training program|Participants perform range of motion exercises for the wrist.
45802230|NCT03297125|Device|Standard Magnetic Resonance Imaging (MRI)|Standard MRI.
45931548|NCT05366790|Behavioral|CEASE and CEASE-A|CEASE (for parents) and CEASE-A (for adolescents) are evidence-based tobacco and vaping cessation interventions delivered in pediatric practices.
45931549|NCT05364697|Device|IoNIR Ridaforolimus-Eluting Coronary Stent System|The IoNIR Ridaforolimus-Eluting Coronary Stent System is a sterile single-use device/drug combination product, comprised of a cobalt chromium (CoCr) alloy-based stent coated with a bioresorbable polymer mesh which is embedded with drug, mounted on a Rapid Exchange (RX) delivery system.
45931550|NCT05360485|Behavioral|MOV'D (Move Often eVery Day)|The MOV'D intervention is a remotely-delivered, peer-supported intervention that delivers exercise snack (2-5 minutes of moderate to vigorous activity) and behavior change technique (BCT) videos to a private social media support group with the goal of interrupting prolonged sitting at work with MVPA minutes.
45931551|NCT05360485|Behavioral|Fitbit Self-Monitoring|All participants receive a Fitbit and are told to monitor their physical activity for the duration of the study period.
45931552|NCT05346913|Behavioral|Internet-delivered Cognitive Behavioural Therapy(ICBT)|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend ~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
45931553|NCT05345587|Other|THESS monitoring|Consultation with the pharmacist to look for possible medication interactions between the oral therapy and the patient's usual treatments and to inform the patient about his treatment to improve QOL and compliance. Consultation and follow-up by a nurse. Weekly notification by THESS Application of the symptoms experienced by the patient over the last 7 days
45652066|NCT05251467|Other|Patient interview (n = approximately 10)|Patient interviews to refine possible questions for the PROM
45802231|NCT03297125|Device|Advanced MRI.|Perfusion and diffusion MRI.
45931554|NCT05340738|Other|LyssnCBT|LyssnCBT is a technology that allows therapists and supervisors access to tools that assist with assessing CBT session fidelity, including speech-to-text transcription, annotation tools, and AI-generated metrics.
45931555|NCT05338944|Behavioral|Dialectical behavioral therapy|Working with psychologists through DBT skills training.
45451484|NCT05398198|Drug|GSK3923868|GSK3923868 dose and administration as per study intervention.
45451485|NCT05398198|Drug|Placebo|Placebo matching GSK3923868 will administered.
45802232|NCT00372827|Drug|Brinzolamide 1% added to Travoprost 0.004%|
45802233|NCT02278315|Drug|I-131-CLR1404|Single IV dose of I-131-CLR1404, increased/decreased by cohort
45802234|NCT02278315|Drug|dexamethasone|40 mg dexamethasone orally once weekly for up to 12 weeks
45802235|NCT02278315|Drug|I-131-CLR1404|Multiple IV dose of I-131-CLR1404, increased/decreased by cohort
45802236|NCT02188147|Device|Short Term Wearable Defibrillator|Short-term Wearable Defibrillator (SWD 1000)
45802237|NCT02794727|Device|Blinded Fitbit|Subjects will wear a blinded Fitbit to monitor activity while in the workplace for 12 weeks.
45931556|NCT05338944|Behavioral|Lifestyle|Working with kinesiologist and registered dietician to improve lifestyle habits.
46073236|NCT02844296|Behavioral|App about exercise|A smartphone App about exercise will be installed in participants' mobile phone.
46073237|NCT02844296|Behavioral|Leaflet about exercise|A leaflet about exercise will be provided for the participants.
46073238|NCT02844296|Behavioral|Video about diet|Video about healthy diet will be played for the participants.
46073239|NCT02844296|Behavioral|App about diet|A smartphone App about healthy diet will be installed in participants' mobile phone.
45451486|NCT05388136|Procedure|Conventional follow up schedule with imaging|Frequent of follow up visit and imaging
45451487|NCT05388136|Procedure|Deintensified follow up schedule without imaging|Less intense follow up visit without imaging
45652067|NCT05251467|Other|Questionnaire (n = 180)|Online questionnaire to evaluate the proposed questions as part of PROM development in a larger population
45652068|NCT05251467|Device|Testing of the pilot PROM in a smartphone app (n = 100)|Daily testing of the pilot PROM in a smartphone app for 2 weeks
45652069|NCT04925167|Drug|Argatroban|Argatroban continuous intravenous injection maintained APTT at 1.5 times of baseline.
45652070|NCT04925167|Drug|unfractionated heparin|unfractionated heparin continuous intravenous injection maintained APTT at 1.5 times of baseline.
45802238|NCT02794727|Device|Unblinded Fitbit|Subjects will be unblinded to the Fitbit display for 12 weeks with set activity goals.
45802239|NCT02795117|Drug|Ivermectin|
45802240|NCT02795117|Drug|Ivermectin (reference)|
45802241|NCT02795117|Drug|Placebo|
45802242|NCT02333071|Drug|Bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
45802243|NCT02333071|Other|Placebo|Placebo
45802244|NCT02795819|Drug|AR-42|AR-42 tablets were taken orally once per day on 3 non-consecutive days during the first 3 weeks of each 4-week cycle. If treatment was interrupted during the cycle, the cycle was to be extended
45802245|NCT02795819|Drug|Pazopanib|Pazopanib tablets were taken orally once daily continuously during each 4-week treatment cycle. There were no scheduled breaks in pazopanib therapy
45802246|NCT02882633|Drug|30ml bolus of bupivacaine|Local anesthetic
45802247|NCT00373607|Drug|Dihydroartemisin-piperaquine|Dihydroartemisin-piperaquine (Artekin) manufactured by Hualijian Pharmaceutical Co. Ltd., Guangzhou, China. Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
45802248|NCT00373607|Drug|Mefloquine + Artesunate|Mefloquine + Artesunate (MAS3). The regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day
45931557|NCT05317221|Other|Not an extra intervention, tissue taken in routine practice will be used.|No extra intervention: using tumour tissue taken during surgery in standard of care.
45931558|NCT05305053|Other|preoperative MDT discussion|high-risk patients are subjected to an MDT discussion among care providers
45802249|NCT02797613|Behavioral|Restricted Reporting|An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important
45931559|NCT05298254|Biological|Non-adjuvanted HSV formulation 1|Two doses of the non-adjuvanted HSV formulation 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
45931560|NCT05298254|Biological|Non-adjuvanted HSV formulation 2|Two doses of the non-adjuvanted HSV formulation 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
45931561|NCT05298254|Biological|Non-adjuvanted HSV formulation 3|Two doses of the non-adjuvanted HSV formulation 3 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
45931562|NCT05298254|Biological|HSV formulation 1 with adjuvant 1|Two doses of the HSV formulation 1 with adjuvant 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
45931563|NCT05298254|Biological|HSV formulation 2 with adjuvant 1|Two doses of the HSV formulation 2 with adjuvant 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
45931564|NCT05298254|Biological|HSV formulation 3 with adjuvant 1|Two doses of the HSV formulation 3 with adjuvant 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
45931565|NCT05298254|Biological|HSV formulation 1 with adjuvant 2|Two doses of the HSV formulation 1 with adjuvant 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
45931566|NCT05298254|Biological|HSV formulation 2 with adjuvant 2|Two doses of the HSV formulation 2 with adjuvant 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
45931567|NCT05298254|Biological|HSV formulation 3 with adjuvant 2|Two doses of the HSV formulation 3 with adjuvant 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
45652071|NCT04812587|Behavioral|exercise intervention program|The experimental group will receive a 12-week combined exercise intervention program with extra emphasis on balance, muscle strength, and walking ability which involved two 2-hour sessions once per week.
45931568|NCT05298254|Drug|Placebo|Two doses of Placebo administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I and Part II of the study.
45451488|NCT01337986|Drug|Dalfampridine/Placebo|Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.
45451489|NCT01337986|Drug|Placebo/Dalfampridine|Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.
45652072|NCT04998565|Other|Routine care|Reverse pressure applied to the areola
45652073|NCT04998565|Procedure|Electrical Acupuncture|Acupuncture on Hegu, Sanyinjiao, Zusanli and Taichong with electrical stimulation
45652074|NCT04998565|Procedure|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation over bil breasts
45652075|NCT04427267|Other|Personal protective equipment from biological hazard|Includes: isolation clothing, mask, eyewear, overshoes
45652076|NCT04817657|Biological|Ad26.COV2.S|Participants will be administered 0.5 milliliter suspension of Ad26.COV2.S 1*10^11 virus particles per milliliter (vp/ml) as intramuscular injection.
45652077|NCT04998721|Behavioral|Promoting First Relationships-Brief|A brief version of the evidence based Promoting First Relationships (PFR) parenting intervention in which a parent is supported in appropriate interpretation of infant cues and in developing skills to effectively parent an infant. Sessions consist of reflective content (observing and reflecting back to the mother on patterns of dyadic interaction) and informational handouts. Reflective content will be delivered in person, and text messaging protocol will deliver informational content at developmentally appropriate times. PFR-B sessions are delivered in primary care settings beginning in the third trimester and continuing postpartum.
45802250|NCT02882711|Drug|Ketamine|Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks and weekly for the following 4 weeks of the study treatment period (8 weeks total).
45802251|NCT02884427|Device|Cathode stimulation|Electrical stimulation through the cathode or negative pole, in which a peripheral nerve will be subject to the passage of a direct current seeking increased excitability and conductivity during the passage of current.
45931569|NCT05298254|Biological|Selected formulation|Two doses of the formulation of the HSV vaccine selected from Part I of the study administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part II of the study.
46073240|NCT02844296|Behavioral|Leaflet about diet|A leaflet about healthy diet will be provided for the participants.
46073241|NCT00633516|Device|Optical Spectroscopy|Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy
46073242|NCT04246632|Device|CapsoCam Colon Capsule Endoscopy|CapsoCam® Colon is intended to provide visualization of the colon and the detection of colon polyps in adults.
45802252|NCT02884427|Device|Anode stimulation|Electrical stimulation through the anode or positive pole, in which a peripheral rib will be subjected to the passage of a direct current seeking to reduce excitability and conductivity during the passage of current.
46073243|NCT03223220|Drug|Ketamine|IV infusion
46073244|NCT03223220|Other|Normal Saline|IV infusion
46073245|NCT03223220|Drug|Midazolam injection|Injection
46073246|NCT02827890|Drug|Januvia Tab. 100mg|Januvia Tab. 100mg*1T/day for 5days, QD, PO
46073247|NCT02827890|Drug|Januvia Tab. 100mg + Duvie Tab. 0.5mg|Januvia Tab.100mg + Duvie Tab. 0.5mg*1T/day for 5 dyas, QD, PO
46073248|NCT04250792|Drug|Naltrexone Pill|role of low dose naltrexone in patients affected with psoriasis
45931570|NCT05290805|Diagnostic Test|ECMO flow rate reduction|ECMO flow rate is reduced for the duration of CT image acquisition (max. 1-2 min.), if the hemodynamic and respiratory situation allows it. Feasibility is determined by the accompanying emergency physician right before the CT scan and adapted to the individually tolerable level (max. 50% of initial flow, no less than 1,5 litre/min). After image acquisition, ECMO flow rate is immediately returned to the initial or clinically optimal value at this moment.
45931571|NCT05289947|Other|Placebo|Caramel, chocolate brown, flavor (E_1982648), dextrin
45652078|NCT04998721|Combination Product|Perinatal Collaborative Care|Collaborative Care (CC) is an integrated care model that is effective in the treatment of perinatal depression. CC provides team driven, population focused, measurement guided and evidence based care to improve access and outcomes, control costs, and increase patient satisfaction.
45802253|NCT02884427|Device|Placebo|Current application without the actual electric conduction to the person occurs. This will be achieved by adjusting parameters while installing another channel and not one that is working.
45802254|NCT02798627|Drug|NS2359|NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.
45931572|NCT05289947|Drug|MLC1501|Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
45931573|NCT05280730|Other|No intervention|There is no intervention
45931574|NCT05276024|Device|iFuse Bedrock technique|Lumbosacral arthrodesis on 2 or more spinal segments (including at least L4, L5 and S1 vertebrae) associated with a sacroiliac fusion procedure according to the Bedrock technique using the iFuse 3D system and iliac fixation.
45931575|NCT05273736|Behavioral|5 Behavioral Change Techniques|"Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal to take your medication as prescribed tomorrow.~Action planning: prompt detailed planning of performance of behavior (must include a setting, frequency, duration, and intensity). Example: Develop a plan for taking your medication.~Self-Monitoring of behavior: establish a method for person to monitor and record their behavior. Example: Did you take your statin medication today?~Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You did not take your statin medication as prescribed yesterday.~Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: Please remember to take your medication soon."
46073249|NCT04244994|Device|Aptima-Combo2 and Aptima Mgen|Self-taken penile meatal swabs versus first-catch urine samples for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium using Aptima-Combo2 and Aptima Mgen
45931576|NCT05264701|Other|Physiotherapist supervised exercise training|Exercise training for 12 weeks will be given by video talk accompanied by a physiotherapist.
45931577|NCT05264701|Other|Exercise training via phone app|Exercise training for 12 weeks will be given over the developed phone application.
45931578|NCT05264701|Other|Physical activity recommendations|The program will be consist of 12 weeks of physical activity recommendations.
45931579|NCT05243615|Behavioral|Guided internet delivered cognitive behavioural therapy|A 10-week internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a stroke. In addition to the online program, a Guide with experience delivering ICBT will provide support by email or phone call once a week. The Guide will spend approximately 15 minutes per week/per client.
45931580|NCT05243615|Behavioral|Stroke rehabilitation mental health education|A 10-week stroke-specific rehabilitation education program for stroke patients in usual care at specialized stroke rehabilitation units. The lessons will include information on spinal cord injury rehabilitation: 1)stroke basics, 2)mental health after stroke, 3)pain after stroke, 4)understanding rehabilitation 5)summary of lessons through an online platform. A Guide will check in with participants once a week to answer any content-related questions. The Guide will spend approximately 15 minutes per week/per client.
45931581|NCT05240664|Behavioral|Have A Say Programme|Each dyad of participants will receive a 4-session ACP programme, which consists of 2 group-based sessions and 2 dyadic sessions, one hour for each session. The group-based sessions are led by nurse which include didactic educational components, guided reflection, videos, and group sharing. Dyads of participants will be provided with information about ACP, the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. The dyadic sessions are facilitated by trained ACP facilitators and guided by an ACP booklet. Dyads of participants will be supported to have an individualized ACP discussion guided by an ACP booklet. By the end of the programme, each dyad of participants will be given an ACP booklet documenting the ACP process.
46073250|NCT02840318|Other|Compassion Intervention|See arm description
45652079|NCT04812431|Biological|Neural precursor cells derived from human embryonic stem cell line|When the Dose Limiting Toxicity (DLT) is not presented in the first three subjects administered with PSA-NCAM(+) NPC, two additional patients are added to the clinical study.
45652080|NCT05011669|Drug|Lurasidone|Oral administration with a meal or within 30 min after eating in the evening. The dosage could be adjusted from Day 8.
45652081|NCT02524665|Other|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
45802255|NCT02798627|Drug|placebo|Placebo pills identical in appearance to the NS2359 will be provided
45802256|NCT02794337|Radiation|SBRT|Intervention involves administering high precision radiation to the tumour in 6-8 fractions over 2-2.5 weeks
45802257|NCT02794337|Procedure|TACE|Involves catheterization of the tumour feeding vessels and injecting 100 mg of doxorubicin drug eluting beads. Maximum 3 TACE procedures are done
45652082|NCT02524665|Other|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
45652083|NCT02524665|Other|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
45652084|NCT02524665|Other|MURAD Clarifying Cleanser (1.5% SA)|Available over the counter.
45652085|NCT02524665|Other|Exfoliating Acne Treatment Gel (1% SA)|Available over the counter.
45652086|NCT02524665|Other|Skin Perfecting Lotion|Available over the counter.
45931582|NCT05240664|Behavioral|Attention-control health talks|Dyads of participants in the control group will receive 4-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health, and healthy diet.
45931583|NCT05236114|Other|Observation|No intervention
45931584|NCT05235828|Behavioral|Sudarshan Kriya Yoga (SKY)|This is the experimental arm of the study, where participants will be trained in a form of breathing based meditation that incorporates different breathing techniques centred around controlling arousal and attention. Participants will be encouraged to learn all of the techniques that are covered during these sessions and also utilize the techniques that are most appropriate for their personal needs. After some initial training sessions, participants will be encouraged to practice their new SKY techniques in environments and situations that they have been avoiding. They would begin with situations that are less triggering, and progress to more difficult situations. At each group session, participants will describe their experiences and discuss ways to continue to incorporate the SKY techniques into their daily lives, until it reaches a point of being natural to use these skills throughout the day, both in practice, and in application.
45931585|NCT05234177|Other|Observation|No intervention
45931586|NCT05217940|Diagnostic Test|Diagnostic tests for anal cancer screening|The initial screening interventions will include the collection of (1) anal cytology; (2) self-collected HPV testing specimens (by subjects); (3) a clinician collected HPV specimen. A digital rectal exam will also be done on all patients.
45931587|NCT05212480|Dietary Supplement|Zinc|For each patient included, a prescription regimen of zinc (in bisglycinate form) is proposed at a dose of 25 mgtwice a day for 15 days for the intervention arm. This dose of zinc is to be taken away from meals.
45931588|NCT05212480|Dietary Supplement|Placebo|For each patient included, a prescription of an identical to the intervention arm concerning shape, smell, taste and color pill of placebo . This dose of zinc is to be taken away from meals.
45931589|NCT05209308|Drug|Zandelisib|Zandelisib taken orally for 7 days of each 28 day cycle
45931590|NCT05209308|Drug|Rituximab|Rituximab IV for 6 cycles
45931591|NCT05209308|Drug|Venetoclax|Orally - Ramp up weeks 1-5
45931592|NCT05208528|Dietary Supplement|ES1 group|Participants will intake 2 capsules of 300 mg/capsule with 50 mg of Bifidobacterium longum ES1 (1E09 CFU of probiotic/day, by taking 2 capsules) and 250 mg of maltodextrin.
45931593|NCT05208528|Dietary Supplement|HT-ES1 group|Participants will intake 2 capsules of 300 mg/capsule with 50 mg of HT-ES1 (1E09 CFU of probiotic/day, by taking 2 capsules) and 250 mg of maltodextrin.
45931594|NCT05208528|Dietary Supplement|Control group|Participants will intake 2 capsules of 300 mg/capsule with 300 mg of maltodextrin.
45931595|NCT05202223|Behavioral|Harmony at HOME (H@H)|H@H is a 6-week telehealth intervention delivered by an occupational therapist during weekly visits.
45931596|NCT05198492|Other|Impact of air pollution|To assess the short- and long- term impact of air pollution
46073251|NCT02827968|Drug|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
45451490|NCT04710862|Behavioral|Breathing training without a device|Breathing training without a mouth device
45652087|NCT04812353|Other|Follow-up of Io-Fix type fixation|Follow-up of patients who underwent a foot- or ankle reconstruction surgery using the Io-Fix system
45652088|NCT03079843|Other|exposure to particulate matter with N 95 facemask|2 hours' / day exposure to particulate matter face mask worn during exposure.
45652089|NCT03079843|Other|exposure to particulate matter with no face mask|2 hours'/ day exposure to particulate matter with no face mask
45652090|NCT04433689|Device|Non-Contact measurement of corneal properties|Corneal Properties will be measurement with the non-contact Corvis ST Air-Puff Tonometer by Oculus Inc.
46073252|NCT02840162|Drug|Celecoxib|Selective inhibition of COX-2 without significant cyclooxygenase-1 (COX-1) inhibition
46073253|NCT02840162|Drug|Placebo|
46073254|NCT02827812|Other|Comprehensive evaluation|At baseline (T0) and after 3-months (T1) all patients will be evaluated with Scales and questionnaire.
46073255|NCT02827812|Other|Physical Intervention at home|A traditional custom-tailored rehabilitative exercise program. The exercises will include functional strengthening, stretching, postural changes and balance activities; - An aerobic training on a cycle ergometer 3 days /week for three months.
45652091|NCT04817423|Other|No intervention|No intervention
45652092|NCT03079765|Behavioral|Behavioral skills training|Participants will receive feedback and error correction on their implementation of the assessment procedures. Feedback will take the form of the experimenter pointing out components of the assessment that are not being conducted accurately and error correction will take the form of the experimenter reviewing the correct way to implement that component of the assessment.
45451491|NCT04710862|Behavioral|Breathing training with a device|Breathing training with a mouth device
45802258|NCT02794337|Drug|Sorafenib|Sorafenib will be initiated 2 weeks before 1st TACE at a dose considered appropriate by the treating clinician. Though 400 mg bid is the recommended dose a lower dose may be used as per the judgement of treating clinician. It will be omitted on the days of TACE and SBRT. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier. Sorafenib can however be stopped in patients who fail to tolerate sorafenib even after dose modifications.
45802259|NCT02886923|Device|Hioxifilcon A Test|contact lens made with hioxifilcon A material
45802260|NCT02886923|Device|Hioxifilcon A With Cosmetic Ring Control|contact lens made with hioxifilcon A material with a cosmetic ring on the lens
45802261|NCT02888093|Device|Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)|
45802262|NCT02590523|Drug|Vancomycin|Intracameral vancomycin injection during cataract surgery
45802263|NCT02590523|Drug|Moxifloxacin|Intracameral moxifloxacin injection during cataract surgery
45802264|NCT02590523|Drug|Placebo|Intracameral placebo injection with BSS during cataract surgery
45802265|NCT02519309|Other|Virta Program|
45931597|NCT05180721|Behavioral|Use of patient portal for diabetes management|A multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).
45931598|NCT05171192|Behavioral|CMAP Plus LTP|The LTP Plus CMAP intervention will be delivered for a period of 12 weeks, including 8 weekly sessions and 2 sessions fortnightly. First 6 sessions will be for a duration of 60-90 minutes and remaining 4 sessions will take approximately 50-60 minutes. All sessions will be delivered by female therapists trained in CMAP and LTP intervention.
45931599|NCT05170035|Procedure|MMS + Autologous patch|A patch of consisting of platelets, leucocytes and fibrin, formed by the patients own blood sample.
45931600|NCT05170035|Procedure|MMS and secondary intention healing|Mohs micrographic surgery (standard of care) (wounds will heal by secondary intention healing)
45931601|NCT05160545|Drug|GNC-035|Administration by intravenous infusion
45931602|NCT05159700|Drug|PRJ1-3024|PRJ1-3024 is provided as capsules and is administered orally once a day.
45931603|NCT05157854|Behavioral|Active in My Home (AiMH)|"AiMH starts with two workshops for staff to introduce them to the intervention and the contributions expected from them. Their task is to participate in a couple of the sessions, inspire the course participant to stick to strategies developed during the sessions and support activity in general between the occupational therapy sessions.~AiMH consists of eight sessions, five individual ones and three in a group. Each session has a theme, such as: activity and health, and is built up with short lessons, using one's senses such as smell or touch, testing a simple activity, and setting goals for an activity one wants to test between sessions. The participants are given around 25 USD to try out that activity."
45931604|NCT05157048|Other|Cigarette A|Participants will be smoke a first type of blinded commercially available cigarette.
45931605|NCT05157048|Other|Cigarette B|Participants will smoke a second type of blinded commercially available cigarette.
45451492|NCT04669288|Drug|Azithromycin|"oral azithromycin (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with active study medication (azithromycin) from a central pharmacy. Azithromycin will be reconstituted with water at the local pharmacy, and will resemble placebo with regards to appearance, flavor, consistency and packaging."
45931606|NCT05156827|Drug|TB006|TB006 diluted in normal saline, administered through IV infusion over an hour
45931607|NCT05156827|Drug|Placebo|Normal saline administered through IV infusion over an hour
45931608|NCT05156242|Device|Active-tDCS priming MCE|tDCS is used to enhance cortical excitability before motor control exercises.
45931609|NCT05156242|Device|Sham-tDCS priming MCE|tDCS will be set at 0 mA for 20 minutes before motor control exercise.
45931610|NCT05156242|Device|NMES priming MCE|NMES is used to enhance lumbar multifidus motor unit recruitment before motor control exercise.
45931611|NCT05156242|Other|Conventional physical therapy|Conventional physical therapy includes modality for pain control, general exercise to improve muscle strength, endurance, and flexibility, and functional training (sit to stand, walking, etc.).
45652093|NCT03079765|Behavioral|Protocol Only|Participants will be given a written protocol describing how to conduct the target assessment procedure.
45652094|NCT05619185|Behavioral|CRAFT Web-Based Intervention|Session 1 addresses CPs' mental health issues and drinking. CPs select reasons why they are seeking help and steps they will take towards those goals. Session 2 is focused on improving their relationship through communication exercises. Session 3 is focused on functional analysis of their partner's drinking, and how to positively reinforce their partner's sobriety and negatively reinforce their drinking. Finally, Session 4 focuses on continuing self-care and talking with their partner about their concerns while interacting with them in healthy ways. The WBI contains audio, video, text, and exercises that utilize digital storytelling and vignettes to convey teaching points - a method utilized by the military to address stigma and increase treatment utilization. Actresses portrayed different experiences that the CP may be going through and modeled skills. CPs clicked on the vignette that they most connected with and followed that character across all the sessions.
45652095|NCT05619185|Behavioral|Phone-Based CRAFT|The phone-based CRAFT intervention consists of six individual sessions with a CRAFT clinician that will explore what they learned from the WBI and additional skills they need. Session content includes positive reinforcement of non-drinking SM behaviors, refraining from interfering in SM's consequences of alcohol use, communication skills, and self-care.
45802266|NCT02895035|Drug|Phenylephrine-ketorolac|Pehnylephrine-ketorolac is a combination of an alpha-one agonist (phenylephrine) and an NSAID (ketorolac). One 4-mL bottle of 1% phenylephrine/3% ketorolac is added to the irrigation solution during cataract surgery.
45802267|NCT02895035|Drug|Epinephrine|Epinephrine is a nonselective adrenergic agonist added to the irrigation solution during cataract surgery.
45802268|NCT02802449|Drug|25 Hydroxy- Vitamin D3 [25 (OH) D3]|Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.
45802269|NCT02802449|Drug|Placebo|
45802270|NCT02803229|Drug|Adderall-XR|
45802271|NCT02803229|Drug|Matched placebo|matched placebo provided for placebo arm
45802272|NCT01938001|Drug|Rituximab|Rituximab 375mg/m^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5
45802273|NCT01938001|Drug|Lenalidomide|Lenalidomide 20mg by mouth (PO) daily on Days 1 to 21 every 28 days up to 12 cycles
45802274|NCT01938001|Drug|Placebo|Placebo (identical matched capsule) PO daily on Days 1 to 21 every 28 days
45931612|NCT05153707|Behavioral|Discharge Education Program|medication reconciliation, medication review, individually prepared patient medicine (pill) card, patient education (based on Health Belief Model by using written material and video, and verbally [by using Teach back method especially for patients with low health literacy]) and counseling (using behavior change techniques based on The Capability, Opportunity, and Motivation Behavior model).
45931613|NCT05153317|Drug|ELX/TEZ/IVA|Fixed-dose combination granules or tablets for oral administration.
45931614|NCT05153317|Drug|IVA|Granules or tablets for oral administration.
45931615|NCT05151003|Other|Data collection|Collection and analysis of data related to AKI epidemiology, treatment and outcomes
45802275|NCT04349293|Procedure|Tissue sampling|Collection of a sample of tumor tissue and a sample of adjacent or counter lateral healthy tissue (if possible) from the surgical room
45931616|NCT05150093|Procedure|Deep Brain Stimulation|Clinically indicated DBS treatment for dystonia or tremor with simultaneous research electrocorticography (ECoG).
45931617|NCT05150015|Device|To assess the feasibility of giving intravenous antibiotics to adult inpatients using elastomeric infusion pumps (EMPs)|Single arm study
45931618|NCT05142111|Behavioral|Therapy|Discussion with therapist
45931619|NCT05141643|Diagnostic Test|PET Scan|Participants will receive a minimum of 4 mCi (148 MBq) and up to a maximum of 10 mCi (370 MBq) of [18F]-FAC intravenously. Injection is performed in conjunction with a dynamic PET acquisition over a site of the disease (pre-selected based on the findings from a previous CT or MRI and FDG PET/CT study done for clinical purpose such as staging). Patients will be offered a second [18F]-FAC PET scan procedure during their SOC treatment. This second scan will be optional.
45931620|NCT05134948|Drug|BMS-986213|Specified dose on specified days
45931621|NCT05134545|Device|Genoss® DCB|Peripheral Drug Coated Balloon
45931622|NCT05134545|Device|IN.PACT Admiral® DCB|Peripheral Drug Coated Balloon
45931623|NCT05134012|Drug|[O-15]-Water PET Myocardial Perfusion Imaging (MPI)|[15-O]-H2O injection is a novel PET imaging agent labeled with the radioisotope [15-O] administered as an intravenous (IV) injection. Participants will receive [15-O]-H2O treatment twice as a part of a single day imaging session. All participants will receive two IV boluses of [15-O]-H2O injection in a peripheral vein; one at rest and one during pharmacological stress.
45931624|NCT05133271|Other|Clinical hemodynamic and echocardiographic evaluation|"Clinical hemodynamic and echocardiographic evaluation in two stages T1 and T2, before performing the spinal anesthesia, carried out by a doctor different from the doctor in charge of the parturient in the operating room to ensure the blind hemodynamic results before the spinal anesthesia, in particular those of the passive leg raise test (PLR) :~T1: clinico-echographic evaluation in dorsal decubitus position (45 °) with cushion under the right buttock.~T2: clinico-ultrasound evaluation after performing the PLR.~Then, clinical hemodynamic evaluation during two periods T3 and T4:~T3: conditioning time of the parturient in the operating room during which clinical hemodynamic monitoring is set up and the basic values of arterial pressures (systolic, diastolic and mean) and heart rate are defined.~T4: period after performing spinal anesthesia until clamping of the umbilical cord."
45931625|NCT05120869|Behavioral|Tailored HPV Education and Professional Skills Intervention Group|The provider education and professional skills intervention will involve audio and visual content and will be delivered in the English language.
45931626|NCT05120869|Behavioral|General HPV Education and Communication Skills Control Group|The general provider education intervention will involve audio and visual content and will be delivered in the English language.
45931627|NCT05119985|Procedure|Peripheral vein cannulation|The target vein is directly identified by ultrasound, the procedure of peripheral venous catheter insertion is performed conventionally, without ultrasound guidance
45931628|NCT05119985|Procedure|Cannulation without ultrasound|Cannulation is done the conventional way without any ultrasound use.
45652096|NCT05619185|Behavioral|CRAFT Workbook|The self-directed CRAFT workbook Table 1.Partners Connect WBI has a parent and partner version that uses CRAFT to help the CP help with understanding, self-care, communication, and actions (e.g., how to react when a partner has been using substances and when they have not been using substances, how to talk to partner so that they are more likely to be heard) and includes more information about communicating than the WBI and several interactive worksheets.
45652097|NCT05619185|Behavioral|Gottman Self-Guided Resources|"To match time spent reviewing the website, CPs will receive an orientation guide that includes the website URL and a 4-week guide for how they can navigate this website for 20-30 minutes per week (e.g., read article 'It's Not My Fault!': Why Defensiveness is Damaging and write down one tool to dissolve defensiveness you're willing to try). We will send reminder emails each week to visit the website and include questions in the emails and our first online follow-up survey asking CPs approximately how many times they visited the website and how long they spent viewing content on the website. Reminder emails will be programmed such that CPs get directed automatically to the website if the CP notes no time spent on it."
45652098|NCT04998175|Procedure|ventriculo-peritoneal shunt|A ventriculoperitoneal shunt is a tube that drains excess cerebrospinal fluid into abdomen
45652099|NCT04427969|Behavioral|prone position|to lay in prone position at least 12 hour in a day at ICU
45652100|NCT04998253|Drug|Effects in oxygenation and hypoxic pulmonary vasoconstriction|"Determination of the anti-inflammatory effect. The anti-inflammatory effect is assessed with serum measurement of interleukin 6 (IL-6), C-reactive protein (CRP), ferritin, DHL (lactic dehydrogenase), taken by venipuncture on admission, at 24 and 48 hours.~The following measurements will be performed: pulmonary artery systolic and diastolic pressure (PASP, PADP respectively), central venous pressure (CVP), pulmonary artery occlusion pressure (PAOP), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), right ventricular stroke work (RVSW) and left ventricular work (LVSW). Stroke volume (and cardiac output) will be computed using the thermodilution technique averaging three consecutive injections with 10 ml of 0.9% saline solution."
45802276|NCT04349293|Procedure|Blood sampling|Collection of a 30mL peripheral blood sample in heparin at several times: during surgical and medical treatment (before surgery, before the start of mAbs and after mAbs)
45802277|NCT02805179|Radiation|High Dose Radiation|Radiation will be delivered once daily for a total of 30 fractions, five days per week.
45802278|NCT02805179|Drug|Temozolomide|Patients will receive concurrent temozolomide (75 mg/m^2 daily for 6 weeks). Adjuvant temozolomide will be given at 150-200 mg/m^2, D1-5 every 28 days for a minimum of six cycles and will be started approximately four weeks following completion of radiotherapy.
45451493|NCT04669288|Drug|Placebo|"oral placebo (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with placebo from a central pharmacy. Placebo will be reconstituted with water at the local pharmacy, and will resemble azithromycin with regards to appearance, flavor, consistency and packaging."
45451494|NCT02262520|Drug|Apixaban|
45451495|NCT02262520|Drug|Digoxin|
45802279|NCT02003053|Device|Inspiratory Muscle Trainer|
45802280|NCT02896595|Device|General Anesthesia with endotracheal tube|Patient randomized to this arm will have general anesthesia with endotracheal tube placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
45802281|NCT02896595|Device|General Anesthesia with laryngeal mask airway|Patients randomized to this arm will have general anesthesia with laryngeal mask airway placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
45802282|NCT02003911|Drug|Azithromycin|Azithromycin suspension (200mg/5mL)
45652101|NCT05289999|Device|Virtual reality headset for first injection|Performing the first ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
45652102|NCT05289999|Device|Virtual reality headset for second injection|Performing the second ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
45652103|NCT04827017|Other|follow up|follow up population
45931629|NCT05112848|Biological|NVX-CoV2373|"Alternating intramuscular (IM) (deltoid) injections of monovalent prototype vaccine premixed with Matrix-M™ adjuvant (0.5 mL) given either as~2 doses (one on Day 0 and one on Day 21 or Day 70) and an injection of placebo (0.5mL) on Day 21 or Day 70, or 3 doses (Day 0, Day 21, and Day 70)."
45931630|NCT05107466|Diagnostic Test|P300 Visually evoked potential|Measurement of the late cortical response, P300 potential to visually evoked stimuli using an oddball paradigm.
45652104|NCT03078439|Other|Medical and neuropsychological assessments|"Assessment of health status and development will be performed in specific centers at 5 and a half years. This check-up includes a complete medical examination to look for visual, hearing, motor impairment and health problems, and psychological tests using standardized tools (WPPSI IV ((Wechsler Preschool and Primary Scales Intelligence)) and NEPSY 2 tests) to assess cognitive development of very preterm children.~A parental questionnaire will be fulfilled to investigate family's social conditions, maternal health, autism spectrum disorders (Social Communication Questionnaire), the child's quality of life and behavioral development (Strengths and Difficulties Questionnaire)."
45802283|NCT02003911|Drug|Placebo|
45802284|NCT04147351|Drug|Atezolizumab Injection; bevacizumab Injection|a PD-L1 inhibitor; anti-angiogenesis
45652105|NCT05324475|Dietary Supplement|BCAA|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle) and nutritional counselling (SC) and 4 gram per day of BCAAs mixture. Ratio between the BCAAs will be Leucine/Isoleucine/Valine=2:1:1
45802285|NCT02004613|Drug|Dexmedetomidine|Dexmedetomidine
45802286|NCT02004613|Drug|Placebo|Normal saline administration matching dexmedetomidine rate of infusion
45802287|NCT02806895|Drug|JZP-110|
45802288|NCT02806895|Drug|Placebo|
45802289|NCT01754779|Drug|Placebo|Matching placebo for both aims.
45802290|NCT01754779|Dietary Supplement|Citric Acid|
45802291|NCT01754779|Dietary Supplement|Potassium Citrate|
45802292|NCT02298361|Other|Health insurance outreach IT tools|"IT tools that support Community Health Centers in children's health insurance outreach efforts (insurance outreach IT tools), adapted from tools proven to support chronic disease management."
45802293|NCT02234219|Procedure|Heart-shape anastomosis|a new operation approach for Hirschsprung disease
45802294|NCT01696513|Procedure|Suction|
45802295|NCT01696513|Procedure|Subcision|
45802296|NCT02149277|Drug|Filgrastim|The fertility specialist will inject the study medication or its placebo on the 6th day of gonadotrophin stimulation for IVF subjects. For the subjects undergoing embryo transfer, the injection will be done once the endometrial lining measure more than 8mm.
45802297|NCT02139605|Procedure|D3 Lymphadenectomy|D3 Lymphadenectomy involves surgical removal of lymph nodes from echelon or compartments 1 to 3 in gastric cancer patients
45802298|NCT02005393|Device|FICE Image Acquisition followed by NBI Image Acquisition|Images Captured with FICE Device, followed by same locations imaged with NBI Image Acquisition System
45931631|NCT05104775|Drug|GNC-035|Administration by intravenous infusion.
45931632|NCT05104073|Behavioral|Intervention|Provided with educational materials, guidelines and instructions.
45931633|NCT05089955|Behavioral|Ambient Experience|MRI examination with Ambient Experience
45802299|NCT02896907|Drug|Oxaliplatin|Given IV
45802300|NCT02896907|Drug|Irinotecan Hydrochloride|Given IV
45802301|NCT02896907|Drug|Leucovorin Calcium|Given IV
45802302|NCT02896907|Drug|Fluorouracil|Given IV
45802303|NCT02896907|Dietary Supplement|Ascorbic Acid|Given IV
45802304|NCT02005549|Drug|bevacizumab [Avastin]|15 mg/kg iv on Day 1 of each 3-week cycle, 5 cycles
45802305|NCT02005549|Drug|docetaxel|75 mg/m2 on Day 1 of each 3-week cycle, 6 cycles
45802306|NCT02005549|Drug|capecitabine [Xeloda]|950 mg/m2, orally twice daily, evening of Day 1 until morning of Day 15, followed by a 7 day rest period, every 3 weeks
45931634|NCT05079412|Other|Chest ultrasound|Chest ultrasound will be performed to eligiable (consented) patient after being on the respiratory support (NIV-NAVA vs NIPPV) for at least 24 hours. Both diaphragmatic function and lung ultrasound score will performed. Investigator interpreting the scans will be blind to patients type of respiratory support or clinical status.
45931635|NCT05075694|Behavioral|Therapeutic Touch|Therapeutic Touch performed in line with the Therapeutic Touch Practice Procedure included the following steps: centering, assessing, rebalancing, reassessing, reexamining, grounding, and closure.
45931636|NCT05075694|Other|Sham Therapeutic Touch|The control group was administered STT instead of TT for 10 minutes for successive 5 days. The practice was implemented in line with STTPP. The practice was implemented by not centering or intending to help to heal, by moving at a longer distance, and by imitating the TT practice protocol visually.
45652106|NCT05324475|Dietary Supplement|Micronutriments|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and Vitamin A 1200 mg RE, Vitamin D3 2000 IU, Thiamine B1 100 mg, Cobalamin B12 10 mcg, Ascorbic acid C 200 mg, Iron 30 mg, Selenium 100 mcg, Zinc 20 mg, Omega-3 PUFA 1 g
45931637|NCT05072197|Device|Mobile device as a support tool for the treatment of women with breast cancer undergoing chemotherapy|This study will develop a Mobile device application providing medical care information and social support for breast cancer women during their chemotherapy treatment to help them receive individually tailored information related to chemotherapy and support from healthcare professionals and peers.
45931638|NCT05059262|Drug|vimseltinib|CSF1R inhibitor
45931639|NCT05059262|Drug|Placebo|Placebo
45931640|NCT05057884|Behavioral|Breathing training|Slow nasal breathing with intermittent end-expiratory apnoea for 15 min twice per day over 12 weeks.
45931641|NCT05050578|Device|Lehfilcon A contact lenses|Commercially available, silicone hydrogel, spherical contact lenses used as indicated
45931642|NCT05050578|Device|Senofilcon A contact lenses|Commercially available, silicone hydrogel, spherical contact lenses used as indicated
45931643|NCT05050578|Device|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
45802307|NCT02897141|Device|Health Management App with symptom strategies|The mVIP group will receive a Health Management App with symptom strategies. A mobile app which includes symptom strategies from the UCSF symptom management manual.
45802308|NCT02897141|Device|Control App|The attention control group will receive an app which asked them about their symptoms but did not provide symptoms strategies
45931644|NCT05046106|Drug|MLC1501|Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
45652107|NCT05324475|Dietary Supplement|standard treatment + placebo|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and maltodextrin 4 g as placebo
45802309|NCT02216864|Procedure|Multiple Subcision|At the start of the procedure, a straight vitrectomy knife will be inserted subdermally and will be slowly advanced parallel to the dermis. Rapid advancement and retraction of the needle under the scarred area in a lancing motion will be performed to abrade the underside of the dermis followed by side to side sweeping motions attempting to break any fibrous attachments to the deeper tissues.
45802310|NCT03645356|Device|Fixed Appliances|Using an MBT-prescription of metallic brackets, patients will be treated in the conventional way
45802311|NCT03645356|Device|Clear Aligners|Using a sequence of clear aligners, patients will be give an aligner every two weeks until the completion of treatment
45802312|NCT04349696|Drug|Mitiglinide|"Day 1: one tablet of Mitiglinide 10mg with 240 ml of water approximately 5 mins before breakfast. An indwelling non-heparin catheter will be placed in an antecubital vein of the forearm or direct venipuncture will be adopted for blood sample collection at belowing time point:~For PK evaluation:~-30 (Predose), 5, 10, 15, 20, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10 hr post dose (a total of 17 samples per subject)~For PD evaluation:~-30 (Predose), 15, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0 hours post dose (a total of 8 samples per subject)"
45802313|NCT03028675|Other|MRI Scan|MRI scans will consist of a 1-hour brain scan for both patients and controls.
45802314|NCT00373997|Procedure|Esophageal and Laryngeal biopsies|one day procedure
45802315|NCT00373997|Procedure|egd with biopsy|standard of care procedure with biopsy
45931645|NCT05046106|Other|Placebo|Caramel, chocolate brown, flavor (E_1982648), dextrin
45931646|NCT05041491|Behavioral|BREAK|The BREAK intervention is a physical activity regimen.
45931647|NCT05041491|Behavioral|ONE|The ONE intervention is a physical activity regimen.
45931648|NCT05040646|Other|Delphi exercise|"During the Delphi exercise both patients and experts will participate in two anonymous online survey rounds where different items/outcomes will be presented that are possibly related to rectal cancer and the W&W program. Both groups are asked to rate each item on a 9 point likert scale with respect to the importancy of the item.~After the two subsequent rounds, participants will be invited to attend a consensus meeting, where final consensus about the most important outcomes will be reached."
45931649|NCT05039931|Drug|GNC-035|Administration by intravenous infusion.
45931650|NCT05035511|Device|tDCS|Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
45931651|NCT05029622|Drug|Triptorelin Pamoate|Triptorelin 6-month formulation for IM on day 1 and Month 6.
45802316|NCT03582020|Dietary Supplement|menu plans|menu plans, recommendations ensuring an optimal nutrient intake according the guidelines of the German Society of Nutrition
45931652|NCT05028361|Biological|mRNA COVID-19|ACIP recommended vaccine
45931653|NCT05028361|Biological|IIV4|ACIP recommended vaccine
45802317|NCT01529983|Procedure|Laser treatment|The treated sites are both lower eyelids and lateral orbits. Each side will be randomized to receive 1550nm-fractionated laser treatment on one side and the contralateral side will receive micro-focused ultrasound treatment every 6-8 weeks for a total of 2 treatments
45451496|NCT04626310|Behavioral|Dialectical behavior therapy - emotion regulation skills training|"Arm 1. Dialectical behavior therapy - emotion regulation skills training follows the emotion regulation skills DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition. This group involves 6 weekly sessions.~Arm 2. Dialectical behavior therapy - interpersonal effectiveness skills training follows the interpersonal effectiveness skills DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition. This group involves 6 weekly sessions."
45652108|NCT03078283|Other|high-fiber food type|In 3 successive experiments, usual diet will be supplemented with snack foods containing fiber of plant, fruit or grain origin.
45652109|NCT03075007|Radiation|Florbetaben F18|10Meq of Florbetaben F 18 via intravenous injection is to be used. Visit duration is approximately 3 hours.
45802318|NCT01808183|Device|Near Infrared Spectroscopy Pads|NIRS pads are commonly used as a noninvasive method of assessing deep tissue perfusion, originally designed to assess cerebral perfusion during anesthesia.
45652110|NCT03075007|Procedure|Transcranial Doppler|All participants will undergo Doppler ultrasonography that measures the velocity of blood flow through the brain's blood vessels. Visit duration is approximately 45 minutes and will be scheduled for either the same day or another day as the PET scan.
45652111|NCT03078205|Other|The dual therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
45802319|NCT02809859|Device|Fisher & Paykel Healthcare CPAP Device|Fisher & Paykel Healthcare CPAP Device
45931654|NCT05028361|Other|Placebo|Saline Control
45931655|NCT05010759|Device|NanoTherm Ablation|Iron nanoparticles are instilled into the prostate cancer lesion and then the particles are heated using a magnetic field and this heating ablates the prostate cancer lesion.
45931656|NCT05010122|Drug|Decitabine and Cedazuridine|Given PO
45931657|NCT05010122|Drug|Gilteritinib|Given PO
45451497|NCT04626310|Behavioral|Dialectical behavior therapy - interpersonal effectiveness skills training|Arm 2. Dialectical behavior therapy - interpersonal effectiveness skills training follows the interpersonal effectiveness skills DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition. This group involves 6 weekly sessions.
45451498|NCT04626310|Behavioral|Interpersonal psychotherapy|Arm 3. Non-skills-oriented interpersonal psychotherapy group follows evidence-based principles on common factors in a group therapy context. This group involves 6 weekly sessions.
45652112|NCT03078205|Other|The triple therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
45652113|NCT02638129|Drug|Naltrexone HCl/Bupropion HCl ER|Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets
45652114|NCT02638129|Drug|Placebo|Naltrexone HCl/bupropion HCl placebo-matching tablets
45652115|NCT02524275|Drug|Capecitabine|Given PO
45652116|NCT02524275|Drug|Docetaxel|Given IV
45652117|NCT02524275|Other|Quality-of-Life Assessment|Ancillary studies
45652118|NCT02524275|Other|Questionnaire Administration|Ancillary studies
45652119|NCT03079687|Drug|Olaparib tablets|Patients will receive olaparib tablets 300mg (two 150mg tablets) twice daily.
45653287|NCT03066115|Procedure|Intravenous Catheter|Two intravenous catheters will be placed for each study visit. One catheter will be used for the intravenous infusion of study drugs (L-NMMA, Ketorolac, and Ascorbic Acid). The second catheter will be used to draw intermittent blood samples at 8-specific time points throughout each study visit to ensure pharmaceutical efficacy and examine systemic physiologic blood variables of interest.
45802320|NCT04768309|Other|Ex vivo exploration of the effect of a probiotic over precursor indole production|Fresh feces in chronic kidney patients and healthy volunteers will be collected. The feces will be instilled in artificial intestine with and without selected probiotics and production of uremic toxins will be measured.
45931658|NCT05010122|Drug|Venetoclax|Given PO
45931659|NCT05003414|Device|GMK Sphere cementless Knee Replacement|Performance of Total Knee Arthroplasty (TKA) with GMK Sphere cementless Knee Replacement
45931660|NCT05002335|Device|Medacta Shoulder System|Performance of Total Shoulder Arthroplasty (anatomic/reverse) with Medacta Shoulder System
45931661|NCT05001594|Device|Active vibratory knee device|The active, wearable device is placed above and below the knee joint. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide vibratory feedback to the subject.
45931662|NCT05000788|Behavioral|Qigong|Eight-Section Brocades Practice: The treatment group will undergo an 8-week Eight-Section Brocades intervention program consists of a total of 16 group training sessions with two 1-hour sessions per week. The treatment group participants will be provided with health qigong exercise in a group format led by qualified qigong instructors. All the health qigong instructors will be trained by a certified Traditional Chinese Medicine (TCM) practitioner with an expertise in health qigong and they are required to pass the certification examination before delivering health qigong intervention at the clinical settings. The Eight-Section Brocades protocol will be used in this study because it is easy to learn by the participants and the clinical effects on psychosocial health were evidenced in previous RCTs. A complete cycle of the Eight-Section Brocades took 12 minutes for completion, which consists of eight sequential and simple forms of movements.
45931663|NCT05000788|Behavioral|Exercise|Exercise Program: Participants in the control group will attend a physical exercise program for 8 weeks (1-hour sessions, 2 times a week). The exercise program will incorporate aerobic fitness, strength training, body weight workouts, balance training, flexibility and stretching into the training plan. The exercise program is provided in a group format, which will be led by qualified physical trainer.
45931664|NCT04994015|Device|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by site clinician/physician/genetic counselor.
45931665|NCT04992936|Dietary Supplement|Extract from the wine industry|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
45931666|NCT04992936|Dietary Supplement|Placebo|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
45652120|NCT04997551|Drug|Colchcine|"In patients not taking lopinavir / ritonavir or any other CYP3A4 or P-glycoprotein inhibitor drugs:~Day 1: 1 single dose of 1 mg orally, in a single dose.~Days 2 to 6: 0.5 mg every 12 hours v.o.~Days 7 to 14: 0.5 mg / 24 hours v.o. In patients taking drugs that inhibit the CYP3A4 system or the P-glycoprotein, these drugs will be attempted to be discontinued. The dose in these cases will be: o 0.5 mg every 72 hours v.o. while taking the drug that interacts.~or 0.5 mg every 24 hours v.o. when, after suspending the interacting drug, at least 5 half-lives of the suspended drug have elapsed, from the last intake of said drug (in the case of lopinavir / ritonavir this would be a total of 24-30 hours) until the 14th day.~In patients older than 80 years or patients with CKD-EPI estimated glomerular renal failure filtration rate between 30 and 50 ml / min / 1.73 m2), the colchicine / placebo dose will be:~o Days 1 to 14: 0.5 mg / day"
45652121|NCT04997707|Drug|Propofol Abbott|in a rate of 75-100 μg/kg/min in P group, and 25μg/kg/min in BA group
45802321|NCT04116619|Other|Guided Imagery Laboratory Session|"On days 1, 2 and 3 of the study, subjects will come to the research testing rooms and be provided with lunch before beginning the laboratory session. After a 40-minute adaptation period, two blood samples will be drawn before imagery (BASELINE). After the second blood draw, a 5-minute baseline period will follow to assess continuous pulse rate, BP, and HRV assessments. The subject and research staff conducting the sessions will be blinded to the order and content of the imagery condition. In each recording, the subjects will listen to the scripts over headphones and will vividly imagine the described situation, 'as if' it were happening right now, for 5 minutes. The research nurse will take a blood draw immediately after the imagery (IMAGERY). After that, three recovery blood draws will be performed at 15-minute intervals (RECOVERY). We will analyze the total of six blood samples for levels of cortisol."
45802322|NCT02810327|Genetic|Genetic Sequencing|Sequencing of the SERPINA1 gene
45802323|NCT04349462|Diagnostic Test|VideoFlurosocopy Swallow Study|VFSS is a radiological examination that can identify the presence, nature and severity of any abnormalities in oropharyngeal, laryngeal and upper esophageal swallow physiology. The VFSS will be administered via a standardized protocol by a registered speech-language pathologist (SLP). During the VFSS, the patient is seated upright and swallows a variety of consistencies (eg. liquids, semisolids and solids) and volumes of barium-coated foods. A dynamic fluoroscopic image will be digitally captured and recorded.
45802324|NCT04349462|Diagnostic Test|Water Sip Test|The steps of the water sip test include; 1. The patient will be given 5 ml of water, and if tolerated 20 ml followed by 50 ml of water (thin fluid) and the patient is assessed for cough/chocking during or after swallowing, wet or weak cough after swallowing. 2. The patient is asked to produce sustained vowel /a/ before and after swallowing of water and voice change after swallowing will be observed and recorded.
45802325|NCT02810873|Device|Positron Emission Mammography|Undergo PEM Positron Emission Mammography scan
45802326|NCT02810873|Device|Positron Emission Tomography|Undergo PET Positron Emission Tomography scan
45931667|NCT04990817|Other|Average American Diet With SoFAS Replaced With Avocado|Replacing energy from solid fats and added sugars (SoFAS) with Avocado as part of an average American diet
45931668|NCT04990817|Other|Average American Diet|Average American diet based on macronutrient analyses from the most recent Nutrition and Health Examination Survey.
46073256|NCT02827812|Other|Home-Based telemedicine program|"A nurse-tutor will follow patients through structured telephone appointments, collecting information about disease status and symptoms, offering advice regarding diet, lifestyle and medications and suggesting changes in therapy, according with the neurologist. The patient's clinical data and any suggestions made will be filled in a personal health electronic record.~A physiotherapist-tutor will supervise the patient's home-based individualized rehabilitation program, through scheduled videoconferences."
45451499|NCT04623268|Diagnostic Test|Ultrasound and questionnaire|One invititation to identified adult offspring to have an ultrasound to detect an AAA. The prevalence in this Group (strata for sex) will be compared to a random selected matched Control group
45802327|NCT02810873|Radiation|Fludeoxyglucose F-18|Undergo Fludeoxyglucose F-18 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
45931669|NCT04981847|Behavioral|Dietary Intervention Meetings|Participants will attend classes once per week for 3 months.
45931670|NCT04962360|Dietary Supplement|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
45451500|NCT05255926|Drug|68Ga-pentixafor|All participants undergo intravenous administration of 68Ga-pentixafor (1.85-3.71 MBq/kg body weight).
45451501|NCT05255926|Device|PET/CT|PET/CT imaging is performed 1 h after intravenous injection of 68Ga-pentixafor.
45451502|NCT02233504|Drug|Exjade® (deferasirox, ICL670)|
45931671|NCT04962360|Dietary Supplement|Placebo|Low caloric formula (Powder added to water) without added vitamins and minerals
46073257|NCT05335538|Diagnostic Test|Patients monitored with TruGraf and TRAC testing|This is an observational study there are no protocol mandated interventions. TruGraf and TRAC results will be utilized in conjunction with standard of care assessments to determine patient management.
45451503|NCT02262598|Drug|Telmisartan|
45451504|NCT02262598|Drug|Hydrochlorthiazide (HCTZ)|
45451505|NCT02262598|Drug|Telmisartan/HCTZ fixed dose|
45451506|NCT04569058|Device|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
45451507|NCT04542382|Drug|Rosuvastatin|"Rosuvastatin will be administered as follows:~Day 1: single dose of 10 mg Rosuvastatin tablet."
45931672|NCT04962334|Dietary Supplement|Nutritional supplementation standardized formula.|Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
45802328|NCT02810873|Drug|Copper Cu 64 TP3805|Undergo copper Cu 64 TP3805 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
45802329|NCT04492358|Drug|Colchicine|Colchicine: ideal dose of 0.3 mg/kg/day (or the dose that approximates that adjusted for age, weight and kidney function, and 0.5 mg and 1 mg tablets)
45802330|NCT04492358|Drug|Prednisone tablet|Prednisone 60 mg/day, in a single dose, during 3 days
45802331|NCT04492358|Drug|standard of care|The standard treatment used in each site will be administered to the patients assigned to the control group.
45802332|NCT04480970|Device|Nasogastric tube placement|All patients enrolled in the study will have a nasogastric tube placed for gastric decompression.
45931673|NCT04962334|Dietary Supplement|Placebo|Low caloric formula (powder added to water) without added vitamins and minerals
45931674|NCT04941963|Diagnostic Test|Chest ultrasound|Patients will undergo chest ultrasound scanning after obtaining parent's consent. each enrolled patient will have one chest ultrasound to assess diaphragmatic function and lung ultrasound severity score.
45451508|NCT04542382|Drug|Rosuvastatin (Inhibitor arm)|"Rosuvastatin will be administered as follows:~Day 8: single dose of 10 mg Rosuvastatin tablet."
45451509|NCT04542382|Drug|Eltrombopag|"Eltrombopag will be administered as follows:~Day 8: single dose of 75 mg Eltrombopag tablet."
45451510|NCT02603614|Drug|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
45802333|NCT04470128|Drug|Stage I: HSK21542 0.5 μg/kg|intravenous injection
45451511|NCT02603614|Drug|Placebo|Placebo control
45652122|NCT04997707|Drug|Sevoflurane Inhalation Solution|in BA group will be calculated by age-adjusted end - tidal MAC as follows: for age of 18-25 years, 26-40 years and ≥40 years MAC will be 2.6%, 2.2% and 1.8% respectively then final concentration to be delivered will be 0.2% lower than calculated half MAC.
45802334|NCT04470128|Drug|Stage I: HSK21542 1 μg/kg|intravenous injection
45451512|NCT03723538|Drug|Dexmedetomidine|patients undergoing tracheal resection and reconstruction surgery were enrolled in this prospective observational pilot study to evaluate dexmedetomidine-based sedation after tracheal surgery in an Intensive Care Unit (ICU). Patients remain electively intubated with an uncuffed nasal endotracheal tube, awake and exhibit spontaneous breathing The neck was maintained in flexion through chin-to-chest sutures. Infusion of dexmedetomidine was started from a dosage of 0.7 μg kg-1 h-1 followed by dose titration to the target level of the sedation Richmond Agitation Sedation Scale, (RASS) score -1/-2 using a dose range of 0.2-1.4 μg kg-1 h-1.
45451513|NCT02234674|Other|Current intensive CDP|"Standard Intensive CDP including~manual lymph drainage,~pressotherapy and~bandaging"
45451514|NCT02234674|Other|intensive CDP where Stendo pulsating suit replaces pressotherapy|The intervention consist to perform daily during 5 days an intensive CDP where pressotheray is replaced by Stndo pulsating suit sessions.
45451515|NCT01337674|Drug|MK-4618|Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
45451516|NCT01337674|Drug|Placebo for MK-4618|Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
45451517|NCT01337674|Drug|Metoprolol|Previously prescribed daily dose of open-label metoprolol for the duration of the study
45451518|NCT01337674|Drug|Amlodipine|Previously prescribed daily dose of open-label amlodipine for the duration of the study
45451519|NCT02600494|Drug|ITI-007 (Lumateperone)|
45451520|NCT02600494|Drug|Placebo|
45451521|NCT02262676|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients treated by Physicians under approved local prescriptions
45451522|NCT02234830|Device|Exoseal closure device|Closure device for femoral artery access closure
45451523|NCT02234830|Device|Angioseal closure device|Closure device for femoral artery access closure
45451524|NCT02233582|Drug|Ibuprofen|We are simply testing if taking ibuprofen upon ascent to altitude is associated with a delayed acclimatization response to the high altitude hypoxia.
45451525|NCT02233582|Drug|Sugar pill|
45652123|NCT04997707|Diagnostic Test|transcranial motor evoked potential(Tcm|using NIM-SPINE™ SYSTEM (2005 Medtronic Sofamor Danek USA, Inc.). The stimulation used is a train-of-five square wave stimulation, 2ms inter-stimulus interval, 500 μs width and 40-220 mA intensity which can be increased with 10 mA steps till muscle answer potential is recorded.
45653288|NCT03066115|Procedure|Transcranial Doppler Ultrasound|MCAv will be measured via the transtemporal window while BAv will be measured through the transforaminal window with 2-MHz transcranial Doppler ultrasound probes (TCD, Neurovision model 500M, Multigon Industries, Inc.; Yonkers, NY, USA)
45653289|NCT04212039|Drug|Saline Solution|0.5 ml/kg saline
45653290|NCT04212039|Drug|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
45931675|NCT04940949|Drug|Lu AF90103|Lu AF90103 - powder for solution for infusion
45451526|NCT02580370|Biological|Botulinum toxin type A|Topical botulinum toxin type A
45931676|NCT04940949|Drug|Placebo|Placebo - powder for solution for infusion
45931677|NCT04927377|Behavioral|AI4DM|Those in the AI4DM intervention arm will receive weekly and bi-weekly calls for six months, access to home and online technology, diabetes-related multimedia educational content, a technology package including a voice-assistive device, wireless glucometer, and wrist-worn activity monitor
45451527|NCT02580370|Biological|Placebo comparator|Topical placebo comparator
45451528|NCT05208112|Drug|M6229|Continuous intravenous infusion of M6229, a low-anticoagulant fraction of heparin. Dose-escalation is based on a modified continual reassessment method (mCRM) including escalation with overdose control (EWOC).
45931678|NCT04927377|Behavioral|Attention-control|Those in the Attention-control Group will receive telecoaching calls at the same frequency of the Intervention Group. Coaching calls will focus on general wellbeing, rather than diabetes-related topics. The Attention-control Group will serve as an untreated comparison group for the Intervention Group.
45931679|NCT04921514|Behavioral|SASRQ questionnaire|"During an interview with a trained psychologist, the presence of acute stress will be assessed by the SASRQ test within one week of the occurrence of a sudden recovered death.~The diagnosis of acute post-traumatic stress disorder is made according to the presence of at least three dissociative symptoms out of five, and other symptoms of re-experiencing, avoidance or marked anxiety or hypervigilance. Each symptom is thus evaluated dichotomously. A symptom is present if the intensity of the response is 3 or more (0 from 0 to 2 and 1 from 3 to 5)."
45931680|NCT04921514|Behavioral|PCL-5 with LEC-5 questionnaire|"This questionnaire will be completed during an interview with a psychologist trained in the protocol, 3 months after the sudden death.~The PCL-5 is a 20-item self-report questionnaire that assesses the 20 symptoms of PTSD according to the DSM-V. It is associated with the LEC-5 questionnaire.~The self-reported scale uses ratings of 0 to 4 to assess each of the symptoms.~A threshold of 38 on the PCL-5 seems reasonable to suggest the presence of PTSD."
45931681|NCT04916418|Drug|Placebo|TTP block with initial dose of placebo (NaCl0.9%) 20 ml per catheter (total volume 40ml), followed by 20 ml per catheter every 8 hours until 72 hours from the first dose has passed.
45451529|NCT02233660|Other|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapies including maneuvers targeted to the areas anatomically related to the median nerve (i.e., cervical spine, shoulder, elbow and wrist) of 30min of duration, once per week.
45931682|NCT04916418|Drug|Ropivacaine|TTP block with initial dose of ropivacaine 0.5% (5 mg / ml) 20 ml per catheter (total volume 40ml), followed by doses of ropivacaine 0.2% (2 mg / ml) 20 ml per catheter every 8 hours until 72 hours from the first dose has passed.
45931683|NCT04906148|Other|Advertisement content (explicit vs. implicit)|Participants will be randomly assigned to view an advertisement with either implicit or explicit harm messaging content
45451530|NCT02233660|Procedure|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
45451531|NCT02233816|Biological|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
45802335|NCT04470128|Drug|HSK21542 0.5 μg/kg|intravenous injection
45931684|NCT04906148|Other|Advertisement content (true vs. misleading)|Participants will be randomly assigned to view an advertisement with either true or misleading messaging content
45931685|NCT04899518|Drug|ALY688 Ophthalmic Solution|Ophthalmic Solution
45802336|NCT04470128|Drug|HSK21542 1 μg/kg|intravenous injection
45931686|NCT04893096|Drug|MOR202|Each patient will be treated for 24 weeks and received a total of 9 doses. During the first treatment cycle, MOR202 will be administered weekly. For the following 5 months, patients will receive one dose every 4 weeks.
45931687|NCT04892511|Other|Adjusted medication|"In patients randomized to perfusion optimization, medication will be adjusted to maintain blood pressure according to the degree of recanalization:~Patients with TICI 2b: systolic blood pressure 140-160 mmHg.~Patients with TICI 2c-3: systolic blood pressure <140 mmHg.~Hypotensive drugs will be used when necessary. Intravenous labetalol is the treatment of choice, administered as a bolus or intravenous infusion. Alternative: urapidil (bolus or continuous infusion pump). If both drugs cannot be used or are insufficient, sodium nitroprusside can be used.~Hypertensive drugs for TICI2b patients whose target pressure is 140-160mmHg and are below this range. Initially, a bolus of physiological saline or 100cc Plasmalyte® will be administered. If this treatment is not effective enough (blood pressure measurements persist <140 mmHg), intravenous phenylephrine will be administered."
45451532|NCT02233816|Biological|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
45451533|NCT02233816|Biological|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
45451534|NCT02233816|Biological|Placebo|A single dose of placebo
45451535|NCT02234908|Behavioral|Contacts|Household contacts who come to the study clinic, present a referral card, and complete TB symptom screening will receive a shopping voucher of $5-10 value.
45451536|NCT02234908|Behavioral|Index|Index subjects will be entered in a prize lottery if any of their contacts complete TB symptom screening at the study clinic.
45451537|NCT02234986|Drug|ENMD-2076|250 mg oral dose, QD for 28 day cycles
45451538|NCT02259556|Biological|CART30|Cells will be infused 1 day after the completion of conditioning regimen.
45451539|NCT02259634|Behavioral|Patient Navigation|Motivational Interviewing
45652124|NCT04997863|Device|Sericin hydrogel sheet impregnated with EBN extract|Sericin hydrogel sheet impregnated with EBN extract will be used as a primary dressing for preventing scar development at one-half of the STSG donor site. Then, the donor site will be covered with adhesive tape (secondary dressing). The application of primary and secondary dressings will be done once daily after shower in the morning or evening. Both dressings will be recommended to wear over the donor site for 8-12 hours per day. Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day. The duration of the dressing application will be 6 months.
45653291|NCT04716413|Drug|Dsuvia|Subject will receive up to 2 doses of Dsuvia. The first dose will be intra-op and the second dose will be post-op (if needed)
45802337|NCT04470128|Drug|HSK21542 2 μg/kg|intravenous injection
45802338|NCT04470128|Drug|Placebo|intravenous injection
45451540|NCT02259712|Other|Hipopressive exercises|45 minutes treatment by hipopressive exercises 2 times per week during 8 weeks. They will be doing in different positions: standing, kneeling, sitting and lying. The patient will be teach a total of 30 exercises. In the week number 8 the women with the physical therapist will choose 3 exercises that will be done daily at home during 20 minutes.
45802339|NCT03488420|Drug|Edoxaban Pill|Subjects will be taking edoxaban 30 or 60 mg
45802340|NCT03447704|Drug|BCD-085|120 mg of BCD-085 subcutaneously at week 0,1 and 2 every other week
45802341|NCT03447704|Other|placebo|2 ml of placebo subcutaneously at week 0,1 2 and every other week, starting from week 16 - 120 mg of BCD-085 subcutaneously at week 16,17 and 18 every other week
45931688|NCT04890132|Behavioral|VOR precision training|Subjects are rotated in yaw using a pseudo-random sum of sines motion (0.5 - 2.0 Hz), view a monitor 1 m away, and are instructed to move their avatar through a maze using a joystick. The size of the maze becomes smaller in real-time when they are successful so that the patient is at the limit of their acuity. This task requires patients to optimize dynamic visual acuity to threshold-level images while rotating. We predict that VOR precision will gradually improve during training and that after training VOR precision will be better than the pre-training data. The sham task is as above but the acuity required to see the maze will set at a much larger level so baseline visual precision will be adequate to perform the task easily.
45931689|NCT04888598|Diagnostic Test|Optical Coherence Tomography (OCT) Angiography|Measurement of retinal vessel density and distribution in the macula using new generation OCT device
45931690|NCT04882527|Device|Non-invasive brain stimulation|Stimulation will be applied once per subject with one mA for 20 minutes over either the left inferior frontal lobe, the right inferior frontal lobe or the right superior parietal lobe.
45802342|NCT02901275|Drug|Within-subject test of blinded study medications|Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
45652125|NCT04997863|Device|Placebo hydrogel sheet|Placebo hydrogel sheet will be used as a primary dressing for preventing scar development at another half of the STSG donor site. Then, the donor site will be covered with adhesive tape (secondary dressing). The application of primary and secondary dressings will be done once daily after shower in the morning or evening. Both dressings will be recommended to wear over the donor site for 8-12 hours per day. Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day. The duration of the dressing application will be 6 months.
45802343|NCT01661426|Behavioral|Low-Carbohydrate Diet|Counseling/instruction on how to follow a healthy low-carbohydrate diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
45802344|NCT01661426|Behavioral|Low-Fat Diet|Counseling/instruction on how to follow a healthy low-fat diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
45802345|NCT02811419|Device|i-scan|examination will be performed with i-scan digital enhancement
45802346|NCT02811419|Device|standard high-definition white light|examination will be performed with high-definition white light
45931691|NCT04882527|Device|Sham stimulation|The electrode positions and the attachment procedures correspond to those of real tDCS but the electrical current will only be ramped up to 1 mA and switched off completely after 30 s of stimulation.
45931692|NCT04879017|Drug|FHD-286|FHD-286 as a single agent
45652126|NCT05010889|Procedure|Peroral endoscopic myotomy (POEM)|POEM is performed as previously described by Inoue et al (Endoscopy 2010), including four main steps mucosal incision, submucosal tunneling, myotomy and mucosal entry closure.
45652127|NCT05010499|Drug|Levobupivacaine|femoral nerve block receives 20 ml of levobupivacaine 0.25%
45652128|NCT05010499|Drug|Levobupivacaine|Fascia iliaca block receives 40 ml of levobupivacaine 0.25%
45652129|NCT05010187|Behavioral|Behavioral: Motivational Interview (MI)|Single-session, brief motivational interview.
45802347|NCT02811965|Other|Pillow Condition 1|The heel is offloaded by placing the heel on a standard hospital pillow.
45802348|NCT02811965|Other|Pillow Condition 2|The heel is offloaded by placing a standard hospital pillow under the calf suspending the heel above the hospital bed mattress.
45802349|NCT02811965|Device|Heel Foam Pillow|An economy heel offloading device constructed of egg shell foam.
45802350|NCT02811965|Device|Offloading Device A|Heel offloading device that utilizes open cell foam to offload the heel. Device has a published clinical study demonstrating effectiveness at reducing heel ulceration rate.
45802351|NCT02811965|Device|Offloading Device B|Heel offloading device that utilizes pressure absorbing filling to offload the heel. Device has a published clinical study demonstrating effectiveness at reducing heel ulceration rate
45802352|NCT02811965|Device|Offloading Device C|Heel offloading device that utilizes a similar pressure absorbing filling to Offloading Device B; however this device does not have published clinical literature demonstrating effectiveness at reducing heel ulceration in the clinic.
45931693|NCT04857333|Diagnostic Test|CT scan|For patients with low-risk pulmonary nodules, follow-up CT scan is recommended
45931694|NCT04857333|Drug|Antibiotics|For pulmonary nodules with features of infectious disease, antibiotics is recommended
45931695|NCT04857333|Procedure|Surgical Resection|For persistent high-risk pulmonary nodules, surgical resection is recommended
45652130|NCT05010187|Behavioral|Behavioral: Health Coaching (HC)|Single-session health coaching.
45652131|NCT03075241|Drug|Zolpidem|Zolpidem tablets, 10mg, 10pm (before bedtime) for 14 nights
45652132|NCT03075241|Drug|Zoplicone|Zoplicone tablets, 7.5mg, 10pm (before bedtime) for 14 nights
45652133|NCT03075241|Drug|Placebo|Inactive or inert pill which will be used as a comparator
45931696|NCT04856449|Behavioral|Dialectical Behavioral Therapy Skills Training|DBT skills training consists of a 6 months training in mindfulness, emotion regulation, interpersonal effectiveness and distress tolerance.
45931697|NCT04856449|Behavioral|EMDR|EMDR sessions will be conducted to reprocess trauma-related memories.
45931698|NCT04855695|Drug|Acalabrutinib|"Each study drug is given according to a different schedule:~Acalabrutinib: Oral, dosage per protocol, start cycle 1 and beyond according to schedule outlined in protocol"
45802353|NCT01637051|Device|Zimmer NexGen® Trabecular Metal Technology (TMT), Monoblock|"A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert."
45652134|NCT03074929|Behavioral|Novel risk communication|The investigators will develop novel risk communication messages to communicate the risks of childhood obesity to parents of children with obesity. The investigators will consider several novel approaches around message content and framing, but primarily, we propose using microsimulation models to forecast a child's long-term health risks, based on his age, race, gender, BMI, and family history of CVD.
45931699|NCT04855695|Drug|Venetoclax|Venetoclax: oral. daily, dosage per protocol, start cycle 3 and beyond according to schedule outlined in protocol
45931700|NCT04855695|Drug|Obinutuzumab|Obinutuzumab: intravenous infusion, dosage per protocol, drug during cycles 2 and beyond according to schedule outlined in protocol
45652135|NCT04997083|Device|Maxillary Expander with Differential Opening (EDO)|The EDO is designed with two expansion screws positioned transversely. When more expansion is required between the canines, the anterior screw can be further activated. Both expansion screws can be activated to open in a parallel configuration. Pivoting corner screws allow for different amounts of expansion without significant risk of binding during activation.
45652136|NCT04997083|Device|Petit face mask|The face mask is anatomical, multi-adjustable, lightweight and an ideal therapeutic alternative for the correction of Class III malocclusion. It consists of forehead cap, chin cap, and cross bar.
45931701|NCT04855136|Biological|BB2121|CAR T Cell Therapy
45652137|NCT04994119|Drug|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
45652138|NCT04994119|Drug|Warfarin|Oral Warfarin (Coumadin) 5 mg film coated tablets
45652139|NCT03074851|Dietary Supplement|low sodium salt|To give free low sodium salt intervention for 2 months
45652140|NCT03074851|Other|informational intervention|to give reporter informational intervention.
45652141|NCT01658943|Drug|Akt Inhibitor MK2206|Given PO
45652142|NCT01658943|Drug|Fluorouracil|Given IV
45652143|NCT01658943|Drug|Oxaliplatin|Given IV
45652144|NCT01658943|Drug|Selumetinib|Given PO
45931702|NCT04855136|Drug|CC-220|Cereblon (CRBN) E3 ligase modulatory compound (CELMoD)
45931703|NCT04855136|Drug|BMS-986405|gamma secretase inhibitor (GSI)
45931704|NCT04855032|Behavioral|Reactive Perturbations|A novel device will be used to apply controlled mediolateral perturbations to participants' trunk as they walk on a treadmill, requiring reactive responses to avoid a loss of balance. All perturbations will have a duration of 200 ms, and will be applied immediately after onset of the swing phase with either the paretic or non-paretic leg. If in a given training session, a participant does not experience any losses of balance, the perturbation magnitude will be increased in the next training session. Perturbations will begin at 3% body weight (BW), and will progress in increments of 3% BW up to a maximum of 15% BW. The structure of the Reactive perturbation session will be identical to that used for Proactive perturbation training sessions, including overground trials, treadmill trials without perturbations, and Perturbed and Catch trials in which Perturbations are delivered.
45931705|NCT04855032|Behavioral|Proactive Perturbations|A novel device will be used to perturb the relationship between pelvis motion and step width by applying mediolateral forces to participants' legs. Participants will first perform a 3-minute overground walking trial at their self-selected speed, in which they do not interact with the perturbation device. Participants will then perform a 3-minute treadmill walking trial at their self-selected speed, in which they again do not interact with the perturbation device. Participants will then perform a series of alternating 3-minute Perturbed and Catch trials, all at their self-selected speed. For the Perturbed trials, perturbations will be delivered in each step throughout the trial. For the Catch trials, perturbations will cease for the final minute of walking. A total of 5 Perturbed and 5 Catch trials will be performed. Finally, participants will perform a 3-minute overground walking trial at their self-selected speed, in which they do not interact with the perturbation device.
45931706|NCT04854603|Other|Food|Dairy products with regular and reduced sugar content and water control.
45931707|NCT04844879|Device|NextAR TKA system|The NextAR TKA system is a surgical guidance system which measures intra-operatively the effect of prosthesis alignment and positioning on soft tissue balance.
45931708|NCT04837053|Other|Digital decision aid for physicians and patients|The intervention consists of three parts: (1) the EKIT tool provides a systematic presentation of individual patient and disease-specific information; (2) it visualizes the fulfilment of the indication criteria recommanded in corresponding german guideline; (3) it presents health information about total knee replacement.
45652145|NCT02600819|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
45652146|NCT02600819|Drug|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily
45652147|NCT03077971|Behavioral|ACT Self-Help|Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach
45652148|NCT03077971|Behavioral|ACT Self-Help with Telephone Support|Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach alongside weekly telephone support calls
45652149|NCT04433533|Drug|Rosuvastatin 20|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of Rosuvastatin 20mg Monotherapy.
45652150|NCT04433533|Drug|Rosuvamibe 10/10|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin10mg/ezetimibe 10mg combination Therapy
45652151|NCT04812275|Procedure|Skin closure|Skin closure
45652152|NCT04996459|Drug|Tislelizumab|Tislelizumab 200mg iv q3w
45652153|NCT04811963|Device|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
45802354|NCT01637051|Device|Zimmer NexGen® Trabecular Metal Technology (TMT), Modular|"A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert."
45802355|NCT01066663|Drug|pyrimethamine|Taken orally once a day
45931709|NCT04837053|Other|Routine care|Care as usual within the included study sites.
45931710|NCT04836936|Device|Auriculotherapy cryopuncture device without nitrogen gas|Auriculotherapy cryopuncture device without nitrogen gas will be administered. Application of this placebo device will be performed in the same manner as the treatment, but without the expulsion of nitrogen gas.
45802356|NCT04093921|Behavioral|MET-based therapy|see previous
45931711|NCT04836936|Device|Auriculotherapy cryopuncture device with nitrogen gas|Auriculotherapy cryopuncture device with nitrogen gas will be administered. The tip of the cryopuncture will be sanitized and placed on each treatment point of the ear, releasing a spurt of nitrogen gas for 2 seconds on each point (6 points total).
45931712|NCT04820868|Device|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
45931713|NCT04814264|Biological|Red blood cells|All transfused red blood cells will be obtained from Canadian Blood Services and will be the standard red blood cell products currently provided in Canada.
45931714|NCT04810390|Drug|Bilastine|Ophthalmic solution 0.6%
46073258|NCT04243668|Procedure|ANTI REFLUX MUCOSAL ABLATION THERAPHY (ARMA)|"In patients fulfilling inclusion criteria and willing for ARMA, the procedure involves ablation of the mucosa of the EGJ using TT knife (ARMA). Subsequently, saline solution mixed with indigo-carmine is injected at the submucosa level to raise a submucosal bleb, followed by ablation of the mucosa along the lesser curvature using TT knife.The approximate duration of the procedure is 40min.~Follow up will include objective evaluation of reflux disease with: upper endoscopy, esophageal manometry, pHmetry,reflux questionnaire."
46073259|NCT04244526|Other|Talking a urine sample|Just taking a urine sample
45931715|NCT04810390|Drug|Placebo|Ophthalmic solution
46073260|NCT02827656|Drug|Decapeptyl|luteal support as described and vaginal progesterone 200 mg 3 times a day
45597961|NCT03524443|Behavioral|Art Therapy treatment|"The main objective is to describe the evolution at 3 months on the alexithymic dimension in the course of a treatment in art therapy, in patients with anorexia nervosa or bulimia.~Art therapy is a generic term grouping different artistic disciplines adapted and used for therapeutic purposes. It is through commitment to creative work that the therapeutic work of elaboration and reflection takes place in contrast to verbal psychotherapies and mediated psychotherapies that use speech as the main therapeutic tool. All forms of practice referring to categories of art can be used: painting, music, modeling, dance, theater and writing"
45652154|NCT04993105|Other|Exercise + Graston.|"In graston + exercises treatment will be same but after exercises added with proper application of graston which included application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin.The Graston tools will be then used to mobilize the tissues of the triceps surae and plantar foot. In areas of increased tissue restriction, more aggressive pressure with graston was applied using increased force and shorter strokes over the areas of restrictionIce was offered as needed for pain management after each session. This will be continued for three sessions. NPRS score, score on FADI and dorsiflexors range will be assessed after treatment of two weeks. Along with conventional treatment.~."
45931716|NCT04788446|Behavioral|Mini-flipped Game-based Learning|The intervention was 8 weeks, forty minutes adjusted Mediterranean diet learning plan once a week, which includes the 20 minutes for the Mediterranean food table game, and the 20 minutes for the Mediterranean diet nutrition course. The topic of the course includes the relationship between Mediterranean diet and dementia, knowledge of Mediterranean diet, how to integrate local food ingredients into the Mediterranean diet, etc.
45931717|NCT04788446|Behavioral|Balanced diet|Given a balanced diet nutrition health education manual for the aged.
46073261|NCT02827656|Drug|hCG luteal support|luteal support as described and vaginal progesterone 200 mg 3 times a day
45652155|NCT04993105|Other|exercise only|gastrocnemius and plantarstretching
46073262|NCT02829450|Other|peritoneal ultrafiltration|Peritoneal fluids should be inserted intraperitoneally for several hours dwell
46073263|NCT02826954|Other|Upper airway assessment, including nasal biopsy|
46073264|NCT02829762|Other|Program of geriatric and Social intervention associated techniques of Domotic and Remote assistance|Implementation of social aids, a monthly social monitoring and home improvement with domotic techniques and remote assistance
46073265|NCT04246398|Other|FMT|"Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.~Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration."
46073266|NCT04246398|Other|FMT - placebo|"Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.~Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration."
46073267|NCT02827578|Drug|Tamsulosin|Tamsulosin
46073268|NCT02827578|Drug|Solifenacin|Solifenacin
46073269|NCT02827578|Drug|Solifenacin placebo|Solifenacin placebo
45931718|NCT04787926|Device|Locking Solution|The total duration of the study treatment period will be 90 calendar days, from Visit 1 Pre-Instillation to the last study-related assessment. Two to 3 instillations (1 per lumen per visit) of DuraLock-C 4.0%, 30.0%, or 46.7% (equivalent to the catheter manufacturer's prescribed priming volume) will be instilled 1 to 3 days apart (with a HD schedule of 3 to 4 times per week); each instillation of CLS will remain in the CVC for approximately 24 to 72 hours ± 12 hours, based on their practice preferences. EOS will take place at the patient's next scheduled dialysis session.
45931719|NCT04785118|Drug|Hyoscine N Butylbromide|Patients will receive IV hyoscine butyl-bromide 20 mg in 2 ml, just before spinal anaesthesia.
45931720|NCT04785118|Drug|Ondansetron|Patients received IV ondansetron 4 mg in 2 ml, just before spinal anaesthesia.
45802357|NCT04093921|Behavioral|Standard Care|To include all recommended outpatient treatments
45931721|NCT04785118|Drug|Saline|Patients received 2 ml of IV normal saline as a placebo just before spinal anaesthesia.
45931722|NCT04775524|Behavioral|Storytelling Through Music (STM)|6 week expressive arts-based program
45931723|NCT04775524|Behavioral|Wait List / Storytelling Through Music-Hybrid|2 week song listening program
45931724|NCT04772131|Device|Desara® One Single Incision Sling|Single incision sling
45931725|NCT04772131|Device|Desara® Blue Transobturator Sling|Standard mid-urethral sling
45931726|NCT04763980|Other|Educational Intervention|Participate in educational session with health coach
45931727|NCT04763980|Other|Genetic Testing|Undergo genetic testing
45931728|NCT04763980|Other|Survey Administration|Complete survey
45931729|NCT04752618|Behavioral|P-STAIR|PCIT+ STAIR
45451541|NCT02259712|Behavioral|Therapeutic education.|"The therapeutic education will be doing during the 8 weeks of treatment. In the first day the knowledge and the briefs of the pelvic floor dysfunction will be assessed. Dietary and behavioral habits will also be discussed. In the second day anatomical and physiological explanation of the pelvic girdle will be the priority. In the third day will be explained the signs and symptoms of the different pelvic floor dysfunctions. In the four day will be analyzed the risk factors that may cause or worsen pelvic floor dysfunctions.~In the fifth day will be begun to correct the bad habits. In the last day will be reviewed the knowledge and new habits acquired during the treatment. In all treatment days will be discussed the doubts of the participant."
45451542|NCT02259712|Other|Pelviperineal physiotherapy|45 minutes physical therapy treatment 2 times per week during 8 weeks. There will be done specific exercises of the pelvic floor muscles and coordination exercises of the pelvic floor muscles with other muscles in different positions. Electrostimulation, biofeedbak, cones and dinamometric devices can be employed to improve the muscle performance.
45652156|NCT03074773|Drug|Dexamethasone|"Dexamethasone is commonly used in the perioperative period to reduce postoperative nausea and vomiting. Additionally, it has been reported to have analgesic effects.~The analgesic effect of epidural or perineural dexamethasone administration is not clear. Dexamethasone might have a local anesthetic effect on nerve by direct membrane action"
45652157|NCT03074773|Device|ultrasound|The growth of ultrasound technology and, with it, our ability to visualize the pleura and other structures in and around the paravertebral space has fueled a tremendous increased interest in performing thoracic paravertebral blocks. These blocks may be used for acute pain control, as an adjunct to general anesthesia for peri-operative pain control and, in some practices, as the primary anesthetic
45652158|NCT03074773|Procedure|paravertebral block|paravertebral block is an effective analgesic technique used in various types of surgery, trauma and chronic pain. it decreases postoperative pain and reduces opioid consumption which in turns improve postoperative pulmonary function hoping for early extubation.
45652159|NCT03074773|Drug|Bupivacaine|it is an amino amide local anesthetic drug
45652160|NCT03074773|Other|isotonic saline|sterile sodium chloride solution at physiological concentration (0.87%); used as diluting agent when added to local anesthetic drug
45652161|NCT03077581|Drug|Transevrsus abdominus plane block|a blunt needle was advanced in the midaxillary line to reach the fascial layer between the internal oblique and transverse abdominis muscles detected by facial click sensation. The LA was slowly injected so as to detect any sign of toxicity or incorrect needle tip position (as resistance) requiring needle repositioning then TAPB was repeated on the opposite side.
45652162|NCT03077581|Drug|Rectus sheath block|In RSB group, 2-3 cm from midline, about 3-5 cm above the umbilicus, the needle was advanced at right angle to the skin. The needle reaches the space between the posterior layer of the rectus sheath and rectus abdominis muscle detected by firm resistance of the posterior wall, The LA was slowly injected then the same steps were repeated on the other side.
45802358|NCT00804427|Dietary Supplement|Fish oil (90% triglycerides)|
45802359|NCT00804427|Dietary Supplement|Fish oil (60% triglycerides)|
45802360|NCT00804427|Dietary Supplement|Fish oil (ethyl esters)|
45802361|NCT00804427|Dietary Supplement|Soy oil|
45804175|NCT04832659|Behavioral|CEASE|The CEASE intervention is considered the accepted standard of care according to national treatment guidelines. Parents of a child scheduled to be seen at a participating pediatric practice will be provided with a brief intake survey. Office staff and clinicians will be trained how to utilize the intake survey system and how to provide evidence-based cessation assistance to parents who smoke. The brief intake survey will conduct screening to identify household smoking. The CEASE system will provide (1) Automatic documentation of smoking cessation services requested; (2) Automatically generated prescription for nicotine replacement therapy for parents who smoke (unless they opt out of receiving the prescription); (3) Automated enrollment in the state's free tobacco Quitline and the SmokeFreeTXT program, a text message program offered by the National Cancer Institute.
45931730|NCT04752618|Behavioral|Supportive Counseling|Non-trauma focused psychotherapy
45931731|NCT04752163|Drug|DS-1594b|Given DS-1594b PO
45931732|NCT04752163|Drug|Azacitidine|Given IV or SC
45931733|NCT04752163|Drug|Cyclophosphamide|Given IV
45931734|NCT04752163|Drug|Cytarabine|Given IT
45931735|NCT04752163|Drug|Dexamethasone|Given PO or IV
45931736|NCT04752163|Biological|Filgrastim|Given SC
45931737|NCT04752163|Drug|Leucovorin|Given IV or PO
45931738|NCT04752163|Drug|Mesna|Given IV
45931739|NCT04752163|Drug|Methotrexate|Given IT
45931740|NCT04752163|Drug|Posaconazole|Given PO
45931741|NCT04752163|Drug|Prednisone|Given PO
45931742|NCT04752163|Biological|Rituximab|Given IV
45802362|NCT04349527|Procedure|Round-block Oncoplastic Breast Conserving Surgeries|We de-epithelize the gap between the double round-lines, and we dissect the dermis from the best localization where we can reach the tumor. If the tumor located close to the skin then we are not performing de-epithelization, we excise it with the skin. We mark every wall of the tumor bed with clips. We dissect the surrounding parenchyma- so called parenchyma pillars- from the pectoral fascia and the skin, and we mobilize it. The line under the skin means, the layer under the subcutis, above the superficial fascia, so gives appropriate blood supply to the skin. After this the incision line should be placed 5 mm from the outer round line, so a dermis pillar should be left, and the skin is dissected from the parenchyma as needed. The outer round line should be tightened with a non-absorbable running Benelli suture to fit the areola then interrupted sutures placed to make tensionless the running intracutaneous suture.
45802363|NCT04349527|Procedure|Retroglandular Oncoplastic Breast Conserving Surgeries|We incise the skin slightly lateral in the IMF, around 7 cm long. We dissect with electrocauther the parenchyma with the pectoral fascia from the pectoralis major muscle at least until the mamilla. We incise the fascia along with the parenchyma which contains the tumor and macroscopically 10 mm safe zone. If the tumor is palpable, we turn the parenchyma slightly inside-out, if not, we localize it at the maximum measurement detected according to the ROLL labeling. After marking the tumor bed, we directly adapt the surrounding parenchyma pillars with absorbable sutures, or inverting sutures, or if it requires, we adapt the tumor bed with so-called dual plane mobilization. After revision, we close the fascia with absorbable running suture over the Redon drain then subcutaneous running suture with absorbable suture and finally intracutaneous skin closure.
45931743|NCT04752163|Drug|Venetoclax|Given PO
45652163|NCT03077581|Drug|local anesthesia infiltartion|40 mls of 0.255 bupivacaine will be infiltrated at skin incision
45802364|NCT01959685|Drug|Androxal|125 mg Androxal, 250 mg Androxal separated by at least 7 days
45802365|NCT01959685|Drug|Placebo|Placebo, single dose
45931744|NCT04752163|Drug|Vincristine|Given IV
45931745|NCT04752163|Drug|Voriconazole|Given PO
45652164|NCT04993573|Other|Questionnaire|Questions about the impact of COVID-19 in their works
45931746|NCT04735926|Drug|Calcifediol 75mcg|Soft gelatin capsule. Oral administration once per week
45652165|NCT04993573|Other|Individual interview|Discussion between the searcher and the participant about representations of COVID-19 and experiences about confinement.
45652166|NCT03073447|Other|Specific blood sample of women under 50 years with acute MI|The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge. Some assays, including hormonal and thrombophilia will be centralized in order to standardize the results and their interpretation. All the biological data will be pooled and analyzed by IVS. a sample of blood will be made for later analysis in the context of a serum bank.
45451543|NCT02259712|Other|Physical Therapy assessment|Pre-treatment, post-treatment, 3, 6 and 12 months after physical therapy treatment. Will be done a specific evaluation of pelvic floor muscles using the Modified Oxford Scale, superficial electromyography, perineometry and dynamometer. For the evaluation of the impact, the signs and the symptoms questionnaires will be completed by the participants.
45451544|NCT02750410|Drug|Dulaglutide|Administered subcutaneously (SC)
45451545|NCT02750410|Drug|Placebo|Administered SC
45652167|NCT05005117|Procedure|Laparoscopic operation|Operation
45652168|NCT05005117|Procedure|Open operation|Operation
45652169|NCT03074461|Procedure|Side-to-End Anastomosis|During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a side-to-end colorectal anastomosis.
45652170|NCT03074461|Procedure|Transverse Coloplasty|During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a transverse coloplasty pouch. For this purpose an end-to-end colorectal anastomosis is initially performed, followed by a longitudinal incision of approx. 8-10 cm length proximal of the anastomosis and a subsequent transverse suture in terms of the coloplasty technique.
45652171|NCT04996537|Other|Micro-video digiral learning|On the digital platform, you can accept courses anytime, anywhere, and repeat learning, answering, leaving messages, or interacting with lecturers.
45652172|NCT04996303|Drug|Routine steroid administration group|Steroid administration with routine dose - Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg kg 7 days
45802366|NCT02901899|Drug|Guadecitabine|Given SC
45802367|NCT02901899|Other|Laboratory Biomarker Analysis|Correlative studies
45802368|NCT02901899|Biological|Pembrolizumab|Given IV
45802369|NCT04333589|Drug|Favipiravir|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.
45802370|NCT02902913|Other|D2i2|Oleocanthal provided in a 2:1 ratio compared to oleacein
45802371|NCT02902913|Other|D2i0.5|Oleocanthal provided in a 1:2 ratio compared to oleacein
45802372|NCT02902913|Other|D2i0|No oleocanthal and no oleacein
45802373|NCT02902913|Drug|Ibuprofen|400 mg of Ibuprofen
45802374|NCT04737161|Biological|T regulatory cells|T regulatory cells isolated by immunomagnetic selection; donor cells collected through large volume apheresis.
45931747|NCT04735926|Drug|Calcifediol 100mcg|Soft gelatin capsule. Oral administration once per week
45931748|NCT04735926|Drug|Calcifediol 125mcg|Soft gelatin capsule. Oral administration once per week.
45931749|NCT04735926|Other|Placebo|Soft gelatin capsule. Oral administration once per week.
45931750|NCT04735926|Other|Placebo|Soft gelatin capsule. Oral administration once per week.
45931751|NCT04726722|Behavioral|internet-based cognitive behavioral theraphy|"When determining the content of the I-CBT program, the participants and therapist will be allowed to choose from a library of treatment modules.~Therapist controlled support and feedback are given weekly and in a structured manner. Participants will be able to contact the therapist when support and feedback is desired"
45931752|NCT04720768|Drug|Binimetinib|MEK inhibitor
45931753|NCT04720768|Drug|Encorafenib|BRAF inhibitor
45931754|NCT04720768|Drug|Palbociclib|CDK4/6 inhibitor
45451546|NCT02750332|Drug|Nitisinone|A single oral dose of Nitisinone 10 mg Tablet will be administered.
45451547|NCT02233894|Drug|Atrovent® - inhalets|
45652173|NCT04996303|Device|Steroid pulse therapy group|Steroid administration with pulse dose - Methylprednisolone 10 mg/Kg (500 mg ~ 1g) pulse 3 days -> Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg/kg 7 days
45931755|NCT04717310|Drug|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
45652175|NCT03077503|Drug|Dexmedetomidine|Dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
45802375|NCT03002753|Behavioral|detached mindfulness|Please see detailed study description.
45802376|NCT03002753|Behavioral|cognitive restructuring|Please see detailed study description.
45931756|NCT04717310|Drug|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
45802377|NCT03417986|Drug|TEP|"For safety reasons the clinical trial will first enroll 14 subjects (7 patients and 7 healthy volunteers) for Group 1a receiving 26 mg TEP daily for 4 days with subsequent safety evaluation, based on adverse events and the safety parameters discussed in the protocol. A second set of patients (Group 1b), which will receive a higher dosage of 52 mg per day for 4 days will be enrolled optionally after recommendation to continue and subsequently treatment Group 2 with a treatment paradigm of 26 mg TEP daily for 54 days will start.~Subjects eligible for participation are subjects with newly diagnosed (within last 12 month) early-to-mild dementia due to AD and healthy volunteers who fulfill all inclusion criteria and have none of the exclusion criteria present at screening."
45802378|NCT02906813|Drug|TAK-935 Tablets|Tablets
45931757|NCT04717310|Drug|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
45802379|NCT02906813|Drug|TAK-935 Oral Solution|Oral solution
46073270|NCT04323930|Device|eyeWatch|The eyeWatch system will be implanted as per the manufacturer's instruction, and trabeculectomy will be performed using mitomycin C as per standard surgical protocols.
45451548|NCT02233972|Drug|Midazolam|
45652176|NCT03077503|Drug|Fentanyl|Fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
45652177|NCT03077503|Drug|0.9% normal saline|0.9% normal saline was use to dilute the study drugs
45652178|NCT03077503|Device|Skull pins|Skull pins were use to stabilized the patent' s head during surgery
45802380|NCT04349228|Drug|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200mg/day
45802381|NCT04349228|Drug|Placebo oral tablet|Placebo of Hydroxychloroquine (HCQ) without any active substance
45802382|NCT03275636|Biological|Peripheral blood stem cells|Hematopoietic stem cell transplantation with PBSC
45802383|NCT02301416|Drug|Phentermine/topiramate|Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.
45802384|NCT02301416|Other|low calorie diet|The low-calorie diet will be individually tailored based on initial resting metabolic rate measurement and co-morbid conditions.
45802385|NCT02815709|Drug|Oliceridine|
45802386|NCT02815709|Drug|Placebo|
45802387|NCT02815709|Drug|Morphine|
45802388|NCT02816723|Behavioral|Mindfulness-based Stress Reduction|mindfulness/meditation/movement training
45802389|NCT02816723|Behavioral|Brain Health|Brain Health Education
45802390|NCT03208868|Dietary Supplement|Leucine enriched essential amino acid (EEA/LEU)|Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
45802391|NCT03208868|Dietary Supplement|Balanced amino acid supplement (BAA)|Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
45802392|NCT02912195|Drug|Intravenous lidocaine|Intravenous lidocaine drip over 10 minutes followed by intravenous lidocaine drip over 50 minutes
45802393|NCT02912195|Drug|Intravenous morphine|Emergency department provider chooses appropriate dose of intravenous morphine
45802394|NCT01960075|Drug|Fosphenytoin|
45802395|NCT01960075|Drug|Levetiracetam|
45931758|NCT04717310|Drug|Vehicle|Twice a day (BID)
45931759|NCT04702256|Drug|Obinutuzumab administration|"Obinutuzumab administration by intravenous infusion (IV), IV of methylprednisolone, oral mycophenolate mofetil, no prednisone (or if required for extrarenal manifestation(s): less than 10mg/day at any time, less than 7.5mg/day after 6 months and less than 5mg/day after 9 months).~Hydroxychloroquine will be strongly recommended for all the patients."
45931760|NCT04702256|Drug|Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil|"IV of methylprednisolone, oral prednisone (according to the PNDS), and oral mycophenolate mofetil.~Hydroxychloroquine will be strongly recommended for all the patients."
45931761|NCT04702256|Drug|Administration of methylprednisolone, paracetamol and dexchlorpheniramine|Prior to infusion of obinutuzumab, patients receiving obinutuzumab will receive premedication including 100 mg of methylprednisolone, paracetamol and dexchlorpheniramine.
45931762|NCT04701359|Device|TiN-alloy based total knee arthroplasty|TiN-alloy based TKA implanted for knee osteoarthritis.
45931763|NCT04701359|Device|CoCr-coating based total knee arthroplasty|CoCr-coating based TKA implanted for knee osteoarthritis.
45451549|NCT02233972|Drug|Ginkgolides Meglumine Injection|
45451550|NCT02233972|Drug|placebo|
45652179|NCT04993417|Other|Motor imagery technique along with EMS|All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. The patients were mentioned to play out the emotional facial appearances for non-verbal correspondence i-e pleasure, misery, interest, appall, dread, irritation and shock. Patients were then requestedto envision himself winking, for instance, envisioning himself in a wonderful and natural social setting, at that point the patient cognitively addresses, with his eyes shut, the movement of decaying the recognized central issues, without creating any specific movement.
45931764|NCT04671966|Drug|Estradiol patch|Brand name Climara for estrogen add back portion of study. Premenopausal women treated with a GnRH antagonist will be randomized to estrogen add-back or placebo. Thus, for women without contradictions to estrogen use, the risks associated with their use for the duration proposed in these studies (i.e., 6 days) are small. The respective estradiol regimen is a standard approved dose for treatment of hot flashes and the prevention of osteoporosis, and this dose will increase E2 to concentrations typically observed during the mid to late follicular phase of the menstrual cycle.
45802396|NCT01960075|Drug|Valproic acid|
45802397|NCT01988246|Drug|Aflibercept|Patients will be assigned to treatment with 2 mg intravitreal Aflibercept injection (0.05 mL or 50 microliters) administered at the time of surgery (post cataract excision) or sham injection.
45802398|NCT01988246|Drug|Sham|Sham injection. No actual injection. No medication is used.
45802399|NCT02821403|Device|clear lens with regular coating|
45802400|NCT02821403|Device|regular coating lens with yellow tint|
45931765|NCT04671966|Drug|Cetrotide|Premenopausal women will be treated with the gonadotropin-releasing hormone (GnRH) antagonist Cetrorelix for 6 days in order to suppress ovarian sex hormones. Cetrorelix may cause an anaphylactic reaction in volunteers with hypersensitivity to cetrorelix, GnRH or any other GnRH analogs, or extrinsic peptide hormones or mannitol. It may also cause hot flashes, headaches, and nausea. These are typically transient and of mild intensity. These effects are all reversible upon cessation of cetrorelix. Absence of pregnancy will be confirmed before drug administration.
45931766|NCT04671966|Other|Fasting|Subjects will abstain from food for 48 hours. Subjects will be allowed water and/or an isotonic saline solution in order to maintain hydration status.
45451551|NCT02234050|Drug|Trabectedin|Trabectedin will be given as a 24-hour infusion every 3 weeks at a starting dose of 1.5 mg/m2 body surface area (BSA), until one of the treatment withdrawal criteria has been met.
45802401|NCT02821403|Device|clear lens with blue-light blocking coating|
45451552|NCT02234050|Other|Local standard of care|Left to the discretion of the investigator
45451553|NCT01337596|Drug|LY2951742|Administered subcutaneously
45451554|NCT01337596|Drug|Placebo|Administered subcutaneously
45802402|NCT01990820|Device|Acclarent Relieva Balloon Sinuplasty|"A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the balloon catheter device will be inserted and the wire/balloon will be threaded through the maxillary sinus ostia. Confirmation of location will be per manufacturer's recommendation with either fluoroscopy or illumination. Following confirmation, the balloon will be dilated under visualization per manufacture's recommendation. After the visualization of the dilated ostia, cultures for aerobic/anerobic examination will be taken and irrigation with 10ml of isotonic sodium chloride will be performed.~Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner."
45652180|NCT04993417|Other|Mime Therapy along with EMS|All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. Mime treatment incorporates self kneading of face and neck, breathing and relaxation works out, activities to synchronize the two sides and diminish synkinesis and for eye and lip closure per the myofascial way to deal with recovery, letter and word practices and expressive activities.
45652181|NCT03074383|Behavioral|Workshop|A 15-minute Individual meetings with each professional (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) of the multidisciplinary team in which diabetes education and self-care topics will be approached.
45652182|NCT03074383|Behavioral|Usual Care|Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
45802403|NCT01990820|Procedure|Adenoidectomy + Maxillary Sinus Irrigation|"A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the maxillary sinuses will be entered via middle meati punctures using either a sterile spinal needle or a curved suction. Sinus contents will be aspirated and sent for aerobic/anaerobic cultures. Irrigation with 10ml of isotonic sodium chloride will be performed. If no material is aspirated initially, the sinus contents will be re-aspirated after irrigation and sent for aerobic/anaerobic cultures.~Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner.~After adequate hemostasis, the patient will be awakened and brought to the recovery room. Depending on the recovery, the child will either be admitted or discharged home."
45931767|NCT04671966|Other|Lower Body Negative Pressure|This test simulates Earth's gravity. The subject will rest on his/her back, with their lower body sealed in an air-tight chamber from the waist down. The chamber is connected to a vacuum that sucks air from the chamber and creates negative pressure inside and around the subject's lower body. As a result, the subject's blood pool shifts towards their legs, away from their chest and arms.
45931768|NCT04653961|Device|DreaMed Advisor Pro DSS-MDI algorithm|The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
45931769|NCT04650399|Biological|Active|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate 1x10E4 TCID50 per dose
45931770|NCT04650399|Biological|Placebo|Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
45802404|NCT01990898|Drug|Cyclosporine|Drug will be provided to patient's at study visit. Drug is to be taken twice daily. Dosage will be calculated at study visit and provided to patient.
45451555|NCT02234206|Drug|Chandrakanthi Choornam (CKC)|"12gm in milk - OD dose; Oral route; 3 Months ( 90days) - duration~Preparation from approved sastric book as per drugs & cosmetic act 1940"
45802405|NCT02822885|Radiation|Ultrasonography|Ultrasonographic assessment of the thickness of the endometrium of the uterus and transvaginal color Doppler ultrasonography for measurements of Pulsatility index and resistance indices of uterine arteries and spiral arteries
45931771|NCT04641702|Drug|Atropine challenge|Atropine challenge. After baseline FLIP, subjects will be administered 15 mcg/kg of intravenous atropine. Two minutes after administration, FLIP will be repeated.
45931772|NCT04641702|Procedure|Esophageal muscle biopsy|Esophageal muscle biopsy. During standard-of-care Heller myotomy or per-oral endoscopic myotomy, 5mm of lower esophageal sphincter and distal esophageal circular muscle will be collected via biopsy forceps.
45652183|NCT05518695|Drug|BAT2022|Eight healthy subjects are planned to be enrolled in each group, 6 on the investigational product and 2 on placebo. Subjects will be randomized (3:1) to receive a single intravenous injection of BAT2022 for Injection or 5% glucose injection. Sentinel dosing will be performed for subjects in each group.Two subjects in each group who have received the first dose will be randomized (1:1) to either the test group or placebo group. After observation for 24 h and the drug is safe and well tolerated, the remaining subjects in this group will be randomized (5:1) to either the test group or placebo group.
45802406|NCT01960387|Drug|Clofarabine|Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5.
45931773|NCT04636320|Device|Contrast-enhanced CMR|Cardiac Magnetic Resonance Imaging (MRI) examinations will be performed at Day 0 visit on clinical systems 1.5 equipped with specific antennas for cardiac imaging. The imaging protocol will last approximately 50 minutes.
45931774|NCT04636320|Diagnostic Test|Exercise test ECG|"A treadmill exercise test with 12 lead ECG monitoring will be performed at M3 visit.~Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls."
45931775|NCT04636320|Biological|Blood sample|"A blood sample will be taken at Day 0 visit for COVID-19 serology, hematocrit measurement, ultra-high sensitive troponin test, low grade markers of inflammation, genetic profiling.~An other blood sample will be taken at M3 visit for a control COVID-19 serology for 30 healthy volunteers."
45931776|NCT04636320|Diagnostic Test|Resting 12 lead ECG|A resting 12 lead ECG will be performed at Day 0 visit.
45931777|NCT04636320|Diagnostic Test|24 hour Holter ECG|A 24 hour Holter ECG will be performed at M3 visit. Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls.
45451556|NCT04476706|Drug|canakinumab|canakinumab
45597962|NCT04744129|Drug|NN414|To investigate the role of NN414 on cerebral hemodynamic in migraine patients
45597963|NCT04744129|Drug|Saline|To investigate the role of NN414 compared with saline cerebral hemodynamic in migraine patients.
45597964|NCT03133117|Radiation|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging (fMRI)
45597965|NCT03705559|Drug|Vaporized Marijuana|Active Marijuana or Placebo, administered through vaporizer
45597966|NCT03705559|Drug|Opioid Agonist|Active Opioid Agonist or Placebo, administered intranasally
45931778|NCT04635527|Drug|IBI318|before surgery IBI318 intravenous injection Q2W,after surgery IBI318 intravenous injection Q4W
45931779|NCT04635527|Procedure|cTACE|conventional transarterial chemoembolization
45931780|NCT04635527|Drug|placebo|before surgery placebo intravenous injection Q2W,after surgery placebo intravenous injection Q4W
45931781|NCT04624750|Drug|Mexiletine|"Patients will be enrolled sequentially into 2 cohorts. Cohort 1 - (patients aged 12 to < 18 years): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Cohort 2 - (patients aged 6 to < 12 years,): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Enrolment for Cohort 2 will begin after initial safety assessment of patients in Cohort 1 by the DSMB and no safety concerns are observed. The dose level for cohort 2 will be confirmed by PK modelling study."
45931782|NCT04622553|Drug|Mexiletine|"Patients will be enrolled sequentially into 2 cohorts.~Cohort 1 - (patients aged 12 to < 18 years):~approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Cohort 2- (patients aged 6 to < 12 years,):~approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period. Enrolment for Cohort 2 will begin after initial pharmacokinetics (PK), safety and efficacy are confirmed in this population, of patients in Cohort 1"
45931783|NCT04618978|Procedure|PSG and actigraphy recording|"Gold standard: electromyographic recording of tibialis anterior muscle during full night polysomnography (PSG).~The new generation actigraphs devices Actiwatch will be combined to PSG as a screening tool: MotionWatch will be placed on the dorsum of feet to record)."
45931784|NCT04616807|Drug|Mexiletine|Observational Study
45931785|NCT04608630|Drug|Denosumab 60 MG/ML|Patients allocated to the Denosumab arm will receive Denosumab 60mg in 1ml, administered via subcutaneous injection on Study Days 1 and 180.
45931786|NCT04608630|Drug|Zoledronic Acid 5Mg/Bag 100Ml Inj|Patients allocated to the Zoledronic acid arm will receive Zoledronic acid 5mg in 100ml 0.9% Sodium Chloride, administered via intravenous infusion over at least 15 minutes on Study Day 1.
45931787|NCT04608630|Drug|Sodium Chloride 0.9% Intravenous|Patients allocated to the placebo arm and Denosumab arm will receive 0.9% Sodium Chloride 100ml administered via intravenous infusion over at least 15 minutes on Day 1.
45931788|NCT04608630|Drug|Sodium Chloride 0.9% Injection|Patients allocated to the placebo arm and Zoledronic acid arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180
45652184|NCT05285475|Other|Exercise and Water Intake|"The exercise protocol for this group will be abdominals, pelvic stretching and kegels exercises (PFM) for three days/week lasting about 30 minutes with approximately 1600-1800ml (8-10 glasses) intake of water for 8 weeks (two consecutive menstrual cycles)~Exercises include:~Piriformis stretching (5 repetitions×20 seconds) Adductor stretching (5 repetitions×20 seconds) Sit-ups (10 repetitions×3 sets) Bridging (10 repetitions×3 sets) Kegels exercises (10 repetions×3 sets) Pelvic elevation (10 repetitions×3 sets) Pelvic rotation (10 repetitions×3 sets) Cobra pose (5 repetitions×20 seconds)"
45802407|NCT01960387|Drug|Cytarabine|Cytarabine at a dose of 1g/m2 daily will be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
45931789|NCT04606472|Drug|SI-B003|Administration by intravenous infusion.
45802408|NCT01991522|Behavioral|Curriculum Group|
45931790|NCT04603183|Drug|Abemaciclib|Patients will receive abemaciclib 150 mg orally twice daily (BID) (300 mg daily, administered as six 50 mg tablets) during each 28 day cycle combined with either letrozole or fulvestrant.
45931791|NCT04603183|Drug|Paclitaxel|Paclitaxel 90 mg/m² infused over 1 hour on Days 1, 8, and 15 of the 28 day cycle, with at least a 6-day time span between separated doses.
45802409|NCT01991522|Behavioral|Self-directed learning group|
45451557|NCT02235220|Other|Composite resin restoration|"Masticatory muscular activity is measured before and after treatment with additive composite resin fillings (Tetric EvoCeram, Ivoclar Vivadent, Schaan, Liechtenstein). A Grindcare (Medotech A/S, Herlev, Denmark) device is used for determination of muscular activity.~A first measurement is conducted, followed by 4 weeks without any intervention. A second measurement is then carried out before restoration of the canine cusps with composite fillings. A third measurement is conducted, again followed by 4 weeks without any intervention. At last a final measurement is conducted."
45652185|NCT04920097|Device|Virtual Auricular Point Acupressure (APA)|Participants will learn how to self-administer APA by themselves.
45802410|NCT02823431|Drug|lidocaine gel|
45802411|NCT02823431|Other|Plain aqueous gel|
45802412|NCT01960465|Device|Continuous positive airway pressure|A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.
45802413|NCT01991990|Drug|placebo|Single i.v. infusion
45802414|NCT01991990|Drug|tocilizumab [RoActemra/Actemra]|Single 8 mg/kg i.v. infusion
45802415|NCT02824913|Drug|P-321 Ophthalmic Solution|
45802416|NCT02824913|Drug|P-321 Ophthalmic Solution placebo|
45802417|NCT01961089|Device|Galilei Lens Professional|Measurement device
45931792|NCT04603183|Drug|Letrozole|Patients will receive 2.5 mg letrozole, orally administered and taken daily during each 28-day cycle combined with abemaciclib.
45931793|NCT04603183|Drug|Fulvestrant|Patients will receive 500 mg fulvestrant, by intramuscular [IM] administration on Days 1 and 15 (±3 days) of the first treatment cycle and Day 1 of each cycle thereafter combined with abemaciclib.
45451558|NCT02262910|Biological|ES414|ES414 is a novel humanized bispecific antibody which is designed to treat mCRPC by redirecting T-cell cytotoxicity against prostate cancer cells expressing prostate-specific membrane antigen (PSMA).
45802418|NCT01961089|Device|IOLMaster|Measurement device
45802419|NCT01961089|Device|Lenstar|Measurement device
45802420|NCT02825849|Biological|Intrauterine infusion of platelet rich plasma|Patients randomized to study group will have 30cc of blood drawn with isolation of platelet rich plasma (PRP) per standard manufacturer's protocol, with subsequent intrauterine infusion of this autologous PRP.
45802421|NCT02057042|Behavioral|Peer-assisted computerized CBT|Patients in the PS-cCBT intervention will receive usual depression care and will also receive: 1) access to Beating the Blues (BTB), an online cCBT program, 2) support of a peer specialists for 12 weeks, 3) a copy of the Depression Helpbook by Wayne Katon and colleagues
46073271|NCT04244838|Diagnostic Test|Gait Analysis|The patients will undergo Gait analysis (integrated movement analysis system) performed at the Complex Laboratory for Movement Analysis and functional-clinical evaluation of the prosthesis of the Rizzoli Orthopedic Institute. The instrumentation used in the Movement Analysis Laboratory consists of a stereophotogrammetric system equipped with eight infrared cameras (Vicon® 460-Oxford system) and 2 dynamometric platforms (Kistler® Instrument, AG Switzerland). The IOR GAIT protocol will be used as a marker set (Leardini et al. 2007). For the evaluation of muscle activation, surface electromyography with 16-channel system will be used (ZeroWire Cometa, Milan). Spatio-temporal parameters, kinematics, kinetics and muscle activation will be evaluated.
45451559|NCT05155696|Dietary Supplement|Experimental: Kefir probiotic drink (supplied by Nourish)|125ml per day of dairy based probiotic drink (Kefir) containing ≥ 50billion colony forming units (CFU), supplied in plain packaging.
46073272|NCT02827734|Device|multiple breath washout tests|
46073273|NCT02827734|Device|impulse oscillometry|
46073274|NCT02827734|Device|body plethysmography|
46073275|NCT02827110|Device|fiberoptic bronchoscope|Tracheal intubation using fiberoptic bronchoscope
45652186|NCT04920097|Other|In-Person Training|Participants will receive in-person training to self-administer APA.
45652187|NCT04920097|Other|Usual Care|Participants will continue to do whatever they are receiving from their oncologist.
45652188|NCT05285319|Radiation|Prostate Only Radiation|Prostate Only Radiation for Intermediate and High Risk Prostate cancer
46073276|NCT02827110|Device|pentax-airway scope|Tracheal intubation using pentax-AWS
45652189|NCT05285319|Radiation|Prostate and Pelvic Lymph Node Radiation|Prostate and Pelvic Lymph Node Radiation for Intermediate and High Risk Prostate cancer
45451560|NCT05155696|Dietary Supplement|Placebo comparator|125ml of non-fermented dairy based placebo (UHT milk) per day, supplied in plain packaging.
45451561|NCT02263066|Biological|BAY14-2222_Kogenate-FS FVIII|Depends on Doctor's decision
45802422|NCT02057042|Behavioral|Enhanced usual care|Patients randomized to EUC will receive the following enhancements: 1) patient education regarding the symptoms of depression and evidence-based depression treatments, 2) a copy of the Depression Helpbook by Wayne Katon and colleagues 3) information about how to access local VA mental health depression treatment resources (groups, individual psychotherapy, etc), and 4) bi-weekly study mailings with depression management tips.
45802423|NCT01961167|Device|Stenting of common and/or external iliacs|Balloon expandable stenting of iliac occlusive disease
46073277|NCT02827110|Procedure|semi-rigid collar|semi-rigid collar immobilization of the cervical spine
46073278|NCT02829372|Drug|CD3/HER2 bispecific monoclonal antibody|Increasing doses, IV on day 1 and 15 of each 28 day cycle
46073279|NCT00899678|Drug|Certolizumab Pegol|"400 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg~*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg"
46073280|NCT00899678|Drug|Certolizumab Pegol|"200 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg~*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg"
46073281|NCT00887484|Drug|BENZOYL PEROXIDE/ CLINDAMYCIN|Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
46073282|NCT00887484|Drug|BENZOYL PEROXIDE/ ADAPALENE|Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
46073283|NCT00794378|Drug|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
46073284|NCT00794378|Drug|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
46073285|NCT03198494|Other|Acoustic 1Hz Stimulation|1Hz acoustic pulses delivered during sleep via headphones
45652190|NCT04136067|Drug|NNC0268-0965|One daily dose of 1.5, 4.0 or 6.0 nmol/kg administered s.c. (subcutaneously, under the skin) for 6 days
45652191|NCT04136067|Drug|insulin glargine|One daily dose of 3.0 nmol/kg administered s.c. for 6 days
45652192|NCT03073291|Behavioral|Responsible Marijuana Vendor Training|Employees at retail recreational marijuana stores assigned to the the responsible marijuana vendor training will register them on TrainToTend online training program, create a user profile, and complete the training within four weeks from initial registration. Personnel who complete the training will receive a certificate of completion. New hires at the stores during the trial will be registered and complete the training within four weeks of commencing work. Separate versions of the training will be available reflecting differences in the laws/regulations on recreational marijuana sales in Colorado, Oregon, and Washington State and the content will be reviewed and approved by state regulators.
45652193|NCT05244291|Other|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 3 times a week or 6 times in 2 weeks.
45652194|NCT03073135|Behavioral|Psychodrama Group Therapy (PGT)|"The psychotherapeutic focus is on the here and now aspect of the patient's relationships. Conflicts are acted out during the sessions, yielding intense emotional re-experience in a safe environment, which will bring further cognitive understanding of past distressful life experiences and hopefully new adaptive ways of expressing and dealing with the problem."
45802424|NCT03008213|Drug|Netupitant and Palonosetron|300 mg of netupitant and 0.5 mg of palonosetron
45451562|NCT05102344|Behavioral|Behavioral Social Skills Training|Behavioral Social Skills Training treatment as usual will include small group semi-structured play, didactic instruction and role-play of basic social skills, including assertion, ignoring provocation, accepting consequences, problem solving, following directions, and self-regulation.
45802425|NCT01959542|Device|MRI|
46073286|NCT03198494|Other|Sham Background Noise|Background Noise used as a control
46073287|NCT00789152|Drug|desloratadine|desloratadine 5 mg daily x 8 days
45931794|NCT04602520|Behavioral|3 Wishes Project|Behavioral: Focused conversations at end-of-life to promote the connections between patients, family members, and clinicians.
45931795|NCT04601428|Biological|IA therapy of HCC with CSR02-Fab-TF|Intra-Arterial Infusion of CSR02-Fab-TF
45931796|NCT04588623|Dietary Supplement|Omnibiotic Stress Repair (OBSR)|OBSR is given orally once daily (3g) for 3 months
45931797|NCT04588623|Other|Placebo|Placebo is given orally once daily (3g) for 3 months
45931798|NCT04585581|Behavioral|time-restricted eating|Participants will be asked to limit the time-window for their daily energy intake to a maximum of 10 hours.
45652195|NCT03073135|Behavioral|Supportive Group Therapy (SGT)|SGT is a form of treatment in which the therapist maintains a therapeutic relationship and a working alliance based on reality, support, clarification, assistance in troubleshooting, strong leadership, partial gratification of dependency needs, legitimating independence, development of pleasurable activities and adequate rest, guidance and advice to deal with current problems. This approach uses techniques to help patients feel safe, accepted, protected, encouraged and not anxious.
45652196|NCT03072979|Radiation|Stereotactic body radiotherapy|Stereotactic body radiotherapy
45652197|NCT05284383|Behavioral|Closed-label nocebo conditioning|"Conditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of a Transcutaneous Electrical Nerve Stimulation (TENS) device (CS) will be repeatedly paired with a moderate intensity pressure pain stimulus, whereas a message indicating the deactivation of the sham device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the conditioning procedure (i.e. activation of the device will increase their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test for a nocebo effect (i.e. to test whether participants score TENS on trials as more painful than TENS off trials)."
45451563|NCT05102344|Behavioral|Animal Assisted Intervention|Behavioral Social Skills Training treatment as usual will include small group semi-structured play, didactic instruction and role-play of basic social skills, including assertion, ignoring provocation, accepting consequences, problem solving, following directions, and self-regulation accompanied by trained therapy dogs
45451564|NCT04309006|Procedure|CTG and customized healing abutment|screw- retained customized healing abutment
45652198|NCT05284383|Behavioral|Closed-label counterconditioning|"Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the counterconditioning procedure (i.e. activation of the device will reduce their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful)."
45802426|NCT01959542|Other|PSA Blood Test|Serum PSA will also be subsequently checked on the same day as each follow-up MR is performed, i.e. TP 1, 2 and 3, and right after finishing EBRT. 1-2 mls of blood will be sampled per blood test.
45802427|NCT03008837|Device|Military Field Stimulator|The Military Field Stimulator (MFS/Neuro-Stim System), a percutaneous electrical neural field stimulation (PENFS) device evolved from PENS, is currently employed by the United States (US) military and used in the VA (contract number V797D-50453). There is some evidence based on a small trial of 20 postoperative patients that suggests PENS may have greater benefit than acupuncture for acute pain.
45802428|NCT03008837|Other|Standard Therapy|Standard therapy for fibromyalgia will include physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist.
45802429|NCT01962025|Procedure|Buttonhole needling technique|the intervention is the type of needling used for home hemodialysis patients. They will be randomized to either buttonhole cannulation or stepladder cannulation
45802430|NCT01992380|Drug|Flortaucipir F18|IV injection, 370 MBq (10 mCi), two doses up to four weeks apart
45931799|NCT04585581|Behavioral|high intensity exercise|Participants will be encouraged to exercise with high intensity 2-3 times per week
45451565|NCT04309006|Procedure|CTG and conventional healing abutment|conventional healing abutment
45931800|NCT04585581|Other|Standard Care|Standard clinical care
45931801|NCT04583891|Behavioral|IntelliCare|IntelliCare is a self-guided, fully automated suite of 6 apps designed for brief, frequent check-ins to promote skill acquisition. IntelliCare has been shown in both general deployment and human-supported trials to be efficacious in reducing symptoms of depression and anxiety.
45931802|NCT04583891|Behavioral|Psychoeducation|The Patient Education app will contain content relevant for general distress management. This includes information about thoughts/worries, prevalence of mood symptoms, CBT strategies for coping with negative affect, and other information typical of education-based mental health apps. The structure of this app will closely mirror patient education websites and apps which mimic the form and structure of apps that target cancer survivors and that primarily provide educational information about cancer and related symptoms.
45931803|NCT04583891|Behavioral|Coaching|The randomization of added coaching vs. no added coaching after 1 week will only be carried out in the IntelliCare group. Coaching is a human supported approach to optimizing the use and benefit of the IntelliCare apps.
45931804|NCT04580134|Drug|clozapine|Biotype 1 and Biotype 2
45931805|NCT04580134|Drug|risperidone|Biotype 1 and Biotype 2
45931806|NCT04574882|Other|Survey|Interested participants may complete the informed consent online. After informed consent, the participant will be asked to share the digital data types that they use (Facebook, Instagram, Twitter, Google search, step data) and then participants will complete a cross-sectional survey.
45931807|NCT04567680|Behavioral|Acceptance and Commitment Therapy to Improve Social Support for Veterans with PTSD|This treatment is designed to help Veterans with PTSD increase social support in family, partner, and peer relationships by reducing experiential avoidance. ACT-SS is specifically designed to address deficits in the entire social support network for Veterans with PTSD.
46073288|NCT00789152|Drug|levocetirizine|levocetirizine 5 mg daily x 8 days
46073289|NCT00886938|Device|Repetitive Transcranial Magnetic Stimulation (rTMS), pilot study|Repetitive transcranial magnetic stimulation, pilot study
45931808|NCT04567680|Behavioral|Present-Centered Therapy|"PCT is designed to provide the emotional support for individuals with PTSD that will assist with recovery. The focus of PCT is on the here and now, including current life difficulties that are directly or indirectly related to the experience of trauma. PCT aims to help the patient consider ways to react to these difficulties."
45451566|NCT02235376|Other|weaning trial of mechanical ventilation|
45931809|NCT04541108|Biological|Pembrolizumab|Intratumoral microdose injection by the CIVO device.
45931810|NCT04541108|Combination Product|MK-0482 + Pembrolizumab|Intratumoral microdose injection by the CIVO device.
45931811|NCT04541108|Combination Product|MK-4830 + Pembrolizumab|Intratumoral microdose injection by the CIVO device.
45931812|NCT04533607|Behavioral|MAAPS|Modular intervention system integrating evidence-based strategies to address core and associated features of ASD and ongoing coaching.
45652199|NCT05284383|Behavioral|Open-label counterconditioning|"Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a open-label verbal suggestions in line with the counterconditioning procedure (i.e. they are told counterconditioning will be used to reduce nocebo effects and they are told the device is sham, but that their pain will still be influenced because of the placebo effect). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful)."
45931813|NCT04532788|Procedure|Customized crosslinking|"In the customized corneal cross-linking protocol (cCXL) a patient-specific treatment pattern, based on the patient's Pentacam images, will be used to treat the cornea. The CXL pattern exists out of 3 concentric circles and is centered on the cone. To estimate the cone location a combination of the thinnest corneal point, maximum anterior elevation and maximum posterior elevation is used. The epithelium is debrided with alcohol within the marked zone. After the application of riboflavin each circle receives a different amount of energy, which gradually decreases with increasing circle size.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
45931814|NCT04532788|Procedure|Standard crosslinking|"In the standard corneal cross-linking protocol (sCXL) the epithelium is debrided with alcohol over a region with a diameter of 9.0 mm. After the application of riboflavin the cornea is irradiated with UVA with a fluence of 10 mW/cm2 during 9 minutes with a diameter of 9.0 mm, resulting in a total energy of 5.4 J/cm2.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
45931815|NCT04529954|Drug|Valproic Acid delivered to ICV|Valproic Acid delivered to ICV via an implantable pump and catheter system
45931816|NCT04525755|Drug|Varenicline 0.5 MG|varenicline comes in bottles of 56 - 0.5 mg pills
45931817|NCT04525755|Drug|Nicotine Replacement Therapy (NRT)|28 day supply of nicotine patch (1 patch x 28 days @ 14 mg) and lozenge (14 per day x 28 days @ 4 mg)
46073290|NCT00783458|Drug|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
46073291|NCT00783458|Drug|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
46073292|NCT02690636|Radiation|radiotherapy|daily fractions, five fractions per week.
46073293|NCT00620659|Drug|Comparator: MK0249|Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).
45652200|NCT05284383|Behavioral|Closed-label extinction|"Extinction consists of a learning and test phase. In the learning phase, slightly painful stimuli are used for all trials. During the testing phase, again a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials)."
45451567|NCT02263144|Procedure|virtual chromo-endoscopy using FICE Fujifilm Technology|For each polyps, any observer will use virtual chromo-endoscopy with FICE Fujifilm Technology
45451568|NCT02554396|Drug|PRX-100|ophthalmic solution
45451569|NCT02554396|Drug|Placebo|saline ophthalmic solution
45451570|NCT02235532|Other|Foramen Herbal Aloe toothpaste|use of aloe-vera toothpaste for 30 days in the test group.
45451571|NCT02235532|Other|fluoride toothpaste|use of signal toothpaste once a day for 30 days in the control group.
45451572|NCT00069095|Drug|Oxaliplatin 130 mg/m^2|Oxaliplatin was administered in a 2 h infusion before the first dose of capecitabine.
45802431|NCT01992380|Procedure|Brain PET scan|positron emission tomography (PET) scan of the brain at 80-100 and 110-130 minutes after injection
45802432|NCT02059070|Drug|Ropivacaine|Post-operative epidural 0.125% Ropivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
45802433|NCT02059070|Drug|Bupivacaine|Post-operative epidural 0.125% Bupivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
45802434|NCT04348994|Device|Non-ablative thermal-only Er:YAG laser therapy|"Each patient will receive 3 sessions of Er:YAG laser treatment for SUI (IncontiLase®).~Single-session treatments will be offered to patients after 18, 24 and 30 months following the initial three sessions."
45802435|NCT01962961|Dietary Supplement|PharmaNAC (N-acetylcysteine)|"PharmaNAC is considered a nutritional supplement and can be obtained without a prescription. All participants will be asked to ingest two tablets twice per day during this trial. For those randomized to PharmaNAC 1800 mg twice daily, this will be two active tablets twice per day. For those randomized to PharmaNAC 900 mg twice daily, this will be one active tablet twice per day and one matching placebo tablet twice per day. For those randomized to placebo, this will be two matching placebo tablets twice per day.~PharmaNAC can be taken with or without food. The effervescent tablets should be dissolved in 8 oz. of water or juice prior to oral intake. Each participant will take study drug and/or matching placebo for 8 weeks (up to 60 days)."
45802436|NCT01962961|Dietary Supplement|Matching placebo|Inactive pill that matches PharmaNAC on taste, color, and appearance.
45931818|NCT04513106|Behavioral|"ACP programme Have a Say"|It is a theory-driven advance care planning programme specifically designed for PWEDs or persons with MCI and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model. Each dyad of participants will receive a 3-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 1 group-based sessions and 2 dyadic discussions. One hour for each session, and once weekly. Dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. They will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participant will be given an ACP booklet documenting the ACP process.
45931819|NCT04513106|Behavioral|Attention-control health talks|Dyads of participants in the control group will receive 3-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants
45931820|NCT04512079|Drug|Enoxaparin|Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl <30 mL/min) Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl <30 mL/min)
45931821|NCT04512079|Drug|Apixaban|(5 mg Q12h; 2.5 mg Q12h for patients with at least two of three of age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL)
45931822|NCT04508725|Diagnostic Test|Doppler Ultrasound|Power doppler measurements will be made
45931823|NCT04508725|Device|Vantage 256 with C5-2v transducer|Vantage 256 with C5-2v transducer, used for power doppler ultrasound, manufactured by Verasonics
45652201|NCT04995991|Behavioral|RRT rhythm only|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the RRT activities comprise only a rhythm accompaniment and no visual cue.
45451573|NCT00069095|Drug|Capecitabine 1000 mg/m^2|Capecitabine was taken within 30 min after the end of breakfast and dinner.
45931824|NCT04508725|Drug|Vascular Endothelial Growth Factor Receptor 2 tyrosine kinase inhibitor|Participants will receive less than 4 weeks of TKI treatment during the first 12 weeks
45931825|NCT04508725|Other|non-ICI therapy|TKI monotherapy, combination of TKI with other kinase inhibitor, localized tumor therapy such as radiation, chemo- or radioembolization
45931826|NCT04498572|Other|dry needling|dry needling for Gluteus Medius muscle in combination with exercises
45931827|NCT04498572|Other|sham dry needling|sham dry needling for Gluteus Medius muscle in combination with exercises
46073294|NCT00620659|Drug|Comparator: placebo|Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
46073295|NCT00620659|Drug|Comparator: modafinil|Patients will be assigned to receive modafinil 200mg oral compressed tablet (OCT), across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
46073296|NCT05188638|Drug|SoftOx Inhaled Solution (SIS)|SIS consists of the active compound, hypochlorous acid (HOCl). Concentrations of SIS refer to the concentration of HOCl in parts per million (ppm).
46073297|NCT05188638|Drug|Placebo|Sterile isotonic saline
45652202|NCT04995991|Behavioral|RRT rhythm + visual cue|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the rhythmic accompaniment is synchronize with a visual cue (the verbal stimuli are highlighted using a red font in synchrony with the rhythm).
45652203|NCT05283135|Drug|risankizumab|Risankizumab (Skyrizi) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease, ulcerative colitis, and psoriatic arthritis.
46073298|NCT00632996|Other|Rehabilitation|Exercise, manual therapy, patient education, posture, home exercise program
46073299|NCT04245930|Procedure|Bovine Pericardial Patch in Immediate Implant Breast Reconstruction|Patients will receive immediate breast implant reconstruction using Bovine Pericardial Patch
45802437|NCT03010631|Drug|Cohort 1: Lubiprostone Capsule, Fasted|Lubiprostone soft gelatin capsule administered under fasted conditions
45802438|NCT03010631|Drug|Cohort 1: Lubiprostone Sprinkle Formulation, Fasted|Lubiprostone sprinkle formulation administered under fasted conditions
45802439|NCT03010631|Drug|Cohort 2: Lubiprostone Sprinkle Formulation, Fed|Lubiprostone sprinkle formulation administered under fed conditions
45802440|NCT03010631|Drug|Cohort 2: Lubiprostone Sprinkle Formulation, Fasted|Lubiprostone sprinkle formulation administered under fasted conditions
45802441|NCT01993238|Device|Liposonix System (Model 2)|Treatment of subcutaneous adipose tissue of the abdomen using high intensity focused ultrasound (Liposonix System Model 2).
45802442|NCT01993238|Drug|Pre-treatment analgesia|Pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
45802443|NCT01965067|Drug|sugammadex|"sugammadex 4.0 mg/kg is administered in deep block state(1 - 2 PTCs) in different temperature state~Reversal effect of sugammadex in temperature state"
45451574|NCT00069095|Drug|Bevacizumab 7.5 mg/kg|Bevacizumab was administered in a 30 to 90 min infusion.
45451575|NCT00069095|Drug|Placebo for bevacizumab 7.5 mg/kg|Placebo control for bevacizumab (volume equivalent to 7.5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
45451576|NCT00069095|Drug|Oxaliplatin 85 mg/m^2|Oxaliplatin 85 mg/m^2 was administered simultaneously with leucovorin in a 2 h infusion.
45802444|NCT00374621|Drug|Misoprostol with or without isosorbide mononitrate|Misoprostol 50 micrograms orally then 100 micrograms every 4 hours for up to four doses until modified Bishop score of 8 or higher was observed vs. the same misoprostol dosing plus isosorbide mononitrate 40 mg vaginally every 6 hours up to two doses total until a modified Bishop sore of at least 8 was observed
45931828|NCT04491578|Behavioral|"ACP programme Have a Say"|Each dyad of participants will receive a 4-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 2 group-based sessions and 2 dyadic discussions. One hour for each session. The group-based sessions are nurse-led, in which dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. The dyadic sessions are led by trained ACP facilitator. Dyads of participants will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participants will be given an ACP booklet documenting the ACP process.
45931829|NCT04490278|Other|Medical Record Review - Inpatient Treatment|Patient characteristics, medical history, and information regarding their inpatient treatment from the electronic medical record
45652204|NCT04995913|Other|Online cognitive behavioral therapy|The intervention includes 9 online modules, 3 face-to-face/online/telephone counseling sessions, and 2 sessions of virtual reality exposure therapy. Participants will learn and practice a variety of the cognitive behavioral skills to cope with their social anxiety. The functions of the EASE Online Program include animation briefing and debriefing, case demonstration videos, assignment and feedback, forum, internal messaging, reminder, online assessment, online booking and progress checking. The duration of the intervention is 14 weeks.
45802445|NCT01960400|Device|transcranial direct current stimulation (tDCS) (active or placebo)|TDCS was delivered according to the method described by Fregni et al. (2006) and the safety parameters related to tDCS application were respected (DaSilva et al., 2011). Direct current was delivered using a battery-driven constant current stimulator coupled to saline-soaked (0.9% NaCl) sponge electrodes (5 X 7 cm). Anodal stimulation was delivered over the M1; the anode was placed over C3 or C4 position in the 10/20 system for the EEG electrode position, contralateral to the affected limb, and the cathode over the opposite supraorbital area (i.e. ipsilateral to the affected limb). In the laboratory, a constant current of an intensity of 2 mA was applied for 20 min/day X 5 consecutive days during the first and the second weeks of GMI. To help maintain the potential effects of the neurostimulation, the tDCS was also applied simultaneously with GMI once a week during the 2 other phases until the end of the six weeks GMI program, for a total of 14 treatment sessions.
45931830|NCT04490278|Other|Online Questionnaires|Patients will complete online questionnaires related to their physical, cognitive and mental health function and inquire about current treatments. The multiprofessional CoV-PICS clinic practitioners will evaluate their responses and, combined with information obtained during their virtual visits, formulate a suggested treatment plan and needed referrals.
45931831|NCT04468165|Drug|Dimethyl Fumarate (DMF)|Gastro-resistant Hard Capsules. Each capsule contains 240mg or 120mg Dimethyl Fumarate
45931832|NCT04461301|Procedure|Multimodal Prehabilitation|A multimodal prehabilitation program (exercise, nutrition, anemia correction and smoking cessation).
45931833|NCT04446728|Behavioral|Training Webinar|The training webinar is a three hour training. The purpose of the study is to implement the Psychosocial Assessment Tool (PAT) in their center.
45931834|NCT04446728|Behavioral|Training Webinar Plus Implementation Enhanced Resources (TIER)|In addition the Training Webinar, sites randomized to Strategy II will identify a Champion and will participate in monthly consultation calls in support of implementation of the PAT
45931835|NCT04437485|Behavioral|Good Days Ahead (GDA)|GDA (Empower Interactive) is an empirically supported, HIPAA compliant, computerized CBT for depression appropriate for primary care patients and people with little computer experience. GDA uses an interactive, multimedia format to deliver 9 45-minute sessions, the structure and content of which mirror face-to-face CBT. General topics include identifying and modifying automatic thoughts, using behavioral activation and other behavioral methods, identifying and modifying schemas, using effective coping strategies, and employing other core CBT methods. GDA is empirically supported - it is acceptable to patients, achieves superior depression outcomes to waitlist comparators, and yields equivalent (noninferior) depression outcomes to standard face-to-face CBT. To minimize time/transportation barriers, GDA sessions occur at the PI's lab or a location with internet access selected by the patient (patient's, family member's, or friend's home).
45931836|NCT04437485|Behavioral|Problem Solving Treatment in Primary Care (PST-PC)|PST-PC is an established, manualized, empirically supported CBT developed for primary care. During the 6-10 30-minute sessions, patients are taught skills for solving problems contributing to depression. We will deliver PST-PC by phone, which has been found to be feasible and efficacious.
45931837|NCT04437485|Drug|Antidepressant Medications|We first considered all FDA-approved antidepressants and excluded those with weight gain effects (tricyclics, paroxetine, mirtazapine) and those rarely used in primary care (MAOIs). Then, we used existing evidence to inform the structure. We made bupropion (an aminoketone) and fluoxetine (an SSRI) our first-line and second-line antidepressants, as meta-analyses indicate that their use is associated with weight loss. We made other SSRIs (escitalopram, sertraline) and SNRIs (desvenlafaxine, duloxetine, venlafaxine) our third-line antidepressants, given their negligible effects on weight. Our team will make recommendations to the patient's PCP, who will write prescriptions. Our team and the PCP will then collaboratively manage pharmacotherapy.
45652205|NCT03077113|Diagnostic Test|4-D CT Scan|The 4-D CT scan shows how the tumor moves when patients breathe so that motion can be taken into account when planning the radiation. This is the usual way of planning lung radiation and everyone in this study will be planned using a 4-D CT scan.
45652206|NCT03077113|Diagnostic Test|SPECT-CT Scan|It may be possible to make a more accurate plan by using a SPECT-CT scan for planning that would result in less damage to healthy lung tissue. This is not yet proven. A SPECT-CT scan uses a special camera to detect radioactivity to produce pictures which can lead to more precise information.
46073300|NCT04245930|Procedure|TiLOOP® Bra Mesh in Immediate Implant Breast Reconstruction|Patients will receive immediate breast implant reconstruction using TiLOOP® Bra Mesh
45931838|NCT04437485|Other|Active Control|(1) The graduate research assistant (RA) will have a 50-minute call with AC patients to review depression materials. The RA will provide a list of Eskenazi Health mental health services and will encourage patients to follow-up with their PCP. We will then send an electronic health record message to the PCP encouraging them to address their patient's depression, note that there are no care restrictions, and provide the same list of services. (2) The RA will call AC patients every 4 weeks to assess depressive symptoms and will notify clinical staff to encourage additional care when indicated. (3) AC patients will receive current primary care for depression. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
45931839|NCT04433364|Other|biological samples, questionnaires and interviews|"Biological samples: to study impact of testing positive for SARS-CoV-2 during pregnancy samples taken in routine clinical care, samples from already existing research biobanks and the newly established COPE biobank will be used. Time-points: inclusion, at delivery mother and fetus. Covid-19 positive group only: 48-96 h, 2 months postpartum for mother and fetus.~Questionnaires: Women and partners in both groups will fill out electronical questionnaires at different time points during pregnancy and until 12 months postpartum based on validated instruments to test for differences in Self-Efficacy, Anxiety and Depression, Health-related quality of life, Sense of Coherence, PTSD Symptoms, Postpartum Bonding, Childbirth experiences and Self-Efficacy of Breastfeeding. The child's health will be assessed regarding infection until 6 weeks of age and development until 4 years.~Interviews: 24-40 women and partners in both groups. Interviews will be conducted 3 to 6 months after childbirth."
45931840|NCT04421560|Drug|Ibrutinib|Capsule, taken by mouth daily
45931841|NCT04421560|Drug|Pembrolizumab|Given as an intravenous injection through a vein (IV) every 3 weeks
45451577|NCT00069095|Drug|Leucovorin 200 mg/m^2|Leucovorin was administered simultaneously with oxaliplatin 85 mg/m^2 in a 2 h infusion.
45931842|NCT04421560|Drug|Rituximab|Given as infusion into a vein (intravenous, IV)
45931843|NCT04420000|Behavioral|Mindfulness|Mindfulness based programme
45931844|NCT04420000|Other|Control|Treatment as usual
45931845|NCT04406649|Drug|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
45931846|NCT04402749|Other|Nephrectomy|Patients underwent nephrectomy
46073301|NCT04245852|Other|Strength education video|The Strength education video must be watched by the patient at the University of Illinois at Chicago Faculty Practice (UICFP) prior to leaving from the 3rd physical therapy visit. The Experimental Group (EG) will watch the video in the waiting room or other quiet available rooms on the 3rd floor within the UICFP. The video will be watched from an iPad/tablet/laptop/desktop computer device as available in the clinic. The EG will also be provided a handout with a link and quick response code to the video on YouTube.com
46073302|NCT04245852|Other|standard PT care|standard PT care
46073303|NCT02547415|Other|questionnaires and psychological testing|"Child/adolescent and parents interview and consultation with both a physician and a psychologist for a somatic and pain indicators assessment within an usual setting.~Then, parents and child or adolescent are interviewed separately using different psychological instruments with only a psychologist:~Psychological (cognitive and projective evaluation) : Intellectual Quotient, mental flexibility, projective evaluation with Rorschach and Thematic Apperception Test, parents and children attachment questionnaires~Psychopathological: anxiety and depression questionnaires, psychiatric disorders evaluation, quality of life, life events questionnaires, family functioning interview."
46073304|NCT05182398|Other|Assesment|Modified Four Square Step Test, Berg Balance Scale, Dynamic Gait Index ,Activity-Specific Balance Confidence Scale
46073305|NCT02843750|Behavioral|Inspiratory Muscle Training-Rehabilitation|"The training will include the following components:~Breathing Awareness~Upper and Lower Extremity Exercise.~Instructions for Inspiratory Muscle Training (IMT) performed using the PFlex valve~Practice at home"
46073306|NCT02843750|Other|Questionnaires|Patient quality of life will be measured using patient-reported outcomes measurement information system (PROMIS) global items. Patients will also complete the Chronic Respiratory Questionnaire (CRQ) and the Medical Research Council Dyspnea Scale (MCR).
45652207|NCT03072901|Device|EndoBarrier Gastrointestinal Liner|The EndoBarrier Gastrointestinal Liner (EndoBarrier) is a nonsurgical metabolic intervention for the treatment of Type 2 diabetes and obesity. By bypassing the duodenum and proximal jejunum, the device may alter signaling pathways that control metabolic processes.1, 2 The effect on patient's glucose levels is immediate as evidenced by meal tolerance testing.3 Since the device also promotes reduced appetite resulting in weight loss, the effect is maintained as the patient loses weight over the implant period. Most patients achieve normal HbA1c and fasting plasma glucose (FPG) levels rapidly within 3-6 months.
45652208|NCT03073057|Drug|Budesonide/formoterol|2 inhalations as a single dose
46073307|NCT02829060|Drug|Nitrofurantoin 100 MG, 7d|7 day course, 100 mg twice daily, PO
45652209|NCT03073057|Other|Charcoal|
45652210|NCT03073057|Drug|Symbicort Turbuhaler|2 inhalations as a single dose
45652211|NCT03073369|Drug|Ergocalciferol 50000 UNT|Oral Ergocalciferol 50000 IU once daily for 6 weeks
45451578|NCT00069095|Drug|Fluorouracil 400 mg/m^2|
45451579|NCT00069095|Drug|Bevacizumab 5 mg/kg|Bevacizumab was administered in a 30 to 90 min infusion.
45451580|NCT00069095|Drug|Placebo for bevacizumab 5 mg/kg|Placebo control for bevacizumab (volume equivalent to 5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
45451581|NCT00086411|Drug|nicotine transdermal system|starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks.
45451582|NCT00086411|Drug|bupropion|150 mg/day X 3 days 300mg/day for 60 days Total 9 weeks
45652212|NCT03073369|Drug|Placebo|Oral Placebo - one capsule once daily for 6 weeks
45451583|NCT00086411|Behavioral|Medication Management|Brief manual based therapy; four 15 minute session over 10 weeks.
45451584|NCT00086411|Behavioral|Mayo Counseling|Manual based therapy; Weekly 30 minute sessions for 10 weeks
45931847|NCT04392622|Drug|D-Limonene Gelcaps|Administered orally at 2 to 8 grams daily
45652213|NCT04995757|Device|Stent Retriever|Stent Retriever for acute ischemic stroke
45451585|NCT00086411|Drug|placebo patch|placebo patch containing no nicotine
45931848|NCT04392622|Radiation|Intensity modulated radiotherapy (IMRT)|Standard of Care -All patients will receive standard radiation treatment of 66 to 70 Gy given in 33 to 35 fractions (2 to 2.12 Gy/fractions) over 6.5 to 7 weeks.
45931849|NCT04392622|Drug|Cisplatin|Standard of Care -Cisplatin as 100 mg/m2 IV
45931850|NCT04392622|Other|Xerostomia questionnaire|Xerostomia questionnaire consists of 4 items on dryness while eating/speaking and 4 on dryness at rest. Patients rate each symptom on an 11 point ordinal Likert scale from 0 to 10, with higher scores indicating greater xerostomia
45931851|NCT04378374|Other|Food-1|Baked food made of lentil flour
45931852|NCT04378374|Other|Food-2|Baked food made of lentil flour and wheat flour
45931853|NCT04378374|Other|Food-3|Baked food made of wheat flour
45931854|NCT04378374|Other|Food-4|Potable water (energy and carbohydrate-free control)
45931855|NCT04362917|Other|There is no intervention|There is no intervention
45931856|NCT04361201|Procedure|Ligament plastic surgery|Ligament plastic surgery of ankle under arthroscopy for recurrent instable ankle reason and failure of medical treatment.
45931857|NCT04361201|Diagnostic Test|RMI and ultrasound|RMI examination at 3 months on operated ankle, and 3 CT scan examinations with elastography module will be performed at planned timeframes.
45931858|NCT04360252|Other|Gracie Diet|"The patient is going to have an encounter with the nutritionist (either face to face or by phone call) and she will provide patient with the requisite nutritional information and will guide patient on how to properly adhere to the diet.~The session is designed to: answer patient questions, educate patients so that patients understand the underlying nutritional concepts that the diet is based upon, support patients by empowering the patients to make healthy nutritional choices consistent with the diet, educate patients regarding the appropriate combinations of healthy foods, and help patients to develop menu samples based on the Gracie Diet when there is interest."
45931859|NCT04332341|Drug|Nicotinamide riboside (NR)|Nicotinamide riboside, PO, 500mgtwice daily for 21, 28, and 35 days
46073308|NCT02829060|Drug|Gentamicin, 5mg/kg|Peri-operative dose: 5 mg/kg of ideal body weight, IV
45931860|NCT04328402|Diagnostic Test|Polysomnography|Polysomnography, referred to as type I, allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables to document tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial and other muscular activity during sleep. The apnea and hypopnea index (AHI) is defined as the number of obstructive apneas and hypopneas per hour of sleep. Obstructive Sleep Apnea is defined in PSG when AHI≥1 and is divided into the following categories, according to severity: mild OSA (AHI 1-4.9), moderate OSA (AHI 5-9.9) and severe OSA (IAH≥10). Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or episodes are greater than or equal to 4 (high frequency SB, severe bruxism).
45931861|NCT04323657|Drug|TC-110 T Cells|TC-110 T Cells
45931862|NCT04323657|Drug|Fludarabine|Flu/Cy Lymphodepletion
46073309|NCT02829060|Drug|Ampicillin 2g|Peri-operative dose: 2 grams, IV
46073310|NCT02829060|Drug|Nitrofurantoin 100 mg, 48 hrs|48 hour course, 100 mg twice daily, PO
45652214|NCT03072823|Dietary Supplement|n-3 Polyunsaturated fatty acid|2 g of Eicosapentaenoic acid (EPA) and 1 g of Docosahexaenoic acid (DHA)
45652215|NCT03072823|Dietary Supplement|placebo|olive oil ethyl esters
45652216|NCT04995679|Procedure|Implant of metaphyseal sleeves in Total knee arthroplasty|Implant of metaphyseal sleeves in Primary and revision TKA
45931863|NCT04323657|Drug|Cyclophosphamide|Flu/Cy Lymphodepletion
45931864|NCT04320251|Procedure|cochlear implant revision surgery|Observation during routine cochlear implant revision surgery
45931865|NCT04318691|Biological|Blood sampling|Blood sampling at baseline and at day-3 (10 ml, EDTA tube), test of NETs.
46073311|NCT02829060|Drug|Gentamicin, 80 mg, 7d|7 day course, 80 mg daily, IM or IV
46073312|NCT02829060|Drug|Gentamicin, 80 mg, 48hr|48 hour course, 80 mg daily, IM or IV
46073313|NCT00838669|Drug|Extended release OROS paliperidone|
46073314|NCT00783146|Drug|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
46073315|NCT00783146|Drug|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
46073316|NCT00783146|Drug|placebo|placebo, once daily for 15 days
46073317|NCT00844675|Drug|rabeprazole|The rabeprazole group will receive oral rabeprazole 20mg twice day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
46073318|NCT00844675|Drug|placebo|The placebo group will receive a placebo by mouth twice a day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
46073319|NCT02837900|Drug|TPX-100 200 mg 4 times weekly for 4 weeks|Ea. subject will received active TPX-100 200mg in the Left knee
45652217|NCT04995289|Other|Prone position on ECMO patient|blood gas analysis before and after PP
45931866|NCT04318691|Procedure|Bronchoalveolar lavage|Bronchoalveolar lavage at admission to the ICU with analysis of cytological, bacteriological, viral and anatomopathological, and test of NETs.
45931867|NCT04288479|Behavioral|Single high-intensity interval training session|10 minutes warming up at low-to-moderate intensity, 8x30 seconds high intensity interval training with fetal heart rate measurement after each 30 second work-bout, 2 minutes recovery at low-to-moderate intensity. Continuous monitoring of maternal heart rate.
46073320|NCT02837900|Drug|TPX-100 200 mg 4 times weekly for 4 weeks|TPX-100 100mg Right
46073321|NCT02826096|Behavioral|Biofeedback therapy|The brief version of biofeedback therapy is conducted by psychologists following the structure way. Biofeedback therapy is six session treatment once a week.
45652218|NCT03076957|Drug|CKD-516 Tablet|CKD-516 PO for 5 consecutive days and 2 days off in Combination with Irinotecan inj.
45802446|NCT01960400|Device|Graded motor imagery (GMI)|The treatment was performed using a software (Recognise™ online) provided by NOI group (http://www.noigroup.com/recognise). As an alternative to the software (for patients without an internet access), the patient could do the exercises with a Recognise™ Flash Cards set consists of 25 left and 25 right matching images (upper limb or lower limb). Using standardized procedures, inspired from the randomized controlled trial conducted by Moseley (2004, 2006), the participants performed the therapy at home, 10 minutes per session, 3x/day, 6 days/week, using the computer software and a mirror box (Lagueux et al., 2012).
45931868|NCT04280458|Behavioral|Intentive rehabilitation|"Intervention included:~psychomotor 5 hours/week ±30 minutes~kinesitherapy 1.5 hour/week ±20 minutes~during 12 months."
45931869|NCT04280458|Behavioral|Routine care|"Intervention included:~kinesitherapy 0.5 hour/week ±10 minutes~psychomotor 30 min/week ±10 minutes during 12 months."
45931870|NCT04278092|Drug|Paclitaxel|Paclitaxel 175 mg/m2, q21
45931871|NCT04278092|Drug|Cetuximab|Cetuximab 400mg/m2 loading dose followed by weekly 250mg/m2
45931872|NCT04273919|Device|HTC Vive with Karuna Virtual Reality Program|HTC Vive head-mounted display and an HTC Vive body tracker adhered to a belt on the patient's low back, which will be placed 2 inches below the waist
45802447|NCT03012191|Drug|Gentamicin Sulfate|Participants will be divided into three cohorts: topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
45931873|NCT04273919|Device|HTC Vive with Lumen Program|HTC Vive head-mounted display with Lumen program
45931874|NCT04271358|Behavioral|Peer Health Coaching|The Peer Coaching group will receive 6 months of peer health coaching via a secure telephone and text messaging system.
45931875|NCT04269759|Other|Survey|pregnant women will answer to a survey regarding their oral health knowledge, attitudes and practices for themselves and their unborn child
45931876|NCT04269759|Other|dental care|pregnant women will have a dental care
45931877|NCT04263285|Device|rTMS|The study team will deliver rTMS five days a week for four weeks, according to a specific and approved protocol for participant positioning, motor threshold determination, and dosing.
45931878|NCT04240106|Drug|Niraparib 100 MG|Niraparib 200 or 300 mg daily (orally) beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
45931879|NCT04240106|Drug|Aromatase Inhibitors|Aromatase Inhibitors beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
45931880|NCT04236492|Procedure|Fresh osteochondral allografting|Transplantation of a fresh osteochondral allograft in the knee
46073322|NCT00831883|Behavioral|Partner-Specific IMB-based HIV risk reduction intervention|5 session partner-specific HIV risk reduction group intervention based on the Information-Motivation-Behavioral Skills model.
46073323|NCT00831883|Behavioral|Healthy Lifestyle|5 session psychoeducational group, designed to provide equivalent time and attention, that focuses on the importance of maintaining a good diet, exercise, and developing health skills.
46073324|NCT02840006|Procedure|General anesthesia only|Induction drugs: Citrate of fentanyl, atracurium, etomidate
45802448|NCT01994486|Drug|Telaprevir and Sofosbuvir|All subjects will have time to read and discuss IRB approved consent form prior to any study procedures. Following proper consenting, subjects will undergo physical exam including ECG and bloodwork prior to baseline visit. Subjects will return for research visits (vitals, collection of AEs, bloodwork, drug accountability) on Day 3, Weeks 1, 2, 3, 4, 6, 8, 10 and 12 of treatment and 4, 12, and 24 weeks after end of treatment. PK samples will be collected at week 2 and week 10.
45802449|NCT01966159|Device|SYNERGY Investigational Device|percutaneous coronary intervention
45802450|NCT01966159|Device|PE Plus Investigational Device|percutaneous coronary intervention
45931881|NCT04229875|Other|CAG Bipolar|See description of CAG Bipolar
45931882|NCT04221373|Device|Ekso™ powered exoskeleton|Powered exoskeletal-assisted walking (EAW) for early training
45931883|NCT04221373|Other|Standard of care|Participants will receive standard of care of acute inpatient rehabilitation.
45931884|NCT04220489|Drug|Ketamine|Intraoperative ketamine and post operative 48 hour ketamine infusion with a standardized general anesthesia protocol.
45931885|NCT04220489|Drug|Placebo Comparator|Participants will receive a 1 mg/kg dose of intravenous saline 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr saline with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure)
45931886|NCT04213456|Dietary Supplement|Nutritional Sport Formula|Powder added to water,high protein and multi vitamins and minerals
45931887|NCT04213456|Dietary Supplement|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals.
45931888|NCT04212962|Behavioral|Transitional care model (TCM)|Patient education about post-discharge self-care and medications, arrangement of needed social services, coordination of information from medical providers interacting with patient
45931889|NCT04212962|Behavioral|Usual care|usual hospital discharge and post-discharge care
45931890|NCT04201262|Biological|Ravulizumab|Participants will receive a weight-based loading dose of ravulizumab via IV infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until end of the Long-Term Extension Period.
45931891|NCT04200365|Drug|Itacitinib|Itacitinib will be administered orally once daily for up to 24 months.
45931892|NCT04196933|Behavioral|Temporal Binding Adaptation - TBW training|The investigators will use a temporal order judgment (TOJ) with a visual (light) cue and a motion (yaw rotation, y-translation) cue. The relative timing of the motion onset and the light are varied and subjects indicate which occurred first by pressing a button after the motion ends. The TOJ task will generate a psychometric curve and the PSS (point of subjective simultaneity) and TBW (temporal binding window) are calculated. Then training focuses on SOAs (stimulus onset asynchronies) near the TBW borders (e.g., PSS +/- 0.5xTBW), starting from 50 ms outside the TBW and moving randomly towards the PSS. The goal of the training is to narrow the TBW -- training trials will be provided for 30 min and after each response the subject is told if their response was right or wrong. After training, the TOJ task is repeated to determine how the TBW has changed. Sham training will be the same as the actual training except that verbal feedback of response accuracy will not be provided.
45931893|NCT04196933|Behavioral|Temporal Binding Adaptation - PSS training|After the PSS and TBW are calculated with the standard TOJ paradigm, 100 training trials are provided where the SOA is set to [PSS - 200 ms], with the goal of shifting the PSS more negative. Then the TOJ task will be repeated but every 10 testing trials will be followed by 10 training trials (SOA = PSS - 200), and this pattern will be repeated 10 times to 100 more training trials interspersed with the Post TOJ data. Subjects will respond after all trials and testing and training will not be distinguished. After this is completed, the new PSS and TBW are calculated. Sham PSS training will be identical to the above except that the 'training' period will consist of random SOAs rather than a series of fixed SOAs.
45652219|NCT04992793|Combination Product|Congenital heart surgery|Paediatric congenital heart surgery
45652220|NCT03077035|Other|glass ionomer sealants|
45931894|NCT04196933|Behavioral|Temporal Binding Adaptation - PSS adaptation with VI stimulation|The adaptation will utilize the same approach used in non-implanted patients. The investigators will provide a repeated, fixed SOA with either the CI or VI leading the other stimulus by 220 ms. After the training period, which will match the number of stimuli pairs provided to our normal vestibular-auditory control subjects undergoing PSS adaptation, the TOJ study is repeated to recalculate the PSS and TBW.
45652221|NCT03077035|Other|resin-based sealant|
45652222|NCT04992325|Diagnostic Test|Anterior segment-optical coherence tomography|Each subject underwent anterior segment -optical coherence tomography to evaluate the total corneal, epthelium and stromal thicknesses.
45931895|NCT04196933|Behavioral|Chronic Motion-modulated Stimulation|To provide 8 hours of 'physiologic' CI and VI inputs during normal activities, the investigators will employ standard motion-modulated stimulation with the VI. This requires pre-adaptation to a 200 pps tonic stimulation rate (to emulate the push-pull design of the native vestibular system allowing modulating stimulation upward or downward with opposite directions of motion). The three electrodes are connected to the head-mounted prosthetic circuit, which consists of three angular velocity sensors (one aligned with the sensitive axis of each canal) such that head rotations in the plane of the given canal modulate the stimulation rate of the corresponding electrode, upward (for ipsi) or downward (for contralateral) head rotations, thereby simulating normal canal-mediated modulations.
45931896|NCT04189107|Drug|Dexamethasone|High-dose dexamethasone peroperative and postoperative on day 2 and 4
45802451|NCT01997216|Device|Delefilcon A multifocal contact lens|Investigational silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
45931897|NCT04189107|Drug|Placebo|low dose dexamethasone peroperative and placebo postoperatively on day 2 and 4
45931898|NCT04179643|Biological|3 x 10e13vg NAN-101|There are 2 components to NAN-101. The first is an active I-1 transgene (AA 1-65 with T35D), and the second is the vector, BNP116, which delivers the gene selectively to the heart after intracoronary administration.
46073325|NCT02840006|Procedure|General anesthesia and Spinal anesthesia|Induction drugs: Citrate of fentanyl, atracurium, etomidate Spinal anesthesia: Bupivacaine hyperbaric, Morphine
46073326|NCT02826252|Drug|Iloprost,(Ventavis, BAYQ6256)|Ventavis (Iloprost) nebulizer solution for inhalation as 10 μg/mL (V10) and 20 μg/mL (V20).
46073327|NCT02826252|Device|I-Neb AAD system|Nebulizer, allows digital recording of inhalation data such as doses, inhalations per day and duration of inhalation (per day) etc.
46073328|NCT02547961|Biological|HER-2-targeting CAR T Cells infusion|HER-2-targeting CAR t cells infusion in breast cancer
45802452|NCT01997216|Device|Lotrafilcon B multifocal contact lens|Commercially marketed silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
45802453|NCT02059928|Device|Intraosseous Device|
45802454|NCT01967641|Drug|buprenorphine/naloxone combination|Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be maintained on 16/4 mg Bup/Nx.
46073329|NCT00844909|Drug|CNTO 136|
46073330|NCT02839928|Drug|Intranasal ketamine|The experimental arm consists of an single intranasal administration of Ketamine (Ketalar).
45802455|NCT03017261|Device|TSolution One®|Total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
45652223|NCT03074071|Behavioral|Hope Enhancement Workshop|Participants in the workshops will be prompted and guided through exercises that help them get in touch with goals that are not explicitly related to cure of disease. These goals will include symptom relief and other personal and or professional objectives.
45652224|NCT01652911|Device|Sernova Cell Pouch|The Cell Pouch™ is an implantable medical device for transplantation of donor islets for Type-1 diabetes as an alternative to the current standard of care using intraportal delivery of islets.
45652225|NCT03073993|Procedure|feeding tube insertion|Feeding tube was inserted in hemodynamically stable babies for purpose of feeding
45652226|NCT04433611|Drug|2% lidocaine|"intrauterine infusion of 2% lidocaine (Rafa laboratories, Israel) just prior to HyFoSy~The VAS consisted of a 10 cm line ranging from 0 to 10 (anchored by 0=no pain and 10=very severe pain). Patients were asked to mark the number that represented their perceived level of pain. Based on the VAS scores, the pain level ratings were classified as: mild (rated 1-3), moderate (4-6) or severe (7-10)."
45652227|NCT04433611|Drug|0.9 % normal saline|intrauterine infusion of 0.9 % normal saline
45652228|NCT04992559|Drug|Consolidation Toripalimab|Toripalimab consolidation therapy after radiotherapy or chemoradiotherapy, 240mg IV, every 3 weeks, until progressive disease (PD), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Toripalimab will be given at a maximum of 12 months.
45802456|NCT01968421|Drug|OM-85 BV|two courses of 7mg of OM-85 or matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
45802457|NCT02314520|Device|peripherally inserted central catheter|Any complication associated with central access
45931899|NCT04154891|Genetic|Trio Whole Genome Sequencing|WGS trio analysis will be performed using the genome data of the index case in addition to the genome data of his parents. This analysis will follow a consensus protocol that contains 3 obligatory steps: first of all, de novo variants (SNV, CNV and others SV) will be examined in the whole genome data set; then, a SNV/CNV/other SV analysis will be performed under a AR or X linked Mendelian mode hypothesis in the whole genomic regions of a OMIM extended list (that contains all genes already involved in human genetic diseases). Finally, analysis will focus on inherited pathogenic variants under an AD mode hypothesis (analysis of variations already reported as pathogenic in clinVar or HGMD pro; CNV or truncating variation in OMIM genes, etc). When these 3 steps analysis is completed then variants of interest identified at each step will be recorded until examination by a specific multidisciplinary meeting.
45931900|NCT04154891|Genetic|Simplex Whole Genome Sequencing|This analysis will be performed using only the index case following a similar strategy than the one used for the WGS trio
45931901|NCT04154891|Genetic|Current French Reference strategy|Actual ANPGM recommendations defined by the following analysis: Fra-X + chromosomal microarray analysis + 44GPS
45931902|NCT04153175|Combination Product|ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC)|Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of CT-010.
45931903|NCT04153175|Combination Product|Placebo delivery via an implantable pump and a cranial port and dual lumen catheter (CIC)|Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of a placebo (saline).
45931904|NCT04136912|Drug|Definity|Perflutren will be administered in split doses using the dosing range and administration type IV bolus) within the perflutren prescribing information. When administered as a bolus, the package insert recommends 10 uL/kg patient weight administered within 30-60 seconds, followed by a 10mL saline flush with a second dose of 10 uL/kg patient weight 30 minutes following the first dose, if needed.
45931905|NCT04136912|Device|Acoustic Angiography|"Acoustic angiography imaging involves a research ultrasound scanner as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. Imaging will be performed within the package insert guidelines for ultrasound system mechanical index (a measurement of output power) when imaging perflutren contrast agent (less than 0.8).~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes."
45931906|NCT04128488|Other|Abdominal MR Imaging|Imaging to evaluate visceral adipose tissue and hepatic lipid content
46073331|NCT02839928|Device|Intranasal atomizer|Ketamine will be applied to each nare via intranasal atomizer
46073332|NCT02839928|Drug|EMLA|
46073333|NCT05018520|Drug|Six Courses of R-CHOP Plus Two Courses of Rituximab|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 21 days for total 2 courses)
46073334|NCT05018520|Drug|Four Courses of R-CHOP Plus Four Courses of Rituximab|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 4 courses) followed by Rituximab (375mg/m2 d1, every 21 days for total 4 courses)
45652229|NCT04992481|Procedure|PMTC|In patients from the study groups I, II, III, IV a professional mechanical tooth cleaning (PMTC) including air-polishing was proceeded on every visit using a glycine-based prophylaxis powder (Air-Flow Soft, EMS, Switzerland).
45652230|NCT04992481|Procedure|fluoride varnish|In patients from groups I, II, III, IV a fluoride varnish of 5% NaF (Profluorid Varnish, Voco, Germany) was applied with a microbrush. Every patient was instructed to stop from drinking and eating for the next two hours (as recommended by the manufacturer).
45652231|NCT04992481|Procedure|gaseous ozone therapy|Patients from groups II and IV were additionally subjected to in-office ozone therapy using OzonyTron-OZ (Mymed, Germany). Ozone was applied on a silicone double-jaw tray of a proper size (allowing even ozone distribution in the oral cavity) following professional mechanical tooth cleaning. A Full Mouth Desinfection program lasting 5 minutes was used.
45652232|NCT04992481|Procedure|domestic octenidin mouth rinse|Patients from groups III and IV received a domestic mouthrinse (Octenidol MD, Schülke, Germany) and were recommended to use 15 ml of the liquid for 30 seconds after evening toothbrushing.
45802458|NCT02314520|Device|centrally inserted central catheter|Central access not associated with any complication
45802459|NCT02913521|Drug|Diclofenac Sodium Gel 1%|
45802460|NCT02913521|Drug|Voltaren Gel|
45451586|NCT00086411|Drug|placebo bupropion|placebo pills
45652233|NCT04992091|Other|constructive debriefing|Constructive debriefing was applied to an interventional group Traditional debriefing was applied on noninterventional group
45652234|NCT02597933|Drug|Nintedanib|
45652235|NCT02597933|Drug|Placebo|
45802461|NCT02913521|Drug|Placebo|
45802462|NCT01969201|Drug|Urofollitrophin|
45802463|NCT01969201|Drug|Follitrophin alpha|
45802464|NCT02062502|Biological|VARIVAX™ New Seed Process|Varicella virus vaccine live manufactured with a new seed process
45802465|NCT02062502|Biological|VARIVAX™ 2007 process|Varicella virus vaccine live manufactured with the 2007 process
45451587|NCT03961997|Drug|Lorlatinib 50 mg|Participants will receive a single dose of lorlatinib 50 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 50 mg on Day 15 of Period 2.
45802466|NCT02062502|Biological|M-M-R II™|Measles, Mumps, and Rubella virus vaccine live
45802467|NCT01962428|Drug|ticagrelor|Patients will receive ticagrelor 360mg loading dose or 180mg loading dose , then 90mg bid maintenance dose starting 12 hours after loading dose.
45802468|NCT01999400|Drug|Pentasa 500 mg capsule x 2 with 240 mL water; single dose|
45931907|NCT04128488|Other|Cardiac MRI/MRS|Imaging to evaluate cardiac function and structure
45931908|NCT04128488|Other|Oral Glucose Tolerance Testing|Blood testing to evaluate changes in glucose and insulin in response to oral glucose load
45931909|NCT04128488|Other|Whole Body, Lumbar Spine, and Hip DEXA Imaging|Imaging to evaluate fat and lean body mass as well as bone mineral density
45931910|NCT04127383|Device|Assessment of Burden of Chronic Conditions (ABCC)-tool|The tool consists of a questionnaire, a visualisation using balloons, and treatment advice. A patient completes the questionnaire before consultation. The questionnaire measures the experienced burden of the chronic condition(s), and several risk factors. The questionnaire consists of a generic part and disease-specific parts. The generic questionnaire will be combined with any amount of disease-specific questionnaires (i.e. COPD, asthma, diabetes type 2 and heart failure), to form a single personalised scale and balloon chart for each individual patient. Outcomes of the questionnaire are visualised using balloons. The healthcare provider opens the visualisation during consultation. A balloon represents a domain, and the colour and height indicate a score on that domain. If a patient and healthcare provider select a balloon by clicking on it, treatment advice is shown by means of pop-ups. Based on the discussion following treatment advice, personal care plans can be determined.
45931911|NCT04124991|Drug|Durvalumab|Radioembolization with Yttrium-90 Microspheres
45451588|NCT03961997|Drug|Lorlatinib 75 mg|Participants will receive a single dose of lorlatinib 75 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 75 mg on Day 15 of Period 2.
45931912|NCT04124991|Radiation|Radioembolization|Radioembolization with Yttrium-90 Microspheres
45931913|NCT04123314|Drug|Psilocybin|Dosing at the first session will be 15 mg/70 kg. For the second session participants will either remain at the initial dose, or increase to 25 mg/70 kg at the discretion of the study team.
45931914|NCT04121741|Other|Singing with Music Therapist|Music therapy sessions will begin with vocal and breathing warm-up exercises for about 10 minutes. The Music Therapist will play the songs (chosen from a list by the subject) to sing along to and will alter the characteristics of the music (volume, tempo, level of support) to ensure a successful experience for subjects and motivate them to put forth more effort into singing the song. The music therapist will continue to coach throughout the 30-minute session, reminding subjects of strategies practiced and how to implement those strategies while singing. Music therapy sessions will be led by Erica Flores, MT-BC, WMTR, Owner of Healing Harmonies Music Therapy, or a member of her team. Erica and her team of MTs were trained in Neurological Music Therapy.
45931915|NCT04121741|Other|Singing with Guided Video|The videos will include a vocal warm-up (10 minutes long). The subject will then have the option to select and sing two songs (10 minutes each), with offerings in four music genres including Folk, Pop, Country, and a Hymn. Each piece will vary in tempo, melodic contour, and rhythm. The total duration of singing via this format will be 30 minutes.
45931916|NCT04121741|Other|Control Arm|30 minute rest period, no singing will take place during this arm. During this rest period a member of the study team will assist the subject in a hearing test using headphones, a tablet, and a trumpet app. This is done to asses the current hearing level of the subject.
45931917|NCT04115267|Radiation|Radiotherapy|Combined modality
45652236|NCT03072667|Drug|Omegaven|Omegaven™ will be initiated at 0.5 gm fat/kg of body weight per day (5cc/kg per day of Omegaven™) for 2 days. On day 3, the rate of Omegaven™ will be increased to 1g/kg (10cc/kg) per day and will remain at this level thereafter unless otherwise indicated.
45931918|NCT04111835|Diagnostic Test|Offering an alternative cervical cancer screening method - hrHPV molecular testing.|"Women randomized to this screening strategy group will take a hrHPV molecular test.~hrHPV-positive - reflex LBC:~Abnormal reflex LBC (ASC-US or worse) -> colposcopy~Normal reflex LBC -> repeat LBC in 6 months~Positive - colposcopy~Negative - rescreen in 3 years~HPV-negative - rescreen in 5 years"
45931919|NCT04109716|Behavioral|Interpersonal Psychotherapy - Adolescent Skills Training|This is an indicated group depression prevention consisting of 2 individual pre-group sessions, 8 weekly group session, and up to 6 individual booster sessions. IPT-AST will be delivered predominately through telehealth.
45652237|NCT04995367|Device|Implementation of a BCI system integrated to the T-FLEX lower-limb exoskeleton in post-stroke patients.|The participants will carry out 4 tasks with a BCI system integrated to the T-FLEX device. The task consists of 1 session that includes 4 conditional experiments: Active ankle movement, passive ankle movement, Motor Imagery Detection with Visual cue, and Motor Imagery Detection with Tactile Stimulation and visual cue.
45652238|NCT05004415|Drug|AT-527 (R07496998)|Study participants will receive a single radiolabeled dose of 550 mg AT-527.
45652239|NCT04912843|Drug|NR082 injection|Intravitreal injection（IVT）
45652240|NCT04912843|Device|Sham Injection|Sham Intravitreal Injection
45652241|NCT04911127|Drug|200mg Cannabidiol by capsules twice daily|200mg twice daily via 50mg capsules
45802469|NCT01999400|Drug|Apriso 375 mg capsule x 3 with 240 mL water; single dose|
45802470|NCT01999400|Drug|Lialda 1200 mg tablet x 1 with 240 mL water; single dose|
45802471|NCT01999400|Drug|Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose|
45802472|NCT02000180|Behavioral|Progressive Group|
45802473|NCT01969435|Drug|Carmustine|
45802474|NCT01969435|Drug|Etoposide phosphate|
45802475|NCT01969435|Drug|Cytarabine|
45802476|NCT01969435|Drug|Melphalan HCl (propylene glycol-free)|
45802477|NCT01965002|Device|MRgHIFU|The InSightec ExAblate 2000 magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue
45802478|NCT01965002|Drug|Aspirin|325 mg PO for deep venous thrombosis (DVT) prophylaxis initiated 2 hours prior to magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) treatment
45802479|NCT01965002|Drug|Enoxaparin|40 mg by subcutaneous (SC) administration, for deep venous thrombosis (DVT) prophylaxis initiated 2 hours prior to magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) treatment
45802480|NCT02304757|Drug|99Tc-MDP|99Tc-MDP, H20000218
45802481|NCT02304757|Drug|Fosamax|H20080172
45802482|NCT02002208|Drug|OC000459|Oral CRTH2 antagonist
45802483|NCT01969747|Drug|Empagliflozin medium placebo|Empagliflozin medium placebo
45451589|NCT03961997|Drug|Lorlatinib 100 mg|Participants will receive a single dose of lorlatinib 100 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 100 mg on Day 15 of Period 2.
45451590|NCT00068393|Drug|Doxorubicin|Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
45652242|NCT04911127|Drug|400mg Cannabidiol by capsules twice daily|400mg twice daily via 50mg capsules
45451591|NCT00068393|Drug|Gemcitabine|Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
45652243|NCT04911127|Drug|Placebo capsules|MCT oil capsules as placebo for CBD
45451592|NCT00068393|Drug|G-CSF (granulocyte-colony stimulating factor)|Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
45652244|NCT04995133|Drug|Colistin|intravenous administration
45652245|NCT04827173|Procedure|transcutaneous medium-frequency alternating current|Patients receive nerve block of right forearm through transcutaneous medium-frequency alternating current
45802484|NCT01969747|Drug|Empagliflozin low placebo|Empagliflozin low placebo
45802485|NCT01969747|Drug|Empagliflozin low placebo|Empagliflozin low placebo
45802486|NCT01969747|Drug|Empagliflozin high placebo|Empagliflozin high placebo
45802487|NCT01969747|Drug|Empagliflozin medium|Empagliflozin medium
45802488|NCT01969747|Drug|Empagliflozin medium placebo|Empagliflozin medium placebo
45802489|NCT01969747|Drug|Empagliflozin high placebo|Empagliflozin high placebo
45802490|NCT01969747|Drug|Empagliflozin high placebo|Empagliflozin high placebo
45802491|NCT01969747|Drug|Empagliflozin medium placebo|Empagliflozin medium placebo
45802492|NCT01969747|Drug|Empagliflozin low placebo|Empagliflozin low placebo
45802493|NCT01969747|Drug|Empagliflozin low|Empagliflozin low
45802494|NCT01969747|Drug|Empagliflozin high|Empagliflozin high
45802495|NCT02002832|Drug|Lurasidone tablets|Lurasidone tablets (40or80mg/day) and Risperidone tablets(Placebo)
45802496|NCT02002832|Drug|Risperidone tablets|Risperidone tablets(2-6mg/day) and Lurasidone tablets(Placebo)
45802497|NCT02010151|Other|NAD-CPR|When Dispatcher detects OHCA, short message service (SMS)about the OHCA event and information about the location of nearest AED is sent to trained laypersons within geographically accessible area.
45802498|NCT01966718|Drug|Repository corticotropin injection|An adrenocorticotropic hormone (ACTH) analogue that stimulates the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances
45802499|NCT02010697|Behavioral|Messages targeting nonsmokers|
45802500|NCT02010697|Behavioral|Messages targeting smokers|
45802501|NCT02004158|Behavioral|Positive psychology intervention|
45802502|NCT02308501|Drug|Lastacaft ®|
45802503|NCT02308501|Drug|Tears Naturale ® (Placebo)|
45802504|NCT02005016|Behavioral|Naming therapy|Participants will receive behavioral therapy which is designed to stimulate semantic (meaning) representations which are required for successful naming (word production). Therapy will be administered for 4 weeks on an intensive schedule (5 days a week, approximately 4.5 hours per day).
45802505|NCT02311309|Other|Control|Control patients were defined as either transfusion using only pre ordered packed red blood cells or peroperative hemoglobin concentration >8 g/dL.
45802506|NCT02311309|Other|Unanticipated bleeding|Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or peroperative hemoglobin concentration < 8 g/dL.
45802507|NCT01967342|Behavioral|Pain Ed|A 10-week psychosocial group treatment for chronic pain that focuses on providing information about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to take ownership of their chronic pain care through building deeper knowledge about their pain condition and their interactions with the health care system.
45802508|NCT01967342|Behavioral|CBT for Pain|A 10-week psychosocial group treatment for chronic pain that focuses on providing information and skills about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to self-manage their chronic pain through building deeper knowledge about and better skills for improving their pain condition and their interactions with the health care system.
45802509|NCT01967342|Other|Usual Care|A comparison condition in which patients receive standard individualized medical care from the federally qualified health center partnering on this study. Care can include basic biological interventions, such as medication or surgery, as well as supplementary care such as chiropractic or physical therapy. However, cost has a pragmatic influence on the amount of services provided, sought, and received.
45802510|NCT02006108|Drug|Feraheme|Therapeutic classification: iron preparations. Use: Off-label use of ultrasmall paramagnetic iron nanoparticle as contrast agent for magnetic resonance imaging
45931920|NCT04109716|Behavioral|Services as usual|Services as usual is expected to be brief periodic sessions (in person or remote) with the school counselor or services in the community.
45652246|NCT04991857|Other|T-FAME-HF|16-week program adopts a hybrid approach to combine nurse-led home visits, an Apps, tele-care and optimized family support to enhance post-discharge disease management, disease monitoring, and patients' access to the nurse, and telephone visits
45652247|NCT04991857|Other|Control group - HF education program|For patients assigned to the control arm will receive HF education program, the care dyad will receive a 16-week HF education program that comprises a home visit by the team nurse, five bi-weekly online training on self-care through videos on Whatapps/ WeChat with two subsequent telephone follow-up.
45652248|NCT04362839|Biological|Ipilimumab|Given IV
45802511|NCT02006108|Other|MRI-GE Healthcare 3 Tesla magnet|All patients will undergo
45931921|NCT04091191|Dietary Supplement|Meta19.01|A specialized nutraceutical containing plant extracts, vitamins and fish oil
45652249|NCT04362839|Biological|Nivolumab|Given IV
45652250|NCT04362839|Drug|Regorafenib|Given PO
45652251|NCT04994821|Device|transcranial direct current stimulator (tDCS)|"Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks"
45802512|NCT02006264|Drug|TDF Intravaginal Ring|The TDF IVR intravaginal ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core compartment comprised of 86% w/w TDF and 14% w/w sodium chloride (NaCl). The TDF intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
45802513|NCT02006264|Drug|Placebo Intravaginal Ring|The placebo ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core comprised of sodium chloride (NaCl). The Placebo intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
45931922|NCT04079894|Other|Standard Movement Protocol|Participant walking, cycling and sitting according to a pre-specified protocol.
45931923|NCT04079894|Device|Accerelerometer Monitoring|7 days of accelerometer monitoring in participants home-environment.
45931924|NCT04074070|Other|Ultrasound examination|Ultrasound examination of joints, tendons and entheses.
45931925|NCT04035629|Combination Product|MagniXene, hyperpolarized 129Xe MRI|"All subjects will undergo hyperpolarized 129-Xenon MR imaging (HP MRI) and conventional proton MR imaging of lung. Hyperpolarized 129Xe gas is prepared in a process termed spin-exchange optical pumping.~Xenon is highly lipophilic and therefore soluble in blood and tissue, making it an excellent tool for imaging the gas in both the air spaces (gas-phase imaging) and dissolved in the lung parenchyma (dissolved-phase imaging). This solubility in combination with xenon's chemical shift properties, results in the possibility of quantifying pulmonary gas exchange and gas transport within the parenchyma.~Additionally, previous images and lung function tests will be reviewed to compare findings and evaluate if there is a correlation between the obtained results."
45652252|NCT04994821|Behavioral|Cognitive Reappraisal|Emotion regulation therapy
45652253|NCT04361669|Other|Medication safety review|Implementation of a medication safety review using a clinical decision support system
45652254|NCT04361591|Other|Observational only|Observational Study
45652255|NCT04991623|Device|Kinesiology taping|We used kinesiology taping in abdominal muscles
45802514|NCT02006342|Drug|Insulin Glargine|
45802515|NCT02006342|Drug|Regular Insulin|
45931926|NCT04004221|Drug|Tislelizumab|200mg intravenously (IV) every 3 weeks (Q3W)
45931927|NCT03966391|Other|Multi-faceted knowledge translation intervention|The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
45931928|NCT03965650|Other|Video coaching exercises|Patients will perform physical exercises following a specifical video coaching program during 6 months.
45931929|NCT03965650|Other|Routine exercises|"Routine method by advising and encouraging patients to perform exercises according to the WHO recommendations during the first 3 months of the study.~Thereafter, patients will have access to the video coaching program of physical activities during the following 3 months."
45652256|NCT04991623|Other|Conventional physiotherapy|We used conventional physiotherapy to comparate
45652257|NCT04360889|Drug|Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)|Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin) is prescribed at a dose of 1000 mg / day Tocopherol is prescribed at a dose of 400 ME/ day
45652258|NCT04360889|Drug|Tocopherol|patients with lower limb lymphedema receiving conservative therapy (elastic compression, to which are added preparations with antioxidant endotheliotropic activity (Tocopherol-400 IU/day)
45652259|NCT04360889|Other|Elastic compression|patients with lower limb lymphedema receiving conservative therapy that includes only the use of elastic compression
45652260|NCT03072589|Drug|Regadenoson infusion|Dose escalation of Regadenoson when given as an infusion
45802516|NCT02006420|Device|ARFI-SVI Ultrasound|Ultrasound imaging of arm and leg lasting approximately 5-10 minutes. Participants will also undergo durometer scoring on the forearm and thigh as part of the study. This lasts approximately 5-10 minutes.
45802517|NCT02062580|Biological|BCG|
45802518|NCT01968356|Drug|3M CHG/IPA Prep Colorless|Apply topically.
45802519|NCT01968356|Drug|3M CHG/IPA Prep Tint|Apply topically.
45451593|NCT00068393|Drug|Neulasta|Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
45451594|NCT01086527|Drug|10 mg tablet of montelukast (Singulair)|Fasting patients will take a single 10 mg tablet of montelukast with 240 ml of Gatorade. Eight blood samples will be drawn to assess the plasma concentration of montelukast over the subsequent 12 hours.
45597967|NCT03524287|Procedure|Robotic Assisted No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Robotic assisted spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma
45597968|NCT03522883|Dietary Supplement|carbohydrate intake prior to exercise|Participants will be submitted to carbohydrate supplementation prior to exercise
45597969|NCT03522805|Device|High-intensity non-invasive ventilation|Single night of high-intensity non-invasive ventilation
45597970|NCT03522727|Behavioral|Single self-incentivising implementation intention|Participants are asked to form a single self-incentivising implementation intention (if-then plans)
45597971|NCT03522727|Behavioral|Multiple self-incentivising implementation intentions|Participants are asked to form multiple self-incentivising implementation intentions (if-then plans)
45652261|NCT05616689|Other|Bundled hyperpolypharmacy|Bundled hyperpolypharmacy playbook to be used by pharmacist, with physician approval, in shared decision making with participant,
45652262|NCT04994743|Drug|CORT113176|CORT113176 lipid capsule formulation for oral administration
45931930|NCT03959878|Device|Constant Pressure Skin Disk|The external disk is made of Dow Corning® Silastic Q7-4850 liquid silicone rubber. Placement of the disk will be done by the gastroenterologist or interventional radiologist during the gastrointestinal gastrostomy tube (GIG) or gastrointestinal jejunostomy tube (GIJ) placement procedure. The gastroenterologist or interventional radiologist will replace the manufacturer's external, adjustable skin disk with the external, adjustable Constant Pressure Skin Disk, by sliding the former off and the latter on to the feeding tube.
45931931|NCT03952611|Procedure|Colonoscopy|Using an instrument called colonoscope which is used to detect colonic polyps
45652263|NCT04994743|Drug|Placebo matching CORT113176|Placebo matching CORT113176 lipid capsule formulation for oral administration
45652264|NCT04812041|Other|CAM-ICU 7 score|A 7-point rating scale (0-7) was derived from the CAM-ICU and RASS assessments 0-2: no delirium, 3-5: mild to moderate delirium, and 6-7: severe delirium.
45652265|NCT04812041|Other|4C Mortality Score|4C Mortality Scores of the patients will be calculated, according to age, gender, number of comorbidities, respiratory rate, SpO2, GCS, urea, and CRP parameters
45652266|NCT03076879|Behavioral|Promoting participation in cervical cancer screening|"Nursing education: Women in the experimental group will be trained three times in total, one for the cervical cancer screening and the other two for the individual.~Reminders by phone; Short messages and calls will be reminiscent of women's participation in cervical cancer screenings.~Home visit; The content of the training is the key to cervical cancer and screening. After the group training, it is aimed to be an interactive education and counseling service in the form of question-answer method which is not understood by home visiting method.~Brochure; The brochure for cervical cancer and screening will be given after group training."
45451595|NCT01086683|Behavioral|Psychosocial rehabilitation course|Groups of 20 cancer survivors participated in a 6-day multi-focused, psychosocial intervention at the Dallund rehabilitation centre. The overall aim was to strengthen each individual's physical, psychological and social functioning. Sharing experiences with other cancer patients and experiencing peer-support was a central issue. The retreat combined lectures, discussions and patient group work on themes such as the treatment of cancer, psychological reactions, spirituality, sexuality and lifestyle. Participants were involved in physical activities, and the daily menu represented a healthy diet. The course was conducted by a multi-disciplinary team. Each participant produced a personal, specific 'action plan', which was intended to serve as a 'booster' after returning to daily life.
45652267|NCT04811885|Other|The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder|The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder
45652268|NCT03072355|Other|Elastic Band|Localized muscle resistance test for shoulder
45652269|NCT03072355|Other|Isokinetic dynamometer|Localized muscle resistance test for shoulder
45802520|NCT01968356|Drug|ChloraPrep|Apply topically.
45931932|NCT03952611|Device|distal Cap|Using an instrument called cap at end of colonoscope which is used to straighten colon folds
45931933|NCT03952611|Device|Endocuff|Using an instrument called Endocuff at end of colonoscope which is used to straighten colon folds
45931934|NCT03934567|Drug|Abexinostat|Abexinostat tablets
45931935|NCT03899220|Behavioral|Project Matter|This intervention includes 5 face-to-face therapy sessions with a trained clinician plus a bidirectional text component that queries mood, substance use, and medication adherence. Both the intervention group and the enhanced treatment as usual (E-TAU) involve a one-session behavioral engagement in care intervention as well as substance use treatment counseling.
45931936|NCT03894462|Behavioral|Attempted Suicide Short Intervention Program|ASSIP is a manualized, three-session intervention, delivered either in-person or via telehealth: In Session 1, the therapist guides the patient in telling the story of their attempt. The session is video recorded. In Session 2, the therapist and patient sit side-by-side to view selections of the video, working together to understand the feelings and events that preceded the attempt. The patient is assigned a homework task. In Session 3, the therapist and patient create a summary of the suicide attempt and what led up to it, along with creating a personal safety plan.
45931937|NCT03894462|Behavioral|Zero Suicide Usual Care|Participants will have access to outpatient treatment in facilities that are adopting NYS Zero Suicide protocols. Those who do not engage in care will nonetheless experience enhanced transition and follow-up contact from the services from which they are discharged.
45931938|NCT03890029|Behavioral|Intervention Training|After pre-testing and randomization, intervention participants will meet in small groups for 60 minutes/week over eight weeks for resilience training. Participants needing extra help will receive it at the end of each session. Controls will be on a minimal attention list, not being trained. After eight weeks, all participants will be post-tested.
45931939|NCT03890029|Behavioral|Control Condition|While intervention participants receive resilience training, the control group will not receive training but will receive minimal attention of a bi-monthly telephone call to indicate to participants that they are still enrolled in the study. A monthly flyer will be mailed to them about wellness and PTSD in recent news coverage. Following completion of an intervention group, participants and controls will be scheduled for post-testing that will be identical to the pre-testing and will occur within two weeks after the final treatment session. After the post-testing and 3-month follow up testing, the controls will be offered the resilience training.
45931940|NCT03887182|Diagnostic Test|functional MRI|Additional sequence (DTI) and functional MRI (fMRI) during the MRI which is done as part of the usual care
45802521|NCT01968356|Drug|Saline|Apply topically.
45802522|NCT02063516|Device|Guardian Laryngeal Mask|Guardian Laryngeal Mask: The Guardian Laryngeal Mask (Ultimate Medical Pty Ltd, Richmond, Vic, Australia) is a new silicone-based single-use extraglottic airway device that forms a seal with the glottis for ventilation and with the hypopharynx for airway protection, and provides a gastric drainage port. In addition, it has a port for suctioning material from the hypopharynx and a pilot balloon valve that constantly monitors intracuff pressure. In the following randomized, non-crossover study, the investigators test if oropharyngeal leak pressures differed between the Guardian Laryngeal Mask and the LMA proseal in paralysed, anaesthetised patients.
45802523|NCT02063516|Device|Proseal Laryngeal Mask Airway|Proseal Laryngeal Mask Airway: Silicon based, reusable, modified dorsal cuff and drainage tube
45802524|NCT02006888|Drug|IBI-10090|
45802525|NCT02006888|Drug|Placebo|Placebo
45931941|NCT03887182|Diagnostic Test|Automated Cortical Brainstem Auditory Evoked Potential|Automated Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG
45931942|NCT03887182|Genetic|whole exome sequencing|A study of all the DNA-encoding exons of the child/parent from a sample taken as part of the usual care
45652270|NCT04426877|Behavioral|Experimental group|The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.
45802526|NCT02007200|Other|Laboratory Biomarker Analysis|Correlative studies
45931943|NCT03887182|Diagnostic Test|Standard Cortical Brainstem Auditory Evoked Potential|Standard Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG
45931944|NCT03887182|Diagnostic Test|multidisciplinary consultation|"multidisciplinary consultation is composed of:~an ENT consultation and audiometry~a speech therapy assessment~a psychometric evaluation"
45931945|NCT03875339|Behavioral|Navigator Guidance|Use of a dedicated Navigator to determine if follow-up and compliance rates can be improved for those infants initially demonstrating an abnormal hearing result.
45931946|NCT03872388|Drug|Atorvastatin|"Patients will receive Atorvastatin per ASCVD guidelines dosed as either a moderate intensity (20mg/day) or high intensity statin (80mg/day). Tablets are available in either 20mg or 80mg and will be dispensed as per standard of care for up to 24 months as part of the study.~Patients may also receive capecitabine concurrently with Atorvastatin per physician discretion as standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day."
45802527|NCT02007200|Drug|Soy Isoflavones|Given PO
45931947|NCT03872388|Drug|Capecitabine|Patients not eligible to receive atorvastatin in group II will be enrolled into non-statin observation group with/without capecitabine treatment. Capecitabine administration will be dosed as per standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day.
45931948|NCT03865940|Drug|Lidocaine|6 mL of 1% lidocaine
45652271|NCT04426877|Behavioral|Control group|The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive the same web-based lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
45931949|NCT03865940|Drug|Guanfacine|250 mcg
45931950|NCT03852550|Other|e-health application|In the first part of this study, an e-health application (MyREADY Transition[TM] BBD App) was developed, targeting the needs of youth with BBD during their transition and transfer from pediatric to adult health care. Program development centered on three core foci of health care transition planning: education, empowerment, and navigation. The intervention has an emphasis on the process of transition in which youth and young adults learn information and develop skills in order to eventually assume maximal responsibility for self-management of their conditions (e.g., learning how to speak directly with health providers) while also providing information to prepare youth for the event of the transfer from pediatric to adult health care.
45802528|NCT02007200|Other|Survey Administration|Ancillary studies
45931951|NCT03846362|Other|HSCT|allogenic HSCT from 5-8 HLA-MM family donor as a first choice for patients with initial high risk of relapse and for patients with MRD2>0,1% and initial intermediate risk
45931952|NCT03844997|Drug|Palcociclib|"Palbociclib is an investigational (experimental) drug that works to induce early G1 arrest by inhibiting CDK4/6, which are two types of CDKs that are overexpressed in AML cell cancer lines. Palbociclib is experimental because it is not approved by the Food and Drug Administration (FDA).~Palbociclib will be supplied as capsules or tablets containing 125 mg equivalents of Palbociclib free base"
45652272|NCT03076801|Behavioral|Choral Singing|In addition to usual medical care, participants in the intervention group will participate in weekly 60-90 minute singing sessions led by professional musicians over a 12-week period. Sessions will begin with a 5-minute physical warm-up of gentle stretching and a 5-minute vocal warm-up. Music will be selected from a variety of genres and eras. Attendance will be taken weekly.
45802529|NCT01969214|Device|IQP-MM-101|"Dissolve the effervescent tablets in half a glass of water, to be taken orally~1 tablet, 3 times a day"
45802530|NCT02008682|Drug|liraglutide|Administered subcutaneously (s.c., under the skin) once daily as add-on to the subject's stable pre-trial metformin dose.
45802531|NCT02008682|Drug|sitagliptin|Administered orally once daily as add-on to the subject's stable pre-trial metformin dose.
45802532|NCT01969448|Procedure|Inframammary Fold Incision or Lateral Radial Incision|
45802533|NCT01969448|Procedure|Lateral Radial Incision|
45802534|NCT01969448|Procedure|Inframammary Fold Incision|
45802535|NCT01969448|Device|Laser-assisted fluorescence angiography|
45802536|NCT01969448|Drug|Indocyanine Green|
45802537|NCT01969916|Drug|Regadenoson|Patients will be given a single dose of Lexiscan (0.4 mg, iv bolus)
45802538|NCT02011490|Drug|sugammadex|sugammadex 4 mg/kg IV bolus
45802539|NCT00373763|Procedure|Fetoscopic tracheal balloon occlusion|
45802540|NCT00373919|Drug|intravenous (IV) administration of erythromycin|
45802541|NCT02916407|Drug|Sevoflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with sevoflurane 2-3 vol%."
45802542|NCT02916407|Drug|Desflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with desflurane 6-7vol%."
45802543|NCT02916563|Device|Blood Glucose Monitoring System Altitude Performance|Performance as assessed against a reference method at an altitude of approximately 10,000 feet.
45802544|NCT02828267|Behavioral|Brief Negotiational Intervention|This is a 5-10 minute conversation using the principles of motivational interviewing between the healthcare practioner and the patient to motivate the patient to identify at risk alcohol use and through self-empowerment create a plan to decrease alcohol use.
45931953|NCT03844997|Drug|CPX-351|CPX-351 (daunorubicin and cytarabine) liposome for injection is a combination of daunorubicin and cytarabine in a 1:5 molar ratio encapsulated in liposomes for intravenous administration. CPX-351 is an investigational (experimental) drug that works as formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. CPX-351 is experimental because it is not approved by the Food and Drug Administration (FDA).
45931954|NCT03832556|Other|CT scan|CT scan with biphasic injection of contrast product
45931955|NCT03832556|Other|MRI examination|MRI with injection of contrast
45931956|NCT03826199|Drug|TDF-FTC|We will investigate the feasibility and acceptability of integrating PrEP into antenatal and postnatal/well-baby services. Upon enrollment in the cascade, all women will be offered PrEP counseling and information, and patients will be followed regardless of their choice to initiate PrEP or not. Participants who initiate PrEP will receive TDF-FTC during the study. At each study visit (every 3-months), women will receive counseling on PrEP adherence or on the risks and benefits of PrEP for women not yet initiated. We will evaluate PrEP initiation and adherence in pregnant and breastfeeding women (N=220) from first antenatal care visit through 12 months post-partum.
45931957|NCT03826199|Behavioral|Counselling on PrEP in antenatal and postnatal care|Information about PrEP will be integrated into regular group education in ANC by existing health care providers during discussion about HIV testing and treatment. During every study visit, PrEP counseling (including adherence counseling for women already on PrEP) will be provided. For women not on PrEP, counselling will be provided on PrEP and HIV prevention.
45931958|NCT03815721|Device|Stimulette r2x+|device for repetitive transcutaneous spinal cord stimulation
45652273|NCT04426799|Other|lemon essential oil|A randomized, pre-test-post-test design was carried out to examine the effectiveness of lemon essential oil in reducing test anxiety in first-year students of the Faculty of Medical Sciences of a private university in Istanbul
45802545|NCT02828267|Behavioral|Standard Booster|This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use.
45802546|NCT02828267|Behavioral|Personalized Booster|This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use. Information in this text will be personalized based on the participants specific reasons for reducing their alcohol use rather than a standard text content.
46073335|NCT02840084|Device|Aspen(TM) Ultrasound System|"Two transducers per breast are applied. There will be 10 30 minute sessions, with 2 sessions per week for five weeks. The transducers will be placed on the medial and lateral positions of the affected breast, and then rotated to the superior and inferior aspects, and finally directly over the nipple-areolar complex. Following treatment, the affected breast will be massaged and bandaged per the Aspen Rehabilitation protocol, and the patient will be provided with home exercises as part of the Aspen Rehabilitation Technique.~The treated breast(s) will be examined both prior to and immediately following each treatment session. To evaluate safety, any adverse events such as swelling, redness, or pain will be assessed. To determine efficacy, any change in the Baker Grade level will be assessed by physical examination. The breasts will be photographed prior to treatment at each visit to assist in evaluation of any visible change in the breasts."
45931959|NCT03812705|Biological|fecal microbiome transplantation|"Stop antibiotics treatment 1 day before fecal microbiome transplantation;~Fasting food 6 hours before fecal microbiome transplantation;~Give Ondansetron intravenously 1 hour before fecal microbiome transplantation for vomiting prevention;~Perform fecal microbiome transplantation under colonoscopy or gastroscopy;~Perform up to 4 times if patient response;~Stop if no response after twice fecal microbiome transplantation."
45931960|NCT03803436|Procedure|Liver transplant|Liver transplant from cadaveric donors
46073336|NCT00838825|Other|introduction of the chronic care model|The care management team is organized according to the chronic care model for health care delivery. They are supported by an information registry for diabetes, receive instruction in self-management, have redesigned their work flow to include delegation of functions to care managers who follow specific guidelines and protocols for managing diabetes
45931961|NCT03803436|Drug|Chemotherapy|mFOLFOX
45931962|NCT03803436|Drug|Chemotherapy|Panitumumab
45931963|NCT03803072|Behavioral|time restricted eating (TRE)|Participants will attend a face-to-face meeting with the researchers at the last day of the first week of data collection (habitual diet and physical activity period) where they will be counselled to consume all food and fluid within a 8-10 h time window of their choice starting no later than 09.00 h for five weeks. During the intervention period, they will be counselled by weekly phone calls to provide encouragement, support and monitoring to improve adherence to the TRE window.
45451596|NCT00068237|Procedure|salivary gland transfer|Seikaly and Jha method of submandibular salivary gland transfer at the time of surgery for the primary tumor and neck nodes on Day 1
45652274|NCT04994353|Dietary Supplement|No supplementation|1st Week: No supplementation
45652275|NCT04994353|Dietary Supplement|High Performance (HP) Inulin|2nd Week: Subjects consumed 20% v/v HP Inulin. Ingredients: 20 gram HP-Inulin diluted with 100 ml distilled water.
45652276|NCT04994353|Dietary Supplement|Isomalto-oligosaccharide (IMO)|3rd Week: Subjects consumed 20% v/v Isomalto-oligosaccharide (IMO). Ingredients: 20 gram IMO diluted with 100 ml distilled water.
45931964|NCT03786627|Other|Combined NMES and motor control|This group will receive the neuromuscular electrical stimulation using interferential mode (6000 Hz, beat frequency 20-50 Hz, scanning effect) on bilateral lumbar multifidus muscles. The intensity will be set at the subject's maximum tolerance. Stimulation will be set at 10 seconds on and 60 seconds off to minimize muscle fatigue. The total stimulation time is 15 minutes. After that, this group will receive 30 minutes motor control training. This motor control training will focus on the control of the lumbar multifidus muscle in various functional tasks. It is believed to restore the motor units in individuals with arthrogenic muscle inhibition. This motor control training will take approximately 30 minutes. This group will receive intervention twice a week for 8 weeks.
45931965|NCT03786627|Other|Motor control and placebo NMES|This group will the neuromuscular electrical stimulation without turning the electrical current for 15 minutes. After that, this group will receive 30 minutes motor control training. This motor control training will focus on the control of the lumbar multifidus muscle in various functional tasks. This motor control training will take approximately 30 minutes. This group will receive intervention twice a week for 8 weeks.
45931966|NCT03776071|Drug|Enzastaurin Hydrochloride|mg
45931967|NCT03776071|Other|Placebo|mg
45802547|NCT02918357|Drug|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
45931968|NCT03776071|Drug|Temozolomide|mg/m^2
45931969|NCT03776071|Radiation|Radiotherapy|Gy
45931970|NCT03775512|Device|RF Ablation with QDOT Micro|Subjects will be ablated using QDOT Micro catheter
45652277|NCT04994353|Dietary Supplement|Combination HP-Inulin and IMO|"4th Week: Subjects consumed20% v/v combination of HP-Inulin and Isomalto-oligosaccharide (IMO).~Ingredients: 20 gram IMO-HP Inulin Mix diluted with 100 ml distilled water."
45802548|NCT02829983|Drug|Clarithromycin|Use of 500mg of Clarithromycin twice a day for 3 days
45802549|NCT02829983|Drug|Placebo|Use of placebo tablets twice a day for 3 days.
45802550|NCT02829983|Other|One-stage full-mouth ultrasonic debridement (FMUD)|One session of Periodontal debridement using ultrasonic device.
45451597|NCT00068237|Radiation|Post-operative radiation therapy|Dose ranging from 54-70 Gy over 5.5-7 weeks, at 2.0 Gy/fraction. Starts within 4-6 weeks of surgery.
45802551|NCT02014129|Drug|LY2835219|Administered orally
45802552|NCT02918669|Radiation|CT Scan|"Patients in the coflex IDE Study who presented at 24 months with a spinous process fracture that will undergo a CT Scan to evaluate the evidence or healing of fracture post-60 months.~There are no other interventions. It is just a onetime CT post 60 month time point."
45802553|NCT04333355|Biological|Convalescent Plasma|Along with the administration of convalescent plasma, patients will continue to receive supportive standard care.
45802554|NCT02012192|Drug|Ganetespib|
45802555|NCT02012192|Drug|Paclitaxel|
45802556|NCT02066792|Drug|D-Cycloserine|D-cycloserine is a medication thought to be associated with fear extinction.
45931971|NCT03774069|Device|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro and sent directly to the patient
45931972|NCT03774069|Other|Medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team according to standard of care
45931973|NCT03749317|Drug|IVIEW-1201|IVIEW-1201; QID; one drop per eye, four times per day (QID) for 7 days
45451598|NCT01086839|Drug|sodium chloride 6%|"one ampoule sodium chloride 6% per day~inhalation use~for 28 days"
45451599|NCT01086839|Drug|sodium chloride 0,9%|"one ampoule sodium chloride 0,9% per day~inhalation use~for 28 days"
45451600|NCT01090817|Drug|Mesenchymal stromal cells (MSC) for infusion|MSC 2X10E6/kg recipient weight are infused over 15 minutes intravenously weekly for 4 weeks
45451601|NCT01093937|Drug|varenicline|One to four 0.5 mg capsules (0.5-2.0 mg) orally per day for ten weeks.
45931974|NCT03749317|Drug|Placebo|Placebo drug; QID; one drop per eye, four times per day (QID) for 7 days
45597972|NCT03522727|Behavioral|Self-generated self-incentivising implementation intentions|Participants are asked to form a self-incentivising implementation intention (if-then plans) without a drop-down menu
45652278|NCT04994353|Dietary Supplement|Dextrose solution|5th Week:Subjects consumed20% v/v Dextrose solution. Ingredients: 20 gram Dextrose powder diluted with 100 ml distilled water.
45652279|NCT04994353|Dietary Supplement|Glucose solution|6th Week:Subjects consumed 20% v/v Glucose solution. Ingredients: 20 gram glucose diluted with 100 ml distilled water.
45652280|NCT04826783|Device|Lasers|The laser tip was applied as vertical and horizontal scan along the subgingival implant . The procedure was carried out on day zero, seven and 14.
45652281|NCT03072745|Diagnostic Test|Neuropsychological assessment|Assessment with a neuropsychological test battery examining different aspects of memory and executive functioning
45652282|NCT04807829|Drug|Nabilone|Nabilone is a synthetic endocannabinoid and CB1 agonist.
45652283|NCT04807829|Drug|Placebo|Inactive placebo comparator
45652284|NCT04994275|Other|no intervention, but presence of ID or not|This is an observational study regarding patients admitted to undergo a major elective surgery supposed to last more than an hour. Investigators will analyzed the incidence of postoperative infections up to 90 days after surgery according to the preoperative iron status: iron deficiency (defined as a ferritin of less than 100 µg/L or <300 µg/L And TSAT<20%) or no iron deficiency
45802557|NCT02066792|Drug|Placebo|Sugar pill
45802558|NCT02066792|Behavioral|Cognitive Behavioral Therapy|This will be a 5-session version of a group CBT protocol with 4-6 patients and 2 therapists per group emphasizing repeated exposure practices. Session 1 involves an introduction and orientation to the CBT model. Sessions 2-5 emphasize repeated exposure tasks, which consist of role-play activities to confront fearful situations in a group setting while disputing cognitive distortions (coupled with the fading of safety behaviors). At the conclusion of each exposure session, patients will be encouraged to continue to apply home-practice strategies (such as giving speeches in front of a mirror). Continued practice of the interventions will be considered part of treatment, and patients will be asked to refrain from alternative treatment for four weeks following completion of the last treatment session.
45931975|NCT03724188|Procedure|surgical parathyroidectomy|total parathyroidectomy, subtotal parathyroidectomy, total parathyroidectomy with autotransplantation
45802559|NCT02922959|Behavioral|Peer Intervention|The Peer Intervention is a 20-minute telephone call delivered by a Peer Interventionist, who is trained to answer questions about the content of the personally-tailored information packets. The primary goal of the call is for the participant and the Peer Interventionist to have an open exchange of information about medication-assisted treatment (MAT) for opioid use disorder.
45931976|NCT03718754|Device|En-Bloc TURB|En-bloc resection will be performed at each center based on local clinical practice and available instruments. Laser resection, hydrodissection with HybridKnife® or electric resection are allowed. All procedures, including cTURB, must be performed with an imaging enhancing technique (PDD / NBI at surgeon's discretion). After resection, a single intravesical instillation of 40mg Mitomycin-C will be performed if clinically feasible.
45931977|NCT03718754|Device|Conventional TURB|En-bloc resection will be performed at each center based on local clinical practice and available instruments. After resection, a single intravesical instillation of 40mg Mitomycin-C will be performed if clinically feasible.
45802560|NCT02922959|Drug|naloxone nasal spray kit|Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose. This nasal spray is approved by the FDA for reversing OODs and has a favorable side-effects profile. A take-home kit will be provided to the patient participants, which may be useful in the event of a future opioid overdose.
45802561|NCT02922959|Behavioral|Personally-tailored opioid overdose prevention education (information packet)|"Personally-tailored information packet with three participant-specific reports (Personal Overdose Risk Factors Report; Medication Assisted Treatment (MAT) Report; and the Opioid Overdose Information Report), and general written information about opioid overdose and treatment for opioid use disorder."
45931978|NCT03703440|Other|Active arm|≥3 group education sessions in addition to usual diabetes care, every 3 months for 12 months
45652285|NCT05619029|Radiation|X-ray|Chest radiographs
45931979|NCT03703440|Other|Control arm|Usual diabetes care, every 3-month for 12 months
45652286|NCT03076645|Behavioral|Facilitator support and education|Group engaged with facilitator support and education
45652287|NCT04811573|Drug|EU-sourced Otezla® (T)|Test Treatment (T)
45931980|NCT03681795|Diagnostic Test|Experimental MRI exam and PET scan exam with radiotracer|MRI exam and PET scan exam with radiotracer
45931981|NCT03674437|Behavioral|Traditional Neurocognitive Assessments|Traditional Neurocognitive Assessments given with pen and paper
46073337|NCT04321746|Drug|Ketamine|ketamine will be administered at a dose of 0.3 mg/kg in normal saline at 0.9% (250 mL)
46073338|NCT04321746|Other|Placebo|the control group will receive only normal saline at 0.9%, with the same physical characteristics of the ketamine solution
46073339|NCT02994680|Device|Three-burner LPG stove|The intervention arm will receive a three-burner LPG stove upon enrollment. The control arm will receive the stove one year after enrollment.
45652288|NCT04811573|Drug|US-sourced Otezla® (R1)|Reference Treatment (R1)
45652289|NCT04811573|Drug|Japan-sourced Otezla® (R2)|Reference Treatment (R2)
45652290|NCT03072511|Behavioral|Spotlight on Smoke-Free Living: Mindsets and Decisions|Intervention will consist of elements to help quit smoking. All intervention elements will be informed by Construal Level Theory.
45652291|NCT03072511|Drug|Transdermal Nicotine Patch|TNP serve as nicotine replacement for individuals who are attempting to stop smoking. They are safe for use and dosing will be determined for each participant based off of manufacturer's recommendations.
45802562|NCT02014363|Drug|ETS6103 (low dose)|
45802563|NCT02014363|Drug|ETS6103 (high dose)|
46073340|NCT02994680|Other|Delivery of LPG tanks|One year supply of LPG fuel, in the form of delivery of 20 kg tank that holds 10 kg of LPG. Delivered to homes.
45802564|NCT02014363|Drug|Amitriptyline|
45931982|NCT03674437|Behavioral|Online Cognitive Battery (Cogsuite)|Cognition (Cogsuite) for a battery that consists of seven measurements.
45652292|NCT05616611|Radiation|High-Intensity laser|intervention that lasted 3 sessions/week for 12 weeks).
45931983|NCT03671811|Drug|Megestrol Acetate|Given PO
45931984|NCT03671811|Biological|Pterostilbene|Given PO
46073341|NCT02994680|Other|Vouchers for LPG tanks|One year supply of LPG, in the form of vouchers to obtain a free LPG tanks from a distribution center. (Beginning one year after enrollment, for one year)
46073342|NCT04043767|Procedure|Measurements of thyromental distances, hyomental distances and neck circumferences|thyromental distances, hyomental distances and neck circumferences using measurement tape by two independent investigators.
45652293|NCT05616611|Other|Traditional physiotherapy exercises|intervention that lasted 3 sessions/week for 12 weeks).
46073343|NCT04243824|Drug|Gallium 68 Macro-aggregated albumin|The radiotracer, Ga-68 MAA, will be administered prior to PET/MRI scan.
46073344|NCT02839694|Drug|decitabine (DAC)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
45652294|NCT05616611|Radiation|Shock Wave therapy|intervention that lasted 3 sessions/week for 12 weeks).
46073345|NCT02839694|Drug|Tetrahydrouridine (THU)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
46073346|NCT02839694|Drug|Celecoxib|400 mg orally twice a day every day for while on DAC-THU therapy
45802565|NCT02833337|Radiation|Cone-beam computed topography|This study used a retrospective database of preexisting data that included patients treated as part of routine periodontal and oral surgery therapy for each patient's needs. All the patients signed an inform consent approving using their radiographic data for research purposes.
45597973|NCT02984761|Radiation|Stereotactic Radiotherapy|Stereotactic radiotherapy uses high doses of ionizing energy to treat cancer cells with image guidance. The treatment is delivered in an outpatient setting, and for purposes of this trial is delivered in 3-5 fractions.
45802566|NCT02067806|Drug|2-chloroprocaine hydrochloride, 1%|Study included male and female adult patients undergoing spinal anesthesia with chloroprocaine, when the planned surgical procedure was not expected to exceeded 40 minutes.
45652295|NCT04991545|Device|Application of Infrared (Active IRD/ IRRIS) device|"The first operator experienced with video-laryngoscopy intubation will do Before inducing anesthesia, the second operator will open the randomization envelope and adhere IRRIS/IRD device to the anterior skin of the neck above the sternal notch according to the group of patients After confirming lack of discomfort during application of the IRRIS/IRD device,~After complete relaxation, Laryngoscopy will be performed by the first operator using video laryngoscope (Glidescope Verathon Medical, BC, Canada or C-Mac Storz, Germany) to insert the tracheal tube. The endotracheal tube will be armed with a malleable stylet and to be molded to a curved 'hockey stick or the same curve of the laryngoscopic blade's shape. We will divide the patient according to device into two groups:~Group A: control group~Group B: Intervention group using Infrared"
45802567|NCT02833415|Drug|[U-13C3] glycerol|Ingestion of [U-13C3] glycerol based on human's body weight such as (50 mg/kg body weight).
45802568|NCT02833415|Drug|Empagliflozin|Active drug
45802569|NCT02833415|Drug|Placebo (for Empagliflozin)|Placebo tablet manufactured to mimic EMPA 10 mg tablet.
45802570|NCT02014519|Procedure|Blood sampling|A blood sample (2.5 mL) will be collected from all subjects
45802571|NCT02014519|Other|Data collection|Active questioning
45802572|NCT04737551|Other|Follow-up only|Only routine follow-up but no treatment
45802573|NCT04737551|Drug|Adjuvant chemotherapy|Chemotherapy regimens will be decided by physicians or MDT teams, basing on patients' physical status, income status, and/or desire. Toxicity was evaluated every cycle and efficacy was evaluated every two cycles. The treatment course of adjuvant chemotherapy was followed the recommendation of NCCN guideline.
45802574|NCT04737551|Radiation|Adjuvant chemoradiotherapy|"Adjuvant CRT could be delivered before or simultaneously with adjuvant chemotherapy. Radiation used 6 MV or 15 MVX-ray beams delivering daily fractions of 180-200cGy to a total dose of 45-55Gy in 25-28 fractions using CT-based, three-dimensional conformal radiation therapy (3DRT), intensity-modulated radiation therapy (IMRT) or tomotherapy (TOMO).~S-1 was administered orally at a dose of 40mg twice a day during radiation day as radiosensitizer through radiotherapy. Antiemetic medications and proton pump inhibitor were prophylactic used to reduce the occurrence of nausea and inhibit gastric acid secretion."
45802575|NCT04737551|Radiation|Adjuvant chemoradiotherapy + Adjuvant chemotherapy|See as above (adjuvant chemotherapy and adjuvant chemoradiotherapy).
45802576|NCT04737395|Device|"upper extremity training program (Meditouch,MSQUARE)"|40 hours of therapy with the Hand Tutor (MediTouch) device and a wearable vest (EkssoUE, Ekso Bionics) for arm rehabilitation
45802577|NCT02012348|Other|Antibacterial soap with triclocarban|
45802578|NCT02012348|Other|Antibacterial soap + benzalkonium chloride|
45802579|NCT02012348|Other|Control soap|
45802580|NCT02016235|Drug|Phosphorus Supplement|250 mg po qid
45802581|NCT02016235|Other|Observation|Baseline blood and urine measurements only
45802582|NCT02834663|Drug|Lucentis|Local anesthesia with T-caine with Saline irrigation. Routine eye drap was done by potadine-cotton ball. Lucentis injected to vitreous cavity, finally dressing.
45802583|NCT01973036|Device|Foley Catheter|The balloon will be inflated with 30 cc of sterile saline. The catheter will be taped to the patient's leg so that traction is maintained. The catheter will be assessed hourly for expulsion by a health care provider by applying gentle traction on the catheter or a vaginal examination if it is unclear by traction. Once the Foley catheter is expelled or 12 hours reached, the induction will be continued with oxytocin per this protocol.
45802584|NCT01973036|Drug|Oxytocin|Each arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
45802585|NCT02017093|Device|Error Enhancement|Patients underwent upper extremity robotic training with the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
45802586|NCT02017093|Device|control treatment|Patients underwent upper extremity robotic training without the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
45802587|NCT02835677|Behavioral|Behavioral|Education and skills building, including problem solving, cognitive restructuring, and stress management
45802588|NCT02310776|Device|Supine automated breast ultrasound scanner|Automated wide-field-of-view breast ultrasound volume scan performed by a sonographer and interpreted by a breast imaging radiologist.
45802589|NCT02310776|Device|High-resolution handheld breast ultrasound|Standard of care, small field-of-view 2D breast ultrasound performed and interpreted by a breast imaging radiologist
46073347|NCT00831961|Procedure|Conjunctival and nasopharyngeal bacteria cultures|Conjunctival and nasopharyngeal bacteria cultures
46073348|NCT00894686|Biological|FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)|Dosage form: solution/suspension; injectable. Dosage frequency: once. Mode of administration: intramuscular.
45597974|NCT02984761|Procedure|Anatomic Pulmonary Resection|An anatomic pulmonary resection is an oncologic procedure that dissects out an anatomically defined segment of the lung to remove all of the lung tissue around a lung tumor. It requires an operation with general anesthesia, with a short hospital stay. The procedure entails removal of lymph nodes inside the chest that might not be easily accessible without an operation.
45653292|NCT04488523|Behavioral|Family-based Telehealth Intervention|"The Family Telehealth intervention focuses on improving parent-child relationships and communication.~For the dyadic version, the intervention involves eleven hours of intervention material; it includes motivational interviews, individual and joint sessions co-led by two separate clinicians. The sessions will be delivered on a weekly basis.~For the caregiver-only version, the intervention involves six hours of intervention material; it includes a motivational interview and individual sessions led by a single clinician. The sessions will be delivered on a weekly basis."
45802590|NCT02017327|Drug|Monoprost|Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use. It is supplied in 0.30 ml single use polyethylene containers. The batch numbers and reanalysis dates will be stated in the certificate of analysis.
45653293|NCT04445701|Drug|AO-176|Humanized monoclonal antibody (mAb) targeting CD47
45802591|NCT02017327|Drug|Lumigan 0.01%|Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.
45802592|NCT02017327|Drug|Lumigan 0.03% Unit Dose|Lumigan® 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.
45802593|NCT02837237|Drug|KBP-5074|"In Part 1 of the study, non-HD patients with severe CKD in Cohort 1 will receive a single oral capsule dose of KBP-5074 on Day 1 following a fast between 2 and 4 hours.~In Part 2 of the study, HD patients with severe CKD will receive a single oral capsule dose of KBP-5074 following a fast between 2 and 4 hours. The dose of KBP 5074 will be administered on Day 1 immediately following a dialysis session."
45802594|NCT02923271|Device|CellControl|Technology that blocks incoming and outgoing calls and texts. CellControl Drive ID will monitor all cellphone use while driving (without blocking) for 3 weeks during baseline measurement period. During the intervention period (5 weeks) cellphone use will be monitored and blocking of incoming calls and texts will be active.
45451602|NCT03956381|Device|Primary Total Hip Replacement with Trinity cup and TriFit TS stem via posterolateral surgical approach.|The participant will undergo surgery using the hip prostheses and surgical approach used by their surgeon Investigator. A patient specific femoral guide, generated by the OPS™ plan preoperatively, will be used during the surgical step of femoral neck resection. These are not study specific procedures as the OPS™ system is already in use by the surgeon Investigator in their standard of practice.
45597975|NCT03522649|Drug|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8~12 hours.
45802595|NCT02018107|Diagnostic Test|N-13 ammonia or F-18 fluorodeoxyglucose|PET tracer
45597976|NCT03522649|Drug|Fluorouracil|Fluorouracil 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by Fluorouracil 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion.
45802596|NCT02018107|Diagnostic Test|PET scan|PET scan
45597977|NCT03522649|Drug|Leucovorin|Irinotecan 180 mg/m^2 followed by or concurrent with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
45653294|NCT04445701|Drug|AO-176 + Dex|Humanized mAb targeting CD47 plus dexamethasone
45802597|NCT02314598|Other|No treatment|
45802598|NCT02018653|Drug|Calcium Alumina-Silicate (CASAD)|1 gram by mouth every 6 hours for up to 6 days.
45802599|NCT02018653|Other|Placebo|1 by mouth every 6 hours for up to 6 days.
45802600|NCT02018653|Behavioral|Questionnaire|Questionnaire completion at baseline about diarrhea and other symptoms.
45802601|NCT02923895|Other|Stannous fluoride|0.454% weight by weight (w/w) stannous fluoride containing 1100 parts per million (ppm) fluoride
45802602|NCT02923895|Other|Sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000 ppm fluoride
45802603|NCT01973348|Device|4-hour AmblyZ glasses|4-hour AmblyZ glasses for moderate amblyopia
45802604|NCT01973348|Device|12-hour AmblyZ glasses|12-hour AmblyZ glasses for severe amblyopia
45802605|NCT01973348|Device|2-hour patching|2-hour patching for moderate amblyopia
45802606|NCT01973348|Device|6-hour patching|6-hour patching for severe amblyopia
45802607|NCT02925143|Other|E-learning course in neuromuscular monitoring|An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.
45802608|NCT02018809|Behavioral|Medication Adherence Partner|
45802609|NCT02018809|Device|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
45802610|NCT02838407|Other|BAL fluid sampling|Following routine BAL procedures at the hospital, collection of BAL fluid samples: at least 2 mL, at Day 0.
45802611|NCT02838407|Other|Nasopharyngeal swab sampling|1 swab, Day 0
45802612|NCT02020135|Drug|PSMA ADC|Upon recommendation from the PI and after Sponsor approval, a subject benefiting from treatment could have received up to eight additional doses Q3W. Subjects were weighed prior to each cycle and dosing was calculated on a mg/kg basis prior to each dose, with a maximum weight of 100 kg for dosing calculations.
45802613|NCT02020369|Biological|Coagulation Factor VIIa (Recombinant)|A cross over design to assess the efficacy of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX
45802614|NCT02839889|Drug|Naloxegol|Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
45802615|NCT02839889|Drug|Placebo|Placebo once daily for two weeks, followed by two week open-label period
45597978|NCT03522649|Drug|Irinotecan|Irinotecan 180 mg/m^2 followed by or concurrent with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
45802616|NCT02012582|Drug|VAS203|i.v. infusion
45802617|NCT02012582|Drug|Saline|i.v. infusion
45802618|NCT01971385|Drug|Squaric Acid solution|
45802619|NCT01971385|Drug|Placebo solution|
45652296|NCT04811807|Device|Subthalamic Nucleaus Deep brain stimulation|In deep brain stimulation (DBS) therapy, a specific anatomical target in the brain is stimulated via surgically fixed electrodes. These electrodes release electrical currents of a specific voltage, wavelength, and frequency. They are connected via subcutaneous wires to a device called an implantable pulse generator (IPG) which is surgically fixed on chest wall, beneath the clavicle. After electrodes and IPG are successfully installed, a clinician will be able to adjust and modulate the stimulation via a remote device connected to the IPG to obtain a maximum potential benefit. Deep brain stimulation has been used in clinics to treat various neurologic diseases including neurodegenerative disorders, mainly movement disorders.
45931985|NCT03657056|Device|BX Pulsar 1002|"LIFUP will be administered to the temporal region on the side to undergo surgery, within the focus producing seizures. The ultrasound will be focused on the highest activity area within the temporal lobe. Functional MRI of the brain will be obtained throughout the LIFUP session.~After the participant is fitted with the transducer they will be placed in the MRI machine and undergo a series of scans. After placing the transducer over the anterior tip of the temporal lobe the participant will undergo fMRI BOLD scans with LIFUP excitation (from (Lee et al., 2015): Tone Burst Duration = 2ms and Pulse Repetition Frequency = 250Hz) at four levels of intensity (720mW/cm2, 1440mW/cm2, 2880mW/cm2 and 5760mW/cm2). Before increasing the intensity, the transducer will be moved approximately 5mm posterior. After the last excitation scan the LIFUP parameters will be changed to inhibitory parameters (from (Yoo et al., 2011): Tone Burst Duration = 0.5ms and Pulse Repetition Frequency = 100Hz)."
45931986|NCT03656146|Other|Food Insecurity Screening Tablet|The intervention is the type of screening modality used to identify food insecurity: verbal face-to-face, or tablet-based screening
45451603|NCT03956381|Device|Primary Total Hip Replacement with Trinity cup and MetaFix stem via direct anterior surgical approach|The participant will undergo surgery using the hip prostheses and surgical approach used by their surgeon Investigator. A patient specific femoral guide, generated by the OPS™ plan preoperatively, will be used during the surgical step of femoral neck resection. These are not study specific procedures as the OPS™ system is already in use by the surgeon Investigator in their standard of practice.
45931987|NCT03656146|Other|Food Insecurity Screening Verbal|The intervention is the type of screening modality used to identify food insecurity: verbal face-to-face, or tablet-based screening
45931988|NCT03625388|Drug|Dasatinib|Film coated tablet contains dasatinib monohydrate
45931989|NCT03622749|Device|Transcranial Magnetic Stimulation (TMS)|Non-Invasive neuromodulation
45931990|NCT03620747|Drug|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: prefilled syringes~Route of administration: subcutaneous"
45652297|NCT03073681|Device|Survey|Patients will complete a survey describing their satisfaction with vision after cataract surgery that was performed at least 2 months prior to study enrollment.
45931991|NCT03613844|Drug|DHA|DHA supplementation
45931992|NCT03613844|Drug|Placebo|Placebo for DHA
45652298|NCT04807751|Drug|Delgocitinib cream|Cream for topical application
46073349|NCT04243434|Drug|Vincristine Sulfate Liposome|Eligible patients will be randomized in a 1:1 ratio to one of 2 treatment cohorts (Cohorts A or B) to receive either the first cycle of treatment with the VSLI-RTU formulation or the Marqibo formulation and crossover to the other formulation for the second cycle.
45652299|NCT04807751|Drug|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
45451604|NCT01094015|Drug|lidocaine-prilocaine cream|Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
45931993|NCT03604198|Drug|relacorilant|CORT125134 is supplied as capsules for oral dosing.
46073350|NCT04243434|Combination Product|CHOP|CHOP to be administered on Day 1 on Cycle 1 & 2 ( 21-day Cycle) & prednisone administration on Days 2 to 5 on Cycle 1 & 2 ( 21-day Cycle)
46073351|NCT04243434|Combination Product|R-CHOP|R-CHOP to be administered on Day 1 on Cycle 1 & 2 ( 21-day Cycle) & prednisone administration on Days 2 to 5 on Cycle 1 & 2 ( 21-day Cycle)
46073352|NCT00832039|Drug|sodium-selenite|An intravenous bolus of 1000 µg followed by a continuous intravenous infusion of 1000 µg/day until patient is discharged from the ICU but not more than 21 applications à 24 hours.
46073353|NCT00832039|Drug|Placebo|An intravenous bolus of placebo followed by a continuous intravenous infusion with placebo until patient is discharged from the ICU but not more than 21 applications à 24 hours.
45802620|NCT01971463|Other|Normal saline|intravenous administration of 500cc of 0.9% NaCl over 30 minutes
45802621|NCT02925611|Drug|Isoflurane|
45802622|NCT02925611|Drug|Desflurane|
45802623|NCT00374153|Behavioral|Feedback|Online personal feedback report
45451605|NCT01094015|Other|gel application for the transmission of ultrasound|3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5ml syringe without needle. Application, with a swab in gel ectocervix
45802624|NCT00374153|Behavioral|Motivational Interview with Feedback|In-person Motivational Interview with personal feedback report
45802625|NCT00374153|Behavioral|Motivational Interview|In-person Motivational Interview only (without a personal feedback report)
45802626|NCT00374309|Drug|VRC-EBOADV018-00-VP|
45802627|NCT02841449|Behavioral|Hypohydrated|Participants remain hypohydrated after the heat tent procedure
45802628|NCT02841449|Behavioral|Rehydrated|Participants rehydrate after the heat tent procedure
45804176|NCT04832659|Behavioral|CEASE + BIO|Children randomized to the CEASE + BIO group will have leftover blood from an already collected blood sample that was taken for a clinically indicated blood draw analyzed for cotinine. Parents of children in the CEASE +BIO group will receive a report of biomarker results followed by proactive outreach from a BIO counselor. The BIO counselor will explain the laboratory results and refer all parents in the household who smoke to tobacco treatment through the parent's primary care provider and/or the state quitline. The BIO counselor will troubleshoot any barriers to obtaining nicotine replacement therapy that may have been prescribed as part of the CEASE protocol and will promote strict smoke-free and vape-free home and car policies. BIO counselors will conduct a maximum of 6 calls per enrolled smoker.
45802629|NCT01973335|Drug|Combination therapy with acetazolamide and low-dose loop diuretics|"Patients receive 500 mg of intravenous acetazolamide immediately after randomization, with 250 mg intravenous acetazolamide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.~Patients receive 2 mg of intravenous bumetanide immediately after randomization, with 1 mg intravenous bumetanide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.~If diuresis <1,5 L while the patient is still considered volume overloaded by his/her treating cardiologist, the dose of acetazolamide is maintained at 500 mg and the dose of bumetanide is maintained at 2mg.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option."
45652300|NCT03072277|Dietary Supplement|Docosa Hexaenoic Acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through 6 months postpartum.
45931994|NCT03599739|Biological|Influenza|Facilities will be asked to complete a survey to evaluate the impact of the influenza vaccine choice on hospitalization risk for the 2017-2018 influenza season.
45931995|NCT03589729|Drug|Cladribine|Given IV
45931996|NCT03589729|Drug|Cytarabine|Given IV
45931997|NCT03589729|Drug|Dexrazoxane Hydrochloride|Given IV
45931998|NCT03589729|Drug|Gemtuzumab Ozogamicin|Given IV
45931999|NCT03589729|Drug|Idarubicin|Given IV
45932000|NCT03585686|Drug|Vemurafenib|vemurafenib 20 mg/kg/day
45932001|NCT03585686|Drug|Cytarabine|100 mg/m2/12 h, days 1-5
45932002|NCT03585686|Drug|2-chlorodeoxyadenosine|6 mg/m2/d, days 1-5
45652301|NCT03072277|Dietary Supplement|Placebo|400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through 6 months postpartum.
45652302|NCT03073837|Other|Rhinovirus Challenge|Challenge with HRV-16 virus
45652303|NCT03072121|Drug|Shexiang Baoxin pill|Conventional western medicine & shexiang baoxin pill
45652304|NCT03072121|Drug|SBP placebo|Conventional western medicine & placebo (for shexiang baoxin pill)
45652305|NCT03072121|Drug|Aspirin Enteric-coated Tablets|100mg tablet, one tablet daily.
45652306|NCT03072121|Drug|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|one tablet daily. (for patients who can't use aspirin)
45652307|NCT03072121|Drug|Atorvastatin Calcium|10 mg tablet, two tablets each night.
45652308|NCT03072121|Drug|Isosorbide Mononitrate Tab 20 MG|1 tablet two times daily.
45652309|NCT03072121|Drug|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg two times daily.
45652310|NCT03072121|Drug|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
45652311|NCT05618873|Device|Flutter device|The flutter was used as follows. Sitting with a straight back and the elbows supported on the table, the patient held the flutter horizontally. The patient inhaled deeply, held their breath for 2 or 3 s and then took the mouthpiece into the mouth and exhaled quietly yet quickly enough to activate the flutter. The patient had to keep their cheeks as stiff as possible. This procedure was repeated 15 times, following which the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times. The patient obtained the maximal vibration sensation by tilting the flutter upwards or downwards by a few degrees.
45652312|NCT05618873|Device|positive expiratory pressure mask|"The PEP-mask was used as follows. Sitting with a straight back and the elbows supported on the table, the patient pressed the mask against the face with both hands. After a quiet inhalation, a slow active exhalation followed. The exhalation was restricted by a resistance selected to cause a positive expiratory pressure of 8-12 cmH2O. The patient exhaled 15 times through the mask.~Thereafter, the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times."
45932003|NCT03569124|Other|Teaching tool for identification of colorectal polyps|This is a teaching session on how to identify the colorectal polyps shot in blue light imaging.
45932004|NCT03543787|Combination Product|Health IT and Peer Support Intervention|"Health IT will support referral system by establishing 1) communication between healthcare providers and peer navigators 2) decision support for clinician to facilitate appropriate referrals 3) tracking of referred patients real-time 4) dashboards to monitor key evaluation metrics.~Peer Support intervention: peer navigators at each level of the referral network will ensure 1) referral adherence by link clinicians and patients 2) health system navigation 3) psychosocial support: leverage their shared disease experience to help patients overcome barriers to health seeking behaviour."
45932005|NCT03541889|Drug|FLT imaging and TK1 blood measurements|F18 labeled thymidine PET/CT scans will be performed. Serum measurements of TK1 will be obtained.
45932006|NCT03503305|Device|adipose-derived stem cell injection|5 ml injection of adipose derived stem cells
45932007|NCT03503305|Drug|Corticosteroid injection|5 ml injection of corticosteroid
45932008|NCT03499509|Other|Low Glycemic Diet|"Low Glycemic (LG) diet: The LG diet will be made up of foods that do not stimulate insulin secretion. The foods that make up the diet will differ depending on the phase of the study. During the weight loss phase, breakfast and lunch will each consist of one or two meal-replacement shakes (e.g., High-Protein SlimFast). Dinner will be a frozen entrée (e.g., Atkins, Lean Cuisine, Healthy Choice) supplemented with a side of vegetables. Snacks will be nuts, berries, and full-fat dairy products (one serving per day), and will be used to adjust the calorie level of each day's meals to individual calorie needs."
45451606|NCT01090895|Drug|Vitamin C|Intravenous infusion of vitamin C (1 g) 10 minutes before percutaneous coronary intervention.
45652313|NCT04993963|Other|Cycle Ergometery Training (Prehabilitation)|Interval training on cycle ergometer: between 40% and 60% Vo2max, perceived exertion <13 on Borg scale 20-30 min/session/day (intermittent of exercise 2-3 mint, followed by 1-2 min of active recovery) Cool down (5 minutes) AROM +Body stretch
45652314|NCT04993963|Other|Control Standard Group|Breathing exercise 15 Reps and Walk (10-15 minutes)
45652315|NCT05618795|Other|minimal gap arthoplasty v/s aggressive gap arthoplasty|Comparative evaluation of aggressive gap arthroplasty with minimal gap arthroplasty in the management of TMJ ankylosis
45652316|NCT04994041|Other|Pelvic floor muscle plus adductor strengthening|20 sessions of pelvic floor muscle strengthening plus adductor is strengthening
45652317|NCT04994041|Other|Pelvic floor muscle exercises|20 sessions of pelvic floor muscle strengthening
45802630|NCT01973335|Drug|High-dose loop diuretics|"Patients receive the double of their daily maintenance dose of oral loop diuretics converted to mg bumetanide as an intravenous bolus after randomization.~Patients continue to receive this dose daily on the next 3 days divided between two administrations with at least a 6 h interval for as long as they are considered volume overloaded by the treating cardiologist.~If diuresis <1,5 L while the patient is still considered volume overloaded by the treating cardiologist, the dose of bumetanide is doubled.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option."
46073354|NCT00832039|Procedure|Procalcitonin guided therapy|"Causal therapy of sepsis is guided by applying the following algorithm:~Day 4: PCT drop from baseline >=50%: no change in causal therapy; PCT drop from baseline <50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.~Day 7, 10, 14: PCT <=1.0 ng/ml: finish antimicrobial therapy; PCT >1.0 ng/ml and PCT drop from last PCT measurement >=50%: finish antimicrobial therapy; PCT >1.0 ng/ml and PCT drop from last PCT measurement <50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control."
46073355|NCT02826564|Drug|pembrolizumab|
45451607|NCT01090895|Drug|Placebo|Intravenous infusion of placebo(saline solution) 10 minutes before percutaneous coronary intervention.
45652318|NCT02597855|Drug|Aflibercept|Total 4 times of intravitreal aflibercept injection was performed
45802631|NCT01973335|Drug|Upfront therapy with oral spironolactone|"Patients randomized to this group receive oral spironolactone (25mg) immediately after randomization and in the morning of each subsequent day unless the serum potassium level is >5 mmol/L.~Note: Investigators and treating physicians are blinded to treatment allocation for this arm, but no matching placebo is provided, so patients are not."
45652319|NCT02597855|Drug|Indocyanine green angiography (intraveonus indocyanine green dye)|At initial visit, indocyanine green angiography was performed. After 1 month of third Aflibercept injection, indocyanine green angiography was performed to evaluate polyp closure.
45652320|NCT04987567|Dietary Supplement|ANTIOXIDANT DHA TRIGLYCERIDE (TRIDOCOSAHEXAENOINE-AOX®)|Pearls of DHA (BrudyNen)
45652321|NCT04987567|Dietary Supplement|PLACEBO (OLIVE OIL)|Pearls manufactured to mimic DHA (BrudyNen).
45652322|NCT04811495|Other|Physiotherapy treatment|A treatment plan is carried out which aims to improve pain, muscle balance and range of motion of the temporomandibular joint.
45802632|NCT02844569|Device|Xenograft bone substitute|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket will be treated with xenograft bone substitute. At 6 months post-extraction a dental implant will be placed at the extraction site.
45802633|NCT02844569|Device|Collagen dressing|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket treated with xenograft bone substitute will receive a collagen dressing to cover the surgical site.
45802634|NCT02844569|Device|3D-collagen matrix|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket treated with xenograft bone substitute will receive a 3D collagen matrix to cover the surgical site.
45802635|NCT01973413|Device|Diabetes Assistant (DiAs)|The Control-to-Range (CTR) algorithm that will be used in DiAs will automatically adjusts insulin delivery in response to CGM values that have exceeded or are predicted to exceed the bounds of a pre-specified blood glucose range.
45802636|NCT01973413|Device|Tandem t:slim Insulin Pump|FDA, market-approved insulin pump.
45802637|NCT01973413|Device|Dexcom G4 Platinum sensor|FDA, market-approved continuous glucose monitor (CGM)
45802638|NCT02927327|Device|Zero Echo Time (ZTE) scan for head attenuation|"The GE SIGNA PET/MR MP26 software platform includes the zero echo time (ZTE) scan for head attenuation and Q.Static. The ZTE MR software feature has the potential to enable better visualization of bones, including those in the head, by employing optimal head attenuation correction in PET/MR.~PET/MR ZTE MRAC"
45802639|NCT02927327|Device|Q.Static (Q. MRAC) for respiratory motion correction|"An improved Q.Static feature with Q. MRAC, where phase matching the MRAC with the quiescent phase is employed to get more accurate attenuation correction for our Q.Static PET images.~PET/MR Q Static (Q. MRAC)"
45802640|NCT02021461|Drug|ESL Banana taste|oral suspension with Banana flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
45802641|NCT02021461|Drug|ESL Grape taste|oral suspension with Grape flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
45802642|NCT02021461|Drug|ESL Tutti-Frutti taste|oral suspension with Tutti-Frutti flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
45802643|NCT02927639|Other|MyDiaText|The intervention will consist of daily text messages sent to the subject's personal mobile device.
45802644|NCT02929667|Drug|Fluoxetine|Standard 6 weeks titration, starting 10 mg per day.
45802645|NCT02929667|Drug|Placebo|Standard 6 weeks titration.
45802646|NCT02021929|Drug|Sorafenib|"Sorafenib is a kinase inhibitor indicated for the treatment of:~Unresectable hepatocellular carcinoma~Advanced renal cell carcinoma~Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment"
45802647|NCT02021929|Drug|Placebo|
45652323|NCT05004103|Other|Cosmetic products application|Female healthy volunteers applied cosmetic products (cleanser and moisturizer) in the morning and afternoon for 1 month. Seven days wash out period will be conducted prior study starts. The evaluation will be conducted before, two weeks after treatment starts, and at the end of the study.
45652324|NCT04807049|Other|Observational|Observational
45802648|NCT02848079|Drug|combined TAS-102 and TAS-OX|Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.
45802649|NCT02022085|Device|Baha Attract System|The Cochlear Baha Attract System incorporates both implantable and external parts. The implantable parts include the BI300 Implant and the BIM400 Implant Magnet, which is intended to be fixated to the BI300 Implant. The external parts include the Sound Processor Magnet (SP Magnet), which, together with the Implant Magnet, constitute the transcutaneous coupling. The SP Magnet incorporates a soft material (Soft pad) at the tissue facing surface that is designed to distribute the pressure over the skin. The Baha Sound Processor attaches to the SP Magnet via a snap coupling.
45802650|NCT02929823|Drug|High Dose SJP-0035 Ophthalmic Solution|0.001% SJP-0035 Ophthalmic Solution
45932009|NCT03499509|Other|High Glycemic Diet|"High Glycemic (HG) diet: The HG diet will conform to United States Department of Agriculture (USDA) guidelines (http://health.gov/dietaryguidelines/2015/guidelines/). The foods that make up the diet will differ depending on the phase of the study. During the weight loss phase, breakfast and lunch will each consist of one or two meal-replacement shakes (e.g., SlimFast). Dinner will be a frozen entrée (e.g., Lean Cuisine, Healthy Choice) supplemented with a side of vegetables. Snacks will be fruit, fat-free dairy products, and low-fat bars (e.g., Optifast), and will be used to adjust the calorie level of each day's meals to individual calorie needs."
45802651|NCT02929823|Drug|Low Dose SJP-0035 Ophthalmic Solution|0.0002% SJP-0035 Ophthalmic Solution
45802652|NCT02929823|Drug|Vehicle of SJP-0035 Ophthalmic solution|0% SJP-0035 Ophthalmic Solution
45802653|NCT02929979|Behavioral|Cognitive Training|Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ (BPI/Posit Science, San Francisco). BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.
45652325|NCT05003869|Procedure|Scar tissue is removed|The patients were divided into two groups according to whether the scar tissue was removed during TCRA operation: study group: resection of uterine scar tissue during TCRA operation;In the control group, the scar tissue covering the anterior, posterior and lateral walls of the uterine cavity was ploughed longitudinally into several narrow strips using needle-like electrodes, and the scar tissue was not excised.
45451608|NCT03956303|Drug|Chirocaine %0.5|Levobupivacaine 8 mg Chirocaine (% 0.5) +20 mcg fentanyl
45932010|NCT03497663|Other|VIA Family intervention|Family based intervention
45932011|NCT03497663|Other|Treatment As Usual|Treatment As Usual
45932012|NCT03479307|Drug|Bilastine Ophthalmic Solution 0.6%|1 drop in each eye at 2 separate times during an 8 day period.
46073356|NCT05333588|Biological|Tumor Infiltrating Lymphocytes (TIL)|The autologous TILs will be intravenous infused into patients.
46073357|NCT02826642|Drug|IDH305|
46073358|NCT02837978|Drug|Tacrolimus|Tacrolimus capsule: 0.5mg to 1mg, po, twice per day (Bid)，adjusted by its concentration in blood or due to patient response. Then may titer down until the endpoint.
45802654|NCT02929979|Behavioral|Cognitive training placebo control|Participants will play a rotating set of commercial computer games at the same dose and frequency as the cognitive training. The investigators selected this control activity because it mirrors the game-like properties of the cognitive training and it will be used to control for contact with research personnel and for the non-specific effects of participant motivation and engagement with daily computerized activities. It also allows for a double blind study design. Games from the website Sporcle will be used and an online account can be created for each participant.
45932013|NCT03479307|Drug|Ketotifen Ophthalmic Solution 0.025% (Zaditen)|1 drop in each eye at 2 separate times during an 8 day period.
45932014|NCT03479307|Drug|Vehicle of Bilastine Ophthalmic Solution|1 drop in each eye at 2 separate times during an 8 day period.
45932015|NCT03467867|Drug|Venetoclax|Venetoclax will be administered as described in the reporting arm.
45932016|NCT03467867|Drug|Rituximab|Rituximab (IV) will be administered as described in the reporting arm.
45932017|NCT03467867|Drug|Rituximab/Hyaluronidase Human|Rituximab/Hyaluronidase Human (SC) ill be administered as described in the reporting arm.
45932018|NCT03465683|Other|ESBL-producing Enterobacteriaceae|Data and biological sample collection
45932019|NCT03452111|Drug|Nestorone + Testosterone Combination Gel|The combined gel is a transdermal treatment that will be applied daily for 52 weeks to a male subject's arms and shoulders. The formulation will be a hydro alcoholic gel. About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume.
46073359|NCT02837978|Drug|MTX|MTX：5mg to 15mg, po, once per week (Qw) until the endpoint or adjusted due to unacceptable toxicity develops.
46073360|NCT00832195|Device|Motion Controlling Running Shoe|Running shoe with thermoplastic mid-foot shank stiffener, denser durometer foam on medial aspect of mid-sole, reinforced heel counter, wider sole-plate, and lateral foam crash-pad.
46073361|NCT00832195|Device|Neutral Running Shoe|Standard running shoe with single density mid-sole foam.
46073362|NCT00885846|Other|Qigong therapy|For 12 weeks, subjects in Qigong therapy group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
46073363|NCT00885846|Other|Progressive resistance training|For 12 weeks, subjects in the PRT group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
46073364|NCT02843828|Device|gait rehabilitation with Samsung Hip Assist v1|Participants will participate in 10 sessions of gait rehabilitation with Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
45451609|NCT03956303|Drug|Chirocaine Heavy 40|Chirocaine (%0.75) + Dextrose 40 mg+20 mcg fentanyl
45451610|NCT03956303|Drug|Chirocaine Heavy 60|Chirocaine (%0.75) + Dextrose 60 mg+20 mcg fentanyl
45652326|NCT04806815|Other|A survey of 60 questions was created through the internet-based 'Google Forms surveys' site.|"The following tests will be used together with the survey;~Menstrual Symptom Questionnaire~Fatigue Severity Scale~Short Form Of Coronavirus Anxiety Scale"
45652327|NCT03072199|Drug|RiTUXimab Injection|Single dose of Rituximab given intravenously within 48hours of myocardial infarction
45652328|NCT04811105|Procedure|steam ablation|32 rats have 1 fistula tract .For 16 rats the investigator will use steam ablation to obliterate and 16 rats will be control group
45451611|NCT03956303|Drug|Chirocaine Heavy 80|Chirocaine (%0.75) + Dextrose 80 mg+20 mcg fentanyl
45932020|NCT03430310|Other|Low Glycemic Diet|The investigators will use a Low Glycemic Load Diet (LG Diet), which emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary (e.g., for vegetarians). Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included. Saturated fat from red meat will be limited to less than 10% of daily caloric intake. The participants will obtain the majority of their fat intake from mono-unsaturated fatty acids (e.g. olive oil), and medium-chain triglycerides (e.g., coconut oil and cream); from nuts and nut butters; and from fresh fish.
45932021|NCT03430310|Other|Control Diet|The Control diet will be compatible with both the American Diabetes Association and The United States Department of Agriculture guidelines. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide <2300 mg/day sodium. Saturated fat will be limited to less than 10% of total energy, and all dairy products will be fat-free (or low-fat). Although the Control diet will be a healthful diet, it will include a greater amount of carbohydrate foods from such sources as bread, potatoes, and pasta that will distinguish it qualitatively from the LG diet. In addition, it will have quantitatively more total energy from carbohydrate than the LG diet.
45932022|NCT03400085|Other|mHealth application|The intervention is an mHealth smartphone application designed for living kidney donors to complete their required 2-year follow-up. It allows the donor to input the answers to the clinical survey responses, as well as upload a picture of their lab values.
45802655|NCT04026529|Other|walking on incline or walking at increasing speed|"Subjects will be prepared for data collection by wearing a form-fitting suit (i.e., wrestling singlet) and obtaining height and body weight. Retro-reflective markers will be placed bilaterally on anatomical locations of the feet, legs, and hips.~be outfitted with the portable metabolic cart and oximeter as in the previous visit. One of two treadmill trials will be performed: 1) at the speed and 2) at the slope +speed determined in the previous visit. Trial order will be randomized among subjects and across visits 3 & 4. For each trial, subjects will be asked to walk on a treadmill for up to 6 minutes. Speed or slope will be increased every 30 seconds and they will be asked to walk for one minute at that speed or"
45451612|NCT01094093|Drug|AMG 139|Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers (Part A) and subjects with moderate-severe psoriasis (Part B).
45451613|NCT01094249|Drug|divalproex sodium ER/paliperidone ER|Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12
45652329|NCT04990999|Procedure|Vestibular Root Extraction|a 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth, then pushing the vestibular pouch in an incisal direction exposing the apical root area, and allowing direct undisturbed access to the root surface
45652330|NCT04990999|Procedure|Atraumatic extractions using periotomes followed by conventional forceps|a sulcular releasing incision suing a micro scalpel was made to detach the surrounding tissues, followed by applying the periotome interproximally into the PDL space, widening the attached periodontal ligaments space.
45802656|NCT02932787|Device|Height-adjustable workstation|
45802657|NCT02023411|Drug|Teriparatide|recombinant human parathyroid hormone (1-34) subcutaneous every day at 8-9 pm
45802658|NCT02023411|Other|Placebo|Placebo
45802659|NCT02851823|Device|Periodontal curettes|
45802660|NCT02851823|Device|Er-YAG+Nd-YAG lasers|
45802661|NCT02023801|Device|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
45932023|NCT03390933|Drug|Fluoxetine|Patients enrolled into Phase II will be prescribed 2 weeks of short-acting fluoxetine 20 mg and will be instructed to take the prescription daily for 2 weeks. Then patients will be prescribed 10 additional weeks of 90 mg (weekly) fluoxetine and will be observed taking it once weekly at the dialysis unit. At the end of the 12 week study period, participants will be provided 4 additional weeks of 90 mg fluoxetine in order to provide sufficient time to follow up with their primary care physician or nephrologist.
45932024|NCT03387787|Device|GlucoTab|"The GlucoTab® system is a computerized decision support system built of an android based front-end user interface and a backend server including the REACTION algorithm. GlucoTab® is able to process blood glucose data and physiological confounders of glycaemia. Subsequently, GlucoTab® provides patient-specific basal, bolus, and correction insulin doses together with visualization and documentation of relevant data.~Insulin doses of recruited patients will be calculated by the GlucoTab System for at least 48 hours and a maximum duration of 21 days."
45932025|NCT03387787|Drug|Insulin Degludec|During the study, patients will be treated with basal Insulin degludec
45597979|NCT02366481|Dietary Supplement|Placebo|Two placebo softgel capsules (containing no vitamin K2) every day for 8 weeks.
45597980|NCT02366481|Dietary Supplement|Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d)|One 90-mcg vitamin K2 softgel capsules (containing no vitamin K2) and one placebo softgel capsule everyday for 8 weeks.
45597981|NCT02366481|Dietary Supplement|High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)|Two 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
45597982|NCT02373891|Drug|Surfolase CR|T1: Surfolase CR (Acebrophylline 200mg) administration after fat intake Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
45652331|NCT04811183|Behavioral|Pharmaceutical consultation|"Selection of patients for a pharmaceutical consultation with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week after hospitalization.~Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week after consultation. Elements on knowledge and adherence of treatment will be collected."
45652332|NCT04901533|Procedure|O-A-A|patient is supine, and the therapist stands on the side to be manipulated. The cranial hand of the therapist globally grasps the patient's skull and turns the patient's neck on that same side. The caudal hand is placed on the patient's face. The technique is performed by an impulse in pure rotation on the side that the cervical region is rotated, with a helical movement.
45802662|NCT02933879|Drug|NVXT topical|topical treatment
45802663|NCT02933879|Drug|Placebo (Vehicle) Topical|Placebo (Vehicle) Topical
46073365|NCT02843828|Other|gait rehabilitation without Samsung Hip Assist v1|Participants will participate in 10 sessions of gait rehabilitation without Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
46073366|NCT00839059|Drug|lenalidomide|"Dose escalation:~Level 0 to level 5, starting with level 1 = 25mg lenalidomide per os daily, Cohorts of 3 patients (to be expanded up to 6 if 1 DLT is observed among the first 3 patients) will be sequentially allotted to progressively higher dose levels of lenalidomide on the basis of the presence and severity of lenalidomide related toxicity encountered in the first cycle or lenalidomide related serious adverse reactions.~Duration of the first cycle: 56days, each following cycle will last 28 days"
45802664|NCT02068820|Device|ISB dye and standard white light imaging|Sentinel lymph node mapping utilizing the da Vinci surgical system and ISB dye with standard white light imaging.
45932026|NCT03364036|Drug|Mavenclad®|Participants received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
45802665|NCT02068820|Device|ICG dye and FireFly fluorescence imaging|Sentinel lymph node mapping utilizing the da Vinci surgical system with ICG dye and FireFly fluorescence imaging.
45932027|NCT03354611|Radiation|Contrast Enhanced Cone Beam Breast CT Scan|"Pre-contrast scan~Begin contrast injection (and saline chaser)~Post-contrast Scan. Start time of post-contrast CE-CBBCT scan is 90-200 seconds after start of injection, depending on method of contrast delivery (bolus vs hand injection)"
45932028|NCT03354611|Drug|Contrast Dye, Iodinated|"1.5-2ml/kg body weight (100 ml maximum) of a low osmolar, nonionic, 300-350 mgI/ml iodinated contrast agent, will be injected at a rate of ~2.0 ml/s, for a total injection time of 30-60 seconds (for a 50 kg subject). This will be immediately followed by a saline chaser from 20 to 40 ml at ~2 ml/s (20 seconds) to maximize dynamic enhancement."
45932029|NCT03338790|Biological|nivolumab|Specified dose on specified days
45932030|NCT03338790|Drug|docetaxel|Specified dose on specified days
46073367|NCT02839538|Procedure|Local Infiltration|Injection at perianal region with ropivacaine 0.75%(20ml)
46073368|NCT02839538|Procedure|Subarachnoidal block|Injection at subarachnoidal space with bupivacaine 0.5% ( 2ml)
45932031|NCT03338790|Drug|enzalutamide|Specified dose on specified days
45932032|NCT03338790|Drug|rucaparib|Specified dose on specified days
45932033|NCT03338790|Drug|prednisone|Specified dose on specified days
46073369|NCT02826018|Drug|ALN-HBV|Ascending doses of ALN-HBV by subcutaneous (sc) injection
46073370|NCT02826018|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
45597983|NCT02373891|Drug|Surfolase CR|T0: Surfolase CR(Acebrophylline 200mg) fasting administration Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
45802666|NCT02855567|Device|Acupuncture needles|Acupuncture needles (29 and 30 gauge) used to perform the acupuncture
45804177|NCT01112072|Drug|Riboflavin|Corneal epithelium removed followed by riboflavin drop administration every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive Intacs placement either immediately before CXL or 3 months before CXL.
45932034|NCT03334942|Behavioral|Child and Family Traumatic Stress Intervention|The Child and Family Traumatic Stress Intervention (CFTSI) is a 5-8 session intervention, initiated within 60 days of trauma exposure for youth reporting acute PTSS. CFTSI is designed for children age 7 and older, and requires the involvement of a caregiver who knows the child well enough to report changes in the child's behavior and symptoms. CFTSI targets modifiable risk and protective factors during the early post-trauma period to promote recovery and reduce PTSS via caregiver-child communication and cognitive and emotional processing. CFTSI uses skill modules (e.g., sleep disturbance, intrusive thoughts, anxiety) to teach effective strategies to decrease a child's PTSS. Coping and communication skills are taught and practiced in caregiver-child sessions and in the home.
46073371|NCT00832273|Device|ELAD®|liver assist system
46073372|NCT02839616|Procedure|orthotopic liver transplantation|
46073373|NCT02826174|Procedure|closed PKP under topical anesthesia|a closed corneal transplantation under topical anesthesia with the anterior chamber maintained
46073374|NCT02826174|Procedure|open-sky PKP under retrobulbar anesthesia|an open-sky corneal transplantation under retrobulbar anesthesia
46073375|NCT02826174|Drug|Anti-Rejection Agents|Anti-Rejection Agents for both groups
46073376|NCT02826174|Drug|Anti-Inflammatory Agents|Anti-Inflammatory Agents for both groups
45653295|NCT04445701|Drug|AO-176 + Dex + Bort|Humanized mAb targeting CD47 plus dexamethasone plus bortezomib
45653296|NCT05465161|Device|Sting Mark Fiducial Marker|Device insertion will occur with the designated needles and through the appropriate organ-specific route and imaging guidance. Multiple STING-MARK fiducials will be inserted. Plain film x-rays in 3 planes of the organs with the marker inserted will be taken and recorded.
45653297|NCT05464147|Device|DynamX Drug-Eluting Coronary Bioadaptor System|DynamX Drug-Eluting Coronary Bioadaptor System Implantation in Coronary Artery Lesion
45653298|NCT03066037|Procedure|regional-anaesthesiological infiltration|Patients with therapy refractory chronic pain are treated with local infiltration techniques using e.g. local anaesthetics, opioids or drug combinations. Targeted structures are e.g. Ganglion stellatum, Ganglion pterygopallatinum, Trigeminal nerve branches (V1-V3). Patients receive a context- sensitive number of blocks in a series of infiltrations depenting on their pain course.
45653299|NCT04995081|Biological|Biological/Vaccine: Allogeneic HB-adMSCs|HB-adMSCs will be administered intravenously to study participants who qualify.
45653300|NCT04995081|Other|Placebo|Sterile Saline Solution 0.9%
45653301|NCT04433377|Procedure|Suprascapular nerve block|A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg / mL + 2.63 mg / mL; 1 mL), 0.5 % bupivacaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 22 gauge 90-mm injector
45653302|NCT04433377|Procedure|Subacromial injection|A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg/mL + 2.63 mg/mL; 1 mL), 2% lidocaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 21 gauge 38-mm injector.
45932035|NCT03323463|Diagnostic Test|F-FMISO PET/CT Scan|All subjects on Cohort A and the first 100 subjects accrued to Cohort B will undergo a pre-treatment F-FMISO scan PET/CT scan pretreatment. For both Cohort A and Cohort B, FMISO scan will be repeated between the 5th-10th RT day if pre-treatment scan is hypoxic. If the repeat 18F-FMISOscan PET/CT demonstrates hypoxia, the subject will receive 70Gy concurrent with 2 cycles of chemotherapy. All subjects accrued onto Cohort B after 100 accruals will undergo only one 18F-FMISO scan done 5-10 treatment days after start of radiation therapy.
45932036|NCT03323463|Radiation|30 Gy over 3 weeks|Treatment will be delivered as one fraction per day on a standard 5 day per week schedule (excluding weekends and holidays), total of 30 Gy over 3 weeks at 2 Gy per fraction each day. The gross nodes, the primary/postoperative bed if applicable, all subclinical areas at risk for disease will receive the same dose at 30Gy.
45932037|NCT03323463|Drug|Cisplatin|Cycle 1 (week 1): At the start of week 1 of IMRT, subjects will receive cisplatin 100 mg/m2 intravenously. They may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 1 and 2, or as a single dose, typically on day 1.
45802667|NCT02856035|Other|Neural feedback plus FES and motor training|We are not testing the feasibility of the imaging methods; that has been well established and is used clinically. We are testing the feasibility of using neural feedback clinical imaging methods in a neural feedback paradigm which involves sequential rtfMRI (phase I) and rtfNIRS (phase II) training; Neurally-triggered, peripherally-directed FES-assist practice of wrist and finger extension will be combined with rtfNIRS training in Phase II; up to 60 total sessions, including additional motor learning sessions without brain neural feedback will be provided in Phase III.
45652333|NCT04901533|Procedure|cranial listening|The patient is in the supine position, and the therapist sitting at the head of the patient. The therapist places his hands on the head of the patient, the thumbs touch each other, without touching the vault cranial. A perception of the cranial rhythm is carried out passively.
45932038|NCT03323463|Drug|Carboplatin|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). Cycle 2 (Week 4): After the three weeks of radiation at week 4 when the subject no longer is receiving radiation therapy, subjects will receive cisplatin 100 mg/m2 intravenously. The may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 22 and 23, or as a single dose, typically on day 22.
45802668|NCT01975519|Drug|TRC105 and Pazopanib|Weekly TRC105 in combination with standard dose Pazopanib.
45802669|NCT02934191|Drug|Celecoxib|Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally
45932039|NCT03323463|Drug|5Fluorouracil|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).
45932040|NCT03323463|Radiation|Proton Therapy|Proton beam using pencil beam delivery either with the Varian or IBA delivery systems will be allowed for Cohort B. Proton beam therapy will be given at the New York Proton Center in New York City, where MSKCC has a well-established business associate agreement and cooperative research agreement with, respectively. If treatment at NYPC is not feasible, patients may be referred to ProCure in Somerset, NJ.
45932041|NCT03315897|Drug|Erythropoietin|40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 12 times as intravenous infusions over 15 minutes.
45932042|NCT03315897|Drug|Saline|1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
45932043|NCT03299660|Drug|Avelumab|Avelumab 10 mg/Kg every 2 weeks for 4 cycles post LCCRT
45932044|NCT03299660|Drug|5 Fluorouracil|5FU continuous infusion 225mg/m2/day during radiotherapy
45932045|NCT03299660|Drug|Capecitabine Pill|Can be administered in place of 5FU infusion. Dose = 825 mg/m2 twice a day on each day of radiotherapy
45932046|NCT03299660|Radiation|Radiotherapy|50.4 Gy in 28 fractions delivered over 5.5 weeks as 5 fractions/week
45932047|NCT03299660|Procedure|Surgical Resection|Surgical resection of tumour mass post radiotherapy and chemotherapy
45932048|NCT03292458|Drug|Sodium Oxybate|Alcohol challenge test and oral administration of a single dose of sodium oxybate and the matching placebo.
45932049|NCT03243058|Biological|ILT-101 (Aldesleukin; IL-2)|Administration of Low-Dose Interleukin-2 (ILT-101) for two years
46073377|NCT02839460|Procedure|Outpatient Muscle Biopsy|Outpatient Muscle Biopsy involving skeletal muscle sample collected from the vastus lateralis muscle
46073378|NCT00621517|Drug|Bupropion|Partipants will receive 150 mg bupropion per night
46073379|NCT00621517|Drug|Placebo|1 capsule nightly for six weeks
46073380|NCT02827266|Drug|Epoetin beta|Participants will receive epoetin beta as a weekly subcutaneous (SC) injection over an 8-week correction phase with 60 international units per kilograms (IU/kg) as starting dose. Baseline weight will be used to determine the dose and adjustments in the dose will be implemented based on the participant's blood hemoglobin levels. Participants with a response to correction treatment will then enter a 4-week extension phase to receive the SC injection every 2 weeks, and those without response will continue at the same weekly dose for a 4-week continuation phase.
46073381|NCT02839226|Drug|AR/101|
46073382|NCT02839226|Drug|Placebo|
45653303|NCT05048589|Drug|Standard-Dose Quadrivalent Influenza Vaccine|For the control arm, the standard-dose quadrivalent influenza vaccines Influvactetra® and Vaxigriptetra will be used.
45802670|NCT02934191|Other|Placebo|Placebo will have the same appearance, taste and consistency as celecoxib. Placebo will consist of calcium carbonate powder suspended in the same syrup as celecoxib. Dose of elemental calcium is 3 mg/kg/day.
46073383|NCT00845221|Drug|Imatinib mesylate 100 mg (Glivec)|260 mg/m2/day tablets
45653304|NCT05048589|Drug|High-Dose Quadrivalent Influenza Vaccine|For the control arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
45932050|NCT03243058|Other|Treatment-Placebo Arm|Administration of Low-Dose Interleukin-2 (ILT-101) for one year, and then placebo for the second year.
46073384|NCT02950844|Other|Novel mapping algorithm|"Mapping and ablation of atrial fibrillation drivers identified by the STAR mapping algorithm.~In a sub-study a novel mapping system (CARTOFINDER, Biosense Webster, Inc, CA) was used in mapping drivers in AF."
45652334|NCT04825925|Device|DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization)|Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, the Platinum was infused. BAI (Bronchial Arterial Infusion ) chemotherapy was followed by DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with Vinorelbine were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.
45652335|NCT05003479|Biological|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
45802671|NCT02934191|Drug|Acetaminophen|Acetaminophen syrup at a dose of 15mg/kg/dose will be given every 4 hours for the first 5 days after surgery. After that point, is given as needed.
45802672|NCT02934191|Drug|Oxycodone|Oxycodone may be used every 4 hours post-operatively to treat breakthrough pain. The most commonly prescribed dose is 0.075mg/kg/dose (suspension) every 4 hours as needed.
45802673|NCT02934347|Procedure|25 degree back-up position|To test whether a 25 degree back-up position improves laryngeal views and makes intubation easier compared to the standard horizontal position
45802674|NCT01975909|Device|Transcranial Magnetic Stimulation|0.2 Hz (5 pulses every six seconds in a counter-clockwise current, followed by the same five pulses in a clockwise current); 10 pulses per region, 30 pulses per session; 5 days a week for 4 weeks.
45802675|NCT02937623|Device|Dissolvable polymer strip containing Novamin (calcium sodium phosphosilicate)|Experimental dissolvable polymer strip containing Novamin (15% weight by weight[w/w] calcium sodium phosphosilicate).
45802676|NCT01977547|Biological|Short storage RBC age|IND obtained to cover the expiration date on the red blood cell unit
45802677|NCT02864069|Behavioral|Walking Intervention|The walking intervention will begin following baseline assessments and will be continued for 12 weeks. Participants will be given a pedometer to use daily and log their daily steps, with an identified goal of increasing step counts by 3000 steps a day over the course of the intervention. After obtaining a week long baseline step count, individuals in the intervention group will progressively increase their step counts by 100 steps daily each week for the first three weeks, by 200 steps daily for weeks four through six, by 300 steps daily for weeks seven through nine, and by 400 steps daily for weeks ten through twelve. Mean baseline step counts for sedentary older adults in our pilot work were 4150 per day; therefore, most participants will almost double their daily activity by the end of the intervention.
45451614|NCT03957785|Device|AlterG Treatment|All participants practiced one session a day of AlterG or TGT (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, FAC-tailored physiotherapist assistance, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination (FAC 2), with the visual supervision of one physiotherapist (FAC 3), or independently without using the handrails (FAC 4). BWS, physiotherapist assistance, and S were checked and adapted to subjects' progresses across the AlterG sessions. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the monthly LBPP gait training was carried out.
45802678|NCT02864069|Behavioral|Cognitive Training Intervention|In the CT condition, participants will use Brain HQ, a computer cognitive training program (Posit Science Corporation, San Francisco, CA), shown to be well tolerated by older adults with positive short- and long-term cognitive outcomes. Participants will use the program 60 minutes/day, 5 days/week for 12 weeks. If participants do not have a home computer/internet access, they can complete the modules at another location such as a public library, senior center, or at the MARC, but training will still be self-directed.
45802679|NCT02864069|Behavioral|Combined Intervention|The combined condition will concurrently follow both the walking and the CT programs as described above.
45802680|NCT02013050|Drug|SGX942|
45802681|NCT02013050|Drug|Placebo|
45802682|NCT01977781|Drug|Tacrolimus|Topical bilateral application of 0.05% Tacrolimus BID for 10 weeks
45802683|NCT01977781|Drug|Methylprednisolone Sodium Succinate|Topical bilateral application of 0.5% methylprednisolone sodium succinate BID for 10 weeks
45932051|NCT03243058|Other|Placebo Arm|Participants in this group will receive a placebo injection for two years.
45451615|NCT01094405|Biological|Recombinant Epstein-Barr Virus (EBV) Vaccine|
45652336|NCT05003479|Biological|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
45652337|NCT04806659|Drug|SH1573 Capsules|Patients from each cohort will be administered SH1573 capsules every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
45652338|NCT03070093|Drug|gilteritinib|oral
45932052|NCT03231969|Drug|Bilastine 0.2%|1 drop in each eye at 3 separate times during a 25 day period.
45932053|NCT03231969|Drug|Bilastine 0.4%|1 drop in each eye at 3 separate times during a 25 day period.
45932054|NCT03231969|Drug|Bilastine 0.6%|1 drop in each eye at 3 separate times during a 25 day period.
45932055|NCT03231969|Drug|Bilastine 0%|1 drop in each eye at 3 separate times during a 25 day period.
45932056|NCT03229941|Procedure|Blood Transfusion|Blood Transfusion
46073385|NCT00832351|Procedure|Mobilisation|Mobilisation
45652339|NCT04806581|Drug|Allogeneic Hepatocyte|Allogeneic hepatocyte with cell numbers L,M,H respectively.
45652340|NCT04806737|Drug|Teriflunomide Oral Tablet|The study will be conducted with two treatment groups in the form of a 2:1 parallel group comparison and will serve to compare oral treatment with 14 mg/d teriflunomide vs. placebo in subjects with well-controlled coeliac disease undergoing gluten challenge. The screening period will be up to 8 weeks, followed by a 7-day run-in treatment period with a loading dose of teriflunomide followed by a 6 day therapeutic maintenance dose, an initial 4-week treatment-free follow-up period and a 6 month closing follow-up.
45653305|NCT05728567|Other|whether the participants had T2DM|whether the participants had T2DM
45932057|NCT03174522|Drug|REX-001|REX-001 is administered through an intra-arterial catheter.
45932058|NCT03174522|Drug|Placebo|Placebo is administered through an intra-arterial catheter.
45932059|NCT04118023|Diagnostic Test|7 Tesla Magnetic Resonance Imaging Test|MAGNETOM Terra - 7T MRI Scanner by Siemens Healthineers. Each patient enrolled will undergo the study imaging test prior to planned diagnostic knee arthroscopy.
45932060|NCT03144765|Procedure|Transanal Total Mesorectal Excision (taTME)|Study procedures consist in 1-team (sequential) or 2-team (combined) low anterior resection with transanal TME using laparoscopic or robotic abdominal assistance.
45932061|NCT03140358|Drug|Atropine sulfate 0.01%|Atropine 0.01%
45652341|NCT03070249|Behavioral|Professional Quality of Life (ProQoL) scale|COMPASSION SATISFACTION AND COMPASSION FATIGUE (PROQOL) measures how compassion for those who are cared for can affect providers in positive and negative ways. Questions about experiences, both positive and negative, as a provider reflecting the frequency experiences within the last 30 days. 1=Never 2=Rarely 3=Sometimes 4=Often 5=Very Often
45932062|NCT03140358|Drug|Placebo|placebo
45932063|NCT03122470|Device|MRI guided biopsy|The MRI guided biopsy will preferentially be performed using a 3 tesla (3T) Siemens Verio, or 3T Siemens Skyra machine. The multiparametric MRI exam will consist of T1-, T2- and diffusion weighted imaging with or without post-contrast perfusion studies. magnetic resonance fingerprinting (MRF) will be performed before contrast injection. The MRI will be interpreted by two specified radiologists from the research team.
45451616|NCT00055601|Drug|cisplatin|Induction: 15 mg/m2 as a 60-minute infusion on days 1, 2, 3, 8, 9, 10, 15, 16, and 17; Consolidation: 15 mg/m2 as a 60-minute infusion on days 1, 2, 8, and 9; Adjuvant: 35 mg/m2 as a 60-minute infusion on days 1 and 8 of each 21-day cycle for 4 cycles.
45802684|NCT02938169|Behavioral|exercise|"stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~walking exercise: treadmill gait with tolerable gait speed~flexibility exercise: stretching exercise(control)"
45802685|NCT04012411|Procedure|Brain MRI|Multimodal brain MRI: volumetry, diffusion tensor, functional rest MRI
45802686|NCT04012411|Procedure|Lumbar Punction|Analysis of BDNF, Tau, NFL and TrkB in cerebrospinal fluid
45802687|NCT04012411|Genetic|Blood sample|Analysis of BDNF, Tau, NFL, and Val66Met polymorphism
46073386|NCT02838056|Drug|epidural injection|drug combination: 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
46073387|NCT04243200|Other|Hypos can strike twice|"The Hypos can strike twice intervention involves ambulance staff providing treatment to patients experiencing hypos and advising them to access follow-up care by their GP/specialist diabetes team. This is backed up by giving patients a Hypos can strike twice information booklet which they can read when they recover."
46073388|NCT02546401|Drug|Insulin Aspart|Injection of Insulin Aspart before or after meals
45451617|NCT00055601|Drug|fluorouracil|Induction: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 15, 16, and 17; Consolidation: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 8, 9, and 10.
45451618|NCT00055601|Drug|paclitaxel|Induction: 50 mg/m2 as a 60-minute infusion on days 1, 8, and 15; Consolidation: 50 mg/m2 as a 60-minute infusion on days 1 and 8; Adjuvant: 50 mg/m2 as a 60-minute infusion on days 1 and 8 of each 21-day cycle for 4 cycles.
45652342|NCT04825691|Diagnostic Test|Immunohistochemistry of prostate biopsy|Sections of formalin fixed paraffin embedded tissue blocks will be stained with ERG oncoprotein. Antibody dilution, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions
45652343|NCT04991233|Procedure|Endoscopic surgery|The endoscopic surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
45652344|NCT04991233|Procedure|Suboccipital craniotomy surgery|The suboccipital craniotomy surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
45802688|NCT04012411|Other|Cognitive evaluation|Symbol Digit Modality Test (SDMT), Stroop test, Trail Making Test, Empan
45802689|NCT02070302|Drug|Botulinum Toxin Type A|40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each
45932064|NCT03122470|Procedure|TRUS biopsy|The TRUS biopsy will be performed per current standard of care. Biopsy cores will be sent to pathology in separately labeled specimen cups. The final pathological results will be compared with pre-biopsy MRI findings.
45932065|NCT03101982|Drug|HBO|Hyperbaric oxygenation (HBO) is defined as breathing of 100% oxygen under elevated ambient pressure in a hyperbaric chamber. HBO is considered a pharmacological therapy.
45932066|NCT03053687|Dietary Supplement|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
45932067|NCT03053687|Dietary Supplement|Placebo|Low caloric formula (Powder added to water) without added vitamins and mineral
45932068|NCT02974075|Procedure|Salvage lymph node dissection|Open pelvic surgery to dissect pelvic lymph nodes. The landmarks for dissection are: 1. Inferior mesenteric artery 2. Ilioinguinal nerve 3. Inguinal ligament 4. Dorsal pelvic floor 5. Urinary bladder
45932069|NCT02971358|Procedure|Radical prostatectomy|Standard radical prostatectomy with extended lymph node dissection is performed.
45932070|NCT02954536|Drug|pembrolizumab|
45932071|NCT02954536|Drug|trastuzumab|
45932072|NCT02954536|Drug|capecitabine|
45932073|NCT02954536|Drug|cisplatin|
45932074|NCT02954536|Drug|Oxaliplatin|Oxaliplatin may be administered instead, at a dose of 130 mg/m2/day as an I.V.over approximately 2 hours on Day 1 every 21-day cycles, up to a maximum of 8 cycles in the absence of disease progression or until other withdrawl criteria are met. Patients may begin with reduced dose of oxaliplatin 104 mg/m2 as starting dose if deemed necessary per the treating physician discretion. Oxaliplatin will be administered after the completion of the pembrolizumab infusion.
45802690|NCT02070302|Drug|Placebo|Placebo (Normal Saline) divided into 2 injections of .4cc each
45932075|NCT02954536|Drug|5-Fluorouracil|Only for patients unable to take oral medications (because of certain circumstances such as malabsorption, difficulty swallowing, or other conditions that could affect intake of oral capecitabine medication), 5-FU may be administered instead, at a dose of 800 mg/m2/day as a continuous infusion over 5 days (Day 1 to Day 5 of each cycle), every 21 days. This decision should be made prior to registration by the treating physician; switching from capecitabine to 5-FU, or vice versa, will not be allowed during the study. 5-FU will be administered after completion of the cisplatin infusion.
45932076|NCT02942173|Biological|CD45RA-depleted peripheral blood mononuclear cells|Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
45932077|NCT02931942|Other|blood withdrawn|venous blood sampling
45932078|NCT02919670|Dietary Supplement|Enterade|
45932079|NCT02919670|Dietary Supplement|Placebo|
45932080|NCT02919670|Other|Standard Supportive Care|
46073389|NCT02827344|Biological|blood sample collection for CTC and MDSC analysis|"Isolation of circulating tumor cells from 2 tubes by ISET filtration module. Peripheral blood samples will be collected for CTC analysis within 7 days before commencing treatment (defined as baseline) and following four cycles of immunotherapy,~Analysis of PD-L1 and PD-L2 expression by immunocytochemistry on CTC~Analysis of the expression of PD-L1, PD-L2 , CTLA4 on the histological specimen by immunohistochemistry"
46073390|NCT02843516|Other|No intervention|No intervention
45451619|NCT00055601|Radiation|radiation therapy|Induction: External beam irradiation, 1.6 Gy, will be given to the pelvis in the first treatment followed by an interfraction period of at least 4-6 hours. During the second treatment, 1.5 Gy will be delivered to the whole bladder for the first five sessions (7.5 Gy) then to the tumor plus a margin for eight sessions (12. Gy). Consolidation: Consolidation therapy will start 7-14 days following a cystoscopic re-evaluation demonstrating a complete response to the induction therapy. 1.5 Gy (per fraction) will be given to the pelvis in two treatment fractions per day, with an interfraction period of at least 4-6 hours.
45802691|NCT02938949|Drug|alirocumab|
45451620|NCT00055601|Drug|Gemcitabine|Adjuvant: 1000 mg/m2 over 30-60 minutes on days 1 and 8 of each 21-day cycle for 4 cycles.
45451621|NCT00055601|Procedure|Radical cystectomy|Operable patients with pT1 or worse tumor response on re-evaluation following induction therapy will have radical cystectomy.
45451622|NCT03957473|Device|Indigo Aspiration System|Indigo Aspiration System with CAT RX Aspiration Catheter and optional Indigo Separator 4
45451623|NCT01094483|Drug|PN400|naproxen 500 mg/esomeprazole 20 mg oral tablet
45451624|NCT01094483|Drug|ASA|Asprin 81 mg enteric coated tablet
45451625|NCT01094483|Drug|Placebo|
45802692|NCT02938949|Drug|placebo|
45932081|NCT02904811|Other|Testing for Ct infection immediately|Self-taken vaginal samples will be immediately tested for Ct infection at the National Reference Centre (CNR) at University of Bordeaux, using a commercially available CE marketed real-time PCR assay.
45932082|NCT02904811|Other|Testing for Ct infection at the end of the study|Self-taken vaginal samples will be tested for Ct infection at the end of the study (M18).
45652345|NCT04810637|Drug|GX-I7|Recombinant human interleukin-7 hybrid Fc
45652346|NCT04353167|Other|observational evaluation|Patients will be evaluated only observationally without intervention
45932083|NCT02899611|Drug|Valproate|ICV Valproate is a dilution of the commercially available Epilim product, which is a sterile intravenous (IV) formulation of Sodium Valproate.
45932084|NCT02851043|Device|pneuRIP (breathing with resistance)|subjects are given a resistance element to breath through
45932085|NCT02851043|Device|Respitrace system (Carefusion) (breathing without resistance)|subjects are asked to breath normally
45932086|NCT02750371|Other|Evaluation of autobiographical memory|Patients will answer several questionnaires one and two years after irradiation treatment end.
45932087|NCT02750202|Biological|Quadrivalent HPV vaccine|Quadrivalent HPV vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.
45802693|NCT01979029|Procedure|preserving the left colic artery|The root of the inferior mesenteric artery(IMA) was carefully dissected and the artery wall was exposed all the way to the bifurcation of the left colic artery(LCA) and the superior rectal artery (SRA), exposing the LCA from its root until the inferior mesenteric vein (IMV) was recognized. Subsequently, dissection was continued along the IMV up to the level of the root of the IMA. Then the sigmoid mesentery was transected from the root of the IMA to the IMV, and the IMV and the root of the SRA were ligated. Finally, the adipose tissue with the lymph nodes in the area surrounded by the IMA, IMV, and LCA was dissected, with preservation of the LCA .
45932088|NCT02750202|Biological|Hepatitis B vaccine|Hepatitis B vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.
45932089|NCT02747758|Device|cathodal transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using cathodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
45932090|NCT02747758|Device|sham transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using a sham-stimulation including ramp up and ramp down of current.
45802694|NCT01979029|Procedure|not preserving the left colic artery|The root of the IMA was exposed and the fatty tissue around the root of the IMA was swept in order to maximize the lymph node retrieval rate. Subsequently, the IMA was ligated 1 cm from the aorta to avoid damaging the nerves.
45802695|NCT02939105|Device|The ZELTIQ CoolSculpting System|The CoolSculpting device will be used to perform treatments.
45802696|NCT02025439|Device|rTMS|
45802697|NCT02025439|Drug|Amantadine|
45802698|NCT02939651|Drug|Pembrolizumab|Pembrolizumab given intravenously at a fixed dose of 200mg every 3 weeks
45932091|NCT02747758|Device|anodal transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using anodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
45932092|NCT02645266|Drug|Aflibercept Injection [Eylea]|Subjects will be administered 2.0mg Aflibercept intraocular injection each month for 5 consecutive months. After the 5th month, the serum cytokine levels in blood work will be assessed as well as patients's visual acuity, and eye pressures. Upon completion of the trial, patients will resume receiving the usual standard of care.
45652347|NCT04987411|Diagnostic Test|Measurement of methane concentrations in exhaled breath|To measure methane concentrations, a near-infrared laser technique-based photoacoustic apparatus will be attached to the exhalation outlet of the ventilator upon arrival of severely injured patients. Exhaled methane levels will be monitored continuously during the first 72 in-hospital hours and will be recorded at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission).
45652348|NCT04987411|Diagnostic Test|Videomicroscopy of the sublingual microcirculation|Orthogonal polarization spectral imaging technique (Cytoscan A/R, Cytometrics) will be used to visualize the microcirculation of the sublingual mucosa of the patients. The OPS technique utilizes reflected, polarized light at the wavelength of the isobestic point of oxyhemoglobin and deoxyhemoglobin (548 nm). The diminution of sublingual microcirculation can refer to circulatory redistribution due to hemorrhage. Sublingual microcirculation of the patients will be visualized and evaluated at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
45652349|NCT04987411|Diagnostic Test|Blood gas and laboratory analysis|Arterial blood gas analysis and laboratory testing of venous blood are routine examinations in clinical practice. Base deficit and lactate are considered as global markers of blood loss and shock, and can be obtained rapidly with blood gas analysis. Hemoglobin and hematocrit values can correspond to the severity of blood loss, and are measured routinely both from arterial and venous blood. Sampling of arterial and venous blood for blood gas and laboratory analyses will be performed at pre-determined time points (directly upon arrival, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
45652350|NCT04987411|Diagnostic Test|Hemodynamic monitoring|Hemodynamic monitoring is an essential part of emergency trauma care. Non-invasive monitoring of blood pressure, heart rate and respiratory rate of patients will be started immediately upon arrival. After patients are stabilized, invasive arterial blood pressure (IABP) monitoring can be started. IABP is considered as the gold standard of blood pressure measurement in critical care as it reflects the fluctuations of blood pressure in real time. Blood pressure and heart rate values will be recorded at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
45802699|NCT01973972|Behavioral|Weight management|Weight management group visits using low-carbohydrate diet followed for weight management.
45802700|NCT01973972|Behavioral|Shared medical appointments (SMA)|Diabetes management group visits for diabetes management.
45653306|NCT03067285|Drug|ELV/COBI/FTC/TAF|Treatment with ELV/COBI/FTC/TAF during 24 weeks since randomized.
45802701|NCT02943941|Other|Reveal LINQ ICM Cardiac Monitor, taped on the subject's chest rather than inserted in the body.|Cardiac Monitor with LINQ™ HF Investigational RAMware download
45802702|NCT02026297|Drug|Tranexamic Acid|1 gram IV over 10 minutes
45802703|NCT02026297|Drug|Placebo; Normal Saline|0.9% Normal Saline
45802704|NCT02070692|Drug|Tamoxifen|7 day course of tamoxifen during an episode of irregular vaginal bleeding
45802705|NCT02070692|Drug|Placebo|7 day course of placebo during an episode of irregular vaginal bleeding
45802706|NCT02026453|Other|Pharmacist obtains admission medication history|
45802707|NCT02026453|Other|Pharmacy technician obtains admission medication history|
45802708|NCT02026687|Drug|Epidural|
45802709|NCT02026687|Drug|Intrathecal|
45802710|NCT02015234|Drug|TNX-102 SL|TNX-102 SL 2.8 mg taken daily at bedtime.
45802711|NCT01974050|Behavioral|Text message surveillance|
45802712|NCT02028247|Behavioral|Personalized Cognitive-behavioral therapy|
45802713|NCT02028247|Behavioral|Standard Practice Cognitive-behavioral therapy|
45802714|NCT02028247|Behavioral|Treatment as Usual|
45802715|NCT01975922|Behavioral|Enhanced Milieu Teaching|Enhanced Milieu Teaching (EMT) is a conversation-based model of early language intervention that uses child interest and initiations as opportunities to model and prompt language use in everyday contexts.
45802716|NCT02028325|Drug|Fluorescein Sodium|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
45802717|NCT02016560|Drug|florbetapir F 18|
45802718|NCT02016560|Drug|Flortaucipir F18|
45802719|NCT02016560|Procedure|Brain PET Scan|positron emission tomography (PET) scan of the brain
45802720|NCT02017574|Behavioral|Reaching Task|Learn a reaching task that requires coordination of the arm segments
45802721|NCT02869295|Drug|NKTR-214|Participants in the dose escalation cohorts will be treated every 21 days (q21d) or every 14 days (q14d) until tumor progression.
45802722|NCT02340104|Drug|Baricitinib|4 milligrams (mg) administered orally
45802723|NCT02340104|Drug|[^13C4D3^15N]-baricitinib|4 micrograms (μg) administered intravenously (IV)
45802724|NCT02869451|Drug|bupropion|Prescribed one week prior to quit and continued until the 6 month follow-up visit.
45802725|NCT02869451|Drug|transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
45802726|NCT02869451|Drug|Nicotine polacrilex|Initiated at smoking quit date.
45802727|NCT02869451|Drug|nicotine lozenge|Initiated at smoking quit date.
45802728|NCT02869451|Behavioral|counseling for marijuana and smoking cessation|5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention
45451626|NCT01583621|Dietary Supplement|Cholecalciferol|The participants will be randomized into one of the four groups. Group 0 will be placebo group, group 1 will receive monthly supervised dose of 18,000 IU (equivalent to 600 IU/day), group 2 will receive monthly supervised dose of 60,000 IU(equivalent to 2000 IU/day), and group 3 will receive 120,000 IU (equivalent to 4000 IU/day) vitamin D3 supplementation for 4 months (16 weeks).
45652351|NCT04991155|Drug|BIA 5-1058|BIA 5-1058 (tablets 100 mg) was administered orally with 240 mL (Part 1) or 270 mL (Part 2 and Part 3) of water, in one period in the morning under fasting conditions (after at least a 10-hour overnight fast), in one period in the morning after a moderate meal, and in the other period at lunch after a moderate meal.
45652352|NCT04825457|Procedure|Anchoring-tip vs. Conventional|"Anchoring-tip: the snare tip was projected from the sheath by 1-2 mm length. Consequently, a small mucosal incision was made at proximal side of lesion. Then the snare was deployed progressively and adjusted around the lesion trying to obtain free margins. At the final step of both conventional and Tip-in EMR, the lesion was resected.~Conventional: After injection of normal saline solution mix, snaring was tried for polyp resection."
45652353|NCT03070015|Behavioral|Nutrisystem|The Nutrisystem Diet was 1000 kcal/day for week 1,and 1200 calories/day for women and 1500 calories/day for men after week 1.Subjects with BMI > 40 added 200 extra calories/day through grocery food add-ins.Subjects received 7 breakfast,7 lunches,7 dinners, and 14 shakes for week 1.Subjects added in vegetables & no-calorie beverages in week 1.After week 1,Nutrisystem provided 7 breakfasts,6 lunches,6 dinners, and 7 (women) or 14 (men) snacks/week.Subjects prepared 1 lunch & 1 dinner on their own weekly. Guidelines were given to allow subjects to select foods that fit within plan guidelines (~50% kcal from carbohydrate,~25% from protein,~25% from fat). Nutrisystem foods were about 60% of kcal target; grocery additions made the balance.Subjects received guidance as typical on Nutrisystem throughout the study period.Subjects were encouraged to call Nutrisystem counselors. Subjects randomized to this participated in Part A (4 weeks) and Part B (additional 8 weeks) of the study.
45802729|NCT02869451|Behavioral|mobile contingency management|treatment that provides money rewards for abstinence from smoking and marijuana
45652354|NCT03070015|Behavioral|Self-Directed DASH|The self-directed Dietary Approaches to Stop Hypertension group received instruction/education with handouts & sample meal plans, which met guidelines for DASH. All subjects followed a 1000 kcal/day DASH diet for week 1. After week 1, women ate 1200 kcal/day & men ate 1500 kcal/day. Subjects with BMI >40 added an extra 200 kcal/day. Subjects randomized to this group received one additional educational session beyond the Randomization visit on how to follow their prescribed meal plan. Subjects in this group only participated in Part A (4-weeks) of the study.
45652355|NCT05618717|Device|Radiofrequency Ablation|Radiofrequency Ablation using irrigated ablation catheter
45652356|NCT03071653|Procedure|Left Cardiac Sympathetic Denervation (LCSD)|The procedure involves the surgical removal of the lower half of the left stellate ganglion (T1) and thoracic ganglia (T2-T4), thereby removing the pro-arrhythmic noradrenergic input to the ventricles
45802730|NCT02340338|Biological|rTSST-1 Variant Candidate Vaccine|"In the absence of adverse events classified as clinically relevant, interval between dose escalations 1 week. Immunization to be repeated at the same dose level 1 - 2 months later. If immunogenicity can be shown after the second administration of 1 µg, the sample size will be increased from 3 + 1 to 9 + 3. Otherwise, the sample size of 3 + 1 will continue until immunogenicity is seen at a higher dose level. If there is no immune response in any dose group after the second immunization, a third injection will be given 4 -8 weeks thereafter in dose groups of 1 µg and above.~Immunogenicity is defined by seroconversion from a TSST-1 Ab titer of < 20 to > 40 or a 4-fold increase in TSST-1 Ab titer .~Patients 3 µg or more will be randomized."
45802731|NCT02305316|Drug|BIA 9-1067 non-micronized|
45802732|NCT02305316|Drug|BIA 9-1067 micronized|
45802733|NCT02944565|Biological|Daratumumab|Given IV
45802734|NCT02870309|Biological|Alpha-1 MP|Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as α1-antitrypsin
45802735|NCT01979276|Drug|Romidepsin|Romidepsin intravenously on days 1 and 15 of a 28-day cycle
45802736|NCT01979276|Drug|pomalidomide|Pomalidomide 4mg daily by mouth on days 1-21 of a 28-day cycle
45802737|NCT01979276|Drug|Dexamethasone|Dexamethasone 40mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle
45802738|NCT02871011|Drug|Nitric Oxide|Delivered as a footbath
45802739|NCT02871011|Drug|Water|Delivered as a footbath
45802740|NCT02343380|Other|calorimetric exam after a standard meal|The calorimetric and metabolic responses to identical meals (a high-protein, low-carbohydrates meal) consumed in the morning (8:00 am) and in the evening (8:00 pm) are measured in healthy volunteers, after standardizing diet, physical activity level, duration of fast and resting
45802741|NCT02871479|Drug|SAN007 5% cream|5% EISO in a cream formulation applied twice a day for up to 28 days.
45802742|NCT02871479|Drug|Placebo|A placebo cream containing the same components as the vehicle for the active intervention arm
45802743|NCT02871479|Drug|SAN007 10% cream|10% EISO in a cream formulation applied twice a day for up to 28 days.
45802744|NCT02344238|Other|ID Capsule|Capsule containing ingestible sensor
45802745|NCT02344238|Dietary Supplement|Riboflavin|50mg
45802746|NCT02344238|Behavioral|Prompts|Reminder calls and/or text messages to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
45802747|NCT02344316|Drug|Melatonin|Taken at 9 PM or 1 hour before bedtime, whichever is earlier
45802748|NCT02344316|Other|Placebo|Matching placebo taken at 9 PM or 1 hour before bedtime, whichever is earlier
45802749|NCT02872103|Drug|F-627|F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles. TA chemotherapy treatments are part of standard-of-care and not the study
45802750|NCT02872103|Drug|Placebo|Placebo subcutaneous injection on Day 2 of the first TA chemotherapy cycle. TA chemotherapy treatments are part of standard-of-care and not the study.
45802751|NCT02344628|Drug|Azithromycin|Comparison of two different dosing strategies for the treatment of yaws
45802752|NCT02345486|Other|0.9% sodium chloride|
45932093|NCT02636504|Device|Laser Doppler Flowmetry|Pulp vitality of teeth is tested with three pulp vitality testing including laser Doppler flowmetry, cold testing, and electric pulp testing.
45932094|NCT02634294|Drug|Peg interferon alfa-2b|Eligible patients were treated with pegylated interferon alpha-2b (Peg Intron®; Schering-Plough (Brinny) Company, Innishannon, County Cork, Ireland) 1~1.5ug/kg qw, until occurrence of grade II or higher grade of acute graft versus host disease, or no response to treatment after 8 doses of treatments.
45802753|NCT02345486|Other|Physiologically balanced fluid|
45932095|NCT02586831|Drug|Anti-Thymocyte Globulin (ATG)|2.5 mg/kg administered as two divided infusions of 0.5 mg/kg and 2 mg/kg on Days 1 and 2.
45802754|NCT02950025|Device|Online, adaptive MR-guided SBRT|Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day. The estimated delivered dose should be calculated using the software on the console. An adapted radiation therapy plan should be generated
45802755|NCT02950025|Device|Online, non-adaptive MR-guided SBRT|Patients will not have online-adaptive treatment planning
45802756|NCT02950025|Other|European Organization for Research and Treatment of Cancer (EORTC) QLQ-30|"30 questions~28 questions about various health issues with answers ranging from 1=Not At All to 4 = Very Much~1 question asking about overall health with answers ranging from 1=very poor to 7 excellent~1 question asking about overall quality of life with answers ranging from 1=very poor to 7=excellent"
45802757|NCT02873585|Device|Stationary intraoral tomosynthesis|Bitewing radiographs using a stationary intraoral tomosynthesis unit
45932096|NCT02586831|Drug|Interleukin 2|1 million IU per dose administered subcutaneously for 5 consecutive days on Days 10-14, and then every two weeks.
45932097|NCT02586831|Drug|Exenatide|2 mg administered subcutaneously weekly for up to 52 weeks.
45451627|NCT03806231|Drug|Outpatient Dinoprostone 10mg|Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women randomized to the outpatient cervical ripening group will be administered the drug prior to their induction and discharged after monitoring and physician approval. They will return for their schedule induction.
45451628|NCT03806231|Drug|Inpatient Dinoprostone 10 mg|Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women who are randomized to the inpatient cervical ripening group will be administered the drug prior to their induction and remain hospitalized.
45932098|NCT02586831|Drug|Adalimumab|50 mg administered subcutaneously once a month for 1 year.
45932099|NCT02586831|Other|ATG Placebo|ATG placebo mimicking Thymoglobulin administered intravenously.
45932100|NCT02586831|Other|IL-2 Placebo|IL-2 placebo mimicking Aldesleukin administered subcutaneously.
45932101|NCT02586831|Other|Adalimumab Placebo|Placebo mimicking Adalimumab administered subcutaneously.
45932102|NCT02586831|Other|Exenatide Placebo|Placebo mimicking Exenatide administered subcutaneously.
45932103|NCT02575677|Other|oxycodone|oxycodone 0,1/kg up to 10 mg sc.
45802758|NCT02873585|Device|Standard conventional bitewing radiography|Bitewing radiographs using a stationary intraoral tomosynthesis unit will be performed after standard bitewing radiography
45802759|NCT02019758|Drug|Oral Viscous Budesonide|Oral Viscous Budesonide - 1 mg/4 mL, 4 mL of slurry twice daily
45802760|NCT02019758|Drug|Fluticasone MDI|Fluticasone multi-dose inhaler - 4 puffs twice daily (880 mcg, twice daily)
45802761|NCT02019758|Drug|Placebo slurry|Slurry of sucralose - 4 mL twice daily
45802762|NCT02019758|Drug|Placebo inhaler|Placebo inhaler - 4 puffs twice daily
45932104|NCT02573831|Drug|Oxycodone|The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
45932105|NCT02573831|Drug|Placebo|The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
45932106|NCT02571881|Procedure|Caesarean section|After caesarean section oxycodone or oxycodone-naloxone prolonged release tablet twice a day is started for pain medication
45932107|NCT02571881|Drug|Oxycodone|
45932108|NCT02571881|Drug|oxycodone-naloxone|
45932109|NCT02571179|Drug|intranasal fentanyl 50 microg dose up to 250 microg|When contraction pain was ≥ 5/10 (numerical rating scale 0= no pain, 10= worst pain), the parturient was given a intranasal fentanyl 50 µg dose. After 15 minutes, if contraction pain was still ≥ 5/10, a second 50 µg intranasal dose was administered. Fentanyl was administered every 15 minute until contraction pain decreased to less than 5/10 or until the maximum fentanyl dose of 250 µg was administered.
45802763|NCT02876159|Biological|2016-2017 Influenza Vaccine|Quadrivalent influenza A/Hemagglutinin Type 1 (H1N1), A/Influenza A virus subtype (A/H3N2) H3N2,and B virus vaccine for Intramuscular (IM) use is a sterile, clear and slightly opalescent suspension administered as a single 0.5 mL intramuscular dose.
45802764|NCT02020304|Drug|combined spinal epidural|Combined Spinal Epidural
45932110|NCT02555189|Drug|Enzalutamide|Given PO
45932111|NCT02555189|Drug|Ribociclib|Given PO
45802765|NCT04349384|Procedure|Colorectal resection|Colon or rectal resection for colorectal adenocarcinoma
45802766|NCT01980589|Drug|Carfilzomib|Carfilzomib administered as a 30-minute intravenous (IV) infusion on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. On Days 1 and 2 of Cycle 1, all participants received carfilzomib at 20 mg/m².
45802767|NCT01980589|Drug|Cyclophosphamide|Cyclophosphamide administered orally (PO) at the dose of 300 mg/m² on Days 1, 8, and 15 of each 28-day cycle.
45802768|NCT01980589|Drug|Dexamethasone|Dexamethasone administered PO or IV at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
45802769|NCT02021942|Drug|SOM230 LAR|SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks.
45932112|NCT02540616|Device|Transcranial Electrical Stimulation|A form of external neuromodulation using electrodes on the surface of the head. We will be using the TCT tDCS device (www.trans.cranial.com) or devices constructed by our research group or collaborators.
45932113|NCT02511418|Drug|Simvastatin|
45932114|NCT02489825|Procedure|Augmentation vertebroplasty|Cement augmentation of fractured vertebral body
45932115|NCT02489825|Procedure|Augmentation and prophylactic vertebroplasty|Cement augmentation of fractured vertebral body and prophylactic augmentation of both adjacent vertebral bodies
45802770|NCT01981057|Other|Numeta|parenteral receipt prescribed with Numeta
45932116|NCT02392078|Device|NeuroBlate System|
45932117|NCT02328573|Behavioral|Communal singing|
45802771|NCT01981057|Other|Individual|parenteral receipt prescribed individually
45932118|NCT02308085|Other|Endocrine therapy interruption|"3 months wash-out between treatment interruption and pregnancy attempt. Up to 2 years interruption to allow pregnancy, delivery, breastfeeding or failure to conceive.~Endocrine therapy resumption. Completion of full duration of endocrine therapy according to individual risk, institutional policy or patient's preference."
45932119|NCT02300961|Behavioral|Cognitive rehabilitation program|
45932120|NCT02278250|Drug|M4344 10 mg BIW|Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
45932121|NCT02278250|Drug|M4344 20 mg BIW|Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
45932122|NCT02278250|Drug|M4344 40 mg BIW|Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
45932123|NCT02278250|Drug|M4344 80 mg BIW|Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
45932124|NCT02278250|Drug|M4344 160 mg BIW|Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
45932125|NCT02278250|Drug|M4344 300 mg BIW|Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
45932126|NCT02278250|Drug|M4344 450 mg BIW|Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
45932127|NCT02278250|Drug|M4344 700 mg BIW|Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
45932128|NCT02278250|Drug|M4344 1050 mg BIW|Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
45932129|NCT02278250|Drug|M4344 1200 mg BIW|Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
45932130|NCT02278250|Drug|M4344 100 mg BID|Participants received M4344 at a dose of 100 mg orally twice daily (BID) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
45802772|NCT02345642|Device|ActiveCare+SFT Supine|
45802773|NCT02345642|Device|VenaFlow Elite Supine|
45932131|NCT02278250|Drug|M4344 150 mg QD|Participants received M4344 at a dose of 150 mg orally once daily (QD) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
45932132|NCT02278250|Drug|M4344 250 mg QD|Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
45932133|NCT02278250|Drug|M4344 350 mg QD|Participants received M4344 at a dose of 350 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
45451629|NCT01091051|Drug|Ustekinumab|Patients randomized to ustekinumab (10 with PPPP and 10 with PPP) will receive ustekinumab at Day 0, Weeks 4 and 16 and placebo at Week 20
45451630|NCT01091051|Drug|Placebo (Soduim Chloride)|Patients randomized to placebo (10 with PPPP and 10 with PPP) will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
45451631|NCT01091129|Device|miraDry System (treatment with energy)|Treatment with microwave energy delivery device as specified by manufacturer's instructions
45451632|NCT01327079|Drug|Methadone|"If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
45451633|NCT01327079|Drug|Methadone|"If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
45451634|NCT01091207|Drug|Sorafenib|The patients will receive daily oral administration of sorafenib 400 mg twice daily.
45802774|NCT02345642|Device|ActiveCare+SFT Standing|
45802775|NCT02345642|Device|VenaFlow Elite Standing|
45802776|NCT02345720|Device|etafilcon - PVP (multi-focal)|The investigational contact lens must be worn at least six hours daily.
45802777|NCT01981759|Drug|D-Cycloserine|Participants will receive 10 administrations of 50 mg of D-Cycloserine by mouth one hour before CBT sessions, weekly, in weeks 3-12.
45802778|NCT01981759|Other|Placebo|Participants will receive 12 weekly administrations of placebo by mouth 1 hour before CBT sessions, from weeks 1-12.
45802779|NCT01981759|Behavioral|Cognitive Behavioral Therapy|Participants will engage in a Cognitive Behavioral Therapy treatment plan designed for psychotic delusions. The program will consist of 12 one hour sessions, once weekly from study week 1-week 12.
45802780|NCT01980524|Drug|acipimox|
45932134|NCT02278250|Drug|M4344 400 mg|Participants received M4344 at a dose of 400 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
45932135|NCT02278250|Drug|M4344 500 mg|Participants received M4344 at a dose of 500 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
45802781|NCT01980524|Drug|Placebo Oral Capsule|
45802782|NCT01982539|Drug|Zipsor®|Administration of Zipsor® (liquid filled capsules) to patients with mild to moderate acute pain: 25 mg/every 6 hours/up to 4 days treament. Drug taken by mouth.
45802783|NCT01980914|Device|iPro2 glucose sensor attachment|At the same time the glucose sensor is started, a trained research nurse will connect the patient to an Icentia CardioSTAT, a continuous ambulatory ECG cardiac monitor.
45932136|NCT02278250|Drug|Carboplatin|Participants received intravenous infusion of Carboplatin at a dose of Area Under Curve5 (AUC5) on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
45932137|NCT02260856|Device|Tantalum Beads & Injector|To measure growth at physis, four tantalum beads will be implanted per physis at baseline and take radiostereometric analysis measurements at all follow up timepoints. Tantalum beads have been used to make detailed three dimensional radiographic measurements in orthopedic and other specialties
45802784|NCT01982695|Drug|Losartan|
45932138|NCT02260856|Procedure|Percutaneous Drill Epiphysiodesis|
45932139|NCT02260856|Procedure|Percutaneous Screw Epiphysiodesis|
45932140|NCT02250326|Drug|nab-paclitaxel IV|nab-Paclitaxel intravenous (IV) infusion
45932141|NCT02250326|Drug|CC-486|Oral CC-486
45932142|NCT02250326|Drug|Duravalumab|
45932143|NCT02225600|Drug|40 IU Intranasal Oxytocin|40 IU intranasal oxytocin
45932144|NCT02225600|Drug|Placebo|Intranasal Placebo
45932145|NCT02225600|Drug|24 IU intranasal Oxytocin|
45932146|NCT02211742|Drug|Dapagliflozin|euglycemic hyperinsulinemic clamp tests and euglycemic oral glucose tolerance clamp tests after the short-term (i.e.: 3 days, equals 10mg / 24h) intake of dapagliflozin
45932147|NCT02101905|Other|Laboratory Biomarker Analysis|Correlative studies
45932148|NCT02101905|Drug|Lapatinib|Given PO
45932149|NCT02101905|Drug|Lapatinib Ditosylate|Given PO
45932150|NCT02101905|Other|Pharmacological Study|Correlative studies
45932151|NCT02101905|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection of tumor
45932152|NCT02081404|Drug|Esomeprazole|standard dose of proton pump inhibitor by mouth once a day for 30 days
45932153|NCT02081404|Drug|Placebo|placebo
45802785|NCT01982695|Drug|Lisinopril|
45802786|NCT02347124|Behavioral|Usual Care Control|Standard quitline counseling and other treatment materials provided through each participating state quitline program + a series of text messages with general health promotion tips.
45802787|NCT02347124|Behavioral|Enhanced Intervention|Standard quitline counseling and other materials provided through each participating state quitline program + oral health-focused counseling + oral health focused text messages + access to additional oral health educational content (website and written materials) + oral health tools (toothbrush, dental floss)
45451635|NCT01094639|Procedure|Scaling root planing|Deep gum cleaning with local anesthesia
45932154|NCT01590862|Device|Deep Brain Stimulator|Medtronic Deep Brain Stimulation device turned on and off
45932155|NCT01567722|Genetic|DNA analysis|This sample will be used for germline DNA analysis.
45451636|NCT01094639|Procedure|Supragingival Prophylaxis|Plaque removal
45451637|NCT03957863|Biological|Plasma collection for EPO assay|Plasma collection for EPO assay
45451638|NCT03956147|Other|Munich Shoulder Questionnaire|Validation and Reability study
45451639|NCT01094873|Biological|AdCh3NSmut|Genetic vaccines against Hepatitis C virus infection
45451640|NCT01094873|Biological|Ad6NSmut|Genetic vaccine against Hepatitis C virus infection
45451641|NCT01091285|Device|Foley Catheter|Foley Catheter 16-19 H
45451642|NCT01091285|Device|Double Balloon Catheter|Double Balloon Catheter for 16-19H
45802788|NCT01981772|Drug|4% lidocaine with 1:100,000 epinephrine|see arm/group description
45802789|NCT01981772|Drug|4% buffered lidocaine with 1:100,000 epinephrine|see arm/group description
45932156|NCT01567722|Genetic|RNA analysis|RNA will be sheared, reverse transcribed, and sequenced to assess transcribed sequences.
45932157|NCT01567722|Genetic|gene expression analysis|Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
45932158|NCT01567722|Genetic|polymorphism analysis|Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
45932159|NCT01567722|Other|biologic sample preservation procedure|Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
45932160|NCT01567722|Other|flow cytometry|Information will include HIV RNA load at time of malignancy diagnosis) and imaging tests, results of the diagnostic tumor biopsy and bone marrow biopsy, and results of flow cytometry, cytogenetics, and molecular studies.
45932161|NCT01567722|Other|medical chart review|Participants will be followed prospectively to record the types of treatment given, and treatment outcome and toxicity.
45932162|NCT01526603|Drug|Carboplatin|Carboplatin intravenously (IV), 425 mg/m2/dose (or if ≤ 12kg, 14.2 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant.
45932163|NCT01526603|Biological|Autologous stem cell infusion|On day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
45932164|NCT01526603|Biological|Granulocyte colony stimulating factor|Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF subcutaneously (SQ) or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir absolute neutrophil count (ANC) > 2000/μL for 3 consecutive days.
46073391|NCT02547181|Behavioral|Behavioral Modification|Patient will be provided with tensor bandage and instructed on specific behaviors to prevent movement of the injured part of the hand.
46073392|NCT02547181|Behavioral|Splint|fibreglass splint
46073393|NCT02826876|Drug|Topical use|Topical use of Ropivacaine in laparoscopic surgery
45652357|NCT03071653|Other|Optimal Medical Therapy|"All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include:~A renin angiotensin system blocker at highest tolerated doses (e.g., enalapril 10mg twice daily or equivalent)~A mineralocorticoid receptor antagonist (e.g., Spironolactone 25-50mg daily or equivalent)~A Beta-blocker (e.g., Carvedilol 25mg twice daily or equivalent)~The use of a loop diuretic and digitalis will be clinically driven and used at the discretion of the attending clinician"
45932165|NCT01526603|Radiation|Radiation therapy|It is suggested that patients who have a complete surgical resection of the primary tumor receive 21.6 Gy external beam radiation therapy (EBRT) to the post-induction chemotherapy, pre-operative primary tumor volume. It is suggested that patients who have an incomplete surgical resection of the primary tumor (residual soft tissue mass measuring >1 cm3) will receive 21.6 Gy EBRT to the postinduction chemotherapy, pre-operative primary tumor volume and an additional boost of 14.4 Gy EBRT to the gross residual tumor (total dose 36 Gy to gross residual tumor volume). Radiation should be given after stem cell transplantation and should start no sooner than 28 days post transplant.
45932166|NCT01526603|Drug|Isotretinoin (13-cis-retinoic acid)|Post-transplant maintenance therapy with cis-RA daily for 14 days every 28 days repeated for 6 months. This phase of the therapy can be initiated by the BMT team and continued by the referring physician. It is recommended to begin Isotretinoin at day 66 post-transplant and no later than day 100. For patients ≤12 kg, isotretinoin (accutane) should be administered at 5.33 mg/kg/dose divided twice daily. For patients >12 kg isotretinoin (accutane) should be administered at 160 mg/m^2/day divided twice a day. Patients should be considered for monoclonal antibody therapy against GD2, such as ch14.18 if such trials are available.
45652358|NCT02604407|Drug|SHP465 12.5mg capsules (one capsule daily)|one capsule daily
45652359|NCT02604407|Other|Placebo|Matching placebo capsule that appears identical in size, weight, shape, and color (one capsule daily)
45932167|NCT01526603|Drug|Melphalan|Melphalan Intravenously (IV), 70 mg/m2/dose (or if ≤ 12 kg, 2.3 mg/kg/dose) once daily x 3 doses on days 7 through 5 pretransplant
45652360|NCT02604407|Drug|SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)|One capsule daily
45652361|NCT04986709|Device|Open repair|Open repair of the aortic arch and descending aorta with or without involvment of the ascending aorta using a hybrid graft.
45652362|NCT04462315|Drug|Everolimus Eluting Coronary Stent System|Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
45652363|NCT04462315|Device|Cobalt chromium balloon expandable stent (non-drug-eluting stent Arm)|Cobalt chromium balloon-expandable stent (non-drug-eluting stent Arm) implantation
45652364|NCT04825535|Behavioral|Standard psychiatry and cognitive behavioral online intervention|The cognitive behavioral online intervention has been assessed in a prior trial. Ritvo, P, Knyahnytska, Y, Pirboglou, M, Wang, W, Tomlinson, G, Zhao, H, Linklater, R, Kirk, M., Katz, J., Harber, L., Daskalakis, ZJ An online mindfulness-based cognitive behavioural therapy intervention for youth diagnosed with major depressive disorders: J Med Internet Res 2021, Mar 17; 23 (3), e24380
45652365|NCT04825535|Behavioral|Standard psychiatry and cognitive behavioural in-person intervention|The effectiveness of standard care office-based group CBT-MM at CAMH is indicated in a past study (n = 119) where depression symptoms reduced (after 16 weeks treatment) by 27% [3,18 ]. The office-based groups follow a carefully conceived structure that centers on the workbook Mind Over Mood (MOM) (Guilford Press) [41]. Key CBT concepts and procedures are conveyed via work sheets that structure personal and group exploration.
45652366|NCT04461067|Diagnostic Test|ultrasonography|Ultrasonography of the stomach is performed to measure the diameter of the antrum
45652367|NCT04806425|Drug|Intralipid|intralipid is given as a preconditioning drug during off bump coronary artery bypass grafting surgery to measure efficacy in decreasing post operative ischemia
45652368|NCT04806425|Drug|Placebo|normal saline is given in same volume to normal saline group over the same duration
45652369|NCT04460677|Behavioral|Emotional Support Plan|The Emotional Support Plan (ESP) is designed to help adults to cope during periods of acute distress, such as those experienced during the COVID-19 pandemic.
45652370|NCT04460677|Behavioral|Daily Monitoring|The daily monitoring will remind participants 4x/day to report on their mood, distress, etc. and use their ESP if needed.
45802790|NCT01982240|Drug|Plecanatide|Plecanatide tablets QD for 12 weeks
45802791|NCT01982240|Drug|Placebo|Matching placebo tablets QD for 12 weeks
45932168|NCT01526603|Drug|Etoposide|Etoposide intravenously (IV), 338 mg/m2/dose (or if ≤ 12kg, 11.3 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant
45932169|NCT01099852|Other|biological sample collection|blood sample collection urine sample cerebrospinal fluid sample
45932170|NCT01099852|Other|Quality of life Questionnaire EuroQol®|Changes in quality of life, measured with the EuroQol® questionnaire 3 and 12 weeks after the onset of dengue fever symptoms.
45932171|NCT01099852|Other|Health Assessment Questionnaire - MDHAQ and RAPID3|Questionnaire used at the 3rd month of follow up.
45932172|NCT01099852|Other|Neuropathic Pain Questionnaire (DN4)|Questionnaire used during the follow up
45932173|NCT00927719|Biological|ACAM2000® smallpox vaccine|Previous vaccination, no vaccine is administered in this study.
45652371|NCT03071731|Drug|Bronchodilators|Administration of a nebulized combination of bronchodilators before the administration of a functional test.
45652372|NCT03071731|Drug|Placebos|Administration of a nebulized placebo before the administration of a functional test
45652373|NCT04809779|Drug|Sintilimab|The PD-1 inhibitor Sintilimab 200mg for intravenous (IV) administration will be given together with three-week epirubincin, cyclophosphamide (EC) × 4 treatments from the second cycle followed by weekly nab-paclitaxel x12 treatments or three-week nab-paclitaxel x4 treatments.
45802792|NCT01982240|Drug|Bisacodyl|Rescue medication
45802793|NCT02029495|Drug|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection
45802794|NCT02029495|Drug|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection
45802795|NCT02029495|Drug|Placebo|Placebo administered via subcutaneous injection until week 24.
45802796|NCT02348606|Drug|JZP-110|
45802797|NCT02348606|Drug|Placebo oral tablet|
45802798|NCT02348684|Radiation|Radiation therapy groups|Radiation Therapy treatment between 2000 and 2007.
45932174|NCT00782769|Drug|Oxybutinyn Vaginal Ring 4mg|
45652374|NCT04809935|Drug|98% dehydrated alcohol|"coeliac plexus is identified and punctured~Injection of 10 mL of .25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol."
45932175|NCT00782769|Drug|Oxybutinyn Vaginal Ring 6mg|
45932176|NCT00761124|Behavioral|Intervention Session|A one-hour discussion group composed of 8-10 Latino men. The session includes an interactive, multimedia presentation led by a facilitator to guide participant interaction.
45932177|NCT00761124|Behavioral|Printed Material|General prostate cancer pamphlet
45932178|NCT00710112|Genetic|gene variations|comparing variations in genes in infants who develop chronic lung disease and other diseases of prematurity and those who do not.
45932179|NCT00496041|Procedure|Registry|A Registry will be used.
45932180|NCT00038688|Behavioral|Peer HIV Education Program|
46073394|NCT02826876|Other|laparoscopic repair of inguinal hernia|intra-operative treatment with ropivacaine Vs placebo in laparoscopic repair of inguinal hernia
46073395|NCT02826876|Other|laparoscopic bariatric surgery|intra-operative treatment with ropivacaine Vs placebo in laparoscopic bariatric surgery
46073396|NCT02839304|Device|Cryoablation System|Pulmonary Vein Isolation, Posterior Wall Isolation. May Include Mitral Line ablation, AF Driver ablation, and Cavo-tricuspid Isthmus ablation as indicated
46073397|NCT04043533|Behavioral|Exercises|The women in the experimental group were given information about the benefits of exercises done in the postpartum period, the time to start these exercises, and the exercises to be conducted in three different phases (mild, medium, severe). The first physical exercise practice was done in the FHC together. In line with the recommendations by ACOG (2015), the women were told to do mild and medium level exercises in the first two weeks, at least five days in a week and at least half an hour daily (ACOG, 2015). They were also told that they should do medium and severe level exercises in the following two weeks. They were asked to mark on the form what time, how long, and at what level they did the exercises every day. The education booklet that included this information and the visuals of the exercises were given to the women in the experimental group. In addition, the women were called once a week in order to check whether the training was applied.
45451643|NCT01094951|Behavioral|ENGAGE|During Stage 2, investigators will train Neighborhood House caseworkers to 1. provide psychoeducation that addresses client-specific barriers to evaluation and care; 2. use shared decision-making strategies to engage seniors and arrive at a decision about where and from whom to receive an evaluation and possible care; and 3. provide connections to preferred community-based mental health services.
45652375|NCT04809935|Device|19G EUSRA needle, Taewoong Medical, Korea|"10W-30W RFA will be applied unilaterally or bilaterally depends on individual anatomical characteristics for 10-50s~Complete ablation of coeliac plexus nervous tissue is confirmed by appearance of air-bubble ultrasound scan"
45451644|NCT01583699|Procedure|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract to capture endomicroscopic pictures from the small bowel, stomach and esophagus.
45652376|NCT04255927|Drug|Coated Vicryl plus|Vicryl plus (Coated Polyglactin 910 with Triclosan)
45652377|NCT04255927|Drug|Coated vicryl|Vicryl (Coated Polyglactin 910 without Triclosan)
45802799|NCT02312713|Behavioral|Internet Based Exercise Training|"Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content."
45802800|NCT02312713|Behavioral|Physical Therapy|Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
45802801|NCT02033083|Device|Laminaria|
45802802|NCT02033083|Device|Dilapan-S|
45932181|NCT04733300|Behavioral|Mindfulness-Based College for Young Adults|"MB-College (MBC) is a 9-week, 9 session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to young adults (18-29). The curriculum, which is based on the manualized and standardized Mindfulness-Based Stress Reduction (MBSR) curriculum is designed to teach participants how to integrate and apply mindfulness in their everyday lives to the range of challenges arising from medical and psychological conditions and life stresses.~MBC will be administered live, online via a video conferencing platform to participants enrolled in the active arms of the study: (1) standard dose MBC and (2) low-dose MBC. Standard dose MBC meets once a week for 2.5 hours for 9 weeks, while low-dose MBC meets for 1.5 hours per week for 9 weeks. There is an all-day retreat that takes place around week six of the program that applies to both MBC programs."
45451645|NCT01583699|Device|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
45451646|NCT01095029|Device|Medtronic InterStim II - 3058|Stimulation with optimal pacemaker settings unilateral and bilateral with standard pacemaker settings: Amplitude sensory treshold, frequency 14 Hz and impulsduration 210 μsec.
45652378|NCT04809857|Other|Exercise|
45652379|NCT03069781|Drug|17β-estradiol|1mg/day for 3-days and 3mg/day for 7-days of Estrance
45802803|NCT01985425|Drug|Colchicine 0.6 mg|
45802804|NCT01985425|Drug|Placebo Colchicine|
45802805|NCT02348918|Drug|Luminate 1.0mg|
45932182|NCT04733300|Other|Health Education for Young Adults|The health education control group will receive young adult-specific online health resources offered through www.youngwomenshealth.org and www.youngmenshealthsite.org. Both websites provide resources to improve mental and physical health, and include opportunities to ask health questions, and learn ways to improve mental and physical well-being.
45802806|NCT02348918|Drug|Luminate 2.0mg|
45802807|NCT02348918|Drug|Luminate 3.0mg|
45802808|NCT02348918|Drug|Avastin|
45802809|NCT02348918|Drug|Luminate 0.5mg|
45802810|NCT01985581|Drug|Guanfacine extended release|
45802811|NCT01985581|Drug|Placebo|
45802812|NCT01985581|Drug|Stimulant therapy|patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)
45932183|NCT00038766|Drug|semapimod|semapipmod 60 mg IV x 5 days
45932184|NCT00038766|Drug|semapimod|IV 30 mg x 5 days
45932185|NCT00038766|Drug|placebo|placebo IV
45932186|NCT00070070|Biological|TICE®-strain BCG|
45932187|NCT00070070|Biological|NY-ESO-1 protein|
45652380|NCT03069781|Drug|Polycose|400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada)
45652381|NCT04986553|Device|Arthrex Clavicle Plates|Arthrex Clavicle Plate for treatment of clavicle fractures
45932188|NCT00070070|Biological|sargramostim|
45451647|NCT01095107|Dietary Supplement|Low fat intake|low fat intake : Intake 35-50 grams of fat per day between meals and snacks
45451648|NCT01095107|Dietary Supplement|Increased fat intake|increased fat intake : Intake > 50 grams of fat per day between meals and snacks
45451649|NCT00054275|Drug|docetaxel|Docetaxel IV infusion weekly for 3 weeks with a one-week break. One cycle is 4 weeks (28 days). Patients' actual weight will be used to calculate dose.
45652382|NCT04427111|Device|Non-titratable-customized mandibular advancement device|The most comfortable protruded mandibular position situated between 60-75% of MMPV was determined according to patient response with 6mm of the vertical interocclusal dimension between maxillary and mandibular central incisors and registered. The upper and lower acrylic resin splints were secured to each other in the posterior region with auto polymerizing acrylic resin and NTC-MADs were obtained. The patients were instructed to wear their non-titratable-customized mandibular advancement device every night.
45652383|NCT03069625|Behavioral|Sit-to-stand test|CF young patients will perform 2 STS tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
45652384|NCT03069625|Behavioral|6-Minute Walk Test|CF young patients will perform 2 6MWT tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
45652385|NCT04809389|Biological|DelNS1-nCoV-RBD LAIV|Genetically engineered live attenuated influenza virus to express the receptor binding domain of SARS-CoV-2's spike protein for triggering human body's immune responses against SARS-CoV-2
45652386|NCT04809389|Biological|Matching placebo|0.9% NaCl solution
45802813|NCT02024204|Drug|Fluticasone propionate 230mcg for 3 Months|
45802814|NCT02024204|Drug|Current Treatment or no treatment|Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
45802815|NCT02024204|Drug|Salmeterol 21mcg for 3 Months|
45932189|NCT00042237|Behavioral|Schema Therapy|
45932190|NCT02573909|Drug|Oxycodone intravenously|Oxycodone intravenously 0,1mg/kg
45932191|NCT02573909|Drug|Oxycodone epidurally|Oxycodone 0,1 mg epidurally
45932192|NCT00018629|Other||
45932193|NCT00042315|Procedure|Chemotherapy|
45451650|NCT00054275|Drug|erlotinib hydrochloride|OSI-774 will be taken 1 hour before or 2 hours after meals. Cycle 1 will be administered at dose level -1.If no grade 3 or 4 toxicity occurs during cycle 1, then the patient may proceed to be treated at dose level 0 for the remaining chemotherapy cycles.
45652387|NCT03069391|Behavioral|physical exercise alone (PES) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week physical exercise-only intervention, then 2-week cognitive exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
45451651|NCT01095185|Drug|Simvastatin|Simvastatin 20 mg for 15 days, then 40 mg until the end of the study.
45932194|NCT00042315|Drug|tariquidar + vinorelbine|
45932195|NCT00042315|Drug|placebo + vinorelbine|
45932196|NCT00018668|Drug|Risperidone|
45932197|NCT00018668|Drug|Olanzapine|
45932198|NCT00018668|Drug|Quetiapine|
45932199|NCT00042354|Drug|clofarabine (IV formulation)|
45932200|NCT00042393|Drug|Adefovir Dipivoxil|
45932201|NCT00042471|Drug|Pramlintide acetate|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
45451652|NCT01095185|Drug|Placebo|Simvastatin placebo
45932202|NCT00042510|Biological|Treatment group|
45932203|NCT00042549|Device|Extracorporeal Shock Wave Lithotripsy|
45932204|NCT00042549|Drug|ursodiol|
45932205|NCT00042588|Drug|Recombinant Chimeric Monoclonal Antibody|
45932206|NCT00018746|Device|repetitive transcranial magnetic stimulation|
45932207|NCT00018785|Procedure|donor bone marrow infusion|
45932208|NCT00038805|Drug|Mylotarg|
45932209|NCT00018824|Drug|NALTREXONE|
45932210|NCT00018824|Drug|Placebo|
45932211|NCT00038844|Drug|Campath-1 H (Alemtuzumab)|Starting Dose of 15 mg by vein daily, 3 days in a row.
45932212|NCT00038844|Drug|Fludarabine|30 mg/m2 by vein daily, 3 days in a row.
45932213|NCT00038844|Drug|Cyclophosphamide|1 gm/m2 by vein daily, 3 days in a row.
45932214|NCT00038844|Drug|Rituximab|375 mg/m2 by vein, given (to some patients only, based on the subtypes of lymphomas) eight days before the transplant and then weekly for a total of 4 doses.
45932215|NCT00018863|Drug|Methylphenidate|
45932216|NCT00038883|Drug|Campath-1H|10 mg/day x 5, starting with the first day of chemotherapy
45932217|NCT00018902|Drug|Fluoxetine|Standard anti-depressant treatment with the SSRI fluoxetine
45802816|NCT04349137|Device|HD-tACS|non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS) low intensive electrical alternating currents (2 mA peak-to-peak) are externally applied to the skull at a frequency of 6Hz to entrain endogenous neural oscillatory activity.
45802817|NCT04349137|Device|sham HD-tACS|sham non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS)
45932218|NCT00018902|Drug|Venlafaxine|Standard antidepressant treatment with the non-SSRI medication venlafaxine
45451653|NCT01583777|Drug|Belinostat|"On Day 1, a single dose of 14C-labeled belinostat (approximately 94 to 105 µCi, 1500 mg) will be administered to the patient as a 30-minute IV infusion.~After Cycle 1 evaluations are completed, and if it is in the best interest of the patient, patients may receive additional cycles of non-radiolabeled belinostat until disease progression, unacceptable toxicity, or initiation of new anticancer therapy. After Cycle 1, Day 21, non radiolabeled belinostat will be administered IV as a 30 -45 minute infusion of 1000 mg/m2 on Days 1 through 5 every 21 days."
45652388|NCT03069391|Device|cognitive exercise alone (iCE) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
45932219|NCT00018902|Behavioral|Cognitive Behavioral Therapy (CBT)|CBT addresses maladaptive beliefs in order to encourage behavioral change
45932220|NCT00018902|Drug|Citalopram|Standard anti-depressant treatment with the SSRI fluoxetine
45932221|NCT00038922|Drug|rhIL-11|
45802818|NCT01982786|Radiation|Image guided external beam radiotherapy with or without brachytherapy boost|image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost
45932222|NCT00018941|Biological|aldesleukin|
45932223|NCT00038961|Drug|fondaparinux sodium|2.5 mg fondparinux sodium, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
45932224|NCT00038961|Other|placebo|placebo, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
45932225|NCT00019019|Drug|carboxyamidotriazole|
45652389|NCT03069391|Device|interactive Physical and Cognitive Exercise (iPACES™)|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
45802819|NCT01982786|Radiation|Brachytherapy|Brachytherapy boost
45932226|NCT00019019|Drug|paclitaxel|
45932227|NCT00039000|Drug|HSPPC-96 or Oncophage|
45932228|NCT00019058|Drug|chemotherapy|
45932229|NCT00019058|Drug|hydroxyurea|
45932230|NCT00019058|Drug|pentoxifylline|
45451654|NCT00053417|Drug|Placebo|Placebo for 15 weeks
45802820|NCT03019055|Biological|CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 0: 2.5 x10^5 CAR-20/19-T cells/kg (starting dose level)"
45802821|NCT03019055|Biological|CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 1: 7.5 x10^5 CAR-20/19-T cells/kg"
45802822|NCT03019055|Biological|CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 2: 2.5 x10^6 CAR-20/19-T cells/kg (goal cell dose)~Phase 1b Expansion Dose Level: 2.5 x 10^6 cells/kg (single infusion)"
45802823|NCT03019055|Biological|CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)|CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.
45802824|NCT03930745|Other|Placebo|Placebo vaginal inserts.
45932231|NCT00019058|Radiation|radiation therapy|
45932232|NCT00039039|Drug|carboplatin|
45932233|NCT00039039|Drug|chemotherapy|
45932234|NCT00039039|Drug|cisplatin|
45932235|NCT00039039|Drug|paclitaxel|
45932236|NCT00039039|Radiation|radiation therapy|
45932237|NCT00019097|Drug|autologous tumor cell vaccine|
45932238|NCT00019097|Drug|keyhole limpet hemocyanin|
45932239|NCT00019097|Drug|melphalan|
45932240|NCT00019097|Drug|sargramostim|
45932241|NCT00039078|Radiation|yttrium Y 90 glass microspheres|
45932242|NCT00019136|Biological|MOv-gamma chimeric receptor gene|
45932243|NCT00019136|Biological|aldesleukin|
45932244|NCT00019136|Biological|therapeutic allogeneic lymphocytes|
45932245|NCT00039117|Biological|oblimersen sodium|Given IV
45932246|NCT00039117|Drug|cytarabine|Given IV
45932247|NCT00039117|Drug|daunorubicin hydrochloride|Given IV
45932248|NCT00039117|Other|laboratory biomarker analysis|Correlative studies
45932249|NCT00039117|Other|pharmacological study|Correlative studies
45932250|NCT00019175|Biological|aldesleukin|
45932251|NCT00019175|Biological|fowlpox virus vaccine vector|
45932252|NCT00019175|Biological|gp100 antigen|
45932253|NCT00039156|Drug|ortataxel|
45932254|NCT00019214|Biological|MART-1 antigen|
45932255|NCT00019214|Biological|aldesleukin|
45932256|NCT00019214|Biological|gp100 antigen|
45932257|NCT00039234|Biological|aldesleukin|
45932258|NCT00039234|Drug|histamine dihydrochloride|
45932259|NCT00019331|Biological|aldesleukin|
45932260|NCT00019331|Biological|ras peptide cancer vaccine|
45932261|NCT00019331|Biological|sargramostim|
45932262|NCT00019331|Drug|DetoxPC|
45932263|NCT00039273|Biological|panitumumab|
45932264|NCT00019409|Drug|asparaginase|
45932265|NCT00019409|Drug|cyclophosphamide|
45932266|NCT00019409|Drug|cytarabine|
45652390|NCT04805723|Procedure|VATS|"Video-assisted thoracoscopic surgery is a minimal invasive technique in which used to diagnose or treat for lung diseases. During this surgery, one or two small incisions are opened via camera and surgical instruments in patient's chest wall. Thus, less muscle and nerve tissue are damaged.~Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung."
45932267|NCT00019409|Drug|daunorubicin hydrochloride|
45932268|NCT00019409|Drug|mercaptopurine|
45932269|NCT00019409|Drug|methotrexate|
45932270|NCT00019409|Drug|prednisone|
45932271|NCT00019409|Drug|therapeutic hydrocortisone|
46073398|NCT04244448|Drug|receive dissolved form of BIKTARVY®|The healthy volunteers will receive dissolved form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
46073399|NCT04244448|Drug|receive crushed form of BIKTARVY®|The healthy volunteers will receive crushed form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
45451655|NCT00053417|Drug|10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)|"2 week up titration (10 mg)~12 weeks stable dose (10 mg)~1 week down titration (10 mg)"
45652391|NCT04805723|Procedure|Thoracotomy|Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung.
45652392|NCT03071575|Biological|Measles-rubella (MR) vaccine at 6 and 9 months|Arm A will receive MR vaccine dose at 6 and 9 months of age
45652393|NCT03071575|Biological|Measles-rubella (MR) vaccine at 9 months|Arm A will receive MR vaccine dose at 9 months of age
45652394|NCT04798391|Drug|Dexamethasone|Steroids and analgesics
45652395|NCT03071497|Diagnostic Test|Non-invasive analysis of Zinc protoporphyrin|In patients fitting the inclusion criteria Zinc protoporphyrin will be measured non-invasively as proxy for iron deficiency. Results will be compared to ZnPP reference values measured via HPLC and with spectroscopical measurements performed on whole blood as well as with blood values (HB, MCH, MCV, ferritin, CRP, transferrin saturation, soluble transferrin receptor) assessed during clinical routine.
45802825|NCT03930745|Drug|TOL-463|TOL-463 is a non-azole vaginal anti-infective drug candidate designed as a dual-indication therapy for BV and VVC.
45652396|NCT05616455|Drug|Propionibacterium Acnes|Application of the gel every 12 hours for 40 days
45451656|NCT00053417|Drug|15 mg fampridine-SR (4-aminopyridine, 4-AP)|"10 mg twice daily for 1 week~15 mg twice daily for 14 weeks~2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (15 mg)~1 week down titration (10 mg)"
45451657|NCT00053417|Drug|20 mg fampridine-SR (4-aminopyridine, 4-AP)|"2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (20 mg)~1 week down titration (15 mg x 3 days, 10 mg x 4 days)"
45451658|NCT00052715|Drug|poly ICLC|
45652397|NCT05616455|Drug|glyceryl trinitrate|Application of the gel every 12 hours for 40 days
45653307|NCT03067285|Drug|DTG/3TC/ABC + ELV/COBI/FTC/TAF|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to ELV/COBI/FTC/TAF for 24 weeks
45802826|NCT02033317|Drug|patiromer|15 grams/day (5 grams 3 times daily) administered orally
45802827|NCT02034019|Drug|Dexamethasone|
45802828|NCT02034019|Drug|Punctum Plug|
45802829|NCT02349152|Drug|Remifentanil|Subjects in the experimental group will receive remifentanil infusion 0.1-0.4ug/kg/minute before induction of anesthesia and continued until skin closure. During cardiopulmonary bypass, remifentanil infusion will be increased to 0.5-1 ug/kg/min as hemodynamically tolerated.
45802830|NCT02349152|Drug|Fentanyl|Subjects in the control group will initially receive intermittent boluses of Fentanyl in the range of 50-250 ug. Additional fentanyl can be given titrated to hemodynamic parameters throughout surgery.
45932272|NCT00019409|Drug|vincristine sulfate|
45932273|NCT00019409|Radiation|radiation therapy|
45932274|NCT00019448|Drug|gp100 antigen|
45932275|NCT00019448|Drug|interleukin-2|
45932276|NCT00039312|Other|Papanicolaou test|
45932277|NCT00039312|Other|cytology specimen collection procedure|
45932278|NCT00039312|Procedure|annual screening|
45932279|NCT00039312|Procedure|colposcopic biopsy|
45451659|NCT03955601|Drug|Haploidentical HSCT using TBI free regimen, ''ATG'' with ''Post transplant cyclophosphamide''|''Busulphan'' will be used in place of ''TBI'' in equivalent myelotoxic dose to facilitate engraftment , ''ATG'' will be used to reduce GVHD and facilitate engraftment while ''combine PBSC'' and/OR ''Bone marrow harvest'' will be used
45932280|NCT00039312|Procedure|comparison of screening methods|
45932281|NCT00019487|Biological|aldesleukin|
45932282|NCT00019487|Biological|gp209-2M antigen|
45932283|NCT00019487|Biological|incomplete Freund's adjuvant|
45932284|NCT00039351|Drug|cyclophosphamide|
45932285|NCT00039351|Drug|prednisone|
45932286|NCT00039351|Drug|vincristine sulfate|
45932287|NCT00039351|Radiation|radiation therapy|
45932288|NCT00019565|Procedure|magnetic resonance imaging|
45932289|NCT00019565|Procedure|positron emission tomography|
45932290|NCT00019565|Radiation|fludeoxyglucose F 18|
45932291|NCT00039390|Drug|capecitabine|Given orally (PO)
45932292|NCT00039390|Drug|gefitinib|Given PO
45932293|NCT00039390|Other|pharmacological study|Correlative studies
45932294|NCT00039390|Other|laboratory biomarker analysis|Correlative studies
45652398|NCT04986319|Diagnostic Test|Serum vitamin D assay|"Trained phlebotomists will collect 10 cc of a Blood sample. Specimen will be preserved at -40ºc for batch analysis.~S Vitamin D, S iPTH, S Calcium, S Alkaline Phosphatase, S PO4, S Mg, S Albumin and S Creatinine will be done in BIRDEM laboratory. Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: The ARCHITECT 25-OH Vitamin D assay is a chemiluminescent micro-particle immunoassay (CMIA). This technology is used for the quantitative analysis of 25(OH) D and aid in the assessment of vitamin D sufficiency."
45652399|NCT02593097|Drug|Metformin|Metformin 500mg twice daily
45652400|NCT02593097|Drug|Matching Placebo|Matching Placebo twice daily
45652401|NCT05003011|Device|Cardiospire|Non-invasive hemodynamic monitoring
45652402|NCT05002855|Other|Enhanced Recovery After Surgery (ERAS)|Multidisciplinary approach to perioperative care.
45932295|NCT00019721|Biological|MART-1 antigen|
45932296|NCT00019721|Biological|aldesleukin|
45652403|NCT04805801|Drug|Emicizumab subcutaneous injection|Safety and efficacy and PK, FVIII inhibitor titers will be evaluated by follow-up observation.
45932297|NCT00019721|Biological|gp100 antigen|
45652405|NCT04990765|Behavioral|Virtual Reality Cognitive Behavioral Therapy (CRAVR)|Participants in the intervention group will scheduled for 3 weekly treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations (6 different scenes from a restaurant) in virtual reality. From scene 1 to scene 6, alchol-related cues increase in intensity in order to perform gradual exposure therapy as a part of CBT. Furthermore, VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.
45652406|NCT04990765|Behavioral|CBT|The active comparator receives 3 conventional cognitive behavioral therapy sessions with 1 week intervals.
45652407|NCT04797923|Drug|1. Treatment: IP chemotherapy + Systemic chemotherapy|1. Treatment: IP chemotherapy + Systemic chemotherapy Day1 + Day 8: IP Paclitaxel 40 mg/m2 every 3 weeks Day1: IV Oxaliplatin 100 mg/m2 every 3 weeks Day 1~14: Capecitabine 1000 mg/m2 PO, BID every 3 weeks
45652408|NCT04797923|Procedure|2. Response evaluation after 4 cycles of IP + systemic chemotherapy|"2. Response evaluation after 4 cycles of IP + systemic chemotherapy~Conversion surgery will be done following diagnostic laparoscopy after 4 cycles of IP + systemic chemotherapy. Additional 4 cycles of IP + systemic chemotherapy wille be done following surgery.~If surgery is impossible after 4th cycle, four additional cycles of treatment will be done, and convertibility will be evaluated.~IP chemotherapy should not exceed total of 8 cycles."
45653308|NCT05071911|Procedure|TAD (Targeted Axillary Dissection)|Dual agent SLNB + resection of proven lymph nodes metastasis marked with clip at diagnosis
45802831|NCT02034175|Device|SomnaPatch|SomnaPatch is a standalone flexible diagnostic skin-adhesive patch with electronics inside. The patch is placed on the patient's face.
45802832|NCT02034175|Device|Polysomnography|Polysomnography performed in a sleep lab is considered a gold standard in diagnosing the sleep breathing disorders.
45802833|NCT02035345|Drug|Carboplatin|
45802834|NCT01985971|Radiation|PET/CT Imaging|
45802835|NCT01986361|Drug|flurbiprofen|A single flurbiprofen 8.75 mg lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
45802836|NCT01986361|Drug|placebo|A single placebo lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
45932298|NCT00019721|Biological|incomplete Freund's adjuvant|
45932299|NCT00019760|Drug|floxuridine|
45932300|NCT00019760|Drug|leucovorin calcium|
45932301|NCT00019760|Drug|melphalan|
45451660|NCT01095263|Device|DBS|130Hz, 90us pulsewidth, 4V Amplitude
45451661|NCT01095263|Device|No Stimulation (Sham)|130Hz, 90us pulsewidth, 0V Amplitude
45451662|NCT01095341|Other|No intervention performed|
45451663|NCT01091597|Procedure|usual PV ablation|usual PV ablation, per above
45802837|NCT01983020|Drug|Lidocaine|
45802838|NCT01983020|Drug|Ketamine|
45802839|NCT01983020|Other|Saline|
45802840|NCT02058511|Drug|Anesthesia Premedication, Induction and Maintenance|"The enrolled patients receive standard of care general anesthesia for knee arthroscopy. No additional pharmacological interventions are performed in study participants.~The administered drugs, as outlined in the arms section, are midazolam, fentanyl, propofol, and sevoflurane. Study patients receive analgesic drugs as needed in the recovery room if they experience pain."
45932302|NCT00039468|Drug|irinotecan hydrochloride|350 or 700 mg/m2 IV every 3 weeks
45932303|NCT00039468|Drug|thalidomide|400mg/day oral
45932304|NCT00019838|Drug|7-hydroxystaurosporine|
45932305|NCT00019838|Drug|fludarabine phosphate|
45932306|NCT00039507|Procedure|conventional surgery|
45932307|NCT00039507|Procedure|radiofrequency ablation|
45932308|NCT00019916|Biological|aldesleukin|
45932309|NCT00019916|Biological|p53 peptide vaccine|
45932310|NCT00019916|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45932311|NCT00039546|Drug|cyclophosphamide|
45932312|NCT00039546|Drug|epirubicin hydrochloride|
45932313|NCT00039546|Drug|gemcitabine hydrochloride|
45932314|NCT00039546|Drug|paclitaxel|
45932315|NCT00039546|Procedure|adjuvant therapy|
45932316|NCT00019955|Procedure|laparoscopic surgery|
45932317|NCT00019955|Procedure|radiofrequency ablation|
45932318|NCT00019955|Procedure|thermal ablation therapy|
45932319|NCT00039585|Drug|imatinib mesylate|
45932320|NCT00019994|Biological|MART-1 antigen|
45932321|NCT00019994|Biological|aldesleukin|
45932322|NCT00019994|Biological|gp100 antigen|
45932323|NCT00019994|Biological|incomplete Freund's adjuvant|
45652409|NCT04798157|Radiation|transcranial doppler|Transcranial Doppler ultrasonography will be done using the ultrasound machine by placing a transducer over the relatively thinner temporal and occipital bones in order to visualize and evaluate the velocities at the circle of Willis.
45932324|NCT00039624|Radiation|Brachytherapy|Patients will receive two HDR brachytherapy implants (950-1050 cGy/implant) before and at the end of a course of external beam radiotherapy (4600 cGy, 2Gy/day).
45451664|NCT01091597|Procedure|Box isolation of pulmonary veins|as above
45802841|NCT02058511|Procedure|Pupillometry after administration of anesthetic drugs|"All study patients receive the standard of anesthetic care. Every time a anesthetic drug has been administered, changes in pupillary oscillations will be recorded.~Assessment of pupil size and movements by shining infrared light into the eye and measuring the reflection over a 20 s period~The administered drugs are:~Midazolam 1-2 mg iv, Fentanyl 1mcg/kg body weight, Propofol for anesthesia induction 2-2.5 mg/kg body weight, Sevoflurane as needed for maintenance of general anesthesia."
45802842|NCT01983566|Drug|BI 207127 high fat|BI 207127 as a single dose after a high fat breakfast
45932325|NCT00020072|Other|laboratory biomarker analysis|
45802843|NCT01983566|Drug|BI 207127 with Omeprazole|BI 207127 as a single dose after 4 days treatment of Omeprazole 40 mg once a day
45932326|NCT00039663|Drug|Pravastatin|
45932327|NCT00039663|Drug|Gemfibrozil|
45932328|NCT00039663|Drug|Rosiglitazone|
45932329|NCT00020111|Drug|arsenic trioxide|
45932330|NCT00039702|Drug|[123] 5-I-A-85380|
45932331|NCT00020150|Drug|O6-benzylguanine|
45932332|NCT00020150|Drug|temozolomide|
45932333|NCT00039858|Drug|Argatroban|
45932334|NCT00020189|Drug|acetylsalicylic acid|
45932335|NCT00020189|Drug|alvocidib|
45932336|NCT00020189|Drug|clopidogrel bisulfate|
45932337|NCT00039936|Behavioral|Cognitive Behavior Treatment|
45932338|NCT00039936|Behavioral|Self Help|
45451665|NCT00051311|Procedure|Stem cell transplantation|Recipients will receive donor stem cells 3 days after conditioning therapy is completed.
45451666|NCT00051311|Drug|Fludarabine|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
45652410|NCT04990453|Other|RPD frameworks fabricated from PEEK material|extracoronal precision attachment RPD frameworks fabricated from PEEK material using milling machine (CAD/CAM technology)
45652411|NCT04805645|Other|No intervention (Retrospective Cohort Observational)|No intervention as this study is a Retrospective Cohort Observational
45652412|NCT03071419|Behavioral|Nutrition and Parenting Intervention|The proposed intervention will evaluate and explore the unique influences that low-income fathers have on their preschool age children's obesogenic behaviors and obesity risk.
45652413|NCT04805567|Device|endocuff|The Endocuff is a device that can be mounted on the tip of an endoscope and may assist to inspect a greater surface of the colonic mucosa by pulling backwards, flattening, and stretching the colonic folds as the endoscope is gradually withdrawn.
45802844|NCT01983566|Drug|BI 207127|BI 207127 as a single dose in fasted state
45802845|NCT01983566|Drug|BI 207127 low fat|BI 207127 as a single dose after a low fat breakfast
45932339|NCT00039936|Behavioral|Partial Self Help|
45932340|NCT00039975|Drug|Indinavir sulfate|
45802846|NCT02059057|Device|LVRC System|
45932341|NCT00039975|Drug|Ritonavir|
45932342|NCT00039975|Drug|Amlodipine|
45932343|NCT00039975|Drug|Diltiazem HCl|
45932344|NCT00020267|Drug|interleukin-2|
45652414|NCT04985617|Other|Warmed Fluids|The IV fluid given to the patients in the intervention group was heated to 36ºC using the medical heating device.
45932345|NCT00020267|Drug|MAGE-12 peptide vaccine|
45932346|NCT00020267|Drug|Montanide ISA-51|
45932347|NCT00040014|Drug|exemestane|
45652415|NCT03071029|Behavioral|Monthly PAFP rates displayed at clinics.|Providers will receive visual and text feedback on their centre's PAFP uptake rates as they compare to the uptake rates of other centres. The feedback will be delivered monthly in a physical paper format.
45802847|NCT01983878|Drug|Ramucirumab|Administered IV
45932348|NCT00020345|Drug|fluorouracil|
45932349|NCT00020345|Drug|gemcitabine|
45932350|NCT00040053|Drug|Ondansetron|
45932351|NCT00020462|Biological|aldesleukin|
45932352|NCT00020462|Biological|autologous tumor cell vaccine|
45932353|NCT00040092|Drug|Virulizin®|
45932354|NCT00020501|Drug|FOLFIRI regimen|
45932355|NCT00020501|Drug|floxuridine|
45932356|NCT00020501|Drug|fluorouracil|
45932357|NCT00020501|Drug|irinotecan hydrochloride|
45932358|NCT00020501|Drug|leucovorin calcium|
45932359|NCT00020501|Drug|melphalan|
45932360|NCT00020501|Procedure|hyperthermia treatment|
45932361|NCT00040131|Drug|IL-10|
45932362|NCT00020540|Biological|recombinant CD40-ligand|
45932363|NCT00020540|Biological|recombinant flt3 ligand|
45932364|NCT00040170|Biological|MVA-MUC1-IL2|
45932365|NCT00020579|Drug|entinostat|
45932366|NCT00040209|Drug|JP 1730|
45932367|NCT00040209|Drug|IV Levodopa|
45932368|NCT00040209|Drug|IV Apomorphine|
45932369|NCT00040248|Drug|Daclizumab|
45932370|NCT02970825|Other|Exercise|Moderate to high intensity physical training
45932371|NCT02970825|Other|Relaxation|Low intensity physical activity and relaxation
45932372|NCT00020618|Drug|morphine sulfate|
45932373|NCT00020618|Procedure|quality-of-life assessment|
45932374|NCT00040287|Behavioral|smoking cessation program|
45932375|NCT00040287|Behavioral|weight control program|
45932376|NCT00020657|Drug|dolasetron mesylate|
45932377|NCT00020657|Drug|granisetron hydrochloride|
45932378|NCT00020657|Drug|ondansetron|
45932379|NCT00020657|Drug|prochlorperazine|
45932380|NCT00020657|Procedure|quality-of-life assessment|
45932381|NCT00040326|Procedure|anteromesial temporal resection|surgical treatment for epilepsy
45652416|NCT03071107|Behavioral|Multi-disciplinary intervention|Participants in the intervention group will receive a multifactorial, interdisciplinary, treatment program intended to target pre-frailty for a 4-month period following randomization (physical meetings at 2-monthly time points with telephone consultations between meetings). The interventions will be individually tailored to each participant based on their frailty characteristics at baseline and amended if other problems are identified during the intervention program. This intervention team will consist of a renal dietitian and physiotherapist, both of whom will be trained and accredited in behavioural therapy intervention skills, and will focus on improving nutritional status and physical strength through resistance exercise training. They will be supported by a Clinical Research Fellow who will provide additional medical assessment to determine any reversible medical causes of frailty.
45932382|NCT00040326|Drug|antiepileptic drugs|pharmacotherapy
45932383|NCT00020696|Drug|cisplatin|
45932384|NCT00020696|Drug|tirapazamine|
45932385|NCT02970630|Drug|Tacrolimus|once a day
45802848|NCT01986686|Procedure|Colon resection|Elective robotic/laparoscopic/open colon resection for diverticular disease.
45932386|NCT02970630|Drug|Everolimus|twice daily
45932387|NCT00020735|Drug|toremifene|
45932388|NCT00020735|Procedure|conventional surgery|
45932389|NCT00020735|Procedure|neoadjuvant therapy|
45932390|NCT00040482|Drug|Cyclophosphamide|
45652417|NCT04990063|Drug|Chemotherapy|Standard chemotherapy drug
45652418|NCT04990063|Biological|Adoptive TKC transfer therapy|TKC: co-cultured autologous NK cells and γδT cells
45653309|NCT01365039|Device|Test, daily disposable contact lens|Test lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
45802849|NCT02351258|Device|70% Isopropyl alcohol embedded caps|Protective cap on central lines
45802850|NCT02351258|Other|Usual Care|"This involves the Best Practice Central Line Maintenance Care Bundle which includes;~Daily assessment whether central line is needed~Central line Site Care~Central line Hub/Cap/Tubing Care"
45802851|NCT02029040|Drug|3% Hypertonic Saline|Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
45932391|NCT00040482|Drug|ATG|
45932392|NCT00040482|Drug|MESNA|
45932393|NCT00040482|Procedure|Radiation therapy|
45932394|NCT00020774|Drug|gemcitabine hydrochloride|
45932395|NCT00020774|Drug|lonafarnib|
45932396|NCT00020774|Procedure|conventional surgery|
45932397|NCT00040521|Drug|Recombinant Human Interleukin-11 (rhIL-11)|
45932398|NCT00020852|Procedure|conventional surgery|
45932399|NCT00020852|Procedure|cryosurgery|
45932400|NCT00040560|Drug|111In-DAC|
45932401|NCT00040560|Procedure|Diagnostic|
45932402|NCT00020891|Procedure|computed tomography|
45932403|NCT00020891|Radiation|radiation therapy|
45932404|NCT00040599|Drug|hMN14 (labetuzumab)|
45932405|NCT00020930|Biological|cetuximab|
45932406|NCT00040638|Drug|TLK286|
45932407|NCT00020969|Drug|arsenic trioxide|
45932408|NCT00040755|Drug|rebimastat|Given orally
45932409|NCT00040755|Other|laboratory biomarker analysis|Correlative studies
45932410|NCT00021008|Drug|picoplatin|
45932411|NCT00040794|Drug|paclitaxel|Given IV
45932412|NCT00040794|Drug|carboplatin|Given IV
45932413|NCT00040794|Drug|gefitinib|Given PO
45932414|NCT00040794|Radiation|radiation therapy|Undergo radiotherapy
45932415|NCT00040794|Other|laboratory biomarker analysis|Optional correlative studies
45932416|NCT00021047|Drug|capecitabine|
45932417|NCT00021047|Drug|carboplatin|
45932418|NCT00021047|Drug|epirubicin hydrochloride|
45932419|NCT00021125|Procedure|adjuvant therapy|
45932420|NCT00021125|Radiation|radiation therapy|
45932421|NCT00040833|Procedure|complementary or alternative medicine procedure|
45932422|NCT00040833|Procedure|pain therapy|
45932423|NCT00021164|Biological|aldesleukin|
45932424|NCT00021164|Biological|incomplete Freund's adjuvant|
45932425|NCT00021164|Biological|telomerase: 540-548 peptide vaccine|
45932426|NCT00040872|Biological|filgrastim|
45932427|NCT00040872|Biological|monoclonal antibody 3F8|
45932428|NCT00040872|Biological|sargramostim|
45932429|NCT00040872|Drug|carboplatin|
45932430|NCT00040872|Drug|cisplatin|
45932431|NCT00040872|Drug|cyclophosphamide|
45932432|NCT00040872|Drug|doxorubicin hydrochloride|
45932433|NCT00040872|Drug|etoposide|
45932434|NCT00040872|Drug|isotretinoin|
45932435|NCT00040872|Drug|thiotepa|
45932436|NCT00040872|Drug|topotecan hydrochloride|
45932437|NCT00040872|Drug|vincristine sulfate|
45932438|NCT00040872|Procedure|autologous bone marrow transplantation|
45932439|NCT00040872|Procedure|bone marrow ablation with stem cell support|
45932440|NCT00040872|Procedure|conventional surgery|
45932441|NCT00040872|Procedure|drug resistance inhibition treatment|
45932442|NCT00040872|Procedure|peripheral blood stem cell transplantation|
45932443|NCT00040872|Procedure|syngeneic bone marrow transplantation|
45932444|NCT00040872|Radiation|radiation therapy|
45932445|NCT00021242|Drug|docetaxel|Continuous IV infusion
45932446|NCT00040911|Procedure|electroacupuncture therapy|
45932447|NCT00040911|Procedure|sham intervention|Undergo electroacupuncture therapy to sham points
45932448|NCT00040911|Procedure|quality-of-life assessment|Ancillary studies
45932449|NCT00040950|Biological|rituximab|
45932450|NCT00040950|Drug|agatolimod sodium|
45932451|NCT00040989|Drug|BAY 56-3722|
45932452|NCT00040989|Procedure|enzyme inhibitor therapy|
45932453|NCT00041028|Drug|EF5|
45652419|NCT04985461|Device|dental occlusion ties maxillo-mandibular fixation|"This research study is being done to determine if dental occlusion ties can adequately align and stabilize jaw fractures. The chief goal of jaw fracture repair is to ensure that the teeth align normally. Traditionally, alignment has been accomplished by using steel wires and bars (having the jaw wired). Dental occlusion ties are newer devices similar to cable ties or zip ties that are wrapped around and/or between some of the teeth and secured. This procedure is intended to hold the teeth in similar alignment as wires, yet with less application time and less damage to the gums."
45652420|NCT04985149|Other|Electromyographic measurement:|"Nerve conduction studies; assesses nerve function and includes motor, sensory, and mixed nerve tests.~Micromed (Italy 2020) EMG device will be used in the electrophysiological examination. Sensory and motor conduction studies will be performed in the lower and upper extremities by paying attention to the extremity temperatures of the cases.~Nerve conduction studies will be performed by another physician who is unaware of the diagnosis of the patients. Bilateral lower extremity sural sensory responses of the patients will be taken.~In the antidromic method in sural nerve conduction examination, the bipolar superficial electrode is placed behind the lateral malleolus; stimulation will be made with bipolar surface electrodes 12-15 cm proximal to the recording site. Initial latency should be < 3.8 ms, amplitude > 10 Mv, and conduction velocity > 36 m/sec in sensory response of the sural nerve."
45802852|NCT02029040|Drug|0.9 % normal saline|Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
45802853|NCT02029196|Other|E-vapour product|Smokers of conventional cigarettes who switch to use an e-vapour product.
45932454|NCT00041028|Other|flow cytometry|
45932455|NCT00041028|Other|immunohistochemistry staining method|
45932456|NCT00021281|Drug|FOLFIRI regimen|
45932457|NCT00021281|Drug|fluorouracil|
45932458|NCT00021281|Drug|irinotecan hydrochloride|
45932459|NCT00021281|Drug|leucovorin calcium|
45932460|NCT00021281|Drug|semaxanib|
45932461|NCT00041106|Drug|gemcitabine hydrochloride|Given IV
45932462|NCT00041106|Drug|cisplatin|Given IV
45932463|NCT00041106|Drug|gefitinib|Given PO
45932464|NCT00041106|Other|laboratory biomarker analysis|Correlative studies
45653310|NCT01365039|Device|SofLens daily disposable contact lens|Control lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
45932465|NCT00021320|Drug|cisplatin|
45451667|NCT00051311|Drug|Cyclophosphamide|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
45932466|NCT00021320|Drug|fluorouracil|
45932467|NCT00021320|Drug|paclitaxel|
45932468|NCT00021320|Procedure|conventional surgery|
45932469|NCT00021320|Procedure|neoadjuvant therapy|
45932470|NCT00021320|Radiation|radiation therapy|
45932471|NCT00041223|Dietary Supplement|IH636 grape seed proanthocyanidin extract|
45932472|NCT00021359|Drug|dexamethasone|
45932473|NCT00021359|Drug|isotretinoin|
45932474|NCT00041262|Drug|cisplatin|
45932475|NCT00041262|Drug|epirubicin hydrochloride|
45932476|NCT00041262|Drug|fluorouracil|
45932477|NCT00041262|Procedure|conventional surgery|
45932478|NCT00041262|Procedure|neoadjuvant therapy|
45932479|NCT00041301|Other|QoL assessment|qol questionnaires
45932480|NCT00021398|Drug|fluorouracil|
45932481|NCT00021398|Drug|leucovorin calcium|
45932482|NCT00021398|Procedure|conventional surgery|
45932483|NCT00021398|Radiation|radiation therapy|
45932484|NCT00048906|Drug|DRX005B|
45932485|NCT00048945|Drug|PEGASYS|
45932486|NCT00021476|Behavioral|Behavioral treatments|
45932487|NCT00021476|Behavioral|Physical therapy|
45932488|NCT00021554|Drug|Enfuvirtide|
45932489|NCT00048984|Other|laboratory biomarker analysis|Correlative studies
45932490|NCT00049023|Radiation|90Y-DOTA-tyr3-OCTREOTIDE|
45932491|NCT00021671|Drug|Erythromycin|
45932492|NCT00021671|Drug|Nevirapine|
45932493|NCT00021671|Drug|Ampicillin sodium|
45932494|NCT00021671|Drug|Metronidazole|
45932495|NCT00049062|Drug|anastrozole|
45932496|NCT00049062|Drug|gefitinib|
45932497|NCT00049101|Drug|erlotinib hydrochloride|
45932498|NCT00049101|Drug|fluorouracil|
45932499|NCT00049101|Drug|leucovorin calcium|
45932500|NCT00049101|Drug|oxaliplatin|
45932501|NCT00394628|Drug|AQ4N|
45932502|NCT00394628|Drug|Temozolomide|
45932503|NCT00394628|Procedure|Radiotherapy|
45932504|NCT00394667|Drug|Tesofensine|
45932505|NCT00049179|Drug|cytarabine|ind and consol: 200 mg/m2/d continuous IV days 1-7
45932506|NCT00049179|Drug|gemtuzumab ozogamicin|ind and consol: 6 mg/m2 IV over 2 hrs day 1, 4mg/m2 IV over 2 hrs day 8
45932507|NCT00394745|Drug|Valsartan|
45932508|NCT00394823|Behavioral|Set of supportive tools/measures vs. standard care|
45802854|NCT02029196|Other|Conventional cigarette|Smokers of conventional cigarettes who continue smoking conventional cigarettes.
45932509|NCT00049218|Biological|Autologous dendritic cell-adenovirus p53 vaccine|
45932510|NCT00049218|Drug|Carboplatin|
45932511|NCT00049218|Drug|Etoposide|
45451668|NCT00051311|Drug|Etoposide|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
45451669|NCT00051311|Drug|Doxorubicin|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
45932512|NCT00021749|Drug|Oblimerson sodium, G3139|
45451670|NCT00051311|Drug|Vincristine|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
45652421|NCT04985149|Other|Ultrasonographic measurement:|Sural nerve ultrasonography (US) will be performed by another clinician (Merve Akdeniz leblebicier) who is experienced in musculoskeletal ultrasonography and unaware of clinical evaluation, using a 6-18 Mhz linear probe. (Mindray -UMT 200, United States) Both sural nerve joints of the patients will be evaluated. The patient will lie on the stretcher in the prone position, the ankle will be out of the bed. The 14 cm above the malleolus will be marked as the main line, the nerve will be detected in the lateral of the tendon of the gastrocnemius muscle and the proximal of the saphenous vein. Nerve diameter measurement will be measured 3 times in mm2 and the average will be taken. Then, possible inflammatory pathologies will be ruled out by providing clinical confirmation using the Doppler mode (11).
45652422|NCT05001997|Dietary Supplement|Lactose free probiotic yogurt|Probiotics are non-pathogenic, live microbes that when eaten or administered In adequate amount, it confer health benefits to host. Only lactose free probiotic yogurt containing cultures such as Lactobacillus acidophilus and Bifidobacterium lactis will be selected.
45652423|NCT01657461|Drug|Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|Standard therapy with Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
45652424|NCT01657461|Device|Solitaire revascularization device|Clot retrieval with the Solitaire revascularization device after patients have received standard therapy with intravenous tissue plasminogen activator
45652425|NCT05001919|Procedure|GTR|intrabony defects treated by surgery and bone graft +collagen membrane
45652426|NCT05001919|Procedure|concentrated growth factor|intrabony defects treated by surgery and bone graft +concenrated growth factor membrane
45652427|NCT05001763|Drug|Prucalopride|Prucalopride, 2mg, tablet. First given 2 days before surgery beginning on POD 1, until defecation or for a maximum of 7 days of postoperative treatment
45652428|NCT05001763|Drug|Placebo|Glucose, 2mg, tablet.
45652429|NCT04989985|Drug|Oxaliplatin+S-1|"Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S-1 S-1: 40~60mg Bid，d1~14, q3w"
45652430|NCT04989985|Drug|Sinitilimab+oxaliplatin+S-1|"Drug: Sintilimab Sintilimab, recombinant humanized anti-PD-1 monoclonal antibody for injection; 200mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S-1 S-1: 40~60mg Bid，d1~14, q3w"
45932513|NCT00049296|Drug|docetaxel|"Patients receive docetaxel IV over 30 minutes once weekly. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of docetaxel and thalidomide until the maximum tolerated dose (MTD) is determined."
45932514|NCT00049296|Drug|thalidomide|"Patients receive oral thalidomide twice daily. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of docetaxel and thalidomide until the maximum tolerated dose (MTD) is determined."
45932515|NCT00021788|Procedure|islet cell transplantation|
45932516|NCT04731402|Other|Acupressure, laughter yoga and mindfulness stress reduction program|Initiatives will be applied to the experimental group. only measurement tools will be applied to the control group
45932517|NCT00021827|Drug|Parathyroid hormone-related protein or ''PTHrP''|
45932518|NCT00049335|Drug|capecitabine|1,000 mg/m^2/dose (2,000 mg/m^2/day) BID, PO, on Days 1-14 of 21 day cycle
45932519|NCT00021866|Behavioral|Differential Abilities Scale|IQ measurement at 3, 4.5 and 6 years of age
45451671|NCT00051311|Drug|Prednisone|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
45802855|NCT02396732|Drug|Aspirin|Daily dose is 81 mg oral tablet
45802856|NCT02396732|Drug|Enoxaparin|Daily dose is by subcutaneous injection and weight based at the discretion of the treating clinician.
45802857|NCT02030288|Behavioral|Relational Agent Intervention|"Relational Agents are on-screen characters that speak to the patient and establish a relationship with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change."
45802858|NCT02031770|Drug|Sodium bicarbonate|Subjects will be treated with oral sodium bicarbonate two to three times per day for a goal serum bicarbonate (HCO3-) of ≥ 23 meq/L.
45802859|NCT02031770|Other|Control|subjects will receive no treatment
45802860|NCT02032550|Other|Preference Based Decision Aid|The objective of the preference based decision aid is to assess the treatment preferences of prostate cancer patients. The investigators will analyze the association between preferences, treatment choice and objective and subjective outcomes. The preference based decision aid will lead to a values-based patient centered treatment decision making. This will ultimately improve clinical decision making, clinical policy process, enhance patient centered care and improve prostate cancer outcomes.
45802861|NCT02352974|Drug|GAD-Alum|
45802862|NCT02352974|Drug|Vitamin D|
45932520|NCT00021866|Behavioral|Neuropsychological Testing|Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age
45932521|NCT04731285|Diagnostic Test|Pressure wire fractional flow reserve|Pressure wire is inserted into coronary arteries. The ratio of the average distal pressure and average aorta pressure is FFR.
45802863|NCT02353754|Drug|Intrathecal morphine injection|0.2 mg
45802864|NCT02353754|Drug|EXPAREL|266 mg
45652431|NCT05242653|Procedure|pressure by a cotton swab|All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with pressure by a cotton swab.
45652432|NCT05242653|Procedure|stromal hydration with the balanced salt solution（BSS）|All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with stromal hydration.
45802865|NCT02354144|Other|Carrageenan-based gel|Carrageenan is a non-toxic gelling agent safe in animals and humans as a potent HPV inhibitor. An anionic polymer derived from red algae, carrageenan has a long history of human use as a stabilizer and emulsifier in many industries. All three major classes of carrageenan act as extremely potent HPV inhibitors and block HPV infection by binding to the viral capsid, thus preventing attachment to the appropriate cell-surface heparan sulfate proteoglycans (HSPG) receptors.
45932522|NCT04731285|Diagnostic Test|CFD-based RuiXin-FFR|"CT-FFR was evaluated in a blinded fashion with a Coarse-to-Fine Subpixel algorithm for lumen contour"
45932523|NCT00049374|Biological|oblimersen sodium|
45932524|NCT00049374|Drug|dexamethasone|
45932525|NCT00049374|Drug|thalidomide|
45932526|NCT00021983|Biological|BL22 immunotoxin|
45932527|NCT00049413|Biological|rituximab|
45932528|NCT00049413|Drug|cyclophosphamide|
45802866|NCT02354144|Other|Control gel|A gel not containing carrageenan
45932529|NCT00049413|Drug|pentostatin|
45932530|NCT00022022|Drug|docetaxel|
45802867|NCT02397122|Biological|platelet-rich fibrin|autologous platelet-rich fibrin was isolated from venous blood of each patient by defined centrifugation methods
45802868|NCT02397122|Procedure|connective tissue graft|connective tissue graft was harvested from the palatal region of each patient by single incision method
45802869|NCT02397122|Procedure|coronally advanced flap|buccal gingival flap was raised by sharp-blunt-sharp dissection and positioned coronally to cover connective tissue graft (and platelet-rich fibrin gel)
45802870|NCT02354378|Drug|Dexmedetomidine|
45802871|NCT02354378|Other|Memory Test|
45932531|NCT00022022|Procedure|quality-of-life assessment|
45932532|NCT00049452|Drug|zoledronic acid|
45932533|NCT00022139|Drug|carboplatin|
45802872|NCT02312726|Procedure|Postplacental IUD insertion|Postplacental IUD insertion using the standardized ring forceps technique (Speroff and Mishell 2008) under ultrasound guidance, within 10-30 minutes of vaginal delivery.
45802873|NCT02399228|Drug|0.25% EISO mouth rinse|A mouth rinse to be used three times a day during the course of radiation and/or chemotherapy to prevent or minimize oral mucositis
45932534|NCT00022139|Drug|fluorouracil|
45932535|NCT00022139|Drug|paclitaxel|
45932536|NCT00022139|Procedure|conventional surgery|
45932537|NCT00022139|Radiation|radiation therapy|
45932538|NCT00049569|Drug|cytarabine|Given IT
45932539|NCT00049569|Drug|methotrexate|Given IT
45932540|NCT00049569|Drug|vincristine sulfate|Given IV
45932541|NCT00049569|Drug|prednisone|Given PO
45932542|NCT00049569|Drug|pegaspargase|Given IM
45932543|NCT00049569|Drug|doxorubicin hydrochloride|Given IV
45932544|NCT00049569|Drug|imatinib mesylate|Given PO
45652433|NCT04989751|Diagnostic Test|Electromyography|Electromyography (EMG) would be used at the baseline for dignoisis and furtue analysis.
45652434|NCT04989751|Diagnostic Test|IDEAL MRI|Muscle-speciifc sequences (e.g. IDEAL) would be used to scan patients at baseline and follow-up stages to characterize the fat fraction and atrophy in different muscles.
45932545|NCT00049569|Drug|cyclophosphamide|Given IV
45932546|NCT00049569|Drug|etoposide|Given IV
45932547|NCT00049569|Biological|filgrastim|Given SC
45932548|NCT00049569|Drug|leucovorin calcium|Given IV
45932549|NCT00049569|Drug|asparaginase|Given IM
45932550|NCT00049569|Drug|therapeutic hydrocortisone|Given IT
45932551|NCT00022178|Drug|cisplatin|
45932552|NCT00022178|Drug|cyclophosphamide|
45932553|NCT00022178|Drug|doxorubicin hydrochloride|
45932554|NCT00022178|Drug|epirubicin hydrochloride|
45932555|NCT00022178|Drug|fluorouracil|
45932556|NCT00022178|Drug|vincristine sulfate|
45932557|NCT00049608|Dietary Supplement|mistletoe extract|
45932558|NCT00049608|Drug|gemcitabine hydrochloride|
45932559|NCT00022217|Drug|carboplatin|
45932560|NCT00022217|Drug|cisplatin-e therapeutic implant|
45932561|NCT00022217|Drug|paclitaxel|
45932562|NCT00049686|Drug|laromustine|
45932563|NCT00022256|Drug|motexafin gadolinium|
45932564|NCT00022256|Radiation|radiation therapy|
45932565|NCT00049725|Drug|Daclizumab|
45932566|NCT00022295|Drug|idronoxil|
45932567|NCT00049764|Drug|Drotrecogin alfa (activated)|
45932568|NCT00049764|Drug|Placebo|
45932569|NCT00022334|Biological|AFP|Increasing doses of AFP will be given to groups of 3 intradermally. Subjects will receive 3 biweekly vaccinations. At least 2 patients at a given dose must have received their complete 3 vaccination schedule with a 30 day observation period after the last vaccination before a higher dose is initiated.
45932570|NCT00022373|Drug|iseganan HCl oral solution|
45932571|NCT00022373|Procedure|management of therapy complications|
45932572|NCT00049803|Drug|sodium oxybate|
45932573|NCT02971826|Device|REVIVETM SE thrombectomy|Mechanical thrombectomy using the REVIVETM SE device in patient with an ischemic stroke due to an intracranial arterial occlusion
45932574|NCT00397761|Drug|capecitabine|
45932575|NCT00397761|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
45932576|NCT00397761|Procedure|neoadjuvant therapy|
45932577|NCT00022412|Dietary Supplement|doxercalciferol|Arm 1: Patients receive doxercalciferol once daily for 28 days. Patients then undergo prostatectomy.
45802874|NCT02033174|Other|Oral fat diet plus water with sugar|All participants were assigned to receive and oral fat diet plus sugar water. Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. Sugar water has equivalent caloric intakes as alcoholic beverages.
45451672|NCT00051311|Drug|Methotrexate|Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD)..
45451673|NCT00051311|Drug|Cyclosporine|Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).
45451674|NCT00051311|Procedure|Apheresis|Donors will undergo apheresis to collect stem cells for a stem cell transplant for the recipient.
45451675|NCT01095419|Other|Massage Therapy|After discharge from the intensive care unit to the ward during the postoperative period, patients which were randomized for 3 nights to receive intervention (Massage Therapy)which were consisted of massage of the neck, shoulders, and back. The massage was initiated with light manual compression and progressed to deep compression. The compression was performed with the inner region of the fingers, hand-shaped clamp, and friction (digital compression with the thumb) on trigger points, cervical traction, and mobilization in all planes (front, back, and sides)
45451676|NCT01095419|Other|Control|no intervention
45652435|NCT05239845|Dietary Supplement|Prebiotic|The bioactive ingredients used in this study include bovine milk fat globule membrane (MFGM), bovine lactoferrin and a prebiotic blend of polydextrose and galactooligosaccharides (PDX/GOS).
45652436|NCT05239845|Other|Control|Maltodextrin
45652437|NCT05239767|Drug|NSAID|We will administer oral NSAIDs
45652438|NCT05001841|Procedure|Lung Transplantation|Double lung transplant
45652439|NCT05239221|Drug|AZP-3601|Lyophilized powder of AZP-3601 to be reconstituted with water for injection before injection
45652440|NCT05239221|Drug|Placebo|Saline solution visually matching active medication
45802875|NCT02033174|Other|Oral fat diet plus alcoholic beverages|Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. In all cases, alcohol represented a daily total amount of 16 g/m2. The content of alcohol was 12% in red wine, 37% in rum, and 35% in brandy.Vodka was tri-distilled and contained 40% alcohol.
45802876|NCT02059213|Drug|Ibrance|
45802877|NCT02059213|Drug|Bicalutamide|
45802878|NCT02059213|Drug|Zoladex|
45802879|NCT02059213|Drug|Lupron Depot|
45802880|NCT02037061|Drug|Bupivacaine|Intraoperatively the patient will receive 10ml of bupivacaine injected into the sacrospinous ligament.
45802881|NCT02037061|Other|Normal Saline|
45802882|NCT03886675|Other|CO2 flushing|As above
45802883|NCT03886675|Other|Saline flushing|As above
45802884|NCT02354534|Drug|Artesunate Suppositories|
45802885|NCT02059993|Device|continuous positive airway pressure|mean continuous positive airway pressure use was at least 4 hours per night;continuous positive airway pressure group received fixed-level continuous positive airway pressure titration using an automated pressure
45802886|NCT02060461|Device|FS200 femtosecond laser LASIK|
45802887|NCT02060461|Device|IntraLase femtosecond laser LASIK|
45451677|NCT01091753|Drug|Valsaltan, amlodipine|nti hypertensive medication time (nocturnal administration vs morning administration
45451678|NCT00049673|Drug|prednisone|Given orally
45451679|NCT00049673|Drug|thalidomide|Given orally
45451680|NCT00049127|Drug|Imatinib Mesylate|Given PO
45451681|NCT00049127|Other|Laboratory Biomarker Analysis|Optional correlative studies
45451682|NCT00049127|Other|Pharmacological Study|Optional correlative studies
45802888|NCT02354924|Device|Biofinity soft contact lens|Biofinity soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
45802889|NCT02354924|Device|Visco soft contact lens|Viso soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
45802890|NCT02060539|Device|Biofinity XR|
45451683|NCT00066365|Biological|sargramostim|given by inhalation, dosage escalation Level 1 Dose: 240 micrograms, Level 2 Dose: 1,000 micrograms, and Level 3 Dose: 1,750 micrograms.
45451684|NCT00066365|Procedure|conventional surgery|thoracotomy
45451685|NCT00048581|Drug|Abatacept|Vials, intravenous (IV), ~10mg/kg abatacept, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
45451686|NCT00048581|Drug|Placebo|Vials, IV, 0mg, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
45451687|NCT00048581|Drug|Abatacept|Vials, IV, ~10mg/kg abatacept, every 4 weeks, 5.5 years
45451688|NCT00048347|Drug|AVONEX|30µg IM every week for 12 weeks
45451689|NCT03955523|Other|Single exercise bout trial|Exercise trial day: 30 min of continuous exercise at 60% VOpeak (or at the least 3 bouts of 10 min at 60% VO2peak separated by no more than 1 minute rest) - power output is set at that determined during the maximum test on the first visit, and adjusted accordingly if there is a deviation >5% VO2peak for at least 3 minutes of exercise.
45932578|NCT00022412|Procedure|conventional surgery|Procedure: Prostatectomy for prostate cancer
45932579|NCT00397800|Biological|rituximab|
45932580|NCT00397800|Drug|cyclophosphamide|
45652441|NCT05001607|Device|Bronchial Blocker|Trial of four methods of pulmonary blockade; one novel method and three published methods.
45652442|NCT05321355|Device|Implantation of vagus nerve stimulation according to clinical indication|no interventions, only observation
45652443|NCT04989673|Other|Biological sampling and collection (serum)|Detection of the dengue virus during the next scheduled biological assessment as part of normal pregnancy monitoring (additional tube of blood) among women from GNES and GNEF groups
45802891|NCT02355158|Drug|clonidine hydrochloride topical gel, 0.1%|
45802892|NCT02033876|Drug|Ursodiol|
45932581|NCT00397800|Drug|fludarabine phosphate|
45932582|NCT00397800|Radiation|yttrium Y 90 ibritumomab tiuxetan|
45932583|NCT00022451|Drug|tipifarnib|
45932584|NCT00022529|Drug|BMS-214662|Given IV
45932585|NCT00022529|Biological|trastuzumab|Given IV
45932586|NCT00022529|Other|pharmacological study|Correlative studies
45932587|NCT02970357|Other|DIAPASON Questionnaire|"50 item questionnaire of the French Youth Diabetes Association to evaluate one's theoretical knowledge about the diabetes disease. 6 main themes are evaluated :~what is diabetes~Monitoring~Hypoglycemia and Hyperglycemia~Nutrition~Insuline"
45652444|NCT04989673|Other|Biological sampling and collection (placenta)|Detection of dengue virus in the placenta of GE patients (additional tube of placenta)
45932588|NCT02970357|Behavioral|WHO-5|5 item questionnaire of the World Health Organization about quality of life
45802893|NCT02061397|Drug|Simvastatin|Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
45932589|NCT00022568|Biological|recombinant vaccinia-TRICOM vaccine|
45802894|NCT02061397|Drug|Sirolimus Oral Product|Eligible patients on sirolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
45932590|NCT00022607|Biological|bevacizumab|
45932591|NCT00022607|Drug|thalidomide|
45932592|NCT00049998|Drug|topotecan|
45932593|NCT00022646|Drug|gemcitabine hydrochloride|
45932594|NCT00022646|Drug|pemetrexed disodium|
45932595|NCT00050037|Procedure|CBT|
45652445|NCT04989673|Other|Questionnaire|Questionnaire on the patient's socio-economic conditions (10-minute interview with the Clinical Research Associate, CRA).
45932596|NCT00022685|Biological|epratuzumab|
45932597|NCT00050076|Drug|MCC-135|MCC-135 50 mg, tablets, orally, twice daily for up to 12 weeks
45932598|NCT00050076|Drug|MCC-135|MCC-135 100 mg, tablets, orally, once daily for up to 12 weeks
45652446|NCT04989673|Other|Data collection|Case Report Form will be completed by a Clinical Research Associate (CRA) from the medical file of the patient concerned and of her child at the 3 visits carried out (Pre inclusion V0 or Inclusion V1, Childbirth V2 and Maternity leave V3).
45652447|NCT02592551|Drug|MEDI4736|MEDI4736 is formulated at 50 mg/mL in 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0.
45802895|NCT02061397|Drug|Everolimus Oral Product|Eligible patients on everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
45932599|NCT00050076|Drug|MCC-135|MCC-135 200 mg, tablets, orally, once daily for up to 12 weeks
45932600|NCT00050076|Drug|Placebo|MCC-135 placebo-matching tablets, orally, once daily for up to 12 weeks
45932601|NCT00022724|Drug|temsirolimus|
45932602|NCT00022802|Device|Image-guided surgical system|
45932603|NCT00050154|Drug|ZARNESTRA, tipifarnib, R115777|
45932604|NCT00022841|Drug|Pamidronate|
45932605|NCT00022880|Drug|Iodine-131 Anti-B1 Antibody|
45932606|NCT00050232|Drug|AVP-923|
45932607|NCT00050271|Drug|Acetyl-L-carnitine|
45932608|NCT00022958|Drug|Iodine-131 Anti-B1 Antibody|
45932609|NCT00050349|Drug|EPO906 epothilone B|
45932610|NCT00050388|Genetic|Allovectin-7®|
45802896|NCT02400710|Behavioral|Clinician-Supported PTSD Coach|Brief primary care-based intervention provided by a mental health clinician who is located in primary care.
45802897|NCT02400710|Behavioral|Self-Managed PTSD Coach|One 10 minute session explaining how to use the PTSD Coach mobile app.
45932611|NCT00050427|Drug|ET743|580 mcg/m2, 3-hour i.v. infusion, on Days 1, 8, and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
45932612|NCT00050427|Drug|ET743|1,300 mcg/m2, 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
45932613|NCT00023153|Drug|Adefovir Dipivoxil|
45932614|NCT00050505|Biological|Live vaccinia virus vaccine|Dryvax undiluted. Cohort A receives undiluted dose of Dryvax vaccine
45932615|NCT00050505|Biological|Live vaccinia virus vaccine|Dryvax with diluent (50% glycerin and 0.25% phenol in sterile water). Cohort A-C receives diluted dose of Dryvax vaccine.
45932616|NCT00023192|Drug|T-Cell Depleted & CD34+Select/w/StemCell Enriched Product|
45932617|NCT00050583|Behavioral|Cognitive Behavioral Therapy|Ten Weekly Sessions of Manualized CBT
45932618|NCT00050583|Behavioral|CBT|Cognitive Behavioral Therapy
45932619|NCT00394862|Drug|multivitamin|
45932620|NCT00050661|Drug|Daclizumab|Humanized anti-CD25 antibodies (anti-TAC), or placebo (saline solution), will be given as intravenous infusions on the following schedule: 2 mg/kg initially (maximum dose 200 mg) infusion given over 60 minutes, followed by a 1 mg/kg (maximum of 100 mg) infusion given over 30 minutes every two weeks thereafter for a total of 8 doses.
45932621|NCT00050661|Device|NB-UVB|total body NB-UVB at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until for a total of 20 ± 2 treatments total.
45932622|NCT00050817|Drug|clopidogrel (SR25990)|
45932623|NCT00023231|Drug|Daclizumab|1 mg/kg/dose at study entry and Weeks 2, 4, 6, and 8
45932624|NCT00023231|Drug|Methylprednisolone/prednisone|Dosage is dependent on weight and varies throughout study. Refer to protocol for more information.
45932625|NCT00023231|Drug|Mycophenolate mofetil|Solution or oral tablet taken daily. Dosage depends on body surface area.
45932626|NCT00023231|Drug|Sirolimus|Oral tablet taken once prior to transplant. Dosage dependent on body surface area.
45932627|NCT00023231|Drug|Bactrim|Oral tablet taken three times per week. Dosage is dependent on weight.
45932628|NCT00023231|Drug|Ganciclovir|Oral tablet taken daily. Dosage is dependent on weight.
45932629|NCT00023231|Drug|Lipitor|Oral tablet taken daily
45932630|NCT00050856|Drug|Enfuvirtide T/20/Ro 29,9800, HIV-1 Infusion Inhibitor|
45932631|NCT00023348|Drug|Isoniazid|
45932632|NCT00023348|Drug|Rifabutin|
45932633|NCT00050895|Drug|Lopinavir/ritonavir|
45932634|NCT00050895|Drug|Efavirenz|
45932635|NCT00050895|Drug|Stavudine|
45932636|NCT00050895|Drug|Zidovudine|
45932637|NCT00050895|Drug|Lamivudine|
45932638|NCT00050895|Drug|Tenofovir disoproxil fumarate|
45932639|NCT00023387|Drug|Rifapentine|
45932640|NCT00023387|Drug|25-desacetyl Rifapentine|
45932641|NCT00023387|Drug|Isoniazid|
45932642|NCT00050934|Drug|oxcarbazepine|
45652448|NCT02592551|Drug|Tremelimumab|Tremelimumab Drug Product is formulated at a nominal concentration of 20 mg/mL in 20 mM histidine/histidine hydrochloride, 222 mM trehalose dihydrate, 0.02% (weight/volume [w/v]) polysorbate 80, 0.27 mM disodium edetate dihydrate (EDTA), pH 5.5.
45652449|NCT02592551|Other|no other name|Neither MEDI4736 nor Tremelimumab will be used.
45652450|NCT04989127|Diagnostic Test|Diagnosis|All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
45652451|NCT04989127|Procedure|traditional osteotomies|In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
45652452|NCT04989127|Biological|Platelet Rich Fibrin|Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
45802898|NCT03876301|Drug|Standard of Care FVIII Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
46073400|NCT04244448|Drug|receive solid form of BIKTARVY®|The healthy volunteers will receive solid form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
45451690|NCT03955523|Dietary Supplement|Single diet trial|Diet trial day The protocol of the diet trial day is identical to that of the exercise trial day, except that exercise is substituted by asking the participant to eat a standardized breakfast meal that it is commonly consumed in a fast-food chain (i.e. cheese and egg McMuffin, double portion of hash browns and an orange pop).
45802899|NCT04349761|Drug|MyMD1|Isomyosamine 5mg capsules
45932643|NCT00023426|Drug|rifapentine|
45652453|NCT04989127|Drug|Antibiotics, Penicillin|Antibiotics are prescribed for the patients.
45932644|NCT00050973|Drug|bexarotene|
45652454|NCT04989127|Drug|Analgesic|Analgesics are prescribed for the patients.
45932645|NCT00023465|Procedure|FDG-PET|
45652455|NCT04989127|Drug|Antibiotic|Patients with penicillin allergy
45652456|NCT05320653|Dietary Supplement|Medical nutrition|Nutrition therapy of the critically ill patients
45932646|NCT00023465|Procedure|spirometry|
45932647|NCT00023465|Procedure|bronchoscopy with BAL|
45932648|NCT00051012|Drug|ONTAK|
45932649|NCT00023504|Biological|Pneumovax|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
46073401|NCT02843594|Procedure|LEEP intervention|Low Energy Endosafe Phaco (LEEP) with micro-interventional lens fragmentation
45451691|NCT03957629|Drug|Tenofovir Disoproxil Fumarate|Oral medication of Tenofovir Disoproxil Fumarate 300mg once per day.
45451692|NCT03957629|Drug|PEG-Interferon alfa 2a|Subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
45652457|NCT04984213|Device|Karma Posterior Fixation Device|Posterior Fixation
45652458|NCT03070873|Device|Perigee and Apogee Mesh|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
45802900|NCT04349761|Drug|Placebo|Placebo
45802901|NCT02401022|Drug|AZD8529|comparison of different dosages of drug
45802902|NCT02062177|Drug|Propofol|70 patients (35 upper endoscopy - 35 colonoscopy) are sedated with propofol TCI (Target Controlled Infusion) pump (concentration 1.2-1.6 mcg/ml).
45802903|NCT02062177|Drug|Midazolam|70 patients (35 upper endoscopy - 35 colonoscopy) in group midazolam are sedated with midazolam 0.04 mg/Kg if aged < 70, 0.03 mg/Kg if aged > 70.
45802904|NCT02034578|Drug|Apixaban|
45802905|NCT02403830|Drug|Methylnaltrexone|Methylnaltrexone will be administered diluted with 5 ml of normal saline as a single iv bolus
45802906|NCT02403830|Other|Placebo|Placebo will be administered as a 0.9% sodium chloride iv injection
45802907|NCT02403830|Drug|Morphine|After methylnaltrexone, patients will receive 5-mg intravenous morphine
45802908|NCT02403830|Drug|Ticagrelor|After morphine administration, patients will receive a 180-mg ticagrelor loading dose
45802909|NCT02036840|Drug|Antibiotic|
45802910|NCT02951195|Drug|VX-152|Tablet for oral administration.
45932650|NCT00023504|Biological|Rabavert|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
45932651|NCT00023504|Biological|Prevnar|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
45932652|NCT00023504|Biological|Tetanus diphtheria toxoid|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
45932653|NCT00051051|Drug|CI-1033|
45932654|NCT00023543|Behavioral|Diet, fat-restricted|Reduction in total, saturated, trans fat, cholesterol, calories. Increase in fiber. Promotion of nutrient-dense, high-volume, low calorie foods.
45932655|NCT00023543|Behavioral|Exercise|Rigorous, stepped care approach to reach 150 min/week of physical activity.
45932656|NCT00051090|Drug|Telbivudine|Administered orally at a daily dosage of 600 mg for a period of 48 weeks
45932657|NCT00051090|Drug|Lamivudine|Administered orally at a total daily dosage of 300 mg for Weeks 24-48
45932658|NCT00051090|Drug|Efavirenz|Administered orally at a daily dose of 600 mg
46073402|NCT02843594|Procedure|Standard Phaco Control|
46073403|NCT02547025|Drug|rabeprazole+3 antibiotics|(rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days.
46073404|NCT02547025|Drug|rabeprazole+bismuth+2 antibiotics|(rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days.
45932659|NCT00051090|Drug|Didanosine|Administered orally at a total dosage of either 400 mg or 250 mg determined by individual weight
45932660|NCT00051090|Drug|Abacavir|Administered orally twice daily in doses of 300 mg
45932661|NCT00051207|Behavioral|Interpersonal Psychotherapy (IPT)|
45932662|NCT00051207|Behavioral|IPT for Depression with Co-occurring Panic and Anxiety Symptoms (IPT-PS)|
45932663|NCT00023621|Drug|celecoxib|
45932664|NCT00051246|Behavioral|Mother-Infant Group Psychotherapy|Mother-infant group psychotherapy consists of weekly 2.5-hour psychotherapy sessions comprised of mother's group therapy, infant developmental therapy, and mother-infant dyadic psychotherapy. Group treatment will last 15 weeks.
45932665|NCT00051246|Behavioral|Interpersonal Psychotherapy|Individual psychotherapy treatment focuses on role transition, interpersonal relationships, and loss. Individual treatment period will last 15 weeks.
45932666|NCT00049140|Drug|EF5|
45932667|NCT00049140|Other|bioluminescence|
45652459|NCT03070873|Device|Gynecare Prolift Mesh|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
45932668|NCT00049140|Other|flow cytometry|
45932669|NCT00049140|Other|immunohistochemistry staining method|
45932670|NCT00049140|Procedure|biopsy|
45932671|NCT00023660|Drug|celecoxib|
45932672|NCT00023660|Drug|cisplatin|
45652460|NCT03070873|Procedure|Traditional Surgery|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
45932673|NCT00023660|Drug|fluorouracil|
45932674|NCT00023660|Radiation|brachytherapy|
45932675|NCT00023660|Radiation|radiation therapy|
45932676|NCT00051285|Drug|Enoximone|Participants receive oral enoximone
45932677|NCT00051285|Drug|Enoximone placebo|Participants receive placebo to match enoximone
45451693|NCT01091909|Procedure|Dental extractions|All dental extractions were performed at an outpatient clinic at the USP Dental School. In addition, all extractions were performed under local anesthesia by the same experienced dentist, in accordance with the standards established by Peterson et al (2008).
45652461|NCT04294901|Behavioral|Direct to patient medication brochure|An EMPOWER medication brochure, adapted to the VA, designed to educate and activate patients. These brochures provide detailed medication information, allow self-testing of indications for use, prompt reflection of experiences with potential side effects, discuss alternative therapies (medication and non-pharmacologic options), and provide a vignette of a patient who successfully stopped the medicine. They were designed for a 6th grade reading level and were based upon theories of patient activation, adult learning, and cognitive dissonance. The visually appealing brochure repeatedly emphasizes that patients should not make any medication changes without first consulting their health care providers.
45652462|NCT05320185|Device|RuiXin-CoronaryAI software|RuiXin-CoronaryAI, based on Computed Tomography Angiography (CTA) and was independently designed by RaysightMed Inc., which has been already authorized by National Medical Products Administration (NMPA).
45802911|NCT02951195|Drug|TEZ/IVA|Fixed-dose combination tablet for oral administration.
45802912|NCT02951195|Drug|IVA|Tablet for oral administration.
45932678|NCT00023699|Drug|gefitinib|
45932679|NCT00051402|Drug|Isoflavones|
45932680|NCT00051441|Drug|Benzydamine Hydrochloride 0.15% Oral Rinse|
45451694|NCT00065507|Drug|Entecavir (ETV)|Tablets, Oral, 1 mg once daily, 96 weeks from the time the last patient is randomized
45652463|NCT04983745|Drug|Combination drug|niraparib and dostarlimab combination
45802913|NCT02951195|Drug|Placebo|Placebo matched to VX-152.
45802914|NCT02951195|Drug|Placebo|Placebo matched to VX-152/TEZ/IVA triple combination (TC).
45802915|NCT02037230|Drug|MK-1775|MK-1775 will be given as an oral capsule on days 1 and 2, and on days 8 and 9 of every 3-week cycle .
45802916|NCT02037230|Drug|Gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1 and 8 of a 3 -week treatment cycle.
45802917|NCT02037230|Radiation|Radiation Therapy|52.5Gy in 25 fractions (2.1Gy/fraction), using intensity modulated radiation therapy (IMRT). Radiation therapy will be administered after chemotherapy.
45802918|NCT02312882|Drug|Tofacitinib|Tofacitinib 5 mg tablet taken by mouth twice a day.
45932681|NCT00023738|Biological|filgrastim|
45932682|NCT00023738|Drug|dacarbazine|
45932683|NCT00023738|Drug|doxorubicin hydrochloride|
45932684|NCT00023738|Drug|ifosfamide|
45932685|NCT00023738|Drug|semaxanib|
45932686|NCT00023738|Procedure|conventional surgery|
45932687|NCT00023738|Radiation|radiation therapy|
45932688|NCT00397917|Drug|Folic acid: 4 mg versus 0.4 mg per day|Folic acid
45932689|NCT00397956|Drug|MK0826, ertapenem sodium / Duration of Treatment: 14 Days|
45932690|NCT00023777|Biological|filgrastim|induction: 5 mcg/kg/d IV or SC starting apx day 15
45932691|NCT00023777|Biological|sargramostim|induction: 250 mcg/m2/d IV or SC starting apx day 1
45932692|NCT00023777|Drug|cytarabine|ind: 200 mg/m2/d continuous IV days 1-7 consol: 200 mg/m2/d continuous IV days 1-5
45932693|NCT00023777|Drug|daunorubicin hydrochloride|ind and consol: 45 mg/m2/d continuous IV days 1-3
45932694|NCT00397995|Procedure|above- or under elbow cast|
45932695|NCT00023816|Drug|carbendazim|
45932696|NCT00398034|Drug|Testosterone Gel|
45932697|NCT00023855|Drug|bortezomib|
45932698|NCT00023855|Drug|doxorubicin hydrochloride|
45932699|NCT00023894|Drug|alvocidib|
45932700|NCT00051480|Genetic|TNFerade|
45932701|NCT00023933|Drug|iodine I 131 monoclonal antibody CC49-deltaCH2|Given IV
45932702|NCT00051597|Drug|SGN-30 (monoclonal antibody)|
45932703|NCT00023972|Drug|exatecan mesylate|
45932704|NCT00023972|Drug|gemcitabine hydrochloride|
45932705|NCT00051675|Drug|ING-1(heMAb)|
45932706|NCT00051714|Behavioral|Family-Based Preventive Intervention|
45932707|NCT00024011|Drug|bortezomib|Given IV
45932708|NCT00024011|Other|laboratory biomarker analysis|Correlative studies
45932709|NCT00051753|Drug|levofloxacin; amoxicillin/clavulanate|
45802919|NCT03020537|Biological|Fluzone|Fluzone (Influenza Virus Vaccine) Suspension for Intramuscular Injection 2013-2014 Formula.
45932710|NCT00024050|Drug|busulfan|
45932711|NCT00024050|Drug|cyclophosphamide|
45932712|NCT00024050|Drug|cyclosporine|
45932713|NCT00024050|Drug|methotrexate|
45932714|NCT00024050|Procedure|allogeneic bone marrow transplantation|
45932715|NCT00024050|Procedure|peripheral blood stem cell transplantation|
45932716|NCT00051792|Behavioral|yoga|
45932717|NCT00024089|Drug|gefitinib|
45932718|NCT00051831|Drug|Emtricitabine|Will be administered as one 200-mg capsule orally daily
45932719|NCT00051831|Drug|Enfuvirtide|Will be administered as a 90-mg (1.0 mL) subcutaneous injection twice daily
45451695|NCT00065507|Drug|Adefovir (ADV)|Tablets, Oral, 10 mg, once daily, 96 weeks from the time the last patient is randomized
45451696|NCT01095575|Drug|normal saline 3 ml, morphine 3mg|On the day of surgery, patients were brought to the operating room (OR) where routine monitors were placed and an epidural catheter was inserted at the level of L3-4 to a distance of 10 cm. All patients received two injections via the catheter: one injection contained 3 mg morphine (MO), and the other contained normal saline (NS) of the same volume. Patients were randomized to receive either NS preoperatively and MO postoperatively or vice versa. The first injection was administered 40 minutes before initiation of surgery, and the second one was given 15 minutes after surgery ended. All epidural catheters were removed before the patients were discharged from the post-anesthesia care unit (PACU).
45451697|NCT03954977|Diagnostic Test|PICC line ultrasound|NICU patient's with PICC lines will be enrolled and blinded ultrasound operators will scan the neonate to find the PICC tip location. This will be compared to the location on the patient's chest x-ray. This process will be repeated each time the patient has a chest x-ray.
45451698|NCT03954821|Device|prefabricated insoles|
45652464|NCT04293653|Other|Protocol for patients above 75 undergoing emergency laparotomy or laparoscopy|See above section
45652465|NCT05238753|Device|Non-invasive electromagnetic stimulation|Non-invasive bilateral electromagnetic stimulation of the phrenic nerve
45451699|NCT00065429|Drug|BB-10901|"I.V. Infusion - See Arms for dosage - Once/Week for three weeks - Until Progression of disease."
45451700|NCT01095731|Drug|Tiopronin|Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
45652466|NCT04984135|Procedure|Percutaneous coronary intervention|All patients were treated with a loading dose of clopidogrel 300 or 600 mg before the procedure followed by maintenance clopidogrel 75 mg daily for 6 months. 100 U/ kg of unfractionated heparin was injected intravenously to maintain an activated clotting time ≥ 250 s during the procedure. For DCB treatment, the patient underwent predilation with an optimal-sized balloon (non-compliant balloon or cutting balloon) based on angiography (balloon-to-vessel ratio of 1.0), with the standard balloon shorter than the intended DCB size. The DCB was sized at 1:1 balloon-to-vessel ratio, delivered rapidly (median of 15 s) and inflated at nominal pressure for 60 s.
45932720|NCT00051831|Drug|Ritonavir|Will be administered as one 100-mg capsule orally twice daily
45652467|NCT04797377|Biological|Autologous ovarian PRP injection|The same day, within 1 hour of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into both ovaries using 11.8 inch (30 cm) single lumen 21G needles. The ovaries will be reached using needle guide preventing vascular or other structures rupture. The needle will be advanced into the centre of the ovarian medula without rotation. The correct tip placement will be confirmed by ultrasound. The activated PRP will be slowly introduced during careful retraction of the needle across the previously traversed ovarian cortex. The final PRP volume will be deposited under the ovarian capsule and the needle exit the ovary. Approximately 0.5 ml of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30 minutes and also be discharged home on the same day.
45802920|NCT02037776|Drug|Rikkunshito|- Oral administration of rikkunshito (2.5 g t.i.d) before meals for 8 weeks
45802921|NCT02037776|Drug|Rikkunshito placebo|- Oral administration of rikkunshito placebo (2.5 g t.i.d) before meals for 8 weeks
45802922|NCT02877095|Drug|Furosemide|subcutaneous furosemide delivered via subcutaneous pump
45932721|NCT00051831|Drug|Saquinavir|Will be administered as five hard gel capsules orally twice daily
45932722|NCT00051831|Drug|Tenofovir disoproxil fumarate|Will be administered as one 300-mg tablet orally daily
45932723|NCT00024128|Biological|anti-thymocyte globulin|
45932724|NCT00024128|Biological|therapeutic allogeneic lymphocytes|
45932725|NCT00024128|Drug|cyclophosphamide|
45932726|NCT00024128|Drug|cyclosporine|
45932727|NCT00024128|Procedure|peripheral blood stem cell transplantation|
45932728|NCT00024128|Radiation|radiation therapy|
45932729|NCT00051870|Device|Magstim Rapid Magnetic Stimulator|
45932730|NCT00051909|Drug|LY451395|
45932731|NCT00024206|Drug|orantinib|Given orally
45932732|NCT00024206|Other|laboratory biomarker analysis|Correlative studies
45932733|NCT00024206|Other|pharmacological study|Correlative studies
45932734|NCT00051948|Drug|TLK286|
45932735|NCT00024245|Drug|pralatrexate|
45932736|NCT00024245|Drug|probenecid|
45932737|NCT00051987|Drug|VELCADE TM (bortezomib) for Injection, or PS-341|
45932738|NCT00024284|Drug|carboplatin|
45932739|NCT00024284|Drug|irinotecan hydrochloride|
45932740|NCT00052026|Drug|carvedilol|low-dose carvedilol administered twice daily for 8 months
45932741|NCT00052026|Drug|placebo|administered twice daily for 8 months
45932742|NCT00052026|Drug|carvedilol|high-dose carvedilol administered twice daily for 8 months
45932743|NCT00024323|Drug|cisplatin|
45932744|NCT00024323|Drug|triapine|
45932745|NCT00052065|Drug|TLK286|
45932746|NCT00024362|Drug|BBR 3464|
45932747|NCT00052104|Behavioral|Cognitive-Behavioral Family Systems Intervention|
45932748|NCT00024401|Drug|DHA-paclitaxel|
45932749|NCT00024440|Biological|filgrastim|
45932750|NCT00024440|Biological|oblimersen sodium|
45652468|NCT05281809|Drug|Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)|This protocol describes the use of an automated cell processor and culture system, the CliniMACS Prodigy device sold by Miltenyi Biotec, for the local manufacture of CAR T-cells targeting the CD19 antigen. The manufacturing process will use a lentiviral vector (CAR19) provided by Lentigen, a wholly owned subsidiary of Miltenyi Biotec, to transfect T-cells collected from eligible patients. Live cells will be harvested by the device after culture and infused intravenously to the patient from whom the cells were originally obtained.
45932751|NCT00024440|Drug|cyclophosphamide|
45804178|NCT05437159|Behavioral|Learning of non-native phoneme combinations: 6 training sessions|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During each training session, the participant will practice producing a set of 8 stimuli (the Fully Learned stimuli). Each of the 8 Fully Learned stimuli will be produced 60 times over the 6 training sessions.
45932752|NCT00024440|Drug|fludarabine phosphate|
45932753|NCT00052182|Biological|EP HIV-1090|
45932754|NCT00024518|Drug|30,000 units hrINF-alpha|
45932755|NCT00024518|Drug|5,000 hrINF-alpha|
45451701|NCT01095731|Drug|Placebo|Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
45932756|NCT00024518|Other|Placebo|placebo was prepared as saline alone with 6mg human serum albumin (HSA).
45932757|NCT00052221|Biological|Epoetin alfa|
45932758|NCT00052221|Other|Placebo|
45932759|NCT00024557|Drug|IL13-PE38QQR|
45932760|NCT00024557|Procedure|targeted fusion protein therapy|
45932761|NCT00024557|Procedure|surgery|
46073405|NCT02547025|Drug|rabeprazole+amox+tetr+levo|(rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days.
45451702|NCT01095809|Drug|bevacizumab|2.5mg at baseline, week 4 and 8. Beyond this initial period if needed reinjection criteria are described in protocol
45451703|NCT01095809|Drug|triamcinolone acetonide|2 mg at baseline; frequency every three months if needed. reinjection criteria are described in protocol
45932762|NCT00052299|Drug|cytarabine|
45451704|NCT00048035|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of iv administration
45451705|NCT01092221|Drug|Allopurinol|Allopurinol 1 capsule 300 mg, BID
45932763|NCT00052299|Drug|etoposide|
45451706|NCT01092221|Drug|Placebo|Placebo 1 capsule, 300 mg, BID
45451707|NCT00047879|Biological|PEG-interferon alfa-2b|0.3 µg/kg of IFN alfa-2b (PEG-Intron once weekly) plus daily oral thalidomide, subcutaneous injection
45451708|NCT00047879|Drug|Thalidomide|Two 50mg tablets (100 mg total dose) every night before bedtime starting on day one.
45451709|NCT03954665|Behavioral|10 km time trial|10 km Cycling time trial test will be conducted to examine the effects of the Exogenous Ketone Salts on time
45451710|NCT03954665|Behavioral|30s Wingate|30s all-out test to measure peak power output
45451711|NCT03954665|Dietary Supplement|Ketone|Supplement containing exogenous ketone salts
45451712|NCT03954665|Behavioral|Baseline 10 km time trial|A baseline 10 km Cycling time trial test will be conducted
45932764|NCT00052299|Drug|gemtuzumab ozogamicin|
45932765|NCT00052299|Drug|idarubicin|
45932766|NCT00052299|Drug|mitoxantrone hydrochloride|
45932767|NCT00052338|Drug|gemcitabine hydrochloride|Given IV
45932768|NCT00052338|Drug|carboplatin|Given IV
45932769|NCT00052338|Drug|bortezomib|Given IV
45932770|NCT00052338|Other|laboratory biomarker analysis|Correlative studies
45932771|NCT04733066|Drug|Teduglutide|Intervention group consists of patients, who receive teduglutide within routine medical care
45932772|NCT00052377|Biological|aldesleukin|Given SC
45932773|NCT00052377|Biological|recombinant interleukin-12|Given SC
45932774|NCT00052377|Other|laboratory biomarker analysis|Correlative studies
45932775|NCT00024674|Drug|SS1(dsFv)-PE38|
45932776|NCT00052416|Drug|thalidomide|
45932777|NCT00052455|Drug|lomustine|
45932778|NCT00052455|Drug|procarbazine hydrochloride|
45932779|NCT00052455|Drug|temozolomide|
45932780|NCT00052455|Drug|vincristine sulfate|
45932781|NCT00052494|Drug|cisplatin|
45932782|NCT00052494|Drug|imatinib mesylate|
45932783|NCT00052494|Drug|irinotecan hydrochloride|
45932784|NCT00395174|Biological|Influenza Vaccination|0.5mL dose for intramuscular injection
45932785|NCT00052572|Drug|ixabepilone|
45932786|NCT00395213|Drug|Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications|Treatment with SSRIs or SNRIs
45932787|NCT00052611|Drug|Celecoxib|
45932788|NCT00395252|Drug|Cetuximab (Erbitux®) and Gemcitabine|"Cetuximab:~Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly for up to 6 months (treatment duration: 24 weeks)~Gemcitabine:~1000 mg/m2 administered on days 1, 8, 15 Cycles will be repeated on day 29, up to 6 treatment cycles will be administered~Mode of administration:~Intravenous infusion"
45932789|NCT00052689|Drug|bortezomib|Given IV
45932790|NCT00052689|Drug|gemcitabine hydrochloride|Given IV
45932791|NCT00052728|Drug|tamoxifen citrate|
45802923|NCT02951273|Other|Study of cerebral blood flow|"Measurements are conducted from before induction of anaesthesia and until 2 hours after the start of surgery and include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, cardiac output, total peripheral resistance, forehead skin blood flow and haemoglobin concentrations, depth of anaesthesia, and frontal lobe, skin, and muscle oxygenation. Further measurements are conducted during hyperventilation before induction of anaesthesia and during hypo-, normo- and hypercapnia during anaesthesia.~Blood samples are obtained from the arterial line for evaluation of the arterial CO2 tension and markers of mesenteric traction syndrome. Total volume of blood sampled is less than 75 ml."
45932792|NCT00052728|Drug|tipifarnib|
45932793|NCT00395369|Drug|intraoperative aprotinin administration|
45932794|NCT00052845|Drug|docetaxel|70 mg/sq m IV infusion over 1 hour Day 2 of ea cycle
45932795|NCT00052845|Drug|estramustine phosphate sodium|280 mg PO tid Days 1-5 of ea cycle
45932796|NCT00052845|Drug|exisulind|Two 125 mg capsules PO bid Days 1-21 of ea cycle
45652469|NCT04989205|Behavioral|Cannabis cessation Program|Lundqvist and Ericsson developed the 'Cannabis Cessation Program' (CCP, Nordic abbreviation: HAP) in Sweden in the 1990s. The method uses a combination of cognitive therapy and psychoeducation and covers the normal withdrawal period for cannabis smoking cessation (up to 8 weeks), comprising ~15 individual sessions. It describes a medical, a psychological, and a social phase, in which the participant is helped to recognize and address typical problems related to each phase, e.g., physical and psychological withdrawal problems. The overarching aim of the program is to help cannabis users to reorganize thinking patterns that developed while they were using cannabis and increase their social and psychological coping skills in relation to quitting cannabis use. The CCP manual has been translated into eight languages, e.g., Norwegian.
45932797|NCT00024986|Drug|Tenofovir DF|
45932798|NCT00025025|Other|sample testing|
45932799|NCT00052923|Biological|filgrastim|
45932800|NCT00052923|Biological|rituximab|
45932801|NCT00052923|Drug|carmustine|
45451713|NCT03954665|Behavioral|Baseline 30s Wingate|A baseline 30s all-out test to measure peak power output
45932802|NCT00052923|Drug|cyclophosphamide|
45932803|NCT00052923|Drug|etoposide|
45932804|NCT00052923|Procedure|peripheral blood stem cell transplantation|
45932805|NCT00052923|Radiation|radiation therapy|
45932806|NCT00025064|Biological|bleomycin sulfate|
45932807|NCT00025064|Drug|chlorambucil|
45932808|NCT00025064|Drug|cisplatin|
45932809|NCT00025064|Drug|dacarbazine|
45932810|NCT00025064|Drug|doxorubicin hydrochloride|
45932811|NCT00025064|Drug|etoposide|
45932812|NCT00025064|Drug|ifosfamide|
45932813|NCT00025064|Drug|melphalan|
45932814|NCT00025064|Drug|prednisolone|
45802924|NCT02357264|Device|Ultrasound|Ultrasound of the chest for the detection of fluid in the lung
45802925|NCT02877485|Drug|Triamcinolone Acetonide|2 sprays sprayed to both nostrils daily for 42 days.
45802926|NCT02877485|Drug|Ayr saline nasal mist|110mcg (2 sprays) sprayed to both nostrils daily for 42 days.
45932815|NCT00025064|Drug|procarbazine hydrochloride|
45932816|NCT00025064|Drug|vinblastine sulfate|
45932817|NCT00025064|Drug|vincristine sulfate|
45932818|NCT00025064|Procedure|peripheral blood stem cell transplantation|
45932819|NCT00025064|Radiation|radiation therapy|
45932820|NCT00053001|Biological|epoetin alfa|
45932821|NCT00053001|Drug|thalidomide|
45932822|NCT00025103|Biological|dactinomycin|
45932823|NCT00025103|Drug|carboplatin|
45932824|NCT00025103|Drug|cyclophosphamide|
45932825|NCT00025103|Drug|doxorubicin hydrochloride|
45932826|NCT00025103|Drug|etoposide|
45932827|NCT00025103|Drug|melphalan|
45932828|NCT00025103|Drug|vincristine sulfate|
45932829|NCT00025103|Procedure|autologous bone marrow transplantation|
45932830|NCT00025103|Procedure|conventional surgery|
45932831|NCT00025103|Procedure|peripheral blood stem cell transplantation|
45932832|NCT00025103|Radiation|radiation therapy|
45932833|NCT00053040|Biological|cintredekin besudotox|IL13-PE38QQR is administered intracerebrally by continuous convection enhanced infusion at a starting concentration of 0.25 μg/mL. Infusion duration will be held constant at 96 hours (4 days). The phase I component of this study is to estimate the maximum safe total flow rate and the maximum safe infusion concentration.
45932834|NCT00053040|Procedure|conventional surgery|Conventional surgery is used for tumor resection prior to catheter placement for IL13-PE38QQR infusion.
45932835|NCT00025142|Drug|FOLFOX regimen|
45932836|NCT00025142|Drug|fluorouracil|
45932837|NCT00025142|Drug|gefitinib|
45932838|NCT00025142|Drug|leucovorin calcium|
45932839|NCT00025142|Drug|oxaliplatin|
45932840|NCT00053118|Biological|filgrastim|IV
45932841|NCT00053118|Drug|carboplatin|IV
45932842|NCT00053118|Drug|etoposide|IV
45932843|NCT00053118|Procedure|bone marrow ablation with stem cell support|IV
45932844|NCT00053118|Procedure|peripheral blood stem cell transplantation|IV
45932845|NCT00025181|Biological|MART-1 antigen|
45932846|NCT00025181|Biological|gp100 antigen|
45932847|NCT00025181|Biological|incomplete Freund's adjuvant|
45932848|NCT00025181|Biological|ipilimumab|
45932849|NCT00025181|Biological|tyrosinase peptide|
45932850|NCT00025181|Procedure|adjuvant therapy|
45932851|NCT00025220|Drug|Thalidomide|Given PO
45932852|NCT00025220|Other|Laboratory Biomarker Analysis|Correlative studies
45932853|NCT00053157|Biological|sargramostim|
45932854|NCT00025298|Drug|amifostine trihydrate|
45932855|NCT00025298|Drug|carboplatin|
45932856|NCT00025298|Drug|cisplatin|
45932857|NCT00025298|Drug|paclitaxel|
45802927|NCT02404532|Device|MIND1 System|Following placement of the Patch by clinic staff, subjects will ingest one placebo-embedded IEM tablet approximately every other hour, for a total of 4 ingestions. Subjects may eat as they wish over the course of the day. Placebo-embedded IEM tablets are being tested to measure the accuracy of IEM detection by the MIND1 system. Clinic staff will record the time of each ingestion of an IEM. Clinic staff will check the compatible computing device (eg, smartphone) at 30-minute intervals for the presence of a timeline ingestion tile and will record the time it is detected by the MIND1 System compatible computing device (eg, smartphone).
45932858|NCT00025298|Radiation|radiation therapy|
45652470|NCT01356251|Behavioral|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either approximately 3-5 surgical patients or approximately 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
45932859|NCT00053196|Biological|anti-thymocyte globulin|2.5mg/kg/day IV infusion over 6 hrs x 4 doses Days -4 to -1 (for MUD and 9/10 related donor transplants only)
45932860|NCT00053196|Biological|G-CSF|5 ug/kg/day subQ injection Day 7 until ANC> 1000/uL for 3 consec days
45932861|NCT00053196|Drug|busulfan|0.8mg/kg IV infusion over 2 hrs q 6 hrs x 8 doses Days -4 thru -3
45932862|NCT00053196|Drug|fludarabine phosphate|30 mg/sq m/day IVBP over 30 min Days -7 thru -3
45802928|NCT02879747|Drug|Genotropin|Children were randomized to either decreased dose by 50% or unchanged dose after 2-3 years of Catch-up growth
45932863|NCT00053196|Drug|methotrexate|5 mg/sq m/day IV infusion Days 1, 3, & 6 for HLA-identical donor transplants and Days 1, 3, 6, & 11 for MUD & 9/10 related donor transplants
45451714|NCT01095965|Behavioral|Nutrition education|Group education on a bi-weekly basis for eight weeks plus written education materials, followed by monthly group problem solving meetings till one year.
45451715|NCT01096043|Drug|Placebo|An infusion of an identically appearing solution of sugar water will be intravenously administered.
45451716|NCT01096043|Drug|Strata 1 CXL-1020|Intravenous infusion of CXL-1020, up-titrated, so that 3 different dosages are administered over 6 hours
45451717|NCT01096043|Drug|Strata 2 CXL-1020|One of 3 different dosages of CXL-1020 administered at a fixed dosage level for 6 hours.
45802929|NCT02880137|Drug|Perflutren Lipid Microsphere|Definity (injectible suspension ultrasound contrast agent) will be diluted with saline for both Pediatric and Adult subjects. For pediatric subjects under 60kg (kilogram), the dose will be 20 MicroL/kg (MicroLiter/kilogram) diluted to the same concentration used in the adult dosing. Hand Injections will be performed at baseline, Pre-peak, and peak perfusion stages.
45802930|NCT02880137|Procedure|RTMPE|Utilizes intravenous administration of biologically-inert microbubbles to assess myocardial perfusion and has demonstrated utility for identifying small vessel coronary artery disease.
45802931|NCT00374387|Drug|Nuvaring|
45932864|NCT00053196|Drug|mycophenolate mofetil|15mg/kg PO bid Day -2 to Day 60, then taper as tolerated (for MUD and 9/10 related donor transplants only)
45932865|NCT00053196|Drug|tacrolimus|target serum level is 5-10 ng/mL. Start with 0.03mg/kg PO bid Day -1 to Day 90, then taper thru Day 150 for HLA identical donor transplants and Day -1 to Day 180 then taper for MUD and 9/10 related donor transplants
45932866|NCT00053196|Procedure|allogeneic cell transplantation|2,000,000-8,000,000 CD34+ cells total via infusion Days 0 and 1
45932867|NCT00053196|Drug|allopurinol|300 mg/day PO Days -8 thru -1
45932868|NCT00025337|Biological|bevacizumab|Given IV
45932869|NCT00025337|Drug|oxaliplatin|Given IV
45932870|NCT00025337|Drug|leucovorin calcium|Given IV
45932871|NCT00025337|Drug|fluorouracil|Given IV
45932872|NCT00398190|Behavioral|Control|Standard anti-tobacco programming
45932873|NCT00398190|Behavioral|Media Literacy|Anti-smoking media literacy curriculum intervention
45932874|NCT00025376|Drug|PS-341|
45932875|NCT00025376|Procedure|Tumor Biopsy|
45932876|NCT04731324|Drug|ZYIL1 capsule|NLRP3 inflammasome inhibitor
45932877|NCT00025415|Drug|imatinib mesylate|Given orally
45932878|NCT00025415|Other|pharmacological study|Correlative studies
45932879|NCT00053235|Genetic|Comparative Genomic Hybridization|Correlative studies
45932880|NCT00053235|Other|Laboratory Biomarker Analysis|Correlative studies
45932881|NCT00053235|Genetic|Polymerase Chain Reaction|Correlative studies
45932882|NCT00025454|Drug|tipifarnib|
45932883|NCT02970279|Behavioral|Behavioural Activation Group (BAG) Psychotherapy|Behavioural activation (BA) is a psychotherapy intervention based on behaviour theory and operant conditioning. It teaches patients to reduce avoidant depressive behaviours and in turn increase the positive reinforcement they receive from their environment for non-depressive behaviours through the use of activity scheduling and pleasant events. For the trial, BA will be delivered in a group format (BAG) and facilitated by two therapists. BAG treatment will consist of eight weekly sessions, lasting two hours and will follow a manualised treatment protocol. Each session will be based on a different topic relevant to the principles of BA and patients will be given between session work to complete to encourage increased participation in rewarding personally meaningful activities.
45932884|NCT00053391|Biological|recombinant CD40-ligand|
45932885|NCT00053391|Biological|therapeutic autologous dendritic cells|
45932886|NCT00025493|Drug|docetaxel|
45802932|NCT00374387|Drug|low-dose combination pill|
45802933|NCT00374387|Drug|minipill|
45652471|NCT01356251|Behavioral|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either 3-5 surgical patients or 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
45652472|NCT04982809|Drug|Betamethasone, Dexamethasone, Prednisolone|Corticosteroids
45652473|NCT04797533|Device|The Body Information Management Systems (BIMS)|"The Body Information Management Systems (BIMS) are advanced biological sensors which monitor human behaviour, activity and basic vital signs. There is a combination of four separate ultra-sensitive weighing scales attached to each of the individual legs of a hospital bed measuring:~Micro-changes in weight distribution~Activity/sleep pattern~In addition to the bed-based system, there will be a wrist worn wearable (Samsung fit gear) that will monitor participants when they are both in and out of bed. These are about the size of a small watch, light weight, water resistant, and will be worn 24/7 by participants. These measure:~Movement and sleep~Heart rate"
45802934|NCT03023891|Drug|Prednisone|Prednisone 60 mg tablet once
45652474|NCT04808765|Procedure|Immediate Breast reconstruction|immediate mastectomy with breast reconstruction with implants or expanders
45802935|NCT03026777|Drug|intravenous crystalloid fluid, 500 mL|
45802936|NCT03028025|Device|StatSeal|Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
45802937|NCT03028025|Device|TR Band|Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
45802938|NCT02955329|Drug|Nicotine|Participants will vape tobacco leaves with nicotine out of the PAX device.
45802939|NCT02955329|Drug|Cannabis|Participants will vape marijuana leaves with nicotine out of the PAX device.
45802940|NCT02955329|Device|PAX Loose Leaf Vaporizer|In all three arms, the participant will be using the same PAX electronic cigarette device. The only difference is whether the participant will be vaping nicotine only, THC only, or nicotine and THC.
45802941|NCT02359058|Drug|Ramucirumab|Administered IV
45802942|NCT02359058|Drug|Capecitabine|Administered orally
45802943|NCT02359058|Drug|Cisplatin|Administered IV
45802944|NCT02359058|Drug|S-1|Administered orally
45802945|NCT02359058|Drug|Oxaliplatin|Administered IV
45802946|NCT02404610|Procedure|Moderate Procedural Sedation with a sedative medication.|procedural sedation with a target sedation depth of moderate. Moderate sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
45802947|NCT02404610|Procedure|Deep Procedural Sedation with a sedative medication.|procedural sedation with a target sedation depth of deep. Deep sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
45802948|NCT02404610|Drug|propofol|
45802949|NCT02359916|Other|Time delays on delivery of less healthy snacks|
45802950|NCT02359916|Other|25%/$0.25 discount on healthy snacks|
45802951|NCT02359916|Other|25%/$0.25 tax on less healthy snacks|
45802952|NCT02405390|Procedure|Video Laryngoscopy|Head motion will be measured by using Polhemus Patriot™ electromagnetic tracking system
45802953|NCT02405390|Procedure|Direct Laryngoscopy|Time for intubation will be measured from the laryngoscope entering the mouth to the endotracheal tube passing through the vocal cords
45802954|NCT02405390|Device|Storz C-Mac® laryngoscope|
45802955|NCT02881775|Device|rTMS and exercise|rTMS at 10 Hz (5 sec on, 55 sec off) and light quadriceps isometric exercise (5% MVIC)
45802956|NCT02881775|Device|Sham rTMS and exercise|rTMS unit is on and running but mu metal is placed between the coil and the skull
45802957|NCT03109769|Behavioral|Mobile phone application|
45802958|NCT03109769|Behavioral|Verbal oral hygiene instructions|
45802959|NCT02957123|Drug|Intranasal auto-M2-BFs|Delivery is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
45802960|NCT03110003|Drug|10 mg Bupivacaine|10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl injected to the epidural space
45802961|NCT03110003|Drug|5 mg Bupivacaine|5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.
45802962|NCT03110471|Behavioral|West Wales Adverse Drug Reaction (WWADR) Profile|Nurse-led medicines' monitoring in care homes: a process evaluation of the impact and sustainability of the West Wales Adverse Drug Reaction (WWADR) Profile and pharmacist involvement
45802963|NCT03110471|Behavioral|usual care|usual care
45932887|NCT00025532|Other|iodine I 131 monoclonal antibody CC49-deltaCH2|
45932888|NCT00053430|Drug|Thalidomide|Tablet taken orally daily
45932889|NCT00053430|Drug|Thalidomide placebo|Placebo tablet taken orally daily
45932890|NCT00025571|Drug|HPPH|
45932891|NCT00025610|Drug|carboplatin|
45932892|NCT00025610|Drug|cyclophosphamide|
45652475|NCT05518071|Drug|CRGD-ZW800-1|Intravenous single bolus injection of the targeted NIR fluorophore cRGD-ZW800-1. This targeted 800nm zwitterionic fluorophore developed by the Hospital Pharmacy Department of LUMC consists of the fluorophore ZW800-1 conjugated to the cRGD peptide
45802964|NCT03111407|Procedure|total knee arthroplasty|surgical procedure in which damaged parts of the knee joint are replaced with an implant.
45932893|NCT00025610|Drug|doxorubicin hydrochloride|
45802965|NCT02958995|Other|No Intervention|
45932894|NCT00025610|Drug|etoposide|
45932895|NCT00025610|Drug|vincristine sulfate|
45932896|NCT00025649|Biological|filgrastim|
45932897|NCT00025649|Drug|busulfan|
45932898|NCT00025649|Drug|carboplatin|
45932899|NCT00025649|Drug|cyclophosphamide|
45932900|NCT00025649|Drug|doxorubicin hydrochloride|
45932901|NCT00025649|Drug|etoposide|
45932902|NCT00025649|Drug|melphalan|
45932903|NCT00025649|Drug|vincristine sulfate|
45932904|NCT00025649|Procedure|autologous bone marrow transplantation|
45652476|NCT05518071|Device|Intraoperative near-infrared fluorescence imaging|Intraoperative imaging will be performed with at least one of the following CE-marked near-infrared (NIR) fluorescence imaging systems: Quest Spectrum imaging platform (v2/3.0) for open-procedures, the Olympus or Karl-Storz system for the diagnostic laparoscopy or the Intuitive Surgical Da Vinci Xi (Firefly-mode) for minimally invasive robot-assisted procedures. With a NIR-imaging system a potential fluorescent signal of the tumor can be evaluated. Furthermore, the Quest Spectrum platform will also be used for evaluation of ex-vivo fluorescence of resected tissue on the back table (Back table imaging) and pathology department (ex-vivo imaging), which shall be performed during and after every procedure.
45802966|NCT03032393|Other|high-power|Subjects will stand with hands on their hips, elbows pointing out and feet approximately one foot apart (high-power) for 20 seconds.
45802967|NCT03032393|Other|low-power|Subjects will stand with hands and arms wrapping around the torso and feet together (low-power) for 20 seconds.
45802968|NCT03114683|Drug|PD1|IBI308 200mg/3 weeks
45802969|NCT02959307|Device|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
45932905|NCT00025649|Procedure|conventional surgery|
45451718|NCT01096043|Drug|Strata 3 CXL-1020|A fixed dose level of CXL-1020 will be administered for the initial 6 hours of treatment in Strata 3 and then dosage will be altered up or downward based on the investigators observation of the patient's condition.
45652477|NCT03068533|Other|8% L-Arginine/calcium carbonate containing toothpaste|use of 8% L-Arginine/calcium carbonate containing toothpaste to relieve hypersensitivity
45652478|NCT03068533|Other|use of strontium acetate toothpaste|use of strontium acetate toothpaste to relieve hypersensitivity
45652479|NCT04804865|Other|prognostic assessment|determination of a prognostic score with 3 clinical and 5 biological parameters.
45932906|NCT00025649|Procedure|peripheral blood stem cell transplantation|
45932907|NCT00053508|Biological|ACAM1000|Group 1 dose: 1.4 x 10-8th PFU/ml (350,000 PFU) Group 2 dose: 2.8 x 10-7th PFU/ml (70,000 PFU) Group 3 dose: 5.6 x 10-6th PFU/ml (14,000 PFU)
45932908|NCT00053508|Biological|vaccinia virus (calf lymph) smallpox vaccine: Dryvax|group 4 dose: 1.6 x 10-8th PFU/ml (250,000 PFU)
45932909|NCT00053547|Drug|paricalcitol injection|
45932910|NCT00025688|Drug|carboplatin|
45932911|NCT00025688|Drug|paclitaxel|
45932912|NCT00053625|Procedure|deep brain stimulation|Deep brain stimulation (DBS) is a surgical intervention used to treat movement disorders such as Parkinson's disease (PD). Target sites of stimulation may differ among patients. The Gpi and STN are two commonly targeted sites within the brain for treatment of PD, yet differences in outcomes between stimulation at the Gpi vs the STN (unilateral and bilateral) are not currently well understood.
45932913|NCT00025727|Drug|Lopinavir/Ritonavir|
45932914|NCT00025727|Drug|Ritonavir|
45932915|NCT00025727|Drug|GW433908|
45932916|NCT00053742|Drug|Modified Vaccinia Virus Ankara TBC-MVA|
45932917|NCT00025766|Device|PCI with stenting|PCI with stenting of the occluded culprit infarct-related artery
45932918|NCT00025766|Behavioral|Optimal Medical Therapy|Participants will receive optimal medical therapy.
45932919|NCT00053781|Drug|perifosine|
45932920|NCT00025805|Drug|G-CSF|
45932921|NCT00053820|Biological|aldesleukin|
45932922|NCT00053820|Biological|recombinant interferon alfa|
45932923|NCT00053820|Drug|fluorouracil|
45932924|NCT04731597|Drug|drug interaction|when two drugs are taken together
45932925|NCT04731090|Drug|IV fluoroquinolone 1 hour preoperatively and oral antibiotics for 24h postoperatively.|IV fluoroquinolone 1 hour preoperatively and oral antibiotics for 24h postoperatively.
45932926|NCT04731090|Other|Urine culture, antibiotic prophylaxis and hydrophilic-coated ureteral access sheaths|Patients had urine culture 10 days before the procedure. In addition to the antibiotic prophylaxis, hydrophilic-coated ureteral access sheaths were systematically used.
45932927|NCT00053937|Drug|pirfenidone|
45932928|NCT00053976|Biological|Daclizumab|
45932929|NCT00053976|Drug|methylprednisolone|
45932930|NCT00053976|Drug|Placebo|
45932931|NCT04733573|Device|Two different occlusal splints|Two different occlusal splints will be used for bruxism management, PPT would be evaluated twice - before and after 30 days of splint therapy using pressure algometer (FPX25, Wagner Instruments, US)
45932932|NCT00054015|Drug|triapine|
45932933|NCT00054054|Drug|cisplatin|
45932934|NCT00054054|Drug|docetaxel|
45932935|NCT00054054|Drug|fluorouracil|
45932936|NCT00054054|Radiation|radiation therapy|
45932937|NCT00026078|Drug|docetaxel|
45932938|NCT00026078|Drug|ifosfamide|
45932939|NCT00026117|Drug|BenFin|
45932940|NCT00026117|Other|placebo|
45932941|NCT04731207|Device|Optovue®|Optical coherence tomography and optical coherece tomography angiography
45932942|NCT00398229|Drug|s.c. human chorionic gonadotropin (Ovitrelle)|S.C. Ovitrelle 250 mcg once
45802970|NCT02959307|Device|Sham Transcranial Light Therapy|The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
45932943|NCT00026156|Drug|docetaxel|
45802971|NCT03114995|Drug|Tirofiban|
45932944|NCT00026156|Drug|vinorelbine tartrate|
45802972|NCT02959853|Drug|Anastrazole|
45802973|NCT02959853|Behavioral|weight loss|
45932945|NCT00054171|Drug|aminolevulinic acid hydrochloride|
45451719|NCT00064337|Biological|filgrastim|
45932946|NCT00026195|Drug|irinotecan hydrochloride|
45932947|NCT00054210|Drug|carboplatin|
45932948|NCT00054210|Drug|paclitaxel|
45451720|NCT00064337|Drug|cyclophosphamide|
45802974|NCT00374465|Drug|Verapamil|
45451721|NCT00064337|Drug|dexamethasone|
45451722|NCT00064337|Drug|melphalan|
45451723|NCT00064337|Drug|thalidomide|
45451724|NCT00064337|Procedure|peripheral blood stem cell transplantation|
45932949|NCT00054210|Drug|paclitaxel poliglumex|
45802975|NCT00374465|Drug|Carvedilol|
45802976|NCT03036215|Behavioral|PACT Experimental Arm|The study will employ a self-management program, entitled Personalized Activated Care and Training (PACT) that is a tailored 8-week progressive web-based training program supported by a health coach to enhance understanding, compliance, and success in improving TMD pain. The program provides 8 weeks of structured didactic and experiential training on exercises and cognitive- behavioral training to reduce risk factors that contribute to delayed recovery and enhance protective factors that have evidence of improving TMD pain.
45802977|NCT02962427|Drug|Sphenopalatine ganglion Block|
45802978|NCT02962427|Procedure|Epidural blood patch|
45802979|NCT02039726|Drug|Quizartinib|20 or 30 mg quizartinib tablets administered orally once daily
45802980|NCT02039726|Drug|Salvage Chemotherapy|Low dose cytarabine (LoDAC); mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin (FLAG-IDA) administered during 28-day cycles
45802981|NCT03036293|Drug|Tenoten|Tablet for oral use.
45802982|NCT03036293|Drug|Placebo|Tablet for oral use.
45802983|NCT02408198|Behavioral|Anxiety intervention|The intervention is based on a brief CBT for psychosis (CBTp) programme, focusing on understanding and managing anxiety processes that contribute to persecutory threat beliefs when in busy urban environments. The novel aspect of this intervention is that it is delivered in a group format. The intervention consists of six sessions which will be delivered on a weekly basis. Throughout the intervention there is an emphasis on setting tasks to practice applying the new skills outside of sessions, to help the person build confidence in being able to manage paranoia and feel less distressed in their daily life.
45932950|NCT02971592|Device|MDcure|reception of real working MDcure - device that does apply the electromagnetic field
45932951|NCT02971592|Other|Mock Device|reception of device that does not apply the electromagnetic field
45932952|NCT00054249|Drug|T900607|
45932953|NCT00026234|Drug|floxuridine|Given intra-arterially
45932954|NCT00026234|Drug|dexamethasone|Given intra-arterially
45932955|NCT00026234|Drug|oxaliplatin|Given IV
45932956|NCT00026234|Drug|capecitabine|Given orally
45932957|NCT00054288|Drug|gemcitabine hydrochloride|
45932958|NCT00054288|Drug|irinotecan hydrochloride|
45932959|NCT00026273|Drug|FOLFIRI regimen|
45932960|NCT00026273|Drug|fluorouracil|
45932961|NCT00026273|Drug|irinotecan hydrochloride|
45932962|NCT00026273|Drug|leucovorin calcium|
45451733|NCT01096121|Drug|Enalapril|"during 1 month : 0,2 mg/kg/day~then during 2 months (if no adverse event): 0,35 mg/kg/day~and then during 6 months (if no adverse event): 0,5 mg/kg/day"
45451734|NCT01096121|Drug|Placebo|Glucose
45451735|NCT00064259|Biological|oblimersen sodium|Given IV
45451736|NCT00064259|Drug|cisplatin|Given IV
45451737|NCT00064259|Drug|fluorouracil|Given IV
45451738|NCT03954197|Other|No hormone|No hormonal injection before oocytes retrieval
45451739|NCT03954197|Other|hCG|a subcutaneous injection of hCG (Choriogonadotropin alpha, Ovitrelle®, Merck Serono, 250 µg) is performed 36 hours before oocytes retrieval
45932963|NCT00054405|Biological|recombinant interleukin-12|Given IV
45932964|NCT00054405|Biological|aldesleukin|Given IV
45932965|NCT00026351|Biological|rituximab|
45932966|NCT00026351|Drug|pentostatin|
45932967|NCT00054444|Drug|Topotecan Hydrochloride Liposomes|Given IV
45932968|NCT00054444|Radiation|3-Dimensional Conformal Radiation Therapy|
45932969|NCT00054444|Drug|Cisplatin|Given IV
45932970|NCT00026429|Biological|denileukin diftitox|
45932971|NCT00054483|Drug|bortezomib|Given IV
45932972|NCT00054483|Other|laboratory biomarker analysis|Correlative studies
45932973|NCT00054483|Other|pharmacological study|Correlative studies
45932974|NCT00026468|Drug|exisulind|
45932975|NCT00054522|Dietary Supplement|calcitriol|
45932976|NCT00054522|Drug|dexamethasone|
45932977|NCT00026585|Drug|Tamoxifen|
45932978|NCT00026624|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
45932979|NCT00026624|Drug|Keyhole-Limpet Hemocyanin|
45932980|NCT00054600|Drug|Methoxsalen|
45932981|NCT00054600|Procedure|Extracorporeal Photopheresis|
45932982|NCT00054678|Drug|MyoCell™|
45932983|NCT00054678|Device|MyoCath™|
45932984|NCT00054795|Drug|Motexafin Gadolinium|
45932985|NCT00026819|Drug|Rofecoxib|
45932986|NCT00054834|Drug|hLL2 (epratuzumab)|
45932987|NCT00026858|Behavioral|collaboration|
45932988|NCT00054873|Drug|tezacitabine|
45932989|NCT00054873|Drug|5-fluorouracil|
45932990|NCT00054912|Biological|EP2101|
45932991|NCT00054951|Drug|MTC-DOX for Injection|
45802984|NCT02040116|Drug|Rituximab Infusion|Participants will receive their first infusion of rituximab at the standard infusion rate provided in the manufacturer labeling. If they tolerate this infusion with a grade 2 of less infusion-related reaction, the next infusion will be administered as a 90 minute rapid infusion.
45932992|NCT00026897|Procedure|Gamma-camera imaging|
45932993|NCT00026897|Procedure|Low-risk biopsy|
45932994|NCT00026936|Procedure|Radiotherapy|
45451740|NCT03954197|Other|GnRH a|a subcutaneous injection of GnRH agonist (triptorelin, Decapeptyl, Ipsen, 0,2 mg) is performed 36 hours before oocytes retrieval
45802985|NCT03037541|Drug|Carac Cream|Carac Cream will be used once daily for seven consecutive days
45802986|NCT03037541|Drug|Placebo Cetaphil cream|Placebo Cetaphil Cream will be used once daily for seven consecutive days
45802987|NCT02986256|Behavioral|Taking pictures|Photograph of foot ulcer with transmission to referring nurse 1 time per week
45802988|NCT02986256|Behavioral|Visit at home|Home visit by the referring nurse every 15 days
45802989|NCT02360774|Drug|Canagliflozin|Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
45802990|NCT02360774|Drug|Placebo|Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
45802991|NCT02361476|Drug|Clonidine|Injection - during surgery
45802992|NCT02361476|Drug|Placebo|Injection - during surgery
45802993|NCT02363270|Procedure|Ketamine|IV Push or or IV Drip
45802994|NCT02042534|Drug|Rivaroxaban|"Rivaroxaban group receive oral rivaroxaban 10 mg once daily for 5 consecutive days, followed by 20 mg or 15 mg in patients with a calculated creatinine clearance of 30-49 ml/min.~The dosage of rivaroxaban is leveraged from results of ROCKET-AF trial, where 20 mg of rivaroxaban was shown to offer balanced efficacy and safety."
45802995|NCT02042534|Drug|Warfarin|To harmonize the warfarin regimen across the sites, fixed algorithm was used in dose calculation, both loading and maintenance, and age, sex, ethnicity, race, weight, height, smoking history, presence of liver disease, indication, baseline INR, target INR and concomitant medication were considered as cofactors (http://www.warfarindosing.org/Source/InitialDose.aspx). Investigators will manage anticoagulation with warfarin per routine clinical care.
45802996|NCT03038399|Drug|Vamorolone 0.25 mg/day/day|Oral administration of 0.25 mg/kg/day daily for 24 months.
45802997|NCT03038399|Drug|Vamorolone 0.75 mg/day/day|Oral administration of 0.75 mg/kg/day daily for 24 months.
45802998|NCT03038399|Drug|Vamorolone 2.0 mg/day/day|Oral administration of 2.0 mg/kg/day daily for 24 months.
45802999|NCT03038399|Drug|Vamorolone 6.0 mg/day/day|Oral administration of 6.0 mg/kg/day daily for 24 months.
45803000|NCT02043704|Drug|IV Acetaminophen|Details covered in arm description.
45803001|NCT03117569|Drug|glecaprevir (300mg)/pibrentasvir (120mg)|glecaprevir (300mg)/pibrentasvir (120mg) for 8 weeks
45803002|NCT02363972|Device|Ellipsys Vascular Access Catheter|A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.
45932995|NCT00398268|Procedure|Kirschner-wire fixation|
45932996|NCT00026975|Procedure|Hyperbaric Oxygen|
45803003|NCT02963597|Device|AirSense™ 10 AutoSet|The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
45803004|NCT02963597|Other|Standard Medical Therapy|Standard medical therapy according to current guidelines.
45803005|NCT02410382|Drug|Dexamethasone|oral dexamethasone 4 mg bid for 14 days
45803006|NCT02410382|Drug|Placebo|oral placebo
45803007|NCT04737005|Procedure|Nano-ceramic hybrid (Grandio Blocs) Endo-crown|Nano-ceramic hybrid
45932997|NCT00398385|Drug|cisplatin|
45451741|NCT00044213|Drug|EDTA|Participants will receive 40 infusions of standard chelation solution.
45803008|NCT03038867|Drug|Duloxetine|Duloxetine orally 60mg daily for 5 weeks, then taper to 30mg daily for 1 week
45803009|NCT03038867|Drug|Placebo|Placebo orally 2 tabs daily for 5 weeks, then taper to 1 tab daily for 1 week
45803010|NCT03039179|Device|polyurethane foam dress|Application of the polyurethane foam dress at the heel in the immediate postoperative period before applied the Walker
45803011|NCT02963987|Other|Food and Beverage Portion Size|Variations of Food and Beverage Portion Size (100% Baseline portions and increased 50% for 150% portions)
45803012|NCT03040427|Drug|F-18 florbetapir|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid).
45803013|NCT03119831|Drug|Alcohol-based Chlorhexidine Gluconate 0.12%|Rinsing with 15ml for one minute twice daily for 14 days
45932998|NCT00398385|Drug|gemcitabine hydrochloride|
45932999|NCT00398385|Procedure|adjuvant therapy|
45933000|NCT00398385|Procedure|conventional surgery|
45933001|NCT00398385|Procedure|neoadjuvant therapy|
45933002|NCT00027014|Drug|St. John's Wort|
45933003|NCT00027014|Drug|oxycodone|
45933004|NCT00027014|Drug|fentanyl|
45933005|NCT00398424|Drug|S-1/Cisplatin|"PK Phase (Part 1), Beginning on Day 1 of the Pharmacokinetic Phase, 30 mg/m2 S-1 will be administered orally BID for 14 days (Days 1 through 14), followed by a 1-week recovery period.~On Day -2 and Day 14 of the Pharmacokinetic Phase, all patients will receive a single dose of 30 mg/m2 S-1 administered orally.~Extension Phase, Patients will receive S-1 at the dose that they tolerated in the PK Phase. S-1 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
45933006|NCT00027053|Drug|Trazodone|50 to 150 mg qhs
45933007|NCT00027053|Drug|Placebo|
45933008|NCT00055068|Behavioral|Cognitive Behavioral Therapy (CBT)|
45933009|NCT00055068|Behavioral|Relaxation Training|
45933010|NCT00027131|Biological|Heat Shock Protein 70-peptide complexes (HSP70)|
45803014|NCT03119831|Drug|Alcohol-free Chlorhexidine Gluconate 0.12%|Rinsing with 15ml for one minute twice daily for 14 days
45803015|NCT03119831|Drug|C31G|Rinsing with 15ml for one minute twice daily for 14 days
45933011|NCT00055107|Drug|Nitazoxanide|
45451742|NCT00044213|Drug|EDTA Placebo|Participants will receive 40 infusions of EDTA placebo.
45451743|NCT00044213|Dietary Supplement|High Dose Vitamin|
45803016|NCT02965781|Drug|SADBE|Topical solution
45803017|NCT02965781|Other|Placebo|Topical solution
45803018|NCT02968277|Device|LifeWalker Upright|LifeWalker (LW) upright walker
45803019|NCT02968277|Device|Predicate Device|Individual's personal walker
45803020|NCT02968277|Device|Standard Rollator|A control rollator device
45803021|NCT03124121|Drug|Golimumab|A biologic agent which acts by antagonising the effects of tumour necrosis factor (TNF) alpha
45803022|NCT04333277|Other|Probiotic|Patients with major depression (both sexes) will receive capsules with 1 × 10^9 CFUs of Lactobacillus helveticus in addition to a conventional antidepressant treatment for 8 weeks.
45803023|NCT04333277|Other|Maltodextrin|Patients with major depression (both sexes) will receive capsules of placebo (maltodextrin) in addition to a conventional antidepressant treatment for 8 weeks
45451744|NCT00044213|Dietary Supplement|High Dose Vitamin Placebo|
45451745|NCT00064025|Other|Laboratory Biomarker Analysis|Correlative studies
45451746|NCT00064025|Drug|Medroxyprogesterone|Given IM
45803024|NCT03041441|Device|MRI algorithm|MRI sequences have been developed that may be able to estimate intracranial pressure in a non-invasive fashion
45803025|NCT03041441|Procedure|Lumbar puncture|Lumbar puncture according to the standard-of-care treatment plan.
45803026|NCT03041441|Procedure|Epidural patching|Epidural patching will be performed to the standard-of -care treatment plan
45803027|NCT03041909|Drug|GBT440|Oral drug
45803028|NCT03042299|Drug|TAK-536|TAK-536 granules.
45803029|NCT03042299|Drug|TAK-536|TAK-536 tablet.
45803030|NCT03043079|Diagnostic Test|Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity|Abdominal Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity (ARFI-SWV)
45803031|NCT02971631|Other|Exendin 9-39|Complete blockade of action of endogenous GLP-1 by Exendin 9-39. Defined as a physiological study, not a clinical trial as such (as advised by the UK MHRA).
45803032|NCT02971631|Other|Placebo|Infusion of 1% human albumin in normal saline
45803033|NCT00374699|Drug|Velcade|
45803034|NCT00374777|Drug|zolpidem MR|oral
45803035|NCT00374777|Drug|nitrazepam|oral
45803036|NCT00374777|Drug|placebo|oral
45803037|NCT03045809|Diagnostic Test|Urogenital infection point-of-care tests|Instead of syndromic management of symptomatic women, the study offers screening of high risk women regardless of symptoms using point-of-care tests for HIV, TV, and BV (all women), syphilis, NG, and CT (when risk score positive), and UTI (when symptomatic).
45803038|NCT02044796|Drug|Cladribine|Given IV
45933012|NCT00055146|Drug|ONTAK|
45933013|NCT00055185|Drug|CD4-IgG2 (PRO 542)|
45451747|NCT00064025|Procedure|Therapeutic Conventional Surgery|Undergo surgical hysterectomy
45451748|NCT01091987|Behavioral|Non-pharmacological approach of insomnia|education on sleep, sleep hygiene, stimulus control, cognitive techniques
45803039|NCT02044796|Drug|Cytarabine|Given IV
45803040|NCT02044796|Biological|Filgrastim|Given SC
45803041|NCT02044796|Other|Laboratory Biomarker Analysis|Correlative studies
45803042|NCT02044796|Drug|Mitoxantrone Hydrochloride|Given IV
45803043|NCT03124823|Device|Rainbow DCI Sensor|Noninvasive pulse oximeter sensor
45803044|NCT03124901|Device|DCI pulse oximeter sensor|
45803045|NCT03124979|Device|LNCS DBI Sensor|Noninvasive Measurement of SpO2
45803046|NCT02045108|Behavioral|Active Retraining|
45803047|NCT02045108|Device|Sham TDCS|
45803048|NCT02045108|Device|Active TDCS|
45451749|NCT03957395|Device|Device: Precision Novi™ system Neurostimulation procedures|SCS with Device: Precision Novi™ system
45803049|NCT02045108|Behavioral|Sham Retraining|
45803050|NCT02973503|Drug|Elbasvir/Grazoprevir Fixed Dose Combination|Evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).
45451750|NCT01096199|Drug|TS-ONE, Cisplatin, RAD001|
45803051|NCT03127943|Drug|Lidocaine|Efficacy for mandibular molar and canine anesthesia
45803052|NCT03047447|Behavioral|Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome|30 adults previously diagnosed with MetS randomly prescribed to one of three groups: a sustained ketogenic diet with no exercise, the participant's normal diet with no exercise, or participant's normal diet with 3-5 days per week of exercise for 30 minutes
45803053|NCT02412098|Drug|Eleclazine|Eleclazine tablets administered orally
45803054|NCT03048383|Drug|OnabotulinumtoxinA Injectable Product|Administered to treat facial synkinesis
45803055|NCT03048383|Drug|AbobotulinumtoxinA Injectable Product|Administered to treat facial synkinesis
45803056|NCT03048383|Drug|Incobotulinumtoxin A Injectable Product|Administered to treat facial synkinesis
45803057|NCT02045264|Drug|Icatibant (30 mg)|On Day 1, subjects will receive a single 30mg subcutaneous injection of icatibant in their abdominal area. Subjects will be discharged from the study on Day 3 after collection of study related assessments
45803058|NCT02975297|Drug|Exenatide|Exenatide Injectable Product will be administered at a dose of 2 mg subcutaneously once a week for 6 weeks.
45803059|NCT02975297|Drug|NRT|Nicotine Patch (21mg) / 24 hours.
45803060|NCT02975297|Behavioral|Counseling|Brief individual behavioral smoking cessation counseling.
45803061|NCT02975297|Drug|Placebo|Normal saline.
45933014|NCT00027170|Device|Siemens MRI scanner|Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.
45933015|NCT00055263|Drug|DN-101|
45933016|NCT00027209|Drug|prempro|
45652480|NCT05281341|Drug|Growth Hormone|In GH groups (Group 4A & 3A), patients will receive additional treatment with GH (Somatropin, 4 IU/day, subcutaneous injection), daily beginning on the initial day of gonadotropin stimulation until triggering the oocyte maturation by hCG. Control groups (Group 4B & 3B) will receive only standard COS without GH supplementation
45803062|NCT02046200|Drug|Ivermectin|Ivermectin is a semi-synthetic macrocyclic lactone used worldwide as a broad-spectrum antiparasitic avermectin.
45451751|NCT03957239|Other|Cranberry Beverage|The cranberry beverage will provide 50 kcals and 4.0 grams of fiber per day from whole milled cranberries, water, cranberry natural flavor and sucralose.
45652481|NCT03068377|Dietary Supplement|Experimental|Soft gel capsules containing a mixture of tomato extract, lutein, zeaxanthin as well as other phytonutrients and vitamins
45451752|NCT03957239|Other|Control Beverage|The control beverage will provide 50 kcals per day and is a color, taste matched sugar sweetened beverage formulated with water, sucrose, citric acid, cranberry natural flavor, malic acid, xanthum gum, sucralose and artificial color (red 40, blue 1).
45451753|NCT01092299|Drug|AZD1446|ER Fast, 90mg, p.o. capsule
45451754|NCT01092299|Drug|AZD1446|ER Moderate, 90mg, p.o. capsule
45652482|NCT03068377|Dietary Supplement|Placebo|soft gel capsules without test material
45803063|NCT02046200|Drug|Placebo|Matched placebo
45451755|NCT01092299|Drug|AZD1446|ER Slow, 90mg, p.o. capsule
45451756|NCT01092299|Drug|AZD1446|MR
45803064|NCT02046200|Drug|Alcohol|
45451757|NCT01092299|Drug|AZD1446|IR, 90 mg p.o. capsule
45451758|NCT01092299|Drug|Placebo|IR
45451759|NCT01092299|Drug|Placebo|ER/MR
45803065|NCT02978339|Drug|Curcumin|Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
45451760|NCT01092377|Dietary Supplement|DHA and EPA Fish Oil capsule|2 DHA/EPA capsules on 4 days per week containing totally 420 mg DHA and 80 mg EPA, providing an average dose of 285.7 mg n-3 fatty acids per day
45451761|NCT01092377|Dietary Supplement|Iron tablet|1 iron tablet containing 50 mg of iron as ferrous sulfate will be administered on 4 days per week, providing an average iron dose of 28.6 mg iron per day.
45451762|NCT01092377|Other|Placebo tablet|Placebo tablet will be administered on 4 days per week and will be identical in appearance to the iron tablet.
45652483|NCT04809155|Behavioral|Girl2Girl|The program has a 'core' 7 weeks of daily messages and then a week 'booster' that is delivered 3 months later.
45803066|NCT02367014|Drug|elamipretide (low dose)|elamipretide (0.01 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
45803067|NCT02367014|Drug|elamipretide (intermediate dose)|elamipretide (0.10 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
45652484|NCT04988659|Other|Exposures|Exposures
45652485|NCT05280249|Other|both aerobic and resistance exercises in the green exercise concept|Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. Participants in this group will be given aerobic and resistance exercises in the open air.
45652486|NCT04809077|Other|Reverse total shoulder replacement|Long-term radiographic and clinical data of patients who underwent a reverse shoulder replacement
45652487|NCT05635981|Other|Clearfil Majesty ES-2 Resin Composit Application to Non-carious Cervical Lesions|A restorative treatment method that is applied to non-carious cervical lesions using composite resin restoration after adhesive material application.
45803068|NCT02367014|Drug|elamipretide (high dose)|elamipretide (0.25 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
45803069|NCT02367014|Drug|Placebo|placebo (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days
45803070|NCT02367872|Drug|TAK-272|TAK-272 tablet
45803071|NCT02979899|Biological|TRC105|TRC105 antibody
45803072|NCT02979899|Drug|Votrient|pazopanib
45803073|NCT00374855|Drug|PPAR alpha|
45803074|NCT00374855|Drug|Hydrochlorothiazide|
45803075|NCT00374855|Drug|Placebo|
45803076|NCT02412644|Drug|apremilast|
45803077|NCT03134963|Other|Transcranial doppler ultrasonography|Measurement of cerebral blood flow whilst undertaking cognitive tasks with TCD monitoring.
45803078|NCT03134963|Other|Blood pressure monitoring|Continuous blood pressure recording
45803079|NCT03134963|Other|Heart rate monitoring|Continuous heart rate monitoring
45803080|NCT03134963|Other|End tidal CO2 monitoring|Continuous ETCO2 monitoring
45803081|NCT03134963|Other|Addenbrooke's cognitive examination|Performance of a memory test
45803082|NCT02980211|Drug|Alveolar Ridge Reconstruction|Reconstruction of dehiscence defects in extraction sockets with a minimally invasive technique using a particulate bone allograft and a non-absorbable dense polytetrafluoroethylene (dPTFE) membrane
45803083|NCT02412956|Behavioral|SmokefreeMOM Text|
45803084|NCT03054077|Other|iPad with downloaded games|iPad with downloaded games will be given to children randomized to group 2 for use during their time in the peri-operative unit
45803085|NCT02046980|Procedure|Gufoni|
45803086|NCT02046980|Procedure|Vibration|
45803087|NCT02046980|Procedure|Sham|
45803088|NCT02983877|Behavioral|iTAB-CV|"Stage 1 of the intervention will be introduced. Researchers will conduct an interview in order to customize iTAB-CV for each participant at the baseline session. In the first month, participants will receive alternating daily texts with educational and motivational content and a daily mood rating request to both monitor their mood and to determine adherence to the intervention.~In the second stage for the following month, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from stage 1."
45803089|NCT02413034|Drug|Cefazolin|Cefazolin (vancomycin in the case of allergy to cefazolin)
45652488|NCT05320029|Device|Gastrointestinal tumor surgery|Only the brand of electric cutting stapler used by different groups was different, and the rest were treated according to routine treatment
45652489|NCT04797689|Behavioral|Trauma Informed Yoga|One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
45451763|NCT01092377|Other|Placebo capsule|Placebo capsules contain medium chain triglycerides and will be identical in appearance and total fat content to the DHA/EPA capsules.
45451764|NCT01096277|Drug|Sitagliptin|oral tablets 100 mg per day for two weeks
45652490|NCT04797689|Behavioral|Trauma Informed Psychotherapy|Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
45803090|NCT02413034|Other|Control group|no antibiotic prophylaxis
45803091|NCT04737473|Drug|Opiod Free Anesthesia|The OFA protocol will entailed induction of anesthesia intravenously by the administration of the following drugs: magnesium sulfate 40mg/kg (without exceeding 2.5g), lidocaine 1.5mg/kg, ketamine 25mg, propofol 1.5-2mg/kg, dexamethasone 8mg and rocuronium
45803092|NCT03136913|Device|Cytoplast® TXT-200|Non-resorbable membrane
45803093|NCT03136913|Device|MinerOss® Cortical and Cancellous Chips (FDBA)|Mixture of allograft mineralized cortical and cancellous chips
45803094|NCT03136913|Procedure|Open Flap Technique|After extraction, the socket wound is left open to heal by secondary intention
45803095|NCT03136913|Procedure|Closed Flap Technique|After extraction, the socket wound is closed by primary closure
45803096|NCT02413580|Biological|IGIV-C|An IV dose of 2 g/kg of IGIV-C was administered over 2 consecutive days at a dose of 1 g/kg per day.
45803097|NCT02985827|Drug|Rohto (r) Hydra|Rohto (r) Hydra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
45803098|NCT02985827|Drug|Systane (r) Ultra|Systane (r) Ultra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
45803099|NCT04707287|Other|No Intervention|No intervention used. This is observational study
45803100|NCT02369900|Drug|Esmolol|
45803101|NCT02369900|Other|Saline|
45803102|NCT03054857|Drug|Dexmedetomidine|After skin incision, the dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
45803103|NCT03054857|Drug|Placebo|The control group received a loading dose and continuous IV infusion of normal saline at the same volume and rate as in the dexmedetomidine group
45803104|NCT02370056|Diagnostic Test|3-dimensional visualization|Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 3D mode
45803105|NCT02370056|Diagnostic Test|2-dimensional visualization|Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 2D mode
45803106|NCT02987231|Procedure|CAF|Periodontal plastic surgery for root coverage by the trapezoidal flap
45803107|NCT02987231|Device|ES|Local electric stimulation for 120 seconds, once a day for a week
45803108|NCT02987231|Device|SHAM|Simulation of electric stimulation protocol. In Sham stimulation non current will be applied
45803109|NCT02414204|Drug|Sildenafil|Sildenafil, a phosphodiesterase 5 inhibitor that enhances the effects of nitric oxide (NO), has been shown in experimental and clinical studies in cardiovascular disease to improve endothelial function and decrease vascular stenosis.
45803110|NCT02414204|Other|Placebo|Placebo will be over encapsulated to identical to drug comparison
45803111|NCT02987621|Device|tDCS|Less than 10V of Transcranial Direct Current Stimulation. Sham 0V of Transcranial Direct Current Stimulation.
45803112|NCT02989493|Drug|Doxazosin|Doxazosin
45803113|NCT02989493|Other|Placebo|Placebo
45803114|NCT02050334|Drug|CC100|CC100 reconstituted in diluent
45803115|NCT02050334|Drug|Placebo|Diluent. Amount to match CC100 dose.
45803116|NCT03062267|Other|Mobile Interventionist|A mobile interventionist is a trained clinician who provides supportive messaging through text messages via mobile devices (i.e. basic / smartphones)
45803117|NCT00355004|Other|counseling intervention|
45803118|NCT00355004|Procedure|fecal occult blood test|
45803119|NCT00355004|Procedure|screening colonoscopy|
45803120|NCT02371850|Drug|Nicoderm patch first, then Aveva patch|This is a single group assignment where each of 10 adult smokers completes 4 procedure days using a Nicoderm CQ nicotine patch (2 days) followed by the application of a generic Aveva patch (2 days). For each patch, heating is applied for one hour at hour 4 on the first procedure day and at hour 8 in the second procedure day (2 days per patch, or a total of 4 days per subject).
45803121|NCT03141281|Behavioral|BrainHQ|BrainHQ
45933017|NCT00055302|Drug|Arimidex 1 mg|Arimidex (anastrozole) 1mg once daily by mouth
45933018|NCT00027248|Drug|MBI 226|
45933019|NCT00055341|Drug|Peginterferon alfa-2a|
45933020|NCT00055341|Drug|Ribavirin|
45933021|NCT00027287|Drug|Vitamin E|
45933022|NCT00055380|Procedure|Oral cytobrushing|
45933023|NCT00027365|Biological|Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A|
45933024|NCT00027365|Biological|NefTat|
45933025|NCT00027365|Drug|AS02A Adjuvant|
45933026|NCT00027365|Biological|gp120W61D|
45933027|NCT00055419|Biological|Cetuximab|400 mg/m2 loading dose Week 1, followed by 250 mg/m2 weekly until disease progression
45933028|NCT00055536|Drug|natalizumab|
45803122|NCT03141281|Behavioral|Rise of Nations|Rise of Nations
45803123|NCT03141281|Behavioral|IADL Training|IADL Training
45803124|NCT03141281|Behavioral|Active Control|Puzzle solving
45803125|NCT02415608|Drug|Ibrutinib|Given orally in 28-day cycles
45803126|NCT03144089|Device|Articulated Oral Airway|The AOA is a novel device which actively displaces the tongue, allowing for a greater cross-sectional area for mask ventilation. The AOA will be evaluated for efficacy of mask ventilation.
45803127|NCT03144089|Device|Guedel oral airway (active comparator)|The Guedel oral airway is a standard oral airway commonly used to facilitate mask ventilation. The Guedel oral airway will be evaluated for efficacy of mask ventilation.
45803128|NCT02051426|Other|D-serine|single P.O. administration of D-serine (2.1g)
45803129|NCT02051426|Other|Placebo|single P.O. administration of Placebo
45803130|NCT03144635|Drug|Grazoprevir plus Elbasvir|An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.
45803131|NCT02313506|Behavioral|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker (Fitbit Flex), and remote counselling by a PT. Intervention will be received immediately.
45803132|NCT02313506|Behavioral|Same intervention with a 1 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 1 Month delay.
45803133|NCT05719298|Device|Respiratory interface|Application of the new interface and accessories and provision of non-invasive respiratory support through the device.
45803134|NCT03145259|Drug|Diclofenac Epolamine Patch|patch
45933029|NCT00027443|Drug|Muromonab-CD3|
45933030|NCT00027443|Drug|Cyclosporine|
45933031|NCT02970240|Procedure|Cardiopulmonary testing|A 2-day consecutive testing on an ergometer cycle
45803135|NCT03145259|Drug|diclofenac sodium solution|solution
45933032|NCT00055614|Drug|topotecan hydrochloride|
45451765|NCT01096277|Drug|Placebo|oral tablet, one per day for two weeks
45933033|NCT00055614|Procedure|adjuvant therapy|
45933034|NCT00027521|Biological|bleomycin sulfate|
45933035|NCT00027521|Drug|electroporation therapy|
45933036|NCT00027599|Biological|bevacizumab|
45933037|NCT00027599|Biological|prostatic acid phosphatase-sargramostim fusion protein|
45933038|NCT00027599|Biological|sipuleucel-T|
45933039|NCT00027599|Biological|therapeutic autologous dendritic cells|
45933040|NCT00027599|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45933041|NCT00055653|Biological|anti-thymocyte globulin|
45933042|NCT00055653|Biological|filgrastim|
45933043|NCT00055653|Drug|busulfan|
45933044|NCT00055653|Drug|cyclophosphamide|
45933045|NCT00055653|Drug|cyclosporine|
45933046|NCT00055653|Drug|fludarabine phosphate|
45933047|NCT00055653|Drug|melphalan|
45933048|NCT00055653|Drug|methylprednisolone|
45933049|NCT00055653|Procedure|umbilical cord blood transplantation|
45933050|NCT00055653|Radiation|radiation therapy|
45933051|NCT00055770|Drug|erlotinib hydrochloride|Given orally
45933052|NCT00055770|Drug|docetaxel|Given IV
45933053|NCT00055770|Other|laboratory biomarker analysis|Correlative studies
45933054|NCT00055770|Other|pharmacological study|Correlative studies
45933055|NCT00027638|Drug|thalidomide|
45933056|NCT00055809|Biological|PEG-interferon alfa-2b|Given SC
45933057|NCT00055809|Biological|bevacizumab|Given IV
45933058|NCT00055809|Other|laboratory biomarker analysis|Optional correlative studies
45933059|NCT00027677|Drug|halofuginone hydrobromide|
45933060|NCT00055848|Genetic|cytogenetic analysis|
45933061|NCT00055848|Genetic|gene mapping|
45933062|NCT00055848|Genetic|microarray analysis|
45933063|NCT00027716|Drug|bortezomib|
45933064|NCT00055887|Drug|carboplatin|
45933065|NCT00055887|Drug|cisplatin|
45933066|NCT00055887|Drug|efaproxiral|
45933067|NCT00055887|Drug|gemcitabine hydrochloride|
45933068|NCT00055887|Drug|paclitaxel|
45933069|NCT00055887|Drug|vinorelbine ditartrate|
45933070|NCT00055887|Procedure|radiation therapy|
45933071|NCT00055926|Drug|CP-724,714|
45933072|NCT00027794|Procedure|conventional surgery|
45933073|NCT00026039|Drug|estrogen|
45933074|NCT00027404|Drug|Fluoxetine|
45451766|NCT01096277|Other|Control|no intervention
45803136|NCT05719220|Behavioral|Group preoperative pelvic floor training|Patients will receive PFT from a trained physical therapist delivered in a group setting of 8-10 people. The investigators allow patients in the PFT group to attend group classes as many times as they want prior to surgery to see if the frequency of training has an effect on outcomes. The treatment group could be required to go to at least 1 group class 4 weeks prior to their procedure, but they could be welcome to attend more if they want further practice and review of the material. A 45-minute group class with basic PFT guidelines could be presented weekly during the study.
45803137|NCT00354692|Drug|Sodium Ferric Gluconate and Iron sucrose|
45933075|NCT00055965|Drug|carboplatin|
45933076|NCT00055965|Drug|cisplatin|
45803138|NCT03146585|Device|PBR assessment|Sublingual microcirculation will be investigated by specialized handheld videomicroscopy device for PBR index.
45933077|NCT00055965|Drug|gemcitabine hydrochloride|
45933078|NCT00027833|Biological|ALVAC-CEA-B7.1 vaccine|
45933079|NCT00027833|Biological|tetanus toxoid|
45933080|NCT00027833|Drug|FOLFIRI regimen|
45933081|NCT00027833|Drug|fluorouracil|
45451767|NCT01584167|Drug|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
45933082|NCT00027833|Drug|irinotecan hydrochloride|
45933083|NCT00027833|Drug|leucovorin calcium|
45933084|NCT00027872|Drug|tipifarnib|Given orally
45933085|NCT00027872|Other|laboratory biomarker analysis|Correlative studies
45451768|NCT01584167|Device|EMCOOLS Flex.Pads|Passive whole-body surface cooling with 10 EMCOOLS Flex.Pads
45803139|NCT05719142|Other|Picture exposure|Participants are shown pictures for 15 minutes; 50 images in total, each shown for 6 seconds, and 3 times in total.
45803140|NCT02375984|Biological|Tumor Infiltrating Lymphocytes (TIL)|Patients will receive an IV adoptive transfer of at least 10^9 tumor-reactive lymphocytes. An IV catheter in the patient's arm or upper chest will be used for cell infusion. The TIL will be administered over 20-30 minutes at room temperature using a standard infusion protocol or by hanging the infusion bag from a stand and allowing gravity to pull the cells down.
45933086|NCT02970201|Other|EpxDialysis|The EpxDialysis intervention consists of automated SMS text or voice messages delivered to the patient's preferred phone number three times per week. These messages provide details about the subject's upcoming hemodialysis session, anticipatory guidance regarding clinically-concerning symptoms, as well as the option for direct call routing to the dialysis center for rescheduling sessions.
45933087|NCT00027911|Biological|NY-ESO-1 peptide vaccine|
45451769|NCT01096355|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
45451770|NCT01096355|Other|diagnostic laboratory biomarker analysis|
45451771|NCT01096355|Other|pharmacogenomic studies|
45451772|NCT01096355|Other|pharmacological study|
45451773|NCT01096433|Device|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
45803141|NCT02989727|Drug|Lamotrigine|Lamotrigine tablets at dosages of 25mg/day for Week 1 and Week 2, 50mg/day for Week 3 and Week 4, 100mg/day for Week 5, and 200mg/day for Week 6, Week 7, and Week 8.
45451774|NCT03956927|Other|S-TPE|S-TPE stimulation session with groups of 8 patients. The simulation is performed by a single patient, the others are observers in a neighbouring room where the scene is projected.
45803142|NCT02989727|Drug|Placebos|Placebo tablets
45451775|NCT03956927|Other|Questionnaires|Pre- and post-simulation administration of self-efficacy and anxiety questionnaires (IASTA Y1 and Y2)
45451776|NCT03953963|Device|HydraSolve T2D™|The HydraSolve T2D™ System will be used to perform the combined minimally invasive laparoscopic and mini-laparotomy procedure to selectively extract excess intra-abdominal fat from the mesentery. All patients will receive standard nutritional counseling and their medications will be adjusted to achieve target levels of blood glucose control.
45933088|NCT00027911|Biological|sargramostim|
45933089|NCT02969967|Device|SaeboFlex|Use of the SaeboFlex orthosis for a set protocol of grasp-release activities for 50 minutes at least 3 times per week, followed by 10 minutes of grasp-release activities without the orthosis for 8 weeks. Will occur in participants' homes after discharge from inpatient rehabilitation with visit from principal investigator to progress program for 1 hour 3 times a week for the first 2 weeks and then once a week for 6 weeks.
45451777|NCT01096511|Drug|Moxifloxacin (Avelox, BAY12-8039)|The treatment with Moxifloxacin 400 mg infusion should comply with the recommendations written in the local product information. The decision about the treatment with Moxifloxacin as well as the duration of treatment is solely up to the attending physician.
45451778|NCT01092455|Drug|Heparin N reduction|Dialysis with Citrasate, acid concentrate plus 100% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 80% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 66.7% of patient's standard heparin N dose.
45933090|NCT00027989|Drug|gemcitabine hydrochloride|
45933091|NCT00027989|Drug|pegylated liposomal doxorubicin hydrochloride|
45933092|NCT00056004|Drug|zileuton|
45933093|NCT00028028|Drug|temsirolimus|Given IV
45933094|NCT00028028|Other|pharmacological study|Correlative studies
45933095|NCT00028028|Other|laboratory biomarker analysis|Correlative studies
45933096|NCT04730817|Device|Virtual Reality Motor-Cognitive Training System|Immersive VR training system tailor-made for the daily living experiences in the Hong Kong context to provide interactive experiences for older people in Hong Kong. The VR training system is designed as a game with 16 progressive levels (anticipating intervention group participants to complete 2 levels per week for 8 weeks) which aim to train their motor and cognitive functions.
45933097|NCT00028106|Drug|[131]I-MIBG|
45933098|NCT00028106|Drug|6-[18F]Fluorodopamine|
45933099|NCT00028106|Drug|[123]I-MIBG|
45803143|NCT02051816|Device|Video Laryngoscopy|
45803144|NCT02051816|Device|Apneic Oxygenation|
45652491|NCT04988581|Other|Intensively integrated care of microvascular risk factors in the intervention group|The intensively integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment for diabetes and comorbidities in a primary care setting, will be delivered by trained primary care physicians, health managers and diabetes specialists. Diabetic microvascular risk factors (glycated hemoglobin [HbA1C], urinary albumin-to-creatinine ratio [ACR], blood pressure [BP], estimated glomerular filtration rate [eGFR], uric acid [UA] and low-density lipoprotein cholesterol [LDL]) will be tested every 3 month for the intervention group and clinical treatment decisions based on the test results will be implemented accordingly when necessary. The intensively integrated care intervention will last for 36 months. HbA1C, ACR, BP, eGFR, UA, LDL, other variables and co-morbidities will be measured at baseline and follow-up visits every 3 month.
45803145|NCT02051816|Device|Direct Laryngoscopy|
45451779|NCT03954275|Other|no intervention|no intervention
45803146|NCT02051816|Device|No Apneic Oxygenation|
45803147|NCT02039947|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules
45451780|NCT02263222|Drug|MDT-10013|
45451781|NCT02264782|Other|Computer-Assisted Intervention|Complete PreView
45652492|NCT05516511|Diagnostic Test|Angiotensin Converting Enzyme test|blood sample is taken SLE patients , healthy control , ACE level will be measured by ELISA kits
45803148|NCT02039947|Drug|Trametinib|Trametinib will be provided as 0.5 mg and 2.0 mg tablets
45803149|NCT02052752|Drug|3% Benzoyl Peroxide|Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
45803150|NCT02052752|Drug|3% Benzoyl Peroxide Placebo|The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
45803151|NCT02052752|Drug|Neutrogena Rapid Clear®|A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
45803152|NCT05719064|Behavioral|Adaptive Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
45803153|NCT05719064|Behavioral|Computer-Delivered Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
45803154|NCT05719064|Behavioral|Automated Text Reminders|Scheduled text reminder to take medication
45803155|NCT03063437|Biological|Encapsulated fecal microbiota preparation|30 capsules
45451782|NCT02264782|Other|Computer-Assisted Intervention|Watch an educational video
45451783|NCT02264782|Other|Questionnaire Administration|Ancillary studies
45803156|NCT03063437|Biological|Encapsulated placebo|30 capsules
45803157|NCT02042131|Behavioral|Treatment As Usual (TAU)|
45803158|NCT02042131|Behavioral|Standard Crisis Response Plan (S-CRP)|
45803159|NCT02042131|Behavioral|Enhanced Crisis Response Plan (E-CRP)|
45803160|NCT02996591|Procedure|25 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for popliteal nerve block|
45803161|NCT02996591|Procedure|10 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for adductor canal nerve block|
45803162|NCT02996591|Drug|Midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg + propofol as needed|
45803163|NCT02996591|Procedure|45-60 mg of 1.5% mepivacaine for spinal anesthesia|
45803164|NCT02996591|Procedure|LMA insertion + titrated propofol infusion + sevoflurane + ketamine 10 mg/hr for general anesthesia|
45803165|NCT03858205|Other|Quality-of-Life Assessment|Ancillary studies
45803166|NCT03858205|Other|Questionnaire Administration|Ancillary studies
45803167|NCT03858205|Radiation|Radiation Therapy|Receive low-dose radiation therapy
45803168|NCT02053376|Drug|Regorafenib|regorafenib (120 mg) (160 mg for second and subsequent treatment cycles)orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle.
45803169|NCT03065075|Drug|Phenazopyridine|Phenazopyridine 200 mg on morning of postoperative day 1
45803170|NCT03066947|Biological|SV-BR-1-GM|See above
45803171|NCT03066947|Drug|Cyclophosphamide|Low dose pre-treatment to reduce regulatory T cells
45803172|NCT03066947|Biological|Interferon-alpha-2b|Low dose given in the vaccine site to boost the immune response
45803173|NCT02042911|Drug|SyB L-0501|SyB L-0501 is administered at 100 mg/m2/day by intravenous infusion on Day 1 and Day 2 followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 cycles. Dose administration can be delayed or discontinued from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle, but dose reduction is permitted from the 3rd cycle.
45803174|NCT02043145|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) as prescribed according to standard of care in clinical practice.
45933100|NCT00056082|Drug|celecoxib|Celecoxib daily for 12 months
45933101|NCT00028145|Behavioral|Adherence assessment|Adherence will be assessed using questionnaires at all study visits.
45933102|NCT00056199|Drug|EYE001|
45933103|NCT01349790|Drug|NewGam|NewGam is a solution of human normal immunoglobulin 10% treated with solvent/detergent and nanofiltered for intravenous administration.
45933104|NCT04730973|Drug|Evolocumab|Evolocumab 140 mg s.c. every two weeks on top of optimal lipid lowering therapy
45933105|NCT04730973|Other|lipid-lowering therapy (LLT)|lipid-lowering therapy (LLT)
45933106|NCT00028379|Procedure|Transcranial magnetic stimulation (TMS)|
45933107|NCT00056238|Drug|NC-758 (Anti amyloidotic [Aß] agent)|
45933108|NCT00028418|Drug|Clofarabine|
45933109|NCT00028496|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given intradermally
45652493|NCT04796987|Diagnostic Test|Convolutional Neural Network|Convolutional neural networks, a machine learning technique, have been used in several industrial and research fields increasingly. The development of computational units and the increasing amount of data led to the development of new methods on artificial neural networks. Deep learning (DL) is a multi-layered neural network in which feature extraction is done automatically. It extends traditional neural networks by adding more hidden layers to the network architecture between the input and output layers to model more complex and nonlinear relationships.
45652494|NCT05237895|Diagnostic Test|Serum Endocan Levels|Detection of Serum Endocan Levels and detection of possible diagnostic association with gestational diabetes
45652495|NCT05453539|Drug|DSPE-DOTA-Gd Liposomal Injection|Single dose, intravenous infusion
45652496|NCT04796753|Other|Basketball Injury Defense|To establish a specific evaluation protocol for youth basketball players.
45933110|NCT00028496|Biological|sargramostim|Given subcutaneously
45933111|NCT00028496|Biological|recombinant fowlpox GM-CSF vaccine adjuvant|Given intradermally
45652497|NCT05237271|Other|Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D)|Educational Materials will detail the diagnostic tests in question. This CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years.
45933112|NCT00028535|Biological|trastuzumab|Given IV
45652498|NCT05237271|Other|Educational Materials on the CVD-T2D and Bundled Metabolic Panel|Educational Materials will detail the diagnostic tests in question.his CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years. The bundled metabolic scores will provide insight into the patient's current metabolic conditions.
45652499|NCT03068299|Other|Dance|Sessions of sixty minutes each, which will take place weekly, totaling 24 weeks (6 months). Ten minutes from the start of each session will be reserved for initial exercises, with movements of the upper limbs, lower, accompanied by a motivational music. The process of identifying and memorizing the movements will be carried out as many times as the group deems necessary. The rhythms include combinations of circular and ballroom dances, including waltz, cha-cha-cha, cancan, among others. In all the sessions, the last fifteen minutes are reserved for a conversation about the dance learned/practiced in the day. It is expected to have reached the proposal of a practice of 15 different choreographies and that this was a pleasant moment for all the participants.
45652500|NCT03068299|Other|Health care guidance|Control group will receive attention, through guidelines for care and health practices for the caregiver and the elderly care recipient. This attention should occur in the same number of sessions of the dance and group intervention group. The control group should follow the same subdivision of the intervention group, in terms of the number of participants per subgroup. The subjects of the guidelines will be raised by the demand of the participants themselves and then worked in an interdisciplinary way.
45652501|NCT05280015|Dietary Supplement|microbiotherapy (GynMDD)|multi-target microbiotherapy add-on venlafaxine
45652502|NCT05280015|Other|placebo|placebo add-on venlafaxine
45652503|NCT03070795|Procedure|early feeding|start oral sips four hours after cesarean section
45652504|NCT03070795|Procedure|delayed feeding|start oral feeding on post operation day 1 (>12hours) after surgery
45652505|NCT04805099|Drug|Checkpoint inhibitor|Treatment with checkpoint inhibitors in patients with preexisting autoimmune disease
45933113|NCT00028535|Drug|paclitaxel|Given IV
45451784|NCT02264860|Dietary Supplement|Zinc and SAMe|The subjects will have the supplements dispensed at visit 2. They will be contacted weekly for the next three weeks to ensure that they are tolerating the supplements without significant side-effects. If these side-effects are significant then the dose of zinc will be decreased for all subjects to 15 mg of elemental zinc/day; if symptoms persist the SAMe dose will then be decreased by 25% (to 1200 mg/day) and then by 50% (to 800 mg/day) if necessary until the supplements are tolerated. 12 mg of zinc and 800 mg of SAMe is the lowest dose possible.
45933114|NCT00028535|Biological|recombinant interleukin-12|Given SC
45652506|NCT04808687|Drug|Nab paclitaxel and S-1|Nab-Paclitaxel: 125 mg/m2 d1, 8, during each 3-week cycle. S-1: Body surface area < 1.25 m2, 40 mg bid; Body surface area ≥ 1.25 m2 < 1.50 m2, 50 mg bid; Body surface area ≥1.5 m2, 60 mg bid, d1-14;during each 3-week cycle.
45652507|NCT05635825|Other|Observational Survey|Collection of a 4-day food record
45803175|NCT02062801|Drug|Ephedrine|Patients received additional doses of ephedrine 10mg IV to a maximum of 30mg if BP remained low (<90mmHg systolic) and/was associated with persistent fetal bradycardia or maternal symptoms of dizziness and nausea
45933115|NCT00056277|Drug|lamotrigine|
45803176|NCT02062801|Drug|Placebo|Patients received normal saline (placebo) administered immediately after combined spinal epidural (CSE) placement
45803177|NCT03152591|Drug|LIK066|LIK066 tablets for oral administration
45803178|NCT03152591|Drug|Placebo|Placebo tablets matching LIK066 tablets, for oral administration
45803179|NCT02063035|Drug|Tranexamic Acid|A single topical application of 3 grams (g) of Tranexamic acid in 100 milliliter (mL) saline.
45803180|NCT02063035|Drug|Placebo|A single topical application of matching placebo, which is 100 mL of normal saline.
45803181|NCT00375245|Drug|Rapamycin (sirolimus)|Weekly oral doses, dose is assigned at the time of study entry
45803182|NCT00375245|Other|Grapefruit Juice|Daily oral doses starting during the second week on study.
45803183|NCT05405933|Diagnostic Test|Propioceptive Neuromuscular Facilitation|Propioceptive Neuromuscular Facilitation With Conventional Therapy for Balance and Gait
45803184|NCT05405933|Diagnostic Test|Balance Exercise|Balance Exercise Along With Conventional Therapy for Balance and Gait
45803185|NCT02043379|Drug|IVIG|Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.
45803186|NCT02043379|Other|Placebo|If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.
45803187|NCT02054156|Drug|azithromycin|3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months
45933116|NCT00028574|Drug|gabapentin|
45933117|NCT00028574|Other|placebo|
45933118|NCT00056355|Drug|UVADEX and UVAR XTS Photopheresis System|
45933119|NCT00056394|Behavioral|Comprehensive Coping Skills Training|10 weekly, 80-minute coping skills treatment sessions, followed by a series of six biweekly follow-up telephone calls.
45933120|NCT00056394|Behavioral|Arthritis Education Sessions|10 weekly, 80-minute treatment sessions, followed by a series of six biweekly follow-up telephone calls. Participants will learn about the nature and treatment of rheumatoid arthritis as well as the benefits of exercise and joint protection.
46073406|NCT02843672|Procedure|Triple Weil´s Osteotomy|"A 10mm longitudinal incision is made with a No.15 blade in the second intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. An intra-articular osteotomy in the metatarsal head is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. A second osteotomy is performed perpendicular to the metatarsal shaft,.The osteotomy is fastened with a 2.0mm snap-off screw.~Once all the osteotomies are completed, the incisions are closed with a 2/0 monofilament suture."
45803188|NCT02054156|Drug|placebo|3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months
45803189|NCT02054156|Drug|Tobramycin solution for inhalation|300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
45803190|NCT03159143|Drug|Docetaxel|Docetaxel (28) is a semi-synthetic taxane which blocks mitosis by preventing microtubule depolymerization. It mediates its actions by binding to a different set of microtubule-associated proteins than paclitaxel. It is administered every 3 weeks as a 30 minute infusion at doses between 60 to 75 mg/m^2.
45803191|NCT03159143|Drug|Oxaliplatin|Alkylating antineoplastic agent. It is administered on day 1 of each cycle at a dose of 110 mg/m^2
45933121|NCT00056394|Behavioral|Standard Care|Usual care from participants' rheumatologists but no treatment sessions.
45652508|NCT04804397|Dietary Supplement|Sucrose|Sucrose sweetened soft drinks
45652509|NCT05279703|Drug|Epinephrine 0.03|epinephrine infusion rate of 0.03 mcg/kg/min
45933122|NCT00056433|Drug|Hydroxyurea|
45933123|NCT00056433|Drug|L-Arginine|
45933124|NCT00056433|Drug|Sildenafil|
45933125|NCT00028613|Radiation|iodine I 131 monoclonal antibody Lym-1|
45451785|NCT02264938|Dietary Supplement|Antioxidant|Oral supplemmentation with antioxidants
45451786|NCT02235766|Other|Echocardiographic assessment|
45652510|NCT05279703|Drug|Epinephrin 0.02|epinephrine infusion rate of 0.02 mcg/kg/min
45652511|NCT05279703|Drug|Epinephrin 0.01|epinephrine infusion rate of 0.01 mcg/kg/min
45652512|NCT05635747|Device|Relizorb Enzyme Cartridge|Tube feeds run across device to digest fats.
45933126|NCT00056511|Drug|Fresh garlic or garlic supplements|
45652514|NCT04796519|Procedure|Total knee arthroplasty|Surgical procedure
45652515|NCT03070639|Behavioral|Safe Sleep Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on the baby's sleep practices. Participant will also receive a free pack'n play, sleep sack, and educational resources on safe sleep.
45652516|NCT03070639|Behavioral|Scald Prevention Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on practices regarding scald risks in the home. Participant will also receive a bath thermometer, candy/frying thermometer, and educational resources on scald prevention.
45652517|NCT05279001|Drug|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
45803192|NCT03159299|Behavioral|Yo Puedo + mHealth|This intervention is an adapted diabetes self-management education program. Study participants will attend group classes weekly for 6 weeks, and receive daily text messages over 6 months.
45803193|NCT02376530|Behavioral|Nutrient profiling|Nutrient profiling system will be present during shopping session.
45933127|NCT02970123|Behavioral|Sit Less, Interact, Move More (SLIMM)|
45933128|NCT00028652|Biological|interleukin-12 gene|
45933129|NCT00028691|Drug|chlorambucil|
45933130|NCT00028691|Radiation|radiation therapy|
45933131|NCT00056589|Drug|catridecacog|Single doses of rFXIII administered intravenously (IV) to two subjects in each of the five dose levels (2, 6, 20, 50 and 75 U/kg).
45933132|NCT00028730|Biological|anti-thymocyte globulin|
45933133|NCT00028730|Biological|filgrastim|
45933134|NCT00028730|Drug|cyclophosphamide|
45933135|NCT00028730|Drug|fludarabine phosphate|
45803194|NCT02376530|Behavioral|Price Changes|Price changes will be present during shopping session.
45803195|NCT02376998|Device|Valiant™ endoluminal procedure|"Thoracic endovascular aortic repair with Endoluminal stent-graft placement (Valiant™ endoluminal stent-graft systems (Medtronic Inc., Santa Rosa, CA, USA) will be performed as follows:~The diameter of the stent graft will be calculated from the largest diameter of the proximal/distal neck with an oversizing factor of 10-20%. The procedures will be done with local or general anaesthesia in case of unstable pre-operative hemodynamic conditions.~After the procedure will be completed, a digital subtraction angiography and echocardiography with color-flow mapping were performed to verify the correct positioning of the stent and to detect any primary endoleak."
45933136|NCT00028730|Drug|thiotepa|
45652518|NCT04804475|Other|Exercise Trainig|SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
45803196|NCT03161327|Device|ABI using QuantaFlo™|"Perform Digital ABI:~Will be performed by the nurse/medical assistant with training to perform this test~The patient will be placed in the supine position, with the arms and legs at the same level as the heart, for a minimum of 5 minutes before measurement.~The optical sensor (similar to a pulse oximeter) will be placed sequentially in the fingers of the hands and feet: Right and left hand fingers and then right and left feet toes.~Usually each digit takes about 15 seconds to obtain a waveform~At the end of 60 seconds, an automated digital ABI will be generated.~Clinical course: If based on Screening questionnaire and digital ABI, I. Patient is diagnosed with PAD- the referring physician and patient will receive a phone call about the same. He/ she will then be advised any further testing/ referral to IR clinic.~II. There is no evidence of PAD- no further action will be taken. The patient will be informed of the same."
45803197|NCT02377700|Device|Xeltis Vascular Patch, Model COR-VP-001|The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis
46073407|NCT02843672|Procedure|Distal metatarsal minimally invasive osteotomy|A 5mm longitudinal incision is made with a MIS blade No.64 in the intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. Under fluoroscopy vision, an extra-articular osteotomy in the metatarsal neck is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. The osteotomies scheduled preoperatively are performed, repeating the same procedure for each ray needing an osteotomy. Once all are completed, the incisions are closed with a 4/0 monofilament suture.
46073408|NCT04242966|Other|Usual Care|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI >30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
46073409|NCT04242966|Other|Higher Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI >30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
45803198|NCT03028753|Device|Bladder scan post void residual|After voiding on the commode, all subjects will have a post void residual measured by bladder scanner
45803199|NCT03028753|Procedure|Straight catheter post void residual|After voiding on the commode and having a post void residual measured by bladder scanner, all subjects will have a post void residual measured by straight catheter performed with usual sterile technique.
45803200|NCT03028753|Procedure|Back fill voiding trial|Prior to catheter removal, all subjects will undergo a back fill voiding trial. The bag of the foley catheter will be removed and the subjects bladder will be filled with 300cc of normal saline (or as much as they can tolerate). The foley catheter will then be removed and the subject will be asked to void on the commode. The voided volume will be measured.
45803201|NCT03068897|Drug|Metaxalone|Metaxalone 400-800mg
45451787|NCT02542384|Drug|CR845 IV 1 mcg/kg|"CR845 IV 1 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed. Saline infusion (IV 0.45%) for fluid replenishment will be provided."
45803202|NCT03068897|Drug|Tizanidine|Tizanidine 2-4mg
45803203|NCT03068897|Drug|Baclofen|Baclofen 10-20mg
45803204|NCT03068897|Drug|Ibuprofen 600 mg|Ibuprofen
45803205|NCT03068897|Behavioral|Educational intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.
45803206|NCT05718986|Other|No intervention|No intervention
45933137|NCT00028730|Procedure|allogeneic bone marrow transplantation|
45933138|NCT00028730|Radiation|radiation therapy|
45933139|NCT00056628|Device|The COGNIShunt® System|
45933140|NCT00028847|Drug|cytarabine|
46073410|NCT04242966|Other|Ultrasound measure|Patients will undergo the ultrasound measures at baseline (within 24 hours of randomization, day 10 days post randomization (if still in hospital) and just prior to hospital discharge. In the event that hospital discharge is prior to day 10, the day 10 measure will not be done.
46073411|NCT00832663|Drug|NSAID|Effect of NSAID ingestion on muscle regeneration
46073412|NCT00832663|Drug|placebo|receive placebo
45933141|NCT00028847|Drug|imatinib mesylate|
45933142|NCT00056667|Behavioral|Relaxation response and cognitive behavioral therapy|The cognitive behavioral therapy program wwill incorporate relaxation training, a modified version of the RA treatment program developed by Bradley et al (1987) and shown to be effective. The cognitive behavioral techniques include problem solving, relabeling, enhanced awareness of pain behaviors, and attention refocusing. The RR component includes instruction in diaphragmatic breathing along with progressive skeletal muscle relaxation. The intervention will be modified from the original program in that neither biofeedback training nor participation of family members will be included. Consequently, the number of weekly group sessions will be reduced from 14 to 12. Homework will be given at the end of each session, to be completed and brought in for review to the next session.
45803207|NCT02049476|Drug|Dexamethasone pellet|"Dexamethasone pellet placement occurs within 14 days of baseline examination; for patients with bilaterally active uveitis, placement of a dexamethasone pellet in the second eye should occur within 14 days of the first implantation or within 30 day of the baseline examination.~Repeated placement is permitted every 3 months based on the best clinical judgment of the doctor and the study protocol."
45933143|NCT00056667|Behavioral|Relaxation response|The relaxation response (RR) consists of a set of integrated physiological changes elicited when a participant engages in the repetitive mental action of focusing on a word, phrase, or image, while passively ignoring distracting thoughts. These changes include decreased oxygen consumption, heart rate, arterial blood pressure, respiratory rate, and arterial blood lactate, along with slight increases in skeletal muscle blood flow. The long-term physiologic changes of participants eliciting the relaxation response are consistent with reduced norepinephrine end organ responsivity. These latter changes provide a plausible psychophysiological mechanism for longer-term actions of the RR.
45933144|NCT00056667|Other|RA education|RA education programs have been widely used to supplement routine medical care. They have been found to be of modest benefit, particularly in terms of knowledge about the condition and its treatment. The long-term effects on pain and level of function are less. When used as an attention control, such educational programs have been found to be as credible and as well attended as the active experimental treatment (Professor Francis Keefe, Personal Communication). In this study, patients randomized to the control condition will receive 8 weekly sessions of RA education, in groups of 6-10 patients each, using portions of the Arthritis Self-Management Program and incorporating printed and videotaped materials available from the Arthritis Foundation.
45933145|NCT00028886|Biological|filgrastim|
45451788|NCT02542384|Drug|CR845 IV 0.5 mcg/kg|"CR845 IV 0.5 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.~Saline infusion (IV 0.45%) for fluid replenishment will be provided."
45451789|NCT02542384|Drug|Placebo IV|"Placebo IV will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.~Saline infusion (IV 0.45%) for fluid replenishment will be provided."
45933146|NCT00028886|Biological|recombinant interferon alfa|
45451790|NCT02511886|Drug|Arbaclofen Placarbil|Arbaclofen Placarbil
45803208|NCT02299297|Drug|Tofacitinib|Dosage/Frequency: 5mg - 10mg, oral, twice daily
45803209|NCT02055404|Device|Delefilcon A spherical contact lens with molded marks|Silicone hydrogel contact lens with 9 different molded marks of varying widths and depths indented into the front surface (S1, S2, S3, S4, S5, S6, S7, S8, and S9). Each lens contained all 9 marks.
45803210|NCT02055404|Device|Etafilcon A toric contact lens|Hydrogel toric contact lens for daily wear, daily disposable use
45652519|NCT05235399|Other|Echo scans|Echo heart scan will be performed on the participating preterm infants on the 5th and 9th day of postnatal life.
45933147|NCT00028886|Drug|cyclophosphamide|
46073413|NCT05333900|Behavioral|Plant-Based Diet|Dietary intervention will consist of following diets high in sulfur- containing amino acids (SAAs) and low in SAAs for 7 days each, with a 14-day washout period between interventions
45803211|NCT03069677|Other|music|patients in this group will receive research-selected music after the golden moment has been completed between the patient, provider, and nursing staff
46073414|NCT04043689|Device|tACS (transcranial Alternate Current Stimulation)|"This is a single-centric comparative randomized controlled blind and cross-over study.~The order of stimulation conditions will be randomized: (right frontal tACS / occipital tACS / tACS PLACEBO). The 3 stimulation conditions will be performed with a wash-out period of at least 1 week. In this study each patient will be his own control"
45803212|NCT03069677|Drug|Midazolam|patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
45451791|NCT02511886|Drug|Placebo|Placebo matched tablets
45803213|NCT03820063|Drug|PTC-Pz|"Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8~Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1~Carboplatin AUC 6mg•ml/min administered intravenously on day 1~Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)~Treatment cycles are repeated on day 22~In case of non pCR; Adjuvant T-DM1, 3.6mg/kg Q 22 days, for 14 cycles."
45803214|NCT02055638|Drug|SRX246|capsules
45652520|NCT04808375|Other||
45803215|NCT02055638|Drug|Placebo|
45933148|NCT00028886|Drug|dexamethasone|
45451792|NCT04235140|Drug|LUM/IVA|LUM/IVA granules for oral administration
45451793|NCT02235844|Biological|Umbilical Cord Mesenchymal Stem Cells|
45652521|NCT04808063|Procedure|Prophylactic mesh implantation|Use of an algorithm for prophylactic mesh implantation in high risk patients after emergency midline laparotomy.
45652522|NCT03070561|Biological|sublingual film with peanut extract|
45933149|NCT00028886|Drug|doxorubicin hydrochloride|
45652523|NCT05514951|Diagnostic Test|Blood sampling|Blood sampling
45652524|NCT04796441|Biological|CAR-γδT|Biological: CAR-γδT; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
45933150|NCT00028886|Drug|melphalan|
45933151|NCT00028886|Drug|thalidomide|
46073415|NCT04250324|Biological|BZ019|A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).
45652525|NCT04988737|Other|Electronic Clinical Decision Support Application|Robust, real-time medication-related clinical decision support application for use in the operating room. The application is fully integrated with existing clinical systems. It provides visual alerts for medication errors and adverse medication events at the point-of-care.
46073416|NCT00839293|Drug|ABT-335|Once, see arm description for more information
45451794|NCT00043979|Drug|F-18 Fluorodeoxyglucose|
45451795|NCT00043979|Biological|therapeutic allogeneic lymphocytes|Lymphocyte cells are collected from a healthy donor by apheresis and infused into the patient with a central venous catheter.
46073417|NCT04201730|Procedure|Enhanced Recovery After Surgery （ERAS）|Preoperative education，Preoperative nutritional support，Preoperative bowel preparation，Preventative applying of antibiotics，Intraoperative warming，Goal-directed fluid therapy，Postoperative analgesia，Postoperative diet, drainage and activity management，Prevention of deep vein thrombosis.
46073418|NCT05660382|Drug|Miconazole (2%) oil and mineral oil|Twice daily application, for 14 days.
45652526|NCT05278845|Drug|SLC-391|SLC-391 is an AXL inhibitor
45652527|NCT05392933|Diagnostic Test|Ultrasound guided piriformis muscle lidocaine injection|Ultrasound guided piriformis muscle (piriformis syndrome) 5 ml %2 lidocaine injection
45652528|NCT04796675|Drug|Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
45451796|NCT00043979|Drug|cyclophosphamide|"Induction - 750 mg/m^2 intravenous (IV) infusion over 30 minutes x 1 dose. Day 5.~Transplant - 1200 mg/m^2 per day IV infusion over 2 hours daily for 4 days; days -6, -5, -4, -3."
45451797|NCT00043979|Drug|cyclosporine|6 mg/kg per dose orally every other day (no day 9 dose).
45652529|NCT05234463|Other|IgAN patients|Adult patients Histologically proven diagnosis of IgA nephropathy Primary and secondary forms of the disease With or without kidney transplantation history Regardless of kidney/graft function Patients followed in the Nephrology Department of Strasbourg University Hospital.
45652530|NCT05635357|Drug|Anastrozole|Anastrozole claim is used as the exposure group.
45652531|NCT05635357|Drug|Exemestane/Letrozole|Exemestane/Letrozole claim is used as the reference group.
45652532|NCT04954677|Other|AI-box|Automatic quality-control system（AI-box）could real-time measure endoscopic inspection completeness, evaluate gastric cleanliness.
45803216|NCT03072953|Drug|APD334|APD334 active treatment
45803217|NCT02044393|Drug|itraconazole|multiple doses of itraconazole given as capsules
46073419|NCT05660382|Other|Placebo|Twice daily application, for 14 days
46073420|NCT00845377|Behavioral|Comprehensive psychosocial support for depressed elderly|The model includes a psychiatric nurse as a care manager, a multiprofessional team with a physiotherapist, psychologist and psychiatrist. Each participant receives individually tailored services such as therapeutic groups, conversation groups, physical exercise, music therapy, art therapy and nutritional counseling
45652533|NCT05233839|Other|Telerehabilitation|Application based video home exercise for the degenerative meniscus injury
45652534|NCT05233839|Other|Paper Based Rehabilitation|Paper instruction based home exercise for the degenerative meniscus injury
45803218|NCT02044393|Drug|BI 691751|single dose BI 691751 given as tablet
45803219|NCT02044393|Drug|BI 691751|single dose BI 691751 given as tablet
45803220|NCT05405465|Drug|Exposure to golimumab|Retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.
45803221|NCT02378402|Other|Proton (1H-) magnetic resonance (MR) spectroscopy|PRESS localized 1D MRS sequence was used on a 3-T MR system. The lipid resonances will be analyzed using the LC-Model algorithm, and a Cramer-Rao lower bound (CRLB) threshold of 50% was used as quality control. Resonances of fatty acid (FA, lipid resonances δ 0.9, 1.3 and 1.6 ppm) and polyunsaturated fatty acid (PUFA, lipid resonance δ 2.1 and 2.3, 2.8, 5.3 ppm) will be evaluated on MRS, with ratios normalized with total TG value.
45803222|NCT00374933|Drug|Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
45803223|NCT00374933|Drug|"Prophylactic delayed ADLI"|"Prophylactic ADLI after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
45803224|NCT00374933|Drug|"Prophylactic delayed activated donor lymphocyte infusion"|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
45803225|NCT02046265|Behavioral|Step Up to Prevention|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
45803226|NCT02046265|Behavioral|Step Up to Prevention: knowledge|Participant receives an individual computer-delivered information session and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
45803227|NCT02046265|Behavioral|Step Up to Prevention:belief|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
45933152|NCT00028886|Drug|vincristine sulfate|
45933153|NCT00028886|Procedure|bone marrow ablation with stem cell support|
45933154|NCT00028886|Procedure|peripheral blood stem cell transplantation|
45933155|NCT00056706|Procedure|Transient deafferentation|
45933156|NCT00028925|Biological|filgrastim|
45933157|NCT00028925|Drug|carboplatin|
45933158|NCT00028925|Drug|topotecan hydrochloride|
45933159|NCT00028925|Radiation|WBRT|
45933160|NCT00398463|Drug|Tirofiban|Tirofiban infusion given as high bolus dose plus standard 14-24 hour infusion
45933161|NCT00398463|Drug|Placebo|Saline infusion will be administered for 14-24 hours
45803228|NCT02046265|Behavioral|Offered HPV vaccine only|Participant is offered the HPV vaccine only by their nurse practitioner in clinic.
45803229|NCT02064907|Drug|Dexlansoprazole Delayed Release Orally Disintegrating Tablets|Dexlansoprazole delayed-release, orally disintegrating (OD) tablets
45652535|NCT05233761|Drug|Defined CBD|300 mg CBD and 8 mg Terpenes administered as two small capsules.
45933162|NCT00028964|Dietary Supplement|Chinese herbs|
45803230|NCT02064907|Drug|Dexlansoprazole Delayed Release Capsules|Dexlansoprazole delayed-release capsules
45652536|NCT05233761|Drug|Placebo|Capsules that smell and look exactly like Defined CBD but contain no CBD or terpenes.
45933163|NCT00028964|Drug|cyclophosphamide|
45933164|NCT00028964|Drug|doxorubicin hydrochloride|
45933165|NCT00028964|Procedure|adjuvant therapy|
45803231|NCT03165617|Biological|QIVc|Cell-derived Quadrivalent Influenza Vaccine for intramuscular use containing each of the 2 influenza type A strains and each of the 2 influenza type B strains
45933166|NCT00423501|Drug|Placebo|sc weekly
45933167|NCT00423501|Drug|taspoglutide|20mg sc weekly
45803232|NCT03165617|Biological|Non-influenza Comparator Vaccine|Non-influenza comparator vaccine for intramuscular use
45803233|NCT02064985|Drug|"Inhibition of Platelet Aggregation by Brilinta(Ticagrelor)"|To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
45803234|NCT00375089|Other|Group 1|Individuals with Prader-Willi syndrome. Monitoring every 6 months.
45803235|NCT00375089|Other|Group 2|Individuals with Early-onset Morbid Obesity.
45652537|NCT04803929|Biological|anti-ILT3 CAR-T|Autologous T cells genetically modified with anti-ILT3 CAR
45652538|NCT05232045|Drug|Automated urinary output collection system group (tight monitoring of urine output)|Automated urinary output collection system group (tight monitoring of urine output)
45652539|NCT04796207|Dietary Supplement|Fish Oil (DPA+EPA 2:1 ratio) Capsules|The Treatment Arm intervention consists of providing participants with 3 grams of DHA and EPA (2:1 weight ratio) in capsular form. In order to meet the required 3 grams of DHA and EPA, participants were given 6 capsules to be taken with meals (preferably breakfast, although capsules were provided at lunch when they couldn't be provided at breakfast). Capsules were given 3 times a week during the regular football season.
45652540|NCT04796207|Dietary Supplement|High Oleic Safflower Oil Capsules|"The Placebo Arm intervention consists of providing participants with 3 grams of high-oleic safflower oil in a 1:1 allocation ratio in capsular form. In order to maintain the study masking, participants in the Placebo Arm were given 6 capsules (the same as the Treatment Arm) to be taken with meals (preferably breakfast, although capsules were provided at lunch when they couldn't be provided at breakfast). Capsules were given 3 times a week during the regular football season."
45933168|NCT00423501|Drug|taspoglutide|10mg sc every 2 weeks
45933169|NCT00423501|Drug|taspoglutide|5mg sc weekly
45933170|NCT00423501|Drug|taspoglutide|10mg sc weekly
45933171|NCT00423501|Drug|taspoglutide|20mg sc every 2 weeks
45933172|NCT00029003|Drug|gefitinib|Given orally
45933173|NCT00029003|Other|laboratory biomarker analysis|Correlative studies
45933174|NCT00029042|Drug|Infliximab|
45933175|NCT00423540|Drug|Intravenous Infusion of Magnesium Sulfate|See Detailed Description.
45933176|NCT00029159|Drug|estrogen|Participants were started on ethinyl estradiol at a daily dose of 50ng/kg at the beginning of the 3rd year of the study. The estrogen was continued until study end.
45652541|NCT05317923|Other|Flow Controlled Ventilation|Anesthesia management in patients with subglottic tracheal stenosis with flow-controlled ventilation using an intubation tube with an inner diameter of less than 3 mm
45803236|NCT05396027|Other|Audio-guided deep breathing|2 weeks of audio-guided deep breathing for participants (healthy and physically disabled)
45933177|NCT00029159|Drug|androgen|Oxandrolone or placebo capsule, .06mg/kg/day, orally, for 2 years
45933178|NCT00029159|Other|placebo|an inactive substance
45933179|NCT00423618|Radiation|radiotherapy|radiotherapy as adjuvant treatment for adults with soft tissue sarcoma extremities
45933180|NCT00029198|Procedure|massage|15 massage given tid
45451798|NCT00043979|Drug|doxorubicin hydrochloride|Induction - 10 mg/m^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
45933181|NCT00029198|Procedure|Sham massage|non-massage touch
45933182|NCT00029237|Behavioral|Cognitive-behavioral relaxation (Positively Living)|
45933183|NCT00029237|Behavioral|Spiritual growth group|
45933184|NCT00029237|Behavioral|Focused Tai Chi|
45933185|NCT00423696|Biological|bevacizumab|
45933186|NCT00423696|Drug|capecitabine|
45933187|NCT00423696|Drug|fluorouracil|
45933188|NCT00423696|Drug|irinotecan hydrochloride|
45933189|NCT00423696|Drug|leucovorin calcium|
45933190|NCT00029276|Procedure|Prefrontal transcranial magnetic brain stimulation|
45933191|NCT02969889|Device|Airtraq|video laryngoscope with a channel
45933192|NCT02969889|Device|ILMA|
45933193|NCT00029315|Drug|Recombinant Tissue Plasminogen Activator (rt-PA)|
45933194|NCT00056745|Biological|TBC-3B|
45933195|NCT00029393|Procedure|Hematopoietic Stem Cell Transplantation|
45933196|NCT00029393|Drug|Immunosuppression|
45933197|NCT00029510|Drug|Magnesium|
45933198|NCT00056823|Drug|rhuFab V2 (ranibizumab)|
45933199|NCT00029627|Drug|Yohimbine|
45933200|NCT02970084|Other|Nutraceutical product based on vitamin K2 (PLAK2)|
45933201|NCT00029666|Device|Neopulse Magnetic Stimulator|
45933202|NCT04730778|Diagnostic Test|serum creatinine and estimated glomerular filtration rate, on daily basis|Assess establishing criteria of CIN through a week after primary PCI
45933203|NCT00029783|Procedure|Distant Healing|
45933204|NCT00056940|Behavioral|Stages of Change|
45933205|NCT00056940|Behavioral|Safety Check approach|
45933206|NCT00056979|Drug|CAMPATH-1H|
45933207|NCT00056979|Drug|Anti-CD45|
45933208|NCT00056979|Drug|FK506|
45933209|NCT00056979|Drug|Fludarabine|
45933210|NCT00029822|Drug|Alfuzosin (SL770499)|
45652542|NCT04786925|Other|Control diet|Control diet: A Mediterranean conventional diet based on the current dietary guidelines of the Spanish Society of Community Nutrition (SENC). Participants were strongly advised to use the Healthy Eating Plate (Harvard) to structure and prepare the main meals (lunch and dinner). In this way, at least ½ of the plate should be composed of vegetables, ¼ of lean protein, and ¼ of low glycemic index carbohydrates. The diet encourages participants to eat 5 times/day (breakfast, lunch, dinner, and two snacks). Overall, the control diet was based on high consumption of vegetables and fruits, whole grains, healthy fats (olive oil), and healthy proteins (legumes, fish, and lean meat). There was not energy restriction in the control diet.
45803237|NCT02065453|Device|disposable device (Ligasure, Covidien)|"One side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien). . We will randomize the side for each energy source used on each side for every case. The number of sides performed by the attending surgeon will equal that of the less experienced resident surgeon."
45803238|NCT02065453|Device|Reusable device|One side of the uterine attachments would be transected using the reusable Robi bipolar and Storz laparoscopic
45803239|NCT03077165|Drug|S42909 100 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
45803240|NCT03077165|Drug|S42909 200 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
45803241|NCT03077165|Drug|S42909 400 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
45451799|NCT00043979|Drug|etoposide|50 mg/m^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
45652543|NCT04786925|Other|Nutriprecision diet|Nutriprecision diet: a Mediterranean balanced diet based on the inclusion of precision foods designed according to the particularities of the senior population. The selected precision foods were a) fruit compote, b) smoothie, c) extruded meat product, d) wholemeal bread, e) wholemeal biscuit and f) microwaveable deep-frozen vegetable products. The diet encourages participants to eat 5 times/day with a conventionally balanced distribution of macronutrients (50% of the total caloric value from carbohydrates, 20% from proteins, and 30% from lipids). There was not energy restriction, although the energy requirements of the participants were adjusted to a BMI of 25 kg/m2 to avoid an overestimate of calorie intake. A mobile application designed and developed to provide volunteers with information about follow-up visits, the assigned diet, recommendations, and messages to motivate them during the intervention. A digital tool for cognitive stimulation.
45803242|NCT03077165|Drug|S42909 800 mg|200 mg Film-coated tablets per os administration,twice a day taken at the end of the morning and at evening meals.
45803243|NCT03077165|Drug|S42909 1200 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
45803244|NCT03077165|Drug|Placebo Oral Tablet|Matching placebo tablets, per os administration, twice a day taken at the end of the morning and at evening meals.
45803245|NCT03170219|Combination Product|subcutaneous furosemide and sc2wear device|subcutaneous furosemide administered via sc2wear device vs. standard of care
45803246|NCT05380583|Behavioral|CRAFT-EP|CRAFT-EP is a behavioral intervention delivered via telehealth with the option for one in-person session (when local guidelines allow in-person care without masks). The coaching session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, problem solving, and planning next steps. The intervention is designed for families of individuals experiencing psychosis and substance use who are enrolled or seeking enrollment in early psychosis outpatient services. Participants will be asked to complete assessments at pre-, mid- (approximately week 4), post-intervention, and a follow-up assessment approximately 12 weeks post-intervention.
45803247|NCT05380583|Behavioral|TAU|Participants may continue to receive their ongoing treatment, if any, which may include psychosocial and/or pharmacological interventions.
45933211|NCT00057018|Procedure|Constraint-induced movement therapy|
45933212|NCT00395681|Drug|Diprivan|Propofol 200 mg versus 350 mg
45933213|NCT00057057|Behavioral|Telephone Care|
45933214|NCT00395720|Biological|MVA85A (TB vaccine)|Intradermal vaccine
45933215|NCT00395720|Biological|MVA 85A|Intradermal vaccine
45933216|NCT00057096|Procedure|On-site vs. referral methods of care|
45803248|NCT00375557|Drug|Divalproex ER|Divalproex ER will be initiated on 250 mg/day, dosed once daily. The daily dose of Divalproex ER will be titrated up 250 mg each day based on patients' response and tolerability, not to exceed a maximum of 2000 mg/day.
45803249|NCT00375557|Drug|Quetiapine|Quetiapine will be initiated in 25 mg/day, with a variable dosing frequency (QD-TID). The daily dose of Quetiapine will be titrated up by 25-50 mg each day based on patients' response and tolerability, not to exceed a maximum of 750 mg/day.
45803250|NCT03177395|Drug|PP100-01 (calmangafodipir)|PP100-01
45803251|NCT03177395|Drug|Acetylcysteine|NAC
45652544|NCT05230875|Behavioral|self-administered questionnaire|"All patients participating in the therapeutic education program will complete a self-administered questionnaire before participation in educational program.~A new identical self-questionnaire will be distributed to patients 3 to 6 months after their participation in the therapeutic education program."
45803252|NCT03078647|Device|Profound|The main intent of the Profound Dermal and Subdermal cartridges for cellulite treatment is to utilize a minimally-invasive approach to directly deliver radiofrequency (RF) energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
45803253|NCT05282069|Drug|DA-8010 Placebo|Participants receive placebo to match DA-8010 orally once a day.
45652545|NCT05276037|Other|Liver transplantation|Both groups will receive the same advantages on the LT waiting list (SE points)
45652546|NCT05275725|Drug|Sildenafil|Dose group 1st dose 2nd dose 3rd dose 4-14th doses Treatment Total dose/day frequency dose/day Group 1: #1-14=2 mg/kg q12h (4 mg/kg/day) Group 2: #1 = 2 mg/kg, #2-14 = 2.5 mg/kg q12h (5 mg/kg/day) Group 3: #1 = 2 mg/kg, #2 = 2.5 mg/kg, #3-14 = 3 mg/kg q12h (6 mg/kg/day) Group 4: #1 = 2.5 mg/kg, #2-14 = 3 mg/kg q12h (6 mg/kg/day) Group 5: #1-14 = 3 mg/kg q12h (6 mg/kg/day)
45803254|NCT05282069|Drug|DA-8010 2.5mg|Participants receive DA-8010 2.5mg orally once a day.
45803255|NCT05282069|Drug|DA-8010 5mg|Participants receive DA-8010 5mg orally once a day.
45803256|NCT05282069|Drug|Solifenacin 5mg|Participants receive solifenacin 5 mg orally once a day.
45803257|NCT05282069|Drug|Solifenacin succinate placebo|Participants receive placebo to match solifenacin 5 mg orally once a day.
45803258|NCT03083093|Diagnostic Test|The initial CTPA will be reviewed|The initial CTPA will be reviewed
45803259|NCT00375323|Drug|NovoSeven|
45803260|NCT05159999|Other|Dry weight target adjustment|Target dry weight will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target.
45803261|NCT05159999|Drug|Anti-hypertensive medications|Anti-hypertensive medications will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target. Adjustment of currently prescribed anti-hypertensive medications will be prioritized before starting new medications. Only standard anti-hypertensive medications will be used, such as RAAS inhibitors, beta-blockers, calcium channel blockers and diuretics.
45803262|NCT03179345|Drug|Gabapentin|
45803263|NCT03179345|Drug|Pregabalin|
45803264|NCT03179345|Other|Placebo|
45803265|NCT03180515|Device|Activa PC+S Neurostimulator|Activa PC+S Neurostimulator is approved for both aDBS and cDBS paradigms.
45803266|NCT03086213|Drug|Propofol|anaesthetic
45803267|NCT03086213|Drug|Sulfentanyl|anaesthetic
45803268|NCT03086213|Drug|Dexmedetomidine|anaesthetic
45803269|NCT03086213|Drug|Lidocaine|local anaesthetics
45803270|NCT03086213|Drug|Ropivacaine|local anaesthetics
45803271|NCT04737083|Genetic|CGH array|a CGH array is systematically offer to women when the fetus show bilateral clubfoot during prenatal ultrasound screening
45803272|NCT03089879|Biological|GVGH Shigella sonnei 1790GAHB vaccine|Single dose administered at Day 1, by intramuscular injection.
45803273|NCT05141513|Radiation|High Dose Rate Brachytherapy (HDR) Intraoperative Radiation Therapy (IORT)|After the patient receives standard of care treatment, they will receive a single dose of radiation (15 Gy) at the time the tumor is surgically removed. Surgeons will then place clips along the blood vessels around the surgical area. These clips will be used to confirm (after surgery) that the expected dose of radiation was received during surgery.
45803274|NCT02378714|Drug|Varenicline|Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.
45933217|NCT00395759|Drug|Optiva artificial tear by Allergan|
45933218|NCT00395798|Device|Soft or stiff cervical collar(device), neck school(behavior)|
45933219|NCT00057135|Behavioral|Unit of use medication packaging|
45933220|NCT00057135|Behavioral|Mailed reminders to patient when medication refills are due|
45933221|NCT00057135|Behavioral|Note to Mental Health Provider when refill is overdue|
45933222|NCT00057135|Procedure|Aligning all prescriptions to fall due on same date|
45933223|NCT00395837|Behavioral|Aerobic exercise|
45933224|NCT00057174|Drug|Disease management of gastroesophageal reflux disease|
45652547|NCT04803617|Other|Assessment of pulmonary function and pectoralis muscle strength|In both groups, forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and FEV1 / FVC ratio were measured with portable spirometer according to the guidelines of the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Maximal inspiratory (MIP) and expiratory pressure (MEP) were evaluated with mouth pressure device as per ATS/ERS guidelines. Sensation of dyspnea was assessed with Modified medical council research scale. Pectoralis muscle strength were measured isometrically using with digital hand held dynamometer.
45803275|NCT02378714|Behavioral|BASC|"The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.~Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions."
45803276|NCT02378714|Behavioral|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.
45803277|NCT03091361|Other|imaging, no intervention|no intervention
45652548|NCT05229939|Other|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
45803278|NCT05091047|Device|Erchonia EVRL|42 procedure administrations with the Erchonia® EVRL™ administered by the subject at home: Twice daily procedure administrations for 3 weeks.
45803279|NCT05718674|Procedure|Extracorporeal Photopheresis|ECP is performed by collecting leucocytes from the patient through leukopheresis and incubating them with 8-MOP and UVA in extracorporeal circulation. The treatment steps are the collection of leucocytes, photoactivation and subsequent reinfusion of the treated cells.
45803280|NCT03091673|Drug|Glucagon|0.5 or 1.0 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
45933225|NCT00395915|Drug|aripiprazole|
45933226|NCT00057213|Drug|Radafaxine|
45933227|NCT00029861|Drug|Rimonabant (SR141716)|
45803281|NCT03091751|Drug|BeneFIX|BeneFIX is a recombinant FIX that contains nonacog alfa, reconstituted in solvent and administered as a single dose of 65-75 IU/kg.
45652549|NCT05275413|Behavioral|family-based mHealth Intervention|The intervention consists of three versions: mother, father, and grandparent. The app consists of health information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos. Each versions have their unique features, such as a platform to ask questions in mother version, a quiz game to promote fathers' knowledge related to father's involvement, educational materials tailored for grandparents. An obstetrician and a social worker will respond to the questions. Details please refer to the proposal.
45803282|NCT02381288|Drug|TAK-448|TAK-448 solution for subcutaneous injection
45803283|NCT02381288|Drug|TAK-448 Placebo|TAK-448 placebo-matching solution for subcutaneous injection
45803284|NCT05364359|Dietary Supplement|Taste-test|Patients will receive a dietary counseling based on a simple taste-test
45803285|NCT05364359|Other|Standard care|Patients will receive a dietary counseling based on a standard dietary counseling for the patient group
45803286|NCT05364281|Other|Intracuff pressure measurement|The intracuff pressures were measured and noted after each position (neck extension and placement of mouth gag), at every 5th minute while the operation and before the extubating.
45803287|NCT02381678|Device|Perimount 2900/6900 Heart Valve|This is a retrospective study which ask the subjects implanted with Perimount Heart Valve during 2001 to 2007 back hospital for follow up visit.
45803288|NCT05363969|Device|Fractionated laser resurfacing|Patients will receive 3-4 treatments with fractionated laser resurfacing
45933228|NCT00029900|Drug|ADI PEG|
45933229|NCT00057291|Behavioral|Responsive caregiving|Responsive caregiving consisted of operational circumstances and training of caregivers.
45933230|NCT00057369|Drug|dalbavancin|
45933231|NCT00057408|Drug|olanzapine (Zyprexa)|Olanzapine tablets given po at a dosage of 2.5 - 20 mg per day for up to 12 weeks.
45933232|NCT00057408|Drug|Placebo|Matching Placebo
45933233|NCT00030056|Drug|GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)|
45933234|NCT00057447|Drug|Interferon Gamma-1b|100 or 200 mcg, SQ, 3x per week
45933235|NCT00057447|Drug|Rituximab|375 mg per square meters, IV, 1x per week
45933236|NCT00030095|Drug|2-methoxyestradiol|
45933237|NCT00057486|Drug|IL-12|
45933238|NCT02969616|Biological|Trinity Elite|cell based allograft
45933239|NCT00030173|Drug|Epothilone D (KOS-862)|
45933240|NCT00057525|Biological|Anthrax|Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
45933241|NCT00057525|Biological|Alhdryogel or PBS|Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
45933242|NCT00057564|Drug|A (Thalidomide + Dexamethasone)|Thalidomide 50mg/day + Dexamethasone 40mg
45933243|NCT00057564|Drug|B (Placebo + Dexamethasone)|Placebo + Dexamethasone 40mg
45652550|NCT05275413|Behavioral|mother-only mHealth Intervention|The expectant mothers in this group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app. The expectant mothers will also have access to a platform in the smartphone app to ask questions about their pregnancy. An obstetrician will respond to the questions.
45803289|NCT05363891|Drug|Natrunix|Natrunix is a unique kind of drug-an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor. Natrunix blocks inflammation in a unique way-it is the only therapeutic that exclusively neutralizes interleukin-1α (IL-1α), a crucial mediator of interleukin-1 inflammation. Targeting IL-1α directly using a natural human monoclonal antibody may provide a safer and more effective means of blocking interleukin-1 in rheumatoid arthritis.
45652551|NCT05275413|Other|Health education|The expectant mothers in the control group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app.
45933244|NCT00030290|Procedure|high-intensity focused ultrasound ablation|
45933245|NCT00030368|Drug|bortezomib|Given IV
45933246|NCT00030368|Drug|paclitaxel|Given IV
45933247|NCT00030368|Other|laboratory biomarker analysis|Correlative studies
45933248|NCT00057603|Procedure|Deep Brain Stimulation|Deep brain stimulation sends electrical signals to specific parts of the brain, which block the impulses that cause neurological dysfunction.
45652552|NCT04795349|Procedure|Vacuum-assisted breast biopsy|In those patients with a radiological complete response by all the radiological imaging methods, a stereotactic biopsy will be performed before surgery. After that, a comparison will be done between the results of the pre surgical biopsy and the definitive pathology of the specimen.
45933249|NCT00030407|Drug|Celecoxib|On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals
45933250|NCT00030407|Drug|Docetaxel|On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days.
45451800|NCT00043979|Drug|fludarabine phosphate|"Induction - 25 mg/m^2 per day intravenous (IV) infusion over 30 minutes daily for 3 days. Days 1, 2, 3.~Transplant - 30 mg/m^2 per day IV infusion over 30 minutes daily for 4 days; days -6, -5, -4, -3."
45451801|NCT00043979|Drug|melphalan|Transplant - 100 mg/m^2 per day intravenous (IV) infusion over 15 minutes for 1 day; day -2.
45652553|NCT04786535|Procedure|Expanded Hemodialysis|"Single-use Theranova 400 Dialyzer~Blood flow (Qb) minimum of 300 mL/min~Dialysis flow (Qd) 500 mL/min~Minimum therapy time of 4 hours~Ultrafiltration necessary to achieve dry weight"
45652554|NCT04786535|Procedure|High-flux Conventional Hemodialysis|"Single-use high-flux hemodialyzer~Blood flow (Qb) minimum of 300 mL/min~Dialysis flow (Qd) 500 mL/min~Minimum therapy time of 4 hours~Ultrafiltration necessary to achieve dry weight"
45652555|NCT04786535|Procedure|Hemodiafiltration|"Single-use high-flux hemodialyzer~Post-dilution mode~Minimum convective volume of 23 L~Blood flow (Qb) minimum of 300 mL/min~Dialysis flow (Qd) 700 mL/min~Minimum therapy time of 4 hours~Ultrafiltration necessary to achieve dry weight"
45652556|NCT05272917|Other|Sensorial tests|Patients will be included in the study between 3 to 6 months after the end of treatment and go to the Paul Bocuse Research Institute to perform several sensorial tests. The same sensorial tests will be completed by healthy volunteers to compare.
45803290|NCT05363891|Drug|Placebo|Placebo
45803291|NCT05363735|Other|Ultrasound Elastography|Patients will be examined by ultrasound elastography.
45803292|NCT00355316|Other|Blood draw|
45933251|NCT00057642|Drug|Sertraline|
45933252|NCT00057642|Drug|Venlafaxine Extended Release|
45933253|NCT02969694|Other|G-STAT questionnaire|"Patients will have a consultation with an addiction specialist physician. During the consultation, the physician ask the patient about these sexual practice and the use of psychostimulants. The patient will answer to the G-STAT questionnaire. This questionnaire allows the physician to perform an initial assessment of the patient's sexual addiction.~The entire consultation takes place in the usual practice of consultations for this addiction."
45933254|NCT00030446|Drug|carboplatin|
45933255|NCT00030446|Drug|erlotinib hydrochloride|
45803293|NCT05363657|Procedure|Partial Nephrectomy (PN)|Conservative removal of kidney tumor. The procedure can be performed either with an open or laparoscopic or robotic approach.
45803294|NCT05363657|Procedure|Radical Nephrectomy (RN)|Surgical removal of the affected kidney. Adrenal removal can be performed according to surgeon choice and clinical characteristics of the renal tumor. The procedure can be performed either with an open or laparoscopic or robotic approach.
45803295|NCT05363657|Procedure|Ablation therapy (AT)|The procedure of tumor ablation performed with radiofrequency or cryoablation. The procedure can be performed either with a laparoscopic approach or percutaneous access.
45803296|NCT05363657|Diagnostic Test|Active Surveillance (AS)|Active surveillance is defined as the initial management including the monitoring of renal tumor size by serial imaging with delayed treatment in case of progression.
45933256|NCT00030485|Drug|erlotinib hydrochloride|
45933257|NCT00057720|Drug|TLK286 HCl for injection|
45933258|NCT00057720|Drug|topotecan hydrochloride for injection|
45933259|NCT00057720|Drug|doxorubicin HCl liposome injection|
45933260|NCT00030524|Drug|gefitinib|
45933261|NCT00030563|Drug|irinotecan hydrochloride|
45933262|NCT00030563|Procedure|adjuvant therapy|
45933263|NCT00030563|Procedure|conventional surgery|
45933264|NCT00030563|Procedure|radiofrequency ablation|
45933265|NCT00030602|Biological|PSA prostate cancer vaccine|
45933266|NCT00030602|Biological|incomplete Freund's adjuvant|
45933267|NCT00057759|Drug|sildenafil citrate|
45933268|NCT00057759|Other|Placebo|Placebo
45933269|NCT00030641|Biological|oblimersen sodium|
45933270|NCT00030641|Drug|docetaxel|
45933271|NCT00057798|Drug|gemcitabine hydrochloride|
45933272|NCT00057798|Drug|vinorelbine ditartrate|
45933273|NCT00057798|Genetic|cytogenetic analysis|
45933274|NCT00057798|Genetic|loss of heterozygosity analysis|
45933275|NCT00057798|Genetic|microarray analysis|
45933276|NCT00057798|Procedure|conventional surgery|
45933277|NCT00057798|Procedure|neoadjuvant therapy|
45933278|NCT00030680|Radiation|radiation therapy|
45803297|NCT02382848|Drug|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
45933279|NCT00057915|Biological|CEA peptide 1-6D|CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
45933280|NCT02969733|Drug|Xylocaine|Xylocaine is administered at a dose of 1.5 mg / kg for induction and then relay by syringe pump at a dose of 1.33 mg / kg / hour will be administered throughout the duration of the intervention and for 24 hours after the end of thereof, to obtain deemed effective plasma concentrations of the order of 0.5 to 5 mcg / mL.
45933281|NCT02969733|Drug|Ketamine|Ketamine will be administered at a dose of 0.5 mg / kg and then relay by syringe pump at a dose of 0.05 mg / kg / hour for the duration of surgery and 24 hours after the end thereof.
45933282|NCT02969733|Drug|isotonic saline serum intravenous administration|
45933283|NCT00030719|Biological|filgrastim|
45933284|NCT00030719|Biological|monoclonal antibody Ch14.18|
45803298|NCT02382848|Drug|Placebo|Prazosin-matched placebo pill
45451802|NCT00043979|Drug|prednisone|Induction - 60 mg/m^2 per day in 2-4 divided doses by mouth daily for 5 days; days 1, 2, 3, 4, 5.
45652557|NCT05272917|Behavioral|food preferences questionnaires|Patients will be included in the study between 3 to 6 months after the end of treatment and go at Institut Paul Bocuse to complete food preferences questionnaires. The same questionnaires will be completed by healthy volunteers to compare.
45652558|NCT04803695|Diagnostic Test|Microbial biofilm diagnose|Usage of new microbiological methods for biofilm detection
45652559|NCT05316987|Radiation|Narrow band ultraviolet B|48 sessions of narrow band ultraviolet
45803299|NCT02382848|Drug|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
45803300|NCT02382848|Drug|Placebo|Prazosin-matched placebo pill
45933285|NCT00030719|Drug|busulfan|
45933286|NCT00030719|Drug|carboplatin|
45933287|NCT00030719|Drug|cyclophosphamide|
45933288|NCT00030719|Drug|etoposide|
45933289|NCT00030719|Drug|isotretinoin|
45933290|NCT00030719|Drug|melphalan|
45451803|NCT00043979|Drug|sirolimus|Initiated on day +3. Patients >40kg, the initial dose will be 2 mg every 24 hours orally. Patients <40 kg, the initial dose will be 1 mg/m^2.
45933291|NCT00030719|Drug|vincristine sulfate|
45803301|NCT03094325|Device|Pre Operative On-pump intraoperative echocardiography|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
45803302|NCT03094325|Device|Pre Operative Transesophageal echocardiography (TEE) imaging|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
45803303|NCT03094325|Device|Post Operative On-pump intraoperative echocardiography|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
45803304|NCT03094325|Device|Post Operative Transesophageal echocardiography (TEE) imaging|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
45451804|NCT00043979|Drug|tacrolimus|Day -1 at least 24 hours before the stem cell infusion at a dose of 0.03 mg/kg/day as a continuous infusion. Twelve hours later oral dose initiated at a dose of 0.1-0.15 mg/kg/day in two divided doses every 12 hours.
45451805|NCT00043979|Drug|vincristine sulfate|Induction - 0.4 mg/m^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days; 1, 2, 3, 4.
45652560|NCT05315817|Device|multiPlus dialysate|Treatment of acute kidney injury patients either with continuous veno-venous haemodialysis (CVVHD) or continuous veno-venous haemodiafiltration (CVVHDF) using the multiPlus dialysate.
45933292|NCT00030719|Procedure|bone marrow ablation with stem cell support|
45933293|NCT00030719|Procedure|conventional surgery|
45933294|NCT00030719|Procedure|peripheral blood stem cell transplantation|
45933295|NCT00030719|Radiation|radiation therapy|
45933296|NCT00030758|Biological|filgrastim|
45933297|NCT00030758|Biological|pegfilgrastim|
45933298|NCT04730895|Drug|Oral 13 cis retinoic acid|Dose of 0.5 mg/kg/day in 2 divided doses orally for 14 days
45933299|NCT04730895|Drug|Aerosolized 13 cis retinoic acid|Dose of Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day
45933300|NCT04730895|Combination Product|13 cis retinoic acid doses orally in combination with spike protein based vaccine|Dose of 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days and also, participants will receive two doses of 5-7.5x10^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart
45933301|NCT04730895|Combination Product|Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine|Dose of Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day for 14 days and also, participants will receive two doses of 5-7.5x10^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart
45451806|NCT00043979|Procedure|peripheral blood stem cell transplantation|Stem cells from a healthy donor are collected and transplanted into the patient using a central venous catheter.
45803305|NCT05718440|Other|Individualisation of uronephrological complications risk factors|description of pelvic disorders in terms of clinical presentation, electrophysiology/urodynamics/anorectal manometry patterns, urethrocystography/urinary ultrasound/defecography results and urinary complications (infections, vesicoureteral reflux), depending on the dysraphim's type and level of injury and to correlate these parameters to the uronephrological risk factors and complications recorded.
45803306|NCT02065687|Drug|Carboplatin|Given IV
45451807|NCT00043979|Drug|Filgrastim|
45451808|NCT00043979|Procedure|Peripheral Blood Stem Cell donation|
45451809|NCT04188808|Other|Bypass surgery|All patients scheduled for elective surgery of PAA and PAD.
45451810|NCT01436032|Drug|N1539|IV
45451811|NCT01436032|Drug|N1539|IV
45451812|NCT01436032|Drug|N1539|IV
45451813|NCT01436032|Drug|Ketorolac Tromethamine|IV
45803307|NCT02065687|Other|Laboratory Biomarker Analysis|Correlative studies
45652561|NCT04925895|Other|Dynamic soft tissue mobilization|Dynamic soft tissue mobilization will be given in the following sequence, In supine position with 90˚ flexion of knee and hip joint deep longitudinal strokes will be applied from distal to proximal direction along with the tightened area of hamstring while passively stretching the hamstring. Total 5 longitudinal strokes will be applied followed by shaking for 20 seconds. Then progressed to the next dynamic technique in the above-mentioned sequence but the patient will be asked to do leg extension actively to achieve reciprocal inhibition of the hamstring muscle. In The next step, the subject will apply a force to the therapist's hand to engage the hamstring eccentrically as the muscle will be lengthened to its end range. In that position, the therapist will apply 5 deep longitudinal strokes from the distal towards the proximal direction on tight hamstring muscles.
45652562|NCT04925895|Other|Proprioceptive neuromuscular facilitation stretching|The position of the patient will be supine lying with 90⁰ flexion of hip. Therapist will passively extend the knee joint where patient will feel a mild stretch. Then therapist will ask the patient to do knee flexion in counter resistance applied by the therapist by using about 50% of his maximum strength and isometric contraction of hamstring muscles will be achieved. Patient will maintain that isometric contraction for 8 seconds then relax on therapist command. Just after relaxation therapist will further stretch the hamstring muscle to the point of mild to moderate painless stretch and patient will hold it for 30 seconds. Three repetitions will be applied in each session.
45803308|NCT02065687|Drug|Metformin Hydrochloride|Given PO
45451814|NCT01436032|Drug|Placebo|IV
45451815|NCT01092533|Drug|Myfortic|Myfortic 360 mg BID (during week 1) Myfortic 720 mg BID (from week 2 on) Maintenance dose Decortin 5mg/d
45451816|NCT01092533|Drug|Decortin|Maintenance dose 5 mg/d
45652563|NCT04925895|Other|Cryotherapy|application of cold pack on knee joint for 10 minutes
45803309|NCT02065687|Drug|Paclitaxel|Given IV
45803310|NCT02065687|Other|Placebo Administration|Given PO
45803311|NCT02065687|Other|Quality-of-Life Assessment|Ancillary studies
45803312|NCT02065687|Other|Questionnaire Administration|Ancillary studies
45803313|NCT03095885|Other|Test Meal|
45803314|NCT02383706|Device|ApneaLink Air|Overnight, home polysomnography device
45803315|NCT02383706|Behavioral|Berlin Quesionnaire|OSA screening questionnaire
45803316|NCT02383706|Behavioral|Epworth Sleepiness Scale|OSA screening questionnaire
45803317|NCT02383706|Behavioral|STOP-BANG questionnaire|OSA screening questionnaire
45803318|NCT02383706|Other|Physical exam|Physical exam of neck, mouth and upper airway
45803319|NCT03096353|Other|Placebo|saline
45803320|NCT03096353|Drug|Naloxone|We will be using naloxone at normal clinical doses as the study drug. Naloxone is an opiate antagonist and has been used since the 1960 s to reverse the effects of opiate overdoses.
45803321|NCT02384096|Device|Conventional single source programming|Precision Spectra SCS System using conventional single source programming.
45803322|NCT02384096|Device|Precision Spectra SCS System advanced programming|Precision Spectra SCS System using advanced programming
45803323|NCT03098615|Drug|Jublia (Efinaconazole 10% Topical Solution)|Efinaconazole 10% Topical Solution will be applied to the great toenail with the DLSO and dermatophytoma.
45803324|NCT05363579|Other|Physiotherapy|Physiotherapy can be defined as a treatment method that focuses on the science of movement and helps people to restore, maintain and maximize their physical strength, function, motion and overall well-being by addressing the underlying physical issues.
45803325|NCT05363579|Other|Tuina therapy|Tuina is mainly applied to the meridians or acupoints by manipulation techniques such as pushing, grasping, pressing and rubbing of the soft tissues or muscles of the body. It is reported to improve circulation and the qi in the body.
45803326|NCT05363579|Other|Physio and Tuina therapy|Physiotherapy mixed with Tuina
45803327|NCT05718284|Device|AIRVO2|APPLICATION OF HIGH FLOW NASAL CANNULA OXYGEN FOR 48 HOURS AFTER ESOPHAGECTOMY
45803328|NCT05718284|Other|STANDARD CARE|APPLICATION OF OXYGEN THROUGH STANDARD CARE FOR 48 HOURS AFTER ESOPHAGECTOMY
45803329|NCT05504798|Other|Selected physical therapy program|Selected physical therapy program one hour three times weekly for six successive weeks including stretching, strengthening, balance, and gait training.
45803330|NCT05504798|Procedure|Interrupted serial casting|Interrupted casting for 5 days a week for six successive weeks using a dual cast which consists of a standard short leg cast and a circular cast from below the knee to above the knee.
45803331|NCT05504798|Device|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation in form of faradic current with frequency of 50 Hz, and intensity of maximum tolerable intensity to produce a visible contraction but as tolerated by the child for ankle dorsiflexors and knee extensors muscles through cast windows over the motor points of these muscles for 30 min 3 times weekly for six successive weeks
45803332|NCT05363501|Drug|IM Naloxone Injection|Single 0.4 mg IM naloxone injection will be administered (1 mL of 0.4 mg/mL injection, into the gluteus maximus muscle using a 23-gauge needle).
45803333|NCT05363501|Drug|Naloxone Nasal Spray|Single 4 mg intranasal naloxone spray will be administered in one nostril (0.1 mL of 4 mg/0.1 mL spray, based on the prescribing information and approved Instructions for Use).
45803334|NCT05363501|Drug|Naloxone Nasal Swab|4 mg naloxone nasal swab administered in nostril
45933302|NCT04730895|Biological|Biological: spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine|Dose of 5-7.5x10^10vp of spike protein based vaccine such as ChAdOx1 nCoV-19 in deltoid of non-dominant arm, 28 days apart
45933303|NCT02969772|Other|Assessment of upper limb variables|International Standards for Neurological and Functional Classification of Spinal Cord Injuries of American Spinal Injury Association (ASIA); Functional Independence Measure (FIM); The following kinematic variables of arm were studied: shoulder, elbow and wrist angles; percentage of time to peak velocity; movement time; peak velocity and movement smoothness (number of velocity peaks and index of curvature); Capabilities of Upper Extremity instrument (CUE); Spinal cord independence measure (SCIM II); electromyography (Clavicular portion of pectoralis major, long head of biceps brachii, anterior and posterior deltoid, triceps and wrist extensors).
45933304|NCT02969772|Other|Training protocol|The strengthening sessions consisted of 20 minutes of electrical stimulation on triceps, extensor carpi radialis longus, extensor digitorum communis, lumbricalis, flexor digitorum superficialis and opponens pollicis muscles. The functional training sessions was performed through movements the reach and palmar grasp with NMES of the several cylindrical and conical objects of different weights (30 minutes sessions).
45933305|NCT00030797|Drug|Irinotecan 70 mg/m2|Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29
45933306|NCT00030797|Drug|Irinotecan 240 mg/m2|Irinotecan i.v. 240 mg/m2 day 1 and day 22
45933307|NCT00058032|Other|screening questionnaire administration|
45652564|NCT04925895|Other|Isometric knee strengthening excercises|"i. Isometric hip adductors exercises in crook lying: Two sets of 10 repetitions with a 10-seconds hold will be carried out.~ii. Isometric quadriceps strengthening exercises in supine lying: A towel roll underneath the knee joint will be used to perform this exercise. Two sets of 10 repetitions with a 10-seconds hold will be performed."
45933308|NCT00058032|Procedure|annual screening|
45933309|NCT00030875|Drug|bortezomib|
45933310|NCT00058071|Drug|amifostine trihydrate|
45803335|NCT05363501|Drug|Naloxone Nasal Swab|8 mg naloxone nasal swab administered in nostril
45933311|NCT00030914|Drug|medroxyprogesterone|
45933312|NCT00030914|Drug|venlafaxine|
45933313|NCT00058149|Drug|gemcitabine hydrochloride|
45933314|NCT00058149|Drug|oxaliplatin|
45933315|NCT00031031|Drug|Kanglaite Injection (KLT)|
45652565|NCT05227755|Dietary Supplement|Soy protein isolate|Participants will receive 120 mls of soy protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
45652566|NCT05227755|Dietary Supplement|Whey protein isolate|Participants will receive 120 mls of whey protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
45803336|NCT05363501|Drug|Naloxone Nasal Swab|12 mg naloxone nasal swab administered in nostril
45803337|NCT05363501|Drug|Naloxone Nasal Swab|12.5 mg naloxone nasal swab administered in nostril
45803338|NCT04736927|Drug|GLPG3667|From Day 3 to Day 8, GLPG3667 capsules q.d. orally in fed state.
45652567|NCT04786379|Procedure|Arthroscopic Irrigation and Debridement|Patients with confirmed septic arthritis treated with multiple small incisions to perform irrigation and debridement with partial synovectomy.
45803339|NCT04736927|Drug|Midazolam|On Day 1 and Day 7 as liquid formulation, orally in fed state.
45803340|NCT02387294|Biological|Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml)|vaccination
45803341|NCT02387294|Biological|Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml)|vaccination
45803342|NCT05352269|Biological|XBI-302|Fecal Microbiota Transplantation Capsules
45803343|NCT05352269|Biological|XBI-302 Placebo|XBI-302 Placebo
45803344|NCT05718206|Device|Magnetocardiography|Both arms underwent magnetocardiogram examination, and three experts interpreted magnetocardiogram results independently.
45803345|NCT02066857|Device|Cast made of generic plaster or fiberglass cast material|Patients will randomly receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture.
45933316|NCT00058227|Drug|alvocidib|Given IV
45933317|NCT00058227|Drug|fludarabine phosphate|Given IV
45933318|NCT00058227|Biological|rituximab|Given IV
45933319|NCT00058227|Other|pharmacological study|Correlative studies
45933320|NCT00031070|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
45933321|NCT00031070|Drug|Cyclosporine|
45933322|NCT00031070|Biological|Hepatitis A Vaccine (Inactivated)|
45933323|NCT00031070|Drug|Efavirenz|
45933324|NCT00031070|Biological|Pneumococcal Conjugate Vaccine, Heptavalent|
45803346|NCT02066857|Device|"Generic off the shelf removable splint"|"Patients will be randomized to receive a generic off the shelf removable splint for treatment of a non-displaced distal radius fracture."
45933325|NCT00031070|Biological|Rabies Vaccine|
45933326|NCT00058305|Drug|bryostatin 1|Given IV
45933327|NCT00058305|Drug|vincristine sulfate|Given IV
45933328|NCT00058305|Other|laboratory biomarker analysis|Correlative studies
45933329|NCT00058461|Drug|ifosfamide|Given IV
45933330|NCT00058461|Drug|etoposide|Given IV
45933331|NCT00058461|Biological|rituximab|Given IV
45933332|NCT00058461|Drug|carboplatin|Given IV
45933333|NCT00058461|Biological|filgrastim|Given SC
45933334|NCT00058461|Drug|methotrexate|Given IT
45933335|NCT00058461|Drug|cytarabine|Given IT
45933336|NCT00058461|Other|laboratory biomarker analysis|Correlative studies
45933337|NCT04732754|Dietary Supplement|Aerobic exercise + Theobroma cocoa (AETC)|Daily consumption of 500mg cocoa in capsules and 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.
45933338|NCT04732754|Dietary Supplement|Control Group (CG)|Daily consumption of placebo capsules for 8 weeks
45933339|NCT04732754|Dietary Supplement|Aerobic Exercise (AE)|Daily consumption of placebo capsules and 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.
45933340|NCT04732754|Dietary Supplement|Theobroma Cocoa (TC)|Daily consumption of 500mg cocoa in capsules for 8 weeks.
45803347|NCT05336045|Procedure|trigger finger release|The A1 pulley and tendon sheath is divided in local anaestethic through a small incision in the palm
45451817|NCT02472418|Drug|DFN-15 Dose A (treatment A)|DFN-15 Dose A administered
45933341|NCT02969577|Behavioral|Exercise Program|Participants will have a personal training session at the first visit. A member of the study team will discuss strength training and cardiovascular workouts for them to complete over the first 6 months of the study. A member of the study team will then talk with the participant every week for the first 3 months and monthly afterwards until month 6. Participants will be sent exercise videos and be given recommendations for the exercise program via phone calls and will be tailored to the individual. Videos and recommendations will be sent directly to the participant's smartphone.
45933342|NCT02969577|Behavioral|Diet and Nutrition Coaching|Diet and nutrition coaching session with an overview of resources on the smartphone. Over the first 6 months, participants will receive healthy recipes and nutritional information on the smartphone.
45933343|NCT02969577|Other|Usual Care with Attention|Participants will receive the usual care for men undergoing ADT. This includes monitoring blood work and answering questions about how they are feeling. Participants will be directed to the IMPACT website for education materials on prostate cancer.
45933344|NCT04711967|Biological|Fecal Microbiota Transplantation|fecal microbiota transplantation
45933345|NCT04711967|Drug|drug|drug
45451818|NCT02472418|Drug|DFN-15 Dose B (treatment B)|DFN-15 Dose B administered
45803348|NCT04940585|Other|ROSE Program|The program includes 6 group sessions and an individual session 4-6 weeks after birth. Each session will last 60 minutes and will be conducted over Webex. The key areas that will be discussed during the sessions include: Psychoeducation, Adjusting to life with baby, Effective communication, Asking for what you need, and Planning for the future.
45933346|NCT00058578|Drug|Cyclophosphamide|
45933347|NCT00058578|Drug|Mesna|
45933348|NCT00058578|Drug|G-CSF|
45451819|NCT02472418|Other|Placebo (treatment C)|Placebo administered
45451820|NCT01092611|Procedure|Blood collection|Once a year after Visit 1 (during a maximum of 4 years). The samples will only be taken in conjunction with, and at the same time as, planned routine blood testing using the same needle-stick.
45451821|NCT01092611|Biological|GSK HIV vaccine 732462|No vaccine will be administered during this long-term follow-up study. Vaccines were administered during the primary studies.
45451822|NCT01431820|Drug|Luliconazole Solution, 10%|Topical
45652568|NCT04786379|Procedure|Open Arthrotomy with irrigation and debridement|Patients with confirmed septic arthritis treated with a single large incision, open arthrotomy to perform irrigation and debridement with partial synovectomy.
45803349|NCT02388386|Device|PROTEUS-SENSOR|An edible sensor system, Proteus Digital™ has been developed for electronically confirming medication adherence, gathering physiologic metrics and communicating these data to patients. The system consists of two major components: an edible sensor and a wearable receiver health monitor. An electrical signal is activated upon ingestion of the Proteus Digital micro-sensor with transmission of this signal to a receiving abdominal patch to quantify medication compliance.
45933349|NCT00058578|Procedure|Leukopheresis|
45933350|NCT00058578|Procedure|Total Body Irradiation|
45451823|NCT01431820|Drug|Vehicle Solution|Topical
45451824|NCT01624636|Drug|Placebo|
45451825|NCT01624636|Drug|LFG316|
45451826|NCT01624636|Drug|LFG316|
45451827|NCT03953885|Other|Fire needle|"Participants wear eye masks and fully expose the lesions. After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation. After selecting an acupuncture needle with a specification of 0.4*40mm and ignites the alcohol lamp, the operator continuously moves the needle from the needle root to the needle tip to burn the red needle to disinfect the needle in the outer flame of the alcohol lamp.~The operator ignites the alcohol lamp, and burns the needle tip and the needle body to the outer flame of the alcohol lamp until it is completely red (the length of the needle burning red is determined by the acupuncture depth), and then rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm."
45451828|NCT03953885|Other|Fire needle Placebo|"Participants wear eye masks and fully expose the lesions (no lesions on the head and face, external genitalia and skin folds). After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation, then selects an acupuncture needle with a specification of 0.4*40mm to prepare for operation.~The operator rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm."
45451829|NCT01092689|Drug|PhiP|1 capsule of 84 micrograms; 15.6 micro-curies [14C]PhIP
45652569|NCT04795115|Other|Auditory rhythmical cueing|Auditory rhythmical cueing intervention targeting balance and gait for 30 minutes x5 per week for 3 weeks.
45652570|NCT05616377|Other|Surgery or Radiotherapy|Participants who underwent target therapy and surgery or radiotherapy were divided into target therapy + local therapy group. Participants who underwent target therapy alone were divided into target therapy alone group
45652571|NCT05616377|Other|before or after target therapy|Participants who underwent surgery or radiotherapy before target therapy were divided into local therapy before target therapy group. Participants who underwent surgery or radiotherapy after target therapy were divided into local therapy after target therapy group.
45451830|NCT01425970|Drug|INX-08189|Tablet, Oral, 25 mg, Once daily (QD), 12 weeks
45451831|NCT01425970|Drug|INX-08189|Tablet, Oral, 50 mg, Once daily (QD), 12 weeks
45451832|NCT01425970|Drug|INX-08189|Tablet, Oral, 100 mg, Once daily (QD), 12 weeks
45451833|NCT01425970|Drug|Placebo matching with INX-08189|Tablet, Oral, 0 mg, Once daily (QD), 12 weeks
45451834|NCT01425970|Biological|Pegylated interferon alfa-2a|Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks
45803350|NCT03810703|Drug|Placebo oral capsule|Placebo oral capsule
45652572|NCT04785755|Drug|Oral standard diuretics therapy|Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).
45652573|NCT04785755|Drug|Hypertonic saline solution|Hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days.
45451835|NCT01425970|Drug|Ribavirin|Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks
45451836|NCT01425970|Drug|INX-08189|Tablet, Oral, 200 mg, QD, 12 weeks
45451837|NCT01425970|Drug|Daclatasvir|Tablet, Oral, 60 mg, QD, 12 weeks
45451838|NCT01583855|Procedure|Catheter ablation for atrial fibrillation, manual|Ablation for atrial fibrillation will be performed manually
45451839|NCT01583855|Device|Ablation using Amigo remote catheter system|Atrial fibrillation ablation will be performed using the Amigo remote catheter system
45652574|NCT04785755|Drug|Etilefrine|Etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
45652575|NCT04351373|Drug|intravenous fluorescein sodium|Injection of IV FS during acoustic neuroma tumor removal
45652576|NCT04351373|Device|YELLOW 560 nm microscope filter (YE560)|The surgeon will utilize the microscope filter after the IV FS is administered
45803351|NCT03810703|Drug|d-amphetamine 10 mg oral capsule|d-amphetamine 10 mg oral capsule
45803352|NCT03810703|Drug|d-amphetamine 20 mg oral capsule|d-amphetamine 20 mg oral capsule
45652577|NCT04244253|Drug|OPC-64005 20 mg , Once-daily|Active, High Dose
45652578|NCT04244253|Drug|OPC-64005 10 mg , Once-daily|Active, Low Dose
45652579|NCT04244253|Drug|Placebo, Once-daily|Placebo
45652580|NCT04785833|Drug|T cell injection targeting CD7 chimeric antigen receptor|Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation
45803353|NCT04819997|Other|Educational Intervention|Participate in videoconference session
45803354|NCT05491382|Procedure|Uphill running|Participants will run at 70% of their maximal oxygen consumption for 60 min at a 10 degree (17.6%) incline.
45803355|NCT05491382|Procedure|Flatland running|Participants will run at 70% of their maximal oxygen consumption for 60 min at a 0 degree (0%) incline.
45803356|NCT05491382|Procedure|Downhill running|Participants will run at 70% of their maximal oxygen consumption for 60 min at a -10 degree (-17.6%) decline.
45803357|NCT05304455|Drug|Apixaban 2.5 MG|From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
45803358|NCT05304455|Drug|Dipyridamole 25Mg Tab|From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
45803359|NCT05304455|Drug|subcutaneous Low Molecular Weight Heparin|From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
45803360|NCT05718050|Diagnostic Test|Mandibular flexure evaluation|A mandibular silicon impression was taken, and a vacuum molded thermoplastic stent with radiopaque fiducial markers (steel ball bearings) on the facial side of the canines and molars was fabricated for each patient. Two Cone Beam Computed Tomographs (CBCTs) were made per patient with their radiographic stent in the mouth at the OVD and MO positions at the University Advanced Digital Diagnostic Center. The CBCT examination was performed without any stitching procedure using a computed tomography (SCANORA 3DX; Dexis LLC) set up at 90 kV, 4 mA and a field of view (FOV) of 140 and 100 mm in height and width respectively, to decrease the radiation dose without affecting the quality of the examination.
45803361|NCT04332965|Procedure|Non-Surgical Periodontal Treatment|Scaling and root planing and polishing with specific curettes were performed to patients and oral hygiene education was provided to each patient.
45803362|NCT02389088|Drug|Letrozole|In Phase II, letrozole, 5 mg/day, will be given for 14 days
45803363|NCT04747691|Diagnostic Test|Bedside gastric ultrasound|Bedside ultrasound exam of the stomach
45803364|NCT02068027|Drug|Clonidine Gel 0.1%|
45803365|NCT02068027|Drug|Placebo|
45803366|NCT05242055|Other|Integrated diagnosis and treatment for CKD|This is an observational study. Investor will not intervene the clinical practice of doctors. In the real world, there would be many factors affect the proceeding of the guidelines contents. There will be integrated diagnosis and treatment during follow-up.
45803367|NCT05717972|Other|Kombucha|"Kombucha is a fermented tea drink that originated in ancient Chinese civilization. It is made by combining tea, juice, and SCOBY (Symbiotic Culture of Bacteria and Yeast).~During the fermentation process, the yeast in the SCOBY breaks down the sugar in the tea releasing friendly probiotic bacteria, giving kombucha its fizzy body and its sweet and tangy taste."
45803368|NCT05233007|Procedure|Minor endoscopic biopsy|As per standard of care
45803369|NCT05717894|Drug|Vitex Agnus Castus Extract|The patient group received two pills containing 200mg of VAC daily for six months
45803370|NCT05231681|Dietary Supplement|Saie Beauty's Hydrabeam Sheer Brightening Under Eye Concealer|Eye Concealer
45803371|NCT04661657|Other|Transthoracic echocardiogram (TTE)|Subjects will undergo TTE imaging.
45933351|NCT04711694|Behavioral|Minfulness-based Intervention|"The proposed MBI is an adaptation from the Mindfulness Based Stress Reduction (MBSR) and Mindfulness based Cognitive Therapy (MBCT) programs to youth. This MBI consists of a total of twelve 90 minutes long sessions, the first 8 being the intervention per se and the last 4 a proposition to the transition to regular practice and a chance to better integrate mindfulness in daily life.~A theme regarding mindfulness is addressed in each session, through meditation practices and exercises. Between sessions, participants are invited to practice at home, using an application designed for this study (the MindApp), where participants can find the recorded practices. Investigators have access to participants' use of the meditation recordings and expect that these data will provide a more objective measure of the amount of home practice."
45933352|NCT00058617|Biological|Injection of EBV Specific CTLs|"Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10^7 cells/m2 Day 14 2x10^7 cells/m2~Group Two Day 0 2x10^7 cells/m2 Day 14 1x10^8 cells/m2~Group Three Day 0 1x10^8 cells/m2 Day 14 2x 10^8 cells/m2~If patients with active disease have stable disease or a partial response by the RECIST criteria at their 8 week or subsequent evaluations they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number as their second injection. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
45933353|NCT04711889|Drug|Ulinastatin|Ulinastatin is taken three times a day.
45933354|NCT04711889|Drug|Saline|Saline is taken three times a day.
45933355|NCT00058656|Procedure|Infusion of Activated & Expanded Autologous T Cells|
45933356|NCT04712006|Drug|JNJ-64304500|Participants will be administered with JNJ-64304500 SC (Dose 1 or 2) injection on Day 1.
45933357|NCT00031109|Biological|gp160 MN/LAI-2|
45451840|NCT02265094|Other|Electroencephalography|EEG recordings during memory tests
45451841|NCT02265094|Behavioral|Neuropsychological assessment|patterns of eye gaze during cognitive tests
45652581|NCT04240899|Other|Tele-yoga|Subjects will undergo 30-minute yoga sessions delivered remotely 2-3 times/week for 6-weeks. The yoga sessions will be delivered one-on-one and will include 5-7 minutes of breathing exercises 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
45652582|NCT04785911|Drug|Antiemetic Combinations|Evaluation of response to treatment of hyperemisis gravidarum (antiemetics and other methods ) by PUQE score
45652583|NCT04240821|Drug|Theophylline ER|Oral theophylline
45803372|NCT04661657|Other|Cardiovascular Magnetic Resonance (CMR) Imaging|Subjects will undergo CMR Imaging using a gadolinium based contrast agent (GBCA).
45803373|NCT02391350|Behavioral|Education and re-assurance|Patients are provided the Back Book and the contents are reviewed emphasizing the favorable natural history of back pain and sciatica and the importance of remaining active.
45803374|NCT02391350|Procedure|Physical Therapy|Physical therapy will consist of repeated exercises, spinal mobilization and mechanical traction in an effort to maximize centralization of symptoms.
45803375|NCT02392208|Drug|Telavancin|A single 5 mg/kg dose of telavancin is administered intravenously (IV).
45451842|NCT03135496|Other|Study of endothelial function biological markers|Study of endothelial function biological markers
45451843|NCT01619332|Drug|Placebo|Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
45803376|NCT02392208|Procedure|Pharmacokinetic Blood Sampling|Blood samples are collected to assess telavancin plasma concentrations.
45803377|NCT05185583|Drug|Methylphenidate Hydrochloride|Participants will receive twice daily doses of Methylphenidate Hydrochloride four hours apart. There will be three dosage schedules, determined based on three weight ranges (20-30kg; 30-40kg; ≥40kg). For children weighing 20-30kg, the maximum daily dose will be 20mg. For children weighing 30-40kg, the maximum daily dose will be 30mg. For children weighing ≥40kg, the maximum daily dose will be 40mg.
45451844|NCT01619332|Drug|Sitagliptin|Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner
45451845|NCT01619332|Drug|LEZ763|LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
45652584|NCT05615285|Other|PERCS Triage and Referral System|Participants will undergo an assessment of physical function and psychosocial wellbeing. Researchers will apply a triage algorithm, based on findings of assessment. Participants will be referred to one of three exercise-based rehabilitation pathways which will best meet their rehabilitation needs. Participants will be re-assessed after 12 weeks. System will be evaluated using RE-AIM framework.
45803378|NCT05185583|Drug|Placebo|Participants will receive twice daily doses of placebo capsules. Gelatine placebo capsules will contain hypromellose, an inert substance.
45803379|NCT04645121|Device|Carbon Monoxide-based Rebreathing|6 minutes Carbon Monoxide-based Rebreathing that estimate blood volume, plasma volume and erythrocyte volume.
45803380|NCT04645121|Device|Bioimpedance|Measures total volume, intra and extracellular volume.
45652585|NCT05225259|Drug|LOXO-260|Oral
45652586|NCT04795193|Procedure|Minimal invasive coronary surgery|Off-pump multi-vessel coronary artery bypass grafting via left thoracotomy under minimally invasive conditions.
45803381|NCT04645121|Radiation|Radioactive labelling of erythrocytes and albumin|Measure blood volume, plasma volume and erythrocyte volume.
45933358|NCT00031109|Biological|Aluminum hydroxide|
45933359|NCT00058734|Biological|Dendritic Cells Pulsed with HIV antigens|
45933360|NCT00031148|Drug|Recombinant Human Keratinocyte Growth Factor (rHuKGF)|
45933361|NCT00058773|Drug|Infusion of EBV Specific Cytotoxic T-Lymphocytes|"EBV specific cytotoxic T-lymphocytes will be given by intravenous injection over 1-10 minutes.~Each patient will receive two injections, 14 days apart."
45933362|NCT00031187|Drug|SGN-15 (cBR96-doxorubicin immunoconjugate)|
45803382|NCT05462444|Other|Skin prick test|Skin prick test with a standard pallete of inhalational and nutritional allergens
45803383|NCT04603937|Drug|KSI-301|Intravitreal Injection
45652587|NCT04795193|Procedure|Off-pump coronary artery bypass surgery|Off-pump multi-vessel coronary artery bypass grafting with conventional thoracotomy.
45803384|NCT04603937|Drug|Aflibercept|Intravitreal Injection
46073421|NCT04582214|Device|MetaNeb® System|The intervention device use in this study is The MetaNeb® System (Hill-Rom; St. Paul, MN). It is an FDA 510k cleared device (k124032), powered by compressed gas, that delivers oscillation and lung expansion (OLE) therapy using both continuous high-frequency oscillation (CHFO) and continuous positive expiratory pressure (CPEP). The device also provides supplemental oxygen when used with compressed oxygen and can deliver aerosol therapy during CPEP and/or CHFO. The therapy is indicated for mobilization of secretions, lung expansion therapy and the treatment and prevention of pulmonary atelectasis. The device also provides supplemental oxygen when used with compressed oxygen.
46073422|NCT02826720|Other|No intervention was applied|No intervention was applied
46073423|NCT00839371|Drug|Propofol|i.v. propofol titration until adequate depth of sedation
45933363|NCT00031187|Drug|Taxotere (docetaxel)|
45652588|NCT05314179|Behavioral|DOULA-AC 1|"Doula and Patient will decide on details of engagement. The components to be included will be: 1) emotional support, 2)practical assistance, 3) family support, and/or 4)legacy building projects as per study protocols.~The nature and type of visits will be determined by the patient and doula."
45652589|NCT05615441|Device|Analgesia Nociception Index monitor|Patients will receive remimazolam-based total intravenous general anesthesia with nociception monitoring with the ANI monitor
45652590|NCT05615441|Device|Standard monitoring|Patients will receive remimazolam-based total intravenous general anesthesia based on hemodynamic monitoring and without nociception monitoring
45652591|NCT04243941|Drug|68Ga-HBED-CC-PSMA|Radioactive tracer used during imaging to help detect PSMA expressing tumor cells
45652592|NCT04794959|Diagnostic Test|Dual-energy CT|CMI patients planned for endovascular stent placement will be contacted and informed about this study prior to their procedure. If they wish to take part in the study, then a date for a pre-operative DECT scan will be arranged. Before scanning the patient will be given a standardized calorie dense drink (Nutridrink). This will take place one week prior to their surgical procedure. Following the surgical procedure, the patient will undergo another DECT scan before discharge.
45803385|NCT04603937|Other|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
45803386|NCT02392286|Drug|Corticosteroid|Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.
45933364|NCT00031265|Procedure|Family Intervention Telephone Tracking|
45933365|NCT00058812|Biological|EBV specific T cells|One injection of 2x10^7 cells/m2 from Day 45 post transplant. If EBV DNA levels remain elevated above 1000 copies/ug or the patient has persistent disease they will be eligible to receive up to 5 additional injections of CTLs at the original dose at monthly intervals.
45933366|NCT00031343|Drug|highly active antiretroviral therapy (HAART)|
45933367|NCT00058851|Procedure|Manual lymph drainage|
45933368|NCT00058851|Procedure|Combined physiotherapy|
45933369|NCT00058851|Procedure|Compression bandaging|
46073424|NCT00839371|Drug|Midazolam|i.v. midazolam titration until adequate depth of sedation
46073425|NCT02837822|Device|Spinal cord stimulator|Spinal cord stimulator is a reversible and minimally invasive neuromodulation device used for the treatment of various diseases related to chronic pain, including CRPS and FBSS. Briefly, this technology uses electrical pulses to generate action potentials in nerve cells that induce paresthesias (buzzing or tingling sensations) in the affected limb and can relieve pain.
45451846|NCT02265172|Procedure|Physiotherapy screening|Physiotherapy screening.
45451847|NCT02265172|Procedure|Standard practice|Orthopaedic surgeon assessment
45933370|NCT02971514|Behavioral|Flossing before Brushing|
46073426|NCT02837822|Procedure|Implantation of a spinal cord stimulator|The electrical pulses are induced by one or more electrodes surgically implanted into the epidural space. These electrodes are usually placed under the skin in the abdomen or upper buttock.
45652593|NCT05218941|Procedure|Implant surgery assisted by passive robotics|Implant surgery without flap assisted by passive robotics (X-Guide®)
45652594|NCT05218941|Procedure|Conventional implant surgery|Flap implant surgery
45803387|NCT04586153|Drug|Meplazumab for Injection|humanized antibody target CD147
45803388|NCT04586153|Drug|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
45803389|NCT04574765|Diagnostic Test|Nasopharyngeal swab|Nasopharyngeal swab for COVID-19
45803390|NCT04574765|Other|Questionnaire collection|Fill out questionnaires regarding exposures and travel history, occupation category, any symptoms in the past 21 days, any face-to-face care of a known COVID-19 positive patients in past 14 days or any children at home who are less than 12 years of age.
45803391|NCT04574765|Other|Optional blood completion|Provide blood samples to look for COVID-19 specific antibodies and/or proteins at the time of enrollment and after 8 weeks.
45803392|NCT04574765|Other|Optional questionnaire completion|Fill out an optional mental health questionnaire.
45933371|NCT02971514|Behavioral|Brushing before Flossing|
45933372|NCT00058890|Drug|Gabapentin|Under code, the study drug was started at 100 mg by mouth 3 times a day for 3 days, to be increased, if necessary and in the absence of side effects, by 300 mg every 3 days to a maximum of 2,400 mg daily in divided doses.
45933373|NCT00058890|Drug|Placebo|
45933374|NCT02969538|Other|Total etching time|Apply 35% phosphoric acid on dentin and enamel by 15 seconds.
45933375|NCT02969538|Other|Half-reduced etching time|Apply 35% phosphoric acid on enamel by 15 seconds and dentin by 7 seconds.
45933376|NCT02969460|Behavioral|Neurotrack Virtual Cognitive Health Program|
45652595|NCT04785599|Behavioral|Exercices|An exercise program. Seven days after lymph node removal, participants began this program at the physiotherapy department. They attended two weekly sessions of 60 minutes each. The sessions at the centre continued for 12 weeks. The program consisted of aerobic exercise, in combination with resistance and stretching exercises.
45652596|NCT04785599|Behavioral|Informative talk|An informative talk: Patients attended a one-hour long talk about lymphedema. The topics covered were a description of the condition, the risks, and preventive measures to include in their daily life. The recommended measures were those from the general consensus of the International Lymphedema Society, the Spanish Rehabilitation Society and The National Breast and Ovarian Cancer Center
45933377|NCT00058929|Drug|treprostinil sodium|
45652597|NCT04785599|Device|Compression garment|"Wearing a flat knit compression garment (CG), class 1. Participants were recommended to wear this CG for an average of 8 hours during the daytime for the first 3 months after surgery, and to remove it at night.~From the fourth month onwards, use of the garment was reduced to 2 hours a day, coinciding with exercises and physical activity."
45933378|NCT00396149|Biological|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
45652598|NCT05314101|Drug|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
45652599|NCT05314101|Drug|bevacizumab|Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 and day 15 of every 4 weeks
45652600|NCT05314101|Drug|TAS-102|Participants will receive TAS-102, 35mg/m2, bid，d1-d5, d8-d12 of every 4 weeks
45803393|NCT05717816|Device|intramedullary nail and plate|fusing Charcot ankle using retrograde intrameudllary femoral nail and plate
45803394|NCT05717738|Procedure|TACE|Procedure of TACE is standardized.
45803395|NCT05717738|Drug|Lenvatinib|8mg; p.o.; q.d.
45803396|NCT05717738|Drug|Anti-PD-1 monoclonal antibody|Advanced HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
45803397|NCT05717738|Drug|Bevacizumab Biosimilar IBI305 plus sintilimab|Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
45803398|NCT05717738|Drug|Bevacizumab plus Atezolizumab|Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
45933379|NCT00396149|Biological|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 50 to 300 µg rBet v 1.
45803399|NCT05717738|Drug|apatinib plus camrelizumab|Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
45803400|NCT05717738|Drug|Sorafenib|400mg; p.o. bid
45803401|NCT05717738|Drug|Donafenib|200mg; p.o. bid
45803402|NCT05717738|Drug|Regorafenib|160 mg; p.o.; q.d.
45803403|NCT04484987|Other|9 hours daily eating window|Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.
45803404|NCT04484987|Other|15 hours daily eating window|Participants assigned to the control group will have to consume all their daily meals and snacks during a 15-hour window for 12 weeks.
45803405|NCT02393378|Drug|Namilumab|Namilumab injection
45652601|NCT02595749|Drug|Oxytocin|
45652602|NCT02595749|Drug|Placebo|
45652603|NCT05218707|Other|GUEDEL Airway|GUEDEL Airway of size '000,00,0,' and '1' will be used.
45803406|NCT02393378|Drug|Adalimumab|Adalimumab SC injection
45803407|NCT02393378|Drug|Methotrexate|Methotrexate tablet
45803408|NCT02393378|Drug|Folic Acid|Folic Acid Tablet
45803409|NCT05443490|Dietary Supplement|Probiotic mixture with three bacterial strains with maltodextrin as a carrier.|Sachets containing a probiotic mixture at concentrations equal to or greater than 1x10^9 colony forming unit (CFU) per dose, with maltodextrin as excipient.
45803410|NCT05443490|Other|Placebo comparator with maltodextrin as a carrier.|Sachets containing maltodextrin
45933380|NCT00396071|Drug|vildagliptin|vildagliptin 100 mg
45933381|NCT00396071|Drug|Placebo|matching placebo
45933382|NCT00058968|Drug|Duloxetine hydrochloride|
45933383|NCT00058968|Drug|placebo|
45933384|NCT00396227|Drug|vildagliptin|vildagliptin as add-on to metformin
45933385|NCT00396227|Drug|thiazolidinedione (TZD)|TZD add-on to metformin
45933386|NCT00396305|Drug|Placebo|Sterile phosphate buffered saline solution.
45933387|NCT00396305|Biological|Trivalent Inactivated Influenza|The trivalent influenza vaccine is a sterile suspension prepared from the allantoic fluids of chicken embryos infected with a specific type of influenza virus. Each 0.5 mL dose of the vaccine contains 15 mcg hemagglutinin (HA) of 3 strains of virus (H1N1, H3N2, and B). The vaccine is a liquid preparation; as such, no diluent is required. It is essentially clear and slightly opalescent in color.
45652604|NCT04794647|Other|Cervical mobilization|A kind of manual therapy tecnique applied to the cervical region
45933388|NCT00059241|Behavioral|Parent-child communication education|
45933389|NCT00059241|Behavioral|Service learning|
45933390|NCT00059241|Behavioral|Classroom health curriculum|
45652605|NCT04794647|Other|Placebo mobilization|It was applied to the randomly selected cervical faset without any pushing or pulling in the same position and the same grip with cervical mobilization.
45652606|NCT04350827|Device|Platelet Rich Plasma|Platelet rich plasma injection into patellar tendon
45803411|NCT04949477|Drug|Dexmedetomidine|the patient will receive intranasal dexmedetomidine at a dose of 1 μg/kg to the patient 45 min. before the procedure.
45803412|NCT04949477|Drug|paracetamol|the patient will receive paracetamol orally [Rx paracetamol 250 mg/ml] at a dose of 20 mg/kg given to the patient 45 min before the procedure by drinking.
45803413|NCT05437796|Device|Hypnotic virtual reality support using hypnosis software Hypno-VR®|Hypnosis software Hypno-VR® (Strasbourg, France) paired with VR headsets Oculus VR® (Menlo Park, CA, USA)
45803414|NCT05437796|Device|No Hypnotic virtual reality|Group without Hypnotic virtual reality
45933391|NCT00396344|Other|Çontrol|Intravenous saline
45933392|NCT00396344|Drug|Hydrocortisone|Intravenous stress dose of hydrocortisone
45933393|NCT00396344|Drug|Hydrocortisone|Intravenous pharmacologic hydrocortisone
45933394|NCT00059280|Biological|Myozyme|20 mg/kg qow or 40mg/kg qow
45933395|NCT00059319|Procedure|single aorta clamp with retrograde cardioplegia|
45803415|NCT04873895|Drug|Axitinib 5 MG|axitinib 5 mg po BID until progression or intolerance
45803416|NCT04873895|Drug|Hydroxychloroquine Pill|hydroxychloroquine 600 mg po BID until progression or intolerance
45933396|NCT00059319|Procedure|multiple aorta clamps with antegrade cardioplegia|
45933397|NCT00031499|Drug|Azithromycin|Single 2 gram oral dose (4 tablets) at Day 1.
45933398|NCT00031499|Drug|Benzathine Penicillin|Supplied in pre-filled syringes containing 1.2 million units of benzathine penicillin; 2.4 million units administered intramuscularly at Day 1, in one or both buttocks.
45933399|NCT00031499|Drug|Doxycycline|Baseline visit, 28 capsules dispensed, for a dose of 100 mg twice a day (BID).
45652607|NCT04350827|Device|Platelet Rich Plasma plus IGF|Platelet rich plasma plus IGF injection into patellar tendon
45933400|NCT00059358|Drug|Ribavirin plus interferon alfa-2b|Oral tablets taken daily
45933401|NCT00059358|Drug|Ribavirin|Oral tablet taken daily
45933402|NCT00059358|Drug|Peginterferon alfa-2b|Subcutaneous injection
45933403|NCT02969343|Behavioral|Patient Safety health information technology|Patient safety technology toolkits on hospital care units
45933404|NCT00031577|Drug|paclitaxel|
45933405|NCT00031577|Radiation|radiation therapy|
45933406|NCT00031616|Drug|brivudine phosphoramidate|
45933407|NCT00059436|Behavioral|Mental effort in muscle strengthening|
45933408|NCT02969304|Drug|dimethyl fumarate|"Off-Label Use: All participants <18 years of age and participants without an MS diagnosis who are prescribed dimethyl fumarate~On-Label Use: All participants >18 years of age with an MS diagnosis who are prescribed dimethyl fumarate"
45933409|NCT00031655|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
45652608|NCT01657305|Drug|Oleogel-S10, non-adhesive wound dressing|1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
45652609|NCT01657305|Device|Non-adhesive wound dressing only|Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
45652610|NCT04785209|Other|Mean platelet volume, lymphocyte number, STEMI clinical risk scores|Lab parameters
45652611|NCT04785131|Other|Prune|daily consumption of 50 grams prune.
45652612|NCT05222763|Behavioral|Web-assisted patient education intervention designed according to the self-regulation model|Implementation of patient education with the website created about care and compliance needs in mastectomy patients obtained as a result of qualitative research.
45652613|NCT05222763|Behavioral|The website where the mastectomy patients handbook|The site where the patient booklet is available as pdf
45803417|NCT04873895|Procedure|trans arterial chemoembolization|segmental or lobar TACE at 4-8 week intervals until entire tummy burden is treated.
45803418|NCT00354926|Biological|AME-133v (LY2469298)|IV 4X weekly X 4
45803419|NCT04855955|Drug|Adipose-Derived Mesenchymal Stem Cells|
45803420|NCT05717660|Combination Product|SBRT on all sites of metastatic disease+Apalutamide|oral Apalutamide 240 mg daily+ stereotactic body radiotherapy on all metastatic sites of disease, administered in 1-8 fractions for a total EQD2 of 50 Gy with an alpha/beta of 10.
45933410|NCT00031655|Biological|donor lymphocytes|Given IV
45933411|NCT00031655|Drug|cyclosporine|Given PO
45933412|NCT00031655|Radiation|total-body irradiation|Undergo TBI
45933413|NCT00031655|Drug|fludarabine phosphate|Given IV
45933414|NCT00031655|Drug|mycophenolate mofetil|Given PO
45933415|NCT00031655|Other|laboratory biomarker analysis|Correlative studies
45933416|NCT00031655|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
45933417|NCT00059514|Behavioral|Modified Project Toward No Tobacco Use|
45933418|NCT00059553|Behavioral|Locomotor treadmill training with body weight support|
45933419|NCT02971553|Device|Upright Resuscitator with PEEP|
45933420|NCT02971553|Device|Upright Resuscitator|
45933421|NCT00059592|Drug|Valacyclovir|
45933422|NCT00031733|Biological|MART-1 antigen|
45933423|NCT00031733|Biological|gp100 antigen|
45933424|NCT00031733|Biological|incomplete Freund's adjuvant|
45933425|NCT00031733|Biological|recombinant interleukin-12|
45933426|NCT00031733|Biological|sargramostim|
45933427|NCT00031733|Biological|tyrosinase peptide|
45933428|NCT00031733|Drug|alum adjuvant|
45933429|NCT00031733|Procedure|adjuvant therapy|
45933430|NCT02969265|Drug|Amlodipine|Amlodipine Capsules
45933431|NCT02969265|Drug|TCV-116CCB|TCV-116CCB Tablets
45933432|NCT02969265|Drug|Amlodipine Placebo|Amlodipine placebo-matching capsules
45933433|NCT02969265|Drug|TCV-116CCB Placebo|TCV-116CCB 8/5 mg placebo-matching tablets
45933434|NCT00031772|Procedure|psychosocial assessment and care|Questionnaire and telephone intervention
45933435|NCT02969070|Dietary Supplement|LopiGLIK™ therapy|4 weeks of LopiGLIK™ therapy 1 capsule/day
45933436|NCT02969070|Dietary Supplement|Armolipid Plus® therapy|4 weeks of Armolipid Plus® therapy 1 capsule/day
45933437|NCT00031811|Drug|raloxifene|
45933438|NCT00031811|Procedure|quality-of-life assessment|
45933439|NCT02969148|Procedure|Laparoscopic bursectomy and D2 lymphadenectomy|The anterior lobe of transverse mesocolon and capsula pancreatis will be dissected with the D2 lymphadenectomy according to the guidelines of National Comprehensive Cancer Network(NCCN) by laparoscopy，this is Laparoscopic bursectomy and D2 lymphadenectomy.
45933440|NCT02969148|Procedure|Laparoscopic D2 lymphadenectomy|D2 lymphadenectomy is carried out according to the guidelines of National Comprehensive Cancer Network(NCCN).
46073427|NCT02826408|Drug|Rabeprazole sodium|WIll study effect of the medication on palpittions
46073428|NCT02826408|Drug|Pacebo|Placebo comparison to active treatment
45803421|NCT05717582|Drug|apalutamide|Patients receive apalutamide 240mg,qd,po.
45803422|NCT05717582|Drug|androgen deprivation therapy|Patients receive systemic ADT.
45933441|NCT02971709|Behavioral|Shade Sail|Shade sails had powder-coated or gout galvanized steel poles and a lighter colored shade cloth to transmit visual light. The shade cloth met Ultraviolet Protection Factor (UPF) ratings to reduce UV under the shade cloth by 94%. The final shade sail designs and sizes were determined with input from parks department staff and complied with all local engineering, building, and planning codes. Shade sails exceeded the minimum safety requirements for strength (for wind and snow load), resistance to light degradation, and UV transmission. The design minimized climbing access points and hazards to adjacent activities.
45652614|NCT04803461|Diagnostic Test|serum and urinary catecholamines|estimation of level of serum and urinary catecholamines before and after excimer light treatment for patient with non segmental vitiligo.
45652615|NCT05222685|Behavioral|Better Together Physician Coaching|Professional group coaching for medical trainees. A 6 month, online, group, positive psychology based coaching program for wellness.
45652616|NCT04794881|Other|24 hours|Performing a lumbar puncture at 24 hours after a traumatic lumbar puncture
45652617|NCT04794881|Other|48 hours|Performing a lumbar puncture at 48 hours after a traumatic lumbar puncture
45652618|NCT05221749|Drug|Nanosilver Fluoride (NSF)|Optimized synthesis of Nanosilver Fluoride
45652619|NCT05221749|Drug|Silver diamine fluoride|Silver Diamine Fluoride
45652620|NCT04426721|Drug|Ozone|10 cc of oxygen-ozone
45652621|NCT04426721|Drug|Hyaluronic Acid|Sinovial forte 32 mg\2ml
45803423|NCT05717582|Procedure|cytoreductive radical prostatectomy with/without pelvic lymph node dissection|Patients receive cytoreductive radical prostatectomy with/without pelvic lymph node dissection.
45803424|NCT05717582|Radiation|metastasis-directed therapy with radiation|Patients receive metastasis-directed therapy with radiation guided by post-treatment oligopersistent metastases.
45933442|NCT00031850|Drug|goserelin acetate|
45933443|NCT00031850|Drug|raloxifene|
45933444|NCT00059631|Drug|Mitoxantrone (Novantrone)|Starting dose of 3 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles.
45451848|NCT02265250|Other|MRI|Noncontrast T1- and T2-weighted 3.0 T MRI of the bilateral carotid, coronary, and superficial femoral arteries
45803425|NCT03101033|Device|Mechanical epidural neuroplasty|Guided by X-ray transillumination,an epidural needle will be inserted through sacral hiatus. A catheter （BS epidural catheter, BioSpine Co., Ltd, Korea） will be inserted through the epidural needle to the epidural space where disc herniation locates, mechanical adhesiolysis will be implemented.
45803426|NCT03101033|Drug|Transforaminal epidural compound betamethasone injection|Guided by X-ray transillumination, A puncture needle will be inserted to the intervertebral foramen in the vicinity of affected nerve root, and steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan®, Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected.
45933445|NCT00059631|Drug|Bortezomib (PS-341)|Starting Dose of 1.4 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.
45933446|NCT00031889|Drug|Exemestane|Exemestane
45933447|NCT00031889|Drug|Exemestane+bicalutamide|Exemestane as in arm I and oral bicalutamide once daily
45933448|NCT00059670|Procedure|Shaker Exercise vs. Traditional Dysphagia Therapy Regime|
45451849|NCT02265250|Other|PET/MRI|Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries
45652622|NCT05221359|Device|ExOlin®|"Implantation of ExOlin® device, safety follow-up followed by a treatment period in which device is used to administer insulin.~Device explanted with a safety follow-up."
45652623|NCT05221359|Drug|Insulin aspart|Use of NovoRapid insulin during all periods of the clinical investigations
45652624|NCT04803071|Dietary Supplement|Experimental group of n-pufas improving cognitive formula|Three times a day, one capsule of n-3pufas improvement cognitive formula capsule (once in the morning, in the evening) and routine treatment for depression, lasting for 12 weeks
45652625|NCT04803071|Dietary Supplement|General fish oil formula product adjuvant treatment control group|The control group: 1 capsule of general fish oil formula (once in the morning, in the evening) three times a day, plus routine treatment for depression, lasting for 12 weeks
45652626|NCT04803071|Dietary Supplement|Placebo assisted treatment group|Three times a day, one capsule of placebo adjuvant therapy (once in the morning, one in the evening) and conventional treatment of depression for 12 weeks
45652627|NCT05219955|Behavioral|Morning Action Plan Execution|Each day, participants are asked to track if they do the morning activity plan.
45652628|NCT05219955|Behavioral|Activity Strategy-based Session with Therapist|Participants will meet weekly with a trained therapist to discuss their prescribed activity plan. If unsuccessful, at weekly follow-ups, participants are asked to refine their plan or make a new one. Each session lasts about 30-45 minutes.
45652629|NCT05219955|Behavioral|Attention-based Session with Therapist|Participants will meet weekly with trained a therapist to talk about stressors they experience, providing an opportunity to voice and self-address their problems. In this control condition, therapists will not deliver any particular strategy except for active listening and referring to the educational materials
45933449|NCT00059709|Procedure|Mediated Negotiation Training|
45933450|NCT00031928|Drug|mafosfamide|
45652630|NCT05219955|Behavioral|Advance sleep-wake time|Some participants will be asked to adjust their sleep schedule to accommodate morning activity engagement by introducing or altering mechanisms known promote early rising (i.e., light exposure, reward and processes, etc.)
45652631|NCT04794413|Drug|Pimavanserin|Pimavanserin is a serotonin receptor inverse agonist used in treatment of psychosis in Parkinson's disease.
45933451|NCT02969226|Procedure|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
45933452|NCT02969226|Procedure|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
45933453|NCT02969226|Procedure|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS >0 and =< 8 cm H2O with PEEP>0 and =< 5 cm H2O
45933454|NCT02969226|Procedure|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece (off the ventilator)
45933455|NCT00031967|Drug|therapeutic melatonin|
45933456|NCT00031967|Radiation|radiation therapy|
45933457|NCT00059826|Biological|interferon-alfa-2b|IV
45933458|NCT00059826|Drug|cisplatin|IV
46073429|NCT00633230|Drug|standardized herbal formula, Sho-saiko-to (SST)|3 capsules containing 700 mg of the Sho-saiko-to (SST) herbal extract/capsule and 28 mg of the excipients, magnesium stearate, and silicon dioxide/capsule 2 x day
46073430|NCT00633230|Other|placebo capsule identical to the active herbal formula|3 placebo capsules 2 x day
46073431|NCT04242888|Other|pragmatic manual therapies|three of the intervention are novel and the rest of the interventions are in practice but seldom used to treat the shoulder disorder.
45803427|NCT03101033|Drug|Caudal epidural compound betamethasone injection|steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan® Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected through the epidural catheter after mechanical epidural neuroplasty.
45652632|NCT05219565|Device|Attractive Targeted Sugar Bait (ATSB)|An ATSB is a A4-sized panel containing thickened fruit syrup laced with a neonicotinoid insecticide, dinotefuran. The syrup-insecticide mixture is covered with a protective membrane that allows mosquitoes to feed through the membrane while preventing non-target organisms from feeding. This device is designed to attract and kill mosquitoes.
45652633|NCT04802993|Other|Resection rates|All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)
45652634|NCT02634307|Drug|ALKS 8700|Administered as specified in the treatment arm.
45652635|NCT01365273|Device|Mepitel One|Dressing
45652636|NCT04793945|Combination Product|topical steroid and 308nm-Excimer light therapy|applying topical steroid in combination with 308nm-Excimer light therapy to treat Alopecia Areata
45803428|NCT03101033|Drug|Epidural hyaluronidase injection|Hyaluronidase of 1500 IU （Sine®, SPH NO.1 Biochemical and Pharmaceutical Co., LTD）will be injected through the epidural catheter after mechanical epidural neuroplasty and caudal epidural compound betamethasone injection.
45803429|NCT04939298|Device|Ultrasound|Ultrasound evaluation of the variation of thickness of abdominal muscles after 7 days of mechanical ventilation.
45803430|NCT04935710|Behavioral|COPE2Thrive|Cognitive Behavioral Therapy-based program to help teens deal with anxiety, stress and depression by showing them how to develop skills needed to stop negative thoughts and start thinking and behaving in more positive ways.
45803431|NCT04935710|Genetic|Usual care|Children at risk who are not randomized to COPE2Thrive at any point of time serve as the control group.
45803432|NCT02069041|Biological|Ramucirumab|Administered IV.
45933459|NCT00059826|Drug|5-fluorouracil|IV
45933460|NCT00059826|Radiation|radiation therapy|
45451850|NCT02265250|Other|Laboratory blood test|Cardiovascular biomarkers
45803433|NCT02069041|Drug|FOLFOX4|Administered IV.
45803434|NCT04920344|Procedure|Transoral Surgery|Patients will undergo transoral surgery
45803435|NCT04920344|Radiation|External Beam Radiation Therapy|Patients in Group II and Group III will undergo External Beam Radiation Therapy (EBRT) RT following transoral surgery.
45803436|NCT04920344|Drug|Cisplatin|Patients in Group III will receive cisplatin, 30 mg/m2, administered intravenously weekly per for 6 weeks.
45803437|NCT04920344|Procedure|Incisional Tumor Biopsy|Incisional biopsy of the primary tumor site will be required to confirm p16/HPV status of the tumor
45803438|NCT04920344|Other|Circulating tumor deoxyribonucleic acid (ctDNA) levels assessment|Assess ctDNA levels at baseline, 2 weeks, 4 weeks, 10 weeks, 24 weeks and 1 year after the surgery.
45803439|NCT04920344|Other|MD Anderson Dysphagia Index|MDADI is a 20 item quality of life questionnaire specifically focusing on swallowing aspects. It was originally designed for head and neck cancer patients. The total score ranges from 20 to 100 with the higher score indicating higher level of function.
45803440|NCT04920344|Other|University of Washington Quality of Life Questionnaire|University of Washington Questionnaire is a 15 item quality of life instrument specifically designed for head and neck cancer patients.
45803441|NCT04920344|Other|Euro-QOL 5 dimension scale questionnaire|A generic quality of life and cost utility instrument widely used and validated for multiple disease settings, including head and neck cancer.
45803442|NCT04920344|Diagnostic Test|Modified barium swallow (MBS) evaluation with aspiration-penetration scale|"The videofluoroscopic modified barium swallow (MBS) study is the gold standard for for the evaluation of dysphagia, and specifically, airway protective mechanisms.~The penetration/aspiration (PEN/ASP) scale is a routinely used eight-point scale designed to describe the depth of bolus penetration into the airway and the patient response to the penetration or aspiration."
45803443|NCT03101111|Biological|MV-CHIK|Lyophilized, life attenuated, measles vectored Chikungunya vaccine; 5E+05 TCID50 (+/- 0.5 log) per dose
45803444|NCT03101111|Biological|MMR-vaccine|Lyophilized mixture of life attenuated Measles, Mumps, and Rubella viruses; 1000, 12500, and 1000, respectively, TCID50 per dose
45803445|NCT05423834|Drug|Tenofovir alafenamide|Chronic hepatitis B patients who are receiving TAF as antiviral therapy for CHB, who were previously treatment naïve.
45803446|NCT05423834|Drug|Entecavir|Chronic hepatitis B patients who are receiving ETV as antiviral therapy for CHB, who were previously treatment naïve.
45803447|NCT03102437|Device|Optimizer Smart System|The Optimizer Smart System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
45803448|NCT04918472|Procedure|MCCE|Mangetically controlled capsule endoscopy will be performed
45933461|NCT00032006|Radiation|brachytherapy|
45933462|NCT00032006|Radiation|radiation therapy|
45933463|NCT00032045|Biological|gp100 antigen|
45933464|NCT00032045|Biological|incomplete Freund's adjuvant|
45933465|NCT00032045|Biological|ipilimumab|
45933466|NCT00059865|Drug|gemcitabine hydrochloride|
45933467|NCT00059865|Drug|pemetrexed disodium|
45933468|NCT00032084|Behavioral|smoking cessation intervention|Physician will deliver the smoking cessation advice, reinforce the established quit date (no sooner than seven days after starting bupropion/placebo), and will distribute patient educational materials and all pharmacotherapy
45933469|NCT00032084|Drug|bupropion hydrochloride|150 mg/day on Days 1-3, 300 mg/day on Day 4-77
45803449|NCT05406635|Diagnostic Test|Biomarkers: Troponins and natriuretic peptides|Biomarker monitored treatment with measurement of NT-proBNP and cTNT / TNI in weeks 0, 9, 18, 30 and 48 of the treatment period.
45933470|NCT00032084|Drug|nicotine|21 mg patch/day for Weeks 2-7; 14 mg patch/day for Weeks 8-9; 7 mg patch/day for Weeks 10-11.
45933471|NCT00032084|Procedure|psychosocial assessment and care|The nurse/CRA will debrief the patients after the brief physician intervention and will follow-up with a series of 5 phone calls to provide booster advice. All advice will be based on the stage of change model (i.e., tailored to the patient's readiness to quit and/or stay off cigarettes).
45933472|NCT00059904|Biological|aldesleukin|
45933473|NCT00059904|Biological|rituximab|
45933474|NCT02968953|Drug|Triheptanoin|A single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome will receive tripheptanoin (UX007).
45933475|NCT00032123|Drug|erlotinib hydrochloride|
45933476|NCT02968875|Device|Endurance Training|40 people will submitted to endurance training: 20 will perform a continuous training and 20 will perform an interval training. The variables that will be analyzed are maximum aerobic power, endurance, heart rate, prehension strength, Mini-Mental State Examination (MMSE), REY's test, biological examination and level of BDNF plasma, before and after the intervention and one month after the end of the intervention and one month after the end of the intervention.
45933477|NCT02968875|Other|therapeutic education meetings|Group of 20 people will be the control group and will not perform ET. However, they will have 9 therapeutic education meetings.
45652637|NCT05312775|Procedure|Double-layer uterine closure|In the intervention group, double-layer closure of the uterus will be performed using unlocked multifilament continuous running sutures for both layers and the endometrial layer will be included in the first layer. The second layer is a continuous running suture that imbricates the first layer
45451851|NCT01616524|Biological|Pegylated interferon lambda (pegIFNλ)|Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
45451852|NCT01616524|Biological|Pegylated interferon lambda (pegIFNλ)|Syringe, Subcutaneous, 180 μg, Once weekly, 12 weeks
45451853|NCT01616524|Biological|Pegylated interferon alfa-2a (pegIFNα-2a)|Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
45451854|NCT01616524|Drug|Ribavirin|Tablets, Oral, 400 mg, Twice daily, 24 weeks
45451855|NCT01616524|Drug|Ribavirin|Tablets, Oral, 400 mg, Twice daily, 12 weeks
45451856|NCT01616524|Drug|Daclatasvir|Tablets, Oral, 60 mg, Once daily, 12 weeks
45451857|NCT01616524|Drug|Placebo matching Daclatasvir|Tablets, Oral, 0 mg, Once daily, 12 weeks
45652638|NCT05312775|Procedure|Single-layer uterine closure|The control group will receive a single-layer closure using unlocked continuous running multifilament sutures and the endometrial layer will be included
45652639|NCT04794257|Device|Neuromonitoring of the recurrent laryngeal nerves|The NIM Vital system (Medtronic, Jacksonville, US) operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid.
45803450|NCT05717426|Other|Open chain exercises|An open chain exercise is one that allows the furthest part of the chain to move freely. For example, picking up a glass of water is an open-chain exercise. The hand affects the elbow and the shoulder as it is not fixed in place. However, it does not effect the rest of your body.
45933478|NCT00059943|Drug|docetaxel|
45933479|NCT00032162|Drug|carboplatin|AUC 6 q4w
45933480|NCT00032162|Drug|pegylated liposomal doxorubicin hydrochloride|20/30/40 mg/qm q4w Dose finding study
45933481|NCT00059982|Drug|perifosine|
45933482|NCT00060021|Procedure|acupuncture therapy|
45933483|NCT00060021|Procedure|management of therapy complications|
45933484|NCT00060021|Procedure|pain therapy|
45933485|NCT00032240|Device|Shoe Insert|
45451858|NCT02263378|Drug|ellagic acid + annona muricata|pills
45803451|NCT05717426|Other|Closed kinetic chain exercises|Closed Kinetic Chain (CKC) exercises or closed chain exercises are exercises or movements where the distal aspect of the extremity is fixed to an object that is stationary.
45451859|NCT02265328|Dietary Supplement|Bovine colostrum|Oral Bovine colostrum 200 ml (20 gram) TDS × 2 months
45652640|NCT04794179|Device|Naida Link CROS|Individuals 65+ who already have Advanced Bionics CII/90K/Ultra cochlear implants will be given Naida Link CROS device to assess the effect the device has on speech understanding in challenging listening situations and on the quality of life in unilateral cochlear implant recipients and their frequent communication partners.
45803452|NCT02069119|Drug|OPC-108459|
45803453|NCT02069119|Drug|Placebo|
45803454|NCT04139135|Drug|HLX10|neoadjuvant treatment phase：HLX10（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：HLX10（4.5mg/kg/3w IV）
45803455|NCT04139135|Drug|Placebos|neoadjuvant treatment phase：placebos（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：SOX
45803456|NCT05714696|Behavioral|Weight discrimination experience|"In the experimental condition, participants will learn that their group members are biased against overweight people but not elderly or racial/ethnic minority individuals, as indicated by the getting to know you summary ratings handout. Participants will also receive negative feedback about their personal attributes by being labeled with negative weight-based stereotypes. Although some ratings will be positive (e.g., they will receive high ratings on being friendly and kind), participants will be rated poorly on attributes viewed as necessary to develop a strong marketing campaign (i.e., motivation to work hard, possessing self-discipline to persist at the task, and competence). After (ostensibly) assembling the group's preferences, the experimenter will inform participants that no one selected them to be their partner, thus they will perform the next few tasks alone. This manipulation has been shown to prompt feelings of social exclusion."
45451860|NCT02265328|Dietary Supplement|Enteral Nutrition|Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 40/kg/day, carbohydrate 67-80%, Fat 20-33%.
45803457|NCT05714696|Behavioral|Control experience|"In the control condition, participants will learn that their group members have positive attitudes toward people with higher body weight, as well as elderly and racial/ethnic minority individuals, as indicated by the getting to know you summary ratings handout. Participants will also receive positive feedback about their personal attributes, as indicated by the summary ratings averaged across the three members. Finally, participants in the control condition will be told that one of their group members had to leave unexpectedly for a family emergency, so pairs cannot be assembled as usual, thus they will perform the next few tasks alone. This manipulation should not prompt feelings of social exclusion."
45803458|NCT05406557|Procedure|Partial pulpotomy|In case of partial pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece with water coolant to a depth of superficial 2-3 mm of pulp chamber.
45803459|NCT05406557|Procedure|Miniature pulpotomy|In case of miniature pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece with water coolant to a depth of superficial 2-3 mm of only affected pulp horn
45451861|NCT02265328|Other|prednisolone|Oral prednisolone 40mg/day × 4 weeks and tapered to <40mg/day for next 4 weeks. (If Lilli score > 0.45 after 7 days, then prednisolone would be stopped)
45451862|NCT02265406|Drug|Anti-Infective Agents|
45451863|NCT02265406|Drug|Placebo|
45451864|NCT01422148|Drug|Amiodarone|oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
45803460|NCT04904354|Device|AcQBlate® Force Sensing Ablation System|Catheter ablation of accessible pulmonary veins with the endpoint of creating electrical isolation for each targeted vein. Additional left and right atrial targets may be ablated as clinically indicated.
45803461|NCT02069353|Device|QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)|
45803462|NCT02069353|Device|Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)|
45803463|NCT04899830|Device|Telepresence robot|From the application installed on a tablet, the patient hospitalized in a center for a period of at least 2 months can start from the center where he is hospitalized the mobile robotic telepresence assistance device installed at home to communicate with his family, his friends, his neighbors,…)
45803464|NCT04011527|Procedure|Rotational Atherectomy in Coronary Lesion/s|
45803465|NCT05440877|Behavioral|VR materials|In the lecture room for the intervention group, participants in the intervention group will be given QR codes for viewing these online videos and VR cardboards, a web including photo hunt sections that allow viewers to find cues for smoking cessation treatment. They are asked to view these videos and photos with their own mobile phones.
45803466|NCT05440877|Behavioral|Tutorial guide|A tutorial guide including description of the smokers' cases
45803467|NCT03103061|Drug|Lexiscan|Coronary vasodilator
45803468|NCT03105479|Drug|Cadazolid|Granules for oral suspension to be administered twice daily
45803469|NCT03105479|Drug|Vancomycin capsule|Capsule containing 125 mg of vancomycin to be administered orally 4 times a day
45803470|NCT03105479|Drug|Vancomycin solution|Vancomycin powder to be administered as oral solution at a dose of 40 mg/kg/day, 3 to 4 times a day
45803471|NCT04852796|Other|Patients with hemopathy|optimal humoral response at 1 month after COVID-19 vaccination
45803472|NCT00355862|Drug|CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)|center specific therapeutic regimen without mTOR inhibition
45933486|NCT02958696|Drug|HTL0018318|Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.
45652641|NCT05311449|Other|Acupressure|The experimental group will start with LI4 points, and continue with P6 and SP6 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
45933487|NCT00032279|Drug|Visilizumab|
45803473|NCT00355862|Drug|Sirolimus|Sirolimus based immunosuppression
45803474|NCT03106337|Device|Shear-Wave Elastography|Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
45803475|NCT03772847|Drug|ginkgolide|ginkgolide plus alteplase
45803476|NCT05345834|Behavioral|Patient Navigation|Participants in arm 2 will receive patient navigation provided by humans (rather than e-navigation) to provide personalized care to include support, resources, and referrals to address psychosocial issues that arise during the perinatal period. Patient navigation is available to participants through 12 months postpartum.
45933488|NCT00060099|Biological|HspE7|
45933489|NCT00032357|Procedure|Ferritin reduction to 25 ng/ml by phlebotomy|
45933490|NCT00060138|Biological|monoclonal antibody CAL|
45933491|NCT00060138|Drug|zoledronic acid|
45451865|NCT01422148|Drug|Minocycline|intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
45652642|NCT05311449|Other|Plasebo acupressure|In the control group, the application will start with the points 1.5 cm around the LI4, P6 and SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
45933492|NCT00032396|Drug|Retisert Implant|
45803477|NCT05345834|Behavioral|Adapted Cognitive-Behavioral Therapy|Participants who do not meet diagnostic criteria (Group 2a) will participate in a prevention group which includes 8 sessions based on culturally adapted CBT for Black/ of African descent populations facilitated by mental health professionals. Participants who meet diagnostic criteria (Group 2b) will participate in individual treatment which includes 12 sessions based on culturally adapted CBT for Black/ of African descent populations.
45803478|NCT02049151|Drug|Tecemotide|Tecemotide injection will be administered once weekly subcutaneously at a dose of 806 microgram up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
45933493|NCT00060255|Drug|busulfan|iv
45803479|NCT02049151|Drug|Placebo|Matching placebo injection will be administered once weekly subcutaneously up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
45803480|NCT02049151|Drug|Cyclophosphamide (CPA)|CPA injection will be administered as a single intravenous infusion at a dose of 300 milligram per square meter (mg/m^2) (to a maximum of 600 mg) 3 days before the first injection of tecemotide.
45803481|NCT02049151|Drug|Saline (sodium chloride)|Matching placebo (saline) injection will be administered as a single intravenous (0.9 percent [%] sodium chloride) infusion 3 days before the first injection of tecemotide-matching placebo.
45933494|NCT00060255|Drug|carboplatin|iv
45933495|NCT00060255|Drug|carmustine|iv
45933496|NCT00060255|Drug|cyclophosphamide|iv
45933497|NCT00060255|Drug|etoposide|iv
45933498|NCT00060255|Drug|melphalan|oral
45933499|NCT00060255|Drug|thiotepa|iv
45933500|NCT00060255|Procedure|autologous bone marrow transplantation|iv
45933501|NCT00060255|Procedure|bone marrow ablation with stem cell support|iv
45933502|NCT00060255|Procedure|peripheral blood stem cell transplantation|iv
45933503|NCT00060255|Radiation|radiation therapy|body x-ray
45933504|NCT00032435|Drug|PAL-40 Active|
45933505|NCT00032435|Drug|PAL-40 Placebo|
45933506|NCT00060294|Biological|rituximab|
45933507|NCT00060294|Radiation|yttrium Y 90 ibritumomab tiuxetan|
45933508|NCT00032474|Drug|Ginkgo biloba extract|
45933509|NCT00060372|Drug|ipilimumab|Given IV
45451866|NCT01421056|Drug|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 24 weeks
45933510|NCT00060372|Drug|therapeutic allogeneic lymphocytes|Given IV
45933511|NCT00398502|Drug|MOA-728|
45933512|NCT00032669|Drug|HAART|
45933513|NCT00060411|Drug|erlotinib hydrochloride|Given IV
45933514|NCT00060411|Drug|fluorouracil|Given IV
45933515|NCT00060411|Drug|leucovorin calcium|Given IV
45933516|NCT00060411|Drug|oxaliplatin|Given IV
45933517|NCT00060411|Biological|bevacizumab|Given IV
45933518|NCT00032708|Biological|Dryvax|
45933519|NCT00060450|Drug|nitric oxide for inhalation|Either 10 or 20 ppm of inhaled nitric oxide for 24 hour post transplant
45933520|NCT00060450|Drug|Placebo|Placebo gas will be given at 10 or 20 ppm for 24 hours post transplant
45933521|NCT00032747|Drug|Vasopressin V2 Receptor Antagonist|
45933522|NCT04730934|Other|Perceived stress scale|Perceived stress scale (PSS) : The PSS is a validated 10-item self-report questionnaire which asks individuals to indicate how often they have found their lives unpredictable, uncontrollable, and overloaded in the last month. The higher scores indicating greater perceived stress.
45933523|NCT04730934|Other|Fibromyalgia impact questionnaire|Fibromyalgia impact questionnaire (FIQ): The FIQ is composed of 10 items. The first item contains 11 questions related to physical functioning - each question is rated on a 4 point Likert type scale. Items 2 and 3 ask the patient to mark the number of days they felt well and the number of days they were unable to work (including housework) because of fibromyalgia symptoms. Items 4 through 10 are horizontal linear scales marked in 10 increments on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety and depression.
45652643|NCT05214729|Diagnostic Test|Fast ultrafiltration challenge|"The fast ultrafiltration challenge will be performed once in all enrolled participants, in the order defined by randomization. The fast ultrafiltration challenge consists of the net removal of 250 ml of ultrafiltrate by setting net ultrafiltration rate to 1000 ml/h, applied for 15 minutes. The cardiac output will be measured before and after the UF challenge, by mean of the transpulmonary thermodilution technique, and its relative variation from baseline will be quantified to evaluate the impact of the UF challenge on cardiac preload.~The UF challenge will be preceded and immediately followed by a postural change maneuver to assess the presence or absence of preload dependence. The postural change maneuver is positive in case of a +10% variation in continuous cardiac index over 1 minute, and is considered as the reference diagnostic test to which UF challenge diagnostic performance will be compared."
45803482|NCT03844295|Device|Activated Inspire® Upper Airway Stimulation System|At first, INSPIRE® device will be active a month
45803483|NCT03844295|Device|Inactivated Inspire® Upper Airway Stimulation System|"After 15 days wash-out INSPIRE® device will be inactivated for a second period of one month."
45803484|NCT05341310|Behavioral|ADHDCoach|ADHDCoach is an individually-tailored intervention to reduce parents' of children diagnosed with ADHD distress.
45933524|NCT04730934|Other|The drugs used before and during the pandemic, the patient's job status, physical activity conditions, pain status|"Drug using: Antidepressant, SNRI, gabapentin, SSRI, myorelaxan, nsaid, paracetamol, pregabalin, tramadol, food supplement.~Job status: Participants were questioned about their occupational status before and during the pandemic as I am a housewife, I quit my job, I worked from home, I worked part-time and there was no change in my job.~Physical activity: I do not have physical activity, I do my daily work at home, I do daily walks, I exercise regularly.~Pain status: Participants were questioned that their pain conditions before and during the pandemic were much worse, worse, a little bad, no change, a little good,  better, It was questioned as much better."
45933525|NCT00032786|Drug|natalizumab|
45933526|NCT02968719|Drug|Donepezil TDS Version A|Donepezil Hydrochloride Transdermal Delivery System (5mg and 10 mg Version B)
45933527|NCT02968719|Drug|Donepezil TDS Version B|Donepezil Hydrochloride Transdermal Delivery System (5 mg and 10 mg Version B)
45933528|NCT02968719|Drug|Aricept|Aricept (5 mg and 10 mg) Donepezil Hydrochloride
45933529|NCT02968719|Drug|Donepezil TDS Version D|Donepezil Hydrochloride Transdermal Delivery System (5 mg Version D)
45933530|NCT02968719|Drug|Donepezil TDS Version E|Donepezil Hydrochloride Transdermal Delivery System (5 mg Version E)
45933531|NCT00060489|Drug|SEROQUEL (quetiapine fumarate) Tablets|
45933532|NCT00032825|Drug|Ketaconazole|
45933533|NCT00032825|Drug|Docetaxel|
45933534|NCT04730700|Procedure|Radiofrequency Ablation with MEE|RFA will be performed in the usual fashion utilizing the MEE instead of the RFA needles routinely used at each institution.
45451867|NCT01421056|Drug|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 20 weeks
45803485|NCT05341310|Other|Treatment as usual|Treatment as usual in the outpatient clinic
45451868|NCT01421056|Drug|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 16 weeks
45451869|NCT02263456|Biological|Replenine®-VF (High Purity Factor IX)|
45803486|NCT00355550|Drug|Tricaprilin|Powder formulation will be mixed in a liquid (approximately 8 oz).
45451870|NCT02263534|Procedure|single incision minisling|midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) in the retropubic direction with its end grasped with an artery forceps till level of perineal membrane closure of the vagina 2 sham incisions if the skin only will be made at suprapubic to maintain blindness posterior colpoperneorraphy will be carried out if needed
45803487|NCT00355550|Other|Placebo|Powder formulation will be mixed in a liquid (approximately 8 oz).
45803488|NCT03726359|Radiation|Fractionated Stereotactic Radiation Therapy|Initial starting dose will be 7 Gy x5= 35 Gy delivered to the planning target volume (PTV). Radiotherapy will be delivered every other day so that the SBRT schedule is completed within 1.5-2 weeks.
45803489|NCT02049307|Drug|Losartan 100mg daily|
45803490|NCT02049307|Drug|Matching placebo|
45803491|NCT05319236|Device|Gabi System|See arm description
45803492|NCT05314556|Behavioral|Group psychotherapy|Additional group psychotherapy for patients with narcolepsy type 1 with standard medication
45803493|NCT05311592|Behavioral|HERO Dads Program|The HERO Dads Program is a 4-week series of workshops for non-custodial fathers that focuses on improving parenting, offering job support, and financial counseling.
45803494|NCT00355628|Drug|KW-2246 (fentanyl citrate)|KW-2246
45803495|NCT02049385|Drug|Diazoxide|A nondiuretic vasodilator thiazide-related agent
45933535|NCT04730700|Behavioral|Conventional Medical Management|Conventional medical management (CMM), which may include physical therapy, home exercise programs, pain medication, and other conservative therapies such as back brace, walking aid, and chiropractic care.
45933536|NCT02971436|Device|FPH Device with SensAwake On + Pressure Support A|FPH Device with SensAwake On + Pressure Support A
45933537|NCT02971436|Device|FPH Device with SensAwake Off + Pressure Support A|FPH Device with SensAwake Off + Pressure Support A
45803496|NCT02049385|Drug|Placebo|Placebo
45652644|NCT05214729|Diagnostic Test|Slow ultrafiltration challenge|"The slow ultrafiltration challenge will be performed once in all enrolled participants, in the order defined by randomization. The slow ultrafiltration challenge consists of the net removal of 250 ml of ultrafiltrate by setting net ultrafiltration rate to 500 ml/h, applied for 30 minutes. The cardiac output will be measured before and after the UF challenge, by mean of the transpulmonary thermodilution technique, and its relative variation from baseline will be quantified to evaluate the impact of the UF challenge on cardiac preload.~The UF challenge will be preceded and immediately followed by a postural change maneuver to assess the presence or absence of preload dependence. The postural change maneuver is positive in case of a +10% variation in continuous cardiac index over 1 minute, and is considered as the reference diagnostic test to which UF challenge diagnostic performance will be compared."
45652645|NCT04784741|Other|Conventional static hamstring muscle stretching|Static stretching protocol had 10 repetitions in total with 15 seconds stretch time and 30 seconds relaxing time of hamstring muscle.
45933538|NCT02971436|Device|FPH Device with SensAwake On + Pressure Support B|FPH Device with SensAwake On + Pressure Support B
45933539|NCT02971436|Device|FPH Device with SensAwake Off + Pressure Support B|FPH Device with SensAwake Off + Pressure Support B
45933540|NCT02971436|Device|Competitor's PAP Released Device + Pressure Support A|Competitor's PAP Released Device + Pressure Support A
45933541|NCT02971436|Device|Competitor's PAP Released Device + Pressure Support B|Competitor's PAP Released Device + Pressure Support B
45803497|NCT03717155|Drug|Avelumab|Participants received avelumab intravenous infusions at a dose of 800 milligram (mg) on Day 1 and Day 8 of each 3-week cycle for the first 4 cycles. Thereafter, administered every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.
45933542|NCT00060645|Drug|ridaforolimus|There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.
45933543|NCT02968797|Device|SafeSed|Monitor respiratory parameters
45933544|NCT00032903|Drug|Gimatecan® (ST 1481)|
45933545|NCT00396422|Drug|RWJ-445380|
45803498|NCT03717155|Drug|Cetuximab|Participants received cetuximab intravenous infusions at a dose of 250 milligram per meter square (mg/m^2) body surface area on Day 1 and 500 mg/m^2 body surface area on Day 8 of first 4 cycles of concurrent chemotherapy. Thereafter, administered given at a dose of 500 mg/m^2 intravenous every 2 weeks in the Maintenance phase, until disease progression or unacceptable toxicities.
45803499|NCT03717155|Drug|Gemcitabine|Participants received gemcitabine intravenous infusions at a dose of 1250 mg/m^2 body surface area on Day 1 and Day 8 in 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.
46073432|NCT04250870|Diagnostic Test|Senior Fitness Test|"Chair stand test:The number of full stands performed on a seated position that can be completed within 30 seconds was recorded.~Arm curl test: The participants were asked to lift weights starting with a full elbow extension and then full flexion.~2-minute step test: The participant was asked to begin stepping as quickly as possible to reach the marked height for two minutes.~Chair sit-and-reach test:The participant could extend right or left knee to a full extension, heel on the floor and ankle in a neutral position of 90 degrees. Then, the participant was asked to reach to the toes.~Back-scratch test:The participant was asked to stand up and place his/her preferred hand over the same shoulder, palm down and fingers extended, and reach down the middle of the back as far as possible.~8-foot up and go test:The participant was asked to get up from a chair without any arm support and walk a distance of 2.44 meters; then turn around a cone and come back to sit down on the chair."
46073433|NCT02839382|Other|Coaching|An external facilitator or coach is assigned 15-20 primary care clinics and will make face-to-face site visits and monthly phone calls for 15 months to support building QI capacity in each assigned practcie
45803500|NCT03717155|Drug|Cisplatin|Participants received cisplatin intravenous infusions at a dose of 75 mg/m^2 body surface area on Day 1 of 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.
45933546|NCT00060684|Drug|Pixantrone (BBR 2778)|
45933547|NCT00060684|Drug|fludarabine|
45933548|NCT00060684|Drug|dexamethasone|
45933549|NCT00060684|Drug|rituximab|
45933550|NCT00396461|Drug|MCT/LCT (1:1)|Emulsion based on 20% MCT/LCT (50:50 ratio)
45933551|NCT00396461|Drug|MCT/LCT/omega-3 (5:4:1)|Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides.
45933552|NCT02971475|Procedure|extracorporeal shock wave lithotripsy|People in this group would be treated with ESWL only.
46073434|NCT02839382|Other|Educational Outreach|Practices randomized to this arm of the study will receive an educational outreach phone call by an academic expert on implementation strategies for use of a cardiovascular risk calculator within their daily work flow and clinic setting
45933553|NCT02971475|Procedure|endoscopic drainage of the main pancreatic duct|People in this group would be treated with ESWL followed be endoscopic drainage in 48 hours.
45933554|NCT02971475|Drug|Analgesics|Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
45933555|NCT00060762|Behavioral|Interpersonal Therapy|20 sessions of interpersonal therapy were provided over a 6-month period
45933556|NCT00060762|Behavioral|Behavioral Weight Loss Treatment|20 sessions of behavioral weight loss treatment were provided over a 6-month period
45933557|NCT00060762|Behavioral|Guided Self Help|10 sessions of guided self help were provided over a 6-month period
45933558|NCT00032942|Drug|Lofexidine|
45933559|NCT00032981|Behavioral|Behavior Therapy|
45933560|NCT00060801|Drug|BIIL 283 BS (Amelubent)|
45933561|NCT00033020|Behavioral|Behavior Therapy|
45933562|NCT02968485|Drug|SHR7390|SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg and 0.5 mg. Multiple tablets of SHR7390 will be administered daily to achieve targeted doses of SHR7390: 0.25 mg-4 mg. Tablets will be orally administered with 240 ml water, once daily, 2 hours after a meal.
46073435|NCT02839382|Other|Site Visits|"Practices randomized to this arm of the study will be given an opportunity to make a site visit to an exemplar practice to learn about innovative approaches to conducting quality improvement activities."
46073436|NCT00573937|Drug|Methadone|Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
46073437|NCT00573937|Drug|Morphine|Oral slow-release morphine 15 mg every 8 hours, and oral immediate-release morphine 10 mg every 4 hours as needed for breakthrough pain.
46073438|NCT02825862|Behavioral|Question-behaviour effect (for affective attitudes)|Investigators propose to investigate the Question-behaviour effect (omit affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on affective attitudes will substituted for non-affective items (e.g. on political parties).
46073439|NCT02825862|Behavioral|Question-behaviour effect (negatively-worded attitudes)|Behavioral: Question-behaviour effect (for negatively-worded attitudes) Investigators propose to investigate the Question-behaviour effect (omit negatively-worded affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on negatively-worded affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on negatively-worded affective attitudes will substituted for non-affective items (e.g. on political parties).
46073440|NCT00845533|Drug|Dihydroartemisinin-Piperaquine|
45451871|NCT02263534|Procedure|tension free vaginal tape|midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) with the applicators in the retropubic direction and 2 skin incision will be made supra pubic through which the applicators will be passed and removed and the tape will be cut at level just below the skin closure of the vagina posterior colpoperneorraphy will be carried out if needed
45652646|NCT04784741|Device|Low amplitude whole body vibration therapy|"Given five sessions of low amplitude whole body vibration therapy for duration of 10 minutes, on alternative days, along with static stretching of hamstring muscles.~Static stretching protocol had 10 repetitions in total with 15 seconds stretch time and 30 seconds relaxing time of hamstring muscle."
45652647|NCT04784741|Device|Biodex Balance System|Pre and post balance assessment by Biodex balance system
45803501|NCT03717155|Drug|Carboplatin|In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles.
45803502|NCT03789097|Drug|Pembrolizumab|200 mg administered as an IV infusion over 30 minutes Q3W
45803503|NCT03789097|Drug|Flt3L|an immune cell growth factor. CDX-301 drug product is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains a nominal 2.5 mg/mL CDX-301 protein in a 1 mL volume of buffered solution composed of sodium phosphate and sodium chloride, with a pH of 7.0.
45803504|NCT03789097|Radiation|Radiation|The target site will get 2 small treatments of radiation.
45803505|NCT03789097|Drug|Poly ICLC|an immune cell activating factor. vials containing 1 ml of 2 mg/mL
45803506|NCT05311046|Diagnostic Test|Pediatric sepsis screening tool (either algorithmic or manual)|All participating institutions employ either an algorithmic, manual, or combined algorithmic/manual pediatric sepsis screening protocol for patients that present with fever and/or a concern for infection. While the specific parameters tested in screening tools differ, they generally consist of tests for a systemic inflammatory response (e.g. SIRS) and/or organ dysfunction (e.g. SOFA) and/or high susceptibility (e.g. immunocompromised) factors.
45803507|NCT02049931|Device|No brace treatment|Patients in the no brace group were allowed to ambulate without any braces as long as it would be tolerable.
45933563|NCT00033059|Drug|Tolcapone|
45933564|NCT00060918|Drug|carvedilol|
45933565|NCT00060918|Drug|metoprolol|
45933566|NCT00033098|Drug|Metyrapone|
45933567|NCT02968641|Drug|Lonafarnib|antiviral farnesyltransferase inhibitor
45933568|NCT02968641|Drug|Ritonavir|CYP 3A4 inhibitor, lonafarnib booster
46073441|NCT00839449|Drug|Eicosapentaenoic acid ethyl ester|Orally administered 900 mg eicosapentaenoic acid ethyl ester three times a day (2700 mg ⁄ day) from the surgery next day to 30 days after the onset of SAH.
46073442|NCT04958538|Drug|Methotrexate|Methylprednisolone 2 mg/kg/day MTX (5-10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II
46073443|NCT02825472|Behavioral|exercise training|3 times per week 30 minutes of exercise training in the target heart rate zone
46073444|NCT02548195|Drug|oxaliplatin and gemcitabine|oxaliplatin and gemcitabine (GEMOX regimen): day 1: oxaliplatin 85 mg/m2, gemcitabine 1000 mg/m2; day 8: gemcitabine 1000 mg/m2 every three weeks for 6-8 cycles in total.
45451872|NCT01418092|Drug|ALKS 37|Capsules for oral administration
45652648|NCT04784741|Procedure|Range of motion of hamstring muscle|Straight Leg Raising to check pre and post Range of Motion by using Goniometer
45652649|NCT05635279|Other||
45933569|NCT00033176|Drug|Alpha Lipoic Acid|
45933570|NCT00033215|Drug|S-3304|
45652650|NCT04802915|Procedure|Intraoperative ERM and ILM staining with their assessment and removal|ERM and ILM staining is performed after vitrectomy. After that we evaluate the condition of macular zone and make a decision to remove the ERM and the need to remove the ILM
45652651|NCT05311215|Drug|SL-1002|SL-1002 injectable solution
45652652|NCT05311215|Drug|Placebo|Matching placebo injectable solution
45933571|NCT02968407|Other|Peer- and self-rating|Participants will be given a print and a e-mail of the modified OSATS global rating scale and will be introduced to how the rating scale is used to rate technical performance. The participant will receive a USB stick each allowing the participant to see a video of his/her own performance and two videos from previous post-test performances from participants enrolled in the course. One video is a video of a participant who performed poorly,the other is from a participant who performed well. The participants will be asked to watch and rate the videos of their peers' performance first and afterwards watch and rate the participants own video performance. The investigators choose to let the participants rate their peers' performances before their own, so the participants will have the best opportunities to self-rate. Participants will be asked to email the results of their ratings to the principal investigator within 3 days. And expert in surgery will also rate the videos using OSATS.
45933572|NCT00060957|Drug|Botulinum toxin type A|
45933573|NCT00060996|Drug|Remodulin® (treprostinil sodium) Injection|
45933574|NCT00061035|Biological|Transgenic Lymphocyte Immunization Vaccine (TLI)|
45933575|NCT00033254|Radiation|radiation therapy|Undergo conventional radiation therapy
45933576|NCT00033254|Drug|thalidomide|Given orally
45803508|NCT02049931|Device|Rigid brace|In rigid brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
45803509|NCT02049931|Device|Soft brace|In soft brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
45933577|NCT00033254|Procedure|quality-of-life assessment|Ancillary studies
45933578|NCT00061074|Drug|Nicotrol|
45933579|NCT00033332|Drug|dexamethasone|
45803510|NCT03655613|Biological|APL-501|Humanized IgG4 monoclonal antibody against programmed death receptor-1 (PD-1)
45803511|NCT03655613|Drug|APL-101|Oral specific c-Met inhibitor
45933580|NCT00033332|Drug|pamidronate disodium|
45933581|NCT00033332|Drug|thalidomide|
45652653|NCT05616143|Device|Isthmus Logic|Patient implanted with Isthmus Logic stent for the treatment of peripheral iliac artery disease
46073445|NCT02548195|Drug|capecitabine|capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.
46073446|NCT02827422|Other|not provided|
46073447|NCT02546089|Other|Autologous Blood Injection|ultrasound-guided autologous blood injection procedure
46073448|NCT02546089|Other|Structured rehabilitation programme|(this intervention is given to patients in both arms of the study) - a standardised structured rehabilitation programme of home exercises that the patient is instructed on how to start, and how to progress during the study period
46073449|NCT02546089|Other|dry needling injection|(this intervention is given to patients in both arms of the study) - ultrasound-guided dry needling injection performed under ultrasound guidance
46073450|NCT04244292|Other|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
46073451|NCT00573859|Drug|ADHD medication|For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication for two consecutive days.
45451873|NCT01418092|Drug|Placebo|Capsules for oral administration
45451874|NCT01416064|Drug|Molindone|The populations will be comprised of male and female pediatric subjects from the 810P202 study. Subject will be converted to a total daily dose of 18 or 36mg of molindone (depending on weight), following enrollment into 810P203. The dosage level may be adjusted at the investigators discretion.
45451875|NCT01594216|Drug|Ruxolitinib|
45451876|NCT01594216|Drug|Exemestane|
45451877|NCT01411150|Drug|Creatine Monohydrate|Up to 30 grams daily creatine monohydrate
45652654|NCT05214573|Drug|Glucagon like peptide 1 receptor agonist|Patients in the data who filled a glucagon-like peptide-1 receptor agonist medication
45652655|NCT05214573|Drug|Sodium-glucose cotransporter 2 inhibitor|Patients in the data who filled a sodium-glucose cotransporter 2 inhibitor
45652656|NCT05214573|Drug|Dipeptidyl Peptidase 4 Inhibitor|Patients in the data who filled a dipeptidyl peptidase-4 inhibitor
45652657|NCT05214573|Drug|Sulfonylurea|Patients in the data who filled a sulfonylurea
45652658|NCT04988191|Drug|Toripalimab|"Neoadjuvant therapy: Toripalimab is given by intravenous infusion at 3mg/kg d1 every 2 weeks for 3 cycles.~Adjuvant therapy: Toripalimab is given by intravenous infusion at a dose of 240mg every 3 weeks for up to 9 cycles."
45652659|NCT04988191|Drug|Bevacizumab|Neoadjuvant therapy: Bevacizumab is given by intravenous infusion at 5mg/kg d1 every 2 weeks for 3 cycles.
45803512|NCT03655613|Biological|Nivolumab|Fully human IgG4 monoclonal antibody against PD-1
45933582|NCT00033332|Drug|zoledronic acid|
45933583|NCT02968680|Procedure|Sentinel Lymph Node Biopsy|Undergo SLNB
45933584|NCT02968680|Device|Ultrasonography|Undergo sonazoid-enhanced ultrasonography
45652660|NCT04988191|Drug|Irinotecan|Neoadjuvant therapy: Irinotecan is given by intravenous infusion at 180mg/m2 d1 every 2 weeks for 2 cycles.
45652661|NCT05310201|Behavioral|Be Well Care Well|Be Well Care Well addresses teacher well-being through activities implemented in the classroom aimed at reducing teacher stress and improving physical activity. A subset of teachers involved in the program will complete classroom observations and cortisol testing to examine additional measures of stress.
45652662|NCT02595437|Drug|Triferic|
45933585|NCT02968680|Drug|Sonazoid|Patients receive sonazoid intradermally (ID) and undergo ultrasound imaging.
45933586|NCT00033410|Drug|carboplatin|
45933587|NCT00033410|Drug|paclitaxel|
45933588|NCT00033410|Drug|tirapazamine|
45933589|NCT00033410|Radiation|radiation therapy|
45933590|NCT00061113|Drug|Fluoxetine + outpatient cognitive behavioral therapy|single fixed morning dose 20 mg X 15 weeks
45933591|NCT00061113|Drug|fluoxetine|20mg, QD x 16 weeks
45933592|NCT00061113|Drug|placebo + CBT|single fixed morning dose X 16 weeks
45933593|NCT00033449|Drug|gefitinib|Given orally
45933594|NCT00033449|Radiation|radiation therapy|Undergo radiation therapy
45933595|NCT00033449|Drug|cisplatin|Given IV
45933596|NCT00033449|Other|laboratory biomarker analysis|Correlative studies
45933597|NCT00061152|Drug|Capsaicin Dermal Patch|
45933598|NCT00033488|Other|cytology specimen collection procedure|
45803513|NCT04820036|Diagnostic Test|Insulin Resistance|Insulin resistance: Fasting glucose and insulin will also be measured to calculate Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), as a surrogate of IR
45933599|NCT00033488|Procedure|annual screening|
45933600|NCT00033488|Procedure|comparison of screening methods|
45933601|NCT00033527|Drug|INS316|
45933602|NCT00033527|Other|sputum cytology|
45451878|NCT02263690|Procedure|Group Drops|The patients in the group Drops received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. The patients in the group Drops received a second drop of proparacaine 0.5% 5 minutes after the drop of povidone iodide 5%
45451879|NCT02263690|Procedure|Group SC|The patients in the group SC received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. In the patients in the group SC, a subconjunctival bleb of anesthesia was created by injecting 0,4 mL of lidocaine 1% into the subconjunctival space 4 mm posterior to the superotemporal limbus with a 30-gauge, 1/2-inch needle attached to a 1-mL syringe.
45451880|NCT02263690|Procedure|Group gel|For the patients in group gel, the gel was placed on the eye before receiving the peri-ocular drop of povidone iodide 5%.
45451881|NCT02265562|Drug|Misoprostol|60 minutes before the surgery 400 μg of misoprostol (2 tablets of 200 μg) inserted rectally
45451882|NCT02265562|Drug|Placebo|60 minutes before the surgery 2 tablet of placebo inserted rectally
45652663|NCT04784975|Other|No intervention|No intervention
45652664|NCT03069001|Drug|Sofosbuvir-Simeprevir|-Sofosbuvir-Simeprevir group included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks.
45652665|NCT03069001|Drug|Sofosbuvir-Ribavirin|-Sofosbuvir-Ribavirin group included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks.
45652666|NCT04784195|Behavioral|Observation|Verification of morfology and functionality of neck muscles
45803514|NCT04820036|Behavioral|Quality of Life Assessment|Quality of life will be assessed using the Chronic Liver Disease Questionnaire.
45803515|NCT04820036|Diagnostic Test|Liver Function Test|EUS-guided liver biopsy and portal pressure gradient measurement
45803516|NCT04820036|Diagnostic Test|Radiologic features of NASH|Controlled attenuation parameter (CAP) and liver stiffness scores assessed by transient elastography (TE)
45803517|NCT04820036|Diagnostic Test|Serologic features of NASH|Laboratory value assessment of alanine aminotransferase (ALT), liver chemistries, platelet counts, albumin and calculated NAFLD Fibrosis Score (NFS).
45803518|NCT04795856|Drug|[11C] acetate|PET Tracer
45803519|NCT00422747|Drug|beclomethasondipropionate|2 x 100 ug dd for two months, via aerochamber
45803520|NCT03766009|Other|Usual Care|Usual Care
45803521|NCT03766009|Other|Web-based decision aid|Web-based decision aid received prior to the surgical consultation
45933603|NCT02968290|Procedure|Cataract Surgery|Implant of intraocular lens hydrophobic or Implant of intraocular lens hydrophilic (Device)
45933604|NCT02968290|Device|Alcon AcrySof SA60AT|Implant of intraocular lens hydrophobic
45933605|NCT02968290|Device|Bausch Lomb AkreosA|Implant of intraocular lens hydrophilic
45933606|NCT00033566|Drug|S-3304|
45933607|NCT00061230|Behavioral|biofeedback-monitored relaxation training|
45933608|NCT00033605|Drug|octreotide acetate|
46073452|NCT00573859|Drug|Placebo|For the placebo condition, participants received placebo pills for two consecutive days.
46073453|NCT04243980|Device|Short anatomical femoral stem in THR|Patients with osteoarthritis after total hip arthroplasty
46073454|NCT04244214|Other|More Stamina|More Stamina is a gamified task organization tool designed to help persons with MS manage their energy, to minimize the impact of fatigue in their day to day life.
45652667|NCT03070717|Procedure|Observation & Diagnosis|SD-OCT, fundus autofluorescence, fundus photography, optional microperimetry, ophthalmic exams (BCVA, optical biometry), blood sampling.
45803522|NCT00355940|Device|Technological Methods|"Usage of technological methods and devices to improve intravascular navigation during endovascular aortic repair.~In this arm we first use an optical pointer to allocate the femoral artery ramification (point of incision) and the lower renal artery (upper confinement of stent graft). Later we use an electromagnetically tracked catheter to find and enter the opening in the main stent graft before placing the second limb. For both optical and electromagnetic tracking we use a custom made navigation system based on 3 dimensional CT images"
45803523|NCT00355940|Device|Regular Fluoroscopy|Usage of conventional fluoroscopy and angiography for intravascular navigation. In this arm standard endovascular aortic repair is performed. The only means of navigation are fluoroscopy and angiography with overlay function (standard).
45803524|NCT00356018|Behavioral|Compliance|
45803525|NCT03286829|Drug|"Tesomet High dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
45803526|NCT03286829|Drug|"Tesomet Low dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
45933609|NCT00033605|Other|placebo|
45933610|NCT00033605|Radiation|radiation|
45933611|NCT02968251|Behavioral|Hand Washing Program (HWP)|HWP consists of integrating hand washing practice in the school health policy, setting up proper hand washing facilities in the intervention schools, training to school teachers, delivering of health talk to schoolchildren and their parents, developing reminders and posters of a simplified 5-step hand washing technique, peer briefing session, take home package (5-steps hand washing, commitment letter, poster, leaflet). The program will be delivered once every week.
45933612|NCT00033644|Biological|sargramostim|
45933613|NCT00033644|Drug|cisplatin|
45933614|NCT00033644|Drug|dacarbazine|
45933615|NCT00033644|Drug|doxorubicin hydrochloride|
45933616|NCT00033644|Drug|mitomycin C|
45933617|NCT00061269|Procedure|Videoscopic-Assisted Retroperitoneal Debridement (VARD)|
45933618|NCT00033683|Drug|CMF regimen|
45933619|NCT00033683|Drug|cyclophosphamide|
45933620|NCT00033683|Drug|docetaxel|
45933621|NCT00033683|Drug|epirubicin hydrochloride|
45933622|NCT00033683|Drug|fluorouracil|
45933623|NCT00033683|Drug|methotrexate|
45933624|NCT00033683|Drug|tamoxifen citrate|
45933625|NCT00033683|Procedure|adjuvant therapy|
45933626|NCT00033683|Radiation|radiation therapy|
45933627|NCT00061308|Drug|Topotecan|
45933628|NCT00061308|Drug|Gemcitabine|
45652668|NCT05165511|Behavioral|PBT-EF|PBT-EF will be delivered to parents only. Parents will be taught general behavioral weight loss skills to apply to their child and themselves including decreasing caloric intake and increasing physical activity, self-monitoring, and goal setting. Additionally, parents will learn compensatory strategies surrounding organization, habit learning, planning, and problem-solving to generalize FBT skills to real-world behaviors (e.g., self-monitoring of food intake). Each session will include interactive exercises to help train an aspect of EF. Skills taught will be presented to be practiced with real-world applications.
45933629|NCT00061347|Procedure|Fiducial marker placement|Placement of fidicual markers under MRI guidance for localization of radiaiton treatment
45933630|NCT00033722|Dietary Supplement|folic acid|
45933631|NCT00033722|Drug|lometrexol|
45933632|NCT00033839|Drug|Civamide (Zucapsaicin)|
45451883|NCT01407874|Drug|Placebo|Oral dose administered daily for 84 days.
45451884|NCT01407874|Drug|Ulodesine (BCX4208) 5 mg|Oral dose administered daily for 84 days.
45451885|NCT01407874|Drug|Ulodesine (BCX4208) 10 mg|Oral dose administered daily for 84 days.
45451886|NCT02263768|Procedure|Oral clinical conditions|Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment
45451887|NCT02265640|Drug|BIIL 284 BS boli|
45451888|NCT02265640|Drug|BIIL 284 BS tablet C|
45652669|NCT04239651|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.
45803527|NCT03286829|Drug|Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition.|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
45933633|NCT00033878|Drug|Noni Extract|
45451889|NCT02265640|Other|standard breakfast|
45451890|NCT01399684|Drug|5-Fluorouracil|Participants will receive 5-fluorouracil 400 milligrams per squared meter (mg/m^2) intravenous (IV) bolus and then 2400 mg/m^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
45451891|NCT01399684|Drug|Bevacizumab|Participants will be administered bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
45933634|NCT00061386|Behavioral|Nutrition and physical activity program|
45933635|NCT00061425|Drug|radiolabeled epratuzumab|
45933636|NCT00033956|Drug|M40403|
45933637|NCT00061464|Drug|pemetrexed|
45451892|NCT01399684|Drug|Folinic acid|Participants will receive folinic acid 400 mg/m^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
45451893|NCT01399684|Drug|MEGF0444A|Participants will be administered MEGF0444A at a fixed dose of 400 milligrams (mg) IV on Day 1 of Cycle 1, followed by subsequent doses of 400 mg every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
45451894|NCT01399684|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m^2 IV infusion over 90 minutes on Day 1 of every cycle for a maximum of 8 cycles.
45803528|NCT03286829|Drug|"Tesomet High dose in fed condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
45933638|NCT00061464|Drug|gemcitabine|
45933639|NCT00061503|Drug|Travoprost|
45803529|NCT00421616|Behavioral|High protein diet study|
45803530|NCT02051335|Drug|Roflumilast|Roflumilast tablets
45933640|NCT00061542|Drug|BETOPTIC S (betaxolol HCl)|betaxolol HC)
45933641|NCT00061542|Drug|Timolol Gel-forming Solution (TGFS)|timolol maleate 0.25% and 0.5%
45933642|NCT04730466|Other|Neuropsychological rehabilitation|The intervention can be carried out in the research unit or in the Parkinson's association. Each session will consist of a series of cognitive stimulation tasks aimed at improving attention, perception and processing speed. These tasks will be applied through the NeuronUp cognitive neurorehabilitation platform to achieve maximum homogeneity and objectivity in their application. The program is programmed and is identical for all patients. Performing tasks through the platform allows us to objectively record the performance of each patient in all tasks.
45933643|NCT00034034|Procedure|Acupuncture|
45933644|NCT00061581|Device|Isolex 300i Stem Cell Selection|
45933645|NCT00061620|Drug|Tezacitabine (FMdC)|7.5 mg/m2 bolus infusion daily x 5
45933646|NCT00034112|Procedure|osteopathic manipulative treatment|
45933647|NCT02968095|Behavioral|Text Message Craving Program|Text messages targeting cravings delivered 2-3 times per day.
45933648|NCT02968095|Behavioral|Self-Help Manual Plus Control Texts|Self-help manual plus motivational text messages delivered 2-3 times per day.
45933649|NCT00034151|Drug|S-8184 Paclitaxel Injectable Emulsion|
45933650|NCT00061659|Drug|ABT-510 - Thrombospondin-1 mimetic|
45933651|NCT00034190|Drug|S-8184 Paclitaxel Injectable Emulsion|
45933652|NCT00061698|Behavioral|Cognitive Behavior Therapy Child Only|Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief.
46073455|NCT00832897|Procedure|Corneal collagen crosslinking|"The patients will be submitted to corneal collagen crosslinking, that consists:~Instillation of riboflavin eyedrop in the cornea for thirty minutes, and after, the patient will stay under the Crosslinking equipment, for more thirty minutes, also receiving riboflavin eyedrop."
45652670|NCT04239651|Other|Internet-Delivered Cognitive Behavior Therapy (iCBT)|Cognitive behavioral therapy (CBT) is an evidence-based, structured, intensive, time-limited, symptom-focused form of psychotherapy recommended for the treatment of major depression and anxiety disorders. Internet-delivered CBT (iCBT) is structured CBT delivered via the internet.
45451895|NCT01399684|Drug|Placebo|Participants will be administered MEGF0444A matching placebo every 14 days until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
45652671|NCT04095091|Device|4D Planar US Transducer|This 4D planar US transducer is being developed and validated to provide a novel image-guidance technique to directly track tumor motion during radiation therapy that is coupled to a pre-treatment calibration training image set consisting of a simultaneous 4D ultrasound and 4D magnetic resonance imaging (MRI) acquisition.
45803531|NCT02051335|Drug|Roflumilast placebo|Roflumilast placebo-matching tablets
45933653|NCT00061698|Behavioral|CBT plus Parent Training|Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief. Parents learned skills that helped their child to apply the strategies they learned. Parents learned how to better communicate positive information that helped their child build a positive core belief. Parents learned how to use reinforcement to support healthy behavior.
45933654|NCT00034229|Drug|Felbamate|
45933655|NCT02968056|Procedure|Radiofrequency ablation|Radiofrequency energy is used for ablation in both arms of this study (Hybrid group and MIS group)
45933656|NCT00034268|Drug|LY900003|
45933657|NCT00034307|Drug|sitaxsentan sodium|
45933658|NCT00061776|Drug|Capsaicin Dermal Patch|
45933659|NCT00034346|Drug|ABX-EGF|
45933660|NCT00034346|Drug|paclitaxel|
45933661|NCT00034346|Drug|carboplatin|
45933662|NCT00034385|Drug|Valganciclovir|
45933663|NCT00034463|Drug|ALIMTA|
45451896|NCT01397968|Drug|YKP3089|Capsule, dose to be titrated Tablet, dose to be titrated
45803532|NCT02051335|Drug|Donepezil|Donepezil overencapsulated tablets
45803533|NCT02051335|Drug|Donepezil placebo|Donepezil placebo-matching overencapsulated tablets
45933664|NCT00034463|Drug|folic acid|
45933665|NCT00034463|Drug|multi-vitamins|
45933666|NCT02971397|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
45933667|NCT02971397|Drug|Cytarabine|Given IV
45933668|NCT02971397|Drug|Daunorubicin Hydrochloride|Given IV
45933669|NCT02971397|Other|Laboratory Biomarker Analysis|Correlative studies
45933670|NCT00396500|Drug|Albendazole (400 mg) and/or Vitamin a|
45933671|NCT00034502|Drug|ALIMTA|
45933672|NCT00034502|Drug|irinotecan|
45933673|NCT00034541|Biological|cetuximab|400 mg/m2 i.v. over 120 minutes
45933674|NCT00034541|Drug|paclitaxel|225 mg/m2, infusion
45933675|NCT00034541|Drug|carboplatin|30-minute AUC = 6, infusion.
45933676|NCT00034580|Drug|olanzapine|
45933677|NCT00034580|Drug|risperidone|
45933678|NCT00034619|Drug|ALIMTA|
45451897|NCT01397968|Drug|Placebo|Placebo capsule Placebo tablet
45451898|NCT01397578|Drug|MABT5102A|Repeating subcutaneous injection
45451899|NCT01397578|Drug|MABT5102A|Repeating intravenous infusion
45451900|NCT01397578|Drug|placebo|Repeating subcutaneous injection
45451901|NCT01397578|Drug|placebo|Repeating intravenous infusion
45652672|NCT04784273|Procedure|Tibiotalocalcaneal Arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
45652673|NCT04784273|Device|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
45652674|NCT04793789|Other|monofocal toric lens|not applicable as patients are already implanted with the monofocal toric lens
45652675|NCT05163171|Other|questionnaire|questionnaire for conjugal violence prevalence
45652676|NCT05353621|Behavioral|VAS reported Stress|VAS reported Stress measurement during simulation
45652677|NCT04426643|Biological|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with collagen solution injected in submucosal space
45803534|NCT02051335|Drug|Scopolamine|Scopolamine subcutaneous injection
45803535|NCT03289481|Dietary Supplement|Active lozenge|nitric oxide generating lozenge
45803536|NCT03289481|Drug|Placebo|placebo tablet
45933679|NCT00034619|Drug|Oxaliplatin|
45933680|NCT00061815|Biological|cetuximab|400 mg/m2 IV
45933681|NCT00061815|Drug|oxaliplatin|85 mg/m2 IV
45933682|NCT00061815|Drug|leucovorin|200 mg/m2 IV
45933683|NCT00061815|Drug|5-fluorouracil|400 mg/m2 IV
45933684|NCT00061815|Drug|5-fluorouracil|600 mg/m2 IV
45933685|NCT00061815|Biological|cetuximab|250 mg/m2 IV
45933686|NCT00061854|Drug|soblidotin|
45933687|NCT00034658|Drug|Posaconazole|
45933688|NCT00398580|Drug|Nanomilled testosterone|
45933689|NCT00398580|Drug|Nanomilled dutasteride|
45933690|NCT00398580|Drug|commercially available dutasteride|
45933691|NCT00034697|Drug|temozolomide|
45933692|NCT00034736|Drug|Levofloxacin|
45933693|NCT02967939|Drug|DA-2802|DA-2802 319mg tablet qd + placebo tablet matching to Viread® 300mg.
45933694|NCT02967939|Drug|Viread®|Viread® 300mg tablet qd + placebo tablet matching to DA-2802 319mg.
45933695|NCT00034775|Drug|risperidone|
45933696|NCT00062049|Biological|recombinant interleukin-7|
45933697|NCT00034814|Drug|Talampanel|Non-enzyme-inducing TLP 35mg TID
45933698|NCT00034814|Drug|Placebo|Enzyme-inducing placebo TID
45933699|NCT00034814|Drug|Talampanel|Enzyme-inducing Talampanel 35 mg TID
45933700|NCT00034814|Drug|Talampanel|Enzyme-inducing TLP 50mg TID
45933701|NCT00034814|Drug|Placebo|Non-enzyme-inducing placebo TID
45933702|NCT00034814|Drug|Talampanel|Non-enzyme-inducing TLP 25mg TID
45933703|NCT00062127|Drug|irinotecan hydrochloride|Given IV
45933704|NCT00062127|Drug|thalidomide|Given orally
45933705|NCT00062127|Other|pharmacological study|Correlative studies
45451902|NCT03135418|Device|Intervention|"Patients will use virtual reality d4evice to play task oriented games like bowling, arrow shooting and home activity simulations which focuses upper extremity abduction, flexion and rotation movements. Each session will be a total of 45 minutes divided to 3 15 minute games. Sessions will held for 6 weeks each monday, wednesday and friday at same time for each patient.~In addition to the virtual reality treatment program conventional rehabilitation therapies including neurodevelopmental facilitation techniques, physiotherapy, and occupational therapy and, where necessary, speech therapy will be applied according to the needs of the patient."
45803537|NCT05650658|Device|His/LBBP|Pacing at the level His-Bundle or left bundle branch is used to correct the underlying conduction abnormality, resulting in a faster and more homogeneous activation of the heart pacing directly via the intrinsic conduction system of the heart accompanied by a right atrial endocardial lead and a right ventricular defibrillator endocardial lead for LVEF≤35% and by a right atrial endocardial lead for LVEF 36-50%.
45933706|NCT00034853|Drug|meloxicam oral suspension|
45451903|NCT03135418|Device|Control|The control group will be included in the virtual reality program only focusing on visual scenes without upper extremity interaction. Bobath therapy, walking exercises, upper extremity active exercises, proprioceptive neuromuscular facial techniques will be applied to the control group for 6 weeks.
45933707|NCT00034853|Drug|naproxen oral suspension|
45933708|NCT02967783|Device|ID adaptor|ID adaptor fixed to the end of a standard ID needle and syringe to facilitate ID administration of the inactivated poliovirus vaccine
45933709|NCT02967783|Device|ID Jet Injector (Tropis, Pharmajet)|ID disposable syringe (needle free) jet injector to facilitate ID administration of the inactivated poliovirus vaccine
45933710|NCT02967783|Device|Needle and syringe|Standard ID needle and syringe for ID administration of the inactivated poliovirus vaccine
45933711|NCT00034892|Drug|Olanzapine, risperidone|
45933712|NCT00062205|Drug|imatinib mesylate|
45933713|NCT00034970|Behavioral|Mindfulness-based at therapy|
45933714|NCT00062244|Biological|oblimersen sodium|Given IV
45933715|NCT00035009|Drug|MK0869, aprepitant|
45933716|NCT00035009|Drug|Comparator: paroxetine HCL|
45933717|NCT00062283|Drug|L-alanosine|
46073456|NCT04043065|Biological|Liver-enriched antimicrobial peptide 2|Infusion of LEAP-2 during a 180 min grated glucose infusion.
46073457|NCT04043065|Other|Placebo|Saline
45933718|NCT00035048|Drug|aprepitant|
45933719|NCT00035048|Drug|Comparator: placebo (unspecified)|
45933720|NCT02967861|Behavioral|Pranayama|Pranayama is the breathing exercise through the nostrils. It enhances the systemic immunity which in turn enhances the overall defense mechanism of an individual.
45451904|NCT01395004|Drug|GSK2110183|GSK2110183 was orally administered at 125 mg once daily.
45652678|NCT04426643|Other|Standard treatment according to the Clinical protocols|Standard treatment according to the Clinical protocols
45803538|NCT05650658|Device|BiVP|"Biventricular pacing has been shown to improve outcomes by delivering synchronized electrical stimuli to the right and left ventricles utilizing an an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.~For LVEF≤35% a biventricular pacemaker-defibrillator will be implanted while for LVEF 36-50% a biventricular pacemaker will be implanted."
45933721|NCT02967861|Procedure|Scaling and root planing|It is a mechanical debridement of dental plaque.
46073458|NCT00839605|Drug|Dexmedetomidine|loading dose:0.3mcg/kg. Infusion of 0.3mcg/kg/hr
46073459|NCT05660304|Device|Cortico-cortical paired associative stimulation|Two brain areas will be stimulated with transcranial magnetic stimulation pulses. The pulses will be delivered with a time difference, on other words, one pulse after another.
45451905|NCT03135652|Radiation|adjuvant SBRT|adjuvant SBRT of liver lesions
45652679|NCT03070405|Drug|Tenofovir disoproxil fumarate 300mg|Single oral dose on the first day of each period
45652680|NCT03070405|Drug|Para-aminosalicylic acid Ca granule 5.28 g|Twice daily oral administration from the first day of each period to the seventh dose
45652681|NCT04238949|Other|Community Health Worker added to diabetes team|A Community Health Worker will be added to the diabetes team caring for a child with new onset type 1 diabetes for 1 year. The intervention includes social determinants of health screening and goal setting, with home visits.
45933722|NCT00035087|Drug|epothilone b|
45933723|NCT00062322|Drug|cisplatin|
45933724|NCT00062322|Drug|irinotecan hydrochloride|
45933725|NCT00062322|Procedure|conventional surgery|
45933726|NCT00062322|Procedure|neoadjuvant therapy|
45933727|NCT00062322|Radiation|radiation therapy|
45933728|NCT00035126|Drug|epothilone b|
45933729|NCT02967705|Behavioral|Pain management group|Chronic pain patients participate in a peer group. They are provided information about chronic pain self-management based on biopsychosocial framework.
45933730|NCT00035165|Drug|epothilone b|intravenous 2.5 mg/m2 as a 5 minutes bolus infusion once every week for three weeks followed by one week off
45933731|NCT00062400|Procedure|psychosocial assessment and care|
45933732|NCT00035204|Drug|galantamine|
45803539|NCT03290027|Drug|DFD-03|DFD-03 Lotion
45933733|NCT02967822|Genetic|Biological samples for patients|Blood samples. Sampling of uterine tissue during surgical intervention (collection of samples for the study only if samples remain after the routine care analyses)
45933734|NCT02967822|Genetic|Biological samples for healthy relatives|Blood samples.
46073460|NCT05660304|Device|Sham cortico-cortical paired associative stimulation|Two brain areas will be stimulated with sham transcranial magnetic stimulation. The sham pulses will be delivered with a time difference, on other words, one pulse after another.
46073461|NCT04043611|Other|Conservative physical therapy management|Tens and hot pack for at least 10 minutes at low back Soft tissue mobilization (Myofascial Release Technique) Maitland's Lumbar segmental mobilization (Grade I & II for pain, Grade III & IV for ROM) Traction (Manual general traction) Neurodynamics (Tensioner technique) Home plan after session (Guided low back exercises):Active Stretching (5-10 repetition with 15-20 second hold), Hamstring, Piriformis McKenzie Prone Extension Exercises
45933735|NCT00062478|Drug|Karenitecin (BNP1350)|Karenitecin 1.0 mg/m2 administered as a single 60-minute IV infusion daily for five consecutive days. The cycle is repeated every 21 days until occurrence of progressive disease or unacceptable toxicity.
45803540|NCT03290027|Other|Placebo Comparator|Vehicle (tazarotene 0%) Lotion
45933736|NCT00035243|Drug|epothilone b|EPO906 administered intravenously at 2.5 mg/m2 as a 5 minute bolus infusion repeated every week for three weeks followed by one week off The final tables and data is not in yet, so I cannot give you info on safety issues.
45933737|NCT00035282|Drug|aprepitant|
45803541|NCT02979158|Procedure|CPB Low Dose|Performing CPB with low dose heparin and coated equipment
45933738|NCT00035282|Drug|Comparator: placebo (unspecified)|
45933739|NCT00062556|Drug|Niacin Extended Release and Lovastatin Tablets|
45933740|NCT00035321|Drug|Olanzapine|
45803542|NCT02979158|Procedure|CPB High Dose|Performing CPB with high dose heparin and uncoated equipment
45803543|NCT02979236|Device|STENTYS Xposition S|
45803544|NCT02300077|Drug|methadone|Escalating dose of methadone up to .3mg/kg.
45933741|NCT00035321|Drug|Fluoxetine|
45933742|NCT00062595|Drug|phylloquinone (K1)|
45933743|NCT00062595|Drug|menatetranone (MK4)|
45933744|NCT02967666|Radiation|FDG ligand|
45933745|NCT02967666|Radiation|DOTANOC ligand|
45451906|NCT03135652|Drug|Chemotherapy|mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
45652682|NCT05473403|Other|Corticosteroid therapy|Administration of high doses of corticosteroids as early as possible. Patient non-responder to treatment should lead to listing for emergency liver transplantation (LT).
45652683|NCT03068065|Drug|Liraglutide|the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
45652684|NCT03068065|Drug|Metformin|the dosage of metformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
45652685|NCT03068065|Drug|Gliclazide|the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of <7.0 mmol/L
45803545|NCT02300077|Drug|Control (Intra-operative administration of opioids, other than methadone)|Intra-operative administration of opioids, other than methadone
45803546|NCT04745546|Device|WeFlow-JAAA Stent Graft System|The abdominal aorta stent graft system consists of the abdominal aorta embedded stent system, the abdominal aorta bifurcation stent system and the extended stent system. The abdominal aorta embedded stent has two embedded branch stents and two fenestrations. It can be combined with a peripheral small stent system of appropriate specifications to reconstruct the superior mesenteric artery, bilateral renal arteries and keep the abdominal trunk unobstructed. At the same time, the combination of the abdominal aorta embedded stent, the abdominal aorta bifurcation stent and the extended stent can solve the proximal renal and transrenal abdominal aortic aneurysm lesions with the upper edge of the abdominal aortic aneurysm body and the lower edge of the superior mesenteric artery opening ≥ 5 mm.
45803547|NCT05272826|Drug|Iberdomide|Available as formulated capsules and administered as oral medication
45803548|NCT05272826|Drug|Bortezomib|Administered as subcutaneous injection
45451907|NCT01549834|Drug|ABT-126|Low Dose
45652686|NCT05109117|Drug|ChapStick Active Performance Unscented|Sunscreen lip balm.
45803549|NCT05272826|Drug|Dexamethasone|Administered as oral medication
45803550|NCT03291041|Drug|Tasimelteon|capsule
45803551|NCT03291041|Drug|Placebo|capsule
45803552|NCT02052661|Biological|Engerix™-B Kinder|Single dose administered intramuscularly in deltoid region of non-dominant arm.
45933746|NCT00035360|Drug|PEG-Intron|
45451908|NCT01549834|Drug|ABT-126|High Dose
45451909|NCT01549834|Drug|placebo|Placebo
45451910|NCT02265718|Drug|Ritalin|1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
45451911|NCT02265718|Drug|Placebo|1 - matching tablet taken once on Day 0 and once on Day 28
45451912|NCT02265718|Drug|Ritalin|1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
45451913|NCT02265718|Drug|Placebo|1 - matching tablet taken once on Day 0 and once on Day 28
45652687|NCT04988347|Combination Product|Spirulina platensis|Active treatment with Spirulina platensis in capsules containing 530 mg, 1 capsule orally each 8 hours, for 60 days
45652688|NCT04988347|Other|Placebo comparator|Placebo in capsules, 1 capsule orally each 8 hours, for 60 days
45933747|NCT00035399|Procedure|Acupuncture|
45933748|NCT00062634|Behavioral|Female condom skills training|
45933749|NCT00062673|Drug|Duloxetine|
45933750|NCT00062673|Drug|Placebo|
45933751|NCT00035438|Drug|St. John's Wort|
45933752|NCT02967744|Drug|NSAID|NSAIDs are among the most common pain treatments for patients with osteoarthritis.
45933753|NCT00035477|Drug|Azimilide Dihydrochloride|125 mg azimilide tablets once a day for 3 days in hospital and 125 mg azimilide tablets once a day for 6 months as outpatient
45933754|NCT00035477|Drug|Placebo|placebo tablets once a day for 3 days in hospital and placebo tablets once a day for 6 months as outpatient
45933755|NCT00062712|Drug|Allogeneic Bone Marrow, Anti-Thymocyte Globulin (Sangstat) & Sirolimus (Wyeth-Ay|
45933756|NCT00062790|Drug|Dutasteride|
45933757|NCT00035516|Drug|Epothilone|
45933758|NCT00062829|Behavioral|Teen Driving: Program for parents|A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
45933759|NCT00035594|Drug|pegfilgrastim|Growth factor (GCSF) administered to promote neutrophil development post-chemotherapy.
45933760|NCT00062907|Biological|Recombinant DNA- pVAX/L523S|
45933761|NCT00062907|Biological|Recombinant adenovirus- Ad/L523S|
45933762|NCT02971241|Behavioral|Intergenerational Mobile Technology Opportunities Program|The themes of the 8-week training session are designed based on the objectives of IMTOP: 1) teach skills of tablet use and diabetes self-management behavior tracking app, 2) introduce online community communication to decrease social isolation and obtain social support from family and friends, young volunteers, health care providers, and diabetes peers who have similar condition/interest/ or disease), 3) teach diabetes self-management knowledge and skills based on the evidence-based Chronic Disease Self-Management Program; and 4) teach mobile technology application to healthcare access and daily needs (i.e., online appointment, online refill, appointment reminder, online health information, online training videos, and virtual classes such as e-newspaper, e-books, related sites, apps).
45933763|NCT00062946|Drug|(18F)fallypride|
45803553|NCT03458429|Drug|GMFFP|Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma
45803554|NCT05258630|Behavioral|Diabetes Homeless Medication Support (D-Homes)|There will be 10 sessions offered within 12 weeks to participants. Sessions will last approximately 30 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide a tailored tool to the patient's needs/goals and tailored diabetes education as needed.
45803555|NCT05258630|Behavioral|Brief diabetes education|Trained diabetes wellness coaches will provide an approximately 15 minutes of instruction about the basic concepts of diabetes. They will use handouts aligned with American Diabetes Association guidelines. They will read these with participants and answer basic questions. Handouts will cover (1) general diabetes knowledge, (2) healthy eating with diabetes, (3) physical activity with diabetes. The coach will also provide a general tool to support medication adherence (e.g. pillbox).
45933764|NCT00062985|Behavioral|Mail-based weight loss intervention|
45933765|NCT00062985|Behavioral|Phone-based weight loss intervention|
45451914|NCT01389700|Drug|SAR279356|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
45652689|NCT05162547|Device|NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay|The NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay (IUO) is a multiplexed, in vitro real-time Polymerase Chain Reaction assay, diagnostic test intended for the simultaneous qualitative detection and differentiation of Influenza A virus (Flu A), Influenza B virus (Flu B), Respiratory Syncytial Virus (RSV) and SARS-CoV-2 RNA
45652690|NCT05473169|Device|Videofluoroscopy|Swallowing assessment
45451915|NCT01389700|Drug|placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
45652691|NCT04452097|Biological|Human umbilical cord mesenchymal stem cells + best supportive care|hUC-MSC product will be administered intravenously in addition to the standard of care treatment.
45652692|NCT04452097|Other|Placebo control + best supportive care|Placebo control will be administered intravenously in addition to the standard of care treatment.
45652693|NCT05213091|Other|Otago Exercise Programme|The first four weeks will be Otago Exercise Programme training and practice. For the next weeks, there will be institution visits and telephone interviews. Individuals will be given an Otago Exercise Programme training booklet, exercise chart and exercise diary to better manage this process. The research will be conducted in small groups (average 6-8).
45652694|NCT05473091|Other|no intervention|retrospective analysis
45652695|NCT05634889|Radiation|De-escalation|No regional radiotherapy. Radiotherapy towards the remaining breast after breast conserving surgery, but no radiotherapy at all after mastectomy.
45652696|NCT05161845|Biological|Measles, Mumps and Rubella Combined Vaccine, Live|0.5ml of reconstituted vaccine per container. 0.5 ml per single human dose containing not less than 3.0 lg CCID50 of both live measles virus and rubella virus and 4.3 lg CCID50 of live mumps virus.
45652697|NCT04802369|Diagnostic Test|Diagnostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of arterial hypertension, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, non-invasive assessment for central arterial pressure waveform analysis and body mass analysis.
45803556|NCT03291197|Drug|Suprascapular and median nerve blocks|Ultrasound guided injection of the median and suprascapular nerve of the affected side.
45803557|NCT05643014|Other|Sample collection|This study will involve three sample collections including buccal cells and urine samples
45803558|NCT04779866|Behavioral|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
45803559|NCT04779866|Behavioral|Self-Administered White Noise Hypnosis|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
45803560|NCT05638880|Drug|Valsartan 80 mg|Valsartan is an angiotensin receptor blocker.
45933766|NCT02967627|Device|Incisional Negative Pressure Wound Therapy (iNPWT)|Incisional Negative Pressure Wound Therapy devices are lightweight, self contained, portable battery powered (or line powered), suction pumps for medical procedures where secretions and other body fluids and infectious materials must be removed through the application of continuous or intermittent negative pressure. The pumps are operated through computer software, having help and alarm features. The device is indicted for management of chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic or pressure), flaps and grafts. The pumps may be used at patient's bedside. These are suitable for use in either hospitals or long term care facilities and nursing homes. These devices will be applied to closed laparotomy incisions with the aim to provide three days of continuous negative pressure of - 100mmHg.
45451916|NCT03135574|Diagnostic Test|MRI T2 sequence of the oculomotor tract|Patients with ophthalmoplegia will benefit from an MRI T2 sequence of the oculomotor tract (additional time of 4 minutes).
45933767|NCT02967627|Device|Sterile Gauze Dressing|In most cases, self-adhesive, absorbent dressings will be used for standard wound therapy. However, surgical teams may decide on alternative forms of sterile gauze dressings, as long as the wound site is kept clean and dry. Dressings should be taken down on the second post-operative day.
45451917|NCT01540864|Drug|HPP404|Administered orally once daily for 26 weeks
45803561|NCT05638880|Drug|Empagliflozin 10 MG|Empagliflozin is an oral hypoglycemic drug.
45803562|NCT05638880|Drug|Levocetirizine|Levocetirizine, Histamine-1 receptor antagonists provide a highly successful approach for controlling allergic and inflammatory conditions
45803563|NCT03411707|Diagnostic Test|Stool DNA test|Stool DNA test could detect specific gene methylation in stool DNA. Blood mRNA test could detect specific set of gene expression in blood.
45803564|NCT00356096|Drug|pramipexole|
45803565|NCT00375635|Procedure|mFPSA treatment|
45803566|NCT03275675|Drug|Oral anticancer medications|All the oral medications for cancer treatment (hormonal, cytotoxic and targeted therapies)
45803567|NCT05637086|Drug|Phenytoin|Phenytoin remains a highly effective anti-epileptic drug, especially in generalized seizure management. Unfortunately, phenytoin efficacy on epileptic seizure is apparently reduced with its chronic use
45933768|NCT00063024|Behavioral|Increased calcium intake|
45933769|NCT00063024|Behavioral|Weight-bearing physical activity|
45803568|NCT05637086|Drug|Pentoxifylline 400 MG|Pentoxifylline (PTX) has a well validated immune modulatory and anti-inflammatory efficacy
45803569|NCT03294629|Device|SensAwake™ modification|SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep.
45803570|NCT04737044|Other|Study 1: MRBS|MRBS as added sugar based on their habitual diet
45803571|NCT04737044|Other|Study 2: White sugar & education module|White sugar for daily usage (<10% daily energy intake)
45803572|NCT04737044|Other|Study 2: MRBS & education module|MRBS for daily usage (<10% daily energy intake)
45933770|NCT00035828|Drug|ABX-IL8|
45451918|NCT01540864|Drug|Placebo|Administered orally once daily for 26 weeks
45451919|NCT01384630|Drug|RA-18C3|200 mg subcutaneous injection
45451920|NCT01381666|Drug|INS316 solution for inhalation|inhalation via nebulizer given for 2 doses for 60 minutes each
45451921|NCT01381666|Drug|hypertonic saline 3% sodium chloride solution|inhalation via nebulizer given for 2 doses for 60 minutes each
45451922|NCT01540630|Drug|CNV1014802|CNV1014802 150mg tid for 28 days. Dose may be increased to 350mg bid following interim evaluation of efficacy.
45451923|NCT01540630|Drug|Placebo|Double-blind placebo comparator for 28 days.
45451924|NCT02266030|Drug|Cilostazol|Pletaal as an active drug
45451925|NCT02266030|Drug|Aspirin|Aspirin as an active comparator
45803573|NCT05230394|Diagnostic Test|Attended Polysomnography in the Lab|Using standard Level 1 polysomnography
45803574|NCT05230394|Diagnostic Test|Unattended Polysomnography in the Home|Using Cerebra's Prodigy system
45803575|NCT03243461|Drug|Temozolomide + Valproic Acid|Valproic acid additionally to simultaneous radiochemotherapy with temozolomide
45803576|NCT05209568|Dietary Supplement|Gluten Powder|Single oral dose of gluten powder
45803577|NCT03296345|Drug|Ketamine|The intervention is IV low-dose bolus ketamine as an adjuvant to standard therapy (IV opiates and NSAIDs).
45803578|NCT00421694|Drug|Bicalutamide|
45803579|NCT00376181|Drug|Pioglitazone and Azilsartan|Pioglitazone 45 mg and Azilsartan 20 mg combination tablets, orally, once daily for up to 24 weeks.
45803580|NCT00376181|Drug|Pioglitazone and Azilsartan|Pioglitazone 45 mg and Azilsartan 40 mg combination tablets, orally, once daily for up to 24 weeks.
45803581|NCT00376181|Drug|Pioglitazone|Pioglitazone 45 mg, tablets, orally, once daily for up to 24 weeks.
45933771|NCT00035867|Drug|TLK199 HCl Liposomes for Injection|
45933772|NCT00035906|Drug|DEX PS DDS®|
45933773|NCT00035984|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
45451926|NCT01535950|Drug|LFG316|
45451927|NCT01535950|Drug|Placebo|Placebo will be administered as sham injections. Sham injections will involve placement of the syringe hub against the sclera, without use of a needle.
45451928|NCT01527916|Drug|placebo|Placebo Comparator
45451929|NCT01527916|Drug|donepezil|Active Comparator
45451930|NCT01527916|Drug|ABT-126|low dose, middle dose, high dose
45451931|NCT01373086|Drug|LFF269|
45451932|NCT01373086|Drug|Eplerenone|
45451933|NCT01373086|Drug|Placebo|
45652698|NCT04988269|Diagnostic Test|Blood sampling|Assessment of circulating levels of plasma ACTH, plasma aldosterone and serum interleukin -6 levels at day 1
45652699|NCT04988269|Diagnostic Test|Saliva sampling|Assessment of diurnal variation of cortisol and DHEA levels in the saliva at 4 different time points during the day (0.800, 12.00, 18.00, 22.00) at day 2.
45652700|NCT05109039|Dietary Supplement|Creatine|Participants will consume 0.1g/kg body weight of creatine with 0.1g/kg body weight of maltodextrin for 42 consecutive days
45652701|NCT05109039|Dietary Supplement|Placebo|Participants will consume 0.2g/kg body weight of maltodextrin for 42 consecutive days
45803582|NCT05607134|Other|selected physical and occupational therapy program|The children in this group will receive a selected physical and occupational therapy programs one hour three times weekly for eight successive weeks.
45933774|NCT00035984|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
45933775|NCT00035984|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
45933776|NCT00035984|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
45803583|NCT05607134|Device|Radial Extracorporeal Shock Wave|The children in this group will receive in addition to the selected physical therapy and occupational program as single session of shock wave intervention once per week for four eight successive weeks using (STORZ MEDICAL AG, Tagerwilen, Schweiz) device. rESWT will be applied on flexor carpi ulnaris, flexor carpi radialis, in the middle of the muscle belly and tendons of flexor digitorum on the palm. The treatment protocol of rESW will follow; 1500 shoots for each muscle; 0.030 mj/mm2; 4 HZ with pressure 1 bar will be used.
45933777|NCT00063102|Drug|ABT-751|
45933778|NCT00063141|Drug|cetuximab|Vial, IV, 400 mg/m² week 1 then 250 mg/m², weekly, until PD/Toxicity/Pt-PI Decision
45933779|NCT00063141|Drug|Irinotecan|Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
45933780|NCT00063141|Drug|Irinotecan|Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
45933781|NCT00036023|Drug|darbepoetin alfa|
45933782|NCT00036062|Drug|Sivelestat|
45933783|NCT02967315|Procedure|Cardiac Magnetic Resonance Imaging (CMRI)|"There will be 2 CMRIs. The first one will be patient's routine clinically schedule CMRI after the patient has fasted for 12 hours.This CMRI uses contrast.~The second CMRI will be the research CMRI after the fluid administration. This CMRI does not use contrast."
45933784|NCT02967315|Procedure|Central venous line placement|An ultrasound guided central line catheter will be placed in the internal jugular vein (IJV) under local anesthesia.
45933785|NCT02967315|Procedure|Chest X-ray|A chest X-ray will be performed for safety reasons to rule out pneumothorax (< 1% risk) after central line placement.
45933786|NCT02967315|Procedure|Fluid administration|Administration of 15cc/kg of normal saline for fluid hydration through peripheral IV that is placed for the MRI contrast administration.
45933787|NCT02967315|Procedure|Blood Draw|One to two teaspoons of blood will be drawn for basic metabolic panel.
45933788|NCT02967315|Procedure|Pregnancy test|A urine pregnancy test will be performed in female subjects.
45933789|NCT02967315|Procedure|Electrocardiogram|12 lead ECG
45933790|NCT00036101|Drug|aripiprazole|
45933791|NCT00063219|Drug|MAC-321|
45933792|NCT00036140|Drug|Investigational drug|
45933793|NCT02967588|Behavioral|Intervention group|"All stages of the intervention will take place during hospitalization. Patients will complete a questionnaire about their personal beliefs about medicines. Patients responses to this questionnaire will form the basis of Session 1 where beliefs about medicines will be discussed. Any negative beliefs or concerns will be discussed and beliefs about drug necessity will be encouraged.~Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose').~Prior to discharge, patients will complete the beliefs questionnaire again to see if there has been any shift in their beliefs about medications. Patients will also be asked to provide detailed feedback about the study. The investigators want to know whether the intervention setting, timing, content and delivery method seem to be acceptable to patients."
45933794|NCT04732403|Other|Patient Position|The patient will be placed in an angle on the surgical table during cystoscopy.
45933795|NCT00036179|Drug|FK463|
45933796|NCT00063297|Drug|R209130|
45933797|NCT00036218|Drug|sumanirole|
45933798|NCT00036218|Drug|ropinirole|
45933799|NCT00063336|Behavioral|Cognitive Remediation|A computerized cognitive rehabilitation treatment with day-program activities
45933800|NCT00063336|Behavioral|Computer-skills training|A computerized cognitive rehabilitation treatment with day-program activities
45803584|NCT05607134|Device|Peripheral magnetic stimulation|"The children in this group will receive in addition to the selected physical therapy program peripheral magnetic stimulation (PMS) therapy for twenty minutes, three sessions per week, for eight successive weeks using Peripheral magnetic stimulation device A MAGNUM XL Pro, Globus, Italia. The PMS consisted of 2000 stimuli at a stimulation frequency of 20Hz, a train duration of 1 second, and an intertrain interval of 2 seconds. Intensity was individually set at 10% to 100% of the maximum stimulus intensity."
45933801|NCT00036257|Drug|CP-461|
45933802|NCT00063375|Behavioral|Computer Based Cognitive Behavioral Therapy|
45933803|NCT00036296|Drug|talampanel|75mg per day divided into 3 doses for 22 days
45933804|NCT00063453|Dietary Supplement|Vitamin E|vitamin E (400 IU/day all rac-α-tocopheryl acetate)
45933805|NCT00063453|Dietary Supplement|Selenium|selenium (200 μg/d L-selenomethionine)
45933806|NCT00063453|Dietary Supplement|Vitamin E placebo|placebo
45933807|NCT00063453|Dietary Supplement|Selenium placebo|placebo
45933808|NCT00036335|Drug|Duloxetine Hydrochloride|
45933809|NCT00036374|Drug|Infliximab|
45933810|NCT02967549|Device|NAVA|NAVA delivered by the Servo-n ventilator (Maquet)
45933811|NCT02967549|Device|PAV|PAV delivered by the Stephanie ventilator (Stephan)
45933812|NCT00036413|Drug|TCH346|
45933813|NCT00036452|Drug|lopinavir/ritonavir|
45933814|NCT00036452|Drug|emtricitabine|
45933815|NCT00036452|Drug|stavudine|
45933816|NCT00036452|Drug|tenofovir DF|
45933817|NCT02967276|Drug|Metformin XR|500 mg tablet: They take 1-5 tablets of 500 mg after dinner. Starting dose of Metformin XR 500 mg. It will have an increase of 500 mg/day each week up to the maximum tolerance from the 2500 mg / day, during the 6 cycles.
45933818|NCT02967276|Drug|Dexamethasone|4 mg tablet: Patients will use 40 mg per day. They take 5-10 tablets 4mg after breakfast and lunch. Patients over age 75 will use 20 mg / day.
45933819|NCT00036491|Drug|Rituximab|Subjects received four weekly infusions of rituximab at a dose of 375 mg/m^2
45933820|NCT00063609|Drug|zoledronic acid|
45933821|NCT02971319|Device|Tc-99M-Tetrofosmin SPECT|
45933822|NCT02971319|Device|F-18 FDG PET|
45933823|NCT00398619|Drug|INCB13739|
45933824|NCT00036647|Drug|Tarceva (erlotinib HCl, OSI-774 )|
45933825|NCT00063648|Biological|EBV-specific autologous CTL|
45933826|NCT00063687|Drug|Oxypurinol|
45933827|NCT00036686|Dietary Supplement|Soy protein isolate|Arm I: Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.
45803585|NCT04736693|Drug|Raloxifene|Raloxifene dispensing claim is used as the reference group.
45451934|NCT02048332|Biological|Viral specific VST Infusion|"VSTs will be infused into stem cell transplant recipients who have evidence of viral infection or reactivation defined as any of the following:~Blood adenovirus PCR ≥ 1,000~Blood CMV PCR ≥ 500~Blood EBV PCR ≥ 9,000~Plasma BKV PCR >1,000~Plasma JC Virus PCR >1,000~Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity in one or more sites.~Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~Evidence of EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies.~Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy.~Evidence of PML or other CNS infection due to JC virus."
45933828|NCT00036686|Other|Placebo|Arm II: Patients receive oral placebo twice daily and oral multivitamins once daily.
45933829|NCT00036764|Drug|ixabepilone|Given IV
45933830|NCT00036764|Other|pharmacogenomic studies|Correlative studies
45933831|NCT00036764|Other|laboratory biomarker analysis|Correlative studies
45933832|NCT00063726|Drug|bortezomib|
45933833|NCT00036842|Drug|arsenic trioxide|
45933834|NCT00063765|Drug|Ciliary Neurotrophic Factor Implant NT-501|
45803586|NCT04736693|Drug|Zoledronic Acid|Zoledronic Acid dispensing claim is used as the exposure group.
45933835|NCT00036881|Dietary Supplement|zinc sulfate|
45933836|NCT00036881|Other|placebo|
46073462|NCT04043611|Other|ELDOA|ELDOA positions (hold for 1 minute,4 alternate days a week) under supervision during session Conservative physical therapy management Tens and hot pack for at least 10 minutes at low back Soft tissue mobilization (Myofascial Release Technique) Maitland's Lumbar segmental mobilization (Grade I & II for pain, Grade III & IV for ROM) Traction (Manual general traction) Neurodynamics (Tensioner technique) Home plan after session (Guided low back exercises):Active Stretching (5-10 repetition with 15-20 second hold),Hamstring,Piriformis
46073463|NCT04242732|Diagnostic Test|CT scan of the knee under weight-bearing with the Cone Beam Computed Tomography (CBCT) scanner system.|The patient will be evaluated under weight-bearing, with knee flexed at 30 ° and therefore with contracted thigh muscles. The measurement and maintenance of the 30 ° of flexion will be controlled by a goniometer applied laterally to the knee and fixed by means of an elastic band.
46073464|NCT04242732|Diagnostic Test|Conventional CT scan|The patient will be evaluated in supine position, with the muscles relaxed and the knee in full extension by conventional CT scan
46073465|NCT00839683|Drug|simvastatin|Tablets, Oral, 20 mg, Single Dose
46073466|NCT00839683|Drug|Dapagliflozin|Tablets, Oral, 20 mg, Single Dose
45803587|NCT04655378|Other|Mass Sepctrometry|Mass spectrometry (LC/MS) of purified immunoglobulins
45803588|NCT04652414|Drug|Prednisone|Prednisone 50mg will be administered enterally for 7 days.
45803589|NCT04652414|Drug|Placebo|This is a matching placebo to prednisone.
45451935|NCT01521598|Drug|SKL11197|SKL11197 drug product contains 150 mg of active ingredient. Dosing will be three times per day.
45451936|NCT01521598|Drug|Placebo|This is the placebo. Patients will be randomized the placebo.
45933837|NCT00063804|Drug|Ritonavir|
45451937|NCT02019004|Drug|Onabotulinum Toxin A|
45451938|NCT02019004|Drug|Incobotulinum Toxin A|
45803590|NCT04736069|Other|Physical therapy program|In the physical therapy program, 20 minutes of hot pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS; 30 to 40 Hz), 6 minutes of ultrasound (US; 1 MHz, 1 to 1.5 Watt/cm2) therapy were applied to both groups. Both of the programs were supervised by physical therapists. A combined range of motion and strengthening exercises were given to both groups to be performed two times a day.
45933838|NCT00063804|Drug|AMD070|
45933839|NCT00036920|Drug|canfosfamide hydrochloride|
45933840|NCT00063843|Biological|Recombinant Protective Antigen, Anthrax Vaccine Adsorbed|
45933841|NCT00036959|Drug|ABT-751|
45933842|NCT02967432|Drug|Mupirocin Topical Ointment|Mupirocin ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
45933843|NCT02967432|Drug|Petroleum Jelly|Petroleum jelly ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
45933844|NCT00036998|Procedure|conventional surgery|
45933845|NCT00036998|Procedure|neoadjuvant therapy|
45933846|NCT00036998|Procedure|thermal ablation therapy|
45933847|NCT00063960|Drug|floxuridine|
45933848|NCT00063960|Drug|irinotecan hydrochloride|
45933849|NCT04732442|Dietary Supplement|Immunonutrition|Impact Oral® Nestle, Switzerland
45803591|NCT04630964|Drug|Psilocybin|psilocybin 25 mg Single Oral Dose
45803592|NCT04630964|Drug|Niacin|niacin 100mg Single Oral Dose
45933850|NCT04732442|Dietary Supplement|Standard Oral Nutritional Support|Fortimel Compact Protein® Nutricia, United Kingdom
45933851|NCT00064116|Biological|rituximab|Rituximab 375 mg/m² i.v. day 1
45933852|NCT00064116|Drug|CHOP regimen|Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
45933853|NCT00037037|Biological|MAGE-10.A2|
45933854|NCT00037037|Biological|MART-1 antigen|
45933855|NCT00037037|Biological|NY-ESO-1 peptide vaccine|
45933856|NCT00037037|Biological|sargramostim|
45933857|NCT00037037|Biological|tyrosinase peptide|
45933858|NCT00064194|Dietary Supplement|selenium|
45933859|NCT00064194|Dietary Supplement|soy protein isolate|
45933860|NCT00064194|Dietary Supplement|vitamin E|
45933861|NCT02971085|Procedure|Active surveillance|Active surveillance cohorts are routinely performed the systematic biopsy ≥ 12 cores by TRUS-guided or MR-TRUS fusion according to the protocol based by time path as 1, 2, 4, 7, 10 years and subsequently every 5 years following initial TRUS biopsy.
45933862|NCT00064233|Drug|dasatinib|
45933863|NCT02967237|Drug|insulin glargine (U300)|Pharmaceutical form: solution Route of administration: subcutaneous
45933864|NCT00037115|Drug|interferon beta 1a|
45652702|NCT05473013|Behavioral|Behavioral Therapy for Eating Disorders|Standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).
45803593|NCT04736459|Procedure|Pre-washed catheter vs. Unwashed catheter in the intrauterine insemination|The pre-washed catheter will be washed with culture medium before intrauterine insemination The unwashed catheter will not be washed with culture medium as a standard intrauterine insemination procedure
46073467|NCT00839683|Drug|simvastatin|Oral, 40 mg, Single Dose
46073468|NCT00839683|Drug|valsartan|Tablets, Oral, 320 mg, Single Dose
46073469|NCT04242420|Diagnostic Test|Genotyping|Genotyping for single nucleotide polymorphisms for Connexin 37&43, Mannose binding lectin (MBL) and transforming growth factor beta (TGF beta) genotypes
46073470|NCT04242420|Diagnostic Test|Lung function|Spirometry,
45451939|NCT01519804|Drug|Placebo|Matching onartuzumab (MetMAb) placebo iv, Day 1 of each 21-day cycle
45803594|NCT05196230|Device|Control Condition (Social Story)|The control condition is a social story, which is treatment as usual for preparing clients for their initial visit at Holland Bloorview's dental clinic. The control condition will be delivered through the study tablet. The investigators will ask parents to read it to their child once a day for the week leading up to their appointment. If the child is reading on their own, the investigators will request that parents be in the room with participants while they are. The social story takes approximately five minutes to read.
45803595|NCT05196230|Device|Experimental Condition (360° Video)|The 360° video is from the point of view of a seated dental client and the participant will be able to explore the scene around them (navigating through the tablet's touch screen). The simulation will include scenes/features that may be anxiety-provoking for some participants. These will include loud noises commonly encountered in the dentist's office (e.g. tooth brushing, dental drills), as well as social stimuli (e.g. the dental clinician), and new environments (e.g., the dental visit room). The investigators will ensure that participants understand that they can stop at any time (e.g., if they are feeling anxious or overwhelmed), and the investigators will ask parents to explore the 360° video with their child for the week leading up to their appointment.
45451940|NCT01519804|Drug|cisplatin/carboplatin|standard dose iv, Day 1 of each 21-day cycle, 4 cycles
45451941|NCT01519804|Drug|onartuzumab|15 mg/kg iv, Day 1 of each 21-day cycle
45803596|NCT05605886|Drug|Solvazinc 50mg|Patients will receive a daily zinc supplement tablets of 50 mg in the morning after breakfast for 4 days prior to injections.
45803597|NCT05605886|Drug|placebo|placebo
45803598|NCT05595044|Drug|Vitamin D|ASD children with vitamin D insufficiency and deficiency will receive vitamin D with dose 300 IU/KG/ day not exceed 5000IU/day for 6 weeks then revaluate serum level of vitamin D if they reach normal level of vitamin D they will receive vitamin D 1000IU/ day till the end of 4 months.
45803599|NCT05595044|Other|Habilitation|Habilitation
45803600|NCT03298841|Device|Zeiss|"This study proposal will highlight the advanced technology features of the Zeiss Lumera surgical operating microscope which include but are not limited to:~Stereo Coaxial Illumination for improved visualization High resolution video screen/co-observation tool to help OR staff anticipate next steps Integrated toric alignment tool Surgical microscope touch screen Cordless foot control for faster turnover between cases"
45803601|NCT05169242|Procedure|Endoclip|In the intervention arm, one or more endoclips will be used to completely close the mucosal defect after polypectomy. Prophylactic clipping will be applied to all post-polypectomy sites. The total number of endoclips used will be recorded.
45803602|NCT04736381|Drug|Belatacept Injection [Nulojix]|Drugs administrated are part of the usual care
45803603|NCT05167058|Device|Cardiologs Platform|Smartwatch recordings interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
45803604|NCT02906657|Other|Medication reconciliation|The medication reconciliation list will be compared to the drugs prescribed by the hospital physician at admission and discrepancies will be analyzed by discussion between the physician and the pharmacist
45803605|NCT03302741|Drug|Botulinum neurotoxin (BTX)|Each patient will receive BTX injections in 2 sites. 100 units at double dilution will be injected at each site.
45803606|NCT03302741|Other|Physical Therapy|Standard physical therapy will be ordered to both groups as part of standard of care for patients after BTX injections to maximize the outcomes.
45933865|NCT00037115|Drug|methotrexate|
45933866|NCT00037115|Drug|methylprednisolone|
45933867|NCT02958540|Biological|SynGEM|Prime / boost vaccination in each group
45933868|NCT02958540|Other|placebo|prime /boost vaccination
45933869|NCT00064272|Drug|ginger extract|Given orally
45933870|NCT00064272|Other|placebo|Given orally
46073471|NCT04242420|Diagnostic Test|Microbiology|Bacterial culture from Sputum or swab
45451942|NCT01519804|Drug|paclitaxel|200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
45451943|NCT02263924|Dietary Supplement|Tocotrienol|Subjects in the intervention arm will take one capsule of 200mg tocotrienol twice daily for 6 months
45652703|NCT05473013|Behavioral|Skills Monitoring On|Integrates behavioral treatment for eating disorders with a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors.
45652704|NCT05473013|Behavioral|Automated Reminder Messages|Integrates behavioral treatment for eating disorders with two randomly time automated push notifications from a smartphone application each week to remind participants about skills they have learned in session to encourage skill use.
45933871|NCT00037154|Drug|Saw Palmetto|
45933872|NCT00064311|Drug|ravuconazole|
45933873|NCT00064389|Drug|levalbuterol tartrate HFA MDI|levalbuterol MDI 90 mcg QID
46073472|NCT04242420|Diagnostic Test|Blood sample|Interleukin-8 assay (via chemiluminescence) blood cell count
45451944|NCT02263924|Dietary Supplement|Placebo capsules|Subjects in the placebo arm will take one capsule of placebo twice daily for 6 months
45933874|NCT00064389|Drug|racemic albuterol|racemic albuterol HFA MDI 180 mcg QID
45933875|NCT00064428|Drug|fondaparinux - UFH not indicated|2.5mg od, sc (1st dose IV) x 8 days or discharge
45933876|NCT00064428|Other|Control - UFH not indicated|Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
45933877|NCT00064428|Drug|Fondaparinux - UFH indicated|2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus x 24-48 hr infusion
45933878|NCT00064428|Drug|Control - UFH|UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
45933879|NCT00064467|Drug|Extended-release bupropion (HCl)|
45933880|NCT00064584|Drug|CT53518|
45451945|NCT02266186|Behavioral|Traditional Cognitive behavioural therapy|Therapist supported live therapy
45652705|NCT05473013|Behavioral|JITAIs|Integrates behavioral treatment for eating disorders with push notifications each week from a smartphone application to remind participants about skills they have learned in session to encourage skill use during app-identified moments of need (i.e., JITAIs, just-in-time adaptive interventions).
45652706|NCT05211921|Device|Multi-Gyn ActiGel Plus|vaginal gel
45652707|NCT04987801|Other|Drug Toxicity|Patients who took over dose of Drugs
45652708|NCT04802291|Behavioral|HomeStyles-2: Obesity Prevention Program for Families with Children in Middle Childhood|Comparison of 2 educational interventions
45803607|NCT03302741|Device|Standard BTX injection (ultrasound guided)|For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the innervation zones (IZs) of the entire muscle.
45933881|NCT00064623|Drug|Capsaicin Dermal Patch|
45933882|NCT00064740|Behavioral|relaxation response|
45933883|NCT02966925|Device|Cellular Matrix BCT-HA Kit|Submucosal injections in the vulva, in the posterior vaginal wall and in the perineum of a combination product made of PRP and HA prepared using the Cellular Matrix BCT-HA medical device
45933884|NCT00064779|Drug|IL13-PE38QQR|
45933885|NCT00064779|Procedure|targeted fusion protein therapy|
45652709|NCT05161611|Drug|Zinc sulfate|10 mg of oral zinc sulfate will be given to neonates per day
45652710|NCT05161611|Other|Placebo|10 mg of normal saline will be given to neonates per day
45803608|NCT03302741|Device|3-dimensional innervation zone (3DIZ) guided injection|Simultaneous surface EMG and intramuscular EMG measurements will be acquired from the spastic biceps of the patients. Patients will be seated comfortably on a height-adjustable chair. The arm to be tested will be secured firmly on a customized apparatus with the elbow joint at approximately 90° of flexion and the shoulder at approximately 45° of abduction and 30° of flexion. The 128-channel unipolar surface EMG signals will be recorded with 2 flexible 2-dimensional 64-channel surface electrode array. A coating fine wire electrode will be inserted into the mid-axial section of the biceps to record bipolar intramuscular EMG signals. Ultrasound scan will be performed on the biceps to identify the location of the inserted wire electrode. Patients will be asked to contract their impaired biceps to perform maximum voluntary contraction of elbow flexion against the vertical plates 3 times.
45803609|NCT02803307|Drug|TLC599|Single dose via intra-articular injection
45933886|NCT00064779|Procedure|surgery|
45933887|NCT00037544|Drug|ReFacto AF|
45933888|NCT00037583|Drug|Gemtuzumab Ozogamicin|
45933889|NCT00064857|Drug|Pycnogenol|
45933890|NCT00037622|Drug|ACH-126, 443 (beta-L-Fd4C)|
46073473|NCT04242420|Diagnostic Test|Induced Sputum|Interleukin-8 assay (via chemiluminescence) blood cell count
45451946|NCT02266186|Behavioral|Internet based Cognitive behavioural therapy|Internetbased CBTwith limited therapist support
45451947|NCT04476394|Drug|[14C]-Anaprazole Sodium enteric-coated capsule|[14C]-Anaprazole Sodium enteric-coated capsule
45652711|NCT05161611|Other|Phototherapy|Neonates will be put under phototherapy
45652712|NCT05634655|Other|no interventions between two groups|no interventions between two groups
45652713|NCT04802525|Other|Moderate-intensity aerobic exercise training|The first group has received Moderate-intensity aerobic exercise training without dietary control, the second group has received a low-fat diet program without exercise intervention, and the third group has received Moderate-intensity aerobic exercise training plus a low-fat diet program for 10 consecutive weeks
45652714|NCT03660475|Drug|Naltrexone|naltrexone formulated as ophthalmic solution
45652715|NCT03660475|Drug|Placebos|Placebo ophthalmic solution
45652716|NCT04802213|Other|Rehabilitation exercise|Rehabilitation exercise use the methods that suggested by previous studies including finger wall climbing, pendulum exercise, and arms lifting.
45933891|NCT00037661|Drug|INS365 Ophthalmic Solution|
45933892|NCT04730622|Diagnostic Test|SARC-F questionnaire|Assessment of muscle performance based on self-reported information about grip strength, assistance with walking, rising from a chair, climbing stairs, and falls.
45933893|NCT04730622|Diagnostic Test|Bone tissue histology|Assessment of histomorphology and matrix-structure of tissue samples obtained from the bone resected during the hip prosthesis positioning.
45933894|NCT04730622|Diagnostic Test|Muscle tissue histology|Assessment of histomorphology and ultrastructure of muscle biopsies taken from the upper portion of the vastus lateralis muscle, which is accessed in the surgical procedure of hip replacement.
45933895|NCT04730622|Diagnostic Test|Myostatin serum levels|Quantification of circulating myostatin, a muscle-specific biomarker that suppresses muscle growth and bone formation.
45933896|NCT04730622|Diagnostic Test|Insulin-like growth factor 1 (IGF-1) serum levels|Quantification of circulating IGF-1, a growth factor that promotes muscle growth and osteogenesis.
45933897|NCT04730622|Other|Frequency food questionnaire|Assessment of dietary habits based on self-reported information about the monthly- weekly- or daily-frequency consumption of main food groups, including cereals and bread, meat, fish, fruit, vegetable, legumes, dairy products, sweets and snacks, drinks, and dietary supplements.
45933898|NCT04730622|Other|Gut microbiota profiling|Assessment of gut microbiome composition on stool samples.
45933899|NCT00037700|Drug|anakinra|
45933900|NCT00037700|Drug|pegsunercept|
45933901|NCT00064896|Procedure|MRI|
45933902|NCT00064935|Procedure|Endometrial biopsy|
45933903|NCT00064974|Drug|CC-5013|CC-5013 10 mg (two 5 mg capsules) daily on days 1-28 every 28 days (28 day cycles)
45933904|NCT00037817|Drug|Decitabine|assigned dose level on day 4 and day 10 of each 34 day cycle
45803610|NCT05585762|Other|Ketone ester|75 mL chocolate flavored beverage containing 25 g of ketone ester. Half a bottle (12.5 g/day) will be consumed for the first 7 days and a complete bottle (25 g/day) will be consumed for the remaining 77 days.
45803611|NCT05585762|Other|Non-ketone placebo|75 mL chocolate flavored beverage containing 25 g of non-ketogenic fat. Half a bottle (12.5 g/day) will be consumed for the first 7 days and a complete bottle (25 g/day) will be consumed for the remaining 77 days.
45803612|NCT02792465|Drug|CFI-402257|
45803613|NCT02792465|Drug|Fulvestrant|
45803614|NCT04568486|Other|Diabetes Empowerment Education Program|The Diabetes Empowerment Education Program (DEEP) is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
45803615|NCT02669537|Device|GoPro Camera|The gopro camera will be used to record the procedure which will be reviewed by the resident prior to performing a second procedure of the same type.
45933905|NCT00037817|Biological|Depsipeptide|assigned dose level on day 4 and day 10 of each 34 day cycle
45803616|NCT05573828|Procedure|ICG angiography to show vascular map of parathyroid glands|Using ICG angiography guided thyroidectomy to identify the vessels feeding the parathyroid glands and then perform the thyroidectomy. After it, ICG angiography is done to predict immediate parathyroid functio
45933906|NCT00037817|Drug|Celecoxib|400mg PO BID on days 4 through 34 of each cycle
45803617|NCT02769611|Drug|Ruboxistaurin|Dose escalation trial. 1st ten patients to receive 64 mg, next 10 patients to receive 128 mg, next 10 patients to receive 256 mg.
45803618|NCT04536350|Drug|Aviptadil 67μg|Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
45803619|NCT04536350|Drug|Placebo 0.9% NaCl solution|Patiens will receive Standard care plus 0.9% NaCl solution three times a day for ten days
45803620|NCT02512445|Behavioral|Trauma Informed Guilt Reduction Therapy|Trauma focused therapy
45933907|NCT00065013|Behavioral|strength training|
45451948|NCT02264002|Drug|Cilobradine low dose 1|
45451949|NCT02264002|Drug|Cilobradine low dose 2|
45451950|NCT02264002|Drug|Cilobradine medium dose|
45803621|NCT02512445|Behavioral|Supportive Care Therapy|Supportive therapy
45803622|NCT04530890|Diagnostic Test|Blood samples|Only blood samples at different times of treatment
45803623|NCT04525820|Drug|Single high dose vitamin D|Patient receives either one dose orally of 140'000 IU (7 ml) of this drug once as an intervention treatment additionally to TAU or the patient receives 7 ml of the placebo Solution (7 ml) in addition to TAU
45803624|NCT04525820|Drug|Placebo|Patient receives a single dose of a placebo solution
45803625|NCT04525820|Drug|Treatment as usual vitamin D|Both groups receive the treatment as usual after the single high dose or the placebo which will be 800 IU per day
45803626|NCT05570708|Drug|MDMA, LSD, psilocybin|"MDMA per os (2 x 100mg) in a group setting~LSD per os (75 and 150 mcg) in a 1:1 setting~Psilocybin per os (15 mg and 25 mg) in a group setting~Three study days are without drug administration: Participants experience the role of the therapist in a 1:1 setting"
45803627|NCT04490330|Other|questionnaire|AUDIT questionnaire (alcohol use disorders identification test)
45803628|NCT03303911|Drug|Cytisine|film-coated tablets; depending on arm assignment, 1 or 2 tablets to be taken with 240 mL water for each dose
45933908|NCT00037895|Procedure|Ambulation training|
45933909|NCT00065052|Behavioral|Behavior modification|
45933910|NCT00037934|Device|Upper extremity robot|Robotic upper extremity neuro-rehabilitation
45933911|NCT00037934|Other|Traditional Supervised Upper Extremity Exercises|Arm ergometer, reaching, and stretching exercises
45933912|NCT00065130|Drug|human insulin|
45933913|NCT00065130|Drug|insulin NPH|
45933914|NCT00065130|Drug|insulin aspart|
45933915|NCT00037973|Behavioral|ventilation feedback|
45933916|NCT00037973|Behavioral|exercise|
45933917|NCT00065169|Drug|Celecoxib|
45933918|NCT00038012|Drug|Thrombopoietin|
45451951|NCT02264002|Drug|Cilobradine high dose 1|
45451952|NCT02264002|Drug|Cilobradine high dose 2|
45451953|NCT02264002|Drug|Metoprolol succinate tablets|
45451954|NCT02264002|Drug|Placebo|
45451955|NCT02264080|Drug|WAL2014|
45451956|NCT02264080|Drug|Placebo|
45451957|NCT01517776|Drug|Cilengitide|Cilengitide 1800 mg/m² i.v. twice weekly with a mandatory platelet-count dependent dose adaptation rule
45451958|NCT01517776|Drug|Temozolomide|Temozolomide 75 mg/m²/d p.o. for 6 weeks, followed by 1 week rest with a mandatory platelet-count dependent dose adaptation rule
45451959|NCT01364662|Drug|SPN-810|administered orally
45451960|NCT01364662|Drug|Placebo|administered orally
45451961|NCT01517698|Drug|Placebo|placebo to RO4917523 orally once a day for 12 weeks
45451962|NCT01517698|Drug|RO4917523 0.5 mg|0.5 mg orally once a day for 12 weeks
45803629|NCT05570162|Other|Diabetes educational program|30-minute long diabetes educational program
45803630|NCT03305159|Drug|Povidone-Iodine|Patients will receive povidone iodine for the surgical preparation of the vagina.
45803631|NCT03305159|Drug|4% Chlorhexidine Gluconate|Patients will receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
45803632|NCT05552690|Procedure|blood draw|10 ml of blood will be draw to genetic analysis (sequencing)
45803633|NCT03306641|Device|Test Contact Lens|Daily disposable contact lens
45803634|NCT03306641|Device|Nelfilcon A|Focus Dailies All Day Comfort contact lens (nelfilcon A)
45933919|NCT00038012|Procedure|Platelet-pheresis|
45933920|NCT00038012|Drug|Carboplatin|
45933921|NCT00065208|Behavioral|Reiki|Energy therapy - 8 biweekly sessions of 30 minutes
45933922|NCT00065208|Behavioral|Pretend Reiki|Touch from untrained pretend practitioners. 8 biweekly sessions of 30 minutes
45933923|NCT00065208|Behavioral|Rest / Guided Imagery|4 weekly sessions of 30 supine rest listening to soft music. One session of Guided Imagery followed at visit 9. Listen to CDs twice a day 3 days prior to and 2 days following surgery (affect only post surgery outcomes)
45933924|NCT00038051|Drug|Hum-195/rGel|Starting Dose = 3 mg/m^2 twice weekly for 2 weeks.
45933925|NCT02967198|Device|CT/US fusion|Fusion of pre-procedure cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
45933926|NCT02967198|Device|ultrasound shear wave elastography|ultrasound shear wave elastography is performed in S-shear wave scanner according to guidelines of ultrasound elastography.
45652717|NCT04802213|Device|joint mobilization device treatment|The joint mobilization treatment used the mobilization device that developed in this research.It is a device developed by using the design of the vibration force generated by the vibration mechanism and the technologies to simulate the mobilization of the shoulder joint.When the subject uses the device, first sit on a seat that can be adjusted according to the user's body shape and buckle the shoulder fixation device. Then use the specially designed shoulder movement setting mechanism of the device to set the user's shoulder movement and movement angle.The next step is to set the direction and magnitude of the vibration force applied by the device to the shoulder joint in accordance with the joint mobilization technique (posterior, anterior, and inferior) that the therapist or user intends to perform to achieve the effect of simulating joint mobilization and increasing joint mobility.
45933927|NCT00038090|Drug|Thalidomide|100 mg capsules by mouth daily each evening
45933928|NCT00038090|Drug|Dexamethasone|20 mg/m^2 taken by mouth each morning on days 1-4, 9-12 and 17-20.
45933929|NCT00065247|Behavioral|Beat Osteoporosis: Nourish and Exercise Skeletons (BONES) Project|
45933930|NCT00038129|Procedure|Intramedullary nail implant|Insertion of an intramedullary nail during tibial fracture fixation with or without prior reaming of the intramedullary canal.
45933931|NCT00065325|Drug|Fulvestrant|intramuscular injection
45933932|NCT00065325|Drug|Exemestane|oral capsule
45803635|NCT04473326|Behavioral|Reinforcement Learning|Participants in the intervention arm will receive up to daily, tailored text messages based on their electronic pill bottle-measured adherence. Given the participants' baseline characteristics and time-varying responses to the messages, a reinforcement learning algorithm will deliver different text messages and adapt over time to determine which type of messaging works best for each individual participant.
45652718|NCT04802213|Device|laser acupuncture device treatment|The laser acupuncture treatment use the laser acupuncture device that developed in this research. A gallium-aluminium-arsenide (GaAlAs, infrared laser) continuous wave diode laser device with a wavelength of 850nm (invisible), a power output of 100 mW, and a spot area of 0.07cm2 was used for laser acupuncture.When performing laser acupuncture treatment, the laser emitted by the device is irradiated on the selected acupuncture points .The acupuncture points (GB 21, LI 4, LI 11, LI 14, LI15, LI 16, SI 9, SI 10, SI 11, TE 14, and TE 15) were determined according to the literature regarding acupuncture application in shoulder pain based on traditional chinese acupuncture.
45933933|NCT00038168|Drug|Estramustine|Intravenous dose
45933934|NCT00038168|Drug|Taxol|Intravenous dose
45451963|NCT01517698|Drug|RO4917523 1.5 mg|1.5 mg orally once a day for 12 weeks
45451964|NCT02266264|Drug|Hydrocortisone|Subjects will be divided into two groups by randomization. The intervention-group will be received 100 milligrams per day of hydrocortisone and the control-group will be received 200 milligrams per day of hydrocortisone in the first three days after enrollment.
45451965|NCT01516918|Drug|VX-222|tablet, 400-mg twice daily
45803636|NCT02163317|Radiation|stereotactic radiosurgery|Undergo MRI-guided focal SRS
45451966|NCT01516918|Drug|telaprevir|tablet, 1125-mg twice daily
45803637|NCT02163317|Device|magnetic resonance imaging|Undergo staging MRI with contrast
45803638|NCT02163317|Other|quality-of-life assessment|Quality of life scores will be summarized graphically and repeated measures of variance will be conducted to test for changes in scores over time
45803639|NCT02163317|Procedure|Serum Prostate Antigen Test|Test of the PSA protein in blood. The test will be run every three months for up to two years during the study.
45933935|NCT00398658|Drug|gentamycin and clindamycin|
45933936|NCT00038207|Drug|Liposomal Vincristine|Vincristine Sulfate Liposome Injection (VSLI) administered via a central venous catheter at 2.0 mg/m2 over 60 minutes every 14 days + 2 days
45933937|NCT00398697|Drug|Perifosine|
45933938|NCT00398697|Drug|Gemcitabine|
45933939|NCT00038246|Drug|Estramustine|140 mg by mouth (po) three times a day on Days 1-5, 8-12
45933940|NCT00038246|Drug|Thalidomide|200 mg by mouth every day once a week with dose escalation every week if no dose limiting toxicity.
45933941|NCT00038246|Drug|Paclitaxel (Taxol)|100 mg/m^2 by vein (IV) over 3 hours Day 3 and Day 10
45933942|NCT00038285|Procedure|Amputation Prevention|
45933943|NCT00398736|Procedure|sonographic measurement of inferior caval vein diameter|
45933944|NCT05434247|Device|Needle choice|The type of needle use was the only intervention
45933945|NCT00398775|Procedure|antibiotic discontinuation|
45933946|NCT05434208|Other|Nurse-led telephonic calls|active telephonic follow-up program by specialist nurses until end-of-treatment (28 days)
45451967|NCT01516918|Drug|ribavirin|tablet, 1000-mg per day for subjects weighing <75 kg and 1200 mg per day for subjects weighing ≥75 kg, twice daily
45451968|NCT01516918|Biological|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
45451969|NCT01508026|Drug|Nebivolol and Valsartan 1|Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg, oral administration, then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration
45803640|NCT02163317|Procedure|Digital Rectal Exam|Exam of rectal health. Performed every three months for up to two years throughout the study.
45803641|NCT02163317|Behavioral|Expanded Prostate Cancer Index Composite|This survey measures a patient's function and bother after prostate cancer treatment. It will be analyzed using ANOVA using data collected every 6 months for up to 2 years of the study.
45933947|NCT00398814|Drug|Perifosine|For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
46073474|NCT00833131|Radiation|Short course of radiotherapy|5 x 5 Gy and afer one week interval consolidating chemotherapy of 3 courses of FOLFOX4
45652719|NCT05211609|Diagnostic Test|Plasmatic 3-O-Methyldopa dosage|Plasmatic 3-O-Methyldopa dosage
45803642|NCT05552144|Device|Hum by Colgate Smart Kids Toothbrush (battery powered) - 490000006871|The first 15 caregivers and their children who meet the inclusion/exclusion characteristics and sign an Informed Consent Form/provide assent will be entered into the study. The caregivers will be asked to supervise the tooth brushing experience of the children with hum Kids toothbrush twice a day for 4 weeks using the associated app. The caregivers will also be asked to fill out questionnaires and participate in interviews regarding the children's brushing habits and experiences.
45652720|NCT05615987|Drug|Onabotulinumtoxina for Injection|200iu/2ml in both groups
45933948|NCT00398814|Drug|Sorafenib|For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
45933949|NCT00065364|Behavioral|Newborn Individualized Developmental Care Assessment Program|
45933950|NCT00065403|Device|Acupuncture|
45933951|NCT05434130|Behavioral|High Dose Exercise|The investigators will initially test and randomize adolescents ages 13-18 years old ≤14 days post-concussion to high dose aerobic exercise (>150 min/week, individualized intensity level) or standard-of-care (symptom limited, self-guided physical activity), and re-test upon symptom resolution and 8-weeks post symptom resolution
45803643|NCT05550428|Device|Pulse Electromagnetic Field device|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions.
45803644|NCT05550428|Device|Sham Pulse Electromagnetic Field device|Sham Pulse Electromagnetic Field Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with a total of 16 treatment sessions.
45933952|NCT00065559|Drug|celecoxib|
45933953|NCT05433974|Biological|Blood sample collection|Blood sample collection : 2 X 6 mL
45933954|NCT00065637|Drug|Teriparatide|Synthetic human parathyroid hormone
45933955|NCT00065637|Drug|Placebo teriparatide|Placebo injections
45652721|NCT05160675|Other||No intervention
45803645|NCT03308669|Drug|Lasmiditan|Administered orally
45803646|NCT03308669|Drug|Placebo|Administered orally
45803647|NCT03308669|Drug|Topiramate|Administered orally
45803648|NCT00356252|Drug|mixed carotenoids|
45803649|NCT01386359|Drug|No Intervention|No Intervention. Subjects are previously treated with Nulojix (belatacept)
45933956|NCT00396578|Drug|aerosolized vancomycin or gentamicin|
45933957|NCT00398853|Dietary Supplement|chromium picolinate 1000 mcg daily vs placebo|chromium picolinate 1000 mcg daily vs placebo
45933958|NCT00398853|Other|Placebo|Placebo
45933959|NCT05433896|Drug|Dasatinib ASD|XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 90 mg Test Formulation
45933960|NCT05433896|Drug|Omeprazole 40 MG|Omeprazole Delayed Release Capsules, USP 40 mg
45933961|NCT05433779|Device|Neosense Umbilical Catheter|The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
45933962|NCT00065715|Dietary Supplement|Echinacea|Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. B) Echinacea angustifolia - 600 mg root yields 150 mg dried extract, standardized to contain 2.0 mg alkamides. Each batch of tablets is analyzed by Reversed Phase - High Peformance Liquid Chromatography to determine the levels of alkamides and caffeic derivatives present. Caffeic acid derivative levels are typically as follows: caftaric acid = 0.5 to 2.0 mg/tablet; cichoric acid = 3.4 to 8.5 mg/tablet; chlorogenic acid = < 0.5 mg/tablet; dicaffeoyl quinic acids (including cynarin) = 0.7 to 2.0 mg/tablet; echinacoside = 1.0 to 1.7 mg/tablet
45933963|NCT00065715|Other|Blinded placebo|Blinded placebo - Coated tablet
46073475|NCT00833131|Radiation|Radiochemotherapy|28 x 1,8 Gy with simultaneous neoadjuvant chemotherapy: two courses of 5-Fu 325 mg/m2/day i.v. bolus and LV 20 mg/m2/day i.v.-bolus over 5 days given during 1-5 and 29-33 days of radiation. Oxaliplatin is given 50 mg/m2 once a week 5 times during 1, 8, 15, 22 and 29 days of radiation.
45652722|NCT04346225|Drug|Hyperpolarized C13|Given by intravenous injection. When receiving two HP 13C pyruvate injections, the injections will be separated by a period of 15-60 minutes
45652723|NCT04346225|Procedure|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body
45652724|NCT05478135|Device|NAVIFY Oncology Hub|NAVIFY Oncology Hub is a platform that aggregates and organizes disparate data into an intuitive, longitudinal view of the patient's cancer care journey. The platform is designed to optimize and support oncology workflows and decision-making by providing quick access to the most relevant data in one place, so that providers can make decisions more efficiently and collaborate more seamlessly.
45803650|NCT05099042|Other|Recommendations and re-orientation towards appropriate physical, mental, and social health ressources|Resources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP.
45803651|NCT02055781|Drug|Pacritinib|
45803652|NCT02055781|Drug|Best Available Therapy|
45451970|NCT01508026|Drug|Nebivolol and Valsartan 2|Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 320 mg, oral administration
45451971|NCT01508026|Drug|Nebivolol and Valsartan 3|Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 20 mg and Valsartan 320 mg, oral administration
45451972|NCT01508026|Drug|Nebivolol 1|Nebivolol Monotherapy 5 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 10 mg, oral administration
45803653|NCT03309449|Device|Syringe and needle|Intramuscular administration of simulated naloxone
45803654|NCT03309449|Device|Intranasal mucosal atomization device|Intranasal atomizer administration of simulated naloxone
45803655|NCT03309449|Device|Nasal spray|Nasal spray administration of simulated naloxone
45803656|NCT05096156|Device|Precision1® Daily Disposable Contact Lens|Soft, spherical contact lens used to correct distance vision.
45933964|NCT05433662|Behavioral|Pandemic Acceptance and Commitment Therapy (Pan-ACT)|Pan-ACT is a 10-session, closed group, transdiagnostic intervention for older adults.
45933965|NCT00069849|Drug|ABT-089|
45652725|NCT03069157|Procedure|lung recruitment maneuver|lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O
45803657|NCT05094440|Behavioral|Dialectical behavioral therapy skills training (DBT-ST)|Pocket Skills is a dialectical behavior therapy skills training (DBT-ST) webapp that includes video lessons, an interactive chatbot AI coach, and in-app exercises to practice DBT skills. The delivery of the app will occur primarily over 1 month, followed by 2 months of follow-up, and will be supplemented with a walk through manual and links to DBT worksheets.
45933966|NCT05433545|Other|Questionnaire|Adolescents with spinal deformity will be asked to fill out a new questionnaire measuring the quality and quantity of adherence to specific physiotherapy exercises performed at home. Patients will be recruited at an outpatient service dedicated to the treatment of vertebral deformities during the monthly sessions with the physiotherapist
45803658|NCT04429100|Diagnostic Test|Magnetic Resonance Imaging|One novel MRI sequence, i.e. the quantitative imaging of macromolecular proton fraction (MPF), will be introduced into this study. MPF is defined as the relative amount of protons associated with macromolecules involved in magnetization exchange with free water protons. This parameter is independent of the pool model used for quantification and the pulse sequences used for data acquisition. Recent studies have found a strong association between MPF and collagen content in the fibrotic liver, indicating MPF is a potential biomarker of early-stage liver fibrosis.
45933967|NCT00065754|Drug|placebo|
45652726|NCT05107557|Biological|Experimental Group|The COVID-19 vaccine was manufactured by Sinovac Research & Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
45933968|NCT00069888|Drug|Docetaxel|
45803659|NCT02056171|Drug|quetiapine|Patients who are diagnosed with delirium and assigned to the intervention arm will receive quetiapine.
45803660|NCT02056171|Other|Placebo|Patients who are diagnosed with delirium and assigned to the placebo arm will receive placebo.
45933969|NCT05433467|Procedure|CT-guided localization for micro hepatocellular carcinoma before surgical resection|After preoperative preparation was completed, on the day of surgery, disposable pulmonary nodular localization needle (Ningbo Sonjiecang Biological Technology Co., LTD., Model: SS510-10) was used for the localization of micro hepatocellular carcinoma that could be found by preoperative CT enhancement or MRI. After the micro hepatocellular carcinoma was located under the guidance of CT, and then the patient was sent to the operating room. During the operation, the lesion was removed according to the tail line of the positioning needle and the position of the positioning needle.
45933970|NCT05433428|Drug|Lubricant Eye Drops|Prolonged use of lubricant eye drops pre and post-op.
45451973|NCT01508026|Drug|Nebivolol 2|Nebivolol Monotherapy 20 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 40mg, oral administration
45803661|NCT03312023|Drug|Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]|1 pill once daily for 12 weeks for Group A
45803662|NCT03312023|Drug|Sofosbuvir 400 MG [Sovaldi]|1 pill once daily for 12 weeks for Group C
45933971|NCT05433428|Drug|Preservative Free|Preservative free eye drops
45451974|NCT01508026|Drug|Valsartan 1|Valsartan Monotherapy 80 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 160 mg, oral administration
45652727|NCT02594735|Drug|Abatacept|Study participation will consist of a screening visit and 5 protocol visits over six months (week 0, week 6, week 12, week 18, and week 24) for each subject, and phone follow-up (week 2, week 4, week 8, week 10, week 14, week 16, week 20, and week 22). At Visit 1, which will be treatment initiation, eligible subjects will be instructed on the use and side effects of subcutaneous abatacept and will be started on the study drug (abatacept 125 mg SQ weekly for subjects with body weight ≥ 50 KG or abatacept 87.5mg SQ for subjects with body weight < 50 KG).
45803663|NCT03312023|Drug|Ledipasvir 90 MG|1 pill once daily for 12 weeks for Group D
45933972|NCT05433428|Drug|Preservative|Eyedrops with preservatives
45933973|NCT00069927|Drug|Adderall-XR®|Adderall-XR® 10 mg/day for 3-12 weeks depending on subject's response
45933974|NCT00069927|Drug|Concerta®|Concerta® 18 mg/day for 3-12 weeks depending on subject's response
45803664|NCT04425122|Diagnostic Test|Upper endoscopy|Upper endoscopy would be performed. Biopsy would be taken from oesophageal cancer tissue and adjacent non-cancerous mucosa
45803665|NCT04425122|Diagnostic Test|Upper endoscopy|Upper endoscopy would be performed. Random biopsy would be taken from normal non-cancer esophageal mucosa.
45803666|NCT02056639|Device|Bioteque cup pessary|
45803667|NCT03839420|Device|CZM IOL|implantation of CZM IOL
45803668|NCT03839420|Device|Competitor IOL|implantation of Competitor IOL
45803669|NCT00900497|Biological|White Blood Cells/Granulocytes|Granulocytes collected by apheresis, cross-matched for ABO-Rh and common antibodies, HLA-mismatched to avoid engraftment
45933975|NCT00069966|Biological|filgrastim|
45933976|NCT00069966|Biological|rituximab|
45933977|NCT00069966|Drug|cisplatin|
45933978|NCT00069966|Drug|cytarabine|
45933979|NCT00069966|Drug|methylprednisolone|
45933980|NCT00069966|Drug|pixantrone dimaleate|
45933981|NCT00069966|Procedure|autologous bone marrow transplantation|
45933982|NCT00069966|Procedure|peripheral blood stem cell transplantation|
45933983|NCT00065832|Behavioral|Reading Instruction|
45933984|NCT00070005|Procedure|conventional surgery|
45933985|NCT00070005|Procedure|management of therapy complications|
45933986|NCT05433038|Device|skeletally anchored maxillary expander|used from day one and activated two times per day for two weeks
45933987|NCT00065871|Behavioral|Contraceptive Screening by Pharmacist|
45451975|NCT01508026|Drug|Valsartan 2|Valsartan Monotherapy 160 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 320 mg, oral administration
45933988|NCT00065871|Behavioral|Contraceptive Prescribing by Pharmacist|
45933989|NCT00065910|Behavioral|Caregiver joint attention intervention|
45933990|NCT05432960|Biological|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
45933991|NCT05432960|Drug|Placebo|Normal Saline (0.9% Sodium Chloride solution)
45933992|NCT00065949|Drug|magnesium sulfate|
45933993|NCT00396617|Device|prothesis voice|The device may be used for patient using another type of voice prosthesis, of for patient undergoing total laryngectomy. This device is definitively placed in two parts:The first one is introduced in the puncture (TEP) through the esophagus (retrograde way). The second part is then clipped on the first one through the tracheotomy orifice (anterograde way).A third part containing the valve can then be clipped in the prosthesis and easily removed in order to change it as often as necessary.
45933994|NCT00396617|Procedure|total laryngectomy|The second part is then clipped on the first one through the tracheotomy orifice (anterograde way).A third part containing the valve can then be clipped in the prosthesis and easily removed in order to change it as often as necessary.
45652728|NCT05159583|Device|In-Home Technology System|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).
45933995|NCT00065988|Device|Dispersed phase amalgam restoration /composite restoration|
45933996|NCT00396695|Procedure|Blood test|
46073476|NCT02826330|Other|biomarkers|fecal microbiota analysis antibodies in serum and saliva DNA polymorphisms
45803670|NCT04368806|Drug|JointStem|Autologous Adipose tissue derived Mesenchymal Stem Cells (AdMSC)
45803671|NCT04368806|Other|Placebo Control|Normal Saline with autologous Serum
45803672|NCT02340091|Device|HA IDF plus|
46073477|NCT00839761|Dietary Supplement|iron fortified rice|
45933997|NCT00066027|Drug|20 mg doxycycline hyclate|Subjects in the LDD group took 20 mg doxycycline hyclate tablets twice daily for two years
45451976|NCT01508026|Drug|Placebo|Dose matched placebo, oral administration
45451977|NCT01357642|Drug|Epinephrine inhalation aerosol|Epinephrine inhalation aerosol, 125 mcg/inhalation, 2 inhalations QID at 4 - 6 hour intervals
45451978|NCT01357642|Drug|Placebo|Placebo for epinephrine inhalation aerosol, formulation without epinephrine
45933998|NCT00066027|Drug|Placebo|Subjects in the placebo group took a placebo look-alike twice daily for two years.
45933999|NCT00396734|Drug|Provigil (Modafinil)|Increase from 100mg to 400mg during 1 month of treatment
45803673|NCT02340091|Device|HA IDF|
46073478|NCT00839761|Dietary Supplement|iron drops|
46073479|NCT02825706|Other|Educational physiotherapy group|20 patients with hemophilia were randomly allocated to an educational intervention or to a control group. The educational intervention was performed every two weeks during 15-week and home exercises were performed once a day, 6 days a week, in the same time
45451979|NCT01357642|Drug|epinephrine inhalation aerosol|epinephrine inhalation aerosol, 220 mcg/inhalation, 2 inhalations QID at 4-6 hour intervals
45803674|NCT04341194|Behavioral|Parent-driven pain management with skin-to-skin contact|The infant is placed naked (except for a diaper and possibly a hat) on the parents' bare chest.
45803675|NCT04341194|Behavioral|Parent-driven pain management with skin-to-skin contact/breastfeeding/parental singing|Live parental infant-directed lullaby singing is an individually tailored, non-verbal, multisensory, multimodal and affective tool to regulate the infant before, during and after venipuncture. Direct breast-feeding has demonstrated efficacy that is equal to, or greater than, sweet taste interventions in reducing behavioral and physiological responses to pain in full-term infants undergoing venipuncture with no demonstrated adverse outcomes. Direct breast-feeding should be considered the preferred first-line analgesic intervention for painful procedures performed on full-term infants.
45934000|NCT00396734|Drug|Topamax (Topiramate)|Increase from 25mg to 200mg in one month (double every week)
45934001|NCT02966964|Drug|DWPUR001|
46073480|NCT00839839|Procedure|Oocyte Vitrification|All oocytes retrieved will be vitrified (rapidly frozen) after egg retrieval. The oocytes will then be warmed on the same day and fertilized per standard IVF-ICSI. Resulting embryos will be transferred back to the patient as per protocol.
45451980|NCT03135340|Procedure|WALANT|These patients will receive local anesthetic for flexor tendon repair injected directly into the operative site on the hand. The local anesthetic used 1% lidocaine with 1:100,000 epinephrine.
45451981|NCT03135340|Procedure|General/regional anesthesia|These patients will receive general/regional anesthesia for flexor tendon repair. This is ropivacaine 0.5% injected by an anesthetist under image-guidance in the axillary region of the arm. If the regional anesthesia is not functioning at the time of OR, this is converted to a general anesthetic as per standard protocol.
45451982|NCT03135340|Drug|WALANT Injection|1% lidocaine with 1:100,000 epinephrine injected directly into operative site. The typical quantity is 5-10cc aliquots.
46073481|NCT02825394|Other|anti-Xa activity point-of-care testing (aXa-POCT)|
46073482|NCT02825394|Other|ecarin clotting time point-of-care testing (ECT-POCT)|
46073483|NCT00845611|Biological|peptide vaccine|peptides emulsified with Montanide ISA51
46073484|NCT00845689|Drug|placebo|NaCl 0,9 %
46073485|NCT00845689|Drug|adenosine|intravenous infusion of adenosine 0, 2 %
45451983|NCT03135340|Drug|Regional Anesthetic Injection|0.5% ropivacaine injected under ultrasound guidance into the axilla. The typical quantity is 30-40cc aliquots.
45451984|NCT01356160|Drug|GS-5885|tablet, 30 mg QD
45451985|NCT01356160|Drug|GS-9451|tablet, 200 mg QD
45803676|NCT02342197|Drug|Decapeptyl|half the dose of Gn agonist
45803677|NCT03182933|Drug|Peripheral Nerve Blockade|Each study arm will receive their respective formulation of local anesthetic, either standard bupivacaine or liposomal bupivacaine upon randomization
45803678|NCT03182933|Behavioral|10 meter walk test on post-operative day 1|Patient asked to walk 10 meters at comfortable pace on post-operative day one when deemed safe to do so by the physical therapist
45934002|NCT02966964|Drug|Placebo|
45934003|NCT02970890|Device|Portable Pain Away™|Portable Pain Away™ device (manufactured by Multi Radiance Medical, Solon - OH, USA) - placebo or active phototherapy
46073486|NCT00845689|Drug|adenosine|intravenous infusion of adenosine 0,2 %
46073487|NCT00845689|Procedure|Liver resection|Liver resection with Pringle maneuver
45934004|NCT00070083|Biological|oblimersen sodium|
45934005|NCT00070083|Biological|rituximab|
45934006|NCT00070083|Drug|cyclophosphamide|
45934007|NCT00070083|Drug|doxorubicin hydrochloride|
45934008|NCT00070083|Drug|prednisone|
45934009|NCT00070083|Drug|vincristine sulfate|
45451986|NCT01356160|Biological|peginterferon alfa-2a|(solution for injection) 180 µg/week
45652729|NCT05159583|Device|Limited In-Home Technology|Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
45652730|NCT03645499|Drug|Topical TA-102 A|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
45934010|NCT00070122|Drug|oxaliplatin|Given IV
45934011|NCT00070122|Drug|leucovorin calcium|Given IV
45934012|NCT00070122|Drug|capecitabine|Given orally
45934013|NCT00070122|Biological|bevacizumab|Given IV
45652731|NCT03645499|Drug|Topical TA-102 B|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
46073488|NCT04196478|Device|doppler ultrasound|a 7.5 MHz ultrasound (US) linear probe is needed, grey-scale ultrasound and Color Doppler and a minimum display facility of the Doppler velocity spectrum for blood flow calculation are mandatory tools.
45652732|NCT03645499|Drug|Topical TA-102 C|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
45652733|NCT03645499|Drug|Topical TA-102 D|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
45803679|NCT03182933|Other|In person and over the phone questionnaire|Presuming the patient has left the hospital each patient will be called on post-operative day 2, 3 to assess nausea, opioid consumption, satisfaction with anesthesia technique, nausea and vomiting as well as pain scores
45803680|NCT03182933|Device|Force transduction of quadriceps strength|Patient will be asked to flex quadriceps at maximal ability and a transducer (Kiio device) will record a force value pre operatively and on post operative day 1
45803681|NCT04324034|Device|vNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is vaginal surgery with a natural approach. The GelPOINT V-path transvaginal access platform is used. It is a device designed to be placed transvaginally to establish a pathway for the insertion of minimally invasive instruments while maintaining insufflation to perform diagnostic or operative procedures. This device also allows a passage for the extraction of operating parts.
45803682|NCT04324034|Procedure|laparoscopy|The surgery by conventional laparoscopy is used
45803683|NCT03183869|Drug|Fecal microbiota|fecal microbial transplantation
45803684|NCT02344225|Drug|Caffeine citrate|Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose)
45934014|NCT00070122|Drug|fluorouracil|Given IV
45934015|NCT00070122|Other|laboratory biomarker analysis|Correlative studies
45934016|NCT05432882|Biological|bi-4SCAR CD19/22 T cells|Infusion of bi-4SCAR CD19/22 T cells at 10^6 cells/kg body weight via IV
45934017|NCT00066144|Drug|Cimicifuga racemosa|
45934018|NCT00066144|Drug|Trifolium pratense|
45451987|NCT01356160|Drug|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
45652734|NCT03645499|Drug|Topical TA-102 E|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
45934019|NCT00066144|Drug|Black cohosh|
45934020|NCT00066144|Drug|Red clover|
45934021|NCT05432609|Diagnostic Test|Weight bearing CT|Weight bearing CT in loaded and unloaded positions
45934022|NCT00070161|Dietary Supplement|EGb761|
45934023|NCT00070161|Drug|donepezil hydrochloride|
45934024|NCT00070161|Procedure|cognitive assessment|
45934025|NCT05432492|Drug|AK112|IV infusion, specified dose on specified days
45934026|NCT00070200|Biological|filgrastim|
45934027|NCT00070200|Drug|cisplatin|
45934028|NCT00070200|Drug|cyclophosphamide|
45934029|NCT00070200|Drug|doxorubicin hydrochloride|
45934030|NCT00070200|Drug|etoposide|
45934031|NCT00070200|Drug|isotretinoin|
45934032|NCT00070200|Drug|melphalan|
45934033|NCT00070200|Drug|topotecan hydrochloride|
45934034|NCT00070200|Drug|vincristine sulfate|
45934035|NCT00070200|Procedure|conventional surgery|
45934036|NCT00070200|Procedure|peripheral blood stem cell transplantation|
45934037|NCT00070200|Radiation|radiation therapy|
45934038|NCT05432336|Diagnostic Test|NGS for endohtalmitis / Multiplex PCR for keratitis|"For endophtalmitis : optimizing culture and NGS will be realized~For keratitis: Multiplex PCR will be added on ocular samples"
45934039|NCT00066339|Drug|gefitinib|
45934040|NCT05432258|Device|Bulk-fill composite resin|Restoration of the mandibular first molars with bulk-fill composite resin as the manufacturer advises after the cavity preparation
45934041|NCT05432258|Device|Nano-fill composite resin|Restoration of the mandibular first molars with nano-fill composite resin as the manufacturer advises after the cavity preparation
45934042|NCT00070239|Drug|alvocidib|Given IV
45934043|NCT00070239|Other|pharmacological study|Correlative studies
45934044|NCT00070239|Radiation|fludeoxyglucose F 18|Correlative studies
45934045|NCT00070239|Other|fluorine F 18 fluorothymidine|Correlative studies
45934046|NCT00070239|Procedure|positron emission tomography|Correlative studies
45934047|NCT05432219|Procedure|endoscopic surgery|endoscopic resection of recurrent nasopharyngeal carcinoma via the transoral retropterygoid nasopharyngectomy approach
45652735|NCT05209425|Dietary Supplement|Vitamin D3|Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.
45652736|NCT04793243|Dietary Supplement|Vitamin D3|Patients received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3
45652737|NCT05158569|Other|Slow breathing exercise group|The patient will be first asked to close one nostril with a thumb and slowly breathe in completely through the other for 6 seconds. This nostril will be then closed and the patient will exhale through the other nostril over a period of 6 seconds. These steps complete one breathing cycle. An attempt will be made to keep the breathing rate is about 5-6 breaths per minute. Such alternate nostril breathing cycles will be repeated continuously for a period of about 15 minutes (3 sets of 5 minutes) in one sitting.
45652738|NCT05158569|Other|Diaphragmatic breathing exercise group|"Patients would be instructed to Sit or lie down in a comfortable place and put their hands on their belly.~Relax the muscles in their neck and shoulders. Breathe in slowly through the nose, keeping their mouth closed. Feel the lungs fill with air and inflate like a balloon while their belly moves outward. Such breathing cycles will be repeated continuously for a period of about 15 (3 sets of 5 minutes) minutes in one sitting."
45803685|NCT02344225|Drug|Ibuprofen|Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days
45803686|NCT02344225|Drug|Ketorolac|Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days
45652739|NCT05472467|Drug|Camrelizumab|200mg IV Q3W. Every three weeks is a cycle
45652740|NCT05472467|Radiation|stereotactic body radiation therapy|stereotactic body radiation therapy for Oligometastases 35Gy/5f(7.0Gy/f,5f per week)
45652741|NCT05472467|Drug|Chemotherapy|"Squamous carcinoma: docetaxel 60 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6 d1, 21 days for one cycle, up to 4 cycles.~Non-squamous carcinoma: pemetrexed 500 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6, d1,21 days for one cycle, up to 4 cycles."
45803687|NCT04319588|Procedure|Parasternal Block+ Infiltration with local anesthetic of access to thoracic drainage|After induction of general anesthesia we will perform an ultrasound-guided Parasternal Block in association with infiltration with local anesthetic of access to thoracic drainage at the end of the intervention.
45803688|NCT04319588|Procedure|Infiltration with local anesthetic of access to thoracic drainage|Infiltration with local anesthetic of access to thoracic drainage at the end of the intervention.
45803689|NCT05078528|Device|Multimodal Mobile Colposcope (MMC)|Women referred for colposcopy due to abnormal cervical screening or follow-up for a history of dysplasia will be recruited into the experimental group of the study. Imaging of study participants will take place during the colposcopy examination.
45803690|NCT03314753|Other|No interventions - retrospective data collection|No new patients will be enrolled within this project; only retrospective data will be collected on performed re-ablations within the FIRE AND ICE Trial
45803691|NCT04739969|Device|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Soterix Neural Navigator neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark)."
45803692|NCT04739969|Device|Sham TBS-DLPFC|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
45803693|NCT05065736|Drug|18F-Clofarabine|The participants enrolled will receive a baseline CFA PET/CT evaluation. Then, the participants will undergo the routine follow up would normally occur for their cancer and its treatment. If this routine follow up and care involves repeat imaging of the cancer, then the CFA PET/CT scan will be repeated at that time (timed according to standard-of-care follow-up imaging), which is expected between a month to about 4 months after the first CFA PET/CT scan. The study period will end 24 hours after this repeat PET/CT scan.
45803694|NCT05060354|Other|Blood draw|Approximately 120 mL whole blood will be collected from each subject at each timepoint
45803695|NCT05057702|Other|Specialized Tumor Board Treatment Plan|Specialized Treatment Plan of up to four FDA approved drugs based on participant's screening results will be assigned by PNOC specialized tumor board
45803696|NCT03318341|Device|Real Stimulation|The device applies wrist vibration at a subthreshold (imperceptible) level.
45803697|NCT03318341|Device|Sham Stimulation|The device applies no vibration.
45803698|NCT02300545|Drug|Pazopanib|
45803699|NCT05040464|Drug|AZA capsules|oral AZA capsules at a daily dose of 2.5 mg per kilogram,
45803700|NCT05040464|Drug|MTX|MTX 25 mg SC once a week
45803701|NCT05040464|Biological|blood sample|The lab tests are: serum albumin, C-reactive protein, thrombocytosis and haemoglobin.
45803702|NCT02979080|Other|Eisensulfat LOMAPHARM 50 mg|Eisensulfat LOMAPHARM 50 mg administration for 120 days
45803703|NCT03817814|Behavioral|web-based questionnaire|Participants will complete a web-based questionnaire examining the decisions patients made about fertility preservation before and after treatment, the factors that influenced their decisions, and the ways in which patients pursue family building after treatment.
45803704|NCT02346643|Device|Implantation with the commercially available Axium Neurostimulator|
45803705|NCT05032664|Other|Home-based aromatherapy programme|1 hour individualised face-to-face training to family caregivers, and 3 weeks aromatherapy intervention delivered by family caregivers (aromatherapy inhalation 2 times per day, each for 1 hour, using 2 drops of Lavandula angustifolia essential oil.
45803706|NCT05032664|Other|Control Group|Wait-list control, no intervention for 3 weeks, then provide home-based aromatherapy
45803707|NCT03589651|Drug|Retifanlimab|"Part 1: INCMGA00012 at the protocol-defined starting dose administered intravenously every 4 weeks, with dose escalation to determine the maximum tolerated dose.~Part 2: INCMGA00012 at the recommended dose from Part 1."
45934048|NCT00070278|Drug|cyclophosphamide|
45451988|NCT01356160|Drug|GS-9451 Placebo|Placebo to match GS-9451 QD
45451989|NCT02264158|Drug|Telmisartan high|
45934049|NCT00070278|Drug|epirubicin hydrochloride|
45934050|NCT00070278|Drug|gemcitabine hydrochloride|
45934051|NCT00070278|Drug|paclitaxel|
45803708|NCT03589651|Drug|Epacadostat|"Part 1: Epacadostat at the protocol-defined starting dose administered orally twice daily, with dose escalation to determine the maximum tolerated dose.~Part 2: Epacadostat at the recommended dose from Part 1."
45803709|NCT03589651|Drug|INCB050465|Part 1: INCB050465 at the protocol-defined starting dose administered orally once daily, with dose escalation to determine the maximum tolerated dose. Part 2: INCB050465 at the recommended dose from Part 1.
45934052|NCT00070278|Genetic|comparative genomic hybridization|
45934053|NCT00070278|Genetic|microarray analysis|
45652742|NCT05208099|Biological|Blood tests|"For patients, it will be performed:~a collection of blood samples (3 tubes of 5 mL) according to the usual medical management, in order to search for cardiovascular comorbidities associated with HS,~A collection of 3 EDTA tubes and 2 additional dry tubes of 5 mL each according to the needs of the study."
45803710|NCT04298606|Other|Quality-of-Life Assessment|Ancillary studies
45803711|NCT04298606|Other|Questionnaire Administration|Ancillary studies
45652743|NCT05208099|Procedure|exeresis|"For patients, it will be performed:~- 6 tissue samples from the total excision specimen: two samples from the acute inflammatory zone (nodule, abscess, fistula) of 1 cm3; two samples from the chronic lesion zone (scar) of 1 cm3 and two samples from the peri-lesion zone (in the margin) of 1 cm3 on fresh tissue."
45652744|NCT05208099|Procedure|abdominoplasty|"For the controls, 6 fresh skin samples of 1 cm3 each will be taken from the abdominoplasty operation:~four in the center,~two in the margin"
45652745|NCT04760639|Diagnostic Test|Breath test|Participants provide a breath sample
45652746|NCT05634421|Other|E-learning|The E-learning is under development at the department of Dermatology from MUMC+.
45803712|NCT04298606|Biological|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given IM
45803713|NCT03186677|Biological|ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg|ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg by intravenous or subcutaneous
45803714|NCT03186677|Biological|BeneFIX|BeneFIX 75 IU/kg, intravenous administration
45934054|NCT00070278|Genetic|mutation analysis|
45934055|NCT00070278|Procedure|conventional surgery|
45934056|NCT00070278|Procedure|neoadjuvant therapy|
45934057|NCT00066378|Drug|anastrozole|
45934058|NCT00066378|Drug|gefitinib|
45803715|NCT03769844|Drug|GM-CSF|Subjects demonstrating immunoparalysis (defined by a whole blood ex vivo LP-induced TNF-alpha production capacity < 200 pg/ml) will receive 7 days of GM-CSF treatment by either the IV or SQ route at a dose of either 125 or 250 mcg/m2/day for 7 days.
45803716|NCT02347345|Drug|Harvoni (Fixed dose combination ledipasvir/sofosbuvir)|Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill daily x 12 weeks
45803717|NCT04230668|Behavioral|Cognitive Processing Therapy with Suicide Risk Management|CPT is an evidence-based treatment for PTSD. This first-line treatment for PTSD will be adapted and combined with SRM into 12 sessions, 60-90 minutes targeting both PTSD and BPD. Individuals assigned to this intervention will attend treatment sessions, and be asked to do treatment homework at home. The primary outcomes are PTSD and BPD severity.
45803718|NCT04230668|Behavioral|Treatment as Usual with Suicide Rick Management|In the Suicide Risk Management only condition, participants will receive 6 weekly sessions over the course of six weeks focused on suicide stabilization and management. Each SRM session will be variable lengths, depending on the participants' suicide risk and can be up to 60 minutes.
45803719|NCT03319277|Other|Decreased opiate prescription|The experimental group will receive 5 tablets of oxycodone 5mg at time of discharge with a paper backup prescription for an additional 10 tablets.
45803720|NCT03319277|Other|Routine opiate prescription|The comparator group will receive 28 tablets of oxycodone 5mg at time of discharge.
45934059|NCT05432102|Diagnostic Test|Pulse oxymetry|Diagnostic intervention to diagnose OSA.
45934060|NCT05432102|Diagnostic Test|Respiratory polygraphy|Diagnostic intervention to diagnose OSA.
45934061|NCT00066417|Drug|cyclophosphamide|
45934062|NCT00066417|Drug|cyclosporine|
45934063|NCT00066417|Drug|fludarabine phosphate|
45934064|NCT00066417|Drug|methylprednisolone|
45934065|NCT00066417|Drug|therapeutic allogeneic lymphocytes|
45934066|NCT00066417|Drug|thiotepa|
45934067|NCT00066417|Procedure|allogeneic bone marrow transplantation|
45934068|NCT00066417|Procedure|biological therapy|
45934069|NCT00066417|Procedure|bone marrow ablation with stem cell support|
45652747|NCT05157789|Other|SMS|In the study, text message will be sent to relatives of the patients for informing and the effect will be determine on the level of anxiety during cardiovascular surgery.
45652748|NCT04793165|Device|Non-hybrid closed-loop system with ARG algorithm|To assess efficacy and safety of non-Hybrid Closed-loop System, without CHO counting
45934070|NCT00066417|Procedure|bone marrow transplantation|
45934071|NCT00066417|Procedure|chemotherapy|
45934072|NCT00066417|Procedure|leukocyte therapy|
45934073|NCT00066417|Procedure|non-specific immune-modulator therapy|
45934074|NCT00066417|Procedure|peripheral blood lymphocyte therapy|
45934075|NCT00066417|Procedure|peripheral blood stem cell transplantation|
45934076|NCT00066417|Procedure|radiation therapy|
45934077|NCT00066456|Radiation|3-Dimensional Conformal Radiation Therapy|
45934078|NCT00066456|Drug|Chemosensitization/Potentiation Therapy|
45934079|NCT00066456|Drug|Docetaxel|Given IV
45934080|NCT05424419|Procedure|Brace therapy|A Chêneau-type brace was made to be worn as a full-time brace or during daytime only (double-brace group), whereas the nighttime brace was produced according to the Charleston approach.
45934081|NCT02967042|Device|18F-PET-TT|can 18F-PET-TT be used as an diagnostic tool in patients with CKD-MBD
45934082|NCT05421611|Biological|STAMARIL|"STAMARIL® contains the 17D-204 vaccine strain, which is used in many currently produced yellow fever vaccines. STAMARIL is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF vaccine virus.~STAMARIL® will be used as a comparator in the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with solvent."
45652749|NCT05634343|Other|Laughter Therapy|"Laughter Therapy, also called therapeutic laughter; It is a kind of exercise that combines unconditional laughter and breathing techniques to reduce pain and stress and to give the individual a general sense of well-being. Laughter therapy is a method of simply laughing for no reason in which the person interacts in a group setting with improvisational or pantomime-like exercises and childlike play without humor, jokes or funny incidents. Thus, it is aimed to benefit from laughter."
45803721|NCT03768440|Procedure|continuous erector spinae block (ESB)|Erector spinae block: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
45451990|NCT02264158|Drug|Telmisartan low|
45803722|NCT03768440|Procedure|continuous paravertebral block (PVB)|The paravertebral space (bound medially by the bodies of the vertebrae, intervertebral discs, and intervertebral foraminae; anterolaterally by the parietal pleura and the innermost intercostal membrane; posteriorly by the transverse processes of the thoracic vertebrae, heads of the ribs, and the superior costotransverse ligament) laying between T4/5 is identified using the ultrasound transducer in a transverse orientation; the needle tip is advanced until it is seen passing under the transverse process, immediately superior to the pleura; the pleura is seen to deflect downward with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
45803723|NCT03768440|Drug|Ropivacaine|Ropivacaine 0.2% will be the drug used for each group (ESB group and PVB group)
45451991|NCT02264158|Drug|Lacidipine high|
45451992|NCT02264158|Drug|Lacidipine low|
45803724|NCT03767426|Behavioral|Sleep Deprivation|Subjects are sleep deprived for an entire night
45934083|NCT05421611|Biological|SII-YFV|"SII-YFV contains the 17D-213 vaccine strain, a derivative of 17D-204 strain which is used in many currently produced yellow fever vaccines. SIIPL imported the YF WHO Primary Seed Virus lot 213-77 from National Institute for Biological Standards and Control (NIBSC) for preparation of the master seed virus, working seed virus and the vaccine. The SII-YFV is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF working seed virus.~SII-YFV will be provided in vial presentation for the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with sterile water for injection."
45934084|NCT00070434|Drug|capecitabine|825mg/m2 BID, PO, daily
45934085|NCT00070434|Drug|fluorouracil|Bolus + IV for 46 hrs on Day 1
45934086|NCT00070434|Drug|irinotecan hydrochloride|IV infusion over 90 min on Day 1
45934087|NCT00070434|Drug|leucovorin calcium|200mg/m2 IV 2 hour infusion on Day 1
45934088|NCT00070434|Drug|oxaliplatin|85mg/m2 IV infusion for 90minutes on Day 1
45934089|NCT00070434|Radiation|radiation therapy|Original Planning Target Volume (PTV1): The total dose to the prescription point shall be 4500 cGy in 25 fractions (Monday - Friday inclusive). Boost Planning Target Volume (PTV2): The cumulative dose within the boost volume to the prescription point shall be 5,040 - 5,400 cGy (per Section 7.5b). Daily Dose: The daily dose to the prescription point of the original and boost volumes shall be 180 cGy. Fractionation: Treatment shall be given 5 days/week. All radiation fields shall be treated once daily.
45934090|NCT00070434|Drug|Pyridoxine|50mg TID, PO daily
46073489|NCT00845767|Procedure|Forearm Vascular Study|"Forearm venous occlusion plethysmography during intraarterial infusion of L-NMMA (2-8 µmol/min) followed by co-infusion of sodium nitroprusside (90-900 ng/min) as a nitric oxide clamp. Forearm blood flow then measured during the clamp in response to infused vasodilators acetylcholine (5-20 mg/min), bradykinin (100-1000 pmol/min), verapamil (10-100 µg/min) and sodium nitroprusside (2-8 µg/min)."
46073490|NCT05660694|Drug|Triamcinolone|Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
46073491|NCT05660694|Drug|Pentoxifylline with Vitamin E|Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
46073492|NCT00833209|Procedure|PET (withdrawal)|3 (18F)FDG-PET (before withdrawal, 3 months, 1 year), 2 MRI (before withdrawal, 1 year), will take the Iowa Gambling Task Test(before withdrawal) and will answer questionnaires measuring psychological dimensions (before withdrawal, 3 months, 1 year)
46073493|NCT00833209|Procedure|Imaging|2 MRI (inclusion, 1 year) ; Iowa Gambling Task Test(inclusion) and questionnaires (inclusion)
46073494|NCT00833209|Procedure|Imaging|1 MRI ; Iowa Gambling Task test and questionnaires.
46073495|NCT05113368|Drug|Regorafenib|Oral regorafenib in a ReDOSplan (80 mg week#1, 120 mg week#2, 160 mg week#3 for cycle #1 then adjust final dose for subsequent cycles based on tolerance during cycle #1) [3 weeks on/1 week off] combined with intramuscular injection of fulvestrant 500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
45451993|NCT02264158|Drug|Placebo|
45451994|NCT01349998|Drug|Product 33525|Daily dosing for 2 weeks each recurrence for patients with tinea pedis and Daily dosing for 1 week each recurrence for patients with tinea cruris and tinea corporis
45451995|NCT02266498|Drug|BIBB 515 BS|
45451996|NCT02266498|Other|Standard breakfast (40 g fat)|
45451997|NCT01345006|Biological|MA09-hRPE|"Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
45451998|NCT02264236|Biological|P10s-PADRE vaccine|"P10s-PADRE vaccine combined with MONTANIDE™ ISA 51 VG Chemotherapy Subcutaneous injection at weeks 2, 3, 5, and 6. 3-Week Interval Immunotherapy Subcutaneous injection at weeks 2, 3, and 4. 2-Week Interval Immunotherapy Subcutaneous injection at weeks 3, 4, and 5."
45451999|NCT02264314|Behavioral|Active Communication Education Program|A behavioral intervention aimed to improve the adherence to the hearing aid in older adults with hearing loss
45452000|NCT02264314|Other|Control|Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
45452001|NCT01476904|Drug|Placebo|0 mcg/inhalation, 2 inhalations QID
45452002|NCT01476904|Drug|Primatene Mist|220 mcg/inhalation, 2 inhalations QID
45652750|NCT05634343|Other|Mindfulness|Mindfulness is purposefully drawing attention in the desired direction so that we can stay in the present moment without judgment. It is also defined as a conscious understanding of what is happening in the moment we live in with an open and loving attitude. According to another definition, mindfulness includes paying attention to what is happening in the present moment, noticing the quality of this attention, and accepting what is noticed without judgment. With conscious awareness, the individual discovers how to live in harmony with all the events that take place in the present moment, place and time, without any evaluation, rather than the sorrows and regrets of the past, the anxieties and worries of the future. Mindfulness helps us to relate to our experiences by enabling us to see the positive-negative, good-bad experiences we have had objectively.
45803725|NCT03767426|Behavioral|Daytime nap|After a night of sleep deprivation, participants will be given a 2 hour nap opportunity
45803726|NCT03323723|Device|SUI Device|Pessary SUI device
45803727|NCT00356564|Biological|hepatitis B vaccine|
45803728|NCT04624295|Drug|Early aspirin Therapy|Early Antiplatelet Therapy is administered within 24 to 48 hours after stroke onset and the dose is determined by the clinician. Aspirin was chosen for antiplatelet therapy.
45934091|NCT05402891|Drug|Lithium Carbonate|Patients will be administered lithiumcarbonate by an oral tablet of 300mg once a day for a duration of 6 months. Starting dose is 200mg for the first 5 days, dosage will be then increased to 300mg. To limit adverse events and side-effects, the lowest effective dose will be administered. The target serum level of lithium is 0.20 - 0.40 mmol/L and this will be maintained by regular lithium level testing.
45934092|NCT00070473|Drug|pemetrexed disodium|
45934093|NCT00066612|Drug|irinotecan hydrochloride|Irinotecan will be given 250 mg/m^2 through intravenous (IV) for 90 minutes on day 1 for every 21 days until tumor progression or unacceptable toxicity or other reason for discontinuation occurs
45934094|NCT05376566|Drug|Hydrochloric Acid (2 M)|Hydrochloric acid (2 M) in a volume corresponding to dead space (0.3-1.0 ml) will be instilled and aspirated 10 min later; the instillation is completed 3 times.
45934095|NCT05376566|Drug|Normal saline|Normal saline in a volume corresponding to dead space (0.3-1.0 ml) will be instilled and aspirated 10 min later; the instillation is completed 3 times.
45934096|NCT00070551|Biological|GTI-2040|Given IV
46073496|NCT05113368|Drug|Fulvestrant|500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
46073497|NCT00848029|Biological|Monovalent inactivated influenza vaccine|Two doses of monovalent inactivated influenza adjuvanted vaccine
46073498|NCT04241952|Other|Exercise|Bedcycling
46073499|NCT02824614|Dietary Supplement|E967-Xylitol|
46073500|NCT02824614|Dietary Supplement|E968-Erythritol|
45652751|NCT04793399|Drug|Bosutinib 400 MG Monotherapy|One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy
45803729|NCT04624295|Drug|Non-Early aspirin Therapy|Antiplatelet therapy will be delayed to beyond 48 hours after stroke onset and may not be initiated until hemorrhagic Infarction has been confirmed absorbed.
45803730|NCT02348593|Drug|JZP-110|
45803731|NCT02348593|Drug|Placebo oral tablet|
45803732|NCT03323801|Drug|13-cis retinoic acid|Accutane is used for the treatment of severe acne
45803733|NCT04197908|Device|EUS-guided gallbladder drainage (EGBD)|As listed in the arms description
45803734|NCT04605263|Device|STN-PPN DBS Surgery|Subject will undergo standard bilateral STN DBS surgery and have 2 additional leads placed in the same burr with bilateral PPN targets
45803735|NCT04605263|Procedure|Deep Brain Stimulation Surgery (DBS)|DBS lead implantation of bilateral STN
45803736|NCT03721640|Other|electrocardiogram|Autonomic and hemodynamic evaluation with different indices (LF, heart rate, Systolic, diastolic and mean arterial blood pressure, SaO2) during a sedation protocol for intubation and surfactant administration according the INSURE or LISA technique.
45803737|NCT04450355|Drug|Nefopam 80mg/day|continuous nefopam infusion
45803738|NCT04450355|Drug|Normal saline|continuous normal saline infusion
45804179|NCT05437159|Behavioral|Learning of non-native phoneme combinations: 1 training session|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During the training session, the participant will practice producing a set of 3 stimuli (the Fully Learned stimuli). Each of the 3 Fully Learned stimuli will be produced 60 times.
45934097|NCT00070551|Drug|cytarabine|Given IV
45934098|NCT00070551|Other|pharmacological study|Optional correlative studies
45934099|NCT00070551|Other|laboratory biomarker analysis|Optional correlative studies
45934100|NCT05303402|Biological|PHH1-V|COVID-19 Vaccine HIPRA, 40 mcg/dose
45934101|NCT02958579|Other|No intervention will be done. Participants are on standard care and the treatments will be recorded because of observational nature of this study.|
45934102|NCT05294237|Behavioral|Happy program|The Happy program consists of handball specific warm-up components and resistance training components and will be available online.
45934103|NCT05294237|Behavioral|Support|The support consists of a coach workshop at the beginning of the season and the opportunity for additional support for the coaches throughout the season.
45934104|NCT00070629|Drug|CPG 7909|CPG 7909 Injection will be administered subcutaneously at a starting dose of 0.20 mg/kg at the beginning of Weeks 2 and 3 of the three-week cycle.
45934105|NCT00070629|Drug|Chemotherapy|"A taxane and a platinum compound given on week one of three-week cycles:~Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6"
45934106|NCT00070629|Drug|Chemotherapy|"A taxane and a platinum compound given on week one of three-week cycles:~Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6"
46073501|NCT00840151|Behavioral|contingency management|Participants randomized to a contingency management treatment condition can earn the chance to win prizes for attending substance abuse treatment.
46073502|NCT04933968|Biological|ALVR106|Infusion, visually identical to placebo
45803739|NCT02349685|Procedure|H. pylori culture and antimicrobial susceptibility test|Antral and body biopsy specimens were evaluated separately. Organisms were identified as H. pylori by Gram staining, colony morphology, and positive oxidase, catalase, and urease reactions. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin (Sigma Chemical Co., St. Louis, Mo.), clarithromycin (Abbott Laboratories, Abbott Park, Ill.), metronidazole (Sigma), tetracycline (Sigma) and moxifloxacin (Sigma) for the H. pylori isolates were examined by use of the serial twofold agar dilution method and the reference of susceptibility testing was according to the recommendations of the Clinical and Laboratory Standards Institute [amoxicillin (AMC), MIC ≥ 0.5 μg / ml; clarithromycin (CLA), MIC > 1.0 μ g / ml; metronidazole (MET), MIC > 8 μ g / ml; tetracycline (TC), MIC > 4 μ g / ml; and moxifloxacin (MOX), MIC > 1 μ g / ml).
45803740|NCT02349685|Drug|14 day PBMT group|Rescue therapy using 14 day PBMT regimen [Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d]
45803741|NCT02349685|Drug|14 day MEA group|Rescue therapy using 14 day MEA regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.)
45452003|NCT01476904|Drug|Epinephrine inhalation|125 mcg/inhalation, 2 inhalations QID
45452004|NCT01337752|Drug|BHQ880|
45803742|NCT03676010|Other|Sarcoma and GIST|No Intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
45803743|NCT03676010|Other|Breast cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
45803744|NCT03676010|Other|Pancreatic cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
45803745|NCT03676010|Other|Renal cell carcinoma|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
45803746|NCT03676010|Other|Colon cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy (adjuvant setting).
45803747|NCT03676010|Other|Solid tumours undergoing image-guided tumor ablation|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
45803748|NCT03326843|Drug|Avatrombopag 60 mg|Oral avatrombopag administered once daily for 5 days prior to procedure.
45452005|NCT01337752|Drug|BHQ880 Placebo|Intravenous infusion
45452006|NCT01337752|Drug|bortezomib|intravenous injection
45803749|NCT02352259|Procedure|Electrochemotherapy|Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin, within 8-30 min after administration of bleomycin application of electric pulses, removal of electrodes.
45803750|NCT02352259|Device|Cliniporator Vitae®|Positioning of electrodes, within 8-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.
46073503|NCT04933968|Biological|Placebo|Infusion, visually identical to ALVR106
46073504|NCT00840229|Drug|Triamcinolone hexacetonide|20 mg
46073505|NCT00840229|Drug|Triamcinolone hexacetonide|1 ml (20 mg) + 6 ml Lidocaine 10 mg/ml
45452007|NCT01337752|Drug|dexamethasone|Oral
45452008|NCT01333540|Drug|TD-1211|Escalating doses
45452009|NCT01333540|Drug|Placebo|Placebo once daily
45452010|NCT02266654|Other|IV fluids|Normal Saline 0.9%
45803751|NCT02352259|Drug|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2), 8 minutes before application of electric pulses
45803752|NCT04155866|Other|Measurement of muscle activation.|Measurement of lower-limb muscle activation during walking for healthy participants.
45803753|NCT02354443|Biological|ProHema-CB Transplant|ProHema-CB, the cellular product, represents the cell populations contained within a human UCB unit after modulation on the day of transplantation by an ex vivo incubation process with the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 (also referred to as FT1050). The cell populations include hematopoietic stem and progenitor cells.
46073506|NCT02825628|Drug|Osteodex|formulation: solution for infusion route of administration: intravenous infusion
45934107|NCT05283200|Behavioral|Yoga|Yoga instructor will teach gentle yoga focused on meditation, breathing exercises, and mindfulness techniques to promote well-being and stress reduction
45803754|NCT03326999|Drug|Obturator nerve regional block|Obturator nerve regional block involves the injection of a local anesthetic called bupivacaine into the upper thigh.
45803755|NCT03326999|Drug|Adductor canal regional block|Adductor canal regional block, which involves injecting numbing medication in the thigh region for pain control.
45934108|NCT05283200|Behavioral|Cognitive Behavioral Therapy|Psychologist will provide patients with psycho-educational and behavioral health strategies to promote seizure prevention and stress management skills
45934109|NCT05283200|Behavioral|Music|Music therapist will teach a variety of ways that participants might incorporate music into their daily lives as a means of self-expression, coping, and stress reduction.
45934110|NCT02958384|Biological|Anti-LeY-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived LeY-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
45934111|NCT05266625|Behavioral|PHOENIX|"PHOENIX is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. PHOENIX is accessed via the participants' smartphone.~The behavioral intervention process involves:~Identifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs.~Each week, PHOENIX asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily."
45934112|NCT05266625|Other|Control App|The app asks patients brief questions about their health but does not include any behavioral therapy.
45934113|NCT01349595|Drug|Bortezomib|"Patients randomized to bortezomib treatment will receive 2, 4-dose cycles of drug followed by a 2 month hiatus. At the end of this time, subjects will be re-evaluated for the appropriateness of receiving a 3rd and 4th cycle of bortezomib. Bortezomib will be given subcutaneously (under the skin). If unable to give subcutaneously, bortezomib will be given as a single IV (injection into vein) over a time of 3 to 5 seconds. Patients will receive up to 4, four-dose cycles of 1.3 mg/m(2) (based on body surface area)."
45934114|NCT05184920|Other|P1012919 nicotine pouch|P1012919, a nicotine pouch with 12 mg of nicotine
45934115|NCT05184920|Other|P1012915 nicotine pouch|P1012915, a nicotine pouch with 8 mg of nicotine
45452011|NCT02266654|Other|Hospital Notification|Prehospital providers will notify the receiving hospital over the radio or telephone that they are transporting a patient who meets Sepsis Criteria
45652752|NCT04793399|Drug|Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection|12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles
45652753|NCT05634265|Behavioral|Vijana-SMART|The Vijana-SMART intervention is a facilitated peer group, delivered through WhatsApp. Intervention messages were developed based on findings from formative interviews and social support theory, which posits that individuals experience social support through informational, instrumental, companionship and emotional forms. Groups will have approximately 25 members and will be facilitated by a study team member, by sending weekly scheduled messages, answering participant questions, and encouraging group discussion. Intervention messages were designed based on guidance from formative interviews; topics include ART adherence, medication side effects, nutritional practices, depression, social support, HIV status disclosure, stigma, positive prevention, substance use, and contraception.
45652754|NCT05157711|Drug|Anusol|Daily at night and in the morning and after each bowel movement for two weeks
45652755|NCT05157711|Drug|Relief [Name]|Daily at night and in the morning and after each bowel movement for two weeks
45803756|NCT03326999|Drug|Saline|Saline as placebo comparator
45803757|NCT04146194|Other|None. This is a non-interventional observational study.|None. This is a non-interventional observational study.
45934116|NCT05184920|Other|P1012914 nicotine pouch|P1012914, a nicotine pouch with 4 mg of nicotine
45652756|NCT05157711|Drug|Placebo|Daily at night and in the morning and after each bowel movement for two weeks
45803758|NCT04952870|Other|Inhaled NO|Newborn or young infants (< 3 months) receiving inhaled NO as part of their treatment for severe respiratory failure
45803759|NCT04952870|Other|routine care|Patients treated for respiratory failure
45934117|NCT05184920|Other|P1013315 nicotine pouch|P1013315, a nicotine pouch with 8 mg of nicotine
45934118|NCT05184920|Other|P1013119 nicotine pouch|P1013119, a nicotine pouch with 12 mg of nicotine
45934119|NCT05184920|Other|P1013218 nicotine pouch|P1013218, a nicotine pouch with 10 mg of nicotine
45803760|NCT02397265|Device|Bi-hormonal closed loop pump|Using a bio-inspired artificial pancreas consisting of a bi-hormonal closed loop pump
45934120|NCT05184920|Other|P1012818 nicotine pouch|P1012818, a nicotine pouch with 10 mg of nicotine
45934121|NCT05184920|Other|P1312915 nicotine pouch|P1312915, a nicotine pouch with 8 mg of nicotine
45934122|NCT05184920|Other|P1312914 nicotine pouch|P1312914, a nicotine pouch with 4 mg of nicotine
45934123|NCT05184920|Other|P1313015 nicotine pouch|P1313015, a nicotine pouch with 8 mg of nicotine
45934124|NCT05184920|Other|P1313314 nicotine pouch|P1313314, a nicotine pouch with 4 mg of nicotine
45934125|NCT05184920|Other|P1312815 nicotine pouch|P1312815, a nicotine pouch with 8 mg of nicotine
45803761|NCT02397265|Device|Standard opened loop pump|Using a standard opened loop pump
45652757|NCT04793321|Device|Baby carrier|"It is made in china.~It is made of Cotton-Polyester.~It has 3 belts - 2 shoulder belts and one waist belt for superior lumbar support. Shoulder straps are padded and adjustable for the parent's comfort. It has webbing straps for shoulder and waist strap adjustment.~It is suitable for newborn to 12-months baby~It is available online at babyshopstores https://www.babyshopstores.com/"
45803762|NCT02397265|Device|Insulin closed loop|Using a closed loop
45803763|NCT04948580|Behavioral|Interaction Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
45934126|NCT05397548|Diagnostic Test|Measurement of levels of circulating exosomal lncRNA-GC1|Each participant was enrolled to assess the levels of circulating exosomal lncRNA-GC1
45934127|NCT02958501|Drug|Colecalciferol|Drug
45934128|NCT05129657|Other|Product A|Usual Brand (UB) filtered, non-menthol or menthol cigarette
45934129|NCT05129657|Other|Product B|P1012914, A nicotine pouch product with 4 mg of nicotine
45934130|NCT05129657|Other|Product C|P1012915, A nicotine pouch product with 8 mg of nicotine
45934131|NCT05129657|Other|Product D|P1012919, A nicotine pouch product with 12 mg of nicotine
45803764|NCT02959489|Behavioral|Alzheimer's Disease Risk Disclosure|Subjects will learn a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
45803765|NCT02959489|Behavioral|Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure|"Subjects will learn their own elevated or not elevated amyloid results and a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type."
45934132|NCT05129657|Other|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
45934133|NCT00066651|Biological|SS1(dsFv)-PE38 immunotoxin|
45934134|NCT05084183|Device|PermeaDerm®|Wound Management Device
45934135|NCT05084183|Device|Mepilex Ag|Wound Dressing
45934136|NCT00398892|Drug|Lipoic acid|Lipoic acid capsules
45934137|NCT05019794|Drug|Infigratinib|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
45934138|NCT00066768|Drug|suramin|Given IV
45934139|NCT00066768|Drug|docetaxel|Given IV
45934140|NCT00066768|Drug|gemcitabine hydrochloride|Given IV
45934141|NCT00066768|Other|laboratory biomarker analysis|Correlative studies
45934142|NCT00066768|Other|pharmacological study|Correlative studies
45934143|NCT00066846|Biological|bevacizumab|
45934144|NCT00066846|Drug|fluorouracil|
45934145|NCT00066846|Drug|leucovorin calcium|
45934146|NCT00066885|Drug|calcitriol + docetaxel|
45934147|NCT04941521|Drug|Exenatide 2 mg [Bydureon]|Exenatide will be purchased commercially as Bydureon® for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 6 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
45934148|NCT04941521|Behavioral|Drug Counseling|Once weekly drug counseling sessions for cocaine use with trained masters-level therapists.
45934149|NCT04934540|Procedure|En bloc resection of bladder tumour|En bloc resection of bladder tumour (ERBT) is a novel surgical technique in which the bladder tumour is resected in one piece
45934150|NCT02966457|Drug|Colistimethate Sodium|Selective oral intestinal decolonization
45934151|NCT04732637|Diagnostic Test|"Test At Home's Proprietary Lollipop Buccal Cavity Swab"|"Self-collected Test At Home's proprietary Lollipop Buccal Cavity Swab with VTM."
45934152|NCT04891913|Drug|SY-007/ Placebo 15mg|15 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
45934153|NCT04891913|Drug|SY-007/ Placebo 30mg|30 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
45934154|NCT04891913|Drug|SY-007/ Placebo 60mg|60 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
45934155|NCT00067041|Drug|Remodulin (treprostinil sodium) Injection|
45934156|NCT04732364|Procedure|ultrasound guided erector spinae plan block using bupivacaine for modified radical mastectomy|Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
46073507|NCT00831441|Drug|Apixaban|Tablets, Oral, 5 mg, twice daily, until study end
46073508|NCT00831441|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, until study end
45803766|NCT02979314|Device|Galvanic Vestibular Stimulation|The investigators aim to study the influence of Galvanic Vestibular Stimulation on the brain mechanisms underlying illusory self-motion and its influence on egocentric mental transformation. As a control condition sham stimulation will be applied by the same device within the same participants in different trials. Participants should not note the difference.
45934157|NCT04732364|Procedure|ultrasound guided erector spinae plan block with bupivacaine and Dexmetonidine for modified radical mastectomy|Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
45934158|NCT04732364|Procedure|ultrasound guided erector spinae plan block with bupivacaine and magnesium slphate for modified radical mastectomy|Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
45803767|NCT03328949|Device|IVL Coronary Lithotripsy System|The coronary intravascular lithotripsy catheter is similar to other balloon devices that are routinely used during angioplasty procedures; however, it has electrodes inside the balloon which are designed to deliver energy to crack the calcified blockage using lithotripsy (acoustic energy).
45803768|NCT00356642|Drug|GW842470X|GW842470X will be available as a yellow smooth water-in-oil cream.
45934159|NCT04732598|Drug|Paclitaxel + bevacizumab therapy|"The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.~[Paclitaxel] 90mg/m^2, day1,8,15, IV [Bevacizumab] 10mg/kg, day1,15, IV"
45652758|NCT04793321|Device|Biodex Balance System|"The Biodex Balance System SD (The Biodex Balance System SD Model 945-300, 115 VAC, Shirley, NY, USA) is used to assess the balance in this study.~It is an objective device that measures dynamic postural stability. It uses a circular platform that allows up to 20˚of of platform tilt in a 360˚ range of motion.~The measures of postural stability score for BBS are the Overall Stability Index (OSI), Medial-Lateral Stability Index (MLSI), and Anterior-Posterior Stability Index (APSI). These indices are standard deviations that assess the path of sway around the zero point from the center of the platform and are measured in degrees. A high score in these stability indices indicates poor balance."
46073509|NCT00833599|Drug|NIRFLI with ICG|We conduct Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic trafficking in subjects. We seek to use the resulting phenotypes acquired in normal and diseased patients to correlate to mutations of specific genes reported to be associated with lymphatic development.
46073510|NCT04242108|Diagnostic Test|Deep learning algorithm based on AS-OCT scans|The OCT scans of study subjects would be imported into the algorithm. Automated classfication of angle width and detection of synechia would be performed by the algorithm. The diagnostic performance of the algorithm would be compared with gonioscopy records.
45652759|NCT04793321|Other|Infant mannequin|The mannequin infant has 3 Kg which corresponds to the infant's age from birth until 1month. This weight is selected as it corresponds to the age at which the infants are frequently carried by the mother .
45652760|NCT04793321|Device|Biodex gait trainer 2 TM|"Gait Trainer 2™ ( model number:950-385, 115 VAC 50/60 Hz, made in the USA) is used for participants to walk on as walking is one of the most common daily life activities. because caregivers commonly walk while carrying their infants as it has a calming effect on crying infants~It consists of :~Display: Use Audio and Visual Biofeedback - real-time biofeedback prompts patients into a proper gait pattern.~Heart Rate Monitoring~Handrail~Open Platform"
45652761|NCT05105997|Drug|Dexamethasone/ Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and dexamethasone 15 minutes before skin incision
45452012|NCT02266732|Device|Stimuplex HNS 12|
45452013|NCT02264392|Procedure|Ultrasound Guided Incision and Drainage|Ultrasound guidance of the abscess drainage
45803769|NCT00356642|Drug|Placebo|GW842470X matching placebo will be available as a yellow smooth water-in-oil cream.
45803770|NCT00356720|Drug|Azithromycin|
45803771|NCT03330041|Device|Fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material
45803772|NCT04121780|Biological|Growth Hormone|"Daily self-injections by subjects:~1-year double-blind phase; 6-month open-label extension for those who received placebo during the double-blind phase"
45803773|NCT04121780|Other|Placebo|"Daily self-injections by subjects:~1-year double-blind phase"
45934160|NCT04732598|Drug|Paclitaxel + bevacizumab + atezolizumab|"The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.~[Atezolizumab] 840 mg/body, day 1,15, IV [Paclitaxel] 90mg/m^2, day1,8,15, IV [Bevacizumab] 10mg/kg, day1,15, IV"
45652762|NCT05105997|Drug|Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and one ml of normal saline 15 minutes before skin incision.
45652763|NCT05283577|Other|Electroacupuncture|EA at 13 standardized acu-points that were chosen for their therapeutic effects: Shenting (GV24), Baihui (DU20), Sinshencong (EX-HN1), Zhongwan (CV12), Guanyuan (CV4), Neiguan (PC6) bilateral, Shenmen (HT7) bilateral, Zusanli (ST36) bilateral, Sanyinjiao (SP6) bilateral, Taixi (KI3) bilateral, Zhaohai (KI6) bilateral, Hegu (LI4) bilateral, Taichong (LIV3) bilateral
45934161|NCT04858022|Behavioral|Visual Acoustic Biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.
45934162|NCT04858022|Other|No treatment - waitlist|10-week period of no treatment
45803774|NCT00375869|Drug|Darbeopoetin|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
45934163|NCT00067080|Drug|ICL670, deferoxamine|
45934164|NCT00396851|Drug|Gurmar|
45803775|NCT00375869|Drug|Normal Saline (Placebo)|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
45803776|NCT00356798|Biological|an inactivated whole virion H5N1 vaccine, adjuvanted|
45803777|NCT03198221|Drug|Golytely|bowel preparation
45803778|NCT03198221|Drug|Clenpiq|bowel preparation
45934165|NCT00396851|Drug|Metformin|
46073511|NCT00840385|Drug|FAD|Fludarabine 40mg/m2 po.d1-3; Adriamycin 50mg/m2 i.v.d1; Dexamethasone 20mg/d po.d1-5.
45803779|NCT05723120|Other|Assessment Respiratory and Neuromuscular|Comparative Score
45803780|NCT03674996|Other|Same day discharge|Discharge of the patient 12 hours after the minimally invasive radical prostatectomy - experimental group
45803781|NCT03674996|Other|Next-day discharge|Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - experimental group
45934166|NCT00067119|Drug|Aggrenox|
46073512|NCT02825784|Dietary Supplement|Renastart|Renastart: specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD).
46073513|NCT02546245|Behavioral|Heroes of Knowledge|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
46073514|NCT02546245|Behavioral|Attention/Time Control Game|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
46073515|NCT02824848|Behavioral|Passive Stretching|Passive stretching and associated strengthening activities to change head/neck and body alignment
46073516|NCT02824848|Behavioral|Perception-Action Approach|Environmental set-up and gentle manual guidance to promote spontaneous exploration of alternative head/neck and body alignment possibilities
45934167|NCT00067119|Drug|Placebo|
45934168|NCT00070824|Procedure|acupuncture|
45934169|NCT00396929|Drug|local intracoronary dosis of Paclitaxel|
45934170|NCT00070863|Behavioral|Individual Cognitive Behavioral Therapy|
45934171|NCT04750772|Diagnostic Test|18F-FDG and 68Ga-DOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
46073517|NCT00848263|Procedure|Volar plate|Treatment with a volar plate (DVR) inserted through a volar incision of 8-10 cm over the distal radius (Henry's approach).
45652764|NCT05283577|Other|Sham-Electroacupuncture|Non-disease related points with electrical stimulation: Pianli (LI6) bilateral, Wenliu (LI7) bilateral, Fuyang (BL59) bilateral, Kunlun (BL60) bilateral, Sanyangluo (TE8), Sidu (TE9) bilateral, Daheng (SP15) bilateral
45652765|NCT04801433|Other|Boleda Supramolecular Active Zinc Conditioner|Boleda Supramolecular Active Zinc Conditioner (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
45652766|NCT04801433|Drug|Capotetriol scalp solution|Capotetriol scalp solution: 30ml/bottle. Two times a day for 4 weeks, topically applied to scalp psoriasis.
45652767|NCT04801433|Other|Supramolecular Hydrogel|Supramolecular Hydrogel (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
45934172|NCT04750772|Diagnostic Test|18F-FDG and 18F-DOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 18F-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
45934173|NCT00399165|Drug|Testosterone Enanthate|Oral Testosterone 400 mg orally for 28 days
45934174|NCT00399165|Drug|Testosterone Enanthate|Oral Testosterone 800 mg orally for 28 days
45934175|NCT00399165|Drug|Dutasteride|dutasteride 0.5 mg orally, once daily for 28 days
45934176|NCT00399165|Other|placebo sesame oil|placebo sesame oil
45934177|NCT00399165|Drug|Dutasteride|24.5 mg po once (Day 0)
45934178|NCT04614701|Procedure|Carotid Artery Ultrasound Measure|"Cardiac output will be assessed by measuring the LVOT diameter in parasternal long-axis window and the LVOT VTI in apical-four window. Carotid artery flow will be measured on the right neck 1-2cm from the bifurcation of the common carotid artery. All measurements will be taken with participants supine and the head of the bed elevated to 45°. measures all at 3 minute intervals.~One-leg compression test: Thigh-sized blood pressure cuff inflated to 60mmHg on middle part of one thigh for 60 seconds. LVOT and CCA measurements taken separately.~Two-leg compression test: Thigh-sized blood pressure cuff inflated on middle part of both thighs for 60 seconds. LVOT and CCA measurements taken separately.~Passive leg raise test: Bed adjusted to place participant at 0° and legs elevated at 45° by use of pillows. After 1 minute, measurements repeated. LVOT and CCA measurements taken separately."
45934179|NCT00067158|Drug|nicotine transdermal system|
45934180|NCT04608110|Drug|ASTX030|In Cycle 1 (28 days per cycle), single dose oral azacitidine formulations will be administered on day -3, followed by subcutaneous (SC) azacitidine on day 1, oral azacitidine formulations and cedazuridine tablets on day 2-7; in Cycle 2 and onward, oral azacitidine formulations and cedazuridine tablets will be administered on day 1-7
45803782|NCT03674996|Other|2-days discharge|Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - control group
45934181|NCT04476368|Other|weekly yoga classes|Weekly 90 min pregnancy-adapted yoga classes lead by certified yoga instructors.
45934182|NCT04476368|Other|walk|20-30 min easy walking
45803783|NCT03203681|Drug|Natesto|4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.
45452014|NCT02264392|Procedure|Blind Incision and Drainage|Incision and drainage of abscess guided by physical exam alone
45803784|NCT04111874|Behavioral|Cognitive Behavioral Teletherapy LTA|Participating families will receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the four videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently.
45803785|NCT04111874|Behavioral|Cognitive Behavioral Teletherapy STA|Participating families will also receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the ten videoconferencing sessions, therapists will guide the parent through the implementation of the program, including explaining materials, assisting to develop planned therapy activities with the child, and problem-solving as needed.
45803786|NCT03207035|Procedure|Axillary brachial plexus block|Ultrasound guided axillary brachial plexus block with local anaesthetic lidocaine with epinephrine
45652768|NCT05105607|Drug|D-4517.2|Subcutaneous (SC) injection
45934183|NCT00398970|Device|Endobronchial ultrasound miniprobe|Endobronchial ultrasound miniprobe is used to identify solid mass in lung parenchyma.
45934184|NCT04445831|Biological|ACI-35.030|Administration of a Low dose of ACI-35.030
45452015|NCT02264470|Other|Not relevant|Not relevant
45452016|NCT01318642|Drug|Gemcitabine|Gemcitabine on days 1, 8, and 15, followed by placebo on days 1 and 15 of every 28 day cycle.
45652769|NCT04793087|Diagnostic Test|Magnetic Resonance Imaging|Comparing 3D T1 versus coronal T1 MRI in detecting Optic Neuritis
45803787|NCT03636464|Other|Blood collection|Pharmacokinetics
45804180|NCT05437159|Behavioral|Learning of novel multisyllabic nonwords|Each trial of the training sessions (total of 6 training sessions over 2 days) will follow a simple reaction time protocol in which a nonword stimulus formed by 2 or 3 syllables that are legal in American English is presented auditorily to the participant, who then produces the stimulus as quickly and accurately as possible. During training, each participant will repeatedly produce 6 nonwords, with each nonword produced a total of 60 times over the 6 training sessions.
45934185|NCT04445831|Biological|ACI-35.030|Administration of a Medium dose of ACI-35.030
45934186|NCT04445831|Biological|ACI-35.030|Administration of a High dose of ACI-35.030
45934187|NCT04445831|Other|Placebo|Administration of Placebo
45934188|NCT04445831|Biological|JACI-35.054|Administration of a Low dose of JACI-35.054
45934189|NCT04445831|Biological|JACI-35.054|Administration of a Medium dose of JACI-35.054
45652770|NCT03494881|Drug|Nucala|All study participants will receive Nucala (2) 100mg SQ injections administered at two different anatomical sites at week zero, 2,4,6, and 8 for a total of 5 doses.
45652771|NCT05206383|Behavioral|Positive message - placebo|"Subjects who will be told that the applied plastering method significantly increases muscle strength (positive message - placebo)."
45652772|NCT05206383|Behavioral|Negative message - nocebo|"Subjects who will be told that the applied plastering method has no effect on muscle strength (negative message - nocebo)."
45934190|NCT00399009|Device|AutoSuture Premium Plus CEEA/Ethicon Proximate ILS|
45934191|NCT04408469|Behavioral|Online EQuIP|This online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
45934192|NCT04408469|Behavioral|Self-monitoring control|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
45934193|NCT02967081|Procedure|Collection of dentinal fluid using a cellulose membrane|After removal of the caries lesion/filling a cellulose membrane (sterile paper point) will be applied with its blunt end to the dentin for 1 min to collect dentinal fluid.
45934194|NCT00070902|Procedure|Lumbar side-posture spinal adjusting|
45934195|NCT00070980|Procedure|Massage therapy|
45934196|NCT02966418|Procedure|Mild Hypoxia Preconditioning|Patients will be treated with mild hypoxia ( Note: The oxygen concentration decreased from 20% to 18%, and keeping at 18%)×7 days，twice a day in the morning and in the afternoon before surgery.
45803788|NCT03632798|Diagnostic Test|ChemoID assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
45803789|NCT03632798|Drug|Chemotherapy|"Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent ovarian cancer.~Chemotherapy list:~Liposomal Doxorubicin;~Docetaxel;~Paclitaxel;~Carboplatin;~Cisplatin;~Gemcitabine;~Topotecan;~Carboplatin, Gemcitabine;~Cisplatin, Gemcitabine;~Carboplatin, Liposomal Doxorubicin;~Carboplatin, Paclitaxel;~Carboplatin, Docetaxel."
45803790|NCT03208673|Device|Optive® Fusion + Optive® Gel Drop|Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep.
45452017|NCT01318642|Drug|AMG 479|Gemcitabine on days 1, 8, and 15, followed by AMG 479 20 mg/kg on days 1 and 15 of every 28 day cycle.
45934197|NCT02966418|Procedure|Sham preconditioning|Patients will be treated with sham preconditioning (oxygen concentration: 21％) ×7 days，twice a day in the morning and in the afternoon before surgery.
45803791|NCT02399917|Drug|Azacitidine|Given SC or IV
45934198|NCT00067314|Drug|Edotecarin|
45934199|NCT00071097|Drug|TMC114/rtv|800mg TMC114/100mg rtv once daily
45934200|NCT00071097|Drug|TMC114/rtv|400mg TMC114/100mg rtv both twice daily
45452018|NCT01318642|Drug|Placebo|Gemcitabine on Days 1, 8, and 15 followed by Placebo 20 mg/kg on days 1 and 15 of every 28 day cycle
45934201|NCT00071097|Drug|TMC114/rtv|400mg TMC114/100mg rtv once daily
45934202|NCT00071097|Drug|TMC114/rtv|600mg TMC114/100mg rtv twice daily
45934203|NCT04180202|Device|Non-invasive central venous pressure|Non-invasive method to measure central venous pressure indicator
45934204|NCT04163666|Behavioral|Mirror therapy|The intervention will take place at the home of the participant for 6 weeks (30 days), during 60-minute sessions, 30 of which will be for mirror therapy, while the remaining 30 minutes will be for task-oriented motor learning
45934205|NCT04163666|Behavioral|Cognitive therapeutic exercise|The intervention will take place at the home of the participant for 6 weeks (30 days), during 60-minute sessions, 30 of which will be for cognoscitive therapeutic exercise, while the remaining 30 minutes will be for task-oriented motor learning
45934206|NCT00067353|Drug|Fluoride varnish|
45452019|NCT01318252|Drug|AL-54478 0.005%|
45452020|NCT01318252|Drug|Latanoprost 0.005%|
45452021|NCT01318252|Drug|AL-54478 Vehicle|Inactive ingredients used as a placebo comparator
45452022|NCT04476160|Dietary Supplement|Cinnamon|children recipe 3 grams by day of cinnamon
45934207|NCT04104152|Other|CSD1902-11|A 2.4% nicotine ENDS product
45452023|NCT01315210|Drug|D-Ribose Powder|5 g TID for 12 Weeks
45452024|NCT01315210|Dietary Supplement|Placebo Powder|5 g TID for 12 Weeks
45452025|NCT01313572|Drug|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
45452026|NCT01313572|Drug|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute
45452027|NCT01474798|Drug|RA-18C3|"For subjects weighing 27-53 kg: 100 mg (1 ml) administered every three weeks by subcutaneous injection.~For subjects weighing > 53 kg: 200 mg (2 ml) administered every three weeks by subcutaneous injection."
45452028|NCT01470664|Drug|FST-100|0.1% dexamethasone and 0.6% polyvinylpyrrolidone iodine (PVP-Iodine)
45452029|NCT01470664|Drug|FST-100 (Component #1)|0.6% PVP-Iodine ophthalmic solution alone
45452030|NCT01470664|Drug|FST-100 Vehicle|FST-100 Vehicle
45452031|NCT01305538|Drug|BMS-954561|
45452032|NCT01305538|Drug|BMS-954561|
45452033|NCT01305538|Drug|Placebo|
45652773|NCT05206383|Behavioral|Neutral message|"Subjects who will be told that the applied plastering method is currently under investigation and the investigators do not know its effects (neutral message)."
45652774|NCT05472155|Device|Bulb syringe|Suctioning with a bulb syringe
45652775|NCT05472155|Device|Suction catheter|Suctioned with a suction catheter
45652776|NCT04450459|Diagnostic Test|ergospirometer test|ergospirometric test will be done before cardiac catheterisation and invasive measurement of FFR
45934208|NCT04104152|Other|CSD1902-12|A 2.4% nicotine ENDS product
45934209|NCT04104152|Other|CSD1902-13|A 2.4% nicotine ENDS product
45934210|NCT04104152|Other|CSD1902-14|A 2.4% nicotine ENDS product
45934211|NCT04104152|Other|CSD1902-21|A 5.0% nicotine ENDS product
45934212|NCT04104152|Other|CSD1902-22|A 5.0% nicotine ENDS product
45934213|NCT04104152|Other|CSD1902-23|A 5.0% nicotine ENDS product
45934214|NCT04104152|Other|CSD1902-24|A 5.0% nicotine ENDS product
45934215|NCT00071136|Drug|pemetrexed|
45934216|NCT00071136|Drug|gemcitabine|
45934217|NCT02970773|Drug|Rivaroxaban Oral Tablet|oral application of Xarelto
45934218|NCT00067392|Procedure|Dental Implant|Dental Implant 4 month time frame
45452034|NCT02265484|Drug|Lactulose+Rifaximin +Bromocriptine|
45452035|NCT02264626|Drug|Remifentanil|infusion at a rate by 0.025 μg kg-1 min-1 every minute to a maximum of 0.15 μg kg-1 min-1.
45452036|NCT01304524|Biological|VGX 3100|1ml of VGX-3100 delivered IM followed by electroporation at Day 0, Week 4 and Week 12.
45452037|NCT01304524|Biological|Placebo|1ml of placebo delivered IM followed by electroporation at Day 0, Week 4 and Week 12.
45452038|NCT01304524|Device|CELLECTRA™-5P|CELLECTRA™-5P is used for electroporation following IM delivery of VGX 3100 or placebo on Day 0, Week 4 and Week 12.
45452039|NCT01302886|Drug|BHQ880|
45803792|NCT02399917|Biological|Lirilumab|Given IV
45452040|NCT01300858|Drug|EGEN-001-301|Patients will be treated with EGEN-001 intra-peritoneally (IP) once every week for 12 weeks and then once every two weeks until disease progression or intolerable toxicity, but for no more than one year. Patients who develop progressive metastases will receive standard chemotherapy concomitant with EGEN-001. Hence, the initial EGEN-001 treatment period will be without chemotherapy. The standard chemotherapy regimen will be FOLFOX or FOLFIRI administered every 2-3 weeks. Patient with progressive disease a second time will be taken off-study. Those who remain progression-free will receive EGEN-001 for up to one year.
45934219|NCT02970734|Behavioral|Breathe|Six web-based cognitive behavioural therapy sessions. Telephone and email support are also provided during the program.
45452041|NCT02264704|Other|High intensity exericse|Participants will exercise at high intensity (70% VO2 peak) intermittently (30 seconds on, 30 seconds off) for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
45452042|NCT02264704|Other|Moderate intensity exericse|Participants exercise at moderate intensity (35% VO2 peak) continuously for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
45934220|NCT02970734|Behavioral|Resource Webpage|Static webpage listing anxiety resources.
45934221|NCT00067431|Drug|Divalproex Sodium (Depakote® Sprinkle Capsules)|
46073518|NCT00848263|Procedure|Dorsal nail plate|Treatment with a dorsal nail plate (DNP) inserted through a 3-4 cm dorsal incision.
46073519|NCT02824458|Drug|Apatinib|Patients will be treated with Apatinib, 250/500/750 mg(dose determined from Part A of study) p.o., daily
45452043|NCT03993262|Drug|Bortezomib|1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
45452044|NCT03993262|Drug|Placebo|1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
45452045|NCT02266966|Drug|F2695|
45452046|NCT02266966|Drug|Placebo|
45652777|NCT04421781|Other|Retrospectively review of medical data in patients treated by Salvage HIFU for isolated macroscopic recurrence in the prostatic bed after radical prostatectomy and salvage or adjuvant EBRT|Patients were treated using dedicated post-EBRT parameters (5-s pulse, 5-s waiting period, 90% of the acoustic power). Between July 2005 and November 2018, at Edouard Herriot Hospital (Lyon, France), 22 consecutive patients were treated with S-HIFU for a local recurrence after RP and salvage or adjuvant EBRT. The oncological outcomes (treatment failure-free survival, progression-free survival), the adverse events and urinary incontinence were retrospectively reviewed.
45803793|NCT02400073|Device|AutoSet for Her|3 months nightly usage of the AutoSet for Her device
45803794|NCT00356486|Drug|Peginterferon alfa-2a, Ribavirin, epoetin-β|Peginterferon alfa-2a(270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (180 µg/week) + Ribavirin(1000-1200 mg/day) for 8 weeks
45803795|NCT00356486|Drug|Peginterferon alfa-2a + Ribavirin for 12 weeks|Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
45803796|NCT02978846|Other|Clinical Observation|Undergo side effects evaluation using cards
45803797|NCT02400463|Drug|Ruxolitinib|
45803798|NCT03604718|Biological|Beltavac® Polymerized with Alternaria alternata|Adminstration of Beltavac® Polymerized with Alternaria alternata according to the routine clinical practice
45803799|NCT03331835|Biological|Brodalumab|Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2-antibody that binds with high affinity to human interleukin 17 receptor A (IL-17RA).> Blocking IL-17RA inhibits IL-17 cytokine-induced responses and results in reduced or normalised inflammation of the skin in subjects with psoriasis.
45803800|NCT03331835|Drug|Fumaric acid esters|Fumaric acid esters have been used to treat psoriasis since 1959. Systemic therapy with fumaric acid esters is based on an established dosing scheme with a gradual increase to improve tolerability, especially with regards to gastrointestinal side effects.
45934222|NCT04094363|Other|Product A|Usual Brand, filtered combustible cigarette
45934223|NCT04094363|Other|Product B|CSD1902-11, an electronic nicotine delivery system
45934224|NCT04094363|Other|Product C|CSD1902-21, an electronic nicotine delivery system
45934225|NCT04094363|Other|Product D|4mg Nicotine gum
45934226|NCT02967120|Other|no intervention|
45934227|NCT00067509|Drug|emergency contraception (estrogen/progesterone)|
45934228|NCT03752996|Device|ACURATE TF™ Aortic Valve System|Transcatheter Aortic Valve Implantation
45934229|NCT00071214|Biological|S. aureus Type 5 and 8 Capsular Polysaccharide Conjugate Vaccine|
45934230|NCT03651284|Behavioral|Aim2Be app with Live Coach + Fitbit + BMI tracking tools|Participants will spend six months using the Aim2Be app setting aims, completing tasks, accessing articles, doing self-assessments, and participating in the social wall. They will also complete a series of questionnaires, dietary recalls, BMI tracking using scales and tape measures, and physical activity tracking using Fitbits. Participants in this condition will have access to the Live Coach and the Virtual Coach. The Live Coach has specialized training in lifestyle and motivational interviewing and will support families in changing their health behaviours through in-app messaging and phone calls. The Virtual Coach gives guidance to families through an avatar that has been programmed using motivational interviewing theory.
46073520|NCT02824458|Drug|Gefitinib|Patients will be treated with Gefitinib, 250 mg p.o., daily
46073521|NCT02824458|Drug|Placebo|
46073522|NCT00833677|Behavioral|Chinese Coping Skills Training|Six-week group behavioral intervention: Chinese Coping Skills Training
46073523|NCT02827188|Other|Mega Team-videogame|Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 30-35 minutes a day, approximately 5 days a week for a minimum of 21 days and a maximum of 25 days.
45452047|NCT02267044|Drug|Ropivacaine|The drug used for the interscalene blocks
45452048|NCT02267122|Procedure|ionic silver-containing dressing|After placing the staples, a ionic silver-containing dressing was placed covering the wound
45452049|NCT02267122|Procedure|Mupirocin ointment application|After placing the staples, Mupirocin ointment application over the wound was performed
45452050|NCT01261312|Drug|SGI-110|"SGI-110 subcutaneous injection administered on Days 1-5~SGI-110 subcutaneous injection administered on Days 1-5 and 8-12"
45452051|NCT01261312|Drug|SGI-110|"SGI-110 administered weekly on Days 1, 8 and 15~SGI-110 administered weekly on Days 1, 4, 8, 11, 15, and 18"
45652778|NCT03424525|Drug|11C-Trimethoprim|[11C]TMP is a radiolabeled imaging agent for positron emission tomography (PET/CT). Most relevant to this protocol, it is for imaging bacterial infection in human subjects. TMP is well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder.
45652779|NCT05104983|Drug|Sirolimus|The investigational drug product to be used in this study is sirolimus, provided in oral suspension.
45934231|NCT03651284|Behavioral|Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools|Participants in this condition will be waitlisted for three months while they receive standard of care (Canadian Health Recommendations for physical activity, dietary habits, screen behaviours, and sleep). Participants will gain access to the Aim2Be app with Virtual Coach after the three month assessment. Participants will then spend three months using the Aim2Be app setting aims, completing tasks, accessing articles, doing self-assessments, and participating in the social wall. For the whole six months, participants will complete a series of questionnaires, dietary recalls, BMI tracking using scales and tape measures, and physical activity tracking using Fitbits. Participants in this condition will have access to the Virtual Coach only. The Virtual Coach gives guidance to families through an avatar that has been programmed using motivational interviewing theory.
45934232|NCT01349673|Drug|Budesonide Foam|Topical
45652780|NCT05104983|Drug|Placebo|Matching placebo
45652781|NCT04801511|Drug|Vitamin C|High-dose Intravenous Vitamin C will be delivered on the day of radiotherapy, in order to reduce the acute toxicity of chemoradiotherapy.
45803801|NCT03523286|Other|RAPID-VT Software guided ablation|Catheter ablation will target VT exit sites at scar margin as determined by the RAPID-VT software
45934233|NCT00071253|Drug|Divalproex Sodium (Delayed-Release Tablets)|
45934234|NCT00071253|Drug|Divalproex Sodium (Extended-Release Tablets)|
45934235|NCT00071253|Drug|Olanzapine|
45803802|NCT02401555|Device|Geenius HIV1/2 Supplemental Assay|The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).
45934236|NCT03493919|Biological|Bexsero|Two doses of Bexsero will be administered on a 0,2-month schedule (Day 1 and Day 61) intramuscularly in the upper deltoid of the non-dominant arm.
45934237|NCT03493919|Biological|Menveo|One dose of Menveo vaccine will be administered intramuscularly in the upper deltoid of the non-dominant arm, at Day 1.
45934238|NCT00067548|Drug|EKB-569|
45934239|NCT03445325|Behavioral|LiGHT v2.1|"The LiGHT mobile program strives to support youth and their families to adopt lifelong healthy behaviours in four areas - eating, physical activity, recreational screen time and sleep - to foster healthy growth and development, to prevent chronic diseases and manage unhealthy weights.~The program includes content that involve the family, and focus on behavioural therapy as well as dietary and physical activity patterns. LiGHT is intended to be engaging and fun, provide virtual and tangible rewards, and interact with participants multiple times per day. In addition, it will feature a mobile social support network and interaction with a live coach with specialized training in motivational interviewing to support youth/families in changing their health behaviours through messaging and phone calls."
45934240|NCT00071292|Behavioral|stress reduction program|
45934241|NCT00071292|Behavioral|meditation|
45652782|NCT04159675|Biological|osteoblast biology study|Describe the in-vitro action of burosumab and vitamin D on human osteoblastogenesis from osteoblasts from patients with craniosynostosis due to HR
45652783|NCT05471765|Device|Withdrawal of Continuous Positive Airway Pressure device|After completing one month of therapeutic management with The Continuous Positive Airway Pressure device and have controlled OSA defined as Apnea Hypopnea Index (AHI) of < 5 while on treatment. At random, a group of participants will cease to use the Continuous Positive Airway Pressure. And they'll have weakly clinic visits where they will fill the Epworth Sleepiness Scale, check their blood pressure, heart rate and undergo Polysomnography for 4 weeks.
45652784|NCT05471765|Device|Alternation usage of Continuous Positive Airway Pressure Device|After completing one month of therapeutic management with The Continuous Positive Airway Pressure device and have controlled OSA defined as Apnea Hypopnea Index (AHI) of < 5 while on treatment. Randomly, these patients will alternatively use The Continuous Positive Airway Pressure device every other day (e.g. They will use the device 4 days and not use it for 3 days of the week) and they'll have weakly clinic visits where they will fill the Epworth Sleepiness Scale, check their blood pressure, heart rate and undergo Polysomnography for 4 weeks.
45652785|NCT05156229|Biological|CDK-003|CDK-003 administered subcutaneously
45652786|NCT03069235|Behavioral|Family member / peer support|supplemental individualized counselling
45652787|NCT03069235|Behavioral|Enhanced intervention with counselor support|"hands on EBF demonstrations"
45652788|NCT03069235|Behavioral|standard of care|one on one and in-group counselling
45934242|NCT03338621|Drug|Pretomanid|200 mg tablets
45934243|NCT03338621|Drug|Bedaquiline|100 mg tablets
45934244|NCT03338621|Drug|Moxifloxacin|400 mg tablets
45652789|NCT04793009|Device|funnel-shaped, intraperitoneal mesh placement|Implantation of a prophylactic, 3D funnel-shaped, intraperitoneal, non-absorbable and synthetic mesh (Dyna Mesh IPST 2x15x15 cm™ and 3x16x16 cm™, FEG Textiltechnik, Aachen, Germany,)
45804181|NCT05437159|Device|Anodal tDCS|Continuous anodal tDCS is delivered to a speech processing area of the brain during a 19-minute speech training session. The tDCS stimulation will ramp up to its maximum value (2 milliamperes) in the minute prior to the training session and maintained at that level throughout the session.
45804182|NCT05437159|Device|Sham tDCS|Sham tDCS stimulation is delivered to a speech processing area of the brain during a 19-minute speech training session. During the minute prior to training onset, the tDCS stimulator is ramped up to 2 milliamperes and then back down to 0.
45934245|NCT03338621|Drug|Pyrazinamide|500 mg tablets
45934246|NCT03338621|Drug|HRZE|isoniazid 75 mg plus rifampicin 150 mg plus pyrazinamide 400 mg plus ethambutol 275 mg combination tablets
46073524|NCT00848341|Device|GUIDANT ICD SYSTEM|
45652790|NCT04230759|Drug|Chemotherapy|"Patients recieve chemotherapy cycles as followed:~Mitomycin-C 12 mg/m², day 1 (maximum single dose 20 mg) 5-FU: 1000 mg/m² per day, continuous i.v. infusion, on day 1-4 and 29-32"
45934247|NCT03338621|Drug|HR|isoniazid 75 mg plus rifampicin 150 mg combination tablets
45652791|NCT04230759|Radiation|Radiation|PTV_A (primary tumor): T1-T2<4cm N+: 28 x 1.9 Gy=53.2 Gy, five fractions per week or PTV_A (primary tumor): T2>=4cm, T3-4 Nany: 31 x 1.9 Gy=58.9 Gy, five fractions per week PTV_N (involved node): 28 x 1.8 Gy=50.4 Gy, five fractions per weeks PTV_Elec (elective node): 28 x 1.43 Gy=40.0 Gy, five fractions per week
45934248|NCT04732169|Drug|Active study drug ( oral CBD)|CBD in single dose syringes
45934249|NCT04732169|Drug|matching placebo|Placebo made with sesame oil flavored with strawberry flavoring in single dose syringes
45934250|NCT00071331|Drug|Tolvaptan|
45934251|NCT03007628|Device|Magpro X100|In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
45934252|NCT03007628|Device|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
45934253|NCT03007628|Other|Treatment as usual (TAU)|Participants will engage in their intpatient treatment program as-usual.
46073525|NCT00840697|Behavioral|Exercises and work related rehabilitation|Treatment in groups, twice a week for 3 weeks. The treatment includes exercises, cognitive intervention and work related rehabilitation. The exercises include fitness, strength and stretching
45452052|NCT04475692|Behavioral|Repetitive, task-specific upper limb practice|A self-directed upper limb intervention (implementing a self-selected dose). This intervention uses an adapted upper limb rehabilitation system to support repetitive upper limb training for stroke survivors.
46073526|NCT00840697|Behavioral|Brief intervention|1 consultation at the physiotherapist, which give advice Summary talk with the physician about activity and work when having neck- and low back pain
46073527|NCT00840697|Behavioral|multidisciplinary exercise group|10 days during 3 weeks. Treatment in groups, exercise and cognitive treatment
46073528|NCT02824146|Other|Lung recruitment maneuver|The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (15 cmH2O of PEEP + 15 cmH2O of driving pressure) for 10 breaths.
45803803|NCT05723042|Other|EMS with CIMT|The interventions are consisted of 3weeks of casting the unaffected limb followed by 5 weeks of transference activities.The assisting hand assessment AHA was used to measure bimanual activity performance at baseline,8 weeks, 16 weeks. 20-minute application of currents and resistance exercises for the respective muscles of the area. The intervention group with 11 patients underwent a program of CIMT for one hour daily for 14 consecutive days or two hours per day, six days per week and a total of 12 weeks. A follow-up will be performed 12 weeks after the intervention. The healthy upper limb will be immobilized by orthosis or cast for six hours a day . Electrotherapy will be applied with TENS for 15 minutes at intervals of 1000ms and with a pulse duration of 50ms. The square wave will be chosen to ensure that there will be sufficient muscle contraction
45803804|NCT05723042|Other|EMS|this group will only receive baseline exercises (ROM and flexibility exercises) than apply electrical stimulations at specific motor points. Electrotherapy will be applied with TENS for 15 minutes at intervals of 1000ms and with a pulse duration of 50ms. The square wave will be chosen to ensure that there will be sufficient muscle contraction
45803805|NCT02402881|Behavioral|Patient-centered education bundle|A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
45934254|NCT02493530|Drug|TGR-1202|"Stage 1 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients already taking therapeutic levels of ruxolitinib, but who are not achieving maximal response at highest tolerated dose of ruxolitinib.~Stage 2 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients who have never been on JAK-STAT inhibitory agents, and includes simultaneously initiation of both ruxolitinib and TGR-1202. TGR-1202 will be administered at or below the recommended dose established in Stage 1.~Expansion will commence after proper combination doses of both agents is established."
45934255|NCT02493530|Drug|ruxolitinib|
45934256|NCT00067626|Dietary Supplement|Chromium|500/1000 mcg oral chromium picolinate taken daily or placebo (crossover)
45934257|NCT00067665|Other|Ultrafiltration|All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
46073529|NCT00834145|Device|A mechanical compression pump|Patients in the experimental arm will receive a NormaTec pump which will be used twice daily during hospitalization and once daily on an ambulatory basis. A cuff is placed over the leg and a pneumatic system automatically compresses the leg according to predefined parameters of pressure, time etc.
45652792|NCT04230759|Drug|Durvalumab|1500 mg, 1h-civ, every 4 weeks (q4w) applied on day -14 (that is 14 days prior to initiation of RCT), day 15 (during RCT), and thereafter q4w (+/- 3d) for a total of 12 doses
45803806|NCT03435848|Drug|BST-236|1 to 4 courses
45934258|NCT02970968|Drug|VLY-686 (Tradipitant)|oral capsule
45934259|NCT02970968|Other|Placebo|placebo oral
45934260|NCT02967159|Drug|Abediterol|Treatment A: Abediterol 2.5 μg via DPI
45934261|NCT02967159|Drug|AZD7594|Treatment B: AZD7594 440 μg via DPI
45934262|NCT02967159|Drug|AZD7594/abediterol|Treatment C: AZD7594/abediterol 440 μg/2.5 μg FDC via DPI
45934263|NCT02967159|Drug|AZD7594 and abediterol|Treatment D: AZD7594 440 μg and abediterol 2.5 μg free combination administered via 2 separate DPIs
45934264|NCT02396342|Genetic|AAV5-hFIX|AAV5hFIX gene therapy
45934265|NCT00067704|Behavioral|Trauma writing|
45934266|NCT00067704|Behavioral|Writing about daily events|
45934267|NCT02274116|Other|SHAM - Intermittent Room Air - room air mixture|Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.21±0.02 (normoxia). Participants will receive treatment 5 times per week for 2 weeks.
45934268|NCT02274116|Other|AIH - Intermittent Hypoxia - hypoxia air mixture|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.10±0.02 (hypoxia). Participants will receive treatment 5 times per week for 2 weeks.
45652793|NCT02704117|Device|Transcranial Magentic Stimulation|This is a form of mild brain stimulation delivered noninvasively. The device delivers pulses of magnetic energy through a coil placed on the scalp. The treatment takes 41 seconds, and takes place for ten sessions, Monday through Friday, over the course of two weeks
45803807|NCT03332459|Drug|Lumicitabine|Participants who received lumicitabine in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
46073530|NCT04241484|Device|Piezowave 2|Piezowave Myofascial Acoustic Compression Therapy (MyACT), which provides mechanical stimuli delivery to improve circulation and provide relief of pain. The focused sound waves produced by the Piezowave MyACT device are classified by a pressure surge, which is followed by a drop in pressure and a brief negative pressure phase low energy/low pressure application. It is this transformation of mechanical stimuli into biochemical signals, or mechanotransduction, which yields the treatment of myofascial and musculoskeletal pain
45652794|NCT05615909|Radiation|Online MR-guided radiotherapy|Online adaptive MR-guided radiotherapy in the Unity MR-linac for localized intermediate risk prostate cancer (60 Gy/20 fx) or low-volume metastatic prostate cancer (36 Gy/6 fx).
46073531|NCT00840775|Device|Catheterization, stent deployment|Standard catheterization procedure including Bare Metal Stent deployment.
46073532|NCT02825238|Other|Supervised exercise program|
45652795|NCT05615909|Radiation|CT-guided radiotherapy|CT-guided radiotherapy in linear accelerators for patients with high-risk prostate cancer (78 Gy/39 fx), intermediate risk prostata cancer (60 Gy/20 Fx) or having salvage radiotherapy (70 Gy/35 fx)
45652796|NCT04453891|Device|Monitoring physiological data with the Hexoskin smart shirt|Participants will be monitored using a validated biometric garment (Hexoskin smart shirt). Cardiorespiratory and activity data will be collected over a 28-day monitoring period. Participants will be invited to wear the shirt during the day and at night.
45652797|NCT05471687|Device|dual-energy dual-layer spectral scanner|Realization of dual-energy dual-layer spectral scanner with stress protocol
45652798|NCT05471687|Drug|Stress protocol with adenosin during dual-energy dual-layer spectral scanner|Injection of intraveinous adenosin dose 0.78 mg/kg during dual-energy dual-layer spectral scanner
45652799|NCT04230369|Behavioral|Exposure-based Internet-CBT|Internet-CBT for anxiety-related asthma 8 weekly modules of CBT delivered over the internet and targeting enhanced function and decreased symptoms of anxiety. Participants work independently from home with the treatment and receive support from experienced Internet-CBT Psychologists through written messages in the secure platform. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
45652800|NCT04230369|Other|Treatment as usual|Patients randomized to treatment as usual will receive the same medical information that participants in the Internet-CBT get, with physiological information about asthma and the importance of medical adherence to achieve well controlled asthma, but without the exposure-based treatment and no therapist support. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
45652801|NCT05471609|Drug|levodopa/carbidopa oral formulation A|Outer sachet 100mg CD/100mg LD and inner sachet 0mg CD /300mg LD
45803808|NCT03332459|Drug|Placebo|Participants who received placebo in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
45934269|NCT00067743|Drug|Lenalidomide|supplied as 5 mg capsules. Dosing as directed by physician but to start at 10 mg per day
45934270|NCT00396968|Drug|AMD3100|
46073533|NCT00840931|Drug|lenalidomide|Patients will take 10 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Patients will receive 4 treatment cycles with 28 days in each cycle.
46073534|NCT00840931|Biological|bystander vaccine|In addition to lenalidomide, during each 28 day cycle patients will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
46073535|NCT02825082|Procedure|Abdominal emergency surgery|all abdominal emergency surgery procedures
46073536|NCT00848419|Drug|Epidural administration of bolus|
46073537|NCT05659992|Drug|azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte|"azacytidine (75 mg/m2/day, days 1 to 7).~cytarabine (75 mg/m2 bid, days 1 to 5).~aclamycin (10 mg/m2/day, day1,3,5).~Chidamide (30 mg/day , days 0,3).~venetoclax (100 mg day 1, 200 mg day 2, 400mg days 3 to 14 ).~granulocyte colony-stimulating factor (5ug/kg/day, day 0 until agranulocytosis recovery)"
46073538|NCT00848575|Device|Flexible Endoscope|
46073539|NCT04242576|Device|Right Left Judgement|It is an application by Noigroup (Neuro Orthopedic Institute), adapted to different devices.
46073540|NCT04242576|Other|Action Observation|Videos of cervical movements.
46073541|NCT04242576|Behavioral|Exercise|Evidence based exercises for the neck.
46073542|NCT00834223|Device|Aquashunt|A shunt which is implanted into the suprachoroidal space.
46073543|NCT04042909|Behavioral|Counter Attitudinal Advocacy|same as Counter Attitudinal Advocacy arm
46073544|NCT04042909|Behavioral|Personalized Normative Feedback|same as Personalized Normative Feedback arm
46073545|NCT00834301|Dietary Supplement|Oral Multivitamin|Oral Multivitamin
45652802|NCT05471609|Drug|levodopa/carbidopa oral formulation B|Outer sachet 100mg CD/0mg LD and inner sachet 0mg CD /400mg LD
45652803|NCT05471609|Drug|levodopa/carbidopa oral formulation C|Outer sachet 50mg CD/200mg LD and inner sachet 50mg CD /200mg LD
45803809|NCT02403895|Drug|Open-label AZD2014|Dual TORC1/TORC2 inhibitor
45803810|NCT02403895|Drug|paclitaxel|Taxane
45934271|NCT00396968|Procedure|Allogeneic Stem Cell Transplantation|
45934272|NCT00067860|Drug|recombinant human growth hormone|
45934273|NCT00067860|Behavioral|diet modification|
45934274|NCT00071409|Drug|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
45934275|NCT00071409|Drug|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
45934276|NCT00071409|Drug|placebo|1.5 mL, once daily, self-administered SC injection for 90 days
45934277|NCT02035085|Drug|CS-1000 labeled SVF cells|Patients will undergo autologous transplantation of CS-1000 labelled SVF cells in a sterile environment.
45652804|NCT03068845|Device|Drug-eluting balloon angioplasty (DEBA)|"DEBA will be performed after pre-dilatation of the target lesion for subjects allocated to the experimental arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
45652805|NCT03068845|Device|Conventional Balloon Angioplasty (CBA)|"CBA will be performed for the target lesion for subjects allocated to the active comparator arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
45803811|NCT03994874|Drug|PolyCore (Polydextrin, L-Carnitine, D-xylitol)|A single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours. Patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change.
45803812|NCT03994874|Drug|Medical therapy including loop diuretic (furosemide) daily dose up to 2.5 mg/kg/day,|During the study, patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change.
45803813|NCT03987776|Behavioral|Anti-inflammatory energy-restricted diet|During 6 months the participants will we asked to use recommended energy-reduced diet with anti-inflammatory properties, based on colorful vegetables and fruits, legumes, nuts, seeds, marine fish, whole-grain products, and daily use of olive oil, green/black tea, multiple spices and herbs.
45803814|NCT03987776|Behavioral|Control energy-restricted diet|During 6 months the participants of control group will be asked to use recommended energy-reduced diet based on standard obesity management (55-60% carbohydrates, 25% fat, 15-20% protein)
45934278|NCT00071448|Drug|insulin human|
45934279|NCT00071448|Drug|insulin lispro|
45934280|NCT00071448|Drug|insulin aspart|
45934281|NCT01547429|Device|Artisan Aphakia Intraocular Lens|Implantation of lens to correct refractive error in aphakic eye
45934282|NCT02599324|Drug|ibrutinib|Ibrutinib administered orally once daily with 8 ounces (approximately 240 mL) of water.
45934283|NCT02599324|Drug|everolimus|Everolimus 10 mg tablets should be taken orally once daily at the same time every day, either consistently with food or consistently without food. Four (4) x 2.5 mg tablets or two (2) x 5.0 mg tablets may be substituted if 10 mg tablet strength is not available.
45934284|NCT02599324|Drug|paclitaxel|Paclitaxel should be administered as a 60-minute (±10 minutes) infusion. Paclitaxel should be given at a dose level of 80 mg/m^2, once weekly, in continual 3 weekly cycles.
45934285|NCT02599324|Drug|docetaxel|Docetaxel administered as a 60 minute infusion (±10 minutes) at a dose level of 60 - 75 mg/m^2 (according to local institutional standard of care), given continually in 21-day cycles.
45934286|NCT02599324|Drug|cetuximab|Cetuximab 400 mg/m^2 administered as a 120-minute IV infusion. The recommended subsequent weekly dose (all other infusions) is 250 mg/m^2 infused over 60 minutes.
45934287|NCT02599324|Drug|pembrolizumab|Pembrolizumab 200 mg intravenous (IV) every 3 weeks.
45934288|NCT01331018|Procedure|Bone Marrow Aspiration|Undergo bone marrow harvest
45934289|NCT01331018|Biological|Filgrastim|Given SC
45934290|NCT01331018|Biological|Genetically Engineered Hematopoietic Stem Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
45934291|NCT01331018|Other|Laboratory Biomarker Analysis|Correlative studies
45934292|NCT01331018|Procedure|Leukapheresis|Undergo leukapheresis
45934293|NCT01331018|Drug|Methylprednisolone|Given IV
45803815|NCT03905252|Other|sample analysis|blood, Random urine sample and 24-hour urine samples
45934294|NCT01331018|Drug|Plerixafor|Given SC
45934295|NCT01331018|Drug|Prednisone|Given PO
45934296|NCT00067899|Drug|Vitamin E with and without Vitamin C|
45934297|NCT00071604|Behavioral|Medication Adherence Therapy|
45934298|NCT00071604|Behavioral|Friendly Support Group|
45934299|NCT01086371|Other|Rhythmic auditory stimulation|Recorded music with embedded beat set 10% above the subject's baseline walking cadence.
45934300|NCT01086371|Other|Walking exercise|Subjects will be walking daily for a total of 20 minutes (may be broken down to smaller time periods.
45934301|NCT00866957|Procedure|Blood draw|A two-time blood draw: one prior to cancer treatment, the second after cancer treatment. Total amount of blood approximately 8 teaspoons (40mL).
45934302|NCT00067938|Drug|lamotrigine|Lamotrigine
45934303|NCT02582593|Device|MedX 1116 Rehab Console|This intervention makes use of transcranially applied near infrared light using light emitting diodes. Near infrared light will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
45934304|NCT02582593|Device|Sham MedX 1116 Rehab Console|This intervention makes use of sham transcranially applied near infrared light using light emitting diodes. Light emitting diodes (but not near-infrared light) will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
45803816|NCT02404285|Drug|Next Science Acne Gel|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
45652806|NCT05370729|Drug|N-acetyl cysteine|Intravenous infusion of NAC 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg body weight in 1000 ml of 5% dextrose over 16 h.
45652807|NCT05471531|Biological|Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine|Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.
45803817|NCT02404285|Drug|Vehicle|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
45934305|NCT02358187|Biological|Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC|Poly-ICLC is administered intramuscularly (i.m.) using sterile technique, as supplied from the vial, and in the amount prescribed for the participant's weight. Patients should receive a dose of acetaminophen (15 mg/kg up to a max of 1000 mg) 30-60 minutes before each poly-ICLC administration. The poly-ICLC treatments will be administered immediately following the vaccine. Patients/parents will be asked to report any temperature elevations and side effects after each treatment.
45934306|NCT00121472|Device|Thoratec HeartMate II Left Ventricular Assist System (LVAS)|Implantation of ventricular assist device to provide hemodynamic support
45934307|NCT02290522|Procedure|Tumor biopsy|Biopsy of lesion for molecular characterization
45934308|NCT02048371|Drug|Regorafenib|Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
45452053|NCT04475692|Other|Conventional care|Conventional care is the standard care offered to stroke patients in their respective settings. In this context it is guided by Royal College of Physicians (2016). For the purposes of this work, conventional care encompasses any rehabilitation or support services accessed by participants within the primary or secondary care setting, including private therapy services, charity-led exercise groups etc. Conventional care will not be specified in the context of this work, as it is complex in nature and varies between settings.
45452054|NCT01255696|Biological|ALV003|
45803818|NCT03333317|Drug|Lumicitabine|Participants will receive oral administration of lumicitabine.
45803819|NCT03333317|Drug|Placebo|Participants will receive oral administration of matching placebo.
45803820|NCT02978690|Drug|BI655130|
45934309|NCT02048371|Drug|Placebo|21 days on and 7 days off
45934310|NCT01809808|Procedure|Surgery for acromegaly|(non-experimental) standard procedure
45934311|NCT01809808|Drug|Medications for acromegaly|(non-experimental) standard procedure
45934312|NCT01809808|Diagnostic Test|Total body magnetic resonance imaging|Subjects will undergo total body MRI with spectroscopy of the muscle and liver before and 3-6 months, 12 and 24 months after surgery or medical therapy for acromegaly.
45934313|NCT01809808|Procedure|Adipose Tissue Biopsy|Subjects will undergo biopsy of subcutaneous adipose tissue before and 12 and 24 months after surgery or medical therapy for acromegaly.
45934314|NCT01556230|Procedure|Surgical intervention for CNFA|(non-experimental) standard procedure
45934315|NCT01556230|Radiation|Radiotherapy for CNFA|(non-experimental) standard procedure
45452055|NCT01255696|Biological|ALV003 placebo|
45452056|NCT02267434|Biological|Low dose AFFITOPE® PD03A + Adjuvant|s.c. injection
45452057|NCT02267434|Biological|High dose AFFITOPE® PD03A + Adjuvant|s.c. injection
45452058|NCT02267434|Biological|Adjuvant without active component|s.c. injection
45452059|NCT03957382|Device|Accero® Stent|The Accero® Stent will only be used in line with the Instructions For Use (IFU). Patients participating in this PMCF (Post- Market Clinical Follow-up) will not be exposed to any additional risk. There are no additional treatments or investigations other than done in the clinical routine.
45452060|NCT01254370|Drug|Latanoprost|0.005%
45803821|NCT02406859|Behavioral|Bowel Biofeedback|Subjects will complete 2 sessions twice a week for 6 weeks of bowel biofeedback training. Subjects will be asked to squeeze and bear down for a period of 5 seconds followed by rest for 10seconds. Following the training, each subject will complete similar training at home for 6 weeks.
45452061|NCT01254370|Drug|Travatan Z|0.004%
45803822|NCT02406859|Behavioral|Anorectal Manometry|Subjects will undergo an anorectal manometry to establish baseline pressure characteristics. If subjects qualify for biofeedback training, they will complete two additional manometries to track the changes occuring during training.
45803823|NCT05722730|Procedure|Pilates Exercises|The intervention group will perform an exercise protocol based on the Pilates method, by a physiotherapist specialized in Pilates and independent of the researchers, using the method's own equipment, with a frequency of 2x/week, for 12 weeks in therapeutic sessions of identical protocols lasting 60 min.
45803824|NCT02406937|Dietary Supplement|Oral intake of Feihe New Formula|Oral intake of Feihe New Formula
45803825|NCT02406937|Dietary Supplement|Oral intake of Feihe Stage 1 Formula|Oral intake of Feihe Stage 1 Formula
45803826|NCT02406937|Dietary Supplement|Breast Feeding|Oral intake of breast milk
45803827|NCT04316975|Other|Study Driven Procurement of Biopsies|Four research biopsies collected at the midpoint of current BE or IMC at Baseline and after reaching CEIM. Biopsies will be used to calculate ML scores both pre and post EET.
45803828|NCT05722496|Other|Aerobic pedaling exercise|aerobic exercise in the form of leg pedaling exercise in semi-supine position using leg ergometer by different intensities
45803829|NCT05722340|Procedure|Non-intubated video-assisted thoracic surgery (NIVATS) for lung biopsy|An epidural anaesthesia associated with mild sedation requiring no ventilation is used.
45803830|NCT05722340|Procedure|Intubated general anaesthesia video-assisted thoracic surgery (IGAVATS) for lung biopsy|Uses a traditional deep anaesthesia and one-lung ventilation
45934316|NCT00073892|Drug|PI-88|250 mg/day injected subcutaneously on four consecutive days each week in a 4- week cycle
45934317|NCT00068055|Drug|Omr-lgG-am|Omr-IgG-am™ 5% is provided in 100 ml bottles (5.0 grams) as a sterile solution containing 5% protein, 10% maltose and water for injection. This product is licensed in Israel, but not in the US.
45803831|NCT03210155|Device|Alpha-Stim AID CES (Active Comparator)|The Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
45934318|NCT00068055|Drug|Polygam® S/D|Polygam® S/D is a solvent/detergent treated, sterile, freeze-dried preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma. When reconstituted (5%) with the supplied diluent (sterile water for injection, USP) Polygam® S/D contains approximately 50mg of protein per ml (approximately 90% is gamma globulin); 3mg/ml human albumin, 22.5 mg/ml glycine, 20 mg/ml glucose, 2mlg/ml polyethylene glycol (PEG), 1 mcg/ml tri-nbutyl phosphate, 1 mcg/ml octoxynol 9, and 100 mcg/ml polysorbate 80.
45934319|NCT00068055|Drug|Placebo|Normal Saline.
45652808|NCT05471531|Biological|Separate vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine|Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0 and one dose of 23-valent pneumococcal polysaccharide vaccine on day 28 in subgroup 1,and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of quadrivalent influenza vaccine on day 28 in subgroup 2.
45652809|NCT04426331|Behavioral|Voucher Without Value Information|"Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital. The voucher included the patient's name, the screener's name, and an expiration date 90 days from the date of screening.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. So, with this voucher, both the exam and the glasses will be completely free."
45652810|NCT04426331|Behavioral|Voucher With Value Information|"Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital, which would normally cost $250. The voucher included the patient's name, the screener's name, an expiration date 90 days from the date of screening, and a statement about the $250 voucher value.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. These services normally cost about $250, but with this voucher, both the exam and the glasses will be completely free."
45934320|NCT01406197|Drug|Experimental: Vaginal progesterone|Vaginal progesterone formulation (150 mg micronized progesterone daily)
45934321|NCT01406197|Drug|Experimental: Topical progesterone|Progesterone will be applied daily (150 mg micronized progesterone)by topical application
45934322|NCT01406197|Drug|Experimental: Intramuscular progesterone|Preterm labor patients will be injected IM with micronized progesterone (50 mg/day).
45934323|NCT01260961|Dietary Supplement|Placebo|The volunteers will start on the 200 mg daily of the placebo and will not increase their dose during the study.
45452062|NCT01254136|Drug|INCB007839 300mg BID|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
45803832|NCT03210155|Device|Alpha-Stim AID CES (Sham Comparator)|The Alpha-Stim® AID CES sham device is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
45803833|NCT02408263|Procedure|Total Hip Replacement (THR) and Total Knee Replacement (TKR)|Total Hip Replacement is a surgical procedure where the cartilage and bone of the hip joint is replaced with artificial materials. Total Knee Replacement involves replacement of all three compartments of the knee the medial, the lateral and patellofemoral compartment.
45803834|NCT03210701|Other|A HIV POCT program adapted for & provided by community pharmacists|Using a Type II hybrid Implementation-Effectiveness study design investigators will assess the implementation and effectiveness of a multi-faceted, integrated, contextualized model of HIV POCT in pharmacies in urban and rural settings in NL and AB, Canada. This design will be flexible, responsive and capable of capturing changing elements at multiple points in time. A mixed methods approach will be used to assess Implementation and Effectiveness aims.
45934324|NCT01260961|Dietary Supplement|Docosahexanoic Acid|The volunteers will start on the 200 mg daily of the DHA capsule and will not increase their dose during the study.
45934325|NCT02957773|Behavioral|Qigong and art activities|Participants join a 90-minute session of integrated Qigong and art activity consisting of 30 minutes Qigong followed by 60 minutes art activity.
45934326|NCT02957773|Behavioral|Art activities|Participants join a 90-minute session that consists of 60-minute art activities followed by 30 minutes daily activities.
45934327|NCT02957773|Behavioral|Qigong|Participants join a 90-minute session that consists of 30-minutes Qigong exercise followed by 60 minutes daily activities (watching television, reading or sitting together).
45934328|NCT02957773|Behavioral|Daily activities|Participants do their daily activities routine for 90-minutes, such as watching television, reading and sitting together or participants can do free individual activities on their own.
45934329|NCT00038363|Procedure|Rehabilitation|
45934330|NCT00038363|Procedure|Subacute care|
45934331|NCT00144508|Drug|MRA (Tocilizumab)|8mg /kg /4week for 52 weeks
45934332|NCT00144508|Other|current treatment|continue current treatment
45934333|NCT00068094|Drug|Probiotic-containing powder|
45934334|NCT00144547|Drug|MRA(Tocilizumab)|8mg/kg(i.v.)/4weeks
45934335|NCT00144586|Drug|MRA(Tocilizumab)|8mg/kg/4 weeks
45934336|NCT00144625|Drug|MRA(Tocilizumab)|8mg/kg/4weeks
45934337|NCT00038402|Drug|Herceptin|Starting dose of 4 mg/kg by vein, then 2 mg/kg weekly after that until the end of all cycles of neo-adjuvant chemotherapy and during FEC therapy for a total of 24 doses.
45934338|NCT00038402|Drug|Taxol|225 mg/m^2 by vein as a continuous infusion over 24 hours each cycle for a total of 4 cycles.
45934339|NCT00038402|Drug|Fluorouracil|500 mg/m^2 by vein on Days 1 and 4 for 4 cycles at 3-4 week intervals.
45934340|NCT00038402|Drug|Cytoxan|500 mg/m^2 on Day 1 of each cycle for 4 cycles.
45803835|NCT04345016|Device|Once-daily remote foot temperature monitoring|Participants were provided a once-daily remote foot temperature monitoring mat (Podimetrics SmartMat; Podimetrics Inc., Somerville MA) which they used for one year or until dying, dropping out of the study, or disenrolling at a member of the health plan administering the study.
45934341|NCT00038402|Drug|Epirubicin|75 mg/m^2 IV on Day 1 of each cycle for 4 cycles.
45934342|NCT00144664|Drug|MRA(Tocilizumab)|
45934343|NCT00144703|Drug|Sirolimus|
45934344|NCT00144703|Drug|Tacrolimus|
45803836|NCT02354833|Drug|Phenylephrine|
45934345|NCT00144820|Drug|Injection of Hyaluronan or Saline|
45934346|NCT00144859|Drug|SB681323|
45803837|NCT02354833|Drug|Norepinephrine|
45934347|NCT00144898|Procedure|Sentinel Node Resection|Sentinel Node Resection
45934348|NCT00144898|Procedure|Conventional Axillary Dissection|Conventional Axillary Dissection
45934349|NCT00038441|Drug|DTI-015|DTI-015 injected through a catheter into center of brain tumor.
45934350|NCT00144937|Drug|Stepwise therapy for dyslipidemia, hypertension and diabetes|
45934351|NCT00144937|Behavioral|Dietary recommendations|
45934352|NCT00144937|Behavioral|Increase in physical activity|
45803838|NCT03337724|Drug|Ipatasertib|Ipatasertib, 400 milligrams (mg), administered orally once a day (QD) on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
45803839|NCT03337724|Drug|Paclitaxel|Paclitaxel, 80 mg/square meter (m^2), administered intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
45803840|NCT03337724|Drug|Placebo|Matching placebo, administered orally QD on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
45803841|NCT04295447|Other|Standard of care|"Observation only or~An optional adjuvant radiation of the prostate bed in case of positive surgical margin"
45803842|NCT04295447|Drug|Apalutamide 60Mg Tab|(4 x 60 mg) once daily on days 1-28 of a 28-day cycle
45803843|NCT04190147|Other|Structural, functional and metabolic eye examinations|Structural, functional and metabolic eye examinations
45934353|NCT00144937|Behavioral|Smoking cessation|
45934354|NCT00071643|Behavioral|Problem Solving Therapy|Problem solving therapy aims to make patients aware of symptoms of problems and link those with behaviors associated with solving them.
45803844|NCT02355067|Behavioral|Social Media Intervention|These women will participate in the intervention through the online Facebook group.
45803845|NCT02355067|Behavioral|Traditional In-Person Intervention|These women will participate in the intervention through a traditional weekly meeting of a group in-person.
45803846|NCT03340337|Device|Neo-Russian|"Subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
45803847|NCT03340337|Device|Aussie|"Subjects will receive Aussie electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
45934355|NCT00071643|Drug|Escitalopram|Participants will receive escitalopram, a selective serotonin reuptake inhibitor.
45934356|NCT00071643|Other|Placebo|Participants will receive a placebo pill.
45934357|NCT00144976|Drug|Tarceva|Tarceva will be administered at dosage 150 mg od one hour before or two hours after meat. Patients will receive Tarceva between 18 and 28 days.
45934358|NCT00145015|Behavioral|Increased dietary intake of salmon or cod|
45934359|NCT00145054|Behavioral|MoodHelper Internet program for Depression Self-Help|
45934360|NCT00405691|Device|"TOPS System - Total Posterior Arthroplasty Implant"|
45934361|NCT00068133|Genetic|Plasmid based Gene Transfer product-VLTS-589|
45934362|NCT00038480|Drug|Lopinavir/Ritonavir|
45934363|NCT04711018|Diagnostic Test|Laryngoscopy|The laryngoscopy is performed with the help of an appropriate size Macintosh blade. The patient's head is held in the sniffing position. External manipulation is not used for improving the view in this investigation.
45934364|NCT00202267|Device|Four-layer Bandage (Elastomeric)|Precise components of the four-layer system depend on the circumference of the ankle. All the bandages are discarded after a single use, usually one week.
45934365|NCT00202267|Device|Short-stretch Bandage (Non-elastomeric)|These bandages are applied in a figure-eight technique; two bandages are applied at full extension in opposite directions up the leg (i.e., clockwise and counter clockwise). The participant will wash the short-stretch wherever possible and reused. The number of bandages supplied to each patient will be recorded on the visit record.
45934366|NCT00202306|Drug|lithium carbonate|
45934367|NCT00038519|Drug|Amprenavir/ritonavir|
45934368|NCT00038519|Drug|Saquinavir/ritonavir|
45934369|NCT00202345|Drug|Iron sucrose|
45934370|NCT00202423|Drug|Sativex|
45934371|NCT00202462|Drug|Testosterone gel|Testosterone gel 7.5 gm qd
45934372|NCT00038558|Drug|Filgrastim SD/01|
45934373|NCT00038558|Drug|Adriamycin|
45803848|NCT03340337|Device|RBS|"Subjects will receive RBS electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
45934374|NCT00038558|Drug|Bleomycin|
45934375|NCT00038558|Drug|Vinblastine|
45934376|NCT00038558|Drug|DTIC|
45934377|NCT00202501|Device|Nasal CPAP (Continuous Positive Airway Pressure)|
45803849|NCT05722106|Behavioral|Persuasive Appeal|Persuasive appeals were manipulated using promotional flyers ostensibly distributed by the Public Health Agency of Canada.
45803850|NCT03340415|Other|Accelerated Rehabilitation plan|early weight bearing after surgery
45652811|NCT05615831|Behavioral|Resistance Training with Blood flow restriction|Participants will perform six weeks of blood flow restriction (60% occlusion) combined with resistance training at 30% of 1RM. The intervention comprises five exercises: incline chest press, seated row, leg press, knee extension, and knee flexion. The protocol is as follows: 30 repetitions followed by three sets of 15 repetitions for a total of four sets and 75 repetitions per exercise. There will be a one-minute recovery between sets where the cuffs remain inflated and a four-minute recovery between exercises where the cuffs will be deflated.
45803851|NCT05722028|Procedure|hysteroscopy|Surgical hysteroscopy without anaesthesia for removal of uterine polyp / retained products of conception.
45652812|NCT05104671|Other|scapular stabilization exercises.|"General Instructions: For all exercises, perform the retraction of the scapula, without performing the elevation of the shoulders, taking the lower angle of the scapula back and down.~The exercise intensity was described as repetitions, sets, and holding time. Commonly, 10-20 repetitions and three to five sets held for 3-10 seconds were performed.and the exercises will be:~towel slide~Scapular Clock:~Scapular Proprioceptive Neuromuscular facilitation:~Inferior Glide.~Scapular Orientation Exercise (SOE):~Protraction and retraction in front of a mirror:"
45803852|NCT02356003|Device|Low frequency repetitive transcranial magnetic stimulation|Baseline high-resolution anatomical magnetic resonance images will allow individualized neuronavigation (Brainsight 2, Rogue Research, Montreal QC) to co-register the transcranial magnetic stimulation Airfilm coil (Magistim, UK) precisely to the supplementary motor area as defined by functional magnetic resonance imaging. Interventional low frequency repetitive transcranial magnetic stimulation parameters will be: intensity 100% resting motor threshold, frequency 1 Hz, duration = 20 minutes (1200 stimulations). Treatments will occur on each weekday at the same time of day for three weeks (15 total). These are standard parameters for low frequency repetitive transcranial magnetic stimulation and are well tolerated in children.
45803853|NCT02356471|Device|Management of Therapy Complications Fitbit Zip (portable pedometer device)|Use pedometer to monitor physical activity
45803854|NCT02356471|Other|Questionnaire Administration|Ancillary studies
45803855|NCT02356471|Other|Quality-of-Life Assessment|Ancillary studies
45934378|NCT00202540|Drug|S18986|
45934379|NCT02966496|Biological|Acri.LISA366D multifocal aspheric IOLs|The implantation of Acri.LISA366D multifocal aspheric IOLs are used in the test group.
45934380|NCT02966496|Biological|TecnisZ9001 multifocal aspheric IOLs|The implantation of TecnisZ9001 multifocal aspheric IOLs are used in the test group.
45934381|NCT00202579|Drug|Ivabradine|
45934382|NCT00038597|Drug|SCH66336|
45803856|NCT03340805|Drug|Lactated Ringer|"LR is a sterile, nonpyrogenic balanced solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5)."
45934383|NCT00202618|Drug|Valsartan|
45934384|NCT00202618|Drug|Amlodipine|
45934385|NCT00202657|Procedure|echocardiography|
45934386|NCT02966808|Behavioral|cognitive and behavioural questionnaires|
45934387|NCT00202696|Drug|nalmefene|Nalmefene HCl film-coated tablets administered orally, twice daily, for total daily dosage of 40 or 80 mg, for 5 weeks (following a 2-week titration period).
45934388|NCT00202696|Other|Placebo|Placebo tablets, administered orally, twice daily for 5 weeks (following a 2-week titration period).
45934389|NCT00202735|Procedure|Arm1:Immobilization in external rotation|Immobilization in external rotation (ER) All patients in the ER group use a prefabricated shoulder immobilizer (Don Joy Ultrasling Er,15˚ version).To control the position,a line at the top of the immobilizer is to be parallel with the frontal plane when the arm is correctly placed in 15 degrees of external rotation.
45934390|NCT00202735|Procedure|immobilization in internal rotation|All the patients in the internal rotation(IR) group are immobilized with their arm/shoulder in internal rotation by using a normal collar and cuff device.
45934391|NCT00038636|Drug|Lopinavir/ritonavir|
45934392|NCT00038636|Drug|Ritonavir|
45934393|NCT00071838|Drug|Daclizumab|
45934394|NCT00202852|Other|Placebo|Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
45934395|NCT00202852|Drug|MTX|Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose >=12.5 mg/week given orally or parenterally, maximum 20 mg/week
45934396|NCT00202852|Biological|Infliximab|Infliximab 3 mg/kg given as an infusion at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
45934397|NCT00202852|Drug|MTX|3 mg/kg infliximab infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose >=12.5 mg/week given orally or parenterally, maximum 20 mg/week
45934398|NCT00202891|Drug|sisomicin|
45934399|NCT00038714|Drug|SGN-00101|
45934400|NCT00202969|Drug|S-1|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 28 repeated 6 weeks.
45803857|NCT03340805|Drug|Normal saline|"Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride."
45934401|NCT00202969|Drug|S-1 plus CDDP|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 21 with a single dose of CDDP 60 mg/m2 will be administered as an 1- to 3-hour IV infusion following the morning dose of S-1 on Day 8. The combination therapy will be repeated every 5 weeks.
45934402|NCT00202969|Drug|5-FU plus CDDP|5-FU 600 mg/m2/24 hours administered intravenously as a CI over 120 hours (Days 1 through 5) along with a 30-minute infusion CDDP 20 mg/m2 from Day 1 through Day 5. The control treatment arm will be repeated every 4 weeks.
45803858|NCT03838484|Drug|Nicotine Patch, 7 Mg/24 Hr|Nicotine patch, 7 mg/24 hour will be applied to the skin.
45652813|NCT05104671|Other|Thoracic manipulation.|• Thoracic Thrust Manipulation: The participants were in high sitting and in prone lying position. The therapist was standing next to the patient in a diagonal stance and also behind the patient during high sitting. Thoracic thrust manipulation demonstrated to manipulate specific thoracic segment mainly mid thoracic.
45934403|NCT00203125|Drug|rasagiline mesylate|0.5 or 1 mg oral, once-daily
45803859|NCT03838484|Drug|Placebo patch|Placebo skin patch will be applied to the skin.
45652814|NCT05104671|Other|Myofascial release.|The subject will be treated with IASTM.applied to the pectoral muscles and medial brachium with the subject in supine and the glenohumeral joint(GH). placed in 120 º abduction to place adequate tension on the selected tissues in the style of pectoral tightness test .The IASTM technique was performed for 20 seconds parallel to the muscle fibers followed by 20 seconds perpendicular to the muscle fibers with the instrument held at a 45 º angle to the skin.The same IASTM protocol of 20 seconds parallel to the muscle fibers and 20 seconds perpendicular to the muscle fibers was applied to the posterior cuff musculature of the GH joint with the subject in prone and arms in 90 º abduction and internal rotation draped over the side of the plinth . While in the same position, the technique was applied to the periscapular musculature including the, trapezoids, rhomboids, teres minor, teres major, and latissimus dorsi.
45803860|NCT02357173|Other|electronic cigarette|
45803861|NCT02357173|Other|cigarette group|
45803862|NCT03336008|Other|no intervention|No intervention but clinical assessement for all recruited subjects
45803863|NCT02357485|Biological|ADSC|Single injection of ADSC
45452063|NCT01254136|Drug|Trastuzumab|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
45803864|NCT03307616|Biological|Ipilimumab|Given IV
45803865|NCT03307616|Biological|Nivolumab|Given IV
45803866|NCT03307616|Radiation|Radiation Therapy|Undergo radiation therapy
45803867|NCT05721872|Combination Product|D-isoascorbic Acid (D-VC) With Arsenic Trioxide (ATO)|"After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I.~Phase 1 - Scheme 1 - single intravenous administration in monotherapy with dose escalation (0.05, 0.1, 0.15 g/kg/day); Scheme 2 - single intravenous administration in the mode of sequential administration with arsenic trioxide with dose escalation of D-isoascorbic acid (0.05, 0.1, 0.15 g/kg/day).~Phase 2 - Study group 1: After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I for at least 15 patients."
45803868|NCT05721872|Drug|FOLFOX/FOLFIRI regimen|"FOLFOX - oxaliplatin 85mg/m2 1 day Leucovorin 200mg/m2 IV 2h, 1, 2 days 5 - Fluorouracil 400mg/m2 IV bolus, 1, 2 days 5 - Fluorouracil 600mg/m2 IV 22h, 1, 2 days~FOLFIRI Irinotecan 180 mg/m2 IV Leucovorin 400 mg/m2 IV Fluorouracil bolus 400 mg/m2 IV Fluorouracil infusional 2400 mg/m2 IV Courses are held every 2 weeks"
45803869|NCT02408965|Drug|Methergine|0.2 mg of methylergonovine maleate
45803870|NCT02408965|Other|placebo|saline placebo to maintain blinding
45803871|NCT03299426|Biological|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Single 0.5-ml intramuscular injection
45803872|NCT03299426|Biological|Meningococcal A Conjugate Vaccine (MCV-A)|Single intramuscular injection. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.
45803873|NCT03246932|Behavioral|Peer-led psycho-education group|A structured, researcher-designed peer-led psycho-education program (6 months), comprising of 12 bi-weekly, 2-hour group sessions.
45934404|NCT00203125|Other|tyramine|50 mg once daily
45934405|NCT00038753|Procedure|Vision Screening|
45934406|NCT00203164|Drug|rasagiline mesylate|rasagiline mesylate 1 mg oral once daily
45934407|NCT00203281|Drug|tacrolimus|
45934408|NCT00203281|Drug|mycophenolate mofetil|
45934409|NCT00203281|Drug|daclizumab|
45934410|NCT00203281|Drug|intravenous immune globulin|
45934411|NCT00203281|Procedure|plasmapheresis|
45934412|NCT00071877|Drug|Replagal|
45934413|NCT00203320|Drug|etanercept given by perispinal administration|
45934414|NCT00038792|Drug|Recombinant Human Keratinocyte Growth Factor|
45934415|NCT00203359|Drug|etanercept given by perispinal administration|
45934416|NCT00410566|Drug|rhASM|Single dose of 0.03mg/kg body weight IV
45934417|NCT00410566|Drug|rhASM|Single dose of 0.1mg/kg body weight IV
45934418|NCT00410566|Drug|rhASM|Single dose of 0.3mg/kg body weight IV
45934419|NCT00410566|Drug|rhASM|Single dose of 0.6mg/kg body weight IV
45652815|NCT04792619|Other|Bobath Approach|The patients in both groups were treated with the exercise program according to the Bobath concept was planned taking the functional needs of the survivors into account, including stretching and facilitation of latissimus dorsi muscle, facilitation of abdominal muscles, placing exercises, training of lumbar spine stabilizers, functional reach of shoulder in different directions. Five sessions of about an hour each were provided to the patients
45652816|NCT04792619|Other|Isometric scapular exercises|Isometric scapular exercises were performed to the patients included to the study group in a sitting position and at 900 of the shoulder flexion and 900 of the shoulder abduction. The patients were exercised by a physiotherapist using isometric contraction in protraction and retraction by a physiotherapist. Isometric contractions lasted 5 seconds and each exercise was repeated 2x15 times. One minute rest period was given between sets
45803874|NCT03246932|Behavioral|Profession-led psycho-education group|A psychoeducation group program (12 sessions, bi-weekly).
45803875|NCT03246932|Other|Routine psychiatric care|Routine psychiatric outpatient care, or Treatment-as-usual (TAU).
45803876|NCT05721794|Other|A multicentric prospective observational longitudinal cohort study.|Observational study on the accuracy of TPUS and MRI in the investigation of perianal fistulae in CD patients.
45803877|NCT02409277|Other|Experimental: Standard vs Intensive e-AT Intervention|Patients will be self-monitoring their symptoms weekly using the e-AT, either the Standard or Intensive versions of the e-AT, completing the Asthma Control Test. As patients complete their assessments each week, the clinics will be able to see how each patient is doing, and follow-up when a patient is showing high symptoms for that week, potentially avoiding Emergency Room visit, and/or hospitalization.
45803878|NCT03220022|Drug|Cyclophosphamide|Given IV
45803879|NCT03220022|Drug|Doxorubicin Hydrochloride|Given IV
45803880|NCT03220022|Drug|Etoposide|Given IV
45803881|NCT03220022|Biological|Filgrastim|Given SC
45803882|NCT03220022|Drug|Ibrutinib|Given PO
45803883|NCT03220022|Other|Laboratory Biomarker Analysis|Correlative studies
45803884|NCT03220022|Biological|Pegfilgrastim|Given SC
45803885|NCT03220022|Other|Pharmacological Study|Correlative studies
45803886|NCT03220022|Drug|Prednisone|Given PO
45803887|NCT03220022|Biological|Rituximab|Given IV
45803888|NCT03220022|Drug|Vincristine Sulfate|Given IV
45934420|NCT00410566|Drug|rhASM|Single dose of 1.0mg/kg body weight IV
45652817|NCT05204667|Drug|380 mg/300 mg comprimidos metocarbamol/paracetamol - 4 times daily|(2 oral tablets 4 times/day up to 7 days (i.e., every 6 hours±1 hour). Ingestion of the tablets can be helped with a small amount of water.
45803889|NCT02410291|Other|Educational video|Patients in the control group will receive standard patient education Patients in the experimental group will receive standard education and an educational video
45803890|NCT05721560|Device|Rotator cuff repair with the SINEFIX|Treatment of rotator cuff lesions of size up to 2 cm using the SINEFIX implant and instruments
45803891|NCT03216356|Behavioral|CBT + ImRs|Cognitive Behavioral Therapy with Imagery Rescripting
45803892|NCT03216356|Behavioral|CBT + I.E.|Cognitive Behavioral Therapy with Imagery Exposure
45803893|NCT03216356|Drug|D-Cycloserine|250 mg DCS (derived from Seromycin 250 mg capsules)
45803894|NCT03216356|Drug|Placebo|polyethylene glycol 3350 powder
45803895|NCT03216356|Drug|Study Pill|250 mg DCS (derived from Seromycin 250 mg capsules) or polyethylene glycol 3350 powder
45803896|NCT03330275|Device|Investigational Contact Lens|JJVC senofilcon A-based contact lens with new UV-blocker
45803897|NCT03330275|Device|Commercial ACUVUE OASYS|senofilcon A
45803898|NCT03330275|Device|Commercial ACUVUE OASYS and Spectacles|Senofilcon A and Spectacles
45803899|NCT02411929|Drug|Unlabeled ertugliflozin for oral use|15 mg oral (3 x 5 mg tablets)
45803900|NCT02411929|Drug|14^C-labeled ertugliflozin for IV use|100 µg (10 µg/mL solution IV) containing approximately 400 nCi 14^C (ie, radiolabeled ertugliflozin)
45934421|NCT00410644|Drug|OROS Hydromorphone HCI|
45934422|NCT00410683|Other|clinical observation|
45934423|NCT00410683|Procedure|adjuvant therapy|
45934424|NCT00410683|Radiation|3-dimensional conformal radiation therapy|
45934425|NCT00038831|Drug|Mylotarg|Starting dose 2 mg/m^2 over 2-hour intravenous infusion on day -12.
45934426|NCT00038831|Drug|Fludarabine|30 mg/m^2 will be given intravenously daily at the same time over 30 minutes on days -5, -4, -3, -2.
45803901|NCT02411929|Drug|14^C-labeled ertugliflozin for oral use|100 µg (10 µg/mL solution oral) containing approximately 400 nCi 14^C (ie, radiolabeled ertugliflozin)
45803902|NCT05715632|Drug|Carrelizumab combined with XELOX|Before surgery, the patient received standard dose of carrelizumab combined with XELOX regimen for 4 courses of treatment, and within 3-4 weeks after the completion of the fourth administration, preoperative imaging examination was conducted to evaluate the efficacy of new adjuvant treatment and the possibility of radical D2 resection, and to receive radical hand surgery for gastric cancer
45803903|NCT05721404|Drug|Icodextrin Peritoneal Dialysis Solution|Icodextrin (Extraneal) for long night dwell
45803904|NCT05721404|Drug|Hypertonic Dextrose solution|Hypertonic Dextrose solution for long night dwell
45803905|NCT00356954|Drug|N-acetylcystein|
45803906|NCT00356954|Drug|ascorbic acid|
45803907|NCT05721326|Other|Sequential EHR Communications|The intervention includes 3 message types: an EHR message, followed by a text message, followed by physician nudge. Each subsequent type will be activated if the previous type does not yield a response.
45803908|NCT05715554|Other|Homeopathy|Individualized homoeopathic medicines on impregnated lactose pellets was prescribed based on totality of physical, emotional, and mental symptoms.
45803909|NCT02358889|Biological|hI-con1|Intravitreal injection of hI-con1 0.3 mg
45803910|NCT02358889|Biological|ranibizumab|Intravitreal injection of ranibizumab 0.5 mg
45934427|NCT00038831|Drug|Melphalan|140 mg/m^2 will be given intravenously over 20 minutes starting 2 hours after the beginning of the fludarabine infusion on day -2.
45934428|NCT00038831|Drug|Anti-thymocyte globulin|Patients with an unrelated or mismatched related donor will receive 0.5 mg/kg on day -3 and 1.25 mg/Kg on days -2 and -1, following the chemotherapy.
45934429|NCT00038831|Procedure|Stem cell transplant|Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation: Infusion of blood stem cells or bone marrow cells on day 0.
45934430|NCT00410722|Dietary Supplement|Whole wheat and bran muffin|
45934431|NCT00410722|Dietary Supplement|Mixed tree nuts|
45934432|NCT00203515|Device|Standard Latex Foley Catheter|
45934433|NCT00203515|Device|Silver Coated Latex Foley Catheter|
45934434|NCT00071955|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
45934435|NCT00071955|Biological|sargramostim|
45934436|NCT00203554|Genetic|Poly methylmetacrylate, PMMA|
45934437|NCT00038870|Biological|Dendritic Cell Activated Lymphocyte|
45934438|NCT00203593|Behavioral|Exercise|
45803911|NCT02358889|Other|Sham injection|No injection is given, a needleless syringe is used to mimic an injection.
45934439|NCT00203593|Device|Blood volume|
45934440|NCT00203593|Procedure|VO2max test|
45934441|NCT00203593|Procedure|Lower body negative pressure|
45934442|NCT00203593|Behavioral|Heart Rate|
45934443|NCT00203593|Procedure|Blood Pressure|
45803912|NCT02978924|Device|tsDCS|20 min of treatment applied at the thoracic level (active electrode) with reference placed on the right shoulder
45934444|NCT00203593|Behavioral|Total Peripheral Resistance|
45934445|NCT00203632|Drug|rosiglitazone/placebo|
45934446|NCT00071994|Drug|gefitinib|Given orally
45934447|NCT00071994|Other|laboratory biomarker analysis|Correlative studies
45934448|NCT00203710|Device|Concentric Retriever Device|
46073546|NCT04242030|Other|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm."
45452064|NCT01254136|Drug|Vinorelbine|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
45803913|NCT03173534|Device|WATCHMAN|WATCHMAN Device is composed of a self-expanding nitinol structure with a porous membrane on the proximal face. The implant device is delivered to the Left Atrial Appendage by femoral venous access and transseptal puncture to enter the left atrium.
45803914|NCT03173534|Device|TAVR|Transcatheter Aortic Valve Replacement
45934449|NCT00038909|Drug|BDDrFVII|
45934450|NCT00203749|Behavioral|Community-Based HIV VCT|"COMMUNITY MOBILIZATION. This component of the intervention uses community outreach to enhance the uptake of VCT, thus increasing the rate of HIV testing and frequency of discussions about HIV and reducing stigma through community education and mobilization.~EASY ACCESS TO VCT. This component is designed to remove practical barriers and increase safety of VCT. Mobile vans or temporary units set up at local community sites will provide free, anonymous VCT in specific, chosen sites where people gather, such as market areas, shopping centers, and community centers.~POST-TEST SUPPORT SERVICES. This component is designed to build psychosocial support to improve the quality of life for individuals diagnosed with HIV. The expected outcomes include a reduction in social harm, an increase in social support through disclosure to those most likely to provide support, and a reduction in internalized stigma. Social support should also decrease the behavioral risk of further transmission."
45934451|NCT00203749|Behavioral|Standard clinic-based VCT|Control communities will receive Standard Clinic-Based VCT (SVCT) instead of the community-based VCT (CBVCT) intervention. Each of these communities will have access to SVCT that reflects local access to health care. The training for VCT counselors will be the same in the CBVCT and SVCT communities; however, no active recruitment for participation in the SVCT services will be made beyond the standard procedures of each clinic for informing patients of services (e.g., telling individual patients that VCT is available, posting of a flyer in the clinic announcing VCT availability, etc). As such, no active outreach or community mobilization will be conducted by the study staff in the SVCT settings (although it is possible that such activities will occur due to local initiative).
45934452|NCT00203788|Behavioral|Individual Placement and Support|Supported education/employment
45934453|NCT00203788|Behavioral|Workplace Fundamentals Module|Group skills training on job/school topics
45934454|NCT00203788|Behavioral|Brokered Vocational Rehabilitation|Vocational rehabilitation through traditional separate state-funded agency
45934455|NCT00203788|Drug|Oral risperidone|Risperidone, starting target dosage was 6 mg, adjusted to level judged optimal by treating psychiatrist
45934456|NCT00203788|Behavioral|Skills training group|Group social skills training that did not focus primarily on work situations
45934457|NCT00072033|Drug|Cisplatin and Docetaxel|cisplatin and docetaxel chemo- and radiochemotherapy
45934458|NCT00397007|Behavioral|Biofeedback-based cognitive-behavioural intervention|
45934459|NCT00203866|Drug|G250 peptide|
45934460|NCT00203866|Drug|IL-2|
45934461|NCT00203905|Drug|5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab|Hydroxyurea at 500 mg PO q 12 hours x 6 days; Bevacizumab at 10 mg/kg as a 90-minute infusion; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
46073547|NCT04242030|Device|Laser doppler flowmetry|Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena for the Heart meridian and Lung meridians.
45934462|NCT00203905|Drug|5-Fluorouracil, Hydroxyurea-[FHX]|Hydroxyurea at 500 mg PO q 12 hours x 6 days; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
45652818|NCT05204667|Drug|380 mg/300 mg comprimidos metocarbamol/paracetamol - 6 times daily|(2 oral tablets 6 times/day up to 7 days (i.e., every 4 hours±1 hour). Ingestion of the tablets can be helped with a small amount of water.
45934463|NCT00203944|Behavioral|Behavioral, Development|
45934464|NCT00072072|Drug|celecoxib|
45934465|NCT00072072|Drug|erlotinib hydrochloride|
45934466|NCT00204022|Drug|Mycophenolate mofetil|Mycophenolate mofetil
45934467|NCT00204022|Drug|Azathioprine|Azathioprine
45934468|NCT00204061|Behavioral|Supportive management|The needs-focused intervention could include psychoeducation, crisis intervention, family counselling and assistance with education or work-related difficulties, according to need. Regular psychotherapy was not permitted.
45934469|NCT00204061|Drug|Amisulpride|Daily doses could range from 50 to 800 mg, with increments of 50 mg at first step and 100 mg at further steps. As a guideline, it was suggested that the dosage be increased as long as attenuated or brief limited intermittent positive symptoms were present. The interval between such steps should be at least 14 days if brief limited symptoms were absent and the APS score had improved.
45652819|NCT04801199|Drug|CPL-2009-0031 140 mg|Patients will receive OD CPL-2009-0031 140 mg for 36 weeks with or without breakfast with a glass of water.
45652820|NCT04801199|Drug|Sitagliptin 100mg|Patients will receive OD Sitagliptin 100 mg for 36 weeks with or without breakfast with a glass of water.
45652821|NCT05104359|Other|Observational|HIV-positive versus HIV-negative patients, individuals with at least 2 measurements of antibody levels, and boosted individuals are the subgroups of interest.
45652822|NCT05102877|Device|Neuromuscular electrical stimulation|Motor stimulation was administered at an intensity sufficient to produce muscle contractions. Sensory stimulation was defined as the threshold when the patient feels a tingling sensation on their skin.
45652823|NCT04340141|Drug|Oxaliplatin|Given IV
45652824|NCT04340141|Drug|Irinotecan Hydrochloride|Given IV
45652825|NCT04340141|Drug|Leucovorin Calcium|Given IV
45652826|NCT04340141|Drug|Fluorouracil|Given IV
45652827|NCT04340141|Procedure|Resection|Undergo surgical resection
45652828|NCT04340141|Other|Questionnaire Administration|Ancillary studies
45652829|NCT05154357|Other|Elastic Sac|Half an hour before the feeding time, the infant will be placed in the elastic sac, be laid in the right lateral position within the nest with an angle of 45 degrees and will be allowed to take a rest within the elastic sac for half an hour. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.
45652830|NCT05154357|Other|Control|Half an hour before the feeding time, the infant will be laid in the right lateral position within the nest with an angle of 45 degrees without performing any different application and will be allowed to take a rest. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.
45934470|NCT00038987|Biological|Wetvax (APSV)|
45934471|NCT00204100|Device|Surface Functional Electrical Stimulation|
45652831|NCT05153421|Device|All'InCath CBC 035M Balloon Dilatation Catheter|Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography with single balloon dilatation catheter.
45652832|NCT05203575|Behavioral|Fast-forwarding in Cycle 1|"The fast-forwarding intervention will consist of a projection of future risk of co-morbidities. A visual projection model will be built using archival data available through the Singapore Diabetes Registry. The projection model will use the current profile of the participant to calculate a risk profile for the participant's potential complications and co-morbidities, which will be presented as a pie chart. The tool will also present alternative scenarios to the participant and visualize how the likelihood of complications or co-morbidities would decrease or increases if his/her habits changed. This will provide the motivational aspect of the intervention.~This intervention takes place during Cycle 1 (first 14 weeks)."
45652833|NCT05203575|Behavioral|Goal-Setting plus Weekly Nudge in Cycle 1|"The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 1 (first 14 weeks)."
45934472|NCT02966652|Drug|DITEST|Lipid formulation of native oral testosterone.
45934473|NCT02966652|Drug|Testosterone undecanoate|Generic treatment for patients with primary or secondary male hypogonadism
45934474|NCT00204139|Procedure|Routine midtrimester pregnany ultrasound scan|
45934475|NCT00204178|Behavioral|Oxidative stress in kidney transplant recipients|
45934476|NCT00204217|Device|endotracheal intubation|
45934477|NCT00039026|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
45934478|NCT00039026|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
45934479|NCT00039026|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
45934480|NCT00039026|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
45934481|NCT00204256|Drug|Iron sucrose|
45934482|NCT00204295|Drug|O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET) - PET|
45934483|NCT00204334|Drug|darbopoeitin|
45934484|NCT00072111|Biological|anakinra|
45934485|NCT00204412|Dietary Supplement|Flax lignan|543 mg SDG per day
45934486|NCT00204412|Behavioral|Exercise (walking)|walking 45 minutes per day 5 days per week
45934487|NCT00204451|Drug|0.75 levonorgestrel|
45934488|NCT00204451|Drug|50 mg ethinyl estradiol/0.5 mg levonorgestrel|
45934489|NCT00204529|Drug|pegylated interferon-alpha-2a|
45934490|NCT00204529|Drug|interferon-alpha-2a|
45934491|NCT00039104|Drug|rebimastat|Given PO
45934492|NCT00039104|Drug|zoledronic acid|Given IV
45934493|NCT00039104|Other|laboratory biomarker analysis|Correlative studies
45803915|NCT03524365|Procedure|RYGB|Roux-&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament , through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy. Lifestyle modification counselling is provided to each patient.
45804183|NCT05437159|Behavioral|Learning of non-native phoneme combinations: 8 training sessions|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During each training session, the participant will practice producing a set of 3 stimuli (the Fully Learned stimuli). Each of the 3 Fully Learned stimuli will be produced 120 times over the 8 training sessions.
45934494|NCT00204568|Drug|Adriamycin|60 mg/m2, d1, W d22
45652834|NCT05203575|Behavioral|Fast-forwarding in Cycle 2|"The fast-forwarding intervention will consist of a projection of future risk of co-morbidities. A visual projection model will be built using archival data available through the Singapore Diabetes Registry. The projection model will use the current profile of the participant to calculate a risk profile for the participant's potential complications and co-morbidities, which will be presented as a pie chart. The tool will also present alternative scenarios to the participant and visualize how the likelihood of complications or co-morbidities would decrease or increases if his/her habits changed. This will provide the motivational aspect of the intervention.~This intervention takes place during Cycle 2 (second 14 weeks)."
45652835|NCT05203575|Behavioral|Goal-Setting plus Weekly Nudge in Cycle 2|"The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 2 (second 14 weeks)."
45934495|NCT00204568|Drug|Trofosfamide|300 mg absolute d1-7, followed by 150 mg absolute continuously
45652836|NCT05445791|Drug|Metformin Hydrochloride|Metformin 500 mg twice daily until disease progression.
45934496|NCT00072150|Drug|bortezomib|Given IV
45934497|NCT00204607|Biological|mRNA|
45934498|NCT00204607|Drug|GM-CSF s.c.|
45934499|NCT00204646|Drug|Adriamycin|
45934500|NCT00204646|Drug|Ifosfamide|
45934501|NCT00204646|Drug|Etoposide|
45934502|NCT00204646|Drug|Carboplatin|
45934503|NCT00204685|Drug|dornase alfa|
45934504|NCT00039182|Drug|erlotinib hydrochloride|Given orally
45934505|NCT00039182|Other|laboratory biomarker analysis|Correlative studies
45934506|NCT04730661|Diagnostic Test|Sit to stand test|"The sit to stand test (or STST) is a test consisting of performing as many sit-to-stand tests as possible in one minute, from a chair without armrests.~We note before and during this test, the SpO2 (pulsed oxygen saturation) (rest value and minimum value during exercise), heart rate (HR), dyspnea on the modified Borg scale as well as the number of chair lifts performed. completely and minimum SpO2 during the recovery phase.~The possible results from this one-minute test are as follows:~If SpO2 <90% or appearance of signs of respiratory distress: Immediate stop of the test and hospitalization~SpO2 <90% or decrease in SpO2 ≥ 4% during the test or during the recovery period: Hospitalization~SpO2 ≥90% and no decrease in SpO2 ≥ 4% during the test or during the recovery period which will be 3 minutes maximum: discharge."
45652837|NCT05445791|Other|Placebo|Placebo 500 mg twice daily until disease progression
45652838|NCT05152875|Other|biological|fungal colonization by weekly cultures
45934507|NCT00204763|Device|Air filled balloon catheter|The new air filled balloon catheter will be tested against the solid state catheter
45934508|NCT00204763|Device|Solid state catheter|The standardly used solid state catheter will be tested against the new air filled balloon catheter
45934509|NCT00204802|Behavioral|Patient-Centered Advance Care Planning|
45934510|NCT00039299|Biological|therapeutic autologous lymphocytes|
45934511|NCT04730310|Procedure|NSQIP Lower Extremity Open (LEO) procedure-targeted dataset (i.e. undergoing Lower extremity open revascularization) from 2014-2019|Infrainguinal, open lower extremity revascularization procedures
45934512|NCT00410839|Procedure|ALA rich diet|
45934513|NCT00410878|Drug|OROS Hydromorphone HCI (slow release)|
45934514|NCT00410995|Drug|Naproxen|
45934515|NCT00039338|Procedure|conventional surgery|Radial hysterectomy
45934516|NCT00039338|Procedure|neoadjuvant chemotherapy|Experimental arm: minimal cumulative cisplatin dose of 225 mg/m2. Comparator arm: cumulative cisplatin dose of 200-240 mg/m2.
45934517|NCT00039338|Radiation|brachytherapy|Brachytherapy at the end of external radiation. Minimal total dose (external with or without external boost + brachytherapy) of 75 Gy EQD2 to point A. Overall treatment less than 50 days.
45934518|NCT00039338|Radiation|radiation therapy|Between 45-50 Gy, in fractions of 1.8 to 2 Gy.
45934519|NCT00039338|Drug|cisplatin|Minimal cumulative 225 mg/m2 (experimental arm). Cumulative 200-240 mg/m2 (comparator arm).
45934520|NCT00072228|Drug|gemcitabine|
45934521|NCT00072228|Drug|soblidotin|
45934522|NCT00072228|Procedure|chemotherapy|
45934523|NCT00204919|Drug|Vitamin D|once-monthly vitamin D oral capsules (50,000 units)
45934524|NCT00204919|Drug|placebo|once-monthly placebo capsules
45934525|NCT00204958|Drug|nutritional supplement|
45934526|NCT00204958|Drug|glutamine popsicle|
45934527|NCT00204997|Procedure|Laparoscopic ovarian transposition|Laparoscopic ovarian transposition
45652839|NCT04801277|Procedure|Electroacupuncture on acupoints vs sham points|Randomized double blinded clinical trial
45934528|NCT00072267|Drug|7-hydroxystaurosporine|
45934529|NCT00072267|Drug|topotecan hydrochloride|
45934530|NCT00039416|Drug|imatinib mesylate|Given orally
45652840|NCT05150457|Drug|BNA035|Anti-epidermal growth factor receptor (Anti-EGFR) and anti-cluster of differentiation 137 (anti-CD137) bispecific antibody
45934531|NCT00039416|Other|laboratory biomarker analysis|Correlative studies
46073548|NCT00834379|Drug|pravastatin sodium|40 mg Tablet
45652841|NCT05477277|Diagnostic Test|MAsS|Add MAsS to standard of care MRI scan
45652842|NCT04792229|Other|Whole Body Viberation|WBV device (frequency of 40 Hz), 3 Minute vibration with 3 minute rest
45652843|NCT05102175|Other|Focus Group|Eligible participants will be invited to a semi-structured focus group discussion. Each group will include 8 -12 participants.
45652844|NCT04800653|Procedure|Stellate ganglion block|Find the position of the stellate ganglion under ultrasound guidance, and inject 0.375% ropivacaine near the stellate ganglion to block the sympathetic nerves in the upper chest and head and neck
45803916|NCT03524365|Procedure|SG|The SG is created using a linear stapler with two sequential 4.8/60-mm green load firings for the antrum, followed by two or three sequential 3.5/60-mm blue loads for the remaining gastric corpus and fundus. The stapler is applied alongside a 48-Fr calibrating bougie. The resection line is performed avoiding the ''critical area'' by resecting the fundus 1.5 cm from the angle of His. Staple lines are buttressed with bovine pericardial strips. The resected stomach is grasped at the antral tip by a laparoscopic grasper and retrieved through one of the trocar sites. A methylene blue dye test by a nasogastric tube is routinely performed at the end of the procedure. The residual gastric remnant capacity is 60-80 ml. Drains are not routinely placed, and the nasogastric tube is removed at the end of the procedure. Upper gastrointestinal contrast (Gastrografin) study is performed on the first postoperative day. Lifestyle modification counselling is provided to each patient.
45934532|NCT00205114|Behavioral|Individualized multifactorial intervention for community-living high-risk older adults|
45934533|NCT00205114|Behavioral|Health professional education program about fall prevention|
45934534|NCT00205153|Behavioral|Pharmacy TEAM monitoring and counseling|Pharmacy team monitors and counsels patient using automatic BP monitors and special TEAM tools for assessing and improving patient adherence, barriers to adherence, lifestyle, drug therapy, BP control, and collaboration with physicians.
45934535|NCT00205192|Procedure|Cardiac resynchronization pacing|various pacemaker modes used over 1 hour
45934536|NCT00072345|Drug|lomustine|
45934537|NCT00072345|Drug|temozolomide|
46073549|NCT00834379|Drug|Pravachol®|40 mg tablet
46073550|NCT02825316|Behavioral|Mediterranean diet|Eight weeks course of Mediterranean diet (rich in plant-based food and low in animal protein and fat).
46073551|NCT02825316|Behavioral|Low residue diet|Eight weeks course of low residue diet (minimal consumption of foods that add residue to the stool, such as raw fruits, vegetables and seeds, as well as nuts, legumes and whole grains).
46073552|NCT02825004|Behavioral|Psychological Intervention|
46073553|NCT00834457|Drug|abacavir/3TC/zidovudine|continued use of oral co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg for 96 weeks
45652845|NCT05203263|Device|(810A-v1) device prototype|Sequence with Serial Number from (810-v1 101) to (810-v1 140). Application on brown spots located on the face (6 treatments during the study).
45652846|NCT05203263|Device|(810B-v1) device prototype|Sequence with Serial Number (810-v1 141) to (810-v1 160). Application on brown spots located on the face (6 treatments during the study).
45934538|NCT00072345|Drug|thalidomide|
45934539|NCT00039455|Biological|trastuzumab|Given IV
45934540|NCT00039455|Drug|alvocidib|Given IV
45934541|NCT00039455|Other|laboratory biomarker analysis|Correlative studies
45934542|NCT00039455|Other|pharmacological study|Correlative studies
45934543|NCT00205231|Drug|etanercept|
46073554|NCT00834457|Drug|abacavir /3TC plus ritonavir boosted lopinavir|fixed dose abacavir 600mg/3TC 300mg one tablet po QD for 96 weeks plus fixed dose ritonavir 33.3mg/lopinavir 133.3mg four tablets po QD for 96 weeks
46073555|NCT04242342|Radiation|Adaptative MR-Guided Stereotactic Body Radiotherapy|"If lesion near organs at risk:~Prescription of 50 Gy in 5 fractions of 10 Gy~3 sessions per week, with MRI guided stereotactic radiotherapy and daily adaptive treatment~If lesion far of organs at risk:~Prescription of 60 Gy in 6 fractions of 10 Gy~3 sessions per week, with MRI guided stereotactic radiotherapy without daily adaptive treatment"
46073556|NCT03851965|Diagnostic Test|Soluble Urokinase Plasminogen Activator Receptor|Preoperative and postoperative determination of the Soluble Urokinase Plasminogen Activator Receptor levels in patients undergoing non-cardiac major surgery.
46073557|NCT02823522|Other|Patients recruitment|Between July and November 2016, the patients included in the previous retrospective study were contacted by phone, mail and e-mail and invited to come back to the respective clinics where they had been initially diagnosed as NCWS patients: the Department of Internal Medicine of the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca (province of Agrigento).
46073558|NCT04241406|Device|Transcutaneous spinal cord stimulation|Electrodes are placed over the back for a 10 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing current intensity during 30 second and decrease intensity subsequentl
45652847|NCT05203263|Device|(810C-v1) device prototype|Sequence with Serial Number (810-v1 161) to (810-v1 200). Application on brown spots located on the face (6 treatments during the study).
45652848|NCT04800497|Procedure|Hepatic resection|Hepatic resection for HCC
45934544|NCT00205270|Drug|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly each season
45934545|NCT00205387|Procedure|cardiac elastography and echocardiography|standard echocardiogram
45652849|NCT04792307|Other|Neuromuscular electrical stimulation , no high protein ice cream supplementation|"A trained operator applies Neuromuscular electrical stimulation treatment to one leg, for approximately 30 minutes per session, three sessions per week with or without high protein ice cream. Treatment can stimulate the nerve controlling the vastus lateralis muscle in the thigh or the nerve controlling the tibialis anterior muscle in the lower leg, or both. In our study, we will aim to stimulate both nerves and muscle groups, on the basis that the maximal effect with result from the maximal amount of muscle stimulated.Treatment is adjusted to generate a specific force and maintained for up to 5 minutes, followed by a rest period and then repeated three times over the typical 30-minute session. The stimulation can vary according to the frequency (pulses per second, typically 10-50Hz).~Additional protein supplementation: high protein ice cream :a single doses of a high protein supplement after each bout of neuromuscular electrical stimulation,"
45934546|NCT04732091|Procedure|Therapeutic ultrasound with 20 usec|A custom designed high mechanical index (MI) impulses at 4-20 usec and >1.0 mechanical index designed for the 1.8 MHz S5-1 transducer
45803917|NCT03524365|Other|Intensive Lifestyle Modification|"Resting calorie requirements will be calculated via the Harris Benedict equation (24) and an activity factor, and subjects will be instructed not to change their activity level other than that suggested by physicians during the study. The diet will contain 1/3 kcal less than the calculated energy expenditure and 30% fat of which 10% saturated, 55% lower glycemic index carbohydrates and 15% proteins.~The participants will be encouraged to gradually increase their walking to achieve 10,000 steps per day. A moderate intensity physical activity program of 1 hour of aerobic exercise 2-3 hours per week will be recommended to all subjects. Their physical activity will be assessed by IPAQ-SF."
45803918|NCT05715476|Procedure|cesarian surgery|The same anesthesia protocol will be applied to the patient group at each altitude. In the sitting position, the spinal space was entered with a 25 gauge Quincke-tipped needle from the L4-5 space and a drop of CSF will be dripped onto the pH paper. Immediately afterwards, 12 mg of 0.5% hyperbaric bupivacaine will be given. The color formed on the pH paper will be noted. Sensory block level will be tested with pinprick test and motor block level will be evaluated with Modified Bromage scale. The number and duration of spinal anesthesia applications, the time of occurrence of sensory block in the T6 dermatome, the time to reach each score of the MB scale, the duration of the operation, the highest level of sensory block and anesthetic complications will be recorded. Sensory block time and motor block time of the patients followed in the service will be recorded.
45934547|NCT00072462|Drug|tamoxifen citrate|Tamoxifen 20mg + Anastrozole placebo
45934548|NCT00072462|Drug|Anastrozole|Anastrozole 1mg + Tamoxifen placebo
45934549|NCT00205426|Drug|Natrecor|Natrecor will be initiated as a bolus dose of 2 mcg/kg followed by a continuous infusion via infusion pump after induction of anesthesia but prior to incision. Natrecor infusion will be started at the recommended rate of 0.01mcg/kg/min. This dose may be adjusted by the investigator(s) only based on hemodynamic monitoring and pulmonary parameters. Study drug will be infused for a minimum of 24 hours and a maximum of 96 hours.
45934550|NCT00205465|Drug|VX-765|
45934551|NCT00205543|Procedure|uvulopalatopharyngoplasty with or without sutures|standard UPPP
45934552|NCT00039494|Drug|erlotinib hydrochloride|Given orally
45934553|NCT00039494|Radiation|3-dimensional conformal radiation therapy|
45652850|NCT05101473|Other|Exercise Therapy|The overall framework will consist of two supervised exercise sessions per week of 30-60 min duration for 12 weeks in order to be able to result in the physiological adaptions that are needed to improve the health of the individual participant.
45934554|NCT00039494|Drug|temozolomide|Given orally
45934555|NCT00205582|Device|Positron Emission Tomography|
45934556|NCT00205621|Device|Positron Emission Tomography|
45934557|NCT00205738|Drug|Risperidone, Olanzapine|
45934558|NCT00072501|Procedure|breast imaging study|
45934559|NCT00072501|Procedure|comparison of screening methods|
46073559|NCT02611635|Drug|VKA: Warfarin (Waran)|VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
45652851|NCT05101161|Behavioral|Neurofeedback|Modulating brain oscillations based on visual neurofeedback
45934560|NCT00072501|Procedure|magnetic resonance imaging|
45934561|NCT00072501|Procedure|radiomammography|
45934562|NCT00072501|Procedure|ultrasound imaging|
45934563|NCT00205816|Drug|Tigecycline|
45934564|NCT00205894|Device|bion microstimulator|
45934565|NCT00205972|Device|Humerus Nail or LC Plate|
45934566|NCT00072540|Drug|celecoxib|
45934567|NCT00072540|Procedure|anti-cytokine therapy|
45934568|NCT00072540|Procedure|antiangiogenesis therapy|
45934569|NCT00072540|Procedure|biological therapy|
45934570|NCT00072540|Procedure|cancer prevention intervention|
45934571|NCT00072540|Procedure|chemoprevention of cancer|
45934572|NCT00072540|Procedure|enzyme inhibitor therapy|
45934573|NCT00072540|Procedure|growth factor antagonist therapy|
45934574|NCT00206011|Procedure|Endoscopic surgery|Open surgical intervention compared to endoscopic intervention
45934575|NCT00039572|Drug|boronophenylalanine-fructose complex|
45934576|NCT00206050|Drug|Esomeprazole|
45934577|NCT00206050|Drug|pantoprazole|
45934578|NCT00206089|Drug|EXANTA|
45934579|NCT00072579|Biological|sargramostim|
45934580|NCT04732247|Drug|Oxytocin nasal spray|Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
45934581|NCT04732247|Drug|Placebo nasal spray|Intranasal treatment with placebo via nasal spray
45934582|NCT00206128|Drug|Seroquel SR|
45803919|NCT03499327|Dietary Supplement|Wheat germ oil (UV treated)|"Wheat germ oil is naturally rich in vitamin D precursors (ergosterol and 7-dehydrocholesterol), which are converted into vitamin D2 and vitamin D3 by a defined UV light irradiation for the present study (wheat germ oil (UV treated).~The wheat germ oil (UV treated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal."
45652852|NCT04800419|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT is a third generation cognitive behavioral approach which uses acceptance and mindfulness processes, and commitment and behavior change processes to produce psychological flexibility. ACT increase adaptive coping through acceptance, cognitive defusion, mindfulness, and perspective-taking exercises while supporting cancer survivors in aligning behavior with their personal values. The objectives of the therapy are for client to learn to focus on behaviors and actions that are in line with their individual values - the things they care about most. ACT facilitates development and maintenance of health behavioral improvements by targeting internal barriers, such as emotional discomfort and self-defeating thoughts, and by fostering connection and commitment to personal values associated with self-management of positive health behaviors. ACT is useful in cancer patients, because it can help them to deal with the negative emotions caused by cancer instead of avoiding these.
45652853|NCT04800419|Behavioral|Mindfulness-based Stress Reduction (MBSR)|The term 'mindfulness' refers to mindful awareness as a way of being - a knowing and experiencing of feelings, thoughts, and perceptions as they arise and pass away each moment. It is a way of relating to all experiences in an open, receptive way, without judging experiences as good or bad (grasping at them or pushing them away). Mindfulness employed two styles of meditations: concentrative meditation involves intentionally focusing attention on a chosen object (e.g. the sensations of breathing) in a sustained way, while receptive meditation involves monitoring the content of experience (e.g. sensations, emotions, thoughts, sounds, etc.) in a non-reactive and non-judgmental way, from moment to moment, with the goal being to recognize the nature of emotional and cognitive patterns. Mindfulness-based stress reduction (MBSR) is an 8-week, standardized group intervention consisting of mindfulness meditation and gentle yoga that is designed to have applications for stress, pain, and illness
45652854|NCT05336201|Behavioral|CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)|Manualized cognitive remediation intervention that includes 1) skills-based remediation (metacognitive training), 2) parent training, and 3) cognitive behavioral approaches. Intervention targets self-management and goal-setting skill building to promote independence in activities necessary for transition of care.
45803920|NCT03499327|Dietary Supplement|Wheat germ oil (untreated)|"commercial available wheat germ oil The wheat germ oil (untreated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal."
45803921|NCT05715398|Drug|BR790+anlotinib|BR790 will be administered orally, variable dose on Day 1 of each 21-day cycle， Anlotinib will be administered as PO fixed dose on Day1-14 of each 21-day cycle
45803922|NCT05715320|Biological|CM310|IL-4Rα monoclonal antibody
45934583|NCT00068211|Drug|ILX651|
45934584|NCT00206167|Drug|Budesonide/formoterol pMDI|
45934585|NCT00206167|Drug|Formoterol Turbuhaler|
45803923|NCT05715242|Behavioral|Core Behavioral Weight Loss Intervention|All participants will receive a 3-month core behavioral weight loss treatment consisting of: self-monitoring weight, steps, and food intake; behavioral lessons; action plans; and tailored feedback. The intervention will be delivered remotely via email and digital tools (such as a smart scale, Fitbit activity tracker, and Fitbit app).
45803924|NCT05715242|Behavioral|Easier Weight Loss Goal|Participants will receive an easier 3-month weight loss goal.
45934586|NCT00039611|Drug|FOLFOX regimen|
45934587|NCT00039611|Drug|fluorouracil|
45934588|NCT00039611|Drug|leucovorin calcium|
45934589|NCT00039611|Drug|oxaliplatin|
45934590|NCT00068289|Drug|bortezomib|
45934591|NCT00206206|Procedure|Hyperglycemia Protocol Procedure|
45934592|NCT00206245|Drug|AZD0865|
45934593|NCT00039767|Drug|Lepirudin|
45934594|NCT00072618|Drug|Exisulind|
45934595|NCT00206284|Drug|AZD0865|
45934596|NCT00072657|Behavioral|Cognitive Behavioral Therapy|The CBT intervention will have three phases: 1) education on the nature of the adjustment process in chronic illness, 2) coping skill development, and 3) generalization and application of skills to everyday situations. Participants in the CBT group will attend 12 weekly group sessions of about 2 hours each.
45934597|NCT00072657|Behavioral|Tai Chi Chih|Participants in the TCC group will learn to perform 18 movements under the guidance of an expert TCC teacher. TCC participants will have 50- to 60-minute biweekly sessions during the 12-week study.
45934598|NCT00072657|Behavioral|Health Education Seminar|Control group participants will attend weekly group educational sessions; these sessions will provide general knowledge about arthritis health and illness, and they will include lectures, demonstrations, and question-and-answer sessions with experts in rheumatology, sleep science, and behavioral medicine.
45934599|NCT00039884|Drug|NESP - Novel Erythropoiesis Stimulating Protein|
45934600|NCT00206401|Drug|Lantus and short acting analogs Vs NPH and short acting analogs|
45934601|NCT00399204|Drug|Pioglitazone vs Metformin|
45934602|NCT00411034|Drug|OROS Hydromorphone HCI|
45934603|NCT00411073|Drug|Darapladib|
45934604|NCT00411112|Procedure|blue and isotopic detection of sentinel lymph nodes|
45934605|NCT00068328|Procedure|psychosocial assessment and care|
45934606|NCT00068328|Procedure|quality-of-life assessment|
45934607|NCT00411190|Drug|Relacatib|Subjects will administer 60 or 120 mg tablets in Session 2
45934608|NCT00411190|Drug|Acetaminophen|Acetaminophen will be administered orally
45934609|NCT00411190|Drug|Ibuprofen|Ibuprofen will be administered orally
45934610|NCT00411190|Drug|Atorvastatin|Atorvastatin will be administered orally
45934611|NCT00411229|Drug|Capecitabine|1,000 mg/m² twice daily. Film coated tablets of 500 mg, 150mg.
45934612|NCT00411229|Drug|Oxaliplatin|IV infusion, 130mg/m²
45934613|NCT00411268|Drug|OROS hydromorphone HCI SR (slow release)|
45934614|NCT00039962|Drug|thymalfasin (thymosin alpha 1)|
45452065|NCT02268292|Behavioral|bicycle exercise|All enrolled subjects received a scheduled twelve-week exercise program. A commercially available bicycle (Giant CS800, Taichung, Taiwan) with an indoor bicycle stand (Giant Cyclotron Mag, Taichung, Taiwan) was used as the home exercise training modality.
45652855|NCT05100537|Behavioral|Mindfulness Based Stress Reduction|The intervention has its roots in meditations and yoga practices. However, it is independent of religious purpose or affiliation.The weekly sessions include a range of mental and bodily practices, including awareness of emotions, awareness of thoughts, awareness of sensations. It involves full awareness of daily activities, using the breath as an anchor for attention.In addition to mindfulness practices and experiential work, psychoeducation and participants' sharing will clarify the issues of stress, stress management and how mindfulness is applied in daily situations and interpersonal communication.
45803925|NCT05715242|Behavioral|Harder Weight Loss Goal|Participants will receive a more challenging 3-month weight loss goal.
45803926|NCT05715242|Behavioral|Easier Step Goal|Participants will receive an easier daily step goal.
45803927|NCT05715242|Behavioral|Harder Step Goal|Participants will receive a more challenging daily step goal.
45803928|NCT05715242|Behavioral|Easier Calorie Goal|Participants will receive an easier daily calorie goal.
45803929|NCT05715242|Behavioral|Harder Calorie Goal|Participants will receive a more challenging daily calorie goal.
45803930|NCT05715242|Behavioral|Easier Eating Window Goal|Participants will receive an easier daily eating window goal.
45803931|NCT05715242|Behavioral|Harder Eating Window Goal|Participants will receive a more challenging daily eating window goal.
45803932|NCT05721170|Drug|Beta blocker|Investigation on beta-blockers in TAVI and brief post-TAVI period.
45803933|NCT03134690|Procedure|delayed start|In this protocol, ovarian stimulation will be started from ninth day of menstrual cycle .
45803934|NCT03134690|Procedure|Conventional|In this protocol, ovarian stimulation will be started from the 2th or 3th day of the menstrual cycle.
45803935|NCT05721014|Other|OsteoStrong|"This training method is an isometric high-impact loading in four different training machines (Spectrum) and balance training on a vibration plate. The four machines are chest press, leg press, pull-down and deadlift. The participants press and/or pull isometrically for around 30 seconds once on every machine.~The training session takes around 20 minutes and is performed individually by the participants with the help of a training instructor."
45803936|NCT05721014|Other|Individually Adapted and Combined Physical Training|"This training method is based on the current recommendations on physical activity for people with osteoporosis. The training is individually adapted strength training combined with balance and weight-bearing exercises.~The training is divided into two training sessions:~Circuit training with ten stations with different exercises for the whole body (strength, balance, endurance, weight-bearing). The participants spend 40 seconds on each station. This is repeated during 40 minutes. The training session starts with a joint warm-up and ends with a cool-down.~Strength training with machines for the whole body with the intensity of up to 70-80 % of one repetition max (1RM). The training session starts with a joint warm-up and and a voluntary individual cool-down.~The training session takes around 60 minutes and is performed in a group with the help of a training instructor."
45934615|NCT00039962|Drug|PEGinterferon alfa-2a|
45934616|NCT00424333|Drug|Inhaled human insulin|
45652856|NCT05100537|Other|continuing a routine life|No intervention will be made in the control group.
45803937|NCT05714618|Diagnostic Test|Gadolinium-enhanced cardiac MRI|Cardiac magnetic resonance imaging (MRI) with a protocol designed to measure myocardial inflammation and fibrosis.
45934617|NCT00206557|Drug|Raloxifene|
45934618|NCT00206557|Drug|Estradiol/dyhydroprogestrone|
45934619|NCT00068484|Drug|topotecan hydrochloride|Given IV
45934620|NCT00068484|Drug|bortezomib|Given IV
45934621|NCT00068484|Other|pharmacological study|Correlative studies
45452066|NCT04476004|Other|scapular-focused exercise|scapular-focused exercise
45934622|NCT00068484|Other|laboratory biomarker analysis|Correlative studies
45934623|NCT00206596|Drug|Sargramostim (Leukine)|Once daily via subcutaneous injection for up 22 weeks
45934624|NCT00206596|Drug|Placebo|Once daily via subcutaneous injection for up 22 weeks
45934625|NCT00206635|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Betaseron was not administered as part of this study, only the treatment and disease status was assessed. As part of the MRI analysis Gadolinium was administered in patients who underwent this procedure
45934626|NCT00040001|Drug|DTI-0009|
45452067|NCT04476004|Other|visual feedback|EMG visual feedback
45452068|NCT02268370|Drug|Dasatinib|
45452069|NCT00039377|Drug|imatinib mesylate|Given PO
45452070|NCT00039377|Drug|methotrexate|Given IT and IV
45452071|NCT00039377|Drug|vincristine sulfate|Given IV
45452072|NCT00039377|Drug|leucovorin calcium|Given IV and PO
45452073|NCT00039377|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
45452074|NCT00039377|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
45452075|NCT00039377|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
45452076|NCT00039377|Radiation|total-body irradiation|Undergo TBI
45452077|NCT00039377|Drug|tacrolimus|Given IV or PO
45452078|NCT00039377|Biological|filgrastim|Given SC
45452079|NCT00039377|Drug|etoposide|Given IV
45452080|NCT00039377|Drug|cyclophosphamide|Given IV
45934627|NCT00206674|Drug|Sargramostim (Leukine)|6µg/kg SARGRAMOSTIM subcutaneous daily for 8 weeks
45934628|NCT00206674|Drug|Placebo|Sterile liquid solution, inactive excipient only subcutaneous daily for 8 weeks
45934629|NCT02966769|Other|Overall survival|Compare overall survival between both groups.
45934630|NCT00206713|Drug|Sargramostim (Leukine)|6 μg/kg sargramostim administered SC once daily for 8 weeks
45652857|NCT04800575|Device|semi-permeable film|Experiment group use semi-permeable film as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or or whenever the dressing is soiled, bloody, or fell off.
45803938|NCT05714618|Diagnostic Test|B Natriuretic Peptide|Measurement of B Natriuretic Peptide on patients' blood samples at 10 and 60+/-15 days.
45652858|NCT04800575|Device|sterile gauze and tape|Control group use sterile gauze and tape as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or whenever the dressing is soiled, bloody, or fell off.
45934631|NCT00206713|Drug|Placebo|Placebo administered SC once daily during the randomized retreatment phase.
45934632|NCT00040040|Drug|Bupropion|
45934633|NCT00206752|Radiation|Radiation therapy|definitive external beam radiation in the ipsilateral neck.
45934634|NCT00206752|Radiation|definitive external beam radiation in the ipsilateral neck|definitive external beam radiation in the ipsilateral neck
45934635|NCT00068523|Biological|anti-thymocyte globulin|anti-thymocyte globulin IV over 4 hours on days -2 to -1
45934636|NCT00068523|Drug|cyclophosphamide|cyclophosphamide IV over 1 hour on days -3 to -2
45934637|NCT00068523|Drug|cyclosporine|oral cyclosporine on days -1 to 100
45934638|NCT00068523|Drug|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
45803939|NCT05714618|Diagnostic Test|Systemic inflammatory markers|Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 10 and 60+/-15 days.
45803940|NCT03059264|Other|Natural history|Longitudinal disease progression
45652859|NCT05203029|Other|Online exercise|Patients in each group will be added to the specific group on Whatsapp, and the schedule and information about the exercise will be explained there. Furthermore, patients will be joined to particular pages on Instagram, and exercises will be performed through Live on that pages. All the patients will exercise for 12 weeks, two or three times every week.
45652860|NCT04349111|Radiation|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
45652861|NCT02634151|Drug|Gemcabene|Two 300 mg tablets and 1 placebo tablet administered orally, once daily for 12 weeks.
45652862|NCT02634151|Drug|Placebo|Three placebo tablets administered orally once daily for 12 weeks.
45652863|NCT04799951|Other|a survey questionnaire to find knowledge, attitude and practices in treatment of breast cancer.|an electronic webbased survey to assess knowledge, attitudes and practices amongst surgeons with regards to breast conservation surgery and mastectomy
45652864|NCT05202639|Other|Questionnaire|"A questionnaire will be sent by e-mail to the mother and to the father separately. A return of the completed questionnaire is expected within 6 weeks via a secure internal platform pertained to the HCL (Hospices Civils de Lyon).~The aim of this questionnaire is to identify the factors associated with the continuation or not of pregnancy after diagnosis of severe fetal pathology and after legal authorization of medical termination of pregnancy given by the Multidisciplinary Center of Prenatal Diagnosis."
45652865|NCT05324579|Behavioral|Behavioral testing during neuronal recordings|Participants undergoing clinically planned neurosurgical procedures will undergo single-neuronal recordings as they perform brief behavioral tasks.
45803941|NCT05713682|Procedure|alveolar ridge preservation|bone grafting at extracted sites
45803942|NCT05720858|Other|Aerobic exercise|Reciprocal straight leg lift, Reciprocal hip knee flexion-extension, Lateral spinal rotation (Spinal rotation), Bridge Exercise, Elbow winging, Hip abduction, trunk extension, Shoulder elevation, Shoulder circulation, Shoulder flexion and extension, Shoulder abduction adduction, Reciprocal lateral trunk flexion and extension, Puching exercise, Mini Squat exercise, Reaching upward with hands reciprocally, Scapular adduction (Hands at waist), Push-ups on the wall, Knee Touch exercise, Arm Circles exercise, Reaching for feet in sitting position, Saw (The saw) exercise.
45803943|NCT03038672|Biological|Nivolumab|Given IV
45934639|NCT00068523|Drug|methylprednisolone|methylprednisolone (oral or IV) on days 5-15
45652866|NCT05148039|Behavioral|Dietician advice|Personalised dietetic advice
45934640|NCT00068523|Procedure|UV light therapy|Patients undergo ultraviolet-B (UVB) light therapy every other day between days -10 and -2 for a total of 3 days. Posttransplantation UVB light therapy: Following PBSC transplantation, patients undergo UVB light therapy twice weekly on week 1 (at least 1 day apart) and three times weekly on weeks 2-4.
46073560|NCT02611635|Drug|NOAC: Rivaroxaban (Xarelto, BAY59-7939)|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
45652867|NCT05147337|Drug|E2511|E2511 tablets.
45652868|NCT05147337|Drug|Placebo|E2511 matched placebo tablets.
45652869|NCT04791917|Behavioral|Eccentric Biceps Flexion|Muscle lengthening biceps exercise
45652870|NCT04791917|Behavioral|Concentric Biceps Flexion|Muscle shortening biceps exercise
45652871|NCT04791605|Other|Gait analysis|Kinematic and kinetic analysis
45652872|NCT04791683|Other|sexaul counseling|Sexual counseling includes interviews about sexual problems in couples who are in the process of infertility treatment and suggestions for solving these problems.
45803944|NCT03038672|Drug|Varlilumab|Given IV
45803945|NCT03003572|Other|Blood samples|Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA).
45803946|NCT05711030|Procedure|Thoracic paravertebral block multiple (3) injections|already described in arm description
45934641|NCT00068523|Procedure|allogeneic bone marrow transplantation|
45934642|NCT00068523|Procedure|peripheral blood stem cell transplantation|Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo PBSC transplantation on day 0.
45934643|NCT00206791|Device|MBCP-Gel (tm)|
45934644|NCT00206830|Device|Triage Profiler S.O.B. Panel|
45934645|NCT00040157|Drug|ACH126-443 (Beta-L-Fd4C)|
45934646|NCT00206869|Behavioral|exercise|
45934647|NCT00206869|Behavioral|heat|
45934648|NCT00206869|Procedure|red light illumination|
45934649|NCT00072735|Procedure|Electrocardiogram|
45652873|NCT04799873|Drug|AAT( Alpha 1 Antitrypsin)|AAT administration based on clinical indication
45803947|NCT05711030|Procedure|Thoracic paravertebral block single injection|already described in arm description
45803948|NCT02957240|Behavioral|Standard Care|"This group will partake in 4 clinic-based intervention sessions (one 1-hr. and 3 subsequent 30-minute sessions) where the focus will be on home program competency/advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home program (3x daily, 15 minutes) to include 10 repetitions of active thumb opposition, active thumb radial abduction, intrinsic minus active stretches, flat fist and composite, finger extension, Elbow flexion and extension, Shoulder scapular rolls, and glenohumeral circumduction.~Edema will be addressed through strict elevation when at rest and every 10 minutes on the hour. When resting in a seated or supine position, clients will be instructed to use pillows to accomplish elevation and to keep elbows in an extended position. Instructions for elevation will be provided immediately following orthopaedic intervention. Strict elevation will be recommended for the first 72 hours of the injury."
45934650|NCT00206947|Drug|donepezil (5-10 mg/day)|Donepezil will be administered in a dose optimized for treatment, to patients who are stabilized on a ziprasidone treatment
45934651|NCT00206947|Drug|Placebo|Placebo will be added to the medication of schizophrenia patients who are first stabilized on a ziprasidone treatment
45934652|NCT00068757|Biological|trastuzumab|
45934653|NCT00068757|Drug|lonafarnib|
45934654|NCT00068757|Drug|paclitaxel|
45934655|NCT00068757|Other|pharmacological study|
45934656|NCT00206986|Drug|clonidine|Either placebo or 25 ug, 50 uG 75 ug or 150 ug of clonidine will be added to the current medication of patients with schizophrenia, who are stable on their current medication
45934657|NCT00206986|Drug|clonidine|0.15 mg of clonidine will be administered to 20 healthy male volunteers
45934658|NCT00207064|Drug|quetiapine|flexible doses according to the clinical condition
45934659|NCT00207103|Drug|Brivanib|Tablets, Oral, 180 mg, once daily, until disease progression
45934660|NCT00207103|Drug|Brivanib|Tablets, Oral, 320 mg, once daily, until disease progression
45934661|NCT00207103|Drug|Brivanib|Tablets, Oral, 600 mg, once daily, until disease progression
45934662|NCT00207103|Drug|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression
45652874|NCT05145699|Device|VR-based post-stroke hemineglect evaluation system|Evaluation system applied with virtual environment using Pico Neo 2 eye
45652875|NCT05201313|Drug|Lidocaine Hydrochloride|nebulization of 3 puffs of 10 mL Lidocaine hydrochloride 10% spray at a distance of 4-5 cm
45934663|NCT00207103|Drug|Brivanib|Tablets, Oral, 800 mg, once daily (5 days on, 2 days off), until disease progression
45934664|NCT00207103|Drug|Brivanab|Tablets, Oral, 1000 mg, once daily, until disease progression
45934665|NCT00040235|Procedure|magnesium|
45934666|NCT00072774|Drug|DVS-233 SR|
45934667|NCT00207220|Procedure|arterial tonometry|used to determine peripheral arterial vascular tone by measuring blood pressure waveforms via a probe attached to the finger.
45652876|NCT05201313|Drug|Mepivacaine Injection|subcutaneous / submucosal infiltration depending on the type of perineal tear of 10 ml of 1% mepivacaine hydrochloride
45652877|NCT05201001|Drug|APX005M|adding immunotherapy with or without radiation therapy to chemotherapy. Low dose radiation therapy is to sensitise tumour cells to immunotherapy.
45652878|NCT04888585|Drug|ABBV-154|Subcutaneous Injection
45652879|NCT04888585|Drug|Placebo|Subcutaneous Injection
45652880|NCT04799561|Behavioral|Multimodal Teleprehabilitation|"Exercise Prescription: patients will be instructed on how to perform aerobic exercise (5 times/week: minimum 30-minute/day) and resistance training (3 times/week: 2-3 sets of 6-8 exercises repeated 8-12 times) at home. Exercise counseling will be weekly, using the video-conferencing application (Zoom).~Nutrition: nutritional status and dietary intake will initially be assessed by the nutritionist using zoom. All patients will receive daily whey protein supplements. Special precautions will be considered if patients have specific medical conditions.~Psychosocial intervention: Patients will have access to 1.5 hours of mental relaxation and coping mechanisms session within the first week of enrolment, using Zoom.~Smoking Cessation: Patients with smoking habits will meet with a respiratory specialist using Zoom, who will establish recommendations and contact the physician for the recommended smoking cessation protocol.~More counseling sessions will be provided as needed."
45652881|NCT05199519|Drug|IBI345|IBI345 CAR-T cell injection by intravenous infusion
45934668|NCT00207220|Procedure|echocardiography|ultrasound test using sound waves to create a moving picture of the heart
45934669|NCT00207259|Behavioral|Reiki & Relaxation Response Therapy with Cognitive Restructuring|"Relaxation Therapy: Practice of focus on breathing or repeated word while ignoring random thoughts without bias. Designed to lower heart rate, blood pressure and stress.~Reiki: Practice of laying on hands by a Reiki therapist in order to channel patient's energy, considered calming and pleasant."
45934670|NCT00040274|Drug|DPC 817|
45934671|NCT00207298|Procedure|Positron Emission Tomography|Each patient will receive an 18F-FDG PET/CT scan
45934672|NCT00207337|Device|Exhale Drug-Eluting Stent|
45934673|NCT00207376|Device|Solysafe Septal Occluder|
45934674|NCT00040313|Drug|pegaptanib sodium (Macugen)|
45934675|NCT00207415|Behavioral|ASHC and CDSMP|
45934676|NCT00072852|Drug|Irinotecan|
45934677|NCT00207454|Behavioral|Social Cognitive Counseling|
45934678|NCT00207493|Behavioral|Kit enhancement to referral|
45934679|NCT00207493|Procedure|patient referral versus contract referral|
45934680|NCT00207532|Drug|folic acid|
45934681|NCT00207571|Behavioral|Computer|
45934682|NCT00040391|Drug|Investigational drug|
45934683|NCT00040391|Drug|Irinotecan|
45934684|NCT00040391|Drug|5-fluorouracil|
45652882|NCT04799639|Drug|Sindilimab +paclitaxel+ cisplantin|standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles
45652883|NCT05144763|Device|ePOCT+|ePOCT+ is an electronic clinical decision support algorithm
45652884|NCT05614973|Procedure|Conventional method|The conventional method utilizes a 18G biopsy gun to acquire three or more tissue cores with the corresponding number of liver capsule punctures. Plugging of the biopsy needle track is not performed.
45934685|NCT00040391|Drug|Leucovorin|
46073561|NCT02611635|Drug|NOAC: Dabigatran etexilate|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
46073562|NCT02611635|Drug|NOAC: Apixaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
46073563|NCT02611635|Drug|NOAC: Edoxaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
45652885|NCT05614973|Procedure|Coaxial method with needle-track plugging|The coaxial method utilizes a 17G coaxial needle with 18G biopsy gun to acquire three or more tissue cores with a single liver capsule puncture. Biopsy needle track is plugged using a slurry of gelatin particles (EGgel S Plus 2000-4000 μm).
45652886|NCT04799093|Diagnostic Test|EyeBOX|Eye-Tracking based diagnostic
45652887|NCT05144373|Behavioral|Gross motor intervention, gross and fine motor intervention|"For gross motor intervention, participants will receive a home-based, parent-administered body-weight supported treadmill intervention from about 10 months of age until walking onset.~For gross and fine motor intervention, participants will receive the same treadmill intervention as illustrated above. In addition, participants will receive a fine motor intervention with practice of reaching and grasping using sticky mittens from about 10 months of age for five months."
45652888|NCT04790981|Other|motor imaginary training|Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi-reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise.
45652889|NCT04790981|Other|physical thertapy training|The Control group received the selected physical therapy program for one hour, three times weekly for three successive months including facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern including.
45652890|NCT05142501|Other|Blood samples|Four consecutive blood sampling throughout the overall follow-up period of 12 months.
45652891|NCT03068689|Procedure|RIPC|RIPC is delivered with a standard blood pressure cuff placed on the upper arm and another standard blood pressure cuff placed on the upper thigh. The cuffs are then simultaneously inflated to 200 mm HG and left inflated for 5 minutes, then deflated to 0 mmHG and left uninflated for 5 minutes. This cycle is repeated twice, so that the RIPC protocol takes 20 minutes in total. If the systolic blood pressure is > 185mm HG the cuffs are inflated to 15 mmHG above that level.
45652892|NCT03068689|Other|Placebo|Placebo
45803949|NCT02957240|Behavioral|Motor Representation Techniques|"Those in this group will receive 4 clinic-based intervention session (one 1-hr. and three subsequent 30-minute sessions) where the focus will be on home program competency and advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home Program will be performed 3x daily for 15 minutes. A Motor Representation Technique (i.e., modified GMI) protocol described by Lagueux et al. will be employed. As originally designed the program was broken into three stages 1) Laterality, 2) Explicit Motor Imagery, 3) Mirror therapy with unaffected hand only and 4) Mirror Therapy with bilateral hands. For the purpose of this study, and given the restraint offered by cast immobilization, the 4th phase will not be used. Each phase will require 1-2 weeks and will be progressed at the discretion of the hand therapist interventionist."
45803950|NCT00358124|Drug|insulin glargine|
45803951|NCT00358124|Drug|rosiglitazone|
45934686|NCT00207610|Behavioral|Daily iron supplements of 65 mg a day for 3 months|
46073564|NCT02611635|Drug|NOAC: Lixiana|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
46073565|NCT05659758|Procedure|Head up positioning during preoxygenation|patients will be preoxygenated in head up position
46073566|NCT02824926|Drug|Dapaconazole|
45652893|NCT04798937|Other|Motivational interviewing|a health education program based on motivational interviewing provided by a nurse
45803952|NCT00358124|Drug|metformin|
45803953|NCT02839070|Other|Sleep/Wake Schedule|Timing of sleep and wake
45803954|NCT00358202|Drug|cefepime|cefepime hydrochloride 1gm IM q24h
45803955|NCT00358202|Drug|ceftriaxone|ceftriaxone 1 gm IM q24h
45803956|NCT05720468|Other|Exercise|Combined endurance and resistance exercise training
45934687|NCT00207610|Behavioral|Universal anemia screening and treatment|
45934688|NCT00207610|Behavioral|Selective anemia screening and treatment|
45934689|NCT00072891|Behavioral|telephone counseling|
46073567|NCT02824926|Drug|Ketoconazole|
46073568|NCT00705471|Biological|Infliximab|None available in the protocol. This was a chart review study, therefore no Infliximab provided during the study.
45803957|NCT05720468|Other|No Exercise|Continue usual level of physical activity; option to participate in exercise training program after 24-week intervention period
45803958|NCT02818400|Procedure|composite tissue allotransplantation|
45934690|NCT00207649|Behavioral|Shared decision-making for PSA screening tool|Interventions to Improve Shared Decision-Making: Prostate Cancer Screening is a prospective study of educational interventions to improve shared decision-making of physicians and their patients about prostate cancer screening. Physicians will be randomized by practice site to receive standard informational brochures (control group) or a novel web-based interactive curriculum that provides education about prostate cancer screening, including potential benefits and harms, fundamentals of effective patient counsel, and shared decision-making. In addition, patients at intervention sites will be randomized to receive either the brochure or a patient-oriented interactive curriculum covering content similar to that contained in the physician tool. Physicians in all groups will also see one unannounced standardized patient (SP) trained to portray a patient interested in discussing PSA.
45934691|NCT00207688|Drug|Infliximab 5 mg/kg|Patients who received infliximab 5 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
45803959|NCT05720234|Drug|avatrombopag|Patients with body weight ≥50kg were given 60mg/day and patients with body weight < 50kg were given 40mg/day for 12 weeks.
45803960|NCT02802566|Dietary Supplement|BMI-based prenatal vitamin|The intervention group receives additional antioxidant micronutrients that we have found to be decreased in obese pregnant women.
45803961|NCT02802566|Dietary Supplement|Standard prenatal vitamin|Standard prenatal vitamin
45803962|NCT03340883|Biological|BION-1301|a solution for intravenous (IV) administration, diluted and administered Q2W
45803963|NCT04142489|Other|solar irradiation and biopsies|the minimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage.
45803964|NCT04736225|Other|Insulin Self-Titration Education Program|The program contents of instruction included blood glucose self-monitoring, types of insulin, insulin self-administration, insulin dose titration, hyperglycemia or hypoglycemia self-management, diet, and exercise.a 20-min one-on-one training session from a nurse on how to self-titrate the insulin dose. The participants were taught to monitor their before-breakfast and before-dinner blood glucose levels at home and adjust their insulin doses accordingly.
45803965|NCT04345172|Device|sub-Tenon's block with a lacrimal dilator group or a Wescott scissors|"Local anaesthetic eye drops were installed into the conjunctiva, followed by iodine 5% aqueous drops to the conjunctival sac for 3 minutes.19 An eye lid speculum was inserted.~In group LD, the conjunctiva and Tenon's capsule were lifted together tightly with a blunt forceps like a tent in the inferonasal quadrant and a punctal dilatator (Castroviejo Lacrimal Dilatator, Katena Products, Inc, Denville, NJ, USA) was placed tangential to the globe creating a round and small hole at 5 mm posterior to limbus (Fig.1). The block was performed using smooth rounded tip, 19 G, 1 inch sub-Tenon's cannula (Visitec, Beaver-Visitec International Ltd, Warwickshire, UK).~In Group WS, after lifting the conjunctiva and Tenon's capsule together with a blunt forceps, incision was performed with a blunt tip Westcott scissors in the inferonasal conjunctival at 5 mm posterior to limbus to expose sub-Tenon's space."
45803966|NCT03341975|Behavioral|SexHealth|To enhance and test our ED SexHealth intervention that provides risk reduction counseling and point-of-care services as well as connections to sustainable, non-episodic sources of care.
45803967|NCT02978378|Other|biomarker levels|The level of the biomarker hyaluronic acid will be measured
45803968|NCT04344704|Other|Single chamber DAI device with floating atrial dipole|DAI for the detection of atrial signals with optimized programming, using Smart, Onset & Stability, and Morphmatch methods
45934692|NCT00207688|Drug|Infliximab 10 mg/kg|Patients who received infliximab10 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
45934693|NCT00207688|Drug|Placebo|Patients who received placebo from C0168T37, C0168T46, C0168T72 studies will be observed.
45934694|NCT00040430|Drug|111In-DAC|
45934695|NCT00040430|Procedure|Diagnostic|
45934696|NCT00068835|Behavioral|Lindamood-Bell training for dyslexia|
45934697|NCT00207766|Drug|infliximab or placebo|
45934698|NCT00207805|Procedure|autologous PBSC transplant|optimal timining of a second autologous transplant
45452081|NCT00039377|Drug|cytarabine|Given IV
45452082|NCT00039377|Other|laboratory biomarker analysis|Correlative studies
45452083|NCT01092845|Drug|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
45452084|NCT01092845|Drug|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
45452085|NCT01096745|Drug|Gemcitabine, Cisplatin|D1,D8 Gemcitabine 1000mg/m2 + N/S 150cc miv over 30mins D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins repeated every 3weeks
45452086|NCT01096745|Drug|S-1, Cisplatin|D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks
45934699|NCT00040469|Drug|Campath -1H|
45652894|NCT05629897|Other|Sessions of cognitive stimulation|40 sessions of cognitive stimulation of approximately 20 minutes duration per session are carried out, using the COPERIA platform.
45652895|NCT05154539|Diagnostic Test|Remote digital assessment|Remote digital assessment of test group participants
45652896|NCT05154539|Diagnostic Test|Conventional physical assessment|Conventional physical assessment of control group participants
45934700|NCT00040469|Drug|Dilantin|
45934701|NCT00040469|Drug|Busulfan|
45934702|NCT00040469|Drug|Cyclophosphamide|
45934703|NCT00207844|Drug|Selenium as sodium selenite|
45934704|NCT00072930|Biological|MEDI-522|IV at a concentration of 50 mg/mL and 10mL vials
45934705|NCT00072930|Biological|Docetaxel + Prednisone* + Zoledronic Acid|IV 75 mg/m2 IV 3-4 mg 5 mg
45652897|NCT04798703|Drug|ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)|12 weekly intravesical instillations of ONCOFID-P-B™ (intensive treatment phase) followed by maintenance phase of the study, during which ONCOFID-P-B™ is furtherly administered once a month for 12 months in patients who achieved a complete response (CR) after the 12 weekly instillations.
45652898|NCT04798313|Drug|MW031|Subjects would receive a single 60mg (1 mL) of MW031 through subcutaneous injection, on the first day of treatment.
45803969|NCT03344861|Drug|Porfimer Sodium|Porfimer sodium (Photofrin®) will be injected intravenously at a dose of 2 mg/kg.
45803970|NCT03344861|Device|Fiber optic|After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). An optical fiber diffuser length matching the tumor length will be placed in the lesion or adjacent to the lesion under fluoroscopy guidance. After the placement of the optical fiber, the laser light will be applied at a dose of 200 J/cm of diffuser length.
45934706|NCT00411307|Drug|OROS hydromorphone HCI|
45934707|NCT00411346|Procedure|Nurse-led telemonitoring|
45934708|NCT00040508|Drug|Sirolimus|
45652899|NCT04798313|Drug|Prolia®|Subjects would receive a single 60mg (1 mL) of Prolia® through subcutaneous injection, on the first day of treatment.
45803971|NCT05719922|Other|Resistance Training|Comparing two different exercise-based treatment methodologies on the clinical outcomes of individuals with persistent knee pain.
45934709|NCT00424411|Drug|Inhaled human insulin (EXUBERA™)|
45803972|NCT02579954|Behavioral|Rehabilitation|
45934710|NCT00424450|Procedure|lower limb artery bypass surgery|bypass of severe atherosclerotic vascular lesion
45934711|NCT00424450|Procedure|percutaneous angioplasty (PTA)|PTA of severe atherosclerotic lesion
45652900|NCT01655823|Drug|Placebo|Sham treatment acting as control arm
45652901|NCT01655823|Drug|Tetrodotoxin|Comparison of different dosages of Tetrodotoxin
45652902|NCT01360645|Drug|OPC-34712 + ADT|Tablet, Oral, 2 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
45934712|NCT00072969|Drug|Daclizumab|
45934713|NCT00424567|Procedure|Fracture surgery|
45934714|NCT00424567|Drug|Cultured Bone Marrow Tissue|
45934715|NCT00424606|Drug|Docetaxel|Docetaxel at the dose of 75 mg/m2 intravenously (IV) every 3 weeks for 4 consecutive cycles
45934716|NCT00424606|Drug|Epirubicin|Epirubicin at the dose of 90 mg/m2 IV every 3 weeks for 4 consecutive cycles
45934717|NCT00424606|Drug|Epirubicin|Epirubicin at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
45934718|NCT00424606|Drug|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
45934719|NCT00040547|Drug|Farnesyl Protein Transferase Inhibitor|
45934720|NCT00208000|Drug|Marine active|
45934721|NCT00068874|Behavioral|Coping skills and cognitive restructuring techniques|This is a cognitive psychoeducational program designed to enhance coping and adaptation to SLE. Participants will attend five study visits over 5 months. The first three visits are biweekly, 45-minute sessions during which the adolescent will be taught coping skills and cognitive restructuring techniques. The coping skills training will include training in relaxation, distraction, and problem-solving skills. The cognitive restructuring techniques will assist adolescents in using more accurate and adaptive cognitive responses.
45934722|NCT00068874|Behavioral|Educational training|Participants will attend five study visits that will include disease-appropriate education materials.
45934723|NCT00208039|Drug|Infasurf|Infasurf 3 cc/kg instilled via endotracheal tube, repeated 3 and 7 days later if infant stable and continues to meet criteria
45934724|NCT02962921|Drug|Insulin LISPRO intravenous loading|intravenous infusion of insulin Lispro.
45934725|NCT00040586|Drug|Monoclonal Antibody J591|
45934726|NCT00040586|Drug|Recombinant Interleukin-2|
45934727|NCT00068913|Drug|Dichloroacetate|
45934728|NCT00208078|Device|pressure support ventilator|Non invasive ventilation 4h/d 5 days a week
46073569|NCT00705549|Drug|Gemcitabine|Gemcitabine I.V at the dose of 1000mg/m2 on Day 1 and Day 8
45652903|NCT01360645|Drug|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
45652904|NCT01360645|Drug|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
45803973|NCT02978768|Other|Exercise|First year, the investigators investigate the effect of 12-week Tai Chi 6-Form accompanied with music rhythm for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
45934729|NCT00208117|Drug|Sertraline (Zoloft)|Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks. Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks). If adverse events occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained.
45934730|NCT00208117|Drug|Simvastatin (Zocor)|The placebo drug will be administered for 8 weeks. To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills.
45934731|NCT00208156|Drug|Mifepristone|
45934732|NCT00040625|Drug|Pemetrexed|
45934733|NCT00040625|Drug|Cisplatin|
45934734|NCT00208195|Drug|Divalproex ER|
45934735|NCT02966535|Device|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1)|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1)
45934736|NCT02966535|Device|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2)|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2)
45652905|NCT05132855|Biological|BNT162b2|BNT162b2 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.
45934737|NCT00208234|Drug|Omalizumab|0.016 mg/kg IgE
45934738|NCT00208234|Drug|Placebo for Omalizumab|Placebo
45934739|NCT00208234|Drug|omalizumab|Monoclonal antibody against IgE. 0.016 mg/kg IgE
45934740|NCT00208273|Drug|Letrozole - Concomitant|
45934741|NCT00208273|Drug|Letrozole - Sequential|
45803974|NCT02978768|Device|Computer-based cognitive training|Second year, the investigators investigate the effect of 12-week computer-based cognitive training games for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
45934742|NCT00208312|Drug|Regadenoson|0.4 mg, bolus intravenous injection
45934743|NCT00208312|Drug|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
46073570|NCT00705549|Drug|Cisplatin|Cisplatin I.V at the dose of 75mg/m2 on Day 1
45934744|NCT00040781|Drug|gefitinib|Given orally
45934745|NCT00040781|Other|pharmacological study|Correlative studies
45934746|NCT00040781|Other|laboratory biomarker analysis|Correlative studies
46073571|NCT00705549|Drug|Docetaxel|Docetaxel I.V at the dose of 75mg/m2 on Day 1
45803975|NCT02978768|Device|Physico-Mental rehabilitation Wii|Third year, the investigators investigate the effect of 12-week Physico-Mental rehabilitation Wii (PM Wii) for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
45803976|NCT03348683|Drug|Propranolol|After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of the one-time study medication, IV Propanolol.
45652906|NCT05132855|Biological|mRNA-1273|mRNA-1273 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.
45934747|NCT00208351|Device|Ultima LX Collared Stem - Non-Polished/Blasted Finished|A collared non-polished/blasted finished cementless femoral component for use in total hip replacement.
46073572|NCT00705549|Drug|Cisplatin|Cisplatin I.V at the dose of 80mg/m2 on Day 1
46073573|NCT00705549|Drug|Vinorelbine|Vinorelbine per os 50mg every Monday, Wednesday and Friday
46073574|NCT00705549|Drug|Pemetrexate|Pemetrexate I.V 500mg/m2 on Day 1
45652907|NCT05132855|Biological|MVC-COV1901|MCV COVID-19 vaccine is a protein subunit vaccine containing S2P S-protein which passes the EUA by Taiwan FDA.
45652908|NCT05197257|Drug|Ga-PSMA-11|The PSMA Sterile Cold Kit, is a kit comprising all needed materials (lyophilized PSMA for PSMA reconstitution, elution vial for Ga and ancillary materials for transfer between vials) to perform a room-temperature radiolabelling of PSMA-11 with Ga. Ga is not part of the kit and should be provided in the form gallium chloride solution following the requirements of the relevant local regulations. PSMA-11 radiolabelled with Ga is administered in patients with prostate cancer recurrence after radical treatment.
45652909|NCT05141799|Device|high intensity laser therapy|Laser treatment is noninvasive and painless and can be easily administered in therapy units for a wide range of conditions. High-intensity laser therapy (HILT) has gained importance for the treatment of different kinds of sports injuries such as tendon injuries, contusions, and muscle spasms.
45803977|NCT03348683|Drug|Placebo|After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of IV Saline
45934748|NCT00208351|Device|Ultima LX Collared Stem - Polished Finished|A collared polished finished cementless femoral component for use in total hip replacement.
45934749|NCT00208351|Device|Ultima LX Collarless Stem - Non-Polished/Blasted Finished|A collarless non-polished/blasted finished cementless femoral component for use in total hip replacement.
45934750|NCT00208351|Device|Ultima LX Collarless Stem - Polished finished|A collarless polished finished cementless femoral component for use in total hip replacement.
45934751|NCT00068952|Drug|Edotecarin|
45934752|NCT00068952|Drug|Temozolomide|
45934753|NCT00068952|Drug|Carmustine (BCNU)|
45934754|NCT00068952|Drug|Lomustine (CCNU)|
45934755|NCT00208390|Device|Summit Tapered Hip System|A cementless, tapered femoral component for use in total hip replacement
45934756|NCT00208429|Device|Pinnacle Acetabular System|
45934757|NCT00040820|Drug|oxaliplatin|
45934758|NCT00208468|Device|European Hip|A cementless femoral component for use in total hip replacement
45934759|NCT00208468|Device|Zweymüller|A cementless femoral component for use in total hip replacement
45934760|NCT00208468|Device|CLS Spotorno|A cementless femoral component for use in total hip replacement
45934761|NCT00208546|Drug|21Capecitabine + bevacizumab + oxaliplatin|3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1.
45934762|NCT00208546|Drug|1Capecitabine + oxaliplatin + bevacizumab + cetuximab|3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1, Ce 250 mg/m2 i.v. day 1, 8, 15 (day 1 cycle 1: 400 mg/m2).
45934763|NCT00068991|Behavioral|HIV skills training program and questionnaire|Two-hour weekly skills training sessions followed by evaluation questionnaire
45934764|NCT00068991|Behavioral|Community-level stigma reduction program|Two-hour training sessions focusing on anti-stigma and anti-discrimination
46073575|NCT02824692|Device|heart lungs and abdomen ultrasound|
46073576|NCT00705627|Drug|neoadjuvant chemotherapy plus concurrent chemoradiotherapy|Drug: cisplatin,fluorouracil. Patients received cisplatin 80mg/m2 on day 1,fluorouracil 4000mg/m2 civ 120 hours every three weeks for two cycles, then received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
46073577|NCT05660070|Behavioral|mobile Social Interaction Therapy by Exposure (mSITE)|mSITE is a blended intervention that integrates brief in-person psychotherapy with context-triggered mobile smartphone intervention and remote telephone coaching.
46073578|NCT00705705|Behavioral|Network leader training|Network leaders will receive a nine-session training segment designed to enable them to motivate their peer networks to reduce sexual risk. The sessions will teach the identified leader of each network how to communicate HIV prevention messages to other members of his or her personal social network. Leaders will be asked to share these messages with other members of their groups.
45934765|NCT00068991|Behavioral|Cross-sectional survey|Survey evaluation of community attitudes towards HIV
45803978|NCT04344782|Drug|Bevacizumab Injection|Treatment includes the administration on day 1 (D1) of an infusion of Bevacizumab 7.5 mg / kg in 100 ml saline for all patients weighing 100 kg or more. In control arm, patient receives standard care.
45652910|NCT05105711|Behavioral|QI coaching intervention|The intervention consists of two main components: a webinar communication workshop and use of the Checkup Coach mobile app. The Checkup Coach intervention begins with a brief (<1 hour), communication training workshop that reviews evidence on HPV vaccination, models guideline-consistent recommendations, trains providers to address parent concerns, and facilitates discussion of shared goals for improving. Next, providers are invited to download and use the Checkup coach mobile app at their discretion for the 12-week study period. Providers complete in-app self-assessments and receive tailored feedback about their HPV vaccine recommendation quality, progress toward improving recommendation practices, a dashboard of aggregate HPV vaccination coverage for patients in their clinic, and tips for addressing parents' concerns about HPV vaccination every time they use the app.
45803979|NCT05693558|Biological|NVD-003, an autologous 3D scaffold free osteogenic graft|Bone correction and grafting surgery
45934766|NCT00208585|Drug|sertraline|
45934767|NCT00040859|Drug|capecitabine|
45934768|NCT00040859|Drug|oxaliplatin|
45934769|NCT00208702|Drug|Triiodothyronine|
45934770|NCT00208702|Other|Placebo|
45803980|NCT05693480|Device|Balance sensor|Participants will engage in the device test, clinical assessment tests, and related user experience surveys to uncover problems in the effectiveness, efficiency, and acceptance of the device prototype. The whole test will last six months, and the outcome will be assessed pre- and post-implementation for comparison and validation. The major testing criteria include the validity and reliability of the device, user experiences, and the accuracy of the device's fall prediction.
45934771|NCT00208702|Drug|Sertraline|
45934772|NCT00208741|Drug|Gabitril|
46073579|NCT00705705|Behavioral|Standard HIV risk-reduction counseling|Participants will undergo interviews about their friendship groups, sexual behavior, substance abuse, STD treatment history, condom use, and beliefs about HIV/AIDS. Participants will undergo a brief session about HIV/AIDS prevention methods after the first interview.
45803981|NCT03835910|Behavioral|Social Incentives and Gamification to Promote Exercise|The intervention will provide social incentives and gamification to promote physical activity.
45452087|NCT03953729|Drug|Ibuprofen|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the drug shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
45452088|NCT03953729|Drug|Placebo|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the placebo shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
45652911|NCT04345289|Biological|Convalescent anti-SARS-CoV-2 plasma|Single infusion of convalescent anti-SARS-CoV-2 plasma (2 x 300 mL)
45934773|NCT00040898|Dietary Supplement|Sho-saiko-to|
45934774|NCT00399048|Drug|OROS hydromorphone HCL ; OxyContin|
45934775|NCT00208780|Drug|Tetrahydrobiopterin|
45652912|NCT04345289|Other|Infusion placebo|Saline 0.9% (600 ml) as an iv single dose infusion
45803982|NCT03835910|Procedure|Corticosteroid Injection given in A-B order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
45803983|NCT03835910|Behavioral|No Social Incentive applied|No social incentive will be applied
45803984|NCT03835910|Procedure|Corticosteroid Injection given in B-A order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
45803985|NCT03351101|Device|Senofilcon C|Senofilcon C Contact Lens
45934776|NCT00208780|Drug|Tetrahydrobiopterin|
45934777|NCT00208819|Drug|risperidone|
45934778|NCT00208819|Drug|quetiapine|
45934779|NCT00208819|Drug|olanzapine|
45934780|NCT00208819|Drug|divalproex|
45934781|NCT04722484|Drug|Vericiguat (BAY1021189)|Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
45934782|NCT00208858|Drug|Topiramate|
45934783|NCT00041015|Drug|cisplatin|
45934784|NCT00041015|Drug|etoposide|
45934785|NCT00041015|Drug|topotecan hydrochloride|
45934786|NCT00073047|Drug|Daclizumab|
45934787|NCT00208897|Drug|Fluoxetine|
45934788|NCT00208936|Drug|Taxol, Cisplatin, 5-Fluorouracil, G-CSF|
45934789|NCT00209014|Drug|Thalidomide|
45934790|NCT00209053|Procedure|Coronary Artery Bypass|
45934791|NCT00041054|Drug|carboplatin|
45934792|NCT00041054|Drug|etoposide|
45934793|NCT00041054|Drug|exisulind|
45934794|NCT02966106|Device|Right prefrontal low frequency rTMS|A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
45934795|NCT02966106|Other|Sham-rTMS|Right prefrontal rTMS sham treatment. A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
45934796|NCT00209209|Drug|Rituximab|antibody
45934797|NCT00209209|Drug|Cyclophosphamide|chemotherapy
45934798|NCT00209209|Drug|Doxorubicin|chemotherapy
45934799|NCT00209209|Drug|Vincristine|chemotherapy
45934800|NCT00209209|Drug|Prednisone|coricosteroide
45934801|NCT00209209|Drug|Fludarabine|chemotherapy
45934802|NCT00209209|Drug|Interferon-alpha|cytokine
45652913|NCT05141019|Diagnostic Test|Panel-based pharmacogenetic genotyping|After providing consent, subjects will be randomized to receive either the immediate pharmacogenetic testing arm or the delayed arm. Subjects in both groups will provide a DNA sample by saliva, buccal cell, or blood at study enrollment. Subjects assigned to the immediate pharmacogenetic genotyping group will be tested and will have their results entered into their electronic health record (EHR) and provided to them within 2-4 weeks. Subjects assigned to the delayed pharmacogenetic genotyping group will also be tested, but their results will not be released until after their participation in the study has ended. Subjects in each arm will complete surveys and questionnaires regarding their medication satisfaction, as well as their healthcare utilization use at baseline and then again at 6- and 12-months. Implementation-specific questions will also be asked to assess the feasibility and sustainability of the intervention as well as assessments of intervention fidelity and adaptations.
45652914|NCT05195463|Other|Exercise intervention|Women with diastasis recti abdominis will do core stabilization exercises for the transversus abdominis muscle with 10 repetitions 3 days a week for 8 weeks. The exercises include diaphragmatic breathing exercises, core stabilization exercises for the transversus abdominis muscle, and pelvic floor contractions
45652915|NCT05195463|Other|Exercise intervention by wearing abdominal corset|In this group, in addition to the first group, core stabilization exercises will be performed by wearing an abdominal corset. Participants will be asked to wear their corsets while performing their exercises.
45652916|NCT05195463|Other|Corset intervention|Participants included in this group will be required to wear only this corset all day (except for the bathroom) for 8 weeks.
46073580|NCT02824770|Behavioral|Dimming of lights and decreasing noise level|The study intervention will include dimming of lights and decreasing noise level. The lights will be dimmed to 40 lux and the doors of the side-room will be closed to decrease the noise level below 40 dB between 11:00 p.m.-5:00 a.m
45452089|NCT03953651|Other|Follow-up|Onset of Major Adverse Cardiovascular Event of death from all causes will be collected at 3 and 6 months after inclusion.
45803986|NCT03351101|Device|Samfilcon A|Samfilcon A Contact Lens
45803987|NCT05692544|Procedure|Phototherapy treatment|only patients was proscribe to phototherapy treatment can participate in the study
45803988|NCT05691452|Behavioral|Sit Less Program|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention.
45452090|NCT01096901|Behavioral|Behavioral Weight loss|Intervention groups will meet weekly for 12 weeks. Weekly meetings will focus on weight loss in women age 30-45 through behavioral weight loss topics. These topics are designed with the Look AHEAD protocols.
45803989|NCT00357188|Drug|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 10 days.
45452091|NCT03953495|Behavioral|Better Together|The Better Together Intervention consists of a 7 self-paced online relationship education modules. Following an introductory and overview module couples will complete each of the following together on their web-connected device (computer, ipad, phone). Each module includes didactic material, demonstration vignettes, and guided discussions or skills building exercises. Module 1 focuses on identifying individual and relationship strengths; Module 2 focuses on destructive communication patterns, Module 3 focuses on positive communication skills; Module 4 teaches a problem-solving technique; Module 5 focuses on stress and coping; Module 6 focuses on relationship expectations and commitment, and Module 7 provides a summary of the program. Each module takes approximately 30 minutes to an hour to complete. Metrics will be assessed at baseline, post-intervention, and at a 3 month follow up.
45803990|NCT00357188|Drug|Atazanavir Sulphate + Ritonavir + Efavirenz|Capsules/Tablets, oral, ATV 400 mg + RTV 100 mg + EFV 600 mg, once daily, 14 days.
45803991|NCT03223337|Drug|Daprodustat (GSK1278863)|Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.
45803992|NCT03834974|Behavioral|Sun Safety Social Media Challenge|Participants will attend a webinar to learn how to create effective social media posts about sun safety and be oriented to the social media accounts on which the messages will be posted. They will be informed that posts should include a sun safety message (e.g., promoting sunscreen use and protective clothing/hats or discouraging risk behaviors like tanning and burning). They will be encouraged to be creative so that the message gets likes and shares. Participants will be encouraged to follow the feeds to see the engagement on their posts, to share the posts in their feed, and to see other participants' posts. Participants will receive a $10 Amazon gift card per post for a maximum of 6 posts ($60). The participant who created the post that receives the most likes, comments, and shares each week will win a $50 Amazon gift card.
45804184|NCT05662514|Dietary Supplement|Bifidobacterium animalis subsp. lactis BLa80|"Test product contain 3 × 109 colony-forming units [CFU] Bifidobacterium animalis subsp. lactis BLa80 strains, for each packet.~Subjects ingested one packet (3 g/packet) of Test product per day (2 hours after taking antibiotics in the evening), for 14 days."
45804185|NCT05662514|Other|Placebo|To maintain the blinding, patients in the control group received placebo included in identical packets. Control product per day (2 hours after taking antibiotics), for 14 days.
45934803|NCT00209209|Drug|pegylated formula Interferon-alpha 2b|cytokine
45934804|NCT00209209|Procedure|chemotherapy: R-CHOP|immuno-chemotherapy
45934805|NCT00209209|Procedure|chemotherapy: R-FC|immuno-chemotherapy
45934806|NCT00209209|Procedure|Interferon maintenance|cytokine
45934807|NCT00209209|Procedure|Rituximab maintenance|antibody
45934808|NCT00209287|Behavioral|Observe patients with inactive ulcerative colitis|Observe patients with inactive ulcerative colitis
45934809|NCT00209326|Drug|FE200440|
45452092|NCT01093001|Other|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
46073581|NCT02824770|Drug|Bupivacaine (Bustesin®) via Pain Buster ® system|Patients will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour
46073582|NCT02824770|Drug|Tramadol HCl (Tramosel®) via PCA system (Gemstar®)|Patients will receive infusion of Tramadol HCl (Tramosel®) via patient-controlled analgesia system (Gemstar®)
46073583|NCT02824770|Procedure|Major abdominal surgery|Any major abdominal surgery (e.g. colectomy, gastrectomy)
46073584|NCT02824536|Drug|3BNC117|Intravenous Infusion of 3BNC117
45652917|NCT05139615|Drug|APD418|Participants will receive a single dose of APD418 as an intravenous (IV) infusion.
45803993|NCT03834974|Behavioral|Digital Health Social Media Challenge|Participants will attend a webinar to learn how to create effective social media posts about using technology to get healthy and be oriented to the social media accounts on which the messages will be posted. They will be informed that posts should mention some way that technology (e.g., mobile apps, wearables) can be used to promote a healthy habit (e.g., diet, exercise). They will be encouraged to be creative so that the message gets likes and shares. Participants will be encouraged to follow the feeds to see the engagement on their posts, to share the posts in their feed, and to see other participants' posts. Participants will receive a $10 Amazon gift card per post for a maximum of 6 posts ($60). The participant who created the post that receives the most likes, comments, and shares each week will win a $50 Amazon gift card.
45934810|NCT00209365|Procedure|exposure to grass pollen/starch granules|
45934811|NCT00209404|Drug|Iodixanol 320 mg I/Ml|
45934812|NCT00041093|Drug|Docetaxel|Given IV
45934813|NCT00209443|Drug|Gadodiamide Injection|
45934814|NCT00399087|Drug|Perifosine|Perifosine oral administration
45934815|NCT00399087|Drug|Docetaxel|IV administration
45452093|NCT01093001|Other|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation
45452094|NCT01093001|Other|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
45452095|NCT01093001|Other|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
45452096|NCT03953339|Procedure|Release or no release of the suprascapular nerve|
45452097|NCT03953573|Other|Survey|Survey completed at 1 day, 8 days 1 or 3 months post delivery
45803994|NCT03223649|Other|Walking Bouts|Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.
45803995|NCT03223649|Other|Sedentary|(Control 'intervention') Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
45803996|NCT02360215|Radiation|Whole brain radiation therapy with hippocampal avoidance|Intensity modulated radiation therapy (IMRT) 30 Gy in 10 fractions once per day, 5 days per week for approximately two week; starting within 21 calendar days after randomization.
45803997|NCT02360215|Drug|Memantine|Given PO daily during and after radiation therapy for a total of 24 weeks. Week 1: 5 mg in the AM, none in the PM; Week 2: 5 mg in the AM, 5 mg in the PM; Week 3: 10 mg in the AM, 5 mg in the PM; Weeks 4-24: 10 mg in the AM, 10 mg in the PM. Should start the same day as radiation therapy, at latest before the fourth radiation treatment.
45934816|NCT00399087|Drug|Prednisone|Oral administration
45934817|NCT00209482|Drug|glucophage XR|
45934818|NCT00411424|Drug|ASK8007|IV
45934819|NCT00411424|Drug|Placebo|IV
45934820|NCT00041171|Drug|Hypericum perforatum|
45934821|NCT00041171|Drug|docetaxel|
45934822|NCT00041171|Other|placebo|
45934823|NCT00209521|Drug|fospropofol|Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from AQUAVAN were 0.7 μg/mL (sedation) and 2.5 μg/mL (maintain anesthesia).
45934824|NCT00209521|Drug|propofol|Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from Disoprivan were 1.0 μg/mL (sedation) and 3.0 μg/mL (maintain anesthesia).
45934825|NCT00209638|Drug|irinotecan|
45452098|NCT01583933|Device|Essix retainer|"The essix retainer is made in a thermoforming copolyester 0.75mm (0.30 , it processed gives a thickness of 0.015 approximately. Retainer will be used molar to molar. subjects in this arm will have this retainer for 24 hours a day for 6 months, they won´t have this device for food intake."
45652918|NCT05139615|Drug|APD418|Participants will receive a single dose of APD418 as an IV infusion.
45652919|NCT05139615|Drug|Placebo|Participants will receive a single dose of APD418 matching placebo as an IV infusion.
45652920|NCT04343105|Procedure|pecto-intercostal plane block|under ultrasound guidance, pecto-intercostal plane block will be performed between 3rd and 4th rib 2 cm lateral to sternal border in supine position at the interfascial plane between pectoralis major muscle and intercostal muscles
45652921|NCT04342793|Drug|Placebo oral tablet|Placebo
45652922|NCT04342793|Drug|ALS-L1023 1,200mg|ALS-L1023
45652923|NCT04342793|Drug|ALS-L1023 1,800mg|ALS-L1023
45803998|NCT02360215|Radiation|Whole brain radiation therapy|Whole brain radiation therapy (WBRT) 30 Gy in 10 fractions once per day, 5 days per week for approximately 2 weeks
45803999|NCT05719688|Device|Mechanical thrombectomy|Treatment of ischemic stroke patients with Mechanical thrombectomy
45804000|NCT05719610|Other|Cawthorne Cooksey Exercises for Balance Training|Group of Exercises used to Increase balance
45804001|NCT05719610|Other|Swiss Ball Exercises|Swiss Ball Exercises
45934826|NCT00209638|Drug|S-1|
45934827|NCT00399126|Drug|Perifosine|Perifosine oral dose
45934828|NCT00399126|Drug|Paclitaxel|Paclitaxel IV
45934829|NCT00209677|Drug|Gemcitabine|
45934830|NCT00209677|Drug|S-1|
45934831|NCT02970578|Procedure|3D printed module|The patients underwent 3D printed module-assisted lumbar pedicle screw placement using the Quandrant system, aiming to restore the stability of the spine.
45934832|NCT00209716|Drug|Taxotere|30 mg/m2, IV (in the vein) on day 1 of each 28 day cycle.
45934833|NCT00209716|Drug|5-Fluorouracil|800 mg/m2, CIV (CIV.in the vein) on day 1~5 of each 28 day cycle.
45934834|NCT00209716|Drug|Briplatin|15 mg/m2, IV (in the vein) on day 1~4 of each 28 day cycle.
45934835|NCT00209755|Procedure|therapeutic drug monitoring of ribavirin and dose adaptation|
45934836|NCT00209794|Drug|Sulfadoxine-Pyrimethamine (Fansidar)|
45934837|NCT00209833|Drug|Cytarabine|
45934838|NCT00209833|Drug|Idarubicin|
45934839|NCT00209833|Drug|Etoposide|
45934840|NCT00209833|Drug|Fludarabine|
45934841|NCT00209833|Drug|G-CSF|
45934842|NCT00209833|Drug|Daunorubicine|
45934843|NCT00041210|Biological|bleomycin sulfate|
45935689|NCT05558488|Other|Meatless, restrictive ketogenic diet|"Each participant received a nutritional plan that was the same qualitatively but differed quantitatively - a 500 kcal reduction based on Estimated Energy Requirement (EER) was assumed. Before the start of the study, each participant obtained information about the basic principles of the ketogenic diet. Diet was designed to be isoproteic (1.8gxKg-1xbody weight-1xday-1) with three meals a day. The distribution of macronutrients during the very low carbohydrate ketogenic diet (KD) was: protein 1.8 gxKg-1xbody weight-1xday-1(~25-30%), fats (~65-70%,with a strong emphasis on the content of omega 3 fatty acids) and carbohydrate (<30gxday-1;<10%).~The food lists encouraged the consumption of fish,raw and cooked vegetables, eggs,fruits with the lowest glycemic index (blueberry, raspberry), plant oils and fats from avocado,olives.Drinks permitted were tea, coffee without sugar and the foods and drinks to be avoided were alcohol,meat (any kind of meat),bread,pasta,rice,milk,dairy and potatoes."
45935690|NCT00044408|Drug|Ruboxistaurin mesylate|
45804271|NCT05385289|Behavioral|A cognitive-behavioral approach of rumination as intervention for overgeneral mode of processing in perfectionism|"The B-experimental phase consists in a 6-session intervention targeting rumination and lasting for 3 weeks. The intervention was derived from 3 manuals: Rumination-Focused Cognitive-Behavioral Therapy for Depression (Watkins, 2016), Overcoming Perfectionism (Shafran et al., 2010), and Cognitive-Behavioral Treatment of Perfectionism (Egan et al., 2014). Participants will attend 2 sessions per week at home. Each week will end with an individual 30 minutes-debriefing session with an experimenter, to ascertain understanding of session content and homework.~Intervention sessions will be given in paper format to participant after the A-baseline-phase. A paper diary was also provided for homework, in addition to the session content caneva. Each session contains (a) theoretical content on ruminations linked to perfectionism, (b) exercises to create alternative habits to ruminations, and (c) homework to become aware of ruminations and to experiment with alternatives."
45653415|NCT05660161|Procedure|Nanofracture|"The planned study intervention consists of nanofracture surgical procedure for the treatment of cartilage lesions of the knee.~Nanofractures will be standardized 9 mm deep perforations in the subchondral bone.~Under arthroscopic view, the cartilage lesion is shaved to expose the margins of the lesion and remove damaged tissue. After a satisfactory lesion debridement is performed, a nanofracture device (Plasmaconcept NanoFx®) is placed through the arthroscopic portal. The awl is repeatedly penetrated through the bone until marrow elements are seen in the joint. The flow of arthroscopic fluid is interrupted to better observe the marrow elements emanating from the nanofracture holes. The distance between two consecutive perforations will be approximately 2-3 mm, and the number of perforations will depend on the cartilage lesion extension. All post-operative procedures, including the rehabilitation protocol, will be carried out according to the usual standard of care."
45653416|NCT04216797|Drug|Diazepam Tablets|Participants will be randomly assigned to either an oral or rectal administration of once daily 10 mg diazepam tablets for four weeks.
45804272|NCT05723276|Drug|Psilocybin|Psilocybin 25mg PO
45804273|NCT01768767|Drug|Placebo|
45804274|NCT01768767|Drug|Ketamine|
45804275|NCT01768767|Drug|Ketamine/Lithium|
45653417|NCT05029401|Drug|DMX-1002|Investigation of the safety, tolerability and pharmacokinetics (PK) in healthy volunteers (Stage 1 - single blind), and the efficacy, safety, tolerability and PK in opioid-dependent patients (Stage 2 - double blind)
45653418|NCT05029401|Drug|Placebo|Matching placebo to the IMP (DMX-1002)
45804276|NCT00358046|Drug|ILY101|
45804277|NCT00376493|Drug|metronidazole and doxycycline|use of metronidazole 500mg/day and doxycycline 200mg/day up to 10 days
45804278|NCT05574530|Dietary Supplement|Colon-delivered multivitamin supplement|6-week intervention of one dietary supplement a day, containing vitamin B2 (10mg), vitamin B3 (4mg), vitamin B6 (1.4mg), vitamin B9 (400μg), vitamin C (200mg) and vitamin D3 (15ug).
45804279|NCT05574530|Dietary Supplement|Placebo supplement|6-week intervention of one dietary supplement a day, containing 200 mg of microcrystalline cellulose.
45804280|NCT00003195|Biological|recombinant interferon alfa|
45804281|NCT00003195|Drug|busulfan|
45804282|NCT00003195|Procedure|allogeneic bone marrow transplantation|
45804283|NCT00003195|Procedure|peripheral blood stem cell transplantation|
45804284|NCT00003195|Radiation|radiation therapy|
45804285|NCT03231917|Procedure|Water Infusion first|In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
45804286|NCT03231917|Procedure|CO2 Insufflation First|In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion .
45804287|NCT03671109|Drug|Dihydroartemisinin-piperaquine (DHA-PPQ)|Following physical examination, recruited women with more than 13 weeks of gestational age will receive IPTp-DHA-PPQ under supervision
46002128|NCT04778059|Drug|Placebo|The placebo formulation will be the USB002 formulated solution without the addition of A(1-7). The placebo will be administered intravenously (IV).
46002129|NCT04777617|Other|DD-cfDNA|We are obtaining samples for donor derived cell free DNA in an observational manner. There is no intervention in this study
45653419|NCT05194267|Device|transcranial direct current stimulation (tDCS)|tDCS alters brain excitability using a weak electric field induced through two electrodes and could potentially improve symptoms of depression
45653420|NCT05029011|Device|BRAEBON VTS|The BRAEBON VTS is a portable device that continuously monitors vital signs. Participants in the study will wear the BRAEBON VTS for 24 hours.
45653421|NCT05028855|Diagnostic Test|Cerebral autoregulation assessment|Cerebral autoregulation assessment will be conducted by specialized neurovascular ultrasound doctors during 0-3 and 10-30 days after stroke onset.The recorded data will be stored for further cerebral autoregulation analysis.
45653422|NCT05027685|Device|The Paradise Ultrasound Renal Denervation System|The CE-marked and commercially available ReCor Medical Paradise Ultrasound Renal Denervation System (Paradise System) is a catheter-based device designed to use ultrasound energy to thermally ablate the nerves surrounding the renal artery and serving the kidney.
45653423|NCT04040569|Radiation|Radiomics on MRI|"Through extracting and analyzing a large number of features from medical imaging, radiomics has shown promising results in treatment outcome prediction for many diseases including breast cancer (45-50). UTSW physics group has developed several new radiomic approaches and radiomic features, such as a multi-objective radiomics model(51) and a new radiomic Shell feature(52). As an exploratory end point for this trial, the investigators will explore the application radiomics using pre-treatment MRI, treatment parameters and clinical characteristics as input to predict pathological response of radiation therapy (XRT) based on pathology report of surgical tissues and local recurrence."
45804288|NCT03671109|Drug|Placebo Oral Tablet|Following physical examination, recruited women with more than 13 weeks of gestational age will receive IPTp-Placebo under supervision
45653424|NCT05025813|Drug|Pembrolizumab|Delivery of neo-adjuvant Pembrolizumab
45653425|NCT04033237|Other|Very low nicotine content cigarettes|Cigarettes containing 0.4 mg nicotine/g tobacco
45804289|NCT02979067|Procedure|Nasal oxygen flow|Nasal oxygen flow during apnoea
45653426|NCT05064501|Diagnostic Test|spirometry|Lung function test: pre and post bronchodilator spirometry
45653427|NCT05064501|Other|Asthma control test|Asthma control test
45653428|NCT05064345|Drug|HB0034|Recombinant Humanized Anti-IL-36R Monoclonal antibody
45804290|NCT05716256|Drug|Ulinastatin|The CIS-ULI group received ulinastatin 5000U/kg followed by cisatracurium 0.1 mg/kg The CIS-NS (control) group received normal saline 0.1ml/kg followed by cisatracurium 0.1 mg/kg. The ROC-ULI group received ulinastatin 5000U/kg followed by rocuronium 0.6 mg/kg The ROC-NS (control) group received normal saline 0.1ml/kg followed by rocuronium 0.6 mg/kg
45804291|NCT05716256|Procedure|TOF monitoring|The acceleromyograph TOF-Watch® SX (Organon, Ireland) is used for TOF monitoring. When the Narcotrend™ index is below 50 and level of anesthesia assessed as deep enough, TOF stimulation is started at 50 mA amplitudes and the setup is checked for any problem concerning the electrodes impedance and local hand temperature. After 1 minute, TOF stimulation is stopped and a tetanic stimulation (each electrical stimulus of 200μs duration and 50 mA amplitude) is delivered at a frequency of 50Hz for 5 seconds. After this procedure the alignment of sensors are checked to see if they are intact and readjust to their initial position if necessary. A no stimulation pause is observed during 3 minutes.
45804292|NCT03667365|Procedure|aortic valve replacement|aortic valve replacement surgical or transcatheter aortic valve replacement (will be decided by the heart team before randomization)
45804293|NCT03667365|Other|strict clinical surveillance|strict clinical surveillance strategy
45804294|NCT03362957|Device|Geniculate Artery Embolization|Gel-Bead Microspheres will be used for geniculate artery embolization (GAE) in subjects with knee osteoarthritis.
45804295|NCT03362957|Diagnostic Test|Sham Procedure|Patients will receive a sham procedure, which will include a diagnostic angiogram
45804296|NCT05630144|Behavioral|HomeMed|The HomeMed intervention is a multidisciplinary deprescribing intervention including home visits and team-based telehealth communication (optional). The components included in the HomeMed intervention include home medication review, medication education and provision of tools to assist the patients with medication administration, assessment of deprescribing targets by a trained geriatric clinical pharmacist, communication with the patient's treating primary care provider about deprescribing recommendation, deprescribing implementation (optional), and deprescribing monitoring (optional). Depending on the patient's treating primary care provider's decision on deprescribing and monitoring, the number of home visits ranges from a minimum of three to more with the entire duration of the intervention ranging from approximately 1 to 3 months.
45804297|NCT01730781|Radiation|[11-C]OMAR|The radiotracer, [11-C]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
45935691|NCT00078273|Behavioral|Personalized Feedback Intervention|Sessions lasted for 60-90 minutes and used Motivational Interviewing (MI) to facilitate discussion of feedback from participants' survey responses. Sessions began with open-ended questions about contextual factors associated with participants' gambling, then review of each feedback section: gambling pattern; perceived gambling norms; positive expectancies and negative consequences of gambling; beliefs about control over gambling; and situational self-efficacy to avoid gambling. Participants were encouraged to consider the feedback in light of their personal goals. All participants received a copy of their feedback, a list of skills for limiting gambling and a resource/referral list.
45653429|NCT05064345|Drug|Placebo|Palcebo
45653430|NCT03939169|Other|Installation of a naso-gastric feeding tube|Insertion of the feeding tube with skin-to-skin contact or whilst being held in the mother's arms, or by using the four hands technique or by performing positional support with appropriate equipment
45676254|NCT04212013|Drug|Ibrutinib|Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis.
45676255|NCT04212013|Drug|Rituximab|Will receive rituximab: 375 mg/m^2 on days 1, 8, 15 and 22 of cycle 1
45804298|NCT00356083|Drug|Methadone|
45653431|NCT05063331|Procedure|Minimally invasive supracervical hysterectomy and sacrocolpopexy (MI-SCH+SCP)|Minimally invasive robotic or laparoscopic supracervical hysterectomy will be done, and the vaginal apex (including cervix) will be suspended utilizing sacrocolpopexy mesh to the anterior spinous ligament.
45653432|NCT05063331|Procedure|Vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)|The uterus will be removed vaginally and the vaginal apex will be suspended utilizing sutures in the uterosacral ligament.
45653433|NCT05623735|Other|Instrument Assisted Soft Tissue Mobilization Group While Lying Prone|"Sliding movements in all directions at 30 - 60 degree angles will be made in the form of mobilizations of 45 seconds with instruments.~Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~Starting with an angle of 60 degrees on the area to be treated, the movement of shifting towards an angle of 30 degrees will be made in all directions for 30 seconds.~The tissue will be mobilized for 30 consecutive seconds, starting from just caudal to your waist and drawing the letter J towards the cranial.~Sliding movements in all directions at 30 - 60 degree angles will be made with instruments in the form of mobilizations for 45 seconds.~Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~30 - 60 degree swipe movement shorter brushing style small movements will be done for 30 seconds."
45653434|NCT05623735|Other|Instrument Assisted Soft Tissue Mobilization Group Combined with Functional Movement|"Sliding movements in all directions at 30 - 60 degree angles will be made in the form of mobilizations of 45 seconds with instruments.~Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~Starting with an angle of 60 degrees on the area to be treated, the movement of shifting towards an angle of 30 degrees will be made in all directions for 30 seconds.~The tissue will be mobilized for 30 consecutive seconds, starting from just caudal to your waist and drawing the letter J towards the cranial.~Sliding movements in all directions at 30 - 60 degree angles will be made with instruments in the form of mobilizations for 45 seconds.~Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~30 - 60 degree swipe movement shorter brushing style small movements will be done for 30 seconds."
45804299|NCT02977832|Dietary Supplement|Odyliresin|Odyliresin 2 ml, 20 drops once daily and alpha-antagonist (alfuzosin 10 mg)
45804300|NCT02977832|Drug|Alfuzosin|10Mg Oral Tablet, Extended Release
45653435|NCT04421547|Drug|Letrozole 2.5mg|This study will investigate the role of Letrozole in patients affected by heavily pretreated platinum resistant ovarian cancer, compared to standard treatment.
45653436|NCT04421547|Drug|Standard single agent chemotherapy|Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on days 1,8,15 every 4 weeks or Gemcitabine 1000 mg/m2 IV over 30 min on days 1,8,15 every 28 days.
45804301|NCT05577091|Genetic|Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes.|"Intratumorally administrate via Ommaya reservoir.~Dose level 0: 1×10^7 autologous Tris-CAR-T cells, one dose, 2 patients.~Dose level 1: 1×10^8/ 5×10^6autologous Tris-CAR-T cells, one dose, 2 patients. The dose of Dose level 1 will refer to the adverse effect of Dose level 0. When 1 of the 2 patients in the Dose level 0 had dose-related toxic side effects, 2 patients in the Dose level 1 could be enrolled. When dose-related side effects occurred in 2 patients in the Dose level 0, the dose should be reduced to 5×10^6cells to continue enrollment.~Dose level2: 5×10^7 autologous Tris-CAR-T cells, weekly administered, maximum 8 weeks, 4 patients. If the results of Dose level 0 and 1 suggested that dose-related toxic side effects could be occurred in the 1×10^7cells dose, the researcher would re-determine the dosage of the multidose clinical exploration study."
45804302|NCT04344236|Drug|Saline oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
45653437|NCT05062629|Genetic|Whole Genome Sequencing|Whole Genome Sequencing
45653438|NCT03910075|Behavioral|I-ACQUIRE - High Dosage|Children in this group will receive 6 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
45653439|NCT03910075|Behavioral|I-ACQUIRE - Moderate Dosage|Children in this group will receive 3 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
45653440|NCT03910075|Behavioral|Usual & Customary Treatment (U&CT)|Children in this group will receive the same U&CT that they had been receiving prior to the baseline assessment. The type and dosage of treatment(s) will be documented weekly.
45653441|NCT05061771|Drug|nomacopan (rVA576)|Nomacopan an inhibitor of complement C5 and LTB4
45653442|NCT05061771|Other|Placebo|Placebo
45653443|NCT05061069|Diagnostic Test|cervical vestibular evoked myogenic potentials (cVEMP)|cVEMPs are ipsilateral, short latency, inhibitory myogenic potentials that assess otolith (mainly saccular) function and the integrity of the inferior branch of the vestibular nerve.
45804303|NCT04344236|Drug|0.5% Povidone/Iodine oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
45804304|NCT04344236|Drug|0.12% Chlorhexidine oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
45804305|NCT01543659|Drug|89Zr-DFO-huJ591|The first 10 patients enrolled in the study will undergo serial whole-body scans to allow assessment of 89Zr-DFO-huJ591 biodistribution. There will be no intervening changes in therapy between the scans. The first 10 patients enrolled will also have serial blood samples drawn for PK analysis (2 -3 mL per time point). The remaining 90 patients enrolled (Patients 11-100) will have only 1 whole-body scan, at a time point to be determined based on the results for the first 10 patients. Biopsies are not mandatory, but highly recommended for the scientific purposes of the study. If feasible and the patient consents, all patients will undergo either or both of the following: (a) core biopsy of soft tissue site of disease; (b) core biopsy of bony site of disease. These biopsies will be performed following the last whole-body scan, prior to initiation of a new intervening therapy, and no more than 4 weeks after 89Zr-DFO-huJ591 administration.
46002492|NCT02190305|Device|Multiplo HBc/HIV/HCV and Reveal HBsAg|All subjects tested with both investigational devices, plus with algorithms of approved assays for HIV and hepatitis B and C.
45935692|NCT00078273|Behavioral|Cognitive Behavioral Intervention|Participants completed either six weekly 1-hour sessions or attend four sessions containing the same content. Sessions covered functional analysis and gambling triggers; challenging cognitive distortions, with emphasis on illusions of control; coping with triggers; assertiveness; and relapse prevention. Participants received a pamphlet covering each week's topic (which was reviewed with the participant if a session was missed), as well as homework sheets and gambling diaries. CBI participants were asked to refrain from gambling for the duration of the group to provide an opportunity to practice and develop skills applicable to gambling and other behavior change situations.
45804306|NCT05571553|Other|Recommendations and reorientation towards healthcare resources|"Phase 1~After completing the CARE© questionnaire, participants will be given recommendations.~After the ESOGER© assessment, the participants will be contacted by the Red Cross who will set up the necessary interventions. They will be informed of the results of the assessments made.~Phase 2~After completing the CARE© questionnaire, participants will be given recommendations.~If their health status is judged fragile by the CARE© score, and after the ESOGER© assessment, the participants will be contacted by the Red Cross who will set up the necessary interventions. They will be informed of the results of the assessments.~For both phases, after 3 (6) months, the participants of the Control group will benefit from the recommendations following the CARE© assessment done at M3 (M6), and if necessary from the ESOGER© assessment and the Red Cross intervention. Throughout the study, they will continue to receive their conventional care."
45804307|NCT05629286|Device|McConnell taping|non-stretch rigid McConnell tape will be applied
45935693|NCT05556499|Diagnostic Test|Biomarker assays|Circulating bone biomarkers assays
45804308|NCT05629286|Device|Patella Stabilizer Brace|An orthotic application that wraps the patellofemoral joint, which has a patellar cavity and supports the patella, and provides stabilization with velcro
45935694|NCT00078351|Procedure|High molecular weight hylan (Synvisc) injection|
45935695|NCT05549050|Other|interdialytic weight gain|interdialytic weight gain during hemodialysis
45935696|NCT00044447|Drug|Glimepiride|
45804309|NCT05558293|Procedure|Scaling and root planing|Full mouth or quadrant SRP
45804310|NCT00383409|Drug|multivitamins|
45935697|NCT05541406|Behavioral|Proud & Empowered|Proud & Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
45935698|NCT04729647|Procedure|Mastectomy|Mastectomy for breast cancer Blood sample for Complete Blood Cell Count and other blood parameters (Delta Neutrophil Index, Immature Granulocyte Count)
45935699|NCT05530018|Behavioral|Brief contact intervention|The brief contact intervention (BCI) will send out text messages to the participants. The text messages will include caring messages, reminders of appointments, and a link to a web page. The web page is anticipated to include safety planning, volitional helpsheet, and resources information. The text messages are anticipated to send out to the participants on a weekly base for 6 weeks in a row, and then change to monthly reminders. The monthly reminders are anticipated to include caring messages, reminders of appointments, and invitations to encourage the participants to click the previous web links again. The monthly reminders are anticipated to send out to the participants three times in a row. In the final reminder, the participants will be told that this intervention is going to end. In total, the participants will receive 9 texts within 5 months.
45935700|NCT05523739|Drug|STI-1558|An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
45935701|NCT00397358|Drug|Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution|
45935702|NCT05519917|Drug|Afatinib|Subjects will receive evaluations at the beginning of treatment, after every three cycles and at the end of the whole study.
45935703|NCT00078390|Drug|S-3304|S-3304 will be administered at the tolerable dose BID along with chemo-irradiation
45653444|NCT03885583|Procedure|thoracic epidural block|thoracic epidural block with bupivacaine 0.25% will be given in the 8th thoracic space using ultrasound
45653445|NCT03885583|Procedure|paravertebral block|paravertebral block with 0.25 bupivacaine will be given at the level of the incision using ultrasound
45653446|NCT03066817|Drug|Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]|50cc of ergocalciferol 8000 IU/ml will be given to participants as a one-time dose.
45653447|NCT03066817|Drug|Propylene Glycol|50cc of propylene glycole will be given to participants as one-time dose, used as placebo
45653448|NCT05060913|Drug|EMLA Cream|Effect of 5% Emla cream on pricking pain measured on VAS scale.
45935704|NCT00078390|Other|Chemo-irradiation|Standard of care chemo-irradiation
45935705|NCT00402844|Device|Transvaginal mesh- PROLIFT®-system|
45653449|NCT05060913|Drug|Benzocaine Gel|Effect of 20% Benzocaine gel on pricking pain measured on VAS scale.
45653450|NCT05060367|Dietary Supplement|Liposomal multivitamin/mineral|Two-capsule dose of liposomal multivitamin/mineral that is nutrient-matched to the standard multivitamin/mineral.
45676256|NCT04212013|Other|Placebo|Placebo capsules will be similarly dosed at 4 capsules daily.
45804311|NCT00383409|Drug|placebo|
45804312|NCT00355537|Drug|Testosterone|Sustanon- intramuscular testosterone 200mg every 2 weeks
45804313|NCT00355537|Drug|0.9% saline|Saline injection intramuscular every 2 weeks
45804314|NCT00003207|Drug|pegylated liposomal doxorubicin hydrochloride|
45804315|NCT00003207|Drug|PSC 833|
45804316|NCT02978144|Radiation|SPECT-CT imaging|Injection of AxV-128 labeled with 99mTc followed by SPECT-CT
45935706|NCT00044486|Drug|Posaconazole oral suspension|
45935707|NCT05518669|Diagnostic Test|Guided Bronchoscopy with Mobile 3D C-arm CT|Guided bronchoscopy with C-arm imaging.
45935708|NCT00074529|Drug|MK0677|
45935709|NCT05516797|Device|Continuous Glucose Monitoring (CGM)|Use of CGM (FreeStyle Libre 2) compared to BGM for glucose monitoring
45935710|NCT05497336|Drug|IBI351|IBI351 is administered orally
46073754|NCT04708704|Dietary Supplement|SODIS-treated erythrosine, prepared in drinking water (0.69 mg/kg bw/day)|Erythrosine will be SODIS-treated to produce photobleached erythrosine. Transparent 500 mL polyethylene terephthalate (PET) plastic water bottles will be commercially purchased (Kirkland Signature Purified Water). All branding information and labeling will be removed from the bottles. Water bottles will be dosed with ~41 mg erythrosine (0.69 mg/kg bw) using an erythrosine stock solution (8.2 g/L) and will be shaken to mix. The erythrosine-dosed bottles will be placed on a metal shelf and exposed to natural sunlight on the roof of Yale Engineering. Sunlight exposure will be conducted until the absorbance value of erythrosine at the absorption maximum of 526 nm falls below 0.05 above baseline, as measured by ultraviolet-visible spectroscopy. The water bottles containing photobleached erythrosine will be stored under refrigeration in the dark until consumption by participants.
46088479|NCT04193657|Other|Daily and weekly triggered symptom monitoring|Participants are invited to complete a daily questionnaire, a weekly questionnaire, and to track daily activity with an electronic activity tracker.
45653451|NCT05060367|Dietary Supplement|Standard multivitamin/mineral|Two-capsule dose of standard multivitamin/mineral that is nutrient-matched to the liposomal multivitamin/mineral.
45804317|NCT02978144|Drug|AxV-128/Tc|Injection of AxV-128 labeled with 99mTc
45653452|NCT05059821|Biological|Peptide cancer vaccine|Vaccine content are personalized peptides vaccine separated from each patients own tumor cells, autologous heat shock protein 70 separated from tumor cells and autologous activated monocytes that administered subcutaneously monthly for six months
45653453|NCT05165251|Drug|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET QD
45653454|NCT05165251|Drug|Amlodipine 5mg|amlodipine 5mg QD
45653455|NCT05165251|Other|Lifestyle intervention|Lifestyle intervention
45653456|NCT04209075|Dietary Supplement|Biomebliss|BiomeBliss is a commercially available powder containing prebiotic fiber (inulin and beta glucan), along with blueberry extract providing polyphenols.
45804318|NCT05553925|Other|Online Weight Management Program with Coaching and Patient Navigator Support|"Patients will enroll in a 12-month digital health program available in online and mobile versions with live, personalized coaching and patient navigator support.~Patient Interface~Digital scale and Fitbit~Brief lessons that focus on helping patients improve their nutrition, exercise, sleep, and stress~Weight, diet, and physical activity tracking~Regular, personalized feedback and support from a health coach~Spanish Version~Patient navigators are non-licensed staff. Their responsibilities will include enrolling patients in the program, monitoring their progress, and updating providers periodically. They also will be able to connect patients with additional resources and services, such as the Center for Weight Management and Wellness, if appropriate."
45804319|NCT00003387|Drug|carboplatin|
45804320|NCT00003387|Drug|chemotherapy|
45804321|NCT00003387|Drug|paclitaxel|
45804322|NCT00003387|Radiation|radiation therapy|
45653457|NCT04209075|Drug|Metformin|Metformin is a commonly used antidiabetic medication, and the only oral medication approved for children and adolescents under 18 years old. Though reasonably effective, gastro-intestinal side effects are common (80% at initiation, and 10-30% after long term use). Metformin dosing at clinically recommended doses will be titrated per protocol during the study.
45804323|NCT05332639|Behavioral|Personalized Risk Estimation for Crohn's Disease (PRE-CD) tool|We will develop a web-based, personalized risk estimation for CD (PRE-CD) tool to quantitate participants' relative risk (RR) and lifetime risk of CD based on known risk factors for disease. We will consider the following risk factors for Crohn's disease: body mass index (BMI), smoking history, NSAID use, intake of fruit, vegetables, and fiber, oral contraceptive use (females), and anti-microbial biomarker positivity. This tool will also display a participants' personalized summary of their risk factors for CD as well as educational tools for modifying these factors. Construction of this tool is based on the Your Disease Risk tool developed by the Siteman Cancer Center at Washington University in St. Louis School of Medicine. The interventional group will also receive standard education about Crohn's disease (comparison group intervention) via the web-based tool.
45804324|NCT05332639|Behavioral|Standard Crohn's Disease Education|The comparison group will receive standard education about Crohn's disease, which will include information regarding the prevalence of disease, clinical presentation including signs and symptoms of disease, and treatment options including available medications. Upon completion of the study, the comparator arm will be given the option of receiving their personalized risk of Crohn's disease with the PRE-CD tool as well.
45804325|NCT03430349|Biological|Novel OPV2 candidate 1|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 1 (S2/cre5/S15domV/rec1/hifi3).~Modifications included the following:~Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~Two modifications in the polymerase 3D to further improve stability of the attenuation and reduce frequency of recombination events~Relocation of a key replication element from the 2C coding region to the 5'-untranslated region, to inhibit recombination."
46088480|NCT04210518|Other|Neuromuscular training|This intervention consisted of a supervised multimodal exercise protocol addressing different aspects of balance including static and dynamic tasks on the injured ankle. The training program comprised 6 exercises that were progressively adapted depending on the patient's execution controlled by an expert physiotherapist
46088481|NCT04210518|Other|Stroboscopic glasses|Patients included in this group performed the same protocol described in the balance training group with the addition of the stroboscopic glasses during the intervention.
45653458|NCT04209075|Dietary Supplement|Placebo|Placebo Comparator
46088482|NCT02844023|Behavioral|Clinical evaluation|With questionnaire.
45653459|NCT04980495|Biological|Efgartigimod concentrate for solution for infusion 20 mg/mL|Patients receiving efgartigimod IV treatment in a continuous treatment regimen
45653460|NCT04980495|Biological|Efgartigimod concentrate for solution for infusion 20 mg/mL|Patients receiving efgartigimod IV treatment in a cyclic treatment regimen
45653461|NCT05151601|Dietary Supplement|Experimental|2 x sachets per day
45653462|NCT05151601|Other|Placebo|2 x sachets per day
46088483|NCT02844023|Other|Paraclinical evaluation|Symptom inflammatory, biomarkers.
46088484|NCT02844023|Device|Imaging|Thoraco-abdominal scanner injected or PET scanner if contraindication for scanner.
46088485|NCT02844023|Other|Ophthalmologic examination|
45653463|NCT04433221|Biological|Multiple sarcoma-specific CAR-T cells and sarcoma vaccines|1 infusion, CART 1x10^6~1x10^7 cells/kg via IV and vaccines 1-5x10^6 irradiated cells via subcutaneous injection
45653464|NCT05138419|Other|"CKD What You Need To Know Workbook System"|139 page Workbook including CKD Action Plan, Web-Based Resources, Interactive CKD Patient education material
45653465|NCT05138419|Other|CKD Action Plan|Goals based on international guidelines that can protect kidney function (1 knowledge and 10 action goals) Patient education material used separately for control arm.
45804326|NCT03430349|Biological|Novel OPV2 candidate 2|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 2 (S2/S15domV/CpG40).~Modifications included the following:~Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~silent non-coding modifications engineered within the capsid (VP1-4) designed to reduce replicative fitness and, potentially, to improve stability of the attenuated phenotype while also reducing transmission."
45804327|NCT02977988|Behavioral|Mindfulness Meditation|MBRP-W is delivered in 12 bi-weekly 80-minute group sessions. Facilitators with previous experience in MBSR and trained in MBRP-W will deliver each group. Each session has a central theme and is divided into five segments consisting of: (a) a welcome meditation or other mindfulness practice, (b) a review of session objectives, (c) a brief didactic psycho-educational presentation and discussion based on the session's theme, (d) experiential and formal meditation or other practices, and (e) readings and assignments for the next class. Participants are expected to learn skill building techniques to reducing stress using mindfulness-based principles to complement their recovery treatment program.
45653466|NCT05138419|Other|CKD Web-based Resource List|CKD Patient education material used separately for control arm
45653467|NCT05138419|Other|Food Label reading exercise|CKD Patient education material used separately in all arms.
45804328|NCT02977988|Behavioral|Brain and Recovery (B&R)|B&R is delivered in 12 bi-weekly 80-minute group sessions delivered by two trained interventionists. The B&R group will receive didactic education on the neurobiology of addiction. B&R contains no information on behavior change, stress reduction, or mindfulness-based or relapse-related content. The intervention was developed over three years with a population similar to those in the study and with input from patients and experts on neurobiology of addiction. Topics include: (1) brain structures and functions related to addiction, (2) effects of various types of substances on the brain, and (3) rewarding effects and how these lead to addiction. Participants are expected to gain knowledge pertaining to the effects of drugs on the brain.
45804329|NCT01542021|Drug|degarelix injection|Treatment will consist of a single 240 mg injection of degarelix 4 ± 1 day before radical prostatectomy, depending on treatment arm.
45653468|NCT05125939|Other|Comparison of ADR|The investigators will compare ADRs using traditional screening-restricted definition and combined screening, surveillance, and diagnostic indication (i.e., overall-non-FIT indication). The impact of addition of FIT+ indication into the overall indication (i.e., overall-FIT indication) on ADR will also be evaluated.
45804330|NCT01542021|Drug|degarelix injection|Treatment will consist of a single 240 mg injection of degarelix 7 ± 1 day before radical prostatectomy, depending on treatment arm.
45804331|NCT01542021|Drug|androgen deprivation therapy|
45804332|NCT04706897|Drug|Dexmedetomidine, ketamine and lidocaine|A loading infusion of syringe (B) containing the a mixture [dexmedetomidine (2 µg/ml), ketamine (0.5 mg /ml) and lidocaine (4 mg /ml)] was started at rate of 0.2 ml/kg/h ten minutes before induction. Then anesthesia was induced with 2 mg/kg IBW of propofol, patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (D) containing normal saline (as masking for fentanyl in the control group).
45804333|NCT04706897|Drug|Normal saline|A loading infusion of the 50 ml syringe (A) containing normal saline was started at rate of 0.2 ml/ kg/hr ten minutes before induction (as masking for mixture in group S). Then anesthesia was induced with 2 mg/kg ideal body weight (IBW) of propofol , patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (C) containing fentanyl (1mic/kg of IBW).
45804334|NCT00003213|Drug|dexamethasone|4 mg Dexamethasone in the morning
45804335|NCT00003213|Drug|granisetron hydrochloride|1 mg Granisetron in the morning
45804336|NCT00003213|Drug|metoclopramide hydrochloride|20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening)
45804337|NCT05716100|Drug|XEN1101|XEN1101 Capsules
45804338|NCT05716100|Drug|Placebo|Placebo Capsules
45804339|NCT04735289|Other|EPIC-COS Food Frequency Questionnaire diet Evaluation|Anthropometric measurements (Body mass Index, Lean and fat body composition evaluation) and diet habits evaluation with EPIC-COS-FFQ
45804340|NCT04735289|Other|Metabolome, Microbiota, Lymphocytes subpopulations|"At diagnosis before any treatment for bone sarcoma will be obtained :~a blood sample for metabolomics analyses~a stool sample for microbiota analysis~Lymphocyte subpopulations (CD3, CD4, CD8, NK) will be analyzed in blood samples"
46088486|NCT02844023|Biological|Dosage of biomarkers|Control patients.
45653469|NCT03065101|Device|Trigen Intertan|While both the Trigen InterTAN and Sliding Hip Screw are marketed and demonstrated to be suitable for treatment of the study indication, the randomisation is considered an intervention as it may be contrary to the treatment chosen by the surgeon were the patient not a study subject.
45653470|NCT03065101|Other|Post-Surgery Follow Up|The current clinical trend is for minimal follow up post-surgery, unless indicated by complications. The study protocol indicated that follow up telephone visits are to be performed at 8 weeks, 12 weeks and 12 months post-surgery and an outpatient follow up visit at 6 months post-surgery. While most outcome measures are conducted via questionnaire, the increase in follow up means that subjects may be exposed to increased ionising radiation.
45653471|NCT03065101|Device|Sliding Hip Screw|Sliding Hip Screw
45935711|NCT05497336|Drug|Cetuximab|Cetuximab is administered intravenously
45804341|NCT01445067|Drug|BMS-927711 (CGRP Antagonist)|Capsule, Oral, 300 mg, Once, One day
45935712|NCT00044525|Drug|BAY59-8862 (Cytotoxic Taxane)|1 h intravenous infusion every 3 weeks
45653472|NCT02520531|Device|Scorpio PS (posterior stable)|Implantation of total knee prosthesis
45653473|NCT02520531|Device|Scorpio NRG PS|Implantation of total knee prosthesis
45653474|NCT05023473|Procedure|Pericapsular nerve group block|patients will receive pericapsular nerve group block
45653475|NCT05023473|Drug|Morphine Sulfate|morphine will be given to both groups as patient-controlled analgesia PCA
45653476|NCT03066661|Drug|Entrectinib|Open-label expanded access, capsules
45653477|NCT04978779|Drug|VIP152|Weekly IV infusion (30 minute) for 21 day cycles.
45653478|NCT04943497|Other|ribociclib|There is no treatment allocation. Patients administered ribociclib by prescription that have started before inclusion of the patient into the study will be enrolled.
45653479|NCT04943497|Other|aplelicib|There is no treatment allocation. Patients administered aplelicib by prescription that have started before inclusion of the patient into the study will be enrolled.
45653480|NCT04943497|Other|mono endocrine therapy|There is no treatment allocation. Patients administered mono endocrine therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
45653481|NCT04943497|Other|chemotherapy|There is no treatment allocation. Patients administered chemotherapy by prescription that have started before inclusion of the patient into the study will be enrolled.
45653482|NCT05022147|Device|High-Frequency-Only Stimulation|Control condition, constant high-frequency DBS stimulation (130Hz)
45653483|NCT05022147|Device|Low-Frequency-Only Stimulation|Experimental condition, constant low-frequency DBS stimulation (60 Hz)
45653484|NCT05022147|Device|Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 50 seconds for high, and 10 seconds for low, respectively.
45653485|NCT05022147|Device|Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 50 seconds for high, and 50 seconds for low, respectively.
45804342|NCT01445067|Drug|BMS-927711 (CGRP Antagonist)|Capsule, Oral, 600 mg, Once, One day
45804343|NCT05716022|Diagnostic Test|Blood Collection|Prior to subject's surgical procedure, blood (about 3 tablespoons (44 mL)) will be collected through a needle in vein for research purposes. The UVA researchers will analyze the biomarkers that are expressed in subject's blood.
45804344|NCT05716022|Diagnostic Test|Bronchoscopy|Following blood collection, the subject will undergo the bronchoscopy for research purposes. While in the operating room, a bronchoscope will be inserted through the breathing tube that is already been placed for the surgery. Subject's airways will be examined with the bronchoscope in both lungs. Ten tablespoons (150 mL) of saline solution will be injected into one of subject airways. The fluid will be re-collected by suctioning it back up with the bronchoscope. The fluid will be collected from the bronchscope.
45804345|NCT03847675|Behavioral|Reach out and Read|"The intervention group will be viewing a video encouraging to read to their children and giving tips on reading methods, in addition will be given a schematic pamphlet highlighting the importance of reading Arabic to children.~After each visit participants will receive an age appropriate book for their child (a total of 3 books). The first book consist of popular nursery rhymes that are usually sung for younger infants. The choice of the 2 other books is based on recommendations from an early child educator according to age specificity.~Focus group conducted by a qualitative researcher will follow the protocol reported by Richard A. Krueger."
45804346|NCT02978066|Other|Spinal anaesthesia|
45804347|NCT00003399|Drug|carmustine|
45804348|NCT00003399|Drug|cisplatin|
45804349|NCT00003399|Drug|cyclophosphamide|
45653486|NCT05022147|Device|Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 10 seconds for high, and 50 seconds for low, respectively.
45804350|NCT00003399|Drug|dexamethasone|
45804351|NCT00003399|Drug|etoposide|
45804352|NCT00003399|Drug|melphalan|
45804353|NCT00003399|Drug|paclitaxel|
45804354|NCT00003399|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45804355|NCT03376061|Drug|Tranexamic Acid|Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
45804356|NCT02978989|Procedure|nonsolo LC|This patient is scheduled to undergo nonsolo laparoscpic cholecystectomy.
46002130|NCT04767594|Drug|Palbociclib + endocrine therapy|Palbociclib + letrozole, or Palbociclib + anastrozole, or Palbociclib + exemestane, or Palbociclib + fulvestrant after prior endocrine therapy In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.
46002131|NCT04767529|Drug|EFX|Administered by subcutaneous injection
45804357|NCT02978989|Procedure|solo LC|This patient is scheduled to undergo solo laparoscpic cholecystectomy.
45804358|NCT02977910|Procedure|repair of deltoid ligament|intraoperative repair of deltoid ligament combined with ORIF
45804359|NCT04656223|Combination Product|MF/IND/GLY plus sensor system|"There is no treatment allocation. Patients administered MF/IND/GLY plus sensor system by prescription that have started before inclusion of the patient into the study will be enrolled.~Subjects will receive MF/IND/GLY together with the Propeller add-on sensor for the Breezhaler® according to label."
45804360|NCT04656223|Drug|FDC therapy|There is no treatment allocation. Patients administered FDC therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
45804361|NCT05715944|Drug|AZD 1222|Vaccine
46002132|NCT04767529|Drug|Placebo|Administered by subcutaneous injection
46002133|NCT04754087|Device|Vivacit-E and Longevity (HXLPE) Liners|This is a dual cohort study in which 150 subjects will receive the Vivacit-E (HXLPE) Liner and 150 subjects will receive the Longevity (HXLPE) Liner.
45935713|NCT05492344|Other|Personalized ventilation|"Patients who are randomized for personalized ventilation with FOCAL ARDS will receive the following ventilator settings:~Positive end-expiratory pressure (PEEP) ≤ 9 cm water (H2O)~Tidal volume: 6 to 8 mL/kg predicted body weight (PBW)~Daily prone positioning~LUS will be repeated every 48-72 hours in supine position for the focal ARDS patients to assess whether they have developed non-focal ARDS during admission. In that case, patients will from then on be treated according non-focal personalized treatment protocol.~Patients who are randomized for personalized ventilation with Non-FOCAL ARDS will receive the following ventilator settings:~PEEP ≥ 15 cm H2O~Tidal volume: 4 to 6 mL/kg PBW~Daily recruitment maneuver"
45653487|NCT05022147|Device|Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 10 seconds for high, and 10 seconds for low, respectively.
45804362|NCT03376295|Drug|LABA and the LAMA tiotropium (LABA-TIO)|combinational drug
45804363|NCT03376295|Drug|LABA and an ICS (LABA-ICS)|combinational drug
45804364|NCT05624684|Diagnostic Test|Multiplex respiratory PCR|The BIOFIRE® FILMARRAY® Pneumonia plus Panel
45935714|NCT05492344|Other|Standard care|"Patient who are randomized in the control group will receive standard care~Tidal volume: 6 mL/kg PBW~PEEP and FiO2 according to the low PEEP and high fraction of inspired oxygen (FiO2) table of the AlVEOLI study~Prone positioning if the Partial Pressure of Oxygen (PaO2) /FiO2 ratio is < 150 mmHg"
45935715|NCT04706143|Biological|COVID-19 Vaccines|different available vaccines: live inactivated, mRNA and viral vector vaccines
45935716|NCT05469490|Radiation|Stereotactic Body Radiotherapy (SBRT)|SBRT is specialize radiation that is effective for ablating tumors at primary and metastatic locations that increases antigen uptake/processing/presentation.
45935717|NCT05469490|Drug|navoximod|A small molecule inhibitor with potent inhibition of IDO1 enzymatic activity as shown both in vitro and in vivo. As the main function of IDO1 is the regulation of acquired immune tolerance, and its expression in tumor- and dendritic cells in tumor draining lymph nodes negatively correlates with cancer prognosis and survival, navoximod-mediated IDO1 inhibition may restore immune reactivity towards tumors.
45935718|NCT05469490|Drug|NLG802 (indoximod Prodrug)|An anti-tumor immunomodulator with the active ingredient of 1-methyl-D-tryptophan (NSC- 721782, 1-MT), which is an inhibitor of the indoleamine 2,3-dioxygenase (IDO) pathway that increases the bioavailability of indoximod by leveraging existing mechanisms of absorption, increasing the exposure of indoximod.
45935719|NCT05421832|Device|Digital Speech Application|A custom smartphone-based speech assessment tool to extract multiple hypothesis-driven acoustic features from patient speech in a real-life environment.
45935720|NCT00078468|Drug|PELITREXOL/AG-2037|
46073755|NCT04708704|Dietary Supplement|Iodine, prepared in drinking water 0.075 mg/kg bw/day)|Iodine used in the study will be in the form of FCC-grade potassium iodide, which will be obtained from VWR. FCC grade potassium iodide meets the requirements set by the Food Chemical Codex and is suitable for all applications in foods and beverages. Iodine (control exposure) will be prepared in 500 mL of drinking water and participants will received single daily doses for 14 days. We will use a targeted dose of 0.75 mg/kg bw.
46073756|NCT00842803|Drug|Albumin infusion (25% albumin)|Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
45653488|NCT05022147|Drug|OFF Dopaminergic Medication|All six device interventions will be performed in medication OFF state
45653489|NCT05022147|Drug|ON Dopaminergic Medication|All six device interventions will be performed in medication ON state
45804365|NCT03843775|Drug|Binimetinib|Dose level 1 binimetinib 45 mg PO BID. Dose level 2 binimetinib 60 mg oral BID
45804366|NCT03843775|Drug|Encorafenib|encorafenib 450 mg oral QD
45804367|NCT05624060|Behavioral|Pelvic Floor Dysfunction Prevention Training|"The Pelvic Floor Dysfunction Prevention Training booklet is cover weight control, perineal hygiene, adequate fluid consumption, not smoking and alcohol use, avoidance of spicy, fizzy and fatty foods and beverages, correct posture and frequency of micturition, prevention of constipation and abdominal pressure."
45804368|NCT05624060|Behavioral|Pelvic Floor Dysfunction Prevention Training and Perineal Massage|"Women will apply perineal massage for an average of 8-10 minutes at least twice a week, starting from the 34th week of pregnancy until delivery. In addition to perineal massage, the Pelvic Floor Dysfunction Prevention Training booklet will be given to participant."
45935721|NCT00397436|Procedure|UV Irradiation|UV irradiation
45935722|NCT05377216|Drug|Stellate Ganglion Block|Left sided percutaneous stellate ganglion block
46002134|NCT04749693|Device|DBLG1 System|Use of DBLG1 System in real life condition
46002135|NCT04743570|Drug|Placebo treatment|Active drug/placebo is given for the first 5 days of admission.
46002136|NCT04743570|Drug|Methylnaltrexone treatment|Active drug/placebo is given for the first 5 days of admission.
46002493|NCT02167711|Drug|SIRT Yttrium-90|
45653490|NCT03712657|Combination Product|ERAS|"preoperative pain control;~avoiding application of ureter;~avoiding application of gastric tube;~avoiding application of irrigation;~avoiding application of drainage;~early exercising postoperatively;~early oral feeding postoperatively;~early discharging."
45653491|NCT05105503|Device|Eko CORE Digital Stethoscope|The digital stethoscope will be used to take 9 recordings around each subject's maturing AVF once per week until study participation is over
45653492|NCT05020977|Other|Blood pressure, physical activity, health|Observational study of work environment, leisure time, blood pressure, physical activity and health
45653493|NCT05057793|Device|geko|The geko device will be self-administered and deliver 12 hours of therapy daily.
45653494|NCT03775629|Drug|Polmacoxib and Tramadol combination|Tramadol hydrochloride , Polmacoxib
45653495|NCT03775629|Drug|Polmacoxib|Polmacoxib
45653496|NCT03775629|Drug|Tramadol hydrochloride|Tramadol hydrochloride (HCl)
46073757|NCT04759170|Other|Music therapy|The effects of receptive music therapy on oral nutrition and the well-being of the Italian premature baby
45653497|NCT04978311|Behavioral|Mirror therapy (MT) priming with task-specific training|In the regimen, participants will perform MT first followed by task-specific training. After completion of MT, participants will practice task-specific training that emphasizes on restoration of essential skills for daily activities. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
45653498|NCT04978311|Behavioral|Mirror therapy priming with impairment-oriented training|In the regimen, participants will perform MT first followed by impairment-oriented training. After completion of MT, participants will practice impairment-oriented training that emphasizes on restoration of movement. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
45653499|NCT04978311|Behavioral|Control therapy|The control group will receive therapeutic training equivalent in duration to the two experimental groups. The control intervention will include practice of gross/fine motor activities, training of activities of daily living, practice to increase range of motions, muscle strengthening, as well as use of adaptive or compensatory technique to alleviate functional deficits. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
45653500|NCT04976205|Radiation|Total Marrow (Lymph-node) Irradiation|To the standard procedure for TMI/TMLI target definition, based on simulation WB-CT acquired 10/15 days before BMT, we acquire: WB- magnetic resonance imaging (MRI) the same day of the simulation WB-CT. A verification WB-CT will be performed 3/4 days before the delivery. Plans will be optimized with Volumetric Modulated Arc Therapy (VMAT) technique.
45653501|NCT01671319|Drug|docetaxel + cyclophosphamide + pegfilgrastim|docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2 IV every 2 weeks x 4 cycles plus pegfilgrastim 6mg sq 24-48 hours post day 1 of each cycle
45653502|NCT05056623|Behavioral|Dyadic pain management program|"Face-to-face part: The DPM will start with 20-30 minutes of physical exercise supervised by research assistant, followed by 20-minutes of pain management education. Communication skills regarding the practice of various pain management techniques by the participants and their caregivers will be taught. At the end of the session, the caregiver and research assistant will help the older adults to make portfolio entries on the activities of the day, to help them recall the various pain-relief methods learned in each class.~Home-based part: An exercise book will be given to guide them in performing exercises at home. It is recommended to perform 30 minutes of exercise, 3 times a week, at home and the more frequent the exercise time, the better.~All participants will join a WhatsApp group to receive teaching materials and videos of the physical exercises learned, for practice at home. The team will produce compact disc (CD) with the exercise video clips to the dyads for revision."
45653503|NCT05056623|Other|Usual care and pain management pamphlet|Usual care and pain management pamphlet
45653504|NCT05055609|Drug|TRE-515|TRE-515 will be administered orally once daily at least 1 hour prior or 2 hours after eating at approximately the same time each day. Dosing will be continuous with no breaks between cycles. Subjects will continue to receive successive cycles of TRE-515 treatment as long as they do not demonstrate progressive disease, experience an unacceptable toxicity, and both the Sponsor and PI consider additional treatment with TRE-515 to be within the best interest of the subject.
46073758|NCT00842881|Device|Healingstone navel belt|6~8hours/day for 3months
45653505|NCT05019885|Drug|Ketamine Hydrochloride|Three times a week (M, W, F) for 2 consecutive weeks.
45653506|NCT05019105|Drug|Placebo|Oral matching placebo
45653507|NCT05019105|Drug|ALKS 1140|Active oral dose of ALKS 1140
45653508|NCT04933747|Drug|Iberdomide|Administration of a single oral dose of 1mg iberdomide in participants
45653509|NCT04933747|Drug|Iberdomide|Administration of a single oral dose of 1mg iberdomide in participants on 2 occasions - once on a dialysis day and once on a non-dialysis day
45935723|NCT00074607|Drug|Gemcitabine|"Schedule~Induction: At Dose Level 1athe first cohort of patients will receive intrathecal gemcitabine on a weekly basis for a total of 6 weeks. If that is tolerated, the subsequent cohort will receive intrathecal gemcitabine on a twice-weekly basis (Dose Level 1b) for a total of 6 weeks. Subsequent cohorts (Dose Levels 2 - 6) will receive intrathecal gemcitabine on a twice weekly basis for a total of 6 weeks (12 doses).~In the absence of disease progression or DLT, patients may proceed to consolidation.~Consolidation: Intrathecal gemcitabine will be administered weekly for a total of 6 doses. The first dose of consolidation will be given 1 week after the last induction dose. In the absence of disease progression or DLT, patients may proceed to maintenance.~Maintenance: Intrathecal gemcitabine will be given twice monthly for 4 months and monthly thereafter. In the absence of progressive disease or dose-limiting toxicity, the total duration of therapy will be 1 year."
45935724|NCT05361616|Device|PBM Ortho|The device will be used by the patients at home for one 8 minutes per day (4 minutes each upper and lower) for 7 days.
45935725|NCT05305885|Drug|Pemetrexed|Intrathecal administration, intraventricular administration or via lumbar puncture, pemetrexed plus dexamethasone, first induction intra-cerebrospinal fluid chemotherapy twice per week for 2 weeks, then once per week for 4 times, 6 weeks in total.
46073759|NCT05164289|Other|Control group|Patients in the control group will have simple consultations on D15, D30, D45, D60 and D75
46073760|NCT05164289|Other|EMDR group|Patients in the EMDR group will have EMDR session on D15, D30, D45, D60 and D75
46073761|NCT05659368|Drug|Tirzepatide|tirzepatide once weekly
46073762|NCT00818649|Drug|bortezomib|1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle
45653510|NCT05018325|Procedure|Colonoscopy with 6 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
45653511|NCT05018325|Procedure|Colonoscopy 9 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
45653512|NCT05018325|Procedure|Colonoscopy 12 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
45804369|NCT05624060|Behavioral|Pelvic Floor Dysfunction Prevention Training and Perineal Massage and Pelvic Floor Exercise|"Women assigned to this group will apply pelvic floor exercise at least 3 days a week 8-12 times a week, starting from the 34th week of pregnancy until delivery. In addition, women will apply perineal massage for an average of 8-10 minutes at least twice a week, starting from the 34th week of pregnancy until delivery. In addition to perineal massage, the Pelvic Floor Dysfunction Prevention Training booklet will be given to participant."
45804370|NCT03381989|Device|ASHI_INTECC Astato XS 20 0.014 guidewire|A coaxial traversal guiding catheter system (typically tandem catheters) directs electrosurgery devices (typically a rigid 0.014 guidewire inside a polymer jacket wire convertor) against the base of the coronary cusp targeted for laceration, using fluoroscopic and/or echocardiographic guidance. Traversal is accomplished by transcatheter electrosurgery by connecting the back end of the 0.014 guidewire to an electrosurgery pencil during short bursts of pure, cutting radiofrequency energy at ap-proximately 30W. The guidewire is repositioned as needed until it crosses the aortic leaflet and is snare-retrieved and externalized. Laceration is performed by positioning the laceration surface along the intended leaflet base, and applying tension on both free ends of the guidewire while simultaneously apply electrosurgery energy (typically 70W) in short bursts, until the laceration is complete and the guidewire is free.
45835591|NCT04782882|Behavioral|Progressive muscle relaxation+laughter therapy|"Laughter therapy:Laughter therapy is a technique that changes the mood by breathing correctly and by combining childish exercises with laughter exercises to turn into real laughter for no reason.~Progressive muscle relaxation procedure:~the participants were asked to tighten and relax large muscle groups in the body with deep breathing exercises. Progressive muscle relaxation was applied to the muscles of the head and face, neck, chest, back, arms, hands, abdomen, hips, legs and feet. The procedure was applied in a dark environment and accompanied by candlelight and relaxing music."
45653513|NCT03064711|Diagnostic Test|Electronyugraphy|Surface electromyography (sEMG) recorded diaphragmatic muscle activity during rest and while performing maximal voluntary ventilation
45653514|NCT04208919|Biological|Donor-derived DCreg|Regulatory dendritic cells that were prepared from a donor leukapheresis will be infused into liver transplant recipients 7 days prior to the start of immunosuppression weaning.
45653515|NCT03064945|Device|Livia|Livia® Transcutaneous Electrical Nerve Stimulation (TENS) is a novel pain management device for women suffering from dysmenorrhea
45835592|NCT01014936|Drug|MSC2156119J|
45835593|NCT01004640|Genetic|DNA analysis|
45835594|NCT01004640|Genetic|Southern blotting|
45835595|NCT01004640|Genetic|cytogenetic analysis|Correlative studies
45835596|NCT01004640|Genetic|polymerase chain reaction|
45835597|NCT01000350|Drug|Saline|IV Normal Saline infused over 30-60 minutes given 3-6 hours PRIOR to exercise study
45835598|NCT01000350|Other|Placebo|Placebo x1 lactose tablet
45835599|NCT01896180|Drug|ALZ-1101|ALZ-1101 Ophthalmic Solution
45835600|NCT01896180|Drug|Latanoprost|Latanoprost 0.005% Ophthalmic Solution
45835601|NCT00981162|Drug|sorafenib tosylate|Given PO
45835602|NCT00981162|Drug|everolimus|Given PO
45835603|NCT00981162|Other|laboratory biomarker analysis|Correlative study
45835604|NCT00981162|Other|pharmacogenomic studies|Correlative study
45835605|NCT00981162|Other|pharmacological study|Correlative study
45835606|NCT00960102|Device|cochlear implant|Multichannel Nucleus cochlear implant
45835607|NCT00960102|Device|hearing aid|Phonak hearing aid
45835608|NCT04755894|Drug|HDDO-1756|single dose
45835609|NCT04755894|Drug|HDDO-17561/HDDO-17562|single dose
45835610|NCT04782024|Dietary Supplement|7-Keto 50mg|
45835611|NCT04782024|Dietary Supplement|7-Keto 25mg|
45835612|NCT04782024|Dietary Supplement|Placebo|
45835613|NCT04389762|Dietary Supplement|daily ingestion of Lactobacillus plantarum PS128|daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)
45835614|NCT04346160|Diagnostic Test|Schirmer Test I|Collection of tear fluid
45835615|NCT04755348|Other|Product A|A 4mg nicotine pouch product
45835616|NCT04755348|Other|Product B|A 4mg nicotine pouch product
45835617|NCT04755348|Other|Product C|A 2mg nicotine lozenge product
45835618|NCT04755348|Other|Product D|A 2mg nicotine lozenge product
45835619|NCT04755348|Other|Product E|A 2mg nicotine lozenge product
45835620|NCT04755348|Other|Product F|A 2mg nicotine lozenge product
45835621|NCT04755036|Other|Survey and case vignette|We sent a survey and case vignette cases to every responsible in each center
45835622|NCT04754958|Device|Immersion in virtual reality using Nordic Neurolab(™) Visual System|In addition to the standard MRI procedure, the VR intervention group will be looking at stereoscopic computer generated images through a pair of head-coil-mounted googles (Nordic Neurolab ™ Visual System). Two markers (color balls) will be fixed on their knees to capture their movement (camera tracking from the outside of the MRI room). The VR scenario will consist in showing a replication of the actual MRI examination room, as seen from the point of view of the participant lying on the MRI bed, but without the MRI tunnel. Participant can see themselves in the large room (a simplified gender-matched avatar), and an entertaining video can be displayed.
45835623|NCT04781868|Drug|Multi-nutrient supplement|Multi-nutrient supplement containing a combination of vitamins, minerals and antioxidants
45835624|NCT04781868|Drug|Placebo|Placebo
45835625|NCT00909012|Dietary Supplement|high oleic sunflower oil|placebo, which does not provide DHA
45835626|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 20 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
45835627|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 40 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
45835628|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 80 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
46073763|NCT00818649|Drug|vorinostat|400 mg orally (po) every day on days 1-14 of a 21 day cycle
46073764|NCT00850213|Device|Endeavor Resolute Stent|Single implantation
46073765|NCT04808544|Drug|Dinalbuphine sebacate|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
46073766|NCT04808544|Drug|Placebo solution|Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
46073767|NCT02822352|Other|Chromoendoscopy|High definition virtual chromoendoscopy
46073768|NCT02861105|Drug|LMWH|LMWH will be given on daily basis subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
46073769|NCT02861105|Other|0.9% saline solution|0.9% saline solution will be given subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
46073770|NCT00842959|Device|Invent ZO|monofocal aspheric IOL for implantation into capsular bag
45653516|NCT05016609|Device|OraQuick HCV Antibody test (OraSure Technologies, Inc)|The OraQuick HCV test is a point of care antibody test for detecting HCV antibodies in fingerstick blood. The test takes 20 minutes to provide a result. Appropriate pre- and post-test counselling will be provided to participants.
45653517|NCT05016609|Device|Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)|Xpert® HCV VL Fingerstick is an in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of Hepatitis C Virus (HCV) RNA in human venous and capillary fingerstick EDTA whole blood. Only participants who return a reactive OraQuick HCV Antibody test will be offered the Xpert® HCV VL Fingerstick test. Appropriate pre- and post-test counselling will be provided to participants.
45457995|NCT03508492|Other|Surgical tinted Nex Clorex 2% applicators|We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.
45653518|NCT05016609|Drug|Sofosbuvir/Velpatasvir (Gilead)|Participants with a detectable HCV antibody will be offered treatment with sofosbuvir/velpatasvir.
45653519|NCT05016141|Behavioral|digital fall prevention program|The participants will receive a digital fall prevention program consisting of fall risk reduction education (modified Matter of Balance), Otago Exercise Program, Personalized S.M.A.R.T Goals, and will use the app to keep track of their health and health events, including falls.
45804371|NCT05623748|Procedure|CTCs isolation/purification and cell number expansion|In the 1st year research project, investigators will further validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion. In the 2nd and 3rd year research project, investigators will optimize the 3-D cell culture model so as to increase the performances of CTC isolation/purification and proliferation. In the optimization process, investigators will explore the effect of cell culture model (e.g. static or perfusion cell culture, and 3-D cell culture using different 3-D scaffolding materials) or biochemical factors (e.g. glucose concentration, serum concentration, pH, or the supplements of growth factors/cytokines) on the the performances of CTC isolation/purification and proliferation.
45835629|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 130 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
45835630|NCT00877500|Other|Best Practice|Receive standard of care
45835631|NCT00877500|Drug|Ixabepilone|Given IV
46073771|NCT00842959|Device|XL Stabi ZO|monofocal aspheric IOL for implantation into capsular bag
46073772|NCT04240158|Drug|IW-6463|IW-6463 Tablet
46073773|NCT04240158|Drug|Matching Placebo|Matching Placebo Tablet
45835632|NCT00875004|Biological|epoetin beta|
45835633|NCT00875004|Drug|systemic chemotherapy|
45835634|NCT00875004|Procedure|quality-of-life assessment|
45835635|NCT00869232|Drug|Velcade|1.0mg/m2 days 1, 5, 8, & 11
45835636|NCT00869232|Drug|Melphalan|10 mg/m2 day 3
45835637|NCT00869232|Drug|Thalidomide|200 mg days 5-8
45835638|NCT00869232|Drug|Dexamethasone|40 mg day 5-8
45835639|NCT00869232|Drug|Cisplatin|10 mg/m2 day 5-8
45835640|NCT00869232|Drug|Adriamycin|10 mg/m2 day 5-8
45835641|NCT00869232|Drug|Cyclophosphamide|400 mg/m2 day 5-8
45835642|NCT00869232|Drug|Etoposide|40 mg/m2 day 5-8
45835643|NCT04781790|Other|Bone Marrow Failure|without interventional intervention . biological collection in the routine care Standard of care of patients with bone marrow failure.
45835644|NCT05320692|Drug|TACE+Camrelizumab+Apatinib mesylate|TACE. Camrelizumab，200mg，iv，once every 3 weeks. Apatinib mesylate, 250 mg, administered orally once daily，once every 3 weeks.
45835645|NCT05320692|Procedure|TACE|TACE Alone.
45835646|NCT01895166|Procedure|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
45835647|NCT01895166|Procedure|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
45835648|NCT04781556|Other|No intervention|All patients treated between 01/01/2017 and 12/31/2018 in the Fracture sector will be screened through the computerized medical file. For patients who meet all the eligibility criteria, the information note, study questionnaire and a stamped envelope will be sent to them by post. Without feedback from him within 30 days of this submission, the patient is considered not to have objected to the study. The patient's information as well as his non-objection will be recorded in his medical file.
45835649|NCT01763580|Drug|Tacrolimus|Oral
45835650|NCT01763580|Drug|Prednisolone|Oral
45835651|NCT04754724|Diagnostic Test|GIMate|Use of GIMate to detect lactose malabsorption
45835652|NCT04754724|Diagnostic Test|H2 Check|Use of H2 Check to detect lactose malabsorption
45835653|NCT04781010|Device|MRI|MRI pattern in children with Leukodystrophy
45835654|NCT00857922|Other|tissue and data repository|Tissue and data will be maintained in a repository for study from consenting subjects.
46088487|NCT04209816|Diagnostic Test|Lipoprotein kinetics|Lipoprotein kinetic apply protocol that endogenously label proteins and fatty acids with stable isotope-labeled amino acid and glycerol tracers. De novo lipogenesis is measured after ingestion of deuterated water to measure newly formed fatty acids in VLDL. Liver fat is measured with magnetic resonance spectroscopy and lipolytic enzymes with heparin test.
46088488|NCT02844335|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
45653520|NCT05024929|Procedure|Whole body scan|"Patients will receive oncogene-specific molecularly targeted therapy independently of this protocol either via commercial supply of an FDA approved agent, or as part of a separate therapeutic clinical trial/compassionate use protocol/single patient investigational new drug (IND).~During screening, patients will undergo a baseline RAI-whole body scan (WBS) to assess RAI-avidity of their tumor per standard of care. Following approximately 28 days of targeted therapy, the WBS will be repeated to determine whether this therapy is associated with an increase in RAI-avidity of their tumor."
45653521|NCT03763305|Drug|Propofol continuous infusion|Propofol intravenous continuous infusion for anesthetic induction and maintenance
45653522|NCT03763305|Drug|Remifentanil|Remifentanil intravenous continuous infusion for anesthetic induction and maintenance
45653523|NCT03763305|Drug|Sevoflurane|Study participants receive fentanyl 1mcg/kg and propofol 1.5~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, desflurane is used to maintain 1 age-related minimum alveolar concentration (MAC).
45653524|NCT03763305|Drug|Desflurane|1 age-related minimum alveolar concentration (MAC) of desflurane inhalation for anesthetic maintenance
45653525|NCT03763305|Drug|Propofol bolus injection|Propofol intravenous injection for anesthetic induction
45653526|NCT03763305|Drug|Fentanyl|Fentanyl intravenous injection for anesthetic induction
45653527|NCT05054361|Diagnostic Test|MAIT cells analysis|For FACS analysis, MAIT cells will be identified as CD3+ CD4- CD161high Vα7.2+ T cells. Surface markers will be analyzed to determine their activation status (CD25, CD69, CD44), their exhaustion (PD1, KLRG1, TIM3), their migration capacity (CCR6), and their proliferation and survival will be analyzed by Ki67 and BCL2 expression.
45653528|NCT05054361|Diagnostic Test|MAIT cytokines production analysis|Cytokine production will be assessed after PMA-ionomycin activation, followed by intracytoplasmic staining with antibodies against IL-2, IFN-γ TNF-α, IL-2, IL-4, IL-10, IL-13, IL-17 and granzyme B. To determine the capacity of MAIT cells to response to TCR stimulation (exhaustion), in vitro stimulation will be performed in the presence of specific bacterial ligands. Activation marker expression will be analyzed by FACS and cytokines released in the supernatant by Cytometry based assay.
45804372|NCT05310019|Other|Physiotherapy and Electroacupuncture|TThe physiotherapy treatment (50min): warm compress with facial thermal blanket, respiratory muscle mobility training and cervical muscle relaxation, facial lymphatic drainage, start of myolymphokinetic exercises for the orbicularis, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma, release of intraoral adhesions, vacuum therapy at 60 mmHg, active exercises free of mandibular movements, maintenance of mandibular opening with wooden tongue depressors. The electroacupuncture treatment lasting another 30 min. Electroacupuncture treatment lasting another 30min. The repetition time of 1 sec; (F1-10 Hz, F2= 45 Hz; 10 mA). Facial acupuncture needles are disposable with 0.20 mm gauge and 10 mm length. Each needle will be inserted at the indicated points, totaling 10 needles and electrodes will be connected to each one. Electrical stimulation will be performed on the face points: E4, Jiachengjiang (extra point), E5, E6, bilaterally and point CV-24.
45835655|NCT00826098|Biological|Platelet Rich Plasma|Addition of PRP to total knee replacement procedure
45653529|NCT05054361|Diagnostic Test|Lactulose/Mannitol Test|After an overnight fast, the patients will drink 50 ml solution of 5 g lactulose and 2 g mannitol. Urine will be collected during before and 5 hours later.
45653530|NCT05054361|Procedure|UGI Endoscopy|Duodenal biopsy collection and analysis. Biopsies will be analyzed by qPCR for the expression of key epithelial molecules such as the fucosyl transferase 2 (fut2), tight junction proteins (occludin, claudin4), antimicrobial peptides (Reg3, LL37) and mucus component (mucin 2). Immune cells function will also be assessed by q-PCR for key cytokines/molecules such as IL-23, IL-17, IL-22, Foxp3, IL-10, TGFb and CVB.
45835656|NCT04381416|Device|SEAD treatment|up to two 30-min endometrial ablation sessions using the IUB SEAD™ device, in a hospital outpatient clinic
45835657|NCT01753830|Device|Durolane|4.5 mL
45835658|NCT01753830|Device|PBS|4.5 mL
45835659|NCT04314492|Procedure|Tonsillectomy|Intracapsular removal of tonsillar tissue (>90%) with coblation
45835660|NCT03990948|Other|Blood sampling|Blood sample collection
45835661|NCT01745250|Device|Emervel Lips|Lip treatment of both upper and lower lip
45835662|NCT01745250|Device|Juvederm Ultra Smile|Lip treatment of both upper and lower lip
45835663|NCT03969420|Drug|Alvocidib (flavopiridol) and cytarabine (Ara-C)|Alvocidib (flavopiridol), administered intravenously, + cytarabine (Ara-C), administered by subcutaneous injection
45835664|NCT03969420|Drug|Alvocidib (flavopiridol)|Administered intravenously
45835665|NCT00760812|Behavioral|Early Social Interaction Project- PII|The PII is an intensive, individualized treatment that teaches parents how to support social communication skills in children with autism by embedding skills practice within everyday routines, activities, and places. Participants will have three 75-minute sessions weekly with study administrators for the first 7 months of the study. Participants will then have two sessions per week for the final 2 months of the study. Children will also practice socialization embedded in normal activities for 25 hours a week outside of study visits.
45835666|NCT00760812|Behavioral|Early Social Interaction Project- IES|The IES intervention provides access to a support group meeting twice monthly for children with autism and their parents. The support group provides information to families and a playgroup where parents may practice intervention strategies under the supervision of study officials knowledgeable about autism spectrum disorders.
45835667|NCT01740492|Drug|Ketamine 0.15mg/kg|0.15mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
45835668|NCT01740492|Drug|Ketamine 0.3mg/kg|0.3 mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
45835669|NCT01740492|Other|Placebo|Placebo injection of 0.9% normal saline of a similar volume (0.05ml/kg)
45935726|NCT05305885|Radiation|Radiotherapy|Concurrent radiotherapy consisted of fractionated, conformal radiation given at a daily dose of 2 Gy. The planning volume consisted of sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii received 40 Gy in 20 fractions, 4 weeks in total, and/or segment of spinal canal received 40 Gy.
45935727|NCT00044564|Drug|Bay 59-8862|75 mg/m2 of BAY 59-8862 intravenously over one hour. Treatment will be repeated once every 3 weeks and tumor measurements will be made every 2 cycles till progression, unacceptable toxicity or consent withdrawal
45653531|NCT05054361|Diagnostic Test|Coxsackie virus B infection status|Serology against CVB and CVB specific-qPCR measurement in gut microbiota samples will be performed in all patients of the three cohorts, and analysis of the gut mucosa by qPCR and immunochemistry with anti-CVB VP1 protein mAb will be performed on a subset of patients.
45653532|NCT05054361|Diagnostic Test|Coxsackie virus B infection status|Stool samples are collected and directly kept under anaerobic condition. Within an hour the samples are processed: one fraction is aliquoted and frozen at -80°C and another fraction is used to prepared fecal supernatant for the bioassay of MAIT ligands, aliquoted and frozen. Bioassay to measure the presence of MAIT cell ligands by bioassays using WT3 cell line as well as plate bound MR117. 16S sequencing of all samples and according to the results obtained with the bioassay and 16S, 10 samples will be selected for metagenomic analysis.
45653533|NCT03066973|Behavioral|BREATHING EXERCISE|The intervention group was instructed on breathing exercise according to the established trial protocol.
45653534|NCT05015283|Procedure|The laparoscopic One-anastomosis gastric bypass will consist of:|gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter < 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 200cm, food branches 100cm exact relationship with mesangial defect
45653535|NCT05015283|Procedure|The laparoscopic Roux-en-Y gastric bypass will consist of:|the laparoscopic Roux-en-Y gastric bypass gastric sac size < 30ml gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter < 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 50cm, food branches 150cm exact relationship with mesangial defect
45653536|NCT03066583|Biological|trephination with placebo|trephination under US guidance and placebo injection
45653537|NCT03066583|Biological|trephination with platelet rich plasma|trephination under US guidance and platelet rich plasma injection
45653538|NCT04972305|Other|Exercise and ergonomics|12 week exercise and fit bike
45804373|NCT05310019|Other|Physiotherapy|The physiotherapy treatment protocol will be divided into 6 meetings: warm compress with facial thermal blanket (5min), respiratory muscle mobility training and cervical muscle relaxation (5min) facial lymphatic drainage (10min), start of myolymphokinetic exercises for the orbicularis oris, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma (5 min), release of intraoral adhesions (5min) vacuum therapy at 60 mmHg (5min), active exercises free of mandibular movements (5 min), maintenance of mandibular opening with wooden tongue depressors (10min).
45935728|NCT00074646|Drug|CC-8490|
45935729|NCT05242549|Behavioral|Fitness and Nutrition Program for Seniors|"Fitness and Nutrition Program for Seniors uses the Trans-Theoretical Model (TTM) as the framework, which includes physical activity training, nutrition education- nursing Information, home-based training, and telecare group care (including APP assistance).~Physical activity training comprised muscle training, joint strengthening, and upper and lower limb resistance exercises for older adults who were frail. After administering nutrition education- nursing Information, participants were encouraged to set their own goals to improve their diet. Home-based training and telecare group care depends on the stages of TTM behavior change of the elderly."
45935730|NCT00078507|Behavioral|Sensory Re-training|
45935731|NCT00078507|Behavioral|Sensory Retraining|Facial Exercises
45935732|NCT00078507|Behavioral|Opening Exercises|
45935733|NCT05224375|Device|Left Atrial Appendage Closure|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System
45935734|NCT05190328|Other|Muscle Energy Technique|"Experimental: Muscle Energy Technique Post isometric relaxation: Patient will perform isometrics on upper trapezius and levator scapulae one by one. Each isometric contraction will be held for 10 seconds and then participants will be asked to relax the contraction with exhalation. This will be repeated five times in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with Muscle energy technique."
45935735|NCT05190328|Other|Active Release Technique|"Experimental: Active Release Technique: Therapist will apply deep pressure on both sides of levator scapulae and upper trapezius muscles (over the area of tenderness) and the patient is instructed to actively move the muscle from the shortened to a lengthened position and thereby breaking adhesions. 1 set of 5 repetitions in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with Active Release Technique."
45935736|NCT00078546|Biological|EBV specific CTL Infusion|"One injection at one of the following dose levels~Dose level I: 2x107/m2 Dose level II: 5x107/m2 Dose level III: 1x108/m2"
45935737|NCT00078546|Biological|Anti CD45 monoclonal antibody|400ug/kg over 6 to 8 hr for 4 days
45935738|NCT05147506|Device|CNRM DTx|A mobile application intervention adapted from the CBT for Depression and CBT for TBI manuals.
45935739|NCT05147506|Other|Psychoeducation Comparison|A mobile application that consists of psychoeducational material regarding depression and brain injury.
45935740|NCT05118061|Diagnostic Test|Ketone|compare diagnostic tests to reference methods
45935741|NCT00078585|Biological|PROSTVAC®-VF/TRICOM™|
45935742|NCT05086237|Other|Text message reminders|Text messages will be sent to parents/guardians of children ages 0 to 17 years who missed their well child visits.
45935743|NCT00044642|Drug|Lorazepam|
46088489|NCT02844335|Biological|NK immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
46088490|NCT02844179|Drug|HTBZ|
46088491|NCT00880074|Drug|Fluorothymidine F-18|Undergo fluorine F-18 fluorothymidine PET
46088492|NCT00880074|Other|Laboratory Biomarker Analysis|Optional correlative studies
46088493|NCT00880074|Procedure|Positron Emission Tomography|Undergo fluorine F-18 fluorothymidine PET
46088494|NCT02844101|Device|GT3X Actigraph accelerometer.|
46088495|NCT04208880|Behavioral|TBH Brain Workout 1.0|TBH Brain Workout program with easy challenge activities.
45653539|NCT04972305|Other|Ergonomics|Fit bike
45935744|NCT05066347|Device|Cardiophone|Cardiophone (ER920W event recorder, Braemar Inc.) is an external loop recorder that has the monitoring and cell phone technology in one unit. Cardiophone evaluates all cardiac beats and rhythm abnormalities that are detected as per the algorithm programmed into the device. These abnormalities are then automatically and immediately transmitted to a central monitoring station in Windsor, Ontario (Canadian Cardiac Care) without the need of any patient intervention (device-triggered transmission). Additionally, the cardiac rhythm can also be transmitted to the monitoring station immediately in the event the patient experiences symptoms, by the touch of a button on the device (patient-triggered transmission).
45935745|NCT05063344|Device|Diagnostic Test: NOWDx Syphilis Test|For this observational trial, the Intervention of interest is the NOWDx Syphilis Test.
45935746|NCT00044681|Drug|risperidone|
45653540|NCT04972227|Drug|CY6463|oral tablets
45653541|NCT04972227|Drug|Placebo|oral tablets
45804374|NCT03244865|Device|LaborView Electronic Fetal Monitor|"Per LaborView directions, electrode application sites will be prepared to reduce skin impedance, electrodes will be applied to the maternal abdomen and FHR data acquired for comparison with CTG data obtained through the traditional monitoring system. The comparison will be performed off-line.~Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus."
45935747|NCT00078624|Other|Traditional exercise therapy for knee osteoarthritis|Exercises include stretching, strengthening, and aerobic exercise
45935748|NCT00078624|Other|Knee stability training|The addition of agility and perturbation training techniques to the traditional exercise program
45653542|NCT03064477|Behavioral|Unified Protocol|Intervention group that carries out the Unified Protocol in a group format
45653543|NCT03064477|Behavioral|Cognitive Behavioral Therapy (TAU)|TAU group that carries out Cognitive Behavioral Therapy in an individual format
45935749|NCT05050123|Behavioral|iPhone Google Cardboard virtual reality meditation/relaxation app|Virtual reality meditation/relaxation app that has 6 scenes of 360° visual imagery with soothing music. The patient can spend about 15 minutes exploring the app.
45935750|NCT05050123|Behavioral|Standard relaxation training|"15 minute sessions of guided imagery using Mayo Clinic Patient Education CD-ROM Relaxation for Your Mind and Body"
45935751|NCT05036629|Device|MRI Protocol|"Eye-tracker Eyelink (eye movements) BIOPAC : (electrodermal resistance) INVIVO Precess : breathing, arterial pressure, pulse,~NIRS Oxymon artinis medical system~tES (transcranial electrical stimulation, Neuroelectrics)"
45653544|NCT04970355|Biological|Erenumab|Pre-filled syringe; s.c. injection
45935752|NCT00044720|Drug|Rapamune|
45935753|NCT00078663|Behavioral|Oral Care|
45935754|NCT04938466|Drug|Long-Acting Growth Hormone (LAGH)|Long-acting growth hormone (LAGH) treatment
45804375|NCT04735523|Drug|Dabigatran|Dabigatran dispensing claim is used as the exposure group
45804376|NCT04735523|Drug|Warfarin|Warfarin dispensing claim is used as the reference group
45804377|NCT03832712|Procedure|Deep Brain Stimulation|Surgical implantation of intracranial leads for deep brain stimulation, extension cables and implantable pulse generator
45935755|NCT04934917|Device|Magnetic Resonance Imaging|Magnetic Resonance Imaging. Pain testing: Temporal summation, Pain thresholds. Assessment of symptoms: Questionnaires. All interventions are made at baseline only (1 time/subject).
45935756|NCT00078741|Behavioral|Cognitive Behavioral Therapy (CBT)|
45935757|NCT00402961|Other|Acupuncture|Acupuncture will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge.
45935758|NCT00402961|Other|Sham Acupuncture|Sham Acupuncture involves the acupuncturist tapping a plastic guiding tube on the surface of the true points to produce some discernible sensation and then immediately tapping a real needle sideways parallel to the skin surface without needle insertion. It will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge,
45935759|NCT00403000|Drug|dutasteride|Oral
45935760|NCT00397553|Drug|Insulin glulisine|
46088496|NCT04208880|Behavioral|Brain Health Book Club|Each week a new chapter will be read that contains new information to enhance brain health.
46088497|NCT04208880|Behavioral|TBH Brain Workout 2.0|TBH Brain Workout program with moderately difficult challenge activities.
46088498|NCT04208880|Behavioral|TBH Memory 1.0|TBH Memory program with easy challenge activities.
45653545|NCT04970355|Drug|Placebo|Pre-filled syring; s.c. injection
45653546|NCT04906213|Drug|Empagliflozin10Mg Tab|Empagliflozin10 Mg daily or placebo daily for 18 months
45653547|NCT04906213|Drug|Placebo|10Mg Placebo Tab
45653548|NCT01670539|Device|HomMed Telemonitor|"A HomMed Telemonitor wireless telemonitoring system collects data on a daily basis, including heart rate, blood pressure, oxygen level, body temperature, weight, responses to 9 pre-programmed questions (including difficulty breathing, fatigue, limited activities, difficulty taking meds, pain). Telemonitored results are transmitted to the research office for analysis and contact to patient by clinical research nurses."
45804378|NCT03832712|Drug|Best Medical Treatment|Unselective β-blockers such as Propanolol
45653549|NCT02252887|Drug|Gemcitabine|
45653550|NCT02252887|Drug|Trastuzumab|
45653551|NCT02252887|Drug|Pertuzumab|
45653552|NCT04431895|Drug|Tofacitinib 5 MG|tofacitinib 5 mg tablet administered twice a day for 6 months
45804379|NCT03809299|Other|Ad libitum meal timing|Research participants will eat meals provided by the study throughout the day, ad libitum
45804380|NCT03809299|Other|Twice a day meals|Research participants will eat meals provided by the study at two intervals during the day, and fast in between.
45804381|NCT05715866|Device|non-invasive neuromodulation through the Nesa device|patients receive non-invasive neurostimulation through the Nesa device
45653553|NCT02516163|Device|Shapematch Cutting Guides|Participants will undergo pre-operative assessment using MRI of the affected limb. At the time of surgery, a repeated-measures methodology will be implemented in which the position of the femoral and tibial cutting guides will be measured using the Navigation system. The same surgeon will position each cutting guide a total of 3 times for each patient. Multiple participants will be assessed by each surgeon. No bone cuts will take place using the patient-specific cutting guides. After the study-specific measurements have been taken, the total knee procedure will resume using the Navigation system and associated instruments. No post-operative evaluations will be undertaken as part of this sub-study
45804382|NCT05715866|Procedure|therapeutic exercise|patients receive adapted therapeutic exercise
45935761|NCT00403039|Drug|Ranibizumab (Lucentis )|
45935762|NCT02965794|Other|Care pathways for colorectal cancer|development of a care pathway for this patient group
45935763|NCT04818073|Device|New FINGER|New FINGER exoskeleton is a robotic device that can provide assistance and resistance to thumb and finger movement
45935764|NCT04786717|Other|core muscle training|The intervention of this group will focus on training the endurance of the core muscle.
45935765|NCT04786717|Other|movement control training|Based from the initial test, the subjects will receive either lumbar flexion control exercise or lumbar extension control exercise. They will perform each lumbar movement control exercise in different position. Starting from the lying position, then progressing to sitting, standing with support, and the last level will be standing without support. Each set of movement will be practiced 10 times, totally 10 sets. It will take approximately 5~8 minutes to finish each movement. The subjects will learn 5~8 types of the movement every week.
45935766|NCT04786717|Other|combined imagery and movement control training|The intervention of this group is mostly same as the movement control training group. The different part is that the first 3 times of the movement will be practiced through image training, so the subjects will not have any real movement, and the last 7 times they will perform the lumbar motor control exercise literally. Each set of movement will be practiced 10 times, totally 10 sets. It will take approximately 5~8 minutes to finish each movement. The subjects will learn 5~8 types of the movement every week.
45935767|NCT04763083|Drug|NVG-111|Open label, continuous iv infusion, escalating doses of NVG-111 for minimum 3 cycles, 21 days on, 7 days off
45935768|NCT04763083|Drug|NVG-111 (RP2D)|Open label, continuous iv infusion at RP2D
45935769|NCT00074763|Biological|Platelet Transfusion|All receive both platelets frozen with Thrombosol and fresh random platelets (FRP), order received is randomized, i.e. receive either FRP then Thrombosol or Thrombosol then FRP.
45935770|NCT04731935|Device|Sparrow Therapy System|Transcutaneous auricular neurostimulation
45935771|NCT04716400|Behavioral|Stop sexual harassment|Teachers will be introduced to a digital course on the prevention of sexual- and gendered harassment. In the course they will provided with a manual containing eight lessons to be held for the pupils. Each lesson will last 45 minutes and consist of a short lecture and practical activities for the pupils.
45935772|NCT00078858|Drug|fludarabine phosphate|Given IV
45935773|NCT00078858|Radiation|total-body irradiation|Undergo TBI
45653554|NCT03064633|Drug|dexamethasone 8 mg|At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both side using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexamethasone group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexamethasone 8 mg.
45804383|NCT05715866|Behavioral|sleep hygiene measures|caregivers receive a brochure with sleep hygiene measures
45804384|NCT00003219|Drug|perillyl alcohol|
45804385|NCT00356551|Behavioral|Family Spirit curriculum|
45804386|NCT03247985|Device|PROLENE Polypropylene Tacking Mesh|Prolene mesh is a polypropylene plastic mesh (10 x 15 cm) implant fixed with titanium tacks
45804387|NCT03247985|Device|ProGrip Self-fixating Mesh|"ProGrip™ self-fixating mesh is a tack-free fixation mesh for use in open & laparoscopic hernia repairs. It is composed of absorbable Monofilament Polylactic Acid micro grips on one surface integrated with a lightweight Monofilament Polyethylene Terephthalate. The micro grips act as a kind of Velcro to the soft tissue surfaces resulting in self-fixation"
45935774|NCT00078858|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBMC transplantation
45935775|NCT00078858|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBMC transplantation
45935776|NCT00078858|Drug|cyclosporine|Given PO
45935777|NCT00078858|Drug|mycophenolate mofetil|Given PO or IV
45935778|NCT00078858|Other|laboratory biomarker analysis|Correlative studies
46002494|NCT01975428|Device|DM Pgm + device|"Disease management program plus a device corresponding to an individual's disease(s):~iBGStar - iPhone enabled capillary blood glucose meter. Subjects test blood glucose up to 4 times per day, every day.~Withings BP monitor - iPhone enabled home blood pressure monitor. Subjects test their blood pressure 2 times per day, up to 3 days per week.~iPhone enabled Alive Cor ECG monitor. Participants take an ECG reading only when symptomatic."
46002495|NCT01975428|Behavioral|Control|All study participants, including participants randomized to the control arm, were enrolled in the HealthComp disease management program, which involved outreach by HealthComp nursing staff for purposes of relaying medical education and wellness information with regard to disease prevention and chronic disease management.
46002496|NCT01941641|Drug|neoadjuvant FOLFOXIRI|
46002497|NCT01941641|Drug|Capecitabine|
46002498|NCT01804634|Drug|Cyclophosphamide|preparative regimen
46002499|NCT01804634|Drug|Fludarabine|
46002500|NCT01804634|Radiation|low dose total body irradiation|
46002501|NCT01804634|Drug|Melphalan|
46002502|NCT01804634|Drug|Tacrolimus|
45935779|NCT04686604|Other|Best practice alert for the notification of patient HFrEF and recommended evidence-based medical therapies (NO drugs are being administered in this trial)|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction, most recent blood pressure and heart rate, most recent potassium and estimated glomerular filtration rate, and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
45653555|NCT03064633|Drug|dexmedetomidine 80 µg|At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both sides using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexmedetomidine group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexmedetomidine 80 µg.
45653556|NCT03064633|Drug|Bupivacaine 0.25% Injectable Solution|38 ml of the solution will be prepared to be used in transversus abdominis plane block
45653557|NCT04950465|Other|Sensodyne Sensitivity & Gum|Sensodyne Sensitivity & Gum toothpaste containing 0.454% SnF2.
45653558|NCT04950465|Other|Crest Cavity Protection Fresh Lime|Crest Cavity Protection Fresh Lime is containing 1150 parts per million fluoride as Sodium fluoride.
45653559|NCT04950465|Other|Sensodyne Repair and Protect|Sensodyne Repair and Protect dentifrice containing 5.0% weight/weight calcium sodium phosphosilicate.
45653560|NCT04877821|Drug|Sintilimab|200mg on days 1 (Q3W) of the neoadjuvant and adjuvant phase of the study; IV injection.
45804388|NCT04329351|Procedure|Guided Bone regeneration|Guided bone regeneration to ridge preservation
45804389|NCT05715788|Drug|Nitric oxide|Nitric oxide inhalation at 20 ppm
45804390|NCT05715788|Behavioral|prone positioning|vatilation in prone position
45935780|NCT00044759|Drug|Piperacillin/Tazobactam (Tazocin)|
45935781|NCT04674202|Other|Phone interview|The participant will have 2 phone interview in which they will be asked about their knowledge of direct oral anticoagulants.
45935782|NCT04665154|Drug|MAS825|single dose i.v. and s.c.
45935783|NCT04665154|Drug|Placebo|single dose i.v. and s.c.
45935784|NCT04612660|Behavioral|Education on cervical cancer prevetnion|Motivational group education by trained bilingual community health educators (CHEs) on cervical cancer prevention
45935785|NCT04612660|Behavioral|Dynamic group interaction|Dynamic group interaction and role play discussion sessions on the benefits of Self-Sample collection HPV testing and procedures;
45935786|NCT04612660|Behavioral|Physician engagement|Engaging community bilingual physicians in cervical cancer screening and referral;
45935787|NCT04612660|Behavioral|Patient Navigation|Patient navigation assistance will be provided to participants who tested HPV positive for further diagnostic testing and treatment.
45935788|NCT04612660|Behavioral|General Health Education|general health education focusing on healthy lifestyle, and prevention of disease through routine health examinations.
46088499|NCT04208880|Behavioral|TBH Memory 2.0|TBH Memory program with moderately difficult challenge activities
46088500|NCT05337839|Procedure|home exercises|stretching, balance and strengthening exercises
45935789|NCT00044798|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|Participants will receive 15 treatments of rTMS over 3 weeks.
45935790|NCT00044798|Drug|Citalopram|After completing treatment with rTMS or sham rTMS, participants will take citalopram for 9 weeks.
45935791|NCT00044798|Procedure|Sham rTMS|Participants will receive 15 treatments of sham rTMS over 3 weeks.
45935792|NCT04598425|Behavioral|Cognitive behavioral therapy for insomnia (CBTi)|Patients will undergo a 7 sessions course in cognitive behavioral therapy for insomnia.
45935793|NCT00074841|Drug|Azithromycin/Chloroquine|
45935794|NCT00074841|Drug|Sulfadoxine-Pyrimethamine/Chloroquine|
45935795|NCT04563598|Behavioral|Intensive lifestyle intervention (ILI)|Lifestyle intervention focused on weight loss through diet and physical activity
46002503|NCT01792934|Drug|XELOX regimen according to standard procedures|
46002504|NCT01792934|Drug|FOLFOX regimen according to standard procedures|
46002505|NCT01792934|Procedure|Surgery|
46088501|NCT04375787|Drug|Atorvastatin|Patients received 80 mg atorvastatin before elective coronary angiography
46088502|NCT00859794|Other|fMRI|Subjects will undergo MRI scanning to gather data about cognitive functions.
45653561|NCT04877821|Drug|Anlotinib|12mg on d1-14 of Cycles 1-8 (Q3W) of the neoadjuvant phase of the study; po. Arotinib is a small molecule multi-target TKI, which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
45653562|NCT04877821|Drug|Nab paclitaxel|100 mg/m² on day 1, 8 and 15 of Cycles 1-4 (Q3W) of the neoadjuvant phase of the study; IV injection.
45804391|NCT04596163|Procedure|Transversus thoracis muscle plane block|After general anaesthesia, transversus thoracis plane (TTP) block, a kind of regional block will be performed near both sides of the sternum under ultrasound guidance using either levobupivacaine or normal saline to both groups of patients. The end point for injection is the fluid spread along the plane just superficial to the transversus thoracis muscle, together with the downward displacement of the pleura.
45804392|NCT00003225|Drug|amifostine trihydrate|Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. Administered every two weeks for 3 cycles.
45804393|NCT00003225|Drug|irinotecan hydrochloride|"10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.~Administered every 14 days for 3 cycles"
45804394|NCT05372588|Drug|NVX-CoV2515|Intramuscular (deltoid) injection of co-formulated Omicron BA.1 SARS-CoV-2 rS vaccine with Matrix-M adjuvant (0.5 mL).
45804395|NCT05372588|Drug|NVX-Cov2373|Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
45804396|NCT05372588|Drug|NVX-CoV2373 + NVX-CoV2515|Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
45653563|NCT04877821|Drug|Carboplatin|AUC 5 on days 1 of Cycles 1-4 (Q3W) of the neoadjuvant phase of the study; IV injection.
45653564|NCT04877821|Drug|Epirubicin|90 mg/m² on day of Cycles 5-8 (Q3W) of the neoadjuvant phase of the study; IV injection.
45935796|NCT04563598|Behavioral|Diabetes support and education (DSE)|Behavioral intervention focused on diabetes support and education
45804397|NCT05372588|Drug|NVX-CoV2540|Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
45935797|NCT04543396|Other|Resistance exercise|A training program designed to enhance core strength, stability, and function will be performed on the Tonal device. Training sessions will occur twice weekly for eight weeks. Performance of this program will be supervised by a designated and clinically trained research team member who will not conduct the statistical analysis and subsequently not be blinded to Group assignment. The program will last approximately 20 minutes in length and incorporate the a series of progressive exercises.
45653565|NCT04877821|Drug|Cyclophosphamide|600 mg/m² on day of Cycles 5-8 (Q3W) of the neoadjuvant phase of the study; IV injection.
45804398|NCT05372588|Drug|NVX-CoV2373 + NVX-CoV2540|Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
45804399|NCT03249779|Device|Scrambler|Scrambler Therapy is a specific form of electrical stimulation which has also been utilized in chronic neurogenic pain11. This modality of therapy differs from TENS in that the goal is to mediate the patient's perception of pain, rather than masking the peripheral pain signal. The results of this modality of treatment may be longer-lasting than TENS, presumably via reduction in central signal generation. Scrambler therapy works through C fibers to retrain the peripheral sensation in the area being treated. Further description of this technology is available at: International Patent PCT/IT2007/000647 and U.S. Patent No. 8,380,317. Literature search does not yield prior studies regarding efficacy of Scrambler therapy in treating RLS
45935798|NCT00078975|Drug|gemcitabine hydrochloride|
45804400|NCT04586959|Device|Surgery with UM|The experimental group will have MIS with the placement of a uterine manipulator
45935799|NCT00078975|Drug|triapine|
45935800|NCT04535557|Drug|Mobocertinib 160 mg|Mobocertinib 160 mg, capsule, orally, once daily in 28-day treatment cycles for up to approximately 4 months.
45935801|NCT04515745|Behavioral|Intensive lifestyle intervention (ILI)|Lifestyle intervention focused on weight loss through diet and physical activity
45935802|NCT04515745|Behavioral|Diabetes support and education (DSE)|Behavioral intervention focused on diabetes support and education
45935803|NCT00044837|Drug|Medroxyprogesterone acetate|
45935804|NCT00044837|Drug|Estradiol|
45653566|NCT02589665|Drug|Mirikizumab|
45653567|NCT02589665|Drug|Placebo|
45653568|NCT04969341|Other|Survey Administration|Complete survey
45804401|NCT04586959|Device|Surgery without UM|The control group will have MIS without the placement of a uterine manipulator
45804402|NCT00356161|Device|interventionally implanted hepatic arterial port catheter|
45804403|NCT03382847|Combination Product|Transplant with HCV positive donor, followed by surveillance and treatment of viremia|Heart transplant with HCV positive donor, followed by treatment for viremia if viremia occurs
45935805|NCT04512274|Device|Test Article|Omeza Collagen Matrix
45653569|NCT04969341|Other|Electronic Health Record Review|Review of medical records
45653570|NCT05011383|Drug|High dose testosterone|High dose testosterone is administered subcutaneously once monthly until progression or toxicity
45653571|NCT01905397|Device|Conventional wound therapy|Sterile bandages and wound coverings
45653572|NCT01905397|Device|Negative pressure wound therapy|The Prevena Incision Management System covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump may be used with the Prevena dressings as well in some situations to achieve negative pressure.
45935806|NCT04457557|Other|Reduced concentration of local anesthetic (ropivacaine)|Reduced concentration of ropivacaine We usually use 0.5% ropivacaine in our facility. The intervention group used 0.15% ropivacaine 15 ml
45935807|NCT04457557|Other|Usual concentration of local anesthetic (ropivacaine)|0.5% ropivacaine 15ml
45935808|NCT00044876|Drug|CDB-2914|
45935809|NCT04453657|Device|FamilyChildCare (provisional name of app)|Parents will provide their child(ren) access to a smartphone, tablet, or computer for approximately 30 minutes, three times per week for 15 weeks with a total dosage of instruction of about 22.5 hours. Parents and providers will receive self-care, parenting, and parent engagement tips and resources through push notifications twice a day. Additionally, daily reminders will be sent to parents through push notification to give their child(ren) access to the learning games. After 15 weeks of app engagement, the providers and parents will be contacted by the PI to notify them of the 15 week time mark and provide the information for post-surveys via Qualtrics.
45935810|NCT00079014|Drug|triapine|Given IV
45935811|NCT00079014|Drug|doxorubicin hydrochloride|Given IV
45935812|NCT00079014|Other|laboratory biomarker analysis|Correlative studies
45935813|NCT00079014|Other|pharmacological study|Correlative studies
45935814|NCT00397475|Drug|Colecalciferol|
45935815|NCT04731740|Drug|Lenvatinib|PO
45935816|NCT04731740|Biological|Pembrolizumab|IV
45935817|NCT04731740|Drug|Chemotherapy|Investigators' choice
45935818|NCT04447339|Procedure|Nipple Sparing Mastectomy|Prophylactic open NSM procedures
45935819|NCT04430920|Other|Intensive intraoperative blood pressure management|Targeting intraoperative mean arterial pressure ≥ 80 mmHg.
45935820|NCT04430920|Other|Conventional intraoperative blood pressure management|Targeting intraoperative mean arterial pressure ≥ 65 mmHg or 60% of the baseline level (use the higher target).
46088503|NCT00859794|Other|Releasing Data|Subjects in the study will be asked to release data about their surgery, and electrostimulation to the research team for analysis.
45653573|NCT05010603|Genetic|Blood Draw|Collection of blood samples for genetic testing
45653574|NCT05010603|Other|Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test|Memory Test
45653575|NCT01697527|Biological|aldesleukin|Given SC
45653576|NCT01697527|Drug|fludarabine phosphate|Given IV
45935821|NCT00074919|Biological|alglucosidase alfa|20 mg/kg qow
45935822|NCT04425148|Device|Transcranial Alternating Current Stimulation (tACS)|tACS is a noninvasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head.
45804404|NCT04735211|Procedure|Surgery|Pediatric Surgery with hospitalized
45804405|NCT00376415|Drug|Lessertia Fructescens|Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.
45935823|NCT04425148|Device|Sham Transcranial Alternating Current Stimulation (sham tACS)|Sham (placebo) simulation of transcranial alternating current stimulation without receiving any real stimulation.
45935824|NCT00044915|Drug|Repinotan HCl (BAYX3702)|All patients receive 1.25 mg of repinotan
45653577|NCT01697527|Drug|cyclophosphamide|Given IV
45935825|NCT00044915|Drug|Placebo|All patients receive 1.25 mg of placebo
45653578|NCT01697527|Other|laboratory biomarker analysis|Correlative studies
45935826|NCT04321408|Drug|Ziconotide Injection|Intrathecal analgesia with Ziconotide
45935827|NCT00079053|Drug|erlotinib hydrochloride|
45935828|NCT00079053|Procedure|adjuvant therapy|
46088504|NCT00859794|Other|Neuropsychological Testing|Subjects will have a neuropsych evaluation as part of their standard of care for surgery. The research team is asking the subject to release their neuropsych evaluations for analysis.
45653579|NCT01697527|Biological|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Undergo NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
45653580|NCT01697527|Biological|dendritic cell vaccine therapy|Given NY-ESO-1-157-165 peptide pulsed dendritic cell vaccine ID
45653581|NCT01697527|Radiation|fludeoxyglucose F 18|Undergo PET scan using [18F] FDG tracer
45653582|NCT01697527|Procedure|positron emission tomography|Undergo fludeoxyglucose F18 PET
45653583|NCT04613843|Other|Water Stirring|Following an active heating protocol, the cooling intervention includes vigorous water stirring throughout cold water immersion.
45653584|NCT04613843|Other|No Water Stirring|Following an active heating protocol, the cooling intervention includes no water stirring throughout cold water immersion.
45804406|NCT00376415|Drug|Placebo|Participants received an identical placebo capsule twice daily for 3 months.
45804407|NCT05303779|Other|Exercise Interventions of Eye Muscles|Application of eye exercise for improving eye control post strabismus surgery
45804408|NCT05303779|Drug|Medication and eye glasses|medication and eye glasses used post strabismus surgery
45935829|NCT04304911|Behavioral|Blended intervention (UP-APP)|Unified Protocol (UP) for transdiagnostic treatment of EDs in the blended intervention (UP-APP)
45935830|NCT04304911|Behavioral|Cognitive Behavioral Therapy (TAU)|TAU group that carries out Cognitive Behavioral Therapy in an individual format
45935831|NCT04294030|Device|Diagnostic Test: NOWDx HSV-2 Test|For this observational trial, the intervention of interest is the NOWDx HSV-2 Test.
45935832|NCT04263298|Drug|Fulvestrant|Fulvestrant 500mg Days 0, 14, 28, then every 28 days
45935833|NCT04263298|Drug|Capecitabine Oral Product|Capecitabine 2000mg/m2 twice daily x 14 days followed by 7 days off
45935834|NCT00423774|Behavioral|Problem-Solving Education|
45935835|NCT00044954|Biological|therapeutic allogeneic lymphocytes|
45935836|NCT00044954|Drug|cyclosporine|
46088505|NCT00859794|Other|Additional electrode implantation|Subjects normally will have anywhere from 100-200 electrodes implanted as part of their surgery. As part of the study, we would implant additional electrodes that are able to record from smaller, more specific parts of the brain to better understand how your brain is wired.
45653585|NCT04457453|Other|Macintosh in sniffing position|Macintosh direct intubation in sniffing position
45653586|NCT04457453|Other|Macintosh in Trendelenburg position and Sellick position|Macintosh direct laryngoscopic intubation in Trendelenburg position and Sellick position
45804409|NCT04734899|Other|Exercise program|Strengthening with resistance bands for tibialis posterior, tibialis anterior, peroneus longus, finger flexors, hip and knee muscles, sheet gathering exercises, fingertip walking exercises, Stretching exercises for gastrocnemius and soleus muscles, plantar fascia stretching, weight transfer on one leg
45804410|NCT04734899|Other|Foot core training|Short foot exercises with passive modeling, active assisted modeling, active modeling, functional training
45935837|NCT00044954|Drug|fludarabine phosphate|
45935838|NCT00044954|Drug|mycophenolate mofetil|
45935839|NCT00044954|Procedure|allogeneic bone marrow transplantation|
45935840|NCT00044954|Procedure|peripheral blood stem cell transplantation|
45935841|NCT00044954|Radiation|radiation therapy|
45935842|NCT04261309|Other|Usual care|Since this is an observational study there will be no interference with the care given by the primary healthcare providers. However, the usual care provided by these and other healthcare utilization used by the patients during follow-up will be recorded during the follow-ups.
45935843|NCT00079092|Drug|procarbazine hydrochloride|
45935844|NCT00079092|Drug|thalidomide|
45935845|NCT00044993|Biological|Ad5CMV-p53 gene|
45935846|NCT00044993|Drug|docetaxel|
45935847|NCT00044993|Drug|doxorubicin hydrochloride|
45935848|NCT00044993|Procedure|conventional surgery|
45935849|NCT00044993|Procedure|neoadjuvant therapy|
45935850|NCT04162210|Drug|Belantamab mafodotin|Belantamab mafodotin will be administered.
45935851|NCT04162210|Drug|Pom/dex (Pomalidomide plus low dose Dexamethasone)|Pomalidomide and Dexamethasone will be administered.
46088506|NCT00859794|Other|Brain stimulation|Subjects may be asked to undergo additional electrical brain stimulation (in addition to what is required for clinical purposes) to map brain function and epileptogenic areas. This may include extended stimulation mapping, low frequency stimulation (CCEPs), and transcranial stimulation.
46088507|NCT05243069|Procedure|Imaging Technique|Undergo 3D scanning
46088508|NCT00825630|Drug|Lansoprazole (Lanton)|Oral administration of Lanzoprazole for 14 days in 25 patients with H.pylori infection
46088509|NCT00825630|Drug|Omeprezole (Losec)|Oral administration of Omeprazole for 14 days in 25 patients with H.pylori infection
45653587|NCT04457453|Other|AceScope in Trendelenburg position and Sellick position|AceScope videolaryngoscopic intubation in Trendelenburg position and Sellick position
45804411|NCT05559320|Device|Ride-on-toy navigation training|The training program will involve a set of activities where children will be encouraged to drive a joystick-operated ride-on-toy to navigate through their physical environment. The training will involve will involve progressively challenging multi-directional navigational games such as shape mazes, treasure hunts, relay races, and obstacle courses that will require children to use their affected arm skillfully to navigate through the courses.
45935852|NCT00079131|Biological|oblimersen sodium|Given IV
45935853|NCT00079131|Other|pharmacological study|Correlative studies
45935854|NCT00079131|Other|laboratory biomarker analysis|Correlative studies
45804412|NCT05559320|Behavioral|Upper extremity functional training|In addition to the navigation practice, along the multi-directional courses, children will complete tasks at multiple stations that will involve both gross and fine motor activities. The goal of the training will be to use their arm for functional goal-directed tasks and games that will involve elements of reaching, grasping, in-hand manipulation, and release. We will use props such as balls, bean bags, cups, cones, and small toys to practice skills such as catching, throwing, picking up, pushing, pulling, opening, closing, etc.
45935855|NCT00045149|Biological|aldesleukin|
45935856|NCT00045149|Biological|therapeutic tumor infiltrating lymphocytes|
45935857|NCT04127110|Drug|Lorlatinib|Lorlatinib is administered orally at the daily dose of 100 mg (four tablets of 25 mg).
45935858|NCT00045188|Drug|imatinib mesylate|Given PO
45935859|NCT00045188|Other|laboratory biomarker analysis|Optional correlative studies
45935860|NCT04125589|Behavioral|Speaking Activity|Participants will engage in a speaking activity where they are given a topic to speak about.
45935861|NCT04125589|Behavioral|Talking Activity|Participants will engage in a talking activity where they may talk about a topic of their choice.
45935862|NCT04107961|Biological|Vaccine|Single intramuscular injection into the deltoid region
46088510|NCT00825630|Drug|Pantoprazole(Controloc)|Oral administration of Pantoprazole for 14 days in 25 patients with H.pylori infection
45935863|NCT04107961|Other|Placebo|Single intramuscular injection into the deltoid region
45935864|NCT00403156|Drug|Imatinib Mesylate /Ranibizumab|
45935865|NCT04099966|Drug|alpha beta depletion|donor cells will be collected and subsequently undergo α/β CD3+/CD19+ cell depletion.
45935866|NCT00045227|Biological|recombinant fowlpox-prostate specific antigen vaccine|
45935867|NCT00045227|Biological|recombinant vaccinia prostate-specific antigen vaccine|
45935868|NCT00045227|Biological|recombinant vaccinia-B7.1 vaccine|
45935869|NCT00045227|Biological|sargramostim|
45935870|NCT00045227|Drug|docetaxel|
45935871|NCT00075075|Drug|Infliximab|
45935872|NCT04072276|Biological|EV71 vaccine|EV71 vaccine with Adjuvant AlPO4 and the placebo (Adjuvant AlPO4 only) were randomly administrated to subject in CT-EV-21 study
45935873|NCT04065451|Drug|Epinephrine|Epinephrine in the submucosal injection fluid
45935874|NCT00075114|Behavioral|Bladder Health Class|A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
45935875|NCT04057612|Other|Esophagus temperature monitoring|Measuring core temperature by esophageal stethoscope
45935876|NCT04057612|Other|Carotid artery temperature monitoring|Measuring temperature on skin near to carotid artery using 3M™ Bair Hugger™ temperature monitoring system
45935877|NCT00045266|Biological|ziv-aflibercept|
45935878|NCT03953131|Procedure|Computed Tomography|Undergo PET/CT
46088511|NCT00825630|Drug|Esomeprazole (Nexium)|Oral administration of Esomeprazole for 14 days in 25 patients with H.pylori infection
46088512|NCT02845427|Device|closed suction drain|using closed suction drain system postoperative
46088513|NCT02845427|Procedure|no suction drain|the surgical wound will be closed with no suction drain
45653588|NCT04826965|Device|Wound Vac is applied|A wound vac or wound vac with cleanse choice dressing, track pad duo, and saline irrigation is applied.
45653589|NCT04426409|Drug|tarivid ointment|Vaseline ointment is applied to both noses.
45653590|NCT04966923|Other|No intervention in this study|Analyses of pathogenic variant TP53 and variants in genetic test
45653591|NCT01411345|Radiation|Standard Salvage Radiation Treatment (SSRT)|A total dose of 68 Gy delivered in 34 fractions to the Clinical Target Volume (CTV), 51 Gy in 34 fractions can be given to the pelvic nodes.
45935879|NCT03953131|Radiation|Gallium Ga 68-DOTATATE|Given IV
45935880|NCT03953131|Procedure|Positron Emission Tomography|Undergo PET/CT
45935881|NCT03948568|Combination Product|Endocrine Therapy and Radiotherapy|Endocrine therapy and radiotherapy administered either concurrently or sequentially
45935882|NCT03938350|Behavioral|Dialectical Behavior Therapy (DBT) Skills Training|Standard DBT skills training is a comprehensive intervention for emotion dysregulation that includes four skills modules: (1) mindfulness skills; (2) emotion regulation skills; (3) interpersonal effectiveness skills; and (4) distress tolerance skills designed to target adaptive skills deficits that define emotion dysregulation. The sessions will be delivered virtually via a HIPAA-compliant video platform.
45935883|NCT03928366|Drug|Propofol|sedation
45935884|NCT03928366|Drug|Remifentanil|remifentanil
45935885|NCT00045422|Biological|recombinant interferon alfa|
45935886|NCT00045422|Drug|imatinib mesylate|
45935887|NCT00075192|Drug|CP-675,206 and leuprolide acetate and bicalutamide|
45935888|NCT00075192|Drug|leuprolide acetate and bicalutamide|
45935889|NCT03772249|Drug|DCR-HBVS|DCR-HBVS is a synthetic ribonucleic acid interference (RNAi) drug that consists of a double-stranded oligonucleotide conjugated to N-acetyl-D-galactosamine (GalNAc) ligands. DCR-HBVS is a sterile solution of the siRNA (DCR-S219) at a concentration of 195 mg/mL in water for injection (WFI).
45935890|NCT03772249|Drug|Placebo for DCR-HBVS|Sterile 9% saline for injection.
45935891|NCT03739411|Radiation|Hyperpolarized Carbon C 13 Pyruvate|Given IV
46088514|NCT00620100|Drug|Docetaxel|
46088515|NCT02845349|Drug|Vortioxetine|The study drug, vortioxetine received approval from the U.S. Food and Drug Administration (FDA) to treat adults with major depressive disorder. This study is being done to determine its effectiveness in a specialized population, i.e. those who have developed major depression after a traumatic brain injury. As patients who have sustained a TBI are medically fragile and sensitive to side-effects of medications, it is important to test the effectiveness and safety of vortioxetine in this population.
46088516|NCT02845349|Drug|Placebo|A placebo comparator will be used in one subset of patients.
45653592|NCT01411345|Radiation|Mapped Tumor Salvage RT (MTSRT)|Dose escalation to the imaging or Dynamic Contrast Enhanced MRI (DCE-MRI)-defined dominant region(s) by dose painting at 2.25 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 68 Gy. The mapped tumor (MT) boost region will receive an absolute dose of 76.5 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 80 Gy in 2.0 Gy fractions.
45653593|NCT04421157|Other|Schroth Exercises|The Schroth approach consists of 3D scoliosis-specific exercises based on kinesthetic and sensorimotor principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. The treatment program consists of scoliotic posture correction and a breathing pattern with the help of proprioceptive and exteroceptive stimulations and mirror control. Traditional exercises program included strengthening back, abdominal, pelvis and shoulder girdle muscles and also muscles in the convex side of the curve, stretching exercises especially for the concave side of the curve, postural training, flexibility exercises for the spine, and breathing exercises. Schroth group received Schroth exercises in addition to traditional rehabilitation for 10 weeks. Patients received 30 sessions for 90 minutes at the clinic for ten-week treatment period.
45804413|NCT05294809|Behavioral|PsyPills|Prescribing personalized rational thinking strategies to change levels of dysfunctional emotionality.
45804414|NCT05294809|Behavioral|Online-Contingent Attention Training, OCAT|Facilitating the disengagement from negative content and engagement of positive one of personally relevant information by providing instruction and feedback on performance.
45804415|NCT05294809|Behavioral|shamOCAT|"The active control group, which consists of the fake version of the OCAT intervention, by offering the same attentional training, without training and feedback on performance."
45804416|NCT03440723|Device|DilaCheck|Measuring device for the measurement of cervical dilation
45804417|NCT03440723|Diagnostic Test|Cervical dilation examination|Sterile vaginal examination using subjective methods for measurement of cervical dilation
45804418|NCT05614076|Procedure|conserved chalky white enamel margins of class V cavities|during cavity preparation, we conserved chalky white enamel margins of class V cavities and then restored them with resin composite restorations,we assessed the restorations with visual inspection using a mirror and explorer according to USPHS Criteria
45804419|NCT05614076|Procedure|Total removal of demineralized enamel margins of class V cavities|during cavity preparation, we removed the total chalky white enamel margins of class V cavities and then restored them with resin composite restorations, we assessed the restorations with visual inspection using a mirror and explorer according to USPHS Criteria
45804420|NCT03838094|Biological|Biodentine|it is a dentin substitute, a new biologically active material facilitates its penetration through opened dentinal tubules to crystallize interlocking with dentin and provide mechanical properties.
45804421|NCT03838094|Biological|MTA|MTA is a powder that consists of fine hydrophilic particles that set in the presence of moisture. MTA consists of tricalcium silicate, tricalcium aluminate, tricalcium oxide and silicate oxide. MTA was considered a remarkable biocompatible material with various clinical applications that include surgical and non-surgical applications such as pulp capping
45804422|NCT03441269|Drug|Oral Ibuprofen|Oral Ibuprofen will be given to all the arms; only the dosage will be different: 400mg vs. 600mg vs. 800mg
45804423|NCT05367596|Behavioral|Continuous Energy Restriction (CER)|Energy intake will be prescribed at approximately 1,200-1,500 kcal/day with high protein. The diet will consist of low-calorie shakes provided by the study, as well as commercially available portion-controlled entrées, fruits/vegetables, and low energy-density foods available in grocery stores.
45804424|NCT05367596|Behavioral|Alternate Day Modified Fasting (ADMF)|Enhanced Care participants will have an alternate between three days of very-low energy intake (VLED; approximately 600-800 kcal/d) and four days of healthy eating (HE) each week. On HE days, participants will consume foods ad libitum for satiety.
45804425|NCT05367596|Behavioral|Group Health Education Sessions|Using video conferencing, all participants will attend weekly approximately 45-60 minutes group health education sessions led by a registered dietitian. The session will deliver a comprehensive nutritional and lifestyle change program to promote lifestyle changes and improve compliance.
45804426|NCT05367596|Behavioral|Late Evening Snack|The participants will have a late evening snack with a protein supplement.
45804427|NCT05367596|Behavioral|Physical activity|All participants will be prescribed moderate-intensity aerobic activities that do not require access to specialized exercise facilities.
45804428|NCT05367596|Behavioral|Self-monitoring|Weekly data related to adherence, food intake, physical activity, weight measurement, and nonserious adverse events will be self-reported via a REDCap survey. Participants will also be provided with a wireless activity tracker to measure total physical activity and intensity of activity objectively. These data will be used to counsel participants in addition to providing valuable feasibility data.
45935892|NCT03739411|Procedure|Magnetic Resonance Imaging|Undergo MRI
45935893|NCT03739411|Radiation|Radiation Therapy|Undergo radiation therapy
45935894|NCT03739411|Drug|Temozolomide|
45935895|NCT00045461|Drug|carboplatin|
45935896|NCT00045461|Drug|ifosfamide|
45935897|NCT00045461|Procedure|hyperthermia treatment|
45935898|NCT00075231|Drug|Kaletra® (lopinavir/ritonavir)|
45935899|NCT00075231|Drug|Combivir® (lamivudine, zidovudine)|
45935900|NCT00075231|Drug|Sustiva® (efavirenz)|
45935901|NCT03724552|Device|Transcranial LED Therapy|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm) is applied to forebrain.
45935902|NCT00403312|Behavioral|Smoking Cessation Behavioral Program|
45935903|NCT00403312|Drug|Nicotine Patch|
45804429|NCT05367596|Behavioral|Remotely Supervised Exercise Sessions|Sessions of 45 minutes duration will be delivered via video conferencing 2-3 times per week.
45804430|NCT03383627|Device|Continuous Glucose Monitoring|"The FreeStyle Libre Pro Flash Glucose Monitoring System is a professional continuous glucose monitoring (CGM) device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. The Freestyle Libre Pro device is FDA approved (PMA# P150021). Participants will use the FreeStyle Libre Pro Flash Glucose Monitoring device according to its approved use, on the back of the arm.~CGM monitoring will be performed on Day 1 by placing the Freestyle Libre Pro on research subjects for intended use of 14 days.~Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis."
45804431|NCT05366426|Other|EMG biofeedback program:|Superficial electrodes and EMG-guided biofeedback will be applied to the perineal region 3 days a week for 8 weeks, so that patients can receive visual and auditory feedback during exercise.
45804432|NCT05366426|Other|Sham EMG biofeededback:|3 days a week for 8 weeks; Surface electrodes will be attached as in the EMG Biofeedback group, but unlike the EMG biofeedback group, they will exercise without any visual and auditory feedback (1).
45804433|NCT05366426|Other|Pelvic floor muscle training home exercise program:|Pelvic floor muscle training home exercise program: A home exercise program was given to all patients who had learned to perform correct pelvic floor muscle contraction with the pre-treatment evaluation. In the home exercise program, patients in three positions (sitting, lying and standing) are required to perform two to three rapid contractions of 15 repetitions in each set, three times a day, followed by slow contractions by keeping the PTC tense for 8-10 seconds, and then give a 10-second rest period after slow contractions. has been told. All 3 groups received PTK exercise program.
45804434|NCT05365490|Procedure|Transcarotid Artery Revascularization (TCAR)|Carotid artery revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
45804435|NCT03252353|Drug|octreotide capsules|octreotide capsules 40 mg/day, 60 mg/day, 80 mg/day (individual dose titration)
45804436|NCT03252353|Drug|Matching placebo|Matching placebo capsules
45804437|NCT05355272|Drug|Recombinant human growth hormone|recombinant human growth hormone (rhGH)
45804438|NCT05355272|Drug|Placebo|placebo
45804439|NCT00358358|Drug|Fluticasone Propionate/Salmeterol 500/50mcg combination|
45804440|NCT00358358|Drug|Fluticasone Propionate 500mcg|
45804441|NCT00358358|Drug|Salmeterol 50mcg|
45804442|NCT05349734|Other|overbody blanket|applying overbody blanket with forced-air blower set to 43℃
45804443|NCT05349734|Other|underbody blanket|applying underbody blanket with forced-air blower set to 43℃
45804444|NCT03252431|Drug|F-627|single dose pre-filled syringe
45804445|NCT03252431|Drug|Neulasta|single dose pre-filled syringe
45804446|NCT03441581|Drug|Eluxadoline|Eluxadoline 100 mg oral tablets BID with food.
45804447|NCT02265510|Drug|INCB052793|Initial cohort dose of INCB052793 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.
45804448|NCT02265510|Drug|gemcitabine|Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency.
45804449|NCT02265510|Drug|nab-paclitaxel|nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency.
45804450|NCT02265510|Drug|dexamethasone|Dexamethasone administered orally at the protocol-specified dose and frequency.
45804451|NCT02265510|Drug|Carfilzomib|Carfilzomib administered intravenously at the protocol-specified dose and frequency.
45804452|NCT02265510|Drug|bortezomib|Bortezomib administered intravenously or subcutaneously at the protocol-specified dose and frequency.
45804453|NCT02265510|Drug|lenalidomide|Lenalidomide administered orally at the protocol-specified dose and frequency.
45804454|NCT02265510|Drug|azacitidine|Azacitidine administered subcutaneously at the protocol-specified dose and frequency.
45804455|NCT02265510|Drug|INCB052793|INCB052793 tablets administered orally at the protocol specified dose strength and frequency.
45804456|NCT02265510|Drug|pomalidomide|Pomalidomide administered orally at the protocol-specified dose and frequency.
45457996|NCT01234051|Drug|Docetaxel, Oxaliplatin|"1. Treatment Schedule~1.1. Docetaxel schedule Docetaxel 35 mg/m2 is administered on day 1 and day 8 by intravenously in 100 mL of 5% dextrose solution over 30 minutes. Dexamethasone 8mg is intravenously administered before 30 minutes, and then orally 4mg every 12 hours over 48 hours. In the event of a hypersensitivity reaction, dimethidine maleate, epinephrine, and intravenous fluids will be required.~1.2. Oxaliplatin schedule Oxaliplatin 100 mg/m2 is given on day 1 by intravenous infusion in 500 mL of 5% dextrose solution over 120 minutes. Therapy will be repeated every 21 days."
45804457|NCT02265510|Drug|INCB050465|INCB050465 tablets administered orally at the protocol specified dose strength and frequency.
45804458|NCT02265510|Drug|INCB039110|INCB039110 tablets administered orally at the protocol specified dose strength and frequency.
45804459|NCT03254147|Drug|warfarin|warfarin
45804460|NCT03254147|Drug|dabigatran|Non-vitamin K dependent oral anti-coagulants (NOACs)
45935904|NCT00403312|Behavioral|Physical Activity|
45935905|NCT00079170|Dietary Supplement|garlic|
45935906|NCT00079170|Drug|docetaxel|
45935907|NCT00045500|Drug|7-hydroxystaurosporine|
45653594|NCT04421157|Other|Core stabilization Exercises|Each exercise session consisted of a warm-up exercise, core stabilization exercise, and a cool-down exercise. The core stabilization exercise was designed with consideration of local, global muscle stability training, global muscle mobility training,and strengthening training of these core structures was carried out progressively advancing more difficult. Traditional exercises program included strengthening back, abdominal, pelvis and shoulder girdle muscles and also muscles in the convex side of the curve, stretching exercises especially for the concave side of the curve, postural training, flexibility exercises for the spine, and breathing exercises. The Stabilization group received Core stabilization in addition to traditional rehabilitation for 10 weeks. Patients received 30 sessions for 90 minutes at the clinic for ten-week treatment period.
45653595|NCT04432753|Behavioral|Lung Cancer Screening Decision Aid with Incidental Findings Information|The intervention consists of a previously tested and developed brief lung cancer screening video decision aid with the addition of information on incidental findings for lung cancer screening.
45653596|NCT04432753|Behavioral|Lung Cancer Screening Decision Aid without Incidental Findings Information|The intervention consists of a previously tested and developed brief lung cancer screening video decision aid that does not include information on incidental findings.
45653597|NCT05473793|Dietary Supplement|Dried chicory root particles|The intervention product consists of chicory root that have been sliced and dried and are provided in the form of particles (~3mm).
45653598|NCT05473793|Other|Placebo|The control arm receives a placebo consisting of rice puff particles.
45653599|NCT01362595|Drug|leucine|"Dosage of leucine will be dependent on body surface area (BSA):~leucine 700 mg/m2/dose by mouth three times a day"
45804461|NCT03254147|Drug|Apixaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
45653600|NCT04421391|Dietary Supplement|QuadraMune(TM)|QuadraMune(TM) is a commercially available nutritional supplement
45804462|NCT03254147|Drug|Edoxaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
45804463|NCT03254147|Drug|Rivaroxaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
45804464|NCT04735601|Procedure|Ahmed Valve|Ahmed valve implantation coated with poly lactic -co-glycolic acid (PLGA) saturated with Mitomycin-C in the management of adult onset glaucoma in Sturge Weber syndrome
45804465|NCT05589194|Behavioral|Nursing Practices Based on Kolcaba's Comfort Theory|Nursing interventions planned to be carried out within the scope of the research will be based on Comfort Theory. Nursing interventions will be planned according to the needs in the physical comfort (diet practice, providing effective and correct pelvic floor muscle contraction, repetitive and regular yoga practice training), psychospiritual comfort (appreciation and encouragement, self-confidence, expressing the feeling of embarrassment, expressing fear, confidence, repetitive and regular practice of yoga practice, meditation), sociocultural comfort (to be informed, to develop effective interpersonal communication, to interact with other women with SUI) and environmental comfort (Informing about making the necessary arrangements to prevent possible situations such as sleep disruption and falling, bad smell, etc. and performing nursing practices by respecting privacy). The yoga practice will carry out with the participation of 60-minute group yoga classes twice a week for 6 weeks.
45804466|NCT04735757|Other|Contrast-enhanced MRI|Contrast-enhanced MRI
45804467|NCT04735757|Other|Measurement of respiratory muscle force|Measurement of the maximum inspiratory and expiratory pressure.
45804468|NCT03384329|Drug|Resveratrol Pill|Resveratrol 500 mg
45653601|NCT05556941|Behavioral|Metacognitive Group Intervention|The investigators developed an initial Meta cognitive group intervention protocol based on the dynamic interactional model of cognition (Toglia, 2005), and specifically tailored it to individuals with schizophrenia.
45653602|NCT05556941|Behavioral|Occupational therapy standard care|Occupational therapy standard care
45653603|NCT05556863|Drug|ELA026|Single dose of ELA026
45653604|NCT05556863|Drug|ELA026|Multiple doses of ELA026
45653605|NCT04949139|Drug|Dextrose 5% in water|Reducing the sodium concentration
45653606|NCT03064399|Procedure|without lateral ligament repairment|microfracture without repairment of the lateral ligament
45653607|NCT03064399|Procedure|lateral ligament repairment|microfracture combined with repairment of the lateral ligament
45804469|NCT03384329|Drug|Placebos|Placebo Pills
45804470|NCT03384953|Behavioral|Clinical Hypnosis - Group Treatment|group treatment
45804471|NCT03384953|Behavioral|Clinical Hypnosis - Individual Treatment|individual treatment
45804472|NCT00359060|Behavioral|Physical activity|
45804473|NCT03443063|Drug|Lemborexant|oral tablet
45804474|NCT05327972|Drug|The investigational medicinal product is incobotulinumtoxinA (XEOMIN®).|Two milliliters of a mixture comprised of XEOMIN® 100 U and saline solution 0.9% will be once injected in the supra-spinatus muscle using ultrasonography guidance.
45804475|NCT05327972|Other|PLACEBO|Two milliliters of a saline solution containing an inactive lyophilisate will be once injected in the supra-spinatus muscle using ultrasonography guidance.
45804476|NCT03256253|Drug|Pregabalin|pregabalin up to 600 mg/day
45804477|NCT00358514|Device|Continuous Compartment Pressure Monitoring|See Detailed Description.
45804478|NCT03256799|Drug|Ivacaftor/Ataluren|Both drugs were given in combination for 48 week study period
45804479|NCT03257189|Device|Physiological signal monitor|Wireless remote monitoring system intended for use by researchers and healthcare professionals for continuous collection of physiological data in home and healthcare settings.
45804480|NCT03257189|Device|Heart rate and heart rate variability comparison device|FDA cleared reference device that monitors heart rate and heart rate variability in subjects
45935908|NCT00045500|Drug|prednisone|
46002506|NCT01792934|Other|radiofrequency ablation (RFA)|
46002507|NCT01792934|Other|transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE)|
46002508|NCT01792934|Radiation|stereotactic body radiation therapy (SBRT)|
45457997|NCT05074381|Other|Dry Needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leadi
45653608|NCT04948983|Other|Decision aid (DA) for breast cancer screening|The online DA for breast cancer screening is a web-based education material to inform women about the benefits and risks associated with the screening. The contents of the DA are: 1) Assessing breast cancer; 2) What is breast cancer screening?; 3) What will happen if I diagnosed with breast cancer?; 4) What is overdiagnosis?; 5) What is false positive?; 6) the statistics of breast cancer screening; 7) Now is my turn, do I want to take it?
45804481|NCT03257189|Device|Respiration rate comparison device|FDA cleared reference device that monitors respiration rate in subjects
45935909|NCT03576157|Other|Kilkari|Kilkari is an outbound service that delivers weekly, time-appropriate audio messages about pregnancy, childbirth, and childcare directly to families on their mobile phones, starting from the second trimester of pregnancy until the child is one-year-old.
45935910|NCT02965560|Diagnostic Test|plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.|
45935911|NCT00045539|Drug|leucovorin calcium|
45935912|NCT00045539|Drug|methotrexate|
45935913|NCT00045539|Drug|thiotepa|
45935914|NCT03519373|Biological|TDaP|Tetanus, Diphteria and Acellular Pertussis vaccine (Boostrix)
45935915|NCT00079248|Biological|therapeutic progesterone|
45935916|NCT00079248|Drug|conjugated estrogens|
45653609|NCT04948983|Other|Standarised information for breast cancer screening|Information provided by the Chilean Ministry of Health in regards to access to breast cancer screening (Age, frequency and costs)
45653610|NCT04426097|Procedure|Cervical Vagal Blockade|Cervical Vagal Blockade with 0.5 % ropivacaine 2.5 ml and 2% xylocaine 2.5 ml
45804482|NCT03257189|Other|Activity classification|Visual annotation of subject posture and other activities used for reference
45935917|NCT00045617|Biological|monoclonal antibody 11D10 anti-idiotype vaccine|
45935918|NCT00045617|Biological|monoclonal antibody GD2 anti-idiotype vaccine|
45935919|NCT00045617|Drug|cisplatin|
45935920|NCT00045617|Drug|etoposide|
45935921|NCT00045617|Radiation|radiation therapy|
45935922|NCT03442309|Device|Silver Diamine Fluoride|Silver diamine fluoride (SDF)
45935923|NCT03442309|Device|Fluoride Varnishes|Fluoride varnish (FV)
45935924|NCT03442309|Device|Glass Ionomer|Glass Ionomer Sealants (GC Fuji IX)
45935925|NCT03399838|Drug|Dexmedetomidine|IN Dex for pediatric procedural sedation at the emergency department
45935926|NCT03399838|Drug|Midazolam|po/pr midazolam as active comparator to dexmedetomidine for pediatric procedural sedation at the pediatric emergency department
45935927|NCT03313492|Behavioral|UV4.me2|"UV4.me2 is an enhanced version of the original UV4.me web intervention and features the many of the same educational material and interactive components. New features/strategies for reach, effectiveness, and implementation include:~A mobile version of the site~Incentives in the form of clickable coupons and links to free samples for sun protection products (e.g., sunscreen)~Behavioral tracking and feedback, where users can set goals, track their progress, and receive tailored feedback"
45935928|NCT03313492|Behavioral|UV4.me|Original version of the UV4.me website, which offers education and tailored responses to interactive quizzes about current sun protective behaviors and barriers to engaging in sun protective behaviors.
45935929|NCT03313492|Behavioral|E-Pamphlet|"A free non-interactive e-pamphlet (Skin Cancer Prevention and Early Detection from the American Cancer Society). Includes information on skin cancer risk and prevention."
45935930|NCT00079287|Drug|carboplatin|
45935931|NCT00079287|Drug|docetaxel|
45653611|NCT04426097|Procedure|Without Blockade|Without Blockade
45653612|NCT05556551|Other|Full Ceramic restoration|Two different dental restoration inserted in patient mouth ( split mouth)
45935932|NCT00079287|Drug|gemcitabine hydrochloride|
45804483|NCT01238211|Drug|Cytarabine|Given IV
45804484|NCT01238211|Drug|Dasatinib|Given PO
45804485|NCT01238211|Drug|Daunorubicin Hydrochloride|Given IV
45804486|NCT01238211|Other|Laboratory Biomarker Analysis|Correlative studies
45804487|NCT00375947|Other|Hand Exercise|
45804488|NCT00375947|Other|sham hand cream|placebo intervention
45804489|NCT04735445|Diagnostic Test|Digital rectal exam and / or anal cytology (day 1 and after 36 months)|For anal screening in MSM man or woman with abnormal cervical cytology, genital warts or having anal sex (day 1 and after 36 months)
45935933|NCT00079287|Drug|paclitaxel|
45935934|NCT00079287|Drug|vinorelbine tartrate|
45935935|NCT02999932|Other|SpO2 directed oxygen therapy|Oxygen therapy was administered to achieve targeted SpO2.
45935936|NCT00045695|Drug|bortezomib|PS-341 bolus intravenous injection twice weekly* for 2 out of every 3 weeks
45935937|NCT02988973|Drug|roxadustat|Oral administration
45935938|NCT02988973|Drug|DA|Subcutaneous administration
45935939|NCT00079365|Drug|fluorouracil|
45935940|NCT00079365|Drug|gemcitabine hydrochloride|
45935941|NCT00079365|Radiation|brachytherapy|
45935942|NCT00079365|Radiation|phosphorus P32|
45935943|NCT00079365|Radiation|radiation therapy|
45935944|NCT00045773|Drug|Sertraline|50 - 200mg, once per day for 12 weeks.
45935945|NCT02839915|Drug|Folinic Acid|Liquid levo-leucovorin via oral route. L-leucovorin is the active isomer.
45935946|NCT02839915|Other|Placebo|Inactive placebo comparator
45935947|NCT00079404|Drug|tanespimycin|Given IV
45935948|NCT02781922|Genetic|Autologous cardiac stem cells (JRM-001)|3x 10^5 cells/kg, single treatment
45935949|NCT00045812|Drug|SCH-58235|
46002509|NCT01792934|Drug|Bevacizumab|may be added to both regimens according to standard procedures
45935950|NCT02606578|Other|Questionnaires|"The study team will collect information from your medical record regarding: demographics, operation, nutritional status, laboratory values, testing results, complications, hospital data, cost, length of stay, past medical history and clinical outcomes.~At your clinical follow-up visits (~4 weeks, 6 months, and 12 months post operation), a study coordinator will meet with you to assess for adverse events and to have you complete research questionnaires. Alternatively, the study coordinator may call you to assess for adverse events and ask if we can mail you the research questionnaires to complete and mail back.~You will also be asked to complete the research questionnaires a minimum of once a year for your lifetime: A study coordinator will call you and ask if we can mail you questionnaires to complete and mail back."
45935951|NCT00079443|Drug|romidepsin|Given IV
45935952|NCT00079443|Biological|rituximab|Given IV
45935953|NCT00079443|Drug|fludarabine phosphate|Given IV
45935954|NCT00079443|Other|laboratory biomarker analysis|Correlative studies
45653613|NCT05556551|Other|Hybrid resin Ceramic restoration|Hybrid resin Ceramic restoration
45653614|NCT04411173|Dietary Supplement|Whey Protein|Each condition (both rice and whey protein) match in color, flavor, and serving size.
45935955|NCT02599363|Drug|Ribociclib (LEE011)|
45935956|NCT02599363|Drug|Paclitaxel|
45653615|NCT05556317|Behavioral|Resistive exercise|advices and resistive exercise
45653616|NCT04411407|Device|PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order|PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order
45804490|NCT04735445|Diagnostic Test|Semestral digital rectal exam and / or anal cytology if abnormal → ANOSCOPY with biopsy|For anal screening in MSM man or woman with abnormal cervical cytology, genital warts or having anal sex (semestral)
45935957|NCT02580838|Drug|OnabotulinumtoxinA|Early OnabotulinumtoxinA group will receive OnabotulinumtoxinA injection when their spasticity develop, late OnabotulinumtoxinA group will have injection at 6 months after emergence of spasticity, the third group will not have OnabotulinumtoxinA intervention.
45935958|NCT00079521|Procedure|Therapeutic Touch|
45935959|NCT02072356|Radiation|yttrium Y 90 glass microspheres|Given Interartrial
45935960|NCT02072356|Other|laboratory biomarker analysis|Alpha-fetoprotein assay
45804491|NCT04735445|Diagnostic Test|Cervical cytology and cervical sample for HPV detection (day 1 and after 36 months)|For Cervix Screening in sexually active woman (day 1 and after 36 months)
45804492|NCT04735445|Diagnostic Test|Semestral cervical cytology and cervical sample for HPV detection|For Cervix Screening in sexually active woman (semestral)
45804493|NCT04735445|Diagnostic Test|Appointment for mammography (day 1 and after 36 months)|For Breast Screening in woman between 50-70 years old (day 1 and after 36 months)
45935961|NCT02072356|Drug|TheraSphere|TheraSphere is delivered into the liver tumor through a catheter placed into the hepatic artery.
45935962|NCT00046085|Behavioral|Online Family Education|Families were provided with private, secure access to the website, which features family-to-family chat capabilities, video lectures on the management of schizophrenia, written materials on important issues in schizophrenia management, professionally facilitated online discussions of the material, and additional resource links.
45935963|NCT00046085|Behavioral|Customary care|Participants received care as usual.
45935964|NCT00403429|Drug|capecitabine|
45935965|NCT00403507|Behavioral|Participation in a monitored exercise program|No contact with control group during 20 weeks.
45935966|NCT00403507|Behavioral|Personalized aerobic and strength training.|Three-days per week for 20 weeks at hospital gym under supervision of exercise specialist.
45935967|NCT00403624|Drug|OXALIPLATIN|
46088517|NCT04117308|Procedure|Classic information|The team delivers to each patient a unique and standardized information brochure including a definition of fetal active movements, and the need to consult if the patient perceives less the movements of her fetus.
45653617|NCT05556083|Drug|Sildenafil 50 mg Oral Tablet and Dapoxitine 3mg Oral tablet|Single blind placebo randomized controlled trial
45653618|NCT05556083|Drug|Placebo oral tablet and Dapoxitine 3mg Oral tablet|Single blind placebo randomized controlled trial
45653619|NCT05556005|Drug|Trimetazidine Dihydrochloride|Trimetazidine Dihydrochloride 35 mg modified release tablet used twice daily
45653620|NCT05556005|Drug|Placebo|Starch tablets used twice daily
45804494|NCT04735445|Diagnostic Test|Annual appointment for mammography|For Breast Screening in woman between 45-70 years old (annual)
46088518|NCT04117308|Procedure|Information by detailed brochure on the fetal active movements account|Delayed single and standardized explanatory card on fetal movements (definition, interests of their follow-up, technique of movements on fetuses, table to fill during the follow-up noting the number of active movements physical feelings at 3 times of the day, managing the decrease in the number of active fetal movements).
45457998|NCT05074381|Other|Sham Needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
45653621|NCT05008809|Drug|mFOLFOX6|Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Leucovorin: 400 mg/m², 1-2 h IV infusion on d1 5-FU: (optional: 400 mg/m² bolus, 2-5 min IV infusion), 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
45653622|NCT05008809|Drug|mFOLFOXIRI|Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Irinotecan: 150 mg/m², 90 min IV infusion on d1 Leucovorin: 400 mg/m², 1-2 h IV infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
45804495|NCT04735445|Diagnostic Test|Semestral appointment for liver ultrasound|"For Hepatic Screening:~Cirrhosis or Chronic HBV, and meet any of the following risk factors:~Asian male> 40 years old~Asian woman> 50 years old~African man or woman~HCC family history"
45457999|NCT02309242|Behavioral|Neuropsychological assessment, MRI|All subjects will be imaged (MRI) on the same 3T Philips scanner with a 32-channel phased-array head coil, located in the radiology department at UZ Leuven. For the neuropsychological assessment we will implement an extended neuropsychological assessment battery: ANT, CMS, Rey, BRIEF, WISC III, PedsQL, STAI, BDi, achenbach questionnaires
45458000|NCT05073835|Drug|Semaglutide 3 mg|Semaglutide 2.4 mg/week, subcutaneous injection. Treatment dose: 16 weeks of dose escalation + 52 weeks of study dose (i.e., 2.4 mg/week).
45458001|NCT05073835|Drug|Placebo|Placebo
45458002|NCT02313142|Behavioral|Leg exercises|
45653623|NCT04373603|Drug|Tranexamic acid|TXA is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, thus inhibiting degradation of fibrin clots and serving as an antifibrinolytic
45653624|NCT04373603|Other|Saline|sodium chloride and water for use as control
45653625|NCT04373603|Drug|Hyaluronic acid|Hyaluronidase is a spreading or diffusing substance which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue
45804496|NCT04735445|Diagnostic Test|Semestral appointment for liver ultrasound|Having chronic liver disease with fibrosis ≥ F3 or Presents chronic HBV
45804497|NCT04735445|Diagnostic Test|Semestral blood collection for alpha-fetoprotein and others hepatic biomarkers determination|Having chronic liver disease with fibrosis ≥ F3 or Presents chronic HBV
45804498|NCT04735445|Diagnostic Test|Fecal occult blood test (day 1 and after 36 months)|"For Colon Screening:~Age between 50-70 years old"
45804499|NCT04735445|Diagnostic Test|Annual fecal occult blood test|"For Colon Screening:~Age older than 40 years"
45804500|NCT04735445|Diagnostic Test|Digital rectal exam and PSA determination (day 1 and after 36 months)|"For Prostate Screening:~Man older than 50 years"
45804501|NCT04735445|Diagnostic Test|Annual digital rectal exam and PSA determination|"For Prostate Screening:~Man older than 50 years"
45804502|NCT04735445|Diagnostic Test|Annual appointment for low dose computed tomography for lung screening|"For Lung Screening: should accomplish~ALL the following criteria:~Age > 40 years~Active smoker or former smoker<3 years, with IPY ≥20. IPY: index of packages-year: nº packages that smoke per day x nº years smoking~No contraindications for thoracic surgery~No lung infection in the last 2 months"
45804503|NCT04735445|Diagnostic Test|Annual general inspection for skin lesions suggestive of malignancy|"For Skin Screening:~Woman ≥18 years Man ≥40 years"
45804504|NCT04344314|Device|Peripheral Intravenous Catheter|Randomised controlled
45804505|NCT05520008|Other|Game-based exercise|Patients in the active group will put on a sensor connected to a tablet to play a game-based foot/ankle exercise twice a day for 5 minutes for four weeks.
45804506|NCT00003231|Drug|cisplatin|
45804507|NCT00003231|Drug|docetaxel|
45804508|NCT00003231|Procedure|surgical procedure|
45804509|NCT00003231|Radiation|radiation therapy|
45804510|NCT03259139|Behavioral|Video games and violence|Participants will be randomly assigned to play a video game which contains either (1) no violent content, (2) violent content with swords, or (3) violent content with guns. The game, rated E, is age appropriate and modded to include guns in the appropriate condition.
45804511|NCT05132036|Other|lung ultrasound|"Subjects are enrolled during their usual session in the hemodialysis unit of the Amiens University Hospital. Before starting the hemodialysis, lung ultrasound according to the 8 sites score and a measure of bioimpedance will be performed in dorsal decubitus. In a 2nd time, an echocardiography is realized. During haemodialysis session, biological analysis and clinical score will be assessed"
45804512|NCT00003405|Biological|recombinant interferon alfa|
45653626|NCT05611073|Diagnostic Test|Visual Acuity|Measurement of distance, intermediate and near visual acuity.
45804513|NCT00003405|Drug|amifostine trihydrate|
45804514|NCT00003405|Drug|bromodeoxyuridine|
45804515|NCT00003405|Drug|cytarabine|
45804516|NCT00003405|Drug|idarubicin|
45804517|NCT00003405|Drug|idoxuridine|
45804518|NCT00003405|Drug|isotretinoin|
45804519|NCT00003405|Drug|mitoxantrone hydrochloride|
45804520|NCT05131646|Drug|CLS-AX|injectable suspension of small molecule tyrosine kinase inhibitor (TKI) administered in the Parent study CLS1002-101
45804521|NCT03260699|Device|OCSI Rehabilitator brace|Guardian Brace features the innovative Rehabilitator™ line of gait correcting, leg strengthening braces. Rehabilitator™ Knee Braces are clinically proven to reduce UNBRACED pain, strengthen the affected leg, and significantly improve function after only 90 days of brace wear.
45804522|NCT00003411|Drug|motexafin gadolinium|
45804523|NCT00003411|Radiation|radiation therapy|
45804524|NCT05128136|Device|Impact of ring size on adherence|The study design is a randomized, open-label, parallel group 3-way crossover study comparing adherence, preference and overall acceptability of 3 different-sized placebo IVRs (IVRs A, B and C) in 24 US couples. At enrollment, each couple will be randomly assigned to 1 of 6 sequences of IVR use: A-B-C, A-C-B, B-A-C, B-C-A, C-A-B or C-B-A. Each couple will use each of the 3 IVRs (IVRs A, B and C) for 30 days per IVR, 90 days total.
45804525|NCT05440721|Device|Treatment A with device Clickotine® (Active intervention)|The intervention regimen around Treatment A is almost entirely user-directed. When a person has a craving, a series of options are available to ease the craving and resist the urge to smoke. The user will also engage with Clickotine® leading up to their quit date to complete a program of 21 Missions, daily activities which help prepare them to quit and keep them off cigarettes. Ideally, the user will open and use Treatment A several times a day.
45935968|NCT01811329|Dietary Supplement|Dairy fat|
45452520|NCT03089996|Procedure|Piezocision|The first maxillary premolars will be extracted with orthodontic purpose. After 3 months of extraction, the orthodontic alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli®, Sorocaba, SP, Brazil). The retraction of the canines will begin using closed nickel-titanium spring (120g). The piezocision surgery will be performed only in one side of the mouth. Three vertical piezo-incisions will be performed near the edentulous region and mesially to the canine root, in the vestibular alveolar cortical bone with the Ultrasonic instrument (BS1 insert Piezotome ™, Satelec Group Acteon Merignac, France) in depth of 3 mm. The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months. The patients will be advised to take analgesics (paracetamol or dipyrone) only if necessary.
45452521|NCT03089996|Procedure|Corticotomy|The first maxillary premolars will be extracted with orthodontic purpose. After 3 months of extraction, the orthodontic alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli, Sorocaba, SP, Brazil).The retraction of the canines will begin using closed nickel-titanium spring (120g).The corticotomy surgery will be performed at the day of begining of canine retraction only in one side of the mouth.A mucoperiosteal flap will be raised from the extraction region to the mesial of the canine.Perforations will be performed using a number 2 spherical drill bit in low speed handpiece under irrigation, only in the cortical none depth.The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months.The patients will be advised to take analgesics (paracetamol or dipyrone) only if necessary.
45653627|NCT05611073|Diagnostic Test|Biometric Data Collection|Measurement of biometric data will be obtained from the Zeiss IOL Master 700, Atlas 9000, and the iTrace.
45804526|NCT05440721|Device|Treatment B with smoking education (control)|The Treatment B app is operated by the National Cancer Institute to provide education and support to smokers seeking to quit. The QG regimen is entirely user-directed. When a user has a craving or wants support or education, they can log into the QG app. The QG app also provides lessons relevant for preparing to quit and beginning to quit.
45653628|NCT05611073|Other|Patient Questionnaire|Patients will complete a Patient Questionnaire to determine their level of spectacle independence and visual acuity satisfaction.
45653629|NCT02519595|Drug|Ketamine IV 1mg/kg|Intervention: Ketamine IV 1mg/kg
45804527|NCT00003243|Biological|aldesleukin|
45804528|NCT00003243|Biological|filgrastim|
45653630|NCT02519595|Drug|Ketamine IV 1.5mg/kg|Intervention: Ketamine IV 1.5 mg/kg
45804529|NCT00003243|Biological|therapeutic allogeneic lymphocytes|
45804530|NCT00003243|Drug|cyclophosphamide|
45804531|NCT00003243|Drug|etoposide|
45804532|NCT00003243|Drug|pegylated liposomal doxorubicin hydrochloride|
45653631|NCT02519595|Drug|Ketamine IV 2mg/kg|Intervention: Ketamine IV 2 mg/kg
45653632|NCT05610917|Combination Product|CBRM (community-based rehabilitation management)|The case group patients will undergo drug treatment (Selective Serotonin Reuptake Inhibitors), health education, cognitive-motor dual task training, cognitive-training.
45653633|NCT05610917|Combination Product|TAR(treatment as routine)|Patients in control group will be treated rountinely which includes drug treatment (SSRIs) and traditional health education.
45653634|NCT04278755|Drug|Drospirenone-Ethinyl Estradiol Oral Tablet|3 Mg-0.03 Mg continuous daily Drospirenone-Ethinyl Estradiol.
45804533|NCT05503550|Drug|Talquetamab|Talquetamab will be administered subcutaneously (SC).
45804534|NCT04344158|Drug|AK105 Injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle.
45804535|NCT04344158|Drug|Anlotinib Hydrochloride Capsules|Anlotinib capsules 10mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
45804536|NCT04344158|Drug|Sorafenib Tosylate Tablets|Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.
45804537|NCT00384345|Device|Bright Light Therapy|
45804538|NCT00384345|Behavioral|Exercise|
45804539|NCT00003249|Drug|carboxyamidotriazole|
45804540|NCT00003249|Drug|chemotherapy|
45804541|NCT00003249|Drug|ketoconazole|
45804542|NCT03268343|Drug|Cytisine|Cytisine 1.5 mg Film-Coated Tablets
45804543|NCT04329663|Device|Indonesian computer-based game prototype|In order to improve the ADHD clinical symptoms and executive function of the player, this game should has challenge similar to memory game which is the player was given object to be memorized and then match the object in accordance to the task given inside the game. With some difficulty leves, this game was tried to trigger players in terms of accuracy and quickness in completing the mission.
45804544|NCT03744637|Drug|MK-5475|Single inhaled dose of MK-5475 120, 165, 240, 300, 360, or 480 ug depending upon randomization
45653635|NCT04277975|Other|Liberal post-discharge opioid prescribing|Opioid prescribed all patients opioids 'in case they are needed' prior to surgery
45804545|NCT03744637|Drug|Placebo|Single inhaled dose of placebo to match MK-5475
45804546|NCT00003255|Drug|carboplatin|
45804547|NCT00003255|Drug|topotecan hydrochloride|
45804548|NCT03269435|Procedure|Greater occipital nerve block with bupivacaine|This is a type of peripheral nerve block. 3cc of 0.5% bupivacaine will be injected adjacent to the greater occipital nerve block blaterally
45804549|NCT03269435|Drug|Metoclopramide|Metoclopramide 10mg IV will be administered over 15 minutes
45804550|NCT00003261|Drug|methotrexate|
45804551|NCT00003261|Drug|zidovudine|
45804552|NCT00003261|Procedure|neoadjuvant therapy|
45804553|NCT00003261|Radiation|radiation therapy|
45804554|NCT05288582|Device|NovaTears|Over-the-counter eye drop
45804555|NCT05503082|Drug|Ubrogepant 50 MG [Ubrelvy]|Ubrogepant 50 MG [Ubrelvy]
45804556|NCT05503082|Drug|Ubrogepant 100 MG [Ubrelvy]|Ubrogepant 100 MG [Ubrelvy]
45804557|NCT03279731|Drug|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.
45935969|NCT01811329|Dietary Supplement|Dairy fat + MFGM|BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
45935970|NCT01811329|Dietary Supplement|Palm fat|
45935971|NCT01811329|Dietary Supplement|Palm fat + MFGM|BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
45935972|NCT00079560|Drug|dronabinol|dronabinol to prevent development of marijuana withdrawal
45935973|NCT00046163|Drug|midodrine hydrochloride (ProAmatine®)|
45935974|NCT01409161|Drug|Arsenic Trioxide|Given IV
45653636|NCT04277975|Other|Restricted post-discharge opioid prescribing|Opioid only if needed after discharge
45804558|NCT03279731|Drug|Placebo|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). It is designed to be identical to the pen used for liraglutide (Saxenda). Placebo product inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection
45804559|NCT04530409|Drug|Early-Corticosteroids|early use of dexamethasone/Methylprednisolone as early as laboratory evidence of high inflammatory markers
45653637|NCT05610839|Behavioral|Acceptance-Enhanced Behavior Therapy|8-module intervention delivering acceptance-enhanced behavior therapy through a fully automated website. This intervention was adapted from the Acceptance-enhanced behavior therapy workbook (Woods & Twohig, 2008).
45935975|NCT01409161|Drug|Gemtuzumab Ozogamicin|Given IV
45804560|NCT03390257|Device|3NT flexible endoscope|The nasal anatomy will be accessed and viewed with the device during Balloon Sinus Dilation
45935976|NCT01409161|Other|Laboratory Biomarker Analysis|Correlative studies
45935977|NCT01409161|Drug|Tretinoin|Given PO
45935978|NCT00079599|Drug|L-carnitine|A study drug, L-carnitine, titrating the doses from 0.5 g to 3 g to reduce the possibility of side effects, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
45935979|NCT00079599|Other|Placebo|A placebo, where patients underwent the dose titration identical to the study patients, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
45935980|NCT00601939|Behavioral|Psychoeducational intervention (PEI)|PEI consists of 10 culturally competent group empowerment psychoeducational sessions. The sessions are directed by a treatment manual and are co-led by two therapists. The sessions are guided by the theory of triadic influence (TTI) model, which incorporates cultural-environmental influences, social-situational influences, and intrapersonal influences into treatment.
45935981|NCT00601939|Behavioral|Enhanced treatment as usual (ETAU)|ETAU contains an adherence protocol plus access to weekly support group and a resource room.
45935982|NCT00278785|Behavioral|Brief Motivational Interview|10-20 minute brief motivational interview
45935983|NCT00079638|Drug|Niacin|
45935984|NCT00079638|Drug|Atorvastatin|
45935985|NCT00079638|Drug|Simvastatin|
45935986|NCT00079638|Drug|Ezetimibe|
45935987|NCT00079638|Drug|Rosuvastatin|
45935988|NCT00017953|Behavioral|Lifestyle Intervention|The lifestyle intervention is implemented with individual supervision and group sessions and is aimed at achieving and maintaining at least a 7% decrease in weight from baseline and 175 minutes per week in physical activity. It is implemented during a four-year period with the most intensive application during the first year, less frequent attention during the next three years, and a minimum of twice yearly contacts during an extended follow-up period. To help participants achieve and maintain weight loss, a variety of diet strategies (e.g. prepared meals and liquid formula), exercise strategies, and optional weight loss medications are utilized based on a preset algorithm and participant progress.
45935989|NCT00017953|Behavioral|Diabetes Support and Education|Participants assigned to diabetes support and education are offered three sessions each year in diabetes management and social support.
45935990|NCT00046241|Drug|Extended-release bupropion hydrochloride|
45935991|NCT00079716|Drug|SGN-40 (anti-huCD40 mAb)|0.5-8 mg/kg IV (in the vein) on Day 1; 0-8 mg/kg on Day 4; 0.5-16 mg/kg on Days 8 and 15; 0-16 mg/kg on Day 29.
45935992|NCT00130468|Drug|Hyalgan (sodium hyaluronate)|
45935993|NCT00130507|Drug|Vinorelbine|
45935994|NCT00130507|Drug|Capecitabine|
45935995|NCT00130507|Drug|Trastuzumab|
45935996|NCT00130546|Device|Paclitaxel-eluting TAXUS(TM)|TAXUS(TM) Paclitaxel-eluting stent
45653638|NCT04093349|Genetic|SPK-3006|adeno-associated viral (AAV) vector
45653639|NCT04062695|Drug|Tofacitinib 5 MG Oral Tablet [Xeljanz]|verum tablets
45653640|NCT04062695|Drug|Placebo oral tablet|tablets containing placebo
45653641|NCT05473637|Diagnostic Test|MRI|Patients will repeat study-protocol MRI at baseline (enrollment) and at least once in 1 year or 2 years follow-up (depends on availability).
45935997|NCT00130546|Device|Sirolimus eluting Cypher Select(TM)|Sirolimus eluting Cypher Select(TM) stent
45935998|NCT00130585|Behavioral|Controlled diet|
45653642|NCT05555927|Device|transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is an non-invasive brain stimulation that is proposed as a possible interventional tool for major depressive disorder. tDCS device that this study used is from Neuroelectrics, Starstim 8, USA.
45653643|NCT04330235|Other|Healthy Default Kids' Beverage Policy|The healthy default kids' beverage policy requires that all restaurants serve only healthy beverages (water, milk, or 100% juice) instead of sugary beverages as the default beverage with children's meals. The policy has been enacted in New York City and Philadelphia and will go into effect in April 2020.
45653644|NCT04330079|Drug|Dapagliflozin 10mg|Dapagliflozin 10mg once daily for 6 months.
45804561|NCT04528303|Genetic|Whole genome sequencing|Genomic sequencing and molecular diagnostic results
45804562|NCT04528303|Genetic|Whole exome sequencing|Genomic sequencing and molecular diagnostic results
45804563|NCT04524403|Drug|Miricorlilant|Miricorilant 600mg for oral dosing
45804564|NCT04524403|Drug|Miricorlilant|Miricorilant 900mg for oral dosing
45804565|NCT04524403|Drug|Miricorlilant|Placebo for oral dosing
45804566|NCT05107934|Biological|RPH-104|solution for subcutaneous injection, 40 mg/mL
45804567|NCT05107934|Drug|Placebo|0.9% Sodium Chloride solution for Injection
46088519|NCT03852251|Biological|AK104|Subjects will receive AK104 by intravenous administration.
45653645|NCT04330079|Other|Lifestyle modification|lifestyle modification (diet and exercise) for 6 months
45804568|NCT03391115|Behavioral|Storytelling Intervention for Patient Participants|The storytelling intervention consists of an audio-recorded interview with each patient participant prompted the participant to share their story with questions such as: tell me about your illness, tell me how your illness has affected your emotions, relationships, and spirituality. The interview transcripts will be used to co-create a 1 page patient story using these criteria:1) written in the first person; 2) nonjudgmental; 3) captures the participant's voice; 4) accurately reflects content of the interview; and 5) non-labeling. Once the story has been approved by the participant, I will upload it to the EHR.
45804569|NCT03391115|Behavioral|Storytelling Intervention for Nurse Participants|"Once the patient's story is uploaded to the EHR, automatic alerts will be sent to the participant's EHR-assigned nurses. For usability testing, nurse participants will 1) provide content expertise of the workflow processes, and 2) put the storytelling intervention through in-house usability testing to check the strength of EHR features and user-friendliness. Data will be collected with exit interviews and completion of a questionnaire: the System Usability Scale which asks them to rank their satisfaction with specific elements such as: how the story is labeled and presented in the EHR, any technical navigation EHR difficulties, and use of the material."
45804570|NCT04343690|Behavioral|Crisis management coaching|Crisis management coaching will be offered to faculty, staff, and trainees dealing with COVID-19 pandemic
45804571|NCT04477837|Drug|Apixaban 5 MG|frequency of heavy menstrual bleeding
45458003|NCT03109834|Dietary Supplement|Meal replacement (MR)|"MR-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d and was advised to replace two meals, i.e. breakfast and dinner, every day with two MR shakes, soups or bars and to prepare their own lunch during 3-month weight loss phase (phase 1).~During 3-month weight stabilization phase (phase 2) MR-S group (MR group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The MR-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)"
45653646|NCT05612945|Other|High-intensity interval training group (HIIT)|"Exercise training sessions will consist in an alternation of brief periods (≤ 60 s) of work performed at high intensity and brief period of passive rest.~Patient will be asked to complete 1 set of 10-15x60-s (or 2 sets of 5-7x60-s) walking intervals. The training intensity in the HIIT group will be set at ≥85% HRpeak recorded during the maximal cardiopulmonary exercise test.~The training intervention will consist of 36 walking sessions spread over 12 weeks. Each training session will lasted 30-60 min. The training intervention will be performed on a treadmill (Cosmed T150, Itlay), which is equipped with harness and chest belt to secure the patients and prevents falling. Each session started with a 5-min walking warm-up and ended with a 5min cool-down. During all the exercise training sessions, HR of the subjects will be continuously monitored (Polar M430, Finland)."
45804572|NCT04477837|Drug|Rivaroxaban 20 MG|frequency of heavy menstrual bleeding
45804573|NCT04477837|Drug|Edoxaban 60 MG|frequency of heavy menstrual bleeding
45804574|NCT04477837|Drug|Dabigatran 150 Mg Oral Capsule|frequency of heavy menstrual bleeding
45804575|NCT05477888|Other|Questionnaires set|Participants will be asked to respond to the demographic information sheet,e-cigarette using characteristics sheet,the Penn State Electronic Cigarette Dependence Index (PS-ECDI ).
45804576|NCT05099588|Other|Other: observational study|Observational study
45804577|NCT03397121|Drug|Inclisiran|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
45804578|NCT03397121|Drug|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
45804579|NCT05267821|Drug|Anakinra|See information in arm/group descriptions
45804580|NCT05267821|Drug|Placebo|See information in arm/group descriptions
45804581|NCT02264574|Drug|Ibrutinib|Ibrutinib will be supplied as 140 mg hard gelatin capsules for oral (PO) administration.
45804582|NCT02264574|Drug|Obinutuzumab|Obinutuzumab will be supplied as 1000 mg/40 mL solution in a single-use vial for intravenous (IV) administration
45804583|NCT02264574|Drug|Chlorambucil|Chlorambucil will be supplied as 2 mg film-coated tablets for oral (PO) administration
45804584|NCT03398213|Other|Acupuncture|Acupuncture
45804585|NCT03398213|Other|Sham procedure|Ear stimulation with plaster
45804586|NCT00356785|Behavioral|health education|
45804587|NCT00356785|Behavioral|food supplementation|
45804588|NCT00356785|Behavioral|food supplementation combined with physical activity program|
45804589|NCT03668821|Other|Questionnaire|Quality of life and frailty questionnaires
45804590|NCT03624049|Other|Exercise|Community based exercise programs held 2-3 times per week
45804591|NCT03624049|Other|Health Class|Community based health class held 1 time per week
45804592|NCT03400163|Drug|BMS-986036|BMS-986036 20 mg QD
45804593|NCT03400163|Drug|Placebo|Placebo QD
45804594|NCT04412863|Drug|VIR-2218|VIR-2218 given by subcutaneous injection
45804595|NCT04412863|Drug|pegylated interferon-alfa 2a|pegylated interferon-alfa 2a given by subcutaneous injection
45804596|NCT05498298|Device|Biopotentials measurement with gtec device|A measurement of 40 minutes is performed with the gtec g.Hlamp to collect biopotential signals. 32 electrodes are attached to the body (abdomen, thorax and back).
45804597|NCT05647746|Device|Compumedics Somfit HSAT device, WatchPAT HSAT device, Compumedics Grael /E-series PSG system|Each intervention is a separate diagnostic device. They will all be operating at the same time
46088520|NCT03852251|Drug|Oxaliplatin|Subjects will receive AK104 in combination with oxaliplatin and capecitabine.
46088521|NCT03852251|Drug|Capecitabine|Subjects will receive AK104 in combination with oxaliplatin and capecitabine.
45653647|NCT05612945|Other|Low-to-moderate intensity training group (LowMod group)|"Exercise training sessions will consist in an alternation of periods of work performed at moderate exercise intensity and period of passive rest. The training approach of the LowMod group will be similar to the training prescription usually adopted in patients with claudication. The exercise training intensity will be set at ≤76% HRpeak recorded during the maximal cardiopulmonary exercise test.~The training intervention will consist of 36 walking sessions spread over 12 weeks. Each training session will lasted 30-60 min. The training intervention will be performed on a treadmill (Cosmed T150, Itlay), which is equipped with harness and chest belt to secure the patients and prevents falling. Each session started with a 5-min walking warm-up and ended with a 5min cool-down. During all the exercise training sessions, HR of the subjects will be continuously monitored (Polar M430, Finland)."
45935999|NCT00130585|Behavioral|folic acid supplement|
45653648|NCT03911687|Behavioral|CONCERN CDS system notification|"The CONCERN CDS will trigger based on analytics of nursing documentation that indicates recognition and concern of patient changes. The CONCERN CDS will alert the care team of the patients risky state to increase team-based situational awareness (i.e., shared understanding of the patient situation) of patients predicted to be at risk for patient decompensating in need of rapid intervention to prevent mortality and associated harm.~Version 1: Burn in phase to evaluate adoption and adaptation to the algorithm being studied. Expected time frame - 3 months~Version 2: Version 2 refined based on continuous monitoring of data. Expected time frame - 3 months~Version 3: Version 3 refined based on continuous monitoring of data. Expected time frame - 3 months"
45653649|NCT05555693|Other|Collecting clinical data, EGG，Brain Metabolomic Characteristics(with Magnetic Resonance Spectroscopy), blood gas data and blood sample|Collecting clinical data(before induction of anesthesia and first day after surgery), EGG（first day after surgery），Magnetic Resonance Spectroscopy data (before induction of anesthesia and first day after surgery)blood gas data(before induction of anesthesia and first day after surgery) and blood sample （before induction of anesthesia and first day, third day and 7th day after surgery）
45653650|NCT00660673|Drug|Levodopa-Carbidopa Intestinal Gel (LCIG)|LCIG for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa (5 mg/mL) in an aqueous gel that is dispensed in a medication cassette reservoir containing 100 mL of LCIG.
45804598|NCT03400475|Drug|Simvastatin|One topical application in peri-implant gingival crevice
45653651|NCT00660673|Device|CADD-Legacy® 1400 ambulatory infusion pump|Portable infusion pump (CADD-Legacy Pump Model 1400) connected to the LCIG medication cassette reservoir.
45653652|NCT00660673|Device|Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)|All participants previously had a PEG-J placed in one of the prior LCIG studies.
45653653|NCT05612867|Dietary Supplement|Vitamin C|Due to clinical research supporting high dose vitamin C, the institution's surgical intensivists started utilizing a high IV vitamin C dose in higher total body surface area burns while continuing to use the standard PO vitamin C dose of 500 mg to 1,000 mg daily on patients with lower total body surface area burns. Looking at the initial 72 hours, patients with smaller burns were given 2,500 mg PO vitamin C and larger total body surface area burns were given 15,000 mg IV vitamin C.
45653654|NCT05473559|Procedure|Adductor canal block with Ipack block or selective tibial nerve block|Ultrasound guided
45653655|NCT05555459|Procedure|Operation|Bone fixation operation in foot or ankle area using bioabsorbable headless screw/s
45653656|NCT03816137|Biological|ConM SOSIP|Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 100 ug and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
45653657|NCT03816137|Biological|EDC ConM SOSIP|Chemically fixed version of recombinant HIV-1 trimeric gp140 Env: EDC-ConM SOSIP. Model immunogens will be used at the dosage of 100 ug and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
45804599|NCT03400475|Other|Placebo|One topical application in peri-implant gingival crevice
45804600|NCT01641900|Drug|eszopiclone|3 mg of eszopiclone for two consecutive nights (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
45804601|NCT01641900|Drug|placebo|placebo capsule for two consecutive nights. (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
45804602|NCT03834571|Drug|Carboplatin|Given IV
45936000|NCT00130585|Behavioral|13C11-labelled folic acid supplement|
46088522|NCT04210674|Other|The traditional medicinal product of Argan spinosa oil|All children were randomly divided into two groups to receive either the traditional medicinal product of Argan spinosa oil or The conventional topical steroid ointment.
45804603|NCT03834571|Drug|Cisplatin|Given IV
45804604|NCT03834571|Drug|Paclitaxel|Given IV
45804605|NCT03834571|Procedure|Patient Monitoring|Undergo active monitoring
45804606|NCT03834571|Radiation|Radiation Therapy|Undergo radiation
45804607|NCT04873674|Other|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
46088523|NCT02691546|Other|blood sample collection|
46088524|NCT00620178|Drug|Candesartan Cilexetil|oral once daily dose
46088525|NCT00620178|Drug|Losartan|once daily oral dose
46088526|NCT05242913|Dietary Supplement|Resistant Potato Starch|Unmodified potato starch containing >60% resistant starch Type 2
45804608|NCT04873674|Other|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
45936001|NCT00079755|Drug|SGN-30 (anti-CD30 mAb)|
45936002|NCT00130624|Procedure|Multidisciplinary intervention: primary or secondary care|
45936003|NCT00130663|Device|PDA blood pressure screening program and chart reminder|
45936004|NCT00130702|Drug|gefitinib|gefitinib (Iressa) at a dose of 750 mg, once per day
45936005|NCT00130741|Drug|CHT - herbal therapy|
45936006|NCT00079794|Drug|Iscar|
45936007|NCT00079794|Drug|mistletoe|
45936008|NCT00130819|Behavioral|Clinic-based substance abuse treatment with buprenorphine|Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
46088527|NCT05242913|Dietary Supplement|Placebo|Fully digestible corn starch
45936009|NCT00130819|Behavioral|Case management and referred substance abuse treatment|Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
46088528|NCT04349982|Diagnostic Test|Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT)|Factorial
45452522|NCT03089996|Device|Control Side|The first maxillary premolars will be extracted with orthodontic purpose. Fixed orthodontic appliance will be bonded (0.022x0.025 slot with MBT prescription in incisors and Standart in the other teeth) with a power arm welded in the bracks upper canines brackets. After 3 months of extraction, the alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli®, Sorocaba, SP, Brazil) between the roots of the second premolars and molars. At that time an intra-oral digital scan will be performed. The retraction of the canines will begin using closed nickel-titanium spring (120g of force) from the power arm to the mini-implant. No surgery will be done at this side. The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months.
45653658|NCT03816137|Biological|ConS UFO|Recombinant HIV-1 trimeric gp140 Env protein: ConS UFO gp140. Model immunogens will be used at the dosage of 100 ug and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle
45653659|NCT03816137|Biological|EDC ConS UFO|Chemically fixed version of recombinant HIV-1 trimeric gp140 Env : EDC-ConS UFO. Model immunogens will be used at the dosage of 100 ug and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
45653660|NCT03816137|Biological|Mosaic SOSIPs|"Mosaic gp140 Env trimers designed to overcome the immunodominance of hypervariable regions of Env~The immunogen will be used at the dosage of 100 ug (3x33ug) and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle."
45804609|NCT05647668|Procedure|Laparoscopic fundoplication|Creation of either a 360° (in Nissen group) or a 270° (in Toupet group) fundoplication wrap over a 30-Fr intra-esophageal bougie.
45804610|NCT00359918|Drug|fibrinolysis|Primary PCI
45804611|NCT00359918|Procedure|Primary PCI|Primary PCI
45804612|NCT04373629|Behavioral|attentional modulation|Attentional instructions when viewing faces will be given
45804613|NCT04373629|Other|perceptual modulation|Faces will be presented of varying durations
45804614|NCT04373629|Other|naturalistic viewing|Faces will be viewed without specific instructions
45804615|NCT03402659|Drug|neflamapimod|40 mg neflamapimod capsule
45936010|NCT00130858|Drug|Topotecan|
45653661|NCT04048759|Behavioral|Remote Low|Participants will attend 40 min remotely delivered group MVPA sessions once a week, receive a step counter, access to resources for increasing MVPA, and one 20-min remotely delivered individual support/education session/wk.
45653662|NCT04048759|Behavioral|Remote High|Participants will attend 40 min remotely delivered group MVPA sessions 3x a week, receive a step counter, access to resources for increasing MVPA, and one 20-min remotely delivered individual support/education session/wk.
45804616|NCT03402659|Other|placebo|matching placebo capsule
45804617|NCT05088980|Device|VOLBELLA with Lidocaine|Facial Injection
45653663|NCT04048759|Behavioral|Personal Coach|Participants will receive a step counter, access to resources for increasing MVPA, and monthly remote individual support/education.
45804618|NCT05270096|Other|Advice|non-interventional study
45804619|NCT00376571|Procedure|Percutaneous coronary intervention|"Comparing treatment of either no side branch treatment versus stenting of main vessel and side branch treatment"
45804620|NCT00376649|Behavioral|lifestyle changing workshop|
45804621|NCT05477420|Other|Decision Aid|Participants in the experimental group would be asked to use the decision aid developed by the study. The decision aid tool will ask participants their preferences on traditional face-to-face and online psychotherapies and how they rank different treatment attributes.
45804622|NCT03612271|Behavioral|mGlide|BP will be automatically transmitted to the providers. The transmitted BP will be used for adjustment of anti-HTN medications as it occurs in clinical practice.
45804623|NCT00376727|Biological|cetuximab|Dose level 0: cetuximab 400 mg/m2 week 1, 250 mg/m2 weekly; Dose level 1: cetuximab 400 mg/m2 week 1, 300 mg/m2 weekly; Dose level 2: cetuximab 400 mg/m2 week 1, 350 mg/m2 weekly; Dose level 3: cetuximab 400 mg/m2 week 1, 400 mg/m2 weekly
45804624|NCT00376727|Genetic|molecular diagnostic method|Tissue and Blood Specimens; IHC Methodology; IHC Scoring; K-RAS Mutation Analysis
45804625|NCT00376727|Other|immunologic technique|Peripheral Blood Mononuclear Cells (PBMC)
45653664|NCT05470907|Device|Hemoperfusion|Commercial membranes for extracorporeal blood purification (hemoperfusion)
45804626|NCT00376727|Other|laboratory biomarker analysis|Cetuximab Pharmacodynamics
45804627|NCT00358592|Device|Mobius™ retractor|
45804628|NCT00358592|Device|traditional metal retraction instruments|
45936011|NCT00130858|Drug|Carboplatin|
45936012|NCT00130897|Drug|Sutent|Sutent, 25, 37.5. or 50 mg daily
45936013|NCT00046319|Drug|BSF 208075|
45936014|NCT00079833|Drug|Esomeprazole magnesium (Nexium)|
45936015|NCT00079872|Drug|Pemetrexed|
45936016|NCT00046358|Drug|Lovostatin|
45936017|NCT00046358|Drug|Ibuprofen|
45936018|NCT00130936|Drug|Epirubicin|
45653665|NCT03644381|Other|Oral Immunotherapy|Starting from a very low level and over a period of several months, participants in the treatment group receive escalating doses of milk. Participants will also have blood and saliva draws to assess parameters of their immune system as well as skin prick testing
45653666|NCT05612711|Drug|Dronabinol|All participants will take both dronabinol and placebo at different points in the study in this crossover design trial.
45653667|NCT04807309|Drug|Danazol Pill|Danazol 200 mg orally twice a day
45653668|NCT04807309|Drug|Placebo|Placebo twice a day
45804629|NCT03282071|Behavioral|Joyful Parenting Intervention|"Two-session interactive talks for parents to promote praise & appreciation, positive thinking, enjoyable parenting (mind) and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.~One family gathering activity (e.g. outdoor / visit / family indoor gathering) to promote and practise quality family communication (enjoyment and sharing)."
45936019|NCT00130936|Drug|Carboplatin|
45936020|NCT00130936|Drug|Capecitabine|
46073774|NCT05758545|Device|COMS One device|The COMS One device incorporates technologies for optical and magnetic stimulation. The optical stimulation component is designed to emit light by two types of light emitting diodes (LEDs) in the wavelength of 660 nm (red) and 830 nm (near infrared) range of the electromagnetic spectra. The magnetic stimulation component is generated by a coil emitting pulse modulated magnetic fields in the extremely low frequency (ELF) range of the electromagnetic spectra. The System is a lightweight, portable device. The device is applied via a single use disposable component (COMStouch) that provides a base and sterile barrier for the unit. The device is attached via a single use strap (COMSfix). The device has been slightly adapted in order to make sure blinding is achieved/maintained. The specific features that have been modified for the purposes of blinding include the following: 1) therapeutic output, and 2) sensor detecting whether the device is lying on the skin.
45804630|NCT05239585|Device|Epilog device|Pilot the use of wireless EEG technology in neonates with mild neonatal encephalopathy and neonates with spells to see if this device can be used to determine the risk for neonatal seizure and need for escalation of care and full scalp EEG
45804631|NCT05265416|Procedure|Piezosurgery|Three vertical incisions will be made (3-mm depth and 8-10 mm length) after anesthesia. The cuts will be performed mesial and distal the upper canine as well as at an equal distance from the upper canine and 2nd premolar.
45804632|NCT05265416|Other|Low-level laser therapy|GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\point) will be applied around the upper canine in 10 sites from buccal and palatal.
45804633|NCT05265416|Device|Traditional treatment|The canine retraction in this group will be performed in conventional method. Closed nickel-titanium coil springs applying 150 g of force per side will be used for retraction of the upper canine.
45804634|NCT00359996|Behavioral|health disparities collaborative|The HDC incorporates rapid quality improvement (QI), a chronic care model, and best practices. This study determines if the HDC improves diabetes care and whether more intensive interventions with additional learning sessions for health centers, provider training in behavioral change, and patient empowerment materials enhance care further.
45804635|NCT00359996|Other|No additional educational sessions|
45804636|NCT05236153|Diagnostic Test|Electroanatomic substrate mapping|Participants will undergo a sinus rhythm RV substrate map using the HD Grid catheter (Abbott) and the Ensite X electroanatomic mapping system (Abbott) prior to TPVR.
45804637|NCT05468606|Biological|GA2|GA2 sporozoites administered by 50 mosquito bites
45804638|NCT05468606|Biological|BCG|0.1 mL BCG vaccine intradermally
45804639|NCT05468606|Biological|YF-17D (fractional ID dose)|0.1 mL YF17D vaccine intradermally
45804640|NCT05468606|Drug|Imiquimod|250mg imiquimod 5% cream topical
45804641|NCT05468606|Other|Mock immunization|50 bites by uninfected mosquitoes
45804642|NCT04301401|Other|Vaginal swabs|On the day of the surgical intervention, vaginal swabs will be taken at various stages of surgery: before vaginal disinfection/draping, directly after disinfection/draping, 1 hour after disinfection, 6 weeks after surgery and 12 months after surgery.
45804643|NCT04301401|Other|Stool samples|Stool samples will also be taken (and collected in a pot devoted to coproculture with an airtight opaque bag given to the patient) at the inclusion visit on the day before surgery and also 6 weeks after surgery (in a second pot with an airtight opaque bag given to the patient at the time of being discharged).
45804644|NCT04301401|Other|Urine samples|Urine samples will also be taken before surgery and 6 weeks after surgery.
45804645|NCT05080244|Dietary Supplement|Probiotics|2 strains 10x10^9 UFC/capsule
45804646|NCT05080244|Dietary Supplement|Placebo|Potato starch and magnesium stearate
45804647|NCT04293289|Other|CICS-1 (investigational device),SPM-011(investigational drug)|Intravenous administration of SPM-011 and neutron irradiation with CICS-1.
45804648|NCT04290871|Drug|Nitric Oxide Gas|Inspired NO/N2 will be delivered at 80 parts per million (ppm) in the first 48 hours of enrollment (within 48 hours after initiation of mechanical ventilation). Weaning from NO will start after 48-h consecutive NO inhalation. The physicians will follow their own institutional weaning protocols.
45804649|NCT04290871|Other|The delivery system will be set up anyway without study gas administration|The delivery system will be set up anyway without study gas administration
45804650|NCT03283787|Device|MicroMatrix® and Cytal™ Wound Matrix 2-Layer|MicroMatrix® and Cytal™ Wound Matrix 2-Layer
45804651|NCT03283787|Device|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
45804652|NCT03283787|Device|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy
45804653|NCT03501979|Drug|Tucatinib|Tucatinib study drug is given in tablet form and taken daily.
45804654|NCT03501979|Drug|Trastuzumab|Trastuzumab is approved by the FDA and is available commercially. Trastuzumab must be prepared and is administered intravenously.
45804655|NCT03501979|Drug|Capecitabine|Capecitabine is approved by the FDA and is available commercially as an oral drug.
45804656|NCT03284411|Device|Spinal Cord Stimulation|Programming
45804657|NCT03465787|Drug|Lurasidone HCL 160 mg|Lurasidone HCL 2 80mg tablets, QD
45936021|NCT00130975|Drug|Candesartan|
45936022|NCT00131053|Drug|Methotrexate|
45936023|NCT00131053|Drug|Prednisolone|
45936024|NCT00131053|Drug|Dexamethasone|
45653669|NCT04744649|Drug|XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S1 S-1: 40~60mg Bid，d1~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA~JS001: 240mg, ivdrip, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40~60mg Bid,d1~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA"
45936025|NCT00131053|Drug|Vincristine|
45936026|NCT00131053|Drug|Pirarubicin|
45936027|NCT00131053|Drug|Cyclophosphamide|
45936028|NCT00131053|Drug|L-asparaginase|
45936029|NCT00131053|Drug|Cytarabine|
45653670|NCT04744649|Drug|JS001+XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~JS001: 240mg, ivdrip, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40~60mg Bid,d1~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA"
45936030|NCT00131053|Drug|Hydrocortisone|
45936031|NCT00131053|Drug|Mercaptopurine|
45936032|NCT00079911|Drug|valacyclovir hydrochloride|valacyclovir hydrochloride
45936033|NCT00131092|Behavioral|The Stanford Active Choices program|
45936034|NCT00131092|Behavioral|The TLC system|
45936035|NCT00131131|Behavioral|Exercise|
45936036|NCT00131170|Procedure|paravertebral block|
45936037|NCT00397592|Drug|Growth Hormone|
45936038|NCT00131209|Dietary Supplement|fortified spread (RUTF)|
45936039|NCT00131209|Dietary Supplement|maize and soy flour|
45653671|NCT04801225|Device|Non-invasive electromagnetic stimulation for acute stroke treatment|Bilateral electromagnetic stimulation to improve blood flow in ischemic regions of acute stroke as an adjunct to current standard-of-care
45653672|NCT05612633|Drug|zelavespib|Oral zelavespib 100 mg will be administered once daily
45936040|NCT00079950|Drug|Pegamotecan|
45936041|NCT00131287|Drug|Extract of Agaricus blazei Murill|
45936042|NCT00131326|Device|Synvisc (hylan G-F 20)|
45936043|NCT00397670|Drug|Drug: BufferGel® with diaphragm|
45936044|NCT00131404|Drug|taranabant|taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.
45936045|NCT00131404|Drug|Comparator: Placebo|Placebo capsule once daily. 52 week treatment period.
45936046|NCT00131443|Drug|Topiramate|
45936047|NCT00079989|Drug|tigecycline|
45936048|NCT00131482|Drug|Chrysalin|Patients were treated with a single percutaneous injection of Chrysalin 3 micrograms at the fracture site at the time of surgery.
45936049|NCT00131482|Drug|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 1 microgram at the fracture site at the time of surgery.
45936050|NCT00131482|Drug|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 10 micrograms at the fracture site at the time of surgery.
45936051|NCT00131482|Drug|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 30 micrograms at the fracture site at the time of surgery.
45936052|NCT00131482|Drug|Placebo|Patients were treated with a single percutaneous administration of placebo at the fracture site at the time of surgery.
45936053|NCT00397709|Drug|I ( isoniazid), II (isoniazid + rifampin )|
45936054|NCT00131521|Drug|mucomyst|
45936055|NCT00131521|Drug|sodium chloride (saline)|
45936056|NCT04726774|Behavioral|Hypnosis|"Two sessions of hypnosis, about 30 minutes each, weekly provided, by a physician trained in medical hypnosis.~Each session was realized as possible during walking, according to the agreement and the physical status of the participant.~Each sessions of hypnosis includes 3 phases : induction, walk perception alteration and post-hypnotic suggestion."
45936057|NCT04726774|Behavioral|Rehabilitation program|Intensive physiotherapy for 2 weeks, with walking and balance exercises, (individual and group exercises). Education of risk of falling and prevention of falls.
45936058|NCT00080028|Drug|Motexafin Gadolinium Injection|
45936059|NCT00131560|Genetic|VRX496-Modified Autologous T cells|Genetic: Anti-HIV antisense
45936060|NCT00131599|Drug|5FU/LV|5FU/LV
45936061|NCT00131638|Drug|Placebo|Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
45936062|NCT00131638|Drug|Palifermin|Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
45936063|NCT00131716|Drug|sulfadoxine-pyrimethamine|
45936064|NCT00046397|Drug|Modified Vaccinia Virus Ankara TBC-M|
45936065|NCT04726930|Procedure|Intercostal nerve blocks|Intercostal nerve block is a regional anesthetic procedure for peri-operative pain management. It inhibits the action of the ipsilateral sensory and motor branches, and produces analgesic effects at the targeted thoracic level.
45936066|NCT04726930|Procedure|Paravertebral block|Paravertebral block is the technique of injecting local anesthetic alongside the thoracic vertebra close to where the spinal nerves emerge from the intervertebral foramen. This produces unilateral, segmental, somatic, and sympathetic nerve blockade, which is effective for anesthesia and in treating acute and chronic pain of unilateral origin from the chest and abdomen
45936067|NCT00131794|Biological|BCG|
45936068|NCT00080145|Drug|Risperidone|
45936069|NCT00080145|Behavioral|Behavior Therapy|
45936070|NCT00403663|Drug|bupivacaine 0.75% with fentanyl and morphine|the following administered once, by spinal injection; 9-12 mg 0.75% hyperbaric bupivacaine 10 mcg fentanyl 100 mcg morphine
45653673|NCT04793893|Device|ReLex Smile|With the ReLex Smile the optical zone (lenticule diameter) and cap diameter are 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule is extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker (ViscotMedster).
45653674|NCT04002661|Drug|Flibanserin|Flibanserin tablet
46088529|NCT04178213|Device|Implantation of ADAPT 3D ALR|The operation is performed through a median sternotomy and with the hemodynamic support of standard cardiopulmonary bypass (CBP). diseased leaflets are excised meticulously. Calcifications at the level of the annulus will be removed just like in any other aortic valve replacement procedure. The annulus will be sized and the appropriate 3D single piece valve will be chosen. The implant technique will consist out of one running suture line at the level of the annulus, followed by fixation of the 3 commissural parts against the aortic wall. Valve competence and function will be assessed visually, and by TEE immediately coming of bypass.
45804658|NCT03465787|Drug|Quetiapine XR 600 mg|Quetiapine XR 2 300 mg tablets, QD
45804659|NCT05071352|Drug|Nefopam|Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours.
45804660|NCT05071352|Drug|Standard of care in the ICU for assessment and management of pain, sedation, and delirium.|In our protocol we use analgiosedation approach (an opioid is used before a sedative to reach the sedation goal), targeting light sedation using richmond agitation sedation scale (RASS) score -1 to 0, and assess delirium using confusion assessment method for the ICU (CAM-ICU).
45653675|NCT04002661|Drug|Placebo|Oral Tablet
45653676|NCT05458583|Procedure|Baseline periodontal measurements (T0)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the bonding session.
45653677|NCT05458583|Procedure|Periodontal measurements (T1)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the 6 months after bonding.
45804661|NCT00376025|Dietary Supplement|Biological Antioxidant Supplementation|Supplementation of affected population with the Phytochemical antioxidant, Garcinia Mangostata in addition to sodium selenate.
45804662|NCT05235763|Other|activity coach|The activity coach educates the patient about physical activity, offers means of manually tracking physical activity, and provides trends of registered activity. Furthermore, it provides weekly summaries of registered physical activity and provides means of setting goals for the following week.
45804663|NCT05235763|Other|sham activity coach|The visual appearance of Optilogg is changed as to make the patient aware that something has happened to it, hence not knowing if it is the real activity coach or not. No new functionality is added, however.
45804664|NCT00376103|Drug|temozolomide|75 mg/m2/day
45804665|NCT00376103|Procedure|Brachytherapy|60 Gy to 1 cm
45804666|NCT00376103|Procedure|External Beam Radiation Therapy|60 Gy
45804667|NCT05261828|Behavioral|Education and rehabilitation associated with personalized follow-up|short multidisciplinary program including education and rehabilitation and a personalized follow-up for patients with subacute and chronic low back pain
45804668|NCT05261828|Behavioral|Reassuring messages and advices|Reassuring messages and advices in agreement with current recommendations
45804669|NCT03836287|Drug|Sofpironium Bromide Gel, 15%|Active
45804670|NCT03836287|Drug|Vehicle|Vehicle gel
45804671|NCT05259878|Other|Adverse Childhood Events|"• The Adverse Childhood Events (ACE) scale is a validated 10-item binary questionnaire (yes or no) that retrospectively measures domains of physical, emotional, and sexual abuse in the first 18 years of life. Scores range from 0 to 10 with higher scores indicating more adverse experiences during patients' childhood."
45804672|NCT03403517|Drug|Methylprednisolone|10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery
45804673|NCT03403517|Drug|Dexamethasone|Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery
45804674|NCT05248880|Drug|AGN-151586|Intramuscular Injection
45804675|NCT05248880|Drug|Placebo|Intramuscular Injection
45804676|NCT04281979|Drug|Study Agent|The study agent will be administered via beverages and/or a capsule. The substances used in the study are legal, non-prescription, and are proven safe for human consumption at the doses used. The study agent may be a depressant (such as alcohol), a stimulant (such as caffeine), or an analgesic (such as aspirin).
45804677|NCT04281979|Drug|Placebo|In the placebo conditions participants will consume beverages and capsules that contain no or very small quantities of the study agent.
45804678|NCT03404219|Behavioral|Motivation and Skills Support (MASS)|Mobile phone-based application to support social skills and social motivation
45936071|NCT00403702|Drug|Oxane HD [oil-RMN3-mixture]|
45936072|NCT00403702|Drug|Densiron [(F6H8)|
45936073|NCT00403741|Behavioral|motivational interviewing|
45936074|NCT00403780|Drug|pregabalin|"Capsule pregabalin 75 mg once or twice daily up to a total dose of 600mg daily (300mg twice daily) for a total of minimum 14 days and maximum 8 weeks.~Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily."
45804679|NCT05466890|Drug|PL8177 Placebo|Approximately 1/4 of randomized patients will receive matching placebo as means of comparison to active treatment PL8177.
45804680|NCT05466890|Drug|PL8177|Approximately 3/4 of randomized patients will receive active PL8177.
45936075|NCT00403780|Drug|placebo|Capsule placebo once or twice daily up to a total dose of 8 capsules(4 capsules twice daily) for a total of minimum 14 days and maximum 8 weeks. Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.
45936076|NCT00080184|Procedure|Low Energy Neurofeedback System|
45936077|NCT00046514|Drug|ABI-007|
45936078|NCT00403819|Drug|Polyethylene glycol 3350 Na bicarbonate NaCl KCl (Movicol)|
45653678|NCT05458583|Procedure|Periodontal measurements (T2)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the 12 months after bonding.
45804681|NCT01640808|Drug|NIK-333(peretinoin)|600mg (8 x 75mg capsules) orally, twice a day
45936079|NCT00403858|Drug|Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)|
45804682|NCT01640808|Drug|Placebo|Placebo (8 x Placebo capsules) orally, twice a day
45804683|NCT03404375|Device|Gauss Triton system|"The Triton system (Gauss Surgical, Inc., Palo Alto, CA) is a novel mobile monitoring platform that combines mobile computing with Gauss Feature Extraction Technology (FET) to directly assess Hb mass (mHb) absorbed by surgical sponges from an image. The device is an iPad like imaging device that will assess blood loss via imaging of the surgical sponges used in the surgery.~The device will be used to calculate blood loss on every patient enrolled in the study."
45936080|NCT00403858|Drug|Lactulose|
45804684|NCT05227885|Other|questionnaire form|A questionnaire will be applied to all participants. A questionnaire form will be applied to collect data on demographic information, pain, disease activity, nutritional habits, physical activity status and physical functional status of the patients included in the study.
45936081|NCT00131833|Biological|Typhoid Vi vaccine|
45936082|NCT00131833|Biological|Meningococcal A (control)|
45936083|NCT00131872|Device|Expedial Vascular Access Graft|
45653679|NCT05458583|Procedure|Retainer failure rates|A retainer with at least one composite pad detachment was considered to be a failure during 1-year follow-up.
45653680|NCT03998605|Behavioral|Abuse Prevention Program|The abuse prevention program will be comprised of nine shared learning modules for the individual with Intellectual Disabilities (ID) and a care provider. Each shared module will contain an action step in the Individual Response Plan and will include video, guided practice and workbook activities to equip persons with ID with a range of judgment, decision-making skills and the efficacy needed for identifying, rejecting, and reporting abuse.
45936084|NCT00080262|Drug|Ixabepilone|Solution, IV, 40 mg/m2, every 21 days, extended, until PD or discontinued for other reasons.
45936085|NCT00046553|Drug|RU-486 (Mifepristone)|
45936086|NCT00131950|Other|physiologic testing|
45804685|NCT05247788|Behavioral|Blood alcohol concentration (BAC) discrimination training|Subjects will receive 0.65 g/kg alcohol to yield a peak BAC of 85 mg/dl (0.085%). They will be trained to accurately estimate their BAC using the Body Scan Exercise with BAC feedback.
45804686|NCT05247788|Behavioral|Performance feedback training|This training element targets the driver's self-efficacy by increasing their awareness of the behavioral impairing effects of alcohol that are experienced at BACs at and even below the legal limit (50-80 mg/dl).
45804687|NCT05247788|Behavioral|Blood alcohol concentration (BAC) discrimination training for controls|Subjects will receive 0.65 g/kg alcohol to yield a peak BAC of 85 mg/dl (0.085%). They will be given a general Body Scan Exercise with no feedback.
45804688|NCT00421681|Behavioral|Fit and Strong! Exercise Program|Fit and Strong! is an 8-week (24 sessions) multi-component exercise and health education intervention, including flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change. Following participation in Fit and Strong!, all study participants are randomly assigned to one of 2 maintenance treatment follow-up groups.
45804689|NCT05068310|Device|Cellular resolution full-field optical coherence tomography|Device: ApolloVue® S100 Image System
45804690|NCT05068310|Device|Confocal microscopy|Device: Vivascope® will be used for skin imaging for a subset of skin lesions.
45936087|NCT00131950|Other|study of socioeconomic and demographic variables|
45936088|NCT00131950|Procedure|breast imaging study|
45936089|NCT00131950|Procedure|study of high risk factors|
45936090|NCT00131989|Drug|sorafenib tosylate|Given orally
45936091|NCT00131989|Other|pharmacological study|Correlative studies
45936092|NCT00131989|Other|laboratory biomarker analysis|Correlative studies
45936093|NCT00132067|Drug|vorinostat|Given orally
45936094|NCT00132106|Drug|phentolamine|
45936095|NCT00132145|Behavioral|Vascular Management Program|
45936096|NCT00132145|Behavioral|Clinical Care Coordinators|
45936097|NCT00132145|Behavioral|Web-based Vascular Tracker for Patient and Physician|
45936098|NCT00132145|Behavioral|Automated Telephone Reminder System|
45936099|NCT00080340|Drug|TLK286 (Telcyta) HCl for Injection|
45936100|NCT00080340|Drug|gefitinib (Iressa)|
45936101|NCT00132184|Drug|Vitamin D|
45936102|NCT00132223|Drug|Contrast agent|
45936103|NCT00132262|Behavioral|Brief intervention based on motivational interviewing|The intervention was an approximately 30 minute discussion about alcohol-related risk behaviors and motivation to change
45936104|NCT00132262|Behavioral|Standard Care including referral for treatment|Standard hospital care provided the patient with information and referral for treatment as necessary.
45936105|NCT00132340|Device|Electrodes|
45936106|NCT00132379|Drug|ABR-217620|10.3, 16.5 or 22 mcg/kg, IV, daily 5 minute bolus injection for 4 consecutive day per cycle; up to 6 cycles
45936107|NCT00132379|Drug|docetaxel|75mg/m^2, IV, single 60 minute infusion, beginning on Day 5 then every third week
45936108|NCT00132418|Drug|Enbrel|Enbrel
45936109|NCT00132418|Drug|Placebo|Placebo
45936110|NCT00132457|Procedure|Self-collected vaginal swab for chlamydia testing|
45804691|NCT05068310|Device|Optical coherence tomography imaging|Device: Vivosight® will be used for skin imaging for a subset of skin lesions.
45936111|NCT00132535|Drug|sulfadoxine-pyrimethamine intermittent preventive treatment|
45936112|NCT00132535|Drug|chloroquine|
45936113|NCT00046709|Drug|Smoked Marijuana|
45653681|NCT03998605|Behavioral|Control Condition|The control group will receive worksheets from the ESCAPE-NOW curriculum.
45804692|NCT05068310|Device|Dermoscopy imaging|Device: Dermoscopy imaging will be conducted using but not limited to dermoscope DermLite FotoX®
45936114|NCT00132574|Behavioral|Minimization of milk and dairy products in the diet|
45804693|NCT03404609|Device|MagPro X100 by MagVenture|Participants received 5 consecutive days of accelerated cTBSmod to the right frontal pole. Each cTBSmod session was comprised of 1800 pulses, delivered in a continuous train of 600 bursts. Each burst contained 3 pulses at 30 Hz, repeated at 6 Hz. Ten sessions were applied per day (18,000 pulses/day, hourly) (90,000 total pulses) using a Magventure Magpro X100. Stimulation was delivered at 90% resting motor threshold (depth corrected). Localite Neuronavigation System was used to position the TMS coil over the individualized stimulation target.
45653682|NCT04983277|Other|no intervention|no intervention
45653683|NCT03201575|Device|Remote Ischemic conditioning|A brachial cuff is positioned around the arm of the patient. Four cycles of [5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation] started as soon as possible after randomization. The intervention is repeated at 12 and 24 hours after inclusion.
45653684|NCT03201575|Device|Patients with no remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient and no inflation or deflation is made.
45804694|NCT05464160|Device|Focal Muscular Vibration using the EVM EVO medical device (Endomedica, Italy)|"FMV will be applied 7 times per week for 3 weeks (21 total applications), using the EVM EVO medical device (Endomedica, Italy), applying an intensity of 100 Hz for a total of 23 minutes."
45804695|NCT05464160|Other|Conventional Rehabilitation|Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc...)
45804696|NCT02263326|Drug|dolutegravir|50 mg tablet by mouth once daily for 48 weeks
45804697|NCT02263326|Drug|lamivudine|300 mg tablet by mouth once daily for 48 weeks
45936115|NCT00132613|Procedure|Observation alone after pericardial drainage|
45936116|NCT00132613|Drug|Pericardial instillation of bleomycin after drainage|
45936117|NCT00132652|Drug|Lamivudine|
45936118|NCT00132652|Drug|Telbivudine|
45936119|NCT00132847|Biological|German Cockroach Allergen extract|
45936120|NCT00046748|Drug|Omalizumab|
45936121|NCT00132886|Drug|tolvaptan|
45936122|NCT00080418|Drug|Liposome Entrapped Paclitaxel Easy to Use|
45653685|NCT04763161|Procedure|Decompressive hemicraniectomy|Decompressive hemicraniectomy in the context of a malignat sylvian ischaemic cerebral accident
45653686|NCT04763161|Procedure|neurosurgical operation|neurosurgical operation on which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach.
45653687|NCT04426955|Drug|Camrelizumab|IV infusion
45653688|NCT04426955|Drug|Paclitaxel|IV infusion
45653689|NCT04426955|Drug|Cisplatin|IV infusion
45653690|NCT04426955|Drug|Placebo|IV infusion
45653691|NCT04426955|Radiation|Radiation|Concurrent Radiation
45804698|NCT02263326|Drug|Continue current antiretroviral regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
45804699|NCT04200391|Other|Very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein."
45804700|NCT02977520|Procedure|Printing, Three-Dimensional|To establish 3D model of cerebral aneurysms and have preoperative evaluation.
45936123|NCT00132925|Drug|Triamcinolone|
45936124|NCT00133003|Drug|Abciximab|0.25 mg/kg of body weight bolus, followed by a 0.125-microg/kg per minute [maximum, 10 microg/min] infusion for 12 hours, plus heparin, 70 U/kg of body weight
45936125|NCT00133003|Drug|Placebo|Placebo consist of placebo bolus and infusion of 12 hours (NaCl 0.9%), plus heparin bolus, 140 U/kg of body weight
45936126|NCT00046787|Drug|OSI-211 (Liposomal Lurtotecan)|
45936127|NCT00133042|Drug|omalizumab|
45936128|NCT00080457|Drug|sitaxsentan sodium|
45936129|NCT00133081|Drug|All registered antiepileptic drugs|
45936130|NCT00133159|Biological|Grass MATAMPL|
45936131|NCT00133198|Drug|Pramipexole|
45936132|NCT00046826|Drug|docetaxel|
45936133|NCT00046826|Drug|estramustine phosphate sodium|
45936134|NCT00046826|Drug|thalidomide|
45936135|NCT00133237|Device|Sirolimus-eluting stent|cypher stent is implanted due to randomization.
45936136|NCT00133237|Device|Paclitaxel-eluting stent|taxus stent is implanted due to randomization.
45936137|NCT00399672|Drug|Interferon injections and ribavirin|Weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.
45936138|NCT00399672|Drug|Interferon injections and ribavirin|Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
45936139|NCT00133276|Drug|Escitalopram|OD 5mg for 2 weeks; OD 10mg for 24 weeks; OD 5mg for 2 weeks
45936140|NCT00133276|Other|Placebo|
45936141|NCT00046865|Procedure|acupressure therapy|
45936142|NCT00046865|Procedure|management of therapy complications|
45936143|NCT00046865|Procedure|nausea and vomiting therapy|
45936144|NCT00131755|Drug|diazoxide|
45936145|NCT00133315|Drug|Infliximab|
45936146|NCT00133315|Drug|Etanercept|
45936147|NCT00133315|Drug|Adalimumab|
45936148|NCT00080496|Drug|Tigecycline|
45936149|NCT00080496|Drug|Imipenem|
45936150|NCT00080496|Drug|Cilastatin|
45936151|NCT02964676|Procedure|ab interno trabeculectomy with Trabectome|123 PACG will be recruited to receive ab interno trabeculectomy with Trabectome and before this surgery, laser peripheral iridectomy will be performed firstly
45936152|NCT02964676|Procedure|trabeculectomy|123 PACG will be recruited to receive trabeculectomy to reduce IOP
45936153|NCT00133354|Drug|Arimidex (Anastrozole)|Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
45936154|NCT00133354|Drug|Placebo|Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
45936155|NCT00133354|Drug|Growth Hormone|GH (Nutropin®, Genentech, So. San Francisco, CA) will be administered throughout the trial at a dose of ~0.3mg/kg.w (no more than 0.4mg/kg.w) given subcutaneously (SC) at bedtime daily. Dose adjustments on the GH dose will be made by the investigator at least every 6mo.
45936156|NCT00133393|Drug|Pentoxifylline|
45936157|NCT00046904|Biological|etanercept|
45936158|NCT00403897|Drug|Polyethylene glycol 3350 Na bicarbonate NaCl KCl|6.9g sachet, oral
45936159|NCT00080574|Procedure|Skin Biopsy|
45936160|NCT00403936|Procedure|OA decompression manipulation|
45936161|NCT00403975|Drug|diquafosol tetrasodium ophthalmic solution, 2%|
45936162|NCT00133432|Drug|Zinc|
45936163|NCT00133471|Biological|Influenza A/H9N2 vaccine|A single lot of monovalent inactivated SA influenza A/H9N2 vaccine. All injections will be administered in a 0.5-mL volume into the deltoid muscle. Dosage levels are: 3.75-, 7.5-, 15-, and 30-mcg of HA of the vaccine strain with and without MF59 adjuvant.
45936164|NCT00133471|Drug|MF59 adjuvant|MF59 adjuvant is an oil-in-water emulsion.
45936165|NCT00046943|Drug|atrasentan hydrochloride|
45936166|NCT00133510|Biological|Trivalent Subviron Influenza vaccine (Fluzone)|
45653692|NCT02630563|Drug|Corticosteroids|Corticosteroids will be administered as per center practice. The choice of corticosteroid drug will also be based on center practice.
45653693|NCT02630563|Drug|Cyclosporine|Cyclosporine will be administered as per center practice.
45653694|NCT02630563|Drug|mycophenolate mofetil|Part 1: Mycophenolate mofetil will be administered as per center practice. Part 2: Mycophenolate mofetil will be administered as per dose determined in Part 1.
45653695|NCT05700695|Drug|Branch Chain Amino Acid|Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm
45653696|NCT05700695|Drug|Lactulose|Oral lactulose will be given to patients in both arms
45653697|NCT05445557|Drug|RZL-012|small synthetic molecule for submental fat reduction
45653698|NCT05445557|Drug|Placebo|Placebo
45936167|NCT00133549|Drug|Placebo|Saline placebo administered in a volume of 0.5 ml intramuscularly.
45936168|NCT00133549|Biological|PNU-IMUNE®23|The 23-valent pneumococcal vaccine (PS) vaccine will contain a mixture of 25 micrograms purified, pneumococcal polysaccharide of each of 23 serotypes of Streptococcus pneumoniae per 0.5 ml dose in isotonic saline and 0.01% thimerosal. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
45936169|NCT00133549|Biological|Nine-valent pneumococcal conjugate (PNCRM9)|Cross-reactive material 197 (CRM 197) is a product of the Corynebacterium diphtheria C7. Vaccine is prepared from pneumococcal polysaccharides of types 1, 4, 5, 9V, 14, 18C, 19F, 23F (2 mcg each) and 6B (4 mcg) covalently linked to CRM197 by reductive amination. The protein-polysaccharide combination is prepared as a lyophilized powder with aluminum phosphage which is reconsitituted before use. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
45936170|NCT00133588|Biological|Trivalent split Inf|
45936171|NCT00080613|Drug|exemestane|
45936172|NCT00080613|Procedure|adjuvant therapy|
45936173|NCT00080613|Procedure|aromatase inhibition|
45936174|NCT00080613|Procedure|conventional surgery|
45936175|NCT00080613|Procedure|endocrine therapy|
45936176|NCT00080613|Procedure|hormone therapy|
45936177|NCT00080613|Procedure|neoadjuvant therapy|
45936178|NCT00080613|Procedure|surgery|
45936179|NCT00047021|Biological|sargramostim|Sargramostim (GM-CSF) subcutaneously beginning on day 14 and continuing until blood counts recover.
45936180|NCT00047021|Drug|cytarabine|high-dose cytarabine IV over 1 hour on days 1-5
45936181|NCT00047021|Drug|mitoxantrone hydrochloride|high-dose mitoxantrone IV over 15-30 minutes on day 5.
45936182|NCT00133627|Drug|Ketotifen|
45936183|NCT00133666|Behavioral|Asthma Communication Education|
45936184|NCT00133666|Behavioral|Standard Asthma Education|
45936185|NCT00133744|Dietary Supplement|folic acid|pills by mouth, one per day, from the first prenatal visit until delivery, 400 micrograms (mcg) folic acid
45936186|NCT00133744|Dietary Supplement|folic acid plus iron|pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe
45936187|NCT00133744|Dietary Supplement|supplements with multiple vitamins and minerals|pills, one per day, from the first prenatal visit until delivery; folic acid 400 mcg, Fe 30 mg, vitamin(vit) A 800 mcg, vit E 10 mg, vit D 5 mcg, vit C 70 mg, vit B1 1.4 mg, vit B2 1.4 mg, vit B6 1.9 mg, vit B12 2.6 mcg, Niacin 18 mg, Zn 15 mg, Cu 2mg, Iodine 150 mcg, Selenium 65 mcg
45936188|NCT00133783|Behavioral|intermedin|
45936189|NCT00080808|Drug|Alprostadil (E1)|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
45936190|NCT00080808|Drug|Papaverine|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
45804701|NCT04344925|Device|Aerosol-reducing Mask|Patient will be put on BIPAP using the aerosol-reducing mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
45653699|NCT04982341|Procedure|prone position|patients are returned from prone to supine position while receiving oxygenation through HFNC
45653700|NCT04426019|Behavioral|CLS Intervention|Promotoras will deliver the CLS program either in face-to-face and/or group sessions to all women within 2 months of the baseline interview. Each session will last approximately 1 to 2 hours, and will include CLS materials adapted for this study.At the conclusion of the CLS program, promotoras will provide information about local and affordable providers delivering low-cost or free breast and cervical cancer screening services. Should a woman require follow-up for abnormal results, referrals will be given to programs,which provides assistance accessing cancer diagnostic and treatment services. Two weeks after delivering the education component of the CLS program, promotoras will call women to provide any further assistance needed. During these follow-up calls promotoras will provide on-going navigation support to women in need of mammography and Pap test screening
45653701|NCT04426019|Behavioral|No CLs intervention|This control arm will receive only usual practice care and will not receive the CLS intervention.They may receive the intervention after study has been completed
45653702|NCT04432987|Drug|Pulmozyme|"PULMOZYME contains an active substance called dornase alpha as an active substance. Dornase alpha is a human-made version of a protein called DNase in your body and is also known as recombinant human deoxyribonuclease 1 or rhDNase.~Drug will be administered at a dose of 2,5 mg/2 times per day for 7 days"
45804702|NCT04344925|Device|Standard Mask|Patient will be put on BIPAP using the standard mask
45804703|NCT05463848|Drug|Pembrolizumab|Intravenous infusion
45804704|NCT05463848|Drug|Olaparib|Pill taken by mouth
45804705|NCT05463848|Drug|Temozolomide|Pill taken by mouth
45804706|NCT00356317|Behavioral|Culturally informed therapy for schizophrenia (CIT-S)|This family therapy consists of 15 video-taped, therapy sessions, each lasting approximately 75 minutes. The 15-session treatment will be broken down into five segments (each lasting approximately three sessions) with the following goals: 1) Fortify a strong sense of family unity; 2) educate about schizophrenia; 3) foster adaptive use of cultural, spiritual and/or existential beliefs in conceptualizing and coming to terms with schizophrenia; 4) teach effective communication training techniques; and 5) and teach useful problem solving strategies.
45804707|NCT00356317|Behavioral|Psychoeducation treatment as usual|This family therapy consists of three weekly sessions focusing on education about schizophrenia.
45804708|NCT05244278|Diagnostic Test|Detection and classification of polyps by Artificial Intelligence Medtronic-GI genius|"The GI-Genius system could reach a sensitivity of 99.7%, a false-positive rate <1%, and performed real-time analysis 82% faster than the endoscopist. The use of this system resulted in a significant increase in ADR compared with the conventional colonoscopy (54.8% vs. 40.4%) in a screening cohort.~Medtronic-GI genius: AI will provide real-time feedback throughout each colonoscopy procedure and alert endoscopists to the presence of a polyp in the endoscopy field by displaying a bounding box on the same screen. Then, endoscopists will first perform optical diagnosis without the aid of the AI using the validated NBI (narrow band imaging) International Colorectal Endoscopic (NICE) and Sano classification systems to distinguish non-neoplastic from neoplastic polyps and express confidence in the prediction of histology during optical diagnosis."
45804709|NCT05647512|Drug|LM-305|Administered intravenously
45804710|NCT05647512|Drug|Dexamethasone|Administered orally
45804711|NCT00356395|Drug|ramipril, candesartan|
45804712|NCT05242640|Other|Mindful attention|Participants will listen to mindful attention audio recordings via headphones
45804713|NCT05242640|Other|Exercise|Participants will complete a moderate-intensity walking program
45804714|NCT05242640|Other|Exercise with mindful attention|Participants will complete a moderate-intensity walking program while listening to mindful attention audio recordings via headphones
45804715|NCT05485038|Procedure|Tumor resection in awake patient|Surgeon performs critical steps of tumor removal in awake patient and controls his/her motor functions by brain mapping and assessing of voluntary movements
45804716|NCT05485038|Procedure|Tumor resection in asleep patient|Surgeon removes tumor in asleep patient and controls his/her motor functions by brain mapping
45804717|NCT00356473|Drug|Atorvastatin|
45804718|NCT04036903|Radiation|computed tomography|thoracic CT examinations for diagnosis, and/or follow-up.
45804719|NCT05461742|Behavioral|Physical activity intervention|While the final content and structure of the intervention will be informed by community advisory board, participants will receive a culturally adapted, Social Cognitive Theory and Transtheoretical Model-based PA intervention. The evidence-based, theory guided aerobic physical activity intervention will systematically build upon the investigators' prior studies and includes the following components: goal setting, in-person physical activity sessions, and written materials.
45936191|NCT00080808|Drug|Phentolamine mesylate|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
45804720|NCT03410875|Drug|Vemurafenib|Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. In case of certain defined toxicities, dose reductions of vemurafenib by 50% (480mg b.i.d.) or interruptions of up to 15 days are permitted. If additional dose reduction is required, vemurafenib may be reduced to 240mg oral b.i.d.
45804721|NCT03410875|Drug|Obinutuzumab|Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered at 1000mg per day on days 1, 8 and 15 during the cycle 2 and 1000mg per day every 4 weeks during the cycle 3 and 4 of treatment.
45936192|NCT00080808|Drug|Sildenafil citrate|Oral sildenafil as needed
45936193|NCT00080808|Procedure|conventional surgery|Unilateral cavernous nerve sparing radical retropubic prostatectomy
45936194|NCT00047099|Drug|cyclophosphamide|
45936195|NCT00047099|Drug|docetaxel|
45936196|NCT00047099|Drug|epirubicin hydrochloride|
45653703|NCT02976389|Other|Financial Incentive: High|dlParticipants in this group will receive an additional $40/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
45936197|NCT00047099|Drug|fluorouracil|
45804722|NCT03407651|Biological|Coagulation Factor VIIa variant|Single intravenous injection of MarzAA, followed by single subcutaneous injection of MarzAA, followed by daily subcutaneous injection of MarzAA for 50 days at final dose level required.
45804723|NCT05461508|Biological|Amoxicillin combined with vonoprazan and fucoidan|Fucoidan was used in combination with amoxicillin and vonoprazan. The purpose of this study was to explore the effect of fucoidan on the eradication rate of Helicobacter pylori and the intestinal flora of subjects.
45804724|NCT05461508|Other|Amoxicillin combined with vonoprazan|Amoxicillin and vonoprazan were used as the study control group
45804725|NCT05459324|Device|HD Study Electrode|The HD Study Electrode is an array of 8 columns of stimulation contacts arranged in 8 rows with a low-volume electrode body. This array of stimulation electrodes contact patterns of bi-poles and tri-poles may be applied to the spinal cord for assessment of dermatomal selective stimulation patterns.
45936198|NCT00047099|Drug|goserelin acetate|
45804726|NCT00356941|Drug|docetaxel|60 mg/m2 on day 1 of each week during radiation therapy
45804727|NCT00356941|Drug|oxaliplatin|Escalating dose per assignment: 20-50 mg/m2 on day 2 of each week during radiation therapy
45804728|NCT00356941|Procedure|radiation therapy|2 Gy Days 1-5 each week, total dose of 70Gy
45936199|NCT00047099|Drug|tamoxifen citrate|
45936200|NCT00047099|Procedure|adjuvant therapy|
45936201|NCT00047099|Radiation|radiation therapy|
45936202|NCT00133822|Drug|Sertraline and Risperidone|
45936203|NCT00133861|Drug|Botulinum toxin|
45936204|NCT00133900|Procedure|Phlebotomy|Peripheral blood draws for evaluation of circulating tumor cells
45936205|NCT00133939|Procedure|Mechanical ventilation|
45936206|NCT00134095|Drug|irinotecan hydrochloride|
45936207|NCT00134095|Drug|tegafur-gimeracil-oteracil potassium|
45936208|NCT00134095|Procedure|adjuvant therapy|
45804729|NCT05456672|Other|Test meals and food baskets|"Interventional dietary study using standardized test meals and personalized food baskets to investigate the impact of food combination on the glycemic response. The study period is organized as follows:~(Day 1: Continuous blood glucose monitoring system (CGM) activation) Days 2 and 3: Two standardized daily menus (breakfast, lunch, afternoon snack and dinner) provided on a randomized crossover basis.~Days 4 to 7: four standardized test meals, participants will be asked to substitute one meal each day (lunch or dinner) for a test meal according to a pre-defined randomization plan.~Days 8 to 10: Participants will be asked to prepare all meals using a food basket containing a mix of standardized and personal preference items.~Days 11 to 13: Participants will be asked to prepare all meals using a food basket containing a mix of standardized and personal preference items and following dietary recommendations developed by the study staff.~(Day 14: CGM sensor removed)"
45804730|NCT03338881|Drug|[14C]-TAK-659|[14C]-TAK-659 solution.
45804731|NCT03338881|Drug|TAK-659|TAK-659 tablets.
45936209|NCT00134095|Procedure|conventional surgery|
45936210|NCT00134095|Procedure|neoadjuvant therapy|
45804732|NCT03450083|Drug|Benralizumab|30mg Benralizumab will be delivered subcutaneously
45936211|NCT00047138|Biological|dactinomycin|
45936212|NCT00047138|Drug|carboplatin|
45936213|NCT00047138|Drug|cyclophosphamide|
45936214|NCT00047138|Drug|doxorubicin hydrochloride|
45936215|NCT00047138|Drug|etoposide|
45936216|NCT00047138|Drug|vincristine sulfate|
45936217|NCT00047138|Procedure|adjuvant therapy|
45936218|NCT00047138|Procedure|conventional surgery|
45936219|NCT00047138|Procedure|neoadjuvant therapy|
45936220|NCT00047138|Radiation|radiation therapy|
45936221|NCT00080847|Biological|oblimersen sodium|Given IV
45936222|NCT00080847|Biological|rituximab|Given IV
45936223|NCT00080847|Drug|cyclophosphamide|Given IV
45936224|NCT00080847|Drug|doxorubicin hydrochloride|Given IV
45936225|NCT00080847|Drug|vincristine sulfate|Given IV
45936226|NCT00080847|Drug|prednisone|Given orally
45936227|NCT00080847|Other|laboratory biomarker analysis|Correlative studies
45936228|NCT00134134|Drug|efalizumab|
45936229|NCT00134173|Drug|torcetrapib/atorvastatin|
45936230|NCT00134173|Drug|atorvastatin|
45936231|NCT00047177|Drug|Oxaliplatin|
45936232|NCT00080886|Biological|rituximab|
45936233|NCT00080886|Drug|carmustine|
45936234|NCT00080886|Drug|cytarabine|
45936235|NCT00080886|Drug|etoposide|
45936236|NCT00080886|Drug|melphalan|
45936237|NCT00080886|Procedure|autologous bone marrow transplantation|
45936238|NCT00080886|Procedure|peripheral blood stem cell transplantation|
45936239|NCT00134212|Drug|Dopexamine and norepinephrine|
45936240|NCT00134212|Drug|Epinephrine|
45936241|NCT00134251|Drug|SLV308|
45936242|NCT00134290|Drug|metformin|
45936243|NCT00134290|Behavioral|"standard diet advice"|
45936244|NCT00134290|Behavioral|"personal diet advice"|
45936245|NCT00047216|Drug|tipifarnib|
45936246|NCT00134329|Procedure|Filling out a questionnaire on the possible occurrence of erectile dysfunction|
45936247|NCT00080925|Biological|filgrastim|
45936248|NCT00080925|Biological|graft-versus-tumor induction therapy|
45936249|NCT00080925|Biological|rituximab|
45936250|NCT00080925|Biological|therapeutic allogeneic lymphocytes|
45936251|NCT00080925|Drug|cyclophosphamide|
45936252|NCT00080925|Drug|cyclosporine|
45936253|NCT00080925|Drug|cytarabine|
45936254|NCT00080925|Drug|doxorubicin hydrochloride|
45936255|NCT00080925|Drug|etoposide|
45936256|NCT00080925|Drug|fludarabine phosphate|
45936257|NCT00080925|Drug|prednisone|
45653704|NCT02976389|Other|Financial Incentive: Middle|Participants in this group will receive an additional $20/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
45804733|NCT03450083|Drug|Placebo|Subcutaneous placebo injection
45804734|NCT03289507|Dietary Supplement|Treatment1|Longvida Capsule formulation A
45936258|NCT00080925|Drug|vincristine sulfate|
45936259|NCT00080925|Procedure|peripheral blood stem cell transplantation|
45936260|NCT04710901|Behavioral|uTECH + YMHP|"uTECH intervention utilizes a machine learning algorithm that leverages baseline data, individual social media use patterns, and strategic opportunistic learning questions to push messages to participants that offer strategic content about biomedical and behavioral HIV prevention. In addition, participants in this arm will also receive the YMHP intervention, which provides a four-session, evidence-based Motivational Enhancement intervention developed as part of the Young Men's Health Project (YMHP) and delivered via Zoom. Participants complete the four-session intervention during the first three months of their enrollment in the study."
45804735|NCT03289507|Dietary Supplement|Treatment2|Longvida Capsule formulation B
45936261|NCT04710901|Behavioral|YMHP|YMHP intervention provides a four-session evidence-based Motivational Enhancement intervention developed as part of the Young Men's Health Project (YMHP) and delivered via Zoom. Participants complete the four-session intervention during the first three months of their enrollment in this study. Months 3-12 are inactive.
45936262|NCT04705831|Drug|Ruconest|C1 Esterase Inhibitor
45804736|NCT03289507|Dietary Supplement|Treatment3|Curcuma longa extract of Rhizomes
45936263|NCT04705675|Behavioral|Breastfeeding Education|The mothers were asked to remember the pseudonyms they used on the pretest and to use the same pseudonym on the posttest. Following the pretest, the mothers in the study group were taken into a separate room at the FHC and asked to breastfeed their infants. The mothers' breastfeeding behaviors were observed. After the breastfeeding, each mother was provided an average 30-minute session of individual education. All of the mothers in the study group received the education from the same researcher. Both audio and visual materials were used in the mothers' training.
45936264|NCT00081003|Genetic|gene expression analysis|
45936265|NCT00081003|Genetic|protein expression analysis|
45936266|NCT00081003|Other|cytology specimen collection procedure|
45936267|NCT00081003|Other|laboratory biomarker analysis|
45936268|NCT00081003|Other|physiologic testing|
45804737|NCT03578549|Device|Pulse Oximetry|Pulse Oximeter is being applied with a special holding tool to test the oximeter for its ability to measure pulpal blood flow, but no effect of the oximeter is being measured. Thus, to that degree the use is observational rather than interventional.
45804738|NCT03245593|Other|Shared-decision making process|Completion of the Ottawa Personal Decision Guide to help guide care with the support of online and printed material describing the therapeutic options available
45936269|NCT00081003|Procedure|breast duct lavage|
45936270|NCT00081003|Procedure|endoscopic biopsy|
45936271|NCT00081003|Procedure|study of high risk factors|
45936272|NCT00047255|Biological|trastuzumab|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
45936273|NCT00047255|Drug|carboplatin|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
46002510|NCT01792934|Procedure|tumor biopsy|at baseline (diagnostic or study) biopsy and after 3 or 4 cycles an optional tumor biopsy
46002511|NCT01751438|Other|Best Systemic Therapy (BST)|Group 1 will continue to receive best systemic therapy (BST).
45804739|NCT03245593|Other|standard care|Care of patients according to standard practice of managing patients with bipolar disorder
45804740|NCT05042960|Other|Brightness|Changing the colors or brightness on the device (computer screen) for one month
45804741|NCT03580343|Drug|tofacitinib|tofacitinib extended release, 11mg, daily, oral
45804742|NCT05445440|Drug|Methotrexate|Specified dose on specified days
45804743|NCT05445440|Drug|Leucovorin|Specified dose on specified days
45804744|NCT05445440|Drug|BMS-986371|Specified dose on specified days
45804745|NCT05445440|Drug|Sulfasalazine|Specified dose on specified days
45452523|NCT03089996|Procedure|Micro-osteoperforations|All micro-osteoperforations will be performed only once time in the experimental group on the same day of the installation of the upper incisors' retraction mechanics. Perforations will be performed with an individualized surgical guide and a 1.6 mm diameter stainless steel surgical drill perpendicular to the alveolar bone, 3 mm deep on the buccal surface, and 5 mm, on the palate. The depth of the perforations will be controlled and standardized by a cursor developed and patented by the research group. Two micro-osteoperforations will be aligned vertically distally from each upper incisor. Due to the proximity of the roots in the cervical third, only the most apical perforation will be performed between the two central incisors. The first perforation will be performed 6 mm away from the gingival margin, and the second, 5 mm from the first, in the vertical direction.
45452524|NCT00961090|Drug|Aminolevulinic Acid|20 mg/kg mixed in 50cc water and taken orally 3 hours prior to surgery
45936274|NCT00047255|Drug|docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
45653705|NCT02976389|Other|Financial Incentive: Low|Participants in this group will receive an additional $10/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
45936275|NCT00047255|Biological|trastuxumab|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
45804746|NCT05041322|Drug|Buspirone|Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.
46002512|NCT01751438|Other|Best Systemic Therapy (BST) + Surgery or Radiation Therapy|Group 2 will receive best systemic therapy in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice.
46002513|NCT01751438|Behavioral|Questionnaires|Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete.
46002514|NCT01751438|Other|Phone Call/Email|Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
46002515|NCT01749969|Drug|isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
46002516|NCT01749969|Drug|lenalidomide|Pharmaceutical form:capsules Route of administration: oral
46002517|NCT01749969|Drug|dexamethasone|Pharmaceutical form:solution or tablet Route of administration: intravenous or oral
45804747|NCT05041322|Drug|Placebo|Subjects take placebo pills (twice a day) for 14 Days.
45804748|NCT00422825|Drug|imatinib|
45653706|NCT05412329|Biological|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CART cells will be administered intravenously.
45653707|NCT05555381|Behavioral|young-D program|"needs detection by means of survey and interviews (mixed-methods)~6 week program (1 hour) on a weekly basis including cognitive behavioural therapy, sleep/stress hygiene education, heart coherence exercises, mindfulness and relaxation exercises"
45653708|NCT05397743|Other|Quality of Life|Questionnaire Perceived stress scale (PSS) + Questionnaire Short form 36 (SF-36) + Questionnaire Visual functioning questionnaire 25 (VFQ-25)
45804749|NCT05039528|Behavioral|Personalized OSA messages|Participants will receive personalized OSA messages designed to nudge and navigate them toward evaluation and treatment for OSA. Participants will complete questionnaires at baseline and at study follow-up.
45804750|NCT05039528|Other|Control|Participants will complete questionnaires at baseline and at study follow-up. At the end of the study period, participants will receive the OSA message intervention.
46002518|NCT01669915|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
46002519|NCT01669915|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
46002520|NCT01669915|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
46002521|NCT01669915|Dietary Supplement|Fish oil placebo|Fish oil placebo
46002522|NCT01653223|Drug|simvastatin|"In short statin group: 20 mg per day, start at 5-7 days before surgery and continue for 7 days.~In long statin group: 20 mg per day, start at 5-7 days before surgery and continue for 6 months."
46002523|NCT01549587|Drug|0.243% sodium fluoride|dentifrice: brush thoroughly twice daily
45936276|NCT00047255|Drug|Docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
45936277|NCT00134368|Drug|Etanercept|
45804751|NCT03453515|Behavioral|HEART|Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.
45936278|NCT00134407|Procedure|Normal diet|
45936279|NCT00134407|Procedure|Nutrition via jejunal needle-catheter|
45936280|NCT00134446|Device|transcranial magnetic stimulation|
45936281|NCT00134485|Drug|torcetrapib/atorvastatin|
45936282|NCT00134485|Drug|atorvastatin|
45936283|NCT00042783|Biological|D1/3-MAGE-3-His fusion protein|
45936284|NCT00042783|Biological|SB-AS02B adjuvant|
45936285|NCT00134524|Procedure|MME procedure|
45936286|NCT00134602|Behavioral|Needs assessment followed by tailored intervention|
45936287|NCT00047294|Drug|celecoxib|
45804752|NCT03453515|Behavioral|Growing Minds|Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
45936288|NCT00047294|Drug|temozolomide|
45804753|NCT05036486|Genetic|next-generation sequencing|Tumor tissue will be collected from advanced BTC patients for real-time next-generation sequencing analysis
45936289|NCT00047294|Drug|thalidomide|
45936290|NCT00047294|Procedure|adjuvant therapy|
45936291|NCT00042822|Drug|romidepsin|
45936292|NCT00134641|Drug|gemcitabine|
45936293|NCT00134641|Drug|vinorelbine|
45936294|NCT00134680|Drug|Letrozole|Letrozole tablets 2.5 mg by mouth daily
45804754|NCT03456245|Device|Vision device validation|Group members had their vision tested with the following devices/methods: Eyenetra NETRA, PlenOptika Quicksee, Right Manufacturing Retinomax K Plus 3, and standard eyesight tests using eye charts, phoropters, and slit lens lamp imaging.
45936295|NCT00134680|Drug|Trastuzumab|Weekly trastuzumab (4 mg/kg loading dose given by IV over 90 minutes folowed by 2 mg/kg given by IV weekly over 30 minutes, provided the previous dose was well tolerated.
45936296|NCT00134758|Drug|Ursodeoxycholic acid|"During 2 years :~between 40 and 50 kg : 500 mg/day~between 51 and 75 kg : 750 mg/day~between 76 and 100 kg : 1000 mg/day"
45936297|NCT00134758|Drug|Placebo|"During 2 years :~between 40 and 50 kg : 2 tabs/day~between 51 and 75 kg : 3 tabs/day~between 76 and 100 kg : 4 tabs/day"
45936298|NCT00081042|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
45936299|NCT00047333|Drug|erlotinib hydrochloride|Given PO
45936300|NCT00047333|Other|laboratory biomarker analysis|Correlative studies
45936301|NCT00047333|Other|pharmacological study|Correlative studies
45936302|NCT00134836|Behavioral|Preventive Primary Care Outreach|Nurse home visit at baseline, 6 months, 12 months, including comprehensive assessment using MDS HC, care planning, referral to appropriate services
45936303|NCT00134875|Drug|Buprenorphine/naloxone|Acute doses of buprenorphine/naloxone in each experimental test session. Doses delivered by either sublingual or parenteral routes, and are: 4/1, 8/2, 16/4 mg.
45936304|NCT00134914|Drug|Buprenorphine|single doses given by sublingual and parenteral routes
45936305|NCT00047411|Other|Cardiopulmonary Resuscitation|Immediate notification of EMS by telephone and prompt initiation of CPR, in accordance with published Basic Life Support guidelines
45936306|NCT00047411|Device|Automatic External Defibrillation|Use the AED first, in accordance with published guidelines for AED use, followed by a call to EMS and perform CPR as in the control group.
45936307|NCT00134953|Drug|Rivastigmine|
45804755|NCT05230940|Biological|TURKOVAC|Inactive COVID-19 Vaccine - TURKOVAC
45804756|NCT05230940|Biological|CoronaVac|It has 600 subunit of SARS-CoV-2 virus antigen
45804757|NCT03586583|Device|FBP|Old processing
45804758|NCT03586583|Device|ISR|New processing
45804759|NCT05229614|Radiation|Carbon Ion Therapy|After confirming the disease stability and upon patient inclusion in the study, hypofractionated carbon ion boost will be administered to one site of disease previously untreated. Patient will be irradiated to a single lesion with a total dose of 24 Gy[RBE], 8 Gy[RBE]/fraction, one fraction/day, for 3 days.
45804760|NCT05229614|Drug|Immunotherapy (Pembrolizumab)|Only cancer patients under treatment with pembrolizumab monotherapy, administered within clinical practice and according to the Italian Drug Regulatory Agency (Agenzia Italiana del Farmaco, AIFA), will be enrolled.
45936308|NCT00042861|Drug|7-hydroxystaurosporine|
45936309|NCT00042861|Drug|fluorouracil|
45936310|NCT00042861|Drug|leucovorin calcium|
45936311|NCT00134992|Drug|Prednisolone acetate|
45936312|NCT00135031|Drug|Bifidobacterium infantis 35624|
45936313|NCT00135070|Drug|Detemir|
45936314|NCT00135109|Drug|SPM 927|
45936315|NCT00042900|Drug|pyroxamide|
45936316|NCT00135148|Procedure|Filling out a questionnaire on libido and possible partner relationship|
45936317|NCT00135148|Procedure|Sex steroid analysis|
45936318|NCT00135187|Drug|VELCADE|"VELCADE will be used biweekly at 1.3 mg/m2 during week 1 and 2 on (days~1, 4, 8, and 11) followed by a 1-week break."
45936319|NCT00135187|Drug|Doxil|Doxil will be administered at 30 mg/m2 IV on day 4
46002524|NCT01549587|Device|toothbrush|brush thoroughly twice daily
46002525|NCT01549587|Device|dental floss|floss the whole mouth once daily
46002526|NCT01549587|Drug|0.454% stannous fluoride|dentifrice: twice daily brush thoroughly for 2 minutes
46002527|NCT01549587|Device|toothbrush|twice daily brush thoroughly for 2 minutes
45936320|NCT00135187|Drug|Dexamethasone|Dexamethasone at 40 mg during the first cycle and 20 mg during cycles 2-6 po or IV daily on days of VELCADE and day after VELCADE (i.e. days 1, 2, 4, 5, 8, 9, 11, 12). The patient will be treated for six 3-week cycles followed by three 5-week maintenance cycles.
45936321|NCT00145093|Drug|Baker's yeast (Bio Chromium)|
45936322|NCT00047450|Drug|Citalopram (Celexa)|Citalopram for 3 months
45936323|NCT00047450|Drug|Placebo|Placebo for 3 months
45936324|NCT00081237|Drug|OSI-7904L|
45804761|NCT05445128|Biological|MGTA-145|MGTA-145 will be administered as an IV infusion
45936325|NCT00081237|Drug|oxaliplatin|
45936326|NCT00145132|Procedure|β-CIT-SPECT, Neurophysiology|β-CIT-SPECT scans and EEG recordings, two assessments each
45804762|NCT05445128|Drug|Plerixafor|240 µg/kg administered subcutaneously
45804763|NCT05433194|Biological|ABO1009-DP|Vaccine
45804764|NCT02977754|Other|This is an observational study|Imaging
45936327|NCT00145171|Drug|apomorphine HCl injection|
45936328|NCT00145210|Drug|Nebivolol and Atenolol|
46088530|NCT04345224|Other|Dynamic tape|A kinesiology tape will be applied to the lateral hip of the affected side to facilitate the gluteus medius muscle activation while the participant is lying down. The first third of one I-strip will begin at the posterior iliac crest without tension to provide an anchor that will not cross the target tissue. The participant will actively flex the adducted hip to allow for the application of the middle third of the tape with approximately 50 percent tension (able to visualize the wave pattern in the tape). Subsequently, with the leg in the original position, the remainder of the tape will be applied without tension, ending approximately at the greater trochanter. Afterward, the second I-strip will be applied in the same manner starting at the anterior iliac crest.
45653709|NCT05555225|Other|Methylome|Epigenetic study : analysis of DNA methylation
45653710|NCT05555147|Drug|nerve block with 0.5% ropivacaine|After general anesthesia, the patients will receive bilateral infraorbital and infratrochlear nerve block 30 minutes prior to surgery. Infraorbital nerve block is performed while using an extraoral approach. A 25-gauge needle was inserted laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. The index finger of the non-dominant hand was positioned above the infraorbital foramen, and the needle was advanced until it was felt beneath the finger. 2 ml of the 0.5% ropivacaine slowly injected after negative aspiration of blood was confirmed. Inserting the needle 1 cm above the inner canthus, targeting the junction of the orbit and the nasal bone, performed infratrochlear nerve block. After negative aspiration of blood, 1 ml of the 0.5% ropivacaine was injected. Contralateral nerve block was performed in the same manner.
45804765|NCT00360074|Drug|Thyroxin, Triiodothyronine|
45804766|NCT05219396|Device|Knee arthroplasty|Your knee should be replaced with mobile bearing (MB), medial congruent (MC) and posterior stabilized (PS) design protheses.
45936329|NCT00047489|Drug|ABT-751|
45936330|NCT00081276|Drug|triapine|Given IV
45804767|NCT02260986|Drug|Dupilumab|Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
45804768|NCT02260986|Drug|Placebo (for Dupilumab)|Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
45804769|NCT02260986|Other|Topical Corticosteroid (TCS)|All participants were required to treatment with a (TCS) using a standardized regimen. It was recommended that participants use triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment for medium potency, and hydrocortisone 1% cream for low potency.
45804770|NCT05421650|Radiation|CCRT|"Radiation: Extended field-external beam radiation therapy (EF-EBRT) + brachytherapy + lymph node boost.~Chemotherapy: Cisplatin 40mg/m2, every week, 4 to 6 cycles.~Radiation and chemotherapy are administered concurrently."
45936331|NCT00081276|Drug|cisplatin|Given IV
45936332|NCT00081276|Other|laboratory biomarker analysis|Correlative studies
45936333|NCT00145366|Drug|Recombinant human thyrotropin (Thyrogen)|
45936334|NCT00145405|Drug|Lanreotide Autogel and Octreotide LAR|
45936335|NCT00145444|Drug|olanzapine|
45936336|NCT00145444|Drug|ziprasidone|
45936337|NCT00145483|Drug|Sildenafil|
45936338|NCT00047528|Drug|Alcon Investigational Agent|
45936339|NCT00145522|Drug|17ß-Estradiol/Dydrogesterone|1/5 mg/day for 12 cycles of 28 days
45936340|NCT00145522|Drug|Tibolone|2,5 mg/day for 12 cycles of 28 days
45936341|NCT00081315|Drug|Amifostine|
45936342|NCT00145561|Drug|Saquinavir and Ritonavir|
45936343|NCT00145639|Drug|Ifosfamide, Carboplatin, Doxorubicin|See Detailed Description for treatment plan.
45936344|NCT00145639|Procedure|Limb Sparing|See Detailed Description for treatment plan.
45936345|NCT00145678|Behavioral|Psychodynamic Therapy|Dynamic deconstructive psychotherapy is a time-limited (12-18 month) manual-based form of psychodynamic therapy that aims to remediate specific neurocognitive capacities responsible for processing of emotional experiences.
45936346|NCT00145678|Behavioral|Optimized Community Care|individual and group psychotherapy in a private practice, clinic, and/or rehab setting, with an eclectic orientation
45936347|NCT00145717|Drug|Plant sterol enriched milk tea|
45936348|NCT00145756|Drug|low sodium high potassium salt substitute|
45936349|NCT00047567|Drug|zonisamide|
45936350|NCT00145834|Behavioral|community based trial|
45936351|NCT04706065|Genetic|SHMT1 polymorphism|It is to identify the role of SHMT1polymorphism in PD and examine the relationship between it and Severity of PD.
45936352|NCT00145873|Drug|nesiritide, continuous infusion|
45936353|NCT00145912|Behavioral|MI + CATCH-IT Internet Site|MI + CATCH-IT Internet Site
45936354|NCT00145912|Behavioral|BA (brief advice) + CATCH-IT Internet site|BA (brief advice) + CATCH-IT Internet site
45936355|NCT00047606|Drug|IOP Lowering Medications|
45936356|NCT00145951|Behavioral|motivational interviewing, brief advice in primary care|motivational interviewing, brief advice in primary care
45936357|NCT00145990|Drug|methacholine|
45936358|NCT00145990|Device|KoKo Digidoser|
45936359|NCT00145990|Device|Rosethal Dosimeter|
45936360|NCT00146068|Drug|Avonex/Zocor|
45936361|NCT00081471|Drug|darbepoetin alfa|0.45 micrograms/kg sc (starting dose) weekly
45653711|NCT05555147|Other|without any nerve block|Patients receiving general anesthesia without Infraorbital and Infratrochlear nerve block.
45653712|NCT02587247|Drug|TF2 antibody/68Ga-IMP-288|TF2 antibody coupled with 68Ga-IMP-288
45804771|NCT05421650|Procedure|Surgical debulking of bulky or multiple lymph nodes|"Open/minimally invasive method.~Surgical debulking of bulky or multiple lymph nodes.~Postoperative imaging evaluation to determine whether the lymph node has been successfully removed."
45804772|NCT05421650|Radiation|CCRT|"Radiation: EBRT/EF-EBRT + brachytherapy + lymph node boost.~Chemotherapy: Cisplatin 40mg/m2, every week, 4 to 6 cycles.~Radiation and chemotherapy are administered concurrently."
45804773|NCT05211284|Drug|Saroglitazar Magnesium 4 mg|Subjects randomized to Saroglitazar Magnesium 4 mg arm will receive Saroglitazar Magnesium 4 mg treatment until the duration of study (72 weeks).
45804774|NCT05211284|Drug|Placebo|Subjects randomized to Placebo arm will receive Placebo treatment until the duration of study (72 weeks).
45653713|NCT02555111|Drug|Xarelto|15mg/day oral administration during 2 to 4 years (based on the recruitment date).
45804775|NCT05483010|Drug|Atorvastatin|Atorvastatin is commercially available.
45804776|NCT05483010|Drug|Rosuvastatin|Rosuvastatin is commercially available.
45804777|NCT05210582|Drug|Afamelanotide|Patients will receive afamelanotide over a three-month period, with an additional three-month follow up.
45804778|NCT05009420|Other|Avocado|avocado served with crackers as breakfast
45804779|NCT05408156|Other|Insoles|semi-flexible non-moulded insole with a 2.5mm coverage with Shore A 28, a 5mm retrocapital bar with a Shore A 22 and a 2mm infracapital bar of the first metatarsal with a Shore A 35, produced in acetate ethylene vinyl (EVA)
45804780|NCT04856826|Device|ultrasound guidance and therapeutic communication|insertion of a peripheral venous catheter with ultrasound guidance and therapeutic communication
45804781|NCT04995536|Biological|CpG-STAT3 siRNA CAS3/SS3|Given intratumorally
45804782|NCT04995536|Radiation|Radiation Therapy|Undergo radiation therapy
45804783|NCT05647356|Drug|Bicalutamide 50 mg|Bicalutamide at a dose of 50mg once daily for 28 days.
45804784|NCT05200676|Device|ePatch|ePatch registers the heart rate continuously when attached to the chest of the participant.
45804785|NCT05200676|Device|SmartPill|SmartPill is swallowed and passes through the digestive system while sending information to a recording device. The pill is passed in the stool and not reused.
45804786|NCT05647278|Drug|Tegoprazan|Tegoprazan 50 mg, tablets, orally, qd given in combination with amoxicillin 750mg capsules, orally, qid for up to 2 weeks.
45804787|NCT05647278|Drug|Esomeprazole|"esomeprazole 20 mg, tablets, orally, bid given in combination with amoxicillin 1000mg，clarithromycin 500mg bid，colloidal bismuth pectin 200mg bid for up to 2 weeks.~OR esomeprazole 20 mg, tablets, orally, bis in die given in combination with amoxicillin 750mg capsules, orally, quarter die for up to 2 weeks."
45804788|NCT05407142|Biological|"CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS"|"Subgroup 1 - 2100 volunteers who will be vaccinated with the Nobivac vaccine twice with an interval of 21 days intramuscularly at a dose of 0.5 ml and revaccinated at 6 months with one dose of the KoviVac vaccine (0.5 ml).~Subgroup 2 - 1400 volunteers who will be vaccinated with CoviVac vaccine three times at intervals of 21 days intramuscularly at a dose of 0.5 ml."
45804789|NCT05407142|Other|The data from volunteers from the control group|Official data on the number of Covid-19 cases during the study period among 3,500 unvaccinated individuals.
45936362|NCT00081471|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|0.6 micrograms/kg sc (starting dose) once every 2 weeks
45936363|NCT00047645|Drug|Interferon-gamma 1b|200 mcg, SQ, 3x per week
45653714|NCT02521415|Drug|ketamine|intranasal (IN) sub-dissociative ketamine (1mg/kg)
45653715|NCT02521415|Drug|fentanyl|Intranasal (IN) fentanyl (1.5 micrograms/kg)
45653716|NCT02521415|Drug|ibuprofen or acetaminophen|10 mg/kg of ibuprofen or 15 mg/kg of acetaminophen will be given to participants prior to the randomized intervention
45653717|NCT02461511|Other|Therapeutic Education|participation in a therapeutic education program on diabetes
45653718|NCT04334525|Behavioral|Choice architecture + repeated exposure|Participants will receive placemats promoting healthier featured kids' meals and the opportunity to redeem their kids' meal token for a toy instead of dessert. Families will also receive a frequent diner card, which after purchasing one of the featured healthier kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period.
45653719|NCT02078141|Drug|18F-deoxyglucose (FDG)|18F-deoxyglucose (FDG) One injection of 3.5 MBq/kg of 18FDG with a minimum of 220 MBq and a maximum of 400 MBq
45653720|NCT02588339|Drug|Panobinostat|Panobinostat (PANO) will begin 5 days (Day -5) before transplant day (Day 0). All participants will take PANO by mouth once a day, three times a week (48 hours apart), every week for 26 weeks (approximately 6 months). PANO will be provided by Novartis as 5-mg pink gelatin capsules.
45804790|NCT04986800|Behavioral|PROACTIVE Parent|PROACTIVE Parent will educate parents about their child's mental health symptoms and treatment, how to talk to the child's therapist to support treatment goals at home and in the community. PROACTIVE Parent will teach parents the function of child behavior, the role of symptomatology in child behaviors, and strategies to promote effective behavior management and healthy coping. Parents will also learn skills to manage their own emotional dysregulation to promote calm parental responding and promote healthy parent-child interaction and communication.
45804791|NCT00360152|Procedure|Fine needle aspiration biopsy (FNAB)|
45804792|NCT00360152|Procedure|Sentinel Lymph Node Biopsy|
45804793|NCT04343924|Other|Scuba diving activities|The subjects of this group daily dive, 5 days per week, for a total of 10 dives at a maximum depth of 6 meters for a maximum duration of 20 minutes in a swimming pool.
45804794|NCT04343924|Other|Virtual reality activities|The subjects of this group will follow virtual reality sessions recreating the environment in which the submarine diver of the GP+ group operates
45804795|NCT05181800|Other|FIRMAGON Cohort|Non-interventional
45804796|NCT02977364|Drug|HS-10241|
45936364|NCT00146107|Behavioral|Diet|10 percent weight loss through diet and behavioral modification
45936365|NCT00146107|Other|Exercise|Multicomponent (resistance, aerobic, balance) exercise three times a week
45936366|NCT00146107|Other|Weight Loss and Exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
45804797|NCT05181020|Behavioral|Maternal Voice Exposure|Main objective of this study is to determine if it is possible to expose preterm infant in a systematic manner to mother's voices before their feeds and to determine if this exposure results in an increase in their oral intake.
45804798|NCT00358748|Drug|Hydrocortisone|See detailed description above.
45936367|NCT00146146|Drug|testosterone undecanoate alone|1000 mg/12 weeks
45653721|NCT02588339|Drug|Sirolimus|Sirolimus will be given the day before transplant and continued daily for at least one year. SIR will be administered starting on day -1 and thereafter. Dosing will be adjusted to maintain therapeutic targets per Moffitt institutional standards.
45936368|NCT00146146|Drug|testosterone undecanoate plus letrozole|TU 1000 mg/12 weeks Letrozole 2.5 mg/day
45936369|NCT00146146|Drug|testosterone undecanoate plus dutasteride|TU 1000 mg/12weeks Dutasteride 0.5 mg/day
45936370|NCT00146185|Drug|ALGRX 3268|
45936371|NCT00146224|Drug|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
45936372|NCT00146224|Drug|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
45936373|NCT00047684|Behavioral|Brief Integrative Therapy|
45936374|NCT00081549|Drug|Aroplatin (Liposomal NDDP, L-NDDP)|
45936375|NCT00146263|Behavioral|Savyon|Computerized cognitive training
45936376|NCT00146263|Behavioral|Control|Usual activity
45936377|NCT00146302|Biological|Bacille Calmette Guerin (BCG)|
45936378|NCT00146341|Drug|Telmisartan/HCTZ|
45936379|NCT00146341|Drug|Telmisartan|
45936380|NCT00146380|Drug|Zidovudine/Lamivudine and either Nevirapine or Nelfinavir|"Zidovudine 300mg po bid from 34 weeks gestation to 6 months postpartum Lamivudine 150mg po bid from 34 weeks gestation to 6 months postpartum AND EITHER Nevirapine 200mg po qd for 2 weeks as lead in then bid from 34 weeks gestation to 6 months postpartum OR Nelfinavir 1250mg po bid from 34 weeks gestation to 6 months postpartum~ARVs continued for those that meet WHO treatment criteria"
45936381|NCT00146380|Behavioral|Breastfeeding for 6 months postpartum|Exclusive breastfeeding till five and one half months with rapid weaning over 2 weeks and cessation of breastfeeding at 6 months when ARVs are discontinued
45936382|NCT00081588|Drug|TMC114|600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
45936383|NCT00146419|Behavioral|Reduction in behaviors capable of sexually transmitting HIV|Clinic-level risk reduction counseling
45936384|NCT00146458|Procedure|18F-fluorodeoxyglucose positron emission tomography|
45936385|NCT00047723|Drug|minocycline|
45936386|NCT00146497|Drug|Budesonide-Surfactant|
45653722|NCT02588339|Drug|Tacrolimus|Tacrolimus as an infusion or as a pill will begin 3 days before transplant (day -3) and following Moffitt institutional guidelines for dosing. Tacrolimus will be given for at least 50 days and participants will remain on Tacrolimus for as long as it is necessary per standard of care.
45653723|NCT01765439|Dietary Supplement|VSL#3 (Original De Simone formulation)|Study subjects will receive two sachets of VSL#3 probiotic (ie 2x900 billions of live bacteria) per day (one in the morning, one in the evening). The intervention period will be 6 weeks (plus or minus 5 days).
45936387|NCT02957890|Biological|Inactivated influenza vaccine (NH formulation)|Round 1 (November): 0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation
45936388|NCT02957890|Biological|Inactivated influenza vaccine (SH formulation)|Round 2 (May): 0.5mL Vaxigrip®, Sanofi Pasteur, containing 45μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the southern hemisphere formulation
45936389|NCT02957890|Biological|Placebo|Round 2 (May): 0.5mL normal saline
45936390|NCT00081627|Drug|CoFactor and 5FU|
45936391|NCT00146575|Device|Sirolimus-eluting stent (Cypher)|patients have been implanted a Cypher stent
45936392|NCT00146575|Device|Paclitaxel-eluting stent (Taxus)|patients have been implanted a Taxus stent
45936393|NCT00146614|Drug|Sirolimus|
45936394|NCT00146614|Drug|Tacrolimus|
45936395|NCT00146614|Drug|Methotrexate|
45936396|NCT00146614|Procedure|Stem Cell Transplantation|
45936397|NCT00047762|Drug|Erlotinib (aka Tarceva or OSI-774)|
45936398|NCT00047762|Drug|Bevacizumab (aka Avastin or Rhu MAb VEGF)|
45936399|NCT00042978|Biological|oblimersen sodium|Given IV
45936400|NCT00042978|Drug|carboplatin|Given IV
45936401|NCT00042978|Drug|etoposide|Given IV
45936402|NCT00405730|Drug|Nepafenac 1mg/ml eye drops, suspension|One drop in the study eye 3 times daily for 23 days
45936403|NCT00405730|Drug|Ketorolac Trometamol 5 mg/ml eye drops, solution|One drop in the study eye 3 times daily for 23 days
45936404|NCT00405730|Other|Nepafenac vehicle eye drops|One drop in the study eye 3 times daily for 23 days
45936405|NCT00405769|Drug|red yeast rice|600 mg 3 caps bid
45936406|NCT00405769|Drug|placebo|3 caps bid
45936407|NCT00424216|Procedure|DC Polarization|
45936408|NCT00047801|Drug|TLK286 in combination with docetaxel|
45936409|NCT00146692|Behavioral|Free medical treatment|
45936410|NCT00043017|Procedure|MRI/MRS|Serial MRI studies evaluated for prognostic properties related to therapeutic response.
45936411|NCT00043017|Radiation|gadopentetate dimeglumine|Imaging agent used for contrast enhancement in each of the MRIs.
45936412|NCT02957812|Device|Custom-made Foot Orthotics (CFO)|Provides longitudinal arch support
45936413|NCT00146731|Drug|SP|
45936414|NCT00146731|Drug|SP + amodiaquine|
45936415|NCT00146731|Drug|AQ + artesunate|
45936416|NCT00146731|Drug|chlorproguanil-dapsone|
45936417|NCT00047840|Drug|ZD6474|
45936418|NCT00047840|Drug|Placebo|
45936419|NCT00047840|Drug|Docetaxel|
45936420|NCT00146809|Drug|Minocyline|
45936421|NCT00146887|Procedure|coronary catheterization|
45936422|NCT00146926|Drug|kétamine 20mg|
45936423|NCT00146926|Drug|ephedrine 3mg|
45936424|NCT00146926|Drug|lidocaine 40mg|
45653724|NCT01752491|Drug|Ascorbate|Intravenous infusion of high-dose ascorbate
45653725|NCT01752491|Drug|Temozolomide|Oral chemotherapeutic
45804799|NCT05396924|Procedure|Rectal temperature measurement|Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer. The data obtained will be analyzed by a blinded researcher. Mean body temperatures measured from 2 different locations (temporal region and rectal mucosa) between the groups will be compared, and the probability of detecting early local and later general hypothermia from the rectal mucosa will be examined
45804800|NCT05396924|Procedure|Temporal temperature measurement|Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer. The data obtained will be analyzed by a blinded researcher. Mean body temperatures measured from 2 different locations (temporal region and rectal mucosa) between the groups will be compared, and the probability of detecting early local and later general hypothermia from the rectal mucosa will be examined
45936425|NCT00147004|Drug|hydrocortisone sodium succinate|50 mg intravenous bolus every six hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and then stopped
45936426|NCT00147004|Drug|Placebo|
45936427|NCT00147121|Drug|Rituximab + Standard CHOP|Rituximab + Standard CHOP
45936428|NCT00147121|Drug|Rituximab + Bi-weekly CHOP|Rituximab + Bi-weekly CHOP
45936429|NCT00147160|Drug|Temozolomide, Cisplatinum|
45936430|NCT04732104|Drug|Lidocaine topical|intranasal spray anesthesia will be administered for achieving pulpal local anesthesia of maxillary anterior and premolar teeth. Xylometazoline OTC decongestant will be used to prolong the duration of anesthesia
45653726|NCT01752491|Radiation|Radiation therapy|External beam radiation therapy
45653727|NCT05700929|Behavioral|Communication skills training for nurses|Aim of the developed training will be to foster patient-centered communication skills of nursing professionals in Germany. The training consists of four modules in which participating nurses will get information regarding patient-centeredness and general communication techniques. Participants will also learn how to response to patients in escalating situations and how to communicate with seriously ill or dying patients. The underlying framework for the training is the Calgary-Cambridge Guide, a well-known model for structuring conversation with patients. Different didactic techniques (i.e. roll-play, video sequences, group discussion) will be applied. The training will be provided in small groups of 10-14 participants each. Two facilitators will give the training, one of them being a nursing professional trained according to the train-the-trainer approach, the other being a member of the research group, who was involved in the development of the training.
45936431|NCT04732104|Drug|Lidocaine Hydrochloride|injectable local anesthesia will be administered to achieve pulpal local anesthesia of maxillary anterior and premolar teeth
45936432|NCT00147355|Drug|ondansetron, ibuprofen, paracetamol|ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
45936433|NCT00147355|Drug|Ondansetron, ibuprofen, paracetamol|Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
45653728|NCT05554991|Dietary Supplement|HMO|Composition comprising of HMO
45653729|NCT05554991|Dietary Supplement|Placebo|Placebo supplementation having the same appearance and dosing regimen as the intervention
45653730|NCT05554991|Behavioral|Parental reassurance and support|Both groups will receive standardized written materials to provide parental reassurance and support, in alignment with local clinical practice
45653731|NCT05554913|Drug|QL0911|This study is designed to study QL0911 for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for cancer
45936434|NCT00147355|Drug|metoclopramide, ibuprofen, paracetamol|metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
45936435|NCT00147355|Drug|Metoclopramide, codeine phosphate, ibuprofen, paracetamol|metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
45936436|NCT00048152|Drug|Corticosteroids|As prescribed
45653732|NCT05554913|Drug|Placebo|Placebo comparator
45936437|NCT00048152|Drug|Neoral|Low dose (target trough level 50-100ng/mL)
45936438|NCT00048152|Drug|Neoral|Standard dose (target trough level 150-300ng/mL)
45936439|NCT00048152|Drug|Zenapax|2mg/kg iv first dose, then 1mg/kg every 2 weeks
45936440|NCT00048152|Drug|mycophenolate mofetil [CellCept]|1g po bid
45936441|NCT00147394|Drug|Risperidone|
45936442|NCT00147472|Other|PET scan in addition to conventional CT imaging|PET scans, Pre and post radiation treatment
45936443|NCT04725682|Drug|Tacrolimus|a single dose of 1 mg capsule per period
45936444|NCT00147511|Drug|linezolid|
45936445|NCT00043095|Drug|gemcitabine hydrochloride|
45936446|NCT00043095|Drug|ixabepilone|
45936447|NCT00048230|Drug|bortezomib|
45936448|NCT00147550|Drug|PD-0325901|Administered orally either once or twice a day; several dosing schedules evaluated; current dosing schedule is 5 days on-drug, 2-days off drug for 3 weeks in a 28-day cycle. Doses evaluated ranged from 1 mg once a day to 30 mg twice daily.
45936449|NCT00147589|Drug|Eplerenone|
45936450|NCT00397332|Drug|Alefacept|IM Alefacept
45936451|NCT00147628|Drug|sildenafil citrate|
45936452|NCT00147628|Drug|placebo for sildenafil citrate|
45936453|NCT00147667|Drug|Erythromycin|
45936454|NCT00048308|Drug|pexelizumab|
45936455|NCT00147706|Procedure|Tailored Healthmedia programs on EHR Patient Portal|
45936456|NCT00147784|Drug|Ribavirin|800 mg pr. os daily, 400 mg morning and 400 mg evening (200 mg/tbl.) for 14 weeks
45936457|NCT00147784|Drug|Pegylated Interferon|180 mikrogram in 0,5 ml solution s.c. once a week for 14 weeks
45936458|NCT00081744|Drug|Tigecycline|
45804801|NCT05178992|Behavioral|Socially Assistive Robot Activity|Participants will attend two weekly sessions with robot activities. Each session will last 30 minutes. Participants will attend robot sessions for 8 weeks.
45804802|NCT05383664|Other|Ultra Violet Light Exposure|Subjects will stand at the determined distance from the UV lamps facing towards them to achieve full body UV exposure. They will stand for the time indicated to achieve the appropriate dose. Each exposure will range from about 1 minute to 4.5 minutes to deliver a dose ranging from 0.22J/cm2 to 0.88J/cm2. Subjects will then rotate to irradiate their back side for the same time to achieve the same dose. On the second visit clinical examination will be conducted for erythema. If no erythema is apparent, the dosage on subsequent visits may increase to the max of 0.88 J/cm2.
45653733|NCT05554757|Device|conventional rubber dam system|rubber dam is a protective sheet with a hole that a dental professional positions over a tooth during an endodontic procedureEndodontists . This allows to isolate the treatment area with a dental clamp around the tooth. The dental sheet is placed around the in the Dental Rubber Dams and then a u-shaped device is hooked around. This isolates the single tooth where dental treatment will be conducted.
45653734|NCT05554757|Device|OPTRADAM|OptraDam Plus is a three-dimensional rubber dam that is flexible and has an anatomical shape, automatically stretched in an oral direction, an automatic hold of the device in the oral cavity is ensured.
45804803|NCT00359606|Drug|5-Fluoro-2-Deoxycytidine (FdCyd)|Given PO and IV
45804804|NCT00359606|Other|Laboratory Biomarker Analysis|Correlative Studies
45936459|NCT00147862|Drug|Tranexamic Acid|
45936460|NCT00147901|Drug|FCCam|After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
45653735|NCT05612321|Device|Vacuum application|vacuum-assisted delivery
45653736|NCT05317247|Diagnostic Test|Cough sounds|The investigators will discover a cough audio signature and then validate it.
45653737|NCT05242601|Other||no intervention
45653738|NCT05554523|Device|Photoacoustic imaging|Photoacoustic imaging
45804805|NCT00359606|Other|Pharmacological Study|Correlative Studies
45804806|NCT00359606|Drug|Tetrahydrouridine (THU)|Given PO and IV
45804807|NCT00359840|Drug|darbepoetin alfa|
45804808|NCT02259582|Drug|Pemetrexed|
45804809|NCT02259582|Drug|Carboplatin|
45804810|NCT02259582|Drug|demcizumab|
45804811|NCT00360386|Drug|Clopidogrel|
45804812|NCT02977208|Procedure|Sparse blood sampling|Blood samples are being collected at times 0, 90 and 240 minutes after gabapentin administration.
45804813|NCT02977208|Procedure|Urine sampling|Urine samples are being collected during the dosing interval, only in patients hospitalized at Hospital Estadual de Américo Brasiliense (HEAB).
45804814|NCT02977208|Procedure|DNA extraction|Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms
45804815|NCT02977208|Drug|Gabapentin|All patients undergoing chronic treatment with gabapentin are being recruited.
45804816|NCT03238651|Drug|TAK-659|TAK-659 Tablets.
45804817|NCT04866108|Drug|fruquintinib plus capecitabine|oral fruquintinib plus capecitabine
45804818|NCT04343768|Drug|Hydroxychloroquine|This Drug will be used in all arms.
45804819|NCT04343768|Drug|Lopinavir / Ritonavir|This Drug will be used in all arms.
45804820|NCT04343768|Drug|Interferon Beta-1A|This drug will be only used in Arm 1.
45804821|NCT04343768|Drug|Interferon Beta-1B|This drug will be only used in Arm 2.
45804822|NCT03221335|Device|EUS-guided RFA|All patients would undergo EUS with a linear array echoendoscope. The location and size of the lesion would be assessed for suitability of treatment. After locating the lesion, the RFA needle would be inserted to the centre of the lesion. RFA would then be initiated and hyperechoic interferences would be observed around the electrode signifying heating of the tissue. The duration of ablation would be according to the size of the lesion.
45936461|NCT02957851|Drug|Medical Air|
46088531|NCT04345224|Other|Rigid tape|The rigid tape will be applied in a standing position. The first tape will be applied from the greater trochanter to the anterior iliac crest. The second from the greater trochanter to the posterior iliac crest. Both tapes are applied with the muscle mass lifted towards the iliac crest.
45653739|NCT04426565|Behavioral|motivational enhancement interview|Motivational interviewing is supported by over 200 randomized controlled trials across a range of target populations and behaviors including substance abuse, health-promotion behaviors, medical adherence, and mental health issues.
45653740|NCT04426565|Behavioral|the individual psychotherapy|It has been demonstrated to be an effective treatment for depression and has been modified to treat other psychiatric disorders such as substance use disorders and eating disorders. It is incumbent upon the therapist in the treatment to quickly establish a therapeutic alliance with positive countertransference of warmth, empathy, affective attunement and positive regard for encouraging a positive transferential relationship, from which the patient is able to seek help from the therapist despite resistance.
45653741|NCT04426565|Behavioral|the group psychotherapy|Group psychotherapy is a key component of milieu therapy in a therapeutic community. The total environment or milieu is regarded as the medium of therapy, all interactions and activities regarded as potentially therapeutic and are subject to exploration and interpretation, and are explored in daily or weekly community meetings. A form of group therapy has been reported to be effective in psychotic adolescents and recovering addicts.
45653742|NCT04426565|Behavioral|the family therapy|"According to a 2004 French government study conducted by French Institute of Health and Medical Research, family and couples therapy was the second most effective therapy after Cognitive behavioral therapy. The study used meta-analysis of over a hundred secondary studies to find some level of effectiveness that was either proven or presumed to exist. Of the treatments studied, family therapy was presumed or proven effective at treating schizophrenia, bipolar disorder, anorexia and substance dependence."
45653743|NCT04328831|Biological|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
45653744|NCT05558813|Diagnostic Test|Cardiac MRI|two cardiac MRIs with Gadolinum injection at 2-year intervals
45936462|NCT02957851|Drug|EMONO|
45936463|NCT00081783|Drug|Xcellerated T Cells|
45936464|NCT00147940|Procedure|Acoustic rhinometry (procedure)|
45653745|NCT05558813|Biological|Blood assays|blood samples for the determination of blood biomarkers of heart failure (BNP, NTproBNP) and for the constitution of a biological collection
45653746|NCT05558735|Other|urine collection|urine collection as part of the care and usual follow-up in the context of suspected prostate cancer
45653747|NCT05558735|Other|canine detection|urine sample will be placed in a detection cone to be sniffed by 6 trained dogs
45452525|NCT01088477|Other|Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol|In patients with acquired antihormonal resistance, eligible for estrogen therapy, a FES-PET scan will be made to determine FES-PET tumor uptake (which corresponds to estrogen receptor expression levels). Immediately after the FES-PET scan, all patients will start with a standard accepted dose of 2mg estradiol TID. Therapy response will be monitored by regular follow-up. RECIST criteria and clinical benefit will be used as criteria. In case of disease progression before end of the study period, estradiol treatment will be stopped.
45804823|NCT05475600|Behavioral|Classical APA group:|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20min / stretching / Objective: to bring the body back to a resting state
45804824|NCT05475600|Behavioral|APA with Exergaming device|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20min / stretching / Objective: to bring the body back to a resting state
45804825|NCT05475600|Behavioral|APA associated with biofeedback relaxation|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à Exergaming device 3 - Cool down: 20min / Biofeedback relaxation device / Objective: to bring the body back to a resting state
45804826|NCT05925972|Procedure|Plane block|Plane block application in laparoscopic hysterectomies
45804827|NCT05925959|Other|Preoperative Weight Management Program|The medical obesity intervention is comprised of monthly visits with an obesity medicine (OM) provider +/- a registered dietitian (in person or virtual). Lifestyle modifications (nutrition, physical activity, stress, sleep), appetite control, and medication side effects will be addressed in all visits. At initial visit, patients will evaluated in person by an OM provider +/- registered dietitian. An individualized intense lifestyle intervention will be implemented with the addition of an anti-obesity medication (phentermine, naltrexone/bupropion, phentermine/topiramate, liraglutide, semaglutide, etc). Medication use will be based on disease risk, patient preference, severity of obesity, contraindications, potential drug interactions and insurance coverage. A diet recommendation will be tailored to the patient's medical and food allergy history. Weight and vital signs will be monitored at each visit. Participants will have a total of 5 follow-up monthly encounters, every 30 +/- 7 days.
45804828|NCT05925946|Dietary Supplement|CURE-DM|"This randomized controlled prospective trial will be of 2 years duration where 150 patients with T2DM from urban areas of Delhi will be screened.~These subjects will be randomized into two groups by computer-generated randomization list using variable block size.~Group A (n, 60, test group)will be received a low-calorie diet along with appropriate exercise counseling; and group B (n, 60, Control group) will be received balanced diet along with exercise advice."
45804829|NCT05925933|Other|Intervention|high protein diet (carbohydrates 45%, protein 29%, and fat 26%) over 8-week periods.
45804830|NCT05925920|Drug|ENT-03|single dose of active drug
45804831|NCT05925920|Drug|Placebo|single dose of placebo comparator
45804832|NCT05925894|Drug|Efficacy of a Standardized Intracameral Combination of Mydriatics and Anesthetic (Mydrane ®) for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma|60 patients with coexisting POAG and cataract who underwent elective cataract extraction. All patients underwent ophthalmic routine examinations including automatic visual field examination, anterior chamber configuration, specular microscopy and arterial blood pressure measurement prior to surgery, 24 hours and 30 days postoperatively. All cataract surgeries were videorecorded, and all measurements were performed using media player. 20 patients received topical mydriatic eye drops, 20 patients received Mydriasert ® whereas 20 patients received intracameral injection of Mydrane ® just after the first incision.
45804833|NCT05925881|Procedure|Surgical Repair of Large to Massive Rotator Cuff Tears|Surgical procedure to reconstruct the rotator cuff
45804834|NCT05925868|Behavioral|mindfulness app|Parents will use the mindfulness app, Headspace, for at least 10 minutes on 4 days/week.
45804835|NCT05925855|Other|US with fastum|apply fastum on trigger point with US
45804836|NCT05925855|Other|US with reparil|apply reparil on trigger point with US
45804837|NCT05925855|Other|US with plain gel|apply gel on trigger point with US
45804838|NCT05925829|Biological|SVF and aaPRP|Stromal vascular fraction and autologous activated platelet-rich plasma
45804839|NCT05925816|Behavioral|Video|Video uses BA techniques for approximately 5 minutes
45804840|NCT05925816|Behavioral|Active game|Game provides positive feedback in response to decisions made by participants
45653748|NCT05558657|Other|Caregiver-led, acupressure combined with nursing intervention|"The intervention group will focus on the Hegu, Zusanli, Tianshu and Zhongwan acupoints. The caregivers can perform acupressure two hours after meals and once a day. And they can first perform acupressure on Zhongwan acupoints, and then Tianshu points on right and left abdomen. And then press Quchi point on the right and left arm. They can use the plan of the hand to massage clockwise on the position which is two inches from the navel for 8 minutes.~Besides, the intervention group will also receive nursing interventions on the basis of receiving acupressure intervention including (1) dietary guidance: help patients to formulate a reasonable diet plan, (2) cultivate regular defecation in patients, ( 3 ) Moderate exercise to increase gastrointestinal motility."
45452526|NCT05456074|Other|Data collection|Retrospective data collection
46073775|NCT05758545|Device|Sham device|The SHAM device incorporates technologies for optical and magnetic stimulation. The optical stimulation component is designed to emit light by two types of light emitting diodes (LEDs) in the wavelength of 660 nm (red) and 830 nm (near infrared) range of the electromagnetic spectra. The magnetic stimulation component is generated by a coil emitting pulse modulated magnetic fields in the extremely low frequency (ELF) range of the electromagnetic spectra. The System is a lightweight, portable device. The device is applied via a single use disposable component (COMStouch) that provides a base and sterile barrier for the unit. The device is attached via a single use strap (COMSfix). The device has been slightly adapted in order to make sure blinding is achieved/maintained. The specific features that have been modified for the purposes of blinding include the following: 1) therapeutic output, and 2) sensor detecting whether the device is lying on the skin.
46073776|NCT04283357|Other|Exercise|Short Foot Exercises
45452527|NCT03961139|Other|Method of feeding; continuous feeding OR bolus feeding|"CF: Infants fed through a naso or orogastric tube in a continuous fashion using syringe pump. Each feed cycle is of 4 hours (3 hrs continuous feeding and 1 hour rest). 6 feed cycles in a day.~BF: Infants fed through a naso or orogastric tube in a gravity dependent bolus feeding every 2-3 hours. Each feed would take approximately 10 minutes."
45452528|NCT01088555|Drug|Sodium thiosulfate|Oral administration of sodium thiosulfate pentahydrate 5% solution (American Regent) 10ml BID x 7 days
45452529|NCT04474132|Device|toxoplasma ICT IgG-IgM BK|a point-of-care device, using blood from finger stick to measure the presence or absence of anti Toxoplasma gondii antibody
45653749|NCT05558657|Other|Caregiver-led, sham acupressure combined with nursing intervention|Control group will receive sham acupressure once a day for 10 days. Sham acupressure is the only difference compare with the intervention group. We will train the caregivers to perform acupressure on Tibia next to Zusanli, the lateral epicondyle of the humerus next to Quchi, the radius next to the tributary groove and last the second metacarpal next to Hegu. Also, they can do massage to the abdomen for 8 minutes. And they use same force as the intervention group.
45804841|NCT05925816|Behavioral|Neutral game|Game without feedback
45804842|NCT05925803|Biological|Anifrolumab (blinded)|Anifrolumab treatment delivered subcutaneously, once weekly for 52 weeks
45804843|NCT05925803|Drug|Placebo (blinded)|matched placebo delivered subcutaneously, once weekly for 52 weeks
45804844|NCT05925803|Biological|Anifrolumab (unblinded, open label)|At Week 52, all patients will receive Anifrolumab subcutaneously once weekly for 52 weeks
45804845|NCT05925790|Diagnostic Test|IL1RA Antibody Assay|-The measurement of anti-interleukin-1 receptor antagonist (IL1RA) antibodies will be performed using the ELISA (Enzyme-Linked Immunosorbent Assay) method,as previously described [Thurner, L., et al., IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination. N Engl J Med, 2022. 387(16): p. 1524-1527].
45804846|NCT05925790|Diagnostic Test|suPAR Testing|"-The quantitative determination of soluble urokinase plasminogen activator receptor (suPAR) levels in blood will be conducted using the commercially available CHORUS suPAR Extended kit (cod. 81414, DIESSE Diagnostica Senese S.p.A., Siena, Italy), based on the principle of the sandwich ELISA method."
45804847|NCT05925777|Device|THEAL (Mectronic, Bergamo)|laser therapy high intensity
45804848|NCT05925764|Diagnostic Test|Whole Slide Image based Deep Learning Signature|Deep Learning Signature Based on Whole Slide Image for Predicting the Novel Grading System In Resected Lung Adenocarcinoma
45804849|NCT05925751|Diagnostic Test|CT/PET/WSI-based Deep Learning Signature|CT/PET/WSI-based Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer
45804850|NCT05925738|Diagnostic Test|PET/CT-based Deep Learning Signature|Deep Learning Signature Based on PET-CT for Predicting the Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer
45804851|NCT05925725|Drug|• harpagozid • boswellin = LOXACON|Exercise therapy
45804852|NCT05925712|Device|AeroFit Seal-In Liner / Socket|Össur AeroFit® solution is a transfemoral breathable prosthetic interface, combining the AeroFit® Seal-In liner and AeroFit® Socket.
45804853|NCT05925712|Device|Seal-In Silicone Liner|Seal-In Silicone Lineris transfemoral prosthetic interface used in combination with a prosthetic socket system.
45804854|NCT05925699|Other|Collection of clinical, radiological, and biological data from patients' medical records|Collection of clinical, radiological, and biological data from patients' medical records
45653750|NCT05700851|Dietary Supplement|Immuno-nutrition supplement|Oral Impact® is a powdered oral nutritional supplement that contains a unique combination of ingredients with immuno-modulating properties, namely omega-3 fatty acids, arginine and nucleotides, as well as soluble fibre.
45804855|NCT05925686|Drug|Tramadol.|Orally single dose administration of Tramadol 75 mg for ultra-rapid metabolizers and 100 mg for extensive and poor metabolizers.
45804856|NCT05925673|Other|Mirror Therapy|Participants will perform exercises with their unaffected arm in front of a mirror with the affected arm hiding behind the mirror. They will watch the reflection of the unaffected arm as they perform the exercises to provide visual feedback that the affected arm is performing the exercises. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
45804857|NCT05925673|Other|Neuromuscular Stimulation (NMES)|Participants will use a portable NMES machine to stimulate the wrist extensors and flexors of the affected arm at a low intensity with the arm relaxed. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
45804858|NCT05925673|Other|Mirror Therapy + NMES|Participants will perform exercises with their unaffected arm in front of a mirror with the affected arm hiding behind the mirror. They will watch the reflection of the unaffected arm as they perform the exercises to provide visual feedback that the affected arm is performing the exercises. During the exercises they will have a portable NMES machine set up to stimulate the wrist extensors and flexors of the affected arm at a low intensity with the arm relaxed. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
45804859|NCT05925660|Diagnostic Test|Mucorales PCR (MucorGenius, PathoNostics, Maastricht, The Netherlands)|Mucorales PCR screening twice weekly during hospitalisation
45804860|NCT05925647|Drug|Messenchymal stem cell secretome|Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
45804861|NCT05925647|Drug|Placebo|NaCl 0,9% infusion
45804862|NCT05925634|Behavioral|RPE (usual care)|Patients in the active comparator group will follow standard exercise prescription protocols in cardiac rehabilitation.
46073777|NCT04283357|Device|Virtual Reality|Exercise with virtual reality
45653751|NCT05554211|Drug|Tranexamic acid|The intervention is a topical application of 50 cc's of 3% tranexamic acid. In the operating room, TxA irrigation will be administered following gentamicin irrigation. TxA irrigation solution will be the last irrigation used prior to wound closure in order to assure maximum benefit derived from TxA administration, if any.
45653752|NCT05554211|Drug|Normal saline|The intervention is a topical application of 50 cc's of 3% tranexamic acid. In the operating room, control NS irrigation will be administered following gentamicin irrigation. NS irrigation solution will be the last irrigation used prior to wound closure in order to assure maximum benefit derived from TxA administration, if any.
45804863|NCT05925634|Behavioral|GXT+THHR (intervention)|Patients in the personalized care group will perform a graded exercise test and the peak heart rate from the test will allow the researcher to calculate a target heart rate range (THRR). Then, the patients will receive psychoeducational feedback (PF) about their test results and exercise performance. After PF, their THRR will be reviewed and how it will be used to guide exercise intensity in CR will be discussed.
46073778|NCT02820558|Drug|Substance P|
45936465|NCT00048386|Biological|autologous neuroblastoma vaccine|A vaccine dose of 0.3 x 108 IL-2 secreting cells/patient/injection will be used. Injections will be given twice monthly for two months, then monthly for four months, for a total of eight vaccine injections over six months.
45804864|NCT05925621|Drug|Lecanemab|Observational study
46073779|NCT04043299|Drug|100% Oxygen|High flow cylinder oxygen will be administered to women with fetal distress during labor
45452530|NCT03172364|Other|Micellar cleanser|Participants will apply the micellar cleanser topically twice a day (morning and evening). Micellar cleanser will be applied on cotton pad and wiped over the entire face and closed eye to gently cleanse. No need to rub or rinse the micellar cleanser.
45804865|NCT05925608|Combination Product|CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs)|CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs) delivered with the Helix transendocardial delivery catheter
45804866|NCT05925595|Device|DM Iniettabile Ginocchio|Knee injection of the investigational device versus active comparator (Jonexa).
45804867|NCT05925582|Other|vestibular based exercise program|this group's participants will involve in vestibular based exercise program
45804868|NCT05925582|Other|calisthenic based exercise program|this group's participants will involve in calisthenic based exercise program
45936466|NCT00147979|Device|Bridging by PTFE with bounded heparin|Bridging by PTFE with bounded heparin
45936467|NCT00147979|Device|Bridging by PTFE without bounded heparin|Bridging by PTFE without bounded heparin
45936468|NCT00148018|Drug|Bortezomib|
45936469|NCT00148018|Drug|Dexamethasone|
45936470|NCT00148057|Behavioral|Low-fat diet|
45936471|NCT00081822|Drug|clofarabine|Clofarabine should be administered by daily intravenous infusion over 2 hours.Following demonstration of DLT at Dose Level -I (22.5 mg/m2/day days 2-6) and demonstration that Dose Level -II (15mg/m2day days 2-6) is the 'optimal phase II dose', an additional Dose Level -1½ (20mg/m2/day, days 2-6) will be added to explore an increased dose of clofarabine intermediate between Dose Levels -I and -II.
45936472|NCT00081822|Drug|Ara-C|Ara-C: Administer Ara-C by continuous infusion of 100mg/m2/day on days 1 to 7 for cycle 1, and on days 1 to 5 for cycles 2 & 3.
46073780|NCT04043299|Drug|21% oxygen|High flow cylinder packaged medical air will be administered to women with fetal distress during labr
45452531|NCT03172364|Other|Micellar foaming cleanser|Participants will use the micellar foaming cleanser topically twice a day (morning and evening). Micellar foaming cleanser will be massaged gently onto wet skin on the face using fingertips. After which participants will rinse thoroughly and pat the skin dry.
45452532|NCT04474210|Drug|JNJ-56136379|Participants will receive JNJ-56136379 tablets orally.
45804869|NCT05925569|Other|Best Practice Advisory Computerized Alert|For patients randomly assigned to the BPA Alert Group, an on-screen electronic alert will be issued during the outpatient clinical encounter than notifies the clinician that their patient should be screened for PA. The clinician will be provided with on-screen details of which patient-specific risk factors qualified them for PA screening and with an option to order a plasma renin activity, aldosterone, and basic metabolic panel. If screening labs are ordered, the clinician will also receive an option to order an eConsult for expert guidance on interpretation of the test results. If the clinician does not order the PA screening labs, they will be able to continue with clinical EHR documentation but will need to select a reason they opted not to follow the alert's evidence-based clinical practice recommendation.
45936473|NCT00148096|Device|Mechanical Heat Recovery Ventilation|De-humidification without loss of heat
45936474|NCT00048425|Drug|Levosimendan|
45936475|NCT00148135|Drug|Carboplatin|
45936476|NCT00148135|Drug|Gemcitabine|
45936477|NCT00148135|Drug|Capecitabine|
45936478|NCT00148174|Behavioral|Intensive telephone followup|Telephone calling
45936479|NCT00399711|Drug|repaglinide and metformin combination tablet|
45936480|NCT00399711|Drug|rosiglitazone and metformin combination tablet|
45936481|NCT00148252|Drug|Mycophenolate mofetil withdrawal|
45936482|NCT00148252|Drug|Cyclosporione A withdrawal|
45936483|NCT00148291|Drug|Patients were randomized to receive either docetaxel 60 mg/m2 on day 1 or vinorelbine 25 mg/m2 on days 1and 8, repeated every 21 days over four cycles.|
45936484|NCT00148330|Drug|Triamcinolone acetate|When indicated, intravitreal triamcinolone (0.1 ml of Kenacort 40© [40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia]) was injected into the vitreous under sterile conditions in a minor procedures area.
45452533|NCT00078767|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|12 weeks of Trauma-Focused CBT (TF-CBT)for youth and parent
45452534|NCT00078767|Drug|Sertraline Pill|12 weeks of Sertraline pill, flexible dosage of 50-150 mg/day, to be administered while receiving TF-CBT
45452535|NCT00078767|Drug|Placebo Oral Tablet|12 weeks of Placebo pill, flexible dosage, of 50-150 mg/day, to be administered while receiving TF-CBT
45452536|NCT04474288|Diagnostic Test|SARS-CoV-2 antibody testing|venipuncture for SARS-CoV-2 IgG
45452537|NCT03208088|Device|etafilcon A Investigational Toric Multifocal Contact Lens|Test Lens 1
45653753|NCT05612165|Device|Transcranial Direct Current Stimulation(tDCS)|The tDCS intervention was conducted for 20 minutes(1000μA) each time, 5 times a week for 2 weeks, a total of 10 times.
45653754|NCT05612165|Device|Sham Transcranial Direct Current Stimulation(sham tDCS)|The sham tDCS intervention was conducted for 20 minutes(0μA) each time, 5 times a week for 2 weeks, a total of 10 times.
45653755|NCT05554055|Biological|Anti Xa activity measurement.|Arterial blood samples of 3cc will be taken during the procedure at each ACT. Blood samples will be sent to the lab for anti Xa activity measurement.
45804870|NCT05925556|Behavioral|Communal Coping Intervention|The components of the intervention were described in the experimental arm.
45936485|NCT00148369|Drug|Safety observation|Subjects previously enrolled in a GDNF protocol observed for 2 years after discontinuation of drug.
45653756|NCT05558345|Behavioral|Contingency Management|A positive reinforcement behavioral treatment with escalating rewards for consecutive negative urine tests, starting at $10 and capped at a maximum of $40 per negative result.
45653757|NCT05543291|Behavioral|renal function|levels of eGFR
45653758|NCT05549921|Biological|NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)|NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)
45653759|NCT05549843|Other|Manual therapy|Each session will last approximately 50-60 minutes, with 1 physiotherapy session per week over a period of 3 weeks. Each session is made up of 10 steps, of which 9 correspond to manual interventions commonly used in the field of manual therapy.
45653760|NCT05553899|Radiation|PET-MRI|magnetic resonance imaging with positron emission tomography scanning using the tracer 18F-FDG
45936486|NCT00048464|Procedure|Infusion of Activated & Expanded Autologous T Cells|
45936487|NCT00405808|Drug|Rimonabant|Once daily in the morning
45936488|NCT00405808|Drug|Placebo|Once daily in the morning
45936489|NCT00081900|Drug|DENSPM )|Each patient will receive DENSPM at an initial dose of 30mg/m^2, then escalating to 120mg/m^2, single IV infusion on D1,3,5,8,10,12 of every 28 days as one cycle, planned for 8 cycles if no withdrawn occur
45936490|NCT00405847|Drug|Dexmedetomidine|
45936491|NCT00148408|Drug|Montelukast|
45653761|NCT05553821|Other|Cold sand bag|A sand bag weighing 3.5-4 kg is applied to the CAG area of patients.
45653762|NCT05553821|Other|A sand bag|A sand bag
45653763|NCT05543213|Behavioral|Action Observation Therapy|A video clip of a series of exercises is shown to the patients, then they practice them according to mirror neurons and observational learning.
45653764|NCT05543135|Diagnostic Test|basic audiological evaluation|pure tone audiometry&immitancemetry
45653765|NCT05543057|Radiation|3DCRT|Three-dimensional conformal radiotherapy (3DCRT)
45653766|NCT05549375|Device|MyHand System Hand Rehabilitation|15 1-hour patient specific sessions using the MyHand System to help improve Hand function in the affected hand of stroke survivors
45653767|NCT05700617|Drug|1:1 Randomization to receive milrinone or dobutamine|Randomized to receive either inotropic agent: milrinone or dobutamine
45653768|NCT05700617|Drug|1:1 Randomization to receive dobutamine or milrinone|Randomized to receive either inotropic agent: milrinone or dobutamine
45653769|NCT05542979|Drug|HH-003 injection|HH-003 injection is administrated via I.V. infusion
45653770|NCT05542979|Drug|Placebo|Placebo is administrated via I.V. infusion
45653771|NCT05542745|Device|palatal and buccal retraction|comparison
45653772|NCT05553743|Biological|COVID-19 Exposure|Have been or may have been exposed to COVID-19.
45804871|NCT05925543|Procedure|Kasai portoenterostomy operation.|Kasai portoenterostomy operation for biliary atresia patients.
45804872|NCT05925530|Drug|Durvalumab|Participants that go on to receive surgery, will receive durvalumab for up to four cycles prior to surgery. Participants that go on to receive CRT will receive durvalumab for up to two cycles prior to CRT. All participants will receive durvalumab every four weeks until disease progression or recurrence or up to 12 months following surgery/CRT, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
45804873|NCT05925517|Other|Graded Motor Imagery (GMI)|"GMI includes three stages. Each session will be 30 minutes, and the GMI program will span over 8 weeks. The first 3 weeks will focus on lateralization, followed by 3 weeks of motor imagery, and the final 2 weeks will involve mirror therapy.~Lateralization: Patients will be asked to differentiate whether the extremities shown in the Recognise™ Knee application belong to the right or left side of their body.~Motor Imagery: Patients will be instructed to imagine slowly and smoothly moving their affected extremities to the posture depicted in the photos in the Recognise™ Knee application and then returning to the starting position.~Mirror Therapy: Using a mirror measuring 90x60 cm² placed between the lower extremities, patients will be instructed to progressively move only their unaffected extremity, then their affected extremity, and finally both extremities."
45936492|NCT00148408|Behavioral|Education|
45452538|NCT03208088|Device|etafilcon A Investigational Toric Multifocal Contact Lens|Test Lens 2
45653773|NCT05553743|Drug|Antibiotic|Have or have not been prescribed one of several commonly used antibiotics including azithromycin, amoxicillin and clavulanic acid, amoxicillin, or nitrofurantoin.
45653774|NCT05553665|Procedure|Medical thoracoscopy|Medical thoracoscopy is a minimally invasive procedure to have access to pleura with combination of visual and medical instrument. The procedure is done with local and light anesthesia. Medical thoracoscopy plays role in basic diagnosis and therapeutic.
45653775|NCT05553665|Diagnostic Test|CRP, D-dimer, ADA, ANA, C3 C4 complements, CA-125, Xpert MTB, LE cell, cytology and histopathology|CRP, D-dimer, ADA, ANA, C3 C4 complements, CA-125, Xpert MTB, LE cell, cytology and histopathology taken from specimen of effusion and smear
45653776|NCT05553665|Drug|Lidocain, fentanyl and midazolam|local anesthetic: lidocaine 2%, fentanyl 100 mg and midazolam 2 mg
45936493|NCT00048503|Drug|ZARNESTRA, tipifarnib, R115777|
45936494|NCT00148447|Drug|escitalopram|
45936495|NCT00043134|Drug|decitabine|
45936496|NCT00048620|Drug|N-acetylgalactosamine 4-sulfatase|
45936497|NCT00148525|Behavioral|Social Cognitive Theory|6 mo dietary intervention. This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on social cognitive theory.
45936498|NCT00148525|Behavioral|goal system theory|This arm received a 6 mo diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on goal systems theory and delivered by an automated telephone system.
45936499|NCT00148564|Drug|olanzapine|treatment with either Olanzapine or Ziprasidone
45653777|NCT05553587|Drug|Amara drops|"The investigational drug is approved with a reduced dossier without indication according to Art. 25 para. 1 KPAV (SR 812.212.24). This study follows the indication text licensed by Swissmedic: … Weleda Amara-Drops can be used for digestive complaints such as heartburn, flatulence and bloating after meals, to stimulate the bile flow and for loss of appetite and nausea. The effect of Weleda Amara drops is based on a balanced mixture of medicinal plants with tonic (invigorating) and aromatic bitter substances, which are suitable for stimulating digestion. Further, no side effects have been reported in past studies so far. All these reasons lead us to the conclusion that this study is only associated with minimal risks and should be classified in risk category A."
45653778|NCT05553509|Other|PER CUTANEOUS TRANSLUMINAL ANGIOPLASTY|SURGICAL DEBRIDEMNT
45804874|NCT05925517|Other|Transcutaneous Electrical Nerve Stimulation (TENS)|Application will be performed using a TENS device and four separate 2 × 2 inch self-adhesive electrodes. The current will be applied to the most painful area of the affected knee. The four self-adhesive electrodes will be positioned in a square pattern, approximately 5 cm apart, centered over the pain point. Conventional TENS will be applied for 30 minutes at a frequency of 100 Hz, pulse width of 100 μs, and intensity below 10% of the motor threshold.
45804875|NCT05925517|Other|Conventional Physiotherapy Program|The routine 60-minute program for OA patients in conventional physiotherapy includes warming up, core stability, pelvic and hip stability, gluteus medius strengthening, knee control and stability (knee flexion and extension control, lunge exercises), knee strengthening exercises (wall-assisted leg press with a ball, step-ups with elastic bands), and functional exercises.
45653779|NCT04322747|Diagnostic Test|Distortion product otoacoustic emissions (DPOAE)|Audiometry for extended high frequencies, DPOAE, and, ECochG measurements will be collected before and after skull-based surgeries.
45653780|NCT02629159|Drug|Placebo for Adalimumab|Administered by subcutaneous injection once every other week
45936500|NCT00148564|Drug|Ziprasidone|treatment with either Olanzapine or Ziprasidone
45936501|NCT00148603|Drug|montelukast|
45936502|NCT00148642|Device|silver salts coated endotracheal tube|intubation with silver coated tube
45653781|NCT02629159|Drug|Adalimumab|Administered by subcutaneous injection once every other week
45653782|NCT02629159|Drug|Placebo for Upadacitinib|Tablets taken orally once a day
45653783|NCT02629159|Drug|Upadacitinib|Tablets taken orally once a day
45936503|NCT00148642|Device|uncoated endotracheal tube|intubation
45653784|NCT05548985|Drug|Midodrine Oral Tablet|oral midodrine tablet (5 mg) 90 min before performing spinal block
45804876|NCT05925517|Other|Home Exercise Protocol|The home exercises will include a warm-up consisting of a 10-minute walk at a normal pace on a flat surface while gently stretching the hamstring and calf muscles. The exercises will also involve straight leg raises, terminal knee extension, isometric contractions of the quadriceps femoris and adductor muscles using a pillow for support, toe raises, single-leg standing, toe taps, and quadriceps strengthening exercises included in the session.
45804877|NCT05925504|Drug|Luspatercept|The starting dose is 1.75mg/kg once every 3 weeks by subcutaneous injection. For rapid hemoglobin rise after 2 consecutive doses at the 1.75mg/kg starting dose, decrease the dose of Luspatercept or interrupt treatment. Otherwise, continue treatment with the dose of 1.75mg/kg once every 3 weeks.
45804878|NCT05925491|Drug|Pembrolizumab|Pembrolizumab administration in combination with chemotherapy for 3 cycles, followed by standard of care
45653785|NCT05548985|Drug|Metoclopramide|oral placebo (metoclopramide 10 mg tablet). 90 min before performing spinal block
45653786|NCT05548829|Biological|Disease severity|Observational, based on biological outcome of Covid-19 infeection. Comparing pheripheral biomakers of Covid-19 patients admitted to hospital due to infection versus Covid-19 patients that recovered at home.
45653787|NCT05698979|Drug|BOTOX INJECTION|"The patient will be treated with a single session with botulinum toxin A injections at the hospital, and the judgmental criteria will be assessed at 1, 3 and 6 months post injections.~The injections will be made in 4 injection points at the palmar or distal plantar fold, at the level of the neurovascular beams, 2h after topical anesthesia by lidocaine cream under occlusion, associated or not with nitrous oxide inhaled at the time of the injections (BOTOX® 100 U).~In the event of multiple lesions, a single limb is injected based on clinical severity (ulcer, gangrene) and ischemia parameters (lowest TCPO2)."
45804879|NCT05925478|Procedure|Ptergyopalatine Fossa Block|Injection of local anesthetic into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
45936504|NCT00048659|Drug|YM598|
45936505|NCT00148681|Drug|Herceptin|Intravenously every week for 12 weeks (weeks 1-12) Intravenously every three weeks for 40 weeks (weeks 32-72)
45936506|NCT00148681|Drug|Navelbine|Intravenously every week for 12 weeks
45936507|NCT00148681|Drug|Doxorubicin|Every 3 weeks for 12 weeks
45936508|NCT00148681|Drug|Cyclophosphamide|Intravenously every 3 weeks for 12 weeks
45936509|NCT00148681|Drug|Paclitaxel|Weekly for 12 weeks (or a similar schedule)
45936510|NCT00148720|Drug|Capecitabine|Taken orally twice a day for 14 days and treatment will repeat every 21 days (1 cycle) for 4 cycles
45936511|NCT00148837|Drug|Peg-interferon alpha 2b (drug)|
45936512|NCT00148837|Drug|Ribavirin (drug)|
45936513|NCT00148837|Drug|Prazosin (drug)|
45936514|NCT00148876|Drug|Capecitabine|Capecitabine 2500 mg/m² orally day 1-14 q day 22
45936515|NCT00148876|Drug|Trastuzumab|Trastuzumab 6 mg/kg body weight every 3 weeks i.v.
45936516|NCT00048698|Procedure|TMS|
45936517|NCT00048698|Procedure|EEG|
45936518|NCT00148915|Drug|ibandronate|
45936519|NCT00148915|Drug|Placebo|matching placebo
45936520|NCT00148993|Biological|Tumor Cell Vaccine|
45936521|NCT00149032|Procedure|DLI sensitized against antigens expressed by the host.|
45653788|NCT05553431|Device|Left bundle branch pacing|Left bundle branch pacing by a CRT device or dual-chamber pacemaker through the pacing lead at left bundle branch region
45804880|NCT05925465|Procedure|Maxillary and mandibular nerve block|receive bilateral combined maxillary and mandibular nerve block
45804881|NCT05925465|Other|Control|not receive any nerve block
45804882|NCT05925452|Drug|GenaKumab|GenaKumab 0.5mg/kg dose group : GenaKumab 0.5 mg/kg, Subcutaneous injection, Q4w, Dose adjustable, The maximum is 4.0 mg/kg; GenaKumab 4.0 mg/kg dose group : GenaKumab 4.0 mg/kg fixed dose, Subcutaneous injection, Q4w
45804883|NCT05925439|Device|Tuohy needle group|Ultrasound-guided S1 transforaminal epidural block with Touhy needle
45936522|NCT00149071|Device|rTMS|15 treatments of rTMS active with a duration of 30 minutes each
45936523|NCT00149071|Device|TMS|Transcraniel Magnetic Stimulation active and sham
45804884|NCT05925439|Device|Quincke needle group|Ultrasound-guided S1 transforaminal epidural block with Quincke needle
45804885|NCT05925413|Drug|Cadonilimab+TACE|Cadonilimab: 15mg/kg Q3W Day1 Select the best TACE treatment strategy. Traditional TACE (cTACE) or DEB-TACE can be selected. TACE treatment can be continued as needed based on disease control. The combination of cadonilimab is given 3 to 7 days after the first TACE treatment, and the subsequent administration of cardonilizumab is given once every 3 weeks, if the time overlaps with TACE treatment, it is generally administered 3 to 7 days after TACE treatment. Treatment was discontinued until intolerable toxicity, death, withdrawal of informed consent, initiation of a new antitumor therapy, or other reason specified in the protocol, whichever occurs first. Patients in this study received cadonilimab for up to 24 months.
45804886|NCT05925400|Device|Virtual Reality during Embryo Transfer|Patients randomized to the study group, will be provided with the VR headset. The VR exposure will take place 5 minutes before the Embryo Transfer (ET) and a 10 min immersion after the ET
45936524|NCT00149071|Device|rTMS|active Transcranial Magnetic Stimulation
45936525|NCT00149071|Device|rTMS|daily for three weeks
45936526|NCT00149110|Procedure|Sleep deprivation|3 days with a normal night between
45936527|NCT00149110|Procedure|Light therapy|Daily light therapy for 29 weeks
45936528|NCT00149110|Procedure|Diurnal rhythms|Keeping the day-night cycle constant by use of educational measures
45936529|NCT00149110|Behavioral|Exercise|Moderate intensity daily exercise for 30 minutes at least
45936530|NCT00149110|Drug|duloxetine|60 mg daily
45936531|NCT00149110|Drug|duloxetine|60 mg daily
45452539|NCT03208088|Device|etafilcon A Investigational Toric Multifocal Contact Lens|Tes Lens 3
45936532|NCT00149149|Drug|Zinc carnosine|
45936533|NCT00149188|Drug|Lanreotide (Autogel formulation)|
45936534|NCT00043212|Drug|Dendritic cell immunotherapy|
45936535|NCT00149266|Procedure|Surgery: abdominal and transhiatal approach|
45936536|NCT00149266|Procedure|Surgery: left thoraco-abdominal approach|
45936537|NCT00048776|Drug|Pletal|
45936538|NCT00149344|Radiation|Vertical scar versus inferior pedicle reduction mammoplasty|Vertical Scar Reduction Mammoplasty Inferior Pedicle Reduction Mammoplasty
45452540|NCT03208088|Device|etafilcon A Investigational Toric Multifocal Contact Lens|Test Lens 4
45452541|NCT03208088|Device|etafilcon A Investigational Toric Multifocal Contact Lens|Control Lens
45936539|NCT00149383|Drug|Rosiglitazone|
45936540|NCT00149383|Drug|Placebo|
45936541|NCT00149422|Device|NT-proBNP measurements|
45936542|NCT00048854|Drug|Sertraline|Patients who meet study criteria will be given 50 mg per day of sertraline to be taken an estimated 2 weeks before menstruation.
45936543|NCT00048854|Other|Treatment as usual (TAU)|At the TAU baseline visit, patients will be told of their diagnosis of PMS/PMDD. Those patients who decide to seek treatment outside of the study protocol or do not wish to seek treatment will be asked to participate in the TAU part of this protocol. Patients in TAU will be contacted monthly to obtain monthly information about how they have been feeling (blinded ratings) using the study measures.
46073781|NCT04705116|Biological|COVID-19 vaccine|At least one dose of a COVID-19 vaccine.
45452542|NCT00889486|Drug|TZP-102|
45452543|NCT00889486|Drug|Placebo|
45653789|NCT05553353|Device|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation that is an FDA approved technique to treat depression.
45653790|NCT05553197|Behavioral|Cognitive Behavioural Therapy (CBT)|20 sessions of face-to-face, individual CBT
45653791|NCT05553197|Other|Ecological Momentary Assessment (EMA)|Two four-week blocks of twice daily ecological momentary assessment (EMA) of symptoms and inter-session processes
45653792|NCT05542511|Diagnostic Test|NanoString nCounter assay|The NanoString nCounter assay by NanoString Technologies will be used to measure blood transcriptional signatures in presumptive TBs. Non-TB participants with elevated transcriptional signature readouts will be investigated for respiratory infections other than Mycobacterium tuberculosis using a next-generation sequencing (NGS)-based respiratory pathogen panel.
45936544|NCT00149461|Behavioral|Written Asthma Action Plan|
45936545|NCT00149500|Behavioral|Coaching|Patients received monthly calls to assist in behavioral change relative to asthma care
45936546|NCT00081978|Drug|TMC125|
45936547|NCT00149539|Drug|Buprenorphine/naloxone|
45936548|NCT00048971|Genetic|mutation analysis|
45936549|NCT00048971|Genetic|polymorphic microsatellite marker analysis|
45936550|NCT00149578|Drug|Gemcitabine Oxaliplatin 5FU and Leucovorin|
45936551|NCT00149617|Drug|Buspirone|
45936552|NCT00043329|Drug|Actimmune Registry|as administered by physician
45936553|NCT00149656|Dietary Supplement|Multivitamins|dietary supplement of multivitamins
45936554|NCT00149656|Dietary Supplement|Selenium|dietary supplement of selenium only
45936555|NCT00149656|Other|Placebo|placebo pill
45936556|NCT00149695|Behavioral|Weekly home delivery of milk products|
45936557|NCT02957500|Device|Mediclore® (adhesion barrier)|
45936558|NCT00049010|Genetic|comparative genomic hybridization|
45936559|NCT00049010|Genetic|cytogenetic analysis|
45936560|NCT00049010|Genetic|fluorescence in situ hybridization|
45936561|NCT00049010|Other|immunohistochemistry staining method|
45936562|NCT00149773|Behavioral|Cognitive Therapy|
45804887|NCT05925387|Other|CANAP Education|The volunteer group included in the research consists of Yeditepe University Nursing Students. All nursing students over the age of 18, at all levels of the nursing program, will be included in the study based on voluntary participation, in accordance with the sample size. The purpose and design of the research will be explained to the 1st, 2nd, 3rd, and 4th-year nursing students. The announcement of the study will be made through Yeditepe University Nursing's social media accounts, and a consent link provided. Participants who sign the document in the consent link and upload it to the shared Google Drive received the pre-test link. Participants who complete all the procedures are provided with a participant certificate prepared by the researchers as an incentive.
45452544|NCT00078377|Drug|Armodafinil|Armodafinil 250 mg once daily in the morning
45804888|NCT05925374|Behavioral|Substance use stigma training|The intervention is an interactive professional educational training that is designed to manipulate behavioral and normative beliefs in order to address bias and alter professional practices towards patients who use drugs.
45936563|NCT00082095|Drug|Pegylated liposomal doxorubicin|Type=exact number, unit=mg/m2, number=40, form=infusion, route=intravenous. Pegylated liposomal doxorubicin will be administered on Day 1 of each cycle. Cycle will be repeated every 28 days, up to 1 year.
45936564|NCT00082095|Drug|Capecitabine|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Capecitabine will be administered at a dosage of 1000 mg/m2 twice daily for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
45936565|NCT00149812|Behavioral|Family Functioning Intervention|
45653793|NCT05552885|Other|Evaluation|The Standardized Mini Mental Test, The American National Institutes of Health Stroke Scale, the Figure of 8 Walk Test, the double-task octagonal gait test, the timed up-and-go test, the 10-meter walk test, and the modified four-square step test will be applied to the stroke patients.
45936566|NCT00149851|Drug|Tegaserod|
45653794|NCT04982263|Diagnostic Test|Blood coagulation profile|Venous blood sample for measurement of blood coagulation profile
45936567|NCT00149929|Drug|Mycophenolate sodium (enteric coated)|
45936568|NCT00049088|Drug|docetaxel|Given IV
45936569|NCT00049088|Biological|bevacizumab|Given IV
45936570|NCT00049088|Other|laboratory biomarker analysis|Correlative studies
45452545|NCT00078377|Drug|Armodafinil|Armodafinil 150 mg once daily in the morning
45452546|NCT00078377|Drug|Placebo|Matching placebo tablets once daily
45653795|NCT05548673|Behavioral|Psychoeducation|The implementation phase is planned for Ankara Yıldırım Beyazıt University (AYBU) Nursing Faculty students. The stress management training program, which consists of eight sessions, is completed in 8 weeks, once a week.
45653796|NCT04727359|Other|FIT64b model project|FIT64b model project: The SHI funds AOK Baden-Württemberg and SVLFG (as an agricultural health insurance fund) have established a contract (duration = at least eight year) with the model hospital for an alternative remuneration / financing of patients treated in the model hospital (FIT64b hospital, UKT). This contract encourages the model hospital an alternative treatment of their patients (with the above mentioned SHI fund), for example fewer inpatient and more outpatient treatment.
45936571|NCT00049088|Other|pharmacological study|Correlative studies
45936572|NCT00149968|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|Patient on MMF treatment completes questionnaire and switch to equimolar doses of Myfortic. Maximum daily dose 1440 mg
45936573|NCT00082134|Drug|ILX651|
45936574|NCT00405886|Drug|Neramexane|Oral tablets, duration: 16 weeks
45936575|NCT00405886|Drug|Placebo|Oral tablets, duration: 16 weeks
45936576|NCT04725448|Drug|Toripalimab|240mg, ivgtt, d1, every 3 weeks until disease progress or intolerable toxicity, up to 2 years of administration
45936577|NCT04725448|Drug|Bevacizumab|7.5mg/kg, ivgtt, d1, every 3 weeks, up to 2 years of administration
45936578|NCT04725448|Drug|Nab-paclitaxel|260mg/m2,d1 or 130mg/m2,d1,8, ivgtt, every 3 weeks, up to 6 cycles
45936579|NCT04725448|Drug|Carboplatin|AUC=4～5, d1, ivgtt, every 3 weeks, up to 6 cycles
45936580|NCT00405925|Drug|Trizivir|
45936581|NCT00405925|Drug|zidovudine,lamivudine,abacavir|zidovudine 300 mg bid, lamivudine 150mg bid, abacavir 300mg bid
45936582|NCT00049166|Drug|erlotinib hydrochloride|Given orally
46073782|NCT02820246|Other|nutrition|type and amount of food eaten or type of oral nutritional supplements as well as enteral or parenteral nutrition
45452547|NCT01107496|Drug|SPN-812|Viloxazine, oral, 300mg, tid, 6 weeks
45452548|NCT01107496|Drug|Placebo|Placebo, oral, tid, 6 weeks
45452549|NCT05085314|Procedure|Ngenuity digital 3D microscope|Cataract surgery under topical anesthesia with the Ngenuity digital 3D microscope, Alcon, Fort Worth, TX
45936583|NCT00049166|Drug|cisplatin|Given IV
45936584|NCT00049166|Radiation|intensity-modulated radiation therapy|Undergo intensity modulated radiation therapy
45936585|NCT00049166|Other|laboratory biomarker analysis|Correlative studies
45936586|NCT00082212|Biological|Cetuximab|400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles
45936587|NCT00150007|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
45936588|NCT00150046|Drug|Everolimus|
45936589|NCT00150085|Drug|cyclosporine micro-emulsion|
45936590|NCT00082251|Drug|Niacin extended release and simvastatin tablets|
45936591|NCT00049244|Drug|capecitabine|
45936592|NCT00049244|Drug|ixabepilone|
45936593|NCT00150124|Drug|MTZ+LT4|
45936594|NCT00150124|Drug|Methimazole|
45936595|NCT00150202|Drug|pegaptanib sodium|
45936596|NCT00049283|Drug|erlotinib hydrochloride|Given orally
45936597|NCT00049283|Drug|docetaxel|Given IV
45936598|NCT00049283|Radiation|radiation therapy|Undergo radiotherapy
45936599|NCT00049283|Procedure|therapeutic conventional surgery|Undergo neck dissection
45936600|NCT00049283|Other|laboratory biomarker analysis|Correlative studies
45936601|NCT00049283|Other|pharmacological study|Correlative studies
45936602|NCT00150241|Drug|CP-526,555 (varenicline)|
45936603|NCT00043368|Drug|PF-3512676|PF-3512676 IV at doses: 0.01mg/kg, 0.16mg/kg and 0.32mg/kg PF-3512676 Injection given by subcutaneous injection at doses: 0.04mg/kg, 0.16mg/kg, 0.20mg/kg, 0.28mg/kg, 0.32mg/kg, 6mg, 10mg, 40mg.
45936604|NCT00150280|Drug|celecoxib and ibuprofen SR|
45936605|NCT00150319|Drug|Vfend®; I.V.|
45936606|NCT00150358|Drug|Sildenafil Citrate|
45936607|NCT00049361|Drug|temozolomide|
45936608|NCT00049361|Drug|thalidomide|
46073783|NCT00961571|Drug|sunitinib and capecitabine|Sunitinib 37.5 mg po once daily Capecitabine 1000 mg po twice daily
45653797|NCT05548595|Dietary Supplement|Investigational|2 tablets are taken with water around the same time every day, ideally after a meal
46073784|NCT02818608|Device|Functional Electrical Stimulation (FES)|Functional Electrical Stimulation (FES) + Sham Transcranial direct brain stimulation (tDCS)
45653798|NCT05548595|Other|Placebo|2 tablets are taken with water around the same time every day, ideally after a meal
45653799|NCT04981951|Drug|Dexmedetomidine|Highly selective α2-adrenergic receptor agonist. With sedative, analgesic, peri-operative sympatholytic and hemodynamic stabilizing properties.
45653800|NCT05548361|Combination Product|active chlorhexidine and placebo probiotic|the randomized patients will be receive active chlorhexidine rinse and placebo probiotic
45653801|NCT05548361|Combination Product|placebo chlorhexidine and active probiotic|the randomized patients will receive placebo chlorhexidine rinse and active probiotic
45804889|NCT05925361|Procedure|Laparoscopic pedicled single flap peritoneum vaginoplasty|After the perineal part of the operation, in which the vaginal cavity will be dissected, a laparoscopy will be started. During laparoscopy, a single flap peritoneum will be harvested. The flap will be checked for adequate blood supply. The flap will be brought down to the (neo) vaginal cavity and sutured around a dilatator cylinder wise.
45804890|NCT05925348|Diagnostic Test|Patients with cardiopulmonary bypass|"Due to the observational design of the study, no study-specific interventions are performed.~Blood samples are measured to analyze blood-levels of endotoxin"
45804891|NCT05925335|Device|Transseptal Transcatheter Mitral valve-in-valve Replacement|Transcatheter transfemoral mitral valve-in-valve replacement is an alternative surgery in patients with severe dysfunction of a degenerated mitral bioprosthesis and high surgical risk for repeat operation. The procedure is performed via femoral vein access. All procedures were carried out using intra-procedural TEE guidance to aid in transseptal puncture. After balloon septostomy, the bioprosthetic valve is introduced through the degenerative valve into the left ventricle and expanded in the mitral position during rapid ventricle pacing.
45936609|NCT00049361|Radiation|radiation therapy|
45936610|NCT00150397|Drug|Tofimilast|
46073785|NCT02818608|Device|Combination of Transcranial direct brain stimulation (tDCS) and FES|Real Functional Electrical Stimulation (FES) + Real Transcranial direct brain stimulation (tDCS)
46073786|NCT04284995|Drug|RUC-4 Compound|All patients will receive a single subcutaneous dose of RUC-4 in the Cardiac Catheterization Lab (CCL) before coronary angiography/percutaneous coronary intervention.
46073787|NCT02820948|Drug|Vitamin E ointment application|Before the skin stapling and after the subcutaneous irrigation with normal saline, sterile Vitamin E acetate ointment was applied in the subcutaneous tissue; 2 ml were applied in the suprapubic incision and 0.5 ml in the rest of port sites.
46073788|NCT04239378|Procedure|socket preservation|Autogenous dentin matrix and collagen membrane(test group) Bovine derived xenograft and collagen membrane (control group)
45452550|NCT05085314|Procedure|Conventional microscope|Cataract surgery under topical anesthesia with a conventional microscope
45653802|NCT05548361|Combination Product|active chlorhexidine and active probiotic|the randomized patients will receive active chlorhexidine rinse and active probiotic
45653803|NCT02628769|Drug|Solithromycin|
45653804|NCT02628769|Drug|Placebo|
45653805|NCT05698901|Drug|Agalsidase beta|The treatment is following local reimbursement criteria and judge by physician
45653806|NCT05552807|Drug|SCT-I10A|Administered intravenously
45653807|NCT05552807|Drug|SCT200|Administered intravenously
45653808|NCT05552807|Drug|paclitaxel|Administered intravenously
45653809|NCT05552807|Drug|docetaxel|Administered intravenously
45804892|NCT05925322|Behavioral|"Engage & Connect Psychotherapy"|9-weeks of weekly psychotherapy sessions focused on social reward exposure
45936611|NCT00150436|Drug|Pregabalin|
45936612|NCT00150475|Procedure|Powered Air purifying respirator|
45936613|NCT00049400|Drug|BMS-247550|BMS-247550 as a 3-hour infusion on Day 1 of a three-week cycle
45936614|NCT00082290|Other|massage therapy|
45936615|NCT00082290|Other|visit with a volunteer|
45936616|NCT00082290|Other|period of quiet time|
45936617|NCT00082290|Behavioral|questionaire about pain|
45936618|NCT00150514|Drug|Oralgen|
45936619|NCT00150514|Procedure|Nasal biopsy|
45936620|NCT00150514|Procedure|Nasal washing|
45936621|NCT00150514|Procedure|Peak nasal inspiratory flow|
45936622|NCT00150553|Drug|Extended-release carbamazepine|
45936623|NCT00150631|Drug|Candesartan|placebo controlled double blind
45653810|NCT04432909|Diagnostic Test|The level of CNV|The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. And the patient will be followed for up to 2 years.
45653811|NCT05698745|Procedure|bioespecimen samples|genetics Serology proteomics Single-cell RNA Hematology Biomarkers metabolome Biopsy microbiota
45653812|NCT04701619|Other|Immuno-inflammatory profile description in patients with ischemic stroke|Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers
45936624|NCT00082446|Biological|Live vaccinia virus vaccine|Dryvax®: 0.25 mL of vaccine will be administered by the standard route of scarification using a bifurcated needle on day 112 for Groups A, B, C, D and F.
45936625|NCT00082446|Biological|MVA Smallpox Vaccine|Imvamune/MVA-BN 1x10^8 will be administered intramuscularly to Group F on day 0 and day 28.
45936626|NCT00082446|Biological|MVA Smallpox Vaccine|Imvamune/MVA-BN Groups A, B C and E will be administered subcutaneously: 2x10^7, 5x10^7, 1x10^8, 1x10^8, respectively, on days 0 and day 28.
45936627|NCT00082446|Other|Placebo|Group E will receive sterile saline placebo for injection via scarification on day 112.
45936628|NCT00082446|Other|Placebo|Group D will receive sterile saline placebo for injection subcutaneously on day 0 and day 28.
45804893|NCT05925322|Behavioral|Symptom Review and Psychoeducation (SRP)|9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging
45804894|NCT05925309|Drug|Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem|Sulperazone 50mg/kg q8h is used intravenously from the first day to the 14th day after KP surgery. Ursodeoxycholic acid 20mg/kg/d p.o, starting from the 5th day after surgery for at least 2 years. Compound glycyrrhizin 20mg/d i.v, 1-4 days after operation, then switch to compound glycyrrhizin tablets 12.5mg b.i.d p.o until 6 months after KP. Methylprednisolone start at 4mg/kg/d i.v on the 8th day after operation, and decrease by 1mg/kg/d every three days. Starting at about the 15th day after operation, methylprednisolone 4mg/kg is given orally every other day, and the dose is gradually reduced at 10-12 weeks. Vitamin AD , D , E , K, are given orally from the 5th day after the KP for at least 2 months. Treatment of cholangitis: sulperazone 50mg/kg q8h i.v., and methylprednisolone could be used. If cholangitis is not controlled, imipenem or meropenem may be used.
45804895|NCT05925309|Drug|Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor|Compound sulfamethoxazole tablet (SMZ/TMP) 25 mg/kg/d p.o. and cefaclor 12.5 mg/kg/d p.o. alternately every 2 weeks, from post-operation day 15 to month 6.
45804896|NCT05925296|Device|magnetic stimulation|Patients in the Experimental group underwent ten sessions of double-site high frequency rTMS over the bilateral primary motor cortex of the lower leg and supplementary motor area, whereas patients in the Active Comparator group underwent ten sessions of single-site active magnetic stimulation with high frequency rTMS over the bilateral primary motor cortex of the lower leg. In addition, patients in the Sham Comparator group underwent 10 sessions of double sham rTMS on motor cortex.
46073789|NCT04283279|Other|Virtual reality exercise|"Participants will do exercises in a virtual environment, solving tasks that require cognitive efforts and motor/balance efforts. The virtual environment/tasks will be delivered through a head-mounted display (goggles). Difficulty will progress from standing/sitting, to walking on a treadmill. The environments that will be used will be both over-the-counter environments, as well as in-house designed environments."
46073790|NCT04283279|Other|Vestibular rehabilitation exercise|Vestibular rehabilitation exercises focus on head and eyes movements, as well as whole-body movements. The aim is to facilitate the use of other sensory organs than the vestibular organs, which will also be relevant to persons who are not receiving sufficient sensory information from the auditory system. The exercises will progress as tolerated, under careful supervision of trained therapists.
46073791|NCT04283279|Other|Control|Participants will not be randomised to either of the exercise interventions, but will be adviced to stay active
46073792|NCT02818686|Drug|TD-1473|
46073793|NCT02818686|Drug|Placebo|
46073794|NCT02860949|Drug|0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 100 mL|
46073795|NCT02860949|Procedure|Drug injection at Anterior soft tissue (25 mL)+Medial gutter area (25 mL)+Lateral gutter area (25 mL)+Posterior capsular infiltration (25 mL)|
45452551|NCT00886600|Drug|losartan potassium|losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
45653813|NCT05552729|Drug|Vitamin D|The patients were given vitamin D supplementation 48 hours after surgery, and the two groups were given different doses of vitamin D supplementation until the postoperative discharge criteria were met. To scientifically evaluate the application effect of early postoperative vitamin D intervention in the improvement of perioperative cognitive function in patients with gastrointestinal tumors.
45653814|NCT05548049|Device|Bone harvesting from ramus area with piezosurgery for autogenous bone augmentation|In this invervention, the piezo-surgical device settings were set to irrigation: '4', function: 'cortical', light: 'auto'. After the full-thickness flap was lifted with the periosteal elevator, superior and vertical osteotomies were performed with the OT-12 piezo-surgical tip. Lower horizontal osteotomies were performed using OT8-L or OT-8-R piezo tips according to the studied quadrant, combining the vertical osteotomy.
45804897|NCT05925283|Drug|Midazolam|oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
45804898|NCT05925283|Drug|Esketamine|intranasal esketamine 1mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
45804899|NCT05925283|Drug|midazolam and esketamine|oral midazolam 0.3mg/kg and intranasal esketamine 0.6mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
45804900|NCT05925270|Behavioral|mhGAP-Remote|One in-person session followed by standardized SMSs to reinforce the concepts learned in the first session. The intervention follows principles of the World Health Organization's Mental Health Gap Action Programme (mhGAP). Study interventionists can provide telephonic support to participants to implement the skills.
45804901|NCT05925270|Behavioral|mhGAP-Standard|Four in-person sessions with up to two booster sessions following the principles of World Health Organization's Mental Health Gap Action Programme (mhGAP).
45936629|NCT00049439|Biological|filgrastim|filgrastim (G-CSF) subcutaneously on days 5-21 and 28-42. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
45936630|NCT00049439|Drug|cyclophosphamide|Oral cyclophosphamide on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
45936631|NCT00049439|Drug|etoposide|Oral etoposide on days 1-3. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
45936632|NCT00049439|Drug|lomustine|Oral lomustine on day 1 (course 1 only). Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
45936633|NCT00049439|Drug|procarbazine hydrochloride|Oral procarbazine on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
45936634|NCT00150670|Drug|TS-1 and cisplatin|TS-1(40-60 mg per body surface area) was given orally, twice daily for 3 consecutive weeks, and 60 mg/m2 cisplatin was given intravenously on day 8, followed by a 2-week rest period, within a 5-week cycle.
45936635|NCT00150670|Drug|TS-1|TS-1(40-60 mg per body surface area) was given orally, twice daily for 4 consecutive weeks, followed by a 2-week rest period, within a 6-week cycle.
45936636|NCT00150709|Drug|Levetiracetam (Keppra)|
45936637|NCT00150748|Drug|Levetiracetam 166 mg|"Active Substance: Levetiracetam~Pharmaceutical Form: Tablet~Concentration: 166 mg~Route of Administration: Oral use"
45804902|NCT05925257|Other|ePRO application and proactive clinical care with nurses.|The investigators defined ePRO intervention as a weekly register of breast cancer patients' symptoms and supportive care needs using the study ePRO App combined with proactive follow-up by nurses guided by predefined clinical algorithms and a weekly cellphone message providing an educational video from a recognised cancer association or health institution. The intervention will be provided for six months with additional three months of post-intervention observation.
45936638|NCT00150748|Drug|Levetiracetam 250 mg|"Active Substance: Levetiracetam~Pharmaceutical Form: Tablet~Concentration: 250 mg~Route of Administration: Oral use"
45936639|NCT00150748|Drug|Levetiracetam 500 mg|"Active Substance: Levetiracetam~Pharmaceutical Form: Tablet~Concentration: 500 mg~Route of Administration: Oral use"
45936640|NCT00150787|Drug|LEVETIRACETAM|
45936641|NCT00150826|Drug|Quinapril|Quinapril will be started at 40mg daily and titrated to 80mg daily for 16 weeks.
45936642|NCT00150826|Drug|Placebo|Placebo will be given in a capsule form once daily for 16 weeks.
45936643|NCT00043407|Drug|CPG 7909|In the phase I portion of the protocol, patients will be included in escalating dose groups: 0.08, 0.12, 0.16, 0.36, 0.54 or 0.81 mg/kg of CPG 7909 Injection. Patients will be treated once weekly subcutaneously for 24 weeks. In the Phase II portion of the trial patients will be treated at the MTD or the highest dose of 0.81 mg/kg identified in the Phase I dose escalation portion of the trial. All patients in Phase I and Phase II will be treated until disease progression or a maximum of 24 weeks.
45936644|NCT00150865|Drug|ropivacaine|
45936645|NCT00150904|Procedure|venous blood puncture|
45936646|NCT00049556|Drug|gefitinib|
45452552|NCT00886600|Drug|Comparator: placebo|placebo capsules to losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
45653815|NCT05548049|Device|Bone harvesting from ramus area with conventional burs for autogenous bone augmentation|In control group, After the full-thickness flap is lifted with the periosteal elevator, using a thin #9 fissure burand the surgical handpiece S-11 Straight tip , the physiodispenser settings are according to the manufacturer's recommendations. The osteotomy was performed after it was adjusted to 40,000 rpm as appropriate. Bone incisions were completed with a round bur to combine the lower horizontal osteotomies and 2 vertical osteotomies. The osteotomies were completed with the help of a thin flat drill, and the block graft was carefully separated from the donor site.
45804903|NCT05925244|Other|Control Condition|Control (no alteration to body mass).
45804904|NCT05925244|Other|+12% Body Mass|Loaded walking exercise (12% increase in body mass using a weighted vest).
45804905|NCT05925244|Other|-12% Body Mass|Unloaded walking exercise (12% decrease in body mass using lower body positive pressure).
45804906|NCT05925231|Diagnostic Test|Box and Block Test|3 attempts of each subtest of the Box and Block Test performed according to the Czech Extended Version of Manual for the Box and Block Test
45804907|NCT05925218|Radiation|Radiotherapy as per standard of care|Adjuvant Radiotherapy +/- systemic therapy as per standard of care
45804908|NCT05925205|Procedure|Muscle energy technique combined with the physical therapy program.|A manual therapy technique
45804909|NCT05925205|Procedure|Strain counterstrain technique combined with the physical therapy program|A manual therapy technique
45804910|NCT05925205|Procedure|The physical therapy program|Electrotherapy and exercise.
45804911|NCT05925192|Other|Observational study|N/A - observational study
45936647|NCT00049556|Other|immunohistochemistry staining method|
45936648|NCT00049556|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
45936649|NCT00049556|Procedure|biopsy|
45936650|NCT00049556|Procedure|sentinel lymph node biopsy|
45936651|NCT00150943|Device|Renal artery stent|
45936652|NCT00043446|Drug|intravenous T900607-sodium|
45936653|NCT00150982|Drug|Mechanism of action of alefacept|
45936654|NCT02957695|Device|Placebo-Neurofeedback|The Intervention used for the control-group consists of a sham-neurofeedback, which is based on a previous eeg-recording and doesn't respond to the actual brain activity. The fact, that it is not a real neurofeedback, cannot be recognized by the patient nor the trainer because the eeg recording is not visible and the program reacts to muscle contractions (where feedback reactions would be expected) but not to brain activity.
45936655|NCT02957695|Device|Active-Neurofeedback|"The neurofeedback-method used in our study is called infra-low frequency neurofeedback Training, developed by S. and S. Othmer. NeuroAmpII® is the device and Cygnet® the corresponding Software used for this method, both are approved as an active medicinal device (CE-marked) in the European Union and in USA (www.eeginfo.com). The device and the Software are produced by the Company BEE Medic GmbH, Kirchberg, CH."
45936656|NCT00049634|Drug|busulfan|
45936657|NCT00049634|Drug|cyclophosphamide|
45936658|NCT00049634|Drug|cyclosporine|
45936659|NCT00049634|Drug|methotrexate|
45936660|NCT00049634|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45936661|NCT00151021|Behavioral|Tailored web-based walking program|
45936662|NCT00151060|Drug|Estramustine|
45936663|NCT00151060|Drug|Etoposide|
45936664|NCT00151060|Drug|Paclitaxel|
45936665|NCT02970435|Behavioral|Video Discharge Instructions|The video discharge instructions, will be provided to the patient at the time of surgical procedure.
45936666|NCT02970435|Behavioral|Telecommunication Reminders|Telecommunication reminders including text messages, email, or phone calls to remind participants how to access the video discharge instruction up to three times before follow-up
45936667|NCT02970435|Behavioral|Standard of Care|Standard of Care: verbal and written discharge instructions for patients after surgery
45936668|NCT00151099|Drug|high caloric drink with protein|
45936669|NCT00151138|Drug|Atenolol (drug), Lisinopril (drug)|
45936670|NCT00049712|Biological|etaracizumab|
45936671|NCT00151177|Device|non-invasive continuous positive airway pressure ventilation|
45936672|NCT00151177|Device|CPAP-treatment|night time CPAP-mask ventilation
45804912|NCT05925179|Procedure|Surgical crown lengthening|Surgical clinical crown lengthening with bone excision
45804913|NCT05925179|Drug|Augmentin|Pre-operative antibiotic prophylaxis (2 g Augmentin)
45804914|NCT05925166|Drug|rhTNFR-Fc|Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
45804915|NCT05925166|Drug|Triamcinolone Acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
45804916|NCT05925153|Other|No intervention|No intervention
45804917|NCT05925140|Drug|Lopinavir / Ritonavir|"Kaletra is a medication that is produced by AbbVie, a pharmaceutical company based in the United States. It is FDA approved for the treatment of HIV-1 infection in adults and pediatric patients. Kaletra contains two active ingredients, lopinavir, and ritonavir, which work together to inhibit the replication of the HIV virus.~Administration dose and duration of treatment: Patients will receive a loading dose (800/200, daily) of lopinavir 400 mg plus ritonavir 100 mg orally every 12 h for 10 days or until discharge, if sooner."
45804918|NCT05925140|Drug|Remdesivir (RDV)|"Remdesivir is provided by the United States as an FDA-approved drug, an antiviral medication developed by Gilead Sciences, and has been authorized for emergency use and approved for the treatment of COVID-19 in certain countries, including the United States.~Administration dose and duration of treatment: intravenously as a 200-mg loading dose on day 1, followed by a 100-mg once daily on days 2-10 or until hospital discharge or death. Duration is generally 5 days or until hospital discharge, whichever is first, but may extend to up to 10 days based on clinical response: For inpatients not requiring IMV and/or ECMO: 5 days; if clinical improvement is not demonstrated, treatment may be extended up to 10 days total. For inpatients requiring IMV and/or ECMO: 10 days."
45804919|NCT05925140|Drug|Tocilizumab|"Actemra is an FDA-approved brand name for Tocilizumab, a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, an immunosuppressive drug produced by Roche. It belongs to a class of medications known as IL-6 receptor antagonists and is designed to suppress the activity of the immune system. By blocking IL-6 receptor signaling, Actemra helps reduce inflammation and is used in the treatment of various autoimmune conditions and cytokine release syndrome.~Administration dose and duration of treatment: TCZ was administered 8 mg/kg intravenously (800 mg per infusion) as a single 60-minute intravenous infusion for 4 Weeks initially. The second infusion (400 mg) after 24 h may be administered based on clinical response in case of respiratory worsening, or 8 mg/kg at T0 followed by 8 mg/kg after 12 h."
45804920|NCT05925140|Other|Corticosteroid Therapy-enhanced Standard Care (CTSC)|(1) Methylprednisone (120mg/24h/IV) followed by 80mg/day (7days), and if necessary, continued with 40mg/day; or a pulse therapy (patient in critical state (360mg/day/IV) for 3 serial days, followed by 80mg/day (7days), and if necessary, continued with a dose of 40mg/day. (2) Standard Care: Normal Saline 0.9% (500cc/24h); vitamins [D (Oravil, 100.000IU/2ml PO STAT), C (10g/250cc in normal saline, 60drops/min/day), B (BECOZYME, 6 ampoules IV STAT)]; Omeprazole (RISEK, 40 mg/day IV); Paracetamol (PREFALGAN, 1g IV each 8h 3 times per day), Ketoprofen (PROFENID, 100mg/12h); Ceftriaxone (ROCEPHIN, 2g/day for 3 consecutive days), Doxycycline (VIBRAMYCIN, 100mg/12h PO for 8 days), Ivermectin (12mg/day for a period of 5 days); TOPLEXIL (Syrup, 10cc/each 8h) or SINECOD (Syrup, 15cc/each 8h); ATORVASTATIN (20mg/day); LOVENOX (40mg/12h if <80kg, or 60mg/12h if >80kg). Tranquillizers: NORMOCALM (400mg/night), XANAX (10mg/day), SEROQUEL (25mg/night), DEPIA (2mg/day), to be administered orally
45804921|NCT05925127|Biological|NVX-CoV2540 (5, 10, 25 μg)|Coformulated Omicron BA.5 SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at concentrations of 10,20, and 50 μg/mL and 100 μg adjuvant per mL.
45804922|NCT05925127|Biological|NVX-CoV2373 (5 μg)|Coformulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 μg/mL and 100 μg adjuvant per mL, respectively.
45804923|NCT05925127|Biological|Bivalent BA.4/5 Omicron subvariant|(coformulated NVX-CoV2373 +NVX-CoV2540) coformulated with Matrix-M adjuvant1
45804924|NCT05925114|Drug|S-309309|Administered as oral capsules
45936673|NCT00151216|Biological|AAV2CUhCLN2 (3x10^12 particle units)|gene transfer; one-time administration via neuro surgery procedure
45452553|NCT00886600|Drug|hydrochlorothiazide (HCTZ)|open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with Sitting Diastolic Blood Pressure (SiDBP) ≥85 mm Hg after 4 weeks of losartan monotherapy (Combination Therapy Period)) orally once daily (q.d.) for 2 weeks
45936674|NCT00082485|Drug|Baclofen|Dose escalation 10-60mg (week 1) 60 mg (weeks 2-7) Dose taper (week 8)
45936675|NCT00082485|Other|Placebo|Placebo
45936676|NCT00148486|Drug|NS 2330|
45936677|NCT00151255|Drug|Cytarabine|100mg/m² kont. i.v. day 1-5 (induction therapy); 1000 mg/m² 2x/die i.v. day 1-3 (first consolidation cycle)
45936678|NCT00151255|Drug|Idarubicin|12mg/m² i.v. day 1+3 (induction therapy); 12mg/m² i.v. Tag 1+3 (second consolidation cycle)
45936679|NCT00151255|Drug|All-trans retinoic acid|45mg/m² p.o. day 4-6, 15mg/m² p.o. day 7-28 (induction therapy); 15mg/m² p.o. day 4-28 (consolidation therapy)
46073796|NCT02860949|Procedure|Drug injection at Anterior soft tissue (34 mL)+Medial gutter area (33 mL)+Lateral gutter area (33 mL|
45653816|NCT05547971|Radiation|intensity-modulated radiation therapy|The patients got intensity-modulated radiation therapy during observation
45653817|NCT03062527|Other|Dietary Intervention: Low vs. moderate glycemic index|
46073797|NCT02690376|Device|Magnetic Assisted Capsule Endoscopy|Swallowed magnetic capsule for endoscopy purposes
46073798|NCT03599765|Other|Best Practice|Receive routine therapy
45452554|NCT02591654|Drug|Pembrolizumab|Each patient will receive pembrolizumab 200mg administered as a 30 minute intravenous (IV) infusion every 3 weeks for an indefinite period.
45653818|NCT05547893|Other|simulation|participating a simulated clinical ethical situation with simulation patients
45653819|NCT04981561|Drug|GATE-251|Single dose of GATE-251
45653820|NCT04981561|Drug|Placebo|Placebo
45936680|NCT00151255|Drug|Mitoxantrone|10mg/m² i.v. day 2-3 (first consolidation cycle)
45936681|NCT00151255|Drug|Etoposid|100mg/m² i.v. Tag 1-5 (second consolidation cycle)
46073799|NCT03599765|Procedure|Local Consolidation Therapy|Receive LCT
45452555|NCT02591654|Drug|FLT PET|FLT PET/CT is increasingly being utilized as an early PD biomarker in cancer given the close association between FLT uptake and proliferative index.
45936682|NCT00049751|Drug|Adalimumab|
45936683|NCT00151294|Drug|escitalopram oxalate antidepressant|
45936684|NCT00151333|Drug|SRA-333|
45936685|NCT00043563|Behavioral|Cognitive-Behavior Therapy|
45936686|NCT00151450|Drug|Pregabalin|
45936687|NCT00151450|Drug|Venlafaxine XR|
45936688|NCT00151489|Drug|pregabalin|
45936689|NCT00151489|Drug|placebo|
45936690|NCT00049790|Drug|recombinant human Angiostatin protein|
45936691|NCT00049790|Drug|paclitaxel|
45936692|NCT00049790|Drug|carboplatin|
45804925|NCT05925114|Drug|Placebo|Administered as an oral capsule that looks identical to S-309309 capsule
45936693|NCT00082524|Drug|caspofungin acetate|Duration of Treatment - 7-90 days
45804926|NCT05925101|Behavioral|Extinction-only condition|In this condition, therapists will place destructive behavior on extinction and deliver no reinforcement for functional communication responses (FCRs).
45804927|NCT05925101|Behavioral|Rate-drop condition|In this condition,we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a VI 15-s schedule. This change from a VI 1.5-s schedule for destructive behavior in baseline to a VI 15-s schedule for the FCR during FCT will produce a large drop in reinforcement rate during FCT relative to baseline.
45804928|NCT05925101|Behavioral|Rate-hold condition|In this condition, we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a yoked VI 1.5-s schedule that exactly matches the rate and timing of reinforcer deliveries for destructive behavior in baseline.
45936694|NCT00406003|Drug|Paroxetine controlled release tablet|Paroxetine will be given as single dose, controlled release tablet with dosing strengths of 12.5, 25 and 37.5 milligrams in fasted state separated by a wash-out period of 10 days.
45936695|NCT00049829|Drug|Zoledronic Acid|
45936696|NCT00406042|Drug|prednisolone acetate 1%|
45936697|NCT00082563|Drug|Azithromycin/Chloroquine|
45936698|NCT00082563|Drug|Chloroquine|
45936699|NCT00151528|Drug|Pregabalin|
45936700|NCT00397787|Drug|sunitinib malate|Given PO
45936701|NCT00082602|Drug|galantamine ER|
45936702|NCT00151567|Drug|Tamsulosin|Oral tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
45936703|NCT00151567|Drug|Placebo|Oral placebo of tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
45936704|NCT00151606|Procedure|Reinforced isolation + Muciprocine|
45936705|NCT00151645|Drug|activated lymphocytes|
45936706|NCT00397826|Drug|MK0733|Duration of Treatment: 12 Weeks
45936707|NCT00151684|Drug|Diazoxide|
45936708|NCT00151723|Procedure|treatment with 131I|
45936709|NCT00151762|Drug|Colesevelam hydrochloride|
45936710|NCT00151801|Drug|estroprogestins|
45936711|NCT00151801|Drug|interferon-beta 1a|
45936712|NCT00151840|Drug|IVIG-L|
45936713|NCT00151879|Drug|SPM 927|
45936714|NCT04725253|Dietary Supplement|Nicotinamide|Nicotinamide, 1,5 gr per day for 7 days.
45936715|NCT04725253|Other|Placebo tablets|Placebo tablets, 1 per day for 7 days.
45936716|NCT00082719|Biological|Recombinant Interferon Alfa|"In all arms, treatment begins at pre-operative visit and continues until cystoscopy.~Arm I: Low-dose interferon alfa subcutaneously (SC) twice daily. Arm II: Interferon alfa as in arm I at a higher dose. Arm III: Interferon alfa SC once daily. Arm IV: Interferon alfa as in arm III at a higher dose."
45936717|NCT00151918|Drug|Lanthanum carbonate|
45936718|NCT00151957|Drug|Methylphenidate Transdermal System|MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks
45936719|NCT00049946|Drug|talnetant|
45936720|NCT00049946|Drug|risperidone|
45936721|NCT00152035|Drug|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.|
45936722|NCT00043602|Behavioral|Standard interpersonal psychotherapy (IPT)|Participants will receive 12 sessions of IPT over 12 weeks.
45936723|NCT00043602|Behavioral|Clinician managed interpersonal psychotherapy (CM-IPT)|Participants will receive 12 sessions of CM-IPT over 1 year.
45936724|NCT00152074|Behavioral|Reduce salt intake|
45936725|NCT04725370|Other|NA - survey instrument|Survey instrument was administered verbally to parents of the Guatemalan cohort.
45936726|NCT00152113|Procedure|Hematopoietic Stem Cell Transplantation|Allogeneic stem cell transplant Haploidentical stem cell transplant Mismatched family member donor stem cell transplant T cell selection CD34 enrichment
45936727|NCT00152113|Device|CliniMACS|
45936728|NCT00152113|Drug|See intervention description|Hydroxyurea and azathioprine were administered for a 3 month period prior to the initiation of the transplant procedure in an effort to help prevent rejection of the donor product. Approximately 10 days prior to the transplant procedure, all participants received the same preparative regimen consisting of Busulfan, cyclophosphamide, low-dose thiotepa, and OKT3. MMF was administered for GVHD prophylaxis. Two separate infusions of donor stem cells were administered with fixed doses of CD3 and CD34 cells. These haploidentical stem cells were processed using the investigational CliniMACS device.
45936729|NCT00049985|Drug|Darbepoetin Alfa|
45936730|NCT00152152|Procedure|Radiostereometric Analysis beads inserted during surgery|
45936731|NCT00152191|Drug|UFT (uracil, tegafur)|uracil, tegafur was orally administered by 300 mg per square meter per day for 2 years
45936732|NCT00152191|Drug|cyclophosphamide, methotrexate, and fluorouracil|cyclophosphamide:100 mg, po, day 1-14 methotrexate:40 mg/m2, day 1, 8 q28 days x 6 cycles fluorouracil:500 mg/m2, day 1, 8
45936733|NCT00152230|Drug|UFT (uracil, tegafur)|to receive oral uracil-tegafur 400 mg square meter for one year
45936734|NCT00152230|Procedure|Surgery alone|Standardized mesorectal excision with selective lateral pelvic lymphadenectomy of stage III rectal cancer.
45936735|NCT00152269|Drug|Asoprisnil|10mg Tablet, oral Daily for 12 months
45936736|NCT00152269|Drug|Asoprisnil|25mg Tablet, oral Daily for 12 months
45804929|NCT05925101|Behavioral|Magnitude-drop condition|In this condition, we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR according to a VI 1.5-s schedule, but we will deliver the reinforcer for just 6 s each time. This change from delivering 60 s of access to the functional reinforcer following destructive behavior in baseline to delivering 6 s of reinforcer access for the FCR during FCT will produce a large reduction in the magnitude of reinforcement relative to baseline.
45653821|NCT05698589|Behavioral|Compassion Focused Therapy|CFT is an experiential therapy. As such, in addition to psychoeducation components (e.g.: compassion from an evolutionary and neuroscientific perspective, the tricky brain problem, emotion regulation systems) and explicit learning of emotion regulation skills (in particular, shame), experiential exercises are provided in-sessions (e.g. : chair work, role plays, guided mental imagery, …) and between sessions practices will be provided with video guides, made available for the participants online (e.g. : soothing rhythm breathing, safe place imagery, compassionate self-imagery, …). The overall aim of the CFT program is to help participants shift from a hostile and critical self-to-self relationship to a more compassionate relationship to self.
45653822|NCT05698589|Behavioral|Ending Self Stigma|Psychoeducation sessions cover topics such as the path from public stigma to self-stigma and modifying self-stigmatizing thoughts. Participants will be encouraged to do home practices (e.g. writing about the pros and cons of self-stigmatizing thoughts) between sessions. The overall aim of the ESS program is to help participants address self-stigma with concrete tools to increase their self-esteem and achieve their goals
45936737|NCT00152269|Drug|Placebo|Placebo, Tablet, oral Daily for 12 months
45936738|NCT00152308|Device|2% rapamycin-eluting YUKONdes PEARL-stent|
45936739|NCT00152308|Device|1% rapamycin-eluting YUKONdes PEARL-stent|
45804930|NCT05925101|Behavioral|Magnitude-hold condition|This condition will be identical to the magnitude-drop condition except that we will deliver 60 s of access to the functional reinforcer contingent on the FCR, so that the magnitude of reinforcement will equal that delivered in baseline for destructive behavior. To ensure that the magnitude of reinforcement does not drop in the magnitude-hold condition, we will yoke the rate and timing of reinforcer deliveries for the FCR during FCT to the rate and timing of reinforcer deliveries for destructive behavior in baseline.
45936740|NCT00152308|Device|YUKONdes PEARL-stent coated with placebo (ethanol)|
45936741|NCT00152347|Drug|Botox|See Detailed Description
45936742|NCT00152386|Drug|Certolizumab pegol (CDP870)|
45936743|NCT00050063|Biological|Therapeutic vaccinations from A5058s|Participants will receive assigned interventions assigned in study A5058s.
45936744|NCT00082836|Biological|rituximab|
46073800|NCT04200612|Behavioral|Equine-Assisted Psychotherapy|Equine-Assisted Psychotherapy (EAP) involves working on the psychological goals set between the client and the mental health professional. This is done through the experiential interactions between the clients and the horse. This experiential aspect is vital as it allows clients to process the emotions, thoughts and behaviors that were expressed during sessions with the horse.
46073801|NCT04200612|Behavioral|Equine-Assisted Activities|Simple interactions with the horses that does not necessarily involve any goals being set between the client and the personnel handling the session. These can involve activities such as grooming or petting of the horse.
45653823|NCT02626819|Behavioral|MOVE! Toward Your Goals|Patients will take an online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals to help them in their weight loss journey. The goals may be supported by the patients' PACT members
45936745|NCT00082836|Radiation|yttrium Y 90 ibritumomab tiuxetan|
45936746|NCT00152425|Drug|Certolizumab Pegol (CDP870)|
45936747|NCT00397865|Behavioral|Educational booklet|Parental perception of educational booklet and evaluating any change in child's weight.
45936748|NCT00152503|Drug|Seletracetam (ucb 44212)|
46073802|NCT04200612|Other|Placebo-control group|This group will only be watching movies related to horses and they are told that this is another form of EAP even though this is not the case. This type of intervention has not been known to provide any therapeutic effect relevant to the study and thus is used as the placebo-control.
46073803|NCT03248063|Drug|Cloxacillin|"Intravenous treatment by cloxacillin, 25 to 50 mg/kg every 4 or 6 hours, without doing less than the minimum daily dose of 8 g/day and without exceeding the maximum daily dose of 12 g/day, administered as a 60-minutes infusion. This treatment will be administered for at least 7 days by intravenous route.~Dosing regimen will be adapted in patients with chronic renal failure (glomerular filtration rate below 30ml/min/1.73m²) and in patient with impaired hepatic function associated with renal impairment whatever the level of the estimation of the glomerular filtration rate, according to SPC."
46088532|NCT04345224|Other|Sham tape|The control group (sham tape application) will receive a single strip of a Kinesio tape across the lateral affected hip without tension in the tape or muscle stretch.
46088533|NCT05242835|Procedure|Standard duodenal switch|Standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)
45936749|NCT00152542|Drug|Inhaled nitric oxide|1 day of iNO at 10 ppm, then 5 ppm of iNO for days 2-7
45936750|NCT00152542|Drug|Placebo|No iNO given for days 1-7
45936751|NCT00043680|Drug|Celecoxib|
45936752|NCT00152581|Drug|Pegylated interferon-alfa2a (Pegasys); ribavirin|
45936753|NCT00152620|Drug|Dexamethasone|
45936754|NCT00152620|Drug|Methylprednisolone|
45936755|NCT00050141|Drug|ZARNESTRA, tipifarnib, R115777|
45936756|NCT00152659|Procedure|Tissue sample (procedure/screening)|Tissue sampling
45936757|NCT00082875|Drug|cilengitide|Given IV
45936758|NCT00082875|Other|pharmacological study|Correlative studies
45936759|NCT00082875|Other|laboratory biomarker analysis|Correlative studies
45936760|NCT04725214|Drug|Anlotinib|Anlotinib With STUPP Regimen
45936761|NCT00152698|Drug|Irbesartan|
45936762|NCT00050180|Drug|Midazolam|
45936763|NCT00050180|Drug|Indinavir|
45936764|NCT00050180|Drug|Saquinavir|
45936765|NCT00152737|Procedure|Exercise test with Transcutaneous oxygene pressure|Ce marked devices
45936766|NCT00152737|Procedure|Ankle and arm pressure values|one test before and one test after surgery
45936767|NCT00082914|Biological|denileukin diftitox|
45804931|NCT05925101|Behavioral|Quality-drop condition|In this condition, we will place destructive behavior on extinction and deliver the reinforcer from the paired-choice assessment that the participant chooses approximately 1/12th as often as the highest preference stimulus from that assessment. This change from the most preferred stimulus from the paired-choice assessment to one chosen 1/12th as often will constitute a large drop in the quality of reinforcement during FCT relative to baseline.
45936768|NCT00152776|Drug|ovaria comp 10 globuli 3 times per day 24 weeks|order of intervention and placebo varies between Groups I-III
45936769|NCT00152815|Drug|antioxidant vitamin E|Vitamin E 800IU per day for 12 months
45936770|NCT00152815|Behavioral|weight reduction and exercise|Patients will be asked to consume a self-selected, low fat, low-calorie diet of approximately 1200 kcal/d, which is consistent with American Heart Association guidelines for healthy weight reduction. Subjects will be provided with a videotape involving a structured 20 min aerobic exercise to be performed 3x/week.
45936771|NCT04725019|Device|active transcranial direct current stimulation|Participants will receive 20 min of tDCS over the scalp during 20 min of motor training.
45936772|NCT04725019|Behavioral|Motor training|Participants will engage in a high number of repetition of movements that use both hands while playing with toys and games. Training will be provided 20 min/day, for 5 consecutive days.
45936773|NCT00043719|Drug|Nitroglycerin ointment|
45936774|NCT00043719|Drug|Calcium supplement with vitamin D|
45936775|NCT00152854|Drug|Acetaminophen|acetaminophen 1g po qid
45936776|NCT00152854|Drug|acetaminophen|acetaminophen 1g po qid for 7 days
45936777|NCT00152854|Drug|placebo, sugar pill|
45936778|NCT00050297|Drug|YM598|
45936779|NCT00152893|Drug|chromium nicotinate|
45936780|NCT00152893|Drug|Placebo|
45936781|NCT00152932|Drug|Dorzolamide 2% drops|
45936782|NCT00152932|Device|HRF and CLBF|
45936783|NCT00083031|Drug|bevacizumab|
45653824|NCT02626819|Behavioral|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
45653825|NCT05699993|Drug|Itraconazole|Itraconazole was administered orally
45936784|NCT00083031|Drug|cyclophosphamide|
45936785|NCT00083031|Drug|methotrexate|
45936786|NCT00406120|Procedure|Fine needle aspiration biopsy|
45936787|NCT00406159|Device|Hyperbaric Oxygen Therapy|
45936788|NCT00050336|Drug|Lonafarnib (SARASAR)|
45936789|NCT00406198|Procedure|venovenous hemofiltration|
45653826|NCT05699993|Drug|IBI351|IBI351 was administered orally
45653827|NCT05699993|Drug|Dextromethorphan|Dextromethorphan was administered orally
45653828|NCT05552651|Drug|Envafolimab|300mg,sc,d1,Q3W;
45653829|NCT05552651|Drug|Albumin-Bound Paclitaxel|130mg/m2,iv,D1,D8,Q3W
45653830|NCT05552651|Drug|Carboplatin|AUC=5, iv,D1,Q3W
45804932|NCT05925101|Behavioral|Quality-hold condition|We will place destructive behavior on extinction and deliver the most preferred reinforcer from the paired-choice assessment on a yoked VI 1.5-s schedule that exactly matches the rate and timing of reinforcer deliveries for destructive behavior in baseline in this condition.
45936790|NCT00153010|Drug|NS 2330 (Tesofensine)|
45936791|NCT00043758|Drug|Tolvaptan|
45936792|NCT00050375|Drug|oregovomab|
45936793|NCT00153049|Drug|Telmisartan|
45936794|NCT00153049|Drug|Hydrochlorothiazide|
45936795|NCT00153049|Drug|Telmisartan + Hydrochlorothiazide|
45936796|NCT00153088|Drug|Telmisartan capsule 40 mg|
45936797|NCT00153088|Drug|Placebo|
45936798|NCT00153088|Drug|Telmisartan capsule 80 mg|
45936799|NCT00083070|Drug|temozolomide|
45936800|NCT00050414|Drug|Trabectedin|Trabectedin 0.58 mg/m2, administered as a 3-hour intravenous infusion, Days 1, 8, and 15 every 28 days for up to approximately 3 years in the absence of disease progression.
45936801|NCT00050414|Drug|Dexamethasone|Dexamethasone 10 mg administered intravenously 30 minutes prior to each trabectedin infusion.
45936802|NCT00153127|Drug|polyethyleneglycol3350|
45936803|NCT00153205|Behavioral|computerized physician order entry|
45936804|NCT00083109|Drug|Fluorouracil|Given IV
45936805|NCT00083109|Other|Pharmacological Study|Correlative studies
45936806|NCT00083109|Drug|Suramin|Given IV
45936807|NCT00153244|Drug|Lamotrigine|
45936808|NCT00153283|Drug|Gabapentin|
45936809|NCT00153322|Behavioral|Nurtition and Physical Activity Education|
45936810|NCT00153361|Behavioral|Discussion Group|
45936811|NCT00153361|Behavioral|Video Discussion Group|
45936812|NCT00050531|Drug|Gleevec|400 mg orally twice daily.
45936813|NCT00050531|Drug|Peg-alpha interferon (Peg-Intron)|PEG-IFN 0.5 mcg/kg each week subcutaneously.
45936814|NCT00050531|Drug|Sargramostim (GM-CSF)|125 mcg/m^2 three times per week subcutaneously.
45936815|NCT00153400|Behavioral|Women's health|
45936816|NCT00153439|Behavioral|Motivational enhancements, parent training|
45936817|NCT00083148|Drug|capecitabine|
45936818|NCT00083148|Drug|irinotecan hydrochloride|
45936819|NCT00153478|Behavioral|Brief Motivational Counseling|
45936820|NCT00153517|Drug|oral versus vaginal metronidazole|
45936821|NCT00050570|Behavioral|Web-based intervention to reduce eating disorder risk factors|
45936822|NCT00153556|Biological|Hib conjugate vaccine (HbOC, Wyeth Vaccines)|
45936823|NCT00153595|Drug|EWO1|
45936824|NCT00083187|Drug|hydroxyurea|
45936825|NCT00083187|Drug|laromustine|
45936826|NCT00153634|Drug|IV amikacin|5-7.5 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
45936827|NCT00153634|Drug|PO azithromycin|250 mg once daily
46073804|NCT03248063|Drug|Cefazolin|Intravenous treatment by cefazolin, 25 to 50 mg/kg every 8 hours (without exceeding the maximum daily dose of 6 g/day), administered as a 30-minutes infusion. This treatment will be administered for 14 days by intravenous route. Dosing regimen will be adapted in case of glomerular filtration rate between 30-50ml/min according to SPC. As currently recommended, investigators will be encouraged to use the intravenous route for the entire duration of treatment. However, in order to interfere as little as possible with usual practice in each center, the antimicrobial therapy will be let to the choice of the physician in charge of the patient after a minimum of 7 days of intravenous treatment.
45804933|NCT05925101|Behavioral|Rate-drop/quality-increase condition|In this condition, we will program the same large drop in reinforcement by delivering reinforcement on a VI 15-s schedule, but we also will increase reinforcement quality by simultaneously delivering the highest quality reinforcer identified during a competing stimulus assessment. We will use the competing stimulus assessment in Ex 4 because it directly assesses the quality of alternative reinforcement relative to the quality of the reinforcer for destructive behavior, whereas the paired-choice assessment could not guarantee that the selected stimulus would be of a higher quality than the reinforcer for destructive behavior.
45804934|NCT05925088|Other|Focus group|Participants will take part in a 1 hour focus group.
46073805|NCT00964223|Drug|Clindamycin and benzoyl peroxide gel (Duac® Topical Gel)|Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
46073806|NCT00964223|Drug|benzoyl peroxide and adapalene gel (EPIDUO™ Gel)|Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
45452556|NCT01098695|Other|Ecological Family Intervention and Treatment (EcoFIT)|Includes the Family Check-Up (in-person intake, family video observations and Assessment questionnaires used to provide and tailored feedback using motivational interviewing techniques) as well as continued tailored intervention services using the Everyday Parenting Curriculum.
46073807|NCT00620815|Biological|MF59-eTIV-H5N1+ placebo /pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)and placebo on day 1 followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1+V3.
46073808|NCT00620815|Biological|Pandemic influenza vaccine + placebo /MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo on day 1 followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1+V3.
46073809|NCT00620815|Biological|Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine, 3-5 weeks later pandemic influenza vaccine , including serology blood draw at V1+V3.
46073810|NCT00620815|Biological|Pandemic influenza vaccine + placebo / MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1, V2 and V3.
46073811|NCT00620815|Biological|Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
45452557|NCT03134872|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
45452558|NCT03134872|Drug|Carboplatin|Carboplatin
45452559|NCT03134872|Drug|Pemetrexed|Pemetrexed
45452560|NCT03952481|Drug|Lifitegrast 5% Ophthalmic Solution|Participants will received lifitegrast 5% ophthalmic solution twice a day in each eye for approximately 4 weeks.
45804935|NCT05925075|Diagnostic Test|Lung Ultrasound|Lung ultrasound to be performed at scheduled intervals as described in individual cohorts.
45452561|NCT05135312|Drug|Etanercept|TNF-alpha inhibitors improve nail psoriasis.
45452562|NCT05135312|Device|OCT|Optical Coherence Tomography is a noninvasive imaging device that can be used to monitor nail disease severity.
45452563|NCT00885196|Drug|Placebo|
45452564|NCT00885196|Drug|AEB071|
45676257|NCT04210583|Device|Vulvovaginal Treatment|"Device model(s) - Venus Fiore™ Device settings and programming internal applicator - 42°C - 45°C Temperature output via automatic temperature control (ATC) (optional treatment).~Duration of exposure and frequency of exposure with internal applicator - one treatment for 12-15 minutes at 12 months (optional treatment).~Device settings and programming external mons pubis and labia applicators - 10-35% output (optional treatment).~Duration of exposure and frequency of exposure external applicators - one treament for 15 minutes for the mons pubis, 10 minutes for labia at 12 months (optional treatment)."
45804936|NCT05925062|Behavioral|QActual|QActual is a phone-based app that offers peer-to-peer support, tracks mental wellness self-assessments, and provides support to users who are in crisis.
45804937|NCT05925049|Drug|Natalizumab|Administered as specified in the treatment arm.
45804938|NCT05925036|Drug|Mesenchymal stem cells|Autologous bone marrow derived MSCs
45804939|NCT05925036|Other|Placebo|Controls
45804940|NCT05925023|Drug|Sirolimus|Oral administration, 1-3 mg/d, sirolimus plasma concentration: 4-15 ng/mL
45452565|NCT03172130|Device|Straight CPAP|
45452566|NCT03172130|Device|Sham CPAP|
45452567|NCT03956771|Behavioral|Real neurofeedback|Regulation of brain activity in real-time with feedback from brain activity measured with MRI from the orbitofrontal cortex of the participant him/herself. Participants receive feedback of their own brain activity in a screen with pictures. Participants are instructed to try to decrease the pictures transparency to reduce the orbitofrontal cortical activity. Psychotherapy strategies to decrease brain responses will be teach to the participants before the intervention.
45804941|NCT05925010|Dietary Supplement|Supplementation with soluble fibre from guar (Optifibre©)|10g of soluble fibre from guar in the form of Optifibre© (dietary food for special medical purposes) is added to the standardized meal (Resource cereal porridge©).
45653831|NCT04981483|Procedure|conservative surgery for uterus in placenta accreta|After removal of the placenta, grasping the cervix from the both lips and one from each side of the cervical canal at the level of the internal os, each uterine angle and grasped the remaining lower uterine segment and Nelaton catheter was inserted inside the cervical canal to avoid closing the cervix with sutures of the uterine incision.Closing the uterine incision;taking suture at the lateral angle of the cervix and suturing it to the lower edge of the uterine angle, then another continuous suture was attached to the upper edge of the uterine incision angle[outside in-in out then out in-in out] and the same technique was repeated on the other side (cervico-isthmic sutures). controlling bleeding from the inner surface of the remaining lower uterine segment was done by 2-3 interrupted sutures between the lower uterine segment and the anterior cervical lip. closing of the uterine incision in continuous non-locking manner
45804942|NCT05924997|Drug|adebrelimab, camrelizumab plus apatinib|adebrelimab (RP2D, Q3W)+ camrelizumab 200mg Q3W+ apatinib 250mg qd, with 3 weeks (21 days) as a treatment cycle
45804943|NCT05924984|Device|perforator locator|During CT scan, the patient was lying on the examination bed in a supine position, with the patient's toes facing up and fixed with an ankle fixator, the perforator was placed on the outside of the patient's thigh, and the base was extended or shortened according to the length of the patient's thigh, so that the iliac pole was located on the anterior superior spine of the patient's iliac and the patella pole was located on the lateral border of the patient's patella, and the positioning point was marked on the skin with a pen. After CT examination, the position of the perforating branch was displayed after 3D reconstruction of blood vessels by computer, and the position of the perforating branch was calculated using the computer position. The perforating branch positioning rod was moved according to the calculated scale to make it correspond to the scale, and the corresponding skin position mark was made according to the perforating branch positioning rod.
45804944|NCT05924971|Drug|Aspirin 81Mg Ec Tab|Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.
45804945|NCT05924958|Drug|Eprolidone|This study assessed the effect of eplerenone on circulating Treg cells in patients with chronic heart failure by detecting the level of aldosterone in venous blood and the activity of Treg cells and the level of inflammatory factors related to it after taking drugs.
45936828|NCT00153634|Drug|IV ceftazidime|50 mg/kg every 8 hours, up to 2 grams every 8 hours
45936829|NCT00153634|Drug|PO ciprofloxacin|500 mg every 12 hours if weight <50 kg 750 mg every 12 hours if weight ≥50 kg
45936830|NCT00153634|Drug|IV meropenem|40 mg/kg every 8 hours, up to 2 grams every 8 hours
45936831|NCT00153634|Drug|IV piperacillin-tazobactam|100 mg/kg of piperacillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
45936832|NCT00153634|Drug|IV ticarcillin-clavulanate|100 mg/kg of ticarcillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
45936833|NCT00153634|Drug|IV tobramycin|2.5-3.3 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
45936834|NCT00050609|Drug|tadalafil|5 mg tadalafil tablet taken by mouth once a day for 8 weeks
45936835|NCT00050609|Drug|tadalafil|20 mg tadalafil tablet taken by mouth once a day for 8 weeks
45804946|NCT05924945|Device|Bridge™ active device|Bridge is a percutaneous nerve field stimulation device
45804947|NCT05924945|Device|Bridge™ sham device|The sham device has the same appearance and will require the same placement technique as the Bridge (active) device but will not deliver electrical impulses.
45804948|NCT05924932|Device|Tandem t:slim X2 with hybrid closed loop system Control IQ, glucose sensor: Dexcom G6|type of hybrid close loop insulin delivery system
45804949|NCT05924932|Device|MiniMed 780G, with hybrid closed loop system SmartGuard, sensor Guardien 4|type of hybrid close loop insulin delivery system
45936836|NCT00050609|Drug|placebo|Placebo tablet taken by mouth once a day for 8 weeks
45936837|NCT00153673|Drug|celecoxib|Celecoxib 200mg bd
45936838|NCT00153673|Drug|Dologesics|Dologesics 2 tablets bd
45936839|NCT00043797|Drug|Lidorestat (IDD 676)|
45936840|NCT00153751|Drug|Traditional Chinese Medicine|They are Common peony root, Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Lactiflorae, Cortex Magnoliae Officinalis, Rhizoma Curcumae Longae, Fructus Schisandrae Chinensis, Pericarpium Citri Reticulatae, and Rhizoma Corydalis Yanhusuo.
45936841|NCT00153751|Drug|Holopon|holopon
45936842|NCT00153751|Other|placebo|placebo
45936843|NCT00153790|Drug|PhosphoLean|
45936844|NCT00050648|Drug|Daclizumab|1mg/kg medication every other week on the odd week (week 1-13).
45936845|NCT00050648|Drug|Cyclosporine|2mg/kg/day orally from Day 0 until Day 90 or a total of 13 weeks.
45936846|NCT00050648|Drug|cyclosporine and Daclizumab|1mg/kg plus low dose cyclosporine (2 mg/kg/day)
45936847|NCT00153829|Behavioral|Multifaceted outreach facilitation for chronic illness care|
46002528|NCT01549587|Drug|0.07% Cetylpyridinium chloride|mouth rinse: rinse with 20 mL of mouth rinse for 30 seconds twice daily
46002529|NCT01549587|Device|dental floss|floss the whole mouth once daily
45936848|NCT00153868|Biological|darbepoetin alfa|The allocation to the treatment arms will be dependent on the schedule of chemotherapy (i.e. weekly, every 2 week, or every 4 week chemotherapy schedules will receive a starting dose of 200 mcg darbepoetin alfa and every 3 week chemotherapy schedule will receive a starting dose of 300 mcg). Non-responders are defined as patients who experience <1.0 g/dL increase in hemoglobin concentrations after 6 weeks. Darbepoetin alfa will be held for hemoglobin concentrations >13.0 g/dL.
45936849|NCT00153907|Drug|Navelbine|Given orally on day 1 and 8 of each cycle, dose will vary. If participant is at highest dose they will take navelbine on day 1, 8 and 15 until disease progression or unacceptable side effects occur.
45452568|NCT03956771|Behavioral|Sham neurofeedback|Regulation of brain activity in real-time with feedback from brain activity measured with MRI from the orbitofrontal cortex of other participant. Participants receive feedback of other participant' brain activity in a screen with pictures. Participants are instructed to try to decrease the pictures transparency to reduce the orbitofrontal cortex activity. Psychotherapy strategies to decrease brain responses will be teach to the participants before the intervention.
45936850|NCT00153907|Drug|Capecitabine|Taken twice a day on days 1-14 until disease progression or unacceptable side effects occur.
45452569|NCT00881452|Drug|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
45804950|NCT05924919|Procedure|Whole-body Passive Heat Therapy (HT)|The whole-body passive heat therapy (HT) intervention will consist of an acute bout of infrared sauna for 25 minutes at 60°C. Participants will lie supine on a memory foam pad.
45804951|NCT05924919|Procedure|Thermoneutral Control (CON)|Participants will remain in a room temperature environment (22°C) underneath the infrared domes for 25 minutes.
45936851|NCT00050726|Drug|Interleukin-2|
45936852|NCT00153946|Drug|Edaravone|30mg/20mL vial, twice per day, not longer than two weeks
45936853|NCT00154024|Drug|atorvastatin|
45936854|NCT00154024|Drug|irbesartan|
45936855|NCT00043836|Drug|ALT-711|
45936856|NCT00154141|Drug|Fibrin sealant (FS2)|
45936857|NCT00154180|Drug|Conjugated equine estrogens 0.45 mg/day|Pill, 1 pill taken daily each month for the study duration
45936858|NCT00154180|Drug|Transdermal estradiol, 50 mcg/day|Patch; 1 patch is applied to the skin weekly. Patch site is rotated on a weekly basis.
45936859|NCT00154180|Drug|Micronized progesterone, 200 mg/day x 12 d/month|capsule, 1 capsule taken daily for the first 12 days of each month for the study duration
45936860|NCT00154180|Drug|CEE , progesterone, estradiol patch or placebo for each|CEE 0.45mg 1 PO QD Progesterone 200 mg 1 PO HS first 12 days of the month estradiol patch use 1 per week
45936861|NCT00154180|Drug|CEE, progesterone, transdermal patch or the placebo|CEE 0.45 mg 1 PO QD or placebo equivalent Prometrium 200 mg 1 PO qHS for first 12 dasy of each month or placebo equivalent transdermal patch 0.05 mg use 1 patch per week or placebo equivalent
45936862|NCT00050765|Drug|MyoCell™ Autologous Myoblasts|
45936863|NCT00154219|Drug|Lumiracoxib (drug)|
45936864|NCT00043875|Drug|lamotrigine|
45936865|NCT00154258|Drug|Clozapine|
45936866|NCT00154336|Drug|Imatinib|
45804952|NCT05924906|Drug|NB002|Strength: 100 mg:5 mL solution in a single-use vial Administration: intravenous infusion
45804953|NCT05924893|Drug|Naltrexone Hydrochloride|naltrexone film
45804954|NCT05924893|Drug|Carboxy methyl cellulose|Carboxy methyl cellulose drops
45452570|NCT00881452|Drug|Placebo|Single unit dose powder of non-active substance administered 3 times per day for 90 days
45936867|NCT00154336|Drug|Methotrexate|
45936868|NCT00154336|Drug|Imatinib Placebo|
45936869|NCT04724785|Other|only monitoring|monitoring the viraemia only
45936870|NCT04724785|Other|monitoring and regimen change if necessary|if those patients agree, the regimen will be changed.
45936871|NCT04724785|Drug|regimen change|Based on ongoing one, regimen will be changed . The principle for adjusting anti-viral regimen is as follows: 1. The patients were treated with second-line drugs: changing ADV to ETV/TAF/TDF , changing LAM to TAF/TDF and changing LdT to TAF/TDF; 2. The patients were treated with ETV: adding or switching to TAF/TDF;3. TAF or ETV is recommended for patients with one or more TDF risk factors, such as > 40 years old, patients with abnormal bone/kidney related indicators or patients with high risk of bone/kidney injuries.【ADV=adefovir dipivoxil, LAM=lamivudine, and LdT=telbivudine , TAF =Tenofovir alafenamide Fumarate, ETV=Entecavir and TDF=Tenofovir disoproxil fumarate 】
45936872|NCT00050804|Drug|sertraline|
45452571|NCT04512170|Drug|HEC585|single or Mulltiple doses up to 10 days
45452572|NCT04512170|Drug|placebo|single or Mulltiple doses up to 10 days
45452573|NCT05210816|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in eight sessions online. Each session will last an average of 60-90 minutes. There will be two sessions for one group per week.
45452574|NCT03952325|Drug|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
45452575|NCT03952325|Drug|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
45452576|NCT03952325|Drug|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
45452577|NCT03952325|Drug|Nivolumab|Nivolumab at 360 mg by intravenous infusion Q3W
45936873|NCT00043914|Drug|lamotrigine|
45936874|NCT04705987|Drug|Colchicine 0.5 MG|Colchicine 0.5 mg/24h Treatment 8 weeks
45936875|NCT04705987|Drug|Placebo|Placebo 1c/24h Treatment 8 weeks
45936876|NCT04705909|Drug|Pitavastatin|Pitavastatin 2 mg oral tablets daily will be given to the patients concomitantly with the intended chemotherapy protocol for the treatment period prior to surgery.
45936877|NCT04705909|Drug|placebo|patients in this group will receive placebo tablets concomitantly with the intended chemotherapy for the treatment period prior to surgery.
45804955|NCT05924880|Drug|durvalumab|Durvalumab 1500 mg as a 60-minute IV infusion in combination with gemcitabine-based chemotherapy Q3W. Upon completing chemotherapy, or discontinuing chemotherapy due to toxicity, durvalumab 1500 mg IV Q4W alone or in combination with gemcitabine.
45936878|NCT04731428|Behavioral|Progressive Relaxation Exercise|Progressive Relaxation Exercise involves stretching sixteen muscle groups while breathing in sequentially, relaxing while exhaling. Exercise can be from head to toe or from foot to head. In order for the technique to be effective, it is important to have affective (music, etc.) and visual aids. During the exercise, the patient should complete the processes of perceiving the tension in his body, maintaining control and getting into a state of relaxation. After the patient is informed about the exercise, the person starts with breathing exercises. A deep but relaxing breath is taken from the nose, and lips are given by contracting simultaneously with relaxation. During this application, the patient keeps contracting the muscle group that he exercises for 10 seconds; the nurse provides the patient to notice the temperature / warming felt in the muscle group.
45936879|NCT04705792|Procedure|Physical activity|Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit.
45936880|NCT00083304|Drug|Efaproxiral|"75 mg/kg, administered over 30 minutes via a central venous access device (CVAD).~Administered 30 minutes prior to the start of whole brain radiation therapy (WBRT) on each WBRT treatment day for 10 days."
45936881|NCT00083304|Radiation|Whole Brain Radiation Therapy (WBRT)|3.0 Gy per day for 10 days (30.0 Gy total) of WBRT.
45936882|NCT00083304|Other|Supplemental Oxygen|"4 L/minute by nasal cannula.~Administered at least 35 minutes prior to WBRT, during WBRT and until 15 minutes after completion of WBRT on all WBRT treatment days."
45936883|NCT04705558|Other|continuous moderate intensity aerobic training|continuous moderate intensity aerobic exercises with ketogenic diet group underwent supervised moderate-intensity exercised on a treadmill at 50%-70% of heart rate reserve for three month
45936884|NCT04705558|Other|ketogenic diet|Ketogenic diet: a low carbohydrate high-fat diet consisted of the following nutrient conformation: 80% fat, 15% protein and 5% carbohydrates, entire daily intake was estimated to be 20-30 g of carbohydrates for three month.
45936885|NCT00154453|Procedure|obtain surgical specimen for analysis|
45936886|NCT00050843|Drug|thalidomide|
45936887|NCT00406237|Drug|tigecycline|Single intravenous dose of tigecycline 50 mg, as a 30-minute infusion
45936888|NCT00406432|Drug|Paroxetine Controlled Release Tablet|Eligible subjects will receive paroxetine controlled release tablet with dose of 25 milligrams.
45936889|NCT00083343|Drug|MK0991, caspofungin acetate/Duration of Treatment: variable|
46073812|NCT00620815|Biological|MF59-eTIV-H5N1 + Placebo/pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)plus placebo followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
46073813|NCT02818764|Procedure|Blood Draw|5 mL of blood from the patients preoperative, postoperative, 1 day and 2 days after surgery for a total of 20 mL.
45653832|NCT05542199|Other|Multicomponent nutrition supplement (MCNS)|Palatable daily nutrition supplement for 12 months containing approximately 300 kcal and a wide range of nutrients and plant constituents with potential to support brain health and cognition.
45452578|NCT03952325|Drug|Pembrolizumab|Pembrolizumab at 200 mg by intravenous infusion Q3W
45452579|NCT03952325|Drug|Atezolizumab|Atezolizumab at 1,200 mg by intravenous infusion Q3W
45452580|NCT03952325|Drug|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
45804956|NCT05924867|Other|plasma activated saline|The plasma activated normal saline used in the intervention was prepared by a self-made machine, and the safety of the plasma activated water produced by the machine has passed the national quality inspection.
45804957|NCT05924867|Other|Routine nursing|For postoperative incision infection group and infected ulcer group, conventional dressing change treatment was given, namely chlorhexidine disinfectant washing, drainage and bandaging; For the fat liquefaction group, conventional treatment was given, namely negative pressure suction.
45936890|NCT00406471|Drug|Ranibizumab (Lucentis)|500 microgram intravitreal injection for 8 months or 300 microgram intravitreal injection for 8 months
45936891|NCT00406510|Drug|Optive, Systane|
46073814|NCT02818764|Procedure|Cerebral Spinal Fluid collection|Fluid collected at the time of dural puncture if patients will undergo spinal anesthesia
46073815|NCT02818764|Device|Electroencephalogram|Test used to detect abnormalities related to electrical activity of the brain will be done during surgery.
46073816|NCT02818764|Device|Cerebral blood flow and oxygen extraction fraction|NIRS measurement of Cerebral blood flow and cerebral tissue oxygen concentration.
46073817|NCT02818842|Other|Primary Health Insurance Fund data|"Data collected are:~First and last name of mother~Age~Mother's date of birth~Theorical date of beginning of pregnancy~Childbirth date"
46088534|NCT05242835|Procedure|Single-anastomosis duodenal switch|Single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)
45452581|NCT04473898|Other|Aerobic Exercise Training|Aerobic exercises using all body muscles and that one can do on their own after being shown online
45452582|NCT04473898|Behavioral|Patient Education|Patient education about covid-19 and hygiene education
45452583|NCT04473898|Other|Respiratory Exercise Training|Respiratory exercises that one can do on their own after being shown online
45653833|NCT05542199|Behavioral|Behavioral weight loss program|Enrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program.
45653834|NCT04981327|Drug|Apixaban 2.5 MG Oral Tablet [ELIQUIS]|Apixaban 5 MG BID versus Apixaban 2.5 MG BID
45653835|NCT05699837|Device|Audio or visual alpha (10Hz) stimulation|Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights, to deliver rhythmic 10Hz or non-rhythmic stimulation
45936892|NCT00154492|Drug|activated recombinant human factor VII|
45936893|NCT00050882|Drug|GM-611|
45936894|NCT00083421|Drug|ONO-2506PO|
45936895|NCT00154570|Device|EGG, 24 hour esophageal pH monitor|
45936896|NCT00154609|Drug|Gu-Sui-Bu (Davallia Divaricata)|
45936897|NCT00154648|Procedure|CE-MRA|
45936898|NCT00050921|Drug|somatropin|
45936899|NCT00050921|Biological|Hepatitis A virus, inactivated|
45936900|NCT00050921|Drug|Keyhole-Limpet Hemocyanin|
45936901|NCT00154687|Drug|Paclitaxel, Cisplatin, 5-Fluorouracil|
45804958|NCT05924854|Other|electroacupuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints). Equipment used in the trial included:~Huatuo brand copper filiform needle (diameter: 0.35×50mm), Suzhou Medical Supplies Factory, Food and Drug Administration firearms production: Suzhou Food and Drug Administration firearms production No. 20010020.~Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675"
45936902|NCT00083460|Drug|PS-341|Arm 1 a dose of 1.0mg/m2. Arm 2 a dose of 1.3mg/m2
45804959|NCT05924841|Drug|BL-B01D1|Administration by intravenous infusion
45804960|NCT05924841|Drug|SI-B003|Administration by intravenous infusion
45804961|NCT05924828|Other|no intervention|no intervention
45804962|NCT05924815|Drug|Aficamten|Oral Tablet
45804963|NCT05924815|Drug|Aficamten-matching Placebo|Oral Tablet
45804964|NCT05924815|Drug|Moxifloxacin|Oral Tablet
45804965|NCT05924802|Dietary Supplement|Ketone Ester|Added to water or lemonade 3 times per day.
45653836|NCT05547815|Biological|5 doses program|Inoculate 5 doses of rabies vaccine, and collect blood at fixed time points to detect neutralizing antibody
45653837|NCT05541965|Other|Reflexology and kegel exercises|"Reflexology is specific to a foot massage, and ıt can use different symptoms for patients.~Kegel exercise is specific an activities and ıt can used for urinary incontinence"
45653838|NCT05547737|Drug|Camrelizumab|Cross - line treatment of Camrelizumab in non-small cell lung cancer
45653839|NCT05547659|Drug|Pregabalin 150mg|Pregabalin 150mg preoperative in unimodal group Pregabalin 150mg preoperative in multi-modal group
45804966|NCT05924802|Dietary Supplement|Placebo|Added to water or lemonade 3 times per day.
45804967|NCT05924789|Other|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
45936903|NCT00083460|Drug|Thalidomide|In cohort 1, a dose of 50mg for cycles 2-8. Cohort 2, 100mg for cycles 2-8. Cohort 3, 150mg for cycles 2-8. Cohort 4, 200mg for cycles 2-8.
45936904|NCT00083460|Drug|Dexamethasone|A dose of 20mg for cylces 3-8.
45936905|NCT00154726|Drug|Paclitaxel-HDFL|
45936906|NCT00154765|Device|sling suspension exercises|
45936907|NCT00154804|Drug|Paclitaxel, Cisplatin,Surgery, CCRT|
45936908|NCT00154843|Drug|Lycopene|A: Lycopene15 mg/day ; B: Lycopene30 mg/day
45936909|NCT00043953|Drug|Lopinavir/ritonavir|
45936910|NCT00043953|Drug|Saquinavir mesylate|
45936911|NCT00043953|Drug|Lamivudine/zidovudine|
45936912|NCT00154882|Drug|Paclitaxel (Phyxol) , Cisplatin|
45653840|NCT05547659|Drug|Acetaminophen 1 G Oral Tablet|Acetaminophen 1 G Oral Tablet preoperative in multi-modal group
45936913|NCT00050999|Drug|ONTAK|
45936914|NCT00051077|Drug|Adefovir dipivoxil|
45936915|NCT00051077|Drug|Peginterferon-alfa-2A|
45936916|NCT00051077|Drug|Ribavirin|
45936917|NCT00051077|Procedure|Liver Biopsy|
45936918|NCT00155233|Drug|Nalbuphine and morphine|
45936919|NCT00051116|Drug|CC-5013|
45936920|NCT00155272|Drug|Thalidomide|
45936921|NCT00044031|Biological|G17DT Immunogen|
45936922|NCT00155311|Procedure|orthodontic treatment|
45936923|NCT00155350|Drug|pioglitazone|
45936924|NCT00155389|Drug|Helicobacter pylori eradication|"For subjects who received the first-line treatment, the costs included the initial 13C-UBT, one-week triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and clarithromycin 500mg twice daily), and the confirmatory 13C-UBT. For subjects in whom the initial treatment failed, the costs further included the re-treatment consisting of ten-day triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and levofloxacin 500mg once daily), and the confirmatory 13C-UBT.~The first round of study was between 2004 and 2005, the second round was between 2008 and 2009, and the third round was between 2012 and 2013."
45936925|NCT00051155|Drug|Travoprost (0.004%)|
45936926|NCT00051155|Drug|Latanoprost (0.005%)/Timolol (0.5%)|
45936927|NCT00044070|Drug|YM872 (zonampanel)|
45936928|NCT00155428|Procedure|rapid prototyping|
45936929|NCT00155428|Procedure|computed tomography|
45936930|NCT00155467|Procedure|CT|
45936931|NCT00051194|Drug|Combination IOP Lowering Therapy|
45653841|NCT05547659|Drug|Celecoxib 400Mg Oral Capsule|Celecoxib 400Mg Oral Capsule preoperative in multi-modal group
45653842|NCT05552417|Other|Pectointercostal facial plan block|Pectointercostal facial group (PI) (n=--) where --children will have bilateral Pectointercostal Block.
45653843|NCT04426175|Device|2D and 3D cutting method using a low energy Femtosecond laser LDV Z8 for LASIK flap cutting|2D and 3D cutting methods were randomly used in same subjects
45653844|NCT05552105|Other|Blood test|Before and after 6-months of anti TNF treatment, blood will be collected using the TruCulture system (2x 1ml in non-stimulated and LPS-stimulated TruCulture tubes) to measure Whole Blood Oxylipin Response, cytokine response, PUFA cell content and gene expression under homeostatic and stimulated conditions (i.e. LPS)
45653845|NCT05541809|Other|Aromatherapy|Peppermint aroma inhalation
45653846|NCT05541809|Other|Placebo|Water inhalation
45653847|NCT05547503|Drug|AFA-281|Part 1: AFA-281 will be administered as a single dose at either 20, 40, 80, 160 or 300 mg Part 2: AFA-281 will be administered twice daily for 14 days at 3 dose levels (TBD)
45653848|NCT05541575|Other|VR films|A new virtual reality course for home care workers to experience the view of dementia people with BPSD and the relative feelings.
45653849|NCT05541419|Drug|Budesonide Nasal|The patient performed a lavage once daily with 2mg dilute budesonide. The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.
45653850|NCT05541419|Drug|Placebos|Composed of 1% glycerin diluted in water. The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.
45804968|NCT05924776|Biological|Plasmodium immunotherapy|Inoculation 1-5 × 10^6 Plasmodium vivax once
45804969|NCT05924763|Device|Biphasic Cartilage Repair Implant (BiCRI)|The Biphasic Cartilage Repair Implant (BiCRI) is a two-phase scaffold composed of poly(lactic-co-glycolic acid) (PLGA) and β-triCalcium phosphate (TCP).
45804970|NCT05924750|Drug|BL-M11D1|Administration by intravenous infusion
45804971|NCT05924737|Other|Sleep deprivatin|40 hours of continuous awakening
45804972|NCT05924737|Other|Sleep recovery|sleep recovery after 40 hours of continuous awakening
45804973|NCT05924724|Device|Flash Glucose Monitoring|The FGM is a non-invasive device typically worn on the upper arm, designed to continuously measure blood glucose levels without the need for fingerstick capillary measurements.
45804974|NCT05924711|Other|Retrospective analysis of demographic and radiographic data previously obtained from the patient.|The patient's demographic data obtained previously by anamnesis and clinical examination will be retrospectively analyzsed. On the other hand, a radiographic evaluation including analysis of the implants, adjacent teeth and maxillary sinuses/sinus membranes shall be performed using computer software.
45936932|NCT00155545|Behavioral|Motion analysis of patients|
45936933|NCT00083538|Drug|Dexamethasone|
45936934|NCT00083538|Drug|Thalidomide|
45936935|NCT00083538|Drug|Cisplatinum|
45936936|NCT00083538|Drug|Adriamycin|
45936937|NCT00083538|Drug|Cyclophosphamide|
45936938|NCT00083538|Drug|Etoposide|
45936939|NCT00051233|Procedure|World Wide Web-Based Psychoeducation|
45936940|NCT04724863|Procedure|Angioscan|"The study procedure foresees to take images during a deep breath as well as deep exhalation. This second measurement does not require the administration of an additional amount of contrast material. However, the exposure time to ionising radiation is doubled. The examination uses helical acquisition in fast mode. The duration of the helix is of the order of 2 seconds in the inspiration phase, then there is a delay of 5 seconds of machine time (half-turn) and again 2 seconds of exposure in the expiration phase, i.e. 4 seconds of actual exposure to ionizing radiation, the time of image taking and 9 seconds the total time of the examination."
45936941|NCT00155662|Behavioral|work-hardening program|
45936942|NCT00083577|Drug|Thalidomide|
45936943|NCT00154414|Drug|liraglutide|
45936944|NCT00406705|Behavioral|Helium-Hyperoxia|
45936945|NCT00044109|Device|Magnets|
45936946|NCT00406744|Drug|Intravitreal injection of Bevacizumab|
45936947|NCT00155935|Procedure|venous puncture|
45936948|NCT00399750|Drug|oxaliplatin|
45936949|NCT00399750|Drug|fluoropyrimidine|
45936950|NCT00399750|Drug|bevacizumab|
45936951|NCT00155974|Biological|Community-based vaccine outreach intervention|
45936952|NCT00156052|Radiation|Conventional whole breast radiation schedule|
45936953|NCT00156052|Radiation|Hypofractionated whole breast radiation schedule|
45936954|NCT00044148|Drug|LY333531|
46073818|NCT02818842|Other|Prenatal Diagnostic Center of Toulouse University Hospital data|"Data collected are :~First and last name of the mother~Mother's birth date~Mother Obstetric history~Course of pregnancy~Drug exposure (name, decision period)~Medical termination of pregnancy (date, cause ...)~Malformations (description, test results, gender of the child,~Weight, height and head circumference, American Pediatric Gross Assessment Record, neonatal pathology)."
46073819|NCT02818842|Other|Mother and child protection data collection|"Date collected are :~Name and surname of Mother~Date of birth of the mother~Obstetric history of the mother (the first certificate to 8 days)~Course of pregnancy (1st certificate to 8 days)~Birth data (1 certificate to 8 days)~Child gender,~Age of the child at the time of the review,~Weight, height and head circumference of the child~American Pediatric Gross Assessment Record (1 certificate to 8 days)~Neonatal diseases (1 certificate to 8 days)~Birth defects (1 certificate to 8 days)~Death (age at death)~History (certificates at 9 and 24 months)~Current diseases (certificates at 9 and 24 months)~Psychomotor development (certificates at 9 and 24 months).~Date of drugs issue~Amount of drug issued~Type of feeding (1 certificate to 8 days)"
45676258|NCT04200690|Other|Interdisciplinary management|"The intervention in this trial consists of the combined efforts of the interdisciplinary team in the combined clinic arm.~The interdisciplinary team consists of dermatologists, gastroenterologists, rheumatologists, nurses, psychologists, dieticians, social workers, physiotherapists, and secretaries. Treatment will be individualized based on clinical, biomarker, phenotypic, and psychosocial characteristics. The medical treatment will follow local, national and international guidelines."
46073820|NCT02818842|Other|Medicalisation Program of Information Systems data|"Data collected are :~First and last name of the mother~Mother's birth date~History of abortions (date and cause)"
46073821|NCT00850369|Other|RBC transfusion|Study subjects will receive monthly transfusions with 2 units of red blood cells
46073822|NCT02861963|Procedure|Experimental: RVOT reconstruction by femoral allogenic vein valve conduit|Right ventricular outflow tract reconstruction using femoral allogenic vein valve conduit under CPB and induced ventricular fibrillation
45804975|NCT05924698|Other|Electrostimulation|Consisting of the use of NMES (biphasic symmetrical pulse, bipolar mode, 50Hz frequency, pulse duration 300 μs at 1:1 ratio) (S82®; Enraf-Nonius BV, Rotterdam, The Netherlands). The self-adhesive electrodes (8x5 cm2 Pals Platinum © type, Axelgaard Manufacturing Co. Ltd, Fallbrook, CA, USA) were placed on the quadriceps muscle. The positives electrodes placed distally on the rectus anterior and vastus externus and negative electrodes were placed proximally on the rectus anterior and vastus internus. The over current program consisted of 8 seconds (s) of work (ON phase) and 8 seconds of rest (OFF phase). The overcurrent program in the ON phase had a rise time of 2 s, a hold time of 4 s and a fall time of 2 s. The intensity of the electric current was increased to the maximum perceived tolerance, achieving a clear contraction without producing fatigue.
45458004|NCT03109834|Other|Control (C)|"During 3-month weight loss phase (phase 1) C-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d without MR for weight control.~During 3-month weight stabilization (phase 2) phase C-S group (C group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The C-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)"
46073823|NCT02861963|Procedure|Systemic-to-pulmonary artery shunts|"Modified Blalock-Taussig shunt performed between the right subclavian and pulmonary arteries or the left subclavian and pulmonary arteries of the type end to side."
45804976|NCT05924698|Other|Blood flow restriction therapy|To attain partial vascular occlusion, a PTS ii portable tourniquet system (Delphi Medical, Vancouver, BC, Canada) with a corresponding size-specific tourniquet was placed around the patient's proximal thigh. This system allows for precise control of cuff pressure throughout training despite the changes in muscle volume that naturally occur while performing exercises. Total limb occlusion pressure (LOP) was identified by determining the pressure required to eliminate a detectable pulse using Doppler ultrasound. Partial vascular occlusion was achieved by setting the tourniquet to 80% of the LOP. This ensured that venous occlusion was obtained while still allowing arterial inflow and was personalized to each patient despite variations in thigh girth, cuff size, and systolic blood pressure. An Easy-Fit Tourniquet Cuff (Delfi Medical, Vancouver, VC, Canada) was used with the PTS ii system.
45804977|NCT05924685|Biological|COVID-19 vaccination|Vaccination
45804978|NCT05924672|Drug|Radium-223|Given IV
45804979|NCT05924672|Procedure|PSMA Positron Emission Tomography (PET) Scan|Undergo PSMA PET/CT
45804980|NCT05924672|Drug|Technetium Tc 99M Medronate|Undergo MDP
45804981|NCT05924659|Other|Neurofeedback|Neurofeedback training
45804982|NCT05924646|Dietary Supplement|Sodium Chloride Capsules|Table salt in slow release capsules.
45804983|NCT05924646|Other|Microcystalline Cellulose Capsules|Microcrystalline Cellulose Capsules (Placebo)
45804984|NCT05924633|Dietary Supplement|Supplement containing a protein hydrolysate + beta glucan (Wellmune®)|Supplement taken daily for 4 weeks.
45804985|NCT05924633|Dietary Supplement|Placebo supplement containing maltodextron|Placebo supplement taken daily for 4 weeks.
45804986|NCT05924620|Drug|finerenone|Patients with PA divided into Intervention group need to take finerenone for 60 days (20mg qd).
45804987|NCT05924607|Other|Standard clamshells method|The patient is asked to lie in a side-lying position with the weak limb up, both hips flexed at 45°, the knees flexed at 90°, and neither the feet nor back not in contact with the wall. Keeping both their heels and the first metatarsal head together, the patient separated their knees and rotated the weak limb upward. The patients is instructed not to tip it backward and to hold the pelvis in a neutral position
45936955|NCT00156130|Radiation|Conventional radiotherapy schedule|50 Gy in 25 fractions over 35 days
45936956|NCT00156130|Radiation|Accelarated radiotherapy schedule|42.5 Gy in 16 fractions over 22 days
45936957|NCT00156169|Drug|Dunaliella|
45936958|NCT00156208|Drug|Asoprisnil|10mg Tablet, oral Daily for 18 months
45936959|NCT00156208|Drug|Asoprisnil|25 mg Tablet, oral Daily for 18 months
45936960|NCT00156286|Drug|Gleevec|
45936961|NCT04731636|Device|G-Branch thoracoabdominal aortic stent system|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with thoracoabdominal aortic stent system.
46088535|NCT04315350|Drug|Curcumin Liposome|Curcumin is given together with prednisolone
46073824|NCT05658744|Behavioral|Video group|Insulin administration video was sent to the mobile phones of the patients assigned to the video group
46073825|NCT00850447|Other|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is a standardized intervention that involves performing cognitive exercises to improve attention, processing speed, and memory through practice. Participants will have one 60-minute CRT session each week for ten weeks. The CRT to be used in the proposed study is CogPack (version 6.0 Marker Software, Mannheim Germany). CogPack demonstrates flexibility in terms of developing a targeted intervention plan based on the levels of baseline cognitive impairment. There are approximately 6 different exercises presented in each training session, with the starting level of difficulty individualized on the basis of baseline neuropsychological performance.
46088536|NCT04315350|Drug|Prednisolone|Prednisolone is given together with curcumin-placebo
45804988|NCT05924607|Other|Targeted VMO strengthening|Targeted VMO strengthening The patient is asked to lie in a supine lying position with arm next to the body. After that asked the patient to perform SLR exercise in an external hip rotation with the simultaneous contraction of the ankle dorsiflexors. Common treatment will be given to each patient includes hot pack for 10 minutes and knee isometric contraction exercises and SLR( 3-5 sets of 10 repetitions
45452584|NCT01583153|Other|Hospital Inpatient Rehabilitation|Those allocated to HI will be admitted to the adjacent rehabilitation hospital, Braeside Rehabilitation Hospital, for 10 days. As per the private sector, HI participants will receive twice-daily supervised physiotherapy comprising 1-1.5 hr class-based exercises and 1-1.5 hr one-to-one therapy. Prior to discharge, participants will be familiarised with the home programme as described in second arm. All participants will be required to complete a diary detailing programme adherence, healthcare utilisation, and social costs relating to carer-burden. Participants will attend the group-based sessions as per HO below for monitoring and progression of programme. An additional FIM outcome measure will be taken for this arm on admission and discharge from the inpatient rehab unit.
45458005|NCT03109834|Dietary Supplement|Verum|"Verum: Specific micronutrient composition with omega-3 fatty acids (capsules)~Verum group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 verum-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase (phase 3).~Duration: 6 months (6.month / baseline II - 12.month)"
45653851|NCT05551637|Dietary Supplement|Kazu Gain Gold|"Kazu Gain Gold is an Oral Nutritional Supplementation made by AIWAIDO Food Joint Stock Company.~Condition: Powder~Color: White to light yellow~Scent: The fresh scent of milk, gracious sugary smell.~Date of use: 24 months from the manufactured date.~User Manual: Mix 6 spoons of Kazu Gain Gold (equal to 49,2 grams) with 180 ml of warm water (The energy density reaches 1kal/ml). Consume 2 glasses per day or follow the directions from the medical staff. The product should consume less than 1 hour. Do not let the child eat the leftovers of the previous meal.~Preserve: Store in a clean, dry place, and keep away from direct sunlight. Opened can or package must be closed and used up within 3 weeks."
45653852|NCT05547113|Diagnostic Test|posturography|In our stabilometric laboratory we use for the posturography two Kistler stabilometric platforms (type 5619A, Switzerland) along with MARS software (version 5.0, Switzerland). We use the SYNAPSIS Subjective Vertical device (version 1.3.2, France) to examine the perception of the subjective visual vertical. The patients should also full fill 5 questionnaires to subjective evaluation of non-vestibular symptoms within ADL and QoL, namely for difficulties related to dizziness, tinnitus, orofacial function disorders and the occurrence of anxiety and depression. For this purpose we use Dizziness Handicap Inventory, Tinnitus Handicap Inventory, Facial Disability Index, Beck's Anxiety Inventory and Beck's Depression Inventory.
45653853|NCT05547035|Behavioral|Patient follow-up of depression|"All patients who agree to participate in the study are diagnosed by their GP/Psychiatrist with a diagnostic assessment instrument called DSM-5. Participants visit their GPs/Psychiatrists at baseline, month 1, month 2, month 3, month 4, month 5 and month 6. At each visit, the GPs/Psychiatrists:~assess the depression severity by using MADRS scale~assess the severity of illness at time of assessment compared with start of treatment by using CGI-S measures~the patient complete the self-administered questionnaire of HAD scale that measures the symptoms of anxiety and depression."
45804989|NCT05924594|Drug|CTx-1301 - Dexmethylphenidate 6.25mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
45804990|NCT05924594|Drug|CTx-1301 - Dexmethylphenidate 12.5mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
45804991|NCT05924594|Drug|CTx-1301 - Dexmethylphenidate 18.75mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
45804992|NCT05924594|Drug|CTx-1301 - Dexmethylphenidate 25.0mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
45804993|NCT05924594|Drug|CTx-1301 - Dexmethylphenidate 31.25mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
45804994|NCT05924594|Drug|CTx-1301 - Dexmethylphenidate 37.5mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
45804995|NCT05924594|Drug|Placebo|Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomized phase.
45936962|NCT00156325|Drug|Escitalopram (Lexapro)|
45936963|NCT00156403|Drug|amlodipine (drug)|
45936964|NCT00051272|Drug|Extended-release Bupropion Hydrochloride|
45936965|NCT00044187|Drug|Sibutramine|
45936966|NCT00156520|Drug|aprotonin; epsilon aminocaproic acid|
45936967|NCT00051350|Other|CARB|
45936968|NCT00083694|Drug|Thalidomide|
45936969|NCT00156637|Behavioral|Team-Based Quality Improvement Intervention|Intervention to improve recommended dosing and side effect monitoring of antipsychotic medications using a team-based quality improvement effort
45936970|NCT00156637|Behavioral|Opinion Leader Intervention|Intervention to improve recommended dosing and side effect monitoring of antpsychotic medications using an Opion leader quality improvement effort
46002530|NCT01356290|Drug|Bevacizumab|10mg/kg, intravenous (iv), biweekly, 1 year
45936971|NCT00156637|Behavioral|Team Based Quality Improvement|Intervention to increase appropriate use of clozapine through a team based quality intervention.
45936972|NCT00156676|Device|Body-weight supported treadmill|
45936973|NCT00156676|Device|Lokomat|
45804996|NCT05924581|Other|Clinical assessment of spinal stiffness|"The clinical stiffness tests will be applied twice to the same patient by the same operator to verify intra-operator variability and twice by two operators at the same time to verify inter-operator variability.~The verification of diagnostic accuracy with respect to the radiographic reference standard will be carried out retrospectively by using the data already available and systematically collected in electronic format during medical visits and physiotherapy sessions."
46073826|NCT00850447|Other|Videogame|Participants will play the videogame Tetris once each week for 30 minutes. Tetris is a video puzzle game that involves manipulating falling shapes. The object of the game is to manipulate these shapes, by moving them sideways or rotating them, to create a horizontal line of blocks without gaps. As the game progresses, the shapes fall faster.
45936974|NCT00156676|Device|Body-weight supported treadmill|
45936975|NCT00156676|Device|Lokomat|
45936976|NCT00051389|Drug|Fosinopril|
45936977|NCT00156793|Procedure|AI-700 contrast-enhanced echocardiography|
45936978|NCT00156871|Behavioral|exercise|
45936979|NCT00156949|Drug|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
45936980|NCT00156988|Drug|cerium nitrate-silver sulfadiazine (cerium-flamazine)|
45936981|NCT00157027|Procedure|Extracorporeal photochemotherapy with UVADEX|"Photopheresis (or extracorporeal photoimmunetherapy [ECP]) is a process developed by THERAKOS, Inc., a Johnson and Johnson Company. During the process of ECP, whole blood is drawn from the patient over several cycles, centrifuged and separated into the components of plasma, white cells (or buffy coat), and red blood cells. A portion of the white cells and the plasma are saved in a separate compartment. The remaining plasma and red blood cells are immediately returned to the patient.~The saved buffy coat (white blood cells) and plasma are inoculated with the photosensitizing agent UVADEX. Photoactivation begins when the suspension is exposed to a prescribed amount of ultraviolet-A light. After photoactivation is complete, the treated suspension is returned to the patient."
45936982|NCT00044226|Drug|ML-04A|
45936983|NCT00157066|Drug|Ergocalciferol|
46073827|NCT03379649|Combination Product|Platelet rich plasma|Patients will have 60ml of blood drawn. Platelet rich plasma will be obtained by placing the blood in the Arteriocyte Magellan device. 0.5ml of Platelet rich plasma will be placed into the uterus at least 48 hours prior to embryo transfer.
46073828|NCT03379649|Combination Product|Placebo|Patients will have 60ml of blood drawn. 0.5ml of embryo culture media (the placebo) will be placed into the uterus at least 48 hours prior to embryo transfer.
46073829|NCT05658900|Other|Enucleation with albumin PRF|"The protocol that will be used in the preparation of albumin PRF~A sample of venous blood, at ten milliliters, at least will be drawn from the patient in a sterile centrifuge tube.~The venous blood sample will be centrifuged at 700 g for 8 minutes.~* Betadine: Povidone-iodine, 7.5% (0.75% available iodine), Purdue Products L.P~The platelet-poor plasma layer will be taken and heated at uniform temperature 75 celsius for 10 minutes in a thermostatic water bath incubator to denature albumin protein forming albumin gel.~Once the albumin gel is cooled, to room temperature for 10 minutes, it will be mixed with the buffy coat layer of PRF using 3 way stop cock and 2 plastic syringes with Luer lock to obtain albumin PRF then leave it in the dappen dish for 5 minutes."
46073830|NCT05658900|Other|Enucleation without albumin PRF|"The full-thickness mucoperiosteal flap will be performed using blade no. 15 and Bard- Parker handles extending one tooth anterior and one tooth posterior to the cystic cavity.~The mucoperiosteal flap will be reflected using the periosteal elevator to expose the bone.~Removal of the overlying bone to expose the cystic lesion. Enucleation of the cyst."
45653854|NCT02630251|Drug|GSK2820151|GSK2820151 is provided as capsules containing 1 mg, 5 mg, 10 mg, 50 mg, or 100 mg of GSK2820151 as free base equivalent to be administered orally. The dosing regimen is as follows: Week 1 - once daily on days 1, 3, 4, and 5; Week 2 - once daily on days 1, 2, 3, 4, 5; and Weeks 3 and beyond - once daily continuously.
46073831|NCT00850681|Drug|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
46088537|NCT04315350|Drug|Placebos|Prednisolone-placebo is given together with curcumin-placebo
45653855|NCT04321109|Other|Allograft|Corticocancellous mineralized allograft
45804997|NCT05924568|Other|Educational session with Keep Your Move in the Tube and PrimusRS|
45804998|NCT05924555|Other|Intermittent cardiopulmonary exercise test|Exercise test with step-change from rest to a relatively low constant workload.
45804999|NCT05924555|Other|Incremental cardiopulmonary exercise test|Exercise test with incremental workload until maximal workload.
45458006|NCT03109834|Other|Placebo|"Placebo group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 placebo-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase.~Placebo contains no micronutrients and omega-3 fatty acids.~Duration: 6 months (6.month / baseline II - 12.month)"
45805000|NCT05924555|Other|Echography of upper leg|Determine upper leg muscle size
45805001|NCT05924555|Other|Hand grip strength with hand dynamometer|Determine muscle strength
45653856|NCT04321109|Other|Collagen cone|Collagen matrix
45653857|NCT05551559|Procedure|bariatric surgery|bariatric surgery
45805002|NCT05924555|Other|Fill in questionnaires regarding physical activity|SQUASH, mMRC, questionnaire designed to report myopathic symptoms in LcFAOD patients.
45835670|NCT00747396|Other|Foster Care Placement|A group of children living in institutions in Bucharest, Romania was randomly assigned to placement in foster care. Foster parents were recruited, consented to background checks, and trained in Romanian. Before placement, foster parents visited their children to begin developing a relationship with the child. Hired foster parents were supported and monitored by project social workers. Foster parents in the BEIP network received frequent visits from the social workers, with visits occurring weekly for several months after placement of the child, then biweekly and later monthly. Foster parents were invited to participate in a support group organized by social workers. Project social workers consulted weekly with US staff experienced in dealing with young children in foster care.
45936984|NCT00051428|Procedure|Reiki (distant and direct-contact)|
45653858|NCT05541263|Behavioral|Mindfulness Based Stress Reduction|The intervention used is an MBSR training which is based on the Mindfulness-Based Stress Reduction programme as developed by Kabat-Zinn (1982). The training consists of 8 weekly sessions lasting 2,5 hours. A silent day of approximately 6 hours is also included, as well as daily home practice assignments of about 45 minutes. During the training participants will learn to focus their attention in the present moment in an accepting and non-judgemental way, rather than ruminating about past and future experiences. The training includes formal exercises during which participants will practice the body scan, sitting meditation, walking meditation and mindful movement. Informal exercises are also included, such as performing a daily activity with full attention to the present experience. The training is led by qualified teachers meeting the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders (www.vmbn.nl)
45805003|NCT05924542|Behavioral|Kelaa Mental Resilience App|"Users can track their stress, wellbeing, and resilience via short in-app questionnaires. The app uses inbuilt sensors in smartphones to measure sleep quality and quantity. Personalized feedback on questionnaire scores and on sleep data are given. Users access structured science-based content on factors contributing to reduced stress and improved well-being. Kelaa provides the user with evidence-based interventions grounded in current research, e.g., from sleep science and psychology. Users can choose from a variety of topics, based on their results from the tracking module and personal interest, and then journey through the self-selected goals. Each goal includes six to seven daily sessions, aiming to increase personal resources by providing information, exercises, and reflection. During each daily session, relevant research and expected benefits are outlined, before users are instructed, e.g., in specific stress management and resilience techniques, to encourage behavior change."
45805004|NCT05924516|Behavioral|Adhera® Fatigue Digital Program|The Adhera® Fatigue Digital Program is delivered via a mobile application and includes personalized educational and interactive content. The program is designed to support the wellbeing of people living with type 2 diabetes, including self-management education and support. This also includes a focus on diabetes-related fatigue.
45805005|NCT05924490|Behavioral|Real-time strategy-based videogame training|Rise of Nation is a complex strategy-based video game, in which individualized-adaptive feedbacks are constantly given to players based on their performance.
45805006|NCT05924490|Behavioral|Semantic Knowledge training|Packages of various cross-word puzzles include word search, word ladder, and word wheel.
45805007|NCT05924477|Procedure|Sulcus tube placement|GDD implantation surgery with tube placement in the ciliary sulcus
45805008|NCT05924477|Procedure|Anterior chamber (AC) tube placement|GDD implantation surgery with tube placement in the anterior chamber
45805009|NCT05924464|Other|Group Preconception Care|Groups of 6-10 patients to initiate biweekly virtual group care sessions on a rolling basis, with completion of enrollment and the virtual curriculum within a year.
45805010|NCT05924451|Behavioral|Immediate Loading|Clinical and radiographic examination of the periimplant soft and hard tissue will be analysed by using gingival index, plaque index, and pocket depth immediately post operative.
45805011|NCT05924438|Drug|Delstrigo|Treatment Group 1 Participants will receive Doravirine, as part of a fixed-dose oral combination with lamivudine and tenofovir disoproxil fumarate (DOR/3TC/TDF, Delstrigo)tablets which are to be administered orally and once daily.
45805012|NCT05924438|Drug|KOCITAF|Treatment Group 2 Participants will receive dolutegravir, as part of a fixed-dose oral combination with tenofovir alafenamide plus emtricitabine (DTG/TAF/FTC, KOCITAF) tablets which are to be administered orally and once daily.
45805013|NCT05924425|Drug|Daridorexant 50 mg|Patients randomized in the experimental group will receive the treatment every evening within 30 minutes of going to bed during one month. The treatment period (Period A or Period B) will be followed by a one-week (range 5-12 days) washout period at home.
45805014|NCT05924425|Drug|Placebo|Patients randomized in the control group will receive the placebo every evening within 30 minutes of going to bed during one month. The treatment period (Period A or Period B) will be followed by a one-week (range 5-12 days) washout period at home.
45936985|NCT00157105|Drug|Antihemophilic factor, recombinant, manufactured protein-free|
45805015|NCT05924425|Procedure|Polysomnography|A full-night polysomnography recording with blood pressure and heart rate monitoring will be performed at night in the Sleep Laboratory from 11 p.m. to 7 a.m. at baseline (before the randomization) and at the end of each period (Period A/M1, Period B/M2). The recording procedure consists of an electroencephalogram, two electrooculograms, an electromyogram, an electrocardiogram, and a videographic recording. This examination is painless (the sensors are glued to the skin for the duration of the recording). The advantages of this video-polysomnography are based on the evaluation of sleep architecture, micro-arousals, respiratory events and nocturnal motor behavior.
45805016|NCT05924425|Behavioral|Neuropsychological assessment|A full neuropsychological assessment will be performed at inclusion, M1, M2
45936986|NCT00157183|Device|Nocturnal oxygen , nocturnal bi-level positive pressure ventilation|
45936987|NCT00083772|Drug|Nesiritide|Initial dose by vein of 2 mcg/kg then infusion by vein of 0.01 mcg/kg/min continuously for 48 hours.
45936988|NCT00157261|Drug|tenecteplase|
45936989|NCT00157300|Drug|Epoetin beta|intravenous, 33000 IU, 3 consecutive days, starting 3-4 hours before transplantation. Total dose 100.000 IU.
45452585|NCT01583153|Other|Hybrid Home Programme (HO)|The HO will be based on what is standard care in the local health district and guidelines for exercise in the elderly and those with osteoarthritis. Approximately 2 weeks post-surgery, participants allocated to the HO will attend 1 group-based exercise session in the Physiotherapy Department (Fairfield Hospital) where the home programme will be rehearsed and exercises individualised as required due to co-morbidities. The programme comprises general aerobic components as well as general functional and muscle-specific exercises focused on restoring knee mobility, lower limb strength, and normal neuromuscular co-ordination and gait patterns. Participants will be able to return for 2-3 sessions over the 6-week period.
45452586|NCT04473586|Device|Spartan Cube CYP2C19 System|Using buccal material, determine the genotype of the *2, *3 and *17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.
45936990|NCT00398060|Behavioral|Cognitive-behavioral life-style counseling|
45936991|NCT00157378|Drug|Risperidone, Haloperidol|
45936992|NCT00406822|Device|OculusGen Biodegradable Collagen Matrix Implant|
45452587|NCT01583231|Other|Prewash|The intervention will be the addition of the prewash utilizing non-antimicrobial soap and water.
45653859|NCT05700383|Behavioral|GetActive with Steps!|GetActive with Steps! is an adaptation of the original GetActive-Fitbit program, a mind-body program for the unique needs of individuals with chronic musculoskeletal pain that incorporates activity skills to help individuals improve all aspects of physical function. The GetActive with Steps! sessions address mind-body skills (e.g., mindfulness, deep breathing, self-compassion), walking skills (e.g., step goals, quota-based pacing), and skills to change thinking (e.g., identify unhelpful thoughts about pain and activity, challenging thoughts). The format is a 10-week program delivered in-person with weekly group sessions and home practice of skills and walking.
46073832|NCT04283591|Procedure|Acupuncture Treatment|Acupuncture Treatment Group will get acupuncture treatment which will be applied to Baihui (DU20), Yintang (EX-HN3) points of the hemiplegic side and bilateral Tai Chong (LR3), Hegu (LI4) points for 4 weeks, twice a week.
45936993|NCT00406861|Drug|montelukast in treatment of ENL reaction|
45936994|NCT00044265|Drug|ramipril|
46073833|NCT04283591|Other|Conventional Rehabilitation Programme|They will continue to receive the conventional rehabilitation programme.
46073834|NCT04238988|Drug|Pembrolizumab|Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
45452588|NCT05197868|Procedure|Intubation with traditional laryngoscope|Participants will be invited to intubate the mannequin with a traditional laryngoscope
45452589|NCT05197868|Procedure|Intubation with a straight blade video laryngoscope|Intubation with a straight blade video laryngoscope
45653860|NCT05700383|Behavioral|Healthy Living for Pain|Healthy Living for Pain is an active intervention that will be dose, attention, and time matches to the GetActive with Steps! program. Healthy Living for Pain is an adaptation of the Health Enhancement Program, developed by Dr. Vranceanu and colleagues from Stony Brook, with adjustments for patients with chronic musculoskeletal pain. The Healthy Living for Pain sessions provide educational information on chronic musculoskeletal pain, the role of sleep and nutrition, physical activity, healthcare management, medication use, and social connection. The format is a 10-week program delivered in-person with weekly group sessions and home practice journaling.
45653861|NCT04980937|Procedure|Microsurgical reconstruction of peroneal nerve with or w/o nerve grafts.|
45653862|NCT05551481|Procedure|To evaluate the clinical performance of indirect resin composite restorations, which were luted with two different resin cement, in posterior teeth for up to 5 years.|resin cement (Variolink II, Ivoclar Vivadent)-self-adhesive resin cement (Relyx U200, 3M ESPE)
45653863|NCT03063229|Device|Accelerometer|Attach a monitor to participants thigh to measure their physical activity for 7 days. The monitor is called the Activpal Micro.
45805017|NCT05924425|Behavioral|Questionnaires on sleep and behavioural problems|Questionnaires on sleep and behavioural problems will be performed at inclusion, M1, M2
45805018|NCT05924425|Procedure|Actimetrics|Measurement of actimetrics for seven days in average (with a minimum of three nights required) prior to the inclusion visit, M1 visit and M2 visit.
45805019|NCT05924425|Procedure|24-hour Ambulatory Blood Pressure Monitoring (ABPM|Evaluation of the 24-hour hemodynamic profile of a patient by multiple and regular blood pressure and heart rate measurements. The ABP will be monitored at inclusion, M1 and M2
45805020|NCT05924425|Other|Biomarker assay|Determination of AD biomarkers (Aβ42, Aβ40, Tau, P-Tau, neurofilament) and proinflammatory cytokines (TNFa, IL6) in serum and cerebrospinal fluid (CSF) and dosage of Orexin-A/hypocretin-1 in the CSF
45805021|NCT05924412|Drug|Intravenous study drug|40mg parecoxib will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incisión
45835671|NCT04780386|Drug|NVP-1805|orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4)
46073835|NCT04238988|Drug|Carboplatin|Chemotherapy medication
45452590|NCT05197868|Procedure|Intubation with a hyper-angulated video laryngoscope|Participants will be asked to intubate the mannequin with a hyper-angulated video laryngoscope
45452591|NCT00948142|Drug|CEM-102|600 mg BID oral tablets for 10-14 days
45452592|NCT00948142|Drug|Linezolid|600 mg BID oral tablets
45452593|NCT00948142|Drug|CEM-102|1500 mg BID oral tablets on Day 1 followed by 600 mg BID oral tablets for a total of 10-14 days
45452594|NCT00947518|Drug|Chlorhexidine|Baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate)
45452595|NCT00947518|Drug|Normal saline|Cleansing the skin (except the face)with baby wipes containing normal saline
45452596|NCT00945802|Drug|FST-201 (dexamethasone 0.1%) Otic Suspension|Instill four drops two times a day
45452597|NCT00945802|Drug|ciprofloxacin 0.3%, dexamethasone 0.1%|Instill four drops two times a day
45452598|NCT01105624|Drug|azithromycin ophthalmic solution, 1%|1 drop BID for the first 2 days and then 1 drop QD for the remainder of treatment period (29 ± 1 day)
45835672|NCT04780386|Drug|NVP-1805-R1and NVP-1805-R2|orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4)
45835673|NCT04780308|Procedure|Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires|The effects of the different types of K-wire configuration on Pediatric Gartland Type 3 supracondylar humeral fractures were evaluated. Pediatric Gartland Type 3 supracondylar humeral fractures operated under general anesthesia with open or closed reduction. After reduction checked by fluoroscopy K-wires applied in different configurations.
45835674|NCT04780854|Drug|Metformin|Participants in the intervention group will be administered metformin tablets 2 gm daily during the chemotherapy treatment duration
45835675|NCT04780854|Drug|Placebo|Participants in the placebo group will be administered metformin free tablet as placebo twice daily
45936995|NCT00406900|Procedure|Treatment of metastatic disease|
45936996|NCT00398099|Drug|MK0826, ertapenem sodium / Duration of Treatment: 14 Days|
45936997|NCT00406939|Genetic|IL-12 gene|
45936998|NCT00406978|Drug|Prednisone|Prednisone will be given orally at the dose of 1.5 mg/Kg for 4 days followed by a 31-day rest period (days 5 through 35)
45936999|NCT00406978|Drug|Melphalan|Melphalan will be given orally at the dose of 0.25 mg/Kg for 4 days,
45452599|NCT01105624|Drug|Visine® for Contacts®|1-2 drops QID for the treatment period (29 ± 1 day)
45452600|NCT01102660|Drug|PH-797804|Tablet, 6 mg once daily for 2 weeks
46002531|NCT01356290|Drug|Thalidomide|3mg/kg, oral, daily, 1 year
46002532|NCT01356290|Drug|Celecoxib|50-400mg, oral bid, daily, 1 year
46073836|NCT04238988|Drug|Taxol|Chemotherapy medication
46073837|NCT00836173|Drug|RICE|RICE treatment: Rituximab by intravenous infusion over 6-8 hours on day 1, Eptoposide by intravenous infusion over 2 hours on day 3-5, a 1-hour infusion of Carboplatin on day 4 and a 24-hour infusion of Ifosfamide on day 4, each cycle is 14 days (2 weeks). Patients will receive 3 cycles of RICE treatment.
45653864|NCT03063229|Other|Anthropomentry|Take skinfold measurements of participants using Harpenden skinfold calipers.
45452601|NCT01102660|Drug|Placebo|Tablet, 0 mg once daily for 2 weeks
45653865|NCT03063229|Procedure|Blood tests|Taking standard clinical blood tests to measure HbA1c, Glucose, FBC, U&E's, LFT's, Coagulation Screen, Lipid Profile, Thyroid Function, and Tacrolimus for transplant patients.
45653866|NCT03063229|Device|BODPOD|Measure body composition using a BODPOD machine. This uses Air displacement plethysmography.
45452602|NCT01102660|Drug|Placebo|Tablet, 0 mg once daily for 2 weeks
45653867|NCT03063229|Procedure|MRI (Magnetic Resonance Imaging)|MRI Scans of abdomen, particularly the livers of islet transplant and insulin pump patients.
45452603|NCT01102660|Drug|PH-797804|Tablet, 6 mg once daily for 2 weeks
45653868|NCT03063229|Other|Food Diary|Participants will keep a 7 day weighed food diary.
45653869|NCT03063229|Device|CGMS (Continuous Glucose Monitoring System)|Participants will wear a CGMS for 7 days to measure their glucose control and pattern over a 7 day period.
45653870|NCT03063229|Other|Questionnaire and Hypo Score|Participants with Type 1 Diabetes will fill in 3 short questionnaires about their Diabetes.
45653871|NCT03063229|Procedure|Mixed Meal Tolerance Test (MMTT)|"The patients will under go a test which involves taking 30 minute glucose and C-peptide levels (blood test from a cannula) for 3 hours. They will consume 150ml of a mixed meal supplement drink Fortisip Compact at the start of the 3 hours, after having no morning insulin, breakfast and not eating anything from midnight the night before."
45653872|NCT03063229|Procedure|Indirect Calorimetry|During the Meal Tolerance Test, the patients will be resting on a bed in the research facility and breathing normally into a clear plastic hood. The machine connected to the hood (GEM) will analyse their resting energy expenditure from the gases expired in their breath. They will have the hood on for 2 hours.
45653873|NCT03063229|Drug|Doubly Labelled Water|The Doubly Labelled water will be prescribed for the participants and they will drink their 100ml dose of the stable isotope. Dose depends on the eight of the participant. The participant will then collect urine samples at home on day 5, 10 and 14 after drinking the water. They will store them in the freezer until they can bring them back to us.
45805022|NCT05924412|Other|Intravenous saline solution|Saline solution (same volume as the study drug) will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incision
45805023|NCT05924399|Behavioral|Affect Labeling Training|(1) Participants will view combat-relevant images and then label the image or how they feel while viewing the image. (2) Participants will view facial expressions and then label the image. (3) Participants will view negative combat- irrelevant images (such as snakes or spiders) and then label the image or how they feel while viewing the image. (4) Participants will complete Go-NoGo trials similar to the fMRI Go-NoGo task described above. Participants will receive all four types of inhibitory training.
45805024|NCT05924386|Procedure|patients reciveing all on 4 fixed mandibular prosthesis usimg conventionally screw retained multiunit abutments|Multiunit abutments is considered a gold standard screw retained abutments. Multi-unit abutments are used to correct for varying heights among the implants, to establish a level restorative platform for the prosthesis, as well as to situate the implant connection even with or just below the gingival surface. Also they are used to correct the angulation of implants, helping to keep the screw access holes away from the facial surfaces of the restoration, and facilitate the path of insertion of prosthesis.
45805025|NCT05924386|Procedure|all on 4 fixed mandibular prosthesis using OTbridge attachment system|"The OT bridge attachment system introduced by (Rhein 83) is a global, well-established system used in the removable prosthetic protocols, the presence of seeger acetal ring placed between the sub-equatorial area of the OT Equator and the cylindrical Extragrade abutment compensates the space between the extragrade abutment and the OT equator attachment correcting the minor misalignments that produced during the prosthetic procedure and resulting in more passive fit."
45805026|NCT05924373|Drug|Human Dental Fulp Stem Cells|Investigational drugs: Based on the initial periodontal treatment (supragingival cleansing, subgingival scaling and root planning), human pulp stem cell injections will be given for a single or two local injection
45805027|NCT05924360|Other|conventional exercise program|The conventional treatment program will be applied to all participants included in the study, consisting of wand, codman, active and passive stretching exercises. This program will be administered to all patients five days a week. Wand exercises will be applied in the directions of flexion, abduction, extension, internal and external rotation, and will consist of 10 repetitions. Codman exercises will be applied in the directions of flexion, abduction, and circular, and will also consist of 10 repetitions. Active and passive stretching exercises will be applied in the directions of flexion, abduction, and external rotation, and will consist of 10 repetitions.
45805028|NCT05924360|Other|Mulligan application|The mobilization with movement technique, a part of Mulligan applications, will be performed twice a week in the directions of flexion, abduction, and external rotation.
45805029|NCT05924360|Other|Maitland application|Maitland Group: The Maitland application will be applied in the anterior-posterior, posterior-anterior, and caudal directions. The Maitland application will be administered at grades 2-3. Patients in this group will receive the application in five sets of 30 seconds, twice a week.
45805030|NCT05924360|Device|TENS|TENS application will be administered for 20 minutes at 100Hz
45805031|NCT05924347|Diagnostic Test|MRI|Longitudinal MRI examination of the thoracic and lumbar spine (T2, T2w, sCT)
45805032|NCT05924347|Diagnostic Test|Scolioscan|3D ultrasound of the spine
45805033|NCT05924347|Diagnostic Test|Skeletal maturity assessment|At one timepoint, a Hand radiograph is taken for digital skeletal maturity assessment
45835676|NCT04780152|Device|Transcranial Direct Current Stimulation|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of tDCS (30 minutes and 2 mA). Anodal stimulation will be applied on F3 according to the intentional 10/20 system, and the cathode will be applied on the contra lateral position (F4).
46002533|NCT01356290|Drug|Fenofibric acid|90mg/m2, oral, daily, 1 year
46073838|NCT00836173|Drug|GaRD Treatment|After RICE treatment, patients will have gallium nitrate IV through a vein continuously over a 7 day period. Patients will also receive rituximab by intravenous infusion over a 3-6 hour period on day 1 of each cycle. Dexamethasone will be given as pills to be taken for 4 days in a row on the first 4 days of each cycle. The length of each cycle is 21 days (3 weeks). All patients will have 2 cycles of GaRD.
46073839|NCT02862041|Device|Echogenic needle - Pajunk sonoplex echogenic needle|Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
46073840|NCT02862041|Device|Non Echogenic needle - Stimuplex Braun Nonechogenic needle|Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
45653874|NCT03063229|Drug|Hepatic Mitochondrial Oxidation breath test|Participants will be given a calculated amount of the stable isotope C-Octanoate, which will be delivered in a water solution. They will then be asked to breath down a small tube into a clear plastic collection bag 10 times over 2 hours.
45805034|NCT05924334|Other|reiki|"Processing steps of Reiki application; During the Reiki process, the practitioner will keep the hands just above the recipient. It will be explained to the individual that he may feel the feeling of temperature, tingling, drowsiness, refreshment or healing during therapy.~During the application, the person does not need to be in a lying position or remove their clothes. It is enough to remove the jewelry on it.~In order to ensure the flow of energy during the application, the arms and legs of the individual should stand open on both sides of the body, and the hands and feet will not be crossed in order not to disrupt the flow of energy.~The practitioner will pass the right side of the individual and correct the energy existing around the body with the right hand to the feet and from top to bottom by correcting the energy field of the individual.~The application time will be between 20 and 30 minutes on average."
45805035|NCT05924334|Other|placebo|placebo
45805036|NCT05924321|Drug|Carbetocin|Single infusion of Carbetocin
45805037|NCT05924321|Drug|Placebo|Single IV infusion of matching placebo
45452604|NCT01102660|Drug|Naproxen|Tablet, 500 mg twice daily for 2 weeks
45452605|NCT01102660|Drug|Naproxen + PH-797804|Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
45452606|NCT01102660|Drug|Naproxen + PH-797804|Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
45452607|NCT01102660|Drug|Naproxen|Tablet, 500 mg twice daily for 2 weeks
45452608|NCT03135106|Drug|Erdafitinib|A single 4-mg of erdafitinib tablet will be administered on Day 1 in Treatment A and on Day 5 in Treatment B and C.
45452609|NCT03135106|Drug|Fluconazole|A 400-mg fluconazole orally (4*100 mg capsules) will be administered from Day 1 to Day 11.
45805038|NCT05924321|Drug|Placebo and Moxifloxacin|Single IV infusion of matching placebo in combination with Single Oral dose of Moxifloxacin
45805039|NCT05924308|Other|electroacupuncture|every time 30 min, 1 times a day, five times a week, 4 weeks for 1 course of treatment, treatment 3 period of treatment.
45805040|NCT05924308|Other|sham acupuncture|Electroacupuncture was connected to the fixed place of Sishencong on the left and right sides of Baihui and Shenting, and the electroacupuncture instrument was returned to zero. Pull out the needle when informed patient for cotton on the above points, to make patients feel the needle was pulled out. The same treatment time of 30 min, 1 times a day, five times a week, 4 weeks for 1 course of treatment, treatment 3 period of treatment.
45452610|NCT03135106|Drug|Itraconazole|A 200-mg itraconazole orally (2*100 mg capsules) will be administered from Day 1 to Day 11.
45452611|NCT00872014|Drug|AMG 386|Two doses of AMG 386 (15 mg/kg) IV QW will be studied
45452612|NCT00872014|Drug|AMG 386|Two doses of AMG 386 (10 mg/kg) IV QW will be studied
45452613|NCT00872014|Drug|Sorafenib|Sorafenib 400 mg PO BID orally twice daily in an every 4 week dosing schedule for 15mg/kg cohort & 10mg/kg cohort
45452614|NCT00871936|Drug|SLx-4090|SLx-4090
45452615|NCT00871936|Other|Placebo|matching tablets
45452616|NCT00871936|Drug|Metformin|
45452617|NCT00870688|Drug|sodium valproate|valproate sustained release minitablets, once daily.
45653875|NCT05546879|Drug|NP137|NP137 at 9 or 14 mg/kg IV will be administered every 21 days.
45653876|NCT05546879|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
45653877|NCT05546879|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle
45653878|NCT05541185|Biological|Nigella sativa oil|1 ml of nigella sativa oil was applied to both knee areas of the nigella sativa oil group by massaging for 2 minutes three times a day for 21 days.
45805041|NCT05924295|Dietary Supplement|Ketone Supplement|Participants will be given 360mg/kg
45805042|NCT05924295|Behavioral|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale will be administered at beginning and end of testing day to tests palatability of supplement
45805043|NCT05924295|Biological|Blood Draw|IV cannula will be inserted at the start of Test Day, and removed at the end of Test Day. Blood samples will be collected at 7 timepoints (possibly 1 more). Cannula will be flushed with a small volume of saline after each sample to maintain patency.
45805044|NCT05924295|Other|Urine Analysis|Prior to consumption of the Study Product, participants will be asked to completely void bladder. And hydration status will be determined via urine specific gravity (USG) reporting <1.025. Urine passed after the ingestion of the study product will be collected in a plastic container; participants will be asked to void their bladder and collect urine at the end of the test day. The volume produced will be recorded at the end of the study and aliquots will be frozen and stored for future analysis
45805045|NCT05924282|Procedure|Curative intent surgery|Curative intent surgery means that surgeons intend to perform R0 resection.
45937000|NCT00406978|Drug|Thalidomide|Thalidomide will be administered orally at the initial dose of 50 mg/day p.o. once daily, with increment of 50 mg after a month to acceptable tolerance (maximum 100 mg), continuously for the entire 6 courses.
45805046|NCT05924256|Drug|SHR-A1811|SHR-A1811
45937001|NCT00406978|Drug|Defibrotide|Lev - 1 Def = 10 mg/Kg (max 0.6 g) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Lev - 1 Def = 1.2 g p.o (400 mg every 8 hours) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Level + 1 Def = 17 mg/Kg (max 1.2 g) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 1 Def = 2.4 g p.o. (400 mg every 4 hours) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 2 Def = 34 mg/Kg (max 2.4 g) as a i.v. injection on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 2 Def = 4.8 g p.o. (800 mg every 4 hours) on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 3 Def = 51mg/Kg (max 3.6 g) as a i.v. injection on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) through day 35 Lev + 3 Def = 7.2 g p.o.(1200 mg every 4 hours ) on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) given p.o. through day 35
45805047|NCT05924256|Drug|SHR 3680 + leuprolide|SHR 3680 + leuprolide
45937002|NCT00157534|Drug|Celgosivir|
45937003|NCT00051467|Genetic|TNFerade|
45937004|NCT00157612|Procedure|a clinical pathway nursing home acquired pneumonia|treatment in nursing homes according to a clinical pathway, which included use of oral anti-microbials, portable chest radiographs, oxygen saturation monitoring, rehydrations and close monitoring by research nurse
45937005|NCT00157651|Drug|warfarin|Daily oral warfarin with INR monitored weekly, adjusted to keep INR between 1.5 and 1.9
45805048|NCT05924256|Drug|SHR-A1921|SHR-A1921
45937006|NCT00157651|Drug|placebo|matching placebo for warfarin, adjusted according to sham INR generated by unblinded warfarin monitor
45937007|NCT00044343|Drug|lapatinib|
45937008|NCT00157690|Drug|Alendronate|70 mg 1x weekly for 12 months
45937009|NCT00157690|Drug|Placebo|70 mg 1 x weekly for 12 months
45937010|NCT00051506|Drug|ALIMTA|
45937011|NCT00051506|Drug|carboplatin|
45937012|NCT00051506|Drug|cisplatin|
45937013|NCT00157729|Drug|pyridoxal-5'-phosphate with and without ACE inhibitor|
45937014|NCT00157768|Device|Implantable cardioverter defibrillator|
45452618|NCT00870454|Drug|Pregabalin 300 mg/d|75 mg/d twice daily for Week 1, followed by 150 mg twice daily for the remainder
45805049|NCT05924243|Drug|RO7486967|For up to approximately 28 days
45937015|NCT00157807|Procedure|bipolar radiofrequency ablation of persistent and permanent AF|
45937016|NCT00157846|Device|CRT-P or CRT-D Device|Upgrade from ICD or pacemaker to CRT-D/CRT-P (Insync III, Insync Marquis, Insync Sentry, Insync Maximo, Concerto)
45937017|NCT00051545|Drug|Seocalcitol|
45937018|NCT00157885|Drug|Amodiaquine plus artesunate; Artekin|
45937019|NCT00158002|Drug|Topiramate|
45937020|NCT05568498|Dietary Supplement|Probiotic|Oral probiotic delivered in powdered form.
45937021|NCT05568498|Dietary Supplement|Placebo|Oral placebo delivered in powdered form.
45937022|NCT00158041|Drug|Amifostine administered subcutaneously|
45937023|NCT00051584|Drug|SGN-15 (cBR96-Doxorubicin Immunoconjugate)|
45653879|NCT05541185|Biological|Naproxen and lidocaine gel|1 ml of Naproxen and lidocaine gel was applied to both knee areas of the Naproxen and lidocaine gel group by massaging for 2 minutes three times a day for 21 days.
45653880|NCT05541185|Biological|Massage|1 ml of vaseline was applied to both knee areas of the massage group by massaging for 2 minutes three times a day for 21 days.
45653881|NCT02518113|Drug|LY3039478|Administered orally
45653882|NCT02518113|Drug|Dexamethasone|Administered orally
45653883|NCT02518113|Drug|Placebo|Administered orally
45653884|NCT05541107|Drug|MAT2203|oral lipid nanocrystal amphotericin B
45653885|NCT05541107|Drug|Amphotericin B|Intravenous Amphotericin B
45805050|NCT05924243|Drug|Placebo|For up to approximately 28 days
45805051|NCT05924230|Other|RL 10ml/kg|Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is >50%, then patients of this group (Group 1) will receive Ringer's lactate 10ml/kg before induction in the receiving area
45805052|NCT05924230|Other|RL 15ml/kg|Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is >50%, then patients of this group (Group 2) will receive Ringer's lactate 15ml/kg before induction in the receiving area
45937024|NCT00051584|Drug|Gemzar (Gemcitabine)|
45937025|NCT00158080|Procedure|hemofiltration|
45937026|NCT00158119|Behavioral|InVEST (Increased Velocity Exercise Specific to Task)|
45937027|NCT00044382|Drug|CC-5013|
45937028|NCT00158158|Drug|Usual Care|If unable to quit at quit date, offered usual care to set another quit date.
45937029|NCT00158158|Other|Smoking Reduction|If unable to quit smoking, reduce smoking rate prior to quit date.
45937030|NCT00051623|Drug|Infliximab|
45937031|NCT00158236|Drug|Buprenorphine|
45937032|NCT00158236|Drug|Buprenorphine and Naloxone|
45937033|NCT00158236|Drug|Hydromorphone|
45937034|NCT00158275|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy focuses on identifying and eliminating maladaptive beliefs and thoughts.
45937035|NCT00158275|Drug|Antidepressants|Antidepressant drugs try to eliminate symptoms of depression such as persistent sadness and disinterest in normal or pleasurable activities.
46002534|NCT01356290|Drug|Etoposide|35-50 mg/m2, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
45937036|NCT00158275|Behavioral|Problem solving therapy|Problem solving therapy identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment.
45937037|NCT00044421|Drug|Ruboxistaurin mesylate|
45653886|NCT03062839|Drug|Melatonin 5 mg|Melatonin 5 mg taken 30 minutes before bed time
45653887|NCT05540951|Drug|VIC|VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
45653888|NCT05540951|Drug|Bevacizumab Plus Chemotherapy|Bevacizumab Plus Doublet or Triplet Chemotherapy
45937038|NCT04724590|Radiation|IMRT(IMAGE GUIDED INTENSITY-MODULATED RADIATION THERAPY )|Evaluation the optic neuropathy in nasopharynx cancer patients treated in our clinic.
45937039|NCT00051662|Drug|efalizumab|
45937040|NCT00158314|Behavioral|Referral to Gamblers Anonymous|
45937041|NCT00158314|Behavioral|Cognitive behavioral therapy|
45937042|NCT00158314|Behavioral|Cognitive behavioral self-help manual|
45937043|NCT00158353|Behavioral|GirlPOWER! mentoring program|GirlPOWER! mentoring program includes monthly 3-hour workshops for youth and mentors combined with monthly supplemental activities to be completed independently by youth-mentor pairs.
45937044|NCT00158353|Behavioral|Traditional mentoring|Traditional mentoring includes a community-based mentoring program, in which the youth-mentor spends time together in activities of their choosing 2 to 4 times a month.
45937045|NCT04724200|Diagnostic Test|Echocardiogram|Echocardiography plays a crucial role in the diagnosis of HF; it is the standard of care imaging modality used to confirm the diagnosis, it permits real-time imaging of the heart and quantitative assessment of cardiac structure and function, crucial for diagnosis.
45937046|NCT00051701|Drug|alemtuzumab|
45937047|NCT04724551|Procedure|pancreatoduodenectomy (PD)|A pancreaticogastrostomy or -jejunostomy duct-to-mucosa was achieved according to the surgeon's preference and pancreatic texture.
45937048|NCT00158431|Procedure|Arthroscopy plus Medical Management|Arthroscopic Surgery
45937049|NCT00158431|Other|Medical Management|education, optimized medication, weight loss where needed, HA or cortisone injections if needed, physiotherapy
45937050|NCT00051740|Behavioral|Cognitive Adaptation Therapy (CAT)|
45937051|NCT00051740|Behavioral|Minimal Environmental Supports (MES)|
45805053|NCT05924217|Other|Survey questionnaire|This survey aims to explore the perception that transgender men have of cervical cancer screening and to identify the challenges they face, the obstacles and the levers to access this prevention program.
45805054|NCT05924204|Radiation|Photobiomodulation|Application of photobiomodulation
46073841|NCT00836251|Dietary Supplement|H218O and 2H2O, administered as a mixed cocktail|0.195 g of H218O and 0.117 g of 2H2O per kg of estimated total body water (TBW), administered as a mixed cocktail
45653889|NCT03062293|Device|Functional Re-adaptive Exercise Device|Exercise intervention 3 times per week for up to 30min. Difficulty and time will be progressed as indicated by clinical presentation, assessed by the Physiotherapist team.
45653890|NCT04966455|Dietary Supplement|Raisins|Daily supplementation of 50 g of rainsins for 3 months
45653891|NCT04964505|Drug|Azacitidine|Given IV or SC
45653892|NCT04964505|Drug|Uproleselan|Given IV
45653893|NCT04964505|Drug|Venetoclax|Given PO
45653894|NCT05540639|Behavioral|Modified Mindfetalness|The pregnant woman is motivated to practice Mindfetalness verbally, by video, by a leaflet and at a website.
45653895|NCT04981093|Drug|Dexamethasone Injection|"Intravenous injection after induction of anesthesia~Injection 0.15mg/kg dexamethasone (2ml)"
45653896|NCT04981093|Drug|Normal saline|2ml of normal saline was injected intravenously after induction of anesthesia
45805055|NCT05924204|Other|Simulation of Photobiomodulation|Simulation of photobiomodulation
45805056|NCT05924191|Device|Photobiomodulation|Intra-oral irradiations wll be performed with a low intensity Laser device at 4 anatomical points, with a wavelength of 660 nm. The extraoral FBM will be applied with 1 cluster (20cm2) with a wavelength of 630nm. Subsequently, the same region will be irradiated with the same cluster, using the 4 LEDs with a wavelength of 850 nm 1 hour before performing the surgery.
45937052|NCT00158470|Drug|efavirenz|
45937053|NCT00158470|Drug|didanosine|
45937054|NCT00158470|Drug|lamivudine|
45937055|NCT00158509|Drug|Valacyclovir|
45937056|NCT05568342|Behavioral|The Effect of Roy Adaptation-Based Nursing Intervention on Stress, Psychosocial Adjustment and Self-Care Power in Hemodialysis Patients: A Randomized Controlled Experimental Study|Pre-test was applied to the patients in Roy and clinical groups using data collection tools. After the pre-test, the patients in the Roy group were trained 6 times in 3 months, twice a month, at home and in the clinic. Nursing interventions were performed using the Roy Adaptation Model in the trainings. At the end of the third month, the post-test data of both groups were collected. During the study, no training or intervention was given to the patients in the clinical group. The nursing education and interventions of this group were carried out by nurses working in the dialysis clinic within the scope of routine practices.
45937057|NCT00158548|Drug|SP, chloroquine, amodiaquine, primaquine, artesunate|
45937058|NCT00051779|Drug|CAL|
45937059|NCT00158587|Drug|primaquine|
45937060|NCT00158626|Behavioral|pelvic floor muscle training|
45937061|NCT00158665|Biological|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine
45937062|NCT00158704|Drug|Hepsera|
45937063|NCT00158782|Drug|GW786034|GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.
45805057|NCT05924191|Drug|Placebo Corticosteroid|Participants will receive 1 hour before the surgery a placebo tablet, with the same physical and organoleptic characteristics, composed of corn starch, without harmful effects on health and simulating Dexamethasone (Celsius Laboratory, Montevideo, Uruguay).).
45805058|NCT05924191|Device|Simulation Photobiomodulation|The irradiation simulations will be practiced in the same anatomical points described in the experimental group. This protocol will be carried out 1 hour before the surgical procedure (Baseline). The Laser device will be disconnected and its beep sound will be recorded and run on simulating the irradiation.
45937064|NCT00158782|Drug|lapatinib|Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.
45937065|NCT00051818|Behavioral|Treatment interruption/reinitiation schedule|
45937066|NCT00158821|Drug|Viread (tenofovir disoproxil fumarate)|Tenofovir DF 300 mg tablets once daily
45937067|NCT00158821|Drug|Sustiva (Efavirenz)|efavirenz capsules 600 mg once daily
45937068|NCT00158821|Drug|Epivir (Lamivudine)|lamivudine 150 mg tablets twice daily
45937069|NCT00158821|Drug|Zerit (Stavudine) Placebo|stavudine placebo capsules twice daily
46073842|NCT04284215|Drug|Albumin paclitaxel combined with cisplatin|Non-resectable stage III non-small cell lung cancer is recommended for concurrent chemoradiotherapy. Paclitaxel and platinum are commonly used in chemotherapy regimens. The aim of this study was to investigate whether paclitaxel albumin combined with cisplatin combined with three-dimensional primary radiotherapy could improve short-term efficacy, local progression-free survival, and reduce treatment-related toxicity. To determine whether paclitaxel albumin combined with cisplatin regimen chemotherapy can be used as a first-line treatment for stage III non-small cell lung cancer with concurrent primary thoracic radiotherapy.
45937070|NCT00158899|Drug|GW501516 oral tablets|
45937071|NCT05568147|Drug|Aspirin tablet|When patients are randomized into the intervention group, they will receive aspirin at the dosage of 100mg orally once every day.
45937072|NCT05568147|Drug|Placebo|When patients are randomized into the placebo group, they will receive placebo orally once a day.
45937073|NCT00051896|Drug|GBR 12909|
45937074|NCT00158938|Device|EASYTRAK 3 left ventricular pacing lead|
45937075|NCT04724473|Drug|Tretinoin Cream 0.025%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
45937076|NCT05567991|Behavioral|Comprehensive Mindulness-Based Intervention (C-MBI)|C-MBI, was administer online via Zoom and included: 10 Integral Meditation classes lasting approximately 35 minutes each, given twice a week (Monday and Wednesday); 10 minutes of yoga exercises focused on breathing and posture before each IM class; and dietary advice. Regarding this latter, the participants received via email a document which entailed non-mandatory dietary suggestions to promote healthy nutrition, sleep and stress-relief. An online lecture held by the nutritionist with a question-and-answer format was also organized. The degree to which to follow this advice was left to the discretion of each participant. The core of our intervention was represented by the IM training, that is a MBI intervention, that simultaneously uses breathing, focusing attention, releasing of physical tensions, thoughts and feeling sensations through internal senses and imagery, allowing a quick relaxation and more deeply a physical, energetic, and spiritual well-being.
45937077|NCT00158977|Device|CONTAK RENEWAL 3 AVT|CONTAK RENEWAL 3 AVT
45937078|NCT00159016|Drug|Glivec|
45653897|NCT05699681|Diagnostic Test|Transthoracic and transesophageal echocardiography|"After induction of anaesthesia and stabilization of hemodynamics, transthoracic echocardiography will be done on a GE Vivid e9 workstation (GE Vingmed, Horton, Norway) with MS5 transthoracic probe with synchronized ECG.~From TTE the following views and measurements will be acquired :~Apical four chamber (A4C) view~Apical two chamber view (A2C) view~Right ventricle (RV) focused A4C view~Right ventricular systolic pressure (RVSP)~Pulmonary arterial acceleration time (PAAT),~Tricuspid annular plane systolic excursion (TAPSE),~Tricuspid annular plane systolic velocity (s'),~Right ventricular fractional area change (RV FAC)~RV free wall strain,~RV myocardial performance index (MPI),~RV isovolumic relaxation time (IVRT),~RV isovolumic acceleration time (IVA)~Invasive PA pressure measurement will be done after surgical exposure with a fine needle and a zeroed transducer by the Surgeon."
45937079|NCT00051935|Drug|Alglucosidase alfa|20 mg/kg (qow); intravenous
45653898|NCT05004831|Drug|fruquintinib plus TAS-102|fruquintinib 4mg/d, qd po, D1-21, Q4W; TAS-102 70mg/m2/d, bid po, D1-5, 8-12, Q4W
45653899|NCT05546489|Behavioral|Lymfit intervention|Wearable activity trackers (Fitbit) were given to participants as a motivational tool and for data collection purposes. Participants received a personalized exercise prescription designed by a kinesiologist. Physiologic metrics were collected by the Fitbit monitors and were stored in the Lymfit database. Self-reported questionnaires measuring health outcomes were collected at baseline and post-intervention.
45937080|NCT00159055|Biological|CMV vaccine|
45937081|NCT00159094|Drug|Doxil and Vinorelbine|
45937082|NCT02965053|Drug|EOS789|
45805059|NCT05924191|Drug|Corticosteroid|The patients will receive Dexamethasone 8 mg (Corodex, Laboratorio Celsius, Montevideo, Uruguay) PO 1 hour before surgery (Almeida et al 2019)
45805060|NCT05924178|Behavioral|exercise rehablitation|Preoperative exercise rehabilitation in experimental group was performed.
45805061|NCT05924178|Behavioral|routine treatment|The control group receives conventional treatment preoperative.
45805062|NCT05924165|Drug|5mg Oxycodone, Q6 PRN|Oxycodone is an opioid that is used to relieve moderate to severe pain.
45805063|NCT05924165|Drug|10mg Ketorolac, Q6 PRN|Ketorolac is an NSAID used to relieve moderately severe pain.
45805064|NCT05924152|Drug|Adagrasib|Adagrasib
45805065|NCT05924152|Drug|Eltrombopag + adagrasib|Eltrombopag + adagrasib
45937083|NCT02965053|Drug|Placebo|
45937084|NCT02965053|Drug|Renvela|
45937085|NCT00159133|Drug|antipsychotics vs. Lorazepam (Drugs)|Early intervention with low-dose antipsychotics vs. lorazepam (up to 3 mg/day) in case of early warning signs of an impending relapse;
45937086|NCT00051974|Drug|VELCADE™ (bortezomib) for Injection (formerly PS-341)|
45937087|NCT00159172|Device|Motor cortex stimulation|
45937088|NCT00159211|Drug|UMULINE NPH|UMULINE NPH at bed time with a increasing dose up to get a fasting glycemia under 1.1 g/l
45937089|NCT00159211|Drug|pioglitazone|30mg daily. After 2 months, if HbA1c has not decreased at least of 1%, the dosage should be increased to 45 mg daily
45937090|NCT00159289|Procedure|Inhalation of LPS|
45937091|NCT00159289|Procedure|Placebo|
45937092|NCT05567718|Behavioral|Paediatric Anaesthesia Emergence Delirium scale|measure emergence delirium in children
45937093|NCT00052013|Drug|PTK787/ZK 222584|
45676259|NCT04200690|Other|Usual-care management|Usual care will be carried out by HCPs that are not otherwise involved in the trial. In usual care the patients will not be offered an interdisciplinary patient-centered care as described, but only attend their usual disease-specific departments at the usual appointments.Treatment will be prescribed as felt appropriate according to local, national and international guidelines by the treating physicians with no set protocol and no restrictions.
45676260|NCT04193904|Drug|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
45805066|NCT05924139|Dietary Supplement|Omega-3 fatty acid|6 capsules per day of 3840 mg that included 1950 mg EPA and 1350 mg DHA
45805067|NCT05924139|Dietary Supplement|Placebo|4 capsules per day of coconut oil
45937094|NCT00159328|Procedure|Magnetic Resonance Guided Focused Ultrasound|
45937095|NCT00159367|Device|Repetitive magnetic stimulation to the quadriceps|
46073843|NCT02816970|Drug|Vildagliptin|1 tablet contains 50 mg vildagliptin
46073844|NCT02816970|Drug|Vildagliptin|1 tablet contains 50 mg vildagliptin
45805068|NCT05924126|Other|empiric antibiotic therapy|septic ICU patient given broad spectrum antibiotic therapy
45805069|NCT05924113|Behavioral|Latin Dance|Latin dance sessions that include a warm-up routine with music, two choreographed dances, and a cooldown routine with music.
45805070|NCT05924100|Drug|Luspatercept Injection [Reblozyl]|"Eligible subjects will receive luspatercept (ACE-536): starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg (with a maximum total dose of 168 mg).~All subjects who have received at least one dose of luspatercept should undergo follow-up evaluations after day 169 with Assessment visits every 24 weeks (168 days) up to 2 years to evaluate evidence of clinical benefit."
45805071|NCT05924074|Biological|Biological sampling|The procedure will consist of an additional bone marrow sample and blood sample
45805072|NCT05924061|Other|Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women|The effect of cathepsin b and pentraxin 3 levels on maternal/fetal outcomes in pregnant women diagnosed with preeclampsia
45805073|NCT05924048|Other|Reducing the Oxygen Concentration From 5% to 2%|Effect of Reducing the Oxygen Concentration From 5% to 2% in arm 1.
45805074|NCT05924035|Device|HBOT|HBOT treatment on a multiplace chamber (OXYHeal Hyperbaric Oxygen Chamber), 100% oxygen at 2.0 atmospheres for 90 minutes - on 4 consecutive days within 3 hours of completion of exercise training (as soon as practically possible). This will occur during week 2 of data collection.
45805075|NCT05924022|Biological|Hyperbaric Oxygen Treatment Full|Participants in the active treatment arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT) prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session.
45805076|NCT05924022|Biological|Hyperbaric Oxygen Treatment Partial|Participants in the sham condition arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT) prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session receiving less than a fully pressurized 100% oxygen dose.
45805077|NCT05924009|Procedure|Transcranial Magnetic Stimulation, TMS|"The best location for evoking an electromyographic (EMG) response of the first dorsal interosseus (FDI) muscle in the dominant hand and the minimum stimulation intensity required to evoke a certain EMG response amplitude (Motor Threshold, MT) are used as reference to determine the best location and stimulation parameters to evoke GEPs.~After identification of the GEP hot-spot, a water load test is administered to determine whether satiety shapes GEP responses.~In subsequent study visits, the water load test is preceded by application of neuromodulatory repetitive TMS (rTMS), targeted to the GEP hotspot."
45805078|NCT05923996|Drug|microbotox|Will be treated by single session of microbotox injection
45805079|NCT05923996|Radiation|fractional carbon dioxide laser|Two sessions of the fractional CO2 laser on this side of the face at 4-weeks intervals
45805080|NCT05923983|Other|Clinical decision support|In the intervention group, the pharmaceutical validation will be based on routine care, often on entry to a ward and by analysis of all the alerts produced by the CDSS. Some alerts will result in a pharmaceutical intervention being provided to the medical team
45805081|NCT05923983|Other|Will not receive Clinical Decision Support|In the control group, the pharmaceutical validation will be based on routine care, often on entry to a ward or in a particular situation
45805082|NCT05923970|Diagnostic Test|Serology for antibody levels - Baseline|Measurement of rubella IgG antibody levels at baseline
45805083|NCT05923970|Diagnostic Test|Serology to assess cell mediated immune (CMI) response - Baseline|Assessment of cell mediated immune (CMI) response to measles, mumps, rubella, and varicella at baseline.
45805084|NCT05923970|Diagnostic Test|Serology for antibody levels - Post third dose of MMR vaccine|Measurement of rubella IgG antibody levels post third dose of MMR vaccine
45805085|NCT05923970|Diagnostic Test|Serology to assess CMI - Post third dose of MMR vaccine|Assessment of cell mediated response (CMI) to measles, mumps, rubella, and varicella post third dose of MMR vaccine.
45937096|NCT00159445|Drug|gemcitabine, capecitabine|
45937097|NCT00044460|Drug|rosiglitazone|
45937098|NCT00159484|Drug|EPO906, celecoxib|EPO906 IV, every three weeks, celecoxib by mouth twice a day every day
45937099|NCT00052052|Drug|interferon-gamma 1b|200 mcg, SQ, 3x per week
45937100|NCT00159523|Dietary Supplement|Probiotic|
45937101|NCT00159523|Biological|placebo|
45937102|NCT00159562|Behavioral|individual education|individual sessions of psycho-education
45937103|NCT00159562|Behavioral|Group education|group psycho-education in 10 weekly sessions and then a session every third month for two years
45452619|NCT00870454|Drug|Carisbamate 800 mg/d|200 mg/d twice daily, titrated up to 400 mg twice daily, as tolerated, by Week 3
46073845|NCT04283123|Behavioral|Automated Bidet|During the first intervention visit, a licensed contractor will install the bidets in participants' homes. The OT will then educate and train the caregiver and care recipient to successfully use the bidet, and make any modifications to the remote as needed. Throughout the intervention, the OT will use motivational enhancement strategies. The OT will make minor modifications to the remote as needed. A second intervention visit will occur 1-2 weeks post-installation to address any new difficulties. Check-in phone calls will be offered to the caregiver and care recipient if needed.
45653900|NCT04642729|Procedure|Fresh Corneal Lenticule Implantation using Relex-Smile Surgery|Knowing that the most important element is damage of stroma we used all preoperative procedures atlas, optic tomography and especially electron microscope. Approximately we planned how much microns we remove and insert, for example we remove 80 µm and we insert fresh corneal lenticule 90 µm with the purpose to remove more dead keratocytes which increase biomechanical instability of corneal metabolism (abnormal increase collagenase activity, decrease proteinase inhibitors, excessive premature keratocyte apoptosis, increase cytokine binding). Fresh Corneal Lenticule and autologous serum contains live stem cells that produce keratocytes, collagen fibers, extracellular matrix which contribute to the regeneration of the cornea, and all this results at increasing of corneal transparency and visual acuity in patients with corneal macular dystrophy.
45653901|NCT05003817|Device|Percutaneous left ventricular unloading|Percutaneous left ventricular unloading involves the placement of a mechanical pump which draws blood from the left ventricle and returns it into the aorta at flow rates approaching native cardiac output.
45805086|NCT05923957|Other|TENS and Exercise|High frequency electrical stimulation was done for thirty minutes per day for five days a week for four consecutive weeks. The stimulator provides a biphasic current of 100 Hz frequency. The pulse duration was 200 msec with an (on-off). Stimulus mode (20sec stimulation, 20 sec pause). The maximal stimulation amplitude was 40 - 60 mA
45805087|NCT05923944|Behavioral|Eco-Rescue|Ecorescue is a gamified adaptation of the multiple object tracking task (MOT) combined with a detection task. It requires to track the spatial position of specific moving targets among visually similar moving distractors, while at the same time detecting briefly flashed events. It was designed to load on attentional control and visuo-spatial working memory. Additionally, targets may express various facial emotions (happy, angry or neutral) requiring some emotional control in addition to attentional control.
45805088|NCT05923944|Behavioral|Bejelewed 3|Bejeweled 3 is a commercially available puzzle video game developed and edited by PopCap Games. The main objective is to swap two adjacent gems of seven colors to create a line or row of 3 or more gems of the same type. When these gems are aligned, they disappear, and points are earned. The goal is to get as many points as possible until it is impossible to line up gems. Bejeweled 3 offers a variety of game modes that players can freely explore at their own pace, enhancing the overall enjoyment and providing increased variability during each gaming session. These game modes typically have shorter durations, with a single game usually lasting less than 5 minutes. Bejeweled 3 was chosen as it requires fewer attentional resources compared to Eco-Rescue and because it was reported to reduce stress and anxiety in adult samples (Russoniello et al. 2009, 2013).
45805089|NCT05923931|Device|cooling blanket|On the basis of the cooling methods of non-cooling blanket group, combine the cooling blanket to cool down. The cooling blanket is required to be activated within 30min after admission. The blanket temperature will be set at 4-10℃, and the target body temperature is 38℃.
45805090|NCT05923931|Device|non-cooling blanket|Patients do not receive cooling blanket according to randomization. Cooling body temperature by: control the temperature of the emergency room to 20-24℃, 4℃ fluid infusion, ice packs, evaporation, etc.
45805091|NCT05923918|Drug|PBK_M2101 2-Day|Subjects who are randomized into group test 1 will receive bowel preparation from evening to next morning.
45805092|NCT05923918|Drug|PBK_M2101 1-Day|Subjects who are randomized into group test 2 will receive bowel preparation on the same-day.
45805093|NCT05923918|Drug|Oral Sulfate Tablet 2-Day|Subjects who are randomized into group active comparative will receive bowel preparation from evening to next morning.
45805094|NCT05923905|Drug|FB1006|30mg/day
45805095|NCT05923905|Drug|Placebo|30mg/day
45805096|NCT05923892|Drug|OPS-2071|There are 3 dose groups of OPS-2071，OPS-2071 tablets, 50 mg、100mg、200mg. Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
45805097|NCT05923892|Drug|placebo|Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
45452620|NCT00870454|Drug|Carisbamate 1,200 mg/d|200 mg/d twice daily, titrated up to 600 mg twice daily, as tolerated, by Week 3
45805098|NCT05923879|Drug|Selinexor combined with lenalidomide and rituximab|Selinexor combined with lenalidomide and rituximab
46073846|NCT04283123|Other|No Intervention|Waitlist control
46073847|NCT04239066|Procedure|Tourniquet|tubularized incided plate (TIP) urethroplasty plus tourniquet
45653902|NCT04981015|Diagnostic Test|Three-day bladder diary|A three-day bladder diary for recording voiding-flow pattern of a women
45653903|NCT05551247|Drug|Envafolimab|300mg,sc,d3,Q3W;
45452621|NCT00870454|Drug|Placebo|Placebo capsules twice daily
46073848|NCT04239066|Procedure|Non-tourniquet|tubularized incided plate (TIP) urethroplasty plus non-tourniquet
45452622|NCT00869986|Drug|dirucotide|500mg, intravenous, every 6 months for 15 months
46073849|NCT04284137|Behavioral|Modified FE-SaLiR|Participants will attend a 60-minute exercise program (modified Wu Qin Xi and Ba Duan Jin) in a non-clinical community setting twice a week and will perform the exercises at home using guided video up to three times a week. Text messages will be sent to remind the participants to do the exercise at home.
45452623|NCT00869986|Drug|placebo|intravenous, once every six months for 15 months
45452624|NCT05096962|Diagnostic Test|Quantitative analysis of SARS-CoV-2 antibodies|The study will evaluate the current presence of infection, specific antibodies at least in the IgG class in blood plasma or serum (antibody tests focusing on two SARS-CoV-2 proteins: S-protein and N-protein).
45452625|NCT05096962|Diagnostic Test|Cellular immunity|Quantification of the level of cellular immunity from venous blood collected in approximately 30% of examined individuals.
45653904|NCT05551247|Drug|recombinant human endostatin (endostatin)|210mg,civ,d1-3,Q3W
45653905|NCT05003505|Other|Follow up|Participants will be followed up at 6, 12 and 24 months with the test of enous blood, vaginal secretions, faeces, and cervical exfoliated cells.
45452626|NCT00869128|Drug|Circadin|2 mg prolonged-release melatonin
45452627|NCT00869128|Drug|Placebo|
45452628|NCT00866476|Biological|CVD 1208S, a Shigella flexneri 2a live, oral vaccine|CVD 1208S consists of freshly harvested ∆guaBA, ∆sen, ∆set S. flexneri 2a strain 2457T suspended in phosphate buffered saline to reach the desired inoculum Form: liquid Dose: 10 to the 9th power CFU in 1.0 ml Route: oral.
45452629|NCT00866476|Other|Placebo|30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
45452630|NCT00866242|Biological|CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a|The challenge strain consists of freshly harvested Shigella flexneri 2a strain 2457T diluted in phosphate buffered saline to reach the desired inoculum Form: liquid Dose 10 to the 3rd power CFU in 1.0 ml Route: oral.
45452631|NCT00945646|Drug|FST-201 (dexamethasone 0.1%) Otic Suspension|Instill four drops times two times a day.
45452632|NCT00945646|Drug|Vehicle|Instill four times two times a day
45653906|NCT05540561|Other|blood collection|Biological analyses in the framework of care with conservation of blood samples
45805099|NCT05923866|Drug|ONO-2808|Oral administration of ONO-2808 at low, middle or high doses once a daily for 24 weeks
45805100|NCT05923866|Drug|Placebo|Oral administration of placebo once a daily for 24 weeks
45805101|NCT05923853|Other|FiO2 titration using electronic alert system|In the intervention arm, arterial oxygen saturation (SaO2) and peripheral oxygen saturation (SpO2) will be initially noted. Based on the correlation between the SaO2 and SpO2 the optimal oxygenation range will be determined. E-alerts will then be used to monitor oxygenation for patients in the intervention arm, based on SpO2 values generated by the patient due to the FiO2 given to the patient through the ventilator. Once an e-alert is sent, the respiratory therapist has 45 minutes for adjusting oxygen. Then the e-alert continues to monitor FiO2 and SpO2 values in this manner for every 45 minute period until the ventilator is attached to the patient.
45805102|NCT05923840|Diagnostic Test|Chemoreflex Testing|The carotid body chemoreflex can be tested by holding carbon dioxide (CO2) constant (isocapnic) and applying hypoxia and hyperoxia. Measurements are then made of expiratory minute volume and of sympathetic activity. The central chemoreflex measures isocapnic and hypercapnic responses in the presence of hyperoxia to suppress the carotid body chemoreflex.
45805103|NCT05923840|Diagnostic Test|Baroreflex testing|Baroreceptors are measured by the change of heart rate (HR) and sympathetic activity with changing blood pressure using the modified Oxford technique. Blood pressure is lowered an amount by a bolus of sodium nitroprusside and then raised by a bolus of phenylephrine. When standing baroreflexes are activated and the investigators will measure chemoreflex activity upright to see how baroreflex effects the chemoreflexes. Similarly chemoreflexes affect the baroreflexes best observed when the patients are supine.
45805104|NCT05923840|Diagnostic Test|Orthostatic stress testing|Orthostatic Stress tests are administered in two forms: a standing test to evoke the initial orthostatic hypotensive response that sensitizes and triggers the carotid body chemoreflex by intermittent stagnant ischemia. And the 70 degree upright tilt test that best identifies causal changes in regional blood volumes and flows and in respiratory patterns of hyperpneic hypocapnia.
45805105|NCT05923827|Device|Omnipod 5 System|The Omnipod 5 system is a tubeless patch pump that receives glucose values and trend data from the glucose sensor every 5 minutes, automatically calculates insulin dose, and sends delivery commands to the Pod for the delivery of insulin.
46073850|NCT04284137|Behavioral|Unmodified Chinese Medicine Exercise|Participants will attend a 60-minute exercise program (Wu Qin Xi and Ba Duan Jin published by the General Administration of Sport of China) in a non-clinical community setting twice a week and will be expected to practice exercise at home using guided video up to three times a week. Text messages will be sent to remind the participants to do the exercise at home.
45653907|NCT04946409|Other|no intervention|no intervention
45653908|NCT05540483|Drug|Disitamab Vedotin combined with Zimberelizumab|Treatment regimen: Disitamab Vedotin , 2.5mg/kg, intravenously D1, once every 14 days (Q2W), combined with Zimberelizumab, 240mg, intravenously D1, once every 14 days (Q2W).
45676261|NCT04193904|Radiation|Hypofractionated Preoperative Radiation|Radiation will be delivered as 30Gy/10 fractions over two weeks.
46073851|NCT04284137|Behavioral|Active Control|Participants will attend a 60-minute health education program once a week.
45805106|NCT05923814|Drug|CD25 prophylaxis|The humanized CD25 antibody was administered at 1 mg/kg iv on days+1 and +4 after HSCT.
45805107|NCT05923801|Device|switch to BT electrode position|use of different electrode positions of ECT device
45937104|NCT00052091|Behavioral|Problem Solving Therapy|A 12 week cognitive behavioral intervention for depression that teaches patients a structured approach to solving social problems.
45937105|NCT00052091|Behavioral|Brief Supportive Therapy|A 12 week intervention for depression that focuses on supporting patients attempts to cope with depression.
45937106|NCT00159640|Drug|PD-217,014|
45937107|NCT00159679|Drug|Pregabalin|
46073852|NCT02817282|Other|Hand hygiene implementation strategy|Implementation strategy: Individual oriented activities. Education based on the different determinants influencing HCWs' behavior. Reminders for supporting the actual performance of HH; by distributing posters. Performance feedback for awareness. Goal setting will be encouraged and the feedback will be used to help HCWs evaluate their success and determine how they could best adapt their behavior in order to reach their goal. Organisational oriented activities. Products and facilities: The physical environment will be adapted by improving the availability of hand based hand rub. Team-oriented activities; The social environment will be adapted by training at a group and individual level, to improve social and descriptive norms. Positive role models will be stimulated through this training.
46073853|NCT03372941|Drug|Dalbavancin|Dalbavancin, a lipoglycopeptide antibiotic, has been approved by the FDA for the treatment of ABSSSI caused by Gram-positive bacteria. A single dose of dalbavancin will be administered in the Emergency Department followed by discharge with close outpatient infectious disease clinic follow-up.
45653909|NCT04963803|Device|Active transcranial direct current stimulation (tDCS)|Active transcranial direct current stimulation will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 20 minutes/session for 10 sessions.
45653910|NCT04963803|Device|Sham transcranial direct current stimulation (tDCS)|Sham transcranial direct current stimulation will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 1 minute to simulate the experience of tDCS, after which the current will be ramped down to zero for the remaining 19 minutes of the session. Participants in this arm will receive sham stimulation for 10 sessions.
45805108|NCT05923801|Device|continue with RUL electrode position|use of different electrode positions of ECT device
45805109|NCT05923788|Diagnostic Test|T1 mapping measurement|T1 mapping values to test the ability of the MRI sequence to detect Gb3 in kidney
45805110|NCT05923775|Procedure|Impacted third molar surgey|The surgery was performed using the classic technique: ten minutes after anesthesia administration, a horizontal and sulcular incision was performed, and a mucoperiosteal envelope flap was elevated. The bone covering the impacted third molar tooth was removed with the use of a surgical handpiece and rotary instrument. During the operation, saline water was applied to the surgical drill with a second hand to protect the bone from developing a high temperature. After extraction of the third molar, the cavity was treated with curettage, irrigated with saline, and sutured.
45805111|NCT05923762|Behavioral|OHRQoL|"Oral health-related quality of life will be measured by the Oral Impact on Daily Performance (OIDP)"
45805112|NCT05923749|Device|Biatain Ag|Biatain with silver
45805113|NCT05923749|Device|Cutimed Siltec Sorbact|comparator device
45805114|NCT05923736|Other|Intima media thickness ultrasound|EIM is a non-invasive ultrasound technique in which an ultrasound-generating probe is conventionally placed opposite the right primary carotid artery. By distinguishing between an inner layer, consisting of the intima and media, and the outer layer, the adventitia, the intima-media thickness can be assessed.
45805115|NCT05923736|Other|hand ultrasound|Performed by the rheumatologist, to quantify the number of synovial thickenings in B mode and the number of synovitis in Doppler mode. The presence or absence of joint erosions on the metacarpophalangeal (MCP), proximal interphalangeal (PPI) or distal interphalangeal (DIP) joints.
45835677|NCT04780152|Device|Placebo-simulation of transcranial direct current stimulation|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of placebo (30 minutes of placebo-simulation tDCS). Placebo will be administered using the same stimulation parameters and the active treatment position of the electrodes, but current wil be aborted 30 seconds after the ascending slope has begun.
45835678|NCT04780152|Drug|Fluoxetine Tablets|Every patient will receive 10 mg of fluoxetine daily the first 2 two weeks, followed by 20 mg daily.
45835679|NCT01737528|Procedure|Transcatheter Aortic Valve Replacement|Minimal invasive implantation of a biological prothesis in Aortic Position
45835680|NCT04779840|Other|anemia assessment|evaluation of anemia status
45835681|NCT01735656|Device|Resolute stents|zotarolimus-eluting Resolute stents made by Medtronic Vascular, Inc (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294951.htm).
45835682|NCT00644280|Drug|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab 1 week prior to tube insertion and then monthly x 2 more injections
45835683|NCT00641316|Procedure|AtraumaticTeeth Extraction|Teeth extraction alone, allowed to heal for 2 months followed by implant therapy to the sites
45835684|NCT00641316|Procedure|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with Freeze-Dried Bone Allograft (FDBA) mixed with Tri-Calcium Phosphate(TCP) allowed to heal for 2 months followed by dental implant therapy to the sites
45835685|NCT00641316|Procedure|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Autologous Platelet-Rich Plasma (PRP) allowed to heal for 2 months followed by dental implant therapy to the sites
45835686|NCT00641316|Procedure|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Platelet-Derived Growth Factors (PDGF) allowed to heal for 2 months followed by dental implant therapy to the sites
45835687|NCT04779762|Other|Crohn's disease exclusion diet (CDED)|Dietary therapy for Crohn's disease
45835688|NCT04779762|Drug|Ustekinumab Injection [Stelara]|Drug for Crohn's disease
45937108|NCT05567679|Drug|Tazverik|Tazemetostat (Tazverik) 200 mg oral tablets; 800 mg by mouth twice daily for 28 days
46073854|NCT02819934|Drug|KD101|after 10 min KD101 administered, 14C KD101 3.52ug/1ml administrated. both of them will be administrate for oral
46073855|NCT00630227|Biological|Biologic Lung Volume Reduction|20 mL Hydrogel
45937109|NCT00159718|Drug|amlodipine|
45937110|NCT00159718|Drug|atorvastatin|
45937111|NCT00052130|Biological|CancerVax vaccine (CANVAXIN)|
45653911|NCT04963803|Behavioral|Language Specific Attention Treatment|This is a specific type of speech-language therapy that focuses on simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this treatment.
45653912|NCT04945707|Drug|Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]|Ferric derisomaltose (Monoferric) 1000 mg X1 (for subject <50 kg, 20 mg/kg
45805116|NCT05923736|Other|EndoPAT™ 2000 system|It's a measurement that detects endothelial dysfunction in coronary arteries using reactive hyperemia.This examination will be carried out in accordance with the manufacturer's instructions by the Rheumatology Department nurse. The patient lies down for the duration of the examination (20 minutes). A probe is placed on the index finger of each hand and a cuff on the left arm. Recording begins with a 5-minute baseline period (at rest), followed by a 5-minute period of arm occlusion, and ends with a 5-minute period of return to normal.
45937112|NCT00159757|Drug|ziprazidone|
45937113|NCT00159835|Drug|atorvastatin|
45937114|NCT00159835|Drug|simvastatin|
45937115|NCT00397410|Device|Hip protectors|
45937116|NCT00052169|Drug|ZD1839 in combination with docetaxel|Docetaxel given as 75 mg/m2 IV every 3 weeks combined with ZD1839 (IRESSA) 250 mg orally daily until disease progression or withdrawal criteria are met.
45937117|NCT04729764|Drug|GP681 Tablet|Designed as 5 dose groups (20mg, 40mg, 60mg, 80mg, 120mg), the starting dose group (20mg) 8 subjects (including 2 placebo), each other 10 subjects (including Placebo (2 cases), male and female.
45937118|NCT00159952|Procedure|intensive insulin therapy|"control: glycemia will be controlled with insulin administration when higher than 215 mg/dL.~treatment: glycemia will be controlled with be controlled with insulin administration when higher than 110 mg/dL"
45937119|NCT00159991|Procedure|Total arterial revascularization|Coronary artery bypass grafting using LIMA and RIMA and/or radial artery grafts
45937120|NCT00159991|Procedure|Conventional revascularization|Coronary artery bypass grafting using LIMA and saphenous vein grafts
45937121|NCT00052208|Drug|gefitinib|Given PO
45452633|NCT00945490|Drug|NX-1207|Single intraprostatic injection of 2.5 mg NX-1207
45452634|NCT00945490|Drug|Placebo|Single intraprostatic injection of placebo
45452635|NCT00077675|Drug|Telavancin|Telavancin 7.5 mg/kg/day, amended to 10 mg/kg/day, IV (intravenously) for up to 14 days
45805117|NCT05923736|Other|X-ray absorptiometry (DXA)|This X-ray examination will be carried out on the Hologic device and the analyses by APEX 4.0 software. Two-photon X-ray absorptiometry (DXA) is a method commonly used to measure bone mineral density. It is based on a scan of the body by an X-ray beam at 2 different energy levels, which enables 3 compartments to be individualized: mineral mass, lean mass and fat mass. This low-radiation method (less than a conventional chest X-ray) is regarded as a benchmark for accurate measurement of both bone mineral density and the various body compartments. The examination lasts 10 minutes and is carried out by the department's electroradiology manipulators
45805118|NCT05923723|Other|FIBNUTRITION|"The dietary product selected for the study is commercially known as FIBNUTRITION, marketed in Colombia by Bio-Nutrition S.A.S with sanitary registration number NSA-001942-2016.~Ingredients of the product:~Flaxseed, Chia seeds, Psyllium, Polydextrose, Oat flour, Apple, Orange, Artificial flavor (Orange), Pineapple, Nopal, Xanthan gum (thickener), Silicon dioxide, Stevia (Natural sweetener), Lactobacillus Acidophilus Bifidus Casei (Prebiotics), Sodium Benzoate (Preservative), and Turmeric (Natural colorant)."
45805119|NCT05923723|Other|Placebo|The placebo is a dietary product composed of maltodextrin, cornstarch, orange flavoring, and stevia.
45937122|NCT00052208|Radiation|radiation therapy|Undergo radiation therapy
45937123|NCT00052208|Other|laboratory biomarker analysis|Correlative studies
45937124|NCT00407017|Drug|Gatifloxacin|
45937125|NCT00407017|Drug|Ketorolac LS|
45937126|NCT00407017|Drug|Pred Forte|
45937127|NCT00407017|Drug|Moxifloxacin|
45937128|NCT00407017|Drug|Nepafenac|
45937129|NCT00407017|Drug|EconoPred Plus|
45458007|NCT04808401|Drug|Oxygen|Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
45937130|NCT00397449|Biological|GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine)|
45937131|NCT00160030|Drug|FOLFOX 4|total treatment of six 2-weekly cycles of FOLFOX 4, the first 3 cycles starting on D1, D15 and D29 concomitant with 5 weeks' radiotherapy.
45937132|NCT00160030|Drug|5-FU / Cisplatin|two cycles of 5-FU / Cisplatin on week 1 and 5 of radiotherapy and two cycles of chemotherapy with 5-FU / Cisplatin on week 8 and 11 (one cycle each three weeks after the end of radiotherapy).
45937133|NCT00160069|Drug|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour infusion, every 3 weeks
45937134|NCT00160069|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-min infusion, every 3 weeks
45937135|NCT00160069|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour infusion, every 3 weeks
45937136|NCT00160108|Behavioral|dietary intervention|
45937137|NCT00052286|Drug|modafinil|
45937138|NCT00160186|Drug|Pancreatin|2 capsules Pancreatin with 25 000 lipase units per main meal (3 meals) and 1 capsule per snack (2-3 snacks)
45937139|NCT00160186|Drug|Placebo|Placebo
45937140|NCT05567484|Drug|Itraconazole|100 mg two capsules of itraconazole were given twice daily to 30 patient group A for one week per month.baseline LFTs were also monitered
45937141|NCT00160225|Drug|Daglutril|
45937142|NCT00160264|Drug|Lactulose, Vitamin D, Calcium|
46073856|NCT04238832|Other|Salt Base Nicotine|Participants will try both free base and salt base nicotine e-liquid and then take home salt base nicotine
46073857|NCT04238832|Other|Free Base Nicotine|Participants will try both free base and salt base nicotine e-liquid and then take home free base nicotine
45458008|NCT03341962|Drug|IMU-838|IMU-838 tablet
45653913|NCT04945707|Drug|Placebo|Normal saline
45937143|NCT00160303|Drug|Prolotherapy|
45937144|NCT00160303|Drug|Local Corticosteroid Therapy|
45937145|NCT00052325|Dietary Supplement|mistletoe extract|
45937146|NCT00397527|Drug|lactoserum|
46073858|NCT02819700|Behavioral|prevalence of behavioural dysexecutive syndrome|Behavioural Dysexecutive Syndrome Inventory (ISDC)
45452636|NCT00077675|Drug|vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
45805120|NCT05923710|Procedure|Primary anterior cruciate ligament repair|Only arthroscopic primary anterior cruciate ligament repair was performed in patients with proximal anterior cruciate ligament tear.
45805121|NCT05923710|Procedure|Primary anterior cruciate ligament repair and lateral extraarticular tenodesis (LET) with iliotibial band|In addition to primary anterior cruciate ligament repair, lateral extraarticular tenodesis was performed using the iliotibial band.
45653914|NCT05698511|Drug|Psilocybin|Multiple dosing of healthy volunteers with up to 25 mg psilocybin separated from each other by at least one week. Participants will be scanned before and after receiving psilocybin on each dosing day. Surveys will be performed on dosing days and after dosing.
45805122|NCT05923697|Behavioral|AF-EMDR|"Investigational treatment~All participants receive four 90 min. AF-EMDR sessions within a timeframe of two weeks following the baseline phase. The AF-EMDR treatment will be provided by the principal investigators, a level II EMDR therapist (RvdH) and an EMDR consultant in training who developed the AF-EMDR protocol. The EMDR therapist (RvdH) will be trained by the EMDR consultant (WM), who is available for consultation. Additionally, both participate monthly in peer-supervision whereby videotaped sessions are discussed. See appendix 1 for a detailed understanding of the AF-EMDR protocol."
45805123|NCT05923684|Behavioral|NLP-based Feedback|Audio recordings will be made using either digital recorders or telehealth platform-generated transcripts. Patient reports will include only the extracted sentences related to content areas. Physician reports will note the extracted statements across each content area, the quality scores for individual statements based on the pre-specified hierarchy, the statements that achieved the highest score across each content area, and feedback on what could be improved. For patients, decisional conflict and risk perception will be assessed before and after receiving the NLP-based feedback. For physicians, the investigators will assess baseline quality of risk communication by pre-specified hierarchy, any changes in individual physician communication over time, and accuracy of risk estimates for key content areas.
45805124|NCT05923671|Diagnostic Test|Histological analysis|Histological staining of gingival biopsies with haematoxylin-eosin.
45805125|NCT05923671|Diagnostic Test|Immunohistochemical analysis|Immunohistochemical staining of gingival biopsies using anti-Vimentin, anti-Collagen I, anti-Collagen V, anti-Elastin, anti-Hyaluronic acid, anti-Smooth muscle actin, anti-Cluster of Differentiation 68 and anti-ki67 antibodies.
45805126|NCT05923645|Device|Transcranial magnetic stimulation (Hf rTMS)|"TMS protocol - 5 Hz High frequency rTMS, at 100% RMT, 60 pulses per train, total 10 trains , gap between 2 consecutive trains of 30 sec, at left IPL and left STG localised using 10-20 EEG based system at P3 and P5 respectively , using figure of 8 coil~1st cycle of 10 sessions over 10 consecutive days, 2nd cycle of 5 sessions over 5 consecutive days , 3rd cycle for 5 sessions over 5 consecutive days ; gap of 6 weeks between 2 consecutive cycles Total 3 cycles per patient"
45805127|NCT05923632|Behavioral|Dijital Game and Health Education|After the children in the experimental group are informed about the digital game designed according to The Roy Adaptation Model (RAM) and The Information-Motivation-Behavioral Skills Model (IMB) in diabetes management, active participation of the children in the digital game will be ensured for 9 weeks; and participation status will be followed in the background of the game. At the end of 9 weeks, children will be asked to complete all stages of the game. Children who do not complete the game will be contacted once a week in line with their background follow-up and reminders will be made.
45805128|NCT05923619|Procedure|Total pulpotomy|Total pulpotomy procedures explained in arm descriptions.
45805129|NCT05923619|Procedure|Root canal treatment|Root canal treatment procedures explained in arm descriptions.
45805130|NCT05923606|Device|Active tACS|Active tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
45805131|NCT05923606|Device|Placebo tACS|Placebo tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
45805132|NCT05923593|Dietary Supplement|MAG oil oral nutritional supplement (ONS)|The study product is suitable for use as an oral nutritional supplement (ONS).The study product contains MAG oil.
45937147|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
45937148|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
45937149|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.30 MT
45937150|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE/0.30 MT
45452637|NCT00934180|Drug|Ondansetron|1 x 8 mg Orally Disintegrating Tablet
45452638|NCT00934180|Drug|Zofran®|1 x 8 mg ODT
45937151|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE
46073859|NCT02861651|Other|DNA sequencing|
46073860|NCT02818530|Device|IOP by tonometer|Electronic tonometer will be used as gold standard for intraocular pressure measurement in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
46073861|NCT02818530|Device|Anterior chamber depth measurement by ultrasound|Anterior chamber depth will be measured by ultrasound in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
46073862|NCT04622904|Drug|lidocaine-magnesium infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of ketamine of 0.35 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 0.2 mg/kg/h of ketamine will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
45458009|NCT03341962|Drug|Placebo|Tablets manufactured to mimic IMU-838 tablets
45653915|NCT05002257|Other|music therapy|Patients included in the intervention arm with music therapy will choose among 3 possible music: music from elsewhere, classical music, today's music. These 3 music thearpy will have an identical duration of 20 minutes.
45653916|NCT05002257|Other|No music therapy|Usual care
45653917|NCT05546255|Drug|Eribulin Mesylate|The recommended dose of Eribulin is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1
45937152|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE/0.60 MT
45937153|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.45 EE
45937154|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.60 MT
45653918|NCT05546255|Drug|Lobaplatin|The recommended dose of lobaplatin is 25mg/m2 administered intravenously over on Days 1
45653919|NCT05001477|Device|TULSA Procedure|Transurethral ultrasound ablation procedure
45805133|NCT05923580|Behavioral|Group- based cardiac telerehabilitation|Group-based cardiac telerehabilitation promotes information, skills, and support for the management of coronary artery disease in coronary patients. The rehabilitation model includes independent familiarization with information content, assignments, and group meetings, as well as the opportunity for a chat and peer support. The intervention is a health professional- lead, and registered rehabilitation model with a start and end.
45805134|NCT05923554|Other|Changes in Probing Depth to non-surgical periodontal therapy|Changes in Probing Depth following non surgical periodontal treatment performed with hand and ultrasonic tips
45452639|NCT02576444|Drug|AZD2281|Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
45653920|NCT05546177|Other|instrumented assisted soft tissue mobilization|The subject will be treated with instrumented assisted soft tissue mobilization, applied to the upper and lower fibers of Pectoral, Trapezius (upper, middle and lower), Rhomboids major , Rhomboids minor, Teres minor, Teres major, and Latissimus dorsi muscles. The IASTM technique was performed for 20 seconds parallel to the muscle fibers followed by 20 seconds perpendicular to the muscle fibers of each one of the selected muscle
45805135|NCT05923541|Drug|RD13-02 cell infusion|Universal CAR-T cells targeting CD7
45937155|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, Placebo
45937156|NCT00052364|Drug|oxaliplatin|Given IV
45937157|NCT00052364|Other|laboratory biomarker analysis|Correlative studies
45937158|NCT00160381|Drug|Asoprisnil|10mg Tablet, oral Daily for 12 months
45937159|NCT00160381|Drug|Asoprisnil|25 mg Tablet, oral Daily for 12 months
45937160|NCT00160381|Drug|Placebo|Tablet, oral Daily for 12 months
45937161|NCT00160420|Drug|Asoprisnil|5mg Tablet, oral Daily for 12 months
45937162|NCT00160459|Drug|Asoprisnil|5 mg Tablet, oral Daily for 12 weeks
45937163|NCT00160459|Drug|Asoprisnil|10 mg Tablet, oral Daily for 12 weeks
45937164|NCT00160459|Drug|Asoprisnil|25 mg Tablet, oral Daily for 12 weeks
45937165|NCT00160459|Drug|Placebo|Tablet, oral Daily for 12 weeks
45937166|NCT00052403|Drug|monoclonal antibody anti-anb3 integrin|
45937167|NCT00052403|Procedure|anti-cytokine therapy|
45937168|NCT00052403|Procedure|antiangiogenesis therapy|
45937169|NCT00052403|Procedure|antibody therapy|
45937170|NCT00052403|Procedure|biological response modifier therapy|
45937171|NCT00052403|Procedure|growth factor antagonist therapy|
46073863|NCT04622904|Drug|lidocaine-ketamine infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of magnesium of 50 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 10 mg/kg/h of magnesium will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
45937172|NCT00052403|Procedure|monoclonal antibody therapy|
45937173|NCT00160498|Drug|Lercanidipine|
45937174|NCT00160537|Drug|Levocetirizine|
45937175|NCT00160576|Drug|Levetiracetam|
45937176|NCT00160849|Drug|Lopinavir/r|
45937177|NCT00160888|Drug|sodium nitroprusside, bradykinin, acetylcholine|
45937178|NCT00052481|Procedure|quality-of-life assessment|
45937179|NCT00160927|Device|local heating|
45937180|NCT00160927|Device|iontophoresis|
45937181|NCT00160927|Drug|actylcholine|
45937182|NCT00160927|Drug|sodium nitroprusside|
45937183|NCT00160966|Drug|Ciclosporin and Mycophenolate-mofetil|according to the Giessen protocol
45805136|NCT05923528|Device|IPL|IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter
45937184|NCT00160966|Drug|Tacrolimus and Mycophenolate-mofetil|according to Giessen protocol
45937185|NCT00160966|Drug|Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus|according to Giessen protocol
45937186|NCT05567016|Other|Active case detection using molecular testing (ACDm)|In the ACDm arm, children will receive ACD using RDT and qPCR 3x yearly with treatment using artemether-lumefantrine (AL) if RDT or qPCR positive. With fevers, participants will receive standard PCD using RDT.
45937187|NCT05567016|Other|Passive case detection using molecular testing (PCDm)|With fevers, participants will receive PCDm, in which qPCR will be done in RDT negatives with treatment using AL if positive.
45937188|NCT05567016|Other|Control (standard of care)|With fevers, participants will receive standard PCD using RDT with treatment using AL if positive.
45937189|NCT00161005|Procedure|PCI|Immediate transport to invasive center after thrombolysis
45937190|NCT00052559|Biological|bevacizumab|Given IV
45937191|NCT00052559|Drug|fluorouracil|Given IV
45937192|NCT00052559|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
45937193|NCT00052559|Procedure|therapeutic conventional surgery|Undergo surgery
45937194|NCT00052559|Other|laboratory biomarker analysis|Correlative studies
45937195|NCT00161083|Drug|ursodeoxycholic acid|
45937196|NCT00044577|Drug|abacavir/lamivudine|
45937197|NCT00044577|Drug|abacavir|
45937198|NCT00044577|Drug|lamivudine|
45937199|NCT00044577|Drug|tenofovir|
45937200|NCT00161122|Biological|trivalent inactivated influenza vaccine|
45937201|NCT00161122|Biological|combined heptavalent pneumococcal conjugate vaccine and trivalent inactivated influenza vaccine|
45653921|NCT05546177|Other|traditional therapy|the patients will receive Transcutaneous electrical nerve stimulation (TENS) to manage the pain,Ultrasound , Exercise including (Range of motion exercises, stretching exercises, and strengthening exercises (Scapular stabilization exercises and rotator cuff strengthening exercises)
45653922|NCT05551091|Dietary Supplement|glycomacropeptide (GMP)|For each of the two baseline visits, women will consume a 300 calorie liquid breakfast meal tolerance test (MTT), eat a standard test lunch ad libitum with recording of food intake, and will then begin the low-dose GMP (25 g BID with meals) or high-dose GMP (25 g TID with meals) for 7 days. On day 7 of each GMP diet, women will come to the Clinical Research Unit (CRU) for a second breakfast MTT followed by lunch. All subjects will stop GMP products for 5-7 days (washout).
46073864|NCT04622904|Drug|lidocaine infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of normal saline 100 mL will be administered preoperatively within 10 minutes. Followingly, normal saline will be administered intraoperatively at a rate of 20 mL/h
45805137|NCT05923528|Device|Heated eye mask|Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms
45937202|NCT00161200|Drug|Ranitidine & Pantoprazole|
45937203|NCT00052637|Drug|hexaminolevulinate|
45937204|NCT00052637|Procedure|biopsy|
45937205|NCT00052637|Procedure|cystoscopy|
46073865|NCT02817048|Device|chest tube|
46073866|NCT02817048|Procedure|VATS without chest tube placement|Patient received Video-Assisted Thoracic Surgery (VATS) wedge resection for peripheral lung nodule without chest tube placement (Tubeless)
46073867|NCT02817048|Procedure|VATS with chest tube placement|
46073868|NCT02817204|Behavioral|Aerobic Exercise|Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks
45452640|NCT02576444|Drug|AZD5363|Patients will be administered AZD5363 at 640 mg twice daily for two days on/five days off (2/7) schedule. Two (2) 200 mg tablets and three (3) 80 mg tablets should be taken twice daily.
45653923|NCT04962711|Other|Heart Failure intervention (Cardio-Oncology Disease Management Plan (CO-DMP)|A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.
45653924|NCT04962711|Other|Usual care|provided by participants' usual healthcare professional(s)
45653925|NCT02629861|Drug|Fremanezumab|"Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration.~The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site."
45653926|NCT02629861|Drug|Placebo|Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
45653927|NCT04945473|Procedure|Endoscopic placement of additional sutures|A new endoscopic suture will be performed in case of a BMI≥30 or total weight loss (TBWL) less than 10%, and relaxation of gastric tubulization during the regular endoscopic follow-up after 6 months from the ESG. The same endoscopic suture technique of the primary ESG will be applied.
45805138|NCT05923528|Device|LipiFlow®|LipiFlow® can control the variables of temperature, pressure, and MG expression technique
45805139|NCT05923528|Device|EyePeace®|The silicone-made flexible hand-held gadget applies regulated, vertical pressure to the closed eyelids.
45805140|NCT05923515|Drug|JMKX000197|for injection
45452641|NCT02576444|Drug|AZD1775|The recommended dose will be available no earlier than March 2016.
45452642|NCT02576444|Drug|AZD6738|Patients will be administered AZD6738 at 160 mg daily for days 1-7 of a 28-day cycle (7/28) schedule. AZD6738 is available as 100, 20, and 10 mg tablets. Tablets should be taken daily.
45805141|NCT05923502|Drug|Duvelisib|This is a real-word. The treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients.
45805142|NCT05923489|Diagnostic Test|Routine Angiography Follow-up|Patients in the RAF group will have routine angiography follow-ups 12 months after revascularization.
45805143|NCT05923489|Diagnostic Test|Routine Clinical Follow-up|Patients in the RCF group will have routine clinical follow-ups 12 months after revascularization, and the physician will decide whether further invasive testing is needed.
45805144|NCT05923476|Drug|Lithium|Lithium + ECT
45805145|NCT05923476|Other|Placebo|Placebo + ECT
45805146|NCT05923463|Behavioral|precision-enhanced feedback email messages|Providers receive customized messages prioritizing metrics in an optimal formatting.
45805147|NCT05923463|Behavioral|standard feedback email messages|Providers receive metrics in a common format.
45937206|NCT00161239|Drug|Doxil, Methotrexate, L-Asparaginase, Prednisone|
45937207|NCT00161278|Drug|Carboplatin|
45937208|NCT00161278|Drug|Paclitaxel|
45937209|NCT00161278|Procedure|Gene expression profiling (analysis) of tumor samples|
45937210|NCT00044616|Drug|Fluoxetine|
45937211|NCT00044616|Drug|Lithium|
45937212|NCT00161317|Behavioral|Living with Hope Program|
45937213|NCT00161356|Drug|Ambisome|5mg/kg IV - one time dose during liver transplant
45937214|NCT00161356|Procedure|Liver Biopsy|post drug delivery (60 min. after completion of Ambisome infusion)
45937215|NCT00052676|Drug|patent blue V dye|
45937216|NCT00052676|Procedure|radionuclide imaging|
45937217|NCT00052676|Procedure|sentinel lymph node biopsy|
45937218|NCT00052676|Radiation|technetium Tc 99m sulfur colloid|
45937219|NCT00161395|Behavioral|Instruction in the Creighton Model Fertility Care System|Instruction in the Creighton Model Fertility Care System.
45937220|NCT00161395|Behavioral|Preconception advice|Preconception advice for diet and frequency of intercourse.
45937221|NCT00161434|Drug|valacyclovir|1 gram daily for 8 weeks
46073869|NCT02817204|Behavioral|Health Education|Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol
46073870|NCT04239300|Behavioral|Delivery in water|Participants delivery in water
45937222|NCT00161434|Drug|placebo|matching placebo for 8 weeks
45937223|NCT00044694|Drug|Placebo 0.01 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.01 mL subcutaneously injected twice daily
45653928|NCT04317989|Other|Practice Facilitation|"Implementing evidence-based protocols and the use of clinical algorithms (for screening, counseling, referral, and MAT) to engage the entire clinical team in a high standard delivery of care.~Promoting a strong use of decision support tools and templates to support the practice workflow.~Optimizing the use of the electronic health record (EHR) to pull clinical data on a monthly basis to guide the change process.~Developing patient registries (e.g., for those identified to have AUD) to identify needed care~Proactive, team-based care with assigned roles and responsibilities to prepare the clinical team to develop needed care and engage patients throughout the entire visit process.~Enhancing the understanding of available counseling and referral resources to ensure that practices are confident that they have appropriate evidence-based intervention options."
45937224|NCT00044694|Drug|Placebo 0.02 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.02 mL subcutaneously injected twice daily
45937225|NCT00044694|Drug|Placebo 0.03 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.03 mL subcutaneously injected twice daily
45805148|NCT05923450|Procedure|Colorectal Resection|Radical resection of colorectal cancer
45805149|NCT05923437|Other|Feeding model group with a chronobiological approach|"Breast milk will be given to the newborns in the intervention group for 3 days in line with the feeding model with a chronobiologic approach simultaneously with the provision from the mother, and the newborn will be ensured to receive breast milk in accordance with the day cycle. Within the scope of the study, firstly, mothers and nurses in the NICU will be informed about the study. Mothers will be asked to put the milk they express between 06:00-17:59 in the daytime breast milk storage bag and the milk they express between 18:00-05:59 in the nighttime breast milk storage bag and bring them to the unit. The brought breast milk will be prepared by the nurses by matching day and night milk according to the dates, with the first milk brought in priority, and the newborns will be fed by using the time of day factor (cycle so that the milk collected during the day will be given during the day and the milk expressed at night will be given at night)."
45805150|NCT05923424|Drug|REGN17092|Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
45937226|NCT00044694|Drug|Placebo 0.04 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.04 mL subcutaneously injected twice daily
45937227|NCT00044694|Drug|AC2993 2.5 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 2.5 mcg (0.01 mL) subcutaneously injected twice daily
45937228|NCT00044694|Drug|AC2993 5.0 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 5.0 mcg (0.02 mL) subcutaneously injected twice daily
45937229|NCT00044694|Drug|AC2993 7.5 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 7.5 mcg (0.03 mL) subcutaneously injected twice daily
45653929|NCT04959279|Other|ED-TREAT|Patients will be assessed and treated based on a clinical decision support system.
45653930|NCT05540249|Dietary Supplement|carbohydrates|Patients will orally consume 355mL CHO after 20:00 the evening before surgery.
45805151|NCT05923424|Drug|Matching Placebo|Single ascending IV or SC administration per the protocol
45805152|NCT05923411|Drug|Single dose of PF-07220060 as first Tablet Formulation|A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions.
45805153|NCT05923411|Drug|Single dose of PF-07220060 as second Tablet Formulation|A single dose of PF-0720060 as the second Tablet Formulation administered under fasting conditions
45653931|NCT05461287|Drug|QLS31904|QLS31904 ONLY
45805154|NCT05923411|Drug|Single dose of PF-07220060 as first Tablet Formulation|A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions at a second dose level
45805155|NCT05923411|Drug|Single dose of PF-07220060 as second Tablet Formulation|A single dose of PF-07220060 as the second Tablet Formulation administered under fasting conditions at a second dose level
45937230|NCT00044694|Drug|AC2993 10.0 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 10.0 mcg (0.04 mL) subcutaneously injected twice daily
45937231|NCT00161551|Device|Vitatron T70 DR|
45937232|NCT00052754|Drug|gefitinib|
45937233|NCT00161590|Drug|CHOP and alemtuzumab|
45937234|NCT00161629|Drug|rhBMP-2/CPM|
45937235|NCT00161668|Drug|Mylotarg|
45937236|NCT05566977|Other|autologous adoptive T regulatory cell transfer.|Identification and count, using flowcytometry, for human Tregs will be based on both positive and negative cell markers, human Tregs are (CD4+, CD25+, CD127-, Foxp3+). Peripheral heparinized venous blood will be used .GMP-Compliant Protocol for the Isolation and Expansion of Tregs for Clinical Application .Cryopreservation of Expanded Tregs .Administration of T reg cells and follow-up of adverse events.
45937237|NCT00052832|Dietary Supplement|doxercalciferol|
45937238|NCT00161707|Drug|Aerosolized, Recombinant Alpha 1-Antitrypsin|
45937239|NCT00044538|Drug|BAY59-8862 (Cytotoxic Taxane)|Intravenous dose over 60 minutes every 3 weeks
45676262|NCT04187326|Behavioral|Facial Microexpression Training|The METT is a well-validated task designed to improve perception of subtle changes in facial expressions, termed microexpressions. Participants with high trait anxiety will return to the lab approximately six months post scan visit to complete this computer-based task. They will receive feedback during the task on their accuracy.
45676263|NCT04161885|Drug|Venetoclax|Tablet; Oral
45937240|NCT00161746|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
45937241|NCT00161785|Biological|FSME-IMMUN 0.5ml|
45937242|NCT00044733|Drug|Mylotarg (gemtuzumab ozogamicin) Injection|
45937243|NCT00161824|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
45937244|NCT00161863|Biological|FSME-IMMUN NEW 0.25 ml|
45937245|NCT00052949|Drug|imatinib mesylate|Given orally
45937246|NCT00052949|Other|laboratory biomarker analysis|Correlative studies
45937247|NCT00161902|Drug|Fibrin Sealant Vapor-Heated Solvent/Detergent-treated|
46073871|NCT00634062|Drug|Lamotrigine|Subject in active active drug group will receive lamotrigine tablets 12.5 per day for the first week of the study. Dose of lamotrigine can be increased to 25mg per day during the second week of the study and may be increased each week thereafter for the next 9 weeks by 25mg per day. Subjects in active treatment group will receive lamotrigine for total of 12 weeks
46073872|NCT00634062|Drug|Placebo|Subjects will receive 12.5mg of inert placebo per day during the first week of the study. Inert placebo can be increased to 25mg per day during the second week of the study and by 25mg per day each week for the next 9 weeks. Subjects can receive a total of 12 weeks of placebo.
45937248|NCT04710745|Diagnostic Test|Peripheral blood samples for routine analysis including NT-proBNP and plasmatic biomarkers.|Sampling of peripheral venous blood for analysis of plasma concentration of plasmatic markers (Apelin, microRNA, FGF-23, IGF-1, IGFBP-1) and routine analysis (laboratory parameters: NT-proBNP, D-dimer, Creatinine Clearance, CRP, Hs-troponin).
45937249|NCT04710745|Diagnostic Test|Echocardiography|"ECHO parameters:~E/e´~Mean e' septal and lateral wall~LA volume (Biplane Area-Length Method)~Left atrial volume index~Diameter of left atrium in PLAX~Severe aortic stenosis~Severe mitral regurgitation~Severe tricuspid regurgitation~Left ventricular end-diastolic diameter~Interventricular septum~Posterior wall~LV Mass~Left ventricular mass index"
45805156|NCT05923411|Drug|Single dose of PF-07220060 as a Tablet Formulation|A single dose of PF-07220060 as a tablet formulation administered under fed conditions
45937250|NCT04710745|Diagnostic Test|ECG Holter monitor|Patient receives an ECG Holter for a 7-day monitoring.
45805157|NCT05923411|Drug|Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration|Single dose of PF-07220060 tablets under fasting conditions and under Proton Pump Inhibitor (PPI) administration (following a 7 day oral rabeprazole tablets daily administration).
45937251|NCT04710745|Diagnostic Test|Standardized Mini-Mental Status Exam (SMMSE)|A screening test for evaluating cognitive performance of patients done in the clinician's office.
45937252|NCT00053027|Biological|rituximab|
45937253|NCT00053027|Drug|cladribine|
45937254|NCT00161980|Drug|Fibrin Sealant VH S/D|
45937255|NCT00161980|Procedure|Surgical intervention alone without Fibrin Sealant VH S/D application|
45937256|NCT00162019|Drug|Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)|
45937257|NCT00162058|Drug|Peflutren Lipid Microsphere Injectable Suspension|
45937258|NCT00162214|Drug|Dasatinib + Ketoconazole|Tablets, Oral, Segment 1: escalating single dose of dasatinib starting at 140 mg q24 hours on Day 1-8; single dose of ketoconazole 200 mg q12 hours on Days 3-8; Segment 2: single daily oral doses of dasatinib, once daily, until disease progression or unacceptable toxicity.
45937259|NCT04731116|Drug|Cannabidiol|Oral Cannabidiol 150 mg twice daily during 14 days
45937260|NCT00407056|Drug|Difluprednate Ophthalmic Emulsion|
45937261|NCT00407095|Drug|Pardoprunox|12-42 mg/day
45937262|NCT04731792|Other|Virtual Reality|a bronchial fibroscopy with a virtual reality helmet
45452643|NCT02530775|Procedure|instrumented spinal fusion with laminectomy|"Once determined that a patient has single level static degenerative spondylolisthesis and is planning to schedule surgery the patient will be approached by a research team member explaining the study and reviewing the informed consent document. If the patient chooses to participate, he or she will be randomized to be apart of the non-instrumented arthrodesis with laminectomy group or the instrumented arthrodesis with laminectomy group. Both are standard approved surgical approaches; however, using instrumentation is the more commonly used approach."
45653932|NCT05546021|Procedure|NOL monitor|"NOL technology uses a multiparameter-based sensor platform, and advanced algorithm, to continuous monitor Autonomic Nervous System (ANS) functions. NOL reflects a patient's nociceptive state and analgesic effect, helping to optimize the administration of systemic and/or regional analgesics and avoiding overdose or underuse of these drugs.~The nociception level is a multiparameter monitor that combines information from the finger photoplethysmogram amplitude, skin conductance, skin conductance fluctuation, heart rate, heart rate variability, and their time derivatives into one index ranging from 0 (absence of noxious stimulation) to 100 (severe noxious stimulation). The nociception level is a composite score derived from a set of physiologic variables (i.e., peripheral effectors of the autonomous nervous system): heart rate, heart rate variability, the amplitude of the photoplethysmogram, skin conductance, skin conductance variability, and the time derivatives of these variables."
45653933|NCT04958733|Procedure|Autologous bone grafting|Autologous bone grafting is the excess bone obtained from graft preparation and the coring reamer
45937263|NCT00405457|Drug|Restasis, Optive Tears|Restasis and Optive Tears use twice daily more frequently if needed
45937264|NCT00053105|Drug|cisplatin|
45805158|NCT05923411|Drug|Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration|Single dose of PF-07220060 tablets given with high-fat, high-calorie meal and under PPI administration (following a 7 day oral rabeprazole tablets daily administration)
45937265|NCT00053105|Drug|cytarabine|
45937266|NCT00053105|Drug|methylprednisolone|
46073873|NCT00633828|Behavioral|Increased physical education in primary school (daily)|Increased physical education in primary school, 40 minutes per day
46073874|NCT00634140|Drug|ezetimibe|ezetimibe 10 mg daily for 4 to 6 weeks
45937267|NCT00053105|Drug|pixantrone dimaleate|
45937268|NCT00407134|Procedure|Different abdominal volumes and different glucose-concentrations during peritoneal dialysis|
45937269|NCT04710472|Device|Mentora App|"Participants will be invited to register their treatment side effects, symptoms, daily activities and exercise and QoL on a health app designed for this purpose.~The Mentora Health App includes a tool based on PRO-CTCAE™, a patient-reported outcome measurement system developed by the National Cancer Institute, version 1.1, that includes 80 symptoms (attachment 1) and has been translated and validated to Portuguese (Portugal) by the authoring entity. These symptoms are graded on a five-point scale from 0 (not present) to 4 (disabling) based on clinical criteria."
45937270|NCT00162331|Drug|Technetium Tc99m Sestamibi|
45937271|NCT00162409|Drug|Folic acid|
45937272|NCT00053144|Drug|cytarabine|
45937273|NCT00053144|Drug|irinotecan hydrochloride|
45937274|NCT00162448|Drug|BMS-394136|Oral Solution, Oral, 100 mg, Single dose, 1 day.
45937275|NCT00162448|Drug|Placebo|Oral Solution, Oral, 0 mg, Single dose, 1 day.
46073875|NCT00634140|Drug|Placebo|placebo for 4-6 weeks
46073876|NCT02819544|Drug|Sodium chloride administration|Sodium chloride administration
46073877|NCT02819544|Drug|Ropivacaine administration|Ropivacaine administration
46073878|NCT02816814|Other|Diet rich in omega-3 fatty acids|A diet rich in omega-3 fatty acids (7g/die) will be administered for 4 months to overwieght women in menopause
45937276|NCT00162487|Drug|Albuterol (1,200 μg) through metered-dose inhaler|
45937277|NCT05562960|Procedure|Plasmapheresis|Regular plasmapheresis to remove anti-NRIP autoantibody
45937278|NCT04724356|Other|Virtual Reality|Intervention was led once per day, five days a week, over 8 weeks.
45805159|NCT05923398|Behavioral|Digital Intervention Group|"Participants will use a Digital Intervention Suite composed of a virtual reality (VR) scenario, a web-based platform, and a wearable device to assess their stress response in near-real time and in a hypothetical stressful scenario.~During the VR scenario, physiological signals such as Galvanic Skin Response (GSR), Electrocardiogram (ECG), Respiratory Independence (RI), and Photoplethysmography will be measured. Additionally, an educational intervention video on how to deal with stress and distress will be shown to participants. We will then request participants to practice the skills taught during the intervention video in the VR scenario.~The wearable device (Oura Ring) will measure sleep, activity, readiness information, heart rate, heart rate variability, body temperature (delta), and respiratory rate. Additionally, the web-based platform will, through questionnaires, assess stress-related symptoms such as loneliness, anxiety, depression, and moral injury."
45937279|NCT04724356|Other|Resistance Exercise|Intervention was led once per day, five days a week, over 8 weeks.
45937280|NCT00053183|Procedure|conventional surgery|
45937281|NCT00053183|Radiation|brachytherapy|
45805160|NCT05923385|Diagnostic Test|Four Square Step Test|These are standardized test which will be applied to subjects with pencil, paper and time recorder.
45937282|NCT00053183|Radiation|radiation therapy|
45937283|NCT00162526|Drug|Tocopherol|
45937284|NCT00162565|Drug|beta-blocker treatment|beta-blocker treatment
45937285|NCT00162604|Drug|Cefuroxime|
45937286|NCT00162643|Drug|zidovudine+lamivudine+lopinavir/ritonavir|
45937287|NCT00162643|Drug|zidovudine + lamivudine + efavirenz|
45937288|NCT00162682|Procedure|Antiretroviral Drug Combination Switching Criteria|Antiretroviral treatment will use the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
45937289|NCT00162682|Procedure|Antiretroviral Drug Combination Switching Criteria|Antiretroviral treatment is monitored using a CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
45653934|NCT04958733|Procedure|Absence of autologous bone grafting|Donor sites will be left unfilled
45937290|NCT00044772|Drug|Venlafaxine ER|
45937291|NCT00162721|Drug|doxorubicin, ifosfamide, cisplatin|
45937292|NCT00053222|Drug|arsenic trioxide|
45937293|NCT00162760|Drug|Thalidomide|
45937294|NCT00162799|Drug|Triflusal (DCI)|
45937295|NCT00044811|Drug|Fexofenadine|
45458010|NCT04782817|Other|Recommendation for high flow nasal cannula oxygen therapy order set|Participants will be assigned post extubation physician order set which recommends the administration of oxygen therapy via HFNC. HFNC is a heated and humidified system that allows prescribed fraction of inspired oxygen (FIO2) levels to be delivered at very high flow rates.
45653935|NCT05540015|Procedure|Third molar extraction by cutting and rotary tools|Extraction of the impacted lower third molar will be conducted using cutting and rotary tools under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). Scalpel will be used for the incision of the soft tissues, rotary instruments will be used for the bone tissue and tooth fragmentation. After the extraction the wound will be sutured by the suture material.
45676264|NCT04161885|Drug|Azacitidine|Subcutaneous (SC) or intravenous (IV) injection
45676265|NCT04161885|Other|Best Supportive Care (BSC)|BSC is the best supportive care, without AML directed therapy, determined per the investigator and institutional guidelines.
45676266|NCT04160052|Drug|Azacitidine|Given SC or IV
45676267|NCT04160052|Drug|Venetoclax|Given PO
45805161|NCT05923359|Other|Apple Watch|Apple Watch
45937296|NCT00162877|Drug|Rabeprazole vs. Esomeprazole|
45937297|NCT00162916|Drug|citalopram|20mg or 40mg, once daily, for 40 weeks
45937298|NCT00162916|Drug|Placebo|Cornstarch
45937299|NCT00053261|Procedure|management of therapy complications|
45937300|NCT00162994|Procedure|adenoidectomy and tymapanostomy|
45937301|NCT04724239|Drug|Sintilimab|200mg IV on Day 1 Q3W
45937302|NCT04724239|Drug|Chidamide|30mg PO BIW each 3-week cycle
45937303|NCT04724239|Drug|IBI305|7.5mg/kg IV on Day 1 Q3W
45937304|NCT05543811|Dietary Supplement|Food for special dietary use|Food for special dietary use (spread) with modified ingredients' content will be included to the diet of 70 patients without significant organic pathology for 14 days receiving standard diet, modified by the inclusion of two portions of the spread, 20 grams each for breakfast and dinner
45937305|NCT00163033|Drug|estetrol|
45937306|NCT00163072|Drug|transdermal Megace|oral vs transdermal levels
45937307|NCT00163111|Drug|VFENDÂ® I.V., Oral|
45937308|NCT00163111|Drug|Conventional amphotericin B|
45937309|NCT00163111|Drug|Diflucan IV, oral|
45937310|NCT00163150|Drug|Atorvastatin|
45937311|NCT02970786|Drug|Injection of 68Ga-NODAGA-E(c[RGDyK])2|Following one injection of 68Ga-NODAGA-E(c[RGDyK])2 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
45937312|NCT00163267|Drug|clopidogrel|Best endovascular treatment either with one or the other drug arm should be investigated
45937313|NCT00163306|Drug|Pantoprazole|
45937314|NCT00044889|Drug|clofarabine (IV formulation)|
45937315|NCT00163345|Drug|Ciclesonide|
45937316|NCT00163384|Drug|Ciclesonide|
45937317|NCT00163423|Drug|Ciclesonide|
45937318|NCT04731038|Drug|Anlotinib, Toripalimab, Paclitaxel, Cisplatin/ Carboplatin|This is a single-arm study with all patients receiving these four drugs.
45937319|NCT05531604|Behavioral|appetitive conditioning|The investigators will examine acquisition and extinction of learned associations to positively-valenced, socially rewarding yet symptom-neutral infant laughter sounds in an appetitive conditioning paradigm. The investigators will also examine spontaneous recovery of this association 24 hours later when re-presented with these cues, and the reinstatement of this association when re-exposed to infant laughter.
45937320|NCT00163462|Drug|Ciclesonide|
45676268|NCT04159805|Drug|TAK-079|TAK-079 subcutaneous injection
45937321|NCT00053300|Drug|thalidomide|oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity
45653936|NCT05540015|Procedure|Third molar extraction by erbium laser with wavelength 2.94 nm|Extraction of the impacted lower third molar will be conducted using erbium laser with wavelength 2.94 nm under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). The soft tissue and bone tissue will be dissected by erbium laser with wavelength 2.94 µm (Erbium laser Smart 2940D plus with the wavelength 2,94 µm, company- DEKA, Italy, registration № 2005/1245). After the extraction the wound will be sutured by the suture material (registration № ФСЗ 2010/06040; 07.08.2018)
45805162|NCT05923346|Other|GLUTLEARN|"The group will be made up of users of the social network Instagram who have celiac disease or are close to a celiac patient (parent/guardian of celiac children or cohabitants).~The intervention will be carried out through the social network Instagram. Participants will be recruited through the same social network. Participants must agree to take part in the study.~The educational intervention will be carried out for one month, where each day a post will be uploaded with specific, truthful and current information. The content of the intervention has been divided into 5 main blocks: 1) general concepts about CD, 2) balanced GFD, 3) food labelling, 4) cross-contact/cross-contamination, 5) new research on CD and useful resources for disease management."
45805163|NCT05923333|Dietary Supplement|B. infantis Rosell®-33|B. infantis Rosell®-33 + maltodextrin
45937322|NCT00053300|Procedure|adjuvant therapy|Patients receive oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
45937323|NCT00163501|Drug|Ciclesonide|
45937324|NCT00163540|Biological|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
45937325|NCT05525598|Behavioral|"One step at a time"|[see 'arms' section for full description]
45805164|NCT05923333|Dietary Supplement|Placebo|Maltodextrin
45805165|NCT05923320|Behavioral|training|The experimental group was given training on infancy vaccines and breastfeeding. The times of the trainings are determined based on the Postpartum Care Management Guide of the Ministry of Health. In the hospital on the first day after birth, 2-7. days and 30-42. Three days in total, trainings were given on breastfeeding and childhood vaccinations by making home visits. The training content has been prepared by taking into account the Ministry of Health Breastfeeding Guide (5) and the Ministry of Health's vaccination calendar and the Primary Care Vaccine Guide. The trainings will be given to the puerperant women individually. About 30 minutes of training will be given and their questions, if any, will be answered.
45937326|NCT05525598|Behavioral|"Get started"|[see 'arms' section for full description]
45937327|NCT00163579|Drug|Bryophyllum|
45937328|NCT00163579|Other|Placebo|
45937329|NCT00053339|Drug|tamoxifen|
45937330|NCT00053339|Drug|trastuzumab|
45676269|NCT04159805|Drug|TAK-079 Placebo|TAK-079 placebo-matching subcutaneous injection
45805166|NCT05923294|Procedure|Coronally advanced flap with connective tissue graft|In both groups, connective tissue graft with a trapezoidal flap design will be applied to the recession area.
45805167|NCT05923281|Drug|K-877 0.2 mg/day (once daily)|K-877 0.2mg tablet
45805168|NCT05923281|Drug|K-877 0.4 mg/day (once daily)|K-877 0.2mg tablet
45805169|NCT05923281|Drug|Placebo (once daily)|Placebo tablet
45937331|NCT00163618|Biological|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
45937332|NCT00407173|Drug|HCV-796|HCV-796 1000mg single dose
45937333|NCT05516082|Device|Lens A|daily disposable hydrogel contact lens - Test Lens 15 minutes of daily wear
45937334|NCT05516082|Device|Lens B|daily disposable silicone hydrogel contact lens - Control Lens 15 minutes of daily wear
45937335|NCT00053378|Drug|paricalcitol injection (Zemplar)|
45937336|NCT00053378|Behavioral|Effects on calcium regulation|
45937337|NCT00053378|Behavioral|Administration of elemental Ca during hypocalcemic ICU pts.|
45937338|NCT00163735|Drug|Administration of wine fined with potential food allergens|
45937339|NCT00163774|Device|Brain oxygenation and microdialysis catheters|
45937340|NCT00163813|Procedure|Early jejunal feeding (using frictional NJ tube)|
45937341|NCT00163813|Procedure|Standard feeding (using nasogastric [NG] tube)|
45937342|NCT00163852|Drug|Normal saline IV, salt tablets|
45937343|NCT02970383|Behavioral|Initial prescription for 10 narcotic tabs|Reduced number of pills in initial prescription post-operatively
45937344|NCT02970383|Behavioral|Inital prescription for 30 narcotic tabs|
45937345|NCT04724122|Other|Observational / Assessment only|The results of this assessment will determine the needs for future interventions
45937346|NCT00163891|Behavioral|Chest physiotherapy|
45937347|NCT05502900|Drug|Melatonin|White round tablets, each with a dose of 5 mg Melatonin. 4 tablets taken simultaneously at night. Tablets can be crushed and/or taken with a glass of water if the patient wish.
45937348|NCT00163969|Drug|ketamine|
45937349|NCT00164008|Drug|zoledronic acid vs pamidronate|
45937350|NCT00164047|Drug|Nitrous Oxide|
45937351|NCT00164086|Drug|atorvastatin|
45937352|NCT05501691|Other|Placebo|Laser Simulation
45937353|NCT05501691|Radiation|445 nm Diode Laser Wavelength|The Axial Surface of Class V Cavity will be Irradiated Using a 445 nm Diode Laser Wavelength
45937354|NCT05501691|Radiation|660 nm Diode Laser Wavelength|The Axial Surface of Class V Cavity will be Irradiated Using a 660 nm Diode Laser Wavelength
45937355|NCT05501691|Radiation|970 nm Diode Laser Wavelength|The Axial Surface of Class V Cavity will be Irradiated Using a 970 nm Diode Laser Wavelength
45937356|NCT00164125|Drug|polyethyleneglycol3350|
45937357|NCT00164164|Drug|HalfLytely|
45937358|NCT00164164|Drug|NuLytely|
45937359|NCT00164203|Behavioral|Cognitive Behavioral Therapy|12-session, weekly, school-based protocol based on cognitive restructuring, tailored to children Grades 3 to 6; comparison with activity control condition of equal duration.
45937360|NCT00164203|Behavioral|School-based CBT|12 sessions, weekly
45937361|NCT00164203|Behavioral|activity control condition|weekly games & activities x 12 weeks
46073879|NCT02816814|Other|Diet with extra virgin olive oil|A diet rich in EVO (25-30g/die) will be administered for 4 months to overwieght women in menopause
45653937|NCT05545709|Procedure|remote robot-assisted spine surgery|Based on the 5G network, the orthopedic robotic remote surgery platform is built at Beijing Jishuitan Hospital, providing primary hospitals with a platform for preoperative consultation, intraoperative communication and surgical robot teleoperation, and postoperative follow-up. With the support of the 5G network, equipment and surgical robots are integrated into the remote surgery service platform, building a high-speed transmission channel between Beijing Jishuitan Hospital and other hospitals.
45653938|NCT05545631|Other|no intervention|no intervention in this study
45653939|NCT02482935|Drug|Abemaciclib|Administered orally
45653940|NCT05551013|Drug|APG-157|"APG-157 is an orally administered drug encased in a hydrogel pastille.~Arms:~Ongoing Stupp protocol (will receive concurrent TMZ + APG-157)~Progression post TMZ (will receive APG-157 only)~Ongoing Optune (will receive concurrent Optune + APG-157)~Progression post Optune (will receive APG-157 only)"
45653941|NCT02513823|Dietary Supplement|2,000 International Units (IU)of vitamin D3|2,000 IU vitamin D taken daily for 10 weeks
45653942|NCT04980859|Drug|Zebutinib&BR or Zebutinib&FCR|Introduction period: Zebutinib 160 mg bid oral treatment for 3 months;Joint stage :6 sessions of Zebutinib FCR( under 60 years of age,Fludarabine 25 mg/m² Q3W, Cyclophosphamide 250 mg/m² Q3W,Rituximab 375 mg/m² Q3W) or BR (over 60 years of age, )(28 days and 1 cycle);Maintenance treatment: after the end of the combined phase, continue the treatment of zebutinib.
45653943|NCT04432519|Procedure|Immediate dental implant placement|Dental implant insertion in the same surgical stage of the tooth extraction, consisting in implant placement in the fresh socket.
45653944|NCT05545475|Drug|Low molecular weight heparin|Anticoagulants were given. When using warfarin, international normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
45653945|NCT05539703|Other|Invitation to get a 2nd booster dose of COVID-19 vaccine|Participants in the intervention group will receive an invitation to get a 2nd COVID-19 booster dose. Those who accept the invitation to be vaccinated will receive the vaccine through their municipality's vaccination service.
45653946|NCT02513745|Device|Conventional|Routine cataract surgery by phacoemulsification before laser-assisted cataract surgery.
45653947|NCT02513745|Device|Refractive Cataract Suite (Verion + ORA)|Laser-assisted cataract surgery with the digital surgical planning and positioning tools, and intraoperative aberrometry.
45653948|NCT05545397|Drug|Propofol|And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
45653949|NCT05545397|Device|EEG montior|And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
45653950|NCT04952727|Biological|Recombinant SARS-CoV-2 Ad5 vectored vaccine|This vaccine contains 5×10^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
45653951|NCT04952727|Biological|Inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research & Development Co., Ltd. 0.5 ml / bottle.
45653952|NCT05539625|Dietary Supplement|MitoQ|"MitoQ in inflammation: In the experimental setting, MitoQ has been extensively studied with clear mode of action on inflammatory mechanisms relevant to IBD:~MitoQ can limit the damage to mitochondria caused by mitochondrial ROS and thereby reducing the leak and oxidisation of mtDNA that are critical to its pro-inflammatory actions within the cell.~MitoQ reduces the inflammatory potential of mitochondrial DNA which have escaped or released from dying inflammatory cells.~MitoQ can influence how the immune cells generate their energy, diverting it away from a more inflammatory type of metabolism (glycolysis) MitoQ can induce autophagy, a cellular recycling mechanism that removes damaged mitochondria. Defective autophagy is heavily implicated in the pathogenesis of IBD.~Hence collectively, MitoQ acts upstream of several pro-inflammatory mechanisms with the net effect to promote resolution of inflammation and mucosal healing."
45653953|NCT05539625|Other|Placebo|Placebo
45805170|NCT05923268|Drug|[99mTc]Tc-G3-(G3S)3C|One single injection of [99mTc]Tc-G3-(G3S)3C, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours
45653954|NCT02512965|Radiation|20 Gy in 5 fractions|
45805171|NCT05923255|Procedure|LISH （Laparoscopic Ileocecal-Sparing Right Hemicolectomy）|Preserve the ileocolic blood vessels, and perform dissection of lymph node groups 203, 202, and 201d along the root of ICV(Ileocolic artery)/ICA(Ileocolic vein). Group 201d lymph nodes are defined as the distal lymph nodes of the ileocolic vessels (colonic branch). Use an intracavitary cutting and sealing device to transect the proximal colon along the predetermined margin, and transect the transverse colon at 10cm distal to the tumor. Perform ileocecal-transverse colonic anastomosis.
45805172|NCT05923255|Procedure|TRH（Traditional Laparoscopic Right Hemicolectomy）|Transect the root of the ileocolic vessels and perform dissection of lymph node groups 203, 202, and 201; sever the roots of the right colic and middle colic vessels, and clear the surrounding lymphoadipose tissue (lymph node groups 211/212/213 and 221/222/223). Transect the transverse colon 10cm distal to the tumor and cut the terminal ileum 10cm from the ileocecal junction. Perform ileum-to-transverse colon anastomosis.
46073880|NCT02819388|Behavioral|Contraceptive counseling|A culturally adapted counselling session lasting up to 45 minutes at the community setting. The interview is based in WHO guidelines and communication tools, in social cognitive theory and in motivational interviewing. Along the interview, topics follow easy to read leaflets prepared to discuss the main benefits of contraception from the view of the immigrant communities, with guided discussions on family planning in the life course, the amount of time required to care children, the economic resources that newborn and children need, and an assessment of the knowledge on the contraceptive methods, and of their current use. Contraceptive methods, abortion and emergency contraception are discussed. Primary health care centre and sexual and reproductive health clinic access is reinforced.
46073881|NCT05658588|Device|Cytosorb|Cytosorb cartridge It is composed of polystyrene divinylbenzene and polyvinylpyrrolidone copolymers and targets molecules in the 5-50 kDa range, which includes the molecular mass of several cytokines
46073882|NCT02818296|Behavioral|Active IU CBM-I|
46073883|NCT02818296|Behavioral|Control CBM-I|
45937362|NCT05459922|Device|Wearable bright light therapy device|Light treatment glasses (Re-timer®) will be used to deliver bright light therapy. This device is available commercially and allows participants to freely move around while receiving light from LEDs positioned below the eyes. Re-timer® can be worn over glasses and does not interfere with vision, reading, or computer work.
45937363|NCT05459922|Device|Wearable placebo light therapy device|The placebo Re-timer® emits light intensity to a level that will not impact sleep and circadian timing and appears identical to the original Re-timer®.
45805173|NCT05923242|Behavioral|Computerized Intervention Authoring Software (CIAS)|CIAS is a web based intervention. The CIAS tool walks the participant through a Motivational Interviewing process whereby they think through the reasons for and against completing screening. CIAS makes use of an automated avatar (Emmi) who is programed to ask them questions and lead them through several topic areas related to screening. The CIAS pathways include options for participants to request a link of resources after they complete each session and for patients to request a list of the cancer treatments listed in their study records in order to confirm their understanding of their cancer history.
45937364|NCT00164242|Drug|Galantamine|
45937365|NCT00162955|Drug|Valsartan|Patients allocated into ARB administration group take Valsartan (80mg/day) from the day of the start of 1st CHOP until the completion of all the evaluations.
45937366|NCT00164281|Drug|Isoniazid|Daily 300 mg isoniazid supplemented with 25 mg pyridoxine for 6 months vs 36 months.
45937367|NCT00164320|Behavioral|TEAM|
45937368|NCT00053573|Biological|Myozyme|20 mg/kg to 40 mg/kg qow
45937369|NCT00044928|Drug|Piperacillin/Tazobactam|
46073884|NCT02818374|Device|oral accessibility spatula (SAB)|
45937370|NCT00164359|Drug|Amodiaquine plus artesunate|
45937371|NCT00164359|Drug|chlorproguanil-dapsone plus artesunate|
45937372|NCT04723849|Dietary Supplement|Auxilie® Immuplus, Envicon Medical, Verona, Italy|"Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study. Height (cm) and weight (kg) were measured for each child at every visit. Endothelial function was assessed using two methodologies: a post occlusive release hyperemic test (PORH) and a heat provocation test (HPT)."
45937373|NCT00164398|Behavioral|HIP: HIV Intervention for Providers|
45937374|NCT00164437|Behavioral|educational CD-ROM|
45937375|NCT00053612|Drug|Vitamin A|
45653955|NCT02512965|Radiation|Conventional SBRT: 24 Gy in 2 fractions|
45937376|NCT00044967|Genetic|microsatellite instability analysis|
45937377|NCT00164476|Behavioral|Preventive Services Prevention Kit|
45937378|NCT00164476|Behavioral|peer mentors (control group)|
45937379|NCT00164515|Behavioral|Personalized exercise programme (PEP)|Physician referred overweight and obese clients to 24 month personalized exercise programme at the U. of Illinois, Chicago
45937380|NCT00164554|Behavioral|Parent-child Interaction Therapy (PCIT)|
45937381|NCT00053651|Behavioral|Survival Skills for Moms with New Babies|
46073885|NCT02819466|Device|3D echography|ultrasound visualization of the stomach in fasting patients.
45653956|NCT05539547|Device|Neuromuscular Electrical Nerve Stimulation|"Application of NMES on quadriceps muscle groups bilaterally~Frequency: >50Hz Pulse duration: 350 - 400µs Intensity: Maximal tolerance (visible quadriceps muscle contraction and/or maximally tolerated by the patient, eliciting a slight discomfort) Time: 30 minutes per session, 7 sessions per week Duty Cycle: 2s on / 18s off Duration: Until discharge to a maximum of 30 days"
46073886|NCT00633906|Behavioral|HORIZONS HIV Intervention|Two-session, group-based interactive HIV prevention intervention
46073887|NCT00633906|Behavioral|enhanced standard-of-care|1 hour group session consisting of an HIV prevention video, a question and answer session with an African American woman health educator, and participation in a group discussion about how to avoid acquiring HIV.
45653957|NCT05539547|Other|Usual Physiotherapy treatment (Chest Physiotherapy and mobility)|Daily chest physiotherapy and mobility
45653958|NCT05545241|Behavioral|Neurofeedback + BART/EEG|"10 sessions of emotional neurofeedback (max of 2 sessions per week and max of 10 weeks).~Before (Baseline, Day 0) and at the study completion (after 10 neurofeedback sessions, Week 5), a EEG record is realized during the BART, assessing risk-taking behavior."
45653959|NCT05545241|Behavioral|BART/EEG only|only the twice EEG record are realized during the BART, assessing risk-taking behavior (every corresponding to the pre and post-neurofeedback evaluations in arm I)
45653960|NCT04941183|Drug|NTR-441|NTR-441
45653961|NCT04941183|Drug|Placebo|Placebo
45937382|NCT00164593|Behavioral|Youth Empowerment Solutions for Peaceful Communities|YES is a multi-faceted program that (1) engages 7th and 8th graders in a youth development program, (2) enhances neighborhood organizations' ability to include youth in their activities, and (3) connects the youth participants and adults in neighborhood organizations (e.g., crime watches, block groups, neighborhood associations) to carry out neighborhood improvement activities (e.g., community gardens, parks cleanup).
45937383|NCT00045006|Drug|vorinostat|
45937384|NCT04723966|Dietary Supplement|TPN|Total parenteral nutrition
45937385|NCT00164632|Behavioral|counselling, exercise, referrals (behavior)|
45937386|NCT00164671|Behavioral|POWER|
45937387|NCT00053690|Behavioral|Cognitive Behavior Treatment|
45937388|NCT00164710|Drug|sulfadoxine-pyrimethamine|
45937389|NCT00164710|Drug|amodiaquine plus sulfadoxine-pyrimethamine|
45937390|NCT00164710|Drug|amodiaquine plus artesunate|
45937391|NCT00164710|Drug|chlorproguanil-dapsone plus artesunate|
45937392|NCT00164710|Drug|lumefantrine-artemether|
45937393|NCT00045045|Procedure|positron emission tomography|
45937394|NCT00045045|Radiation|fludeoxyglucose F 18|
45937395|NCT00164749|Drug|Placebo and ginkgo extract|Placebo once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
45937396|NCT00164749|Drug|Curcumin and ginkgo extract|1 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
45937397|NCT00164749|Drug|Curcumin and ginkgo extract|4 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
45653962|NCT05539235|Drug|different degrees of adjustment of the injection interval|"Treatment was an intravitreal injection of 0.5 mg conbercept using modified T&E treatment plans. After 3 months of monthly intravitreal injections, the patients were randomly divided into two groups, and the degree of adjustment of the injection interval was divided into 2 weeks and 4 weeks."
45805174|NCT05923229|Behavioral|Mindfulness Based Walking Therapy (MBWT)|MBWT is a modified version of the Mindfulness Based Stress Reduction (MBSR) program that incorporates more walking mediations and is acceptable for people with Parkinson disease and freezing of gait.
45653963|NCT04940403|Device|Burt|18 one-hour sessions of unimanual upper-limb tasks during robot-assisted training with the Burt.
45653964|NCT04940403|Device|Burt + BurtVision|18 one-hour sessions of combination of unimanual and bimanual upper-limb tasks during robot-assisted training with the BurtVision.
45653965|NCT05545163|Device|I-gel with standard insertion technique|"Standard I-gel insertion technique (grasping I-gel from integral bite block site and cuff facing towards chin and pressing down the manikin chin. I-gel introduced in patient's mouth in a direction towards hard palate. Then I-gel slided downwards and backwards along hard palate with a continuous but gentle push until a definitive resistance is felt)~Modified jaw thrust technique (grasping I-gel from integral bite block site and cuff facing towards chin and pressing down manikin chin. I-gel introduced in patient's mouth in a direction towards hard palate with gently advancing into oropharynx. Then after, I-gel left in oral cavity and both hands used to thrust jaw by lifting angle of mandible with little fingers and other fingers to stabilise jaw. And, at this point, both hand's thumbs used to apply balance force from I-gel stem head towards final placement position by looking at integral bite block mark at incisor teeth level)"
45805175|NCT05923229|Other|Freezing of Gait (FOG) Education|Participants will receive materials to read weekly about FOG and track their usual care regimens.
45452644|NCT02530775|Procedure|non-instrumented spinal fusion with laminectomy|"Once determined that a patient has single level static degenerative spondylolisthesis and is planning to schedule surgery the patient will be approached by a research team member explaining the study and reviewing the informed consent document. If the patient chooses to participate, he or she will be randomized to be apart of the non-instrumented arthrodesis with laminectomy group or the instrumented arthrodesis with laminectomy group. Both are standard approved surgical approaches; however, using instrumentation is the more commonly used approach."
45452645|NCT00929968|Biological|Placebo|
45937398|NCT00164788|Drug|Intravenous bolus injection of esomeprazole|80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
45937399|NCT00164788|Drug|Oral esomeprazole|40mg every 12 hours for 24 hours
45937400|NCT00053768|Biological|filgrastim|
45937401|NCT00053768|Drug|EPOCH regimen|
45937402|NCT00053768|Drug|cyclophosphamide|
45937403|NCT00053768|Drug|doxorubicin hydrochloride|
45937404|NCT00053768|Drug|etoposide|
45937405|NCT00053768|Drug|prednisone|
45937406|NCT00053768|Drug|vincristine sulfate|
45937407|NCT00053768|Radiation|radiation therapy|
45937408|NCT04724083|Diagnostic Test|biomarkers|new diagnostic biomarkers
45937409|NCT00045123|Drug|tarenflurbil|
45937410|NCT00045123|Procedure|adjuvant therapy|
45937411|NCT00164827|Device|Endoscopic placement of Capsule endoscope adjacent to the peptic ulcer|
45805176|NCT05923216|Dietary Supplement|High dose OIT|Patients will receive daily a high dose of the sesame paste (1200 mg sesame protein) mixed with well-tolerated fruit mousse or bread.
45805177|NCT05923216|Dietary Supplement|Low dose OIT|Patients will receive daily a low dose of the sesame paste (300 mg sesame protein) mixed with well-tolerated fruit mousse or bread.
45937412|NCT00164866|Drug|Omeprazole|
45937413|NCT00164905|Device|Doppler ultrasound probe|Applying to ulcer base to assess the blood flow underneath the ulcer
45937414|NCT00164944|Procedure|Colonoscopy|To determine the adenomas during colonoscopy
45937415|NCT00164944|Procedure|Colonoscopy|To determine the adenomas during colonoscopy
45937416|NCT00407212|Drug|TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)|
45937417|NCT02969954|Other|Self-efficacy for diabetes management|Participants at both sites will watch a 12 minute video featuring the digital stories on diabetes. Following the video, participants will engage in a brief facilitated discussion regarding motivations and barriers to diabetes management, led by a trained Spanish-speaking facilitator.
45937418|NCT00165061|Procedure|Esophagectomy|
45452646|NCT00929968|Biological|VAK694|
45937419|NCT00165061|Procedure|Chemoradiation|
45937420|NCT00165100|Procedure|Dynamic Area Telethermometry (DAT)|
45937421|NCT05411835|Dietary Supplement|Nutritional Ketone Supplement|Mix of sodium, calcium, and magnesium salts of D-beta-hydroxybutyrate with nicotinamide riboside chloride, flavors and stevia sweetener
45937422|NCT05411835|Dietary Supplement|Isocaloric Placebo Supplement|Maltodextrin with flavors and stevia sweetener
45937423|NCT00165139|Drug|Vincristine|Described under detailed description
45937424|NCT00165139|Drug|Cyclophosphamide|Described under detailed description
45937425|NCT00165139|Drug|Adriamycin|Described under detailed description
45937426|NCT00165139|Drug|Etoposide (VP-16)|Described under detailed description
45937427|NCT00165139|Drug|Cisplatin|Described under detailed description
45937428|NCT00165139|Drug|Carboplatin|Described under detailed description
45937429|NCT00165139|Drug|Melphalan|Described under detailed description
45937430|NCT00165139|Drug|Ifosfamide|Described under detailed description
45937431|NCT00165139|Drug|G-CSF (granulocyte-colony stimulating factor)|Described under detailed description
45937432|NCT00165139|Drug|Mesna|Described under detailed description
45937433|NCT00053807|Biological|aldesleukin|
45937434|NCT00053807|Biological|recombinant interferon alfa|
45937435|NCT00053807|Drug|fluorouracil|
45937436|NCT00053807|Procedure|adjuvant therapy|
45937437|NCT00165178|Drug|prednisone|Induction Phase: Given orally or intravenously Days 0-28 Intensification Phase: Given orally Days 1-5 of each cycle Continuation Phase: Given orally Days 1-5 of each cycle
45937438|NCT00165178|Drug|dexamethasone|Intensification Phase: Given orally days 1-5 of each cycle Continuation Phase: Given orally days 1-5 pf each cycle
45653966|NCT04433143|Drug|Minocycline hydrochloride capsules were taken orally|Lumenis OneTM, OPT tender system produced by American Medical Science Company; Use four of the filters. Acne filter has a wavelength of 400-600/800-1200nm. Three pulses were used for treatment, with a pulse width of 5.0ms, a pulse delay of 30ns, and an energy density of 15j /cm2. The instrument parameters were selected according to the skin lesion characteristics, age and tolerance.
45653967|NCT02477553|Behavioral|DA - Quantitative|
45653968|NCT02477553|Behavioral|DA - Verbal|
45452647|NCT00929968|Drug|Fluticasone|
45805178|NCT05923203|Other|Electric and acoustic stimulation (EAS) technology in the implanted ear(s)-this is the combination of a cochlear implant (CI) and hearing aid (HA) in the implanted ear(s)|This is a clinical fitting of an FDA approved EAS system for study participants that have received or who are scheduled to receive a CI based on clinical recommendations (i.e. not study related). We will activate the CI sound processor's integrated HA circuit to allow for low-frequency acoustic amplification and mid-to-high frequency electric stimulation in the implanted ear(s) using recommended and accepted clinical practices and audiologic verification. EAS fitting will be completed using FDA approved clinical software and thereby is within the electrical and clinical specifications of the FDA approved device and accompanying software.
45937439|NCT00165178|Drug|doxorubicin|Induction Phase: Intravenously on Days 0,1 Intensification Phase: Intravenously on Day 1 of each cycle
45805179|NCT05923190|Drug|Enfortumab vedotin|EV will be administered at standard dose of 1.25 mg/kg IV on days 1 and 8 with pembrolizumab 200 mg IV on day 1 of a 21-day cycle for 6 cycles
45937440|NCT00165178|Drug|E. coli asparaginase|Intensification Phase: In the muscle weekly. Dose will vary
45937441|NCT00165178|Drug|vincristine|Induction: Intravenously on days 0, 7, 14, 21 MLL Intensification Phase: Intravenously on Days 1, 8, 15, 22 CNS Therapy: Intravenously on Day 1 Intensification Phase: Intravenously on day 1 of each cycle Continuation Phase: Intravenously on Day 1 of each cycle
45937442|NCT00165178|Drug|methotrexate|Induction: Intravenously on Day 2 MLL Intensification: Intravenously on Days 1, 8 Intensification: (when doxorubicin completed) Intravenously or into the muscle weekly Continuation: Intravenously or into the muscle weekly
45937443|NCT00165178|Drug|Leucovorin|Induction Phase: Intravenously or orally begins 36 hours after methotrexate MLL Intensification: Intravenously or orally begins 36 hours after methotrexate
45937444|NCT00165178|Drug|Asparaginase|Induction: Into the muscle on Day 4 MLL Intensification: Into the muscle on Days 16, 23
45937445|NCT00165178|Drug|cytarabine|Induction: Intrathecal on Days 0, 14, 28 MLL Intensification: Intravenously on Days 15, 16, 22, 23
45937446|NCT00165178|Drug|Methotrexate/Hydrocortisone|Induction: Intrathecal on Days 14, 28 MLL Intensification: Intrathecal on Days 2,9
46073888|NCT02819154|Behavioral|phone call to evaluate the social changes, emotional, professional a cohort of patients following ICU stay|"phone call to evaluate the social changes, emotional, professional a cohort of patients following ICU stay. Investigators will use :~Questionnaire SF 36: Only the first two questions of the SF-36 are used exploring the felt quality of life at the time of the telephone call and in comparison with the period before hospitalization in intensive care.~Stress Assessment Questionnaire posttraumatic (Revised Impact of Event Scale, IES-R)~ADL: Assessment of independence in activities of daily life"
45452648|NCT01099007|Behavioral|In Person|Participants in the In Person group have weekly visits for the 12 weeks to the research office. The first visit can last up to one and a half hours and each subsequent visit can last approximately one hour. Group meetings provide appropriate nutrition and physical activity information as well as behavioral change strategies. Sessions also include some light physical activity (equal to brisk walking).
45653969|NCT01665911|Drug|1.5 mg Sodium Fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
45937447|NCT05401968|Behavioral|Osteoporosis patient education|During osteoporosis patient education the participants get knowledge about e.g. osteoporosis, medication, and diet, and they participate in physical exercises. Though, differences between municipalities exist. The participants meet in groups and face-to-face.
45653970|NCT01665911|Drug|1.5 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
45653971|NCT01665911|Drug|3 mg sodium fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
45937448|NCT00165217|Drug|Capecitabine|
45937449|NCT00165217|Drug|Thalidomide|
45937450|NCT00165295|Drug|Sildenafil citrate (Viagra)|
45937451|NCT00053885|Drug|PTK787/ZK 222584|oral
45937452|NCT00165334|Drug|Cetuximab|
45937453|NCT00165334|Drug|Vinorelbine (Navelbine)|
45937454|NCT00165373|Drug|rhEndostatin|Given by continuous infustion for 28 days (one of two dosing groups) for a total of 2 cycles. Treatment can be extended if tolerated well.
45937455|NCT05352750|Biological|SON-1010|SON-1010 multiple ascending dose
45653972|NCT01665911|Drug|3 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design
45805180|NCT05923190|Drug|Pembrolizumab|Pembrolizumab will be administered on day 1 of a 21-day cycle
45805181|NCT05923177|Drug|SPECT|One single injection of [123I] I-(HE)3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6, 24 and 48 hours.
45937456|NCT00165412|Procedure|breast MRI|Repeated once a year for three years
45937457|NCT00165412|Procedure|Mammogram|Repeated once a year for three years
45937458|NCT00165451|Drug|Thalidomide|Oral administration once daily at night starting at 3mg/Kg for 6 months.
45937459|NCT00165451|Drug|Celecoxib|Oral administration twice daily starting at 100mg/dose for 6 months.
45937460|NCT00165451|Drug|Etoposide|Oral administration once daily at night starting at 50mg/m2 3 weeks on and 3 weeks off for 6 months.
45937461|NCT00165451|Drug|Cyclophosphamide|Oral administration once daily at night starting at 3.5mg/m2 3 weeks on and 3 weeks off for 6 months.
45937462|NCT00053924|Drug|perifosine|
45937463|NCT00165490|Drug|Cetuximab|Given once per week on weeks 1-8 and restarted 4 weeks after surgery, once weekly for 6 months.
45937464|NCT00165490|Drug|Cisplatin|Given once per week on weeks 1, 2, 4,and 5.
46073889|NCT02819076|Other|pain scale|
45653973|NCT01665911|Other|Non-fluoridated milk, 200 ml|Each subject will use this product during one of the five treatment periods in the crossover study design.
45653974|NCT03063073|Drug|Dexmedetomidine Injection [Precedex]|ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine (markyrene R sigma -Tec, Egypt) plus (1 µg/kg) Dexmedetomidine Injection [Precedex]
45653975|NCT03063073|Drug|Bupivacaine|
45653976|NCT02452359|Device|Venus Versa|The Venus Versa system consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers non-coherent light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated.In this study, the IPL applicator SR580 will be evaluated for the treatment of Striae Distensae, depending on the patient's skin type.
45653977|NCT04620733|Drug|Seladelpar 10 mg|Seladelpar 10 mg one capsule daily for double-blind period, for a duration of up to 12 months
45653978|NCT04620733|Drug|Placebo|One capsule daily for double-blind period, for a duration of up to 12 months
45653979|NCT04620733|Drug|Seladelpar 5 mg|If down-titration needed, one capsule daily for double-blind period, for a duration of up to 12 months
45653980|NCT05538923|Other|No intervention was given to the patients|This study was an observational epidemiological study.
45653981|NCT05544851|Other|Education|"Participants who meet the sample selection criteria will be informed about the scope of the study and their verbal and written consent will be obtained. Women who met the sample selection criteria and were accepted into the study group will be randomly assigned to the intervention and control groups. Personal Information Form, Behaviors for Protection from Sexually Transmitted Diseases Scale will be applied to the participants in the intervention and control groups."
45653982|NCT05550155|Device|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment|a 4-month maintenance procedure of active rTMS
45805182|NCT05923164|Diagnostic Test|MAP-BC (Myofascial Adhesions in Patients after Breast Cancer) Evaluation Tool|It's a tool to evaluate scar tissues that occured after breast cancer treatment. It quantitatively measures myofascial adhesions. The degree of adhesion is scored for each area at 3 different depth levels (skin, superficial, deep) as a 4-point scale (0: no adhesion - 3: severe adhesion). Axillary scar, breast/mastectomy scar, m. pectoralis region, frontal chest wall, lateral chest wall, axilla and inframammary fold are evaluated separately. Sum of the scores from three levels of each area gives the total score. The minimal total score is: 0 and the maximum total score is 63.
45805183|NCT05923164|Diagnostic Test|Patient And Observer Scar Assessment Scale ( Observer Subscale)|This assesment tool consists of two different scales evaluated by the observer and the patient.The observer scale rates five variables, which include vascularity, pigmentation, thickness, relief, pliability and surface area, between 1-10 points (1:normal skin). The total score ranges from 5 to 50.
45805184|NCT05923151|Procedure|The cranial-caudal mixed medial approach|"Expose the fusion fascia of Transverse colon mesocolon and stomach, and cut the gastrocolic ligament. The mesentery of Transverse colon was dissociated from the medial side to the lateral side along the gastroepiploic vessels to expose the branches of Henle's trunk and the right colon vessels. The dorsal mesentery of the small intestine is cut along the yellow white line, and free cephalically along the Toldt space to separate the posterior space of the Ascending colon and the anterior space of the pancreas and duodenum behind the Transverse colon. The right colon blood vessels were dissected along SMV from the projection of ileocolic blood vessels, and the blood vessels were cut off by high ligation, and the lymph nodes at the root of Mesentery were cleared. Through a small incision in the middle of the abdomen, the right colon and mesentery were completely removed to complete digestive tract reconstruction."
45805185|NCT05923138|Dietary Supplement|MULTIDOMAIN NUTRITIONAL INTERVENTION: DIET, EXERCISE AND NUTRITIONAL SUPPLEMENTS|"Nutritional intervention (diet, dietetic recommendations and/or supplements). Participants will receive specific recommendations about diet, energetic dietetic supplementation, oral nutritional supplements, exercise... The Nutrition Team (formed by cardiologists, dieticians, nurses...) will closely monitor patients with periodic visits and reassessment of nutritional status and compliance with recommendations."
45805186|NCT05923138|Dietary Supplement|CONTROL|Standard treatment (usual recommendations in patients with heart failure)
45805187|NCT05923125|Behavioral|Graded-Intensity Treadmill Exercise Protocol|The exercise protocol will be administered by the principal investigator or other trained study staff under the supervision of the PI in the stress testing laboratory of NYU Langone Health - Tisch Hospital. The exercise protocol duration will vary by participant, but is likely to be between 8 and 25 minutes in duration.
45805188|NCT05923099|Drug|LEO 138559|LEO 138559 given by injection just under the skin
45805189|NCT05923099|Drug|Placebo|Placebo given by injection just under the skin
45805190|NCT05923086|Drug|ORE001|Administration before major meal
45805191|NCT05923086|Drug|Placebo|Administration before major meal
45805192|NCT05923073|Drug|Guselkumab|Guselkumab will be administered either intravenously or subcutaneously.
45805193|NCT05923073|Drug|Placebo|Placebo matching to guselkumab will be administered subcutaneously.
45805194|NCT05923060|Drug|Topical Aminolevulinate|Topical Levulan Kerastick is applied to actinic keratoses.
45805195|NCT05923060|Procedure|Photodynamic therapy (PDT)|PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells.
45805196|NCT05923060|Procedure|Red light illumination|To occur post-PTD; used for activation of ALA during photodynamic therapy.
45805197|NCT05923047|Drug|Mepolizumab|Patients in the Mepolizumab arms will receive 100 mg of subcutaneous mepolizumab every 4 weeks for a total of 12 doses in addition to daily topical corticosteroid treatment
45805198|NCT05923047|Procedure|Polypeptomy|This group will undergone in-office nasal polypectomy.
45805199|NCT05923021|Other|cheek acupuncture|Cheek acupuncture therapy refers to a new painless acupuncture therapy for treating systemic diseases by acupuncture at specific points on the cheek. This therapy was founded by Professor Wang Yongzhou, a scholar in France. Cheek acupuncture therapy takes the Yellow Emperor's Internal Classic as the theoretical basis, and organically integrates holographic theory, the theory of ascending and descending qi, the theory of Big Three Jiao, the theory of simultaneous treatment of mind and body, and the theory of the book of Changes.In this study, we use the big three jiao points, head points, and neck points in cheek acupuncture therapy to treat depression. These acupoints are considered effective in long-term clinical applications.
45937465|NCT00165490|Drug|Irinotecan|Given once per week on weeks 1, 2, 4,and 5.
45937466|NCT00165490|Device|Radiation therapy|Once daily for 28 treatments (5 1/2 weeks)
45805200|NCT05923008|Drug|IBI130|Subjects will receive IBI130 until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
45937467|NCT00165490|Procedure|Surgery|Surgery performed 4-8 weeks after chemoradiation therapy.
45937468|NCT00165568|Drug|Bevacizumab|
45452649|NCT01099007|Behavioral|At Home|Participants in the At Home group receive a workbook from the research staff at their baseline visit that outlines an accepted nutrition and physical activity program to complete on their own.
45452650|NCT00929188|Drug|JNJ-42160443|Type=1, unit=mg, number=10, form=solution for injection , route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
45937469|NCT00165607|Drug|MENATETRANONE|
45937470|NCT00165685|Drug|Sibutramine Hydrochloride Monohydrate|
45937471|NCT00045279|Biological|PEG-interferon alfa-2b|
45452651|NCT00929188|Drug|Placebo|Form=solution for injection, route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
45937472|NCT00053963|Drug|romidepsin|Given IV
45937473|NCT00165763|Drug|donepezil hydrochloride (Aricept)|5 mg donepezil HCl given once a day and increased to 10 mg per day if side effects, when present, are tolerated.
45937474|NCT00165802|Drug|E7974|Maximum Tolerated Dose defined as 0.45 mg/m^2 administered on Day 1 only of a 21-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
45937475|NCT00165880|Drug|E7070|
45452652|NCT03957083|Drug|Oxytocin|Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
45653983|NCT05550155|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|a 4-month maintenance procedure of sham rTMS
45653984|NCT04429009|Device|ZEPHYRx Respiratory Therapy (RT) System|A breath controlled video game system for respiratory therapy
45653985|NCT04429009|Device|Standard Incentive Spirometer|A simple (not digital) plastic device that contains a piston that rises inside the device and measures the volume of your breath
45653986|NCT02476617|Drug|ombitasvir/paritaprevir/ritonavir|ombitasvir/ABT-450/ritonavir tablets
45653987|NCT02476617|Drug|dasabuvir|dasabuvir tablets
45653988|NCT02476617|Drug|ribavirin|ribavirin tablets
45452653|NCT04945616|Drug|Aspirin、clopidogrel、placebo or SHR2285|groupA： Aspirin + clopidogrel + placebo or SHR2285 (dose 1) ；
45653989|NCT05550077|Diagnostic Test|Optical Coherence Tomography|Intravascular evaluation for vessel wall structure of intracranial atherosclerotic stenosis by application of optical coherence tomography
45805201|NCT05922995|Drug|Tasimelteon|20 mg capsules taken on a nightly basis
45805202|NCT05922982|Drug|norepinephrine weaning protocol|MAP-based (MAP > 65 mmHg) norepinephrine weaning protocol
45805203|NCT05922982|Drug|norepinephrine weaning protocol and guided by the HPI|MAP-based (MAP > 65 mmHg) norepinephrine weaning protocol and guided by the HPI (HPI<80) delivered by the Acumen IQ medical device.
45805204|NCT05922956|Other|Facial emotion recognition test|Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires
45805205|NCT05922943|Behavioral|Harmony & Health program|Harmony & Health program may help improve psychosocial wellbeing in participants and if improvements in physical activity and wellbeing can last after the program ends. Yoga combines gentle movements, breathing exercises, relaxation techniques, and meditation all tailored to the participant's needs.
45937476|NCT00045318|Drug|exatecan mesylate|
45937477|NCT00054002|Procedure|adjuvant therapy|Lung surgery
45937478|NCT00054002|Procedure|conventional surgery|Lung surgery
45937479|NCT00054002|Drug|porfimer sodium|iv
45937480|NCT04723693|Other|Qualitative Interview|A single one hour semi structured qualitative interview
45937481|NCT00165919|Other|None. Not a clinical trial. Specimens taken for basic research in laboratory.|
45937482|NCT00166075|Procedure|Computer screen with community resource printout|Patients participated in the screening process via a computer kiosk. Questions regarding IPV and mental health symptoms were asked using validated tools
45937483|NCT00045357|Biological|therapeutic autologous lymphocytes|
45937484|NCT00054041|Biological|HspE7|Given subcutaneously
45937485|NCT00054041|Procedure|therapeutic conventional surgery|Undergo large loop excision
45937486|NCT00054041|Other|laboratory biomarker analysis|Correlative studies
45937487|NCT00166153|Drug|Mycophenolate Mofetil|
45937488|NCT00166192|Procedure|Jessner's solution chemical peel|
45937489|NCT00166192|Procedure|Trichloroacetic acid chemical peel|
45937490|NCT00166270|Device|ExAblate 2000|
45937491|NCT00054119|Drug|Cositecan|Given IV
45937492|NCT00054119|Other|Pharmacological Study|Correlative studies
45937493|NCT00166309|Drug|FEIBA and NovoSeven|
45937494|NCT00166348|Behavioral|Cognitive Group Therapy|
45937495|NCT00166387|Procedure|Blood draw|A single blood draw.
45937496|NCT00054197|Drug|gemcitabine hydrochloride|
45937497|NCT00054197|Drug|paclitaxel poliglumex|
45937498|NCT00054197|Drug|vinorelbine tartrate|
45937499|NCT00045396|Drug|tipifarnib|Given orally
45937500|NCT00166426|Drug|Exisulind|
45937501|NCT00166465|Drug|ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen)|
45452654|NCT04945616|Drug|Aspirin、clopidogrel、placebo or SHR2285|groupB： Aspirin + clopidogrel + placebo or SHR2285 (dose 2)
45452655|NCT04945616|Drug|Aspirin、ticagrelor、placebo or SHR2285|groupC： Aspirin + ticagrelor + placebo or SHR2285
45452656|NCT05194436|Device|AeviceMD|The AeviceMD will be placed on the patient to detect wheeze and perform auscultation.
45937502|NCT00166582|Device|electronic medication monitoring system|
45937503|NCT00166582|Behavioral|parent-adolescent communication and problem-solving skills|
45937504|NCT00166621|Drug|Buspirone|
45937505|NCT00054236|Biological|anti-thymocyte globulin|anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1
45937506|NCT00054236|Biological|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.
45937507|NCT00054236|Drug|cyclophosphamide|cyclophosphamide IV over 2 hours on days -3 to -2
45937508|NCT00054236|Drug|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
45937509|NCT00054236|Procedure|umbilical cord blood transplantation|Patients undergo multiple unit umbilical cord blood transplantation on days 0-1.
45937510|NCT00054236|Drug|methylprednisolone|Patients unable to tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.
45937511|NCT00166660|Behavioral|NIDCAP (Newborn Individualized Developmental Care)|The NIDCAP model aims to create a relationship-based developmentally supportive care environment for the preterm infant and family. The theory proposes that care implementation that takes into account the infants' thresholds of disorganization is most supportive of long term outcome. Specifically, the intervention consisted of weekly neurobehavioral observations and reports of the experimental group infants' behavior with suggestions for parents and staff in ways to support each infant's development. The developmental specialists formally observed each infant's behavior weekly throughout the hospitalization, starting with the phase of the infant's initial stabilization, and then every seven days throughout hospital discharge and to 2wCA.
45805206|NCT05922930|Drug|TROP2-CAR-NK|Given by IV (vein)
45653990|NCT05550077|Procedure|Percutaneous transluminal angioplasty and stenting|Percutaneous transluminal angioplasty and stenting will be performed follow the standard or adjusted according to OCT evaluation.
45653991|NCT04428307|Other|Conditional artemisinin combination therapy subsidy|An additional discount on WHO-approved quality assured ACTs will be offered to individuals with a positive RDT.
45805207|NCT05922930|Drug|Cyclophosphamide|Given by IV (vein)
45937512|NCT00166699|Procedure|ultrasound|The use of ultrasound to guide the insertion of combined spinal epidural needle
45937513|NCT00045474|Procedure|adjuvant therapy|
45805208|NCT05922930|Drug|Fludarabine|Given by IV (vein)
45805209|NCT05922917|Device|pulsed-field ablation|application of pulsed-field energy for pulmonary vein isolation and linear ablations
45805210|NCT05922904|Drug|Brentuximab vedotin|Given by IV (vein)
45805211|NCT05922904|Drug|Doxorubicin Hydrochloride|Given by IV (vein)
45937514|NCT00045474|Radiation|iodine I 125|
45937515|NCT00166777|Procedure|exercise training|
45937516|NCT00054392|Drug|carboplatin|
45937517|NCT00054392|Drug|gemcitabine hydrochloride|
45937518|NCT00054392|Drug|paclitaxel|
46073890|NCT02818140|Procedure|Ropivacaine TQL block|Unilateral ultrasound-guided TQL block with 30 mL ropivacaine 0.75% 30 min prior to the surgical procedure
45653992|NCT04428307|Other|Testing incentive|A small incentive will be paid to the provider each time they perform a malaria rapid diagnostic test.
45653993|NCT05538845|Device|Screw fixation|Screw fixation to patients
45653994|NCT05538845|Device|Suture button|Suture button for patients
45653995|NCT04618705|Behavioral|Smoking Cessation|Participants will start a smoking cessation program.
45653996|NCT05549999|Diagnostic Test|North Star Ambulatory Assessment|North Star Ambulatory Assessment is an ambulatory assessment developed specifically for Duchenne Muscular Dystrophy.
45653997|NCT05699213|Diagnostic Test|Lung MRI|MRI of the lung
45452657|NCT04473820|Drug|Vapocoolant spray|The spray will be applied continuously from 25 cm distance for less than 5 seconds to the cannulation site.
45805212|NCT05922904|Drug|Pembrolizumab|Given by IV (vein)
45937519|NCT00166816|Drug|sirolimus, cyclosporine, tacrolimus|
45937520|NCT00166855|Procedure|dynamic MRI and bone marrow sampling|
45937521|NCT00399828|Device|TRI-ACTIVE LASERDERMOLOGYTM (DEKA M.E.L.A., Itália)|
45937522|NCT04723732|Drug|Myrrh mouthwash|1% mouthwash solution of commiphora myrrha, made from Commiphora Myrrha resin extract.
45937523|NCT04723732|Drug|Chlorhexidine mouthwash|0.2% mouthwash solution of chlorhexidine gluconate.
45937524|NCT04723732|Drug|Normal saline|0.9% solution of sodium chloride, containing 9 g/L Sodium Chloride (154 mEq/L sodium and 154 mEq/L chloride)
45937525|NCT00054431|Drug|imatinib mesylate|Given orally
45937526|NCT00054431|Drug|decitabine|Given IV
45653998|NCT05699213|Diagnostic Test|Blood Draw|Blood Draw
45805213|NCT05922904|Drug|Dacarbazine|Given by IV (vein)
45805214|NCT05922878|Drug|ALTO-300|ALTO-300 capsule QD
45805215|NCT05922878|Drug|Placebo|Placebo capsule QD
45805216|NCT05922865|Device|KNEESUP smart knee assistive device + KNEESUP care APP|In KNEESUP smart knee assistive device + KNEESUP care APP group, participants used the KNEESUP intelligent knee assistive device. Participants wore a knee brace with a sensor module on one side of the leg, the sensor could connect with the KNEESUP care APP which were installed in participant's mobile phone. The APP was designed with an individualized exercise program and the knee brace sensor could detect the action moment of the participants during exercise. This equipment could help the participants to achieve professional-level home rehabilitation.
45805217|NCT05922865|Device|KNEESUP care APP|In KNEESUP care APP group, the participants only used the KNEESUP care APP which was installed in the mobile phone. The APP was designed with an individualized exercise program. Participants could follow the APP to do the exercise program according to their own conditions.
45805218|NCT05922865|Behavioral|Healthy consulation|In Healthy consulation group, participants received routine outpatient health education.
45805219|NCT05922839|Drug|Zanubrutinib|Zanubrutinib 160mg, orally, twice daily, for a minimum of 3 months, and for effective patients, continue to use for 2 years after achieving optimal therapeutic effect.
45937527|NCT00054431|Other|laboratory biomarker analysis|Correlative studies
45937528|NCT05259306|Device|Insightec Exablate Neuro MR-guided focused ultrasound transducer|This study will be utilizing the Insightec Exablate Neuro MR-guided focused ultrasound transducer to deliver low-intensity ultrasonic energy precisely and safely to the target region of the brain. MRgFUS has been FDA approved at high-intensity to treat essential tremor and Parkinson's disease associated tremor. Device premarket approval number (PMA) is P150038, and FDA approval notice was July 11, 2016. This study will be using this device not to make any lesions in the brain (as it is currently FDA approved), but instead to use the precision and non-invasive nature of the device to target the MD thalamus region of the brain at intensities currently approved by the FDA for transcranial ultrasound.
45937529|NCT00167011|Procedure|CT|
45805220|NCT05922813|Biological|BMI2004|hyaluronidase, recombinant
45937530|NCT00167089|Behavioral|Treadmill Training|Partian body weight support treadmill training, 30 min/day * 3 days /week
45653999|NCT05535725|Drug|application of powdered vancomycin in the surgical wound as prophylaxis against the occurrence of surgical site infection|on the application of powdered vancomycin in the surgical wound as prophylaxis against the occurrence of surgical site infection at La Paix State University Hospital Haiti over 2 years.Both groups benefited from the same preoperative asepsis protocol. One hour before the incision, 1g of intravenous ceftriaxone is administered to the patients, this dose is maintained during the 48 hours postoperative every 12 hours. At discharged the two groups of patients received oral cloxacilin 500mg three times a day for one week. Patients are dressed every 2 days until the surgical wound has healed. Patients are seen in the outpatient clinic at 2, 4, and 6 weeks, then at one year. We selected 215 patients and retained 204.
45805221|NCT05922813|Other|0.9% NaCl|Normal Saline
45654000|NCT03062137|Diagnostic Test|blood gas sampling|
45654001|NCT05698355|Other|Telerehabilitation Treatment|Telerehabilitation includes self-massages for pelvic floor muscle, sex education, breathing, myofascial releasing with wand, and pelvic floor relaxing exercises.
45654002|NCT04980235|Diagnostic Test|transperineal 3D ultrasound|All ultrasound volumes were acquired 7days after delivery and another examination 6weeks post-delivery by one experienced sonographers using a GEVoluson p8 (GE Healthcare) equipped with a 4-8-MHz curved array 3Dultrasound transducer
45805222|NCT05922800|Device|Electro Press Needle|"Body acupoints will be stimulated by the press needles 0.25mm in diameter and 2mm in length and ear acupoints will be stimulated by the press needles 0.25mm in diameter and 0.9mm in length (all from ZhenXing Brand, Hangzhou Yuanli Medical Appliance Factory, China). After sterilization of the local skin, the needle will be pressed to the acupoints and the tape will be sticked to the skin. Then, the electric device (φ44×15.8mm Type ZXHPAMDZB-02C) together with the electrode patch will be sticked to the surface of skin (on top of the sticky tapes of the press needle) in the area of CV4 and bilateral EX-CA1, and bilateral SP6 respectively. The electric device will be switch to the mode of dense intermittent wave, and the current intensity will be increased gradually till the muscles around jumps slightly.All the needles on the body acupoints will be removed after each session, while those on the auricular acupoints can be kept for as long as 6 hours (removed before going to bed)."
45805223|NCT05922800|Drug|Gamma-Oryzanol|The patients in this group were given orally gamma-oryzanol tablets 20mg each time, three times a day, for 6 months.
45805224|NCT05922787|Other|Reiki|In the study, women received four Reiki sessions once a week for four weeks from the researchers with Usuı Shiki Ryoho Reiki 1
45805225|NCT05922774|Device|Cervical VEMP testing|cervical vestibular evoked myogenic potentials
45805226|NCT05922761|Drug|Belumosudil|Kinase inhibitor, tablet taken orally
45805227|NCT05922761|Drug|Fluticasone|Via inhalation by metered-dose inhaler.
45805228|NCT05922761|Drug|Azithromycin|Semi-synthetic macrolide antibiotic, taken orally
45805229|NCT05922761|Drug|Prednisone|Corticosteroid, taken orally
45805230|NCT05922761|Drug|Montelukast|Leukotriene Receptor Antagonist, taken orally
45805231|NCT05922748|Other|imaging|Brain activation is demonstrated by measuring signal changes in brain regions. Activations will be determined by comparison between conditions and in relation to periods of rest
45805232|NCT05922748|Other|Evoked Potentials|EEG signals, referenced to the right mastoid, were digitised at 125 Hz with an elliptical low-pass input filter at 49 Hz
45805233|NCT05922748|Other|MEG|MEG signals reflect changes in magnetic field evoked by changes in neuronal activity
45805234|NCT05922748|Behavioral|Behavioural tests|Behavioural tests will be evaluated.
45805235|NCT05922735|Behavioral|Questionnaire|Serology from remaining blood sample Self-questionnaire about sexual behavior during the epidemy mpox
45805236|NCT05922722|Other|Decision-making tool|The shared decision-making tool is a paper tool or an electronic version which will be available in the clinics for clinic team's use.
45805237|NCT05922722|Other|Questionnaire|Questionnaire to assess participant's understanding of the decision-making tool
45805238|NCT05922709|Drug|CS12192 capsule|Participants receive CS12192 orally single or multiple doses
45805239|NCT05922709|Drug|Placebo capsule|Participants receive placebo matching CS12192 orally single or multiple doses
45805240|NCT05922696|Drug|Cholecalciferol|50.000IU weekly in Group A , or 200.000IU monthly in Group B
45805241|NCT05922683|Drug|Vivomixx|"Vivomixx (a mixture of Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), as VivomixxAll consenting participants will be randomized into the treatment to control arm, receiving either Vivomixx or a placebo for 8 weeks.~During the study, women will visit the healthcare center or vice-versa on a bi-weekly basis to receive sachets of Vivomixx or a placebo according to their trial arm."
45805242|NCT05922683|Device|CapScan®|"The only non-standard sample collection instrument is the CapScan device. The CapScan Collection Capsule (Capsule) is a non-invasive device that collects gastrointestinal samples along the GI tract that are then analyzed outside the body. Samples collected by the Capsule will be expressed, then undergo DNA sequencing and mass spectrometric analysis to determine the identity and function of the bacterial and host cells in the different regions of the GI tract and compared to similar analyses conducted on concomitantly collected stool samples."
45805243|NCT05922670|Behavioral|The Behavioral Health-Works Suicide Prevention Program for Sexual and Gender Minority Youth|BH-Works is a web-based, comprehensive program for suicide prevention. The BH-Works program is a systems-level intervention that provides tools and resources to make organization adoption more feasible.
45805244|NCT05922657|Device|Cerene|Real world use of Cerene.
45805245|NCT05922644|Device|SCS|21 days of cervical spinal cord electrical stimulation treatment in addition to routine brain resuscitation and rehabilitation awakening treatment.
45805246|NCT05922644|Other|Conventional|Routine brain resuscitation and rehabilitation awakening treatment.
45805247|NCT05922631|Procedure|Airway pressure release ventilation|ventilator parameters were set according to the study protocol, P high: Tidal volume (VT) was set at 6ml/kg of ideal body weight, and plateau pressure (Pplat) was measured. Initial Phigh was set at Pplat, usually 20-32 cmH2O. The APRV end-expiratory flow rate was set at 75% of the peak expiratory flow rate.
45937531|NCT00054470|Biological|trastuzumab|
45805248|NCT05922631|Procedure|low tidal volume|The ARDSnet method was used for LTV mechanical ventilation, and the tidal volume was set according to 4-8ml/kg, so that the Pplat was <30cmH2O
45805249|NCT05922618|Device|PEMFS|"I-ONE® is a medical device certified by the Ministry of Health as a Medical Device (risk class II A) for the treatment of inflammatory and degenerative tissue pathologies. The device consists of a signal generator and an applicator, called a solenoid. The solenoid will be placed on the joint, not necessarily in direct contact with the skin. The device works with a rechargeable battery and is equipped with an hour counter to assess patient compliance.~Treatment with I-ONE® therapy will start within 3-7 days of recruitment, will last 6 hours a day and will be maintained for 60 days. The treatment will be carried out at home and the device will be delivered directly to the patient's home by courier."
45805250|NCT05922605|Drug|S-ketamine & Ropivacaine|The experiment group (Group S) will receive a mixture of ropivacaine 0.2% 1 ml／kg and preservative-free S-ketamine 0.5 mg/kg caudally for postoperative analgesia.
46073891|NCT02818140|Procedure|Saline TQL block|Unilateral ultrasound-guided TQL block with 30 mL of saline 0,9% 30 min prior to the surgical procedure
45937532|NCT00054470|Drug|tipifarnib|
45937533|NCT00167128|Device|hearing aid, Phonak EduLink-FM System|
45937534|NCT05220852|Combination Product|Dry needling with exercise|"At the initial session, dry needling will be given to their upper trapezius muscles' hyperactive trigger sites, and EX will continue for a minimum of three times per week.~Cranio-cervical spine flexion is the exercise.~Extension of the cranio-cervical spine Exercice 3 Shoulder Elevation 4-Retraining of the scapular muscles Every exercise should be done for 30 se"
45452658|NCT04473820|Drug|Lidocaine-Prilocaine cream|A finger tip (0.5 gr) of the cream will be applied in 4 square cm at cannulation site and will be covered with closed dressing for 45 minutes.
45452659|NCT05064332|Drug|PF-06650833|400 mg by mouth (PO) Once daily (QD) for 11 days
45452660|NCT05064332|Drug|Ethinyl estradiol (EE) and levonogestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
45452661|NCT01088633|Other|Exhaled particle analysis|"At visit 2, the exhaled particle analysis will be performed. Subjects will be asked to breath through the device and to perform several breathing maneuvers such as deep breathing, shallow breathing, rapid breathing, slow breathing. These measurements will be repeated after 2 hours on the same day.~Visit 3:~After a baseline exhaled particle analysis, the subjects will inhale nebulized saline (2.5 ml of a 0.9 % NaCl-solution). Aerosol generation and transport will be recorded immediately after the end of inhalation as well as 2 hours and 4 hours after the start of inhalation using the same techniques as in visit 2."
45452662|NCT00858052|Device|Saline-filled breast implant [IDEAL IMPLANT (R)]|Breast augmentation
45805251|NCT05922605|Drug|Ropivacaine|The experiment group (Group C) will receive ropivacaine 0.2% 1 ml／kg plain and equial volume saline caudally for postoperative analgesia.
45805252|NCT05922592|Procedure|crestal sinus lift using ballon technique|The sinus membrane will be elevated by using balloon technique with simultaneous Implant placement.
45805253|NCT05922592|Procedure|crestal sinus lift using densah burs|The sinus membrane will be elevated by using Densah burs with simultaneous Implant placement
45805254|NCT05922566|Combination Product|fMRI + Mukbang videos|Specific video program + fMRI will be allocated to the participants in this group. The specific video program includes control videos without food information, eating and food images without sound, chewing and swallowing sound without images, and Interactive content in Mukbang. Participants will undergo structural image scans, resting state scans, and task state scans. The task-fMRI will be performed while watching Mukbang to explore the activation of brain functional areas.
45937535|NCT05220852|Other|Exercise|"patients in this group are going to have onley neck exercise for 2 weeks minimum 3 times a week.~Cranio-cervical spine flexion is the exercise.~Extension of the cranio-cervical spine Exercice 3 Shoulder Elevation 4-Retraining of the scapular muscles Every exercise should be done for 30 se"
45937536|NCT00167167|Procedure|Donor Lymphocyte Infusion|"Certain immune cells in your donor's blood called lymphocytes have been shown to fight cancer after bone marrow transplantation. We plan to transfuse large numbers of donor's lymphocytes in the hope of activating the recipient's immune system to attack cancer."
45937537|NCT00167284|Behavioral|physician and patient education; physician practice redesign|
45937538|NCT00054548|Biological|oblimersen sodium|Given IV
45937539|NCT00054548|Drug|paclitaxel|Given IV
45937540|NCT00054548|Other|laboratory biomarker analysis|Correlative studies
45452663|NCT03956459|Other|Patients with a cancer for which a FDG-PET scanner must be performed|"For each patient, 2 consecutive PET-CT scanners will be performed using 2 different systems of PET-CT scanners:~Discovery MI~Discovery IQ~Only one contrast agent injection (FDG) will be given for both scanners."
46073892|NCT02818140|Drug|Ropivacaine|
45452664|NCT05057546|Drug|GnRH antagonist|GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)
46073893|NCT02818140|Drug|Saline|
46073894|NCT02818140|Device|Ultrasound|
46073895|NCT02818452|Other|Oatmeal + OatWell28XF|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
45805255|NCT05922553|Behavioral|Active Ingredient Mukbang|Mukbang videos include the items which can truly improve the appetite of children with cancer, such as food images, eating sound and interactivity.
45937541|NCT00054548|Other|pharmacological study|Correlative studies
46073896|NCT02818452|Other|Oatmeal|
46073897|NCT02818452|Other|Hot cereal|
46073898|NCT04238208|Drug|Lidocaine 5% patch|5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm
45805256|NCT05922553|Behavioral|Common Mukbang|Common Mukbang videos made and uploaded by the famous Mukbang makers.
45805257|NCT05922553|Behavioral|General short videos|Short videos that don't contain any food cues.
45937542|NCT00167323|Behavioral|Adherence therapy|
45937543|NCT00167362|Behavioral|Cognitive enhancement therapy (CET)|Using 80 to 100 hours of graduated exercises in computer assisted training, coupled with structured but unrehearsed in vivo social group interactions, CET tries to shift an early developmental reliance on effortful, serial and verbatim cognitive processing to a more gistful, less effortful and spontaneous abstraction of social themes. CET uses attention, memory and problem solving software from three exercises from Ben-Yishay's Orientation Remediation Module (the Attention Reaction Conditioner, Zero Accuracy Conditioner, and Time Estimates) that are graduated in difficulty and designed to enhance vigilance, selective attention, the ability to shift between auditory and visual modalities, and rapid decision-making.
45937544|NCT00167362|Behavioral|Enriched supportive therapy (EST)|EST is the commonly recommended (Spaulding 1992) treatment for control and experimental subjects in psychosocial trials. EST is a two-staged treatment that requires weekly one-hour sessions in Phase 1 and biweekly sessions in Phase 2. Some practice principles (e.g., psychoeducation and relaxation training) are provided during the group exercises for CET patients, but individually for EST patients. No attempt is made to control for hours of contact between EST and CET, since offering three hours of supportive therapy to EST subjects is neither logistically feasible nor faithful to the goals and methods of supportive therapy. Further, neurobiological hypotheses related to treatment specificity would be best tested by clear differences in treatment intensity and content.
45937545|NCT00045513|Drug|7-hydroxystaurosporine|
45937546|NCT00045513|Drug|fludarabine phosphate|
45805258|NCT05922540|Other|Intravenous thrombolysis|Intravenous thrombolysis with alteplase within the time window of stroke onset in stroke patients
45937547|NCT00167401|Drug|docetaxel|
45937548|NCT00167401|Drug|cisplatin|
45937549|NCT00167401|Procedure|radiation treatment|
45937550|NCT00167479|Drug|risperidone (Risperdal)|
45937551|NCT00054587|Biological|Trastuzumab|8 mg/kg at month M6, followed by a maintenance dose of 6 mg/kg every 3 weeks for a 1 year (i.e. 18 injections in total)
45805259|NCT05922527|Procedure|Combined regenerative technique|Periodontal regenerative technique using amnion chorion membrane combined with DFDBA in a putty form
45937552|NCT00054587|Drug|Cyclophosphamide|500 mg/m², D1 and every 3 weeks
45937553|NCT00054587|Drug|docetaxel|on day D1 of each cycle : dose: 75 mg/m², route: i.v. injection over 1 hour, every 3 weeks
46073899|NCT04238208|Drug|Capsaicin 8% Patch, Per 10 Square Centimeters|8% Capsaicin patch [8% w/w] 640 µg/cm² of adhesive, patch area 280 cm2 (20 cm x 14 cm), (Qutenza®; capsaicin 179 mg patch, Astella Pharma Europe Ltd. Chertsey, UK)
45937554|NCT00054587|Drug|Epirubicin|100 mg/m², D1 and every 3 weeks
45937555|NCT00054587|Drug|Fluorouracil|500 mg/m², D1 and every 3 weeks
46073900|NCT04238286|Procedure|Dry needling|All the participants will be placed in a prone position on the bench. Once the subject is settled, we will localize a nodule within the palpable taut band, confirming its presence after inducing local twitch response by palpation. After placing the MTrPs, the area will be sterilized with an alcohol solution colorless spray [Skin-des. Agupunt ®]. The puncture method used in the true dry needling groups will be the Hong's fast in-fast out technique, described as the most aggressive technique in the MTrPs treatment, using a needle of 0.32 x 40 mm. The intervention will be implemented until the subject reports the presence of seven local twitch reactions to the controller.
46073901|NCT02816502|Behavioral|Stress Management Skill Building Program A|Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
46073902|NCT02816502|Behavioral|Stress Management Skill Building Program B|Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
46073903|NCT02816112|Drug|Ciprofloxacin|Antibiotic
45937556|NCT00167518|Drug|Triamcinolone acetate|
45937557|NCT00167557|Drug|Pegylated Interferon|180mcg SC weekly starting 30 days post transplant
45458011|NCT04782817|Other|Provider choice standard care order set|Participants will receive order set with provider choice of standard care therapy.
45937558|NCT00167557|Drug|Ribavirin|goal dose 13mg/kg starting 120 days post transplant for a minimum of 48 wks
45937559|NCT00167557|Procedure|Liver Biopsy|Liver biopsies performed at 9 points in time from time of liver transplant
45458012|NCT01234597|Drug|INSULIN GLARGINE (HOE901)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
45458013|NCT01234597|Drug|INSULIN GLULISINE (HMR1964)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
45805260|NCT05922527|Procedure|Open flap debridement|Open flap debridement
45805261|NCT05922501|Drug|Isatuximab|An IgG1-derived monoclonal antibody that targets CD38 proteins, administered intravenously.
45805262|NCT05922501|Drug|Belantamab mafodotin|An antibody-drug conjugate that is the combination of an antibody targeting BCMA and a drug, administered intravenously.
45937560|NCT00167596|Device|Near Infrared Spectroscopy|resuscitation will be based on Surviving Sepsis Campaign guidelines AND on increasing StO2 to 80% or more in at least 2 out of the 3 following sites: thenar, masseter and deltoid
45458014|NCT02313220|Drug|Dapagliflozin|Oral use
45937561|NCT00167596|Device|conventional|resuscitation will be based according to Surviving Sepsis Campaign
45937562|NCT00167635|Behavioral|cognitive-behavioral|Cognitive-behavioral over 9 weeks
46002535|NCT01356290|Drug|Cyclophosphamide|2.5mg/kg, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
46002536|NCT01356290|Drug|Etoposide phosphate|0.5mg, intrathecal, day 1-5, every four weeks, alternating with intrathecal liposomal cytarabine, 1 year
45654003|NCT05535647|Drug|Regorafenib and HAIC|Regorafenib: oral 80mg/day, D1-21, Q28d; HAIC with FOLFOX: hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
45458015|NCT02313220|Drug|Exenatide|Powder and solvent for suspension for injection, prolonged release suspension. Subcutaneous use.
45937563|NCT00167674|Drug|Combined short-course zidovudine/nevirapine|300 mg of ZDV was given twice daily from 34 weeks gestation until labor then every 3 hours until delivery; 200 mg of NVP was given as a single oral dose at the onset of labor; and a single 2 mg/kg (6 mg if birthweight > 2.5 kg) oral dose of NVP suspension was administered to the infant within 72 hours of delivery.
45937564|NCT00167674|Drug|HAART|300 mg of zidovudine (ZDV), 150 mg of lamivudine, and 200 mg nevirapine (NVP) was given twice daily from 34 weeks gestation until six months after delivery.
45937565|NCT05205915|Device|tDCS intervention applied by Starstim device|Stimulation will be applied using the Starstim device, with current delivered via four Starstim Pi electrodes (circular electrodes with a contact of area of 3.14 cm2) embedded in the headpiece. All study subjects will use the same fixed montage (electrode locations and currents). The montage has been designed to optimize anodal stimulation in the desired target area while avoiding stimulation off target.
45937566|NCT00054626|Drug|cisplatin|
45937567|NCT00054626|Drug|gemcitabine hydrochloride|
45937568|NCT00054626|Procedure|adjuvant therapy|
45937569|NCT00167713|Drug|Ibuprofen|
45805263|NCT05922501|Drug|Pomalidomide|An immunomodulatory agent, capsule taken orally.
45937570|NCT00167791|Drug|rituximab|Rituximab 375mg/m2 IV weekly times 4 weeks
45937571|NCT00045591|Drug|celecoxib|100 mg PO bid
45937572|NCT00045591|Drug|Celecoxib|400 mg PO bid
45937573|NCT00167830|Behavioral|Motivational Interviewing|Biweekly meetings with a behavior specialist to review subject's progress with the protocol and explore challenges subject is facing in adopting healthy lifestyle behaviors.
45937574|NCT00167830|Behavioral|Strength and Cardiovascular Conditioning|Subjects take part in an exercise program to include 30 minutes of cardiorespiratory exercise at 70% maximum heart rate, and 30 minutes of strength training on Nautilus machines.
45654004|NCT05535647|Drug|FOLFOX|Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
45654005|NCT03064321|Behavioral|Insomnia Intervention|The SHUTi intervention is based on a cognitive behavioral treatment for insomnia (CBT-I) and organized into six structured, weekly online sessions. Each week the participants will complete a 30-minute interactive learning module and to complete daily online sleep diaries will be used.
45805264|NCT05922501|Drug|Dexamethasone|A glucocorticoid which is a substance that stops inflammation cause by immune system disorders, tablet taken orally.
45805265|NCT05922488|Procedure|Umbilical cord milking|Umbilical cord milking : uncut umbilical cord and squeeze it from the placenta several times toward the infant usually within 20 seconds.
45805266|NCT05922488|Procedure|delayed cord clamping|delayed cord clamping: delivery the delivering obstetrician will wait at least 60 s before clamping the umbilical cord
45805267|NCT05922475|Dietary Supplement|Protein|"Post-exercise protein group consumed protein immediately after exercise sessions.~Pre-sleep protein group consumed protein 30 minutes before sleep."
45805268|NCT05922475|Other|Placebo|Resistance exercise training only group did not consume supplemental protein.
45937575|NCT00167830|Behavioral|Food selection and portion control|Subjects meet on a biweekly basis with a registered dietitian who presents educational information about healthy food selection and portion control.
45937576|NCT00167869|Behavioral|dairy peptides|
45805269|NCT05922462|Dietary Supplement|Greek yogurt|For 16 weeks, athletes will consume 2 servings/day of 175 g GY (0% MF, flavoured, 130 calories, 17 g protein, 225 g calcium; e.g., OIKOS High Protein GY)
45805270|NCT05922462|Dietary Supplement|Whey protein|For 16 weeks, athletes will consume 2 servings/day of 2/3 of a scoop of commercially available WP powder (flavoured, ~29 g, 120 calories, 19 g protein, 112.5 g calcium; e.g., PURE Whey Protein, Walmart)
45937577|NCT00167908|Drug|Ethyol (drug)|
46073904|NCT02816112|Drug|Neupogen|Granulocyte-colony stimulating factor
46073905|NCT04238130|Diagnostic Test|Perioperative ctDNA Dynamic Monitoring|To apply ctDNA dynamic monitoring in early stage NSCLC patients with driver mutations positive at baseline
46073906|NCT02818062|Biological|Cytokines dosage in Aqueous humor|Specify details not covered in associated Arm Description.
46073907|NCT02815722|Drug|SP2086|The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
46073908|NCT02815722|Drug|Simvastatin|The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
46073909|NCT04238442|Device|A&D TM-2657W oscillometric device|Assessing the accuracy of the A&D TM-2657W oscillometric device using International Standards Organization validation protocol. This involves comparing the accuracy of the A&D device to 2 observer mercury auscultation (gold standard).
45654006|NCT03064321|Other|Information Control|Information on websites that are general health promoting
45937578|NCT00167947|Drug|Cyclosporine|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
45937579|NCT00167947|Drug|Steroids|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
45937580|NCT00167947|Drug|Rapamune (Sirolimus)|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
45654007|NCT05535569|Drug|Nivolumab, Paclitaxel|Increasing dose levels of paclitaxel (70 mg/m2 or 80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle) in combination with a fixed dose of nivolumab (3 mg/kg on Days 1 and 15 of a 28-day treatment cycle) will be explored using a 3+3 design to evaluate the safety and tolerability and to determine a MTD.
45654008|NCT04980079|Procedure|Primary ureterscopy URS|Ureteral dilatation will be done when the stone size exceeds 10 mm to facilitate the extraction of the fragments. Ureteroscopic lithotripsy will be done using a 6.5:7.5 Fr semi-rigid ureteroscope and holmium laser. The ureteric stent will last for one week after lithotripsy
45654009|NCT04980079|Procedure|deferred ureteroscopy URS|insertion of a double -J stent or percutaneous nephrostomy (PCN) at first , then a deferred ureteroscopy URS will be done .
45654010|NCT05538455|Device|PC4L solutions|Two different versions of the PC4L system will be tested. A fully equipped version and a cloud-based system that requires only a smartphone and a wearable sensor (Fitbit Versa 2). 25% of participants will use the full system, the remaining 75% will use the cloud-based system. As part of the decision support system, the PC4L platform includes a recommendation component. This component collects information from different sources available (directly from sensors, cognitive games, questionnaires, and the multimodal fusion engine), and under clinical and professional guidance, after evaluating the potential improvement or worsening of patients' conditions, issues personalized recommendations to address identified problems. The recommendations relate to the following areas: physical activities; sleep; cognitive; nutrition. These recommendations will generally be sent to the PC4L application on the patients' smartphone, where they will appear as pop-up notifications.
45654011|NCT04980313|Device|Xenogenic collagen matrix|Use of xenogenic collagen matrix for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
45805271|NCT05922449|Procedure|Thoracic Paravertebral Block|Patients randomly assigned to PV group will be placed in lateral position, and punctured using the out of plane technique guided by ultrasound (Shenzhen Huasheng Navi low-frequency convex array probe). 15 ml of 0.5% ropivacaine was administered to the T4 and T7 thoracic paravertebral spaces respectively, for a total of 30 ml. After injection, the pleura of the punctured segment and adjacent segments could be obviously moved down. Upon successful puncture, the patient was transferred to the supine position. After 5, 10, and 15 minutes, the range of sensory blockage was tested at T3~T8 to cover the surgical area.
45805272|NCT05922436|Drug|QLG2071|intravenous injection
45805273|NCT05922436|Drug|Cleviprex®|intravenous injection
45937581|NCT00054743|Procedure|Blood draw|
45937582|NCT00167986|Drug|vancomycin-resistant enterococci and ESBL|
45937583|NCT00168025|Drug|Immunoglobulins Intravenous (Human)|
45458016|NCT02313220|Drug|Placebo|Oral and Subcutaneous use.
45458017|NCT05071963|Device|Treatment of Intracranial Aneurysms|Embolization of aneurysms using the Pipeline™ Flex Embolization Device with Shield Technology™
45458018|NCT02313298|Radiation|Stereotactic Body Radiotherapy|IMRT or similar techniques that use inverse treatment planning
45458019|NCT02309320|Biological|ALX-0171|
45458020|NCT02309320|Other|Placebo|
45937584|NCT05205876|Behavioral|Eddii mobile application|Participants will use the Eddii mobile application in the intervention arm.
45937585|NCT00168181|Procedure|Submandibular gland Transfer|
45937586|NCT00168181|Drug|Salagen|
45937587|NCT00054821|Procedure|Ankle distraction permitting motion|External fixator is applied to ankle joint for 85 - 95 days; ankle motion is permitted
45937588|NCT00054821|Procedure|Ankle distraction without motion|External fixator is applied to ankel joint for 85 - 95 days; ankle motion is not permitted
45937589|NCT00407251|Drug|Patupilone|
45937590|NCT00045669|Drug|imatinib mesylate|
45937591|NCT00407290|Drug|neostigmine|
45937592|NCT00407329|Procedure|transurethral resection of the prostate|resection of prostate
45937593|NCT00407368|Procedure|Blood Sample|
45937594|NCT00407407|Drug|ABI-007|80mg/m^2 to 150mg/m^2 IV every 3 weeks
45937595|NCT00407407|Drug|Carboplatin|6 AUC IV every 3 weeks on the same day as ABI-007
45937596|NCT05180682|Other|Gait Training|"the physical therapist will provide different protocol at different weeks in the following way.~first week: first fitting and initial Gait training second week: Specific Gait Training third week: Advance Gait Training fourth week: Functional Training"
45937597|NCT00407446|Drug|sildenafil|
45937598|NCT00168376|Device|Transcranial Magnetic Stimulation|
45937599|NCT00168415|Biological|Botulinum Toxin Type A|100 U up to 6 times during the study depending on the response to treatment
45937600|NCT00168493|Drug|antidepressants primarily selective serotonin reuptake inhibitors|normal clinical dosages used according to clinical response as determined by a psychiatrist
45937601|NCT00168532|Drug|Sulfamethoxazole-Trimethoprim|
45937602|NCT00168571|Biological|Measles vaccine|
45937603|NCT00168610|Drug|Vitamin A|
45654012|NCT04980313|Device|Autogenous connective tissue graft|Use of connective tissue graft for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
45654013|NCT05544539|Drug|Ozone-Based Agent|In the study group Ozone oil was placed inside the socket of the extracted tooth following suturing of the flap
45805274|NCT05922423|Behavioral|MBSR|Week 1: Introduce mindfulness theory knowledge to participants and guide them to engage in mindfulness breathing training; Week 2: Sitting meditation, explaining the essence of meditation and practicing with music; Week 3: Explain the connotation of walking meditation, inform the participants of precautions, and guide them to practice; Week 4: Explain the connotation and requirements of body scanning, guide participants in practice; Week 5: Introduce the connotation of hatha yoga and guide participants to practice; Week 6: Explain the meaning of mindfulness sounds and thoughts, guide participants to practice; Week 7: Explain the characteristics of non selective perception, combined with music practice; Week 8: Emphasize mindfulness to promote health, encourage participants to practice internalization, and develop into their own patterns.
45937604|NCT04731948|Dietary Supplement|Folic Acid|400µg Folic Acid per day for 16 weeks
45937605|NCT04731948|Dietary Supplement|2 µg Vitamin B12|2 µg Vitamin B12 per day for 16 weeks
45805275|NCT05922423|Behavioral|health education|For cancer patients who have entered the comfort group, automatic tweets and health knowledge related to science popularization will be provided knowledge
45805276|NCT05922410|Radiation|cone beam computed tomography|cone beam computed tomography
45937606|NCT04731948|Dietary Supplement|10 µg Vitamin B12|10 µg Vitamin B12 per day for 16 weeks
45937607|NCT04731948|Dietary Supplement|50 µg Vitamin B12|50 µg Vitamin B12 per day for 16 weeks
45805277|NCT05922384|Drug|KL-7SHRNA injection solution|Patients continue to receive HAART throughout treatment until meet the criteria of interruption of HAART.
45805278|NCT05922371|Diagnostic Test|NuQ H3.1 Nucleosome Assay|Serial analysis on whole blood of nucleosome levels until resolution of sepsis or discharge.
45937608|NCT00168649|Drug|Vitamin A|
45937609|NCT00054860|Biological|EP HIV-1090|
45937610|NCT00168688|Dietary Supplement|multi micronutrient supplement|
45805279|NCT05922358|Combination Product|Anti-allergic treatment|"For grade I-III hypersensitivity to oxaliplatin, oxa 0.01 mg/ml, 0.1 mg/ml and 5 mg/ml were used in sequence for skin test. 5% GS was used as a negative control. Test results are read within 15 to 20 minutes.~Grade IV: Permanently stop using oxaliplatin; Grade I-II: Take orally (cetirizine 10 mg bid, dexamethasone 8 mg bid, ranitidine 150 mg bid*3dose) the day before the next cycle of oxaliplatin. The infusion rate is 50% of the original rate; if a grade II hypersensitivity reaction occurs again, the treatment method is the same as that of a grade III hypersensitivity reaction.~Grade III: Oral drugs are the same as above. 0.5h before oxaliplatin: dexamethasone 10mg iv, cimetidine 40mg iv, promethazine 25mg im. The first bag of 10% total amount of oxaliplatin + 5% GS500ml: 5ml/h*1h, 45ml/h*1h, then 225ml/h*2 hours; then dexamethasone 10mg iv; the second bag of 90% total Oxa +5%GS500ml: 100ml/h*0.5h, then 150ml/h*3 hours."
45805280|NCT05922345|Drug|TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules|"AL2846 capsules is a multi-targeted small molecule receptor tyrosine kinase inhibitor.~TQB2450 Injection is an anti-programmed death-1 (PD-L1)."
45805281|NCT05922345|Drug|TQB2450 matching placebo, docetaxel injection, AL2846 matching placebo|Docetaxel injection is a type of chemotherapy for treatment of different types of cancer.
45937611|NCT00168688|Dietary Supplement|MN1|Vitamin A 800 μg RE, Vitamin D 200 IU, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.4 mg, Niacin 18 mg, Folic acid 400 μg, Vitamin B6 1.9 mg, Vitamin B12 2.6 μg, Vitamin C 70 mg, Zinc 15 mg, Iron 30 mg, Copper 2.0 mg, Selenium 65 μg, Iodine 150 μg
45937612|NCT00168688|Dietary Supplement|MN2|Vitamin A 1600 μg RE, Vitamin D 400 IU, Vitamin E 20 mg, Vitamin B1 2.8 mg, Vitamin B2 2.8 mg, Niacin 36 mg, Folic acid 800 μg, Vitamin B6 3.8 mg, Vitamin B12 5.2 μg, Vitamin C 140 mg, Zinc 30 mg, Iron 30 mg, Copper 4.0 mg, Selenium 130 μg, Iodine 300 μg
45937613|NCT00168727|Drug|ibritumomab tiuxetan (Zevalin®)|
45937614|NCT00168766|Drug|Interferon-beta-1a (Avonex) plus methylprednisolone|oral administration given on 3 consecutive days, monthly as described in protocol.
45937615|NCT00054899|Biological|EP2101|
45937616|NCT00407524|Drug|AKL 1|
45937617|NCT00168883|Drug|Carboplatin|
45937618|NCT00168883|Drug|Paclitaxel|
46073910|NCT00634218|Behavioral|Mail-based Self-help plus Internet-based Smoking Treatment|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants.
45937619|NCT00168883|Drug|Vinorelbine|
45937620|NCT04731909|Drug|Toripalimab|Toripalimab 240mg,ivgtt,d1,q3w.
45937621|NCT04731909|Drug|Anlotinib|Anlotinib 12 mg/d,d1-14,q3w,4-6 cycles in total. In maintenance treatment period, Anlotinib 12 mg/d,d1,Oral for 2 weeks and stop for 1 week.
45937622|NCT04731909|Drug|Cisplatin|75mg/m2,d1,q3w,4-6 cycles in total.
45458021|NCT03739489|Procedure|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation was a technique able to modulate the brain circuit restoring the function.
45654014|NCT05544539|Drug|Placebo|In the control group Ozone oil syringe was placed inside the socket of the extracted tooth without applying the oil
45937623|NCT04731909|Drug|Carboplatin|AUC=5,d1,q3w,4-6 cycles in total.
45937624|NCT00168922|Drug|Bendamustin/Ribomustin|
45937625|NCT00054938|Drug|pravastatin|
45937626|NCT00054938|Drug|aspirin|
45937627|NCT00054938|Drug|ramipril|
45937628|NCT00054938|Drug|Vitamins: B6, B12, and folate|
45937629|NCT00054938|Behavioral|heart health educational program|
45937630|NCT00168961|Dietary Supplement|High Protein Energy, Fresenius-Kabi (nutritional intervention)|
45805282|NCT05922332|Dietary Supplement|Rich medium chain fatty acid milk powder group|In intervention group,there are 32 infants.They will be fed with rich medium chain fatty acid milk powder, formula with MCT content of 39%, total energy of 68kcal/100ml, and feeding frequency at a 3-hour interval
45458022|NCT01139749|Drug|oral isotretinoin|capsules of 20 mg a day, every other day, for six months
46073911|NCT00634218|Behavioral|Self-Help Manual plus Telephone counseling|Participants will receive a self-help manual specifically developed for LGBT smokers plus 6 telephone-based counseling sessions. The counseling sessions focus on the development of a personalized plan to quit smoking and occur over a 3 month period.
45654015|NCT04979689|Other|Intensive physical therapy|Intensive physical therapy treatment protocol was given for 3 months 3 times a week including 1.5- 2-hour session. Pre and post treatment assessments were taken. It included stretching for 20 min, Proprioception on ball for 20 minutes, quadruped for 10 min, vibration therapy for 20 min, tapping twice a month for 5 days, sensory therapy with beans for 20 min, supine lying with hand below head for 10-15 min, texturing for 15 min and activity of making tower with cups and hitting in outward direction for 15-20 min.
45654016|NCT04979689|Other|Non intensive physical therapy|Non intensive therapy included 45 min session 3 times a week for 3 months. Pre and post treatment assessments were taken. The protocol included stretching for 20 min, cross friction massage for 15 min, Ball catch and throw for 15 min. progression was made from light to heavy weight ball.
45805283|NCT05922332|Dietary Supplement|Regular milk powder group|In control group,there are 32 infants.They will be fed regular milk powder,formula with MCT content of less than 30%, total energy of 67kcal/100ml, and feeding frequency at a 3 hours interval
45805284|NCT05922319|Other|No intervention|No intervention because it is a retrospective study for outcomes
45805285|NCT05922306|Drug|PEGylated recombinant human interferon alpha-2b injection|Continuous combination therapy: pegylated interferon alpha-2b 180µg, subcutaneously once a week for 96 weeks, combined with NAs throughout the treatment period.
45805286|NCT05922306|Drug|PEGylated recombinant human interferon alpha-2b injection|Pulsed combination therapy: pegylated interferon alpha-2b 180µg once weekly by subcutaneous injection for 8 weeks with 4 weeks off for a total treatment duration of 96 weeks, combined with NAs throughout the treatment period.
45937631|NCT00169000|Drug|Capecitabine|"Capecitabine at the following dose levels for 14 days every 21 days, beginning with dose level 1~Dose level -2 600 mg/m2 po BID~Dose level -1 700 mg/m2 po BID~Dose level 1 825 mg/m2 po BID~Dose level 2 1000 mg/m2 po BID"
45937632|NCT00169000|Drug|Docetaxel|75 mg/m2 over one hour on day 8 of each cycle
45937633|NCT00045747|Drug|7-hydroxystaurosporine|
45805287|NCT05922293|Other|blow bottle|When you blow through a tube into water in a bottle, the pressure in the airways increases. This opens up the passageways between bronchioles, allowing air to flow behind the mucus and push it into the larger airways. This way, it will be easy to remove the mucus by coughing or huffing.
45937634|NCT00045747|Drug|fluorouracil|
45937635|NCT00169039|Drug|Clozapine|
45937636|NCT00169039|Drug|Chlorpromazine|
45937637|NCT00169078|Drug|Chloroquine|
45937638|NCT00054977|Drug|GM-CT-01|IV infusion over 30 minutes of 6 Dosages escalated from 30 to 280 mg/m2, given for 4 consecutive days in a 28 days cycle.
45937639|NCT00054977|Drug|5-fluorouracil|IV infusion over 30 minutes at Dosage of 500 mg/m2, given in-combination with GM-CT-01, for 4 consecutive days in a 28 days cycle.
45937640|NCT00169117|Behavioral|Songs/posters aimed at behaviour change|This was a behavioural intervention, using songs and posters composed/designed by community members which aimed at behaviour change to increase repair and maintenance of mosquito nets
45937641|NCT05176743|Behavioral|Unconditional Cash Transfer (UCT)|The UCT consists of three $100 VISA merchandise cards provided monthly via mail to participants randomized to the intervention arm. Merchandise cards can be used anywhere that VISA is accepted. Participants in the UCT arm will also receive Usual Care, including referral to the patient support services team and nutritional pamphlets.
45937642|NCT00169156|Drug|Rituximab|375 mg/m2 D1
45937643|NCT00169156|Drug|Prednisone|40 mg/m2 D1 to D5
45937644|NCT00169156|Drug|Doxorubicine|50 mg/m2 D1
45937645|NCT00169156|Drug|Cyclophosphamide|750 mg/m2 D1
45937646|NCT00169156|Drug|Vincristine|1,4 mg/m2 D1
45937647|NCT00169195|Drug|Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)|
45937648|NCT00398255|Behavioral|self-management program|
45937649|NCT00169234|Biological|PCV7, Prevnar®|Randomized to receive 0.1mL, 0.5mL, 1.0mL or 2.0mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
45937650|NCT00169234|Biological|Pneumovax 23|Randomized to receive 0.5mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
45937651|NCT05130099|Other|Interdisciplinary complex intervention|"The interdisciplinary complex intervention lasts 12 weeks and includes the 4 following components;~Patient-education: a 2-hours group-based digital session, including information about fatigue, training theory, psychological strategies and nutrition, all in relation to chronic fatigue (CF).~Physical exercise program: two weekly sessions with aerobic exercise and resistance training. The participants are instructed to do the same program in the unsupervised sessions as in the supervised sessions. After the first 12 weeks exercise period, the participant and the physiotherapist makes an individually tailored plan for exercise and follow-up the next 12 weeks.~Cognitive behavioral program: 6 group-based online sessions lead by two psychologists, based on elements from cognitive behavioral therapy to reduce and/or manage CF. Each session lasts for 135 minutes.~Nutritional counselling: 3 individual sessions by a clinical dietitian. Each session lasts for 30-60 minutes."
45937652|NCT00169273|Behavioral|Structured behavioral weight loss group|Structured group weight loss program
45937653|NCT00169273|Behavioral|Weight loss and cognitive-behavioral depression group|Structured group program for weight loss and depression
45937654|NCT00169312|Behavioral|behavioral dietary intervention|
45937655|NCT00169312|Dietary Supplement|dietary intervention|
45805288|NCT05922293|Other|percussion|"Percussion technique should be performed for about 30 seconds and simultaneously with no more than three or four lower thoracic expansion exercises.~Do this for a total of 10 breaths,~Perform two huffs, and~Cough.~Close their mouth around the tube and exhale slightly forcefully for 3 seconds to produce bubbles. Such exhalations were conducted in two sets of ten, with a five-minute pause in between. For each subject, a fresh, disposable tube and bottle were utilized"
45452665|NCT00855712|Device|Organ Care System|The Organ Care System (OCS) is a portable organ perfusion and monitoring system intended to preserve a donated heart in a near normal physiologic beating state during transport for eventual transplantation into a recipient. The OCS maintains organ viability by providing a controlled environment that simulates near-normal physiological conditions, continuously perfusing the donated heart with warm, oxygenated blood, supplemented with the Solution Set. The blood is collected from the donor and continuously circulated to the organ in a closed circuit along with the Solution. The OCS preserves and monitors the organ's perfusion and metabolic state after explantation from a donor and connection to the device, during transportation to the recipient site, and until disconnection from the device.
45805289|NCT05922280|Other|subtalar and talo-crural mobilization|"Traction, Antero Posterior (AP) and Postero Anterior (PA) Maitland Grade III oscillatory mobilizations of 2Hz with 120 oscilations per minute, 3 sets for 5 minutes with 1 min of rest between sets at subtalar and talocrural joint would be performed. The mobilization would be large amplitude rhythmic oscillations from the joint mid into end-range muscle spasm/stiffness (translation taken to tissue resistance). Duration will be 20 minutes with 2 sessions per week, total 12 sessions would be performed on each patient in the total period of 6 weeks.~Patients will be guided to follow self foot care examination given by IWGDF Guidelines."
45937656|NCT00169312|Other|educational intervention|
45937657|NCT00169312|Other|internet-based intervention|
45452666|NCT00855712|Device|Cold Cardioplegia Solution|This is the standard of care solutions used to arrest and preserve the donated heart during transport until arrival at recipient hospital
45937658|NCT00169312|Other|preventative dietary intervention|
45937659|NCT00169312|Procedure|evaluation of cancer risk factors|
45452667|NCT05210842|Other|Endoscopy|The procedures are performed using a flexible therapeutic linear array echoendoscope.
45937660|NCT00398333|Dietary Supplement|Eicosapentaenoic acid enriched nutritional supplement|Oral intake of nutritional supplementation: a maximum of 480 mL or a minimum of 240 mL daily during the first 3 months of the study.
45937661|NCT00169468|Drug|Rituximab -CHOP plus Velcade|
45937662|NCT00169507|Biological|Pneumococcal (vaccine)|
45937663|NCT00169546|Drug|Salmeterol/fluticasone propionate|
45937664|NCT00169546|Drug|Fluticasone propionate|
45937665|NCT00398372|Drug|Rituximab|
45937666|NCT00398372|Drug|Epratuzumab|
45937667|NCT00169585|Drug|Levofloxacin oral tablets|
45937668|NCT05015556|Procedure|Minimal invasive volar plating|Muscle sparing osteosynthesis, no casting postoperatively
45937669|NCT04723888|Dietary Supplement|alpha-ketoglutarate|alpha-ketoglutarate supplements
45937670|NCT00169624|Drug|Metformin|
45937671|NCT00169624|Drug|Gliclazide|
45937672|NCT00169702|Behavioral|weight management program|12 sessions, psychoeducation
45937673|NCT00169702|Behavioral|weight management program|2 weekly, 12 sessions, psychoeducational weight management
45937674|NCT00407641|Drug|Tinzaparin administration|Patients will receive tinzaparin during the HD session
45937675|NCT00407641|Drug|Heparin administration|Patients will receive Heparin as an anticoagulant during the HD session.
45937676|NCT00407680|Drug|Intensive therapy Valsartan,Fluvastatin|
45937677|NCT00169741|Other|Renogram|Subjects who enroll in this study will undergo a nuclear scan called a renogram to assess renal function prior to surgery (baseline), approximately one hour after surgery (to assess percutaneous effects on renal function) and finally approximately 6 weeks post-operatively (to assess return to baseline).
45937678|NCT00169780|Radiation|High definition helical CT (64 head scanner)|"Patients who require a CT scan for diagnostic purposes prior to kidney stone surgery will undergo a high definition helical CT rather than the standard CT scan. This high resolution scan will then be reviewed by the researchers to help determine the type of treatment needed for the kidney stone removal. The aim is to see if the higher resolution will show more of the stone anatomy which will help the surgeon determine if the stone will be amenable to shock wave lithotripsy or if another type of treatment would best serve the patient needs."
45937679|NCT00169819|Drug|Abciximab|
45937680|NCT00169858|Biological|Engerix-B|10 mkg per dose; 3 doses according to 0, 1, 6 month schedule; booster doses 5, 10 or 15 years post-primary vaccination.
45937681|NCT00055133|Drug|Micellar Paclitaxel for Injection|
45937682|NCT00169897|Behavioral|Pulmonary rehabilitation (teaching and exercise)|After a 4-week education program, patients took part to home-based rehabilitation or outpatient hospital-based rehabilitation for 8 weeks. Patients were subsequently followed for 40 weeks to complete the one-year study.
45937683|NCT00169936|Device|Magnetocardiograph|
45937684|NCT00169975|Device|Magnetocardiograph|MCG and ECG recordings sequentially at the four pre-defined bed positions and watches the real-time magnetocardiogram traces on the computer screen. At each position, nine sensors record MCG data, thus forming a 3 x 3 point grid square with point-to-point separation of 40 mm. The number of cardiac cycles recorded at each position should be adequate for signal averaging. Recording time per position is typically 90 seconds. At the end of 4 sequential recordings, raw, unfiltered MCG data are stored.
45937685|NCT02970188|Behavioral|Time Restricted Feeding|consuming all daily calories within an 8 hour feeding window
45937686|NCT00170014|Device|Magnetocardiograph|
45937687|NCT00170053|Drug|Sirolimus|10 mg oral loading dose followed by 5 mg/day. Measure Sirolimus level weekly and adjust to level of 10-15 ng/ml.
45937688|NCT00055250|Drug|Gemcitabine|
45937689|NCT00055250|Drug|LY293111|
45937690|NCT00055250|Drug|placebo|
45937691|NCT00170209|Drug|Isoniazid|The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-15 mg/kg/day (max=300mg/day). Total duration of treatment is 9 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
45805290|NCT05922280|Other|International Working Group of the Diabetic Foot care guidelines|"Patients will continue their usual activities according to International Working Group on Diabetic Foot (IWGDF) guidelines including the measures of inspecting the feet, self- examination for callus, pre-ulcerative signs or deformity. They will be restrict barefoot walking in-door and outdoors. To wash their feet daily with careful drying, to use emollients to prevent dryness and cut their nails straight across. Monitor the foot skin temperature for inflammation, wear orthotic insoles for preventing abundant callus.~Patients will perform active ROM exercises 5 times per week for duration of 30 minutes for 6 weeks:Ankle pumps, Supination and Pronation, Drawing score from 0 to 9, Leg Flexion and Extension"
45937692|NCT00170209|Drug|Rifampin|The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-20 mg/kg/day (max=600mg/day). Total duration of treatment is 4 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
45937693|NCT00170248|Device|computer-based decision support for asthma management|The asthma management decision support system uses data from the patient problem and medication list to provide patient-specific management recommendations based on Canadian Consensus guidelines for asthma management. Web-enabled technology for asthma education nurses is used to collect home-monitoring information from patients between visits and feedback to primary care physicians in accordance with options selected by the physician for each patient.
45937694|NCT00170287|Procedure|ICD Ablation plus VT-ablation|ICD-Therapy for the treatment of unstable VT´s plus catheter ablation for substrate modification
45937695|NCT00170287|Device|ICD Therapy|ICD Therapy for the Treatment of unstable VT´s
45937696|NCT00170326|Procedure|dual-chamber pacemaker implantation|Dual Chamber pacing via conventional DDD(R) right ventricular pacemaker or in case of ICD indication a standard dualchamber ICD device.
45937697|NCT00170326|Procedure|biventricular dual-chamber pacemaker implant|Biventricular pacemaker system or in case in ICD indication a BIV ICD
45937698|NCT00170365|Behavioral|Restorative Yoga|
45937699|NCT02964091|Drug|sofosbuvir/ledipasvir|
45937700|NCT00055328|Behavioral|Problem-Solving Treatment for Primary Care|
45937701|NCT00170404|Drug|Folic Acid|
45937702|NCT00170404|Drug|Micronutrients: Vitamins B1, B2, B6, Niacin, B12, C, E.|
45937703|NCT00170404|Drug|Selenium|
45937704|NCT00170404|Drug|Vitamin A|
45937705|NCT00170443|Biological|rHAO Trivalent Influenza Vaccine|
45937706|NCT00055367|Drug|natalizumab|
45937707|NCT00170677|Drug|Topotecan|Topotecan 4,0 mg/m² administered in day 1, 8 und 15 as i.v. infusion for 30 minutes. A cycle lasts 28 days.
45937708|NCT00170677|Drug|Topotecan|Topotecan 1,25 mg/m²/day, day 1-5 as i.v. infusion of 30 minutes. Repeat after 21 day.
45937709|NCT00170716|Device|Cortical Stimulation and rehabilitation|Cortical stimulation is provided concomitantly with rehabilitation therapy. Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
45937710|NCT00170716|Other|Rehabilitation|Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
45937711|NCT00055445|Drug|IdB 1016|
45937712|NCT00170755|Drug|Darifenacin|Darifenacin 7,5 mg tablets, Darifenacin 15 mg tablets administered once daily
46073912|NCT00634218|Behavioral|Self-Help Manual|Participants will receive a self-help smoking cessation manual specifically developed for LGBT smokers. The manual provides information on quitting smoking and encourages the development of a personalized quit plan through various activities and exercises.
45654017|NCT05538377|Other|Focal Vibration|This group will receive a multicomponent exercise program based on specific literature for effective training. In addition, this group will perform the strength and endurance exercises with focal vibration on the vastus internus, externus and biceps femoris. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
45654018|NCT05538377|Other|Control Group|This group will receive the same multicomponent exercise program than the other group based on specific literature for effective training. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
45654019|NCT03822871|Drug|CTT1403|Escalating doses of 0.75 GBq - 13.5 GBq will be administered in an accelerated to traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort. Patients meeting eligibility criteria with demonstrated cessation of disease progression will be offered a second dose of the study drug, CTT1403.
45937713|NCT00170794|Drug|Everolimus (RAD001)|
45937714|NCT00170833|Drug|Everolimus|
45937715|NCT00170872|Drug|Lumiracoxib|
45937716|NCT00170911|Drug|AAE581|
45937717|NCT00170989|Drug|valsartan plus hydrochlorothiazide|
45452668|NCT00850174|Drug|Oxcarbazepine|600 mg Tablet
45937718|NCT00171028|Drug|valsartan|
45937719|NCT00055484|Drug|zonisamide|
45937720|NCT00171067|Drug|valsartan|
45937721|NCT00171067|Drug|lisinopril|
45937722|NCT04994106|Drug|AZD5462|Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.
45937723|NCT04994106|Drug|Placebo|Participants will receive Placebo matched to AZD5462.
45937724|NCT00171106|Drug|valsartan|
45937725|NCT00171145|Drug|Darifenacin|Darifenacin 15 mg tablets once daily
45937726|NCT00171145|Drug|Placebo|Placebo tablets once daily
45937727|NCT00171184|Drug|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
45937728|NCT00171184|Drug|Placebo|Placebo tablet once daily with sham titration
45937729|NCT00055523|Drug|Adalimumab (D2E7)|
45937730|NCT00171262|Drug|Fluvastatin|
46073913|NCT00634218|Behavioral|Self-Help Manual plus Internet-based Intervention plus Telephone Counseling|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants. Smokers will also receive 6 telephone-based counseling sessions which occur over a 3 month period
45452669|NCT00850174|Drug|Trileptal®|600 mg Tablet
46073914|NCT04237818|Dietary Supplement|Placebo drink|consume 2 bottle (30 mL) per day for 56 days
45452670|NCT00849862|Drug|Levetiracetam|750 mg Tablet
45805291|NCT05922267|Other|ACTIVE CYCLE OF BREATHING TECHNIQUES|"The participants in group A will be given ACBT with conventional chest physiotherapy .~Instruction for patient~Try to keep your chest~Take a long, slow and deep breath in, through your nose if you can.~At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing~Breathe out gently and relaxed, like a sigh. Don't force the air out.~Repeat 3 - 5 times.~If the patient feels light-headed then it is important that they revert back to the breathing control phase of the cycle~Huffing"
45805292|NCT05922267|Other|SLOW EXPIRATION WITH OPEN GLOTTIS IN LATERAL POSITION|The participants in group B will be given slow expiration with open glottis in lateral posture and conventional chest physiotherapy .In this technique, a patient adopts a lateral posture or a lateral decubitus posture. The affected lung is in the dependent position. A patient commences breathing normally, at tidal volumes. They are then instructed to perform a series of slow expirations with an open glottis. Expiration from functional residual capacity to the end of the expiratory reserve volume are encouraged to achieve maximum inflation . To assist in maintaining an open glottis, a mouthpiece may be used, to decrease the degree of airway compression A series of three ELTGOL may be performed, with each series composed of approximately 10 slow and deep expirations. In between each series of maneuvers, a rest period (around 1-2 minutes) is provided, with the patient staying in the same position. A typical treatment lasts for around 20 minutes
45805293|NCT05922254|Other|Active cycle of breathing technique|The ACBT technique consists of three different breathing techniques: breathing control, thoracic expansion exercises and forced expiration technique. 1. Breathing Control 2. Thoracic Expansion Exercises: 3. Forced Expiration Technique:
45805294|NCT05922254|Other|Autogenic drainage|Huffing or blowing the nose helped to get rid of any secretions in the upper airways. The therapist was placed close enough to hear the subject's breathing while sitting to the side and slightly behind the patient. Both the physiotherapist's hand and the subject's hands were put on the subject's abdomen to feel the activity of the abdominal muscles. The patient inhaled slowly through the nose while using their diaphragm and holding their breath for two to three seconds to allow collateral ventilation to bring air behind their secretions. Exhalation was done through the mouth. The palm of the therapist placed on the upper chest felt the vibration of the mucous. Their positions were disclosed by the vibrations' frequency.
45805295|NCT05922241|Other|Costophrenic assisted cough|Therapist places the hands on the costophrenic angles of the patient's rib cage. During the patient's inspiration, the therapist applies a series of three repeated quick-stretch contractions down and in to encourage maximal inspiration. At the end of expiration, the therapist applies a quick stretch down and in on the patient's lower chest to facilitate a stronger diaphragmatic and intercostal muscle contraction. While instructing the patient to cough, the therapist applies strong pressure through the hands in toward the central tendon of the patient's diaphragm
45805296|NCT05922241|Other|Anterior chest compression|The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process
45805297|NCT05922228|Other|neural flossing with proprioceptive neuromuscular facilitation|neural flossing technique for 5minutes, 10 repetitions×1 set, 3 days/week contract relax technique of proprioceptive neuromuscular facilitation for 5 minutes, 10 repetitions ×1 set, 3 days/week total of 15 sessions were given as 3 sessions/week up to 5 weeks, each session consisting of 10 minutes
45805298|NCT05922228|Other|Neural flossing without proprioceptive neuromuscular facilitation|neural flossing technique for 5minutes, 10 repetitions×1 set, 3 days/week total of 15 sessions were given as 3 sessions/week up to 5 weeks, each session consisting of 5 minutes
45805299|NCT05922215|Other|Dynamic Balance training|The Experimental group will be given the Baseline treatment comprising of Stretching & Static balance training (i.e. heel and toe raises, alternate rising of the left and right foot above the floor and tandem standing.) alongside Dynamic Balance training which will include (weight shifting forward, backward, sideward, and diagonally with eyes opened and eyes closed, walking toe-to-heel barefoot, side walking, reverse walking and one-foot jumps), and Progressive activity training (such as stepping over/on obstacles, throwing and catching a ball, and kicking a ball.) for 40 minutes per day, twice each week for 8 weeks.
46073915|NCT04237818|Dietary Supplement|Chenopodium Formosanum and Fagopyrum Esculentum Extract drink|consume 2 bottle (30 mL) per day for 56 days
46073916|NCT04237740|Drug|relenvatinib|The enrolled patients are treated with lenvatinib (dose: body weight < 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
45452671|NCT00849862|Drug|Keppra®|750 mg Tablet
45452672|NCT05341648|Other|Aerobic Exercise Training|Warm-up: 5 minutes Aerobic Training Treadmill/cycle ergometer Frequency:3 days a week Intensity:40-70% of HR max(Start from 40% than increment to as per patient tolerance) Total Duration:6 weeks. Duration of each session:15-30 mins. Cool-down: 5 minutes
45452673|NCT05341648|Other|Home Plan|"Positions to ease breathlessness~Controlled breathing/Deep breathing*10 Reps* TD,s~Progressive Muscle Relaxation Exercises.~ROM & Flexibility Exercises. 3 days a week for 6 weeks."
45452674|NCT00077207|Drug|carboplatin|Given IV
45452675|NCT00077207|Drug|temozolomide|Given orally
45452676|NCT00077207|Drug|vincristine sulfate|Given IV
45452677|NCT05627284|Procedure|Stoma reversal with bio-mesh placement|Patients will receive stoma reversal. During the surgery, a bio-mesh is placed beyond the peritoneum on the surgical site to strengthen the abdominal wall.
45452678|NCT05306938|Behavioral|Adolescent Wellness Visit|Adolescent Wellness Visits (AWVs) are a new health service platform for reaching young adolescents with HTC and other evidence-based prevention services which are clinic-based and school-facilitated. The AWVs bundle the following health screenings, education, and counseling on: nutrition, vision, dental, mental health (depression), contraception, sexually transmitted infections, and optional HIV testing.
45452679|NCT01099085|Drug|Simvastatin|simvastatin 40 mg qd daily
45452680|NCT01099085|Drug|Placebo|Placebo
45452681|NCT05296018|Other|Mandala coloring page|Mandala program will be applied three days a week (30 minutes) for 8 weeks.
45452682|NCT03206918|Drug|Zanubrutinib|Zanubrutinib 160 mg (two - 80 mg white opaque capsules) taken by mouth (PO) twice a day (BID)
45937731|NCT04954248|Diagnostic Test|Injected radiotracer with PET Insert|"Informed consent will be obtained before beginning any study procedures.~Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed."
45805300|NCT05922215|Other|Static balance training|The Control group will continue their regular school schedule, which will include participation in physical education activities at the same frequency. Along with that Baseline treatment including Static balance training (i.e. alternate rising of the left and right foot above the floor and tandem standing.) only, at the same intervals and for the same length of time as the intervention group, with the exception of additional Dynamic balance training and progressive activity training.
45937732|NCT00171379|Drug|Enteric-Coated Mycophenolate Sodium|
46073917|NCT00634296|Other|Inspiratory muscle added by aerobic to aerobic alone|Inspiratory muscle added by aerobic to aerobic alone
46073918|NCT02816034|Behavioral|Visuo-motor rotation|Participant moves a cursor on a screen by sliding a pen over a digital tablet. Participants perform a center-out movement, aiming to a target that appears over one of a set of eight markers radially distributed. In several block of trials, the mapping of the pen position to the cursor is rotated.
46073919|NCT02816034|Behavioral|Explicit strategy|Participant is provided with an explicit instruction as to how counteract the effects of the visuo-motor rotation via aiming to a marker adjacent target
45805301|NCT05922202|Other|Assessment of cardiovascular events, cardiovascular mortality, all-cause mortality, and mortality due to COPD at 12 and 24 months|At 12 and 24 months of follow up, cardiovascular events (including hospital admissions), deaths due to cardiovascular disease, deaths due to all-cause, deaths due to COPD will be recorded in COPD outpatients group.
46073920|NCT02817984|Biological|Acellular Adipose Tissue (AAT)|The components of the adipose-derived scaffold are all naturally occurring AAT proteins and proteoglycans that provide a natural scaffold. The nature of the AAT also enhances host tissue integration since matrix components can be easily degraded by cell-secreted enzymes as tissue remodeling takes place. Mechanisms for matrix turnover are already established in host cells, avoiding any concerns over proper clearance of scaffold materials from the body.
46073921|NCT02817750|Drug|zolpidem hemitartarate tablet 3.5 mg (fasting + post-prandial)|zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial
46073922|NCT02817750|Drug|zolpidem hemitartarate tablet 3.5 mg (post-prandial + fasting)|zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting
46073923|NCT02817672|Behavioral|PRIME 1.0|Mobile application designed to improve psychosocial functioning and motivational deficits (sans NLP-powered dashboard).
46073924|NCT02817672|Behavioral|PRIME 2.0|Mobile application designed to improve psychosocial functioning and motivational deficits (with NLP-powered dashboard).
46073925|NCT02815410|Drug|levetiracetam|Patients in this group are with newly diagnosed glioblastoma patients who are supposed to be treated with concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy with temozolomide (TMZ). Patients ( intervention Group) will be given levetiracetam (LEV) from the beginning of treatment till after the adjuvant chemotherapy with TMZ is over.
45654020|NCT03822871|Drug|CTT1057|Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
45654021|NCT03822871|Drug|68Ga-PSMA-11|Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
45654022|NCT05544383|Behavioral|Interdisciplinary Pain Education Program|It is an operative group model, with the objective of promoting education in pain, where the patient occupies an active and central space in the learning process, with work focused on the dysfunctional beliefs of chronic pain, performing programmed tasks to promote autonomy in activities daily life and behavior change. The group works with one meeting per week, during the routine opening hours of the clinic, with each day a theme of a professional area being addressed, totaling 5 meetings, lasting approximately two hours.
45937733|NCT00171418|Drug|Tegaserod|
45937734|NCT00171457|Drug|Tegaserod|
45937735|NCT00055562|Drug|CC 5013|
45937736|NCT00171496|Drug|Cyclosporine microemulsion|
45937737|NCT00171496|Drug|Tacrolimus|
45937738|NCT00171535|Drug|valsartan/amlodipine|
45937739|NCT00171574|Drug|Valsartan|
45937740|NCT00171574|Drug|Valsartan plus HCTZ|
45937741|NCT00171574|Drug|Lisinopril|
45937742|NCT00171613|Drug|Octreotide|
45937743|NCT04920981|Other|atezolizumab|observational
45937744|NCT00055640|Biological|rituximab|Rituximab IV over 3-6 hours.Treatment repeats every 21 days for 3-8 courses.
45937745|NCT00055640|Drug|cyclophosphamide|Cyclophosphamide IV over 30 minutes. Treatment repeats every 21 days for 3-8 courses.
45937746|NCT00055640|Drug|doxorubicin hydrochloride|Doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 3-8 courses.
45937747|NCT00055640|Drug|prednisone|Oral prednisone on days 1-5. Treatment repeats every 21 days for 3-8 courses.
45937748|NCT00055640|Drug|vincristine sulfate|Vincristine IV over 5 minutes on day 1. Treatment repeats every 21 days for 3-8 courses.
45937749|NCT00055640|Genetic|microarray analysis|genetic testing
45937750|NCT00171652|Drug|Diclofenac sodium gel 1%|
45937751|NCT00171691|Drug|Diclofenac Topical Sodium Gel 1%|
45937752|NCT00171769|Drug|Certoparin|
45654023|NCT05544383|Other|Conventional Physiotherapy treatment|The therapeutic approach consists of rehabilitation methods and techniques, with the aim of restoring, developing and conserving the patient's physical capacity and functionality, including manual therapy and kinesiotherapy, in addition to the use of resources such as electrotherapy, thermotherapy and auriculotherapy. The treatment is performed at the Physiotherapy outpatient clinic, twice a week, with an average duration of 45 minutes, for a period that lasts an average of 10 sessions in clinical cases of chronic musculoskeletal pain.
45805302|NCT05922189|Other|SBS Decompression Technique|The investigator who applied the technique stood on the right side, laterally to the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard, and with a glove on his right hand. Then, he contacted the volunteer's sphenoid wings with his left hand and asked the volunteer to open her mouth, contacting the upper dental arch with the second and third fingers of his right hand. Subsequently, the investigator brought both hands together, followed by an inspiration towards the floor and then a translation towards the ceiling until he felt the structures relax, with a maximum duration of 5 minutes. A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique.
45805303|NCT05922189|Other|Placebo Technique|The investigator was standing, on the right side, laterally to the headboard of the table with feet flat on the floor, at an appropriate level in relation to the headboard of the volunteer's and with a glove on his right hand. Then, he contacted the participant's sphenoid wings with his left hand and asked her to open her mouth. With the second and third fingers of the right hand, he made contact with the upper dental arch. These contacts were maintained for 2 minutes, without moving. A second investigator sat on a chair, placed on the opposite side of the table with the stopwatch in his dominant hand, in order to time the application time of each technique.
45805304|NCT05922176|Other|Evaluation of clinical indicators, Sample collection before& after immunotherapy|"A. Evaluation of clinical indicators before immunotherapy~Symptom Scale for Rhinitis: Total Nasal Symptom Score (TNSS), Rhnitis Quality of Life Questionnaire(RQLQ)~American house dust mite-specific immunogloblin G4 (sIgG4)~American house dust mite-specific immunogloblin E (sIgE)~B. Sample collection before immunotherapy~Skin: Skin test using minimally invasive microstructure patch stripping method~Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)~C. Evaluation of clinical indicators 4 to 6 months after immunotherapy~: Treatment is performed for about 4 months, and the progress of treatment is evaluated through the evaluation of the following clinical indicators.~same as examination in 'A'~D. Sample collection after 4 to 6 months of immunotherapy same as examination in 'B'"
45805305|NCT05922176|Other|Sample collection before& after immunotherapy|"B. Sample collection before immunotherapy~Skin: Skin test using minimally invasive microstructure patch stripping method~Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)~D. Sample collection after 4 to 6 months of immunotherapy~Skin: Skin test using minimally invasive microstructure patch stripping method~Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)"
45805306|NCT05922163|Device|Evidence-based VR simulation|Evidence-based VR simulation videos on BTs for nursing students were developed, including 1) animated blood formation physiology and side effects of BT and 2) 360° BT nursing practice.
45805307|NCT05922150|Radiation|low level laser therapy|LLLT induces cellular biostimulation, speeds up tissue regeneration, enhances wound healing, and reduces pain and swelling through an anti-inflammatory effect. This is because the LLLT increases phagocytic activity, and the number and diameter of lymphatic vessels, decreases the permeability of blood vessels and restores microcapillary function
45452683|NCT01093703|Other|Medication Adjustment|"Awake SBP≤135/85mmHg and patient is on once daily medications: Switch BP medications to pm period.~Awake SBP SBP≤135/85mmHg and patient is on bid medications (e.g. metoprolol bid): Increase pm dose of the medication. If medication is already is at maximal dose or there is contraindication for increasing the dose (e.g. bradycardia), add another BP medicine in the evening time.~Awake SBP≤135/85mmHg and patient is not on anti-hypertensive medications: Add BP medication at the pm period.~Awake SBP>135/85mmHg: increase dose of antihypertensive medications or add more medications. All medications to be given in the evening time."
45452684|NCT01088867|Other|Acupuncture|Electroacupuncture
45452685|NCT04504994|Behavioral|inclusion condition|cyberball game: ex- versus over-inclusion condition
45805308|NCT05922150|Drug|ozone gel|ozone is effective antimicrobial (viricidal, bactericidal, and fungicidal). Other well-known benefits include immunological modulatory and stimulating effects and anti-inflammatory, biosynthetic, anti-hypoxic, and bioenergeticseffects
45452686|NCT01093781|Drug|Aliskiren|Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.
45654024|NCT04425551|Procedure|laser light|laser light destruction of telangiectatic vessels of lower eyelid margin via selective thermolysis
45805309|NCT05922137|Behavioral|Usual Diet advice|The usual diet advice include recommendations in guidelines, such as reducing salt and limiting alcohol consumption
45805310|NCT05922137|Behavioral|Oriental Intervention for Enhanced Neurocognitive Health (ORIENT) diet|The ORIENT diet has the same basic components of the Dietary Approaches to Stop Hypertension (DASH), Mediterranean and MIND diets, but uniquely adjusting some of components according to the evidence derived from Asian prospective cohorts and the Chinese eating habits.
45805311|NCT05922124|Drug|Cefiderocol|Test drug regimen
45805312|NCT05922124|Drug|Ampicillin-sulbactam|Synergistic combination
45805313|NCT05922124|Drug|Colistin|Historical comparator
45805314|NCT05922124|Drug|Meropenem|Historical comparator synergistic combination
45805315|NCT05922111|Device|cervical ripening balloon for one hour|The cervical ripening balloon will be left in place for one hour and after balloon removal the induction of labor will proceed at the discretion of the attending physician at labor and delivery room
45805316|NCT05922111|Device|cervical ripening balloon for twelve hours|The cervical ripening balloon will be left in place for for twelve hours and after balloon removal the induction of labor will proceed at the discretion of the attending physician at labor and delivery room
45937753|NCT04869657|Behavioral|Coaches with Children's Hospital of Philadelphia (CHOP) Research Consultant Support|Coaches employed by the school district will support the implementation of three evidence-based practices, while themselves being remotely supported by CHOP research consultants.
45937754|NCT04869657|Behavioral|Coaches without CHOP Research Consultant Support|Coaches employed by the school district will support the implementation of three evidence-based practices without any additional support from CHOP research consultants.
45654025|NCT05538299|Behavioral|questionnaire, KAP|Diagnostic studies including questionaire, CXR, spirometry, clinical assesment, occupational safety training
45654026|NCT03064165|Drug|Bupivacaine-epinephrine|Nerve block with 15 mL bupivacain 5 mg/mL with epinephrine 5 µg/mL.
45805317|NCT05922098|Other|Texture Modified Foods Manual for chewing dysfunctions in older adult|Texture Modified Foods Manual for chewing dysfunctions (including IDDSI)
45805318|NCT05922085|Other|Ultrasound|performed within 3 hours prior to extubation
45937755|NCT00171808|Drug|Letrozole|
45937756|NCT00171847|Drug|Letrozole|
45937757|NCT00171847|Drug|Trastuzumab plus Letrozole|
45937758|NCT00171847|Drug|Letrozole|
45937759|NCT00055679|Drug|cyclophosphamide|
45937760|NCT00055679|Drug|epirubicin hydrochloride|
45937761|NCT00055679|Drug|fluorouracil|
45937762|NCT00171886|Drug|Octreotide|
45937763|NCT00171964|Drug|Zoledronic acid in combination with therapy|
45937764|NCT00172003|Drug|Zoledronic acid|
46073926|NCT02817438|Behavioral|Good Days Ahead|Good Days Ahead is a web-based program based on the principles of Cognitive Behavioral Therapy (CBT). It can be used to supplement traditional psychotherapy, or as a stand-alone intervention. There are 9 lessons that address Thinking Skills, Behavioral Skills, Schemas, and Coping Tools. Lessons include videos from expert therapists and a Practice Section in which patients complete forms for self-monitoring symptoms and challenging negative thoughts.
45654027|NCT03064165|Procedure|Sham block|Injection as for obturator nerve block, but with placebo
45654028|NCT03064165|Procedure|Obturator nerve block|Postoperative obturator nerve block
45654029|NCT03064165|Drug|Sodium Chloride 9mg/mL|Placebo
45805319|NCT05922085|Other|nasofibroscopie|performed within 24 to 36 hours after extubation
45805320|NCT05922072|Procedure|Nasogastric aspiration for measurement of Residual Gastric Volume|The patients enrolled in this study undergoing elective general anesthesia,their mean gastric residual volume will be measured by taking Nasogastric tube aspirate.
45654030|NCT05544149|Radiation|Thoracic radiotherapy|Thoracic radiotherapy for ES-SCLC after first line immunecheckpoint inhibitors
45805321|NCT05922072|Procedure|Nasogastric Aspiration for Measurement of Gastric pH|The patients enrolled in this study undergoing elective general anesthesia,their mean gastric gastric PH will be measured by taking Nasogastric tube aspirate.
45937765|NCT00172081|Drug|placebo|Daily subcutaneous injection with placebo
45937766|NCT00172081|Drug|ALX1-11|PTH (1-84) 100 mcg injected subcutaneously into the thigh or abdomen
45937767|NCT00055718|Dietary Supplement|silymarin|
45937768|NCT04830306|Behavioral|Exercise|Completion of exercise in accordance with assigned protocol
45937769|NCT00172120|Drug|ALX1-11|
45937770|NCT00055757|Drug|tipifarnib|Given orally
45937771|NCT00055757|Drug|cisplatin|Given IV
45937772|NCT00055757|Drug|gemcitabine hydrochloride|Given IV
45937773|NCT00055757|Other|laboratory biomarker analysis|Correlative studies
45937774|NCT00172159|Procedure|Hepatic resection|
45937775|NCT00172198|Drug|Omegaven 10%|
45937776|NCT00399867|Drug|Simvastatin|
45937777|NCT00055835|Drug|carboplatin|*AUC=5 (by modified Calvert formula), IV, over 15 minutes; given q 21 days for a maximum of 3 cycles (1 cycle = 21 days)
45937778|NCT00055835|Drug|cisplatin|75 mg/m2 (maximum dose 150 mg), IV, rapid infusion; given q 21 days for 2 cycles (1 cycle = 21 days)
45937779|NCT00055835|Drug|gemcitabine hydrochloride|800 mg/m2, IV, over 30 minutes; given on Days 1 & 8, q 21 days, for a maximum of 3 cycles (1 cycle = 21 days)
45937780|NCT00055835|Drug|paclitaxel|200 mg/m2, IV, over 3 hours; given q 21 days for a maximum of 3 cycles (1 cycle = 21 days)
45937781|NCT00055835|Procedure|neoadjuvant therapy|Neoadjuvant chemotherapy (paclitaxel, carboplatin, and gemcitabine)
45654031|NCT05535491|Other|Educational and Research Hospital|breathing exercise
45654032|NCT05535413|Drug|UTD1 combined with capecitabine|"UTD1: 30mg/m2/day, once a day, continuously from day 1 to day 5, 21 days as a treatment cycle.~Capecitabine: 2000mg / m2 / day, continuously from day 1 to day 14, orally twice a day, 21 days as a treatment cycle."
45654033|NCT05538143|Other|Comprehensive ED syncope/presyncope management tool|This is a data-only, prospective observational cohort study to validate the performance metrics of the Canadian Syncope Risk Score in a diverse population of patients evaluated in community EDs of a U.S. integrated health care system.
45937782|NCT00055835|Radiation|radiation therapy|Radiation treatments will be delivered once daily. Treatment will be given 5 days per week at a dose of 180 to 200 cGy per day. All fields will be treated everyday.
45937783|NCT00172354|Drug|Hydrocortisone|
45937784|NCT04796181|Device|Neteera 130H|The Neteera 130H will used to perform measurements in proximity to study participants.
45937785|NCT00172510|Procedure|blood drawing|
45937786|NCT02964286|Device|The Electric vibrating massager,SAMPO®|The technique used is The electric vibrating massager ''SAMPO®'', and patients are taught to apply the strong mode on the 15 specific points,5 min each, 3 times a day from Monday to Friday during chemotherapy course. The intervention follow the points are used to stimulate the hematopoietic function. According to their anatomical location: upper extremity are Hegu (LI4), Quchi (LI11); lower extremity are Xuehai (SP10); Sanyin-jiao (SP6), Taixi (K3), Zusanli (ST36), Taichong (LV3); and the top of head is Baihui (GV20). The used of all the points, except for Baihui (GV20), is bilateral.
45937787|NCT00055874|Biological|recombinant interferon alfa|
45937788|NCT00055874|Drug|cytarabine|
45937789|NCT00055874|Drug|hydroxyurea|
45937790|NCT00055874|Drug|imatinib mesylate|
45937791|NCT00055874|Procedure|allogeneic bone marrow transplantation|
45937792|NCT00055874|Procedure|autologous bone marrow transplantation|
45937793|NCT00055874|Procedure|peripheral blood stem cell transplantation|
45937794|NCT00045786|Drug|CC-1088|400 mg/day (200 mg orally twice a day) 800 mg/day (400 mg orally twice a day) 1200 mg/day (600 mg orally twice a day) 1500 mg/day (500 mg orally three times daily)
46073927|NCT02814630|Biological|Xolair|The patients will receive one subcutaneous injection of Xolair® (omalizumab) at a dose of 300 mg on Days 1, 30, and 60. This dose is based on the results of the international, multicenter, randomized, double-blind, placebo-controlled study which demonstrated that omalizumab significantly decreased clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of H1-antihistamines (Maurer et al., 2013)
46073928|NCT04295382|Device|Software Application|A software application targeting suicidal ideation via interactive exercises.
45452687|NCT03206216|Diagnostic Test|Diode Laser fiber type Selective Stimulator (DLss)|A laser device to assess pain sensitivity to stimulation
45654034|NCT03813199|Drug|ABX464 50mg|ABX464 is a new anti-inflammatory drug
45654035|NCT03813199|Drug|Matching Placebo|placebo matching with ABX464
45452688|NCT03961217|Radiation|Radiotherapy|Radiotherapy as part of cancer treatment
45805322|NCT05922059|Device|Transcutaneous vagus nerve stimulation|Auricular transcutaneous vagus nerve stimulation will be used in the left cavity of the external ear with a stimulation frequency of 20-30 Hz for half hour. Monophasic rectangular waveforms will be used, and the intensity will be adjusted below the patient's pain threshold.
45452689|NCT01088945|Behavioral|Enhanced Discharge process|Health Coaching prior to discharge, with an enhanced discharge binder to reinforce the teaching of the Health Coach
45654036|NCT03813199|Drug|ABX464 100mg|ABX464 is a new anti-inflammatory drug
45654037|NCT03813199|Drug|Methotrexate|MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study
45654038|NCT05537909|Other|Biological sample collection|All patients and their controls will be asked to provide a urine, stool, saliva and blood sample during a follow-up visit. Patients will not be specifically asked to take these samples, they will be taken during a follow-up visit, during which these samples are usually already taken.
45654039|NCT03064009|Other|Infection|This is an observational trial
45654040|NCT05699135|Drug|Avelumab first-line maintenance|Patients with LA/mUC who following 4-6 cycles platinum chemotherapy and have not progressed, received avelumab, recommended dose of 10mg/kg body weight, intravenously administered over 60 minutes every 2 weeks
45805323|NCT05922059|Device|Heart rate variability biofeedback|The patient will receive visual HRV feedback during resonance frequency breathing. Finally, the patient will be instructed to maximize their peak-to-peak HRV and attain the phase between respiration and HRV changes as closely as possible
45805324|NCT05922059|Other|Standard-care physiotherapy|consists of cervical mobilization on the painful segment, isometric exercise for neck flexors, and a combination of strengthening and stretching exercises from sitting position; cervical extensors strengthening exercise using red color Thera-band and stretching exercises upper trapezius of the painful side.
45937795|NCT00407719|Drug|Bevacizumab|
45937796|NCT04732845|Biological|Fully human anti CD19 CAR-T Cell Dose|"Level -1 (1 x 10^5 cells/kg) Level 1 [Starting Dose] (5 x 10^5 cells/kg) Level 2 (1 x 10^6 cells/kg) Level 3 (2 x 10^6 cells/kg)~Infusion of CAR-T cells will occur over 5-30 minutes."
45937797|NCT04732845|Drug|Fludarabine|25 mg/m2 daily from day -5 to -3
45937798|NCT04732845|Drug|Cyclophosphamide|60mg/Kg on day -6
45937799|NCT00055913|Biological|bevacizumab|Given IV
45937800|NCT00055913|Drug|erlotinib hydrochloride|Given orally
45937801|NCT00055913|Other|laboratory biomarker analysis|Correlative studies
45937802|NCT04723654|Device|Skin Sensor|Placement of wireless wearable vital sign monitors on patients for up to 48 hours
45937803|NCT00045864|Drug|Recombinant Human Interleukin-2 and Rituximab|
45937804|NCT00172939|Procedure|foreskin from healthy adults|
45937805|NCT00055952|Drug|exatecan mesylate|
45937806|NCT00173017|Device|wearing N95 masks|
45937807|NCT02970149|Other|NA (observational)|
45937808|NCT00173251|Procedure|obtain surgical specimen for analysis|
45937809|NCT00045903|Behavioral|Exposure and Ritual Prevention (Cognitive Behavioral Therapy)|
45937810|NCT00045903|Behavioral|Stress Management Therapy (Cognitive Behavior Therapy)|
45937811|NCT00055991|Drug|bexarotene|This drug is a retinoid. The anti-tumor action of retinoids, as well as their potential in chemoprevention, supports the need to further identify the spectrum of responsive tumors, to identify the molecular mechanisms associated with retinoid action, and to identify and develop new retinoids that have unique properties and an improved therapeutic index.
45937812|NCT00173407|Procedure|immunohistochemical, methylation, gene transfection|
45937813|NCT04631484|Drug|Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)|20 ml (2 ampoules, 10 ml each) dissolved in 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days.
45937814|NCT04631484|Drug|Placebo|20 ml of 0.9% sodium chloride (2 ampoules of 10 ml each), added to 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days
45937815|NCT00173524|Behavioral|PharmacoEconomic Assessment|Collecting PE data.
46002537|NCT01356290|Drug|Cytarabine|16-30mg, intrathecal, twice weekly for two weeks out of every four weeks, alternating with intrathecal etoposide phosphate, 1 year
46002538|NCT01254903|Procedure|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation treatment.
46073929|NCT02816268|Other|Pulmonary vein isolation|
45654041|NCT03791593|Drug|Evolocumab|Evolocumab is a human IgG2 monoclonal antibody, it will add to patient treatment during 12 months.
45654042|NCT04732715|Behavioral|CaRE Course|Participants will complete the CaRE Course over a 6-8 week time period. The curriculum of the CaRE course will include topics addressing caregiving for a PLWD during a pandemic, navigating the healthcare system for a PLWD, guiding and managing daily life, and self care.
45654043|NCT03064243|Drug|apatinib|apatinib 500mg po. qd.
45654044|NCT05537831|Device|Ultrasound|The ultrasound will be used to assist with the delivery of a hematoma block in patients with distal forearm fractures.
45654045|NCT05543993|Drug|Bivalent COVID-19 Booster|Bivalent COVID-19 Booster by Pfizer or Moderna
45654046|NCT03765619|Drug|Aspirin|250 patients will be randomized to receive postoperative Aspirin.
45654047|NCT05698043|Drug|CKD-386(5)|Test
45654048|NCT05698043|Drug|D013, D326, D337|Reference
46073930|NCT00619957|Drug|Placebo tablet|one placebo once a week for two years followed by one 35 mg risedronate once a week for two years
46073931|NCT00619957|Drug|Risedronate|one 35 mg risedronate once a week for two years followed by one 35 mg risedronate once a week for two years
46073932|NCT02816190|Procedure|prone position|
46073933|NCT02815956|Device|percutaneous tibial nerve stimulation|
45654049|NCT05537675|Other|To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax|Measure SUVmean (Standard Uptake Value) and SUVmax on PET exams
45654050|NCT04979845|Other|Telerehabilitation|Patients will receive telerehabilitation sessions for 12 weeks including aerobic and strengthening exercises
45805325|NCT05922046|Device|Leap Motion Controller on flat display|The LMC is a device with a Universal Serial Bus (USB) device capable of detecting the movement of hands and fingers. It is small in size and you need to connect the USB device to the computer and place your hands above the LMC. First, training will be carried out with the Leap Motion Controller instrument for 5 minutes, for a presentation and interaction with it, in the initial meeting. From the second meeting, the service protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games, about 2 minutes of rest was adopted. They were chosen through the website www.leapmotion.com¸ in order to relate them to the functional movements of the upper limbs in daily life tasks.
45937816|NCT04731194|Behavioral|Performance-based financial incentive program|"Enhance policy awareness through verbal communication with patients, distributing picture-rich fliers to patients, and putting up large posters in public places of the villages.~Support patients' registration in the reimbursement system~Follow-up patients after the first, third, and sixth months after the start of the study, measuring blood pressure and blood glucose level. Encourage patients to purchase medications from public institutions and to take their medications on time.~Receive financial incentives based on performance in the amount of 3 RMB per patient enrolled (first month) and 5 RMB per patient (at third and sixth month) buying medications with reimbursement from the policy."
45937817|NCT00173641|Procedure|blood drawing|
46073934|NCT02815956|Device|Placebo|
46073935|NCT02815878|Behavioral|Enhance Wellness|A 6-month health promotion intervention which pairs participants with a wellness coach to identify and pursue a health-related goal of their choosing.
46073936|NCT02815800|Dietary Supplement|ETHNODYNE VISIO|
46073937|NCT04529304|Device|Bilateral Bispectral Index and EEG|"raw-EEG and spectrographic EEG-visualization based on the Medtronic Device Bilateral BiSpectral Index"
46073938|NCT00851149|Device|Sangvia blood sampling system|Blood collected from abdominal aortic repair patients are compared against blood collected from total hip replacement patients
45452690|NCT05257642|Other|REThink Game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
45452691|NCT05095064|Drug|Onivyde® + 5-FULV|Nanoliposomal irinotecan (Onivyde®) in combination with 5-fluorouracil and leucovorin (5-FU/LV)
45452692|NCT03952247|Device|Single Use Bronchoscopy for PDT|optical guidance of percutaneous tracheotomy is done by single use bronchoscopy
45937818|NCT00045981|Drug|ALT-711|
45937819|NCT00173719|Device|Standard cane|
45452693|NCT03952247|Device|Conventional Multi Use Bronchoscopy for PDT|optical guidance of percutaneous tracheotomy is done by conventional multi use bronchoscopy
45452694|NCT05627050|Device|An Online Augmented Reality (AR) Training Platform|The hardware system is based on camera depth sensor and combined with 3D human tracking technology and intelligent technology, to monitor, correct and record the user's whole body movements in real-time, and the users can follow the training program.
45452695|NCT01093859|Drug|PRX-105|Sterile solution for intravenous injection
45937820|NCT00056030|Biological|cetuximab|
45937821|NCT00056030|Drug|fluorouracil|
45937822|NCT00056030|Drug|leucovorin calcium|
45937823|NCT00056030|Drug|oxaliplatin|
45937824|NCT00173758|Procedure|co-culture of embryos and endometrial cells|
45937825|NCT00046020|Drug|Venlafaxine ER|
45937826|NCT00173875|Drug|Iressa|
45937827|NCT04605081|Drug|Naltrexone and Bupropion (NB) medication|NB medication will be taken daily in pill form.
45937828|NCT04605081|Other|Placebo|Placebo will be inactive and taken daily in pill form.
45937829|NCT00173953|Procedure|immune response|
45937830|NCT00407836|Biological|T cell vaccination|Approximately 10-20 million glutaraldehyde fixed CD4 responsive autologous T cells in 1-2 ml, per vaccine injection.
45937831|NCT00407836|Biological|T cell vaccination|Approximately 10-20 million autologous CD4 reactive T cells per each vaccine injection
45937832|NCT00407875|Procedure|Intensity Modulated External Beam Radiation Therapy|
45937833|NCT04599504|Drug|Lisdexamfetamine Dimesylate (Medication)|Medication will be taken daily in pill form.
46073939|NCT04519476|Drug|Selinexor|Selinexor (KPT-330) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.
46073940|NCT04519476|Drug|Lenalidomide|Immunomodulatory drug
46073941|NCT04519476|Drug|Methylprednisolone|Glucocorticoid, steroid
46073942|NCT02546011|Other|Fetal Heart Rate Monitor|Standard of care, not part of research
45452696|NCT03169244|Drug|Bupropion|Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
45654051|NCT04979845|Other|Video exercise|Patients will receive video instructions for home based exercises
45654052|NCT05699057|Behavioral|Suicide GROUP|CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains. Finally, we will To document the prevalence of tendency to suicide among medical students in the Egyptian Universities and analyse associated risk factors and any correlated determents.
45654053|NCT03062215|Behavioral|Space from Depression|Space from Depression programme (Yo puedo sentirme Bien -Spanish version) consists of seven modules of cognitive-behavioural therapy. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page.
46073943|NCT00961415|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3-week cycle
46073944|NCT00961415|Drug|cisplatin|75mg/m2 iv on day 1 of each 3-week cycle
45654054|NCT05543603|Drug|Lacer Clorhexidina Colutorio|15 ml 0,12% Chlorhexidine, one minute rinse
46073945|NCT00961415|Drug|pemetrexed|500mg/m2 iv on day 1 of each 3-week cycle
46073946|NCT00836329|Behavioral|Intensive Glucose Management|Participants in the intensive glucose management group will undergo strict management of their blood glucose levels with a target whole blood glucose level of 100-140 mg/dL preoperatively, intraoperatively, and postoperatively in the intensive care unit (ICU). Once meals are started, targets for glycemia management will be (a) fasting: 80-140 mg/dL, (b) postprandial: 140-180 mg/dL. Prior to hospital discharge, participants will receive an in-depth diabetes education session. After hospital discharge, participants will attend monthly study visits for 6 months so that study researchers can monitor their glycemia management.
45654055|NCT05543603|Drug|Lacer Clorhexidine 0.20% Colutorio|15 ml 0,2% Chlorhexidine, one minute rinse
45654056|NCT05543603|Drug|Gingilacer Encías Delicadas Colutorio|15 ml 0,10% cymenol + 0,10% zinc chloride, one minute rinse
45654057|NCT05543603|Drug|Distilled water|15 ml distilled water, one minute rinse
45654058|NCT04979923|Drug|Lidocaine|Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs
45654059|NCT05543525|Other|Echocardiography|Transthoracic echocardiography
46073947|NCT00836329|Behavioral|Traditional Glucose Management:|Participants will receive traditional management of blood glucose levels while in the hospital. They may receive insulin several times a day, based on the results of glucose monitoring.
46073948|NCT04237662|Procedure|Root Instrumentation|Instrumentation of the root surface in order to achieve debridement
46073949|NCT04237662|Device|Enamel Matrix Derivative application|Enamel Matrix Derivative will be applied in the sites with at least 6 mm of pocket depths
46073950|NCT02815488|Drug|CHF6297 (Part 1 - SAD)|Single doses of CHF6297 at each period (for up to 3 periods per subject)
45654060|NCT05543525|Other|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing
45654061|NCT04434937|Drug|parsaclisib|parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits
45805326|NCT05922033|Drug|Patient-led Insulin (intervention group)|Individuals randomized to this arm will initiate night-time insulin of 10 units. The type of basal insulin will be left to the discretion of the provider with levemir or glargine preferred over NPH. On day 0 of initiation of insulin, the patient will initiate night-time (or prior to sleep if alternate sleep schedule) insulin of 10 units (glargine, detemir, or NPH). Patient will check their fasting blood glucose in the morning and record their values. If the value is below 70 they will decrease their insulin dosage that night by 2 units; if the value is above 95 they will increase their insulin dosage that night by 2 units; and if the value is between 70 and 95, they will maintain the same insulin dosage that night. The patients will continue this algorithm for the remainder of the pregnancy. If the patient does not have a fasting blood glucose, the patient will maintain the dose of basal insulin at the prior dose.
45805327|NCT05922033|Drug|Provider-led Insulin (standard care)|Individuals randomized to this arm will receive standard care and titration of insulin will be determined by the individual providers.
45805328|NCT05922020|Other|Oxygen gas|Administration of Oxygen by inhalation
45805329|NCT05922007|Other|Validation of the Questionnaire|Validation of the Czech version of the Patterns of Activity Measures-Pain scale (POAM-P/CZ)
45805330|NCT05922007|Other|Prospective quantitative study - questionnaire survey|A questionnaire survey will be carried out using the questionnaire set three times
45805331|NCT05921994|Other|secukinumab|Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC.
45937834|NCT04599504|Other|Placebo|Placebo will be inactive and taken daily in pill form.
45654062|NCT04519411|Diagnostic Test|Transpulmonary pressure measurements|Transpulmonary pressure measurements
45654063|NCT03714997|Procedure|Walking training|Practice of walking training in variable contexts, including multiple tasks and environments specific to the patients' deficits and community walking goals.
45937835|NCT00173992|Behavioral|Balance and Exercise|
45937836|NCT00056069|Other|questionnaire administration|Participants complete questionnaires regarding caregiver demands and family information over 25-30 minutes within 3-4 months of the initiation of the child's treatment and at the completion of the first year of the child's treatment.
45937837|NCT04582422|Other|"Touch Therapy"|During the waiting process, first follow the touch flow chart and perform the touch in the waiting area for 10 minutes. When visiting the treatment chair, the companion will be asked to touch the child's unilateral hand for 5 minutes during the consultation process. A small chair is provided to accompany the child for a total of 15 minutes. The two groups will use the chip tool again after the consultation
45937838|NCT00174226|Drug|Atomoxetine|
45937839|NCT00174226|Drug|Buspirone|
45937840|NCT00056147|Drug|denufosol tetrasodium (INS37217)|
45937841|NCT00174304|Drug|Amlodipine/atorvastatin single pill|
45937842|NCT00174343|Drug|exemestane (Aromasin®)|
45654064|NCT03706885|Drug|Sustiva Pill|One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks
45654065|NCT01665599|Drug|Testosterone gel (FE 999303)|
45654066|NCT04979221|Drug|Cyproheptadine|Cyproheptadine 8mg three times a day during 10 days
45654067|NCT04503109|Device|Nalu Neurostimulation System|The Nalu Neurostimulation System is a Spinal Cord Stimulation system
45654068|NCT05697887|Dietary Supplement|Ketogenic diet|The ketogenic diet (KD) has been shown as an effective alternative for patients with drug-resistant epilepsy
45654069|NCT05697809|Drug|OXU-001|Suprachoroidal sustained release dexamethasone acetate
45654070|NCT05697809|Device|Semi-automated suprachoroidal illuminated microcatheter|Ophthalmic administration device
45654071|NCT05697809|Drug|Ozurdex® Ophthalmic Intravitreal Implant|Ophthalmic dexamethasone intravitreal implant
45654072|NCT01671085|Drug|LY3015014|Administered SQ
45654073|NCT01671085|Drug|Placebo|Administered SQ
45654074|NCT05537363|Other|Health education|Participants in the control group will receive health educational guidelines. Guideline contents include home-based exercise program, nutrition recommendations, and fall prevention education.
45654075|NCT05537363|Other|Multicomponent training|Multicomponent exercises will be designed according to the results of Part I of our study. Results of Part I of this study will determine the contributing factors of agility, such as muscle strength, endurance, and cognitive function. A physical therapist will train the participants 3-4 exercises (3-4 factors) in each session. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
45654076|NCT05537363|Other|Agility training|The agility-based task-specific exercises will be conducted in this group and will incorporate stop-and-go, change in direction, change in velocity, acceleration and deceleration training. There are four training configurations with 3 levels of difficulty, which will be manipulated by increasing speed, distance, number of repetitions, number of directions, congruency, and/or complexity of the task, or by decreasing the number and duration of the rest intervals. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
45805332|NCT05921981|Behavioral|Multisensorial Stimulation|Multisensory stimulation in newborns involves the deliberate and simultaneous activation of multiple sensory modalities to provide sensory experiences that promote development and enhance learning. Newborns are naturally inclined to explore and make sense of their environment through their senses, including touch, sight, sound, taste, and smell.
45805333|NCT05921981|Behavioral|White Noise|White Noise
45805334|NCT05921968|Drug|Intravenous iron sucrose|"200 mg elemental iron in 100 ml 0.9 NaCl intravenous over 20 -30 minutes daily up to the total dose)~o The dose of the total iron sucrose to be administrated was calculated from the following formula: Total dose required = weight (kg) x (target Hb in g\dL - actual Hb in g\dL) x 2.4 + 500 mg rounded up to the nearest multiple of 100 mg"
45805335|NCT05921968|Drug|Lactoferrin|100 mg twice daily orally before breakfast and dinner
45805336|NCT05921955|Device|Optiflow high-flow nasal cannula system|Using the Optiflow high-flow nasal cannula system to supply oxygen for maternal.
45805337|NCT05921942|Drug|Metformin|500 mg twice daily or 1000 mg once daily
45805338|NCT05921929|Drug|Fluoroethylnormemantine (FENM)|Single ascending oral dose administration according to the following scheme: 20, 40, 80, 120-160, 200-240, 260-320mg/kg (six dose levels). The three upper dose levels to be administered (120-160, 200-240, 260-320mg/kg) will be precisely determined with the data collected at the end of the first three dose levels administered.
45805339|NCT05921916|Drug|MBF-018 oral capsules|MBF-018 oral capsules PPAR gamma receptor partial agonist
45805340|NCT05921916|Drug|Placebo oral capsule|Placebo oral capsule solid microcrystalline cellulose
45805341|NCT05921903|Biological|RSVPreF3 OA Investigational Vaccine|The investigational vaccine will be administered intramuscularly as 1 dose to RSV_IC_1 and RSV_HA groups, and 2 doses to RSV_IC_2 group).
45805342|NCT05921890|Drug|GS3-007 oral liquid|The dosage was calculated according to body weight, once a day or twice a day.
45805343|NCT05921877|Diagnostic Test|venous sampling|venous sampling
45937843|NCT04556214|Procedure|Liver Transplant|Liver Transplant
45937844|NCT00174421|Drug|Treatment with Genotropin in different dosages|
45937845|NCT00174499|Drug|2 mg nicotine gum|2 mg nicotine gum
45937846|NCT00174499|Drug|4 mg nicotine gum|4 mg nicotine gum
45937847|NCT00174538|Drug|Codeine (30 mg)|
45937848|NCT00174577|Drug|Risperidone|
45937849|NCT00046137|Drug|teriparatide|
45937850|NCT00046137|Drug|raloxifene|
45937851|NCT00046137|Drug|placebo|
45937852|NCT00056225|Drug|Folate|
45937853|NCT00056225|Drug|Vitamin B6|
45937854|NCT00056225|Drug|Vitamin B12|
45937855|NCT00174616|Drug|Oxaliplatin, capecitabine, radiotherapy|"Oxaliplatin 50mg/m² I.V. 2 hours weekly x 5 doses~Capecitabine 825mg/m² P.O. B.I.D. daily x 5 days x 5 weeks~Radiotherapy 45 Gy total (1.8Gy/dose) 25 fractions daily x 5 days x 5 weeks"
45937856|NCT00174655|Drug|Doxorubicine + docetaxel sequential|doxorubicin 75 mg/m² i.v. day 1, q 21 days for 3 cycles, followed by docetaxel 100 mg/m² i.v., 1 hour infusion, day 1, q 21 days for 3 cycles, followed by CMF for 3 cycles
45937857|NCT00174655|Drug|doxorubicine + cyclophosphamide sequential|doxorubicin 75 mg/m² i.v. day 1 q 21 days for 4 cycles, followed by CMF (C: cyclophosphamide 100 mg/m² orally days 1-14, M: methotrexate: 40 mg/m² i.v. days 1 and 8, FU; 5-fluorouracil: 600 mg/m²) i.v. days 1 and 8, q 28 days for 3 cycles
45937858|NCT00174655|Drug|doxorubicine + cyclophosphamide combined|doxorubicin 60 mg/m² i.v. + cyclophosphamide 600 mg/m² i.v., day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
45937859|NCT00174655|Drug|doxorubicine + docetaxel combined|doxorubicin 50 mg/m² i.v. + docetaxel 75 mg/m² i.v. 1 hour infusion (1 hour after doxorubicin), day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
45937860|NCT00174694|Drug|Telithromycin|
45937861|NCT00174733|Drug|Ciclesonide (XRP1526)|
45937862|NCT00056264|Drug|Infliximab|
45937863|NCT00174772|Drug|docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy|docetaxel (75mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemoradiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy
46002539|NCT01047540|Drug|AIC316|Oral administration
45654077|NCT03063931|Drug|Magnesium: Magnésium UPSA Action Continue®|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
45805344|NCT05921864|Other|Passive heat exposure|Participants will be exposed to heat in a chamber.
45805345|NCT05921864|Other|Active heat exposure|Participants will participate to a 6-hour run.
45805346|NCT05921851|Other|no intervention|no intervention
45805347|NCT05921838|Other||
45805348|NCT05921825|Diagnostic Test|Red cell distribution width|Blood will be drawn from the peripheral vein, arterial or a central catheter. This procedure will be done at diagnosis, 3 ,7, 14 and 21 days of sepsis
45654078|NCT03063931|Drug|Placebo: Lactose|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
45654079|NCT03980483|Biological|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
45654080|NCT03980483|Drug|Tofacitinib 5 mg|Tofacitinib cap (over encapsulated 5mg tablet) to be administered orally.
45805349|NCT05921825|Diagnostic Test|lactate albumin ratio measurement|Blood will be drawn from the peripheral vein, arterial or a central catheter. This procedure will be done at diagnosis, 3 ,7, 14 and 21 days of sepsis
45805350|NCT05921812|Diagnostic Test|real time pcr|evaluate the expression of certain circulating microRNAs by real time pcr
45805351|NCT05921799|Procedure|Blood specimen collection|Routinely collect citrate blood and native blood from patients as required by their condition.
45805352|NCT05921786|Device|Electrophysiological system and multiphoton microscopy|Electrophysiological system is used for examining voltage variation in biological samples. And multiphoton microscopy is a common type of nonlinear optical microscope.
45937864|NCT00174772|Drug|docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin|docetaxel (20mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
45937865|NCT00174811|Drug|telithromycin (HMR3647)|
46073951|NCT02815488|Drug|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF6297 at each period (for up to 3 periods per subject)
46073952|NCT02815488|Drug|CHF6297 (Part 2 - MAD)|Twice daily doses of CHF6297 for 7 days
46073953|NCT02815488|Drug|Placebo (Part 2 - MAD)|Twice daily doses of placebo matching CHF6297 for 7 days
45937866|NCT00174850|Drug|Gaitril|
45937867|NCT02963779|Drug|LY2775240|Administered orally
45937868|NCT02963779|Drug|Placebo|Administered orally
45937869|NCT02963779|Drug|Apremilast|Administered orally
45937870|NCT00056303|Behavioral|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up is a 10 session in-home intervention that targets synchrony, nurturance, and calming parental behavior.
45937871|NCT00056303|Behavioral|Developmental Education for Families|Developmental Education for Families is a 10-session in home intervention that targets children's cognitive development.
45937872|NCT00174889|Drug|Pregnenolone|
45937873|NCT00046176|Drug|abacavir/lamivudine|
45937874|NCT00046176|Drug|abacavir|
45937875|NCT00046176|Drug|lamivudine|
45937876|NCT00174928|Drug|Lansoprazole|Lansoprazole 0.5 mg/kg/day suspension, orally, once daily for up to 5 days.
45937877|NCT00174928|Drug|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
45937878|NCT00175045|Drug|Lansoprazole|Lansoprazole 30 mg, intravenous injection, once daily for up to 7 days.
45937879|NCT00175045|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 7 days.
45937880|NCT00056381|Drug|Anidulafungin|
45937881|NCT00175084|Behavioral|Comparison of dietary protein amino acid profile|Healthy adults over 50 years of age (men and postmenopausal women) will be assigned to one of two diets differing in lysine to arginine ration (0.7 vs. 1.4) for a 5 week period and then switched to the alternate diet, with a 2 to 4-week washout period, in a randomized crossover design. Blood samples will be collected three times in the fasted state and once 4-hours after the evening meal during the last week of each dietary period of measurement of concentration of plasma lipids, lipoproteins, apolipoproteins, arginine, C-reactive protein, nitrites/nitrates, homocysteine, lecithin-cholesterol acetyltransferase (LCAT), cholesteryl ester transfer protein (CETP), and LDL-receptor messenger ribonucleic acid (mRNA) expression.A 24-hour urine sample will be collected at the end of each phase to measure F2-isoprostanes as an indicator of whole body oxidation.
45937882|NCT00175123|Drug|Botulinum A toxin|Intravesical injection. 12 IE/kg b.w.
45937883|NCT00175240|Behavioral|Evidence summaries endorsed by local opinion leaders|
45937884|NCT00175279|Behavioral|Opinion leader generated and endorsed evidence summaries|
45937885|NCT00175318|Behavioral|Motivational Interviewing|Beginning at 12 months of age, regular application of fluoride varnish will be an option that a mother in the MI group may choose for her child. Control families will receive dental health information from a pamphlet, and will have access to fluoride varnish at local dental clinics.
45937886|NCT00175357|Drug|Methadone|The dose of the drug will be determined by a physician. The oral drug will be administered 1 dose per days, 7 days per week.
46073954|NCT02815488|Drug|CHF6297 (Part 3)|Twice daily doses of CHF6297 for 14 days
46073955|NCT02815488|Drug|Placebo (Part 3)|Twice daily doses of placebo matching CHF6297 for 14 days
46073956|NCT02815488|Drug|CHF6297 (Part 4)|Twice daily doses of CHF6297 for 7 days
45654081|NCT03980483|Drug|Placebo to GSK3196165|Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/pre-filled syringe (PFS) to be administered SC.
45654082|NCT03980483|Drug|Placebo to tofacitinib|Placebo cap (containing lactose) to be administered orally.
45654083|NCT03980483|Drug|Methotrexate|Stable oral dose of MTX as SoC.
45654084|NCT03980483|Drug|Folic (or folinic) acid|Folic (or folinic) acid >=5 mg/week.
45654085|NCT04979455|Other|Core temperature monitoring|Core temperature will be monitored on the day of exercise
45654086|NCT04979455|Behavioral|Questionnaires|Questionnaires will be completed at baseline and on the day of exercise
45654087|NCT04979455|Other|Heart rate monitoring|Heart rate will be monitored on the day of exercise
45654088|NCT04979455|Other|Urine collection|Urine samples will be collected at baseline and on the day of exercise
45654089|NCT04979455|Other|Sleep monitoring|Sleep will be monitored at baseline and on the day of exercise
45805353|NCT05921773|Device|AI-fNIRS neurofeedback device|The device, with AI-fNIRS signals serving as brain monitor to indicate the level of anxiety, provides mindfulness training through visual and auditory cues to help participants modulate their brain activity, and thus alleviates anxious states.
45805354|NCT05921773|Device|AI-fNIRS neurofeedback device with sham signals|The sham control consists of playbacks of someone else's real AI-fNIRS neurofeedback and will be provided 3 times a week, for a total of 4 weeks.
46073957|NCT02815488|Drug|Placebo (Part 4)|Twice daily doses of placebo matching CHF6297 for 7 days
46073958|NCT00851227|Drug|conivaptan hydrochloride|intravenous
46073959|NCT00850837|Drug|Acidform Lubricant|5 g application of acid buffered gel (pH = 3.5)
46073960|NCT00850837|Drug|HEC gel|5 g application of hydroxyethylcellulose gel
46073961|NCT00850915|Other|community IPT|"In the intervention group, the household contacts of enrolled TB/HIV co-infected patient are visited at home by community health workers. Those contacts providing informed consent and considered fit (assessed by simple questionnaire) are assumed not to have active TB and are eligible for IPT. They are offered isoniazid at 300mg (5 mg per Kg for children) once daily for 6 months, regardless of their HIV-status.~In the control group, in line with routine care, eligible index cases are requested to send their contacts to the clinic for evaluation. Contacts presenting to the clinic will be screened for TB and receive IPT, if under 5 years and when active TB is ruled out as per the current national guidelines.~All contacts (both intervention and control group) are followed up monthly to assess occurrence of symptoms suggestive of TB."
45654090|NCT04979455|Other|Blood collection|Blood samples will be completed at baseline
45654091|NCT04979455|Other|Saliva collection|Saliva samples will be collected at baseline and on the day of exercise
46073962|NCT02811276|Other|Diet|The High-Protein Diet Group will receive a eucaloric diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement (Almased®) for one and a half day. Participants will consume 1 gram ± 0.1 of Almased® per kg of body weight mixed with linseed oil and skim milk in their breakfast, lunch and dinner. Two snacks (afternoon and evening) composed of 1 gram ± 0.1 of Almased® per kg of body weight mixed with vegetable juice and linseed oil will also be provided.
46073963|NCT03365609|Drug|triple therapy|Omeprazole+Amoxicillin+Clarithromycin
45654092|NCT04979455|Other|Throat swab collection|Throat swab samples will be collected at baseline and on the day of exercise
46073964|NCT03365609|Drug|sequential therapy|the first 7 days : Omeprazole+Amoxicillin, the last 7 days: Omeprazole+Clarithromycin+Metronidazole
46073965|NCT03365609|Drug|bismuth quadruple therapy|Omeprazole+Amoxicillin+Metronidazole+Colloidal Bismuth Subcitrate
46073966|NCT03365609|Drug|concomitant therapy|Omeprazole+Amoxicillin+Clarithromycin+Metronidazole
45805355|NCT05921760|Drug|Ivosidenib|ivosidenib taken once daily
45805356|NCT05921760|Drug|Recommended Combination Dose (RCD) of ivosidenib|The RCD of ivosidenib taken once daily
46073967|NCT05636904|Drug|prostaglandin F2a analogue in vehicle solution high dose|Topical treatment for 24 weeks
45805357|NCT05921760|Drug|Nivolumab|Nivolumab taken by intravenous infusion
45805358|NCT05921760|Drug|Ipilimumab|Ipilimumab taken by intravenous infusion
45805359|NCT05921747|Other|Standard core stability exercise program|The core stability exercises included Bridging, Pelvic rotation, Abdominal Tuck in, Knee to chest and Squatting. Pre and post measurement will be taken before and after the session.
45805360|NCT05921747|Device|Off-the-shelf virtual reality system|HTC Vive (HTC Corporation, Bellevue, WA) VR Head-Mounted Display (110º field of view, 1080 × 1200 pixels/eye, 90 Hz refresh) along with the Vive hand controllers and trackers to provide an immersive VR experience. The Vive Tracker can be used to track limb and trunk position and motion while in a VR experience. This setup will be paired with a gaming computer with the power to run a VR experience at a high frame rate to mitigate the risk of motion sickness. KVET™( Karuna Virtual Embodiment Training) consists of 10-30 minute sessions of exercises in an embodied VR experience.
45937887|NCT00175357|Drug|Diamorphine hydrochloride|The dose of the drug will be determined by a physician. The injected drug will be administered up to 3 doses per day, 7 days per week.
45937888|NCT00046254|Drug|Zoledronic Acid|
45937889|NCT00175396|Procedure|Androgen suppression, radiotherapy|Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by an external beam radiation boost lasting 3.2-4 weeks (32 Gy in 16 equal fractions).
45937890|NCT00175396|Procedure|Androgen suppression, radiotherapy, iodine 125 brachytherapy|Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by iodine 125 brachytherapy carried out 14-25 days after the last external beam treatment.
45937891|NCT00056459|Drug|Vatalanib|
45937892|NCT00175435|Biological|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator
46073968|NCT05636904|Drug|prostaglandin F2a analogue in vehicle solution low dose|Topical treatment for 24 weeks
46073969|NCT05636904|Drug|active ingredient-free vehicle solution to DLQ01|Topical treatment for 24 weeks
46073970|NCT05636904|Drug|Minoxidil 5% Topical Solution|Topical treatment for 24 weeks
46073971|NCT00836485|Drug|Ketotifen 4.0% Patch|This investigational drug is a transdermal patch indicated to treat allergic conjunctivitis. Application is intended for overnight wear between 8-10 hours.
46073972|NCT00836485|Drug|Placebo|The control is a placebo patch that contains only the inactive ingredients of ketotifen.
46073973|NCT00836485|Drug|Olopatadine 0.2%|1 gtt/eye on two separate occasions
45654093|NCT04979455|Other|Stool collection|Stool samples will be collected at baseline and on the day of exercise
45654094|NCT03621631|Behavioral|Optimized Tai Chi intervention|Optimized Tai Chi intervention
45654095|NCT03621631|Behavioral|Traditional Tai Chi intervention|Traditional Tai Chi intervention
45654096|NCT03611881|Behavioral|Counseling|4 or 8 weeks of behavioral counseling support to promote smoking cessation.
45654097|NCT03611881|Drug|Nicotine patch|2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.
45654098|NCT03611881|Behavioral|Community Resource|Counselor-facilitated referral to a community-based program to address social needs.
45654099|NCT03063775|Device|BioOss® + Mucograft Seal®|Placement of BioOss®-Collagen into the extraction socket. The Mucograft Seal® Membrane is then applied to the socket.
45937893|NCT00175435|Biological|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
45937894|NCT00175435|Biological|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
45937895|NCT00175474|Procedure|knee surgery|
45937896|NCT00175513|Drug|Valacyclovir (Valtrex)|
46002540|NCT01047540|Drug|AIC316|Oral administration
45937897|NCT00407992|Device|Occipital nerve stimulation ON|Implant of an occipital nerve stimulator switched ON
45654100|NCT03063775|Other|FGG + Bio-Oss®|Placement of BioOss®-Collagen into the extraction socket. The FGG is then attached to the socket.
45654101|NCT03063775|Other|FGG + Gelatine sponge (Spongostan®)|Placement of a Gelatine sponge into the extraction socket, then attaching the FGG to the socket.
45654102|NCT03063775|Device|Spongostan®+ Mucograft® Seal|Placement of a Gelatine sponge into the extraction socket, then attaching the Mucograft® Seal Membrane to the socket
45654103|NCT03063541|Drug|Acetylsalicylic acid|100 mg daily as one tablet
45654104|NCT03063541|Other|intensive blood pressure control|Patients are encouraged to seek any therapy to have a systolic blood pressure of 120 or below. They will be provided with a blood pressure measurement device and are advised to control blood pressure daily.
45937898|NCT00407992|Device|Occipital nerve stimulation off|Implant of an occipital nerve stimulator switched OFF
45654105|NCT04978753|Drug|Anlotinib|"Anlotinib: 12mg/time (BSA≥1.6 m2) or 10mg/time (BSA<1.6 m2), once a day orally, taking two weeks and stopping for one week;~Almonertinib: 110mg, orally once a day;"
45805361|NCT05921734|Procedure|AF-termination Group|Each center completes the ablation according to the above ablation procedure. The choice of ablation strategy is not restricted, but efforts should be made to achieve termination of AF during the ablation procedure. If cannot terminate AF for safety or other reasons involving difficulties to remap AFEGM or creating a complete conduction block despite the operator's best efforts, then direct current conversion (DCCV) was performed.
45937899|NCT00175552|Behavioral|Psychotherapy Training|
45937900|NCT02970474|Device|Conventional Bolus|Conventional bolus is mold made from Super stuff powder, superflab, or paraffin wax and made to fit the contours of the body.
45937901|NCT02970474|Device|3D Printed Bolus|The 3D printed bolus is also made from Super stuff powder, superflab, or paraffin wax, however it uses CT scans to print a molded bolus from the images of the participant's body.
45937902|NCT00175591|Procedure|Administration of a femoral nerve block (bupivacaine HCL)|No details specified
45937903|NCT00175630|Procedure|Administration of a femoral nerve block (bupivacaine HCL)|See Detailed Description
45937904|NCT00175669|Drug|Botox injections|Data not known.
46073974|NCT00836485|Drug|Artificial tears|1 gtt/eye on two separate occasions
46073975|NCT02860871|Other|infrared spectroscopy|
46073976|NCT02814240|Other|NMR|
46073977|NCT02814240|Biological|Blood samples|
46073978|NCT02814240|Other|fibroscan|
45654106|NCT03545737|Other|Measurement|The distances between the midpoint of the thyroid cartilage to suprasternal notch base on body surface measurement add the distance between suprasternal notch to carina of trachea according to chest CT
45654107|NCT03545737|Other|Formula|The formula base on patient's height as a guide for the intubation of a Left-sided Double-lumen tube
45654108|NCT03063853|Other|Removal of surgical clips at day 4 post operative vs day 8 post operative|Removal of surgical clips at day 4 post operative vs day 8 post operative
45654109|NCT03063853|Procedure|Elective cesarean delivery|non emergent elective cesarean delivery
45654110|NCT03062761|Other|Infant Formula with prebiotics|Intervention group: Partially hydrolysed whey protein based infant formula containing prebiotics.
45654111|NCT03062761|Other|Standard Infant Formula|Control group: Intact cow's milk protein based infant formula containing prebiotics
45654112|NCT03063151|Diagnostic Test|Surface Electromyography (EMG)|
45654113|NCT04978597|Drug|Opicapone 50 mg|Capsule, 50 mg, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
45654114|NCT04978597|Drug|Placebo|Capsule of to matching placebo, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
45654115|NCT03490513|Drug|anastrozole (1 mg/day)|Participants will take Anastrozole 1mg per day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.
45654116|NCT03490513|Drug|Placebo|Participants will take a placebo tablet every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.
45654117|NCT03467191|Drug|Alcohol|target BAC .08%
45654118|NCT03467191|Other|Placebo|placebo beverage
45937905|NCT00056537|Drug|ABR-217620|Starting dose: 0.5 mcg/kg; subsequent doses: individual, based on pre-treatment level of anti-SEA/E-120, body weight, and toxicities observed in prior patients on study; IV; one bolus injection each day for 5 consecutive days; up to 3 cycles
45937906|NCT00408031|Drug|D-cycloserine|D-cycloserine (DCS , Seromycin) is a broad spectrum antibiotic, in use for over thirty years against tuberculosis, that acts as a partial agonist at the NMDAR-associated GLY site.
45937907|NCT00175747|Drug|Inhaled Budesonide 800 µg twice daily|
45937908|NCT04493619|Drug|PLX2853|PLX2853 tablets
45937909|NCT04493619|Drug|Carboplatin|Carboplatin IV injection, 5 mg•min/mL
45937910|NCT00175864|Drug|Seletracetam (ucb 44212)|
45937911|NCT00056576|Drug|Zonisamide|
45937912|NCT00175903|Drug|Levetiracetam|Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
45937913|NCT00175903|Drug|Carbamazepine Controlled Release (CBZ-CR)|Daily dose of 600-1600 mg CR oral tablets, 200 mg and 400 mg twice daily.
45937914|NCT00175903|Drug|Valproate Extended Release|Daily dose of 1000-2000 mg ER oral tablets, 300 mg and 500 mg twice daily.
45937915|NCT00056654|Drug|Leuprolide acetate|45 mg Intramuscular injection 6 month depot formulation
45937916|NCT00175981|Drug|sildenafil, fluvoxamine|
46002541|NCT01047540|Drug|AIC316|Oral administration
46002542|NCT01047540|Drug|AIC316|Oral administration
46073979|NCT00851305|Device|Endomicroscope (Pentax, Tokyo, Japan)|A Pentax EC3870K endomicroscope which can produce conventional white light endoscopic images and confocal images at the same time with a optical slice thickness of 7 μm, a lateral resolution of 0.7 μm, a scanning depth of 0 to 250 μm, a pixel density of 1024×512 pixels (at an image acquisition rate of 1.6 frames/second)，and a field of view of 475 μm×475 μm.
45805362|NCT05921734|Procedure|Prespecified-ablation Group|Each center completes the prespecified ablation according to the above ablation procedure. Although there is no restriction on the choice of ablation strategy, Ablation must be performed following the PVI plus strategy, which can be combined with one or more additional ablation procedures, but each ablation must achieve its own endpoints, such as bidirectional block of linear damage, posterior wall isolation, etc. After completing the preset ablation steps, DCCV will be performed. If AF is terminated after or during ablation, it is also considered the endpoint of ablation in this group, but the preset ablation steps must be completed.
46073980|NCT00851305|Device|Gastroscopes (Pentax, Tokyo, Japan)|Conventional white light gastroscopes (Pentax EG-2940 gastroscopes)
46073981|NCT05647590|Procedure|Chemotherapy|3 months of platinum doublet chemotherapy (cDDP / CBDCA + Pemetrexed, NVB)
46073982|NCT05647590|Procedure|Radiotherapy (RT) + Stereotactic Body Ratio Therapy (SBRT)|"RT to primary tumor + SBRT to all oligometa (max. 10 intra / extracranial lesions, intracranial SD / PR)~SBRT V < 100 ml, if technically possible fractionation RT (40 - 50 Gy / 16 - 20 fractions), SBRT (30 Gy / 1 fraction, 50 - 60 Gy / 3 - 5 fractions) 3 - 6 weeks … maintenance"
46073983|NCT05647590|Procedure|Maintenance chemotherapy|Maintenance chemotherapy will follow 3-6 weeks after RT.
46073984|NCT00963599|Drug|Comparator: montelukast/loratadine|montelukast 10 mg/loratadine 10 mg tablet taken once daily at bed time for 2 weeks
45805363|NCT05921721|Device|EOS|This modality simultaneously captures biplanar radiographs (anteroposterior and lateral images) through the whole-body slot scanning with patients in standing position with ultralow irradiation
45805364|NCT05921708|Other|Assessment1|International Physical Activity Questionnaire (IPAQ) (Short)
45805365|NCT05921708|Other|Assesment2|Physical Appearance Comparison Scale-Revised (PACS-R)
45805366|NCT05921708|Other|Assessment3|Sociocultural Attitudes Towards Appearance Questionnaire -4-Revised (SATAQ-4R)
45805367|NCT05921708|Other|Assessment4|Body-Cathexis Scale (BCS)
45805368|NCT05921708|Other|Assessment5|Mobile Health, Exercise Preferences and Social Media Questionnaire
46073985|NCT00963599|Drug|Comparator: montelukast|montelukast 10 mg tablet taken once daily at bed time for 2 weeks
46073986|NCT00963599|Drug|Comparator: loratadine|loratadine 10 mg tablet taken once daily at bed time for 2 weeks
46073987|NCT00963599|Drug|Comparator: placebo|placebo tablet taken once daily at bed time for 2 weeks
45452697|NCT03169244|Drug|Placebo Oral Tablet|Placebo will be initiated on Day 1 and continue throughout the course of the study.
45452698|NCT01099163|Dietary Supplement|Tonalin SG1000T FFA|
45452699|NCT02486042|Drug|Omegaven|Infants will receive nutritional supplementation with omega-3 fatty acids (omegaven).
45654119|NCT04328779|Other|The multi-task overground walking training|The multi-task overground walking training group will undertake overground walking training while concurrently perform motor and cognitive tasks for 30 minutes per session, 3 times a week for 4 weeks.
45654120|NCT04328779|Device|The multi-task treadmill walking training|The multi-task treadmill walking training group will train the same set of motor and cognitive tasks while walking on the treadmill for 30 minutes per session, 3 times a week for 4 weeks.
45654121|NCT04328779|Other|Traditional rehabilitation|Traditional rehabilitation will train strength, balance, and gait for 30 minutes per session, 3 times a week for 4 weeks.
46073988|NCT00851383|Biological|Ad35-GRIN/ENV|This is a dose-escalation trial. Each group will receive the Ad35-GRIN/ENV vaccine at different dosage levels.
46073989|NCT00851383|Biological|Ad35-GRIN|This is a dose-escalation trial. Group D will receive the Ad35-GRIN vaccine.
46073990|NCT05636592|Drug|Statin|statins will be taken according to directions.
46073991|NCT02814006|Other|health educational video|visualization of health educational video
46073992|NCT04285385|Other|Lavender aromatherapy|0.10 ml of lavender essential oil
45452700|NCT02486042|Dietary Supplement|Standard lipids (primarily omega-6 fatty acids)|Infants will receive nutritional supplementation with standard intralipid, composed primarily of omega-6 fatty acids.
45452701|NCT00920764|Drug|Placebo for Atrasentan 0.2 mg/mL solution|10 mL oral solution, daily, 8 weeks
45452702|NCT00920764|Drug|0.25 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
45452703|NCT00920764|Drug|0.75 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
45452704|NCT00920764|Drug|1.75 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
45452705|NCT05376046|Biological|Erythrocytic parameters and thrombin generation assay measurement|Erythrocytic parameters and thrombin generation assay measurement
45805369|NCT05921695|Drug|Normal Saline infusion and Ringer lactate infusion|The heat stroke patients will be infused with different chlorine concentrations fluid during the emergency department.
45805370|NCT05921682|Other|observation|This study is an observational study. Patients will receive conventional cooling measures and organ function support.
45805371|NCT05921669|Behavioral|Provide breastfeeding education|Providing breastfeeding education within the first 24 hours after birth
45805372|NCT05921656|Other|Construction and evaluation of airway leakage risk model of patients with endotracheal tube|"Conduct statistical analysis on general information, respiratory data, tracheal catheter data, and cross-sectional area of the patient's airway to clarify the current status of airway leakage and related influencing factors.~Based on multivariate logistic regression, a line chart prediction model for predicting the risk of airway leakage in patients with tracheal catheters is constructed. The clinical efficacy of the prediction model is evaluated by using the area under the ROC curve, the Calibration scatter plot, and the DCA decision line, respectively, to assess its discrimination, calibration, and clinical practicality."
46002543|NCT01047540|Drug|Placebo|Oral administration
46002544|NCT00712751|Behavioral|questionnaires|"Participants randomized to the Usual Care arm will receive standard care . For women, this is defined as the care that participants who are not in the intervention receive; we will ask these participants what psychosocial care they are receiving to track usual care. For men, usual care will consist of a standardized referral to the men's Sexual Medicine Program at MSKCC and written information in the form of the American Cancer Society (ACS) booklet on Sexuality after Cancer. Individuals randomized to Usual Care will not receive any additional counseling sessions from the study interventionists until they are done with the follow up interviews and then it will be offered to them. Follow up questionnaires will assess all study participants at 4 and 8 months after baseline."
45654122|NCT03457675|Device|Activa PC+S DBS implant for OCD|"DBS system consists of the Activa PC+S Neurostimulation System:~Model 37604 Activa PC+S Neurostimulator Model 37087 DBS Extension Model 37441 Patient Programmer Model 8181 Sensing Programmer Model 8180 Sensing Programmer Software Nexus D2/D3 System Nexus D2/D3 Application Programming Interface (API) Dow Corning Medical Adhesive, Medtronic Part #080118 Model 3387/3389 DBS Leads Model 37022 External Neurostimulator Model 8840 N'Vision Clinician Programmer Model 8870 Application Card Model 37642 Patient Programmer Model 37092 Patient Programmer Antenna"
45654123|NCT03457675|Other|One Month Blinded Discontinuation Period|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
45654124|NCT03439345|Drug|Fenofibrate 145 mg|One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
45805373|NCT05921643|Device|verre bioactif 45S5 GlassBONE|All patients will benefit from surgical management for a first stage cholesteatoma in the operating room under general anesthesia. The surgical technique (closed technique) is the reference technique for the management of cholesteatoma in adults. It involves a cartilaginous removal to reconstruct the attical region. Then a filling material is used to fill the mastoid (GlassBONE™ or Bonalive™), and above all to stabilize the cartilaginous fragment to prevent a recurrence. The mastoid filler used is left to the discretion and habits of the surgeon.
45937917|NCT04420533|Behavioral|Behavior therapy alone|"reduction of fluid intake at specific times aimed at reducing urinary frequency when most inconvenient;~moderation of intake of caffeine or alcohol, which may have a diuretic and irritant effect, thereby increasing fluid output and enhancing frequency, urgency and nocturia;~use of relaxed and double-voiding techniques;~urethral milking to prevent post-micturition dribble;~distraction techniques such as penile squeeze, breathing exercises, perineal pressure, and mental tricks to take the mind off the bladder and toilet, to help control storage symptoms;~bladder retraining that encourages men to hold on when they have sensory urgency;~reviewing the medication and optimising the time of administration or substituting drugs for others that have fewer urinary effects (these recommendations apply especially to diuretics);~providing necessary assistance when there is impairment of dexterity, mobility or mental state;~treatment of constipation."
45937918|NCT04420533|Drug|Mirabegron 50 MG Extended Release Oral Tablet|Betmiga prolonged-release tablets (mirabegron) 50mg QDAC PO
45937919|NCT00176020|Drug|nicotinic acid|
45937920|NCT00176059|Drug|intravenous immunoglobulins (IVIG)|
45937921|NCT00176059|Procedure|kidney transplantation|
45937922|NCT00176098|Procedure|Hypnoanalgesia; Hypnotic shielding|
45937923|NCT02969993|Other|Questionnaires|evaluating the voice outcome by the fullfilment of the voice handicap index
45937924|NCT00176137|Procedure|preoperative radiochemotherapy|
45937925|NCT04413591|Behavioral|Community based combination HIV prevention package|The intervention compares the efficacy of a community-based comprehensive HIV/STI prevention package compared to standard of care (HIV testing, counseling, and referrals) among Female Sex Workers.
45937926|NCT00176176|Device|EEG|
45937927|NCT00176215|Procedure|survival failure of more than 20 %|
45937928|NCT00176293|Drug|dexamethasone|oral dexamethasone, 12mg BID on days 1, 2, 3, 4, & 5 of each 28-day cycle
45937929|NCT00176293|Drug|doxorubicin|Doxorubicin 50mg/m^2 I.V. on day 5
46073993|NCT04285385|Other|Sham aromatherapy|0.10 ml of mineral oil
45452706|NCT03034304|Biological|MASCT-I|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
45654125|NCT03439345|Drug|Placebo Oral Tablet|One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
45937930|NCT00056693|Drug|Sunitinib|Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity
45937931|NCT00176332|Drug|rosuvastatin|
45937932|NCT00176371|Behavioral|physical exercise|
45937933|NCT00176410|Drug|fluvastatin|40mg fluvastatin daily
45937934|NCT00176449|Drug|Bupropion SR|150mg twice a day (starting with 150mg once a day for three days)
45937935|NCT00176449|Drug|Placebo Oral Tablet|Comparable placebo
45937936|NCT00398450|Biological|recombinant interferon alfa-2b|
45937937|NCT00398450|Drug|azacitidine|
45937938|NCT00046293|Drug|Reopro|
45937939|NCT00046293|Drug|Retrovase|
46073994|NCT04016467|Other|Thoracic manipulation|High velocity, small amplitude thrust treatment to spine that elicits a neurophysiologic response.
45937940|NCT00176527|Biological|recombinant interferon alfa-2b|
46073995|NCT04016467|Other|Sham thoracic treatment|Hand placement on thorax without thrust.
46073996|NCT02811120|Other|venepuncture only|single venepuncture
45937941|NCT00176527|Drug|docetaxel|
45937942|NCT00176527|Drug|estramustine phosphate sodium|
45937943|NCT00176527|Drug|isotretinoin|
45937944|NCT00176527|Genetic|polyacrylamide gel electrophoresis|
45937945|NCT00176527|Genetic|protein expression analysis|
45937946|NCT00176527|Other|immunohistochemistry staining method|
45937947|NCT00176566|Drug|Lozenge Intake|of green tea lozenges weighing 6 grams each, containing 0.45 grams of green tea solids eight (8) times daily for 12 weeks to patients with oral leukoplakia compared to the administration of a lozenge that does not contain green tea (i.e. a placebo lozenge).
45937948|NCT00176683|Procedure|Capnography|device which measures carbon dioxide at intubation
45937949|NCT00398489|Biological|trastuzumab|
45937950|NCT00398489|Drug|anastrozole|
45937951|NCT00398489|Drug|cyclophosphamide|
45937952|NCT00398489|Drug|docetaxel|
45937953|NCT00398489|Drug|epirubicin hydrochloride|
45937954|NCT00398489|Drug|goserelin acetate|
45937955|NCT00398489|Drug|tamoxifen citrate|
46073997|NCT02862821|Other|HR-EEG|
46073998|NCT00851461|Drug|Goserelin|Goserelin 10.8 mg SC every 3 months
46073999|NCT00851461|Procedure|Electrophysiologic study|Nerve conduction study Electromyogram
46074000|NCT00851461|Procedure|tissue biopsy|skin and muscle biopsy before and after treatment every year
46074001|NCT04205136|Drug|Spironolactone|If tolerated and serum potassium <5.0 meq/L, the dose will be increased to 50 mg (2 pills) after 4 weeks. If serum potassium is >5.0 but less than 5.5 or creatinine >4.0 mg/dL, the dose will be adjusted to 25 mg every other day; if potassium levels ≥5.5 in a non-hemolyzed blood sample, the medication will be discontinued.
45452707|NCT03034304|Drug|Ifosfamide|2g/m2/d, intravenous drip for 30min. Administration is conducted for continuous 5 days. After 4 weeks, the above cycle is repeated for 6 continuous cycles
45452708|NCT03034304|Drug|PD1 antibody|200 mg/every two weeks ,four weeks is a cycle. Subjects were treated with MASCT-I combined with PD1 antibody until disease progression, MASCT-I intolerance or study completion. If PD1 antibody intolerance occurs, MASCT-I therapy alone will continue. MASCT-I and PD1 antibody are adminnistered according to their respective drug cycle without interfering with each other.
45654126|NCT03408379|Other|Collection of blood sample in aneurysm|"In case of an endovascular treatment :~A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the procedure, an intra aneurysmal blood sample (1mL) will be taken during the procedure and a blood sample (arterial) of 1 mL will be taken at the end of the procedure.~Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit.~In case of a surgery treatment :~A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the surgery.~A Tissue sample will be taken during the surgery~Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit."
45805374|NCT05921643|Device|verre bioactif S53P4 Bonalive|All patients will benefit from surgical management for a first stage cholesteatoma in the operating room under general anesthesia. The surgical technique (closed technique) is the reference technique for the management of cholesteatoma in adults. It involves a cartilaginous removal to reconstruct the attical region. Then a filling material is used to fill the mastoid (GlassBONE™ or Bonalive™), and above all to stabilize the cartilaginous fragment to prevent a recurrence. The mastoid filler used is left to the discretion and habits of the surgeon.
45805375|NCT05921630|Other|Education|Patient education before pulmonary function test
45805376|NCT05921617|Other|No intervention|Routine care
45805377|NCT05921604|Drug|Baclofen 10mg|which will include 50 patients scheduled for sleeve gastrectomy and will receive 10 mg oral baclofen 1 h before anesthesia.
45937956|NCT00398489|Procedure|adjuvant therapy|
45937957|NCT00398489|Procedure|conventional surgery|
45937958|NCT00398489|Procedure|neoadjuvant therapy|
45937959|NCT00398489|Radiation|radiation therapy|
45937960|NCT00046332|Drug|GW810781|
45937961|NCT00176722|Other|table tilt|One group randomized to table tilt. One group will be flat.
45452709|NCT03034304|Drug|Adriamycin|60mg/m2, from the first day of each cycle, it is used for 1-2 days, intravenous drip. Repeat the above cycle after 4 weeks, no more than 8 cycles
45452710|NCT03034304|Drug|Gemcitabine|1000 mg/m2, Intravenous drip for about 30 min, used on the first and eighth days of each cycle, and every 3-4 weeks as a cycle
45452711|NCT03034304|Drug|Cisplatin|70mg/m2, Use on the first day of each chemotherapy cycle, intravenous drip for 30-120 min, and every 3-4 weeks as a cycle;
45452712|NCT03034304|Drug|Carboplatin|5mg/ml/min, Use it on the first day of each chemotherapy cycle, intravenous drip for 30 minutes, and every 3-4 weeks as a cycle
45937962|NCT00176761|Drug|Interleukin-2 (IL-2)|
45452713|NCT00918814|Drug|LIPO-102|Subcutaneous Injection
45452714|NCT00918814|Drug|Placebo|Placebo
45452715|NCT00917020|Drug|Nasal CO2|As-Needed during the 14 day Treatment Period
45452716|NCT00917020|Drug|Inactive Placebo Gas|Placebo
45452717|NCT05052398|Drug|PSP NEURO SERUM|PSP NEURO SERUM is a topical product that contains a concentration of Paralytic Shellfish Toxins of 10 micrograms/mL of equivalent of Gonyautoxin 2/3. Each patient will apply 1 g of PSP NEURO SERUM in their hands.
45805378|NCT05921604|Drug|Gabapentin|which include 50 patients scheduled for sleeve gastrectomy and will receive 600 mg oral gabapentin 1 h before anesthesia.
45805379|NCT05921591|Drug|IRL201104|Lyophilised powder for reconstitution for IV dosing
45805380|NCT05921591|Drug|Placebo|Matching placebo for IRL201104
45805381|NCT05921578|Diagnostic Test|Pre-operative planning based on CBCT|Pre-operative planning based on CBCT
45937963|NCT00176956|Procedure|Skin Biopsy|Skin biopsy.
45937964|NCT00176995|Drug|15% Eflornithine Hdyrochloride|
45937965|NCT00177034|Drug|Narrow Band UVB Treatment|
45937966|NCT02963818|Other|Smartphone breathalyzer device/app use|Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.
46074002|NCT04205136|Drug|Placebo|Subjects assigned to the placebo group will take one pill for the first 4 weeks and a second pill for the remaining 8 weeks.
46074003|NCT00851539|Behavioral|Video|Behavioral Intervention Video
46074004|NCT02815332|Drug|BPX-01 1% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
46074005|NCT02815332|Drug|BPX-01 2% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
46074006|NCT02815332|Drug|BPX-01 Vehicle Topical Gel|Approximately 1 gram applied once daily for 12 weeks
46074007|NCT00923923|Behavioral|stress|compare levels of stress
46074008|NCT02811042|Device|Ambu AuraOnce|Oropharyngeal leak pressure was determined by closing the expiratory valve of the anaesthesia breathing system and a fixed gas flow of 3 l minute-1. The airway pressure at which an equilibrium was reached was noted (maximum allowed 40 cm H2O).
46074009|NCT02811042|Device|Ambu AuraGain|The airway tube view was scored using an established scoring system (4=only vocal cords visible; 3=vocal cords plus posterior epiglottis; 2=vocal cords plus anterior epiglottis; 1=vocal cords not seen)
46074010|NCT02811354|Drug|AZD9291|oral administration as a single daily dose of 80 mg
45937967|NCT02963818|Other|BAC estimator app use|Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.
45654127|NCT04977973|Behavioral|Self-guided programme on body image|"Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program."
45654128|NCT04977973|Behavioral|Self-guided programme on cooperation|"Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program."
45654129|NCT04285879|Device|Blood Flow Restriction using Delfi Personalized Tourniquet System|The Delfi Tourniquet System is designed to be used in conjunction with exercise. The system automatically determines the degree of occlusion and allows for safe regulation of pressure. Patients will then complete exercises with the use of this device following the Owens Recovery Science Protocol
45654130|NCT04977661|Drug|Vitamin E|Vitamin E is one of the body's most effective chain-breaking antioxidants that has shown to delay the pathogenesis of NASH.
45654131|NCT04977661|Drug|Ursodeoxycholic acid|is a metabolic by-product of intestinal bacteria and has been proven to be useful in the non-surgical treatment of cholesterol gallstones and primary biliary cirrhosis (PBC)
45654132|NCT04977661|Drug|Pentoxifylline|"it is a well-tolerated medication that improves blood~viscosity and erythrocyte rheological characteristics in individuals with peripheral vascular disease 20. In addition, PTX is a nonspecific phosphodiesterase inhibitor that increases cyclic adenosine monophosphate (cAMP) levels while decreasing TNF-a gene transcription"
45654133|NCT04977895|Diagnostic Test|Minimal residual disease (MRD) monitoring|Minimal residual disease (MRD) assay using IgH-V(D)J NGS and FCM
45654134|NCT04977427|Drug|Dextenza 0.4Mg Ophthalmic Insert|Dexamethasone inserted into lower punctum at the end of cataract surgery in order to control inflammation in the eye for the following 30 days after surgery.
45805382|NCT05921565|Behavioral|Interventional Behavioral Arm|All participants will receive a weight loss intervention that includes 8 coaching sessions guided by a workbook they will at their baseline visit. During these sessions, they will meet with a health coach individually for up to 10-15 minutes via telephone or video conference to learn and discuss weight loss strategies. Health coaches will provide feedback and instruction (by phone or email) based on progress and challenges encountered during the intervention. Participants will receive a weight management app custom-built for the research study. The app will display participants' dietary intake, physical activity, and weight data and goals on the smartphone, and participants will use the app to log dietary intake, physical activity, and weight daily.
45805383|NCT05921552|Behavioral|Resistance Training|Participants will be encouraged to perform approximately 30 minutes of resistance training exercises twice per week, until they undergo surgery. Exercises will be performed using resistance tubes (Bodylastics Inc) and the included accessories (handles and anchor straps) to perform resistance exercises. During Zoom sessions, certified exercise trainers will guide participants to utilize equipment to perform resistance exercises with proper form. Each groups resistance training session will span approximately 1 hour, including a brief warm-up, stretching, and 2 sets of ≥12 repetitions for each of 5 exercises: single arm chest press, single arm row, lateral raise, squat (or chair stand), and resistance tube deadlift.
45805384|NCT05921552|Behavioral|Aerobic Training|Participants will be encouraged to perform ≥30 minutes of moderate-intensity aerobic exercise on ≥3 days per week. Aerobic exercise intensity will be guided by heart rate zones, with participants exercising at 50-70% of their age-predicted maximum heart rate in bouts of at least 10 minutes at a time. Participants will be encouraged to gradually increase exercise intensity and duration until they are meeting the recommendation
45805385|NCT05921539|Drug|steroid hydrodilatation|ultrasound-guided steroid hydrodilatation
45805386|NCT05921539|Drug|axillary nerve injection|ultrasound-guided axillary nerve injection
45805387|NCT05921526|Diagnostic Test|Point-of-care lung ultrasound|Participants assigned to the intervention group will receive POCLUS which will be performed by one of the trained pediatricians. The procedure involves 12 views: two anterior views, two lateral views and two posterior views on both chest walls
45937968|NCT02963818|Other|Text messaging procedure|Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
45937969|NCT00423527|Drug|levetiracetam|Levetiracetam tablets 500 mg, total daily dose 3000 mg
45654135|NCT04977427|Drug|Prednisolone Acetate 1% Oph Susp|Standard Prednisolone taper following cataract surgery, QID for one week, followed by TID for one week, BID for one week, and QDaily for one week, then stop.
45937970|NCT00177112|Procedure|clean patient preparation for cystoscopy|
45654136|NCT03327805|Dietary Supplement|Choline|Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) for 28 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of choline bitartrate the evening before the third testing session to study its acute effects.
45654137|NCT03327805|Dietary Supplement|Placebo|Participants will consume 1000 mg (2x500 mg) of placebo for 28 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of placebo the evening before the third testing session to study its acute effects.
45654138|NCT04275895|Behavioral|Evaluation of different attention or/and postural activities|"The children, equipped with a head-mounted display (HMD), will indicate as quickly as possible the direction of a fish that can be surrounded by congruent or not flankers (Inhibition) and/or preceded by signal (Alert)~The children, equipped with a HMD and a joystick, will vertically turn a randomly inclined stick~The children will stand on a force plate watching a cartoon, gazing a fixation cross or eyes closed~The children, equipped with an augmented reality headset, will perform 2 levels of difficulty of 3 attention tasks standing on a force plate:~They will click as quickly as possible when they see a frog among successively appearing animals (vigilance task)~They will give the name of an animal appearing at one of the windows displayed (visual search task)~They will count the number of yellow lions oriented to the right among several animals of different color and direction (inhibition task)~Growth trajectory will be retrieved from health booklet"
45654139|NCT04977505|Device|pushlock|The surgery procedure was performed with pushlock for fixation
45805388|NCT05921526|Diagnostic Test|Chest X-ray (digital images)|Participants assigned to the chest X--ray group will be sent to the Radiology department to get a CXR (digital) which will be performed by radio technicians like in routine care. Anteroposterior and/or posteroanterior chest images will be obtained. Reading/ reporting of the digital images will be done by both the radiologist and the enrolling pediatrician. The image/ clinical expert review panels (IERP/ CERP) will also have access to the images for review.
45805389|NCT05921513|Procedure|Free Gingival Graft Procedure|This procedure is done to increase the width of keratinized gingiva around teeth or dental implant. The healing of the palatal wound at the donor site will be recorded.
45805390|NCT05921500|Drug|sodium peborate|Internal bleaching of discolored primary anterior teeth by using sodium peborate
45835689|NCT04779996|Diagnostic Test|Laboratory Samples|"After full vaccination with a Covid 19 vaccine, the following laboratory samples will be taken one time only, two weeks after full dose vaccination: i. Serologic rapid test (IgG, IgM) ii. Serum quantitative immunoglobulin levels iii. CD4 level iv. CD8 level~Laboratory samples will be taken at Hospital Auxilio Mutuo Laboratorio Clínico. Likewise, the Immuno Reference Lab might be used as an alternative.~Since monoclonal antibody therapy can induce hypogammaglobulinemia, we will measure gammaglobulin levels to correlate with antibody response to vaccine. Similarly, we will evaluate the CD4 and CD8 counts."
45937971|NCT00177112|Procedure|sterile patient preparation for cystoscopy|
45937972|NCT00177229|Behavioral|Family-based treatment|20 weekly group contacts with individual coaching over first 6 months, brief monthly contacts over next 6 months, no contacts over last 6 months. Medical monitoring throughout study period.
45937973|NCT00408109|Drug|VRC-AVIDNA036-00-VP|
45937974|NCT00408148|Drug|Placebo|Undistinguishable placebo tablets
45937975|NCT00408148|Drug|Rimonabant|White film-coated, for oral administration containing 20 mg of active rimonabant
45937976|NCT00397566|Drug|HIV Integrase Inhibitor (BMS-707035)|
45835690|NCT04778202|Diagnostic Test|blood sample collection|blood sample collection by venipuncture four both groups and MRI for breast cancr patient group
45835691|NCT04777968|Drug|Silver diamine fluoride|a layer of 38% SDF solution was topically applied to the cavity using a micro brush, immediately followed by a saturated Potassium Iodide KI solution using a micro brush also, then a creamy white precipitate was immediately formed, KI was applied until the white precipitate turned clear.
45937977|NCT00177346|Device|CAS with cerebral protection|
45654140|NCT04977505|Device|gryphon|The surgery procedure was performed with Gryphon for fixation
45835692|NCT04779606|Drug|Ocular gel|3 drops instilled in the right eye
45835693|NCT05295654|Other|Kinect validation|Participants will perform several movements while both the vicon and kinect are measuring.
45835694|NCT01722708|Drug|Clindamycin|Oral clindamycin 300 Milligrams*2/Day for a week
45835695|NCT01722708|Drug|Metronidazole|Oral metronidazole 500 Milligrams*2/Day for a week
45835696|NCT04779450|Other|Kinesiotherapy protocol|The kinesiotherapy protocol is an exercise-based treatment designed to gain upper limb range of motion and muscle strengthening.
45835697|NCT04779450|Other|Usual orientations|Usual orientations for post-breast cancer women, such as skin care, return to activities, upper limb functionality, self-care, lymphedema, and physical activity practice.
45835698|NCT04777890|Other|suboccipital inhibition|The therapist will seat at the patient's head height and place his second, third, fourth and fifth fingertips'over the patient's suboccipital area during a 10-minute period.
45835699|NCT04777890|Other|INYBI|The therapist will place the INYBI at the suboccipital area, specifically placing the fingers of the instrument at the lower border of the occipital. If needed, a rolled towel will be placed behind the INYBI, in order to maintain the physiological lordosis, checking out that the patient doesn't make a cervical extension. Then the therapist will press the vibration button and turn it off after 10 minutes. All patients will receive the treatment with the INYBI's hardest head with a 50 HZ frequency.
45805391|NCT05921487|Behavioral|Time Restricted Eating|Time Restricted Eating Protocol: Subjects will be instructed to limit caloric consumption to a 12-hour TRE window for the first two weeks of the study, and then transition to a 10-hour TRE window. The window start-time will be self-selected (individualized). During the eating window, subjects will not be restricted on types or quantities of food consumed, and will be advised to continue their usual diets. Subjects will not be required to monitor their caloric intake. During the fasting period, subjects will be encouraged to stay hydrated and drink ample water. Outside the designated eating window, subjects are only permitted to consume medication, water, or zero-calorie herbal drinks such as unsweetened tea or black coffee.
45805392|NCT05921448|Biological|Vaxigripetra|Tetravalent intramuscular vaccine. Mechanism of action: The vaccine induces an immune reaction involving antibody production.
45937978|NCT00177346|Device|CAS without cerebral protection|
45937979|NCT00423566|Biological|MVA85A (Tuberculosis vaccine)|
45805393|NCT05921448|Biological|Flumist|Tetravalent live attenuated influenza vaccine administered as a nasal spray. Mechanism of action: Not fully understood according to the prescribing information, but may involve influenza-specific T-cells and antibodies (serum and mucosal).
45805394|NCT05921435|Drug|CKD-341, D958|A single dose of 1tablet under fasting condition
45937980|NCT00177385|Behavioral|Modest sleep deprivation with sleep hygiene education|
45937981|NCT00177424|Drug|sertraline|Subjects will initially be started on either sertraline 12.5mg/d or placebo and will receive this dose for 3 days. Subjects will then be increased to 25mg/d for 4 days, then 50mg/d for 7 days, then increased to 75mg/d. Seventy-five mg per day is the target dose for the remainder of the subject's participation in the study. The study medication will not be titrated past 75mg/d.
45937982|NCT00177424|Drug|Placebo|matching placebo tablets
45937983|NCT00397605|Drug|Synthetic cannabinoids (1:1 ratio of THC % CBD)|Randomized crossover study of 2 weeks of active study medication (maximum daily dosage of 60 mg) vs. 2 weeks of matching placebo.
45937984|NCT00177463|Drug|L-carnosine|an antioxidant and AGE inhibitor, 500 mg/day, increasing each week in titration reaching 2000 mg/day in 4 weeks and maintained for rest of trial
45937985|NCT00423644|Drug|Darinaparson|420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest for up to six months
45937986|NCT00177502|Behavioral|behavioral exercise intervention|
45937987|NCT00177541|Behavioral|Biofeedback, pelvic floor muscle training, fMRI|Biofeedback, pelvic floor muscle training, fMRI
45937988|NCT00177580|Drug|Pravastatin|
45937989|NCT04723342|Drug|Blinatumomab|"Blinatumomab, intravenously, as continuous 24 hours infusion 1-7 days - 5 μg/m2/day, 8-28 day - 15 μg/m2/day~1 course after induction treatment"
45937990|NCT00177619|Drug|Alendronate|
45937991|NCT00056810|Drug|4-aminopyridine (4-AP)|
45452718|NCT00914602|Drug|Sinemet 25-100 Oral Tablet|After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days.
45452719|NCT00914602|Drug|XP21279|Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
45452720|NCT00914602|Drug|Carbidopa Pill|
45452721|NCT02484950|Biological|Mesenchymal stem cell augmentation in rotator cuff repair|Patients undergoing mesenchymal stem cell augmentation will receive a total injection of 6 milliliters (mL). Of this, 3 mL will be injected in the tendon at the junction between bone and tendon, while 3 mL will be injected in the bone at the site of the surgical footprint.
45937992|NCT00397644|Behavioral|Prompting (survey instrument/resources list) (behavior)|
45937993|NCT00177697|Behavioral|behavioral weight loss program|
45452722|NCT02484950|Procedure|Standard arthroscopic rotator cuff repair|All patients will undergo full thickness rotator cuff repair using a double row, transosseous-equivalent (TOE) repair with anchor/suture technique. Acromioplasty will be performed in all patients. Alternate procedures such as biceps tenotomy/tenodesis and distal clavicle excision will be performed at the discretion of the surgeon and recorded.
45452723|NCT00914290|Drug|IPX056|IPX056 ER capsule containing 10 mg baclofen
45452724|NCT00914290|Drug|Baclofen IR|Encapsulated baclofen tablet 5 mg per capsule
45452725|NCT00914290|Drug|Placebo IPX056|Placebo capsule for IPX056
45452726|NCT00914290|Drug|Placebo IR|Placebo encapsulated baclofen placebo tablet
45937994|NCT00177775|Drug|MucoMilk product|
45937995|NCT04161183|Device|Extracoporeal shock wave therapy|Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 6 weeks
45937996|NCT04161183|Device|Placebo|Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second but no energy once a week for 6 weeks
45937997|NCT00177853|Drug|celecoxib|Patients will start celecoxib (200mg PO BID) beginning 3-5 days prior to chemoradiation at home and receive the drug until 30 days following the completion of chemoradiation.
45937998|NCT00177853|Drug|irinotecan|Preoperative chemoradiation will consist of escalating doses of irinotecan (30 50 mg/m2 IV) once weekly for a total of 4 doses.
45937999|NCT00177853|Procedure|concurrent radiotherapy|50.4 cGy of standard external beam radiation. The radiation will be given in 28 treatments of 1.8 cGy per treatment over 5.5 weeks. This will be given in an outpatient setting.
45938000|NCT00177892|Procedure|sleep disruption|experimentally-induced Sleep Fragmentation
45938001|NCT00177892|Procedure|sleep with and without positive pressure|OSAH patients with and without chronic positive airway pressure therapy
45938002|NCT00397683|Drug|MK0822|
45938003|NCT00178009|Behavioral|self-paced instruction|Patients and caregivers review a DVD as often as they wish on how to care for routine and emergency procedures associated with their artificial heart
45938004|NCT00178048|Drug|paroxetine|
45938005|NCT00056927|Behavioral|Anti-smoking Socialization Program|
45938006|NCT00178165|Procedure|Skill Training Condition - problem solving training|
45938007|NCT00178165|Procedure|REACH for TLC (Telephone Linked Computer) system|
45938008|NCT00056966|Drug|ANTI-CD45|400ug/kg Day-5 through Day-2
45938009|NCT00056966|Drug|CAMPATH-1H|Day -8 through Day -6 Dosed per Institutional SOP
45654141|NCT04261855|Drug|Avelumab|All patients will receive avelumab intravenously (IV) at 10 mg/kg every 2 weeks for 24 months or until unacceptable toxicity or evidence of disease progression
45654142|NCT04261855|Radiation|External Beam Radiation Therapy (EBRT)|Patients allocated to Arm A will receive EBRT on 2 occasions, 8-10 weeks apart
45805395|NCT05921422|Other|Cognitive assessment|"All participants will receive cognitive assessment with a core battery (CPCog) and a supplemental battery.~The core battery includes standardized tests of general cognitive functioning (intelligence) and visual-spatial abilities, as well as a questionnaire on executive functioning in daily life. The supplemental battery assesses attention, executive functioning, memory, fatigue, and symptoms of mental health issues (including symptoms of anxiety, depression, and attention deficit hyperactivity disorder/ADHD)."
45835700|NCT04777890|Other|INYBI + upper cervical manipulation|The participant will also be treated with the INYBI during a 10-minute period. After that, the therapist will carry out the upper cervical manipulation technique. Keeping the patient's head on an upper cervical flexion position, the therapist will turn his/her head to the maximum possible rotation, always maintaining its longitudinal axis. Once this is done, a high velocity and short articular amplitude manipulation in rotation will be carried out
45835701|NCT04778124|Procedure|Hemorrhoidal Arterial Ligation (HAL) and Recto Anal Repair (RAR)|All patients underwent hemorrhoidal artery ligation on multiple sites according to pulsations detected by the doppler transducer and mucopexy (RAR) at the sites of prolapse.
45835702|NCT04778124|Procedure|Excision of thrombosed hemorrhoid / Hemorrhoidectomy /|One patient with mucosal necrosis of the hemorrhoidal cushion postoperatively underwent hemorrhoidectomy with excision of necrotic tissues.Furthermore, 2 patients who presented with hemorrhoidal thrombosis postoperatively underwent emergency surgery with supplementary excision of the thrombosed hemorrhoid. In addition, 9 patients who experienced recurrence of hemorrhoidal disease after undergoing HAL-RAR surgery, were treated with hemorrhoidectomy according to the Milligan-Morgan procedure.
45835703|NCT04777812|Diagnostic Test|Rectal and buccal swabs|The oral and intestinal flora is collected from buccal and rectal swabs.
45835704|NCT02316678|Other|No intervention|There is no intervention
45835705|NCT03726528|Diagnostic Test|Measurements of left ventricular pressure and volume|Patients with suspected Takotsubo syndrome (typical ballooning in left ventriculography without significant obstructive coronary artery disease that sufficiently explains the contraction abnormalities) will undergo continuous online measurements of left ventricular pressure and volume using conductance catheters. Cardiac magnetic resonance (CMR) imaging will be performed in patients without contraindications for optimized morphological characterization and exclusion of important differential diagnoses.
45835706|NCT04777578|Other|Dry needling|Dry needling based on fast-in fast-out technique in the teresa major muscle
45938010|NCT00056966|Drug|FK506|Day -2 through Day 30 dose adjusted to maintain level between 5-15 ng/ml.
45938011|NCT00056966|Drug|Fludarabine|Day-8 through Day-5 30 mg/m2
45452727|NCT04710524|Drug|Placebo|Placebo BID for 13 weeks
45654143|NCT04261855|Radiation|Lutetium-177 (177Lu)-DOTATATE|Patients allocated to Arm B will receive 177-Lu-DOTATATE treatment on 2 occasions, 8-10 weeks apart
45654144|NCT03295123|Other|phone interview with the mother|it's a telephone survey about children's health
45654145|NCT03267043|Behavioral|Family Nurture Intervention (FNI)|Subjects will be guided by the nursing staff through an enhanced program of mother/infant interactions, which include skin-to-skin holding.
45835707|NCT04754568|Other|Virtual reality instructional design|60 minute immersive VR experience with branching method information delivery, physical therapy assessment, and diagnosis.
45835708|NCT04754568|Other|Role-playing instructional design|60 minute traditional role-playing with standardized patient
45835709|NCT01896492|Drug|NAC|NAC 2gm plus cc 100mg from 3rd day of the cycle till day 8 with u/s follow up of the follicular growth.
45835710|NCT04754490|Diagnostic Test|Speech Recognition|Speech Recognition
45835711|NCT01711632|Drug|Vemurafenib|Patients will receive vemurafenib at a dose of 960mg orally b.i.d. continuously in cycles of 4 weeks (28 days) as outpatient. A bone marrow aspirate and/or biopsy will be performed after the first cycle for research purposes only. After the completion of the third cycle, a repeat bone marrow aspirate and/or biopsy will be performed for assessment of response and evaluation of MRD. Following the third cycle assessments, patients who achieve complete response (CR) with detectable MRD or partial response (PR) may continue with vemurafenib for up to 3 additional cycles at the treating physician's discretion (Cycles 4-6). Patients who achieve CR without MRD will be observed as part of post-treatment followup, and may be re-treated with vemurafenib after relapse (as per below). Patients who achieve no response (NR) after the initial 3 cycles of vemurafenib will be removed from the study. They will be followed every 3 months as part of posttreatment followup for a total of 12 months.
45835712|NCT04756206|Drug|Dutasteride 0.5 mg|patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.
45835713|NCT04756206|Drug|Placebo|patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.
45835714|NCT04777500|Device|Auricular transcutaneous electrical nerve stimulation device|We are investigating whether taVNS can relieve chronic pain symptoms associated with Fibromyalgia.
45835715|NCT04777188|Procedure|Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy|Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller;Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts for up to 12 min and the ablation power is gradually increased from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
45654146|NCT03267043|Behavioral|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
45805396|NCT05921409|Dietary Supplement|Extra Virgin Olive oil-supplemented Mediterranean Diet Intervention|"This intervention (treatment) consist of taking Extra Virgin Olive Oil (treatment group made up of 103 patients and 22 healthy people) for 6 months, accompanied by Mediterranean diet-based menus. During this time, blood and stool samples were taken at different points: before the start of the intervention (T0), 3 months after the start (T1), at the end of the intervention in the sixth month (T2) and 6 months after leaving the study (TF). Hence, a total of 4 time points were taken for analysis: T0, T1, T2, TF. Additionally, and following these same time points, the physical and psychological health status of the participants will be evaluated using the SF-36 health questionnaire. Similarly, the course of the pathology in terms of the Fibromyalgia Impact Questionnaire (FIQ) score were recorded."
45835716|NCT04745598|Behavioral|Control group: Dental Model|- Patients receive a demonstration of plaque control methods (modified Bass dental brushing technique and the use of the electric toothbrush) using a dental model.
45654147|NCT04235257|Biological|HPV vaccine|Gardasil 9 Bivalent HPV VLP Vaccine, one-fifth dose Nonavalent HPV VLP Vaccine, one-fifth dose
45654148|NCT04977193|Biological|LY011|CAR-T
45654149|NCT04977115|Procedure|Intraocular caliper-assisted capsulotomy|Intraocular caliper is a modified intraocular caliper with standard calibration on the rinse needle.
45835717|NCT04745598|Behavioral|Computer-assisted teaching format group|- Patients receive a Powerpoint presentation containing:
45835718|NCT04745598|Behavioral|Plaque-disclosing group|- Patients place a few drops of a plaque-disclosing solution on the tongue and run the tongue over all the teeth and gums. With the aid of a hand mirror, patients can observe the stained plaque residue on their teeth
45452728|NCT04710524|Drug|FM101 150 mg BID|FM101 (150 mg) BID for 13 weeks
45452729|NCT04710524|Drug|FM101 300 mg BID|FM101 (300 mg) BID for 13 weeks
45452730|NCT04473118|Other|Survey|An online-based questionnaire sent to participants via email
45452731|NCT00057941|Drug|anastrozole|Given orally
45452732|NCT00057941|Drug|gefitinib|Given orally
45452733|NCT00057941|Drug|fulvestrant|Given intramuscularly
45654150|NCT04977115|Procedure|Verion navigation system-assisted capsulotomy|Verion Image Guided System (Alcon Laboratories, Inc.) is a digital image guidance system consisting of a diagnostic reference unit and a surgery pilot for intraoperative surgical assistance. The device can be used to align toric intraocular lens during surgery as well as support manual creation of a capsulorhexis with a predefined target diameter.
45835719|NCT04745598|Behavioral|Intra-oral camera group|- An ACTEON Soprocare® intraoral camera is used during the examination and explanation of oral hygiene strategies.
45835720|NCT04779060|Drug|intrathecal fentanyle|25 mic fentanyle added to heavy bupivacaine for spinal anesthesia
45835721|NCT04779060|Drug|dexamethasone|8 mg dexamethasone give intrathecally for spinal anaesthesia
45835722|NCT04779060|Drug|saline|normal saline will be mixed with bupivacaine intrathecally
45835723|NCT04778826|Procedure|Lymphadenectomy|radical bloc dissection of all mediastinal lymph node stations
45835724|NCT04778514|Drug|Dual Prevention Pill|a single over-encapsulated DPP containing a PrEP tablet and a COC
45835725|NCT04778514|Drug|PrEP and combined oral contraceptive (COC) as two separate tablets|PrEP tablet and a COC as two separate tablets
45835726|NCT04777110|Drug|Esketamine|The main anesthesiologist standing on the right side of the patient injects esketamine (0.25 mg/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later for 30 s;
45835727|NCT04777110|Other|Saline|The main anesthesiologist standing on the right side of the patient injects saline (0.05ml/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later, the injection time is 30 s
45835728|NCT04776876|Biological|Retifanlimab|Given IV
45835729|NCT04776876|Drug|Telotristat Ethyl|Given PO
45835730|NCT04776642|Other|Biobank for Left atrial appendage tissue|Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
45835731|NCT04776642|Other|Biobank for Blood|Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
45835732|NCT04776642|Other|Biobank for One or more of following fat patches: epicardial fat, subcutaneous fat, pericardial fat, visceral fat.|Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
45835733|NCT05291208|Combination Product|Combined tACS and Cognitive Training Program|The program contemplates 12 WM training sessions based on tasks of storage and manipulation of verbal and visuospatial information, with a frequency of twice a week during six weeks (total of 12 sessions). Patients will receive real electrical stimulation for 10 minutes during verbal working memory task. This includes 10s periods of phase-in and 10 s of phase-out and will be done in parallel with the cognitive intervention program in sessions 1, 2, 3, 4, 5, 7, 9, and 10. The electrical stimulation will be applied with two 3x1 arrays of electrodes. The central stimulation electrodes will be positioned in F3 and CP3 (10-20 system). The AC stimulation will be one mA from the baseline to the stimulation peak. The stimulation will have a gamma sine waveform (80Hz) over the positive phase of the theta oscillation (6Hz; Alekseichuk et al., 2016) phase-locked between arrays with impedances always under 10 kOhm.
45835734|NCT05291208|Behavioral|Traditional Cognitive Training Program|Participants will start a cognitive intervention program identical to the intervention group. Still, unlike the intervention group, they will receive placebo electrical stimulation, i.e., an electrical current will be applied for a short period at the beginning of the session (30 seconds), and then the stimulation will be stopped. This procedure induces a sensation in the skin similar to the real stimulation without generating a detectable impact on the brain state. They will be performed in parallel to the cognitive intervention program in sessions 1, 2, 3, 4, 5, 7, 9, and 10.
45835735|NCT04776486|Drug|Iohexol|"Intravenous injection of 5 ml of iohexol (Omnipaque) to calculate the glomerular filtration rate (area under the curve).~Blood samples (2 ml) and urine (2 ml minimum) are to be collected for the determination of iohexol clearance at the following time points: pre-dose, 5 minutes, and 1, 2, 3, 4, 5, 6 hours post dose."
45835736|NCT01982058|Other|communication intervention|
45835737|NCT01982058|Other|counseling intervention|
45835738|NCT01982058|Other|nutrition intervention|
45938012|NCT00056966|Radiation|Total Body Irradiation|Day-1 single dose 450 cGy
45938013|NCT00056966|Procedure|Stem cell infusion|Patients will receive peripheral blood stem cells from a HLA matched or one antigen mismatched related or unrelated donor (target CD34+ cell count >2 x 106/kg). When peripheral stem cells are unavailable or insufficient, bone marrow (target mononuclear cell count >2 x 108/kg) will be substituted.
45938014|NCT00178243|Procedure|3D Conformal Radiation Therapy and Radiosurgery|
45938015|NCT00178282|Procedure|Pelvic Floor Muscle exercises|
45938016|NCT00178321|Device|earplugs|
45938017|NCT00178360|Behavioral|Music Therapy|"During individual Music Therapy sessions, subjects will participate in a variety of active music-making opportunities, including: playing musical instruments, singing, improvising, learning relaxation techniques, song writing, and/or lyric analysis. The activities for each session will be determined by both subject and therapist, and will be selected based on preference, emotional state, and desired goals for the day.~Group music therapy sessions will focus on improving socialization, depression, and group dynamics. In this setting, the Music Therapist will choose from the following interventions:~Group singing~Group drumming~Music assisted relaxation~Group song writing~Lyric analysis~Improvisation~Music with art"
45938018|NCT00178438|Device|Capsule Endoscopy|
45938019|NCT00178516|Other|behavior, procedure|
45938020|NCT00178555|Device|DCI Video Intubation System-Macintosh Laryngoscope|
45938021|NCT00178555|Device|Macintosh Laryngoscope|
45938022|NCT00178672|Device|Angioguard XP distal protection device|Standard of care stenting of carotid arteries protocol is used.
45938023|NCT00178672|Procedure|Heart Catheterization -Angioplasty|Standard of care carotid stenting. A catheter is inserted in the femoral vein into the carotid artery where a balloon is inflated and shortly thereafter a stent is placed in the target lesion area.
45938024|NCT00178672|Device|stenting|stenting of carotid arteries
45938025|NCT00178750|Device|18G Tuohy epidural needle|
45938026|NCT00178750|Device|CompuFlo® computerized syringe pump|
45938027|NCT00178828|Drug|sertraline|Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
45938028|NCT00178828|Drug|bupropion|Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
45452734|NCT00057941|Other|laboratory biomarker analysis|Correlative studies
45938029|NCT00408187|Drug|voclosporin|voclosporin 0.4 mg/kg po BID
45938030|NCT00408187|Drug|Ciclosporin|ciclosporin 1.5 mg/kg po BID
45938031|NCT00408187|Drug|Placebo|Placebo
45938032|NCT00408226|Drug|MKC-1|capsules, twice daily for 14 days in 21 day cycle
45938033|NCT00408226|Drug|pemetrexed|standard dosing of 500 mg/m2 infused every 21 days
45938034|NCT00408265|Behavioral|Contingency Management|
45938035|NCT00408304|Drug|omega-3 fatty acid|
45938036|NCT02963896|Drug|gentamicin|intratympanic application of gentamicin 2m/80mg - 3x application -0,5 ml
45938037|NCT00178945|Drug|Botulinum Toxin Type A|
45938038|NCT00397722|Drug|GW876008|
45938039|NCT00397722|Drug|paroxetine|
45938040|NCT00179023|Drug|Trimethaphan|Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 2-4 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1 hour
45938041|NCT00179023|Drug|Trimethaphan|Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 30 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1-2 hours
45938042|NCT00179023|Drug|Pseudoephedrine|30mg tablet,VO. Single dose.
45938043|NCT00057005|Drug|CAMPATH-1H|Day-8 through Day-6 according to institutional SOPs
45938044|NCT00057005|Drug|Anti-CD45|Day-5 400 μg/kg
45938045|NCT00057005|Drug|Ara-C|day-7 through day-5 3000 mg/m2 q 12h
45938046|NCT00057005|Drug|Cyclophosphamide|Day-7 through Day-6 45 mg/kg
45938047|NCT00057005|Drug|Mesna|Days -7 and -6 45 mg/kg divided into 5 doses
45938048|NCT00057005|Radiation|Total Body Irradiation|150 cGy x 2 (5/6 matched related) 180 cGy x 2 (5/6 matched unrelated)
45938049|NCT00179062|Drug|olanzapine versus risperidone|Participants are to be randomized to olanzapine or risperidone. Antipsychotic medication will be given as per package insert daily for the twelve month duration of the trial.
45938050|NCT00179101|Procedure|Deep Brain Stimulation|
45938051|NCT00179140|Drug|nutritional supplementation|oral administration of protein supplement (Nepro) during hemodialysis; every other day, 3 days per week for 6 months; Nepro is a lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat
45938052|NCT00179140|Behavioral|exercise|either before or during hemodialysis, patients will perform a leg press exercise; every other day, 3 days per week, for 6 months
45938053|NCT00057044|Behavioral|education and reminder|
45938054|NCT00179179|Drug|nutritional supplementation|2 oral ingestions per study visit of protein supplement containing a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat; 6 study visits over a 12-month period
45938055|NCT00179179|Behavioral|exercise|resistance training on a duel leg press consisting of 3 sets of 8-12 repetitions; the first 5 study visits over a 12-month period
45938056|NCT00179218|Drug|nutritional supplementation|oral administration of 2 cans of protein supplement (lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat); every other day, 3 days per week, for 6 months
45938057|NCT00179218|Behavioral|exercise|leg press exercise; every other day, 3 days per week, for 6 months
45938058|NCT04723459|Other|ivermectin impregnated mask|mask with ivermectin nano solution
45938059|NCT00179257|Drug|sertraline (Zoloft)|
45938060|NCT00057083|Other|Telemedicine Care|
45938061|NCT04723498|Diagnostic Test|screening questionnaire|Fill in screening questionnaire
45938062|NCT00179335|Procedure|Blood drawing to determine drug levels|
45938063|NCT00179374|Behavioral|Tailored telephone intervention of education|Tailored telephone intervention to promote metabolic control of diabetes
45938064|NCT00179374|Behavioral|Print educational intervention|diabetes educational materials by mail
45938065|NCT00408382|Drug|atorvastatin, Lipitor|
45938066|NCT00179452|Behavioral|Yoga|
45938067|NCT00046371|Drug|THERATOPE® vaccine|
45938068|NCT00179491|Behavioral|Intercessory Prayer|14 days of intercessory prayer from 3 sites
45938069|NCT00057122|Drug|Isoniazid|300mg
45938070|NCT00057122|Drug|Rifapentine|Rifapentine 900 mg
45938071|NCT00057122|Drug|Rifampin|Rifampin 600 mg
45938072|NCT00179530|Behavioral|Relaxation Response|Relaxation training
45938073|NCT00179569|Behavioral|Relaxation response|8 weeks of relaxation response training
46074011|NCT04285398|Other|Ophthalmic examinations|Slit-lamp examination, IntraOcular Pressure, Visual Acuity, Visual Field, Full-field Stimulus Threshold, Dark adaptometry, Color Vision testing, Optical Coherence Tomography, Fundus AutoFluorescence and Adaptive Optics imaging.
46074012|NCT04285398|Other|Mobility Test|Functional test to evaluate mobility and postural condition of patients
45835739|NCT01982058|Other|questionnaire administration|
45835740|NCT01068210|Behavioral|Exercise Training|The overall goal for all the exercise training groups will be 3 supervised exercise sessions per week an intensity between 50 to 100% of the individually determined VO2peak for aerobic training and an intensity between 50% to 85% of 1-RM for resistance training. All the exercise interventions are designed such that participants begin exercising at a low intensity (~50%-60% VO2peak / 1RM) that is subsequently increased to more moderate to vigorous intensity (~70%-100% VO2peak / ~70-85% 1RM) when appropriate. All interventions will be individually tailored to each patient following the principles of aerobic or resistance training prescription guidelines for adults.
45938074|NCT00179608|Drug|CC-5013|
45938075|NCT02970227|Other|Observation|None, observation only
45938076|NCT00179686|Drug|CC-5013|
45938077|NCT00179725|Drug|CC-5013|
45938078|NCT00179725|Drug|liposomal doxorubicin|
45938079|NCT04723381|Other|web based education|Expert support and consultancy were received for the design and preparation of the web page.
45938080|NCT00046449|Drug|Investigational Seasonal Affective Disorder (SAD) Drug|
45938081|NCT00179764|Procedure|Immunoablative Hematopoietic PBSC Transplant|Immunoablative conditioning chemotherapy regimen, followed by transplantation of peripheral blood stem cells on Day 0 of the conditioning regimen.
45938082|NCT00179764|Procedure|Busulfan pharmacokinetics|Pharmacokinetics of once-a-day dosing of intravenous busulfan as a 3-hour infusion
45938083|NCT00179764|Radiation|Central Nervous System (CNS) prophylaxis radiation|"Patients diagnosed with ALL over 1 year of age and without prior CNS disease will receive CNS prophylaxis radiation to the whole brain prior to transplant.~Patients diagnosed with ALL with prior CNS disease over the age of 1 year will be treated with prophylaxis radiation to the whole brain and spine prior to transplant."
45938084|NCT00057161|Behavioral|Coordinated Representative Payeeship with Case Management|
45938085|NCT00179803|Procedure|Stem Cell Transplant|"Group A: recurrent medulloblastoma, recurrent germ cell tumor~Cytoxan treatment~Stem cell autologous harvest~Group B: GBM, high grade astrocytoma, rhabdoid tumors, pineoblastoma, or supratentorial PNET~Carboplatin and Etoposide treatment~Autologous stem cell harvest~The preparatory regimen used for Stem Cell Rescue #1 will be Carboplatinum, VP-16 and Thiotepa. If the patient has recuperated his ANC to >1,000 within 50 days after Stem Cell Rescue #1, (sustained without G-CSF support) a neuroradiographic evaluation will be performed. If there is lack of progression, the patient will then proceed to Stem Cell Rescue # 2 with Cyclophosphamide and Melphalan, followed by stem cell rescue."
45938086|NCT00179842|Procedure|Stem Cell Transplant|
45938087|NCT00179881|Drug|Carboplatin|
45938088|NCT00179881|Drug|Thalomid|
45938089|NCT00179881|Procedure|External Beam Radiation Therapy|
45938090|NCT00046488|Drug|IDEC-152|6 Dosing groups: 125mg/m2 weekly x 4, 250mg/m2 weekly x 4, 375mg/m2 weekly x 4, 500mg/m2 weekly x 4, 500mg/m2 3 times first week then weekly x 3, 500mg/m2 3 times per week x 4
45938091|NCT00179920|Drug|Carboplatin|
45938092|NCT00179920|Drug|VP-16|
45938093|NCT00179920|Procedure|Local Surgery|
45938094|NCT00179920|Procedure|Cryotherapy|
45938095|NCT00179920|Procedure|Laser hyperthermia|
45938096|NCT00057200|Procedure|Telephone, videophone care|
45938097|NCT00180037|Drug|Coenzyme Q10 Nanodispersion (Nanoquinone)|
45938098|NCT00180037|Drug|Placebo|
45938099|NCT00180076|Drug|Budesonide|
45938100|NCT04063761|Device|esophageal cooling device (Attune Medical, Chicago, IL)|Prospective, single center pilot study
45938101|NCT00057239|Drug|Radafaxine|
45938102|NCT00180115|Drug|Cytarabine Dosage|
45938103|NCT00046527|Drug|ABI-007|
45938104|NCT00180310|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
45938105|NCT00180310|Device|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
46074013|NCT02813772|Dietary Supplement|Milk formula NAN Sensitive, Nestle|Infants randomized to group 1 will receive the milk formula NAN Sensitive, Nestle for a period of 4 weeks.
46074014|NCT02813772|Dietary Supplement|Milk formula Optipro, Nestle|Infants randomized to group 1 will receive the milk formula NAN Optipro, Nestle for a period of 4 weeks.
46074015|NCT02814942|Device|Cardiac Resynchronization Therapy|Cardiac resynchronization therapy with or without ICD
46074016|NCT02810808|Procedure|1+PRN|PRN intravitreal injections of Ranibizumab 0.5mg guided by BCVA stabilization after the injection of the same does at the first month.
45805397|NCT05921409|Dietary Supplement|Olive oil-supplemented Mediterranean Diet Intervention|"This intervention (treatment) consist of taking Olive Oil (placebo group made up of 103 patients and 22 healthy people) for 6 months, accompanied by Mediterranean diet-based menus. During this time, blood and stool samples were taken at different points: before the start of the intervention (T0), 3 months after the start (T1), at the end of the intervention in the sixth month (T2) and 6 months after leaving the study (TF). Hence, a total of 4 time points were taken for analysis: T0, T1, T2, TF. Additionally, and following these same time points, the physical and psychological health status of the participants will be evaluated using the SF-36 health questionnaire. Similarly, the course of the pathology in terms of the Fibromyalgia Impact Questionnaire (FIQ) score were recorded."
45805398|NCT05921396|Procedure|Nasal patency - rhinomanometry|Nasal patency before and after the pituitary adenoma surgery will be assessed using rhinomanometry.
45938106|NCT00180349|Device|Endotak Reliance|Endotak Reliance is a defibrillation lead delivering pacing and defibrillation therapy to the ventricle as needed.
45938107|NCT00057278|Drug|gabapentin|
45938108|NCT00180427|Device|ICD|
45938109|NCT04729569|Procedure|Feather edge finish line preparation|Tooth preparation with feather edge finish line will be done to posterior teeth to receive all ceramic full coverage zirconia crowns.
45938110|NCT04729569|Procedure|Deep chamfer finish line preparation|Tooth preparation with deep chamfer finish line will be done to posterior teeth to receive all ceramic full coverage zirconia crowns.
45938111|NCT00180505|Device|ABSOLUTE™: Self-Expandable Peripheral Nitinol Stent|A prospective, non-randomized, multi-center study to investigate the performance of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries. Follow up at 30, 180, 270, 365 days and 2 years.
45938112|NCT02969603|Other|Magnetic Resonance Imaging|Magnetic Resonance Imaging as reference
45938113|NCT02969603|Other|Magnetic Resonance combined with Positron Emission Tomography|Comparison with MRI only, to assess muscular activity, creation of anatomic images of muscle activity and resolution of metabolic activity distribution within exercising skeletal muscle
45938114|NCT00180544|Device|Stenting: Renal Artery|Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.
45938115|NCT00180583|Device|Guidant GALILEO Intravascular Radiotherapy System|Treatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
45938116|NCT00180622|Procedure|Spirometry|
45938117|NCT00180622|Procedure|Exhaled Nitric Oxide and Carbon Monoxide|
45938118|NCT00180622|Procedure|Exhaled Breath Condensate|
46074017|NCT02810808|Procedure|3+PRN|PRN intravitreal injections of Ranibizumab 0.5mg guided by BCVA stabilization after the first three monthly intravitreal injections of the same does.
46074018|NCT02810808|Drug|Ranibizumab|Ranibizumab - a recombinant, humanized monoclonal antibody Fab that neutralizes all active forms of VEGF-A was recently approved by the Food and Drug Administration for the treatment of all angiographic subtypes of subfoveal neovascular age-related macular degeneration
45452735|NCT05010824|Behavioral|Sleep hygiene practices and behavioural intervention|The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem. The second and third session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. Follow-up phone calls provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
45452736|NCT01099319|Dietary Supplement|Renalof|One 325 mg Renalof tablet (Orally administered) every 8 hours, for 6 months.
45452737|NCT01099319|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) every 8 hours, for 6 months
45452738|NCT03005522|Drug|oral dexamethasone|Patient will be dosed with either placebo or with the study drug, 10mg oral dexamethasone, to be administered by mouth one time in the ED
45452739|NCT03005522|Drug|Placebo Oral Capsule|dosed with placebo
45452740|NCT02998736|Drug|Cialis|"Cialis 20 mg daily by mouth for 16 day. 5 days prior to surgery, day of surgery and 10 days post surgery.~Influenza vaccine 0.5mL day of surgery"
45452741|NCT02998736|Biological|Influenza vaccine|One 0.5mL intramuscular injection the day of surgery
45452742|NCT00075881|Drug|bortezomib|Given IV
46074019|NCT00619801|Drug|Levocetirizine|Levocetirizine dihydrochloride 1.25 mg oral drops formulation (5 drops containing 5mg/mL) dosed twice a day for 2 weeks
46074020|NCT00619801|Drug|Placebo|Placebo oral drops (5 drops) dosed twice a day for 2 weeks.
45805399|NCT05921396|Procedure|Nasal patency - nasal inspiratory peak flow|Nasal patency before and after the pituitary adenoma surgery will be assessed using nasal inspiratory peak flow..
45938119|NCT00180622|Procedure|Induced Sputum|
45938120|NCT00180622|Procedure|CT Scan|
45938121|NCT00180622|Procedure|Blood test|
45938122|NCT00180622|Procedure|St Georges Questionnaire|
45938123|NCT00180622|Procedure|Bodypletysmography|
45452743|NCT00075881|Other|laboratory biomarker analysis|Optional correlative studies
45452744|NCT00840268|Drug|Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel|
45452745|NCT00840268|Drug|Hydroxypropyl Guar Galactomannan Vehicle|Inactive ingredients used as a placebo comparator
45452746|NCT00838630|Drug|Cilostazol 100 mg tablets|1 x 100 mg
45452747|NCT00838630|Drug|Pletal® 100 mg tablets|1 x 100 mg
45938124|NCT00057317|Drug|Ro 205-2349|
45938125|NCT00180700|Behavioral|Hypnosis|
45938126|NCT00180739|Procedure|Magnetic Resonance Guided Focused Ultrasound|
45938127|NCT00180778|Drug|Low dose steroids|
45938128|NCT00180856|Procedure|Radiofrequency ablation|
45938129|NCT00180895|Drug|Rituximab|
45654151|NCT04224415|Drug|C225+CPT-11|"Patients will receive Systemic C225+CPT-11 every 14 days:~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1"
45654152|NCT04869085|Behavioral|e-PainSupport|Patients and caregivers assigned to the e-PainSupport condition will download the app on their own device, or they will be given a project tablet with wireless capability if they do not have their own device. All receive specific training for the intervention. They will also receive a hardcopy of the e-PainSupport manual and a trouble-shooting guide. Contact information will be provided in the app and on paper for technical problems. Caregivers complete Education Module, and patients may complete it. Caregiver or patient will fill out Pain Report daily. Pain Summary for Nurses is an automatically generated graphic summary of patients' Pain Reports over time. Nurses have access to this information during the time the patients and caregivers use e-PainSupport.
45805400|NCT05921370|Drug|Silodosin 8 mg|"This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 3 days before their scheduled retrograde intrarenal surgery.~silodosin is an alpha blocker which act to dilate the ureter to facilitate access sheath placement"
45805401|NCT05921370|Drug|Placebo|"This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 3 days before their scheduled retrograde intrarenal surgery.~Group B (the control group): Patients will receive Placebo for 3 days before their scheduled retrograde intrarenal surgery."
45805402|NCT05921357|Other|Questionnaire|Questionnaire and examine
45805403|NCT05921344|Device|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
45805404|NCT05921331|Device|The RJBC-APP|The RJBC-APP consists of the following features: 1. Login, logout, setting, and modification of personal information. 2. Full-course management included registering for information on the surgical treatment, viewing the results of the multidisciplinary team (MDT) discussion, generating the treatment process according to the MDT discussion, receiving the reminder of the treatment, confirming the completion of the treatment, filling in the follow-up information, and consulting a specialist nurse. 3. Questionnaire and feedback.
46074021|NCT02815020|Other|Boot Camp Translation - community-participatory process|Series of meetings and conference calls with expert presentation on patient self-management support, facilitated discussion, and creation of product to bring to community to improve patient self-management support
46074022|NCT04237506|Behavioral|Targeted ballet dance|The one-hour ballet dance class will be provided twice per week for six weeks. The syllabi are adapted from the Joffrey Ballet Academy and Royal Academy of Dancing that are targeting grades primary to level 1 and typically developing kids at the age of 6 to 10 years old. PI will be the class instructor, and the class structure will follow the guidelines in 'Dance program for physical rehabilitation and participation in children with cerebral palsy' by Lopez-Ortiz et al.
45805405|NCT05921331|Other|Routine post-surgical follow-up|The routine post-surgical follow-up is conducted in the outpatient clinic.
45938130|NCT00180934|Procedure|Reirradiation with concomitant chemotherapy|
45938131|NCT00180973|Drug|Hydroxyurea|
45938132|NCT04729491|Drug|Dutasteride 0.5 mg|Use of dutasteride 0.5mg/day q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.
45938133|NCT04729491|Drug|Azithromycin|Azithromycin 500mg/day for 05 days
45938134|NCT04729491|Drug|Nitazoxanide|500mg twice daily for 06 days
45938135|NCT04729491|Drug|Placebo|Use of placebo q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.
45938136|NCT00057356|Drug|conivaptan|IV
46074023|NCT02545777|Drug|diclofenac sodium enteric-coated|
45938137|NCT00057356|Drug|placebo|IV
45938138|NCT00181012|Drug|Lidocaine|
45938139|NCT00181051|Device|Alaris AEP monitor|
46074024|NCT02545777|Drug|Oral medicine of tonifying spleen and descending turbid|Ingredient:cortex phellodendrine, rhizoma atractylodis, radix cyathula, coix seed, cotton Bi Xie,rhizoma smilacis glabrae
46074025|NCT02545777|Drug|Steeping and washing medicine of descending turbid and clearing heat|Ingredient: turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica,garden balsam stem, pseudobulbus cremastrae seu pleiones
46074026|NCT02545777|Drug|Wet wrapping medicine of descending turbid and clearing heat|Ingredient:turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica, pseudobulbus cremastrae seu pleiones.
46074027|NCT04117152|Other|Latent class mixed modeling|To identify CAV trajectories after heart transplantation using a contemporary unsupervised trajectory-based approach known as latent class mixed modeling
46074028|NCT00851617|Device|Threshold® IMT|The IMT group was trained using the threshold IMT device with a 40% MIP load. Each training session consisted of 5 sets with 10 breaths, twice a day
46074029|NCT02810886|Drug|68Ga-(HBED-CC)-PSMA|68Ga-PSMA-ligand intravenous administration duration is around one minute. Once the patient is injected, the tracer needs 60 minutes to be evenly distributed through the body. PET/CT images will then be performed.
45938140|NCT00181090|Behavioral|Modified Atkins diet|
45938141|NCT00181129|Behavioral|home based self paced walking program|
45938142|NCT00181246|Drug|Transdermal Fentanyl|
45938143|NCT00181558|Drug|Atrasentan|
45938144|NCT00181558|Drug|Zoledronic Acid (Zometa)|
45938145|NCT00181597|Drug|Trilostane|Taken orally once a day for three days then twice daily thereafter.
45938146|NCT00181597|Drug|Hydrocortisone|Taken orally with trilostane.
46002619|NCT04646304|Other|Objective Feedback (Motion Capture)|Participants assigned to the objective feedback group will be given a report after completing Set 1 and Set 2. This report will outline their performance for each significant factor (identified in Phase 1) relative to a target interval, derived from the staff surgeon group average (± one standard deviation). Participants assigned to the objective feedback group will then be able to repeat the tasks knowing which variables to improve.
45654153|NCT04223401|Other|Prehabilitation|"Patients will undergo 6 Minutes Walking Test (6-MWT), spiroergometry (VO2 max; AT), a grip strength test, a timed Up & Go (TUG) test, 10 m sprint test and sit to stand test before and after prehabilitation. The trimodal intervention will involve:~Nutritional intervention~Psychological intervention~Exercise intervention"
45654154|NCT04437199|Drug|Tricaprilin|"Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of 12.5 g of AC-SD-03 contains 5 g of the active ingredients (tricaprilin)"
45654155|NCT04437199|Drug|Placebo|Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.
45654156|NCT03239899|Drug|Pembrolizumab|Participants will receive one dose of 2mg/kg of pembrolizumab IV at Week 0.
45805406|NCT05921318|Combination Product|Beijing protocol|"For patients <55 years and HCT-CI≤ 3：Ara-C(4g/m2/day,-9 days),Bu(9.6mg/kg,-8 days to -6 days),Cy(1,800mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days)~For patients ≥ 55 years or HCI-CI>3：Ara-C(2g/m2/day,-10 days to -9 days),Bu(9.6mg/kg,-8 days to -6 days),Flu(30mg/m2/day,-6 days to -2 days),Cy(1,000mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days)."
45805407|NCT05921305|Drug|MTX|MTX (5mg/m^2/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR
45805408|NCT05921305|Drug|Corticosteroid|Corticosteroid Methylprednisolone 2 mg/kg/day was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg/kg/day prednisone (or 0.2mg/kg/day methylprednisolone).
45805409|NCT05921292|Combination Product|Omeza Products Used in Combination|"Subjects in this single-arm study will have the targeted wound/ulcer treated with Omeza combination therapy which includes the use of the following products:~Omeza Lidocaine Lavage~Omeza Collagen Matrix~Omeza Skin Protectant At each treatment (on days 0, 7, 14, 21, and 28; +/- 3 days each), the patient's wound/ulcer will be cleaned with Omeza Lidocaine Lavage. Omeza Collagen Matrix will be applied as the primary dressing and Omeza Skin Protectant will be applied on periwound and surrounding intact skin. Treatments may be repeated during an optional 8 additional weeks (on days 35, 42, 49, 56, 63, 70, and 77; +/- 3 days each)."
45938147|NCT03972384|Behavioral|Post-ICU Problem Solving|"We have adapted the Cognitive Orientation to Daily Occupational Performance (CO-OP) as the Post-ICU Problem Solving intervention to be delivered in the home to patients following an illness that required an ICU stay. CO-OP is a form of meta-cognitive strategy training that teaches individuals to identify and prioritize problematic daily activities, identify barriers impeding performance, generate and evaluate strategies addressing these barriers, and generalize learning through practice. Thus, strategy training teaches skills that can be used to address disability in real-life activities, and is integral to personalized rehabilitation services. CO-OP has been adapted in numerous settings and most recently, it is being utilized successfully in patients with acquired cognitive dysfunction following acute stroke. This represents a useful intervention, tested in similar populations with minimal risk to the participants and potential for maximal benefit for this population."
45938148|NCT00181636|Drug|Galantamine-CR|
45938149|NCT00181675|Drug|galantamine HBr|
45938150|NCT00181753|Drug|standard vs. glutamine enteral or parenteral feeding.|Patient in each group will continue on the same diet for > 3 days before we conduct stable isotope tracer measurements.
45938151|NCT00181753|Dietary Supplement|Stable isotope tracer study|7 hours of primed constant infusion
45938152|NCT00181753|Dietary Supplement|Stable isotope study|7 hours of primed constant infusion of stable isotope tracers.
45938153|NCT00181753|Dietary Supplement|Stable isotope tracer study|7 hours of primed constant stable isotope tracer infusion.
45938154|NCT00181753|Dietary Supplement|Stable isotope tracer study|7 hours primed constant infusion of stable isotope tracer study
45452748|NCT02996474|Drug|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion every 3 weeks. Every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
45452749|NCT02996474|Drug|Decitabine|Will be administered at a dose of 20 mg/m^2 by continuous intravenous infusion over 1 hour repeated daily ordinarily on days 8 through 12 and 15 through 19 of alternative cycles (ie: cycles 1, 3, 5, 7). Decitabine should be repeated every 6 weeks.
45938155|NCT00181831|Device|Proton Magnetic Resonance Spectroscopy|
45938156|NCT00181870|Drug|carbamazepine ER (Equetro)|
45938157|NCT00181909|Behavioral|Smoking cessation counseling delivered by telephone|
45938158|NCT00181948|Drug|atomoxetine (Strattera)|
45938159|NCT00181987|Drug|methylphenidate HCl (Concerta)|
45938160|NCT00182026|Behavioral|personal feedback report|A computer-generated feedback report that provides personalized diabetes self-management recommendations to participants based on their responses to a self-administered questionnaire.
45938161|NCT00182104|Drug|Warfarin vs ASA|
45654157|NCT03217045|Other|nutrition protocol introduction|Growth comparison of 2 cohorts of infants evaluated in a before-after design
45938162|NCT00182143|Drug|LMWH (Fragmin, dalteparin)|Placebo AM dose (normal saline) and LMWH (Fragmin, dalteparin) 5000IU PM dose
45938163|NCT00182143|Drug|Unfractionated Heparin|5000 IU BID
45938164|NCT00182182|Behavioral|Primary care based disease management strategy|
45938165|NCT00182221|Procedure|MDA D-Dimer Testing|
45452750|NCT00821002|Drug|Latanoprost|Comparison of punctal plug placement between upper and lower puncta
45458023|NCT01139749|Drug|salicylic acid and ciclopirox olamine|Topical salicylic acid and ciclopirox olamine shampoo for scalp and face cleansing, every other day, for six months
45938166|NCT00180388|Procedure|endoscopic vein harvesting|
45938167|NCT00180388|Procedure|open vein harvesting|
45938168|NCT00182260|Drug|Proton Pump Inhibitors|
45938169|NCT00182260|Procedure|Laparoscopic Nissen Fundoplication|
45938170|NCT00408538|Drug|UC-781 microbicide gel (0.1% and 0.25%)|
45938171|NCT00408538|Drug|placebo|
45938172|NCT00408577|Drug|L-arginine|
45938173|NCT00408616|Biological|Grazax-R|Grass tablet, 75.000 SQ per day for one year
45938174|NCT00408616|Biological|Grazax Placebo|Grazax Placebo, 0 SQ tablet per day for one year
45938175|NCT00408655|Drug|paclitaxel|Given IV
45938176|NCT00408655|Drug|carboplatin|Given IV
45938177|NCT00408655|Drug|temsirolimus|Given IV
45938178|NCT00182299|Procedure|porcine small intestine submucosa (SIS)|
45654158|NCT03061981|Drug|Placebo|After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period.
45654159|NCT03061981|Drug|Metformin|Subjects in the IE cohort will receive 500 mg metformin (IR formulation) at 12 hours on Day 1 and a single oral dose of the IMP with 500 mg metformin (IR formulation) after an overnight fast on Day 1, in Treatment Period 2.
45805410|NCT05921266|Dietary Supplement|Urolithin A|Participants in the intervention group will receive 500 mg of urolithin A twice daily for 4 weeks (1,000 mg daily in total). The supplement will be administered in the form of softgels (4 softgels in total).
45938179|NCT00182377|Drug|Pentastarch (displace either 500 ml or 1000 ml of pump prime with pentastarch)|
45938180|NCT00182416|Device|pacemaker|
45938181|NCT00182455|Drug|Topiramate|25 - 400 mg/day x 12 weeks
45938182|NCT00182455|Drug|Placebo|25 - 400 mg/day x 12 weeks
45938183|NCT00182494|Behavioral|Modified diabetes prevention protocol & Metformin|
45938184|NCT00182533|Drug|Sertraline|25 - 200 mg/day x 16 weeks
45938185|NCT00182533|Drug|Placebo|25 - 200 mg/day x 16 weeks
45938186|NCT00182572|Drug|buprenorphine|
45452751|NCT03667924|Behavioral|PorchLight Project|Senior Companions (or other LSS-MN volunteers providing senior companionship services) who deliver the PorchLight Project will complete online CARES® Dementia Care Specialist training modules, additional trainings delivered by the research team (1. overview of the PorchLight Project, 2. review of the National Consensus Guidelines on Palliative Care, 3. review of the list of guided questions, and 4. review of journaling approach and LTSS resources), and participate in unstructured monthly check-ins (discussions and case review as applicable) with the research team.
45805411|NCT05921266|Other|Placebo|Participants in the control group will receive 0 mg of urolithin A twice daily for 4 weeks. The placebo will be administered in the form of identical excipient-matched softgels (4 softgels in total).
45805412|NCT05921253|Device|PARASYM TENS unit|Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a preset position of one ear for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study.
45938187|NCT00182572|Drug|naltrexone|
45938188|NCT00182572|Procedure|behavior therapy|
45938189|NCT00182572|Procedure|voucher-based contingency management|
45938190|NCT00182611|Drug|cisplatin|
45938191|NCT00182611|Drug|tegafur-gimeracil-oteracil potassium|
45938192|NCT00182611|Procedure|adjuvant therapy|
45938193|NCT00182611|Procedure|conventional surgery|
45938194|NCT00182611|Procedure|neoadjuvant therapy|
45938195|NCT00182650|Biological|aldesleukin|
45938196|NCT00182650|Biological|rituximab|
45938197|NCT00182650|Biological|therapeutic autologous lymphocytes|
45938198|NCT00182650|Drug|fludarabine phosphate|
45458024|NCT03508414|Behavioral|ketogenic diet|Patients receive a ketogenic diet, which is carbohydrate-reduced with a high amount of fat.
45654160|NCT03061981|Drug|DA-1241|After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period .
45654161|NCT02510001|Drug|PF-02341066|PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously
45938199|NCT00182806|Drug|gemcitabine hydrochloride|IV over 30 minutes on days 2 and 9. Courses repeat every 21 days.
45938200|NCT00182806|Drug|irinotecan hydrochloride|IV over 90 minutes on days 1 and 8. Courses repeat every 21 days.
45938201|NCT00408733|Other|Medication Education Tool|Picture and Icon-based Customizable Educational Tool
45938202|NCT00182845|Drug|Donepezil|
45654162|NCT02510001|Drug|PD-0325901|PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.
45938203|NCT00182884|Drug|Donepezil|
45938204|NCT00182962|Behavioral|Geriatric Resources for Assessment & Care of Elders (GRACE)|
45938205|NCT00183001|Drug|Vitamin K|
45938206|NCT00183040|Drug|Topical testosterone|
45938207|NCT00183040|Drug|Recombinant human growth hormone|
45938208|NCT00183079|Behavioral|Motivationally-focused brief alcohol intervention|Brief, motivationally-focused alcohol intervention
45938209|NCT00183118|Behavioral|Adapted Enhanced-RESPECT (HIV prevention intervention)|
45938210|NCT00057395|Drug|Aroplatin (Liposomal NDDP, L-NDDP)|
45938211|NCT00183157|Behavioral|Brief Motivational Intervention|One-third of the enrollees will receive an assessment, a brief motivational interview performed by a trained peer counselor, direct referrals to community-based resources for adolescents, and a 10-day follow-up phone call. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
45938212|NCT00183157|Behavioral|Assessment and list of resources|One-third will receive only the assessment and a list of community resources. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
45938213|NCT00183157|Behavioral|Referral to Community Resources|All patients aged 14 to 21 get a brief alcohol and drug screen, and those whose scores indicate they drink or use marijuana are invited to participate in the study. One-third of the enrollees will receive only a list of resources. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
45938214|NCT00183235|Drug|aripiprazole (up to 15 mg/day) for 8 days|
46002620|NCT04645914|Behavioral|Use of nicotine product (smoking/vaping)|The smokers/vapers are consuming during the study one nicotine product of their own. The dose is the same as each individual is consuming regularly
46002621|NCT04684433|Other|Data extraction from medical files|Data extraction from medical files
45938215|NCT00183313|Behavioral|Nurse case management|Nurse case management is a population-based medical case management program to improve the delivery of primary medical care to patients with serious mental illness in a Community Mental Health Center (CMHC) in Atlanta GA. The treatment draws on elements from the primary care, nursing case management, chronic disease, health behavior change literature, and from the study team's experience in integrating primary care services for patients with serious mental illnesses.
46074030|NCT00634374|Device|Rx Medibottle|Comparing use of the Rx medibottle to the oral syringe in delivering a one-time dose of prednisolone syrup
46074031|NCT00962741|Drug|Etanercept|Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
45938216|NCT00183313|Behavioral|Usual care|Usual care includes standard mental health services.
45654163|NCT02510001|Drug|Binimetinib|Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days
45654164|NCT02452047|Drug|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, IV infusion once every 6 hours
45938217|NCT00057434|Drug|multivitamin|
45654165|NCT02452047|Drug|Colistimethate sodium (CMS)|Colistimethate base activity 300 mg (~720 mg CMS) IV infusion loading dose, followed by colistimethate base activity 75 mg to 150 mg (~180 to 360 mg CMS), depending on renal function, once every 12 hours
45938218|NCT02963662|Procedure|laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass was one of the interventions pre-specified to be administered to participants. The patients undergo Roux-en-Y gastric bypass (RYGB group) following a comprehensive evaluation for the surgical indication
45654166|NCT02452047|Drug|Imipenem+Cilastatin|Imipenem+cilastatin 200 mg to 500 mg, depending on renal function, IV infusion once every 6 hours
45654167|NCT02452047|Drug|Placebo to CMS|Placebo to CMS IV infusion once every 12 hours
45654168|NCT04925505|Procedure|Interscalene brachial plexus blocks with ultrasound guidance under general anesthesia|Ultrasound-guidance, interscalene brachial plexus blocks, in-plane technique, perineural injection, 0.5% ropivacaine 12.5ml and 0.2% lidocaine 12.5ml
45654169|NCT02475369|Drug|pancrelipase|
45654170|NCT02474589|Drug|tecovirimat|Study is based on Animal Regulatory Rule
45654171|NCT02474589|Other|Placebo|Does not apply
45805413|NCT05921253|Device|PARASYM TENS unit (Placebo)|"Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a different position of one ear compared to the experimental arm for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study."
45805414|NCT05921240|Other|observational study, no intervention|no intervention
45805415|NCT05921227|Behavioral|VAULT Phase 6|VAULT is an input-based word learning intervention based on principles of statistical learning.
45805416|NCT05921214|Behavioral|VAULT Phase 5|This is an input-based vocabulary learning treatment based on principles of statistical learning.
45938219|NCT02963662|Procedure|laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy was the other intervention pre-specified to be administered to participants. The patients undergo sleeve gastrectomy (SG group) following a comprehensive evaluation for the surgical indication
46074032|NCT00851773|Drug|semaglutide|0.1 mg once weekly, s.c. injection
46074033|NCT00851773|Drug|semaglutide|0.2 mg once weekly, s.c. injection
46074034|NCT00851773|Drug|semaglutide|0.4 mg once weekly, s.c. injection
45654172|NCT02586233|Drug|DS-1040b|DS-1040b for IV infusion (0.6 mg to 9.6 mg) over 6-hour period
45654173|NCT02586233|Drug|Placebo|0.9% sodium chloride (placebo comparator) for IV infusion over 6-hour period
45654174|NCT03936101|Diagnostic Test|Prenatal Genomic Sequencing|Whole genome sequencing (which initially will be masked and reported as exome only)
45654175|NCT03862157|Drug|Azacitidine|Given IV or SC
45654176|NCT03862157|Drug|Pevonedistat|Given IV
45654177|NCT03862157|Drug|Venetoclax|Given PO
45654178|NCT05592431|Device|High Frequency Oscillatory Ventilation with Volume Guarantee (SLE6000;SLE)|ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P and high-frequency tidal volume (VThf).
45654179|NCT05592431|Device|High Frequency Oscillatory Ventilation (SLE6000;SLE)|ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P
45654180|NCT05537285|Device|Individualized Accelerated Intermittent Theta Burst Stimulation (Ind-aiTBS)|active side magnetic coil stimulation applied to individualized target in the left dorsal lateral prefrontal cortex.
45805417|NCT05921201|Behavioral|Relax, Reflect, and Empower mobile application|Participants in the RRE group will select an Avatar from a pool of 20 Avatars as their companion over the 3 months. The Avatar wellness check-in in the RRE group includes a daily wellness check-in of 5-minute/day (4 days/week), and a weekly full wellness check-in of 15 minutes/week for 3 months. The daily brief check-in includes a wellbeing and mood check and a 3-minute relaxation meditation. The weekly full wellness check-in includes reflection activities in addition to the daily check-in activities.
45938220|NCT00183508|Behavioral|Cognitive behavioral therapy|Participants will learn cognitive behavioral strategies for symptom reduction
45938221|NCT00183508|Behavioral|Psychoeducation|Participants will receive psychoeducation regarding common reactions to traumatic events
45938222|NCT02963389|Drug|Tripegfilgrastim|
45938223|NCT00183547|Behavioral|"Living in Harmony depression prevention program"|Weekly therapy sessions consisting of cognitive behavioral therapy (CBT), culturally-relevant education, and support
45938224|NCT00183547|Behavioral|Depression-prevention education and support|Weekly therapy sessions offering general depression-prevention education and support
46074035|NCT00851773|Drug|semaglutide|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
46074036|NCT00851773|Drug|semaglutide|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, 1.2 mg once weekly for 6 weeks, s.c. injection
46074037|NCT00851773|Drug|placebo|0.1 mg once weekly, s.c. injection
46074038|NCT00851773|Drug|placebo|0.2 mg once weekly, s.c. injection
46074039|NCT00851773|Drug|placebo|0.4 mg once weekly, s.c. injection
45654181|NCT05537285|Device|Standard Accelerated Intermittent Theta Burst Stimulation (Std-aiTBS)|active side magnetic coil stimulation applied to standardized target in the left dorsal lateral prefrontal cortex.
46074040|NCT00851773|Drug|placebo|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
46074041|NCT00851773|Drug|placebo|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, followed by 1.2 mg once weekly injections for 6 weeks, s.c. injection
46074042|NCT04376112|Other|Pharmacist and pillpack intervention|These participants will be randomized into one of the following two cohorts: standard of care (SOC) and pharmacy intervention group (blister packaging + MTM services). For pharmacy intervention (PI) group, the POCT will be used to measure HbA1c and blood pressure (BP) at baseline, 3, and 6 months during medication therapy management (MTM) service. Recommendation from MTM services will be documented in the patients' electronic medical records (EMRs) and shared with their primary care providers. For the SOC group, HbA1c and BP will be measured at the physician's office and researchers will have an access to participants' EMR.
46074043|NCT04376112|Other|Standard of care|None. Regular visits to primary care physician. Will measure HbA1c and blood pressure at baseline, 3, and 6 months
45654182|NCT05537285|Device|Sham Accelerated Intermittent Theta Burst Stimulation (Sham)|sham side magnetic coil stimulation applied to the left dorsal lateral prefrontal cortex.
45654183|NCT05537207|Device|low level laser therapy|low level laser therapy (LLLT) on the acupuncture points. inadition to non-steroidal anti-inflammatory drugs.The parameters of the laser device are wave length of 904 nm, maximum average power of 5 milli Watts, a maximum repetition rate of 5 kHz, energy of up to 30 J/cm², and energy density of 2 J/cm2
45654184|NCT05537207|Other|non-steroidal drugs|All women will receive non-steroidal anti-inflammatory drugs in the form of Brufen (Ibuprofen), 400 mg, 3 times per day after meals, for 6 weeks, as described by their gynecologist.
45654185|NCT05537129|Procedure|Total Gastrectomy|The laparoscopic or open total gastrectomy with D2 lymphadenectomy was performed according to the Japanese gastric cancer treatment guidelines.
45654186|NCT02474355|Procedure|T790M+ Testing|If a previous lab report is unavailable, the patient will need to have T790M+ testing.
45938225|NCT00057512|Drug|M4N|Dose escalation study of M4N administered intratumorally on days 1, 8 and 15. Dose escalated in cohorts on three weeks schedule to a target of 20 mg/cm3 tumor volume.
45654187|NCT02474355|Procedure|Baseline Visit Blood & Urine Testing|Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
45805418|NCT05921188|Behavioral|VAULT Phase 4|Children will receive an input-based word learning treatment that is designed based on principles of statistical learning.
45938226|NCT00183586|Behavioral|Family therapy (FT)|FT is a family-based treatment that will be given for a total of 24 hours over the course of 12 months.
45938227|NCT00183586|Behavioral|Individual therapy (IT)|IT is an ego-oriented psychotherapy treatment that will be given for a total of 24 hours over the course of 12 months.
45938228|NCT00183742|Drug|liposomal doxorubicin and docetaxel|
46002622|NCT04646070|Procedure|Reduction mammaplasty|Breast reduction surgery
46074044|NCT02813304|Behavioral|Gradual reloading|Participants will be asked to perform isometric strengthening exercises in lateral rotation and abduction. Participants will place their affected arm by the side with the elbow gently tucked in close to the body, elbow flexed at 90°, and the thumb pointing upwards. The opposite hand will resist the lateral rotation and abduction. They will be asked to push against the uninvolved hand, building up to sub-maximal pressure (approximately 50% to 75% of the maximum possible force) over five seconds. Then the contraction will be slowly released. A maximum pain level of 5/10 will be accepted when performing the contraction. Elevation movements will also be performed 3 times a day in the frontal, sagittal and scapular plane.
46074045|NCT02813304|Behavioral|Rest and cryotherapy|Participants will be asked to apply ice wrap on their painful shoulder 3 times a day over the area of pain for 15 minutes. They will be asked to place the ice wrap inside a damp towel cloth (minimise the risk of an ice burn) and secure around the shoulder with a towel. After the 15 minutes, they will be asked to perform gentle, slow, pain free shoulder movements that do not provoke pain. All participants will be provided with a commercial ice wrap. They will also be asked to avoid painful movements, working above shoulder level, repeated or sustained elevation movements and lifting weights.
46074046|NCT00851929|Drug|Ambrisentan|ambrisentan 5 mg/day for month month, then 10 mg/day for 3 additional months
46074047|NCT02813460|Drug|Formulation A (ALS-008176)|Reference formulation, 60 mg/mL ALS-008176 oral suspension without sweetener/flavor.
46074048|NCT02813460|Drug|Formulation B (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 12 mg/mL sucralose.
46074049|NCT02813460|Drug|Formulation C (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and strawberry flavor.
46074050|NCT02813460|Drug|Formulation D (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and strawberry flavor.
46074051|NCT02813460|Drug|Formulation E (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and cream vanille flavor.
45654188|NCT02474355|Procedure|Baseline ECG|ECG to ensure absence of any cardiac abnormality
45654189|NCT02474355|Procedure|Visual Slit-Lamp Testing|Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
46002623|NCT00545987|Device|TriGrid™ Delivery System|Subjects will be administered the study drug using Ichor Medical Systems' intramuscular TriGrid™ delivery device.
45654190|NCT02474355|Drug|AZD9291 Dosing|Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
45805419|NCT05921175|Device|RGT+ tSCS + conventional physiotherap|Subject will undergo 16 sessions of robotic gait training (RGT) + tSCS+ conventional physiotherapy in 8-10 weeks. Subject will walk with EksoGT for gait training during RGT training. Components of conventional physiotherapy will include upper/lower limb ergometry and strength training as prescribed by the attending physiotherapist based on their assessment. During tSCS, cathodes will be placed on the T11 and L1 spinous process. Reference/Ground electrodes placed over the ASIS It will be on biphasic mode with an overlap frequency of 10kHz, Burst Frequency of 30Hz, Pulse width of 1ms. Stimulation intensity ranges from 5-100 mA and will be adjusted according to the patient's response. The tSCS stimulation duration for each session will be 45 minutes in conjunction with the RGT training.
45805420|NCT05921175|Device|RGT+ conventional physiotherapy|Subject will undergo 16 sessions of robotic gait training (RGT) + conventional physiotherapy in 8-10 weeks. Subject will walk with EksoGT for gait training during RGT training. Components of conventional physiotherapy will include upper/lower limb ergometry and strength training as prescribed by the attending physiotherapist based on their assessment.
46074052|NCT02813460|Drug|Formulation F (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and fantasy fruit flavor.
45654191|NCT02474199|Biological|darTregs|A single intravenous infusion as described administered over a 20-30 minute interval with close monitoring prior to, during, and after the infusion.
45654192|NCT02474199|Drug|Acetaminophen|Pre-medication for darTregs infusion. A dose of 15 mg/kg will be administered 30 to 60 minutes prior to the darTregs infusion.
45805421|NCT05921162|Biological|Gene Therapy product:vMCO-I|Safety evaluation to monitor long term effects of previously injected vMCO-I in RP patients
45835741|NCT01068210|Behavioral|Progressive Stretching|The ultimate goal for the progressive stretching program is 3 individual stretching sessions. All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
46074053|NCT02813460|Drug|Formulation G1 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
46074054|NCT02813460|Drug|Formulation G2 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
46074055|NCT02813460|Drug|Formulation G3 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
46074056|NCT02813460|Drug|Formulation H1 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
46074057|NCT02813460|Drug|Formulation H2 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
45654193|NCT02474199|Drug|Diphenhydramine|Pre-medication for darTregs infusion. A dose of 1-2 mg/kg diphenhydramine will be administered 30 to 60 minutes prior to the darTregs infusion.
45835742|NCT04753944|Dietary Supplement|Active Comparator: Probiotic|The evaluation of the influence of a probiotics therapy on mood improvement and the reduction of depressive symptoms in women in the perimenopausal age group.
45835743|NCT04753944|Dietary Supplement|Placebo group|Patients will be introduced for 5 weeks with placebo consisting of starch, maltodextrins and vegetable protein. The placebo dose is going to be 4 capsules daily. The treatment will be administered two times a day, during breakfast and supper.
45835744|NCT01895400|Drug|Renexin (cilostazol 100mg + gingko biloba extract 80 mg)|Take Renexin 1T bid po medication for 8 weeks
45835745|NCT01895400|Drug|Placebo|Take placebo drug 1T bid po medication for 8 weeks
45835746|NCT04753866|Device|Facial scanner|The Bellus3D facial scanner will be used to scan the patient before and after implant rehabilitation in order to produce .obj files that allow 3D comparisons and to obtain discrepancy values regarding lip support.
45654194|NCT02474199|Drug|Immunosuppression (IS) Withdrawal|"Subjects:1.) who fulfill study eligibility criteria will withdraw IS 2.) enter the study on calcineurin inhibitor (CNI) monotherapy or a CNI-based regimen with either Prednisone or MMF as a second IS medication 3.) will proceed with changes in CNI dosing according to the protocol's CNI withdrawal algorithm.During the last 2 weeks of IS withdrawal (e.g., Step 2 in algorithm -CNI reduced 25%-pre darTregs), a single dose of darTregs will be infused IV. The subject will then, if eligible, proceed with IS withdrawal within 2 weeks after the infusion. Eligible subjects meeting the primary endpoint of 75% reduction in CNI from baseline after darTregs will be offered the opportunity to continue IS withdrawal until complete discontinuation of IS."
45835747|NCT04754256|Behavioral|Council of Nutrition Appetite Questionnaire - test for applicability in Danish COPD patients|Council of Nutrition Appetite Questionnaire - test for applicability in Danish COPD patients and for correlation of scores with lung function, CAT-score and other
45835748|NCT05605626|Other|the better retaining of skills|identify which teaching program has the better retaining of skills
45835749|NCT04753554|Device|ORI group|The patient group whose oxygenation will be managed by ORI values. Hyperoxia or hypoxia will be prevented by using also blood gas analysis in critically ill patients.
45835750|NCT04753554|Other|Conventional group|In this patient group oxygenation will be managed as usual, using blood gas analysis.
45835751|NCT05272098|Other|Group A will receive myofascial release therapy + conventional physical therapy|myofascial release therapy (4 sessions per week). It soft, deep and non-manipulative form of treatment that involves the application of gentle pressure while stretching the body's connective tissue. A specialized form of touch, somatic sense, and specific body movement protocols are the three steps involved in the myofascial release therapy + hot pack (15min) + back care advice and postural modification. A total of 45 min session four times a week.
45835752|NCT05272098|Other|Group B will receive endurance training of the trunk extensor muscles + conventional physical therapy|It will be treated with endurance training of trunk extensor muscles. Erector spinae and latissimus dorsi will be included. The exercise protocol will be in four levels Bilateral shoulder left in prone position+ contralateral arm and leg lift in prone position+ both hands behind head and bilateral shoulder lift +bilateral shoulder lift with arm fully elevated + Hot pack (10 min) + back care advice and postural modification. A total of 45 min sessions four times a week.
45805422|NCT05921149|Dietary Supplement|Fasting Mimicking Diet (Xentigen by L'Nutra)|L-Nutra Xentigen is a product which will provide all the food to be consumed by subjects during 3 days prior to chemotherapy and for 24 hours after chemotherapy. Xentigen is a plant-based diet program designed to attain fasting-like effects while providing both macro- and micronutrients to minimize the burden of fasting and adverse effects. The FMD consists of 100% ingredients that are generally regarded as safe (GRAS) and comprises proprietary vegetable-based soups and broths, energy bars, energy drinks, cracker snacks, herbal teas, and supplements. The FMD consists of a 4-day regimen that provides approximately 1100 kilocalories for the first day and approximately 500 kilocalories per day for the second to the fourth day. Subsequently, a day 5 of transition diet (approximately 800 kilocalories) is provided to avoid the refeeding syndrome.
45805423|NCT05921149|Drug|Carboplatin|Given IV
45805424|NCT05921149|Drug|Paclitaxel|Given IV
45805425|NCT05921149|Dietary Supplement|Standard diet|Normal diet
45938229|NCT02965248|Drug|Standard adjuvant systemic chemotherapy|"Patients undergo radical surgery with standard adjuvant systemic chemotherapy (mFOLFOX6/CapeOx/sLV5FU2/Cape).~mFOLFOX6: oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~CapeOx: oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~sLV5FU2: leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~Cape: capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles."
45938230|NCT02965248|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed|Raltitrexed (3 mg/m2) is added to the perfusate after attaining 42 degrees of inflow temperature and last for 60 minutes.
45938231|NCT02965248|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin|Before the beginning of HIPEC, 5-FU 400 mg/m2 and leucovorin calcium 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (130 mg/m2) is added to the perfusate after attaining 42 degrees inflow temperature with a total of 30 minutes perfusion time.
45938232|NCT00183781|Behavioral|FITT: Family Intervention - Telephone Tracking|
45938233|NCT00183820|Drug|paclitaxel, gemcitabine, and oxaliplatin|"Paclitaxel 170 mg/m2 IV d 1 14 days~Gemcitabine 800 mg/m2 IV d 1 14 days~Oxaliplatin 100 mg/m2 IV d 1 14 days"
46074058|NCT02813460|Drug|Formulation H3 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
46074059|NCT02813538|Drug|Indocyanine green clearance|To evaluate liver function by injection of indocyanine green by a peripheral vein and measure its clearance
46074060|NCT02813538|Other|Thromboelastometry|To evaluate blood coagulation impairment by obtaining blood sample from a peripheral vein and measure anticoagulant proteins levels plus obtaining thromboelastometry
46074061|NCT02813382|Drug|Bupivacaine|Spinal anesthesia was performed using 10.5mg bupivacaine with added sufentanil (2µg).
46074062|NCT02813382|Drug|Prilocaine|Spinal anesthesia was performed using 60mg prilocaïne with added sufentanil (2µg).
45654195|NCT02474199|Procedure|Study Mandated Procedures|Blood draws (venipuncture); collection of peripheral blood mononuclear cells (PBMCs) by a procedure known as leukapheresis or venipuncture; buccal (cheek) swab for HLA typing; liver biopsies (per protocol and for cause).
45654196|NCT02450487|Drug|Piroxicam|After extraction of at least one third molar, 100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed. For the pharmacokinetics of piroxicam saliva samples will be collected from 10 of these patients at different times after ingestion of a capsule of 20 mg Piroxicam (before, 1, 2, 3, 4, 5, 6, 8, 11, 24, 48 and 72 hours after ingestion).
45805426|NCT05921110|Procedure|Pericapsular nerve group block 0,25%|"Used for postoperative anagesia after hip operations under spinal anaesthesia.~Drug: Bupivacaine (Block Drug)~For block performances, 0,25% Bupivacaine will be used at 20 ml volume."
45805427|NCT05921110|Procedure|Pericapsular nerve group block 0,16%|"Used for postoperative anagesia after hip operations under spinal anaesthesia.~Drug: Bupivacaine (Block Drug)~For block performances, 0,16% Bupivacaine will be used at 20 ml volume"
45805428|NCT05921097|Diagnostic Test|Histamin-induced axon-reflex flare response|Histamin-induced axon-reflex flare response
45938234|NCT02969720|Dietary Supplement|Phytosterols|Oral daily consumption of 2 grams of phytosterols (8 ml) per 180 days.
45938235|NCT02969720|Dietary Supplement|Titanium Dioxide|Oral daily consumption of Titanium Dioxide (8 ml) per 180 days.
45938236|NCT00183859|Drug|irinotecan|Intraperitoneal Irinotecan given every three weeks
45938237|NCT02963428|Behavioral|Enhanced Care|"In addition to standard of care, the study participants will also receive:~i. An initial consult with a licensed, Registered Dietician Nutritionist (RDN); ii. Regular tele-health check-ups (10-20 mins/check-up) with the RDN until delivery; iii. Exposure to personal GWG chart; iv. Letter from physician stating the recommendations for GWG over the course of the pregnancy."
45938238|NCT03898050|Procedure|transcutaneous cardiac pacing|transcutaneous cardiac pacing
45938239|NCT00183898|Drug|oxaliplatin, capecitabine|cetuximab 400 mg/m2, followed by weekly cetuximab 250 mg/m2 with oxaliplatin 130 mg/m2 on day 1 (every 3 weeks) with capecitabine 850 mg/m2 bid, daily on days 1-14, every 3 weeks.
46002624|NCT00545987|Device|conventional intramuscular injection|administration of an HIV-1 vaccine encoding the gag, env, pol, nef, and tat antigens (ADVAX)by conventional intramuscular injection
46074063|NCT02813382|Drug|Chloroprocaine|Spinal anesthesia was performed using 40mg hyperbaric 2-chloroprocaïne with added sufentanil (2µg).
46074064|NCT00619645|Drug|busulfan|
46074065|NCT00619645|Drug|cyclosporine|
46074066|NCT00619645|Drug|fludarabine phosphate|
46074067|NCT00619645|Drug|mycophenolate mofetil|
46074068|NCT00619645|Procedure|allogeneic hematopoietic stem cell transplantation|
46074069|NCT00619645|Procedure|peripheral blood stem cell transplantation|
46074070|NCT02810730|Procedure|Pancreatic MRI|Pancreatic MRI in the 6 months following the first consultation
45805429|NCT05921097|Diagnostic Test|Local heating-induced axon-reflex flare response|Local heating-induced axon-reflex flare response
45805430|NCT05921097|Diagnostic Test|2-point discrimination tasks|2-point discrimination tasks
46074071|NCT02861027|Procedure|PPTHA|The control group will receive Protocol Physiotherapeutic Total Hip Arthroplasty (PPTHA), consisting of guidelines on the care and post THA. The PPTHA, is held once a day, for 60 minutes, accompanied by a physiotherapist and has the following composition: 1 day) oral guidance and exercise to strengthen the gluteal muscles and muscles of the thigh, with recommendation for 3 repetitions of 12 movements, for each financial year. Patients are encouraged to sit outside the bed, after the exercises; Day 2) patients perform exercises the first day and begin the March training, with the aid of a Walker or crutches Canadians for the room; Day 3) patients perform exercises and are encouraged to walk in the hallway of the hospital wing. Day 4) reassessment and discharge.
46074072|NCT02861027|Procedure|FES and PPTHA|The PPTHA associated with FES. The stimulation protocol of FES is performed with the patient positioned in supine position in bed. After cleaning the skin, two electrodes are positioned in the posterolateral region of the thigh in motor point of the medium gluteus muscle. The total time for application of the apparatus 30 min per day totaling more 1 min per day as suggested in specialized references. The intensity is adjusted according to the tolerance of the patient. The apparatus used is wavelength Ibramed Neurodyn Compact.
46074073|NCT00852007|Biological|DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1|1.2 x 10e7 dendritic cells per dose. One dose delivered intradermally (i.d.) and into a node (i.n.). Two weeks after this,two injections i.d. 2 weeks apart. Optional booster injections at 6 (i.d. and i.n.) and and 12 months (i.d.).
46074074|NCT02810574|Behavioral|Cognitive training|
46074075|NCT02810574|Device|Noninvasive brain stimulation (active)|Neuroconn DC-STIMULATOR PLUS
46074076|NCT02810574|Device|Noninvasive brain stimulation (sham)|Neuroconn DC-STIMULATOR PLUS
46074077|NCT02545699|Device|G-EYE™ Colonoscopy|G-EYE™ Colonoscopy
46074078|NCT02545699|Device|Standard Colonoscopy|Standard Colonoscopy
46074079|NCT02810262|Other|Bone metastases biopsy|The vast majority of bone biopsy are performed under CT-scan. In some rare cases, the histology will be performed during surgery (either biopsy of the bone metastasis or surgical piece when treating a fracture).
46074080|NCT00852085|Behavioral|Enhanced community service|Two educational sessions and volunteering at a local community service site
46074081|NCT00852085|Behavioral|Group MI|Four group counseling sessions and two directed observational visits to an emergency department
46074082|NCT02545855|Device|High-flow nasal cannula therapy|All subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current HOT. The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
46074083|NCT02545855|Device|Home oxygen therapy (HOT)|All subjects will continue their current HOT which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
46074084|NCT05584410|Other|Patient information|Patient education according to national guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
45654197|NCT02473965|Drug|IGIV-C|"Run-Phase: 1 loading dose of 2 g/kg IGIV-C and 2 maintenance doses of 1 g/kg IGIV-C~Corticosteroid Tapering/IGIV-C Maintenance Phase: 1 g/kg IGIV-C every 3 weeks for up to 36 weeks"
45654198|NCT02473965|Drug|Placebo|
45805431|NCT05921097|Diagnostic Test|NC-Stat DPNCheck|NC-Stat DPNCheck
45654199|NCT04939311|Drug|VB-201|One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
45654200|NCT04939311|Drug|Placebo|One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
46074085|NCT05584410|Other|Smartphone application based exercises|Individually based exercise programs individualized exercises where instructions are given through real-time video or pictures in combination with written descriptions.
46074086|NCT05584410|Other|Web based exercises|Generic OA exercise, including about 20 different exercises, provided by real-time videos and written description
45654201|NCT02472795|Drug|Matching placebo|One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
45654202|NCT02472795|Drug|Cenerimod|One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
45805432|NCT05921097|Diagnostic Test|QST|QST
45805433|NCT05921097|Diagnostic Test|Biothesiometry|Biothesiometry
45805434|NCT05921084|Behavioral|MIND diet intervention|The MIND diet intervention, composed of the consumption of whole grains, dark green leafy vegetables, dark red/yellow vegetables, other vegetables, berries and citrus, poultry, fish and seafoods, beans and legume, nuts, olive and seed oils, and green tea, and restricting red and processed meats, animal fat, fried foods, and sweets and pastries.
45805435|NCT05921084|Behavioral|General dietary advice|General dietary advice
45805436|NCT05921071|Drug|Tranexamic acid|One gram of tranexamic acid (Hexakapron) is administered intravenously before surgery
45805437|NCT05921071|Drug|Placebo|patients will receive 10 ml of normal saline 0.9% intravenously.
45805438|NCT05921058|Drug|Secretome|Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
45805439|NCT05921058|Drug|Placebo|NaCl 0,9% infusion
45805440|NCT05921045|Other|modification of clinical approach in clinical practice at time 0|evaluation of modification in clinical approach after training
45805441|NCT05921045|Other|modification of clinical approach in clinical practice at 6 months|evaluation of modification in clinical approach after retraining
45805442|NCT05921032|Other|Exercise intervention|8 weeks of exercise with two session in a week
45805443|NCT05921019|Device|laser acupuncture|This study will use the Handylaser Trion laser manufactured by RJ Laser, Germany.
45938240|NCT04730765|Procedure|left elective colectomy (Surgical Experimental Group)|Conventional laparoscopic resection of the sigmoid colon is performed using four ports. The left colon is mobilised from the lateral side along Gerota's fascia. The splenic flexure is mobilised at the discretion of surgeons. The mesentery of the sigmoid colon is then medially fenestrated at the promontory level. The superior rectal artery as well as the inferior mesenteric artery and vein are identified and are cut using tissue-sealing devices. A linear stapler device is applied for division of the large intestine. The sigmoid is retracted through a Pfannenstiel incision or enlargement of the left lower abdominal incision. Colorectal anastomosis is performed using a double stapling technique following open resection of the affected colon.
45938241|NCT04730765|Drug|antibiotic therapy (medical Control Group)|Antibiotic treatement for 10 days by oral or intravenous administration
45938242|NCT00183937|Drug|PS 341|PS 341 1.6 mg/m2 IV (in the vein) on days 1 and 8 of each 21 day cycle up to 12 cycles.
45938243|NCT00183937|Drug|Docetaxel|Docetaxel 75mg/m2 IV (in the vein) on day 1 of each 21 day cycle up to 12 cycles.
45938244|NCT02963467|Procedure|cigarette|smoking 4 conventional cigarettes
45938245|NCT02963467|Procedure|"dummy cigarette"|"smoking a dummy cigarette"
45938246|NCT00408772|Biological|bevacizumab|
45938247|NCT00408772|Drug|capecitabine|
45938248|NCT00408772|Drug|oxaliplatin|
45938249|NCT00408772|Procedure|conventional surgery|
45938250|NCT00408772|Procedure|neoadjuvant therapy|
45938251|NCT00408772|Procedure|radiofrequency ablation|
45938252|NCT00408850|Drug|Pioglitazone|15 mg per day for 6 weeks and 30 mg per day for further 6 weeks
45938253|NCT00408850|Drug|sugar pill|One capsule daily for 6 weeks followed by two capsules per day for next 6 weeks
45938254|NCT00057590|Behavioral|Care manager outreach and monitoring|
45938255|NCT00408967|Drug|Tucotuzumab celmoleukin (EMD 273066)|
46074087|NCT05584410|Other|Group based information|OA specific information at three different group meeting (physical or digital) led by a physiotherapist, an occupational therapist and / or dietitian (each rehab clinic makes its own arrangement).
45938256|NCT00183976|Drug|Pegylated Liposomal Doxorubicin (Doxil) and Rituximab|
46074088|NCT05584410|Other|Supervised rehabilitation|The patient is offered to regularly exercise at the clinic, individually or in a group under supervision from a physiotherapist.
46074089|NCT05584410|Other|Self-monitoring|Patients will be followed by validated questionnaires and function tests (30 sec Chair-to-stand test) every six months until three years after the start of treatment. The patients will get a report of the results and a research coordinator will contact the patients if their symptoms/function has worsen and discuss further treatment
46074090|NCT05584410|Behavioral|Motivational notifications|Automatic and daily reminders and / or motivational notifications
45805444|NCT05921019|Device|sham laser acupuncture|This study will use the sham Handylaser Trion laser manufactured by RJ Laser, Germany,and without any laser beam delivering
45805445|NCT05921006|Drug|RJ4287|Oral，tablets，Once daily for 14 days
45805446|NCT05921006|Drug|Placebo|Oral，tablets，Once daily daily for 14 days
45805447|NCT05920980|Drug|lidocaine|Patients in the lidocaine groups, lidocaine 1.5mg/kg/h was continuously infused (using ideal body weight) during the whole procedure, postoperative analgesia pump with lidocaine (lidocaine 50mg/kg, sufentanil 2ug/kg, glassetron 12mg), diluted to 200ml with saline until 72h after surgery. Blood samples will be collected from some patients in the lidocaine group for the measurement of lidocaine plasma concentration.
45938257|NCT00046683|Drug|alemtuzumab|
45938258|NCT00184015|Drug|Bevacizumab and Bortezomib|Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.0 or 1.3 mg/m2 on days 1, 4, 8 and 11 every 21 days
45938259|NCT00184015|Drug|Bevacizumab and Bortezomib|Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.6 or 1.8 mg/m2 on days 1 and 8 every 21 days
45938260|NCT00057629|Behavioral|Prolonged Exposure (PE)|Prolonged Exposure (PE) consists of 10 weekly 90-minute treatment sessions, which may be extended up to 20 sessions, depending on client response. Treatment procedures include education about common reactions to trauma, breathing retraining, prolonged (repeated) exposure to trauma memories, repeated in vivo exposure to situations the client is avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises as well as beliefs about self and the world.
45938261|NCT00057629|Behavioral|Treatment as usual group therapy (TUGT)|TUGT is delivered in ten weekly sessions, with 5 to 7 members and two counselors per group. There is not a formal, structured format for these groups; the counselors are sensitive to the participants' needs and follow their lead in terms of content covered in discussions and exercises. TUGT is conceptualized as supportive counseling and is based on the idea that members gain social support and information from one another.
45938262|NCT00057629|Behavioral|Supportive counseling (SC)|Supportive counseling is an individual therapy delivered in 10 weekly, 90 minute sessions. During this treatment, the therapist helps the patient identify daily stresses that may or may not be related to traumatic events and discusses them in a supportive non-directive mode with a problem-solving orientation. The therapist uses active listening, encouragement of expression of feelings, praise, and encouragement. The goal of this present-focused treatment is to provide support and to help the client to identify problems and stresses of daily living and to help her cope with these. No instructions for exposure are given.
45938263|NCT00184132|Procedure|Psychiatric intensive care unit in Norwegian home style|
45938264|NCT00184132|Procedure|Psychiatric intensive care unit sparsely furnished and not decorated|
45938265|NCT00184171|Drug|Budesonide|Budesonide 9 mg
45938266|NCT00184171|Drug|Bismuth|Bismuth mixture
45938267|NCT00184171|Drug|Fiber|Fiber for control
45938268|NCT00046722|Drug|Smoked Marijuana|
45938269|NCT00057668|Behavioral|Multi-Setting Early Intervention|
45938270|NCT00057668|Behavioral|Community Intervention|
45938271|NCT00184249|Procedure|Bipolar radiofrequency ablation|Ablation using CE marked bipolar ablation devices
45805448|NCT05920980|Drug|Placebo|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 mL.
45654203|NCT02507349|Behavioral|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
45654204|NCT02507349|Behavioral|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
45654205|NCT02506881|Drug|Darbepoetin alfa|
45654206|NCT02506257|Drug|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
46074091|NCT05584410|Other|Home based rehabilitation|Individualized exercises that the patient performs on their own, i.e. at home or at a gym.
46074092|NCT00852163|Drug|Clofarabine with Busulfan|Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days
45805449|NCT05920967|Drug|Dexamethasone Palmitate|a single paraverteal space infusion of 21 ml of the first dose of analgesia, consisting of 0.5 percentage ropivacaine 20 ml and dexamethasone palmitate 1ml. Then, a continuous paraverteal nerve block pump was connected for postoperative analgesia. The liquid of the pump was 250 ml 0.2 percentage ropivacaine. The background of the pump was set to 5 ml/h and PCA was set to 5 ml at an interval of 30 min.
46074093|NCT00851071|Behavioral|Cognitive Behavioral Therapy|Three 45 minute CBT sessions scheduled over a 3 month period.
46074094|NCT04237038|Procedure|laparoscopic Nissen fundoplication short gastric vessel division|Randomized clinical trial conducted in forty patients submitted to SGVD and forty patients without SGVD. Patients were evaluated with standarized questionnaires to measure the degree of satisfaction in relation to surgical procedure and to the quality of life. A randomized clinical trial was conducted with 87 patients submitted to laparoscopic Nissen fundoplication between February 2013 to december 2014 according to the guidelines established by the Mexican Consensus for the study of Gastroesophageal reflux disease (GERD
45805450|NCT05920967|Drug|Dexamethasone Sodium Phosphate|a single paraverteal space infusion of 21 ml of the first dose of analgesia, consisting of 0.5 percentage ropivacaine 20 ml and dexamethasone sodium phosphate 1ml. Then, a continuous paraverteal nerve block pump was connected for postoperative analgesia. The liquid of the pump was 250 ml 0.2 percentage ropivacaine. The background of the pump was set to 5 ml/h and PCA was set to 5 ml at an interval of 30 min.
45805451|NCT05920954|Procedure|ERCP|Repeat ERCP
45938272|NCT00184327|Behavioral|Intensive family therapy - inpatient|2-4 weeks (5days) family inpatient assessment and treatment
46074095|NCT00855517|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
46074096|NCT02690220|Device|TiLOOP® PRO Plus A|The standard operation method for the surgical repair of anterior prolapse is via the obturator membrane. The mesh is placed trans-vaginally using the TiLOOP® Application Set to place the mesh arms.
46074097|NCT00855673|Device|Intermittent Mechanical Compression|FM220 device
46074098|NCT00855673|Drug|Control|Standard medical treatment
46074099|NCT02814864|Drug|Mesenchymal Stromal Cell (MSC) injections|12 patients suffering of PRD (LENT-SOMA scale>2) will receive Mesenchymal Stromal Cell (MSC) injections
45654207|NCT02506257|Drug|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
45654208|NCT02506257|Drug|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
45654209|NCT02506257|Drug|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
45938273|NCT00184327|Behavioral|Diagnostic assessment - child and adolescent psychiatry|
45938274|NCT00057707|Drug|Modafinil|Placebo 1 week-Wash out 1 week - Drug 1 week (or vice versa)
45938275|NCT00057707|Procedure|Functional MRI|
46074100|NCT00855829|Device|Miniature Actilady device active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).~The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
46074101|NCT00855829|Device|Miniature Actilady device not active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).~The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
46074102|NCT02810496|Genetic|blood collection for mutation characterization|
46074103|NCT00855907|Other|clinical evaluation|"Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.~Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography."
46074104|NCT05583942|Device|trascutaneous auricular vagus nerve stimulation|The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.
45938276|NCT00057707|Procedure|Neuropsychological Testing|
45938277|NCT02963584|Other|decision aid|The related information about CTO and PCI procedures will be told to the patients thoroughly.
45938278|NCT00184366|Drug|efalizumab|efalizumab
45938279|NCT00046761|Drug|ONO-2506|
46074105|NCT05583942|Device|Sham device|The device will appear to function but no electrical stimulation will be delivered.
46074106|NCT00855985|Procedure|type of anastomosis after pancreaticoduodenectomy|pancreaticojejunostomy (arm 1) versus pancreaticogastrostomy (arm 2)for reconstruction of the pancreatic remnant after pancreaticoduodenectomy
46074107|NCT02815176|Other|Blood sampling|Sampling the blood including DNA to investigate the thrombotic profile
46074108|NCT02809794|Device|Fisher & Paykel Healthcare CPAP Device|Fisher & Paykel Healthcare CPAP Device
46074109|NCT04187274|Device|IKORUS technology|Ikorus technology is a new micro perfusion device measuring via urethral photoplethysmography, the urethral perfusion index (uPI) in patients equipped with an urinary catheter.
46074110|NCT02814474|Other|Na-3-hydroxybutyrate|Infusion of Na-3-hydroxybutyrate (0.18 g/kg/hour) for 390 minutes
45654210|NCT02506101|Device|narrow-band ultraviolet B phototherapy|There are two types of UVB: broad band and narrow band, with the major difference being that narrow band emits a smaller range of ultraviolet light, typically 311-312 nm. NB-UVB is a clinically indicated treatment for vitiligo lesions and treatments are usually administered in an outpatient setting 3 times a week.
45654211|NCT02505945|Drug|Omeprazole|
45654212|NCT02505945|Device|LINX Reflux Management System|
45654213|NCT02505867|Device|Adaptive Servo Ventilation|Participants are provided with an Adaptive Servo Ventilation (ASV) device for targeted treatment of SDB during inpatient hospitalization or shortly after discharge.
45805452|NCT05920941|Drug|[14C]JAB-21822|Single oral administration of Carbon-14 labeled JAB-21822 800 mg/100 μCi on empty stomach
45938280|NCT00184444|Behavioral|Hypoxic interval training|4 x 4 minutes interval training in hypoxic air, 3 times per week at 90-95% HR max
45938281|NCT00184444|Behavioral|Normoxic interval training|4 x 4 minutes normoxic interval training, 3 times per week at 90-95% HR max
46074111|NCT02814474|Other|Saline|Infusion of 0.9 % saline
46074112|NCT02812836|Device|Manometry|Each patient will be investigated first by anorectal manometry, standard protocol of conventional parameters will be recorded such as: resting pressure, squeeze pressure, bear down manoeuver, thresholds of sensation and threshold of recto anal inhibitory reflex. 3D picture of anal canal will be recorded. After that balloon with 50 ml of water will be inserted into the rectum and patient will be asked to expel the device within 1 min in privacy.
46074113|NCT02544919|Drug|SMOF lipid (SMOFLIPID) pre treatment|Experimental Arm
45938282|NCT00184483|Procedure|Lichtenstein's operation|Lichtenstein's operation to repair primary unilateral inguinal hernia
45654214|NCT02472639|Device|Ostom-i Alert Sensor|Wear the Ostom-i Alert Sensor
45805453|NCT05920928|Radiation|Short course radiotherapy with concurrent capecitabine(825mg/m2)|Compared to conventional treatments, short-term radiotherapy has lower fraction numbers but higher radiation doses per fraction. capecitabine is given during treatment time (825mg/m2)
46074114|NCT05625438|Device|HandyMotion Treatment Program|A pair of sensor-based wireless remote controllers to allow the performance of functional exercises and games that target arm movement.
46074115|NCT02812914|Other|Low-cost gas stove|Women will be provided with a 3-burner liquid propane gas stove and one year's supply of gas
46074116|NCT02812914|Behavioral|Peer education classes|Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution
46074117|NCT02812914|Behavioral|Resource-intensive behavioral intervention approach|Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution. Additionally, peer educators will visit each home after group classes to help the woman, and key decision-makers in her family, identify top priority strategies to reduce air pollution. Using a checklist, peer educators will observe whether household members are adhering to tailored strategies at subsequent home visits, and provide ongoing support to women and their families.
45805454|NCT05920928|Radiation|Long course radiotherapy with concurrent capecitabine(825mg/m2)|Long-term radiation is administered in conjunction with concomitant capecitabine (825mg/m2)
45938283|NCT00184483|Procedure|Prolene Hernia System|Prolene Hernia System to repair primary unilateral inguinal hernia
45805455|NCT05920915|Other|non-interventional clinical research|This study is a non-invasive clinical trial designed to observe the effect of applying cold to the neck area to effect of venous cannulation pain
45805456|NCT05920902|Other|routine therapy of acute ischemia stroke|Routine therapy of acute ischemia stroke based on the guidelines, which generally includes two parts: evaluation and medicine treatment. Evaluation includes peripheral blood test, radiologic examination, electrophysiological examination, ultrasonic examination. Medicine treatment includes drug therapy and rehabilitation.
46074118|NCT02812680|Other|Blood Draw|Blood draw to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy.
46074119|NCT00818259|Drug|Experimental: aprepitant|aprepitant powder for suspension, 125 mg/sachet, PO
46074120|NCT00818259|Drug|Experimental: fosaprepitant|fosaprepitant lyophilized powder for suspension, 115 mg/vial or 150 mg/vial, IV
46074121|NCT00818259|Drug|Comparator: ondansetron|ondansetron solution for infusion, IV, administered per local standard of care
46074122|NCT00818259|Drug|Ondansetron|ondansetron solution for infusion, IV, administered per local standard of care
46074123|NCT00818259|Drug|Dexamethasone|dexamethasone solution for infusion, IV, administered per local standard of care
45938284|NCT02969759|Other|Skin Biopsy|
45938285|NCT00184522|Drug|Aflurax|
45654215|NCT02472639|Other|No Ostom-i Alert Sensor|Patient will not use device
45654216|NCT02472405|Device|595/1064nm Multiplex Laser|The multiplex cynergy laser will be used for this study. A third of the scar will solely be treated with the 595nm PDL.
45654217|NCT02472405|Device|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week).
45938286|NCT00184522|Drug|esomeprazole|
45938287|NCT00184561|Drug|biphasic insulin aspart|
45938288|NCT00184639|Drug|insulin detemir|
45938289|NCT00184678|Drug|somatropin|
45938290|NCT00058097|Drug|tipifarnib|Given orally
45938291|NCT00058097|Radiation|radiation therapy|Undergo radiation therapy
45938292|NCT00184756|Drug|somatropin|
45938293|NCT00184795|Drug|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|One tablet per day for 24 weeks
45654218|NCT03194971|Other|Tumor samples from patients treated with TTFields at initial diagnosis.|Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
45654219|NCT03194971|Device|Tumor samples from patients treated with TTFields at tumor recurrence.|Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
46074124|NCT02810028|Behavioral|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT) is a form of cognitive behavioural therapy focused explicitly on promoting psychological flexibility. An ACT programme suits the aims of the study because it targets avoidance of distress, promotes acceptance of illness through motivating meaningful activity outside of illness, improves the processes that underlie beliefs rather than by directly challenging beliefs, thus reducing possible trivialisation of the understandable distress caused by living with MD.
45938294|NCT00184795|Drug|0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)|One tablet per day for 24 weeks
46074125|NCT02809950|Other|oral carbohydrate beverage|oral carbohydrate beverage (12.8% carbohydrates, 50 kcal/100ml, 290 mOsm/kg, NO-NPO®, Daesang WelLife Co., Ltd., Korea) 400ml in the evening of the day before surgery and at 6 am on the day of surgery, respectively
46074126|NCT02809950|Other|control group|NPO from midnight of the day before surgery
46074127|NCT02809872|Other|Diagnostic Thoracic Ultrasound|
46074128|NCT00913575|Other|preoperative neuromuscular training|The neuromuscular training group will receive a minimum of 8 and a maximum of 24 training sessions; as well as 4 sessions of the Knee OA School.
46074129|NCT00913575|Behavioral|knee OA School|The education group will only receive 4 sessions of the Knee OA School.
45654220|NCT04213885|Combination Product|PXL 330 Platinum device/Riboflavin|30mW, 5 sec, 5 sec off, 10 minutes of illumination
45654221|NCT02448771|Drug|Palbociclib|
45654222|NCT02448771|Drug|Bazedoxifene|
45654223|NCT02504541|Combination Product|Testosterone enanthate auto-injector|Dose Adjustment 50 mg or 75 mg or 100 mg based upon Testosterone levels
45654224|NCT04924257|Drug|Esketamine nasal spray|Patients will receive two treatments per week for four weeks (maximum of eight treatment sessions) or until clinical remission (MADRS <10).
45654225|NCT04924257|Procedure|Electroconvulsive therapy|Patients will receive three treatments per week for four weeks (maximum of 12 ECT treatments) or until clinical remission (MADRS <10).
45654226|NCT04924179|Drug|Tislelizumab plus Fruquintinib and SBRT|Fruquintinib:5mg ,qd,po, d1-d14, 21 days for a cycle;Tislelizumab Injection:200mg，IV,d1,21 days for a cycle;SBRT:8-10Gy×5F,qod,in 10 days.
45654227|NCT04975945|Drug|Ceftriaxone Sodium|Intravenous vs local action
45654228|NCT03053479|Procedure|Laparoscopic sacrocolpopexy|see arm/group descriptions
45805457|NCT05920889|Drug|Semaglutide|0.5mg subcutaneous injection of the drug before or during EVT, and 7 days after the procedure. i.e. patient will receive a total of 2 injections.
45805458|NCT05920876|Drug|QLS32015|Participants will receive subcutaneous (SC) injection of QLS32015. Eight dose groups were proposed, 21 days as a treatment cycle.
45654229|NCT03053479|Procedure|Transvaginal mesh procedure|see arm/group descriptions
45654230|NCT03053479|Procedure|Amreich-Richter procedure|see arm/group descriptions
45654231|NCT03034603|Dietary Supplement|Nutri-jelly with PEITC|Nutri-jelly with PEITC resulted from an addition of tested amount of PEITC, which was shown in animal model to delay cancer growth, into Nutri-jelly.
45654232|NCT03034603|Dietary Supplement|Nutri-jelly|Nutri-jelly is an edible nutritious gel for patients with chewing and swallowing difficulties. One milligram of Nutri-jelly contains approximately 1 kcal.
45654233|NCT03061747|Device|Assesment of outcome of implantable device patients|Evaluation during follow-up of the occurrence of atrial arrhythmias, hospitalizations, and of death.
45805459|NCT05920863|Procedure|TACE|TACE: pharmorubicin 30mg, oxaliplatin 50mg, cycle 4-5 week.
45805460|NCT05920863|Drug|Tislelizumab, Lenvatinib|Tislelizumab: 200mg, cycle 3 week. Lenvatinib: weight <60kg, 8mg/day; weight ≥60kg, 12mg/day.
45805461|NCT05920850|Other|Educational Video about LDCT lung cancer screening|A culturally tailored video that provides education about the process LDCT lung cancer screening
45938295|NCT00184795|Drug|placebo|Placebo tablets for 24 weeks
45938296|NCT00058253|Drug|tanespimycin|Given IV
45938297|NCT00058253|Drug|docetaxel|Given IV
46074130|NCT02809638|Other|ultrasound elastography|
45654234|NCT03063307|Procedure|Atraumatic Restorative Treatment|
45654235|NCT03063307|Other|Silver Diamine Fluoride|
45654236|NCT03061825|Device|Zenith Alpha™ Abdominal Endovascular Graft|Zenith Alpha™ Abdominal Endovascular Graft for the treatment of abdominal aortic or aorto-iliac aneurysm.
45654237|NCT02970565|Behavioral|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact.
45654238|NCT02970565|Behavioral|Nutrition and Play Intervention|Mothers and children in the Play and Nutrition group will play educational and nutrition-focused games.
45805462|NCT05920850|Other|A culturally tailored shared decision-making tool|A culturally tailored shared decision-making tool that educates participants about the shared decision-making process
45805463|NCT05920850|Other|Flip chart|The use of a flip chart that reinforces the information provided in the video and shared decision-making tool
45805464|NCT05920850|Other|Navigation support|Navigation support for participants who express interest in LDCT and quitting smoking.
45938298|NCT00046800|Drug|OSI-211 (Liposomal Lurtotecan)|
45805465|NCT05920837|Device|MyotonPRO|Muscles' viscoelastic properties assess with myotonPRO.
45938299|NCT00184834|Behavioral|quality of life|
45938300|NCT00184873|Behavioral|Health Counseling|
45938301|NCT00058292|Biological|filgrastim|Given at a dose of 5 μg/kg, subcutaneously daily, beginning on Day 0 (stem cell transplant day) until white blood cells measure greater than 1500/ul.
45938302|NCT00058292|Biological|rituximab|Intravenous infusion of 250 mg/m2 on treatment days -22 and -14 (day 0 = stem cell transplant).
46074131|NCT04326192|Device|Research electrode|A second electrode will be placed percutaneously by Tuohy needle in the epidural space at the same time as the SCS trial implant; at lateral T1-2 area randomly assigned to the left or right side of the lateral epidural space, at the time of the procedure. Placement of electrodes is not experimental, but the placement of a second electrode is a research-driven procedure.
46074132|NCT05578482|Drug|Dicloxacillin Oral Capsule|Randomized to either systemic dicloxacillin & elocon or placebo & elocon
46074133|NCT05578482|Drug|Elocon 0.1 % Topical Cream|Both groups are treated with elocon for five days.
45654239|NCT04434313|Device|Delivery of iStride™ device gait treatment using telemedicine|The gait device used in this study mimics the actions of the split-belt treadmill but can be used during overground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking. This research aims to adapt the delivery mechanism of treatment with the iStride™ device to include telemedicine. The telemedicine platform of reference in this study, the Moterum Digital Platform, is an integrated therapeutic platform which offers an activity library, real-time video conferencing, and outcomes tracking. Our primary study objective is to determine if telemedicine is a safe and feasible delivery method for treatment with the iStride ™ gait device.
45654240|NCT04975711|Drug|HIP2105|Test drug
45654241|NCT04975711|Drug|RLD2104|Reference drug
45805466|NCT05920837|Other|Box and Block Test|Upper extremity's functionality assess with Box and Block Test.
45805467|NCT05920824|Diagnostic Test|Echocardiogram|Ultrasound scan of the heart
45805468|NCT05920811|Other|conventional obturator|restoration of midline maxillary defect with obturator made of cast metal , heat cure acrylic resin
45805469|NCT05920811|Other|3 d printed obturator|restoration of midline maxillary defect with obturator made of SLM metal , 3 d printed resin
45805470|NCT05920798|Procedure|Biopsy|Undergo biopsy
45805471|NCT05920798|Procedure|Biospecimen Collection|Undergo blood sample collection
45805472|NCT05920798|Procedure|Computed Tomography|Undergo CT
45654242|NCT04874935|Drug|Lansoprazole|administration of lansoprazole 60 mg twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
45654243|NCT04874935|Drug|Placebo|administration of Placebo capsule twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
45805473|NCT05920798|Procedure|Magnetic Resonance Imaging|Undergo MRI
45805474|NCT05920798|Biological|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
45805475|NCT05920798|Biological|Pembrolizumab|Given IV
45805476|NCT05920798|Procedure|Pheresis|Undergo apheresis
45835753|NCT04753476|Biological|Injection of Secretome-MSCs|"Injection of Hypoxic Secretome-MSCs intramuscular (deltoideus) :~Day 1: 1 cc every 12 hours~Day 2: 1 cc every 12 hours~Day 3: 1 cc every 12 hours"
45835754|NCT04753476|Drug|Standard treatment of Covid-19|Patients will be given Standard treatment of Covid-19 which accordance with National protocol
45835755|NCT05605392|Other|Deinstitutionalization process|"Phase 1: Comprehensive geriatric assessment to evaluate who might be a candidate for deinstitutionalization.~Phase 2: Intervention:~Support plan: design a plan agreed upon with the participant to provide resources to the person's needs and which guarantees support during the transition and beyond.~Transition process: progressive withdrawal of support in the institution and implementation of support and adaptation in the community, with different types of accommodation depending on the needs and preferences of each participant. Coordination with primary care teams, social services, and other community resources.~Case follow-up and gradual withdrawal of the project team. If the process does not go as the person expects, or difficulties are encountered that cannot be resolved, the participant will have the option and choice, if desired, to return to the residence at any time during the process."
45835756|NCT05171946|Drug|S.opt.FL COVID-19 pDNA vaccine|Low-Dose: (1mg) level
45835757|NCT05171946|Drug|S.opt.FL COVID-19 pDNA vaccine|Mid-Dose: (2mg) level
45835758|NCT05171946|Drug|S.opt.FL COVID-19 pDNA vaccine|High-Dose: (4mg) level
45835759|NCT05605314|Other|Cyclosporine|eye drop
45835760|NCT04775940|Procedure|Perforated collagen membrane|Horizontal Bone Augmentation using Perforated Collagen Membrane
45835761|NCT04775940|Procedure|Occlusive collagen membrane|Occlusive collagen membrane
45835762|NCT02089464|Device|NBS-guided rTMS|
45835763|NCT02089464|Device|Sham rTMS|
45835764|NCT02089464|Procedure|Task oriented rehabilitation|
45835765|NCT04775862|Drug|investigator choice re-challenge with anti EGFR Rx|Upon second progression, patients will be enrolled into the study as per inclusion criteria and consent, and a cfDNA blood test will be drawn, and RAS status will be examined. If RAS is wildtype, then the investigator will decide whether to re-challenge with an anti EGFR antibody , or give SOC third line chemotherapy (Regorafenib or TAS-102).
45835766|NCT05605158|Drug|Pioglitazone 30mg|Pioglitazone 30 mg will be administered orally once daily for 24 weeks.
45835767|NCT05605158|Drug|Empagliflozin 10 MG|Empagliflozin 10 mg will be administered orally once daily for 24 weeks.
45835768|NCT04754880|Diagnostic Test|Comparison of oxidative and antioxidative markers between groups|Oxidant and anti-oxidant markers
45835769|NCT05598762|Genetic|Tape strips|Tape strip is a minimally invasive method that captures the stratum corneum. It is use to identify skin biomarkers in atopic dermatitis.
45835770|NCT01053234|Dietary Supplement|Standardised meals|
45835771|NCT02090088|Drug|Not applicable- observational study|
45835772|NCT05162820|Dietary Supplement|100 mg Solarplast|100 mg Solarplast delivered in capsules with the carrier of rice dextrin and medium chain triglycerides consumed daily at breakfast for 60 days
45835773|NCT05162820|Dietary Supplement|Placebo|rice dextrin and medium chain triglycerides in capsules consumed daily at breakfast for 60 days
45835774|NCT03433170|Procedure|Quadrupled semitendinosus graft|Quadrupled ST graft as unique graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
45835775|NCT03433170|Procedure|ST-Gracilis graft|Use of both semitendinosus and gracilis graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
46074134|NCT04237428|Biological|CD19 CAR-T cells infusion|"Biological: CD19 CAR-T cells infusion Biological: CD19 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD19 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD19 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD19 CAR-T cells are infused into patients for one time, the number of infused CD19 CAR-T cells are 0.5-4×10^6/kg."
45805477|NCT05920785|Diagnostic Test|Determination of the level of interleukins in the blood, stool analysis for the intestinal microbiome, general clinical tests, glucose tolerance test, hormonal profile|"comprehensive laboratory and instrumental diagnostics in accordance with federal clinical guidelines on obesity (Peterkova V. A., 2021), including:~general blood test, general urine test,~biochemical blood analysis (total protein, urea, creatinine, total bilirubin, AST, ALT, total cholesterol, high and low density lipoproteins, triglycerides, uric acid, alkaline phosphatase, C-reactive protein),~hormonal profile (T4 free, TSH, cortisol, C-peptide, fasting insulin, stimulated insulin),~glycated hemoglobin,~- glucose tolerance test,~ultrasound examination of abdominal organs, kidneys (in the presence of arterial hypertension),~blood pressure monitoring.~Special laboratory methods:~Blood test to determine the level of HCRP, pro-inflammatory cytokines (leptin, IL-1b, IL-6, IL-8, tumor necrosis factor-α).~analysis of feces for microbiota by MALDI-TOF mass spectrometry,~bioimpedance measurement."
45835776|NCT03370614|Other|IBS Group|Participants will receive approximately 2 months of dietary and nutritional counseling.
45654244|NCT04975477|Procedure|Esophagogasrtoduodendoscopy and liver stiffness|Time frame between elastography measurement and esophagogastroduodendoscopy is within 6 months.
45654245|NCT04975477|Procedure|hepatic venous pressure gradient|A method was used to evaluate portal pressure.
45835777|NCT03370614|Other|Healthy Control Group|Participants will not receive any dietary or nutritional counseling.
45835778|NCT04775238|Other|Silver nanoparticles|AgNPs (19±5 nm)
45654246|NCT03061591|Dietary Supplement|Wholistic Turmeric capsules|Oral capsules of wholistic Turmeric capsules (Pukka herbs) curcumin (each capsule 0.5100 m gr curcumin) for a total of 4 gr/d divided twice daily.
45654247|NCT03061591|Other|Placebo|Placebo capsules
45654248|NCT02961361|Drug|ropivacaine|40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
45835779|NCT04775238|Other|Copper nanoparticles|CuNPs (150-350 nm)
45835780|NCT05595798|Diagnostic Test|Airmod breathing sound monitoring|Respiratory monitoring and sedation depth monitoring will be applied during procedural sedation.
45835781|NCT01896882|Other|Sodium restriction|
45835782|NCT05580978|Behavioral|GEM|The intervention group will be given Libre 2 supplies for 4 months, an activity monitor, and the 4-chapter GEM paper guide. The intervention group will complete a virtual or inperson study visit where they will receive instructions on how to apply their unblinded Freestyle Libre and connect it to the study account, as well as how to register their Fitbit to the study account. Participants will receive one telephone call to review use of the GEM Guide and call at two weeks and six weeks later when the probability of dropouts from lifestyle intervention peaks. Participants will follow the self-directed GEM guide for 4 months (a 1-month treatment period followed by a 3-month maintenance period) while wearing a FitBit activity monitor and a Freestyle Libre 2 CGM.
45835783|NCT05580978|Other|Routine Care|Participant's current prediabetes treatment.
45835784|NCT05580042|Drug|AC-1101|For each patient, once daily (QD)
45835785|NCT05579652|Diagnostic Test|Abdominal tension measurement|A tensiometer scale will be used to measure the tension needed to pull each side of the abdominal wall to midline
45835786|NCT04775160|Device|SmartSafe|"The SmartSafe Ecological Momentary Intervention is contained in the MEmind smartphone application and consists of a Safety plan, an Enhanced contact via app (app-EC) intervention, and a mental toolbox. The Safety plan is a set of personalized coping strategies that the patient can use in a suicidal crisis. Our safety plan was adapted to a digital environment, including the possibility to activate pre-recorded messages, lead to websites with health resources, or put the patient in contact with the emergency services. The Enhanced contact via app (app-EC) intervention is inspired by the SIAM project and consists in messages that will be sent via the MEmind app inquiring patients about their mental well-being and informing them of the means to request preferential or urgent care. The mental toolbox contains videos relaxation techniques videos and behavioral activation and mentalization exercises."
45835787|NCT03404388|Behavioral|Balance Training|4 days of a challenging balance training task
45835788|NCT03288480|Drug|PT-112|This is a single arm study
45835789|NCT01895478|Behavioral|PACCI-ED use|Attending physicians were allowed to view the patient's PACCI-ED prior to completing the assessment form. Attendings were told at the time of the child's ED visit that the PACCI-ED is used to assess a child's asthma control and medication adherence, and that they could use it to complete the outcomes assessment form.
45835790|NCT03095742|Diagnostic Test|Low MAP|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
45835791|NCT03095742|Diagnostic Test|High MAP|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
45835792|NCT03094026|Behavioral|Lumosity|Computer-based online cognitive training program using the Lumosity cognitive training program.
45835793|NCT03094026|Behavioral|Lumosity (waitlist control)|Computer-based online cognitive training program using the Lumosity cognitive training program. The control group will receive the intervention after a waiting period of 12 weeks.
45835794|NCT04774770|Behavioral|HED-Start|The HED-Start Program is a cognitive-behavioral intervention based on self-management and motivational interviewing principles.
45835795|NCT01614990|Drug|Macimorelin|Subjects will receive macimorelin (1 mg/kg) and matching placebo (Powerade®) daily for 7 days.
45835796|NCT01614990|Drug|Placebo|placebo (Powerade®) daily for 7 days.
46074135|NCT05577546|Other|Moor S brace treatment|The rigid MOOR-S Brace controls the thoracic, lumbar and pelvis blocks very tightly, is modelled and produced according to deformity type and patients body size considering the standardization of the MOOR-S Model. It is a CAD-CAM design-based rigid torocolumbosacral orthosis, using polypropylene material, which is opened from the front, and tightness can be adjusted by the patients with the help of straps. Additional corrective forces can be applied with pads that can be added to the brace. The amount of corrective forces in the MOOR-S brace is decided by the experienced orthotist, taking into account risk of progression, the flexibility of the spine deformity, Cobb angle, bone maturation and age. An external stimulus is provided that directs the protracted shoulder to slightly to the posterior by the shoulder part, located on the anterosuperior side of the brace.
46074136|NCT05577546|Other|Schroth Three-Dimensional Scoliosis Exercise Treatment|Schroth Three-Dimensional Scoliosis Exercise Treatment has the main features of physiotherapeutic scoliosis-specific exercises: 1) Three-dimensional self-correction, 2) Training activities of daily living (ADL), and 3) Stabilization of the corrected posture. The basic principles of the Schroth method are autoelongation, deflection, derotation, rotational angular breathing and stabilization. Exercise therapy will be carried out at the brace center once a week with the researcher, and 45 min a day, 4 days a week in the form of home exercises. The number of exercise sets and repetitions will be determined by the physiotherapist according to the patient, considering deformity severity and flexibility, generalized joint hypermobility, bone maturation, menarche status and the risk of progression. Compliance with the home exercise program (frequency and duration) will be recorded by the patients in a home exercise diary for 12 weeks.
46074137|NCT02809560|Procedure|Induced sputum method using hypertonic serum|Collection of expectoration in sterile vial, conserved in ice all along the examination
46074138|NCT02809404|Drug|Everolimus|
46074139|NCT00619099|Drug|decitabine|Schedule A: decitabine will be administered subcutaneously (SQ) daily for 3 consecutive days (Days 1 to 3) every 28 days. The dose will be 20 mg/m^2/day. One course will be considered 28 days.
45654249|NCT02961361|Drug|ropivacaine mixed with dexmedetomidine|40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
45654250|NCT04974229|Other|In line with the Dutch guideline for non-specific low back pain, Standard usual care for non-specific low back pain was applied.|In line with the Dutch guideline for non-specific low back pain, Standard usual care or non-specific low back pain was applied.
45654251|NCT04974931|Device|PREVENA Incision Management System|Eligible participants, i.e. participants meeting inclusive criteria, will be randomised in equal proportions and divided into two arms. The PREVENA dressings will be applied to the
45654252|NCT04975165|Procedure|Total knee arthroplasty|Bilateral surgery in one arm and staged surgery in another arm during total knee arthroplasty
45654253|NCT04974073|Drug|PHY606|Danggui Buxue Tang is a well-known TCM formula indicated for anemia through immune modulation and increase energy metabolism
45805478|NCT05920772|Behavioral|KickAsh! intervention|The general aim of the KickAsh! intervention is to prevent smoking initiation in adolescents living in vulnerable socioeconomic situations. The intervention exists of different components concerning smoking prevention. Most components have a direct influence on smoking initiation by affecting several determinants of the adolescents. These components include smoke-free games, mood boards, a smoke-free camp, the Kick some Ash!-challenge and exercises concerning self-efficacy and skills. Yet, some of the components target adolescents by influencing their environment, i.e. smoking policy in the organisation and youth workers as role models. All components are developed using a combination of theoretical methods to change or influence these determinants or environmental factors.
45938303|NCT00058292|Drug|Carmustine|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Carmustine is given at a dose of 300 mg/m2 intravenous infusion over a 2 hour period on treatment day -6 (Day 0 = stem cell transplant).
45938304|NCT00058292|Drug|cytarabine|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Cytarabine is given at a dose of 100 mg/m2 intravenous infusion over a 1 hour period, every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
45938305|NCT00058292|Drug|etoposide|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Etoposide is given at a dose of 100 mg/m2 intravenous infusion over a 2 hour period every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
45938306|NCT00058292|Drug|melphalan|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Melphalan is given at a dose of 140 mg/m2 as an intravenous infusion over a 1 hour period on treatment day -1 (Day 0 = stem cell transplant).
45938307|NCT00058292|Procedure|peripheral blood stem cell transplantation|On day 0, a minimum of 2.0 X 106 CD34+ cells/kg unselected peripheral blood progenitor cells (PBPC) will be reinfused following institutional guidelines for the reinfusion procedure.
45452752|NCT03662308|Device|Heated Vest|Heated vest that regulates its heat output based on the user's skin, the user's core temperature, and the ambient temperature
45452753|NCT03662308|Device|Non-Heated Vest|A similarly insulated (compared to the experimental vest), but non-heated vest
45654254|NCT04975087|Other|Patients group|Patients will complete the mentioned questionnaires.
45654255|NCT04973995|Behavioral|several physical examinations|By using physical examinations, the incidence of these physical examinations corresponding to shoulder muscls injury
45654256|NCT04974853|Combination Product|Cardio-complement|Ayurvedic combination of Terminalia Arjuna, Withania Sominifera, Garcinia Cambogia and piperine (as bioenhancer) in pre-specified dosage.
45654257|NCT02725177|Drug|Repository Corticotropin Injection|"Treatment with ACTHAR Gel for 24 weeks~Initial treatment with 80 units daily for ten days (induction phase)~Maintenance treatment with 80 units twice weekly (maintenance phase)"
45654258|NCT02725177|Drug|Repository Corticotropin Injection -Treatment Extension|24 open label extension permitted in subjects who respond to treatment
45452754|NCT03134794|Behavioral|Educational intervention applying the traffic light system (TLS)|The TLS emerged to facilitate consumers' decisions. It has been applyied in medical decision making.
45452755|NCT00820924|Drug|LAPATINIB|LAPATINIB 1500MG ORAL DOSE DAILY
45452756|NCT00820300|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the experimental doses of Latanoprost-PPDS for 4 months or until loss of efficacy.
45654259|NCT04973839|Behavioral|Video optimizing expectations before PMR (unguided) + Progressive Muscle Relaxation (PMR)|Participants watch a video aiming to optimize participants' expectations before undergoing a single PMR session without personal support of the experimenter (unguided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
45805479|NCT05920759|Diagnostic Test|Cerebral blood flow|Transcranial Doppler (TCD) is a non-invasive diagnostic tool used to estimate cerebral blood flow velocity (CBFV), cerebral autoregulation, cerebrovascular reactivity (CVR), intracranial pressure, cerebral perfusion pressure as well as other indicators of cerebral hemodynamics and autoregulation.
45938308|NCT00058292|Radiation|yttrium Y 90 ibritumomab tiuxetan|Patients will receive 90Y2B8 at a variable dose on treatment day -14 (Day 0 = stell cell transplant). The initial dose calculated to deliver no more than 100 cGy to critical organs (liver, lung). Doses will be escalated based on cohort of enrollment.
45938309|NCT03816774|Drug|PEG split-dose and simethicone|Patients in active comparator arm are instructed to take 250mg simethicone pill 15 minutes before PEG dose on the previous evening plus 250mg simethicone pill 15 minutes before PEG dose ending 3 hours before colonoscopy
45805480|NCT05920746|Other|Kinesiotherapy with magnetotherapy|Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 10-20 Hz, type of impulse: bipolar, rectangular pulse
45805481|NCT05920733|Behavioral|Nurse-led health coaching|This project is an 6-month program providing an initial 2-month intensive evaluation and personalized virtual individual health coaching experience that is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making. This intensive period will then be followed by monthly 30-minute Nurse Coach assessment and individual coaching 'check-in' virtual visits, continued use of the electronic platform tools and health tracking system, and access to group 'virtual coaching' on tailored topics of interest to the cohort.
45938310|NCT00184912|Drug|caffeine|
45805482|NCT05920720|Behavioral|Self-guided Personalized Treatment|Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
45938311|NCT00184912|Drug|Technetium-TC99m-labeled Annexin A5|
45938312|NCT00184912|Procedure|ten minutes forearm ischemia|
45938313|NCT00184912|Procedure|ischemic forearm exercise|
45938314|NCT00184951|Drug|Rosuvastatin|
45805483|NCT05920707|Drug|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0. 1ml), three puffs per nostril one every 30 seconds.
45805484|NCT05920707|Drug|Intranasal Arginine Vasopressin|Administer arginine vasopressin (20 IU) intranasally, 6 individual 0.1 ml puffs (3.33 IU/0. 1ml), three puffs per nostril one every 30 seconds.
45805485|NCT05920707|Drug|Intranasal placebo|Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds.
45805486|NCT05920694|Device|Continuous Positive Airway Pressure Device (CPAP)|Metabolic studies will be performed before and after initiation of CPAP therapy, which is currently the first-line standard of care for treatment of patients with OSA, both with and without hypoxia.
45835797|NCT05433558|Other|Neuropsychological Rehabilitation|Neuropsychological Rehabilitation
45835798|NCT04774614|Procedure|anterior laminate veneers|VITA ENAMIC multiColor
45835799|NCT05074134|Drug|[14C]-TNP-2092|Subjects will receive a single intravenous (IV) dose of 300 mg/3 µCi [14C]-TNP-2092 administered over 60 minutes (± 10 minutes).
45835800|NCT03318978|Drug|[14C]-benzo[a]pyrene|Oral micro-dose range (25, 50, 100 and 250 ng)
45835801|NCT05421546|Dietary Supplement|Spermidine or Placebo|The supplement, Spermidine, is made mainly from wheatgerm and can be bought in health food shops. It is a powder that can be easily dissolved in water and taken as a drink. The 'placebo' is a sugar powder that can be similarly dissolved in water and taken as a drink.
45452757|NCT00814372|Drug|MBX-102|capsule
45452758|NCT00814372|Drug|Placebo|matching placebo
45835802|NCT05415774|Device|1 : S-C1-C2|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~Standard stimulation~125Hz at both STN and SNr for C1,~125Hz for STN and 60 for SNr for C2"
45835803|NCT05415774|Device|2 : S-C2-C1|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~Standard stimulation~125Hz at both STN and SNr for C1,~125Hz for STN and 60 for SNr for C2"
45835804|NCT05415774|Device|3 : C1 - S - C2|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~Standard stimulation~125Hz at both STN and SNr for C1,~125Hz for STN and 60 for SNr for C2"
45835805|NCT05415774|Device|4 : C1 -C2 - S|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~Standard stimulation~125Hz at both STN and SNr for C1,~125Hz for STN and 60 for SNr for C2"
45835806|NCT05415774|Device|5 : C2 - S - C1|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~Standard stimulation~125Hz at both STN and SNr for C1,~125Hz for STN and 60 for SNr for C2"
45835807|NCT05415774|Device|6 : C2 - C1 - S|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~Standard stimulation~125Hz at both STN and SNr for C1,~125Hz for STN and 60 for SNr for C2"
45835808|NCT05390970|Procedure|Platelet-rich plasma injection|Injection of autologous platelet-rich plasma into the anterior vaginal wall
45835809|NCT05390580|Device|transcutaneous auricular vagal nerve stimulation|Stimulus of the auricular branch of the vagal nerve with the transcutaneous auricular vagal nerve stimulation.
45835810|NCT05390580|Device|Sham transcutaneous vagal nerve stimulation|Patients assigned to the controls arm will have no electricity applied to the Auricular Branch of the Vagus Nerve. Stimulus will be provided to the lobule of the ear, which is not innervated by the Auricular Branch of the Vagus Nerve.
46074140|NCT00619099|Drug|decitabine|Schedule B: decitabine will be administered SQ every 7 days for 21 days (Days 1, 8, and 15) followed by 7 days without an administration of decitabine. The dose will be 20 mg/m^2/day. One course will be considered 28 days.
45654260|NCT04973839|Behavioral|Video optimizing expectations before PMR (guided) + Progressive Muscle Relaxation (PMR)|Participants watch a video aiming to optimize participants' expectations before undergoing a single PMR session with the personal support of the experimenter (guided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
45805487|NCT05920694|Other|Delayed Continuous Positive Airway Pressure Device (CPAP)|Metabolic studies will be performed before and after the study period of 12 weeks. After 12 weeks, participants will immediate receive CPAP therapy, which is currently the first-line standard of care for treatment of patients with OSA, both with and without hypoxia.
45805488|NCT05920681|Procedure|Transanal irrigation|The patient lies on the left or right side, depending on the main hand, the knees are bent. With the main hand, he carefully introduces the TAI tip lubricated with lubricant. The TAI bag is filled with warm water - d it can be boiled or just from the tap. The contents of the TAI bag are slowly administered through the anus. The duration of the TAI is about 15-20 minutes. Afterwards, the subject goes to defecate until the bowel is empty. This action should be repeated daily.
45805489|NCT05920681|Combination Product|Best supportive care|Diet modification, Loperamidum if needed, diapers, etc.
45805490|NCT05920668|Drug|Orelabrutinib|Orelabrutinib monotherapy for CLL/SLL 12 cycles
45805491|NCT05920655|Diagnostic Test|Optic coherence tomography|Eye examination of patients with optic coherence tomography test by an ophthalmologist
45805492|NCT05920642|Drug|Intrathecal morphine administration|Administration of morphine into the spinal canal.
45805493|NCT05920642|Drug|Parenteral administration of analgesics|Standard postoperative pain management of analgesics using parenteral route of administration.
45805494|NCT05920629|Behavioral|Alcohol consumption|After written consent, patients will enter a run-in period of 2 weeks where they will be asked not to drink any alcohol beverage. Patients with a successful run-in period will be randomized on a 1:1 basis stratified by baseline LVEF (<50% vs. ≥50%), sex and study site. 110 patients will be assigned to moderate alcohol consumption (1 standard unit a day), and 110 patients to abstinence (no alcohol beverages) for 12 months. We will perform a first echocardiography at randomization and a second at 12 months' follow-up.
45805495|NCT05920616|Other|Magnetic Resonance Imaging|Completion of Magnetic Resonance Imaging of the brain, heart, lungs, and liver with and without contrast.
45805496|NCT05920616|Other|Ultra-High Resolution Computed Tomography (CT) Scan|Completion of a high resolution CT scan of the lungs and high resolution CT of the coronary arteries.
45805497|NCT05920590|Other|PNF|"The protocol will be individualized and will last 45 minutes. The following techniques will be applied:~Application of the hold - relax technique to increase the range of motion of knee flexion.~Rhythmic initiation with the application of diagonal trunk and lower limb shapes.~Application of stabilizing reversals from a sitting and standing position.~Application of dynamic reversals from a standing position.~Rhythmic stabilization.~Combination of isotonics.~Gait retraining."
45938315|NCT02963545|Other|Usual care patients in neurology department|patients characteristics, history, clinical signs chronology and usual medical care by the emergency units, cerebral infarction area
45938316|NCT02963545|Biological|blood and urines sampling|Collection samples for biochemical determinations of serotonin pathway and kynurenine pathway parameters determinations
45938317|NCT02963545|Procedure|Psychiatric evaluation|depression scale, impulsivity scale, hostility scale , tobacco consumption questioning
45938318|NCT00184990|Drug|Aminoguanidine|
45938319|NCT00184990|Drug|endotoxin|
45938320|NCT00058331|Biological|epoetin alfa|
45938321|NCT00185029|Procedure|Ferumoxtran-10 enhanced MRI (MRL)|
45938322|NCT00185068|Drug|Olmesartan medoxomil|
45938323|NCT00185068|Drug|Olmesartan medoxomil/hydrochlorothiazide|
46074141|NCT02812992|Drug|Nab-paclitaxel|
45938324|NCT00185068|Drug|Hydrochlorothiazide|
45938325|NCT00185107|Drug|Colesevelam Hydrochloride|
45938326|NCT00185107|Drug|Ezetimibe|
46074142|NCT02812992|Drug|Gemcitabine|
46074143|NCT02812992|Other|Best Supportive Care|
45938327|NCT00185107|Drug|Simvastatin|
45938328|NCT00185146|Drug|Pactimibe|
45938329|NCT00058448|Drug|docetaxel|
45938330|NCT00185185|Drug|Olmesartan medoxomil|
45938331|NCT00185185|Drug|Atenolol|
45938332|NCT00185185|Drug|Hydrochlorothiazide|tablets
45938333|NCT00185185|Drug|olmesartan medoxomil|tablets
45805498|NCT05920590|Other|PNF plus Tendon Vibration|Participants in this group will be given the same exercise program as Group 1 combined with the application of tendon vibration. Tendon vibration will be applied on both quadriceps' tendons in three weekly sessions (not on the same day as the exercise program). To implement the protocol, 100 Hz frequency mechanical stimulation will be applied.
45938334|NCT00185185|Drug|atenolol|tablets
45938335|NCT00185224|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|7 treatment cycles of 28 days each (no tablet-free intervals); Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27 - 28: Placebo
45938336|NCT00185224|Drug|SH D00264A (Triquilar)|7 treatment cycles of 28 days each (no tablet-free intervals);Days 1-6: 0.03 mg EE + 0.05 mg LNG; Days 7-11: 0.04 mg EE + 0.075 mg LNG; Days 12-21: 0.03 mg EE + 0.125 mg LNG;Days 22-28: Placebo
45938337|NCT03785028|Behavioral|working memory and attention|working memory and attention tasks
45654261|NCT04973839|Behavioral|Neutral video before PMR (unguided) + Progressive Muscle Relaxation (PMR)|Participants watch a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session without personal support of the experimenter (unguided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
45805499|NCT05920590|Other|Conventional Home-based Physiotherapy Program|"Participants in this group will follow a conventional six-week home physical therapy program that will include:~Range exercises of the knee joint and the ankle joint of the operated limb.~Stretching of the muscles of the lower limbs.~Walking inside and outside the house.~Exercises to strengthen the muscles of the lower limbs."
45805500|NCT05920577|Other|exergames and resistance training|"In each session, the participants will receive 40 minutes of combined use of exergaming and resistance training. The participants will practice the exergames using the gaming system Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan). The gaming software Nintendo Switch Sports will be adopted in which arrays of exergames are available to strengthen both the upper and lower extremity muscle and improve the balance ability of participants. The exergaming programme will consist of both upper (badminton game and tennis game) and lower (soccer game) extremity games. For week 1 and 2, the participants will first practice 1-minute warm up exercise (stretching exercises) and then the 3 exergames. For week 3 to 12, the participants will receive the same warm up exercise and exergames as if week 1 and 2 but there will be an addition of light cuff weight for resistance training."
45938338|NCT00185263|Genetic|AdF5FGF-4 vs. Placebo|Intracoronary infusion
45938339|NCT00185302|Drug|Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|MS-275, 3 mg on Days 1 and 15 of a 4-week cycle
45938340|NCT00185302|Drug|Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|MS-275, 7 mg on Days 1, 8 and 15 of a 4-week cycle
45938341|NCT00185341|Drug|CCR1-Antagonist (BAY86-5047, ZK811752)|Given orally in a dose of 600 mg three times daily over 12 weeks
45452759|NCT00814372|Drug|Actos|over-encapsulated to match MBX-102 and placebo
45938342|NCT00185341|Drug|Placebo|Placebo
45938343|NCT03784014|Drug|Nilotinib|Target: KIT, PDGFRA, CSF1R Nilotinib will be administered orally, 400 mg twice daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
45938344|NCT03784014|Drug|Ceritinib|Target: ALK, ROS. Ceritinib will be administered orally, 450mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
45938345|NCT03784014|Drug|Capmatinib|Target: MET. Capmatinib will be administered orally, 400mg twice daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
45938346|NCT03784014|Drug|Lapatinib|Target: ERBB2, EGFR. Lapatinib will be administered orally, 1500mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
45938347|NCT03784014|Drug|Trametinib|Target: KRAS, NRAS, HRAS, PTPN11, NF1, MAP2K. Trametinib will be administered orally, 2 mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
45654262|NCT04973839|Behavioral|Neutral video before PMR (guided)+ Progressive Muscle Relaxation (PMR)|Participants watch a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session with the personal support of the experimenter (guided).The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
45938348|NCT03784014|Combination Product|Trametinib and Dabrafenib|"Target: KRAS, NRAS, HRAS, PTPN11, NF1, MAP2K, BRAF. Trametinib will be administered orally, 2mg once daily on a continuous basis. Dabrafenib will be administered orally, 150mg twice daily, on a continuous basis.~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation."
45452760|NCT00814372|Drug|Metformin|greater than or equal to 1500 mg/kg day
45452761|NCT05042050|Behavioral|A-iMAPS|Imagery therapy targeting Psychosis-Related PTSD
45458025|NCT03508414|Behavioral|Intermittent therapeutical fasting|Patients fast for 1 week every six months. Additionally, the patients do an intermittent fasting, that is to say they do not eat for at least 14 hours a day.
45654263|NCT04852783|Device|Contour Neurovascular System|Endovascular embolization of wide-necked, bifurcated saccular intracranial aneurysms.
45938349|NCT03784014|Combination Product|Olaparib and Durvalumab|Target: PDL1, PARP. Olaparib will be administered orally, 300mg twice daily on a continuous basis. Dabrafenib will be administered intraveinously, 1500mg on day 1 every 4 weeks. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
46074144|NCT04018573|Behavioral|PATHS Sexual Communication Toolkit|The PATHS Sexual Communication Toolkit is a self-guided, online intervention. The toolkit is comprised of 6 modules, covering a range of topics relevant to increasing parents' motivation, self-efficacy, and intention for communicating about sex. Material is presented in a variety of modalities (e.g., text, videos of experts, videos of other parents describing their experiences). Parents set personalized goals for themselves regarding activities and conversations they want to have with their sons, selecting from a menu of options provided by the intervention. A 1-month booster module queries parents about whether they have achieved their goals, and provides customized content to support the behaviors parents have yet to enact.
46074145|NCT04018573|Behavioral|Parent Support Film|"Lead with Love is a 35-minute education entertainment film created to provide support, information, and behavioral guidance to parents of lesbian, gay, or bisexual (LGB) children. Drawing from stage-based models of behavior change, and social cognitive theory, it aims to help parents progress through the process of coming to accept their child's sexual orientation, recognizing the importance of their behaviors and reactions to their child's health, and accepting their child's sexual orientation, and engaging in behaviors that are more supportive and less rejecting. This is achieved by telling the true stories of four families and how they responded to the news that their child was LGB, and by having experts (psychologists, teachers, clergy) provide information and guidance."
46074146|NCT02812446|Other|IAI infection|
45805501|NCT05920577|Other|Resistance training|The resistance training programme consists of 2 parts, the upper limb and lower limb resistance exercises. For the upper limb resistance exercises, the participants will first practice 5-minute warm up of upper limb using ergometer and then undergo 2 resistance exercises, including handgrip and elbow flexion. For the lower limb exercise, the participants will also first practice 5-minute warm up of lower limb using ergometer and then undergo 3 resistance exercises, including squatting, single-leg standing and knee extension.
45805502|NCT05920564|Other|Upper fibers of trapezius stretching|The Upper fibers of trapezius stretching intervention involves specific stretching exercises designed to target the upper fibers of the trapezius muscle. The stretching exercises will be performed under the guidance of a licensed physical therapist and will involve extending the neck while gently pulling the head downward to stretch the upper fibers of the trapezius muscle. The intervention is designed to improve neck range of motion, reduce pain intensity, and reduce disability in patients with cervical spondylosis. The duration and frequency of the stretching exercises will be standardized across participants, and adherence will be monitored throughout the study period.
46074147|NCT02812446|Other|Staphylococcus aureus nasal carriage infection|
46074148|NCT00856063|Drug|atomoxetine (or placebo)|Each child will be randomized to receive either ATMX or placebo in the 1st crossover phase followed by the alternative drug condition in the 2nd crossover phase. The study drug (ATMX or placebo) will be administered BID and will be titrated blindly based on clinical response and tolerability. ATMX will be initiated at 0.5 mg/kg/day for 3 days. Based on clinical response, ATMX dose will be titrated to 0.8 mg/kg/day during week 1, 1.4 mg/kg/day during week 2, and a maximum of 1.8 mg/kg/day during week 3, unless serious untoward effects intervene.
45805503|NCT05920564|Other|Standard care|The Control Group in this study will receive standard care, including heat treatment and strengthening exercises, but will not receive the specific Upper fibers of trapezius stretching intervention that is being tested in the Treatment Group.
46074149|NCT04188210|Other|Presence of elbow pain in patients with end stage renal disease|The Beck Depression Inventory (BDI), the Nottingham Health Profile (NHP) scores were measured for all patients to evaluate depression symptoms and health-related quality of life. The elbow pain presence was asked to all the patients, the patients with elbow pain were also evaluated with The Disabilities of the Arm, Shoulder and Hand Score (Q-DASH) and Visual Analogue Scale (VAS). VAS detected as pain during rest, activity, night and pain at last week.
46074150|NCT00856141|Device|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
46074151|NCT00856141|Device|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
46074152|NCT02812758|Device|transthoracic echocardiography|recording of data on cardiac output measured non-invasively by transthoracic echocardiography, including the SVV
46074153|NCT00856219|Dietary Supplement|Enteral Continuous|Continuous Tube Feeding for 72 hours
46074154|NCT00856219|Dietary Supplement|Enteral Intermittent|Intermittent Tube Feedings
46074155|NCT00856219|Dietary Supplement|Parenteral Continuous|Parenteral Continuously for 72 hours
46074156|NCT02812602|Drug|Lidocaine patch|Lidocain patch will be applied around the surgical wound about 20 minutes before removal of staples.
45805504|NCT05920551|Other|Gastrocnemius Stretching Exercises|The gastrocnemius stretching exercises will be performed by patients in the study group. These exercises will involve stretching the gastrocnemius muscle in a controlled manner to improve flexibility and reduce tension in the plantar fascia.
45805505|NCT05920551|Other|Standard care|Ultrasound therapy: A therapeutic ultrasound device will be used to apply ultrasound waves to the plantar fascia area for pain relief and to promote healing. The frequency, intensity, and duration of the ultrasound therapy will be determined by the treating physical therapist based on individual patient needs.Fascia strengthening exercises: Patients will be instructed to perform exercises targeting the intrinsic foot muscles and the plantar fascia to improve strength and function. Examples of these exercises include toe curls, towel scrunches, and arch lifts. Patients will be asked to perform these exercises daily, with the specific number of repetitions and sets determined by the physical therapist.
45805506|NCT05920538|Drug|Nicardipine|Subcutaneous infiltrate drug at puncture site by ultrasound-guided
45805507|NCT05920538|Other|Normal saline|Subcutaneous infiltrate NSS at puncture site by ultrasound-guided
45805508|NCT05920525|Device|Electrical stimulation|A specific device will be used to stimulate the remodeling procedures in the alveolar bone.
46074157|NCT02812602|Drug|placebo|Placebo patch will be applied around the surgical wound about 20 minutes before removal of staples.
45654264|NCT04839601|Device|RNS System|The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
45654265|NCT02426281|Drug|nab-paclitaxel|nab- paclitaxel 125mg/m2 D1, 8 15 every 4 weeks.
45805509|NCT05920525|Procedure|Traditional retraction of the front upper teeth|The retraction will be performed using coil springs which will help in moving the anterior teeth backward without the need to employ any additional procedure or device to accelerate this movement.
45938350|NCT03784014|Drug|Palbociclib|"Target: CDK4, CDK6. Palbociclib will be administered orally, 125mg once daily, 3 weeks on/1 week off.~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation."
45938351|NCT03784014|Drug|Glasdegib|Target: SMO. Glasdegib will be administered orally, 300 mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
45938352|NCT03784014|Drug|TAS-120|Target: FGFR. TAS-120 will be administered orally, 20 mg once daily on a continuous basis. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation.
45938353|NCT03784014|Other|Next Generation sequencing exome|Both frozentumor material (archived or newly obtained) and blood sample collection will be used for genetic profiling
45938354|NCT00409084|Procedure|endoscopic variceal band ligation|endoscopic variceal band ligation
45938355|NCT00058487|Drug|epirubicin hydrochloride|
45938356|NCT00058487|Drug|thalidomide|
45458026|NCT03508414|Behavioral|Active comparator|The control group is receiving a vegetarian-focused diet according to the current recommendations of the German Society for Nutrition (DGE) for MS patients.
45654266|NCT02426281|Drug|gemcitabine|gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
45654267|NCT02448537|Drug|PM01183|
45654268|NCT02448537|Drug|Doxorubicin|
45654269|NCT02448537|Drug|Gemcitabine|
45654270|NCT03062371|Behavioral|Playgroup|A semi-structured gathering of caregivers and their children in a community setting developed and implemented by a skilled provider.
45654271|NCT03062683|Other|Lactate, prolactin and creatine kinase conc.|Lactate, prolactin and creatine kinase conc. in blood samples were measured
45654272|NCT04838743|Drug|IDegLira|"Patients will be treated with commercially available Xultophy® (IDegLira) in a pre-filled pen injector (FlexTouch®) at the discretion of the treating physician in accordance with the Xultophy® label in Japan.~The decision to initiate treatment with Xultophy® is at the treating physician's discretion according to the approved Xultophy® label in Japan and independent from the decision to include the patient in the study."
45805510|NCT05920512|Drug|Sodium valproate extended-release tablets|Sodium valproate extended-release tablets 0.5g/day; sirolimus tablets 1mg/day and calcitriol capsules 0.25μg/day.
45938357|NCT00409162|Device|Eraser TM device, with washing fluid|
45938358|NCT00185419|Drug|Yasmin|30 µg ethinylestradiol, 3mg drospirenone
45938359|NCT00185419|Drug|Marvelon|30 µg ethinylestradiol, 150 µg desogestrel
45938360|NCT00185536|Behavioral|Packaging and identification of source|
45938361|NCT03758274|Behavioral|CBT by Phone to Promote Treatment|Structured phone intervention to identify concerns about getting alcohol use disorder treatment and to work through those concerns using cognitive behavioral principles.
45938362|NCT03758274|Other|Reading the Subject a Pamphlet on Obtaining Alcohol Use Disorder Treatment|The pamphlet was created by the National Institute on Alcohol Abuse and Alcoholism to describe evidence based treatments available for alcohol use disorder and how to obtain such treatment.
45938363|NCT00185575|Drug|duloxetine|
45938364|NCT00185653|Procedure|Autologous followed by non-myeloablative allogeneic transplantation|
45938365|NCT00185770|Behavioral|Reducing television and other screen time (SMART curriculum)|
45938366|NCT00058526|Biological|Immunotherapeutic SB719125 (Primary)|Intramuscular injection
45938367|NCT03731832|Drug|MLN9708|Study drug will be given as a single, oral dose of 4.0 mg weekly (day 1, 8 and 15) for 3 weeks, followed by 1 week without study drug in a 28-day cycle
45938368|NCT03731832|Drug|Pomalidomide 4 MG Oral Capsule|Study drug will be given as an oral dose of 4.0 mg on day 1 until day 21, followed by 1 week without study drug in a 28-day cycle.
45938369|NCT03731832|Drug|Dexamethasone|Dexamethasone will be administered as a single, oral dose of 40 mg/day weekly on day 1, 8, 15 and 22 in patients from 18 to 74 years old. For patients ≥ 75 years old dose has to be reduced to 20 mg/day with the same treatment schedule.
45938370|NCT03731832|Drug|Cyclophosphamide|Cyclophosphamide will be administered once daily as an oral dose of 50 mg on cycle days 1 to 21, followed by one week without drug in a 28-day cycle.
45938371|NCT00185848|Radiation|[18F]FHBG|< 7mCi and 2 ug, iv
45938372|NCT00185887|Drug|Terbutaline|Terbutaline 250 micrograms intravenously for intrapartum fetal resuscitation. Nitroglycerine 400 micrograms intravenously for intrapartum fetal resuscitation.
45938373|NCT02963350|Drug|BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)|
45938374|NCT00186004|Device|Continuous Glucose Monitor|Subjects are fitted with a CGM system and perform self blood glucose measures three or more times per day for 3 days.
45938375|NCT00058604|Biological|Intravenous injection of EBV specific CTLs|Each patient will receive injections of 2x10e7 , 5x10e7 , or 10e8 CTLs/m2 via IV injection. 6 weeks = 1 course
45938376|NCT00186082|Drug|Cefotetan or Cefoxitin vs placebo|"Cefotetan or Cefoxitin, 1 g intravenously, or Clindamycin, 900 mg intravenously.~Normal Saline, 100 ml intravenously for placebo arm."
45938377|NCT00186238|Procedure|high dose chemotherapy then autologous hematopoietic cell transplant|
45938378|NCT00186277|Drug|Oxaliplatin|Calculated per patient
45938379|NCT00186277|Drug|Taxotere|Calculated per patient
45938380|NCT02969642|Device|Argus Migraine Treatment device|treatment of Migraines targeting Sphenopalatine ganglion
45938381|NCT00186316|Biological|Idiotype-pulsed allogeneic dendritic cells|
45938382|NCT00186355|Procedure|high dose chemo then auto hematopoietic cell transplant|
45938383|NCT00186394|Procedure|ablative allogeneic hematopoietic cell transplantation|
45938384|NCT03611595|Drug|Cabozantinib|Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles
45938385|NCT03611595|Drug|13-cis-retinoic acid|13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
45654273|NCT03060265|Drug|Paracetamol|Administrating Paracetamol IV pre-cesarean section
45654274|NCT03060265|Drug|PLACEBO|Administrating SALINE IV pre-cesarean section
45654275|NCT04836247|Behavioral|Disclosing Recovery: A Decision Aid and Toolkit|Participants will be guided through a workbook and accompanying worksheet designed to help them: (1) decide whether or not they want to share information about their substance use with others, and (2) build skills for disclosing (e.g., planning what to say). Importantly, the intervention is not designed to encourage participants to disclose or not disclose, but rather to help participants decide whether they want to disclose based on their own goals and values.
45654276|NCT04836247|Behavioral|Mindfulness|Participants will be able to choose from several guided meditations to promote mindfulness
45654277|NCT02504151|Drug|Cannabidiol|
45654278|NCT02504151|Drug|Placebo|
45654279|NCT03060109|Other|Blood draw within 12 hours of injury|
45654280|NCT02448381|Drug|SGX301 (synthetic hypericin)|0.25% SGX301 in USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm^2 fluorescent light.
45654281|NCT02448381|Drug|Placebo|USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm^2 fluorescent light.
45654282|NCT02448225|Procedure|Computed Tomography|Undergo 18F-FDG PET/CT - standard of care
45654283|NCT02448225|Procedure|Computed Tomography|Undergo 18F-FSPG PET/CT
45654284|NCT02448225|Radiation|fluorodeoxyglucose F-18|Undergo 18F-FDG PET/CT - standard of care
45654285|NCT02448225|Drug|Fluorine F 18 L-glutamate Derivative BAY94-9392|Undergo 18F-FSPG PET/CT
45654286|NCT02448225|Other|Laboratory Biomarker Analysis|Correlative studies
45938386|NCT00186472|Behavioral|Brief Cognitive Behavioral Treatment|
45938387|NCT00058682|Drug|Anidulafungin|
45938388|NCT00186511|Behavioral|workbook/journal on coping with breast cancer|
45938389|NCT00186511|Behavioral|supportive expressive group therapy using videoconferencing|
45938390|NCT00186550|Behavioral|Supportive Expressive Group Psychotherapy|
45938391|NCT00186550|Behavioral|Education|
45938392|NCT00186589|Drug|90Y Ibritumomab tiuxetan|
45458027|NCT03506230|Behavioral|Incentives|A bonus to buy their medications if they reduce their HBA1c
45654287|NCT02448225|Procedure|Positron Emission Tomography|Undergo 18F-FDG PET/CT - standard of care
45654288|NCT02448225|Procedure|Positron Emission Tomography (PET)|Undergo 18F-FSPG PET/CT
45654289|NCT02503215|Device|Compression Stockings|To evaluate the effects of compression stockings on fluid shift and sleep apnea in hemodialysis patients with obstructive sleep apnea
45654290|NCT02447991|Drug|Rizatriptan|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.
45938393|NCT00186667|Procedure|high dose chemotherapy and autologous hematopoietic cell transplant|
45654291|NCT02447991|Drug|Placebo|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.
45654292|NCT02586155|Drug|Apabetalone|100 mg capsule
45654293|NCT02586155|Drug|Placebo|Capsule manufactured to mimic RVX000222 100 mg capsule
45654294|NCT02586155|Drug|Atorvastatin|High-Intensity Statin
45654295|NCT02586155|Drug|Rosuvastatin|High-Intensity Statin
45654296|NCT05697731|Diagnostic Test|Vidiac Score|Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.
45654297|NCT05696093|Drug|cotrimoxazole|Use of cotrimoxazole therapy for enterobacterial VAP
45654298|NCT05696093|Drug|standard antibiotic therapy|Use of standard antibiotic therapy for enterobacterial VAP
45654299|NCT02446743|Biological|rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)|One dose of the vaccine administered intramuscularly in the deltoid area of the non-dominant arm.
45654300|NCT02586077|Drug|Exparel|
45654301|NCT05536739|Device|Robotic hip exoskeleton|The intervention is an experimental robotic hip exoskeleton that has been previously developed by the team. It is used to improve walking gait performance.
45654302|NCT05536661|Other|Preservative free hyaluronic acid artificial tear|Ocular lubricant
45654303|NCT03241121|Behavioral|Time restricted feeding|To eat only during a self-selected window of 12 hours, with no advice on nutrition quality, quantity or caloric intake
45938394|NCT00186706|Drug|Selenium|
45938395|NCT00409201|Drug|reboxetine adjuvant therapy|
45938396|NCT00058721|Drug|I-123-5-IA85380|
45938397|NCT00046878|Drug|O6-benzylguanine|
45938398|NCT00046878|Drug|carmustine|
45938399|NCT00186745|Drug|Tinzaparin|Dose: 175 IU/kg subcutaneously once daily, up to 7 days. Dose reduction as per protocol if anti-Xa levels exceed pre-defined limits.
45938400|NCT00186784|Procedure|Transcranial Magnetic Stimulation (TMS)|treatment for 10 days
45938401|NCT00186823|Device|Miltenyi Biotec CliniMACS|A stem cell selection device.
45938402|NCT00186823|Procedure|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
45938403|NCT00186823|Drug|TBI, systemic chemotherapy and antibodies as follows:|Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3. Rituximab was provided prior to transplant for PTLPD prophylaxis. In addition to T cell depletion of the donor product, cyclosporine was administered for GVHD prophylaxis.
46002625|NCT00546026|Other|placental function assessment|Formal assessment of placental function in mid-gestation by placental morphology and uterine artery Doppler at 20-22 weeks and re-interpretation of prior biochemical tests for Down's syndrome and spina bifida.
46002626|NCT00546065|Drug|esomeprazole treatment|concomitant esomeprazole treatment
46002627|NCT00558324|Procedure|LASIK|Mechanical microkeratome Hansatome 160 microns
46002628|NCT00558324|Procedure|LASIK|Mechanical microkeratome K 3000 130 microns
45938404|NCT00186862|Drug|Interleukin-2|"A genetically modified (retroviral) allogeneic tumor vaccine coupled with the human interleukin-2. Patients were treated with 4 injections of these gene-modified tumor cells. The first two were given at weeks 1 and 2. Patients then had a 2 week rest and the remaining 2 injections were given at weeks 4 and 5. A complete evaluation for evidence of toxicity and response were performed at week 8.~At this week 8 evaluation, if there was no excessive toxicity, progressive disease requiring therapy, and if more transduced cells are available, patients had the option to receive 4 additional injections. These additional injections were separated by 1 month at the higher of the two dosage levels originally received."
45938405|NCT03551964|Drug|Cangrelor|"Cangrelor: IV bolus 30 μg/kg (application < 1 minute), immediately followed by continuous infusion in the dose of 4 μg/kg/min. To accelerate the initiation of therapy, tables containing calculations of the bolus dose in ml and the speed of infusion therapy for individual weights will be prepared.~Cangrelor therapy will be stopped after circulatory stabilization - when sBP > 100 mmHg persists for one hour / when IABP will be terminated / when vasoactive treatment with norepinephrine, dopamine (in the dose ≥ 5 μg/kg/min) will be stopped, but not later than 4 hours after PCI~30 minutes before stopping Cangrelor infusion, administration of initial dose of crushed Ticagrelor 180 mg and then Ticagrelor maintenance dose 90 mg twice a day for 12 months."
45938406|NCT03551964|Drug|Ticagrelor|Initial dose crushed Ticagrelor 180 mg. Maintenance dose Ticagrelor 90 mg twice daily for 12 months.
45938407|NCT00058760|Behavioral|NIA intervention (after school health promotion didactic program)|
45654304|NCT03241121|Behavioral|Regular dietary advices|Regular dietary advices by a trained dietitian or research nurse according to current nutrition guidelines
45938408|NCT00186940|Drug|Rasburicase|Rasburicase 0.2 mg/kg/dose by the intravenous route for up to 7 days.
46074158|NCT00852319|Behavioral|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
45654305|NCT03241121|Device|Eating patterns|Data collection on eating patterns via the smartphone app
45654306|NCT05591807|Other|Electroacupuncture|insert the acupuncture needle to SJ3(left side) and connect the electroacupuncture device for 15min, 2mA and 2Hz
45654307|NCT05536583|Procedure|Laparoscopic sleeve Gastrectomy|Laparoscopic sleeve Gastrectomy
45654308|NCT05536505|Genetic|Adjuvant treatment for MRD positivity|The MRD positive group would receive icotinib as adjuvant treatment. When the peripheral blood MRD turned negative, the subjects entered the drug withdrawal observation period. When the MRD turned positive again, the subjects resumed icotinib treatment. If EGFR T790M mutation was found, researchers would resume medication and choose osimertinib therapy.
45654309|NCT05695937|Dietary Supplement|phytosterol|2g/day will be provided to the participants, aiming to guarantee a minimum of 800mg/day of free phytosterols.
45654310|NCT05695937|Dietary Supplement|krill oil|2g/day will be provided to the participants, aiming to guarantee a minimum of 400mg/day of eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids.
45654311|NCT05695937|Other|Placebo phytosterol|Placebo of phytosterol, in the same quantity of the active phytosterol
45654312|NCT05695937|Other|Placebo krill oil|Placebo of krill oil, in the same quantity of the active krill oil
45654313|NCT05536271|Drug|Bisoprolol Fumarate|antihypertensive medicine prescribed for acute coronary syndrome patients
45654314|NCT03157115|Device|Kinocardiography|"This device records the electric and mechanic function of the heart. With electrodes and adequate electronics, ECG is recorded. 6 degrees of freedom accelerometers are also included in the device to measure the micro accelerations of the body at the body surface when the device is placed on the skin. Using physics principles and adequate calibration, those accelerations allow us to calculate parameters such as kinetics energies related to cardiac contractility.~During a standard echocardiography appointment for a patient suffering from a cardiovascular condition with/without heart failure, the cardiologist will monitor the heart of the patient with the Kino device (examination lasting a few minutes with the patient lying down on a bed). Data will be matched between the control group and the experimental group."
45654315|NCT05536193|Drug|Topical Metformin Emulgel and salicylic acid|"Combination Product: Topical metformin emulgel topical metformin emulgel will be used on the left side of the face twice daily (home use).~Procedure/Surgery: Salicylic acid Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.~Other Names:~• 2-hydroxybenzoic acid"
45654316|NCT05536193|Diagnostic Test|Insulin- Like growth factor (ILGF-1)|3 ml blood for serum sample for estimation of Insulin- Like growth factor (ILGF-1) by ELISA kit will be taken from every patient before and after use of topical metformin.
45654317|NCT05535881|Behavioral|Strengths to Grow Program|In an online, self-directed format, the Strengths to Grow program will present the principles of strength-based parenting using videos, pictures, reflection questions, and written text. The intervention will communicate that a) every child has a unique set of strengths and that b) noticing and developing these strengths can enhance child and family well-being. It will also provide concrete steps that parents can follow to talk with their child about strengths, and it will provide ideas for family activities that would allow family members to express strengths. Participants will be invited to respond to reflection questions at various points throughout the program.
45805511|NCT05920499|Other|AUDIT and Feedback|"AUDIT and Feedback is a well-known quality intervention that according to the last Cochrane review leads to small but potentially important improvements in professional practice (Ivers N et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev 2012, 6:Cd000259).~Standardized automated AUDITs are available in most EHR systems in Belgium. Feedback, on the other hand, is only available in specific registration networks. At study baseline the performance in INTEGO practices will be measured. Afterwards a standardized clinical AUDIT to identify patients that may benefit from pneumococcal vaccination will be implemented in the EHR of all INTEGO practices. The Feedback will only be implemented in the intervention group."
45938409|NCT00186979|Drug|Irinotecan, ZD1839, Vincristine, Cefixime, Cefpodoxime.|See Detailed Description section for details of treatment interventions.
45938410|NCT00058799|Biological|Dose Level 1|Leukemic Blasts 2 x 10^7; IL-2 Fibroblasts 2 x 10^7; CD40L Fibroblasts 2 x 10^5
45938411|NCT00058799|Biological|Dose Level 2|Leukemic Blasts 2 x 10^7; IL-2 Fibroblasts 2 x 10^7; CD40L Fibroblasts 2 x 10^5
45938412|NCT00058799|Biological|Dose Level 3|Leukemic Blasts 2 x 10^7; IL-2 Fibroblasts 2 x 10^7; CD40L Fibroblasts 4.2 x 10^7
45938413|NCT00187018|Biological|Bone marrow transplant|
45938414|NCT00187057|Drug|vinblastine, vincristine, prednisone, daunorubicin|See Detailed Description section for details of treatment interventions.
45938415|NCT00187057|Drug|doxorubicin, methotrexate, cyclophosphamide, L-asparaginase|See Detailed Description section for details of treatment interventions.
45938416|NCT00187057|Drug|etoposide, cytarabine, mercaptopurine|See Detailed Description section for details of treatment interventions.
45654318|NCT04425707|Drug|Ivermectin|use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt
45654319|NCT05697185|Drug|Evolocumab|Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
45654320|NCT05695781|Drug|BRM421 Ophthalmic Solution|A topical drop of BRM421 ophthalmic solution.
45938417|NCT00187057|Drug|dexamethasone, procarbazine|See Detailed Description section for details of treatment interventions.
45938418|NCT00187057|Procedure|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
46074159|NCT00852319|Behavioral|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
45654321|NCT05695781|Drug|Vehicle|A topical drop of vehicle (minus active) ophthalmic solution.
45654322|NCT02583425|Drug|DFN-11 Injection|
45654323|NCT05535803|Biological|Olfactory mucosa-derived mesenchymal stem cells|Autologous olfactory mucosa-derived mesenchymal stem cells
45938419|NCT00046917|Drug|alvocidib|Given IV
45938420|NCT00046917|Drug|irinotecan hydrochloride|Given IV
45938421|NCT00046917|Drug|cisplatin|Given IV
45938422|NCT00187174|Drug|Everolimus|The drug is given orally in 28 day courses.
45938423|NCT00187213|Device|Cardiac Resynchronization Therapy|
45654324|NCT05535803|Other|Patients treated according to current clinical protocols|Patients treated according to current clinical protocols
45938424|NCT00058838|Drug|sumanirole|
45938425|NCT00187252|Device|Atrial Overdrive Pacing|Pacemaker/ ICD implant
45938426|NCT00187291|Device|T-Wave Alternans test|
46074160|NCT02809170|Dietary Supplement|Arginine|Arginine is an amino acids
46074161|NCT02809170|Dietary Supplement|Citrulline|Citrulline is an amino acid
46074162|NCT00837109|Behavioral|Veteran Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting
46074163|NCT00837109|Behavioral|Treatment-as-usual|Treatment-as-usual in the Trauma Recovery Program (that does not specifically target PTSD symptoms)
45654325|NCT01719887|Device|Conservative treatment|Conservative treatment with functional brace.
45654326|NCT01719887|Procedure|Operative treatment|Operative treatment with open reduction and internal fixation using 4,5mm locking compression plate.
45654327|NCT01719887|Other|Physiotherapy|Physiotherapy is arranged to both groups at 3 and 9 wks.
45654328|NCT05511233|Dietary Supplement|feeding with breastmilk within 48 hours after surgery|Electronic health records of babies who feed and not fed with breastmilk within 48 hours after surgery
45654329|NCT02581163|Drug|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
45654330|NCT02581163|Drug|Dasabuvir|Tablet
45654331|NCT02581163|Drug|Ribavirin|Tablet
45654332|NCT05591495|Procedure|laparoscopy in upper abdominal surgical emergencies in adults|evaluation the role of laparoscopy in upper GIT emergencies in adults
45938427|NCT03538938|Behavioral|1-Call Quitline Counseling|The 1-Call Quitline Counseling will be provided by the Wisconsin Tobacco Quit Line (WTQL) and consists of 1 proactive call using a standard, evidence-based protocol lasting approximately 20 minutes; ad hoc calls that are initiated by the participant are also available.
45938428|NCT03538938|Behavioral|4-Call Quitline Counseling|The 4-Call Quitline Counseling will be provided by the Wisconsin Tobacco Quit Line (WTQL) and consists of 4 proactive calls that use a standard, evidence-based protocol with each call lasting approximately 20 minutes; ad hoc calls that are initiated by the participant are also available.
45938429|NCT03538938|Drug|Nicotine patch|Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD).
45938430|NCT03538938|Drug|Nicotine Patch and Nicotine Lozenge|The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); the Nicotine Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking).
45938431|NCT03538938|Behavioral|SmokefreeTXT|SmokefreeTXT support is a national program offered at no cost to users (apart from data/minute costs charged by cellular providers about which enrollees are advised at enrollment) and is sponsored by the National Cancer Institute. This program sends up to 5 messages per day for up to 2 weeks prior to the target quit day and 6 weeks following the target quit day (total duration may be longer if participants elect to change the target quit day). The text messages offer tips to help enrollees achieve their goal of quitting smoking and offer real-time interactive tips when participants text in responses indicating cravings, negative moods, or slips. Participants have the option to reset quit dates and have the option to unsubscribe at any time by texting STOP to the program.
45938432|NCT03538938|Behavioral|No SmokefreeTXT|Proactive information about enrolling in adjunctive SmokefreeTXT text messaging support is not offered.
45654333|NCT05591417|Procedure|Bilevel Erector spinae plane block|Patients will receive bilevel erector spinae plane block with bupivacaine
45938433|NCT03538938|Behavioral|Financial Incentives for Treatment Engagement|Incentives for treatment engagement are for each counseling session and for staying enrolled in SmokefreeTXT for six weeks. These incentives are designed to bolster motivation to stay engaged in treatment and to offset the costs and effort of treatment engagement (in terms of cell phone minutes).
45938434|NCT03538938|Behavioral|No Financial Incentives for Treatment Engagement|No Financial Incentives for Treatment Engagement are offered.
45938435|NCT00187330|Drug|Intravenous N-acetylcysteine|
45805512|NCT05920486|Device|High-Intensity Laser Therapy (HILT)|High-Intensity Laser Therapy (HILT) is a non-invasive treatment that utilizes high-powered lasers to deliver therapeutic doses of energy to damaged tissue. In this study, HILT will be used to treat sacroiliitis, a condition that affects the sacroiliac joint in the lower back and pelvis. HILT will be administered using a Class IV laser with a wavelength of 980 nm, power output of 10 W, spot size of 0.5 cm, and a dose of 60 J/cm2 per session. The laser will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. The aim of HILT is to promote cellular repair and regeneration, reduce pain, and improve function in patients with sacroiliitis. Participants in the HILT group will receive HILT treatment as the primary intervention in this study.
45938436|NCT00187408|Drug|Low Molecular Weight Heparin (dalteparin)|
45938437|NCT00187447|Drug|indomethacin (two different dosing regimens)|
45938438|NCT02969564|Other|scintigraphy 99mTc-MDP-SPECT/CT.|SPECT/CT will be performed for every patient in the frame of their clinical follow up
45938439|NCT02969564|Other|18F-NaF-PET/MR|a 18F-NaF-PET/MR will be performed, in the frame of this clinical study, to the patients to assess the difference of sensitivity of the 2 exams
45938440|NCT00187525|Drug|Memantine|
45938441|NCT00187564|Drug|controlled-release oral alpha-lipoic acid|
45938442|NCT00187603|Behavioral|tobacco cessation program|
45654334|NCT05591417|Procedure|Bilateral Erector spinae plane block with dexamethasone|Patients will receive bilevel erector spinae plane block with bupivacaine and dexamethasone
45654335|NCT05591417|Procedure|Bilateral Erector spinae plane block with dexmedetomidine|Patients will receive bilevel erector spinae plane block with bupivacaine and dexmedetomidine
45654336|NCT05591417|Drug|Intravenous morphine|Intravenous morphine 0.1 mg/kg
45654337|NCT05535179|Drug|honeysuckle and semen oroxyli solution|The patients in the treatment group were instructed to gargle the solution containing honeysuckle and semen oroxyli (25 mL) four times a day for 2 weeks.
45654338|NCT05462405|Procedure|Experimental group|In the setting phase subjects will be in recumbent position. A microneurography needle (0.2mm diameter isolated Tungsten micro-electrode) will be placed under the skin. An identical (not isolated) reference needle tip will be inserted within 2 cm of the first electrode. These are connected to a recording system (ADInstruments PowerLab). Once sympathetic activity can be measured using the needles, a sympathetic specific test will be used to calibrate the measurement and recording system. In the testing phase sequential pacing and CNT delivery will be programmed for a few minutes, the whole procedure expected to last less than 2 hours.
45654339|NCT05679089|Device|early detection test|Blood collection and early detection testing
45654340|NCT05591261|Behavioral|ePREP|6-session online psychoeducational program with supporting coach calls
45654341|NCT05688527|Other|Cleansing Balm|DermResults Cleansing Balm w/ Avocado Oil twice daily
45654342|NCT05688527|Other|Toning Essence|DermResults Advanced Toning Essence w/ Mineral Booster twice daily
45938443|NCT00046995|Drug|carboplatin|
45938444|NCT00046995|Drug|fluorouracil|
45938445|NCT00046995|Drug|leucovorin calcium|
45938446|NCT00046995|Procedure|adjuvant therapy|
45938447|NCT00058955|Drug|sodium oxybate, triazolam and pentobarbital|sodium oxybate, triazolam and pentobarbital
45938448|NCT00187759|Drug|cephalexin|
45938449|NCT00187798|Drug|Metformin HCl|Subjects will be given a single oral dose in tablet form containing 850 mg of metformin
45938450|NCT00187837|Procedure|SW|Stepwise removal of carious tissue in 2 stages
45938451|NCT00187837|Procedure|DCE|one complete excavation
45938452|NCT00058994|Drug|anecortave acetate|
45938453|NCT00187915|Drug|Mycophenolate mofetil + Tacrolimus|Target MPA exposure to 30-60 mg/L/h during first month post-transplant
45938454|NCT00187915|Drug|Mycophenolate mofetil + Cyclosporin|Target MPA exposure to 30-60 mg/L/h during first month post-transplant
45938455|NCT00047034|Drug|eribulin mesylate|Given IV
45938456|NCT00047034|Other|pharmacological study|Correlative studies
45938457|NCT00047034|Other|laboratory biomarker analysis|Correlative studies
45938458|NCT00187993|Drug|Growth hormone|
45938459|NCT00188032|Procedure|Computer-Assisted diagnostic Decision Support|
45938460|NCT00188032|Procedure|written diagnostic guidelines|
45938461|NCT00188032|Procedure|electronic therapeutic reminders|
45938462|NCT00188071|Drug|paracetamol|
45938463|NCT00188071|Drug|ketoprofen|
45938464|NCT00188071|Drug|ketoprofen + paracetamol|
45938465|NCT00188110|Procedure|Water-Enema Computed Tomography|
45938466|NCT00188149|Drug|Combined chemotherapy (ABVD, BACOPP-D)|
45938467|NCT00188149|Procedure|Radiation therapy|
45938468|NCT00188188|Drug|quinipril|
45938469|NCT00188227|Drug|Midazolam (sedative)|
45938470|NCT00188227|Drug|Piritramid (analgetic)|
45938471|NCT00188227|Behavioral|Cognitive exercises|
45938472|NCT00188266|Drug|cisplatinum combined with infusional fluorouracil (5 FU)|Continuous 5FU via intravenous PICC line + 4 doses of Cisplatin every 2 weeks
46002629|NCT00558324|Procedure|LASIK|Femtoseconds laser 100 microns
46002630|NCT00546143|Drug|Omalizumab|
46002631|NCT00546143|Drug|Omalizumab|
46002632|NCT00546143|Drug|Omalizumab|
45654343|NCT05688527|Other|Facial Serum|DermResults Advanced Serum w/ Hyaluronic Acid twice daily
45654344|NCT05688527|Other|Moisturizer|DermResults Advanced Moisturizer w/ Hyaluronic Acid twice daily
45654345|NCT05688527|Other|Eye Cream|DermResults Advanced Eye Cream w/ Hyaluronic Acid twice daily
45654346|NCT05589857|Device|IPAD|Participants will play a game using the iPad's standard camera, which will show you your hospital room and the decal/stickers s as they appear in the real world.
45654347|NCT05589857|Device|Augmented Reality|Participants will play a game through (device camera and application) that add virtual or digital characters and items that let participants view the real world.
45805513|NCT05920486|Device|Sham High-Intensity Laser Therapy (HILT)|Sham HILT is a non-invasive treatment that mimics the appearance and sensation of HILT but does not deliver any laser energy to the affected tissue. In this study, Sham HILT will be used as a control intervention for the treatment of sacroiliitis. The device used for Sham HILT will look and feel the same as the HILT device, but will not emit any laser energy. The device will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. The aim of Sham HILT is to provide a credible control intervention that does not have any specific therapeutic effect on the sacroiliac joint. Participants in the Sham HILT group will receive Sham HILT treatment as the primary intervention in this study.
45805514|NCT05920473|Device|rTMS with Magstim Rapid 2 magnetic stimulation device|The study will involve the utilization of the Magstim Rapid 2 magnetic stimulation device to administer rTMS treatment to the participants. The coil will be positioned tangentially on the scalp, specifically targeting the hot spot (thumb movement area) in the ipsilateral cerebral hemisphere. During the stimulation protocol, a 10-Hz stimulation will be applied for 2 seconds, followed by a 10-second rest period. This cycle will be repeated 50 times. The treatment will be administered once daily, from Monday to Friday, for a continuous period of two weeks.
45805515|NCT05920473|Device|sham control with Magstim Rapid 2 magnetic stimulation device|In the sham group, patients received sham stimulation using the the Magstim Rapid 2 magnetic stimulation device with the same protocol. The coil was positioned to target the same hot spot, with an angulation parallel to the gyrus to further reduce the potential impact of rTMS.
45805516|NCT05920460|Behavioral|Cognitive Behavioral Therapy Program|"Brief description of the Cognitive Behavioral Therapy program is given below:~Session 1: Mutual understanding and rapprochement~Session 2: Sleep hygiene education~Session 3: Psychoeducation about stimulus control strategies; monitoring sleep environments, and identification of behavioral habits at bedtime, dysfunctional beliefs, and attitudes about sleep.~Session 4: Training on relaxation techniques~Session 5: Psycho education about depression~Session 6: Cognitive restructuring~Session 7: The terminating session"
45805517|NCT05920447|Device|LMA|Monitor the ventilatory parameter and incidence of complications
45805518|NCT05920434|Other|randomized controlled study|randomized controlled study,no drugs or devices were administered to the participants.
45938473|NCT00047073|Drug|Rapamycin|"Phase 1: Initial dose 6mg on day 1 and then 2mg each day for 5-7 days before surgery. No dosing during surgery recovery. After recorvery 6mg loading dose on day 1 then 2mg each day. Cycle is every 4 weeks.~Dose escalation: Level 2: 15mg load/5mg/day, Level 3: 30mg load/10mg/day, Level 4: 45mg load/15mg/day.~Phase 2: Will utilize dose established in phase I. Dosing schedule will remain the same."
45938474|NCT00047073|Procedure|Surgery|Surgical resection.
45938475|NCT00047073|Procedure|Supportive Care|"Corticosteroids should be used in smallest dose to control symptoms of cerebral edema and mass effect.~Anti-seizure medications should be used as indicated. Febrile neutropenia may be managed according to local institution's infectious disease guidelines.~If neurosurgical management is required for reasons not due to tumor progression, these procedures must be documented."
45938476|NCT00188305|Behavioral|General health counselling and risk information|General health counselling and risk information
45938477|NCT00188344|Procedure|pneumatic dilatation|"The patient is on a liquid diet for 2 days prior to procedure. A sedative and pain killer by IV are given and the throat will be sprayed with local anesthetic.~The gastroenterologist may perform an endoscopy prior to the dilatation to safely guide the dilator into position. A special dilator with a small balloon will be passed down the esophagus until it meets the stomach then the balloon will be inflated with air until the narrow part of the esophagus is opened. The patient will then be assessed for any perforation of the esophagus and monitored in the post-procedure unit for a few hours."
46002633|NCT04645992|Device|active TENS|study group will receive only one session of yoga eye exercise for 20 minutes followed by TENS by placing electrodes on skin over urinary bladder (BL) acupoints 61 and 62 for 20 minutes
45654348|NCT02193295|Behavioral|Caloric Restriction|Dietary intervention to reduce lipid content in liver and muscle with minimal overall weight loss. Weekly visits for measurements of body weight, body composition, blood glucose and MRS measurements of liver and muscle lipid.
45654349|NCT05589545|Device|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis|A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by an ensemble of standard dental implants and zygomatic dental implants, following the All-on-4 Hybrid Concept.
45654350|NCT01938547|Drug|clevidipine|
45654351|NCT05685485|Procedure|Standard Implantation|Traditional Ahmed plantation without vicryl ligature
45654352|NCT05685485|Procedure|Tied off Tube|Ahmed implantation with vicryl ligature
45676270|NCT04145037|Drug|AVR-RD-02|AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase).
45805519|NCT05920421|Procedure|diaghragm affection by ultrasound before and after the blocks|the participant will assess diaphragm sparing in each block and evaluate effectiveness of infraclavicular subomohyoid blocks and subomohyoid subscapularis blocks according to intraoperative and postoperative analgesia and diaphragm affection and comparing them with interscalen and with each others
45938478|NCT00188344|Procedure|laparoscopic myotomy with partial fundoplication|The abdomen is inflated with gas and cameras and instruments are inserted. The junction between the esophagus and stomach is identified. The muscle of the lower esophageal sphincter is divided. A portion of the stomach wall is secured to the lower esophagus. After surgery the patient is taken to the recovery room and when well enough moved to a ward. The patient may be discharged the following day.
45938479|NCT00188383|Drug|Amantadine|
45938480|NCT02969447|Drug|Administration of 10 units of intra venous oxytocin after fetal expulsion|
45938481|NCT03494946|Procedure|Liver transplantation|
45938482|NCT03494946|Drug|Chemotherapy|May include chemotherapy, TACE, SIRT or other available treatment options.
45938483|NCT00188422|Procedure|low dose CT|
45654353|NCT05695625|Other|Spinal anesthesia + bilateral erector spine plane block|"Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position. At the end of the surgery, patients were given a sitting position with the help of 2 people for USG-guided ESPB. The high-frequency linear USG probe was placed in the midline at T12 level, after the spinous process visualized, the transverse process was visualized by moving probe 3-4cm laterally. After confirming the location of the needle tip with 1-2ml hydrodissection, 10 ml bupivacaine + 10 ml salin was applied both right and left sides.~Postoperative period: If patients' VAS value >4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values >4, 1000mg paracetamol intravenously was administered."
45805520|NCT05920408|Drug|EXS21546|EXS21546 Granule in Capsule
45938484|NCT00188461|Device|CT Thorax|
45938485|NCT00188578|Procedure|Intensity Modulated Radiation Therapy Boost|All patients shall receive a continuous course of IMRT consisting of 25.2 Gy in 14 fractions over 3 weeks
45938486|NCT00188617|Drug|GEFITINIB|250 mg once a day for 28 days before surgery
45654354|NCT05695625|Other|Spinal anesthesia|"Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position.~Postoperative period: If patients' VAS value >4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values >4, 1000mg paracetamol intravenously was administered."
45938487|NCT00047112|Drug|cisplatin|
45938488|NCT00047112|Drug|fluorouracil|
45938489|NCT00047112|Procedure|conventional surgery|
45938490|NCT00047112|Procedure|neoadjuvant therapy|
45938491|NCT00047112|Radiation|radiation therapy|
45938492|NCT00188656|Procedure|CT thorax|
45654355|NCT05695547|Other|VR educational video|Patients will be educated with our specifically made VR video in the settings of our hospital to make patients more familliar with the spaces and to explain them the procedure.
45938493|NCT02963038|Biological|Autologous CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
45938494|NCT00059189|Device|Magstim Rapid Magnetic Stimulator|
45938495|NCT00409279|Behavioral|Information, counseling and support|individual-family consultation, support group, and ad hoc consultation
45938496|NCT00409318|Drug|Etanercept|50 mg SC q week
45938497|NCT00409318|Drug|Placebo|SC q week
45938498|NCT03492762|Drug|Cu-DOTA-ECL1i|Radiolabeled probe called Cu-DOTA-ECL1i that recognizes CCR2 and propose to image CCR2 in the lung to ultimately guide diagnosis and therapy.
45938499|NCT00409357|Drug|SL77.0499-10 (alfuzosin hydrochloride)|
45938500|NCT00409396|Procedure|Urinary PGEm level|Level of PGEm in urine compared to CRP and fecal calprotectin levels in patients with ulcerative colitis.
45938501|NCT00409396|Procedure|fecal calprotectin|Level of fecal calprotectin in comparison to urinary PGEm and serum CRP levels.
45938502|NCT00059267|Drug|HBIG, Epivir, Hepsera|
45938503|NCT00188773|Drug|N-acetylcysteine, intralipid, heparin|One visit subject will receive N-acetylcysteine plus intralipid and heparin, another visit n-acetylcyksteine plus saline, another visit intralipid and heparin and another visit saline alone
45938504|NCT00188812|Drug|donepezil hcl|
45938505|NCT03432546|Other|Non-interventional|Non-interventional
45938506|NCT00188851|Drug|therapeutic management strategy|
45938507|NCT02963194|Drug|Oxytocin|
45938508|NCT02963194|Drug|Placebo|
45938509|NCT00059306|Drug|aspirin|Participants receive aspirin + placebo, specifically: aspirin (325 mg) with placebo (an inactive substance). Participants will take 1 of each pill a day until the end of the study.
45458028|NCT04748419|Radiation|consolidative hypofractionated radiation therapy (hfRT)|Consolidative hfRT will start from 6.5Gy x 2 fractions and dose escalate to 10Gy x 2 fractions in a 3+3 design
45938510|NCT00059306|Drug|clopidogrel|Participants will receive aspirin + clopidogrel, specifically: aspirin (325 mg) with clopidogrel (75 mg)-- Participants will take 1 of each pill a day until the end of the study.
45938511|NCT00059306|Other|Target of Blood Pressure|Participants will be assigned to one of 2 groups of blood pressure control. The difference between the two groups is the target level of systolic blood pressure-either 130-149 mmHg or below 130 mmHg; to do so, the scientists will use medications that are already in the market for blood pressure management.
45938512|NCT00059306|Other|placebo|an inactive substance
45938513|NCT00188929|Procedure|PET Scan with [18F]Fluoro-2-deoxyglucose (FDG)|
45938514|NCT03428373|Drug|Rivaroxaban|Rivaroxaban 10mg daily
45938515|NCT03428373|Drug|ASA|ASA 81mg
45938516|NCT00425542|Other|Outpatient care (vs traditional inpatient care)|Patients randomized to the outpatient arm are discharged from the emergency department within 24 hours after randomization. Patients randomized to the inpatient arm are admitted to the hospital and are discharged based on the decision of the managing physician at the hospital.
45938517|NCT00188968|Procedure|Nasal Continuous Positive Airway Pressure|
45938518|NCT00188968|Procedure|Synchronized Nasal Positive Pressure Ventilation|
45938519|NCT00189007|Drug|Allopurinol sodium|Allopurinol sodium 500 mg / 50 mL, intravenously, single dose
45938520|NCT00189007|Drug|Mannitol|Mannitol 500 mg/50 mL water for injection, intravenously, single dose
45654356|NCT05684159|Drug|NM8074|NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period. Patients in Cohort 2 will receive weekly doses of 10 mg/kg for a total of 4 doses from Day 1 to Day 22 followed by biweekly doses at 20 mg/kg for a total of 5 doses from Day 29 to Day 85.
45654357|NCT05697107|Drug|Ripretinib Oral Tablet|Oral kinase inhibitor
45654358|NCT05415371|Behavioral|Standard Care + Financial Incentives|Financial incentive participants will receive standard care and receive incentives for completing counseling calls and for abstinence.
45805521|NCT05920395|Other|Electro-acupuncture|Patients lie supine on the treatment bed, and after routine disinfection, a 0.30×60mm or 0.30×40mm disposable sterile acupuncture needle is inserted directly into the acupoint. Once obtaining qi, the needle is manipulated with even reinforcing and reducing techniques to maintain needle sensation. Acupoints selected include Zhongwan, Zusanli, Neiguan, and Tianshu, connected to the 6805-All electro-acupuncture therapy device. Zhongtuo and Tianshu acupoints are connected to a set of electrodes, with the positive pole connected to Zhongtuo and the negative pole connected to one side of Tianshu. The stimulation uses sparse and dense wave pulses with a frequency of 2Hz/100Hz, with the stimulation intensity determined based on individual patient tolerance. Each session lasts for 30 minutes, with a treatment frequency of once every other day, for a total of 4 weeks.
45654359|NCT05415371|Other|Standard Care|Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.
45654360|NCT05586737|Drug|Rituximab|1 gram rituximab twice with two weeks interval
45654361|NCT05678933|Drug|Azacitidine|Azacitidine (75mg/ m2) will be administered at day 1-5 by subcutaneous injection of each 21-day cycle.
45805522|NCT05920395|Other|Sham electro-acupuncture group|Shallow acupuncture needles are used and then disconnected from the electrode. They are tied with black tape and connected to the sham electrode. The device is not powered on, and the rest of the treatment is the same as the electro-acupuncture group.
45805523|NCT05920382|Procedure|Radiofrequency ablation of peripheral nerves.|Randomized double-blind clinical trial where we will apply thermal radiofrequency to the sensory terminal branches of the femoral nerve in the knee, including the vasto medial nerve, vasto lateral nerve, vasto intermedio nerves, and the infrapatellar branch of the saphenous nerve.
45805524|NCT05920369|Other|low-energy extracorporeal shockwave and a tailored exercise program|"the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a range of 0.056-0.068 mJ/mm.~Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises"
45938521|NCT00399945|Drug|Tobramycin|
45938522|NCT00059345|Procedure|Acupuncture|Electroacupuncture treatments provided two times per week for 6 weeks
45938523|NCT00059345|Procedure|Placebo acupuncture|Placebo acupuncture treatments provided 2 times per week for 6 weeks
46074164|NCT02809326|Behavioral|17 week Exposure Therapy Control Arm|15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies
45654362|NCT05678933|Drug|Chidamide|Chidamide (20 mg) will be taken orally twice a week for two weeks of each 21-day cycle.
45654363|NCT05678933|Drug|Cyclophosphamide|Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
45654364|NCT05678933|Drug|Epirubicin|Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
45654365|NCT05678933|Drug|Vincristine|Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.
45654366|NCT05678933|Drug|Prednisone|Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.
45654367|NCT05678855|Behavioral|A randomızed Controlled Study with pre-test and post-test|The intervention in this study is to apply multimedia-based instruction in distance education to the experimental group. control group students received distance education through traditional teaching. Experimental group students received distance education through interactive teaching prepared with multimedia tools. Experimental group, interactions were made using applications such as Icebreaker, Puzzle, QR code, Mentimeter, and Padlet. In addition, animation, infographics, animated slides (Multimedia tools) were used for the experimental group.In the control group, plain narration was given. Tests were administered to both groups before and after the intervention.
45938524|NCT00059345|Other|Usual Care|Usual care for knee osteoarthritis
45938525|NCT00189046|Behavioral|driving and laboratory tests|
45938526|NCT00189085|Drug|simvastatin and ezetimibe|
45938527|NCT00189124|Drug|Dehydroepiandrosterone (DHEA)|
45938528|NCT00189163|Drug|Pioglitazone|30 mg, taken orally, once per day, for 48 weeks
45938529|NCT00189163|Drug|Placebo Oral Tablet|Sugar Pill, taken orally, once per day, for 48 weeks
45938530|NCT00059384|Behavioral|Concentration-controlled therapy|
45938531|NCT00399984|Behavioral|Asthma Education Program|interactive seminars regarding daily inhaled corticosteroids
45938532|NCT00189358|Drug|ZD1839|
45938533|NCT00189358|Drug|tamoxifen|
45938534|NCT00189397|Drug|azathioprine and corticosteroids for Parthenium dermatitis|
45654368|NCT05357495|Behavioral|Affective Posner fMRI frustration induction task|During the frustration induction paradigm, children play a game with monetary reward. The game is rigged, thus inducing frustration. The control task does not have any reward component. All participants complete both the control task scanning session and the frustration induction scanning session.
45654369|NCT05678777|Device|Galvanic Skin Response|The probe will be attached to the patient's finger and the Galvanic Skin Response will be measured
45654370|NCT05678621|Drug|trimethoprim-sulfamethoxazole (co-trimoxazole)|Doxycycline is an alternative for participants with hypersensitivity to co-trimoxazole.
46074165|NCT02809326|Behavioral|Trauma Management Therapy|TMT consists of 29 treatment sessions administered over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during Social and Emotional Regulation (SER). Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
45458029|NCT04748419|Drug|Durvalumab 50 MG/ML|Durvalumab 10 mg/kg via a 60-minute iv infusion every two weeks ± 3 days for up to 12 months
45654371|NCT05678621|Drug|amoxycillin/clavulanic acid and ciprofloxacin|clindamycin is an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.
45654372|NCT05678621|Drug|Immunoglobulins|Intravenous monthly immunoglobulin or subcutaneous weekly immunoglobulin
45654373|NCT05338073|Diagnostic Test|Known 3Dx Test|Cancer tissue is cultured and treated with a panel of FDA approved chemotherapy and targeted therapies at a range of doses. Cell growth and phenotypes are measured to determine which treatment or treatment combinations would yield the best results for a patient. Test results are compared to actual patient outcomes collected at 3, 6, 9, and 12 months post tissue collection to determine the predictive power of the Known 3Dx Test
45654374|NCT05334953|Device|ESWT|"Group 1 (n = 17) will be given two times a week, total 5 sessions of ESWT + home exercise program~Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises"
45654375|NCT05334953|Device|Phonophoresis|"Group 2 ( n=17) will be given five times a week total 10 sessions of diclofenac phonophoresis + home exercise program~Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises"
45654376|NCT05334953|Device|Ultrasound|"Group 3 (n=17) will be given five times a week total 10 sessions of ultrasound therapy+ home exercise program~Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises"
45654377|NCT05334953|Other|Control group|Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises
45654378|NCT05697029|Drug|Tetrandrine|tetrandrine TID for 28 days
45654379|NCT05240729|Procedure|Infraclavicular brachial plexus block|Using ultrasound in 3different techniques of infraclavicular brachial plexus block
45654380|NCT05530577|Drug|Semaglutide|Semaglutide (subcutaneous)
45654381|NCT05530577|Drug|Sham/placebo|Sham subcutaneous injection
45654382|NCT04722263|Radiation|Radiotherapy|15 Gy in 3 fractions
45654383|NCT04718909|Drug|Regorafenib + sintilimab|"Regorafenib: 160 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).~Sintilimab: 200mg i.v. q3w."
45654384|NCT04718909|Drug|Regorafenib|160 mg p.o. qd for 3 weeks of every 4 week cycle.
45654385|NCT05216549|Other|Water-based exercise|8 weeks x 2 times per week for 45 min
45654386|NCT05216549|Other|Land-based exercise|8 weeks x 2 times per week for 45 min
45654387|NCT05214989|Behavioral|Tailored intervention|Tailored intervention designed to address individual barriers to cardiac rehabilitation participation
45654388|NCT04708613|Diagnostic Test|Cognitive/Neuropsychological Testing|Comprehensive testing of cognitive function and brain health.
45654389|NCT04708613|Diagnostic Test|Vestibular/Ocular-Motor Testing|A series of tests and questionnaires that asses vestibular function, balance, ocular-motor coordination, and reflexes.
45654390|NCT04708613|Diagnostic Test|Sleep Evaluation|A full assessment of sleep health, including insomnia (duration, frequency, daytime consequences) and other sleep disorders such as obstructive sleep apnea. Overnight sleep study is included.
45654391|NCT04708613|Diagnostic Test|MRI, High-Resolution|A high-resolution MRI to provide qualitative and quantitative assessments of brain structure.
45654392|NCT04708613|Diagnostic Test|Health & Physical Exam|Participants will undergo an executive history and physical exam of all body systems.
45654393|NCT04708613|Diagnostic Test|Physical Function|These assessments will involve a series of tests and questionnaires that focus on physical function.
45654394|NCT04708613|Diagnostic Test|Blood Testing and Biomarker Analysis|"A blood draw will be performed to measure standard clinical labs as part of a full history and physical, as well as additional analysis of biomarkers indicative of brain health.~An optional lumbar puncture will be performed and CSF samples (20-30 mL) stored in the NCTC Biorepository until shipment to the CLIA-certified laboratory.~Both CSF and blood samples will be analyzed for t-tau, p-tau, and Aβ42 and stored for future testing,"
45654395|NCT04708613|Diagnostic Test|Applanation Tonometry|Hearth health is evaluated through testing of arterial stiffness and pulse wave reflections using a high fidelity applanation tonometer.
45654396|NCT04708613|Diagnostic Test|PET brain imaging|PET imaging of the brain using tau and amyloid ligands.
45654397|NCT04708613|Drug|[C-11]6-OH-BTA-1|PET imaging of the brain using an amyloid ligand.
45654398|NCT04708613|Drug|[F-18]AV-1451|PET imaging of the brain using a tau ligand.
45654399|NCT05674175|Biological|Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)|CART22-65s are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD22 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
45654400|NCT05674175|Biological|Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)|HuCART19 cells are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD19 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
45654401|NCT05183399|Device|GORE® VIABAHN® Endoprosthesis|
45938535|NCT00189514|Drug|pramlintide acetate|Subcutaneous injection, twice a day or three times a day, at doses of 120mcg, 240mcg, or 360mcg
45938536|NCT00189514|Drug|placebo|subcutaneous injection, three times a day, volumes equivalent to 120mcg, 240mcg, or 360mcg of pramlintide acetate
45938537|NCT00189553|Drug|Pegylated liposomal doxorubicin|30 mg/m² every 4 weeks during 6 cycles or until progression
45938538|NCT00189553|Drug|Carboplatin|AUC 5 every 3/4 weeks during 6 cycles or until progression
45938539|NCT00189553|Drug|Paclitaxel|175 mg/m² at day 1 every 3 weeks during 6 cycles or until progression
45938540|NCT00400023|Drug|S-1|"During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.~During the S-1 Extension Phase (Part 2), S-1 30 mg/m2 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
45938541|NCT00400023|Drug|FT|During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.
45938542|NCT00189592|Device|ArthroCare TOPAZ™ MicroDebrider™ using Coblation|Percutaneous treatment of plantar fascia using the Topaz device. No incision performed.
45938543|NCT00189592|Procedure|Surgical Fasciotomy|Standard surgical fasciotomy using an incision to treat the plantar fascia.
45938544|NCT00189631|Procedure|UFT/LV|
45938545|NCT00189631|Procedure|Observation|
45938546|NCT03396081|Behavioral|PRADO-IC|"Help of administrative employees to schedule the first medical visits after an hospitalization for heart failure.~Home nurse's visiting program, during 2 to 6 months after the hospitalization for heart failure."
45938547|NCT03396081|Behavioral|No intervervention Usual Care|Advices about the care pathway, provided by care givers. Prescription of home nurse's visits if needed.
45938548|NCT00189670|Procedure|6 TEC q 3 weeks|
45938549|NCT00189670|Procedure|4 EC q 2 weeks followed by 4 TXT q 2 weeks|
45938550|NCT00189670|Procedure|4 TXT q 2 weeks followed by 4 EC q 2 weeks|
45938551|NCT00189709|Drug|Micafungin|IV
45938552|NCT00189709|Drug|fluconazole|IV
45938553|NCT02969330|Device|Stimulator|
45938554|NCT02969330|Dietary Supplement|Glucose|300ml tap water with 75g glucose
46074166|NCT02809326|Behavioral|Intensive 3-Week Trauma Management Therapy|Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon. Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
45654402|NCT05379881|Behavioral|Common Elements Toolbox (COMET)|COMET is an unguided single-session intervention (SSI) combining elements of cognitive-behavioral therapy (CBT) and positive psychology.
45654403|NCT05373719|Other|No intervention; observational|No intervention; observational
45654404|NCT05177393|Other|Assessment of patient-reported outcomes (PROs)|Questionnaires will be administered to participants
45938555|NCT04722796|Device|TAVR with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution)|Transcatheter aortic valve replacement (TAVR) with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution)
45938556|NCT04722796|Device|TAVR with Venus A plus using annular sizing and THV implantation technique|Transcatheter aortic valve replacement (TAVR) with Venus A plus using annular sizing and THV implantation technique (Traditional sizing strategy)
45938557|NCT02965287|Other|Serum metabolomics profiling|The serum samples will be used to get a metabolomic profile
45938558|NCT00189748|Drug|Tacrolimus|
46074167|NCT02809248|Device|ZES|stent implantation (zotarolimus eluting stent)
45654405|NCT04315337|Behavioral|Virtual Kitchen Training|VR Training will include repeated practice of a single, everyday task in a non-immersive VR context (e.g., VR Breakfast) using a laptop with a touch-screen interface for four days over the course of one week.
45654406|NCT04133363|Procedure|Ridge preservation using L-PRF/FDBA layered technique|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA layered technique
45654407|NCT04133363|Procedure|Ridge preservation using L-PRF/FDBA|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA
45654408|NCT04133363|Procedure|Ridge preservation using L-PRF|Atraumatic tooth extraction following by socket grafting using L-PRF
45938559|NCT00189787|Drug|tacrolimus|
45938560|NCT00059462|Drug|Interleukin-2 SA|HAART and Bay 50-4798
45938561|NCT00059462|Drug|HAART|HAART alone
45938562|NCT00189826|Drug|tacrolimus|immunosuppression
45938563|NCT00047190|Drug|tipifarnib|Given PO
45938564|NCT00047190|Other|laboratory biomarker analysis|Correlative studies
45938565|NCT00189904|Biological|IMVAMUNE (MVA-BN)|
45938566|NCT02969291|Behavioral|Reduced Sedentary Time Intervention (RSTI)|Following 7 days of baseline activity monitoring a study investigator will download the information from the monitor, evaluate the periods of sedentary behavior and create a tailored RSTI for each participant. For example, the investigator may notice a long stretch of sitting in the evening following a meal and identify several exercises that can be done indoors during that time, or if the participant is amiable to walking breaks and a period after work is identified the investigator might suggest the appropriate walking activity at that time. This program has been successful in sedentary overweight office workers and investigators will use similar techniques.
45938567|NCT00189943|Biological|MVA-BN|
46002137|NCT04736030|Behavioral|Intervention|Twelve weekly sessions will be led by Ms. Schneider and Ms. Montañez supported by Drs. Arredondo and Ayala and student research assistants. Mothers and daughters will participate in weekly virtual 1.5-hour sessions that include didactic teaching, skill building (including PA parenting and communication skills training), interactive discussions, PA, and homework review (homework examples: 30-min walks, practicing communication strategies). Mothers and daughters will attend sessions together, with 10-12 mother-daughter dyads participating in each series. Sessions 2-12 will include at least 30 min PA. Sessions will discuss strategies to engage in PA outside the sessions (goal of 60-min MVPA daily).
45938568|NCT04722913|Diagnostic Test|Photogrametry , flexion rotation (FRT) test, Diagnosis of CGH according diagnostic criteria of the Cervicogenic Headache International Study Group (CHISG)|"Photogrammetry is the science and technology of obtaining reliable information about physical objects and the environment through the process of recording, measuring and interpreting photographic images and patterns of electromagnetic radiant imagery and other phenomena.~Flexion rotation (FRT) test:~FRT is a manual examination technique with high sensitivity and specificity. It is performed with the patient in supine by passively taking the cervical spine into full flexion. End-range cervical flexion imparts ligamentous tension that impedes movement at vertebral segments below C2.7 Maintaining the flexion position, the patient's head is then rotated to each side until the patient reports pain or the operator determines that end of motion has been achieved. It is then determined if a restriction in ROM is present."
45938569|NCT03247374|Device|"ProComp5 Infiniti Biofeedback"|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. At the beginning of the bio-feedback session, a surface electrode will be applied to the mylohyoid muscle. The computer will produce visual feedback of the muscular activity on the screen. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: they are requested to do classical maneuvers that favour swallowing efficacy that is effortful swallow, supraglottic swallow, and Masako maneuver. The experimental group will perform this training for 45 minutes."
45805525|NCT05920369|Other|low-energy extracorporeal shockwave|the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a range of 0.056-0.068 mJ/mm.
45805526|NCT05920369|Other|tailored exercise program|Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises
45938570|NCT03247374|Other|Standard Speech and Language Therapy|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy receiving verbal feedback from the speech and language therapist. They are requested to do classical maneuvers that favour swallowing efficacy that is effortful swallow, supraglottic swallow, and Masako maneuver. The control group will perform this training for 45 minutes."
45938571|NCT00189982|Drug|Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|"Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator). Once the treatment regimen was established, the regimen was to be maintained for the duration of the study, unless clinical reasons necessitated a change.~The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care."
45938572|NCT00190021|Drug|donepezil|
45938573|NCT00190060|Drug|Transdermal testosterone gel (Testogel 1% )|Transdermal testosterone gel (Testogel 1% ), 50 mg/d for 6 months
45938574|NCT00190060|Drug|Matched transdermal placebo gel|Matched transdermal placebo gel, 50mg/d for 6 months
45654409|NCT05160155|Procedure|Serratus Anterior Plane Block|Serratus anterior plane block will be performed unilaterally, under US guidance.
45805527|NCT05920356|Drug|Sotorasib|Oral administration
45805528|NCT05920356|Drug|Pembrolizumab|Intravenous administration
45938575|NCT00047229|Biological|oblimersen sodium|
45938576|NCT00047229|Drug|doxorubicin hydrochloride|
46074168|NCT02809248|Device|BMS|stent implantation (bare metal stent)
45938577|NCT04722874|Device|Ortho-k lenses|Ortho-k lenses will be administered nightly.
46074169|NCT00837187|Drug|Intravenous dexmedetomidine|100 ug
46074170|NCT00837187|Drug|Intranasal dexmedetomidine|100 ug
45654410|NCT05160155|Procedure|Intercostal Block|Intercostal Block will be performed unilaterally, under US guidance.
45654411|NCT02627677|Drug|Ponatinib 30 mg QD|Ponatinib 30 mg, taken orally once daily.
45938578|NCT04722874|Device|RLRL|RLRL will be performed twice a day with an interval of at least 4 hours, each treatment last 3 minutes. Nightly treatment should be performed at least 30 minutes before ortho-k lens insertion.
45654412|NCT02627677|Drug|Ponatinib 15 mg QD|Ponatinib 15 mg, taken orally once daily.
46074171|NCT02809482|Other|Eucaloric feeding|3 days of a diet designed to maintain energy balance
46074172|NCT02809482|Other|Overfeeding|3 days of a diet designed to induce a 40% positive energy balance
46074173|NCT00962585|Drug|Placebo|
46074174|NCT00962585|Drug|S-equol|"Eligible patients meeting all study entry criteria were randomly assigned to receive one of the following active treatments for 4 weeks:~S-equol 10 mg BID (20 mg total daily dose)~S-equol 50 mg BID (100 mg total daily dose)~S-equol 150 mg BID (300 mg total daily dose)"
46074175|NCT00856453|Behavioral|Home yoga practice|training for and tracking of patient's practice of yoga at home
45654413|NCT02627677|Drug|Nilotinib 400 mg BID|Nilotinib 400 mg, taken orally twice daily.
45654414|NCT05677841|Other|Stabilization exercise+lifestyle recommendation|Exercise program was given both spinal stabilization exercises focusing on the pelvic floor 3 days a week for eight weeks and a booklet related to the lower urinary system symptoms, the structure of the pelvic floor and healthy behavioral strategies recommendations (fluid intake, diet, weight control etc. )
46074176|NCT00856453|Behavioral|yoga classes|organized out of home classes for yoga
46074177|NCT04236960|Biological|Meningococcal Group ACYW135 Conjugate Vaccine|1 dose in Stage 1 (2~55 yrs), 2 doses in Stage 2 (7~23 mos), and 3 doses in Stage 3 (2&3 mos)
45654415|NCT05677841|Other|lifestyle recommendations|The control group will be given a booklet related to the lower urinary system symptoms, the structure of the pelvic floor and healthy behavioral strategies recommendations (fluid intake, diet, weight control etc. )
45654416|NCT05660603|Other|control|patients will receive standard general anesthesia
45938579|NCT00190099|Device|Dexamethasone-Eluting Stent|
45938580|NCT04722640|Drug|SKYRIZI|SKYRIZI
45938581|NCT00190138|Device|Bi-ventricular pacing|
45938582|NCT02963077|Drug|A4250|
45938583|NCT02963077|Drug|CRC (A3384)|
45938584|NCT02963077|Drug|Questran|
45938585|NCT02963077|Drug|Placebo|
45938586|NCT00047268|Drug|cytarabine|
45938587|NCT00047268|Drug|mercaptopurine|
45938588|NCT00047268|Other|laboratory biomarker analysis|
45654417|NCT05660603|Procedure|LSP|patients will receive standard general anesthesia followed by ultrasound-guided combined lumbar and sacral plexus blocks with 40 ml of bupivacaine 0.25%.
45938589|NCT00047268|Procedure|allogeneic bone marrow transplantation|
45938590|NCT00047268|Procedure|biopsy|
45938591|NCT00047268|Procedure|peripheral blood stem cell transplantation|
45938592|NCT00190216|Device|Magnetic stimulator|
45938593|NCT00190255|Procedure|CY2PC9 genotyping|CY2PC9 genotyping
45938594|NCT00190294|Drug|MIFEPRISTONE 200 mg and misoprostol 400 µg|MIFEPRISTONE 200 mg and misoprostol 400 µg
45938595|NCT03238365|Biological|Nivolumab|Given IV
45938596|NCT03238365|Drug|Tadalafil|Given orally
45938597|NCT03238365|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45938598|NCT00059618|Drug|PS-341 (Bortezomib)|Starting dose 0.8 mg/m^2 given by vein over 5-10 seconds Day 1, 4, 8 and 11 of 28 day cycle for 8 cycles.
45938599|NCT00059618|Drug|Carboplatin|AUC 5 by vein administered over one hour Day 1 of 28 day cycle for 8 cycles.
46074178|NCT00621985|Drug|dexamethasone|Dexamethasone will be given at a dose that equals 1/50 of the total daily hydrocortisone dose of the patient. It will be given in solution form at 10 PM for 3 days.
46074179|NCT00621985|Drug|Hydrocortisone|Subjects were given their baseline hydrocortisone regimen which was three times daily for 4 of the subjects and twice daily for one subject. Doses were given at 8 AM, 2 PM, and 8 PM. The 2 PM time point was skipped for the subject who received hydrocortisone twice daily. Doses ranged from 6.9 to 18.5 milligrams per meter squared per day and were based on each individual's baseline regimen.
45654418|NCT05660603|Procedure|CP|patients will receive standard general anesthesia followed by ultrasound-guided circum-psoas blocks with 40 ml of bupivacaine 0.25%.
45654419|NCT05660603|Device|Ultrasound|ultrasound
45654420|NCT03059875|Behavioral|Medical consultation for a Standardized Geriatric Evaluation|
45654421|NCT05677685|Device|VISUPRIME|twice daily
45654422|NCT05677685|Device|Placebo|twice daily
45654423|NCT04964479|Drug|TQB2450 injection|1200mg injection once every 3 week
45938600|NCT00190333|Drug|escitalopram|escitalopram
46074180|NCT02812368|Drug|Clonidine|
46074181|NCT02812368|Drug|Placebo (for clonidine)|Placebo pill manufactured to mimic clonidine
46074182|NCT02545621|Other|RAGE TXNIP Inflammasome axis|
46074183|NCT02547805|Drug|ALLN-177|ALLN-177 7,500 units (5 capsules) PO TID with meals
46074184|NCT02547805|Drug|Placebo|Placebo 5 capsules PO TID with meals
45654424|NCT04964479|Drug|Anlotinib Hydrochloride Capsules|12mg capsule once daily
45654425|NCT04964479|Drug|Pembrolizumab injection|200mg injection once every 3 week
45654426|NCT04964479|Drug|Placebo|Placebo capsule once daily
45654427|NCT04964401|Procedure|Thoracic paravertebral block vs Erector spinae plane block|Thoracic paravertebral block and erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
45654428|NCT04964245|Device|accelometer|the respiration parameters are measured using an accelometer.
45654429|NCT04964245|Device|thermographic camera|the respiration parameters are measured using an thermographic camera.
45654430|NCT04964245|Device|Electrical Impedance Tomography|the respiration parameters are measured using an electrical impedance tomograhy.
45938601|NCT00190372|Behavioral|Controlled diet|Controlled diet
45938602|NCT00190372|Behavioral|Self-hypnotic relaxation|Self-hypnotic relaxation
45938603|NCT00190411|Drug|celiprolol|celiprolol
45938604|NCT00190411|Drug|Control|Untreated controls excluding betablockers
45938605|NCT00190450|Biological|graft intracerebral of foetal neurons|graft intracerebral of foetal neurons
45938606|NCT00059657|Drug|Ecraprost in lipid emulsion|
45938607|NCT00047307|Drug|alvocidib|Given IV
45938608|NCT00047307|Drug|gemcitabine hydrochloride|Given IV
45938609|NCT00047307|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
45938610|NCT00047307|Other|laboratory biomarker analysis|Correlative studies
45938611|NCT00190489|Drug|AC (ADM 40mg/m2+CPA 500mg/m2) q21 days x 6 cycles|
45938612|NCT00190489|Drug|Docetaxel 60mg/m2 every 21 days for 6 cycles|
45938613|NCT00190489|Drug|AC and Docetaxel 60mg/m2 alternately q21 days for 6 cycles|
45938614|NCT00190528|Drug|neoadjuvant chemotherapy + radical hysterectomy|
45938615|NCT00190528|Procedure|radical hysterectomy|
45938616|NCT00190567|Drug|duloxetine|
45938617|NCT00190567|Drug|Placebo|
45938618|NCT02969252|Drug|Rifamycin SV-MMX® 600|
45938619|NCT03169842|Device|pancreatic cyst fluid glucose analysis using a bedside glucometer|Small amount of pancreatic cyst fluid will be analyzed for glucose level using a bedside glucometer from EUS-FNA procedures.
45938620|NCT00190606|Drug|Duloxetine|
45938621|NCT00190606|Procedure|Pelvic Floor Muscle Training (PFMT)|
45938622|NCT00190606|Procedure|Imitation PFMT|
45938623|NCT00190606|Drug|placebo|
45938624|NCT00190645|Drug|Duloxetine|
45938625|NCT00190723|Drug|Enzastaurin|
45938626|NCT00190762|Drug|Pemetrexed|
45938627|NCT00190801|Drug|pemetrexed|
45938628|NCT00190801|Drug|cisplatin|
45938629|NCT00047346|Drug|erlotinib hydrochloride|Given PO
45938630|NCT00047346|Other|pharmacological study|Correlative studies
45938631|NCT00047346|Other|laboratory biomarker analysis|Correlative studies
45938632|NCT00190840|Drug|pemetrexed|
46074185|NCT02814552|Other|HTN PRA App|The HTN PRA App will be used to adjust standard of care medication dosages for high blood pressure drugs which may include: thiazide diuretic (water pill), usually called hydrochlorothiazide (HCTZ) or chlorthalidone, and an ACE inhibitor or an angiotensin receptor blocker.
45938633|NCT02969135|Behavioral|Progressive early passive and active movement|Post-surgical physical therapy including active exercise
45938634|NCT02969135|Behavioral|Limited early passive movement|Post-surgical physical therapy including passive mobilisation
45938635|NCT00190879|Drug|Atomoxetine hydrochloride|
45938636|NCT00190879|Drug|placebo|
45938637|NCT00190918|Drug|Pemetrexed|
45938638|NCT00188500|Behavioral|atkins diet|
45805529|NCT05920343|Drug|Rivaroxaban 10 MG|The intervention in the experimental arm will be rivaroxaban, 10 mg PO once daily (prophylactic dosing) for 180 days after the start of systemic therapy or until one of the primary study outcomes occurs (VTE or major bleeding).
45654431|NCT04964245|Device|Mattress Sensor|the respiration parameters are measured using an Mattress pressure
45654432|NCT04964167|Combination Product|Plant extract|Natural plant extract
45938639|NCT00188500|Behavioral|ability to follow low carbohydrate diet|
45938640|NCT00190957|Drug|Atomoxetine|
45654433|NCT03059797|Drug|Anlotinib|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
45654434|NCT03059797|Drug|Placebo|Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
45805530|NCT05920343|Other|Placebo control|Identical to Rivaroxaban intervention except participants will receive a matched placebo instead of the study drug
45654435|NCT02501811|Biological|Mesenchymal Stem Cells (MSC)|15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
45654436|NCT02501811|Biological|c-kit+ cells|15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
45938641|NCT00190957|Drug|placebo|
46074186|NCT02814552|Other|Blood Sample|Blood sample for plasma renin activity activity will be obtained at least once (at baseline) and if BP is not controlled after 1-3 months, an additional blood sample may be obtained.
46074187|NCT02544841|Behavioral|Safer Sex Intervention (SSI)|Safer Sex Intervention (SSI) is an in-person, individual-level, clinic-based intervention implemented by a female health educator trained in the intervention. It is intended to be implemented in one initial session lasting 30-50 minutes and three booster sessions lasting 10-30 minutes at one, three, and six month intervals.
45458030|NCT02309476|Device|PASCAL Laser, Green Laser 0.75|"Barely Visible Pascal laser grid using 532nm green wavelength, 0.75 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
45654437|NCT02501811|Biological|Placebo (Plasmalyte A)|15 transendocardial injections of 0.4ml placebo administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
45654438|NCT04432129|Behavioral|IBBIS II|"The IBBIS-II service consists of:~Mental health assessment.~Planned integrated service. The participant has the same employment specialists and care manager throughout the intervention. A joint plan is made with shared decisions between the participant, the employment specialist and the care manager. There is a focus on disclosure (openness about illness) and involvement of relatives and significant others.~Vocational rehabilitation. Focus on return to work with ongoing assessment of job goals, competencies and need of support. Participants receive help in contacting existing employers (employed) and potential employers (unemployed). Unemployed participants are offered an individualized job search effort. The focus is on competitive jobs within the community.~Treatment consists of stepped care with structured treatment guidelines.~When the participant has obtained work the team continues to offer support."
45654439|NCT04432129|Behavioral|Service as Usual|Service as usual consists of standard mental health care and vocational rehabilitation
45654440|NCT04964011|Other|Board game intervention|In this study, the two groups, the Board game group (12-week board game intervention) and Health promotion group (12-week general health promotion intervention).
45654441|NCT02585999|Device|Xulane Contraceptive Patch|Extended use (12 weeks) of contraceptive patch
45805531|NCT05920330|Other|Nasal Plug|Please see the arm description for details.
45938642|NCT00190996|Drug|Duloxetine Hydrochloride|
45938643|NCT00190996|Drug|placebo|
45938644|NCT00191035|Drug|Atomoxetine|
45654442|NCT04963621|Behavioral|Child-Adolescent Emotion and Stress Intervention Program|Intervention programs include Emotion and Stress Intervention for children with emotional and stress problems
45938645|NCT00191074|Drug|somatropin, rDNA origin, for injection|
45938646|NCT02922894|Procedure|Acute episodic hypoxia|The subjects will undergo 30 minutes of baseline monitoring followed by 15 episodes of one minute of episodic hypoxia with supplemental CO2 to maintain isocapnia. This is followed by a 45 minute recovery period.
45938647|NCT02922894|Procedure|Supplemental oxygen|Supplemental oxygen therapy for 6 weeks
45938648|NCT02922894|Drug|Trazodone|100mg before bedtime
45938649|NCT02922894|Drug|Placebo|One placebo pill before-bedtime
45938650|NCT02922894|Procedure|Sham|Room air will be administered instead of episodic hypoxia or supplemental oxygen..
45938651|NCT00191230|Drug|gemcitabine|
45938652|NCT00191230|Drug|carboplatin|
45938653|NCT00191230|Drug|cisplatin|
45938654|NCT00059696|Procedure|Constraint-Induced Movement Therapy|
45938655|NCT02963155|Other|Blood samples|
45938656|NCT00191347|Drug|pemetrexed|
45938657|NCT00191347|Drug|gemcitabine|
45938658|NCT00191425|Drug|Teriparatide|
45938659|NCT00191425|Drug|Raloxifene|
45938660|NCT02910726|Procedure|Sentinel Lymph Node Biopsy|
45938661|NCT02910726|Drug|indocyanine green (ICG)|
45938662|NCT00191464|Drug|premeal insulin lispro mixtures|
45938663|NCT00191464|Drug|insulin glargine|
45938664|NCT00191464|Drug|metformin|
45938665|NCT02969174|Other|zimin Lu,Guo Sa|chengzhong Liu
46002634|NCT04645992|Device|sham TENS|control group will be treated with the same protocol as the study group but with the TENS unit is off .
45654443|NCT05696951|Other|Transamine 200mg iv|In the intervention group, intravenous TXA (Transamine) 1000 mg dissolved in 100 mL 0.9% sodium chloride was administered intravenously within 10 minutes as a loading dose within the first 30 minutes at the end of the surgery. After the end of the loading dose, a maintenance dose of 120mg/hour TXA was infused in 500ml (60ml/hour) SF. The placebo group was given 100ml of saline in the first 30 minutes, followed by a maintenance dose of 60ml/hour of saline for 8 hours.
45805532|NCT05920304|Device|virtual Hospital at Home (vHaH)|"Participants randomized to vHaH will transferred home for home-based admission. Participants will be provided with equipment for self-monitoring (respiratory rate, oxygen saturation, blood pressure, heart rate and temperature). They will receive an app on their smartphone or tablet for transferring of self-measurements and communication with the hospital during their home-based admission.~Supporting the telemedicine concept, a mobile hospital-based care team will perform clinical tasks including intravenous administration, blood samples and on-site clinical assessment in the participant's home, when relevant.~Daily ward rounds will be conducted as video consultations. Before leaving the hospital, participants will receive thorough education on how to self-monitor and how to use the app."
45938666|NCT04723030|Drug|carleilizumab+apathy mesylate+radiotherapy+paclitaxel (albumin-bound)|"Carrilizumab ：200mg,q2w; Apatinib :250mg,d1; which is taken continuously for 5 days and stopped for 2 days, and stopped for 2 weeks after radiotherapy.~Taxol :125mg/m2,q2w; Gemcitabine :1000mg/m2, q2w; cisplatin :25mg/m2, q2w; Radiotherapy:30Gy, divided into five times and completed within one week."
45938667|NCT00191503|Drug|Pemetrexed|
45938668|NCT00191503|Drug|Gemcitabine|
45938669|NCT00191542|Drug|Atomoxetine|
45938670|NCT00191542|Drug|Placebo|
45938671|NCT00059735|Drug|E7070|
45654444|NCT05695313|Drug|OnLife®|"It is administered for the duration of PACLITAXEL chemotherapy with the first administration performed 5 days before the first PACLITAXEL administration. The OnLife supplement will be continued for another 4 weeks after the last PACLITAXEL administration.~One tablet in the morning and one in the evening daily"
45938672|NCT00191581|Drug|Humalog Mix 50|
45654445|NCT05695313|Other|Placebo|"It is administered for the duration of PACLITAXEL chemotherapy with the first administration performed 5 days before the first PACLITAXEL administration. Placebo will be continued for another 4 weeks after the last PACLITAXEL administration.~One tablet in the morning and one in the evening daily"
45654446|NCT01444495|Radiation|Preoperative radiotherapy|Preoperative radiotherapy 5x5 Gy (total dose of 25 Gy)
45805533|NCT05920278|Device|Pulse oximeter|Devices (2) were placed on the finger and the fingertip. Blood samples were taken at each stable level of oxygenation.
45805534|NCT05920265|Procedure|Quadratus Lumborum plain Block|ultrasound guided Quadratus Lumborum plain Block using 0.5 ml/kg bupivacaine 0.25% .
45938673|NCT00191581|Drug|Human Insulin Mix 50:50|
45938674|NCT00191620|Drug|Gemcitabine|
45938675|NCT00191620|Drug|cisplatin|
45938676|NCT00191659|Drug|Atomoxetine Hydrochloride|
45938677|NCT00191698|Drug|atomoxetine hydrochloride|
46074188|NCT02544841|Behavioral|Female Sexual Health|Female Sexual Health is a knowledge-based intervention that intends to provide information on how STIs are contracted, the consequences of contracting STIs, and how to prevent them. Female Sexual Health includes the information-only component of the first session of SSI and baseline exposure to a health educator but does not include booster sessions.
45654447|NCT01444495|Procedure|Surgery|Total mesorectal excision of rectal cancer
45805535|NCT05920265|Procedure|fascia iliaca block|ultrasound guided fascia iliaca block using 0.5 ml/kg bupivacaine 0.25%
45805536|NCT05920265|Diagnostic Test|control group|no intervention
45938678|NCT00191698|Drug|placebo|
45938679|NCT02969096|Procedure|Targeted Cryoablation Therapy|A cryoprobe is inserted percutaneously under CT guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively.
45654448|NCT01439269|Behavioral|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
45938680|NCT02470299|Drug|Ketorolac|"Ketorolac tromethine 15 mg or 30 mg doses will be administered via intravenous (IV) push undiluted over 15 - 30 seconds~Ketorolac will be dosed according to FDA approved recommendations. For planned three daily dose (IV) based on clinical scenario:~Patients < 65 years of age: Daily dose of 30 mg for three doses.~Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses~Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose"
45938681|NCT02470299|Other|Placebo|"Equivalent volume of normal saline will be set in the syringe for each daily dose registered for the patient in a blinded fashion. The volume will be determined by the dose calculation as follows: For planned three daily dose (IV) based on clinical scenario:~Patients < 65 years of age: Daily dose of 30 mg for three doses.~Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses.~Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose"
45938682|NCT00191737|Drug|Atomoxetine|
45938683|NCT00191893|Drug|teriparatide|
45938684|NCT00191932|Drug|Duloxetine|
45938685|NCT00059813|Biological|recombinant interferon alfa|Given SC
45938686|NCT00059813|Biological|oblimersen sodium|Given IV
45938687|NCT00059813|Other|pharmacological study|Correlative studies
45938688|NCT00191971|Drug|Gemcitabine|
45938689|NCT00047502|Drug|Lonafarnib (SCH66336)|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day."
45938690|NCT00047502|Drug|Imatinib Mesylate (Gleevec)|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day.~Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day."
45938691|NCT00192049|Drug|Gemcitabine|
45938692|NCT00192049|Drug|mitomycin C|
45654449|NCT02582255|Biological|Sabin mOPV2|"Polio Sabin™ Mono Two (oral) is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2. Magnesium chloride is used as a stabilizer. Polio Sabin™ Mono Two (Oral) contains trace amounts of neomycin sulphate and polymyxin B sulphate.~One dose of vaccine (0.1 mL) is contained in two drops which are delivered from the polyethylene dropper supplied with vaccine."
45654450|NCT04973761|Other|Zirconium crowns|Prefabricated pirmary anteroir teeth zirconium crowns
45654451|NCT04973761|Other|Strip composite crowns|Strip composite crowns
45654452|NCT04973371|Diagnostic Test|Home-based point-of-care (POC) TB testing using GeneXpert device + MTB/RIF test|Those who screen positive for TB using the standard 4-question screener will be offered a GeneXpert® [Cepheid, Sunnyvale, CA] MTB/RIF test in their home with referral for clinic-based TB treatment initiation for those who receive a positive MTB/RIF test result.
45654453|NCT03061435|Procedure|Screening anal Pap smear - No high-resolution anoscopy|75% of patients with negative cytology on their anal Pap smear will not receive high-resolution anoscopy
45654454|NCT03061435|Procedure|Screening anal Pap smear - High-resolution anoscopy|25% of patients with negative cytology on their anal Pap smear will receive high-resolution anoscopy. All patients with positive (abnormal) cytology on their anal Pap smear will receive high-resolution anoscopy.
45654455|NCT04432363|Device|Transcranial direct current stimulation|Direct current application over the scalp to stimulate and change the excitability of the cortical areas underneath the electrodes (in this case left primary motor cortex and left dorsolateral prefrontal cortex).
45654456|NCT02500719|Device|Computational Model - Real-time Support Vector Machine|A support vector machine algorithm will be applied in real-time to fMRI data to identify distributed patterns of co-activated brain regions that specifically encode high emotional arousal (i.e,. high SCR) to the stress/trauma memory (note, this is equivalent to predictions of fitted Q-iteration in which the all actions are specified as zero, reward is equal to the support vector machine predicted arousal, and the discount factor of 0). The resulting idiosyncratic brain map would inform the neurofeedback phase in the next stage of fMRI data collection. This approach will first be piloted in the healthy participant group, then implemented in the PTSD participant group.
45805537|NCT05920252|Behavioral|Vira|"Intensive outpatient DBT supported by the Vira platform. The Vira app is installed on the patient's smartphone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Patients will be asked to use Vira for the duration of their intensive outpatient treatment. Patients' use of the Vira app is supported by practitioners, who can schedule just-in-time reminders (i.e., nudges) to arrive in the user's phone at scheduled times to support their behavior change plan and DBT treatment. The Vira Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the practitioner's workflow."
45805538|NCT05920252|Behavioral|Treatment as Usual (TAU)|Intensive outpatient DBT + EARS app (passive data monitoring software)
45805539|NCT05920239|Diagnostic Test|Magnetic resonance imaging (MRI)|MRI imaging is a diagnostic technique that uses magnetic fields and radio waves to create detailed images of the body's internal structures. It provides high-resolution images of soft tissues, organs, and bones, allowing for the detection and evaluation of various medical conditions.Two experienced radiologists specializing in musculoskeletal imaging will evaluate the images obtained through conventional MRI. Cases demonstrating involvement, characterized by findings such as thickening exceeding 4 mm in the inferior glenohumeral capsuloligamentous complex, signal increase indicating edema on fluid-sensitive sequences, and a reduction in axillary recess volume (greater than 0.53 ml), will be included in the study.
45938693|NCT00192088|Drug|pemetrexed|
45938694|NCT00192088|Drug|oxaliplatin|
45938695|NCT00192127|Biological|FluMist|A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0.
45938696|NCT00192127|Other|Placebo|A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0
45938697|NCT00059852|Drug|erlotinib hydrochloride|
45938698|NCT00059852|Drug|gemcitabine hydrochloride|
45938699|NCT00047541|Drug|Alcon Investigational Agent|
45938700|NCT00192166|Biological|CAIV-T|
46074189|NCT02861729|Other|Vita Suprinity|zirconia reinforced lithium silicate partial coverage restorations
46074190|NCT02861729|Other|IPS e.max|lithium disilicate partial coverage restorations
46074191|NCT02814318|Biological|Vaginal and rectovaginal swab cultures|The only intervention that will occur in this study is obtaining vaginal and recto-vaginal swab cultures upon admission to the labor and delivery room and every two hours to follow until 8 hours after administration of IV vancomycin or IV penicillin.
46074192|NCT02808000|Device|BIP Foley (latex) or BIP Foley -silicone|
45938701|NCT00192205|Biological|CAIV-T or TIV|
45938702|NCT00192244|Biological|CAIV-T, Liquid|
45938703|NCT00192283|Biological|CAIV-T|The total single-dose volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril).
45938704|NCT00192283|Other|Placebo|A single dose of placebo volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril).
45654457|NCT05677373|Drug|BRD4 Inhibitor PLX2853|Given PO
45654458|NCT05677373|Drug|Trametinib|Given PO
45938705|NCT00192322|Biological|CAIV-T 10^7|a single intranasal 0.2 mL dose of liquid CAIV-T 107 (approximately 0.1 mL into each nostril)
45938706|NCT00192322|Biological|CAIVT 10^5|a single intranasal 0.2 mL dose of CAIV-T <10^5
45938707|NCT00192322|Biological|Placebo|a single intranasal 0.2 mL dose of placebo
45938708|NCT00192322|Biological|TIV|commercially available TIV injected intramuscularly
45938709|NCT00047580|Drug|tizanidine hydrochloride capsule|
45938710|NCT02968901|Drug|macitentan|used in open label
45938711|NCT02968901|Drug|tadalafil|used in open label
46074193|NCT02808000|Device|Standard catheter|
45805540|NCT05920239|Diagnostic Test|Sonoelastography|Sonoelastography is a medical imaging technique that combines ultrasound imaging with elastography. It is used to assess the mechanical properties and stiffness of tissues in the body.The probe will be carefully positioned perpendicular to the anterior part of the glenohumeral capsuloligamentous complex (IGHCC), ensuring no pressure is applied and preventing anisotropy. It will be specifically oriented in the coronal plane towards the axillary recess. The grayscale examination will reveal irregularly thickened and heterogeneous structures at the axillary recess level in the patient group. On the other hand, in the control group, measurements will be taken from the anterior band of the normal, thin, smooth, and homogeneous structure of the IGHCC.
45654459|NCT05677373|Procedure|Computed Tomography|Undergo CT with contrast
45805541|NCT05920226|Device|pacemakers implantation and assessment of cardiac function and cardiac fibrosis|"150 patients will be implanted with pacemakers. In addition to the echocardiography, contrast-enhanced cardiac MRI and peripheral venous blood sampling for myocardial fibrosis markers, the tests described above will be repeated at 1 (V1), 12 (V2), 24 (V3) months after inclusion. Echocardiography and peripheral venous blood sampling for myocardial fibrosis markers detection will be repeated to all patients before pacemakers implantation and after 6,12 and 24 months of observation period. Contrast-enhanced cardiac magnetic resonance imaging (MRI) will be performed before pacemaker implantation and 6 months after surgery.~In addition, pacemakers programming data will be evaluated after 1, 12, 24 months after inclusion in the study (atrioventricular delay, percentage of ventricular stimulation, episodes of high atrial frequency, fibrillation/atrial flutter, ventricular tachycardia)."
45805542|NCT05920226|Diagnostic Test|assessment of cardiac function and cardiac fibrosis|The patients who do not require a pacemaker placement will undergo diagnostic testing such as echocardiography, contrast-enhanced cardiac MRI and peripheral venous blood sampling for myocardial fibrosis markers.
45805543|NCT05920213|Drug|Polyethylene Glycols|280g/ 24 hours for 5 days
45805544|NCT05920213|Drug|Lactulose oral solution|60-120 ml per day for 5 days
45805545|NCT05920213|Drug|L-ornithine L-aspartate|30g/24 hours in 3 divided doses for 5 days
45805546|NCT05920200|Procedure|open non-mesh hernia repair|A groin and femoral hernia non-mesh repair. An umbilical hernia non-mesh repair. A ventral and incisional hernia non-mesh repair.
45805547|NCT05920200|Procedure|open mesh hernia repair|"A groin and femoral hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures for Lichtenstein. Self-fixating mesh is also possible.~An umbilical, ventral, incisional hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures."
45805548|NCT05920200|Procedure|MIS hernia repair|"A groin and femoral minimal invasive hernia repair (TAPP, eTEP). The mesh is affixed with tack/no-fixation. Self-fixation mesh is also possible.~An umbilical, ventral, incisional minimal invasive hernia repair (eTEP, IPOM,). The mesh is affixed with tack and no-fixation ."
45805549|NCT05920187|Other|Mediterranean diet and Anti-inflammatory diet|"Cases will be randomly allocated to two groups: Mediterranean diet group (following dietary intervention based on MD), and Anti_inflammatory diet group(following dietary intervention based on IBD-AIF). Patients of the control group will not be instructed to follow a specific dietary intervention.~Evaluation of adherence of cases to dietary intervention will be at two points of time: after four weeks and after 12 weeks by using Mediterranean Diet Serving Score (MDSS) for MD adherence and Anti- Inflammatory Diet Serving Score for IBD- AID adherence. The AID Serving Score (AIDSS) is based on the latest update of the Anti-Inflammatory Diet Pyramid, using the recommended consumption frequency of foods and food group."
45805550|NCT05920174|Device|NEO|Subjects will be implanted with the NEO device.
45805551|NCT05920161|Behavioral|Socially Evaluated Cold Pressor Test|The SECPT is a brief validated laboratory-based stress induction containing both physical and social elements
45805552|NCT05920161|Behavioral|Control|This is matched to the SECPT but with warm instead of cold water
45805553|NCT05920148|Procedure|Knee arthroplasty|At multiple timepoints (i.e., ± 6 weeks before, and 1 day, 1 week, ± 2 weeks, and ± 6 weeks after surgery) before and after total knee replacement surgery blood will be collected to assess immune functioning
45805554|NCT05920135|Drug|BBT-207|BBT-207 given orally alone
45805555|NCT05920122|Drug|2% Chlorhexidine gluconate with 70% alcohol|Patients will be prepared similarly using the appropriate number of 26mL Chloraprep sticks for their body surface area. The lever will be pinched to activate the ampoule and release the antiseptic. The solution will be given time to partially load in the sponge. The sponge will be pressed against the skin area where the incision is intended moving back and forth for 30 sec , then working up towards the upper edge of the surgical field and then working from below the incision sight to the upper thighs. The antiseptic will be given time to dry (3 min)
45805556|NCT05920122|Drug|4% Chlorhexidine Gluconate aqueous solution|Patients will be scrubbed preoperative with an applicator that contain 4% chlorohexidine aqueous solution (3 consecutive applications) liberally over 2 minutes followed by drying with sterile towel. The area scrubbed will be the same as the chloraprep group.
45938712|NCT00192361|Biological|CAIV-T|
45938713|NCT00192400|Biological|CAIV-T|
45938714|NCT00192439|Behavioral|High Risk Respiratory Disease|
45938715|NCT00192478|Biological|Medi-524|IM doses of MEDI-524 administered at 3 mg/kg or 15 mg/kg at 30 day intervals
45938716|NCT02439255|Other|Laboratory Biomarker Analysis|Correlative studies
45938717|NCT02439255|Dietary Supplement|Phytochemical|Given black raspberry (BRB) nectar per oral (PO)
45938718|NCT02439255|Other|Placebo|Given PO
45654460|NCT05677373|Procedure|Magnetic Resonance Imaging|Undergo MRI with contrast
45654461|NCT05677373|Procedure|Biospecimen collection|Undergo collection of blood
45654462|NCT05677373|Procedure|Biospecimen collection|Correlative studies
45938719|NCT02439255|Other|Screening Questionnaire Administration|Ancillary studies
45654463|NCT04963855|Drug|GT300|SIngle oral dose
45654464|NCT04963855|Drug|Microcrystalline cellulose|placebo
45654465|NCT03061357|Behavioral|Activity tracker|Misfit Flash (Misfit Wearables Co., Burlingame, CA) activity tracker
45654466|NCT05695235|Device|CGM|Wearable continuous glucose monitoring systems (CGMS) provide a minimally invasive means of passively tracking ambulant interstitial fluid glucose levels in real time.
45654467|NCT05695235|Device|Oura ring|Wearable sleep tracking device
45938720|NCT00059891|Procedure|conventional surgery|
45938721|NCT00059891|Procedure|management of therapy complications|
45654468|NCT05695235|Behavioral|Cognitive tasks and questionnaires|Participants will be prompted daily to fill out a short set of wellbeing questions and perform a short alertness test on their mobile phones and laptop.
45654469|NCT05051579|Drug|LY3502970|Administered orally
45938722|NCT00192517|Drug|MEDI-522|4 mg/kg (for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
45654470|NCT05051579|Drug|Placebo|Administered orally
45805557|NCT05920109|Procedure|ESP block|Patients in the experimental group will have a continuous Erector Spinae Plane Block within the first 6 hours post-admission, with a continuous 1ml/h infusion of Ropivacaine (2mg/ml) associated with a 25 ml bolus every 6h. The catheter will be used from the trauma bay to the ICU as long as possible with a dedicated infusion pump (with a bolus mode). In case of accidental catheter removal, a second introduction of ESP block catheter is allowed within the first 24 hours. In case of continuous ESP block failure (incidence < 5% of the total experimental group), patients will be switched to the control group.
45938723|NCT00192517|Other|Placebo|4 mg/kg(for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
45938724|NCT00192556|Behavioral|food|
45938725|NCT00192595|Drug|Tenofovir|
45938726|NCT00192595|Drug|Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)|
45938727|NCT04730726|Device|MSOT Acuity Echo|Hybrid optoacoustic and ultrasonography imaging
45938728|NCT01760850|Other|educational intervention|Engage in the Esperanza y Vida educational information session for breast and cervical cancer
45938729|NCT01760850|Other|educational intervention|Engage in an educational information session for diabetes
45938730|NCT01760850|Other|questionnaire administration|Ancillary studies
45938731|NCT00192634|Drug|Emtricitabine 200mg - Tenofovir 300mg|1 tablet once daily for 96 weeks
45938732|NCT00192634|Drug|Abacavir 600mg - Lamivudine 300mg|1 tablet once daily for 96 weeks
45938733|NCT00192673|Drug|PEG-asparaginase|
45938734|NCT00192712|Drug|irinotecan, gemcitabine|
45938735|NCT00047658|Drug|Interferon-gamma 1b|200 mcg, SQ, 3x per week
45938736|NCT02958644|Dietary Supplement|Synbiotics|12g / day synbiotics (fructo-oligosaccharide and probiotics) supplemented orally for 90 days
45938737|NCT02958644|Dietary Supplement|Placebo|12g / day placebo (polydextrose) supplemented orally for 90 days
45938738|NCT00192829|Procedure|Blood sample withdrawal|
45938739|NCT00192868|Procedure|Distal protection and drug eluting stent|
45458031|NCT02309476|Device|PASCAL Laser, Green Laser 1|"Barely Visible Pascal laser grid using 532nm green wavelength, 1 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
45938740|NCT00209235|Behavioral|Neurocognitive and psychosocial testing|Neurocognitive and psychosocial testing
45938741|NCT02958722|Procedure|diagnostic hysteroscopy|Endoscopic procedure to visualize uterine cavity
45938742|NCT02958722|Drug|physiological solution|
45938743|NCT02958722|Drug|carbon dioxide|
45938744|NCT00192946|Procedure|Temporary cardiac resynchronization therapy|
45938745|NCT00192985|Device|Nitrofuranzone coated bladder catheter|
46074194|NCT03312257|Combination Product|Multifocal D +2.50 add & 0.01% atropine|Biofinity Multifocal D +2.50 add is a monthly disposable contact lens commercially available from CooperVision; 0.01% atropine is low-dose atropine compounded by local pharmacy.
46074195|NCT00856687|Drug|PF-03893787|Oral, two doses 12 hours apart
46074196|NCT00856687|Drug|Placebo|Oral, two doses 12 hours apart
45938746|NCT00193024|Drug|Docetaxel|
45938747|NCT00193024|Drug|Epirubicin|
45938748|NCT00193102|Drug|Thalidomide|Thalidomide
45938749|NCT00193102|Drug|Capecitabine|Capecitabine
45654471|NCT04973215|Other|no intervention|this is not an intervention study
45654472|NCT05695001|Device|Efferon CT|Efferon CT is a cylindrical body made of polycarbonate, filled with spherical granules of polymer hemocompatible macroporous styrene-divinylbenzene copolymer of super cross-linked type and isotonic sodium chloride solution. The device is manufactured according to TU 32.50.50-001-12264678-2018, has passed the necessary tests and is registered in Russia as a medical product RZN 2019/8886.
45654473|NCT05041907|Drug|Nirmatrelvir/ritonavir (e.g. PAXLOVID™)|Nirmatrelvir 300mg BD for 5/7 Ritonavir 100mg BD for 5/7
45654474|NCT05041907|Drug|Monoclonal antibodies|Monoclonal antibodies: 300mg tixagevimab/ 300 mg cilgavimab given once on D0
45654475|NCT05041907|Drug|Fluoxetine|Fluoxetine 40mg OD for 7/7
45654476|NCT05041907|Drug|Molnupiravir|Molnupiravir 800mg BD for 5/7
45654477|NCT05041907|Drug|Nitazoxanide|Nitazoxanide 1.5g BD 7/7
45654478|NCT05041907|Other|No treatment|No treatment (except antipyretics- paracetamol)
45654479|NCT05041907|Drug|Ensitrelvir|Ensitrelvir 375mg OD D0 and 125mg OD for a further 4/7
45938750|NCT00060086|Dietary Supplement|pomegranate juice|Subjects receive oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
45938751|NCT00193141|Drug|Paclitaxel|
45938752|NCT00193141|Drug|Carboplatin|
45938753|NCT00193141|Drug|5-Fluorouracil|
45938754|NCT00193297|Drug|Topotecan|
45938755|NCT00193297|Drug|Paclitaxel|
45938756|NCT00193297|Drug|Carboplatin|
45938757|NCT00083928|Drug|Å6 subcutaneous injection|
45938758|NCT00193336|Drug|ZD1839|
45938759|NCT04722562|Drug|Vericiguat (BAY1021189)|Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
45938760|NCT02958488|Device|High Flow Nasal Cannula|
45938761|NCT00193531|Drug|Paclitaxel|
45938762|NCT00193531|Drug|Carboplatin|
45938763|NCT00193531|Drug|Etoposide|
45938764|NCT00193570|Drug|Topotecan|
45938765|NCT00193570|Drug|Docetaxel|
45938766|NCT00047736|Drug|Tarceva (erlotinib HCl)|
45938767|NCT00409552|Behavioral|Virtual Reality based distraction|Participants will undergo virtual reality based distraction using the head display while they go through the pain process.
45938768|NCT00409552|Behavioral|VR with flat projection display|VR with flat projection display
45938769|NCT00409552|Behavioral|non-interactive video with head display|non-interactive video with head display
45654480|NCT05041907|Drug|Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)|Molnupiravir 800mg BD for 5/7, Nirmatrelvir 300mg BD for 5/7, Ritonavir 100mg BD for 5/7
45805558|NCT05920096|Other|Diabetes specialist nurse-led multi-component smoking cessation intervention|"Aims to:~inform participants on the association between smoking and diabetic complications;~motivate and encourage smokers to quit;~support participants in using the appropriate behavioural skills to quit smoking and avoid relapse.~In the first session, the participants will be supported to set a Target Quit Date (TQD) within two weeks. Participants will be followed up within a week (or two weeks max.) from their TQD. Those who report having not smoked (for ≥24 hours from the time of assessment) will be provided with a final follow-up session within five weeks from their set TQD (three sessions in total). Conversely, those who report still smoking will be encouraged to set another TQD and will be seen again in one (or two weeks max.) and five weeks from their new TQD (four sessions in total). The participants will also receive a six-week supply of Nicotine Replacement Therapy (NRT) nicotine patch and/or spray to use for a few days prior to their TQD and on quitting."
45938770|NCT00409552|Behavioral|non-interactive video with with flat projection display|non-interactive video with with flat projection display
45938771|NCT00409591|Drug|Maternal and infant nevirapine|"In women, one NVP 200 mg tablet at onset of labor;~In neonates, NVP oral suspension 6 mg in the delivery room immediately"
45938772|NCT00409591|Drug|Maternal placebo and infant nevirapine|"In women, one placebo tablet at onset of labor;~In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours~Comparison between Arms 1 and 2 is double-blinded."
45805559|NCT05920096|Behavioral|Health Promotion and Disease Prevention Directorate's one-to-one smoking cessation service (standard care)|A behavioral smoking cessation intervention based on motivational interviewing and delivered by trained tobacco cessation facilitators within community health centres. Participants will be provided with 20-minute counseling sessions based on their needs.
45938773|NCT00409591|Drug|Maternal lopinavir+ritonavir|- In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery
45805560|NCT05920083|Other|CPAP withdrawal|2 weeks of CPAP withdrawal
45805561|NCT05920070|Procedure|therapeutic mammoplasty|therapeutic oncoplastic surgeries in cases of breast cancer
45938774|NCT00409591|Drug|zidovudine|In addition, all women and infants in the 3 arms will receive standard ZDV prophylaxis, as per Thai and WHO guidelines.
45938775|NCT00083967|Drug|denufosol tetrasodium (INS37217) Intravitreal Injection|
45938776|NCT00409630|Drug|fluticasone|
45938777|NCT00409669|Device|Barraquer tonometer|barraquer tonometer
45938778|NCT00060125|Drug|tipifarnib|Given orally
45938779|NCT00060125|Other|laboratory biomarker analysis|Correlative studies
45938780|NCT00193648|Drug|Rosiglitazone (Avandia)|oral drug administration
45938781|NCT00193648|Drug|Adalimumab (Humira)|Injection of drug biweekly
45938782|NCT00193687|Drug|bifeprunox|
45938783|NCT00193726|Drug|Tab Premarin (Ethinyl estradiol)|Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy
45654481|NCT05041907|Drug|Sotrovimab|Sotrovimab 500mg given once on D0
45654482|NCT05041907|Drug|Monoclonal antibodies|Monoclonal antibodies: 600mg casirivimab/ 600mg imdevimab given once on D0
45654483|NCT05041907|Drug|Favipiravir|Favipiravir 1800mg BD D0 and 800mg BD for a further 6/7.
45938784|NCT00193726|Drug|Placebo|Placebo once a day for 5 days prior to each cycle of chemotherapy
46074197|NCT00856687|Drug|Montelukast|Oral, two doses 12 hours apart
46074198|NCT02862665|Drug|iron isomaltoside 1000 (Monofer®)|The patients will receive iron isomaltoside 1000 (Monofer®) as an i.v. infusion of 1000 mg (diluted with normal saline, 10 mg/ml) twice; 3 days before surgery and 3 days after surgery. They will receive iron isomaltoside 1000 (Monofer®) 1000 mg over 15 min.
46074199|NCT02862665|Drug|normal saline 100 ml|The patients will receive normal saline 100 ml as an i.v. infusion twice; 3 days before surgery and 3 days after surgery. They will receive normal saline 100 ml over 15 min.
46074200|NCT02807922|Drug|Zopiclone|
46074201|NCT02807922|Drug|Placebo|
46074202|NCT00861367|Drug|transurethral surgery with or without aspirin|aspirin 100mg once a day, transurethral surgery with or without aspirin
45654484|NCT05041907|Drug|Ivermectin|Ivermectin 600micrograms/kg/day for 7/7.
45654485|NCT05041907|Drug|Remdesivir|Remdesivir 200mg D0 and 100mg for a further 4/7.
45938785|NCT00047775|Drug|BiDil|
45938786|NCT00193765|Procedure|Elective neck dissection in early oral cancer|Elective neck dissection in early node negative oral cancers at the time of primary surgery
45938787|NCT00193765|Procedure|Therapeutic Neck Dissection|There is no active intervention for the neck at the time of primary surgery. Therapeutic Neck Dissection at the time of nodal relapse
45938788|NCT00060203|Drug|brostallicin|"Patients receive brostallicin IV over 10-30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of brostallicin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity."
45938789|NCT00193804|Radiation|IMRT|IMRT in cervical cancers
45938790|NCT00193843|Procedure|Post-operative chemoradiotherapy / accelerated radiotherapy|
45938791|NCT00193882|Drug|Cisplatin|80mg/m2 IV day 1
45938792|NCT00193882|Radiation|Radiotherapy|35 Gy in 15 fractions
45938793|NCT00193882|Drug|5-Fluorouracil|800mg/m2/day IV days 1 - 4
45938794|NCT00060242|Drug|fosbretabulin disodium|Combretastatin A4 phosphate IV over 10 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses beyond documentation of the CR.
45938795|NCT00192751|Behavioral|Psychoeducational group sessions|
45938796|NCT00193921|Drug|Vinorelbine|IV, 25mg/m2, days 1, 8, 22
45805562|NCT05920057|Behavioral|constructive emotional management interventions|The Constructive emotional management interventions sessions were conducted in the activity rooms of the elderly clubs where the researchers met the participants. Participants completed a baseline evaluation of the outcome measures of the researched variables after being found to be eligible for the current study and indicating their willingness to participate willingly. After explaining the study's objectives to participants, the researchers themselves delivered the Constructive Emotional Management Interventions program, which had been vetted by experts in the field.
45938797|NCT00193921|Radiation|High dose Radiotherapy|External beam radiation, 40 Gy/20#/5 per week
45938798|NCT00193921|Drug|Gemcitabine|200mg (flat dose) IV days 1, 8, 15
45654486|NCT04963309|Other|endotracheal tube extubation in the operating room|endotracheal tube extubation in the operating room
45654487|NCT05019209|Drug|House Dust Mite Allergen|D. pteronyssinus lyophilisate dissolved in 5% sodium chloride solution, spray dried
45938799|NCT00193921|Drug|Cisplatin|20mg/m2, IV, weekly
45938800|NCT00193921|Radiation|High Dose Radiotherapy|External beam radiation, 30 Gy/15#/5 per week
45938801|NCT00047814|Drug|FK788|
45938802|NCT00193960|Procedure|1) Intraocular pressure 2) visual acuity|
46074203|NCT04285073|Device|Paclitaxel-eluting graft|Implantation of e-PTFE Grafts inner surface-treated with paclitaxel as access for hemodialysis
46074204|NCT02807766|Behavioral|Behavior modification|Each group has 30 subjects and experiences six months' training.
45654488|NCT05019209|Other|Allergen-free air|No allergen added to room ventilation of allergen challenge chamber
45654489|NCT04963387|Other|Whole body vibration|Balance and muscle strengthening exercises with whole-body vibration, strengthening exercise included straight leg raise with weights, and balance training including walking heel to toe for 20 steps. In this study frequency of 30Hz (4 weeks), with 0.9 mm vertical displacement was used.
45654490|NCT04963387|Other|Balance and Strengthening exercise|Balance and strengthening exercises includes straight leg raise with weights 10 reps. and tandem walk 20 steps 3 days in week for 4 weeks
45805563|NCT05920044|Other|balance and proprioception training program.|"The program will include exercises focused on improving ankle stability and joint position sense, such as single-leg stance, wobble board, and resistance band exercises.~Participants will attend two supervised sessions per week and perform home-based exercises 3-4 times per week.~Progression of exercises will be individualized based on participant performance and tolerance."
45938803|NCT00060320|Dietary Supplement|black cohosh|
45938804|NCT00060320|Other|placebo|
45938805|NCT00193999|Device|Placement of nasogastric tube|
45938806|NCT00194038|Drug|Aripiprazole|Patients were continued on treatment with their existing mood stabilizing medication, and upon enrollment were initiated on aripiprazole augmentation treatment. The initial starting dose of aripiprazole was 5 mg/day, with gradual upward titration as tolerated. Initiation of new additional antipsychotic medications was not permitted during the course of the study, and antipsychotic medications prescribed at study start were tapered and discontinued by week 4 of the study if possible.
45938807|NCT00194194|Behavioral|moderate|moderate behavioral management with RD
45938808|NCT00194194|Device|Resting Metablic Rate measurements|intensive behavior management
45938809|NCT00060359|Drug|Carboplatin|Given IV
45938810|NCT00060359|Drug|Paclitaxel Poliglumex|Given IV
45938811|NCT00060359|Other|Pharmacological Study|Correlative studies
45938812|NCT00194272|Drug|Methotrexate|Two dose methotrexate
45938813|NCT00194350|Procedure|Test for Factor V Leiden gene mutation|
45938814|NCT00194428|Behavioral|Almond enriched diet|Subjects will consume 2 oz. of almond per day in addition to a low-fat diet
45654491|NCT05694299|Device|Nasal bridle|Bridle Pro® Nasal Tube Retaining System (Applied Medical Technology Inc., Brecksville, OH, USA)
45654492|NCT05694299|Other|Nasal patch|Regular adhesive tape for medical use.
45654493|NCT05674253|Drug|Dexmedetomidine + Hydrocortisone|Patients will receive dexmedetomidine 0.7 ɥg/kg/hr IV infusion before aortic cross-clamping, and will be continued intra-operatively and in ICU till weaning from mechanical ventilation Patients also will also receive Hydrocortisone 100 mg intravenous (IV) before aortic cross-clamping then 100 mg every 8 hours after surgery which will be continued for 48 hours
45654494|NCT04954417|Diagnostic Test|Radiological scanning|The collected specimens subject to normalized Micro-CT and MSCT image acquisition, image reconstruction using standard algorithms, and bone structure observation using bone algorithms to obtain high-quality, standardized axial images.
45654495|NCT04954417|Other|Deep learning|We will use a conditional generation adversarial network-based image mapping technique to train the mapping model between MSCT images and Micro-CT images, find the correspondence between the image information contained in each of MSCT and Micro-CT, and finally obtain high-resolution micro-CT-like images.
45938815|NCT00194428|Behavioral|Low fat caloric diet|Low fat caloric diet
45938816|NCT00084045|Procedure|Intrapartum HIV counseling/testing|
45938817|NCT00084045|Procedure|Postpartum HIV counseling/testing|
45938818|NCT00398528|Drug|Glatiramer acetate, (Copaxone®)|
45938819|NCT00398528|Drug|IFN-β-1a, (Avonex®)|
45938820|NCT00194467|Drug|valganciclovir|900 mg once a day for 8 weeks
45938821|NCT00194467|Drug|placebo|matching placebo, once a day for 8 weeks
45938822|NCT00194506|Behavioral|Internet co-management module|
45938823|NCT00194545|Behavioral|Medication diaries|Caregivers expected to complete medication diaries daily
45938824|NCT00194584|Behavioral|7 week Building on Family Strengths Program|Parents in intervention group attend a 2 hr class for seven weeks. These classes provide information, time for discussion and creation of an action plan for the parent to complete in the intervening week.
45938825|NCT00194623|Drug|Botulinum Toxin A (Botox)|
45938826|NCT00047931|Drug|VRC-HIVDNA009-00-VP|
45938827|NCT00194701|Behavioral|Walking exercise|
45938828|NCT00194740|Drug|Docetaxel|60 mg/m2, IV, day 1 of each 21 day cycle
45938829|NCT00194740|Drug|Vinorelbine|27.5 mg/m2, IV, days 8 & 15 of each 21 day cycle
45938830|NCT00194740|Drug|Filgrastim|5 µg/kg/day s.c., to be administered days 2-21 of each cycle.
45938831|NCT00194818|Drug|Asacol (mesalamine)|Available in 400mg delayed release tablet. Randomized to either 6 tablets BID (4.8 g/day) or 4 tablets TID (4.8 g/day) for a total of 12 weeks.
45938832|NCT00084123|Behavioral|Healing Touch Therapy|
46074205|NCT02807766|Behavioral|Behavior modification and sensory integration training|Each group has 30 subjects and experiences six months' training.
46074206|NCT02807766|Behavioral|Behavior modification and applied behavioral analysis|Each group has 30 subjects and experiences six months' training.
45654496|NCT04954417|Procedure|Bio-mechanical testing|we will cut a standardized cubic sample from the vertebral cancellous bone , obtain the bio-mechanical performance index of this cancellous bone sample by mechanical experiments, and analyze the correlation between bone structure of Micro-CT-like images and bio-mechanical index.
45654497|NCT02500641|Drug|Febuxostat 80/120mg/day|Starting dose and dose regimen of Febuxostat : the initial daily dose is 80 mg. In case the patient has the serum urate concentration > 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained for the duration of the study.
45654498|NCT02500641|Drug|Allopurinol 100 up to 600mg/day|Starting dose and dose regimen of allopurinol : the initial daily allopurinol dose is 100 mg, to be increased by 100 mg every 2 weeks in patients with serum urate concentration >6 mg/dl. The maximum daily dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg.
45654499|NCT02500641|Drug|Colchicine|Colchicine 0.5 mg tablets.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD
45654500|NCT02500641|Drug|Naproxen|Naproxen sodium 550 mg film coated tablets. In case of colchicine intolerance patients will be treated for at least 6 months with Naproxen 550 mg BID and Omeprazole (20-40 mg once daily), if indicated to be used.
45654501|NCT02500641|Drug|Omeprazole|Omeprazole 20 mg capsules, co-administered to patients for gastric protection.
45938833|NCT00084123|Behavioral|Relaxation Therapy|
45654502|NCT05662553|Procedure|ENB guided MWA combined with VATS|"ENB guide MWA combine ENB, microwave ablation and 3D reconstruction technology, and guide the probe in the airway to the target lesion for ablation therapy, which is safe and effective. For patients with synchronous bilateral multiple primary pulmonary nodules, ENB guide MWA combined with VATS treatment can not only avoid the risk of bilateral surgery, but also complete the one-stop treatment, which is a new treatment mode."
45654503|NCT05662553|Procedure|sequential surgery|Bilateral surgery is a traditional treatment, but it will lead to increased intraoperative risk and postoperative complication rate, and more likely to lead to postoperative complications such as decreased quality of life and cardiopulmonary dysfunction.
45654504|NCT04973293|Drug|sintilimab|Sintilimab 200 mg, 4 cycles of treatment before surgery
45654505|NCT04973293|Drug|bevacizumab|bevacizumab 15 mg/kg, 4 cycles of treatment before surgery
45654506|NCT05657249|Diagnostic Test|Non-contrast focused MRI|non-contrast liver MRI focusing on HCC surveillance in a short scan time.
45654507|NCT04962997|Other|Data collection|"Investigator will ensure the completion of a hetero-administered questionnaire which will be carried out in French, English, Portuguese or Spanish depending on the language spoken by the participant, including informations related to Demography and socio-economic conditions, Addictions, Work and studies, Housing, Health coverage, Gender and sexuality, Vulnerabilities and violence, Recourse to care, State of physical health, Mental Health, Prevention and Sexually Transmitted Infections (STIs), Checkup, Transition path and clinical complications and Dermatological problems.~Investigator will collect the data relating to the clinical examination, dermatological examination and the search for STIs (blood and / or urine) carried out in the routine care of the participant in a case report form (CRF).~The estimated duration of the interviews and the consultation is approximately 1 hour per patient."
46074207|NCT02807766|Behavioral|Behavior modification and TEACCH|Each group has 30 subjects and experiences six months' training.
45805564|NCT05920044|Other|Usual care|"Participants will continue their usual care, including general strength and flexibility exercises.~No specific balance and proprioception training will be provided."
45805565|NCT05920031|Other|Cross-education|Participants will perform resistance exercises at 60% of their 1 repetition maximum (1RM) with the less affected limb. The intervention will be performed three times per week for 8 weeks. Each session will consist of three sets of 15 repetitions of bicep curls, tricep extensions, and wrist flexion/extension exercises with a 1-minute rest period between sets. The exercises will be performed in a seated position, with the participant's forearm resting on a table and the therapist providing manual resistance. The therapist will be positioned in front of the participant.
45938834|NCT00084123|Behavioral|Standard Care|Standard Care
46074208|NCT00861445|Drug|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage 400mg/day, intake in the morning and in the evening, intake for 10 weeks
46074209|NCT00861445|Other|Placebo|Placebo tablets two times a day for 10 weeks
46074210|NCT04284059|Drug|Placebos|Placebo, vitamin AD and vitamin D are identical in the appearance to guarantee blind. The patients need to administrate 3 capsules once a day for 8 weeks.
45938835|NCT00194857|Drug|erythropoietin, GCSF|
45938836|NCT02968862|Other|observational|The study will involve adult patients undergoing elective thoracolumbar-sacral spine surgery involving 1-5 spine levels, at the Brigham and Women's hospital that have an anticipated post surgical hospital stay of one to three days. These patients will be randomly assigned by the BWH Investigational Drug Service to one of three different groups, each consisting of 33 patients. This is an observational studies with subjects in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive a therapeutic intervention, but the investigator does not assign specific interventions to the subjects of the study.
45938837|NCT00194935|Drug|Topotecan|
45938838|NCT00194974|Drug|methyldopa|
46074211|NCT04284059|Dietary Supplement|vitamin AD|A vitamin AD capsule contains vitamin A 2000 IU and vitamin D 700 IU. The patients need to administrate 3 capsules once a day for 8 weeks.
46074212|NCT04284059|Dietary Supplement|vitamin D|A vitamin D capsule contains vitamin D 400 IU. The patients need to asministrate 6 capsules/time, once a day for 2 weeks, then change to 5 capsules/time, once a day for 6 weeks.
46074213|NCT00856765|Device|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
45938839|NCT00194974|Drug|labetalol|
45654508|NCT04972669|Device|Electrical Acupuncture Stimulation|Participants received acupuncture at bilateral Baliao. After skin disinfection, sterile adhesive pads were placed on bilateral Baliao, and acupuncture needles were inserted through the adhesive pads. Following needle insertion, small, equal manipulations of twirling, lifting, and thrusting were performed on all needles to reach de qi. Electrodes from the electroacupuncture apparatus were attached transversely to the needle handles. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 2-15 Hz. Participants received 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
45654509|NCT04972669|Device|sham Acupuncture|Participants received sham acupuncture at locations one inch besides bilateral Baliao without needle insertion. Electrodes from the electroacupuncture apparatus were attached transversely to the needle handles. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 2-15 Hz. Participants received 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
45938840|NCT00194974|Drug|nifedipine|
45805566|NCT05920031|Other|Mirror therapy|Participants will perform bilateral upper limb movements while observing the reflection of the less affected limb in a mirror. The intervention will be performed three times per week for 8 weeks. Each session will consist of 10 minutes of mirror therapy, with the participant seated in front of a mirror. The participant will perform various upper limb movements, such as reaching and grasping, while observing the mirror reflection of the less affected limb. The therapist will be positioned beside the participant, providing verbal cues and feedback as necessary.
45938841|NCT00194974|Drug|clonidine|
45938842|NCT00195130|Behavioral|There are no interventions in this study|
46074214|NCT00856765|Device|Bare metal stent|Bare metal stent
45938843|NCT00060437|Drug|perifosine|
46074215|NCT00856765|Device|Drug eluting stent|Paclitaxel eluting stent
46074216|NCT00852709|Drug|Clofarabine|On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
46074217|NCT00852709|Drug|Cyclophosphamide|Single-agent cyclophosphamide will be administered by 2-hour IVI on Day 0 of cycle 1. On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
46074218|NCT05612256|Diagnostic Test|Electrical impedance tomography (EIT)|EIT is the measurement of impedance changes of the lung against the flow of alternating electrical currents applied to the thorax. The signal of the electrodes is transmitted to a monitor, which enables real-time assessment of lung aeration and changes in lung volume. EIT is able to reconstruct impedance changes with a high temporal resolution and allows calculation of tidal volumes, relative stretch of lung tissue and areas of poor ventilation. Areas with impedance changes of < 10 % of the maximum impedance changes are called 'Silent Spaces'.
46074219|NCT05612256|Diagnostic Test|Forced oscillation technique (FOT)|FOT enables non-invasive assessment of lung mechanics using sound waves to inform about the respiratory impedance of the respiratory system (Zrs). Reactance of the respiratory system (Xrs) as part of Zrs is a surrogate measure of compliance of the respiratory system. Xrs was previously used to identify optimal PEEP level, i.e., the PEEP at highest compliance equivalent, in newborn infants using a setup requiring research-specific hardware and software. The FOT module integrated in the commercially available neonatal ventilator is routinely used. FOT measurements are performed twice at each PEEP level to assess the reproducibility of the measurements.
46074220|NCT05612256|Diagnostic Test|Saturation oxygenation pressure index (SOPI)|SOPI is assessed non-invasively and calculated from standard monitoring parameters such as PEEP, fraction of inspired oxygen pressure (FiO2) and peripheral oxyhaemoglobin saturation (SpO2) (PEEP x FiO2 x 100) / SpO2). SOPI is used to provide information on ventilation to perfusion ratio dependent on PEEP level.
45938844|NCT00195208|Drug|Pantoprazole for approximately 9 weeks|
45938845|NCT02963116|Drug|AZD5718 IR tablet|
45938846|NCT02963116|Drug|AZD5718 oral suspension|
45938847|NCT02963116|Drug|Rosuvastatin tablet|
45938848|NCT00195247|Drug|TTI-237|
46074221|NCT03242447|Behavioral|e-Practice Self-Regulation|e-PS-R utilizes 'blended learning', the combination of online and face-to-face instruction, and incorporates online videos and interactive elements that have been shown to be effective with high-risk youth. e-PS-R consists of eight 30-minute e-learning sessions for youth participants and four 30-45 minute one-on-one in-person meetings between youth and a trained facilitator.
45938849|NCT00195286|Drug|piperacillin/tazobactam|
45938850|NCT02969057|Other|Breakfast with rice bran oil gel|25 grams of rice bran oil gel
45938851|NCT02969057|Other|Breakfast with rice bran oil|25 grams of rice bran oil
45938852|NCT02969057|Other|Breakfast with palm oil gel|25 grams of palm oil gel
45938853|NCT02969057|Other|Breakfast with palm oil|25 grams of palm oil
45938854|NCT00195325|Drug|TTI-237|
45938855|NCT00084201|Drug|Cranberry juice|
45938856|NCT00084201|Drug|Amoxicillin|
45938857|NCT00195364|Drug|Etanercept|
45938858|NCT00195481|Drug|Rapamune|
45938859|NCT00195520|Drug|Totelle®|
45938860|NCT00195559|Drug|Levonorgestrel/Ethinyl Estradiol|
45938861|NCT00084240|Drug|Azithromycin/Chloroquine|
45938862|NCT00084240|Drug|Sulfadoxine-Pyrimethamine/Chloroquine|
45938863|NCT02968823|Other|Licorice|ExtractumLiquiritiaeFluidum, 1 g diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 2
45938864|NCT02968823|Other|Sugar water|Sugar gargle: Sirupus Simplex (sugar 5 g) diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 2
45938865|NCT00195598|Drug|VENLAFAXINE|
45938866|NCT00195598|Drug|Paroxetine|
45938867|NCT00195637|Drug|Immune Globulin|
45938868|NCT00195754|Drug|divalproex sodium|
45654510|NCT05061173|Other|Aerobic exercise training Group|Aerobic Exercise includes Treadmill walking At Week 1-2, intensity of 40-45% Heart rate maximum (HR max), 3 days/week, for 30 minutes At Week 3-4, intensity of 45-50% HR max, 3 days /week, for 30 minutes At Week 5-6, intensity of 50-60% HR max 3 days per week, for 30 minutes
45805567|NCT05920031|Other|Conventional Physical Therapy|articipants will receive conventional rehabilitation for post-stroke upper limb motor impairments, which may include exercises such as range of motion, stretching, and strengthening of the affected limb, as well as other therapies such as electrical stimulation or constraint-induced movement therapy. The intervention will be individualized for each participant and will be performed three times per week for 8 weeks. The frequency, duration, and intensity of the exercises will be gradually increased over the course of the intervention, based on the participant's progress. The exercises may be performed in a seated or standing position, depending on the participant's ability and preference. The therapist will be positioned in front of or beside the participant, providing verbal cues and feedback as necessary.
45654511|NCT05061173|Other|Resistance Exercise Training Group|"Resistive Exercises includes (a) Leg press b) Quadriceps extension c) Bicep curl d) Hip abduction.~At Week 1-2, 10 repetitions 1 set, 3 days/week, for 30 minutes At Week 3-4, 2 sets of 10 repetitions, 3 times /week for 30 minutes At week 5-6, 2 sets of 10 repetitions with 5 sec hold 3 times per week for 30 minutes"
45805568|NCT05920018|Dietary Supplement|Vivomixx®|Daily application of four sachets, i.e. 1.800 bio bacteria/day for 48 weeks
45938869|NCT02968706|Device|High Flow Nasal Cannula|Heated humidified high flow oxygen of 50 L/min at FiO2 of 40%
45938870|NCT02968706|Device|Conventional Nasal Cannula|Supplemental oxygen of 2-5 L/min
45938871|NCT02968706|Other|Patient satisfaction questionnaire|Questionnaire
45938872|NCT00195793|Drug|fenofibrate|
45938873|NCT00195793|Drug|ezetimibe|
45938874|NCT00195793|Drug|atorvastatin|
45938875|NCT00195871|Drug|Prednisone, vincristine, daunorubicin , cyclophosphamide , L.-asparaginase, cytosine-arabinoside, methotrexate, etoposide|coventional dosages
45938876|NCT00195871|Procedure|hematopoietic stem cell allograft|conventional procedures
45938877|NCT00195910|Drug|Morphine|0.1 mg/kg IV morphine
45938878|NCT00195910|Drug|Hydromorphone|0.015 mg/kg IV hydromorphone
45938879|NCT00048009|Drug|Dual Integrin Antagonist|
45938880|NCT00195949|Procedure|Laparoscopic pyloromyotomy|
45938881|NCT00195988|Drug|tacrolimus, steroids, mycophenolate mofetil|
45938882|NCT00196027|Device|PFX Closure System|
45654512|NCT05061173|Other|Combined Exercise Training Group|"Combined Exercise training includes [Aerobic: Treadmill walking + Resistive Training: a) Leg press b) Quadriceps extension c) Bicep curl d) Hip abduction] Time will be reduced to 15 minutes for both trainings in respective weeks. Aerobic Exercise includes Treadmill walking At Week 1-2, intensity of 40-45% Heart rate maximum (HR max), 3 days/week, for 15 minutes At Week 3-4, intensity of 45-50% HR max, 3 days /week, for 15 minutes At Week 5-6, intensity of 50-60% HR max 3 days per week, for 15 minutes~Resistive Exercises At Week 1-2, 10 repetitions 1 set, 3 days/week, for 15 minutes At Week 3-4, 2 sets of 10 repetitions, 3 times /week for 15 minutes At week 5-6, 2 sets of 10 repetitions with 5 sec hold 3 times per week for 15 minutes"
45654513|NCT04962451|Drug|ticagrelor + ASA|On day 1, ticagrelor loading dose (2 tablets, ticagrelor 90mg) was given, followed by ticagrelor 90mg, twice daily Basic treatment: the first day received ASA loading dose, 300-325mg, and the server received ASA 75-100mg, once a day
45654514|NCT04962451|Drug|Placebo+ASA|Placebo loading dose on day 1 (2 tablets, matched with ticagrelor 90mg), followed by placebo twice daily (matched with ticagrelor 90mg) Basic treatment: the first day received ASA loading dose, 300-325mg, and the server received ASA 75-100mg, once a day
45805569|NCT05920018|Dietary Supplement|Conjugated linoleic acid (CLA/Tonalin® FFA 80)|Daily application of two capsules p.o., i.e. 2g/day for 48 weeks
45805570|NCT05920018|Other|Maltose placebo|Daily application of four sachets for 48 weeks
45805571|NCT05920018|Other|Sunflower oil placebo|Daily application of two capsules p.o for 48 weeks
45938883|NCT00196144|Device|Individualized Programming of PVAB|Performance of a test to detect far-field R-wave sensing
45938884|NCT00196144|Device|Nominal PVAB|nominal pacemaker settings
45938885|NCT00196183|Procedure|trigger-guided catheter-ablation|trigger-guided ablation of paroxysmal atrial fibrillation
45938886|NCT00196183|Procedure|trigger+substrate-guided catheter ablation|trigger-+substrate guided ablation of paroxysmal atrial fibrillation
45938887|NCT00060476|Drug|rofecoxib|
45938888|NCT00060476|Drug|Comparator: placebo (unspecified)|
45938889|NCT04729335|Diagnostic Test|phonocardiac spectrometry|Detection and application of organic disease with phonocardiac spectrometry
45938890|NCT00196222|Procedure|RF-ablation|RF ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
45938891|NCT00196222|Procedure|cryo ablation|Cryo ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
45938892|NCT00060515|Drug|RG2133 (2',3',5'-tri-O-acetyluridine)|
45938893|NCT00084279|Drug|Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin|interferon gamma-1b: 0.25 and 0.5 mL, SQ, 3x per week interferon alfacon: 0.3 mL and 0.5 mL, SQ, once a day Ribavirin: 2 capsules in a.m., 3 capsules in p.m.; daily
45938894|NCT00196378|Drug|Synthetic Conjugated estrogens, B|1 (0.3mg) tablet daily
45938895|NCT00196378|Other|Placebo|1 tablet daily
45938896|NCT00196417|Drug|Standard heparin (UFH) versus certoparin (LMWH)|
45938897|NCT00196456|Procedure|photosensitisation|
45938898|NCT00060554|Drug|fondaparinux sodium|
45938899|NCT00060554|Drug|heparin|
45938900|NCT00060554|Procedure|percutaneous coronary intervention (PCI)|
45938901|NCT00048087|Drug|ZD1839|250 mg by mouth daily each day for 4 weeks.
45938902|NCT00048087|Drug|Docetaxel|30 mg/m2 by IV on day 1 weekly for the first 3 weeks of each 4 week course.
45938903|NCT00196495|Device|Polypropylene Mesh|
45938904|NCT00196534|Drug|Human Thrombin|
45938905|NCT00196534|Drug|Bovine Thrombin|
45938906|NCT00196573|Procedure|Shoulder bursectomy alone|
45938907|NCT00048126|Drug|Irinotecan|100mg/m2 iv on days 1, 8, 15 and 22 of each 6 week cycle.
45938908|NCT00048126|Drug|capecitabine [Xeloda]|1000mg po bid
45938909|NCT02968745|Other|Observational study|Canadian Occupational Performance Measure (COPM) was applied to identify the main occupational performance problems
45938910|NCT00196612|Drug|emtricitabine, FTC (drug)|
45654515|NCT05059925|Other|Structured gym activities|"Planned and structured activities such as Strength training~Dumbbell Exercises (1kg with 2 sets of 10 repetitions)~Sit-ups (2 sets of 10 repetitions)~Stair climbing, (2 sets of 10 stairs up and down)~Squat (2 sets of 10 repetitions) Flexibility training • Tai chi (Peng. Lu, chi, an Tsai, lieh, chou, Kao (Hold each posture for 20 seconds)) • Pilates (Breathing., Shoulder bridge, Leg lifts (Hold each pose for 20 seconds)) • Stretching techniques (Neck stretch, Shoulder stretch, Side stretch Hold each stretch for 20 seconds))."
45805572|NCT05920005|Drug|candesartan cilexetil + chlorthalidone + amlodipine|Antihypertensive drugs in a single tablet (association candesartan cilexetil 16mg + chlorthalidone 12.5mg + amlodipine 5mg)
45938911|NCT00196612|Drug|didanosine, ddI (drug)|
45938912|NCT00196612|Drug|efavirenz (drug)|
45938913|NCT00196651|Drug|IL-2|
45938914|NCT00196651|Biological|LIPO-6T|
45654516|NCT05059925|Other|Traditional aerobic activities|"Activities performed such as~Treadmill Time: 10 minutes Intensity: 60 to 80% of target heart rate~Cycle ergometer Time: 10 minutes Intensity: 60 to 80% of target heart rate~Elliptical exercises Time: 10 minutes Intensity: 60 to 80% of target heart rate"
45654517|NCT04962295|Other|No intervention|No intervention
45938915|NCT00196651|Biological|ALVAC VIH 1433|
45938916|NCT00196690|Drug|Donepezil|
46074222|NCT03242447|Behavioral|Video Health Group|The video for the control condition will be The Toxic Life Cycle of a Cigarette, a 17-minute video that details the negative effects that cigarettes have on the environment and on people who manufacture and use cigarettes.
45654518|NCT05010083|Behavioral|diet and lifestyle program|See description of main arm.
45805573|NCT05920005|Drug|Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)|Antihypertensive drugs in a single tablet (association valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)
45805574|NCT05919992|Drug|Metyrapone 250 mg Oral Tablets|During one phase of the study: Metyrapone (pills of 250mg) on empty stomach: Day 1 0-1-1, day 2 1-2-2, day 3 2-3-3 day 4 3-4-4 day 5 4-4-4 day 6 4-4-4 day 7 4-0-0
45805575|NCT05919992|Drug|Hydrocortisone 19.9mg s.c., pulsatile with a flow rate of 10μl/s|Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 7 in a total daily dose of 19.9mg
45938917|NCT00196729|Drug|Thyrogen + Radioiodine (131I)|
45938918|NCT00196768|Drug|Arsenic trioxide|
45938919|NCT00196768|Drug|Trisenox|
45938920|NCT00084396|Drug|letrozole|
45938921|NCT00084396|Procedure|conventional surgery|
46074223|NCT00861523|Drug|thiamine & promethazine|thiamine 100 mg IV promethazine 25 mg IV
46074224|NCT02811978|Drug|Bortezomib|Participants will receive 1.3 mg/m^2 bortezomib on Days 1, 4, 8, and 11 of a 3 week cycle.
46074225|NCT02811978|Drug|Dexamethasone|Participants will receive Dexamethasone at a dose of 20 mg PO on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
45805576|NCT05919992|Drug|Placebo 250 mg Tablets|During another phase of the study: identical looking placebo pills starting Day 1 0-1-1, day 2 1-2-2, day 3 2-3-3 day 4 3-4-4 day 5 4-4-4 day 6 4-4-4 day 7 4-0-0
45805577|NCT05919992|Drug|Placebo (0,9% NaCl solution)|Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 7
45805578|NCT05919979|Behavioral|34-hour fasting in sedentary conditions|Participants will fast for 34h after a standardized breakfast, refraining from physical activity.
45938922|NCT00196807|Behavioral|patient decision aid (print-based)|To evaluate the impact of the decision aid intervention (information plus decision aid (IDA) vs. usual care (UC)), and timing of intervention delivery (at Home (pre-screening) vs. in the Clinic (screening day)) on key patient outcome variables of PCa knowledge and decisional satisfaction.
45938923|NCT00196846|Drug|Goserelin|
45938924|NCT00060632|Drug|ridaforolimus|"Administered intravenously once weekly for 4 weeks (1 cycle).~In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles."
45938925|NCT00409864|Procedure|Endoscopic biliary stenting, Percutaneous biliary stenting|percutaneous 10 F stent, endoscopic 10 F stent insertion
45938926|NCT00196885|Drug|N-acetylcysteine|
45938927|NCT00048204|Drug|GW597599B|
45938928|NCT00048204|Drug|paroxetine|
45938929|NCT00196924|Biological|HPV-16/18 L1/AS04|
45938930|NCT02968511|Biological|fecal microbiota transplant|Fecal microbiota transplant for the treatment of severe, complicated C. difficile infection
45938931|NCT00196963|Biological|Meningococcal (vaccine)|
45938932|NCT00197041|Biological|RTS,S/AS02A|
45938933|NCT00197080|Drug|Ropinirole Extended Release (XR)|
45938934|NCT00060671|Drug|rituximab|
45938935|NCT00060671|Drug|Pixantrone (BBR 2778)|
45938936|NCT00197158|Biological|Hepatitis B vaccine|
45938937|NCT00197197|Drug|GW873140|
45938938|NCT00409903|Drug|Eprosartan|
45938939|NCT00084435|Drug|cisplatin|75 mg/m2 IV, Day 1, q 21 days for 3 cycles
45938940|NCT00084435|Drug|docetaxel|15 mg/m2 IV, Day 1, 1 7 days for 6 doses
45938941|NCT00084435|Radiation|radiation therapy|200 cGy/day, Days 1-5, q week for 6 weeks
45938942|NCT00197275|Biological|Hib-MenAC mixed with Tritanrix™-HepB|
45938943|NCT00060710|Drug|CP-461|
45938944|NCT00197314|Behavioral|circular muscle exercises versus pelvic floor exercises|
45938945|NCT00197353|Drug|Epidural bupivacaine (dose/concentration/volume ranging)|
45938946|NCT02962999|Drug|Ketamine|After induction, patients will be received 1 mg/kg ketamine bolus, then administered 0,5 mg/kg/hour ketamine infusion intraoperatively.
45938947|NCT02962999|Drug|Saline|After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively.
45938948|NCT00084513|Biological|trastuzumab|
45938949|NCT00084513|Drug|imatinib mesylate|
45938950|NCT00060749|Drug|Docosahexaenoic Acid (DHA) Dietary Supplement|
45805579|NCT05919979|Behavioral|34-hour fasting with high-intensity exercise|Participants will fast for 34h after a standardized breakfast, performing a high-intensity exercise session 6-10 hours aprox. after starting the fasting period.
45805580|NCT05919966|Other|Chlorhexidine bathing|The procedure involved pouring an entire bottle (200ml) of 2% CHG solution (PBF Biotech, Taipei, Taiwan) onto a pre-packed set of eight single-use cotton wipes before each bathing session. A minimum of six wipes were required to thoroughly cover the entire body, including the bilateral upper and lower extremities, front and back of the trunk, perineum, and buttocks.
45938951|NCT04710589|Radiation|CTV|According to the clinical conditions of the patients, they will be assigned to two groups based on the doctor's recommendations and their own wishes
45938952|NCT00197431|Drug|S-1|
45938953|NCT00197470|Procedure|IL-1, TNF-alpha, Il-10|
45938954|NCT00197509|Behavioral|Sit-To-Stand Protocol and Extra Practice in Sit-To-Stand|
45938955|NCT00084591|Drug|capecitabine|
45938956|NCT00084591|Procedure|conventional surgery|
45938957|NCT00084591|Procedure|neoadjuvant therapy|
45805581|NCT05919953|Device|Virtual reality|Immersive virtual reality neck exercises targeting relaxation, mobility, control, and speed of movement, using the Pico G2 4K headset.
45938958|NCT00084591|Radiation|radiation therapy|
45938959|NCT04730453|Procedure|ENB-guided ablation therapy combined with VATS|After receiving multidisciplinary assessments, Lesion A will receive ENB-guided ablation therapy and Lesion B will receive VATS at the same time.
45938960|NCT00197548|Dietary Supplement|Multivitamins-vitamins B-complex, C, and E|One daily oral dose of 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 mg of C, and 30 mg of vitamin E from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
45938961|NCT00197548|Dietary Supplement|Placebo|One daily oral dose of a placebo pill taken from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
45938962|NCT00197587|Drug|Nevirapine|All women received a background of zidovudine from 34 weeks' gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.
45938963|NCT00197587|Drug|No intervention|All women received a background of zidovudine from 34 weeks'gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.
45938964|NCT00197704|Dietary Supplement|Multivitamins|5000 IU of retinol, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 of C, 200 mg of E, 0.8 mg of folic acid, and 100 mcg of selenium taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
45938965|NCT00197704|Other|Placebo|Placebo pill taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
45654519|NCT04953715|Other|collection of body microbioma|A prospective, observational microbiome study of adult kidney transplant recipients receiving mycophenolate mofetil and tacrolimus maintenance immunosuppression. Participants will be studied post-transplant for mycophenolate pharmacokinetics and microbiome samples collected. Clinically measured tacrolimus trough concentrations will also be evaluated. Associations among mycophenolic acid enterohepatic recycling and metabolite formation, tacrolimus troughs, immunosuppression adverse effects, diarrhea and microbiome will be studied.
45654520|NCT04980833|Drug|Alpelisib|Participant's treatment plan has been established by the treating physician, within the global compassionate use framework. Doses permitted are 50, 125, 200 and 250 mg.
45805582|NCT05919953|Behavioral|Therapeutic education|"Several brochures will be given to participants. These brochures will cover the general principles of pain, the persistence of pain, tips for managing chronic non-specific pain, and the use of immersive virtual reality in the rehabilitation of chronic non-specific neck pain.~The information provided in the brochures will be discussed with the physiotherapist during the teleconsultations in order to individualize the therapeutic education."
45938966|NCT00197743|Dietary Supplement|Vitamin A + Beta Carotene|one daily oral dose of 30 mg beta-carotene + 5000 IU preformed vitamin A
45938967|NCT00197743|Dietary Supplement|Multivitamins|one daily oral dose of 20 mg thiamine (vitamin B-1), 20 mg riboflavin (vitamin B-2), 25 mg vitamin B-6, 100 mg niacin, 50 ug cobalamin (vitamin B-12), 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid
45938968|NCT00197743|Other|Placebo|Placebo pill
45938969|NCT00084630|Drug|imatinib mesylate|Given orally
45938970|NCT00084630|Other|laboratory biomarker analysis|Correlative studies
45938971|NCT00197782|Biological|Hib conjugate vaccine|
45938972|NCT00197821|Biological|pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
45938973|NCT02963233|Procedure|Closed reduction and percutaneous pinning and immobilization|
45938974|NCT02963233|Procedure|Non-operative reduction and immobilization|
45938975|NCT00084669|Drug|venlafaxine|
45938976|NCT00084669|Drug|zolpidem tartrate|
45938977|NCT00084669|Procedure|management of therapy complications|
46074226|NCT00630149|Drug|Pemetrexed (Alimta)|500 mg/m2 in Cycle 1, every 3 weeks, with folic acid and vitamin B12 supplementation.
46074227|NCT02812056|Drug|Alisertib|"Dose Escalation Phase:~Starting dose of Alisertib: 30 mg by mouth 2 times a day on Days 1 - 7 each 21 day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."
46074228|NCT02812056|Drug|TAK-228|"Dose Escalation Phase:~Starting dose of TAK-228: 1 mg by mouth daily Days 3 - 18, with the exception of 2 mg daily Days 3 - 7 and 10 - 14 schedule in a 21 day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."
45938978|NCT00197860|Biological|tumor antigen loaded autologous dendritic cells|DC vaccination regime consists of primary 10 intradermal injections of 1-2 weeks interval (q1w x 4 → q2w x 6). HLA-A2 positive patients are treated with survivin and telomerase peptide-pulsed dendritic cells, and HLA-A2 negative patients are treated with allogeneic tumor lysate-pulsed dendritic cells i.d. 1,6 mg Thymosin alpha 1 (Zadaxin®, SciClone) is administered s.c. twice a week and from the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.
45654521|NCT04916249|Drug|Tibetree Pain Relieving Plaster|Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.
45654522|NCT04916249|Other|Placebo|Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.
45654523|NCT04953793|Behavioral|TAY SUCCESS|TAY SUCCESS stands for transition age youth supported, comprehensive cognitive enhancement and social skills. The cognitive-behavioral intervention teaches a number of strategies for executive functioning, social cognitive functioning and social communication.
45938979|NCT00060827|Device|Head Impact Recording Technology (HIRT)|
45938980|NCT00197899|Drug|E. Coli endotoxin|
45938981|NCT00197938|Procedure|Measurement of rectal lactic acid.|
45938982|NCT00197977|Behavioral|Educational program to address patients' expectations|
45938983|NCT00060866|Drug|Propranolol|
45805583|NCT05919940|Dietary Supplement|Dietary Supplement: additional substitution of protein|"Day one (admission) no nutrition is applied.~Protein target is increased as follows:~to a level of 1,2g/kg/d on day 1 after ICU admission~to a level of 1,4g/kg/d on day 2 after ICU admission~to a level of 1,6g/kg/d on day 3 after ICU admission~to a level of 1,8g/kg/d on day 4 after ICU admission~to a level of 2,0g/kg/d from day 5 onwoards~Additional protein is given within 2 hours after mobilization respectively:~to 0,125g/kg/d on day 1 after ICU admission~to 0,2g/kg/d on day 2 after ICU admission~to 0,25g/kg/d on day 3 after ICU admission~to 0,3g/kg/d from day 4 after ICU admission onwoards"
45805584|NCT05919940|Device|Neuromuscular electrical stimulation|twice daily 60 minutes till day 28 or ICU discharge
45938984|NCT00198016|Device|Coil|
45805585|NCT05919940|Other|Early Mobilization|at least 20 minutes a day following the SOMS concept. Duration: till 28 day or ICU discharge
45938985|NCT00048360|Drug|Extended-release bupropion hydrochloride|
45938986|NCT00198055|Drug|aripiprazole|Aripiprazole 5 mg per day for 2 weeks, then can be increased to 10mg per day if tolerated for 2 weeks, then can be increased to 15 mg per day for 4 weeks.
45938987|NCT00198094|Drug|Sertraline and Alprazolam XR|
45938988|NCT00198172|Drug|Cisplatin plus Epirubicin|
46074229|NCT04283825|Behavioral|Psychological and physical rehabilitation based humanistic care|This Psychological and physical rehabilitation based humanistic care regimen is generated from the experience of the National medical team members in Wuhan, from our hospital. In addition to the routine therapy, we will apply this comprehensive humanistic care regimen to the patients according to their condition. The patients will be stratified by the severity and receive different combinations of Psychological and physical rehabilitation activities.
45654524|NCT04953793|Other|Usual Care|Usual care involved the typical vocational supportive education program delivered in the educational setting
45938989|NCT02968628|Other|Video Electroencephalogram (EEG)|Single neonatal video EEG at 24 hrs to 5 days of life during birth hospitalization. Neonatal scalp leads, respiratory and nasal leads. Approximately 60 minute recording.
45938990|NCT02968628|Other|Point-of Care Blood Sugar Testing|One-time heel-stick point-of-care blood sugar testing at time of EEG.
45938991|NCT02968628|Other|Medical Record Data Extraction|Medical record data extraction from both maternal obstetric and neonatal medical record for variables known to impact EEG and neurodevelopmental outcomes.
45938992|NCT02968628|Other|Maternal Questionnaire|One-time maternal questionnaire related to smoking practices, ETOH consumption, level of education, and body mass index.
45938993|NCT00198250|Drug|venlafaxine|Venlafaxine taper dose from 37.5mg for one week to 75 mg for 3 weeks
45938994|NCT00084708|Dietary Supplement|calcitriol|
45938995|NCT00084708|Drug|dexamethasone|
45938996|NCT00084708|Drug|gefitinib|
45938997|NCT00198289|Drug|Aurexis® (tefibazumab)|
45938998|NCT00198367|Drug|Cisplatin-Gemzar|
45938999|NCT00198367|Drug|Cisplatin-Navelbine-Radiotherapy|
45939000|NCT00198367|Drug|Carboplatin-Taxol-Radiotherapy|
45939001|NCT00198406|Procedure|diagnostic and therapeutic management|
45939002|NCT02968589|Behavioral|Training|
45939003|NCT00198445|Drug|Bromfenac|One drop in study eye every 12 hours for 14 days
45939004|NCT00198445|Drug|Placebo|One drop in study eye every 12 hours for 14 days
45939005|NCT00198484|Drug|Vitrase|
45939006|NCT00048399|Drug|Fludarabine|
46074230|NCT04042207|Device|Low Glucose Predictive Suspend system|consists of sensor-augmented pump therapy (SAP) / Low Glucose Predictive Suspend system (with predictive low glucose management technology)
45654525|NCT04953871|Drug|TNF Inhibitor|TNF inhibitors are widely used in patients with spondyloarthritis
45654526|NCT04866719|Device|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
45939007|NCT00048399|Drug|CAMPATH 1H|
45654527|NCT03059719|Biological|Exenatide injection(Byetta)|
45654528|NCT03059719|Biological|PB-119 injection|
45939008|NCT00048399|Drug|FK506|
45939009|NCT00048399|Procedure|Stem Cell Transplantation|
45939010|NCT00060905|Drug|Divalproex Sodium (Depakote ER)|
45939011|NCT00198523|Drug|Prednisolone and Tobramycin|
45939012|NCT00198523|Drug|Prednisolone|
45654529|NCT04980599|Dietary Supplement|probiotic drink with Lactobacillus paracasei K56|Probiotic drink (K56 10^11CFU) 350ml/d for 60days
45654530|NCT04980599|Dietary Supplement|maltodextrin|maltodextrin ,for 60days
45939013|NCT00198562|Drug|Amlodipine, Losartan|amlodipine: 2.5-10 mg once daily for 5 years losartan: 25-100 mg once daily for 5 years
45939014|NCT00409942|Drug|Torasemide Prolonged Release|Torasemide Prolonged release 10mg/day up to 40mg/day, treatment duration:8 months
45939015|NCT00409942|Drug|Furosemide|Furosemide 40mg/day up to 160mg/day, Treatment duration:8 months
45939016|NCT00084786|Drug|docetaxel|
46074231|NCT04042207|Device|DBLHU System|DBLHU system embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
46074232|NCT04204577|Drug|Apatinib Mesylate|Evaluation of the efficacy and safety of simple local ablation, local ablation combined with apatinib, local ablation combined with apatinib and PD-1 antibody SHR-1210 for advanced liver cancer.
45654531|NCT04980599|Dietary Supplement|Probiotic powder E3|Probiotic powder 3.0g/d (K56 10^10cfu) 60days;
45654532|NCT04980599|Dietary Supplement|Probiotic powder E5|probiotic powder 8g/day for 60days
45654533|NCT04980599|Dietary Supplement|probiotic capsule E7|probiotic k56 capsule, 2capsules/d (10^7cfu) for 60days
45654534|NCT04980599|Dietary Supplement|probiotic capsule E9|probiotic k56 capsule, 2capsules/d (10^9cfu) for 60days
45654535|NCT04980599|Dietary Supplement|probiotic capsule E10|probiotic k56 capsule, 2capsules/d (10^10cfu) for 60days
45654536|NCT04980599|Dietary Supplement|probiotic capsule E11|probiotic k56 capsule, 4capsules/d (10^11cfu) for 60days
45654537|NCT04972435|Diagnostic Test|Contrast sensitivity|All subjects performed the contrast sensitivity measurement preoperatively and one time at 2 months postoperatively.
45654538|NCT03060031|Drug|Oxytocin|Oxytocin intranasal administration, 40 IU, 5 puffs per nostril at 4 IU per puff delivered approximately 45 minutes prior to pain tasks.
45654539|NCT03060031|Drug|Placebo|Placebo intranasal administration, 5 puffs per nostril delivered approximately 45 minutes prior to pain tasks
45654540|NCT05619575|Device|CP1170 sound processor|The CP 1170 sound processor will be used to determine the hearing performance with the new implementation of ForwardFocus in SCAN 2 (SCAN 2 FF), as assessed by speech perception in noise.
45654541|NCT05619575|Device|CP1150 Sound processor|Active comparator off the ear sound processor.
45654542|NCT02499783|Biological|adalimumab|subcutaneous injections of adalimumab
45939017|NCT00084786|Drug|gefitinib|
45939018|NCT02968667|Behavioral|Empowerment|6 weeks of empowerment program and supported face to face discussion
45939019|NCT00409981|Device|paclitaxel coated balloon catheter (device with drug)|
45939020|NCT00410020|Behavioral|Alpha-linolenic enriched diet|
45939021|NCT00048438|Drug|paricalcitol|
45939022|NCT00410098|Behavioral|Bikram Yoga|
45939023|NCT00060983|Procedure|Body weight supported locomotor training|
45939024|NCT00060983|Procedure|Functional electrical stimulation|
45939025|NCT00198601|Drug|Gentamicin in Uniject Pre-filled syringe|
45939026|NCT00198640|Procedure|Antibiotic use|
45654543|NCT02499783|Other|placebo|subcutaneous injections of placebo
45939027|NCT00198679|Drug|Chlorhexidine|
45939028|NCT00198757|Behavioral|Medifast Plus for Diabetics Meal Replacement Supplements|
45939029|NCT00198757|Behavioral|Standard ADA recommended diet for type 2 diabetics|
45939030|NCT00084825|Drug|Docetaxel|30 mg/m^2 IV on days 1, 8, 15, and 22 every 42 days
45939031|NCT00084825|Drug|Imatinib mesylate|600 mg orally daily
45939032|NCT00198796|Biological|H10407|The primary objective of the proposed clinical investigation is to validate a dose for ETEC H10407 that will cause diarrhea in 50% or more of subjects without causing high output diarrhea
45939033|NCT00198835|Behavioral|Maternal nutrition and infant feeding advice|
45939034|NCT00198874|Behavioral|Integrated Family and Cognitive-Behavioral Therapy|The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
45939035|NCT00198874|Other|Education|Drug education curriculum was delivered to participants assigned to this condition.
45939036|NCT00198913|Behavioral|lower fat food supplied and education|
45939037|NCT00198913|Behavioral|gift cards for grocery foods and written education|
45939038|NCT00048477|Drug|L-NMMA and Sodium Nitrite|
45939039|NCT02968472|Genetic|prophylactic 4SCAR19 cells|Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
45939040|NCT00198952|Drug|DietPro|
45939041|NCT00198952|Drug|Placebo|
45939042|NCT00199147|Drug|Cytarabine|
45939043|NCT00199147|Drug|Etoposide|
45939044|NCT00199147|Drug|Idarubicin|
45939045|NCT00199147|Drug|G-CSF|
45939046|NCT00199147|Drug|Fludarabine|
45939047|NCT00199147|Procedure|Stem cell apheresis|
45939048|NCT00199147|Procedure|Stem cell transplantation|
45939049|NCT00199186|Drug|imatinib|
45939050|NCT00199186|Drug|vincristine|
45939051|NCT00199186|Drug|cyclophosphamide|
45939052|NCT00199186|Drug|cytosine arabinoside|
45939053|NCT00199186|Drug|dexamethasone|
46074233|NCT02809092|Biological|NK Cells + Chemotherapy Starting|"Drug: G-CSF G-CSF daily by vein starting on Day -7 until post nadir of absolute neutrophil counts (ANC) are equal or over 1000.~Other Names:~Filgrastim Neupogen Drug: Fludarabine monophosphate 30 mg/m2 by vein on Days -6, -5, -4, -3, and -2.~Other Names:~Fludarabine Phosphate Fludara Drug: Cytarabine 2 g/m^2 by vein on Days -6, -5, -4, -3, and -2.~Other Names:~Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride Procedure: Natural Killer (NK) Cell Infusion NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema."
45654544|NCT04972045|Drug|CuminUP60®|4 capsules, 400 mg / capsule
45654545|NCT04972045|Drug|Curcumin capsules|4 capsules, 400 mg / capsule
45654546|NCT04953481|Other|survey|The general information, home care status and functional status of ALS patients and family caregivers were collected.
45805586|NCT05919823|Drug|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.
45805587|NCT05919823|Drug|Placebo|Placebo Capsules
45805588|NCT05919810|Other|Probiotic|Oral probiotic
45805589|NCT05919810|Dietary Supplement|Oral herbal powder supplement|oral herbal powder
45805590|NCT05919771|Other|rock climbing|Vertical ascent of a surface specifically designed to elicit the skills that might be required to scale a naturally occurring rock formation
45939054|NCT00199186|Drug|idarubicin|
45939055|NCT00199186|Drug|methotrexate (intrathecal)|
45939056|NCT00199186|Drug|AraC (intrathecal)|
45939057|NCT00199186|Drug|dexamethasone (intrathecal)|
45939058|NCT00084903|Procedure|Colposcopic biopsy|Two small samples of cervical tissue (biopsy) removed from 2 sites as spectroscopy readings.
45939059|NCT00084903|Procedure|Light-Scattering Spectroscopy|Spectroscopy readings taken in 2 regions of cervix.
45939060|NCT00199225|Drug|Rupatadine|
45939061|NCT00199225|Drug|moxifloxacin|
45939062|NCT00199225|Procedure|Continous electrocardiographic register|
45939063|NCT00199225|Procedure|Pharmacokinetic profile|
45939064|NCT00061022|Drug|NXY-059|
45939065|NCT00199264|Drug|Albaconazole oral solution|
45939066|NCT00199303|Drug|pre-operatively followed by 30 mg three times per day after surgery|
45939067|NCT00199342|Drug|KW-2871|potentially therapeutic monoclonal antibody for the treatment of advanced stage four melanoma
45939068|NCT00048516|Drug|paricalcitol capsule|
45939069|NCT00199420|Drug|Istradefylline (KW-6002)|
45654547|NCT04953949|Device|NU-MAX®|Topical Hemostat
45654548|NCT03059017|Drug|Salbutamol Sulphate|salbutamol sulphate packaged as aerosol
45939070|NCT00199498|Device|Apical RV lead placement|RV lead implanted ( according to randomization )at the apex
45654549|NCT03059017|Drug|Niosomes|Niosomes
45654550|NCT05691413|Other|Other: Product X facial cleanser|Product X facial cleanser contain olive oil, virgin coconut oil, butylene glycol and hyaluronic acid
45654551|NCT04971421|Diagnostic Test|ctDNA - circulating tumor DNA|lcWGS and WGS of circulating tumor DNA
45654552|NCT04971421|Diagnostic Test|TEP - Tumor Educated Platelets|sequencing miRNA from TEPs
45654553|NCT05691335|Procedure|Standard CXL|Epithelium-off CXL performed by removal of corneal epithelium, instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 30 minutes.
45654554|NCT05691335|Procedure|Accelerated CXL|Epithelium-off CXL performed by removal of corneal epithelium, instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 5 minutes.
45654555|NCT05691335|Procedure|Transepithelial CXL|Epithelium-on CXL performed by instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 5 minutes.
45654556|NCT04772885|Drug|KT-474/Placebo|KT-474 or matching placebo oral tablet(s)
45654557|NCT04772885|Drug|KT-474|KT-474 oral tablet(s)
45805591|NCT05919745|Drug|Ibuprofen 600 mg|Preoperative delivery of ibuprofen per os.
45805592|NCT05919745|Drug|Placebo|Preoperative delivery of placebo per os.
45939071|NCT00199498|Device|Septal RV lead placement|RV lead is implanted (according to randomization), on septum
45939072|NCT02970396|Behavioral|self-management|
45939073|NCT00199576|Drug|Methylprednisolone|
45939074|NCT00199615|Procedure|PET|Intravenous injection of glucose labeled Fluor 18.Le patient remains fasted at least 6 hours before the start of the examination. The review lasted 1 hour, during which the patient should not move.
45939075|NCT00199654|Procedure|PET|
45939076|NCT00084942|Drug|capecitabine|
45939077|NCT00084942|Drug|gemcitabine hydrochloride|
45939078|NCT02968394|Drug|omalizumab|
45939079|NCT00199771|Drug|7.5% NaCl in 6% dextran 70 solution|
45939080|NCT00084981|Drug|decitabine|Given IV
45939081|NCT00084981|Drug|valproic acid|Given PO
45939082|NCT00084981|Other|pharmacological study|Correlative studies
45939083|NCT00084981|Other|laboratory biomarker analysis|Correlative studies
45939084|NCT00199927|Drug|Fluvastatin|Starting dose of Fluvastatin of 40 mg/day uptitrated to 80 mg/day
45939085|NCT00199927|Drug|standard therapy|standard therapy
45939086|NCT00061061|Behavioral|Behavior Therapy|
45939087|NCT00199966|Drug|Divalproex sodium extended release|
45939088|NCT00200005|Device|Type: Implantable neurostimulator; InterStim|Treatment with InterStim Therapy: all patients meeting inclusion/exclusion criteria undergo test screening and those who have successful outcomes receive a permanent implant.
45654558|NCT04962061|Other|Cognitive Training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer- or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general.
45939089|NCT00085020|Biological|trastuzumab|
45939090|NCT00085020|Drug|lapatinib ditosylate|
45654559|NCT04962061|Other|Aerobic and resistance exercises|Participants will follow a periodized exercise training program with thrice-weekly 60 minutes trainings. The sessions will start with a 5-10mins warm-up, followed by aerobic and resistance trainings, and ends with a 5-10mins cool-down and stretching period. Intensity of aerobic sessions will be monitored with heart rate chest strap and should match with the moderate to vigorous intensity zone as defined by the ACSM (65% of Heart Rate maximum or more and a Perceived Exertion higher than 12 on the 6 to 20 Borg scale). Exercise intensity and duration will be gradually increased during the program. After aerobic training, a 15-20mins resistance training will be performed with a gradual progression of higher intensities and/or numbers of sets. The one maximal repetition (1RM) will be assessed for each RT movements at baseline, during (each 3 months) and at the end of the program. RT intensities will go from 40 to 70% of 1RM, with 8 to 10 forms of exercise involving majors muscle groups.
45654560|NCT04962061|Other|Stretching and Toning|Participants in the active control condition will take part in three 60 minutes stretching and toning sessions per week. Each session will start with a five-minutes warm-up, followed by fifteen min of body stretching exercises mainly in a seated position and finish with a five-minutes cool down. Participants will engage in four muscle-toning exercises (light intensity) using dumbbells or resistance bands, two exercises designed to improve balance, one yoga sequence, and one exercise of their choice. Intensity of stretching and toning sessions will be monitored with heart rate chest strap and should not exceed the light intensity zone as defined by the ACSM (64% of Heart Rate maximum or less and a Perceived Exertion lower than 11 on the 6 to 20 Borg scale).
45939091|NCT00200044|Device|Gatekeeper Reflux Repair System|The Gatekeeper System™ consists of a specialized 16-mm overtube assembly, a 2.4-mm diameter prosthesis delivery system (1-mm diameter needle, dilator, and 2.4-mm diameter sheath), a pushrod assembly and Gatekeeper Prosthesis. Up to 4 prostheses will be implanted at the initial procedure and retreatment with up to four more prostheses will be allowed at 3-months if the subject has a GERD HRQL score >15.
45939092|NCT00061100|Behavioral|Behavior Therapy-RISE|manually-guided HIV intervention RISE: Reduce high risk Intravenous drug use and unsafe Sexual Encounter
45939093|NCT00061100|Behavioral|Standard prevention Education|standard psychosocial Education for HIV/hepatitis prevention
45805593|NCT05919745|Drug|Acetaminophen|Both groups will be given rescue medication in the form of 1,000 mg tabs of acetaminophen every 6 hours per os as needed for pain (maximum allowed daily dose 4,000 mg per FDA) and will be allowed to receive ibuprofen or other analgesic medication as needed if pain is not controlled by acetaminophen alone. The subjects will receive the rescue medication pills at the end of the surgical appointment.
45805594|NCT05919706|Behavioral|Patient Education with Game-Based Mobile Technology and Motivational Interviewing|Education program, game-based mobile technology and motivational interview were applied to the patients in the experimental group. The patients' self-management, quality of life, and satisfaction level scores for the intervention were determined.
45805595|NCT05919316|Device|Rhinophototherapy|Intranasal rhinophotometer to be used at home for 4.5 minutes three times daily for 14 days
45805596|NCT05919316|Drug|Nasonex Nasal Spray|50mcg/dose, 2 sprays each nostril (morning or evening) once daily for 14 days
45805597|NCT05919238|Combination Product|Padeliporfin Vascular Targeted Photodynamic (VTP) therapy|The laser light fiber with inflatable balloon to dam SMA blood flow during light illumination will be placed by an Interventional Radiologist in the SMA via a transfemoral artery approach. The balloon will be inflated to impede blood flow for total of 10 minutes during light illumination
45805598|NCT05919173|Drug|Bupivacaine Hcl 0.25% Inj|Bupivacaine 0.25% Dose: 1mL/kg
45939094|NCT00200083|Device|Transcend II Model 8848|"All subjects will be implanted with the IGS device and then randomized to on or off for 12 months. After 12 months all subjects will be turned on through 24 month follow up."
45939095|NCT00410176|Behavioral|sanitation and personal hygiene|
45939096|NCT00085059|Drug|boronophenylalanine-fructose complex|
45939097|NCT00410215|Drug|picosalax plus bisacodyl|10 mg bisacodyl three and two nights prior to colonoscopy, followed by two sachets picosalax
45939098|NCT00410215|Drug|picosalax|two sachets of picosalax taken orally the day prior to colonoscopy
45939099|NCT00410215|Drug|sodium phosphate|two 45 ml bottles of sodium phosphate the day prior to colonoscopy
45939100|NCT00061139|Behavioral|Pediatric Constraint-Induced Movement therapy|
45939101|NCT00061139|Behavioral|Conventional pediatric motor rehabilitation therapy|
45939102|NCT00410254|Drug|HCV-796|
45939103|NCT00410254|Drug|midazolam|
46074234|NCT04041193|Behavioral|SIDERA^B|The group will receive a kit home-based (a tablet home, access to a daily individualized training program). Five sessions for a week (3 components: monitoring, motor rehabilitation acitivities, motivational support)
46074235|NCT04041193|Behavioral|Usual Care Program|Usual Care program activities (paper and pencil at home)
46074236|NCT02862587|Drug|Chemotherapy|Cisplatin：60mg/m2，Gemcitabine：1g/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
46074237|NCT02862587|Biological|precision cells|precision cells DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
46074238|NCT00852787|Drug|Digoxin immune fab|Intravenously one time
46074239|NCT00852787|Drug|Placebo|Intravenously one time
46074240|NCT00634452|Biological|MDX-1401|IV weekly for 4 weeks
46074241|NCT02545465|Drug|Riociguat (Adempas, BAY63-2521)|As per the treating physicians discretion
45939104|NCT00410293|Procedure|NT-proBNP testing|
45939105|NCT00200122|Device|Spinal Cord Stimulation|
46074242|NCT02808936|Procedure|Remote ischemic preconditioning|three cycles of ischemia (5 min) / reperfusion (5 min) of available upper or lower limb with an automated machine using blood pressure cuff
46074243|NCT02808936|Procedure|Sham control|The patients had the same pneumatic cuff around the upper arm and similar maneuvers were performed, but pressure was not applied to the cuff.
45654561|NCT04755413|Other|Medical/Behavioral therapy|"Sedentary lifestyle: Advise increasing exercise to at least 30 minutes of moderate-intensity aerobic activity 5 days a week.~Overweight/Obese: Advise calorie reduction, dietician consultation.~Smoking: standard smoking cessation advice and literature and medical therapy as indicated to include Wellbutrin, nicotine patch etc.~High LDL cholesterol: a) Start high dose statin if patient not on high dose statin.~b) If on high dose statin, add ezetimibe 10mg daily c) If statin intolerant, start ezetimibe 10mg, colestid or other bile sequestrant combination.~d) If still not at goal, start PCSK-9 inhibitor e) LDL cut off of <55mg/dl in diabetes~Blood Pressure optimization treatment following 2020 International Society of Hypertension Global Hypertension Practice Guidelines.~Diabetes management: HbA1c goal 6.5%"
45654562|NCT04755413|Other|Standard of Care|Participants will receive standard of care therapy prescribed by their primary care physician and/or cardiologist.
45805599|NCT05919173|Drug|Bupivacaine Hcl 0.25% Inj plus Dexmedetomidine 1micro/kg|Bupivacaine Hcl 0.25% Inj plus Dexmedetomidine 1micro/kg Dose: 1 mL/kg
45805600|NCT05919004|Diagnostic Test|App-based spirometer|App-based spirometer to perform serial spirometry to assess lung function variatione
45805601|NCT05918692|Drug|BMF-500|Investigational Product
45654563|NCT04755413|Other|Registry|Participants with BRS of 0 will get measurements of BRS at the time-points specified for the randomized subjects and also for adverse events.
45654564|NCT04938245|Device|Spinal Cord Stimulation|"Intraoperatively, stimulation at 12 Hz will be performed as the leads are moved into the targeted position. Amplitude will be increased to 15 mA maximum total until a response is seen on any electrode and held for 10 seconds. Stimulation and recording will be performed using the Neuralynx stim/record system.~Post-operatively, the electrodes will be tested for impedance by the clinical system and then they will be connected to the Neuralynx stim/record system. Electrode stimulation patterns will be applied with increasing amplitude until ECAPs responses are seen on recording electrodes. 42 Hz stimulation will be performed with an amplitude sweep of 0mA-10mA. At each amplitude, stimulation will be applied for 4 seconds followed by 2 seconds of rest. Pulse width will be varied from 30-450 microseconds to test effective amplitude. Bursting stimulation will be applied to detect differences in ECAPs as above."
45654565|NCT04971577|Drug|Simvastatin 40mg|participants will receive a capsule containing 4 tablets simvastatin 10 mg (40 mg total) every 24 hours at night
45805602|NCT05918640|Drug|Lurbinectedin|Lurbinectedin will be administered on a Day 1, Day 4 schedule every 21 days. Doses will be determined in the phase 1 portion of the trial.
45939106|NCT00200239|Behavioral|Eating breakfast with portion and unportioned foods|Behavioral: eating breakfast with portion and unportioned foods
45939107|NCT00200278|Behavioral|PROJECT STRIDE|
45939108|NCT00061178|Drug|rhuMAb VEGF (Bevacizumab)|
45939109|NCT00200317|Behavioral|Internet and print-based interventions|
45939110|NCT00200395|Drug|Tarceva|OSI-774 will be supplied as 25 mg (non -film coated) 100 and 150 mg (film coated) tablets in separate bottles, containing 30 tablets respectively.
45939111|NCT00200434|Drug|Nebivolol|
45939112|NCT00061217|Device|Unrectified prosthetic socket|
45805603|NCT05918601|Other|Health-risk behaviors|Participants will be asked about the priority they place on engagement in health-related lifestyles, such as quitting drugs, alcohol, smoking or exercising regularly.
45805604|NCT05918601|Other|Theory of planned behavior, Self-determination theory|The participants will be asked to quit drugs immediately or progressively with the ultimate goal of quitting drugs completely.
45805605|NCT05918601|Other|Assist them to adhere to their schedule of quitting drugs throughout the study period|The participants will receive instant messaging via WeChat or WhatsApp from peer supporters to assist them to adhere to their schedule of quitting drugs throughout the study period.
45939113|NCT00061217|Device|Rectified prosthetic socket|
45939114|NCT00200473|Drug|Nebivolol|
45939115|NCT02962804|Drug|Nivolumab|240 mg per IV infusion over 60 minutes every 14 days (+/- 2 days) until disease progression or participant withdrawal from study
45939116|NCT02962804|Radiation|Radiation|Radiation to at least 1 site (up to 3) of primary or metastasis, 5 fractions - delivered over 2 weeks, starting 1-3 days post-nivolumab administration. Recommended dose range is 6 Gy-12 Gy per fraction.
45939117|NCT00048555|Drug|IDEC-114|Dose Group 1 - 125 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions Dose Group 2 - 250 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions Dose Group 3 - 375 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions Dose Group 4 - 500 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions
46074244|NCT04041271|Other|Cervical range of motion (CROM)|Subjects will perform full-range cervical flexion, extension, side-bending and rotation actively in sitting position. In supine position, cervical flexion-rotation will be performed passively by the assessor.
46074245|NCT04041271|Other|Pressure pain threshold (PPT)|A digital algometer with rubber head will be used to apply pressure on the muscles of subjects. When the subjects start to feel pain, the algometer will be removed immediately.
46074246|NCT04041271|Other|Cranial-cervical angle (CCA)|Subjects will stand in a relaxed position with colour markers on the earlobe and C7 spinous process. A photo of the head posture will be taken to calculate the included angle between the markers and the horizontal line.
46074247|NCT04041271|Other|Jaw kinematics|Jaw kinematics is measured by Ultrasonic Jaw Motion Analyzer (Zebris). The subjects will perform jaw opening, closing, lateral left, lateral right and protrusion for three times.
46074248|NCT04041271|Other|Muscle activation|Surface electromyography is used to assess the activities of bilateral masseter, anterior temporalis, sternocleidomastoid muscle and upper trapezius. Subjects will perform jaw resting and clenching.
45939118|NCT00200512|Drug|apomorphine HCl injection|
45939119|NCT00200551|Drug|Cyclosporin, mycophenolate mofetil, antilymphocyte serum and corticoids.|
46074249|NCT02811900|Procedure|Roux en Y gastric bypass|Laparoscopic RYGB is performed as following: a gastric pouch of approximately 30mL was obtained using successive firings of the Endo GIATM linear stapler, followed by the creation of an antecolic alimentary limb of 150cm and of a biliopancreatic limb of 75cm. A gastrojejunal anastomosis was fashioned with the PCEEA™ 28 circular stapler until 2012, and using the Endo GIA™ linear stapler afterwards. The mesenteric defect and Petersen's defect were closed using a non-absorbable running suture.
45654566|NCT04961983|Behavioral|Comprehensive Travel Health Education Model|"The comprehensive travel health education model consists of:~Online training: 10 hours (2 days) online education via Zoom. The topics that will be delivered during the training includes:~The potential roles of tour guides in tourists' health,~The importance of travel health information for tourists,~Assessment of tourist's health risks,~Prevention and first aid of various travel health problems Topics related to tour guides will be delivered by the tourism experts, while topics related to travel health will be provided by travel medicine experts, Faculty of Medicine, Udayana University. Participants will also receive a travel health guide book.~Weekly travel health Information sharing through WhatsApp group for 2 months."
45654567|NCT03061123|Other|Questionnaire|
45654568|NCT04961749|Other|Whole body vibration training|Whole-body vibration training applies a vibration stimulus to an individual as they are standing on a side-alternating platform. The vibration creates small muscle contractions in the lower extremity musculature which has been shown to improve function and ambulatory function.
45654569|NCT04953013|Drug|sodium bicarbonate|Drug exposure
45654570|NCT04953169|Other|Biobank Video|The video describes the process of biobanking with visuals
45654571|NCT04953169|Other|Non-Video|The non-video group will receive a written informed consent
45654572|NCT04425655|Drug|Fludarabine|30mg/m2 days 1 through 5
45654573|NCT04425655|Drug|Vyxeos|100U/m2 days 1, 3 5 in induction, 65U/m2 days 1 and 3 for consolidation
45805606|NCT05918601|Other|Assist them to adhere to their schedule of desirable health-related lifestyles/quitting drugs throughout the study period|The participants will receive instant messaging via WeChat or WhatsApp from peer supporters to assist them to adhere to their schedule of desirable health-related lifestyles/quitting drugs throughout the study period.
45654574|NCT04970719|Drug|Baricitinib|4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course
45654575|NCT04970719|Drug|Dexamethasone|and 6 mg* of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course
45805607|NCT05918601|Other|(AWARD) model|Participants receive a brief intervention using the Ask, Warn, Advise, Refer and Do-it-Again (AWARD) model
45805608|NCT05918601|Other|Receive four independent 1-minute videos|The participants will receive four independent 1-minute videos which focus on the health risks associated with abusing drugs and the benefits of quitting drugs.
45939120|NCT00200551|Drug|Cyclosporin, mycophenolate mofetil, antilymphocyte serum without corticoids.|
45939121|NCT00061256|Drug|Alendronate|
45939122|NCT00061256|Drug|Calcium carbonate|
45654576|NCT04970719|Drug|Remdesivir|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5-day total course
45654577|NCT02468193|Drug|Osilodrostat|Osirodrostat 1mg, 5mg & 10mg in the form of film-coated tablets was used for oral administration.
45805609|NCT05918575|Device|Noninvasive ventilation alternating with high flow nasal cannula|A total of 24 hours of prophylactic respiratory support will be provided using NIV alternating with HFNC with total NIV usage of 16 hours and HFNC usage of 8 hours.
45805610|NCT05918575|Device|High flow nasal cannula|A total of 24 hours of prophylactic respiratory support will be provided using HFNC alone.
45805611|NCT05918445|Drug|PM8002|IV infusion
45805612|NCT05918406|Combination Product|Nasal Guide|Use of Nasal Guide with administration of Tyrvaya (varenicline solution 0.03 mg) BID
45805613|NCT05918185|Procedure|Biospecimen Collection|Undergo blood sample collection
45805614|NCT05918185|Other|Comprehensive Geriatric Assessment|Undergo cGA
45805615|NCT05918185|Other|Electronic Health Record Review|Medical records are reviewed
45805616|NCT05918185|Other|Survey Administration|Complete surveys
45939123|NCT00061256|Drug|Vitamin D|
45939124|NCT00200590|Drug|acetaminophen and nalbuphine|
45939125|NCT00200590|Drug|acetaminophen and morphine|
45939126|NCT00200590|Drug|acetaminophen and reduced dosage of prostaglandin|
45939127|NCT00400101|Biological|Virosome-formulated synthetic peptides (malaria vaccine)|
45939128|NCT00200629|Procedure|Adenosine SPECT myocardial perfusion imaging|
45939129|NCT00200629|Procedure|Combined adenosine / exercise SPECT myocardial perfusion imaging|
45939130|NCT00200668|Drug|FDG = fluorodeoxyglucose|
45654578|NCT04970797|Drug|Xinglouchengqi decoction|the composition of Xinglouchengqi decoction: 9 g raw rhubarb, 9 g mirabilite, 6 g dananxing, 30 g quangualou decoction was uniformly prepared by the pharmacy department of our hospital. Decoction form was adopted, one dose per day, one dose of 200 mL decoction, and the decoction was taken in morning and evening twice and half an hour after meals. The observation period was 5 days: from 72 hours to 7 days after onset.
45939131|NCT00200707|Procedure|Intracoronary injection of autologous bone marrow mononuclear cells|
45654579|NCT04970485|Behavioral|Talking Matters|Group-level, facilitator-led behavioral intervention for 14-19 year old Black and African American adolescents with an intergenerational component to reduce teen pregnancy, strengthen protective factors to improve optimal health, and increase access to trusted adults.
45654580|NCT04431817|Device|KinetiGait|This device is an Intel RGB depth camera that relays video to gait analysis software. The images will be taken from amputees walking at a self-selected pace on a treadmill.
45654581|NCT02466555|Behavioral|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment, ask health related questions of the patients and respond to any pertinent inquiries. The Music Therapist will then engage the patients and member(s) of the Adult Sickle Cell Disease team in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
45805617|NCT05918146|Drug|Dextrose|Dextrose injection plus physical therapy
45805618|NCT05918146|Drug|Normal saline|Normal saline injection plus physical therapy
45805619|NCT05918133|Drug|PM8002|IV infusion
45805620|NCT05918133|Drug|nab-paclitaxel|IV infusion
45805621|NCT05918107|Drug|PM8002|IV infusion
45805622|NCT05918107|Drug|Pemetrexed|IV infusion
45805623|NCT05918107|Drug|Cisplatin|IV infusion
45805624|NCT05918107|Drug|Carboplatin|IV infusion
45805625|NCT05918055|Drug|KPT-8602|5-10 mg PO daily for 10-14 days based on dose level
45805626|NCT05918055|Drug|Inqovi|Inqovi will be administered via oral route once daily on Days 1-5 of each treatment cycle, according to guidelines outlined in the FDA product label.
45805627|NCT05917964|Drug|LP-168 tablet|LP-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
45805628|NCT05917938|Drug|NNC0194-0499|NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.
45939132|NCT04711577|Behavioral|Track clinician-determined symptoms|Participants will track clinician-determined symptoms
45805629|NCT05917717|Procedure|Neuroprotective 'bundle of care'|"This includes the 3 devices:~Head up cardiopulmonary resuscitation (HUP-CPR)~Active compression decompression CPR~Impedance threshold device (ITD)"
45805630|NCT05917496|Other|LENA tool: Language ENvironment Analysis|"Recording of the language environment of the child at home, in daily environment, with the LENA.~The parameters recorded relate to four domains: adult words, conversation turns, child vocalizations and exposure to electronic media.~The LENA box is worn for 10-16 hours, with a minimum of 10 consecutive hours. the families make 2 separate recordings of 6 months at T1 and T2."
45805631|NCT05917496|Behavioral|Return of the analysis of the data of LENA|The analysis of the LENA data is carried out by the speech therapist using the LENA Pro Version Software v3.4, during the times T1 and T2. The return of the analysis of the data collected via the LENA will be made to the family of the patient after T1 and after T2 and personalized advice will then be given to parents with the aim of improving their child's language skills.
45805632|NCT05916950|Device|Thor laser atherectomy|Treatment of de novo calcified lesions with laser atherectomy and calcium modification using the Thor system
45805633|NCT05916911|Dietary Supplement|Glizigen|"Treatment initiation: Treatment should be started simultaneously with the appropriate oral and intravaginal formulation after the last menstrual period or immediately in menopausal patients.~A total of 60 single doses of intravaginal use and 60 doses of oral solution should be given to each patient.~The intravaginal gel should be applied every night before going to sleep by inserting the cannula completely into the vagina and pressing the tube until the entire contents of the tube are poured into the vagina, then removing the cannula from the vagina while continuing to press the tube to avoid retrograde aspiration of the product. Application of the intravaginal gel should be discontinued during days of menstrual bleeding.~The oral solution should be administered by drinking 1 vial every morning without interruption for 60 days from the start of treatment. It can be taken either on an empty stomach or with food."
45939133|NCT04711577|Behavioral|Track clinician-determined and self-determined symptoms|Participants will track clinician-determined symptoms and a self-determined symptom
45939134|NCT00048594|Drug|aprepitant|
45939135|NCT00048594|Drug|Comparator: placebo (unspecified)|
45939136|NCT00200746|Drug|Arginine|Amino Acid Arginine
45939137|NCT00200824|Drug|Soy Isoflavone Nutritional Supplements|
45939138|NCT00200863|Device|Monochromatic visible light exposure|Monochromatic light in the visible range from 420-620 nm up to 60uW/cm2 for 6.5 hours
45939139|NCT00061295|Procedure|Body weight support treadmill training|
45939140|NCT00200941|Drug|Topiramate|
45805634|NCT05916911|Other|Placebo|"Treatment initiation: Treatment should be started simultaneously with the appropriate oral and intravaginal formulation after the last menstrual period or immediately in menopausal patients.~A total of 60 placebo single doses of intravaginal use and 60 placebo doses of oral solution should be given to each patient.~The placebo intravaginal gel should be applied every night before going to sleep by inserting the cannula completely into the vagina and pressing the tube until the entire contents of the tube are poured into the vagina, then removing the cannula from the vagina while continuing to press the tube to avoid retrograde aspiration of the product. Application of the intravaginal gel should be discontinued during days of menstrual bleeding.~The placebo oral solution should be administered by drinking 1 vial every morning without interruption for 60 days from the start of treatment. It can be taken either on an empty stomach or with food."
45805635|NCT05916547|Procedure|pancreatic extracorporeal shock wave lithotripsy|Pancreatic extracorporeal shock wave lithotripsy is based on the principle of shock wave energy. Whenever energy is abruptly released in an enclosed space, shock waves are generated and then cross to the surface of pancreatic duct stones to cause further fragmentation.
45805636|NCT05916170|Behavioral|Text-only Warnings|Text-only warnings about one health harm will be displayed in the hookah cafés where data collection is being conducted.
45805637|NCT05916170|Behavioral|Pictorial Warnings|Pictorial warnings about one health harm will be displayed in the hookah cafés where data collection is being conducted.
45805638|NCT05916170|Behavioral|No Warnings|No warnings posted in the hookah café
45805639|NCT05913973|Drug|Pvs230D1-EPA/Matrix-M|Pvs230 domain 1 (Pvs230D1) is a recombinant protein consisting of subdomain 1 of native Pvs230 (Val-226 to Gly-427, Figure 2) produced in Pichia pastoris. The synthetic gene sequence was optimized for P. pastoris expression and cloned into the expression vector pPICZ(alpha)A, which also encodes a pre-prosecretory alpha-factor sequence.
45805640|NCT05913089|Drug|TQB2450 injection + Chemotherapy|"TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Chemotherapy is a systematic treatment that kill fast growing cells."
45805641|NCT05913089|Drug|TQB2450 injection + Anlotinib Hydrochloride Capsule|"TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor."
45805642|NCT05912777|Radiation|Scanner|Scanner to be performed by patients
45805643|NCT05912517|Drug|Nipocalimab|Nipocalimab will be administered as an intravenous infusion.
45939141|NCT00085176|Procedure|management of therapy complications|
45939142|NCT00085176|Procedure|psychosocial assessment and care|
45939143|NCT00201019|Behavioral|Physician-pharmacist collaborative intervention|Participants receive assessment and medication and lifestyle recommendations from a clinical pharmacist.
45939144|NCT00201058|Behavioral|Tailored Web-based Asthma Management|Web-based asthma management
45939145|NCT00201058|Behavioral|Generic web-based asthma education|4 computer sessions over a period of 180 days
45939146|NCT00201136|Behavioral|Lifestyle interventions to lower blood pressure for patients|Weight loss, DASH dietary pattern, increased physical activity, reduced salt intake, moderation of alchohol intake.
45939147|NCT00201136|Behavioral|MD CQI-type intervention|CQI-type intervention for MD adherence to JNC guidelines for BP management
45939148|NCT00201214|Drug|Citrulline|Phase I - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with dosage escalation study 50mg/kg, 100mg/kg, 150mg/kg IV at 6, 12, 24, 48 hours post operative. Phase II - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with 9mg/kg/hr continuous IV starting 4 hours post bolus and infusing for 48 hours or discharge from PCCU.
45939149|NCT00048633|Drug|Chemotherapy|
45805644|NCT05912517|Drug|Placebo|Placebo will be administered as an intravenous infusion.
45805645|NCT05911243|Procedure|Acupressure Therapy|Undergo auricular acupressure
45805646|NCT05911243|Other|Best Practice|Receive usual care
45805647|NCT05911243|Procedure|Biospecimen Collection|Undergo collection of blood samples
45805648|NCT05911243|Other|Questionnaire Administration|Ancillary studies
45805649|NCT05911152|Procedure|Intracorporeal anastomosis|Surgeons perform totally laparoscopic intracorporeal digestive reconstruction after specimen resection
45805650|NCT05910996|Procedure|Conversion from vv-ECMO to va-ECMO|Conversion from vv-ECMO to va-ECMO
45805651|NCT05909202|Device|Sham VR|Nature-based non-immersive VR program
45805652|NCT05909202|Device|Active VR|Nature-based immersive VR program
45805653|NCT05907759|Drug|Daratumumab SC|Daratumumab SC (daratumumab and hyaluronidase) is administered subcutaneously (SC) as 1800 mg/30,000 units weekly for a total of 8 weeks (8 doses) followed by every 2 weeks for a total of 16 weeks (8 doses) followed by every 4 weeks for up to 96 weeks (24 doses)
45805654|NCT05907746|Drug|Mycophenolate Mofetil|15 mg/kg IV three times per day starting on day +5 until approximately day +30 (+/- 2 days)
45805655|NCT05907746|Drug|Tacrolimus|0.02 mg/kg IV daily starting on day +5
45805656|NCT05907746|Drug|Post-Transplant Cyclophosphamide|50 mg/kg IV daily on days +3 and +4
45805657|NCT05907746|Radiation|Total Body Irradiation|200cGy on day -1
45805658|NCT05907746|Procedure|Hematopoietic Cell Transplant|stem cell transplant on day 0
45805659|NCT05907746|Drug|JSP191|Single 0.6 mg/kg IV infusion administered between days -13 and day -10
45805660|NCT05907746|Drug|Cyclophosphamide|14.5 mg/kg IV daily on days -6 and -5; for 7/8 Unrelated or Haploidentical Donor, prior to transplant.
45805661|NCT05907746|Drug|Fludarabine|30 mg/m2 IV over 30 minutes daily. For 8/8 Matched Related or Unrelated Donor, fludarabine dose will be on days -4, -3, and -2. For 7/8 Unrelated or Haploidentical Donor, fludarabine dose will be on days -6, -5, -4, -3, and -2.
45654582|NCT04960969|Other|Time-restricted feeding for 4 weeks|Participants in this group will follow a time-restricted diet for 28 days. Consumption of only non-energy drinks will be allowed for 16 hours. During the 8-hour eating period, there will be no restriction on the content of the diets.
45654583|NCT04972201|Device|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
45654584|NCT02466399|Drug|POLAT-001|Subconjunctival injection
45805662|NCT05905835|Device|Synaptic Cryoablation System|The Synaptic Cryo Balloon must be used to isolate all targeted pulmonary veins. Entrance block will be confirmed in all targeted pulmonary veins (PVs) after a 20-minute waiting period or provocative testing with adenosine or isoproterenol. Any additional ablation in the LA beside PV isolation is not allowed in this protocol. Additional ablation of the cavo-tricuspid isthmus (CTI) with a conventional market-approved RF catheter is allowed only in case a typical atrial flutter is documented in prior patient history or occurs during the case (either spontaneously or inducible).
45805663|NCT05904990|Device|High Intensity Laser|High Intensity Laser
45805664|NCT05904938|Device|Lenodiar Pediatric|Medical Device made of natural substance
45805665|NCT05904938|Other|Placebo|Product appearance similar to verum without clinical efficacy
45805666|NCT05904743|Biological|Afrezza|Pharmaceutical form: powder Route of administration: inhalation
45805667|NCT05904743|Biological|insulin degludec|Pharmaceutical form: solution for injection Route of administration: subcutaneous
45805668|NCT05904743|Biological|Rapid-acting Insulin Analog|Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
45805669|NCT05904743|Biological|Basal Insulin|Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
45805670|NCT05904093|Drug|Fostamatinib|Fostamatinib will be administered orally, at a dose of 100 mg twice a day for 14 days and if tolerated, will be escalated to a dose of 150 mg, orally, twice a day for 28 days (total 42 days).
45805671|NCT05902000|Device|Carotid Stenting|Emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first) the extracranial carotid artery lesion will be left to the interventionist discretion.
45805672|NCT05902000|Procedure|Thrombectomy|Intracranial thrombectomy is an endovascular procedure. In the experimental group, thrombectomy will be completed with extracranial carotid stenting.
45805673|NCT05902000|Drug|Dual antiplatelet treatment|Dual antiplatelet therapy is administered after 24 hours of imaging follow-up excluding intracranial hemorrhagic complications. Aspirin Enteric-coated Tablets (Bay Aspirin) 100mg once a night+Clopidogrel Sulfate Tablets (Plavix) 75mg once daily. If there is no contraindication, maintain for more than 1 month, then adjust the dosing regimen according to the guidelines.
45805674|NCT05902000|Drug|Intraoperative Drug Treatment|Tirofiban is used as an adjunct to endovascular therapy. The currently recommended dosing regimen is a combined intra-catheter arterial administration of a loading dose of 0.4 μg/(kg-min) for 30 min (total dose not to exceed 1 mg)， followed by intravenous pumping of 0.1μg/(kg-min) for 24-48h, and adjustment of dosing in conjunction with CT.
45939150|NCT00201253|Other|Bronchoalveolar lavages and venipunctures only|
45939151|NCT02968238|Behavioral|Cognitive-behavioral therapy|10 weekly sessions of cognitive-behavioral therapy
45939152|NCT02968238|Behavioral|Yoga|10 weeks of biweekly yoga sessions (N = 20)
45654585|NCT02466399|Drug|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution q.d., evening
45654586|NCT03059251|Biological|Obinutuzumab|Obinutuzumab will be administered as intravenous infusion for 6 cycles (28 days per cycle): 100 milligrams (mg) on day 1 Cycle 1, 900 mg on day 2 Cycle 1, 1000 mg on days 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6.
45805675|NCT05900713|Other|dynamic neuromuscular stabilization training|DNS methods demonstrated efficacy in improving global trunk stabilizing patterns with noted gains in extremity movement and strength
45805676|NCT05900713|Other|balance exercises plus diaphragmatic breathing|The balance exercises is balance exercises while standing and walking The patient assume a semi-Fowler's position and perform diaphragmatic breathing.
45805677|NCT05900466|Drug|Metformin|500 mg Metformin ER tablets once daily in the morning for 8 weeks
45805678|NCT05900466|Drug|Placebo|Matching tablets once daily in the morning for 8 weeks
45805679|NCT05898828|Drug|Nivolumab|Nivolumab 480 mg flat dose via intravenous infusion on Day 3 of every cycle starting at Cycle 2, for intended duration of 1 year.
45805680|NCT05898828|Drug|Entinostat|Entinostat (5 mg) self-administered on Days -14 and -7 prior to the first vaccination cycle, then entinostat (3 mg) self-administered on Days 1, 8, 15, and 22 of each vaccine cycle (Cycles 1-6). Entinostat continuation for subjects with immunologic response and NED during additional 2 vaccine injections.
45805681|NCT05898828|Biological|Montanide(R) ISA-51 VG Adjuvant|H1299 cell lysate with Montanide(R) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mg lysate protein in 2-2.5 mL Montanide(R) ISA-51 VG adjuvant; lysate concentration will be 8-10 mg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
45939153|NCT00201331|Drug|leucovorin+5-FU|
45939154|NCT00048672|Drug|Gleevec|Starting dose of 400 mg orally daily.
45939155|NCT00061412|Behavioral|Comprehensive program to improve reading and writing skills|
45939156|NCT00201682|Drug|Etanercept|25 mg SQ twice weekly weeks 1-5
45939157|NCT00201682|Drug|Rituximab|(375 mg/m2) Using Stepped-Up Dosing Thrice Weekly, weeks 2-5
45939158|NCT00410332|Drug|Traumeel S|homeopathic remedy
45939159|NCT00410332|Drug|Placebo|placebo drug, identical in size, form and taste as treatment remedy
45939160|NCT00048711|Drug|N-acetylgalactosamine 4-sulfatase|
45654587|NCT04936191|Device|DynamX Bioadaptor|Patients received percutaneous coronary intervention in a similar way to a traditional DES. Patients first receive radial artery or femoral artery cannulation with anticoagulation during the intervention. All coronary angiograms are carefully measured by at least 2 orthographic views and performed under the same standard conditions. After adequate predilatation of the target lesion, the coronary stenting will be performed. All patients will receive a loading dose of acetylsalicylic acid and a P2Y12 inhibitor pre-procedure followed by dual antiplatelet therapy for at least 6 months.
45654588|NCT04970251|Drug|Aflibercept Ophthalmic|Panretinal photocoagulation and intravitreal aflibercept (2 mg/0.05 ml) injection were given, and trabeculectomy with mitomycin C was performed within 2 weeks after intravitreal aflibercept injection.
45939161|NCT00410371|Drug|Lamotrigine|Lamotrigine
45939162|NCT00410371|Drug|GI267119|25 mg ODT
45939163|NCT00410449|Drug|Alpha tocopherol|
45805682|NCT05898828|Biological|H1299 Cell Lysates|H1299 cell lysate with Montanide(R) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mg lysate protein in 2-2.5 mL Montanide(R) ISA-51 VG adjuvant; lysate concentration will be 8-10 mg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
45805683|NCT05898646|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
45805684|NCT05898646|Biological|Daratumumab|Given SC
45939164|NCT00061451|Drug|Pemetrexed|
46074250|NCT02811900|Procedure|Sleeve gastrectomy|Laparoscopic SG is performed as following: after greater curvature mobilization, the gastric tube was calibrated over a 36F bougie and transection started approximately 5-6 cm from the pylorus toward the left diaphragmatic crus, using successive firings of 3.5- or 4.8-mm-high staples, depending on gastric thickness.
46074251|NCT02811900|Procedure|Gastric banding|Laparoscopic gastric banding is performed as following: a perigastric tunel is performed by blunt dissection and the banding is calibrated over the stomach.
45654589|NCT04201353|Behavioral|Conditional Cash Transfer|The intervention is a monthly cash transfer of 22,500 Tanzanian Shillings (~$10) for up to 6 months conditional on visit attendance.
45654590|NCT03058861|Behavioral|Play Nicely Program|Play Nicely multimedia program and handbook that provides education about healthy discipline strategies.
45654591|NCT04970017|Radiation|Cardiac MRI, Echocardiography|Magnetic resonance imaging, Echocardiography
45805685|NCT05898646|Procedure|Echocardiography|Undergo echocardiography
45805686|NCT05898646|Other|Questionnaire Administration|Ancillary studies
45805687|NCT05898646|Procedure|X-Ray Imaging|Undergo x-ray imaging
45805688|NCT05897268|Procedure|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
45939165|NCT00061451|Drug|Gemcitabine|
45939166|NCT00410527|Drug|Merrem|
45939167|NCT00221377|Device|Intubation using tracheal tubes with or without cuff|
45939168|NCT00048750|Drug|Micafungin|IV
45939169|NCT00048750|Drug|Placebo|IV
45939170|NCT00221416|Drug|Aripiprazole|5-20 mg/day
45939171|NCT02968316|Other|BIA measurement|observation only
45939172|NCT00221455|Behavioral|Patient diabetic self-management using the diabetic patient portal tools|
46074252|NCT02811900|Procedure|Intragastric balloon|Flexible endoscopy is used to place intragastric balloon for a maximum interval of six months.
46074253|NCT00961259|Drug|Fenofibric Acid 35 mg Tablet|1 x 35 mg tablet administered after an overnight fast of at least 10 hours
45939173|NCT00221455|Behavioral|A variety of educational interventions for non-adopters of the technology, and for non-compliant patients.|
45939174|NCT00221494|Drug|citalopram + tiodothyronine, or + pindolol, or + placebo|
45939175|NCT00061490|Behavioral|Behavioral weight control and lifestyle exercise|16 weekly educational meetings vs. waitlist control
45939176|NCT00221611|Drug|Administration of intrathecal baclofen|
45939177|NCT00221650|Drug|Peginterferon alfa2a|
45939178|NCT00221650|Drug|Ribavirin|
45939179|NCT00048789|Procedure|Extracorporeal Photopheresis|
45939180|NCT00221689|Drug|baclofen (drug)|
45939181|NCT02968121|Drug|Brexpiprazole, OPDC-34712|
45939182|NCT00221728|Device|Radiofrequency|
45939183|NCT00221728|Procedure|conservative surgery|
45939184|NCT00221767|Device|Brindley technique (bladder system)|Sacral posterior rhizotomies and implantation of Brindley device on sacral anterior roots
45939185|NCT00221806|Device|endothelialised prosthesis|
45939186|NCT00412789|Drug|Patupilone|
45939187|NCT00048828|Drug|Olanzapine|Participants will receive olanzapine for 12 weeks.
45939188|NCT00048828|Drug|Clozapine|Participants will receive 12 weeks of clozapine.
45939189|NCT00061529|Drug|Brimonidine Tartrate Ophthalmic Solution|
45939190|NCT00412906|Drug|Escherichia Coli Endotoxin|
45939191|NCT00221845|Drug|ACE Inhibition|ACE inhibitor ramipril (6 mg/m²/day) will be given to all subjects.
45939192|NCT00221845|Drug|Intensified Blood Pressure Control|Any antihypertensive drugs except ACE inhibitors and angiotensin receptor blockers will be allowed.
46074254|NCT00961259|Drug|Fenofibric Acid 35 mg Tablet|3 x 35 mg tablets administered after an overnight fast of at least 10 hours
45805689|NCT05897268|Drug|Tislelizumab|a PD-1 immune check inhibitor
45805690|NCT05897268|Drug|Lenvatinib|Lenvatinib capsules
45805691|NCT05897177|Behavioral|Subjective Scale of Stigma and Discrimination (SISD).|"Subjective Scale of Stigma and Discrimination (SISD) A sixdimension self-administered scale will be used that included statements with which the participants agreed or disagreed. The scale consists of 23 Likert-type items and responses range from 1 (completely in disagreement) to 5 (completely in agreement), grouped together to represent the six indicators making up this part of the scale"
45805692|NCT05896020|Drug|SHR- A1811|Subjects with gynaecological malignancies
45805693|NCT05895929|Drug|Mepolizumab|In vitro exposure of human nasal epithelial cells to mepolizumab
45654592|NCT02465931|Other|Paper and Pencil Informed Consent|Paper-based informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, simplified overview of informed consent form will be provided in person just once. For MacArthur Competence Assessment Tool (MacCAT) Questions, All questions will be asked after the disclosure information has been presented. Questions will have the same wording as experimental condition. Procedures will mimic MacCAT/flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). There will be multiple choice options rather than open-ended. Finally, data collection will be done through paper and pencil.
45805694|NCT05895773|Drug|Povidone-Iodine|Povidone Iodine 0.5% plus glycyrrhizin acid 2.5 mg/ml as a nasal and an oropharyngeal spray (mint flavored) will be applied 4 times per day.
45805695|NCT05895773|Drug|Saline spray|Normal saline 0.9% as a nasal and oropharyngeal spray (Mint flavored) will be applied 4 times per day.
45805696|NCT05895266|Drug|ABBV-903|Oral Tablet
45805697|NCT05895266|Drug|Midazolam|Oral Liquid
45805698|NCT05895019|Drug|Propofol|Propofol was administered using TCI pump induction with a starting target effect concentration of 1.0ug/ml. The target concentration was increased by 0.2-0.5ug/ml if the patient did not reach unconsciousness after 1 min of stabilization of the target concentration. The propofol concentration recorded at this time was the target concentration the patient was induced to unconsciousness. The state of consciousness was tested every 60 s by the investigator, and clinical trial data were collected for 5 min; after that, clinical trial data were recorded before and after induction of anesthesia at 5 min after induction of anesthesia, at intubation and skin dissection, and 1, 3, and 5 min after intubation and skin dissection, respectively.
45805699|NCT05894473|Other|Motor-Motor Dual Task Physical Exercises|Only physical exercise and motor dual tasks will be given
45805700|NCT05893342|Diagnostic Test|Preoperative frailty diagnostic|The preoperative evaluation of the patient will be carried out through the application of different scales that evaluate frailty (Edmonton frailty test, Barthel Index, Mini-mental test, Charlson Index) and a postoperative follow-up will be carried out for the diagnosis of complications during the first 90 postoperative days.
45805701|NCT05893056|Procedure|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
45805702|NCT05893056|Drug|Tislelizumab|a PD-1 immune check inhibitor
45805703|NCT05893056|Drug|Lenvatinib|Lenvatinib capsules
45805704|NCT05891626|Behavioral|Group intervention|"An enhanced electronic reminder mechanism specialized on vaccines and actively highlight vaccine standing orders in the system.~Set up a data benchmarks, so clinic managers or providers are able to aggregate immunization data, red flag missed opportunities, and facilitate modifying vaccine promotion plans.~Other components:~missed opportunities and doubts/hesitancy about immunization as a whole;~specific questions with regard to specific vaccines;~health conditions and socioeconomic/demographic vulnerabilities (insufficient resources in health literacy, linguistic or cultural considerations); and~challenges in patient-clinician interactions. These components will be addressed through team training/meetings, pamphlets, physician-led speech in online videos, and group messages via MyChart on the clinic level."
45805705|NCT05891548|Drug|CLS-AX|CLS-AX will be administered by suprachoroidal injection into the study eye on Day 1 and then every 12 to 24 weeks as determined by protocol-defined disease activity criteria.
45805706|NCT05891548|Drug|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 8 weeks (Q8W).
45805707|NCT05891379|Drug|Inebilizumab|Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inelizumab is given during IVMP.
45805708|NCT05891379|Drug|oral immunosuppressant|Oral immunosuppressants (azathioprine or mycolate mofetil) are initiated during IVMP.
45805709|NCT05890729|Drug|XTMAB-16 or Placebo|Infusion
45939193|NCT00221845|Drug|Add-on Angiotensin Receptor Blockade|In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication.
45939194|NCT00085761|Drug|Capsaicin Dermal Patch|
45939195|NCT00221884|Procedure|Ultrasound|
45805710|NCT05889650|Procedure|External Lumbar drainage|ELD @ 15 or 20mmHg based on intervention arm with maximum of 10ml/hour drainage
45805711|NCT05889546|Procedure|Biospecimen Collection|Lung, liver, skin, subcutaneous metastases, and blood specimens may be collected via rapid autopsy within 10 hours of expiration.
45805712|NCT05889182|Drug|Upadacitinib|Oral Tablets
45805713|NCT05889182|Drug|Placebo|Oral Tablets
45805714|NCT05888324|Other|Questionnaires|Questionnaires by phone at 1 and 6 months after inclusion
45805715|NCT05888311|Device|Liquid bandage|Two 3x3cm areas will be marked on the forearm of the subjects (1 area for treatment and 1 will be kept as a control, without treatment, according to randomization). Within each marked area, a circular marking will be made in an area of 1.5 cm² in diameter. After marking, 0.003 mg of powdered activated carbon will be applied. During application, the technician will wrap the index finger with a piece of plastic film and apply the charcoal by pressing constantly to ensure homogeneity. Excess activated carbon will be removed with a blower. The experimental product will be applied to the area with charcoal that will be the treatment area, according to randomization. The experimental product will be applied to the area by a technician. After the application of the powdered activated carbon, the experimental product will be applied with a brush applicator in one of the previously randomized areas. The amount of product applied corresponds to a mass of 0.015 g to 0.020 g.
45939196|NCT02968199|Behavioral|A brief intervention|The content of the intervention includes: (1) asking about tobacco use; (2) advising cessation; (3) assessing willingness to quit; (4) assisting in the attempt to quit; and (5) arranging follow-up.
45939197|NCT00221962|Drug|Aripiprazole|Open label
45939198|NCT02968160|Drug|Telmisartan 40mg + Rosuvastatin 20mg|
45939199|NCT02968160|Drug|Telmisartan 80mg + Rosuvastatin 20mg|
45939200|NCT02968160|Drug|Telmisartan 40mg, 80 mg|
45939201|NCT02968160|Drug|Rosuvastatin 20mg|
45939202|NCT00222040|Radiation|Ultrasound|2-MHz, low intensity transcranial ultrasound
45939203|NCT00222040|Drug|Levovist|D-Galactose and palmitic palmitique intravenous 4 g
45939204|NCT00222079|Drug|Esomeprazole (Nexium)|
45939205|NCT00085878|Drug|SB-485232|
46074255|NCT00961259|Drug|Fenofibric Acid 105 mg Tablet|105 mg tablet administered after an overnight fast of at least 10 hours
45939206|NCT00222118|Behavioral|labor/birth preparation classes|prenatally, peer counselor/advanced practice nurse team, hospital visit, peer counselor telephone support for 4 weeks
45654593|NCT02465931|Other|Digital Informed Consent Tool|Paper informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, the participant can go through the tablet-based tool up to 3 times. All questions will be embedded within the vignettes/presentation of disclosure information. Question will use simplified wording, similar to flipchart. Procedures will mimic MacArthur Competence Assessment Tool (MacCAT) /flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). Multiple choice options will be utilized rather than open-ended. Finally, response data stored within tool and exported to dataset for analysis.
45805716|NCT05888311|Other|Activated carbon|Two 3x3 cm areas will be marked on the forearm (anterior region) of the subjects (1 area for treatment and 1 area that will be kept as a control, no treatment, according to randomization). Within each marked area, a circular marking will be made in an area 1.5 cm² in diameter (about one inch). After marking, 0.003 mg of powdered activated carbon will be applied to the demarcated circular areas. The activated carbon will be applied by a trained technician. During application, the technician will wrap the index finger with a piece of plastic wrap (for better sliding of the charcoal) and apply the charcoal by pressing constantly to ensure homogeneity during application. Excess activated charcoal in the application areas will be removed with a rubber hand blower (Bellows).
45939207|NCT00222118|Other|intervention|prenatal classes and phone calls from peer counselor, peer counselor/lactatin consultant, hospital visit, telephone support to 4 weeks postpartum
45939208|NCT00222118|Other|usual care|no intervention
45939209|NCT00222196|Procedure|lifestyle, PTA|
45939210|NCT00222235|Drug|d-cycloserine|
45654594|NCT04961125|Genetic|germline variants|Variants of 139 genes associated with different hereditary cancers and polyposis were screened by next-generation sequencing.
45654595|NCT04201197|Drug|Inje cocktail|Acute drug exposure
45939211|NCT00222235|Drug|glycine|
45939212|NCT00222235|Drug|placebo|
45939213|NCT00222274|Behavioral|RSA Biofeedback|RSA Biofeedback Condition. The biofeedback will consist of 10 weekly sessions of training, at the same time of day for each subject. The details of the procedure for RSA biofeedback are described in Appendix A. One single practitioner, a certified biofeedback technician, will provide the biofeedback following the aforementioned protocol. In each session, 20 minutes of biofeedback will be delivered using a J&J C-2+ Physiograph. The participant will be taught to breathe at her resonant frequency, as a first step to training the individual how to produce maximal increases in amplitude of RSA.
46074256|NCT00852865|Drug|Lactobacillus farciminis|1 capsule per day. Each capsule containing 4*109 CFU
46074257|NCT00852865|Drug|Placebo|1 capsule per day
46074258|NCT02807688|Behavioral|Health Promotion Intervention|"The intervention package consists of the following elements:~i. educational sessions on the importance of diet and fitness; ii. motivational interviews to maintain participants in the program, to discuss participants' physical conditions, habits and opinions as to diet and fitness; iii. monitoring the participation in the program and health behaviour, specifically for diet and fitness, and adherence to the intervention on diet and fitness; iv. regular physical exercise under the guide and supervision of an expert trainer."
46074259|NCT04283747|Diagnostic Test|Serum immunoglobulin titer|Serum IgG and IgM levels, VZV titer every 6 month at before rituximab administration 3 times
45654596|NCT04201197|Drug|THC Cannabis extract|Acute drug exposure
45654597|NCT04201197|Drug|THC/CBD Cannabis Extract|Acute drug exposure
45654598|NCT04970329|Drug|Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. and Dextran 0.1%Hypromellose 0.3%,|Drugs will be given to two group and third group will kept on placebo.
45654599|NCT02465463|Procedure|Fecal microbiota transplant (FMT)|250 mL of donor stool will be infused into the colon by flexible sigmoidoscopy
45654600|NCT02465463|Device|flexible sigmoidoscopy|
45654601|NCT04970095|Device|Maxillary Expander with Differential Opening (EDO)|The EDO is designed with two expansion screws positioned transversely. When more expansion is required between the canines, the anterior screw can be further activated. Both expansion screws can be activated to open in a parallel configuration. Pivoting corner screws allow for different amounts of expansion without significant risk of binding during activation.
45654602|NCT04970095|Device|Petit Face Mask|"The face mask is anatomical, multi-adjustable, lightweight and an ideal therapeutic alternative for the correction of Class III malocclusion.~consist of forehead cap chin cap cross bar"
45654603|NCT04960657|Drug|glibenclamide|Oral administration of glibenclamide/placebo. To investigate the role of PACAP38 on cranial arteries in healthy volunteers after glibenclamide/placebo administration .
45654604|NCT04960657|Drug|PACAP38|PACAP38 infusion
45654605|NCT02464059|Drug|Vitamin D3|Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks in individuals with reduced vitamin D levels.
45654606|NCT04969159|Other|no intervention|standard treatment in the clinical routine
45654607|NCT04960501|Procedure|New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella|New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella
45654608|NCT04960423|Procedure|Long Segment Fixation and Fusion|Long Segment Fixation and Fusion
45654609|NCT02463357|Dietary Supplement|Quercetin|
45654610|NCT02463357|Drug|Nifedipine extended release|
45805717|NCT05888207|Drug|Savolitinib|Savolitinib will be administered as a single oral dose on Day 1 of Period 1 and on Day 5 of Period 2.
45805718|NCT05888207|Drug|Fluvoxamine|Only fluvoxamine will be administered as a twice daily oral dose from Days 1 to 4 of Period 2. On Day 5 of Period 2, subject will receive a twice daily oral dose of fluvoxamine along with savolitinib. On Day 6 of Period 2, subject will receive a twice daily oral dose of fluvoxamine alone.
45654611|NCT02463357|Drug|Methazolamide|
45654612|NCT02463357|Drug|Metformin|
45805719|NCT05884554|Drug|PF-07817883|Experimental
45654613|NCT02463357|Drug|Placebo|
45939214|NCT00222274|Behavioral|EEG Biofeedback Condition|EEG Biofeedback Condition. Participants assigned to this condition will receive 10 sessions of EEG alpha biofeedback. In each session, 20 minutes of biofeedback will be delivered using a J&J I-330-C2+ physiograph. The participant will learn how to modify specific brainwave activity known as alpha. In particular, participants will be taught to increase amplitude of alpha in the range of 8-12 Hz. Increased amplitude is this range is associated with relaxation and reduction of anxiety, but not baroreflex gain. Participants will also practice for two 20-minute periods daily using the same methods used to increase alpha found in lab sessions.
45939215|NCT00061646|Drug|ABT-510/Thrombospondin-1 mimetic|
45939216|NCT00061646|Drug|Carboplatin/Taxol|
45939217|NCT00222352|Diagnostic Test|Point of Care cTnL testing|"The study design will be a phase IV prospective, randomized (1:1), parallel-group trial utilizing concurrent controls. The experimental group of interest will be patients receiving the POC cTnI test, and the control group will be patients receiving the central laboratory cTnI test.~The treating physician will be blinded to the randomization and will receive only the POC results from half the study patients and only the laboratory results for the remaining half."
45939218|NCT00085956|Drug|Arzoxifene|
45939219|NCT00085956|Drug|Placebo|
45939220|NCT00222430|Procedure|Fluoroscopy|Use of fluoroscopy during arterial insertion of coronary catheter
45939221|NCT00222430|Procedure|Active Comparator|Standard coronary angiography technique; no fluoroscopic assistance
45805720|NCT05884398|Drug|Apalutamide|Apalutamide will be administered orally from Day 1 of Cycle 1 till 6 months in initial treatment phase and then in main treatment phase from Day 1 of Cycle 7 up to at least 18 months.
45805721|NCT05884398|Drug|Androgen-deprivation Therapy (ADT)|The choice of ADT will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
45805722|NCT05883852|Drug|Docetaxel|Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer
45939222|NCT00222469|Drug|bevacizumab|10mg/kg IV on Day 1 Q 2 weeks
45939223|NCT00222469|Drug|gemcitabine|1000mg/m2 as fixed-rate infusion at 10mg/m2/min on Day 1 and Q 2 weeks.
45939224|NCT00222469|Drug|oxaliplatin|100mg/m2 on Day 2 and Q 2 weeks.
45939225|NCT00222547|Drug|Vitamin A|
45939226|NCT00222547|Drug|Albendazole|
45939227|NCT00086034|Drug|Motexafin gadolinium|
45939228|NCT02968082|Drug|Scopolamine|Patch will be applied under the ear of the opposite side of operation, at 9 p.m. of the day before the operation day. Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at a recovery room and the ward. After that, nausea will be continuously assessed every 4 hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will also be counted. Basic clinical characteristics and the number of antiemetic administration will be identified through medical records.
45654614|NCT02463357|Drug|Nitrite|
45654615|NCT04960345|Device|Brainlab Knee 3|Brainlab knee 3 navigation system is a kind of imageless computer-assisted navigation system.
45654616|NCT02579759|Drug|PXT3003 dose 1|Liquid oral solution, 5 ml twice a day, morning and evening with food
45654617|NCT02579759|Drug|PXT3003 dose 2|Liquid oral solution, 5 ml twice a day, morning and evening with food
45654618|NCT02579759|Drug|placebo|Liquid oral solution, 5 ml twice a day, morning and evening with food
45654619|NCT04960189|Procedure|Acupuncture|Acupuncture will be performed bilateral on fibular aspect of the leg, in the depression anterior and distal to the head of the fibula by using 0,25x50mm needles.
45654620|NCT04935255|Other|Blood sampling - Pharmacokinetic assessment|Two pharmacokinetic assessments will be performed (on day 2 and day 4). Each pharmacokinetic assessment consists of 10 samples (5 ml blood).
45654621|NCT04960267|Device|Use of pre-peritoneal drainage after rTAPP|Use of pre-peritoneal drainage after rTAPP
45654622|NCT04960033|Behavioral|FRAX|The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was ≥20% or the 10-year probability of HF was ≥3%.
45654623|NCT04952935|Procedure|True Acupuncture|Delivery of four acupuncture seeds (no needles involved) to the head and neck area at true acupuncture points.
45654624|NCT04952935|Procedure|Sham Acupuncture|Delivery of four acupuncture seeds (no needles involved) to the head and neck area at non-acupuncture points.
45805723|NCT05883852|Drug|carboplatin|Carboplatin is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.
45805724|NCT05883852|Drug|Trastuzumab|Trastuzumab is a humanized monoclonal antibody derived from recombinant DNA,
45805725|NCT05883852|Drug|Pertuzumab|Pertuzumab is a recombinant humanized monoclonal antibody that specifically binds to the extracellular dimerization domain (subdomain Ⅱ) of epidermal growth factor receptor 2(HER2).
46074260|NCT00861679|Procedure|Transplantation with Stem Cells from Umbilical Cord|"According to results from published experiences in children following suggestions are given:~Number of Cells:~Number of nucleated cells infused exceed 2,5x10*7/kg recipient BW or~Number of nucleated cells collected exceed 3x10*7/kg BW~Number of CD34+ cells infused exceed 2x10*5/kg Recipient BW~GVHD-prophylaxis:~• MSD: CSA 3 mg/kg as described in the protocol + Prednisolone 1 mg/kg (day O to day 15, then tapering until day 28)~• UD: as above + additional immunosuppression according to local protocols; ATG might increase risk of infectious complication and might be replaced by other drugs according to local protocols.~HLA-matching for unrelated CB: a matched UB is defined by 6/6 HLA matches (A, B antigenic medium resolution and DRB1 allelic) and allocate to the transplantation group MD. Less than 6/6 HLA matches allocate the patient to the MMD group.~If many choices available ABO- major incompatibility should be avoided."
46074261|NCT04111926|Drug|Dexmedetomidine|A loading dose of dexmedetomidine (0.6 μg/kg) was administered during a 10-minute period before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery.
45939229|NCT02968082|Drug|Placebo|Patch will be applied under the ear of the opposite side of operation, at 9 p.m. of the day before the operation day. Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at a recovery room and the ward. After that, nausea will be continuously assessed every 4 hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will also be counted. Basic clinical characteristics and the number of antiemetic administration will be identified through medical records.
46074262|NCT04111926|Drug|Placebo|Volume-matched normal saline was administered in the same rate for the same duration as in the intervention group.
45458032|NCT02309476|Device|PASCAL Laser, 70% Yellow Laser 0.75|"Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
45654625|NCT04895111|Diagnostic Test|Endobronchial ultrasound strain elastography|Measurement of tissue elasticity of hilar and mediastinal lymph nodes through strain elastography measured during an endonbronchial ultrasound examination
45654626|NCT04150939|Procedure|Core Biopsy|Undergo core biospy
45654627|NCT04150939|Procedure|Cryosurgery|Undergo cryoablation
45654628|NCT04150939|Drug|Immunotherapeutic Agent|Receive standard of care immunotherapy
45654629|NCT05600465|Behavioral|Behavioral Activation + Occupational Therapy|In the BA-OT Approach, the PI will use an evidence-based 4-step process (Goal-Plan-Do-Check) to assist the older adults to develop strategies to plan and execute daily health self-management activities. BA-OT teaches older adults with MCC and functional limitations to 1) set achievable and meaningful activity goals, 2) engage in action planning that includes brainstorming strategies to overcome barriers, 3) evaluate the results after performing the activity, and 4) to modify the plan or choose a new goal, then generalize strategies to new problems. By assisting participants to develop daily routines and integrate safe health self-management activities into these routines, occupational therapists are providing strategies that support adaptation in the face of stressful situations.. Goal examples may include adapting and scheduling exercise plans, or exploring assistive devices and strategies for safe and healthy meal preparation.
45939230|NCT00222625|Drug|rFVIIa + (vit K in AO patients)|
45654630|NCT05600465|Behavioral|Enhanced Usual Care|Fitbit, 1 hour training, handout on managing chronic conditions
45654631|NCT04969393|Device|High intensity laser therapy|"Fifteen treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 5 weeks in succession via EXAND MY 1064 nm Laser system, Mectronic Medicale, Italy. Patients in group (A) received HILT along with the conventional physical therapy program. The session involved 3 subphases: (1) The Initial phase Analgesic phase, (2) In the intermediate phase Trigger point phaseand (3)The final phase Bio-stimulation phase was applied for 6 minutes with a slow scanning in several parallel longitudinal lines."
45654632|NCT04969393|Other|Conventional Physical Therapy|Fifteen treatment sessions that involved using a neutral custom volar splint alongside neural and tendon gliding exercises. the splint was used at night and while performing strenuous activities during the day for 5 weeks. While nerve and tendon gliding exercises was repeated 10 times at each session and patients were encouraged to apply exercise 3-5 times per day for 5 weeks.
45654633|NCT04960111|Device|RSA|application of tantalium microsphere around knee prosthesis and RSA X-ray post operative to detect early mobilization in follow up.
45654634|NCT04888169|Device|SMART Mobile App - Attention Bias Modification|ABM involves placing the probe behind the neutral stimulus on 100% of the trials.
45654635|NCT04888169|Device|SMART Mobile App - Attention Control Training|ACT involves placing the probe behind the neutral stimulus on 50% of trials, and behind the threat stimulus on 50% of trials.
45654636|NCT04888169|Device|SMART Mobile App - Placebo Training|Placebo training only includes neutral stimuli.
45805726|NCT05883852|Drug|Epirubicin|Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.
45805727|NCT05883852|Drug|cyclophosphamide|An anticancer (antitumor or cytotoxic) chemotherapy drug that is classified as an alkylating agent. Alkylating agents are compounds that prevent the normal connection of the double helix chain by adding an alkyl group to the guanine base of the DNA molecule. It causes breaks in DNA strands, affecting the ability of cancer cells to proliferate.
45939231|NCT00222625|Drug|FFP or aPCC+ vit K in AO treated patients|
46074263|NCT04041349|Drug|mouse nerve growth factor|mouse nerve growth factor of 20 UG (9000 U)/day for 14 consecutive days by intramuscular injection
45654637|NCT04888169|Device|SMART Mobile App - Control|Participants will only answer questions.
45939232|NCT00222664|Biological|Hep-V Vax|
45939233|NCT00222703|Behavioral|Smoking relapse prevention|
45939234|NCT00222742|Procedure|induced moderate hypothermia|Subjects assigned to the treatment arm will be cooled to 32-33 °C for 48 hours and then slowly warmed.
46074264|NCT00961181|Device|Paclitaxel Releasing Balloon|Percutaneous coronary intervention with paclitaxel releasing balloon
45939235|NCT02968043|Other|physiotherapeutic scoliosis specific exercises|Physiotherapeutic scoliosis specific exercises (PSSE) is recommended as a first step in the treatment of AIS to halt curve progression by SOSORT guidelines. The PSSE program will be personalized according to the subject's curves characteristics. The program includes patient and family education, 3D self-correction, stabilizing exercises, balance training, breathing exercises, and training in activities of daily living. A physiatrist will give a detailed explanation of the aims, importance, methods, and procedure of an intervention to patients and their parents. Each subject will receive guidance from multiple physiotherapists to ensure that the treatment effects are the result of the protocol and not any particular physiotherapists.
45805728|NCT05883371|Other|Root-cause autoimmune treatment program|The AndHealth autoimmune treatment program combines validated and guideline-driven approaches along with emerging evidence-based modalities. The program includes a comprehensive assessment of disease severity, analysis of root causes and comorbidities, and an evaluation of the patient's readiness for implementing important lifestyle changes. This is followed by the development of an optimized and personalized plan to achieve and sustain clinical remission while monitoring their progress. Each patient participating in the AndHealth program receives a personalized care plan developed by the patient's medical provider in collaboration with a team of healthcare specialists. Helping a patient manage everyday lifestyle decisions can have a profound effect on their ability to achieve and maintain remission. The AndHealth Program has organized these into four basic groups of lifestyle behaviors: 1.) Dietary/Nutrition, 2.) Sleep/Circadian, 3.) Stress/HPA axis, and 4.) Physical Activity.
45805729|NCT05882929|Other|Watching Cartoons|The cartoon will be watched after the child comes to the service after the operation and the postoperative period is prepared (taking the vital signs, putting on the clothes, controlling the bleeding, telling the feeding time, etc.).
45939236|NCT02968043|Other|generalised physiotherapy exercises|Generalised physiotherapy exercises includes stretching and strengthening activities. Little evidence is in favor of generalised physiotherapy exercises. Each subject will receive guidance from multiple physiotherapists.
45939237|NCT00222820|Drug|escitalopram|
45939238|NCT00222820|Behavioral|Interpersonal Psychotherapy|
45654638|NCT04968691|Other|Telerehabilitation based exercise treatment|The telerehabilitation group will be shown how to do the exercises online by the researcher before each session, 3 sessions a week for 6 weeks, with mobile telecommunication applications, and it will be ensured that the patients do the exercises correctly and are followed up. In addition, at the beginning of each week, videos with the exercise content of that week will also be sent.
45654639|NCT04968691|Other|Home based exercise treatment|n the study, exercise cards were given to the control group and the exercise treatment they were asked to do at home 3 sessions a week for 6 weeks
45939239|NCT00222898|Procedure|DNA analysis of pancreatic cyst fluid / buccal swab|
45939240|NCT00085332|Drug|docetaxel|
45939241|NCT00222937|Behavioral|Lessac-Madsen Resonant Voice Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
45939242|NCT00222937|Behavioral|Casper-Based Confidential Flow Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
45654640|NCT04959955|Diagnostic Test||
45939243|NCT00222976|Drug|Naproxen|Treatment allocation either A Naproxen PO + placebo PR or B Placebo PO + Naproxen PR
45939244|NCT00223015|Drug|Fluvastatin, Tacrolimus, Mycophenolat Mofetil|
45939245|NCT00061763|Drug|Deferasirox|
45654641|NCT04951843|Dietary Supplement|Black soybean koji product|Black soybean koji product
45654642|NCT04968769|Other|ischemic compression|manual therapy
45939246|NCT00223054|Drug|tacrolimus|retrospective analyze of drug levels in comparison to polymorphism
45654643|NCT04968769|Other|kinesio taping|elastic therapeutic taping
45939247|NCT00223054|Drug|sirolimus|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
45939248|NCT00223054|Drug|everolimus|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
45939249|NCT00223054|Drug|cyclosporin A|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
45939250|NCT00223093|Drug|TAIZ|
45939251|NCT00085371|Drug|triapine|Given IV
45939252|NCT00223132|Device|Absorbable sutures|
45939253|NCT00223210|Drug|Quetiapine|Active Quetiapine
45939254|NCT00223210|Drug|PLacebo|Placebo
45939255|NCT00061802|Drug|risperidone, quetiapine|
45939256|NCT00223249|Drug|Quetiapine|
45939257|NCT00223288|Drug|Lexapro|
45654644|NCT04968769|Other|exercise|posture exercises
45654645|NCT04952155|Drug|IL-2|The administration period was divided into 6 courses. 6 cycles of IL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks, followed by a 2-week break in treatment. The adminstration course was 24 weeks.. The 24-week follow-up period was followed after the treatment.
45654646|NCT04884971|Drug|Intestinal microbiota transplant (IMT)|Two size 00 capsules from a single lot will be taken daily. Approximately 2.0 x 10^11 bacteria from a healthy donor are contained in each capsule.
45939258|NCT00085449|Biological|alemtuzumab|
45939259|NCT00085449|Drug|cyclosporine|
45939260|NCT00085449|Drug|fludarabine phosphate|
45939261|NCT00085449|Drug|melphalan|
45939262|NCT00085449|Drug|mycophenolate mofetil|
45939263|NCT00085449|Procedure|peripheral blood stem cell transplantation|
45939264|NCT00085449|Radiation|radiation therapy|
45939265|NCT00061841|Behavioral|exercise|
45939266|NCT00223405|Device|crown placement|
45939267|NCT00223483|Genetic|Isolation of genomic DNA|One time blood draw
45939268|NCT02965209|Procedure|motorized spiral enteroscopy|Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach. When the region of interest in the small bowel is reached by NMSE standard endoscopic techniques, e.g. argon plasma coagulation (APC), forceps biopsy or endoscopic mucosal resection (EMR) are performed for treatment and/or tissue acquisition.
45939269|NCT00061880|Drug|forodesine hydrochloride|
45939270|NCT00223522|Device|MEMS caps|
45939271|NCT00223561|Drug|methylphenidate|
45939272|NCT00223600|Behavioral|Nutritional and life style counseling|
45676271|NCT04139902|Drug|Dostarlimab (TSR-042) (singly)|"If patients are randomized to Dostarlimab (TSR-042) alone, during the Pre-operative Phase, 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1.~Surgery will occur 1-4 weeks after completion of the pre-operative phase.~During the Post-operative phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks (Cycles 5-10) for approximately 48 weeks."
45939273|NCT02967770|Other|Molecularly Tailored Second Line Therapy|This trial is designed to assess the efficacy of MTT vs. SOC therapy as second-line therapy in patients with metastatic pancreatic cancer.
45939274|NCT02967770|Drug|Standard of Care Second Line Therapy|
45939275|NCT00085488|Biological|autologous tumor cell vaccine|
45939276|NCT00085488|Biological|therapeutic autologous dendritic cells|
45939277|NCT00223639|Drug|Topiramate|200mg twice a day
45939278|NCT00223717|Drug|Clonidine|0.1-0.2mg po. Single dose.
45939279|NCT00223717|Drug|Nitroglycerin transdermal|0.05-0.2 mg patch. 1 application. Alone or in combination with DDAVP.
45939280|NCT00223717|Drug|Dipyridamole/ Aspirin (Aggrenox)|dipyridamole 200 mg and aspirin 25 mg po. Single dose.
45939281|NCT00223717|Drug|Desmopressin (DDAVP)|0.2 - 0.6mg po. Single dose. Alone or in combination with nitroglycerin transdermal or nifedipine
45939282|NCT00223717|Drug|Sildenafil|25- 100 mg po. Single dose.
45939283|NCT00223717|Drug|Nifedipine|10-30 mg po. Single dose.
45805730|NCT05882929|Other|ball spin|ball squeezing will be applied after the child comes to the service after the operation and after the postoperative period preparation is made (taking the vital signs, dressing the clothes, controlling the bleeding, telling the feeding time, etc.).
45805731|NCT05882760|Drug|Tetric N Bond Universal®|Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Etch & Rinse Tetric - N - Bond (Ivoclar)
45939284|NCT00223717|Drug|Hydralazine|10-50 mg po. Single dose
45939285|NCT00223717|Drug|Hydrochlorothiazide|12.5-100 mg po. Single dose.
45939286|NCT00223717|Drug|Placebo|Po or patch. Single dose.
45939287|NCT00223717|Drug|Bosentan|62.5 -125 mg po. Single dose.
45939288|NCT00223717|Drug|Diltiazem|30-60 mg po. Single dose.
45939289|NCT00223717|Drug|Eplerenone|50-100 mg po. Single dose.
45939290|NCT00223717|Drug|guanfacine|1-3 mg po. Single dose.
45805732|NCT05882760|Drug|Self Etch Tetric N Bond Universal®|Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Self Etch Tetric N Bond Universal®
45805733|NCT05882760|Drug|GC Fuji IX, GC, Japan®|Cavities will be restored with GC Fuji IX, GC, Japan®
45939291|NCT00223717|Dietary Supplement|L-arginine|6-17 g po. Single dose
45939292|NCT00223717|Drug|captopril|25-50 mg PO. Single dose.
45939293|NCT00223717|Drug|carbidopa|25-200 mg PO. Single dose.
45939294|NCT00223717|Drug|losartan|25-200 mg PO. Single dose.
45939295|NCT00223717|Drug|metoprolol tartrate|25-100 mg PO. Single dose.
45939296|NCT00223717|Drug|nebivolol hydrochloride|2.5-40 mg PO. Single dose.
45939297|NCT00223717|Drug|prazosin hydrochloride|0.5-1 mg PO. Single dose.
45939298|NCT00223717|Drug|tamsulosin hydrochloride|0.4-0.8 mg PO. Single dose.
45939299|NCT00223717|Other|Head-up tilt.|Head of the bed elevated 10 degrees (7 inch) or whole bed tilted head-up 5 degrees in reverse trendelenburg (head of the bed elevated 7 inches)
45805734|NCT05882760|Drug|Activa TM Bioactive Restorative ®|Cavities will be restored with Activa TM Bioactive Restorative ®
45805735|NCT05882695|Drug|SPG302|synthetic small molecule
45805736|NCT05882695|Drug|Placebo|Placebo
45939300|NCT00223717|Drug|aliskiren|aliskiren (Tekturna) 150-300mg po single dose
45939301|NCT00223717|Other|Local heat stress|Passive heat-stress using a commercial heating pad applied over the abdomen and part of the torso
45939302|NCT00061919|Drug|Carboplatin, etoposide & thalidomide|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.
45939303|NCT00061919|Drug|Carboplatin, etoposide & placebo|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.
45939304|NCT00223756|Other|Low Vision Intervention - Outpatient Training Program|Patients receive LV therapy as outpatients
45939305|NCT00085527|Drug|depsipeptide|
45939306|NCT00223834|Behavioral|single session of Motivational Interviewing|
45939307|NCT00223873|Procedure|Penile Vibratory Stimulation|
45939308|NCT00223912|Device|ERGYS BikeFunctional Electrical Stimulation Ergometry|A
45939309|NCT00061958|Drug|arsenic trioxide|Given IV
45939310|NCT00223951|Drug|R89674 (generic name not yet established)|
45939311|NCT00224068|Drug|Sodium ferric gluconate, ferrous sulfate, standard of care|
45939312|NCT00224146|Drug|oxybutynin transdermal delivery system (Oxytrol(r))|
45939313|NCT00061997|Dietary Supplement|inositol|
45939314|NCT00224185|Procedure|Bronchopulmonary Lung Lavage|Lung Lavage is a Washing. Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways. Once the fluid has been collected, the fluid is centrifuged and the cells are collected and counted.
45939315|NCT00224185|Procedure|Bronchial Brushing|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently (in up to 20 different sites in the large and small airways) to obtain epithelial cells lining the airway. Cells collected by airway brushing will be washed, counted, and evaluated for viability. They will also be studied for differential cell count by standard procedures. Collected airway cells will be used to carry out studies assess expression of various genes and to study viral gene transfer.
46074265|NCT02807610|Drug|Inj Etomidate|Induction of anesthesia using IV Etomidate 0.3mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0'.2mg kg-1 and IV Fentanyl 2ug kg-1.
45654647|NCT04959721|Combination Product|Injection with triamcinolone acetonide, bupivacaine, and normal saline|"Triamcinolone acetonide is a synthetic corticosteroid medication used intra-articularly to treat various joint conditions. Bupivacaine is a medication used to decrease feeling in a specific area. In nerve blocks, it is injected around a nerve that supplies the area, or into the spinal canal's epidural space. Saline is most commonly used as a sterile 9 g of salt per litre (0.9%) solution, known as normal saline.~The procedure will be performed with the patient in a prone position under a C-arm fluoroscopy scanner, with the thorax rests on 2 pillows, flexing the neck maximally, and the head turns 60-90° away from the side of injection. The C-arm tube will be angled cephalad, until it was at a tangent to the cervical facet joint space. A 26-gauge, 90 mm spinal needle will be inserted parallel to the C-arm beam. To confirm intra-articular placement of the needle tip, an arthrogram of the cervical facet joint will be performed by injecting 0.3 mL of contrast."
45654648|NCT04717739|Device|TTFields|Tumor Treating Fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
45805737|NCT05881538|Other|Exercise group|Participants will perform a 16-week High Intensity Interval Training exercise program, twice a week. The intervention will be conducted telematically with real time supervision.
45939316|NCT00224185|Procedure|Bronchial Wall Biopsy|This is a safe and widely used investigative method in pulmonary medicine. In this procedure, a small biopsy forceps is passed through the bronchoscope and, under direct vision, a small biopsy (in up to 5 sites) is obtained from the bronchial wall. A biopsy obtains tissue to a depth of 2-3 mm, and includes epithelial and subepithelial tissue.
45805738|NCT05881200|Device|Magnetic mitohormesis|"The BIXEPS machine employs gentle pulsed magnetic signals specifically tuned to activate the natural powerhouse (mitochondria) within muscle. Brief 10-minute MM sessions with the device recreate similar biological and metabolic effects as exercise, but without physical stress or strain. It is intended to improve the strength and function of users, promoting overall fitness and well-being. Just like exercise, these effects accumulate with time.~Subjects will receive 12 sessions of 10 minute treatments"
45939317|NCT00085722|Procedure|Dextrose Prolotherapy|Injection procedure: 50% dextrose is diluted with .9% 'normal' saline and 1% lidocaine to achieve 15% dextrose for ligament injections and 25% dextrose for intra-articular injection.
45939318|NCT00085722|Procedure|Saline Prolotherapy|7 mL 9% 'normal' saline and 3mL 1% lidocaine
45939319|NCT00085722|Other|At-home physical therapy exercise group|Subjects in the at-home physical therapy exercise group will receive a patient information pamphlet about knee osteoarthritis and conservative care instructions for standard at-home physical therapy exercises
45939320|NCT00062036|Biological|aldesleukin|
45939321|NCT00062036|Biological|filgrastim|
45939322|NCT00062036|Biological|incomplete Freund's adjuvant|
45939323|NCT00062036|Biological|interleukin-2 gene|
45939324|NCT00062036|Biological|therapeutic tumor infiltrating lymphocytes|
45939325|NCT00062036|Drug|cyclophosphamide|
45939326|NCT00062036|Drug|fludarabine phosphate|
45939327|NCT00224263|Drug|Lingzhi (Ganoderma)|
45939328|NCT00224302|Drug|Duloxetine|
46074266|NCT02807610|Drug|Injection Propofol|Induction of anesthesia using IV Propofol 2mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0.2mg kg-1 and IV Fentanyl 2ug kg-1
45939329|NCT00224341|Device|Pacemaker Vitatron Selection 9000|
46074267|NCT02807610|Drug|Placebo for Propofol|After premedication with IV midazolam 0.2mg/kg and IV Fentanyl 2ug/kg Placebo was given.
46074268|NCT00861835|Other|ROSE|rapid on-site evaluation by cytopathology
46074269|NCT04041661|Other|Active tDCS plus gait training|Participants in experimental group will accept Active tDCS which combined with treadmill
45458033|NCT02309476|Device|PASCAL Laser, 70% Yellow Laser 1|"Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
45939330|NCT00224341|Device|Pacemaker Vitatron T70|
45939331|NCT00062075|Drug|romidepsin|Given IV
45939332|NCT04729062|Drug|Pegcetacoplan|Complement (C3) Inhibitor
45939333|NCT00224380|Behavioral|Using Medications Effectively|
45939334|NCT00224419|Behavioral|Motivational interviewing for smoking cessation|All participants received a tailored CBT (TCBT) intervention that included: a written self-help guide, info about the importance of reducing nicotine exposure to the fetus, 5 face to face and 1 telephone counseling session. Women in the TCBT + NRT arm were guided through a process of deciding on nicotine gum, lozenge or patch. To minimize fetal exposure, the dose of NRT was customized to the woman's current level of smoking. Women who smoked 5-10 cigarettes a day were given the 14 mg patch or instructed to use one 2 mg lozenge or 2 mg piece of gum to replace each cigarette she usually smoked per day. Those who smoked 11 cigarettes or more per day were given the 21 mg patch or instructed to use no more than one lozenge (2 mg) or piece of gum (2 mg) to replace each cigarette she usually smoked per day, not to exceed 15 lozenges or pieces of gum per day.
45939335|NCT00224419|Behavioral|Cognitive behaviors therapy|6 counseling sessions delivered over the phone or in person
45939336|NCT00224419|Drug|CBT + NRT|Includes CBT from arm 1 plus choice of NRT (lozenge, gum, or patch) tailored to smoking amount
45939337|NCT00224458|Drug|Truvada|
45939338|NCT00224458|Drug|efavirenz|
45939339|NCT00062114|Biological|rituximab|
45939340|NCT00062114|Radiation|yttrium Y 90 ibritumomab tiuxetan|
45939341|NCT00224497|Drug|SB-742457|
45939342|NCT00095043|Drug|MK0928, gaboxadol|
45939343|NCT00095043|Drug|Comparator: placebo|
45939344|NCT00224536|Procedure|Intracoronary bone marrow cell transfer|
46074270|NCT04041661|Other|Sham tDCS plus gait training|Participants in control group will accept Sham tDCS which combined with treadmill
46074271|NCT00857077|Drug|Sulfadoxine-pyrimethamine|
46074272|NCT00857077|Drug|Placebo|
45939345|NCT00224575|Other|diagnosis reassessment|Strategy of diagnosis reassessment following a decision tree.
45939346|NCT00224575|Other|Diagnosis strategy and subsequent therapeutic reassessment|Performed by geriatricians, following a decision tree, based on medical history, electrocardiogram, cardiac echotomography and stress scintigraphy
45939347|NCT04722133|Drug|HERZUMA+mFOLFOX|Herzuma (Trastuzumab-pkrb) 4mg/kg after 6mg/kg loading D1 5FU 400mg/m2 bolus+2400mg/m2 infusion for 46 hrs D1 Leucovorin 200mg/m2 D1 Oxaliplatin 85mg/m2 D1 every 2 weeks
45939348|NCT00095082|Drug|insulin detemir|
45939349|NCT00095082|Drug|insulin glargine|
45939350|NCT00095082|Drug|insulin aspart|
45939351|NCT00224614|Procedure|Allogenic transplantation|
45939352|NCT00062231|Drug|amoxicillin-clavulanate potassium|
45654649|NCT04959565|Behavioral|Nutritional behavioral intervention|The participants will get access to an online platform where the FUEL recovery program will be initiated with session 1 immediately after baseline testing and the athletes are requested to follow the lectures lead by highly experienced sports dietitians for the respective weeks. Every other week for 16 weeks (8 sessions in total) participants will be offered individual nutrition counselling (one intervention group) by highly experienced sports nutritionists in each country, based on Motivational Interviewing, the individual's environmental and biological prerequisites, and the Transtheoretical Model, focusing on the individual's readiness to act on a new healthier behavior
45654650|NCT04959565|Behavioral|Nutritional behavioral intervention|The participants will get access to an online platform where the FUEL recovery program will be initiated with session 1 immediately after baseline testing and the athletes are requested to follow the lectures lead by highly experienced sports dietitians for the respective weeks.
45939353|NCT00062231|Drug|ciprofloxacin|
45939354|NCT00062231|Drug|moxifloxacin hydrochloride|
45939355|NCT00062231|Procedure|management of therapy complications|
45939356|NCT00224653|Procedure|Mechanical Ventilation|
45939357|NCT00224692|Drug|Low dose ketamine|
45939358|NCT00224809|Drug|Angiotensin-Converting Enzyme Inhibitors|
45939359|NCT00224809|Procedure|Coronary Artery Bypass Graft|
45654651|NCT04968613|Drug|Madopar monotherapy|In addition to basic treatment, the patient also received Madopar treatment
45939360|NCT00224809|Drug|Angiotensin Receptor Blockers|
45654652|NCT04968613|Drug|senfrol monotherapy|In addition to the basic treatment, the patient also received the rofosson treatment
45654653|NCT04968613|Drug|placebo monotherapy|In addition to basic treatment, the patient also received selegiline treatment
45805739|NCT05880537|Biological|Nexeon Arterial Venous Allograft|Nexeon AVX allograft for hemodialysis access in end stage renal disease
45805740|NCT05879913|Device|Coronary CT Angiography (CCTA)|Coronary computed tomographic angiography (CCTA) scan is a highly accurate noninvasive technique for detection of coronary artery plaque.
45805741|NCT05879484|Drug|pembrolizumab|"Phase Ib: Pembrolizumab 200mg will be administered by IV infusion every 3 weeks.~Phase II: Pembrolizumab 200mg will be administered by IV infusion every 3 weeks."
45939361|NCT00224809|Drug|Spironolactone|
45939362|NCT00224809|Drug|Aspirin|
45939363|NCT00224809|Drug|Clopidogrel|
45939364|NCT00224809|Procedure|Surgical Ventricular Restoration|
45939365|NCT00224848|Behavioral|Palm-Pilot Intervention|"Both groups received guideline dissemination, patient activation materials, continuing education (CE) and feedback based on baseline chart audit. The intervention included academic detailing (AD) and a hand-held computerized decision support tool that provided patient-specific, ATPIII-based risk stratification and treatment recommendations. CE sessions offered information relevant to ATPIII and JNC7 and focused on the evidence base. AD offerings focused on strategies to apply concepts to practice and were specific to the randomized arm. Investigators visited each practice at baseline to educate physicians about the guideline and evidence supporting prevention of CVD, and to provide training on use of the Palm tool. Visits were conducted as lunch and learn sessions. The tool was a modified version of NHLBI's PDA decision support program and indicates specific drug therapies and dosages needed to achieve cholesterol reduction and prints documentation. A user's manual was developed."
45654654|NCT04968535|Device|StimaWELL|mid frequent electrotherapy mat covering the whole spinal cord with different stimulation protocols installed
45805742|NCT05879484|Drug|valemetostat|"Phase Ib: Valemetostat will be given orally every day of every cycle (DL-1: 100mg, DL1: 150mg, DL2: 200mg).~Phase II: Valemetostat will be given orally daily at the recommended phase 2 dose."
45805743|NCT05879458|Drug|Ritlecitinib|200 mg QD for 8 weeks followed by 100 mg for 16 weeks
45939366|NCT00095160|Drug|852A|
45939367|NCT00062270|Drug|cisplatin|
45939368|NCT00062270|Drug|docetaxel|
45939369|NCT00062270|Drug|gefitinib|
45939370|NCT00062270|Drug|gemcitabine hydrochloride|
45939371|NCT00062270|Procedure|conventional surgery|
45939372|NCT00062270|Procedure|neoadjuvant therapy|
45939373|NCT00062270|Radiation|radiation therapy|
45939374|NCT00224926|Procedure|Scalp Brushing|sterile, soft-head toothbrush massaged on scalp
45939375|NCT00413023|Drug|GW679769|
45939376|NCT00095277|Drug|Darbepoetin Alfa|
45939377|NCT00062309|Radiation|radiation therapy|
45939378|NCT00413101|Drug|epoetin beta [NeoRecormon]|At a dose to achieve and maintain an Hb level of 120-135g/L
45939379|NCT00413179|Drug|Metformin|
45939380|NCT00413179|Drug|Clomiphene citrate|
45939381|NCT00413179|Drug|Placebo|
45939382|NCT00413257|Drug|Nefopam|0,3mg/kg IV bolus preoperative and 65 µg/kg/h during H48 postoperative
45939383|NCT00413257|Drug|néfopam|bolus Néfopam (0,3mg/kg) during 10 min at the end of surgery and 65 µg/kg/h during postoperative H48
45939384|NCT00413257|Drug|Placebo comparator|bolus NaCl during 10 min at the end of surgery and during postoperative H48
45939385|NCT00062348|Drug|boronophenylalanine-fructose complex|
45654655|NCT03058549|Behavioral|Family Expectations|Relationship education and referral services for expectant couples.
45939386|NCT00062348|Drug|sodium borocaptate|
45654656|NCT04676555|Drug|Ocrelizumab|There is no treatment allocation. Patients administered Ocrelizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
45939387|NCT00062348|Procedure|conventional surgery|
45939388|NCT00224965|Behavioral|Behavior Therapy|
45939389|NCT00095316|Drug|Caspofungin|Caspofungin is an antifungal agent of the echinocandin class of glucan synthase inhibitor. Subjects receive Caspofungin acetate 50mg/day IV for 28 days.
45939390|NCT00095316|Other|Placebo|Normal saline equivalent to that used to deliver the caspofungin given intravenously as a single daily dose infused over approximately 1 hour for 28 days
46074273|NCT00629993|Behavioral|Academic Detailing|It will involve multiple intervention components, some of which are standardized across physicians (i.e., self learning packets, post-tests for CME credit, CD-ROMS, videos, newsletters, culturally sensitive patient education materials, office staff informational sessions, chart and patient reminders, and a general office routine for cervical cancer counseling, including performance feedback, as well as media-ready materials). Academic detailing and the specific office routines will be customized to each physician, although the frequency of the detailing visits will be routinized across all participants, to reduce cost and to maximize its potential for dissemination.
46074274|NCT02808624|Drug|L-CARNOSINE|L-CARNOSINE is a supplement given with chemotherapy to prevent peripheral neuropathy.
46074275|NCT00857155|Other|Clopidogrel withdraw prior to CABG|Patients on clopidogrel are stratified into time-based platelet function recovery groups as determined by point of care methods and based on these groups clopidogrel is withdrawn at a pre-specified timepoint before surgery.
46074276|NCT02860013|Device|Telemedicine|
45654657|NCT04676555|Drug|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
45654658|NCT02445963|Biological|Shigella flexneri 2a InvaplexAR|The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.
45654659|NCT04314167|Drug|Lowering cholesterol concentrations by PCSK-9 inhibitor|Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
45654660|NCT04968301|Device|ultrasound Doppler|A cross-sectional study:the development of the hip joint was studied by measuring the anatomical circumference of the capsular muscle of the iliac joint with ultrasound Doppler
45654661|NCT05575427|Drug|Minocycline|The patients will receive minocycline oral between 7-28 days
45654662|NCT05575427|Drug|Levofloxacin or Cotrimoxazole|The patients will receive levofloxacin or cotrimoxazole oral between 7-28 days
45654663|NCT05575427|Drug|Placebo|Capsule without active compound
45654664|NCT03059095|Behavioral|Yoga & Meditation|Yoga is an ancient Indian science and way of life that includes the practice of specific postures, regulated breathing, and meditation.mindfulness-based stress reduction, an intervention that teaches individuals to attend to the present moment in a nonjudgmental, accepting manner
45654665|NCT04959253|Combination Product|Psilocybin assisted therapy|A package of psychological therapy and a single dosing session of psilocybin.
45939391|NCT00225004|Procedure|DEXA scan|orto
45654666|NCT04959253|Combination Product|Placebo assisted therapy|A package of psychological therapy and a single dosing session of placebo.
45805744|NCT05879432|Drug|LSALT Peptide|LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity, potentially minimizing off-target or other adverse effects. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
46074277|NCT02544685|Dietary Supplement|Probio-Fix Inum|"Dose of Probio-Fix Inum: 1 capsule daily first 14 days + 1 capsule twice daily for the rest of prophylaxis duration~Probio-Fix Inum: each capsule contains 2.7 billion lyophilized probiotic bacteria Lactobacillus rhamnosus GG, LGG, American Type Culture Collection (ATCC) 53103 and Bifidobacterium animalis subspecies. lactis BB-12 Chr. Hansen Beneo Synergy 1: oligofructose-enriched inulin"
46074278|NCT02544685|Dietary Supplement|Beneo Synergy 1|Dose of Beneo Synergy 1: depends on the age of the patient (full dose variation: 0,2g/100ml milk formula - 12g/daily), gradually increased as tolerated by the patient every 2-3 days in first 8-12 days
46074279|NCT02544685|Other|Placebo|Same dosage regimen as active drugs
46074280|NCT04264091|Other|Observational|Observational
45939392|NCT00225043|Drug|Epinephrine/phenylephrine|
45939393|NCT00225082|Drug|Nucleoside analogue switch|stavudine switched to tenofovir
45939394|NCT00062387|Drug|perifosine|
45939395|NCT00225121|Drug|PF-00299804|investigational drug by oral route (escalating doses depending on safety) administered until progression
46074281|NCT02808468|Behavioral|Brief Cognitive Therapy|Cognitive strategies to help achieve balanced thinking around sexual assault and alcohol use
45939396|NCT00095355|Drug|Lithium|
45654667|NCT02499159|Drug|Liposomal Bupivicaine|266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.
45654668|NCT02499159|Drug|0.25% standard bupivicaine|standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.
45654669|NCT01664039|Drug|Travoprost 0.004% ophthalmic solution|Ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad® preservative
45805745|NCT05879432|Drug|Placebo|0.9% saline solution
45805746|NCT05878938|Drug|NNC0365-3769 (Mim8) PPX|Participants will receive Mim8 PPX once-weekly dosing (QW), once every two weeks dosing (Q2W), or once-monthly dosing s.c. injection using a prefilled fixed dose DV3407-C1 pen-injector for 26 weeks.
45805747|NCT05878067|Drug|ABBV-444|Eye drops
45654670|NCT01664039|Drug|Bimatoprost 0.01% ophthalmic solution|Ophthalmic solution containing benzalkonium chloride (BAK)
45939397|NCT00095355|Drug|Divalproex|
45939398|NCT00225160|Drug|acetyl L-carnitine|
45939399|NCT00225199|Drug|Visanne (BAY86-5258, SH T00660AA)|orally once daily
45939400|NCT00225199|Drug|Placebo|orally once daily
45939401|NCT00225238|Drug|esomeprazole (PPI)|
45939402|NCT00062426|Biological|bevacizumab|
45939403|NCT00062426|Drug|capecitabine|
45939404|NCT00062426|Drug|fluorouracil|
45939405|NCT00062426|Drug|leucovorin calcium|
45939406|NCT00062426|Drug|oxaliplatin|
45939407|NCT00225316|Procedure|Acupuncture|See Detailed Description.
45939408|NCT00095433|Drug|rhuFab V2 (ranibizumab)|
45939409|NCT00225355|Drug|Rosiglitazone|
45939410|NCT00225433|Drug|follitropin beta|Follitropin beta
45939411|NCT00225433|Drug|ganirelix acetate|Ganirelix acetate
45939412|NCT02967926|Procedure|Endoscopic Retrograde Cholangioscopy by SpyGlass (ERCS)|Digital SpyGlass Cholangioscopy to facilitate common bile duct stone removal
45939413|NCT00225472|Device|Modified Viaspan|
45654671|NCT04968145|Other|Home To Stay Mobile Health Application|"Home to stay is an integrated discharge monitoring system with a mobile application. Features of the application include a Daily Health Check to report on post-operative recovery, picture taking capability to photograph incisions/wounds and educational information on post-operative care at home.~Patients will complete a Daily Health Check on post-discharge Day #1-14, #21 and #30. The Daily Health Check consists of a series of questions specific to colorectal surgery as well as the Quality of Recovery (QoR-15) questionnaire. After completion, the participant will receive a list of recommendations tailored to their responses including relevant education modules, to contact the surgical team or in urgent cases to go to the nearest emergency room. The participants' responses will be monitored daily via a secure web site. Any participants' responses in the extreme ranges are automatically red flagged and notify the health care team that a follow up telephone call is required."
45654672|NCT02445573|Other|EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In EA group, participants were needled at bilateral BL33 at an angle of 30 to 45 degree inward and downward, and at bilateral BL35 slightly toward upside and outside, to a depth of 50 to 60 mm using acupuncture needles of size 0.30×75 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral BL33 and BL35 (using real electrodes) respectively, with a continuous wave of 50 Hz and a current intensity of 1-5 milliampere (mA) for 30 min. Participants were treated with EA 3 sessions a week on alternate days for 6 successive weeks.
45805748|NCT05876650|Other|Pilates exercises|Pilates exercises starts with warm up, followed by 6 main exercises that are Swan, Swimming, Prone press up, Dart, Arm arch and Scarecow. The session will end with the cool down exercises. Each exercise will be repeated 10 times for 5 sets. Patients will be treated 3 times per week for 4 consecutive weeks.
45805749|NCT05876650|Other|Yoga|Yoga will start with warm up followed by 6 yoga poses which are Warrior pose 1, Triangle pose, Child pose, Cow face pose, Bound angle pose, half bow poseThe session will end with a cool down pose. Each yoga pose will be held for 8-10 breathes Patients will be treated 3 times per week for 4 consecutive weeks.
45939414|NCT00095472|Drug|L-NMMA|
45939415|NCT00095472|Drug|Sodium Nitrite|
45939416|NCT02962258|Drug|Torrent's Olmesartaan medoxomil, Amlodipine and Hydrochlorothiazide Tablets|oral, crossover
45939417|NCT02962258|Drug|Tribenzor of Daichi Sankyo Inc. USA|oral, crossover
45939418|NCT00225511|Drug|Effexor XR|
45939419|NCT00225511|Drug|Milnacipran|
45939420|NCT02967809|Device|echography|cardiac and pulmonary echography
45939421|NCT00095511|Drug|aripiprazole|
45939422|NCT00225550|Drug|ADH -1 (Exherin™)|
45939423|NCT00225589|Drug|Rosuvastatin calcium|
45939424|NCT00225628|Behavioral|Computerized Reminders Medications Monitoring|
45939425|NCT00225628|Behavioral|Computerized Test Results Management Application|
45939426|NCT00225628|Behavioral|Computerized Reminders Hypertension Management|
45939427|NCT00225628|Behavioral|Computerized Reminders Osteoporosis Screening and Mgt|
45939428|NCT02967887|Drug|cisplatin and 5-fluorouracil|Hepatic arterial infusion of Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system (chemoport)
45939429|NCT00095589|Genetic|loss of heterozygosity analysis|
45939430|NCT00095589|Genetic|microarray analysis|
45939431|NCT00095589|Genetic|microsatellite instability analysis|
45939432|NCT00095589|Other|cytology specimen collection procedure|
45939433|NCT00095589|Other|laboratory biomarker analysis|
45939434|NCT00095589|Procedure|computed tomography|
45939435|NCT00095589|Procedure|cystoscopy|
45939436|NCT00225667|Drug|Irbesartan|
45939437|NCT00225706|Drug|Caldolor|
45939438|NCT00225745|Procedure|Blood draw|One blood draw prior to first treatment
45939439|NCT00225823|Drug|GW685698X|
45939440|NCT00062465|Drug|TwHF|
45939441|NCT00095667|Drug|lapatinib ditosylate|Given orally
45939442|NCT00095667|Other|laboratory biomarker analysis|Correlative studies
45939443|NCT00225862|Drug|ropinirole|
45939444|NCT00062504|Drug|Talampanel|10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks
45939445|NCT00095706|Drug|Bevacizumab (drug), Herceptin (drug)|
45939446|NCT00225901|Drug|Recombinant human hepatocyte growth factor|
45939447|NCT00225979|Drug|Octreotide LAR|
45939448|NCT00226018|Device|Hand Adapter (Organon, Oss, the Netherlands)|Randomization of acceleromyography with or without Hand Adapter to dominant or non-dominant arm. Contralateral neuromuscular transmission is measured with mechanomyography (The gold standard of neuromuscular monitoring)
45939449|NCT00226018|Device|Placebo|placebo
45654673|NCT02445573|Other|sham EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In sham EA group, participants were needled at sham BL33 and sham BL35, which were about 20 mm lateral to BL33 and BL35, respectively, with blunt needle tips piercing adhesive pads and not piercing the surface of the skin, using placebo needles of size 0.30×25 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral sham BL33 and sham BL35 (using sham electrodes) respectively. The parameters of sham EA apparatus and the treatment course were the same as in the EA group.
45654674|NCT05645705|Other|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
45654675|NCT05645705|Other|LISTERINE Cool Mint Antiseptic Mouthwash|Participants will use 20 mL of LISTERINE Cool Mint Antiseptic Mouthwash for 30 seconds after brushing twice daily.
45654676|NCT05645705|Other|Listerine Advanced Gum Alcohol|Participants will use 20 mL of Listerine Advanced Gum Alcohol Rinse for 30 seconds after brushing twice daily.
45654677|NCT05645705|Other|Listerine Advanced Gum Zero|Participants will use 20 mL of Listerine Advanced Gum Zero Rinse for 30 seconds after brushing twice daily.
45654678|NCT05645705|Other|LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint|Participants will use 20 mL of LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint Rinse for 30 seconds after brushing twice daily.
45654679|NCT04968067|Device|App group|In addition to the usual care, the participant will receive a health talk related to CHD care, a CHD app and a briefing from a trained research nurse (A). The app provides features such as structured e-educational contents and supportive features such as knowledge platform and member area.
45654680|NCT04968067|Device|Nursing telephone advice (NTA) group|All subjects will continue their usual care with prescribed medical treatments and follow-ups if any. By appointment, a trained nurse will provide a health talk related to the CHD care. In addition to the above usual care, three monthly 20-minute telephone follow-ups supplemented by take home leaflet will be provided by a trained research nurse for up to 3 months. Patients can ask about their related health problems, if any. The team has set up a telephone advice guide to support the research nurse in giving phone advice and text messages. .In summary, all two groups will receive from a nurse similar educational content as that related to their CHD and care. The only difference will be the re-enforcement and continual support provided through an app, telephone nursing advice and leaflet.
45654681|NCT05644613|Other|aerobic exercise on land|aerobic exercise on land in form of walking on the treadmill
45654682|NCT05644613|Other|aerobic exercise in water|aerobic exercises in water in form of walking on the treadmill
45654683|NCT02445339|Drug|XR-NTX+CM (Extended-Release Naltrexone plus Care Management)|The intervention arm will receive extended-release naltrexone (XR-NTX) 380mg (4 mL) to be administered as an intramuscular gluteal injection every 28 days up to 12 doses total. Expedited referral to alcohol-medical management. Care Management will include coordination of health care and social services for at least 12 months. Harm-reduction counseling and motivational interviewing to identify and work towards goals. The Standard care arm will receive an expedited alcohol-medical management referral.
45654684|NCT04951375|Procedure|arthroscopic repair|arthroscopic repair
45654685|NCT04699877|Drug|Gilteritinib|Oral
45805750|NCT05876546|Device|Liquid bandage|"The product will be applied to the right and/or left back of the research participants for three consecutive weeks. The research participants should come [to the research site] three times in a week for application/reading. (1st to 3rd week).~After this induction period, research participants will be at rest for at least 10 days. (4th to 5th week).~They should return to reapply the investigational product that will be removed after approximately 48 hours and should come [to the research site] for the readings. (6th week) Participants will undergo a final clinical dermatological evaluation to evaluate possible signs and sensations of discomfort."
45939450|NCT02967731|Drug|480 Mometasone Furoate Sinus Drug Depot|Management of Chronic Sinusitis
45939451|NCT00095745|Drug|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-30mg Aripiprazole, once daily, 52-weeks.
45939452|NCT00226057|Drug|Raptiva|Open Label
45654686|NCT04951531|Procedure|BPTB double-bundle allograft|The patient underwent surgery of arthroscopic double-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
45654687|NCT04951531|Procedure|BPTB single-bundle allograft group|The patient underwent surgery of arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
45654688|NCT04951531|Procedure|BPTB single-bundle autograft group|The patient underwent surgery of arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) autograft．
45939453|NCT00226096|Drug|Labetalol Hydrochloride|
45939454|NCT00226096|Drug|Metoprolol tartrate|
45939455|NCT00226096|Drug|Hydralazine Hydrochloride|
45939456|NCT00226096|Drug|Glycerol Trinitrate|
45939457|NCT00226096|Drug|Phentolamine mesylate|
45939458|NCT00226096|Drug|Nicardipine|
45939459|NCT00226096|Drug|Urapidil|
45939460|NCT00226096|Drug|Esmolol|
45939461|NCT00226096|Drug|Clonidine|
45939462|NCT00226096|Drug|Enalaprilat|
45939463|NCT00226096|Drug|Nitroprusside|
45939464|NCT00062543|Procedure|Hepatic artery infusion of CD34+ cells|Donor's cells infused directly into liver through a groin catheter (hepatic artery).
45939465|NCT00062543|Device|Cobe Spectra|Mononuclear cells (MNC) collected by continuous-flow centrifugation using a blood cell separator (Cobe Spectra).
45939466|NCT00226135|Drug|lithium or lamotrigine|
45939467|NCT00226174|Drug|Curcuminoids|
45939468|NCT00075348|Genetic|mutation analysis|
45939469|NCT00226213|Procedure|Peripherally Inserted Central Catheter Placement|
45939470|NCT00062582|Drug|Roflumilast|
45654689|NCT04934787|Device|ENMS-BSF assisted gait training|"ENMS-BSF will correct the foot-drop and foot inversion during post-stroke walking.~Each participant will receive 20 sessions device assisted training, with an intensity of 3-5 sessions/week, 1 hr/session.~In each session, a participant will complete the device-assisted walking on flat ground with a natural speed and with the aid of a four-pronged cane."
45939471|NCT00226252|Procedure|Instruction Only|Video details an individual propelling a manual wheelchair with biomechanically correct propulsion technique.
45939472|NCT00226252|Procedure|Instruction and Feedback|Individuals will watch video of correct propulsion technique and will receive real-time feedback from the SMART Wheel as they push their wheelchair to help optimize their propulsion technique.
45939473|NCT00400374|Drug|Erlotinib|Patients will be given Erlotinib (dose escalation from 50 mg, 75 mg, and 100 mg) once daily continuously for 6 months.
45939474|NCT00400374|Drug|Celecoxib|Celecoxib, 400 mg, daily for 6 months.
45939475|NCT00226291|Other|Synthesized evidence report|Each consultation response included a documented bibliographic search strategy with corresponding references, a targeted list of full-text articles, and a written synthesis and critique of the relevant research materials.
45939476|NCT00226330|Drug|Tesaglitazar|(0.5 or 1 mg)
45939477|NCT00226330|Drug|Pioglitazone|(15, 30 or 45 mg)
45939478|NCT00075426|Drug|arsenic trioxide|
45939479|NCT00062621|Procedure|Combined bone marrow and kidney transplant|
45939480|NCT00226369|Drug|CY-1503|
46074282|NCT04281563|Other|massage with MCT oil (group 1)|Two trained nurse took turns performing standardized massage techniques in group 1 and group 2. The difference was that in group 1, the neonates received massage with MCT oil, and in group 2, the neonates received massage without using the oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation (13), which were given three times a day for 7 consecutive days. The massage force was approximately 300 grams, and the massager practiced applying the pressure by using a food scale. The massage was given in the prone and supine positions, and the actions included gentle touching of the head, back and limbs for five 1-min periods, followed by six passive flexion/extension movements lasting 10 s apiece for each arm, then each leg, and finally both legs together for a total of five 1-min periods. Premature infants in the oil massage group received massage with 10 mL/kg/day of MCT oil divided equally into three applications.
45654690|NCT04951765|Drug|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
45654691|NCT04951765|Drug|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
45654692|NCT04951765|Drug|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
45654693|NCT04951765|Drug|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
45654694|NCT04951765|Drug|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
45805751|NCT05876546|Device|Saline Solution|"The product will be applied to the right and/or left back of the research participants for three consecutive weeks. The research participants should come [to the research site] three times in a week for application/reading. (1st to 3rd week).~After this induction period, research participants will be at rest for at least 10 days. (4th to 5th week).~They should return to reapply the investigational product that will be removed after approximately 48 hours and should come [to the research site] for the readings. (6th week) Participants will undergo a final clinical dermatological evaluation to evaluate possible signs and sensations of discomfort."
45805752|NCT05875467|Other|SE3 Game|A prototype online game designed to increase environmental health literacy
45939481|NCT00226408|Drug|Interferon-alpha-2b|
45939482|NCT00226447|Drug|Pegylated Interferon|
45939483|NCT00226447|Drug|Lamivudine|
45939484|NCT00062660|Drug|Tipranavir|Tipranavir 250 mg soft elastic capsules
45939485|NCT00413296|Drug|levetiracetam|Tablets, dosage 500 mg each ( 1-6 tablets/day)for20 wks
45939486|NCT00413296|Drug|Placebo|Placebo, Tablets, no active ingredient in the tablets, (1-6tablets/day)for 12 wks in the 2nd phase of the study.
45939487|NCT00413296|Drug|Levetriracetam|Tablets, 500 mg each (1-6 tablets/day) for 8 wks during the open label phase and for 12 wks during the 2nd phase of the study.
45939488|NCT02965482|Device|Wright Nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
45939489|NCT02965482|Device|Aerogen Solo Nebulizer|Aerogen Ltd., Galway, Ireland
45939490|NCT00413452|Drug|Etanercept|50 mg once weekly
45939491|NCT00413491|Procedure|MR mammography|MR mammography
45939492|NCT00413491|Procedure|MR|MR
45939493|NCT00226486|Other|multifactorial intervention|Identification of medical, cardiovascular, physical risk factors for falls; e.g. vision, drug-use, depression, carotid sinus syndrome, orthostatic hypotension, etc. Individual intervention; treatment of disease, drug review, pacemaker, exercises, new glasses, all if indicated.
45939494|NCT00226486|Other|Usual care|No intervention, but ususal care after an accidental fall.
45939495|NCT00226525|Procedure|skin sensitivity test|
45939496|NCT00095823|Drug|Antidepressant + Placebo|Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
46074283|NCT02811588|Device|Non-invasive ventilation|
45805753|NCT05875090|Diagnostic Test|Glaucoma Screening|Non-invasive diagnostic techniques will screen subjects in primary care setting for the existence of Glaucoma and categorised them in a binary system: referrable vs non-referrable to a Hospital-based Glaucoma Clinic
45939497|NCT00095823|Drug|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
45939498|NCT00226564|Drug|Alfentanil|
45939499|NCT00062699|Drug|Zemplar (paricalcitol injection)|
45939500|NCT00062699|Drug|Calcijex|
45939501|NCT00226603|Behavioral|Specific training programme (behavior)|
45939502|NCT00226642|Drug|Sertralin|
45939503|NCT00226642|Behavioral|Cognitive-behavioral therapy|
45939504|NCT00226642|Drug|Placebo|
45939505|NCT00226642|Behavioral|Non-specific supporting group therapy|
45939506|NCT02962453|Device|Morning walk|gait training with Morning walk three times during 5 minutes with 5 minute break a day over 5 weekdays
45939507|NCT02962453|Device|Ground Walker|gait training with ground walker until corresponding 200 steps during 5 minutes with 5 minute break a day over 5 weekdays
46074284|NCT00857467|Drug|NRL001|Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 1 g rectal suppository, with a 7-day washout period between dosing.
46074285|NCT00857467|Drug|NRL001|Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository, with a 7-day washout period between dosing.
46074286|NCT00817635|Drug|LCI699|LCI699 oral capsules
45805754|NCT05874843|Diagnostic Test|Thromboelastography (TEG 6S)|The TEG 6s assays are performed in a microfluidic cartridge which only requires a small amount of a patient's blood be transferred to the cartridge for analysis. The vibration frequency of the blood meniscus at which resonance occurs is used to create a clot dynamics tracing.
45805755|NCT05873205|Biological|Isatuximab|All participants enrolled on the study will receive isatuximab intravenously as a single agent
45805756|NCT05872360|Dietary Supplement|Bundle Group 1 with Nutrilite Lifestyle|All-plant protein booster: 2 spoons (15g), twice per day. Calcium & Magnesium：3 tablets one time per day. Glucosamine: 2 tablets two times per day. 20 minutes training with EMS (Electric Muscle Stimulation) per day. Practice according to Nutrilite Lifestyle Guideline per day.
45939508|NCT02965521|Behavioral|Website and text messages|Participants receive a personalized diet report, access to a digital health dietary intervention, and text messages for 12 weeks.
45805757|NCT05872360|Dietary Supplement|Bundle Group 2 without Nutrilite Lifestyle|All-plant protein booster: 2 spoons (15g), twice per day. Calcium & Magnesium：3 tablets one time per day. Glucosamine: 2 tablets two times per day. 20 minutes training with EMS (Electric Muscle Stimulation) per day.
45805758|NCT05872360|Dietary Supplement|Control Group 1|Placebo: 2 spoons (15g), twice per day. Placebo for Calcium & Magnesium：3 tablets one time per day. Placebo for Glucosamine: 2 tablets two times per day.
45805759|NCT05872360|Dietary Supplement|Control Group 2 with Nutrilite Lifestyle|Placebo: 2 spoons (15g), twice per day. Placebo for Calcium & Magnesium：3 tablets one time per day. Placebo for Glucosamine: 2 tablets two times per day. Practice according to Nutrilite Lifestyle Guideline per day.
45939509|NCT00226681|Behavioral|Nursing Telephone Support Protocol|
46074287|NCT00817635|Drug|Eplerenone|Eplerenone oral capsules
46074288|NCT00817635|Drug|LCI699-matching Placebo|LCI699-matching placebo oral capsules
46074289|NCT00817635|Drug|Eplerenone-matching Placebo|Eplerenone-matching placebo oral capsules
46074290|NCT02861339|Device|Opthalmologic measure with DM OPD scan III (Nidek)|Bilateral measure of corneal refractometry, pachymetry, topography and aberrometry
46074291|NCT00853177|Procedure|MEOPA inhalation|N2O of 50% and 50% O2
45654695|NCT04951765|Drug|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
45654696|NCT03674931|Behavioral|musical practice|Intensive weekly musical keyboard training over 12 months
45654697|NCT03674931|Behavioral|music education|Recreative weekly musical courses without practice over 12 months
45654698|NCT04959409|Drug|Topical analgesia (EMLA or AMETOP)|Whether topical analgesia has or has not been administered to each child prior to them receiving an inhalational induction of anaesthesia
45654699|NCT03058939|Drug|Paclitaxel|Administered to all patients for a minimum of 8 doses with a possible maximum of 16 doses.
45805760|NCT05871606|Drug|iNO|Inhaled Nitrous Oxide
45805761|NCT05870839|Biological|VXCO-100|Sterile liquid for injection
45805762|NCT05868668|Device|Focused shockwave|Storz Duolith SD-1 (Storz Medical, Tagerwilen, Switzerland)
45939510|NCT00226681|Behavioral|Usual Care|
45939511|NCT00226720|Procedure|Outpatient detoxification program|Outpatient detoxification program
45939512|NCT00226798|Drug|Capecitabine (Xeloda)|
45939513|NCT00399243|Drug|Sumatriptan 4mg Statdose injection|4mg Sumatriptan Statdose injection for use as acute therapy in a cluster headache. Consistency of response in three attacks will be measured
45939514|NCT00226837|Drug|Nitrous oxide|nitrous oxide by inhalation during induction
45939515|NCT00226915|Drug|Paclitaxel+Carboplatin|Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
45939516|NCT00226915|Drug|Paclitaxel+Carboplatin|Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles
45939517|NCT02967497|Drug|YQ1|Oral administered powder
45939518|NCT00095862|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|
45939519|NCT00095862|Biological|recombinant interferon alfa|
45939520|NCT00095862|Drug|cyclophosphamide|
45939521|NCT00226954|Drug|zoledronic acid|
45939522|NCT00226993|Drug|CPG 7909|
46074292|NCT00853177|Procedure|xylocaine|Ampoule-bottle of 20 ml
46074293|NCT02861495|Device|Humeral Compression/Distraction (CD) Nail|Surgical fixation of humeral shaft fractures with Humeral Compression/Distraction (CD) Nail implant
46074294|NCT00924079|Drug|nalbuphine|oral dosage form, 66 mg, single dose
46074295|NCT04264247|Diagnostic Test|routine fetal ultrasonography at 11-14 weeks|routine fetal ultrasonography at 11-14 weeks
45654700|NCT03058939|Drug|Perjeta|Only administered to patients with HER2-positive disease.
45805763|NCT05868668|Device|Radial wave|Zimmer enPuls Pro (Zimmer MedizinSysteme GmbH, Neu-Ulm, Germany)
45939523|NCT00227032|Drug|erlotinib hydrochloride|"300 mg, per day for subjects taking EIAEDs~150 mg, per day for those NOT taking EIAEDs"
45939524|NCT00062855|Procedure|Skin Biopsy|
45939525|NCT00062855|Genetic|Gene Modified Neuroblastoma Cells|"The first two injections will be given at week 1 and week 2 (i.e., separated by one week). Patients will then have a two-week rest and the remaining two injections will be given (again separated by one week) at week 4 and week 5.~A complete evaluation for evidence of toxicity and response will be performed at week 8 (after a 3 week rest).~At the 8 week (month 2) evaluation, in the absence of progressive disease requiring therapy without excessive toxicity and if more transduced cells are available, the patient will have the option to receive four additional SC injections each separated by 1 month at the higher of the two dosage levels they originally received."
45458034|NCT02309476|Device|PASCAL Laser, 40% Yellow Laser 0.75|"Pascal EM at 40% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
45805764|NCT05868668|Device|Sham treatment|Handheld sham probe
45939526|NCT00227071|Behavioral|exercise|
45805765|NCT05866406|Behavioral|Time restricted eating|Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.
45939527|NCT00095901|Drug|Capecitabine|
45939528|NCT00227110|Drug|Pioglitazone|30 mg/d for 8 weeks and titrated to 45 mg/d until completing 6 months of treatment.
45939529|NCT00227110|Drug|Placebo|Placebo is given to match pioglitazone.
45939530|NCT00062894|Drug|Iodine I 131 Tositumomab|
45939531|NCT00227188|Drug|Pneumococcal 7-valent conjugate vaccine Prevnar|
45805766|NCT05866406|Behavioral|Extended eating window|Participants assigned to the control group will have to consume all their daily meals and snacks during a 14-hour window for 12 weeks.
45805767|NCT05866406|Behavioral|Healthy diet|Participants will be provided nutrition education and counselling to follow a diet consistent with the existing guidelines for chronic disease prevention.
45805768|NCT05863702|Behavioral|Penny|The chatbot will assist patients who have not been see for cancer follow-up care, with scheduling follow-up appointments, labs, scans, specialty appointments, and monitor compliance with the appointments made.
45939532|NCT00096057|Biological|monoclonal antibody HuHMFG1|
45939533|NCT00227383|Device|Electroacupuncture (device)|
45939534|NCT00227422|Biological|Mencevax ACWY|
45939535|NCT00062933|Procedure|Laparotomy|
45939536|NCT00227461|Drug|Wait first, then levetiracetam|Levetiracetam 250 mg orally twice daily for 7 days. This will increase to 500 mg oral twice daily for 7 days the following week. If this dose is tolerated, it will then be increased to 750 mg orally twice daily for another 7 days and then increased to 1000 mg orally twice daily for 7 days.
45939537|NCT00227461|Drug|Levetiracetam first, then wait|subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design
45939538|NCT00227500|Drug|Pravastatin|
45939539|NCT00096096|Drug|mycophenolate mofetil|
45939540|NCT00096096|Drug|tacrolimus|
45939541|NCT04721899|Dietary Supplement|Vitamin D|Vitamin D 50,000 IU once per week for 4 weeks, followed by 50,000 IU once every 2 weeks for 4 weeks
45939542|NCT00062972|Drug|donepezil|
45939543|NCT00062972|Drug|glucose|
45939544|NCT00227656|Biological|PEG-interferon alfa-2a|Once a week subcutaneous injection for 21 days, beginning at 180 mcg per week. Repeated for additional 21 days to begin at the same time as repeat 21 day Capecitabine cycle.
45939545|NCT00227656|Drug|Capecitabine|1000 mg/m^2 twice daily during first 14 days of each 3-week cycle (2 weeks on, 1 week rest).
45939546|NCT00227695|Biological|rituximab|comparing two maintenance schedules of Rituximab
45939547|NCT00096213|Procedure|conventional surgery|surgery
45939548|NCT04722289|Behavioral|Together on Diabetes|Social and emotional support'; 'Assistance in daily management'; and 'Linkage to healthcare services'
45939549|NCT00227734|Drug|capecitabine and oxaliplatin + cetuximab|cetuximab
45939550|NCT00227734|Drug|capecitabine and oxaliplatin|capecitabine and oxaliplatin without cetuximab
45939551|NCT00063011|Behavioral|Calcium rich diet|
45939552|NCT00063011|Behavioral|Weight bearing exercise|
45654701|NCT03058939|Drug|Herceptin SC|Only administered to patients with HER2-positive disease.
45654702|NCT03058939|Drug|Tamoxifen|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
45654703|NCT03058939|Drug|Letrozole|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
45654704|NCT03058939|Drug|LHRH agonist|Administered to all premenopausal patients.
45654705|NCT03058939|Drug|FEC|Only administered to patients who received paclitaxel and carboplatin, and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
45939553|NCT00227773|Drug|octreotide acetate|
45939554|NCT00227773|Drug|vatalanib|
45939555|NCT00227773|Procedure|anti-cytokine therapy|
46074296|NCT00853255|Biological|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine administered by nasal spray
45805769|NCT05862545|Drug|BGF (budesonide/glycopyrrolate/formoterol fumarate)|BGF is a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LABA and a LAMA. The decision to start treatment with BGF must be made by the treating physician according to the subjects' medical need and a positive benefit/risk balance. The decision to prescribe BGF must be independent of enrolment into the study, must be determined by the treating physician and should be taken according to the standard of current best medical practice and national guidelines.
45654706|NCT03058939|Drug|Carboplatin|Only administered to patients who receive paclitaxel and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
45805770|NCT05859529|Drug|JS002|The drug was administered by a single subcutaneous injection
45805771|NCT05859360|Other|Physical performance and cardiovascular health measures|"Retinal vessel analysis~Muscle ultrasound~Knee extension~Voluntary activation~spiroergometry"
45805772|NCT05857553|Other|Unconditional Cash Transfer|Unconditional monthly transfer of $500 to household
45805773|NCT05857553|Other|No Direct Cash Transfer|No intervention
45805774|NCT05857514|Drug|Rectal Indomethacin|Prophylactic Rectal indomethacin 100mg for prevention of post ERCP pancreatitis
45805775|NCT05857514|Procedure|Prophylactic Pancreatic duct stenting|Prophylactic pancreatic duct stenting with rectal indomethacin 100 mg for prevention of post-ERCP pancreatitis
45805776|NCT05857007|Device|Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids|Ten patients with hyperglycemia or/and diabetes in the neuro ICU requires subcutaneous insulin with concomitant high dose glucocorticoids will wear Libre 2.0 CGM for either 14 days or their stay in the neuro ICU
45676272|NCT04139902|Drug|Dostarlimab (TSR-042) and TSR-022 (combination)|"If patients are randomized to the combination, Dostarlimab (TSR-042) and TSR-022, during the Pre-operative Phase, Dostarlimab (TSR-042) 500mg and TSR-022 300mg will be administered through an IV over 30 minutes on Cycle 1 Day 1 and then again on Cycle 2 Day 1.~Surgery will occur 1-4 weeks after completion of the pre-operative phase.~During the Post-operative Phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks."
45676273|NCT04136509|Procedure|sinus floor elevation|sinus floor elevation with the lateral technique
45805777|NCT05853367|Drug|MK-0472|Oral Administration
45805778|NCT05853367|Biological|Pembrolizumab|IV infusion
45805779|NCT05852925|Other|Traditional Venipuncture|Traditional blood collection is performed and the necessary amount of blood is collected into the collection tubes (either SST or Lithium Heparin tubes based on the biomarker being tested).
45805780|NCT05852925|Device|Tasso+|The Tasso+ is the blood self-collection device used in the study and this device enables the collection of microliter capillary whole blood samples into compatible reservoirs. In this study, the reservoirs utilized include either SST or Lithium Heparin microtainers based on the biomarker being tested.
45805781|NCT05852548|Behavioral|Parent-Mediated Intervention|Children with ASD will participate in a 6-month parent-mediated intervention that will include direct intervention and parent education.
45805782|NCT05851911|Biological|sars-cov-2 vaccine or infection|Whether to vaccinate COVID-19 vaccine, or infect with sars-cov-2
45939556|NCT00227773|Procedure|antiangiogenesis therapy|
45939557|NCT00227773|Procedure|biological therapy|
45939558|NCT00227773|Procedure|endocrine therapy|
45939559|NCT00227773|Procedure|enzyme inhibitor therapy|
46074297|NCT02807532|Other|atrial fibrillation|In the case-control trial, patients with atrial fibrillation 7 days after surgery will be assigned to an atrial fibrillation group.
46074298|NCT02807532|Other|non-atrial fibrillation|In the case-control trial, patients without atrial fibrillation 7 days after surgery will be assigned to a non-atrial fibrillation group.
46074299|NCT00861991|Behavioral|Perspective taking instruction|Students were asked to take the perspective of their standardized patients during clinical skills examinations
45805783|NCT05851170|Other|The use of warm compresses and almond oil on the perineum during second stage|"Hot water from the tap at a temperature of (45-590c) will be poured into a container, and will be changed every 15 minutes.~Timing of the start: when the baby's head descends in the pelvic canal and the woman feels the need to push The intervention: warm compresses will be attached to the perineum between the pressures During the pressing - almond oil will be applied. Meanwhile, the compresses will be returned to a bowl containing hot water. Every 15 minutes until birth the water will be replaced with hot water at an initial temperature of 45-590c.~It is necessary to use compresses for a minimum of 10 minutes, and a maximum of 30 minutes."
45805784|NCT05851170|Other|Use of almond oil use (routine care) during second stage|Routine care in the department is the use of almond oil during the second stage of pregnancy, during pushing.
45939560|NCT00227773|Procedure|growth factor antagonist therapy|
45939561|NCT00227773|Procedure|hormone therapy|
45939562|NCT00227773|Procedure|protein tyrosine kinase inhibitor therapy|
45939563|NCT00227773|Procedure|somatostatin analogue therapy|
45939564|NCT00227812|Drug|Bupropion|
45939565|NCT00096291|Other|Doxorubicin followed by Paclitaxel|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel Paclitaxel followed by Doxorubicin"
45939566|NCT00096291|Other|Paclitaxel followed by Doxorubicin|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
45939567|NCT00227890|Behavioral|MI/CBT|
45939568|NCT00227890|Behavioral|RT/TU|
45939569|NCT02967302|Drug|Morphine Sulfate|active intervention
45654707|NCT04515875|Behavioral|Daily Engagement Meaningful Activity (DEMA)|This group will receive 7 individualized sessions, 1 face-to-face session at week 1 and via 6 bi weekly telephone sessions delivered by a trained intervener. DEMA will use the principles of problem-solving therapy and consistent with the overall goals of this intervention; and will provide autonomy support, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed. Each session consists: 1) MCI dyads are guided to use the principles of problem-solving therapy to review their personalized, self-selected meaningful activities and plan next steps to continue the activity, identify and establish a plan for additional activities; and 2) the intervener and dyad discuss one of the 6 topics in the Toolkit such as introducing of the intervention and meaningful activity concepts, understanding MCI, its treatments, management, resources, and planning for the future.
45939570|NCT02967302|Drug|Triamcinolone|active control
45939571|NCT02967302|Drug|placebo|placebo control
45939572|NCT00096330|Dietary Supplement|dietary intervention|oral folic acid supplementation once daily on days 57-84
45939573|NCT00096330|Dietary Supplement|folic acid|oral folic acid supplementation once daily on days 1-56.
45939574|NCT04721860|Behavioral|Backward Locomotion Treadmill Training (BLTT)|12-training sessions of reverse treadmill training (no bodyweight support) over four weeks.
45939575|NCT04721860|Behavioral|Forward Locomotion Treadmill Training (FLTT)|12-training sessions of forward treadmill training (no bodyweight support) over tfour weeks.
45676274|NCT04136509|Procedure|bone core biopsy|After 6 month healing time reentry took place and bone core biopsy samples were collected from the augmented bone of the maxillary sinuses with a trephine drill. Biopsy samples were collected from the sites where the dental implants were to be placed.
45676275|NCT04136509|Device|dental implant placement|During reentry after bone biopsy dental implants were placed.
45805785|NCT05850130|Other|Acupuncture intervention|"6 weeks of acupuncture once a week. The acupuncture intervention will consist of weekly session administered over a period of 6 weeks (± 4 days). A two-way verum acupuncture treatment protocol will employ 8 selected acupoints.~After week 7, patients included in Arm A may receive an optional 6 weeks of acupuncture. This option of acupuncture continuation will be left to the patient choice in agreement with a physician acupuncturist."
45805786|NCT05850130|Other|No acupuncture|The patient in the Arm B will not receive acupuncture treatment for a period of 6 weeks after randomization (weeks 1-6) and during the following weeks 8-13 (acupuncture intervention) if its NRS score is <4/10 at week 7. If the patient' NRS score is ≥ 4/10 at week 7, the patient in control Arm B will receive the same acupuncture intervention that the patient in the Arm A (6 weeks).
45939576|NCT02962492|Drug|Exenatide/Exenatide extended release|Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
45939577|NCT02962492|Drug|Dapagliflozin|Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
45805787|NCT05849480|Drug|oxaliplatin|Oxaliplatin (130 mg/m2) will be administered IV on Day 1 of each cycle, every 21 days (up to 6 cycles).
45805788|NCT05849480|Drug|capecitabine|Capecitabine (750 mg/m2 every 12 hours) will be administered orally with an intermittent schedule: 2 weeks on, 1 week off, of each cycle, every 21 days (up to 6 cycles).
46074300|NCT00817479|Drug|Dexamethasone|20 MG OF DEXAMETHASONE OR PLACEBO
46074301|NCT00817479|Drug|Placebo|Placebo saline
46074302|NCT02811822|Drug|GMI-1271|
46074303|NCT00853411|Drug|prednisone|Druing asthma exacerbation, subjects will be dosed to prednisone.
45805789|NCT05849480|Biological|Keytruda|Pembrolizumab (200 mg) will be given IV on Day 8 of each cycle every 21 days (up to 6 cycles).
45939578|NCT02962492|Drug|Placebo|Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
45939579|NCT00227929|Procedure|Care Management|
46074304|NCT04030533|Drug|Guselkumab (SC): Dose 1|Participants will receive a single dose of guselkumab (dose 1) subcutaneously.
46074305|NCT04030533|Drug|Guselkumab (SC): Dose 2|Participants will receive a single dose of guselkumab (dose 2) subcutaneously.
46074306|NCT04030533|Drug|Guselkumab (IV): Dose 1|Participants will receive a single IV infusion of guselkumab (dose 1).
46074307|NCT04030533|Drug|Guselkumab (IV): Dose 2|Participants will receive a single IV infusion of guselkumab (dose 2).
46074308|NCT04030533|Drug|Ustekinumab 6 mg/mL|Participants will receive a single IV infusion of ustekinumab 6 mg/mL solution.
46074309|NCT02807298|Drug|4%articaine|intraligamentary injections of 0.9 ml of 4%articaine and 1:100,000 epinephrine
46074310|NCT02807298|Drug|2% Lignocaine|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
46074311|NCT02807298|Drug|Epinephrine|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
46074312|NCT04041427|Drug|Albendazole Pill|Albendazole 400mg po
46074313|NCT04041427|Other|High fat content diet|High fat content diet
46074314|NCT04041427|Other|Moderate fat content die|Moderate fat content die
46074315|NCT00961961|Drug|Lithium / Fluoxetine|Individualized Daily Dosage
46074316|NCT00961961|Drug|Lithium / Placebo|Individualized Daily Dosage
46074317|NCT03847051|Diagnostic Test|MRI|Brain MRI without intravenous contrast
46074318|NCT02811666|Device|Assessment of sarcopenia by CT-Scan|
46074319|NCT02811666|Device|hand gauge|
45458035|NCT02309476|Device|PASCAL Laser, 40% Yellow Laser 1|"Pascal EM at 40% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
45654708|NCT04515875|Behavioral|Information Support (IS)|This group will attend 1 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer disease educational brochure from the Alzheimer's Association (AA). The face-to-face sessions will take place at the IADC Clinical Core clinic, Indiana University Center of Excellence of Women's Health clinic, or Indiana School of Nursing conference room that based on patient-caregiver dyad's preference. Then they will receive 6 bi weekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials. After completing Time 4 data collection, the patient-caregiver dyads will receive DEMA Self-Management Tool kit package through mail.
45654709|NCT03061045|Drug|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|All patients enrolled in this study will undergo contrast enhanced ultrasound examination for assessment of brain perfusion.
45654710|NCT04951297|Other|None, just observation|None ,just observation test
45654711|NCT03058471|Drug|Methotrexate|methotrexate arm will be given methotrexate starting at 10 mg weekly to be increased to 25 mg maximum in subsequent visits gradually
45939580|NCT00063050|Behavioral|Physical activity and nutrition intervention|
45805790|NCT05849480|Biological|CDX-1140|CDX-1140 (0.36-1.5 mg/kg; per assigned dose level) will be given IV on Day 8 of each cycle every 21 days (up to 6 cycles).
45805791|NCT05849467|Drug|89 Zr-Df-crefmirlimab|"an 80 kDa minibody (Mb) with high~affinity to CD8 glycoprotein (binding EC50 = 0.4 nM) that is conjugated with deferoxamine (Df)~and radiolabeled with the positron emitting radionuclide, Zr-89 (T1/2 78.4 hours)."
45805792|NCT05846789|Drug|Carboplatin|Carboplatin will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.
45939581|NCT00227968|Behavioral|Interpersonal Social Rhythm Therapy (IPSRT)|
45805793|NCT05846789|Drug|Tocilizumab|Tocilizimab 8 mg/ actual body weight in kg IV q4 weeks
45805794|NCT05846646|Drug|IMSA101|Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
45805795|NCT05846646|Drug|Immune checkpoint inhibitor|1st infusion on Cycle 1 Day 2, and then thereafter as per product label
45805796|NCT05846646|Radiation|PULSAR|1st day of Cycles 1, 2 and 3.
45939582|NCT00227968|Behavioral|Clinical Status and Symptom Response Therapy (CSSRT)|
45939583|NCT00096369|Drug|tamoxifen citrate|
45805797|NCT05846516|Drug|VSV-GP154|Injection
45805798|NCT05846516|Drug|ATP150|Injection
45805799|NCT05846516|Drug|ATP152|Injection
45805800|NCT05846516|Drug|Ezabenlimab|Infusion
45939584|NCT00228007|Drug|Antidepressant Medication|
45939585|NCT00228046|Drug|Divalproex Sodium|
46074320|NCT02610933|Drug|rivaroxaban|replacement of vitamin K antagonist by rivaroxaban
45654712|NCT03058471|Drug|NSAID|this arm will be given NSAID to the tolerable full dose with pantoprazole
45654713|NCT03058471|Drug|Steroids|inj. depot methyl prednisolone 80 mg ,2 doses deep intramuscularly given one week apart to all patients who have 5 or more swollen or tender joints
45654714|NCT03060967|Behavioral|Computer-based tasks|Computer-based tasks designed to assess size and time discrimination capacities of food and control images
46074321|NCT02610933|Dietary Supplement|Vitamin K2|Vitamin K2 supplementation
46074322|NCT02807220|Drug|Imuneks 10mg|Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
46074323|NCT04042441|Drug|Insulin Degludec/Insulin Aspart|Insulin Degludec/Insulin Aspart (Ryzodeg®) as prescribed by the patient's treating physician. The decision to initiate or switch into treatment with commercially available Ryzodeg® has been made before, and independently from, the decision to include the patient in this study.
45654715|NCT02579603|Drug|Nintedanib|Nintedanib 150mg bid
45654716|NCT02579603|Drug|Pirfenidone|
45805801|NCT05846087|Behavioral|sleep retraining therapy|Sleep retraining therapy improves sleep efficiency (total sleep time/total time in bed) by reducing the amount of time spent in bed awake. The digitally designed version which SleepFix delivers uses an algorithm which requires the users current sleep times and ideal wake-up time to determine when one should get into bed to fall asleep and when one should get out of bed.
45805802|NCT05846087|Other|sleep health education modules|educational modules about sleep and insomnia; its causes; and its impact on various aspects of life. This information is arranged into three modules which will be provided to participants over three weeks.
45939586|NCT00228046|Drug|Methylphenidate|
45939587|NCT00228046|Drug|Dextroamphetamine|
45939588|NCT00228046|Drug|Mixed Amphetamine Salts|
45939589|NCT00228046|Behavioral|Family Counseling|
45939590|NCT00228046|Behavioral|Behavior Management Training with Parents|
45939591|NCT00063089|Drug|S. aureus Immune Globulin Intravenous (Human) 5%|
45939592|NCT00096408|Procedure|Total Abdominal Hysterectomy|For patients with clinical stage I disease, removal of the uterus and both tubes and ovaries are considered current standard treatment in Australia.
45939593|NCT00096408|Procedure|Total Laparoscopic Hysterectomy|The technique of total laparoscopic hysterectomy (TLH), utilising the McCartney tube, has been developed by Anthony J. McCartney over the last 10 years. It allows the completion of the hysterectomy entirely laparoscopically, without the need for additional vaginal surgery.
45939594|NCT00228163|Drug|teriflunomide (HMR1726)|tablet, oral administration once daily.
46074324|NCT02859935|Behavioral|Screening and feedback|Screening via questionnaires on mental health problems and feedback on the questionnaires
45654717|NCT04958629|Other|familial hypercholesterolemia|Among the selected patients with hyperlipidemia, those who met the diagnostic criteria of FH were included in the study cohort as FH group.
45939595|NCT00063128|Drug|insulin|"Administer subcutaneous regular human insulin 30 to 60 minutes before meals, or administer insulin lispro within 15 minutes before meals.~Inject into abdomen only."
45654718|NCT04958863|Other|Surgical mask|Use of a surgical mask during test
45654719|NCT04958863|Other|Polyester reusable mask|Use of a polyester reusable mask during test
45654720|NCT04416841|Behavioral|Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
45939596|NCT00063128|Drug|human insulin inhalation powder (HIIP)|"Administer HIIP within 15 minutes before meals.~Administer doses in one-capsule increments equivalent to approximately 2 IU or 6 IU of subcutaneous insulin.~Target treatment goals during the treatment sequence are the same as for patients using preprandial injectable insulin"
45805803|NCT05845645|Drug|UCB0599|Study participants will receive pre-specified doses of UCB0599 in 3 different formulations administered orally in a pre-specified sequence during the Treatment Periods of Part A and B
45805804|NCT05845645|Other|Esomeprazole|Study participants will receive fixed dose of esomeprazole administered orally in a pre-specified sequence during the Treatment Period of Part A. This is a non-investigational medicinal product (NIMP) in this study.
45939597|NCT00228241|Device|AAI vs. DDD vs. BIV pacing in different patients groups|
45654721|NCT04416841|Behavioral|Fitness Walking|Participants would take fitness walking training 1 hour/session, 3sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes fitness walking and 10 minutes cool-down exercises in the fitness walking training, the exercise intensity was 50% to 70% of the maximum heart rate. Besides, they would also take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
45939598|NCT00075465|Drug|docetaxel|
45939599|NCT00075465|Drug|epirubicin hydrochloride|
45654722|NCT04416841|Behavioral|Standard Diabetic Care Education|Participants would take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
45654723|NCT05696639|Procedure|Aneurysm embolization|All patients underwent Aneurysm embolization surgery, the cerebral venous will be observed intraoperatively.
45654724|NCT04967911|Other|Rhythmic stabilization exercises|"PNF techniques and Conventional Treatment:~Experimental group received rhythmical Stabilization Technique on shoulder joint on all shoulder movements up to 1 minute in supine position For stability of joint ,re-establish dynamic rotator cuff stability and to enhance MS strength and decrease pain.~Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps).."
45654725|NCT04967911|Other|conventional treatment|Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps)..
45654726|NCT04291079|Biological|SRK-181|anti-latent TGFβ1 monoclonal antibody
45805805|NCT05845645|Other|Placebo|Study participants will receive placebo comparator administered orally in a a pre-specified sequence during the Treatment Period of Part B.
45805806|NCT05843409|Behavioral|Mindfulness-based stress reduction (MBSR)|Mindfulness-based stress reduction may be associated with short-term effects on pain intensity and physical functioning. Patients will be randomized into 2 groups. The experimental group will receive MBSR sessions, with the frequency and duration specified in the study protocol. The sessions will be free and carried out by expert staff
45939600|NCT00228280|Procedure|Mineral Trioxide Aggregate (MTA)|retrograde rootfilling with MTA or smoothening of the orthograde root-filling, gutta-percha
45939601|NCT00228319|Dietary Supplement|Oral Ascorbic Acid|4 grams per day for 12 months
45939602|NCT00228319|Drug|Paclitaxel|Six cycles
45939603|NCT00228319|Drug|Carboplatin|Six cycles
45939604|NCT00228319|Drug|Sodium Ascorbate|Intravenous infusion at 0.5 gram/min twice weekly over 1-2 hours at a dose to achieve levels of 400 mg/dl for 12 months
45939605|NCT00228319|Dietary Supplement|Oral Mixed natural Carotenoids with Vitamin A|Capsule containing mixed carotenoids and vitamin A. Participant to take 1 daily for 12 months
45939606|NCT00228319|Dietary Supplement|Vitamin E|500 IU per capsule and participant to take 1 capsule daily for 12 months
45939607|NCT02962180|Device|Dermabrasion with dermaroller|o The dermaroller is passed on the treated depigmented area. This technique is based on tiny microwounds performed using 540 microneedles (0.2mm length) which should allow the penetration of the suspension cells into the epidermis to obtain a good repigmentation.
45939608|NCT00096525|Drug|lenalidomide|
45939609|NCT00228358|Drug|ex vivo-expanded HER2-specific T cells|Laboratory-expanded T cells, given IV
45939610|NCT00228358|Drug|cyclophosphamide|Given IV
45939611|NCT00228358|Biological|denileukin diftitox|Given IV
45939612|NCT00228358|Other|flow cytometry|Intracellular cytokine staining (correlative study)
45939613|NCT00228358|Other|immunoenzyme technique|ELIspot assay (correlative study)
45939614|NCT00228397|Drug|CCI-779|
45939615|NCT00228436|Drug|peginesatide|
45939616|NCT02967575|Device|cTDR|"The surgical procedure for the Triadyme-C total disc replacement corresponds to the standard surgical technique for cTDR:~Implantation through a standard anterior cervical approach~Midline identification~Routine discectomy with endplate preparation and decompression~Implant sizing and trial implantation~Keel preparation~Implant preparation and loading of the appropriate Triadyme-C implant~Triadyme-C insertion, positioned as close to the midline as possible"
45939617|NCT00075543|Drug|docetaxel|
45939618|NCT00075543|Drug|oxaliplatin|
45939619|NCT00228475|Drug|Pulmicort (budesonide) Turbuhaler|
45939620|NCT00228514|Drug|Rosuvastatin|
45939621|NCT00228514|Procedure|Positron emission tomography|
45654727|NCT04291079|Biological|anti-PD-(L)1 antibody therapy|approved anti-PD-(L)1 antibody therapy for each tumor type
45939622|NCT00228592|Drug|HepeX-B|
45939623|NCT00228592|Drug|Hepatitis B Immune Globulin (HBIg)|
45654728|NCT04951141|Biological|anti-GPC3 CAR-T cells|A single arm, open-label pilot study is designed to determine the safety and efficacy of anti-GPC3 CAR-T cells in patients with GPC3-positive advanced liver cancer.
45654729|NCT04283045|Behavioral|JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the TA.
46074325|NCT00817089|Drug|Placebo Oral Tablet|Placebo pill
45654730|NCT04283045|Behavioral|JASPER Plus+|"JASPER Plus+ refers to direct instruction of social communication targets of pointing to share, showing gesures, and give to share gestures, and play targets at the child's target play level.~JASPER Plus+ will occur at a table top with repeated trials of instruction until the child can produce the desired behavior on their own."
45654731|NCT03060889|Drug|Tranexamic acid|10 mg/kg body weight will be given with induction of anesthesia by intravenous infusion
45654732|NCT04578041|Device|TRPMS (Transcranial Rotating Permanent Magnet Stimulation)|"TRPMS ( is administered through a head cap worn by the participant and controlled by QHTimeStimulate application via computer tablet.~Modality: Excitatory stimulation~Frequency: 5 Hz~Interval between stimulus: 100 ms~Duration of each stimulus: 25 ms~Duration of stimulation: 40 minutes~Position of microstimulators: over primary motor cortex and supplementary motor area for Arm 1; over left and right dorsolateral prefrontal cortex for Arm 2"
45654733|NCT04578041|Other|Aerobic Exercise Program|Aerobic exercise consisting of 40 minutes of cycling training with a seated elliptical machine. The daily physical activity program will consist of three 10-minute bouts of aerobic exercise interspersed with two 5-minute bouts of rest. The participants will exercise maintaining their Heart Rate (HR) at least between 60-80% of the maximum age-related HR.
45654734|NCT04578041|Other|Computerized CT (Cognitive Training)|"Computerized cognitive training (CT) consisting of 40 minutes Brain-HQ training.~The adaptive cognitive training games also serve to engage them during the stimulation session, and to keep them seated at the computer for the entire duration of the session."
45654735|NCT04950829|Device|Conventional brackets|These brackets are used in a conventional way, where the orthodontist used to apply elastic parts to engage the arch to the slot of the brackets.
45654736|NCT04950829|Device|Self-ligating brackets|These brackets do not need to use elastic parts to engage the arch to the brackets. The orthodontist can use sliding caps to open and close the slots of these brackets.
45805807|NCT05842577|Device|VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)|The motor exercises were performed using inertial sensors for the acquisition and processing of the movement performed by the patient. The patient was trained to perform these exercises using visual and auditory feedback in a serious game environment. The exercises were aimed at the rehabilitation of balance and at the improvement of motor performance in lower limbs (e.g., maintaining balance on one leg, marching in place, standing on tiptoe, squatting, etc.). The therapists involved in the study customized the protocol of exercises in TR mode according to the characteristics and needs of the subject.
45805808|NCT05842577|Other|At-home conventional rehabilitation|The CG rehabilitation was an active comparator treatment and consisted of a written home-based self-administered booklet with conventional motor activities tailored for each subject. The motor activities were chosen and adapted from a specialized manual. The motor exercises were aimed at the rehabilitation of balance and at the improvement of motor performance in lower limbs (e.g., maintaining balance on one leg, marching in place, standing on tiptoe, squatting, etc).
45939624|NCT00063206|Drug|DVS-233 SR|
45654737|NCT04950829|Procedure|Self-Ligating Brackets with flapless corticotomy|"These brackets do not need to use elastic parts to engage the arch to the brackets. The orthodontist can use sliding caps to open and close the slots of these brackets.~Flapless corticotomy will be performed in order to stimulate acceleration in tooth movement during the orthodontic treatment in this group only."
45939625|NCT00075621|Drug|filgrastim|16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection
45939626|NCT00075621|Drug|melphalan|200 mg/kg over 2 days
45939627|NCT00075621|Procedure|autologous peripheral blood stem cell transplantation|autologous peripheral blood stem cell transplantation
45939628|NCT00413569|Procedure|cervical spine surgery|
45939629|NCT00228865|Procedure|Pulsatile IV insulin therapy|Diabetic pts are given pulsatile iv insulin on a weekly basis determined by weekly phys orders based on pt response and insulin resistance. Cognitive testing is performed quarterly to track progress
45939630|NCT00228865|Procedure|Effects of Pulsatile IV Insulin on Cognitive functions|Diabetic patients receive weekly treatment of Pulsatile Intravenous Insulin therapy. Dosage is determined each week by the patient's Endocrinologist based upon the patient's response and insulin resistance.
45939631|NCT00228904|Procedure|Placebo|Control patients diagnosed with diabetic neuropathy are tested at baseline and every six months thereafter to compare to patients treated with pulsatile intravenous insulin therapy
46074326|NCT00817089|Drug|Naltrexone|50 mg of naltrexone prior to challenge session
46074327|NCT02807064|Drug|Bifidobacteria|0.5 ml per os all days for 2 months
46074328|NCT02807064|Drug|placebo|0,5 ml per os all days for 2 months
46074329|NCT04282577|Diagnostic Test|urinary nephrin and alpha one microglobulin|urinary nephrin and alpha one microglobulin are biomarkers of glomerular filtration barrier injury and tubular injury respectively measured by ELISA
46074330|NCT02804802|Other|questionnaire|dietary habits and physical activity questionnaire
46074331|NCT00853801|Behavioral|Lifestyle intervention and provider feedback|"Patients receive lifestyle education and counseling after each visit with their primary care provider. Lifestyle modification goals are set and progress monitored. Frequency is dependent on frequency of visits with primary care provider which can range from one month to nine months.~Primary care providers of the intervention patients receive one education session at the commencement of the study covering the diagnosis and treatment of metabolic syndrome and pre-diabetes. Feedback on provider performance as assessed by provider documentation of diagnosis and treatment recommendations compared to patient outcomes is given every six months."
45654738|NCT05564195|Diagnostic Test|Postoperative cognitive function|"Digital cognitive tests - Mindmore-P, will be used to assess neurocognitive capacity and includes tests of verbal episodic memory, executive functions, visuospatial function and attention. The cognitive tests are self-administered on a touch screen tablet (10.1 20-30 min Windows). The Mindmore-P is a web-application running on a full-screen Chrome browser. The test is administered by using a capacitive touchscreen with features that record detailed information such as timing, pauses, and lifting of finger from the touchscreen. Speech recognition is used in the screening of verbal memory and language."
46074332|NCT04282499|Procedure|combined exercise|Patients will be undergone to aerobic exercises in addition to the resistance training.
45654739|NCT04951219|Drug|Resmetirom|Tablet
45676276|NCT04136509|Diagnostic Test|Cone Beam Computed Tomography scans (CBCT)|Preoperative CBCT scans are carried out before dental implant placement, 6 months after sinus floor elevations. Postoperative CBCT scans are taken 3 years after sinus floor augmentations.
45676277|NCT04136366|Drug|ADX-2191 (intravitreal methotrexate 0.8%)|ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy
45676278|NCT04136366|Other|Standard surgical care procedure|Standard surgical care performed upon completion of pars plana vitrectomy
45676279|NCT04124432|Drug|Cannabis|Cannabis will be smoked
45676280|NCT04124432|Drug|Nicotine|Nicotine will be smoked or vaporized
45805809|NCT05842122|Behavioral|Pharmacy PrEP/PEP for a fee|"Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) HIV testing, and 4) PrEP (30-day supply at initiation; 90-day supply at refill visits) or PEP dispensing (28-day supply) among those determined eligible.~Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery~Cost to client: 250 KES per pharmacy PrEP/PEP visit~Payment to pharmacy:* 0 KES per pharmacy PrEP/PEP visit *Pharmacies paid by the research team (i.e., the implementor in this trial)"
45805810|NCT05842122|Behavioral|Pharmacy PrEP/PEP for free|"Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) HIV testing, and 4) PrEP (30-day supply at initiation; 90-day supply at refill visits) or PEP dispensing (28-day supply) among those determined eligible.~Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery~Cost to client: 0 KES per pharmacy PrEP/PEP visit~Payment to pharmacy:* 250 KES per pharmacy PrEP/PEP visit *Pharmacies paid by the research team (i.e., the implementor in this trial)"
45805811|NCT05842122|Behavioral|Pharmacy PrEP/PEP for free, with HTS counselor support|"Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) HIV testing, and 4) PrEP (30-day supply at initiation; 90-day supply at refill visits) or PEP dispensing (28-day supply) among those determined eligible.~Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery with support from a HTS counselor (to assist with screening and HIV testing)~Cost to client: 0 KES per pharmacy PrEP/PEP visit~Payment to pharmacy:* 100 KES per pharmacy PrEP/PEP visit *Pharmacies paid by the research team (i.e., the implementor in this trial)"
45805812|NCT05839951|Drug|Regorafenib (BAY73-4506, Stivarga®)|Oral multitargeted kinase inhibitor
45805813|NCT05839951|Drug|TAS-102 (trifluridine and tipiracil, Lonsurf®)|Oral cytotoxic chemotherapy
45805814|NCT05839951|Drug|Bevacizumab|VEGFR inhibitor
45805815|NCT05839353|Other|SBAR training by serious game|SBAR training by serious game
45805816|NCT05838482|Device|CT Photon-Counting|Enrolled subjects will complete an exam using the photon-counting CT, with or without IV contract as indicated. Images will then be compared with the previously acquired CT conducted as standard of care.
45805817|NCT05838456|Device|Viz.AI software|Viz.AI software performs artificial intelligence-based automated detection of large vessel occlusions and alerts the AIS care team.
45805818|NCT05838287|Drug|Pioglitazone|Participants will be taking Pioglitazone tablets 1/day for 24 weeks.
45805819|NCT05838287|Drug|Placebo|Placebo for Pioglitazone
45805820|NCT05838170|Drug|Lotilaner Gel, 2.0%|Lotilaner Gel, 2.0% (TP-04) is an aqueous gel formulation of lotilaner, a member of the isoxazoline family of compounds and parasiticide that selectively inhibits parasite-specific gamma-aminobutyric acid (GABA)-gated chloride channels (GABA-Cls).
45805821|NCT05838170|Other|Vehicle control gel|Aqueous gel
46074333|NCT04282499|Procedure|aerobic exercise|Patients will be trained through the aerobic exercises only.
46074334|NCT02804958|Procedure|STEMI treated with primary PCI|Primary percutaneous coronary intervention was performed according to the current standard guidelines. Coronary angiography was performed using standard techniques. The use of thrombectomy devices, intravascular ultrasound, intra-aortic balloon pump, and percutaneous cardiopulmonary support was up to the operator.
45805822|NCT05837494|Drug|Intra-articular Ozone and corticosteroids|"patients will undergo one session a week for a total of four sessions of intra-articular knee injection with combination of 5ml (25 μg/ml) ozone injection + 2 ml lignocaine 2% + 2 ml Betamethasone sodium phosphate 4 mg.~Under aseptic precautions. A22-gauge needle was positioned inferior-laterally into the infera-patellar pouch, injection of 2 ml of 4 mg Betamethasone sodium phosphate, and 2 ml injection lignocaine 2% was injected slowly (over 1-2 minutes). The needle was left in space for the 5 ml (25 μg/ml) ozone injection. Patients were advised to avoid strenuous activity for 2-3 days following the intra-articular injection."
45939632|NCT00228904|Procedure|Pulsatile IV insulin delivery (humalog, humulin, novolog)|Patients with diagnosed diabetic neuropathy have objective testing and questionnaires performed at baseline and every six months thereafter to evaluate and analyze progress of diabetic neuropathy after start of treatment of pulsatile intravenous insulin therapy
45939633|NCT00228982|Drug|Ceftobiprole medocaril|
45805823|NCT05837494|Drug|intra-articular PRGF Method|"Patients will undergoes two doses with 2 weeks interval by injection of already synthetic plasma rich in growth factors [PRGF] vial intra-articularly.~This vial is formed of lyophilized cake of platelet growth factors in a tightly sealed container stored at 2-8◦C which synthesized under complete aseptic technique by activation of platelets to release its growth factors and cytokines which help in knee cartilage regeneration and act as potent anti-inflammatory to reduce the pain.~Prior to usage, reconstitution of the product was done using 1 ml saline and 1 ml lignocaine 2% followed by gentle vial rubbing for 3 min then, the mixture was kept at ambient temperature for 5 min to ensure complete protein re-hydration."
45805824|NCT05837481|Behavioral|Meditation|Guided meditation utilizing breath awareness, body scan and visualization techniques
45805825|NCT05837390|Device|Cervical stiffness assessment|The cervical stiffness is assessed by using the licensed, CE-marked Pregnolia System, during a sterile speculum examination. The single-use, sterile Pregnolia Probe is placed on the anterior lip of the cervix at 12 o'clock position and a recording of cervical stiffness is generated over maximum 60 seconds (typically ̴15 seconds) and displayed as Cervical Stiffness Index (CSI) in mbar. The measurement is repeated 3 consecutive times without any time lag.
45805826|NCT05837390|Other|Cervical length measurement|Cervical length measurement will be obtained via transvaginal ultrasound using a GE Voluson E10 ultrasound machine and 7.5MHz transvaginal probe. All measurements will be performed with the woman in a supine position with an empty bladder in the sagittal plane measuring from the internal to external cervical OS. The full length of the cervical canal will be visualized with the closed portion of cervix remaining being measured. Three measurements are taken with the shortest being documented as the final assessment.
45805827|NCT05837390|Other|Fetal fibronectin|Vaginal swab collection. The specimen will be obtained from the posterior fornix over 10 seconds using the polyester tipped swab provided in the Hologic specimen collection kit. This sample will be then be stored frozen and processed using the Rapid fFN 10Q System (HOLOGIC, Marlborough, MA, USA) within 3 months.
45805828|NCT05836506|Drug|ABBV-903 Tablet Form 1|Oral Tablets
45805829|NCT05836506|Drug|ABBV-903 Tablet Form 2|Oral Tablets
45805830|NCT05836298|Other|Non-surgical periodontal treatment|Each selected patient underwent randomly, without anaesthesia, after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional Quadrant Scaling and Root Planing (SRP) or MINST
45805831|NCT05836012|Biological|HIL-214|2 injections - given at 4 months and the second at 6 months of age.
45805832|NCT05836012|Biological|Placebo|2 injections - given at 4 months and the second at 6 months of age.
45805833|NCT05835752|Drug|RAY1225|Administered SC
45939634|NCT00228982|Drug|Vancomycin|
45939635|NCT00229021|Drug|doripenum|
45805834|NCT05835752|Drug|Placebo|Administered SC
45805835|NCT05835752|Drug|RAY1225|Administered SC
45939636|NCT00063284|Device|Magstim Rapid Magnetic Stimulator|
45939637|NCT00229060|Drug|doripenem|
45939638|NCT00075660|Drug|triapine|
45939639|NCT00229099|Drug|GerEPO|
45939640|NCT00229138|Drug|EC-MPS, Tacrolimus|
45939641|NCT00063323|Drug|Bupropion|
45939642|NCT00229177|Drug|ONO-2506|Once daily one-hour intravenous infusion at 12/mg/kg/hr for 7 days
45939643|NCT00229177|Drug|ONO-2506|Once daily one-hour intravenous infusion at 0 mg/kg/hr for 7 days
45939644|NCT00229177|Drug|ONO-2506|Once daily one-hour intravenous infusion at 8 mg/kg/hr for 7 days
46074335|NCT00857701|Device|Knee Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
45805836|NCT05835752|Drug|Placebo|Administered SC
45805837|NCT05835752|Drug|RAY1225|Administered SC
45805838|NCT05835752|Drug|Placebo|Administered SC
45939645|NCT00096603|Drug|Raptiva (efalizumab)|
45939646|NCT00229216|Drug|Tinidazole|
45805839|NCT05835219|Drug|REBYOTA™|REBYOTA™ is administered in the rectum
45939647|NCT00229255|Other|high frequency of meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
45654740|NCT04344665|Other|Virtual Care and Remote Automated Monitoring|Patients will measure daily vitals (blood pressure, heart rate, respiratory rate, oxygen saturation, temperature, weight) with remote monitoring technology and complete recovery surveys daily in home after discharge from hospital. Patients will interact with a virtual nurse daily on days 1-15 and every other day from days 16-30. If the patient's RAM measurements exceed predetermined thresholds, the patient reports specific symptoms (e.g., shortness of breath), a drug error is identified, or the virtual nurse has concerns about the patient's health that they cannot resolve, the virtual nurse will escalate care to a pre-assigned and available physician. Physicians will add or modify treatments as needed, and if required, they will have the patient come to an outpatient facility for evaluation or management. Via secure video or text messaging, patients will also have access to a virtual nurse at night, for any urgent issues.
45939648|NCT00229255|Other|twice a day meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
45939649|NCT02967653|Drug|Atorvastatin|Member of drug class called statins, primarily used as a lipid-lowering agent and the prevention of events associated with cardiovascular disease
45939650|NCT00096642|Behavioral|Cognitive Behavioral Therapy|Cognitive behaviour versus standard care
45805840|NCT05832892|Drug|surufatinib|"In phase Ib, surufatinib will be orally administrated 200 mg once a day (QD) or 250 mg QD per cohort escalation assignment on a 21-day cycle.~In phase II, surufatinib will be orally administrated at RP2D as determined in phase Ib."
45939651|NCT00229333|Drug|Escitalopram|
45939652|NCT00229372|Behavioral|Prolonged Exposure (PE) therapy|
45939653|NCT00229411|Behavioral|simulation training|
45939654|NCT00229450|Drug|Estrogen|0.625 mg/day of conjugated Estrogen
45939655|NCT02967419|Other|No Intervention|
45939656|NCT00229528|Drug|Paxil-CR|
45805841|NCT05832892|Drug|KN046|Nab-paclitaxel will be administrated at 125 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
45805842|NCT05832892|Drug|gemcitabine|Gemcitabine will be administrated at 1000 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
45939657|NCT00075699|Drug|cisplatin|
45939658|NCT00075699|Drug|mitomycin C|
45939659|NCT00075699|Drug|vincristine sulfate|
45939660|NCT00075699|Drug|vinorelbine tartrate|
45939661|NCT00075699|Procedure|pain therapy|
45939662|NCT00075699|Procedure|psychosocial assessment and care|
45939663|NCT00075699|Procedure|quality-of-life assessment|
45939664|NCT00229567|Drug|Lidocaine infusion plus ketamine injection|
45939665|NCT00229645|Drug|Quetiapine Fumarate (Seroquel®)|
45939666|NCT02967341|Other|Ciprofloxacin administration|Ciprofloxacin will be administered via the PAC directly followed by a NaCl 0.9% flush to wash the PAC. At least 1 hour afterwards 500 microliter of blood will be drawn via the PAC. Directly hereafter a blood draw of 500 microliter will be performed either via capillary blood sampling or via a venipuncture. If an anaesthesia is foreseen for another procedure (e.g. a lumbar puncture or an osseous punction), we will strive to perform the peripheral blood draw under anaesthesia.
45939667|NCT00229684|Drug|Tesaglitazar|2 mg once daily in oral form
45939668|NCT00229684|Drug|pioglitazone|45 mg once daily in oral form
45939669|NCT00096720|Drug|levodopa|
45939670|NCT00096720|Drug|Mirapex (pramipexole)|
45939671|NCT00096720|Procedure|[123I]ß-CIT and SPECT imaging|
45939672|NCT00229762|Behavioral|phone call from nurses - informational only|
45939673|NCT00413608|Drug|Clopidogrel|Clopidogrel
45939674|NCT00424684|Procedure|collection of blood sample|
46074336|NCT03296033|Drug|Enoxaparin|The intervention is the implementation of a 36-hour time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing.
45939675|NCT00229801|Radiation|MRI|
45939676|NCT00096759|Behavioral|Tai Chi Chih|
45939677|NCT00096759|Behavioral|Relaxation training|
45939678|NCT00229840|Procedure|Functional MRI, Diffusion Tensor Imaging|
45939679|NCT04730687|Device|Traditional non surgical mechanical therapy|Mechanical instrumentation in all groups was made with titanium Gracey curettes (8mm in diameter, Langer ½, item code: 7103, Kohler Medizintechnik, GmbH & Co, Ltd, Stockach, Germany).
45939680|NCT04730687|Device|Diode laser assisted non-surgical mechancal therapy|One week after mechanical treatment, a 940 nm diode laser (Ezlase®, Biolase Technology, Inc., San Clemente, CA) with a 300 µm diameter optical fiber tip applied approximately 1 mm above the most apical part of the peri-implant pocket, parallel to the implant surface (E3-9 mm).
45939681|NCT04730687|Device|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|1 week after mechanical treatment, 2780 nm Er, Cr: YSGG laser (Waterlase®, Biolase Technology, Inc., San Clemente, CA), short pulse '' H '' with 500 µm diameter fiberoptic periodontal tip (RFPT5-14 mm) mode has been applied.
46074337|NCT03296033|Drug|Enoxaparin|This is the historical control arm. 24 hours removed from their last dose (time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing)
46074338|NCT00857779|Biological|subcutaneous immunotherapy|7 injections
46074339|NCT05758389|Drug|Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU|evaluate the efficacy and safety of immunotherapy combined with chemotherapy
46074340|NCT02860793|Other|Bone marrow aspiration|
46074341|NCT02860793|Other|Blood sampling|
45805843|NCT05832892|Drug|Nab paclitaxel|Nab-paclitaxel will be administrated at 125 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
46074342|NCT00857935|Drug|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse, one or two, 10-minute topical treatments (7 days apart)
46074343|NCT00857935|Drug|NIX Creme Rinse - 1% permethrin|NIX Creme Rinse: one or two, 10-minute topical treatments (7 days apart)
45939682|NCT04722094|Diagnostic Test|Full periodontal chart|A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.
45939683|NCT04722094|Other|Saliva sampling|Saliva samples for miRNAs detection will be taken before starting the visit.
45939684|NCT00229918|Drug|triamcinolone acetonide|
45939685|NCT00096798|Drug|Ethyl-eicosapentanoic acid (ethyl-EPA)|
45805844|NCT05832398|Drug|FOLFOX , FOLFIRI or FOLFOXIRI regimens|FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFIRI (irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFOXIRI (irinotecan 150mg/m2, and folinic acid 400mg/m2, oxaliplatin 85 mg/m2, 5-fluorouracil 3200 mg/m2 48-h continuous infusion) for 6 cycle
45805845|NCT05832398|Drug|FOLFOX or CapeOX regimens|FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle CaoeOX (Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)
45805846|NCT05831995|Drug|ABM-168|Dosage: 0.5 mg; 2 mg; 6 mg; once daily by oral administration
45939686|NCT00229996|Drug|Oral Contraceptive|
45939687|NCT00229996|Drug|Depot-Leuprolide/Norethindrone|
45805847|NCT05829356|Biological|H3 mRNA / LNP Vaccine|"Pharmaceutical Form: Suspension for injection~Route of Administration: Intra-Muscular"
45805848|NCT05829356|Biological|Quadrivalent recombinant influenza Vaccine (RIV4)|"Pharmaceutical Form: Solution for injection in a pre-filled syringe~Route of Administration: Intra-Muscular"
45939688|NCT00230035|Procedure|Leukapheresis|
46074344|NCT02808234|Procedure|One or two level lumbar interbody fusion surgery|One or two level lumbar interbody fusion surgery with allograft derived from human amnion and amniotic fluid.
46074345|NCT02808234|Other|Nucel|Allograft derived from human amnion and amniotic fluid
46074346|NCT04282655|Other|Treatment Guardian Milk Warmer (Medela TM)|Infants were randomized to receive prepared syringes of breast milk via the continuous milk warmer (treatment arm)
46074347|NCT04282655|Other|Control|Standard warming procedure of breast milk in syringe prior to feeding.
46074348|NCT00853879|Dietary Supplement|Folic Acid, Vitamin B6, Vitamin B12|"Intervention #1. A combination of the following vitamin supplements: 2.5mg of folate, 25mg of vitamin B6 and 2mg of vitamin B12. This combination will be described as triple therapy with folate."
46074349|NCT00853879|Dietary Supplement|B6, B12, L-methylfolate|Intervention #2. A combination of the following vitamin supplements: 2.8mg of L-methylfolate, 25 mg of vitamin B6 and 2mg of vitamin B12.
45939689|NCT00230035|Procedure|Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)|
45939690|NCT00230035|Procedure|Autologous CD34+HPC transplantation (HSCT)|
45939691|NCT00230035|Procedure|Plasmapheresis|
45939692|NCT00230035|Drug|Rabbit anti-thymocyte globulin|
45939693|NCT00230035|Drug|Methylprednisolone|
45939694|NCT00230035|Drug|Growth colony stimulating factor (G-CSF)|
45939695|NCT00230035|Drug|Corticosteroids|
45939696|NCT00230035|Drug|Mycophenolate mofetil|
45939697|NCT00230035|Drug|Azathioprine|
45939698|NCT00230035|Drug|Intravenous immunoglobulin|
45939699|NCT00230035|Drug|Methotrexate|
45939700|NCT00230035|Drug|Rituximab|
45939701|NCT00230035|Drug|Leflunomide|
45939702|NCT00063401|Biological|Cetuximab:|400 mg/m2 loading dose, 250 mg/m2 weekly, six 21-day cycles
45939703|NCT00063401|Drug|Paclitaxel|175 mg/m2 Day 1, six 21-day cycles
45939704|NCT00063401|Drug|Carboplatin|AUC = 6 Day1, six 21-day cycles
45939705|NCT00230074|Drug|TCH346|
45939706|NCT00230113|Dietary Supplement|Omega-3 fatty acid diet supplementation|4 gm fish oil per day
45939707|NCT00230113|Dietary Supplement|safflower oil|4 gm per day safflower oil
45939708|NCT00230152|Device|Imaging|
45939709|NCT00096837|Drug|Motexafin Gadolinium Injection|
45939710|NCT00230191|Drug|RK-0202|
45939711|NCT04721509|Device|Experimental : Smartphone-based telemedicine with the app 'Songaree diabetes'|Experimental group: outpatient clinic and offline education every 12 weeks plus telemedicine and education with smartphone app 'Songaree diabetes' every 2 weeks for 24 weeks
45939712|NCT00230230|Drug|SCH 486757|
45939713|NCT00230269|Procedure|PET-CT|
45939714|NCT00230347|Procedure|Stereotactic radiosurgery|
45939715|NCT00230386|Device|MRI|
45939716|NCT04730414|Drug|Full-spectrum hemp (0.018% THC)|Topical Application
45805849|NCT05828667|Other|Incorporation of CT and/or c-MRI derived myocardial scar with 3D electroanatomical mapping (EAM).|CT and/or c-MRI derived myocardial scar will be merged with 3D electroanatomical mapping (EAM) prior to the ablation to allow for readily localization and characterization of VT substrates and potential re-entry circuits to be ablated. This is done with the intent to limit the repeated number of inductions and prolonged point-by-point voltage mapping that often result in hemodynamic instability.
45939717|NCT00230464|Drug|LAF 237|
45654741|NCT04967755|Drug|Jing-Si-Herbal-Tea|Eligible patients were randomized to receive routine treatment alone based on the Novel Coronavirus Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (Eleventh edition 2021) (control group) or the combination of routine treatment and JSHT (1 drink thrice daily for 7 days) (JSHT group) at the discretion of the attending clinicians. Routine treatment generally consisted of the supportive treatment such as oxygen therapy, antiviral medications and symptomatic therapies. Adherence to the study medications, clinical outcomes, the use of concomitant medications and adverse events were recorded. The following data were collected at admission: demographics, body mass index, smoking history, comorbidities, CURB-65 Score for pneumonia. Hemogram, laboratory testing, chest X-ray, and nucleic acid assays of SARS-CoV-2 were evaluated at admission and after randomization and on 7th day.
45654742|NCT04950907|Diagnostic Test|vats|Use uniportal tubeless VATS to obtain the biopsy
45654743|NCT04950907|Diagnostic Test|CT-guided fine needle biopsy|Use CT-guided fine needle to obtain the biopsy
45805850|NCT05828459|Drug|OT-A201|OT-A201 IV infusion qw or q2w
45805851|NCT05828459|Drug|IMids|Combination regimen for hematological malignancy Lenalidomide: 25 mg on Days 1 to 21 of each 28-day cycle; or Pomalidomide: 4 mg on Days 1 to 21 of each 28-day cycle
45805852|NCT05828459|Drug|Bevacizumab|Combination regimen for solid tumor Bevacizumab: 10 mg/m² q2w
45805853|NCT05828459|Drug|Paclitaxel|Combination regimen for solid tumor Paclitaxel: 175 mg/m² q3w
45805854|NCT05828459|Drug|TBD Compound|Combination regimen for hematological malignancy
45805855|NCT05828277|Drug|repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005)
45805856|NCT05828147|Drug|Rituximab|Rituximab will be administered as two IV infusions of 1000 mg each, given two weeks apart at Day 0 and Week 2. All subjects will receive 40 mg of prednisone orally the night before and morning of each infusion with diphenhydramine and acetaminophen orally thirty to sixty minutes prior to each infusion of rituximab. Subjects will remain on their baseline standard medical regimen.
45805857|NCT05828108|Drug|Bitopertin|Dose Escalation: Monthly (every 4 weeks) up to a maximum dose of 60 mg bitopertin (5 mg, 10mg, 20mg, 40mg, 60mg). At each monthly (4 week) interval, a complete blood count (CBC) with differential and a reticulocyte analysis (including reticulocyte hemoglobin) will be collected prior to taking the higher dose. If the absolute reticulocyte count (ARC) is 60,000 /microL or higher, the subject will hold at the current dose level (or return to that level if escalation has already occurred) for an additional 4 weeks. If, after 8 weeks at that dose, response criteria are met this will be considered the minimum effective dose (MED) and shall be the treatment dose throughout the remainder of the study unless modifications are indicated.
45805858|NCT05827874|Drug|Nipocalimab|Nipocalimab will be administered as an IV infusion.
45805859|NCT05827874|Biological|Tdap|Tdap will be administered as an IM injection.
45805860|NCT05827874|Biological|PPSV23|PPSV23 will be administered as an IM injection.
45939718|NCT00096915|Drug|Darbepoetin Alfa|"QM administration for 32 weeks, allowable doses:~15, 20, 30, 40, 50, 60, 80, 100, 150, 200, 300, 400, 500, 600 and 800 mcg"
45939719|NCT00230503|Drug|pradefovir mesylate|
45939720|NCT00230503|Drug|adefovir dipivoxyl|
45939721|NCT02962219|Behavioral|Pre-operative Exercise Programme (my-PEP)|A pre-operative personalised exercise programme (my-PEP) consisting of: 1) actions to promote exercise, using behavioural change techniques (BCTs), 2) home inspiratory muscle training (IMT), 3) a home exercise programme (HEP) - which is also current standard care, 4) a 4 week hospital-supervised aerobic and muscle strengthening programme (Hos-PEP) .
45939722|NCT02962219|Behavioral|Home Exercise Programme (HEP)|Written advice on exercise at home
45939723|NCT00424723|Drug|Pemetrexed|Given intravenously over 10 minutes every 21 days (21 days equals one cycle). Subjects will continue to receive pemetrexed as long as their disease does not worsen and they do not experience any serious side effects.
45939724|NCT00230542|Drug|Carboplatin|Given intravenously following pemetrexed over 30-45 minutes once every three weeks for 6 cycles (18 weeks)
45939725|NCT00230542|Drug|Pemetrexed|Given intravenously over 30 minutes once every three weeks for 6 cycles (18 weeks)
45939726|NCT00063479|Drug|Zoledronic Acid|
45939727|NCT00097032|Drug|risperidone; quetiapine|
45939728|NCT00230581|Drug|DDP225|
45939729|NCT02962336|Drug|Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets|Oral, crossover
45805861|NCT05824559|Drug|ME-344|ME-344 will be administered intravenously (IV)
45805862|NCT05824559|Drug|Bevacizumab|Bevacizumab will be administered intravenously (IV)
45939730|NCT02962336|Drug|Tribenzor Tablets of Daichi Sankyo Inc, USA|Oral, crossover
45939731|NCT00075738|Drug|cisplatin|
45939732|NCT00075738|Drug|fluorouracil|
45939733|NCT00075738|Drug|irinotecan hydrochloride|
45939734|NCT00075738|Drug|leucovorin calcium|
45939735|NCT00230659|Other|Blood sample to be taken.|Blood sample to be taken.
45939736|NCT00230698|Drug|topiramate|
45939737|NCT00230776|Drug|pregabalin|
45939738|NCT00230776|Drug|placebo|
45939739|NCT00075777|Drug|valproic acid|250 mg by mouth twice a day
45939740|NCT02967614|Drug|[A]|One eye drop(about 40ul) / Day1 ~ Day8 / BID
45939741|NCT02967614|Drug|[B]|One eye drop(about 40ul) / Day1 ~ Day92 / BID
45939742|NCT02967614|Drug|[A]+[B](1)|One eye drop(about 40ul) / Day9 ~ Day100 / BID
45939743|NCT02967614|Drug|[A]+[B](2)|One eye drop(about 40ul) / Day93 ~ Day100 / BID
45939744|NCT00230815|Device|Follitropin alfa injected by Pen device|Follitropin alfa will be injected subcutaneously by Pen device at a dose of 75 International Unit (IU) and 150 IU in subjects aged 18-34 and 35-40 years, respectively, for 5 days. Dose will be adjusted on stimulation Day 6 until ovulation triggering criteria will met.
45654744|NCT04692233|Behavioral|Qigong Baduanjin|Qigong Baduanjin will comprise eight standardized movements. It is practiced as a combination of body movements, breath control, and mindful meditation, which is designed to improve qi function.
46074350|NCT00853879|Dietary Supplement|B6, B12, Placebo|"Intervention #3. A combination of the following vitamin supplements: 25mg of vitamin B6 and 2mg of vitamin B12 without supplementary folate or L-methylfolate. This combination will be described as triple therapy with placebo"
46074351|NCT00634530|Behavioral|Dietary Advice|The specific dietary advices according to nutritional status. Main advices: reduction of fat and sugar intake, increase of total energy, dairy intake of vegetables and fruits.
46074352|NCT05271279|Biological|OVV-01 Injection+IBR900 Cell Injection|"2 dose gradients are used for the OVV-01 injection, and the total infusion dose of IBR900 cell injection is 4.0×10^9 cells per cycle.~OVV-01 injection will be first administered at W1D1 and then at W4D1 followed by every 2 weeks as a treatment cycle, for a total of 6 doses; after the test in the high-dose group is completed, the investigator and sponsor will determine whether to adjust the dosing frequency of OVV-01 (such as once a week) based on the result evaluations. The IBR900 cell injection will be first administered at W1D3 and W1D5 for 2 infusions, and then at W4D3 and W4D5, followed by every 4 weeks as a cycle, for a total of 4 doses, and cell infusions will be conducted at W1, W4, W8 and W12, respectively."
45654745|NCT04692233|Behavioral|Light flexibility exercise|Each session will include seated and standing stretches that target upper (neck, arms, upper back, shoulders, back, and chest) and lower body (quadriceps, hamstrings, calves, and hips), as well as trunk rotations.
45654746|NCT04950595|Other|Plant-based mince|Spaghetti bolognaise meal made with plant-based mince
45654747|NCT04950595|Other|Beef mince|Spaghetti bolognaise meal made with beef mince
45654748|NCT04421365|Device|neurofeedback brain-computer interface (BCI)|The integrated components of BCI system include the high-density EEG, 3D-VR, and a built-in ML platform as a real-time neural signal decoder and neurofeedback controller.
45654749|NCT04411589|Device|magnifying endoscopy with optical enhancement system|A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. After visualization in white light mode, the stomach was reinspected by using OE mode2. Then, in vivo diagnoses of lesions were made by using OE mode1 according to VS theory. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.
45654750|NCT04411589|Device|white light endoscopy system|A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.
45654751|NCT04958395|Diagnostic Test|FFR and d-FFR|Measure FFR and d-FFR
45654752|NCT03060733|Other|Post-Therapy|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
45654753|NCT04311827|Other|Serratus Anterior Plane Block|Injection of bupivacaine 75mg above the serratus anterior facial plane in the anterior axillary line
45805863|NCT05824325|Drug|SHR-A1811|HER2 ADC
45805864|NCT05824325|Drug|TROP2 ADC|TROP2 ADC
45805865|NCT05824208|Behavioral|PRENAYOGA - prenatal yoga|The intervention is a prenatal yoga module developed for prenatal women. Intervention details: bi-weekly yoga classes (60 minutes of duration) will be delivered in person in a yoga studio in London for 8 consecutive weeks. Participants will be provided with yoga mats, blocks, bolsters and yoga straps at the studio. The class will be adapted to pregnancy and for all levels of ability, focusing on slow movements and body awareness. The content of the class will include loosening exercises (warm up exercises), simple postures (standing, balancing, sitting, kneeling, supine and restorative poses), breathing exercises and meditation. Classes will be delivered by an internationally certified and trained yoga teacher and will be accompanied by soft instrumental music.
45805866|NCT05823987|Drug|H101|a modified human recombinant type 5 adenovirus with genetic modifications
45805867|NCT05823987|Drug|Tislelizumab|a PD-1 immune check inhibitor
45805868|NCT05823987|Drug|Lenvatinib|Lenvatinib capsules
45805869|NCT05823467|Drug|TMP-SMX DS|Oral Antibiotic - used to treat post operative wound infections.
46074353|NCT03293147|Other|HPLC-MS/MS-guided intervention|The HPLC-MS/MS-guided intervention consists of providing partially or totally non-adherent hypertensive patients with information on the results of their HPLC-MS/MS-based urine analysis combined with tailored targeting of the main reason(s) for the deviation from the prescribed antihypertensive treatment
46074354|NCT03293147|Other|Standard care|Standard care for hypertensive patients
45654754|NCT04958317|Other|Early exercise|Participants will exercise for 30 minutes prior to an evening meal.
45654755|NCT04958317|Other|Late exercise|Participants will exercise for 30 minutes after an evening meal.
45805870|NCT05823467|Device|ciNPT dressing|Negative pressure wound VAC placed on incision post operatively.
45805871|NCT05823337|Dietary Supplement|selenium+ diet|Selenium functions as an active site component of an antioxidant enzyme, glutathione peroxidase, and helps scavenge free radicals.
45805872|NCT05823337|Dietary Supplement|only diet|diet suitable for pregnancy
45805873|NCT05822843|Drug|ESG206|Administered via intravenous (IV) infusion
45805874|NCT05822752|Drug|Budigalimab|Intravenous (IV) Infusion
45805875|NCT05822752|Drug|Livmoniplimab|Intravenous (IV) Infusion
45805876|NCT05822752|Drug|Lenvatinib|Oral: Capsule
45805877|NCT05822752|Drug|Sorafenib|Oral: Tablet
45805878|NCT05822440|Drug|PF-07817883|Single oral dose (period 1) or co-administered with itraconazole (period 2)
45805879|NCT05822440|Drug|Itraconazole|Interacting drug which will be given for 7 days in period 2
45805880|NCT05821595|Drug|JYB1907|for injection
45939745|NCT00230815|Device|Recombinant Human Choriogonadotropin (r-hCG)|Recombinant Human Choriogonadotropin (r-hCG) injection will be administered as a single dose of 250 microgram subcutaneously when at least 1 follicle, but not more than 3 follicles, reached a mean diameter greater than or equal to (>=)17 mm and estradiol levels are approximately 150 picogram per milliliter (pg/mL) per mature follicle.
46074355|NCT00862147|Behavioral|ICDP|Parent training group
46074356|NCT00862147|Behavioral|Treatment as usual|Parent and/or child focused interventions
46074357|NCT04171843|Genetic|PBCAR269A|Allogeneic anti-BCMA CAR T-cell
46074358|NCT04171843|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
45939746|NCT04721587|Device|Virtual Reality|"The patients of the VR Group will be subjected to the same hysteroscopy technique as the Standard of Care Group, but additionally a VR device will be applied where a distraction VR environment (Underwater Game) will be reproduced during the exploration"
45805881|NCT05820841|Drug|R-miniCHOP + Acalabrutinib|"Rituximab i.v.: 375 mg/m2 (D0)~Cyclophosphamide i.v.: 400 mg/m² (D1)~Doxorubicin i.v.: 25 mg/m² (D1)~Vincristine i.v.: 1 mg (D1)~Prednisolone p.o.: 40 mg/m² D1 to D5~Acalabrutinib 100 mg p.o. twice daily starting from D1 of first R-miniCHOP cycle continuously to D21 of cycle 8.~Cycles repeated every 3 weeks"
45939747|NCT00230854|Drug|EMZ702|
45805882|NCT05820841|Drug|R-miniCHOP|"Rituximab i.v.: 375 mg/m2 (D0)~Cyclophosphamide i.v.: 400 mg/m² (D1)~Doxorubicin i.v.: 25 mg/m² (D1)~Vincristine i.v.: 1 mg (D1)~Prednisolone p.o.: 40 mg/m² D1 to D5.~Cycles repeated every 3 weeks"
45939748|NCT00097071|Drug|insulin lispro|
45654756|NCT04950751|Biological|candidate vaccine, SCB-2020S|a recombinant SARS-Co-2 trimeric S-protein (from B.1.351 variant) subunit vaccine for COVID-19
45654757|NCT04950361|Other|talocalcaneal coalition|patients with talocalcaneal coalition
45654758|NCT04528199|Drug|[18F]FLOR (FC303) Injection|Single dose of 10 ±1 millicurie (mCi) of [18F]FLOR (FC303) injection followed by the PET/CT scan.
45654759|NCT04967131|Other|PNF exercises|PNF exercises were applied in 3 sets of 15 repetitions based on movement in the diagonal plane, using head, neck and chin patterns. Contractions were sustained for at least 10 seconds.
45654760|NCT05546957|Drug|Aspirin|Administered orally once per day (QD)
45654761|NCT05546957|Drug|rivaroxaban low dose|Administered orally twice per day (BID)
45654762|NCT05546957|Drug|rivaroxaban high dose|Administered orally QD
45654763|NCT04950205|Drug|Sevoflurane inhalant product|propofol plus 1% sevoflurane after open Carotid artery until the end of surgery
45676281|NCT04122976|Drug|Darolutamide(Nubeqa, BAY1841788)|The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
45676282|NCT04103450|Drug|Vibegron|oral administration
45805883|NCT05820711|Drug|MSC|"Injection of MSCs into submandibular glands at pre-specified dose level:~Dose -1: 5 (4 - 6) x10^6 MSCs (to be used only if Dose level 1 is not tolerated) per gland (0.5 ml)~Dose 0: 10 (8 - 12) x10^6 MSCs per gland (1 ml)~Dose 1: 20 (16 - 24) x10^6 MSCs per gland (2 ml)"
45939749|NCT00097071|Drug|insulin aspart|
45939750|NCT02967380|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
45939751|NCT02967380|Drug|Gadobenate Dimeglumine|Given IV
45939752|NCT02967380|Drug|Gadobutrol|Given IV
45939753|NCT02967380|Radiation|Gadopentetate Dimeglumine|Given IV
46074359|NCT04171843|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
46074360|NCT04171843|Drug|Nirogacestat|Allogeneic anti-BCMA CAR T-cell
46074361|NCT04282265|Dietary Supplement|Placebo|Oral placebo capsules will be taken consisting of maltodrextrin daily for 11 weeks
46074362|NCT04282265|Dietary Supplement|Red Spinach Extract (RSE)|Oral capsules containing 2g of Red Spinach Extract will be consumed daily for 11 weeks
46074363|NCT05498610|Drug|NNC0480 0389|"Participants will get 1 injections of NNC04800389. It will be injected with a needle into a skin fold on the abdomen.~The study will last for a maximum of 72 days"
46074364|NCT05498610|Drug|Semaglutide|"Participants will get 1 injections of semaglutide. It will be injected with a needle into a skin fold on the abdomen.~The study will last for a maximum of 72 days"
46074365|NCT02611011|Device|Congo Red Test (GV-005)|The GV-005 is a simple test has been developed to detect unfolded or misfolded proteins in urine.
46074366|NCT03911076|Biological|PVX-2|pNGVL4a-Sig/E7(detox)/HSP70 (naked DNA plasmid priming vaccine) TA-CIN (HPV16 L2E7E6 fusion protein booster vaccine)
46074367|NCT03911076|Other|Placebo|PBS and PGC
46074368|NCT02860559|Biological|TBX-1400|Hematopoietic stem cells transplantation
46074369|NCT03845803|Other|Reducing sedentary behaviour|Implementing sit/stand workstations at work
46074370|NCT00815919|Drug|bortezomib|Given intravenously at a dose of 1.3 mg/m^2 once a week for the first four weeks of a five week cycle for a total of 3 cycles
45654764|NCT05544461|Behavioral|eNutri personalised nutrition advice|eNutri is a web-based app that administers an FFQ and delivers PN advice to the user. The advice is generated from their responses in the FFQ and considers their sex and dietary restrictions (such as whether they eat meat) so the reports are unique to each participant. This report (referred to as a 'healthy eating report') will also include an interactive component, allowing the participant to reflect on the advice received and set personal healthy eating goals to motivate behaviour change. The messages presented in the report have been developed by the eNutri Team, including a registered dietitian and registered nutritionist and are in line with UK dietary guidelines (primarily the EatWell Guide).
45654765|NCT04415047|Device|JenaValve Trilogy Heart Valve System|TAVR with JenaValve Trilogy Heart Valve System
45654766|NCT05540093|Other|high power pain threshold ultrasound|After explaining the procedure, and the trigger points will be marked by a physical therapist that . Then, the hand placed next to the prone position with the head in the neutral position, and the hands placed next to the body. The frequency was set to 1 MHz, and the intensity increased from 0.5 to 2 until the patient reported an unpleasant sensation. The probe will be held there for 4 s; then, the intensity was reduced by 50%, and the probe was moved over and around the trigger point. This process is done several times for three minutes.
45939754|NCT04721782|Other|smoking|to assess the effect of smoking of fetal liver circulation with prenatal Doppler Ultrasonography
45939755|NCT00075855|Drug|therapeutic testosterone|
45939756|NCT00075855|Other|placebo|
45939757|NCT00231049|Drug|AG-707|
45654767|NCT05540093|Other|traditional therapy|the patients will receive traditional therapy in the form of postural correction exercise, active range of motion and stretching exercise for cervical muscles
45939758|NCT00063596|Drug|Vitamin A supplementation|
46074371|NCT00815919|Drug|Prednisone|Taken orally once a day at a dose of 0.5-1 mg/kg. Dose reduction may be initiated after 1 cycle of therapy. A suggested taper is 10-25% every 1-2 weeks.
45654768|NCT03924479|Device|PowerBreathe (Breathing muscle training)|The breathing muscle breathing training will consist of using the PowerBreathe training for 8 weeks. The PowerBreathe is an inspiratory pressure threshold trainer.The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device.
45654769|NCT05696405|Procedure|VATS resection of MEPA|VATS resection of mediastinal parathyroid adenoma
45654770|NCT05696327|Other|Tyler Twist Exercises|Tyler twist exercises are the group of exercises which are used to strengthen wrist ex tensors.The protocol consists of several steps using colored twist-able bands and patients are guided to actively perform the steps for their grip strength development.
45654771|NCT05696327|Other|conventional physical therapy|Conventional physiotherapy (Ultrasound + Cross Friction Massage for 10 minutes + Wrist extensor stretching and Isotonic wrist extensor strengthening.)
45654772|NCT03838601|Drug|MET-4|Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
45654773|NCT05592041|Drug|Banaba Leaf Extract|a herbal extract in the form of Bigel
45654774|NCT02625259|Drug|TAK-117|TAK-117 capsules
45654775|NCT02625259|Drug|Lansoprazole|Lansoprazole capsules
45654776|NCT02625259|Drug|TAK-117|TAK-117 tablets
45805884|NCT05819957|Other|Therapeutic Education Program (TEP)|the TEP lasts 12 months, being structured into 6 modules.
45805885|NCT05818709|Device|HAC 22L|Subcutaneous and/or Supraperiosteal injection
45805886|NCT05818696|Behavioral|Lethal Means Counseling (LMC)|The research interventionist uses a guiding approach to identify methods for secure firearm storage and reflects the participant's reasons for and against secure firearm storage, with a particular focus on the service member's verbalized reasons for wanting to adopt or use the identified storage methods.
45805887|NCT05818696|Behavioral|CBT for Uncertainty - Enhanced (CUE)|CUE consists of a 1-hour manualized intervention that uses interactive content to enhance participant learning of critical intervention components. The session includes (1) psychoeducation regarding the role of IU in exacerbating anxiety/mood sensations, (2) practice identifying and challenging maladaptive thoughts about uncertainty and accompanying distress, and (3) behavioral activities to challenge participants' capacity to handle uncertainty.
45805888|NCT05818683|Drug|JNJ-78278343|JNJ-78278343 will be administered subcutaneously.
45939759|NCT00231166|Drug|HCD122|
45939760|NCT00097110|Drug|Vitamin C and E|
45939761|NCT00231205|Procedure|Revascularization|
45939762|NCT00231244|Device|CYPHER Sirolimus-Eluting Coronary Stent|CYPHER Sirolimus-Eluting Coronary Stent
45939763|NCT00231322|Drug|praziquantel|
45939764|NCT00231439|Drug|IvIg|
45939765|NCT00231517|Drug|topical opiod|
45939766|NCT00231517|Drug|morphine sulphate in intrasite gel|
45939767|NCT00075894|Drug|L-alanosine|
45939768|NCT00231556|Drug|topiramate|
45939769|NCT00231595|Drug|topiramate|
45939770|NCT00063674|Behavioral|Nutrition Education|
46074372|NCT03903744|Procedure|Cardioneuroablation|The electroanatomical map of the right (RA) and left (LA) atrium will be created and anatomically-based ablation of GP will be performed. Ablation in the RA is started from the supero-posterior area (superior right atrial GP), to the middle-posterior area (posterior right atrial GP). In the LA, ablation is started at the site of the anterior right GP and is continued downwards along the anterior part of a common vestibulum of the right pulmonary veins (PV), opposite to the right-sided ablation lesions. Finally, area of right inferior GP, close to the RIPV is ablated under intracardiac echocardiography control. Using this technique, GP's located close to the left PV are not ablated. We use a pure anatomic approach without identification of GP.
46074373|NCT02808078|Device|Gait training with augmented reality|20 sessions (30 min. duration) over 4 weeks of gait training with augmented reality.
46074374|NCT02808078|Device|Standard training|20 sessions (30 min. duration) over 4 weeks of gait training without augmented reality.
46074375|NCT02545153|Drug|Tisseel, Baxter (Aprotinin and Fibrinogen)|After introducton of t tube and closure of the incision with running sutures, fibrin sealant is applied on the incision.
46074376|NCT02545153|Drug|Control|No fibrin sealant applied
45939771|NCT00063674|Behavioral|After-school dance class|
45654777|NCT04958083|Diagnostic Test|multiphase ECG-gated contrast-enhanced CT|Compared with current standard CT imaging, the dynamic CT protocol provides incremental functional information, which is potentially helpful to the individuals under study (such as early awareness for future complications and potential prediction of outcomes). Due to the nature of the acquisition, a wider R-R acquisition window will result in a higher radiation burden than a standard protocol. However, the study protocol will replace the standard routine CT image protocol as it contains both the routine anatomic information and incremental functional information. The time required for the image acquisition and associated radiation will be slightly higher; the additional information from multiple reconstructed phases will justify a slightly higher radiation burden in a usually elderly population. The estimated radiation dose for the standard imaging protocol is approximately 8 mSv. The estimated radiation dose for the modified dynamic CT image acquisition is approximately 18 mSv.
45939772|NCT04721470|Procedure|Combined therapy|Patients undergoing combined therapy
45939773|NCT04721470|Procedure|Microwave ablation|Patients undergoing Microwave ablation
45939774|NCT04721470|Procedure|Transarterial chemoembolization|Patients undergoing Transarterial chemoembolization
45805889|NCT05818683|Drug|Cetrelimab|Cetrelimab will be administered by intravenous infusion.
45805890|NCT05817942|Drug|Filgotinib|Jyseleca
45939775|NCT00097149|Procedure|Systematic pediatric care|
45939776|NCT00231634|Drug|topiramate|
46074377|NCT02800746|Drug|Ferric carboxymaltose|Ferric carboxymaltose 15 mg/kg mg is intravenously administered on 7-10 day before surgery.
45939777|NCT00231673|Drug|Topiramate|Increasing dosing of topiramate gradually to 200 mg daily by mouth, dose maintenance for 12 weeks, then decreasing dose until stopped over 12 weeks
46074378|NCT02800746|Drug|Placebo|normal saline 100 ml is intravenously administered on 7-10 day before surgery
46074379|NCT00913653|Drug|LCZ696|
46074380|NCT04042129|Other|gynecologic operations with urological complications|
46074381|NCT02804880|Behavioral|HAR|Smokers will be introduced to various smoking cessation (SC) services in Hong Kong (using the referral card) and be motivated to use the services. Field research staff will assist on-site booking SC services for smokers. Tailored messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent via instant messaging (IM) services (e.g. WhatsApp, WeChat) to smokers after initial contact.
46074382|NCT02804880|Behavioral|LTM|Fix-schedule SMS messages will be sent to encourage them to book the smoking cessation services appointment. Smokers are required to book the SC appointments by themselves.
46074383|NCT02804880|Behavioral|AWARD|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again: to repeat the intervention during tel. follow-ups.
46074384|NCT02804880|Other|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans."
45939778|NCT00097188|Drug|rituximab|
45805891|NCT05817812|Drug|Efanesoctocog alfa|Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
45805892|NCT05817669|Biological|Efgartigimod|Patients receiving efgartigimod infusions
45939779|NCT00231790|Drug|MK-0634 50 mg|one capsule orally, once daily in morning
45654778|NCT02577107|Drug|ranibizumab|
45654779|NCT02577107|Drug|Conbercept|
45654780|NCT04958473|Drug|Sintilimab|PD-1 inhibitor，Sintilimab 200mg IV, every 3 weeks.
45654781|NCT04958473|Drug|Axitinib|Tyrosine kinase inhibitor，licensed for use in treatment of renal cell carcinoma. Oral treatment Axitinib given 5 mg PO BID.
46074385|NCT02804880|Other|A4 leaflet|The 2-side color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
46074386|NCT02804880|Behavioral|Brief advice|Very brief, minimal and general smoking cessation advice
46074387|NCT02804880|Other|12-page booklet|12-page smoking cessation self-help booklet
46074388|NCT05758155|Other|mental health literacy training supported by creative drama|nursing students will be given two hours of mental health literacy training supported by creative drama one day a week for 4 weeks.
45654782|NCT04957927|Drug|Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age|Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age
45654783|NCT01161953|Genetic|Genetic Analysis|Perform Genome Wide Association Studies.
45805893|NCT05817669|Biological|Placebo|Patients receiving placebo infusions
45805894|NCT05817591|Drug|Capsaicin 8%|In current practice, capsaicin patch treatment is offered to patients with a 24-hour average pain level measured by the EN numerical scale : EN scale is > 4
45939780|NCT00231790|Drug|MK-0634 125 mg|one or three capsules orally, once daily in morning
45939781|NCT00231790|Drug|Placebo for MK-0634|one, two, three or four capsules orally once daily in morning
45939782|NCT00231829|Drug|Celecoxib|
45939783|NCT00231907|Biological|FluMist|Live attenuated influenza vaccine (LAIV) containing approximately 10^7 TCID50 of each of the 3 influenza strains. 0.5 mL total dose volume administered intranasally via spray applicator (approximately 0.25 mL into each nostril). Administration of Flumist in children under 5 years of age is investigational.
45939784|NCT00231907|Biological|Fluzone|Trivalent inactivated vaccine (TIV), licensed Fluzone preservative free pediatric dose, 0.25 mL administered intramuscularly to the anterolateral thigh muscle or deltoid muscle.
45939785|NCT00231946|Drug|VP4896|
45939786|NCT00075933|Drug|ARQ 501|
45939787|NCT00231985|Behavioral|Habit reversal therapy|Habit reversal therapy consists of awareness training, relaxation training, self-monitoring, and competing response training.
45939788|NCT00231985|Behavioral|Supportive therapy|Supportive therapy focuses on educating participants about tics: how tics present themselves, the causes of tics, the common conditions that may occur along with tics, and environmental factors that may affect their tics (e.g. family, social, school, stress).
45939789|NCT00063713|Drug|VELCADE TM (bortezomib) for Injection|
45939790|NCT00232024|Drug|Tegaserod|
45805895|NCT05816590|Other|Med@HOME Mobile App|Meds@HOME is a software application designed for use on a personal mobile device. The app allows primary caregiver to create routines where they can detail how to perform the routine, start date and time, and frequency (daily, weekly, monthly). Optional push notifications can be set so that users are alerted to an upcoming routine. Only primary caregivers can create, edit, and delete routines. All caregivers can check off on routines and receive notifications. Caregivers can also post notes related to routines or events. App enables an inventory of caregiver troubleshooting strategies and inventory reminders.
45654784|NCT04957849|Procedure|The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery|The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery
45939791|NCT00232063|Drug|ciclosporin|
45939792|NCT00232102|Drug|Tegaserod|
45939793|NCT00232219|Drug|Fish oil|
45939794|NCT00232258|Drug|Nolpitantium besylate|
45939795|NCT00063752|Drug|PI-0824|
45939796|NCT00097227|Biological|Cetuximab|"(Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~A cycle of therapy was defined as 3 weeks in Arm A and 4 weeks in Arm B."
45939797|NCT00097227|Drug|Carboplatin|(AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.
45654785|NCT04957849|Procedure|Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach|Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach
45939798|NCT00097227|Drug|Paclitaxel|225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks. OR 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.
45939799|NCT00232297|Drug|SSR149744C|
45939800|NCT00232336|Drug|quetiapine|
46074389|NCT05758155|Other|mental health literacy training supported by classroom instruction|nursing students will be given mental health literacy training supported by two hours of classroom instruction one day a week for 4 weeks.
45654786|NCT04688801|Drug|Chemotherapy Drugs, Cancer|Chemotherapy± Radiotherapy after surgery
45654787|NCT04688801|Drug|Immunotherapy|Chemotherapy + Immuonotherapy ± Radiotherapy after surgery
45654788|NCT04957771|Other|Supervise and guide regular exercise|Aerobic exercise, evaluated by cardiopulmonary exercise test, 3-5 times a week
45654789|NCT00912041|Device|Placement of the BrainGate2 sensor(s) into the motor-related cortex|Up to four 4x4 mm BrainGate2 sensor(s) are placed into the motor-related cortex (including speech-related areas of cortex), connected to one or two percutaneous pedestals. Neural recordings are made at least weekly for a year or more.
45654790|NCT04966975|Other|neoadjuvant chemotherapy|The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.
45654791|NCT04957459|Other|No intervention|No intervention
45805896|NCT05815693|Behavioral|mindfulness-based stress reduction (MBSR) and cognitive behavioral therapy (CBT)|Patients with long-term consequences of COVID-19 (Chronic pain, anxiety, depression or insomnia) enrolled and randomly assigned to receive MBSR (n = 63), or usual care (n = 62). MBSR (training in mindfulness meditation and yoga) were delivered in 12 months with 2-hour groups each 2 months. Usual care included anything care participants received such as drug therapy.
45805897|NCT05815160|Drug|Debio 0123|Administered as capsules.
45654792|NCT04682561|Behavioral|Supportive Trauma Exposure Preparation Program|The Supportive Trauma Exposure Preparation Program is based on the theory that the ability to set compassionate boundaries will enhance acceptance of the reality of trauma in the workplace, and will also increase the cognitive/emotional/physical energy needed to engage in adaptive emotional strategies in response to trauma exposure. Therefore, the goal of therapy is to learn to set compassionate boundaries and engage with oneself and others from a perspective of self-empowerment and acceptance of life events. Concepts and skills will be addressed through the following modules: 1) understanding of trauma and its effects, 2) personal rights and boundaries, 3) emotional literacy, 4) distress tolerance and emotion regulation skills building, 5) communication skills building, 6) self-compassion and acceptance, and 7) enhancing self-care.
45654793|NCT04950049|Drug|Dexamethasone|receive 2ml dexamethasone (5mg/ml)
45654794|NCT04950049|Other|Diluted dexamethasone 5ml|receive 5ml dexamethasone (2mg/ml) diluted with 5% glucose
45654795|NCT04950049|Other|Diluted dexamethasone 10ml|receive 10ml dexamethasone (1mg/ml) diluted with 5% glucose
45654796|NCT04950049|Other|Diluted dexamethasone 20ml|receive 20ml dexamethasone (0.5mg/ml) diluted with 5% glucose
45805898|NCT05815160|Drug|Etoposide|Administered as IV infusion.
45805899|NCT05815160|Drug|Carboplatin|Administered as IV infusion.
45805900|NCT05814627|Drug|Upadacitinib|Oral Tablets
45939801|NCT00232375|Drug|Insulin|
45939802|NCT00063791|Drug|Bortezomib|
45939803|NCT00232414|Drug|Quetiapine|
45939804|NCT00232453|Procedure|Combined Radiation and Chemotherapy|
45939805|NCT00232492|Drug|Placebo males|Intravenous saline bolus (Placebo-control) males
45939806|NCT00232492|Drug|Ketamine 0,1 mg/kg males|0,1 mg/kg ketamine iv bolus males
45939807|NCT00232492|Drug|Ketamine 0,3 mg/kg males|0,3 mg/kg ketamine iv bolus males
45939808|NCT00232492|Drug|Ketamine 0,5 mg/kg males|0,5 mg/kg ketamine iv bolus males
45939809|NCT00232492|Drug|Placebo females|Intravenous saline bolus (Placebo-control) females
45939810|NCT00232492|Drug|Ketamine 0,1 mg/kg females|0,1 mg/kg iv bolus ketamine females
45939811|NCT00232492|Drug|Ketamine 0,3 mg/kg females|0,3 mg/kg iv bolus ketamine females
45939812|NCT00232492|Drug|Ketamine 0,5 mg/kg females|0,5 mg/kg iv bolus ketamine females
45939813|NCT00075972|Behavioral|Mood Tolearance|
45939814|NCT00075972|Behavioral|Mood Management|
45939815|NCT00075972|Drug|Nicotine Replacement therapy|
45939816|NCT00063869|Drug|Etanercept|
45939817|NCT02962531|Drug|IX-01 caplets 1600 mg (4 x 400 mg), fasted|oral dose under fasted conditions
45939818|NCT02962531|Drug|IX-01 caplets 1600 mg (4 x 400 mg), fed|oral dose under fed conditions
45939819|NCT02962531|Drug|IX-01 aqueous dispersion 1600 mg (20 mL), fasted|oral dose under fasted conditions
45939820|NCT00232531|Drug|Niaspan|
45939821|NCT00232570|Drug|quetiapine|
45939822|NCT00232609|Device|GameCycle Exercise System|
45939823|NCT00097266|Drug|Placebo|Tablets/capsules, oral, 0 mg, once daily, 3 weeks (switched to arm B for an additional 9 weeks).
45805901|NCT05814627|Drug|Adalimumab|Subcutaneous Injection
45939824|NCT00097266|Drug|Aripiprazole|Tablets, oral, 15-30 mg, once daily, 12 weeks.
45939825|NCT00097266|Drug|Haloperidol|Capsule, oral, 5-15 mg, once daily, 12 weeks.
45939826|NCT00063947|Drug|erlotinib hydrochloride|Given orally
45939827|NCT00063947|Drug|gemcitabine hydrochloride|Given IV
45939828|NCT00063947|Radiation|radiation therapy|Undergo radiotherapy
45654797|NCT04966897|Dietary Supplement|GlycosBio Nutritional Supplement + PERT placebo|"The lipid (fat) in the GlycosBio Nutritional Supplement (GBNS) was provided in the form of a re-structured lipid monoacylglyceride (MAG) produced by the study sponsor. MAGs are readily absorbed by enterocytes without the need of digestion by pancreatic lipases. The MAG oil is produced enzymatically from almond oil. The product also contains essential amino acids, carbohydrates as simple sugars and fat-soluble vitamins and minerals. The GBNS to be administered in a volume sufficient to supply 0.5 g of MAG per kg of body weight"
45654798|NCT04966897|Dietary Supplement|Standard Nutritional Supplement + PERT|A 5.9% fat triacylglycerol-based commercially available nutritional supplement (Boost Plus®, Nestlé Health Science, Bridgewater, NJ) in a volume sufficient to supply 0.5 g of TAG per kg of body weight over the same time period and PERT capsules (24,000 iu/capsule) at a dose of 2,500 iu of lipase activity per gram of fat ingested.
45939829|NCT00063947|Other|laboratory biomarker analysis|Correlative studies
45939830|NCT00232648|Drug|Pulmicort (budesonide) Respules|
45805902|NCT05814627|Drug|Upadacitinib Matching Placebo|Oral Tablets
45939831|NCT00232687|Drug|Aripiprazole|Tablets, Oral, 15 mg fixed dose (week 1-5) flexible dose 10-30 mg (week 6-12), once daily, 12 weeks.
45805903|NCT05814627|Drug|Adalimumab Matching Placebo|Subcutaneous Injection
45939832|NCT00232687|Drug|Aripiprazole|Tablets, Oral, Uptitration: 5 mg (week 1), 10 mg (week 2 and 3), 15 mg(week 4 and 5) flexible 10-30mg from week 6-12, once daily, 12 weeks.
45939833|NCT00232726|Drug|CP-4055 (ELACYT)|
45939834|NCT02967185|Behavioral|Brief Behavioral Therapy for Insomnia|Treatment will consist of 4 weekly, 1 hour sessions and will be conducted by a trained graduate assistant on an individual basis. Treatment components will include education about aging and sleep. It will also include instruction in techniques designed to: (a) promote good sleep habits, (b) restrict the use of the bed and bedroom to sleep and sleep-conducive activities, (c) modify bed and wake times to better match the participants sleep needs, and (d) promote relaxation. Daily home practice of these techniques will be encouraged. Participants will maintain logs of their home practice sessions and will continue to record their daily sleep habits throughout treatment.
45939835|NCT00097305|Behavioral|Body-Oriented Therapy|
45939836|NCT00097305|Behavioral|Standardized Massage Therapy|
45939837|NCT00232765|Device|CYPHER Sirolimus-Eluting Stent|CYPHER Sirolimus-Eluting Stent
45939838|NCT00232765|Device|Uncoated BX VELOCITY Balloon-Expandable Stent|Uncoated BX VELOCITY Balloon-Expandable Stent
45939839|NCT00232804|Device|Bx Cypher stent|
46074390|NCT00854035|Drug|MK-0431/ONO-5435|Double-blind period (16 wk); 50 mg QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50mg QD to 100mg QD
46074391|NCT00854035|Drug|MK-0431/ONO-5435|Double-blind period (16 wk); placebo QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
45939840|NCT00232843|Device|stent|Cordis SMART™ nitinol self-expanding stent.
46074392|NCT00957905|Drug|Alvocidib Hydrochloride|Given IV
46074393|NCT00957905|Drug|Fluorouracil|Given IV
46074394|NCT00957905|Drug|Leucovorin Calcium|Given IV
45805904|NCT05811533|Other|Spencer's MET with conventional therapy|Patients will be asked to lie in a side lying position with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand provided force into the restrictive barrier of shoulder in 7 different movements. During all the movements, patients will ask to use their muscle energy 20% against the slight resistance offered by the therapist for 3-5 seconds. The patient then asks to relax and exhale after that shoulder joint will move beyond the barrier to achieve the next barrier. After 20 sec of rest, this technique will be repeated 3-5 times
46074395|NCT00957905|Drug|Oxaliplatin|Given IV
45939841|NCT00232843|Device|angioplasty|balloon angioplasty
45939842|NCT02958566|Drug|Acetaminophen|
45939843|NCT02958566|Drug|Gabapentin|
45939844|NCT02958566|Drug|Orphenadrine|
45939845|NCT02958566|Drug|Lidocaine|
45939846|NCT02958566|Drug|Marcaine|
45939847|NCT02958566|Drug|Ketamine|
45939848|NCT02958566|Drug|Methadone|
45939849|NCT02958566|Drug|Tramadol|
45939850|NCT02958566|Drug|Ketorolac|
45939851|NCT02958566|Drug|Morphine Sulfate|
45939852|NCT02958566|Drug|Fentanyl|
45939853|NCT02958566|Drug|Dilaudid|
45939854|NCT02958566|Drug|Hydrocodone-Acetaminophen Tab 5-325 MG|
45939855|NCT02958566|Drug|Morphine Sulfate|PCA
45939856|NCT02958566|Drug|Fentanyl|PCA
45939857|NCT02958566|Drug|Dilaudid|PCA
45939858|NCT02958566|Drug|HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET|Breakthrough
45939859|NCT00097344|Drug|Atamestane|
45939860|NCT00097344|Drug|Toremifene|
45939861|NCT00097344|Drug|Letrozole|
45939862|NCT00097344|Drug|Aromatase inhibition|
45939863|NCT00097344|Drug|Estrogen receptor blocker|
45939864|NCT00097344|Procedure|Hormone therapy|
45939865|NCT00097344|Procedure|Endocrine therapy|
45939866|NCT00097344|Procedure|Antiestrogen therapy|
45939867|NCT00232882|Drug|Candesartan Thiazide|Candesartan 16 mg for 4 weeks then added hydrochlorothiazide for 4 weeks
45939868|NCT00232882|Drug|Atenolol Thiazide|Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks
46074396|NCT02804724|Other|No intervention|
45939869|NCT00232882|Drug|Thiazide Candesartan|Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
45939870|NCT00232921|Drug|caudal volume 1|
45805905|NCT05811533|Other|Post-Facilitation Stretch with conventional therapy|Muscle Energy Technique [Post Facilitation Stretch)] for the shoulder joint will be applied with 3 repetitions per set, 1 session per day. Patient will be instructed to perform a full strength contraction of the muscle to be stretch for 10 seconds. The muscle is then allow to fully relax, whereupon a rapid stretch of the affected muscle will be performed and will held in position by the physician for 15 sec. Patient will be asked to relax and whole cycle will be repeated
45939871|NCT00232921|Biological|caudal volume 2|
45939872|NCT00232921|Drug|caudal volume 3|
45939873|NCT00232960|Procedure|Radiotherapy 50 Gy|
45939874|NCT00413647|Drug|CardioPET|
45939875|NCT00064064|Drug|gemcitabine hydrochloride|
45654799|NCT03737045|Other|Decision Aid|Participants will test decision aid prototypes that are designed to assist them in choosing a medication.
45654800|NCT03730259|Other|Web-based Tailored Intervention Preparation for Surgery|A Tailored Internet-based Preparation Program for Perioperative Anxiety and Pain (WebTIPS) is developed using the conceptual framework of the Triple Aim that evaluates the intervention within the context of clinical efficacy, improved child and parent experience, and reduced resource utilization during the surgical episode. WebTIPS aims at reducing perioperative anxiety and pain in children via an internet-based platform with short message service (SMS) two-way communication between a healthcare provider and patient.
45654801|NCT05587673|Drug|Methylprednisolone|High dose steroid injected directly into the inflamed bowel segment(s) via its arterial blood supply.
45939876|NCT00064064|Drug|triapine|
45939877|NCT00413686|Drug|AZD7762|intravenous infusion
45939878|NCT00413686|Drug|Gemcitabine|weekly intravenous infusion
45939879|NCT00233038|Procedure|Ethanol injection into a cyst|
45939880|NCT00097383|Drug|ALIMTA plus Epirubicin|
45939881|NCT00233077|Behavioral|Patient Assistance|Patients will be surveyed to assess their knowledge about cancer & its treatment, experience with & access to health care system, trust, depression, social support & self-efficacy. A Brief Screening Needs Assessment will be done to ascertain practical, informational or psychosocial needs; based on their responses, an individualized action plan to connect with patient assistance programs will be created for the intervention group. We will ask intervention patients if they connected with any programs in their action plan. For those who didn't connect, we will give their name to an outreach worker. The outreach worker will call patients and identify reasons for not contacting the assistance programs.
45939882|NCT00233077|Behavioral|Information only|Control patients will be sent a pamphlet about breast cancer & its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
45939883|NCT00064103|Biological|Ad5CMV-p53 gene|Given intramucosally or as oral rinse
45939884|NCT00064103|Other|laboratory biomarker analysis|Correlative studies
45939885|NCT00233155|Drug|Capsaicin Dermal Patch|
45939886|NCT00233194|Procedure|Observational follow-up study of adenotonsillectomy|Studies of sleep, behavior, cognition, and daytime sleepiness
45939887|NCT00097422|Drug|OPT-80|
45939888|NCT00233233|Behavioral|Standardized Asthma Education Program|
45939889|NCT00064142|Drug|halofuginone hydrobromide|Applied topically
45939890|NCT00064142|Other|placebo|Applied topically
45939891|NCT00064142|Other|laboratory biomarker analysis|Correlative studies
45939892|NCT00064142|Other|pharmacological study|Correlative studies
45939893|NCT00233350|Device|use of navigated 3D ultrasound during surgery|
45939894|NCT00233428|Procedure|Blood Draw|
45939895|NCT00064181|Drug|FOLFIRI regimen|
45939896|NCT00064181|Drug|capecitabine|
45939897|NCT00064181|Drug|celecoxib|
45939898|NCT00064181|Drug|fluorouracil|
45939899|NCT00064181|Drug|irinotecan hydrochloride|
45939900|NCT00064181|Drug|leucovorin calcium|
45939901|NCT00233506|Drug|CpG 7909|
45939902|NCT00233545|Drug|miltefosine|
45939903|NCT00233545|Drug|antimony|
45939904|NCT00233584|Procedure|Pulmicort (budesonide) pMDI|
45939905|NCT00233623|Drug|Iressa (Gefitinib)|
45939906|NCT00233623|Drug|Irinotecan|
45939907|NCT00233623|Drug|5Fluorouracil|
45939908|NCT00233623|Drug|Leucovorin|
45939909|NCT00233662|Drug|Alefacept|
45939910|NCT00076089|Drug|Roflumilast|
45939911|NCT00064220|Drug|soblidotin|
45939912|NCT00233740|Device|OPTEASE Vena Cava Filter|
45939913|NCT00233779|Device|SIROLIMUS-ELUTING, HEPARIN-COATED CoCr BALLOON-EXPANDABLE STENT|
45939914|NCT00233818|Device|Sirolimus-coated Bx VELOCITY Stent|
45939915|NCT00076206|Drug|CCI-779|
45939916|NCT00076206|Drug|Placebo|
45939917|NCT02958683|Other|Chest wall motion analysis|Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect
45939918|NCT00233857|Procedure|Auricular acupuncture|
45939919|NCT00233896|Drug|Oral beclomethasone dipropionate (drug)|
45939920|NCT00233935|Other|placebo|Given PO
45939921|NCT00233935|Drug|defined green tea catechin extract|Given PO
46074397|NCT04042597|Drug|Anlotinib Hydrochloride|anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
46074398|NCT02804568|Drug|ALKS 3831|Oral capsule, daily administration
46074399|NCT00862225|Drug|Placebo|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
45654802|NCT02444793|Drug|PF-05082566|Part 1: PF-05082566 dose escalation; Increased doses of PF-05082566 IV are administered at appropriate intervals. Part 2: MTD of PF-05082566 IV established in Part 1 is administered.
45654803|NCT02444793|Drug|KW-0761|Part 1: KW-0761 IV administered at appropriate intervals. Part 2: KW-0761 IV administered at appropriate intervals at the MTD dose for the combination.
45654804|NCT04957381|Behavioral|Group exercises|Group exercises including aerobic, resistance and stretching exercise. Once a week for 8-12 weeks.
45939922|NCT00233974|Procedure|PET (positron emission tomography)|Following conventional segmental mastectomy with or without needle localization, the patient will then undergo intraoperative PET-probe evaluation
46074400|NCT00862225|Drug|Desloratadin|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
46074401|NCT00862225|Drug|IG-RD-001 / Ze 339|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
45452762|NCT05037682|Other|Dissemination and Implementation Research|The study will employ a research and implementation design that attempts to balance scientific rigor, research good practices, primary care implementation preferences and numerous limitations related to the study context. A waitlist-controlled, staggered implementation study will be conducted with three groups of 15 practices introduced to the intervention in 3-month intervals, each baseline overlapping with interim measurements of care quality and process outcomes in concurrent groups in every 3 months, followed by a final data collection at the end of the intervention in months 16 and 17, including baseline measures plus semi-structured interviews. The groups and their sequence will not be randomized, but practice characteristics will be used to distribute them among the three groups based on location, type, size and patient mix to maximize the balance of practices among the groups.
45654805|NCT04957069|Procedure|fixation|double row fixation with 3-4 wire anchors
45654806|NCT04957069|Procedure|primary repair|end-to-end repair
45654807|NCT04966429|Drug|Maraviroc|Tablets
45654808|NCT04956913|Device|Mac Grath|Patients of this group were intubated using Mac Gath videolaryngoscope
45805906|NCT05811520|Other|Scapular stabilization exercises with conventional therapy|The patient will sit on the knees in 90° flexion position, and a Swiss ball will be placed between the chest and stomach. From the side, the earlobe, acromion of scapula, and pelvis should made a straight line. Four general exercises will be included with 2 sets of 15 repetitions, holding for 10 sec
45805907|NCT05811520|Other|Thoracic extension exercises with conventional therapy|Thoracic extension exercises consist of three exercise protocols
45805908|NCT05811351|Drug|JNJ-81201887|JNJ-81201887 will be administered as intravitreal injection.
45805909|NCT05811351|Drug|Prednisone|Prednisone will be administered as oral capsule.
45654809|NCT04956913|Device|Macintosh|Patients of this group were intubated using the Macintosh Laryngoscope
45654810|NCT04949659|Procedure|Laparoscopic appendectomy|Laparoscopic appendectomy performed with defined, randomized to level of pressure for pneumoperitoneum
45654811|NCT04949581|Other|bioelectric therapy|the patient will receive microcurrent therapy from a supine lying position. the negative electrode on the incision area and the positive electrode proximal. the intensity will be less than 20 microamperes and frequency at 20 HZ.
45654812|NCT04949581|Other|cardiac rehabilitation program|the patient will receive cardiac rehabilitation program
45654813|NCT04949971|Behavioral|High volume group|Thea High tidal volume of the exposed group was 10ml/kg ideal body weight
45654814|NCT04966195|Radiation|stereotactic body raiotherapy|stereotactic body radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis
45654815|NCT04965883|Procedure|Excision and Grafting|reconstruction of deep burn by grafting
45654816|NCT04965883|Procedure|dressing then delayed grafting|multiple dressing and delayed grafting
45654817|NCT04949347|Biological|glaucoma drainage device implantation|Glaucoma drainage device implantation, a 350 mm2 Baerveldt (BG 101-350) GDD (Johnson and Johnson, Santa Ana, CA, USA) was performed using glycerin-preserved, human-donor, corneoscleral tissue ( the remaining from a heterologous, human-donor corneal button, obtained from the International Eye Bank of Thailand, after a clear corneal graft had been used for penetrating keratoplasty.) The tissue had been preserved in glycerin using the sterile technique and kept in a medical refrigerator for no longer than 6 months.
45805910|NCT05811351|Other|Placebo|Prednisone matching placebo will be administered as oral capsule.
45805911|NCT05811351|Drug|Triamcinolone|Triamcinolone (corticosteroid injection) periocular injection will be administered as per local practice.
45805912|NCT05811351|Other|Sham Procedure|Sham injections matching to single JNJ-81201887 injection and matching to corticosteroid (triamcinolone) periocular injection will be administered.
45805913|NCT05803551|Drug|Ketamine Hydrochloride|Intravenous 0.5 mg/kg infusions of ketamine for three consecutive days, 24 hours apart, with no more than 1mg/kg or 60 mg/day regardless of body weight
45939923|NCT00234091|Drug|Abacavir|8 mg/kg (up to 300 mg/dose) take orally twice daily
45939924|NCT00234091|Drug|Efavirenz|200 to 600 mg taken orally once daily
45939925|NCT00234091|Drug|Lamivudine|4 mg/kg (up to 150 mg/dose) taken orally twice daily
45939926|NCT00234091|Drug|Lopinavir/Ritonavir|230 mg/57.5 mg/m^2 body surface area taken orally twice daily with food
45939927|NCT00234091|Drug|Nelfinavir|45-55 mg/kg taken orally twice daily with food
45939928|NCT00234091|Drug|Nevirapine|120 mg/m^2 once daily for first 14 days, tehn 200 mg/m^2 (up to 400 mg/day) twice daily
45939929|NCT00234091|Drug|Zidovudine|180-240 mg/m^2 every 12 hours (up to 300 mg/dose)
45939930|NCT00064376|Drug|paricalcitol|
45939931|NCT00234130|Procedure|nocturnal vs conventional dialysis|
46074402|NCT02804646|Drug|recombinant human endostatin|endostar was continuous intravenous transfusion for 7 days，with the dose of 15mg/m2 for one day
45805914|NCT05803551|Drug|Placebo|Intravenous 0.9% saline infusions for three consecutive days.
46074403|NCT02804646|Drug|pemetrexed plus cisplatin or carboplatin|the dose of pemetrexed was 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin.
45805915|NCT05798039|Behavioral|ENRICH|Participants will receive additional heart health-focused materials and guidance in sessions with their nurse home visitor. The nurse will help them choose and work towards behavior goals to support their health. This will include goals for activity, diet, weight, blood pressure, diabetes, smoking, social relationships, sleep, parenting, and getting health care.
45805916|NCT05797246|Drug|Bevacizumab|10 mg/kg IV every three weeks for 3 cycles and then every 6 weeks for a total treatment course of 11 cycles for approximately 1 year total.
45805917|NCT05797233|Biological|Anti-CD19 and anti-CD20 bicistronic CAR T- cells|0.66x10^6 CAR+ T - 10x10^6 CAR+ T cells/kg (weight based dosing per cohort) infused on day 0
45805918|NCT05797233|Drug|Cyclophosphamide|500 mg/m^2 IV infusion over 30 minutes on days -5, -4 and -3
45805919|NCT05797233|Drug|Fludarabine|30 mg/m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
45939932|NCT00234169|Drug|VTP195183|"VTP195183: 60mg/m2 orally daily G-CSF: 10mcg/kg/day subcutaneously Provision is made for dose reduction of VTP195183 in the event of unexpected dose-limiting toxicities G-CSF10mcg/kg/day will commence on day 1 and will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.~Patients will be treated with VTP195183 alone at 60mg/m2/day from day 1 to day 7. On day 8 VTP195183 will be continued and G-CSF10mcg/kg/day will be added. VTP195183 plus G-CSF will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first."
45939933|NCT04721704|Drug|Clarithromycin+ Amoxicillin + Omeprazole|In Group A: Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI will be given to children
45939934|NCT04721704|Drug|Metronidazole +Amoxicillin + Omeprazole|Group B: Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI
45939935|NCT02958605|Device|Smartphone apps|If already own a smartphone application dedicated to calculate medication dosage for children, the participant will be allowed to use his/her own application. Otherwise, the resident will be offered to chose among a list of applications paid by the research team (PediSafe, PediStat, Palm Pedi, Safedose, EZdrip peds). He/she will be instructed to practice with a few time at home before doing the simulations.
45939936|NCT02958605|Device|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
45939937|NCT00234208|Procedure|Medical thoracoscopy|
45939938|NCT00234208|Procedure|Simple chest tube drainage|
45939939|NCT00076284|Drug|GW873140|
45939940|NCT00234247|Other|Long Term Follow-Up|Extended and enhance the follow-up of the NHLBI iNO RCT by assessing the effects of iNO use on: 1.) long term clinical and childhood developmental outcomes; 2.) family impact, and; 3.) healthcare costs of prematurity-associated respiratory failure.
46074404|NCT00862303|Biological|DC-CIK|Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.
46074405|NCT00862303|Drug|IL-2/IFN-α|Patients receive treatment of IL-2 or IFN-α.
46074406|NCT02768831|Other|CPAP|Sealing the airway by holding CPAP of 20 cmH2O in the anesthesia circuit and slowly inflating the cuff until no air leak is heard with a stethoscope placed in the suprasternal notch.
45805920|NCT05796791|Drug|Ketamine Hydrochloride|IM ketamine given in weekly session for a total of 3 weeks
45805921|NCT05796791|Behavioral|Motivational enhancement therapy|Brief motivational based therapy
45805922|NCT05794152|Other|Standardized breakfast|Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.
45805923|NCT05794152|Other|Standardized snack|Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.
46074407|NCT02768831|Other|Tidal volume|The ratio of the inspired to expired tidal volume will be determined using the following formula: (TVinspired - TV¬expired)/TVinspired. The peak inflating pressure (PIP) required to achieve the set TV will be noted. The air in the cuff will then be increased or decreased as needed to achieve a set delivered ratio of 0.9-1.0.
46074408|NCT00854191|Device|simulator training|4 half-day of simulator ERCP practice as endoscopist and/or assistant followed by usual training
46074409|NCT02807142|Biological|NC 1 cell therapy|All patients will be treated with NC1
45805924|NCT05794152|Other|Standardized lunch|Participants will be provided with a standardized lunch 2 h after they have the standardized snack.
45805925|NCT05792566|Other|Atomic app|Using the Atomic app to improve physical activity
45805926|NCT05789745|Drug|Recombinant human plasma gelsolin|intravenous administration of either 6, 12, 18, or 24 mg/kg at time 0, 12, 36, 60 and 84 hours
45805927|NCT05789745|Other|placebo|intravenous administration of saline control at time 0, 12, 36, 60 and 84 hours
45805928|NCT05788406|Other|Short foot exercises, Dynamic balance exercises and insole|Short foot exercises is used to improve muscle strenght, Dynamic balance exercises is used to improve balance and insole is used to improve MLA
45805929|NCT05787899|Other|Hypothermia Protocol|Subject's who will be treated with the hypothermia protocol for Hypoxic Ischemic Encephalopathy as standard of care.
45939941|NCT00234403|Drug|gefitinib and fulvestrant|
45939942|NCT00064415|Drug|arformoterol|Arformoterol inhalation solution, 50 mcg QD
45939943|NCT00064415|Drug|Salmeterol|Salmeterol MDI, 42 mcg BID
45939944|NCT00234442|Drug|Iressa (Gefitinib)|
45939945|NCT00400413|Procedure|fMRI|
45939946|NCT00234481|Drug|XL844|
45939947|NCT00076323|Drug|Primaquine|
45939948|NCT00234598|Procedure|Toothbrushing only|Toothbrushing three times per 24 hours without chlorhexidine
45939949|NCT00234598|Procedure|Chlorhexidine only|Chlorhexidine oral rinse twice per 24 hours without toothbrushing
45939950|NCT00234598|Procedure|Toothbrushing and Chlorhexidine|Toothbrushing three times per 24 hours plus chlorhexidine twice per 24 hours.
45939951|NCT00234637|Drug|Rivastigmine, memantine|
46074410|NCT02858297|Drug|Glucosamine sulfate|Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan with recently reported immunoregulatory capacity and anti-inflammatory effect
46074411|NCT02858297|Drug|triamcinolone acetonide|Topical corticosteroid
46074412|NCT00858325|Drug|Daptomycin|4mg/kg and 6 mg/kg dissolved in 0.9% sodium chloride for injection, administered intravenously over 30 minutes.
45654818|NCT04956367|Procedure|Ablative fractional carbon dioxide laser combined with autologous platelet-rich plasma|Carbon dioxide laser (Smaxel.878.4810) was FDA-approved device used in dermatology practice. PRP was described as having growth factors to be used to promote healing.
46074413|NCT04236648|Procedure|Minimally-invasive non-surgical therapy (MINST)|subgingival root debridement with a minimally-invasive approach using piezoelectric/ultrasonic instruments
46074414|NCT04200846|Behavioral|Exercise intervention|Subjects in this group will be asked to exercise 5 days a week. Two days on-site with an Exercise Physiologist and the other 3 days at home.
45654819|NCT04956367|Device|CO2 laser with PRP|CO2 laser with PRP
46074415|NCT02804490|Dietary Supplement|Conventional white maize|Women and their infants will receive 2 meals/day prepared with conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
45654820|NCT04956367|Device|CO2 laser with placebo|CO2 laser with placebo
46074416|NCT02804490|Dietary Supplement|Provitamin A carotenoid biofortified maize|Women and their infants will receive 2 meals/day prepared with provitamin A carotenoid biofortified orange maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
46074417|NCT02804490|Dietary Supplement|Preformed vitamin A fortified maize|Women and their infants will receive 2 meals/day prepared with preformed vitamin A fortified, conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
45805930|NCT05786196|Device|Ab-interno canaloplasty utilizing the iTrack Advance device|360 degree microcatheterization and viscodilation of Schlemm's canal
45805931|NCT05786196|Device|Ab-interno canaloplasty utilizing the OMNI Surgical System|360 degree microcatheterization and viscodilation of Schlemm's canal
45654821|NCT04956601|Radiation|vaginal brachytherapy/pelvic external beam radiotherapy|high-dose-rate vaginal brachytherapy; pelvic external beam radiotherapy
46074418|NCT00960323|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1.
46074419|NCT00960323|Drug|Atorvastatin|Atorvastatin (1 x 40 mg tablet) administered once daily on Days 15-28.
46074420|NCT00960323|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with a single dose of 40 mg atorvastatin in the morning on Day 28 after an overnight fast.
46074421|NCT00617929|Biological|anti-thymocyte globulin|administer 3 mg/kg intravenously (IV) over 4 hours on days -6, -5 and -4.
46074422|NCT00617929|Biological|rituximab|administered 375 mg/m^2 intravenously (IV) in 1 mg/mL normal saline on day -7.
45805932|NCT05784844|Drug|Meropenem|Carbapenem antibiotic
45805933|NCT05784844|Drug|Micafungin|Echinocandin antifungal
45939952|NCT00064454|Drug|OPC-6535 Tablets (drug)|
45939953|NCT00413803|Procedure|4-hour thrice weekly in center hemodialysis|conventional hemodialysis
46074423|NCT00617929|Drug|clofarabine|administered 30 mg/m^2 intravenously (IV) over 1 hour on Days -4, -3, and -2.
46074424|NCT00617929|Procedure|stem cell transplantation|administered on Day 0 per institutional guidelines.
46074425|NCT02804412|Other|Control group|This is the control group with 14 h treatment over 10 workdays.
46074426|NCT02804412|Other|CIAT-group|Examine the efficacy of CIAT (30 h over 10 workdays) versus Control-group and communication treatment group.
46074427|NCT02804412|Other|communication treatment group (CTG)|Examine the efficacy of CTG (30h over 10 wokrdays) versus CIAT-group and control group
46074428|NCT00862381|Drug|Hydrocortisone|hemisuccinate d'hydrocortisone, 200mg per 24 hours, 48 hours of treatment
46074429|NCT00862381|Drug|Placebo|NaCl 0.9%
45654822|NCT04965961|Drug|EPO|Please refer to the arm description
45654823|NCT04965961|Other|Control group - saline injection|Please refer to the arm description
45805934|NCT05784363|Drug|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9 percent (%) Sodium Chloride (NaCl).
45805935|NCT05784363|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
45654824|NCT04966039|Other|No intervention.|There was no intervention.
45676283|NCT04098835|Behavioral|ASCEND|ASCEND is a behavioral intervention that combines computer-based cognitive exercise, strategy coaching with a neuropsychologist, and homework exercises in order to improve attention, working memory, and cognitive control after stroke.
45676284|NCT04091217|Drug|Atezolizumab|Atezolizumab 1200 mg will be administered intravenously every 3 weeks.
45676285|NCT04091217|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg will be administered intravenously every 3 weeks.
45676286|NCT04081688|Drug|Atezolizumab 1200 MG in 20 ML Injection|Given IV every 3 weeks (cycle is 21 days)
45805936|NCT05784129|Drug|Guselkumab|Guselkumab will be administered subcutaneously.
45805937|NCT05784129|Drug|Placebo|Placebo will be administered subcutaneously.
45805938|NCT05783960|Other|administration questionary|Questionnaire will be compared to 24h sodium and potassium urinary excretion (reference). A Bayesian network and a multiple regression will be used to validate the questionary
45805939|NCT05783726|Other|Control|Participants will be shown images of juice, bread, yogurt, cookies, and cereal without any added front-of-package labels.
45939954|NCT00413803|Procedure|8-hour thrice weekly in center hemodialysis|long dialysis
45939955|NCT00234676|Drug|Premarin ®|Premarin ® 0.625 mg per day orally
45939956|NCT00076362|Drug|Sandostatin LAR|
45939957|NCT00234754|Procedure|TVT Surgery TOT Surgery|TVT surgery and TOT surgery
45939958|NCT00234793|Behavioral|Problem-Solving Skills Training|
45939959|NCT00234871|Drug|trandolapril/verapamil|2/180 mg QD with forced titration after 4 weeks to 4/240 mg QD
45654825|NCT04956055|Other|Reflexology|The patient will be kept in a lying position. First, the patient will be given four minutes of hand reflexology on each hand with warming and stimulation techniques.Reflexology will be applied to the left hand with the thumb of the right hand, the thumb of the left hand and the special points in the right hand. It will be applied to the fingers, palm, back of the hand, and finally the wrists, respectively, starting with the fingertips and using special reflexology techniques (a total of six minutes for each hand separately). By sending a moderate stimulus, a total of 20 minutes of reflexology session will continue.Since the patient reveals and uses his own internal energy at the end of the session, nobody should talk to the patient until five minutes after the procedure. Survey questions and vital signs would be examined five minutes after the session and the research with the participant would end.
45654826|NCT04955977|Other|Physical exercise program|"Step 1 • Diaphragmatic reeducation: • Aerobic capacity: Intensity: zone 2, 60% HRMax, 4-6 / 10 Borg Scale; Charge: 20 m.~Step 2 • Aerobic capacity: Intensity: zone 2, 65% HRMax, 4-6 Borg Scale; Charge: 25 m. • Muscular strength: Method: Pyramidal; Intensity: 3-4 / 10 Omni-Res; Load: 20% 1RM; Series: 3; Reps: 1. • Flexibility and elasticity: Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s.~Step 3 • Aerobic capacity: Intensity: zone 3, 70% HRMax, 5-6 / 10 Borg scale, Load: 25 m. • Muscular strength: Method: Pyramidal; Intensity: 4-5 / 10 Omni-Res; Load: 30% 1RM; Series: 4; Reps: 10. • Flexibility and elasticity: Method: active stretching; Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s.~Step 4 •Aerobic capacity: Intensity: zone 3, 75% HRMax, 6-7 / 10 Borg scale, Load: 30 m. • Muscular strength: Intensity: 5-6 / 10 Omni-Res; Load: 40-50% 1RM; Series: 4 s; Reps: 13. • Flexibility and elasticity: Method: active stretching; Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s."
45654827|NCT04955977|Other|Health education in COPD|Week 1-2: Health education: COPD and respiratory care at home. Week 3-4: Importance of daily physical activity in COPD. Week 5-6: Early Signs of COPD Exacerbation and Action Plan Week 7-8: Use and care of respiratory devices at home.
45654828|NCT04956211|Procedure|Periodontal therapy|Patients will receive a standard regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one or two sessions within 2 days) with curettes and ultrasonic instruments.
45805940|NCT05783726|Behavioral|Nutriscore Label|A front-of-package Nutriscore label will be applied to images of juice, bread, yogurt, cookies, and cereal. This label applies a score of A, B, C, D, or E based on the product's nutrition profile.
45654829|NCT04949035|Diagnostic Test|Assessment of mental state and quality of life|Patients qualified for rehabilitation will be assessed for stress levels as well as symptoms of anxiety and depression and quality of life before rehabilitation began
46074430|NCT02800668|Device|DJBL (Duodenal jejunal bypass liner, EndoBarrier)|Implantation of EndoBarrier after medical and patient's decision, Duration of treatment 12 months in maximum, follow up for 4 weeks after Explantation, follow up during treatment by physical examination, ECG control, sampling and analysis of blood parameters, mixed meal tolerance tests only for diagnostic purposes to assess gut hormonal changes and metabolic parameters
46074431|NCT02860637|Other|Questionnaires|Sexual function was assessed by the International Index of Erectile Function (IIEF) and level and degree of injury were determined following the guidelines of the International Standards for Neurological and Functional Examination Classification of Spinal Cord Injury.
45654830|NCT04948879|Procedure|Vascular resection/reconstruction|The resection of a major blood vessel with or without reconstruction
45654831|NCT04948957|Drug|Esmolol|
45654832|NCT04948957|Drug|Nitroglycerin|
45676287|NCT04081688|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT between cycle 1 and cycle 2 (each cycle is 21 days)
45805941|NCT05783726|Behavioral|Adapted Peruvian Nutrient Label|A front-of-package octagonal nutrient label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label text informs consumers if a product is high in sugar, saturated fat, or salt/sodium. These labels were developed by the Peruvian government and adapted by investigators.
45805942|NCT05783726|Behavioral|Guideline Daily Amount Label|A front-of-package Guideline Daily Amount label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label shows the amount and percent of daily value of calories, total fat, saturated fat, sugar, and sodium in one serving of a product.
45805943|NCT05782244|Drug|Sildenafil Citrate low dose|Sildenafil citrate 20 mg, oral, TID
45805944|NCT05782244|Drug|Placebo|Placebo, oral, TID
46074432|NCT00858481|Drug|Spinosad Creme Rinse - Vehicle Control|One or two, 10-minute topical applications (7 days apart)
46074433|NCT00858481|Drug|Spinosad Creme Rinse|0.5% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
46074434|NCT00858481|Drug|Spinosad Creme Rinse|1.0% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
46074435|NCT00858481|Drug|Spinosad Creme Rinse|2.0% Spinosad Creme Rinse - one or two, 10-minute topical applications (7 days apart)
45939960|NCT00234871|Drug|Lotrel (amlodipine/benazepril)|5/10 mg QD with forced titration after 4 weeks to 10/20 mg QD
45805945|NCT05782244|Drug|Sildenafil medium dose|Sildenafil 40 mg, oral, TID
45654833|NCT04948801|Drug|Epclusa (sofosbuvir and velpatasvir)|Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A inhibitor fixed-dose combination for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.
45654834|NCT04948255|Other|Health and Safety Executive's (HSE) Management Standards Indicator Tool (MSIT) to measure work-related stress|Questionnaire
45654835|NCT04965415|Behavioral|Health Links + Leadership Training|Help businesses undergo transactional (i.e., business management practices) and transformational (i.e., business leadership and culture) change. Transactional change component: Health Links is an existing community-based intervention that seeks to help businesses - especially small and medium-sized businesses - incorporate Total Worker Health (TWH) programming into their business practices through assessment, advising, and certification. There is evidence that this consultation intervention is effective at helping businesses develop and implement policies and programs.Transformational change component: The experimental arm includes TWH leadership training for small business owners and other senior leaders. This is a three-month training that includes assessments, in-person training, and virtual training transfer activities. The goal is to help the leader understand their organization's current approach to TWH, identify areas for improvement, and to take action.
45939961|NCT00234910|Drug|Tenofovir DF|TDF 300mg QD for 72 wks
45654836|NCT04965415|Behavioral|Health Links|Health Links is an existing community-based intervention that seeks to help businesses - especially small and medium-sized businesses - create a culture of both safety and health. Health Links does this by helping businesses incorporate Total Worker Health (TWH) programming into their business practices through assessment, advising, and certification. There is evidence that this consultation intervention is effective at helping businesses develop and implement policies and programs.
45654837|NCT04948567|Other|split-dose of Magnesium Sulfate solution|purgative for bowel preparation
45805946|NCT05782244|Drug|Sildenafil high dose|Sildenafil 80 mg, oral, TID
45805947|NCT05780177|Behavioral|Brief Behavioral Treatment for Insomnia (BBTI)|Participants in this arm will receive 4 sessions (20-60 minutes) of a brief behavioral treatment for insomnia called BBTI. Relaxation techniques are not a component of BBTI.
45805948|NCT05780177|Behavioral|Progressive Muscle Relaxation Training (PMRT)|Participants in this arm will receive 4 sessions (20-60 minutes) of progressive muscle relaxation training called PMRT.
45939962|NCT00234910|Drug|lopinavir/ritonavir with 2 Nucleoside RTIs|LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks
45939963|NCT00400452|Behavioral|wheelchair skills training|
45654838|NCT04948567|Other|split-dose of PEG|purgative for bowel preparation
45654839|NCT04955665|Procedure|bone block procedure|a 20 × 15 × 3 mm3 bone block was cut from the lateral malleolus, rotated backwards 45°, and sutured back to the periosteum of the lateral malleolus using non-absorbable sutures.
45939964|NCT00234949|Drug|cefdinir|
45939965|NCT00234949|Drug|cephalexin|
45939966|NCT00234988|Drug|sibutramine hydochloride monohydrate|10 mg QD with the option to increase dose to 15 mg QD up until Week 4
45939967|NCT00235027|Other|Adverse Drug Event Monitoring|The intervention in this study is the presentation of medication safety alerts in the electronic medical record to improve patient outcomes and safety.
46074436|NCT05494008|Procedure|Korean herbal medicine treatment|Korean herbal medicine treatment is a treatment using complex extract of medicinal herbs prescribed by a Korean medicine doctor who has completed specialized education to diagnose the health condition and symptoms of patients with post-traffic accident syndromes.
46074437|NCT05494008|Procedure|Non-Korean herbal medicine treatment|acupuncture, pharmacoacupuncture, cupping, chuna
46074438|NCT02858141|Other|Data collection|
46074439|NCT00858559|Device|Implantable cardioverter defibrillator with Home Monitoring function|Implantable cardioverter defibrillators can send data from its diagnostic and therapy memory via wireless Home Monitoring on a daily basis to an internet based platform, securely accessed by the attending physician
46074440|NCT00858559|Device|Standard implantable cardioverter defibrillator|Implantable cardioverter defibrillators used as standard devices without Home Monitoring
46074441|NCT02800590|Drug|ABP-700|
46074442|NCT02860481|Procedure|blood sample for FSHR analysis|
46074443|NCT02860481|Procedure|blood sample for FSHR analysis|
45676288|NCT04081688|Drug|Varlilumab 3 mg/kg|Given IV every 3 weeks (cycle is 21 days)
45939968|NCT00064571|Procedure|vocal fold medialization|
45939969|NCT00064571|Procedure|vocal fold reinnervation|
45676289|NCT04081389|Drug|Celecoxib|Given PO
45676290|NCT04081389|Drug|Cyclophosphamide|Given IV
45676291|NCT04081389|Drug|Doxorubicin|Given IV
45939970|NCT00400491|Drug|Cholecalciferol (vitamin D)|Cholecalciferol capsule 20.000 IU twice per week for 6 months
45939971|NCT00400491|Drug|Placebo|Placebo capsule twice a week, identical to the cholecalciferol capsules
45939972|NCT00235066|Device|PCI|PCI with Cypher Sirolimus-Eluting Stent
45939973|NCT00235105|Drug|Adalimumab 40 mg sc every other week|
45939974|NCT00235144|Device|sirolimus-coated Bx Velocity stent|drug-eluting stent
45939975|NCT00235144|Device|uncoated Bx Velocity stent|bare-metal stent
45939976|NCT00400530|Drug|MK0217, alendronate sodium / Duration of Treatment: 1 Month|
45939977|NCT00400530|Drug|Comparator: Alendronate-Teva / Duration of Treatment: 1 Month|
45939978|NCT00064610|Drug|VELCADE TM (bortezomib) for Injection|
45939979|NCT00235183|Other|plasma|transfusion of more than 15 mL/Kg of plasma
45939980|NCT00235222|Drug|stavudine|
45939981|NCT00235261|Drug|Pregabalin|
45939982|NCT00235261|Drug|Dexamethasone|
45805949|NCT05779605|Device|Home-based training|Patients will be instructed to perform three weekly training sessions at home (30 to 50 min/session, at an intensity of 70-85% of their maximum heart rate). Patients in the home training group complete the first three training sessions in the clinic under direct supervision. During these sessions, patients are introduced to the duration and intensity of training. The trainer will provide remote guidance (feedback on training frequency, duration, and intensity) via telephone call once a week. During exercise, patients will use a wearable heart rate monitor (Polar M430, a commercially available device designed for long-term use). Patients will be instructed to properly use the wearable sensor and upload training data to a web-based platform (Polar Flow) via the Internet. Furthermore, patients will be asked to choose their preferred training modality at home (cycling, walking, Nordic walking) and receive instructions and advice.
45654840|NCT04955665|Procedure|Reattachment of the superior peroneal retinaculum|two suture anchors (Mini Quickanchor,DePuy Mitek) were inserted into the postero-lateral ridge of the lateral malleolus without damaging the cartilaginous ridge, after which the SPR was reattached to the lateral malleolus with the anchored suture. The inner layer of the false pouch was incised, and the outer layer (periosteum) was sutured with the SPR in a pants-over-vest style.
45939983|NCT00235300|Biological|Thymoglobulin [Anti-thymocyte Globulin (rabbit)]|1.5 mg/kg per day, for a maximum of 5 doses
45939984|NCT00235300|Drug|Simulect (basliximab)|20 mg per day on 2 days
45939985|NCT00064649|Device|Transurethral Microwave Thermotherapy (TUMT)|type of minimally invasive surgical therapy for BPH
45939986|NCT00064649|Device|Transurethral Needle Ablation (TUNA) Therapy|type of minimally invasive surgical therapy for BPH
45939987|NCT00064649|Drug|Finasteride and Alfuzosin|finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg
45654841|NCT04965571|Genetic|genetic test|Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA)
45654842|NCT04955509|Other|MRI|conventional MRI and diffusion MRI
45939988|NCT00097656|Other|multi-center, randomized, controled periodontal therapy|periodontal therapy
45452763|NCT03134638|Drug|SY-1365 (Part 1)|"Two dosing schedules will be evaluated in dose escalation and a dose(s)/schedule(s) will be determined for Part 2:~Twice weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle.~Weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28 day) cycle."
45654843|NCT03060655|Biological|PLGA-Mg material|The PLGA-Mg material was used to accomplish the fixation of fragments. Then, the clinical outcome was assessed.
45654844|NCT03060655|Biological|titanium alloy|Traditional fixation was titanium alloy. the clinical outcome was assessed.
45654845|NCT04419181|Drug|Docetaxel|Dose: 75 mg/m2 q3w
45654846|NCT04419181|Drug|Carboplatin|Dose: area under the concentration-time curve [AUC] 6 q3w
45654847|NCT04419181|Drug|Trastuzumab|Dose: 8-mg/kg loading dose, 6-mg/kg maintenance dose q3w
45805950|NCT05779605|Device|Center-based training|Patients receive three training sessions a week with 30 to 50 min duration at 70 - 90% of their maximal heart rate at the outpatient clinic under direct supervision. Exercise modalities will be walking on a treadmill, riding a bicycle ergometer, and resistance training. Physiotherapists will track the attendance rate and training adherence during the training program.
45805951|NCT05778071|Combination Product|eneboparatide|Supplied as a solution (concentration of 250 mcg/mL or 500 mcg/mL) in single-patient-use prefilled pens
45452764|NCT03134638|Drug|Carboplatin|Carboplatin will be administered on Day 1 of each 3 week (21-day) cycle (Part 2 only)
45452765|NCT03134638|Drug|Fulvestrant|Fulvestrant will be administered as an intramuscular (IM) dose of 500 mg every 2 weeks for the first 3 doses on Day 1 and Day 15 of the first 28-day cycle (Cycle 1), and on Day 1 of the second 28 day cycle (Cycle 2), and monthly thereafter starting on Day 1 of Cycle 3 (Part 2 only)
45654848|NCT04419181|Drug|Pertuzumab|Dose: 840-mg loading dose, 420-mg maintenance dose q3w
45654849|NCT04419181|Drug|Trastuzumab emtansine|Dose: 3.6mg/kg q3w
45654850|NCT03060187|Other|KU Score|Exam with a max score of 10 and min score of 0. Designed as a preoperative assessment of the patient's airway.
45654851|NCT04955353|Dietary Supplement|AVC-H2|A total of 2.5g AVC-H2 daily (2 tablets in the morning and 2 in the evening)
45654852|NCT04955353|Dietary Supplement|Placebo|A total of 2.5g placebo daily (2 tablets in the morning and 2 in the evening)
45654853|NCT03060343|Biological|Zeushield Cytotoxic T Lymphocytes|"Three dose levels will be evaluated. Dose Level One: 1.0×10^5 cells/kg, Dose Level Two: 1.0×10^6 cells/kg, Dose Level Three: 1.0×10^7 cells/kg.~At the discretion of the investigator, if patients with active disease have stable disease or a response at week 8 or on subsequent evaluations, they are eligible to receive up to 6 additional infusions at 8 to 12 week intervals."
45654854|NCT04955119|Diagnostic Test|Fusion imaging contrast-enhanced ultrasound|"Fusion imaging contrast-enhanced ultrasound will be performed for patients with invisible lesion at conventional ultrasound.~Drug: SonoVue"
45805952|NCT05778071|Combination Product|Placebo|Placebo is supplied as a solution (containing the excipient solution for eneboparatide) in single-patient-use prefilled pens
45805953|NCT05777759|Device|New Dermal Filler|hyaluronic acid
45805954|NCT05777759|Device|FDA appoved Dermal Filler|hyaluronic acid
45805955|NCT05777603|Drug|aerosolized aztreonam|antibiotic with gram-negative bacteria coverage
45654855|NCT04965103|Procedure|SCR|Superior Capsule reconstruction
45654856|NCT04965103|Procedure|Bridging|Tendon repair with graft interposition
45654857|NCT04954963|Diagnostic Test|Reduce metal artifacts examination|patients undergo reduce metal artifacts examination
45676292|NCT04081389|Drug|Doxorubicin Hydrochloride|Given IV
45676293|NCT04081389|Drug|Paclitaxel|Given IV
45805956|NCT05777603|Drug|aerosolized vancomycin|antibiotic with gram-positive bacteria coverage
45805957|NCT05777603|Drug|pembrolizumab|standard of care therapy/monoclonal antibody for patients with advanced NSCLC
45939989|NCT00235339|Behavioral|Exercise training|Standard exercise training at the hospital, two times per week for twelve weeks
45939990|NCT00235339|Behavioral|Exercise training|Interval exercise training with high intensity on treadmill. Subjects exercise two times per week for twelve weeks
45939991|NCT00235417|Procedure|Bone marrow transplantation|
45805958|NCT05775848|Drug|BBP-418 (ribitol)|The BBP-418 drug product is provided as Granules for Oral solution consisting of BBP-418 drug substance and silicon dioxide in a multilaminate sachet with a foil barrier. Silicon dioxide is generally regarded as safe and listed in the FDA IIAD. Silicon dioxide is a compendial excipient and is commonly used in pharmaceutical dosage forms. The BBP-418 Granules for Oral Solution are provided in sachets to provide 3 g BBP-418 per sachet. The BBP-418 Granules for Oral Solution are reconstituted in water for oral administration.
45452766|NCT03134638|Drug|SY-1365 (Cohort 2)|In combination with carboplatin, SY-1365 will be administered by intravenous infusion over 1 or 2 hours for 2 weeks of each 3 week (21-day) cycle (Part 2 only)
45452767|NCT03134638|Drug|SY-1365 (Cohort 5)|In combination with fulvestrant, SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28-day) cycle (Part 2 only)
45654858|NCT03060421|Device|Aquamid reconstruction|Aquamid Reconstruction is a Polyacrylamide hydrogel that contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape. Aquamid Reconstruction is biocompatible, non-absorbable non-biodegradable, stable, and sterile. T Aquamid Reconstruction is injected into the knee joint cavity.
45654859|NCT04955041|Other|MRI|T2* MRI
45805959|NCT05775848|Other|Placebo|A placebo matched for similar taste and appearance was compounded at the clinical pharmacy with sucralose as a 0.35 mg/mL oral solution in purified water (USP) in a glass container. Sucralose is similar in taste to the compounded drug product.
45805960|NCT05773066|Device|Belotero® Intense Lidocaine|Dermal hyaluronic acid (HA) filler for lip augmentation.
45805961|NCT05773066|Device|Restylane® Silk|HA gel for lip augmentation.
45805962|NCT05773053|Drug|NT 201|Clostridium botulinum neurotoxin type A (150 kiloDalton [kD], free of complexing proteins) powder for solution for injection.
45805963|NCT05773053|Drug|NT 201 Placebo|NT 201 Matching-placebo.
46074444|NCT00815295|Drug|Sorafenib|Phase 1 - Dose level 1 : Sorafenib will be given 200 mg twice daily oral, Phase 1 - Dose level 2 : Sorafenib will be given 400 mg twice daily oral, Phase 2 : Sorafenib will be given at the maximum tolerated dose from Phase 1
45452768|NCT03134638|Drug|SY-1365 (Part 2 Single Agent)|SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle
45452769|NCT04473664|Drug|Quizartinib|Single dose of 30 mg quizartinib to be administered orally
45805964|NCT05772897|Behavioral|Circle of Security Parenting program|The Circle of Security Parenting (COSP) program is an 8- week group parenting course that was designed using decades of attachment research to foster a secure attachment by teaching parents to read and respond to infant cues, and to recognize the interplay between their own psychological and emotional experiences and the emotional regulation of their infants. The COSP program provides parents with relationship tools and techniques for understanding their children's needs in new ways that provide lasting security for the child and more satisfaction for the parent. There are two major themes in the program: 1) teaching parents how to read their children's behavior and use it as a guide for meeting their needs and 2) helping parents to understand how their own early attachment relationships have influenced them as a person, and how those influences show up in their parenting and impact their ability to help regulate their child and respond to their needs.
45805965|NCT05771090|Device|Sokru device|Different induced glycaemic states in people living with diabetes (PwD).
45805966|NCT05770102|Drug|Atezolizumab|"Adult participants will receive 1200 mg of atezolizumab intravenously every 21 days.~Paediatric participants will receive atezolizumab at a dose of 15 mg/kg (maximum 1200 mg) every 21 days.~Participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent."
45805967|NCT05768880|Biological|SC-CAR4BRAIN|Courses of weekly intravenous SC-CAR4BRAIN infusions for 3 weeks, then 1 week off
45805968|NCT05768139|Drug|STX-478|STX-478 is a second generation, mutant-selective, oral PI3Kα small molecule allosteric inhibitor.
45805969|NCT05768139|Drug|Fulvestrant|Fulvestrant will be administered according to local labeling.
45805970|NCT05765903|Other|Standard of Care|"Diagnosis education~Follow-appointment scheduling assistance~Offer resources in the community~Offer weekly follow-up calls for one month"
45805971|NCT05765903|Other|Enhanced Care|"Social Determinants of Health (SDoH) assessment~Set-up Home Health Services (HHS), Mobile Integrated Healthcare (MIH) or Resources, Education and Access to Community Health (REACH).~Additional educational training using computer tablet devices, such as iPads"
46074445|NCT00815295|Drug|Cetuximab|Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly.
45452770|NCT03205046|Drug|acalabrutinib|Acalabrutinib is a selective, irreversible small molecule Bruton's tyrosine kinase (BTK) inhibitor.
45452771|NCT03205046|Drug|vistusertib|Vistusertib is an inhibitor of mechanistic target of rapamycin (mTOR) kinase
45654860|NCT04954885|Procedure|Biospecimen Collection|Undergo stool sample
45654861|NCT04954885|Other|Physical Performance Testing|Undergo short physical performance battery
45654862|NCT04954885|Other|Physical Performance Testing|Perform 6-minute walk test
45654863|NCT04954885|Other|Questionnaire Administration|Complete questionnaires
45654864|NCT04965805|Device|cold plasmaJet kINPen Med|experimental, non-inferiority
45654865|NCT04965805|Device|Best practice wound dressings|comparative,
45676294|NCT04081389|Biological|Recombinant Interferon Alfa-2b|Given IV
45805972|NCT05765812|Drug|Debio 0123|Administered as capsules.
45805973|NCT05765812|Drug|Temozolomide|Administered as capsules.
45805974|NCT05765812|Radiation|Radiotherapy|Administered in accordance with the local clinical practice and applicable Radiation Therapy Oncology Group (RTOG) or the European Organization for Research and Treatment of Cancer (EORTC) guidelines.
45805975|NCT05764733|Drug|Bisphosphonate|medicine used to treat bone problems, called osteopenia or osteoporosis
45939992|NCT04710511|Other|Child and Youth Resilience Measure - Revised (CYRM-R)|(CYRM-R): questionnaire , answered by the child (PMK): questionnaire, answered by the parent
45939993|NCT00097734|Drug|ertapenem|
45939994|NCT00064727|Drug|Avandia (Rosiglitazone)|
46074446|NCT00854269|Procedure|surgery|cervical biopsy or specimen of hysterectomy
46074447|NCT04235790|Device|Eye Tracking Device|Eye tracking glasses
45939995|NCT00064727|Drug|Avanclia (Rosiqlitazone)|
45939996|NCT04710316|Diagnostic Test|SARS-CoV-2 screening by molecular biology|SARS-CoV-2 RT-PCR in nasopharyngeal swab targeting 2 regions of the viral genome
45654866|NCT02624713|Behavioral|obesity treatment|"Parents' education groups for nutrition and healthy behavior with a dietician and a social worker every 2 weeks for5 months, for a total of 10 meetings. This part of the intervention aimed at providing parents with effective tools for modification of lifestyle and the family environment.~Children's individual therapy consisted of 6 individual meetings with a family physician, a physical therapist specializing in children's physical activity, and a dietician. This part of the intervention aimed at modifying nutrition and lifestyle; the physical therapist can help children incorporate physical activity into their routine.~Physical activity groups for the children, with individual physical fitness monitoring. twice a week for 6 months. ."
45676295|NCT04081389|Drug|Rintatolimod|Given IV
45805976|NCT05764733|Behavioral|Resistance Training/Bone-Loading Exercise|Exercise in small groups three days per week under the supervision of exercise physiologists. Heart rate and blood pressure will be measured before and after each session and participants will warm-up by walking or cycling for five minutes at a slow pace. All RT exercises will be conducted on machines which accommodate different body sizes and allow small increments in resistance, both important considerations for low functioning older adults with obesity.
45805977|NCT05764733|Other|Placebo|capsules identical to the active alendronate capsules without any active ingredients with the same dosing and follow up as BIS treatment group.
45805978|NCT05763160|Drug|RZL-012|Ready to use drug product for injection into the subcutaneous fat
45805979|NCT05760989|Device|Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System|Replacement of the native tricuspid valve through a transcatheter approach
45939997|NCT04710316|Diagnostic Test|Serological screening|Serological screening of caregivers at D0, M1, M2, M3 (anti-nucleocapsid antibodies).
45939998|NCT04710082|Procedure|Photorefractive keratectomy (PRK)|Photorefractive keratectomy (PRK) is a surgical procedure used by ophthalmic surgeons to treat patients presented with refractive errors and involves corneal epithelial removal followed by application of excimer laser to correct different refractive errors including Myopia, Hyperopia and Astigmatism.
45939999|NCT00235534|Behavioral|Immediate initiation of OCPs|
45940000|NCT00235534|Behavioral|Delayed initiation of OCPs|
45940001|NCT00235651|Drug|Amphotericin B|
45940002|NCT00097812|Drug|zoledronic acid|
45940003|NCT00235690|Procedure|Blood draws|PK samples obtained around a clinical dosing of colistin
45940004|NCT00235690|Other|Blood draw|PK blood samples will be obtained around a clinical dosing of colistin
45940005|NCT00064766|Drug|doxycycline|
45940006|NCT00235729|Drug|Lofexidine|Lofexidine is an alpha2-adrenergic-agonist with mild to moderate antihypertensive actions. It is mainly used in the alleviation of opioid withdrawal signs and symptoms.
45940007|NCT00235729|Drug|Placebo|Placebo is an exact match of lofexidine, less the active ingredient.
45940008|NCT04721080|Other|Functional Outcome Measurements|Dyspnea Exercise capacity Quality of life assessment
45940009|NCT00064805|Behavioral|Cognitive Therapy to Improve Reading|
45452772|NCT04884698|Device|Stimit Activator|"The Stimit Activator Device is composed of three components.~A magnetic stimulator generating current pulses~A novel Stimit coil design optimized for phrenic nerve stimulation~A coil positioning device for quick, easy and reproducible coil positioning"
45452773|NCT02397434|Radiation|Adjuvant EBRT|Radiation up to a median dose of 50 Gy in 25 fractions will be delivered with IMAT to the pelvic lymph node regions. If there is a positive surgical margin, the operative bladder bed will be included in the radiation field. A simultaneous integrated boost to positive lymph nodes will be delivered.
45676296|NCT04072380|Drug|SUVN-G3031|SUVN-G3031 Tablets
45676297|NCT04072380|Drug|Placebo|Placebo Tablets
45805980|NCT05760794|Procedure|Non-barbed delayed absorbable suture|The non-barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 PDS (polydioxanone). The vaginal mesh will be attached with at least four interrupted sutures on the anterior vagina and posterior vagina.
45805981|NCT05760794|Procedure|Barbed delayed absorbable suture|The barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 V-Loc. The vaginal mesh will be attached with a running V-Loc on the anterior and posterior vagina.
45805982|NCT05760313|Drug|Linaclotide|Capsule; oral
45805983|NCT05760313|Drug|Placebo|Capsule; oral
45940010|NCT00235807|Procedure|Tinnitus Masking|Sound therapy with Tinnitus Masking is intended to produce immediate relief from the discomfort caused by tinnitus (Vernon, 1977; 1987; Vernon, 1988). If maskers or combination units are used, the masking sound can be set at any level the patient chooses to attain maximum relief. Relief using masking noise can be accomplished using the external sound of the masker, which is generally a more acceptable sound than the tinnitus.
45940011|NCT00235807|Procedure|Tinnitus Retraining Therapy (TRT)|The TRT procedure adheres as closely as possible to the methodology described by Dr. Pawel Jastreboff. For TRT, sound therapy is used to facilitate long-term habituation to tinnitus (Jastreboff, 1999b).
45940012|NCT00235807|Procedure|Tinnitus Education (TED)|TED represents tinnitus treatment that would typically be provided by audiologists using hearing aids and counseling (although for this study the counseling has been structured and expanded to be equivalent in length to the other two groups).
45940013|NCT00235846|Procedure|vein harvest|Conventional open vein harvest or endoscopic vein harvest
45940014|NCT00235885|Drug|adalimumab|
45940015|NCT00235924|Drug|soy isoflavone|
45940016|NCT04728750|Procedure|Enucleation of a tumor of the pancreas|Enucleation of a tumor in the pancreas is feasible and safe, as it offers a minimally invasive approach, and morbidities are fewer than open or conventional approach
45940017|NCT00235963|Drug|Simvastatin|
45940018|NCT00236002|Drug|Alendronate|Alendronate 70mgm once a week for one year
45940019|NCT00064922|Behavioral|Behavior Therapy|
45940020|NCT00236041|Drug|ACTIQ®|
45805984|NCT05759364|Drug|IV Papaverine 80 mg|Opium alkaloid antispasmodic drug
45940021|NCT00097890|Drug|Replagal (Agalsidase Alfa)|
45940022|NCT00097890|Drug|Replagal|
46074448|NCT00630383|Biological|Live Hookworm Larvae|25 live hookworm will be applied to the arm and will infect transdermally. They will be eradicated after 48 weeks.
45452774|NCT04855526|Drug|High THC/No CBD Marihuana|high THC (65 mg THC) and no CBD (0 mg CBD)
45654867|NCT03058081|Device|High Flow nasal cannula|High intensity Constant Work-Rate exercise test with High Flow Nasal Cannula in COPD patients involved in a Pulmonary Rehabilitation Program after an exacerbation (< 7 days after hospital discharge). High Flow nasal will be administered through nasal cannula using the Airvo2 (Fisher&Paykel)
45805985|NCT05759364|Drug|Placebo|Placebo
45940023|NCT00236119|Drug|CEP-701 20mg|Dosages of oral CEP-701 20mg will be given twice daily. Escalation to the next higher dosage, CEP-701 40mg, may occur once the first 8 patients at the current dosage have completed 8 weeks of treatment without adverse events or laboratory abnormalities. Patients who remain in Cohort 1 will continue on the 20mg dosage until study completion.
45805986|NCT05757869|Drug|Milvexian|Milvexian will be administered orally.
45654868|NCT04430179|Drug|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|300 mg every other week for 24 weeks
45654869|NCT04430179|Other|Placebo|No active drug
45940024|NCT00236119|Drug|CEP-701 40mg|Dosages of oral CEP-701 40mg will be given twice daily.Escalation to the next higher dosage, CEP-701 60mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 2 will continue on the 40mg dosage until study completion.
45654870|NCT04946929|Drug|Ticagrelor Oral Tablet [Brilinta]|Ticagrelor, 2-3mg/kg, 12h, p.o.
45805987|NCT05757869|Drug|Apixaban|Apixaban will be administered orally.
45940025|NCT00236119|Drug|CEP-701 60mg|Dosages of oral CEP-701 60mg will be given twice daily. Escalation to the next higher dosage, CEP-701 80mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 3 will continue on the 60mg dosage until study completion.
45654871|NCT04946929|Drug|Low molecular weight heparin|half amount low molecular weight heparin
45654872|NCT04933045|Device|Arthrex InternalBrace|Placement of Arthrex InternalBrace for anatomic distal tibiofibular ligament augmentation to stabilize the ankle syndesmosis during surgery.
45654873|NCT03058159|Other|fMRI|fMRI scans will be acquired before and after a 40 min nap slot in the afternoon. Functional connectivity between brain region will be assessed analyzing the scans with the CONN toolbox of the Statistical Parametric Mapping (SPM) software.
45805988|NCT05757869|Drug|Placebo|Milvexian matching milvexian placebo will be administered orally.
45940026|NCT00236119|Drug|CEP-701 80mg|Dosages of oral CEP-701 80mg will be given twice daily. Patients who have moved to Cohort 4 will continue on the 80mg dosage until study completion.
45940027|NCT04721275|Other|measurement of pronostic sepsis scores|qSOFA, NEWS and MEDS sores are measured to each patient admitted in the emergency department with a suspicion of infection (excluding localized infection as abscess, angina, cystitis).
45805989|NCT05757869|Drug|Apixaban Placebo|Apixaban matching apixaban placebo will be administered orally.
45452775|NCT04855526|Drug|High THC/High CBD Marihuana|high THC (65 mg THC) and high CBD (50 mg CBD)
45452776|NCT04855526|Drug|No THC/No CBD Marihuana|no THC (0 mg THC) and no CBD (0 mg CBD); placebo drug
45452777|NCT03204812|Biological|Durvalumab|Given IV
45654874|NCT02624791|Device|1-DAY ACUVUE® MOIST contact lenses|spherical contact lenses worn during simulated driving tests
45805990|NCT05755035|Biological|TAK-881|Participants will receive SC infusion of TAK-881 on Day 1.
45805991|NCT05755035|Biological|HYQVIA|Participants will receive SC infusion of HYQVIA on Day 1.
45805992|NCT05754957|Drug|Milvexian|Milvexian will be administered orally.
45452778|NCT03204812|Biological|Tremelimumab|Given IV
45452779|NCT04837352|Other|Study of the role of sociocognitive factors|Questionnaires
45654875|NCT02624791|Device|1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses|toric contact lenses worn during simulated driving tests
45654876|NCT02624791|Other|No contact lenses|simulated driving tests
45654877|NCT03058237|Drug|Arbaclofen Placarbil SR|One low dose oral tablet of Arbaclofen Placarbil sustained release (SR) in the fasted state.
45654878|NCT03058237|Drug|Arbaclofen Placarbil MR Prototype A|One low dose oral tablet pf Arbaclofen Placarbil modified release (MR) Prototype A in the fasted state; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
45805993|NCT05754957|Other|Placebo|Placebo will be administered orally.
45805994|NCT05754931|Other|Deep neck flexors training + Conventional therapy|Hold for 10 sec and repeated 10 times.Patients will be treated 3 times a week for 4 consecutive weeks
45805995|NCT05754931|Other|Muscles energy techniques + conventional therapy|position of patient is in maximal comfort and lengthening After engaging the barrier use of an isometric contraction Feel the release and lengthen the muscle repeated for 4 time per session Patients will be treated 3 times a week for 4 consecutive weeks
45940028|NCT00236158|Device|AAIR/DDDR pacemaker|Pacemaker with single lead or dual lead
45940029|NCT00413881|Procedure|WAVEFRONT- GUIDED LASIK ENHANCEMENT|Laser treatment to correct residual refractive error left over from initial LASIK correction using wavefront guided LADARvision 4000 excimer laser system
46074449|NCT00630383|Other|Histamine|0.01% histamine solution is pipetted onto a plaster dressing.
46074450|NCT04042519|Diagnostic Test|Lung function test was performed on the subjects with Jaeger lung function instrument of Germany.|This Jaeger lung function instrument of Germany is used to test the pulmonary ventilation function of COPD patients. Since the condition requires drug control and treatment, the drug cannot be stopped.
46074451|NCT04042519|Diagnostic Test|Agilent 1290 Infinity LC system (UHPLC, Santa Clara CA) was used for Targeted metabolite detection.|We used the Agilent 1290 Infinity LC system mass spectrometer to analyze and detect metabolite peaks of patients according to retention time and mass/charge ratio after preliminary experiments and derivatization.
45654879|NCT03058237|Drug|Arbaclofen Placarbil MR Prototype B|One low dose oral tablet of Arbaclofen Placarbil modified release (MR) Prototype B; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
45654880|NCT03058237|Drug|Arbaclofen Placarbil IR|One low dose oral capsule of Arbaclofen Placarbil immediate release (IR) in the fasted state.
45654881|NCT04947241|Drug|PD-1 inhibitor+ Gemcitabine + Cisplatin|"Before surgery, patients will receive therapy as follows:~PD-1 inhibitor: 240mg (day1) , intravenous, Q3W, 2cycles; cisplatin: 80 mg/m2(day1), intravenous , intravenous, Q3W, 2cycles Gemcitabine: 1000mg/m2(day1and day8), intravenous, Q3W, 2cycles"
45654882|NCT04946539|Diagnostic Test|Ultrasonography|Enthesitis assessment via ultrasonography
45654883|NCT03058393|Other|Teach-Back Lesson|A teach-back lesson will be given to providers (teach-back group) who have challenging clinical discussions with patients
45654884|NCT04944511|Drug|Toripalimab Injection|Toripalimab Injection used for mixed chimerism between 80%-95% in HLH patients. Dose: 240mg toripalimab Injection, two weeks later, the same dose will be repeated if patients have some improve in the chimeric rate.
45654885|NCT04944043|Drug|TQ05105 Tablet|TQ05105 tablet is a JAK inhibitor, which can inhibit the abnormal activation of JAK2-V617F mutation, thereby inhibiting the sustained abnormal activation of JAK / STAT pathway.
45654886|NCT03057925|Device|Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
45654887|NCT04410991|Drug|Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
45654888|NCT04410991|Drug|Teriflunomide HMR1726|"Pharmaceutical form: Tablet~Route of administration: Oral"
45654889|NCT04410991|Drug|Placebo to match Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
45654890|NCT04410991|Drug|Placebo to match Teriflunomide|"Pharmaceutical form: Tablet~Route of administration: Oral"
45654891|NCT04933279|Dietary Supplement|iodine-containg spareribs soup|administrated a 150 ml - 200 ml of iodine-containg spareribs soup delivering ≈ 600 µg or 1200 µg iodine
45654892|NCT04933279|Dietary Supplement|intrinsic iodine in natural kelp|administrated 45 g or 80 g natural kelp delivering ≈ 600 µg or 1200 µg iodine (intrinsic iodine). The natural kelp will be approximately produced in an experimental barn feeding supplementary iodine to reach a final iodine intake of ≈ 600 µg or 1200 µg. The iodine intake of natural kelp will be adjusted to the required dose by determing iodine content in the natural kelp.
45654893|NCT03057301|Device|iCare home tonometer|All subjects will be taught to use the home care tonometer.
45805996|NCT05754632|Device|Blood Flow Restriction using Delfi Personalized Tourniquet System|The Delfi Tourniquet System is designed to be used in conjunction with exercise. The system automatically determines the degree of occlusion and allows for safe regulation of pressure. Patients will then complete exercises with the use of this device.
45940030|NCT00413881|Procedure|CONVENTIONAL LASIK ENHANCEMENT|Laser treatment to correct residual refractive error left over from initial LASIK correction using LADARvision 4000 excimer laser system.
45940031|NCT00414037|Drug|Eszopiclone|
45940032|NCT00414037|Drug|Placebo|Placebo-treatment
45940033|NCT00236236|Device|Cardiac Resynchronization Therapy|
45654894|NCT04932655|Drug|simufilam|Simufilam 100 mg oral tablets: the Phase 3 oral tablet for the first 3 arms and the Phase 2 tablet for the 4th arm.
45654895|NCT04943809|Device|POD 26P AY FT|Routine cataract surgery
45654896|NCT04943809|Device|POD 26P AY F|Routine cataract surgery
45654897|NCT04946695|Other|Telefisio India|Implement telephysiotherapy programmes in low-resource areas.
45676298|NCT04068103|Drug|Capecitabine|Given PO
45676299|NCT04068103|Drug|Fluorouracil|Given IV
45676300|NCT04068103|Drug|Leucovorin|Given IV
45676301|NCT04068103|Drug|Leucovorin Calcium|Given IV
45940034|NCT00236275|Drug|Fluoro-L-thymidine-(18F)|Fluoro-L-thymidine-(18F)
45940035|NCT00236353|Drug|risperidone|
45940036|NCT00236392|Drug|rabeprazole|
45654898|NCT03058003|Diagnostic Test|Posturography Evaluation|Posturography testing using the extended modified Clinical Testing of Sensory Integration in Balance (ext_mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, feet shoulder width, with eyes open or closed, arms to the side and free to move, gazing forward, and breathing normally, with head straight, turned right or left, flexed or extended
45654899|NCT03058003|Other|Central Sensitization Inventory|Standard chronic pain questionnaire: the subjects will be required to score each of the 25 items on a scale from 0 (never) to 4 (always)
45654900|NCT02577029|Drug|ARC-520|ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.
45654901|NCT02577029|Drug|entecavir|0.5 mg once daily; oral
45654902|NCT02577029|Biological|pegylated interferon alpha 2a|180 mcg; subcutaneous injection once weekly
45805997|NCT05754151|Behavioral|MAYA Mobile Application|The mobile cognitive behavioral therapy (CBT) application, MAYA, teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, exposure and psychoeducation (i.e. information about anxiety and depression). The application includes an interactive dashboard to provide the user with statistics for tracking progress toward their goals. Although the MAYA application is new, its content and structure are similar to how CBT- a well-established and widely used psychosocial intervention - is commonly delivered in the more traditional setting of a psychotherapist's office.
45654903|NCT02577029|Drug|tenofovir disoproxil|300 mg once daily; oral
45654904|NCT02577029|Drug|antihistamine|All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.
45654905|NCT04932889|Other|Survey|A detailed anamnesis was retrospectively recorded about age, gender, body mass index, education, working, the presence of any chronic disease (diabetes mellitus, hypertension, chronic obstructive pulmonary disease, cardiac disease, cancer, rheumatological disease…), smoking, duration of symptoms, usage of supplementing vitamins such as vitamin D,C, zinc…, treatment place (home quarantine, hospital, intensive care unit), duration of home quarantine and hospital treatment, the number of months since the onset of Covid-19 symptoms, usage of anticoagulants, treatment drugs such as hydroxychloroquine, favipiravir. Also the symptoms during the period of Covid-19 infection were recorded from patient files; cough, fever, dyspnea, chest pain, loss of smell and taste, sore throat, headache, no symptom, musculoskeletal symptoms such as: muscle, low back, back, joint pain.
45654906|NCT04932889|Other|Laboratory parameters|The laboratory values of 182 patients, presence of chest computed tomography findings of 206 patients and symptoms of all patients during the period of Covid-19 infection, were retrospectively recorded. Laboratory values of hemoglobin, leucocyte, lymphocyte, platelet, C-reactive protein, erythrocyte sedimentation rate, ferritin, d-dimer, were recorded.
45676302|NCT04068103|Drug|Oxaliplatin|Give IV
45676303|NCT04068103|Other|Patient Observation|Undergo active surveillance
45940037|NCT02961907|Procedure|PEPCI|"Both parents will receive:~consultation with a psychiatrist then psychologist follow-up if required, addiction specialist physician consultation then liaison nurse follow-up if required~endocrinologist consultation then dietitian follow-up if required~actiphysician consultation and follow-up if required This program will be added to the usual routine course Both parents will receive a 3 months personalized follow-up if required from the multi disciplinary consultation and before the first ART attempt."
45805998|NCT05753735|Drug|Piperacillin/Tazobactam|Piperacillin/Tazobactam 3.375 g IV every 6 hours while inpatient following surgery, not to exceed 10 days
45805999|NCT05753735|Drug|Amoxicillin/ Clavulanic acid|Amoxicillin/ Clavulanic acid 875/125 mg every 12 hours after discharge to complete 10 days total antibiotics
45806000|NCT05749926|Biological|Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech)|A single administration of COVID-19 vaccine will be performed at D0, depending on randomization
45806001|NCT05749926|Biological|VidPrevtyn® Beta vaccine (Sanofi/GSK)|A single administration of COVID-19 vaccine will be performed at D0, depending on randomization
45806002|NCT05749146|Behavioral|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
45654907|NCT04932889|Other|chest computed tomography|Typical findings of chest CT were; bilateral, multifocal, peripheral ground glass opacities with/without consolidation, including the fissures, close to visceral pleural surfaces. Covid-19 Reporting and Data System (CO-RADS) was used for chest CT. CO-RADS assigns scores from 1 (very low suspicion of Covid-19) to 5 (very high suspicion of Covid-19).
45940038|NCT00236431|Drug|Galantamine hydrobromide|
45940039|NCT00097929|Drug|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months|
45654908|NCT04946617|Drug|undefined|Rinsing with mouthwashes
45940040|NCT00236470|Drug|risperidone|
45940041|NCT00236509|Drug|topiramate|
45940042|NCT02962141|Device|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|Treatment group
45940043|NCT02962141|Device|Balloon Dilatation Catheter|Control group
45806003|NCT05741710|Drug|Methylone|Methylone capsules, given orally, once a week for 4 weeks
45806004|NCT05741710|Drug|Placebo|Placebo capsules to match methylone, given orally, once a week for 4 weeks. NOTE: Placebo is only in Part B
45940044|NCT00065000|Behavioral|Water, Cafeteria and Staff Health Promotion|
45940045|NCT00076401|Drug|Motexafin gadolinium|
45940046|NCT00236548|Drug|risperidone|
45940047|NCT00236587|Drug|risperidone|
45940048|NCT00236626|Drug|topiramate|
45940049|NCT00065039|Behavioral|Promotion of a healthy diet and physical activity|
45940050|NCT00065039|Behavioral|Avoidance of Alcohol, Drugs, and Tobacco|
45452780|NCT04946552|Diagnostic Test|PET Scan|Participants will come to the PET Center to undergo the whole body [11C]MRB PET scan. An intravenous bolus dose of MRB (~20mCi) will be injected by an infusion pump. PET data will be acquired dynamically for 120 min using the Siemens mCT-X whole-body PET/CT scanner using continuous bed motion to image multiple PET bed acquisitions from the top of the head to the lower abdominal region.
45654909|NCT04946383|Drug|Dasatinib plus Quercetin|Dasatinib plus Quercetin
45654910|NCT04943653|Drug|Paclitaxel|"intraperitoneal paclitaxel~20mg/BSA(Body Surface Area), 40mg/BSA, 60mg/BSA (phase I)~recommended dose (phase II)"
45940051|NCT00236665|Drug|topiramate|
45940052|NCT00399282|Drug|Omega-3 and Vitamin E supplementation|
45806005|NCT05741528|Drug|SEP-363856|SEP-363856 tablet
45806006|NCT05741476|Drug|DBV712|DBV712 250 mcg epicutaneous system.
45806007|NCT05741476|Other|Placebo|DBV712 matching placebo epicutaneous system.
45806008|NCT05741047|Other|a2Milk skim milk powder|a2Milk skim milk powder (1L) containing A2 β-casein only
45806009|NCT05741047|Other|Yili skim milk powder|Yili skim milk powder (1L) containing A1 and A2 β-caseins
45806010|NCT05740566|Drug|Tarlatamab|Tarlatamab will be administered as an IV infusion.
45940053|NCT04721041|Procedure|Washed Microbiota Transplantation (WMT)|Washed microbiota suspension (5u) delivered through nasogastric tube, nasojejunal tube or oral. Dose and frequency: 5u, three times.
45940054|NCT00236704|Drug|topiramate|
45940055|NCT00065078|Procedure|Home dispensing of contraception|
45940056|NCT00236743|Drug|topiramate|
45940057|NCT00236782|Drug|norelgestromin + ethinyl estradiol; mercilon|
45940058|NCT00097968|Drug|everolimus|
45940059|NCT00236821|Drug|levofloxacin|
45806011|NCT05740566|Drug|Lurbinectedin|Lurbinectedin will be administered per local SOC.
45806012|NCT05740566|Drug|Topotecan|Topotecan will be administered per local SOC.
45806013|NCT05740566|Drug|Amrubicin|Amrubicin will be administered per local SOC.
45806014|NCT05740540|Device|IRS-8|Implanted Receiver Stimulator (IRS) delivering 8 channels of stimulation. Appropriate for muscle-based (intramuscular or epimysial) electrodes only
45806015|NCT05740540|Device|IST 12 & IST 16|Implantable Stimulator Telemeter (IST) that provides 12 independent channels of stimulation with the option of 2 channels of bipolar myoelectric signal recording, or 16 independent stimulus channels. Suitable for muscle-based or nerve cuff electrodes such as the CWRU Spiral, Flat Interface Nerve Electrode (FINE) or Composite-Flat Interface Nerve Electrode (C-FINE).
45806016|NCT05739981|Drug|Paclitaxel|Paclitaxel 175 mg/m2 IV
45806017|NCT05739981|Drug|Carboplatin|Carboplatin AUC 5-6 IV
45940060|NCT00236860|Drug|topiramate|
45940061|NCT00065117|Drug|ZD6126|
45940062|NCT00065117|Drug|Placebo|
45940063|NCT00065117|Drug|5-fluorouracil|
45940064|NCT00065117|Drug|leucovorin|
45940065|NCT00065117|Drug|oxaliplatin|
45940066|NCT02961868|Other|Abdominal and supra-aortic trunks vascular imaging|Abdominal and supra-aortic trunks vascular imaging (angiography, CT-angiography or MR-angiography) will be performed 3 years after inclusion. This imaging will be compare to initial imaging (which is a part of usual care, not an intervention added by the study) in order to assess FMD progression.
45940067|NCT02961868|Genetic|Blood sampling (genetic)|A sample of blood will be taken to meet the objective of estimating the rate of genetic polymorphism that may influence disease progression or be associated with complications.
45940068|NCT02961868|Other|Blood sampling (biomarkers)|A sample of blood will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
45940069|NCT02961868|Other|Urine sampling|A sample of urine will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
45940070|NCT00237016|Drug|doxycycline treatment|
45940071|NCT00237094|Behavioral|Nurse Practitioner led multidisciplinary team approach|
45940072|NCT00237133|Drug|Letrozole|1 tablet of Letrozole 2.5 mg orally adminnistered once a day
45940073|NCT00065195|Procedure|Moving touch therapy|
45940074|NCT00065195|Procedure|Nonmoving touch therapy|
45654911|NCT04942951|Diagnostic Test|Gynecological examination|Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
45806018|NCT05739981|Drug|Bevacizumab|BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: [1] Cycle 1, [2] the last cycle of neoadjuvant therapy immediately preceding ICS, and [3] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.
45806019|NCT05739981|Drug|GEN1|IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
46074452|NCT04042519|Diagnostic Test|Routine blood test|Blood routine test results include CRP, PCT, white blood cell count, red blood cell count, neutrophil percentage, eosinophil, basophil, et al.
46074453|NCT02806830|Drug|Optive|Optive eye drops will be prescribed to each included patients after their second intravitreal injection; patients will received 1 drop in the affected eye 2 times a day during 3 days
45654912|NCT04942951|Other|Pelvic Organ Prolapse Quantification (POP-Q)|Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
45654913|NCT04942951|Other|Incontinence Consultation Questionnaire-Short Form (ICIQ-SF) questionnaire|ICIQ-SF questionnaire was applied to the Study group to determine the severity of urinary incontinence.
45654914|NCT04942951|Other|Pregnancy-Related Anxiety Questionnaire-Revised 2 (PRAQ-R2) questionnaire|PRAQ-R2 questionnaire was applied to the whole pregnant cohort included in the study to determine their anxiety status.
45654915|NCT02577887|Device|Patients implanted with a St. Jude Medical pacemakers|
45654916|NCT04943029|Drug|Carrelizumab|Camrelizumab: 200mg, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 3 cycles; Adjuvant therapy: 16cycles.
45654917|NCT04943029|Drug|Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)|Nab-paclitaxel: 260mg/m^2, IV, day 1 of each 21-day cycle, 3 cycles; Pemetrexed: 500 mg/m^2, IV, day 1 of each 21-day cycle, 3 cycles.
45654918|NCT04943029|Drug|Carboplatin|Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 3 cycles.
45654919|NCT04943029|Procedure|Surgery|Surgery must be done within the 4th-6th week from day 1 cycle 3 of neoadjuvant treatment (4-6 weeks after day 1 of cycle 3)
45654920|NCT05236283|Diagnostic Test|Blood Culture|Blood Culture
45654921|NCT04932499|Other|Standard of Care|Participants randomly assigned to this intervention will receive standard of care given to all patients undergoing total knee arthroplasty at our institution as outlined in the Common Care Pathway for Total Joint Replacement. Outcome assessments will be completed pre-operatively, each day while in hospital and 7 and 14 days postoperative.
45806020|NCT05739162|Device|Apollo Endoscopic Suture System|Endoscopic Sleeve Gastroplasty (ESG), and endoscopic minimally-invasive weight loss procedure, utilizing a suturing device to reduce the stomach volume by 70-80% through the creation of sleeve. This is accomplished by a series of endoscopically placed stitches through the stomach wall.
45806021|NCT05739162|Behavioral|Lifestyle Intervention|Low-calorie healthy diet personalized by a dietician according to individual patients' needs and conducive to weight loss. Physical activity will be encourage and assessed.
45806022|NCT05737732|Device|Circadian Effective Lighting|Participants will receive lighting with a spectrum of 300K, 500 lux to the eye level between 7:00am and 10:00am in the morning, and hospital lighting (<100lux) during the afternoon between 10:00am and 6:00pm. In the evening this group of participants will receive lighting with a spectrum of 3000K, <50lux at eye light level between 6:00PM and bedtime.
46074454|NCT03203135|Behavioral|Nutritional prevention programme|The nutritional prevention programme will offer a wide range of food and physical activity activities adapted to the life of the company (example: culinary demonstration, physical activity, provision of fruit baskets, etc.) .
45654922|NCT04932499|Other|Mindfulness Meditation|"In addition to standard of care, participants randomly assigned to the treatment group will be given a 45-60 minute teaching session on mindfulness meditation. Upon completion of this session, participants will be given homework recordings of a body scan exercise and asked to listen to the recording daily for the two-week period prior to surgery. Participants will be asked to listen to their recording immediately prior to their surgery and daily while in hospital. In addition, participants assigned to mindfulness intervention will receive standard of care as outlined in the control group. Outcome assessments will be completed pre-operatively, each day while in hospital and 7 and 14 days postoperative."
45654923|NCT05535101|Device|Intermittent theta burst transcranial magnetic stimulation (iTBS)|The amphetamine users will undergo a one-month iTBS intervention. From Week 1 to Week 4, subjects will be treated five times a week.
45806023|NCT05737732|Device|Circadian Ineffective Lightning (CIL)|Participants will receive lower lighting levels in the morning (lighting with A spectrum of 300k, <50lux to the eye level between 7:00am and 10:00am) and the same lighting levels throughout the rest of the day.
45940075|NCT00237172|Drug|Imatinib Mesylate|once daily
45940076|NCT00237211|Drug|Letrozole|
45940077|NCT00098007|Drug|Everolimus (Certican)|
45940078|NCT00237250|Drug|vildagliptin|
45940079|NCT00065234|Procedure|Acupuncture|
45940080|NCT00237289|Drug|topiramate|
45940081|NCT00237328|Drug|Heparin|Heparin will be used as the intra-operative anticoagulant
45940082|NCT00237367|Drug|rabeprazole and pantoprazole|
45940083|NCT00098046|Drug|famciclovir|
45940084|NCT00237406|Procedure|interactive voice response|
45940085|NCT00065273|Drug|risperidone|
45940086|NCT00065273|Drug|clozapine|
45940087|NCT00065273|Drug|olanzapine|
45940088|NCT00237445|Drug|telithromycin|
45940089|NCT00237445|Drug|azithromycin|
45940090|NCT00237484|Drug|Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin|"Powder for intravenous infusion (100 mg strength), intravenous, single dose of 5 mg/kg, at Day -7, prior to initiation of the following combination therapy:~powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks"
45940091|NCT00237484|Drug|Combination of (a) pegylated interferon alfa-2b and (b) ribavirin|"Powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks"
45940092|NCT00237523|Drug|IoGen (molecular iodine)|
45654924|NCT05535101|Device|Sham stimulation|Sham stimulation was delivered using the same protocol as active stimulation, but with the TMS coil rotated by 90 degrees with the edge of the coil touching the scalp.
45940093|NCT00098085|Biological|HSPPC-96|
45940094|NCT04721431|Diagnostic Test|Myotonometric assessment|MyotonPro device is vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.These stimulations induce damped natural oscillations in the tissue and the device records these oscillations using an accelerometer. Muscle tone, elasticity, and stiffness are calculated separately by the device
45940095|NCT04709887|Procedure|Wound treatment|According to the guidelines and recommendations of the International Diabetic Foot Working Group, ulcer surface debridement, negative pressure suction drainage, and routine dressing were performed until the wound healed or the end of the trial.
45940096|NCT04709887|Procedure|Vascular intervention surgery|Segmented distal angiography under the guidance of digital subtraction angiography (DSA) were perform after local anesthesia. The superficial artery is expanded by a 3-4 mm balloon.
45940097|NCT04709887|Procedure|Tibial transverse transport surgery|In the anteromedial area of the proximal tibia of the affected limb, the external fixation frame was compared with the area along the midline of the medial longitudinal axis of the proximal tibia. Subsequently, two 3.0 Steinmann pins were inserted through the single layer of cortical bone. The skin was cut along the long axis with the 3.0 Steinmann pin as the centre, and the subcutaneous tissue was separate bluntly to expose the periosteum. The Steinmann pins were used as the centre point for the drilling on four sides with a 2.0 drill bit and use of a rapid osteotomy device; the length of each side was 2.5 cm. Subperiosteal osteotomy was performed with a 5-mm narrow bone knife at an angle of 15°-30° to the bone surface. The surgeons should pay attention to protect the blood supply of the periosteum during this procedure. The external fixators were fixed with 4.0 Steinmann pins at the distal and proximal ends. The subcutaneous tissue and skin were sutured.
45654925|NCT04932421|Behavioral|Emotion Detectives: Unified protocol for transdiagnostic treatment of emotional disorders in children (UP-C)|"UP-C is a transdiagnostic and emotion-focused cognitive-behavioral group intervention for children aged 6-12 years old with emotions disorders (i.e., anxious and/or mood disorders) and their parents. UP-C unifies cognitive-behavioral, contextual (eg. mindfulness) and parental training techniques aiming to reduce the intensity and frequency of children's clinical symptomatology.~The intervention consists of 15 weekly group sessions (90 minutes per session; 5-8 children and parents per group) conducted by at least two clinical psychologists trained in the UP-C. The sessions start with the parents and children together (15 minutes); then, one psychologist conduct the session with the group of children while the other psychologist conduct the session with the group of parents, simultaneously (60 minutes); finally, the session ends with the group together (15 minutes). This is a structured and manualized intervention with a manual for the therapist and a workbook for the child and parents."
45654926|NCT04932421|Other|ABC of Emotions|"ABC of Emotions is a psychoeducational group intervention for children with anxiety and/or mood disorders, aged between 6 to 12 years. ABC of Emotions consists of 5 group psychoeducation sessions (about 90 minutes per session; 5-8 children per group). This is a structured and manualized intervention, with a manual for the therapist and a workbook for the child.~The contents of the sessions were developed by the researchers of this study and are based on classic psychoeducational cognitive-behavioral therapies (CBT) strategies. Since anxiety disorders are more frequent in childhood than mood disorders (e.g., Merikangas et al., 2009), this program is essentially based on psychoeducation materials focused on emotions such as anxiety and fear. However, the same materials are available in an attachment, adapted for use with children to whom the main emotion is not fear/anxiety, but sadness (as in mood disorders)."
45654927|NCT04943107|Other|no intervention|no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..
45654928|NCT03660059|Drug|Peficitinib|Oral
45654929|NCT03660059|Drug|Plaebo|Oral
45806024|NCT05737238|Behavioral|Intervention during phase B: Compensatory brain game supporting Goal Management Training intervention|The investigational treatment is only given during the intervention phase (phase B), and consists of six treatment sessions. In the treatment sessions, patients learn and apply the GMT algorithm. This means that the multiple steps of the GMT as well as the actual performance of the IADL-task goals will be learned under guidance of a therapist. In order to facilitate generalization, patients will learn to use the algorithm during the performance of untrained tasks by playing the treatment supporting Plan Game. Because of this, patients are able to practice the application of the GMT algorithm independently at their own home. Besides, the intervention also includes a Plan Tool. This is a mobile application that can be used as an aid during the performance of (instrumental) activities of daily living (IADL) tasks in order to perform activities more independently. The GMT treatment sessions are given twice a week (max. 60 minutes for each attendance).
45806025|NCT05736562|Dietary Supplement|Ritual Epre Multimineral-Vitamin Supplement|The Ritual Epre supplement is a commercially available multivitamin-mineral supplement designed for pregnant and lactating women.
45940098|NCT00065312|Drug|naveglitazar|
46002138|NCT04718025|Drug|Ticagrelor 90mg|Up to day 30 after ACS, all enrolled patients will receive standard-dose ticagrelor 2x90mg as a part of dual antiplatelet therapy. Participants in SDTA arm will continue treatment with ticagrelor 2x90mg until 12 months post-ACS, while patients in LDTA and LDTP will be switched to low-dose ticagrelor 2x60 mg starting on day 31.
46002139|NCT04718025|Drug|Ticagrelor 60mg|Starting from day 31, LDTA and LDTP patients will receive low-dose ticagrelor 2x60mg until 12 months post-ACS.
45654930|NCT03660059|Drug|Disease-modifying antirheumatic drugs (DMARDs)|"As necessary concomitant medications, DMARDs listed below will be administered orally unless specified.~For subjects who are inadequate responders to methotrexate (MTX): MTX. For subjects who are intolerant of MTX: either of DMARDs listed; hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod."
45452781|NCT04946552|Dietary Supplement|Mixed Meal Test|High Carbohydrate Mixed Meal Test (MMT): participants will be studied after a 10-hour overnight fast. A nurse will insert an intravenous (IV) catheter and subjects will ingest a liquid meal (65% carbohydrate, 20% fat, and 15% protein, corresponding to 40% of daily energy expenditure, in ~16 ounces) to be prepared by the Hospital Research Unit Metabolic Kitchen. Blood samples will be collected at -10, 0, 15, 30, 60, 90, and 120 min) for measurement of glucose, insulin and C-peptide concentrations. Plasma samples will be drawn at baseline and throughout the MMT for measurement of additional hormones (such as thyroid hormones, and catecholamines) and free fatty acids (FFA) levels.
45654931|NCT04943263|Other|Tracheal Temperature|Temperature measured from the endotracheal tube compared with the esophageal temperature
45654932|NCT04932343|Diagnostic Test|cohort study|no intervention
45654933|NCT04943185|Device|XEN gel microstent implantation|"Two differents implantation :~Ab interno : Operative intervention Ab externo : Slit lamp intervention"
45940099|NCT04710121|Other|Virtual Reality Glasses|Virtual Reality Glasses (VRG), one of the methods of distracting attention; widely used in clinical medical care to relieve symptoms by providing the opportunity to create therapeutic environments for the evaluation and treatment of medical conditions. Virtual reality is a computer simulation technique that enables individuals to hear and feel the sounds and corresponding stimuli accompanying the visual image through headphones. The most basic feature that distinguishes virtual reality (VR) glasses from similar applications is that it gives individuals a real feeling. VR has helped to distract patients from mental processing and reduce the amount of pain. Virtual reality glasses, which are inexpensive to apply and use, do not cause side effects, and can be used in the recovery of the individual, are an intervention that can be preferred in nursing practices.
45654934|NCT03657251|Genetic|liquid biopsy|Participants will be asked to provide up to a maximum total 40 mL of blood for all of the required sample collection. Peripheral blood will be collected from patients who consent to the protocol. These samples will be obtained at a time scheduled by the participant with the phlebotomy service provider, and will be collected at the participant's home. Patient peripheral blood samples can be obtained at diagnosis or at any time in follow up.
45654935|NCT04942873|Other|adherence|PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran, rivaroxaban and wafarin
45654936|NCT03634319|Device|Beacon Aqueous Microshunt|"The Beacon Aqueous Microshunt is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye.~Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma."
45654937|NCT04946227|Drug|Pembrolizumab 200mg +Paclitaxel 80mg/m2|Pembrolizumab 200mg +Paclitaxel 80mg/m2
45806026|NCT05736562|Dietary Supplement|Placebo Control|This is a customarily designed blank placebo provided by Ritual.
45806027|NCT05735652|Device|SpaceOAR Hydrogel|The SpaceOAR System is an in-situ formed absorbable hydrogel that is administered transperineally (with transrectal ultrasound guidance) between the prostate and rectum
45806028|NCT05734625|Drug|Bupivacaine HCl 0.5% Injectable Solution|Will receive 0.5 ml (supratrochlear) to 1.0 ml (supraorbital, auriculotemporal) to 1.25 ml (greater and lesser occipital) for each nerve block.
45806029|NCT05734625|Drug|Methylprednisolone 40 MG Injection|Will receive 10 mg (0.25 ml) mixed with 1.25 ml Bupivacaine 0.5% for each greater or lesser occipital nerve block.
45806030|NCT05731492|Drug|Macitentan|Macitentan will be administered orally.
45806031|NCT05730205|Drug|Nexplanon 68 MG Drug Implant|Progestin contraceptive device
45806032|NCT05729373|Drug|SEP-363856|once daily tablet
45806033|NCT05729373|Drug|Placebo|once daily tablet
45806034|NCT05728736|Drug|Lemborexant 25 mg|Lemborexant 25mg will be taken nightly for two consecutive nights.
45806035|NCT05728736|Drug|Placebo|Placebo will be taken nightly for two consecutive nights
45806036|NCT05725837|Drug|Paroxetine|Paroxetine, 40mg/day, once a day, for 05 consecutive days or 24 hours after shock resolution
45806037|NCT05724199|Drug|Rocatinlimab|Subcutaneous (SC) injection
45654938|NCT04945915|Other|blood sampling|There was no intervention because this reasearch is observational study.
45654939|NCT04945525|Other|Care Continuity Program|The Care Continuity Program is an online patient self-assessment tool used by prescribers of opioids to better identify patient risk factors and opioid therapy benefit. This tool is completed by the patient, outside of the office, using an internet enabled device and follows a compliance driven protocol developed by analyzing case law against physicians in mis-prescribing opioid cases. Results, in the form of a date and time stamped legal report, are instantly transmitted to the prescriber's electronic health records, mitigating the prescriber's civil and criminal risk. A brief of findings is displayed within the software through a dashboard and on the summary page of the report. Prescribers may use the summary page to help them identify the appropriateness of initiating opioid therapy and/or continuing opioid therapy.
45654940|NCT04932187|Drug|Capecitabine, Camrelizumab|This is a single-arm study with all patients receiving these two drugs.
45654941|NCT04931719|Combination Product|PRP+Artz group|The patients in the PRP+Artz group received one intraarticular Artz injection (2.5 ml) followed consecutively by one intraarticular injection of PRP (3ml).
45654942|NCT04931719|Combination Product|PRP+ HYAJOINT Plus group|The patients in the PRP+HYAJOINT Plus group received one intraarticular HYAJOINT Plus injection (3ml) followed by one intraarticular injection of PRP (3ml).
45654943|NCT04945681|Biological|Pneumococcal conjugate vaccine|Mass campaign offering simultaneous pneumococcal conjugate vaccination to all children aged below 15 years of age living in Digaale camp, Somaliland. Children aged below 12 months receive 2 doses of vaccine, spaced 4 weeks apart. All other children receive one dose.
45806038|NCT05724199|Other|Placebo|SC injection
45806039|NCT05724108|Procedure|Biospecimen Collection|Undergo collection of blood samples
45654944|NCT04945291|Behavioral|New way of counting calories using the hands|The participants will learn how to estimate the portions and calories content of food using their hands as a measurement tool;
45806040|NCT05724108|Procedure|Computed Tomography|Undergo CT
45806041|NCT05724108|Drug|Lutetium Lu 177 Dotatate|Given IV
45806042|NCT05724108|Procedure|Magnetic Resonance Imaging|Undergo MRI
45806043|NCT05724108|Drug|Triapine|Given PO
45806044|NCT05720364|Drug|TP-05 (lotilaner oral), fasted group|TP-05 (lotilaner oral), fasted group
45452782|NCT04946552|Diagnostic Test|Muscle sympathetic nerve activity (MSNA)|Recording of multiunit postganglionic muscle sympathetic nerve activity (MSNA) will be made from the common peroneal nerve as it winds around the fibular head with the subject in the supine position with the subject's thigh comfortably supported. This procedure requires to first trace the course of the nerve using small electrical stimuli applied to the surface of the skin over the nerve or use of ultrasound to visually assist.
45654945|NCT04945291|Behavioral|Mobile applications|the participant will use a mobile application to log their calories
45806045|NCT05720364|Drug|TP-05 (lotilaner oral), high-fat group|TP-05 (lotilaner oral), high-fat group
45806046|NCT05720364|Drug|TP-05 (lotilaner oral), low-fat group|TP-05 (lotilaner oral), low-fat group
45654946|NCT04942795|Device|Compliant balloon|Use of a compliant balloon when ADAPT fails to reach the clot site
45654947|NCT04931173|Other|IVA+OA versus IVA+MBP+OA|Non-inferiority RCT comparing IVA+OA+MBP vs IVA+OA to reduce surgical site infection following colon surgery
45806047|NCT05720039|Device|Robotic NSM|Robotic-assisted Nipple sparing mastectomy procedures
45806048|NCT05720039|Procedure|Open NSM|open nipple-sparing mastectomy procedures
45806049|NCT05719558|Drug|ASP1002|intravenous (IV) infusion
45806050|NCT05719311|Drug|adrulipase|Enteric microgranule formulation of adrulipase.
45806051|NCT05717140|Biological|Aerosol Sargramostim|Given via inhalation with nebulizer
45806052|NCT05717140|Procedure|Biospecimen Collection|Undergo collection of blood samples
45806053|NCT05717140|Procedure|Computed Tomography|Undergo CT
45806054|NCT05717140|Procedure|Magnetic Resonance Imaging|Undergo MRI
45806055|NCT05717140|Other|Medical Device Usage and Evaluation|Use Aerogen Solo nebulization device
45806056|NCT05717140|Biological|Nivolumab|Given IV
45806057|NCT05714865|Drug|Surfactant|Laryngoscopy is performed, and BLES® surfactant is administered through BLEScath™ (a thin catheter) into the trachea to a spontaneously breathing preterm infant with respiratory distress syndrome who is being managed on CPAP
45806058|NCT05714345|Biological|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
45806059|NCT05714345|Drug|Fludarabine|Chemotherapy for lymphodepletion
45806060|NCT05714345|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
45940100|NCT00098124|Drug|milnacipran hydrochloride|
45806061|NCT05714345|Genetic|ALLO-501A|ALLO-501A is an allogeneic CAR T cell therapy targeting CD19
45806062|NCT05713799|Drug|Placebo|Placebo
45940101|NCT04709848|Other|None - standard of care|Observational study only. Pre-screening group were not screened for Strongyloides, as per the standard of care at the time. Screened group were screened for Strongyloides, because the standard of care at our centre changed.
45806063|NCT05713799|Drug|Mirabegron|selective beta3-AR agonist approved
45806064|NCT05713799|Drug|Alpha-lipoic acid|ALA is an antioxidant that is available over the counter
45806065|NCT05711615|Procedure|Biopsy|Undergo tissue biopsy
45806066|NCT05711615|Procedure|Biospecimen Collection|Undergo blood sample collection
45806067|NCT05711615|Procedure|Computed Tomography|Undergo CT scan
45654948|NCT04942561|Device|Samsung Gear VR|Participants 13 -21 years old can use the Samsung Gear VR. The VE is mobile based (Samsung with the Gear VR) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
45940102|NCT04709965|Diagnostic Test|Face2Gene|This study investigates whether a new diagnostic intervention (Face2Gene facial recognition software) is better than using standard approach to diagnosis.
45940103|NCT04710160|Drug|Novel fast-setting calcium silicate cement (Protooth)|In form of power and liquid to be mixed together to form a paste.
46074455|NCT02610699|Other|Conventional otoscope|The conventional analogue otoscope will be used to provide a two-dimensional view of the ear canal. Clinicians will use this for one month periods for a total of 3 months.
46074456|NCT02610699|Other|Smartphone otoscope|The smartphone otoscope is a pocket size smartphone attachment that uses technology and light source of a smartphone to capture reproducible images of the middle ear and tympanic membrane. Images and videos can be transmitted via real-time communication software from the device to another smartphone. Clinicians will use this for one month periods for a total of 3 months.
45676305|NCT04060862|Drug|Ipatasertib|Phase 1b: Ipatasertib, 300 mg starting dose administered orally once daily (PO QD) during an initial 5-7 day run-in period, then continued on Days 1-21 during the first cycle. Starting with Cycle 2, Day 1 ipatasertib will be taken orally once daily on Days 1-21 of each 28-day cycle. Phase 3: Ipatasertib, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
45452783|NCT04946552|Diagnostic Test|Oral Glucose Tolerance Test|Following a 10-hour overnight fast, a nurse will insert an intravenous (IV) catheter. Subsequently, subjects will ingest 7.5 oz of Glucola, which contains 75 g of dextrose in orange flavored water. Blood samples will be taken at -15, 0, 10, 20, 30, 60, 90 and 120 minutes (after glucola ingestion) for the measurement of plasma glucose, insulin, and C-peptide concentrations, and calculation of measurements of insulin sensitivity index (Matsuda Index). Approximately 40 mL of blood will be drawn at this visit.
45806068|NCT05711615|Procedure|Magnetic Resonance Imaging|Undergo MRI
45806069|NCT05711615|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
45806070|NCT05711615|Drug|Peposertib|Given PO
45806071|NCT05711056|Behavioral|Sociobehavioral Intervention|"Utilizes two primary evidence-based strategies:~Delivering OUD consultation via telemedicine, which has been demonstrated to be a safe and effective means for initiating MOUD with buprenorphine; and,~Incorporating psychosocial support in the form of PRC, whose involvement in patient care is associated with increased treatment retention and MOUD initiation."
45806072|NCT05710861|Device|F-HIFU|A F-HIFU treatment will be performed with the Focal-One® machine according to the predefined treatment area for each patient using the standard procedure in place in each therapeutic center and according to the user's manual edited by the company, under locoregional or general anaesthesia.
45806073|NCT05710861|Procedure|Radical Prostatectomy|A Radical Prostatectomy will be performed according to the standard procedure in place in each center, under general anaesthesia, through an open, laparoscopic or robot-assisted laparoscopic approach
45806074|NCT05710640|Device|Active tcVNS or Sham tcVNS|tcVNS is administered with a study device that gives off mild electrical impulses through the skin to stimulate the vagus nerve (a nerve that travels underneath the skin in your neck and head). This stimulation triggers a chemical response through the nerves and has been found to be effective in reducing pain and inflammation in several diseases.
45806075|NCT05710640|Device|Active tcVNS|tcVNS is administered with a study device that gives off mild electrical impulses through the skin to stimulate the vagus nerve (a nerve that travels underneath the skin in your neck and head). This stimulation triggers a chemical response through the nerves and has been found to be effective in reducing pain and inflammation in several diseases.
45806076|NCT05709899|Other|nerve blocks|Comparison of ultrasound-guided erector spinae plane block and transmuscular quadratus lumborum block for postoperative analgesia in abdominal cancer surgeries.
45940104|NCT00065351|Drug|CC-5013|CC-5013 - oral - 30mg daily on days 1-21 every 28 days
45940105|NCT04709809|Device|Retinal Vessel Analyzer recordings with electrocardiographic (ECG) gating|Video recordings of ocular fundus, an analysis of dynamic vessel diameters and putting them in ECG context.
45940106|NCT04709770|Drug|2-liters polyethylene glycol with citrate and simethicone|Low-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.
45940107|NCT04709770|Drug|4-liters polyethylene glycol with simethicone|High-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.
45940108|NCT04709770|Dietary Supplement|Low-residue diet|Diet before colonoscopy.
45940109|NCT04709731|Drug|Ponatinib 15mg QD|Ponatinib 15 mg tablet, taken orally once daily
46074457|NCT03118505|Device|Infuse Bone Graft|Infuse Bone Graft + Mastergraft Strip + local bone autograft + posterior fixation
46074458|NCT03118505|Device|Medtronic DBM|Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation
46074459|NCT02806752|Drug|Triamcinolone Acetonide|Intravitreal inject 0.5mg of Ranibizumab and 2mg of Triamcinolone Acetonide.
46074460|NCT02806752|Drug|Ranibizumab|Intravitreal inject 0.5mg of Ranibizumab.
46074461|NCT00854425|Drug|L-asparaginase|L-asparaginase 600mg/m2 days 1-7 repeated every 3 weeks for a total of 6 cycles
45654949|NCT04942561|Device|Merge VR|Participants 10-21 years can use the Merge. The VE to be used in this study is mobile based (Pixel with the Merge) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
45940110|NCT04709731|Drug|Ponatinib 30mg QD|Ponatinib 30 mg tablet, taken orally once daily
45806077|NCT05709860|Behavioral|EMC2 PrEP Educational Tool|Patients will receive an interactive PrEP Educational Tool. This interactive tool will be securely sent via the patient portal. After logging into their portal, patients will have the opportunity to review the information on their own time.
45806078|NCT05709860|Behavioral|Discrete Scheduling of a Dedicated PrEP Visit|Within the interactive PrEP Educational Tool, patients who choose to will have the opportunity to discretely schedule a dedicated PrEP visit with a primary care clinician trained on PrEP delivery. The clinician will have time reserved to allow for 'rapid' scheduling.
45940111|NCT00098163|Biological|ALVAC-HIV vCP1521|One 1-ml dose of HIV-1 vaccine administered after birth on or before Day 3 and at weeks 4, 8, and 12.
45940112|NCT00098163|Biological|ALVAC HIV-1 vCP1521|One 1-ml dose of HIV-1 vaccine placebo administered after birth on or before Day 3 and at Weeks 4, 8, and 12.
46074462|NCT00814983|Procedure|Naive T-cell Depleted Stem Cell Transplant|"The Isolex device from Baxter will be used to perform the cell selection procedure. After the CD34 selected stem cell graft has been collected, the CD34- flow-throughfraction will be depleted of CD45RA+ naive T-cells. To accomplish this, a second immunomagnetic bead selection process will be performed on the Isolex device, making use of a GMP-grade murine anti-human CE45RA antibody. This depleted fraction will comprise the donor lymphocyte inoculum given to the transplant recipient along with the stem cell component on day 0 of transplant."
46074463|NCT00814983|Procedure|Stem Cell Transplant No Manipulation|These patients will be transplanted with unmanipulated peripheral blood stem cells.
46074464|NCT00814983|Device|Isolex device from Baxter|
46074465|NCT02804256|Other|Blood Sample Collection|10 patients with ICCs to provide a second blood sample (20mls - 2 tablespoons) on top of the samples that will be collected for the biorepository.
46074466|NCT05757999|Drug|Magnesium Sulphate|A magnesium sulphate infusion (60 mg kg-1, total volume 100 ml, infusion rate 10 ml min-1) will be administered to patients 10 min. before induction of anesthesia.
46074467|NCT05757999|Drug|Saline|The patients will be pretreated with either an intravenous 0.9% saline infusion (total volume 100 ml, infusion rate 10 ml min-1) 10 min. before induction of anesthesia.
46074468|NCT02544529|Drug|Echothiophate Iodide 0.03% Ophthalmic Solution|one drop to each eye three times per week for 18 weeks
45654950|NCT04942171|Procedure|Atrial fibrillation catheter ablation group|"Pulmonary vein isolation~Additional treatment for lesions caused by non-pulmonary veins~Esophageal temperature monitoring to prevent damage to the esophagus~Evaluation of procedure time and radiofrequency ablation time~Evaluation of complications after the procedure~Rhythm follow-up after the procedure is conducted in accordance with the above study design.~Conduct a survey on cognitive function and emotion before and 12 months after the procedure"
45676306|NCT04060862|Drug|Placebo|Phase 3: Matching placebo, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
45940113|NCT00398645|Drug|GW685698X 200mcg,GW685698X 200mcg and 400mcg|
45940114|NCT00237562|Procedure|Large loop electrosurgical excision|
45940115|NCT00237601|Other|obstetric care|
45940116|NCT00414154|Behavioral|Group based multidisciplinary patient education programme|
46074469|NCT02544529|Drug|Carboxymethylcellulose Sodium (0.5%)|one drop to each eye three times per week for 18 weeks
46074470|NCT02806596|Drug|Sevoflurane|After at least 4 minutes of stable inspired sevoflurane concentration, that concentration will be titrated to obtain a targeted bispectral index (BIS) level required for perform laryngoscopy. This level was initially set at 40, based on a preliminary study showing that such level of BIS was obtained at the laryngoscopy after common general anesthesia induction. For the next patients, BIS target was set according to a sequential allocation method (up and down).
46074471|NCT02610621|Procedure|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
46074472|NCT04282031|Drug|BPI-1178|BPI-1178 once daily on Days 1 to 21 of a 28-day cycle
46074473|NCT04282031|Drug|Fulvestrant|Fulvestrant 500mg intramuscularly on Days 1 and 15 of Cycle 1, and on Day 1 of Cycle 2 and beyond
46074474|NCT04282031|Drug|Letrozole|Letrozole 2.5 mg once daily of a 28-day cycle
46074475|NCT00854503|Drug|Simvastatin|20 mg/day in one oral administration
45940117|NCT00098202|Drug|Low phytic acid maize|
45940118|NCT00098202|Drug|Zinc|
45940119|NCT00398684|Drug|Single dose nevirapine to the mother and to the child|One maternal 200 mg NVP dose at the onset of labor, and one dose of infant NVP (0.6 ml/6mg) between 48-72 hours after birth. [Infants less than 2,500g received only 0.2mL/kg]
45940120|NCT00398684|Drug|Single dose nevirapine to the mother and placebo to the child|One maternal 200 mg NVP dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. [Infants less than 2,500g received only 0.2mL/kg]
45940121|NCT00398684|Drug|Single dose placebo to the mother and to the child|One maternal placebo dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. [Infants less than 2,500g received only 0.2mL/kg]
45940122|NCT00237640|Drug|Cinnamon or placebo 500 mg capsule twice daily|Cinnamon 500 mg capsule twice daily or placebo capsule twice daily
46074476|NCT00854503|Drug|Rosuvastatin|20 mg/day in one oral administration.
46074477|NCT00854659|Drug|ABT-102|BID tablets, 7 days of treatment
46074478|NCT00854659|Drug|Placebo|BID tablets, 7 days of treatment
45940123|NCT00237679|Behavioral|Neuromuscular Electrical Stimulation|Through low voltage current delivered through the skin, motor nerves are excited, causing muscle contraction.
45654951|NCT04942171|Drug|Medical therapy group|"Use of beta-blockers or calcium channel blockers for pulse rate control~Antiarrhythmic drugs are administered to patients with highly symptomatic atrial fibrillation symptoms even after pulse rate control.~If symptoms are not controlled even with antiarrhythmic drugs, electrical conversion to restore sinus rhythm.~To prevent cerebral infarction, maintain optimal anticoagulant therapy according to the risk score for cerebral infarction.~Conduct a questionnaire on cognitive function and emotion before and 12 months after the procedure"
45940124|NCT00237679|Behavioral|Unstimulated|No current is generated.
45940125|NCT00076440|Drug|Leuprolide acetate|
45940126|NCT00237757|Behavioral|Information feedback|The experimental arm consisted of a six month staff training period. The core of the intervention consisted of a concentrated 2.5 day workshop in Atlanta for 29 rehabilitation team leaders from 15 VA hospitals. Several weeks after the workshop, participants received a custom action plan developed on issues discussed in the workshop. The experimental arm also received a summary of results of the initial survey along with comparative data from all other sites. During the subsequent 5 months after the workshop, research staff maintained regular contact with research participants through telephone and videoconferencing. The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes.
45654952|NCT04944823|Other|Clinical follow-up for 24 months|Sampling and clinical follow-up for 24 months
45940127|NCT00237757|Behavioral|Information feedback|The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes. In addition, participants in the comparison arm were invited to contact the research staff for help in interpreting data or to set-up a process improvement initiative.
45940128|NCT00237874|Drug|Aripiprazole|
45940129|NCT00064961|Behavioral|Individualized dietary-control and exercise program|
45452784|NCT04946552|Other|Body Composition, Percent Body Fat & Percent Body Water (Tanita scale)|will be assessed using bioelectrical impedance analysis Tanita® scale; which is a special multi frequency segmental body composition analyzer that delivers a very mild electrical current that allows measurement of fat mass, percent body fat, fat free mass, total body water, and percent body water. This test will be performed at screening visit.
45654953|NCT04930939|Other|Aerobic training cardiac rehabilitation program|Moderate continuous training sessions and high intensity interval training sessiones were used to carried out aerobic training
45940130|NCT00064961|Behavioral|Weight-management and smoking cessation maintenance|
45940131|NCT00064961|Behavioral|Smoking Cessation program|
45940132|NCT00237913|Drug|Aripiprazole|Tablets, Oral, 10 - 30 mg, Once daily, 26 weeks.
45940133|NCT00237913|Drug|Olanzapine or Quetiapine or Risperidone|Olanzapine: Tablets, Oral, 5-20 mg, Once daily, 26 weeks. OR Quetiapine: Tablets, Oral, 100-800 mg, Once daily, 26 weeks. OR Risperidone: Tablets, Oral, 2-8 mg, Once daily, 26 weeks.
45940134|NCT00398723|Device|Narrowband UVB|Treatment three to seven times weekly for a total of 12 to 26 weeks (36 to 168 treatments). Dosing of NB-UVB will begin at 100-280 mJ/cm2, depending on tolerance and skin type, and will be titrated 10-20% per session until clinical efficacy or symptomatic erythema
45940135|NCT00237952|Drug|EDTA chelating agents|
45654954|NCT03597347|Drug|Molgramostim nebulizer solution|300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
45654955|NCT03597347|Device|PARI eFlow nebulizer system|PARI eFlow nebulizer system
45654956|NCT04944355|Other|ultrasound|diagnosis of morbid adherent placenta and incidence of urinary tract injuries during surgery
45940136|NCT00098241|Drug|Certican|
45654957|NCT04942015|Drug|Honghuaruyi Wan|Honghuaruyi Wan is the traditional Tibetan prescription, clinical research has proved that Honghuaruyi Wan can significantly reduce risk mouse dysmenorrhea caused by oxytocin, improve dysmenorrhea model of mice body torsion times and improve the estrogen and progestogen operator Netherlands rat pituitary estradiol and prolactin level, at the same time also can reduce the amount of TNF alpha, thus improving endometriosis dysmenorrhea.(Pill (15 pills/plate ×2 plates/box))
46074479|NCT02610543|Drug|UCB5857|Active Substance: UCB5857 Pharmaceutical form: Capsule Concentration: 5 mg, 10 mg, 30 mg Route of administration: oral
46074480|NCT02610543|Drug|Placebo|Active substance: Placebo Pharmaceutical Form: Capsule Route of administration: oral
46074481|NCT00854737|Dietary Supplement|cytidine|cytidine (2g po daily for 4 months)
46074482|NCT00854737|Dietary Supplement|omega-3 fatty acids|omega-3 fatty acids (4g po daily for 4 months)
45654958|NCT04942015|Drug|Placebo of Honghuaruyi Wan|Honghuaruyi Wan simulation agent. Made of starch,dextrin and edible pigment from Tibet Qizheng Tibetan Medicine Co.,Ltd. ( Pill (15 pills/plate ×2 plates/box))
45940137|NCT00237991|Biological|Hepatitis A|
45940138|NCT04721119|Procedure|Local Infiltration Anesthetic|For the local infiltration anesthetic, patients will receive 20 cc of 0.5% ropivacaine, by intra-articular injection performed by the surgeon. The injection is done at the end of the surgical procedure, after suturing the incision.
46074483|NCT00854737|Drug|placebo|sugar pill
45940139|NCT04721119|Procedure|Local Infiltration Anesthetic + Adductor Canal Block|For the local infiltration anesthetic, patients will receive 20 cc of 0.25% ropivacaine, by intra-articular injection performed by the surgeon. The injection is done at the end of the surgical procedure, after suturing the incision. For the adductor canal block, patients will receive 20 cc of 0.25% ropivicaine, through injection performed by the anesthesiologist. The injection is done under the sartorius muscle, in mid-thigh, using ultrasound guidance.
45940140|NCT00398840|Drug|ARQ 171|
45940141|NCT00238030|Drug|L-thryoxine|2 mcg/kg iv or 2 mcg/kg po at time of enrollment
45806079|NCT05708092|Behavioral|NeuroResource Facilitation (NRF)|"NRF is defined as a specialized service that promotes access to services and coordinates care specific to the needs of individuals with brain injury.~Possible resources include vocational services, medical assistance, Social Security (SSI or SSDI if appropriate), and other organizations that can support reentry. If needed to gain access to services and organizations, the facilitator will also provide participants with a summary that includes results from brain injury screenings questionnaire, neurocognitive (thinking abilities) tests, and symptoms. The researchers will share information and coordinate with prison and parole staff about participation in the study. Participant's information will also be shared with resources that could help participants after release, such as funding sources and brain injury services. After release from SCI, the NRF facilitator will assist the participant with all the preparation and logistics associated with the resources the participant applied to."
45940142|NCT00238030|Drug|iv thryoxine|thyroxine 2 mcg/kg iv
45654959|NCT04941859|Behavioral|acupoint massage and application|Patients in the experimental group were treated with acupoint application combined with acupoint massage on the basis of standard treatment for acute poisoning. When the patient began to launder the stomach, the acupoint was applied to Shenque (umbilical). After the end of the gastric launder, Shenque acupoint and Zusanli diarrhea method (referring to counterclockwise and strong stimulation) were massaged for 15 minutes, and the massage frequency was Q8H.
45654960|NCT04942249|Other|No intervention|No intervention
45654961|NCT05228015|Drug|IK-930|tablets for oral administration
46074484|NCT02800044|Device|Wearing a non-invasive glucose sensor|Glucose readings will be obtained from both a glucometer (fingerstick readings) and from the non-invasive glucose sensor at the following four timepoints: fasting, 1.5 to 2 hours after consuming a meal, and before and after 15-30 minutes of moderate exercise on a stationary bicycle.
45654962|NCT04431427|Device|Biliary drainage with PC-SEMS|partially covered metallic biliary stent insertion during ERCP
45654963|NCT04431427|Device|Biliary drainage with U-SEMS|Uncovered metallic biliary stent insertion during ERCP
45654964|NCT04930627|Drug|Empagliflozin|dosis depending on body weight: <20 kg 5 mg 1x/day; 20-40 kg 2 x 5 mg; >40 kg 2 x 10 mg
45806080|NCT05707702|Biological|Probiotic oral lozenges|Participants in this arm will be be instructed to take a lozenge daily for 6 weeks. They will also receive oral dysplasia standard of care.
45806081|NCT05707702|Other|Standard of care for oral dysplasia|Oral dysplasia standard of care includes clinical surveillance and risk factor reduction (such as smoking cessation).
45806082|NCT05707208|Drug|ST-01|A sustained release lidocaine formulation designed for the treatment of acute and chronic pain.
45940143|NCT00238069|Device|CPAP machine as a result of sleep study|
45654965|NCT03057769|Drug|Papillary epinephrine spraying|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
45940144|NCT00238147|Drug|capecitabine|
45940145|NCT00238147|Drug|carboplatin|
45940146|NCT00238147|Drug|docetaxel|
45940147|NCT00238147|Procedure|conventional surgery|
45654966|NCT03057769|Drug|Papillary saline spraying|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
45654967|NCT03057769|Drug|Indomethacin|All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
45654968|NCT05508269|Genetic|quantitative polymerase chain reaction(QPCR) for four genes|quantitative polymerase chain reaction(QPCR) for four genes
45676307|NCT04060862|Drug|Palbociclib|Palbociclib, administered PO QD on Days 1-21 of each 28-day cycle.
45676308|NCT04060862|Drug|Fulvestrant|Fulvestrant, 500 mg administered as two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15 and Day 1 of each subsequent 28-day cycle.
45940148|NCT00238147|Procedure|neoadjuvant therapy|
45940149|NCT00238147|Radiation|radiation therapy|
45940150|NCT00065390|Drug|Pyrimethamine|
45940151|NCT00238225|Dietary Supplement|calcitriol|
45940152|NCT00238225|Drug|dexamethasone|
45940153|NCT00238225|Drug|ketoconazole|
45940154|NCT00076518|Drug|Fenofibrate|
45940155|NCT00076518|Drug|Fish Oil|
45940156|NCT00238342|Genetic|proteomic profiling|
45940157|NCT00238342|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
45940158|NCT00238342|Procedure|biopsy|
45940159|NCT00065546|Other|Estrogen plus choline depletion diet|Post-menopausal subjects receive estrogen and are then challenged with a low choline diet to determine if estrogen protects them from induction of choline deficiency.
46074485|NCT05223153|Diagnostic Test|Optical Coherence tomography angiography|Measurement retinal vessel density in the superficial and deep capillary plexuses using OCTA in children with anisometropic amblyopia
46074486|NCT00858715|Drug|aspirin|100 mg aspirin
46074487|NCT00858715|Drug|clopidogrel|75 mg (Arm 1) and 150 mg (Arm 2)
46074488|NCT02806284|Biological|PPSV23, Act-HIB|"described in Arm description"
46074489|NCT02544997|Drug|Poziotinib|12mg P.O. for 2wks q21days
45654969|NCT05508269|Procedure|Cardiac biopsy, blood sampling|In the studied thirteen peripheral blood subjects, five milliliters blood samples were taken from each patient in potassium EDTA tubes, immediately inserted in liquid nitrogen container and then stored in -80 refrigerators. All studied thirteen cardiac tissue subjects were underwent cardiac biopsy after PCI in order to take two specimens from the left ventricle using judkin right seven french catheters for femoral access and cardiac bioptome 2.3 mm wide. All cardiac specimens were collected in cryotubes, immediately inserted in liquid nitrogen container and then stored in -80 refrigerators.
45654970|NCT05531045|Diagnostic Test|PET/CT|FDG PET/CT assessed after 2 cycles of chemotherapy with PERCIST criteria
46074490|NCT00960869|Drug|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
46074491|NCT00960869|Drug|EC-Aspirin 325 mg|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
46074492|NCT02799888|Drug|Maraviroc|Maraviroc will be administered 300mg twice daily and start on day -2 end on day +30 after stem cell transplant for 33 days.
45806083|NCT05707208|Drug|1% Lidocaine HCL|Currently approved lidocaine
46074493|NCT02799888|Drug|Cyclosporine (in HLA-Unrelated Donor Transplantation)|Cyclosporine will be given intravenously at a dose of 2-3 mg/kg starting Day -1. Subsequent dosing will be based on blood levels. Patients were advanced to oral cyclosporine once they could tolerate. The dose should be adjusted accordingly to maintain a suggested target serum level of 150-250 ng/mL. In the absence of aGVHD, the oral cyclosporine dose was reduced by approximately 5% weekly, beginning on or near day 100, and therapy was usually discontinued by Day 180 after transplantation or relapse.
46074494|NCT02799888|Drug|Tacrolimus (in HLA-Mismatched Related Donor Transplantation)|Tacrolimus will be given orally at a dose of 0.05 mg/kg twince a day or intravenously at a dose of 0.03 mg/kg starting Day -3. Subsequent dosing should be adjusted accordingly to maintain a suggested target serum level of 5-10 ng/mL. Tacrolimus taper can be initiated at a minimum of 100 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
45806084|NCT05706753|Drug|Milvexian|Milvexian will be administered orally.
45806085|NCT05706753|Drug|Midazolam|Midazolam will be administered orally.
46074495|NCT02799888|Drug|Methotrexate|Methotrexate will be administered intravenously at a dose of 15 mg/m^2 on day +1, and 10 mg/m^2 on day +3, +6 and +11 after HSC transplantation.at the doses of 15 mg/m^2 IV bolus on Day +1, and 10 mg/m^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +11 dose of methotrexate will be not given to those patients who fail to reach white blood cell count (WBC) of more than 1.0×10^9/L.
46074496|NCT00618787|Device|COPA AMD (note: name is not an acronym)|Foam dressing impregnated with Polyhexamethylene Biguanide
46074497|NCT00618787|Device|COPA (note: name is not an acronym)|Regular foam dressing without PHMB
45806086|NCT05706753|Drug|Ethinylestradiol|Ethinylestradiol will be administered orally.
45806087|NCT05706753|Drug|Drospirenone|Drospirenone will be administered orally.
45940160|NCT00065546|Other|Placebo plus choline depletion diet|Post-menopausal women are randomized to receive a placebo and are then subjected to a low choline diet to determine if clinical signs of choline deficiency can be induced.
45940161|NCT00065546|Other|Pre-menopausal women with SNPs given a low choline diet|Pre-menopausal women with specific genetic polymorphisms in genes related to choline metabolism are placed on a choline depletion diet to determine if the SNPs increase or decrease the risk of diet-induced choline deficiency.
45940162|NCT00238381|Procedure|5 cm colon-J-pouch|5 cm colon-J-pouch with/without temporary protective ileostomy
45940163|NCT00238381|Procedure|side-to-end anastomosis|side-to-end anastomosis with/without temporary protective ileostomy
45940164|NCT00238381|Procedure|straight coloanal anastomosis|straight coloanal anastomosis with/without temporary protective ileostomy
45940165|NCT00098280|Drug|Eculizumab|
45940166|NCT00238459|Drug|Patients elected to take licensed drugs. The vaccine was not provided for evaluation|Note:In August 2007 we were notified by the manufacturer that the experimental vaccine was no longer being made and would no longer be available for this study. Too few participants have received the vaccine or placebo to conclude anything about potential efficacy
45940167|NCT00238459|Drug|multiple licensed drugs not randomized|
45458749|NCT04338178|Procedure|Multidisciplinary outpatient program|Multidisciplinary outpatient program including several consultations with endocrinologists, dietitians, psychologists, nutritionists and/or physical activity coaches. Patients are regularly followed and educated about the importance of lifestyle changes including healthy dietary habits and exercise in weight reduction and maintenance. Patients are also usually given information about nutritional value of various foods and few simple exercises for decreasing and maintaining body weight. This program is therefore planned as part of the usual care and responds to the recommendations of good practice for obesity
45654971|NCT04633577|Drug|Lidocaine IV|A bolos of 1.5mg/kg lidocaine will be administered before induction. Then, infusion of 4mg/kg/h lidocaine will maintain during procedure.
45654972|NCT04633577|Drug|0.9% normal saline|0.9% normal saline
45806088|NCT05706233|Procedure|Erector Spina Plane Group|ESPB had been applied postoperatively: from T8 level, 20mL bupivacaine %0,5 + 5ml %2 lidocaine was applied.
45806089|NCT05706233|Procedure|IV analgesic intervention|IV analgesics had been applied: All meperidine boluses are dosed in line with the pain intensity as follows: 10 mg if NRS > 3, 20 mg if NRS > 5, 30 mg if NRS > 8. If NRS score is not reduced at least 20% when compared to prior one, additional meperidine bolus is applied.
45654973|NCT04941625|Diagnostic Test|serum cystatin C|blood sampling
45654974|NCT04941625|Diagnostic Test|serum beta-microglubulin|blood sampling
45654975|NCT04941625|Diagnostic Test|urine|neutrophil gelatinase-associated lipocalin
45940168|NCT00238459|Drug|multiple licensed antiretroviral drugs; not randomized|
45940169|NCT00238459|Other|Intended vaccine not provided, Licensed drugs provided, but were not investigated|
46074498|NCT02860715|Drug|GX-I7|Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
46074499|NCT02860715|Drug|Placebo|This is the placebo of GX-I7 described above.
45654976|NCT03534323|Drug|Duvelisib|This drug is designed to stop cancer growth by blocking a protein called phosphatidylinositide 3-kinase (PI3K), which is important for the survival of CLL cells.
45654977|NCT03534323|Drug|Venetoclax|Venetoclax targets a protein called BCL-2, which helps cancer cells survive.
46074500|NCT02800200|Procedure|Platelet rich plasma|Sono-guided injection with 3 cc Platelet rich plasma were performed in both groups.
45458750|NCT04289428|Diagnostic Test|Xpert® HBV DNA fingerstick point of care assay|Xpert® HBV DNA point of care assay from finger-stick whole blood
45654978|NCT04944589|Procedure|ROOT CANAL TREATMENT|Clinical endodontics involved in the goal of preventing and treating microbial contamination of pulps comprises of a number of treatments. Root canal endodontic therapy has one specific set of aims: to cure or prevent peri-radicular periodontitis, to conserve their natural teeth in function and aesthetics.
45654979|NCT04922125|Combination Product|Pulse flour|Traditionally processed pulse flour in vitro digestion conditions were related to potentially influence appetite sensations.
45654980|NCT04922125|Combination Product|Pre-processed pulse flour|Pre-processing of pulse flour was related to altered in vitro digestion conditions and thus suggested to potentially influence appetite sensations.
45654981|NCT04922203|Other|in Situ Simulation|2 sessions of in situ simulation with 4 crisis scenarios and debriefing focused on non technical skills
45654982|NCT04922047|Drug|tislelizumab and BCG|Tislelizumab 200 mg administered by intravenous infusion every 3 weeks in first year and continue to second year based on physician choose. BCG 120 mg induction therapy administered via intravesical instillation (once weekly for 6 weeks). BCG induction therapy is followed by maintenance therapy (once weekly for 3 weeks at months 3, 6, 12, 18, 24m).
45654983|NCT03057535|Drug|Sodium Bicarbonate|
45806090|NCT05705050|Drug|Aminophylline group|Patients will receive 4 mg/kg aminophylline diluted in 100 ml normal saline over 20 minutes after induction of anesthesia and positioning of patients in lithotomy position.
45806091|NCT05705050|Other|Control group|Patients will receive 100 ml normal saline over 20 minutes after induction and lithotomy positioning.
45806092|NCT05704738|Drug|Rocatinlimab|Subcutaneous (SC) injection
45806093|NCT05704738|Drug|Placebo|SC injection
46074501|NCT02800200|Device|shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs).
45806094|NCT05703685|Drug|18F-PF-06445974|Injected IV followed by PET scanning
45806095|NCT05703607|Biological|Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection|Intramuscular injection
45806096|NCT05703607|Biological|Candidate 1: PF-07915234: VZV modRNA Suspension for Injection|Intramuscular injection
45458751|NCT04289428|Diagnostic Test|Point of Care ALT|Point of Care ALT from finger-stick whole blood
45654984|NCT03057535|Drug|Sodium Chloride|
45654985|NCT04407013|Other|Enhanced supportive care based on standardized care pathway|Enhanced supportive care based on standard care pathway is consisted of 1) symptom management (symptom assessment and according management) and 2) coping enhancement (nurse-led counseling). The enhanced supportive care will be provided 5 times, according to the standardized care pathway.
45806097|NCT05703607|Biological|Candidate 2: PF-07921188: VZV modRNA Suspension for Injection|Intramuscular injection
45806098|NCT05703607|Biological|Candidate 3: PF-07921186: VZV modRNA Suspension for Injection|Intramuscular injection
45806099|NCT05703607|Biological|Shingrix|Intramuscular injection
45806100|NCT05703607|Biological|Selected Vaccine Candidate group (Dose level, Schedule)|Intramuscular injection
45806101|NCT05703607|Biological|Shingrix - SSB|Intramuscular injection
45806102|NCT05702034|Drug|Milvexian|Milvexian will be administered orally.
45806103|NCT05702034|Drug|Placebo|Placebo will be administered orally
45940170|NCT00238498|Drug|vildagliptin|
45940171|NCT00238537|Drug|Alteplase t-PA|
45940172|NCT02967146|Device|adhesive barrier|After having axillary dissection, investigator has to inject the mediclore on op site directly and suture the site.
45940173|NCT00098319|Drug|Folic acid (0.4mg vs. 4.0mg)|
45940174|NCT00238732|Drug|Bazedoxifene/Conjugated Estrogen|
45940175|NCT00065585|Procedure|Accupuncture|
45940176|NCT00076557|Genetic|Adeno-Associated Viral with Human Factor IX|
45940177|NCT00238849|Drug|Oxaliplatin|
45654986|NCT04407013|Other|Control group with usual care|Control group will receive usual care (symptom monitoring only)
46074502|NCT00813813|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
45654987|NCT04941235|Device|ultrasound and nerve stimulator|nerve stimulator and ultrasound guided interscalene brachial plexus block
45654988|NCT04921891|Procedure|Infraclavicular nerve block|The investigators performed an infraclavicular nerve block to the operated arm group to provide anesthesia.
45654989|NCT04921891|Procedure|Without nerve block|The upper extremity without block was assigned as the control group, and a comparison was made between the two upper extremities.
45654990|NCT04406389|Drug|Enoxaparin sodium|"Intermediate Dose Prophylaxis Arm:~0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min --OR-- 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 ml/min~Therapeutic Dose Anticoagulation Arm:~1 mg/kg subcutaneously every 12 hours"
45654991|NCT04406389|Drug|Unfractionated heparin|"Intermediate Dose Prophylaxis Arm:~7,500 units subcutaneously every 8 hours~Therapeutic Dose Anticoagulation Arm:~Dosed to target anti-Xa level 0.3 - 0.7 IU/mL or activated partial thromboplastin time (aPTT), according to institutional protocol"
45654992|NCT04406389|Drug|Fondapariniux|"Intermediate Dose Prophylaxis Arm:~2.5 mg daily subcutaneously~Therapeutic Dose Anticoagulation Arm:~Dose by weight:~If greater than or equal to 100 kg: 10 mg daily~If less than 100 kg but greater than or equal to 50 kg: 7.5 mg daily~If less than 50 kg: 5 mg daily"
45654993|NCT04406389|Drug|Argatroban|"Therapeutic Dose Anticoagulation Arm:~Dosed according to institutional protocol"
45654994|NCT04941079|Other|no intervention|no intervention
45654995|NCT03057457|Device|NGAL Test|The purpose of this study is to demonstrate that BioPorto Diagnostic's NGAL test is able to assist in determining the risk for acute kidney injury for patients who have been admitted to the intensive care unit.
45654996|NCT04921579|Procedure|En masse retraction|Retraction stated on a 0.017''x 0.025'' Stainless steel wire using elastomeric chain ( force applied 200 g per side) extending between the crimpable hooks and the mini-screw.
45654997|NCT04921579|Procedure|Two-Step retraction|Retraction of canine started on a 0.017''x0.025'' Stainless steel wire using elastomeric chain ( force applied 150 g per side) followed by anterior teeth retraction on 0.017''x0.025'' Stainless steel wire using elastomeric chain ( force applied 160 g per side) extending between crimpable hooks and the mini-screw.
45654998|NCT04921657|Drug|Rosuvastatin 10mg|
45654999|NCT04930471|Drug|Metformin|Treatment with Metformin as prescribed by the treating physician.
45655000|NCT04921813|Other|3 dimensional scoliosis exercise|Schroth exercises
45655001|NCT04921813|Other|Balance Exercise|Balance-coordination exercises
45655002|NCT04921813|Other|Brace treatment|Brace usage
45655003|NCT04930393|Procedure|Nerve Block - either PECS II or axillary ring|In addition to an interscalene nerve block, one of these two interventions will be administered to assess pain control after a biceps tenodesis
45655004|NCT03057223|Device|3D-printed patient-specific titanium plates|3D-printed patient-specific titanium plates will be used in patients.
45806104|NCT05701657|Other|Diet A|This diet has high amounts of fruits/vegetables, whole grains, and beans, moderate amounts of dairy, meat/poultry/eggs, fish, nuts/seeds, and vegetable oils, and very low amounts of sugar sweetened drinks and desserts. Menus are developed for 1600kcal, 2100kcal, 2600kcal and 3200 kcal.
45940178|NCT00238888|Procedure|asthma control awareness|Repeated assessments of the child's asthma control using the Asthma Quiz for Kidz, with recommendation for asthma education and medical visit
45940179|NCT00238888|Procedure|Usual care|Recommendation for asthma education and/or follow-up at the physician's discretion
45940180|NCT00238927|Drug|inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days)|
45655005|NCT04940923|Diagnostic Test|MRI|"T2 weighted and DTI MRI images of brachial plexus and wrist. Quantitative sensory tests include warm and cold detection and pain thresholds, paradoxical heat sensation, mechanical detection thresholds, mechanical pain sensation and thresholds, wind up ratios, vibration thresholds and pressure pain thresholds.~Clinical tests include standard neurological tests and test for heightened nerve mechanosensitivity.~Blood serum to analyse inflammatory proteins. Questionnaires include neck disability index, painDETECT, PTSD8, pain catastrophising scale, eq-5D-5L, DASS 42 and global perceived recovery"
45655006|NCT04940689|Drug|Dexmédétomidine 0.5 g/kg + lidocaine 1.5 mg/kg|The patient will be anesthetized with Dexmedetomidine 0.5 g / kg + lidocaine 1.5 mg / kg for the induction instead of morphin.
45806105|NCT05701657|Other|Diet B|This diet has high amounts of refined grains, meat/poultry/egg, sugar sweetened drinks, sweets, snacks, desserts, and processed foods. It has a moderate amount of dairy and low amounts of fruits/vegetables, whole grains, and fish. Menus are developed for 1600kcal, 2100kcal, 2600kcal and 3200 kcal.
45806106|NCT05701657|Other|Diet C|This diet has moderate-high amounts of vegetables, meat/poultry/egg, fish, nuts/seeds, and fats/oils, low amounts of fruits and dairy, and very low amounts of grains and sugars. Menus are developed for 1600kcal, 2100kcal, 2600kcal and 3200 kcal.
45940181|NCT00065624|Drug|lipoic acid|
45940182|NCT00238966|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
45940183|NCT00239044|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
45940184|NCT00098358|Drug|Zileuton|
45940185|NCT04720924|Device|Computer-aided Real-time Automatic Quality-control System|EGD automatic quality-control system(AQCS),developed based on deep convolutional neural network (DCNN) models,could facilitate real-time detection of upper gastrointestinal lesions, assess inspection completeness and mucosal visibility, and calculate time of EGD procedure.
45940186|NCT00065663|Genetic|GAM501|
46074503|NCT02803866|Behavioral|Training program CAP-PREM|1ºAfter recruitment parents will fill the PMP S-E tool and the psychological tests evaluating their stress and depression . 2º parents will receive the training program during 4 weeks. 3º: before hospital discharge parents will fill again the PMP S-E tool and the psychological test evaluating their depression and anxiety
45655007|NCT04940689|Drug|Remifentanil|The patient will be anesthetized with morphin.
45655008|NCT02576951|Drug|Galcanezumab|Administered SC
45655009|NCT02576951|Drug|Placebo|Administered SC
45655010|NCT04921501|Device|HD ECG|This experimental procedure is a passive, non-invasive, high-density surface ECG recording using 128 skin electrodes.The electrodes are positioned on strips of 10 electrodes to be prepared with adhesive tape and coated with conductive gel before installation on the patient. The total duration of the acquisition is 10 to 30 minutes.
45655011|NCT04921501|Device|Conventional 12-lead ECG|This standard 12-lead ECG is defined on the HD ECG, from electrodes F13, G3, G14, H5, H15, H25 corresponding to the precordial electrodes. 4 limb electrodes will be added for the frontal leads. Thus, the HD and 12-lead ECGs will be obtained simultaneously.
45655012|NCT04921267|Behavioral|training|training with filtered speech
45655013|NCT05530811|Drug|Dexamethasone|The suprazygomatic maxillary nerve block approach will be performed with a 27-gauge 38-mm needle following aseptic preparation of the skin and using the anatomical landmarks. The puncture site will be at the frontozygomatic angle formed by the zygomatic arch and posterior orbital rim. After inserting the needle perpendicular to the skin and contacting the greater wing of the sphenoid (approximately 20 mm deep), the needle will be partially withdrawn, reoriented approximately 20° anterior and 10° inferior, and advanced 35 to 38 mm to direct the needle into the pterygopalatine fossa. After negative blood aspiration, the prepared solution will be injected over 20 s on each side. Massage of injection point with pressure for 2 min will be done. No additional local anesthetic will be injected by the surgeon either peri-incisional or submucosal.
45655014|NCT05530811|Drug|Bupivacaine|0.5% bupivacaine
45655015|NCT04940845|Drug|HS-20090-2|Subcutaneously injection of HS-20090-2 (60mg/1mL) once on the first day
45655016|NCT04940845|Drug|Prolia|Subcutaneously injection of Prolia® (60mg/1mL) once on the first day
45655017|NCT05507567|Drug|Neumifil|Liquid for intranasal spray administration
45655018|NCT05507567|Drug|Placebo|Liquid for intranasal spray administration
45655019|NCT04921111|Drug|SCT1000|Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells)
45655020|NCT04921111|Drug|Gardasil®9|Recombinant 9 or 4 valent human papillomavirus vaccine
45655021|NCT04921111|Drug|placebo|aluminium phosphate
45655022|NCT04921111|Drug|Gardasil®|Recombinant 4 valent human papillomavirus vaccine
45655023|NCT05530733|Procedure|Pacifier|Pacifiers produced for premature babies will be used in the study. Pacifiers will be made of silicone material suitable for premature baby health and will not contain any harmful substances. A separate pacifier will be used for each baby, and pacifiers will be sterilized before use.
45655024|NCT05530733|Procedure|Breast milk|For babies assigned to the pacifier with breast milk group, their own breast milk will be applied by dripping 1 ml into the pacifier.
45940187|NCT00239083|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
46074504|NCT02857985|Device|3D RA|3D RA is realised just after angioplasty.
45940188|NCT00239122|Behavioral|Recovery Therapy (Cognitive Behaviour Therapy for psychosis)|
45940189|NCT00239161|Drug|Levofloxacin|
45940190|NCT00239200|Drug|Lapatinib|
46074505|NCT02857985|Device|MRI|MRI is realised between 24h and 96h post angioplasty.
46074506|NCT00862615|Other|Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.|"Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.~Isotopes are :~(13C)bicarbonate (0.09 mg/kg fat-free mass) and L(1-13C)leucine (1.3 mg/kg fat-free mass) (intravenous way) L-(5,5,5 2H3) leucine(0.09 µmoles/(kg de fat-free mass.min) (oral way)"
45655025|NCT03387917|Drug|TLD-1|TLD-1 is a new liposomal formulation of the anthracycline doxorubicin.
45655026|NCT03387917|Drug|Caelyx|Caelyx is a liposomal formulation of the anthracycline doxorubicin
45655027|NCT03057145|Drug|Prexasertib|LY2606368 is a checkpoint kinase 1 (CHK1) inhibitor that is being developed as a treatment for patients with advanced cancer
45655028|NCT03057145|Drug|Olaparib|Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor.
45655029|NCT05421065|Drug|Psilocybin|1 25mg dose
45655030|NCT05421065|Drug|Ketamine|1 300mg oral dose
45655031|NCT04921423|Behavioral|Situational simulation teaching|The intervention included communication theory and skills, aging trend and knowledge, teaching plans for elderly nursing, activities for the elderly and visual experience, application and debriefing of empathy.
45655032|NCT04425005|Other|Home-based exercise|Home-based exercise training, supervised by videoconference.
45940191|NCT00065702|Drug|Active liquid remedy|
45940192|NCT02961829|Drug|Maraviroc|antiretroviral intensification
45940193|NCT02961829|Drug|Dolutegravir|antiretroviral intensification
45940194|NCT02961829|Biological|Dendritic Cell Vaccine|Therapeutic vaccination
45940195|NCT02961829|Drug|Auranofin|purging
45940196|NCT02961829|Drug|Sirtuin Histone deacetylase inhibitor|latency disruption
46074507|NCT04118621|Device|chest ultrasound|detection of postoperative pulmonary complications after cardiothoracic surgery
45655033|NCT03056989|Drug|SPX-101|Inhalation solution twice daily for 7 days.
45940197|NCT00239239|Drug|Darbepoetin alfa|darbepoetin alfa SC dosing 0.45 mcg/kg 3 times per week through study day 40. Optional extended treatment period: 200 mcg Q2W through study day 110
45940198|NCT00414349|Drug|Topical analgesic|max. 3 plasters per day for PHN patients max. 4 plasters per day for DPN patients
45940199|NCT00414349|Drug|oral intake|300 to 600 mg per day taken orally
45940200|NCT00414349|Drug|Topical analgesic|3 plasters for PHN patients per day 4 plasters for DPN patients per day
45940201|NCT00065741|Drug|silymarin|
45940202|NCT00098397|Drug|romidepsin|Given IV
45940203|NCT00098397|Other|laboratory biomarker analysis|Optional correlative studies
46074508|NCT00859105|Drug|Imiquimod 5%: manufactured by Apotex|Treatment applied as a thin layer to target area once a day, 2 days each week, 16 weeks
45940204|NCT00414427|Procedure|Intraarticular steroids|
45655034|NCT04940455|Other|Educational digital platforms|The digital educational platforms will be implemented through games of questions and answers, simulated cases sent via google forms about the nurse's performance in a critical care unit facing the patient with signs and symptoms of sepsis. The questions in the games will aim to develop clinical judgment and quick decision-making in nursing students in order not to compromise the health care of the patient in sepsis.
45655035|NCT04920877|Other|Infection Prevention|Preventing central catheter-related bloodstream infections in intensive care units
45806107|NCT05701657|Other|Liquid Mixed Meal Tolerance Test|A liquid mixed meal tolerance test will occur in Module 1 and Module 3. For this test, participants will drink two servings of Ensure® Original, vanilla flavor. The meal will also contain acetaminophen (Tylenol) which will show how the smoothie moves through the participant's gut.
45806108|NCT05701657|Other|Diet-Specific Mixed Meal Tolerance Test|The diet-specific mixed meal tolerance test is administered at the end of each dietary intervention period in Modules 2 and 3. The meal test is a breakfast meal similar to the one eaten on the 14-day diets. Thus, three test meals will be used, one for each of the three test diets (Diet A, Diet B, Diet C). The energy (kcal) level of the breakfast meal will be based on each participant's diet prescription. The nutritional composition diet-specific MMTT will be the same test meal for all participants.
45806109|NCT05699772|Behavioral|Telehealth-delivered Group Lifestyle Balance for people with TBI (tGLB-TBI)|The GLB-TBI was modified from the Diabetes Prevention Program Group Lifestyle Balance (DPP-GLB) by a group of stakeholders using a community based participatory research approach. The GLB-TBI is modified for people with Traumatic Brain Injury and addresses their unique weight loss and healthy lifestyle needs.
45940205|NCT00239278|Drug|budesonide/formoterol, 2x 200/6 microgram. 4 times daily|
45940206|NCT00239278|Drug|prednisolone, 30 mg once daily and placebo|
45940207|NCT00239317|Drug|Tamusulosin|
45940208|NCT02966990|Device|Hand Orthotic Devices|Orthotic device made to provide the patient with better hand function
45940209|NCT00239395|Drug|Meloxicam ampoule|
45940210|NCT00239395|Drug|Meloxicam tablet|
45940211|NCT00076635|Drug|Interferon gamma-1b|200 mcg, SQ, 3x per week
45940212|NCT00239434|Drug|tiotropium inhalation powder capsule|
45940213|NCT00239434|Drug|ipratropium bromide Metered Dose Inhaler|
45940214|NCT00239473|Device|5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
45940215|NCT00239473|Device|10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
45940216|NCT00239512|Drug|Indomethacin and Ibuprofen|
45940217|NCT00076674|Drug|Intravenous Levodopa|
45940218|NCT00239551|Drug|Prevacid|Effect of Prevacid on prostaglandin levels at 8 weeks; EGD (esophagogastroduodenal endoscopy) with biopsy at day 1 & EGD with biopsy at 8 weeks
45940219|NCT00239629|Drug|Teriparatide|
45940220|NCT00239629|Drug|Strontium ranelate|
45676309|NCT04049591|Drug|Higher Dose UFH|Centre wide policy of administering 100 U/kg bolus of intravenous UFH for elective PCI procedures
45806110|NCT05699772|Behavioral|Brain Health Group (BHG)|The BHG was developed by researchers and clinicians at Baylor Scott & White Institute for Rehabilitation.
46074509|NCT00859105|Drug|Adara 5% Cream US|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
46074510|NCT00859105|Drug|Adara 5% Cream Canada|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks.
45806111|NCT05699525|Behavioral|Personalized MAYA Mobile App|All new material in the personalized condition will be introduced within the first four weeks and will contain modules targeting participant's personal symptom profiles. The remaining two weeks in the personalized condition will consist of practicing previously learned skills.
45806112|NCT05699525|Behavioral|General MAYA Mobile App|New material will be introduced to participants over all the six weeks of the intervention and will include all application modules.
45940221|NCT00239629|Procedure|Transiliac bone biopsy|
45940222|NCT00098436|Drug|laromustine|
45940223|NCT00098436|Drug|temozolomide|
45940224|NCT00239707|Drug|GIP|One-time 20 ng/kg/min infusion over 3 hours
45940225|NCT00239707|Drug|Modified GIP|One-time infusion over 3 hours; dose to maintain desired biological effect of below 140 mg/dl
45940226|NCT00239707|Drug|Normal Saline|one-time infusion over 3 hours
45940227|NCT00065819|Behavioral|HIV Symptom Education Program|
45940228|NCT00239746|Drug|Ibuprofen|200mg taken orally daily for 6-12 weeks
45940229|NCT00239746|Drug|Placebo|200mg matched placebo taken orally daily for 6-12 weeks
45940230|NCT00239785|Drug|FTY720|
45940231|NCT00239824|Behavioral|Strength training of the pelvic floor muscles|"Group A followed a pelvic floor muscle exercise course consisting of intensive pelvic floor muscle training with follow up instructions (training group or DVD instructions)by a physiotherapist;3 x 10 contractions daily.~Group B were instructed to train the pelvic floor muscles 3 x 10 contractions daily without follow up instructions by a physiotherapist."
45940232|NCT00239824|Behavioral|strength training of the pelvic floor muscles with or without follow up instructions by a physiotherapist|
45940233|NCT00065858|Drug|BufferGel|
45940234|NCT00239863|Drug|FTY720|
45940235|NCT00239902|Drug|FTY720|
45940236|NCT00098514|Drug|talotrexin ammonium|
45940237|NCT00239980|Drug|dalteparin|50, 100, 150 IU/kg administered subcutaneously once daily for 3 cycles of chemotherapy
45940238|NCT00240019|Drug|Addition of furosemide 20 mg oral bid to baseline regimen|
45940239|NCT00065897|Procedure|Amniocentesis|
45940240|NCT00065897|Procedure|Transabdominal chorionic villus sampling (TA CVS)|
45940241|NCT00240058|Drug|Regional phenylephrine arterial infusion, Nitric Oxide Clamp|
45940242|NCT00098553|Drug|everolimus|
45940243|NCT00240175|Other|No Intervention|No Intervention
45940244|NCT00240214|Drug|sirolimus|Tablet, dosage is determined by trough level
45940245|NCT00240253|Drug|pramlintide acetate|Clear, colorless, sterile solution for SC injection
45940246|NCT00065936|Drug|Naltrexone hydrochloride|
45940247|NCT00065936|Procedure|Transcutaneous sensory nerve stimulation|
45940248|NCT00240292|Drug|Rosuvastatin|
46074511|NCT00859105|Drug|Imiquimod Vehicle|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
45655036|NCT03234881|Behavioral|MOVE!|Participants randomized to the MOVE!(or TeleMOVE!) arm only. MOVE! is 16 weeks of 60-minute weekly groups that are led by a physical therapist, dietician, and/or clinical health psychologist. Clinicians utilize materials available online and encourage the use, but do not require or provide food diaries. TeleMOVE! is a 90-day program utilizing technology to provide home-based messaging focusing on health education and as needed clinician contact. *TeleMOVE! was added as an option since many in-person MOVE! programs were on pause due to the pandemic.
45940249|NCT00240409|Drug|Pramipexole|
45940250|NCT00240409|Drug|Bromocriptine|
45940251|NCT00240448|Drug|telmisartan 80 mg/hydrochlorothiazide 25 mg|
45940252|NCT00240448|Drug|valsartan 160 mg/hydrochlorothiazide 25 mg|
45940253|NCT00240448|Drug|placebo|
45806113|NCT05697679|Behavioral|Releasing Weight-1|Perception: Data such as diet and exercise are evaluated at baseline to make participants feel the current problem. After communication, personalized plans are made and implemented together. After grouping, the training of diet and exercise related knowledge is carried out for one week, and the activation training of physical movement ability is carried out in the second week. This is followed by a detailed 16-week intervention program consisting of jogging and High-intensity Interval Training. The training program is structured in three cycles, with an incremental pattern: both frequency and duration of the sessions are increased. Each session is composed of a warm-up, a high-intensity interval exercise, and a cool down. Weekly information reminders are provided through Wechat and the exercise plan is timely adjusted according to personal conditions. Participants are asked to record their daily diet, and their diet is assessed weekly and given professional advice.
45806114|NCT05697679|Behavioral|Releasing Weight-2|Health education is carried out by distributing diet and exercise related knowledge manuals and videos, and health plans are made. The exercise is evaluated once a month and the diet is evaluated once a week.
45806115|NCT05697380|Behavioral|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted.
45940254|NCT00065975|Procedure|massage therapy|
45940255|NCT00065975|Procedure|chiropractic|
45940256|NCT00065975|Procedure|acupuncture|
45940257|NCT00098631|Drug|lapatinib ditosylate|Given orally
45940258|NCT00098631|Other|laboratory biomarker analysis|Correlative studies
45940259|NCT00240565|Drug|Tositumomab 450 mg|Unlabeled TST
45940260|NCT00240565|Drug|Tositumomab 35 mg|TST labeled with 185 megaBecqueral (mbq) of iodine 131
45940261|NCT00066014|Procedure|Implant Overdenture Treatment|All overdenture treatment modalities were provided to each subject using a crossover design.
45655037|NCT03234881|Behavioral|MOVE!+CBT|Participants randomized to the MOVE!+CBT arm will attend the 16 weeks of 60-minute weekly MOVE! or 90-days of the TeleMOVE! Treatment groups, along with up to 10 clinician-led individual sessions over a 3-month period. Participants will also be given a patient treatment manual to read at home, food diaries that will be expected to be completed on a daily basis, and gradually increase daily physical activity.
45655038|NCT04929925|Diagnostic Test|serum procalcitonin in acute bacterial meningitis|Serum Procalcitonin estimation will be done by Cobas e411Roch diagnostic,Switzerland apparatus by immunoassay method (electrochemiluminescence immunoassay) by using sample serum or plasma heparin or EDTA with reference range less than 0.5ng/ml ( no sepsis) but 0.5-2ng/ml)follow up is recommended) and more than 2 (sepsis)
45655039|NCT04930003|Biological|QazCoVac-P -COVID-19 Subunit Vaccine|QazCoVac-P (Subunit) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
45940262|NCT00240604|Drug|Rosiglitazone|4 mg rosiglitazone per day
45940263|NCT00240643|Drug|SB424323|
45940264|NCT00076791|Drug|Emtricitabine/Tenofovir disoproxil fumarate|900 mg of TDF combined with 600 mg emtricitabine
45940265|NCT00076791|Drug|Tenofovir disoproxil fumarate|600 mg oral dose of TDF
45940266|NCT00066053|Procedure|Periodontal Treatment: SRP|Scaling and root planing. Subgingival tissue removal. Fluorides as needed. Oral hygiene instructions. Oral hygiene instructions.
45940267|NCT00066053|Procedure|Referral|
45940268|NCT00240682|Drug|cetuximab|Dosage form: bottles of 50 ml, 2 mg/ml; Dosage:400 mg/m2 initial dose followed by 250 mg/m2 by infusion every week; Number of Cycles : until progression or unacceptable toxicity develops.
45940269|NCT00240721|Drug|topiramate|
45940270|NCT00240760|Drug|Memantine Hydrochloride|
45940271|NCT00066092|Drug|pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for PBPC mobilization
45940272|NCT00066092|Drug|filgrastim|Filgrastim given daily for PBPC mobilization
45940273|NCT00066092|Drug|pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for PBPC mobilization
45940274|NCT04720807|Drug|Letrozole combined with anlotinib hydrochloride|Letrozole combined with anlotinib hydrochloride in the treatment of platinum-resistant recurrent ovarian cancer.
45940275|NCT00098826|Drug|ispinesib|Given IV
45940276|NCT00098826|Other|laboratory biomarker analysis|Correlative studies
45940277|NCT00098826|Other|pharmacological study|Correlative studies
45940278|NCT00240799|Drug|acetaminophen extended release|
45940279|NCT00240799|Drug|placebo|
45940280|NCT00240838|Drug|acetaminophen extended release caplets|
45940281|NCT00240877|Biological|AV024|0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
45940282|NCT00240877|Other|Placebo|Placebo mist consisting of normal allantoic fluid. 0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
45940283|NCT02965404|Biological|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
45940284|NCT02965404|Biological|control live attenuated varicella vaccine|The control vaccine was manufactured by Shanghai Institute of Biological Products Co., Ltd. (SIBP)
45940285|NCT02965404|Biological|diluent of lyophilized vaccine|The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology
45940286|NCT00240955|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
45940287|NCT00241072|Drug|valsartan|24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG)
45940288|NCT00241111|Drug|zoledronic acid|
45940289|NCT00414505|Device|Intradermal Acupuncture Treatment|
45940290|NCT00066131|Procedure|Periodontal scaling and root planing|Hard and soft tisse deposits (plaque and calculus) are removed from the tooth and tooth root using hand and ultrasonic instruments.
46074512|NCT02610387|Device|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation for 20 minutes plus balance training for 20 minutes for 5 consecutive days.
46074513|NCT02610387|Device|Sham tDCS|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation plus balance training for 20 minutes for 5 consecutive days.
46074514|NCT02804334|Procedure|Psychiatric Questionnaires|
45655040|NCT04930003|Other|Placebo|The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)
45655041|NCT04940143|Drug|Botulinum toxin type-A (Onabotulinum toxin type-A)|Botulinum toxin-A (Onabotulinum toxin type-A/Botox®) injection will be administered from three different points, two on the medial head of the gastrocnemius muscle and one point on the lateral head with total 3-6 units/kg dose, under the guidance of electrical stimulation for the detection of the target neuromuscular junction.
45806116|NCT05695339|Drug|Resiniferatoxin|An injection of 1-2 ml bupivacaine 0.5% will be placed around the affected branch of the neuroma (aiming at its proximal end) and dorsal adjacent tissue including the skin dorsally to the neuroma. This is to prevent pain caused by any microscopic spills of RTX during the. A second local anesthetic depot will be placed 1-2 cm proximally to the injection site around the affected branch of the plantar nerve to prevent pain caused by passive current transmission by axonal RTX excitation. Following the course of the affected nerve branch and ultra-sound visualization of the injection site, 0.5-2 ml bupivacaine 0.5% will be injected perineurally. Once the site has sufficient nerve block, the required RTX dose in a solution of 0.25 ml will be injected directly proximal to the Morton s neuroma under ultra-sound visualization.
45806117|NCT05693805|Behavioral|Tai Chi|The remote delivery Tai Chi protocol that will be developed in this study for Veterans with PTSD and pain will be adapted from a protocol that has been well-tested in previous trials All components of the program derive from the classical Yang-style Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Sessions will last 60 minutes, twice a week for 12 weeks. Experienced instructors will follow the Tai Chi protocol with rigorous quality control procedures. We will provide the patients with printed materials on the Tai Chi program, including Tai Chi principles, practice techniques, and safety precautions. Every session will include: warm up and a review of Tai Chi principles; breathing techniques; meditation with Tai Chi movement; and relaxation.
45940291|NCT00066131|Procedure|Scaling and root planing|Delivered using hand and powered scalers and with topical or local (injected) anesthetics as needed. Procedures performed over 1 to 4 90-minute visits.
45940292|NCT00241150|Drug|VALSARTAN|
45940293|NCT00076869|Drug|MK0991, caspofungin acetate|
45940294|NCT00076869|Drug|Comparator: amphotericin B|
45940295|NCT00076869|Drug|Comparator: lipid formulation of amphotericin B and/or azole|
45940296|NCT00066248|Drug|cyproheptadine hydrochloride|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
45940297|NCT00066248|Drug|megestrol acetate|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
45940298|NCT00241189|Drug|rapamycin|
45655042|NCT04940143|Other|Physical Therapy|After the botulinum toxin-A injection, the patients will be included in the comprehensive physiotherapy program thrice a week for a total of 12 weeks. The physiotherapy program will be consisted of the ankle range of motion and stretching, strengthening of the antagonist muscles, proprioception exercises, functional walking training and static and dynamic balance training.
46074515|NCT02804334|Procedure|Blood draw|
46074516|NCT00859183|Drug|Sirolimus|cumulative loading dose of 8 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
46074517|NCT00859183|Drug|Sirolimus|cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
45940299|NCT00241189|Drug|methotrexate|
45655043|NCT03057067|Procedure|Embolization of pelvic vein varicosities|Embolization of pelvic vein varicosities
45655044|NCT03056911|Drug|Ozone|Pain relief with chemonucleolysis by using ozone regard to age, sex, ASA score, and complications.
45655045|NCT04929613|Behavioral|Mindfulness-Based Resilience Training|2.5-day intensive MBRT training sessions.
45655046|NCT04920409|Other|FAWGT diet|Composed of 15% protein, 55% CH and 30% fat of which < 10% was SFA, 14% MUFA and 6% PUFA in the overall total caloric content.
45940300|NCT00241228|Device|Venovenous haemofiltration (renal replacement therapy)|High Volume ultra filtration (70 ml/kg/h)
45940301|NCT00241228|Device|Venovenous haemofiltration (renal replacement therapy)|Conventional Volume (35 ml/kg/h)
45940302|NCT00241267|Device|Dedicated ultrasonographic probe during bronchoscopy|
46074518|NCT00859183|Drug|Placebo|Placebo oral
46074519|NCT05757765|Other|deprescribing pharmacotherapy approach (DPA)|A new way of medication review in patients with sarcopenia. This method is based on previous scientific research and is aimed at minimizing pharmacotherapy. The aim is to combat symptoms and complaints and to stop (preventive) medication as much as possible
46074520|NCT05757765|Other|STOPP-START deprescribing approach (SSA)|The usual care in the geriatric medicine in the Netherlands consisting of a medication review based on the STOPP-START criteria. These criteria have been combined in a protocol that describes when certain medication(groups) must be continued or discontinued for specific patient characteristics.
46074521|NCT02803944|Drug|Azithromycin|
46074522|NCT00859261|Procedure|Experimental 3D Breast Ultrasound imaging|Subjects will be seated and have the indicated breast positioned in the 3D breast ultrasound imaging device. An ultrasound gel will be applied to the breast by the technician. The breast will be gently compressed between the ultrasound plates to facilitate the 3D (dimensional)breast imaging. This imaging session will take approximately 30 minutes to complete.
45676310|NCT04049591|Drug|Lower Dose UFH|Centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures
45940303|NCT00098943|Biological|CNGRC peptide-TNF alpha conjugate|
45655047|NCT04920409|Other|Usual diet (UD)|Consisted of 16% protein, 54% carbohydrates (CH) and 30% fat of which 15% was saturated fat (SFA), 10% monounsaturated fat (MUFA) and 5% polyunsaturated fat (PUFA)in relation to the total caloric content
45940304|NCT00066326|Drug|imatinib mesylate|
45940305|NCT00066326|Drug|tanespimycin|
45940306|NCT00241345|Drug|Valganciclovir|
45655048|NCT04920721|Other|no intervention|no intervention descriptiv study
45655049|NCT04939675|Drug|Zonisamide 100mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
46074523|NCT00859261|Procedure|Experimental Photoacoustic Imaging|Subjects will be placed in a seated position for the photoacoustic tomography(PAT) imaging. The subjects will be given a laser protective mask to wear. Each subject will be instructed how to wear this mask(goggles) to protect their eyes during the imaging session. Pulse monitor leads may be placed on their chest to allow the computer to record the images of blood flow in the breast. The breast will be placed on the laser device platform and positioned so that the laser beam is appropriately directed to the targeted area of the breast. During the imaging the temperature of the skin under laser light, will be checked often with a thermometer to make sure that the skin is not getting too hot. This laser based imaging scan will take approximately 10 minutes to complete.
46074524|NCT05297721|Other|Knowledge|Measuring the level of knowledge about skin tears
46074525|NCT02803710|Other|Microbiological study|
45655050|NCT04939675|Drug|Levetiracetam 500mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
46074526|NCT04042675|Diagnostic Test|observational study|There will be two groups in this study. One of the groups will consist of 30 parkinson's patients aged between 40-75 years and 1-3 according to Hoehn-Yahr stage. The other group will consist of 30 healthy individuals between the ages of 40-75 and without any neurological disorders. Participants' respiratory muscle strength, exercise capasity, fatigue and physical activity levels will be assessed. All asessements will done for only one time.
45655051|NCT04939675|Drug|LamoTRIgine 50mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
46074527|NCT02803554|Other|Plasma|Blood plasma from donors aged 25 years or younger
45655052|NCT04939285|Procedure|PEEP|The patients who met the withdrawal screening criteria were randomly divided into low pressure support level PSV spontaneous respiration test.The duration of the spontaneous breathing test was 30 minutes, and the results of the spontaneous breathing test were evaluated at the end of the test.
46074528|NCT00960011|Device|PROGRIP|Use of PROGRIP mesh for open inguinal hernia repair
46074529|NCT00960011|Device|POLYPROPYLENE|Use of Polypropylene mesh in open inguinal hernia repair
45458036|NCT04737031|Other|Clinician Nudge|"Investigators will use the Best Practice Alert functionality within the EMR as the conduit to the point of decision-making. Epic currently fires a BPA for each new patient presenting to ACC within the Medical Assistant check-in and vital sign workflow, requiring that medical assistants assess tobacco use status within the past 30 days and satisfy the alert with one of three possible answers. Upon opening the Epic Order tab at a patient's next visit after the screening encounter, clinicians will receive the implementation strategy, placed directly over the order interface. The clinician will be required to acknowledge or opt-out when presented with the order. Opting-out will require clinicians to acknowledge a reason for opt-out using a checklist or free text."
45655053|NCT04929691|Device|CPAP helmet|helmet-based CPAP ventilation for eligible patients; assess the feasibility and acceptability of the helmet-based CPAP ventilation
45940307|NCT00241345|Drug|Ganciclovir|
45940308|NCT00241384|Procedure|External beam radiation|
45940309|NCT00241384|Procedure|Pd-103|
45940310|NCT00076947|Biological|EnvPro|
45940311|NCT00241423|Drug|exenatide|subcutaneous injection, 5mcg twice a day for one week; then 10 mcg twice a day for one week
45655054|NCT04929691|Other|Standard of care non-helmet based CPAP ventilation|Standard of care ventilation without helmet-based CPAP
45676311|NCT04046445|Drug|ATP128|5-6 SC injections
45676312|NCT04046445|Drug|BI 754091|≥ 7 IV infusions
45676313|NCT04046445|Drug|VSV-GP128|1 single IV injection
45676314|NCT04046224|Biological|ST-920|Single dose of investigational product ST-920
45676315|NCT04032704|Drug|ladiratuzumab vedotin|Intravenous (into the vein; IV) infusion
45940312|NCT00241423|Drug|Placebo|subcutaneous injection, equivalent volume to 5 mcg exenatide twice a day for one week; then equivalent volume to 10 mcg exenatide twice a day for one week
45940313|NCT00241501|Drug|Esomeprazole (Nexium)|
45940314|NCT00066404|Biological|recombinant adenovirus-hIFN-beta|
45940315|NCT00076986|Drug|IL13-PE38QQR|
45940316|NCT00076986|Procedure|surgery and catheter placement (2 procedures)|
45940317|NCT00076986|Drug|prolifespan 20 with carmustine implant (GLIADEL® Wafer)|
45940318|NCT00076986|Procedure|surgery and wafer placement (1 procedure)|
45940319|NCT00241540|Drug|Esomeprazole|
45940320|NCT00066443|Biological|pegfilgrastim|Dose escalation schedule A&B = 6mg fixed dose once per cycle on day 2
45940321|NCT00066443|Drug|docetaxel|Dose Escalation schedule A = 75-85 mg/m2 Dose Escalation schedule B = 50-75 mg/m2
45940322|NCT00066443|Drug|epirubicin hydrochloride|Dose escalation schedule A = 75-120 mg/m2 IV Dose escalation schedule B = 50-90 mg/m2 IV
45940323|NCT04720690|Device|Vicorder: pulse wave velocity, pulse wave analysis, stroke volume, cardiac output|Measurement of arterial stiffness and cardiac output
45940324|NCT04720690|Device|NICaS|Measurement of cardiac output
45940325|NCT04720690|Device|Echocardiography and ultrasound of arteries|Measurement of cardiac output; measurement of intima-media thickness of arteries
45940326|NCT00241579|Drug|Smoked Cannabis|
45940327|NCT00098982|Drug|bortezomib|
45940328|NCT00098982|Drug|fluorouracil|
45940329|NCT00098982|Drug|leucovorin calcium|
45940330|NCT00098982|Drug|oxaliplatin|
45655055|NCT04939129|Diagnostic Test|The research is terminated by calculating the percentage of PVI changes with SAB formed by LRM after fluid challenge.|Measurements will begin after a hemodynamically stable period in the supine position.Heart rate, central venous pressure, systolic, diastolic and mean arterial pressure, peripheral oxygen saturation, PVI and BIS baseline values (baseline 1) will be recorded.LRM will be automatically adjusted in the mechanical ventilator(30 cm H2O/30 seconds) and all hemodynamic parameters where the maximum change at the end of 30 seconds, will be recorded(after LRM), and the differences initial baseline values will be calculated and recorded as percentages.After the recording of the second values, the crystalloid infusion at 10ml/kg will be made to the patient through the peripheral venous line within 15minutes, new baseline values will be taken before the test(baseline 2).After fluid replacement, LRM will be repeated in the same way. The values after LRM(Fluid Challenge-FC) will be recorded and differences between basal 2 values will be calculated and recorded as percentages.
45655056|NCT04938583|Biological|Oregovomab|"Oregovomab will be administered on day1 cycle 1, 3, 5, and 9. A minimum of 3 patients will be enrolled into each cohort (2 mg or 1 mg).~2 mg (starting dose), dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes"
45655057|NCT04938583|Drug|Bevacizumab|15mg/Kg Day 1 (every 21 days) until progression
45940331|NCT00241618|Drug|Pegylated interferon alpha 2|
45940332|NCT00241618|Drug|Ribavirin|
45655058|NCT04938583|Drug|Paclitaxel|175 mg/m^2, Day 1 x 6 cycles (every 21 days)
45655059|NCT04938583|Drug|Carboplatin|AUC 5 IV Day 1 x 6 cycles (every 21 days)
45676316|NCT04032704|Drug|pembrolizumab|200mg given by IV on Day 1 of each 21-day cycle
45676317|NCT04028674|Device|Laryngeal Pacing Device|Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
45676318|NCT04024293|Device|Goldfish (GF)|The GF lens (SCL) will be place on participant's eye for a 24h IOP recording session
45940333|NCT00241657|Biological|BCG|
46074530|NCT02545231|Drug|Pitavastatin 1mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
46074531|NCT02545231|Drug|Pitavastatin 4mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
46074532|NCT02545231|Drug|Placebo|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
45940334|NCT00066482|Biological|bleomycin sulfate|Given IV over 10 minutes. Children ≥ 12 months: 15 units/m2/dose Children < 12 months: 0.5 units/kg/dose Day 1 (Week 1, 4, 7, 10)
45940335|NCT00066482|Biological|filgrastim|Given SQ once daily 5 micrograms/kg/dose Starting on Day 6 (Week 1, 4, 7, 10) Daily until ANC > 5,000/uL
45940336|NCT00066482|Drug|cisplatin|Children ≥ 12 months: Given IV over one hour Dose: 20 mg/m2/dose Days 1-5 (Week 1,4,7,10) Children < 12 months: Given IV over 4 hours, 0.67 mg/kg/dose Days 1-5 (Week 1,4,7,10)
46074533|NCT02610309|Behavioral|Family-Based Crisis Intervention|This intensive ED-based intervention with suicidal adolescents and their families includes cognitive behavioral skill building, psychoeducation, enhancing therapeutic readiness, safety planning, and co-creation of a joint crisis narrative.
45940337|NCT00066482|Drug|cyclophosphamide|Given IV over 1 hour. Children ≥ 12 months: Level 1: 1.2 g/m2/dose Level 2: 1.8 g/m2/dose Level 3: 2.4 g/m2/dose Children < 12 months: Level 1: 40 mg/kg/dose Level 2: 60 mg/kg/dose Level 3: 80 mg/kg/dose Day 1 (Week 1, 4, 7, 10)
45940338|NCT00066482|Drug|etoposide|Given IV over 1 hour. Children ≥ 12 months: 100 mg/m2/dose Children < 12 months: 3.3 mg/kg/dose Day 1-5 (Week 1, 4, 7, 10)
46074534|NCT02803632|Behavioral|questionnaires|
46074535|NCT02803632|Device|actigraphic recording|
46074536|NCT05757453|Device|MHealth|Mobile application
46074537|NCT00854815|Procedure|Irrigation|Irrigation of the area with at least 500ml NS using the power suction/irrigator
46074538|NCT00854815|Procedure|No Irrigation|Suction only using suction/irrigator
46074539|NCT02803788|Drug|ramosetron, ondansetron, dexamethasone|prevention of post-operative nausea vomiting
46074540|NCT05188287|Behavioral|HealthyCells|Smoking cessation smartphone app
46074541|NCT04281953|Diagnostic Test|High frequency audiometry|Simple hearing test
46074542|NCT04281953|Other|Short-Form 36-Item Questionnaire (SF-36)|Questionnaire on quality of life (Short Form 36 Item- SF-36)
46074543|NCT04281953|Other|Hearing handicap inventory for adults/elderly (HHIA/HHIE)|Questionnaire on Hearing loss (Hearing handicap inventory for adults/elderly- HHIA/HHIE)
46074544|NCT04281953|Other|Tinnitus handicap inventory (THI)|Questionnaire on Tinnitus (Tinnitus Handicap Inventory)
46074545|NCT04041505|Behavioral|(feeding modality)|The intervention is a change in feeding modality: in both arms, infant's will consume mother's milk. The difference in arms is the modality in which human milk is consumed: either directly from the breast, or from a bottle.
45940339|NCT00066482|Procedure|conventional surgery|Stage III/IV extragonadal tumors: biopsy followed by a definitive surgical excision after maximal chemotherapy effect, likely after 4 cycles of therapy
45940340|NCT00066482|Biological|MESNA|Given IV or oral. The total daily MESNA dose is equal to at least 80% of the daily CPM dose. The oral dose of MESNA is 2x the IV dose. Day 1 (Week 1,4,7,10) To be given with CPM.
45655060|NCT04938739|Other|Cognitive Behavioral Therapy|"The first 6 sessions: the cognitive part was explained with the support of a PowerPoint presentation using diagrams, images, and texts. The therapist explained the lumbar engine behavior, the neurophysiologic basis of pain, the importance of the participant's involvement in the treatment (e.g., coping and motivation), and the maintenance of good ergonomics which was aimed at modifying the physiologic response to the pain system.~The second 12 sessions: concepts viewed in the first session were revised; as well, the operant and respondent parts were explained."
45655061|NCT04938739|Other|Home program exercises|Each session will include 10 minutes of aerobic activity (walking or stationary bicycle), followed by five types of muscle stretches and eight types of ground exercises aimed at strengthening the lumbar muscles responsible for stabilization.
45806118|NCT05693805|Behavioral|Wellness program|The Wellness intervention that will be developed for this study will consist of 60-minute sessions that meet twice a week for 12 weeks, and will be facilitated by doctoral level psychology staff and/or psychology trainees who will be supervised by staff. The Wellness intervention will be based on the VA Whole Health Program which helps individuals identify and achieve their personal health goals. The Whole Health Program include modules that address physical activity, personal development, healthy eating and drinking, stress management, relationships, personal surroundings, and spirituality. Using the SMART goals model, participants will set health and wellness goals each week. Discussions about ways to address potential barriers will be included in this condition.
45806119|NCT05693753|Device|Use of XCM for the treatment of MAGRs with mCAF technique|After local anaesthesia, mCAF technique will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
45806120|NCT05693753|Procedure|Treatment of MAGRs with CTG|After local anaesthesia, mCAF technique will be performed. CTG will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
45806121|NCT05693454|Drug|Infiltration with NaCl|Local wound infiltration at the end of spine surgery with NaCl
45806122|NCT05693454|Drug|Infiltration with Ropivacain|Local wound infiltration at the end of spine surgery with Ropivacain
45806123|NCT05693454|Drug|Infiltration with a combination of Levobupivacaine and Tramadol|Local wound infiltration at the end of spine surgery with a combination of Levobupivacaine and Tramadol
45940341|NCT00099060|Drug|lapatinib ditosylate|"For patients receiving enzyme inducing anti-epileptic drugs (EIAEDs):~Phase I: starting dose for first cohort: 1000 mg GW572016 po b.i.d.; actual dose assigned at registration; intra patient dose escalation permitted ONCE in phase I patients ONLY if specified criteria met (see section 8.6).~Phase II: Recommended phase II dose from phase I portion of the study, given po b.i.d.~For patients NOT receiving enzyme inducing anti-epileptic drugs (NON-EIAEDs):~• Phase II: 750 mg GW572016 po b.i.d.~For all patients:~• Dose reductions as required based on adverse events."
45940342|NCT00241813|Behavioral|Mindfulness Meditation (MM) Program|Participants will take part in a mindfulness meditation (MM) program.
45940343|NCT00241813|Behavioral|Health Education Control Program (CTL)|Participants will take part in a health education control program (CTL)
45940344|NCT00241813|Behavioral|Lifeskills Program (LP)|Participants will take part in a lifeskills program (LP).
45655062|NCT04938349|Behavioral|Dual task perturbation training|Participants will play six cognitive games targeting working memory, executive functioning, visuomotor reactions, and language fluency provided in standing. Following which they will receive 12 slips without performing cognitive task (Single task training) at the highest intensity and 12 slips during standing while performing a cognitive task (dual task). Also, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
45655063|NCT03055975|Diagnostic Test|Detection of residual vital bacteria in the root canal space|Detection of residual vital bacteria in the root canal space. No intervention, as it is an observational study. Vital bacteria are looked for in the samples taken from the root canal space.
45655064|NCT04929301|Other|Antenatal milk expression|Hand-expression of breast milk in pregnancy
45655065|NCT04929301|Other|Education handouts|Educational breastfeeding handouts
45806124|NCT05691504|Procedure|Biopsy|Undergo biopsy
45806125|NCT05691504|Procedure|Biospecimen Collection|Undergo collection of blood
45940345|NCT00241852|Behavioral|Asthma: It's a Family Affair!|Intervention families will receive a comprehensive program with two complementary components: (1) a school-based intervention to empower middle school students to manage their asthma and (2) parent training to teach their caregivers childrearing skills that support the youth's growing autonomy and need to self-manage their disease. The student component is comprised of 6, 60 minute group workshops; the caregiver component consists of 5, 90-minute group workshops.
45452785|NCT04946552|Diagnostic Test|CT Scan|A CT scan will be performed for attenuation correction and to help delineate the BAT and other regions of interest (ROIs). Images will be reconstructed with an ordered subset expectation maximization algorithm using point spread function correction and time-of-flight information. To delineate fat (WAT, BAT) and skeletal muscle regions of interests (ROIs), CT images are first resliced to match the resolution and location of PET images. As performed in previous studies 2, a supraclavicular ROI is first manually drawn on the CT images. Within that area, the fat ROI is segmented using the CT images and an intensity window from -200 to -50 HU. Subsequently the fat ROI is segmented into WAT and BAT ROIs by using the 11C-MRB PET images: Standardized Uptake Value (SUV) ≥ 1.25 for BAT, SUV < 1.25 for WAT.
45806126|NCT05691504|Drug|Cobimetinib|Given PO
45940346|NCT00241852|Behavioral|Asthma and Stress Comparator|Caregivers assigned to the Asthma and Stress Comparator group will receive a single educational workshop focusing on the developmental changes adolescents experience, how these changes may cause stress, and ways to cope with stress. The children will also participate in a single school-based session on similar topics. Both caregivers and students will learn basic asthma facts.
45940347|NCT00099099|Behavioral|Caloric Restriction (CR)|
45940348|NCT00241891|Behavioral|Single behavior intervention|Focused on changing beverage choices which may have a significant impact on weight.
45940349|NCT00241891|Behavioral|Multiple behavior interventions|Focused on multiple behaviors (nutrition, beverages, physical activity, and sedentary lifestyle) which may have a significant impact on weight.
45940350|NCT00241891|Behavioral|Control Intervention unrelated to weight|Focused on standard intervention strategies unrelated to weight including bullying prevention.
45940351|NCT00241930|Behavioral|Integrating drug treatment into HIV services|
45940352|NCT00066599|Drug|voriconazole|
45940353|NCT00242008|Drug|Rotigotine|
45940354|NCT00099138|Behavioral|Caloric Restriction (CR)|
45940355|NCT00099138|Behavioral|Exercise|
45655066|NCT03055663|Other|Sedation by watching virtual reality sedative program|Patients watch three-dimensional virtual reality program with headset and headphone during surgery.
45940356|NCT00242047|Biological|Japanese (Tokyo) 172 Bacille Calmette Guerin (BCG).|
45458752|NCT04289428|Diagnostic Test|Xpert® HBV DNA point of care assay from dried blood spot|Xpert® HBV DNA point of care assay from dried blood spot
45655067|NCT03055663|Procedure|Sedation by using intravenous sedative|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
45655068|NCT03055663|Drug|Midazolam|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
45655069|NCT04928443|Other|Scar dressing group|Patients treated with scar dressing for surgical scar care are invited to participate this study and allocated in scar dressing group despite the length of caring period.
45655070|NCT04928443|Other|Regular care group|Patients receiving regular scar care are retrospectively identified with matching factors, such as gender, age, length of surgical wound and surgical procedure.
45655071|NCT04920019|Procedure|Thoracic continuous epidural analgesia|"Continuous epidural catheter (Portex ™, Epidural Minipack , Smiths Medical), infused with 0.0625% bupivacaine (Marcaine™, Aspen Holdings) with morphine (morphine M&H™) 0.02 mg/ml 5 ml/h postoperative until POD3 morning Connected with The Sapphire ™ Infusion System Patient-Controlled-Analgesia (PCA) pump(fentanyl (fentanyl-Hameln™, Siam Bioscience): intravenous bolus mode only 15 ug/bolus, lockout interval 5 minutes, 4-hour limit 200 ug)~Postoprative analgesia: intravenous paracetamol (infulgan ™, Yuria-Pharm), tablet paracetamol (SaRa ™), Parecoxib (Dynastat ™, Pfizer), Etoricoxib (Arcoxia ™, MSD)"
45655072|NCT02621047|Drug|Alectinib|Participants will receive alectinib as per the dosage schedule mentioned in arm description.
45940357|NCT00242086|Procedure|CT, PET and MRI|
45940358|NCT02958332|Other|video game program|Participants will use the Wii console and the Wii balance board, to play different video games which imply shoulder movements. They will receive 5 individual sessions of 30 minutes.
45806127|NCT05691504|Procedure|Computed Tomography|Undergo CT
45940359|NCT00242164|Drug|Dialysate Magnesium (Concentration)|
45940360|NCT00099177|Drug|ibandronate [Bondronat]|6mg iv on days 1-3, and 50mg po from day 22 to week 24
45940361|NCT00099177|Drug|zoledronic acid|4mg iv on day 1, and every 3-4 weeks
45940362|NCT02962024|Drug|Morphine Sulfate|
45940363|NCT02962024|Drug|Bupivacaine Hydrochloride|
45940364|NCT00066638|Drug|Romidepsin|Given IV
45940365|NCT00066638|Other|Laboratory Biomarker Analysis|Correlative studies
45940366|NCT00242203|Drug|Zometa|
45940367|NCT00242203|Drug|Epirubicin|
45940368|NCT00242203|Drug|Docetaxel|
45806128|NCT05691504|Procedure|Echocardiography|Undergo ECHO
45806129|NCT05691504|Procedure|Magnetic Resonance Imaging|Undergo MRI
45806130|NCT05691504|Procedure|Multigated Acquisition Scan|Undergo MUGA
45806131|NCT05691504|Drug|Pelcitoclax|Given IV
45806132|NCT05691478|Procedure|Bone Scan|Undergo bone scintography
45806133|NCT05691478|Drug|Cabozantinib S-malate|Given PO
45806134|NCT05691478|Drug|Cisplatin|Given IV
45806135|NCT05691478|Procedure|Computed Tomography|Undergo CT
45806136|NCT05691478|Drug|Doxorubicin Hydrochloride|Given IV
45940369|NCT00242203|Drug|Trastuzumab|ONLY for patients that are Her-2 overexpressing by 3+ by ICH for FSH
45940370|NCT00242203|Radiation|External beam radiation|
45940371|NCT00242203|Procedure|Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection|
45940372|NCT00077025|Drug|Gefitinib|ZD1839 (gefitinib, IRESSA) 250 mg/DAY PO + 1 mg Anastrozole (ZD1033, Arimidex)
45940373|NCT00077025|Drug|Anastrozole|1 mg Anastrozole (ZD1033, Arimidex) + PLACEBO 1 TABLET/DAY PO
45940374|NCT00242281|Drug|APC-111 MP Tablet, 775 mg|
45940375|NCT00242320|Drug|Roflumilast|to investigate the effect of 500 µg Roflumilast tablets once daily versus placebo
45940376|NCT00242320|Drug|Placebo|
45940377|NCT00242359|Drug|omalizumab|
45940378|NCT00066716|Drug|carboplatin|Dosed to an AUC of 6 by the Calvert formula, intravenously over 1 hour after paclitaxel on days 1, 22, and 43.
45940379|NCT00066716|Drug|celecoxib|400 mg orally BID begins 3-7 days before the first dose of chemotherapy to the morning of surgery. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year total, that is, 1 year from the date of surgery + 2 weeks unless tumor recurrence is documented.
45655073|NCT03057691|Other|antidepressive and anti-anxiety therapy|These therapies include antidepressants, antianxiety drugs and psychotherapy. Subjects choose the therapy follow their own will. All of the above-mentioned therapies are identified by experienced psychiatrists in the same center. The treatment information will be recorded in each visit. The study is considered non-interventional, and no antidepressive or anti-anxiety therapies are mandated.
45806137|NCT05691478|Procedure|Magnetic Resonance Imaging|Undergo MRI
45806138|NCT05691478|Drug|Methotrexate|Given IV
46074546|NCT05757375|Other|Mulligan Manuel Therapy Consept|Mulligan ankle taping is a noninvasive, painless, low-cost, and easily applicable technique of the Mulligan manual therapy concept. It is frequently used in cases of ankle instability. In healthy people, it is a method to prevent ankle sprains.
45655074|NCT03057379|Other|Vaccine Reminder Recall|The investigators will be sending recall notices via phone call to 11-17 year olds who are eligible but lacking HPV vaccine doses recorded in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention)
45806139|NCT05691478|Procedure|Surgical Procedure|Undergo surgery
45940380|NCT00066716|Drug|paclitaxel|200 mg/m2 as a 3-hour intravenous infusion on days 1, 22, and 43.
45940381|NCT00066716|Procedure|adjuvant therapy|"Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~Operation will be performed within 6-12 hours from the last dose of celecoxib.~Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection.~Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year."
45940382|NCT00066716|Procedure|conventional surgery|"Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~Operation will be performed within 6-12 hours from the last dose of celecoxib.~Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."
45940383|NCT00066716|Procedure|neoadjuvant therapy|"Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~Operation will be performed within 6-12 hours from the last dose of celecoxib.~Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."
45940384|NCT00077103|Biological|filgrastim|filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.
46074547|NCT02800278|Other|observational|describe bone status and outcome of odontoid fracture
45806140|NCT05691478|Procedure|X-Ray Imaging|Undergo X-ray
45806141|NCT05691270|Behavioral|IN-Control (Birth Control Navigator Program)|Pilot Study of IN-Control Program within the state of Indiana
45806142|NCT05684952|Drug|Shenlingcao Oral Liquid|Shenlingcao oral liquid (200ml/bottle) is comprised of American Ginseng (Panacis Quinquefolii Radix), Lucid Ganoderma (Ganoderma), Rose (Rosae Rugosae Flos) and fermented Cordyceps powder.
45806143|NCT05684523|Drug|Valerian-Hop Extract|herbal drug
45940385|NCT00077103|Biological|pegfilgrastim|filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.
45940386|NCT00077103|Drug|cisplatin|cisplatin IV over 30-60 minutes on day 1
45940387|NCT00077103|Drug|doxorubicin hydrochloride|doxorubicin IV over 5-10 minutes
45940388|NCT00077103|Drug|fosbretabulin disodium|Combined Modality Phase:Patients also receive CA4P IV over 10 minutes weekly on the fifth day of radiotherapy. Beginning 4-6 weeks after the completion of the combined modality phase, patients receive CA4P IV over 10 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses.
46074548|NCT02859701|Drug|AK002|IV AK002
46074549|NCT02859701|Other|Placebo|
45458753|NCT02115139|Drug|Ipilimumab|Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles
45806144|NCT05684523|Drug|Placebo|Placebo
45806145|NCT05683834|Drug|Matrix-M1 Adjuvant|Matrix-M1 is composed of 2 types of 40 nm-sized particles each with a different saponin fraction (fraction A and fraction B) combined with cholesterol and phospholipid.
45806146|NCT05683834|Drug|EBV gp350-Ferritin Vaccine|The EBV gp350-Ferritin vaccine is composed of Helicobacter pylori non-heme ferritin fused to EBV gp350 which self-assembles to form a nanoparticle. The vaccine is supplied in single-use vials at a concentration of 250 micrograms/mL in 1.7 mM KH2PO4, 5 mM Na2HPO4, 150 mM NaCl, 5% sucrose, pH 7.4 (diluent).
45806147|NCT05683834|Other|Placebo Comparator|Normal Saline
45806148|NCT05681650|Biological|HypoSti.CAR-HER2 T cells|Dose escalation: dose -1 (1×10^6 cells/kg) ,dose 1 (3×10^6 cells/kg) , dose 2 (6×10^6 cells/kg), dose 3 (1×10^7 cells/kg), dose 4 (1.5×10^7 cells/kg). Dose expansion: RP2D
45806149|NCT05681650|Drug|Albumin-bound paclitaxel|Administered intravenously at dose of 100-200mg/m2 on day -5
45806150|NCT05681650|Drug|Cyclophosphamide|Administered intravenously at a total dose of 15-30mg/kg on day -3 and day-2
45806151|NCT05681650|Drug|Fludarabine|Administered intravenously at dose of 30mg/m2/d on day -3 and day -2 only in the first infusion of HypoSti.CAR-HER2 T cells
46074550|NCT02610153|Drug|Vitamin K Antagonist|The vitamin K antagonists exert their anticoagulant effect through inhibition of the enzyme complex of vitamin K epoxide reductase subunit 1 with subsequent reduction of the gamma-carboxylation of certain glutamic acid molecules endpoints located on factors coagulation II (prothrombin), VII, IX and X and protein C or its cofactor protein S. This gamma-carboxylation has a significant bearing on the interaction of coagulation factors referenced with calcium ions. Without this reaction, blood clotting cannot be initiated. The dose must be adjusted to each patient at baseline and after regular basis, since the sensitivity to anticoagulants varies between individuals and can also vary throughout the treatment. For this, the Prothrombin Time (PT) is used and standardized ratio called International Normalised Ratio (INR).
46074551|NCT02799966|Device|Myndmove|20 sessions of 1 hour treatments with the MyndMove device (functional electrical stimulation) to the muscles of the upper limb(s), conducted 3 to 5 times per week, over 4 to 7 weeks.
45452786|NCT04946552|Other|Body Composition, Percent Body Fat & Percent Body Water (DXA Scan)|For better accuracy, measurement of percent fat and percent body water will be obtained with whole body Dual X-Ray Absorptiometry (DXA) scan (Hologic®) on screening-OGTT visit. The scanner arm will move over the participant's body from feet to head. The machine uses a small amount of radiation (one tenth of the amount of radiation from a chest x-ray) to measure body fat, muscle and bone density.
45806152|NCT05680337|Device|TENS|TENS stimulation will occur within 10 minutes. HRV parameters will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.
45806153|NCT05680142|Procedure|superficial cervical plexus block|The superficial cervical plexus block is applied as part of our routine protocol for postoperative pain control. Group sCPB will be administered from the C4 level by entering the posterior border of the sternocleidomastoid muscle from the right side of the neck.
45806154|NCT05680142|Procedure|cervical erector spinae plane block|The cervical erector spinae plane block is applied as part of our routine protocol for postoperative pain control. Group cESP is applied to the fascia between the semispinalis capitis muscle and the posterior scalene muscle of the C6 or C7 transverse process.
45806155|NCT05675449|Drug|Elranatamab|BCMA-CD3 bispecific antibody
45806156|NCT05675449|Drug|Carfilzomib|proteasome inhibitor
45940389|NCT00077103|Radiation|radiation therapy|Beginning on day 22, patients undergo radiotherapy twice daily, 5 days a week, for 3-4 weeks.
45940390|NCT00242398|Device|AN69 ST|
45940391|NCT00242437|Device|Hemostatic matrix|
45940392|NCT00242437|Device|bovine thrombin|
45806157|NCT05675449|Drug|Maplirpacept|CD47-SIRP alpha-directed
45806158|NCT05675410|Procedure|Biospecimen Collection|Undergo blood sample collection
45940393|NCT00242476|Drug|MK0822A|
45940394|NCT00242515|Procedure|CD8+ T-cell depleted donor lymphocyte infusion|
45452787|NCT04900454|Biological|DVX201|Single infusion of DVX201, an allogeneic NK cell therapy derived from CD34+ hematopoietic stem cells
45655075|NCT04928365|Drug|Anti-PD-1 monoclonal antibody|Anti-PD-1 therapy
45655076|NCT04938037|Procedure|US guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine|nerve block
45655077|NCT04431271|Procedure|Robot-assisted hernia repair|Inguinal hernia repair was performed using the DaVinci Xi robotic system
45676319|NCT03993171|Drug|gold nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
45676320|NCT03941860|Procedure|Biospecimen Collection|Undergo collection of blood samples
45676321|NCT03941860|Procedure|Bone Marrow Aspirate|Undergo bone marrow aspirate
45806159|NCT05675410|Biological|Bleomycin Sulfate|Given IV
45806160|NCT05675410|Drug|Brentuximab Vedotin|Given IV
45806161|NCT05675410|Procedure|Computed Tomography|Undergo CT and/or PET-CT
45806162|NCT05675410|Drug|Cyclophosphamide|Given IV
45806163|NCT05675410|Drug|Dacarbazine|Given IV
45806164|NCT05675410|Drug|Doxorubicin Hydrochloride|Given IV
45806165|NCT05675410|Drug|Etoposide|Given IV
45806166|NCT05675410|Drug|Etoposide Phosphate|Given IV
45806167|NCT05675410|Other|Fludeoxyglucose F-18|Undergo FDG-PET
45806168|NCT05675410|Radiation|Involved-site Radiation Therapy|Undergo ISRT
45940395|NCT04729920|Device|Mechanical insufflation/exsufflation device (MI-E)|download of device (MI-E) data and self-reported satisfaction with the device
45940396|NCT00066794|Biological|filgrastim|5 mcg/kg/d IV or SC starting apx day 15
45940397|NCT00066794|Biological|sargramostim|250 mcg/kg/d IV or SC starting apx day 15
45940398|NCT00066794|Drug|cyclosporine|ind: 6 mg/kg load IV over 2 hrs days 0-2 followed by 16 mg/dg/d continuous IV days 2-74 consol: 6 mg/kg load IV over 2 hrs days 0-2 followed by 16 mg/dg/d continuous IV days 2-50
45940399|NCT00066794|Drug|cytarabine|ind: 200 mg/m2/d cont IV days 2-74
45940400|NCT00066794|Drug|daunorubicin hydrochloride|ind: 45 mg/m2/d cont IV days 2-74
45940401|NCT00242554|Drug|Zoledronic acid|
45940402|NCT00242593|Drug|Rosiglitazone|4 mg twice daily oral rosiglitazone or placebo pill for 18 months
45940403|NCT00242671|Procedure|Isocapnic Hyperponea|
45940404|NCT00242749|Drug|Gefitinib, Cisplatin and Radiotherapy|
45940405|NCT04728594|Behavioral|Social Proof|Email
45940406|NCT04728594|Behavioral|Reframing|Email
45940407|NCT04728594|Behavioral|Scarcity Message|Email
45940408|NCT00242788|Drug|Gefitinib and capecitabine|
45940409|NCT00242827|Drug|Oral CEP-701|
45806169|NCT05675410|Procedure|Magnetic Resonance Imaging|Undergo MRI and/or PET-MRI
45806170|NCT05675410|Biological|Nivolumab|Given IV
45806171|NCT05675410|Procedure|Positron Emission Tomography|Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
46074552|NCT04281641|Diagnostic Test|TCHP|"Drug: Trastuzumab 8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV Other Name: Herceptin~Drug: Pertuzumab 840 mg as a loading dose, then 420 mg every 3 weeks, IV Other Name: Perjeta~Drug: carboplatin at target area under the plasma concentration-time curve (AUC) 6~Drug: docetaxel at a starting dose of 75 mg/m2 then to 60mg/m2 (q3w).~All study drugs were administered intravenously.~Procedure: 18-FDG-PET and 68 Ga-Affibody HER-2 Imaging PET will be performed at baseline, on day 15 and before surgery~Genomic alterations (mutations/somatic rearrangements) are detected at baseline, on day 15 and before surgery."
45806172|NCT05675410|Drug|Prednisolone|Given PO
45940410|NCT00242866|Drug|GW274150|The tablets used in this study will contain either 5mg or 30mg of GW274150
45940411|NCT00242866|Other|Placebo|Placebo to Match GW274150
45940412|NCT00066872|Drug|imiquimod|
45940413|NCT00066872|Procedure|conventional surgery|
45940414|NCT00242905|Behavioral|Study of memory using MRI|Study of memory using MRI
46074553|NCT00862693|Drug|Calcitriol|0.5ug/Biw
46074554|NCT02799576|Device|Curved needle|In this arm, the curved block needle will be used for regional blockade
46074555|NCT02859311|Drug|Withdrawal of therapy|Withdrawal of heart failure therapies (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists and loop diuretics)
45655078|NCT04919785|Device|Deep brain stimulation|Stereotactic functional neurosurgery was first developed in 1947 and is today an established treatment for movement disorders. The surgical procedure is initiated by mounting a stereotactic frame on the head of the patient and a magnetic resonance image (MRI) is performed. Using a computerized navigational system the target structure is identified on the MRI and a trajectory chosen. In the operating theatre a burrhole is made on each side of the midline for the implantation of two electrodes. The electrodes are about 1.3 mm in diameter with several contacts at their distal end. An extension cable is tunneled under the skin, connecting the electrodes with a neuropacemaker placed below the clavicle in a subcutaneous pocket. The hospitalization time after surgery is dependent on the time needed for programming of the device, but the patients can usually return home within 3-5 days.
45806173|NCT05675410|Drug|Prednisone|Given PO
45806174|NCT05675410|Drug|Procarbazine Hydrochloride|Given PO
45806175|NCT05675410|Other|Questionnaire Administration|Ancillary studies
45806176|NCT05675410|Drug|Vinblastine Sulfate|Given IV
45940415|NCT00077142|Drug|TAC-101|Once daily by mouth on days 1-14, repeat every 21 days for 2 courses.
45940416|NCT00242944|Drug|Pitavastatin|Pitavastatin 4mg per day
45940417|NCT00242944|Drug|Atorvastatin|Atorvastatin 20mg per day
46074556|NCT05297487|Device|early use of intermittent positive pressure breathing|standard care associated with daily and early use of intermittent positive pressure breathing
45676322|NCT03941860|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
45806177|NCT05675410|Drug|Vincristine Sulfate|Given IV
45806178|NCT05674955|Diagnostic Test|Circuit weight versus aerobic training|"Circuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014)~B- Aerobic training:~This mode of exercise will be conducted for study group B as follows:~Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises.~Frequency: Three times / week (Nishi et al., 2011).~C-Traditional medical treatment:~This treatment will be conducted for all group A, B and C."
45806179|NCT05673200|Procedure|Biopsy|Undergo biopsy
45806180|NCT05673200|Procedure|Biospecimen Collection|Undergo collection of blood
45806181|NCT05673200|Procedure|Computed Tomography|Undergo CT
45806182|NCT05673200|Drug|Decitabine and Cedazuridine|Given PO
45806183|NCT05673200|Procedure|Magnetic Resonance Imaging|Undergo MRI
45806184|NCT05673200|Drug|Paclitaxel|Given IV
45806185|NCT05673200|Biological|Pembrolizumab|Given IV
45806186|NCT05672108|Procedure|Computed Tomography|Undergo CT
45806187|NCT05672108|Drug|Ethiodized Oil|Given IA
45940418|NCT00242983|Procedure|quality-of-life assessment|
45940419|NCT00243100|Drug|vorinostat|Given orally
45940420|NCT00243100|Drug|gemcitabine hydrochloride|Given IV
45940421|NCT00099216|Drug|Rivastigmine|
45940422|NCT00243139|Device|Mandibular advancement device (activator)|
45940423|NCT00066989|Drug|Staphylococcus aureus Immune Globulin (Human) 5%|
45940424|NCT00243178|Drug|clopidogrel (SR25990C)|75 mg once daily in combination with aspirin
45940425|NCT00243217|Drug|SPM 936|
45940426|NCT00243256|Drug|Cholecalciferol|
46074557|NCT00859417|Procedure|Traditional surgery|Traditional surgical method without prosthesis (correction of the anterior prolapse through vaginal tract with the use of autologous tissue).
46074558|NCT00859417|Device|Perigee® prosthesis|Surgical method with Perigee® prosthesis
45940427|NCT00099255|Drug|SGN-30|
45940428|NCT00243295|Drug|rhBMP-2/CPM|
45940429|NCT00243334|Other|Integration of advanced clinical decision support with ambulatory computerized physician order entry|Actiobable Reminders related to medication monitoring, preventive care and chronic disease management, and test result follow-up are administered either during the visit or between visits.
45940430|NCT00243373|Device|Barcode technology/eMAR|
45940431|NCT00243451|Other|PET scan & fMRI|Subjects will be screened and if applicable for the study will be scheduled for an MRI. At the third visit they will complete the PET scan. They will return at 6, 12, 24, and 36 months and complete another PET scan at the last visit.
45940432|NCT00099294|Drug|Glufosfamide|
45940433|NCT00243490|Procedure|Photodynamic therapy using Photosan and LumaCare™ Lamp Model LC-122M|
45655079|NCT04928833|Other|Pilates Training|Pilates training was carried out as group exercises for about 1 hour, 3 days a week for 8 weeks. Before starting the exercise training, all subjects were taught the key elements of Pilates in 1 session. Pilates training started with standing exercises for warming up and centering in the supine position. Training continued with upper and lower extremity movements. The intensity of the exercises was increased using different positions and elastic bands. Stretching exercises and posture exercises were used during the cooling period. All exercises were started with 10 repetitions and then increased to 20. In order for the patients to perform the movements correctly, each movement was first demonstrated by the physiotherapist. The movements that the patients could not do were applied by modifying them in a suitable way.
45655080|NCT04928833|Other|Control group|Breathing exercises, active range of motion exercises and relaxation exercises were given to the control group as a home program. They were asked to do the exercises 3 days a week for 8 weeks.
45655081|NCT04919473|Biological|Gene Therapy product:vMCO-I|The vMCO-I is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
45806188|NCT05672108|Drug|Mitomycin|Given IA
45806189|NCT05672108|Procedure|Transarterial Chemoembolization|Undergo TACE
45806190|NCT05672108|Device|Tris-acryl Gelatin Microspheres|Given IA
45806191|NCT05670106|Drug|[177Lu]Lu-PSMA-617|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.
45806192|NCT05670106|Other|Best supportive/best standard of care (BS/BSOC)|Best supportive/best standard of care as defined by the local investigator
45806193|NCT05670106|Drug|68Ga-PSMA-11|single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).
45940434|NCT00243529|Biological|autologous dendritic cell vaccine|
45940435|NCT00243568|Drug|Vicriviroc|
45940436|NCT00067145|Behavioral|Face-to-face maintenance program|
45806194|NCT05669599|Biological|AMG 133|Participants will receive AMG 133 through 48 weeks.
45806195|NCT05669599|Drug|Placebo|Participants will receive placebo through 48 weeks.
45940437|NCT00067145|Behavioral|Internet maintenance program|
45655082|NCT04937569|Drug|Ivermectin Tablets|4-days course of Ivermectin 400 microgram/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast
45806196|NCT05668741|Drug|VX-522 mRNA therapy|Oral inhalation using nebulizer.
45806197|NCT05668429|Drug|Ibrexafungerp|carbon-14 ([14^C])-Ibrexafungerp
45806198|NCT05668351|Radiation|SUPR-SABR treatment|SUPR-SABR prescription dose to the PTV_4000 will be 8 Gy per fraction for five fractions. The prescription dose to PTV_3625 will be a minimum of 7.25 Gy per fraction for five fractions. SABR will be delivered 2-3 times a week, every other day. There will be a minimum of 40 hours between fractions and maximum of 128 hours between fractions.
45806199|NCT05668104|Dietary Supplement|Jing Si Herbal Tea Liquid Packet|The preliminary data demonstrated that the Jing Si Herbal Tea Liquid Packet may improve gastrointestinal symptoms and anxiety in patients with Coronavirus disease 2019(COVID-19). Therefore,this study aims to investigate the impact of the Jing Si Herbal Tea Liquid Packet on psychophysical burden and metabolites of microbiota in patients with FD through a double-blind randomized manner.
45806200|NCT05668104|Dietary Supplement|Jing Si Herbal Tea Liquid Packet Placebo|Compared with the improvement effect of Jing Si Herbal Tea Liquid Packet, to avoid participants thinking that the improvement is due to psychological effects.
45806201|NCT05667246|Other|Caffeinated Coffee|"Subjects would be randomized to a group Caffeinated and subjects will be 95 mg of caffeine in caffeinated coffee."
45806202|NCT05667246|Other|Decaffeinated Coffee|"Subjects would be randomized to a group Decaffeinated and subjects will be no caffeine in decaffeinated coffee."
45806203|NCT05666726|Other|Pain|Thermal pain
45806204|NCT05666726|Other|Stress|Stress state induction
45806205|NCT05666726|Behavioral|Craving|Snack craving induction
45806206|NCT05666726|Behavioral|Frustration|Real effort task
45806207|NCT05666726|Behavioral|Negative valence emotion|Passive video watching with emotional valence
45940438|NCT00243607|Other|hydrotherapy according to Kneipp rules|2-5 applications of hydrotherapy according to Kneipp rules (self application) per day
45806208|NCT05665361|Drug|Sasanlimab|Sasanlimab will be given (SC on day 1 of every cycle, starting on day 1 (+/- 5 days) of cycle 2).
45940439|NCT00243646|Radiation|External beam radiation|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant
45940440|NCT00243646|Drug|Lupron|9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
45940441|NCT00243646|Drug|Casodex|9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
45940442|NCT00099333|Drug|exenatide|Exenatide 5 mcg subcutaneously injected twice daily for 4 weeks; then 10 mcg subcutaneously injected twice daily for 12 weeks.
45655083|NCT04937257|Other|Virtual Reality|The training included the following in the specified order: (1) A tutorial with an introduction to the program and a overview of the correct donning and doffing sequence, based on Center for Disease Control (CDC) guidelines, (2) a training mode to practice the correct sequences with step-wise feedback, and (3) a testing mode that repeated until the sequence was completed perfectly without any mistakes. A study member was present to assist with the device and record the duration of training.
45655084|NCT04937257|Other|E-module|The instructional video included step-by-step instruction and demonstration of adequate donning and doffing procedures. The 14-slide presentation contained the same content as used by the home institution for competency training, based on Center for Disease Control (CDC) guidelines. Participants were instructed to review the material however they liked and their duration of training was recorded.
45940443|NCT00099333|Drug|Insulin|Insulin will be taken according to the subject's current regimen
45655085|NCT04937335|Other|intratumoral hemorrhage|Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.
45940444|NCT00243685|Other|Laboratory Assay|Chemotherapy
45940445|NCT00243685|Other|Mick Assay|Chemotherapy doctor determined from results
45940446|NCT00243724|Drug|Esomeprazole|
45940447|NCT00243763|Drug|TKI258|
45806209|NCT05665361|Drug|Palbocicilib|Palbociclib will be given PO for 21 days of every 28-day cycle, starting on day 1 of cycle 1.
45940448|NCT00067184|Device|Toitu 320/325|Fetal monitor
45940449|NCT00243880|Drug|lovastatin|investigators will treat the patients within 24 hours of symptom onset with short term high-dose lovastatin at escalating dosage. The escalating dosage levels will be 1, 3, 6, 8, and 10 mg/kg per day for 3 days.
45655086|NCT04919005|Other|Virtual Environment|The Virtual Environment was called SorrisoTur and consists of 10 mini-games with difficulty levels in a limited number of cities and mini-games distributed in a thematic scenario of the map of Brazil. The virtual environment consists of the cognitive training mini-games within a theme for all screens, mini-games, and information. The interventions with the Virtual Environment were administered in periods of one hour, twice a week, for a month.
45655087|NCT04927507|Behavioral|Internet plus nursing home rehabilitation|"The observation group was given the Internet plus nursing home rehabilitation mode.~Relying on mobile app and wechat public service platform, patients can get online guidance of rehabilitation training video through app and wechat, and get professional rehabilitation guidance at any time."
45806210|NCT05664490|Behavioral|Youth Friendship Bench SA|The intervention includes: 5 individual counseling sessions; one optional in-person or WhatsApp-based group counseling session; optional remote counseling sessions; and optional one-way SMS messages to provide reminders about upcoming visits. During the initial session, participants will meet with the trained counselor to discuss mental health challenges, identify problems in their life that affect their mental health and PrEP use, generate alternative solutions, make decisions about the alternatives, and collaboratively decide on a plan to implement the solutions. During follow-up counseling sessions, participants will discuss progress in implementing solutions to address the problems they identified in prior sessions with the lay counselor. They will also discuss any other mental health challenges and problems in their life that affect their mental health and PrEP use which they would like to address.
45806211|NCT05663866|Drug|Dexamethasone|Dexamethasone will be administered orally.
45806212|NCT05663866|Drug|Montelukast|Montelukast will be administered orally.
45806213|NCT05663866|Drug|Methotrexate|Methotrexate will be administered subcutaneously.
45806214|NCT05663866|Drug|Amivantamab|Amivantamab will be administered intravenously.
45940450|NCT00243997|Behavioral|Becoming Parents Program|Couple focused educational program for couples adding a new baby to the family-21 hours of workshops during pregnancy with two three hour workshops after the baby is born.
45940451|NCT00244075|Dietary Supplement|nutritional supplement|either oral nutritional formula (Nepro) or intravenous IDPN solution will be administered during hemodialysis; Nepro has a total calorie amount as well as protein, carbohydrate and fat content that are comparable to that of IDPN, and will be provided at four equal amounts with 1-hour intervals throughout the study (150 ml for a total of 600 ml over 4 hours of hemodialysis); IDPN consists of 225 ml of amino acids at a concentration of 15%, 112.5 ml of dextrose at 50% and 112.5 ml of lipids at 20%, will be given at a rate of 150 ml/hr, and will provide 209 kcal/hr
46074559|NCT02859467|Other|Kinesio Taping and Inhibitory Treatment Techniques|"Kinesio Taping on trapezius, infraspinatus, and paravertebral muscles~Inhibitory Treatment Techniques:~Release Technique of the trapezius muscle.~Release Technique for scalene muscles.~Technique suboccipital inhibition.~Technique hands crossed for induction dorsal superficial fascia."
46074560|NCT02859467|Other|Exercise and Electrical Stimulation Therapy|Session for general physical activities (joint mobility, muscle strength and elasticity), and electrical stimulation therapy on para vertebral muscles.
46074561|NCT00854971|Biological|TKCell|Biological/Vaccine: TKCell
45806215|NCT05663866|Drug|Lazertinib|Lazertinib tablets will be administered orally.
45806216|NCT05663320|Other|virtual educational based transition intervention self-paced|study intervention is a standardized, virtual educational video on CAH that will be delivered self-paced
45806217|NCT05661604|Other|No Intervention|This is an observational study to assess the incidence and key disease characteristics of symptomatic acute respiratory viral infections in a high-risk population at risk for poor outcomes. Duration of each participant will be 12 months.
45806218|NCT05655598|Drug|Palbociclib Oral Product|125 mg/day (FDA approved dose) or the last tolerated dose before progression for 21 days of a 28-day cycle
45940452|NCT00244075|Drug|recombinant human growth hormone (rcGH)|subcutaneous administration of 75 micrograms/kg/day of rcGH for 3 consecutive days
45940453|NCT00244075|Behavioral|exercise|either dual leg press (3 sets of 8-12 repetitions) beginning 30 minutes prior to hemodialysis, or modified stepper (minimum of 15 minutes up to a maximum of 90 minutes, depending upon the patient's tolerance) beginning 15 minutes post initiation of hemodialysis
45940454|NCT00244114|Drug|blood draw|Single blood sample collected to perform histamine release assay.
45940455|NCT00244114|Procedure|Blood draw|Single blood sample collected to perform histamine release assay.
45940456|NCT00244153|Drug|intraarticular morphine|
45940457|NCT00244153|Drug|intraarticular dexamethasone|
45655088|NCT04937101|Drug|Chlorpheniramine-Codeine|When the filter tester is sensitive, he opened the random letter group envelope to the notification letter manager and jointly confirmed the classification of the message group. The test group used the chlorpheniramine beacon, the physiological surface was used, and the local lesions of fine particles were used in the focus. Injection therapy. No form of anesthesia is used during injection. A total of injection treatment, at intervals, each treatment and the last treatment, treatment and safety after 1 month.
45655089|NCT04431505|Other|apoptosis|study of apoptotic changes due to anaesthesia
45655090|NCT04937023|Drug|Ursodeoxycholic acid gel|Following scaling and root planing in intrabony defects UDCA gel will be injected
45655091|NCT04937179|Procedure|Ischemic Conditioning Low - Sham Comparator|The use of a Hokanson rapid inflator cuff to restrict blood flow at 25mmHg for 5 minutes followed by a 5 minute reperfusion period, repeated for 5 cycles.
45655092|NCT04937179|Procedure|Ischemic Conditioning High - Active Comparator|The use of a Hokanson rapid inflator cuff to restrict blood flow at 225mmHg for 5 minutes followed by a 5 minute reperfusion period, repeated for 5 cycles.
45655093|NCT04936711|Device|Resteck Shiatsu Neck and Back Massager|back massager device sold on the market that can readily be purchased online or in store
45655094|NCT04936711|Drug|Marcaine|Marcaine spray at incision site after closure
45940458|NCT04729803|Behavioral|Experimental: Attention Guidance + Exposure|"Participants will receive a brief standardized psychoeducation module, presented via a video recording.~Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes.~Between speeches participants will have a 1-minute break.~Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial.~The experimental attention guidance condition: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given target audience members to focus their gaze on during the their impromptu response. They will be told that they should look at and focus on the target audience member for the whole response."
46074562|NCT05757063|Other|Sedation with propofol|After spinal anesthesia, patients will be sedated with propofol.
45806219|NCT05655598|Drug|TAS-116|120 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
45806220|NCT05655598|Drug|TAS-116|80 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
45806221|NCT05655598|Drug|TAS-116|40 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
45806222|NCT05653219|Biological|Ianalumab|Concentrate for solution for infusion for intravenous use
45676323|NCT03941860|Procedure|Computed Tomography|Undergo CT scan
45806223|NCT05653219|Drug|Eltrombopag|Film-coated tablet for oral use
45806224|NCT05653219|Drug|Placebo|Concentrate for solution for infusion for intravenous use.
45806225|NCT05652478|Drug|Tenofovir alafenamide|25mg tenofovir alafenamide (TAF) one tablet orally once a day for 8 days.
45806226|NCT05652478|Drug|Dolutegravir|50mg dolutegravir (DTG) one tablet orally once daily for 8 days.
45676324|NCT03941860|Drug|Ixazomib Citrate|Given PO
45806227|NCT05652465|Device|Intermittent theta burst repetitive transcranial magnetic stimulation (iTBS)|Device described in protocol
45676325|NCT03941860|Drug|Lenalidomide|Given PO
46074563|NCT05757063|Other|sedation with dexmedetomidine|After spinal anesthesia, patients will be sedated with dexmedetomidine.
46074564|NCT02799498|Device|Auto-injector device|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
46074565|NCT02799498|Other|Etanercept (ENBREL®) via Manual injection|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
46074566|NCT02799498|Drug|Etanercept (ENBREL®)|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
45806228|NCT05652335|Drug|JNJ-79635322|JNJ-79635322 will be administered as SC injection.
45806229|NCT05651711|Drug|Rocatinlimab|Rocatinlimab will be administered through a subcutaneous (SC) injection.
45806230|NCT05651711|Other|Placebo|The matching placebo will be administered through a SC injection.
45806231|NCT05650632|Drug|ABBV-383|Intravenous Infusion
45806232|NCT05649358|Device|Lactate sensor (Lactisense)|Non-invasive monitoring of interstitial lactate levels during and after exercise.
45806233|NCT05649137|Drug|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
45806234|NCT05649137|Drug|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
45806235|NCT05649137|Drug|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
45806236|NCT05648591|Drug|Iloperidone|oral tablet
45806237|NCT05647889|Drug|Jet lidocaine|Jet lidocaine will be applied before PVC and PVC will be performed 3 minutes later.
45806238|NCT05647889|Combination Product|Ice|Ice will be applied for 1 minute before PVC, and then PVC will be performed.
45940459|NCT04729803|Behavioral|Active Comparator: Exposure Alone|"Participants will receive a brief standardized psychoeducation module, presented via a video recording.~Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes.~Between speeches participants will have a 1-minute break.~Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial."
45940460|NCT04729803|Behavioral|Experimental: Attention Control + Exposure|"Participants will receive a brief standardized psychoeducation module, presented via a video recording.~F~Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes. During each call participants will be prompted by one of the audience members.~Between speeches participants will have a 1-minute break.~Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial.~The experimental attention control condition: (1) the intervention rationale will include information about the importance of attention control; (2) participants will be given target at the center of the screen to focus their gaze on during the their impromptu response. They will be told that they should look at and focus on the target for the whole response."
45940461|NCT02967029|Drug|Esmolol Hydrochloride|the influence of brevibloc as a hypotensive agent on rSO2
45940462|NCT02967029|Drug|Remifentanil Hydrochloride|the influence of remifentanyl as a hypotensive agent on rSO2
45940463|NCT00244192|Drug|infliximab (Remicade)|
45940464|NCT00244231|Drug|Nidadd|
45940465|NCT00244270|Device|totally implantable vascular access device|totally implantable vascular access device
45940466|NCT00077181|Drug|cytarabine|Given IV
45940467|NCT00077181|Drug|triapine|Given IV
45655095|NCT04936945|Procedure|Temporomandibular joint arthroscopy plus intra-articular injection|patients with TMJ degenerative joint diseases Wilkes stages IV, V not responding to conservative treatment will undergo operative diagnostic arthroscopic treatment then at the end of the procedure intra-articular injection of platelet rich plasma or hyaluronic acid will be done.
45655096|NCT04936789|Device|IMES|Surgical implantation of IMES
45655097|NCT04936555|Other|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
45940468|NCT00077181|Other|laboratory biomarker analysis|Correlative studies
45940469|NCT00244309|Drug|tamsulosin and/or dutasteride|
45655098|NCT04918615|Procedure|PCI|Patients in experimental group will undergo PCI with drug coated balloon catheter to treat the side branch of the coronary bifurcation lesion.
45655099|NCT04927273|Other|Survey|Surveyed neurological and orthopedic surgeons
45655100|NCT03056521|Other|preoperative information about pain|It is information about analgesics, post operative pain, complications of pain, benefits of pain treatment and non pharmacologic treatment options.
45806239|NCT05647889|Other|Standard PVC procedure|Standard PVC procedure will be applied
45806240|NCT05647850|Other|No intervention|No intervention
45806241|NCT05647473|Behavioral|Routine treatment|Participants will be educated on ways to avoid induced hypotensive states, such as avoiding prolonged standing, standing after exercise, being nervous, eating several carbohydrate-rich foods, drinking alcohol, and being in a warm environment (such as a sauna). Participants will be encouraged in a comfortable home environment, such as a sit-down bath. If there are no contraindications, they are advised to increase their salt intake to approximately 10 grams per day and adjust their fluid intake to 2-3 liters per day. They will also be encouraged to perform lower-body strength training and moderate, non-strenuous activities. Seriously ill patients will be proposed to raise the head of their bed during sleep, wear tight clothing, eat small meals, and reduce alcohol intake.
45806242|NCT05647473|Drug|AM|Patients will receive astragalus daily 15g for 24 weeks
45806243|NCT05646862|Drug|Inavolisib|Participants will be administered a 9 milligram (mg) inavolisib tablet orally once a day (PO QD) on Days 1-28 of each 28-day cycle.
45806244|NCT05646862|Drug|Fulvestrant|Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle.
45940470|NCT00244348|Drug|Oxaliplatin (via HAI)|
45940471|NCT00244348|Drug|5 Fluorouracil (systemic)|
45940472|NCT00244387|Drug|SPM 962|
45940473|NCT00077220|Drug|carboplatin|
45940474|NCT00077220|Drug|paclitaxel|
45940475|NCT00077220|Procedure|adjuvant therapy|
45940476|NCT00077220|Radiation|radiation therapy|
45940477|NCT00244426|Drug|indobufen|Indobufen capsules 100 and 200mg
45940478|NCT00244426|Drug|aspirin|Acetylsalicylic acid capsules 300mg
45940479|NCT00398957|Drug|OROS® Hydromorphone HCL; OROS® Dilaudid; Dilaudid SR (slow release); Naltrexone (an opioid antagonist).|
46074567|NCT02799420|Device|GastroFlex UHD, Cellvizio; Mauna Kea Technologies, Paris, France|The patients who enrolled the pCLE group will undergo endoscopic biopsy using pCLE. The cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy was done at the most suspicious parts of the cancerous lesion.
46074568|NCT02799420|Device|white light endoscopy (WLE)|The patients who enrolled this group will undergo endoscopic biopsy under standard white light endoscopy
45655101|NCT04431349|Drug|Ticagrelor 180mg|Patient received loading dose of ticagrelor for coronary angiography within 2 days prior to OPCAB or CABG.
45940480|NCT00099450|Drug|INS50589 Intravenous Infusion|
45940481|NCT00398996|Drug|Early versus intermediate versus late initiation of ART|Initiation of once daily ddI (400 / 250mg), 3TC (300mg) and EFV (600mg)during the intensive phase of TB therapy or during the continuation phase of TB therapy or once TB therapy has been completed
45940482|NCT00244504|Drug|moxonidine|moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery
45940483|NCT00244660|Procedure|Frequent blood pressure measurements|
45940484|NCT00244660|Behavioral|Education|
45940485|NCT00099489|Drug|Interferon Beta-1a|
45940486|NCT00244699|Behavioral|MI Alone or Plus Mindfulness-Based Skills Training|
45940487|NCT00067262|Drug|Divalproex Sodium Extended-Release Tablets|
45940488|NCT00244738|Dietary Supplement|Castor oil|Patients who received castor oil for labor induction
45940489|NCT00244738|Dietary Supplement|Sunflower oil|Patients who received sunflower oil as a placebo
45655102|NCT04431349|Drug|Clopidogrel 75mg|Patient received loading dose of clopidogrel for coronary angiography within 2 days prior to OPCAB or CABG.
45806245|NCT05646862|Drug|Alpelisib|Alpelisib will be administered to participants at the approved dose in combination with fulvestrant: 300 mg taken PO QD and on days 1-28 of each 28-day cycle.
45940490|NCT00244816|Drug|Taxoprexin|
45806246|NCT05646836|Drug|Cevostamab|Cevostamab will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
45940491|NCT00244894|Procedure|acupuncture therapy|Acupuncture treatments will be administered by a qualified practitioner twice a week for the first four weeks and once per week for an additional 6 weeks. Sterile, disposable Seirin needles will be placed bilaterally at the point Gallbladder 34, and along the spine at Bladder 15, Bladder 23, and Bladder 32. Low intensity electrostimulation at 2 Hz will be used for both Bladder 23 and Bladder 32. Points will also be placed unilaterally at Governing vessel 20, Heart 7, Pericardium 6, Liver 2, and Spleen 6
45806247|NCT05646836|Drug|XmAb24306|XmAb24306 will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
45940492|NCT00244894|Procedure|fatigue assessment and management|Patients will utilize the Pittsburgh Sleep Quality Index (PSQI) to assess if the patient is an overall good sleeper or a poor sleeper.
45940493|NCT00244894|Procedure|hot flashes attenuation|Patients will be asked to report hot flash frequency and severity daily using the hot flash diary (HFD) and hot flash severity guidelines (HFSG) throughout the treatment period.
45940494|NCT00244894|Procedure|management of therapy complications|Short Form Health Survey (SF-36) will be used to assess the patient's overall vitality.
45806248|NCT05646836|Drug|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
45940495|NCT00244894|Procedure|quality-of-life assessment|Hot Flash Related Daily Interference Scale (HFRDIS)will be used to self-report hot flash related quality of life.
45940496|NCT00077259|Drug|epothilone D|
45940497|NCT00067301|Drug|Polyunsaturated Fatty Acids (PUFA)|
45940498|NCT00067301|Drug|Citalopram|
45940499|NCT00244972|Other|Laboratory Biomarker Analysis|Correlative studies
45940500|NCT00244972|Drug|Sorafenib Tosylate|Given PO
45452788|NCT04874168|Device|TAP block|bilateral ultrasound-guided TAP block was performed using a 12-4-MHz linear array transducer (ClearVue 350; Philips, Bothell, WA) placed transversely between the iliac crest and costal margin in the anterior axillary line and slid medial-lateral to visualize the external oblique, internal oblique, and trans-versus abdominis muscles; the most lateral (posterior) position obtaining a satisfactory ultrasound image was used
45806249|NCT05646706|Drug|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment was continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
45806250|NCT05646706|Drug|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
45940501|NCT00244972|Drug|Tipifarnib|Given PO
45940502|NCT00245089|Biological|dactinomycin|
45452789|NCT02339090|Drug|Somavaratan|Somavaratan will be administered per dose and schedule specified in the arm description.
45452790|NCT02339090|Drug|rhGH|rhGH will be administered per dose and schedule specified in the arm description.
45655103|NCT03056677|Dietary Supplement|Control|200mls water will be given prior to a mixed carbohydrate meal
45655104|NCT03056677|Dietary Supplement|Normal Whey protein|Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
45655105|NCT03056677|Dietary Supplement|Modified whey protein|Modified whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
45655106|NCT04431583|Procedure|Bariatric surgery- single surgeon service|
45806251|NCT05646706|Drug|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
45806252|NCT05644951|Device|Hot AXIOS system used for EPASS|EUS-guided double-balloon-occluded gastrojejunostomy bypass with Hot AXIOS system
45940503|NCT00245089|Drug|cyclophosphamide|
45940504|NCT00245089|Drug|vincristine sulfate|
45940505|NCT00099528|Drug|REN-1654|
45940506|NCT00067340|Drug|Chlorhexidine mouth rinse|women received daily chlorhexidine oral rinses for two weeks prior to delivery of the infant.
45940507|NCT00067340|Other|Xylitol chewing gum|Women were asked to chew xylitol chewing gum three times per day following the birth of their infant for up to two years postpartum
45940508|NCT00245167|Procedure|Tracheal Aspirate Fluid|
45940509|NCT00245206|Drug|Aripiprazole|Participant will take aripiprazole. Dosing will be determined by each participant's psychiatrist.
45940510|NCT00245206|Drug|Olanzapine|Participant will take olanzapine. Dosing will be determined by each participant's psychiatrist.
45940511|NCT00245206|Drug|Risperidone|Participant will take risperidone. Dosing will be determined by each participant's psychiatrist.
45655107|NCT04431583|Procedure|Bariatric surgery- multiple surgeon + multidisciplinary team approach|
45940512|NCT00245245|Drug|recombinant porcine coagulation factor VIII (OBI-1)|
45940513|NCT00245323|Behavioral|Smoking status as a routine vital sign|
45940514|NCT00067379|Procedure|interceptive orthodontic treatments|orthodontic procedures
45940515|NCT00077298|Biological|cetuximab|Given IV
45940516|NCT00077298|Biological|bevacizumab|Given IV
45940517|NCT00077298|Drug|irinotecan hydrochloride|Given IV
45940518|NCT00077298|Other|laboratory biomarker analysis|Correlative studies
45940519|NCT00245362|Biological|CG 8020 and CG 2505|
45940520|NCT00245401|Device|CYPHERTM Sirolimus-Eluting Coronary Stent|
45940521|NCT00245440|Drug|Azithromycin|250 mg tablets; 2 tablets once daily (500 mg) for 3 days
45940522|NCT00245440|Drug|Telithromycin|400 mg tablets; 2 tablets once daily (800 mg) for 5 days
45940523|NCT00245479|Drug|Primary nocturnal enuresis|Desmopressin
45655108|NCT04431583|Procedure|Bariatric surgery: formalized streamlined multiple surgeon + multidisciplinary team approach|
45655109|NCT04431115|Other|Interviews|Interviews for stakeholders
45655110|NCT03055741|Drug|Donepezil|5mg or 10mg, once a day, 24 weeks
45806253|NCT05643144|Device|Continuous Glucose Monitoring|CGM education and glucose data collection for 14 days with a device. Interviews with dyads to assess experience and awareness of hypoglycemic events.
45655111|NCT03055741|Drug|DHP1401|Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks
45655112|NCT03055741|Drug|Placebo|Placebo was administrated in two divided dosed a day for 24 weeks
45655113|NCT04926883|Other|bulk-fill composite resin restorations|bulk-fill composite resin restorations up to 5mm layer thickness
45655114|NCT04414657|Other|blood sampling for biobank|blood sampling for biobank
45655115|NCT04926805|Device|CPAP with Mask A|CPAP mask
45655116|NCT04926805|Device|CPAP with Mask B|CPAP mask
45655117|NCT04936087|Other|The World Health Organization 8 steps for manual wheelchair service delivery|"All study participants were provided with a new wheelchair, a wheelchair cushion, and wheelchair services, delivered by trained wheelchair service providers, according to the WHO 8-step wheelchair service delivery process including assessment, fitting, and a 30-minute individual or group training on 7 wheelchair skills, device care, and pressure injury prevention techniques. Additionally, wheelchair maintenance reminders were sent through a text message service (SMS) to a sub-cohort of participants.~Wheelchair users were provided with one of three different, International Standards Organization (ISO) tested, wheelchair models according to the users' needs and availability: standard, active, and all-terrain models. All wheelchairs were provided with a basic contour cushion made of polyurethane foam. However, whenever a risk of pressure injury was identified for a study participant, wheelchair providers fabricated a pressure-relief cushion."
45655118|NCT04936165|Procedure|Low-Level Laser Therapy|Use 810-nm-photosource to irradiate the participants' brain and forearm for 10 minutes with a water-cooling radiator to keep it at 25 ± 0.5 ℃.
45655119|NCT04926727|Other|Survey|Observational study
45655120|NCT03055819|Device|Brow Lift|Minimally Invasive Brow Lift
45655121|NCT04927039|Drug|5ml of inhaled normal saline|After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
45655122|NCT04927039|Drug|20μg (2ml) of inhaled iloprost (Ventavis®) and 3ml of inhaled normal saline|After the initiation of OLV, mixture of iloprost 2ml and normal saline 3ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
45655123|NCT04926493|Biological|microbiological characterization|microbiological characterization of endotracheal tube biofilm
45655124|NCT04918303|Device|SKNA recording|"The coupled recording of the sympathetic nervous activity of the skin and of an ECG will be carried out using the ME6000 device, CE marked, from the Bittium company.~It will be performed for a maximum period of one hour at Day 1, Post-procedure between Day 1 and discharge from hospital, and month 6"
45655125|NCT04917679|Drug|Eltrombopag plus diacerein|In the combination group, eltrombopag will be administered orally at an initial dose of 75mg daily for 14 days, and diacerein will be given orally at an initial dose of 50mg bid concomitantly for 14 days (D1-D14). During treatment period, treating physicians will modify the dosage of trial treatment to maintain participants' platelet count at the range of 50 - 150 × 10^9/L as follows: (1) if platelet count is less than 150 × 10^9/L, continue the original treatment (eltrombopag 75mg daily plus diacerein 50mg bid); (2) if platelet count is between 150 × 10^9/L to 250 × 10^9/L, the treatment will be modified to eltrombopag 50mg daily plus diacerein 50mg bid; (3) if platelet count is over 250 × 10^9/L, original treatment (both eltrombopag and diacerein) need to be stopped, and platelet count should be reexamined every other day, and the treatment (eltrombopag 50mg daily plus diacerein 50mg bid ) will be restarted until platelet count is below 100 × 10^9/L.
45655126|NCT04917679|Drug|Eltrombopag|In the monotherapy group, eltrombopag also will be administered orally at an initial dose of 75mg daily for 14 days (D1-D14), and the individualized dosage could be modified by treating physicians to maintain participants' platelet count between 50 × 10^9/L to 150 × 10^9/L.
45655127|NCT03055585|Biological|Wolbachia-infected Aedes aegypti mosquitoes|Deployment of Wolbachia-infected Aedes aegypti mosquitoes
45655128|NCT03055585|Other|standard practice dengue control|standard practice dengue control activities conducted by dengue control program
45676326|NCT03941860|Other|Placebo Administration|Given PO
45676327|NCT03941860|Procedure|Positron Emission Tomography|Undergo PET scan
45806254|NCT05642195|Biological|Montanide (Registered Trademark) ISA-51 VG Adjuvant|H1299 cell lysate with Montanide (Registered Trademark) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
45676328|NCT03941860|Other|Quality-of-Life Assessment|Ancillary studies
45806255|NCT05642195|Biological|H1299 Cell Lysates|H1299 cell lysate with Montanide (Registered) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered Trademark) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
45940524|NCT00400608|Drug|ADVAIR HFA|
45940525|NCT00400608|Drug|ADVAIR DISKUS|
45940526|NCT00245596|Drug|sildenafil|
45940527|NCT00245674|Drug|amisulpride|
45940528|NCT00245713|Drug|levetiracetam|
45940529|NCT00067457|Drug|alosetron|
45940530|NCT00102843|Procedure|supplementation with folic acid and betaine|
45940531|NCT00245752|Device|acupuncture|acupuncture in points bilaterally: BL 67, LI 4, SP6, one in GV20.
45940532|NCT00245791|Drug|Levofloxacin|
45940533|NCT00245830|Procedure|Ischemic Preconditioning|Experimental: Hepatic Ischemic Preconditioning blood flow to the liver will be cut off by hilar clamping for ten minutes followed by release of the clamp prior to removal of the liver from the donor.
45940534|NCT00245869|Procedure|Contrast-enhanced Ultrasound|
45940535|NCT00400647|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
45940536|NCT00400647|Drug|Mycophenolate mofetil|
45940537|NCT00245908|Drug|azithromycin|
45940538|NCT00245947|Drug|ERB-041|
45655129|NCT04926649|Procedure|Differential ventilation to the non-dependent lung|When the hypoxemia occurs during sing lung ventilation in robot-assisted cardiac surgery, the non-dependent lung will be ventilated with normal tidal volume in conventional ways and the surgery procedure have to be ceased. In this trial, the non-dependent lung will be ventilated with the continuous positive airway pressure (CPAP) or the high-frequency low-volume ventilation (HFLVV) to prevent the hypoxemia.
45655130|NCT03055351|Behavioral|Stop&Go Intervention|Stop&Go intervention will be based on Self-determination theory. Patients will participate in four practically-oriented training sessions, focused on (1) nutrition and oral hygiene, (2) sleep habits and self-care, (3) physical activity and exercise, and (4) smoking cessation. In addition, the entire inpatient detoxification centre will be adapted to encourage autonomous physical activity and to reinforce the ideas presented in the training sessions.
45940539|NCT00245986|Procedure|Blood draw|
45655131|NCT02443155|Drug|NNC0114-0006|NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 weeks. Subjects will continue their pre-trial insulin treatment
45806256|NCT05642195|Drug|N-803|N-803 via subcutaneous injection in the abdomen at dose of 15 ug/kg every 4 weeks, on Day 1 of each cycle. N-803 dosing will be calculated using a weight obtained within 5 days prior to the first dose. Dose re-calculated at the beginning of each subsequent cycle in the event of a 10% or greater weight change.
45940540|NCT00067496|Drug|Modafinil|
45940541|NCT02961556|Drug|AJG555|Participants will receive 1 to 6 sachets daily per participants' age and conditions.
45940542|NCT00400725|Drug|Clobex Shampoo 0.05%|twice weekly
45940543|NCT00400725|Drug|clobex shampoo placebo|twice weekly
45940544|NCT00246064|Drug|infliximab|
45940545|NCT00246103|Drug|Valproic acid|Beginning Dose, Level 1: 15 mg/kg/day.
45940546|NCT00246103|Drug|Epirubicin|Beginning Dose, Level 1: 75 mg/m^2.
45655132|NCT02443155|Drug|liraglutide|Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment
45655133|NCT02443155|Drug|placebo|Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment
45806257|NCT05642195|Device|Ventana PD-L1 (SP263 or SP142) assay|FDA-approved assays used off-label for study as treatment determining in-vitro diagnostic devices to assess subject PD-L1 quantitation. Testing will be performed on provided archival samples or on fresh sample that is collected at screening for confirmation of diagnosis; no additional sample collection for purposes of PD-L1 testing.
45940547|NCT00246103|Drug|5-fluorouracil|For breast cancer participants treated at MTD of Valproic acid and Epirubicin: 5-fluorouracil 500 mg/m^2.
45940548|NCT00246103|Drug|Cyclophosphamide.|For breast cancer participants treated at MTD of Valproic acid and Epirubicin: cyclophosphamide 500 mg/m^2.
45940549|NCT00246142|Biological|Botulinum toxin type A|
45940550|NCT00067535|Drug|Cocaine-Related Disorders|
45940551|NCT00102882|Drug|fluticasone propionate/salmeterol|
45940552|NCT00102882|Drug|salmeterol xinafoate|
45940553|NCT00246181|Procedure|radiation therapy|Patients will receive 3 fractions
45940554|NCT00246220|Drug|methylphenidate hydrochloride|
45940555|NCT00424801|Drug|Lercanidipine|Individual titration, max. dose 20 mg OD for 8 months
45940556|NCT00424801|Drug|Valsartan|Individual titration, max. dose 160 mg OD for 8 months
45940557|NCT00424801|Drug|Nicorandil|Individual titration, max. dose 20 mg BD for 8 months
45940558|NCT00424801|Drug|Doxazosin|Individual titration, max. dose 4 mg OD for 8 months
45940559|NCT00424801|Drug|Moxonidin|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 0,2 mg OD for 8 months
45940560|NCT00424801|Drug|Pindolol|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 10 mg OD for 8 months
45940561|NCT00424801|Drug|Amiloride, hydrochlorothiazide|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 1 tbl. OD for 8 months
45940562|NCT02966951|Biological|Adipose tissue derived mesenchymal stem cell|Intra-articular adipose tissue derived mesenchymal stem cell injection.
45940563|NCT00246298|Drug|epoetin alfa|
45940564|NCT00246415|Drug|Memantine|
45940565|NCT00246532|Drug|Morphine|Patients will be given morphine sulfate oral medication until their back pain is adequately controlled.
45940566|NCT00246532|Drug|Placebo|Patients will receive placebo tablets.
45940567|NCT00067574|Behavioral|Structured treatment interruption|
45940568|NCT00246610|Drug|Nelfinavir mesylate, 625 mg|Nelfinavir 625 mg [dosed orally as 1250 mg BID (two 625 mg tablets given orally BID)] plus Combivir (lamivudine 150 mg plus zidovudine 300 mg BID dosed orally) administered with food. Subjects will start treatment at their baseline visit. Subjects will be treated for up to 26 weeks during pregnancy plus 6 weeks postpartum.
45940569|NCT00102921|Drug|CCX282-B|
45940570|NCT00246688|Drug|Sagopilone (BAY86-5302 , ZK219477)|10.5 mg lyophilized sagopilone per vial
46074569|NCT00617851|Biological|Lot A of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot A) administered intramuscularly
45806258|NCT05637801|Device|Sensory Stimulation System (GS120) - Active|Sensory Stimulation System (GS120) - Active settings
45806259|NCT05637801|Device|Sensory Stimulation System (GS120) - Sham|Sensory Stimulation System (GS120) - Sham settings
45806260|NCT05637112|Other|None (Observational study)|Not Applicable since Observational Study
45806261|NCT05635916|Drug|Liposomal bupivacaine|Adductor canal block with injection of 10cc 13.3% liposomal bupivacaine combined with 10cc 0.50% bupivacaine within one hour following surgery
45940571|NCT00246727|Drug|Selected Vegetable and Herb Mix|The phytomix consists of 19 vegetable and herbs in a highly concentrated form. These vegetables and herbs were selected based on their anti-cancer and immune-enhancing activities. Each batch of raw materials has gone through a very strict quality control (QC) scheme to make sure the product meets our QC standards and devoid of deleterious contaminations, such as heavy metals, pesticides, aflatoxin, and microorganisms. The manufacturing process is tightly controlled to ensure batch-to-batch consistency. The final product, a 20 gram freeze-dried powder, is sealed in a pouch. In our previous studies, patients who ingested phytomix daily for 17-60 months showed no clinical sign of adverse effect.
45655134|NCT03055117|Behavioral|Group-based exercise rehabilitation|Group- based physiotherapy-led exercise rehabilitation
45940572|NCT00244543|Drug|R89674 (generic name not yet established)|
45940573|NCT04728516|Drug|Vonoprazan-based dual eradication therapy for two weeks|Patients with ACS after PCI, associated with positive Hp need a long-term DAPT treatment. We conducted a study on the prevention of gastrointestinal bleeding between vonoprazan-based dual eradication therapy for two weeks and pantoprazole for six months of a rountine therapy.
45940574|NCT04728516|Drug|amoxicillin|amoxicillin
45940575|NCT04728516|Drug|Pantoprazole|Pantoprazole
45940576|NCT00246883|Procedure|Exercise|
45940577|NCT00067613|Other|Benchmarking Management Practices|"The Benchmarking intervention included:~Data feedback: Using existing data from the NRN Generic Database and Key Care Practices Survey at their NICU to collect data on the perceptions of care.~Training in Continuous Quality Improvement (CQI) Techniques~Review of best existing evidence~Site visits to the Centers with the Lowest Rates of BPD~Selection of Practices to change: Each site team selected practices for modification at their own center"
45655135|NCT03055117|Behavioral|Individual exercise rehabilitation|Individual physiotherapy-led exercise rehabilitation
45655136|NCT03055117|Behavioral|Home exercise|Supervised home exercise
45940578|NCT00067613|Other|Standard Management Practices|Centers assigned to the control group continued to receive routine information on their own center's outcomes, and all information routinely supplied within the NRN. Control centers did not participate in organized discussions of the interventions applied within the Benchmarking centers. At the completion of the study, Control Centers were offered a workshop on the Benchmarking techniques.
45940579|NCT00246922|Drug|Roflumilast|
45940580|NCT00400998|Drug|Fluticasone Propionate|"Subjects will receive the following treatment regimen over one of two dosing periods within each of the three study phases:~- Intranasal FPANS (Fluticasone Propionate aqueous nasal spray) 200 mcg once daily for 8 to 14 days i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL (microlitres) i.e. 50 mcg fluticasone propionate."
45655137|NCT04935541|Drug|Dexmedetomidine infusion|After Dexmedetomidine infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
45940581|NCT00400998|Other|Matched FPANS placebo|"Subjects will receive the following placebo treatment regimen over one of two dosing periods within each of the three study phases:~Intranasal FPANS placebo once daily for 8 to 14 days (i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL."
45655138|NCT04935541|Drug|Remifentanil infusion|After Remifentanil infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
45655139|NCT04925791|Diagnostic Test|standardized pre-conditioning treatment|3 rounds of 5 minutes of full occlusion alternating with 5 minutes of reperfusion while seated.
45655140|NCT04925791|Diagnostic Test|Partial occlusion|3 rounds of 5 minutes of partial occlusion alternating with 5 minutes of reperfusion while seated.
45655141|NCT04935151|Procedure|holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser
45940582|NCT00247039|Dietary Supplement|Solgar Israel|Dietary Supplement: garlic natural compound one pill, 450 mg active garlic extract (Solgar, Israel), bid.
45940583|NCT00247039|Other|Placebo capsules|placebo capsules
45676329|NCT03941860|Other|Questionnaire Administration|Ancillary studies
45806262|NCT05635916|Drug|Bupivacaine|Adductor canal block with injection of 20cc 0.5% bupivacaine within one hour following surgery
45806263|NCT05635409|Biological|STEM-PD|STEM-PD is a cryopreserved cell product, consisting of ventral midbrain dopaminergic progenitor cells derived from the clinical-grade hESC line RC17. STEM-PD will be administered using a non-CE marked class III neurosurgical medical device, the Rehncrona-Legradi device, bilaterally in one surgical session to the putamen.
45940584|NCT00247078|Biological|widow spider antivenom|3 vials of antivenom capable of neutralizing 600 LD50 of L. mactans
45806264|NCT05634408|Device|ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management (A1D)|TEST Lens
45806265|NCT05633654|Drug|Sacituzumab govitecan-hziy (SG)|Administered intravenously
45806266|NCT05633654|Drug|Pembrolizumab|Administered intravenously
45806267|NCT05633654|Drug|Capecitabine|Tablets administered orally
45806268|NCT05633355|Drug|Rocatinlimab|Subcutaneous (SC) injection
45806269|NCT05630781|Drug|Placebo|comparator taken for ~10 days
45940585|NCT00247078|Biological|Placebo|
45940586|NCT00067652|Behavioral|Education and awareness about body image issues.|
45940587|NCT00247117|Drug|Metformin|
45655142|NCT04935151|Procedure|Bipolar resection of the prostate|cystoscopic transurethral resection of the prostate using bipolar energy
45655143|NCT04935073|Drug|Prescription of traditional Chinese Medicine named Er Zhi Wan combined with Si Wu Tang|The medicines used in this study including Radix et Rhizoma Ligustrum 15 g, Radix Morindae Sinensis 12 g, Fructus Lycii 15 g, Semen Cuscutae 20 g, Radix Rehmanniae 15 g, Radix Angelicae Sinensis 10 g, Radix Paeoniae Alba 10 g, Ligusticum wallichii 6 g, Poria cocos 15g, Polygonatum 15g, eclipta 10g. which will be taken for 10-15days.After the ET, the treatment group will continue to take Chinese herbal medicine, changing to Shou Tai pills ( Morinda officinalis 15 g, Teasel 15g，Cuscutae 20 g, Eucommia ulmoides 15 g, Rehmannia 15 g, Cornus officinalis 15 g, loranthus parasiticus 20 g, Ligustrum lucidum 15g, Salvia miltiorrhiza 10g, Scutellaria baicalensis 10g, Atractylodes macrocephala 15g); which will be taken for 14days. The hospital will be responsible for the decoction of 200 mL per dose, 1 dose per day, divided into 2 doses in the morning and in the evening.
45655144|NCT04935073|Drug|Recombinant Human Follitropin Alfa for Injection、Fructose Injection、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder for Injection|The intervention starts from the 5th day of the menstrual cycle and lasts to the day before IVF-ET.
45655145|NCT04934761|Procedure|Fluid challenge strategy|Patients received 2ml/kg of succinylateol gelatin within 10 min for fluid shock therapy after grouping, taking SVV as the management target. If SVV< 13% after shock therapy, the shock therapy was stopped and the infusion was maintained with 4ml/kg/h of crystal solution. If SVV ≥ 13% and ΔSV <10%, the individual would be excluded from the experiment. If SVV ≥ 13% but ΔSV≥10%, 2ml/kg of succinylateol gelatin was given again within 10 min for liquid shock therapy until SVV<13%, and 4ml/kg/h of crystal solution was maintained after reaching the target. If SVV≥ 13% after two shock treatments, they were excluded from the experiment. We excluded patients whose intraoperative bleeding ≥400ml and operative time ≥5 hours from the group.
45655146|NCT04934761|Procedure|conventional strategy|4ml/kg/h of crystal solution was maintained. We excluded patients whose intraoperative bleeding ≥400ml and operative time ≥5 hours from the group.
45806270|NCT05630781|Drug|Belsomra|randomized, double-blind, placebo-controlled crossover design study: Participants will undergo a baseline scan followed by 2 acute drug administration scans where suvorexant or placebo is administered in a randomized manner where both the participant and study staff administering drug are blind. Following the second acute scan, participants will continue with the drug they received at Scan 2 for approximately 10 days. After the first chronic scan, participants will switch to the other drug for an additional 10 days and then scanned a final time.
45806271|NCT05629390|Drug|Lotilaner|Lotilaner Ophthalmic Solution
45655147|NCT04934605|Procedure|Cochlear implantation|Cochlear implantation
45806272|NCT05629390|Drug|Vehicle Control|Vehicle of TP-03 ophthalmic solution
45655148|NCT04934059|Drug|Yuxuebi tablet|0.5g/ tablet
45655149|NCT04934059|Drug|Placebo tablet|0.5g/ tablet
45655150|NCT04917835|Device|PLADUO(PX1000)|Three sessions of argon- and nitrogen- NTAPP treatment at 1-week interval. Two passes of argon-NTAPP treatment and two passes of nitrogen-NTAPP treatment were sequentially performed in each session. Argon plasma at a pulse energy of 0.8 J/pulse with a 12 msec of pulse duration and nitrogen-plasma at a pulse energy of 0.75 J/pulse delivered with a 7 ms of pulse duration.
45655151|NCT04917991|Dietary Supplement|Extra Virgin Olive Oil-enriched chocolate spread|the intervention consists in the administration of 100g Extra Virgin Olive Oil-enriched chocolate spread each day for 14 days.
45655152|NCT04917991|Dietary Supplement|Palm Oil-enriched chocolate spread|the intervention consists in the administration of 100g Palm Oil-enriched chocolate spread each day for 14 days.
45806273|NCT05629208|Drug|Edecesertib|Tablets administered orally
45806274|NCT05629208|Drug|Edecesertib Placebo|Tablets administered orally
45806275|NCT05628103|Drug|SEP-363856|SEP-363856 flexibly dosed
45806276|NCT05624957|Drug|Lidocaine epinephrine|Under aseptic condition every one litre of fluid irrigation will be mixture with 10 ml of lidocaine 2% and 0.25mg epinephrine and the last one use before end of surgery dexamethasone 8 mg will be added.
46074570|NCT00617851|Biological|Lot B of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot B) administered intramuscularly
45655153|NCT04917757|Diagnostic Test|1mg Dexamethasone test|For each patient a 1mg dexamethasone test has been performed.
45655154|NCT04917289|Drug|Chemotherapy|Started chemotherapy or change the current adjuvant therapy
45655155|NCT04917913|Dietary Supplement|Digestive enzyme blend|Subjects will take 3 capsules (one per meal) of digestive enzymes (50mg) daily for 30 days.
45655156|NCT04917913|Dietary Supplement|Placebo|Subjects will take 3 capsules (one per meal) of a placebo (50mg) daily for 30 days.
45655157|NCT04925869|Other|Observational study|Observational study
45655158|NCT04925635|Behavioral|experimental group|"The arteriovenous fistula care mobile health application will be installed and promoted on the smart phones of the patients in the experimental group. Arteriovenous fistula care mobile health application will be installed in daytime groups during working hours during or at the end of dialysis according to the patient's request. In addition, the information contained in the arteriovenous care mobile health application will be verbally explained to the patients and their relatives, as well as shown in practice. The training results were evaluated by the researcher in the 1st and 3rd months in the Scale for Evaluation of Self-Care Behaviors Related to Arteriovenous Fistula in Hemodialysis Patients, Final Level of Renal Failure Compliance Scale, Arteriovenous Fistula Care Education Knowledge Level Evaluation Form (Post-Training Section) and  Visual Benchmarking Scale ."
45806277|NCT05624957|Drug|Epinephrin|0.25 mg epinephrine mixed with one litre of fluid irrigation
45806278|NCT05624554|Drug|Nemtabrutinib|65 mg administered orally daily until disease progression, unacceptable toxicity, or discontinuation criteria met
45806279|NCT05624554|Drug|Fludarabine|25 mg/m^2 administered via intravenous (IV) infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles
45806280|NCT05624554|Drug|Cyclophosphamide|250 mg/m^2 administered via IV infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles
46074571|NCT00617851|Biological|Lot C of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot C) administered intramuscularly
46074572|NCT00617851|Biological|Comparator influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine administered intramuscularly
45940588|NCT00247156|Procedure|Acupressure treatments and NAET treatments|
45940589|NCT00247195|Behavioral|Culturally Congruent Assessment and Treatment|Referral, engagement, and treatment is done following the cultural formulation model in DSM-IV in which patients' views and expectations about depression treatment are included in the assessment and treatment process.
45940590|NCT00247234|Behavioral|Schema Therapy|group based schema therapy
45940591|NCT00247234|Behavioral|standard care|standard psychiatric out-patient care
45940592|NCT00247312|Radiation|Pd-103|
45940593|NCT00401076|Drug|SA-001|0.25 g of SA-001 pellets/capsule, 12 capsules/day for 52 weeks
45940594|NCT00247351|Procedure|Cryoablation|
45940595|NCT00247390|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 42 weeks.
45940596|NCT00247390|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 42 weeks.
45655159|NCT04925635|Behavioral|control group|"Patients in the control group will receive arteriovenous fistula care training and a training booklet will be given. The information contained in the booklet will be explained orally to the patients and their relatives by the researcher, and will also be shown in practice. The results of the training were determined by the researcher at the 1st and 3rd months of the Self-Care Behaviors Scale for Arteriovenous Fistula in Hemodialysis Patients, End Stage Renal Failure Compliance Scale, Arteriovenous Fistula Care Training Information Level Assessment Form (Post-training section) and Visual It will be evaluated with the Comparison Scale."
45940597|NCT00067691|Procedure|Acupuncture|
45655160|NCT03055273|Behavioral|SOCIABLE|SOCIABLE services involve a nurse, and occupational therapist and a handyman to support function among older adults with end stage renal disease. There is particular emphasis on supporting the social function and the physical and everyday living function.
45806281|NCT05624554|Drug|Bendamustine|Administered via IV infusion on Days 1 and 2 of each 28-day cycle up to 6 cycles. The first dose is given as 70 to 90 mg/m^2. Subsequent doses may be escalated up to 90 mg/m^2, if applicable and as per local guidelines
45940598|NCT00247468|Procedure|Strict Glucose Control|
46074573|NCT00617851|Biological|All 3 consecutive lots of influenza virus vaccine pooled|1 injection of the pooled trivalent subunit influenza virus vaccine administered intramuscularly
45655161|NCT04916899|Drug|Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol|Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Adminstration way: Oral
45655162|NCT04933981|Diagnostic Test|Nasopharyngeal swab for SARS-CoV-2|in the interventional group, regular, i.e. twice to three times weekly, SARS-CoV-2 testing was offered to health-care workers and visitors of nursing homes
45655163|NCT04925245|Other|Clinical Reminder|Clinical reminder in the electronic medical record
45806282|NCT05624554|Biological|Rituximab|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m^2 (cycle 1) followed by 500 mg/m^2 for remaining cycles
45940599|NCT00099606|Drug|Dasatinib|Tablets, Oral, Dose Finding Study - Range was 35 mg BID, 5 days on/2 days off - 120 mg BID Continuous Daily Dosing, Once daily, Patients remained on study until treatment discontinuation due to unacceptable toxicity, disease progression or death.
45940600|NCT00247507|Drug|acetylcysteine|
45940601|NCT00247546|Behavioral|Multifactorial prevention|
46074574|NCT02806440|Drug|Low dose naltrexone|Active comparator
45655164|NCT04933357|Radiation|Dose escalation|Dose escalation to poor responders to achieve dose equivalent more than 80 Gy using SBRT boost
45655165|NCT04933357|Radiation|Standard dose|Standard dose to good responders to achieve dose equivalent of 70 Gy.
45806283|NCT05624554|Biological|Truxima|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m^2 (cycle 1) followed by 500 mg/m^2 for remaining cycles
45806284|NCT05624554|Biological|Ruxience|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m^2 (cycle 1) followed by 500 mg/m^2 for remaining cycles
45940602|NCT00247585|Drug|Ethanol (Bourbon or Vodka)|
45940603|NCT00099645|Drug|Mifepristone|
45940604|NCT00247663|Drug|Letrozole|
46074575|NCT02806440|Drug|Placebo|Placebo comparator
46074576|NCT02544295|Behavioral|Clinical interview|
46074577|NCT02544295|Behavioral|Virtual reality task|
46074578|NCT00913809|Drug|Desipramine HCL 100 mg Tablets Cord Laboratories|
46074579|NCT00913809|Drug|Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc|
46074580|NCT02806362|Drug|Ombitasvir/paritaprevir/ritonavir|Tablet
46074581|NCT00855049|Drug|Acetaminophen|Intranasal acetaminophen administration
46074582|NCT00855049|Drug|Acetaminophen|Oral acetaminophen administration
45806285|NCT05624554|Biological|Riabni|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m^2 (cycle 1) followed by 500 mg/m^2 for remaining cycles
45940605|NCT00247702|Drug|warfarin|
45940606|NCT01349660|Drug|Bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks
45940607|NCT01349660|Drug|BKM120|BKM120 orally (PO) once daily
45940608|NCT00247741|Drug|spinal administration of articaine|
45940609|NCT00247741|Drug|spinal administration of lidocaine|
45940610|NCT00247780|Procedure|Pulmonary vein isolation and cavotricuspid ishtmusblock|
45940611|NCT00247819|Procedure|Blood draw|
45940612|NCT00247897|Drug|Skin antisepsis|See Detailed Description
45940613|NCT00099684|Drug|Ezetimibe|
45940614|NCT00247936|Procedure|Laparoscopic Esophagectomy|Laparoscopic Esophagectomy
45940615|NCT00067730|Drug|Drotrecogin Alfa (activated)|
45940616|NCT00248014|Device|Mandibular Advancement Via A Functional Appliance|Functional appliance
45940617|NCT00248053|Drug|curcumin|curcumin 500 mg by mouth, three times a day for 9 months
45940618|NCT00248092|Drug|NRP104|
45940619|NCT00067769|Behavioral|Internet-based intervention UCanPoopToo|Internet-based intervention to administer Enhanced Toilet Training (ETT).
45940620|NCT00067769|Behavioral|treatment as usual|Routine clinical care.
45940621|NCT00103155|Procedure|conventional surgery|
45940622|NCT00103155|Procedure|radiofrequency ablation|
45940623|NCT00248131|Drug|Octreotide acetate in microspheres|
46074583|NCT02799030|Drug|BF-200 ALA 1%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
45940624|NCT00248209|Drug|Wellbutrin XL|Patients randomized to the bupropion treatment group will receive bupropion XL150 mg in the AM for 7 days increasing to 300mg/day (single daily dose). The investigator can increase the dose to 450mg per day at Day 28 if clinically indicated.
45940625|NCT00248248|Drug|liposomal doxorubicin|Doxil at 50mg/m2 infused over one hour every 3 or 4 weeks for 3-6 cycles
45940626|NCT00067847|Behavioral|State-directed nutrition policy change|
46074584|NCT02799030|Drug|BF-200 ALA 3%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
46074585|NCT02799030|Drug|BF-200 ALA 10%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
45655166|NCT04916821|Dietary Supplement|propolis|Propolis may be blocked virus entry to cells, and some receptor binding and some cell signal molecules
45806286|NCT05621941|Behavioral|Game-Supported Goal Management Training|The investigational treatment is based on a compensatory strategy training named Goal Management Training (GMT). The investigational treatment will include GMT in combination with a compensatory strategy game which allows the patient to learn and apply the algorithm of GMT in a safe and controlled environment. This means that the multiple steps of the GMT will be learned during the treatment sessions under guidance of a therapist as well as in their own home environment by using the compensatory strategy game.
46074586|NCT02799108|Device|NIRS|High-resolution EEG-fNIRS recording lasting a maximum of 30 minutes by using expressive and receptive language paradigms
46074587|NCT02799108|Device|fMRI|fMRI acquisition under the same stimulation conditions
45655167|NCT04916665|Drug|Teduglutide|bridging intestinal failure with teduglutide until reconstruction
45806287|NCT05621941|Behavioral|Information Group|In the information group, patients are informed about non-specific consequences of acquired brain injury, aimed to increase patient's insight into their condition and with that improving functioning. The program consists of the following subjects: 1) cause of brain injury, 2) information processing and attention, 3) memory, 4) planning and performance, 5) fatigue, 6) changes in emotion and behavior and 7) processing and adjustments.
45940627|NCT00248365|Biological|Theralux extracorporeal photochemotherapy|
45940628|NCT00099723|Drug|VSL#3|
45940629|NCT00248443|Procedure|Fiberoptic bronchoscopy and bronchoalveolar lavage|
45940630|NCT02961478|Drug|IOHEXOL|Estimate iohexol clearance at the end of stay in intensive care for patients who had an episode of acute renal failure.
46074588|NCT00812955|Drug|ABT-143|Once daily for 8 weeks
46074589|NCT00812955|Drug|simvastatin|Once daily for 8 weeks simvastatin capsules 40 mg
45452791|NCT04868318|Other|Very-high protein enteral formula|Peptamen® Intense VHP (37% protein)
45806288|NCT05621291|Diagnostic Test|NGS testing|antigen immunophenotype agnostic approach for disease detection using blood and bone marrow samples
45452792|NCT04868318|Other|Standard-high protein enteral formula|Peptamen® (16% protein)
45655168|NCT04933201|Other|Music|Perioperative musical intervention
45655169|NCT04933201|Other|Routine perioperative treatment|Routine perioperative treatment
45655170|NCT04925323|Biological|BLOOD SAMPLES|BLOOD SAMPLES
45655171|NCT04925323|Biological|surgical tissue samples|unused surgical tissue removed during plastic surgeries
45806289|NCT05621239|Biological|BNT162b2|BNT162b2 half dose and full dose
45940631|NCT00248482|Drug|Cisplatin|Cisplatin 60mg/m2 IV day 1 every 21 days x 4 cycles
45940632|NCT00248482|Drug|Gleevec™|Gleevac 400 mg po BID (800mg/day)- fo patients with objective response or stable disease.
46074590|NCT04235478|Drug|Combination Product: triamcinolone and saline|a mixture of 3 mL 0.09%saline and 2 mL 80 mg triamcinolone (kenacort-a)
46074591|NCT05511480|Behavioral|Interference through learning of a competing motor skill.|Interference through the learning of a competing motor skill.
46074592|NCT05511480|Behavioral|No interference|No interference through the continuation of learning same motor skill
46074593|NCT00619489|Drug|vedolizumab|Vedolizumab for intravenous (IV) infusion
45452793|NCT04857242|Diagnostic Test|Apnea test, alveolar recruitment|Alveolar recruitment following the phase of apnea testing
45452794|NCT02947646|Device|BabyGentleStick™ ON|experimental intervention
45806290|NCT05620823|Drug|Povorcitinib|Oral; Tablet
45806291|NCT05620823|Drug|Placebo|Oral; Tablet
45940633|NCT00248482|Drug|irinotecan|Irinotecan: 65 mg/m2 IV days 1, 8 every 21 days x 4 cycles
45940634|NCT00103233|Biological|trastuzumab|
45940635|NCT00103233|Drug|vinorelbine tartrate|
45940636|NCT00248521|Drug|alvespimycin hydrochloride|
45940637|NCT00248677|Behavioral|Behavioral Family-Based Intervention|Behavioral family intervention
45940638|NCT00248677|Behavioral|Behavioral Parent-Based Intervention|Behavioral Parent-Only Intervention
45940639|NCT00248716|Drug|Ferrous gluconate and iron polysaccharide complex|Children with anemia will receive 5mg per kg per day of one of study medications. Treatment period for 3 months
46074594|NCT02806206|Drug|Prucalopride|A single 2 mg oral dose of prucalopride will be given to each study participant just before the ingestion of the capsule endoscopy pill.
46074595|NCT02806206|Drug|Placebo|A single dose of a placebo pill will be given to each study participant just before the ingestion of the capsule endoscopy pill.
45452795|NCT02947646|Device|BabyGentleStick™ OFF|active comparator
45655172|NCT02460159|Drug|EZ 10 mg/Atorva 20 mg FDC|
45655173|NCT02460159|Drug|EZ 10 mg/Atorva 10 mg FDC|
45655174|NCT04925011|Drug|Roxadustat|Starting doses of 20, 50, 70 or 100 mg/30,70,90,or 120mg based on weight and dialysis or not.
45940640|NCT00067925|Behavioral|Incorporating More Physical Activity and Calcium in Teens (IMPACT) Program|
45940641|NCT00248755|Procedure|mucociliary clearance scan|
45940642|NCT00103272|Drug|tanespimycin|Given IV
46074596|NCT04042363|Device|Transorbital electrical stimulation (Eyetronic Next Wave 1.1)|"Calibration phase: The patient will use a response button to indicate the threshold from which he feels a luminous sensation (phosphene). In a second step, he will use the same answer button to indicate the stimulation frequency from which the phosphenes become continuous.~Stimulation phase: From these 2 parameters (amplitude and frequency), the stimulation session will begin for a duration of approximately 40 to 50 minutes, the settings being dependent of the individual thresholds."
46074597|NCT04042363|Device|Transorbital electrical stimulation (Eyetronic Next Wave 1.1) - Sham stimulation|The calibration phase is identical to the active stimulation. During the stimulation phase, the operator will manually interrupt the stimulation 60 seconds after the start of the session.
46074598|NCT00855205|Drug|Rituximab|Rituximab will be administered by IV infusion at a dose of 1000 mg (1 g) on day 1 and 15
46074599|NCT02803320|Drug|SPF 50 Y65 110 (BAY 987516)|Subjects applied the assigned products to all sun-exposed areas of their face and body liberally and evenly, in accordance with instructions. Sun exposure was divided into two periods. Each period consisted of direct sun exposure (out of water; Cycle A) and water exposure (Cycle B). Cycles A and B were repeated two times before study closeout.
45655175|NCT04924855|Other|Blood sampling (4 per year)|Blood sampling (4 per year)
46074600|NCT00859729|Biological|pVAXrcPSAv53l (DNA encoding rhesus PSA)|5 doses, 4 weeks apart
45655176|NCT04913155|Radiation|Low-dose CT screening|Low-dose computed tomography with lung nodule evaluation (LungRADS1.1, highrisk score group), randomized reporting of coronary artery calcium score and emphysema score
45655177|NCT02498067|Behavioral|rPlan dual protection waiting room app intervention|
45655178|NCT04916353|Drug|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder pain
45806292|NCT05620433|Other|Joint Effort|The Joint Effort intervention is available in the form of an iPhone mobile application (running on iOS 13 and higher) in French language. It aims to support young adults in school who have used cannabis in the past month into taking action on their cannabis use.
45940643|NCT00103272|Drug|bortezomib|Given IV
45806293|NCT05620433|Other|Brief normative feedback and standard information|The brief normative feedback is based on the frequency of cannabis use. Participants will also be offered basic reliable non-personalized information on lower-risk cannabis use in the form of official public websites.
45806294|NCT05619744|Drug|RO7616789|RO7616789 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective part.
45806295|NCT05619744|Drug|Tocilizumab|Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants >/= 30 kg or at 12 mg/kg for participants < 30 kg.
45806296|NCT05617677|Drug|Deucravacitinib|Specified dose on specified days
45655179|NCT04916353|Drug|Triamcinolone Acetonide.|Triamcinolone Acetonide 40mg/1ml injection
45806297|NCT05617677|Other|Placebo|Specified dose on specified days
45806298|NCT05616650|Drug|18F-DCFPyL|Each participant will receive a single IV dose of 18F-DCFPyL by bolus injection. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi; dose variations will be in accordance with the Nuclear Regulatory Commission (NRC) standard dose variation (i.e., 20%) permitted for diagnostic clinical studies.
45940644|NCT00248872|Behavioral|Intervention Group|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
46074601|NCT00859729|Device|DERMA VAX™ intradermal DNA delivery system|in vivo electroporation is applied after each DNA injection
45655180|NCT02497755|Behavioral|App for smartphone|A smartphone app will send psychoeducation and reminders to patients to complete self-report data, will collect passive data, and will provide aggregated information to a provider dashboard.
45655181|NCT02497755|Device|smartphone|
45655182|NCT03056599|Drug|Multiple drug microinjection|This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
45655183|NCT03056599|Device|CIVO device|Feasibility of assessing drug response to precise local injection of anti-cancer drugs using Presage's CIVO device in soft tissue sarcoma patients undergoing surgery.
45655184|NCT04924465|Other|Follow-up|Follow-up of clinical data, laboratory tests, radiological data and pulmonary function tests
45655185|NCT04916275|Other|Cognitive tests|Optional tests: Corsi block-tapping task, Stroop test and Iowa gambling task
45655186|NCT02619175|Device|Stroke Subjects Perturbation-Based Balance Training|
45655187|NCT02619175|Device|Stroke Subjects Weight Shifting and Gait training|
45655188|NCT04924231|Behavioral|astigmatism|astigamatism at least 1 month after the cataract surgery
45655189|NCT03056443|Device|Continuous Positive Airway Pressure (CPAP)|The auto-CPAP group will be scheduled for follow-up with a phone call at 2 - 3 weeks post discharge, then in sleep medicine clinic at 1 month (+2 weeks) and 6 months (+2 weeks) to assess their progress on CPAP.
45655190|NCT04915885|Other|Routine care|Routine contraceptive counseling and routine method availability
45806299|NCT05616650|Radiation|Stereotactic Body Radiation Therapy|Intensity modulated radiotherapy will be delivered to a dose of 26Gy in two fractions with the second fraction performed within 8 days of the first session.
45806300|NCT05613426|Drug|Rosuvastatin 20 mg|Very early use of Rosuvastatin before primary PCI in anterior STEMI
45806301|NCT05613426|Drug|Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]|Very early use of Evolocumab before primary PCI in anterior STEMI
45806302|NCT05612347|Diagnostic Test|FIT|Annual FIT
45655191|NCT04915885|Other|Package of contraceptive counseling interventions|The implementation package will be co-designed by providers and clients during the formative and research design phases
45655192|NCT04915885|Other|Expanded methods|Expanded range of contraceptive methods as recommended by national policies
45806303|NCT05612347|Diagnostic Test|Colonoscopy|One time surveillance colonoscopy
45655193|NCT04915963|Dietary Supplement|Vitamin D supplementation|Patients are randomized to receive vitamin D or placebo and followed up for 15 days at maximum to investigate the safety and clinical efficacy of the supplements
45655194|NCT04915807|Drug|Ramucirumab and paclitaxel|Ramucirumab/paclitaxel as a second-line chemotherapy after May 1, 2018, when health insurance coverage for the combination therapy started
45940645|NCT00248911|Behavioral|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
45940646|NCT00248950|Behavioral|Positive affect induction and /or self affirmation induction|
45940647|NCT00067964|Behavioral|small changes in physical activity and diet|
45940648|NCT00248989|Drug|Dehydroepiandrosterone|3.0 ml of 0.3% DHEA cream applied on the skin twice daily.
45940649|NCT00248989|Drug|Placebos|3.0 ml of placebo cream applied on the skin twice daily.
45940650|NCT00249106|Biological|ADVAX|
45655195|NCT04915807|Drug|Taxane, irinotecan, or fluoropyrimidine-based single or combined chemotherapy|Taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy as a second-line therapy
45806304|NCT05612178|Biological|3BNC117-LS|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) or placebo at weeks 0, 20 and 40.
45806305|NCT05612178|Biological|10-1074-LS|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10- 1074-LS (dosed at 10 mg/kg) or placebo at weeks 0, 20 and 40.
45806306|NCT05612178|Other|Sterile Saline|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) or placebo at weeks, 20 and 40.
45806307|NCT05612100|Other|Electronic Health Record Review|Ancillary studies
45806308|NCT05612100|Other|Questionnaire Administration|Complete alopecia questionnaires
45806309|NCT05612100|Other|Survey Administration|Complete alopecia surveys
45940651|NCT00068042|Drug|Pegvisomant|
45940652|NCT00068042|Drug|Sandostatin LAR|
45940653|NCT00249145|Drug|risperidone|
45940654|NCT00099801|Drug|FTY720|
45655196|NCT04915651|Device|Gallbladder Cryoablation|Percutaneous cryoablation of the gallbladder.
45655197|NCT01360021|Drug|Symbicort|Breath actuated metered dose inhaler
45655198|NCT01360021|Drug|Symbicort|Actuation counter pressured metered dose inhaler
45806310|NCT05611775|Device|Triaxial accelerometer|Monitors placed on the waist, thigh, and bilateral ankles. Accelerometry will measure patients' physical activities in the free-living environment for 4 consecutive days. The patients will wear the monitor during waking hours and remove it during sleeping, showering, and swimming time.
45806311|NCT05610657|Drug|Mitapivat|Mitapivat tablets
45806312|NCT05608876|Drug|Tigilanol Tiglate|Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
45940655|NCT00414583|Other|No intervention|Observational study, only laboratory analysis and diagnostic interventions done; no drug tested
45940656|NCT00414622|Drug|DMXB-A|
45940657|NCT00414739|Drug|Benzalkonium chloride|
45655199|NCT01360021|Drug|Budesonide|Actuation counter pressured metered dose inhaler
45655200|NCT04924309|Other|Exposure: donor sperm|One group use donor sperm through the process of assisted reproduction and the other uses husband's semen.
45655201|NCT04915573|Diagnostic Test|Specimen|Sputum will be collected in clean disposable containers
45940658|NCT00103350|Drug|TG100-115|
45940659|NCT00068081|Drug|Capsaicin Dermal Patch|
45940660|NCT00249223|Drug|Risperidone Long acting injectable|
45940661|NCT00249262|Drug|Taxoprexin|
45940662|NCT00249301|Drug|MLN8054|MLN8054 will be administered orally in multiple divided daily doses for 7 days to 21 consecutive days. A 14-day recovery period will follow each dosing period, regardless of its duration. MLN8054 will be supplied in capsules of 5 mg or 25 mg with dose strength expressed as the milligrams of active drug (free acid). MLN8054 will be given on an empty stomach. Patients will be instructed to take nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose.
45940663|NCT00099840|Procedure|Procalcitonin guided antibiotic therapy|
45940664|NCT00249340|Behavioral|Weight Watchers|
45940665|NCT00249340|Behavioral|brief behavioral weight loss treatment|
45940666|NCT00249340|Behavioral|brief behavioral + Weight Watchers combined treatment|
45940667|NCT02967224|Drug|insulin glargine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45940668|NCT02967224|Drug|insulin glargine (U100)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45940669|NCT02967224|Drug|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45940670|NCT02967224|Drug|insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45940671|NCT02967224|Drug|insulin degludec|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45940672|NCT02961595|Biological|Oral Polio Vaccine (OPV)|Serial Oral Polio Vaccine (OPV) was given to intervention group instead of inactivated poliovirus vaccine (IPV).
45940673|NCT04720495|Procedure|One stage ridge splitting with simultaneous implant placement|"A full mucoperiosteal flap was raised using the sharp periosteal elevator to expose the bone crestally and buccally.~An inverted U-shaped bone cut, down to the cancellous bone, was done in the undercut area with a piezoelectric device.~The horizontal bone cut was made apical to the most concave point in the undercut area with a distance of 3 mm.~The two vertical bone cuts were placed at least 1 mm away from the adjacent roots and extended beyond the undercut area.~The released bone end was minimally elevated using a periosteotome through a greenstick fracture.~All implants were installed with the implant shoulders flush to the bone level using a low-speed drilling procedure."
45655202|NCT04912219|Device|Microneedling|"Skin will be pretreated with topical 15% lidocaine creaml for 20 minutes. Water-soaked gauze will then be used to remove the lidocaine gel. Treated skin will be cleaned with 70% ethyl alcohol, allowed to dry, and then treated with hyaluronic acid gel.~Manual traction will be applied to the skin of the treatment arm, and the SkinPen microneedle device with 0.5mm microneedles attached will be passed over the forearm skin in a cross-hatch pattern until an endpoint of fine pinpoint bleeding is achieved.~Manual pressure with sterile ice water compresses will be used until hemostasis is achieved.~This will be repeated for a total of four treatments one month apart"
45655203|NCT04915339|Behavioral|Physical activity|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables…) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation…).
45655204|NCT04915339|Behavioral|cognitive training|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables…) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation…).
45655205|NCT04915339|Behavioral|combined physical and cognitive training|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables…) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation…).
45655206|NCT04923373|Other|telerehabilitation|"Procedure for both groups:~I pre surgery evaluation~initial training in hospital~physiotherapeutic programme telerehabilitation versus standard 7 times a week~Therapy duration: 6 weeks post-surgery II 6weeks post-surgery evaluation"
45655207|NCT04923373|Procedure|standard physiotherapy|standard physiotherapy
45655208|NCT04915417|Radiation|Stereotactic Ablative Body Radiotherapy (SABR)|Patients will receive 27-30 Gy in 3 fractions to the planning target volume (PTV) with a simultaneous in-field boost to the metabolically active areas of the gross tumor volume (GTV) to a maximum of 45 Gy. Patients will be treated every other day.
45655209|NCT04912297|Biological|10-valent pneumococcal conjugate vaccine, PCV10|10-valent pneumococcal conjugate vaccine, PCV10
45655210|NCT02497287|Drug|Esketamine (Intranasal Spray)|Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants will self-administer esketamine intranasally (56 mg or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years) once weekly then individualized to either once weekly or once every other week based on the severity of depressive symptoms. Transferred-entry responder participants from ESKETINTRD3005 >= 65 years old will start at a dose of 28 mg in Week 5.
45655211|NCT02497287|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
45655212|NCT02497287|Drug|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. The minimum therapeutic dose is 10 mg/day. Participants >= 65 years of age will be titrated up to 20 mg/day, but can lower the dose to 10 mg/day for tolerability.
45676330|NCT03910907|Drug|Comparison of two standard of care regimens|Treatment according to results of laboratory detection of resistance markers
45806313|NCT05608434|Behavioral|Floreo Virtual Reality application|Floreo VR is a novel VR-based cognitive training therapy for ADHD. It incorporates multiple learning modules, each of which targets a neuropsychological domain relevant to ADHD (inhibitory control, sustained attention, working memory, delay discounting, temporal processing, processing speed). The demands of the training intervention adapt to the subject s practice-driven improvements in performance. Specifically, when the subject is deemed to perform adequately well at a given level of difficulty, the training adapts by presenting a more challenging difficulty. This adaptation to the subject s performance is designed to allow for continued incremental improvements in the trained domains. The VR games take place in a spaceship themed environment. The VR training is designed to be used at home, under the supervision of a parent.
45806314|NCT05608434|Behavioral|Floreo Virtual Reality application - non-adaptive|This is a non-adaptive version of the Floreo VR application, created to serve as a control intervention in the present study. This control intervention will consist of the same training modules, but the performance demands will be kept low.
45806315|NCT05605899|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
45806316|NCT05605899|Drug|Cyclophosphamide|Administered intravenously
45806317|NCT05605899|Drug|Fludarabine|Administered intravenously
45806318|NCT05605899|Drug|Etoposide|Administered intravenously
45806319|NCT05605899|Drug|Rituximab|Administered intravenously
45806320|NCT05605899|Drug|Doxorubicin|Administered intravenously
45806321|NCT05605899|Drug|Vincristine|Administered intravenously
45806322|NCT05605899|Drug|Prednisone|Administered orally
45806323|NCT05603065|Drug|Tislelizumab + cisplatin + paclitaxel|Tislelizumab 200mgD1 + cisplatin 75mg/m^2D1 + paclitaxel 150mg/m^2D1 Q3W 3 cycles
45806324|NCT05603065|Drug|Tislelizumab + radiotherapy|Tislelizumab 200mgQ3W 3 cycles + radiotherapy (23 times in total, 1.8 Gy per dose, 5 times a week)
45806325|NCT05602779|Device|tVns Program|Participants will use the Neuvana Xen device 30 minutes a day for 3 days. The device delivers stimulation through the left ear via an ear bud. Participants can use the device at any time of day.
45940674|NCT04720495|Procedure|Two-stage ridge splitting with implant placement|"The first surgery is the same as one stage ridge splitting Four weeks later, after revascularization between the bone block and the mucoperiosteum, the second surgery will be performed.~A crestal incision was done and the envelope flap slightly elevated to preserve the blood supply.~The implants will be placed in the same manner as one stage ridge splitting"
45940675|NCT00103428|Biological|CG7870|
46074602|NCT02806674|Device|The eradication times of the patients|The patients who have failed more than 2 eradication courses with standardized treatment were the refractory infection of H. pylori group,and patients who succeeded at the first standardized treatment were the successful treatment group
45806326|NCT05602779|Other|Phone App Program|Participants will have access to a specially designed phone app in order to play a game designed for this study. Approximately half of the participants will be able to connect with a fellow participant who is matched as their peer for social support.
45452796|NCT04774484|Other|High Intensity Interval Training|After the acclimatization session and assessment of eligibility, a graded exercise test (GXT) will be given to the participant. After checking their vitals, the HIIT program will be performed on recumbent cycles. The first two weeks of training will consist of a gradual ramp where subjects will perform a moderate intensity cycling program consisting of a 5-minute warm up followed by progressively longer continuous cycling starting at 15 minutes and progressing up to 30 minutes prior to starting the HIIT training. For the HIIT training subjects will perform 5 minutes of low to moderate steady state cycling to warm up. Following the warm up, the subjects will complete the 4x4 HIIT program. This will consist of 4 minutes of cycling at 85% of the subject's maximum heart rate (HR) followed by 4 minutes of a low intensity cycling period for recovery.
45452797|NCT02926352|Behavioral|Extinction Training|Up to 40 min. of self-directed repeated exposure to a fear-provoking situation.
45655213|NCT02497287|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
45806327|NCT05602779|Combination Product|tVNS and Phone App Program|Participants will have both the Neuvana Xen Device and the full version of our program's phone app. They will use the device and full app access for 30 days.
45806328|NCT05602779|Other|Enhanced Treatment as Usual|Participants will have access to our program's phone app so the can play the game and will be called weekly to complete risk assessments.
45452798|NCT02926352|Device|Low-Level Laser Therapy|1064nm light used to modulate a biological function and induce a therapeutic effect.
45655214|NCT02497287|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated for participants < 65 years of age up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day. For participants >= 65, it can be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
45806329|NCT05602740|Device|Harmony|Passive recording of the head pulse
45806330|NCT05602623|Device|Adaptive Optics System (AO)|Subjects will have their higher and lower order aberrations corrected with the AO system.
45806331|NCT05601973|Drug|Amivantamab|Amivantamab is given at a fixed dose of 1750 mg (if baseline body weight is <80 kg) or 2100 mg (if baseline body weight is ≥80 kg), i.v. every 3 weeks, until disease progression, or intolerable toxicity.
45806332|NCT05601973|Drug|Lazertinib|Lazertinib is given at a dose of 240 mg, orally, once daily. Treatment with lazertinib continues until disease progression or intolerable toxicities.
45806333|NCT05601973|Drug|Zirabev|Bevacizumab (Zirabev®) is administered at a dose of 15mg/kg, i.v. every 3 weeks, until disease progression, or intolerable toxicity.
45806334|NCT05601882|Drug|Upadacitinib|Oral Tablets
45940676|NCT00249418|Behavioral|Contingency management|Rewards (prizes) for abstinence
45940677|NCT00249457|Behavioral|Contingency management|Invited to attend the Therapeutic Workplace 3 hr per day, Monday through Friday. Each day when a participant reported to the workplace, she was required to provide a urine sample. If the sample tested negative for opiates and cocaine, she was allowed to work that day. Participants who gained entrance to the workplace participated in basic skills education and job skills training throughout each 3-hr work shift.
45940678|NCT02961673|Biological|HU-014 Inj|Clostridium botulinum type A
45940679|NCT02961673|Biological|Botox Inj|Clostridium botulinum type A
45940680|NCT00249535|Behavioral|Contingency management|Rewards (prizes) for abstinence
45940681|NCT00099918|Drug|vildagliptin|
45940682|NCT00249574|Drug|Buprenorphine/naloxone|Human subjects HIV, HCV
46074603|NCT02806674|Device|The result of 13C-urea breath test after treatment|The intervention focused on the results from the result of 13C-urea breath test after treatment.The two groups were treatment based on the antibiotic susceptibility testing. Eight weeks after treatment,a 13C-urea breath test was performed on patients.The successful treatment group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients after the second standardized treatment.
46074604|NCT00859807|Drug|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
45452799|NCT02926352|Device|Sham Low-Level Laser Therapy|Placebo dose version of LLLT.
45452800|NCT05442008|Drug|Erenumab 70/140 mg s.c.|Monoclonal antibody directed against the receptor of the Calcitonin Gene Related Peptide (CGRP)
45806335|NCT05601882|Drug|Dupilumab|Subcutaneous Injection
45806336|NCT05601700|Drug|Letrozole tablets|ATC: L02BG04
45806337|NCT05601700|Drug|carboplatin AUC 5 and paclitaxel 175 mg/m2|ATC: L01XA02 and ATC: L01CD01 respectively
45806338|NCT05601362|Device|Gamified Attention Bias Modification|Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT).
45806339|NCT05601362|Device|Gamified Placebo Training|Placebo version of Gamified Attention Bias Modification. (Identical version of the gamified behavioral intervention without manipulation designed to decrease negative attention bias).
45940683|NCT00249574|Drug|pegInterferon|intervention drug 1. buprenorphine/naloxone. street-recruited heroin users induced on bup/naloxone for period of 3-6 months, after which the second intervention is offered. intervention drug 2: pegInterferon/ribavirin. subjects interested in initiation treatment for HCV are offered pegInterferon, 180ug SQ/wk and ribavirin, 800-1200 mg daily for the standard duration of HCV treatment as dictated by genotype.
45940684|NCT00249652|Behavioral|TAP|12-session motivational interviewing-based telephone intervention.
45655215|NCT04923607|Drug|TQC2731|TQC2731 injection
45655216|NCT04923607|Drug|Placebo|Matching placebo with no active ingredients
45940685|NCT00249652|Other|TAU|The usual care group will receive the same medical services they would otherwise receive if they were not in this study.
45806340|NCT05600920|Drug|Recombinant human interleukin (IL) 7-hyFc|Structural Formula: NT-I7 is a fusion protein comprising human IL-7 fused to the human IgD hinge region. This in turn is fused to the N-terminal region of CH2 from IgD and two key regions of the antibody IgG4: C-terminal region of CH2 and the entire CH3 region. NT-I7 will be administered by IM injection once every 12 weeks for a total of 3 doses, with the final dose at week 24. In the absence of treatment delays due to AEs, a treatment course of 24 weeks will be pursued in all enrolled participants. The dose levels to be used in this study are 240, 480, and 720 microgram/kg. NT-I7 dosing will be determined using the weight recorded at the screening visit. The dose will be based on the participant s actual body weight, unless the participant has a BMI >=30 kg/m2, in which case adjusted body weight will be used.
45806341|NCT05600426|Drug|cyclosporine|cyclosporine
45940686|NCT00249691|Drug|Topiramate + Cognitive Behavioral Therapy|Topiramate up to 300 mg per day
45940687|NCT00249691|Drug|Placebo + Cognitive Behavioral Therapy|Placebo twice a day
45940688|NCT00068198|Biological|Dryvax|
45940689|NCT00103467|Biological|rPA102 Vaccine|
45940690|NCT00249730|Drug|Sildenafil|
45940691|NCT00249847|Drug|Paroxetine controlled-release|2-12.5 mg tablets, orally, every day for 4 weeks
45940692|NCT00249847|Drug|Conjugated equine estrogen|0.625 mg tablet, orally, every day for 4 weeks
45940693|NCT00249886|Drug|Citalopram|
45940694|NCT00249925|Behavioral|Home-Based Intervention|
45940695|NCT00249925|Behavioral|Multi-component home-based intervention|
45940696|NCT00249964|Drug|Combination Treatment - Cohort 1|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 75 mg/m2 per day from day 2 to day 6."
45806342|NCT05600426|Procedure|Matched Unrelated Donor Hematopoetic Stem Cell Transplant|Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)
45806343|NCT05600426|Drug|horse anti-thymocyte globulin (ATG)|horse anti-thymocyte globulin (ATG)
45806344|NCT05600426|Drug|rabbit anti-thymocyte globulin (ATG)|rabbit anti-thymocyte globulin (ATG)
45806345|NCT05600426|Drug|Methotrexate|methotrexate
45806346|NCT05600426|Drug|Fludarabine|fludarabine
45940697|NCT00249964|Drug|Combination Treatment - Cohort 2|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 100 mg/m2 per day from day 2 to day 6."
46074605|NCT00859807|Drug|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
45452801|NCT03524092|Drug|Mirikizumab SC|Administered SC
45452802|NCT03524092|Drug|Mirikizumab IV|Administered IV
45655217|NCT04911985|Device|Measurement of the Cardiac Output/ Cardiac Index|Semiinvasive Measurement of the Cardiac Output/ Cardiac Index with the Pulsion device
45655218|NCT04912141|Drug|conestat alfa or placebo|"Conestat alfa will be dosed by body weight at 50 U/kg (maximum 4200 U) or 100 U/kg (maximum 8400 U).~Placebo will consist of normal saline (NaCl 0.9%). The interventions will be given to the patients by IV-line."
45655219|NCT04915105|Diagnostic Test|Markers data from PBMCs|Prescreen markers from patient individual PBMCs treating with streptococcus and different biologics.
45806347|NCT05600426|Drug|Cyclophosphamide|cyclophosphamide
45806348|NCT05600426|Radiation|low-dose total body irradiation (TBI)|low-dose total body irradiation (TBI)
45806349|NCT05600426|Procedure|Immunosuppressive Therapy (IST)|Immunosuppressive Therapy (IST)
45806350|NCT05597020|Drug|Daridorexant|Daridorexant is available as oral film-coated tablets at a strength of 50 mg.
46074606|NCT04065126|Behavioral|Physical activity intervention|Ten sessions (two hours each) with physical activity and psycho-educational components.
45940698|NCT00249964|Drug|Combination Treatment - Cohort 3|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 125 mg/m2 per day from day 2 to day 6."
45940699|NCT00249964|Drug|Combination Treatment - Cohort 4|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 150 mg/m2 per day from day 2 to day 6."
45940700|NCT00068276|Dietary Supplement|cholecalciferol|
45940701|NCT00250003|Behavioral|Preventive home visits|
46074607|NCT04065126|Behavioral|Brief psycho-education|Two brief lectures with psycho-educational components, soon after baseline assessment and in connection to follow-up assessment.
46074608|NCT00859885|Drug|Antithrombotic treatment|antiplatelets, anticoagulants
45452803|NCT03524092|Drug|Placebo SC|Administered SC
45452804|NCT03331562|Drug|Pembrolizumab|pembrolizumab solution for infusion
45452805|NCT03331562|Drug|paricalcitol|Paricalcitol solution for injection
45452806|NCT03331562|Drug|placebo|normal saline solution for injection
45452807|NCT04714736|Device|Coronary angiography using DyeVert system|Invasive diagnostic and/or interventional cardiovascular procedures in the setting of acute coronary syndrome using DyeVert system.
45940702|NCT02961712|Biological|NK cells|single intravenous injection of NK cells (0.9~1*10^9)
45940703|NCT02961712|Biological|amniotic epithelial cells|single intrathecal injection of amniotic epithelial cells
46002140|NCT04718025|Drug|Aspirin|Up to day 90 after ACS, all enrolled patients will receive aspirin 1x100mg as a part of dual antiplatelet therapy. Starting from day 91, LDTP patients will discontinue aspirin and proceed with low-dose ticagrelor monotherapy until 12 months post-ACS, while patients in LDTA and SDTA will continue aspirin 1x100 mg until 12 months post-ACS.
45452808|NCT04714736|Procedure|Coronary angiography using conventional manual injection syringe.|Invasive diagnostic and/or interventional cardiovascular procedures in the setting of acute coronary syndrome using conventional manual injection syringe.
45940704|NCT00250042|Drug|Gleevec and Arsenic Trioxide|Pts. who fit the inclusion criteria, & were on imatinib, 400 mg/day, will be treated with a month of imatinib at 800 mg/d in divided doses (400mg bid) & then started on arsenic trioxide. Pts. already on imatinib 800 mg/day may be started on arsenic trioxide. Pts. unable to tolerate 800 mg/d should be treated at the max. dose tolerated above 400 mg/d. A total of 16 weeks of arsenic trioxide treatment will be administered (15 weeks of maintenance). Pts. are to continue on imatinib 800 mg/day,(or the max. tolerated dose) while receiving the arsenic trioxide. If a pt. has been taken off the arsenic trioxide, they should be continued on gleevec 800 mg per day (or the maximum tolerated dose) until there is evidence of progression of disease.
45940705|NCT00068315|Drug|bortezomib|Given IV
45806351|NCT05597020|Drug|Placebo|Placebo matching daridorexant is provided as identical-looking oral tablets, formulated with the same inactive ingredients (excipients) as the active tablets.
45806352|NCT05596409|Drug|Elacestrant|Starting dose 400 mg elacestrant dihydrochloride administered orally once daily for an estimated 6 months of treatment.
45806353|NCT05592938|Radiation|rPBI|External beam partial breast reirradiation (rPBI) using 26Gy in 5 fractions delivered daily over 1-week
45806354|NCT05592418|Drug|Rintatolimod|100 to 400 mg twice weekly
45940706|NCT00068315|Drug|fludarabine phosphate|Given IV
45940707|NCT00068315|Biological|rituximab|Given IV
45655220|NCT04923451|Device|Active Trans-cranial direct current stimulation (tDCS)|5 active sessions (1/day for 5 consecutive days) of tDCS (NeuroConn DC), active anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode, 2 mA, during 30 min will be performed
45940708|NCT00250081|Procedure|Upper Extremity Tendon transfer|
45940709|NCT00250081|Procedure|Botulinum Toxin injections in Upper Extremity|
45655221|NCT04923451|Device|Sham Trans-cranial direct current stimulation (tDCS)|5 placebo sessions (1/day for 5 consecutive days) of sham tDCS (NeuroConn DC), anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode during 30min will be performed
45806355|NCT05592418|Other|Placebo / Normal Saline|40 to 160 mL twice weekly
45806356|NCT05590585|Drug|dupilumab|Administered by subcutaneous (SC) injection once every 2 weeks (Q2W) following a loading dose
45806357|NCT05590585|Other|Topical emollient (moisturizer)|Moisturizer should be applied twice daily, as per physician's recommendation, as defined in protocol.
45806358|NCT05588414|Procedure|Standardization of the sentinel node detection procedure|All patients included in the study underwent the same pre- and intra-operative procedure, consisting of a double systematic sentinel node detection, using sequential ICG and isotopic technique. The patient is his own control for the analysis of the performance of the ICG technique alone compared to the combined ICG and isotopic technique.
45940710|NCT00250081|Procedure|Regularly ongoing therapy|
45940711|NCT00250120|Drug|L9NC: Liposomal 9-Nitro-20 (S)-Camptothecin|delivery mode: inhalation
45940712|NCT04720573|Drug|Neostigmine|50 mcg/kg neostigmine was used under the guidance of TOF monitoring after cessation of anesthesia.
45940713|NCT04720573|Drug|Sugammadex|2 mg/kg sugammadex was used under the guidance of TOF monitoring after cessation of anesthesia.
45940714|NCT00103545|Biological|ACA 125|
45940715|NCT00250198|Drug|STA-5326|
45940716|NCT00068432|Drug|Celecoxib|Oral celecoxib twice daily on days 1-28. Courses repeat every 4 weeks.
45940717|NCT00068432|Drug|Gemcitabine Hydrochloride|Receive gemcitabine by vein (IV) over 65 minutes on days 1, 8 and 15. Courses repeat every 4 weeks.
45940718|NCT04720261|Drug|Caplacizumab|Analyse of ADAMTS13 activity in patients with aTTP treated with Caplacizumab in order to help adapting the treatment with caplacizumab in TTP patients
45940719|NCT00250237|Drug|Haloperidol|Haloperidol 1mg twice daily during 72hours
45940720|NCT00250237|Drug|placebo|Placebo 1mg twice daily during 72hours
45655222|NCT04922385|Other|Cognitive Behavioural Therapy|This study is an open waitlist control study. Eligible participants will be assigned to a treating clinician and will complete 4 weeks of treatment, followed by a post-treatment assessment (2 weeks later). If a treating clinician is not immediately available, participants will be placed on their waitlist for 4 weeks. They will then be assessed after 4 weeks and undergo the 4 week treatment, followed by the post-treatment assessment (2 weeks later).
45940721|NCT00099957|Drug|vildagliptin|
45655223|NCT04923061|Other|Acupressure|In the acupressure group, heart meridian 7th point (HT7), large intestine meridian 4th point, stomach meridian 36th point (ST36) and spleen meridian 6th point (SP6) will be applied. Tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Subsequently, consecutive (breathing rhythm) compressions will be applied to the acupressure points determined by the researcher, without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief Since the symmetry of the selected four different points will also be applied to the other extremity, a total of 16 minutes of compression will be applied to each point, provided that it is two minutes. Each nurse's session will be approximately 20 minutes, depending on the preparation and compression time on each point.
45806359|NCT05587192|Diagnostic Test|18F-PSMA-1007 PET/CT based on diagnostic model|All enrolled patients will receive 18F-PSMA-1007 PET/CT based USTC diagnostic model before gaining the final pathological diagnosis to be used as experimental arm.
45806360|NCT05585138|Other|segmental breathing exercise|Group-A (interventional group) will receive segmental breathing exercises and deep breathing. segmental breathing exercise will be performed by taking a deep and long breath from nose patient inhale air in to lungs and in exhalation therapist will apply pressure on intercostal spaces at apical, lateral and posterior for one month 5 days a week and 2 sessions per day for 15 minutes for each patient. conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2 times a day.
45806361|NCT05585138|Other|deep breathing|conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2 times a day. . deep breathing exercise will be performed by taking a deep and long breath from nose patient inhale air in to lungs and will exhale through mouth.
45940722|NCT00250315|Drug|Dobutamine|
45940723|NCT00068471|Drug|anidulafungin|
46074609|NCT00859885|Device|percutaneous device closure of PFO|umbrella device for PFO closure
45806362|NCT05585125|Drug|Beta blocker|"The intervention is a two-arm crossover withdrawal/reversal design (On [A] vs Off [B]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta-blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences.~Other names:~atenolol betaxolol bisoprolol metoprolol nebivolol nadolol propranolol acebutolol penbutolol pindolol carvedilol labetalol sotalol metoprolol succinate metoprolol tartrate"
45940724|NCT00250354|Drug|Risperidone oral solution|
45940725|NCT00250393|Drug|Istradefylline (KW-6002)|
45940726|NCT02961634|Device|Nailner 2 in 1|Nailner 2 in 1 is a combination of assets that alter the pH of the nail and is used as an adjunct in the treatment of onychomycosis.
45940727|NCT02961634|Drug|Ciclopirox 8%|Ciclopirox 8% is a glaze used in the treatment of onychomycosis
45940728|NCT00103584|Biological|LC16m8 Smallpox Vaccine|
45940729|NCT02966717|Drug|Rituximab|Rituximab is a human-mouse-chimeric monoclonal antibody which was approved in 1997 for the treatment of cancer.
45940730|NCT02966717|Drug|conventional therapy|Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on.
45940731|NCT02966717|Drug|Mesenchymal stem cells|Mesenchymal stem cells (MSCs), which belongs to mesoderm, is a kind of somatic stem cell with the ability of self-replication and the potential of multi-directional differentiation.
45940732|NCT00250471|Procedure|Percutaneous Coronary Intervention (PCI)|
46074610|NCT02803398|Other|Compression bandages application and interface pressure measurements|Bandages, which are applied in a spiral pattern on the leg, are composed of Biflex 16 (Thuasne) and/or Rosidal K (Lohmann & Rauscher).
46074611|NCT02798874|Drug|Ticagrelor|ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery
46074612|NCT02798874|Drug|Clopidogrel|Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery
46074613|NCT00860041|Behavioral|pain questionnaires|
46074614|NCT02799264|Drug|Cabotegravir 30 mg|Cabotegravir (GSK1265744B ) is available as white to almost white, oval shaped, film coated tablet, of weight 515 mg. The tablet contains micronized cabotegravir, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, and magnesium stearate. Each tablet is equivalent to 30 mg cabotegravir and needs to be taken orally with 240 mL of water. Cabotegravir tablet will be administered to subjects either in fasting condition or following a high fat meal.
46074615|NCT02806518|Procedure|DIRT|An infrared camera is used to capture video sequences of thermal images before, during and after exposure of the lower abdomen to a cold challenge.
45940733|NCT00250510|Behavioral|Simulated insurance reimbursement|Participants were told they would have the possibility of being reimbursed 50% ($150) of their initial fee ($300) if they: 1) paid the fee in advance or committed 3 monthly payments in advance, 2) attended 10 of 12 class sessions, and 3) lost at least 6% of their current body weight during the program.
46074616|NCT00959699|Drug|PegIFN-2b|PegIFN-2b (1.5 μg/kg/week subcutaneously)
46074617|NCT00959699|Drug|RBV|Ribavirin (600-1400 mg/day, orally, divided into two daily doses)
46074618|NCT00959699|Drug|Placebo to Boceprevir|Placebo to boceprevir (orally, three times per day)
46074619|NCT00959699|Drug|Boceprevir|Boceprevir (800 mg, orally, three times per day)
46002141|NCT04711148|Other|placebo|placebo
46002142|NCT04711148|Drug|orelabrutinib|Orelabrutinib is a white, round, uncoated tablet
45655224|NCT04923061|Other|Sham acupressure group|In the sham group, acupressure will be applied on the bone region where the meridians do not pass, approximately 1-1.5 cm away from the HT7, LI4, ST36, SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
45655225|NCT04932759|Behavioral|music listening|music listening during dental treatment
45655226|NCT04911907|Drug|utidelone injection|Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle
45655227|NCT03056287|Behavioral|Aerobic exercise|treadmill aerobic exercise; 3 sessions per week, 40 minutes per session
45940734|NCT00250549|Behavioral|Post test video|We compared the educational effectiveness of a 15-minute posttest counseling video with the normal practice of a session with an HIV counselor.Patients in the experimental group watched an HIV posttest educational video.
45806363|NCT05585125|Drug|Beta blocker|"The intervention is a two-arm crossover withdrawal/reversal design (On [A] vs Off [B]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta-blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences.~Other names:~atenolol betaxolol bisoprolol metoprolol nebivolol nadolol propranolol acebutolol penbutolol pindolol carvedilol labetalol sotalol metoprolol succinate metoprolol tartrate"
45806364|NCT05583552|Drug|Imetelstat|Intravenous injection
45806365|NCT05583422|Genetic|DPYD or UGT1A1 variants|any CLIA certified lab can be used for confirmatory testing after patients have been identified through Michigan Genomics Initiative (MGI)
45806366|NCT05582694|Biological|UB-421|UB-421 is a genetically engineered IgG1/kappa humanized monoclonal antibody with binding specificity to the human CD4 receptor complex. The dose of UB-421 will be 5 mg/kg given by intravenous infusion every 1 weeks for a total of 26 doses.
45806367|NCT05582629|Drug|JT001|JT001 administered orally in tablet form every 12 hours for 5 days
45806368|NCT05582629|Drug|Placebo|Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days
45806369|NCT05581173|Device|Purastat SAP gel application|Purastat is a fully synthetic matrix scaffold that can be applied through an endoscopic catheter. Purastat is FDA approved and commercially available. Purastat is a peptide solution that self assembles at physiological potential Hydrogen(pH) and forms a gel comprising a network of nanofibers. Its benefits in hemostasis and tissue healing and its biocompatibility have been previously demonstrated in animal models and also in human cases. When the gel comes into contact with blood or tissue fluids, the change in potential hydrogen (pH) and salt concentration causes fiber formation and gelation that block the blood vessels in the hemorrhagic area to generate hemostatic effects and also prevention of scar tissue formation.
45806370|NCT05579600|Behavioral|Caring Contacts letters|Caring Contacts involves sending individuals at risk for suicide brief, non- demanding messages of care.
45806371|NCT05579600|Behavioral|Reports, re-engagement, and training|Behavioral health providers will receive training in reaching out to and re- engaging patients who pass through the justice system, as well as training in suicide risk assessment (the Columbia Suicide Severity Rating Scale; C-SSRS) and response (the Safety Planning Intervention; SPI).
45806372|NCT05578976|Drug|Epcoritamab|Subcutaneous Injection (SC)
45806373|NCT05578976|Drug|Cyclophosphamide|Intravenous (IV) Injection
46074620|NCT02798796|Device|MRI|All patients will be submitted to MRI
46074621|NCT02803008|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation number - SR15-46-Z13-072)
45655228|NCT03056287|Other|Repetitive transcranial magnetic stimulation|Repeated non-invasive brain stimulation to the left dorsolateral prefrontal cortex.
45655229|NCT04911829|Behavioral|Psychotherapy|
45655230|NCT04911595|Diagnostic Test|exercise oximetry|transcutaneous oxygen pressure is measured at the skin level on chest , buttocks and calves during a walking test 3.2 km*:h 10% slope. From the test result the decrease from rest of oxygen pressure (DROP) index is calculated to estimate muscle ischemia
45806374|NCT05578976|Drug|Rituximab|IV Infusion
45806375|NCT05578976|Drug|Vincristine|IV Infusion
45806376|NCT05578976|Drug|Doxorubicin|IV Infusion
46074622|NCT02806128|Drug|Human Urinary Kallidinogenase for Injection|Patients need to complete laboratory tests within a specified time and to complete the experimental requirements of medication time
45655231|NCT04911595|Diagnostic Test|thallium scintigraphy|Muscle thallium fixation is measured immediately after a walking test 3.2 km*:h 10% slope and at 4 hours after the test. From the test result the difference of late and early radioactivity is calculated at the buttock and calf level and normalized to total body radioactivity to estimate muscle ischemia
45655232|NCT02458287|Biological|Bococizumab 150mg|Bococizumab autoinjector (pre-filled pen) combination Product. 150mg every 2 weeks for 10 weeks, subcutaneous injection.
45806377|NCT05578976|Drug|Prednisone|Oral; Tablet
45940735|NCT00250627|Drug|Saredutant succinate (SR48968C)|
45452809|NCT00814294|Drug|placebo|placebo capsule,0 units, quater in die (QID) for 18 weeks
45655233|NCT02458287|Biological|Bococizumab 75mg|Bococizumab autoinjector (pre-filled pen) combination Product. 75mg every 2 weeks for 10 weeks, subcutaneous injection.
45655234|NCT02458287|Biological|Bococizumab 150mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination Product. 150mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
45940736|NCT00099996|Drug|SCH-58235|
45940737|NCT00099996|Drug|Ezetimibe|
45940738|NCT00250666|Procedure|PCT measurement|Peripheral blood samples were collected in the morning, using vacuum tubes (BD Vacutainer SST II Plus plastic tubes; Becton Dickinson Diagnostic Systems, Allschwil, Switzerland). Circulating plasma PCT levels were measured with a time-resolved amplified cryptate emission technology assay (Kryptor PCT; Brahms AG, Hennigsdorf, Germany), with an assay sensitivity of 0.06 mg/L, approximately fourfold above mean normal levels. Measurements were performed 7 days a week.
45940739|NCT00250744|Drug|Aprepitant vs. Gabapentin|Gabapentin 300mg PO QHS day -2; 300mg PO BID day -1; 300mg PO TID days 0 through +5.
45940740|NCT00250744|Drug|Aprepitant vs. Gabapentin|Aprepitant 125mg PO 60 minutes prior to chemotherapy on day 0; 80 mg PO QAM on days +1 and +2.
45940741|NCT00414778|Drug|LHT344|
45940742|NCT00103623|Drug|Plenaxis|
45940743|NCT00068510|Biological|therapeutic autologous dendritic cells|
45806378|NCT05578898|Behavioral|CLEAR Care Companion (CC) application|The CLEAR CC application is an EPIC-based, electronic application, downloaded to the patient's Smartphone or Tablet. The CLEAR CC leverages patient-reported symptoms assessment vis-a-vis push notifications to complete clinically meaningful questions and validated questionnaires pertaining to symptoms that serve as early indicators of readmission. The CLEAR CC application will send notifications beginning two days prior to surgery and continue until the 6 week post operative appointment.
45940744|NCT00414856|Drug|AFQ056|
45940745|NCT00250861|Drug|Rituximab|
45940746|NCT00250861|Drug|Aldesleukin|
45940747|NCT00068549|Drug|Gemcitabine Hydrochloride|Given IV
45940748|NCT00068549|Drug|Cisplatin|Given IV
45940749|NCT00068549|Radiation|Radiation Therapy|Undergo whole pelvis radiotherapy
45940750|NCT00068549|Radiation|Internal Radiation Therapy|Undergo brachytherapy
45452810|NCT00814294|Drug|Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)|Oral HDV-I Caps; 15 U; quater in die (QID) for 18 weeks.
45452811|NCT00814294|Drug|Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)|Oral HDV-I; Caps; 5 U; quater in die (QID) for 18 weeks.
45452812|NCT05441228|Device|Oculus Quest 2|Oculus Quest 2 is virtual reality headset with 2 hand control remotes. Beat Saber application will be used on Oculus Quest 2.
45452813|NCT05441228|Device|Mirror therapy box|Mirror therapy is provided by mirror therapy box by placing it in sagittal plane of patient.
45655235|NCT02458287|Biological|Bococizumab 75mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination product. 75mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
45655236|NCT04914715|Device|Non-invasive High Frequency Oscillatory Ventilation|We are planning to use (Medin-CNO) for non-invasive ventilation. This machine has option to deliver NHFOV with frequency of 5-20 (300-1200 breathe/min), Amplitude of 1-10, flow1-17.5 liter/min, fiO2 21-100% and integrated pressure triggered sensitivity option.
45806379|NCT05578872|Drug|ANV419|ANV419 administered by intravenous (IV) infusion
45806380|NCT05578872|Drug|Pembrolizumab|Pembrolizumab administered by intravenous (IV) infusion
45452814|NCT00724048|Drug|ACR16 10 mg|ACR16 capsules: 10mg twice daily
45452815|NCT00724048|Drug|ACR16 22.5 mg|ACR16 capsules: 22.5mg twice daily
45452816|NCT00724048|Drug|ACR16 45 mg|ACR16 capsules: 45mg twice daily
45806381|NCT05578872|Drug|Ipilimumab|Ipilimumab administered by intravenous (IV) infusion
45806382|NCT05578781|Behavioral|Music Therapy|Music Therapy is a music session with a live therapist and has been shown to reduce pain and anxiety. If effective the music medicine in this RCT will be used help design a full R01 study
45806383|NCT05578781|Behavioral|Music Medicine|Music Medicine is an audio recorded music therapy session that will be played for the participant. This will be the same music session that will be played live in the music therapy session.
45806384|NCT05578781|Behavioral|Control group|Control group will listen to an audio recording of text being spoken by the board certified music therapist
45806385|NCT05577715|Drug|MORAb-202|Specified dose on specified days
45940751|NCT04720183|Drug|Sulfasalazine|On Day 1, Day 5 and Day 9, a single oral dose of sulfasalazine tablets in fasted state.
45940752|NCT04720183|Drug|GLPG3970|On Day 5 and Day 9, a single dose of GLPG3970 oral solution in fasted state.
45940753|NCT00100035|Procedure|Polarity therapy|
45940754|NCT00250900|Behavioral|Prescription Fill Status|
45940755|NCT00250939|Biological|Myozyme|20 mg/kg qow
45452817|NCT00724048|Other|Placebo|Placebo capsules
45452818|NCT04438642|Procedure|shoulder finishline|tooth will be prepared having shoulder finishline.
45452819|NCT04438642|Procedure|butt joint with bevel|tooth will be prepared having butt joint with bevel finishline.
45452820|NCT02038634|Drug|Betamethasone|
45452821|NCT02038634|Device|Ultrasound|Ultrasound guided injection using GE Healthcare LOGIQ e Ultrasound
45452822|NCT00808288|Drug|PF-00610355|oral, inhaled, dry powder, 600ug, OD
45452823|NCT00808288|Drug|PF - 00610355|oral, inhaled, dry powder, 300ug, OD
45452824|NCT00808288|Drug|PF- 00610355|oral, inhaled, dry powder, 100ug, OD
45452825|NCT00808288|Drug|Placebo|oral, inhaled, dry powder, placebo, OD
45452826|NCT00808288|Drug|Salmeterol|salmeterol, 50ug, BID
45452827|NCT03636308|Drug|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle or day 1 and 8 of 21 day cycle.
45452828|NCT03636308|Drug|S1|S-1 is orally administered (BSA<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle.
45452829|NCT03636308|Drug|Gemcitabine|Gemcitabine is given at 1000mg/m2 intravenously on d1 and 8 of each 21 day cycle.
45452830|NCT04438486|Behavioral|Group A|specific dietary advice for Hyperuricemia
45940756|NCT00250978|Drug|bevacizumab with chemotherapy, Pleur-XTM catheter placement|After Pleur-XTM catheter placement patients will receive bevacizumab 15mg/kg IV x 1 dose as a single agent.Three weeks later, chemotherapy will be initiated according to routine clinical practice along with continued use of bevacizumab.
45940757|NCT00068666|Drug|temozolomide|
45940758|NCT00068666|Radiation|radiation therapy|
45940759|NCT00103701|Drug|Dasatinib|Tablets, Oral, 15- 240 mg, Once or twice daily, 0-3 years depending on response.
45940760|NCT00251017|Procedure|Vancomycin|Two hour creatinine clearance before and after vancomycin
45940761|NCT00251017|Procedure|DNA are extracted from the whole blood of subjects|
45940762|NCT00251056|Drug|mannitol|120mg BD
45940763|NCT00251056|Drug|mannitol|40 mg BD
45940764|NCT00251056|Drug|mannitol|240mg BD
45940765|NCT00251056|Drug|mannitol|400mg BD
45940766|NCT00251095|Drug|Taxol|
45940767|NCT00251095|Drug|TOCOSOL Paclitaxel|100 mg/m2/week
45940768|NCT00100074|Drug|Lobeline|
45940769|NCT00251134|Drug|Zodin (drug)|1 gram omega-3-acid ethyl esters 90 daily for a period of 12 months
45452831|NCT04438486|Dietary Supplement|Group B|Barely Green（three times a day, 5g(10 tablets)） dietary advice for Hyperuricemia as Group A
45940770|NCT00251134|Drug|Olive oil (placebo)|1 gram olive oil daily for a period of 12 months
45655237|NCT04914715|Device|Conventional Invasive Ventilation|Invasive ventilation will be started following endotracheal intubation, mode will be selected as Synchronized Intermittent Mandatory ventilation (SIMV) with rate of 25-60 breath/min, flow of 8 liter, positive inspiratory pressure (PIP) of 14-25, Positive end expiratory pressure (PEEP) 4-5, fio2 of 21-40.
45655238|NCT04914871|Behavioral|Protocol UN Lifeguard Kids in the Tunja version|"The experimental protocol UN Lifeguard Kids in the Tunja version done by the researcher following the guidelines of International organizations such as the American Heart association and European Resuscitation Council.~The intervention consists of 3 sessions of 60 minutes of theoretical and practical exercises on BLS, developed within the usual class schedule."
45655239|NCT04914871|Behavioral|Educational session accident prevention and wound management|It will be provided to the control group
45452832|NCT03476980|Procedure|Randomized to Umbilical Cord Milking at birth|The subjects in this group were randomized to UCM X4 at birth. This procedure infuses a placental transfusion of blood by milking the umbilical cord towards the infant at birth.
45655240|NCT02441517|Drug|Enzalutamide|Participants were administered four 40-mg capsules orally once daily and taken as close to the same time each day as possible and could be taken with or without food.
45655241|NCT03688347|Procedure|Nasal Swab|The swab is removed from packaging, moistened with sterile water if needed to prevent any discomfort to the participant. The swab is gently inserted less than one inch into the anterior nare (nostril) until resistance is met at turbinate. Then it is rotated several times against nasal wall and repeated in other nostril using the same swab.
45655242|NCT03688347|Procedure|Oral Swab|The swab is removed from packaging, moistened with sterile water if needed to prevent any discomfort to the participant. The swab is gently rubbed along the inside of the participant's cheek for 5-10 seconds.
45655243|NCT03688347|Other|Stool Collection|A stool collection kit will be sent home with each participant. It will include instructions on how to collect the stool specimen and how to return the kit.
45655244|NCT03688347|Genetic|Microbiome analysis|Study of microbial communities found in and on the human body.
45806386|NCT05576532|Drug|BCL2 Inhibitor plus IM2 regimen|oral bcl-2 inhibitor plus IM2(Ifosfamide plus Mitoxantrone or Idarubicin plus methotrexate) chemotherapy
45806387|NCT05575063|Device|Investigational Healon Endocoat|Ophthalmic Viscoelastic device
45940771|NCT00068744|Drug|cisplatin|
45940772|NCT00068744|Drug|fluorouracil|
45452833|NCT03476980|Procedure|Randomized to Delayed Cord Clamping at birth|The subjects in this group were randomized to DCC at birth. At delivery, the obstetrician was instructed to delay clamping of the umbilical cord for 60 seconds.
45940773|NCT00068744|Drug|mitomycin C|
45940774|NCT00068744|Radiation|radiation therapy|
45940775|NCT00251173|Behavioral|Strengths Based Case Management (SBCM)|
45452834|NCT03455608|Behavioral|RE-ACTIVE|Reactive intervention started promptly if/when dysphagia is identified
45452835|NCT03455608|Behavioral|PRO-ACTIVE EAT|Early low intensity proactive intervention started before RT commences
45806388|NCT05575063|Device|Control Healon EndoCoat|Ophthalmic Viscoelastic device
45806389|NCT05574959|Device|investigational IOL Model DEN00V|Eligible subjects will be randomized in a 1:1 ratio to receive the investigational IOL Model DEN00V in both eyes for the duration of the study.
45806390|NCT05574959|Device|control IOL Model ZCB00/DCB00|Eligible subjects will be randomized in a 1:1 ratio to receive the control IOL Model ZCB00/DCB00 in both eyes for the duration of the study.
45806391|NCT05573074|Device|Transcranial Photobiomodulator|Transcranial photobiomodulator delivers Near-Infrared Radiation (NIR) continuous middle irradiance (291.7 mW/cm2) to patients' foreheads.
45806392|NCT05573074|Device|Sham|Transcranial Photobiomodulator delivers sham irradiance odes of 0 mW/cm2
45940776|NCT00251173|Behavioral|Motivational Enhancement Therapy (MET)|
45940777|NCT00251173|Behavioral|Brief Informational Feedback (BIF) session|
45940778|NCT00251212|Behavioral|Adapted Motivational Interviewing & Skills Training|Single session, 45 minute brief intervention during Emergency Department Visit
45940779|NCT00251251|Device|Optimal Medical Therapy plus ICD|ICD vs CRT/ICD
45940780|NCT00251251|Device|Optimal Medical Therapy plus CRT/ICD|ICD vs CRT/ICD
45940781|NCT00100113|Drug|GBR 12909|
45940782|NCT00068783|Drug|imatinib mesylate|Given orally
45940783|NCT00068783|Other|laboratory biomarker analysis|Correlative studies
45940784|NCT00251290|Procedure|auto-titrating continuous positive airway pressure|Continuous positive Airway pressure (CPAP) use for 90 days post TIA
45940785|NCT00251329|Drug|neoadjuvant chemotherapy|
45940786|NCT00251368|Drug|9-Aminocamptothecin (9-AC)|
45940787|NCT00103779|Drug|SGN-40 (anti-huCD40 mAb)|1 mg/kg IV (in the vein) on Day 1; 1-2 mg/kg IV on Day 4; 2-4 mg/kg IV on Day 8; 3-8 mg/kg on Days 15, 22 and 29.
45940788|NCT00251407|Drug|Taxotere|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
45940789|NCT00251407|Drug|Cisplatin|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
45940790|NCT00251407|Drug|CPT-11|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
45940791|NCT02966522|Drug|Thalidomide|
45940792|NCT02966522|Drug|Dexamethasone|
45940793|NCT00251446|Drug|Vinflunine|320 mg/m2 as a 20-minute IV infusion
45940794|NCT00251485|Drug|Cetuximab|Cycle 1: 400 mg/m2 (given as a 2-hour infusion) on Day 1, then 250 mg/m2, Day 8 (given as a 1-hour infusion) subsequent cycles:250 mg/m2, Day 1 and Day 8 (given as a 1-hour infusion)
45940795|NCT00100152|Drug|MK0752, (Notch Inhibitor)|
45940796|NCT00251524|Drug|Bevacizumab, Oxaliplatin, Pemetrexed|Avastin 15 mg/kg IV, Alimta 500 mg/m2 IV given over 10 minutes, Eloxatin 120 mg/m2 IV given over 2 hours
45940797|NCT00068861|Drug|metformin XR|
46074623|NCT04280861|Other|Multicomponent Intervention|Multicomponent intervention conducted by and expert psychologist that target different aspects of the caregiving experience (affective responses, communication skills, burden experience, social support and loneliness, cognitive performance, the practice of mindfulness and health-related behaviours). The number of sessions will be 8, 1 session of 90 minutes a week, and the number of participants will be 12-14 per group. In some sessions other collaborators will be invited to participate (social workers, physiotherapist).
45655245|NCT03688347|Genetic|DNA Banking|Secure, long term storage of an individual's genetic material.
45655246|NCT03688347|Procedure|Skin Swab|Gentle rubbing of the swab will be applied to the skin on the dorsal part of the hand.
45940798|NCT00068861|Drug|clomiphene citrate|
45940799|NCT00251602|Drug|Atropine|One-time 10 mcg/kg infusion over 30 minutes, followed by a 10 mcg/kg bolus
45940800|NCT00251602|Drug|Propranolol|One-time 0.8mg/kg/hr infusion (maximum dose not to exceed 20mg) over 20 minutes, followed by either atropine or normal saline
45940801|NCT00251602|Drug|Normal Saline|One-time 0.25 ml/min infusion over 30 minutes
45940802|NCT02961166|Drug|IgM enriched Immunoglobulins|Treatment for 3 days
45940803|NCT00103818|Drug|gaboxadol|Duration of Treatment: 3 months
45940804|NCT00103818|Drug|Comparator: placebo (unspecified)|Duration of Treatment: 3 months
45940805|NCT02961439|Behavioral|Epworth Richmond's Echocardiography Focused Year|a year long echo teaching program
45940806|NCT02961127|Other|Venous blood was collected|Venous blood was collected by standard vein puncture in fasting condition
45655247|NCT03056131|Device|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
45655248|NCT03056209|Drug|KL1333 25 mg|oral administration, single dose, 25 mg 1 tab
45655249|NCT03056209|Drug|KL1333 50 mg|oral administration, single dose, 25 mg 2 tabs
45655250|NCT03056209|Drug|KL1333 100 mg|oral administration, single dose, 100 mg 1 tab
45940807|NCT00100191|Procedure|uterine artery embolization|
45940808|NCT00100191|Procedure|hysterectomy|
45940809|NCT00251680|Drug|Lapaquistat acetate and lipid-lowering therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
45940810|NCT00251680|Drug|Lipid-lowering therapy|Lapaquistat acetate placebo-matching tablets, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
45940811|NCT00251797|Drug|Irinotecan|Irinotecan: 300 to 350 mg/m2 mixing with 250 cc. Dextrose injection. IV infusion over 90 minutes D1 and repeat every 21 days
45940812|NCT00251797|Drug|Thalidomide|Thalidomide 50 mg capsule starting from 4 tablets per day Oral D 3 to D 19 of each cycle
45940813|NCT00251836|Procedure|Laparoscopic hand-assisted donor nephrectomy|
45940814|NCT00251875|Device|online health information journal|
45940815|NCT00069017|Biological|MEDI-522|MEDI-522 is formulated in a sterile isotonic solution of 10 mM histidine-HCl at pH 6 containing 100 mg of MEDI-522 protein at a concentration of 100 mg/mL.
45940816|NCT00069017|Other|Placebo|Placebo for MEDI-522 contains 10 mM histidine-HCl at pH 6, 0.1% Tween-80, 1.5% Mannitol, 4.3 µg/mL Vitamin B12, and 2 µg/mL D&C Yellow #10.
45940817|NCT00251914|Drug|Esomeprazole|
45940818|NCT00100269|Drug|Menevit anti-oxidant|
45940819|NCT00399074|Drug|sulfadoxine pyrimethamine|Monthly SP
45940820|NCT00100308|Drug|Unfractioned heparin|Low-dose continuous-infusion, 500 units/hour per seven days
45940821|NCT00100308|Drug|saline|Saline placebo
45940822|NCT00251953|Drug|Tesaglitazar|
45940823|NCT00251953|Drug|Metformin|
45940824|NCT00399113|Drug|188Re-PTI-6D2|monoclonal antibody
45940825|NCT00251992|Drug|Esomeprazole|
45940826|NCT00103935|Drug|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 0.8 mcg
45940827|NCT00103935|Drug|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 2.0 mcg
46074624|NCT04086589|Other|Observational study without intervention|Observational study without intervention
45655251|NCT03056209|Drug|KL1333 200 mg|oral administration, single dose, 100 mg 2 tabs
45806393|NCT05573035|Biological|LYL845|LYL845 is an autologous tumor infiltrating lymphocyte (TIL) enhanced via Epi-R, a proprietary epigenetic reprogramming technology
45655252|NCT03056209|Drug|KL1333 400 mg|oral administration, single dose, 100 mg 4 tabs
45655253|NCT03056209|Drug|KL1333 600 mg|oral administration, single dose, 100 mg 6 tabs
45655254|NCT03056209|Drug|KL1333 800 mg|oral administration, single dose, 100 mg 8 tabs
45655255|NCT03056209|Drug|Placebo|oral administration, placebo
45655256|NCT02457819|Drug|Dasotraline|Dasotraline 2 mg, 4 mg, 6 mg, once daily, flexibly dosed
45655257|NCT03056053|Drug|Zolpidem|Commercially available tablets of zolpidem (5 or 10 mg) for oral use
45655258|NCT04914325|Combination Product|peek|After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction
45655259|NCT04922905|Other|NEURO +|"The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~the Peri traumatic distress inventory (Jehel et al., 2005)~and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)~Neuro + patients will also have a Brain MRI, cerebrospinal fluid analysis, EEG, as well as an ambulatory sleep recording and electromyography depending on the symptoms observed."
45655260|NCT04922905|Other|NEURO -|"The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~the Peri traumatic distress inventory (Jehel et al., 2005)~and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)"
45806394|NCT05572684|Drug|NC410|NC410 will be given intravenously (IV) every 2 weeks
45806395|NCT05572684|Drug|Pembrolizumab|Pembrolizumab 400mg will be given IV every 6 weeks.
45806396|NCT05572515|Drug|Teclistamab|Teclistamab will be administered subcutaneously.
46074625|NCT02859545|Behavioral|Emotional Validation Training for Romantic Partners|In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to validate the individual with chronic pain's pain-related distress and given education about validation. This involves an approximately 45-minute brief, interactive training.
45452836|NCT03455608|Behavioral|PRO-ACTIVE EAT + EXERCISE|Early high intensity proactive intervention started before RT commences
45452837|NCT00836056|Drug|Clindamycin 300 mg capsule|1 x 300 mg
45452838|NCT00836056|Drug|Cleocin HCl 300 mg capsules|1 x 300 mg
45655261|NCT04914559|Other|Oral nutrition supplement - control|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.
45655262|NCT04914559|Other|Oral nutrition supplement - test|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.
45655263|NCT02496039|Drug|NUEDEXTA®|NUEDEXTA® only
45655264|NCT04911205|Other|Preoperative training program|Patients of intervention group (N=44) followed a 6-week supervised high-intensity preoperative training program. They had a session of preoperative resistance training five days per week for a period of 6 weeks before TKA. Each session was supervised by a physiotherapist specifically trained in progressive resistance training. The duration of each session was approximately 60 minutes. If a participant missed a training session, it was attempted to substitute the session on an alternative day.
45655265|NCT04922307|Procedure|Blood Sparing Protocol|Acute Normovolemic Hemodilution, Cell Saver, and/or Veno-venous Bypass
45655266|NCT04922307|Procedure|Standard Blood Replacement|Allogenic blood transfusion as determined intra-operatively
45655267|NCT04911283|Other|Brucella serology test|MCs type 1 and type 2 patients were examined in terms of Brucella serology by using agglutination with Coombs test.
45452839|NCT03200912|Drug|Ingenol Mebutate (Picato®)|Brand product
45806397|NCT05572515|Drug|Pomalidomide|Pomalidomide will be administered orally.
45806398|NCT05572515|Drug|Bortezomib|Bortezomib will be administered subcutaneously.
45806399|NCT05572515|Drug|Dexamethasone|Dexamethasone will be administered orally in PVd and intravenously or orally in Kd.
45806400|NCT05572515|Drug|Carfilzomib|Carfilzomib will be administered intravenously.
45806401|NCT05569759|Drug|zetomipzomib|Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
45806402|NCT05569759|Drug|placebo|Subcutaneous injection of placebo
45806403|NCT05569759|Drug|zetomipzomib in open-label extension|Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
45940828|NCT00103935|Drug|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 0.8 mcg.
45940829|NCT00103935|Drug|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 2.0 mcg.
45940830|NCT00399152|Drug|Perifosine|Perifosine Oral Dose
45940831|NCT00399152|Drug|Sunitinib Malate|Sunitinib oral dose
45940832|NCT00252031|Behavioral|Dialectical Behavioral Therapy|
45940833|NCT00103974|Biological|BHT-3009-01|
45655268|NCT04911283|Other|Medical history for brucellosis|Both of the MCs groups and healthy controls were investigated for their medical history regarding brucellosis.
45940834|NCT04719559|Device|Laser-assisted drug delivery|All patients received treatment using the same protocol with the same fractional ablative carbon dioxide laser (eCO2 PlusTM, manufactured by Lutronic, South Korea). Each patient was applied with Lidopin 5% cream (Panion & BF Biotech Inc.), which remained on the scar for 30 min for pain relief before each laser course. Later, the Lidopin 5% cream was gently removed using a normal saline-rinsed gauze, and the scar was treated with a fractional ablative carbon dioxide laser with two passes under a 10,600 nm wavelength, 120 mm spot size, pulse energy of 50 mJ, 30 W of power, and a density of 200. A topical steroid cream (clobetasol propionate, 0.05%) was evenly applied on the scar gently back and forth using a cotton swab immediately after the laser treatment. The patients underwent five full courses by the same doctor according to the same protocol, with each course given 4 weeks apart.
45940835|NCT00252070|Behavioral|Functional Exercise for People with Arthritis (FEPA)|
45655269|NCT02441283|Drug|ABT-493|ABT-493 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
45940836|NCT00069056|Procedure|Laser Treatment|
45806404|NCT05567289|Procedure|Blood sample collection|"Enrolled patients will undergo sequential blood collection beginning prior to conditioning, then on the day of transplant (day 0), followed by days 7, 14, 21, 28, 56 (2 months) and 90 (3 months) post-transplant.~Bone marrow aspirates taken within this period as part of routine care will also be collected, these are typically performed around day 100 and whenever there is suspicion of disease recurrence.~The study will also collect an additional blood sample at the onset of treatment for aGvHD for those who receive systemic corticosteroids (PO or IV steroid equivalent to ≥0.5mg/kg prednisolone)."
45806405|NCT05567289|Procedure|Bone marrow aspirate|Bone marrow aspirates taken within this period as part of routine care will also be collected, these are typically performed around day 100 and whenever there is suspicion of disease recurrence.
45940837|NCT00252109|Behavioral|Popular Opinion Leader|Popular opinion leaders of social networks are identified and attend 4 sessions to prepare them to have casual conversations with persons in the social networks that are meant to shift social norms to embrace safer behaviors (e.g., increased condom use, fewer sexual partners)
45940838|NCT04719598|Behavioral|congnitive behavioural therapy|CBT Sessions divide into three main components; 1) cognitive interventions, concerns with cognitive restructuring attempts to change maladaptive thought about thoughts about sleep into more adaptable . 2) Behavioral intervention: concerns with Relaxation training, stimulus control, and sleep restriction promote relaxation and help to establish healthy sleep habits. 3) Psychoeducational interventions: Providing information about the connection between thoughts, feelings, behaviors, and sleep.
45940839|NCT00104013|Drug|xaliproden (SR57746A)|
45940840|NCT00252148|Biological|ADMVA|experimental HIV vaccine, MVA vector expressing HIV clade C env, gag, pol, nef, and tat
45940841|NCT00069134|Dietary Supplement|sulfur amino acids|Sixteen (16) children with edematous SCU will be randomly assigned to either a supplement of SAA or an isonitrogenous amount of alanine
45940842|NCT04719715|Diagnostic Test|Indirect immunofluorescence (IIF) , myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays|Measurement and evaluation of the ANCA testing
45940843|NCT00252226|Drug|Quetiapine|
45940844|NCT04719754|Diagnostic Test|Vaginal swab|The other vaginal swab will be cultured on blood agar, chocolate agar, MacConkey agar and Sabourauds dextrose agar. The cultures will be incubated at 37ºC for 24-96 h or until the colonies appear.
45940845|NCT00100347|Drug|PPI-2458|
45452840|NCT03200912|Drug|Generic Ingenol Mebutate|Generic formulated to have the same therapeutic effect of the brand
45806406|NCT05567185|Drug|Erdafitinib Intravesical Delivery System|Erdafitinib intravesical delivery system will be administered.
45806407|NCT05567120|Other|PATH-Care|Individuals will receive the 8-session PATH-Care intervention, delivered virtually (via videoconference or phone) to mitigate negative emotions and stress experienced by informal caregivers of individuals with ADRD. The therapist in the first session will also guide the participant in the tablet-based exercises (WELLPath).
45806408|NCT05566756|Other|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.
45806409|NCT05566730|Behavioral|CT-MICART App|App designed with the goal of treating CUD in African American adults
45940846|NCT00252304|Drug|Zinc (zinc sulphate)|Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
45940847|NCT00252304|Drug|Placebo|Placebo
45452841|NCT03200912|Drug|Vehicle Foam|It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
45452842|NCT00806806|Drug|SKY0402|Local administration of SKY0402 followed by noxious stimulus
45452843|NCT00806806|Drug|Placebo|Local administration of Placebo followed by noxious stimuli
45940848|NCT00069173|Behavioral|Project FAB (Fitness and Bone)|
45940849|NCT00252343|Drug|SR58611A|
45940850|NCT00252421|Drug|Nitroglycerin ointment 15 mg/day daily for 24 month|Nitroglycerin ointment 15 mg/day applied daily for 24 mth
45452844|NCT00799552|Drug|RX-10045|RX-10045 eye drop
45452845|NCT00799552|Drug|Placebo|Placebo eye drop
45655270|NCT02441283|Drug|ABT-530|ABT-530 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
45655271|NCT04922359|Drug|Lidocain|Patients received 1.5mg/kg of intravenous lidocaine during induction of anesthesia and 1.5 mg/kg/h for anesthesia maintenance.
45940851|NCT00252421|Drug|Placebo ointment daily for 24 month|Placebo ointment applied daily for 24 mth
45940852|NCT00252460|Device|Computed Tomography Scan and Magnetic Resonance Imaging|
45940853|NCT00252616|Behavioral|trophic enteral feeds|10cc/hr
45940854|NCT00252655|Drug|Rapamune and Prograf|
45940855|NCT00252772|Drug|Tesaglitazar|
45940856|NCT00252772|Behavioral|Dietary and Lifestyle counseling|
45940857|NCT00252811|Drug|Gefitinib|
45940858|NCT00069251|Drug|Bupropion|
45940859|NCT00252889|Drug|Topotecan and pegylated doxorubicin|Doxil 40 mg/m2 day 1 and topotecan was to be escalated in cohorts of patients
45655272|NCT04922359|Drug|normal saline|Patients received 0.075ml/kg of intravenous normal saline during induction of anesthesia and 0.075ml/kg/h for anesthesia maintenance.
45655273|NCT03054493|Behavioral|no intervention|no intervention
45940860|NCT00252928|Other|Sodium dichloroisocyanurate (NaDCC) tablets|Intervention arm receives NaDCC tablets to use for to disinfect their household water for use for 20L of water. Ideally, disinfection occurs every day.
45655274|NCT04910737|Procedure|extended posterior circumferential decompressive surgery|After the pedicle screws were implanted, laminectomy was performed. Kyphotic correction was done through a temporary rod to reduce the tension of spinal cord. The posterior 1/3 of the vertebral body was resected using a high-speed drill, preserving the anterior wall of the spinal canal to protect the cord from disturbance. The dissection of adhesion at the anterior side of spinal cord was to be done through a posterolateral direction. The region of posterior resection was expanded, including bilateral residual articular processes, transverse processes and pedicles. Slightly press down the ossified lesion, and detach it from the dura mater (perform a sharp dissection if necessary) followed by completely removal. If cerebrospinal fluid leakage was encountered during the process, autologous fat, fascia or gelatin sponge can be applied locally for packaging.
45655275|NCT02495883|Other|Ethanol|50ml of 40% Ethanol
45655276|NCT02495883|Drug|Propranolol|Beta blocker
45655277|NCT04910893|Device|Cytokine Adsorption|Cytokine adsorption therapy will be provided continuously for 72 hours by means of the CytoSorb® (CytoSorbents Corporation, Monmouth Junction, USA) column, run in series to a veno-venous continuous hemodialysis system, which will be exchanged every 24 hours.
45655278|NCT04910893|Other|Standard of Care|Standard intensive care of patients suffering septic shock
45655279|NCT02495025|Behavioral|Telephone-based developmental screening and care coordination|
45655280|NCT04910659|Other|acupuncture|P6, LI4 and LI 11 stimulation
45806410|NCT05566730|Behavioral|Control|App designed with the goal of treating CUD in African American adults, with participants just tracking their use of cannabis and not receiving treatment videos
45452846|NCT01983410|Behavioral|The risk assessment questionnaire|
45806411|NCT05566561|Drug|Postoperative analgesia management|Intravenous 0.5 mg/kg tramadol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. Patients in all groups will be attached to IV PCA containing 10 mcg/ml fentanyl, 10 mcg bolus without infusion dose, and 10 min lock time protocol. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
46074626|NCT02859545|Behavioral|Chronic Pain Education Training for Romantic Partners|In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to ask health professionals questions about treatment options and given health education about chronic pain. This involves an approximately 45-minute brief, interactive training.
46074627|NCT02798718|Dietary Supplement|full-fat milk|intake 250ml full-fat milk per day, do not intake any other dairy products
46074628|NCT02857907|Other|Blood sample|A blood sample is performed one year after kidney transplantation.
46074629|NCT04236570|Device|Thermode(hot plate) and cold water bath|Standardized protocol will consisted of stimulus test (TS) generated by thermode and conditioning stimulus (CS) using cold water bath.
46074630|NCT04236570|Device|TENS(transcutaneous electrical nerve stimulation)|TENS protocol will consisted of test stimulus (TS) and conditioning stimulus (CS) both generated by TENS
46074631|NCT02798640|Device|Celliant|100% Celliant garment
46074632|NCT02798640|Device|Control|Control Garment
45655281|NCT04910347|Drug|Nivolumab|"Dosage within 12 weeks after the end of concurrent chemoradiation therapy. Nivolumab 360mg Intravenously administered every 3 weeks.~As a consolidation regimen, administration of Nivolumab is administered for up to a total of 1 year until disease progression or unacceptable to toxicity occurs."
45655282|NCT04914169|Device|ICRS|The ICRS enables a stationary bike to automatically adjust the pedaling resistance (i.e. training intensity) according to the subject's heart rate. The training intensity is determined by monitoring whether the subject is able to maintain a 50-70 cycles/min cadence with 60-80% HRR. Subjects heart rate was detected by a wearable device for heart rate, synching with the stationary bike.
45655283|NCT02439957|Drug|Brincidofovir|
45655284|NCT02439957|Drug|Valganciclovir|
45655285|NCT04913857|Behavioral|24-week SUDOKU Training Programme|12-week face-to-face training session and a 12-week facilitated self-practice
45655286|NCT04913857|Other|Control Arm (wait-list)|wait-list comparison group will receive the same program upon completion of the 6-month posttest evaluation on study outcomes
45655287|NCT04914013|Other|no intervention|no intervention
45655288|NCT02494401|Other|Internet-based self-management program|
45655289|NCT02494401|Other|Scleroderma book|
45655290|NCT03054415|Procedure|endoscopy|colonic biopsies during endoscopy and anal manometry with barostat and anal endoflip
45806412|NCT05564377|Drug|Binimetinib|Given PO
45806413|NCT05564377|Procedure|Biopsy|Undergo biopsy
45806414|NCT05564377|Procedure|Biospecimen Collection|Undergo blood collection
45806415|NCT05564377|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
45806416|NCT05564377|Procedure|Bone Scan|Undergo bone scan
45940861|NCT00252928|Other|Placebo|Placebo
45940862|NCT00100386|Procedure|Intensive Control Strategy|
45940863|NCT00100386|Behavioral|Standard Control Strategy|
45940864|NCT00253006|Procedure|Tissue examination for protein- and mRNA-expression of NO|
45940865|NCT00253045|Behavioral|Motivational groups|Motivational interviewing in group format
45940866|NCT00253084|Drug|IPX054 200 mg|IPX054 containing 50 mg carbidopa and 200 mg levodopa
45940867|NCT00253084|Drug|CD-LD IR|CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
45655291|NCT04922515|Other|Oral and rectal swabs for microbiome sequencing|Oral swabs and rectal swabs are collected non-invasively.
45940868|NCT00253084|Drug|IPX054 Placebo|Placebo to match IPX054 200 mg
45655292|NCT04922437|Procedure|Native bladder implantation|Continent catheterizable channel implanted in the detrusor of the native bladder
45655293|NCT04922437|Procedure|Enterocystoplasty implantation|Continent catheterizable channel implanted by seromuscular plicature on the front wall of the bladder augmentation
45655294|NCT04913545|Diagnostic Test|using salivary miRNA (412,512)|quantitative real time polymerase chain reaction to detect the salivary miRNAs 412,512) to indicate the malignant transformation in potientially malignant oral lesions.
45940869|NCT00253084|Drug|CD-LD IR Placebo|Placebo to match CD-LD IR
45655295|NCT04913935|Diagnostic Test|Muscle-Skeleton Ultrasonography|postero-anterior radiography
45452847|NCT01983410|Other|Blood specimens|
45655296|NCT04910191|Diagnostic Test|Electronic stethoscope|Electronic stethoscope
45655297|NCT02457195|Drug|granisetron|Application granisetron transdermal patch preoperatively
45655298|NCT04913779|Drug|Anti-SARS-CoV-2|Purified F(ab')2 Fragments of Equine hyperimmune Serum with anti-SARS-CoV-2 neutralizing activity (titer 1/5120 or higher)
45655299|NCT04913779|Drug|Placebo|Administration of 10 ml of a control-solution without neutralizing activity against SARS-CoV-2, administered in slow intravenous infusion (10 ml diluted in 100 ml of saline solution, administered over 50 to 60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0 when incorporated into the study -initial dose- and at 48 hours -second dose-).
45655300|NCT04904497|Behavioral|Early Occupational Therapy|"Occupational therapists will implement the following activities:~Polysensory stimulation: external stimulation for increasing the level of alertness. It will be implemented with SAS 2 one session each 24 h.~Cognitive stimulation: bundle of exercises for activating mental functions, i.e: alertness, visual perception, memory, calculus, problem solving, praxis, language. Patients with SAS 3, 4 and 5. In SAS <2, 6> environmental orientation will be considered~Basic activities of daily living (BADLs): promotion of independence that initially practice hygiene, personal grooming. Patients with SAS 3, 4 and 5~Motor function Stimulation: exercises to keep the patient's upper extremities active and functional. Patients with SAS with 3,4 and 5. Patients with SAS 1 and 2 will use adaptations to prevent edema and bedsores on vulnerable body areas~Education: trained family members and health staff about the intervention process"
45655301|NCT04913623|Procedure|Hip Replacement|The hip replacement surgery is when a damaged hip is replaced with artificial one
45655302|NCT03054259|Drug|Rituximab|1000mg rituximab infusions on days 1 and 15 (monoclonal antibody)
45655303|NCT03054259|Drug|Methylprednisolone|100mg infusion on days 1 and 15
45655304|NCT03054259|Drug|Normal Saline|250ml infusion on days 1 and 15
45655305|NCT02456727|Procedure|Group/Community Acupuncture|Acupuncture treatment in a group setting.
45940870|NCT00253123|Drug|risperidone|
45940871|NCT00069407|Procedure|Electroconvulsive Therapy|Electroconvulsive therapy
46074633|NCT02798562|Device|Native and dynamic contrast-enhanced CT|
45452848|NCT01983410|Other|tumor tissue samples will be requested|
45655306|NCT02456727|Procedure|Individual Acupuncture|Acupuncture treatment in an individual setting.
45655307|NCT03054025|Device|Smart Phone Monitoring Device|Use activity tracker application
45655308|NCT04910035|Other|Exercises Training|SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
45655309|NCT03052387|Other|assigned intervention|"* Local anesthesia with vasoconstrictor(V.C) used for hemostasis.~chin block graft~Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~The donor site is usually the chin area, its approached using local anesthesia with VC at symphysis region.~Low vestibular incision exposing the symphysis area to the inferior border of the mandible.~Using fissure bur to harvest the graft for the defect.~Closure using vicryl 3-O sutures."
45655310|NCT04909879|Biological|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
45655311|NCT04909879|Drug|Placebo|Excipient solution
45655312|NCT04894513|Other|Kabat motor control re-education therapy|Kabat motor control re-education therapy that includes specific movements with predefined patterns of facial muscles exercises, which is spiral and diagonal movements involve the facial muscles, which are brought to train in global patterns. The program of treatment for three times per week for six weeks.
45806417|NCT05564377|Procedure|Computed Tomography|Undergo CT
45806418|NCT05564377|Procedure|Echocardiography|Undergo ECHO
45806419|NCT05564377|Drug|Fluorouracil|Given IV
45806420|NCT05564377|Drug|Fulvestrant|Given IM
45806421|NCT05564377|Drug|Ipatasertib|Given PO
45806422|NCT05564377|Drug|Leucovorin|Given IV
45806423|NCT05564377|Procedure|Magnetic Resonance Imaging|Undergo MRI
46074634|NCT00617773|Biological|hu3S193|20 mg/m2, intravenous, weekly for a maximum of 3 cycles (of 8 weeks each)
45806424|NCT05564377|Procedure|Multigated Acquisition Scan|Undergo MUGA
45806425|NCT05564377|Procedure|Mutation Carrier Screening|Undergo tumor mutational screening
45806426|NCT05564377|Drug|Nilotinib Hydrochloride Monohydrate|Given PO
45806427|NCT05564377|Drug|Olaparib|Given PO
45806428|NCT05564377|Drug|Oxaliplatin|Given IV
45806429|NCT05564377|Drug|Paclitaxel|Given PO or IV
45806430|NCT05564377|Drug|Palbociclib|Given PO
45806431|NCT05564377|Biological|Panitumumab|Given IV
45940872|NCT00253162|Drug|risperidone|
45940873|NCT00253201|Drug|galantamine hydrobromide|
45940874|NCT00253240|Procedure|Screening|
45940875|NCT00253240|Procedure|Management|
45655313|NCT04894513|Other|conventional selected program|the conventional selected program in the form of electrical stimulation (Faradic current) of affected muscles, facial muscle exercise program in front of the mirror, and home advices.
46074635|NCT00956813|Dietary Supplement|flaxseed|Given orally
45940876|NCT00100425|Procedure|Viceral Perception Testing|
45452849|NCT00835666|Drug|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
45655314|NCT04921137|Other|No endocrine therapy|No endocrine therapy given
45806432|NCT05564377|Procedure|Positron Emission Tomography|Undergo PET
45655315|NCT04921137|Other|Endocrine therapy|Endocrine therapy given for at least 5 years
45655316|NCT04894201|Radiation|Dental Panoramic Radiographs|Exposure to dental panoramic radiographs
46074636|NCT00956813|Other|placebo|Given orally
45655317|NCT03052465|Other|Test soup meal feeding intervention|Cream of chicken soup (400g) (or mushroom for vegetarians) (Heinz, Wigan, UK) used as a test meal intervention. The nutrient content /100g is: energy (kcal) 51, protein (g) 1.5, carbohydrate (g) 4.7, fat (g) 2.93
45655318|NCT04893889|Diagnostic Test|Shear-wave elastography|Myocardial shear wave elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity.
45655319|NCT02456103|Drug|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
45452850|NCT00835666|Drug|PROSCAR®|1 x 5 mg, single dose fasting
45452851|NCT00835588|Drug|Pantoprazole Sodium 40 mg delayed-release tablets|1 x 40 mg
45655320|NCT04894357|Other|Phenotypic resistance measure|SDM experiments: Reverse transcriptase mutants of HIV-1 will be obtained by site-directed mutagenesis using specific primers introducing the expected mutations into plasmids pNL4.3 and CRF02_AG. HIV-1 stocks will be obtained by transfecting 293-T cells with the various HIV-1 molecular clones. 48 hours after transfection, the viral supernatants will be recovered, quantified for HIV-1p24gag antigen (Vidas BioMérieux) and frozen at -80°C.The single-cycle virus titers will be determined on HeLa-P4 cells in which the expression of b-galactosidase is inducible by the HIV Tat protein. Phenotypic analysis: creation of replication competent chimeric viruses through homologous recombination between patient or laboratory virus-derived PCR fragments and the corresponding NL4-3 vector where the whole Gag-PR, RT-RNaseH or IN coding regions have been deleted through inverse PCR. The susceptibility to Doravirine will be calculated through a single round infection assay in TZM-bl cells.
45655321|NCT04909411|Other|OPHTHALMOLOGICAL ASSESSMENT|assessment of eye mobility (search for heterophoria or strabismus), visual acuity, visual fields, external structures and funduscopic examination
45655322|NCT04909411|Other|NEUROPSYCHOLOGICAL ASSESSMENT|completion of WISC-5, Vineland Adaptive Behavior Scale II and Strengths and Difficulties Questionnaire
45655323|NCT04399603|Other|no intervention-mechanistic study|no intervention-mechanistic study
45655324|NCT01653327|Drug|Ketamine|Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
45806433|NCT05564377|Drug|Selumetinib Sulfate|Given PO
45806434|NCT05564377|Drug|Sotorasib|Given PO
45806435|NCT05562453|Device|FlowOx 2.0|Subjects randomized to tretament with the investigational device will receive treatment with -40 mmHg intermittent negative pressure for 60 minutes per day.
45940877|NCT00253279|Procedure|PET Scans|Healthy volunteers will undergo one PET Scan; bur patients will undergo a maximum of 3 PET scans over 2 years after injury; a maximum of 2 will be done while inpatient; one after d/c.
45940878|NCT02966678|Procedure|Color Vision Test|Farnsworth Panel D15/Hue test plus Ishihara charts
45940879|NCT00253318|Drug|Docetaxel|40 mg/m^2 IV over 1 hour on Day 1.
46074637|NCT00860119|Drug|alprazolam sublingual tablet|1 mg alprazolam sublingual tablet, given as a single dose to each subject
46074638|NCT00860119|Drug|alprazolam oral tablet|1 mg alprazolam immediate release oral tablet, given as a single dose to each subject
46074639|NCT02802930|Drug|SPF 50 Y65 110 (BAY987519)|Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
46074640|NCT02802930|Drug|SPF 50 Y51 002 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
46074641|NCT02802930|Drug|SPF 15 V27 104 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
45452852|NCT00835588|Drug|PROTONIX® 40 mg delayed-release tablets.|1 x 40 mg
45655325|NCT01653327|Drug|Placebo|
45655326|NCT04903561|Device|ColliPee|The GP will hand over the self-sampling kit to the women, after obtaining informed consent, and the women then takes the self sample at home or in the doctor's office (predefined), according to the respective users manual.
45655327|NCT03053869|Drug|Benzodiazepine - limited use strategy|"No routine use of any intraoperative benzodiazepines.~Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia."
45655328|NCT03053869|Drug|Benzodiazepine - Ad libitum strategy|"Administration of some benzodiazepine to most patients undergoing cardiac surgery.~Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy)."
45806436|NCT05562453|Device|FlowOx2.0 (Sham)|Subjects randomized to treatment with the comparator will receive treatment with -10 mmHg intermittent negative pressure for 60 minutes per day.
45806437|NCT05558696|Drug|bomedemstat|LSD1 inhibitor
45806438|NCT05558150|Drug|Ilaprazole|Ilaprazole 10mg
45806439|NCT05558150|Drug|Aceclofenac|Aceclofenac 100mg
45940880|NCT00253318|Drug|RAD001|30 mg orally on Days 1 and 8.
45940881|NCT00253318|Drug|Dexamethasone|8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
45940882|NCT00100464|Drug|Paroxetine|
45940883|NCT00100464|Drug|5HTP|
45940884|NCT00253396|Drug|Unfractionated heparin|
45940885|NCT00253396|Drug|Enoxaparin|
45655329|NCT03053947|Drug|Intranasal Ketamine|Administration of intranasal ketamine at a dose from 3 to 9 mg/kg for safe and effective procedural sedation for laceration repair in the ED for children aged 1 to 12 year-old.
45655330|NCT04893733|Drug|Vitamin B Complex|"Patients with established AKI will be randomized to received IV vitamin B complex each 1 hours for 5 consecutive days versus placebo.~Every patients will also received Institution standard of care for AKI"
45655331|NCT04893421|Device|MOLLI Localization|Patients will be implanted with a MOLLI seed using a specialized introducer needle under imaging guidance. A special handhold probe and detection system will be used intraoperatively to assist in excision.
45655332|NCT04903483|Other|bispectral index monitoring|intraoperative single-channel electroencephalography monitoring of the depth of anesthesia
45655333|NCT04903405|Other|No intervention|No intervention is involved in this study
45655334|NCT04903639|Diagnostic Test|sleep study|The polysomnography consists of electroencephalogram (EEG), electrooculogram (EOG), electrocardiogram (ECG), electromyogram (EMG), pulse oximetry, thoracic and abdominal straps, body posture sensor, nasal thermistor and nasal cannula to assess respiratory flow and pressure and bipolar channel limb movements (tibialis anterior). Electrodes and sensors were attached to patients by sleep physiologist. Data collection was obtained following signal perception by preprocessed computer (DOMINO Software, ver. 2.6.0; SOMNO Medics GmbH).
45655335|NCT03051139|Behavioral|Multi-component LTVV implementation strategy|Multicomponent LTVV implementation strategy consisting of: 1) physician orientation, 2) physician audit and feedback, and 3) clinical decision support comprised of a) an ARDS screening tool using a natural language processing (NLP) algorithm, b) EHR-based tasks for clinicians to complete, and c) a clinician reminder system.
45655336|NCT03053323|Behavioral|Lifestyle Intervention|The lifestyle intervention consists of three components: nutrition, physical activity, and other areas of wellness. The intervention is administered individually each week for 10 weeks and is tailored for women with a history of depression who are in the first trimester of pregnancy or trying to conceive.
45655337|NCT03053557|Behavioral|Social Skills Coach|Social Skills Coach is a multi-platform interactive device that engages users with information and skills learned in social skills training programs. The program includes a web application and provider dashboard and encourages users to practice skills on the app and use them in the real world and then report how the application of skills was experienced.
45655338|NCT04903171|Other|INCENTIVE VISITING A GARDEN : ENRICHED OR CONVENTIONAL SENSORY GARDEN|Carers invites every the participants of group 2 and 3 visiting their respective gardens (enriched or conventional sensory garden)
45655339|NCT03053635|Drug|TLD1433 infusion and photodynamic therapy (PDT) treatment|TLD1433 is infused into the bladder, followed by repeated rinsing and treatment of bladder wall with photodynamic therapy (PDT).
45655340|NCT03053011|Other|Vibrating bracelet|A bracelet with vibrations triggered randomly overnight. The sleeper's awakening capability will be evaluated each time the bracelet vibrates (5 times in the night).
45655341|NCT04909489|Other|cross-sectional study without intervention|cross-sectional study without intervention
45655342|NCT04893031|Drug|Tocilizumab|400mg or 800 mg IV tocilizumab treatment according to patient clinical severity
45655343|NCT02493855|Drug|Ombitasvir/ABT-450/Ritonavir|Ombitasvir/ABT-450/ritonavir combination tablets
45655344|NCT02493855|Drug|Dasabuvir|Dasabuvir tablets
45655345|NCT02493855|Drug|Ribavirin (RBV)|Ribavirin tablets
45655346|NCT04147585|Other|Intermittent Reduced Calorie Diet (IRCD)|Three cycles of a 5-day Intermittent Reduced Calorie Diet over three months.
45655347|NCT04902157|Diagnostic Test|Cycle threshold|cycle threshold number
45655348|NCT04892563|Procedure|Erector Spinae Plane Block|Nerve block with local anesthetic in the erector spinae plane
45806440|NCT05556447|Behavioral|Internet delivered pain coping skills training|Participants in the intervention group will complete 8 weeks of pain coping skills training delivered online
45806441|NCT05554380|Procedure|Biopsy|Undergo tumor biopsy
45806442|NCT05554380|Procedure|Biospecimen Collection|Undergo blood collection
45940886|NCT00069446|Drug|rhuMAb VEGF (telbermin)|
45655349|NCT04892563|Drug|IV Analgesia|IV analgesia, typically Morphine/Opioid medications
45940887|NCT00253474|Biological|PEG-interferon alfa-2a|
45940888|NCT00253552|Biological|filgrastim|
45940889|NCT00253552|Drug|busulfan|
45940890|NCT00253552|Drug|cyclophosphamide|
45655350|NCT04892251|Combination Product|MORE+KAP|Mindfulness-Oriented Recovery Enhancement plus two sessions where 0.5 to 1.5 mg/kg of ketamine are administered intramuscularly
45655351|NCT04892251|Behavioral|MORE|Mindfulness-Oriented Recovery Enhancement
45655352|NCT04909255|Drug|mirabegron|use beta-3 agonist for sjogren syndrome patient
45655353|NCT04909255|Drug|oxybutynin, tolterodine, solifenacin|use anti-muscarinic agent for patient with overactive bladder syndrome
45806443|NCT05554380|Procedure|Computed Tomography|Undergo CT scan
45806444|NCT05554380|Drug|Ipatasertib|Given PO
45806445|NCT05554380|Procedure|Magnetic Resonance Imaging|Undergo MRI
45806446|NCT05554380|Drug|Paclitaxel|Given IV
45806447|NCT05552859|Drug|Insulin glargine 300 U/mL|Insulin glargine 300 U/mL in the SoloStar pen, self-administered once daily for 24 weeks.
45806448|NCT05552859|Drug|Insulin degludec 100 U/mL|Insulin degludec 100 U/mL will be self- administered once daily for 24 weeks.
45806449|NCT05550532|Drug|Aticaprant|Aticaprant tablet will be administered orally.
45940891|NCT00253552|Drug|cyclosporine|
45940892|NCT00253552|Drug|etoposide|
45940893|NCT00253552|Drug|methotrexate|
45940894|NCT00253552|Procedure|allogeneic bone marrow transplantation|
45940895|NCT00253552|Radiation|radiation therapy|
45940896|NCT00253591|Drug|cisplatin|
45940897|NCT00253591|Drug|vinorelbine tartrate|
45940898|NCT00253591|Radiation|radiation therapy|
45655354|NCT03052231|Device|caremessage|Central to the mobile health information service is the interactive and personalized text-based message system that delivers actionable and tailored health content to participants: office visit appointment reminders; medication adherence reminders; and general health education messages.
45940899|NCT00253669|Other|laboratory biomarker analysis|
45940900|NCT00253669|Other|physiologic testing|
45806450|NCT05550532|Other|Placebo|Placebo tablet will be administered orally.
45655355|NCT04891939|Other|Health education lessons (Smart-Kid's program)|The intervention is designed for all students, including never-smokers and students at high risk for smoking. Therefore, some contents are intended to influence those high-risk youth within the larger student audience by targeting the stages of the smoking acquisition process including, preparation, initiation, experimentation, regular use, and addiction (Mayhew et al., 2000). The intervention is also focused on addressing risk factors for smoking initiation and continue use (Hansen et al., 2015; So & Yeo, 2015). These risk factors are, therefore, grouped into four major groups namely; personal factors, behavioral factors, environmental factors and sociodemographic factors
45940901|NCT00253669|Procedure|management of therapy complications|
45940902|NCT00253786|Other|Intensive multifactorial therapy|Blood glucose control: HbA1c < 6.2% Blood pressure control: SBP < 125 mmHg, DBP: < 75 mmHg Lipid profile: T-cho < 180 mg/dl, LDL-cho < 100 mg/dl, HDL-cho >40 mg/dl Dietary intervention: TDEI < 30 kcal/kg/day, sodium < 5 g/day, protein < 0.8 g/kg/day Pharmacological intervention: ACE-Is or ARBs, HMG-CoA reductase inhibitors, multivitamins Instruction by co-medicals: Taking medicines, smoking cessation, nutrition care
45940903|NCT00253786|Other|Standard therapy|Blood glucose control: HbA1c < 6.9% Blood pressure control: SBP < 130 mmHg, DBP: < 80 mmHg Lipid profile: T-cho < 200 mg/dl, LDL-cho < 120 mg/dl, HDL-cho >40 mg/dl, Dietary intervention: TDEI < 25-30 kcal/kg/day, sodium < 6 g/day, protein < 1.0 g/kg/day Pharmacological intervention: No restrictions (continuing prior therapy) Instruction by co-medicals: No restrictions (continuing prior therapy)
45940904|NCT00069524|Drug|oyster mushroom|
45940905|NCT00253825|Device|mCIMT combined with or without eye patching|
45940906|NCT04719481|Drug|Pravastatin Sodium 80 MG|daily oral administration of 80mg
45655356|NCT04891939|Other|School Health and Education Program (SHEP)|The SHEP is the usual health and education program been done in all schools, and also has tobacco control component. This is will be used as the control for the intervention.
45655357|NCT04892095|Other|No intervention|This is an observational cross-sectional study. No intervention is considered.
45806451|NCT05548556|Drug|Placebo|Participants will receive subcutaneous (SC) placebo every 4 weeks (Q4W)
45940907|NCT04719481|Drug|Placebo|daily oral administration
45940908|NCT00253903|Drug|eplivanserin (SR46349)|oral administration
45806452|NCT05548556|Drug|RO7204239|Participants will receive SC RO7204239 Q4W
45806453|NCT05544552|Drug|TYRA-300|TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.
45806454|NCT05538130|Drug|PF-07799544|Tablet
45940909|NCT00253903|Drug|placebo|oral administration
45940910|NCT00253942|Procedure|Injecting bee venom as a treatment for OA|
45655358|NCT04891861|Drug|Apixaban|Direct Oral Anticoagulation all at label dose and frequency
45806455|NCT05538130|Drug|PF-07284890|Tablet
45806456|NCT05538130|Drug|PF-07799933|Tablet
45806457|NCT05538130|Drug|encorafenib|Capsule
45806458|NCT05537740|Drug|BAY3375968|Intravenous (IV) infusion
45806459|NCT05537740|Drug|Pembrolizumab|IV infusion
45806460|NCT05536791|Drug|Dabigatran Etexilate (DE)|Dabigatran Etexilate (DE)
45806461|NCT05536440|Drug|PF-07261271|IV or SC
45806462|NCT05536440|Drug|Placebo|IV or SC
45806463|NCT05535946|Drug|ABX464|Administered once daily in the morning with food
45806464|NCT05535946|Drug|Placebo|Administered once daily in the morning with food
45806465|NCT05535244|Drug|Cevostamab|Cevostamab will be administered by IV infusion in 21-day cycles.
45806466|NCT05535244|Drug|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
45940911|NCT00069563|Behavioral|Reaching Educators, Children, and Parents (RECAP)|
45940912|NCT00104130|Drug|KOS-862|
45940913|NCT00254020|Drug|Citalopram|Patients who are found to have major depression will be referred to a psychologist
45940914|NCT00254059|Procedure|Ambulatory diagnosis and titration with nasal CPAP using over night oxymetry and auto CPAP and vs conventional diagnosis and titration using polysomnography|
45940915|NCT00254137|Drug|capecitabine|
46074642|NCT02802930|Drug|Sodium chloride [NaCl]|Negative control (200 µL, 0.9% sodium chloride [NaCl]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
45940916|NCT00254137|Drug|irinotecan|
45940917|NCT00254137|Drug|oxaliplatin|
46074643|NCT00855283|Drug|IN NEO|20 mg Neostigmine via intranasal and sublingual administration
46074644|NCT00855283|Drug|IN NEO|40 mg Neostigmine via intranasal administration
46074645|NCT00855283|Drug|IN NEO|60 mg Neostigmine via intranasal administration
45806467|NCT05531292|Device|Model C0002|Eligible subjects will be randomized in a 1:1 ratio to the investigational IOL Model C0002 in both eyes for the duration of the study.
45806468|NCT05531292|Device|Model ZCB00/DCB00|Eligible subjects will be randomized in a 1:1 ratio to the control IOL Model ZCB00 in both eyes for the duration of the study.
45806469|NCT05528510|Drug|Guselkumab Dose 1|Guselkumab (Dose 1) will be administered as SC injection.
45806470|NCT05528510|Drug|Guselkumab Dose 2|Guselkumab (Dose 2) will be administered as SC injection.
45806471|NCT05528510|Drug|Guselkumab Dose 3|Guselkumab (Dose 3) will be administered as SC injection.
45806472|NCT05528510|Other|Placebo|Placebo will be administered as SC injection.
45940918|NCT00254137|Drug|cetuximab|
45940919|NCT00069602|Device|Continuous Glucose Monitoring System (CGMS)|
45940920|NCT00069602|Device|GlucoWatch G2TM Biographer (GW2B)|
45940921|NCT00104169|Drug|Epoetin Alfa|
45940922|NCT00415090|Drug|Nevirapine|Switch one of ARV drugs to Nevirapine
45452853|NCT03200366|Behavioral|Tailored DVD|"A 20 minute tailored DVD titled Approaches to Colon Testing is viewed by participants. It is designed to encourage CRC screening uptake by colonoscopy or FIT by increasing the participant's CRC knowledge and beliefs about the benefits of screening, reducing barriers to screening, and increasing self-efficacy for screening by demonstrating how these tests are performed."
45940923|NCT00415129|Biological|A/H5N1 inactivated, split-virion influenza virus|0.5mL, Intramuscular
45940924|NCT00415129|Biological|A/H5N1 inactivated, split-virion influenza virus|0.5mL, Intramuscular
46074646|NCT00855283|Drug|IN NEO + IN Glycopyrrolate|Intranasal or sublingual Neostigmine (at effective dose: 20, 40, or 60 mg) + 4-12 mg intranasal or sublingual Glycopyyrolate
46074647|NCT00855283|Drug|IV Visit|2mg NEO and .4mg GLY given intravenously to see if the subject responds to the intervention. If they respond, then they will proceed to the IN portion of the study.
46074648|NCT04236024|Other|Board game|The students in the experimental group will play board game to learn medication about 30-60 minutes.
45655359|NCT04902313|Behavioral|Awareness and insight Modules (AiM)|12 week of daily reflection and meditation exercises, delivered by mobile phone text messages, after 3-4 live introduction sessions.
45655360|NCT04891783|Device|ultrasonography|The Carotid US examination will be performed by a radiologist, according to the same protocol in the different participating hospitals. It will include the measurement of cIMT in the common carotid artery and the detection of focal plaques in the extracranial carotid tree following the Mannheimconsensus[26]. Plaque is defined as a focal protrusion in the lumen at least cIMT>1.5 mm, protrusion at least 50% greater than the surrounding cIMT, or arterial lumen encroaching >0.5 mm [26]. The cIMT will be determined as the average of three measurements in each common carotid artery. The final cIMT is the largest average cIMT (left or right). Patients with carotid plaques will be considered as having very high CV .
46074649|NCT04236024|Other|Traditional lecture|The students in the comparison group will receive medication lecture using PPT slides about 30-60 minutes.
45655361|NCT03053167|Drug|Irinotecan|Irinotecan: 180mg/㎡+NS250ml, ivgtt, 90min, d1 Every 3 weeks
45655362|NCT03053167|Drug|Raltitrexed|Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks
45655363|NCT03052543|Device|BIS™ Complete 2--Channel Monitor|monitor depth of anesthesia
45806473|NCT05526716|Biological|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
45806474|NCT05526716|Biological|QIV|Single 0.5 mL IM injection
45806475|NCT05526716|Biological|Matching Placebo for V116|Single 0.5 mL of sterile saline IM injection
45806476|NCT05525390|Device|Extended Reality Behavioral Activation|"Participants will choose at least four activities to complete in Oculus extended reality over the course of the week. These activities are chosen from the Oculus and may include video 360, social interactions, gaming, etc."
45806477|NCT05525390|Behavioral|Behavioral Activation in real-life|Participants will choose at least four pleasurable and/or mastery activities to complete over the course of the week in real life.
46074650|NCT00862927|Other|Breath Sample|Breathe into machine measuring carbon monoxide.
46074651|NCT00862927|Other|Saliva Sample|Chew cotton ball for 30 seconds for cotinine measurement.
45655364|NCT04902079|Device|Device for Cardiac Contractility Modulation Therapy (CCM)|Evaluate the effect from CCM Therapy in HF population
45655365|NCT04901923|Drug|ACP-196|Participants will receive ACP-196 oral capsule(s) in all parts.
45655366|NCT04901923|Drug|Itraconazole|Participants will receive itraconazole 200 mg capsules BID from Days 4 to 8 with meals and then 200 mg capsule QD on Day 9 under fasting state.
45655367|NCT04901845|Other|No intervention provided|Study is provided in the usual daily practice of the physicians without interventions made in their practice
45806478|NCT05521997|Drug|Telaglenastat|-800 mg twice per day by mouth
45806479|NCT05521997|Radiation|Radiation treatment|"Standard of care~External beam radiation therapy delivered daily 4 days a week and 1 day per week of brachytherapy."
45806480|NCT05521997|Drug|Cisplatin|"Standard of care~Weekly administration of cisplain"
45940925|NCT00254176|Dietary Supplement|Parenteral cysteine-HCl supplementation|cysteine-HCl supplementation 121 mg per kg per day
45940926|NCT00254176|Dietary Supplement|Placebo - added premasol|Premasol 121 mg per kg per day
45940927|NCT00100542|Behavioral|Psychiatric interviews|Measures and questionnaires regarding mental health, pain, and adherence to treatment. No actual treatment or intervention is given as part of this study.
45940928|NCT00254215|Behavioral|high protein & low glycemic index diets|
45940929|NCT00254254|Drug|Exenatide - Exenatide - Placebo|Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose, followed by placebo 0.02 mL, single dose. All are subcutaneous injections.
45940930|NCT00254254|Drug|Exenatide - Placebo - Exenatide|Exenatide 2.5 mcg, single dose, followed by placebo 0.02 mL, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
45940931|NCT00254254|Drug|Placebo - Exenatide - Exenatide|Placebo 0.02 mL, single dose, followed by Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
45940932|NCT00069719|Drug|Glaucoma therapy|
46074652|NCT00862927|Behavioral|Questionnaire|6 surveys, taking approximately 30 minutes total.
46074653|NCT00862927|Behavioral|View Virtual Reality Scenes|Use virtual reality helmet and hand-held controller to answer questions about 4 viewing scenes while wearing physiological measurement skin sensors, approximately 6 minutes.
45806481|NCT05521178|Diagnostic Test|Electrocardiogram|ECG to monitor electrical activities of the heart on each visit
45806482|NCT05521178|Diagnostic Test|Echocardiogram|Echocardiogram at baseline and 6 months
45806483|NCT05521178|Diagnostic Test|Cardiac magnetic resonance imaging|Cardiac MRI at baseline and 6 months
45806484|NCT05521178|Device|Mobile cardiac telemetry|Mobile cardiac telemetry at baseline and 6 months
45806485|NCT05521178|Diagnostic Test|Blood pressure monitoring|Home blood pressure monitoring three times per week
45806486|NCT05521178|Diagnostic Test|Blood draw|Blood draw at baseline, 3 and 6 months
45940933|NCT00254371|Procedure|Androgen Replacement|
45940934|NCT00254449|Drug|NGX-4010|
45940935|NCT00104286|Drug|Troxatyl™ (Cytotoxic Chemotherapeutic)|
45940936|NCT00254644|Procedure|Morphological and functional MRI|one time
45940937|NCT00069758|Drug|SDX-105|
45806487|NCT05521087|Drug|JNJ-75276617|JNJ-75276617 will be administered orally.
45806488|NCT05521087|Drug|Fludarabine|Fludarabine chemotherapy will be administered as intravenous (IV) infusion for participants with AML.
45655368|NCT04908007|Other|Qualitative analysis for professionals|"3 individual interviews with the different categories of professionals most involved during the crisis in each university hospital. In the first phase, the points of improvement identified will be analyzed In the second phase, good practices and innovations will be analyzed. For these first two phases, the duration of one hour was chosen because it is difficult to mobilize the professionals for longer. Individual interviews are preferred, but group interviews are possible with no more than three people so that everyone can express himself or herself. Finally, individual interviews of 15 to 30 minutes will be conducted with some of the people interviewed previously in order to identify the costs of the dysfunctions or problems encountered during the crisis.~Questionnaires with establishments associated with the crisis management, the ARS AuRA and France Assos Santé AuRA.~Analysis of evidence documents in the university hospitals"
45940938|NCT00254683|Device|PET/CT with FDG|PET/CT before start of neoadjuvant CRT, at 6 weeks, 12 weeks, following CRT completion and 12mo, 24mo following CRT for those considered complete responders
45940939|NCT00254722|Drug|Autologous bone marrow precursor cell harvest and transplant|Bone marrow harvest (3 ml/kg of body weight) performed between 12 and 30 hours post injury, followed by single intravenous infusion of bone marrow progenitor cells - target dose is 6x10^6 mononuclear cells/kg body weight, administered within 36 hours of injury
45940940|NCT00104364|Drug|MK0731|
45940941|NCT00254761|Drug|Cannabis|
45806489|NCT05521087|Drug|Cytarabine|Cytarabine chemotherapy will be administered as IV infusion for participants with AML.
45940942|NCT02961088|Other|Pasta as part of a low GI/GL diet|
45940943|NCT00254800|Drug|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
45940944|NCT00254800|Drug|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
45940945|NCT00254800|Drug|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
45940946|NCT00104403|Drug|GW679769|
45940947|NCT00104403|Drug|Dexamethasone|
45940948|NCT00104403|Drug|Ondansetron Hydrochloride|
45940949|NCT00069836|Drug|Rosiglitazone/metformin|
45452854|NCT03200366|Behavioral|Patient Navigation|Participants talk by telephone with a Patient Navigator who is a trained nurse. The Patient Navigator determines if participants viewed the tailored DVD and answers any questions about the content. The Patient Navigator then provides telephone counseling on CRC and screening tests to: (1) increase knowledge, perceived benefits, and self-efficacy; (2) reduce barriers; (3) enhance access; and (4) provide social support.
45806490|NCT05521087|Drug|Intrathecal Chemotherapy|Intrathecal chemotherapy will be administered as IV infusion for participants with AML or B-cell ALL.
45806491|NCT05521087|Drug|Dexamethasone|Dexamethasone chemotherapy will be administered as IV infusion for participants with B-cell ALL.
45806492|NCT05521087|Drug|Vincristine|Vincristine chemotherapy will be administered as IV infusion for participants with B-cell ALL.
45940950|NCT00254878|Drug|Methylphenidate hydrochloride|
45806493|NCT05521087|Drug|Pegaspargase|Pegaspargase chemotherapy will be administered as IV infusion for participants with B-cell ALL.
45806494|NCT05519475|Drug|ALN-HSD|Administered by subcutaneous injection (SC)
45940951|NCT00254917|Biological|Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine|0.5 mL, IM
45940952|NCT00254917|Biological|Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine|0.5 mL, IM
45940953|NCT00254956|Drug|ciclesonide (XRP1526)|
45940954|NCT04719676|Other|Core strength training using unstable surface|"Training would include big 3 exercises as described by McGill. These include the curl-up, side bridge, and quadruped position on unstable surface"
45940955|NCT04719676|Other|The stable surface would be gym floor.|"Training would include big 3 exercises as described by McGill. These include the curl-up, side bridge, and quadruped position on stable gym Floor"
45940956|NCT04728672|Other|Kinesio Tape|Kinesio Tape
45940957|NCT04728672|Other|Micropore Tape|Micropore Tape
45940958|NCT00255073|Drug|baclofen|
45940959|NCT00069875|Drug|Gemcitabine|
45940960|NCT00069875|Drug|LY293111|
46074654|NCT02805738|Drug|CKD-390|CKD-390 1 Tablet (48 weeks)
45452855|NCT00713518|Drug|0.5 mg ranibizumab|
45452856|NCT00713518|Drug|3 mg PF-04523655|
45452857|NCT00713518|Drug|1 mg PF-04523655|
45806495|NCT05519475|Drug|Placebo|Administered by SC injection
45940961|NCT00069875|Drug|cisplatin|
45940962|NCT00255112|Behavioral|family based cognitive behavior therapy|newly developed family based cognitive behavior therapy for children with separation anxiety disorder over 5 years old
45940963|NCT00255229|Drug|Glutamine|Glutamine 10 g four times daily starting two days before treatment for six days in total
45940964|NCT00255229|Other|Placebo|Glutamine placebo
45940965|NCT00255268|Drug|Goserelin|
45940966|NCT00255268|Drug|Bicalutamide|
45940967|NCT00104442|Drug|Rivastigmine|
45940968|NCT00255307|Drug|CVT-E002 ginseng extract|
45940969|NCT04719091|Device|Lubricity|Oral spray
45940970|NCT00255385|Drug|Micronutrient (Zinc and Iron) fortification|
45940971|NCT00255385|Drug|Pre and Probiotic fortification|
45940972|NCT00255424|Drug|ferumoxytol or oral iron|
45940973|NCT00069992|Radiation|Total Body Irradiation|Total body irradiation of 450cGy as a single dose, day -6
45940974|NCT00069992|Drug|Fludarabine|Fludarabine 30mg/m2 Day -5 to -2
45940975|NCT00069992|Drug|Campath 1H|Campath 1H dosing as per institutional SOPs Day -5 to -2
45940976|NCT00255463|Drug|Anastrazole|
46074655|NCT02805738|Drug|viread|viread1 Tablet (24 weeks), CKD-390 1 Tablet (from 24 weeks to 48 weeks)
46074656|NCT02857673|Behavioral|Child Abuse Prevention Problem Solving|The CAPPS intervention includes problem solving, motivational interviewing, and referral to existing services. Intervention providers will conduct three core problem solving sessions and three sessions tailored to the common problems experienced by parents of CSHCN: caregiver burden, difficulties navigating complex medical services, and social isolation. Intervention providers will use their motivational interviewing skills during regular, ongoing interactions with their clients to enhance willingness to participate meaningfully in CAPPS sessions. Referral to existing services in the medical home and in the community will occur as needs arise during CAPPS sessions.
46074657|NCT02857673|Behavioral|Active Control Group|Parents in both study groups will receive the standard medical and social work services offered in the patient-centered medical homes where their children receive care. In addition, to account for potential surveillance bias, families in the control group will be contacted by a member of the study team six times over 12 weeks, approximating the frequency of contact that the intervention group receives from the CAPPS providers.
46074658|NCT00855361|Drug|Rabeprazole sodium|One single daily dose of rabeprazole sodium 1 mg as a microgranule formulation for up to 28 consecutive days (Part 1), and one single daily dose of rabeprazole sodium 2 or 3 mg as a microgranule formulation for up to 28 consecutive days (Part 2). The study drug will be administered through a nasogastric or orogastric tube.
45452858|NCT03134482|Procedure|IVM|No gonadotropin is used, but hCG priming is utilized 36 hour before oocyte maturation.
45655369|NCT04908007|Other|Quantitative analysis for Professionals|"A self-assessment of the three phases of the crisis management process (preparation, crisis management, crisis recovery) will be carried out in the participating establishments using the WHO grid with the target persons identified within the establishments.~This step will use the crisis response assessment tool developed by the WHO following the H1N1 pandemic in 2011. This grid will be adapted beforehand to the COVID-19 situation and to the local organization by the study's scientific committee. The dimensions investigated will be : Command and control, Communication, Safety and security, Triage, Surge capacity, Continuity of essential services; Human resources, Logistics and supply management, Post-disaster recovery.~The grids will be sent to the 4 university hospitals to be filled in with the target audience recommended by the WHO methodological guide.~The results of this self-assessment will be linked to and interpreted with the results of the interviews in phase 1."
45940977|NCT00255463|Drug|Gefitinib|
45940978|NCT00255502|Drug|metoprolol succinate|
45806496|NCT05519215|Device|ECHELON 3000 Stapler|There is no intervention, beyond necessary clinical care, in this study. Echelon 3000 Stapler is used for transection and resection in LSG or lung surgical procedure per its IFU.
45806497|NCT05518149|Drug|Aticaprant|Aticaprant 10 mg tablet will be administered orally.
45806498|NCT05518123|Drug|Rimegepant|Rimegepant 75 mg Oral Disintegrating Tablet (ODT) taken every other day during Double-blind Treatment (DBT) phase
45806499|NCT05518123|Drug|Placebo|Matching placebo with every other day dosing during DBT phase
45940979|NCT00255541|Drug|Tesaglitazar|
45940980|NCT00255541|Drug|Glibenclamide|
45940981|NCT00070031|Drug|edotecarin|
45940982|NCT00255580|Drug|Smoked cannabis|
46074659|NCT02798406|Biological|DNX-2401|On Day 0, following brain tumor biopsy and confirmation of recurrent tumor, a single injection of DNX-2401 is administered directly into the brain tumor.
45452859|NCT03134482|Procedure|Minimal stimulation IVF|IVF with minimal use of gonadotropin, i.e. 150 or less IU of recombinant FSH, followed by hCG triggering in GnRH antagonist protocol.
45806500|NCT05514912|Drug|Cisplatin|Given IV
45806501|NCT05514912|Drug|Gemcitabine Hydrochloride|Given IV
45940983|NCT00255619|Device|Baxter's UltraBag® and FMC Andy·Disc®|
45806502|NCT05514912|Drug|Infigratinib Phosphate|Given PO
45806503|NCT05514912|Drug|Nab-paclitaxel|Given IV
45806504|NCT05514444|Biological|MK-4464|MK-4464 administered as an IV infusion every three weeks according to allocation and dose escalation.
45806505|NCT05514444|Biological|Pembrolizumab|Pembrolizumab 200 mg administered as an IV infusion every three weeks.
45806506|NCT05509582|Drug|fostamatinib|Subjects will receive fostamatinib at the same dose as the dose they receive at the time of rollover. The dose could be reduced to 100mg daily, 150 mg daily, 100 mg twice a day if a dose-limiting adverse event occurred. After the initial 12 weeks on the extended access (total of 24 weeks of treatment), subjects will have the option to start tapering fostamatinib if they are maintaining hematologic recovery. Subjects with persistent (=2 readings, 2 weeks apart) loss of hematologic response, defined as Hb<9g/dL and/or PLT< 30 X 10^9/L can increase their dose to next higher dose. Once count stabilization again occurs, a slow dose reduction to next lowest dose (100mg or 150mg) can be performed to identify the lowest dose necessary to keep counts over these thresholds.
45940984|NCT00104481|Behavioral|cognitive behavior therapy|
45452860|NCT00795418|Biological|Placebo|Placebo comparator
45452861|NCT00795418|Biological|CAD106|
45452862|NCT04560296|Behavioral|Community-based E-Health Program|Community-based E-Health Program will be developed to engage and empower older adults to manage the chronic conditions effectively.
45940985|NCT00104091|Drug|TP-38|TP-38 is a recombinant chimeric protein composed of the epidermal growth factor (EGFR) binding ligand (TGF-α)and a genetically engineered form of the Pseudomonas exotoxin, PE-38.
45940986|NCT00255658|Drug|sorafenib tosylate|Given orally
45940987|NCT00255658|Drug|temsirolimus|Given IV
45940988|NCT00255658|Other|laboratory biomarker analysis|Correlative studies
45940989|NCT00070148|Drug|Megestrol Acetate|Megace by mouth for 12 weeks
45940990|NCT00070148|Drug|Oxandrolone 20 mg|20 mg/day for 3 months (12 weeks)
46002143|NCT04666948|Device|vancomycin model-informed precision dosing|A CE labelled dosing calculator is used for a priori and a posteriori calculation of vancomycin dose using a target AUC between 400-600 mg*h/L
46002144|NCT04666948|Drug|Vancomycin|Vancomycin treatment
46002145|NCT04660539|Drug|satralizumab|Satralizumab will be administered by SC injection in the abdominal or femoral region at a dose of 120 mg (fixed dose) Q4W for up to 3 years
46074660|NCT02798406|Biological|pembrolizumab|Sequential intravenous administration every three weeks beginning 7-9 days after Day 0/DNX-2401
45940991|NCT00255697|Procedure|psychosocial assessment and care|Patients undergo a 45-minute interview in person or by phone to provide demographic data and to complete quality of life questionnaires, including Functional Assessment of Cancer Therapy (FACT), Spiritual tool, Quality and Satisfaction with Treatment (QUEST), and Profile of Mood State (POMS), at baseline and at 3 and 12 months. Caregivers undergo a 20- to 30-minute interview in person or by phone to provide demographic data and complete quality of life questionnaires, including the Caregiver Reaction Assessment (CRA), Quest, and POMS, at baseline and at 3 and 12 months. Caregivers complete the Quality of Death and Dying (QODD) questionnaire 2-3 months after the patient's death.
45940992|NCT00255697|Procedure|quality-of-life assessment|Patients undergo a 45-minute interview in person or by phone to provide demographic data and to complete quality of life questionnaires, including Functional Assessment of Cancer Therapy (FACT), Spiritual tool, Quality and Satisfaction with Treatment (QUEST), and Profile of Mood State (POMS), at baseline and at 3 and 12 months. Caregivers undergo a 20- to 30-minute interview in person or by phone to provide demographic data and complete quality of life questionnaires, including the Caregiver Reaction Assessment (CRA), Quest, and POMS, at baseline and at 3 and 12 months. Caregivers complete the Quality of Death and Dying (QODD) questionnaire 2-3 months after the patient's death.
45806507|NCT05509400|Drug|Rimegepant|DB Phase: Rimegepant 75 mg Orally Disintegrating Tablet (ODT)
45940993|NCT04719169|Diagnostic Test|Dynamic MRI enema|Dynamic MRI enema
45940994|NCT04719169|Diagnostic Test|Fluoroscopic enema|Fluoroscopic enema
45655370|NCT04908007|Other|Quantitative analysis for Patients|"A questionnaire of patients' perceptions on the same perimeter (crisis and post-crisis management, from the point of view of points of improvement and good practices) will be constructed and sent by the management of the establishments to all patients hospitalized for 48 hours or more during the first wave and who have left their email address (methods similar to the e-satis survey). The online questionnaire survey is preferred in order to get away from the emotion and for feasibility reasons. This patient experience questionnaire adapted to COVID will be co-constructed with expert/partner patients and user associations.~Four dimensions will be investigated : The perception of the quality of the information received by the patient, The nature of the information on the specific health protection protocol from which the patient benefited, The patient's consideration of the overall context, during and after, The effects of the health context on the overall management of the patient"
45806508|NCT05509400|Drug|Placebo|DB Phase: matching placebo
45806509|NCT05509400|Drug|Rimegepant|OLE Phase: Rimegepant 75 mg ODT in association with each of the first 5 qualifying migraines
45806510|NCT05507580|Drug|Upadacitinib|Oral tablet
45806511|NCT05507216|Drug|ABX464|Administered once daily in the morning with food
45940995|NCT00255775|Dietary Supplement|broccoli sprout extract|
45940996|NCT00255775|Procedure|complementary or alternative medicine procedure|
45940997|NCT00100581|Drug|Efavirenz|
45940998|NCT00100581|Drug|Lamivudine|
45940999|NCT00100581|Drug|Lopinavir/ritonavir|
45941000|NCT00100581|Drug|Pegylated interferon alfa-2a|
45806512|NCT05507216|Drug|Placebo|Administered once daily in the morning with food
45806513|NCT05507203|Drug|ABX464|Administered once daily in the morning with food
45806514|NCT05507203|Drug|Placebo|Administered once daily in the morning with food
45806515|NCT05506943|Drug|CTX-009|IV infusion on day 1 and 14 of every 28 day cycle
45806516|NCT05506943|Drug|Paclitaxel|IV infusion on day 1, 8, and 15 of every 28 day cycle
45806517|NCT05504707|Biological|HER2 - primed Dendritic cells|"Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs.~Participants will be treated at the following dose levels:~Dose level 1: HER2 - primed Dendritic cells dose 10-20 million Dose level 2: HER2 - primed Dendritic cells dose 30-50 million Dose level 3: HER2 - primed Dendritic cells dose 80-100 million"
45941001|NCT00100581|Drug|Ribavirin|
45941002|NCT00100581|Drug|Tenofovir disoproxil fumarate|
45941003|NCT04719325|Other|Herbert screw|Fracture line exposed through intra-oral approach. bone reduction into proper anatomical occlusion and application of Herbert screw
45941004|NCT04719325|Other|Lag screw|Fracture line exposed through intra-oral approach. bone reduction into proper anatomical occlusion. Application of either lag screw according to Champy's osteosynthesis lines.
45941005|NCT00070187|Biological|aldesleukin|Given IV
45941006|NCT00070187|Biological|filgrastim|Given IV
45941007|NCT00070187|Biological|recombinant interferon gamma|Given IV
45941008|NCT00070187|Drug|carmustine|Given IV
45941009|NCT00070187|Drug|cyclosporine|Given IV
45941010|NCT00070187|Drug|cytarabine|Given IV
45941011|NCT00070187|Drug|etoposide|Given IV
45941012|NCT00070187|Drug|melphalan|Given IV
45941013|NCT00070187|Procedure|autologous bone marrow transplantation|
45941014|NCT00070187|Procedure|bone marrow ablation with stem cell support|
45941015|NCT00070187|Procedure|peripheral blood stem cell transplantation|
45941016|NCT00255931|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy and Relaxation/biofeedback
45941017|NCT00255931|Behavioral|Attention Placebo|Untrained relaxation
45655371|NCT04908007|Other|Tools development|"Development of tools to prepare for situations of uncertainty : In the third phase of the project, design thinking workshops will be organized (within the HCL) to develop training (in the form of simulation) in order to appropriate virtuous practices in situations of uncertainty. The purpose of these training sessions will be to improve the institution's ability to learn in a situation of uncertainty and thus to develop its reliability.~The aim of these workshops is to provide tools for raising awareness of situations of uncertainty to all hospital staff."
45806518|NCT05504707|Biological|HER3 - primed Dendritic cells|"Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs.~Participants will be treated at the following dose levels:~Dose level 1: HER3 - primed Dendritic cells dose 10-20 million Dose level 2: HER3 - primed Dendritic cells dose 30-50 million Dose level 3: HER3 - primed Dendritic cells dose 80-100 million"
45941018|NCT00104559|Behavioral|iMIC-generated consent form and tutorial|Computer-based consent form and tutorial
45941019|NCT00104559|Behavioral|Standard paper consent form|Standard paper consent form
45452863|NCT04560296|Behavioral|usual self-management and follow up with doctors/nurse|usual self-management and follow up with doctors/nurse as planned in the community nurse post.
45452864|NCT00712426|Drug|Creatine Monohydrate|Up to 40 grams daily, powder form creatine monohydrate, taken for the trial duration
45806519|NCT05502523|Procedure|Pulmonary Artery-First Surgical Technique|Undergo pulmonary artery first surgical technique
45941020|NCT00415246|Drug|Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)|
45941021|NCT00415285|Drug|Docetaxel|
45941022|NCT00415285|Drug|Capecitabine|
45452865|NCT00712426|Drug|Placebo|Up to 40 grams daily, powder form placebo (inactive substance), taken for the trial duration
45452866|NCT04468958|Biological|SAB-185|SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
45452867|NCT04468958|Other|Normal saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
45452868|NCT04540718|Other|Exercise|50 minutes of exercise, consisting of 20 minutes of resistance followed by 30 minutes of aerobic, three times a week for eight weeks.
45806520|NCT05502523|Procedure|Biospecimen Collection|Correlative studies
45806521|NCT05502237|Drug|Zimberelimab|Administered intravenously
45806522|NCT05502237|Drug|Domvanalimab|Administered intravenously
45806523|NCT05502237|Drug|Pembrolizumab|Administered intravenously
45806524|NCT05502237|Drug|Carboplatin|Administered intravenously
45806525|NCT05502237|Drug|Cisplatin|Administered intravenously
45806526|NCT05502237|Drug|Paclitaxel|Administered intravenously
45806527|NCT05502237|Drug|Nab-paclitaxel|Administered intravenously
45941023|NCT00415285|Drug|Docetaxel/Capecitabine|
45941024|NCT00256009|Drug|Cytotec|
45941025|NCT00100620|Drug|Zoledronic Acid|
45941026|NCT00070265|Drug|oxaliplatin|Given IV
45941027|NCT00070265|Drug|capecitabine|Given orally
45941028|NCT00070265|Procedure|therapeutic conventional surgery|Undergo surgical resection
45941029|NCT00070265|Other|laboratory biomarker analysis|Correlative studies
45941030|NCT00256048|Procedure|Nasojejunal feeding|
45941031|NCT00256087|Drug|Probiotic Lactobacillus|
45941032|NCT00256087|Other|Lactose Powder|
45941033|NCT04709536|Drug|IBI306|Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
45941034|NCT04709536|Drug|Placebo|Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
45941035|NCT00256165|Device|Tissue valve|Aortic valve replacement
45941036|NCT00104598|Drug|Bupropion|
45941037|NCT00104598|Behavioral|Smoking Abstinence Program|This investigation was a randomized controlled study of two framed message conditions for smoking cessation in combination with open label bupropion SR (300 mg/day). Two hundred fifty-eight cigarette smokers were randomly assigned to receive either gain- or loss-framed video and printed messages encouraging smoking abstinence. Preproduced video and printed information were chosen as the intervention media because of their reliability in delivering specific framed messages. All participants were seen at a community mental health center for 6 months and received a 7-week supply of bupropion SR.
45941038|NCT00256321|Drug|Oxaliplatin|Oxaliplatin 70mg/m2 IV on Days 1 and 8
45941039|NCT00256321|Drug|Capecitabine|Capecitabine 1000mg/m2 PO BID from Days 1 through 14.
45941040|NCT00256321|Drug|Celecoxib|Celecoxib 400mg PO BID from Days 1 through 21.
45941041|NCT00070304|Biological|filgrastim|Given by mouth or IV, 5 micrograms/kg/dose (up to 10 micrograms/kg/dose) daily starting on day 9 for a minimum of 7 days and until the ANC is greater to or equal to 1,500/uL.
45655372|NCT03050905|Drug|VEKIRAX|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (Viekirax).~Study Regimen: ombitasvir+paritaprevir+ritonavir (25+150+100mg once daily)"
45806528|NCT05502237|Drug|Pemetrexed|Administered intravenously
45941042|NCT00070304|Drug|gemcitabine hydrochloride|Given IV over 100 minutes dose 1000 mg/m2/dose in 500 ml NS on days 1 and 8
46074661|NCT02857751|Behavioral|Surf therapy|The NMCSD surf therapy program is approximately 6 weeks in duration. Each surf therapy session lasts 2-3 hours and occurs in a group setting that can accommodate up to 20 service members per session. Each service member is paired with a surf instructor who works with him or her each week for the 6-week session. Goals are individually-tailored to the service member (based on participant's level of comfort in the water, experience with surfing, etc.) and can incorporate both physical and psychological objectives.
46074662|NCT02798484|Device|Diffusion-weighted Nuclear Magnetic Resonance Imaging (MRI)|MRI examinations performed on two devices: Ingernia 3 Testla (Philips) on the Horta site of the CHU Brugmann hospital, and Area 1,5 Tesla (Siemens) on the Brien site of the CHU Brugmann hospital. Diffusion sequences last 6 minutes and are already performed in the standard of care. Compared to the standard of care, one additional MRI will be performed one month after the start of the neo-adjuvant treatment, with diffusion analysis.The post-processing of the examinations will be realized with the Syngo Onco Care application of Siemens.
46074663|NCT04040725|Drug|Rogaratinib|Rogaratinib is an oral drug that inhibits FGFR. Mutations in FGFR help bladder cancer grow.
45806529|NCT05502159|Drug|M-TAPA|Under aseptic conditions, a high-frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with total of 40 ml (20 ml for each side) of %0,25 bupivacaine.
46074664|NCT00955955|Other|6(S)-5-MTHF(Deplin)|Deplin is a medical food. Patients will take 15 mg/day of deplin.
45655373|NCT03050905|Drug|EXVIERA|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Dasabuvir (Exviera).~Study Regimen: dasabuvir (250 mg twice daily)"
45941043|NCT00070304|Drug|vinorelbine tartrate|Given IV over 6-10 minutes (central venous catheter). Dose 25 mg/m2/dose on days 1 and 8
45941044|NCT00256360|Drug|dose dense with neulasta|
45941045|NCT00256438|Device|Transcranial Direct Current Stimulation|
45941046|NCT00256477|Behavioral|Sudarshan KRIYA Breathing Technique|
46074665|NCT00955955|Other|Placebo|Inactive substance
46074666|NCT02798328|Device|TEG6s DOAC Cartridge|Testing subjects for presence of DOAC
46074667|NCT04052581|Procedure|POEM-TIF|Transoral Incisionless Fundoplication (TIF) following Per oral Endoscopic Myotomy (POEM) in the same session
46074668|NCT05550636|Drug|BI 1015550|BI 1015550
46074669|NCT05550636|Drug|midazolam|midazolam
46074670|NCT00860197|Dietary Supplement|Fully torrefied coffee|Fully torrefied coffee
46074671|NCT00860197|Dietary Supplement|Partially torrefied coffee|Partially torrefied coffee
45452869|NCT04540718|Other|Sauna|15 minutes of sauna exposure immediately after exercise intervention, three times a week for eight weeks.
45806530|NCT05502159|Drug|EOB|In the supine position, a high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed on the midaxillary line between the spina iliaca anterior superior and the umbilicus. Using the In-Plane technique, 5 ml of saline will be injected under the external oblique muscle of the block needle and the block location will be confirmed. After the block location is confirmed, 20 ml of 0.25% bupivacaine will be administered. The same procedure will be applied to the other side (40 ml of 0.25% bupivacaine in total).
45941047|NCT00100737|Drug|interleukin-2|
45941048|NCT00100737|Drug|rituximab|
46074672|NCT02857829|Dietary Supplement|CAF+|CAF+ will be a blend consisting of caffeine (100 mg), L-theanine (200 mg), vinpocetine (40 mg), L-tyrosine (300 mg), pyridoxine (1 mg), and cobalamin (20 mg).
45452870|NCT00708292|Drug|AUY922|
45452871|NCT00708292|Drug|Bortezomib|
45452872|NCT00708292|Drug|Dexamethasone|
45452873|NCT03636620|Device|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization
45452874|NCT03636620|Device|radiofrequency ablation/microwave ablation|radiofrequency ablation/microwave ablation
45452875|NCT00699790|Drug|CCR2 Antagonist|Tablets, Oral, 50 mg, once daily, 12 weeks
45655374|NCT03050827|Drug|3% oxybutynin|Topical Gelnique 3%TM (3% oxybutynin) applied daily for 20 weeks in type 2 diabetic subjects with established peripheral neuropathy. Subjects will be randomized into placebo or active drug arms and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 by 2 region of skin adjacent to the initial biopsy site. Treatment will continue daily for 20 weeks, with monthly phone calls to monitor compliance.
45655375|NCT03050827|Drug|Placebo|Non-active placebo for 3% oxybutynin
45655376|NCT04891159|Other|Shared decision making|The intervention consists of 5 components: 1) Online shared decision making training (2 hours, e-learning); 2) Individual coaching for doctors by a shared decision making expert; 3) Implementation of the shared decision making; 4) Link to institutional approaches to patient engagement; 5) Integration of the shared decision making into the multidisciplinary consultation meetings of the Cystic Fibrosis Centers Competences.
45452876|NCT00699790|Drug|Placebo|Tablets, Oral, 0mg, once daily, 12 weeks
45655377|NCT04900909|Device|Aortic Valve Replacement|Surgical replacement of aortic valves
45655378|NCT04891003|Diagnostic Test|Ultrasonography|The identification of optimal ultrasonografic tecniques for determining the location , size and the surgical methods of intestinal endometriotric nodules.
45655379|NCT04907461|Procedure|LAPTAP|Laparoscopic guided Transverse Abdominus Plane block
45941049|NCT00256516|Other|Eco-Atkins diet (high vegetable protein and vegetable fat)|
45941050|NCT00256516|Other|NCEP diet|
46074673|NCT02857829|Dietary Supplement|Caffeine-alone|Caffeine (100 mg)
46074674|NCT02857829|Other|Placebo|Rice flour
46074675|NCT02805894|Drug|NBTXR3 activated by IMRT only|Single local administration of NBTXR3 by injection into the prostate gland prior to the IMRT treatment
46074676|NCT02805894|Drug|NBTXR3 activated by Brachytherapy & IMRT|Single local administration of NBTXR3 by injection into the prostate gland prior to the Brachytherapy & IMRT treatment
45655380|NCT04907617|Other|FAW|After the induction of anaesthesia, for patients assigned to groups 1 and 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of <36.5°C.
45941051|NCT00256555|Drug|Nutropin AQ|
45655381|NCT04907617|Other|Warmed fluids|In patients assigned to groups 2 and 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet.
45655382|NCT04907617|Other|Combination|"After the induction of anaesthesia, for patients assigned to groups 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of <36.5°C.~In patients assigned to groups 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet."
45655383|NCT04907617|Other|Control|The patients assigned to group 4 will only receive 'routine care'. They will not be given intraoperative forced-air warming or heated IV and irrigation fluids.
45655384|NCT02438787|Drug|Placebo|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1.
45806531|NCT05498428|Drug|Amivantamab|Amivantamab will be administered subcutaneously by manual injection.
46074677|NCT00860275|Drug|BMS-708163|Capsule, Oral, 50 mg, once, Day 1
45655385|NCT02438787|Drug|Ustekinumab 45 mg|Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 2.
46074678|NCT00860275|Drug|BMS-708163 + Ketoconazole|(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day Day 12 (Ketoconazole) - Tablet, Oral, 400 mg, daily, 1 day
45806532|NCT05498428|Drug|Lazertinib|Lazertinib will be administered as an oral tablet.
45806533|NCT05498428|Drug|Carboplatin|Carboplatin will be administrated by IV infusion.
45806534|NCT05498428|Drug|Pemetrexed|Pemetrexed will be administered by IV infusion.
45806535|NCT05498428|Drug|Direct Oral Anticoagulant (DOAC)|DOAC will be administered orally.
45941052|NCT00256594|Device|prescription form|Two prescription pads contained modified forms and two prescription pads were similar to the prescription pads the prescriber had been using. Providers completed 100 standard and 100 modified prescriptions
45941053|NCT00070343|Biological|oblimersen sodium|
45941054|NCT00070343|Drug|dacarbazine|
46074679|NCT00860275|Drug|Ketoconazole|Tablet, Oral, 400 mg, daily, 16 days
45806536|NCT05498428|Drug|Low Molecular Weight Heparin (LMWH)|LMWH will be administered subcutaneously.
45806537|NCT05496296|Device|Altrazeal® Transforming Powder Dressing|Pressure injury wounds will be evaluated at each study visit (cleaned, photographed, measured) and a dressing will be applied according to the study arm
45941055|NCT00104715|Drug|antiandrogen therapy|
45941056|NCT00104715|Drug|docetaxel|
45806538|NCT05491031|Other|magnetic resonance spectroscopy|Investigation of the association, in patients with multiple sclerosis, between MRI biomarker data at inclusion and progression of physical disability during follow-up (6, 12, 18 and 24 months) assessed by a composite endpoint EDSS plus (EDSS, 9HPT, T25FW)
45806539|NCT05490771|Procedure|Biopsy|Undergo tumor biopsy
45941057|NCT00104715|Drug|goserelin acetate|
45941058|NCT00104715|Procedure|orchiectomy|
45941059|NCT00256672|Device|Thoraco-Lumbar-Sacral-Orthoses (TLSO) / Flex-Foam|TLSO back brace, Flex-Foam (Posterior Opening)
45941060|NCT00256711|Drug|Gefitinib|
46074680|NCT00860275|Drug|Fluconazole|Tablet, Oral, 1 day 400 mg then 3 days 200 mg
46074681|NCT00860275|Drug|BMS-708163 + Fluconazole|(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day (Day 12) (Fluconazole) - Tablet, Oral, 200 mg, daily, 13 days
46074682|NCT00630617|Behavioral|Diet, Physical activity, Physical inactivity|Community based participatory research design
45655386|NCT02438787|Drug|Ustekinumab 90 mg|Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 3.
45941061|NCT00256711|Drug|Vinorelbine|
45941062|NCT00070382|Drug|darbepoetin alfa|darbepoetin alfa administered at a dose of 200ug once every 2 weeks over a 16-week treatment period
45655387|NCT02438787|Drug|Golimumab 50 mg|Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Group 1, 2 and 3.
45941063|NCT00070382|Drug|epoetin alfa|epoetin alfa administered at a dose of 40,000U once every week over a 16-week treatment period
45941064|NCT00104754|Drug|liposomal SN-38|
45941065|NCT04709380|Other|Radiotherapy plus Toripalimab|Intensity modulated radiotherapy has shown important role in the treatment of hepatocellular carcinoma (HCC), especially for advanced disease with portal vein tumor thrombosis (PVTT), or hepatic vein tumor thrombosis. Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).
45941066|NCT04709380|Drug|Sorafenib|Sorafenib is a multi-targeted oral drug for the treatment of cancer.Treatment of inoperable advanced renal cell carcinoma ,inoperable or distant metastatic primary hepatocellular carcinoma and so on.
45655388|NCT04901065|Drug|Xylocaine|The study intervention was the administration of 10 mg of intranasal lidocaine in one nostril using 1 spray of 0.1mL of a 10% lidocaine solution 5 minutes before NPS. This was done using the standard long nozzle
46074683|NCT02798250|Other|Dual-hormone closed-loop|Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, closed-loop will be initiated. At 9:00, a standardized breakfast (45g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will be allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions. The intervention day will end at 13:00.
46074684|NCT02798250|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).
45806540|NCT05490771|Procedure|Computed Tomography|Undergo CT
45806541|NCT05490771|Drug|Copanlisib Hydrochloride|Given IV
45941067|NCT00256789|Procedure|Radiation|
45941068|NCT00256789|Drug|Chemotherapy|
45941069|NCT00256828|Drug|didanosine + lamivudine + efavirenz|
45655389|NCT04901065|Drug|Placebo|The control group received the placebo with the same application technique using an empty bottle of lidocaine 10% with the same long nozzle for delivery
45655390|NCT04430803|Dietary Supplement|Hydrogen-rich water|A tablet that produces hydrogen dissolved in a glass of water
45655391|NCT04430803|Other|Control Water|A glass of tap water
45655392|NCT04412005|Other|No intervention|No intervention
45655393|NCT02493777|Drug|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 doses: 20, 40, 60, 80 or 100 mg
45655394|NCT02493777|Drug|Placebo|
45655395|NCT04890691|Device|Feel Bright Light|During the first waking hour, the participants will be required to wear the light visor (either therapeutic or placebo light) for 30 minutes/day for 4 weeks.
45806542|NCT05490771|Procedure|Magnetic Resonance Imaging|Undergo MRI
45806543|NCT05488652|Other|Time restricted eating|not more than 10 hrs. eating window daily goal for 6 months
45806544|NCT05488314|Drug|Capmatinib|Capmatinib will be administered orally.
45941070|NCT00070421|Procedure|complementary or alternative medicine procedure|
45941071|NCT00070421|Procedure|management of therapy complications|
45941072|NCT00070421|Procedure|psychosocial assessment and care|
45941073|NCT00100776|Drug|Olanzapine|
45941074|NCT00256945|Procedure|dental restorative material surface preparation|
45941075|NCT00070538|Drug|cytarabine|
45941076|NCT00070538|Drug|laromustine|
45941077|NCT00257023|Drug|paliperidone|
45941078|NCT00257062|Drug|Levofloxacin|
45941079|NCT00100854|Drug|erlotinib hydrochloride|Given orally
45941080|NCT00100854|Drug|fulvestrant|Given intramuscularly
45941081|NCT00257101|Behavioral|self-medication monitoring|
45941082|NCT00257140|Drug|levofloxacin|
45806545|NCT05488314|Drug|Amivantamab|Amivantamab will be administered as IV infusion.
45806546|NCT05484739|Other|Water Spray|Participants will receive water spraying on their body throughout the climate chamber exposure.
45806547|NCT05484739|Other|Fan|Participants will be exposed to a fan throughout the climate chamber exposure.
45806548|NCT05484739|Other|Water Spray and Fan|Participants will receive both water spraying and a fan throughout the climate chamber exposure.
45806549|NCT05484739|Other|Control|Participants will NOT receive either water spray or a fan exposure.
45806550|NCT05480384|Drug|Nivolumab|Nivolumab, 360 mg IV every 3 weeks for 17 doses (12 months)
45941083|NCT00257218|Behavioral|Life style modification|
45941084|NCT00255814|Radiation|radiation therapy|
45941085|NCT00257257|Drug|Rimonabant (SR141716)|
45941086|NCT00257296|Other|Screening and Intervention|Screening for intimate partner violence and providing a multi-faceted intervention which depends on the needs of the patient
45941087|NCT00257296|Other|Usual Care|Screening for intimate partner violence and provide enhanced usual care which includes providing resource list, educating medical staff and partner violence and instructing physicians to help all patients regardless of assigned arm.
45941088|NCT00257335|Procedure|IMRT|
45941089|NCT00070616|Drug|Palifermin 6 x 60 μg/kg/day|
46074685|NCT02798250|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
46074686|NCT02798250|Device|Dexcom G4 Platinum glucose sensor|
45655396|NCT04890457|Device|Vagus nerve stimulation via tragus|The device will send stimulus intensity around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
46074687|NCT02798250|Device|Accu Chek Combo insulin pump|
45655397|NCT04890457|Device|Sham stimulation via earlobe|The device will send stimulus intensity around 0.5mA via earlobe in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
45655398|NCT04890223|Behavioral|Brief MI intervention|Brief MI intervention
45655399|NCT04890223|Behavioral|Placebo intervention|Generic health advice consultations and self-help smoking cessation booklets
45655400|NCT03052699|Procedure|vaginal Cesarean Section|follow-up to patients operated for vaginal Cesarean Section
45806551|NCT05480384|Drug|Trastuzumab deruxtecan|Given in combination with Nivolumab.
45806552|NCT05480124|Device|tACS brain stimulation treatment|Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. tACS will be delivered by passing a small electrical current via the tACS electrodes to the scalp to stimulate brain activity during a computerized behavioral task. The effect of active stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.
45806553|NCT05480124|Device|Sham stimulation treatment|Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. Sham tACS will be delivered by passing a transient (approximately 12 seconds ) small electrical current via the tACS electrodes during a computerized behavioral task. The effect of sham stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The sham stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.
45806554|NCT05473429|Device|TSA2 Thermosensory Stimulator|TSA thermal analyzer uses the thresholds for four sub-modalities to measure thermal sensory threshold. This device is capable of heating or cooling the skin as needed to detect heat and cold tolerance and to deliver thermal stimuli.
45806555|NCT05471180|Other|protective spray film|Skincare will be maintained with 3M Cavilon ® Cleansing Solution and the use of 3M Cavilon ® Protective Spray Film.
45655401|NCT04907149|Drug|GLPG3970 film-coated tablet|Participants will receive a single oral dose of GLPG3970.
45655402|NCT04907149|Drug|[14C]GLPG3970 solution for infusion|Participants will receive an i.v. microtracer microdose.
45655403|NCT04907149|Drug|[14]GLPG3970 oral solution|Participants will receive a single oral dose [14C]GLPG3970.
45806556|NCT05471180|Device|photobiomodulation therapy|application in 8 points of the affected perineum region, these applications will occur 1 x a day every 24 hours for three days.
45806557|NCT05470010|Behavioral|Mindfulness|A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state through meditation and gentle mindful movements.
45941090|NCT00070616|Drug|Palifermin 2 x 180 μg/kg/day|
45941091|NCT00070616|Radiation|radiotherapy|
45941092|NCT00070616|Drug|Chemotherapy|
45941093|NCT00257374|Drug|Gatorade, Pedialyte and New Solution|
45655404|NCT04431037|Dietary Supplement|Early oral feeding/Enhanced recovery after surgery protocols|Early oral feeding refers to NG tube and foley's catheter removed within 12 hours and patients allowed oral sips on day 1 with gradual shift to liquid diet after 12 hrs and semisolid food started after 24 hours later.Patients were given i/v antibiotics,painkillers and i/v PPIs and shifted to oral pain killers on 2nd POD.
45655405|NCT03052621|Procedure|Omental transposition|Harvesting the omentum to cover irradiated defects of breast cancer
45655406|NCT04906681|Device|i-ACT|i-ACT is a Microsoft Kinect-based system that provides individualised exercises based on patients own goalsetting.
46074688|NCT00865111|Drug|Bupropion 150 mg Extended-Released Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
46074689|NCT00865111|Drug|Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
46074690|NCT02802618|Other|Interactive 3D visualization technique|The pulmonary rehabilitation consists of exercise training during two times/week for 10 weeks and a theoretic part presented with 3D visualization technique.
46074691|NCT00863005|Drug|K201|Cream
46074692|NCT00863005|Drug|K201|
45941094|NCT00257413|Procedure|Transplantation of autologous endothelial progenitor cells|
45941095|NCT00257452|Drug|tiotropium 18 mcg or 54 mcg qd|
45941096|NCT00257452|Drug|placebo matching tiotropium qd|
45941097|NCT00257452|Drug|moxifloxacin 200 mg|
45941098|NCT00257491|Drug|Telmisartan|
45941099|NCT00257491|Drug|Telmisartan/HCTZ|
45941100|NCT00104793|Drug|carboplatin|
45941101|NCT00104793|Drug|irinotecan hydrochloride|
45941102|NCT00070655|Drug|SR34006 (idraparinux sodium) Injection|
45941103|NCT00070655|Drug|vitamin K antagonist (warfarin or acenocoumarol) tablets|
45941104|NCT00257530|Drug|Imiquimod|
46074693|NCT00860353|Drug|AZD2551|Single dose of oral solution.
46074694|NCT00860353|Drug|Placebo|Single dose of oral solution
46074695|NCT00863083|Behavioral|Multifamily weight management intervention|8 week multifamily group weight management intervention incorporating behavioral health, nutrition, and activity disciplines.
46074696|NCT04018339|Drug|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
46074697|NCT04018339|Drug|Placebo|Capsules containing an inert placebo
46074698|NCT02802696|Drug|Furosemide|A bolus dose of 20mg furosemide (20mg/2mL) will be given intravenously by slow intravenous push within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
46074699|NCT02802696|Drug|Normal Saline|A single bolus dose of 2 mL normal saline will be given intravenously immediately within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
45941105|NCT00257569|Drug|Cetirizine Dry Syrup|
45941106|NCT04709146|Diagnostic Test|Audio-Vestibular evaluation|Diagnostic evulation with audiometry, Tympanography, SVV, VHIT, VNG.
45941107|NCT00257647|Other|SV40 vectors carrying siRNA|in vitro only use of gene therapy
45941108|NCT00100893|Dietary Supplement|IH636 grape seed proanthocyanidin extract|Dose escalation as follows: 50 mg/day, 300 mg/day, 1000 mg/day, 2000 mg/day, 2800 mg/day, 4000 mg/day, 4800 mg/day and 6000 mg/day in separate patient groups for each dosage
46074700|NCT00860431|Drug|AST-120|6g/day (3 times a day)
46074701|NCT02802774|Other|Plaster Splint|The custom plaster splint is the historical standard. The surgical incision is dressed with non-stick gauze, 4x4 gauze pads, cotton padding, a plaster splint applied to the palmar surface of the palm and forearm, and then a cloth wrap to keep it all in place. Patients will wear the plaster splint for 2 weeks post-op.
45655407|NCT04906915|Drug|Ketamine|The efficacy of ketamine was assessed by calculating oxygen supply and consumption
45655408|NCT04890379|Drug|Dimethyl fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
45806558|NCT05469425|Behavioral|Preoperative home-based exercise training|"Home-based aerobic and resistance exercise training (preoperative period)~Dose of aerobic exercise:~Type: Walking~Frequency: 3 sessions per week~Duration: 30 minutes~Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~Progression: Increase the walking duration in 10 minutes (after week 2)~Dose of resistance exercise:~Type: Six exercises for upper and lower limbs using bodyweight and free-wights of 1-2kg~Frequency: 2 sessions per week~Duration: 2 sets x 15 repetitions~Rest in-between sets: 45 seconds~Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~Progression: Increase the number of sets (3 sets of 15 repetitions after week 2)~Weekly telephone supervision: A physical therapist will carry out weekly telephone calls with all participants to monitor adverse events and recommend strategies to overcome barriers that arise during the exercise program."
45806559|NCT05467748|Drug|Tazemetostat|combination of oral tazemetostat and intravenous pembrolizumab treatment for patients with advanced non-small cell lung cancer
45806560|NCT05466682|Behavioral|Smartphone-Based Progressive Muscle Relaxation Therapy (PMR)|Relaxation technique delivered via RELAXaHEAD app.
45806561|NCT05466682|Behavioral|Monitored Usual Care (MUC)|Standard of care plus daily symptom reporting using the RELAXaHEAD app electronic diary.
45806562|NCT05462704|Drug|Ferric derisomaltose|Participants assigned to the IV iron group will receive a single IV infusion of 1000 mg ferric derisomaltose (Monoferric, Pharmacosmos Therapeutics Inc., Morristown, NJ) in 250 mL given over 20 minutes.
45941109|NCT00257764|Behavioral|behavioral swallowing exercises/ strategies|
45941110|NCT00257803|Drug|Oxytocin|See detailed description
45941111|NCT00257803|Drug|Saline solution|See detailed description
45941112|NCT00070694|Drug|MDL100.907|
45941113|NCT00257842|Procedure|Standard treatment, sham feedback and biofeedback therapy|
45941114|NCT00401115|Drug|MS-R001 (rapamycin)|Subconjunctival injection in various dosages
45941115|NCT00401115|Drug|MS-R001 (rapamycin)|Intraocular injection in various dosages
46074702|NCT02802774|Other|Velcro Brace|The Velcro wrist brace is a commercially available over-the-counter splint which will initially be fitted over a thin layer of non-stick gauze, 4x4 gauze, and cotton padding. Patients will be asked to wear the brace as much as possible for the first 2 weeks post-op.
45941116|NCT00257881|Drug|CMD-193|
46074703|NCT02802774|Other|Soft Dressing|Patients in the soft dressing group will have non-stick gauze, 4X4 gauze, cotton padding, and a cloth wrap. It will be the same dressing as the custom splint without the plaster slab. Patients wear the soft dressing for the first three days post-op.
46074704|NCT04041739|Diagnostic Test|fungal osteomyelitis culture and sensitivity|swabs from ulcer tissue and bone biopsy for culture and sensitivity test and blood sampling
46074705|NCT02802462|Behavioral|HIT|3-minute intervals at 40% and 80%VO 2max
46074706|NCT02802462|Behavioral|MCT|sustained 60%VO 2max
45655409|NCT04890379|Drug|Placebo|Placebo 240mg orally twice daily for 3 consecutive days
45676331|NCT03909139|Biological|BMAC|A bone marrow biopsy needle will be inserted through an arthroscopy portal and directed to the acetabuloplasty site. Bone marrow is aspirated then centrifuged. From the centrifuged sample, the buffy coat layer (layer of cells, found between the red blood cells and the plasma layers) is removed. The buffy coat layer contains mesenchymal stromal cells. This is called BMAC or Bone Marrow Aspirate Concentrate. The BMAC will be injected into the intra-articular space.
45941117|NCT00257959|Drug|amiodarone beta blocker sotalol|
45941118|NCT00257998|Procedure|Mobilization|manualtherapy techniques
45941119|NCT00070733|Drug|testosterone enanthate|
45941120|NCT00070733|Drug|duastride|
45941121|NCT00258037|Behavioral|Pelvic Floor Muscle training|
45941122|NCT00401154|Other|Stationary Cycling|Use of a stationary bicycle for exercise
45941123|NCT00258076|Drug|EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE|
45941124|NCT00258115|Drug|salsalate|
45941125|NCT00070811|Procedure|Lip revision surgery|Full or partial muscle thickness lip revision surgery.
45806563|NCT05462704|Drug|Ferrous sulfate|325mg ferrous sulfate tablets (65 mg of elemental iron), 1 to 3 orally per day.
45941126|NCT00258193|Drug|MD-1100 Acetate|
45941127|NCT00100971|Drug|autologous tumor cell vaccine|
45941128|NCT00100971|Drug|therapeutic autologous dendritic cells|
45941129|NCT00100971|Procedure|tumor cell-derivative vaccine therapy|
45941130|NCT00258232|Drug|capecitabine|
45941131|NCT00258232|Drug|celecoxib|
45941132|NCT00258232|Drug|irinotecan hydrochloride|
45941133|NCT00258271|Biological|filgrastim|
45941134|NCT00258271|Drug|cladribine|
45941135|NCT00258271|Drug|cytarabine|
45941136|NCT00258271|Drug|imatinib mesylate|
45941137|NCT00258388|Drug|custirsen sodium|"640mg IV for 2 hours - Cycle 1: Days -7, -5, -3, 1, 8, 15 (4 week cycle)~Subsequent cycles:~weekly on days 1, 8, 15 (3 week cycles)"
45941138|NCT00258388|Drug|docetaxel|75mg/m2 IV for 1 hour - Day 1 every 3 weeks (3 week cycles)
45941139|NCT00258388|Drug|prednisone|5mg PO BID
45655410|NCT04900285|Device|Delta Dental Oral Device|"The oral device is designed to move the genioglossus forward, with interior attachments to maintain the placement of the tongue on the floor of the mouth forward. In addition, bite plates made of the Ethylene-vinyl acetate (EVA) plastic were fabricated and embedded with the mouthpiece to encourage subjects to bite down and push the tongue under the interior lower attachment. The upper plate is made of the same material and slightly opens the bite to improve oral air flow further. The primary component of the mouthpiece is fabricated with Vistamaxx material, which is semi-crystalline 2mm co-polymer that can be molded by the user with Nurse assistance to provide a custom fit.~The subject will be fitted by moistening and heating in a microwave. Tthe research staff member will assist to ensure proper fit with both the lower and upper dental devices.~The subject then completes the data collection portion regarding using the SnoreLab app and survey completion as previously described."
45655411|NCT03052777|Behavioral|Telephone counselling|The intervention is a 12 week telephone counselling exercise program where participants will receive weekly telephone counselling that targets key theoretical behavior change constructs. Participants will also receive a copy of Canada's Physical Activity Guideline.
46074707|NCT00865267|Drug|Ultravate® 0.05% ointment, single exposure|A: Experimental Subjects received Bristol-Myers Squibb Company formulated products
45655412|NCT04906837|Diagnostic Test|Trans aortic valve implantation|Measurement of the membranous septum on the pre TAVI scanner and the valve implantation height
45655413|NCT04906291|Other|Toothpaste use|Brushing three times a day
45941140|NCT00258466|Radiation|radiation therapy|
45655414|NCT04900129|Combination Product|Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm%|inhaled vapor containing Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm% twice daily in addition to conventional treatment. That is, 100 gram of emulsion contain diclofenac sodium 1 gram, N-acetyl cysteine 1.2 gm, menthol 20 mg, and methyl salicylic acid 50 mg.
45806564|NCT05460871|Drug|Pregabalin 75mg|participants will receive pregabalin orally 75mg twice daily x 7 days prior to surgery, then 150mg twice daily x 7 days after surgery, followed by 75mg twice daily x 7 days, then stop.
46074708|NCT02798172|Drug|Alogliptin and Metformin|The patients in the control group were given metformin (1,000 mg, bid po) and the patients in the intervention group were given metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)
46074709|NCT00865423|Drug|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
46074710|NCT00865423|Drug|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
45806565|NCT05460390|Other|Therapeutic drug monitoring (TDM)|Serum trough level of adalimumab and anti-adalimumab antibody will be obtained at time of enrollment and every 3 months until the end of the study. Adalimumab dose optimization goal will be to achieve trough drug level in the range of 5 -8 μg/mL.
45806566|NCT05459181|Diagnostic Test|HeartCare|Using HeartCare platform as a tool to successfully augment immunosuppressant agents through regular surveillance allowing minimization of doses and number of agents.
45655415|NCT04929483|Drug|BIO89-100|Subcutaneous injection
45655416|NCT02616601|Drug|Generic Fluorouracil Cream|Topical cream, generic formulation of the brand product.
45655417|NCT02616601|Drug|Carac® (Fluorouracil) Cream|Topical cream, brand product.
45806567|NCT05457998|Diagnostic Test|Flutemetamol F18 Injection|PET imaging of Abeta amyloid
45806568|NCT05457998|Diagnostic Test|[18F]-RO6958948 Injection|PET imaging of Tau aggregates
45806569|NCT05457998|Diagnostic Test|[18F]-MK-6240 Injection|PET imaging of Tau aggregates
45806570|NCT05457790|Behavioral|ACT Intervention|1-week baseline data collection period followed by an 8-week ACT intervention period focusing on acceptance, cognition defusion (i.e., not letting thoughts about sleep control behavior), present moment awareness, perspective taking, values, and committed actions.
45941141|NCT00101088|Drug|imatinib mesylate|Given orally
45941142|NCT00101088|Drug|temsirolimus|Given IV
45941143|NCT00101088|Other|laboratory biomarker analysis|Correlative studies
45941144|NCT00258505|Procedure|Procedure: intracranial monitoring up to 9 days after injury|
45941145|NCT00258622|Drug|NS1209|
45941146|NCT00258622|Drug|Lidocaine|
45941147|NCT00423761|Drug|midazolam|
45941148|NCT00423761|Drug|GW876008|
45941149|NCT00258661|Procedure|Osteopathic Manipulative Treatment|In addition to conventional treatment for pneumonia, a 10-minute standardized OMT protocol + 5-minute nonstandardized component was performed twice daily for the duration of hospitalization.
46074711|NCT02798016|Procedure|Platelet-Rich Plasma|This Platelet-Rich Plasma will be taken from each patient and is going to be used in the treatment of atrophic acne scars
46074712|NCT02798016|Procedure|Micro-needling|Micro-needling will be applied on the acne scars in one side of the face.
46074713|NCT02544139|Other|Chagas Detect Plus|
46074714|NCT00955721|Drug|Gemcitabine|Intravenously (IV) on Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.
45655418|NCT02616601|Drug|Vehicle Cream|Topical cream, placebo. Has no active ingredient.
45655419|NCT04927845|Behavioral|StriveWeekly|"The intervention (app.striveweekly.com) delivers content via independent modules. Principles covered in content modules: Psychoeducation; Self-monitoring; Values-based goal-setting; Behavioral activation; Cognitive restructuring; Sleep hygiene; Time management; Interpersonal avoidance exposures; Physical exercise; Mindfulness; Relaxation strategies; Maintenance planning. Modules get released week-by-week, and participants are self-guided through content. To facilitate skills practice, every module is accompanied by: a weekly intro email and reminder emails; an extras section for tips/suggestions; and a weekly prize drawing. The Dashboard section of the intervention displays user progress, including self-rating graphs and a history log of skills practice. The Campus section of this dashboard provided: campus-specific announcements; referrals to relevant campus wellness resources; and an anonymous livestream of all campus users' activity."
45655420|NCT02492997|Device|Venus Versa|The Venus Versa system is a console that supports an applicators that simultaneously emits radio frequency (RF) and a Pulsed Magnetic Field (PEMF). This combination of energy can raise the temperature of treatment area quickly and homogeneously. The Pulsed Magnetic Field is induced by short pulses of electrical current through coil in the applicator. The magnetic field penetrates into the skin and results in Foucault (Eddy) electrical currents around the cell membranes of the treated tissues. Foucault currents change the electrical potential of charged receptors on the bi-lipid cell membrane layer of dermal cells, which results in the stimulation of molecular and cellular activities and reactions.
45655421|NCT02492997|Other|Glycerine gel|Gel used to protect the skin from the RF energy and to assist with energy distribution
45655422|NCT03052075|Other|Retrospective Data Review|Retrospective, uncontrolled pre- and post-test design in a case series of approximately 250 patients who underwent parathyroidectomy at MD Anderson Cancer Center (years 1990 - 2013 ) and had bone density measures recorded at baseline and at one year post-surgery. Data extracted from the surgical oncology database for bone mineral density measures for each patient at multiple sites including the lumbar spine, total hip (right/left), femoral neck (right/left), and distal 1/3 radius. All measures recorded from two time points: presurgical (baseline) and postsurgical (all follow-up available dates beginning at 1 year post-parathyroidectomy).
45655423|NCT04906603|Device|Theta Burst Stimulation|TBS will be administered three times per day and three days per week for four weeks (totaling 12 TBS intervention visits and 36 TBS intervention sessions). Each TBS intervention session will last approximately 10 minutes (stimulation parameters = 50 Hz, 3 pulses, 10 bursts, 10 second cycle time, 60 cycles, 1800 total pulses).
45655424|NCT02437305|Behavioral|ABCDEs of Melanoma Skin Cancer|Modified melanoma educational intervention that is targeted towards people of color.
45655425|NCT02437305|Behavioral|ABCDEs of Melanoma|Conventional melanoma educational intervention.
45655426|NCT03051919|Other|observation|
45655427|NCT04393207|Drug|Liposomal bupivacaine (LB)|Transverse abdominis plane block will be performed and the neurofascial plane between the internal oblique and the transverse abdominis will be infiltrated with liposomal bupivacaine + bupivacaine or with bupivacaine alone.
45655428|NCT04393207|Drug|Dexamethasone and methylprednisolone (CG)|Transverse abdominis plane block will be performed and the neurofascial plane between the internal oblique and the transverse abdominis will be infiltrated with with bupivacaine alone.
45655429|NCT04393207|Drug|Control group (Bupivacaine)- (BPG)|Transverse abdominis plane block will be performed with plain bupivacaine
45655430|NCT02492841|Drug|Mineral trioxide aggregate|Mineral trioxide aggregate
45655431|NCT02492841|Drug|Calcium hydroxide|Classic calcium hydroxide root canal repair material. Inorganic compound (CA(OH)2. It is the gold standard direct pulp cupping material.
45655432|NCT02492841|Drug|Biodentine|Biodentine (trademark). Septodont. Biodentine root canal repair material. A predose capsule plus five drops of calcium chloride solution.
45655433|NCT04817917|Biological|Japanese Encephalitis Vaccine (Vero Cell), Inactivated;|The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. For participants from Group 1 and Group 2 who haven't completed the JE immunization schedules, a booster dose of JEV-I will be administered at 6 years old.
45806571|NCT05457790|Behavioral|Waitlist|1-week baseline data collection period followed by 8 weeks of maintaining usual routine followed by an 8-week intervention focusing on acceptance, cognition defusion (i.e., not letting thoughts about sleep control behavior), present moment awareness, perspective taking, values, and committed actions.
45806572|NCT05455684|Drug|Aticaprant|Aticaprant will be administered orally as tablets.
45806573|NCT05455684|Other|Placebo|Placebo will be administered orally as tablets.
45941150|NCT00258661|Procedure|Light-touch Treatment|In addition to conventional treatment for pneumonia, a 10-minute standardized light-touch protocol (designed to mimic OMT standardized protocol) + 5-minute auscultation of carotid bruits, heart, and lungs was performed twice daily for the duration of hospitalization.
45941151|NCT00104910|Radiation|Internal Radiation Therapy|
45941152|NCT00104910|Radiation|3-Dimensional Conformal Radiation Therapy|
45941153|NCT00104910|Biological|Cetuximab|Given IV
45941154|NCT00104910|Drug|Cisplatin|Given IV
45941155|NCT00415324|Drug|eribulin mesylate|Given IV
45941156|NCT00415324|Drug|cisplatin|Given IV
45941157|NCT00415324|Other|laboratory biomarker analysis|correlative study
46074715|NCT00955721|Drug|Oxaliplatin|Intravenously (IV) on Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.
46074716|NCT00955721|Drug|Sorafenib|Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops.
45941158|NCT00415324|Other|pharmacological study|correlative study
45941159|NCT00258700|Biological|Haemophilus influenzae type b- and meningococcal (vaccine)|
45941160|NCT00258739|Drug|Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine|Docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy. Further on, 2 Docetaxel cycles and gemcitabine according to arm 2.
45806574|NCT05455424|Drug|Niraparib Oral Product|Niraparib ([3S]-3-[4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl] piperidine [tosylate monohydrate salt]) is an orally available, potent, and highly selective PARP1 and PARP2 inhibitor. The excipients for niraparib are lactose monohydrate and magnesium stearate. Niraparib will be supplied in bottles containing 72 capsules of 100 mg. The capsules should be swallowed whole with water. The capsules should not be chewed or crushed and can be taken without regard to meals.
45806575|NCT05455424|Other|Active Symptom Control|ASC could involve regular specialist follow up; structured assessment of physical, psychological, and social problems; and appropriate treatment, including palliative radiotherapy and steroids.
45941161|NCT00258739|Other|Docetaxel + gemcitabine + carboplatin + radiotherapy|Docetaxel 40 mg/ m² days 1, 8, 21 and 28 with gemcitabine 1200 mg/ m² days 1, 8, 21 and 28 followed by concomitant treatment with docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy (2 Gy/day, 5 days per week and for 6 weeks).
45655434|NCT04817917|Other|No prospective interventions|The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. Participants from Group 3-5 have completed the JE immunization schedules with JEV-I or/and JEV-L. No prospective intervention will be given.
45655435|NCT04412161|Procedure|Liver transplantation|Living donor liver transplantation
45941162|NCT00258778|Drug|Human Glucocerebrosidase (prGCD)|
45806576|NCT05455320|Drug|Talquetamab|Talquetamab will be administered subcutaneously.
45806577|NCT05455320|Drug|Daratumumab|Daratumumab will be administered subcutaneously.
45806578|NCT05455320|Drug|Pomalidomide|Pomalidomide will be administered orally.
45806579|NCT05455320|Drug|Dexamethasone|Dexamethasone will be administered orally or intravenously.
45806580|NCT05453903|Drug|JNJ-75276617|Participants will receive JNJ-75276617.
45806581|NCT05453903|Drug|Venetoclax (VEN)|Participants will receive VEN.
45806582|NCT05453903|Drug|Azacitidine (AZA)|Participants will receive AZA.
45941163|NCT00104949|Biological|trastuzumab|
46074717|NCT02802540|Drug|Nabilone|Patients going to take 0.5 mg capsules of nabilone (CESAMET) the first 2 weeks and then increased to 1 mg to complete 8 weeks.
46074718|NCT02802540|Drug|Placebo|Patients going to take capsules of placebo until complete 8 weeks.
46074719|NCT00865501|Drug|spironolactone|25mg per oral once daily
46074720|NCT00865501|Drug|placebo|placebo
46074721|NCT04277351|Device|Transcranial alternating current stimulation|Focal transcranial stimulation over auditory cortex by means of 5 electrodes delivering an electric current (max. 2mA). In addition to active stimulation, also a placebo (sham) stimulation is employed as a control condition. All subjects included in the study receive all tACS stimulation conditions.
45655436|NCT02436915|Other|Real tDCS|Transcranial direct current stimulation (tDCS) enables noninvasive, selective and sustained modulation of cortical activation. tDCS works by sending low-level currents between two or more scalp electrodes, which alters brain polarity and thus, perfusion and cortical excitability.
45806583|NCT05453903|Drug|Cytarabine|Participants will receive cytarabine
45806584|NCT05453903|Drug|Daunorubicin or Idarubicin|Participants will receive daunorubicin or idarubicin
45806585|NCT05452564|Drug|Baricitinib 2 MG Oral Tablet|Baricitinib, a Janus Kinase inhibitor drug for viral infections, will be administered orally to subjects randomized to this intervention. The dose will be 2 mg orally for ten weeks. This will be compared with placebo intervention. Follow up visits will take place at week 1,2,4 and 10.
45806586|NCT05452564|Drug|Placebo|Patients randomized to the placebo group will receive 2 mg oral daily placebo for ten weeks. Follow up visits will happen for both groups at weeks 1, 2, 4 and 10.
45806587|NCT05448313|Behavioral|Dyadic intervention|Dyads comprising a Veteran and cohabitating support person will participate in the 16-week VA MOVE! weight loss program delivered by video platform. They will then participate in 6 group sessions focused on weight maintenance skills. Communication skills will be taught throughout the intervention.
45806588|NCT05448313|Behavioral|Veteran-only intervention|Veterans will participate in a 72-week weight management program delivered by video platform. 16 sessions will address weight loss, with 6 additional ones addressing weight loss maintenance.
45806589|NCT05447923|Other|Educational Intervention|Undergo education for colorectal cancer screening
45806590|NCT05447923|Other|Fecal Immunochemical Test|Undergo FIT testing
45806591|NCT05447923|Behavioral|Patient Navigation|Undergo patient navigation for positive FIT results
45941164|NCT04709068|Device|Current Health|wearable device and tablet used to collect health measures at home
45941165|NCT00070928|Drug|valerian|
45941166|NCT00258934|Biological|Inactivated, split-virion influenza vaccine|0.1 mL single annual dose
45941167|NCT00258934|Biological|Inactivated, split-virion, influenza virus|0.5 mL single annual dose
45941168|NCT00258973|Procedure|Carotid Ultrasound performed in office practice|
45941169|NCT00101127|Biological|filgrastim|
45655437|NCT02436915|Other|Sham tDCS|For sham tDCS, current will only be applied for the first 60 seconds of each 20 minute session. This is a reliable sham control as sensations arising from tDCS diminish considerably after the first minute of stimulation.
45655438|NCT04815499|Dietary Supplement|Food supplement|ARACOMPLEX® is an authorized food supplement that contains maca extract, vitamin complexes and ions, and that improves the quality of life of the patient.
45655439|NCT04815499|Dietary Supplement|Placebo|Placebo has a composition that makes its weight and organoleptic characteristics are identical to ARACOMPLEX®.
45655440|NCT04398901|Other|Neurodevelopmental assessments|The investigators will evaluate multiple domains of neurodevelopment at age 3, 4, 5 and 7 years using parental questionnaires and child exams. At age 7 years, the children will have a non-sedated quantitative brain MRI.
46074722|NCT02797704|Drug|Aflibercept|Eylea (aflibercept) Injection is a prescription medicine administered by injection into the eye.
45806592|NCT05447923|Other|Questionnaire Administration|Complete questionnaire about colorectal cancer screening and healthcare
45806593|NCT05445882|Drug|Bintrafusp alfa|Bintrafusp alfa (1,200 mg) will be given via IV infusion every 2 weeks for up to 3 years.
45806594|NCT05445882|Drug|N-803|N-803 (15 mcg/kg) subcutaneous injection will be given every 2 weeks for up to 3 years.
45941170|NCT00101127|Biological|pegfilgrastim|
45941171|NCT00101127|Drug|docetaxel|
45941172|NCT00101127|Drug|gemcitabine hydrochloride|
45806595|NCT05445882|Biological|BN-Brachyury|BN-Brachyury collectively refers to the priming doses (MVA-BN-Brachyury) and the boost doses (FPV-Brachyury). MVA-BN-Brachyury subcutaneous injection will be given as 2 priming doses 2 weeks apart. FPV-Brachyury subcutaneous injection will follow MVA-BN-Brachyury injection 2 weeks later every month for 6 months total, then every 3 months until reaching 2 years. After 2 years FPV-Brachyury may be continued at 6-month dosing intervals for up to 3 years.
45941173|NCT00259051|Drug|Omeprazole|
45941174|NCT00259129|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice a day (bid) (2 x 200 mg tablets)
45941175|NCT00070967|Procedure|Acupuncture|
46074723|NCT00865579|Drug|Safinamide|"The Investigational Medicinal Product will be provided by the Sponsor in the form of tablets at dosage strengths of safinamide 50 mg (small - 7 mm) or safinamide 100 mg (large - 9 mm).~Trial Medication is to be taken once daily, in the morning."
46074724|NCT02860325|Device|NIV-NAVA|Non-invasive ventilatory support by means of neurally adjusted ventilatory assist (SERVO-n, Maquet, Solna, Sweden)
46074725|NCT02860325|Device|Conventional|Non-invasive ventilatory support by means of nCPAP or non-synchronized nIPPV (Infant Flow, CareFusion)
46074726|NCT02805582|Drug|10ml ropivacain 0.5%|Ultrasound guided nerve block
45655441|NCT04814875|Drug|ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)|"Pegylated liposomal doxorubicin (30 mg/m²) will be administered intravenously on Day 1 of each 28-day cycle; carboplatin (AUC5) will be administered intravenously on Day 1 of each cycle.~ATX-101 will be administered intravenously on Day 2 of each cycle in three escalation cohorts: 20, 30, and 45 mg/m² according to a 3+3 design."
45655442|NCT04812535|Drug|IFX-1|IFX-1 Monotherapy
45655443|NCT04812535|Drug|IFX-1 + pembrolizumab combination therapy|IFX-1 + pembrolizumab combination therapy
45655444|NCT04413097|Procedure|Delayed Cord Clamping with Low Oxygen concentration|During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and low oxygen concentration (FiO2 0.30) will be provided.
45655445|NCT04413097|Procedure|Delayed Cord Clamping with High Oxygen concentration|During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and high oxygen concentration (FiO2 1.0) will be provided.
45806596|NCT05444530|Biological|VAC85135|Participants will receive VAC85135 as IM injection.
45806597|NCT05444530|Drug|Ipilimumab|Participants will receive Ipilimumab as IV infusion.
45806598|NCT05443594|Device|FARAPULSE Ablation System|Pulsed Field Ablation to isolate the Pulmonary Veins and Posterior Wall using the FARAPULSE Ablation System.
45806599|NCT05440422|Drug|anifrolumab|This is a double blind placebo-controlled study to characterize whether blocking type I IFN receptor signaling with anifrolumab will lead to improvements in vascular function, decreases in vascular inflammation and modulation of biomarkers of vascular risk in patients with SLE.
45941176|NCT00259168|Drug|Nateglinide|
45941177|NCT00259207|Procedure|Pulmonary valve insertion|Pulmonary valve insertion
45941178|NCT00259207|Procedure|medical surgery hybride|medical surgery hybride
45941179|NCT00259246|Drug|Peptide YY infusion|
45941180|NCT00259324|Behavioral|Diet and Activity|Diet and Activity
45941181|NCT00259363|Drug|Oxaliplatin|oxaliplatin 60/mg/m2/15 days, 5-FU 225 mg/m2/day 5 weeks during radiotherapy (RT) 45 Gys/25 days
45941182|NCT00104988|Drug|temozolomide|75 mg/m^2/day PO daily for 6 weeks followed by a 2-week break
45941183|NCT00104988|Drug|thalidomide|200 mg/day PO daily
45941184|NCT00415402|Drug|Vitamin D3|
45941185|NCT00415441|Procedure|Physiotherapy program|
45941186|NCT00415441|Procedure|Placebo physiotherapy treatment|
45941187|NCT00415558|Device|Microwave Ablation System|
45806600|NCT05440422|Other|Placebo|non-active substance comprised of 25 mM histidine/histidine-HCl, 50 mM lysine-HCl, 130 mM trehalose, and 0.05% (w/v) polysorbate 80, with a pH of 5.9.
45806601|NCT05438316|Drug|Ramipril tablet 10 mg|Ramipril is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of ramipril.
45655446|NCT02492763|Drug|MK-8521|Dose strengths: 180 μg QD administered subcutaneously. A 2-step dose escalation regimen [60 μg, 120 μg] over the first 2 weeks is used to achieve the final dose up to 180 μg.); 300 μg QD administered subcutaneously (A 3-step dose escalation regimen [60 μg, 120 μg, 180 μg] over the first 3 weeks is used to achieve the final dose up to 300 μg.
45655447|NCT02492763|Drug|Placebo|Double dummy matching placebo for the MK-8521 and placebo arms: matching placebo for MK-8521 300 μg QD administered subcutaneously; matching placebo for MK-8521 180 μg QD administered subcutaneously. A dose escalation regimen consistent with that of the MK-8521 300 μg and 180 μg arms of the study; mock escalation will be performed over the first 2 to 3 weeks.
45806602|NCT05438316|Drug|Tritace® tablet 10 mg|Tritace® is manufactured by Sanofi-Aventis Deutschland GmbH, Germany. Each tablet contains 10 mg of ramipril.
45806603|NCT05438043|Drug|Daratumumab|Daratumumab will be administered either intravenously or subcutaneously.
45806604|NCT05438043|Drug|Carfilzomib|Carfilzomib will be administered intravenously.
45806605|NCT05438043|Drug|Dexamethasone|Dexamethasone will be administered either orally or intravenously.
45806606|NCT05438043|Drug|Lenalidomide|Lenalidomide will be administered orally.
45806607|NCT05438043|Drug|Pomalidomide|Pomalidomide will be administered orally.
45806608|NCT05436548|Other|Supervisor-employee frequent check-ins to identify and address work stressors|Supervisors will complete three training modules: 1) how and why the check-ins are expected to address burnout; 2) how to demonstrate supportive supervision during the check-ins process, and 3) principle of quality improvement applied to the check-ins
45941188|NCT00259402|Drug|Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)|OXALIPLATIN 60 mg/m2/d, CISPLATIN 55 mg/m2/d, 5-FU 600 mg/m2/d with dose range and followed by radiotherapy
45452877|NCT04505462|Other|Therapeutic diet|A special healthy diet for dialysis patients
45452878|NCT05429216|Procedure|mEMR-C procedure|A transparent cap with an inner groove (MH-593; Olympus, Tokyo, Japan) was attached to the forward-viewing colonoscope. After the endoscope was inserted into the rectum, a crescent-shaped electrosurgical snare was passed through the sheath and looped along the inner groove of the cap. Submucosal injections were not required in this method. The tumor was suctioned into the cap and grasped by tightening the snare. After confirming the appropriate snare placement, both the tumor and overlying mucosa were resected using electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and the resected tumor was sent for pathological examination. Endoscopic examination was repeated without a transparent cap to evaluate the wound carefully in cases of perforation or bleeding and to ensure the absence of residual tumor tissues. If there was spurting or active bleeding, hot forceps were used to stop the bleeding.
45655448|NCT02492763|Drug|Liraglutide|Dose strength: 1.8 mg QD administered subcutaneously. A 2-step dose escalation regimen (0.6 mg, 1.2 mg) over the first 2 weeks is used to achieve the final dose up to 1.8 mg.
45941189|NCT00259441|Drug|Simvastatin|
45941190|NCT00400842|Drug|SA-001|0.25 g of SA-001 pellets/capsule, 12 capsules/day for 7 days
45806609|NCT05436548|Other|Usual practice waitlist controls|If the check-ins are successful in reducing burnout, supervisors at the control clinics will be offered the training modules
45806610|NCT05436470|Device|PK Papyrus|The PK Papyrus is a balloon mounted stent that will be administered during standard of care treatment of pseudoaneurysms.
45806611|NCT05436444|Biological|A/Mallard/Ohio-99/MM4/1989 H10N7|The human challenge virus will be administered intranasally to each participant using a nasal atomizer. A total volume of up to 2 mL will be administered split between both nostrils of each participant.
45806612|NCT05435495|Procedure|Single-photon emission computed tomography|Imaging procedure
45941191|NCT00400842|Drug|SA-001|0.25 g of SA-001 pellets/capsule, 6 capsules/day for 7 days
45941192|NCT00400842|Drug|Placebo|Placebo
45941193|NCT00259480|Behavioral|Home Based Intervention|occupational therapy
45941194|NCT00259519|Procedure|Induction of delivery|Induction of delivery
45458037|NCT04737031|Other|Patient Nudge|Patients will receive a message sent through myPennMedicine following establishment of their smoking status (at the screening encounter). In all cases, the message will include information specific to the upcoming appointment with the oncology clinician.
45806613|NCT05435495|Procedure|Blood Draw|Blood draw for future research tests (45-60 mL).
45806614|NCT05435495|Procedure|Tumor Biopsy|Guided biopsy of lesion
45941195|NCT00259558|Drug|retarded release phosphatidylcholine|
45941196|NCT00259597|Procedure|breast ductal lavage|breast ductal lavage and nipple aspiration done once
45941197|NCT00071201|Drug|Adefovir Dipivoxil for oral suspension, 2 mg/mL|
45941198|NCT00259636|Drug|zonisamide|zonisamide 100 mg -300 mg daily vs placebo
45941199|NCT00259675|Drug|carboplatin/gemcitabine, carboplatin/taxol|
45941200|NCT00105105|Drug|Mifepristone|
45941201|NCT00259714|Drug|dialysate sodium individualization|"Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (individualized)."
45941202|NCT00259714|Drug|standard dialysate sodium|The prescribed dialysate sodium is 140 mEq/L
45806615|NCT05432700|Other|LactApp|"LactApp® provides personalised answers that can be arrived at through different pathways, which vary according to the profile of the user and the options she selects, allowing data sampling through an Ecological Momentary Assessment.~The app will remind of:~The first month: baby's breastfeeding position, frequency of feeds, number and consistency of stools, general breast care, average weight gain; in mothers who gave some supplementation, advice and support for them to try re-breastfeeding.~From the second to the third month: advice on expressing milk to create a reserve just in case they went back to work or had to be absent from home for a day, instructions on how to handle and preserve milk.~From the fourth to the sixth month: indications to use the stored milk (if it was created) and techniques for administering it to the infant, the importance of maintaining the EBF and the inadvisability of offering other types of milk or food."
45941203|NCT00071240|Drug|Somatropin (recombinant human growth hormone)|3.0mg sc daily for 6 months, followed by 1.5mg sc daily for 6 months. Dose stopped, held or reduced by study investigators as indicated by adverse events
45941204|NCT00259753|Drug|Bevasiranib|
45941205|NCT00259792|Drug|Budesonide/formoterol Turbuhaler|
45941206|NCT00105144|Drug|Micafungin|IV
45941207|NCT00105144|Drug|Caspofungin|IV
45452879|NCT05429216|Procedure|ESD procedure|ESD was performed as the standard procedure and has been widely described and used. First, dots were marked approximately 5 mm from the periphery of the lesion using coagulation. Subsequently, a diluted sodium hyaluronate solution with indigo carmine dye was injected submucosally. Mucosal incision and submucosal dissection were performed using a T-Type ESD Knife (Micro-Tech, Nanjing, China) or Dual-knife (Olympus Medical, Tokyo, Japan). After resection was completed, all visible vessels on the artificial wound were thoroughly coagulated to prevent postoperative bleeding.
45452880|NCT00790660|Drug|ASP1941|Oral
45452881|NCT00790660|Drug|Placebo|Oral
45452882|NCT01330082|Other|Adjunctive Photodynamic Therapy|using Light-emitting diod(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark) in the presence of toluidine blue O (TBO)
45806616|NCT05431699|Diagnostic Test|ScreenFire HPV test|ScreenFire HPV test (Atila BioSystems, Inc, Mountain View, CA) uses isothermal amplification to detect 13 high risk (hr)HPV types directly from clinical samples in approximately one hour. The test can be run on any real-time PCR machine and gives separate results for hrHPV types 16 and 18, as well as a pooled positive result for 13 other hrHPV types. The human cellular gene beta-globin is used as an internal control to measure sample adequacy. ScreenFire can be self-collected and does not require batching. AmpFire® obtained CE-mark in 2017.
45452883|NCT01330082|Other|Light-emitting diod Irradiation|625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark
45806617|NCT05431699|Diagnostic Test|careHPV test|The careHPV (QIAGEN, Gaithersburg, MD) test was developed in a public-private partnership specifically for use in low-resource settings. It is a simplified, robust, and affordable HPV test that does not distinguish specific HPV types; rather, it gives a positive result if any of 14 hrHPV types is present in the specimen. Electricity is necessary to run the test, but it does not need running water or air conditioning. In order to be most cost effective, the samples must be run with a full plate of 96 samples. Results take 3-4 hours to complete.
45941208|NCT00259831|Drug|CVT-E002 (Cold-FX); a natural health product|
45941209|NCT00259870|Drug|SB-773812|
45941210|NCT00259870|Drug|Olanzapine|
45941211|NCT00259909|Other|GSK questionnaire|GSK questionnaire will demonstrate the validity, reliability and responsiveness as a tool for measuring subject-reported outcomes during an acute exacerbation of chronic obstructive pulmonary disease.
45941212|NCT00259909|Other|St. George's Respiratory Questionnaire|The SGRQ is a 50-item questionnaire with 76 weighted responses. It provides a Total score and three component scores: Symptoms (distress caused by respiratory symptoms), Activity (physical activities that cause or are limited by breathlessness), and Impacts (social and psychological effects of the disease). The Total score and each of the SGRQ sub-scores are scored from 0 to 100 where 0 indicates best and 100 indicates worst health.
45941213|NCT00259909|Other|Acute Short Form 12 version 2|The Acute SF-12v2 is a multipurpose short-form questionnaire with only 12 questions with two summary scores, the SF-12 Physical Component Summary (PCS-12) and the SF-12 Mental Component Summary (MCS-12). The scoring range for the PCS-12 and MCS-12 is 0 to 100, with a lower score indicating a poorer level of health
45941214|NCT00259909|Other|Global Efficacy questionnaire|Global Efficacy questionnaire will be administered in an electronic form to validate test-retest reliability, responsiveness and minimum important difference (MID)
45941215|NCT00071279|Drug|SR34006 (idraparinux sodium) Injection|
45941216|NCT00400959|Procedure|cd133+cell intracoronary administration|
45452884|NCT01330082|Other|applying Photosensitizer|toluidine blue O is applied at the bottom of each periodontal pocket
45452885|NCT00835354|Drug|Cefprozil for oral suspension 250 mg/5 mL|1 x 250 mg/5 mL, single-dose fasting
45941217|NCT00259948|Procedure|Aerobic exercise training|
45941218|NCT00259987|Drug|Lapatinib (GW572016) oral tablets|
45941219|NCT00260026|Drug|Docetaxel|
45941220|NCT00260026|Drug|Jin Fu Kang|
46074727|NCT00860509|Other|Low Phytosterol and High Phytosterol Diets|Diets with 600 or 100 mg of daily phytosterols for 4 weeks were given to each subject, in random order
45452886|NCT00835354|Drug|CEFZIL® for Oral Suspension 250 mg/5mL|1 x 250 mg/5 mL, single-dose fasting
45452887|NCT04874480|Drug|Decitabine|Given IV
45452888|NCT04874480|Drug|Tegavivint|Given IV
45941221|NCT00260143|Drug|Testosterone enanthate|
45941222|NCT00260143|Drug|Placebo|
46074728|NCT04281095|Drug|Botulinum toxin type A|Total of 20U/0.5mL is intramuscularly administered to five points of the glabellar region, 4U/0.1mL each
46074729|NCT02797938|Device|Taper guard tube|Taper guard tube was intubated
46074730|NCT02797938|Device|Cylindrical tube|Cylindrical tube was intubated
45655449|NCT02492763|Drug|Metformin|Metformin immediate release (IR) or metformin extended release (XR) administered ≥1000 mg QD as background therapy
45806618|NCT05431699|Procedure|Colposcopy and biopsy|A colposcopic exam with biopsy entails visual magnification of the cervix and the removal of a small piece of cervical tissue. After the application of acetic acid 5% onto the cervix, a device called a colposcope allows the clinician to visually identify changes consistent with HPV. Areas of the cervix where lesions appear (or if not, randomly selected sections) are then biopsied (small piece of sample removed) and an endocervical curettage is performed (removing a small section from the inside of the cervix). Tissue specimens are then sent to the lab for pathology diagnosis.
45806619|NCT05431699|Procedure|Gas-based cryotherapy|"Cryotherapy is performed to treat high-grade cervical precancer. First, a speculum is introduced into the vagina to identify the cervix. Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer. If the cervix is able to be fully evaluated and there are no signs of invasive cancer, a metal probe is inserted into the vagina and the tip is pressed against the cervix. Compressed carbon dioxide or nitrous oxide gas at a temperature of approximately -50ºC/-58ºF freezes the tip and creates an ice ball on the cervix. The ice ball ablates or destroys the abnormal cells."
45941223|NCT00105222|Drug|Sodium Nitrite|
45941224|NCT00260221|Behavioral|using VR hypnosis/distraction and audio hypnosis|a between subject comparison using VR hypnosis and VR distraction and audio hypnosis for pain control
45941225|NCT00260260|Drug|Oxycodone|
45941226|NCT00105300|Drug|Adalimumab|
45941227|NCT00071474|Procedure|shamanic healing|
45941228|NCT00260338|Biological|stem cell|mesenchymal stromal cell
45941229|NCT00260377|Procedure|Coronary artery bypass surgery|
45941230|NCT00260416|Procedure|Primary angioplasty with stent and abciximab|
45941231|NCT00260494|Other|acupuncture|standardized acupuncture intended to improve blood flow and reduce edema to lower extremity.
45941232|NCT00260494|Other|sham acupuncture|standardized sham acupuncture at same sites as acupuncture.
45941233|NCT00071591|Behavioral|Functional Adaptation Skills Training (FAST)|
45941234|NCT00260611|Drug|Oxaliplatin|
46088538|NCT00621660|Procedure|Acupuncture|"Acupuncture was administered bilaterally to the standard antiemetic point2-4 pericardium six (PC6) located between the tendons of palmaris longus and flexor carpii radialis at two body-inches proximal of the wrist crease. Sharp needles, diameter 0.25 x length 40 millimetres, were inserted into a depth of a half body-inch. One body-inch (or a cun in traditional Chinese medicine context) is equivalent to the greatest width of the individual patients´ thumb at the distal phalanx, approximately one and a half centimetres or one American thumb. The needles were manipulated three times (at the start, middle and end of the treatment session) by twirling, thrusting and lifting until deqi occurred."
45452889|NCT00698230|Drug|INCB013739|INCB013739 5 mg QD tablet
45655450|NCT04899817|Drug|Granisetron|The drug is given after induction of general anesthesia
45655451|NCT04905667|Drug|GB221|6 mg/kg, single dose, intravenous infusion, 90-100 min
45941235|NCT00260611|Drug|Taxotere|
45941236|NCT00424086|Biological|Inactivated seasonal influenza vaccine (split virus, vero cell derived)|
45941237|NCT00424086|Biological|Inactivated seasonal influenza vaccine (split virus, egg derived) [licensed control vaccine]|
45941238|NCT00260650|Behavioral|Heart PACT Program|patient activation intervention
45941239|NCT00260728|Device|vascular access graft implantation|vascular access graft implantation
45452890|NCT00698230|Drug|INCB013739|INCB013739 15 mg QD tablet
45655452|NCT04905667|Drug|Herceptin|6 mg/kg, single dose, intravenous infusion, 90-100 min
45655453|NCT03050749|Device|Princess® VOLUME|Princess® VOLUME injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
45655454|NCT02491671|Device|Hemopatch|
45655455|NCT02491671|Procedure|standard preventive measures|
45941240|NCT00260767|Drug|HEC placebo gel|
45941241|NCT00071630|Behavioral|Cognitive Behavioral Therapy|
45941242|NCT00101205|Drug|oxaliplatin|Given IV
45941243|NCT00101205|Drug|etoposide|Given IV
45941244|NCT00260884|Behavioral|conventional gastrectomy or radical lymph node dissection|
45941245|NCT00260923|Drug|aliskiren|
45655456|NCT04889677|Drug|Danicopan|
45655457|NCT04889677|Drug|Placebo|
45655458|NCT04397107|Drug|IL-2|Patients were received low dose recombinant human Interleukin-2
45655459|NCT02453841|Drug|Oxymetazoline|
45655460|NCT04430647|Procedure|combined phacoemulsification and ultrasound ciliary plasty (Phaco-UCP)|performing ultrasound ciliary plasty then performing standard phacoemulsification
45941246|NCT00071669|Procedure|Acupuncture|
45941247|NCT00424918|Behavioral|Physical Activity, reduced sedentary behavior|
45941248|NCT00261001|Biological|Transcutaneous mode of administration|
45941249|NCT00261001|Biological|Intramuscular mode of administration|
45941250|NCT00261079|Drug|Fexofenadine|
45941251|NCT02966600|Other|Progressive resistance exercise|The intervention group participated in sixteen PRE training sessions for eight weeks: two sessions per week on non-consecutive days, sixty-seventy min each one.
45941252|NCT02966600|Other|Physical Activity|The control group followed its usual weekly physical activity routine
45941253|NCT00261118|Drug|Rituximab|Rituximab 1g in 500 mls Normal Saline Placebo 500 mls Normal Saline
45941254|NCT00105378|Behavioral|Dutch EASYcare Study Geriatric Intermediate Care Programme|
45941255|NCT00261157|Device|InTouch Telerounding Robot|
45941256|NCT00261196|Drug|Collagenase|Anterior shoulder capsule injection
45941257|NCT00261235|Behavioral|Supported Employment|
45941258|NCT00261235|Behavioral|Using Strengths in Employment System (USES)|
45941259|NCT00105417|Drug|IL-7|
45941260|NCT00071747|Drug|lamotrigine|
45941261|NCT02961049|Procedure|Gingival displacement|Gingival displacement with a gingival cord (#0, #00 or #000) with specific spatula.
45941262|NCT02961049|Procedure|Enamel and dentin etched|Enamel and dentin etched with 35% phosphoric acid for 30 and 15 seconds, respectively.
45655461|NCT04430647|Procedure|Phacoemulsification alone|standard phacoemulsification for catarct extraction
45655462|NCT03081689|Drug|Nivolumab 360 mg|Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months
45941263|NCT02961049|Procedure|Selective enamel etched|Selective enamel etched with 35% phosphoric acid for 15 seconds.
45806620|NCT05431699|Procedure|Thermal ablation|Thermal ablation is utilized to treat high-grade cervical precancer. First, a speculum is introduced into the vagina to identify the cervix. Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer. If the cervix is able to be fully evaluated and there are no signs of invasive cancer, the tip of the device is heated to 100ºC and applied directly to the cervix for 1-2 minutes, which ablates or destroys the abnormal cells.
45806621|NCT05429372|Genetic|PF-06939926|All participants will receive a single dose of PF-06939926 on Day 1.
45806622|NCT05429268|Drug|Tafasitamab|Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.
45806623|NCT05429268|Drug|Lenalidomide|Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles.
45806624|NCT05427734|Device|Jaspr2.0|Participants assigned to this condition will receive access to Jaspr2.0 and its companion mobile app, Jaspr-at-Home, for 12 weeks.
45806625|NCT05427734|Device|Active-Control app + electronic wellness resources brochure|Participants assigned to this condition will receive access to Virtual Hope Box, a well-regarded suicide prevention self-help app, for 12 weeks plus an electronic wellness resources brochure.
45806626|NCT05427370|Procedure|Revascularization by PCI|"Contemporary, State-of-the-art PCI techniques will be encouraged in STICH3C, based on the most recent evidence and clinical practice guidelines recommendations. The best practices to be followed include the use of physiological and intravascular guidance, new-generation drug-eluting stents or scaffolds, rotational or orbital atherectomy for extensive calcifications, recommended bifurcation techniques, chronic total occlusion for viable segments by experienced operators, and trans-radial access.Planned temporary ventricular support is permitted by experienced operators when deemed indicated."
45941264|NCT02961049|Procedure|Wash and dry|Wash and dry with absorbent paper.
45941265|NCT02961049|Device|Total-etch adhesive system|Two layers of pirmer/bond on enamel and dentin with a brush.
45941266|NCT02961049|Device|self-conditioning adhesive system|One layer of acid/pirmer on enamel and dentin with a brush following to one layer of bond with a brush.
45452891|NCT00698230|Drug|INCB013739|INCB013739 50 mg QD tablet
45655463|NCT03081689|Drug|Paclitaxel 200mg/m2|Paclitaxel 200mg/m2 IV Q3W
45655464|NCT03081689|Drug|Carboplatin AUC 6|Carboplatin AUC 6 IV Q3W
45655465|NCT04889365|Diagnostic Test|SG Diagnostics COVID-19 Antigen Rapid Test Kit|SG Diagnostics COVID-19 Antigen Rapid Test Kit (self-use)
45655466|NCT04889365|Diagnostic Test|Polymerase chain reaction (PCR) test|Professional collection of a second swab sample, for confirmation by PCR
45655467|NCT04889131|Behavioral|Yoga Program Immediately|free 12 week yoga program, twice a week for 75 minutes each
45655468|NCT04889131|Behavioral|Wait-Listed Control|assigned to take the Yoga Program in 12-weeks
45655469|NCT04889131|Other|Activity Monitor|Garmin VivoSmart activity monitor throughout study
45806627|NCT05427370|Procedure|Revascularization by CABG|The surgical revascularization strategy will be tailored according to the individual patient's coronary anatomy, left ventricular remodeling, aortic atherosclerosis, co-morbidities, local expertise, and surgical judgement. An internal thoracic artery will be used to graft the left anterior descending in all cases. Multi-arterial grafting may be considered in patients without significant co-morbidities and with expected limited vasopressor use, or in patients without saphenous conduits. Choice of on- vs. off-pump surgery is influenced by LV size, associated valvular disease, and aortic atherosclerosis, as well as surgeon experience, but on-pump surgery is recommended routinely. The use of adjunctive intra-aortic balloon support or other cardiac support is not routinely recommended in stable patients; the intra-aortic balloon support is the first line mechanical support.
45806628|NCT05426525|Drug|Empagliflozin|Participants will take 10mg empagliflozin per day for 2 weeks. Absent contraindications, dosing will be increased to 25 mg empagliflozin per day for the next 11 weeks.
45806629|NCT05426525|Drug|Multivitamin-Placebo|Participants will take 1 multivitamin per day for 13 weeks.
45941267|NCT02961049|Procedure|Photoactivated|Photoactivated for 20 seconds
45941268|NCT00261274|Biological|A-ECO|
45941269|NCT00261274|Biological|Saline|
45941270|NCT00261313|Drug|Neulasta|6mg Neulasta to be given approximately 24 hours afer each cycle of chemotherapy
45941271|NCT00261313|Drug|Aranesp|If Hb drops below 110, 300mcg Aranesp will be administered.
45941272|NCT00101244|Drug|ispinesib|Given IV
45941273|NCT00101244|Other|laboratory biomarker analysis|Correlative studies
45941274|NCT00101244|Other|pharmacological study|Correlative studies
45941275|NCT00261352|Drug|Tesaglitazar|
45941276|NCT00261352|Drug|Metformin|
45941277|NCT00261352|Drug|Fenofibrate|
45655470|NCT04130867|Procedure|pHRM|Pharyngeal high--resolution manometry (pHRM) provides direct and objective measurement of pressure changes in the pharynx that characterize basic mechanisms of swallowing.
45655471|NCT04130867|Procedure|VFSS|Videofluoroscopic Swallow Study (VFSS) enables real-time visualization of bolus flow during swallow movement.
45941278|NCT00261391|Drug|Marimastat|
45655472|NCT04888663|Drug|Trastuzumab + Ramucirumab + Paclitaxel|For both Phase Ib and II: Trastuzumab 4 mg/kg (loading dose) followed by 2 mg/kg on Days 1, 8, 15 and 22, and ramucirumab 8 mg/kg on Days 1 and 15, as well as paclitaxel will be administered intravenously in a 4-week cycle (every 28 days) For Phase Ib, Paclitaxel 80 or 70 mg/m2 (according to dose level) will be administered on Days 1, 8, 15 For Phase II, paclitaxel at RP2D (80 or 70 mg/m2) will be administered on Days 1, 8, 15 of each cycle
45655473|NCT04662905|Device|Evoke Spinal Cord Stimulation (SCS) System|ECAP-controlled, closed-loop SCS
45452892|NCT00698230|Drug|INCB013739|INCB013739 100 mg QD tablet
45452893|NCT00698230|Drug|INCB013739|INCB013739 200 mg QD
45941279|NCT00071942|Biological|recombinant vaccinia-MUC1 vaccine|Given intradermally
45941280|NCT00071942|Biological|recombinant vaccinia-TRICOM vaccine|Given intradermally
45941281|NCT00071942|Other|laboratory biomarker analysis|Correlative studies
45941282|NCT00071942|Procedure|quality-of-life assessment|Ancillary studies
45655474|NCT04899427|Drug|orelabrutinib|Orelabrutinib will be given as 150mg per day orally, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
45655475|NCT04899427|Drug|Sintilimab|Sintilimab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
45655476|NCT04899427|Drug|Tislelizumab|Tislelizumab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
45655477|NCT02453685|Drug|biphasic insulin aspart 30|Injected s.c./subcutaneously once daily with the largest meal Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
45655478|NCT02453685|Drug|insulin glargine|Injected s.c./subcutaneously once daily at the same time every day, with the possibility of treatment intensification with insulin aspart (Basal-bolus arm) Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
45655479|NCT02453685|Drug|insulin aspart|Injected s.c./subcutaneously once daily.
45655480|NCT04658771|Device|MR-HIFU treatment|"MR-HIFU is an innovative technology that allows for non-invasive thermal ablation of tissues and tumors by integrating an external high intensity focused ultrasound (HIFU) transducer with a conventional MRI scanner.~The focused ultrasound transducer is placed outside of the body and generates and focuses acoustic energy to heat tumors or other pre-defined focal regions of tissues inside the body. Because the acoustic energy is precisely focused over tiny areas of tissue, potential thermal injury to surrounding tissues is minimal. Cell death inside the selected treatment area occurs via coagulative necrosis while avoiding injury to intervening and adjacent tissues."
45806630|NCT05426213|Device|Robot-assisted Bronchoscopy (Monarch Platform)|Robotic assisted bronchoscopy biopsy procedures will be performed using the Monarch platform.
45806631|NCT05425940|Drug|XL092|Supplied as tablets; administered orally daily
45806632|NCT05425940|Drug|Atezolizumab|Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once in a 3-week cycle (q3w)
45806633|NCT05425940|Drug|Regorafenib|Supplied as 40 mg tablets; administered orally daily at 160 mg for the first 21 days of each 28-day cycle
45806634|NCT05424822|Drug|JNJ-80948543|JNJ-80948543 will be administered as SC injection.
45806635|NCT05423717|Drug|Daridorexant 10 mg|Daridorexant will be taken orally, once daily in the evening during the treatment period.
45806636|NCT05423717|Drug|Daridorexant 25 mg|Daridorexant will be taken orally, once daily in the evening during the treatment period.
45806637|NCT05423717|Drug|Daridorexant 50 mg|Daridorexant will be taken orally, once daily in the evening during the treatment period.
45806638|NCT05423717|Drug|Placebo|Placebo will be taken orally, once daily in the evening during the treatment period.
45941283|NCT00261430|Behavioral|GAIN Acceptance Approach|
45806639|NCT05419635|Drug|Asundexian (BAY2433334)|Study intervention BAY2433334 will be administered as tablet taken orally.
45941284|NCT00261469|Drug|topiramate|
45806640|NCT05417698|Other|Exercise Only (Ex only)|Unsupervised, home-based, equipment-free high-intensity interval training of 20 minutes exercise performed 3 times a week, for a duration of 8-weeks. Participants will perform exercises to their own suitability in a progressive manner throughout the 8-weeks. Exercises will be exerted at least ≥80% of predicted heart rate maximum (HRmax; 220-age) during the high-intensity intervals, as well as at least 17 out of 20 Rate of Perceived Exertion on the Borg Scale.
45941285|NCT00261508|Drug|risperidone|
45941286|NCT00261547|Drug|Rituximab|All subjects will be treated with Rituximab 1000 mg (1 g) intravenously on days 1 and 15.
45941287|NCT00261586|Drug|aspirin, acetaminophen, ibuprofen, naproxen, celecoxib, rofecoxib|
45941288|NCT00072020|Drug|zoledronic acid|
45941289|NCT00072020|Procedure|adjuvant therapy|
45941290|NCT00072020|Procedure|neoadjuvant therapy|
45941291|NCT00261625|Drug|alendronate|
45941292|NCT00261664|Device|telehomecare|
45941293|NCT00261703|Drug|Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Docetaxel 75 mg/m2, Day 1 of the cycle + Cisplatin 75 mg/m2 Day 1 + 5-FU 750 mg/m2/day in 24-h continuous infusion for 5 days. 3 cycles will be administered, every 21 days, before the local-regional treatment (same as control group)
45941294|NCT00261703|Drug|Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Cisplatin 100 mg/m2 Day 1, 5-FU 1000 mg/m2/day in 24-h continuous infusion for 5 consecutive days. 3 cycles will be administered every 21 days, before the local-regional treatment (same as control group)
45806641|NCT05417698|Other|Exercise and Mediterranean Diet (Ex + MedDiet)|"Participants in Ex+MedDiet arm adhere to a non-caloric restrictive Mediterranean diet throughout the 8-weeks comprising of a diet encompassing a focus on minimally processed food, incorporating a wide variety of fruits, vegetables, legumes and wholegrains, whilst utilising olive oil as the main source of fat. They will be encouraged to eat more oily and white fish, with moderate consumption of nuts, poultry and dairy products, and low consumption of red/processed meat and alcohol.~Participants will also perform unsupervised, home-based, equipment-free high-intensity interval training of 20 minutes exercise performed 3 times a week, for a duration of 8-weeks. Participants will perform exercises to their own suitability in a progressive manner throughout the 8-weeks. Exercises will be exerted at least ≥80% of predicted heart rate maximum (HRmax; 220-age) during the high-intensity intervals, as well as at least 17 out of 20 Rate of Perceived Exertion on the Borg Scale."
45655481|NCT04888975|Device|Dayspring Active Wearable Compression System|Dayspring Active Wearable Compression System
45655482|NCT04655963|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
45655483|NCT04899739|Diagnostic Test|Echoendoscopy|Peripancreatic lymph nodes and at a distance from the pancreas assessment by endoscopic ultrasound, elastography an doppler to record their anatomical location and characteristics. All lymph nodes suspected of metastatic disease will be marked with sterile black ink.
45655484|NCT04918797|Biological|COVAXIN|Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®)
45806642|NCT05415384|Device|Cryoablation of Intercostal Nerves|Using Atricure device, cryoice, intercostal nerves 3-8 will be ablated in the experimental arm. This is in addition to mechanical fixation of rib fractures and multimodal systemic therapy.
45452894|NCT00698230|Drug|Placebo comparator matching INCB013739|Orally once daily tablet
45452895|NCT00698230|Drug|Metformin|
45806643|NCT05415384|Procedure|Standard surgical treatment of patients with multiple rib fractures|Standard surgical treatment of patients with multiple rib fractures
45941295|NCT00261703|Other|Cisplatin + radiotherapy|Cisplatin 100 mg/m2 on days 1, 22 and 43 simultaneously with radiotherapy (2 Gy x 1/day, 5 days per week for 7 weeks-tumor- and 2 Gy x 1/day, 5 days per week for 6 weeks- lymph nodes)
45941296|NCT00261742|Drug|Penicillin versus cefuroxim per os|
45941297|NCT00072059|Biological|methoxy polyethylene glycol epoetin beta|
45452896|NCT04433468|Device|RIPC|The tourniquet attached to the upper limb was inflated and blocked for 5 minutes, then deflated for 5 minutes to restore blood flow and induce ischemic preconditioning.
45941298|NCT00261781|Behavioral|Treadmill training|Walking on a treadmill 3 times per week for 6 weeks
45941299|NCT00261820|Drug|tacrolimus|
45941300|NCT00261820|Drug|mycophenolate mofetil|
45941301|NCT00261820|Drug|methylprednisolone|
45941302|NCT00261820|Drug|prednisolone|
45941303|NCT00261820|Drug|sirolimus|
45452897|NCT01330238|Drug|Zoledronic acid vs. placebo|Single infusion of zoledronic acid or placebo
45452898|NCT00790426|Drug|TKI258|
45941304|NCT00261859|Behavioral|BNI|behavioral- brief intervention
45941305|NCT00261898|Procedure|Increase sleep|
45941306|NCT00072098|Biological|adenovirus vector|
45941307|NCT00072098|Biological|interleukin-12 gene|
45941308|NCT00261937|Drug|Inhaled Furosemide vs Placebo (Normal Saline)|
45941309|NCT00105495|Drug|Ferriprox (deferiprone)|
45941310|NCT00105495|Drug|Desferal (deferoxamine)|
45941311|NCT00261976|Drug|Infliximab (Remicade)|This is an non-interventional study. Participants took the study product as part of their medical routine.
45941312|NCT00072137|Biological|Recombinant Fowlpox-TRICOM Vaccine|Given intravesically
45941313|NCT00072137|Biological|Recombinant Fowlpox GM-CSF Vaccine Adjuvant|Given intravesically
45941314|NCT00072137|Procedure|Therapeutic Conventional Surgery|Undergo cystectomy
45941315|NCT00072137|Other|Pharmacological Study|Correlative studies
45941316|NCT00072137|Other|Laboratory Biomarker Analysis|Correlative studies
45452899|NCT01330472|Drug|Xanax XR tablets 3 mg (sourced from Caugus)|Tablets, 3 mg, single dose
45452900|NCT01330472|Drug|Xanax XR tablets 3 mg (sourced from Barceloneta)|Tablets, 3 mg, single dose
45452901|NCT00697918|Drug|RWJ-333369|100 mg to 400 mg twice daily
45452902|NCT00835276|Drug|Fexofenadine 180 mg tablets|1 x 180 mg
45452903|NCT00835276|Drug|ALLEGRA® 180 mg tablets|1 x 180 mg
45452904|NCT04718740|Drug|fluzoparib|Group A: Caffeine, vitamin K, warfarin, omeprazole, and midazolam with or without fluzoparib Group B: Repaglinide and bupropion with or without fluzoparib
45655485|NCT05530187|Device|Electronic Patient-reported Outcomes-based Model of Care|Patients in the intervention arm of this study will report symptoms weekly through an electronic symptom questionnaire. For the first 3 months of the 6 month intervention, they will reassess the reported symptoms daily. A team of oncology nurses will contact patients by telephone if they declare a new or worsening symptom. The nurses will use a triage algorithm to identify patient needs (self-care, remote follow-up or in-person assessment).
45655486|NCT04905355|Device|Virtual reality|The VR used during the ambulatory orthopedic surgery allows immersive experience in HD-2D virtual environment. Patient can choose among movies, cartoons, entertainments offered for visualization during the surgery
45655487|NCT03051841|Drug|CKD-581|Intravenously on Days 1, 8 of each 21-day treatment cycle.
45941317|NCT00105573|Behavioral|Maternal interpersonal psychotherapy (IP)|Participants will receive 16 weekly sessions of maternal IP designed to directly treat maternal depression.
45941318|NCT00105573|Behavioral|Infant-parent psychotherapy|Participants will receive 1 year of in-home, infant-parent psychotherapy, an intervention addressing relationship difficulties between depressed mothers and their infants.
45941319|NCT00105573|Behavioral|Informational meetings plus treatment as usual|Participants will be invited to attend informational meetings as well as be referred to local services available to people with depression.
45655488|NCT04905043|Drug|Acalabrutinib|Participants will receive a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2).
45655489|NCT04905043|Drug|SmartPill®|Participnats will receive a single oral dose of wireless motility/pH capsule (SmartPill®) on Day 1 (Period 1) and Day 4 (Period 2).
45941320|NCT00262015|Biological|· Meningococcal C conjugate vaccine; Meningococcal A/C Polysaccharide vaccine (partial dose)|
45941321|NCT00262054|Drug|Bivalirudin|bivalirudin to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
45452905|NCT03344536|Drug|Fulvestrant|Fulvestrant will be administered according to its approved dose of 500 mg intramuscularly on days 1, 15, 29 and then every 28 days (+/-3 days) thereafter.
45806644|NCT05414981|Drug|ABI-H3733|25 mg or 100 mg tablets for oral administration
45941322|NCT00262054|Drug|Un-fractionated heparin|UFH is given as an intravenous bolus of 140 units/kg followed by infusion of placebo 1.75 mg/kg per hour for the duration of the procedure.
45941323|NCT02966366|Device|Cochlear implant|
45941324|NCT00105612|Device|Memory and Organizational Aid|
45941325|NCT00105612|Behavioral|Standard Informed Consent Process|The informed consent protocol for a hypothetical early-phase drug trial will be administered by a trained interviewer in the patient's home
45941326|NCT00262132|Drug|Mycophenolate|
45941327|NCT00262210|Drug|Cyclophosphamide Epirubicin Etoposide Prednisolone|
45941328|NCT00262249|Drug|somatropin|
46088539|NCT00621660|Procedure|Sham|Sham acupuncture was administered bilaterally to a non-acupuncture point two body-inches proximal of PC6 with the telescopic Park sham device16, 0.30 x 40 millimetres (fully extended length). That needle looks identical with a real needle but is blunted and glides upwards into its handle instead of penetrating, which gives an illusion of penetration. The marking tubes hold the needles in place. The therapist gave an illusion of manipulation by turning the needle three times, each time for a couple of seconds until the needle touched the skin, but no deqi occurred. Except when placing and manipulating the sham needle, it was not pressed against the skin at all.
45655490|NCT03050983|Device|IPI|Enable the IPI algorithm and IPI alarm algorithm
45655491|NCT02436759|Drug|RVL-1201|RVL-1201 Ophthalmic Solution 0.1%
45655492|NCT02436759|Drug|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
45806645|NCT05414981|Drug|Placebo|25 mg or 100 mg tablets for oral administration
45806646|NCT05413018|Drug|CC-486|Specified dose on specified days
45806647|NCT05413018|Other|Placebo|Specified dose on specified days
45452906|NCT03344536|Drug|Debio 1347|Debio 1347 will be administered orally daily (1 cycle is 28 days) and the dose of Debio 1347 could be deescalated.
45452907|NCT01759238|Drug|Capecitabine|825mg/m2 per os bid
45806648|NCT05407714|Device|SpaceOAR Treatment|"SpaceOAR System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR System to reduce the radiation dose delivered to the anterior rectum.~The SpaceOAR System is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time."
45452908|NCT01759238|Drug|Bevacizumab|7.5 mg/kg
45452909|NCT01759238|Radiation|Radiotherapy|(conventional or intensity-modulated and image-guided radiotherapy)
45655493|NCT04888741|Drug|Thymoglobulin|GVHD prophylaxis
45655494|NCT04888741|Drug|Cyclophosphamide|Post transplant cyclophosphamide strategy for GVHD prophylaxis
45655495|NCT04888741|Drug|Cyclosporine|immunosuppressant
45452910|NCT00697762|Drug|RWJ-333369|200 mg tablet twice daily for 12 weeks
45655496|NCT04888741|Drug|Sirolimus|immunosuppressant
45452911|NCT00697762|Drug|RWJ-333369|100 mg tablet twice daily for 12 weeks
45452912|NCT00697762|Drug|Placebo|Placebo tablet twice daily for 12 weeks
45452913|NCT03299062|Diagnostic Test|Cytology and Immunohistochemistry|Determine if nasal swabs can provide an adequate sample for evaluation using cytology and immunohistochemistry for alpha-synuclein, A-beta and p-tau staining.
45655497|NCT04888741|Drug|Mycophenolate Mofetil|immunosuppressant
45655498|NCT04888819|Drug|DWP14012|DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks
45655499|NCT04888819|Drug|DWP14012|DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
45655500|NCT02436681|Device|MIROMESH|
45806649|NCT05403580|Drug|Olanzapine|Given PO
45806650|NCT05403580|Drug|Placebo Administration|Given PO
45806651|NCT05403580|Other|Questionnaire Administration|Ancillary studies
45806652|NCT05403138|Drug|Daratumumab|Induction Phase: (8mg/kg) via intravenous (IV) evey 2 weeks for two cycles. Maintenance Phase: (4mg/kg) IV every 4 weeks.
45806653|NCT05403138|Drug|Placebo|Induction Phase: matching placebo (8mg/kg) via intravenous (IV) every 2 weeks for two cycles; Maintenance Phase: matching placebo (4mg/kg) IV every 4 weeks.
45806654|NCT05402384|Drug|AVTX-801|Medical grade D-galactose
45806655|NCT05402384|Drug|Placebo|Placebo
45806656|NCT05402345|Drug|GlcNAc-GlcN|GlcNAc eye drops
45806657|NCT05402345|Other|Placebo|Placebo eye drops
45941329|NCT02966327|Device|Bilateral leg compression stockings|Prescribed Jobst Elvarex compression class 1 (18 to 21 mmHg) standard or custom-made stockings for both lower limbs with or without panty; participants will be recommended to wear the garments for 12 to 16 hours daily for at least 6 months post-operatively.
45941330|NCT02966327|Behavioral|Individualized exercise|Individualized education on exercise according to the Canadian Physical Activity Guidelines and self-lymphatic drainage techniques
45941331|NCT02966327|Behavioral|Lymphedema risk reduction|Standard education on lymphedema risk reduction along with printed materials from the Lymphedema Association of Quebec
45941332|NCT00105651|Behavioral|Combined nursing invention|
45941333|NCT00262288|Drug|i.v. recombinant human C1 inhibitor|
45941334|NCT00262327|Drug|Antangiogenesis|
45941335|NCT00262327|Genetic|endostatin gene|
45941336|NCT00262366|Device|Comparison of automatic CPAP versus fixed CPAP|
45941337|NCT02966288|Drug|Toradol|3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.
45452914|NCT00835042|Drug|Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|1 x 15/25 mg
45655501|NCT03052153|Other|No investigational intervention performed for this study|No investigational intervention for the purpose of this study was performed; data collected is retrospective data previously collected for non-research purposes.
45655502|NCT04927065|Biological|mRNA-1273.211|Sterile liquid for injection
45806658|NCT05399992|Other|Inclisiran|Prospective observational study. There is no treatment allocation. Patients who are receiving or intend to receive inclisiran are eligible to enroll into this study.
45806659|NCT05399446|Behavioral|Diabetes Body Project|The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.
45806660|NCT05399446|Behavioral|Educational Group|We selected a T1D management/Eating disorder psychoeducational comparison condition to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
45806661|NCT05398796|Biological|mRNA -1215|mRNA-1215 is a novel mRNA vaccine that encodes for the secreted prefusion stabilized F component covalently linked to G monomer (pre-F/G) of Malaysian strain NiV, resulting in a post-expression trimerization.
45941338|NCT02966288|Drug|Oral NSAID|800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
45941339|NCT00262405|Drug|zileuton|
45655503|NCT04927065|Biological|mRNA-1273|Sterile liquid for injection
45806662|NCT05398445|Drug|AMG 451|Participants will receive AMG 451 subcutaneously.
45655504|NCT04927065|Biological|mRNA-1273.617.2|Sterile liquid for injection
45655505|NCT04927065|Biological|mRNA-1273.213|Sterile liquid for injection
45806663|NCT05398445|Drug|Placebo|Participants will receive a placebo subcutaneously.
45806664|NCT05396872|Other|Participant Surveys|Online surveys administered post appointment
45806665|NCT05396872|Other|Mobile app|Mobile application installed on mobile device
45806666|NCT05394324|Device|Intervention|No study treatments will be administered during this retrospective study. However, data will be collected from medical records of patients who have been treated with subject devices of this study.
45941340|NCT00262405|Drug|azathioprine/prednisone|
45941341|NCT00262444|Procedure|Different turning frequencies|
45655506|NCT04927065|Biological|mRNA-1273.529|Sterile liquid for injection
45655507|NCT04927065|Biological|mRNA-1273.214|Sterile liquid for injection
45806667|NCT05394220|Diagnostic Test|16S rRNA gene amplicon sequencing|molecular sequencing for the microbiome in parapneumonic effusion
45941342|NCT00262483|Drug|VX-950|
45941343|NCT00262483|Drug|ribavirin|
45941344|NCT00262483|Drug|peginterferon alfa-2a|
45941345|NCT00262561|Drug|Aspirin|The effect of Aspirin on platelet function was assessed.
45941346|NCT00105690|Behavioral|Telemedicine intervention|
45452915|NCT00835042|Drug|UNIRETIC® 15/25 mg tablets|1 x 15/25 mg
45452916|NCT04685746|Behavioral|Balanced Growth Protocol|Assessment of the Balanced Growth Protocol, consisting of audiovestibular testing, motor and cognitive tasks
45452917|NCT03290248|Biological|B244 suspension|B244 suspension in 30ml/bottle
45452918|NCT03290248|Biological|Vehicle|Vehicle, 30ml/bottle
45655508|NCT04927065|Biological|mRNA-1273.222|Sterile liquid for injection
45655509|NCT04927065|Biological|mRNA-1273.815|Sterile liquid for injection
45655510|NCT04927065|Biological|mRNA-1273.231|Sterile liquid for injection
45655511|NCT03051685|Drug|DFN-15 Dose 1|
45655512|NCT03051685|Drug|DFN-15 Dose 2|
45655513|NCT03051685|Drug|DFN-15 Dose 3|
45655514|NCT03051685|Drug|Active Comparator|
45941347|NCT00415675|Procedure|Motion CT Scans|A total of up to 12 scanning sessions used to understand how the tumor and other organs move while breathing.
45941348|NCT00072215|Drug|cisplatin|given IV
45941349|NCT00072215|Drug|ifosfamide|given IV
45941350|NCT00072215|Drug|paclitaxel|given IV
45941351|NCT00072215|Drug|vinblastine|given IV
45941352|NCT00415714|Device|Portable Biofeedback|
45941353|NCT00262678|Drug|EN3267|
45941354|NCT00105729|Behavioral|Intensive referral to 12-step self-help groups|
45941355|NCT00262717|Device|HIV drug resistance tests based upon genotype testing|
45941356|NCT00262795|Drug|Fludarabine|Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
45941357|NCT00262795|Drug|Chlorambucil|Chlorambucil p.o. (0,4 mg - max. 0,8 mg/kg/d, d1) q15d, max. 12 month
45941358|NCT00072332|Drug|cisplatin|
45941359|NCT00072332|Drug|edotecarin|
45941360|NCT00105768|Behavioral|Advisor-Teller Money Management-Substance Abuse Counselling|
45941361|NCT00263029|Drug|Oxaliplatin|60mg/m² as a 2-hour intravenous infusion every week for 5-6 week
45941362|NCT00263029|Drug|Capecitabine|500mg tablets and 150mg tablets. 750mg/m² bd given approximately 12 hours apart
45655515|NCT04888351|Other|Comparison of complications between mastectomies with IBR and mastectomies without IBR|"Precocious complications (less than 3 months after surgery) are classified with Clavien's classification : hematoma, seroma, stitches, antibiotics, transfusion.~Tardive complications (after 3 months until 1 year) are more specifics : hematoma, seroma, tardive infections, asymmetry, removing of implant, breaking up of implant, skin necrosis, capsular contractures, implant loss, chronic pain."
45655516|NCT04888351|Other|To analyze variations of number of patients eligibles to IBR|Including patients with differents classic risk factors : T3, T4, tobacco, diabetes, overweight and obesity, hypertension, age over 70, thoracic irradiation in the past
45941363|NCT00263029|Radiation|Radiotherapy|Planned total dose of 45-50.4Gy (with cone down) in 25-28 fractions
45941364|NCT00263068|Drug|Rotigotine|"Transdermal Patch 1 per day for 24 hours containing:~1.125mg/day 2.25mg/day 4.5mg/day 6.75mg/day"
45806668|NCT05392192|Drug|ADX-629|Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
45941365|NCT02966444|Other|MUFA-rich HF Meal|
45941366|NCT02966444|Other|PUFA-rich HF Meal|
45941367|NCT02966444|Other|SFA-rich HF Meal|
46088540|NCT02845193|Device|Modified Nasoalveolar molding|Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is routine step in Grayson's nasoalveolar molding technique).
46088541|NCT02845193|Device|Taping|Infants will receive a tape only on the upper lip segments to mold it to touch each other.
46088542|NCT02845193|Device|CAD/NAM|computer aided design NAM
46088543|NCT05242757|Other|Mixed-activated Killer Immune Cells|Mixed-activated Killer Immune Cells Peripheral intravenous infusion therapy
46088544|NCT04056468|Drug|Mobocertinib|Mobocertinib capsule.
45655517|NCT04904731|Other|Prone position|Patients were assisted in NIV in supine position that was switched in prone position for clinical purpouse
45655518|NCT04904887|Procedure|phacoemulsification|phacoemulsification with implantation of EYEHANCE IOL
45655519|NCT04078243|Device|CardioMEMS HF System|The CardioMEMS HF System is the first and only FDA-approved wireless heart failure monitor. The system is a safe, reliable way to help your patients manage their heart failure.
45655520|NCT04898881|Other|Breast Human Milk|Interventional drug is given to the neonates 2 minutes before the heel lance
45655521|NCT04898881|Other|24 % Sucrose|0.5 ml of sucrose given once 2 minutes prior to procedure
45655522|NCT04904185|Drug|Cyclophosphamide|Cyclophosphamide 500 mg/m2 is administered i.v. on day -4, -3 and -2
45655523|NCT04904185|Drug|Fludarabine Phosphate|Fludarabine Phosphate 30 mg/m2 is administered on day -4 and -3
45655524|NCT04904185|Biological|Multiple Antigen Specific Endogenously derived T cells|Antigen specific, ex vivo expanded T cells derived from peripheral blood T cells
45806669|NCT05392192|Drug|Placebo|Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
45806670|NCT05389423|Drug|Vincristine|0.4 mg/m2/day administered by CIVI on days 1 to 4
45806671|NCT05389423|Drug|Prednisone|60 mg/m2/day administered orally on days 1 to 5
45806672|NCT05389423|Drug|Doxorubicin|10 mg/m2/day administered by CIVI on days 1 to 4
45941368|NCT00101634|Drug|Paliperidone palmitate|
45941369|NCT00263107|Procedure|telerounding versus bedside rounding|
45941370|NCT00263146|Procedure|recruitment maneuver|
45941371|NCT00263185|Dietary Supplement|Vitamin D|
45941372|NCT00263185|Dietary Supplement|Calcium carbonate|
45941373|NCT00263185|Drug|Vitamin D|
45941374|NCT00263185|Other|Placebo|
45941375|NCT00263263|Device|sirolimus-eluting stent|
45941376|NCT00263263|Device|bare metal stent|
45941377|NCT00072488|Procedure|computed tomography|
45941378|NCT00072488|Procedure|magnetic resonance imaging|
45941379|NCT00072488|Procedure|positron emission tomography|
45941380|NCT00101673|Drug|vildagliptin|
45941381|NCT00263302|Drug|dexamethasone|
45941382|NCT00263419|Behavioral|Mindfulness Based Stress Reduction|8 weeks mindfulness based stress reduction (MBSR) based on body and meditation practices that aims at cultivation of openness, awareness of the present moment and acceptance of all internal and external experiences. It is assumed that this allows to act more reflectively rather than impulsively.
45941383|NCT00263458|Other|Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting|Eligible opioid-dependent HIV-infected patients are randomly assigned to receive buprenorphine opioid agonist treatment for 12 months either in an integrated HIV primary care setting (intervention group) versus a non-integrated substance use treatment clinic setting (comparison group).
45941384|NCT00101712|Drug|vildagliptin|
45941385|NCT00101712|Drug|Vildagliptin Placebo|
45941386|NCT00072527|Drug|carboplatin|IV
45941387|NCT00072527|Drug|cisplatin|IV
45941388|NCT00072527|Drug|etoposide|IV
45655525|NCT04904185|Drug|Pembrolizumab|Pembrolizumab 2 mg/kg is administered on day -1 and on day 21. The medicine is administered over 30 minutes
45806673|NCT05389423|Drug|Etoposide|50 mg/m2/day administered by CIVI on days 1 to 4
45806674|NCT05389423|Drug|Pomalidomide|An initial dose of 3mg administered orally for 10 days in all cycles. In cycle 1, it will start 5 days before DA-EPOCH; in cycles 2-6, it will start on day 1. Administered at an MTD dose for the expansion phase.
45941389|NCT00072527|Drug|irinotecan hydrochloride|IV
45941390|NCT00072527|Radiation|radiation therapy|
45655526|NCT04898725|Dietary Supplement|Vitamin D3|Vitamin D3 4800IU daily
45655527|NCT04887961|Drug|PLD and Trabectedin rechallenge|Platinum partially sensitive patients i.e. patients who recur with a platinum free interval between 6 and 12 months, who have previously received pegylated liposomal doxorubicin and are suitable for rechallenge with pegylated liposomal doxorubicin (PLD) with the combination of trabectedin (Yondelis®) and relapsed ovarian cancer fully platinum sensitive patients not able to receive or not willing to receive other platinum treatments
45655528|NCT04887883|Behavioral|Resistance exercise|Participants performed 8 weeks of resistance training and muscle biopsies were taken before and 24 h before and after the program.
45655529|NCT04887649|Drug|Morphine|morphine 3 mg
45655530|NCT04887649|Drug|saline solution|4 cc of saline solution in epidural cateter in postpartum
45655531|NCT04887649|Drug|Morphine|morphine 2 mg for epidural cateter in postpartum
45941391|NCT00263497|Device|Temporary tuber-ischii bearing prosthesis|Tuber ischii-bearing holster is connected by hinged metal bars to foot device to enable immediate postoperative mobilization of transtibial amputees. No other medical interventions or pharmaceutical treatment.
45941392|NCT00263536|Procedure|Interpersonal Psychotherapy|
45941393|NCT00263653|Biological|Haemophilus influenzae type b- and meningococcal (vaccine)|
45941394|NCT00105807|Behavioral|participation in low intensity exercise|
45655532|NCT03050437|Drug|Cisplatin|cisplatin is added to Pem/cis arm
45655533|NCT03050437|Drug|Pemetrexed|Pem is applied to both arms
45655534|NCT03050593|Diagnostic Test|MRI scan, Echo scan|
45655535|NCT02436135|Drug|Idelalisib|Idelalisib tablets administered orally for 24 weeks
45655536|NCT02436135|Drug|Ruxolitinib|Ruxolitinib will be administered per standard of care according to package insert
45655537|NCT04898569|Drug|Ferinject|Ferric carboxymaltose injection
45655538|NCT04898569|Drug|Normal Saline Flush|placebo
45655539|NCT03050515|Biological|Fecal Microbiota Transplantation|This is a single arm study. All participants will receive a single fecal transplant to determine effectiveness in treating refractory recurrent urinary tract infections.
45655540|NCT02489799|Behavioral|Advance care planning video|This is a video involving interviews with patients, a family member, two surgeons, an anesthesiologist, and an ICU nurse; these interviewees describe the typical events during a hospitalization for a major surgery and encourage the viewer to do some planning before surgery - the planning includes: (i) naming a person to make decisions for the participant, (ii) having a conversation with that person about goals and values, and (iii) continuing that conversation with the participant's surgeon.
45941395|NCT00105807|Behavioral|participation in art and music activities|
45941396|NCT00263692|Biological|Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3|
45941397|NCT00072605|Drug|VRC-EBODNA012-00-VP|
45941398|NCT00263770|Device|soft palate implant|
45452919|NCT04680520|Other|Experimental (Doublebase Gel® or Diprobase Cream®)|Emollient (Doublebase Gel® or Diprobase Cream®) use on the skin. The emollient should be applied at least once a day.
45941399|NCT00263770|Other|Positive airway pressure (PAP)|which is air delivered by a mask worn over the nose during sleep
45452920|NCT04680520|Other|Best practice skin care advice booklet|This is a booklet containing advice on best practice skin care. This will contain information on avoiding soap etc.
45655541|NCT02489799|Behavioral|Control video|This is a video showing the history of The Johns Hopkins Hospital and emphasizing that The Johns Hopkins Hospital is a great place to receive medical care.
45655542|NCT05457699|Radiation|SABR|SBAR to PSMA-PET visible disease at maximal systemic therapy response.
45655543|NCT05457699|Other|no RT|no SABR, continued systemic therapy per SOC
45655544|NCT04391257|Device|geko™|Assess if cardiac pacemakers detect geko™ electrical output pulse.
45655545|NCT04917861|Biological|mRNA-1893|Solution for injection
45655546|NCT04917861|Biological|Placebo|0.9% sodium chloride solution for injection
45655547|NCT04884841|Other|Patients diagnosed with postoperative complications|Patients diagnosed with postoperative complications (Acute kidney injury, Chronic Kidney disease, Infection, Delirium, MACCE, Myocardial infarction, Postoperative pulmonary complications, major bleeding, ECMO, IABP....)
45655548|NCT04884841|Other|Patients without postoperative complications|Patients without postoperative complications
45655549|NCT04884529|Behavioral|Chair-yoga program|8-week chair yoga program with gentle postures, breathing techniques, and mindfulness.
45655550|NCT04884217|Drug|Pro-ocular™ Topical Gel|Pro-ocular™ Topical Gel 1% is applied dermally to the forehead twice-daily
45806675|NCT05389423|Drug|Cyclophosphamide|750 mg/m2 administered IV on day 5
45806676|NCT05389423|Drug|Rituximab|375 mg/m2 administered IV on day 1 (only for CD20+ tumors)
45806677|NCT05388669|Drug|Lazertinib|Lazertinib tablets will be administered orally.
45806678|NCT05388669|Drug|Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)|Amivantamab injection will be administered subcutaneously by manual injection
45941400|NCT00101751|Drug|biphasic insulin aspart|
45941401|NCT00101751|Behavioral|dietary regimen|
45941402|NCT00263809|Device|Pathogen Reduction Technology|
45941403|NCT00263926|Biological|wasp venom|
45941404|NCT00263965|Drug|Tesaglitazar|
45941405|NCT00263965|Drug|Metformin|
45941406|NCT00263965|Behavioral|Dietary and lifestyle modification counseling|
45655551|NCT04884217|Drug|Placebo Topical Gel|Placebo is a toopical gel without active ingredient applied dermally to the forehead twice-daily
45806679|NCT05388669|Drug|Amivantamab Intravenous|Amivantamab will be administered by IV infusion
45806680|NCT05386888|Drug|GFH018|80mg BID 7-Day on/ 7-Day off oral
45655552|NCT03050281|Other|Simulation/Cadaver lab|The primary focus of this study is to determine whether the use of a comprehensive, combined, and simplified approach of using cadavers and simulation laboratories to train third-year medical students will have a beneficial effect on student performance in the OB-GYN and surgical clerkships.
45655553|NCT03050281|Other|Lectures|Standard Anatomy lectures were offered.
45655554|NCT02435277|Drug|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
45655555|NCT02435277|Drug|Mid Metformin|1100 mg L Leucine in combination with 250mg Metformin BID
45941407|NCT00264043|Device|emboli capturing guidewire device combined with stent|AngioGuard™ device and Bx Velocity™ stent
45452921|NCT04667962|Other|Online questionnaire|Participants will have to complete 3 online self-questionnaires: the first one at enrollment, the second one 1 month after enrollment (M1) and the third one 3 months after enrollment (M3). Each questionnaire will take an estimated 20 minutes to complete.
45655556|NCT02435277|Drug|High Metformin|1100 mg of L Leucine in combination with 500 mg Metformin BID
45655557|NCT02435277|Drug|Metformin|500 mg Metformin BID until day 14 with dose escalation at day 14 to 850 mg Metformin BID
45655558|NCT04898335|Device|Tendyne Mitral Valve System|Tendyne Mitral Valve System for mitral valve disease in a commercial setting
45655559|NCT02420223|Drug|Propranolol|
45452922|NCT00834964|Drug|Venlafaxine 25 mg Tablets|1 x 25 mg, single-dose fasting
45655560|NCT02433483|Drug|Cytarabine|Given by either intrathecal (IT) or intravenous (IV) route.
45655561|NCT02433483|Drug|Intrathecal Triples|given IT.
45655562|NCT02433483|Biological|HPC-A|Given IV.
45806681|NCT05386888|Drug|Toripalimab|240mg Q3W IV
45806682|NCT05386888|Drug|Paclitaxel|200 mg/m^2 IV
45452923|NCT00834964|Drug|Effexor® 25 mg Tablets|1 x 25 mg, single-dose fasting
45655563|NCT02419755|Drug|Bortezomib|Bortezomib will be given as a 1 mg/mL solution intravenous (IV) push over 3 to 5 seconds. For subcutaneous (SQ) administration, bortezomib will be mixed at 2.5 mg/ml.
45655564|NCT02419755|Drug|Vorinostat|Vorinostat should be taken orally (PO) with food.
45655565|NCT02419755|Drug|Mitoxantrone|Given by intravenous (IV) injection.
45655566|NCT02419755|Drug|Cytarabine|Given by intravenous (IV) injection.
45655567|NCT02419755|Drug|Methotrexate|Methotrexate will be given intrathecally (IT) along with hydrocortisone and cytarabine.
45655568|NCT02419755|Drug|Hydrocortisone|Hydrocortisone will be given intrathecally (IT) along with methotrexate and cytarabine.
45655569|NCT02419755|Drug|Peg-L-Asparaginase|Given by intravenous (IV) or intramuscular (IM) injection.
45655570|NCT02419755|Drug|Erwinia L-Asparaginase|To be used in case of allergy or intolerance to PEG-Asparaginase. Given by intravenous (IV) or intramuscular (IM) injection.
45806683|NCT05386888|Drug|Carboplatin|AUC6 IV
45655571|NCT02419755|Drug|Dexamethasone|Given orally (PO) or intravenously (IV).
45655572|NCT02419755|Drug|Mercaptopurine|Given orally (PO).
45655573|NCT02419755|Drug|Doxorubicin|Given intravenously (IV).
45655574|NCT04914195|Drug|Leuprolide Acetate 3.75 MG/ML|Leuprolide Acetate/ Leuprorelin is a depot injection administered as a subcutaneous injection once every month.
45655575|NCT04913025|Drug|Nivolumab|60-minute IV infusion, as a flat dose of 480mg
45655576|NCT04913025|Drug|Pembrolizumab|60-minute IV infusion, as a flat dose of 400mg
45655577|NCT02488551|Device|Computer-delivered CALM|This intervention includes the delivery of CALM via computer
45655578|NCT02488551|Other|Manual-delivered CALM|This active comparison condition includes the delivery of CALM via manual
45806684|NCT05386888|Drug|Cisplatin|75 mg/m^2 IV
45806685|NCT05386888|Drug|Pemetrexed|500 mg/m^2 IV
45806686|NCT05386888|Radiation|Thoracic Radiation Therapy (TRT)|Thoracic Radiation Therapy (TRT)
45806687|NCT05386888|Drug|Paclitaxel|45 mg/m^2 IV
45806688|NCT05386888|Drug|Carboplatin|AUC2 IV
45806689|NCT05386888|Drug|GFH018|80mg BID 14-Day on/ 14-Day off oral
45655579|NCT02488239|Device|CRT-P indicated patients|Patients who are indicated for a CRT-P device are planned to be implanted with a CRT-P device
45655580|NCT02488005|Device|Ultrasound|An ultrasound of the small bowel will be done by a radiologist or ultrasound technician. Subject should not eat or drink anything (i.e. no food and no water/beverages) for 8 hours prior to their ultrasound appointment
45655581|NCT02487771|Drug|DHA|600 mg DHA capsule
45655582|NCT02487771|Drug|Placebo Capsule|600 mg of Soybean Oil and Corn Oil, which does not contain any DHA
45655583|NCT01359943|Biological|secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
45655584|NCT01359943|Drug|placebo|Matching placebo to AIN457 i.v. and to AIN457 s.c..
45655585|NCT04898101|Drug|Acalabrutinib|Participants in Cohort 1 will receive a single 100 mg oral capsule dose of acalabrutinib on Day 1.
45655586|NCT04898101|Drug|Microtracer [14C]ACP-196|Participants in Cohort 1 will receive a single microtracer (<10 μg; ≤1 μCi) IV solution dose of [14C]ACP-196 as a 5-mL IV push over 2 minutes on Day 1. Participants in Cohort 2 will receive a single 100 mL dose of acalabrutinib 1 mg/mL oral solution containing a microtracer dose (<10 μg; ≤1 μCi) of [14C]ACP-196 on Day 1.
45655587|NCT04884451|Behavioral|Lifestyle modification|Diet and physical activity modification and behavioral approach
45655588|NCT02432703|Drug|JNJ-42165279|Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
45806690|NCT05386888|Drug|Toripalimab|3mg/kg Q2W IV
45941408|NCT00105846|Procedure|Home care telemedicine|
45941409|NCT00264082|Drug|Zometa(drug)|
45941410|NCT00072683|Drug|tolvaptan|
45941411|NCT00264160|Drug|AMN107|
45941412|NCT00264199|Drug|GLP-1|iv. by weight (1.0 pmol/kg/min )
45941413|NCT00264199|Drug|placebo|same rate of infusion as GLP-1
45941414|NCT00101790|Drug|pamidronate|There will be four study groups, each with 7 subjects randomly assigned to pamidronate and 4 to placebo. The groups will occur in succession, not parallel. The dosage for group 1 will be 30 mg , 60 mg for group 2, and 90 mg for group 3. Group 4 will receive 2 treatments of 90mg IV pamidronate or placebo.
45941415|NCT00264277|Drug|Vitamin K antagonist (Coumarin anticoagulants)|
45941416|NCT00264316|Procedure|bone marrow-derived stem cell transfer|
45941417|NCT02966561|Behavioral|Pedometer-based activity promotion|"The central components of the 2 x 45 minutes lasting pedometer-based physical activity behaviour change intervention BCI are the following behaviour change techniques (BCTs):~Instruction on how, where and when to perform the behaviour~Prompt goal setting for physical activity~Prompt self-monitoring of behaviour~Feedback on behaviour. Participants receive a pedometer and a booklet with a physical activity diary and associated information on the importance of goal setting and keeping a physical activity diary, exercise recommendations, possibilities to stay active after rehabilitation and appropriate physical activities."
45941418|NCT02966561|Behavioral|Short patient education and exercise|"The central components of the 2 x 45 minutes lasting intervention are revisions of knowledge of the pulmonary rehabilitation (standard care) in combination with related exercises:~Revision of knowledge on exercise recommendations~Revision of knowledge on possibilities of self-regulation of endurance training exercise intensity with the rate of perceived exertion (BORG-Scale)~Revision of self-regulation of endurance exercise intensity~Revision of strengthening activities consistent with the exercise recommendations.~Participants receive a booklet with information on the rate of perceived exertion, exercise recommendations, possibilities to stay active after rehabilitation and appropriate physical activities."
45941419|NCT02966561|Other|Pulmonary rehabilitation (Standard care)|Standard care is an in-patient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention based on a patient assessment followed by a combination of patient-tailored therapies. PR lasts on average 25 days. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current COPD-guidelines; physical training (4-5 units/week endurance training [45 min] and 3 units/week of strength training [45 min] per week, 7 units/week whole body vibration muscle training/week); structured COPD-patient education (6 hours patient education COPD + 1 hour device training); respiratory physiotherapy in groups [2-4 units/week with 45 min]. PR is implemented by an interdisciplinary rehabilitation team.
45941420|NCT00415753|Behavioral|No antibiotics if se-procalcitonin is below stated limit|
46074731|NCT02860403|Procedure|motor imagery|Intervention consisted of supervised MI during which the participants were trained to imagine performing a single-joint wrist extension movement and a multiple-joint reach-to-grasp movement using tenodesis. The two movements were practiced in separate blocks and each 45 minute MI session consisted of six to eight blocks. Within a given block patients; i) performed the movement once, ii) imagined it using visual imagery (between five and ten repetitions), iii) performed the movement again, and iv) imagined it using kinesthetic imagery (between five and ten repetitions). All movements (performed and imagined) were timed by the experimenter to ensure that the durations of both imagined and physically practiced movements were similar. Imagery vividness was controlled with self-rated assessments using a visual analogic scale (from 0, the image or feeling was absent, to 10 when it was as clear or intense as physical practice).
46074732|NCT02802306|Device|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System
45806691|NCT05386394|Device|Active tDCS + Language Therapy|Active tDCS stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 milliamps (mA)/cm2; estimated total charge 0.048 Coulombs (C)/cm2) in a ramp-like fashion for a maximum of 20 minutes. Language therapy will be conducted in conjunction with stimulation and will target oral and written naming.
46074733|NCT00863161|Drug|AZD3355|capsule, oral, single dose
46074734|NCT04281407|Dietary Supplement|Visbiome|2 capsules of Visbiome, a probiotics supplement, twice a day (morning and evening) for 28 days
46074735|NCT02802150|Dietary Supplement|Zanthoxylum Schinifolium Seed Oil(4g/day)|parallel design
46074736|NCT02802150|Dietary Supplement|Soy Bean Oil;placebo(4g/day)|parallel design
46074737|NCT02857595|Behavioral|Online Behavioral Weight Loss program|
46074738|NCT02857595|Behavioral|Weight Loss Nomogram|
46074739|NCT02857595|Behavioral|Bite Counter|
45655589|NCT02432703|Drug|Placebo|Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
45655590|NCT04887727|Dietary Supplement|Crystalline amino acids to assess myofibrillar protein synthesis rates|Amino acid dose = 0.25g/kg bodyweight
45655591|NCT04887727|Dietary Supplement|Crystalline amino acids to assess whole-body protein turnover, amino acid oxidation, and net protein balance|Amino acid dose = 0.25g/kg bodyweight
45655592|NCT04887493|Drug|Misoprostol|Misoprostol 25µg will be used for both the study arms
45655593|NCT04898257|Dietary Supplement|Multistrain probiotic|After completion of screening phase, during baseline visit, eligible patients will be assigned to Lactibiane Tolerance® 10 billion CFU 1 capsule twice a day on an empty stomach (30 minutes before breakfast and 30 minutes before dinner).
45806692|NCT05386394|Device|Sham tDCS + Language Therapy|During sham stimulation, current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Language therapy targeting oral and written naming will be administered during sham tDCS stimulation.
46074740|NCT00863239|Drug|ribavirin|Co-administered in all arms: oral ribavirin, 200 mg capsules. Subjects with body weight < 65 kg: 800 mg/day; Subjects with body weight 65-85 kg: 1000 mg/day; Subjects with body weight > 85 kg: 1200 mg/day.
45655594|NCT02486757|Drug|micronized progesterone|
45655595|NCT02486757|Drug|transdermal estradiol|
46074741|NCT00863239|Drug|Locteron™ (controlled-release interferon alpha 2b)|investigational controlled-release recombinant interferon alpha 2b formulated in 1500/77/23 PolyActive microspheres as a lyophilized powder, reconstituted with carboxymethyl cellulose immediately before subcutaneous injection every other week as part of the treatment of chronic hepatitis C
45655596|NCT04887103|Other|Hot water application|Pregnant women will apply hot water to their legs before going to sleep for a week.
45806693|NCT05382403|Device|Jada® System|This is a U.S. FDA-cleared device intended for treatment of PPH when conservative management is warranted. The device is made of medical grade silicone. The distal end, which is placed in the uterus, is an elliptical loop. The circular cervical seal, just outside the external cervical os, is filled with 60 - 120 mL sterile water. Low-level vacuum (80 ± 10 mm Hg) is applied and pooled blood is evacuated from the uterus as it collapses. Once there is no bleeding, the device remains in the uterus for at least 1 hour. The suction is then disconnected, the seal emptied of water, the device left in place, and the patient monitored for an additional 30 minutes. If bleeding remains controlled, the device is removed. If bleeding is uncontrolled with the Jada® System patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy.
45806694|NCT05382403|Other|Standard care|Patients in this group will receive care according to the treatment algorithm for PPH from uterine atony at the two teaching hospitals in Ghana. Possible interventions include additional uterotonics, tranexamic acid, and condom catheter balloon uterine tamponade. If bleeding is uncontrolled, patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy.
45941421|NCT04719286|Device|MinSafeStart app|The intervention is the opportunity of using the MinSafeStart app. Women can register their NVP severity in the app by answering a few questions daily. Based on this, they will get tailored advice on NVP, and get alert when they should see a doctor.
46074742|NCT00863239|Drug|PEG-Intron™|commercially available pegylated interferon alpha 2b injected subcutaneously weekly in a dose of 1.5 ug/kg as part of the treatment of chronic hepatitis C
46074743|NCT02805270|Other|medication reconciliation intervention|medication reconciliation intervention comprises medication reconciliation on admission and discharge, bedside medication counseling and take-home medication list
46074744|NCT02802072|Device|Enterprise stent implantation|Enterprise stent system (Johnson & Johnson (Shanghai) Medical Equipment Co.,Ltd., China) is a closed loop self-expanding stent system that is made of Ni-Ti alloy. It consists of a self-expanding stent and a delivery system.
46074745|NCT02802072|Drug|Only aspirin medication|Only aspirin medication will be conducted, initial dose is 300 mg/d, 200 mg/d 6 months later, and 100 mg/d 1 year later.
46074746|NCT04276883|Drug|Sublingual film containing Dexmedetomidine (BXCL501)|Sublingual film containing Dexmedetomidine (BXCL501)
45655597|NCT04887181|Other|Teethmate Desensitizer|Powder and liquid contained in the material were mixed. It was applied to the buccal surface of the sensitive tooth. then it was washed away from the tooth surface. 1-4 sessions were applied until the sensitivity disappeared.
45655598|NCT04887181|Other|Gluma Desensitizer|The material was applied to the buccal surface of the tooth with sensitivity. It was washed with water and removed from the tooth surface. 1-4 sessions were applied until the sensitivity disappeared.
45806695|NCT05379595|Drug|Amivantamab|Amivantamab will be administered as intravenous infusion.
45806696|NCT05379595|Biological|Fluorouracil|Fluorouracil will be administered as intravenous infusion.
45655599|NCT04887181|Other|Hybrid Bond|It was applied to the buccal surface of the sensitive tooth with an applicator. It was cured with a LED light device. Dentin sensitivity was checked with evaporative air application. The process was repeated until the sensitivity disappeared.
45655600|NCT04883515|Dietary Supplement|Oral glutamine supplementation|patient will receive oral glutamine supplementation 10 g Ter In Die during 8 weeks
45655601|NCT04883515|Dietary Supplement|Oral protein powder supplementation|patient will receive oral protein powder supplementation10 g Ter In Die during 8 weeks
45655602|NCT04883515|Procedure|Insulin-resistance evaluation|Homeostasic model assessment of insulin resistance test will be performed at baseline, Week 8 and Week 16
45655603|NCT04883515|Procedure|Functional intestinal disorders evaluation|Functional intestinal disorders will be measured by the IBS severity score and feces consistency by Bristol scale at baseline, Week 8 and Week 16
45941422|NCT00105885|Procedure|telephone care|Patients randomized to receive telephone care will be scheduled to see their provider at twice the recommended clinical visit interval, and two ten-minute telephone contacts will be scheduled at a specific time at standard 0.67 and 1.3 times the multiple of the recommended interval.
45941423|NCT04709029|Drug|Dexamethasone intravenous|Evaluation of intravenous dexamethazone in prevention of postdural puncture headache
45941424|NCT04709029|Drug|Dexamethasone intrathecal|Evaluation of intrathecal dexamethazone in prevention of postdural puncture headache
45941425|NCT00072722|Drug|CC-4047|
45941426|NCT04708795|Drug|AP701|Preparation of Cannabis flowers (Cannabis flos)
45941427|NCT04709497|Procedure|viscotrabeculotomy (VT)|viscotrabeculotomy (VT)
46074747|NCT04276883|Drug|Placebo Film|Placebo Film for BXCL501
46074748|NCT00865657|Drug|Alprazolam 3 mg Extended Release Tablets, single dose|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
46074749|NCT00865657|Drug|XANAX XR® 3 mg tablets, single dose|B: Active comparator Subjects received Pharmacia & Upjohn Company formulated products under non-fasting conditions
45806697|NCT05379595|Biological|Leucovorin|Leucovorin will be administered as intravenous infusion.
45806698|NCT05379595|Biological|Oxaliplatin|Oxaliplatin will be administered as intravenous infusion.
45806699|NCT05379595|Biological|Irinotecan|Irinotecan will be administered as intravenous infusion.
45806700|NCT05378893|Drug|DR10624 for injection|administered via subcutaneous injection
45806701|NCT05378893|Drug|Placebo|administered via subcutaneous injection
45806702|NCT05378529|Other|Lp(a) Screening|Participants will provide demographic information and have a blood draw for Lp(a) levels if they are unknown.
45806703|NCT05375994|Drug|avutometinib (VS-6766) and adagrasib|The RP2D of VS-6766 + adagrasib determined in Part A will be used in Part B dose expansion
45806704|NCT05375929|Drug|Abrocitinib 100 mg|Orally administered, abrocitinib 100 mg tablets QD
45806705|NCT05375929|Drug|Abrocitinib 200 mg|Orally administered, abrocitinib 200 mg tablets QD.
45941428|NCT04709497|Procedure|visco-circumferential-suture-trabeculotomy (VCST) .|visco-circumferential-suture-trabeculotomy (VCST)
46074750|NCT02801994|Device|PAV, Puritan Bennett 980 ventilator|The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min. As it is not possible to calculate directly the PTPmus at bedside, the investigators will use as a substitute its main component, the pressure peak muscle of the airways according to the previous report from Carteaux et al. This setting has been described extensively and its use has been the subject of a feasibility study in 50 patients. After a 20-minutes stabilization period, a 30-minutes recording will be performed.
46074751|NCT00863395|Procedure|skin biopsy|Lidocaine 1% c Epinephrine for local anesthesia
46074752|NCT02939183|Drug|Immediate Release (IR) Formulation|Immediate Release (IR) Formulation
45806706|NCT05375825|Procedure|Cytoreductive surgery|Cytoreductive surgery: minimally invasive (VATS/robotic) or open (thoracotomy)
45655604|NCT04883593|Drug|TA103|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
45806707|NCT05375825|Drug|LMB-100|1000 mcg/mL (DL1) post-operative dose as a single 90-minute normothermic intrathoracic perfusion using a closed circuit and roller pump with a heat exchanger following maximal cytoreductive surgery
45941429|NCT04709497|Procedure|combined VT-Trabeculectomy with MMC (VT-Trab).|combined VT-Trabeculectomy with MMC (VT-Trab).
45941430|NCT00105963|Behavioral|Education about infant crying|
45655605|NCT04883593|Drug|Placebo Control|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
45655606|NCT04883203|Drug|Vit-D 0.2 MG/ML Oral Solution [Calcidol]|ARM 1 : Cholecalciferol 200,000 IU / 1 mL .
45655607|NCT04883203|Drug|Physiological Irrigating Solution|ARM 2 : placebo
45806708|NCT05375825|Diagnostic Test|Immunohistochemical Assay for Mesothelin|Performed at screening to determine mesothelin expression; separate testing of tumor mesothelin expression will be assessed retrospectively in resected tumor tissues. The device is not diagnostic; protocol assessment of mesothelin expression status will only be used to help to increase the possibility that all persons enrolling on the study might derive benefit from therapy.
45806709|NCT05372042|Behavioral|CBT Text Messages|CBT skills based text messages delivered 3x per week for four weeks
45806710|NCT05371054|Device|Vysis LSI MYC Break Apart Rearrangement Probe Kit|MYC rearrangement FISH testing is performed using the Vysis LSI MYC Break Apart Rearrangement Probe (Abbott Molecular, Inc.) in the Chromosome Pathology Section, Laboratory of Pathology, CCR, NCI. This kit is not FDA approved. It is being used as a treatment determining in-vitro diagnostic device in this study.
45806711|NCT05371054|Drug|venetoclax|administered orally, days 1-10, per specified dose level; every 21 days for up to 12 cycles, or until disease progression or unacceptable toxicity
45806712|NCT05371054|Drug|VIP152|administered intravenously, days 2 and 9, per specified dose level; every 21 days for up to 12 cycles, or until disease progression or unacceptable toxicity
45941431|NCT04708912|Other|Observation|The study parameters will be obtained at the time of recuirement (Basal)
45941432|NCT04708873|Other|High intensity interval training|4x4 min intervals of high intensity treadmill running (80-95% of HRR, RPE 7-10 on Borg's category ratio scale of perceived exertion) interspersed with active recovery (slow jogging or fast walking at 50-70% HRR). HIIT-Resistance exercises 2 sessions per week, RPE 5 (hard) 6-8 RM, 1-3 sets of as many repetitions as possible in 60 seconds, active recovery 20-60 seconds b/w exercises,
45806713|NCT05371054|Drug|prednisone|administered orally, days 1-10, at a dose of 100 mg; every 21 days for up to 12 cycles, or until disease progression or unacceptable toxicity
45941433|NCT04708873|Other|Moderate Intensity Continuous Training|Moderate intensity continuous Aerobic exercises (Stationary cycling for 15-20 min followed by treadmill walking for 15-20 min) at 55-70% 55-70% of HRR, RPE 3-4 on Borg's category ratio scale of perceived exertion. The session will be preceded by 5-7 minute warm-up &amp; 7-10 min cool-down.
45941434|NCT00399191|Drug|stable isotope of iron, dysprosium|
45941435|NCT00264355|Drug|cyclosporine A|
45941436|NCT00264394|Behavioral|Updated CHD risk profiles|Provision of computer generated CHD risk profiles
45941437|NCT00264394|Behavioral|Guidelines|provision of guidelines for CHD risk factor management only
45941438|NCT00106041|Behavioral|Veterans Integrated Palliative Care Nurse Case Manager|Palliative Care nurse case management
45806714|NCT05367440|Drug|AZD5305|Patients will receive an oral dose of AZD5305 once daily
45941439|NCT00264433|Drug|ADH -1 (Exherin™)|
45806715|NCT05367440|Drug|Enzalutamide|Patients will receive an oral dose of Enzalutamide once daily
45941440|NCT00264472|Drug|ADH300004|5 mg
45941441|NCT00264511|Procedure|Hyperbaric Oxygenation|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
45941442|NCT00101829|Drug|Rituximab|1000 mg intravenous infusion
45941443|NCT00264589|Behavioral|8 weeks individualized training program|no drugs added
45655608|NCT04883047|Other|holistic birth support strategies|"Holistic Birth Support Strategies are composed of birth-supporting practices that were created by Horn and D'Angelo (2017) within the scope of the Algorithm for Coping with Birth Pain and recommended for coping with labor pain. Holistic Birth Support Strategies; It includes four parameters: physical comfort, emotional comfort, informative support and advocacy."
45655609|NCT04897555|Device|LLLT|This is a low-level light (LED) device configured in the shape of a headband, operating at 650 +/-10 nanometers and 940 +/- 10 nanometers, that contains 12 of each wavelength for a total of 24 LEDs.
45806716|NCT05367440|Drug|Abiraterone Acetate|Patients will receive an oral dose of Abiraterone Acetate once daily
45806717|NCT05367440|Drug|Darolutamide|Patients will receive an oral dose of Darolutamide twice daily
45941444|NCT00072839|Drug|ALX-0600|teduglutide
45941445|NCT00072839|Drug|placebo|placebo solution injected subcutaneously
45941446|NCT00072839|Drug|teduglutide 0.05|0.05 mg/jg/d subcutaneous daily injection into thigh or abdomen
45941447|NCT00072839|Drug|teduglutide 0.2 mg|0.2 mg/kg/d subcutaneously injected into thigh or abdomen
45941448|NCT00072839|Drug|Teduglutide 0.05 dose|0.05 mg/kg/d subcutaneous daily injection into thigh or abdomen
45941449|NCT00072839|Drug|teduglutide 0.1 mg dose|0.1 mg/kg/d daily subcutaneous injection into thigh or abdomen
45941450|NCT00264628|Drug|GW679769|
45941451|NCT00264667|Drug|GW677954|
45806718|NCT05364944|Drug|Debio 4126|Intramuscular (IM) injection
45806719|NCT05364944|Drug|Sandostatin LAR|Sandostatin LAR will be administered as IM injection as pre-study treatment dose prior to Debio 4126 administration
45941452|NCT00101946|Drug|683699|
45941453|NCT00264706|Drug|Nona-L-arginine|
45941454|NCT00264745|Behavioral|TASK intervention|The Telephone Assessment and Skill-building Kit (TASK) is an individualized 8-week intervention program geared toward reducing depression and improving general health in stroke caregivers.
45806720|NCT05364944|Drug|Somatuline ATG|Somatulin ATG will be administered as deep subcutaneous (SC) injection as pre-study treatment dose prior to Debio 4126 administration
45806721|NCT05364554|Drug|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
45806722|NCT05363683|Procedure|Squat Biofeedback|The intervention group will complete bilateral squats with each limb on a separate portable force plate. They will receive real-time visual feedback on a 32-inch screen during all squats. Biofeedback conditions will be progressed from simplest (ground reaction force only) to most complex (ground reaction force plus center of pressure). This intervention will be included in additional to standard care post-operative physical therapy.
45806723|NCT05363683|Procedure|Standard Care|Standard care post-operative physical therapy
45806724|NCT05363644|Biological|BioDFence G3|Placement of a sheet of BioDFence® G3 will be applied to the neurovascular bundle on participants undergoing an elective Full Nerve Sparing Radical Prostatectomy for primary treatment of prostate cancer.
45806725|NCT05363020|Drug|S-Adenosyl-L-Methionine (Sam-E)|400 mg capsule
45806726|NCT05363020|Drug|Placebo|400 mg identically appearing placebo
45941455|NCT00264745|Behavioral|Attention Control|Minimal intervention beyond initial hospital visit.
45941456|NCT00264823|Behavioral|Use of Memory Aids to take medications|Experimental participants will receive an integrated intervention tailored to the communication and comprehension of the individual, and will include memory aid devices, education regarding side effects and other treatment aspects, and active community outreach. For those who fail to adhere using the basic intervention, a treatment cascade that increases in intensity will be implemented. Using 80% adherence as a target, the cascade will include involvement of family and significant others in prompting participants through use of beepers, cellphones, and for those who still fall short of 80% adherence, directly observed therapy.
45941457|NCT00106158|Biological|protein vaccination|
45941458|NCT00264862|Procedure|DynaCT|
45941459|NCT00264901|Drug|insulin detemir|
45941460|NCT00264979|Procedure|Simultaneous surgery|Simultaneous surgery of colorectal cancer and synchronous liver metastases
46074753|NCT02939183|Drug|Gastro-Retentive (GR) Formulation|Gastro-Retentive (GR) Formulation
46074754|NCT02939183|Drug|Dexamethasone|Dexamethasone
46074755|NCT02939183|Drug|Pomalidomide|Pomalidomide
45452924|NCT03239938|Behavioral|Modern pain neuroscience approach|The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.
45655610|NCT04882969|Device|Fractionated Thulium laser|LaseMD Lutronic Laser is a 1927-nm fractionated thulium laser, which is better absorbed by water than non-ablative 1,540-nm erbium glass laser energy. The laser energy and power can be customized to target a specific penetration depth and achieve selective photothermolysis in skin while mitigating injury to surrounding tissue. The thermal energy generated by the laser has been shown to facilitate the delivery of kerafactor, which contain hair growth factors to stimulate follicular progenitor cell proliferation and differentiation into follicular keratinocytes to promote hair growth.
45655611|NCT03051529|Other|combined spinal epidural anesthesia|After approval by local research ethics committee of the Faculty of Medicine, and informed written consent obtained from all patients, 24 patients having dilated cardiomyopathy, subjected to vascular surgery in the lower half of the body under CSEA
45655612|NCT02418819|Drug|PF-06412562 3mg BID|PF-06412562
45655613|NCT02418819|Drug|PF-06412562 9mg BID|PF-06412562
45655614|NCT02418819|Drug|PF-06412562 45mg BID|PF-06412562
45655615|NCT02418819|Other|Placebo|Placebo
45655616|NCT04886869|Dietary Supplement|caffeine|oral consumption
45655617|NCT04886947|Procedure|stem cell transplantation|After surgical repair of alveolar cleft using gingivoperiosteoplasty, processed and stored autologous stem cells will be added at the repair site. After which the patient will be followed up for bone regeneration and this will be compared to control where no stem cell is added.
45655618|NCT04897477|Drug|Azacytidine, Bendamustine and Piamprizumab|Azacytidine by means of subcutaneous injection, Bendamustine and Piamprizumab intravenous infusion
45655619|NCT04886713|Diagnostic Test|Adipose and myocardial tissue sampling|After median sternotomy tissue samples will be collected from the epicardial space, the abdominal wall and the myocardium.
45655620|NCT04886713|Diagnostic Test|Cardiac magnetic resonance imaging|"Magnetic resonance imaging will be performed at 1.5 Tesla ('Intera', Philips Medical Systems, Best, The Netherlands). All subjects will be examined in the supine position with initial anatomy scans to cover the thorax to the first sacral vertebrae. The magnetic resonance imaging protocol is summarized in Figure 4.~The following imaging parameters will be acquired:~Biventricular end-diastolic and end-systolic volume, ejection fraction, stroke volume~Biventricular mass, wall thickness~T1 mapping; native and > 10 minutes post contrast injection as an estimate of left ventricular diffuse fibrosis and extracellular volume~Late enhancement for detection of regional fibrosis and scar~Myocardial feature tracking for analysis of deformation/motion~Epicardial fat volume"
45655621|NCT04886713|Diagnostic Test|Cardiopulmonary exercise testing|After completion of a regular cardiac rehabilitation program patients are scheduled to undergo their discharge examination at 3 to 4 weeks after the operation in order to be functionally characterized. Cardiopulmonary exercise testing will be performed, if possible by patients condition, on a mechanically braked bicycle ergometer and respiratory gas exchange analysis via a mouthpiece or facemask.
45655622|NCT04882813|Drug|Dapagliflozin|Dapagliflozin dispensing claim is used as the exposure group.
45655623|NCT04882813|Drug|Sitagliptin|Sitagliptin dispensing claim is used as the reference group.
45655624|NCT04882891|Device|Actimyo|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
45655625|NCT04897243|Drug|Biktarvy|B/F/TAF (Biktarvy®) is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements. Participating patients will receive the medication free of charge.
45655626|NCT04897243|Behavioral|Patient Experience|To capture and integrate the patient experience, this study will collect patient-reported experience measures, conduct qualitative interviews, and engage patients as well as providers.
45655627|NCT04886557|Procedure|L4-L5 decompression and dynamic instrumentation|All surgeries were performed by a senior surgeon using a traditional midline approach. Stability-preserving lumbar decompression with facet joint undercutting was performed to preserve the facet joints as much as possible. In cases of severe stenosis, a bilateral partial facetectomy (< 25%) was performed for adequate decompression. Posterior tension of the supra- and inter-spinous ligaments was preserved at the most cranial level. Patients were encouraged to ambulate after drain removal and wear a soft lumbar orthosis for at least 3 months after the operation.
45806727|NCT05361811|Behavioral|Waitlist|8 weeks of maintaining usual routine followed by 8-week intervention that emphasizes mindfulness, acceptance, perspective taking, and values-based actions.
45806728|NCT05361811|Behavioral|ACT Intervention|8-week intervention that emphasizes mindfulness, acceptance, perspective taking, and values-based actions.
45806729|NCT05361798|Drug|M9241|In the safety lead in, M9241 will be given in de-escalating doses (starting dose 16.8 mcg/kg, and de-escalated if needed to 12 mcg/kg, or 8 mcg/kg) every 4 weeks for 3 doses. Within 4 weeks after completing SBRT, those participants receiving immunotherapy agents will receive M9241 by subcutaneous injection at dose determined during the safety lead in every 4 weeks for 3 doses.
45806730|NCT05361798|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT to the prostate will be delivered in 5 fractions of radiation each of 7.25-8.0 Gy, every other day over the course of 10 business days (2-3 weeks). The total dose will be 36.25-40 Gy
45941461|NCT00264979|Procedure|Sequential surgery|Sequential surgeries of colorectal cancer and synchronous liver metastases: the metastases surgery will be programmed 12 to 14 weeks after the primary tumour exeresis.
45941462|NCT00265018|Drug|Adriamycin|
45941463|NCT00265018|Drug|Bleomycin|
45941464|NCT00265018|Drug|Vinblastine|
45941465|NCT00265018|Drug|DTIC|
45941466|NCT00265018|Radiation|30 Gy IF-RT|
45941467|NCT00265018|Radiation|20 Gy IF-RT|
45941468|NCT00101985|Drug|talnetant|
45941469|NCT02961010|Behavioral|Keeping Safe|A whole school Preventative Education programme
45941470|NCT00265057|Drug|ADH -1 (Exherin™)|
45941471|NCT00265135|Drug|CNTO 328|Patients will receive CNTO 328 at dose levels ranging from 1, 3, 6, and 12 mg/kg in Part 1 of the study to determine the maximum tolerated dose for Part 2 of the study. Patients will receive 2 well tolerated dose levels of CNTO 328 from Part 1 of the study every 3 weeks in Part 2 of the study. Patients will receive 6 mg/kg of CNTO 328 every 2 weeks in Part 3 of the study.
45655628|NCT04897087|Other|patient safety event|This study will explore the perceptions of patients, carers and relatives who have experienced a patient safety event. Telephone interviews will be undertaken lasting up to 60 minutes This study involves NHS patients, their carers or relatives. We will ask participants about their experience of being involved a patient safety event and the barriers and enablers to participation in the review. We will ask what 'good' patient involvement in patient safety reviews should look like from those with lived experience. This is because we wish to understand from their perspective what matters to them when things go wrong and how best to involve them.
45941472|NCT00106197|Drug|Bupropion|Participants will start with 150 mg daily. If no adverse symptoms, dosage will be increased to twice daily. Treatment will last for 8 weeks.
45941473|NCT00265252|Drug|Alendronate|
45941474|NCT00072995|Behavioral|Four Diets Differing in Macronutrient Composition|
45941475|NCT00072995|Behavioral|Diets Low in Saturated Fat|
45806731|NCT05359445|Biological|IMA401 (Phase Ia)|Weekly intravenous infusions in escalating dose levels
45941476|NCT00265291|Drug|fluoxetine or desipramine|fluoxetine 5-40 mg/day desipramine 50-150 mg/day
45941477|NCT00265369|Drug|Spores of Bacillus Clausii Probiotic Strain|
45941478|NCT00265408|Drug|aspirin|
45941479|NCT00265408|Drug|warfarin|
45941480|NCT00102024|Drug|Unconjugated IDEC-159|
45941481|NCT00102024|Drug|111In-IDEC-159|
45806732|NCT05359445|Biological|IMA401 (Phase Ib)|Treatment at recommended dose for extension (RDE) with weekly intravenous infusion
45941482|NCT00102024|Drug|90Y-IDEC-159|
45941483|NCT00265447|Behavioral|Strength training|3 months of strength training
45941484|NCT00265447|Behavioral|Aerobic conditioning|3 months of aerobic conditioning
45941485|NCT00265447|Behavioral|Delayed exercise|delayed exercise control group
45806733|NCT05353972|Drug|IMG-007 or placebo|intravenously administered
45941486|NCT00073034|Drug|EAA-090|
46074756|NCT02801916|Other|0 grams oat bran|200 milliliters water plus 0 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
45806734|NCT05353140|Device|The WATCHMAN/WATCHMAN FLX device|Watchman device was an umbrella-shaped, self-expanding, nitinol structure with a porous partial polyethylene terephthalate membrane (160 um mesh) and 10 struts. The membrane portion of the structure faces into the body of the left atrial to block embolization of thrombus and provide scaffolding on which endothelialization can occur. The On July 21st, 2020, the FDA approved the next generation LAAO device, named Watchman FLX. This newiteration of the Watchman LAAO platform offers full capability of recapture and redeployment of the device, decreasedmetallic exposure, an increased number of contact points for sealing, a fully rounded delivery shape, and precision anchors designed to provide optimal device engagement with the LAA.
45941487|NCT00265486|Drug|Recombinant human Erythropoietin|Adm 100 U/kg sc 1 hour before completing exercise in protocol
45941488|NCT00265603|Procedure|Extracorporeal Photochemotherapy With Transimmunization|The photopheresis apparatus and procedure will be identical to that currently used. Patients will receive intravenous 8-MOP (UVADEX®) directly into the photopheresis apparatus, to yield a concentration of 50-200 ng/ml of drug. The blood will be leukapheresed to obtain a buffy coat and will then be passed through the contiguous closed circuit ultraviolet A exposure device, delivering the desired 1-2 joules/cm2 of ultraviolet A energy. In this manner 2-4 molecules of 8-MOP will be induced to bind covalently to thymines of the leukocyte DNA. At that point, the single variation from the standard treatment will be initiated. Instead of returning the patient's cells and the saline to the patient, the bag will be detached from the apparatus. KLH (depyrogenated, endotoxin-free; Calbiochem-Novabiochem Corp., San Diego, CA) will be added at a concentration of 10 g/ml to the DC-rich leukocyte culture prior to overnight culture.
45941489|NCT00102102|Drug|[18F]SPA-RQ|
45941490|NCT00265642|Drug|Irbesartan|one tablet of 150 mg/d during 2 years
45941491|NCT00265642|Drug|placebo|one tablet per day during 2 years
45941492|NCT00265681|Behavioral|Phone counseling and written materials|
45941493|NCT00265720|Other|Control|Written materials only
45941494|NCT00265720|Other|Reduced out of pocket expense|Reimbursed up to $500 out of pocket expense for CRC screening
45941495|NCT00265720|Behavioral|one on one education|one on one education with a health educator
45941496|NCT00265720|Behavioral|Group education|Education in a small group
45941497|NCT00265837|Biological|graft versus host disease prophylaxis/therapy|
45941498|NCT00265837|Procedure|allogeneic bone marrow transplantation|
45941499|NCT00265837|Procedure|in vitro-treated bone marrow transplantation|
45941500|NCT00106236|Behavioral|exercise|
45941501|NCT00265876|Drug|AZD0530|Taken daily every 4 weeks
45941502|NCT00265876|Drug|gemcitabine hydrochloride|1000mg/m2 IV weekly
45941503|NCT00073112|Drug|ABT-751|
45941504|NCT00265915|Biological|rituximab|
45941505|NCT00265915|Biological|sargramostim|
45941506|NCT00106275|Behavioral|Mindfulness Based Stress Reduction|
45941507|NCT00265954|Behavioral|internet, in-person and internet+in-person|All participants receive an 18 month behavioral weight loss program that meets weekly for the first 6 months and monthly for the next year.
45941508|NCT00265993|Drug|enoxaparin|"All patients will be treated with enoxaparin 1.5 mg/kg, once a day, subcutaneously for up to 10 days.~Long-term oral anticoagulation will be started in all patients after 24 hours of initiation of enoxaparin treatment and continued at least for 3 months."
45941509|NCT00266071|Behavioral|Cutaneous response|
45941510|NCT00073151|Drug|ABT-751|
45941511|NCT00266149|Drug|Oral contraception|
46074757|NCT02801916|Other|4.5 grams oat bran|200 milliliters water plus 4.5 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
46074758|NCT02801916|Other|13.6 grams oat bran|200 milliliters water plus 13.6 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
45655629|NCT03049891|Other|Data abstraction|The investigators will abstract clinical data from down-referral sites and from NHLS to determine whether children made it to their down-referral sites or whether children are in care at a different facility.
45655630|NCT03049891|Other|Tracing questionnaire|The investigators will attempt to contact and visit caregivers of children who are determined to be LTF from DNH or from down-referral sites. If located and after providing consent, caregivers will be administered a tracing questionnaire, or a verbal autopsy if their child has died.
45655631|NCT03049891|Other|Tier.net|For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.
45655632|NCT02576639|Drug|CNP520|
45655633|NCT02576639|Drug|Placebo|Matching placebo to CNP520 was supplied in capsules.
45655634|NCT03049579|Dietary Supplement|Weiquan Yogurt with probiotics|150 ml daily consumption for a total of 12 weeks
45655635|NCT03049579|Dietary Supplement|Weiquan Yogurt without probiotics|150 ml daily consumption for a total of 12 weeks
45655636|NCT02418585|Drug|Esketamine|Participants will self-administer either 56 mg or 84 mg of esketamine, intranasally, twice per week as a flexible dose regimen in the Double-Blind Induction Phase.
45806735|NCT05353140|Drug|Rivaroxaban + Clopidogre|Previous pivotal trials have shown that in patients with atrial fibrillation and requiring antiplatelet treatment, a NOAC plus clopidogrel regimen was associated with a lower incidence of bleeding events as compared with a warfarin-based triple antithrombotic strategy. Therefore, the current expert opinions and consensus of North American Societies recommend a NOAC plus a P2Y12 inhibitor in patients with AF and PCI. In the present study, Rivaroxaban + Clopidogre are required for 45 days in LAAO group after LAAO.
45806736|NCT05353140|Drug|Aspirin + Clopidogrel|Aspirin + Clopidogrel are required from 46 days to 12 months after LAAO.
45806737|NCT05351944|Behavioral|Dialectical behavioral therapy skills for the intervention experimental group A|Our hypothesis is that impulsive aggression as evidenced by inflammatory biomarkers might improve by targeting executive dysfunctions with Dialectical Behavioural Therapy skills modules directed to the children and their parents in the form of response inhibition dysfunctions with Dialectical Behavioural Therapy mindfulness and distress tolerance skills modules, emotion regulation executive dysfunctions with Dialectical Behavioural Therapy emotion regulation skills module and socioenvironmental factors with interpersonal effectiveness and walking the middle path Dialectical behavioural therapy skills modules.
45806738|NCT05351944|Drug|psychoeducation or Atomoxetine or stimulants according to ADHD severity|the control group (group B) will receive psychoeducation and medications targeting ADHD symptoms (Atomoxetine or stimulants according to FDA approved dose according to age and weight ) according to the international guidelines for management of ADHD according to symptom severity
45806739|NCT05351801|Drug|THC (Dronabinol)|Participants will receive a target dose of 10mg per day of THC (Dronabinol).
45806740|NCT05351801|Drug|CBD (Epidolex)|Participants will receive a target dose of 800 mg per day of CBD (Epidolex).
45806741|NCT05351801|Drug|THC + CBD (Nabiximols)|Participants will receive a target dose of 10.8 mg / 10 mg per day of THC + CBD (Nabiximols).
45806742|NCT05351801|Drug|Placebo|Placebo
45806743|NCT05350774|Drug|IV normal saline|IV normal saline 250ml for 5 days
45806744|NCT05350774|Drug|IV immunoglobulin|IVIg - IV immunoglobulin 0.4g/kg/day for 5 days
45806745|NCT05347485|Drug|Cilta-cel|Cilta-cel will be administered as an IV infusion.
45806746|NCT05347485|Drug|Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)|Lymphodepleting therapy (cyclophosphamide and fludarabine) will be administered intravenously.
45452925|NCT03239938|Behavioral|Usual care evidence-based physiotherapy|The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
45452926|NCT03070522|Drug|Prednisone|oral prednisone for 7 days during pulmonary exacerbation
45655637|NCT02418585|Drug|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase.
45655638|NCT02418585|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
45941512|NCT00266149|Drug|Lamotrigine|
45655639|NCT02418585|Drug|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
45655640|NCT02418585|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
45655641|NCT02418585|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
45655642|NCT04896853|Biological|ProTrans®|Allogeneic Wharton's jelly (WJ) Mesenchymal Stromal Cells
45655643|NCT05530031|Procedure|trabeculotomy ( angle glaucoma surgery )|a scleral flap is raised at the selected site with UBM and a cutdown in shlemm's canal is performed, a metal trabeculotome is used to cannulate and tear through a section of the inner wall of SC and trabeculum into the AC. Closure of the scleral flap and conjunctiva with 10/0 nylon. Viscoelastic is used to dilate the schlemm's canal, form the anterior chamber and decrease the risk of hyphema.
45655644|NCT04897165|Other|Resilience training with mobile HRV-BfB based on an e-learning approach (with digital lectures)|A 4-week resilience training with a mobile HRV-BfB device. Participants received access to three online lectures at the start of the first, third, and forth training week (each lasting 60 minutes) to receive a theoretical base on resilience and to learn how to exercise with the HRV-BfB device. Participants were asked to exercise three times a day for 5 minutes in their occupational and leisure time with the HRV-BfB device.
45655645|NCT04897165|Other|Resilience training with mobile HRV-BfB based on a blended learning approach (with live lectures)|A 4-week resilience training with a mobile HRV-BfB device. Participants attended three live lectures at the start of the first, third, and forth training week (each lasting 90 minutes) to receive a theoretical base on resilience and to learn how to exercise with the HRV-BfB device. Participants were asked to exercise three times a day for 5 minutes in their occupational and leisure time with the HRV-BfB device.
45655646|NCT05529875|Drug|Propofol|intravenous propofol using target-controlled infusion (TCI) devices.
45655647|NCT05529875|Drug|sevoflurane|inhalator sevoflurane using sevoflurane vaporizer sevoflurane vaporizer.
45806747|NCT05347095|Drug|Guselkumab|Guselkumab will be administered subcutaneously/IV infusion.
45806748|NCT05347095|Drug|Placebo|Matching placebo will be administered subcutaneously/IV infusion.
46074759|NCT02801916|Other|27.3 grams oat bran|200 milliliters water plus 27.3 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
46074760|NCT00865813|Procedure|Punch Biopsy|"Instillation of anesthetic eye drops.~Asepsis~Placement of surgical cloths and drapes~Infiltration of the involved region with anesthetic solution plus adrenalin in1:200.00 dilution.~Trephination of the most typical area of the lesion with a punch (2mm in diameter) of stainless steel by applying gentle pressure and twisting the trephine until its introduction into the suspicious lesions~Removal of the excised tissue with the aid of an insulin needle or conjuntival forceps, the base then bein cut with an number 11 surgical blade"
45806749|NCT05346393|Procedure|TIPS|A transjugular intrahepatic portosystemic shunt (TIPS) is implanted into the cirrhotic liver
45806750|NCT05346393|Drug|Standard of Care|Administration of Terlipressin and Albumin according to Standard of Care
45806751|NCT05346055|Behavioral|Engage Prism (2.0)|Brief Behavioral Treatment for Depression (Engage) combined with tablet-based social support system (Prism 2.0)
45806752|NCT05340465|Drug|Darbepoetin Alfa|Infants in groups 2-5 will be started on Darbe 10 mcg/kg/week between 72 and 84 hours after birth.
45806753|NCT05340465|Drug|Low Molecular Weight Iron Dextran|Infants in groups 2 and 3 will be given LMW-ID IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
45806754|NCT05340465|Drug|Ferumoxytol injection|Infants in groups 4 and 5 will be given FMX IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
45806755|NCT05340465|Drug|Oral iron supplements|Infants in group 1 will receive standard care in the UW NICU with iron started on day 7 if tolerating 100 mL/kg/day enteral feeding. Iron supplements are adjusted every 2 weeks based on ferritin, zinc protoporphyrin to heme ratio and complete blood count (CBC).
45941513|NCT00106314|Drug|Dehydroepiandrosterone [DHEA]|
45941514|NCT00415792|Drug|Arvekap, Pregnyl|
45941515|NCT00073190|Behavioral|Osteoporosis Education|
45941516|NCT00415831|Drug|ELC200 (carbidopa+levodopa+entacapone)|
45941517|NCT00102141|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 3 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
45941518|NCT00102141|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 2 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
45941519|NCT00102141|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 1 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
45941520|NCT00102141|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
45941521|NCT00102141|Drug|Placebo|Placebo, given as tablets orally once daily in the morning for 8 weeks
45655648|NCT03051451|Drug|combination metformin hydrochloride/ fluoxetine 500/20 mg|"Group A will receive metformin 1000 mg and 40 mg of fluoxetine; after the increment phase.~All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition"
45806756|NCT05339958|Dietary Supplement|Nutrafol® Men Hair Growth Nutraceutical|Nutrafol® Men contains patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. These ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, USPlus Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, Bioperine (piperine), Cynatine HNS (solubilized keratin), and Capsimax (capsaicin).
45806757|NCT05339958|Other|Placebo Supplement|The placebo capsules contain no active ingredients.
46074761|NCT00860821|Drug|AZD8309|oral solution 30 mg/g, dose: 300mg bid for 3 days
46074762|NCT00860821|Drug|AZD8309|oral solution 30 mg/g, dose: 300mg bid for 3 days
46074763|NCT02801838|Drug|Morphine|If the physician in charge of the patients judges it necessary, after the optimization of the ventilators settings, if the patient remains uncomfortable, a second therapeutic intervention using a maximum of 10mg morphine titration may be performed. After this second therapeutic intervention, a third non-verbal measure of respiratory discomfort will be performed with the IC-RDOS. Concomitantly, EEG and EMG will be again recorded over a of 15-minutes period.
46074764|NCT00863473|Procedure|Surgical treatment with LCP|
45452927|NCT03070522|Drug|Placebos|Placebo
45806758|NCT05339412|Behavioral|Training Tool for Preventing HIV/AIDS among Teens (PHAT) Life|The technology-based training tool will train facilitators to deliver the behavioral health intervention PHAT Life, which is an innovative HIV/STI, substance use, and mental health intervention for juvenile offenders. The training tool reviews each of PHAT Life's 8 sessions. The curriculum targets broad psychosocial factors implicated in HIV/STI-risk behavior, including promoting positive attitudes toward HIV/STI prevention, self-efficacy to reduce risk, and less substance misuse and sexual risk taking. Content emphasizes the importance of emotion regulation skills to manage strong feelings, uses goal setting and training in positive thought processes to plan ahead, encourages recognition of personal responsibility in future outcomes, and helps youth identify strategies and behaviors to accomplish short- and long-term goals.
45806759|NCT05338775|Drug|Talquetamab|Talquetamab will be administered as a subcutaneous (SC) injection.
45806760|NCT05338775|Drug|Teclistamab|Teclistamab will be administered as a SC injection.
45806761|NCT05338775|Drug|PD-1 Inhibitor|The PD-1 inhibitor will be administered as an intravenous injection.
45806762|NCT05337735|Drug|XmAb20717|Given by vein (IV)
45806763|NCT05337137|Drug|Relatlimab|Specified dose on specified days
45806764|NCT05337137|Drug|Nivolumab|Specified dose on specified days
45806765|NCT05337137|Drug|Bevacizumab|Specified dose on specified days
45806766|NCT05337137|Other|Placebo|Specified dose on specified days
45806767|NCT05334784|Device|Impella ECP|Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
46074765|NCT04276025|Other|Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
46074766|NCT04040881|Behavioral|Remote monitoring using smartphone accelerometer|"Patients will be instructed to carry the smartphone around their hips during waking hours, regardless of whether they are at home or outside (a nylon hip holster will be provided) and to keep it turned on at all times.~Daily steps will be recorded for at least seven days before the start of chemotherapy, and the median baseline number of daily steps will be calculated for each patient.~On the first day of chemotherapy, patients will receive side effect education as per standard of care. Patients will be instructed to continue carrying the smartphone daily as indicated for the entire duration of the first three chemotherapy cycles.~At the end of the follow-up period (or sooner in cases of early interruption of chemotherapy due to toxicity or disease progression; a change in chemotherapy regimen; or hospitalizations lasting ≥3 days), patients will rate their satisfaction with the intervention using a Likert-scale questionnaire and open-ended questions."
46074767|NCT02797860|Drug|Rocuronium|comparison of onset time and duration of rocuronium using Train of Four watch
46074768|NCT00860899|Drug|clonidine, levobupivacaine|One hour prior to skin incision, on epidural catheter, patients received 5 µg/kg of clonidine [Catapres®, Boehringer Ingelheim, Germany], 7 mL of 0.25% levobupivacaine [Chirocaine®, Abbott S.p.A., Italy] or 7 mL of saline.The study was designed to compare clonidine and levobupivacaine, and than both with the control group, in order to asses their analgesic and immunomodulation efficacy.
46074769|NCT02797782|Other|Detection of anti HBs antibody titer|All samples will be analyzed for anti HBs antibody titer using ELISA kits.
46074770|NCT02797626|Procedure|Primary retroperitoneal lymph-node dissection (pRPLND)|Open or laparoscopic robotic-assisted nerve-sparing retroperitoneal lymph node dissection (modified template RPLND, if possible ipsilateral nerve-sparing)
45941522|NCT00266305|Behavioral|Fish oil (Dry n-3, BASF)|5 g/oil daily for the first four month of lactation
46074771|NCT00863629|Drug|Insulin|In the CGC group, continuous insulin infusion was started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell <180 mg/dl, insulin infusion was tapered slowed down and eventually stopped. In the IGC group, insulin infusion was started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. After the start of insulin infusion protocol a glycemic control was provided every hour in order to obtain three consecutive values that were within the goal range. Plasma glucose levels were checked every two hours in both CGC and IGT patients throughout the study period. The infusion lasted until stable glycemic goal (ICG group: 80-140 mg/dl; CGC group: 180-200 mg/dl) at least for 24 h. Subcutaneous insulin was initiated at the cessation of the infusion. Insulin was given as short-acting insulin before meals and intermediate long-acting insulin in the evening, in both group.
45655649|NCT03051451|Drug|combination metformin hydrochloride/ fluoxetine 1000/20mg|"Group B will receive metformin 1700 mg and 40 mg of fluoxetine; after the increment phase.~All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition"
45806768|NCT05333445|Behavioral|educational program|"Education for the management of AF is carried out in a structured way, following the Bowyer model using the following pre-specified subtitles: How the heart works; Causes and risk factors of AF; Symptoms of AF; Goals of treatment in atrial fibrillation ; ''preparation for the ablation procedure''; and Lifestyle Modification. The technique consists of discussing the main subtitles and adapting the visit line to the needs of each patient"
45806769|NCT05333445|Behavioral|risk factors management|identify risk factors and offer guidance based on management strategies for the specific risk factor in each case
45806770|NCT05333445|Behavioral|telephone and e-mail contact|patients will also be provided with a phone number and email to contact the nurse for any concerns outside the designated times within the twelve-month follow-up.
45806771|NCT05333445|Other|usual care|standard care
45806772|NCT05332522|Behavioral|Neuroplasticity-based Computerized Cognitive Remediation|"The nCCR has two major components: Bottom up and Top down training.~Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
45806773|NCT05332405|Drug|Indocyanine green|The subject will receive 3mL of ICG followed by 10 mL of sterile saline intravenously as per the Spy Elite protocol. Within minutes of the injection, the SPY machine will be turned on and focused on the nerve. The SPY machine gives a digital read out of the % fluorescence when the dye reaches the nerve. This number correlates with blood flow or vascularity.
45806774|NCT05332145|Behavioral|MAP to Health|In Phase 1, participants will complete the web-based interview and Aim 1 measures, assessing acceptability and usability of the intervention. The investigators will review whether the intervention appropriately gathers information needed to program theory-based, personalized text messages. After completing the measures, a list of text messages for that participant will be generated and sent to the participant for review. Participants will review the text messages and rate the extent to which the messages are personalized. In Phase 2, the investigators will conduct a proof-of-concept pilot trial in which participants will complete a 4-week pretest monitoring period and an 8-week pilot trial of the intervention, with assessments of Self-Determination Theory mechanisms and meaning salience at pretest (-4 weeks), baseline (0 weeks), midpoint (4 weeks) and posttest (8 weeks). In addition, participants will wear accelerometers to assess physical activity during the 12 weeks.
45806775|NCT05328297|Drug|JNJ-55308942|JNJ-55308942 capsules will be administered orally.
45806776|NCT05328297|Drug|Placebo|Matching placebo capsules will be administered orally.
45806777|NCT05327114|Drug|Nipocalimab|Nipocalimab will be administered intravenously.
45806778|NCT05327114|Drug|Placebo|Placebo will be administered intravenously.
45806779|NCT05325866|Drug|Bemarituzumab|Intravenous (IV) infusion.
45806780|NCT05316155|Drug|Erdafitinib Intravesical Delivery System|Erdafitinib intravesical delivery system will be administered.
45941523|NCT00266344|Drug|MK0928, gaboxadol / Duration of Treatment 3 Weeks|
45941524|NCT00266344|Drug|Placebo / Duration of Treatment 3 Weeks|
45941525|NCT04718974|Other|mHealth call for life system/ tool using IVR ( interactive voice response)|The tool capitalises on a basic mobile phone's core utilities of voice and short messaging services. The system design, development, testing and evaluation was done by Janssen and the Grameen Foundation (http://motechsuite.org/index.php/implementations). In 2015, Janssen Global Public Health Research and Development, in close collaboration with the Infectious Diseases Institute Kampala (IDI), developed Call for Life Uganda (CFLU) tailored to the needs of PLHIV in Uganda
45941526|NCT00266539|Drug|E-TRANS Fentanyl hydrochloride; Morphine|
45941527|NCT00266578|Drug|Fluticasone Propionate|Flovent vs. placebo daily for 3 months
45941528|NCT00073268|Behavioral|Exercise|
45655650|NCT03051451|Drug|Placebo Oral Tablet|Group C will receive placebo oral tablet; All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition
45941529|NCT00266617|Drug|epoetin alfa|
45941530|NCT00266734|Device|RPS Adeno Detector|
46002146|NCT04660539|Drug|azathioprine (AZA)|Participants are permitted to use AZA during the study as background immunosuppressive treatment at a maximum dose of 3 milligram per kilogram per day (mg/kg/day)
45941531|NCT00266773|Behavioral|Chronic pain therapeutic interactive voice response (TIVR) system|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls
45941532|NCT02966132|Behavioral|iMD|Interactive video education delivered on a tablet computer
45941533|NCT02966132|Behavioral|NPA|
45941534|NCT00266929|Procedure|surgical|surgical treatment of odontoid fractures
45941535|NCT00266929|Procedure|conservative treatment|conservative stabilization of fractures
45941536|NCT00102219|Drug|Pemetrexed|
45806781|NCT05314647|Dietary Supplement|lutein|daily dose of 5 mg lutein
45655651|NCT02417961|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
45941537|NCT00102219|Drug|Doxorubicin|
45806782|NCT05314647|Dietary Supplement|placebo|daily dose of 0 mg lutein
45806783|NCT05314231|Drug|ALXN1720|All enrolled participants will receive a single dose of ALXN1720 on Day 1 followed by a Post-treatment and Follow-up Period (92 days).
45806784|NCT05312697|Biological|Setrusumab|A fully human anti-sclerostin monoclonal antibody (mAb)
45806785|NCT05312411|Biological|SCRI-E2CAR_EGFRtv1|Autologous CD4+ and CD8+ T cells that have been genetically modified to express antiFL(FITC-E2)
45941538|NCT01349569|Drug|Lenalidomide|Dosage forms: 5, 10, 15 and 25 mg capsules. Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5- 25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
46074772|NCT02859857|Drug|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).
46074773|NCT02805348|Drug|Bixalomer|Oral
46074774|NCT00860977|Drug|valacyclovir|oral valacyclovir 500mg twice daily
46074775|NCT00860977|Drug|Placebo|Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
45655652|NCT03049657|Device|Angiolite|Percutaneous coronary intervention
45806786|NCT05312411|Drug|UB_TT170|Bispecific small molecule adapter formulated with phosphate buffered saline
45806787|NCT05309265|Other|Multidisciplinary vocational rehabilitation intervention|"Information aims to provide tailored information concerning the work law protection (this support is already provided for all patients, regardless the type of disease, and also for citizens);~Occupational therapy aims to facilitate the reintegration in the previous workplace through the development of a rehabilitation intervention to overcome work difficulties in agreement with employee, employer and occupational physician,~Social support aims to find new job opportunities (for those who have lost the employment due to the disease) through the giving of support in job search, curriculum preparation, skill analysis, professional retraining and education."
45806788|NCT05308446|Biological|Cetuximab|Given IV
45941539|NCT01349569|Biological|Allogeneic Myeloma Vaccine|A total of 4 vaccines will be administered. The first three at monthly intervals and a booster at 6 months from the initial vaccine. Each vaccination will consist of five total intra-dermal injections, two each in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). Each dose will be administered on an outpatient basis. The subject must be observed in the clinic for at least 30 minutes after vaccination is completed.
45941540|NCT01349569|Biological|Prevnar-13|Prevnar-13 will be administered at 0.5ml dose by intramuscular injection at the same time as GVAX vaccine.
45941541|NCT00073346|Behavioral|Cognitive Behavioral Treatment|
45655653|NCT03049657|Device|Xience|Percutaneous coronary intervention
46074776|NCT02805192|Device|Size Measurement by a Smart phone App|
45452928|NCT00783406|Drug|PF-00610355|dry powder inhaler, 1472 mcg, single dose
45655654|NCT05529719|Other|Clinical Pilates Exercises|Participants in the experimental group were included in the clinical Pilates intervention, which consisted of three weekly sessions for 50 minutes for 12 weeks. Clinical pilates sessions were performed by a clinically Pilates-certified instructor and a physiotherapist. The intervention was divided into three sections. Each session started with the warm-up section. The warm-up part started with breathing exercises, pelvic tilt centering, activation of deep trunk and pelvic floor muscles, and joint mobility. The Clinical Pilates exercises section consisted of matte level strength and flexibility exercises involving the trunk, upper and lower extremities. Finally, a cooling part was done that included some flexibility exercises.
45655655|NCT03050047|Biological|BCD-100|Anti-PD1 monoclonal antibody
45655656|NCT02869217|Drug|Cyclophosphamide|
45655657|NCT02869217|Biological|TBI-1301|
45655658|NCT02869217|Drug|Fludarabine|
45806789|NCT05308446|Drug|Encorafenib|Given PO
45806790|NCT05308446|Biological|Nivolumab|Given IV
45806791|NCT05307692|Drug|Seltorexant|Seltorexant 20 mg will be administered orally as a tablet.
45806792|NCT05307692|Drug|Placebo|Matching placebo will be administered orally as a tablet.
45806793|NCT05306418|Drug|Mim8|"For treatment part 1, all participants will start on once-weekly treatment and continue on this regimen until week 26. For treatment part 2, starting at week 26, all participants will be offered the choice to remain on once-weekly or switch to once-monthly dosing.~Mim8 will be injected with a thin needle into the skin"
45806794|NCT05303090|Drug|H101|H101 intratumorally injection starts at day 0.
45806795|NCT05303090|Drug|Tislelizumab|Tislelizumab plus lenvatinib will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
45806796|NCT05303090|Drug|lenvatinib|lenvatinib (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
45941542|NCT00106509|Drug|tolevamer potassium-sodium (GT267-004)|
45941543|NCT00267163|Drug|donepezil|
45941544|NCT00267163|Drug|Placebo|
45941545|NCT00267241|Other|Mechanical Ventilation|Four different types of assisted ventilation (pressure support, pressure support plus sigh, BIPAP, variable ventilation)
45941546|NCT00267319|Drug|Glatiramer acetate|
45941547|NCT00073385|Drug|Pivanex|
45941548|NCT00073385|Drug|Docetaxel|
45941549|NCT00267358|Drug|RC-1291 HCl|
46074777|NCT00865891|Drug|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under fasting conditions
45655659|NCT04886089|Device|Pleth variability index for prediction of post-induction hypotension|The use of the baseline Pleth variability index values for prediction of occurrence of post-induction hypotension
45655660|NCT04896463|Radiation|Abdominal ultrasound (US)|abdominal examination with US device
45655661|NCT04885933|Diagnostic Test|sarcopenia measurement|BIA for fat free muscle mass hand grasp strength
45806797|NCT05303064|Drug|OLZ/SAM|OLZ/SAM refers to the fixed dose combination of olanzapine and samidorphan. The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day. The starting dose of samidorphan will be 5 or 10 mg.
45806798|NCT05303064|Drug|Olanzapine|The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day
45806799|NCT05299606|Device|Transbronchial Microwave Ablation|Transbronchial microwave ablation will be performed using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone.
45806800|NCT05296798|Drug|Phesgo|Phesgo will be administered subcutaneously (SC) at a fixed non-weight-based dose. In the induction therapy phase, a loading dose (1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase [rHuPH20]) will be administered in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses (600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20) will be administered once every 3 weeks (Q3W).
45806801|NCT05296798|Drug|Giredestrant|A 30 milligram (mg) capsule of giredestrant will be taken orally once a day on Days 1 to 21 of each 21-day cycle.
45941550|NCT00267358|Drug|Placebo|
45941551|NCT00102258|Drug|Growth Hormone Therapy|
45941552|NCT00267436|Behavioral|Community PROMISE|The Community PROMISE begins with a community assessment to identify HIV risk factors. Once risk factors have been identified, individuals from the targeted at-risk community are recruited and trained to be peer advocates. Trained peer advocates interview members of the community about their behavior. Role model stories are written based on the interviews. Role model stories are personal accounts from individuals in the target population which explain how and why they took steps to practice HIV risk-reduction behaviors and the positive effects the choice has had on their lives. Each week, peer advocates distribute role model stories and supplies, such as condoms, to 10 to 20 members of their social networks.
45941553|NCT00267514|Drug|sevelamer carbonate (Renvela®) sevelamer hydrochloride (Renagel ®)|sevelamer carbonate powder dosed TID with meals for four weeks followed by sevelamer hydrochloride tablets dosed TID with meals for four weeks
45941554|NCT00267514|Drug|sevelamer hydrochloride (Renagel ®) sevelamer carbonate (Renvela®)|sevelamer hydrochloride tablets dosed TID with meals for four weeks followed by sevelamer carbonate powder dosed TID with meals for four weeks
45941555|NCT00267553|Drug|Atamestane|
45655662|NCT04883125|Drug|Pioglitazone 15mg|pioglitazone (7.5-30 mg) once daily plus imatinib 400 mg 6 months
45655663|NCT04882423|Other|grilled hamburger (7 oz) with no vegetables|Test meal 1: grilled hamburger (7 oz) with no vegetables
45655664|NCT04882423|Other|grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)|Test meal 2: grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)
45941556|NCT00267553|Drug|toremifene|
45941557|NCT00267553|Drug|letrozole|
45941558|NCT00106548|Drug|tocilizumab [RoActemra/Actemra]|4mg/kg iv / month
45941559|NCT00106548|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv / month
45941560|NCT00106548|Drug|Placebo|iv / month
45941561|NCT00106548|Drug|Methotrexate|10-25mg/week
45941562|NCT00267709|Drug|Visilizumab|
45941563|NCT00267787|Other|genetic analysis|standard of care
45941564|NCT00073463|Genetic|tgAAVCF|
45941565|NCT00267826|Drug|Rituximab|Intravenous infusion of 1000mg Rituximab (anti-CD20) on days 1 and 15 to patients with atopic dermatitis
45941566|NCT00425620|Drug|SinuNase|Lavage
45941567|NCT00073502|Drug|OSI-7904L|
45941568|NCT00267943|Drug|telmisartan 80 mg + hydrochlorothiazide 25 mg|
45941569|NCT00102297|Drug|FG-3019|
46074778|NCT00865891|Drug|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under fasting conditions
45655665|NCT04882423|Other|grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)|Test meal 3: grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)
45655666|NCT04882423|Other|grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).|Test meal 4: grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).
45655667|NCT05529563|Procedure|LSG|LSG
45452929|NCT00783406|Drug|PF-00610355|dry powder inhaler, 736 mcg, single dose
45655668|NCT04882267|Behavioral|Team and Technology|Subjects will receive access and instruction on multiple home exercise apps. They will receive phone calls once a week from care team members for motivational interviewing to encourage exercise.
45655669|NCT05534633|Other|Choice of STBBI test(s)|Participants may receive a point of care HIV test, and/or point of care HCV test, and/or dry blood spot test, which can test for HIV, HCV, and syphilis, at the participants' choice.
45655670|NCT04430413|Biological|Platelet Rich Plasma|Autologous PRP obtained via double centrifugation process of the participant's blood sample. PRP was prepared by the double Spain strategy.
45655671|NCT04882345|Drug|Almonertinib|"Almonertinib is a class 1 new drug,the third-generation small molecule EGFR TKI, which can irreversibly and highly selectively inhibit EGFR sensitive mutations (such as exon 19 deletion and L858R mutation) and T790M resistance mutations.~Patients meeting the criteria for inclusion and exclusion were included in the Almonertinib treatment group and received 110 mg of Almonertinib orally once a day."
45655672|NCT05529485|Procedure|Cataract surgery by phacoemulsification|Cataract surgery by phacoemulsification
45806802|NCT05296798|Drug|Docetaxel|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Docetaxel will be administered at 75 milligrams per metre squared of body surface area (mg/m2) intravenously over 60 (±10) minutes on Day 1 of each cycle for 4 to 8 cycles (a cycle is 21 days); this dose may be escalated to 100 mg/m2 if the initial dose was well tolerated.
45806803|NCT05296798|Drug|Paclitaxel|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Paclitaxel will be administered at 80 milligrams per metre squared of body surface area (mg/m2) intravenously over a minimum of 1 hour on Days 1, 8, and 15 of each cycle for 4 to 8 cycles (a cycle is 21 days); this weekly regimen is considered as one complete cycle whenever 3 weekly doses are given.
45655673|NCT04882033|Drug|Concurrent chemoradiotherapy plus anlotinib|"Anlotinib: for cycle 1-6. P.O; QD; from days 1 to 14 in a 21-day cycle. 8mg in low-dose groups (3 subjects). 10mg in middle-dose groups (3 subjects). 12mg in high-dose groups (3 subjects).~Chemotherapy:~For cycle 1/4/5/6. Etoposide 100mg/m2, d1-3, q3w; Cisplatin 25mg/m2 d1-3, q3w. For cycle 2/3. Etoposide 50mg/m2, d1-3, q4w; Cisplatin 25mg/m2 d1-3, q4w.~Radiotherapy:~For cycle 2/3.Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy."
45806804|NCT05296798|Drug|LHRH Agonist|A luteinizing hormone-releasing hormone (LHRH) agonist will be administered every 28 days to pre- and peri-menopausal women and all male participants while receiving giredestrant in Arm B. An LHRH agonist may be administered to male participants and pre- and peri-menopausal female participants receiving tamoxifen in Arm A, and should be administered to those receiving an aromatase inhibitor in Arm A. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
45941570|NCT00073541|Drug|EMD 72000|
45941571|NCT00415948|Device|Biomarkers|
45655674|NCT05474183|Drug|Ketamine|drug
45941572|NCT00415987|Procedure|Hematopoietic Stem Cell Transplantation|
45941573|NCT00401232|Procedure|Blood Collection|Blood Collection
45941574|NCT00416026|Behavioral|Educational/Counseling/Training|
45941575|NCT04711265|Drug|Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine|Intramuscular injection with 3 doses of QHPV
45941576|NCT00268138|Drug|elmex gel|elmex gel once a week
45941577|NCT02966171|Drug|HMPL-453|oral administration
45941578|NCT00102375|Drug|Topotecan|
45941579|NCT00268177|Drug|Salmeterol/fluticasone propionate 50/500mcg Diskus|
45941580|NCT00268216|Drug|Salmeterol 50mcg/ Fluticasone Propionate 500mcg|
45452930|NCT00783406|Drug|PF-00610355|dry powder inhaler, 368 mcg, single dose
45452931|NCT00783406|Drug|Placebo|Placebo
45452932|NCT03038854|Other|Test GUM|Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
45941581|NCT00073580|Drug|Angiomax (bivalirudin) anticoagulant|): 250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of the procedure with the option to increase or decrease the infusion rate in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT+) >300 seconds. A low-dose infusion could be administered in the preoperative phase (up to 48 hours before the procedure) and in the postoperative phase (up to 14 days after the procedure) as clinically indicated for management of HIT/TS. An initial dose of 0.1 mg/kg IV bolus followed by an IV infusion of 0.2 mg/kg/h titrated to a desired activated partial thromboplastin time (aPTT), eg, 1.5-2.5 times baseline aPTT, was recommended.
45941582|NCT00401271|Drug|OPC-67683|
45941583|NCT00401271|Drug|Rifafour e-275|
45452933|NCT03038854|Other|Standard GUM|Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
45452934|NCT03038854|Other|Cows' milk|Homogenized store-bought full fat cow's milk.
45452935|NCT00834574|Drug|Cefdinir for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single dose fasting
45452936|NCT00834574|Drug|OMNICEF® for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single dose fasting
46002147|NCT04660539|Drug|mycophenolate mofetil (MMF)|Participants are permitted to use MMF during the study as background immunosuppressive treatment at a maximum dose of 3000 mg/day
45806805|NCT05296798|Drug|Optional Endocrine Therapy of Investigator's Choice|For participants in Arm A, optional endocrine therapy of investigator's choice is allowed based on the standard of care, and it can include an aromatase inhibitor or tamoxifen with or without an LHRH agonist, or gonadal ablation. The decision to include or exclude this option must be made prior to randomization.
45806806|NCT05295459|Drug|LYR-210|LYR-210 drug matrix (mometasone furoate)
45655675|NCT04885777|Drug|Lidocaine|"Initially, a nasopharyngeal swab was performed on each group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, one ml of a solution containing 20 mg/ml of lidocaine, was applied to each nostril of the participants in the Lidocaine group. Thus, a total of 40 mg of lidocaine, 20 mg for each nostril, was given to the individuals of the Lidocaine group. The second samples were collected after waiting 5 minutes following the administration of the solution."
45655676|NCT04885777|Other|Placebo|"Initially, a nasopharyngeal swab was performed on placebo group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, the Placebo group received only a total of 2 ml of 0.9% NaCl (one ml for each nostril). The second samples were collected after waiting 5 minutes following the administration of the solution."
45655677|NCT05529407|Device|Simple Vaginal Tampon|Use of single use vaginal tampons
45655678|NCT05529407|Device|Glass Vaginal Trainer|Use of glass vaginal trainers
45806807|NCT05295459|Drug|Sham procedure control|Sham procedure control
45941584|NCT00073619|Behavioral|Cognitive-behavioral group therapy|School-based anxiety preventive intervention (cognitive-behavioral group therapy) originally designed for Australian children that was culturally and contextually modified for inner-city children exposed to community violence. Participants received the weekly intervention and rewards for participating in the assessments.
45941585|NCT00401310|Drug|Comparator: Placebo|Placebo IV infusions 1hr/daily over 7 days.
45806808|NCT05295459|Other|Background therapy|Daily Saline Irrigation
45806809|NCT05294367|Drug|Magnesium Chloride-based Lotion|Given topically
45941586|NCT00401310|Drug|Comparator: MK0724|MK0724 8 mg/kg/hr 1 hr/daily over 7 days.
45806810|NCT05294367|Other|Quality-of-Life Assessment|Ancillary studies
45806811|NCT05294367|Behavioral|Special Diet Therapy|Consume magnesium rich foods
45806812|NCT05287347|Diagnostic Test|Blood Specimen|"Blood samples will be collected from study participants at one time-point in the study, for the following:~tumor markers CEA and CA 19-9: 2 ml blood will be collected.~glycomics: 0.5 cc blood will be collected~ctDNA: 20 cc blood will be collected"
45806813|NCT05286827|Drug|Olaparib|Administered orally (300 mg) twice daily continuously for 21-day cycles for up to 2 years.
45806814|NCT05284838|Other|Error Management Training (Difficult)|Error Management Training is used to teach head computed tomography interpretation. Participants encounter difficult questions.
45806815|NCT05284838|Other|Error Management Training (Easy)|Error Management Training is used to teach head computed tomography interpretation. Participants encounter easy questions.
45806816|NCT05284838|Other|Error Avoidance Training|Error Avoidance Training used to teach head computed tomography interpretation.
45806817|NCT05284747|Drug|Evolocumab|Evolocumab will be provided as a single-dose, prefilled autoinjector pen (AI/pen) for fixed dose subcutaneous (SC) injection.
45806818|NCT05284747|Drug|Routine Lipid Management|Routine lipid management therapies will be administered at the discretion of the investigator per SoC.
45806819|NCT05283304|Drug|Buprenorphine injection (BUP-Inj)|Sublingual Buprenorphine induction, then SublocadeTM, Indivior injectable (300mg)
45806820|NCT05283304|Other|Placebo injection|Sublingual buprenorphine induction, then Placebo injectable (300 mg)
45806821|NCT05281484|Drug|CNM-Au8|"CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bipyramid, tetrahedron, decahedron, planar spheroids).~Highly pure elemental Au nanocrystals are suspended in USP purified deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) nominally concentrated to up to 0.5 mg/mL (500 ppm)."
45806822|NCT05275023|Drug|JNJ-73763989|JNJ-73763989 will be administered subcutaneously.
45806823|NCT05275023|Drug|PD-1 inhibitor|PD-1 inhibitor will be administered as IV infusion.
45806824|NCT05275023|Drug|Tenofovir Disoproxil|Tenofovir disoproxil film-coated tablets will be administered orally.
45941587|NCT00073658|Drug|Citalopram|
45941588|NCT00073658|Drug|Risperidone|
45941589|NCT00268255|Drug|gefitinib|
45941590|NCT00268255|Procedure|adjuvant therapy|
45941591|NCT00268255|Procedure|enzyme inhibitor therapy|
45941592|NCT00268255|Procedure|neoadjuvant therapy|
45941593|NCT00268255|Procedure|protein tyrosine kinase inhibitor therapy|
45941594|NCT00268255|Procedure|radiation therapy|
45941595|NCT00268255|Procedure|radiosensitization|
45941596|NCT00268294|Device|Cardiac Resynchronization Therapy|
45941597|NCT00102414|Drug|Gemcitabine|
45941598|NCT00268333|Drug|fluorouracil|
45941599|NCT00268333|Drug|leucovorin calcium|
45941600|NCT00268333|Drug|oxaliplatin|
45941601|NCT00268333|Procedure|neoadjuvant therapy|
46074779|NCT02797392|Behavioral|Lifestyle intervention|1) Systematic collection of information on lifestyle risk factors using questionnaire 2) Risk estimation and stratification into risk groups based on questionnaire data and information from the electronic patient record (EPR) using validated risk estimation models, 3) An individual electronic health profile with personalized advise on lifestyle change and 4) targeted preventive services incl. lifestyle counseling at the GP or the municipality for citizens at increased risk of lifestyle disease and citizens with risk behavior, respectively.
45655679|NCT04885855|Drug|Sofosbuvir 400 MG|Sofosbuvir is a direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5B (NS5B)
45655680|NCT04885855|Drug|Ravidasvir 200mg|Ravidasvir is an investigational direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5A (NS5A)
45655681|NCT04886011|Combination Product|placebo gel|just methyl cellulose gel was applied to the ulcer
45941602|NCT00073697|Drug|Escitalopram|Participants will receive escitalopram for a minimum of 32 weeks or approximately 8 months. Participants whose symptoms become stabilized will continue the initial treatment for another 6 months.
45655682|NCT04886011|Combination Product|camel whey protein gel|camel whey protein gel was prepared and dissolved in methyl cellulose gel base and applied to the ulcer
45806825|NCT05275023|Drug|Tenofovir Alafenamide|TAF film-coated tablets will be administered orally.
45806826|NCT05275023|Drug|Entecavir|ETV film-coated tablets will be administered orally.
45806827|NCT05272631|Device|Retrograde Femoral Nail Advanced|No drug will be given as part of this study. Participant will undergo surgery with RFNA based on the surgeon's decision and the site's SOC.
45806828|NCT05272631|Device|Tibial Nail Advanced|No drug will be given as part of this study. Participant will undergo surgery with TNA based on the surgeon's decision and the site's SOC.
45806829|NCT05272150|Drug|Guselkumab|Participants will receive guselkumab as subcutaneous injection.
46074780|NCT02797236|Biological|SF2a-TT15 vaccine|
45806830|NCT05272150|Drug|Placebo|Participants will receive placebo as subcutaneous injection.
45806831|NCT05270837|Drug|Pegvaliase|Pegvaliase 2.5mg/10mg/20mg/40mg/60mg self-administered from 1 time up to 7 times a week
45806832|NCT05270837|Other|Diet Only|Diet Control
45806833|NCT05265273|Drug|Nipocalimab|Nipocalimab will be administered as an IV infusion.
45655683|NCT05196659|Behavioral|Integrated comprehensive cardiovascular disease management|"Electronic Health Record-Decision Support Software (EHR-DSS):~Electronic patient health record storage~Management prompts to the clinical team (following algorithms)~Structured follow-up schedule with automatic reminders to patients, clinical team, and non-physician health worker~Non-physician health worker-led continuity of care:~- individually tailored follow-up and guidance regarding treatment adherence as well as help in resolving issues related to access, convenience, cost of care, and equity~Text-message based reminders for a healthy lifestyle~Patient diary containing visual assessment tool for adherence to medication (VITA) and reinforcement tool for lifestyle modification~Quarterly audit and feedback to the clinical team"
45655684|NCT04895683|Behavioral|Text message content|Behavioural science-informed text messages aimed at improving COVID-19 vaccination uptake.
45655685|NCT05534555|Diagnostic Test|FebriDx|Testing of finger-prick blood sample using FebriDx
45655686|NCT04885621|Dietary Supplement|nutrisystem-D|Nutrisystem meal replacements and Glytec glucomander-outpatient algorithm for insulin management decisions
45806834|NCT05264207|Behavioral|Nursing students' home-visit programme|"12-week home-visit program conducted by nursing students. Participants will receive weekly 45-minute visits. The visits will aim to promote self-care behaviours and will focus on:~Self-care of chronic conditions and medication management~Healthy habits: physical activity and healthy eating~Access to social support resources~Patients' rights and autonomous decision-making~The visits program will follow the WHO recommendations for the implementation of health promotion activities. All topics will be assigned 3 visits. In the first visit, the students will assess the participants' information needs and preferences in relation to the topic addressed and will provide generic information about it. In the second visit, the students will present individually-tailored information and will use individually-adapted strategies to convey such information. In the third visit, the student will explore the impact of the two previous visits and reinforce self-care behaviours."
45806835|NCT05264207|Behavioral|Standard care from Public Andalusian Health Service|Standard care offered by the Public Andalusian Health Service in its portfolio of services for older adults with multiple chronic conditions and complex health conditions. As part of these services, older adults with multiple chronic conditions receive generic, written information on healthy eating, adapted physical activity, abandonment of toxic habits, environmental safety and emotional management when they are first diagnosed with a chronic condition. The action plans or protocols established in the care processes aimed at older people with chronic multimnorbidity do not include periodic home visits.
45941603|NCT00073697|Behavioral|Interpersonal Psychotherapy|Participants will receive interpersonal psychotherapy (IPT) for 8 months and possibly an additional 6 months.
45941604|NCT00073697|Other|Escitalopram plus IPT|Participants whose symptoms become stabilized will continue the initial treatment for another 6 months. Those who do not will have the second treatment added to their regimen until remission occurs.
45941605|NCT00268372|Drug|cisplatin|
45941606|NCT00268372|Drug|docetaxel|
45941607|NCT00268372|Drug|5-fluorouracil|
45941608|NCT00268372|Procedure|surgery|
45941609|NCT00268372|Radiation|radiation therapy|
45941610|NCT00268411|Drug|gemcitabine hydrochloride|
45941611|NCT00268411|Drug|oxaliplatin|
45941612|NCT00073736|Drug|MB07133 300mg/m2/day|7-day continuous infusion in 28-day cycles
45941613|NCT00073736|Drug|MB07133 600 mg/m2/day|7-day continuous infusion in 28-day cycles
46074781|NCT02797236|Biological|SF2a-TT15 vaccine + adjuvant|
46074782|NCT02797236|Biological|Placebo|
46074783|NCT02797236|Biological|Placebo + adjuvant|
46074784|NCT00863785|Drug|Corticoids plus N Acetyl Cysteine|40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
46074785|NCT02801526|Drug|CKD-330 16/5mg - A|
46074786|NCT02801526|Drug|Candesartan 16mg and Amlodipine 5mg|
45941614|NCT00073736|Drug|MB07133 1200 mg/m2/day|7-day continuous infusion in 28-day cycles
45655687|NCT05534399|Procedure|Intra-vesical BoNTA injections|"Intra-vesical BoNTA injections will be performed according to the protocol currently applied by the department.~They will be performed in the operating room or in the outpatient clinic under strict asepsis, including the wearing of sterile gloves by the surgeon associated with an antiseptic brushing of the patient and the establishment of sterile fields.~A rigid or a flexible cystoscope will be used.~After the introduction of the cystoscope under visual control, complete bladder emptying will be performed. The bladder will be filled again, slowly and at low pressure to allow the bladder mucosa to expand.~BoNTA (BOTOX® 200 U) will be diluted as follows: BOTOX® 200 U: in 30 mL of saline solution~The solution obtained will be injected all along the bladder wall, sparing the trigone in 20 (BOTOX® 200 U) points using a Bonee®-type needle.~A complete bladder emptying will be performed at the end of the procedure."
45655688|NCT03051295|Other|Dental health information form|The format in which dentists receive information about diagnostic test results and efficacy of treatment.
45655689|NCT04379401|Device|Cardiac Resynchronization Therapy (ON vs. OFF)|This study involves study participants, who already received cardiac resynchronisation therapy implantation for clinical reasons. CRT is authorized for medical use by Swissmedic in Switzerland and all implanted devices are CE-approved.
45655690|NCT02632721|Drug|Decitabine|
45941615|NCT00073736|Drug|MB07133 1800 mg/m2/day|7-day continuous infusion in 28-day cycles
45941616|NCT00073736|Drug|MB07133 2400 mg/m2/day|7-day continuous infusion in 28-day cycles
45655691|NCT02632721|Drug|BI 836858|
45655692|NCT05529095|Drug|Apomorphine Sublingual Film|Sublingual Apomorphine initial dose 10 mg, titrated depending on symptomatic response.
45655693|NCT05529095|Drug|Placebo|Placebo (sugar pill)
45655694|NCT01596127|Drug|Intrathecal Rituximab|"Phase I: Starting dose Rituximab 10 mg intrathecally twice weekly until 2 consecutive CSF samples are negative for the presence of blast cells. Thereafter, rituximab 10 mg intrathecally weekly for additional 4 weeks, followed by intrathecal rituximab 10 mg administered once every other week for an additional 8 weeks.~Phase II Starting Dose of Rituximab: Maximum tolerated dose from Phase I."
45806836|NCT05263388|Drug|REKOVELLE (Follitropin Delta)|REKOVELLE administered as single daily subcutaneous injections in the abdomen. The starting dose of REKOVELLE is 15 μg fixed for the first four stimulation days. Dose adjustments may be implemented on the day of starting the gonadotropin-releasing hormone (GnRH) antagonist (stimulation day 5 or day 6) or later, can occur no more frequently than every second day. At each dose adjustment, the daily REKOVELLE dose can be increased or decreased by 5 μg based on the subject's response. The minimum REKOVELLE dose is 5 μg and the maximum REKOVELLE is 20 μg. Subjects can be treated for a maximum of 20 days.
45806837|NCT05263388|Other|GONAL-F (Follitropin Alfa)|GONAL-F administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F is 225 IU fixed for the first four stimulation days. Dose adjustments may be implemented on the day of starting the GnRH antagonist (stimulation day 5 or day 6) or later, can occur no more frequently than every second day. At each dose adjustment, the daily GONAL-F dose may be adjusted by 75 IU based on the subject's response. The minimum GONAL-F dose is 75 IU and the maximum GONAL-F dose is 300 IU. Subjects can be treated for a maximum of 20 days.
45806838|NCT05259943|Drug|Psilocybin first|Participants will receive 8 doses of 2mg psilocybin.
45941617|NCT00268489|Biological|bevacizumab|
45941618|NCT00268489|Drug|pemetrexed disodium|
45655695|NCT05534321|Radiation|Prophylactic Radiotherapy|Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), and stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT) techniques may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.
45806839|NCT05259943|Drug|Placebo first|Participants will receive 4 doses of placebo followed by 4 doses of 2mg psilocybin
45941619|NCT00268528|Behavioral|Compliance Monitoring|Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap
45941620|NCT00268528|Other|Laboratory Biomarker Analysis|Correlative studies
45941621|NCT00268528|Drug|Mercaptopurine|Given PO
45941622|NCT00268528|Drug|Methotrexate|Given PO
45941623|NCT00268528|Other|Questionnaire Administration|Ancillary studies
45941624|NCT00268528|Other|Study of Socioeconomic and Demographic Variables|Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap
45941625|NCT00106782|Procedure|Transcranial Electrical Polarization (TEP)|
45941626|NCT00073814|Drug|Levalbuterol tartrate MDI|levalbuterol MDI 90 mcg QID
45941627|NCT00073814|Drug|racemic albuterol MDI|racemic albuterol MDI 180 mcg QID
45941628|NCT00073814|Drug|Placebo|Placebo MDI QID
45941629|NCT00102453|Drug|Pentoxifylline|Pentoxifylline dosing: 20mg/Kg/day in a 20 mg/mL solution. Maximum dose of 1200mg/day. Dosing split into two equal parts taken morning and night with food.
45941630|NCT00073853|Procedure|Autologous Incubated Macrophages (cell therapy)|
45941631|NCT00268567|Drug|leflunomide combined with prednisone|
45941632|NCT00268606|Behavioral|cognitive-behavioral therapy|
45941633|NCT00268645|Drug|Insulin Glargine|
45941634|NCT00268684|Drug|Erlotinib, Temozolomide|
45941635|NCT00106821|Drug|Tiotropium Bromide Inhalation Powder|
45941636|NCT00073931|Biological|filgrastim|5 µg/kg/day subcutaneously
45941637|NCT00073931|Biological|sargramostim|250µg/m2/d subcutaneously
45941638|NCT00073931|Procedure|autologous bone marrow transplantation|autologous stem cells given via central catheter
45941639|NCT00073931|Procedure|peripheral blood stem cell transplantation|autologous stem cells given via central catheter
45941640|NCT00073931|Radiation|tositumomab and iodine I 131 tositumomab|given intravenously (test dose of 1.7-10 mg/kg tositumomab antibody radiolabeled with ~10 mCi I-131) or via central catheter (therapy dose of 1.7-10 mg/kg tositumomab radiolabeled with individually calculated therapy dose of I-131)
45941641|NCT00268723|Drug|Levalbuterol tartrate HFA MDI|levalbuterol MDI 90 mcg QID
45806840|NCT05255991|Drug|Placebo|Placebo administered QID
45655696|NCT05534321|Drug|Standard of care systemic therapy|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
45655697|NCT03051373|Drug|nanoparticle albumin-bound paclitaxel, S-1|Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
45655698|NCT03051373|Drug|Gemcitabine, cisplatin|Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
45655699|NCT04881331|Other|Analysis of electrosurgical smoke.|Patients undergo standard of care surgical removal of the malignant breast tumor. Electrosurgical knife is used to cut tissues according to standard practice. Fraction of the surgical smoke is captured for analysis and video record of the point of view of the surgeon is captured with a head-mounted camera.
45655700|NCT04895059|Drug|Rosuvastatin (20mg) /Ezetimibe (10mg) in fixed dose|Form: Tablets Dosage: 20 mg Adminstration way: Oral
45655701|NCT04895059|Drug|Rosuvastatin 20mg|Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration way: Oral
45655702|NCT04895059|Drug|Ezetimibe 10mg|Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration way: Oral
45655703|NCT04391413|Device|Use of OCT to guide the angioplasty procedure|OCT will be performed and OCT data used to choose and/or modify procedural strategy. The OCT system used will be the Ilumien Optis system, and Dragonfly Optis probe.
45806841|NCT05255991|Drug|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
45806842|NCT05255991|Device|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
45806843|NCT05254600|Behavioral|RISE for Nurse Leaders Program|Psychoeducational sessions designed to impact resilience, insight, self-compassion, and empowerment
45806844|NCT05252533|Drug|Ustekinumab|This study does not provide dosing instructions for ustekinumab but will engage participants who have been treated with ustekinumab by their corresponding HCPs independent of this study.
45806845|NCT05251948|Drug|Atezolizumab|Atezolizumab is administered by IV infusion on Day 1 of each 21 day cycle. Treatment until progressive disease.
45941642|NCT00268723|Drug|Placebo|Placebo MDI QID
45941643|NCT00268840|Drug|Docetaxel|Docetaxel 50 mg/m2 ou 35 mg/m² (suivant le bilan hépatique) à J1 et J15 toutes les 4 semaines
45941644|NCT00268840|Drug|Gemcitabine|Gemcitabine 1200 mg/m2 à J1 et J15 toutes les 4 semaines
45941645|NCT00268879|Drug|Renzapride|Placebo Renzapride 4 mg QD Renzapride 2 mg BID
45941646|NCT00106860|Drug|a benzodiazepine drug|
45941647|NCT00268918|Drug|Docetaxel|Participants may continue receiving study drug as long as their disease does not worsen
45941648|NCT00268918|Drug|PTK787|Participants may continue receiving study drug as long as their disease does not worsen
45941649|NCT00268957|Drug|Sevelamer carbonate (Renvela®)|sevelamer carbonate powder dosed once per day with largest meal
45806846|NCT05251948|Drug|Capecitabine|Capecitabine is administered orally twice daily on Days 1-14 of each 21 day cycle. Treatment for up to six cycles.
45806847|NCT05251948|Drug|Oxaliplatin|Oxaliplatin is administered by IV infusion on Day 1 of each 21 day cycle. Treatment for up to six cycles.
45806848|NCT05251948|Drug|Tiragolumab|Tiragolumab is administered by IV infusion on Day 1 of each 21 day cycle.
45806849|NCT05251948|Drug|AB011|AB011 is administered by IV infusion on Day 1 of each 21 day cycle. Treatment until progressive disease.
45806850|NCT05250973|Drug|Daratumumab|Daratumumab will be administered subcutaneously.
45806851|NCT05250973|Drug|Cyclophosphamide|Cyclophosphamide will be administered either orally or IV.
45806852|NCT05250973|Drug|Bortezomib|Bortezomib will be administered by SC injection.
45941650|NCT00268957|Drug|Sevelamer hydrochloride (Renagel®)|Sevelamer hydrochloride tablets dosed three times a day with meals
45941651|NCT00073970|Drug|celecoxib|400mg, given twice daily
45941652|NCT02961400|Other|PUSH text messages|The intervention is designed to remind participants of treatment components.
45941653|NCT02961400|Other|PULL text messages|The intervention is designed to remind participants to recall treatment components.
45941654|NCT02961400|Behavioral|TranS-C|The Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates evidence-based treatments derived from basic research on the circadian system.
45941655|NCT02961400|Behavioral|PE|Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
45941656|NCT00102492|Drug|GW679769|
45941657|NCT00269035|Drug|SB773812|SB-773812 tablets will be available with dose strength of 60 mg
45941658|NCT00269035|Drug|Risperidone|Risperidone tablets will be available with dose strength of 3 and 6 mg
45941659|NCT00269074|Drug|IDEA-070|
45941660|NCT00074009|Drug|bortezomib|
45941661|NCT00269230|Device|Pacing Lead|Left ventricular pacing lead
45941662|NCT00269269|Drug|antihypertensive drug|
45941663|NCT00269269|Behavioral|placebo|
45941664|NCT00269308|Procedure|Chiropractic Manual treatment + home exercise ( procedure+behavior)|"The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation and mobilization with light soft tissue massage as indicated to facilitate the manual therapy.~Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active"
45655704|NCT05467475|Drug|BI 1819479|BI 1819479
45655705|NCT05467475|Drug|Esomeprazole|Esomeprazole
45655706|NCT05528705|Biological|LAENNEC|Subacromial spatial administration
45655707|NCT05528705|Other|0.9% normal saline|Subacromial spatial administration
45655708|NCT04430491|Diagnostic Test|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
45655709|NCT05534165|Drug|Tecovirimat|600 mg po BID
45655710|NCT05534165|Drug|Placebo|identical placebo 600 mg po BID
45655711|NCT04895137|Drug|mFOLFOX6+Bevacizumab+PD-1 monoclonal antibody treatment combinations|mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations in patients with local advanced microsatellite stability colorectal cancer
45941665|NCT00269308|Procedure|Supervised rehabilitative exercise + home exercise|"The rehabilitative exercise program will consist of 20, 1 hour small-group sessions. It is a modification of exercise protocols used in previous studies by the investigators and others and incorporates recommendations of leading rehabilitative exercise specialists. The program will include exercises that reduce joint stiffness and relax elastic structures resulting in lower joint loads during movements.~Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active"
46074787|NCT05227495|Behavioral|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~They will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
46074788|NCT05227495|Behavioral|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
45806853|NCT05250973|Drug|Dexamethasone|Dexamethasone will be administered orally or IV.
46074789|NCT02805426|Drug|Tranexamic Acid|
45452937|NCT04879966|Drug|Infliximab|Infliximab was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher
45452938|NCT04879966|Drug|Corticosteroid|Corticosteroids was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher
45452939|NCT00834418|Drug|Leflunomide 20 mg Tablets|1 x 20 mg, single-dose fasting
45452940|NCT00834418|Drug|ARAVA™ 20 mg Tablets|1 x 20 mg, single-dose fasting
45806854|NCT05244304|Drug|Tinlarebant|Tinlarebant drug substance is a white to off-white substance and is dispensed as a tablet for oral administration.
45806855|NCT05244304|Drug|Placebo|Not active drug
45806856|NCT05243329|Drug|Psilocybin|10 mg or 25 mg oral aqueous psilocybin solution
45806857|NCT05242562|Drug|Plenvu|a recently developed 1 liter bowel preparation fluid that is often used in clinical practice. Patients will receive a split dose protocol, low-residue diet 2 days before colonoscopy, and clear liquid diet 1 day before colonoscopy.
45941666|NCT00269308|Behavioral|Home exercise|Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
45452941|NCT04621318|Drug|Denosumab|60 mg, single-dose
45452942|NCT00834340|Drug|Glimepiride 4 mg Tablets|1 x 4 mg, single-dose fasting
45452943|NCT00834340|Drug|AMARYL® 4 mg Tablets|1 x 4 mg, single-dose fasting
45655712|NCT04885387|Device|chest CT|chest CT pectus deformities diagnostic
45655713|NCT04885387|Device|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device pectus deformities diagnostic
45676332|NCT03901456|Behavioral|Care to Plan|Care to Plan (CtP) is an online care planning tool that provides a succinct and clear overview of various types of ADRD caregiver interventions, administers a brief validated assessment of risk, and generates individualized service recommendations for Alzheimer's disease and related dementia (ADRD) caregivers as well as resources that link users to a selected recommendation. Caregivers will complete the tool with the guidance of a CtP interventionist (Senior Care Navigator/Riverside Health System staff). The interventionist will discuss CtP recommendations with caregivers and help caregivers enroll in a recommended support service if so desired.
45806858|NCT05242562|Drug|Moviprep|a 2 liter widely established 2 liter bowel preparation fluid that is commonly used in clinical practice. Patients will receive a split dose protocol, low-residue diet 2 days before colonoscopy, and clear liquid diet 1 day before colonoscopy.
45806859|NCT05242484|Biological|Guselkumab|Guselkumab will be administered as subcutaneous injection.
45941667|NCT00106899|Procedure|Magnetic Resonance Imaging (MRI)|MRI scans
45941668|NCT00106899|Procedure|Positron Emission Tomography (PET)|PET scans
45941669|NCT00106899|Procedure|Lumbar Puncture (LP)|collection of cerebrospinal fluid
45806860|NCT05242484|Biological|Golimumab|Golimumab will be administered as subcutaneous injection.
45806861|NCT05242484|Biological|JNJ-78934804|JNJ-78934804 will be administered subcutaneously as per defined regimen.
45806862|NCT05242484|Drug|Placebo|Placebo will be administered as subcutaneous injection.
45806863|NCT05242471|Biological|Guselkumab|Guselkumab will be administered as subcutaneous injection.
45806864|NCT05242471|Biological|Golimumab|Golimumab will be administered as subcutaneous injection.
45941670|NCT00074048|Drug|BL22|Dosing via IV on Days 1,3, and 5.
45941671|NCT00269347|Procedure|Chiropractic Spinal Manipulation|
46074790|NCT02805426|Drug|Placebo|
45806865|NCT05242471|Biological|JNJ-78934804|JNJ-78934804 will be administered subcutaneously as per defined regimen.
46074791|NCT02805426|Drug|Misoprostol|
45655714|NCT04885309|Procedure|Nerve Stimulator-guided Obturator Nerve Block|Following the confirmation of spinal anesthesia level in the patients in the ONB group while in the lithotomy position, ONB was applied unilaterally or bilaterally, depending on the tumor position. A needle with a nerve stimulator was advanced vertically 2 cm below and 2 cm from the pubic tubercle. The needle is inserted through the skin and into the lower ramus of the pubic bone. When contraction was observed in the adductor muscle groups and the aspiration was negative, 10 mL 0.25% levobupivacaine at 0.3-0.5 mA was administered. The operation was started 10 minutes after the injection. TURBT operations were performed with a 30 degree optic and a 26 F bipolar resectoscope. All spinal anesthesia and ONB procedures were performed by the same anesthesia team. All TURBT operations were performed by the same surgeon.
45806866|NCT05242471|Drug|Placebo|Placebo will be administered as subcutaneous injection.
46074792|NCT00866203|Drug|HDS vs ProMECE/CytaBOM|
46074793|NCT02805036|Device|echocardiography|• Prospective, simultaneous recording of the cardiac output (measured non-invasively via transthoracic echocardiography) and a number of parameters commonly monitored in the surgical intensive care unit (CVP, SBP/DBP/MBP).
45941672|NCT00269347|Procedure|Exercise|
45941673|NCT00269347|Behavioral|Self-care|
45941674|NCT00269386|Drug|Clarithromycin|Clarithromycin S/R 1g once daily April 2004 - Clarithromycin S/R (Klaricid XL) ceased to be abailable and subsequent patients will receive standard Clarithromycin 500mg bd
45941675|NCT00269386|Drug|Placebo|
45941676|NCT00269425|Behavioral|American Heart Association Step 2 diet|Low fat diet with patient education and diet analysis
45452944|NCT00683722|Drug|Prochymal™|IV infusion of ex- vivo cultured adult human mesenchymal stem cells.
45452945|NCT00683722|Drug|Placebo|IV infusion of excipient of Prochymal™.
45452946|NCT04596436|Other|no intervention|no intervention
45806867|NCT05238766|Behavioral|DEAL|The DEAL protocol is an Acceptance and Commitment Therapy and Behavioral Activation informed clinical protocol to undermine accommodation and help parents adhere with behavioral treatment plan components.
45806868|NCT05237297|Drug|Ilaprazole|Ilaprazole 10mg
45806869|NCT05237297|Drug|Naproxen|Naproxen 500mg
45806870|NCT05237297|Drug|Aceclofenac|Aceclofenac 100mg
45806871|NCT05237297|Drug|Celecoxib|Celecoxib 200mg
45941677|NCT00269425|Behavioral|Mediterranean diet|Mediterranean style diet with patient education and diet analysis
45806872|NCT05235971|Behavioral|Episodic Future thinking|"During a visit with the study team, participants will identify personally-relevant reminders, or cues, that they will receive up to 3 messages a day via text-message over a two-week period.~The messages will describe positive, non-alcohol related events at future time points to facilitate extension of temporal consideration toward future-focused perspectives.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected"
45806873|NCT05235971|Behavioral|Volitional choice|"Volitional choice creates structured if-then plans to dismantle context-linked alcohol use The messages sent over a two-week period facilitate alternative, healthier choices by identifying and linking risky cues with alternative actions. Participants will receive up to 3 messages a day for 14 days that include assessment and intervention messages.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected."
45941678|NCT00269503|Procedure|Prone Distraction|
45941679|NCT00269503|Procedure|Side-Posture Manipulation|
45941680|NCT00269503|Procedure|Side-Posture Manipulation & Prone Distraction|
46074794|NCT02805036|Device|Arterial oximetry|measured by co-oximetry of a blood sample taken via the arterial catheter implemented for critical care
45452947|NCT04473274|Drug|Pioglitazone|Receive pioglitazone 15mg - 30mg daily
45806874|NCT05235971|Behavioral|Monitoring only|"Participants will receive general psychoeducation about alcohol use, mental health, resources, and a description of the assessments to be completed over a two-week field testing period.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected."
45941681|NCT00269503|Procedure|Usual Care (Control Group)|
45941682|NCT00074087|Drug|pegylated liposomal doxorubicin hydrochloride|
45941683|NCT00269542|Drug|Zinc and iron folic acid - Intervention|The intervention group tablet contained 10 mg of elemental zinc, 12.5 mg of iron and 50 micrograms of folic acid.
45941684|NCT00269542|Drug|Iron Folic Acid alone - Placebo|The control group tablets were similar in composition, appearance and taste except it contained placebo for zinc.
45452948|NCT00679588|Drug|Semuloparin Sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
45452949|NCT00679588|Drug|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
45452950|NCT00679588|Drug|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
45452951|NCT00151996|Drug|Methylphenidate + SPD503 (Guanfacine hydrochloride)|
45452952|NCT00151996|Drug|Amphetamine + SPD503|
45452953|NCT02889874|Radiation|Omission of radiation therapy|Omission of radiation therapy (adjuvant endocrine therapy only).
45941685|NCT00269581|Other|Educational CD-rom|Educational CD-Rom
45941686|NCT00269581|Other|Headstrong CD-rom|Headstrong CD-rom
45941687|NCT00269620|Drug|ethinyl estradiol/etonogestrel vaginal ring|vaginal ring for cyclic use (3 weeks in, 1 week out)
45941688|NCT00269620|Drug|ethinyl estradiol/norelgestromin transdermal contraceptive|contraceptive patch worn for 7 days and replaced for use for 3 consecutive weeks followed by a one-week patch free interval
45806875|NCT05235945|Behavioral|Online exercise intervention|Described in arm descriptions
45806876|NCT05231278|Device|nCLE aided RANB biospy|nCLE aided RANB biopsy procedure using the Monarch® robotic-assisted navigational bronchoscopy platform and Cellvizio® I.V.E. system with AQ-Flex™ 19 Confocal Miniprobe™ used in combination with Fluorescein.
45452954|NCT02871856|Diagnostic Test|Low dose CT|low-dose screening CT of chest for lung cancer detection
45806877|NCT05230784|Other|AirOk Air Purifier|The AirOk purifier nests on a locally developed patented technology that combines HEPA (grade H12) and a novel EGAPA (Effective Granular Adsorbent Particulate Arrestor) to reduce indoor air pollution. The HEPA filter removes all particulate matter up to 0.3 µm in aerodynamic diameter, and the dual stratified EGAPA filter removes other pollutants such as sulfur, nitrous oxide, carbon oxide, volatile organic compounds, allergens, and mold.
45941689|NCT00424125|Behavioral|Enhanced Pharmacy Care|"Participants randomized to Enhanced Pharmacy Care will have their prescriptions electronically transmitted or faxed to one of the five participating pharmacies.~Pharmacists will then provide real-time, targeted education around the purpose and use of the new and refilled ICS medications to study participants and their families at each point of contact, including rationale for their use, device teaching, dosage review, and importance of compliance. Families randomized to enhanced care will also be contacted monthly by phone and mail with reminders to fill their controller medications prescriptions and to seek ongoing longitudinal asthma care with their primary care providers."
45806878|NCT05230784|Other|Placebo Air Filter|Participants in the placebo arm will receive an air purifier with only the EGAPA filter.
45806879|NCT05229172|Device|Volume Targeted Ventilation|There is no study specific intervention planned. Procedures will be conducted according to standard of care of each participating hospital and the instructions for use of the study device.
45941690|NCT00424125|Behavioral|Control|Usual care.
45806880|NCT05229107|Device|Cereset Research|Device: Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
45806881|NCT05228470|Drug|Elranatamab|BCMA-CD3 bispecific antibody
45806882|NCT05226689|Device|POROUS TIBIA BASEPLATE W/ JRNY LOCK|Fixed-bearing POROUS TIBIA BASEPLATE W/ JRNY LOCK and a Legion cruciate-retaining High-Flex or Deep-dish XLPE tibial insert
45452955|NCT00831532|Drug|Dimebon|Dimebon 5mg in healthy controls
45941691|NCT00416065|Device|PET/CT imaging|
45806883|NCT05224102|Drug|Faricimab|Participants will receive 6-milligram (mg) intravitreal (IVT) faricimab injections once every 4 weeks (Q4W) up to Week 20, followed by 6-mg IVT faricimab injections once every 8 weeks (Q8W) up to Week 52. Participants will return for the Week 56 safety follow-up visit after ≥28 days following their last study treatment.
45655715|NCT04880941|Behavioral|Progressive Relaxation Exercise|In the progressive relaxation technique, the tension and anxiety in skeletal muscles are relatively relieved.
45655716|NCT02326805|Other|Laboratory Biomarker Analysis|Correlative studies
45655717|NCT02326805|Other|Placebo Administration|Given SC
45655718|NCT02326805|Biological|Rilimogene Galvacirepvec|Given SC
45941692|NCT00074204|Drug|carboplatin|Carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
46074795|NCT04235946|Other|accompanied and adapted water polo program|"Validated questionnaires in French will measure fatigue, quality of life, post-traumatic growth and the coach-athlete relationship. All questionnaires will be administered face to face before the sessions by a member of the social psychology research team.~The collection of qualitative data (semi-structured interviews) will be carried out by one of the members of the research team in social psychology on three occasions (inclusion, Week 10 and Week 20) in order to assess the psychological variables of interest (quality interpersonal relationships, self-esteem, post-traumatic growth) and their dynamics.~Physiological variables (weight, fat / lean mass, capacity of the operated arm) will be evaluated monthly. The physical measurement data will be recorded in an electronic case report form"
46074796|NCT00861133|Device|Sleuth AT Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
46074797|NCT00573469|Drug|D9421-C, 9mg|D9421-C 9 mg was given once daily for 8 weeks.
46074798|NCT00573469|Drug|D9421-C, 15mg|D9421-C 15 mg was given once daily for 8 weeks.
46074799|NCT00573469|Drug|Placebo|D9421-C matching placebo was given once daily for 8 weeks.
46074800|NCT02796066|Drug|Vehicle|Applied once a day
46074801|NCT02796066|Drug|TSN2898|Applied once a day
46074802|NCT02796066|Drug|TSN2898|Applied once a day
45452956|NCT00831532|Drug|Dimebon|Dimebon 5mg in mild hepatic impairment patients
45452957|NCT00831532|Drug|Dimebon|Dimebon 5mg in moderate hepatic impairment patients
45655719|NCT04880551|Radiation|Fluoroscopy|In this study the patient will be exposed to radiation during the fluoroscopy for lungs. There is a small chance of alopecia. There is a rare chance that the patients skin may turn red or be damaged.
45655720|NCT05528627|Other|Pectoral Nerve (PECs) block|Pectoral Nerve (PECS) blocks were performed on the side of surgery, using the ultrasound-guided technique 30 min before the implantable cardiac electronic device (pacemaker, implantable cardioverter defibrillator) insertion procedure
45676333|NCT03901456|Behavioral|Usual Care|"Receive care as usual.~Note: If eligible, participants in this control group will be asked if they are interested in enrolling in a similar, additional feature of the study to test the Care to Plan tool following the initial 6-month study."
45806884|NCT05223920|Drug|Bomedemstat|Capsule (oral)
45806885|NCT05222555|Drug|Tafasitamab|tafasitamab will be administered intravenously at protocol defined timepoints
45806886|NCT05222555|Drug|Lenalidomide|lenalidomide will be administered orally at protocol defined timepoints
46074803|NCT02796066|Drug|TSN2898|Applied once a day
45941693|NCT00074204|Drug|docetaxel|"Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.~Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.~In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
45941694|NCT00074204|Drug|gemcitabine hydrochloride|Gemcitabine IV over 30-60 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
45941695|NCT00416143|Procedure|bed rest|
45941696|NCT00416143|Drug|prednisone - oral corticosteroid 1mg/kg/D for 1 week|
45941697|NCT00416221|Drug|Lexapro, an antidepressant medicine|
46074804|NCT00870259|Dietary Supplement|Optifast VLCD|Meal replacement, three times daily for 8 weeks
45452958|NCT00831532|Drug|Dimebon|Dimebon 5mg in Severe Hepatic Impairment
46074805|NCT02801292|Drug|Ketamine|Single bolus of Ketamine .25 milligrams per kilogram of weight.
45806887|NCT05219968|Drug|LYR-210|LYR-210 drug matrix (mometasone furoate)
45806888|NCT05219968|Drug|Sham procedure control|Sham procedure control
45806889|NCT05219968|Other|Background Therapy|Daily Saline Irrigation
46074806|NCT02544061|Biological|NM-IL-12|single 12 µg unit subcutaneous (SC) dose of NM-IL-12
46074807|NCT02544061|Drug|Placebo|single subcutaneous dose
46074808|NCT02801058|Other|Osteopathic manipulative treatment|Osteopathic manipulative techniques on thoracic diaphragm
45452959|NCT00830206|Other|Azithromycin|Oral Suspension
45806890|NCT05219162|Genetic|Gene Profile explore|"Tumor tissue samples will be obtained by biopsy."
45806891|NCT05218499|Drug|BI 907828|BI 907828
45806892|NCT05218499|Drug|Doxorubicin|doxorubicin
45806893|NCT05218434|Drug|AX-158|Oral administrations of AX-158
45806894|NCT05217927|Drug|Rimegepant 75mg daily dosing|Daily
45806895|NCT05217927|Drug|Rimegepant 75mg every other day dosing|Every other day
45941698|NCT00416221|Behavioral|Physical Activity|
45941699|NCT00416221|Behavioral|Mood Management Skills|
45941700|NCT00416221|Behavioral|Personalized support from a Family Nurse Practitioner|
45941701|NCT00269737|Drug|Fentanyl Transdermal Therapeutic System (TTS)|
45941702|NCT00074243|Drug|CC-8490|
45941703|NCT00269776|Drug|Placebo|Treatment C: Three OROS placebo tablets once daily + 1 placebo capsule 3x times/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
45941704|NCT00269776|Drug|OROS (methylphenidate HCl)|Treatment A: 1, 2, or 3 OROS methylphenidate 18-mg tablets + 0, 1, or 2 OROS placebo tablets (3 tablets in total) once daily + 1 placebo capsule 3x/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
46074809|NCT02690142|Drug|Placebo|Single dose i.v.
46074810|NCT02690142|Drug|ABY-035 i.v.|Single dose i.v.
46074811|NCT02690142|Drug|ABY-035 s.c.|Single dose s.c.
46074812|NCT00863863|Drug|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
46074813|NCT00863863|Drug|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under non-fasting conditions
46074814|NCT03853044|Drug|Chidamide|Chidamide 20mg per day administered orally on Day 1, 4, 8, 11 of each 21-day cycle for 6 cycles
46074815|NCT03853044|Drug|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
46074816|NCT03853044|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 IV, administered on Day 1 of each 21-day cycle.
46074817|NCT03853044|Drug|Vincristine|Vincristine 1.4 mg/m^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
45452960|NCT00830206|Drug|Zithromax®|Oral Suspension
45452961|NCT04854070|Device|IVUS|IVUS-guided approach in patients with complex coronary lesions undergoing PCI
45452962|NCT04854070|Device|Angio|Angio-guided approach in patients with complex coronary lesions undergoing PCI
45452963|NCT04472962|Other|Pre-exercise meal|Mixed meal with low-carbohydrate-high-protein content
45452964|NCT04472962|Other|Pre-exercise meal|Mixed meal with high-carbohydrate-low-protein content
45452965|NCT04464070|Dietary Supplement|niacin|induce biosynthesis of PGD2
45452966|NCT04464070|Drug|aspirin|inhibition of cyclooxygenase
45452967|NCT04464070|Other|PGD2|labeled precursor
45806896|NCT05217927|Drug|Placebo comparator dosing|Placebo comparator
45806897|NCT05216952|Drug|Ulipristal Acetate Tablets|90mg (three 30mg tablets) administered orally once
45806898|NCT05216952|Drug|Misoprostol Pill|800mcg (four 200mcg pills) administered vaginally once 6-18 hours following ulipristal acetate
45806899|NCT05215340|Drug|Datopotamab Deruxtecan|Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
45806900|NCT05215340|Drug|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
45806901|NCT05214365|Device|Pacemaker implantation and conventional cardiac pacing|Patients will have the pacemaker implanted in the electrophysiology laboratory. Electrode will be implanted (in the apical or septal portion) according to the criteria of the implanting physician.
45806902|NCT05214365|Device|Conduction system pacing implant|Right ventricular lead was placed to get his bundle or left bundle branch.
45806903|NCT05213676|Drug|Inhaled Nitric Oxide (iNO) use|The center will use iNO per their usual protocol in the initial resuscitation period (defined as birth through stabilization and CDH repair). No center will alter any component of their standard clinical practice guideline or protocol governing CDH care.
46074818|NCT03853044|Drug|Prednisone|Prednisone 60mg/m2 , Maximum 100 mg , (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
46074819|NCT00870337|Drug|everolimus|
46074820|NCT02797158|Procedure|TAVI procedure|Targeted and selected revascularization guided on myocardial ischemia detection after the TAVI procedure by using single photon emission computed tomography (SPECT) myocardial perfusion imaging.
46074821|NCT00866437|Drug|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L~Estradiol 1mmol/L~Estrone 3mmol/L~Estriol 3mmol/l~Controls:~Saline (NaCl) 0.9%~Ethyl Oleate with 10% Benzyl Alcohol~Histamine phosphate 1mg/ml (epicutaneous- prick test)"
45941705|NCT00269776|Drug|Ritalin (methylphenidate)|Treatment B: 5, 10, or 15-mg tablets (encapsulated/single capsule) 3 times a day + 3 OROS placebo tablets once daily for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
45941706|NCT00269815|Drug|methylphenidate HCl|
45941707|NCT00269854|Drug|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
45941708|NCT00269854|Drug|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
45941709|NCT00269854|Drug|Infliximab 20 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 20 mg/kg will be administered as infusion at Week 0, 2 and 6.
45941710|NCT00269854|Drug|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
45941711|NCT00269893|Drug|Abciximab|0.25 mg/kg of body weight of abciximab either bolus or infusion.
45941712|NCT00269893|Drug|Placebo|Matching Placebo soulution either bolus or infusion.
45655721|NCT04880005|Behavioral|Clinical decision support|"Based on the phenotyping and algorithms developed by the hospital specialists at Odense University Hospital and Holbæk Hospital in collaboration with GPs, the individual GPs and their patients will receive individualized recommendations on lifestyle interventions and pharmacological treatments.~The GPs will receive specific clinical decision support (CDS) recommendations on what drugs to prescribe to each patient based on the phenotyping in accordance with a clinical decision support tool (Cambio) and the updated guidelines at all times (Sparrow 2019). The treatment advice to the GPs will be adjusted annually based on treatment effect, re-phenotyping, and updated knowledge of the treatment of T2D. Furthermore, psychiatric, socioeconomic and/or cultural challenges and other determinants for frailty will be a part of the individualized intervention provided to patients by the GPs, again based on the specialist advice."
45676774|NCT04587999|Other|bladder stimulation|"The bladder stimulation technique requires the presence of 2 people:~The child must be held by an adult (caregiver or parent) under the armpits, legs dangling.~the first person (the investigator), performs the stimulation technique consisting of: rapid tapping (frequency of about 100 / min), over the pubic area, at the level of the bladder, alternated with external rotational movements of the pits lumbar, in the kidneys. Alternate these 2 maneuvers every 30 seconds.~The second person starts the stopwatch at the start of the stimulation, and is about to collect the urine, 2nd jet in a sterile pot~The maneuver ends as soon as urine is obtained, and will be stopped after 5 minutes in case of failure."
45806904|NCT05213676|Other|De-implementation of Inhaled Nitric Oxide (iNO) use|The center will stop using iNO in the initial resuscitation period (defined as birth through stabilization and CDH repair).
45806905|NCT05213624|Drug|BI 764198|BI 764198
45806906|NCT05213624|Drug|Placebo|Placebo matching BI 764198
45806907|NCT05211739|Device|Lehfilcon A toric contact lenses|FDA-cleared silicone hydrogel toric contact lenses used as indicated
45806908|NCT05211739|Device|Comfilcon A toric contact lenses|Commercially available silicone hydrogel toric contact lenses used as indicated
45806909|NCT05211739|Device|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
45458038|NCT03503110|Other|electrocorticography with electrostimulation|The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
45941713|NCT00074321|Drug|irinotecan hydrochloride|Given IV
45941714|NCT00074321|Drug|oxaliplatin|Given IV
45941715|NCT00074321|Drug|capecitabine|Given PO
45941716|NCT00074321|Other|laboratory biomarker analysis|Correlative studies
45941717|NCT00074321|Other|pharmacological study|Correlative studies
45941718|NCT00102609|Drug|Doxorubicin|Doxorubicin 50 to 75 mg/m2 administered intravenously on Day 1
45941719|NCT00102609|Drug|Trabectedin|Trabectedin 0.9 to 1.3 mg/m2 administered intravenously on Day 1 every 3 weeks for up to 6 cycles
45941720|NCT00102609|Drug|Dexamethasone|Dexamethasone 20 mg administered intravenously within 1 hour before the start of doxorubicin
45941721|NCT00269932|Drug|levofloxacin|
45941722|NCT00269971|Drug|epoetin alfa|
45941723|NCT00270010|Drug|epoetin alfa|
45941724|NCT00270049|Drug|epoetin alfa|
45941725|NCT00107016|Drug|RAD001, Letrozole 2.5mg|
45941726|NCT00107016|Drug|Letrozole 2.5mg|
45941727|NCT00270088|Drug|epoetin alfa|
45941728|NCT00270127|Drug|Epoetin alfa|
45941729|NCT00270166|Drug|epoetin alfa|
45941730|NCT00074399|Drug|Nevirapine|Tablet taken orally daily. Dosage depends on age and body surface area
45941731|NCT00074399|Drug|Nevirapine placebo|Placebo tablet taken orally daily
46002148|NCT04660539|Drug|oral corticosteroids|Participants are permitted to use oral corticosteroids (prednisolone equivalent) during the study as background immunosuppressive treatment at a maximum dose of 15 mg/day
46002149|NCT04660526|Other|Rapid cardiac arrest recognition that triggers immediate priority EMS/first responder dispatch by 911 operators|EMS first responders will recognize cardiac arrest and respond immediately, increasing time to dispatch
46002150|NCT04660526|Other|Systematic bystander resuscitation instruction by 911 operators|911 operators will be able to describe how to administer CPR over the phone.
46002151|NCT04660526|Other|Comprehensive community training of lay people in CPR and AED use.|Training of lay people regarding CPR and AED use.
46002152|NCT04660526|Other|Optimized first responder performance including earlier use of AEDs.|First responders will recognize where AEDs are located and use them appropriately
46002153|NCT04643158|Drug|AZD1402|Randomised participants will receive oral inhalation of AZD1402, via DPI.
46002154|NCT04643158|Drug|Placebo|Randomised participants will receive oral inhalation of matching placebo via DPI.
45655722|NCT04880005|Behavioral|Digital Lifestyle Coaching|As part of DICTA, the patients are offered a personal health coach (dietician, nurse, occupational therapist, or physiotherapist) through the complex eHealth intervention (Liva). Patients will receive personalized empathic, relation driven coaching on healthy lifestyle on the individual patient's preferences (e.g. increased physical activity, healthier diet, weight loss, smoking cessation, personal goal setting, tailored information, peer to peer support), including optimal pharmacological treatment (Komkova 2019). The collaborative eHealth tool will give health coaches access to patient registered outcome measurements (PRO), information. This forms the basis of the individual coaching and is partly supported by artificial intelligence (AI) to improve the coaching by the health coaches (Holzinger 2016).
45941732|NCT00270244|Behavioral|Group interpersonal psychotherapy for depressed adolescents (IPT-AG)|Participants assigned to IPT-AG will attend two to three, 40-minute individual pre-group sessions, followed by 12, 90-minute group therapy sessions and two additional individual sessions-one midway through the group sessions and another upon completion of group therapy. Sessions will focus on problems in interpersonal relationships.
45655723|NCT04880005|Behavioral|Integration to Standard Electronic Health Record|Data on physical activity, steps, diet goal fulfillment, smoking status etc., are being provided for GPs in a web-based solution integrated into the GPs' health record system. Integration with the GP system XMO (covering 52% of all Danish GPs) has been finalized.
45941733|NCT00270244|Behavioral|Treatment as usual (TAU)|TAU will consist of counseling sessions as regularly conducted by the school clinic social worker and/or referral to another agency.
45941734|NCT00107055|Drug|REN-1654|
46074822|NCT00866437|Drug|Skin test panel|"Hormones:~Progesterone 1mmol/L~Estradiol 1 mmol/L~Estrone 3 mmol/L~Estriol 3mmol/l~Controls:~Saline (NaCl) 0.9%~Ethyl Oleate with 10% Benzyl Alcohol~Histamine phosphate 1mg/ml (epicutaneous- prick test)"
46074823|NCT02797002|Other|Assessment|
46074824|NCT00863941|Drug|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
45655724|NCT05528471|Other|Dietary intervention|To compare an iso-caloric, low fructose diet (~5% of total energy intake (TEI); HFCS max: 10-15% of total fructose intake) to an iso-caloric, higher fructose diet (~10% of TEI; HFCS max 20-30% of total fructose intake) in adolescents with NAFLD. The 10% higher fructose diet is part of standard of care and is NOT the intervention.
45655725|NCT05377697|Other|Dry lavender flower scent|Participants in the experimental group will be informed about the effects of lavender scent on sleep and lavender sachets will be given. They will be informed that they should put these lavender sachets in their pillows every day and sleep with a lavender sachet for the next month, and that they should not make any changes in their rooms or beds other than the lavender sachet.
45655726|NCT05528393|Diagnostic Test|Blood sampling|blood sampling
45655727|NCT01595581|Drug|Testosterone|8 weeks of testosterone administration beginning 2 weeks before ACL surgery
45655728|NCT01595581|Drug|Placebo|8 weeks of saline administration beginning 2 weeks before ACL surgery
45655729|NCT05534009|Other|Follow up of the first known immunization event|"The baseline for enrolment into the study is defined by the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline. In subjects with natural infection, the viral variant must be determined for each prospective case by analysis of a nasopharyngeal swab obtained as soon as possible at diagnosis. For historical cases where the variant was not determined and a contemporary nasopharyngeal swab has not been stored, the viral variant may be inferred when a specific variant was dominating the geographic area according to official records available at local health agencies. However, the variant assignment will be labelled as putative, rather than proved.~HCWs can be enrolled in the category of:~(i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection."
45655730|NCT03050125|Device|Hypo-osmolar drop 1|180 mOsmol sterile saline drops used as a contact lens rewetting drop.
45941735|NCT00270283|Drug|epoetin alfa|
45941736|NCT00270322|Drug|Marcaine 0.166% + Fentanyl 3.33 mcg/ml|
45941737|NCT00270322|Drug|Morphine sulphate|
45941738|NCT00270361|Drug|nesiritide|
45941739|NCT00270361|Drug|usual long term cardiac medications|
45941740|NCT00270361|Drug|nesiritide|
45941741|NCT02966249|Drug|Levobupivacaine|3 ml Levobupivacaine 0.5% (15mg) given intrathecally
46074825|NCT00863941|Drug|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
45941742|NCT02966249|Drug|Dexmetomidine intravenously|Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously 10 min before spinal anesthesia in total knee arthroplasty
45941743|NCT02966249|Drug|Normal Saline added intrathecally|Normal Saline added to 5μgr dexmetomidine up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty
46074826|NCT02795910|Behavioral|Outreach education training|Printed copies of the patient management tool (PMT) and outreach education training
46074827|NCT02795910|Behavioral|No outreach education training|Printed copies of the patient management tool (PMT) without outreach education training
45941744|NCT02966249|Drug|Normal Saline intrathecally|0,5 ml Normal Saline given intrathecally given once for spinal anesthesia in total knee arthroplasty
45941745|NCT02966249|Drug|Ringer's Lactate solution intravenously|Continuous infusion of Ringer's Lactate solution given intravenously, starting 10 minutes before spinal anesthesia up to the end of the operation
46074828|NCT00870415|Procedure|quality-of-life assessment|
46074829|NCT00870415|Procedure|therapeutic conventional surgery|
46074830|NCT00812565|Drug|Placebo|Commercially available 0.9% isotonic sodium chloride solution.
46074831|NCT00812565|Biological|octagam 10%|octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.
46074832|NCT02801214|Other|fMRI|
46074833|NCT00866515|Drug|Ketoconazole + GW642444M|Ketoconazole 400mg OD days 1-6, GW642444M 25ug single dose on D5
46074834|NCT00866515|Drug|Placebo + GW642444M|Placebo to match D1-6 + GW642444M 25ug single dose on D5
46074835|NCT02795754|Drug|GSK2838232 PIB|GSK2838232 will be available as oral suspension for reconstitution, will be administered as 50, 100 and 200 mg in Part A and as 20, 50, 100 or 200 mg in Part B.
46074836|NCT02795754|Drug|GSK2838232 IR1|GSK2838232 will be available as film-coated tablet for oral use
45806910|NCT05209438|Device|Cereset Research|Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
45941746|NCT02966249|Drug|Dexmetomidine intrathecally|5 μgr dexmetomidine given intrathecally once for anesthesia in total knee replacement
45452968|NCT05388994|Other|Exercise|The initial implementation for the 8-week combined exercise program consisted of a progressive aerobic exercise program with a lower extremity bike (Ergoline Ergoselect 200; Ergoline GMBH, Bitz, Germany). All sessions are individually supervised and conducted. Training intensity was started at 70% of maximum aerobic capacity and training intensity was increased by 5% of VO2peak every two weeks. Pedal speed was fixed at 50 rpm throughout 8 weeks of training. Exercise sessions; It started with a 5 minute warm-up period (30% of VO2peak), followed by a total of 40 minutes with a 30-minute load period and a 5-minute cool-down period (without resistance).
45941747|NCT00270400|Drug|nesiritide|
45941748|NCT00107094|Drug|Abraxane|
45941749|NCT00270439|Procedure|removal of omentum|patients with type 2 diabetes had their omentum removed
45941750|NCT00270478|Drug|Erythropoietin and Hydroxyurea|
45941751|NCT00270517|Drug|EDP-420 / Duration of Treatment - 3 days|
45941752|NCT00270517|Drug|Telithromycin / Duration of Treatment - 7 days|
45941753|NCT00270556|Drug|tenofovir disoproxil fumarate|
46074837|NCT02795754|Drug|GSK2838232 IR2|GSK2838232 will be available as film-coated tablet for oral use
45941754|NCT00270556|Drug|Abacavir|
46074838|NCT02795754|Drug|Placebo PIB|Oral suspension of hydromellulose acetate succinate will be supplied as powder-in-bottle for reconstitution.
45655731|NCT03050125|Device|Hypo-osmolar drop 2|240 mOsmol sterile saline drops used as a contact lens rewetting drop.
45655732|NCT03050125|Device|Iso-osmolar drop|300 mOsmol sterile saline drops used as a contact lens rewetting drop.
45655733|NCT05373563|Procedure|cesarean section women|The test will be applied to women who have had a cesarean section and the Turkish validity and reliability of the scale will be determined according to the answers given.
45655734|NCT03048955|Device|Superion® IDS|Device is a non-fusion, spinal column load-sharing device used to stabilize the spine at the implanted leve
45655735|NCT03048955|Procedure|Direct decompression Surgery|A surgical procedure - the control
46074839|NCT02795754|Drug|Ritonavir|It is to be purchased by site. It will be white film-coated ovaloid tablets for oral administration.
45655736|NCT04885153|Drug|Fenofibrate|Patients were given simvastatin 10 mg and fenofibrate 200 mg daily for three months and were evaluated monthly.
45655737|NCT04885153|Drug|Placebo|Patients were given simvastatin 10 mg and placebo (lactic acid) 200 mg daily for three months and were evaluated monthly.
45655738|NCT04302311|Diagnostic Test|Holter monitoring|Use of smart device application and technologies to assess for arrhythmias
45941755|NCT00107211|Biological|therapeutic autologous dendritic cells|
45941756|NCT00107211|Procedure|conventional surgery|
45941757|NCT00107211|Procedure|neoadjuvant therapy|
46074840|NCT00864019|Drug|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under non-fasting conditions
45452969|NCT00829504|Drug|Ropinirole HCl 0.25 mg Tablets|1 x 0.25 mg
45452970|NCT00829504|Drug|Requip® 0.25 mg Tablets|1 x 0.25 mg
45452971|NCT00779428|Drug|Tanespimycin|"Solution, IV~This is a one arm study with the dose, frequency, and duration assigned as per previous protocol (KOS-953, 17-AAG)"
45941758|NCT00270673|Procedure|Early lactate-directed therapy|
45941759|NCT00074438|Drug|methotrexate|Oral or parenteral repeating dose
45941760|NCT00074438|Drug|rituximab|Intravenous repeating dose
46074841|NCT00864019|Drug|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under non-fasting conditions
46074842|NCT02800980|Procedure|Drainage and sclerotherapy.|Lymphocele percutaneous / transvaginal drainage with a use of a vascular catheter followed by sclerotherapy.
45452972|NCT00829426|Drug|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose fasting
45655739|NCT04302311|Diagnostic Test|Kardia/AliveCor monitoring|Kardia/AliveCor monitoring
45655740|NCT03048643|Behavioral|Outpatient parenteral antibiotic therapy|Subjects randomized to OPAT will complete IV antibiotic therapy for infective endocarditis as an outpatient according to published guidelines.
45655741|NCT05528315|Drug|ABX-002|ABX-002
45655742|NCT05528315|Drug|Placebo|Placebo
45941761|NCT00074438|Drug|corticosteroids|Intravenous repeating dose
45941762|NCT00074438|Drug|placebo|Intravenous repeating dose
45941763|NCT00270751|Procedure|1 apical pleurectomy|
45941764|NCT00270751|Procedure|2 pleural abrasion + minocycline pleurodesis|
45941765|NCT00107367|Procedure|conventional surgery|
45941766|NCT00107367|Radiation|intraoperative radiation therapy|
45941767|NCT00270829|Drug|nesiritide|Drug given intrarenally or placebo
45941768|NCT00270868|Procedure|Double guide wire technique|
45941769|NCT00270868|Procedure|Standard bile duct cannulation|
45941770|NCT04730375|Drug|Dexmedetomidine Injection [Precedex]|two different doses dexmedetomidine bolus then maintenance infusion till end of surgeries and evaluation of lung mechanics and oxygenation
45941771|NCT00270907|Drug|CT-2103|135 mg/m^2 IV on Day 1.
45806911|NCT05207982|Behavioral|Family Based weight management program|"Weight management program that involve the patient AND a family member or a care taker. Families will receive a 12-week FBT adapted for first episode psychosis. This will be delivered in 12 weekly meetings with a trained case manager and two eating plan education sessions. Both the patient with psychosis and parents are targeted for eating and activity/exercise change to ensure a change in the shared family environment, which will also help weight control in both sets of participants, as well as medical issues that accompany obesity, including glycemic control, hypertension and hyperlipidemia. If parents are not overweight/obese, they will still target improved health behaviors. They will learn about GREEN, YELLOW, and RED foods (healthy vs. unhealthy foods), energy density, glycemic index of foods, reducing serving sizes, eating less, healthy lifestyle and programmed activity programs and recording their diets and activity."
45655743|NCT04884997|Drug|toripalimab|toripalimab 3mg/kg, Q2w;
45941772|NCT00270907|Drug|Gemcitabine|1000 mg/m^2 IV on Day 1 and 8.
45655744|NCT04884997|Drug|Temozolomide Injection|Temozolomide 150mg/m2,d1-5,Q4w
45941773|NCT00107445|Drug|EF5|Given IV
45941774|NCT00270946|Device|Bilayered Cellular Matrix (OrCel)|
45655745|NCT03048721|Procedure|Skin Tape Stripping|For psoriasis group, tape-stripping will be done in both involved and uninvolved skin. The tape-stripping will be performed within 2.5 cm of the first punch biopsy. For healthy control group, tape-stripping will be performed on normal skin, within 2.5. cm of the first punch biopsy.
45655746|NCT03048721|Procedure|Punch Biopsy|For psoriasis group, one punch biopsy will be taken from each of the following areas: involved skin, tape-stripped involved skin, uninvolved skin, and tape-stripped uninvolved skin. For healthy control group, one punch biopsy will be taken from each of the following areas: normal skin and tape-stripped normal skin (within 2.5 cm of the first punch biopsy).
45941775|NCT00270985|Behavioral|Almonds in a calorie controlled diet|Prescribed daily dose of Almonds in calorie controlled diet for adults with pre-type 2 diabetes
45941776|NCT00270985|Behavioral|Nut free diet|Calorie controlled diet free of nuts for adults with pre-type 2 diabetes
45806912|NCT05207670|Drug|Mosunetuzumab (Cohorts A-C)|Participants will receive SC mosunetuzumab for up to 17 cycles and for optional maintenance (Cohort A only)
45806913|NCT05207670|Drug|Mosunetuzumab (Cohorts D-E)|Participants will receive SC mosunetuzumab for up to 34 cycles
45806914|NCT05207670|Drug|Tocilizumab|Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab
45806915|NCT05206110|Drug|10 mg IV ketorolac|Patients undergoing LAVH, RARP or TLH will receive half an hour before the end of surgery, 10 mg ketorolac (IV). Also, 10 mg IV ketorolac will be given 8h and 16h after the surgery
45941777|NCT02965937|Other|Story-centred care intervention program|"Participants in the intervention group received the Story-Centred Care Intervention Program once a week for four weeks."
45941778|NCT02965937|Other|Health consultation control condition|The control group received a health consultation from researchers once a week for four weeks.. The health consultation will be tailored to the participants' needs. Based on a previous study12, the health consultation will include pain management, healthy nutrition, how to make best use of medical services and education and counselling for individual health-related concerns.
45941779|NCT00271063|Drug|Liposomal Annamycin|3-day IV infusion
46074843|NCT02800980|Procedure|Drainage alone.|Lymphocele percutaneous / transvaginal drainage with a vascular catheter alone (without sclerotherapy).
46074844|NCT00812487|Drug|Intravenous insulin|Patients will receive continuous insulin infusion through the vein.
46074845|NCT00812487|Drug|Subcutaneous insulin|4 injections of insulin/day
45452973|NCT00829426|Drug|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose fasting
45806916|NCT05206110|Drug|30 mg IV ketorolac|Patients undergoing LAVH, RARP or TLH will receive half an hour before the end of surgery, 30 mg ketorolac (IV). Also, 30 mg ketorolac will be given 8h and 16h after the surgery
45941780|NCT00107484|Drug|ferumoxtran-10|
45941781|NCT00107484|Procedure|magnetic resonance imaging|
45941782|NCT00107484|Procedure|sentinel lymph node biopsy|
45941783|NCT00416260|Other|High Frequency Oscillation and Tracheal Gas Insufflation|Intermittent combined use of High Frequency Oscillation and Tracheal Gas Insufflation until the PaO2/inspired oxygen fraction ratio remains above than 150 mm Hg for more than 24 hours.
46074846|NCT04235868|Biological|Stem cell-derived derived pleiotropic factor|After debridement, the wounds in experimental group apply stem cell-derived lyophilized powder, and use foam dressing to wrap the wound; apply once every 2-3 days.
45941784|NCT00074477|Drug|R092670|
45655747|NCT04879771|Procedure|Receive gastrointestinal endoscopy|patients receive gastrointestinal endoscopy in the morning or afternoon
45655748|NCT03048565|Behavioral|MBSR|Mindfulness is a skill that helps people manage their thoughts so that the stressful impact of unhelpful thoughts can be limited. The aim of the mindfulness based intervention in this study is to help caregivers manage stressful thoughts and events and help them respond to life stressors in a positive way.
45655749|NCT04879693|Device|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
45655750|NCT04885075|Drug|IV diazepam|inj.diazepam 0.2mg/kg/dose stat
45655751|NCT04885075|Drug|I/N Midazolam|intranasal midazolam 0.2mg/kg/dose stat
45676775|NCT04587999|Other|Quick wee|"The Quick wee technique requires the presence of only one person:~Stimulation of the suprapubic area by circular movements, with a cold and wet compress held by sterile forceps.~Collection of urine in a sterile container."
45941785|NCT00416338|Device|film dressing by adhesive|
45941786|NCT00107523|Drug|cytarabine|
45941787|NCT00107523|Drug|idarubicin|
45941788|NCT00107523|Drug|pravastatin|
45941789|NCT00416377|Biological|bleomycin sulfate|
45941790|NCT00416377|Drug|chlorambucil|
45941791|NCT00416377|Drug|dacarbazine|
45941792|NCT00416377|Drug|doxorubicin hydrochloride|
45941793|NCT00416377|Drug|prednisolone|
45941794|NCT00416377|Drug|procarbazine hydrochloride|
45941795|NCT00416377|Drug|vinblastine sulfate|
45941796|NCT00416377|Drug|vincristine sulfate|
45941797|NCT00416377|Radiation|radiation therapy|
46074847|NCT04235868|Biological|fibroblast growth factor|After debridement, the wounds in control group apply fibroblast growth factor to the wound surface, and use foam dressing to wrap the wound; apply once every 2-3 days.
45806917|NCT05201794|Drug|JNJ-64281802|JNJ-64281802 tablets will be administered orally as per the defined regimens.
45806918|NCT05201794|Drug|Placebo|Matching placebo for each dose level as tablet will be administered orally.
45806919|NCT05201781|Drug|Cilta-cel|Participants who had received cilta-cel in previous studies will be followed up in this study. No additional study treatment will be administered to participants in this study.
45806920|NCT05201183|Combination Product|Fludarabine + Total Marrow Irradiation|"Patients will receive total marrow irradiation TMI on Day -11 to Day -7 in two fractions per day. The TMI dose will be escalated in successive cohorts compromised of 3-6 patients as follows:~Cohort 1 1.4 (Gy/fraction) Cohort 2: 1.6 (Gy/fraction) Cohort 3 1.8 (Gy/fraction) Cohort 4 2.0 (Gy/fraction) Cohort 5 2.2 (Gy/fraction)~Patients will receive Fludarabine (30 mg/m2/day) on Day -6 to Day -2 followed by allo-HSCT on Day 0."
45806921|NCT05197049|Drug|Guselkumab Dose 1|Guselkumab (Dose 1) will be administered by subcutaneous (SC) injection.
45941798|NCT00271258|Drug|SODIUM DIVALPROATE|
45655752|NCT01610687|Drug|GW-1000-02|Contained THC and CBD as extract of Cannabis sativa L. Each 100 μl actuation delivered a dose containing 2.7 mg THC and 2.5mg CBD. The maximum permitted dose was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
45655753|NCT04884919|Device|Regular Gauze|Regular gauze
45655754|NCT04884919|Device|Chitosan Dressing|Dressing made of chitosan material
45941799|NCT02965859|Drug|Metacavir Enteric-coated Capsules 80mg|Metacavir Enteric-coated Capsules 80mg
45941800|NCT02965859|Drug|Metacavir Enteric-coated Capsules 160mg|Metacavir Enteric-coated Capsules 160mg
45941801|NCT02965859|Drug|Metacavir Enteric-coated Capsules 320mg|Metacavir Enteric-coated Capsules 320mg
46074848|NCT02800902|Drug|placebo|Oral prophylaxis followed by placement of placebo gel
45941802|NCT02965859|Drug|Metacavir Enteric-coated Capsules Placebo 240mg|Metacavir Enteric-coated Capsules Placebo 240mg
46074849|NCT02800902|Drug|Rosuvastatin|Oral prophylaxis followed by placement of rosuvastatin gel
46074850|NCT02800902|Drug|Atorvastatin|Oral prophylaxis followed by placement of atorvastatin gel
46074851|NCT05756595|Drug|HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)|This group will inject once a week. Evaluation of pain score after 30 seconds and 3 hours.
46074852|NCT02796768|Other|3D US Scanning|3D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
46074853|NCT02796768|Other|2D US Scanning|2D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
46074854|NCT04034043|Device|ceramic-on-ceramic total hip arthroplasty|ceramic-on-ceramic, cementless total hip arthroplasty for post-traumatic hip osteoarthritis.
46074855|NCT02796690|Other|nasal swabs will be collected|After formal consent, nasal swabs are collected for each participant. SA nasal carriage and its susceptibility to methicillin is determined using a rapid PCR technique (GenExpert, Cepheid). Each participant is asked to complete a short questionnaire regarding some demographic variables, smoking habits, long-term medication, sector of activity, and direct manipulation of the pathogen.
46074856|NCT00617461|Drug|GEn 1200mg/day|1200mg/day gabapentin enacarbil
46074857|NCT00617461|Drug|GEn 3600mg/day|3600mg/day gabapentin enacarbil
46074858|NCT02795130|Procedure|Sclerotomy closure|Comparison between two suture materials: 1) 8-0 polyglactin 910, 2) 6-0 plain gut
46074859|NCT00812331|Drug|TMC435|From Day 1 to Day 7 all participants will take 200 mg TMC435350 as a single medication orally (by mouth) once daily.
45655755|NCT04879303|Behavioral|Robot-assisted social skill intervention|Social robotics will be used by the instructor to teach social skills to the children with ASD for 12 weekly sessions.
45655756|NCT04879303|Behavioral|Human-only instruction programme on social skill training|The children will receive only the human-delivered training throughout the 12 sessions, with the content and sequence of activities the same as the robotic intervention group.
45676776|NCT01822353|Dietary Supplement|Dietary supplement|Milk, egg or nut oral immunotherapy
45806922|NCT05197049|Drug|Guselkumab Dose 2|Guselkumab (Dose 2) will be administered by SC injection.
45806923|NCT05197049|Drug|Guselkumab Dose 3|Guselkumab (Dose 3) will be administered by SC injection.
45806924|NCT05197049|Drug|Placebo|Placebo will be administered by SC injection.
45806925|NCT05196152|Behavioral|MomMoodBooster|MomMoodBooster is an empirically validated online intervention for perinatal women.
45806926|NCT05196152|Behavioral|Phone Coaching|Phone coaching calls occur weekly in conjunction with MomMoodBooster online modules.
45806927|NCT05194839|Drug|RIST4721|RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
45806928|NCT05194839|Drug|Placebo|Matching placebo
45806929|NCT05190770|Drug|Triamcinolone Acetonide|Triamcinolone acetonide is a derivative of prednisolone with high glucocorticoid activity and low mineralocorticoid activity. It is applied topically.
45941803|NCT02965859|Drug|Metacavir Enteric-coated Capsules Placebo 160mg|Metacavir Enteric-coated Capsules Placebo 160mg
45941804|NCT02965859|Drug|Metacavir Enteric-coated Capsules Placebo 320mg|Metacavir Enteric-coated Capsules Placebo 320mg
45941805|NCT02965859|Drug|Adefovir Dipivoxil Capsule10mg|Adefovir Dipivoxil Capsule10mg
45941806|NCT02965859|Drug|Adefovir Dipivoxil Capsule Placebo 10mg|Adefovir Dipivoxil Capsule Placebo 10mg
45941807|NCT00271297|Behavioral|Pelvic floor muscle training|
45941808|NCT00271336|Drug|Pentoxifylline|
45941809|NCT00107562|Behavioral|Adolescent Safer Sex Social Network Intervention|
45941810|NCT00271414|Drug|Duragesic® (fentanyl) Transdermal Therapeutic System (TTS)|
45941811|NCT00271453|Drug|Durogesic® (fentanyl transdermal drug delivery system)|
46074860|NCT04233996|Drug|Piperacillin-Tazobactam 4 g-0.5 g|Patients with FN who empirical treatment with piperacillin-tazobactam 4g/6h
46074861|NCT04233996|Drug|Cefepime 2000 mg|Patients with FN who required empirical treatment with cefepime 2g/8h
46074862|NCT04233996|Drug|Meropenem 1000 mg|Patients with FN who required empirical treatment with meropenem 1g/8h
46074863|NCT03802812|Device|Thin bronchoscope and VBN|targeted washing at more adjacent TB lesion using thin bronchoscope and virtual bronchoscopic navigation system
46074864|NCT00870493|Drug|Aliskiren|Aliskiren 300 mg daily oral
45806930|NCT05190770|Drug|Oleogel-S10|Oleogel-S10 consists of birch bark extract (TE): 10 mg/100 mg; Sunflower oil, refined: 90 mg/100 mg. It is applied topically.
45941812|NCT00271492|Drug|Atrasentan|1 10mg capsule to be taken daily for 6 month study period.
45655757|NCT05533931|Other|Resistive Breathing Training group|The patients performed two sessions each of 15 minutes session of resistive breathing for four days a week for six weeks using an inspiratory resistive device. Ask patient to take long slow inspirations while breathing through the resistive device
45655758|NCT05533931|Other|inspiratory hold technique|With the patient in a comfortable position such as side lying or reclined, the therapist may assist the patient by placing both hands on abdominal area to provide proprioceptive feedback. Then in a relaxed tone of voice therapist instructs the patient to sniff quickly through the nose three times with slow, relaxed exhalations
45806931|NCT05185947|Drug|Paclitaxel|Paclitaxel: Intraperitoneal (IP) paclitaxel will be dosed at 60 mg/m2 to be infused over 1 hour on Day 1 of each 3-week cycle; participants with unresectable, but stable or responding disease after C1 through C3 will dose increase IP paclitaxel to 80 mg/m2 for Cycles 4-6. Intravenous (IV) paclitaxel will be infused over 1 hour on Day 2 of the first week of Cycle 1, followed by Day 1 of the subsequent treatment weeks; IV paclitaxel will be dosed at 60 mg/m2 for Week 1 of Cycle 1 and, if tolerated, at 80 mg/m2 for subsequent treatments.
45806932|NCT05185947|Drug|Nilotinib|Oral nilotinib will be dosed at 300 mg twice daily. Nilotinib will be administered continually from the loading dose (Day -4) leading up to laparoscopy #2 onward.
45806933|NCT05183412|Device|The Sedakit Oncomfort VR glasses (30-minutes Aqua program)|During placement of ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery, patients are subjected to a 30-minutes VR program (Oncomfort SA, Wavre, Belgium) 'Aqua' via a head-mounted display and headphone. The patients watch a VR underwater view of the ocean while listening to speeches to induce relaxation and meditation.
45806934|NCT05183412|Procedure|Ultrasound-guided regional nerve block and hand surgery without VR glasses|During placement of ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery, patients are NOT subjected to a 30-minutes VR program (Oncomfort SA, Wavre, Belgium) 'Aqua' via a head-mounted display and headphone.
45941813|NCT00271492|Drug|Atrasentan|1 10mg capsule per day for the 6 month study period.
45941814|NCT00271492|Drug|atrasentan|One 10 mg capsule per day for 6 month study period
45806935|NCT05183412|Procedure|Ultrasound-guided regional nerve block and hand surgery with VR glasses|Ultrasound-guided regional nerve block and hand surgery with VR glasses
45941815|NCT00271687|Behavioral|Exercise training|
45941816|NCT00271726|Procedure|Osteosynthesis with palmar locking plate|
45941817|NCT00271726|Procedure|Osteosynthesis with external fixator|
45941818|NCT00271726|Procedure|Osteosynthesis with Kirschner wires|
45941819|NCT00271765|Drug|INO-1001|
45941820|NCT00271804|Drug|bortezomib|
45941821|NCT00107601|Drug|Insulin|
45941822|NCT00074633|Behavioral|Health at Every Size (HAES)|
45941823|NCT00074633|Behavioral|Diet (Traditional, moderate energy restriction)|
45941824|NCT00271921|Behavioral|Calorie controlled diet|
45941825|NCT00271960|Behavioral|CenteringPregnancy|Following the initial intake into obstetric care in the usual manner, participants will be invited to join with 8 to 12 other women/couples/teens with similar due dates, meeting together regularly during their pregnancy.
45941826|NCT00271960|Behavioral|CenteringPregnancyPlus|CenteringPregnancyPlus is a modified program that integrated HIV/STD prevention components with the group prenatal care model. Participants will learn skill-building in the areas of efficacy, risk assessment, negotiation skills and prevention.
45941827|NCT00271960|Behavioral|Usual care|Participants will receive usual prenatal care.
45941828|NCT00271999|Behavioral|Nocturnal home hemodialysis|Six times per week nocturnal home hemodialysis
45655759|NCT04879381|Other|Sputum samples|During consultation, one expectoration will be performed.
45676777|NCT01821963|Drug|Pegylated Interferon Alfa 2a|Starting dose: 180 mcg subcutaneously once weekly.
45676778|NCT01821963|Drug|Ribavirin|Starting dose: 1,000 mg by mouth daily.
45941829|NCT00272077|Drug|Insuline glargine|
45941830|NCT00107640|Behavioral|Patient-provider education|Experimental patients received an intervention consisting of the following components: written reports and educational materials, a telephone health educator intervention (at baseline, 3 and 6 months), and a brief provider intervention.
45941831|NCT00272116|Drug|Zinc and vitamin A single dose at enrollment|10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children
45941832|NCT00272116|Drug|Placebo and vitamin A single dose at enrollment|Placebo was plain glucose. Vitamin A 100,000 IU to infants and 200,000 IU to older children
45941833|NCT00272155|Behavioral|Educational intervention|Educational outreach visits to the CME-groups, work-shops, audit and feedback
45941834|NCT00272155|Behavioral|Educational intervention program|The 433 recruited GPs had a total of 1336 717 office consultations of which 171 679 (12.8%) were RTIs encounters for 118 621 different patients. The GPs participated in peer continuing medical education (CME) groups in southern Norway. A multifaceted intervention was tailored, where key components were educational outreach visits to the CME-groups, work-shops, audit and feedback. Prescription Peer Academic Detailers conducted the educational outreach visits. During these visits, evidence-based recommendations of antibiotic prescriptions for RTIs were presented and software handed out for installation in participants PCs, enabling collection of prescription data. These data was linked to corresponding data from the Norwegian Prescription Database (NorPD). Main outcomes are baseline proportion of inappropriate antibiotic prescriptions for RTIs and change in prescription patterns compared to baseline one year after the initiation of the tailored pedagogic intervention.
45941835|NCT00272194|Device|Ambu Laryngeal Mask|
45941836|NCT00272194|Device|Aintree Exchange Catheter|
45941837|NCT00272194|Device|Laryngeal Mask Airway|
45941838|NCT00272272|Behavioral|Music Therapy|Listening to Music while standing
45941839|NCT00272350|Drug|Steroids|
45941840|NCT00272350|Drug|ZD6474|
45941841|NCT02966054|Behavioral|Digital Health Physical Activity Intervention Group|Print materials on exercise after cancer, Fitbit Flex for 12 weeks, and daily Text Messages for 12 weeks
45941842|NCT00272428|Behavioral|ascorbic acid, vitamin E, beta carotene, selenium, zinc|
46074865|NCT00870493|Drug|Placebo|starch tablet, 300 mg/day
45806936|NCT05183217|Behavioral|Online Continence promotion program without tailoring|The online continence promotion program has five sections (Introduction, Exercise, Bladder, Bowels, Care Seeking) that build knowledge, self-efficacy, and skills to set action and coping plans relevant to a participant's symptoms. This online program is based on an in-person, small-group program that has demonstrated effectiveness to improve both urinary and bowel incontinence in women age 50 and above. Participants will receive automated weekly reminders reminding them to re-visit the program, regardless of their individual user activity.
46074866|NCT02795208|Procedure|Lung recruitment maneuver|The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (20 cmH2O of PEEP + 20 cmH2O of driving pressure) for 10 breaths.
45806937|NCT05183217|Behavioral|Online Continence promotion program with tailoring|"The online continence promotion program has five sections (Introduction, Exercise, Bladder, Bowels, Care Seeking) that build knowledge, self-efficacy, and skills to set action and coping plans relevant to a participant's symptoms. This online program is based on an in-person, small-group program that has demonstrated effectiveness to improve both urinary and bowel incontinence in women age 50 and above. Participants will receive tailored output (personalized cues, emphasis on relevant content, individualized and tailored reminders about their goals) based on a computer algorithm incorporating unique user inputs (individual factors). Inputs will be reassessed every 2 weeks for retailoring so that personalization evolves over the course of the intervention."
45655760|NCT05528237|Device|Flocked swab paired with Roche Cobas 4800|Consenting individuals will insert the sterile flocked swab into the vagina, rotate at least once, and store in the provided dry tube. The sample will be stored at ambient temperature and routed to the lab for HPV testing with Roche Cobas 4800.
45941843|NCT00272467|Drug|Rebamipide|"Brand name: Mucosta® Tab.~Generic name: Rebamipide.~Chemical name:~(±)-2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propionic acid.~Formulation: Tablet (White, film-coated tablet).~Strength: One tablet contains rebamipide 100mg.~Storage condition: 15℃~25℃.~Manufacturer: Korea Otsuka Pharmaceuticals"
46074867|NCT00864331|Radiation|radiation|39 Gy in 13 daily fractions of 3 Gy
45941844|NCT00272467|Drug|Omeprazole|"Brand name: Losec® Cap.~Generic name: Omeprazole.~Chemical name:~5-melthoxy-2-{{{4-melthoxy-3.5-dlmethyl2-pyridinyl}methyl}sulp- hinyl}-1H-benzimidazole sodium. 4) Formulation: Capsule. 5) Strength: One capsule contains omeprazole 20mg. 6) Storage condition: 15℃~25℃. 7) Manufacturer: AstraZenaca Korea."
45941845|NCT00272506|Drug|inhaled corticosteroid|
45941846|NCT00272506|Drug|long-acting beta2-agonist|
45941847|NCT00272545|Behavioral|Normalization of Eating (NOE)|The NOE is a 6-week program based on principles of CBT. Participants will receive individual therapy, as well as take part in group and family therapy sessions. In addition, participants will be supervised while eating meals.
45941848|NCT00272545|Behavioral|Treatment As Usual (TAU)|Treatment as usual will include standard care for a person with an eating disorder.
45941849|NCT00107718|Drug|SB-485232|
46074868|NCT00864331|Other|Chemotherapy and radiotherapy|Chemotherapy followed by low dose palliative radiotherapy
46074869|NCT00864331|Drug|Chemotherapy|Chemotherapy given alone
46074870|NCT00864331|Other|Palliative radiotherapy and chemotherapy|Low dose palliative radiotherapy followed by chemotherapy
46074871|NCT00812253|Drug|Intravenous insulin|Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
45452974|NCT00152464|Drug|Placebo|Pharmaceutical form: Oral drops Route of administration: Oral use
45452975|NCT00152464|Drug|Levocetirizine|Pharmaceutical form: Oral drops Concentration: 5 mg/ml Route of administration: Oral use
46074872|NCT00812253|Drug|Subcutaneous insulin|Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
45452976|NCT00827008|Drug|Neramexane mesylate|Up-titration treatment period of 5 weeks up to 75mg Neramexane mesylate oral per day followed by 49 weeks treatment maintenance
45452977|NCT00675844|Drug|elvucitabine|10 mg elvucitabine daily as part of an ART regimen
45452978|NCT04472806|Drug|Toripalimab|"Toripalimab, humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.~Toripalimab treatment after chemotherapy in combination with Endostar, 240 mg, Q3W, up to 2 years."
45452979|NCT04472806|Drug|chemotherapy in combination with Endostar|chemotherapy+ Endostar
45452980|NCT00674440|Drug|F-DOPA|0.08-0.16 mCi/kg once
45452981|NCT00674440|Radiation|PET scan|
45941850|NCT00272584|Drug|Risperidone|
45941851|NCT00272623|Procedure|Seldinger technique or venous cut-down for port placement|
45941852|NCT00272662|Drug|peginesatide|
45941853|NCT00399230|Drug|Optive|
45941854|NCT00272701|Drug|Esomeprazole|
45941855|NCT00272701|Drug|Other PPI marketed in Sweden|
45941856|NCT00107757|Drug|GW685698X|
45941857|NCT00272740|Drug|Fulvestrant|
45941858|NCT00074750|Drug|DTGM|Starting dose: 2 mcg/kg by vein three times a week (M,W,F) for two consecutive weeks.
45941859|NCT00416533|Drug|docetaxel|
45941860|NCT00416533|Drug|doxorubicin hydrochloride|
45941861|NCT00416533|Drug|prednisone|
45676779|NCT01821963|Drug|Telaprevir|Starting dose: 750 mg by mouth 3 times a day.
45676780|NCT01821729|Drug|FOLFIRINOX|Oxaliplatin via IV on Day 1 over 2 hours; Irinotecan via IV on Day 1 over 90 minutes, 5FU via IV on Day 1 over 2-4 minutes
45676781|NCT01821729|Drug|Losartan|Taken orally every day during Phase I for all 8 cycles
45941862|NCT00272857|Genetic|Retrovirus Construct|This study will use an experimental gene transfer procedure performed in a laboratory to insert a new FA gene into the participant's bone marrow cells. The gene-corrected bone marrow cells will then be re-infused into the participant and participants will be observed for successful gene transfer
45941863|NCT00107796|Drug|Modafinil|
45941864|NCT00272896|Drug|Vasoactive intestinal peptide|
45941865|NCT00272935|Drug|Cenestin 0.3 mg Tablets|1 tablet daily
45941866|NCT00272935|Other|Placebo|1 tablet daily
45941867|NCT00272974|Behavioral|Clinic-based counseling|
45655761|NCT05533853|Other|Posture corrective exercises|The exercises are of two types strengthening exercises and starching exercise ,). The strengthening exercises are to be done for 15 repetitions in 2 sets, Progression will be by increasing to 3 sets and adding 1 Kilogram of resistance in dumbbells exercises, the targeted muscles are teres minor, infraspinatus, medial and lower trapezius, rhomboids, and cervical flexor muscles. On the other hand, stretching exercises are to be hold for 30 seconds for 2 sets then progressed to 3 sets, the targeted muscles are pectoralis minor, sternocleidomastoid and levator scapulae.
46074873|NCT02790294|Device|Magnetic Resonance Imaging|The routine spine MRI protocol will be utilized, which includes the following sequences: haste localizer, sagittal T1, T2, and short-T1 Inversion Recovery (STIR), axial T2 for lumbar spine or axial gradient echo for cervical and thoracic spine, axial T1, post contrast sagittal and axial T1. All scans will be obtained using a 1.5 Tesla magnet.
45655762|NCT05533853|Other|Denneroll extension traction|The participants will be instructed to lie supine and keep their legs extended. Based on the apex of each participant's cervical curvature on the initial radiograph, the therapist will position the apex of the denneroll in one of two regions (mid cervical placement or lower cervical placement). The duration of the traction session will start at 2-3 min and increased 1 min per session until reaching the goal of 20 min, the traction will repeated three times per week for 6 weeks
45655763|NCT03048409|Other|Enteral Formula|Enteral feeding with a peptide-based formula.
45941868|NCT00273013|Drug|GW274150|GW274150 will be available as 30 mg white oval tablets.
45941869|NCT00273013|Drug|Singulair|Singulair will be available as over encapsulated 10 mg orange tablets.
45806938|NCT05179876|Drug|Macitentan|Participants will receive oral dose of macitentan 10 milligrams (mg) tablet once daily.
45806939|NCT05179876|Drug|Selexipag|Participant will receive oral dose of selexipag tablet twice daily at the dose strength corresponding to their maintenance dose at the end of their parent study. Available strengths: 200, 400, 600, 800, 1000, 1200, 1400 and 1600 micrograms.
45941870|NCT00273013|Drug|Placebo|Matching placebo for Singulair and GW274150 will be available.
45941871|NCT00107835|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine was applied topically. The study drug remained on the treatment area for 20-30 minutes for minor dermal procedures and 60 minutes for major dermal procedures
45806940|NCT05179876|Drug|FDC of Macitentan and Tadalafil|Participants will receive oral FDC of macitentan 10 mg and tadalafil 40 mg once daily during the course of the study as already received in the parent studies.
45806941|NCT05178095|Device|Artificial intelligence|Colonoscopy with the aid of artificial intelligence for the detection of colonic polyps
45806942|NCT05178095|Device|No Artificial Intelligence|Colonoscopy without the aid of artificial intelligence for the detection of colonic polyps
45806943|NCT05176483|Drug|XL092|XL092 orally once daily (qd)
45806944|NCT05176483|Drug|Nivolumab|360 mg IV infusion once every 3 weeks (q3w)
45806945|NCT05176483|Drug|Ipilimumab|1 mg/kg IV infusion once every 3 weeks (q3w) for maximum of four doses
45941872|NCT00074789|Behavioral|Modified Interpersonal Therapy|Psychiatric mental health nurses will meet with participants 10 times, an hour each time, over a period of 14 weeks. The nurses will continue to work with the mothers over the next 8 weeks by phone, conducting 5 fifteen minute phone sessions.
46074874|NCT00870571|Drug|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
45941873|NCT00074789|Behavioral|Attention control/usual care|Participants will receive the usual care for depression.
45941874|NCT00273091|Device|ICD with CRT therapy|permanently CRT pacing
45941875|NCT00273130|Procedure|transnasal endoscopy|
46074875|NCT00870571|Drug|NorvasC® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fed conditions
46074876|NCT02796612|Other|no intervention|Patients do not receive any interventions but are treated according to current standard of care.
46074877|NCT02796612|Behavioral|delivery of a take-home brochure|Content of brochure is dealing with symptoms, as well as mammographic and ultrasound findings, which need further investigation, will be addressed. The procedure of the breast biopsy itself will be explained in detail. The time in which the histological diagnosis can be expected will be indicated and follow up in case of a benign histology and the necessary therapy in case of breast cancer will be addressed.
45941876|NCT00273130|Procedure|transoral thin endoscopy|
45941877|NCT00273208|Behavioral|10 week behavioral intervention program|
46074878|NCT02796612|Behavioral|patient care by a psychologically trained physician|The physicians who perform the biopsies will be instructed by means of a psychological training how to give structured and standardized information in order not only to inform comprehensively, but also to meet the patients' emotional needs.
46074879|NCT05756439|Drug|Intravenous Sedatives with or Without Analgesia|Participants having dental surgery with conscious intravenous sedation
45806946|NCT05176483|Drug|Nivolumab|3 mg/kg IV infusion once every 3 weeks (q3w) for first four doses, and then 480 mg IV infusion once every 4 weeks (q4w)
45941878|NCT00107874|Drug|misoprostol|
45941879|NCT00074828|Drug|LY517717|
46074880|NCT05445336|Behavioral|PREVENT Program|PREVENT (Person-centred Routine Fracture PreEVENTion) is a scalable model for delivering routine assessments and interventions on diet and supplements, multifactorial fall and fracture prevention strategies, and medications to long term care teams to treat residents at high risk of fracture.
46074881|NCT00616759|Procedure|electroconvulsive therapy|electroconvulsive therapy as usual
46074882|NCT00616759|Procedure|electroconvulsive therapy plus propofol|electroconvulsive therapy identical to the comparator group except that propofol 0.5 mg/kg is given intravenously 15 seconds after the electrical stimulation at each treatment in order to terminate the ECT-induced seizure
46074883|NCT00616759|Drug|propofol|Propofol 0.5 mg/kg intravenously given 15 seconds following electrical stimulation
45806947|NCT05176483|Drug|Nivolumab|480 mg IV infusion once every 4 weeks (q4w)
45806948|NCT05176483|Drug|Nivolumab + Relatlimab|IV administration of nivolumab + relatlimab
45806949|NCT05176288|Drug|Axitinib|Taken Orally
45806950|NCT05176288|Drug|Palbociclib|Taken Orally
45941880|NCT00074828|Drug|enoxaparin|
45941881|NCT00273247|Drug|Interferon alpha-2b|
45941882|NCT00273286|Behavioral|family diabetes management intervention|a clinic-integrated, low intensity, multi-component behavioral intervention
45655764|NCT05528081|Other|Phone interview|Participants will be interviewed by phone at 3, 12, 24 months after the baseline MRI scans.
45452982|NCT02146924|Biological|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes|Given IV
45806951|NCT05176288|Drug|Avelumab|Intravenous infusion
45941883|NCT00107913|Drug|Doxil|
45655765|NCT04879147|Diagnostic Test|Evalution of thyroid function|Determination of TSH, free T4, free T3, SPINA-GT, SPINA-GD and Jostel's TSH index
45655766|NCT04878835|Biological|intralesional ranibizumab|Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL
45941884|NCT00074867|Drug|CP-547,632|
45806952|NCT05175092|Procedure|Living Donor Liver Transplantation|The LDLT will be performed by the UW Division of Transplantation in accordance with the standard of care for this operation.
45806953|NCT05172258|Procedure|Biopsy|Undergo biopsy
45941885|NCT00273403|Behavioral|Maintenance in Care Services|
45941886|NCT00273403|Behavioral|Access to Care Services|
45806954|NCT05172258|Procedure|Biospecimen Collection|Undergo collection of blood samples
45941887|NCT00273442|Drug|timolol maleate|
45655767|NCT05528003|Procedure|Commercialized single-access port devices|Two kinds of commercialized single-access port devices were used.
45655768|NCT03049423|Device|MRI scans|30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.
45941888|NCT00273442|Drug|dorzolamide/timolol maleate fixed combination|
45941889|NCT00401427|Drug|trastuzumab|
45941890|NCT00401427|Drug|vinorelbine|
46074884|NCT02795364|Procedure|Structural Image Guidance|Resecting the tumor in accordance with the margin on MRI T1W-enhanced delineation
45655769|NCT03049423|Diagnostic Test|MRI scans and general physical examination|30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
45941891|NCT00273481|Drug|dorzolamide 2%/timolol maleate 0.5% fixed combination|
45941892|NCT00273481|Drug|latanoprost 0.005%/timolol maleate 0.5% fixed combination|
45941893|NCT00273481|Drug|timolol maleate 0.5%|
45452983|NCT02146924|Biological|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
45452984|NCT02146924|Other|Laboratory Biomarker Analysis|Correlative studies
45452985|NCT02106598|Drug|fluorescent cRGDY-PEG-Cy5.5-C dots|
45655770|NCT05114057|Other|Renal Angina Index (RAI)|Risk-stratification tool using measures of risk and presence of injury to predict Acute Kidney Injury
45655771|NCT04878523|Dietary Supplement|multi berries juice|Testing product
45655772|NCT04878523|Dietary Supplement|Placebo drink|Blank
45655773|NCT05112809|Device|Cochlear Stimulation System (CSS)|Cochlear stimulation with surround sound and noise cancellation
45655774|NCT04390009|Diagnostic Test|Entire-body PET-CT scans|Entire-body PET-CT scans will be performed with state-of-the-art scanners with different manufacturers' models including Siemens Biograph Vision, United Imaging uEXPLORER and possibly other recently FDA-approved PET-CT scanners.
45806955|NCT05172258|Procedure|Computed Tomography|Undergo CT
45806956|NCT05172258|Drug|Ipatasertib|Given PO
45941894|NCT00273481|Drug|placebo|
45941895|NCT00074906|Drug|Venticute|Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment
45941896|NCT04719130|Other|Multimodal circuit exercise|A structured and supervised multimodal exercise circuit twice a week, under 12 weeks program. The circuit workout program consists of 8 exercises, divided into motor coordination, balance, strength, and aerobic exercises. The exercises will be employed in a reserved room inside of the Basic Health Units. The sessions of exercises will last approximately 50 minutes,
46074885|NCT02795364|Procedure|Metabolic Image Guidance|Aggressive resecting of the tumor in accordance with the margin on MRS CNI delineation
46074886|NCT00870649|Biological|Bilhvax vaccine (Sh28GST)|Four vaccine sc administrations over a year associated with chemotherapy (PZQ)
46074887|NCT00870649|Biological|placebo|Four placebo sc administrations over a year associated with chemotherapy (PZQ)
46074888|NCT02796456|Other|blood sample|
46074889|NCT00812097|Device|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|The MENTOR® MemoryShape™ Breast Implant is a silicone elastomer mammary device with a textured surface.
45806957|NCT05172258|Biological|Pembrolizumab|Given IV
45806958|NCT05172245|Procedure|Biopsy|Undergo tumor biopsy
45806959|NCT05172245|Procedure|Biospecimen Collection|Undergo blood sample collection
45806960|NCT05172245|Drug|Cisplatin|Given IV
45806961|NCT05172245|Procedure|Computed Tomography|Undergo CT
45806962|NCT05172245|Drug|Ipatasertib|Given PO
45806963|NCT05172245|Procedure|Magnetic Resonance Imaging|Undergo MRI
45806964|NCT05172245|Procedure|Positron Emission Tomography|Undergo PET
45806965|NCT05172245|Radiation|Radiation Therapy|Undergo radiation therapy
45941897|NCT04719130|Other|Multidisciplinary lectures|Multidisciplinary lectures on pain and usual care provided by the Basic Health Units. A cycle of multidisciplinary lectures on pain will be offered by professionals in physical education, nursing, physiotherapy, medicine, psychology and social work that will take place in the Basic Health Units every 15 days.
45941898|NCT00273520|Drug|Telithromycin|
45941899|NCT00273559|Drug|prednisone|group 2 will remain on 5 mg of prednisone for at least 90 days post transplant.
45941900|NCT00108030|Procedure|Partial Body-weight supported Treadmill Training|
45941901|NCT00108030|Procedure|PBWST + Power training|
45941902|NCT00108030|Procedure|"Usual physiotherapy care"|
45941903|NCT00273598|Procedure|Moss Miami Spine Instrumentation System|
45941904|NCT00273598|Procedure|Universal Spine Instrumentation System|
45941905|NCT00273676|Procedure|Conversion to oral antibiotic treatment after 3 days of intravenous antibiotic treatment|
45655775|NCT04390009|Drug|Amyvid radiopharmaceutical|Amyvid (F18-florbetapir) will be evaluated for binding to white matter of the peripheral and central nervous system of participants
45655776|NCT05527925|Device|MRI|Brain testing of patients using MRI
45655777|NCT04872283|Procedure|great toe (1st metatarsophalangeal joint) fusion|Great Toe joint fusion surgery
45806966|NCT05171777|Drug|Atezolizumab|Atezolizumab will be administered on Day 1 of each 21-day cycle. Participants will receive atezolizumab according to their assigned route of administration (i.e., SC or IV) for the first three treatment cycles. At Cycle 4, participants will cross-over and receive atezolizumab administered according to the alternative route of administration for Cycles 4-6. This period of 3+3 cycles in both treatment arms constitutes the study Treatment Cross-over Period. After Cycle 6, participants will select how they would like atezolizumab to be administered (SC or IV) for the Treatment Continuation Period. The Treatment Continuation Period will continue until Cycle 16 for participants with early-stage NSCLC or until loss of clinical benefit, as determined by the investigator according to local standard of care, for patients with advanced NSCLC.
45806967|NCT05170204|Drug|Alectinib|Participants will receive oral alectinib twice daily with food.
45806968|NCT05170204|Drug|Entrectinib|Participants will receive oral entrectinib once daily, with or without food.
45941906|NCT00273715|Procedure|Surgical wound closure techniques|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
45655778|NCT04872283|Drug|IV Ketorolac|Participants will receive 30mg of intravenous (IV) ketorolac will be given during surgery
45941907|NCT00273715|Procedure|Surgical wound closure techniques (Comparator)|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
45655779|NCT04872283|Drug|Ketorolac Pill|Participants will receive 20 tablets of 10mg ketorolac, with instructions to take 1 tablet orally every 6 hours for pain
45655780|NCT04872283|Drug|5/325mg Oxycodone-Acetaminophen|Participants will receive 30 tablets of 5/325mg oxycodone-acetaminophen with instructions to take 1 or 2 tablets by mouth every 4 to 6 hours as needed for pain
45941908|NCT00108108|Drug|HCD122|
45941909|NCT00273832|Procedure|coronary artery computed tomography angiogram|
45941910|NCT00273832|Procedure|single photon emission computed tomography|
45941911|NCT00075062|Procedure|Flexible Sigmoidoscopy|
45655781|NCT04872283|Drug|Aspirin 81Mg Ec Tab|Participants will receive 81 mg aspirin twice daily as a preventive measure against deep venous thrombosis (DVT)
45806969|NCT05170204|Drug|Pralsetinib|Participants will receive oral pralsetinib daily on an empty stomach.
45806970|NCT05170204|Drug|Durvalumab|Participants will receive IV durvalumab every 4 weeks.
45941912|NCT00075062|Procedure|Rectal Biopsy|
45941913|NCT00273871|Drug|Cyclosporin or tacrolimus|
45941914|NCT00273949|Drug|lactulose|
45941915|NCT00108147|Procedure|Circuit Training|
45941916|NCT00108147|Procedure|Cardiac Rehabilitation|
45452986|NCT00773344|Drug|Tanespimycin|"Solution, IV, Weekly two hour infusion, 4-cycles until disease progression or DLT~This is a one-arm study with 4 fixed doses of Tanespimycin (225mg/m2, 300mg/m2, 375mg/m2 and 400mg/m2)"
45655782|NCT05182385|Drug|Blinatumomab|"All patients with hematological relapse will additionally receive Blinatumomab immunotherapy (first cycle: 9 ug/d c.i.v. on d1 until d7 and 28 ug/d c.iv. on d8 until d28; second cycle: 28 ug/d c.iv. on d1 to d28) in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab).~All patients with molecular relapse will additionally receive Blinatumomab immunotherapy at 28 ug/d c.iv. on d1 until d28 in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab.)~Patients eligible for a second cycle shall not receive Blinatumomab starting dose independent from relapse type."
45655783|NCT05182385|Drug|Venetoclax|"In phase I of the study all eligible patients will receive increasing doses of Venetoclax on days -7 to -1 (Venetoclax dose-titration) in the first cycle and continuous dosing of Venetoclax at a pre-specified target dose (TD, p.o., once daily, d1 to d42) in six-week cycles for a maximum of two cycles.~In phase II of the study all eligible patients will receive the recommended phase 2 dose (RP2D) of Venetoclax in six-week cycles for a maximum of two cycles. RP2D will be MTD.~Patients eligible for a second cycle shall not receive Venetoclax dose-titration independent from relapse type."
45655784|NCT04871581|Device|NTI-tss|FDA cleared device for prophylactic treatment of medically diagnosed migraine pain
45941917|NCT00108147|Procedure|Flexibility and toning|
45941918|NCT00273988|Drug|nevirapine|
45941919|NCT00274027|Drug|tiotropium bromide|
45806971|NCT05169736|Behavioral|Cognitive Behavioural Therapy|Intervention based on cognitive behavioural therapy principles and adapted to mental health problems related to the climate crisis. Intervention's main purpose is to increase management of mental health issues such as depressive symtoms, stress, worry and anxiety related to the coronavirus pandemic and increase quality of life in the current situation. Intervention contains psycho-educational elements as well as examples and exercises.
45806972|NCT05167825|Drug|Macitentan|Macitentan will be administered orally as a tablet.
45941920|NCT00075101|Drug|Dexamethosone|10 day study cycle: 5 day observation pre-steroid,5 day observation post-steroid
45941921|NCT00274066|Drug|Tiotropium + placebo|
45941922|NCT00274066|Drug|Tiotropium + ipratropium|
45941923|NCT00274066|Drug|Tiotropium + fenoterol|
45941924|NCT00274105|Drug|telmisartan|
45941925|NCT00274105|Drug|Placebo|
45941926|NCT02964624|Other|Rehabilitation|Protocol will consist of three exercise/week for eight weeks. Each session will begin with the evaluation of pain by the volunteer. Starting with a warm up exercise in a cycle ergometer (CEE), for 5 minutes at free cadence, then the intensity will be set at 90% of the intensity obtained during the incremental test and maintained for 10 min. Afterward, four sets of three different resistance exercises (RE) will be performed at 70% of the load correspondent to 1RM test with one minute interval between sets and exercises. During CEE Borg scale will be taken every two minutes and during RE the OMNI scale taken at the end of every set to monitor the intensity. At the end of the session, cool down global stretching exercises for inferior members will be performed and the VAS evaluated.
45941927|NCT00274144|Drug|telmisartan 40 mg|
45941928|NCT00274144|Drug|placebo 40 mg|
45941929|NCT00075140|Genetic|Mutation in the gene|
45941930|NCT00274300|Biological|pPJV7630 administered by PMED|
45655785|NCT04871581|Device|Placebo|Similar to Device, but having no influence on clenching intensity
45655786|NCT05533619|Drug|Proton pump inhibitor|Inpatients using proton pump inhibitor
45941931|NCT00108186|Drug|Celecoxib|Eight subjects will be assigned to one of three cohorts. Subjects will receive Celecoxib in escalating doses per cohort, starting with 200mg twice a day by mouth; 400mg twice a day by mouth; and increasing to 600mg twice a day by mouth, for a total of 7 days. Subjects will have blood taken before the start of Celecoxib, and after completion of 7-days of Celecoxib.
45806973|NCT05165810|Behavioral|Same-day ART initiation [experimental]|Participants assigned to same-day ART initiation will be offered standard, first-line ART on the day of trial enrollment. Participants, will be provided with focused counseling and instructions on where to follow-up for ongoing HIV care (either community-based HIV care or government-based HIV care, depending on randomization).
45941932|NCT00274339|Drug|Prevacid 30mg BID|
45941933|NCT00274339|Behavioral|Lifestyle changes of exercise and diet changes for weight loss and avoidance of reflux inducing foods.|
45941934|NCT00416611|Behavioral|Implementation of guidelines|
45941935|NCT00075179|Drug|Nesiritide (Natrecor)|Given initially as a bolus (2 mcg/kg) and than infused for 30 minutes (0.01 mcg/kg/min) during right heart catheterization.
45941936|NCT00075179|Procedure|Right Heart Catheterization|Small tubes placed in neck vein to heart as means of measuring pressure in heart and lungs; treatment with nesiritide delivered during procedure.
45941937|NCT00416650|Drug|erlotinib hydrochloride|All patients will receive 150 mg orally daily
45941938|NCT00108225|Other|LoBag Diet - test phase|A Low Biologically Available Glucose (LOBAG30), weight maintaining diet consisting of 30% carbohydrate, 30% protein, 40% fat will be provided to subjects for 5 weeks.
45941939|NCT00108225|Other|LoBAG Diet - control phase|A control, weight maintaining diet consisting of 55% carbohydrate, 15% protein, 30% fat will be provided to subjects for 5 weeks
45941940|NCT00274378|Device|ALLOMATRIX injectable putty in distal radius fractures|
45941941|NCT00274417|Drug|dutasteride|
45941942|NCT02965430|Device|AL-SENSE|A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis
45655787|NCT04871347|Drug|TWP-101|IV infusion
45655788|NCT04589533|Other|educational program|The educational program will be based on: a outreach visit (a 3-h face-to-face meeting between a trained diabetes specialist from outside the Center and the staff of the Center itself) and a distance learning (FAD).The educational programme will be focused on current Diabetes Guidelines recommendations and based on possible deviations from the best clinical practice observed during phase1
45941943|NCT00274495|Drug|Rosiglitazone and Pegasys/Ribavirin|
45941944|NCT00108264|Biological|Tumor RNA transfected dendritic cells|
45941945|NCT00274534|Drug|Tiotropium|
45941946|NCT00274534|Drug|Salmeterol|
45941947|NCT00075257|Drug|DVS-233 SR|
45941948|NCT00274573|Drug|Tiotropium bromide|
45655789|NCT05527769|Procedure|mastectomy + immediate breast reconstruction|pre- or retro pectoral prosthesis
45941949|NCT00108381|Behavioral|tailored cognitive behavior therapy|tailored psychological treatment
45655790|NCT05524805|Device|BTL-785-7 Treatment|Treatment of wrinkles with the BTL-785-7 applicator to the BTL-785F system.
45655791|NCT04466761|Dietary Supplement|Monosaccharide Powder|Monosaccharide powder dissolved in water.
45655792|NCT04466761|Other|Placebo Comparator|Placebo (cellulose powder).
45655793|NCT04425083|Other|no intervention|no intervention
45676782|NCT01821729|Radiation|Proton Beam Radiation|30-45 minutes per day, daily Monday-Friday
45676783|NCT01820637|Device|The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)|Drug-eluting SFA self-expanding stent
45806974|NCT05165810|Behavioral|Standard ART initiation [usual care]|Participants randomized to standard ART initiation will not initiate ART on the day of trial enrollment, but only after linking to their assigned source of HIV care (either community-based HIV care or government-based HIV care, depending on randomization). In standard ART initiation, patients typically, complete an intake visit at the HIV clinic, with baseline laboratory testing, and return to the clinic approximately 2 weeks later to begin ART.
45941950|NCT00108381|Behavioral|standard care|standard psychological treatment
45941951|NCT00274612|Drug|Telmisartan|
45941952|NCT00274612|Drug|Ramipril|
45941953|NCT00075374|Drug|docetaxel|"Patients receive docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~OR Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, every 2 courses during study treatment, and then at study completion.~Patients are followed at 1 month and then every 2-3 months thereafter."
45941954|NCT00274690|Drug|GW679769|
45941955|NCT00274729|Behavioral|Mono Unsaturated Fatty Acids in Obesity|
45941956|NCT00274807|Biological|filgrastim|
45941957|NCT00274807|Drug|cytarabine|
45941958|NCT00274807|Drug|etoposide|
45941959|NCT00274807|Drug|mitoxantrone hydrochloride|
45941960|NCT00274885|Drug|oxaliplatin|
45941961|NCT00274885|Procedure|management of therapy complications|
45941962|NCT00277147|Drug|BB IND 6989|
45941963|NCT00277186|Other|New Care Continuum|Patient experience surgery through newly designed arthroplasty continuum
45941964|NCT00277225|Drug|Abatacept|
45941965|NCT00277264|Drug|Tiotropium (Spiriva®)|
45941966|NCT00108420|Drug|Prazosin|
45941967|NCT00277303|Drug|XL999|XL999 will be administered at 2.4 mg/kg as a 4-hour intravenous (IV) infusion. Subjects will receive XL999 infusions weekly for 8 weeks of treatment unless drug-related toxicity requires dosing delay. In the absence of progressive disease and unacceptable toxicity, subjects may receive XL999 treatment weekly for up to a year on this study. After 8 weeks, at the discretion of the investigator, one dose of four may be omitted for a subject's convenience.
45941968|NCT00075413|Drug|arsenic trioxide|
45941969|NCT00277342|Procedure|measurement of lipid-induced hepatic insulin resistance|
45941970|NCT00277381|Behavioral|Automated feedback regarding drug adherence|
45941971|NCT00108459|Behavioral|Low Carbohydrate Diet|
45941972|NCT00277420|Behavioral|Comprehensive weight management|
45655794|NCT05527613|Other|whatsapp application with oral hygiene reminder for orthodontic patients|Participants with orthodontics will be randomly assigned to receive the WhatsApp application, through which oral hygiene reminders will be sent using images and videos containing necessary information, and at the same time they will receive verbal instructions on oral hygiene
45655795|NCT05524649|Dietary Supplement|Food Supplement 1|Probiotic single strain formulation containing Bifidobacterium longum CECT7894 for 3 months 5 drops/day
45941973|NCT00277498|Drug|Xalacom|
45941974|NCT00277498|Drug|Xalatan|
45806975|NCT05165810|Other|Community-based HIV care [experimental]|Participants randomized to community-based HIV care will be referred to PWID-focused integrated care centers (ICCs) for ongoing HIV clinical management - a prototype of decentralized HIV care in India. ICCs will provide free HIV care that will adhere closely to Indian HIV treatment guidelines and, when relevant, to local HIV treatment standards.
45941975|NCT00277498|Drug|Timolol|
46074890|NCT05226247|Procedure|Spontaneous breathing trial|To perform cardiac and lung echography before and during a spontaneous breathing trial
45806976|NCT05165810|Other|Government-based HIV care [usual care]|Participants randomized to government-based HIV care will be referred to government-based HIV clinics for ongoing HIV clinical management. Government-based clinics provide free HIV care that adheres closely to Indian HIV treatment guidelines
46074891|NCT02790216|Procedure|Brachytherapy|Biopsies will be obtained after intraoperative plan to rule out significant cancer outside a high risk planning target volume
45806977|NCT05165810|Behavioral|Enhanced adherence support [experimental]|Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to enhanced adherence support will receive an intensive, tailored adherence intervention lasting a maximum of 6 months, with two components: 1) tracking and outreach, and 2) psychosocial support and navigation. These will aim to equip PWID with skills to independently manage their ART using motivational interviewing and strengths-based case management.
46074892|NCT05227183|Behavioral|The virtual version of the Social stress task : V-TSST|The task consists in a brief presentation about the abilities of participants followed by an arithmetic task in front of a virtual 3D audience projected and one researcher in a room.First, participants have 5 minutes to prepare an exhibition about their qualities, their strengths and defects, and, why they identify with them. During this period virtual reality shows a closed curtain, and sounds from the audience can be heard. In the second phase, the curtain is raised and the participant must expose his speech during 5 minutes. Audience will remain attentive during 2 minutes, then audience will change to a restless attitude. The third phase consists of subtracting back a two-digit number from a four-digit number, as quickly as possible, starting again if participant makes a mistake. A debriefing of the test is scheduled at the end of the protocol, to remind patients of the purely fictional nature of this test. The visit will only end after a return to the baseline emotional state
46074893|NCT02610075|Drug|AZD1775|All patients will receive intervention with AZD1775 orally. Patients will continue to receive treatment with AZD1775 until disease progression, intolerable toxicity, or discontinuation criteria are met.
45806978|NCT05165810|Behavioral|Routine adherence support [usual care]|Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to routine adherence support will receive a guideline-based, HIV clinic-based adherence counselling intervention lasting a maximum of 6 months
45941976|NCT02965664|Drug|PresbiDrops (CSF-1)|PresbiDrops (CSF-1) is a topical ophthalmic drug.
45941977|NCT02965664|Drug|Placebo|Placebo drops contain the same ingredients as PresbiDrops except for the active ingredients
46074894|NCT00866593|Drug|Generic Escitalopram|10mg/d or 20mg/d
46074895|NCT00866593|Drug|Innovator Escitalopram|10mg/d or 20mg/d
46074896|NCT02795286|Device|Artis Haemodialysis Machine w/ ASIST Software - Isonatremic|
46074897|NCT02795286|Device|Artis Haemodialysis Machine w/ ASIST Software - Isotonic|
46074898|NCT02795286|Device|Artis Haemodialysis Machine w/o ASIST Software|
46074899|NCT00866671|Drug|nelarabine|Nelarabine is a prodrug of 9-β-D-arabinofuranosylguanine (ara-G), a deoxyguanosine analogue.
46074900|NCT04030611|Diagnostic Test|tongue diagnosis system|This study apply TCM diagnostic tools for clinical diseases, providing objective diagnostic data for evaluation to assess the association of blood stasis and DR.
45452987|NCT02742766|Drug|GSK3008356|This intervention is available as 0.5, 1, 5, and 25 mg white oral tablet. The formulation will be used to administer dose of 5 mg, 10 mg, 30 mg, 45 mg, 75 mg, 90 mg, 125 mg, 180 mg, 200 mg, and 250 mg total daily dose during the study.
45655796|NCT05524649|Dietary Supplement|Food Supplement 2|Probiotic single strain formulation containing Pediococcus pentosaceus CECT8330 for 3 months 5 drops/day
45655797|NCT05524649|Dietary Supplement|Placebo|5 drops/day for 3 months of sunflower oil
45676784|NCT02172911|Biological|INO-3112|1.1 mL intramuscular (IM) injection of INO-3112 (VGX-3100 + INO-9012) was administered followed immediately by electroporation (EP) with CELLECTRA™-5P on Day 0, Week 4, Week 8, and Week 12.
45941978|NCT00108498|Drug|mirtazapine|
45941979|NCT00277537|Drug|Mannitol|320mg BD 12 weeks followed by 40 weeks open label
45941980|NCT00277537|Drug|placebo|BD for 12 weeks
45941981|NCT00277576|Biological|ppdpSC18 administered by PMED|
45941982|NCT00075452|Drug|gemcitabine hydrochloride|
45941983|NCT00075452|Drug|oxaliplatin|
45941984|NCT00108537|Drug|bupropion and transdermal patch|
45941985|NCT00108537|Drug|transdermal patch and nicotine inhaler|
45941986|NCT00277654|Drug|Risperidone|risperidone 0.5mg up to 4mg daily vs. placebo
45941987|NCT00277693|Drug|Spironolactone (drug)|
45941988|NCT00277732|Procedure|Pharmaceutical care at baseline and follow-up visits over 6 months|
45941989|NCT00277771|Behavioral|Standard behavioral treatment (SBT) for weight loss|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Standard paper diaries are used for self-monitoring.
45941990|NCT00277771|Behavioral|SBT for weight loss using a PDA|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Personal Digital Assistants (PDAs) are used for self-monitoring.
45655798|NCT04878133|Diagnostic Test|OCT - optical coherence tomography|"The principle by which OCT works is similar to ultrasound, although light waves close to infrared are used instead of ultrasounds.~In practice, the light waves, emitted into the vessel through a special catheter positioned in the coronary artery, meet the surrounding structures and are partly absorbed and partly reflected by them. The reflected waves are picked up by a sensor positioned on the catheter and analyzed through software that produces images visible live on a special console."
45655799|NCT05527535|Diagnostic Test|Diabetic retinopathy screening by artificial intelligence|Screening diabetic patients' eyes with AI through digital health platform
45806979|NCT05165472|Other|Quadri-pulse theta burst stimulation|High frequency transcranial quadri-pulse theta burst stimulation prior to hand motor function training
45806980|NCT05164250|Drug|REGN5458|
45452988|NCT02742766|Drug|Placebo|This intervention is available as white oral tablet. The formulation will be used as a matching placebo for GSK3008356 during the study.
45452989|NCT01858948|Drug|Omega|Omega-3 supplements
45941991|NCT00277771|Behavioral|SBT for weight loss using a PDA with feedback messages|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Personal Digital Assistants with a customized feedback program are used for self-monitoring.
45452990|NCT01858948|Drug|Placebo|Similar in shape and color to Omega supplements
45941992|NCT00108576|Drug|Divalproex|anticonvulsant; mood stabilizer
46074901|NCT02794818|Behavioral|Produce boxes with nutritional education|"CSA produce boxes prescribed to study participants with free online nutritional education included"
46074902|NCT00866827|Other|Protocols for Treatment|Determine protocols for treatment of airway vascular malformation and to evaluate results from treatment of these lesions.
46074903|NCT02796378|Drug|Training+Simvastatin+Q10-placebo|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10-placebo.
45806981|NCT05163392|Device|Silverlon|SIlver-plated biopatch
45452991|NCT01858948|Drug|Quetiapine fumarate|Prior to randomization to Omega/placebo, patients were started on 100 mg BID of quetiapine, and the dose adjusted based on tolerability and response. The quetiapine target dose is 400-600 mg.
45655800|NCT05527535|Diagnostic Test|Diabetic retinopathy screening by healthcare personnel|Screening diabetic patients' eyes by conventional method (healthcare personnel)
45452992|NCT00770848|Drug|AMG 102|Investigational product to be given at safe dose from phase 1b, will be administered by IV Q3W.
45676785|NCT02172911|Device|CELLECTRA™-5P|CELLECTRA™-5P was used for EP following IM delivery of INO-3112 on Day 0, Week 4, Week 8, and Week 12.
45676786|NCT02120027|Drug|Ibodutant 10 mg|Oral tablet, to be given once daily.
45806982|NCT05163392|Device|Control|Tegaderm without biopatch
45806983|NCT05162781|Behavioral|Speed of Processing Training|"This training component targets cognitive processing speed, i.e., how quickly individuals process information that they receive through their senses. Cognitive processing speed is thought to be a basic capacity of the brain that underlies several other cognitive functions. Training is implemented using a web-based computer game, in which participants are required to fixate on a target at the center of the screen and identify targets in the periphery. The game is made progressively more difficult, in small increments, as participants gain mastery by increasing the speed at which targets are presented and increasing the number of distractors."
45806984|NCT05162781|Behavioral|Instrumental Activities of Daily Living In-lab Training|The training component is thought to bridge SOPT training, which targets a basic cognitive capacity, and IADL performance in daily life. This training component will involve repeated trials in which participants will practice carrying out simulated IADL tasks in the lab under the supervision of the trainer. The training will follow shaping principles, i.e., task requirements will be made progressively more challenging, in small increments, as participants gain mastery. Frequent, positive feedback will be provided.
45806985|NCT05162781|Behavioral|Cognitive Transfer Packagke|This training component is designed to transfer improvements in cognition from the treatment setting to everyday life. Elements of this package include negotiating a behavioral contract about the roles of the participant and family caregiver in the treatment, monitoring behavior outside the lab, and assigning performance of IADL as homework.
45806986|NCT05162781|Behavioral|Family Caregiver Coaching|One or more family members of the participant will receive coaching on how to best support the participant in carrying out the in-home components of the intervention.
45941993|NCT00108576|Other|placebo|Look-a-like placebo
45941994|NCT00075491|Drug|fenretinide|Given orally
45941995|NCT00075491|Procedure|therapeutic conventional surgery|Undergo surgery
45941996|NCT00075491|Other|pharmacological study|Correlative studies
45941997|NCT00075491|Other|laboratory biomarker analysis|Correlative studies
45941998|NCT00277888|Procedure|Femoral route for hemodialysis|
45941999|NCT00277888|Procedure|Jugular route for hemodialysis|
45942000|NCT00108615|Drug|Metformin|
45942001|NCT00108615|Drug|Pioglitazone|
45942002|NCT00108615|Drug|Metformin|
46074904|NCT02796378|Drug|Training+Simvastatin-placebo+Q10-placebo|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin-placebo and Q10-placebo.
46074905|NCT02796378|Drug|Training+Simvastatin+Q10|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10 400 mg/day.
46074906|NCT00864409|Drug|ropivacaine 0,2%|Local wound infiltrtation with 170 mL ropivacaine 2 mg/mL
46074907|NCT00864409|Drug|saline.9%|Wound infiltration with 170 mL sterile saline
46074908|NCT00864487|Drug|Neratinib|HKI-272
45452993|NCT00770848|Drug|AMG 102|Investigational product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment, will be administered by IV Q3W.
45452994|NCT00770848|Drug|Mitoxantrone|Administered Q3W for a maximum of 12 cyles
45452995|NCT00770848|Drug|Placebo|Placebo
45452996|NCT00770848|Drug|Prednisone|5 mg orally BID
45452997|NCT00672412|Drug|GPO-Vir Z30 tablet|Tablet consisting of ZDV 30 mg/3TC 15 mg/NVP 28 mg taken orally twice daily
45452998|NCT00672412|Drug|Lamivudine|Oral suspension containing 10 mg 3TC in each mL. Dosage depends on weight.
45655801|NCT04877899|Device|EchoGo|"EchoGo Core is a stand-alone software application. Echocardiograms should be acquired under the supervision of a physician and standard clinical protocols which includes focused apical 2, 3 and 4 chamber views. The results contain calculated measurements that will be returned to the interpreting physician. These results are intended as an additional input to standard diagnostic pathways and should only be used by a board-certified cardiologist/physician.~EchoGo Core is intended to be used for the quantification and reporting of results of cardiovascular function to support physician diagnosis. EchoGo Core is indicated for use in adult populations."
45806987|NCT05162781|Behavioral|Follow-up Phone Calls|After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis after.
45942003|NCT00108615|Drug|Pioglitazone|
45806988|NCT05162781|Behavioral|Healthy Lifestyle In-lab Training|This training component is designed to promote lifestyle changes that support brain fitness. Participants will receive education and coaching in the lab on relaxation, healthy nutrition, and healthy sleep.
45942004|NCT00108615|Radiation|CT scans|To measure changes in adipose tissue volumes
45655802|NCT05533385|Other|Allergenic extract|In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.
45942005|NCT00108615|Procedure|Oral glucose tolerance test|To detect a change in glucose tolerance
45942006|NCT00075569|Biological|HspE7|500 micrograms of SGN-00101 (HspE7, Nventa, San Diego, CA) is a novel therapeutic vaccine consisting of a fusion protein containing an M. bovis BCG heat shock protein (Hsp65) covalently linked to the entire sequence of HPV 16 E7.
46074909|NCT00866983|Drug|sildenafil (Revatio) 20 mg TID|To provide access to sildenafil for patients completing the A1481244 study, resides in Brazilian States where Revatio™ is not supplied by Health Secretary and are judged by the Investigator to derive clinical benefit from continued treatment with sildenafil. It will be supplied until the patient gets access to Sildenafil through Brazilian State Health Secretary from where the patient resides.
46074910|NCT04235166|Other|Current risk scores|Current risk scores for assessing the prognosis of acute upper gastrointestinal bleeding in cirrhosis were used.
46074911|NCT04235166|Other|New risk scores|New risk scores for assessing the progress of acute upper gastrointestinal bleeding in cirrhosis was used.
45942007|NCT00278044|Procedure|blood sampling and medical records|
45942008|NCT00278083|Drug|Study drug administration|
45942009|NCT00278083|Procedure|Tuberculin intradermal skin test|
45942010|NCT00278083|Procedure|Lung function test for FEV1|
45942011|NCT00278083|Procedure|Asthma symptom scores diary|
45942012|NCT00278083|Procedure|Quality of life diary|
45942013|NCT00278083|Procedure|Breath nitric oxide|
45942014|NCT00278083|Procedure|Breath condensate|
45942015|NCT00278083|Procedure|Sputum induction|
45942016|NCT00278083|Procedure|Blood sampling|
45942017|NCT00278083|Procedure|Urinalysis|
46074912|NCT00870805|Procedure|bilateral ultrabrief ECT|Bilateral ECT at 3-4 times seizure threshold with an ultrabrief pulse (0.3ms)
46074913|NCT00870805|Procedure|bilateral standard ECT|Bilateral ECT with at 1.5 times seizure threshold with a standard pulse (1.0ms)
45655803|NCT05524493|Diagnostic Test|Structural MRI|We will examine migraine and epilepsy patients as well as healthy controls using conventional structural MRI in the brain and spinal cord including T1-, T2-, and T2*-weighted sequences
45655804|NCT05524493|Diagnostic Test|Quantitative MRI|We will examine migraine and epilepsy patients as well as healthy controls using quantitative MRI in the brain and spinal cord. This includes multi-parameter mapping (MPM) and quantitative susceptibility mapping (QSM).
45806989|NCT05162781|Behavioral|Healthy Lifestyle Transfer Package|This training component is designed to support integration into everyday life of the lifestyle changes training in the lab. Elements of this package include negotiating a behavioral contract about the roles of the participant and family caregiver in the treatment, monitoring behavior outside the lab, and assigning relaxation exercises, for example, as homework.
45806990|NCT05160584|Other|No intervention|There is no interventional treatment component for participants with RRMM in this study.
45942018|NCT00278122|Biological|sargramostim|
45942019|NCT00278122|Drug|paclitaxel|
45942020|NCT00108654|Drug|VRC-HIVADV014-00-VP|
45942021|NCT00075647|Drug|temsirolimus|Given IV
45942022|NCT00075647|Other|laboratory biomarker analysis|Correlative studies
45942023|NCT00416689|Procedure|assessment of therapy complications|
45942024|NCT00416689|Procedure|quality-of-life assessment|
45942025|NCT00278239|Procedure|cognitive assessment|
46074914|NCT00870805|Procedure|right-unilateral ultrabrief ECT|Right-unilateral ECT at 6 times seizure threshold with an ultrabrief pulse (0.3ms)
46074915|NCT00870805|Procedure|right-unilateral standard ECT|Right-unilateral ECT with at 5 times seizure threshold with a standard pulse (1.0ms)
46074916|NCT05226013|Drug|Polyglycol lated urate oxidase for injection|Single dose escalation
45942026|NCT00278239|Procedure|psychosocial assessment and care|
45942027|NCT00278239|Procedure|quality-of-life assessment|
45942028|NCT00278278|Drug|cisplatin|Given IV
45942029|NCT00278278|Drug|etoposide|Given IV
45942030|NCT00278278|Drug|ifosfamide|Given IV
45942031|NCT00278278|Drug|lomustine|Given IV
45942032|NCT00278278|Drug|methotrexate|Given IV
45942033|NCT00278278|Drug|prednisone|Given IV
45942034|NCT00278278|Drug|vincristine sulfate|Given IV
46074917|NCT05226013|Drug|Placebo|Placebo
45942035|NCT00108771|Drug|ZR-02-01 Fentanyl Transdermal Matrix Patch|Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period.
46074918|NCT00870883|Drug|N-acetylcysteine and deferoxamine|N-acetylcysteine bolus dose of 50mg/kg/4h, by a manutention of 100mg/kg/day during 2 days and deferoxamine single dose of 1g administered 15mg/kg/h.
46074919|NCT00870961|Dietary Supplement|cholecalciferol|Given orally
45655805|NCT05524493|Diagnostic Test|Diffusion MRI|We will examine migraine and epilepsy patients as well as healthy controls using diffusion MRI in both brain and spinal cord.
45655806|NCT05524493|Diagnostic Test|fMRI|We will examine migraine and epilepsy patients as well as healthy controls using resting-state and task fMRI (including sensory stimulation using pain stimulus) in both brain and spinal cord.
45942036|NCT00108771|Drug|Placebo Patch|Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period
45942037|NCT00278434|Drug|Zoledronate|
45942038|NCT00278434|Other|Placebo (Saline)|
45942039|NCT00075686|Biological|cetuximab|Loading dose: Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only). Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 & days 1,8,15,22 of all subsequent cycles
45942040|NCT00075686|Drug|gemcitabine hydrochloride|1000mg/m2 IV over 30 minutes
45942041|NCT00278551|Biological|Immune ablation and hematopoietic stem cell transplant|Autologous Hematopoietic Stem Cell Transplant
45806991|NCT05157113|Drug|Dropless Regimen|"Intraoperative subconjunctival injection of triamcinolone acetonide (20mg) delivered 4-5 mm posterior to the limbus at the end of surgery.~Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~No postoperative drops."
45806992|NCT05157113|Drug|Standard Regimen|"Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~Neomycin/Polymyxin B ophthalmic solution: one drop to the operative eye four times daily for 1 week, then stop.~Ketorolac 0.5% ophthalmic solution: one drop to the operative eye four times daily for 1 month or until the bottle runs out.~Prednisolone acetate 1% ophthalmic solution: one drop to the operative eye four times daily for 1 month, then stop."
45942042|NCT00278590|Biological|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation will be performed.
45655807|NCT05524493|Diagnostic Test|MR Spectroscopy|We will examine migraine and epilepsy patients as well as healthy controls using MR Spectroscopy in both brain and spinal cord.
45942043|NCT02964858|Radiation|Standard Arm|Radiation will be started within 3-4 weeks of completion of chemotherapy. Computed Tomography (CT)scan will be acquired for treatment planning, which will be done using External Beam Planning System. The target volumes will be defined by clinical examination, staging Positron Emission Tomography with CT (PET-CT) and response PET-CT. The staging PET-CT will be fused and co-registered with the planning CT scans for target volume delineation. For Involved Field Radiotherapy,Clinical target volume (CTV) will include the entire nodal region depending on the site involved. For Involved Site RT , CTV will include the involved nodal volume in the staging PET-CT. For extranodal sites, the CTV will include the involved extranodal region as per the staging PET-CT. The total dose will be prescribed to the Planning Target Volume based on dose uniformity guidelines. All patients will be treated with 3 Dimensional Conformal Radiotherapy or Intensity Modulated Radiotherapy where indicated.
45942044|NCT02964858|Radiation|Experimental Arm|Radiation will be started within 3-4 weeks of completion of chemotherapy. Computed Tomography (CT)scan will be acquired for treatment planning, which will be done using External Beam Planning System. The target volumes will be defined by clinical examination, staging Positron Emission Tomography with CT (PET-CT) and response PET-CT. The staging PET-CT will be fused and co-registered with the planning CT scans for target volume delineation. For Involved Field Radiotherapy,Clinical target volume (CTV) will include the entire nodal region depending on the site involved. For Involved Site RT,CTV will include the involved nodal volume in the staging PET-CT. For extranodal sites, the CTV will include the involved extranodal region as per the staging PET-CT. The total dose will be prescribed to the Planning Target Volume based on dose uniformity guidelines. All patients will be treated with 3 Dimensional Conformal Radiotherapy or Intensity Modulated Radiotherapy where indicated.
45942045|NCT00278707|Drug|GTA: Glyceryltriacetate|
45942046|NCT00278746|Drug|Zinc and ORS|Government and private providers and village health workers were trained to prescribe zinc and ORS for use in diarrheal episodes in 1 month to 5 years old children in intervention communities
45942047|NCT00278746|Drug|ORS only|Promoted routine management of diarrhea in underfive with ORS
45942048|NCT00278824|Drug|Matrix Transdermal Fentanyl/CHADD Drug Delivery System|Patch applied every 3 days for 15 days
45942049|NCT00278824|Drug|Placebo Patch|Placebo patch applied every 3 days for 15 days
45942050|NCT00278902|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
45942051|NCT00278941|Drug|Quetiapine Fumarate Sustained Release|
45942052|NCT00075842|Dietary Supplement|Valeriana officinalis extract|Given orally
45942053|NCT00075842|Other|placebo|Given orally
46074920|NCT00870961|Other|placebo|Given orally
46074921|NCT00811941|Drug|Placebo|as-needed use, tablets, orally, 52 weeks
45452999|NCT00672412|Drug|Nevirapine|Oral solution containing 10 mg NVP in each mL. Dosage depends on weight.
45453000|NCT00672412|Drug|Zidovudine|Oral solution containing 10 mg ZDV in each mL. Dosage depends on weight.
45453001|NCT01468922|Drug|Pazopanib|Vascular endothelial growth factor (VEGFR) inhibitor
45453002|NCT01468922|Drug|ARQ 197|Hepatocyte growth factor receptor (mesenchymal-epithelial transition factor [c-MET]) inhibitor
45453003|NCT01381094|Drug|AKB-6548|oral dose administered once daily for 42 days
45655808|NCT04389073|Drug|Vinorelbine 40mg|Two tablets per day, three times a week. Vinorelbine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
45676787|NCT02120027|Drug|Placebo|Oral tablet (identical in appearance and weight to ibodutant tablets) to be given once daily.
45676788|NCT01850823|Drug|placebo|
45676789|NCT01850823|Drug|Mometasone Nasal Spray|
45676790|NCT01850823|Drug|Mometasone nasal spray|
45942054|NCT00278980|Drug|C-peptide|
45942055|NCT00279019|Drug|GSK233705|GSK233705 will be given orally with dosing strengths of 10, 50, 100 and 250 micrograms/blister via the DISKUS inhaler.
45942056|NCT00279019|Drug|Tiotropium|Tiotropium will be given orally as overfoiled strips of 5 capsules, each containing 18 micrograms of tiotropium (as bromide monohydrate) administered via a HandiHaler device.
45942057|NCT00279019|Drug|Placebo|Matching placebo will be given orally as overfoiled strips of 5 capsules, each containing lactose
45942058|NCT00108849|Drug|estradiol, 10 mcg|
45942059|NCT00279058|Procedure|Immunotherapy treatment for melanoma|
45942060|NCT00279097|Device|High Frequency Chest Wall Oscillation|
45942061|NCT02965742|Device|Stratos|A machine made by DMS group.
45942062|NCT02965742|Device|"Hologic QDR 4500A"|A machine made by Hologic inc.
45942063|NCT02965742|Device|"Hologic HORIZON A"|A machine made by Hologic inc.
45655809|NCT04389073|Biological|Toripalimab 240mg|Toripalimab 240 MG IV infusion every 3 weeks. Toripalimab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
45655810|NCT04389073|Biological|Bevacizumab 5 mg/kg|Bevacizumab 5 mg/kg IV infusion every 3 weeks. Bevacizumab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
45942064|NCT00108927|Behavioral|TRANSLATE|
45655811|NCT04389073|Drug|Cyclophosphamide 50 mg|50 mg per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
45942065|NCT00279175|Biological|Intracoronary infusion of enriched bone marrow-derived progenitor cells|
45942066|NCT00279175|Biological|Placebo medium supplemented with autologous serum|
45655812|NCT04389073|Drug|Capecitabine 500Mg Oral Tablet|500mg three times a day. Capecitabine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
45655813|NCT04389073|Drug|Cisplatin|Cisplatin 50mg/m2 IV infusion every 3 weeks. Cisplatin will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
45676791|NCT01820559|Drug|Placebo|Tablets
45806993|NCT05156398|Drug|Rimegepant|Rimegepant 75mg or 50mg (2 X 25mg) ODT
45453004|NCT01381094|Drug|Placebo|oral Placebo administered once daily for 42 days
45806994|NCT05156398|Drug|Placebo|Matching placebo 75mg or 50mg (2 X 25mg) ODT
45806995|NCT05155709|Drug|siremadlin|Siremadlin is a capsule taken orally once a day (QD) and comes in 10 mg, 20 mg and 30 mg strengths
45806996|NCT05155709|Drug|venetoclax|Venetoclax is a tablet taken orally once a day (QD) and comes in 10 mg, 50 mg and 100 mg strengths.
45806997|NCT05155709|Drug|azacitidine|Azacitidine is a powder for suspension for injection or powder for solution for infusion taken intravenously or subcutaneously according to standard local clinical practice
45806998|NCT05155618|Procedure|INTERVENTION GROUP|Personalized advice to prevent side effect according to their health status will be provided by a dietitian and a physiotherapist.
45942067|NCT00279253|Drug|clonidine (drug) intravenously|
45942068|NCT00279292|Procedure|Celiac Plexus Neurolysis|
45942069|NCT00109044|Drug|Escitalopram|
45942070|NCT00279448|Drug|exemestane|On tablet of 25 mg per day during 5 years
45942071|NCT00279448|Drug|tamoxifen|Two tablets of tamoxifen 10 mg per day during 2.5 to 3 years followed by one tablet of exemestane 25 mg per day during 2 to 2.5 years for a total duration of 5 years of treatment
45942072|NCT00075959|Drug|NXY-059|
45942073|NCT00109083|Drug|RWJ-333369|
45453005|NCT01330550|Dietary Supplement|High fiber sugar free biscuit|Dosage form:Biscuit, Dosage:1.94gram fiber/slice, Frequency:9 slices/meal;3 times/day. Duration:8 weeks
45806999|NCT05155293|Drug|AVT06 (proposed aflibercept biosimilar)|Patients will receive IVT injections of AVT06
45807000|NCT05155293|Drug|Eylea® (Aflibercept)|Patients will receive IVT injections of Eylea®
45942074|NCT00279487|Drug|Gabapentin|
45942075|NCT00279487|Drug|Placebos|
45942076|NCT00279565|Drug|buprenorphine|
45942077|NCT00279565|Drug|methadone|
45942078|NCT00279565|Drug|pegylated interferon alfa-2b plus ribavirin|
45942079|NCT00075998|Drug|"Interferon gamma-1b (Actimmune)"|200 mcg, SQ, 3x per week
45942080|NCT00279604|Behavioral|'Problem Profile Intervention' vs. WHO-Brief Intervention|
45942081|NCT00109122|Biological|zoster vaccine live (Oka/Merck)|
45942082|NCT00109122|Biological|Comparator: placebo (unspecified)|
45942083|NCT00279643|Procedure|Laser Hair Removal|
45942084|NCT00279682|Behavioral|treatment guidelines and depression care management|
45942085|NCT00076037|Biological|HIV CTL MEP administered with RC529-SE adjuvant|
45942086|NCT00076037|Drug|GM-CSF|
45942087|NCT00279721|Procedure|IMRT|
45942088|NCT00109161|Drug|Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)|
45942089|NCT00279760|Drug|Belatacept|
45942090|NCT00279760|Drug|Abatacept|
45942091|NCT00279799|Behavioral|Afiya HIV Prevention Intervention|Group-based session plus individually tailored HIV prevention phone sessions
45942092|NCT00279799|Behavioral|Afiya HIV prevention intervention|Afiya group-based intervention + nutrition phone sessions (attention control)
45942093|NCT00076076|Drug|Roflumilast|
45942094|NCT00279838|Procedure|Computer Assisted Navigation Knee Replacement|
45942095|NCT00109200|Drug|Xolair (omalizumab)|
45942096|NCT00416728|Drug|Aliskiren|
45942097|NCT00416728|Drug|Valsartan|
45942098|NCT00416767|Drug|fluorouracil|
45942099|NCT00416767|Drug|irinotecan hydrochloride|
45942100|NCT00416767|Drug|leucovorin calcium|
45942101|NCT00076115|Drug|Risperidone|
45942102|NCT00109239|Drug|rhuMAb VEGF (Bevacizumab)|
45942103|NCT00279994|Procedure|Exercise therapy|
45942104|NCT00279994|Device|Accelerometer (PAM; Personal Activity Monitor)|
45942105|NCT00279994|Procedure|Oral Exercise Therapy advise|
45942106|NCT00280033|Biological|Aluminum hydroxide|Provided in vials that contain 0.8 mL volume per vial.
45942107|NCT00280033|Biological|Inactivated Influenza A/H5N1 Vaccine (Chiron)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 60 mcg/mL A/H5N1 HA as determined by single radial immunodiffusion. It may be formulated with MF59 or aluminum hydroxide. Dosages: 7.5 mcg, 15 mcg, 30 mcg, or 45 mcg.
45942108|NCT00280033|Biological|MF-59|Proprietary experimental adjuvant. Provided in vials that contain 0.7 mL volume per vial.
45655814|NCT05175443|Other|Exercise|Participants will be trained, by a physical therapist, to perform a set of four daily exercises requiring 1 sets of 2 minutes for each exercise totaling 8 minutes of targeted exercise per day for 8 weeks of the intervention. These exercises will be progressed or modified every 2-4 weeks to assure the participant is receiving maximal benefit for their exercise intervention.
45942109|NCT00280033|Drug|Placebo|Saline placebo.
45942110|NCT00280072|Device|Renal Assist Device|
45942111|NCT00109278|Biological|V205C, measles, mumps, and rubella virus vaccine live|
45942112|NCT00109278|Biological|Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|
46074922|NCT00811941|Drug|Nalmefene|18.06 mg as-needed use, tablets, orally, 52 weeks. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
46074923|NCT04235088|Other|Somatosensory intensive intervention|The intensive somato-sensory intervention will take place during 3 weeks, 5 days per week, for 2 hours per day (30 hours of practice). During the week-ends, some somato-sensory written activities will be explained and handed to each family (6 hours of practice) Therapy sessions will be carried out in groups and each child will have his or her own therapist in charge of his or her treatment along the whole intervention. A daily check-list, design for that purpose, will be used by the therapist in order to register the gradually increased complexity of the activities and individual progression. The principal investigator will supervise all the interventions in order to assure their uniformity, adjusting the somato-sensory training protocol to the individual needs of each subject.
46074924|NCT00864565|Drug|Fentanyl 25 μg/h transdermal system, single application|A: Experimental Subjects received Corium International, Inc formulated products
46074925|NCT00864565|Drug|Duragesic 25 μg/h transdermal system single application|B: Active comparator Subjects received Jassen Pharmaceutica Products, L.P. formulated products
45676792|NCT01820559|Drug|ESL 1200 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
46074926|NCT02789904|Other|blood taking|Blood taking will be done for chest pain patients presenting with chest pain at 0, 1 and 2 hour
45942113|NCT00280111|Biological|116E AGMK|Single dose of 116E 10^5 FFu
45942114|NCT00280111|Drug|I321|Single dose of I321 10^5 FFu
45942115|NCT00280111|Drug|Placebo|1 crystal of potassium permanganate dissolved in the bicarbonate buffer to colour match the vaccine
45942116|NCT00280228|Behavioral|Adolescent Skills Parent Management Parent-Adol Negotiation|Acute treatment for 12 weeks followed by three monthly booster sessions.
45942117|NCT00280228|Behavioral|Treatment as Usual|Standard outpatient treatment for behavioral problems and substance use
45942118|NCT00280267|Drug|Testosterone gel|
45942119|NCT00280306|Other|No interventions|No intervention
45942120|NCT00109317|Drug|Raptiva (efalizumab)|
45942121|NCT00076232|Drug|Acyclovir|400 mg tablet taken orally twice daily
45942122|NCT00076232|Drug|Acyclovir placebo|Oral tablet taken twice daily
45942123|NCT00280345|Procedure|Trabeculectomy|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork
45942124|NCT00280345|Procedure|Trabeculectomy and cataract surgery|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork and the removal of the cataract
45942125|NCT00280345|Procedure|Cataract surgery|Removal of the cataract from the eye
45942126|NCT00280423|Drug|GW679769|
45942127|NCT00109356|Drug|AQ4N (Chemotherapy)|
45942128|NCT00280462|Drug|Nifedipine (drug)|Nifedipine (Adalat®, Bayer, Leverkusen, Germany) dose: 15µg/kg bolus infusion over 5 minutes; 0.2 µg/(kg.min) maintenance dose infusion period 25 minutes
45942129|NCT00280462|Drug|L-Arginin (drug)|L-Arginin (Clinalfa AG, Läufelfingen, Switzerland) 30% sodium chlorid solution, dose: 1g/min over 30 minutes
45942130|NCT00280462|Drug|Placebo|Placebo
45942131|NCT00280501|Drug|Quetiapine (drug)|Quetiapine (Seroquel 100mg-film-coated tablet, AstraZeneca Vienna, Austria) Dose: 100 mg tablet oral single dose
45942132|NCT00280501|Drug|Sulpiride (drug)|Sulpiride (Dogmatil 200mg-tablet, Synthélabo Groupe, Le Plessis Robinson, France) Dose: one half of 200 mg tablet oral single dose
45942133|NCT00280501|Drug|Placebo|Placebo
45942134|NCT00280540|Drug|Valsartan/Hydrochlorothiazide|
45942135|NCT00076349|Drug|bendamustine and rituximab|Patients will receive rituximab on the first day of a cycle at a dose of 375 mg/m2, followed on the second and third day of a cycle by SDX-105 (bendamustine) at a dose of 90 mg/m2/day of treatment. Four cycles are planned. Patients will receive a dose of rituximab alone 7 days prior to the first cycle of the combination and a dose of rituximab 28 days after the last cycle of the combination. If there is documented disease regression, a fifth and sixth cycle of SDX-105 plus rituximab may be administered.
45942136|NCT00280618|Drug|Oxaliplatin|
45942137|NCT00416845|Drug|FTY720|
45942138|NCT00280696|Drug|Levetiracetam 250 mg|"Active Substance: Levetiracetam~Pharmaceutical Form: Film-coated tablet~Concentration: 250 mg~Route of Administration: Oral Use"
45942139|NCT00280696|Drug|Levetiracetam 500 mg|"Active Substance: Levetiracetam~Pharmaceutical Form: Film-coated tablet~Concentration: 500 mg~Route of Administration: Oral Use"
45655815|NCT04371445|Drug|Dexamethasone Ophthalmic Insert|DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care including topical antibiotics.
45655816|NCT04371445|Drug|Prednisolone Acetate 1% Oph Susp|Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care including topical antibiotics.
45655817|NCT05524337|Behavioral|white noise|"Dr. Harvery Karp's song The Happiest Baby, consisting of intrauterine sounds only, will be used for white noise. The sound will be set to 45 db."
45655818|NCT05524337|Behavioral|therapeutic touch|In the group where therapeutic touch will be applied, the heel blood collection procedure and the study will be explained to the family, and after the consent is obtained, the therapeutic touch will be applied to the baby 5 minutes before, during and after the procedure.
45655819|NCT05524337|Behavioral|white noise and therapeutic touch|the group where therapeutic touch and white noise will be applied together, after the family is informed about the procedure, white noise will be listened to 5 minutes before, during and 5 minutes after the heel blood collection, and therapeutic touch steps will be applied during this time.
45807001|NCT05154747|Drug|Cabotegravir, Rilpivirine Drug Combination|"Cabotegravir LA 600mg as a 3mL IM injection. The product is packaged in a 3mL USP Type I glass vial. Each vial is for single-dose use. CAB LA injectable suspension is to be stored according to the product label at room temperature (<30oC). CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol3350, mannitol, and water for injection.~Rilpivirine LA 900mg as a 3mL IM injection. Each single-dose vial contains 900mg/3mL rilpivirine. RPV LA injectable suspension should be stored according to the product label refrigerated at 2-8oC and should be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, and water for injection.~Cabotegravir Long-Acting (CAB LA) will be given IM into one buttock, and Rilpivirine Long-Acting (RPV LA) will be given IM into the opposite buttock."
45942140|NCT00280696|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Film-coated tablet~Concentration: 250 mg and 500 mg~Route of Administration: Oral Use"
45807002|NCT05154747|Drug|TLD|Dolutegravir 50mg oral with tenofovir disoproxil fumarate (245mg) and lamivudine (300mg) in a fixed dose combination or Dolutegravir 50mg oral with tenofovir alafenamide fumarate (25mg) and lamivudine (300mg) (l/TAF) oral in a fixed dose combination
45807003|NCT05154240|Drug|INS018_055|INS018_055 is a small molecule compound. INS018_055 has good solubility in water and was chemically and physically stable at different temperatures.
45807004|NCT05154240|Drug|Placebo|Placebo
45942141|NCT00076388|Drug|Gefitinib|
45942142|NCT00076388|Drug|Docetaxel|
45942143|NCT00109512|Drug|NBI-56418 (GnRH antagonist)|
45942144|NCT00109512|Drug|placebo|
45942145|NCT00280774|Drug|Memantine|
45942146|NCT00280813|Behavioral|Supportive Treatment in Addiction Recovery (STAR)|
45942147|NCT00109551|Drug|zinc sulphate dietary supplement|
45942148|NCT00109551|Drug|iron sulphate-folic acid dietary supplement|
46074927|NCT00864643|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
46074928|NCT00864643|Drug|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
45807005|NCT05151640|Drug|Nintedanib|Nintedanib
45807006|NCT05150054|Device|CardioFlux|Not an intervention
45807007|NCT05149573|Device|Pulsed Electromagnetic Field (PEMF) Device|BEMER PEMF device consists of a B. Body (full body mat), B. Pad (targeted pelvic pad), and Control Unit which powers the device. Both B. Body and B. Pad must be plugged in simultaneously into the Control Unit and activated individually. B. Body must be placed on a flat surface (e.g. floor, bed, reclining chair, etc) for best results.
45942149|NCT00280930|Drug|Letrozole|
45942150|NCT00280969|Drug|atazanavir arm|Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.
45942151|NCT00280969|Drug|efavirenz|Patients are treated with efavirenz 300mg along with Epzicom.
45942152|NCT00281008|Drug|ISIS 301012 or Placebo|50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
45942153|NCT00281008|Drug|ISIS 301012 or Placebo|100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
45942154|NCT00281008|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
45942155|NCT00281008|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
45942156|NCT00281047|Drug|FP-10|
45942157|NCT00109629|Drug|VRC-HIVDNA016-00-VP|
46074929|NCT00871039|Drug|Propofol|Patients to be sedated for up to 72 hours with study drug propofol
46074930|NCT00871039|Drug|Midazolam|Patients to be sedated for up to 72 hours with study drug midazolam
45942158|NCT00109629|Drug|VRC-HIVADV014-00|
45942159|NCT00281125|Drug|PTK787 and Pemetrexed with or without Cisplatin|
45942160|NCT00281203|Procedure|blood drawing|blood will be drawn on the entry visit and will starting the intravenous (IV) line on the day of bronchoscopy
45942161|NCT00281203|Procedure|fiberoptic bronchoscopy|A flexible instrument will be passed through the mouth and into the lungs. Portions of the lungs will be washed, by injecting and immediately suctioning out a small amount of fluid. The entire return will be used for research purposes, and no results will be reported to the participant. Bronchoscopy is performed once.
45942162|NCT00109746|Dietary Supplement|chromium picolinate|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
45942163|NCT00281242|Other|blood draw|All subjects undergo blood draws at study visits and at the time of COPD exacerbation visits.
46074931|NCT04233684|Diagnostic Test|rapid urease test|"Rapid urease test is the test for H. pylori infection by detect the change of pH by urease enzyme metabolism.~Pathologic test for H. pylori by H&E stain and Giemsa stain Gold standard is a immunohistochemistry."
46074932|NCT00867061|Drug|ON 01910.Na Concentrate|5-day continuous intravenous dosing of ON 01910.Na given every 2 weeks (1 cycle) at a dose of 800 mg/m2/day or 1500mg/m2/day for up to 24 cycles.
45655820|NCT05364905|Drug|Chemotherapy|Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
45655821|NCT04230577|Device|Real LED Intervention|A series of Real at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, 810nm (NIR), Vielight Neuro Alpha Head Frame Device (with NIR intranasal).
45655822|NCT04230577|Device|Sham LED Intervention|A series of Sham at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, Vielight Neuro Alpha Head Frame Device (with intranasal) with Sham LEDs that emit no photons. Sham and Real Devices look and feel identical.
45655823|NCT05533307|Diagnostic Test|observational analysis of mediolateral episiotomy with arizona sexuel function scoring after 3 months of normal vaginal birth|ASEX (ARİZONA SEXUEL FONCTİON SCORİNG) TEST
45655824|NCT03049267|Drug|Apremilast|Fifteen patients will be supplied of apremilast for daily oral use; 16 weeks.
45655825|NCT03049267|Drug|Placebo Oral Tablet|Five patients will be supplied with placebo tablets with identical labeling as apremilast for daily use; 16 weeks.
45655826|NCT02615509|Radiation|Imaging on experimental tomo device|The system used for imaging in the experimental arm is the Philips MicroDose tomography system. The system used for imaging in the active comparator is a standard FFDM system
45655827|NCT05524259|Dietary Supplement|Myo-inositol and routinely recommended folic acid|Participants randomly allocated to the intervention group will receive 4 grams myo-inositol added to their routinely recommended 0.4 mg folic acid supplement, divided over two daily sachets of sugary powder throughout pregnancy.
45655828|NCT05524259|Dietary Supplement|Routinely recommended folic acid|The control group will receive similar looking sachets of supplements containing only the standard dose of 0.4 mg folic acid without the added myo-inositol supplement as part of the current standard-of-care recommendation.
46074933|NCT02794740|Drug|X0002|External Spray
45655829|NCT03047317|Biological|MABp1|Single dose of intravenous MABp1
45655830|NCT05533151|Device|Respiratory muscle training|All patients will be initially educated by a physiotherapist and instructed to independently perform the home exercise program including respiratory muscle training. The training will be performed using the Airofit PRO device. This breathing training on a suitable resistance will be performed twice a day for 6 weeks. The intervention will be conducted under a researcher's supervision via smartphone App.
45655831|NCT04112095|Drug|Norgestrel 0.075 mg tablets|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 24 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet."
45655832|NCT04052971|Drug|ABN401- Escalation Phase|Dose administration: Escalation Phase The regular dose levels of ABN401 will range from 50 mg to 1800 mg QD daily for 21 days.
45676793|NCT01820559|Drug|ESL 800 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
45676794|NCT01818765|Procedure|Trans-ventricular-septal placement of LV pacing lead|
45676795|NCT01818765|Other|Pre-procedure speckle-tracking echocardiography|Assessment of site of latest mechanical activation
45807008|NCT05149573|Device|Sham Pulsed Electromagnetic Field (PEMF) Device|The sham PEMF device appears identical to the BEMER PEMF device, with all of the same components and accessories, but does not emit a pulsed electromagnetic field.
45807009|NCT05146739|Drug|Cytarabine|Given IV and IT
46074934|NCT02794740|Drug|Placebo|External Spray
46074935|NCT02543827|Biological|MV140|The subjects will receive daily dose of MV140 during 3 or 6 months
45807010|NCT05146739|Drug|Fludarabine|Given IV
45807011|NCT05146739|Drug|Leucovorin|Give PO or IV
45807012|NCT05146739|Drug|Triple Intrathecal Chemotherapy|Given IT
45807013|NCT05146739|Drug|Uproleselan|Given IV
45807014|NCT05145192|Device|COSMED K5 CPET (Cardiopulmonary Exercise Test)|In this randomized crossover trial of eligible adults, we will compare peak measurements of oxygen consumption (VO2) and carbon dioxide production (VCO2) during three maximal cardiopulmonary stress exercise tests (CPET), each seven to ten days apart. Subjects will be randomized into either the K5 or ParvoMedics (PM) group for their first CPET using a 1:1 randomization scheme and will serve as their own control in the subsequent test seven to ten days after the previous one. After both a K5 and a PM CPETs have been completed, the participants will complete an additional K5 CPET for test-retest reliability. A within-subjects analysis will be performed.
45807015|NCT05145192|Device|ParvoMedics CPET|ParvoMedics CPET
45807016|NCT05144984|Drug|NNC0480-0389|A weekly dose of NNC0480-0389, dose increased in each cohort. The study will last for about 41weeks.
45942164|NCT00279877|Procedure|Kyphoplasty|kyphoplasty
45942165|NCT04730297|Drug|paracetamol 500 mg plus codeine 30 mg preoperative administration|each patient 30 minutes before surgery received paracetamol 500 mg plus codeine 30 mg
45942166|NCT04730297|Drug|ibuprofen 400 mg preoperative administration|each patient 30 minutes before surgery received ibuprofen 400 mg
46074936|NCT02543827|Biological|Placebo|The subjects will receive daily dose of placebo during 3 or 6 months
46074937|NCT05756283|Behavioral|Multimodal Prehabilitation|"EXERCISE~Supervised exercise~High intensity interval training~Strength exercise~Home-based exercise / promotion of physical activity~Low-moderate intensity aerobic training~Inspiratory muscle training~Low-moderate intensity strength training~NUTRITION: nutrition education and optimization. Intake of 0.4g/kg of whey isolate after every supervised training.~PSYCHOSOCIAL: mindfulness, cognitive reframing and coping strategies."
45655833|NCT04052971|Drug|ABN401- Expansion Phase|"Dose administration: Expansion Phase The expansion phase of the study will use the dose and schedule determined to be most appropriate in the dose escalation portion of the study. This may be the MTD and/or the RP2D and will consist of cohorts of NSCLC patients with c-MET dysregulation.~Patients will receive ABN401 800 mg, administered orally once daily for 21 days until disease progression, unacceptable toxicity, or patient withdrawal."
46074938|NCT03834714|Device|Near Infrared Light|NIR Light Therapy will be administered with the Earlight Generation 1.4 device during 2 out of the 4 sessions. It will be administered to each ear individually for 30 minutes per ear.
46074939|NCT03834714|Other|Noise Stimulus|Noise stimulus will be administered, open ear, to continuous broadband noise up to 25% of the allowable daily dose of noise per the AFI 48-127 Occupational Noise and Hearing Conservation Program.
45807017|NCT05144984|Drug|Semaglutide|A weekly dose of semaglutide, same dose in each cohort. The study will last for about 41weeks.
45942167|NCT04730297|Drug|Placebo oral tablet preoperative administration|each patient 30 minutes before surgery received placebo
45942168|NCT00399269|Drug|Recombinant Human Erythropoietin alpha|
45942169|NCT00281281|Drug|vancomycin|
45942170|NCT00281359|Device|With heat|heat pad followed by dynamic splinting
45942171|NCT00281359|Device|No heat|No heat added to tissue prior to dynamic splinting
46074940|NCT03834714|Device|Sham Near Infrared Light|Sham NIR Light Therapy will be administered with the Earlight Generation 1.4 device during 2 out of the 4 sessions. It will be administered to each ear individually for 30 minutes per ear.
46074941|NCT05756205|Device|Immersive Virtual Reality (IVR)|"The intervention will consist of an Immersive Virtual Reality (IVR) application with virtual reality goggles Oculus GO, to reduce anxiety during pregnancy. This application lasts 14 minutes by the use of mindfulness techniques based on breathing, mindfulness and passive muscle relaxation. It consists of three modules that can be chosen completely or separately.~The aspects that conform this intervention will be: information about, the most common perinatal mental health problems, exercises based on attention to breathing (mindfulness-relaxation), 6 weeks of duration, for 14 minutes a day, knowledge from involved personnel of the number of times the woman has connected and the time she has done the exercise, satisfaction questions to pregnant women after pregnancy, alerts to notify the principal investigator if there is a problem with e-health, and, finally, an email address to contact the principal investigator."
46074942|NCT02794662|Procedure|Oxygen Environment|FiO2 delivered by servo-controlled incubator
46074943|NCT02794662|Procedure|Nasal Cannula Oxygen|FiO2 delivered by nasal cannula
46074944|NCT00864799|Drug|Misoprostol|Comparison of 3 routes of administration of misoprostol for termination of pregnancy 14-24 weeks
45655834|NCT05524181|Other|Telehealth Integrated Primary Care (TIPC)|The TIPC model of intervention incorporates video visits across research clinicians and patients' existing care clinicians for more synergized and accessible care provision for a given clinical indication. The first TIPC visit will center around the patient setting care goals for themselves and their caregiver with the help of a palliative care physician. The second TIPC visit will focus on assessing goal attainment and also close the care loop between their existing care team, a research-appointed palliative care team, and their involvement in the study.
45676796|NCT01818765|Other|Acute response assessment|Cardiac output monitoring
45807018|NCT05144984|Drug|Placebo (NNC080-0389)|A weekly dose of placebo (NNC0480-0389). The study will last for about 41weeks.
45807019|NCT05144984|Drug|Placebo (semaglutide)|A weekly dose of placebo (semaglutide). The study will last for about 41weeks.
45807020|NCT05144243|Drug|Venetoclax|Tablet: Oral
45807021|NCT05144243|Drug|Azacitidine|Subcutaneous Injection (SC)
45807022|NCT05143281|Drug|Dexamethasone 0.4 MG [Dextenza]|Ophthalmic Intracanalicular Insert
45807023|NCT05140174|Other|Radical Healing and Internalized Stigma (RHIS) Training|8-hour RHIS training includes, readings that discuss radical healing and internalized stigma, access to didactic information regarding radical healing and internalized stigma. Therapists will role play certain scenarios that may involve minority stress experiences and discuss with the trainers different types of responses that could be therapeutic. The training will focus on the most up to date research regarding transgender mental health, minority stress, radical healing, and role-plays that focus on these processes.
46074945|NCT04234776|Drug|Ketamine|(0,75 mg/kg) saline solution (15 mg) Escitalopram (5 mg) Aripiprazole
46074946|NCT04234776|Diagnostic Test|Cognition|Composite tools
45942172|NCT00281398|Behavioral|Questionnaire|
46074947|NCT04234776|Other|Suicide risk|MADRS (10) and HAM-D (3)
46074948|NCT04234776|Other|Depression thoughts|EPD
45942173|NCT00109785|Procedure|positron emission tomography|
45942174|NCT00109785|Radiation|fludeoxyglucose F 18|
45942175|NCT00109785|Radiation|iodine I 124 iododeoxyuridine|
45942176|NCT00281437|Behavioral|choice of exercise program|
46074949|NCT04234776|Other|Quality of life and disability|Quality of life and disability
46074950|NCT04234776|Other|Clinical and epidemiological factors|Variables and categories
46074951|NCT04234776|Device|Safety of ketamine IM|Vital signs
45942177|NCT00281476|Drug|Simvastatine|
46074952|NCT04234776|Other|Tolerability of ketamine IM|UKU-SERS, YOUNG, CADSS and BPRS-12.
45942178|NCT00416923|Biological|rituximab|
45942179|NCT00416962|Drug|amantadine hydrochloride|
45942180|NCT00416962|Drug|oseltamivir phosphate|
45942181|NCT00109824|Drug|decitabine|Given IV
45942182|NCT00109824|Drug|valproic acid|Given PO
45942183|NCT00109824|Other|pharmacological study|Correlative studies
45942184|NCT00109824|Other|laboratory biomarker analysis|Correlative studies
45942185|NCT00417001|Procedure|Aroma therapy|
45942186|NCT00417040|Other|internet-based intervention|Use the STAR database system
45942187|NCT00417040|Other|assessment of therapy complications|Use the STAR database system
45942188|NCT00417040|Other|Questionnaire Administration|Ancillary studies
45942189|NCT00109863|Biological|hu14.18-IL2 fusion protein|
45942190|NCT00281515|Drug|Lonafarnib|100mg/twice a day during chemotherapie,in maintenance phase 200 mg twice a day
45942191|NCT00281554|Drug|RSD1235|IV
45655835|NCT05257993|Drug|JPI-547|"Subjects are administered this investigational product once a week for 5 days, and have wash-out period for 2 days (5 Days on-2 Days off).~The investigational product is administered orally in a fasting state for 2 hours before and after meals at the same time (e.g., a certain time in the morning).~Capsules should be swallowed whole and should not be chewed, crushed or split."
45655836|NCT05257993|Drug|modified FOLFIRINOX|"After IV administration of Oxaliplatin 65 mg/m2 for 2 hours~After IV administration of Leucovorin 400 mg/m2 for 2 hours + IV administration of Irinotecan 135 mg/m2 for 90 minutes (Irinotecan is started 30 minutes after the start of Leucovorin administration and administered simultaneously during the last 90 minutes of Leucovorin administration, but administered separately using a Y-connector without mixing)~Continuous IV infusion of 5-FU 2400 mg/m2 for 46 hours~Repeated administration every 2 weeks on a 14-day cycle"
45655837|NCT05257993|Drug|Gemcitabine-nab-paclitaxel|"After IV administration of nab-paclitaxel 100 mg/m2 for 30 minutes~IV administration of Gemcitabine 1000 mg/m2 for 30 minutes~Administration on Days 1, 8, and 15 on a 28-day cycle"
45655838|NCT05533073|Drug|A1: Etoricoxib / Tramadol Fixed dose combination|Sachet with granules (Laboratorios Silanes S.A. de C.V.). Formula : 90 mg/ 50 mg Pharmaceutical Form: Sachet with granules Dosage: 100 mL (90 mg/ 50mg) Administration way: oral
45807024|NCT05139238|Drug|Labetalol|Intravenous labetalol, a short acting ant-hypertensive
45807025|NCT05139238|Drug|Nifedipine|Oral nifedipine, a short acting ant-hypertensive
45807026|NCT05138614|Other|Medication for Opioid Use Disorder|medication management
46074953|NCT05756049|Other|compare antibiotic duration of therapy|To compare antibiotic duration of therapy before and after the implementation of the PCT protocol in the ICU.
46074954|NCT00871273|Drug|capecitabine|film-coated tablet 1250 mg/m2 twice daily 14 days for 14 days. Number of cycles: 3 cycles pre-operatively and 3 cycles post-operatively unless there is evidence of disease progression on chemotherapy
46074955|NCT05755971|Other|Combination taping|Elastic and rigid tapes applied together for six weeks
46074956|NCT00867295|Drug|cefazolin Sodium|cefazolin Sodium 1g i.v. before operation
46074957|NCT00867295|Drug|placebo|placebo
46074958|NCT04200144|Device|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty with Overstitch (Apollo Endosurgery)
46074959|NCT00867373|Behavioral|Education Intervention|The intervention is a short educational handout regarding BMI and the effect of parental weight status on children.
45942192|NCT00109941|Biological|opioid growth factor|OGF was administered in saline at 250 ug/kg intravenously over 45 minutes
45942193|NCT00109941|Biological|metenkephalin, OGF-opioid growth factor|OGF given in saline iv 250 ug/kg weekly
45942194|NCT00281593|Drug|Telmisartan|
45942195|NCT00281593|Drug|Ramipril|
45942196|NCT00281710|Drug|Methylprednisolone|
46074960|NCT04031001|Device|No-React Non-valved Conduit|Operative replacement of infected graft or implantation in infected area.
46074961|NCT03831516|Diagnostic Test|Non Invasive Electroanatomical Mapping|All patients will undergo non contrast CT chest and be fitted with the Medtronic CardioInsight wearable 252 electrode vest. Non invasive electroanatomical maps of the ventricular arrhythmia will be created. All patients will be then brought to the electrophysiology laboratory and undergo an invasive electrophysiology study and ablation of the ventricular arrhythmia.
45655839|NCT05533073|Drug|A2: Etoricoxib|Arcoxia®, Schering Plough S.A. de C.V. A2: Pharmaceutical Form: Tablet Formula: 90 mg Dosage: 1 tablet of 90 mg Administration way: oral
45655840|NCT05533073|Drug|A3: Tramadol|Tradol®, from Grünenthal GMBH. Pharmaceutical Form: Capsule Formula: Each capsule contains 50 mg Dosage: 1 capsule of 50 mg Administration way: oral
45655841|NCT04050553|Drug|Tirzepatide|Administered SC
45655842|NCT04050553|Drug|Placebo|Administered SC
45807027|NCT05138614|Behavioral|MISSION Critical Time Intervention|offering intensive community-based services that decrease in intensity over time
45807028|NCT05138614|Behavioral|MISSION Peer Support|including 11 recovery-oriented sessions from someone with lived experience of co-occurring disorders
45942197|NCT00076544|Drug|Ziconotide|
45942198|NCT00281749|Procedure|TELEPHONE CALL|
45942199|NCT00281788|Drug|capecitabine|
45942200|NCT00281788|Drug|carboplatin|
45942201|NCT00281788|Drug|paclitaxel|
45942202|NCT00281788|Radiation|radiation therapy|
45942203|NCT00281866|Drug|erlotinib hydrochloride|
45807029|NCT05138614|Behavioral|MISSION Dual Recovery Therapy|comprised of 13 structured co-occurring disorders treatment sessions
45655843|NCT03946891|Drug|Inhaled Furosemide|Subjects in the A arm will receive 1 mg/kg of inhaled furosemide Q 24 hours for 3 days. This will be followed by a washout period of a day followed by 1 mg/kg of intravenous furosemide Q 24 hours for 3 days.
45655844|NCT03946891|Drug|Intravenous Furosemide|Subjects in the B arm will receive 1 mg/kg of intravenous furosemide Q 24 hours for 3 days followed by a washout period, which is then followed by 1 mg/kg of inhaled furosemide Q 24 hours for 3 days.
45942204|NCT00281905|Drug|carboplatin|
45655845|NCT05524103|Drug|ALMB-0166|A single dose of ALMB-0166 injection.
45655846|NCT05257915|Drug|Perampanel|"For patients ≥12 years old, the initial dose is 2 mg/d, and according to the clinical response and tolerance of the patient, the dose is increased to the minimum clinically effective dose in increments of 2 mg, and the interval between dose increases is not less than 2 weeks.~For patients <12 years, according to the actual clinical situation, the initial dose and addition plan are judged by the investigator."
45807030|NCT05132439|Drug|Metformin ER|Oral medication typically used for Type 2 diabetes with presumed anti-inflammatory properties
45807031|NCT05132439|Drug|placebo|Matched to active study drug
45807032|NCT05132088|Drug|semaglutide 50 mg|"Participants will have semaglutide for 68 weeks and will have 1 tablet every morning.~Dose gradually increased to 50 mg."
46074962|NCT05227807|Behavioral|mouth opening exercise|The intervention group receives an oral exercise intervention, including a 30-minute individual training, a multimedia oral exercise education video along with a print education booklet, and three follow-up phone calls.
45942205|NCT00281905|Drug|cisplatin|
46074963|NCT05227807|Behavioral|Usual care|routine care including written mouth exercise instructions
46074964|NCT02794506|Drug|Propolis|Propolis capsules was taken by the experimental group for 6 months after receiving scaling and root planing (SRP).
46074965|NCT02794506|Drug|Placebo|Placebo capsules was taken by the control group for 6 months after receiving scaling and root planing (SRP).
46074966|NCT04040491|Drug|PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine|PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Gemcitabine is a cytosine nucleoside derivative, its main metabolite incorporates into DNA in cells and mainly acts on G1 / S phase.
45458039|NCT03503110|Other|dRMI|The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
45655847|NCT04300049|Drug|Glucagon Infusion|Study participants will receive glucagon infusion (6ug/kg/min for 12 hours) 12 hours.
45655848|NCT04300049|Other|Saline|Study participants will receive saline infusion for 12 hours.
45942206|NCT00281905|Drug|cyclophosphamide|
45942207|NCT00281905|Drug|methotrexate|
45942208|NCT00281905|Drug|vincristine sulfate|
45942209|NCT00281905|Radiation|radiation therapy|
46074967|NCT02794584|Drug|sufentanil anesthesia|Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
45676797|NCT01850589|Other|Aggressive Therapy|"Pharmacotherapy adjuncts offered at no cost are as follows:~Chantix (varenicline) GlaxoSmithKline,~Zyban (bupropion) Pfizer,and Nicoderm/Nicorette (nicotine nasal spray, inhaler, transdermal patches and gum) GlaxoSmithKline."
45676798|NCT01818531|Drug|Adductor canal block|
45807033|NCT05132088|Drug|placebo (semaglutide)|Participants will have placebo tablets for 68 weeks and will have 1 tablet every morning.
45807034|NCT05130190|Device|RF Treatment|ProVu treatment probe will be energized and RF energy delivered in a pre-programmed, controlled method based on the predetermined size of the affected tissue.
45807035|NCT05127850|Behavioral|Consultation audio recording app|Smartphone or tablet mobile application which allows for voice recording
45807036|NCT05126173|Device|Deep Ensemble for the Recognition of Malignancy (DERM)|An AI-based diagnosis support tool
45807037|NCT05123599|Drug|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously.
45807038|NCT05123599|Biological|JNJ-64300535|JNJ-64300535 deoxyribonucleic acid (DNA) vaccine injection will be administered intramuscularly.
45807039|NCT05123599|Drug|ETV monohydrate|ETV monohydrate film-coated tablets will be administered orally.
45942210|NCT00110058|Biological|recombinant interferon alfa|
45942211|NCT00110058|Biological|therapeutic allogeneic lymphocytes|
45942212|NCT00110058|Drug|cyclosporine|
45942213|NCT00110058|Drug|fludarabine phosphate|
45942214|NCT00110058|Drug|imatinib mesylate|
45942215|NCT00110058|Drug|mycophenolate mofetil|
45942216|NCT00110058|Procedure|peripheral blood stem cell transplantation|
45942217|NCT00110058|Radiation|radiation therapy|
45655849|NCT05257837|Behavioral|Gun handling behavior|Children will play in an observed room for 20 minutes. Aside from a selection of toys, two real handguns will be placed in a drawer. The handguns have been modified so they cannot fire. Inside the magazine, the handgun contains no bullets. Instead, it contains a sensor that counts the number of times the trigger is pulled with sufficient force to discharge the gun. This allows us to distinguish reliably the children who pull the trigger from those who handle the gun but do not pull the trigger
45655850|NCT05257837|Other|Debriefing|Children and their parents will be debriefed on the actual purpose of the study, including the role of the safety video and how the movie clips were edited.
45942218|NCT00281944|Drug|oxaliplatin|Given IV
45942219|NCT00281944|Drug|fluorouracil|Given IV
45807040|NCT05123599|Drug|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablets will be administered orally.
45942220|NCT00281944|Drug|leucovorin calcium|Given IV
45942221|NCT00281944|Other|pharmacological study|Correlative studies
45655851|NCT05166629|Behavioral|Eatable Alphabet|Eatable Alphabet is a set of kitchen activity cards developed by ChopChop Family, in collaboration with the American Academy of Pediatrics, with funding from the CDC (https://www.chopchopfamily.org/eatable-alphabet/). It includes a series of alphabet cards with family-friendly recipes.
45655852|NCT05166629|Behavioral|Usual Care|Please see above description of usual care.
45655853|NCT04870723|Behavioral|eHealth for Covid-19 prevention and support|3-session online peer-counseling intervention based on motivational interviewing and psychoeducation
45942222|NCT00281944|Procedure|positron emission tomography|Undergo PET scan
45942223|NCT00281944|Procedure|computed tomography|Undergo PET/CT scan
45942224|NCT00281983|Biological|alemtuzumab|
45942225|NCT00281983|Biological|anti-thymocyte globulin|
45942226|NCT00281983|Biological|filgrastim|
45942227|NCT00281983|Biological|rituximab|
45942228|NCT00281983|Biological|therapeutic allogeneic lymphocytes|
45942229|NCT00281983|Drug|busulfan|
45942230|NCT00281983|Drug|cyclophosphamide|
45458040|NCT01140607|Drug|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
45458041|NCT02305810|Drug|Everolimus 10 mg daily|everolimus is a recently approved mTOR inhibitor in advanced progressing well/moderately differentiated pancreatic neuroendocrine tumors
45655854|NCT05527145|Procedure|Minimally invasive surgery|Surgery with decompression. Central decompression of the stenotic segment with undercutting of the lateral recesses.
45655855|NCT05527145|Procedure|Percutaneous Spacer|percutaneous image guided outpatient procedure that enables interspinous spacer insertion and fusion
45655856|NCT04870879|Procedure|Liver Transplant|Liver Transplant from cadaveric donors
45655857|NCT04870879|Drug|Chemotherapy|Chemotherapy
45676799|NCT01818531|Drug|Lumbar plexus block|
45807041|NCT05123599|Drug|TAF|TAF film-coated tablets will be administered orally.
45807042|NCT05120141|Other|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
45807043|NCT05120141|Other|American Dental Association (ADA) Ref Toothbrush|Participants will use soft bristled Toothbrush for brushing teeth twice daily.
45807044|NCT05120141|Other|Prototype 1 Mouth Rinse|Participants will use 20 mL of Prototype 1 Mouth Rinse for 30 seconds after brushing twice daily.
45807045|NCT05120141|Other|Prototype 2 Mouth Rinse|Participants will use 20 mL of Prototype 2 Mouth Rinse for 30 seconds after brushing twice daily.
45942231|NCT00281983|Drug|cyclosporine|
45942232|NCT00281983|Drug|fludarabine phosphate|
45942233|NCT00281983|Drug|methotrexate|
45942234|NCT00281983|Drug|mycophenolate mofetil|
45942235|NCT00281983|Procedure|peripheral blood stem cell transplantation|
45942236|NCT00281983|Radiation|radiation therapy|
45942237|NCT00282022|Drug|laromustine|
45942238|NCT00282061|Drug|Melatonin|
45942239|NCT00282100|Drug|Gefetinib (Iressa)|
45942240|NCT00282139|Drug|Aripiprazole|
45942241|NCT00110253|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel is composed of a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine, which was applied topically. The S Caine Peel was applied at approximately 1 mm in thickness and remained on the treatment area for 30 or 60 minutes
45942242|NCT00282178|Drug|Hydrochlorothiazide|25-50 mg once daily
45942243|NCT00282178|Drug|Placebo|Once daily
45942244|NCT00282178|Drug|Candesartan|16-32 mg once daily 12 weeks
45655858|NCT03849625|Drug|aspirin, NSAIDs, paracetamol|Perform skin test and/or provocation test with aspirin, paracetmol, or suspected NSAIDs in questionable cases
45655859|NCT03046849|Other|next-generation sequencing|Use next-generation sequencing to test germline mutation.
45655860|NCT03046693|Drug|Group A Citicoline 1000 mg oral tablet|Citicoline 1000 mg will be repackaged and given to Group A for 60 days
45655861|NCT03046693|Drug|Group B placebo oral tablet|Placebo will be repackaged and given to Group B for 60 days
45942245|NCT00282217|Drug|Sirolimus|
45655862|NCT05257369|Device|Blue-Green LED photoherapy|Continuous phototherapy for 24 h, for newborns placed incubators or radiant warmers will interrupted only for feeding and nursing for 20 - 30 min every three hours.
45655863|NCT04632329|Device|Negative Pressure Treatment via the Mercury Multi-Pressure Dial|Negative Pressure Treatment via the Mercury Multi-Pressure Dial
45655864|NCT03327493|Diagnostic Test|Biological|"We will assess in all patients under ECLS for the treatment of a cardiogenic shock at day 0 (ECLS initiation) day 3 and day ECLS weaning :~Biological assessment:~Adrenoreceptors α1, α2, β1, β2, β3 on monocytes and lymphocytes T helper by flow cytometry~Lymphocytes Th1/Th2 pattern by flow cytometry~Cytokines on plasma : Interleukin (IL) 4, IL 12, TNF α, INF γ , IL1, IL6, IL10~Clinical assessment:~Hemodynamic parameters~Cumulated doses of catecholamines~Cardiac output variation measured by echocardiography during a standardized weaning procedure of ECLS at a constant mean arterial pressure (only on day 3 and Day ECLS weaning)"
45655865|NCT05523791|Dietary Supplement|Fortiral|Twice a day, patients took 10 g of powder containing 92.5% whey protein with 2.7% cysteine; emulsifier: soy lecithin, lactose free to be reconstituted with 150-200 ml of water.
45942246|NCT00282373|Device|mild hypothermia|
45655866|NCT05523791|Dietary Supplement|Mg++|Twice a day, patients took 2.250g of magnesium pidolate (=184 mg of Magnesium++ ione) powder twice a day to be reconstituted with 150-200 ml of water
45655867|NCT03049345|Procedure|Sentinel Lymph Node Sampling|The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Sentinel lymph nodes and resected specimens will be analyzed by permanent section.
45807046|NCT05120141|Other|Prototype 3 Mouth Rinse|Participants will use 20 mL of Prototype 3 Mouth Rinse for 30 seconds after brushing twice daily.
45807047|NCT05120141|Other|Listerine Cool Mint Mouth Rinse|Participants will use 20 mL of Listerine Cool Mint Mouth Rinse for 30 seconds after brushing twice daily.
45942247|NCT00282451|Drug|biphasic insulin aspart|
45942248|NCT00282451|Drug|insulin aspart|
45942249|NCT00282490|Device|Nerve stimulator|
45807048|NCT05120141|Other|Hydroalcohol Mouth Rinse|Participants will use 20 mL of Hydroalcohol Mouth Rinse for 30 seconds after brushing twice daily.
45942250|NCT00282529|Device|High Risk Lymphedema Education and Device Intervention|
45942251|NCT00282607|Drug|DA-8159|
45942252|NCT00282646|Procedure|intraarterial stem cell therapy|catheter delivery of stem cells
45942253|NCT00282646|Other|Stem cells|intraarterial application of bone marrow mononuclear cells versus placebo
45655868|NCT03049345|Drug|Radioactive Tracers|see above
45655869|NCT03049345|Drug|Methylene Blue 20 MG/ML|see above
45807049|NCT05119907|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
45807050|NCT05119231|Procedure|Pulmonary Vein Isolation|Catheter ablation (radiofrequency ablation or cryoablation) of atrial fibrillation according to local standard
45807051|NCT05119231|Other|Sham-Pulmonary Vein Isolation|Sham-Pulmonary Vein Isolation in deep sedation for at least one hour including femoral vein/artery puncture with introduction of sheaths and electrical cardioversion in presence of current atrial fibrillation
45807052|NCT05116735|Procedure|laparoscopic partial cystectomy with omentoplasty|laparoscopic partial cystectomy with omentoplasty
45942254|NCT00282685|Procedure|Intraarterial bone marrow progenitor cell transplantation|catheter delivery of stem cells
45942255|NCT00282724|Drug|Liarozole|
45942256|NCT00110292|Behavioral|Age-specific parenting newsletters and developmental toys|
46074968|NCT02794584|Procedure|Hybrid closure|Hybrid closure of ventricular septal defects through the delivery system without cardiopulmonary bypass by transthoracic minimally invasive small incision.
45942257|NCT00110292|Behavioral|Parent-completed Ages & Stages Questionnaires|
45942258|NCT00110292|Behavioral|Clinic-based distribution of children's books|
45942259|NCT00282763|Drug|MK0686|
45942260|NCT00282958|Drug|Botulinum Toxin type a (Botox)|
45942261|NCT00282997|Drug|pregabalin|
45942262|NCT00283036|Drug|Irbesartan|
45942263|NCT00076817|Biological|ALVAC-HIV (vCP205)|Canarypox virus vector vaccine
45942264|NCT00076817|Biological|ALVAC-HIV (vCP205)|Canarypox virus vector vaccine placbo
45942265|NCT00110370|Drug|Lispro Mixture Therapy|
45942266|NCT00110370|Drug|Glargine Basal-Bolus Therapy|
45942267|NCT00283114|Drug|lintuzumab|1.5 - 8 mg/kg IV (in the vein) on Days 1, 8, 15, 22 and 29 of Cycle 1; 1.5 - 8 mg/kg IV (in the vein) every other week for all subsequent cycles
45942268|NCT00283153|Behavioral|Facial Affect Recognition Training|A series of pictures of faces displaying various emotions are presented one at a time using a computerized training program.Participants are taught to recognize how emotions affect facial features such as the mouth and eyes.Participants are also taught how to recognize their own emotions.
46074969|NCT02794584|Procedure|Control|Surgical closure of ventricular septal defects with cardiopulmonary bypass by routine open thoracotomy.
46074970|NCT05227651|Drug|AK104|IV infusion,Specified dose on specified days
46074971|NCT02794272|Device|tDCS|
45807053|NCT05116163|Behavioral|Individuation Intervention plus implicit bias educational modules|"Providers in the intervention are will be instructed to watch a brief set of freely available educational lessons and then they will meet with study team members to discuss their individuation countermeasure intervention. Providers will be given a choice of several individuation-related questions to better understand the unique characteristics of each patient. Once the provider decides on his/her choice phrases, the research team will assist with the development of a smart phrase (also called dot phrase) to allow them to incorporate this into a note. Once a week, providers in the intervention arm will receive an email reminding them to incorporate this question and the documentation into their encounters."
45942269|NCT00283153|Other|Stories of Emotional Inference|Participants are presented with a series of short stories one at a time. Each story presents various contextual cues regarding the emotions the characters are likely to experience. Participants learn to connect the cues to specific emotions.
46074972|NCT02794272|Device|sham-tDCS|
46074973|NCT00864877|Device|biodegradable fixation system (Inion OTPS FreedomPlateTM)|
46074974|NCT00811473|Drug|Quetiapine XR|Oral treatment with 150 up to 300 mg/day once daily in the evening
46074975|NCT00811473|Drug|Placebo|Oral treatment once daily in the evening
45942270|NCT02960581|Biological|PGT121 3mg/kg IV|3mg/kg administered by IV Infusion
45942271|NCT02960581|Biological|PGT121 10mg/kg IV|10mg/kg administered by IV infusion
45942272|NCT02960581|Biological|PGT121 30mg/kg IV|30mg/kg administered by IV infusion
46074976|NCT02788500|Other|Incidence of sports-related injuries and illnesses|The SRIIP-study is an epidemiological cohort study aimed to prospectively collect self-report data on sports-related injuries and illnesses incidence and risk exposure during training and competition for approximately one year among Swedish para-athletes.
46074977|NCT00864955|Radiation|UVA and UVB irradiation|"4 cutaneous biopsies for Ex-vivo irradiation~Determination of the minimal erythemic dose of UVA and UVB for each volunteer"
46074978|NCT02789748|Device|Kinesthetic stimulation|Activation of mechanoreceptors by vibration bursts
46074979|NCT00871507|Drug|JNJ-38431055 Dose 1|Liquid suspension/solution of JNJ-38431055 administered as a single dose
45655870|NCT02575079|Device|Parafilm|Single-use, pre-cut sections of parafilm over the central venous catheter (CVC) hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC until it is removed.
45655871|NCT05526911|Drug|TBAJ-876|"Day 6 to Day 13: 200 mg TBAJ-876 oral suspension, fed~Day 14 to Day 19: 165 mg TBAJ-876 oral suspension, fed~Day 20 and Day 21: 200 mg TBAJ-876 oral suspension, fasting~Day 22 to Day 24: 150 mg TBAJ-876 oral suspension, fed"
45655872|NCT05526911|Drug|TBAJ-876|"Day 6 to Day 13: 200 mg TBAJ-876 oral suspension, fed~Day 14 to Day 19: 165 mg TBAJ-876 oral suspension, fed~Day 20: 200 mg TBAJ-876 oral suspension, fasting~Day 21 to Day 24: 150 mg TBAJ-876 oral suspension, fed"
45655873|NCT05526911|Drug|Midazolam|Day 1 and Day 20: Midazolam oral syrup: 2 mg, fasted
45655874|NCT05526911|Drug|Digoxin|Day 2 and Day 21: Digoxin tablet: 0.25 mg, fasted
45655875|NCT05526911|Drug|TLD|Day 1 and Day 20: fixed dose combination of dolutegravir 50 mg + tenofovir disoproxil fumarate 300 mg + lamivudine 300 mg, fasted
45655876|NCT03046771|Behavioral|Transport PLUS group|The Transport Plus EMTs will offer to perform the FHA and DCA for all transports of patients aged 65 or older, who are being transported from The Mount Sinai Hospital to a private residence.
45655877|NCT03048175|Procedure|Wisdom tooth removal|After inferior dental and buccal nerve anesthesia a triangular full thickness flap with releasing incision on the mesio-buccal aspect of the second molar is designed. Ostectomy is then performed and tooth is sectioned and gently elevated. Once all the tooth components are extracted, the socket is carefully inspected and flap is sutured with interrupted sutures.
45942273|NCT02960581|Biological|PGT121 3mg/kg SC|"3mg/kg administered by SC injection~Placebo: None"
45942274|NCT02960581|Biological|Placebo (0.9% Sodium Chloride Injection USP (Saline))|
45942275|NCT00076856|Drug|Temozolomide|
45655878|NCT04870489|Combination Product|Isotretinoin and CO2 laser|Patients must complete at least 2 months of Isotretinoin prior to starting the study and then continue it for the duration of the 3 months of treatment with the CO2 laser.
45942276|NCT00110409|Behavioral|Asthma Education in Adults|The intervention involves enhancing asthma education, asthma self-efficacy and asthma-related social support and is administered during a single in-person session in the ED (or hospital for admitted patients) followed by telephone reinforcement.
45942277|NCT00110409|Behavioral|Standard Emergency Room Asthma Education|Participants will receive standard emergency room education about asthma.
45942278|NCT00283192|Drug|Sertraline|
46074980|NCT00871507|Drug|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose.
46074981|NCT00871507|Drug|Placebo|Placebo suspension/solution and Placebo capsule administered as single doses
46074982|NCT00871507|Drug|JNJ-38431055 Dose 2|Liquid suspension/solution of JNJ-38431055 administered as a single dose
46074983|NCT02789826|Procedure|Laparoscopic gastrectomy|Patients allocated to the 'laparoscopic gastrectomy' arm will receive gastrectomy via laparoscopy.
46074984|NCT02789826|Procedure|Open gastrectomy|patients allocated to the 'Open gastrectomy' group will receive gastrectomy via laparotomy
46074985|NCT05094141|Other|Virtual reality|Virtual reality game
46074986|NCT02793960|Drug|topical BPM31510 3.0% Cream|Application of drug to lesions of epidermolysis bullosa
46074987|NCT00865033|Drug|Metformin HCL Tablets, 1000 mg Sandoz|
46074988|NCT00865033|Drug|Glucophage 1000 mg|
46074989|NCT04234932|Drug|Netarsudil Ophthalmic|Topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution (Rhopressa and Roclatan)
46074990|NCT00871663|Drug|SCH 727965|Dose escalation of SCH 727965 IV administered in 28-day cycles, on Days 1, 8, and 15 of each 28-day cycle.
46074991|NCT00867607|Drug|MRX-6|b.i.d treatment for 21 days
45655879|NCT04870489|Device|Co2 laser|After 6-12 months of no treatment for acne the patient comes to do second side of face only laser treatment
45655880|NCT02574845|Drug|Rosuvastatin|
45655881|NCT02574845|Drug|Metformin HCl|
45655882|NCT02574845|Drug|Furosemide|
45942279|NCT00283231|Behavioral|Paced Respiration|
45655883|NCT05526833|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed on the scalp of the subject's head. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in speech perception.
45655884|NCT05526677|Device|x-guide dynamic navigation system|One implant placement is assisted with x-guide dynamic navigation system. The other implant placement is assisted with static surgical guide
46074992|NCT00867607|Drug|Steroid|b.i.d. 21 days
45655885|NCT05349227|Behavioral|Digital Health Coaching Program|Coaching consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
45807054|NCT05116163|Other|Implicit bias educational modules|Providers in the comparator arm will be given the same implicit bias educational modules to complete.
46074993|NCT02794350|Device|Cochlear implant|
46074994|NCT00876109|Drug|GDC-0941|GDC-0941 will be administered in escalating oral doses QD or BID in Groups A and B, respectively. In Group C, the dose/regimen will be determined on the basis of data from Groups A and B. The overall starting dose will be 15 mg administered in the first cohort enrolled in Group A.
45655886|NCT05349227|Device|Fitbit|Device: Fitbit A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
46074995|NCT04234074|Device|Volusense paediatric monitoring device|Comparison of Volusense paediatric monitoring device to full cardiorespiratory polysomnography.
45655887|NCT05532761|Other|self-administered questionnaires|"In order to describe the experience of CAR-T cell therapy of DLBCL patients, a pharmaceutical follow-up is carried out the day before the injection (baseline) and at 1, 3, 6, 9, 12 and 18 months. These follow-ups consist of interviews with the patient and the delivery of self-administered questionnaires. The interviews will investigate drug consumption, the use of self-medication and complementary alternative therapies and the adverse effects of interest. The self-questionnaires will focus on exploring multidimensional quality of life, social and professional life, anxiety-depression or uncertainty tolerance through internationally validated questionnaires.~No supplementary visits will be needed : interviews with the research team will occur at the end of hematologic consultations."
45655888|NCT04301453|Other|Maternal Scent|Mothers will wear a breast pad during their visit. The breast pad will be placed in the hats of infants for 24 hours.
45655889|NCT05336123|Behavioral|Hatha Yoga|Weekly hatha yoga classes lasting 10 weeks.
45655890|NCT05336123|Behavioral|Health Education|Weekly health education classes lasting 10 weeks.
45655891|NCT02614183|Drug|Galcanezumab|Administered SC
45655892|NCT02614183|Drug|Placebo|Administered SC
45655893|NCT05523011|Drug|Exosome ointment|100 µg MSC exosomes/g ointment
45655894|NCT05522933|Other|4 weekly musculoskeletal health promotion workshops with stretching and muscle-strengthening exercise|The modified online multidimensional musculoskeletal health promotion program will consist of 4 weekly workshops for 90-minute each for a group size of 8-12 participants. The topics of the workshop are: (1) exercise and health & work; (2) prevention of musculoskeletal problems; (3) musculoskeletal health and traditional Chinese medicine; and (4) mental health and community resources. Each workshop will consist of stretching and muscle strengthening exercises (30 minutes), a health education topic (about 45 minutes), and a question-and-answer period (about 15 minutes).
45655895|NCT05334485|Drug|Pyridostigmine Bromide|Oral 60mg pyridostigmine bromide
45655896|NCT05334485|Other|Placebo|Oral starch placebo
45655897|NCT05526209|Procedure|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia
45807055|NCT05114798|Behavioral|Time restricted eating|daily ad libitum food intake, 8-h 12pm - 8pm, 6 m active weight loss phase; 10-h 10am-8pm, 6 m maintenance phase
45807056|NCT05114798|Behavioral|Calorie Restriction|daily 25% calorie restriction, 6 m active weight loss phase; 100% energy needs, 6 m maintenance phase
45807057|NCT05111626|Drug|Bemarituzumab|Bemarituzumab will be administered as intravenous (IV) infusion.
45807058|NCT05111626|Drug|Nivolumab|Nivolumab will be administered as IV infusion.
45942280|NCT00283270|Behavioral|Brief counselling|
45942281|NCT00283270|Behavioral|Behavior|
45942282|NCT00283309|Drug|Memantine|
45942283|NCT00283309|Drug|Riluzole|
45807059|NCT05111626|Drug|mFOLFOX6|5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion.
45807060|NCT05111626|Other|Placebo|Placebo will be administered as IV infusion.
45807061|NCT05109975|Drug|Debio 0123|Debio 0123 orally during 21-day treatment cycles.
45942284|NCT00401466|Device|Implantable Cardioverter Defibrillator|ICD with Biotronik Home Monitoring capability
45942285|NCT00076934|Drug|RG2077 (CTLA4-IgG4m)|RG2077
45942286|NCT00417157|Drug|recombinant FSH (Puregon, Organon, The Netherlands)|
45942287|NCT00417157|Drug|GnRH antag: Ganirelix (Orgalutran, Organon, The Netherlands)|
45942288|NCT00417157|Drug|hCG (Pregnyl, Organon, The Netherlands)|
45942289|NCT00283426|Drug|Soluble beta-1,3/1,6-glucan|
45942290|NCT00283465|Drug|Epoetin alfa|
45942291|NCT00283543|Drug|Gliadel Wafer|
45942292|NCT00283543|Drug|Temozolomide|
45942293|NCT00283543|Procedure|Limited field radiation|
45942294|NCT00283582|Drug|rhTPO|
45942295|NCT00077012|Drug|QLT0074|
45942296|NCT00077012|Drug|Photodynamic therapy|
45942297|NCT00283621|Drug|Aranesp (darbepoetin alfa)|
45942298|NCT00283621|Drug|Neulasta (pegfilgrastim)|
46074996|NCT04040803|Device|Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS)|Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS) are two (CE marked medical devices) new, non-invasive (over the scalp) brain stimulation (NIBS) techniques. Both tACS and tRNS deliver a weak current continuously across the brain using pads placed over the scalp, which has been shown safe and well-tolerated by healthy adults and patients. These two techniques are able to softly alter physiological function within the brain. tACS can influence the brainwaves which have been demonstrated to play important roles in movement, sensation, and thinking functions. tACS and tRNS have been investigated for several years and have been shown to be safe, well tolerated and produce beneficial results in hand movement, hearing, and working memory.
45655898|NCT04870567|Radiation|Stereotactic ablative radiotherapy|Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
45453006|NCT01315184|Behavioral|Recovery Line Support System|"Full time access (24 hours/7 days per week) to an automated, telephone-based, interactive, voice response (IVR)system for 4 weeks.~The program was developed based on a behavioral theory of substance abuse, and comprises four components: 1) self-assessment 2) learning about skills , 3) activities for current help and skills training, and 4) Feedback."
45655899|NCT04870567|Radiation|High dose rate brachytherapy|Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
45655900|NCT05526131|Other|Questionare|"Assessing the presence or the absence of depression:~By structured clinical interview for DSM-IV Axis disorder (SCID-I) and Hamilton Depression Rating Scale (HAM-D) for diagnosing depression and exclusion of other psychiatric disorders."
45676800|NCT02171429|Drug|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6 and 8.
46074997|NCT02794194|Other|Proprioceptive training on a whole body vibration platform|The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on a Fitvibe Excel Pro vibration platform (Fitvibe, Bilzen, Belgium).
46074998|NCT02794194|Other|Proprioceptive training with the BOSU® on the floor|The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on the floor.
45453007|NCT01315262|Drug|Sildenafil|1:1 Viagra 100 mg daily (taken either at bedtime - if sexual intercourse is not expected - or 1 hour prior to sexual intercourse, no more than one 100 mg dose of sildenafil per day) vs. Viagra 100mg OD (i.e. one hour prior to sexual intercourse)
45453008|NCT03197558|Combination Product|Tymbion Iontophoresis and Tube Delivery System (TDS)|Subjects will receive active Tymbion iontophoresis and tube insertion using the Tube Delivery System in all ears indicated for tube placement.
45453009|NCT03197324|Drug|Bexagliflozin|Bexagliflozin tablets, 20 mg
45453010|NCT03197324|Drug|Digoxin|2 0.25 mg Digoxin tablets (total dose 0.5 mg digoxin)
45453011|NCT01330706|Drug|Polihexanide|The investigators compared intraoperative antiseptic irrigation using 0.9% saline solution and 0.1% polihexanide.
45676801|NCT02171429|Other|Adalimumab Placebo|Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
45807062|NCT05105152|Biological|SC-DARIC33|Infusion with SC-DARIC33 followed by intermittent oral rapamycin administration
45807063|NCT05103904|Other|Laboratory Biomarker Analysis|Correlative studies
45807064|NCT05103904|Drug|Lenvatinib|Given PO
45807065|NCT05100342|Diagnostic Test|Point score prediction tool for 30-day survival|"This tool requires laboratory data including white blood cell count, neutrophil-lymphocyte ratio, blood urea nitrogen, bilirubin, albumin, lactate dehydrogenase, and red cell distribution, as well as number of attendances to the emergency room in the past 100 days, the site receiving radiation therapy, and the primary cancer type. Each data point correlates with a point value, which are tallied to generate a final score.~The scores range from 0-20, with 0 giving the highest chance for survival at 30 days and 20 giving the lowest chance for survival at 30 days"
45807066|NCT05099328|Behavioral|Recast Therapy|Recast therapy is when a interventionist uses the child's own productions as a platform for restating or recasting the child's speech with corrections or alterations to focus on a particular syntax target.
45942299|NCT00283621|Drug|Adriamycin|
45942300|NCT00283621|Drug|Ifosfamide|
46074999|NCT02789592|Drug|Melatonin PR|For experimental treatment of RBD
46075000|NCT02789592|Drug|Clonazepam|For experimental treatment of RBD
45807067|NCT05099328|Behavioral|Syntax Stories|Syntax stories are specially constructed stories read verbatim designed to teach a syntax target.
45453012|NCT01330784|Drug|hMG-HP|
45453013|NCT03162614|Biological|RTS,S/AS01E|Subjects will receive intramuscular injection of RTS,S/AS01E.
45807068|NCT05093582|Drug|Levcromakalim|12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least 3 days in between.
45807069|NCT05093582|Drug|Saline|12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least 3 days in between.
45453014|NCT03162614|Biological|RTS,S/AS01B|Subjects will receive intramuscular injection of RTS,S/AS01B.
45942301|NCT00283660|Dietary Supplement|10 mg zinc oxide|10 mg zinc oxide
46075001|NCT02789592|Drug|Melatonin PR placebo|Placebo pill manufactured to mask melatonin PR 2mg tablet
46075002|NCT02789592|Drug|Clonazepam placebo|Placebo pill manufactured to mask clonazepam 0.5mg tablet
45942302|NCT00283660|Other|Placebo|Placebo pill taken five days a week for six months.
45942303|NCT00401583|Drug|GW786034 (pazopanib)|Pazopanib will be given as monohydrochloride, 100 and 500 mg tablets.
45942304|NCT00401583|Drug|Probe drugs|probe drugs will be oral midazolam (3 mg), warfarin (10 mg), omeprazole (40 mg), caffeine (200 mg), and dextromethorphan (30 mg).
45942305|NCT00077051|Drug|cisplatin|
45942306|NCT00077051|Drug|cytochlor|
45942307|NCT00077051|Drug|tetrahydrouridine|
45655901|NCT05256433|Other|Group-A|IASTM Certified IASTM practitioner will be performing the technique with emollient lubricant in which brushing and sweeping stroke will be applied for plantar fascia and fanning and sweeping stroke technique for calf muscles for the duration of 10 minutes to eliminate the inflammation. Active calf stretching and passive plantar fascia stretching will be performed for the correction of shortened tissue, and to prevent re-injury. The frequency stretching will be 5 repetitions for each with 10 seconds hold.
45807070|NCT05092269|Drug|Ustekinumab|Ustekinumab will be administered as a SC injection.
45453015|NCT03162614|Procedure|Sporozoite-infected mosquitoes challenge.|"Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the subjects. For each subject, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored. If required additional mosquitoes will be allowed to feed until a total of five infected mosquitoes with a minimum of 2+ salivary gland scores have fed.~The challenge occurs approximately 90 days (three months) after the last vaccination.~Subjects will be monitored during 28 days after having bitten by mosquitoes and when parasites are found in their blood, they will be treated with appropriate anti-malarial drugs."
45453016|NCT03160898|Drug|Reldesemtiv|Oral tablet
45942308|NCT00077051|Radiation|radiation therapy|
45942309|NCT00283699|Drug|albendazole|Active drug or placebo dosed bid p o for 8days
45655902|NCT05256433|Other|Group-B|Manual massage includes transverse friction massage for plantar fascia, flexor digitorum brevis, and deep massage for calf muscle for the duration of 10 minutes to eliminate the tightness and increase the blood flow. Active calf stretching and passive plantar fascia stretching will be performed for the correction of shortened tissue, and to prevent re-injury.
45942310|NCT00283699|Other|placebo|an inactive substance
45942311|NCT00283738|Device|BioSTAR Septal Repair Implant System|PFO Closure
45942312|NCT00283738|Procedure|Sham Procedure|Catheterization
45942313|NCT00283777|Drug|Chromium Picolinate|
45453017|NCT03160898|Drug|Placebo|Oral tablet
45453018|NCT01330940|Dietary Supplement|Orange soda|32 ounces per day
45655903|NCT05522621|Drug|TJAOA102|Once enrolled, participants will be administrated TJAOA102
45655904|NCT05256043|Diagnostic Test|Diabetes Diagnosis|HbA1c > 6.5%
45655905|NCT05532527|Drug|Microwave ablation combined with Camrelizumab and chemotherapy|Microwave ablation combined with Camrelizumab and chemotherapy
45655906|NCT05231941|Drug|Lidocaine IV|Bolus and infusion of lidocaine will be administered
45655907|NCT05231941|Drug|Ropivacaine|Bilateral TAP block will be given to these patients
45655908|NCT05217745|Dietary Supplement|MLCT Oil|1st 12 weeks: frozen ready to eat meals prepared with the oil Last 12 weeks: own diet with provided snacks containing the oil
45655909|NCT05217745|Dietary Supplement|LCT Oil (Corn Oil)|1st 12 weeks: frozen ready to eat meals prepared with the oil Last 12 weeks: own diet with provided snacks containing the oil
45807071|NCT05090826|Device|Model ZFR00V|Investigational intraocular lens replaces the natural lens removed during cataract surgery in one or both eyes.
45807072|NCT05090813|Device|Model ICB00|Investigational intraocular lens replaces the natural lens removed during cataract surgery in one or both eyes.
45807073|NCT05090384|Drug|Prednisone|Prednisone starting dose of 0.5 mg/kg; for patients who respond clinically and continue to have low biomarkers will be tapered rapidly; those that are not clinically responding or whose biomarkers increase will be treated per their treating physicians plan or by standard of care
45942314|NCT00283855|Behavioral|Online Self-Management|Online Self-Management
45942315|NCT00110448|Drug|Aspirin|Aspirin 81 mg or 100 mg per day
45942316|NCT00110448|Drug|No aspirin|No aspirin use
45942317|NCT00077090|Drug|hyperbaric oxygen|
45942318|NCT00283972|Device|LAP-BAND System|
45942319|NCT00284011|Dietary Supplement|SAMe|800 mg dose daily for 4 weeks.
45942320|NCT00284011|Other|Placebo|2 placebo pills daily for 4 weeks.
45942321|NCT00284167|Behavioral|tailored web-based weight management intervention|
45942322|NCT00284206|Drug|long-acting injectable risperidone|
45942323|NCT00110487|Drug|ERB-041|
45942324|NCT00284284|Device|Use of a rehabilitation brace|
45942325|NCT00284323|Drug|Adenosine|
45942326|NCT00284362|Procedure|Arthroscopic or open surgery for hallux rigidus|
45942327|NCT00110526|Genetic|Ad.hIL-12|Ad.hIL-12 intraprostatic injection IND
45942328|NCT00284401|Procedure|Evaluation of the placement of the Delta prosthesis|
45942329|NCT04730024|Other|Not applicable(observational study)|Not applicable(observational study)
45942330|NCT04718701|Drug|Anlotinib+Toripalimab+Nab-paclitaxel|Using combination treatment of anlotinib (12 mg, po. qd.) plus toripalimab (240 mg, ivgtt. q3w.) and nab-paclitaxel (260 mg/m2, ivgtt, q3w) with every 3 weeks as a cycle.
45807074|NCT05090215|Behavioral|Aerobic and resistance training 12 week exercise programme|See arm/group description
45655910|NCT05216575|Drug|Administration of Almitrine|Administration of Almitrine (intravenous bolus of 0.5 mg/kg over 30 minutes followed by a continuous perfusion of 16 mg/kg/min in responders)
45655911|NCT05522543|Other|Conventional treatment with Passive translatoric intervertebral glides|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets • Core stabilization exercise (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan (bridges, knee to chest, cat and camel stretch and prone press ups"
45655912|NCT05522543|Other|Conventional treatment with manual segmental lumbar traction|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• Manual lumbar Traction (L1-L5) for 15-20 sec x5 sets • Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets) • .Core stability exercises (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan"
45655913|NCT05147597|Other|Questionnaire|"Cases diagnosed with Idiopathic pulmonary fibrosis (IPF) in the chest diseases outpatient clinic will be informed about the study, and the informed consent form will be signed by the specialist physician and demographic information will be obtained from the cases who accepted to be included in the study.~The surveys will be contacted by the patient at 1-week intervals and answered by the patient by the responsible researcher and chest diseases physician."
45942331|NCT00284479|Behavioral|Walking 45 mins 2x p.w.|
45655914|NCT05522387|Drug|XPro1595|Each enrolled patient will be treated with 1.0 mg/kg of XPro1595 as a subcutaneous injection once a week for 12 to 15 months, for a total exposure to XPro1595 of up to 18 months, depending on their previous study.
45942332|NCT00110565|Device|Pulsed magnetic field pad|
45942333|NCT00077168|Drug|anastrozole|
45655915|NCT05532449|Drug|Intravenous dizocine|Intravenous dizocine (0.03mg/kg diluted to 5 ml)
45655916|NCT05532371|Other|Aerobic exercise training combined with lower limb strengthening|The participants performed aerobic exercise training and lower limb strengthening during this intervention.
45655917|NCT05532371|Other|Dual-task training combined with lower limb strengthening group (DG)|The participants performed dual-task training combined with lower limb strengthening during this intervention.
45655918|NCT05532371|Other|Aerobic exercise training combined with dual-task training and lower limb strengthening|The participants performed aerobic exercise training combined with dual-task training and lower limb strengthening during this intervention.
45655919|NCT05532371|Other|Only lower limb strengthening group (CG)|The participants performed only lower limb strengthening group during this intervention.
45942334|NCT00077168|Drug|tamoxifen citrate|
45807075|NCT05090215|Diagnostic Test|Venous blood sampling|full blood count, urea & electrolytes, C-reactive protein, coagulation screen, liver function tests, erythrocyte sedimentation rate.
45807076|NCT05090215|Diagnostic Test|Muscle Ultrasound|Ultrasound of vastus lateralis to ascertain muscle structure (thickness, pennation angle and fascicle length)
45942335|NCT00077168|Procedure|adjuvant therapy|
45942336|NCT00077168|Radiation|radiation therapy|
45942337|NCT00284596|Procedure|High tibial osteotomy|HTO
46075003|NCT00867685|Drug|AZD2624|Single dose of 40 mg AZD2624 liquid suspension, PO
46075004|NCT00867685|Drug|AZD2624|Single dose of 40 mg AZD 2624 (2x20mg tablets), PO
46075005|NCT02794038|Device|Soberlink Cellular Device|BAC breath analyzer
46075006|NCT02794038|Device|BACtrack S80 Pro|BAC breath analyzer
45942338|NCT00284635|Procedure|Fast track vs conventional|
45942339|NCT00284674|Device|Hip prosthesis (re-cap, m2a-magnum and C2a-taper)|
45942340|NCT00284713|Procedure|intracoronary infusion of BMC|catheter delivery of stem cells
45807077|NCT05090215|Diagnostic Test|Cardiopulmonary exercise testing (CPET)|The assessment of anaerobic threshold as a measure of changes in aerobic function between the two groups will be assessed using CPET
45807078|NCT05090215|Behavioral|Quality of life questionnaire completion|The use of validated questionnaires to assess quality of life parameters; Duke Activity Status Index (DASI), EORTC-QLQ C30 (quality of life for cancer patients) and the International Physical Activity Questionnaire (IPAQ).
45807079|NCT05089734|Biological|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
45807080|NCT05089734|Drug|Docetaxel|Administered intravenously
45942341|NCT00110604|Behavioral|folic acid (0.8 mg)|
45942342|NCT00284752|Drug|Abraxane|This is a Phase II single-arm study for first-line chemotherapy of patients with hormone refractory metastatic prostate cancer. Eligible patients will be chemotherapy naive and will receive weekly Abraxane 100mg/m2 IV over 30 minutes. These will be 4-week cycles with patients receiving Abraxane 100 mg/m2 weekly for 3 weeks and one week off for rest. Patients will continue on therapy until disease or PSA
46075007|NCT00876421|Drug|Placebo|Placebo / 12 weeks
46075008|NCT00876421|Drug|Tolterodine|4mg / 12 weeks
46075009|NCT00876421|Drug|ONO-8539|low dose / 12 weeks
46075010|NCT00876421|Drug|ONO-8539|medium dose / 12 weeks
46075011|NCT00876421|Drug|ONO-8539|higher dose / 12 weeks
45807081|NCT05087992|Drug|BI 905711|BI 905711
45807082|NCT05087992|Drug|FOLFIRI|FOLFIRI
45807083|NCT05087992|Drug|Bevacizumab|Bevacizumab
45942343|NCT02965508|Other|Home-based Primary Care|Care in the programs is inter-professional and team-based. Each physician leads a team charged with the care of a panel of patients and directs the team's activities. New patients are assigned a Mount Sinai Visiting Doctors (MSVD) primary care physician or the Chelsea Village House Calls Program (CVHCP) who makes an initial visit within 2 weeks of the patient's enrollment in the program. The primary care physician completes a comprehensive medical history and physical exam during the initial visit including standardized assessments of physical functioning and cognition. The primary care physician then provides ongoing management of the patients' acute and chronic health problems, including palliative and home hospice care when needed, every 2 to 12 weeks as determined on a case-by-case basis.
45807084|NCT05086692|Drug|MDNA11 Monotherapy|MDNA11 will be administered by the IV route on a once every 2 weeks (Q2W) dosing schedule. Provisional dose cohorts for monotherapy dose escalation doses ranging from 0.003 to 0.6 (mg/kg): until determining the Recommended Dose for Expansion (RDE).
45807085|NCT05086692|Drug|Combination (MDNA11 + pembrolizumab)|MDNA11 in combination with pembrolizumab
45942344|NCT02965508|Other|Usual Care|Office based care
45942345|NCT00284791|Drug|Lamotrigine (drug)|
45942346|NCT00284791|Drug|Fluoxetine (drug)|
45942347|NCT00284791|Drug|sertraline (drug)|
45942348|NCT00284830|Device|Implantable Pulse Generators|dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization
45942349|NCT00110643|Device|CoolTouch II laser|
45655925|NCT02352103|Procedure|Retzius sparing radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
45807086|NCT05085405|Behavioral|Clinician notification|"An anticoagulation clinic nurse sends a templated letter to the patient's clinician and identifies the patient as high risk for upper GI bleeding, summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), provides a link to guidance on evidence-based use of antiplatelet therapy, and asks that the clinician manage any medication changes.~In this arm, patients receive no additional interventions beyond that provided during treatment as usual."
45807087|NCT05085405|Behavioral|Clinician Notification with Nurse Facilitation|"An anticoagulation clinic nurse sends an individualized letter to the patient's clinician which identifies the patient as high risk for upper GI bleeding and summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), but in addition includes a summary of the patient's history of atherosclerotic cardiovascular disease and a concise guidance summary on appropriate use of antiplatelet therapy for relevant indications. The anticoagulation nurse will assist with order entry for any new medications and also provide education on medication changes to the patient upon request by the clinician.~In this arm, patients receive no additional interventions beyond that provided during treatment as usual."
45942350|NCT00284869|Drug|LPS|
45942351|NCT02965586|Drug|intrathecal|intrathecal block will be performed in sitting position using 25 G spinal needle at either the L3-L4 or L4-L5 intervertebral spaces.
45942352|NCT00284908|Drug|S-Tenatoprazole-Na (STU-Na)|30 mg, 60 mg, 90 mg and 120 mg of STU-Na for 5 days every morning
45942353|NCT00284947|Drug|basiliximab|40 mg once every 28 days intravenously for 24 weeks
45942354|NCT00284947|Drug|MMF/EC-MPS|1g MMF or 720mg EC-MPS p.o twice daily
45942355|NCT00284947|Drug|Corticosteroids|Oral corticosteroids, equivalent to prednisone p.o, ≥ 5mg daily or ≥ 10mg on alternate days
45655926|NCT02352103|Procedure|Vattikuti Urology Institute radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
45655927|NCT02352103|Device|da Vinci Surgical System|The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon's capabilities and offer a state-of-the-art minimally invasive option for major surgery.
45655928|NCT05146037|Other|CO2 and saline flushing|TAVI valves will be prepared by flushing with CO2 to displace any retained air during manufacturing and preparation. The valves will then be flushed with saline as per IFU.
45942356|NCT00110682|Drug|Imiquimod used as an adjunct to cryotherapy|
45942357|NCT00285025|Drug|SR57667B|
45942358|NCT00417196|Drug|QAX576|
45942359|NCT00077246|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
45655929|NCT05146037|Other|Saline flushing|TAVI valves will be flushed with saline only as per IFU.
45655930|NCT04870021|Biological|recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm),|recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm), intramuscular in the anterolateral part of either of thighs
45676802|NCT02171429|Drug|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 [Day 1], 4, 8, and 12 [clinical remitters only]).
45942360|NCT00285064|Procedure|CT|
45942361|NCT00285103|Drug|SPC2996|
45942362|NCT00110721|Drug|GM-CT-01 plus 5-Fluorouracil|Single use vials, combined regimen of GM-CT-01 / 5-Fluorouracil (280 mg/m2 /500 mg/m2) given for 4 consecutive days in a 28 day cycle until disease progression.
45942363|NCT00417235|Device|Chlorhexidine Sponge (Biopatch TM)|dressing with chlorexidrine sponge versus dressing without chlorexidrine sponge
45942364|NCT00417235|Behavioral|7-day catheter dressing frequency|dressing changes every 7 days versus every classical change every 3 days
45942365|NCT00399386|Procedure|EP|
45942366|NCT00399386|Procedure|ICD|
45942367|NCT00399386|Procedure|Ablation|
45942368|NCT00425035|Drug|Panitumumab (ABX-EGF)|
45942369|NCT00110760|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel was composed of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine and was applied topically. S-Caine Peel was applied with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
45942370|NCT00110760|Drug|Placebo Peel|Placebo Peel applied topically with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
45942371|NCT00285142|Drug|rosiglitazone|
45942372|NCT00285181|Drug|Simvastatin|
45942373|NCT00077324|Genetic|proteomic profiling|
45942374|NCT00077324|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
45942375|NCT00077324|Procedure|biopsy|
45942376|NCT00077324|Procedure|surgery|
45942377|NCT00285220|Procedure|Laparoscopic Truncal Vagotomy|
45942378|NCT00285298|Drug|Pentoxifylline|
45942379|NCT00285298|Drug|Placebo|
45942380|NCT00285337|Procedure|Laminectomy and Laminoplasty|Posterior versus anterior approach to laminectomy and laminoplasty
45942381|NCT00417313|Device|periosteal electro-acupuncture (osteopuncture).|
45942382|NCT00285376|Drug|vilazodone|titration to 40mg tablets qd for 8 weeks
45942383|NCT00077363|Drug|tipifarnib|Given PO
45942384|NCT00077363|Drug|capecitabine|Given PO
45942385|NCT00285415|Drug|Docetaxel and Carboplatin|docetaxel (75 mg/m2) + carboplatin (AUC 6) IV every 3 weeks X 6 cycles
45942386|NCT00285454|Procedure|Retrograde coronary venous delivery of cells.|
45942387|NCT00285493|Drug|Antibiotics|
45942388|NCT00110799|Drug|SB497115|Approximately 160 subjects will be randomized equally to one of four treatment groups of approximately 40 subjects (A-D). Subjects will receive oral tablets of SB-497115-GR at 30mg, 50 mg, 75 mg or placebo administered once daily for a total of 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
45942389|NCT00110799|Other|Placebo|Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
45942390|NCT00285571|Behavioral|Controlled Feeding Intervention|
45942391|NCT00285688|Procedure|gastroscopic examination|gastroscopic examination for tissue biopsy and real time PCR for gene study
45942392|NCT00285727|Drug|Ropinirole CR|
45942393|NCT00110838|Procedure|Supplementation with fish oil versus placebo|
45942394|NCT00077402|Drug|fenretinide|
45942395|NCT00285766|Drug|Selegiline Transdermal System|
45942396|NCT00285805|Drug|Rosiglitazone versus placebo|
46075012|NCT02794116|Procedure|Conventional Sealants|It is a preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
45807088|NCT05085405|Behavioral|Clinician Notification / Patient Activation|"An anticoagulation clinic nurse sends a templated letter to the patient's clinician and identifies the patient as high risk for upper GI bleeding, summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), provides a link to guidance on evidence-based use of antiplatelet therapy, and asks that the clinician manage any medication changes.~Patient Activation:~An anticoagulation clinic nurse sends the patient an 8-page written guide, either through the patient portal or by mail. The guide provides education on upper GI bleeding risk and encourages patients to talk with their clinician about medication changes to reduce their bleeding risk."
45655931|NCT04870021|Behavioral|Short text messages and calls to parents for compliance to routine immunization schedule|After the discharge of mothers from hospital, preformed, short text messages (SMS) were sent to parents, reminding them of the due date for as per the vaccination schedule. One day after the due date of the vaccine shot, a phone call was made to confirm the child was vaccinated or not
45655932|NCT04144387|Procedure|Myelogram|Two additional myelograms will be performed comparing to standard of care.
45655933|NCT05142215|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention using drug eluting stents and contemporary CTO PCI techniques on background of optimal medical therapy.
45655934|NCT05142215|Procedure|Placebo percutaneous coronary intervention|Placebo percutaneous coronary intervention procedure on background of optimal medical therapy.
45655935|NCT05525897|Other|Psychoeducational|The focus of the course is to teach students the fundamental theories, and practices of soft skills, as well as providing cases and material that give students the opportunity to learn from real life experiences.
45655936|NCT05522231|Drug|Fruquintinib+Sintilimab|Fruquintinib, 5 mg, QD, PO, 2 weeks on/1 week off, 3 weeks/cycle; Sintilimab, 200 mg, IV infusion, Q3W, 3 weeks/cycle.
45655937|NCT05522231|Drug|Axitinib / Everolimus|Axitinib, 5 mg, twice daily (BID), PO, 3 weeks/cycle, dose escalation will be at the investigator 's discretion based on clinical;Everolimus, 10 mg, QD, PO, 3 weeks/cycle.
45942397|NCT00285805|Drug|response (sodium excretion) to amiloride infusion|
45942398|NCT00285805|Drug|response (sodium excretion) to furosemide infusion|
45942399|NCT00285844|Behavioral|weight loss|
45942400|NCT00285844|Drug|thiazolidinedione|
45942401|NCT00077441|Drug|bortezomib|Given IV
45942402|NCT00077441|Other|laboratory biomarker analysis|Correlative studies
45942403|NCT00285883|Drug|Invirase|
45942404|NCT00285883|Drug|Norvir|
45942405|NCT00110877|Drug|LPV/rtv|One 400mg LPV tablet twice daily with 100mg RTV
45942406|NCT00110877|Drug|TMC114/rtv|Two 300mg TMC114 tablets twice daily with 100mg RTV
45942407|NCT00285961|Device|Cork splint materials (instead of plaster splint)|
45942408|NCT00286000|Drug|Administration of high dose simplified folfiri|
45942409|NCT00077519|Drug|tipifarnib|
45942410|NCT00077519|Radiation|radiation therapy|
45942411|NCT00286039|Procedure|Blood sampling|Blood sampling is used.
45942412|NCT00286117|Drug|Anastrozole|oral
45942413|NCT00286117|Drug|Tamoxifen|oral
45942414|NCT00286195|Device|Multi-Link Frontier Coronary Stent System|Bare metal stent
45942415|NCT00110916|Drug|Intra-articular metHuIL-1ra (anakinra)|anakinra
45942416|NCT00110916|Drug|placebo|placebo
45942417|NCT00077558|Drug|fludarabine phosphate|
45942418|NCT00077558|Drug|triapine|
45942419|NCT00286273|Drug|trisodium citrate|for regional anticoagulation of the extracorporeal CVVH circuit
45942420|NCT00286273|Drug|nadroparin|for anticoagulation of the extracorporeal CVVH circuit
45942421|NCT00286312|Drug|Atorvastatin|
45942422|NCT00286351|Drug|Combined treatment with Arimidex and Zoladex before IVF|
45942423|NCT00286390|Procedure|Acupuncture|
45942424|NCT00110955|Drug|Darbepoetin alfa|Q3W 300 mcg darbepoetin alfa
45807089|NCT05085405|Behavioral|Clinician Notification with Nurse Facilitation / Patient Activation|"An anticoagulation clinic nurse sends an individualized letter to the patient's clinician which identifies the patient as high risk for upper GI bleeding and summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), but in addition includes a summary of the patient's history of atherosclerotic cardiovascular disease and a concise guidance summary on appropriate use of antiplatelet therapy for relevant indications. The anticoagulation nurse will assist with order entry for any new medications and also provide education on medication changes to the patient upon request by the clinician.~Patient Activation:~An anticoagulation clinic nurse sends the patient an 8-page written guide, either through the patient portal or by mail. The guide provides education on upper GI bleeding risk and encourages patients to talk with their clinician about medication changes to reduce their bleeding risk."
45807090|NCT05085392|Behavioral|Trauma-Informed Yoga|6 weeks of twice weekly trauma-informed yoga for 45 minutes per session
45807091|NCT05083182|Drug|Ustekinumab|Ustekinumab will be administered as subcutaneous injection.
45807092|NCT05083182|Drug|Guselkumab|Guselkumab will be administered as subcutaneous injection.
45942425|NCT00110955|Drug|Placebo|Q3W dosing of placebo
45942426|NCT04730180|Device|Transcranial Magnetic Simulation|Brain stimulation treatment will be performed using FDA-cleared TMS coils according to their intended use of treatment of medication resistant depression by targeting the dorsolateral prefrontal cortex.
45942427|NCT04730180|Device|Mixed reality neuronavigation|Targeting of the dorsolateral prefrontal cortex will be performed with the help of a mixed reality neuronavigation system.
45942428|NCT00286507|Procedure|Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel.|Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with or without ILM peeling
45942429|NCT00286585|Drug|Inhalational anesthetic|Sevoflurane, dosage according to the physician in charge
45942430|NCT00286585|Drug|Intravenous anesthetic, propofol|Propofol, dosage according to the physician in charge
45942431|NCT00111072|Drug|dexamethasone 0.01% solution|
45942432|NCT00286624|Biological|Allogeneic Islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. First infusion to contain at least 5,000 islet equivalents/kg body weight. Subsequent infusions to contain at least 3,000 islet equivalents/kg body weight.
45942433|NCT00286624|Drug|Everolimus|Loading dose of 3 mg PO on day -2 relative to transplant, followed at least 12 hours later by dose of 1.5 mg PO BID. The daily dose will be adjusted according to the whole blood 12-hr trough to target 3-15 ng/ml for the first 3 months and 3-12 ng/ml thereafter.
45942434|NCT00286624|Drug|anti-thymocyte globulin|A total of 6 mg/kg IV over 12 hours on days -2, -1, 0, +1, and +2. The dose will be 0.5 mg/kg on day -2, 1.0 mg/kg on day -1, and 1.5 mg/kg on days 0, +1, and +2.
45942435|NCT00286624|Drug|Cyclosporine|Cyclosporine started on day +1 relative to the first islet transplant. Initial dose of 3 mg/kg/day administered in 2 divided doses; then adjusted to maintain target levels of 400 (350-500) ng/mL for the first three months following islet transplant and 300 (200-350) ng/mL thereafter.
45942436|NCT00077597|Drug|epoetin|3 times a week iv, as prescribed.
45942437|NCT00077597|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|0.4 micrograms/kg iv (starting dose) once every 2 weeks
45655938|NCT05522231|Drug|Fruquintinib|Fruquintinib, 5 mg, QD, PO, 3 weeks on/ 1 week off, 4 weeks/cycle.
45655939|NCT04877509|Biological|Selenium, Zinc and Copper, Vitamin A, D, E plasma concentrations during patient hospitalization|Micronutrient assays on heparinized plasma.
45655940|NCT05525819|Drug|Control group|The cases will be subjected to spinal anesthesia with a 3 ml volume (2.5 ml of hyperbaric bupivacaine 10 mg in addition to 0.5 normal saline). 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
45942438|NCT00286702|Device|hand splint|
45942439|NCT00286780|Drug|AT-101|80 mg of AT-101 once daily for three days every other week, 375 mg/m2 of rituximab weekly for up to 12 weeks
45655941|NCT05525819|Drug|Intrathecal group|The cases will be subjected to the same anesthetic mixture as controls with adding dexmedetomidine 5 μg in the saline component. 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
45655942|NCT05525819|Drug|Intravenous group|The intravenous group will receive 2.5 ml of hyperbaric bupivacaine (10 mg), in addition to intravenous dexmedetomidine, which will be started at 1 μg/kg loading dose diluted in 50 ml saline administered within 10 min, followed by maintenance at a 0.4 μg/kg/h dose diluted in 200 ml saline till the end of the procedure.
45655943|NCT03044743|Drug|Fludarabine|To modify immune micro-environment
45942440|NCT00111111|Drug|Etanercept|
45655944|NCT03044743|Drug|Cyclophosphamide|To modify immune micro-environment
45655945|NCT03044743|Drug|Interleukin-2|To sustain the survival of infused T cells
45807093|NCT05083169|Drug|Daratumumab|Daratumumab will be administered SC injection.
45807094|NCT05083169|Drug|Pomalidomide|Pomalidomide will be administered orally.
45807095|NCT05083169|Drug|Dexamethasone|Dexamethasone will be administered orally or intravenously.
45807096|NCT05083169|Drug|Bortezomib|Bortezomib will be administered SC injection.
45807097|NCT05083169|Drug|Teclistamab|Teclistamab will be administered SC injection.
45942441|NCT00286819|Drug|the FEC75 and 95 regimen|"Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Arm B: the FEC90 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.~All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle.~Six cycles of adjuvant chemotherapy will be administered in both arms (A + B"
45942442|NCT00286858|Device|Insignia Ultra and Insignia AVT|Regular AV-Delay increase to allow for intrinsic AV conduction, if present.
45942443|NCT00077714|Drug|Paliperidone ER|
45942444|NCT00417352|Device|Brace|
45807098|NCT05082688|Biological|Herpes zoster vaccination (Shingrix, GSK)|Shingrix is an ASO1-adjuvanted herpes zoster vaccination used to prevent shingles and its associated complications in at-risk populations
45807099|NCT05082688|Biological|Influenza Vaccine (Fluarix Tetra Northern Hemisphere 2021 or 2022, GSK)|Fluarix Tetra is a quadrivalent inactivated influenza vaccine
45807100|NCT05082688|Biological|Placebo|0.9% NaCl
45807101|NCT05071664|Drug|Guselkumab|Guselkumab will be administered as a SC injection.
45942445|NCT00417352|Device|Added mass|
45807102|NCT05071664|Drug|Golimumab|Golimumab will be administered as a SC injection.
45942446|NCT00417391|Drug|RR110 (Tamibarotene)|1 mg RR110
45942447|NCT00417391|Drug|RR110 (Tamibarotene)|4 mg RR110
45942448|NCT00111150|Drug|Tenofovir Disoproxil Fumarate 300 mg daily|
45942449|NCT00417430|Drug|ICI 182,780 (Faslodex)|
45942450|NCT00077753|Drug|enoxaparin sodium|
45942451|NCT00417469|Device|NADGL|
45942452|NCT00417508|Dietary Supplement|Sip feeding|Daily supplement with sip feeding, 2 packages(each package containing 200 ml,20 g protein and 300 kcal)
45942453|NCT00417508|Dietary Supplement|Dietary Advice|The patients will receive ordinary dietary advice with a recommendation of four meals per day or similar dietary advice and no daily sip feeding supplements.
45942454|NCT00111189|Drug|Placebo|Placebo every 4 wk up to 24 mo
46075013|NCT02794116|Procedure|Resin Sealants|It is a resin sealants to preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
46075014|NCT04235010|Device|Genius toothbrush|Patients brushed their teeth twice a day for 2 minutes. An integral timer was used in the genius toothbrush group.
46075015|NCT04235010|Device|Manual toothbrush|Patients brushed their teeth twice a day for 2 minutes. During brushing, patients in manual group assigned to use their brushes were provided with a digital timer.
45676803|NCT02171429|Other|Etrolizumab Placebo|Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 [Day 1], 4, 8, and 12 [clinical remitters only]).
45807103|NCT05071664|Drug|Placebo|Placebo will be administered as a SC injection.
45807104|NCT05068440|Drug|Zanubrutinib|administered orally as capsules
45807105|NCT05067283|Drug|MK-1084|Oral dose
45676804|NCT01818297|Device|PrimeAdvanced® neurostimulator system|Neurostimulator and associated components
45676805|NCT01818141|Drug|Vancomycin|Vancomycin 125mg by mouth every 6 hours for 10 days
45676806|NCT01818141|Drug|Fidaxomicin|Fidaxomicin 200mg by mouth every 12 hours for 10 days
45676807|NCT01849497|Biological|Evolocumab Pre-filled Syringe|Evolocumab subcutaneous injection via a single use, disposable pre-filled syringe.
45676808|NCT01849497|Biological|Evolocumab AI/pen|Evolocumab subcutaneous injection via a handheld mechanical (spring-based) autoinjector/pen.
45807106|NCT05067283|Biological|Pembrolizumab|Intravenous infusion of 200 mg
45807107|NCT05067283|Drug|carboplatin|Per label
45807108|NCT05067283|Drug|pemetrexed|Per label
45807109|NCT05067283|Biological|cetuximab|Per label
45807110|NCT05067283|Drug|oxaliplatin|Per label
45807111|NCT05067283|Drug|leucovorin|Per label
45807112|NCT05067283|Drug|5-fluorouracil|Per label
45807113|NCT05065190|Drug|nintedanib|nintedanib
45807114|NCT05065190|Drug|Placebo|Placebo
45942455|NCT00111189|Drug|Paliperidone Palmitate|25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
45942456|NCT02960698|Other|IRM and comportemental tasks|
45942457|NCT00077792|Drug|Enoxaparin sodium (XRP4563)|
45942458|NCT00286897|Drug|E2007|
45942459|NCT00111267|Behavioral|vitamin B12 supplementation|
45942460|NCT00111267|Behavioral|vitamin B12 + folic acid combined supplementation|
45942461|NCT00286936|Drug|Zolpidem|
45942462|NCT00077831|Behavioral|neurobehavioral development|observational study of infant and child development
45942463|NCT00286975|Behavioral|Leadership development program educational intervention|
45942464|NCT00287092|Biological|DT5aP-IPV-Hib 5-component Pertussis vaccine|0.5 mL, IM
45942465|NCT00287092|Biological|Infanrix® -IPV+Hib|0.5 mL, IM
45942466|NCT00111306|Drug|epratuzumab|
45942467|NCT00287131|Procedure|Procedure - Adoptive cell transfer|Procedure - Adoptive cell transfer
45942468|NCT00077870|Drug|ocrelizumab|
45942469|NCT00287170|Drug|Delayed Release 6MP or Calcitriol vs. Purinethol|
45942470|NCT00287209|Drug|Amiodarone|
45942471|NCT00287248|Drug|[123I] IMPY & SPECT Imaging|Subjects will be injected with 7mCi of [123I]IMPY, followed by SPECT imaging
45942472|NCT00077948|Drug|Enoximone|Enoximone administered orally
45942473|NCT00077948|Drug|Metoprolol succinate|Metoprolol succinate administered orally
45942474|NCT00077948|Drug|Placebo to match enoximone|Placebo to match match enoximone administered orally
45942475|NCT00077948|Drug|Placebo to match metoprolol succinate|Placebo to match metoprolol succinate administered orally
45942476|NCT00111345|Drug|Anthracyclines|3x12 mg/qm
45942477|NCT00111345|Drug|liposomal daunorubicin|3x80 mg/qm
45942478|NCT00111345|Drug|2-CDA|2x6 mg/qm
45942479|NCT00111345|Drug|AI|AI
45942480|NCT00287326|Drug|Bupivacaine, Clonidine, Morphine|
45942481|NCT00287443|Procedure|Oral Glucose tolerance test|
45942482|NCT00287443|Procedure|Whole body protein turnover|
45942483|NCT00287443|Procedure|IV glucose tolerance test|
45942484|NCT00287443|Procedure|Indirect Calorimetry|
45942485|NCT00287443|Procedure|Dual Energy X-ray Absorptiometry (DEXA)|
45655946|NCT05532293|Drug|MSP008-22|MSP008-22 is a small molecule with demonstrated anticancer activity in-vitro & in vivo studies. As several anticancer drugs are also good antiviral drugs, it was anticipated that MSP008-22 can also be a promising anti-COVID drug. Accordingly, in vitro assay studies and in an in vivo study in golden Syrian hamster were conducted where MSP008-22 has shown good anti-SARSCoV2 effects.MSP008-22.
45655947|NCT05532293|Other|Placebo|Placebo tablets identical in appearance, taste and smell to the tablets of MSP008-22
45655948|NCT03044665|Drug|Rosuvastatin|Subjects will start rosuvastatin 20 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level as current US guideline.
45655949|NCT03044665|Drug|Rosuvastatin plus ezetimibe|Subjects will start single combination pill of rosuvastatin 10 mg plus ezetimibe 10 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level.
45655950|NCT05525429|Behavioral|Nutrition Education|Multidimensional nutrition education will be provided.
45942486|NCT00287443|Procedure|Growth Hormone Stimulation Test|
45655951|NCT03046537|Diagnostic Test|Breath test|Collecting breath test from participants
45655952|NCT03046615|Device|EEG Electrode Patch|The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that we would commonly use for recording.
45942487|NCT00287482|Drug|Essiac|
45807115|NCT05064735|Drug|semaglutide 2.4 mg|semaglutide subcutaneous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
45655953|NCT03046615|Device|Standard Needles|Needles are placed in the muscles surrounding the eye to measure eye movements.
45655954|NCT04877353|Device|NIV|NIV applied for approximately 30 to 45 min at 2- to 4-h intervals for 48 h following surgery
45655955|NCT05521841|Procedure|Erector Spinae Plane Block(Bilateral Ultrasound Guided Erector Spinae Plane Block)|"Bilateral USG guided Erector Spinae Plane Block:~Drug used 20 ml of 0.25% Bupivacaine in each side. Total 40 ml volume. Dosage 100mg Ultrasound transducer will be placed in a cephalocaudal orientation over the back at 10th thoracic vertebral level.~The probe will then slowly be moved laterally until the transverse process is visible The trapezius muscle and erector spinae muscle will be identified as superficial to the transverse process.~A 25-gauge Quincke spinal needle (Romsons spinal needle, Quincke type)will be inserted using an in-plane approach in the cephalad to the caudal direction and towards the transverse process.~A 5ml bolus of local anesthetic will be given. Erector spinae muscle plane is then visualized separating from the transverse process.~The local anesthetic is then injected in 5 ml increments, with aspiration after every 5 ml to avoid intravascular injection Same procedure will be repeated on the other side"
45655956|NCT05521841|Procedure|Transversus abdominis plane block(Bilateral Ultrasound-guided bilateral Transversus abdominis plane block)|"Bilateral Ultrasound-guided bilateral Transversus abdominis plane block Drug used 20 ml of 0.25% Bupivacaine in each side. Total 40 ml volume. Dosage 100mg The linear transducer will be placed in the transverse plane at the lateral abdominal wall in the mid-axillary line, between the lower costal margin and the iliac crest.~Abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized.~Bowel movement and visualization of hypoechoic peritoneum would further guide the block.~The needle will be inserted in-plane and advanced until the tip is between the internal oblique and the transversus abdominis muscle.~After negative aspiration, 20 mL of 0.25% bupivacaine is injected in a 5ml increment ,aspirating after every 5ml injection.~Same procedure will be repeated on the other side."
45942488|NCT00077987|Drug|SU011248|
45676809|NCT02147093|Device|Test (multi-focal)|contact lens was to be worn a daily wear.
45676810|NCT02147093|Device|Control (Sphere)|contact lens was to be worn a daily wear with spectacles
45807116|NCT05064735|Drug|semaglutide 2.4 mg (placebo)|semaglutide subcutanous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
45807117|NCT05062915|Diagnostic Test|HINTS|HINTS (Head Impulse, Nystagmus, test of skew) V-HIT (Head impulse test google assisted) MRI: 3-4 MRI of the brain including the posterior fossa Vestibular rehabilitation for all patients with a vestibular deficit.
45807118|NCT05062889|Drug|5-Fluorouracil continuous infusion FOLFOXIRI schedule|3200 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
45807119|NCT05062889|Drug|5-Fluorouracil bolus FOLFOX schedule|400 mg/sqm iv bolus, day 1. To be repeated every two weeks for a maximum of 12 cycles.
45942489|NCT00287521|Drug|AL-37807 Ophthalmic Suspension, 1.0%|One drop in the study eye(s) once daily for 28 days
45942490|NCT00287521|Drug|Latanoprost, 0.005% (Xalatan)|One drop in the study eye(s) once daily for 28 days
45807120|NCT05062889|Drug|5-Fluorouracil continuous infusion FOLFOX schedule|2400 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
45807121|NCT05062889|Drug|Oxaliplatin FOLFOX and FOLFOXIRI schedule|85 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
45807122|NCT05062889|Drug|Oxaliplatin CAPOX schedule|130 mg/sqm iv over 2 hours, day 1. To be repeated every three weeks for a maximum of 8 cycles.
45942491|NCT00287521|Other|AL-37807 Vehicle|One drop in the study eye(s) once daily for 28 days
45942492|NCT00287521|Drug|Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%|One drop in the study eye(s) once daily for 28 days
45942493|NCT00111423|Drug|Pegsunercept (PEG sTNF-RI)|
45942494|NCT00287560|Drug|propofol (drug)|
45942495|NCT00078026|Drug|Apomine|
45942496|NCT00287638|Device|CPAP|Continuous positive pressure device with a time clock
45942497|NCT00287638|Device|placebo|no CPAP
45942498|NCT00111462|Drug|Darbepoetin alfa|
45942499|NCT00287677|Biological|recombinant human Growth Hormone|Growth Hormone during 6 months (30UG/KG/DAY)
45942500|NCT00287677|Biological|Vaccination|Vaccination (Hepatitis A+B + tetanus toxoid) at week 16
45942501|NCT00287677|Drug|HAART|HAART all over the trial
45942502|NCT00287755|Drug|S-1|S-1 capsule at a dose of 80 mg/m2 b.i.d. for 4 weeks followed by 2 weeks rest.
45942503|NCT00078065|Drug|Xcellerated T Cells|
45655957|NCT05525351|Device|Bispectral index (BIS) or Patient State Index (PSI)|After giving routine anesthetic medications, the investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI). BIS is maintained between 40 - 60 and PSI between 25 - 50. The vital signs, BIS or PSI are recorded automatically and continuously through computerized software. Upon conclusion of the surgery or examination, the patient is observed until return of consciousness (MOAA/S = 5) before sending them to the recovery unit.
45807123|NCT05062889|Drug|L-Leucovorin|200 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
45676811|NCT04170465|Drug|Metformin Hydrochloride 850 mg Tablets|Oral administration of Metformin hydrochloride 850 mg tablets (1700 mg/day) daily until the completion of neoadjuvant chemotherapy cycles
45676812|NCT04170465|Drug|AC-T chemotherapy regimen|AC: (Doxorubicin 60 mg/m2 IV + cyclophosphamide 600 mg/m2 IV) for 4 cycles every 3 weeks followed by Taxol cycles (Paclitaxel 80 mg/m2 IV) once weekly for 12 weeks.
45807124|NCT05062889|Drug|Capecitabine|Capecitabine 1000 mg/sqm/bid per os from day 1 to day 14. To be repeated every 3 weeks until 8 cycles. Available as 500 and 150 mg tablets.
45807125|NCT05062889|Drug|Irinotecan|165 mg/sqm iv over 60 minutes, day 1. To be repeated every two weeks for a maximum of 12 cycles.
45807126|NCT05062889|Drug|Trifluridine/Tipiracil|35 mg/m2/bid per os days 1-5 and 8-12. To be repeated every 4 weeks until 6 cycles. Available as 20 and 15 mg tablets.
45807127|NCT05057520|Other|Questionnaire|Completion of the questionnaire by the patient after consultation with the general practitioner
45807128|NCT05053399|Device|Model Series ZXT|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
45807129|NCT05052801|Drug|Bemarituzumab|Intravenous (IV) infusion
45807130|NCT05052801|Drug|mFOLFOX6|mFOLFOX6 administered as a combination of oxaliplatin and leucovorin as IV infusions. 5-FU administered as bolus followed by additional administration as IV infusion.
45676813|NCT02119325|Dietary Supplement|25% fibre|Test is a powdered beverage with an active component of 25% of fibre (resistant maltodextrin)
45807131|NCT05052801|Drug|Placebo|IV infusion
45807132|NCT05052268|Drug|XTX202|XTX202 Monotherapy
45807133|NCT05050097|Drug|Talquetamab|Talquetamab will be administered subcutaneously.
45807134|NCT05050097|Drug|Carfilzomib|Carfilzomib will be administered as an IV infusion.
45807135|NCT05050097|Drug|Daratumumab SC|Daratumumab will be administered subcutaneously.
45807136|NCT05050097|Drug|Lenalidomide|Lenalidomide will be self-administered orally.
45807137|NCT05050097|Drug|Pomalidomide|Pomalidomide will be self-administered orally.
45807138|NCT05049798|Drug|Guselkumab|Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.
45807139|NCT05049798|Drug|IL-17i|Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice.
45807140|NCT05049577|Device|Analgesia/Nociception Index (ANI)|V1 and V5 electrocardiographic positions as per the manufacturer's recommendations. The ANI was continuously recorded and displayed with a frequency of 1 Hz. ANI scores measured immediately before propofol administration, half-dose administration (1mg/kg), and full-dose administration (2mg/kg)of propofol.
45807141|NCT05048875|Drug|JNJ-64281802 (sentinel high dose)|Group 1a, JNJ-64281802 (high dose: 600-mg loading dose/200-mg maintenance dose)
45807142|NCT05048875|Drug|JNJ-64281802 (remaining high dose)|Group 1b, JNJ-64281802 (high dose: 600-mg loading dose/200-mg maintenance dose)
45807143|NCT05048875|Drug|JNJ-64281802 (medium/low dose)|Group 2, JNJ-64281802 (low dose: 40-mg loading dose/10-mg maintenance dose) AND JNJ-64281802 (medium dose: 200-mg loading dose/50-mg maintenance dose)
45807144|NCT05048875|Drug|JNJ-64281802 (dosing regimen X)|"Group 3, JNJ-64281802 (dosing regimen X)~Up to 3 dosing regimens can be selected for evaluation in Cohort 2 based on interim analysis data from Cohort 1. The number of participants in total and the number of participants on active and placebo per group will depend on the number of dosing regimens in Cohort 2."
45807145|NCT05048875|Drug|JNJ-64281802 (dosing regimen Y)|"Group 4, JNJ-64281802 (dosing regimen Y)~Up to 3 dosing regimens can be selected for evaluation in Cohort 2 based on interim analysis data from Cohort 1. The number of participants in total and the number of participants on active and placebo per group will depend on the number of dosing regimens in Cohort 2."
45807146|NCT05048875|Drug|JNJ-64281802 (dosing regimen Z)|"Group 5, JNJ-64281802 (dosing regimen Z)~Up to 3 dosing regimens can be selected for evaluation in Cohort 2 based on interim analysis data from Cohort 1. The number of participants in total and the number of participants on active and placebo per group will depend on the number of dosing regimens in Cohort 2."
45807147|NCT05048875|Drug|Placebo|No therapeutic effect, used as a control in testing new drugs
45807148|NCT05046158|Device|Transforming Powder Dressing|Altrazeal transforming powder dressing is methacrylate-based powder dressing made from the same materials used in the production of contact lenses. Upon hydration, the powder transforms into a moist, non-occlusive barrier that covers and protects the wound from exogenous bacteria while helping manage exudate through vapor transpiration.
45807149|NCT05046158|Other|Standard of care topical wound agents and dressings|Standard wound dressings such as gauze or foams. Moisture regulating topical agents may also be used to prepare the wound bed.
45453019|NCT01331174|Device|Pulsed short wave|The treatment was performed with 2 devices named Diatermed II (Carci, São Paulo, SP, Brazil), previously calibrated, carrying frequency of 27.12MHz, peak power of 250W, and pulse duration of 400µs. All these parameters are predetermined in the device according to the manufacturer. We used the maximum power provided by the machine in a pulsed form with a pulse frequency of 145Hz, resulting in a mean power of 14.5W.
45942504|NCT02960932|Device|ultrasound scanner|Ultrasound scanner used to the SSI technical reproducibility.
45942505|NCT00111501|Behavioral|Tobacco Use Disorder|Web-based psychoeducational intervention culturally-tailored to the LGBT community including a social support component
45655958|NCT05525351|Drug|Propofol|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Propofol is given via target control pump with typical target effect-site propofol concentration 1-5 ug/mL according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
45807150|NCT05045703|Dietary Supplement|Vitamin A palmitate|Vitamin A palmitate, 15,000 IU daily for 4 months
45942506|NCT00111501|Behavioral|Standard Web-based intervention|General psychoeducational Web-based smoking cessation intervention
45807151|NCT05041478|Procedure|Cold Snare Endoscopic mucosal resection with adjuvant snare tip soft coagulation|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy. Lesion then removed with a stiff thin-wired snare. Following this defect margins are treated with electrocautery to create a rim of ablated tissue.
45807152|NCT05041478|Procedure|Cold Snare Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy. Lesion then removed with a stiff thin-wired snare.
45807153|NCT05040971|Drug|Semaglutide 2.4 mg|Administered subcutaneously (s.c., under the skin) once weekly as well as reduced-calorie diet and increased physical activity for 52 weeks. Doses gradually increased to 2.4 mg
45807154|NCT05040971|Drug|Placebo|Administered subcutaneously once weekly (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 52 week
45942507|NCT00287794|Drug|diazepam, melatonin|Administration of diazepam or such drugs may improve the sleep disturbance of patients with RA.
45942508|NCT00287833|Other|placebo|Given orally
45942509|NCT00287833|Drug|Bowman-Birk inhibitor concentrate|Given orally
45942510|NCT00287911|Drug|cisplatin|intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36
45942511|NCT00287911|Drug|topotecan hydrochloride|intravenously continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36 -Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined
45942512|NCT00287911|Radiation|brachytherapy|Some patients may also undergo brachytherapy
45942513|NCT00287911|Radiation|radiation therapy|once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36
45942514|NCT00078104|Procedure|Extraction of wisdom teeth|
45942515|NCT00287950|Drug|carboplatin|
45942516|NCT00287950|Drug|cisplatin|
45942517|NCT00287950|Drug|cyclophosphamide|
45942518|NCT00287950|Drug|etoposide|
45942519|NCT00287950|Drug|vincristine sulfate|
45942520|NCT00287950|Procedure|adjuvant therapy|
45942521|NCT00287950|Procedure|conventional surgery|
46075016|NCT00872053|Device|Anklebot|"The Anklebot is a robotic device that is worn via a leather boot and knee brace (Fig.1). As the participant goes through a series of ankle-training games, the Anklebot can assist ankle movement throughout 3 planes."
46075017|NCT00872053|Device|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs over a treadmill through position controlled trajectories that mimic normal human gait patterns.
45453020|NCT01331252|Other|semi-recumbent|Patient rests in a semi-recumbent body position
45453021|NCT01331252|Other|supine|Patient rests in a supine position
45676814|NCT02119325|Dietary Supplement|0% fibre|Placebo is an energy matched powdered beverage
45676815|NCT01816893|Other|Hypoglycemic hyperinsulinemic clamp|
45676816|NCT01816893|Other|Euglycemic hyperinsulinemic clamp|
45942522|NCT00287950|Procedure|neoadjuvant therapy|
45942523|NCT00287950|Radiation|radiation therapy|
45942524|NCT00288028|Drug|bortezomib|Dose of Bortezomib* Level 1: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 21 days; Level 2: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 28 days; Level 3: 1.0 mg/m2 on Day 1, 8, 15 - Every 28 days; Level 4: 1.0 mg/m2 on Day 1, 8, 15 - Every 35 days
45942525|NCT00111540|Drug|exenatide|subcutaneous injection, 5 mcg, twice a day for 4 weeks (transition period), then 10 mcg twice a day till study termination
45942526|NCT00288106|Other|Follow-up|No additional drug was given; clinical observation of men diagnosed with prostate cancer who were previously randomized and treated on PCPT
46075018|NCT04233450|Other|BodyBabe questionnaire|assessment of young mothers' perceptions using self-questionnaires
46075019|NCT00872131|Drug|Sertraline|Oral sertraline will begin at 50 mg per day, then increase to 75 mg per day on Day 8, then increase to 100 mg per day on Day 15. The dose may be increased to 150 mg per day on Week 8, based on clinical response and medication toleration.
46075020|NCT04233294|Drug|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
45942527|NCT02965547|Device|Remote ischemic conditioning equipment|The RIPC consisted of 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm and other side thigh. This intervention was undertaken one time in total.
45655959|NCT05525351|Drug|Alfentanil|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0~1000mcg according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
45655960|NCT05525351|Drug|Dexmedetomidine|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical Dexmedetomidine ranged from 0.5-1 ug/kg/hr according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
45807155|NCT05039021|Device|HARMONIC 1100 Shears|HARMONIC 1100 Shears is used for vessel transection according to instructions for use.
46075021|NCT04233294|Drug|Camrelizumab|Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
46075022|NCT04233294|Drug|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
45453022|NCT03193736|Device|MINIject implant|"MINIject implant is used to reduce intra-ocular pressure (IOP) in the eye through a minimally-invasive Glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery."
46075023|NCT00872209|Drug|0.3% Ciprofloxacin Ear Drops|4 gtt BID for 7 days.
46075024|NCT00872209|Drug|0.3% Ciprofloxacin Foam Otic Cipro|1 application, BID for 7 days
46075025|NCT02788110|Other|Noninvasive neurally adjusted ventilatory assist (NIV NAVA)|Neurally adjusted ventilatory assist (NAVA) is a mode of ventilation that uses a functional naso/orogastric tube with embedded electrodes which detect diaphragmatic contractions (called the Edi signal). NAVA uses this Edi signal to synchronize ventilator support to the patient's own respiratory efforts and to support these efforts as needed.
45807156|NCT05036707|Device|Xenodiagnosis Ticks|Larval ticks will be obtained from Dr. Sam Telford from a laboratory maintained tick colony at Tufts Veterinary School. These ticks are hatched from eggs laid by ticks that have fed only on specific pathogen free laboratory animals that were purchased from established vendors.
46075026|NCT02788110|Other|Nasal intermittent positive pressure ventilation (NIPPV)|"Nasal intermittent positive pressure ventilation (NIPPV) or noninvasive pressure control ventilation (NIV PC) is a mode of ventilation delivering unsynchronized puffs of air or breaths to a baby through nasal cannulae."
46075027|NCT00872287|Procedure|Laparoscopic Cholecystectomy|Four ports classic laparoscopic cholecystectomy
46075028|NCT00872287|Procedure|SILS|Single transumbilical incision laparoscopic cholecystectomy
45807157|NCT05036707|Procedure|skin biopsy|2-3 mm skin punch biopsies will be performed.
45807158|NCT05036707|Procedure|blood draw|Peripheral blood draws will be performed.
45807159|NCT05036070|Device|Model C0001|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
45807160|NCT05036070|Device|Model ZCB00|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
45807161|NCT05033392|Drug|Toripalimab Injection|A domestic PD-1 antibody
45807162|NCT05029921|Drug|Ustekinumab|Ustekinumab will be administered as an IV injection in induction phase and as a SC injection in maintenance phase.
45942528|NCT02965547|Procedure|Intravenous blood collection|Nurses will collect intravenous blood 6ml twice(at baseline and 1h after RIPC).The blood samples will be stored for laboratory test.The blood samples only use for the trial.
46075029|NCT02787876|Drug|Pegteograstim|
46075030|NCT00872365|Behavioral|Regular aerobic physical exercise|Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.
46075031|NCT00872365|Dietary Supplement|Micronutrients|Zinc 30mg, Magnesium 400mg, Beta-carotene 9 mg, Tocopherol 30mg, vitamin C 200mg y Niacin 100mg.
46075032|NCT00872365|Other|Activities of daily living + placebo|"Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist and prenatal care.~Placebo Comparator: Equivalent to placebo (maltodextrin)."
46075033|NCT03637062|Drug|Progesterone|progeaterone:Utrogestan is one of the normal drugs in China to prevent spontaneous preterm birth, the Utrogestan used in this study is from Laboratories Besins International.
46075034|NCT03637062|Device|pessary|pessary: The cervical pessary is a vaginal device (silicone ring) that is used to treat pregnant women for preventing spontaneous preterm birth.
46075035|NCT04040647|Behavioral|mobilization and ambulation|6-min walk test (6-MWT)
46075036|NCT02793882|Drug|18F-Fluorocholine PET/CT|
46075037|NCT02787954|Procedure|TACE|Procedure for giving chemotherapy directly to tumor cells.
46075038|NCT02787954|Procedure|Y-90|Using a combination of radiation and chemotherapy directly on the tumor cells to cause cell death.
46075039|NCT02787954|Procedure|MWA|Using heat to kill tumor cells.
46075040|NCT02787954|Procedure|IRE|Using energy to disrupt tumor cell activity, thereby causing cellular death.
46075041|NCT02793804|Device|Oraquick (made in Thailand)|
46075042|NCT02793570|Other|observational|
45807163|NCT05029414|Procedure|Endovascular Therapy|Endovascular treatment of stroke is the non-surgical treatment for the sudden loss of brain function due to blood clots. The blood clot is removed from the blood via devices (i.e. stent-retriever, aspiration catheters and balloon guide) to achieve revascularization.
45942529|NCT02965547|Procedure|dCA measurement|Serial measurements of dCA were performed at 7 time points, baseline, 1h, 3h, 6h, 9h, 12h, 24h after RIPC.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
45942530|NCT00288145|Behavioral|WOW, Working On Wellness weight management|Treatment site, worksite-based health promotion activities such as self-directed campaigns, lectures, small group programs, online programs, environment interventions (food service and physical)--all with focus on nutrition, physical activity and/or weight management.
45655961|NCT04869865|Dietary Supplement|9-day detoxification cleanse and 1 week of pre-cleanse transition|Subjects will participate in the full 9-day Springtime Home Cleanse, including the week prior to a pre-cleanse transition period. The cleanse includes a transition week, 9 days of a monodiet, internal oleation with ghee, external oleation, herbs, purgation, and an enema. During this time, subjects will also attend daily online meetings on Facebook Live throughout the cleanse and on AyurPrana's AyurLearn online portal to participate in guided mediation and yoga. Subjects will also use these platforms to access daily cleanse instructions and journaling topics.
45655962|NCT04869475|Drug|Arsenic trioxide|This is a single-arm study with all patients receiving arsenci trioxide.
45655963|NCT05521763|Behavioral|ensuring the availability of influenza vaccine supply & developing influenza vaccine awareness|"The four interventions will be:~i) ensuring the availability of influenza vaccine supply; ii) developing influenza vaccine awareness; iii) both ensuring influenza vaccine supply and developing influenza vaccine awareness and iv) control arm with no intervention."
45655964|NCT03044821|Procedure|Open-Uterus Fetal Repair|Single arm study. All patients will receive the open-uterus fetal repair.
45655965|NCT05117255|Behavioral|Negative Emotions and Addiction Tools Program (NEAT)- Cognitive Behavioral Therapy|The program provides simplified clinical, learning and neuroscience-based education about the vicious cycle in which negative affect serves to motivate drinking, which, in turn, worsens negative affect. Participants also learn how each of three skills (breathing control, cognitive restructuring, problem solving) was designed to disrupt a specific element of the vicious cycle that includes physiological, psychological and behavioral processes.
45807164|NCT05028569|Drug|BOTOX|Intramuscular Injection
45807165|NCT05028569|Drug|Placebo|Intramuscular Injection
45807166|NCT05027945|Drug|Post-Transplant Cyclophosphamide (PTCY)|Post-Transplant Cyclophosphamide: 50 mg/kg IV daily over 2 hours on days +3 and +4, dosed according to ideal body weight
45807167|NCT05027945|Drug|Cyclophosphamide (CY)|For 7/8 Matched Related or Unrelated or Haploidentical Donor, prior to transplant 14.5 mg/kg IV daily on days -6 and -5
45942531|NCT00288184|Drug|Allopurinol|Allopurinol adminsitered one 200mg capsule by mouth twice daily. Placebo capsule once daily during crossover
45942532|NCT00288184|Drug|Placebo|
45453023|NCT03275168|Behavioral|Intervention|Sexual partners will receive dyadic counseling and support for condom negotiation after receipt of individual evidence based HIV/STI prevention intervention (Sister-to-Sister (female) and Focus on the Future (male).
45655966|NCT05117255|Behavioral|Progressive Muscle Relaxation Training (PMRT)|PMRT is a standard stress management coping skill that entails tensing and releasing specified muscle groups to obtain deep muscle relaxation.
45655967|NCT05521685|Procedure|Endoscopic Ultrasound (EUS) administration of cyanoacrylate tissue adhesive to control bleeding gastric varices|Subjects will have undergone treatment and been enrolled into the existing registry.
45655968|NCT02612155|Biological|Infusion of autologous cord blood|Infants who meet study enrollment criteria will receive up to 2 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells.
45807168|NCT05027945|Drug|Fludarabine|40 mg/m2 IV over 30 mins daily For 8/8 Matched Related or Unrelated Donor Fludarabine dose will be on days -6, -5, -4, and -3 For 7/8 Matched Related or Unrelated or Haploidentical Donor Fludarabine dose will be on days -6, -5, -4, -3, and -2
45942533|NCT02960542|Behavioral|HELP Prevent Cancer Intervention|This Behavioral: Lifestyle Weigh Loss Intervention involves a dietary weight-loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight-loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight-loss of .3 kg/week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 minutes/week.
45942534|NCT00288223|Drug|Telithromycin|one daily intake of 800 mg (i.e. 2 x 400 mg tablets) per os in a single intake with a meal for 5 days.
45942535|NCT00078143|Behavioral|Behavior Therapy|
45942536|NCT00288262|Drug|melatonin 0.5 mg|
45942537|NCT00111579|Biological|CAIV-T|A total vol. of 0.2 mL will be administered intranasally (approx. 0.1 mL into each nostril)for ea. of two doses.
45942538|NCT00111579|Other|TIV|A total vol. of 0.25 will be administered intramuscularly for each of two doeses.
45942539|NCT00288301|Behavioral|Weight loss intervention|weight loss intervention
45942540|NCT00288340|Device|functional magnetic resonance imaging|
45942541|NCT00288379|Drug|formoterol|
45942542|NCT00288379|Drug|budesonide/formoterol|
45942543|NCT00078182|Drug|Tenofovir DF|
45942544|NCT00288418|Device|Central Venous Catheter|7-French x 20-cm, triple lumen, short-term CVC vs. 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU
45942545|NCT00111618|Drug|AS1404 (DMXAA)|
45655969|NCT02612155|Biological|Placebo|Infants who meet study enrollment criteria will receive up to 2 placebo infusions composed of an equivalent volume (volume of product that would have been administered if the infant randomized to the intervention arm) of packed red blood cells (PRBCs) from the red cell compartment of the separated cord blood unit.
45655970|NCT05100251|Drug|WBC100|"The first stage: single dose escalation according to classic 3+3 dose escalation method. 6 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QD. The second dose group is 1mg QD. The third dose group is 1.5 mg QD. The fourth dose group is 2.0 mg QD. The fifth dose group is 2.5 mg QD. The sixth dose group is 3.0 mg QD. In each dose group, patients take WBC100 once on cycle 0. After a washout period of 2 days, patents start subsequent 4 weeks cycles until progression disease or intolerable toxicity. In each cycle, patient was on WBC100 every for 3 weeks and off for 1 week.~The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage enroll 12 pancreatic patients with positive c-myc expression."
45655971|NCT05100017|Drug|Methocarbamol|Patients will receive oral Methocarbamol 750mg every six hours as needed for pain post ureteroscopy in addition to the standard postoperative pain regimen.
45655972|NCT05100017|Drug|Oxybutynin|Patients will receive oral Oxybutynin XL 10mg daily for pain post ureteroscopy in addition to the standard postoperative pain regimen.
45655973|NCT04366531|Behavioral|START-VET|prison reentry program
45655974|NCT04366531|Other|Treatment as usual|This intervention involves no additional services above what is provided by the local health care system
45655975|NCT04876885|Other|Educational video|Three two-minute educational videos about COVID-19 vaccine development and dissemination
45655976|NCT05532137|Behavioral|e-12HR app|"The 'feedback' e-12HR version: This version of the application allows to calculate the Mediterranean Diet Serving Score (MDSS) index; additionally, this version is designed to promote the Mediterranean diet with two specific automatic functions:~Evaluation of the user's MDSS index.~Identification of the food groups for which the user has not fulfilled the Mediterranean diet recommendations (in addition, this version also provided the user the consumption recommendations established for these food groups)."
45942546|NCT00288457|Device|Ureteral Stent|Ureteral stents are not investigatory but rather part of standard of care. In this study, we were interested in having patients fill out pre and post-operative questionnaires so that we could compare their symptoms with the length of their ureter and the stent placed.
45655977|NCT04865185|Diagnostic Test|Xylocaine spray 100mg/ml|Topical application
45655978|NCT04865185|Diagnostic Test|Ethanol|Topical application
45942547|NCT00399425|Drug|bemiparin (low molecular weight heparin)|
45942548|NCT00417586|Device|Specialized Doppler Ultrasound Instrument|Patients with a reading of 140 cm/sec or higher will be referred for further duplex screening
45942549|NCT00111696|Biological|MEDI-522|Supplied at a concentration of 50 mg/mL in both 2 mL and 10mL vials
45655979|NCT05518565|Other|No intervention|No intervention
45655980|NCT04865107|Biological|UC-MSCs|3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)
45655981|NCT04865107|Biological|Placebo|PlasmaLyte A and 5% Human Albumin
45655982|NCT05531903|Device|Description of Slow pathway signals to facilitate ablation|3D endocardial mapping in order to identify slow pathway signals and abolish or modificate them after radiofrequency ablation
45655983|NCT03046459|Biological|BNZ132-1-40|pegylated peptide inhibiting IL-2, IL-9 and IL-15
45655984|NCT03046381|Drug|Tocilizumab|Tocilizumab 162mg 1x weekly s.c.
45807169|NCT05027945|Radiation|Total Body Irradiation (TBI)|For 7/8 Matched Related or Unrelated or Haploidentical Donor, 200cGy on day -1
45807170|NCT05027945|Drug|Busulfan|AUC Targeted Dose based on busulfan test dose PKs, IV infusion over 3 hours once daily (3.2 mg/kg IV per day will be the default dose) per the below time frame: For 8/8 Matched Related or Unrelated Donor Busulfan dose will be on days -6, -5, and -4 For 7/8 Matched Related or Unrelated or Haploidentical Donor Busulfan dose will be on days -4 and -3
45807171|NCT05027945|Drug|Sirolimus|Sirolimus: on day +5 5mg PO loading dose q4h for 3 doses, then 5 mg PO q24h starting on day +6
45807172|NCT05027945|Drug|Mycophenolate mofetil (MMF)|Mycophenolate mofetil (MMF): 15 mg/kg IV over 2 hours BID starting on day +5 until approximately day +35 (+/-2 days)
45807173|NCT05027945|Drug|Busulfan test dose|0.8 mg/kg IV over 2 hours
45807174|NCT05027945|Procedure|Allogeneic HSCT|stem cell transplant on day 0
45942550|NCT00288496|Drug|polyethylene glycol bowel lavage solution|
45655985|NCT05521373|Device|ultrasound cervical selective nerve root block|"A (7-12) MHz linear transducer will be applied to the symptomatic side of the neck in the transverse plane. The targeted nerve root of each patient will be identified by moving the transducer cranially from the C7 transverse process as a reference point.~After the targeted nerve root identified, a needle will be gently introduced toward the dorsal aspect of the nerve root under real-time US guidance with an in-plane approach. The needle tip will be placed between the nerve root and posterior tubercle outside of the intervertebral foramen and the vessels will be around the nerve root with color Doppler. On confirmation of the absence of abnormal findings and careful aspiration, 3 cc of the treatment drug composed of dexamethasone (10 mg) and 0.2% lidocaine, will be injected under real-time US guidance"
45655986|NCT05521373|Device|ultrasound and fluoroscopy-guided cervical selective nerve root block|The targeted transverse process was identified by slowly moving the probe in all directions with the 7th cervical spine transverse process as the reference point. a spinal needle 22 G was inserted. First, 1 ml of the contrast media was injected. The antero-posterior images were obtained to confirm the distribution or spread pattern of the injected contrast media with C-arm fluoroscopy. The following steps were initiated after confirming for proper shadowed contrast of the nerve root and absence of intravascular injection of the contrast media. Three cc of the treatment drug, composed of dexamethasone (10 mg) and 0.5 % lidocaine will be injected after confirming the absence of abnormal findings.
45655987|NCT05521295|Other|no intervention|no intervention in this study
45655988|NCT04876807|Drug|ACP-196|In Parts 1, 2, and 3, participants will receive oral Dose 1 of ACP-196 (reference or acidic formulation as applicable) on Day 1, Day 3, Day 8, and Day 10.
45655989|NCT04876807|Drug|Omeprazole|Participants will receive omeprazole in all parts as: on Day 8 and Day 10 with water in Part 1; on Day 8 with water and on Day 10 with acidic beverage in Part 2; on Day 8 with water and on Day 10 with grapefruit juice in Part 3.
45655990|NCT05518409|Biological|Detection of cytof in peripheral PBMC|Each subject needs to take 5ml of peripheral venous blood to extract PBMC cells, and then conduct cytof detection. This is a mass spectrometry flow cytometry method based on single cell level. It has the ability to analyze all immune cells with high resolution.
45655991|NCT05518409|Drug|Donepezil for patients with AD and DLB|The subjects in AD and DLB groups were given donepezil at an initial dose of 5mg and then increased to 10mg one month later. Lasting for 1 year.
45655992|NCT02614729|Other|Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN)|Diet contains all plant proteins. Meals are evenly distributed throughout the day.
45655993|NCT02614729|Other|Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
45655994|NCT02614729|Other|High Protein-Beef, Even Distribution (HP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
45807175|NCT05024773|Drug|ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)|Schedule: once a week for 12 consecutive weeks (induction therapy). Patients who achieve a complete response at the end of the induction phase will enter the maintenance phase, during which ONCOFID-P-B is administered once a month for 12 months until recurrence or progression of the disease.
45807176|NCT05020236|Drug|Elranatamab|subcutaneous
45807177|NCT05020236|Drug|Daratumumab|Daratumumab / hyaluronidase, subcutaneous
45807178|NCT05020236|Drug|Pomalidomide|oral
45942551|NCT00288535|Procedure|PCI of bifurcated coronary lesions using sirolimus coated stents in modified T-Stenting -Technique|
45942552|NCT00399464|Drug|alfuzosin|
45942553|NCT00111735|Drug|Thyroxine|
45942554|NCT00288652|Drug|[S,S]-Reboxetine|
45942555|NCT00399503|Procedure|Spectral T Wave Alternans|
46075043|NCT02788032|Other|EnergieShake oral supplement|The participants will be given EnergieShake® powdered nutritional supplement twice daily during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days followed by an 8 day intervention on EnergieShake®
45807179|NCT05020236|Drug|Dexamethasone|oral
45807180|NCT05019716|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
45807181|NCT05019716|Procedure|Biopsy|Undergo biopsy
45942556|NCT00399503|Procedure|Modified Moving Average T Wave Alternans|
45942557|NCT00399503|Procedure|Baroreceptor Sensitivity|
45807182|NCT05019716|Procedure|Chest Radiography|Undergo chest x-ray
45807183|NCT05019716|Drug|Cisplatin|Given IV
45942558|NCT00399503|Procedure|Heart Rate Variability|
45942559|NCT00399503|Procedure|Heart Rate Turbulence|
45942560|NCT00399503|Procedure|Deceleration Capacity|
45942561|NCT00399503|Procedure|Signal Averaged ECG|
45942562|NCT00288691|Drug|Asoprisnil (BAY86-5294)|5mg/day
46075044|NCT02789436|Drug|L. reuteri Prodentis® lozenges|Twice daily, for 28 days
46075045|NCT02789436|Other|Placebo lozenges|Twice daily, for 28 days
45942563|NCT00288691|Drug|Asoprisnil (BAY86-5294)|10mg/day
45942564|NCT00288691|Drug|Asoprisnil (BAY86-5294)|25mg/day
45807184|NCT05019716|Procedure|Computed Tomography|Undergo CT or PET-CT
45807185|NCT05019716|Drug|Etoposide|Given IV
45807186|NCT05019716|Procedure|FDG-Positron Emission Tomography|Undergo FDG-PET
45807187|NCT05019716|Procedure|Magnetic Resonance Imaging|Undergo MRI
45655995|NCT02614729|Other|High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)|Diet contains combination of beef and plant proteins. Meals are unevenly distributed throughout the day.
45807188|NCT05019716|Procedure|Positron Emission Tomography|Undergo PET-CT
45807189|NCT05018078|Biological|Coronavirus vaccine|Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
45942565|NCT00288691|Drug|Placebo|Placebo
45942566|NCT00111774|Drug|ABX-EGF|
46075046|NCT02789280|Behavioral|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated"
45807190|NCT05016882|Drug|NNC0194 0499 50 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months
45807191|NCT05016882|Drug|Placebo (NNC0194-0499)|Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months
45807192|NCT05016882|Drug|Semaglutide 3 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months
45807193|NCT05016882|Drug|Semaglutide placebo|Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months
45942567|NCT00288730|Drug|nesiritide|
46075047|NCT02789280|Other|Wait list|will receive the behavioral activation condition after one week of completing baseline assessment.
46075048|NCT02793648|Drug|Ascorbic Acid|Two daily oral doses of 200mg of encapsulated vitamin C twice a day, administered at breakfast and dinner
46075049|NCT02793648|Drug|Alpha tocopherol|Two daily oral doses of 200mg of encapsulated vitamin E twice a day, administered at breakfast and dinner
45655996|NCT05531825|Device|A device for detecting arteriovenous fistula vascular function|An innovative design based on PVDF piezoelectric membrane by combining all kinds of technologies including NB-iot/4G transmission mode to realize real-time monitoring and feedback of the health status of arteriovenous fistula vessels
45655997|NCT05518331|Drug|avatrombopag|Avatrombopag, 40-60 mg (body weight < 80 kg, 40 mg per day; body weight > 80 kg, 60 mg per day) orally once daily for at least 3 months and followed up for 3 months to determine hematological response and evaluate the drug security.
45807194|NCT05016882|Drug|NNC0174 0833 10 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 once weekly The study will last for about 19 months
45807195|NCT05016882|Drug|NNC0174 0833 placebo|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 placebo once weekly The study will last for about 19 months
45807196|NCT05009979|Drug|F18-FDG|Within approximately 2 weeks of each 18F-DCFPyL PET/CT scan, participants will be scanned with a 18F-FDG PET/CT imaging at the NIH Clinical Center using standard procedures. The 18F-FDG PET/CT imaging performed will allow the localization of viable tumor sites and characterize their FDG metabolism for comparison with 18F-DCFPyL imaging. The 18F-FDG PET/CT imaging will consist of an 18F-FDG injection and PET/CT imaging performed approximately 1 hour post 18F-FDG injection. A corresponding low dose CT scan for attenuation correction and co-registration purposes will be performed prior to the PET image.
45807197|NCT05009979|Device|MRI|A standard of care CT and/or MRI will be performed within 2 months of each 18F-DCFPyL PET/CT.
45807198|NCT05009979|Device|CT|A standard of care CT and/or MRI will be performed within 2 months of each 18F-DCFPyL PET/CT.
45807199|NCT05009979|Drug|F18-DCFPyL|Each subject will receive a single IV dose of 18F-DCFPyL by bolus injection at a rate of approximately 1 ml/3-5 sec. The maximum amount of injected active drug will be less than 4.02 microgram. The target administered activity will be 9 mCi. The 18F-DCFPyL PET/CT imaging will consist of the 18F-DCFPyL injection, followed by a approximately 45 min dynamic CT imaging of a single bed position (including the liver lesion), and a static whole-body PET/CT imaging (top of head to mid-thighs) performed at 1 hour (+/- 10 minutes) post 18F-DCFPyL injection. Only a single injection of 18F-DCFPyL is required. The initial 45 minutes dynamic regional scan will be used to determine the kinetics of 18F-DCFPyL within the tumor as compared with normal liver and other background.
45807200|NCT05008757|Other|no drug|no intervention
45807201|NCT05007782|Drug|GS-1811|Administered intravenously
45942568|NCT00417742|Behavioral|Service delivery through a Headache Management Program|
45942569|NCT00399581|Procedure|High Frequency Oscillatory Ventilation-Hi|HFOV will be conducted with recruitment maneuvers and with a table of mPaw and FiO2s that include higher mPaw's.
45942570|NCT00399581|Procedure|High Frequency Oscillatory Ventilation-Lo|HFOV will be conducted without routine recruitment maneuvers and with a table of mPaw and FiO2s that include relatively low mPaw's.
45807202|NCT05007782|Drug|Zimberelimab|Administered intravenously
45942571|NCT00288769|Drug|daily sublingual tablets Vitamin B12 1000 mcg versus placebo|
45942572|NCT00288808|Device|Hemosense (PT/InR point of care device)|
45942573|NCT00111852|Drug|Desmoteplase|Desmoteplase 90 mcg/kg, intravenous administration.
45942574|NCT00111852|Drug|Desmoteplase|Desmoteplase 125 mcg/kg, intravenous administration.
45942575|NCT00111852|Drug|Placebo|Dose-Match Placebo, intravenous administration.
45942576|NCT00288925|Drug|Z-360|
46075050|NCT02793648|Drug|PLACEBO|Two daily oral doses of 200mg of encapsulated placebo, administered at breakfast and dinner
45807203|NCT05007730|Dietary Supplement|Transitional-state food therapeutic nutrition supplement|"Participants will consume at least one snack-sized package of the transitional-state food supplements per day across the intervention trial."
45942577|NCT00399620|Procedure|Gingival crevicular fluid samples (this procedure is added to the subject usual medical follow-up).|
45942578|NCT02960971|Procedure|Thoracic surgery for lung cancer|Lung cancer resection performed via Video-assisted thoracoscopic surgery (VATS) and/or thoracotomy, including lobectomy, bilobectomy, pneumonectomy, resection of the tracheobronchial bifurcation, wedge resection, sleeve resection and combinations hereof.
45942579|NCT00288964|Device|Hattler Respiratory Assist Catheter|
45942580|NCT00289003|Drug|Soluble beta-1,3/1,6-glucan|
45942581|NCT00289042|Drug|Enoxaparin|
45942582|NCT00111891|Drug|niacin (+) laropiprant|
45942583|NCT00111891|Drug|Comparator: placebo (unspecified)|
45942584|NCT00289081|Device|Total Knee Replacement|Rotating Platform (RP) Cruciate Retaining Knee implant
45942585|NCT00289081|Device|Total knee replacement|Rotating Platform (RP) Cruciate Substituting Knee implant.
45942586|NCT00289237|Behavioral|Lifestyle intervention|
46075051|NCT02789358|Other|Conventional cryotherapy dosage|Cryotherapy dosage: 180 seconds applications until block of the pulmonary vein plus 1 bonus freezing of 180 seconds
46075052|NCT02789358|Other|Experimental cryotherapy dosage|"cryotherapy dosage: applications time to block of the vein plus 60 seconds long until block of the vein plus 1 bonus freezing of 120 seconds"
45655998|NCT04876573|Drug|Cyproheptadine Hydrochloride 4 MG|"Phase 1: Cyproheptadine 4 mg three time a day for 10 days, per oral administration associated to Standard care of COVID 19 patient currently recommend by WHO~Phase 2: Cyproheptadine 8 mg three time a day for 10 days, per oral administration associated to Standard care of COVID 19 patient currently recommend by WHO~The dose will be adjusted according to the renal function."
45655999|NCT05521139|Diagnostic Test|drug sensitivity results|drug sensitivity results including the carbapenem-resistant Klebsiella pneumoniae and carbapenem-sensitive Klebsiella pneumoniae
45656000|NCT03046147|Procedure|Roux-en-Y gastric bypass|Roux-en-Y gastric bypass surgery for morbid obesity
45807204|NCT05007080|Biological|Ad26.COV2.S|Ad26.COV2.S will be administered as intramuscular (IM) injection.
45807205|NCT05005728|Combination Product|vudalimab + carboplatin + cabazitaxel or docetaxel|Vudalimab IV, carboplatin IV, cabazitaxel or docetaxel IV
45807206|NCT05005728|Combination Product|vudalimab + olaparib|Vudalimab IV, olaparib oral
45807207|NCT05005728|Biological|vudalimab monotherapy|Vudalimab IV
46075053|NCT02789358|Device|Arctic Front Advance ST Cryoenergy Balloon Catheter|Electrical isolation of pulmonary veins with Arctic Front Advance cryoballoon
46075054|NCT02789358|Drug|Adenosine triphosphate|12 mg of adenosine triphosphate are administrated intravenously to test dormant conduction in pulmonary veins apparently disconnected
46075055|NCT02789358|Device|nECG platform Nuubo®|30 days electrocardiographic monitoring system to detect atrial fibrillation episodes after ablation
45807208|NCT05005728|Combination Product|vudalimab + cabazitaxel or docetaxel|Vudalimab IV, cabazitaxel or docetaxel IV
45807209|NCT05003843|Device|Indigo Aspiration System|Indigo Aspiration System
45807210|NCT05003804|Biological|STMC-103H|STMC-103H is a live biotherapeutic product (LBP) containing a consortium of intestinal bacteria
45807211|NCT05003804|Biological|Placebo|Powder containing excipients found in STMC-103H: magnesium stearate, mannitol and silicon dioxide.
45942587|NCT00111930|Drug|DHEA|
45942588|NCT00289354|Drug|Chromium Picolinate (600 mcg Cr) + biotin (2 mg)|
45942589|NCT04711499|Behavioral|Fatigue|The intervention will be assessing the participant in a fatigued state compared to a non fatigued state
45942590|NCT00289393|Behavioral|Perceived outcome by both patient and physician|
45942591|NCT00289432|Behavioral|Psychoeducative|The experimental group consists of five weekly 2-hours sessions, focusing on coping with diagnosis and treatment
45942592|NCT00289432|Other|Support group|Standard Hospital follow-up support group
45942593|NCT00289510|Biological|Inactivated influenza vaccine (whole virion, Vero cell-derived)|
45942594|NCT00289510|Biological|Inactivated influenza vaccine (egg derived) [licensed control vaccine]|
45942595|NCT00111969|Device|Celacade™ system|
45942596|NCT00289588|Drug|Mupirocin (drug)|
45942597|NCT04711538|Device|MRI|imaging inner ear and petrous bone of the candidate by MRI and CT
45942598|NCT00289627|Drug|ipilimumab (MDX-010, BMS-734016)|IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
45942599|NCT00401661|Drug|Alfuzosin|One tablet of 10mg once daily at the end of evening meal
45942600|NCT04711616|Behavioral|physical therapy intervention|physical therapy interventions include thermal therapy, electrical therapy, manual therapy, and therapeutic exercise.
45942601|NCT00289705|Procedure|Surgery|Laparoscopic Roux-en-Y gastric bypass
45942602|NCT00289822|Drug|intracoronary infusion of progenitor cells|
45942603|NCT00289861|Drug|Risperidone|
45942604|NCT00289861|Drug|placebo|
45942605|NCT02964663|Device|esCCO|comparison of non-invasive monitoring esCCO vs VV on cardiac output measurements
45942606|NCT00289939|Behavioral|Motivational interviewing to reduce risk for HIV and DV|
45942607|NCT04711460|Behavioral|observation|Young participants versus Old participant scores at admission and discharge were compared
45942608|NCT00290017|Drug|talabostat|
45942609|NCT00290017|Drug|pemetrexed|
45656001|NCT05521061|Dietary Supplement|2-fucosyllactose|Volunteers will be visited to provide the investigational product/placebo to the diets of the patients included in the study for 3 months, and the use of the investigational product/placebo will be monitored. Parents will be trained by their fellows to provide synthetic breast milk oligosaccharides/placebo, the products to be used in the study will be provided by the scholars on a weekly basis, and their daily intake and possible problems will be monitored through weekly interviews. In this study, it is planned to supplement the diet of the placebo group with 1.5 g/day maltodextrins to approximately half of the diet and to supplement the other half with 3 g/day maltodextrins, after the group was randomized within itself. Effects of these doses on metabolic control are not expected. Maltodextrine is in powder form, its dosage of up to 3 g/day has a negligible effect on blood glucose, it has a neutral taste, it is cheap and easy to find, and it is safe and ineffective.
45656002|NCT03046069|Other|Telephone interviews|Qualitative concept elicitation telephone interviews will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
45656003|NCT03046069|Other|In-person focus groups|Qualitative concept elicitation in-person focus groups will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
45656004|NCT03046069|Other|DCE surveys- cognitive interviews|Draft version of the DCE surveys will be tested with subjects in cognitive interviews to explore the saliency of the attribute choices and assess whether the attributes are understandable, meaningful and comprehensive.
45656005|NCT03046069|Other|Modified DCE|The modified DCEs will be piloted with subjects with COPD in each country to refine the underlying design and ensure that information is collected in an efficient way to enable the statistical analysis to be as precise as possible.
45656006|NCT03046069|Other|Online DCE survey|An online DCE survey questionnaire will be given to the subjects to identify subject preferences, priorities and treatment goals.
46075056|NCT04233372|Drug|Delstrigo|"Doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo®) 100 mg doravirine, 300 mg lamivudine,300 mg tenofovir disoproxil fumarate equivalent to 245 mg de tenofovir disoproxil.~1 covered tablet for day .( will be administered 28 days maximum)"
45807212|NCT05002660|Behavioral|Group 1 (Intervention)|The investigators will evaluate the efficacy of the CC curriculum in a 24-months community-based randomized controlled trial. They will compare changes in CVD-related anthropometric, behavioral, and psychosocial parameters between subjects in intervention and control communities.
45942610|NCT00112008|Drug|De Novo Administration of Darbepoetin Alfa|Administration Q2W for 18 weeks. starting dose is 0.75 mcg/kg rounded to the nearest dose: 20, 30, 40, 50, 60, 80, 100, 150, 200 0r 300 mcg. Titrate to maintain Hb within 11.0 - 13.0 g/dL
46075057|NCT03847506|Drug|Ezetimibe/Rosuvastatin|Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Candesartan cilexetil 8 mg placebo
45807213|NCT05002660|Behavioral|Group 2 (Control)|Group 2 will be offered the same activities as Group 1 after the conclusion of the research study.
45807214|NCT05001880|Biological|Atezolizumab|Given IV
45807215|NCT05001880|Biological|Bevacizumab|Given IV
45807216|NCT05001880|Procedure|Biospecimen Collection|Undergo blood and tissue sample collection
45807217|NCT05001880|Drug|Carboplatin|Given IV
45807218|NCT05001880|Procedure|Computed Tomography|Undergo CT scan
45942611|NCT00290056|Drug|Eicosapentanoic acid (EPA) and Docosahexanoic acid (DHA).|3.6 gram oral supplementation for 6 months.
45942612|NCT00290134|Drug|Fispemifene once daily for 4 weeks|
46075058|NCT03847506|Drug|Candesartan cilexetil/Amlodipine besylate|Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Ezetimibe/Rosuvastatin 10 mg/10 mg placebo + Candesartan cilexetil 8 mg placebo
46075059|NCT03847506|Drug|Candesartan cilexetil|Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil 8 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg placebo
45807219|NCT05001880|Procedure|Cytoreductive Surgery|Undergo surgery
45807220|NCT05001880|Drug|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
45807221|NCT05001880|Drug|Pemetrexed|Given IV
45807222|NCT05001880|Procedure|Positron Emission Tomography|Undergo PET scan
45942613|NCT04711421|Device|4 VIVOFIT-|Feedback on number of steps taken by patint, as recorded by pedometers, provided by research team
45942614|NCT00112086|Drug|Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)|
45942615|NCT00290173|Drug|efficacy of oral ritodrine in maintaining uterine quiescence|
45942616|NCT00290212|Drug|Natto capsules (food suppl.) cont. 360 microg. vit K2/day|
45942617|NCT00290212|Drug|Placebo capsules|
45942618|NCT00290368|Procedure|Skin Prick Test|
45942619|NCT00290368|Procedure|Nasal allergen challenge|
45656007|NCT04876183|Other|Selfapy for Binge Eating Disorder|Web-based intervention for Binge Eating Disorder with six mandatory weekly sessions covering topics related to eating behaviors, emotion regulation, and stress management, followed by an optional set of up to six modular specialization areas based on individual therapy goals. During the intervention, participants can access an online chat providing crisis management, answering questions concerning the exercises, and technical support. The chat does not include the opportunity to discuss individual topics and concerns about treatment.
45807223|NCT05001516|Drug|LM-302|All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-302 intravenous infusion on day 1 until meet the criteria of treatment discontinuation or withdraw, whichever occurs earlier.
45807224|NCT04994717|Drug|Blinatumomab|Continuous intravenous (cIV) infusion
45807225|NCT04994717|Drug|Low-intensity chemotherapy regimen|Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.
45807226|NCT04994717|Drug|SOC chemotherapy regimen|Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.
45807227|NCT04992507|Procedure|Anesthesia Procedure|Given TIVA
45942620|NCT00290368|Procedure|Nasal filter paper placement|
45807228|NCT04992507|Drug|General Anesthesia Procedure|Given inhaled volatile anesthetics
45807229|NCT04992507|Procedure|Resection|Undergo surgical resection
45942621|NCT00290368|Procedure|Nasal lavage|
45942622|NCT00290368|Procedure|Nasal scrape|
45807230|NCT04990037|Drug|CAN04|Administered intravenously
45656008|NCT04864873|Diagnostic Test|Metagenomic next generation sequencing using Oxford Nanopore|See previous.
45807231|NCT04990037|Drug|FOLFIRINOX|Administered intravenously
45807232|NCT04989816|Drug|Trastuzumab Deruxtecan|Trastuzumab deruxtecan (T-DXd) by intravenous infusion
45942623|NCT00290368|Procedure|Nasal symptoms score|
45942624|NCT00290485|Drug|Imatinib mesylate|
45942625|NCT00078221|Device|Rheopheresis blood filtration|
45942626|NCT00112164|Drug|Xigris|
45807233|NCT04989595|Device|MyIUS app|Data will be self-reported by participants through the MyIUS app.
45807234|NCT04987307|Drug|Efavaleukin alfa|Efavaleukin alfa will be administered by subcutaneous (SC) injection.
45807235|NCT04987307|Drug|Placebo|Placebo will be administered by SC injection.
45807236|NCT04987203|Drug|Tivozanib|Tivozanib will be administered orally.
45807237|NCT04987203|Drug|Nivolumab|Nivolumab will be administered via intravenous infusion.
45807238|NCT04985812|Drug|JNJ-67484703|Participants will receive JNJ-67484703.
45807239|NCT04985812|Drug|Placebo|Participants will receive placebo to JNJ-67484703.
45807240|NCT04980092|Other|one-year follow-up|patients will be followed during the year after ICU discharge, in order to assess kidney function, and muscle and bone health
45807241|NCT04978116|Diagnostic Test|Chest X-Ray (CXR)|"The 3 following imagings will be performed in the emergency room: chest X-Ray (CXR), low-dose CT scan (LDCT) and lung ultrasonography (LUS) will be performed for all included patients, but only one will be available to the clinician in charge of the patient according to the allocation arm.~The blinding will be maintained during the first 5 days, and hence will not influence the diagnosis and the treatment of the patient.~The clinician in charge will be asked to assess on a 3-level Likert scale the probability of pneumonia (high, intermediate, low level) while considering all available clinical and biological data, plus the imaging modality according to the randomization arm."
45807242|NCT04978116|Diagnostic Test|Low-dose CT scan (LDCT)|See above in CXR paragraph
45942627|NCT00290524|Behavioral|Oral alimentation started 12 hours after colorectal surgery|
45942628|NCT00290563|Drug|MK0594|
45942629|NCT00078260|Drug|pemetrexed|"A: 500 mg/m2, IV, q 21 days until disease progression~B: 900 mg/m2, IV, q 21 days until disease progression"
45942630|NCT00290602|Drug|Methylprednisolone sodium succinate|
45942631|NCT00112203|Drug|Itopride|
45942632|NCT00290641|Biological|filgrastim|
45942633|NCT00290641|Biological|graft-versus-tumor induction therapy|
45942634|NCT00290641|Drug|cyclophosphamide|
45942635|NCT00290641|Drug|cyclosporine|
45942636|NCT00290641|Drug|fludarabine phosphate|
45942637|NCT00290641|Drug|mycophenolate mofetil|
45942638|NCT00290641|Procedure|umbilical cord blood transplantation|
45942639|NCT00290641|Radiation|radiation therapy|
45942640|NCT00290680|Drug|bortezomib|
45942641|NCT00290680|Drug|celecoxib|
45942642|NCT02960815|Biological|Intanza|
45942643|NCT02960815|Biological|Mutagrip|
45942644|NCT02960815|Drug|Aldara|
45942645|NCT00112281|Drug|Tilarginine Acetate Injection intravenous infusion|
45942646|NCT00290719|Drug|cisplatin|
45942647|NCT00290719|Drug|gefitinib|
45942648|NCT00290719|Drug|irinotecan hydrochloride|
45942649|NCT00290719|Procedure|conventional surgery|
46075060|NCT02689908|Radiation|computed tomography|low dose protocol of thorax ct
45656009|NCT04864873|Diagnostic Test|Standard microbiological diagnostic pathway|See previous.
45656010|NCT05518253|Biological|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
45656011|NCT05518253|Biological|CD70 CAR-T cells|Administration method: intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
45656012|NCT04864717|Drug|Doxycycline 100mg po once daily x 6 months|active intervention
45807243|NCT04978116|Diagnostic Test|Lung ultrasonography (LUS)|See above in CXR paragraph. LUS will be performed by another clinician than the one in charge of the patient
45807244|NCT04976530|Device|DrugSorb-ATR system|Sorbent hemoperfusion system integrated into the cardiopulmonary bypass (CPB) circuit
45807245|NCT04976530|Device|Sham comparator|Sham comparator in similar position to the investigative device, but NOT integrated into the cardiopulmonary (CPB) circuit
45942650|NCT00290719|Procedure|neoadjuvant therapy|
45942651|NCT00290719|Radiation|radiation therapy|
45942652|NCT00290836|Drug|Human fibrinogen/thrombin and bovine aprotinin (TachoComb H)|
45656013|NCT04864717|Drug|Isotretinoin 40 mg po once daily x 6 months|active intervention
45656014|NCT04876495|Dietary Supplement|Whey protein isolate|"Instantized BiPRO® 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.~Other ingredients in the whey protein shake:~Tropicana Trop50 Orange Juice 207mL~Water 43 mL~Sucralose 0.5g~The total energy 233.47Kcal.~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
45656015|NCT04876495|Dietary Supplement|Potato protein isolate|"Solanic®100 48g (equiv. 45.3g of total protein) presented to participants in a form of a shake.~Other ingredients in the potato protein shake:~Tropicana Trop50 Orange Juice 250mL~Sucralose 0.5g~The total energy 233.46Kcal~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
45656016|NCT04876495|Dietary Supplement|Rice protein isolate|"Oryzatein® Silk 90 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.~Other ingredients in the rice protein shake:~Tropicana Trop50 Orange Juice 183mL~Water 67mL~Sucralose 0.5g~The total energy 233.43Kcal~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
45656017|NCT04876261|Dietary Supplement|Oliphenolia® bitter|"ingredients: concentrated watery extract of olives 94%, lemon juice 6%~35 mg hydroxytyrosol, 0,24 mg Oleuropein"
45807246|NCT04973254|Other|CAB-RPV LA|Monthly administration of injectable HIV medication
45807247|NCT04973254|Other|Standard treatment within an HIV clinic|Standard of care for HIV positive patients will be provided in the HIV clinic that may include HIV medication or may include oral medications.
45807248|NCT04969939|Drug|Semaglutide 2.4 mg and NNC0165-1875 2.0 mg|NNC0165-1875 will be co-escalated once-weekly subcutaneously with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
45942653|NCT00290875|Behavioral|Use of Xrays for diagnosis|
45942654|NCT04729556|Device|Sericin and chitosan cream|A novel film-forming cream containing sericin and chitosan
45942655|NCT00290914|Drug|Vilazodone|
45942656|NCT00290953|Drug|SR48692|
45942657|NCT00290992|Drug|rasburicase (SR29142)|
45942658|NCT00291031|Behavioral|Imagery Rehearsal Therapy (IRT)|"Imagery Rehearsal Therapy is given by psychologists, psychotherapists or psychiatrists. The IRT therapists are all trained by Annette van Schagen, principal investigator.~IRT consists of six 1-hour sessions. The six sessions are given in a period of three months. Each session is described in the IRT Manual. The IRT Manual is devised by the principal investigator Annette van Schagen in colaboration with Victor Spoormaker PhD. There is a patient version of the IRT manual available for the patients, which includes descriptions of the IRT sessions and homework assignments."
45942659|NCT00078455|Drug|ILX651|
45942660|NCT00112320|Procedure|PVR plus RV remodeling|PVR and surgical RV remodeling, which includes bioprosthetic pulmonary valve insertion and resection of akinetic scarred areas on the anterior RV wall to reduce RV volume
45942661|NCT00112320|Procedure|Standard PVR|PVR alone, which includes bioprosthetic pulmonary valve insertion and, when present, resection of right ventricular outflow tract (RVOT) aneurysm
45942662|NCT00291070|Drug|L-theanine|This study will examine the effects of L-theanine (an amino acid found in green tea) on the behavior, cognitive performance and sleep quality of boys with ADHD.
46075061|NCT05361954|Drug|STI-1386|Second generation oncolytic virus
45942663|NCT00291109|Drug|letrozole 2.5 mg|
45942664|NCT00291148|Drug|paroxetine|
45942665|NCT00291148|Drug|pregabalin|
46075062|NCT04232904|Procedure|Transversus abdominous plane block (TAP Block)|TAP block which is a peripheral nerve block preferred to postoperative pain management.
46075063|NCT02788266|Procedure|connective tissue graft+composite resin|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus composite resin
46075064|NCT02788266|Procedure|connective tissue graft+ glass ionomer|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus resin modified glass ionomer cement
45942666|NCT00078494|Drug|EBV-LMP-2|
45942667|NCT00291304|Procedure|MRI|pre-surgery
45942668|NCT00291382|Drug|Salmeterol/fluticasone propionate combination|
45942669|NCT00078533|Biological|CMV CTL infusion|Three dose levels will be explored. The lowest dose level will be 1x10^7cells/m2 and the highest will be 1x10^8/m2. 3-6 pts will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval. Additional patients will be treated at dose level 1 in order to assess the secondary objective of virus-specific immunity from the CTL infusions
45942670|NCT00291460|Device|inspiratory muscle training|
45942671|NCT00112476|Drug|bryostatin 1|Given IV
45942672|NCT00112476|Drug|temsirolimus|Given IV
45942673|NCT00291538|Drug|bortezomib|
45942674|NCT00291616|Drug|Pegylated Interferon-alpha2a|180 microgram s.c. injection weekly
45942675|NCT00291616|Drug|Thymosin alpha1 & Pegylated Interferon-alpha2a|Pegylated interferon 180 microgram s.c. injection weekly Thymosin 1.6 mg s.c. injection twice per week
46075065|NCT02788266|Procedure|connective tissue graft+giomer|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus giomer
46075066|NCT04234620|Drug|Toripalimab injection|240 mg/6 mL/vial. The recommended dose of Toripalima is 3 mg/kg, intravenous infusion every 2 weeks until disease progression or intolerable toxicity.
45453024|NCT03275168|Behavioral|Individual evidence-based STI/HIV prevention intervention|Sexual partners will receive individual evidence-based HIV/STI prevention counseling without partner debrief and/or practice negotiating condom use.
45656018|NCT04876261|Dietary Supplement|Oliphenolia®|"ingredients: grape juice concentrate 70%, concentrated watery extract of olives 30%~38 mg hydroxytyrosol, 0,28 mg Oleuropein"
45656019|NCT04876261|Dietary Supplement|La Vialla Extra Virgin Olive Oil containing 5 mg hydroxytyrosol|"extra virgin olive oil~5 mg hydroxytyrosol"
45656020|NCT05518097|Other|Conventional physical therapy program|Patients with knee osteoarthritis underwent a total of 15 sessions of conventional physical therapy program including hotpack, US, TENS, and exercise 5 days a week, for 3 weeks. Hot pack was applied for 10 minutes, ultrasound was applied continuously at 1 MHz, 1.0 W/cm2 for 10 minutes, and TENS was applied for 30 minutes according to the patient's tolerance. The exercise program consisted of an active, active-assisted range of motion and isometric quadriceps strength training.
45656021|NCT05518019|Dietary Supplement|The Daily Supplement|"Each serving of the dietary supplement (defined as 1 softgel) contains the following formulation:~Organic Broad Spectrum Hemp Extract 35mg Bio-Terpene Complex 52mg Palm Monoglycerides Organic Hemp Seed Oil, Clove Bud Oil, Black Pepper Berry Essential Oil Curcumin (Turmeric Root) Essential Oil~Inactive ingredients: Organic Flaxseed Oil, Gel Shell (Modified Tapioca Starch, Glycerin, Purified Water, Maltitol"
45656022|NCT05517785|Other|Motor performance tests|Performance of 5 motor tests: plank, single leg stance test, standing long jump test (broad jump), 4 x 10 agility test and 20 m shuttle run tests (beeps), after taking ADHD drug or not taking the drug before motor tests performance
45656023|NCT02613871|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
45656024|NCT05531747|Other|Skin biopsy|A maximum of 2 superficial skin biopsies (epidermis/dermis), allowing 10 hair follicles to be obtained, at the edge of the affected area, in healthy territory (excluding the face and folds but not excluding the pubic region), at initiation visit.
45656025|NCT05531747|Other|Blood sample|42mL of blood (6 tubes of 7mL) sampled at initiation visit
45656026|NCT04425161|Other|Fluid challenge (0.9 % NaCl)|500 ml Fluid challenge of (0.9 % NaCl) will be given
45656027|NCT04875949|Procedure|Immunoabsorption/plasmapheresis procedure|
45807249|NCT04969939|Drug|Semaglutide 2.4 mg and placebo 2.0 mg|NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
45807250|NCT04969939|Drug|Semaglutide 2.4 mg and NNC0165-1875 1.0 mg|NNC0165-1875 will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
45807251|NCT04969939|Drug|Semaglutide 2.4 mg and placebo 1.0 mg|NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
45807252|NCT04968912|Other|Placebo|Placebo infusion will be administered intravenously.
45807253|NCT04968912|Drug|Nipocalimab|Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.
45942676|NCT00078572|Drug|capecitabine|Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2 and for the combination arm was 2000 mg/m2.
45807254|NCT04968912|Drug|Standard of Care Treatment|Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.
45942677|NCT00078572|Drug|lapatinib (GW572016)|Lapatinib 1250 mg orally once daily
45942678|NCT00291733|Drug|Levetiracetam|500mg (2 tabl of 250) for one week and 1000mg (4 tabl of 250) for one week
46075067|NCT03618420|Drug|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
46075068|NCT03618420|Drug|Iohexol Inj 300 mg/mL|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
46075069|NCT04234308|Drug|Polyglycolic Acid|Periodontal and periimplant flaps closed with at least one suture with Polyglycolic Acid Absorbable suture, synthetic, 4-0. (TAGUM®).
46075070|NCT04234308|Drug|Catgut|Periodontal and periimplant flaps closed with at least one suture with Chromic Gut Absorbable suture, natural, 4-0. (TAGUM®)
46075071|NCT04234308|Drug|Polytetrafluoroethylene|Periodontal and periimplant flaps closed with at least one suture with expanded Polytetrafluoroethylene Non absorbable suture, synthetic, 4-0. (TAGUM®)
45942679|NCT00291733|Drug|Placebo|Placebo tabl
45942680|NCT00112515|Drug|modafinil|
45942681|NCT00112515|Procedure|cognitive assessment|
45942682|NCT00112515|Procedure|psychosocial assessment and care|
46075072|NCT04234308|Drug|Polyamide|Periodontal and periimplant flaps closed with at least one suture with Nylon Non absorbable sutures, synthetic, 4-0. (TAGUM®)
46075073|NCT00617305|Drug|Ambrisentan|Ambrisentan was administered orally once daily; dose level was 5 mg for the first 4 weeks, followed by 10 mg for the remainder of the study; ambrisentan was supplied as 5-mg and 10-mg tablets.
46075074|NCT00617305|Drug|Placebo|Placebo to match ambrisentan was administered orally once daily.
46075075|NCT00617305|Drug|Sildenafil|Sildenafil was administered at the dose previously established for each subject (20-100 mg) orally three times daily. Sildenafil was supplied as 20-mg tablets, or formulated as sildenafil citrate in 25-, 50-, or 100-mg tablets.
45942683|NCT00112515|Procedure|quality-of-life assessment|
45942684|NCT00291772|Drug|Pramlintide|Basal and bolus pramlintide subcutaneous infusion
45942685|NCT00078611|Drug|natalizumab|
45942686|NCT00291811|Drug|AMD3100 + G-CSF|Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
45942687|NCT00291850|Drug|Paclitaxel, Cisplatin, Pegfilgrastim|
45942688|NCT00112554|Drug|cytarabine|Given IV
45942689|NCT00112554|Drug|laromustine|Given IV
45942690|NCT00112554|Other|placebo|Given IV
45942691|NCT00291889|Biological|Mtb72F/AS02.|
45942692|NCT04718311|Drug|Oral lichen clinical Healing evaluation|Treatments were topically applied for 5 days
45656028|NCT05520671|Other|Gamified online quizzing platform|"TESLA-G is a novel gamified quizzing platform designed based on Bloom's taxonomy of learning domains. Questions will be created in blocks, where each block will test a specific topic within a specialty (endocrine surgery has been selected for this study). Each block has 5 questions, and each question corresponds to each level of Bloom's taxonomy and each level in game.~For this study, we aim to create 56 blocks of 5 questions, totalling 280 questions. All questions will be created by two board-certified general surgeons and one endocrinologist, and validated by the research team.~The aim of the game is for players to get as many points as they can before the timer runs out. Gamification elements include levels, countdown timer, lives, a point multiplier system, leaderboard rankings and a personalised dashboard.~Participants in the intervention group will be provided with a link to access TESLA-G, sent from an automated Telegram bot; this access will be provided for 14 days."
45807255|NCT04968184|Drug|Placebo|Participants will orally receive placebo matching to KBP-5074 tablets QD.
45807256|NCT04968184|Drug|KBP-5074|Participants will orally receive KBP-5074 tablets, from 0.25 mg to a maximum dose of 0.5-mg QD.
45807257|NCT04967287|Device|MyopiaX|MyopiaX treatment twice a day
45807258|NCT04967287|Device|Myopia control spectacles|To be used all as prescribed
45942693|NCT00291928|Drug|Part A|Part A Cohort 1: HuMax-CD20 300 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 2: HuMax-CD20 700 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 3: HuMax-CD20 1000 mg at Days 0 and 14 or Placebo at Days 0 and 14
45942694|NCT00291928|Drug|Part B|Part B Group 1: HuMax-CD20 300 mg at Days 0 and 14 Group 2: HuMax-CD20 700 mg at Days 0 and 14 Group 3: HuMax-CD20 1000 mg at Days 0 and 14 Group 4: Placebo at Days 0 and 14
45942695|NCT00291967|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
45807259|NCT04962698|Behavioral|Visual motor imagery (MI)|Subjects will relax their muscles and perform conventional visual mental imagery (MI). With the guidance of audio instruction, the subjects will imagine the grasp and release motions with the right arm for 2 s in each motion in their mind. There will be no proximal muscle contraction.
46075076|NCT00617305|Drug|Tadalafil|Tadalafil was administered at the dose previously established for each subject (not to exceed 40 mg per day) orally once daily. Tadalafil was supplied as 20-mg tablets.
45807260|NCT04962698|Behavioral|Kinesthetic MI|The same MI procedure as Visual MI will be performed, except that the subjects will focus on the kinesthetic sensation that they would feel with the imagined motions.
46075077|NCT02793102|Other|Olfactory workshop|Twenty odorants are selected: 10 evoke a food (including 5 pleasant and unpleasant 5) and 10 suggest a non-food source
46075078|NCT02793102|Other|Somesthesia workshop|Kinesthetic time or time for moving the body (30 min), and kinesthetic sensations (duration 10 min), and Talk Time
45807261|NCT04962698|Behavioral|Robotically augmented practice|Subjects will perform robotically augmented mental practice for grasp and release motions with the activation control of the proximal muscles. During this task, subjects will also imagine the kinesthetic sensation that they would feel with the corresponding motions with the right arm.
45807262|NCT04962698|Behavioral|Robotically augmented practice without MI|Subjects will perform the robotically augmented practice without MI.
45807263|NCT04962698|Behavioral|Proximal muscle contraction|Subjects will perform the robotically augmented practice with visual feedback of virtual robot actions on a monitor.
45807264|NCT04962698|Behavioral|Robotic action observation|Subjects will relax their muscles and focus on observing the computer-controlled grasp and release actions of the robotic prosthesis.
45807265|NCT04962698|Behavioral|Rest|Subjects will rest without a task.
45942696|NCT00078689|Drug|Daclizumab|
45942697|NCT00292006|Device|Computerized tomography|
45942698|NCT00292084|Drug|Celgosivir|
45942699|NCT00112632|Drug|imatinib mesylate|
45942700|NCT00112632|Procedure|conventional surgery|
45942701|NCT00112632|Procedure|neoadjuvant therapy|
45942702|NCT00275392|Behavioral|Vestibular rehabilitation|vestibular adaptation and substitution exercises
45942703|NCT00275392|Behavioral|Placebo|placebo vestibular exercises
45942704|NCT00078845|Drug|Amifostine|500 mg three times a week.
45942705|NCT00275353|Behavioral|Individualized Symptom Education|
45942706|NCT00275314|Drug|Valganciclovir|
45942707|NCT00275275|Drug|Requip PR|Requip 24-Hour once a day for one month
45942708|NCT00275275|Drug|Mirapex|All subjects started the study on Mirapex. They were all then switched to Requip PR based on a conversion factor of 1:3, 1:4 or 1:5.
45942709|NCT00112710|Drug|carboplatin|
45942710|NCT00112710|Drug|cisplatin|
45942711|NCT00112710|Drug|gemcitabine hydrochloride|
45942712|NCT00275236|Drug|Rotigotine|
45942713|NCT00275197|Drug|Sertraline and Elzasonan Combination|
45942714|NCT00275197|Drug|Sertraline|
45942715|NCT00275197|Drug|Placebo|
45942716|NCT00078923|Dietary Supplement|soy isoflavones|
45942717|NCT00078923|Procedure|neoadjuvant therapy|Prostatectomy or Brachytherapy
45942718|NCT00078923|Other|Placebo|Arm I: 4 placebo capsules Arm II: 3 placebo capsules Arm III: 2 placebo capsules
45942719|NCT00275158|Drug|L-Arginine Supplementation|
45942720|NCT00102726|Drug|SB497115|SB497115/Placebo will be administered for at least 2 cycles. Additional cycles are permited if: 1) chemotherapy is continued, 2) the subject appears to be benefitting from the study drug, and 3) the subject has not encountered greater than moderate toxicity with the study drug. The maximum number of cycles would be 8.
45942721|NCT00102726|Other|Placebo|Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
45942722|NCT00275119|Drug|fluorouracil|
45942723|NCT00275119|Drug|gemcitabine hydrochloride|
45942724|NCT00275119|Drug|oxaliplatin|
45942725|NCT00275119|Radiation|radiation therapy|
45942726|NCT00275080|Drug|vorinostat|Given orally
45942727|NCT00275080|Drug|decitabine|Given IV
45942728|NCT00078962|Biological|GTI-2040|Given IV
46075079|NCT02793102|Other|Auditory workshop|Twenty extracts of music tracks (30 seconds each) are built in the same fashion as those used during the workshops, but are different.
45656029|NCT05520671|Other|Conventional quizzing platform|"The conventional quizzing platform will be a modified version of TESLA-G with all gamification elements removed. The same set of questions as the gamified version will be used. Upon entering the quiz, a question stem and five choices will be shown. When an option is selected, the right answer along with its explanation will be indicated. The next question will then be sent, and this process repeats until the participant leaves the platform or has answered every question.~Questions will be queued in blocks, with each block corresponding to a particular topic in endocrine surgery. Unlike the gamified version, questions within each block will be randomised, regardless of their level on the Bloom's taxonomy. Participants will also not be informed of the level of Bloom's taxonomy for individual questions. The access link to the platform will be sent to participants from an automated Telegram bot, and this access will last for 14 days."
45656030|NCT04869709|Drug|Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate 12mg IM q24h for 2 doses
45656031|NCT04869631|Other|The outcome of an intervention is not evaluated, but aortic stenosis and additional amyloidosis are compared.|We aim to compare patients with aortic valve stenosis with and without cardiac amyloidosis.
45656032|NCT05021081|Device|TRP-200|JJVC Investigational Contact Lens
45656033|NCT05021081|Device|ACUVUE Oasys 1-Day|JJVC Marketed Contact Lens
45656034|NCT04864327|Behavioral|Brief smoking cessation advise|The tobacco cessation protocol consisted of performing a routine assessment (asking) of cigarette use; providing advice on the importance of quitting; performing an assessment of the tobacco user's readiness to quit; assisting in setting a quit date; and making arrangements for follow-up visits. This protocol is popularly known as the 5A's strategy (The first 3A's should be delivered to all smokers regardless of their willingness to quit). Tobacco users were identified by staff nurses. Clinicians provided brief advice on quitting, and the researcher assessed the patient's dependence and readiness to quit. Patients who were not ready to quit were motivated to consider quitting, whereas those who were ready to quit were referred to practitioners who could assist them and follow them in the tobacco cessation clinic
45656035|NCT05520515|Other|Aquatic Training Plus Health Education|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. Sessions last 45 min (5 min of warm-up, 35 min of exercise, and 5 min of stretching) throughout the intervention period. The intervention is performed at the thermal pool sector of Clube Brilhante in Pelotas city. The pool water temperature is maintained between 30-32°C, with participants immersed in the depth level between the xiphoid process and shoulders. The aquatic training group performs the following water aerobics exercises: stationary running, frontal kick, cross-country skiing, and butt kick during the stimulus and jumping jacks during the active recovery. The training session is collective, with 3 to 6 participants, supervised by two experienced instructors, one outside and one inside the pool. The group also receives the booklet and the offer of weekly meetings of an educational program (30 min before one of the training sessions) with the same interactive lectures.
45807266|NCT04961944|Other|Disease assessment|"A comprehensive evaluation of the disease's extension, its impact on function, quality of life, and the search for phenotype/endotypes will be performed.~The association between endotypes and disease progression will be tested."
45807267|NCT04959474|Other|Best Practice|Given standard dietary recommendations
45807268|NCT04959474|Radiation|Stereotactic Body Radiation Therapy|Undergo SABR
45807269|NCT04959474|Procedure|Sentinel Lymph Node Biopsy|Undergo sentinel lymph node biopsy
45807270|NCT04959474|Other|Questionnaire Administration|Ancillary studies
45807271|NCT04959474|Other|Quality-of-Life Assessment|Ancillary studies
45807272|NCT04959474|Procedure|Resection|Undergo surgical resection
45807273|NCT04959474|Other|Dietary Intervention|Undergo a caloric restriction diet
45807274|NCT04956640|Drug|LY3537982|Oral
45807275|NCT04956640|Drug|Abemaciclib|Oral
45807276|NCT04956640|Drug|Pembrolizumab|Intravenous
45807277|NCT04956640|Drug|LY3295668|Oral
45807278|NCT04956640|Drug|Cetuximab|Intravenous
45807279|NCT04956640|Drug|Pemetrexed|Intravenous
45807280|NCT04956640|Drug|Cisplatin|Intravenous
46075080|NCT04232748|Drug|first line systemic treatment for colorectal cancer|systemic chemotherapy (capecitabine or fluorouracil, oxaliplatin or irinotecan, with or without biological agents including cetuximab, bevacizumab, or panitumumab.
46075081|NCT02793024|Behavioral|Intervention|Adolescents in the intervention arm will receive 3 face to face session about making smart shopping choices. The following 9 weeks will consist of utilizing social media to improve shopping choices.
46075082|NCT02792868|Other|24 h urines analyses|patient collects urines during 24h
45807281|NCT04956640|Drug|Carboplatin|Intravenous
45942729|NCT00078962|Drug|gemcitabine hydrochloride|Given IV
45942730|NCT00078962|Other|laboratory biomarker analysis|Correlative studies
45942731|NCT00078962|Other|pharmacological study|Correlative studies
45942732|NCT00275041|Biological|cetuximab|
45942733|NCT00275041|Drug|irinotecan hydrochloride|
45942734|NCT00274963|Drug|bendamustine hydrochloride|
45942735|NCT00274963|Drug|mitoxantrone hydrochloride|
45942736|NCT00130429|Drug|PYM50028|
45942737|NCT00102765|Drug|fluticasone propionate/salmeterol powder|
45942738|NCT00102765|Drug|fluticasone propionate powder|
45942739|NCT00130390|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily for 28 days
45656036|NCT05520515|Other|Land Training Plus Health Education|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. Sessions last 45 min (5 min of warm-up, 35 min of exercise, and 5 min of stretching) throughout the intervention period. The intervention occurs at the School of Physical Education, Federal University of Pelotas. Depending on weather conditions, the land training group will perform aerobic training with walking/running exercises in a flat outdoor environment or inside a multi-sport gym. The training session will be collective, with 3 to 6 participants, supervised by two experienced instructors, one at the starting point and the other following the movement of the participants. In addition, the group receives the booklet and the offer of weekly meetings of an educational program (30 min before one of the training sessions) with the same interactive lectures.
45656037|NCT05520515|Other|Health Education|The intervention occurs at the School of Physical Education, Federal University of Pelotas. The intervention consists of an educational program with weekly lectures of approximately 30 min. The lectures are led by a qualified health professional, using expository and interactive approaches on topics that cover basic knowledge related to breast cancer and complementary therapies. Additionally, each participant receives a self-care booklet containing information about the topics addressed during the meetings. Qualified professionals give lectures on the following topics: 1) fatigue and quality of life; 2) anxiety and depressive symptoms; 3) body image and sexual function; 4) self-esteem; 5) self-care; 6) sleep; 7) cognitive function; 8) symptoms in the arm and breast; 9) pain and arthralgia; 10) body composition and bone health; 11) eating habits; 12) physical activity.
45656038|NCT05520437|Dietary Supplement|Omega-3 fatty acids|Participants received Omega-3 supplements (NAMEDSPORT) in the form of softgels over a period of 12 weeks. The supplement is certified by the International Fish Oil Standards™ (IFOS™) Program. Daily dose contained a total of 3276 mg of Omega 3 (4000 mg of fish oil of which: EPA 2234mg; DHA 916mg).
45656039|NCT05520437|Dietary Supplement|Placebo|Participants will receive a placebo in the form of MCT oil capsules with no effect on the hypothesized outcome.
45656040|NCT02612077|Other|Observational Chemotherapy|No intervention - Observational standard practice chemotherapy
45656041|NCT02612077|Drug|Concomitant Bevacizumab|No intervention - Observational concomitant bevacizumab
45656042|NCT04622735|Combination Product|nefopam hydrochloride 30mg / paracetamol 500mg X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
45656043|NCT04622735|Drug|Paracetamol 500 Mg Oral Tablet X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
45656044|NCT04622735|Drug|Nefopam HCl 30 MG Oral Tablet X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
45656045|NCT03045991|Behavioral|aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
45656046|NCT03045991|Behavioral|control training|The control training program will receive 30 minutes non-aerobic exercise training, including stretching muscle skills, joint mobility exercises; in addition to one 30-minute session of unstructured mental activities, such as reading books or reading educational films.
45656047|NCT03045991|Behavioral|cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
45656048|NCT04615559|Diagnostic Test|Contrast enhanced ultrasound|CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion information
45656049|NCT05517629|Other|It is an observational cross-sectional study|It is an observational cross-sectional study
45656050|NCT03046303|Procedure|ERAS|optimized pain control, restricted I.V. fluids, early initiation of post-operative oral feeding and enforced mobilization
45656051|NCT05075135|Device|Swibrace 3D-splint|"The Swibrace 3D splint is a custom-made splint. For scanning of the forearms, the investigators will use the scanner HandySCAN300 and the therewith delivered software VXElements, the latter being necessary to create an accurate scan on the computer.~Printing of the splint will be done by Materialise, Belgium."
45942740|NCT00130390|Other|Placebo|One placebo tablet twice daily for 28 days
45942741|NCT00079079|Drug|carboplatin|
45942742|NCT00079079|Drug|cisplatin|
45942743|NCT00079079|Drug|gemcitabine hydrochloride|
45942744|NCT00130312|Drug|Sulodexide|100 mg gelcap in the morning and evening
45942745|NCT00130312|Drug|Placebo|1 placebo gelcap in the morning and evening
45942746|NCT00130273|Behavioral|Managed problem solving|Participants in the managed problem solving group will have four study visits and will receive three phone calls for the first 3 months of the study, and one phone call every month for the following 9 months. At each study visit, participants will identify barriers to adherence. During the phone calls, participants will be asked about any steps they have taken to improve their adherence. A medication event monitoring system (MEMS) will be used to assess participants' treatment adherence. MEMS uses microelectronic monitors on the caps of medication bottles to record the timing and frequency of bottle openings. Participants whose adherence has decreased or remained the same at the end of 12 months will be evaluated for regimen changes. Blood collection at the beginning and end of the study will be used to measure viral load and CD4 count.
45942747|NCT00130273|Behavioral|Standard care|Participants will receive standard of care for 12 months.
45942748|NCT00130234|Drug|Xolair® (Omalizumab)|
45942749|NCT00119301|Drug|leucovorin calcium|
45942750|NCT00119301|Drug|methotrexate|
45942751|NCT00119301|Drug|trimetrexate glucuronate|
45942752|NCT00079118|Drug|docetaxel|
45942753|NCT00079118|Drug|irinotecan hydrochloride|
45942754|NCT00130195|Drug|imatinib|
45942755|NCT00130195|Drug|cyclophosphamide|
45942756|NCT00130195|Drug|daunorubicin|
45942757|NCT00130195|Drug|vincristine|
45942758|NCT00130195|Drug|prednisolone|
45942759|NCT00130195|Drug|methotrexate|
45942760|NCT00130195|Drug|cytarabine|
45656052|NCT05075135|Device|Plaster cast|The conservative gold standard treatment of distal radius and scaphoid fractures is applying a plaster cast. Therefore, patients in the control group follow standard therapy procedures.
45656053|NCT04875559|Other|Standardised multimodal pain treatment regimen|"Preoperatively:~Paracetamol 1000 mg p.o.~Celecoxib 400 mg p.o.~Dexamethasone 12 mg p.o.~Perioperatively:~Ondansetron 4 mg IV~Bupivacaine 2.5 mg/mL, 20 mL LIA~Oxycodone 0.15 mg/kg IV (Oxycodone 0.25 mg/kg for ALND)~Postoperatively:~Paracetamol 1000 mg p.o. every 6h PRN~Ibuprofen 400 mg p.o. every 6h (day 1-5) PRN~Oxycodone 5 mg IV or 10 mg p.o. PRN~Ondansetron 4 mg IV or p.o. PRN"
45656054|NCT04875637|Diagnostic Test|WAI-MEMR|Using wideband acoustic reflectance for middle-ear muscle reflex.
45656055|NCT05520359|Device|Mobility Device|Use of mobility device during session.
45656056|NCT05520359|Device|Spinal Stimulation|A stimulator will be used non-invasively stimulate the spine at the neck and/or lower back (cervical and/or lum
45656057|NCT05070923|Behavioral|HealthyLifetime|HL augments existing case management services by focusing on building the participant's personal capacity for independence in self - care skills, health behavior change, and health decision making. The HL program coordinates and interfaces with the enrollee's primary medical provider, case managers, and caregivers as necessary
45656058|NCT05531669|Behavioral|PLAY Project|PLAY consultants coached caregivers monthly for 12 months to improve caregiver-child interaction using videotape and written feedback within a developmental framework.
45656059|NCT05531669|Behavioral|Parental Education|Each study center provides welcome course and parent guide for families with ASD children monthly.
45656060|NCT02613481|Drug|Poly-L-Lactic Acid (Sculptra) injection|1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.
45656061|NCT04864015|Device|Mouthpiece B1(Mouthpiece MPC-ST GMDN:62534 Generic name: Endoscopic bite block, basic, reusable|Use of a Mouthpiece B1 during standard EGD instead of a conventional mouthpiece
45656062|NCT05298917|Device|silicone hydrogel contact lens|silicone hydrogel contact lens
45656063|NCT04385251|Other|Data Collection|"DATA COLLECTION AT ENROLLMENT:~Demographics; Symptoms and health status; Co-morbidities; Targeted medications; Specimen Collection (substudy at selected sites): Upper respiratory swab, blood for serum storage.~DATA COLLECTION AT DAYS 7, 14 & 28:~Vital and hospitalization status; Symptoms and health status"
45656064|NCT05293067|Diagnostic Test|high-sensitive troponin|Values of high-sensitive troponin would be measured as follows: 1) preoperatively - one day before the planned intervention and 2) postoperatively - 8 hours after the operation and the first day after the operation.
45656065|NCT04864093|Diagnostic Test|muscular ultrasound|respiratroy and muscular ultrasound
45656066|NCT05531591|Drug|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
45656067|NCT05531591|Drug|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
45656068|NCT05531591|Drug|Switch to bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
45656069|NCT05531591|Drug|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
45656070|NCT05531591|Drug|Switch to nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
45656071|NCT04384705|Other|research specific blood sample|"one blood sample before the epidemic phase~one blood sample during epidemic phase~one blood sample after epidemic phase"
45656072|NCT05517551|Procedure|robotic assisted radical prostatectomy|Patients who will undergo robotic-assisted laparoscopic prostatectomy surgery
45656073|NCT05067647|Device|ENSEAL X1 Curved Jaw Tissue Sealer|ENSEAL X1 curved jaw tissue sealer is used for transecting and sealing vessels during thoracic, urologic, or ENT procedures according to instructions for use.
45656074|NCT05520125|Biological|Mesenchymal stem cells enriched by extracellular vesicles|Mesenchymal stem cells enriched by extracellular vesicles
45656075|NCT05520125|Other|Standard treatment of bone defects|Standard surgical treatment of bone defects
45656076|NCT04297319|Procedure|Laser diiodo|3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks It is an outpatient procedure, not anesthesia required.
45656077|NCT04297319|Procedure|Laser Placebo|3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks. It is an outpatient procedure, not anesthesia required.
45807282|NCT04956354|Device|ANNE™ Monitoring System (2 sensors) - version B|"ANNE™ is a wireless vital sign monitoring device that uses soft, flexible, skin-mountable biosensors (ANNE™ Chest and ANNE™ Limb) with Bluetooth® 5 enabled and encrypted data communication to an iPad application. Study sensors to be applied on patients are:~Sensor 1 - A chest unit (ANNE™ Chest) with embedded battery, sensors, and a three-axis accelerometer that captures the following signals: electrocardiography (ECG), temperature, seismocardiography (SCG) and the chest wall movements.~Sensor 2 - A limb unit (ANNE™ Limb) with embedded battery that captures the photoplethysmography (PPG) and SpO2 signals."
45942761|NCT00130195|Drug|dexamethasone|
45656078|NCT05067491|Behavioral|Augmented reality exposure therapy|Virtual objects will be placed in the patient's visual field, superimposed on their real environment for exposure therapy.
45656079|NCT05517395|Behavioral|health nutrition education|The participants in intervention group will receive health nutrition education based on a health belief model including nutrition health education (booklet), and telephone call support.
45656080|NCT05517395|Behavioral|usual care|Control group will only receive usual care. Usual care is routine measurement of children including height, length, weight, head circumference, monitoring children's activities, and monitoring the immunization status of children.
45656081|NCT05048615|Drug|Venetoclax 100 MG|Patients will receive oral Venetoclax at a fixed dose of 100mg/day from day 1 to day 21 per cycle for a maximum of 2 cycles.
45656082|NCT05048615|Drug|Itraconazole capsule|Patients will receive oral itraconazole at a dose of 100 mg every 12 hours from day 1 to day 21.
45656083|NCT05048615|Drug|Azacitidine Injection|Patients will receive a maximum of two cycles of daily subcutaneous Azacitidine at a dose of 75 mg/m2 (maximum 100 mg) from day 1 to day 7.
45656084|NCT05531435|Drug|local anaesthetic injection|Local anesthetic injection of articaine 4% + adrenaline 1/100.000 (Septanest, Septodont, Saint Maur des Fossés, France) with 30G - 9 mm needle (DENTAL HI TEC, ZI de l'Appentière, Mazières-en-Mauges, France).
45656085|NCT05517317|Combination Product|Autologous BMMC transplantation|One administration of autologous bone marrow mononuclear cells via the hepatic artery
45656086|NCT05517239|Drug|Gemcitabine, Oxaliplatin|Gemcitabine 1,000 mg/m2 infusion for 30minutes and followed by oxaliplatin 100mg/m2 infusion for 2hours on day1. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
45656087|NCT05517161|Behavioral|INSIGHT|See Keegan et al., 2020
45656088|NCT05519813|Drug|Metformin|Use Metformin for 3 months to treat PCOS
45656089|NCT05519813|Drug|Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets|Use Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets for 3 months to treat PCOS
45656090|NCT05517005|Dietary Supplement|Hype Bites Supplement|"The ingredients of the vitamin supplement are:~Chocolate liquor Sugar Cocoa butter Vanilla extract Vitamin B12 (as methylcobalamin) Tapioca Gum arabic Coloring (radish, apple, black currant) Carnauba Wax"
45656091|NCT05519657|Other||
45656092|NCT05082311|Other|Observational study|This is an observational study
45656093|NCT05519501|Device|SyntrFuge System|Microsized Adipose Tissue
45656094|NCT05519501|Procedure|Standard of Care|Offloading
45656095|NCT02613403|Drug|MK-3682B|Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.
45656096|NCT02613403|Drug|Ribavirin|Ribavirin 200 mg capsules, taken twice daily by mouth as part of a weight-based dosing regimen. Depending on participant body weight, total daily dose of Ribavirin may be 800, 1000, 1200 or 1400 mg per day.
45656097|NCT05531279|Drug|PEG-rhG-CSF|PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected; PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected; RhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.
45656098|NCT05003531|Drug|IBI112 dose 2|Participants will receive placebo or dose 2 IBI112 SC
45656099|NCT05003531|Drug|IBI112 dose 4|Participants will receive placebo or dose 4 IBI112 SC
45656100|NCT05003531|Drug|IBI112 dose 1|Participants will receive placebo or dose 1 IBI112 SC
45656101|NCT05003531|Drug|IBI112 dose 3|Participants will receive placebo or dose 3 IBI112 SC
45656102|NCT05003531|Drug|placebo|Participants will receive placebo SC
45656103|NCT04875403|Other|Inspiratory muscle trainning|linear load device, associated with the resisted training. The initial training load for each participant will be adjusted to 25% of MIP. Each week, the researcher determines the new values for load (1 to week 25%, 2 to week 35%;. 3 to week 40%;. 4 to week 45%;. 5 to week 50%.).
45656104|NCT04875403|Other|Exercise|exercise bike for 30 minutes, which will be divided into 10 minutes for the foot heating and 20 minutes for the workout aerobic exercise that will have to maintain a target training heart rate
45656105|NCT05267093|Procedure|Acupuncture|Sterile single-use stainless steel needles (size 0.3 mm × 25 mm) will be utilized. After local skin disinfection with 75% alcohol wipes, acupuncturists will insert needles perpendicularly into the Ashi points to a depth of approximately 2-3 mm; horizontally into the Baxie points toward the wrist to a depth of 5-10 mm; and perpendicularly into Houxi (SI3) and Waiguan (TE5) to a depth of approximately 5-10 mm. The depth of needling will vary based on the participant's body sizes. After insertion, all needles except those in the Ashi points will be manually manipulated to achieve De qi sensations. All the needles will be retained for 30 min and then gently removed. Participants will take acupuncture treatment three times per week for a total of 12 sessions in 4 consecutive weeks.
45942762|NCT00394303|Drug|Intraoperative continuous insulin infusion|Nomogram specified in appendix
45942763|NCT00394303|Other|Control|Glucose management according to the discretion of the anesthesiologist aimed to maintain glucose levels <200 mg.dl, reflecting current practice.
45942764|NCT00394381|Procedure|Infusion of autologous CIK cells|Autologous CIK cells will be infused at timed intervals after autologous transplant for AML for group 1 patients, and with or without some cytoreduction treatment for group 2 patients
45942765|NCT00119340|Drug|cyclosporine|
45656106|NCT05267093|Procedure|Sham acupuncture|The sham needles with blunt tips (size 0.3 mm × 25 mm) will be used in the control group. Acupuncturists will gently lift and twist the sham needles to simulate the treatment procedure, thus blinding the patients to the intervention. Acupuncturist will firstly sterilize the areas of acupoints, then apply the adhesive pads on the surface of Ashi points, Baxie points, Houxi (SI3) and Waiguan (TE5) and insert the sham needles without penetrating. The duration and frequency of treatment sessions will be the same as in the acupuncture group.
45942766|NCT00119340|Drug|fludarabine phosphate|
45942767|NCT00119340|Drug|mycophenolate mofetil|
45942768|NCT00119340|Procedure|peripheral blood stem cell transplantation|
45942769|NCT00119340|Radiation|radiation therapy|
45942770|NCT00130156|Drug|Bunazosin|Patients will be randomized to the add-on treatment with Bunazosin (Detantol-R) 3 mg once-daily after breakfast for a total of eight weeks.
45656107|NCT05519267|Behavioral|MBSWSC|MBSWSC is a unique mindfulness-based programme for social work and self-care which has been specifically developed for online delivery. The MBSWSC programme is embedded within key cognitive and emotion regulation, and stress coping theory (Maddock et al. 2019a). This programme combines mindfulness practices with psychoeducation with the aim of allowing participants to reduce any negative thinking about the past and future by learning skills that will allow them to focus on the present. It will also focus on how to effectively apply these newly acquired mindfulness skills in social work practice. The MBSWSC programme comprises 6x1.5 hour sessions, delivered weekly, over a 6 week period. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
45656108|NCT05519267|Behavioral|MBSC|MBSC is a modified, condensed Mindfulness Based Intervention; with a key focus on self-compassion. Key practices in this condensed programme were chosen for their relevance and utility to social workers. The MBSC programme comprises 3x1 hour sessions delivered over a 6 week period, with one session every two weeks. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
45656109|NCT03044119|Biological|Dental Implant with PRFM|placement of a minimum of two adjacent dental implants being randomly assigned into (G1) - Dental implant with PRFM
45656110|NCT03044119|Biological|Dental Implant with PRFM and PBMSCs|placement of a minimum of two adjacent dental implants being randomly assigned into (G2) - Dental implant with peripheral blood mesenchymal stem cells embedded in PRFM.
45656111|NCT04863937|Device|Distal Thigh Compression Garment, Knee Sleeve|Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device
45656112|NCT03044275|Other|New adhesive strip|This is a newly developed adhesive strip that in the future might be part of an ostomy device
45656113|NCT03044275|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid). The adhesive is a part of an ostomy device
45656114|NCT04640597|Device|BioMimics 3D Vascular Stent System|Patients with BioMimics 3D Vascular Stent System
45656115|NCT04874701|Drug|Capsimax|Capsimax, 2 capsules per day, for 12 weeks Medicinal ingredient: Capsicum annuum Quantity (per capsule): 100.0 mg
45656116|NCT04874701|Other|Energy restriction|Personalised diet plan targeting a 500 kcal/day energy restriction
45656117|NCT03045835|Device|BASKA mask|Baska mask will be inserted during induction of anaesthesia and once patient is in an adequate anaesthetic depth
45656118|NCT03045835|Device|Endotracheal intubation|Endotracheal intubation will be carried out during induction of anaesthesia and once patient is in an adequate anaesthetic depth
45656119|NCT05516693|Other|Myofacial muscle training protocol.|Muscle training for orofacial motricity stimulation
45656120|NCT04874779|Other|non|follow up investigations
45656121|NCT05002127|Drug|Evorpacept (ALX148)|IV Q2W
45656122|NCT05002127|Drug|Trastuzumab|IV Q2W
45656123|NCT05002127|Drug|Ramucirumab|IV Q2W
45656124|NCT05002127|Drug|Paclitaxel|IV Days 1, 8, and 15 of a 28-day cycle
45656125|NCT04863547|Other|Data collection|Data collection
45656126|NCT04874389|Diagnostic Test|Multimodal Assessment|Participants will complete BISQ/health questionnaire and proceed to each testing station with 15 minute rest breaks in between randomly ordered assigned stations.
45656127|NCT05531201|Procedure|collaboration general practitioner and physiotherapist|training general practitioner and physiotherapist
45807283|NCT04956354|Device|ANNE™ Monitoring System (2 sensors) - version C|"ANNE™ is a wireless vital sign monitoring device that uses soft, flexible, skin-mountable biosensors (ANNE™ Arc and ANNE™ Limb) with Bluetooth® 5 enabled and encrypted data communication to an iPad application. Study sensors to be applied on patients are:~Sensor 1 - ANNE™ Arc with a Lithium-Polymer battery that contains a 6-axial inertial measurement unit (IMU), which includes a 3-axis gyroscope and 3-axis accelerometer, a power management component, an analog front-end component, passive electrodes for ECG, and bio-impedance feature that capture the following waveforms: heart rate (HR), respiratory rate (RR) and skin temperature.~Sensor 2 - A limb unit (ANNE™ Limb) with embedded battery that captures the photoplethysmography (PPG) and SpO2 signals."
45656128|NCT04869163|Other|Non-red meat|Red meat analogues and alternatives
45656129|NCT04873921|Other|sterile kinesio taping|Application area will be cleaned and dried prior to application to increase the adhesiveness of the tape and application will be done by an experienced physiotherapist during ACLR surgery.
45656130|NCT04869241|Diagnostic Test|surface EMG|Carrying backpacks forward or backward
45807284|NCT04956354|Device|ANNE™ Monitoring System (2 sensors) - version C|"ANNE™ is a wireless vital sign monitoring device that uses soft, flexible, skin-mountable biosensors (ANNE™ Arc and ANNE™ Limb) with Bluetooth® 5 enabled and encrypted data communication to an iPad application. Study sensors to be applied on patients are:~Sensor 1 - ANNE™ Arc with a Lithium-Polymer battery that contains a 6-axial inertial measurement unit (IMU), which includes a 3-axis gyroscope and 3-axis accelerometer, a power management component, an analog front-end component, passive electrodes for ECG, and bio-impedance feature that capture the following waveforms: heart rate (HR), respiratory rate (RR) and skin temperature.~Sensor 2 - A limb unit (ANNE™ Limb) with embedded battery that captures the photoplethysmography (PPG) and SpO2 signals."
45942771|NCT00130156|Drug|Doxazosin|Patients will be randomized to the add-on treatment with Doxazosin (Doxaben XL) 4 mg once-daily after breakfast for a total of eight weeks.
45656131|NCT04429867|Drug|Hydroxychloroquine|Hydroxychloroquine 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
45656132|NCT04429867|Drug|Placebo|Placebo 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
45656133|NCT04604561|Device|EnVisio SmartClip|The Envisio SmartClip is an FDA-cleared (approved) device for localization of in-breast lesions. While using The EnVisio™ Navigation System, the system will detect the presence of the SmartClip™ Soft Tissue Marker(s) and provide real-time three-dimensional navigation during the surgery.
45656134|NCT04604561|Device|EnVisio™ Navigation System|The EnVisio™ Navigation System acquires and analyzes electromagnetic signatures that display the relative distance, depth, and direction from the tip of the electrosurgical tool to the implanted SmartClipTM(s) within the surgeon's field of view during the procedure.
45656135|NCT03044041|Drug|Tranexamic Acid|IA (intra-articular) tranexamic acid after capsule closure
45656136|NCT05038709|Device|The Pink Pad Hip Kit|The pad is placed between the patient and the traction table to reduce pressure to the pudendal nerve exerted by the perineal post.
46075083|NCT03608202|Behavioral|POCUS protocol group|"The findings of multiorgan ultrasound can modify diagnoses and treatments and immediate interventions (eg volume loading with saline solution, pleural or pericardial drainage, initiation of diuretics, increase in positive end expiratory pressure, etc.).~This protocol is performed in the first 24 h of admission to the Intensive Care Unit (ICU) and is repeated at 24 h."
45656137|NCT03047941|Diagnostic Test|Determination of optimal cutoff values.|The results of the four scores will be compared with the results of the polysomnography (PSG). A statistical analysis will be performed to determine the optimal cutoff value of each of the four scores to detect severe OSA patient with hypoxemia.
45656138|NCT04863391|Diagnostic Test|Referrable versus Non Referral AMD diagnostic test|Artificial intelligence read reports Referrable versus Non Referral AMD
45656139|NCT04869007|Device|hysterosonography|Isthmocele mesured by hysterosonography before ART procedure
45656140|NCT05029427|Other|High molecular weight β-glucan oat cookies|Two cookies that contains 4g beta glucan made from oats will be consumed per day.
45656141|NCT05029427|Other|Control wheat based cookies|Two cookies that made from cream of wheat without beta glucan will be consumed per day.
45656142|NCT04429789|Behavioral|Active-Alert Hypnosis|Participants in this arm will receive four one-hour weekly sessions that will include training in a rapid self-hypnosis method. Participants will learn how to use waking hypnosis to manage fatigue using exercises with sensory experiences.
45656143|NCT04429789|Behavioral|Traditional Hypnosis|Participants in this arm will receive four one-hour weekly sessions where participants will learn how to use hypnosis along with relaxation. The exercises and suggestions included in the training will be adapted from the protocol used in a series of studies on the efficacy of self-hypnosis training for the management of chronic pain in persons with disabilities, and from a therapist guide of procedures and hypnotic suggestions for chronic pain.
45656144|NCT05518955|Behavioral|Virtual reality and eye mask|Participates will receive a virtual reality program 30 min before their sleep and combine with the sleep routine program for consecutive 2 nights in the ICU.
45656145|NCT04863235|Behavioral|Control Group|Eight week behavioural change program aimed to increase physical activity plus information on general health topics among individuals with prediabetes.
45656146|NCT04863235|Behavioral|Intervention Group|Eight week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes.
45807285|NCT04954898|Device|Study Lens: TECNIS Multifocal Toric 1-piece lens, Model ZMT|Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with TECNIS Multifocal Toric 1-Piece IOL.
45942772|NCT00130156|Drug|Valsartin|After wash-out period, the eligible subjects will be treated with Valsartin (Diovan) 80 mg as the mono therapy for 5 weeks. If the blood pressures are inadequately responded, then the patients will be randomized to either Bunazosin (Detantol-R) or Doxazosin (Doxaben XL) along with Valsartin as the add-on treatment for 8 weeks.
45942773|NCT00130117|Drug|r-metHuLeptin|Starting dose: 0.08mg/kg once daily Subcutaneous injection.
46075084|NCT03608202|Other|Control group|Routine protocol of the treating team is followed
46075085|NCT02792712|Drug|Ticagrelor|Ticagrelor 180 mg LD，then 90 mg BID
46075086|NCT02792712|Drug|Clopidogrel|Clopidogrel 300 mg LD，then 75 mg QD
45942774|NCT00130117|Drug|Oral Contraceptive Pills (OCPs)|Sprintec taken orally once daily.
45942775|NCT00130117|Other|Placebo|placebo (no active medication)
45942776|NCT00119418|Drug|TU 025 Keishi Bukuryo Gan|
45942777|NCT00079157|Biological|incomplete Freund's adjuvant|
45942778|NCT00079157|Biological|sargramostim|
46075087|NCT02787720|Other|Family centered empowerment model|The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Perceived threat, Problem solving, Educational partnership, and Evaluation
45656147|NCT03048097|Drug|Fluorodeoxyglucose|a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET)
45656148|NCT03048097|Drug|Rubidium|used in PET scans
45942779|NCT00079157|Biological|telomerase: 540-548 peptide vaccine|
45942780|NCT00112398|Procedure|Extended interventions by advanced level prehospital providers|may include rapid sequence intubation (RSI) airway management, blood transfusions, surgical procedures, etc.
45942781|NCT00130078|Drug|1.0% C31G SAVVY vaginal gel|
45656149|NCT03048097|Diagnostic Test|FDG-PET/CT with Rb82 Myocardial Perfusion Imaging|A 18-20 gauge catheter equipped with a 3-way stopcock will be inserted preferably in the antecubital vein. Cardiac FDG-PET imaging will be performed on the YNHH GE Discovery ST PET/CT scanner following a high fat/low carbohydrate diet and a prolonged fast as is current clinical protocol. Resting ECG-gated dynamic Rb-82 PET imaging will be performed using 20-30 mCi of Rb82 as per YNHH clinical imaging protocol and established clinical guidelines. FDG-PET imaging will be performed following a high fat/low carbohydrate diet (instructions provided to patient) and a fast of greater than 12 hours. The patient will be injected with the same dose of FDG (8-10mCi) as they received for their index clinical examination. Cardiac FDG imaging will be performed using a single 3D acquisition over the heart. Low-dose CT images (120 kV, 50-150 mA based on BMI) for the purposes of attenuation correction will be performed before Rb82 and FDG imaging sequences.
45807286|NCT04953143|Behavioral|LiverPal Intervention|"Inpatient longitudinal palliative care intervention~- Patients will complete baseline assessments and will be followed by the palliative care clinicians delivering the LiverPal intervention during each of their hospitalizations over a 3 month period~LiverPal intervention domains include the following:~Therapeutic relationship~Symptom management~Coping with illness~Prognostic awareness and illness understanding~Treatment decision-making~End-of-life care"
45942782|NCT00130000|Drug|Eculizumab|
45807287|NCT04951622|Drug|Nipocalimab|Nipocalimab will be administered as an IV infusion.
45942783|NCT00129883|Behavioral|Professional education|
45942784|NCT00129883|Behavioral|Implementation of a Critical Care Pathway|
45942785|NCT00129883|Behavioral|Professional audit and feedback|
46075088|NCT02787720|Other|Continuous care model|The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Orientation, Sensitization, Control, and Evaluation
45942786|NCT00129883|Behavioral|Process analysis and redesign|
45807288|NCT04951622|Drug|Placebo|Matching placebo will be administered as an IV infusion.
45656150|NCT05512403|Drug|PET/CT with 18F-DOPA|"A 18F-FDOPA PET exam is then performed (acquisition of 30 minutes in List Mode format) according to the French guidelines for PET neuro-oncological indications (Verger et al. Med Nuc, 2020, (5)).~Patient preparation and acquisition:~4 hours of fasting~No carbidopa premedication~2 MBq / kg of 18F-FDOPA~Dynamic acquisition in List Mode format for 30 min starting simultaneously with the patient's injection~Low dose scanner for attenuation correction"
45656151|NCT03048253|Biological|OrienX010|Beijing biological technology co., LTD. Research and development of the source and force of recombinant human GM-CSF herpes simplex virus injection (OrienX010), is a genetically engineered type 1 herpes simplex virus (HSV - 1) as the carrier insert GM-CSF gene therapy drug.Its carrier is made of isolated from patients with oral Chinese wild single blister virus type I (CL1), after gene recombination technology successively removing ICP34.5, ICP47 and insert the deactivation ICP6 gene, and at the site of the original ICP34.5 insert guided by IE promoter of hCMV human GM-CSF gene.
46075089|NCT00867763|Procedure|In vitro maturation and in vitro fertilization|No gonadotropin, eggs harvested early
45656152|NCT05516303|Genetic|Genetic polymorphism|One blood tube will be taken for genetic testing
46075090|NCT00867763|Procedure|Low doses of gonadotropin stimulation.|Gonadotropin followed by conventional IVF
45656153|NCT05516303|Diagnostic Test|Measurement of fingolimod and fingolimod-phosphate concentrations|Measurement of fingolimod and fingolimod-phosphate concentrations before usual drug administration time
45656154|NCT04863079|Drug|Pembrolizumab Injection [Keytruda]|Pembrolizumab 200 mg IV, Q3W, up to one year or disease progression or intolerance.
45807289|NCT04951609|Drug|Seltorexant|Participants will receive a single oral dose of seltorexant.
46075091|NCT02789202|Other|Silver diamine fluoride|Treatment of initial dental caries lesion in occlusal surface using the silver diamine fluoride.
45807290|NCT04951609|Drug|Placebo|Participants will receive matching placebo orally.
45807291|NCT04949828|Drug|CREON|Oral Capsules
45807292|NCT04949191|Drug|Pemigatinib|Pemigatinib tablets taken by mouth once daily as per protocol
45807293|NCT04949191|Drug|Retifanlimab|Retifanlimab is administered over 60 minutes once every 4 weeks (Day 1 of a 28-day cycle)
45807294|NCT04949191|Drug|Pembrolizumab|Commercially labeled products
46075092|NCT02789202|Other|Fluoride Varnish|Treatment of initial dental caries lesion in occlusal surface using the fluoride varnish
46075093|NCT00811395|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
45807295|NCT04943042|Drug|Avatrombopag|According to prescription
45807296|NCT04940039|Drug|Risperidone 3 mg|Participants will receive 3 mg oral risperidone tablet once daily for 3 days.
45807297|NCT04940039|Drug|Paliperidone Palmitate 50 mg eq.|Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks).
45807298|NCT04940039|Drug|Paliperidone Palmitate 75 mg eq.|Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks.
45807299|NCT04940039|Drug|Paliperidone Palmitate 100 mg eq.|Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks.
45807300|NCT04940039|Drug|Paliperidone Palmitate 150 mg eq.|Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks.
45942787|NCT00119457|Drug|TTP889|
45942788|NCT00079235|Drug|temsirolimus|Given IV
45942789|NCT00079235|Other|laboratory biomarker analysis|Correlative studies
45942790|NCT00129844|Drug|Motexafin Gadolinium|
45942791|NCT00129805|Drug|MCI-9042|
45942792|NCT00129805|Drug|Aspirin|
46075094|NCT00811395|Drug|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
46075095|NCT00811395|Drug|Interferon-β [IFN-β]|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
46075096|NCT00811395|Drug|Glatiramer Acetate [GA]|Solution in prefilled syringe for subcutaneous injection
45942793|NCT00129727|Drug|Paclitaxel|Given intravenously
45942794|NCT00129727|Drug|Carboplatin|Given intravenously
45942795|NCT00129727|Drug|Bevacizumab|Given intravenously
45942796|NCT04727814|Other|Computer-aided detection system overlaid colonoscopy videos analysis|Analysis of computer-aided detection system overlaid videos from colonoscopies performed with water exchange or air insufflation method.
45942797|NCT00129688|Drug|cloxacillin and amikacin (once or twice daily dosage)|
45942798|NCT00298207|Behavioral|Walking (behavior)|
45942799|NCT00079352|Drug|alvocidib|Given IV
45942800|NCT00079352|Drug|gemcitabine hydrochloride|Given IV
45656155|NCT05512325|Drug|Gene evolution and molecular response under Bevacizumab treatment|Patients with glioma were routinely treated with temozolomide chemotherapy from the 4th week after operation, for 5 days continuously, once every 4 weeks, with a single dose as follows: Single dose = BSA (body surface area) * 150mg/m2/day BSA(Body Surface Area)=[weight (kg)* height (cm)/3600]2, According to the molecular pathological grade (WHO CNS5 grade), it is decided whether to combine radiotherapy (GBM combined with radiotherapy) and temozolomide combined with bevacizumab (600mg) in the course of tumor progression, Recording image changes
45656156|NCT04868383|Behavioral|Use of smart phone technology to support medication adherence and uptake|Use of smart phone technology to support medication adherence and uptake
45942801|NCT00079352|Drug|irinotecan hydrochloride|Given IV
45656157|NCT05518643|Procedure|ERAS protocol|ERAS protocol as described above
45656158|NCT03047863|Drug|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 4 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
45656159|NCT03047863|Drug|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 4 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
45942802|NCT00119496|Drug|rosiglitazone|oral tablet, 4mg bd for 4 weeks
45807301|NCT04940039|Drug|Paliperidone Palmitate 175 mg eq.|Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks.
45656160|NCT04868227|Dietary Supplement|FULTIUM D3 VITAMIN D3|VITAMIN D3 SUPPLEMENT
45656161|NCT04863001|Drug|Antiarrhythmic drug|all classes of antiarrhythmic drugs used in pediatrics cardiology unit assiut university
45807302|NCT04940039|Drug|Paliperidone Palmitate 263 mg eq.|Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks.
45807303|NCT04940039|Drug|Paliperidone Palmitate 350 mg eq.|Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks.
45807304|NCT04940039|Drug|Paliperidone Palmitate 525 mg eq.|Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks.
45942803|NCT00119496|Drug|theophylline|Oral theophylline, 200mg bd
45942804|NCT00119496|Drug|beclomethasone|inhaled beclomethasone, 200mcg bd
45656164|NCT04868149|Procedure|Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS)|Surgery procedure
45807305|NCT04932941|Drug|MP1032|Hard gelatin capsules for oral administration.
45807306|NCT04932941|Drug|Placebo|Placebo capsules matched to MP1032 for oral administration.
45807307|NCT04929210|Drug|Guselkumab|Guselkumab will be administered as subcutaneous injection.
45807308|NCT04929210|Drug|Placebo|Matching placebo will be administered as subcutaneous injection.
45807309|NCT04928846|Biological|Telisotuzumab Vedotin|Intravenous (IV) Infusion
45807310|NCT04928846|Drug|Docetaxel|IV Infusion
45807311|NCT04927884|Biological|N-803|"Dose: 15 μg/kg subcutaneously (SC)~Frequency: administered on Day 8 of each cycle (every 3 weeks)"
45942805|NCT00119496|Drug|inhaled beclomethasone and oral theophylline|inhaled beclomethasone (400mcg/day), oral theophylline (400mg/day)
45942806|NCT00298285|Drug|enoxaparin|
45942807|NCT00298324|Drug|Myfortic|1440mg twice daily
45942808|NCT00298324|Drug|Prednisone and Cyclosporine|Prednisone and Cyclosporine given according to protocol. The drugs are tapered according to patient response
45942809|NCT00298441|Drug|chondroitin sulfate-iron colloid|
45942810|NCT00079430|Procedure|adjuvant therapy|
45942811|NCT00079430|Drug|paclitaxel|Given IV
45942812|NCT00079430|Drug|carboplatin|Given intraperitoneally
45942813|NCT00079430|Biological|bevacizumab|Given IV
45942814|NCT00119535|Behavioral|Implementation of Proactive Diabetes Eye Care Program|
45942815|NCT00298597|Drug|granulocyte - colony stimulating factor (G-CSF)|
45942816|NCT00298597|Drug|erythropoetin (EPO)|
45942817|NCT00298636|Drug|adenosine|
45942818|NCT00086112|Drug|risperidone oral tablets|
45942819|NCT00079469|Behavioral|smoking cessation intervention|
45942820|NCT00079469|Drug|bupropion hydrochloride|
45942821|NCT00298675|Drug|BSI-201 (iniparib)|BSI-201 administered intravenously (IV), 2x weekly
45942822|NCT00298675|Drug|irinotecan|Irinotecan administered weekly, IV.
45942823|NCT00298714|Drug|Losartan|
45942824|NCT00298753|Procedure|fluid restriction for 14 days (15ml fluid per kg weight)|
45942825|NCT00298792|Behavioral|Cognitive Behavioral Treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety.
45942826|NCT00298792|Behavioral|Cognitive-behavioral treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety
46075097|NCT00867841|Procedure|nasopharyngeal swab|PCR of NP swab for Mycoplasma, Chlamydophila, pneumococcus, pneumococcus macrolide resistance genes.
46075098|NCT02792946|Drug|Acebrophylline|
46075099|NCT00876499|Behavioral|Questionnaire|A total of 8 questionnaires regarding fatigue taking approximately 30 minutes each, given before radiation therapy, weekly during, and after completion.
46075100|NCT00872443|Other|Data collection|"Collection of characteristics of interauricular septum, characteristics of the CVA, and headache history.~Collection of anamnesis data, surgical past history, especially at the moment of the implement of prothesis, collection of dtat of transthoracic echography, transcranial echodoppler, holter ECG, cerebral MRI."
45656165|NCT04873531|Drug|Neostigmine|"For the N group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
45942827|NCT00079508|Drug|Angiomax (bivalirudin)|250 mg vial administered as 1.0 mg/kg intravenous (IV) bolus and 2.5 mg/kg/h IV infusion during the procedure with the option to administer additional 0.1 to 0.5 mg/kg boluses to increase the level of anticoagulation as clinically indicated. A low-dose infusion could have been administered in the preoperative phase (up to 48 hours before the procedure) and in the postoperative phase (up to 14 days after the procedure) as clinically indicated for management of HIT/TS. A starting bolus of 0.1 mg/kg and/or an infusion of 0.2 mg/kg/h titrated to a desired activated partial thromboplastin time (aPTT), eg, 1.5-2.5 times baseline aPTT, was recommended.
45942828|NCT00298870|Drug|Isoniazid|Modified daily isoniazid dose : approx. 7.5 mg/kg, 5 mg/kg and 2.5 mg/kg for rapid, intermediate and slow acetylators, respectively
45656166|NCT04873531|Drug|Normal saline|"For the NS group, neostigmine normal saline (0.09 cc/kg; the same volume of the group N) will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
45656167|NCT03045601|Diagnostic Test|CT-FFR|Invasive FFR and CCTA With CT-FFR
45656168|NCT03045601|Diagnostic Test|Stress echocardiography|Stress echocardiography and invasive FFR
45656169|NCT02572817|Biological|High-titer anti-influenza plasma|Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of at least 1:80
45656170|NCT02572817|Biological|Low-titer anti-influenza plasma|Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of 1:10 or less
45656171|NCT04862845|Drug|Duloxetine and Pregabalin|will be received pregabalin with duloxetine 90 minutes preoperatively, then pregabalin every 12 hours with duloxetine once daily postoperatively until the fifth postoperative day.
45656172|NCT04862845|Drug|pregabalin|received pregabalin with a placebo capsule at 90 minutes preoperatively, then every 12 hours postoperatively with a placebo capsule once daily until the fifth postoperative day.
45656173|NCT04862845|Drug|sham|received two placebo capsules at 90 minutes preoperatively then placebo capsules every 12 hours, with one capsule daily postoperatively until the fifth postoperative day.
45656174|NCT04873687|Device|External Counter Pulsation (ECP) therapy|ECP therapy consist of 36 session, each session @1 hour/day, six days a week with initial pressure of 300mmHg
45656175|NCT04873609|Behavioral|Patient portal message|Direct-to-patient message via the electronic patient portal (MyHealth) with HCV antibody lab order directed to their preferred laboratory
45656176|NCT04873141|Drug|Tocilizumab 200 Mg/10 mL (20 Mg/mL) INTRAVEN VIAL (ML)|Tocilizumab was given according to weight in patients with cytokinme releasew syndrome (CRS).
45656177|NCT04862377|Drug|Poractant Alfa Intratracheal Suspension [Curosurf]|"Poractant alfa (Curosurf®):~First dose of treatment: 200mg/Kg. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg."
45656178|NCT04862377|Drug|Budesonide 0.5 MG/ML|"Poractant alfa (Curosurf®) + Budesonide nebulizer solution (Budesonida Aldo-Unión 0.5mg/mL suspensión para inhalación por nebulizador®):~First dose: 200mg/Kg of surfactant + 0.25mg/Kg of budesonide. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg of surfactant + 0.25mg/Kg of budesonide."
45656179|NCT05516225|Drug|PBCLN-003|Human Milk Oligosaccharide Concentrate
45807312|NCT04927884|Biological|PD-L1 t-haNK|"Dose: ~2 × 10^9 cells intravenously (IV)~Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks)"
45656180|NCT04867993|Drug|Amikacin|15 mg/kg/36h
45656181|NCT04873219|Device|manufacturing a complete dental prosthesis|dental treatment to replace missing teeth
45656182|NCT04988009|Other|Electronic Health Record Review|Review of medical chart
45656183|NCT04988009|Other|Survey Administration|Complete survey
45656184|NCT04872985|Drug|Pyrotinib|400 mg orally once per day
45656185|NCT04872985|Drug|Epirubicin|100 mg/m2,q3W*4
45656186|NCT04872985|Drug|Doxorubicin Hydrochloride Liposome Injection|30mg/m2, q3w*4
45656187|NCT04872985|Drug|Cyclophosphamide|600 mg/m2, q3w*4
45656188|NCT04872985|Drug|Docetaxel|100 mg/m2, q3w*4
45807313|NCT04927884|Drug|Sacituzumab Govitecan-Hziy|"Phase 1b:~Dose level 1: Sacituzumab govitecan-hziy (7.5 mg/kg IV) Dose level 2: Sacituzumab govitecan-hziy (10 mg/kg IV) Dose level -1 (if needed): Sacituzumab govitecan-hziy (5.0 mg/kg IV)~Phase 2: Dose based on Phase 1b Recommended Phase 2 Dose (IV)~Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks)"
45807314|NCT04927884|Drug|Cyclophosphamide|"Dose: 25 mg capsules taken twice per day by mouth (PO)~Frequency: to be taken Days 1-15 and 15-19 of each cycle (every 3 weeks)"
45942829|NCT00298870|Drug|isoniazed|Conventional standard daily isoniazid dose : approx. 5 mg/kg b.w. for all
45656189|NCT04872985|Drug|Nab paclitaxel|120mg/m2 qw*12
45656190|NCT04872985|Drug|Placebo|400 mg orally once per day
45656191|NCT04872907|Device|adhesive system|adhesive system G-BOND. It will be applied to healthy temporary anterior and posterior teeth The adhesive system (on side defined by randomization) will be renew at 6, 12, 18 months, on all three sides due to the physiological wear of the temporary teeth (and therefore the wear of the material).
45807315|NCT04925089|Other|Blood and Tissue collection|Blood and tissue will be collected and analyzed for detection of ctDNA and genetic change
45807316|NCT04923958|Diagnostic Test|Novel mycobacterial culture techniques|We will evaluate tests intended to make culture more sensitive, faster, and have less contamination.
45807317|NCT04923958|Diagnostic Test|Novel sputum smear microscopy techniques|We will evaluate new staining techniques or visualization methods to increase the sensitivity of smear microscopy.
45807318|NCT04923958|Diagnostic Test|Sputum-based molecular assays|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
45807319|NCT04923958|Diagnostic Test|Tongue swab-based molecular assays|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
45807320|NCT04923958|Diagnostic Test|Urine LAM assays|We will evaluate urine LAM assays incorporating techniques such as analyte concentration, higher sensitivity or specificity antibodies, or enhanced visualization to improve LAM detection.
45656192|NCT04872907|Device|fluoride varnish|The reference drug is a fluoride varnish at 22,600 ppm of the brand Duraphat 50 mg / ml, dental suspension. The varnish is applied to healthy temporary anterior and posterior teeth, on the three sides of the teeth. The reference treatment (on side defined by randomization) will be renew at 6, 12, 18 months, on all three sides due to the physiological wear of the temporary teeth (and therefore the wear of the material).
45656193|NCT04872907|Drug|flowable composite|"Composite Essentia HiFlo. It will be applied on healthy temporary molar grooves (on side defined by randomization).~Complete or partial renewal of the fluid composite in the grooves of the molars in the event of total or partial loss at 6, 12, 18 months"
45656194|NCT02566109|Diagnostic Test|Fast MRI|The fast MRI is a 10 minute MRI scan that will be used to determine if cardiovascular injury can be detected early while patients are receiving chemotherapy treatment.
45656195|NCT04868071|Behavioral|Physical Exercise|Exercise interventions were carried out over a total of 16 weeks in the mornings (08:00 am-12:00 am) under the supervision of at least two fitness instructors. Participants performed four exercises for lower limbs (Figure 9): 1st) squat on the chair, 2nd) seated unilateral hip flexion, 3rd) seated unilateral knee extension, and 4th) bilateral calf raise with 12-15 submaximal repetitions avoiding fatigue (i.e., inability to complete a repetition in a full range of motion). The number of sets was increased linearly during the first month, such that one set was performed in the 1st week, two sets in the 2nd week, 3 sets in the 3rd week, and 4 sets in the 4th week. Subsequently, participants performed the main exercise period. After a brief warm-up, participants performed the same exercises that were performed during the familiarization period using an adjustable weight vest and ankle weights (DOMYOS®, Shangai, China).
45656196|NCT04861909|Device|AT LISA tri 839MP|Non interventional study
45656197|NCT03047707|Diagnostic Test|S-Shearwave and TE|S-Shearwave elastography and Transient elastography (TE) are performed to evaluate hepatic stiffness.
45656198|NCT02566031|Drug|Indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI
45656199|NCT02566031|Drug|Tiotropium|Capsules for inhalation delivered via HandiHaler® device
45656200|NCT04861753|Other|Reiki and back massage|In the current study, at the beginning of the treatment, the researcher held his hands 2-3 cm above the patient sand adjusted the aura of the patient by making circular movements from the head to the feet. After this process of aura attunement, the researcher placed his hands directly on the patient's body. In the areas where the practitioner had placed his hands for an average of three minutes, starting from between the eyes, the researcher felt various degrees of warmth and tingling in his palms. Only the back was left exposed to prevent the patient becoming cold. The researcher took a little non-aromatic baby oil in hand and heated it, then began a 20-minute-long massage. The massage consisted of 6.5 minutes of effleurage (stroking), 3.5 minutes of petrissage (kneading), 13 minutes of effleurage and seven minutes of petrissage.
45656201|NCT04861675|Procedure|Full mouth rehabilitation under general anaesethia|Assessment of change in oral health related quality of life , body growth status and oral hygiene status for children with special health care needs after full mouth rehabilitation under general anesethia,
45656202|NCT04901039|Other|Lung ultrasound|Decompensated HF patients will be evaluated at admission and prior to hospital discharge with a range of tools including lung ultrasound imaging
45656203|NCT04901039|Other|Echocardiography|Comprehensive echocardiography with evaluation of filling pressures
45656204|NCT04901039|Other|Peripheral venous pressure|Assessment of peripheral venous pressure
45656205|NCT04901039|Other|Magnetic resonance imaging|Cardiac magnetic resonance imaging
45656206|NCT04901039|Other|Pulmonary scintigraphy|Assessment of pulmonary perfusion with scintigraphy
45656207|NCT04861519|Other|Collecting invasive FFR measurements.|Invasive FFR measurements from the patient's hospital records will be collected.
45656208|NCT04769765|Other|Definition of the Individualized Care Pathway|Implementation of an individualized care pathway defined in concertation with a multidisciplinary tele-expertise meeting held every 3 months for one year. These multidisciplinary tele-expertise meetings will be held between each of the normal routine consultations which are part of the normal, basic diabetic program which includes a consultation with a dietitian, monitoring by a state-registered nurse and treatment prescribed by the patient's general practitioner (with or without a consultation with the clinical pharmacist).
45656209|NCT03045523|Drug|GLPG2222 150 mg q.d.|GLPG2222 150 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
45656210|NCT03045523|Drug|GLPG2222 300 mg q.d.|GLPG2222 300 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
45807321|NCT04923958|Diagnostic Test|Blood-based host immune response assays|We will evaluate assays measuring host immune response parameters intended for use at near point of care or point of care.
45807322|NCT04923958|Diagnostic Test|Breath-based assays|We will evaluate assays assessing volatile organic compounds or exhaled breath condensate for near point of care of point of care detection of TB.
45807323|NCT04923958|Diagnostic Test|Artificial intelligence-based digital health tools|We will evaluate AI-based algorithms evaluating images (chest x-ray, ultrasound) or sounds (cough sounds, lung sounds) including an Infrasound-to-ultrasound e-stethoscope (Level 42 AI, USA).
45807324|NCT04923958|Diagnostic Test|Phage-based assays|We will evaluate assays using phages to lyse mycobacterial cells for detection of DNA or antigens.
45942830|NCT02960386|Other|Machine Learning Algorithm|The algorithm will help participants improve physical activity by sustaining long term engagement with their fitness tracker.
45807325|NCT04923958|Diagnostic Test|Cartridge-based molecular assays for detecting drug resistance|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
45807326|NCT04923958|Diagnostic Test|Sequencing-based assays for detecting drug resistance|We will evaluate targeted and whole genome sequencing assays.
45807327|NCT04923893|Drug|Bortezomib|Bortezomib will be administered SC.
45942831|NCT00298909|Behavioral|physical exercise|physical exercise
45942832|NCT00298909|Drug|niaspan (extended-release niacin)|niaspan (extended-release niacin)
45942833|NCT00298909|Drug|niacin|niacin extended-release
45942834|NCT00298909|Other|control|control
45942835|NCT00119574|Procedure|Collaborative Chronic Illness Model|
45942836|NCT00079547|Behavioral|Low-calorie diet|low-calorie diet
45807328|NCT04923893|Drug|Dexamethasone|Dexamethasone will be administered orally.
45807329|NCT04923893|Drug|Lenalidomide|Lenalidomide will be administered orally.
45807330|NCT04923893|Drug|Cilta-cel|Cilta-cel infusion will be administered.
45656211|NCT03045523|Drug|Placebo|Placebo administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
45656212|NCT04984967|Device|Insertion of peripheral venous catheter with micro-guide|After antisepsis, the vein is punctured using a needle. Then the micro-guide is inserted to the first landmark, which indicates the passage of the micro-guide beyond the end of the needle. After the needle removed, the peripheral venous catheter is placed on the micro-guide. The guide is then removed, the peripheral venous catheter can be used.
45656213|NCT04984967|Other|Classic insertion of peripheral venous catheter, without micro-guide|After antisepsis, the catheter is introduced into the vein by a needle which is subsequently removed while the catheter remains in place.
45807331|NCT04923893|Drug|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
45656214|NCT04872829|Device|cataract surgery|"All patients underwent cataract surgery under 1 year of age (mean age 8 months, range 6-12) performed with the same surgical technique: two 1.2 mm clear corneal incision, continuous curvilinear capsulorhexis with a diameter of approximately 6.0 mm and intraocular lens implantation, posterior capsulotomy and anterior vitrectomy.~IOL power was calculated using Sanders-Retzlaff-Kraff (SRK)/II formula. Multifocal IOL implantated was Alcon AcrySof ReSTOR SN60D3, while the monofocal one was Alcon AcrySof SN60AT.~According to the Infant Aphakia treatment Study, the IOL power was calculated as a function of the child age17, with an undercorrection ranging from 4 to 6 D."
45656215|NCT03045211|Device|Dynamic Standing Table|The dynamic standing table is a height-adjustable standing table which gives periodic cues to the user to make stepping movements.
45656216|NCT05515991|Other|SUPPORT-DIALYSIS with Access to Output Report and Information Hub|"SUPPORT-Dialysis is a symptom assessment response toolkit, consisting of a screening and response component. Participants will be screened for symptoms and distress using an electronic assessment(ePROMs). Output reports based on ePROMs scores will be provided to patients as well as the clinical care team.~Participants at Toronto General Hospital will complete the screening every 4 weeks for 6 months, and each time the output report will be provided to both patients and the clinical team.The second, response component of the intervention is the information support and self-management hub (https://symptomcare.org). All participants and the clinical team will be given access to this website, which provides information about self-management for patients as well as management advice for healthcare professionals."
45656217|NCT05515991|Other|SUPPORT-DIALYSIS Only|SUPPORT-Dialysis screening will also be implemented at Humber River Hospital, but participants and clinical team will not be receiving the output screening report or be given access to the information hub with symptom management resources.
45807332|NCT04923893|Drug|Fludarabine|Fludarabine will be administered intravenously.
45807333|NCT04922554|Drug|Omadacycline Oral Tablet|omadacycline 300 mg orally, once daily (150 mg tablets x 2)
45807334|NCT04922554|Drug|Placebo|placebo tablets resembling omadacycline orally, once daily (x 2 tablets)
45807335|NCT04922281|Device|Insertable Cardiac Monitor|Implantable device that provides accurate daily transmission of cardiac electrical data for arrhythmia detection.
45807336|NCT04920578|Drug|JNJ-69095897|JNJ-69095897 will be administered orally in Parts 1, 2 and 3.
45942837|NCT00079547|Behavioral|low-carbohydrate diet|low-carbohydrate diet
45942838|NCT00299026|Device|NIRx(TM) Paclitaxel-Coated Conformer Coronary Stent System|
45942839|NCT00299065|Drug|Zileuton injection|
45942840|NCT00086229|Drug|Glucosamine|
45656218|NCT04872361|Procedure|Low PEEP|Patients will be ventilated with a PEEP of 4 cm H2O and no RMs throughout the study
45656219|NCT04872361|Procedure|High PEEP|PEEP of 10 cm H2O will be applied
45656220|NCT04872361|Procedure|High PEEP/RM|PEEP of 10 cm H2O and RM (30 cm H2O for 30 s) immediately after the second lung ultrasonographic examination and repeated every 30 minutes till emergence
45807337|NCT04920578|Other|Placebo|Matching placebo will be administered orally in Parts 1 and 3.
45807338|NCT04919512|Drug|TAR-200|TAR-200 will be administered.
45807339|NCT04919512|Biological|Cetrelimab|Cetrelimab will be administered.
45807340|NCT04915495|Diagnostic Test|LuViva Advanced Cervical Scan|Multimodal hyperspectral device
45807341|NCT04915183|Drug|Atorvastatin|For the interventional arm of the study, subjects will be provided with atorvastatin (20 mg) or placebo to be taken daily by mouth or by feeding tube. The tablets may be taken whole or crushed according to patient swallowing capabilities and preference.
45807342|NCT04915183|Other|Placebo|placebo will be formulated to also contain a white powder such that the atorvastatin and placebo are indistinguishable even if a capsule is opened.
45807343|NCT04914429|Drug|Guselkumab|Guselkumab 100 mg will be administered as a SC injection.
45807344|NCT04914429|Drug|Placebo|Matching placebo will be administered as a SC injection.
45807345|NCT04910386|Drug|Envafolimab plus Gemcitabine&Cisplatin|Envafolimab a programmed death ligand immune check inhibitor Per Investigator decision
45807346|NCT04910386|Drug|Gemcitabine&Cisplatin|The standard of care for the patients with unresectable/metastatic biliary tract cancer
45807347|NCT04908722|Biological|Ad26.COV2.S|Participants will receive intramuscular (IM) injections of Ad26.COV2.S.
45942841|NCT00086229|Drug|Chondroitin|
45942842|NCT04718623|Diagnostic Test|Quantitative determination of serum Presepsin (sCD-14), and Syndecan-1 concentrations|Quantitative determination of serum Presepsin (sCD-14), and Syndecan-1 concentrations by ELISA technique
45942843|NCT00079586|Drug|Heparin|Unfractionated Heparin per institutional practice
45942844|NCT00079586|Drug|Bivalirudin|1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion
45942845|NCT00418132|Drug|Thalidomide|Thalidomide at a dose of 50 mg/day. The dose will be increased to 100 mg/day at Week 2, then to 200 mg/day at Week 4, and finally to 300 mg/day at Week 6.
46075101|NCT05083065|Biological|Covid-19 vaccine|"First dose or complete cycle of Comirnaty (Pfizer/BioNTech) vaccine~First dose or complete cycle of Spikevax (Moderna) vaccine~First dose or complete cycle of AstraZeneca/Vaxzevria vaccine~Complete cycle of vaccination using one type of vaccine for the first dose and a different type for the second dose~Janssen (Johnson & Johnson) vaccine (single dose)"
46075102|NCT02792634|Procedure|Sleeve-Gastrectomy, Roux en Y gastric bypass|
45656221|NCT04872361|Device|Lung ultrasonogrphy assessment|"The thorax will divided into 12 quadrants, each of them will be assigned a score of 0-3 as 0, normal lung sliding with fewer than three single B lines~three or more B lines~coalescent B lines~consolidated lung. The LUS (0-36) will be calculated with higher scores indicating more aeration loss"
45656222|NCT03045367|Procedure|Phacoemulsification, intraocular lens implant, vitrectomy.|Cataract extraction, intraocular lens implant, vitrectomy, epiretinal membrane and inner limiting retinal membrane peeling.
45807348|NCT04908683|Biological|Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF|Participants will receive a single IM injection of an RSV vaccine.
45807349|NCT04908683|Biological|Placebo|Participants will receive a single IM injection of matching placebo.
45807350|NCT04905693|Drug|Inhaled Treprostinil|Inhaled Treprostinil (6 mcg/breath) administered QID
45807351|NCT04905693|Device|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
45807352|NCT04901572|Diagnostic Test|QISI device|QISI device will simulate its use in ICSI procedures and evaluate sperm cells according to WHO guidelines.
45807353|NCT04899336|Biological|ExPEC9V|ExPEC9V will be administered as an IM injection.
45807354|NCT04899336|Other|Placebo|Matching placebo will be administered as an IM injection.
45807355|NCT04898790|Behavioral|CHAMPS-II adapted to adults 60+ years in HCT setting|CHAMPS-II is an evidence-based physical activity program designed to increase physical activity in sedentary older adults with multiple chronic health conditions. This is an individually tailored program that provides information, skills, training, and problem-solving support to older adults. Participants will engage in progressive, light to moderate-intensity physical activity throughout the HCT process, with the support of physical therapists, physical activity counselors, and their care-partner. They will take part in supervised exercise sessions; unsupervised exercise sessions; counseling sessions to address barriers, motivators, goals, and safety; and receive telephone support. Walking is the primary mode of aerobic activity, with training in flexibility, strengthening and balance exercises also included. An exercise kit will be provided, consisting of an intervention workbook, therapeutic resistance bands, and activity logs.
46075103|NCT00876577|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin injection with/without sequential tablet treatment according to the local product information
45807356|NCT04898790|Other|Survivorship education active control|Participants receiving the survivorship education program will receive a workbook of education materials, and participate in individual and/or small group education sessions on topics important to HCT survivors; assignments intended to provide reinforcement of education via practical and engaging activities; and telephone contacts for support and reinforcement of materials. Participants will be encouraged to choose topics of interest to them for additional focus, to enhance participation.
45942846|NCT00418132|Drug|Placebo thalidomide|Participants will receive placebo thalidomide. The placebo dose will be increased through to Week 6.
45942847|NCT00299260|Biological|CMV gB vaccine|20 micrograms
45942848|NCT00299260|Drug|Placebo|normal saline
45942849|NCT00119613|Drug|placebo|placebo
45942850|NCT00119613|Drug|darbepoetin alfa|darbepoetin alfa
46075104|NCT05079789|Drug|Amiloride|Treatment with amiloride, start dose 5 mg
46075105|NCT05079789|Drug|Furosemide|Treatment with furosemide, start dose 40 mg
45807357|NCT04898543|Biological|M-CENK, Suspension for Infusion, Cryopreserved (M-CENK)|M-CENK will be administered 4 times via intravenous (IV) infusion on days 1, 8, 15 and 22. The dose of MCENK will be 0.25 - 0.75 × 10e9 cells per infusion.
45807358|NCT04898543|Biological|N803|N803 15 μg/kg will be administered subcutaneously on days 1 and 15.
45942851|NCT00299338|Drug|SP01A|
45942852|NCT00299377|Drug|Abciximab i.v.|
45942853|NCT00299377|Drug|Abciximab i.c.|
45942854|NCT00079625|Drug|Th2/Tc2 Cells|
45942855|NCT00299455|Drug|amoxicillin-clavulanate|Amoxicillin clavulanate 40 mg/kg/day divided into two daily doses for 7 days. Capsules will be produced by pulverizing amoxicillin clavulanate tablets (Augmentin 875 mg; manufacturer Glaxo SmithKline Beecham; ATC Code: J01CR02) and mixing that with lactose monohydrate. Each capsule will contain Augmentin tablet powder 68 mg and lactose monohydrate 572 mg. This means amoxicillin 40 mg and clavulanate 5,7 mg respecting the dose per 2 kg.
45942856|NCT00299455|Drug|Placebo|Placebo twice a day for 7 days. Placebo capsules contain lactose monohydrate 640 mg.
45942857|NCT00299533|Drug|Fish oil (Super Omega-3, 4 caps/d) vs. placebo|
45942858|NCT00299572|Drug|alendronate (Fosamax)|
45942859|NCT00079664|Behavioral|Tai Chi|
45942860|NCT00299611|Drug|Sertraline|Tablets, 50mg each, (1-3TABLETS/DAY) during the Open-label phase for first 8 wks.
46075106|NCT02787798|Drug|valsartan/sacubitril 100 mg|Treatment with 100 mg tablets during 2 to 4 weeks
46075107|NCT02787798|Drug|valsartan/sacubitril 200 mg|Treatment with 200 mg tablets during 2 to 4 weeks
46075108|NCT02787798|Procedure|Microneurography|Microneurography recording of sympathetic nervous system activity in muscle destiny
46075109|NCT00867919|Behavioral|Behavioral Family Treatment|"11 to 15 sessions of a cognitive behavioral family therapy that will be developed during the course of this study and will address the following:~parent-adolescent conflict~adolescent development~support and closeness~behavioral activation~response to adolescent negative affect~relapse prevention~suicide prevention, if necessary"
46075110|NCT00867919|Other|Community-based treatment as usual|Treatment as usual, which will most likely consist of 8 to 10 sessions of community-based depression treatment
46075111|NCT02792556|Device|Urine pregnancy test|Urine pregnancy test Check Top after transvaginal ultrasound
45453025|NCT04014998|Other|Virtual Reality|Virtual reality group will have virtual reality for 20 minutes in addition to motor control exercises for 20 minutes. Virtual reality will apply using Oculus Go. On the other hand control group will have only exercise for 40 minutes. Exercises will include same exercises in both groups, but exercise group will perform exercises twice compared to virtual reality group.
45656223|NCT04763681|Behavioral|Couple HOPES Guided, Internet-Delivered, Self-Help Intervention|Couple HOPES is a guided self-help intervention for individuals with PTSD and their partners based on Cognitive-Behavioral Conjoint Therapy for PTSD (Monson & Fredman, 2012). This intervention consists of text and video-based content across seven intervention modules and phone and online-based coaching sessions with a paraprofessional. Participants are able to complete these modules in their own home or private location of their choosing. The primary outcomes are PTSD symptoms, relationship satisfaction, and the mental health and wellbeing of partners of those with PTSD.
45656224|NCT04861129|Procedure|Bowen therapy|Intervention is provided weekly for 6 sessions lasting 30-40 mins per treatment session
45656225|NCT04861129|Procedure|Sham Bowen therapy|Sham Intervention is provided weekly for 6 sessions lasting 30-40 mins per treatment session
45656226|NCT05507489|Drug|Jinzhen oral liquid or Jinhuaqinggan granules|Jinzhen oral liquid, for 3 years old, 10 ml once, twice a day; for 4 to 7 years old, 10 ml a time, 3 times a day; for 8 to 18 years old, 15 ml a time, 3 times a day.The dosage and usage of Jinhua Qinggan granules were determined by the researcher according to the patient's condition. The drugs were medicated for 14 days.
45656227|NCT04761341|Drug|NUTROF TOTAL|1 per day over a course of 3 months
45656228|NCT05507411|Radiation|Neoadjuvant Radiotherapy|41.4Gy/23F
45656229|NCT05507411|Drug|Neoadjuvant Chemotherapy|Paclitaxel for Injection （Albumin Bound): 50mg/m^2 QW Carboplatin: AUC=2 QW
45656230|NCT05507411|Drug|Immunotherapy|Camrelizumab 200mg Q3W
45942861|NCT00299611|Drug|Levetiracetam|Tablets, dosage 500mg each tablet (1-4tablets/day)for 8 wks during the 2nd phase of the study.
45942862|NCT00299611|Drug|Placebo|Tablets, No active ingredient, (1-4tablets/day) for 8 wks during the 2nd phase of the study.
45942863|NCT00299650|Drug|cisatracurium|
46075112|NCT02609997|Procedure|Phacomulsification lens removal cataract surgery with single-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with single-piece IOL.During Phacoemulsification.
46075113|NCT02609997|Procedure|Phacomulsification lens removal cataract surgery with three-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with three-piece IOL.During Phacoemulsification.
45942864|NCT00299650|Drug|Placebo|physiological serum infusion
46075114|NCT02609997|Drug|Subconjunctival dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery. Topical anesthesia, consisting of a single drop of 0.5% proparacaine (Alcaine, Alcon Laboratories), was administered three times at intervals of 5 minutes prior to surgery
46075115|NCT02609997|Device|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells
46075116|NCT02609997|Drug|proparacaine|0.5% proparacaine (Alcaine, Alcon Laboratories)
46075117|NCT00876655|Drug|TR-701 di-sodium phosphate salt|One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700)
46075118|NCT00876655|Drug|TR-701 free acid phosphate|One 182 mg capsule of TR-701 free acid phosphate (equivalent to 150 mg TR-700)
45453026|NCT01235936|Drug|AKB-6548|Different dose levels
45453027|NCT01156220|Drug|Furosemide|Injection, 40 mg, single dose over 5 min
45453028|NCT01156220|Drug|aminohippurate sodium|Injection, 500 mg, single dose over 5 min
45453029|NCT01021202|Procedure|Percutaneous dilation tracheostomy|Percutaneous dilation tracheostomy using Ciaglia blue rhino system (Cook medical, Limerick, IRELAND). Tracheostomy is conducted by two experienced physicians with (video-)bronchoscopic control and continuous monitoring of ECG, blood pressure, pulse and peripheral oxygen saturation.
45453030|NCT01331330|Device|Deep Brain Stimulation|Normal DBS Programming
45453031|NCT01331330|Device|Deep Brain Stimulation|Low Programming
45656231|NCT05507333|Device|Gedea pessary|Daily administration of the Gedea pessary during 6 days
45656232|NCT05515913|Other|Nutritional status|Nutritional status of children as analyzed by anthropometric indices was under study
45656233|NCT05515913|Behavioral|Eating behavior|The eating behavior of ASD children as analyzed by frequency of refusal of new food, sensitivity to food, food allergy and gastrointestinal systems was under study
45656234|NCT05515913|Other|Urine iodine concentration|the 24 urine iodine concentration of all subjects was under study
45656235|NCT05515913|Other|Nutrient intake|The nutrient intake as analyzed by three days food diary and major meal proximate analysis of subjects was under study
45656236|NCT05515913|Other|Dietary assessment|The food frequency and dietary diversity of all subjects as analyzed by food frequency questioner, dietary diversity score and food variety score was under study
45656237|NCT05515913|Other|Childhood autism rating scale|The autistic severity of ASD diagnosed children was under study as analyzed by childhood autism rating scale diagnosis
45656238|NCT04603625|Other|postural management|postural management in sitting position
45656239|NCT02569853|Drug|DFN-11|
45656240|NCT02569853|Other|Placebo|
45656241|NCT05512013|Drug|Ibuprofen 800 mg|Ibuprofen taken orally 2 hours prior to exercise
45942865|NCT00299650|Drug|Cisatracurium besilate|Cisatracurium besilate infusion (900mg/day)
45942866|NCT00299767|Procedure|sequential cord blood transplantation|Infused on Day 0
45942867|NCT04727853|Drug|irinotecan liposome injection|Drug: irinotecan liposome injection
45942868|NCT00299806|Drug|Aliskiren|
45942869|NCT00299845|Drug|Lansoprazole|
45942870|NCT00299884|Drug|Lipitor 20 mg|A/A for 6 weeks
45942871|NCT00299884|Drug|Combination Ezetrol 10 mg and Lipidil Supra 160 mg|a/a for 6 weeks
45942872|NCT00119652|Drug|quetiapine fumarate (Seroquel)|
45942873|NCT00119652|Drug|paroxetine|
45942874|NCT00119652|Behavioral|mood stabilizing activity|
45942875|NCT00299923|Drug|Peginterferon alfa-2a, Ribavirin, Amantadine|
45942876|NCT00299962|Biological|Adenoviral-mediated Interferon-beta|BG00001 at doses 1.5 x 10e12 and 3 x 10e12 viral particles Days 1 and 8
45656242|NCT05512013|Drug|Celecoxib 200mg|Celebrex taken orally 2 hours prior to exercise
45656243|NCT05512013|Drug|Flurbiprofen 100 mg|Flurbiprofen taken orally 2 hours prior to exercise
45656244|NCT05512013|Drug|Placebo|Inert placebo taken orally 2 hours prior to exercise
45942877|NCT00299962|Biological|SCH 721015|Comparison of different doses and frequency of investigational agent
45942878|NCT00079742|Drug|Nutropin AQ [somatropin (DNA origin) injection]|
45942879|NCT00418171|Drug|Ziprasidone|
45656245|NCT04894643|Radiation|Proton Ions|According to the radiation plan (between 50.4 and a maximum of 60.2 Gy) after Chemotherapy with Nab-PACLitaxel (Abraxane®) + Gemcitabine and concomitant to Capecitabine.
45656246|NCT04894643|Drug|Nab-PACLitaxel|"Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~It will be administered as intra venous infusion over 30 minutes."
45656247|NCT04894643|Drug|Gemcitabine|"Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~Gemcitabine will also be administered as intra venous infusion over 30 minutes immediately after Nab-PACLitaxel."
45656248|NCT04894643|Drug|Capecitabine|Concomitant to proton-radiotherapy (on the same days, within week 14-19)
45656249|NCT04894643|Procedure|Surgical resection of the pancreas (when feasible)|Pre surgical re-evaluation will be performed at week 21 after enrollment. Patients fulfilling surgery-entry criteria, which consist of no distant metastasis, no massive ascites, no massive pleural effusion, no serious infection, no serious, unresolved chemoradiotherapy related, adverse events and adequate organ system function, will undergo surgery on week 22 (± 1 week). This should be performed via laparotomy.
45656250|NCT05511857|Behavioral|Self-distancing, third-person self-talk.|The participants will engage in self-distancing, third-person self-talk.
45656251|NCT05511857|Behavioral|Self-immersed, first-person self-talk.|The participants will engage in self-immersed, first-person self-talk.
45656252|NCT05511857|Behavioral|Distraction|The participants will engage in a distraction task.
45656253|NCT05511623|Drug|tislelizumab|standard radiotherapy with concomitant cisplatin 40mg/m2 once every week for 5 weeks, combined with tislelizumab (200 mg, day 1) once every 3 weeks until disease progression or intolerable toxicity occurs or one year.
45656254|NCT05511623|Other|concurrent chemoradiotherapy|standard radiotherapy with concomitant cisplatin 40mg/m2 on day 1 once every week for 5 weeks.
45656255|NCT05511545|Other|Patient Education Booklet|Excretory system organs, signs and symptoms to be seen in kidney and ureteral stones, treatment methods, ureteroscopy procedure, what to do before and on the morning of surgery, and surgery, using the training booklet prepared by the researchers in line with the recommendations of the European Association of Urology and the relevant literature. An average of 25-30 minutes of training was given in the patient's room in an encouraging language, allowing the patient to ask questions about the situations he would encounter in the clinic after the surgery. She started asking questions she didn't understand. Afterwards, the questions of the patients were answered and the patient was given a training booklet.
45807359|NCT04898543|Other|Apheresis collection of lymphocytes (part A)|Subjects in cohort 1 will participate in apheresis collection of lymphocytes (part A) and will not receive any investigational therapy in this study.
45807360|NCT04895722|Biological|Pembrolizumab|400 mg or 200 mg pembrolizumab administered via IV infusion.
45807361|NCT04895722|Biological|Pembrolizumab/Quavonlimab|Co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) fixed-dose combination (FDC) administered via IV infusion.
45807362|NCT04895722|Biological|Pembrolizumab/Favezelimab|Co-formulated pembrolizumab/favezelimab (200 mg/800 mg) FDC administered via IV infusion
45807363|NCT04895722|Biological|Pembrolizumab/Vibostolimab|Co-formulated pembrolizumab/vibostolimab (200 mg/200 mg) FDC administered via IV infusion
45942880|NCT00418171|Drug|Olanzapine|
45942881|NCT00119691|Drug|Nesiritide|Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
45807364|NCT04895722|Biological|MK-4830|800 mg MK-4830 administered via IV infusion
45807365|NCT04895709|Drug|BMS-986340|Specified dose on specified days
45807366|NCT04895709|Drug|BMS-936558-01|Specified dose on specified days
45807367|NCT04895709|Drug|Docetaxel|Specified dose on specified days
45807368|NCT04895436|Drug|Venetoclax|Oral tablet
45807369|NCT04895436|Drug|Obinutuzumab|Intravenous (IV) infusion
45807370|NCT04895215|Drug|AB-2004|Taken 3 times daily with food
45807371|NCT04895215|Drug|Placebo|Take 3 times daily with food
45807372|NCT04894708|Procedure|colonoscopy|addition of polyp detection algorithm by Fujifilm
45807373|NCT04890093|Drug|PEN-866|PEN-866 will be given as an IV infusion once every week for the first two consecutive weeks out of every three-week (21 day) cycle.
45807374|NCT04890093|Drug|Vincristine|Vincristine will be given at a dose of 1.5 mg/m2 by IV on days 1 and 8 of each 21-day cycle
45807375|NCT04890093|Drug|Temozolomide|temozolomide will be given at a dose of 100 mg/m2, orally on days 1-5, of each 21-day cycle
45942882|NCT00300040|Drug|Hemoglobin glutamer 250 - bovine|intravenous - 250ml/dose - 32.5g Hb (Concentration 13 +/- 1g/dL)
45942883|NCT00300040|Drug|6% Hydroxyethylstarch|250ml for intravenous infusion
45942884|NCT00079820|Biological|ACAM3000 MVA Vaccine|Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days
45942885|NCT00300079|Drug|brinzolamide 1.0%|
45942886|NCT00300118|Drug|budesonide|9 mg
45942887|NCT00300118|Drug|mesalazine|4.5 g
45942888|NCT00079859|Drug|Implitapide|
45942889|NCT00300157|Device|Percutaneous coronary intervention with Taxus stent|
45942890|NCT00119730|Drug|Fludarabine|Given on days 1-3 of each 28-day cycle
45942891|NCT00119730|Drug|Mitoxantrone|Given on day 1 of each 28-day cycle
45942892|NCT00119730|Drug|Rituximab|Given on day 1 of each 28-day cycle
45942893|NCT00119730|Drug|Zevalin|After two cycles if there is no disease progression, zevalin treatment will be given. Rituximab will be given followed by an imaging dose of zevalin. Two or three scans will be performed over a week to determine if it is safe to give the full treatment dose of zevalin. The treatment dose is given with the second infusion or rituximab, seven days after the first dose.
45656256|NCT04752137|Drug|Indocyanine green|The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
45656257|NCT04752137|Device|SPY-PHI|The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
45656258|NCT05506865|Drug|Indacaterol|Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
45807376|NCT04889989|Device|Microwave Ablation|Percutaneous microwave ablation using the NeuWave Microwave Ablation System for non-small cell lung cancer or oligometastatic lung tumors
45807377|NCT04889144|Other|Communication Intervention|Participate in PLAN intervention
45656259|NCT05506865|Drug|Tiotropium|Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
45656260|NCT05506709|Device|Seawater nasal spray|Subjects will use the nasal spray (moderately hypertonic solution based on 100% natural sea water rich of marine trace elements with added manganese and calcium) at least once and up to 6 times as necessary per day during the 14-day test period. Each application is composed of two irrigating sprays per nostril for a total of 4 sprays per application.
45942894|NCT00300196|Biological|Ancrod (Viprinex)|0.167 IU/kg/hr IV for 2-3 hours
45942895|NCT00300196|Drug|Placebo|0.6 mL/kg/hr
45656261|NCT03048019|Drug|Tirofiban|Patients will receive Tirofiban during the PCI procedure
45807378|NCT04889144|Other|Best Practice|Receive usual care
45807379|NCT04889144|Other|Questionnaire Administration|Ancillary studies
45942896|NCT00079898|Procedure|Acupuncture|
45942897|NCT00119769|Drug|Placebo|Placebo, 0.7 mg/day injected subcutaneously
45942898|NCT00119769|Drug|Genotropin (human recombinant Growth hormone)|Genotropin, 0.7 mg/day injected subcutaneously
45453032|NCT03192488|Drug|Cetirizine|Cetirizine tablet 10 mg
45453033|NCT03192488|Drug|Placebo oral capsule|Gelatin placebo
45807380|NCT04882878|Other|Placebo|Placebo will be administered intravenously.
45807381|NCT04882878|Drug|Nipocalimab|Nipocalimab dose 1 and dose 2 will be administered intravenously.
45807382|NCT04882878|Drug|Standard-of-care treatment|Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.
45807383|NCT04882098|Drug|Guselkumab|Participants will receive guselkumab as SC injection.
45807384|NCT04882098|Drug|Placebo|Participants will receive matching placebo as SC injection.
45807385|NCT04882072|Drug|Ustekinumab|Participants will receive IV infusion and SC injection of ustekinumab.
45807386|NCT04882072|Other|Placebo|Participants will receive IV infusion and SC injection of matching placebo.
45807387|NCT04882072|Drug|Glucorticoid Taper Regimen|Glucocorticoid will be administered orally.
45807388|NCT04881058|Device|RF Non-Invasive Treatment|Self-controlled single-arm group using the PicoSure device.
45807389|NCT04880031|Drug|BOS-580|BOS-580 will be administered by subcutaneous injection
45942899|NCT00300313|Drug|Escitalopram|10 to 20 mg / day
45942900|NCT00300313|Drug|Placebo|1-2 capsules
45942901|NCT00399659|Drug|Tegaserod|
45942902|NCT00300352|Drug|Folic Acid|
45942903|NCT00300508|Drug|Anastrozole|
45942904|NCT00300547|Procedure|MR colonography|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
45942905|NCT00086463|Drug|Iloprost or placebo|
45942906|NCT00079976|Drug|Tigecycline|
45942907|NCT00079313|Drug|Imatinib|
45942908|NCT00086268|Drug|zoledronic acid|
45942909|NCT00086268|Drug|Taxotere|
45942910|NCT00086268|Drug|Carboplatin|
45942911|NCT00300586|Drug|observation|observation, second line chemotherapy if progression
45942912|NCT00300586|Drug|gemcitabine|1250 mg/m² D1, D8 q21 days
45942913|NCT00300586|Drug|erlotinib|150 mg daily
45942914|NCT04718467|Biological|Recombinant COVID-19 vaccine (Sf9 cells)|Three doses of Recombinant COVID-19 vaccine (Sf9 cells) (40μg) at the schedule of day 0, 21, 42.
45942915|NCT04718467|Biological|Placebo|Three doses of Placebo (1.0ml) at the schedule of day 0, 21, 42.
45942916|NCT00080015|Drug|Diflomotecan (BN80915)|
45942917|NCT00300625|Procedure|Application of the San Francisco Syncope Rule|
45942918|NCT00086541|Drug|Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks|
45942919|NCT00300664|Drug|Human Growth hormone|
45942920|NCT04718038|Drug|Cetuximab combind mFOLFOX6/FOLFIRI|Cetuximab 500mg/m2 ivgtt 2h d1 ,q14d;mFOLFOX6: Oxaliplatin 85mg/m2 ivgtt 2h d1, 5-Fu 400mg/m2 iv d1,Lefucovorin 400mg/m2 ivgtt 2h d1, 5-Fu 2.4/m2 CIV 46h, q14d; FOLFIRI: CPT-11 180mg/m2 ivgtt 60-90mins d1, 5-Fu 400mg/m2 iv d1,Lefucovorin 400mg/m2 ivgtt 2h d1,5-Fu 2.4/m2 CIV 46-48h, q14d
45942921|NCT00080054|Drug|Motexafin Gadolinium Injection|
45942922|NCT04718233|Drug|Sildenafil 25Mg Tablet|Sildenafil citrate at a dose of 25mg will be administered orally in patients with recurrent pregnancy loss
45942923|NCT04718233|Drug|Placebo Oral Tablet|placebo will be administered orally in patients with recurrent pregnancy loss
45942924|NCT00119886|Drug|Botulinum toxin|
45942925|NCT00080093|Behavioral|Individual feedback and specially-tailored manuals|Individual feedback and specially-tailored manuals
45942926|NCT00080093|Behavioral|General HIV information feedback and the best-available information|General HIV information feedback and the best-available information
45942927|NCT00300859|Behavioral|brief motivational intervention|
45942928|NCT04727346|Radiation|CBCT|Cone Beam Computed Tomography
45942929|NCT04727346|Procedure|DISE|Drug Induced Sleep Endoscopy
45656262|NCT03048019|Drug|Cangrelor|Patients will receive Cangrelor during the PCI procedure
46075119|NCT05424900|Behavioral|Rethink game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.
46075120|NCT02609919|Drug|Gadoteric Acid|MRI Contrast Agent
45656263|NCT05506631|Procedure|Outpatient Foley balloon placement|Cervical ripening with balloon placement in the outpatient setting
45656264|NCT05506631|Procedure|Inpatient Foley Balloon placement|Cervical ripening with balloon placement in the inpatient setting
45656265|NCT05506553|Device|Intervention arm - Eyhance Toric II Intraocular Lens|Bilateral cataract extraction and insertion of Eyhance Toric II Intraocular Lens
45656266|NCT05506553|Device|Control Arm - Alcon IQ Toric Intraocular lens|Bilateral cataract extraction and insertion of Alcon IQ Toric Intraocular Lens
45656267|NCT05506397|Other|Acupressure|Acupressure is a technique based on stimulating certain points on the body with stimulation methods such as hands and fingers.
45656268|NCT04140773|Dietary Supplement|D-serine|Capsule D-serine
45656269|NCT04140773|Other|Placebo|Capsule D-serine
45656270|NCT05506319|Other|Norepinephrine|"The patients will be randomized for the initial suspension of norepinephrine (norepinephrine group).~Interruption means suspension for at least 24 hours."
45656271|NCT05506319|Other|Vasopressin|"The patients will be randomized for the initial suspension of vasopressin (vasopressin group).~Interruption means suspension for at least 24 hours."
45656272|NCT05506241|Device|Dynavision D2|Use of the Dynavision will be comprised of six 3-minute or nine 2-minute sessions with 30 seconds to one-minute rest in between. All Dynavision sessions require clients to scan the 4' by 4' vertical board and hit the lit targets one at a time. Participants will be able to depress targets with their left or right hand, in standing or sitting.
45656273|NCT05511467|Behavioral|Visuomotor learning task|Participants undergo functional magnetic resonance imaging during the performance of the visuomotor learning task. The visuomotor learning task involves holding a device in the hand that measures the strength of the grip when squeezing the 'gripper'.
45656274|NCT05506007|Drug|DA-5216|"During the cross-over [Part A], patients will be randomly assigned to receive one of the following treatment sequences:~Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8."
45656275|NCT05506007|Drug|DA-5216-R|"During the cross-over [Part A], patients will be randomly assigned to receive one of the following treatment sequences:~Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8."
45656276|NCT05506007|Drug|DA-5216|"During the cross-over [Part B], patients will be randomly assigned to receive one of the following treatment sequences:~Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8."
45656277|NCT05506007|Drug|DA-5216|"During the cross-over [Part B], patients will be randomly assigned to receive one of the following treatment sequences:~Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8."
45656278|NCT05515757|Behavioral|Mobile-app based contingency management|We are adapting an evidence-based outpatient mobile-app based CM intervention to the hospital setting for hospitalized patients with stimulant use disorders requiring prolonged hospitalization. Participants will be enrolled into an 8-week mobile-app based contingency management intervention.
45656279|NCT04975139|Device|RS-fMRI|Advanced imaging method that can identify the spatiotemporal distribution of the intrinsic functional networks within the brain
45656280|NCT05505929|Device|Biofreedom Ultra|The BioFreedomTM Ultra CoCr DCS is a combination product consisting of two key components: the cobalt chromium stent platform coated abluminally with the active ingredient BA9TM (polymer and carrier free) and the delivery system.
45807390|NCT04880031|Drug|Placebo|Placebo will be administered by subcutaneous injection
45807391|NCT04879732|Device|ACTIS|ACTIS Hip stem
45807392|NCT04876092|Drug|JNJ-67856633|Participants will receive JNJ-67856633 orally.
45807393|NCT04876092|Drug|Ibrutinib|Participants will receive Ibrutinib orally.
45807394|NCT04875884|Device|Modified MRI|A technical modification to the standard MRI which only affects radiofrequency pulse polarization attempting to optimize the image quality. All other factors, including pulse sequence parameters, and patient and coil positioning is similar to that of the standard MRI.
45807395|NCT04873362|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg every three weeks (Q3W) for 14 cycles.
45942930|NCT00300937|Dietary Supplement|Coenzyme Q10|100 mg oral BID starting at week 20 until delivery
45942931|NCT00418210|Radiation|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT)|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT; 38.5 Gy in 3.85 Gy fractions bi-daily over 5 consecutive working days
45942932|NCT00080132|Drug|implitapide|
45942933|NCT00418249|Drug|AS101|
45942934|NCT00119925|Behavioral|patient education|patient leaflets about national guideline contents
45453034|NCT03192488|Other|Hypoxia|Exposure to a 14.3% oxygen environment simulating an altitude of 3,000m/9,000ft
45453035|NCT03192176|Drug|Fezolinetant|Oral Capsule
45942935|NCT00119925|Behavioral|professional audit and feedback (guideline adherence)|feedback on current practice according to quality indicators
45942936|NCT00119925|Behavioral|professional education (communication/shared decision making)|educational tools for professionals concerning communication and shared decision making
45942937|NCT00119925|Other|information tools|tools and checklists to improve information provision
46075121|NCT00867997|Other|Chemoactive (remineralizing, neuroactive) dentifrice treatment|Chemoactive (remineralizing, neuroactive) dentifrice treatment
46075122|NCT00867997|Other|Clearfil S3 Bond; Clearfil Liner Bond 2 Protect Liner F|Self-etch DBA followed by a hydrophobic resin layer
45656281|NCT04591067|Other|Testing of physical capacity|"This cross-sectional study will involve evaluation of physical capacity by assessment of:~Gait function~Muscle activity during walking~Endurance during walking~Hip muscle strength~Hip range of motion~Hip and muscle-tendon-related groin pain~Hip and groin related patient-reported outcome measures (PROMs)"
45656282|NCT05515133|Other|stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
45656283|NCT04725071|Dietary Supplement|Impact Advanced Recovery|L-arginine and omega-3 rich supplement
45656284|NCT04725071|Dietary Supplement|Boost High Protein|conventional supplement
45656285|NCT05505851|Other|Control|Hip Flexor Stretch 30 seconds hold 3 repetitions on each side Thoracolumbar extensors stretch 30 second holds 3 repetitions Abdominal Curl ups with hands at side 10 repetitions 2 sets Progression: • Abdominal curl up with arms crossed • Abdominal curl ups with hands behind head Pelvic bridging 10 seconds hold 10 repetitions 2 sets
45656286|NCT05505851|Other|Sequential Core Stability Corrective Exercise Approach|"Corrective Exercises~Diaphragm Training Program As per standardized pulmonary rehabilitation guidelines,. Participant will be advised to breathe in gently with an improved tidal volume for ten repetitions, then after a short interval of break 15 repetitions will be done again. 30 Repetitions in set of 15, 15 with the interval rest. 2 sets.~Pelvic floor Muscle training Participants will be asked to do pelvic floor training with high intensity (close to maximum) contractions with holding each muscle contraction for 6-8 seconds with relaxation of 6 seconds. Total 8 to 12 contractions.~Core Stability exercises~Beginning~Progressing~Advanced"
45656287|NCT05515055|Other|Blood test|1 blood sample extra to standard of care is taken
45656288|NCT04969445|Biological|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
45656289|NCT05505695|Other|Brace and Exercise Treatment|Schroth exercises, which are a specific exercise method for scoliosis, were given to the experimental group for 8 weeks, different from the control group.
45656290|NCT05505695|Other|Brace Treatment|Among the patients included in the study, those who wore braces but did not agree to exercise constituted the ''Brace Group'' of the study.
45656291|NCT04945187|Other|Nurse-led consultations based on electronic patient-reported outcomes|The patients will weekly answer electronic patient-reported outcomes during chemotherapy and the answers will be used proactive in nurse-led consultations.
45656292|NCT05505539|Drug|5-fluorouracil|Given intralesionally by injection
45807396|NCT04873362|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg Q3W for 14 weeks.
45807397|NCT04873362|Drug|Placebo|Placebo matched to atezolizumab will be administered at a dose of 1200 mg Q3W for 14 cycles.
45807398|NCT04873362|Drug|Trastuzumab|Trastuzumab will be used to complete 14 cycles of study treatment if trastuzumab emtansine is discontinued for toxicity not considered to be related to the trastuzumab component of the drug.
45942938|NCT00300976|Behavioral|Lifestyle consultation: weight control, diet, exercise|"Behavioral: Lifestyle modification including weight control, with the goal of BMI 22.~Drug: Drugs are added in a stepwise manner to control blood glucose, blood pressure and lipid metabolism, using mainly hypoglycemic drugs, ACEI/ARB and statins, respectively. Management goals are: HbA1c < 6.2%, BP < 120/75 mmHg, HDL-C 40 mg/dL , LDL-C < 80 mg/dL, TG < 120 mg/dL.~Follow-up study (Not provided)"
45942939|NCT00300976|Behavioral|Lifestyle consultation: weight control, diet, exercise|"Behavioral and Drug: The physician in charge is to administer appropriate therapy in accordance with the Guidelines.~Follow-up study (Not provided)"
45942940|NCT00301015|Device|Rapid diagnostic test for malaria|We used Paracheck Pf® (Orchid Biomedical Systems, India) as rapid diagnostic test in this trial
45942941|NCT00301054|Drug|Ferrous sulphate|
45656293|NCT04588103|Other|Heat therapy|Lower limb warm water immersion (42 degrees C)
46075123|NCT00867997|Other|Clearfil S3 Bond; Premise Flowable resin-based composite|Restoration with a dentin bonding agent (DBA) and flowable resin-based composite
45656294|NCT04588103|Other|Exercise training|Moderate-intensity cycling exercise (~40-59% VO2 reserve)
45656295|NCT04943315|Procedure|Monolithic zirconia|posterior crowns
45807399|NCT04870918|Behavioral|self-care intervention|Health education will be carried out by the nurse.
45807400|NCT04868773|Drug|Cabozantinib|Oral cabozantinib
45807401|NCT04868773|Drug|TAS-102|Oral TAS-102 (trifluridine and tipiracil)
45807402|NCT04866810|Behavioral|Intervention Arm|High fiber, plant based diet + exercise prescription with ACT sessions
45807403|NCT04866810|Behavioral|Control|Standard diet and exercise recommendations
45807404|NCT04865029|Other|Placebo injection and placebo pill|Standard of Care consistent with the National Institutes of Health (NIH) COVID-19 Treatment Guidelines
45807405|NCT04865029|Drug|Estradiol Cypionate 5 mg/ml|Standard of Care along with Estradiol Cypionate 5mg intramuscular injection at admission.
45942942|NCT00301054|Drug|Sulphadoxine-Pyrimethamine|
46075124|NCT04114500|Diagnostic Test|serum estradiol and progesterone|blood sample for measuring serum estradiol and progesterone level on the same day of FET
45942943|NCT00301093|Biological|GM-K562 cell vaccine|Once weekly for 3 vaccination, then every other week for 3 vaccinations, and then every month for 3 vaccinations until the participant has received a total of 9 vaccinations
45656296|NCT04943315|Procedure|Metal-ceramic|posterior crowns
45656297|NCT04292717|Behavioral|Gait training|All participants will receive training three times a week for 6 weeks (18 training sessions) at the University Hospital Balgrist, Spinal Cord Injury Centre. Each exercise session will last for 1 hour and will be conducted and supervised by an experienced physical therapist.
45656298|NCT05514977|Procedure|Erector spine plane block|Thoracic ESPB
45656299|NCT04140539|Biological|OTL-101|Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo using a lentiviral vector (LV) encoding the human adenosine deaminase (ADA) gene.
45656300|NCT05505461|Drug|neoadjuvant Radiation plus SOX and PD-1 antibody|"Patients will be given the perioperative treatment as below once recruited:~First, neoradiation (5w) will be given: intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas. PD-1 antibody will be started concurrent the radiation for 2 cycles.~The neochemotherapy (SOX) and PD-1 antibody will be given for 2 cycles after 1 week since radiation completed ; Patients will rest 2 weeks after the last cycle of neochemotherapy, and evaluation will be performed during this time. And D2 surgery will be performed if resectable.~SOX and PD-1 antibody will be given q3w. Adjuvant chemotherapy: We advise starting 4 cycles of SOX regimen in 3-8w after surgery."
45656301|NCT05505383|Other|Exercise training|People with multiple sclerosis will be received a supervised physiotherapy and rehabilitation program.
45656302|NCT05514743|Procedure|6 minute walk test , Blood pressure monitoring|"Heart rate monitors can assess a person's heart rate and reveal whether it is high or low. Heart rate Trusted Source is a clinical indicator of overall cardiac health, and it can also help a person determine their performance during a workout.~Six minute walk test:~It will be carried out before and after interventions to determine the patients functional capacity (in the 7th.day &in the 21st.day.) It will be used as a training tool as well as an assessment tool. They will receive conventional physical therapy program which includes deep breathing exercise in form of (diaphragmatic, apical and costal breathing), Training about right way of cough and early ambulation from bed for 3 sessions / week, twice daily for 21 days."
45656303|NCT05511311|Procedure|Resistance Training|Resistance training developed by the researcher (SCR-RSCM) for 12 weeks
45807406|NCT04865029|Drug|Progesterone 200 mg Oral Capsule|Standard of Care along with Progesterone 200mg by mouth daily for 5 days starting at admission.
45656304|NCT05511311|Procedure|Standard Therapy|Standard therapy for 12 weeks
45656305|NCT05514665|Device|Diffuse Optical Tomography|Neonates once hemodynamically stable will undergo diffuse optical tomography measurements of functional brain connectivity at the bedside within 3-7 days after birth.
45656306|NCT05514275|Drug|Endostatin and Capecitabine|Patients received radiotherapy Combined With Endostatin(37.5mg/m2, continuous intravenous infusion for 120h, D-7, D8, D22, D36) and Capecitabine( 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles)
45656307|NCT04877249|Behavioral|Split-belt treadmill training|1. Split-belt gait training without or with any resistance, 2. Facilitating the knee extension during the terminal swing phase of gait cycle to identify the impact on the propulsive force generation of paretic leg
45656308|NCT05510999|Other|Placebo|One capsule of placebo will be taken twice daily for 24 weeks.
45807407|NCT04859660|Drug|Tamsulosin|Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.
45807408|NCT04859660|Drug|Placebo|Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.
45656309|NCT05510999|Dietary Supplement|Water soluble pollen extract fraction|Each capsule contains 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (360 mg/day) for 24 weeks.
45807409|NCT04855708|Other|Virtual visit|Patients randomized to this group will have a virtual 2-week post-operative visit
45807410|NCT04855708|Other|Office visit|Patients randomized to this group will have a in-person 2-week post-operative visit
45807411|NCT04847739|Procedure|Seton Placement|This treatment consists of inserting a seton (a soft flexible tube or nonabsorbable string) into the subject's perianal fistula. The seton will be removed by a study doctor at study visits as applicable.
45656310|NCT05510999|Dietary Supplement|Lipid soluble pollen extract fraction + water soluble pollen extract fraction|Each capsule contains a combination of 9 mg of lipid soluble pollen extract fraction and 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (18 mg/day and 360 mg/day, respectively) for 24 weeks.
45807412|NCT04847739|Drug|AVB-114|AVB-114 consists of stem cells taken from a subject's fat tissue seeded into a bioabsorbable plug. AVB-114 will be inserted into the subject's fistula by a study doctor on Day 0.
45807413|NCT04847063|Drug|Mitomycin C|Arm 2, intraperitoneal (IP) Mitomycin C monotherapy: dosing divided into two 60-mL syringes, 30 mg per syringe. 30 mg will be given at time = 0, and the remaining 10 mg of the dose will be given at time = 60 minutes. Part of Arm 4: Mitomycin C co-therapy 15 mg/m2 for 60 minutes, given at time = 0 with cisplatin
45942944|NCT00301093|Drug|imatinib mesylate|Participants will continue on current dose
45942945|NCT00086658|Drug|mepolizumab|
45807414|NCT04847063|Drug|Cisplatin|Part of Arms 3 and 4, intraperitoneal (IP)cisplatin co-therapy: 75 mg/m2 for 60 minutes, mixed in 1 L of 0.9% sodium chloride. For cisplatin-based HIPEC, intravenous sodium thiosulfate given as a loading dose of 7.5 g/m2 in 150 mL 0.9% sodium chloride at the time of introducing cisplatin into the perfusion circuit, followed by a 12-hour pump-based infusion of 25.56 g/m2 in 1 L 0.9% sodium chloride
45807415|NCT04847063|Procedure|Heated Intraperitonial Chemotherapy|Heated Intraperitonial Chemotherapy (HIPEC) with with standardized doses of chemotherapeutic agents as indicated by the subject's Arm assignment
45942946|NCT00301171|Drug|Inhaled Fluticasone|
45942947|NCT00080210|Drug|Puricase|
45942948|NCT00301210|Drug|Tramadol|oral doses four times per day
45942949|NCT04727463|Procedure|Sphincteroplasty|Overlapping sphincteroplasty
45656311|NCT05510999|Dietary Supplement|Lipid soluble pollen extract fraction|Each capsule contains 9 mg of lipid soluble pollen extract fraction. One capsule of will be taken twice daily (18 mg/day) for 24 weeks.
45656312|NCT05510999|Dietary Supplement|Water soluble pollen extract fraction + cranberry powder|Each capsule contains a combination of 42 mg of water soluble pollen extract and 125 mg of cranberry powder. One capsule will be taken twice daily (84 mg/day and 250 mg/day, respectively) for 24 weeks.
45807416|NCT04847063|Drug|Doxorubicin|Part of Arm 3: intraperitoneal (IP) Doxorubicin co-therapy 15 mg/m2 for 60 minutes, given at time = 0 with cisplatin
45807417|NCT04847063|Drug|Oxaliplatin|Arm 1, intraperitoneal (IP) Oxaliplatin: 200 mg/m2 for 90 minutes, mixed in 250 mL of 5% dextrose solution. For oxaliplatin-based HIPEC, intravenous 5-fluorouracil given at a dose of 400 mg/m2 in 250 mL 0.9% sodium chloride over 10 minutes, co-administered with intravenous leucovorin at 20 mg/m2 in a separate bag of 250 mL 0.9% sodium chloride
45807418|NCT04847063|Drug|5-Fluorouracil|Part of Arm 1, for oxaliplatin-based HIPEC: intravenous 5-fluorouracil given at a dose of 400 mg/m2 in 250 mL 0.9% sodium chloride over 10 minutes, co-administered with intravenous leucovorin at 20 mg/m2 in a separate bag of 250 mL 0.9% sodium chloride
45942950|NCT00080327|Drug|Aripiprazole|Tablets, Oral, 2mg, Once daily, 6 weeks.
45942951|NCT00080327|Drug|Aripiprazole|Tablets, Oral, 5mg, Once daily, 6 weeks.
45942952|NCT00080327|Drug|Aripiprazole|Tablets, Oral, 10mg, Once daily, 6 weeks.
45942953|NCT00080327|Drug|Placebo|Tablets, Oral, 0mg, Once daily, 6 weeks.
45942954|NCT00301288|Procedure|Autologous stem cell transplant|
45942955|NCT00301327|Drug|Summers 5% L.A.|
45942956|NCT00301405|Drug|Thalidomide|Open label drug
45942957|NCT00301444|Device|mirror-box treatment|
45807419|NCT04847063|Drug|Sodium Thiosulfate|Part of Arms 3 and 4, for cisplatin-based HIPEC: intravenous sodium thiosulfate given as a loading dose of 7.5 g/m2 in 150 mL 0.9% sodium chloride at the time of introducing cisplatin into the perfusion circuit, followed by a 12-hour pump-based infusion of 25.56 g/m2 in 1 L 0.9% sodium chloride
45942958|NCT00301444|Behavioral|Mental visualization|
45807420|NCT04844450|Drug|JNJ-75220795|JNJ-75220795 will be administered subcutaneously.
45807421|NCT04844450|Drug|Placebo|Matching placebo will be administered subcutaneously.
45942959|NCT00080366|Drug|1-Octanol|
45942960|NCT00301483|Drug|Hemoglobin-based oxygen carrier-201 (HBOC 201)|HBOC-201 is an investigational solution of sterile, ultrapurified, glutaraldehyde polymerized, modified bovine hemoglobin (Hb) in a balanced electrolyte solution. HBOC-201 has an Hb concentration of 12-14g/dL. HBOC-201 is an isosmotic solution that is stable for at least 36 months at 2-30ºC. It requires no reconstitution and can be administered directly into a peripheral or central vein. Blood typing is not required because all other cellular components, including the RBC membranes that carry the blood group antigens, have been removed.
45656313|NCT05505149|Other|physiotherapy|Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
45942961|NCT00301483|Other|Standard of Care|Standard Therapy
45656314|NCT05505071|Device|DANTE SPACE sequence|investigational MRI sequence less than 15 minutes
45942962|NCT00301522|Device|TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation|Paclitaxel-Eluting Coronary Stent, Slow-Formulation
45942963|NCT00301522|Device|Express2|Coronary Stent System
45942964|NCT00080405|Drug|Bortezomib|
45942965|NCT00119964|Behavioral|internet based weight management tools|
45942966|NCT00292123|Drug|Methadone|
45656315|NCT05504993|Other|Frequency of AECOPD|No intervention has been applied. 92 COPD patients divided into 2 groups according to their comorbidity level. Than these groups were compared for their AECOPD frequency
45656316|NCT05514119|Drug|Fenofibrate|160mg once daily orally for 12 weeks
45942967|NCT00292123|Behavioral|Contingency Management|
45942968|NCT00080444|Drug|aprepitant|aprepitant capsules
45942969|NCT00080444|Drug|ondansetron|ondansetron IV preparation
45942970|NCT00080444|Drug|dexamethasone|dexamethasone tablets
45942971|NCT00080444|Drug|placebo to aprepitant|Matching placebo to aprepitant capsules
45942972|NCT00080444|Drug|placebo to dexamethasone|Matching placebo to dexamethasone tablets
45656317|NCT05514041|Drug|Varenicline solution|OC-01 nasal spray 0.03 mg
45942973|NCT00080444|Drug|rescue medication|Participants are allowed to take rescue medication throughout for nausea or vomiting. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are: 5-HT3 antagonists, phenothiazines, butyrophenones, benzamides, corticosteroids, benzodiazepines, domperidone, H1-receptor antagonist, and piperazine derivatives.
45942974|NCT00086736|Drug|bicalutamide|
45942975|NCT00086736|Drug|eflornithine|
45942976|NCT00086736|Drug|oral eflornithine placebo|
45942977|NCT00086736|Drug|oral bicalutamide placebo|
45942978|NCT00292201|Drug|Atorvastatin|The treatment group will receive Atorvastatin 80 mg po once per day for 4 weeks. The placebo group will receive an identical placebo pill po once per day for 4 weeks.
45942979|NCT00292240|Behavioral|Brief motivational substance use intervention|
45942980|NCT00292279|Drug|Omega-3 fish oil emulsion (Omegaven )|Patients of the treatment group received 0.2 g fish oil (10% Omegaven, Fresenius Kabi, Bad Homburg, Germany) and 1.0 g soy bean oil per kg BW per day
45942981|NCT00292279|Drug|long-chain triglyceride|the control group received 1.2 g soy bean oil (Intralipid, Sino-Swed,Wuxi,China)
45942982|NCT00080522|Behavioral|Monitoring by HIV-trained primary care nurses|
45942983|NCT00080522|Behavioral|Community-based directly observed therapy (DOT)|
45942984|NCT00080522|Drug|stavudine|
45942985|NCT00080522|Drug|lamivudine|
45942986|NCT00080522|Drug|efavirenz|
45942987|NCT00080522|Drug|zidovudine|
45942988|NCT00080522|Drug|didanosine|
45942989|NCT00080522|Drug|lopinavir/ritonavir|
45942990|NCT00086775|Biological|alemtuzumab|
45942991|NCT00086775|Biological|rituximab|
45942992|NCT00086775|Drug|fludarabine phosphate|
45942993|NCT00292357|Procedure|Application of autologous bone marrow|
45807422|NCT04840303|Behavioral|LevelMind@JC Mental Wellness Youth Hubs|Mental Wellness Youth Hubs Intervention aims to set up a series of community-based hubs for young people to enhance cognitive abilities, personal strengths and overall mental well-being. Among the experimental group participants (hub users), they are further divided into three tiers according to their psychological distress level. Tier 1 are youths with mild psychological distress level, who will be invited to participate in some innovative and interesting youth projects and activities (e.g., board game and floral artistry). Tier 2 are youths who have moderate level of psychological distress, or at risk for mental illness. Trained social workers will offer them with specific interventions (e.g., CBT, sleep intervention) according to their needs. Tier 3 are youths with severe level of psychological distress who are at risk for mental disorders. Diagnostic and medical assessment services will be delivered by psychiatrist or clinical psychologists.
45942994|NCT00292435|Drug|Read vine leaf extract (AS 195)|
45656318|NCT05514041|Drug|Placebo nasal spray (OC-01 Vehicle Nasal Spray)|Placebo nasal spray (OC-01 Vehicle Nasal Spray)
45656319|NCT04691531|Device|The use of classical Gauge 22 needle|After induction of general anesthesia, patients will undergo caudal block by using classical Gauge 22 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
45656320|NCT04691531|Device|The use of classical Gauge 27 needle|After induction of general anesthesia, patients will undergo caudal block by using Gauge 27 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
45656321|NCT05513963|Behavioral|Clairity|Treatment group participants will complete study session using the Clairity tool in between regularly scheduled therapy visits.
45656322|NCT04667663|Drug|Daratumumab|Daratumumab (1,800mg) will be administered by a subcutaneous injection once every week for 2 cycles (Cycles 1-2), then once every 2 weeks for 4 cycles (Cycles 3-6), and following this (Cycle 7 onwards), patients will receive daratumumab once every four weeks.
45656323|NCT04667663|Drug|Cyclophosphamide|Cyclophosphamide will be administered PO at 50mg daily for all cohorts in the study.
45942995|NCT00292474|Device|percutaneous coronary intervention|
45942996|NCT00086892|Biological|cetuximab|
45942997|NCT00086892|Drug|carboplatin|
45942998|NCT00292513|Device|standard suture (5-0 prolene), topical skin adhesive (dermabond), absorbable suture (5-0 Chromic gut)|
45942999|NCT00292552|Other|Novel endpoint determination|Novel endpoint determination
45943000|NCT00292708|Drug|Cefmetazole (drug)|
45943001|NCT00086931|Drug|capecitabine|oral dose escalating, twice daily.
45943002|NCT00086931|Drug|oxaliplatin|IV over 2 hours on days 1, 8, 15, 22, and 29.
45656324|NCT04667663|Drug|Pomalidomide|Pomalidomide will be administered PO on days 1-21 of each 28 day cycle. The dose will be specified by the dose level to which the patient has been enrolled.
45656325|NCT04667663|Drug|Dexamethasone|Dexamethasone will be administered PO at 40mg on days 1, 8, 15 and 22 of each 28 day cycle.
45656326|NCT04666259|Drug|ABL001|Asciminib will be supplied as 20 mg or 40 mg strength tablets will be administered orally in accordance with the assigned cohort.
45656327|NCT05510765|Behavioral|Transportation service|Improved transportation assets applied to all aspects of subjects life
45807423|NCT04838769|Device|REZŪM|Subjects randomized to receive the REZŪM treatment will receive standardized treatment, following the Instruction for Use.
45943003|NCT00086931|Procedure|conventional surgery|curative-intent surgery 6-8 weeks after the completion of chemoradiotherapy
45943004|NCT00086931|Procedure|neoadjuvant therapy|chemotherapy and radiation prior to surgery
45943005|NCT00086931|Radiation|radiation therapy|once daily 5 days a week for 5.5 weeks
45943006|NCT00080639|Other|physiologic testing|
45943007|NCT00080639|Procedure|study of high risk factors|
45943008|NCT00292747|Drug|Drotaverine|
45943009|NCT00292747|Drug|Drotaverine Placebo|
45943010|NCT00292747|Drug|Ibuprofen|
45943011|NCT00292747|Drug|Ibuprofen Placebo|
45943012|NCT00292786|Behavioral|Walking Practice with Functional Electrical Stimulation|
45943013|NCT00292786|Behavioral|Walking Practice|
45943014|NCT00292825|Device|Pacemaker treatment, pacemaker programmed as active = CLS|Pacemaker treatment with closed loop function(CLS)
45943015|NCT00292825|Device|Pacemaker, programmed as passive = VVI 30 beats per minute (bpm)|pacemaker treatment as VVI 30 bpm
45943016|NCT02958410|Biological|Anti-CD30-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD30-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
45943017|NCT00120003|Drug|Candesartan Cilexetil|4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
45943018|NCT00120003|Drug|Placebo|4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
45943019|NCT00292864|Drug|SNS-032 Injection|
45943020|NCT00292903|Behavioral|Brief interpersonal psychotherapy|IPT-B sessions include evaluation of participants' level of depression, identification of any difficulties or problems that participants may be experiencing, and review of how to manage these problems using skills learned during treatment.
45943021|NCT00292903|Behavioral|Facilitated referral for treatment as usual|F-TAU includes providing verbal and written information regarding depressive symptoms and a referral for treatment at a behavioral health clinic.
45943022|NCT00201721|Drug|Pentostatin|2 mg/m2 IV over 30 minutes in 250 mL NS on day 1 during cycles 1-6.
45943023|NCT00201721|Drug|Rituximab|For the first week only: Day 1 of therapy 100 mg IV over 4 hours. Day 3 of therapy 375 mg/m2 IV at 50 mg/hr and increase by 100 mg/hr at 30-minute intervals to a maximum of 400 mg/hr. Day 5 of therapy 375 mg/m2 IV at 100 mg/hr for the first 15 minutes the remainder goes in at 45 minutes. The remaining weeks 375 mg/m2 will be repeated as a single IV infusion Day 1 of Week 4, 7, 10, 13 and 16 during cycles 2-6.
45943024|NCT00201721|Drug|Cyclophosphamide|600 mg/m2 IV in 250 mL NS over 30 minutes on day 1 cycles 1-6
45943025|NCT00201799|Drug|Infliximab|"A total of 6 doses of Infliximab will be administered as follows:~Dose 1: 10 mg/kg IV one day prior to commencing the myeloablative preparative regimen Dose 2: 10 mg/kg IV on day 0 to be given after peripheral blood stem cell infusion Dose 3: 10 mg/kg IV on day +7 Dose 4: 10 mg/kg IV on day +14 Dose 5: 10 mg/kg IV on day +28 Dose 6: 10 mg/kg IV on day +42"
45943026|NCT00080678|Drug|Docetaxel|
45943027|NCT00080678|Drug|Imatinib Mesylate|
45943028|NCT00086970|Drug|ifosfamide|Given IV
45943029|NCT00086970|Drug|O6-benzylguanine|Given IV
45943030|NCT00201916|Procedure|5250 cGy/20 fractions over 28 days|see above
45943031|NCT00201916|Procedure|6600 cGy/33 fractions over 45 days|see above
45656328|NCT05504759|Other|splint|Resting is the first step of treatment in lateral epicondylitis. Patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
45656329|NCT05504759|Other|steroid|Betamethasone Dipropionate + Betamethasone Sodium Phosphate-1 ml will be administered once at the beginning of the study to patients who will receive steroid injection, one of the local injection treatments. Steroid injection will be applied to the most sensitive point on the lateral epicondyle. Afterwards, patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during daytime hours for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
45656330|NCT05504759|Other|dry needling|The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x30 mm needles will be used for dry needling. Dry needle treatment will be applied to the painful trigger points in the forearm extensor group muscles with the stick-pull technique, 1 session per week, for a total of 2 sessions. Afterwards, the patients will be given a 2 weeks rest protocol (works that may strain the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The purpose of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. During the treatment of lateral epicondylitis, home exercises will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
45656331|NCT02570711|Drug|ACP-196|ACP-196 capsule
45807424|NCT04838769|Drug|alpha blocker and 5-alpha reductase inhibitor|Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor. This arm will therefore represent local standard of care.
45807425|NCT04837937|Behavioral|Caregiver vs. Patient [Beginner]|Participants will be assigned a 'Caregiver vs. Patient' [Beginner] online negotiation exercise. All participants will complete this exercise, so it will serve as the constant.
45807426|NCT04837937|Behavioral|Caregiver vs. Caregiver|Participants will be assigned a 'Caregiver vs. Caregiver' online negotiation exercise.
45807427|NCT04837937|Behavioral|Caregiver vs. Physician|Participants will be assigned a 'Caregiver vs. Physician' online negotiation exercise.
45807428|NCT04837937|Behavioral|Caregiver vs. Patient [Advanced]|"Participants will be assigned a 'Caregiver vs. Patient [Difficult]' online negotiation exercise. This exercise is advanced compared to the constant since it involves negotiating more than one conflict."
45943032|NCT00201955|Drug|Rebamipide|
45943033|NCT00080795|Biological|filgrastim|
45943034|NCT00080795|Drug|cisplatin|
45943035|NCT00080795|Drug|doxorubicin hydrochloride|
45943036|NCT00080795|Drug|gemcitabine hydrochloride|
45943037|NCT00080795|Drug|ifosfamide|
45943038|NCT00080795|Procedure|conventional surgery|
45943039|NCT00080795|Procedure|neoadjuvant therapy|
45943040|NCT00120081|Biological|Na-ASP-2/Alhydrogel Hookworm Vaccine|The recombinant hookworm protein Na-ASP-2 formulated on aluminum hydroxide adjuvant (Alhydrogel), in one of three dose concentrations, compared to a saline placebo control.
45943041|NCT00120081|Biological|Saline placebo|Inactive saline placebo control
45943042|NCT00201994|Drug|Tolvaptan|
45807429|NCT04836559|Drug|JNJ-40411813|JNJ-40411813 will be administered orally.
45807430|NCT04836559|Drug|Placebo|Placebo will be administered orally.
45943043|NCT00202033|Behavioral|frequency of self monitoring blood glucose|Evaluate the impact of self monitoring blood glucose frequency on glycemic control in patients with type 2 diabetes.
45943044|NCT00202111|Procedure|Laparoscopic-assisted colectomy|
45943045|NCT00202111|Procedure|Conventional open colectomy|
45943046|NCT00080834|Drug|DJ-927|
45943047|NCT00120120|Drug|Lenalidomide (CC-5013)|Lenalidomide 2-5 mg capsules taken one time per day
45943048|NCT00202150|Behavioral|Application of a management action plan|
45943049|NCT00202189|Drug|Budesonide|Nebulized Budesonide (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered to subjects once only.
45943050|NCT00202228|Drug|cofactor supplementation (thiamine, riboflavin, L-carnitine)|Thiamine: 50 mg po od; Riboflavin: 100 mg po od; L-carnitine: 990 mg po bid.
45943051|NCT00080873|Drug|Traumeel S|
45943052|NCT00080873|Other|Placebo|
45943053|NCT00087009|Biological|beta-glucan|Given orally
45943054|NCT00087009|Biological|rituximab|Given IV
45943055|NCT00306319|Drug|moxifloxacin|
45943056|NCT00306358|Drug|Vitamin B12 (Cyanocobalamin)|
45943057|NCT00306397|Drug|Rapamycin|Sirolimus perorally following kidney transplantation, randomisation after protocol biopsy at months three to a) Sirolimus - MF- or b) low dose tacrolimus - sirolimus -MMF -
45943058|NCT00418600|Drug|Hectorol® (doxercalciferol capsules)|Hectorol capsules at 1.0 times current injection dose
45943059|NCT00418600|Drug|doxercalciferol capsules, Hectorol®|Hectorol capsules at 1.5 times current injection dose
45656332|NCT02570711|Drug|Nab-paclitaxel|Nab-paclitaxel infusion
45943060|NCT00418600|Drug|doxercalciferol capsules, Hectorol® capsules|Hectorol capsules at 2.0 times current injection dose
45807431|NCT04829994|Device|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures being performed within the study are identical to the surgical procedures subjects would receive as part of SOC.
45943061|NCT00087048|Drug|topotecan hydrochloride|
45943062|NCT00080951|Drug|fluorouracil|
45943063|NCT00080951|Drug|irinotecan hydrochloride|
45943064|NCT00080951|Drug|leucovorin calcium|
45943065|NCT00080951|Drug|oxaliplatin|
45656333|NCT02570711|Drug|Gemcitabine|Gemcitabine infusion
45656334|NCT05513729|Drug|Canagliflozin|According to the guideline of type 2 diabetes，canagliflozin will be given to 40 patients with type 2 diabetes combined with NAFLD as first-line choice if accompanied with indicators of high risk or established atherosclerotic cardiovascular disease, chronic kidney disease or heart failure, independently of HbA1c level. It can be also given to T2DM combined with NAFLD if their HbA1c above target.
45656335|NCT05513729|Drug|Pioglitazone|According to the newest guideline of Diabetes，pioglitazone will be given to 40 patients with T2DM combined with NAFLD if their HbA1c above target.
45656336|NCT05504603|Drug|zanubrutinib and rituximab|zanubrutinib 160mg PO BID d1-28; rituximab 375mg/m2 IVGTT d1,8,15,22. Other name: Part A
45453036|NCT03192176|Drug|Placebo|Oral Capsule
45453037|NCT01642004|Biological|Nivolumab|
45656337|NCT05504603|Drug|zanubrutinib and rituximab|zanubrutinib 160mg PO BID d1-28; rituximab 375mg/m2 IVGTT d1. Other name: Part B
45656338|NCT05504603|Drug|BEAM pretreatment|semustine 250mg/m2 PO d1; etoposide 200mg/m2 IV d2-5; cytarabine 400mg/m2 IV d2-5; melphalan 140mg/m2 IV d6.
45656339|NCT05504603|Drug|zanubrutinib maintenance|zanubrutinib 160mg PO BID.
45807432|NCT04829357|Device|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures being performed within the study are identical to the surgical procedures the subjects would receive as part of SOC.
45943066|NCT00301561|Procedure|Simplified follow-up approach of ARV treatment|"Simplify treatment follow-up :~some clinical consultations will be performed by nurses under the physicians' responsibility ;~the CD4 cell count and HIV-1 viral load will not be available for the management of patients ;~the biologic assessment for tolerability will be limited"
45943067|NCT00301561|Procedure|Standard follow-up approach of ARV treatment|"Standard treatment follow-up :~all clinical consultations will be performed by physicians ;~the CD4 cell count and HIV-1 viral load will be available for the patients management routinely ;~the biologic assessment for tolerability will be available as needed"
45943068|NCT02958072|Other|LeucoPatch|LeucoPatch is an fully autologous growth factor-containing dressing
45453038|NCT01642004|Drug|Docetaxel|
45943069|NCT00301600|Drug|Mycophenolate mofetil|MMF,1.0g/d
45943070|NCT00301639|Drug|OROS methylphenidate hydrochloride|
45943071|NCT00301639|Drug|methylphenidate hydrochloride|
45943072|NCT04730141|Other|Patient mobilization with pre-operative mobilization training and mobilization protocol|Postoperative mobilization for the first 24 hours
45656340|NCT05510609|Device|BK 5000 Ultrasound Machine|Both 2D and 3D ultrasound is being used. 3D using optical tracking.
45656341|NCT05510531|Behavioral|Diabetes Survival Skills Training|During the course of the DSS sessions, participants receive blood glucose logs, glucose meters; lancets, testing strips and demonstration insulin pens with injecting pillow will only be used in class. In summary, the DSS is focused on increasing knowledge, motivation, and self-efficacy and decreasing diabetes related distress, IMB components relevant to incarcerated persons and proximal to behavior change, through engagement, return demonstrations, skill practice, and positive reinforcement.
45656342|NCT05513573|Drug|HLX07|1500 mg, D1，Q3W
45656343|NCT05513573|Drug|HLX10|300 mg, D1, up to 2 years,Q3W
45656344|NCT05513573|Drug|placebo|1500 mg, D1，Q3W
45656345|NCT05513573|Drug|chemotherapy|gemcitabine 1000 mg/m2, D1,D8; cisplatin 80 mg/m2,D1；Q3W, up to 6 cycles
45656346|NCT04863131|Biological|EXG-5003|COVID-19 self-replicating mRNA vaccine
45656347|NCT04863131|Biological|Placebo|placebo solution
45656348|NCT05504447|Other|"Rong-Yang Zhengyifang tea bag"|One tea bag is 4 grams, 3 bags per day, for a total of 7 days
45807433|NCT04829318|Drug|Esketamine|Esketamine will be self-administered as nasal spray.
45943073|NCT00301678|Behavioral|behavioral dietary intervention|
45943074|NCT00301678|Other|educational intervention|
45943075|NCT00301678|Other|preventative dietary intervention|
45943076|NCT00087087|Drug|pemetrexed disodium|
45943077|NCT00301795|Biological|oblimersen sodium|Given IV
45943078|NCT00301795|Biological|rituximab|Given IV
45943079|NCT00301795|Other|laboratory biomarker analysis|Correlative studies
45943080|NCT00080990|Drug|alvocidib|Given IV
45943081|NCT00080990|Drug|fluorouracil|Given IV
45943082|NCT00080990|Drug|oxaliplatin|Given IV
45943083|NCT00080990|Drug|leucovorin calcium|Given IV
45943084|NCT00301912|Biological|filgrastim|
45943085|NCT00301912|Drug|busulfan|
45943086|NCT00301912|Drug|fludarabine phosphate|
45943087|NCT00301912|Drug|methotrexate|
45943088|NCT00301912|Drug|tacrolimus|
45943089|NCT00301912|Procedure|allogeneic bone marrow transplantation|
45943090|NCT00301912|Procedure|allogeneic hematopoietic stem cell transplantation|
45943091|NCT00301912|Procedure|peripheral blood stem cell transplantation|
45943092|NCT00301951|Biological|anti-thymocyte globulin|
45943093|NCT00301951|Biological|sargramostim|
45943094|NCT00301951|Drug|busulfan|
45943095|NCT00301951|Drug|fludarabine phosphate|
45943096|NCT00301951|Drug|mycophenolate mofetil|
45943097|NCT00301951|Drug|tacrolimus|
45943098|NCT00301951|Procedure|umbilical cord blood transplantation|
45943099|NCT00301990|Biological|aldesleukin|
45943100|NCT00301990|Biological|bevacizumab|
45943101|NCT00081029|Procedure|management of therapy complications|
45656349|NCT05504447|Other|placebo tea bag|One tea bag is 4 grams, 3 bags per day, for a total of 7 days
45656350|NCT05504369|Other|Magnetic tape|Tape with magnetic nanoparticles applied to the skin
45656351|NCT05504369|Other|Placebo tape|Tape without nano particles applied to the skin
45807434|NCT04829318|Drug|SSRI/SNRI|Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the summary of product characteristics (SmPC) (or local equivalent, if applicable). During this LTE study, investigators will be allowed to switch individual participant's SSRI/SNRI for tolerability issues.
45943102|NCT00081029|Radiation|radiation therapy|
45943103|NCT00120198|Drug|CDOP plus rituximab|
45943104|NCT00302185|Procedure|Acupuncture|Insertion of sterile, single-use acupuncture needles at 10-20 points including PC.6, HT.7, St.36, SP.6, and LR.3. Needles were connected to an electrical stimulator to mimick traditional manual stimulation with alternating patterns of stimulation for 20 minutes.
45943105|NCT00302185|Behavioral|Nurse-led supportive care|20-30 minutes of supportive attention from an experienced palliative nurse.
45807435|NCT04829175|Device|Intervention|There is no intervention, beyond necessary clinical care, in this registry. The surgical procedures being performed within the registry are identical to the surgical procedures patients would receive as part of SOC.
45943106|NCT00302224|Drug|2S, 4R Ketoconazole (DIO-902)|
45943107|NCT00081068|Biological|alemtuzumab|
45943108|NCT00087165|Biological|GTI-2040|
45943109|NCT00087165|Drug|docetaxel|
45656352|NCT05513495|Other|The effect of drip versus intermittent feeding on splanchnic oxygenation|After preterm delivery the infants were randomly assigned to one of two feeding modalities: drip (3-hour continuous) or intermittent (bolus in 10 minutes).
45943110|NCT00087165|Drug|prednisone|
45656353|NCT05513417|Device|Bloom Pod|Pelvic floor program consisting of exercise performed while using the device, education and behavioural change
45656354|NCT05504213|Drug|HS-10352 combined with fulvestrant (Stage 1)|"Drug: HS-10352 HS-10352 will be administered at escalating doses orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28 day cycle.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days)."
45656355|NCT05504213|Drug|HS-10352 combined with fulvestrant (Stage 2)|"Drug: HS-10352 participants will be enrolled into Cohort 2 (endocrine therapy-resistant) and Cohort 3 (endocrine therapy-sensitive or naïve) respectively and HS-10352 will be administered at the recommended dose identified in Part 1.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days)."
45656356|NCT04424771|Behavioral|Maslach Burnout Inventory (MBI)|The Maslach Burnout Inventory is an introspective psychological inventory consisting of 22 items pertaining to occupational burnout.
45656357|NCT02570165|Drug|Batefenterol|Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister
45656358|NCT02570165|Drug|Umeclidinium/ Vilanterol|Umeclidinium/Vilanterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain umeclidinium blended with lactose and magnesium stearate with a unit dose strength of 62.5 mcg per blister and the second strip will contain vilanterol blended with lactose and magnesium stearate with a unit dose strength of 25 mcg per blister
45807436|NCT04829058|Device|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures that were performed in subjects within this study are identical to the surgical procedures the subjects would have received as part of SOC.
45807437|NCT04828486|Drug|Futibatinib|Given PO
45807438|NCT04828486|Biological|Pembrolizumab|Given IV
45943111|NCT00302263|Drug|Metobes-compound|
45807439|NCT04828486|Other|Quality-of-Life Assessment|Ancillary studies
45943112|NCT00302302|Drug|L-arabinose|
45943113|NCT00302341|Drug|Pafuramidine maleate (DB289)|Oral tablet, 100 mg bid, 14 days
45943114|NCT00302341|Drug|Trimethoprim-Sulfamethoxazole (TMP-SMX)|15 mg/kg, oral tablet split tid X 21 days
45943115|NCT00087204|Drug|becatecarin|Given IV
45943116|NCT00087204|Other|laboratory biomarker analysis|Correlative studies
45943117|NCT00302380|Radiation|PET imaging using C-11 altropane as the ligand.|A one-injection protocol will be used for the study. C-11 Altropane will be injected manually as an intravenous bolus.
45943118|NCT00302419|Drug|intracoronary infusion,|streptokinase, 250,000 units
45943119|NCT00302419|Procedure|primary percutaneous coronary angioplasty|
45943120|NCT00302497|Drug|basiliximab|
45943121|NCT00400140|Device|Hyperopic lens|+3 D glasses
45943122|NCT00081107|Drug|epothilone D|
45943123|NCT02960425|Dietary Supplement|Delivra TM Livsport preworkout cream|High versus low dose topical creatine
45943124|NCT02960425|Dietary Supplement|Placebo|Topical placebo
45943125|NCT04717882|Device|CDSS-OPTIMED|The CDSS-OPTIMED is a software program that provides the physician with a personalized alert on whether to consider stopping or starting medication for a specific patient.
45943126|NCT00302536|Drug|Tacrolimus|Tacrolimus
45943127|NCT00081224|Drug|capecitabine|
45943128|NCT00081224|Drug|celecoxib|
45943129|NCT00081224|Radiation|radiation therapy|
45943130|NCT00081224|Procedure|surgery|
45943131|NCT00120237|Drug|Misoprostol|600 mcg oral misoprostol administered during third stage of labor
45943132|NCT00302575|Behavioral|Collaborative Behavioral Management|
45943133|NCT00302575|Procedure|Integrated parole and outpatient addiction treatment|
45656359|NCT02570165|Drug|Placebo|Placebo will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip) containing lactose
45656360|NCT04661813|Other|EXTRA-CVD Virtual Care|"The original EXTRA-CVD intervention was developed to improve blood pressure and cholesterol control among People Living with HIV. The intervention will be adapted to the post-COVID healthcare delivery landscape as a virtual intervention delivered by phone, teleconference, internet support groups, and nurse care coordination."
45656361|NCT05513339|Device|WHOOP strap 4.0|Subjects will wear the WHOOP strap 4.0 for continuous physiologic monitoring.
45656362|NCT05513183|Procedure|Intraoperative blood and peritoneal fluid samplings during HIPEC|"- Intraoperative samplings of blood and peritoneal fluids during HIPEC :~Blood sampling of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90, 120 min)~Peritoneal fluid sampline of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90 min)"
46075125|NCT05755659|Drug|Fosaprepitant Dimeglumine for Injection|The specification of Fosaprepitant Dimeglumine for injection is 150 mg, and the usage and dosage is: when preventing nausea and vomiting caused by HEC, this product is used in combination with dexamethasone and 5-HT3 antagonist. The dosage of Fosaprepitant Dimeglumine for injection is 150 mg, and the infusion time is 20-30 minutes. The intravenous infusion is completed 30 minutes before the beginning of chemotherapy on the first day.
45656363|NCT05510453|Other|Low-intensity online intervention (LiON)|"The LiON in the current study is comprised of three core modules identified to be core areas of stress and needs of participants based on clinical experiences of the research team. The three modules include (1) stress management, (2) sleep and relaxation, and (3) problem-solving skills.~Each module consists of four 1-on-1 sessions which will be conducted through online platforms (such as Zoom) that lasts for 45 minutes. Participants will attend these sessions once a week.~The control group will receive the intervention after a waiting period of 4 weeks."
45807440|NCT04827615|Behavioral|Ambuja Cement Foundation's Non Communicable Disease Program|"Government level: Strengthening linkages with Govt; Ensuring availability & affordability of NCD diagnostics and treatment; Establishing a follow-up mechanism with patients to ensure continuity of care & medication compliance~Provider level: Capacity building of frontline workers; Promotion of interface between community & service provider~Community level: Screening of hypertension & diabetes for all adults ≥30 years in the village in coordination with Govt under 'population based screening'; Create awareness of modifiable risk factors and lifestyle change among high-risk population; Community mobilization & active participation in various health marker days; Formation of support groups, women's groups, self help groups, with involvement of people living with NCDs~Individual level: Behavior change communication with messages on NCD risk factors; Nutrition awareness on healthy and unhealthy food practices"
45807441|NCT04826341|Drug|Berzosertib|Berzosertib will be supplied as 20 mg/mL M6620 to be diluted with 5% dextrose in water solution before intravenous infusion.
45807442|NCT04826341|Drug|Sacituzumab Govitecan|Sacituzumab Govitecan will be administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles.
45807443|NCT04823663|Device|Implant|In the scope of the CRM procedure and subsequent follow-up, the registry will provide information on the use of the Boston Scientific CRM products/components and combination of those products/components with competitor product(s) per hospital's standard of care.
45656364|NCT05513105|Diagnostic Test|Iron study of neonates|Blood sambles
45656365|NCT05510375|Dietary Supplement|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
45656366|NCT05510375|Dietary Supplement|Multivitamin|Multivitamin
45656367|NCT05510375|Dietary Supplement|Cocoa extract placebo|Cocoa extract placebo
45807444|NCT04823663|Procedure|Electrophysiologic procedure|In the scope of the EP procedure and subsequent follow-up, the registry will provide information on the use of the Boston Scientific Electrophysiology products/components and capital equipment products and combination of those products/components with competitor product(s) per hospital's standard of care.
45807445|NCT04822181|Drug|Semaglutide|Semaglutide administrated subcutaneously (under the skin) once weekly there will be a period of dose escalation before reaching the target dose.
45943134|NCT04717999|Biological|NKG2D CAR-T|The NKG2D CAR-T will be administrated via intracerebroventricular injection through an Ommaya catheter. Standard treatments such as temozolomide will be stopped during the infusion of NKG2D CAR-T.
46075126|NCT02788968|Other|MRI|"Conventional reasoning tasks in both  with and without cognitive conflict and realized during an MRI"
46075127|NCT00913887|Drug|Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)|
46075128|NCT00913887|Drug|Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)|
46075129|NCT00913887|Drug|Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
46075130|NCT00872677|Behavioral|Diet|Talk to study dietitian (eight in person or by phone) weekly for the first 3 months, every other week for the next 3 months and monthly thereafter.
45807446|NCT04822181|Drug|Placebo|Placebo administrated subcutaneously (under the skin) once weekly.
45943135|NCT00120276|Device|Less invasive mitral valve repair|
45943136|NCT00081302|Biological|cetuximab|
45943137|NCT00081302|Drug|carboplatin|
45943138|NCT00081302|Drug|paclitaxel|
45656368|NCT05510375|Dietary Supplement|Multivitamin placebo|Multivitamin placebo
45943139|NCT00081302|Radiation|radiation therapy|
45943140|NCT00302653|Drug|Rasburicase|Rasburicase 0,20mg/Kg/Day once a day 3-7 days
45943141|NCT00418288|Drug|glucagon-like-peptide-1|intravenous infusion of 1.2pmol/kg/min for 7 hours
45943142|NCT00418288|Drug|placebo|intravenous infusion of 1.2pmol/kg/min
45943143|NCT00418327|Drug|Tarceva (Erlotinib Hydrochloride)|tablets of 25 mg, 100 mg and 150 mg 75 to 150 mg/m² Once daily
45656369|NCT05512715|Procedure|radioactive iodine|radioactive iodine 15mci
45656370|NCT05510219|Drug|intravenous rapid infusion of obinutuzumab|This study was a prospective, single-arm, open-label, phase IV clinical trial that included patients with B-cell non-Hodgkin's lymphoma who visited the Department of Hematology, Jiangsu Provincial People's Hospital. All patients were treated with the standard infusion regimen of obinutuzumab in cycle 1, and for patients who did not develop severe infusion-related reactions (IRRs) in cycle 1, a rapid 90-min obinutuzumab infusion regimen was used from cycle 2 onward while recording any occurrence of infusion reactions in different treatment cycles.
45656371|NCT05503745|Other|CBT-F+MIT|The aim is to develop healthier strategies for managing negative thoughts and feelings antecedent to ED and for engaging patients in social interactions that meet their relational basic wishes. They will thus understand that perfectionism and the need for control they experience through ED are coping strategies developed within interpersonal patterns of interaction with significant others, where low self-esteem and emotive dysregulation play a central role. MIT aims to improve individuals' capacity to make sense of their own affect and cognitions and become aware of being driven by maladaptive, rigid and biased schemas about self and others, to form a richer understanding of the mind of the others and use this knowledge to react in more adaptive ways to social difficulties or evolutionary selected wishes. MIT also enables individuals to reflect on how these schemas may act as triggers for ED behavior and to develop more effective coping strategies in face of interpersonal stressors.
45807447|NCT04818060|Other|Clinical Assessments|A neurological evaluation will be administered to all participants at baseline, 1 year and 2 year follow-up visits. Motor exams and premorbid IQ assessments will be video-recorded for rater reliability assessments conducted randomly throughout the research project.
46075131|NCT00872677|Other|Spiritual counseling|Spiritual counselor weekly in months 6-9, every other week in months 9-12 and monthly thereafter.
46075132|NCT02789124|Other|Carotid Doppler Measurement in response to passive leg raise|The investigators will measure Carotid Flow time in the semi-recumbent position, then lay the patient flat and do a passive leg raise. The investigators will then meausre Carotid Flow Time at 1 minute, 2 minutes, and 3 minutes. Patients who have 10 % increase in stroke volume on the Flotrac / Vigileo monitor will be considered fluid responders. The investigators will try to identify an optimum % increase of Carotid Flow Time that can predict fluid responsiveness.
45807448|NCT04818060|Diagnostic Test|MRI Scan|At baseline and 2 year follow-up all participants will undergo a 60-minute 3T MRI scanning session which will consist of measures of the volume of brain tissue and cerebral spinal fluid, as well as connections in the brain measuring water pathways and pictures of the brain active and at rest.
45807449|NCT04818060|Diagnostic Test|Lumber Puncture (LP)|Participants will be asked to complete a LP at both onsite study visits (baseline and 2 year follow-up). Blood collection following the procedure will consist of about 80mL and will be stored at a repository for biomarker analysis.
45807450|NCT04811560|Drug|JNJ-75276617|JNJ-75276617 is administered orally.
45807451|NCT04808427|Device|TULSA-PRO|Transurethral MR-Thermometry Guided Ultrasound Ablation of the Prostate
45807452|NCT04807517|Drug|Buspirone|All participants in the study will receive open-label treatment with orally administered buspirone for the full duration of the 16-week trial. Buspirone has high affinity for serotonin 5-HT1A and 5-HT2 receptors and moderate affinity for dopamine D2 receptors. It is approved for the management of generalized anxiety disorder in adults.
45807453|NCT04806919|Drug|Progesteron TID|increasing the dose
45807454|NCT04806347|Biological|TCRαβ+/CD19+ depleted Hematopoietic stem cell (HSC) graft|After undergoing a disease specific conditioning regimen (standard of care), participants will receive peripheral blood stem cell transplant from a haploidentical donor or closely matched unrelated donor, depleted of TCR αβ+ and CD19+ cells using the CliniMACS TCR α/β-biotin and CD19 Systems.
45943144|NCT00087282|Drug|alvocidib|
45943145|NCT00087282|Drug|irinotecan hydrochloride|
45943146|NCT00418366|Drug|MK0431, sitagliptin phosphate / Duration of Treatment : 1 Days|
46075133|NCT05049369|Device|Polysomnography|Polysomnography is performed one time overnight
46075134|NCT05181865|Drug|1 mg/kg IV FL-301|N = 1
46075135|NCT05181865|Drug|3 mg/kg IV FL-301|N = 3-6
46075136|NCT05181865|Drug|10 mg/kg IV FL-301|N = 3-6
46075137|NCT05181865|Drug|20 mg/kg IV FL-301|N = 3-6
45943147|NCT00418444|Behavioral|Group Therapy Intervention|
46075138|NCT05181865|Drug|30 mg/kg IV FL-301|N = 3-6
46075139|NCT05181865|Drug|RP2D, IV FL-301|Pancreatic Cancer N = 30
46075140|NCT05181865|Drug|RP2D, IV FL-301|Gastric Cancer (Including GEJ) N = 30
46075141|NCT05181865|Drug|RP2D, IV FL-301|Other Solid Tumors N = 30
46075142|NCT05043207|Diagnostic Test|uAud|Patients will receive hearing aid treatment based on an audiometry obtained with an user-operated automated audiometry procedure
45943148|NCT00120315|Drug|esomeprazole|esomeprazole, original Nexium, 40 mg pills Up to once a day
45943149|NCT00120315|Procedure|Helicobacter pylori c-13 breath test|Breath test done at entry to find Helicobacter pylori
45943150|NCT00081380|Drug|Seroquel®, quetiapine fumarate (atypical antipsychotic)|
45943151|NCT00081380|Drug|lithium (mood stabilizer)|
45943152|NCT00081380|Drug|divalproex (mood stabilizer)|
45943153|NCT00418483|Biological|Plasmin (Human) 25 mg|Plasmin (Human) 25 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
45943154|NCT00418483|Biological|Plasmin (Human) 50 mg|Plasmin (Human) 50 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
45943155|NCT00418483|Biological|Plasmin (Human) 75 mg|Plasmin (Human) 75 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
45943156|NCT00418483|Biological|Plasmin (Human) 100 mg|Plasmin (Human) 100 mg
45943157|NCT00418483|Biological|Plasmin (Human) 125 mg|Plasmin (Human) 125 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
45656372|NCT05503745|Other|CBT-E|In the first Stage, the treatment will be focused on achieving a shared understanding of the patient's eating disorder and the related maintenance factors. In this phase the patient will be helped to regulate and stabilize his eating habits and so to address his weight concerns. In the second stage, progress made is reviewed in detail. In the third stage, the sessions will be focused on the central processes that are maintaining the psychopathology of the patient's eating disorder. In particular, this involves in addressing concerns about weight and body shape, cognitive and caloric dietary restriction, events and emotions that affect nutrition. In phase three and four clinical perfection, low global self-esteem, intolerance of emotions and interpersonal difficulties are also addressed. Towards the end of the third stage and during the fourth stage, procedures will be also implemented to minimize the risk of short- and long-term relapse.
45656373|NCT02564471|Drug|Chloroquine|FDA approve dosing schedule
45656374|NCT02564471|Drug|Atovaquone and Proguanil|FDA approve dosing schedule
45656375|NCT02564471|Drug|Doxycycline|FDA approve dosing schedule
45656376|NCT02564471|Biological|Rabies Vaccine|FDA approve dosing schedule
46075143|NCT05043207|Diagnostic Test|Traditional audiometry|Patients will receive hearing aid treatment based on an audiometry obtained with an traditional audiometry procedure
45656377|NCT05503667|Drug|Furmonertinib|Furmonertinib 80 mg/day for 16 weeks
45656378|NCT05503667|Drug|Bevacizumab|bevacizumab 400 mg/4 weeks i.v. for 4 times
45656379|NCT04411979|Other|treatment-as-usual plus aerobic walking|aerobic walking
45807455|NCT04806347|Device|CliniMACS® System|The CliniMACS Cell Selection System is based on magnetic-activated cell sorting mechanism. The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures.
45807456|NCT04805957|Dietary Supplement|Sulforaphane|Sulforaphane comes from eating certain cruciferous vegetables. In this case the pills are made from broccoli seeds.
45807457|NCT04805892|Diagnostic Test|BIOZEK COVID-19 Antigen Rapid Test|The BIOZEK COVID-19 Antigen Rapid Test is used for the detection of SARS-CoV-2 antigens in nasopharyngeal swab specimens from individuals who are suspected of having COVID-19.
45807458|NCT04804579|Behavioral|Fall Prevention Intervention|The intervention will aim to reduce fall risk through weekly virtual group meetings and at-home exercise assignments to address physical and environmental factors that may put participants at a higher risk of experiencing a fall.
45807459|NCT04801758|Other|Analytical Treatment Interruption|"Participants will stop taking their HIV medication and will stay off HIV medication unless and until the HIV levels in their blood show that their immune system is not controlling their HIV or they meet other ART re-start criteria as noted in section Detailed Description."
45807460|NCT04798248|Behavioral|Momentary Affect Regulation - Safer Sex Intervention (MARSSI)|MARSSI is an individual-level intervention that involves a one-hour manualized session with a sexual reproductive health (SRH) counselor, followed by one-month of daily use of a mobile health app and a final 20-minute booster session with the SRH counselor.
45807461|NCT04798248|Behavioral|Podcast Health Group|Participants assigned to the Podcast Health Group will listen to ~20 minute podcast episode put out by the Susan G. Komen Foundation about family history of breast cancer; the podcast does not include information related to the outcomes of interest for the study.
45807462|NCT04797884|Device|TheraBionic Device|Each treatment day consists of three courses of 60-minute treatments to be administered in the morning, at noon, and in the evening. Each 6-week treatment period will be considered a cycle of treatment. With the exception of the first 60-minute treatment, which will be delivered at one of the recruiting site, all other treatments will be self-administered at the patient's home.
45807463|NCT04797884|Device|Placebo Device|Each treatment day consists of three courses of 60-minute treatments to be administered in the morning, at noon, and in the evening. Each 6-week treatment period will be considered a cycle of treatment. With the exception of the first 60-minute treatment, which will be delivered at the recruiting site, all other treatments will be self-administered at the patient's home.
45807464|NCT04797884|Device|Quality of Life Assessment|Ancillary services
45807465|NCT04797780|Drug|Tamibarotene + Azacitidine|"Tamibarotene will be administered at 6 mg twice per day (BID) (orally) each day on Days 8 through 28 of each 28-day treatment cycle (total daily dose of 12 mg).~Azacitidine will be administered at 75 mg/m2 (intravenously or subcutaneously) each day on Days 1 through 7 of each 28-day treatment cycle. If dosing on Days 6 and 7 is not possible due to logistical limitations, these doses may be delayed to Days 8 and 9. Tamibarotene/placebo is permitted to overlap with azacitidine on Days 8 through 9 of this alternative schedule."
45807466|NCT04797780|Drug|Tamibarotene Matched Placebo + Azacitidine|"Tamibarotene matched placebo will be administered at twice per day (BID) (orally) each day on Days 8 through 28 of each 28-day treatment cycle.~Azacitidine will be administered at 75 mg/m2 (intravenously or subcutaneously) each day on Days 1 through 7 of each 28-day treatment cycle. If dosing on Days 6 and 7 is not possible due to logistical limitations, these doses may be delayed to Days 8 and 9. Tamibarotene/placebo is permitted to overlap with azacitidine on Days 8 through 9 of this alternative schedule."
45943158|NCT00418483|Biological|Plasmin (Human) 150 mg|Plasmin (Human) 150 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
45943159|NCT00418483|Biological|Plasmin (Human) 175 mg|Plasmin (Human) 175 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
45943160|NCT00302692|Drug|Esmolol|
45943161|NCT00302692|Drug|Metoprolol|
45943162|NCT00087360|Other|counseling intervention|
45943163|NCT00087360|Other|physiologic testing|
45943164|NCT00087360|Procedure|evaluation of cancer risk factors|
45943165|NCT00302770|Drug|quetiapine|
45943166|NCT00302809|Dietary Supplement|Concord Grape Juice|Approximately 16 oz of grape juice or placebo
45943167|NCT04718077|Other|Intraosseus|IO dexamethasone injection Dexamethasone 4 mg
45458754|NCT02047981|Drug|Azithromycin|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
45656380|NCT05512637|Diagnostic Test|Step 1 - Screening ; Step 2 - Clinical interview|"Step 1: screening is performed by online parental questionnaires (SRS-2, Identidys scale, DCDQ, parental concerns questionnaire ) via a web platform. Parents and registered doctors will be informed by mail in case of negative screening; In case of positive screening, they will be called by phone in order to give them the results and to invite them for a clinical and semi-structured interview.~Step 2: The semi-structured interview will be performed by a psychologist specialized in NDD in order to clinically confirm the results of the screening and refer the child to care and interventions, by mail to the registered doctor. Around 12 months after this interview, parents will be called by phone to collect a description of the referral and their satisfaction about the screening process."
45656381|NCT05512481|Drug|Camrelizumab|"NEOADJUVANT:~All participants will receive neoadjuvant therapy with combination of Camrelizumab、Apatinib and Temozolomide for 2 cycle；~SURGERY: All participants will have melanoma surgery after 2 cycles of treatment~ADJUVANT: Participants will receive Camrelizumab every 3 weeks for 1 year"
45656382|NCT02563067|Drug|QAW039|QAW039 150 mg once daily
45656383|NCT02563067|Drug|QAW039|QAW039 450 mg once daily
45807467|NCT04797585|Other|Laparoscopic supracervical hysterectomy|Laparoscopic supracervical hysterectomy
45807468|NCT04797585|Other|Vaginal hysterectomy|Vaginal hysterectomy
45807469|NCT04796779|Device|Tandem t:slim X2 with Control-IQ Technology Pro|"The Tandem t:slim X2 with Control-IQ Technology Pro is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is very similar to the commercially available t:sli X2 with Control-IQ but modified to accept the lower weight and Total Daily Insulin of the studied population."
45807470|NCT04796779|Device|Standard Care (SC)|Standard of Care consists in the participant existing insulin therapy (prior to enrollment) in conjunction with a study Dexcom G6 CGM. Existing insulin therapies are defined as multiple daily injections of insulin (MDI) or use of an insulin pump without hybrid closed-loop control capabilities (low-glucose suspend or predictive low-glucose suspend functionality is permitted).
45807471|NCT04796779|Device|Tandem t:slim X2 with Control-IQ Technology V1.5|"The Tandem t:slim X2 with Control-IQ Technology V1.5 is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is derived from the commercially available t:slim X2 with Control-IQ, with additional features."
45807472|NCT04793815|Procedure|Cryo-activation|The cryo-activation procedure involves the insertion of a cryoprobe in the tumor bed with subsequent application of very low temperatures leading to cell necrosis and tumor antigens release.
45807473|NCT04793815|Drug|Pembrolizumab|Following the cryo-activation procedure, patients will sequentially be treated with pembrolizumab (anti-PD-1) monotherapy.
45943168|NCT04718077|Other|Submucoal|SM dexamethasone injection Dexamethasone 4 mg
45943169|NCT00302887|Device|combined ultrasound therapy|
45943170|NCT00302887|Procedure|connective tissue manipulation|
45943171|NCT04727268|Other|No intervention|No interventions present in this study.
45943172|NCT00302926|Procedure|energy restriction and maintenance|
45943173|NCT00302965|Drug|Frozen Plasma|
45943174|NCT00081536|Drug|Aroplatin (Liposomal NDDP) in combination with capecitabine|
45943175|NCT00303004|Drug|Bosentan and Sildenafil|
45943176|NCT04727190|Procedure|Transbronchial Cryobiopsy|The eligible patient will be randomized to TBCB group to receive transbronchial cryobiopsy.
45943177|NCT04727190|Procedure|Transbronchial Forceps Biopsy|The eligible patient will be randomized to TBFB group to receive transbronchial forceps biopsy.
45943178|NCT00303043|Procedure|Mixed venous saturation monitoring|Mixed venous saturation monitoring
45943179|NCT00303082|Drug|Lactobacillus rhamnosus GR1 and Lactobacillus reuteri RC-14|
45943180|NCT00081575|Drug|Tigecycline|
45943181|NCT00081575|Drug|Levofloxacin|
45943182|NCT00303160|Drug|vitamin C & E supplements|
45943183|NCT00087399|Drug|gabapentin|
45656384|NCT02563067|Drug|Placebo|Placebo once daily
45656385|NCT02568683|Drug|Entospletinib|ENTO spray dried dispersion tablets administered orally twice daily while in a fasted state
45656386|NCT02568683|Drug|Vincristine|VCR administered intravenously
45656387|NCT05502731|Drug|Filgotinib|Filgotinib is a small molecule that reversibly inhibits Janus kinases (JAK, selectively JAK 1), thereby inhibiting downstream signalling events induced by various pro-inflammatory and regulatory cytokines.
45943184|NCT00087399|Drug|antidepressant|
45943185|NCT00081614|Drug|Avastin (bevacizumab)|
45943186|NCT00081614|Drug|Tarceva (erlotinib HCl)|
45943187|NCT00303199|Drug|ZIO-101 (Darinaparsin)|IV zio-101 (Darinaparsin) give for 5 consecutive days to be repeated every 28 days for up to 6 months
45943188|NCT00303238|Drug|Rose hips extract + blueberry/blackberry extract + resveravine|
45943189|NCT00303238|Drug|Rose hips extract + blueberry/blackberry extract + Aframomum melegueta extract|
46075144|NCT02788890|Procedure|Scaling without LA|The patient will undergo a supragingival scaling procedure without local anesthesia
46075145|NCT02788890|Procedure|Simple restoration under LA|The patient will undergo a simple dental restoration procedure under local anesthesia
45656388|NCT05502731|Drug|Adalimumab|Adalimumab is a monoclonal antibody selectively inhibiting the pro-inflammatory cytokine TNF-alpha.
45656389|NCT04842773|Diagnostic Test|Ultrasound measurement|Ultrasound measurement of sarcopenia in an elderly population
45656390|NCT04633811|Dietary Supplement|Low Oxalate Diet before Weight Loss|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 6 days. 2 x 24 hour urines will be collected on days 3 and 4.
45656391|NCT04633811|Dietary Supplement|Oral load of oxalate and sucralose before Weight Loss|Subjects will ingest 100mg carbon-13 oxalate, and 2 grams of sucralose on day 5 of the 6-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively
45656392|NCT04633811|Dietary Supplement|Optifast VLCD Program|Subjects will go on a 10-week Intestive level Optifast VLCD weight loss program
45656393|NCT04633811|Dietary Supplement|Optifast VLCD Transition Phase|After completion of the 10-week Optifast VLCD Program, subjects will be weaned off the Optifast products for 4 weeks.
45656394|NCT04633811|Dietary Supplement|Low Oxalate Diet after Weight Loss|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 11 days and collect 2 x 24 hour urines on days 8 and 9
45656395|NCT04633811|Dietary Supplement|Oral load of oxalate and sucralose after Weight Loss|Subjects will ingest 100mg carbon-13 oxalate, and 2 grams of sucralose on day 10 of the 11-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively
45656396|NCT05502497|Other|Observational|No application will be made to the control group.
45656397|NCT05502497|Other|IASTM Technique Application|Instrument-assisted soft tissue mobilization will be applied to the legs of the individuals to be treated with ultrasound gel for 2 minutes.
45656398|NCT04287413|Behavioral|Physiotherapist-led primary care model for back pain|"Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination.~Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans."
45656399|NCT04287413|Behavioral|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
45656400|NCT05503277|Device|LTSD|measuring seal pressure
45656401|NCT05503277|Device|i-gel|measuring seal pressure
45807474|NCT04793360|Device|LiverCare|The LiverCare kits contains Streck tubes and PAX gene tubes, which will be collected at the surveillance schedule outlined above, but also prior to any liver biopsy or DSA measurement. For patients who have a histological diagnosis of allograft rejection who are undergoing treatment, serial monitoring of LiverCare will be performed following the schedule above. All research blood tests will be timed with standard clinical testing to avoid any additional needle sticks.
45807475|NCT04789408|Drug|Cyclophosphamide|Administered intravenously
46075146|NCT02788890|Procedure|Simple exodontia under LA|The patient will undergo a simple dental extraction procedure under local anesthesia
46075147|NCT05036499|Behavioral|Personalized Feedback Intervention|Providing corrective normative feedback on alcohol use, psychoeducation on the interplay between pain and alcohol use, and providing exercises to target pain-related anxiety
46075148|NCT00872755|Procedure|Nissen|Laparoscopic Nissen Fundoplication
45656402|NCT05510141|Other|Virtual reality gaming|Instead of nitrous oxide, which is the standard procedure, virtual reality gaming is applied to reach pain reduction in minor surgery procedures
45656403|NCT05510141|Drug|Nitrous oxide|Standard procedure
45807476|NCT04789408|Drug|Fludarabine|Administered intravenously
45807477|NCT04789408|Biological|KITE-222|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
45807478|NCT04788511|Drug|Semaglutide|"Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~Dose gradually escalated from 0.25 mg until target dose. The study will last for approximately 59 weeks."
45943190|NCT00303238|Drug|Rose hips extract + resveravine + Aframomum melegueta extract|
45943191|NCT00303277|Drug|simvastatin|simvastatin 40 mg tablets once per day for 12 weeks
45943192|NCT00303277|Drug|pravastatin|pravastatin 80 mg tablets once per day for 12 weeks
45943193|NCT00303394|Drug|IL-1Ra|
45943194|NCT00303433|Drug|Namenda|
45943195|NCT00081809|Drug|autologous human tumor-derived HSPPC-96|
45943196|NCT00303550|Drug|Intravenous iclaprim|
45943197|NCT00303550|Drug|Intravenous linezolid|
45943198|NCT00120354|Procedure|Blood Testing|
45943199|NCT00120354|Procedure|Percutaneous Liver Biopsy|
46075149|NCT00872755|Procedure|Gastropexy|posterior gastropexy
45656404|NCT05502419|Procedure|Neural slump mobilization|Slump stretching will be performed with the patient in the long sitting position with the patient's feet against the wall to assure the ankle remained in 0 degree dorsiflexion. The therapist will apply over pressure to the cervical spine flexion to the point where the patient's symptoms will be reproduced. The position will be held for 30 s. A total of 5 repetitions will be completed.
45656405|NCT05502419|Procedure|Conventional Physical Therapy|Moist heat with hydro collator pack, Maitland Mobilization for Lumbar spine, Therapeutic exercise: Core stability exercises
45656406|NCT05503199|Device|Combination of one Perclose ProGlide or ProStyle (Abbott Vascular) and one Angio-Seal (Terumo).|Combined suture- and plug-based VCD strategy after TF-TAVI.
45656407|NCT05503199|Device|Combination of two ProGlides or ProStyles (Abbott Vascular).|Pure suture-based VCD strategy after TF-TAVI.
45656408|NCT05503121|Diagnostic Test|3D motion analysis, muscle activation, biomarker analysis|Participants with nonspesific low back pain and control group will be analysed with 3D motion analysis sistem, sEMG and will be checked the biomarkers. Then the data will be compared.
45943200|NCT00120354|Procedure|Lamivudine Therapy|
45943201|NCT00399698|Drug|Risperdal|
45807479|NCT04788511|Drug|Placebo (semaglutide)|"Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~The study will last for approximately 59 weeks."
45656409|NCT04823039|Other|Blood sample taken|For patients with sepsis who require vaccination during hospitalization, we will analyze the immunogenicity of pneumococcal conjugate vaccine (PCV13) by taking blood samples
45656410|NCT05503043|Drug|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
45656411|NCT05503043|Drug|Normal saline|Patients are received equal volumes of saline intravenously until the end of the surgery
45656412|NCT04579211|Diagnostic Test|urine lipoarabinomannan (LAM)|Investigate the utility of urine LAM as a test to identify individuals at very low risk for having a sputum culture positive for NTM.
45656413|NCT02563925|Radiation|Brain radiotherapy or Stereotactic Radiosurgery|
45656414|NCT02563925|Drug|Tremelimumab|
45807480|NCT04781907|Procedure|Tissue Expansion|Tissue expanders are used to increase the soft tissue envelope after mastectomy to provide adequate and healthy coverage of prosthetic breast implants.
45943202|NCT00303589|Drug|Standard care|As prescribed
45656415|NCT02563925|Drug|HER2 directed therapy|
45656416|NCT02563925|Drug|Durvalumab|
45943203|NCT00303589|Drug|beta-lactam|750mg iv q8h
45943204|NCT00303589|Drug|beta-lactam|1500mg iv q8h
46075150|NCT02792400|Drug|LY2403021|Glucagon receptor antagonist
45656417|NCT01663727|Drug|Bevacizumab [Avastin]|Intravenous repeating dose
45656418|NCT01663727|Drug|Paclitaxel|Intravenous repeating dose
45656419|NCT01663727|Drug|Placebo|Intravenous repeating dose
45656420|NCT04607135|Device|Acoustic radiation force impulse (ARFI)|"Sound waves are sent in a series and are expected to push on the prostate and move it a very small amount (the width of a hair). The stiffer the structure (prostate), the less it will move. This motion will be detected by the ultrasound system"
45656421|NCT04607135|Device|Ultrasound|Standard ultrasound imaging session, ultrasound sound waves are sent into the tissue and bounce off of structures to make an image that appears on a screen
45656422|NCT05509985|Biological|ASKG315|Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.
45656423|NCT05509829|Device|Negative pressure wound therapy|Negative pressure wound therapy using PICO14.
45656424|NCT02614261|Drug|Galcanezumab|Administered SC
45656425|NCT02614261|Drug|Placebo|Administered SC
45807481|NCT04781816|Drug|SAR443122|Pharmaceutical form: Capsule Route of administration: Oral
45807482|NCT04781816|Drug|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
45807483|NCT04775082|Drug|Liraglutide|"The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.~The dose will increase each week over 4 or 5 weeks until the final dose is reached."
45807484|NCT04775082|Drug|Placebo|The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.
45807485|NCT04773522|Drug|Talquetamab|Talquetamab will be administered subcutaneously.
45943205|NCT00303706|Procedure|Endoscopic Radial Artery Harvest|
45943206|NCT00081848|Drug|rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM|
45943207|NCT00081848|Drug|rF-CEA(6D)/TRICOM|
45943208|NCT00081848|Drug|Recombinant Fowlpox-GM-CSF|
45943209|NCT00081848|Drug|Celecoxib|
45943210|NCT00120432|Drug|1% tropicamide and 10% phenylephrine|single dose vs three doses of 1%tropicamide and 10%phenylephrine
46075151|NCT02792400|Drug|LY2403021 placebo|
46075152|NCT02792400|Procedure|Standardised liquid meal|
46075153|NCT02792400|Drug|Linagliptin|DPP-4-inhibitor
46075154|NCT02792400|Drug|Linagliptin placebo|
46075155|NCT02792400|Drug|Empagliflozin|SGLT2-inhibitor
46075156|NCT02792400|Drug|Empagliflozin placebo|
45943211|NCT00303745|Drug|capecitabine|
45943212|NCT00303745|Drug|irinotecan hydrochloride|
45943213|NCT00303784|Drug|Goserelin|3.6mg implant, in pre-filled syringe
45943214|NCT00303784|Drug|Estradiol|Each patch contains 3 mg of estradiol hemihydrate in a patch size of 30 cm2, releasing 100 micrograms of estradiol per 24 hours.
45943215|NCT00081887|Drug|Clofarabine|Starting dose is 10 mg/m^2 as a 1-hour infusion into a vein once every 2 weeks for 4 weeks (1 cycle).
45943216|NCT00303940|Drug|carboplatin|
45943217|NCT00303940|Drug|talabostat mesylate|
45943218|NCT00303940|Drug|temozolomide|
45943219|NCT00303940|Other|pharmacological study|
45943220|NCT00304018|Biological|anti-thymocyte globulin|
45943221|NCT00304018|Biological|sargramostim|
45656426|NCT04859023|Diagnostic Test|saliva sample combined to an anterior nare self-swabbing (Self-samples)|Tested by antigenic test.
45656427|NCT04859023|Diagnostic Test|saliva sample (Self-sample)|Tested by RT-PCR.
45656428|NCT04859023|Other|Survey of SARS-COV-19 knowledge|collection of : socio-professional characteristics, questions on health literacy on the transmission of the virus and barrier gestures, adherence to barrier gestures, isolation modalities in case of positivity, motivations for participating in this screening campaign.
45943222|NCT00304018|Drug|busulfan|
45656429|NCT04859023|Other|Survey of acceptability of the different self-samples.|collection of : assessment and acceptability of the tolerance of self-samples.
45656430|NCT03043261|Behavioral|Williams LifeSkills|Online multi-media interactive training modules which address 10 core skills to improve coping, stress management and interpersonal relationships.
45807486|NCT04768920|Behavioral|MI-CBT Teletx|"Participants will first receive a 20-45 min phone or video session focused on raising participants' motivation to engage in treatment activities and psychoeducation material about substance use (i.e. engagement session) including possible discussion about risks of substance use, value of alternative healthier activities, and the community and crisis resources pamphlet. The evidence-based manualized psychosocial programs that will be delivered via telehealth are adaptations of cognitive behavioral therapy, motivational interviewing, and other psychosocial interventions to enhance initial and ongoing treatment engagement. TeleTx consists of up to 8 ~30-50 minute psychosocial sessions delivered via phone or videoconference platform (e.g. Zoom etc)"
45807487|NCT04765384|Biological|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S.
45943223|NCT00304018|Drug|etoposide|
45943224|NCT00304018|Drug|fludarabine phosphate|
45943225|NCT00304018|Drug|prednisone|
45943226|NCT00304018|Drug|tacrolimus|
45656431|NCT03043417|Behavioral|CHC's given the intervention|CHC's NOT given the intervention
45656432|NCT03042325|Drug|Alogliptin|Alogliptin tablets
45656433|NCT03045445|Diagnostic Test|Double Low-Dose protocol CT|Double low-dose protocol CT (Low radiation dose quadriphasic liver CT and low dose of iodine contrast media) at spectral dual energy CT scanner
45656434|NCT03045445|Diagnostic Test|Standard protocol CT|standard protocol CT (standard dose quadriphasic liver CT and standard dose of iodine contrast media) at spectral dual energy CT scanner
45656435|NCT01594411|Diagnostic Test|Corus CAD|Age/Sex/Gene Expression Score (ASGES)
45656436|NCT01594333|Drug|Methotrexate|Tablet, Oral, Target dose 15-20 mg weekly plus 1.0 mg folic acid 6 days/week
45656437|NCT01594333|Drug|Placebo|Tablet, Oral, weekly plus 1.0 mg folic acid 6 days/week
45656438|NCT04860895|Diagnostic Test|AP-23|AP-23 newly developed point of care system as a well-automated combination of multi-spectral technology and a distributed cloud computing A.I. system which has been developed to detect COVID-19.
45656439|NCT04860583|Other|Renal ultrasound|
45656440|NCT03042247|Diagnostic Test|FDG PET/TC and FDG PET/MRI|Combined assessment with FDG PET/TC and PET/MRI
45656441|NCT04338529|Drug|Binosto 70Mg Effervescent Tablet|As discussed in group descriptions
45943227|NCT00304018|Procedure|allogeneic hematopoietic stem cell transplantation|
45943228|NCT00304018|Procedure|umbilical cord blood transplantation|
45943229|NCT00081926|Drug|Gleevec|
45943230|NCT00304135|Drug|cisplatin|
45943231|NCT00304135|Drug|gemcitabine hydrochloride|
45943232|NCT00304135|Drug|oxaliplatin|
45656442|NCT03042403|Other|Breath stacking|During initial rest period, the volunteer remained seated for 10' in spontaneous breathing. Right after, the measurement of arterial pressure, of SpO2 (%), of heart rate, of respiratory frequency and applied to a modified effort perception Borg. During carrying out of the breath stacking technic, the volunteer remained seated, being requested to hold the mask on his/her face not allowing air scape, The volunteer was oriented to inhale normally and exhale all the air during expiration for 20 seconds, and the variables were assessement again the same variables of control. In the final rest period, right after technic end, the volunteers remained seated for 10 minutes in spontaneous breathing and again the same variables of control at the 10th minute were assessed.
45943233|NCT00087477|Drug|Pivanex|
45943234|NCT00304174|Behavioral|Motivation to eat|Participants will use a computer program to earn food (a yogurt shake) by tapping on the keyboard. More taps on the keyboard will result in a larger amount of food earned by the end of the day. Once experimentation is complete on Day 1, participants will be instructed to eat as much as they can. On Days 2 and 3, participants will be given a small serving of the yogurt shake prior to beginning the computer task. Following the computer task, they will be instructed to either eat until they are comfortable (without restricting or binging), or eat as much as they can.
45943235|NCT00081965|Procedure|acupuncture therapy|
45656443|NCT04858633|Drug|Hydroxychloroquine (HCQ)|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total 5 tablets, cumulative dose of 2000 mg )
45943236|NCT00081965|Procedure|hot flashes attenuation|
45943237|NCT00081965|Procedure|management of therapy complications|
45943238|NCT00304213|Drug|Testosterone|
45943239|NCT00304252|Drug|Interferon beta-1a|
45656444|NCT04858633|Other|Standard care|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene
45656445|NCT04858633|Other|Placebo|Tablet placebo one tablet 12 hourly on day one followed by one tablet once weekly for 3 weeks (total 5 tablets)
45656446|NCT04867291|Dietary Supplement|Pizza|Portion equivalent to 200 µg of iodine (half a pizza), consumed with ~450mL of water.
45656447|NCT04867291|Dietary Supplement|Seaweed Sheets|Portion equivalent to 200 µg of iodine (~10g), consumed with two slices of white bread and ~450mL of water.
45656448|NCT04867291|Dietary Supplement|Seaweed Powder|Portion equivalent to 200 µg of iodine (1 capsule), consumed with two slices of white bread and ~450mL of water.
45656449|NCT04867291|Dietary Supplement|Potassium iodide|Portion equivalent to 200 µg of iodine (1.3 tablets), consumed with two slices of white bread and ~450mL of water.
45807488|NCT04763421|Device|ENSEAL X1 Curved Jaw|ENSEAL X1 Curved Jaw is used for vessel transection according to instructions for use.
45807489|NCT04762888|Procedure|Computed Tomography|Undergo PET/CT
45943240|NCT00120471|Drug|Tenofovir disoproxil fumarate|600-mg tablet taken orally once daily
45943241|NCT00120471|Drug|Tenofovir disoproxil fumarate|4-mg/kg oral suspension taken at birth and on Days 3 and 5 after birth
45656450|NCT04867447|Diagnostic Test|Psychological trauma evaluation|"Psychological trauma exposure is assessed by validated scales:~Childhood Trauma Questionnaire (CTQ)~Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)~Cumulative Trauma Scale.~The Holmes and Rahe Stress Scale.~Other clinical scales used:~Positive and Negative Syndrome Scale (PANSS).~Dissociative Experiences Scale (DES)~Mini-Mental State Examination (MMSE)."
45656451|NCT03043495|Procedure|Ultrasound guided supraclavicular brachial plexus block|ultrasound guided Supraclavicular brachial plexus block
45656452|NCT03043495|Drug|Dexamethasone|Various doses of Dexamethasone (2, 4 & 8 mg) to be used as an Adjuvant to Local anesthetic drugs
45656453|NCT03043183|Procedure|perioperational nutrition surpport|Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
45656454|NCT03042949|Device|Blood pressure measurement|Blood pressure measurement with a standard plethysmograph
45656455|NCT03042949|Device|Blood pressure measurement with the new device|Blood pressure measurement with the optical sensor, Elfor -1 device.
45656456|NCT03043027|Drug|liposomal bupivicaine|local anesthetic
45656457|NCT03043027|Drug|Bupivacaine|local anesthetic
45656458|NCT03043027|Drug|Saline Solution|saline injection
45656459|NCT04861207|Drug|Cladribine|The conditioning regimen used will be cladribine-based at a dose of 5 mg / m2 for 5 days (iv.) and total body irradiation at a total dose of 12 Gy in three fractions.
45656460|NCT04858165|Procedure|MY GERYFS PROTOCOL|The MY GERYFS will be introduced through a guideline document, dissemination through the department of nursing, notices on the intranet and provision of large signs indicating that MY GERYFS are in progress and the times of meals for each ward. The developed protocol in phase 1 and 2 will be tested in single-centre in a before and after study for its feasibility and safety. In the pre-study, patients will be given usual care. In the post-study, patients will care according to the developed protocol. Clinical outcomes such as malnutrition risk, medical background, anthropometry data, nutrition-focused physical findings, dietary intake, mealtime barrier, Hospital Foodservices satisfaction will be recorded.
45807490|NCT04762888|Drug|Gallium Ga 68 Gozetotide|Given IV
45807491|NCT04762888|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
45943242|NCT00120471|Drug|Tenofovir disoproxil fumarate|6-mg/kg oral suspension taken at birth and daily for 7 days after birth
45458755|NCT02047981|Drug|Placebo|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
45656461|NCT04858321|Procedure|Passive heating|8-12 x1 h water immersion (to the clavicle, @40 °C, rectal temperature ~38.5 °C and <39 °C) sessions over a period of 14 days.
45656462|NCT04858087|Other|Screening and treatment|Students were screened by mRDTs and treated with artemether-lumefantrine if positive
45656463|NCT04867057|Drug|Trichomylin for SAD|Healthy subject meeting eligibility criteria will be randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.
45807492|NCT04762888|Procedure|Positron Emission Tomography|PET/MRI or PET/CT
45807493|NCT04762134|Drug|Doxycycline Hyclate|STI PrEP arm: doxycycline capsules 100mg orally daily for 12 months STI PEP arm: doxycycline 200mg orally once within 24-72 hours following each sexual encounter deemed at risk (i.e. condomless anal or oral sex), to a maximum of six pills (i.e. 600 mg total) per week
45807494|NCT04759586|Drug|Cyclophosphamide|Given IV
45807495|NCT04759586|Drug|Doxorubicin Hydrochloride|Given IV
45807496|NCT04759586|Drug|Etoposide Phosphate|Given IV
45807497|NCT04759586|Procedure|FDG-Positron Emission Tomography and Computed Tomography Scan|Undergo FDG-PET/CT
45807498|NCT04759586|Biological|Filgrastim|Given SC
45807499|NCT04759586|Biological|Nivolumab|Given IV
45943243|NCT00082043|Drug|Dutasteride|
45943244|NCT00082043|Drug|Placebo oral capsule|
45943245|NCT00304291|Drug|Mitoxantrone|
45656464|NCT04867057|Drug|Placebo for SAD|Healthy subject meeting eligibility criteria will be randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.
45656465|NCT04867057|Drug|Trichomylin for MAD|Healthy subject meeting eligibility criteria will be randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally for total of 9 days of dosing.
45656466|NCT04867057|Drug|Placebo for MAD|Healthy subject meeting eligibility criteria will be randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally for total of 9 days of dosing.
45656467|NCT03041935|Procedure|Ilioinguinal/iliohypogastric nerve block|See arm description
45656468|NCT03041935|Procedure|Caudal-epidural nerve block|See arm description
45943246|NCT00304369|Drug|Metronidazole|
45656469|NCT03041935|Drug|Acetaminophen|See arm description
45943247|NCT02965092|Genetic|Second generation CAR-T cells|
45656470|NCT03041935|Drug|Sevoflurane|See arm description
45943248|NCT00082082|Drug|Thymalfasin (thymosin alpha-1)|
45807500|NCT04759586|Biological|Pegfilgrastim|Given SC
45656471|NCT03041935|Drug|Remifentanil|See arm description
45656472|NCT03041935|Drug|Propofol|See arm description
45656473|NCT03041935|Drug|Morphine|See arm description
45807501|NCT04759586|Drug|Prednisolone|Given PO
45943249|NCT00082082|Procedure|Trans arterial chemoembolization (TACE)|
45943250|NCT04717960|Procedure|nasal submucosal injection of platelet rich plasma|"The selected region will be inﬁltrated with a cold saline solution with addition of 1 mL of adrenaline and 25 mL of 2% lignocaine per 500 mL saline.~Platelet-rich plasma is prepared by drawing 10 mL of blood sample from the patient.~The blood will be centrifuged at 1530 g for 10 min to obtain platelet-poor plasma.~This will again centrifuged at 2720 g for 10 min to get platelet-rich plasma.~Approximately 1 mL of platelet-rich plasma will be obtained from 10 mL blood. Usually amount of about 3ml is needed to be injected in each nostril at the affected sites of inferior and middle turbinates, septum and floor of the nose. Platelet rich plasma injected into the affected area after degranulating the platelet by adding 0.5 mL of calcium chloride.~Injection interval of 2 weeks (up to total 3 consecutive injections).~Follow-up duration: 4 months"
45943251|NCT00304447|Drug|Mylotarg|
45943252|NCT00082121|Drug|TP10|
45943253|NCT00087711|Drug|pemetrexed|500 mg/m2, IV q 21 days x 6 cycles
45943254|NCT00087711|Drug|gemcitabine|1250 mg/m2, IV, day 1 and 8 q 21 days x 6 cycles
45943255|NCT00087711|Drug|cisplatin|75 mg/m2, IV, q 21 days x 6 cycles
45943256|NCT00304564|Behavioral|Music Listening|subjects listen to music
45943257|NCT00304603|Other|No intervention|No treatment was given to the patients as this is an observational study.
45943258|NCT00304642|Drug|dapivirine (TMC120) vaginal gel|
45943259|NCT00082160|Behavioral|Meditation|
45943260|NCT00082160|Procedure|Functional Magnetic Resonance Imaging|
45656474|NCT03041935|Drug|Ondansetron|See arm description
45656475|NCT03041935|Drug|Dexamethasone|See arm description
45656476|NCT03041935|Drug|Ketorolac|See arm description
45656477|NCT03041935|Drug|Ropivacaine|See arm description
45656478|NCT03042013|Drug|ASP8273|Oral
45807502|NCT04759586|Drug|Prednisone|Given PO
45807503|NCT04759586|Radiation|Radiation Therapy|Undergo radiation therapy
45807504|NCT04759586|Biological|Rituximab|Given IV
45807505|NCT04759586|Biological|Rituximab and Hyaluronidase Human|Given SC
45807506|NCT04759586|Drug|Vincristine Sulfate|Given IV
45807507|NCT04758195|Procedure|Transanal irrigation|Transanal irrigation (TAI) is performed using the irrigation bag, electronic irrigation system, or balloon catheter with syringe. TAI is performed with up to 2000 ml tap water every 24-48 hours (3-7 times per week) over the course of 6 months.
45943261|NCT00304681|Drug|OROS*-Methylphenidate|
45943262|NCT00304720|Drug|Tacrolimus and MMF|
45943263|NCT00082199|Drug|Aripiprazole|Tablets, Oral, 2-30mg, Once daily, 12 weeks.
45943264|NCT00082199|Drug|Placebo|Tablets, Oral, Once daily, 12 weeks.
45943265|NCT00120510|Drug|Efavirenz|Non-nucleoside reverse transcriptase inhibitor dosed at 600mg taken by mouth every 24 hours at bedtime
45943266|NCT00120510|Drug|Lamivudine/Zidovudine|Nucleoside reverse transcriptase inhibitor dosed at 150mg/300mg fixed dose combination taken by mouth every 12 hours
45943267|NCT00304759|Procedure|7800 cGy/39 fractions in 8 weeks|see above
45943268|NCT00304759|Procedure|6000 cGy/20 fractions in 4 weeks|see above
45943269|NCT00304798|Behavioral|Hospital admission|
45943270|NCT02960269|Other|interprofessional back pain assessment|team assessment and education with urban physical therapist and rural nurse practitioner via telehealth
45943271|NCT00087750|Drug|Quetiapine|
45943272|NCT00082238|Other|Stable isotopes|Stable isotopes were used to quantify gluconeogenesis GNG, hepatic glucose production (HGP), and protein breakdown.
45943273|NCT00304837|Genetic|pVGI.1 (VEGF-2)|
45943274|NCT00304993|Drug|fenofibrate|
45656479|NCT04857853|Other|Exercise Without Rest Break|"Participants in the exercise group will receive 'Exercise Breaks', of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.~Exercises include shoulder shrugs, neck tilts, wrist and forearm stretch, back and hip stretch, upper body stretch, hamstring stretch, upper back stretch, hand/finger stretch. Side stretch and neck stretch.~Follow up 3 times a week for 5 weeks."
45943275|NCT00304993|Drug|niacin|
45943276|NCT00304993|Drug|rosiglitazone|
45943277|NCT00120549|Procedure|Assisted embryo hatching|
45943278|NCT00082277|Drug|Anastrozole|1mg/Day Oral
45807508|NCT04758195|Other|Best supportive therapy|Best supportive therapy consists of dietary modification, pelvic floor muscle training, biofeedback, and necessary medication.
45807509|NCT04752358|Genetic|Autologous genetically modified ADP-A2M4CD8 cells|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1
45807510|NCT04743934|Drug|Flibanserin 100 MG|Flibanserin 100mg tablets taken by mouth daily at bedtime
45807511|NCT04743934|Drug|Placebo|Visually identical placebo tablets taken by mouth daily at bedine
46075157|NCT04030221|Other|fluid infusion|250 ml of liquid will be given within 10 minutes for each patients, and the hemodynamic parameters before and after fluid infusion will be recorded. Then the experiment is completed.
45807512|NCT04743934|Drug|Androgen deprivation therapy|Androgen deprivation therapy consisting of a GnRH agonist or antagonist, choice of agent at discretion of treating physician.
46075158|NCT04040023|Drug|Iron and vitamin Deficiencies Correction Program|"Preoperative:~For patient with iron deficiency: Intravenous iron supplementation For patient with folic acid or vitamin B12 deficiency : oral vitamin supplementation For patient with anemia: pre operative erythropoietin injections~Postoperative:~Systematic iron supplementation"
46075159|NCT04040023|Other|PBMi: Training program to improve transfusion practices|Training program to sensitize health care staff to streamline the use of transfusion targeting the following points: limit perioperative and post operative hemodilution; to adapt the transfusion threshold to the tolerance of the patient to anemia in per and postoperative; justify the use of RBC transfusion by setting up a questionnaire; encourage transfusion of RBC unit by unit.
46075160|NCT05755581|Drug|Hormonal Antineoplastics|the Neoadjuvant endocrine therapy group will receive neoadjuvant hormonal therapy.
45807513|NCT04739813|Biological|obinutuzumab|administered intravenously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
45807514|NCT04739813|Drug|prednisone|administered orally, days 1-7, at a dose of 100 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
45807515|NCT04739813|Drug|Revlimid|administered orally, days 1 and 14, at a dose of 15 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
45807516|NCT04739813|Biological|Polatuzumab|administered intravenously, on day 2, at varying doses of 1.4-1.8 mg/kg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
45807517|NCT04739813|Drug|ibrutinib|administered orally, days 1-14, at a dose of 560 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
45943279|NCT00082277|Drug|Risedronate Sodium|35mg/week, oral
45943280|NCT00305032|Procedure|gastric balloon insertion|patient would be offered endoscopic gastric balloon insertion
45807518|NCT04739813|Drug|venetoclax|administered orally, days 2-14, at a dose of 800 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
45807519|NCT04737720|Drug|Recombinant LCAT|iv infusion
45807520|NCT04736329|Drug|Telmisartan|Telmisartan (20 up to 80mg) for RAAS inhibition, as part of heart failure therapy.
45943281|NCT00305071|Drug|compound cranberry extract tablet|
45943282|NCT00305149|Procedure|interim therapy scintigraphy study gallium scan or PET/CT|
45943283|NCT00305149|Procedure|"interim gallium or PET/CT"|
45943284|NCT00120588|Drug|magnesium|
45943285|NCT00305266|Drug|intravenous gammaglobulin|individual dose
45943286|NCT00082316|Drug|Capsaicin Dermal Patch|
45943287|NCT00305383|Drug|Viramidine|
45943288|NCT00305383|Drug|Peginterferon alfa-2b|
45943289|NCT00305422|Drug|Quetiapine fumarate|
45943290|NCT00305422|Drug|Risperidone|
45943291|NCT00305461|Drug|Ciclesonide|Effect of Ciclesonide on Quality of Life
45943292|NCT00082394|Drug|Trizivir|
45943293|NCT00082394|Drug|atazanavir|
45943294|NCT00082394|Drug|Combivir|
45943295|NCT00305500|Drug|escitalopram|
45943296|NCT00087828|Drug|Cranberry juice cocktail|
45943297|NCT00305539|Drug|adalimumab|40 mg sc / for 3 months
45943298|NCT00305539|Drug|placebo|placebo
45943299|NCT00305617|Other|antitumor drug screening assay|
45943300|NCT00305734|Drug|bortezomib|Given IV
45943301|NCT00305734|Drug|gemcitabine hydrochloride|Given IV
45943302|NCT00305734|Other|laboratory biomarker analysis|Correlative studies
45943303|NCT00082472|Drug|Doxorubicin HCl Inhalation Solution|
45943304|NCT00082472|Drug|Docetaxel|
45943305|NCT00082472|Drug|Cisplatin|
45943306|NCT00087867|Drug|SCIO-469|two 30-mg capsules three times daily
45943307|NCT00087867|Drug|SCIO-469 and bortezomib|In addition to SCIO-469, patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1, 4, 8, and 11 of a 21-day cycle, followed by a 10-day rest period
45943308|NCT00305812|Drug|dexamethasone|
45943309|NCT00305812|Drug|lenalidomide|
45943310|NCT00305812|Drug|melphalan|
46075161|NCT05755581|Drug|Chemotherapy drug|the Neoadjuvant chemotherapy group will receive neoadjuvant chemotherapy.
46075162|NCT00868075|Procedure|Chest physiotherapy|Twice daily for 8 weeks
46075163|NCT00868075|Procedure|Chest Physiotherapy + Exercise Program|Twice daily chest physiotherapy and Three times weekly exercise program (two sessions supervised)for 8 weeks
46075164|NCT02792010|Device|Hip cartilage MRI|Hip cartilage MRI
46075165|NCT05017155|Drug|Mexiletine|Mexiletine is a sodium channel blocker shown to be effective in reducing myotonia in a multi-centre randomised trial.
45656480|NCT04857853|Other|Exercise With Rest Break|"Participants in the exercise with rest break group will receive 'Exercise Breaks', of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.~Participants will also receive 'Supplemental Micro Breaks', of 30 seconds after every 15 minutes of working on a static computer workstation Follow up 3 times a week for 5 weeks."
45656481|NCT04857853|Other|Rest Break|"Participants in the rest breaks group will receive 'Supplemental Micro Breaks', of 30 seconds after every 15 minutes of working on a static computer workstation in addition to the two 'Conventional Rest Breaks' of 15 minutes twice a day during the work hours.~Follow up 3 times a week for 5 weeks. During the rest breaks, participants will not perform any exercises."
45807521|NCT04735068|Drug|Binimetinib Pill|Patients will be treated with B 45 mg two times daily and HCQ 400 mg twice daily beginning on day 1. The dose of HCQ is based on an ongoing Phase 1 trial, and may be modified in a future amendment prior to the first patient enrolled. Efforts will be made to ensure dose homogeneity throughout the trial. Treatment will be administered on an outpatient basis on a 28 day cycle
45656482|NCT03042793|Biological|PD-L1 peptide vaccine|PD-L1 peptide given subcutaneously with Montanide ISA-51
45656483|NCT03042871|Drug|0.5mg intravitreal ranibizumab|Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerland) via a pars plana transcleral injection through 30-gauge needle at 3.5 to 4mm of inferotemporal limbus. Levofloxacin eye drops ( Cravit Eye Drops, Santen, Japan) was instilled 4 times a day in the study eye before the treatment at least 1 day. Povidone-iodine (5%, Luofushan Pharmaceutical Co., China) was applied to the conjunctiva bulbi and the fornices for at least 3 minutes before injection. Patients were instructed to continue the levofloxacin eye drops 4 times a day for 3 days
45807522|NCT04735068|Drug|Hydroxychloroquine Pill|Patients will be treated with B 45 mg two times daily and HCQ 400 mg twice daily beginning on day 1. The dose of HCQ is based on an ongoing Phase 1 trial, and may be modified in a future amendment prior to the first patient enrolled. Efforts will be made to ensure dose homogeneity throughout the trial. Treatment will be administered on an outpatient basis on a 28 day cycle
45943311|NCT00305890|Behavioral|Lifestyle Behavioral Weight Management Program|The lifestyle behavioral weight management program will focus on lifestyle, exercise, attitudes, relationships, and nutrition. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.
45943312|NCT00305890|Behavioral|Pain-Coping Skills Training|The pain-coping skills training will focus on minimizing maladaptive over-reactions and enhancing adaptive strategies to control and decrease pain. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.
45943313|NCT00305890|Other|Standard Care|Standard care will include routine medical care.
45943314|NCT00082511|Drug|Prasterone (GL701)|"There were 4 arms to the study:~During a previous 6 month db RCT, patients received either prasterone 200 mg/day or placebo. Upon entry into this open-label study, they were re-assigned by randomized allocation to receive either prasterone 200 mg/day or 100 mg/day. Hence, there were 4 possible treatment arms extending over the 18 months of observation between the double-blind study and the subsequent 12 month open-label extension study."
45943315|NCT00305929|Drug|Treatment with Tookad VTP|
45943316|NCT00305929|Drug|Treatment with Tookad VTP|Tookad 2 mg/kg
45943317|NCT00305929|Drug|Treatment with Tookad VTP|2 mg/kg
45656484|NCT03042637|Drug|Acthar Gel and Tacrolimus|Combination therapy with Acthar Gel and Tacrolimus (0.5-3.0 mg BID) following 6 months of ACTH therapy only
45656485|NCT03045133|Drug|Methadone|Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
45943318|NCT00305968|Behavioral|patient education|Patient education group
45943319|NCT00306046|Drug|Bisphosphonate treatment|
45453039|NCT03975530|Behavioral|Precision Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive a customized version of Family Spirit that is unique to your circumstances. The two sites randomized to provide the Precision approach will receive additional training on how to provide it.
45656486|NCT03045133|Drug|Morphine|Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
45807523|NCT04734106|Drug|Desert Harvest Aloe Vera Capsules|600 mg pure, freeze-dried aloe vera super-concentrate with a minimum of 200 mg glycosaminoglycan per capsule.
45807524|NCT04734106|Other|Placebo Capsules|550mg of Avicel microcrystalline cellulose per two-piece, hard-shelled gelatin capsule.
45807525|NCT04730544|Drug|Nivolumab 480mg + Ipilimumab|Nivolumab 480 mg q4w + Ipilimumab 1 mg/kg q6w
45807526|NCT04730544|Drug|Nivolumab 240 mg + Ipilimumab|induction phase : Nivolumab 240 mg q3w + Ipilimumab 1 mg/kg q3w and then maintenance : Nivolumab 480 mg q4w
45807527|NCT04730271|Device|Total Knee Replacement|Subjects will be implanted with an ATTUNE Primary total knee replacement.
45807528|NCT04729959|Biological|Atezolizumab|Given IV
45943320|NCT00306085|Genetic|Autologous bone marrow cells|
45943321|NCT00306124|Drug|Levodopa|
45807529|NCT04729959|Procedure|Biospecimen Collection|Undergo blood sample and tumor tissue collection
45807530|NCT04729959|Procedure|Conventional Surgery|Undergo surgery
45807531|NCT04729959|Radiation|Fractionated Stereotactic Radiation Therapy|Undergo FSRT
45943322|NCT00306241|Biological|HPV-16/18 L1 VLP AS04|
45943323|NCT00306280|Device|Phototherapy|
45943324|NCT00082589|Drug|Eplerenone|
45943325|NCT00313924|Drug|DETRUSITOL|
45943326|NCT00306436|Procedure|comprehensive management|
45943327|NCT00306475|Drug|divalproex sodium ER|divalproex sodium ER1000 mg
45943328|NCT00306475|Drug|placebo|placebo identical in appearance to active comparator
45943329|NCT00306514|Biological|CYT004-MelQbG10|
45943330|NCT00306553|Biological|CYT004-MelQbG10|
45943331|NCT00306631|Drug|MKC-1|Oral capsules, 30 mg and 100 mg capsule strengths; administered twice daily for 14 days in a 28 day cycle
45943332|NCT00082667|Drug|gefitinib|
45943333|NCT00082667|Procedure|Surgery|
45656487|NCT04866745|Device|Magnetotherapy plus exercise|The VARIMAG-4E magnetotherapy device will be used. It is a pulsed radiofrequency energy device. The device has a voltage of 220V, 4 amps of intensity, 50 Hz of frequency and a maximum power of 100 Gauss. For the active treatment application, the patient will be in supine position and will introduce both knees in the 50 cm coil in case of bilateral knee osteoarthritis. In the case of unilateral knee osteoarthritis, the affected knee will be introduced in the 30cm coil. The duration of the treatment will be 20 minutes, the frequency administered will be 50 Hz and a power of 100 Gauss.
45656488|NCT04866745|Device|Microwave plus exercise|The application of deep heating therapy will be with the patient in a sitting position. The VARITRON 250-EP microwave device will be used with a frequency of 2450 MHz and a maximum output power of 250W. In the case of unilateral knee osteoarthritis, the circular applicator with a diameter of 170mm will be placed approximately 15 cm from the knee. The duration of the session will be 20 minutes, 10 minutes over the internal face and 10 minutes over the external face of the knee. In the case of bilateral knee osteoarthritis, the large lumbar applicator will be placed approximately 15 cm from the anterosuperior face of both knees for 20 minutes. The patient will have to perceive a moderate heat sensation.
45656489|NCT04866745|Device|Sham Magnetotherapy plus exercise|The protocol and device will be the same in the active/placebo treatment. The sham device does not emit an electromagnetic field. The energy from the active device is not felt by the user, and the active device cannot be distinguished in any way from the placebo device.
45807532|NCT04729959|Procedure|Magnetic Resonance Imaging|Undergo MRI
45943334|NCT00306709|Behavioral|culturally adapted behavior change|Behavior change strategies which have been modified to include spirituality, AA cultural materials and examples woven into the lesson plans, and sustained peer support.
45807533|NCT04729959|Biological|Tocilizumab|Given IV
45807534|NCT04728893|Drug|Nemtabrutinib|Nemtabrutinib tablets administered PO QD.
45807535|NCT04721548|Drug|Minoxidil Topical Foam|Apply 1 mL of solution twice a day.
45807536|NCT04721548|Drug|Placebo|1 mL of solution twice a day.
45807537|NCT04720157|Drug|177Lu-PSMA-617|administered intravenously once very 6 weeks (1 cycle) for 6 cycles
45807538|NCT04720157|Drug|68Ga-PSMA-11|Single intravenous dose of approx. 150 Megabecquerel (MBq)
45807539|NCT04720157|Drug|ARDT|Administered orally on a continuous basis as per package insert and guideline
45807540|NCT04720157|Drug|ADT|ADT are administered as per physician order
45807541|NCT04718493|Procedure|Self-expandable metal stent|Endoscopic stenting of intestinal stricture related to Crohn´s disease
45807542|NCT04718493|Procedure|Balloon dilatation|Endoscopic balloon dilatation of intestinal stricture related to Crohn´s disease
45807543|NCT04717414|Drug|ACE-536|Subcutaneous Injection
45807544|NCT04717414|Other|Placebo|Subcutaneous Injection
45807545|NCT04717089|Other|overnight intensive recovery / extended post anaesthetic care in PACU|From January 2020, during COVID-19 first pandemics in Hong Kong, a bundle of interim measures was implemented with the joint efforts of the Department of Anaesthesia and Operating Theatre Services (A&OT) and Intensive Care Unit (ICU), and two ordinary recovery beds were converted into extended post anesthetic care in PACU (ExRR), based on the concept of overnight intensive recovery (OIR) to provide level 2 intensive care to patients undergoing major or ultra-major operations or having multiple comorbidities warranted intensive care in the immediately postoperative periods. This was conducted over 3 pandemic waves in Hong Kong.
45943335|NCT00306748|Drug|MD-1100 Acetate|
45943336|NCT00082784|Drug|Bortezomib|Given IV
46075166|NCT05017155|Drug|Lamotrigine 25Mg Oral Tablet, Extended Release|Lamotrigine is an alternative sodium channel blocker that has been shown to be effective in one randomised controlled trial. It is currently used as a licensed medication for other neurological conditions.
46075167|NCT05162131|Drug|Bentracimab (PB2452) 100 mg or Placebo|"Experiment 1-a: 100 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)~Drug: PB2452 infusion 30 minute - 12-hour infusion"
46075168|NCT05162131|Drug|Bentracimab (PB2452) 300 mg or Placebo|"Experiment 1-b: 300 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)~Drug: PB2452 infusion 30 minute - 12-hour infusion"
46075169|NCT05162131|Drug|Bentracimab (PB2452) 1000 mg or Placebo|"Experiment 1-c: 1000 mg Bentracimab (PB2452) or Placebo (no Ticagrelor)~Drug: PB2452 Infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion"
45807546|NCT04713475|Biological|PBGM01|AAVhu68 viral vector
45807547|NCT04712799|Drug|Otrivin|oxymetazoline nasal spray
45807548|NCT04712734|Drug|Iloperidone|oral tablet, long-acting injection
46075170|NCT05162131|Drug|Bentracimab (PB2452) 1000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 2: 1000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
46075171|NCT05162131|Drug|Bentracimab (PB2452) 3000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 3: 3000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
45943337|NCT00082784|Drug|Alvocidib Hydrochloride|Given IV
45943338|NCT00082784|Other|Pharmacological Study|Correlative studies
45943339|NCT00306826|Drug|pioglitazone|
45943340|NCT00306826|Drug|simvastatin|
45943341|NCT00306826|Drug|pioglitazone + simvastatin|
45943342|NCT00306904|Drug|bevasiranib|
45943343|NCT00082823|Biological|ziv-aflibercept|
46075172|NCT05162131|Drug|Bentracimab (PB2452) 9000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 4: 9000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
45656490|NCT04860115|Procedure|Modified pectoralis block (PEC II) and pecto-intercostal fascial plane block (PIFB)|"PECS II: Ultrasound guided block involving injection of 20 ml of 0.25% L-bupivacaine with dexmetomidine into an interfascial plane between the serratus anterior muscle and the external intercostal muscles followed by the needle withdrawal into an interfascial plane between the pectoralis major and pectoralis minor muscle where further 10ml will be administered.~PIFB: Ultrasound guided block involving injection of 10 ml of 0.25% L-bupivacaine with dexmetomidine into an iterfascial plane between the pectoralis major and the intercostal muscles approximately 2 cm laterally from the sternum to cover T2 to T6 dermatomes."
45656491|NCT02609659|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
45807549|NCT04712474|Behavioral|In-home decluttering practice|"The in-home decluttering intervention comprises 10, 1.5-hour home-visits over the course of 10 weeks.~These home visits are personalized, goal-oriented and focused on decluttering. They include 1) a brief check-in, 2) guided unclutter time 3) a reflective period during which participants share their thoughts and objectives for the coming week, and 4) homework assignments."
45943344|NCT00306943|Biological|Influsplit SSW®|
45656492|NCT02609659|Drug|ribavirin|Tablet
45656493|NCT04856995|Other|exposure to surgical smoke during surgery|No intervention was made. During the surgery, complaints and throat cultures were taken before and after exposure to surgical smoke. Simultaneously, 45 air samples are taken in the operating room before, during and after the operation.
45656494|NCT04859881|Other|No intervention|No intervention
45656495|NCT04429711|Drug|Ivermectin Oral Product|3mg Capsules, 12-15mg/ day for 3 days
45656496|NCT04429633|Drug|Candesartan|If GLS decreased less than 18% or LVEF decreased to 45-50% during the treatment of adjuvant trastuzumab, start candesartan medication.
45656497|NCT04856839|Diagnostic Test|high throughput sequencing and electromyography|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
45656498|NCT03042091|Drug|Polyethylene Glycol|Given orally
45656499|NCT03042091|Drug|Neomycin|Given orally
45656500|NCT03042091|Drug|Metronidazole Hydrochloride|Given orally
45656501|NCT03042091|Procedure|Therapeutic Conventional Surgery|Undergo colorectal resection
45656502|NCT04859569|Drug|LY01011|subcutaneously (SC) once every 4 weeks (Q4W)
45656503|NCT04859569|Drug|Xgeva®|subcutaneously (SC) once every 4 weeks (Q4W)
45943345|NCT00087945|Drug|Abacavir sulfate|
45943346|NCT00087945|Drug|Abacavir sulfate, lamivudine, and zidovudine|
45943347|NCT00082862|Biological|recombinant interferon alfa|
45943348|NCT00082862|Drug|cisplatin|
45943349|NCT00082862|Drug|gemcitabine hydrochloride|
45943350|NCT00082862|Procedure|hyperthermia treatment|
45943351|NCT00306982|Biological|Fluarix|
45943352|NCT00307021|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|3-dose intramuscular injection, 2 different formulations
45943353|NCT00307099|Drug|Meropenem|Meropenem 1 gram intravenously every 8 hours for 3 days (9 doses), then an additional 5 days if the Clinical Pulmonary Infection Score is greater than 6.
45943354|NCT00307099|Drug|Standard antibiotic therapy|Standard intravenous antibiotic therapy for a minimum of 8 days.
45943355|NCT00082940|Biological|denileukin diftitox|
45943356|NCT00307138|Drug|hetastarch|
45943357|NCT00307177|Biological|Trivalent inactivated influenza vaccine|Standard Trivalent inactivated influenza vaccine, licensed. Arm A receives standard dose of 15 mcg IM on day 0.
45656504|NCT04859959|Diagnostic Test|Gallium-68 Pentixafor PET/CT|Intravenous injection of one dosage of 74-222 MBq (2-6 mCi) Gallium-68 Pentixafor. Tracer doses of Gallium-68 Pentixafor will be used to image adrenal lesions by PET/CT.
45656505|NCT04856605|Procedure|surgery|regular surgery
45656506|NCT04856371|Drug|CYH33|Participants will receive oral CYH33 once daily on Days 1-28 of each 28-day cycle.
45656507|NCT04856371|Drug|Fulvestrant|Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1, 15 on Cycle 1 (28-day cycle) and Day 1 at each 28-day cycle thereafter.
45656508|NCT04856371|Drug|Letrozole|Participants will receive oral letrozole once daily continuous on Day 1-28 of each cycle.
45656509|NCT04856371|Drug|Palbociclib|Participants will receive palbociclib once daily continuous on Day 1-21 of each 28-day cycle.
45656510|NCT04866277|Other|Fast-track referral for reference services|Activation of fast-track referral for specialized units and care programs for the four psychosocial and behavioural risk factors under study.
45656511|NCT03041779|Drug|Diclofenac Sodium 50Mg Suppository|
45656512|NCT03041779|Drug|Paracetamol 500Mg Suppository|
45656513|NCT02612779|Drug|Elotuzumab|
45656514|NCT02612779|Drug|Pomalidomide|
45656515|NCT02612779|Drug|Dexamethasone|
45656516|NCT02612779|Drug|Nivolumab|
45656517|NCT02612623|Drug|Gefapixant|Gefapixant tablets administered by mouth twice daily for 8 weeks
45943358|NCT00307177|Biological|Trivalent Baculovirus-expressed Influenza HA vaccine|Trivalent Baculovirus-expressed influenza HA vaccine (Recombinant rHA0): Arms B, C and D receive 15 mcg, 45 mcg or 135 mcg IM dose on Day 0.
45943359|NCT00120705|Drug|darbepoetin alfa|
45943360|NCT00307216|Behavioral|Graduated Recovery Intervention Program (GRIP)|GRIP is a manual-based comprehensive psychosocial intervention for people recovering from an initial episode of nonaffective psychosis. The purpose of GRIP is to improve occupational functioning after first-episode psychosis and promote goal pursuit and effective illness self-management. Participants assigned to receive TAU plus GRIP will attend therapy sessions weekly for up to 36 weeks, in addition to routine appointments. GRIP includes four phases, each of which focuses on one of the following topics: engagement and wellness management, substance use, persistent symptoms, and functional recovery.
45656518|NCT02612623|Drug|Placebo (for gefapixant)|Matching placebo to gefapixant tablets administered by mouth twice daily for 8 weeks
45656519|NCT04859335|Radiation|gammaknife radiosurgery|Patients will undergo questionnaires before the gammaknife radiosurgery, then one year and three years after the intervention.
45656520|NCT03041857|Radiation|Observational use of fluoroscopy|
45943361|NCT00307216|Behavioral|Treatment as usual (TAU)|Participants receiving TAU will meet with their case-manager and health care providers on an as-needed basis.
45943362|NCT00082979|Genetic|cytogenetic analysis|
45943363|NCT00082979|Genetic|proteomic profiling|
45943364|NCT00082979|Other|cytology specimen collection procedure|
45943365|NCT00082979|Other|immunohistochemistry staining method|
45943366|NCT00082979|Other|laboratory biomarker analysis|
45943367|NCT00082979|Procedure|breast duct lavage|
45943368|NCT00307255|Drug|gemcitabine hydrochloride|1000 mg/m2 on days 1 and 8 of each 21 day cycle
45943369|NCT00307255|Drug|paclitaxel albumin-stabilized nanoparticle formulation|260 mg/m2 to 340 mg/m2 (dose will depend on when subject enters the study). Paclitaxel will be given on day 1 of each 21 day cycle (every 3 weeks)
45943370|NCT02960152|Other|diagnostic|full-mouth periodontal examination
46075173|NCT05162131|Drug|Bentracimab (PB2452) 18000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 5: 18000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
46075174|NCT00868153|Drug|Levonorgestrel IUS (Mirena , BAY86-5028)|One group
46075175|NCT02791932|Behavioral|Exercise|See description above.
46075176|NCT04232592|Biological|Inject a solution of stem cell preparation|The control group was injected with a solution of stem cell preparation
46075177|NCT04232592|Biological|Inject stem cells|Three dose groups were designed: low dose group, medium dose group and high dose group.
46075178|NCT00868387|Other|energy-restricted, CHO-restricted diet|carbohydrate content of the diet < 40% Frequency: daily Duration: 12 months
46075179|NCT00868387|Other|energy-restricted, CHO-rich diet|carbohydrate content of diet > 55% Frequency: daily Duration: 12 months
46075180|NCT04234230|Other|Prevalence Survey|Questionnaire survey on self-management
45656521|NCT04809961|Other|I-care app|A smart phone app to enable healthcare worker peer support for improved workplace wellbeing.
45656522|NCT04808011|Device|Intelligent Dialysis Assistant (IDA)|The IDA is intended for home dialysis for subjects who are stage 5 kidney diease patients and who perform Peritoneal Dialysis. The system is used deveral times a day for approximately 20 minutes for each cycle. During the interventional period, subjects will use only the investigational IDA system for their in/out exchanges.
45656523|NCT04866355|Other|Lumbar spine manipulation|Lumbar spine manipulation
45656524|NCT04866355|Drug|Hyoscine and Ibuprofen|hyoscine (20 mg) and ibuprofen (400 mg) administered by oral via.
45656525|NCT04866121|Procedure|Acupuncture|A standardized acupuncture protocol will be administered
45656526|NCT04849819|Drug|Corticosteroids, immunosuppressors, biological agents|We do not prescribe new medications to patients but only observe their adverse effects on the eye.
45656527|NCT02607865|Drug|semaglutide|Oral administration once-daily
45656528|NCT02607865|Drug|sitagliptin|Oral administration once-daily
45943371|NCT00088023|Drug|PT-523 for Injection|
45943372|NCT00307411|Drug|Growth hormone|
45943373|NCT00083018|Genetic|cytogenetic analysis|
45943374|NCT00083018|Genetic|proteomic profiling|
45943375|NCT00083018|Other|cytology specimen collection procedure|
45943376|NCT00083018|Other|immunohistochemistry staining method|
45943377|NCT00083018|Other|laboratory biomarker analysis|
45943378|NCT00083018|Procedure|breast duct lavage|
45943379|NCT00307450|Drug|Levetiracetam|up to 200 mg per day in two dosages per day.
45943380|NCT00307528|Biological|Pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Five different formulations, each administered to one Group
45943381|NCT00307528|Biological|Pneumovax 23™|Single dose intramuscular injection.
45943382|NCT00120744|Drug|Ondansetron Oral Disintegrating Tablet|
45943383|NCT00307567|Biological|Pneumococcal (vaccine)|
45943384|NCT00083057|Drug|gefitinib|
45943385|NCT00083057|Drug|paclitaxel|
45943386|NCT00083057|Radiation|radiation therapy|
45943387|NCT00088062|Drug|STA-5326|
45943388|NCT00307606|Drug|Solu-medrol 125 mg|
45943389|NCT00083096|Drug|lonafarnib|
45943390|NCT00083096|Drug|temozolomide|
45943391|NCT00307645|Drug|Cyclophosphamide|
45943392|NCT00307645|Drug|Mycophenolate mofetil|
45943393|NCT00307645|Drug|Azathioprine|
45943394|NCT00307645|Drug|Prednisone (and methylprednisolone)|
45943395|NCT00120783|Drug|Indinavir|
45943396|NCT00120783|Drug|Lamivudine|
45943397|NCT00120783|Drug|Ritonavir|
45943398|NCT00307723|Drug|bevacizumab|Intravenously on days 1, 15 and 29 of the first cycle. Intravenously on days 1, 15 of each 28-day cycles for cycles 2-5.
45943399|NCT00307723|Drug|5-Fluorouracil|Continuous infusion on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-38 of cycle one.
45943400|NCT00307723|Drug|Oxaliplatin|Intravenously on dasy 1, 8, 15, 22, 29, 36 of cycle one.
45943401|NCT00307723|Drug|gemcitabine|Intravenously on days 1, 8, 25 of every 28-day cycle for cycles 2-5.
45943402|NCT00307723|Procedure|External Beam Radiation Therapy|Monday through Friday ending on day 38 of cycle 1
45943403|NCT00307762|Behavioral|intensified gait trainer|Intensity and type of rehabilitation after stroke. Gait trainér + or overground walking + other gait-oriented physioteharpy. The third group (control patients) received traditional (ordinary) physiotherapy witn o efforts to intensify it.
45943404|NCT00083135|Biological|filgrastim|
46075181|NCT00872911|Dietary Supplement|Amino acids|mixed pure crystalline amino acids for human use (Ajinomoto), 15 g/d
46075182|NCT00872911|Drug|Exercise|progressive exercise training
45656529|NCT02607865|Drug|placebo|Oral administration once-daily
45807550|NCT04704648|Procedure|Surgical|"The treatment involves excision only of the conjunctival lesion with 3 mm margins. Surgeons (registered as investigators at each site) will perform the operation in accordance with the procedures outlined in the AMC-104 manual of procedures (MOP).~As part of the study patients will be asked to return for follow-up evaluation 1 week, 6 weeks, 6 months, and 12 months after surgery. At each of these follow-up visits, the AMC-certified ophthalmologist will obtain a thorough ocular history as well as a history of AIDS-defining illnesses and perform a slit-lamp examination of both eyes, complete with templated drawings of the conjunctiva, and careful examination of the cornea for limbal stem cell deficiency."
45656530|NCT04856137|Drug|Rituximab Paclitaxel Ruxolitinib|Rituximab 375mg/m2 on D1 of each cycle Paclitaxel 200mg/m2 on D1 of each cycle Ruxolitinib continuously given (D1-21)
45656531|NCT03041545|Device|Fitbit|Women enrolled in the study will be asked to wear a Fitbit from one week prior to chemotherapy until six months post-chemotherapy. The Fitbit is a watch-sized, wrist worn, physical activity tracker. A button, when pressed, displays the wearer's accumulated daily steps, mileage, and steps climbed.
46075183|NCT02791620|Device|a nanofractional radiofrequency device|A nanofractional radiofrequency device. noninvasive fractional radiofrequency device that provides ability to control and adjust the ratio of ablation and coagulation effect. Venus Viva, licensed by Health Canada, is cleared by the FDA for ablation and resurfacing dermatological procedures.
46075184|NCT00873067|Procedure|Additional Complex Fractionated Electrograms ablation|Atrial fibrillation ablation with pulmonary vein ablation and roof line. In addition, complex fractionated atrial electrograms ablation will be performed, lasting at most 30 minutes.
45656532|NCT04849195|Other|No intervention|No intervention
45656533|NCT04849351|Drug|HMPL-689|All patients are to receive monotherapy of HMPL-689 30 mg QD continuously in 28-day treatment cycles.
45656534|NCT03044899|Procedure|All surgeries in adult patients|All surgeries in adult patients
45656535|NCT03045055|Device|Remote ischemic conditioning.|The RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 200 mmHg during the ischemia period. RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
45656536|NCT03045055|Procedure|Endovascular treatment.|Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
45656537|NCT03045055|Device|Sham remote ischemic conditioning|The sham RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 30 mmHg during the ischemia period. Sham RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
45656538|NCT04855903|Device|Covirtua Cognition software|Cognitive training with Covirtua Cognition software
45943405|NCT00083135|Procedure|autologous bone marrow transplantation|
45656539|NCT04849117|Procedure|Ultrasound guided Bilateral Transversus Thoracis Muscle Plane block|"In the TTMP block group, an ultrasounded guided TTMP block was performed by an anesthesiologist, in ICU, before tracheal tube removal. Between the 4th et 5th rib, on each side, 40 ml of Ropivacaine 2 mg/ml, in association with Clonidine, was injected single-shot in the tranversus thoracis muscle plane. The targets of local anesthetic were the anterior branches of intercostal nerves from T2 to T6. Dexamethasone 8 mg was injected intravenously."
45656540|NCT04848493|Biological|COVID-19 vaccines|This is an observational prospective study whose general objective is to assess the impact of COVID-19 vaccination in terms of induction of humoral and cell-mediated immune responses in selected fragile (altered immunocompetence) populations.
45656541|NCT04855591|Drug|SHR-1703|SHR-1703 will be administered subcutaneously
45943406|NCT00083135|Procedure|peripheral blood stem cell transplantation|
46075185|NCT00873067|Procedure|Standard atrial fibrillation ablation procedure|Standard procedure for persistent atrial fibrillation including circumferential pulmonary vein ablation and roof line, both being tested. No other lines or lesions will be performed.
46075186|NCT02789046|Procedure|peripheral intravenous catheterization|success or failure intravenous placement on first attempt and factors associated with failed intravenous catheterization
45656542|NCT04855591|Drug|Placebo|Placebo of SHR-1703 will be administered subcutaneously
45656543|NCT04848649|Other|Study arm|Questionnaires, blood sample, skin (for psoriasis patients) or digestive (for IBD patients) biopsy and swab testing
45656544|NCT04855279|Other|neutral sodium fluoride|Topically applied
45943407|NCT00083135|Radiation|iobenguane I 131|
45656545|NCT04855279|Other|ACP-CCP gel|Topically applied
45656546|NCT04855279|Other|nano-hydroxyapatite solution|Topically applied
45656547|NCT04855279|Other|glycerine|Topically applied
45656548|NCT04848259|Drug|Normal saline|Saline will be applied after surgery
45807551|NCT04704154|Drug|Regorafenib, (Stivarga, BAY73-4506)|"Intake orally, starting with 3x 30 mg tablets every day (once daily.) for 21 days of every 28-day cycle (21 days on, 7 days off).~If the starting dose is well tolerated dose can be escalated to 120 mg (4x30 mg tablets)."
45943408|NCT00307840|Drug|paricalcitol|
45943409|NCT00120822|Drug|Folic acid|
45943410|NCT00307879|Drug|Drug: G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
45943411|NCT00307879|Procedure|collection of mobilized peripheral blood stem cells|
45943412|NCT00307879|Procedure|Intracoronary infusion of mobilized cells|
45943413|NCT00088101|Drug|STA-5312|
45943414|NCT00307918|Device|acupuncture|
45943415|NCT00083213|Biological|ziv-aflibercept|
45943416|NCT00307957|Device|Pillar Palatal Implants|
45943417|NCT00307996|Drug|Coenzyme Q10 (drug)|
45943418|NCT00083252|Drug|talabostat (PT-100) tablets|
45656549|NCT04848259|Drug|Dexamethasone|Dexamethason will be given IV before surgery
45656550|NCT04848259|Drug|Honey|Honey will be applied locally after surgery
45656551|NCT04848259|Drug|Dexamethasone and honey|Dexamethason will be given IV before surgery and then Honey will be applied locally after surgery
45656552|NCT03040609|Behavioral|Visual-behavioral Scale at day 1|To perform the classification with the scale by caregiver.
45807552|NCT04704154|Drug|Nivolumab (Opdivo)|480 mg administered on Day 1 of each treatment cycle.
45656553|NCT03040609|Behavioral|Test-retest at the end of 2 weeks|To perform the classification with the scale by orthoptist at the end of 2 weeks
45656554|NCT03040609|Behavioral|Test at 6 months|To perform the classification with the scale by orthoptist at the end 6 months.
45656555|NCT04848571|Combination Product|Fetal Protection Pill|A Chinese medicine used in pregnant women for fetal protection, including mainly radix polygoni multiflori, Rehmannia glutinosa.
45656556|NCT04840537|Procedure|endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure of ERCP|endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure for exploration of an indeterminate biliary stenosis and biliary drainage
45656557|NCT03038971|Biological|Dose Level 1|Short and Tall Ragweed Mix
45656558|NCT03038971|Biological|Dose Level 2|Short and Tall Ragweed Mix
45943419|NCT00083252|Drug|cisplatin|
45943420|NCT00088140|Drug|IDN-6556|
45943421|NCT00088140|Drug|Placebo|
45943422|NCT00308152|Drug|Infusion of 1 litre of normal saline before colonoscopy|Prehydration with normal saline
45943423|NCT00418639|Drug|Nitazoxanide|
45943424|NCT00418678|Drug|Cesamet|2 mg BID on Days 2-5.
45943425|NCT00120861|Drug|valopicitabine|
45656559|NCT03038971|Biological|Placebo|Saline with 0.4% Phenol
45656560|NCT03039127|Device|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
45656561|NCT03039049|Drug|Triptorelin 0.1 mg|a single dose of Triptorelin 0.1 mg subcutaneously administered 6 days after oocyte retrieval.
45656562|NCT03038893|Diagnostic Test|Point Of Care Ultrasound (PODUS)|Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
45807553|NCT04699864|Diagnostic Test|Screening of DR and DME with artificial intelligence using NeoRetina|Macula-centered eye color fundus photos will be acquired by DIAGNOS team using a non-mydriatic digital camera (without pupil dilation). After a numerical treatment, retinal images will be analyzed by NeoRetina artificial intelligence (AI) algorithm in order to find eye lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded by NeoRetina according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
45943426|NCT00120861|Drug|pegylated interferon|
45943427|NCT00120861|Drug|ribavirin|
45943428|NCT00418756|Drug|Nilotinib|Semi-synthetic antibiotic derivative of rifamycin B and is known to induce cytochrome P-450 (CYP) enzymes.
45943429|NCT05446142|Drug|Encorafenib capsule formulation (CAP)|A single encorafenib dose of the CAP formulation
45943430|NCT05446142|Drug|Encorafenib first formulation|first formulation
45656563|NCT03038893|Diagnostic Test|Echo Doppler Ultrasound (EDUS)|Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
45656564|NCT03040453|Device|Microwave ablation|
45656565|NCT03040453|Device|Irreversible electroporation|
45656566|NCT04848181|Drug|cyproterone acetate|two weeks Cyproterone acetate administration before TURP
45656567|NCT04848181|Drug|finasteride|two weeks finasteride administration before TURP
45656568|NCT04848181|Drug|no treatment received|no treatment received before TURP
45943431|NCT05446142|Drug|Encorafenib second formulation|second formulation
45943432|NCT05446142|Drug|Rabeprazole tablet|Proton-pump inhibitor
45943433|NCT00308191|Drug|Formoterol Fumarate|
45943434|NCT00308191|Drug|Tiotropium Bromide|
45943435|NCT00308269|Drug|Vintafolide IV Bolus|Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
45943436|NCT00308269|Drug|Vintafolide IV Infusion|Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
45943437|NCT00308386|Behavioral|Nurse Case Management intervention|Intervention is meeting with nurse case managers
45943438|NCT00308425|Drug|Enteric-coated Mycophenolate sodium (EC-MPS), valsartan|
45943439|NCT00308464|Drug|PHA-794428|
45943440|NCT00088296|Procedure|Blood Draw|
45943441|NCT00083330|Drug|VRC-HIVADV014-00-VP|
45943442|NCT00308503|Drug|eplivanserin (SR46349)|oral administration
45943443|NCT00308503|Drug|placebo|oral administration
45656569|NCT04848415|Other|Point-of-Care Ultrasound|Patients admitted to the ED with abdominal pain and suspicion of bowel obstruction : realization of a Point-of-Care Ultrasound after clinical exam by the Emergency Physician in charge as a standard of care. Beside usual findings, the investigators will search for signs of bowel obstruction: dilated and incompressible small bowel loop, back-and-forth peristalsis sign. Determination of probability of small bowel obstruction. Realization of a computed tomography in search of small bowel obstruction.
45656570|NCT04847791|Dietary Supplement|Bovine lactoferrin|Oral Administration of Bovine Lactoferrin -fixed dose 800 mg / day for 30 days
45656571|NCT04847791|Dietary Supplement|Placebo administration|capsule identical with the same amount as an inert compound, starch of corn powder), according to the same pattern of use.
45656572|NCT04848103|Behavioral|Radial extracorporeal shockwave therapy|Radial extracorporeal shockwave therapy group include Therapeutic modality(Transcutaneous electrical nerve stimulation [TENS], Microwave thermotherapy, and Superficial heat therapy), Range of motion exercise(Continuous passive motion and Active range of motion exercise).
45453040|NCT03975530|Behavioral|Standard Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit.Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive Family Spirit lessons based on a standard program schedule.
45807554|NCT04699864|Diagnostic Test|Routine ophthalmological evaluation of DR and DME|Standard of care eye examination (blind assessment) will be performed by an ophthalmologist of the CHUM in order to find lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded by the doctor according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
45807555|NCT04699864|Diagnostic Test|Manual grading of DR and DME by CHUM ophthalmologists based on retinal photographies acquired by Diagnos|Ophthalmologists of the CHUM will revise the macula-centered eye color photos acquired by DIAGNOS in order to find lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded (blind assessment) according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
45943444|NCT00308542|Drug|dexamethasone|
45807556|NCT04698343|Device|Noninvasive Peripheral Nerve Stimulation (NPNS)|NPNS device programmed to deliver active stimulation.
45807557|NCT04696809|Drug|Teclistamab|Teclistamab will be administered subcutaneously.
45807558|NCT04687774|Device|ExaltTM Model D Single-Use Duodenoscope|The Exalt™ Model D Single-Use Duodenoscope is a sterile, single-use endoscope that facilitates access to the duodenum, delivery of accessories, and live video when connected to an Exalt™ Controller.
45807559|NCT04687098|Drug|Idarubicin|12 mg/m2/day; intravenous, administration at induction phase, days 1 to 3.
45807560|NCT04687098|Drug|Ara-C|"200mg/m2/day, intravenous at induction phase; days 1-7.~- High dose during consolidation phase. In patients up to 60 years 3g/m2/12hours days 1,3,5, and patients 60 to 70 years: 1.5g/m2/12hours days 1,3,5."
45453041|NCT03264560|Behavioral|Telepsychiatry|A total of 6 synchronous or asynchronous telepsychiatry interventions conducted via telecommunications done at baseline, 1 month, 2 months, 3 months, 6 months, and 12 months.
45807561|NCT04687098|Drug|G-CSF|"Administration at induction phase to remission days 1 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatment arises 30x10e9/L.~Administration at consolidation phase day 7."
45943445|NCT00308659|Procedure|FOB protected distal microbiological samplings|
45943446|NCT00308776|Procedure|Cholecystokinin (CCK) infusion|Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline plus CCK.
45943447|NCT00308776|Procedure|Saline infusion|Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline only.
45943448|NCT00308815|Device|Automatic CPR machine|
45943449|NCT00308854|Procedure|Photodynamic Therapy|
45453042|NCT03907826|Drug|PD-1 blocking antibody|Toripalimab 240mg, D1, every 3 weeks per cycle
45453043|NCT03907826|Drug|GP|Gemcitabine 1.0g/m2, D1 and D8; Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
45453044|NCT03907826|Radiation|IMRT|IMRT 60-66Gy, 1.8-2.0Gy/f/day
45453045|NCT01331486|Dietary Supplement|Hawthorn|Hawthorn standardized extract liquid capsule
45453046|NCT01331486|Dietary Supplement|Placebo capsule|Matched placebo liquid capsule
45453047|NCT00042289|Drug|atazanavir/cobicistat|atazanavir/cobicistat 300/150 mg q.d.
45453048|NCT00042289|Drug|darunavir/ritonavir dosage #1|darunavir/ritonavir twice daily 600/100 mg b.i.d.
45453049|NCT00042289|Drug|darunavir/ritonavir dosage #2|darunavir/ritonavir twice daily 800/100 mg b.i.d.
45807562|NCT04687098|Procedure|Allogeneic matched or unrelated donor transplant.|To be performed in patients in the intermediate or adverse risk groups.
45807563|NCT04687098|Procedure|Autologous peripheral blood stem cell transplant|To be considered in patients in the intermediate risk group without an available allogeneic donor and negative measurable residual disease, per center decision.
45943450|NCT00120900|Drug|GW406381|
45943451|NCT00083408|Drug|Pamidronate|
45943452|NCT00083408|Drug|Thalidomide|
45943453|NCT00308893|Genetic|Genetic analysis|Compare BDNF polymorphism among responders and non-responders
45943454|NCT00308932|Drug|HFA FP MDI|
45943455|NCT00308971|Drug|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 4 months
45943456|NCT00308971|Drug|alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 4 months
45943457|NCT00308971|Drug|placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 4 months
45943458|NCT00308971|Drug|placebo|placebo for alpha lipoic acid; 2 pills daily for 4 months
45943459|NCT00120939|Drug|Motexafin Gadolinium|
45943460|NCT00083447|Drug|TransMID™|
45656573|NCT04847869|Device|Ellex Integre NIR laser|The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
45656574|NCT03041389|Behavioral|CCBT-I Group|Every patient will have a unique password to access to CCBT-I. The program consists of 5 cores: sleep log, day's lesson, activities, relaxation and progress. Each day, the patients fill in sleep logs before getting the day's lesson. Filling sleep log will be reminded daily by the program coach from Sleep Center.
45453050|NCT00042289|Drug|darunavir/ritonavir dosage #3|darunavir/ritonavir twice daily 900/100 mg b.i.d.
45943461|NCT00309049|Drug|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of IV oral and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
45453051|NCT00042289|Drug|elvitegravir/cobicistat|elvitegravir/cobicistat 150/150 mg q.d.
45656575|NCT03041389|Behavioral|Control Group|Reading material only including recommendations about sleep hygiene, stimulus control and sleep restriction. Access to the CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program), if proven effective, after the study is completed.
45807564|NCT04687098|Procedure|Measurable residual disease|To be performed either with molecular monitoring or, if not applicable, by flow cytometry. Pre-stablished cut-off values are defined for decision-making.
45807565|NCT04685135|Drug|MRTX849|21 day cycles
45807566|NCT04685135|Drug|Docetaxel|21 day cycles
45807567|NCT04683406|Drug|ZSP1273 600 mg|3 X 200-mg tablet taken orally
45943462|NCT00309049|Drug|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral IV and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
45943463|NCT00309049|Drug|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral oral and IV dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
45943464|NCT00309088|Drug|tacrolimus|oral
45943465|NCT00309088|Drug|placebo|oral
45943466|NCT00309127|Behavioral|Multidisciplinary team care|
45943467|NCT00083486|Drug|epoetin alfa|
45943468|NCT00120978|Drug|Advair|
45453052|NCT00042289|Drug|dolutegravir|dolutegravir 50 mg q.d.
45943469|NCT00120978|Drug|Flovent|
45453053|NCT00042289|Drug|tenofovir alafenamide fumarate (TAF)|TAF 25 mg q.d. without cobicistat or ritonavir boosting
45807568|NCT04683406|Drug|Placebo to Oseltamivir|Placebo capsules matching oseltamivir2 X 75-mg
45807569|NCT04683406|Drug|Oseltamivir(oral)|2 X 75-mg tablet taken orally
45807570|NCT04683406|Drug|Placebo to ZSP1273|Placebo capsules matching ZSP1273 600 mg
45943470|NCT00309205|Drug|dapivirine (TMC120) vaginal gel|
45453054|NCT00042289|Drug|TAF w/cobicistat|TAF 10 mg q.d. with cobicistat
45453055|NCT00042289|Drug|TAF w/cobicistat or ritonavir|TAF 25 mg q.d. with cobicistat or ritonavir boosting
45453056|NCT00042289|Drug|efavirenz|efavirenz 600 mg q.d.
45453057|NCT00042289|Drug|darunavir/cobicistat|darunavir/cobicistat 800/150 mg q.d.
45453058|NCT00042289|Drug|lopinavir/ritonavir dosage #1|lopinavir/ritonavir 800/200mg b.i.d.
45453059|NCT00042289|Drug|atazanavir/ritonavir/tenofovir dosage #1|atazanavir/ritonavir/tenofovir 300/100/300mg q.d.
45656576|NCT04847713|Other|extraction of blood samples|Two blood samples (3.5 ml each) will be collected directly into purple K2-EDTA tubes and stored at 4°C for up to 24 hours for analysis
45656577|NCT04376593|Drug|18F-αvβ6-BP|Subjects will be injected once per imaging session (a maximum of 3 imaging sessions) with up to 10 mCi (±20%) of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 secs).
45656578|NCT03041155|Behavioral|Muscle respiratory training|Muscle respiratory training during hemodialysis sessions
45656579|NCT03041233|Other|Observation / Data Collection|"The following data will be reviewed / collected:~BASELINE VISIT: Patient demographics; Atrial fibrillation History; Cardiovascular history; Cardiac medical history.~ABLATION PROCEDURE: Devices used; Ablation parameters; Ablation success definition and result; Operator feedback (Device combination chosen, device maneuverability, ease of use in combination with other device); Number, experience and type of attending personnel; Definition of standard of care (follow-up procedures and occurrence).~6 and 12 MONTH FOLLOW-UP (+/- 30 DAYS): Recurrence of atrial arrhythmias: list of atrial arrhythmias since last visit, classify episodes, duration of the episodes; Changes in therapy; In case of Repeat Ablation Procedures, reconnections and new ablations will be recorded."
45656580|NCT04375813|Drug|eRapa|0.5mg eRapa (encapsulated rapamycin) oral capsules
45656581|NCT04375813|Drug|Placebos|placebo capsules visually identical to eRapa oral capsules
45656582|NCT03041077|Dietary Supplement|Instaflex Advanced|Joint function
45943471|NCT00309283|Drug|Long-acting somatostatin|Patients randomized to treatment will be given intramuscularly long-acting somatostatin (Sandostatin-LAR, Novartis, Basel) at the dose of 40 mg every 28 days (in two intragluteal 20 mg injections).
45943472|NCT00309283|Other|Saline solution|Patients randomized to placebo will be given intramuscularly the same volume of solvent used to dissolve somatostatin every 28 days (in two intragluteal injections).
45943473|NCT00083525|Drug|WX-UK1 in combination with Capecitabine|
45943474|NCT00309322|Drug|Phentolamine Mesylate (NV-101)|
45943475|NCT04727502|Drug|Duloxetine|duloxetine
45943476|NCT04727502|Drug|Pregablin|Pregablin
45943477|NCT00309361|Drug|Phentolamine Mesylate (NV-101)|
45943478|NCT00088491|Drug|Intramuscular Olanzapine Depot|
45943479|NCT00088491|Drug|Oral Olanzapine|
45943480|NCT00309439|Procedure|ALA-rich diet|
45943481|NCT00083564|Drug|STR(TM) (Skeletal Targeted Radiotherapy, Holmium-166-DOTMP)|
45943482|NCT00309517|Drug|Fluourouracil|
45943483|NCT00309517|Drug|Leucovorin|
45943484|NCT00309517|Drug|MAb 17-1A|
45943485|NCT00121017|Drug|Kaletra (lopinavir/ritonavir)|
45943486|NCT00121017|Drug|Sustiva (efavirenz)|
45943487|NCT00121017|Drug|Truvada (emtricitabine/tenofovir disoproxil fumarate)|
45943488|NCT04729673|Device|Digital caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)|Measuring the vertical distance between the tip of the upper and the lower canine.
45943489|NCT00309556|Drug|Epirubicin|6 cycles 75mg/m2 i.v. day 1 q3w
45807571|NCT04682197|Device|Cereset Research|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
45807572|NCT04680897|Behavioral|Early restriction release|Participants will no longer have restrictions on vaginal penetration 2 weeks after surgery.
45807573|NCT04680897|Behavioral|Standard restriction recommendation|Participants will return to intercourse after 6 weeks
45807574|NCT04680052|Drug|tafasitamab|tafasitamab will be administered IV for 12 cycles
45807575|NCT04680052|Drug|rituximab|Rituximab will be administered IV on cycles 1 - 5
45807576|NCT04680052|Drug|lenalidomide|Lenalidomide will be administered PO for 12 cycles
45807577|NCT04680052|Drug|placebo|placebo will be administered IV for 12 cycles
45943490|NCT00309556|Drug|Docetaxel|6 cycles 75mg/m2 i.v. day 1 q3w
45943491|NCT00309556|Drug|Capecitabine|6 cycles 1000mg/m2 oral, day 1-14 q2d
45943492|NCT00309556|Drug|Trastuzumab|cycle 1: 8mg/kg i.v. day 1 cycle 2-6: 6mg/kg i.v. day 1 (=6 cycles q3w)
45807578|NCT04678401|Radiation|Radiation|Total Myeloid and Lymphoid Irradiation (TMLI) delivered through Radiation Oncology institutional standards
45807579|NCT04678401|Drug|Fludarabine|Given intravenously -10 to -6 days prior to hematopoietic stem cell transplant (HSCT)
45943493|NCT00402207|Drug|extrafine HFA-beclomethasone|
45943494|NCT00402207|Drug|HFA-fluticasone|
45943495|NCT00309595|Device|stent|Cordis SMART™ Nitinol Stent System
45943496|NCT00309595|Device|balloon|balloon angioplasty
45943497|NCT00399737|Drug|repeated intake of fermented milk followed by a single oral dose of an ACE inhibitor|
45943498|NCT00309634|Biological|4 adjuvanted pandemic influenza candidate vaccines|
45943499|NCT00309634|Biological|4 non-adjuvanted pandemic influenza candidate vaccines|
45943500|NCT00088569|Drug|0-15 Water|
45943501|NCT00309712|Drug|fenofibrate 160 mg and placebo|
45943502|NCT00309712|Drug|simvastatin 20 mg and placebo|
45943503|NCT00309712|Drug|fenofibrate 160 mg and simvastatin 20 mg|
45943504|NCT00121056|Drug|Enbrel®|
45943505|NCT00121056|Drug|Kineret®|
45656583|NCT03041077|Dietary Supplement|Placebo|Placebo
45656584|NCT04847245|Drug|Pregabalin 75mg tid + Duloxetine|Pregabalin capsules were administered orally (75 mg, 3 times a day), combined administration of duloxetine (60-120 mg/day）.
45656585|NCT04847245|Drug|Intravenous administration of esketamine 0.125 mg/kg+Duloxetine|Intravenous administration of esketamine 0.125 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
45807580|NCT04678401|Drug|Thiotepa|Given intravenously on day -10 and day- 9 prior to hematopoietic stem cell transplant (HSCT)
45943506|NCT00309790|Drug|sildenafil|
45943507|NCT00418795|Drug|recombinant human porphobilinogen deaminase (Porphozym)|
45943508|NCT00083603|Biological|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10^7 pfu /2mL administered in each deltoid
45807581|NCT04678401|Drug|Cyclophosphamide|Given intravenously with Mesna on day -8 and day- 7 prior to hematopoietic stem cell transplant (HSCT)
45807582|NCT04678401|Drug|Mesna|Given intravenously with Cyclophosphamide on day -8 and day -7 prior to hematopoietic stem cell transplant (HSCT)
45807583|NCT04678401|Biological|Treg-enriched donor cell|Given intravenously -4 day prior to hematopoietic stem cell transplant (HSCT)
45807584|NCT04678401|Biological|Unmodified donor T Cell|Given intravenously -1 day prior to hematopoietic stem cell transplant (HSCT)
45807585|NCT04678401|Procedure|CD34+ Haplo Peripheral Blood Stem Cell|CD34+ Haplo Peripheral Blood Stem Cell Transplantation
45807586|NCT04677504|Drug|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
45807587|NCT04677504|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg intravenously on Day 1 of each 21-day cycle after atezolizumab.
45807588|NCT04677504|Other|Placebo|Placebo matching bevacizumab will be administered intravenously on Day 1 of each 21-day cycle after atezolizumab.
46075187|NCT00876811|Dietary Supplement|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries daily for four weeks, followed by a four week period of non-treatment.
46075188|NCT00876811|Dietary Supplement|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries for two weeks, then consumption of two-cups frozen red raspberries for an additional two weeks, followed by four weeks of non-treatment.
46075189|NCT00876811|Dietary Supplement|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries for two weeks, then consumption of four-cups frozen red raspberries for an addition two weeks, followed by four weeks of non-treatment.
46075190|NCT02791776|Other|Scoliosis|"self-administered questionnaire (SRS 30) to assess the state of health and disability of patients.~Collection of patient's radiographic and clinical parameters"
45656586|NCT04847245|Drug|Intravenous administration of esketamine 0.25 mg/kg +Duloxetine|Intravenous administration of esketamine 0.25 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
45656587|NCT04847245|Drug|Intravenous administration of esketamine 0.50 mg/kg+Duloxetine|Intravenous administration of esketamine 0.50 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
45656588|NCT04799899|Behavioral|Adapted MBCT|The adapted MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health.
45656589|NCT04799899|Behavioral|Cardiac Health Enhancement|The cardiac health enhancement control group will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will learn about depression and cardiac health.
45807589|NCT04677504|Drug|Cisplatin|Cisplatin will be administered intravenously at a dose of 25 mg/m^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
45807590|NCT04677504|Drug|Gemcitabine|Gemcitabine will be administered intravenously at a dose of 1000 mg/m^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
45807591|NCT04677465|Device|RheOx Bronchial Rheoplasty|bronchial rheoplasty is a staged procedure wherein pulsed electric fields are delivered to the right lung in the first treatment visit, and then the left lung is treated approximately 1 month later.
45807592|NCT04677465|Device|Sham Procedure|staged sham procedure wherein bronchoscopy is performed, the catheter is inserted into the right lung, but energy is not delivered; then the same steps are performed in the left lung approximately 1 month later (no energy is delivered to the patient)
45807593|NCT04676087|Procedure|Extracorporeal Photopheresis|Undergo ECP
45807594|NCT04676087|Biological|Mogamulizumab|Given IV
45807595|NCT04676087|Other|Quality-of-Life Assessment|Ancillary studies
45807596|NCT04673357|Drug|Ustekinumab|Ustekinumab will be administered intravenously in induction period and subcutaneously in maintenance period.
45807597|NCT04673357|Drug|Placebo|Matching placebo will be administered as SC injection.
45807598|NCT04672590|Other|Primary exposure is hypoxia (no intervention)|The primary exposure, hypoxia, will be defined as severe, non-severe or none for each participant, based on pre-defined criteria.
45807599|NCT04671459|Combination Product|TTFields and SRS|SRS procedure will be delivered within 7 days after start of TTFields therapy . A 5-day SRS regimen is allowed. TTFields should be interrupted in time of SRS and start immediately after.
45807600|NCT04670874|Other|Quality-of-Life Assessment|Complete quality of life questionnaire
45943509|NCT00083603|Biological|rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT)|Vaccines administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid
45943510|NCT00083603|Biological|Empty TBC-FPV|Empty FPV 10^9 pfu/2mL administered as two separate 1 mL intramuscular injections, one into each deltoid.
45943511|NCT00083603|Biological|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10^8 pfu /2mL administered in each deltoid
45943512|NCT00083603|Biological|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10^9 pfu /2mL administered in each deltoid
45943513|NCT00083603|Biological|TBC-MVA and TBC-FPV|Empty MVA 10^7 pfu/2mL administered into each deltoid
45943514|NCT00083603|Biological|TBC-MVA and TBC-FPV|Empty MVA 10^8 pfu/2mL administered into each deltoid
45807601|NCT04670874|Other|Questionnaire Administration|Complete quality of life questionnaire
45807602|NCT04663802|Behavioral|RT-targeted accountable justification|This strategy will require that the RT enter an explicit rationale in the EHR if he/she enters a tidal volume value greater than 6 cc/kg into the flowsheet, similar to the physician-targeted accountable justification strategy.
45943515|NCT00083603|Biological|TBC-MVA and TBC-FPV|Empty MVA 10^9 pfu/2mL administered into each deltoid
45807603|NCT04663802|Behavioral|Default order set|With the default order set strategy, some mechanical ventilation order settings will be pre-populated to be consistent with LPV, including the mode and tidal volume, automatically calculated as 6 cc/kg of the patient's ideal body weight (as determined by each patient's height and gender, which are entered into the EHR on admission). The physician will have the option to opt out of any of the specified LPV settings and select other values.
45943516|NCT00418873|Drug|Zotepine|Oral
45943517|NCT00418873|Drug|Risperidone|Oral
45943518|NCT00088608|Drug|SOM230 s.c.|
45943519|NCT00309868|Drug|neseritide|
45943520|NCT00310024|Drug|bortezomib|Given IV
45943521|NCT00310024|Drug|vorinostat|Given orally
45943522|NCT00310024|Other|laboratory biomarker analysis|Correlative studies
45943523|NCT00310024|Other|pharmacological study|Correlative studies
46075191|NCT03840187|Diagnostic Test|Digital cervicography|Colposcopist findings and digital cervicography employing Gynescope system
45453060|NCT00042289|Drug|rifampicin|rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
45453061|NCT00042289|Drug|ethambutol|ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.
45453062|NCT00042289|Drug|isoniazid|isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
45807604|NCT04663802|Behavioral|physician-targeted accountable justification|When a physician enters a mechanical ventilation order for a tidal volume that is greater than 6 cc/kg ideal body weight, an alert will appear requiring the physician to enter a reason for choosing a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The physician will not be able to sign the mechanical ventilation order set until after a response is entered.
45807605|NCT04663802|Other|Standard of Care|ICUs and clinicians will deliver standard of care to patients with no intervention
45453063|NCT00042289|Drug|pyrazinamide|pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w.
45453064|NCT00042289|Drug|kanamycin|kanamycin (2nd line TB drug)
45453065|NCT00042289|Drug|amikacin|amikacin (2nd line TB drug)
45943524|NCT00088647|Drug|MST-997|
45943525|NCT00310063|Procedure|acupressure therapy|Acupressure wristband
45943526|NCT00310063|Procedure|sham intervention|Sham wristband
45943527|NCT00310141|Behavioral|Smoking cessation intervention|6 weeks of computer delivered treatment for quitting smoking
45943528|NCT00310141|Other|Counseling intervention|In-person counseling (5 sessions)
45943529|NCT00310141|Drug|Nicotine patch|6-week supply of the nicotine patch
45453066|NCT00042289|Drug|capreomycin|capreomycin (2nd line TB drug)
45943530|NCT00088686|Drug|Capsaicin (Intramucosal Injection)|
45943531|NCT00310219|Procedure|computed tomography|
46075192|NCT02788734|Other|Web-based survey|This study protocol consists of one anonymous survey. Each participant can complete only one survey. The survey will take approximately 25 minutes to complete. The survey is designed to identify items that best reflect the symptom severity and functional status in patients with CTS and CMT. A unique link to the survey will be included in an email invitation distributed to all adult CMT or HNPP patients self-registered in the RDCRN INC Contact Registry. Upon clicking the link, the participant will be directed to the IRB-approved online consent form. Upon providing consent, the participant will be directed to the online survey.
46075193|NCT00876889|Drug|Riluzole|50mg PO (by mouth) every 12 hours starting within 12 hours of injury and continuing for 14 days (28 doses).
46075194|NCT00873145|Procedure|HMRS|Modular prosthetic replacement of the humerus and elbow.
45943532|NCT00310219|Procedure|positron emission tomography|
45943533|NCT00083681|Drug|Thalidomide|
45943534|NCT00083681|Drug|Dexamethasone|
45943535|NCT00083681|Drug|Cytoxan|
45943536|NCT00083681|Drug|Etoposide|
45943537|NCT00083681|Drug|Cisplatin|
45943538|NCT00083681|Drug|G-CSF|
45943539|NCT00310258|Behavioral|Drug use prevention intervention|
45943540|NCT00121095|Drug|Samarium Sm-153 lexidronam + Docetaxel|1 mCi/kg Sm153 + 75 mg/m2 docetaxel
45943541|NCT00310297|Drug|Insulin Glulisine|
45943542|NCT00310336|Drug|S-adenosyl-L-methionine|
45943543|NCT00310336|Drug|betaine|
45943544|NCT00310336|Drug|pegylated interferon alpha2b|
45943545|NCT00310336|Drug|ribavirin|
45943546|NCT00088764|Behavioral|Coping skills training|8 sessions of pain and stress coping skills training
45943547|NCT00088764|Behavioral|Written emotional disclosure|4 sessions of writing about stress
45943548|NCT00088764|Behavioral|Arthritis education|8 sessions of learning about rheumatoid arthritis
45943549|NCT00088764|Behavioral|Health behavior writing|4 sessions of writing about various health behaviors
45943550|NCT00310453|Biological|ALK Grass tablet|
45943551|NCT05568602|Diagnostic Test|Dexamethasone suppression test|1 mg Dexamethasone overnight suppression test for screening of hypercortisolism
45943552|NCT00310492|Biological|subcutaneous immunotherapy|Updosing by 16 injections to 100,000 SQ-U
45943553|NCT00121212|Procedure|carbon-11 acetate PET scan|
45943554|NCT00310531|Drug|Menostar (Estradiol, BAY86-5435)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
45943555|NCT00310531|Drug|Raloxifene|Raloxifene tbl. (60 mg/day)
45943556|NCT00310570|Device|Circumferential thermoplastic thimble splint|
45943557|NCT00310570|Device|"dorsal aluminium foam Mexican Hat splint"|
45943558|NCT00310570|Device|stack splint (control)|
45943559|NCT05568446|Behavioral|Social virtual reality|The participants will receive eight training sessions in 4 weeks (2 sessions per week). Each session is about 20 minutes.
45656591|NCT04840225|Other|Measurement of biomarkers for inflammation and anemia|Measurement of biomarkers for inflammation and anemia, in addition to standart clinical measurements
45807606|NCT04662086|Drug|Acebilustat|100 mg capsule administered orally once daily
45453067|NCT00042289|Drug|moxifloxacin|moxifloxacin (2nd line TB drug)
46075195|NCT03550404|Behavioral|Seasons of Care App|A web-based mobile application (app) called the Seasons of Care Elder Navigation Guide will assist elders, their families/caregivers, healthcare providers, outreach workers, and other community members in navigating healthcare and insurance systems. The app has the added advantage of being easy to update to respond to future changes in health care and insurance, and sustainable because it is not dependent on intensive training, developing, and retaining of individuals in professional navigation positions.
46075196|NCT00868465|Drug|Artemether-Lumefantrine|Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h [+/-90 min] after the initiation of treatment). AL is currently the first line treatment in Tanzania
46075197|NCT00868465|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (DP; Artekin; Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets), with a dihydroartemisinin dose of 2.5 mg per kilogram and a piperaquine phosphate dose of 20 mg per kilogram daily for 3 days. DH is registered in Tanzania as Artekin and has been tested extensively in Asia and recently in clinical trials in Uganda and Rwanda
45453068|NCT00042289|Drug|levoflaxacin|levofloxacin (2nd line TB drug)
45453069|NCT00042289|Drug|ofloxacin|ofloxacin (2nd line TB drug)
45453070|NCT00042289|Drug|ethionamide/prothionamide|ethionamide/prothionamide (2nd line TB drug)
45807607|NCT04662086|Drug|Camostat|200 mg (2 x 100 mg tablet) administered orally four times daily (800 mg total daily dose).
45807608|NCT04662073|Drug|Camostat|200 mg (2 x 100 mg tablet) administered orally four times daily (800 mg total daily dose).
45807609|NCT04662073|Drug|Placebo|Placebo to match camostat administered orally four times daily
45943560|NCT05568446|Behavioral|Traditional social skills|The participants will receive eight training sessions in 4 weeks (2 sessions per week). Each session is about 20 minutes.
45943561|NCT00310609|Drug|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
45943562|NCT00121290|Drug|SJG-136|Given IV
45943563|NCT00121290|Other|laboratory biomarker analysis|Correlative studies
45943564|NCT00121290|Other|pharmacological study|Correlative studies
45453071|NCT00042289|Drug|terizidone/cycloserine|terizidone/cycloserine (2nd line TB drug)
45453072|NCT00042289|Drug|para-aminosalicylic acid (PAS)|para-aminosalicylic acid (PAS) (2nd line TB drug)
45453073|NCT00042289|Drug|high dose INH|high dose INH (2nd line TB drug)
45453074|NCT00042289|Drug|bedaquiline|bedaquiline (2nd line TB drug)
45453075|NCT00042289|Drug|clofazamine|clofazamine (2nd TB drug)
45453076|NCT00042289|Drug|delamanid|delamanid (2nd line TB drug)
45453077|NCT00042289|Drug|linezolid|linezolid (2nd line TB drug)
45453078|NCT00042289|Drug|pretomanid|pretomanid (2nd line TB drug)
45453079|NCT00042289|Drug|ethinyl estradiol|oral contraceptives formulated with 30-35 μg ethinyl estradiol
45453080|NCT00042289|Drug|etonogestrel implant|etonogestrel implant contraceptive
45453081|NCT00042289|Drug|nevirapine|nevirapine 200 mg twice a day
45453082|NCT00042289|Drug|amprenavir|amprenavir 1200mg twice a day
45453083|NCT00042289|Drug|abacavir|abacavir 300mg twice a day
45656592|NCT04839913|Diagnostic Test|Antibodies testing|Serologic test for both SARS-COV-2 IgG and IgM
45656593|NCT04839835|Other|waiting room enriched with music, paintings and artificial plants|waiting room enriched with music, paintings and artificial plants
45656594|NCT04847401|Diagnostic Test|H. pylori stool antigen|using H. pylori antigen kits in stool
45656595|NCT04846699|Procedure|per-cutaneous stone extraction|percutaneous nephrolithotripsy for renal stones by different renal access
45656596|NCT04847089|Device|Motor imagery BCI training|Motor Imagery (MI)-BCI training, 2-3 hours, 3 times/week for 4 weeks.
45807610|NCT04658862|Biological|Cetrelimab|Participants will receive intravenous Cetrelimab.
45807611|NCT04658862|Drug|TAR-200|Participants will receive intravesical TAR-200.
45807612|NCT04658862|Drug|Cisplatin|Participants will receive cisplatin intravenously.
45943565|NCT00310648|Biological|Influenza vaccine|
45943566|NCT00309673|Drug|lidocaine / Prilocaine|
45943567|NCT00310687|Procedure|BLOOD DRAW|
45943568|NCT05568368|Other|No intervention|no intervention
45943569|NCT00310726|Other|abrupt weaning at 4 months|abrupt weaning at 4 months
45943570|NCT00310726|Other|Continued exclusive breastfeeding|Continued exclusive breastfeeding
45943571|NCT00310765|Drug|Pregabalin|First 7 weeks 75 or 150 mg of pregabalin po BID. Start at 75 mg and increase to 150 mg po BID if no improvement after 3 days
45943572|NCT00310765|Drug|Pregabalin|75 mg po BID
45943573|NCT00088803|Genetic|molecular genetic technique|
45656597|NCT04846621|Drug|Potassium Channel Opener|Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
45943574|NCT00088803|Genetic|polymerase chain reaction|
45943575|NCT00088803|Genetic|polymorphism analysis|
45943576|NCT00310843|Drug|Nevirapine|Patients with HIV-1 infection who have taken or are currently taking nevirapine
45943577|NCT05568290|Other|Saliva|"individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
45943578|NCT05568290|Other|gingival crevicular fluid|GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.
45807613|NCT04658862|Drug|Gemcitabine|Participants will receive gemcitabine intravenously.
45943579|NCT00310921|Drug|Misoprostol|
45943580|NCT05568212|Drug|Durvalumab|Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL
45943581|NCT05568212|Drug|Olaparib tablet|Olaparib tablets (100 mg and 150 mg strengths) supplied in high-density polyethylene (HDPE) bottles.
45943582|NCT05568212|Drug|Single-agent chemotherapy|Investigator's choice single-agent chemotherapy regimen
45943583|NCT05568212|Drug|Platinum doublet chemotherapy|Investigator's choice platinum doublet chemotherapy
45943584|NCT00310999|Device|Shikani Optical Stylet|
45943585|NCT00121329|Drug|Intrauterine lidocaine infusion 4%|
45807614|NCT04658862|Radiation|Conventional radiation therapy|Participants will receive conventional radiation therapy for bladder (64 gy).
45807615|NCT04658862|Radiation|Hypo-fractioned radiation therapy|Participants will receive hypo-fractioned radiation therapy for bladder (55 gy).
45943586|NCT00311038|Drug|ONO-1101|
45656598|NCT04846621|Drug|Calcium channel blocker|Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
45656599|NCT04846777|Device|Mindfulness ecological momentary intervention|Access to a smartphone-delivered mindfulness ecological momentary intervention with the Personal Analytics Companion (PACO) app that regularly prompts participants to practice various mindfulness skills at 5 preset times each day.
45656600|NCT04846777|Device|Self-monitoring placebo|Access to a smartphone-delivered self-monitoring placebo with the PACO app that regularly prompts participants to practice self-monitoring at 5 preset times each day.
45656601|NCT04846543|Other|MRI Scan|MRI scan
45807616|NCT04657224|Drug|JNJ-64264681|JNJ-64264681 capsules will be administered orally.
45807617|NCT04657224|Drug|JNJ-67856633|JNJ-67856633 capsules or tablets will be administered orally.
45943587|NCT00311077|Drug|Insulin Glulisine|
45943588|NCT00311116|Drug|Vitamin E|
45943589|NCT00311194|Behavioral|6 months readmission rate to hospital|
45943590|NCT05568056|Behavioral|Visualizing and Verbalizing for Language comprehension and Thinking|The V/V intervention program is a language remediation program designed by Dr. Nanci Bell, and developed by the Lindamood-Bell Learning Processes (LBLP) (Bell, 1991b). It has been widely used among children with reading disorders, but not with children with ASD. This intervention is based on the use of nonverbal sensory input, in the form of imaged gestalts, in order to develop oral and written language comprehension, establish vocabulary, and develop higher order thinking skills (Bell, 1991a,b).
45943591|NCT00311272|Biological|MelCancerVac|
45943592|NCT00088959|Drug|erlotinib hydrochloride|Given orally
45943593|NCT00088959|Drug|celecoxib|Given orally
45656602|NCT04854655|Other|Conventional resin composite|nanofilled resin composite
45656603|NCT04854655|Other|Activa Presto|calcium and phosphate hybrid material
45656604|NCT04854655|Other|Giomer|fluoride releasing hybrid material
45807618|NCT04657146|Other|Biorepository|"Tumor collection (> 1cm3): Intraoperatively~Peripheral blood collection:~Intraoperatively (60mL)~Post-resection (30mL)~Post- standard of care treatment (30mL)~Bone marrow aspiration:~Intraoperatively (10mL)~Post-resection (5mL)~Post- standard of care treatment (5mL)"
45807619|NCT04656418|Biological|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant monoclonal antibody
45807620|NCT04656418|Drug|Placebo|Buffer without active ingredient
45807621|NCT04647877|Drug|phenytoin cream|Phenytoin cream to be applied on the neuropathic pain area
45807622|NCT04647877|Other|Placebo cream|Placebo cream to be applied on the neuropathic pain area
45807623|NCT04644770|Drug|JNJ-69086420|Participants will receive IV injection of JNJ-69086420.
45807624|NCT04640025|Drug|itacitinib|Participants will self-administer itacitinib orally using intact tablets with water and without regard to food.
45807625|NCT04634552|Drug|Talquetamab|Talquetamab will be administered SC until disease progression.
45943594|NCT00088959|Other|laboratory biomarker analysis|Correlative studies
45943595|NCT05568017|Other|peptide receptor radionuclide therapy with Y-90-DOTATOC|Patients with unresectable or borderline resectable pNETs will recive PRRT with 90Y-DOTATOC
45943596|NCT00311350|Drug|MOA-728|
45943597|NCT00311389|Drug|Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
45943598|NCT00311389|Drug|Latanoprost 0.005%/Timolol 0.005% ophthalmic solution|Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
45943599|NCT00311428|Biological|Influenza|
45943600|NCT00399776|Radiation|Bone Density Test|Evaluating bone mineral content and bone metabolism in adolescents on antipsychotic therapy compared to healthy adolescents
45943601|NCT00088998|Biological|bevacizumab|
45943602|NCT00088998|Drug|capecitabine|
45943603|NCT00088998|Drug|docetaxel|
45943604|NCT00311467|Drug|Capecitabine, Interferon, Interleukin|"Capecitabine orally from day 1 to 14 at a dose of 1000 mg/m2 twice daily every 21 days.~Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6 MIU/d.~Interleukin-2 subcutaneously on days 1 to 4 in weeks 3 + 4 +8 + 9,13+14 at a dose of 4.5 MIU/day.~Group B~Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.~Efficacy evaluations will be performed every 14 weeks of treatment in both groups"
45943605|NCT00311545|Biological|CNTO 328|Anti-IL-6 chimeric monoclonal antibody
45656605|NCT03038737|Other|bre.flex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon RDP is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
45807626|NCT04633447|Drug|Guselkumab|Guselkumab will be administered subcutaneously.
45807627|NCT04633447|Drug|Placebo|Matching placebo will be administered subcutaneously.
45943606|NCT02965157|Biological|CART20|
45943607|NCT00089037|Drug|methotrexate|
46075198|NCT00868543|Procedure|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 150cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
46075199|NCT00868543|Procedure|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 250cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
46075200|NCT02689986|Drug|Bendamustine, Rituximab|Bendamustine, Rituximab
46075201|NCT00876967|Device|metallic single use blade|metallic single use blade
46075202|NCT00876967|Device|plastic single use blade|plastic single use blade
46075203|NCT00876967|Device|metallic reusable blade|metallic reusable blade
46075204|NCT02788812|Procedure|Open modified Lichtenstein repair|Open Lichtenstein Hernioplasty
46075205|NCT02788812|Procedure|Laparoscopic TAPP inguinal hernia repair|Laparoscopic TAPP Hernioplasty
46075206|NCT02791464|Behavioral|Transcendental Meditation program|a mental technique using a mantra or 'soothing sound' that refines the thought process enabling the mind to 'transcend' its own thinking process and experience a state of pure consciousness. Subjects practice this technique twice a day for 20 minutes sitting in chair with eyes closed.
45807628|NCT04633252|Drug|ADT|For mCSPC patients: Androgen Deprivation Therapy (ADT) may include GnRH agonist or monthly degarelix converted to GnRH agonist after 3 months. For mCRPC patients: ADT will be continued as per standard of care.
45807629|NCT04633252|Drug|Prednisone|For mCSPC patients, prednisone is optional and if given, should be taken orally, at 5 mg once a day. For mCRPC patients, prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day as is the patient s preference.
45943608|NCT00089037|Drug|sirolimus|
45807630|NCT04633252|Drug|M7824|M7824 (2400 mg) will be administered as a 1 hour intravenous (IV) infusion once every three weeks.
45807631|NCT04633252|Drug|Docetaxel|Docetaxel 75mg/m^2 will be administered intravenously every 21 days (i.e., a 3-week cycle) for up to 6 cycles in mCSPC and until progression or unacceptable toxicity in mCRPC.
45943609|NCT00089037|Drug|tacrolimus|
45943610|NCT00418990|Drug|Multivitamin/Mineral supplements|
45943611|NCT00311662|Drug|Tonabersat|Tablet 40mg daily for 12 weeks
45943612|NCT00311662|Drug|Placebo|Tablet once daily for 12 weeks
45943613|NCT05567939|Other|Natural course of disease|Sample and questionnaire collection
45943614|NCT02965326|Procedure|Nasal swab; rectal biopsy.|Nasal epithelial cells will be obtained by nasal swabs from patients of the three arms; intestinal epithelial cells will be obtained, by rectal biopsy, only from patients treated by CFTR modulators.
45943615|NCT00311740|Drug|Valsartan|
45943616|NCT00311740|Drug|Hydrochlorothiazide|
45943617|NCT00311779|Drug|Spinosad Creme Rinse|
45807632|NCT04633252|Drug|M9241|M9241 at escalating doses and then at RP2D will be administered as a subcutaneous injection every three weeks.
45943618|NCT00311818|Drug|Insulin glargine|
45943619|NCT00121407|Drug|Visudyne for injection|
45943620|NCT00311857|Drug|Cetuximab|
45943621|NCT00311857|Drug|Temozolomide|
45943622|NCT00311857|Procedure|Radiation therapy|
45943623|NCT05567705|Other|The attitudes of doctors working in the surgical clinic of a university hospital for patient blood management: a survey-based study|No intervention required
45943624|NCT00311896|Drug|Bemiparin|
45943625|NCT00311896|Drug|Placebo|
45943626|NCT00121446|Drug|tenecteplase|
45807633|NCT04632992|Drug|Entrectinib|Entrectinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 600 milligrams (mg) per day once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
45807634|NCT04632992|Drug|Inavolisib|Inavolisib will be self-administered by participants orally at home (except on clinic days) at the same time each day, on a starting dose of 9 mg/day QD until disease progression, intolerable toxicity, or consent withdrawal.
45943627|NCT00121446|Drug|enoxaparin|
45807635|NCT04632992|Drug|Alectinib|Alectinib will be self-administered by participants orally at home (except on clinic days), at the same times each day, on a starting dose of 600 mg twice a day (BID) until disease progression, intolerable toxicity, or consent withdrawal.
45807636|NCT04632992|Drug|Ipatasertib|Ipatasertib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg QD until disease progression, intolerable toxicity, or consent withdrawal.
45943628|NCT00121446|Drug|clopidogrel|
45943629|NCT00121446|Procedure|percutaneous coronary intervention|
45943630|NCT05567666|Device|Optilume Catheter System|Optilume Catheter System, which is a Dilation Drug Coated Balloon (DCB) Catheter
45943631|NCT00311935|Procedure|method of hernia repair|
45943632|NCT00311974|Drug|Dihydralazine|
45656606|NCT03038737|Other|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
45656607|NCT04854421|Device|VBC|Body Composition will be measured using the VBC system that takes under 60 seconds per scan. Image capture for VBC will include taking a series of four photos using a smartphone camera. Data from the camera will be downloaded to a local computer and then securely sent to the cloud for automated analysis and results generation. We will conduct two consecutive scans (image captures) for each research participant.
45656608|NCT04846153|Other|Human-based Quantification of Airway Stenosis|Human-based Quantification of Airway Stenosis From Bronchoscopic Images.
45656609|NCT04846153|Device|Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.|Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.
45943633|NCT00312013|Drug|Nadroparin|Patients will received all standard anti-cancer treatments. Therapeutic doses of nadroparin will be administered, subcutaneous for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2 week periods of therapeutic doses will be given for a total of 6 cycles each separated by a 4 week wash out. The study treatment period ends at week 46 regardless of the number of cycles achieved.
45943634|NCT05567627|Biological|Genetic: GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
45943635|NCT05567627|Biological|Genetic: GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
45943636|NCT00121524|Drug|Epinephrine|Epinephrine 1 mg is given iv. every 3 min during CPR
45943637|NCT00121524|Device|Intravenous needle|An intravenous needle in placed as soon as possible during CPR
45943638|NCT00121524|Drug|Atropine|Atropine 3 mg iv in initial systole
45943639|NCT00121524|Drug|Amiodarone|amiodarone 300 mg iv after repeated failed defibrillation attempts
45943640|NCT00312130|Drug|Vildagliptin|
45943641|NCT00089115|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
45453084|NCT00042289|Drug|lopinavir/ritonavir dosage #2|lopinavir/ritonavir (Kaletra) 400/100mg twice a day
45807637|NCT04632992|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).
45943642|NCT00089115|Biological|rituximab|
45943643|NCT00089115|Biological|sargramostim|
45943644|NCT00312325|Drug|Prednisolone|
45943645|NCT00312403|Procedure|Blood Sample|A single venous blood sample will be taken (10 ml).
45943646|NCT05567471|Biological|BBV154 Intranasal Vaccine|Administered BBV154 vaccine in form of drops (0.5 mL) via intranasal route
45943647|NCT05567471|Biological|Intramuscular vaccine COVAXIN|Administered BBV152 vaccine via intramuscular route
45943648|NCT05567471|Biological|Covishield|Administered vaccine via intramuscular route
45943649|NCT00089154|Biological|apolizumab|Given IV
45943650|NCT00089154|Other|laboratory biomarker analysis|Correlative studies
45943651|NCT00089154|Other|pharmacological study|Correlative studies
45943652|NCT00312442|Drug|Treatment with WST09 Vascular Photodynamic therapy|
45943653|NCT00312481|Drug|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|Split dose, 1-litre solution in the evening prior to colonoscopy and second dose in the morning prior to colonoscopy
45943654|NCT00312481|Drug|NA picosulfate magnesium citrate|150 ml solution before 8am on day prior to colonoscopy and 150ml solution 6 to 8 hours later.
45943655|NCT00312520|Drug|prednisolone|
45943656|NCT00312520|Drug|methylprednisolone|
45943657|NCT05567432|Procedure|thyroidectomy|use diathermy or ligasure for homeostatic during thyroidectomy
45943658|NCT00312559|Behavioral|Yoga Training|
45943659|NCT00089193|Biological|incomplete Freund's adjuvant|
45656610|NCT04854577|Procedure|Opioid Free Anesthesia|Patients will be administered a combination of a pre-incisional pecto-intercostal fascial plane block and a standardized opioid free anesthetic regimen consisting of dexmedetomidine, esketamine and lidocaine.
46075207|NCT00955409|Biological|ACC-001(3µg) + QS21|Vanutide Cridificar (ACC-001) 3µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
46075208|NCT00955409|Biological|ACC-001(10µg) + QS21|Vanutide Cridificar (ACC-001) 10µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
46075209|NCT00955409|Biological|ACC-001(30µg) + QS21|Vanutide Cridificar (ACC-001) 30 µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
45656611|NCT04854577|Procedure|Traditional Anesthetic Regimen|Patients will be administered a traditional anesthetic regimen which is based on sufentanil dosage. The dosage is at the discretion of the attending anesthesiologist.
46075210|NCT05390892|Drug|SGLT2 inhibitor|Empagliflozin, dapagliflozin, or canagliflozin
46075211|NCT05390892|Drug|GLP-1 receptor agonist|Dulaglutide, liraglutide, semaglutide
45656612|NCT04846465|Other|Screening in picture archiving and communication system (PACS) .|Screening in picture archiving and communication system (PACS) , the images of the participants who underwent computed tomography (CT) of the femur and acetabulum.
45656613|NCT04846075|Behavioral|Ramadan fasting, praying, and welfare for poor|Abstaining from food, drink, smoking, and sexual activity duirng daytime; ritualistic praying at specific time of a day for five or more times; volunteering for communities or donation
45807638|NCT04632992|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
45943660|NCT00089193|Biological|multi-epitope melanoma peptide vaccine|
45943661|NCT00089193|Biological|sargramostim|
45943662|NCT00293098|Drug|deferiprone|oral administration of 75 mg/kg/day in three divided doses, usually in combination with deferoxamine therapy
45943663|NCT00293176|Drug|Donepezil Hydrochloride|Subects will receive a starting dose of 5 mg orally. Dose-escalation from 5 mg to 10 mg will occur at the Week 9 Visit.
45453085|NCT00042289|Drug|indinavir/ritonavir dosage #1|indinavir/ritonavir 800/100mg twice a day
45453086|NCT00042289|Drug|fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg twice a day
45453087|NCT00042289|Drug|lopinavir/ritonavir dosage #3|lopinavir/ritonavir (Kaletra) 533/133 mg twice a day
45943664|NCT00293176|Drug|Placebo|Subjects will receive matching placebo tablets.
46075212|NCT05390892|Drug|Combination drug|SGLT2 inhibitor and GLP-1 receptor agonist
45656614|NCT04860427|Device|trapezoidal condylar plate|trapezoidal condylar plate open reduction and fixation
45656615|NCT04860427|Device|two miniplates|two miniplates open reduction and fixation
45656616|NCT04839445|Procedure|General anesthesia + TAP block|Post induction TAP block for intra and postoperative analgesia.
45656617|NCT04839445|Procedure|General anesthesia + ESP block|Pre induction ESP block for intra and postoperative analgesia.
45656618|NCT04845841|Drug|Elinzanetant (BAY3427080) treatment A|Single oral dose
45656619|NCT04845841|Drug|Elinzanetant (BAY3427080) treatment B|Single oral dose
45656620|NCT04845607|Drug|Amiodarone Injection|Amiodarone continuous infusion during 24 hours from return of spontaneous circulation.
45656621|NCT04142515|Other|no intervention|no intervention
45656622|NCT04845763|Other|FQoR-15 questionnaire|The FQoR-15 questionnaire (French version) consists of 15 questions concerning five domains (the patient's feelings, comfort, pain, dependence on the health care team and psychological well-being). Two to three minutes are required to complete all the questions. If the patient is not able to read the questionnaire himself, a third person can ask the patient the questions orally. In the case of ambulatory surgery, the patient is contacted by telephone to answer the questionnaire. Each item is scored from 0 to 10 and the total score is the sum of the score obtained for each item, i.e. a score from 0 to 150.
45656623|NCT04853797|Drug|Ivabradine|To investigate the role of ivabradine on levcromakalim-induced migraine in patients with migraine without aura.
45807639|NCT04632992|Drug|Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf|PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab once every 3 weeks.
45807640|NCT04632992|Drug|Tucatinib|Tucatinib 300 mg will be administered orally BID continuously starting from Cycle 1 Day 1 onwards.
45943665|NCT00121563|Drug|Thalidomide, Ibuprofen or Diazepam|
45943666|NCT00293332|Biological|bevacizumab|Neoadjuvant therapy with 15 mg/kg, IV on Day 1 of each 21 day cycle for the first 2 cycles.
45943667|NCT00293332|Drug|carboplatin|Neoadjuvant therapy, AUC 6, IV on day 1 of each 21 day cycle for 3 cycles.
45943668|NCT00293332|Drug|docetaxel|Neoadjuvant therapy, 75 mg/m2, IV on day 1 of each 21 day cycle for 3 cycles.
45943669|NCT00293332|Procedure|conventional surgery|Standard surgery after 3 cycles of neoadjuvant therapy with docetaxel, carboplatin, and bevacizumab. Bevacizumab is given for the first 2 cycles only.
45943670|NCT00293371|Drug|docetaxel|
46075213|NCT00877123|Drug|Oral vitamin D 100,000 IU|Oral vitamin D 100,000 IU once a month for three consecutive months.
46075214|NCT00877123|Drug|Placebo|similar placebo once a month for three consecutive months
46075215|NCT00868777|Procedure|Sinus grafting using allogenic bone|Surgical bone grafting procedure oriented to provide enough bone volume in atrophic posterior maxillary segments, when placement of endosteal implants is planned in order to restore missing teeth.
45943671|NCT00293371|Drug|prednisone|
45943672|NCT00293371|Drug|vatalanib|
45943673|NCT05567276|Behavioral|Non-Violent Resistance parental training|Non-Violent Resistance parental training
45943674|NCT00293410|Drug|clofarabine|
45943675|NCT00293410|Drug|cyclophosphamide|
45656624|NCT04853797|Drug|Calcium|To investigate the role of calcium on levcromakalim-induced migraine in patients with migraine without aura.
45943676|NCT00121602|Drug|Darbepoetin Alfa|Initial dose, frequency and route of administration of study drug will be the same as that administered for darbepoetin alfa prior to enrollment. Frequency either once a week or once every two weeks, frequency may not change for duration of study. Route of administration either subcutaneous or intravenous, route of administration may not change for duration of study. Study drug provided in pre-filled syringes at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100 or 150 ug.
45943677|NCT00293488|Drug|polyamine analogue PG11047|
45656625|NCT04845529|Device|transcranial direct current stimulation (tDCS)|We will apply tDCS to the patients' brains for 20 minutes at the intensity of 1.5mA. Each patient will undergo the three sessions (separated by at least 24h to minimize carry-over effects), in a pseudo-randomized order across patients.
45656626|NCT04845295|Other|resistance training|Both experimental groups performed two exercises to target elbow flexor and knee extensor muscles: biceps curl on a Scott bench and parallel barbell squat, respectively. All sessions were performed at the same time (13-15 h), with a minimum 48 h rest between sessions on the same days during the week. For both groups, the intensity of load (1RM%) and number of sets were as follows: in the first three weeks the subjects exercises with ̴ 60% of 1RM in 3 sets, while during the next four weeks the load was set at ̴ 70% of 1RM in 4 sets. All repetitions were performed until muscular failure. The pause between sets was 2 minutes.
45656627|NCT04845373|Other|Mediterranean diet|Diet intervention:Mediterranean diet
45656628|NCT04845373|Other|Control diet: Low fat diet|Low fat diet
45656629|NCT03040531|Dietary Supplement|Genistein aglycone|27mg bid in tablets
45656630|NCT03040531|Drug|Alendronate Oral Tablet|70 mg/week in tablets
45807641|NCT04632992|Drug|Investigator's Choice of Chemotherapy|Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.
45656631|NCT03040531|Dietary Supplement|Calcium + vitamin D3 tablet|500mg Calcium + 200 IU Vitamin D3 bid in tablets
45656632|NCT03040375|Behavioral|Peer counselling|
45656633|NCT04839055|Drug|Coenzyme A Combined With Abiraterone|Abiraterone 4 pieces per day. Coenzyme A 200U
45656634|NCT04839055|Drug|Abiraterone|Abiraterone
45656635|NCT04838821|Biological|Anti SARS-CoV-2 equine hyperimmune serum|All participants in the treatment groups will receive a single intravenous infusion on day 1 containing the specified dose according to their assigned group 12mg/kg, 30 mg/kg or 56mg/kg. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
45656636|NCT04838821|Biological|placebo|All participants in the placebo group will receive a single intravenous infusion on day 1 containing a specified volume of a saline IV solution preparation. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
45807642|NCT04632992|Drug|Paclitaxel|The dose of paclitaxel is 80 mg/m2 administered by IV infusion on Days 1, 8, and 15 of each 28-day cycle. The paclitaxel infusion will be delivered over at least 60 minutes for each dose per institutional guidelines and administered after the oral dose of ipatasertib.
45807643|NCT04632992|Drug|Tiragolumab|Following the administration of atezolizumab and an observation period, participants will receive 600 mg tiragolumab at a fixed dose administered by IV infusion on Day 1 of each 21-day cycle.
45807644|NCT04632992|Drug|Pralsetinib|Pralsetinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg/day (four 100-mg capsules per day) once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
45943678|NCT00293527|Drug|Interferon Alpha-2b|
45943679|NCT00293605|Procedure|Total Hip Replacement|Implantation of one of 3 stem designs
45943680|NCT04711161|Drug|GRN-300|A salt-inducible kinase (SIK) inhibitor
45943681|NCT04711161|Drug|Paclitaxel|Microtubule inhibitor
45943682|NCT00293644|Drug|Diclectin®|Participants will begin with an initial dose of 20mg (2 tablets), taken at bedtime. The dose of Diclectin® will be adjusted to match symptoms.
45943683|NCT00293683|Device|Insorb absorbable skin staple|
45943684|NCT00293761|Drug|Travoprost, Investigational|One drop in study eye once daily for 13 days
45943685|NCT00293761|Drug|Travoprost (TRAVATAN)|One drop in study eye once daily for 13 days
45943686|NCT00293800|Drug|Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
45943687|NCT00293800|Drug|Latanoprost 0.005% Ophthalmic Solution (XALATAN)|Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
45943688|NCT00293800|Drug|Timolol 0.5% Ophthalmic Solution|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
45943689|NCT00293800|Other|Timolol Vehicle|Placebo
45943690|NCT00423969|Drug|Galantamine|
45943691|NCT00423969|Drug|Escitalopram|
45943692|NCT00293839|Drug|oxybutynin chloride|
45943693|NCT00293878|Drug|Disodium Ascorbyl Phytostanol Phosphate (FM-VP4)|
45943694|NCT00293917|Drug|Tacrolimus Cream|
45943695|NCT04710771|Other|Prone Lying Position|patient lies on his/ her stomach facing floor.
45943696|NCT04710771|Other|alternate nostril breathing|patient inspires with one nostril at a time, right or left one by one and expires by mouth.
45943697|NCT05567081|Drug|Triamcinolone Acetonide 40mg/mL|Deep perineural injection with 1cm corticosteroid mixed with 1ml lidocaine hydrochloride.
45807645|NCT04630028|Drug|Ustekinumab Dose Based on BSA and Body Weight|As per BSA and body weight Ustekinumab will be administered SC and IV.
45807646|NCT04630028|Drug|Matching Placebo|Placebo will be administered subcutaneously.
45656637|NCT04853485|Device|repetitive transcranial magnetic stimulation (rTMS)|All subjects with early psychosis will be divided into three subgroups determined by their psychotic symptoms and cognition. There are three rTMS strategies: (1) For subgroup 1, characterized by negative symptoms, iTBS over cerebellum and 1 Hz over right DLPFC; (2) For subgroup 2, characterized by cognition deficits, 20 Hz over the left inferior parietal cortex; (3) For subgroup 3, characterized by positive symptoms: 10 Hz over ACC.
45656638|NCT04838665|Drug|0.5% cyclopentolate and 2.5% phenylephrine|Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI) dropped every 5 minutes for two doses
45943698|NCT05567081|Drug|PRP|Deep perineural injection with 3ml PRP at the thickest part of the ulnar nerve.
45943699|NCT00294034|Device|Pacemaker|
45943700|NCT00294073|Procedure|Fascia Iliaca Block|
45943701|NCT00294073|Procedure|Femoral Block (with stimulating catheter)|
45943702|NCT00294073|Procedure|Femoral Block (without stimulating catheter)|
45943703|NCT04710927|Device|Silver Diamine Fluoride|A single application of SDF 38% (Riva Star) on dry affected molar for 1 minute and immediately restored using HVGIC
45943704|NCT04710927|Device|Papain-Based Gel|Papain based Gel (Papacarie Duo) will be applied to the MIH affected molar for 60 seconds and repeated if required. The molar will be treated with SDF and restored using HVGIC
45943705|NCT04710927|Device|High Viscosity Glass Ionomer Cement|The molar will be restored with HVGIC
45943706|NCT05567042|Other|No intervention|No intervention
45656639|NCT04838665|Drug|0.5% tropicamide + 0.5% phenylephrine|Single instillation of 0.5% tropicamide + 0.5% phenylephrine
45656640|NCT04838665|Drug|0.5% tropicamide + 0.5% phenylephrine with a cotton wick|Single instillation of 0.5% tropicamide + 0.5% phenylephrine with a cotton wick weighing 0.02 milligrams placed in the inferior fornix for the entire 45 minutes
45656641|NCT03038659|Device|Penile Duplex|Measuring intima media thickness
45656642|NCT04845061|Drug|Nebivolol Tablets|cardio selective beta-1 blocker
45656643|NCT03040765|Drug|Denosumab 60 MG/ML Prefilled Syringe|Denosumab 60 MG/ML will be administered to 20 patients with b-thalassemia major
45807647|NCT04629599|Behavioral|Interpersonal psychotherapy for major depression following perinatal loss|Participants in the IPT condition will receive 12 group sessions and 2 individual (pre-group and 1-month booster) sessions as outlined in the manual The individual sessions prepare patients to use the group effectively, to keep group members focused on their treatment goals, and to maintain treatment gains. In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. These sessions are important because relationship distress is common following perinatal loss. Our IPT intervention allows new women to enter the group every 4 weeks of the 12-week group. Group sessions are semi-structured, and each woman will cover the four group topics three times, approaching each topic from a different stage in the mourning process.
45943707|NCT00294112|Drug|Prochymal™ adult human mesenchymal stem cells|Cells in plasmalyte and containing dimethylsulfoxide
45943708|NCT00294112|Drug|adult human mesenchymal stem cells|two infusions, one week apart, each comprising adult human mesenchymal stem cells
45943709|NCT00294151|Procedure|Vertebroplasty|
45943710|NCT00417820|Drug|BCT194|
45943711|NCT00089271|Drug|alvespimycin hydrochloride|Given IV
45453088|NCT00042289|Drug|atazanavir/ritonavir dosage #1|atazanavir/ritonavir 300/100 mg once a day
45453089|NCT00042289|Drug|didanosine delayed release (Videx® EC)|didanosine delayed release (Videx® EC) 400 mg once a day if weight > 60 kg; 250 mg once a day if weight < 60 kg
45453090|NCT00042289|Drug|emtricitabine|emtricitabine 200 mg once a day
45656644|NCT03040765|Drug|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic Acid 5Mg/Bag 100Ml Inj will be administered to 20 patients with b-thalassemia major
45943712|NCT00089271|Other|laboratory biomarker analysis|Correlative studies
45943713|NCT00417898|Drug|Aspirin|
45943714|NCT00294190|Drug|Topotecan|Topotecan 6mg/m2 IV weekly x 6 consecutive weeks followed by a 2 week break.
45943715|NCT00294229|Procedure|manipulative therapy|
45943716|NCT05565872|Behavioral|Urban training|A community-based exercise intervention (Urban Training) by using public spaces and urban walkable trails, adapted to each patient needs and capabilities
45943717|NCT02960503|Drug|Azithromycin|Study participants will be randomized to the treatment arm (azithromycin 500 mg three times a week for 6 months).
45943718|NCT02960503|Other|Placebo|Study participants will be randomized to the control arm (placebo three times a week for 6 months).
45943719|NCT00089310|Radiation|technetium-99|0.25 mCi in 4 equal doses
45943720|NCT00294268|Behavioral|cognitive behavioural therapy|20 weekly sessions of CBT integrated with motivational enhancement strategies
45943721|NCT00294307|Behavioral|Augmented Standard Care (ASC)|Standard hospital care and, if referred, home care plus early identification of CI during the patients' hospitalization by trained research assistants with immediate verbal feedback and documentation to patients' primary nurses, attending physicians and discharge planners [low intensity];
45943722|NCT00294307|Behavioral|Resource Nurse Care (RNC)|Standard hospital and, if referred, home care plus early identification of CI during the patient's hospitalization (ASC) and hospital care by RNs trained in the use of expert clinical guidelines developed to enhance the care management of hospitalized cognitively impaired elders and to facilitate their transition from hospital to home [medium intensity];.
45656645|NCT04853953|Other|Incidence of bleeding complications in ARDS patients on veno-venous ECMO|All bleeding complications (especially cerebral bleedings) will be analyzed in the study groups. At the bleeding event, laboratory parameters of coagulation will be collected and the intensity of the ECMO treatment
45807648|NCT04629599|Behavioral|Coping with Depression|The Coping with Depression (CWD) course is a structured, manualized psycho-educational group treatment for MDD. The CWD course is based on social learning theory which posits that depression is associated with a decrease in pleasant and an increase in unpleasant person-environment interactions. The problems shown by depressed individuals are viewed as behavioral, with cognitive patterns that can be unlearned or relearned. Its effectiveness is comparable to other forms of psychotherapy in depression. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. As in the pilot trial, CWD will consist of an individual pregroup session, 12 group therapy sessions (allowing new women to enter every 4th session) and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
45943723|NCT00294307|Behavioral|Advanced Practice Nurse Care (APNC)|Standard hospital care plus ASC and transitional care starting in the hospital and substituting for standard home care and provided by Advanced Practice Nurses (APNs) with advanced training in the management of CI patients using an evidence-based protocol designed specifically for this patient group and their caregivers [high intensity].
45943724|NCT05565521|Radiation|Dose escalation + Reduced Margin Adaptive Radiotherapy|Concurrent chemoradiation with temozolomide (TMZ) over 3 weeks (40Gy in 15 fractions). The gross tumor volume (GTV) plus margin will be boosted simultaneously (SIB) to 52.5 Gy in 15 fractions. Radiation will be delivered on the MR-Linac with a reduced clinical target volume (CTV) margin of 5 mm and a weekly online adaptive approach.
45943725|NCT00294346|Drug|AV608|
45943726|NCT04706091|Drug|Suvorexant|10-mg or 20-mg suvorexant capsules
45943727|NCT04706091|Other|Placebo|Matching placebo capsules
46075216|NCT00873223|Drug|liraglutide|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
46075217|NCT00873223|Drug|insulin detemir|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
46075218|NCT00873301|Procedure|vestibulectomy|Evaluation of the outcome of vestibulectomy which is the treatment of vulvar vestibulitis
46075219|NCT00873379|Dietary Supplement|melatonin|one half of a 1 mg tablet of GNC rapid dissolving Melatonin, NPN (natural product number) 80001380, available over the counter in Canada
46075220|NCT00873379|Dietary Supplement|placebo|half a white placebo tablet
46075221|NCT03489174|Other|Monthly Pregnancy Screening|Pregnancy test will be administered once per month during weekly urine testing for drug levels.
46075222|NCT03489174|Other|Usual Care|Usual care.
46075223|NCT00877201|Drug|CDR2|
46075224|NCT02787486|Other|Blood sampling for Laboratory Developed Test (LDT) analysis|Each enrolled subject, either in the first or second trimester, will donate up to 50 mL (just over 3 tablespoons) of whole blood for development of the LDT
46075225|NCT00868855|Drug|Bradykinin|Bradykinin, 0.2 ug - 2ug/minute, one time intracoronary infusion over 6 minutes. Drug (bradykinin) will be infused into the left main coronary artery via diagnostic catheter (JL4) at an escalating rate of 0.2, 0.6, 2 g/ml (1ml/min). A 5F Multipurpose catheter will be advanced to coronary sinus for blood sampling.
46075226|NCT00615901|Drug|cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim|C (cyclophosphamide) 600 mg/m2 M (methotrexate) 40 mg/m2 F (fluorouracil) 600 mg/m2 P (PEG-filgrastim ) 6 mg. Eight doses of CMF q 14 days with PEG-filgrastim administered approximately 24 hours after chemotherapy. Day 14, is also considered day 1 of the next cycle.
45807649|NCT04629547|Drug|Suvorexant 20 mg|Suvorexant 20mg will be taken nightly for 24 months.
45807650|NCT04629547|Drug|Placebo|Placebo will be taken nightly for 24 months.
45943728|NCT00294385|Drug|Docetaxel|
46075227|NCT03436290|Behavioral|Palliative Care Intervention|These patients will receive the palliative care intervention.
46075228|NCT03842683|Other|CGM|This study seeks to assess CGM accuracy and develop prediction models for hypoglycemia detection and no intervention is therefore applied.
45453091|NCT00042289|Drug|tenofovir|tenofovir 300 mg once a day
45453092|NCT00042289|Drug|nelfinavir dosage #1|nelfinavir [625 mg tablets] 1250 mg twice a day
45453093|NCT00042289|Drug|tipranavir/ritonavir|tipranavir/ritonavir 500/200 mg twice a day
45656646|NCT01668667|Drug|GSK1838262 600 mg|Drug: GSK1838262 600 mg/day Comparison of 3 doses
45656647|NCT01668667|Drug|GSK1838262 450 mg|Drug: GSK1838262 450 mg/day Comparison of 3 doses
45656648|NCT01668667|Drug|GSK1838262 300 mg|Drug: GSK1838262 300 mg/day Comparison of 3 doses
45656649|NCT01668667|Drug|GSK1838262 Placebo match|Drug; GSK1838262 placebo to match 600 mg, 450 mg, 300 mg doses
45807651|NCT04629339|Drug|INCB086550|INCB086550 will be administered orally twice a day.
45943729|NCT00294385|Drug|Gemcitabine, Docetaxel|Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
45943730|NCT00294385|Drug|Docetaxel|rm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
46075229|NCT02791074|Other|NTproBNP|To assess its level in the blood, as a marker of heart failure presence and severity.
46075230|NCT02791074|Other|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
46075231|NCT02791074|Other|Arterial tonometry|A noninvasive method to obtain arterial pressure waveform.
46075232|NCT05353842|Behavioral|WOWii Program|Workout on Wheels Internet Internvention (WOWii) which includes: 1) WOWii website to guide participants in an exercise program, 2) home exercise starter program; 3) weekly support from a peer facilitator via online (video) meetings.
45807652|NCT04627922|Drug|N-Acetyl cysteine|The investigators will examine N-acetyl cysteine to treat concurrent tobacco use disorder and cannabis use in a double-blind, placebo-controlled RCT. Sixty regular cigarette smokers with current tobacco use disorder and cannabis use will be randomized to receive NAC 3600 mg per day over 8 weeks.
45807653|NCT04627922|Other|Placebo comparator|The investigators will examine N-acetyl cysteine to treat concurrent tobacco use disorder and cannabis use in a double-blind, placebo-controlled RCT. Sixty regular cigarette smokers and cannabis users with current tobacco use disorder will be randomized to receive placebo per day over 8 weeks.
45943731|NCT05564156|Behavioral|Intervention groups|The drugs used by the participants within 24-48 hours after hospitalization were recorded. In the case of new prescribing, the recommendations made by the investigators to the physician are recorded in intervention group. The medication reconciliation report will be evaluated before the discharge of the participants and possible omissions discussed with the physician in charge. A detailed medication review will be accomplished by the investigators during the hospitalization of the participants.
45807654|NCT04627922|Behavioral|Cognitive behavioral therapy (CBT)|Participants in both groups will receive 8 weekly cognitive behavioral therapy sessions for substance use disorder targeting both tobacco and cannabis use.
45807655|NCT04622306|Device|Control Latex Condom C, Polyurethane Condom A, Polyurethane Condom B|Condom functionality study to determine failure rates
45943732|NCT00294424|Procedure|Short waiting time|
45656650|NCT04852939|Other|Bowen's technique|"Initially, cup move is performed which requires a vertically rolling Bowen move over the posterior border of the deltoid muscle above the axillary crease.~The subject's arm is held flexed at 90 degrees at mid-chest height. Then, the elbow is slowly and passively moved in the direction of the opposite shoulder.~After maximal adduction of the arm, the therapist firmly taps the lateral aspect of the shoulder with the heel of his/her hand.~The arm is then carried back to the original start position, where the therapist gently moves superiorly and slightly laterally over the anterior fibers of the deltoid. The arm is then carefully lowered.~The therapist strives to undertake a minimum of moves and procedures to trigger the body's own self-healing powers and assess how much pressure to use and where and when to perform a move to release the build-up of stress.~40-minute sessions thrice a week for 6 weeks."
45656651|NCT04852939|Other|Conventional physical therapy|"Hot pack and transcutaneous electrical nerve stimulator (TENS) for 15 minutes.~Pendulum stretch, 10 revolutions.~Cross body stretch, 4 repetitions.~Towel stretch/hand behind the back, 4 repetitions.~Isometric internal and external rotation exercises. 40-minute sessions thrice a week for 6 weeks."
45943733|NCT00294424|Procedure|Non-fixed waiting time|
45943734|NCT00294463|Drug|Tibolone|
46075233|NCT00868933|Other|Low glycemic index dietary intervention program|The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.
46075234|NCT00868933|Other|simple lifestyle advice|The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
45656652|NCT03040219|Drug|Folic Acid|Tablets
45807656|NCT04621448|Behavioral|Moving Together|"Two-way livestreaming virtual group classes will be offered for 1 hour, 2 days/week for 12 weeks to all participants. Classes will be led by a trained instructor who will demonstrate all movements and will provide brief explanations for the goals of movements. Consistent with the in-person program, classes will focus on the 7 guiding principles of Moving Together:~repetition with variation (to promote procedural learning);~progressive, functional movements (to improve daily function);~slow pace and step-by-step instruction (to minimize cognitive demands);~participant-centered goal orientation (to enhance personal meaningfulness of movements);~body awareness, mindfulness and breathing (to encourage present-centeredness);~social interaction (to promote meaningful connection); and~positive emotions (to promote feelings of well-being."
45807657|NCT04619420|Drug|JNJ-63733657|JNJ-63733657 low or high dose will be administered by IV infusion.
45807658|NCT04619420|Drug|Placebo|Placebo matching to JNJ-63733657 will be administered by IV infusion.
45943735|NCT00294463|Drug|Estradiol|
45943736|NCT00294463|Drug|Estradiol + Medroxy Progesterone Acetate|
45943737|NCT00294502|Drug|Gentamycin/citrate, Minocycline/EDTA|
45943738|NCT00089349|Biological|alemtuzumab|Given IV
46075235|NCT02788422|Other|Video discharge instructions|Online video containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
46075236|NCT02788422|Other|Standard of Care|One page paper handout containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
46075237|NCT00869011|Other|Endurance exercise|Endurance exercise, 3 times weekly for 35-45 minutes, 12 weeks.
45943739|NCT00089349|Drug|methotrexate|Given IV
45943740|NCT00089349|Drug|mercaptopurine|Given PO
45943741|NCT00294541|Drug|ICA-17043|
45943742|NCT05562908|Procedure|Pedicled|Surgical procedure: A prior marking was made on both sides of the LIMA and its veins with bi-polar technique. Hereafter the LIMA and its veins were dissected free with scissor and forceps. Clips were added to all side branches. When the full length of LIMA was obtained, the LIMA and its veins were divided distally by adding clips on the peripheral part of the vessels and proximately dividing by scissor. A vessel-clamp was placed distally and the pedicled LIMA placed in the jugular cavity with a cloth containing papaverine.
45943743|NCT05562908|Procedure|Surgical skeletonised|Surgical procedure: The fascia of the LIMA was opened with a scissor. Hereafter the LIMA was dissected free with scissor and forceps, clips on all LIMA side-branches and divided by scissor. When the full length of LIMA was obtained, the LIMA was divided distally by adding clips on the peripheral part of the vessel and proximately dividing by scissor. A vessel-clamp was placed distally, and the skeletonised LIMA placed in the jugular cavity with a cloth containing papaverine.
46075238|NCT02790918|Other|6MWT|Each patient will also receive 6MWT at cardiovascular rehabilitation and preventive cardiology laboratory. Besides the distance covered in meters or converted measure (such as feet) over 6 minutes, a portable metabolic system is used to measure oxygen uptake during exercise (VO2 testing) for each patient.
46075239|NCT02790918|Other|Cardiovascular Magnetic Resonance Imaging (CMRI)|MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
46075240|NCT00616603|Drug|Ropivacaine|20 ml of 0.2% ropivacaine injected locally as regional anesthesia given once.
45656653|NCT03038503|Drug|Methylene Blue|after defined refractory shock (need NE>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr*4 hr (intervention add on to standard care)
45656654|NCT03038503|Drug|Terlipressin|after defined refractory shock (need NE>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
45656655|NCT02608879|Procedure|Oral Mucosa Deterging and Periodontal Debridement (OMDP)|OMDP consists of a regimen of frequent professional oral prophylaxis including tooth cleaning, tooth polishing and flossing, and the cleaning of the periodontum and oral mucosa. This is an intervention that is implemented prior to and maintained throughout the entire cycle of the radiation or chemoradiation.
45656656|NCT02608879|Procedure|Standard of Care Oral Hygiene Instructions|Subjects assigned to this intervention will receive standard of care oral hygiene instructions, including in-person instruction and materials to reference at home. Subjects will also have their teeth brushed and flossed bi-weekly by a dental professional.
45656657|NCT02608879|Procedure|Dental scaling, ultrasonic|An ultrasonic dental scaler will be used to clean the teeth
45656658|NCT02608879|Other|Chlorhexidine|Non-alcoholic chlorhexidine will be used as part of the OMDP protocol
45807659|NCT04617938|Behavioral|TACUNA plus Wellness Circle|TACUNA provides three virtual workshops (one hour each) that use motivational interviewing and a virtual Wellness Circle (WC). The workshops combine a 30-minute discussion of opioid, alcohol and marijuana use, and social networks with another 30 minutes focused on three different traditional practices (one per workshop). TACUNA was adapted from our three-session workshop, MICUNAY (Motivational Interviewing and Culture for Urban Native American Youth) protocol, which was developed and tested for urban AI/AN adolescents and from focus groups conducted in Year 1. For the Wellness Circle, youth will have members of their social network virtually attend these once-a-month gatherings. The WC will bring people together to celebrate health and wellness and tradition. The WC will focus on the importance of social networks in making healthy choices, and provide discussion on the role that AOD use and engagement in traditional practices among members of their social networks affect their choices.
45656659|NCT04852549|Other|Oculomotor exercise|"While holding the head in the middle position, holding two colored objects in both hands, looking at the object in the right hand without turning the head, counting up to 10 and looking at the object in the left hand and counting up to 10,~While holding a fixed head in the middle position and holding a colored object in the right hand, following the object with the eyes while moving the right hand from right to left without turning the head and returning,~With the head fixed in the middle position, with the right hand on the left, eyes are fixed on the hand-held colored object and turn the head to the right and left.~The head will be fixed in the middle position, the eyes will be fixed on the colored object held in the right or left hand and the arm and the head will be turned to opposite directions."
45656660|NCT04142125|Drug|Rivaroxaban 2.5 Mg Oral Tablet bid|Pts will receive rivaroxaban + aspirin
45656661|NCT04142125|Drug|Acetylsalicyclic acid 81 mg tablet qd|Pts will receive ASA
45656662|NCT04852393|Procedure|Block|cervical medial branch block
45656663|NCT04852705|Biological|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
45656664|NCT04852705|Biological|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
45656665|NCT03040297|Device|Tracheal gas insufflation 6 L/min|Endotracheal flow (6 L/min) of respiratory gases with standard FiO2
45656666|NCT03040297|Device|Tracheal gas insufflation 11 L/min|Endotracheal flow (11 L/min) of respiratory gases with standard FiO2
45656667|NCT03040297|Device|Tracheal gas insufflation catheter, without gas flow|Tracheal gas insufflation catheter, without gas flow
46075241|NCT00616603|Drug|Dexamethasone|8mg Dexamethasone injected locally along with ropivacaine for regional anesthesia given once.
46075242|NCT00616603|Drug|Dexamethasone|2ml(8mg)Dexamethasone given once intravenously.
46075243|NCT00616603|Drug|Normal Saline|2ml of normal saline given once intravenously.
46075244|NCT02787330|Behavioral|Control Group|Sessions will not be designed around a specific theme related to childhood cancer and sibling relationships. Activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
45807660|NCT04617938|Behavioral|Opioid Education Workshop|The virtual opioid education workshop draws from prevention and education materials supplied and recommended by the National AI/AN Technology and Transfer Center, which is funded by SAMHSA. Materials are culturally relevant educational packages addressing opioid use through recorded webinars, toolkits, and other resources.
45943744|NCT05562908|Procedure|Thunderbeat skeletonised|Surgical procedure: With Thunderbeat the fascia of LIMA was opened. The LIMA was dissected free with Thunderbeat including all side-branches. When the full length of the LIMA was obtained, the LIMA was divided distally by adding clips on the peripheral part of the vessel and proximately dividing by scissor. A vessel-clamp was placed distally, and the skeletonised LIMA placed in the jugular cavity with a cloth containing papaverine.
45943745|NCT00294580|Drug|Maloprim|
45656668|NCT04852315|Dietary Supplement|Caffeine|Gelatine capsule with caffeine (3 mg/kg body mass of caffeine) (Bulk Powders, London, United Kingdom). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
45656669|NCT04852315|Dietary Supplement|Placebo|Gelatine capsule with placebo (Cellulose; Guinama, Valencia, Spain). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
45656670|NCT03038425|Drug|Normal Saline|This is the placebo intervention - normal saline infused in the adductor canal via a catheter. There are no anticipated therapeutic effect
45943746|NCT00294619|Drug|growth hormone|subcutaneous injection, once-weekly
45943747|NCT00089388|Drug|cilengitide|Given IV
45656671|NCT03038425|Drug|Ropivacaine|This is the treatment intervention - ropivacaine 0.2% infused in the adductor canal via a catheter. This will provide analgesia to the knee after TKA
45943748|NCT05562479|Biological|Sars Cov 2 infection|Donors recovered from Sars Cov 2 Infection
45943749|NCT05562479|Biological|Sars Cov 2 vaccination|Egg Donors vaccinated
45943750|NCT00294736|Drug|Tarceva|Dose Escalation: 150-350+ mg/day
45943751|NCT00294775|Drug|Candesartan|
45453094|NCT00042289|Drug|lopinavir/ritonavir dosage #4|lopinavir/ritonavir (Kaletra) tablets 600/150 mg [3 tablets] twice a day
45656672|NCT03038191|Device|Neuroelectrics Enobio 8(R)|Monitoring
45943752|NCT00121680|Drug|E7080|Oral.
45943753|NCT00294814|Device|Proximal anastomosis using Heartstring anastomotic device|
45943754|NCT00294853|Procedure|MDCT calcium score|
45943755|NCT00294892|Drug|carbamazepine and nevirapine|Carbamazepine 400mg and Nevirapine 200mg are taken just before delivery during labor.
45943756|NCT00294892|Drug|Nevirapine|Nevirapine 200mg is taken prior to delivery during labor.
45943757|NCT00089427|Drug|IL13-PE38QQR|
45943758|NCT00089427|Procedure|Surgery for placement|
45943759|NCT00089427|Procedure|Radiation therapy|
45943760|NCT00089427|Drug|Temozolomide with radiation therapy|
45943761|NCT00294931|Drug|irinotecan|
45943762|NCT00294931|Drug|carboplatin|
45943763|NCT00294931|Drug|bevacizumab|
45943764|NCT00295048|Behavioral|Computer Assisted Cognitive Remediation (CACR)|
45656673|NCT04844047|Other|Exercise|refer to arm descriptors
45656674|NCT04844047|Other|Exercise|refer to arm descriptors
45656675|NCT04843969|Behavioral|Stress induction|Exposure to a psychosocial stressor
45656676|NCT04843969|Behavioral|Control stress exposure|Exposure to a control task (no stress)
45656677|NCT04843969|Behavioral|Cue induction|Exposure to a smoking-related task
45656678|NCT04843969|Behavioral|Neutral cue exposure|Exposure to neutral cues
45807661|NCT04615403|Drug|Travoprost|Implantation and exchange of a Travoprost Intraocular Implant through a clear corneal incision
45807662|NCT04614246|Drug|BAY1817080|Tablet, oral administration
45807663|NCT04614246|Drug|Elagolix|Tablet, oral administration
45807664|NCT04614246|Drug|Placebo|Tablet, oral administration
45943765|NCT02958423|Device|Transcranial DCS Healthy Volunteers|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of healthy volunteers
45943766|NCT02958423|Device|Transspinal DCS Healthy Volunteers|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of healthy volunteers
45807665|NCT04611802|Biological|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.
45656679|NCT04851769|Drug|PCSK9 inhibitor plus statin|Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
45943767|NCT02958423|Device|Transcranial DCS CPP patients|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of CPP patients
45656680|NCT04851769|Drug|standard statin therapy|Patients will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day.
45656681|NCT04851769|Procedure|Coronary imaging follow-up|coronary angiography and OCT imaging at week 36 ± 2 weeks follow-up
45656682|NCT04843813|Dietary Supplement|Lutein|Participants will consume daily soft gels containing the lutein supplement.
45656683|NCT04843813|Dietary Supplement|Placebo|Participants will consume daily soft gels containing the safflower oil.
45943768|NCT02958423|Device|Transspinal DCS CPP patients|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of CPP patients
46075245|NCT02787330|Behavioral|Experimental Group|The experimental group will be detailed, session by session, in the manual written for this purpose. It addresses on topic per session (respecting each other, medical information about cancer, family relationships, sibling's fears and feelings, relationship between siblings, relationships at school, generating hope.
45807666|NCT04611802|Other|Placebo (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.
46075246|NCT00873535|Drug|Varenicline|This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
45807667|NCT04611802|Biological|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)|In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0 or Day 21
45807668|NCT04611802|Other|Placebo (Crossover Vaccination period)|In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of placebo (0.5 mL) on Day 0 or Day 21
46075247|NCT00873535|Drug|Placebo|This group (n=40) will receive matching placebo capsules in the identical dosing regimen described for the Varenicline arm. The group will consist of heavy smokers who are heavy drinkers (n=20) and heavy smokers who are social drinkers (n=20).
46075248|NCT02787174|Other|Asthma Medication Adherence Education|
46075249|NCT02790996|Drug|Vancomycin|Vancomycin is an antibiotic used to treat a number of bacterial infections.It is recommended intravenously as a treatment for complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant S. aureus.
46075250|NCT00810693|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1mg tid - 2.5mg tid orally for 12 weeks
45656684|NCT04851925|Other|MR Fingerprinting|Specific Magnetic Resonance Imaging protocol
45656685|NCT04843189|Procedure|Da Vinci Robotic Surgery|Da Vinci Robotic Surgery
45656686|NCT04843267|Drug|Tislelizumab|Tislelizumab in first-line treatment of Hodgkin's lymphoma
45656687|NCT04843657|Behavioral|Observation for symptom distress|Observation for symptom distress
45807669|NCT04611802|Biological|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)|In Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
45807670|NCT04611802|Biological|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)|In Second Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
45943769|NCT00295126|Procedure|cellular therapy : Autologous platelet concentrate (APC)|
46075251|NCT00810693|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1.5mg tid orally for 12 weeks
45453095|NCT00042289|Drug|raltegravir|raltegravir 400 mg twice a day
45656688|NCT04838899|Radiation|Stereotactic Body Radiation Therapy (SABR)|SABR to oligoprogressive metastases while continuing abiraterone therapy
45943770|NCT00295165|Drug|Sargramostim (Leukine)|Sargramostim 6 mcg/kg subcutaneously once daily
45807671|NCT04609826|Drug|JNJ-74856665|JNJ-74856665 will be administered orally.
46075252|NCT00810693|Drug|Placebo|Matching Placebo tid orally for 12 weeks
46075253|NCT00573313|Drug|S-adenosylmethionine|Alcoholic liver disease patients received drug at dose of 400 mg three times daily for 24 weeks.
46075254|NCT00573313|Drug|Placebo|Alcoholic liver disease patients received identical size and shape sugar pill placebo three times daily for 24 weeks.
46075255|NCT02790840|Drug|Omeprazole|20 mg oral capsules administered once daily for 10 days
46075256|NCT02790840|Drug|Omeprazole|40 mg oral capsules administered twice daily for 10 days
46075257|NCT02790840|Drug|Gefapixant|Gefapixant oral tablets (15 mg administered as two 7.5 mg tablets) administered twice daily for 15 days
45453096|NCT00042289|Drug|etravirine|etravirine 200 mg twice a day
45807672|NCT04609826|Drug|AZA|AZA will be administered IV infusion or SC injection.
45807673|NCT04609826|Drug|VEN|VEN tablet will be administered orally.
45943771|NCT00295165|Drug|Placebo|Placebo subcutaneously once daily
45943772|NCT02958618|Procedure|"30 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 30 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
45943773|NCT02958618|Procedure|"60 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 60 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
45943774|NCT02958618|Procedure|"180 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18 ) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 180 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
45943775|NCT02960464|Device|Transcranial direct current stimulation|
45943776|NCT02960464|Device|Sham Transcranial direct current stimulation|
45943777|NCT00121758|Biological|LIPO-5|
45943778|NCT00295243|Drug|Topotecan|
46075258|NCT02790840|Drug|Gefapixant|Gefapixant oral tablets (30 mg administered as four 7.5 mg tablets) administered twice daily for 15 days
46075259|NCT05225779|Diagnostic Test|12- derivation Electrocardiography|6 precordial and 4 extremity electrodes will be placed at appropriate anatomical points and a total of 6 12-lead ECGs will be taken at different anesthesia depths before anesthesia induction and throughout the operation.
45656689|NCT03037957|Device|ARIES Group A Strep Assay|
45453097|NCT00042289|Drug|maraviroc|maraviroc 150 mg or 300 mg twice a day
45453098|NCT00042289|Drug|atazanavir/ritonavir dosage #2|atazanavir/ritonavir 400/100mg once a day
45453099|NCT00042289|Drug|tenofovir/atazanavir/ritonavir dosage #2|tenofovir/atazanavir/ritonavir 300/400/100 mg once a day
45453100|NCT00042289|Drug|nelfinavir dosage #2|nelfinavir [625 mg tablets] 1875 mg twice a day
45807674|NCT04609020|Device|JUVÉDERM|JUVÉDERM VOLBELLA with Lidocaine Treatment of any fine lines and medium-sized skin depressions. Can also be used for enhancement and pouting of the lips to correct structural defects such as asymmetry, contour deformities, volume loss. JUVÉDERM VOLIFT with Lidocaine Intended for the treatment of any deep skin depressions due to conditions such as premature aging. Can also be used for face contouring and volume restoration to correct facial structural defects such as asymmetry, contour deformities, volume loss in the lips, cheeks, chin, lower face. JUVÉDERM VOLUMA with Lidocaine Intended to restore volume of the face JUVÉDERM VOLITE with Lidocaine Intended for treatment, by filling, of superficial cutaneous depressions such as fine lines and for additional improvement of skin quality attributes such as hydration and elasticity. JUVÉDERM VOLUX with Lidocaine Intended to restore and generate facial volume in chin and mandible areas
45807675|NCT04609020|Drug|BOTOX|Indicated for the treatment of hyperkinetic facial lines.
45807676|NCT04609020|Device|HArmonyCA Lidocaine|HArmonyCa Lidocaine injectable gel is a dermal filler intended for facial soft tissue augmentation.
45943779|NCT00295282|Drug|MDX-1100 (anti-CXCL10 human monoclonal antibody)|Patients will receive a single dose of MDX-1100 at 0.3, 1.0, 3.0 or 10 mg/kg as a 60 minute intravenous infusion. Patients who respond to treatment may receive up to an additional 3 doses of MDX-1100.
45943780|NCT00295360|Behavioral|no intervention, pathophysiological study|
45943781|NCT00121797|Procedure|urine culture|
45943782|NCT00121797|Drug|antibiotics according to culture|
45943783|NCT00295399|Device|The Jerusalem Telerehabilitation System|
45943784|NCT00295438|Device|Robot-Based Tele-Echography (TER)|Robot-Based Tele-Echography, ultrasound performed by the radiologist
45943785|NCT00295438|Device|ultrasound method FAST|FAST,ultrasound performed by the emergency doctor
45943786|NCT00295477|Genetic|VRX496|In Step 1 of the protocol, each subject will receive up to 2 cycles of VRX496. Each treatment cycle consists of 3 infusions of VRX496.
45943787|NCT00295516|Procedure|Fetal Middle Cerebral Artery Doppler measurement|
45453101|NCT00042289|Drug|indinavir/ritonavir dosage #2|indinavir/ritonavir 400/100 mg twice a day
45453102|NCT00042289|Drug|rilpivirine|rilpivirine (25 mg q.d.)
45656690|NCT04852081|Drug|Palbociclib|Palbociclib is in the form of oral capsules. Palbociclib, capsule, 125 mg taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbociclib should be taken with food
45656691|NCT04852081|Drug|Ribociclib|Ribociclib, tablets, 600mg orally (three 200 mg tablets)taken once daily with or without food for 21 consecutive days followed by 7 days off treatment
45656692|NCT04852081|Drug|Abemaciclib|Abemaciclib in combination with fulvestrant or an aromatase inhibitor: 150 mg twice daily Abemaciclib as monotherapy: 200 mg twice daily. (2.1)
45656693|NCT04852081|Drug|Letrozole|Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
45943788|NCT00089622|Drug|Intravenous Levodopa|
45943789|NCT00089622|Drug|Lisuride Transdermal System|
45943790|NCT00295555|Drug|Effects of doxazosin on morning surge in diabetic patients|
45943791|NCT05524727|Other|Concept-guided, personalized, motor-cognitive training by means of an exergame|12 weeks, two times per week for 30-40min
45943792|NCT00295594|Drug|tacrolimus|Immunosuppression
46075260|NCT02362997|Drug|Pembrolizumab|Anti-PD-1 monoclonal antibody
46075261|NCT02790762|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion, and repeated every week for four times.
45943793|NCT00121875|Drug|somatropin (rDNA)|"Form/Strength: 10 mg aqueous suspension; 5 mg/ml~Dosage/Frequency: 0.35 mg/kg/week, daily divided doses~Duration: 6 months with 3-month washout period"
45453103|NCT00042289|Drug|darunavir/ritonavir dosage #4|darunavir/ritonavir once daily 800/100 mg q.d.
45656694|NCT04852081|Drug|Anastrozole|Anastrozole will be dosed daily at a fixed dose of 1 mg/day throughout the study.
45656695|NCT04852081|Drug|Tamoxifen|Tamoxifen will be dosed daily at a fixed dose of 20 mg/day throughout the study.
45807677|NCT04608539|Drug|Ferric Derisomaltose|Single-dose intravenous infusion, 20 mg/kg body weight, postoperative day 1
45807678|NCT04608539|Drug|Ferrous sulfate|Oral therapy, 100 mg twice daily, from postoperative day 4 until 4-week follow-up
45656696|NCT04852081|Drug|Fulvestrant|Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
45656697|NCT04852081|Drug|Exemestane|Exemestane will be dosed daily at a fixed dose of 25mg/day throughout the study.
45656698|NCT04852081|Drug|Alpelisib|Alpelisib will be dosed daily at a fixed dose of 300 mg/day throughout the study.
45807679|NCT04608539|Drug|normal saline|Single-dose infusion (placebo), postoperative day 1
45807680|NCT04607044|Device|SALVATION™ EXTERNAL FIXATION|Wright Medical's lower extremity devices used to treat neuropathic patients
45807681|NCT04606381|Drug|Ami-LC-MD|Participants will receive amivantamab admixed with rHuPH20 SC infusion.
45807682|NCT04606381|Drug|Ami-LC|Participants will receive amivantamab SC infusion.
45807683|NCT04606381|Drug|Ami-HC|Participants will receive amivantamab SC infusion.
45943794|NCT00295672|Drug|Vinorelbine|
45943795|NCT05500001|Behavioral|Supporting Patients by Family Education in Psychotic Illness Group|Psychoeducation for families supporting young adults with psychosis.
45943796|NCT00295711|Drug|Bicifadine|
45943797|NCT00295789|Drug|chemotherapy: Paclitaxel/Cisplatin|Drug: chemotherapy: Paclitaxel/Cisplatin
45943798|NCT00295789|Drug|chemotherapy: Paclitaxel/Carboplatin|Drug: chemotherapy: Paclitaxel/Carboplatin
45943799|NCT00089700|Drug|TNX-355|
45943800|NCT04718584|Drug|Human Anti-PD-L1 Monoclonal Antibody Injection (LDP)|All participants will receive treatment with LDP 10mg/kg once every two weeks, every 2 weeks will be a cycle. In Cort 1, surgical treatment will be performed within 2 weeks after the end of 3 cycles of treatment.
45943801|NCT00417937|Drug|azelaic acid 15% gel|15% gel, topically applied once daily for six weeks
45943802|NCT00417937|Drug|azelaic acid 15% gel|15% gel, topically applied twice daily for six weeks
45943803|NCT00418054|Drug|Nitazoxanide plus peginterferon alfa-2b|
45943804|NCT00418054|Drug|Peginterferon alfa-2b|
45943805|NCT00295828|Other|Pegaptanib Sodium Injection/Panretinal Photocoagulation|Pegaptanib Sodium Injection is a single dose prefilled syringe and is formulated as a 3.47 mg/mL solution. Combined with an ocular laser procedure.
45943806|NCT00295828|Procedure|Panretinal Photocoagulation (PRP)|Ocular Laser Procedure
45943807|NCT00295906|Other|educational intervention|
45943808|NCT00295906|Other|internet-based intervention|
45943809|NCT05461976|Behavioral|Home-based self-management exercise program|Session 1 will includes education about stroke. Session 2 will includes feedback on behaviour performance on initial measurement outcomes, health consequences of the physical inactivity, answering an exercise preferences questionnaire, generation of a list of goals, delivering a smartband and a diary to self-monitoring. Session 3 will includes reviewing of goals and strategies to self-monitoring, encouragement, rising barriers to exercise and potential solutions to them, development of a weekly schedule physical exercise, implementation of the physical exercise session with participant and delivering a paper-exercise guide. Session 4 will includes reviewing of goals and weekly schedule physical exercise, encouragement, problem solving/coping planning, reviewing strategies to self-monitoring and showing to participant a video with another stroke survivors which are physically active. Sessions 5 and 6 will be the same as session 4 with exception of vicarious reinforcement.
45943810|NCT00295945|Drug|fentanyl citrate|
45656699|NCT04851457|Drug|Intravenous tirofiban combination therapy|Patients will enter the tirofiban treatment protocol immediately within half an hour after randomization and prior to the femoral artery puncture. Tirofiban is administered as an intravenous bolus dose of 10 μg/kg injection within 3 min and then by an intravenous infusion at a rate of 0.1 μg/(kg·min) for 24 hours.
45656700|NCT04851067|Other|Dry Needling and Therapeutic Exercises (DNTEx)|Already included in arm/group descriptions.
45943811|NCT00295945|Drug|hydromorphone hydrochloride|
45943812|NCT00295945|Drug|ropivacaine hydrochloride|
45943813|NCT00121914|Procedure|percutaneous ethanol instillation (PEI)|
45943814|NCT00295984|Drug|nicotine|
45656701|NCT04851067|Other|Manual Therapy and Therapeutic Exercises (MTTEx)|Already included in arm/group descriptions.
45656702|NCT04838509|Other|no intervention|retrospective descriptive without intervention
45807684|NCT04606381|Drug|Ami-HC-CF|Participants will receive amivantamab co-formulated with rHuPH20 as SC infusion.
45943815|NCT00296023|Biological|anti-thymocyte globulin|
45807685|NCT04606381|Drug|Lazertinib|Participants will receive lazertinib orally as a film-coated tablet.
45807686|NCT04601103|Drug|No SLS toothpaste|Toothpaste no Sodium Lauryl Sulfate
45943816|NCT00296023|Biological|filgrastim|
45943817|NCT00296023|Biological|therapeutic allogeneic lymphocytes|
45943818|NCT00296023|Drug|busulfan|
45943819|NCT00296023|Drug|fludarabine phosphate|
45943820|NCT00296023|Drug|methotrexate|
45943821|NCT00296023|Drug|tacrolimus|
45656703|NCT04843033|Drug|SH3809 tablet|Starting dose 2mg,oral administered once daily. If tolerated subsequent cohorts will test increasing doses (4mg,6mg,8mg,10mg,12mg) of SH3809.
45656704|NCT02608099|Drug|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
45807687|NCT04601103|Drug|Medium SLS toothpaste|Less than or equal to X ppm Sodium Lauryl Sulfate
45807688|NCT04601103|Drug|High SLS toothpaste|More than or equal to X ppm Sodium Lauryl Sulfate
45807689|NCT04601103|Device|Anti-plaque|Rinse prevents bacterial adherence to teeth
45943822|NCT00296023|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
45943823|NCT00296023|Procedure|peripheral blood stem cell transplantation|
45943824|NCT00121953|Drug|Rosiglitazone|
45807690|NCT04599855|Drug|Esketamine 56 mg|Esketamine 56 mg will be self administered as nasal spray.
45807691|NCT04599855|Drug|Esketamine 84 mg|Esketamine 84 mg will be self administered as nasal spray.
45807692|NCT04599855|Drug|Placebo|Matching placebo will be self administered as nasal spray.
45807693|NCT04599010|Other|Dietary intervention|energy-restricted diet appropriate for resting metabolic rate using FFM as proxy
45943825|NCT00296062|Biological|bevacizumab|Phase II: IV over 30-90 minutes on days 1 and 15 of each course.
45943826|NCT00296062|Drug|capecitabine|Phase I: oral capecitabine twice daily on days 1-7 and 15-21.Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of capecitabine (during both odd- and even-numbered courses) until the maximum tolerated dose (MTD) is determined.Phase II:receive capecitabine (at the MTD determined in phase I(odd-numbered courses)
45943827|NCT00296062|Drug|irinotecan hydrochloride|Phase I: irinotecan hydrochloride IV over 90 minutes on days 1 and 15 during course 1 and all subsequent odd-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.Phase II: receive capecitabine (at the MTD determined in phase I) in combination with irinotecan hydrochloride (during odd-numbered courses)
45943828|NCT00296062|Drug|oxaliplatin|"Phase I: oxaliplatin IV over 2 hours on days 1 and 15 during course 2 and all subsequent even-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Phase II: oxaliplatin (during even-numbered courses) as in phase I"
45943829|NCT00296101|Behavioral|Physical Activity|
45943830|NCT00296179|Drug|zolpidem tartrate|
45807694|NCT04597437|Drug|Zanamivir|Intravenous zanamivir
45807695|NCT04597437|Other|Placebo|In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.
45807696|NCT04594993|Device|INFINITY™ with ADAPTIS™ Technology Total Ankle System|Total Ankle Replacement
45807697|NCT04591392|Device|reSept ASD Occluder|Transcatheter closure of secundum ASD using a permanent implant
45943831|NCT05456087|Drug|incobotulinumtoxin A|Up to 150 units of incobotulinumtoxin A will be injected at up to 30 injection sites within the hair loss area
45943832|NCT00296218|Drug|Irbesartan|
45943833|NCT00089856|Biological|Immunotherapy with allogeneic prostate vaccine|Immunotherapy with allogeneic prostate vaccine
45943834|NCT00089856|Drug|Chemotherapy (Taxotere and prednisone)|Chemotherapy (Taxotere and prednisone)
45943835|NCT04718428|Diagnostic Test|Nail Ultrasonography|The MyLab 60 (Esaote Biomedica Genoa, Italy) device and linear probe were used. Nails were examined in B-mode grayscale and power Doppler.
45943836|NCT00296257|Drug|SMP-114|
45943837|NCT00296452|Behavioral|behavior|
45943838|NCT00122031|Device|Deep Brain Stimulation with Medtronic Activa Neurostimulator|Deep brain stimulation (DBS) at 130 Hz
45943839|NCT00296530|Drug|fluticasone propionate/salmeterol|
45943840|NCT00296530|Drug|fluticasone propionate|
45943841|NCT00296530|Drug|montelukast|
45807698|NCT04588922|Drug|GFH009|In the dose escalation part, the dose levels will be escalated following the Bayesian optimal interval (BOIN) design. In the expansion part, patients will be assigned based on tumor type(s).
45943842|NCT05428436|Drug|BI 1015550 ICF|BI 1015550 intended Commercial Formulation (iCF)
45943843|NCT05428436|Drug|BI 1015550 TF2|BI 1015550 trial formulation 2 (TF2)
45943844|NCT00296569|Drug|MK0686|
45943845|NCT00090012|Drug|Olanzapine|
45943846|NCT00090012|Drug|Quetiapine|
45453104|NCT03953911|Biological|Mobile Clinic|This intervention involves the availability of a free mobile clinic operated by Cedar-Sinai Medical Center providing free HPV vaccinations at school campuses.
46075262|NCT00877357|Biological|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
46075263|NCT04232826|Biological|single dose of CNCT19|"Dose A: 1.00 x 10^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose B: 2.00 x 10^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose C: 4.00 x 10^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide"
45453105|NCT03953911|Behavioral|Educational Sessions for Parents|This intervention involves providing free weekly educational sessions for parents of students at the participant schools pertaining to the HPV Vaccination.
45453106|NCT03952117|Device|transcranial direct current stimulation|tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
45453107|NCT01584193|Procedure|Ultrasound-guided subclavian vein puncture|Central venous access port implementation through ultrasound-guided subclavian vein puncture and Seldinger technique
45453108|NCT01584193|Procedure|Cephalic vein dissection|Central venous access port implementation through cephalic vein dissection and cutdown
45453109|NCT02886728|Drug|Filgotinib|Tablet(s) administered orally once daily
45453110|NCT02886728|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
45807699|NCT04586660|Drug|XGEVA®|Participants will receive XGEVA® 120 mg subcutaneously (SC) once every 4 weeks (Q4W) with a loading dose of 120 mg SC on day 8 and day 15.
46075264|NCT00873613|Procedure|Use of Non-dilated retinal photography|Kowa Non-Myd alpha-D Non-dilated fundus camera will be used to obtain photographs.
45453111|NCT02886728|Drug|MTX|Capsule(s) administered orally once weekly
45453112|NCT02886728|Drug|Placebo to match MTX|Capsule(s) administered orally once weekly
45807700|NCT04586166|Device|RP Sling|Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure.
45807701|NCT04586166|Device|SIS|Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure.
45453113|NCT00039871|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron (peginterferon alfa-2b) administered at a dose of 1.5 mcg/kg subcutaneously (SC) once a week (QW) for up to 48 weeks
45453114|NCT00039871|Drug|REBETOL (ribavirin; SCH 18908)|REBETOL (ribavirin) administered on a weight basis: 800-1400 mg/day orally (PO) for up to 48 weeks
45458042|NCT01142869|Drug|Cetuximab|The starting dose will be intravenous (IV) cetuximab 400 mg/m2 body surface area administered as a 120-minute infusion once a week . The subsequent weekly doses will be IV cetuximab 250 mg/m2 administered as a 60-minute infusion. The maximum infusion rate must not exceed 10 mg/min.
45807702|NCT04585789|Drug|JNJ-73763989|JNJ-73763989 will be administered subcutaneously once every 4 weeks up to Week 44.
45943847|NCT00296608|Drug|fluorouracil|
45943848|NCT00296608|Drug|leucovorin calcium|
45943849|NCT00296608|Procedure|conventional surgery|
45943850|NCT00296608|Radiation|radiation therapy|
45943851|NCT00296686|Drug|Tranylcypromine|standard dose:60 mg/d for a minimum of 8 weeks, a maximum of 17 weeks; high dose for non-remitters: up to 120 mg/day for a maximum of 9 weeks.
45943852|NCT00296686|Drug|Dextroamphetamine|up to 40 mg/day for 9 weeks, in combination with high dose of tranylcypromine for patients not remitting on the standard or high doses of tranylcypromine alone.
45943853|NCT00296686|Drug|Triiodothyronine|For patients not remitting on higher dose of tranylcypromine plus dextroamphetamine: Up to 75 mg/day for 8 weeks(+/- dextroamphetamine) (max 8 weeks) in combination with highest does of tranylcypromine (up to 120mg/day).
45943854|NCT00122070|Drug|Quetiapine Fumarate|Dosage can vary from 50 to 150 mg at PI's discretion
45943855|NCT00296803|Drug|clopidogrel|
45943856|NCT00296842|Behavioral|Early psychological intervention|Psychoeducation, trauma narrative, provision of coping skills
45943857|NCT00296881|Device|PERIOWAVE|
45943858|NCT05418140|Other|Ultrasound diagnosis of adenomyosis|The diagnosis of adenomyosis will be made using transvaginal ultrasound scan (TVS) (2D and 3D Ultrasound and applying Morphological Uterus Sonographic Assessment (MUSA) criteria (Van den Bosch et al, 2015).
45943859|NCT00296920|Device|Deep Brain Stimulation|
45943860|NCT00090090|Drug|Elsamitrucin|
45943861|NCT00296959|Drug|topiramate (drug)|
45943862|NCT00297076|Drug|GW873140|
45943863|NCT00297154|Behavioral|Lifestyle Modification (diet, exercise, and behavior)|Patients recieve weekly sessions with dietician, replace 2 meals/day with meal replacement beverage, and initiate a walking program.
45943864|NCT05391620|Other|Cardiac rehabilitation with 3/7 method|"HIIT ( 2 min 80% wmax: 2 min 50% wmax) during 30 minutes 3/7 method 3 rep (15 sec of rest), 4 rep (15 sec), 5 rep (15 sec), 6 rep (15 sec), 7 rep. (total volume : 25 repetitions) at 70 of 1 repetition Leg press, Dips Press, Leg curl, Traction and Leg extension.~1 minute between each machine is planned."
46075265|NCT02790684|Drug|DS-8500a|
45453115|NCT01096693|Drug|Urocortin 2, Urocortin 3|"After a 20 minute infusion of intra arterial saline, healthy volunteers will receive ascending doses of intra arterial Urocortin 2 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively), Urocortin 3 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively) and Substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release [2, 4 and 8 pmol/min]). This will be co-infused with either Astressin 2B (in one of the two doses determined from Protocol 1) or saline placebo.~Bilateral venous blood sampling will be performed at baseline, immediately before the start and after each dose of Urocortin 2 and 3, to later estimate net release of tPA and PAI-1 and for plasma measurements of Urocortins 2 and 3."
45453116|NCT01096693|Drug|Saline placebo|"After 20 minutes of intra arterial saline infusion, incremental doses of Urocortin 2, 3 and Substance P will be administered (in doses similar to Active comparator arm), co infused with saline placebo.~Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
45458043|NCT01139905|Other|lopinavir/ritonavir|standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour.
45458044|NCT03502954|Biological|ABY-039|ABY-039
45458045|NCT03502954|Biological|Placebo|Placebo
45656705|NCT02608099|Drug|Uninterrupted apixaban|Intervention description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
45943865|NCT05391620|Other|Cardiac rehabilitation with 3X9 method|"HIIT ( 2 min 80% wmax: 2 min 50% wmax) during 30 minutes 3X9 method 9 rep 1 minute of rest, 9 rep (1 min) and 9 rep (total volume : 27 repetitions) at 70 of 1 repetition Leg press, Dips Press, Leg curl, Traction and Leg extension.~1 minute between each machine is planned"
45943866|NCT00297193|Procedure|Autologous haematopoietic stem cell transplant|All patients will be mobilised prior to randomisation. Those receiving early transplantation will be compared over the first year with those whose transplant has been delayed.
45943867|NCT00297271|Other|Current treatment practice of each participating physician|Patients will be observed for the evaluation of current management strategies.
45807703|NCT04585789|Drug|JNJ-56136379|JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
45807704|NCT04585789|Drug|Entecavir (ETV)|ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
45807705|NCT04585789|Drug|Tenofovir disoproxil|Tenofovir disoproxil will be administered orally once daily up to 48 weeks as NA treatment.
45807706|NCT04585789|Drug|Tenofovir alafenamide (TAF)|TAF will be administered orally once daily up to 48 weeks as NA treatment.
45807707|NCT04585789|Drug|PegIFN-alpha-2a (Optional)|PegIFN-alpha-2a injection will be administered subcutaneously once weekly after Week 40 for either 12 or 24 weeks.
45807708|NCT04581499|Combination Product|DynamiCare Motivation Support Program|DynamiCare is an evidence-based, multi-service platform that combines software, smartphone and pocket-sized alcohol and drug testing hardware, and recovery services, designed to remotely deliver evidence-based methodologies to facilitate people's motivation and accountability to overcome alcohol, nicotine and other drug use disorders, whether in formal treatment or not.
45943868|NCT00122148|Behavioral|Feedback on provision of care|
45943869|NCT00297349|Drug|Topiramate|Individualization of the treatment should begin from 25 mg for 1 week.
45943870|NCT05377307|Genetic|Pell's lentiviral-based gene-edited immune cell therapy|No study drug or other planned treatment will be administered. Subjects who previously received Pell's lentiviral-based gene-edited immune cell therapy will be evaluated the safety and efficacy.
45943871|NCT00297388|Drug|Risperidone, long-acting injectable|
45656706|NCT04842877|Drug|Valemetostat tosylate|200mg QD continuously until disease progression, consent withdrawal, unacceptable drug-related toxicity, lost to follow-up, major protocol deviation, pregnancy, termination by sponsor or death, whichever occurs first.
45656707|NCT04842565|Drug|Sintilimab|Sintilimab (200mg ivdrip D1 Q3W)
45656708|NCT04842565|Device|TACE|TACE will be performed by clinical demand, the interval between two TACEs is not less than 4 weeks.
45943872|NCT00297466|Drug|transdermal nicotine patches|
45943873|NCT00297466|Behavioral|Motivational interview|
45943874|NCT00297505|Drug|citalopram|
45943875|NCT00090129|Drug|Onercept|Onercept will be administered subcutaneously three times a week at a dose of 150 mg, for 12 weeks of first treatment (FT) period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment or until relapse, whichever occurs first. Subjects then will be reassigned to either Onercept (150 mg) or placebo, subcutaneously three times a week, for 16 weeks. Subjects not showing 75 percent improvement in PASI score at Week 12 will receive only Onercept (150 mg) subcutaneously three times a week, for 40 weeks as open-label treatment.
46075266|NCT02786862|Other|independent ventilation|comparison conventional and independent 1:1 ventilation
46075267|NCT00877435|Behavioral|Cognitive behavioral therapy (CBT)|
46075268|NCT02790372|Other|Case conferencing|Intervention nursing homes carries out regularly case conferencing based on comprehensive geriatric assessments. Case conferencing is carried out each month for nursing home patients included in the study
46075269|NCT00869245|Other|OU - Cardiac MRI|During ED evaluation, patients are randomized to cardiac MRI or conventional care testing.
46075270|NCT00869245|Other|OU - Conventional Care Testing|Patients in the conventional testing arm will undergo testing as determined by their treating physician.
45943876|NCT00090129|Drug|Placebo|Matching Placebo will be administered subcutaneously three times a week, for 12 weeks in the FT period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment and then again assigned to either placebo or Onercept (150 mg), subcutaneously three times a week, for 16 weeks.
45656709|NCT04850755|Drug|Selinexor in combination with nivolumab and ipilimumab|Patients will commence at dose level 1. One cycle is 42 days (6 weeks) for all three agents. At dose level 1, selinexor will be dosedorally weekly, and nivolumab at 2 weekly + ipilimumab 1mg/kg 6 weekly. Patients can have dosing interruptions or reductions of any drug independently of one another, depending on the drug causing the toxicity
45943877|NCT00297544|Drug|Viagra|
45656710|NCT03038035|Drug|MLC901|24 weeks intervention with orally MLC901. 2 capsules 3 times a day
46002155|NCT04643158|Drug|Short acting beta agonist (SABA) (rescue medication)|"In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods. All participants should refrain from taking a SABA as rescue medication 6 hours prior to pulmonary function tests.~Dosage levels: 100 μg per nominal dose 90 μg per nominal dose pro re nata (as required) (PRN)"
45656711|NCT03038035|Drug|Placebo|24 weeks intervention with orally placebo. 2 capsules 3 times a day
45656712|NCT03037801|Device|Intrapulmonary Percussive Ventilation (Percussionaire Corp, Sandpoint, Idaho)|IPV physiotherapy 3 times a day
45656713|NCT04850131|Procedure|Desarda repair|Desarda is a new tissue-based technique developed from applying the externally oblique muscle aponeurosis in the form of an undetached strip making the posterior wall in the inguinal canal stiffer. This paper focuses on analyzing comparisons between mesh-free Desarda repair and the Lichtenstein technique for the treatment of hernia inguinalis
45807709|NCT04581499|Other|Untreated or Routine Care Control Group|No specific intervention, i.e., research participation plus any community-based treatment the individual seeks to obtain.
45807710|NCT04578756|Drug|Cariprazine Flexible Dose|1 capsule to be taken orally at approximately the same time of day (morning or evening)
45807711|NCT04577833|Drug|Niraparib|Niraparib will be administered orally.
45807712|NCT04577833|Drug|Abiraterone Acetate (AA)|Abiraterone Acetate will be administered orally.
45458046|NCT01236313|Procedure|TEE report|Information will be collected during cardiac surgery.
45458047|NCT03506152|Diagnostic Test|Serum Procalcitonin|Seven ml of blood was drawn in gel separator tubes within 24 hours of admission in ICU for Procalcitonin determination
45656714|NCT04842487|Drug|R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide，hydroxyldaunorubicin，Vincristine，Prednisone）)|Lenalidomide：25mg po QN,d1-10 Rituximab: 375mg/m2, ivdrip, d1 Cyclophosphamide: 750mg/m2, iv or ivdrip, d1 Hydroxyldaunorubicin: 50mg/m2, iv or ivdrip, d1 Vincristine： 1.4 mg/m2 , iv（max：2mg）, d1 Prednisone: 60mg/m2, po, d1-5 every 3 weeks was a course of treatment
45656715|NCT04842331|Drug|RESP301, a Nitric Oxide generating solution|Participants will receive institutional SOC for the treatment
45656716|NCT03040063|Procedure|Combined endovascular approach (EVAR)|"puncture of SFA in orthograde position if possible~DSA through 4F dilator, proof of occlusion~wire test~Heparin 70-80 IU/kg i.a.~implantation of peripheral stent graft VIABAHN~implantation of peripheral stent SUPERA into stent graft~insertion of strait flush catheter for local thrombolysis~administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTT 1,5-2x) according to the department standards~control angiography in 12 hrs or earlier according to clinical status and symptoms~repeated angiography in 24 hrs"
45656717|NCT03040063|Procedure|Standard optimal therapy (OPT)|"puncture of SFA in orthograde position if possible~DSA through 4F dilator, proof of occlusion~wire test~Unfractionated heparin 70-80 IU/kg i.a.~insertion of strait flush catheter for local thrombolysis~administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTTT 1,5-2x)~control angiography in 12 hrs or according to clinical status and symptoms~repeated angiography in24 hrs~Final result review, vascular team consultation and indication for surgical or conservative management of popliteal artery aneurysm."
45807713|NCT04577833|Drug|Prednisone|Prednisone will be administered orally.
45807714|NCT04576117|Procedure|Biospecimen Collection|Undergo blood sample collection
45807715|NCT04576117|Procedure|Magnetic Resonance Imaging|Undergo MRI
45807716|NCT04576117|Other|Quality-of-Life Assessment|Ancillary studies
46002156|NCT04643158|Drug|Run-in medications (ICS-LABA combination)|"During the Run-in Period, the participants are required to maintain on their ICS-LABA dose. Controller medications (eg, ICS LABA) should remain at a stable dose and be taken after study intervention as applicable.~These drugs are used as standard of care."
46002157|NCT04642430|Drug|Apixaban|Refer to Apixaban group
46075271|NCT02352389|Other|Blood sample|Blood samples will be drawn and analyzed at Day 0, 7, 14, 21, and 28
46075272|NCT02352389|Other|Nasal swab|Obtained on Day 0, 7, 14, 21 and 28.
46075273|NCT02352389|Other|Oropharyngeal swab|Obtained on Day 0, 7, 14, 21 and 28.
46075274|NCT02352389|Other|Stool sample|Obtained on Day 0, 7, 14, 21 and 28.
46075275|NCT02352389|Other|Symptom checklist|Obtained on Day 0, 7, 14, 21 and 28.
45807717|NCT04576117|Other|Questionnaire Administration|Ancillary studies
45656718|NCT04841941|Device|G4 Multifocal soft contact lens with a 54% water content for presbyopia|"The participants must agree to wear lenses from a trial set with the fit assessed according to the Fitting Guide. Prescription lenses will then be ordered from the manufacturer."
46002158|NCT04642430|Drug|Rivaroxaban|Refer to Rivaroxaban group
45807718|NCT04576117|Drug|Selumetinib Sulfate|Given PO
45807719|NCT04576117|Drug|Vinblastine Sulfate|Given IV
45807720|NCT04576091|Procedure|Biospecimen Collection|Undergo blood sample collection
45807721|NCT04576091|Procedure|Computed Tomography|Undergo CT and/or PET-CT scan
45453117|NCT03951181|Behavioral|LEAP-MS|The LEAP-MS intervention is a co-produced, digital interactive education and activity tool, specifically developed for PwPMS. The tool includes multimedia education about being active with PMS, tailored physical activity ideas and interactive functions enabling the development of personalised activity programmes, goal setting and activity logs. The digital tool works in conjunction with support from trained physiotherapists. The feasibility study will evaluate how the LEAP-MS intervention can be used in practice.
45453118|NCT01100905|Other|Iron-containing food product|
45453119|NCT00015457|Drug|Amlodipine plus Botulinum toxin|
45453120|NCT01331564|Behavioral|electronic intervention during pregnancy and postpartum|Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy and to follow a healthy lifestyle postpartum to minimize postpartum weight retention
45656719|NCT04841863|Device|MyPlan digital health platform|Inclusion in the active group involves the use of MyPlan digital health tool that aims to improve clinical-patient communication, enahnce patient empowerment, improve early detection of side effects and allows professionals to individualize interventions.
45656720|NCT04841863|Other|Satndard care|Inclusion in the control group do not involves the use of MyPlan digital health tool. Patients will receive the standard of care.
45656721|NCT04833673|Behavioral|PMR: Progressive Muscle Relaxation|tensing and relaxing the body muscles accompanied with deep breathing
45656722|NCT04833673|Behavioral|BRT:Benson Relaxation Technique|relaxation using mental imagery and mediation
45656723|NCT04837885|Procedure|Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection|Intra-hepatic injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
45656724|NCT04837885|Procedure|Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection|intravenous injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
45656725|NCT04837885|Drug|LUTATHERA® by intra-arterial hepatic (IAH) injection|"One treatment dose of LUTATHERA® by IAH injection for the 10 first patients with an PET/CT ratio greater then 3.~The LUTATHERA® by intra-arterial hepatic injection treatment is realised after the conventional treatment by 4 intravenous administrations"
45656726|NCT04837885|Procedure|Scan|Scans after completion of LUTATHERA® treatment injection
45656727|NCT03039829|Dietary Supplement|Creatine nitrate, low dose|Creatine nitrate at 3.0 grams (2.0 grams creatine, 1.0 gram nitrate, 3.0 grams dextrose)
45656728|NCT03039829|Dietary Supplement|Creatine nitrate, high dose|Creatine nitrate at 6.0 grams (4.0 grams creatine, 2.0 grams nitrate)
45656729|NCT03039829|Dietary Supplement|Placebo|Placebo at 6.0 grams (6.0 grams dextrose)
45656730|NCT04833595|Behavioral|Mindfulness practice|Mindfulness is hypothesised to include reflective practice. Therefore, reflective questions are asked in the questionnaire for intervention group but not for control group.
45453121|NCT01331564|Behavioral|electronic intervention during pregnancy|Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy.
45656731|NCT03039907|Procedure|Total Knee Arthroplasty|Total knee arthroplasty
45656732|NCT04833205|Drug|Nimotuzumab|Nimotuzumab 200 mg was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping, the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks
45807722|NCT04576091|Drug|Elimusertib|Given PO
45807723|NCT04576091|Biological|Pembrolizumab|Given IV
45807724|NCT04576091|Procedure|Positron Emission Tomography|Undergo PET-CT scan
45807725|NCT04576091|Other|Quality-of-Life Assessment|Ancillary studies
45807726|NCT04576091|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45807727|NCT04575597|Drug|Molnupiravir|Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
45807728|NCT04575597|Drug|Placebo|Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
45807729|NCT04572633|Device|HistoSonics Histotripsy|The HistoSonics System (System) is intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.
45807730|NCT04571138|Biological|SCRI-CAR22v2|Single infusion of SCRI-CAR22v2
45807731|NCT04569591|Drug|Acthrel|Intravenous administration of ovine CRH (Acthrel (Registered Trademark) 1 mcg/kg up to a maximum dose of 100 mcg) results in selective increase in ACTH activity of pituitary adenomas within two minutes and peaks between 10-15 minutes.
45807732|NCT04567602|Drug|PAH medication|There will be no specific interventions.
45807733|NCT04564755|Drug|abrocitinib|Participants will receive abrocitinib 100 mg or 200 mg orally once a day as directed by the investigator's clinical judgement
46002159|NCT04630080|Device|Scalp cooling|Scalp cooling is a physical method to reduce chemotherapy-induced alopecia
45807734|NCT04562792|Drug|Daunorubicin|Eligible patients with relapsed and/or refractory acute leukemia will receive daunorubicin 6.75mg/m2 daily for 5 consecutive days.
45943878|NCT05365685|Behavioral|Low energy turnover|"Low Energy Turnover. The adolescents with ingest low energy intake at lunch and breakfast and will not perform physical exercise during the day. The will will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.~Moderate Energy Turnover. The adolescents with ingest moderate energy intake at lunch and breakfast and will perform one 45 minutes physical exercise during the day. The will will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.~High Energy Turnover. The adolescents with ingest high energy intake at lunch and breakfast and will perform two 45-minute physical exercises during the day. The will will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals."
45656733|NCT03036475|Device|Sienna+ injection|Subcutaneous injection of Sienna+ in the morning of operation day
45943879|NCT00297583|Drug|Insulin Glulisine|
45943880|NCT00297661|Device|Sirolimus-eluting stent|
46075276|NCT05003349|Other|Occlusal Splint (OS).|OS will be made of heat-cured acrylic by the same specialized dentist. These intraoral devices will be flate, rigid, will cover the entire dental arch, and will have the lowest possible height. The perimeter of the splint will have at least 11 dental contacts, light, symmetrical and pinpoint as possible. The patients will be instructed to use the splint every night during the study Two supervisions will be carried out 30 and 60 days after the use of the OS, in order to stabilize the contact points.
46075277|NCT05003349|Other|Pain Neuroscience Education (PNE).|"A power point presentation with metaphors and animated videos will be used. The PNE will be held in 10 sessions of 20 minutes each. The intervention will be developed using content according to the book Explain Pain and the web page www.retrainpain.org."
45656734|NCT03037645|Drug|SNS-062|SNS-062 will be orally administered twice daily and available in capsules containing either 25 mg or 100 mg of active ingredient.
45656735|NCT04371913|Radiation|600cGY x 5 fractions|Patients will be treated with the fractionation of 30 Gy in 5 fractions over 1-2 weeks, which is the accelerated fractionation scheme of choice for RT naïve patients at New York Presbyterian using EBRT.
45807735|NCT04562389|Drug|Selinexor|Participants will receive a dose of 40 or 60 mg selinexor oral tablets QW.
45656736|NCT04370665|Device|Exablate BBBD with Cerezyme|"Blood Brain Barrier Disruption via Exablate to deliver Cerezyme.~Other Names:~Exablate Neuro"
45807736|NCT04562389|Drug|Selinexor|Participants will receive a dose of 60 mg selinexor oral tablets QW.
45656737|NCT04312243|Drug|Inhaled nitric oxide gas|Control group: a SARS-CoV2 rt-PCR will be performed if symptoms arise. Treatment group: the subjects will breathe NO at the beginning of the shift and before leaving the hospital. Inspired NO will be delivered at 160 parts per million (ppm) for 15 minutes in each cycle. A SARS-CoV-2 rt-PCR will be performed if symptoms arise. Safety: Oxygenation and methemoglobin levels will be monitored via a non-invasive CO-oximeter. If methemoglobin levels rise above 5% at any point of the gas delivery, inhaled NO will be halvened. NO2 gas will be monitored and maintained below 5 ppm.
45453122|NCT01331564|Behavioral|Control|Control women will receive non-weight related content during both time periods at the project website.
45453123|NCT01331720|Drug|hMG-HP|
45656738|NCT04841551|Drug|Kybella Flanks|10 subjects will be treated with Kybella in the flanks
45656739|NCT03037567|Behavioral|Modified Weight Watchers plan|Weight Watchers is a structured lifestyle modification program that includes a food plan based on balanced diet and healthy eating, activity plan designed to promote progressive physical activity increase, group support and cognitive behavior modification. Participants attend weekly in-person group meetings led by a trained Weight Watchers meeting leader and have a suite of electronic tools available through an iPhone app.
45656740|NCT04833049|Drug|TAK-994 Oral Tablet|TAK-994 tablet.
45656741|NCT04833049|Drug|[14C]TAK-994 Intravenous Infusion|[14C]TAK-994 intravenous infusion.
45656742|NCT04833049|Drug|[14C]TAK-994 Oral Suspension|[14C]TAK-994 oral suspension.
45807737|NCT04562389|Other|Placebo|Participants will receive a matching placebo of selinexor oral tablets QW
45656743|NCT04841161|Behavioral|Balance function, gait ability, weight- distribution and weight-shifting|Healthy adults and stroke patients accepted two measurements within a week. Balance function, gait ability, weight- distribution and weight-shifting during sit-to-stand, quite standing, and weight-shifting toward the forward foot.
45807738|NCT04562389|Drug|Ruxolitinib|Participants will receive a dose of 15 or 20 mg ruxolitinib oral tablets BID.
45807739|NCT04559620|Other|Maternal voice|Maternal voice (song/ words) played in the incubator for 30mins x4/day x 7 days
45807740|NCT04557098|Drug|Teclistamab|Teclistamab will be administered SC.
45943881|NCT00297661|Device|Paclitaxel-eluting stent|
45943882|NCT00297700|Behavioral|Active referral|
45943883|NCT00090207|Drug|MK0869, aprepitant / Duration of Treatment: 3 days|
45943884|NCT00090207|Drug|Comparator: ondansetron / Duration of Treatment: 4 days|
45943885|NCT05338268|Behavioral|CBT for Loneliness|CBT delivered over the course of 8, ~45 minute sessions delivered via telehealth.
45943886|NCT05338268|Behavioral|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
45943887|NCT00297739|Drug|Risperidone|
45943888|NCT04718272|Procedure|thoracic drainage management|After uniportal VATS pulmonary lobectomy, the traditional silicone tube which placed through the surgical incision was removed in the operating room in the experimental group.
45943889|NCT00090246|Drug|MK0869, aprepitant|
45943890|NCT00090246|Drug|Comparator: ondansetron IV|
45807741|NCT04557059|Radiation|Radiotherapy|Participants will receive radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), which will start within 4 weeks after randomization.
45807742|NCT04557059|Drug|LHRHa|Participants will be administered with LHRHa (example, leuprolide, goserelin, triptorelin acetate) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12 or as a 6-monthly depot preparation within 3 days after randomization.
45656744|NCT04841161|Behavioral|Weight- distribution and weight-shifting training program|The stroke patients received a weight-shifting training program , 30 minutes/time, 2-5 days a week for 2-3 weeks(8 sessions). After training, they accepted a post-test within a week.
45656745|NCT04841239|Other|Herbal topical formulation|
45943891|NCT00297817|Biological|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
45807743|NCT04557059|Drug|Apalutamide|Participants will receive therapeutic dose of apalutamide 240 mg once daily for 180 Days.
45943892|NCT00297817|Biological|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
45453124|NCT03564470|Drug|Chidamide|Chidamide will be administrated at dose of 10mg/day in chidamide arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for chidamide arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (chidamide, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.
45458048|NCT05044429|Drug|Intravenous Lidocaine|Patient will receive intravenous lidocaine 1.0-1.5 mg/kg/hour for 48 hours post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
45656746|NCT04841395|Diagnostic Test|Intravaginal ejaculatory latency time (IELT), Arabic Index of Premature Ejaculation (AIPE), Morningness-Eveningness Questionnaire (MEQ)|Self-estimated intravaginal ejaculatory latency time IELT is defined as the time between the onset of vaginal intromission and the onset of intravaginal ejaculation. In the present research, self-estimated IELT duration was obtained as a result of interviews with the participants. Moreover, Arabic Index of Premature Ejaculation (AIPE), International Index of Erectile Function (IIEF-5), Pittsburgh Sleep Quality Index (PSQI) and Morningness-Eveningness Questionnaire (MEQ) were administered to all participants.
45656747|NCT03036241|Device|Conventional angioplasty|Angioplasty with conventional balloon
45656748|NCT03036241|Device|Angioplasty with drug-eluting balloon|Angioplasty with drug-eluting balloon
45656749|NCT03037333|Procedure|Transvenous cardiac pacing guided by fluoroscopy|Transvenous cardiac estimulation
45807744|NCT04554966|Drug|ABBV-382|Intravenous (IV) infusion
45656750|NCT03037333|Procedure|Transvenous cardiac pacing guided by ECG/ECHO|Transvenous cardiac estimulation
45656751|NCT03039517|Device|ACTitouch|The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.
45656752|NCT03039517|Device|Compression garments (stockings)|"Compression garments (stockings) now serve as the generally recommended standard of care for patients post DVT and will be utilized as the control compression method in this study. Compression garments utilized in this study will be below the knee style with a pressure range of 30-40 mmHg. If a patient does not have compression garments as indicated, these stockings will be provided."
45807745|NCT04554966|Drug|ABBV-382|Subcutaneous (SC) injection
45807746|NCT04554966|Drug|Placebo for ABBV-382|Intravenous (IV) infusion
45807747|NCT04551521|Drug|Vemurafenib|960 mg twice daily during run-in Phase, followed by 720 mg twice daily
45807748|NCT04551521|Drug|Cobimetinib|60 mg once daily
45807749|NCT04551521|Drug|Atezolizumab|840 mg every 2 weeks
45807750|NCT04551521|Drug|Trastuzumab|8 mg per kilogram of body weight as a loading dose, followed by 6 mg per kilogram every 3 weeks
45807751|NCT04551521|Drug|Pertuzumab|840 mg as a loading dose, followed by 420 mg intravenously every 3 weeks
45807752|NCT04551521|Drug|Alectinib|600 mg twice daily
45807753|NCT04551521|Drug|Ipatasertib|400 mg once daily
45943893|NCT00297817|Biological|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the placebo following a 0,2,6 vaccination schedule.
45943894|NCT00297856|Biological|Boostrix®|Single dose
45943895|NCT00297856|Biological|Td (Tetanus diphtheria) vaccine|Single dose
45943896|NCT05327465|Other|Aerobic and resistance exercise|Perform exercise at home with virtual supervision, including aerobic exercise (e.g.,cycling), which can improve cardiovascular (heart) and lung function, and resistance exercise (e.g., dumbbell lifting and using resistance band. The exercises will be performed three times per week for 16 weeks, and virtually supervised by a professional exercise trainer
45943897|NCT05327465|Other|Usual Care|Maintenance of baseline exercise levels for 16 weeks with an offer to perform the same exercise (aerobic and resistance exercise) program after 16 weeks.
45807754|NCT04551521|Drug|Atezolizumab|1200 mg every 3 weeks
45807755|NCT04551521|Drug|Atezolizumab|1200 mg in the first cycle, followed by 840 mg every 3 weeks
45807756|NCT04551521|Drug|Atezolizumab|1,200 mg every 3 weeks
45807757|NCT04551521|Drug|Inavolisib|9 mg once daily
45807758|NCT04551066|Drug|parsaclisib|parsaclisib will be administered QD orally
45807759|NCT04551066|Drug|ruxolitinib|ruxolitinib will be administered BID orally
45807760|NCT04551066|Drug|placebo|placebo will be administered QD orally
45807761|NCT04550377|Drug|Cannabidiol|The drug product to be used in this study is an oral formulation of CBD
45807762|NCT04550377|Drug|Placebo|non-active medication
45807763|NCT04546724|Biological|VLA1553|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose
45807764|NCT04546724|Biological|Placebo|Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
45943898|NCT00297895|Procedure|Completion Lymphadenectomy|complete lymph node dissection of lymph node basin with positive node
45943899|NCT00297895|Procedure|Monitoring with nodal ultrasound|serial ultrasound monitoring of SLND positive basin. If recurrence detected, subject has CLND.
45943900|NCT00090324|Drug|quetiapine fumarate tablets|
45943901|NCT00297934|Device|Pro-adjuster mechanical spinal manipulative device|
45943902|NCT00297973|Procedure|Blood pressure measurements|
45943903|NCT00297973|Procedure|Blood samples|
45943904|NCT00122226|Drug|Lopinavir/ritonavir + zidovudine + lamivudine|
45943905|NCT00122226|Drug|Lopinavir/ritonavir + nevirapine|
45943906|NCT05200559|Drug|Pembrolizumab|Pembrolizumab is a humanized monoclonal immunoglobulin (Ig) G4 antibody that inhibits lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response, allowing the immune system to target and destroy cancer cells.
45943907|NCT05200559|Drug|E7777|E7777 or denileukin diftitox is a recombinant cytotoxic fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met1-Thr387)-His and for human interleukin-2 (Ala1-Thr133), indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor.
45656753|NCT03039361|Behavioral|Equine Assisted Psychotherapy|Therapist will use Equine Assisted Growth and Learning Association (EAGALA) modeled Equine Assisted Psychotherapy.
45807765|NCT04546711|Other|Ketogenic Diet|The ketogenic diet (KD) is a high fat, very low carbohydrate diet
45943908|NCT00298012|Drug|Methotrexate|
45943909|NCT05198648|Other|Trigeminal cardiac reflex|Trigeminal cardiac reflex occurred during the cerebellopontine angle tumor surgery.
45943910|NCT05198648|Other|Non-trigeminal cardiac reflex|No trigeminal cardiac reflex occurred during the cerebellopontine angle tumor surgery.
45656754|NCT03039439|Procedure|Biospecimen Collection|Previously collected tumor tissue and blood samples
45656755|NCT03039439|Other|Laboratory Biomarker Analysis|Correlative studies
45656756|NCT04840771|Procedure|Endoscopic Endonasal Pituitary Surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter.
45656757|NCT04837651|Device|Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test|Subjects will receive an Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test within 4 weeks of receiving their first COVID-19 injection. Within 3-4 weeks of receipt of their final COVID-19 vaccine dose, subjects will receive another Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test.
45656758|NCT04837651|Device|T-Detect COVID T-cell blood test|A select number of subjects will also receive a qualitative SARS-CoV-2 t-cell immunity test, the T-Detect COVID test, within 3-4 weeks of receipt of their final COVID-19 vaccine dose.
45656759|NCT04832581|Behavioral|The Self-Care Behavior Development Program|This program, which is based on the Orem Self Care Model, includes anatomical, physiological and hormonal changes, urinary system infections and preventive measures during pregnancy. The program is different from other researches in that it is based on a methodological theory and is created with up-to-date information.
45656760|NCT04832191|Device|CE-SM|contrast enhanced spectral mammography &contrast enhanced magnetic resonance imaging
45656761|NCT03039205|Drug|Clopidogrel|Clopidogrel 600 mg loading dose + 75 mg q.d. for 7 to 9 days
45656762|NCT03039205|Drug|Ticagrelor|Ticagrelor 180 mg loading dose + 90 mg b.i.d. for 7 to 9 days
45656763|NCT04837261|Drug|Propranolol|3 mg/kg/d, divided in four doses when age less than 3 months and in three doses when age more than 3 months
45656764|NCT04837261|Drug|Flecainide|80 mg/m2/d
45656765|NCT04837261|Drug|Amiodarone|Single dose of 10 mg/kg/d 10-14 days, 5 mg/kg/d
45943911|NCT00298051|Procedure|Delayed umbilical cord clamping|
45943912|NCT00298129|Device|Ambulatory blood pressure monitoring|
45656766|NCT04792645|Drug|Placebo|Pill that contains no medicine
45943913|NCT00298168|Drug|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
45943914|NCT00298168|Drug|placebo|0.9% normal saline administered IV as a single bolus infusion with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
45943915|NCT00298168|Drug|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 10 mg YSPSL in 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
45943916|NCT00322426|Device|Sensory Cueing Device|
45943917|NCT00322504|Procedure|Accupuncture|
45943918|NCT00122304|Drug|eculizumab|
45943919|NCT00322543|Device|Corio™ Pimecrolimus-eluting stent|
45943920|NCT00399854|Device|Dhermia® - Industra Mecânica Fina Ltda|
45943921|NCT00313963|Drug|Magnesium Sulfate|Intravenous Magnesium Sulfate (100 mg/Kg, Max 2 gram/dose) 8 hourly.
45943922|NCT00313963|Drug|Normal Saline|Intravenous Placebo (Normal Saline in equivalent amount to magnesium sulfate 100 mg/Kg, Max 2 gram/dose) 8 hourly.
45943923|NCT00314002|Device|Mechanical Thrombectomy|
45943924|NCT00122343|Drug|ridaforolimus|AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.
45943925|NCT00314041|Biological|Meningococcal C|
45943926|NCT00314041|Biological|DTP/Hib|
45943927|NCT00314080|Drug|Botulinum AntiToxin|
45943928|NCT00314080|Procedure|neuro-electrophysiologic study, repetitive nerve stimulation|
45943929|NCT00314080|Procedure|Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
45943930|NCT00314158|Drug|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop twice daily in each study eye for six months
45943931|NCT00314158|Drug|Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension|One drop twice daily in each study eye for six months
45943932|NCT00314158|Drug|Timolol 5 mg/ml eye drops, solution|One drop twice daily in each study eye for six months
45943933|NCT05147051|Drug|Meglumine Sodium Succinate|500 ml of 1.4% solution IV at a rate of at least 4 ml and not more than 10 ml per minute
45458049|NCT05044429|Drug|Transversus abdominis plane (TAP) block|Subject will receive 0.2% Ropivacaine at 6-10ml/hour through transversus abdominis plane (TAP) block for up to five days post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
45656767|NCT04792645|Drug|Memantine|Cognition-enhancing medication
45943934|NCT05147051|Drug|Placebo|Ringer's solution, 500 ml IV at a rate of at least 4 ml and not more than 10 ml per minute
45943935|NCT00314197|Behavioral|Telephone Linked Care - Behavior Change Counseling System|
45656768|NCT04832035|Other|"coordinated and peer supported mental health care"|Health services, coordination of services, method to support utilization
45656769|NCT04832035|Behavioral|"standard psychotherapeutic care in the public healthcare system"|Psychotherapeutic services that are financed by the public health insurance system.
45656770|NCT04792177|Behavioral|Emotion regulation skills training|The intervention will involve an online emotion-regulation skills training for individuals with sexual problems. It will last for 8 weeks, encompassing psycho-educational and emotion-regulation skills components. Every week participants will gain access to a different intervention module of the training, containing videos, presentation slides, written support material and a recommendation of activities to be completed until the following week of training. Participants are expected to dedicate 30 minutes to one hour per week to complete each module.
45943936|NCT00314197|Behavioral|Telephone-linked behavioral counseling|
45943937|NCT00090480|Biological|HyperAcute - Breast cancer vaccine|Cells will be injected intradermally for four weeks for four cycles. Dosage will vary from 10 million to 100 million HAB cells.
45656771|NCT04832347|Other|Exercise|Exercise Group will be given stabilization exercises for a total of 24 sessions, 3 times a week for 8 weeks, each session for 45 minutes.
45943938|NCT00314275|Device|Coronary Artery Stenting|Drug eluting stent
45943939|NCT00314275|Device|Endeavor|Drug eluting stent
45943940|NCT00322660|Drug|Adrenaline|
45943941|NCT00322699|Procedure|Whole bladder laser light treatment as an alternative to radical cystectomy|The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
45943942|NCT00322699|Drug|Photofrin|The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
45656772|NCT04832347|Other|Vagus Nerve Stimulation|Vagus therapy will be applied for 8 weeks, 3 times a week for a total of 24 sessions, each session for 30 minutes.
45943943|NCT00122421|Behavioral|Pharmacist recommendations to primary care providers|recommendations based on chart review by pharmacist, given to pcp at time of visit
45943944|NCT00122421|Other|pharmacist recommendations|recommendations based on chart review by pharmacist, given to pcp at time of visit
45943945|NCT00322933|Procedure|renal replacement therapy (intermittent or continuous)|
45943946|NCT00322972|Drug|Mass treatment with oral azithromycin to an entire community|For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. For study arm C and D, nasopharyngeal swabs will be collected from 10 randomly selected children among the 60 participants under 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
45943947|NCT00090558|Drug|nitroglycerin|
45943948|NCT00323011|Drug|Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab|
45943949|NCT00323050|Biological|Haemophilus influenzae type b- and meningococcal (vaccine)|
45458050|NCT05044429|Drug|Quadratus Lumborum (QL) Block|Subject will receive 0.2% Ropivacaine at 6-10ml/hour through quadratus lumborum (QL) block for up to five days post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
45656773|NCT04428697|Procedure|Sungurtekin Technique|Sungurtekin technique was performed through the base of the posterior fissure; thus, no additional incision was necessary in the lithotomy position. The mucosa was dissected along the submucosal plane, starting at the hypertrophic papilla, and extended for 1.5 cm, a 0.5-cm section of the bottom part of the internal anal sphincter was measured and marked with a ruler. Next, the internal sphincter bundle was measured with a sterile scale and a mark was placed at 1 cm towards the proximal end. The internal sphincter cut with cautery .
45943950|NCT00323089|Procedure|microcoil insertion and excision|The objective of this study is to determine if subcentimetre pulmonary nodules can be accurately and safely excised by endoscopic stapling devices after they have been localized using CT and marked with a microcoil device.
45943951|NCT00323128|Procedure|Calculation of inuline clearance|Calculation of inuline clearance.
45943952|NCT00323128|Procedure|Measuring serum creatinine|Measuring serum creatinine.
45656774|NCT04831489|Radiation|Imaging|pre and postoperative CT scan of lung
45656775|NCT04831879|Device|GONDOLA AMPS|The Gondola device is composed of two units, one per foot, each having two motors that activate rounded stimulation tips that interact with the target points. It delivers mechanical, pressure-based stimulations, sequentially in each of the four points, for the duration of 6 seconds per point. This treatment cycle is repeated 4 times, for an overall treatment duration of less than 2 minutes
45943953|NCT00323206|Biological|IL-12p DNA|Plasmid IL-12 will be administered as an intratympanic (IT) injection.
45943954|NCT00323206|Procedure|Intratumoral Electroporation|The electroporation apparatus with the electrical contacts will be placed around the tumor site and activated.
45943955|NCT04730102|Procedure|Rectal washout|Rectal washout is performed intraoperatively before transection and means irrigation of the rectum following the closure of the rectal lumen below the tumour with a purse string suture. Rectal washout is performed with a total of 500 ml sterile water. Fluid samples are collected after every 100 ml by instilling 50 ml of saline after each washout. A sixth sample is collected from the presacral cavity.
45943956|NCT04717531|Drug|Pyrotinib|400mg, qd, po, day 1-21
45943957|NCT04717531|Drug|Trastuzumab|6 mg/kg, day 1
45943958|NCT04717531|Drug|Pertuzumab|420 mg, day 1
45943959|NCT04717531|Drug|Docetaxel|100 mg/m2, day 1
45943960|NCT04717531|Drug|Epirubicin|90mg/m2, day 1
45943961|NCT04717531|Drug|Cyclophosphamide|600 mg/m2, day 1
45943962|NCT04728789|Drug|Avatrombopag 20 MG|Avatrombopag 20mg/week to 60mg/day, starting at 20mg/day and increased by 20 mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L.
45943963|NCT00323245|Behavioral|Physiotherapy for urinary incontinence|See Detailed Description.
45458756|NCT04098016|Behavioral|Digital Intervention|Participants will receive: 1) tailored behavior change goals, 2) self-monitoring with tailored feedback, 3) skills training.
45943964|NCT00323323|Drug|CHOP|CHOP will be given 60-120 minutes following SQ administration of Alemtuzumab as follows: cyclophosphamide 750 mg/m2 IV on day 1, doxorubicin 50 mg/m2 IV on day 1, vincristine 1.4 mg/m2 (maximum dose = 2 mg) IV on day 1, and prednisone 100 mg PO on days 1-5.
45943965|NCT00323323|Drug|Alemtuzumab|Single agent Alemtuzumab given subcutaneously (SQ) on week #1. Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1. If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5.
45943966|NCT00323323|Procedure|Plasma Samples|Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose.
45943967|NCT00323401|Other|Antenatal classes|3 sessions of 3 hours each
45943968|NCT00122499|Drug|tadalafil|
45943969|NCT00312598|Drug|Aripiprazole|
45943970|NCT00312637|Procedure|Magnetic Resonance Spectroscopy|
45943971|NCT00312676|Procedure|Rapid versus slow conversion|
45656776|NCT04831645|Device|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
45943972|NCT00312754|Drug|Atazanavir|
45943973|NCT00312793|Device|stimulation of the quadriceps muscle with Myospare|
45943974|NCT00312832|Drug|switching; dose reduction|
45943975|NCT05035706|Procedure|Biopsy|Undergo biopsy
45943976|NCT05035706|Procedure|Biospecimen Collection|Undergo blood and tissue sample collection
45943977|NCT05035706|Other|Electronic Health Record Review|Medical records reviewed
45943978|NCT05035706|Other|Photography|Photographs taken
45943979|NCT00312871|Drug|Epoetin alfa|
45656777|NCT04831645|Procedure|Tibiotalocalcaneal Arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
45807766|NCT04546477|Device|Stent implantation|"Procedure can be conducted via either contralateral or antegrade approach. After a successful target lesion crossing, predilate the lesion using either plain old balloon angioplasty (POBA) or (if necessary) any available specialty balloon. The inflated diameter of the balloon should approximate the diameter of the vessel just distal to the lesion. Proper vessel preparation should achieve diameter of 1:1 to healthy vessel (with ≤20% residual stenosis, as per operator's assessment). Adjunctive debulking devices are prohibited.~Final stent selection should be confirmed after a proper vessel preparation, considering the reference vessel diameter (RVD) for the optimal 1:1 stent-to-vessel sizing. The implanted dual layer length would encompass the entire lesion with the micromesh, covering it from healthy to healthy tissue. Post-dilatation of the stent for more optimal placement may be done at operator's discretion, using standard angioplasty with uncoated balloon."
45656778|NCT04824937|Drug|Telaglenastat|Capsule, taken by mouth
45656779|NCT04824937|Drug|Talazoparib|Capsule, taken by mouth
45807767|NCT04544813|Drug|JNJ-77474462|Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).
45943980|NCT00090675|Drug|ZD1839|
45943981|NCT00312910|Drug|Probiotics-Bio-plus|
45943982|NCT00312949|Behavioral|Interactive Website on management of schizophrenia|Participants in the web-user group will sit with a laptop computer, answer questions about themselves and their treatment, receive feedback on care that may be inconsistent with current recommendations, and receive suggestions on how to discuss this with their physicians.
45943983|NCT00312949|Behavioral|Written materials and video on management of schizophrenia|Participants in the written materials/video group will be given the reading material and will watch a 20-minute video.
45943984|NCT05027438|Behavioral|Cognitive Behavioral Therapy for Insomnia|A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
45943985|NCT05027438|Behavioral|Deprescribing|The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
45656780|NCT03037099|Behavioral|Enhanced GI Concept Education|
45656781|NCT04836949|Device|Shear Wave Elastography of prostate|A 12-core template biopsy is planned as during a conventional prostate biopsy. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. The elasticity of each area is evaluated and region with the maximum Young's modulus value is selected and targeted for biopsy. Additional biopsy for suspicious lesions can be performed at the discretion of the practitioner.
45807768|NCT04544813|Drug|Anakinra|Participants will receive a SC injection of anakinra 100 mg once daily for 3 days.
45943986|NCT00312988|Drug|Hycamtin|
45943987|NCT00312988|Drug|Gemcitabine|
45943988|NCT00313027|Radiation|PET scan|
45943989|NCT00122538|Drug|Efavirenz (EFV)|
45943990|NCT00122538|Drug|Lamivudine (3TC)|
45943991|NCT00122538|Drug|Didanosine (ddI)|
45943992|NCT00313105|Drug|Smokeless tobacco (Oliver Twist pellets)|individual visits with counseling
45943993|NCT00313105|Behavioral|smoking cessation counseling|individual visits
45943994|NCT04994756|Procedure|Stroke/Thrombectomy/Aneurysm-specific surgical procedures|Participants are retrospectively and/or prospectively entered into registry based on disease indication and respective surgical procedure.
45943995|NCT00313183|Drug|pramlintide acetate|single subcutaneous doses of 15mcg and 30mcg
45943996|NCT00122577|Drug|Tenofovir|
45943997|NCT00122577|Drug|Atazanavir|
45943998|NCT00122577|Drug|Ritonavir|
45943999|NCT00313261|Drug|Clevudine|
45944000|NCT00419029|Behavioral|telephone-administered motivational interviewing|telephone motivational interviewing
45944001|NCT00419029|Behavioral|control|brief telephone check-in (no motivational interviewing)
45807769|NCT04540497|Drug|Inebilizumab|Inebilizumab is a monoclonal antibody that depletes B cells.
45944002|NCT00425074|Drug|slow release acetyl salicylic acid|150 mg in capsules via oral, during 14 days.
45944003|NCT00425074|Drug|ASA|normal release acetylsalicylic acid
45944004|NCT00425074|Drug|SR-ASA|slow release acetylsalicylic acid 150 mg
45944005|NCT00425152|Drug|fluorouracil|
45944006|NCT00425152|Drug|leucovorin calcium|
45944007|NCT00425152|Drug|levamisole hydrochloride|
45944008|NCT00090714|Genetic|pVGI.1(VEGF2)|
45944009|NCT00314314|Drug|Intranasal Insulin|Intranasal spray; 40 IU qid; 8 weeks
45656782|NCT04836949|Device|Conventional Prostate Ultrasound|A conventional 12-core template biopsy is planned. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. Random biopsy of each area is performed. Additional biopsy of suspicious hypoechoic nodular lesions can be performed at the discretion of the practitioner.
45656783|NCT04836793|Other|Additional biological samples|Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected
45944010|NCT00314314|Drug|Diluent|Intranasal spray; 8 weeks
45944011|NCT00314392|Behavioral|Information (behavior)|
45944012|NCT00314431|Procedure|Care coordination by telephone contacts with a nurse|
45656784|NCT04428073|Biological|Covax-19™|Therapeutic vaccine for SARS-CoV-2 infection
45656785|NCT04824313|Diagnostic Test|Chest CT|Chest CT without intravenous contrast material
45656786|NCT04824313|Diagnostic Test|Chest CTA|Chest CT with intravenous contrast material
45656787|NCT04824235|Other|Amniotic Chorion Membrane and Bio-Oss xenograft|Bioxclude Amniotic Chorion Membrane with xenograft (Bio-Oss) for ridge preservation
45656788|NCT04824235|Other|Amniotic Chorion Membrane only|Bioxclude Amniotic Chorion Membrane only
45656789|NCT04824157|Other|Non|Follow up
45656790|NCT04824001|Other|exercise stress echocardiography|Stress echocardiography test. The standardized exercise test was conducted by 50-W semi-recumbent cycling for 3 min. Stress echocardiograph images were acquired at the third minute of cycling to ensure that subjects had reached a steady-state HR.
45656791|NCT03036085|Drug|Liposomal bupivacaine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline.
45807770|NCT04540497|Other|Placebo|Placebo
45807771|NCT04539366|Drug|Cyclophosphamide|Given IV
45807772|NCT04539366|Drug|Fludarabine Phosphate|Given IV
45807773|NCT04539366|Biological|GD2-CAR-expressing Autologous T-lymphocytes|Given IV
45807774|NCT04538664|Drug|Amivantamab|Amivantamab will be administered as an IV infusion at a dose of 1400 mg (1750 mg if body weight is >=80 kilogram [kg]) by once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is >=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3.
45807775|NCT04538664|Drug|Pemetrexed|Pemetrexed will be administration as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arms A and B.
45807776|NCT04538664|Drug|Carboplatin|Carboplatin will be administration as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle.
45656792|NCT03036085|Drug|Bupivacaine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
45944013|NCT00122616|Biological|Peginterferon alpha-2a (Pegasys®)|Peg-Interferon Alpha2a by subcutaneous injection, 180µg, once weekly
45944014|NCT00122616|Drug|Ribavirin|Ribavirin: tablet oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over 75 kg, once daily
45944015|NCT00122616|Drug|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
45944016|NCT00122616|Drug|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
45944017|NCT04984070|Drug|Oral Contraceptives, Combined|One of the three medications like ethinylestradiol (35 μg) and cyproterone acetate, drospirenone and ethinylestradiol tablets (I) and (Ⅱ) will be used as an antiandrogen.
45944018|NCT04984070|Drug|Metformin Pill|Metformin is used to lower insulin resistance or to modulate hyperinsulinism.
45944019|NCT04984070|Other|lifestyle intervention|Weight control including calorie restriction and moderate exercise will be recommended to obese PCOS patients
45944020|NCT00314509|Drug|Ciclesonide/Formoterol Combination|
45944021|NCT00314548|Drug|PGE1 (prostacyclin)|alprostadil nebulization
45944022|NCT00314548|Drug|normal saline|nebulize for 30 mins
45944023|NCT00314587|Procedure|1 or 2 elastic stable intramedullary nails|
45944024|NCT00314626|Drug|efavirenz|Efavirenz
45944025|NCT00314626|Drug|Abacavir+lamivudine|Abacavir+lamivudine
45944026|NCT02960074|Biological|Fecal Microbiota Capsule|We will treat patients with oral encapsulated frozen FMT over 2 days.
45944027|NCT00314665|Drug|Thalidomide|
45944028|NCT00314704|Drug|dopamine versus norepinephrine|
45944029|NCT00090909|Drug|cisplatin|
45944030|NCT00090909|Drug|dexamethasone|
45944031|NCT00090909|Drug|gemcitabine hydrochloride|
45944032|NCT04943627|Drug|Balstilimab (BAL)|Anti-PD-1 Monoclonal antibody
45944033|NCT04943627|Drug|Topotecan|Chemotherapy
45944034|NCT04943627|Drug|Vinorelbine|Chemotherapy
45944035|NCT04943627|Drug|Gemcitabine|Chemotherapy
45944036|NCT04943627|Drug|Irinotecan|Chemotherapy
45944037|NCT04943627|Drug|Pemetrexed|Chemotherapy
45944038|NCT00314743|Drug|Ondansetron|
45944039|NCT00314743|Drug|Dexamethasone|
45944040|NCT00314743|Drug|Aprepitant|
45807777|NCT04535544|Drug|JNJ-73763989|JNJ-73763989 will be administered as a SC injection.
45807778|NCT04535544|Drug|Placebo|Matching placebo to JNJ-73763989 will be administered as a SC injection.
45807779|NCT04535544|Drug|Entecavir (ETV) monohydrate|ETV monohydrate film coated tablet will be administered orally.
45944041|NCT00314782|Drug|ZD4054 (Zibotentan)|oral tablet
45944042|NCT00314782|Drug|Docetaxel|intravenous infusion
45944043|NCT00314782|Drug|Placebo|
45944044|NCT00122655|Drug|non-nucleoside reverse transcriptase inhibitors|
45944045|NCT00122655|Drug|nucleoside reverse transcriptase inhibitors|
45656793|NCT03036085|Drug|Epinephrine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
45656794|NCT03036085|Drug|Normal saline|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline or with bupivacaine plus epinephrine plus normal saline.
45656795|NCT05618431|Other|NIPT|This research aims to develop and validate a new method for non-invasive prenatal testing
45656796|NCT04823767|Other|Single anastomosis sleeve jejunal bypass with hiatal repair|Single anastomosis sleeve jejunal bypass with hiatal repair
45807780|NCT04535544|Drug|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally.
45807781|NCT04535544|Drug|Tenofovir alafenamide (TAF)|TAF film coated tablet will be administered orally.
45807782|NCT04535414|Device|Cellvizio (Registered trademark)Real-Time In Vivo Cellular Imaging Platform with Confocal Miniprobes|Participants of both study arms will undergo confocal endomicroscopy of the gastric mucosa until sufficient data for statistically accurate and reliable application of machine learning (i.e., computer models), currently believed to total the first 50 enrolled participants.
45807783|NCT04535414|Device|Olympus GIF 190 endoscope|Participants will undergo white light endoscopy. The mucosa of the stomach may be thoroughly washed before examination, as medically indicated, and inspection will include repeated inflation and deflation to check distensibility and any abnormal appearing areas will additionally be biopsied. Nontargeted biopsies will be obtained as indicated per the assigned Arm.
45807784|NCT04533529|Drug|Seltorexant|Seltorexant tablet will be administered orally once daily.
45807785|NCT04533529|Drug|Placebo|Matching placebo tablet will be administered orally once daily.
45807786|NCT04530565|Procedure|Biospecimen Collection|Correlative studies
45944046|NCT00122655|Drug|protease inhibitors|
45944047|NCT00314821|Drug|ropinirole|
45944048|NCT00314860|Drug|ropinirole Extended Release (XR)|
45944049|NCT04928339|Drug|Bupivacaine Injection|10mL of 0.25% bupivacaine
45944050|NCT04928339|Drug|Liposomal bupivacaine|15mL of 133mg liposomal bupivacaine
45944051|NCT04928339|Other|Saline|25mL saline control
45944052|NCT00091104|Biological|MART-1:27-35 peptide vaccine|
45944053|NCT00091104|Biological|aldesleukin|
45656797|NCT04836871|Combination Product|DFPP combined with chemotherapy|Double filtration plasmapheresis combined with chemotherapy
45656798|NCT04836481|Other|Serum Sample Collection|Each patient will have 5 serum samples collected for analysis after a minimum six consecutive doses. Patients receiving LEV8 will have sampled collected at hours 0.5, 1, 4, 6, and 8. Patients receiving LEV12 will have sampled collected at hours 0.5, 1, 4, 8, and 12.
45807787|NCT04530565|Biological|Blinatumomab|Given IV
45807788|NCT04530565|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
45807789|NCT04530565|Drug|Cyclophosphamide|Given IV
45656799|NCT04831333|Other||
45807790|NCT04530565|Drug|Cytarabine|Given IV or IT
45807791|NCT04530565|Drug|Dasatinib|Given PO
45807792|NCT04530565|Drug|Dexamethasone|Given PO or IV
45807793|NCT04530565|Drug|Doxorubicin Hydrochloride|Given IV
45807794|NCT04530565|Procedure|Echocardiography|Undergo ECHO
45807795|NCT04530565|Procedure|Electrocardiography|Undergo ECG
45807796|NCT04530565|Procedure|Lumbar Puncture|Undergo lumbar puncture
45944054|NCT00091104|Biological|filgrastim|
45944055|NCT00091104|Biological|incomplete Freund's adjuvant|
45944056|NCT00091104|Biological|therapeutic autologous lymphocytes|
45944057|NCT00091104|Biological|therapeutic tumor infiltrating lymphocytes|
45944058|NCT00091104|Drug|cyclophosphamide|
45944059|NCT00091104|Drug|fludarabine phosphate|
45944060|NCT00091104|Procedure|autologous hematopoietic stem cell transplantation|
45944061|NCT00091104|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45944062|NCT00091104|Radiation|total-body irradiation|
45944063|NCT00314938|Drug|PHA-794428|
45944064|NCT04893278|Other|Virtual reality|Use of Virtual reality goggles during procedure
45944065|NCT00313339|Drug|Intra-coronary infusion|In our study there will be four dosing cohorts (5, 10, 20 and 30 x 106) of CD34+ cells.
45944066|NCT00313378|Drug|Hypothetica|
45944067|NCT00122694|Drug|carbon monoxide|
45944068|NCT00313417|Dietary Supplement|Creatine monohydrate|Up to 10 grams
45944069|NCT00313417|Other|Placebo|Placebo will be given in the same way and appearance as the active treatment
45944070|NCT00313456|Drug|Satraplatin|Satraplatin is an oral platinum analogue that has shown promising activity in multiple tumor settings. Satraplatin (40 to 80 mg/m2/day) will be administered orally on days 1 to 5 of a 21 day cycle.
45944071|NCT04861727|Other|MRPA procedure|The patient will receive the device for BP measurement at home for a week and two daily measurements will be taken, one in the morning (between 6 and 10 am) and one in the afternoon / evening (between 6 pm and 10 pm), for seven days. At the end of the procedure, it is expected to record 14 measurements (representing a total of 42 in seven days), but it is considered feasible when at least 10 results are recorded, respecting the number of two measurements per day, in the periods oriented. Participants who do not reach the satisfactory number of measures or do not check between the times mentioned above, will be invited to repeat the procedure
45656800|NCT04831255|Drug|triamcinolone acetonide extended-release injectable suspension|ZILRETTA (triamcinolone acetonide extended-release injectable suspension) injection in the glenohumeral joint administered under ultrasound guidance.
45944072|NCT04861727|Other|Pharmaceutical intervention|The suggestion procedure, for this research, is defined as the pharmaceutical act of forwarding a letter of suggestion to the prescriber, previously agreed with the patient, based on clinical evaluation, review of pharmacotherapy, adherence to treatment and result of the MRPA procedure.
45944073|NCT00313534|Drug|masoprocol|
45944074|NCT00313573|Procedure|management of therapy complications|
45944075|NCT00313573|Procedure|pain therapy|
45944076|NCT00313573|Procedure|psychosocial assessment and care|
45656801|NCT04831177|Procedure|Laser in situ keratomileusis|Laser in situ keratomileusis LASIK is a procedure used to correct different types of ametropia through a creation of corneal flap whether with femtosecond laser or mechanically with a microkeratome followed by application of excimer laser to correct different refractive errors including Myopia, Hyperopia and Astigmatism.
45656802|NCT02432235|Drug|Camidanlumab tesirine|Intravenous (IV) infusion.
45656803|NCT04916535|Other|diagnostic flow|exams to estimate the risk of adverse events in patients with MAD
45656804|NCT02431533|Dietary Supplement|PX0612|PX0612 is a probiotic contained in a veggie capsule.
45656805|NCT02431533|Dietary Supplement|Di-Calcium Phosphate|Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
45656806|NCT02416791|Device|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
45656807|NCT02416791|Device|Active tDCS|Active tDCS will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
45656808|NCT02416791|Device|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
45656809|NCT02416791|Other|Physical Therapy|Physical therapy will be administered for 40 minutes.
45656810|NCT02416791|Other|Occupational Therapy|Occupational therapy will be administered for 40 minutes.
45656811|NCT02414841|Drug|Vonapanitase|
45807797|NCT04530565|Drug|Mesna|Given IV
45807798|NCT04530565|Drug|Methotrexate|Given IV or IT
45656812|NCT02414841|Drug|Placebo|
45656813|NCT02413593|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
45656814|NCT02413593|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45656815|NCT04942353|Behavioral|Home-based Exercise Rehabilitation.|Based on physical therapist or exercise physiologist assessment, subjects will receive an individualized exercise prescription for frequency, duration, and intensity of walking and strength training (including exercises using light-weight hand-weights and upper and lower body exercises using resistance bands). Research team will provide updated exercise prescription based on Garmin watch/Datos app activity data and Datos app data (including Borg scale).
45656816|NCT04942353|Behavioral|Usual Care|Patients receive a standardized recommendation to increase their walking activity to 30 minutes 5 days/week.
45656817|NCT04942275|Drug|Pre-therapeutic imaging test|The radiopharmaceutical used for lung perfusion PET consists in human albumin macroaggregates labeled with Ga-68 (68Ga-MAA). 68Ga- MAA are administrated intravenously.
45807799|NCT04530565|Procedure|Multigated Acquisition Scan|Undergo MUGA
45807800|NCT04530565|Drug|Ponatinib Hydrochloride|Given PO
45807801|NCT04530565|Drug|Prednisone|Given PO
45944077|NCT00313573|Procedure|quality-of-life assessment|
45656818|NCT01652703|Biological|Evolocumab|Administered by subcutaneous injection
45656819|NCT01652703|Other|Placebo|Administered by subcutaneous injection
45944078|NCT00313690|Drug|Bortezomib, Docetaxel and Cisplatin|
45944079|NCT00402402|Procedure|Tuberculin skin test|
45944080|NCT00402402|Procedure|Quantiferon-TB Gold assay|
45944081|NCT00313807|Drug|Amino Acid|7% amino acid infusion
45656820|NCT01652469|Drug|Erlotinib|Erlotinib 150 mg/day p.o. continuously with 21 days cycle.
45807802|NCT04530565|Drug|Vincristine Sulfate|Given IV
45807803|NCT04530513|Radiation|Stereotactic ablative radiotherapy - Level 1|6Gy x 2 fractions to all sites in 2 weeks
45807804|NCT04530513|Radiation|Stereotactic ablative radiotherapy - Level 2|6Gy x 3 fractions to all sites in 3 weeks
45807805|NCT04530513|Radiation|Stereotactic ablative radiotherapy - Level 3|6Gy x 4 fractions to all sites in 4 weeks
45807806|NCT04530513|Radiation|Stereotactic ablative radiotherapy - Level 4|6Gy x 5 fractions to all sites in 5 weeks
45944082|NCT00313807|Drug|Placebo|0.9% Saline Infusion
45944083|NCT00313885|Drug|eplivanserin (SR46349)|oral administration
45944084|NCT00313885|Drug|placebo|oral administration
45944085|NCT00091143|Biological|gp100 antigen|
45944086|NCT00091143|Biological|incomplete Freund's adjuvant|
45944087|NCT00091143|Biological|keyhole limpet hemocyanin|
45944088|NCT00091143|Drug|fludarabine phosphate|
45944089|NCT00091143|Procedure|peripheral blood stem cell transplantation|
46002160|NCT04609176|Drug|Camrelizumab plus Apatinib and SOX|Camrelizumab 200mg, day1; Apatinib 250mg qd p.o.;Oxaliplatin 130 mg/m2 day1; S-1 40-60 mg (calculated according to the body surface area) bid day1-14. 3 weeks for one cycle.
45807807|NCT04530513|Radiation|Stereotactic ablative radiotherapy - De-escalation Level|6Gy x 1 fraction to all sites in 1 week
45944090|NCT04898452|Other|A new model of interaction across health services with use of welfare technology and telemedicine|Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
45944091|NCT04767919|Procedure|Standard Percutaneous Nephrolithotomy (sPCNL)|Endoscopic stone procedure using a laser placed in the kidney through an 30 Fr access sheath following balloon dilation.
45944092|NCT04767919|Procedure|Minimally Invasive Percutaneous Nephrolithotomy (MIP)|Endoscopic stone procedure using a laser placed in the kidney through an 18 Fr access sheath following either balloon dilation or dilation using a single step metal dilator.
45656821|NCT01652469|Drug|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion every 21 days.
45656822|NCT02429427|Drug|Celecoxib|Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.
45944093|NCT04671329|Device|Affirm Contrast Biopsy procedure|Contrast Enhanced Digital Mammography (CEDM) is an extension of the existing indication for diagnostic mammography with the Selenia Dimensions system and 3Dimensions system. Biopsy targeting can be done on captured contrast enhanced images (scout and stereo pair). The CEDM application shall enable contrast enhanced breast imaging using a dual energy technique. This imaging technique can be used as an adjunct following mammography and/or ultrasound exams to localize a known or suspected lesion. Affirm Contrast Biopsy is intended for patients recommended for biopsy who have had a suspicious finding on previous contrast enhanced imaging or have lesions that may be occult under other modalities.
45944094|NCT00091182|Drug|oxaliplatin|Given IV
45944095|NCT04635280|Device|any closed-loop automatic insulin delivery system (or artificial pancreas) CE-marking|A closed-loop automatic insulin delivery system includes a combination of an insulin pump, a continuous glucose monitoring system and a dedicated terminal.
45944096|NCT04729790|Drug|PRIM-DJ2727|oral FMT capsules
45944097|NCT04593901|Behavioral|Video and App Review|"Scenario Review: The scripts and/or videos will be iteratively reviewed by individual and small groups of home healthcare personnel using Zoom, Microsoft Teams, or similar. The participants will review scripts and/or recordings of the scripts and discuss how well each situation has been represented, how to improve it, and whether it is applicable in their agency.~App Review: Following review of the scenarios, participants will review the smartphone app currently under development, including the control buttons, their placements, and other features of the screen interface. The first 9-12 participants (approximately) will be asked to provide feedback on the app's layout, control locations, and overall appearance. Once suggested changes have been made, the app will then be reviewed by the remaining participants for final review and usability assessment."
45656823|NCT02429427|Other|Placebo|Two capsules once daily with food
45656824|NCT04911465|Device|Flashback CRI T1 Tablet|Collect continuous data on the compensatory reserve index, a measurement of a patient's central volume status.
45656825|NCT05370573|Other|No intervention|Observational - no interventions
45656826|NCT02412735|Drug|Rexlemestrocel-L|Rexlemestrocel-L injection
45807808|NCT04524871|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.
45656827|NCT02412735|Drug|Rexlemestrocel-L + HA Mixture|Rexlemestrocel-L was combined in 1:1 by-volume ratio with HA solution and the resulting mixture was injected
45656828|NCT02412735|Drug|Placebo|Saline control solution
45807809|NCT04524871|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.
45807810|NCT04524871|Drug|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
45807811|NCT04524871|Drug|Tocilizumab|Tocilizumab will be administered at a dose of 8 mg/kg by IV infusion on Day 1 of each 21 day cycle.
45807812|NCT04524871|Drug|TPST-1120|TPST-1120 will be administered at a dose of 1200 mg by mouth on Days 1-21 of each 21 day cycle.
45807813|NCT04524871|Drug|RO7247669 2100 mg|RO7247669 will be administered at a dose of 2100 mg by IV infusion on Days 1 and 15 of each 28 day cycle.
46002161|NCT04609176|Drug|Camrelizumab plus Apatinib|Camrelizumab 200mg, day1; Apatinib 250mg qd p.o. 3 weeks for one cycle.
45656829|NCT02412657|Drug|Dexamethasone|After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.
45656830|NCT02412657|Drug|Normal Saline|
45807814|NCT04524871|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 10 mg/kg by IV infusion on Days 1 and 15 of each 28 day cycle.
45807815|NCT04524871|Drug|RO7247669 600 mg|RO7247669 will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
45807816|NCT04524871|Drug|RO7247669 1200 mg dose|RO7247669 will be administered at a dose of 1200 mg every 3 weeks.
45807817|NCT04524871|Drug|ADG126|ADG126 will be administered at a dose of 6 mg/kg by IV infusion on Day 1 of every other cycle (cycle length = 21 days).
45944098|NCT04586452|Diagnostic Test|AAA Group (Aim 3A)|"The primary goal is to relate preoperative 64Cu-DOTA-ECL1i AAA uptake with CCR2+ cell activity in AAA tissue collected at the time of open repair. We will image AAA patients pre-operatively and collect tissue at the time of open repair in an attempt to demonstrate ex-vivo tissue corroboration of our imaging findings (n=20, 10 women and 10 men).~Participants with AAA will undergo routine clinical evaluation including ultrasound, CT scan and scheduling of open surgical repair. We will record age and tobacco use. If a renal function blood test has not been performed within the past 90 days, we will draw ~2 teaspoons of blood for a creatinine test. A contrast dye will be used for the CT portion of the PET-CT scan. Those having open surgery, their PET/CT imaging will be within 7-14 of the surgery and if available, collection of discarded aortic tissue at the time of surgery."
45944099|NCT04586452|Diagnostic Test|Non-AAA Group|We will determine the retention of 64Cu-DOTA-ECL1i in abdominal aorta of non-AAA volunteers (n=10, 5 women and 5 men). This group of participants will have a documented absence of AAA by screening ultrasound that was previously obtained as part of standard care. Both men and women, above the age of 40, with or without active tobacco use will be considered for participation.
45944100|NCT04586452|Other|Ex Vivo Human AAA Specimens (Aim 2A)|The primary objective of this sub-aim is to assess the sensitivity and specificity of 64Cu-DOTA-ECL1i binding to ex vivo to human AAA specimens from the Washington University Vascular Surgery Biobank (VS-BB). We will first perform a histopathological evaluation of human AAA specimens (n=75, including samples from this study) and categorize them based on clinical status (e.g, diameter) and degree of inflammation. We will consider healthy, nonatherosclerotic aorta (n=25) as negative controls, and non-aneurysmal aortas (n=25) from patients that have undergone surgery for aortoiliac occlusive disease as positive controls.
45944101|NCT04586452|Other|Relationship between radiotracer and CCR2 (Aim 2B)|The objective of this sub-aim is to better understand the relationship between the levels of CCR2+ inflammatory cells and the inflammatory and clinical status of AAA, to gain insight into the importance of proinflammatory monocytes/macrophages in the development of AAA disease at the time of elective AAA repair. We will correlate the level of MMP expression and activity, as well as cytokine profiles, of each specimen, with the associated histopathological features. The relationship between 64Cu-DOTA-ECL1i binding and CCR2 expression in tissues with different degrees of disease severity will be evaluated using Pearson or Spearman correlation coefficients. This will allow us to speculate as to how tracer uptake will perform in vivo and what that uptake represents in regard to disease severity.
46002162|NCT04593940|Drug|Infliximab|study drug or matching placebo
45656831|NCT02428413|Device|ISO-Gard Mask|to scavenge waste anesthetic gases from patients and provide supplemental oxygen
45807818|NCT04524364|Device|Pulsed Field Ablation (PFA) Therapy|Participants will undergo PFA therapy with a compatible ablation catheter when used with Multi-Channel irreversible electroporation (IRE) Generator (deliver trains of high-voltage bipolar pulses of short duration on separate channels to a multi-electrode ablation catheter) and Circular IRE Catheter (indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with an IRE Generator, for cardiac ablation).
45807819|NCT04523207|Drug|Apalutamide|Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) oral tablets during the main study and sub-study.
45807820|NCT04523207|Drug|ADT|Participants will receive ADT intramuscular or subcutaneously during the main study.
45656832|NCT02428413|Device|Standard oxygen mask|Provide supplemental oxygen
45656833|NCT02412111|Drug|Ivacaftor|
45656834|NCT02412111|Drug|Tezacaftor/Ivacaftor|
45656835|NCT02427477|Device|senofilcon A|Subjects will wear the contact lenses in both eyes for seven days
45656836|NCT02427477|Device|delefilcon A|Subjects will wear the contact lenses in both eyes for seven days
45656837|NCT02427399|Other|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests.
45656838|NCT02427399|Other|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders.
46002163|NCT04593940|Drug|Abatacept|study drug or matching placebo
45807821|NCT04523207|Drug|Relugolix|Participants will receive 120 mg of relugolix following a loading dose of 360 mg of (3 tablets of 120 mg each) relugolix during the sub-study.
46002164|NCT04593940|Drug|Remdesivir|Standard of Care
46002165|NCT04593940|Drug|cenicriviroc (closed to enrollment as of 3-Sep-2021)|study drug or matching placebo
45656839|NCT02427399|Other|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
45656840|NCT02427399|Other|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called.
45656841|NCT02426541|Drug|Dapagliflozin|Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
45656842|NCT02426541|Drug|Placebo|Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
45656843|NCT02484651|Drug|Sugammadex|Reversal of deep neuromuscular block
45656844|NCT02484651|Drug|Rocuronium|Maintenance of deep neuromuscular block
45656845|NCT02410551|Drug|Pacritinib|200 mg by mouth twice a day for 60 days.
45656846|NCT02410551|Drug|Busulfan|Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days.
45656847|NCT02410551|Behavioral|Questionnaires|Questionnaires completed at baseline, 1, 3, 6, and 12 months after transplant.
45656848|NCT02410551|Behavioral|Phone Calls|Phone calls made by study staff to participant on second and third week of each month.
45656849|NCT02410551|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation (Allo TP) 60 days after starting Pacritinib but not more than 180 days.
45656850|NCT02410551|Drug|Fludarabine|Fludarabine taken along with Busulfan as per standard of care as preparative regimen for allogeneic stem cell transplantation (Allo TP).
45453125|NCT03564470|Drug|Dasatinib|Dasatinib will be administrated at a dose of 100mg/day in dasatinib arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for dasatinib arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (dasatinib, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (dasatinib, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.
45656851|NCT02424591|Drug|Ketamine|Infusion at a rate of 10 mcg/kg/min
45807822|NCT04521231|Drug|Blinatumomab|Blinatumomab will be administered as a subcutaneous (SC) injection.
45807823|NCT04520113|Behavioral|Household contact tracing|Household contact tracing to test and diagnose Tuberculosis of household contacts of Tuberculosis patients.
45807824|NCT04519658|Drug|CIN-107|CIN-107 tablets by mouth once daily
45807825|NCT04519658|Drug|Placebo|placebo tablets by mouth once daily
45807826|NCT04519619|Drug|Aflibercept (Eylea, BAY86-5321)|Administration by intravitreal injection
45807827|NCT04514510|Drug|Isoquercetin|"Isoquercetin (quercetin-3-O-beta-D-glucoside, also referred to as isoquercitrin) is a naturally occurring monoglucoside of the most studied and widely consumed bioflavonoid, quercetin.~Isoquercetin given at 1000 mg, once daily by mouth for 28 days."
45807828|NCT04514510|Drug|Placebo|"Silicified microcrystalline cellulose NF, Ascorbic acid, Nicotinic acid, Mg stearate, Silica and Colloidal Anhydrous Ph. Eur./Colloidal Silicon dioxide USP/NF.~Placebo give at 1000 mg, once daily by mouth for 28 days."
45807829|NCT04513912|Drug|Seltorexant|Participants will receive seltorexant over-encapsulated tablet orally.
45807830|NCT04513912|Drug|Matching placebo to Seltorexant|Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.
45807831|NCT04513912|Drug|Quetiapine XR|Participants will receive quetiapine XR capsule orally.
45807832|NCT04513912|Drug|Matching placebo to Quetiapine XR|Participants will receive placebo capsule matching to quetiapine XR orally.
45807833|NCT04511702|Biological|Pegloticase with MTX|Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period
45807834|NCT04511039|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
45807835|NCT04511039|Drug|Talazoparib Tosylate|Given PO
46002166|NCT04590235|Drug|Selumetinib|"All eligible subjects will first receive a single oral dose of selumetinib 25 mg/m^2. After a washout period of 2 days, oral selumetinib 25 mg/m^2 twice daily will be administered continuously. Subjects will continue to receive selumetinib until disease progression or unacceptable drug-related toxicity, whichever occurs first.~10 mg and 25 mg capsules strengths available."
46002167|NCT04562090|Drug|mirabegron|Mirabegron was administered as single oral dose of 25 mg or 50 mg sustained-release tablet
45453126|NCT01574144|Device|AVIVO™ PiiX Patch Monitor System|External monitoring for 30 days post-discharge.
45656852|NCT02424591|Other|Placebo|Placebo IV
45656853|NCT02408523|Drug|Lacosamide Tablet|"Active Substance: Lacosamide~Pharmaceutical Form: Film-coated Tablet~Concentration: 50 mg~Route of Administration: Oral use"
45656854|NCT02408523|Drug|Lasosamide Oral Solution|"Active Substance: Lacosamide~Pharmaceutical Form: Oral Solution~Concentration: 10 mg/ml~Route of Administration: Oral use"
45656855|NCT02408523|Other|Placebo Tablet|"Active Substance: Placebo~Pharmaceutical Form: Film-coated Tablet~Concentration: 50 mg~Route of Administration: Oral use"
45807836|NCT04509700|Drug|Parsaclisib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
45807837|NCT04509700|Drug|parsaclisib + itacitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
45807838|NCT04509700|Drug|parsaclisib + ruxolitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
45807839|NCT04509700|Drug|parsaclisib + ibrutinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.
45807840|NCT04504916|Drug|Zilovertamab vedotin|Intravenous infusion
45807841|NCT04501679|Drug|Nemolizumab|Participants will receive either 30 mg or 60 mg dose of nemolizumab as SC injection.
45807842|NCT04501679|Drug|Placebo|Participants will receive matching placebo as SC injection.
45807843|NCT04501367|Drug|Dexamethasone Intracanalicular Insert, 0.4 mg|To determine post-surgical resolution of pain, inflammation, and cystoid macular edema outcomes when treated with one DEXTENZA (lower eye lid canaliculus) compared to topical steroid treatment in patients who undergo vitrectomy with internal limiting membrane peel surgery
45807844|NCT04501367|Drug|Dexamethasone Intracanalicular Insert, 0.4 mg|To determine post-surgical resolution of pain, inflammation, and cystoid macular edema outcomes when treated with two DEXTENZA (upper and lower canaliculi) compared to topical steroid treatment in patients who undergo vitrectomy with internal limiting membrane peel surgery
45807845|NCT04501367|Drug|Prednisone acetate 1%|To reduce post-surgical pain and inflammation in patients who undergo vitrectomy with internal limiting membrane peel surgery
45807846|NCT04500483|Diagnostic Test|indirect calorimetry|measurement of resting energy expenditure using indirect calorimetry
45807847|NCT04500288|Device|LEFT Device|LEFT device is a novel electronic wearable device that was developed as a sleep position therapy for patients who suffer from nighttime gastroesophageal reflux symptoms. It is simple, noninvasive and low-cost technology which has been developed by Side Sleep Technologies B.V. Singel, Amesterdam, The Netherland.
45807848|NCT04497844|Drug|Niraparib|Participants will receive Niraparib 200 mg once daily.
45807849|NCT04497844|Drug|Abiraterone acetate (AA)|Participants will receive AA 1000 mg once daily.
45656856|NCT02408523|Other|Placebo Oral Solution|"Active Substance: Placebo~Pharmaceutical Form: Oral Solution~Concentration: 10 mg/ml~Route of Administration: Oral use"
45807850|NCT04497844|Drug|Prednisone|Participants will receive prednisone 5 mg once daily.
45807851|NCT04497844|Drug|Placebo for Niraparib|Participants will receive matching placebo for Niraparib once daily.
46075278|NCT05003349|Other|Motor Imagery (MI).|"The participants will have to judge the laterality of different cervical images presented on the screen of a cell phone. The laterality task will be executed using an application called Recognize Neck, developed by the NOI group. The procedure will begin with a familiarization test with the Basic level followed by a laterality discrimination task. It will be performed using 20 images, with 5 seconds for each image, beginning with the Vanilla program and progressively increasing the difficulty using the Context and Abstract programs. The estimated time to complete the task will be about 10 minutes per session."
46075279|NCT05003349|Other|Action Observation (AO).|The patients will see videos showing the jaw and cervical exercises with the same series and repetitions that they will actively perform in the session. Therefore, the training of the action observation will be carried out dynamically. The patient will be asked to think and visualize the movement that he/she will have to perform later. It is estimated 10 minutes per session for the AO.
46075280|NCT05003349|Other|Jaw and Neck Exercises (JNE)|A jaw and neck exercise program will be carried out in 3 series of 10 repetitions per session will be planned with 1minute rest between exercise. The exercises will be executed with a total time per session of 20 minutes, initially in the clinic and later at home. In the clinic, verbal and tactile instructions will be provided for the correct execution of the exercises and later they will be sent through WhatsApp and / or mail to perform them at home.
46075281|NCT05003349|Other|Counselling.|Counselling include education about the anatomical, biomechanical and psychosocial factors relationed with temporomandibular disorders, guidance regarding the parafunction jaw activities for eg will be taught the resting postural position of the mandible (teeth apart, lips slightly touching and tongue not pushing against the teeth).
46075282|NCT02787252|Device|Implant procedure, Freedom Spinal Cord Stimulation System|A needle is carefully inserted near the spinal cord. The stimulator is then slide through the needle to lay close to the spinal cord. The end of the stimulator is then sutured underneath the skin of the back.
46075283|NCT04204109|Other|Interprofessional case-based learning|"The trial is an educational intervention where groups of healthcare professionals receive the same case-based learning: one group receives case-based learning with healthcare professionals of various professional backgrounds (experimental) versus another group receiving case-based learning with healthcare professionals exclusively of the same professional background (control).~The educational intervention consists of a case that is developed for the purpose of the intervention.~The participants in the experimental group will be randomised into six teams who will receive interprofessional case-based learning. The experimental group will be made up of healthcare professionals from various groups. The participants in the control group will be randomised in groups of one profession"
45656857|NCT04830319|Other|Pilates Method|includes exercises in soil, that associate the correct respiratory movement with muscular strengthening and control, stretching from the eccentric movement, selective upper and lower trunk movements. There will be used accessories described by the method for their realization. Participants will perform the first week of awareness and body alignment exercises for 10 minutes, 10 minute breath perception, 10 minute proximal muscle accuracy and control, and 10 minute stretches; from the second week will be included selective trunk movements, with muscle strengthening of lower limbs. Rest intervals will be performed between exercises.
45807852|NCT04496960|Drug|tofacitinib|XELJANZ(R) is the citrate salt of tofacitinib. Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo [2,3-d]pyrimidin-4-ylamino) -beta-oxo-1-piperidinepropanenitrile, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) It is freely soluble in water and has a molecular weight of 504.5 Daltons. XELJANZ(R) is supplied for oral administration as 5 mg tofacitinib (equivalent to 8 mg tofacitinib citrate) white round, immediate-release film-coated tablet. Each tablet of XELJANZ(R) contains the appropriate amount of XELJANZ(R) as a citrate salt and the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, HPMC 2910/Hypromellose 6cP, titanium dioxide, macrogol/PEG3350, and triacetin.
45807853|NCT04496960|Other|Placebo|white, round, film-coated tablet
45807854|NCT04491617|Other|Standard opioid prescribing|Patients are routinely prescribed opioid medications in addition to non-opioids.
45807855|NCT04491617|Other|Restrictive opioid prescribing|Patients are prescribed non-opioid pain medications, and will be prescribed opioids only if they request them.
45807856|NCT04490057|Drug|Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler|Participants will be prescribed both long-acting and short-acting nicotine replacement therapy.
45807857|NCT04490057|Drug|Varenicline or bupropion|Participants will be prescribed varenicline (Chantix) or bupropion (Wellbutrin).
45807858|NCT04490057|Behavioral|Contingency Management|Participants will be financially rewarded for abstinence to tobacco.
45807859|NCT04489823|Device|Amplatzer Valvular Plug III|Transcatheter closure of a paravalvular leak using Amplatzer Valvular Plug III
45807860|NCT04487392|Drug|Estrogen vaginal cream group (group A)|The participants selected for group A will be provided with estriol 0.01% vaginal cream, which should be applied at home: 1 intravaginal applicator at night, daily for 2 weeks, followed by 2 times a week, on alternate days (Monday - Thursday) for another 2 weeks.
45807861|NCT04487392|Radiation|Photobiomodutation group (group B)|The participants selected for group B will be undergo photobiomodulation with red LED. With the participant in the lithotomy position, the speculum will be introduced into the vaginal canal and a vaginal wash with 0.9% saline will be performed to remove secretions. Afterwards, the speculum will be removed and the device with a red LED inserted up to about 6 cm from the introitus. A non-lubricated condom will be used in the LED device for patient protection. Sessions will take place once a week for 4 weeks.
45944102|NCT04586452|Diagnostic Test|AAA Group (Aim 3B-Reproducibility)|We will demonstrate consistent 64Cu-DOTAECL1i uptake by performing repeated imaging studies in a separate group of non-surgical AAA patients (n=20, 10 women and 10 men). Completion of this sub-aim will provide support for the use of 64Cu-DOTA-ECL1i PET for evaluating AAA disease in a reliable fashion. These participants will have another PET/CT imaging study performed 10-14 days after the first PET/CT in order to determine the ability to reproduce the uptake results of Cu-64-DOTA-ECL1i. The physician will assess the participant's willingness and eligibility to have a second PET/CT scan.
45944103|NCT00122733|Drug|loxapine|
45944104|NCT04563208|Drug|Placebo|Placebo administered on Days 1-5
45944105|NCT04563208|Drug|DuACT|Day1: RBV 600 mg BID and NTZ 500 mg BID Days 2-5: RBV 400 mg BID and NTZ 500 mg BID
45944106|NCT04519879|Other|Clinical Observation|Undergo clinical observation
45944107|NCT04519879|Other|Patient Observation|Undergo active surveillance
45944108|NCT04519879|Other|Questionnaire Administration|Ancillary studies
45944109|NCT04519879|Drug|White Button Mushroom Extract|Given PO
45944110|NCT02965131|Procedure|Temporary portocaval shunt|The hepatic artery, bile duct, and portal vein are dissected and clamped. The retrohepatic vena cava is preserved with selective clamping of the hepatic veins during total hepatectomy. Then, temporary portocaval shunt is constructed by end-to-end anastomosis of the portal vein stump to the middle and left hepatic vein trunk or by end-to-side anastomosis of the stump to the infrahepatic vena cava depending on the remaining length of the vessels.
45944111|NCT04468633|Device|Baerveldt 350 implant|The Baerveldt implant is an FDA-approved silicone, non-valved implant.
45656858|NCT04830319|Other|task-oriented training protocol|The control-test group (CTG) will initiate the task-oriented training protocol. The task-oriented training protocol will include functional exercise drills, such as sit-up and workout, obstacle course workout, speed-and-direction workout, balance workout, work-up and downhill workout, each tasks performed for eight minutes, with two minutes of rest between them. The difficulty in carrying out the tasks will be progressively adjusted. At all times, individuals will be instructed to contract the pelvic floor musculature. After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. Next, the CTG group will perform 20 sessions of Pilates exercises.
45656859|NCT04836403|Other|Sinus and nasal quality of life survey questionnaire (SN-5)|"The SN-5 consists of five questions on a 7-point scale that assesses the frequency of the following symptoms: (1) nasal obstruction, (2) sinus infection, (3) allergies, (4) emotional distress, and (5) activity limitations. The scoring system is as follows: 1 indicates none of the time, 2 indicating hardly any time at all, 3 indicates a small part of the time, 4 indicates some of the time, 5 indicates a good part of the time, 6 indicates most of the time, and 7 indicates all of the time. Higher scores indicate more severe sinonasal symptoms. One item from a global faces scale scored from 0 to 10 is used to evaluate overall QoL related to nasal or sinus disease. Higher scores on this scale indicate a less severe impact of nasal or sinus disease. The scores from the first five items (1-7 each)"
45807862|NCT04487080|Drug|Amivantamab|Participants will receive amivantamab intravenously.
45944112|NCT04468633|Device|Ahmed ClearPath 350 implant|The Ahmed ClearPath is a non-valved glaucoma drainage device.
45453127|NCT03685760|Other|Reiki therapy|Reiki, a complementary health approach where trained practitioners place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. Reiki therapists will administer the Reiki intervention (i.e., a 30-minute treatment in which the subject is lightly touched for 3 minutes at each of 10 standardized Reiki hand positions).
45807863|NCT04487080|Drug|Osimertinib|Participants will receive osimertinib capsules orally.
45944113|NCT04432012|Drug|Dexamethasone Sodium Phosphate 4 mg/ml intravenous|Perioperative intravenous injection of 3 ml of solution (9mg of dexamethasone)
45944114|NCT04432012|Drug|Dexamethasone Sodium Phosphate 4 mg/ml intra-articular|Perioperative intra-articular injection of 3 ml of solution (9mg of dexamethasone)
45944115|NCT04383496|Behavioral|Physical Activity|In-person, virtual conferencing, and telephone sessions, wearable device for daily feedback and motivation
45807864|NCT04487080|Drug|Lazertinib|Participants will receive lazertinib tablets orally.
45807865|NCT04487080|Drug|Placebo|Participants will receive matching placebo orally.
45807866|NCT04485546|Drug|cenegermin-bkbj|Cenegermin-bkbj ophthalmic solution administered as one drop in affected eye(s) every 2 hours 6 times daily for 8 weeks
45807867|NCT04483479|Drug|Active Investigational Treatment ENT-01|ENT-01 will be administered in tablet form, once daily in escalating doses followed by a fixed-dose for 12 weeks.
45807868|NCT04482933|Drug|Biological G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
45807869|NCT04480541|Behavioral|Roadmap 2.0 information system|Caregivers and patients download the Roadmap 2.0 app on their own mobile phones/tablet
45807870|NCT04480541|Other|Wearable activity sensor|Caregivers and patients will receive a Fitbit wearable activity sensor
45807871|NCT04480541|Other|Survey administration|Caregivers and patients will be asked to complete health-related quality of life surveys
45807872|NCT04478344|Other|Ultrasound guided hydrodissection of superior cluneal nerve|Intervention procedure: hydrodissection to the superior cluneal nerve entrapment; Device for guidance of injection: high-resolution ultrasound ; Drug for injection: a mixture of 1 mL of 50% dextrose, 4 mL of 1% lidocaine, and 5 mL of 0.9% normal saline
45807873|NCT04476446|Drug|Esketamine|Participants will receive esketamine at doses of either 56 mg or 84 mg intranasally once or twice a week based on the investigator's clinical judgment.
45944116|NCT04613141|Device|WalkingTall-PD|Smart garment (socks, insoles or ankle bands) delivering rhythmic haptic stimuli to the ankle timed with preferred cadence. Smart phone application delivers auditory cues synchronised with haptic stimuli. Smart phone application delivers a neurorehabilitation program.
45944117|NCT04613141|Other|Mobility-plus|Active 'pseudo placebo' comparator using a paper-based body weight exercise program.
45944118|NCT00091299|Drug|warfarin|
45944119|NCT04363957|Other|Brachytherapy video|Patients will watch a video that contains information about brachytherapy
45944120|NCT04363957|Other|Standard Brachytherapy Consent Process|Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.
45944121|NCT04607603|Drug|Cannabidiol Oral Product|Cannabidiol is administered in capsules. Each capsule contains 200mg of CBD administered 3 times daily to a total of 600mg per die
45944122|NCT04607603|Drug|Placebo|Placebo will be administered in capsules of identical appearance to CBD capsules in 3 doses per die
45944123|NCT00122772|Radiation|Radiotherapy|"External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy"
45944124|NCT00122772|Radiation|Radiotherapy|"External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy"
45944125|NCT00122772|Radiation|Radiotherapy/Cisplatin|"External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy~Cisplatin 40 mg/sqm weekly"
45944126|NCT00122772|Radiation|Radiotherapy/Cisplatin|"External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy~Cisplatin 40mg/sqm weekly"
46075284|NCT00877513|Behavioral|Smoking cessation|Smoking cessation program over 8 weeks, consisting of cognitive behavioral counseling every 2 weeks along with adjunctive use of bupropion
45656860|NCT04836091|Behavioral|Waitlist|From day 31 to day 60 (ie., during month 2) of the trial, participants in the waitlist arm will be granted access and instructed to use the OurPlan program as directed. The OurPlan program includes 4 modules covering topics of communication, HIV/STI prevention, HIV/STI statistics, and stigma / discrimination. Each module contains content, questions, and an activity for the participant and couple to complete. OurPlan also includes a resource locator using GPS-capabilities to allow participants to find sexual health resources, as well as a calendar and reminder system. One goal of OurPlan is to help both partners of the couple create and use a risk-reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own and partner-related attitudes toward these strategies.
45807874|NCT04475497|Other|Blood management|Treatment will include PO iron, IV iron, B12 or folate per blood management algorithm.
45807875|NCT04475497|Other|Usual care|Usual care per surgeon preference can include iron by mouth or no iron therapy.
45807876|NCT04472416|Device|VRD in addition to standardized analgesic protocol|Use of VRD in addition to standardized analgesic protoco for abdominal VAC dressing change
45807877|NCT04471844|Device|Optune®|"Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division.~In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.~In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.~The study treatment plan will continue for 24 months, if no tumor progression."
45807878|NCT04468984|Drug|Navitoclax|Tablet; Oral
45807879|NCT04468984|Drug|Ruxolitinib|Tablet; Oral
45807880|NCT04468984|Drug|Best Available Therapy (BAT)|Tablet/Capsule; Oral or Solution for Subcutaneous Injection
45807881|NCT04468659|Drug|Lecanemab|IV infusion.
45807882|NCT04468659|Drug|Placebo|IV infusion.
45807883|NCT04466150|Drug|Ocrelizumab|open label biomarker study
45807884|NCT04459507|Other|No intervention|No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through participant charts and prospective data will be collected in accordance with clinical practice at the participant's clinic visits.
45807885|NCT04457362|Diagnostic Test|Diagnostic Arthroscopy using the Arthrex NanoScope|"A diagnostic arthroscopy will be performed with the Arthrex NanoScope.~Structures evaluated:~Radial styloid~Proximal scaphoid articular cartilage~Scaphoid fossa~Radioscaphocapitate (RSC) ligament~Long radiolunate (LRL) ligament~Short radiolunate (SRL) ligament~Scapholunate (SL) ligament~Proximal lunate articular cartilage~Lunate fossa~Triangular fibrocartilage complex (TFCC) The attending performing the diagnostic arthroscopy will make an initial diagnostic assessment based on the presence/location/severity of synovitis, articular cartilage integrity, ligament injury and determine the intended treatment."
45807886|NCT04457362|Diagnostic Test|Diagnostic Arthroscopy using standard arthroscopic instruments|"A diagnostic arthroscopy will be performed with the standard arthroscopic instruments.~Structures evaluated:~Radial styloid~Proximal scaphoid articular cartilage~Scaphoid fossa~Radioscaphocapitate (RSC) ligament~Long radiolunate (LRL) ligament~Short radiolunate (SRL) ligament~Scapholunate (SL) ligament~Proximal lunate articular cartilage~Lunate fossa~Triangular fibrocartilage complex (TFCC) The attending performing the diagnostic arthroscopy will make the final diagnostic assessment based on the presence/location/severity of synovitis, articular cartilage integrity, and ligament injury and determine the final treatment."
45944127|NCT04346212|Diagnostic Test|Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)|We will assess dysphagia, nutritional status and needs of compensatory treatment (fluid and nutritional adaptation) in patients with COVID-19 disease. We will also collect clinical data, information about swallowing and nutritional status and needs through the electronical medical history of the patients and by telephone call at 3 and 6 months follow-up, as well as clinical complications.
45944128|NCT04314934|Drug|ANAVEX2-73|Oral capsules
45944129|NCT04600934|Device|Shockwave|Shockwave Medical, Inc. Peripheral Lithoplasty® System
45944130|NCT04600934|Device|Plain old balloon angioplasty|POBA
45944131|NCT00091338|Biological|MART-1 antigen|
45944132|NCT00091338|Biological|gp100 antigen|
46075285|NCT02786784|Other|6 week exercise treatment|This six-week exercise programme was developed based on the current recommendations, consisting of four exercises to strengthen gluteus medius and maximus muscle, as well as the quadriceps muscle. In addition, two exercises to stretch the hamstrings muscles and to increase the ankle dorsi range of motion were included.
45807887|NCT04455230|Genetic|FLT190|FLT190 is a recombinant adeno-associated viral (AAV) vector (AAVS3) containing the human αGLA gene as a single stranded (ss) deoxyribonucleic acid (DNA).
45807888|NCT04450069|Combination Product|CLBR001 and SWI019|Investigational immunotherapy for B cell malignancies
45807889|NCT04442737|Drug|D/C/F/TAF FDC|A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.
45807890|NCT04442737|Drug|TAF/FTC FDC|TAF/FTC ARV regimen will be administered once daily.
45807891|NCT04442737|Drug|INI Based Regimen|The integrase (INI) inhibitors (for example, bictegravir, dolutegravir, elvitegravir/cobicistat, and raltegravir) will be administered in combination with TAF/FTC, as appropriate. Regimen may consist of a single tablet regimen or a combination of two separate pills.
45453128|NCT03685760|Other|Sham Reiki|Sham (pretend) Reiki therapists will administer the sham Reiki intervention (i.e., a 30-minute treatment in which the subject is lightly touched for 3 minutes at each of 10 standardized Reiki hand positions). Sham providers do not have Reiki training.
45807892|NCT04442295|Drug|STK-001 - Single Ascending Doses|Experimental : Single Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Four dose levels will be evaluated ( 10mg, 20mg,30mg, 45mg and 70mg ).
45807893|NCT04442295|Drug|STK-001 - Multiple Ascending Doses|Experimental : Multiple Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Three dose levels will be evaluated ( 20mg,30mg and 45mg ).
45807894|NCT04439539|Drug|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously.
45807895|NCT04439539|Drug|PegIFN-alpha-2a|PegIFN-alpha-2a injection will be administered subcutaneously.
45807896|NCT04439539|Drug|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally.
45807897|NCT04439539|Drug|Tenofovir alafenamide|Tenofovir alafenamide film-coated tablet will be administered orally.
45807898|NCT04439539|Drug|JNJ-56136379|JNJ-56136379 will be administered orally.
45807899|NCT04439526|Drug|Guselkumab|Participants with moderate facial and/or genital psoriasis treated with guselkumab (as prescribed by their physician) in real world practice will be observed in this study.
45807900|NCT04439136|Drug|Afatinib Dimaleate|Given PO
45807901|NCT04439123|Drug|Capivasertib|Given PO
45807902|NCT04439110|Biological|Trastuzumab Emtansine|Given IV
45807903|NCT04435782|Drug|JNJ-67896049|Participants will receive tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52.
45807904|NCT04432831|Drug|Faricimab|Faricimab will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen.
45807905|NCT04432831|Other|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 16 weeks of this study in order to maintain the masking of the initial faricimab PTI.
45807906|NCT04428112|Behavioral|Building Better Caregivers Workshop|"Workshops consist of small group or about 20-25 persons. Two peer co-facilitators (caregiver themselves) will guide workshop activities. Participants will receive a workshop booklet. Each week, participants will log on at least 2-3 times for a total time of approximately two hours. Participants do not require real time attendance at pre-determined times."
45944133|NCT00091338|Biological|incomplete Freund's adjuvant|
45944134|NCT00091338|Biological|recombinant interleukin-7|
46075286|NCT05001399|Behavioral|Holographic Memory Resolution® (HMR)|Clients will participate in Holographic Memory Resolution® (HMR) administered by a trained HMR practitioner. Clients will be introduced to relaxation techniques and safe scene identification. This exercise encourages the client to identify a place in which they feel safe and where nobody can be there without client's invitation. Clients will then describe the place and associated colors of the experience, how the colors move in their body, and how they move through their safe scene. The subsequent 2-3 sessions will continue to explore safe scene and color therapy.
45656861|NCT04836091|Behavioral|Intervention|From day 1 to day 60 (ie., entire 2 month duration) of the trial, participants in the intervention arm will be granted access and instructed to use the OurPlan program as directed. The OurPlan program includes 4 modules covering topics of communication, HIV/STI prevention, HIV/STI statistics, and stigma / discrimination. Each module contains content, questions, and an activity for the participant and couple to complete. OurPlan also includes a resource locator using GPS-capabilities to allow participants to find sexual health resources, as well as a calendar and reminder system. One goal of OurPlan is to help both partners of the couple create and use a risk-reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own and partner-related attitudes toward these strategies.
45807907|NCT04428112|Behavioral|Attention Control|Participants will receive two brief 15-30 minutes phone calls by study staff, and will receive a handbook on dementia and caregiver resources while they wait for the workshop.
45807908|NCT04427293|Drug|Lenvatinib|Lenvatinib 12mg daily for 7 days prior to surgery
45807909|NCT04427293|Drug|Pembrolizumab|Pembrolizumab 200 mg IV on day 1
45807910|NCT04424316|Biological|RSVpreF|RSV vaccine (RSVpreF)
45807911|NCT04424316|Biological|Placebo|Placebo
45807912|NCT04424290|Drug|BI 764524|Powder for solution for intravitreal injection.
45944135|NCT04298671|Behavioral|Yoga-Pilates|As above
45944136|NCT04560023|Other|Exposition to multimedia content|Video and images watched on a tablet. Patient could decide which information want to watch.
45944137|NCT00122811|Drug|Indapamide SR 1.5mg; Perindopril 2-4mg|
45944138|NCT04224025|Other|exercise and respiratory therapy|three weeks in-Hospital exercise Rehabilitation program with continuation at home (total 15 weeks).
45944139|NCT04188262|Combination Product|NVS Therapy|Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS light Fiber, and NVS light source.
45944140|NCT04132414|Diagnostic Test|NIRS open|Treatment according to protocol in phases of cerebral hypoxia.
45807913|NCT04406714|Behavioral|Trial Mailed FIT Intervention - Age Group 50-75|Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in an envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call.
45807914|NCT04406714|Behavioral|Sub-Study Mailed FIT Intervention Enhanced Envelope - Age Group 45-49|"Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in an enhanced envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. The enhanced envelope is a yellow padded envelope with a USPS tracking label and sticker message: Important information from your doctor. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call."
45944141|NCT04551170|Drug|Theophylline|oral theophylline
45944142|NCT04551170|Drug|Placebo|Placebo capsule or elixir
45944143|NCT00122850|Drug|Duloxetine|
45944144|NCT00122850|Drug|venlafaxine|
45944145|NCT00122850|Drug|placebo|
45944146|NCT04542278|Drug|Prednisone|used to reduce inflammation
45944147|NCT03975439|Diagnostic Test|Hemoglobin A1C|Finger stick hemoglobin A1C
45944148|NCT03975439|Diagnostic Test|Urinalysis|Urinalysis by dip stick looking for urine protein level
45944149|NCT03975439|Diagnostic Test|Whole blood creatinine level|Finger stick looking for serum creatinine as an estimate of renal function
45944150|NCT00091377|Drug|cisplatin|IV 40 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
45944151|NCT00091377|Drug|paclitaxel|IV 80 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
45944152|NCT00091377|Drug|phenoxodiol|IV 3 mg/kg
46002168|NCT04560920|Other|Availability of contextual PGD at the visit|Contextual PGD will be availability in a display at the visit.
45807915|NCT04406714|Behavioral|Sub-Study Mailed FIT Active Comparator Plain Envelope - Age Group 45-49|Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in plain envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. The plain envelope is a white envelope without a USPS tracking label or sticker message. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call.
45807916|NCT04402788|Drug|Atezolizumab|Given IV
45656862|NCT04836169|Device|InCaveo's EOA system with integrated mobile CBT|integrated pain management therapeutic and tapering system including a software apt that manages and tracks patient-reported outcomes, including pain levels, medication use, quality of life
45807917|NCT04402788|Procedure|Biospecimen Collection|Undergo blood and tissue collection
45656863|NCT04836013|Dietary Supplement|combined Lactobacilli|1 oral stick per day for 30 days starting the day of antibiotic treatment
45656864|NCT04836013|Other|Placebo|1 oral stick per day for 30 days starting the day of antibiotic treatment
45656865|NCT04822909|Drug|Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet|"The study patients will be treated with oral apremilast, administered initially a dose of 10 mg once daily, gradually increasing to reach the maximal therapeutic dosage of 30 mg twice daily before end of 1st week of starting the therapy.~The treatment will be continued till 6 months and we will taper the steroids by 10mg/ 2 weeks till 20mg and then 5 mg/ 2 weeks till discontinuation of steroids.~If a patient worsens after treatment or develops any serious adverse event after initiation of treatment, he will be withdrawn from the study.~If there is no response to the treatment and we are unable to taper steroids after 12 weeks of therapy then the patient will be withdrawn from the study"
45656866|NCT04831099|Drug|Testosterone gel|The route of administration is transdermal.
45656867|NCT04831099|Drug|Placebo|The route of administration is transdermal
45807918|NCT04402788|Procedure|Computed Tomography|Undergo CT
45807919|NCT04402788|Procedure|Magnetic Resonance Imaging|Undergo MRI
45807920|NCT04402788|Procedure|Positron Emission Tomography|Undergo PET
45807921|NCT04402788|Radiation|Radiation Therapy|Undergo radiation therapy
45807922|NCT04397276|Drug|JNJ-70218902|JNJ-70218902 will be administered.
45807923|NCT04397263|Drug|Guselkumab|Guselkumab will be administered intravenously for the first 3 doses and then subcutaneously for the subsequent doses.
45807924|NCT04391842|Combination Product|Sustained Acoustic Device with 1% Diclofenac patch|"Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 with 1% diclofenac patch~Other Names:~ZetrOZ ultrasound device~wearable ultrasound device~long duration ultrasound~LITUS device~long duration low intensity device"
45807925|NCT04383262|Drug|Lexiva|A repurposing approach, prospective, placebo-controlled clinical trial of Lexiva (used at the FDA approved, manufacturers recommended dose for HIV (1,400mg twice daily) for 12 weeks in medically refractory patients with clinically diagnosed moderate/severe LPR (RSI ≥ 20, RFS ≥ 11 and MII-pH confirmed laryngeal reflux events).
45807926|NCT04380454|Device|Functional electrical stimulation (FES)|Functional electrical stimulation (FES) is a targeted intervention that provides motor level stimulation-induced cues to improve ankle propulsion. An electrical stimulator will be used to deliver stimulation during walking (Grass S8800 stimulator with SIU8TB stimulus isolation unit; UDel stimulator). A customized, real-time system will be used to control the stimulator and deliver stimulation during appropriate phases of the gait cycle. Stimulation will be delivered to the ankle dorsiflexors when the subject's foot is in the air (swing phase). Stimulation will be delivered to the ankle plantarflexors during the terminal stance phase of gait. 30-Hz variable frequency stimulation trains 170 will be delivered during gait. The intervention comprises 3 training sessions per week for a total of 12 training sessions. FES intensity is determined at the start of every training session as motor-level stimulation that elicits appropriate functional movements.
45807927|NCT04380454|Other|Fast treadmill walking|Fast treadmill walking (Fast) is a non-targeted intervention where no specific instructions are provided to target practice to the paretic leg or specific ankle deficits. The intervention comprises 3 training sessions per week for a total of 12 training sessions. Each training session includes six 6-minute walking bouts with 5-minute breaks between bouts.
45807928|NCT04373057|Dietary Supplement|Galacto-oligosaccharide|GOS will be administered at determined dose levels per protocol once daily from about 30 days before transplant to about 4 weeks after transplant.
45807929|NCT04373057|Dietary Supplement|Maltodextrin|Maltodextrin will be administered at comparable dose level as GOS (in Phase II) once daily from about 30 days before transplant to about 4 weeks after transplant.
45807930|NCT04372615|Drug|Inebilizumab|"RCP: Blinded treatment on Day 1, Day 15,~Inebilizumab group: Inebilizumab 300 mg intravenous (IV)~Placebo group: IV matching placebo Prior to enrollment, all participants will receive standard of care, including high-dose corticosteroids (minimum of 3 days of treatment, 1 g methylprednisolone daily or equivalent) AND either IVIg (total dose range between 1.2 and 2 g/kg) OR plasmapheresis (defined as 5 or 6 exchanges).~Rescue therapy will be given to participants in either treatment group based on the results of the Week 6 assessments. Rescue therapy is cyclophosphamide 750 mg/m2 IV followed by additional doses every 28-30 days until the mRS score is ≤ 3 (at site Principal Investigator's discretion under standard of care)."
45807931|NCT04372615|Drug|Placebo|The placebo group will receive IV matching placebo on Day 1 and Day 15,
46002169|NCT04560647|Other|No intervention - Psoriasis Subject|Not currently treated plaque psoriasis patients
45656868|NCT04830085|Procedure|Hysterectomy|Hysterectomy (abdominal, vaginal or laparoscopic)
45656869|NCT04822831|Behavioral|45 Degree Semi-recumbent Position With Upper Limb Exercise Training|The experimental group was given 45 degree Semi-sitting 2 hrs and upper-limb exercise training 10 mins once a day, and this intervention kept 4 weeks.
45944153|NCT03968731|Other|Zocular Eyelid System Treatment|Zocular products contain okra-infused Zocusome micelles that gently lift and clear the oil, debris, and residue on eyelid margins. THerefore, the ZEST treatment is expected to improve signs and symptoms of Meibomian gland dysfunction (MGD) and reduce Contact lens discomfort associated with MGD.
45656870|NCT04822831|Behavioral|no 45 Degree Semi-recumbent Position With Upper Limb Exercise Training|The control group was with usual treatment.
45656871|NCT04830241|Drug|Antidepressant|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of neonatal hypotonia newborns following in utero exposure to antidepressant drugs, with a chronology compatible with the drug toxicity
45656872|NCT04302337|Procedure|Curettage adenoidectomy with transoral endoscopic ablation|Transoral endoscopic examination of nasopharynx at the end of cold curettage adenoidectomy, and, if found, ablation of residual tissue.
45807932|NCT04372108|Drug|Ustekinumab|Participants who are new users of ustekunumab will be included in the cohort. No study treatment will be administered as a part of this study.
45807933|NCT04372108|Drug|Other Biologic Therapies|Participants who are new users of other biologic therapies (for examples for example, infliximab, adalimumab, or vedolizumab administered as per the prescription record) will be included in this cohort. No study treatment will be administered as a part of this study.
45656873|NCT04302337|Procedure|Conventional cold curettage adenoidectomy|Conventional cold curettage adenoidectomy without endoscopic examination for residual tissue.
45807934|NCT04370795|Drug|Sirolimus|Post transplant immunosuppressant drug
45807935|NCT04370795|Drug|Busulfan|Conditioning drug
45807936|NCT04370795|Drug|Horse -Anti-thymocyte|Immune suppression conditioning drug
45807937|NCT04370795|Drug|G-CSF|Used to prevent infection and neutropenic fevers caused by chemotherapy
45807938|NCT04370795|Radiation|Total Body Irradiation (TBI)|Conditioning (only patients in Group 1 will receive TBI)
45944154|NCT03962959|Device|TBS|TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.
45944155|NCT04716556|Biological|Convalescent plasma|Convalescent plasma will be collected by healthy donors, recovered by COVID19 and, after standard preparation and dosage of neutralizing antibodies, it will be administered to patients with SARS-CoV2 pneumonia
45944156|NCT00091416|Biological|VRC-HIVADV014-00-VP|
45944157|NCT03897868|Drug|HCP1803|HCP1803
45944158|NCT03897868|Drug|Amlodipine|Amlodipine
45944159|NCT03897868|Drug|Losartan|Losartan
45944160|NCT03897868|Drug|Placebo|Placebo
45944161|NCT04508348|Other|Human Milk|Exclusive Human Milk diet
45944162|NCT04508348|Other|Standard of Care|This diet will include mother's milk and/or formula
45944163|NCT00122889|Drug|Garlic powder with high allicin content|
45944164|NCT00122889|Drug|Garlic powder with low allicin content|
45944165|NCT00122889|Drug|Garlic oil|
45944166|NCT00122889|Drug|Aged garlic|
45944167|NCT04453787|Other|Arch support orthoses with forefoot medial wedge|The degree of forefoot wedge will be 3 degree. If needed, it could be adjusted. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
45944168|NCT04453787|Other|Arch support orthoses|The arch support of the orthoses could be adjusted depends on the evaluation of subject. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
45944169|NCT04453787|Other|Flat insole|The flat insole used as a placebo intervention. The shape of this insole is flat, and made by soft EVA. It only provide shock absorbtion without any support. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
45944170|NCT04729868|Drug|Levobupivacaine(chirocaine) plus dexmedetomidine(precedex)|evaluate the efficacy of levo-bupivacaine alone and with dexmedetomidine in Ultrasound guided infraclavicular brachial plexus block for hand and forearm surgeries
45944171|NCT03818386|Drug|AGuIX®|"3 intravenous injection at 100mg/kg~D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT)~Fr1: AGuIX® injection before the first radiation session~Fr6: AGuIX® injection before the sixth radiation session"
45944172|NCT03818386|Radiation|Whole Brain Radiation Therapy|30 Gy in 10 fractions of 3 Gy over 2-3 weeks
45944173|NCT00122928|Behavioral|Diet|Healthy Choices in vending machines; Healthy Choices in cafeteria; Catering (Healthy Choices in site meetings, shutdowns, OT meals, etc.); Targeted Messages: Nutrition; Site Based Rewards and Recognition - Individual Employees Weight Management Tracking Program
45944174|NCT00122928|Behavioral|Exercise|Walking Paths/Routes; Weight Management Tracking Program; Targeted Messages: Physical Activity; Site Based Rewards and Recognition - Individual Employees
46002170|NCT04560647|Other|No intervention - Control Subject|Control subjects without plaque psoriasis and no family history of psoriasis
46002171|NCT04557189|Drug|TAK-951|TAK-951 SC injection
45656874|NCT03036943|Radiation|Fluciclovine|Fluciclovine (18F) PET/CT scan completed >= 48 hours prior to surgical resection for breast cancer
45656875|NCT03036865|Drug|BOS161721|Single dose administered IV or SC
45656876|NCT03036865|Drug|Placebo|Single dose administered IV or SC
45807939|NCT04370756|Dietary Supplement|Beetroot Juice|Participants randomly assigned to the EX + BR group will consume 140 mL beetroot juice containing approximately 12 mmol of nitrate 3 hours prior to the supervised exercise training component.
45656877|NCT04835389|Biological|AlloGen Liquid|Amniotic fluid
45807940|NCT04370756|Other|Exercise Training|Participants will perform 8 weeks of supervised exercise training at a frequency of 3x per week.
45807941|NCT04369911|Procedure|Acupuncture|Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
45807942|NCT04360681|Drug|Lofexidine|BID dosing, and a max daily dose of 1.6 mg/day
45944175|NCT00122928|Behavioral|Environmental Obesity Program - Healthy Culture|Site Goal Setting; Work Group Alignment to Site Goals; Reporting to Senior Leadership; Leadership Training; Site Leadership, Cross Discipline Teams, Work Groups, Healthy Culture Focal Point Rewards and Recognition
45807943|NCT04360681|Drug|Placebo oral tablet|Placebo
45656878|NCT04835389|Drug|Placebo|0.9% normal saline
46075287|NCT02790450|Drug|Benzbromarone|1x200mg Benzbromarone will be applied after baseline measurements during right heart catheterization. The effects of the drug on the pulmonary hemodynamics will be assessed after 2 hours.
46075288|NCT00873691|Device|ICD|Intervention isn an ICD. Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
45656879|NCT04832893|Diagnostic Test|steady intensity aerobic test of 30 minutes long|the use of different type of masks during an aerobic exercise
45656880|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
45656881|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X2 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
45656882|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 3 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
45807944|NCT04349436|Biological|RP1, intra-tumoral injection, oncolytic virus|Genetically modified herpes simplex type 1 virus
45807945|NCT04344795|Drug|TPST-1495 twice daily|TPST-1495 administered orally twice daily
45807946|NCT04344795|Drug|TPST-1495 once daily or on intermittent schedule|TPST-1495 administered orally once daily or on intermittent schedule
45807947|NCT04344795|Drug|Pembrolizumab|Pembrolizumab dosed per label recommendations
46075289|NCT00630461|Biological|Clinical Center Reference Endotoxin|single inhalation challenge
45453129|NCT03191630|Behavioral|Fitbit (Control)|Study procedures include group sessions at the OSU Transplant Clinic with 10-12 participants for 6 months and a 6-month maintenance phase without contact from study personnel until month 12. Session 1 for the control group will be identical to the Intervention with the only exception being that participants in the control group will not be asked to increase their step goal. Throughout their participation, subjects will be asked questions only about their use of the Fitbit activity tracker. The research team will not be in contact with them for 6 months, after which time there will be a final group session.
45458051|NCT03506074|Diagnostic Test|Flavor test|The flavor test was developed, validated and patented (patent no. 0001426253 of the Italian Ministry for the Economic Development). It consists of a series of 20 aromatic extracts, corresponding to routine dietary use flavors for Italian people. At each administration, participants were invited to identify the aromatic by making a choice from 5 proposed items. A total of 21 aromatics (including one blank) were administered sequentially. The flavor score (FS) was calculated as the sum of correctly identified aromatics and ranged from 0 to 21.
45458052|NCT01139983|Genetic|DNA analysis|
45458053|NCT01139983|Genetic|RNA analysis|
45458054|NCT01139983|Genetic|fluorescence in situ hybridization|
45807948|NCT04339751|Drug|Vorinostat|Administration of Vorinostat
45656883|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
45656884|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X mg IV every 2 weeks. Treatment with avelumab will continue until disease progression
45656885|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks which can be escalated to X4 mg every 2 weeks based on safety and efficacy. Treatment with avelumab will continue until disease progression.
45656886|NCT04367935|Drug|Pentoxifylline|Pentoxifylline tablets 400mg three times daily for 2 months
45656887|NCT04829773|Drug|Palovarotene|oral capsules
45656888|NCT04829773|Drug|midazolam|oral syrup
45807949|NCT04337255|Other|Behavioral Dietary intervention ( MIND Diet)|The MIND diet is a hybrid of the Mediterranean and DASH diets but with selected modifications based on the most compelling evidence in the diet dementia field. The MIND diet has the same basic components of the DASH and Mediterranean diets, such as emphasis on natural plant based foods and limited animal and high saturated fat foods, but uniquely specifies green leafy vegetables and berries as well as food component servings that reflect the nutrition dementia evidence.
45807950|NCT04337255|Other|Behavioral Usual Care Diet Intervention|The Usual Care diet is comprised of both westernized (e.g. Steak, Mac n Cheese) and healthy ( veggie chili) food components
45807951|NCT04337203|Behavioral|SHARE-S Implementation Program|The program consists of three components: An electronic referral among clinical teams for potential participants, patient engagement with survivorship care planning guidelines through self-management/health coaching. One coaching call before a clinic visit (60 minutes) and two coaching calls after the clinic visit (30 minutes each). Participants will also receive automated, tailored text messages (daily for three weeks before and after a clinic visit for a total of six weeks).
45944176|NCT04409990|Diagnostic Test|Shear Wave Elastography|SWE value of rectal lesions
45944177|NCT03807778|Drug|TAK-788|TAK-788 capsule
45944178|NCT04371614|Behavioral|Prime Time Sister Circle|The PTSC is a multi-faceted, facilitated, curriculum- and community-based, intensive, support group intervention with 25-30 mid-life African American women per group.
46075290|NCT02790528|Drug|Atorvastatin|20mg QD
46075291|NCT02790528|Drug|Placebo|Placebo drug will be administered.
45656889|NCT04822285|Behavioral|Psychological Triaging Intervention|The PTI intervention followed the path of RAPID Psychological First Aid model of John Hopkins University (Everly& Lating 2012). The content of the PTI represents a simple structure that is revolved around five core phases including (R: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition& follow up).
45656890|NCT04822285|Behavioral|Routine psychological support|For the comparison group, the researchers provided them with routine psychological support that mainly revolved around enhancing their self-compassion, practicing mindfulness exercises, keeping them socially connected with their family and peers. Moreover, adopt a healthy lifestyle such as; engage in physical activity, eating a well-balanced diet, and sleeping well.
45656891|NCT04829695|Drug|Artesunate-amodiaquine drug combination|Artesunate-amodiaquine is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
45656892|NCT04829695|Drug|Artemether-lumefantrine drug combination|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
45807952|NCT04334759|Drug|Durvalumab|Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks
45807953|NCT04334759|Drug|Standard Chemotherapy|Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation
45807954|NCT04334759|Drug|Ipilimumab and Nivolumab|Ipilimumab 1 mg/kg every 6 weeks and Nivolumab 360 mg every 3 weeks or 3 mg/kg every 2 weeks for up to 2 years
45807955|NCT04330248|Drug|Erdafitinib|Participants will receive single oral dose of erdafitinib tablets on Day 1 in Period 1 and on Day 28 in Period 2.
45807956|NCT04330248|Drug|Carbamazepine|Participants will receive an oral dose of carbamazepine tablets from Day 15 to 35 in Period 2.
45807957|NCT04328844|Drug|IOA-244|IOA-244 will be administered orally once daily (QD)
45807958|NCT04328844|Drug|Avelumab Injection|Avelumab will be administered IV every 2 weeks
45807959|NCT04328844|Drug|Pemetrexed|Pemetrexed will be administered IV every 3 weeks
45807960|NCT04328844|Drug|Cisplatin|Cisplatin will be administered IV every 3 weeks
45807961|NCT04328844|Drug|Ruxolitinib|Ruxolitinib will be administered orally twice a day (BD)
45807962|NCT04327024|Drug|Verinurad|"The treatment will be titrated in 3 steps for target low dose (3 mg), intermediate dose (7.5 mg) and high dose (12mg) of verinurad.~Drug: Allopurinol The treatment will be titrated in 3 steps. Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol."
45807963|NCT04327024|Drug|Allopurinol|Study treatments will be titrated in 3 steps: Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol
45807964|NCT04327024|Drug|Placebo for verinurad|Matching Capsule
45807965|NCT04327024|Drug|Placebo for allopurinol|Matching tablet
45807966|NCT04322149|Drug|AT-1501|AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
45807967|NCT04316637|Drug|Arimoclomol|Participants receive prescribed arimoclomol by oral administration
46075292|NCT04039711|Procedure|Vaginal self-sampling|The objective is to determine the non-inferiority of vaginal self-sampling compared with vaginal/cervical classical sampling, and evaluate the possibility of using it in all clinical situations indicating the prescription of such a procedure to screen for genital infections (GIs), sexually transmitted infections (STIs) and group B streptococcus (GBS) asymptomatic carriage in pregnant women.
46075293|NCT00953615|Drug|Thalidomide|Titrate to 400 mg daily for 6 months
46075294|NCT02787096|Device|LaxIRM|Dynamic knee laxity measurement coupled to MRI for the diagnosis of ACL tear
46075295|NCT00873769|Drug|Inhaled Loxapine 10 mg|Staccato Loxapine 10 mg, single dose
46075296|NCT02785614|Drug|trazodone hydrochloride prolonged-release tablet|150 mg, oral administration, 1 per day
45458055|NCT01139983|Genetic|microarray analysis|
45458056|NCT01139983|Genetic|polymerase chain reaction|
45807968|NCT04315272|Drug|Azithromycin|Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
45807969|NCT04315272|Drug|Placebo|Placebo
45807970|NCT04314531|Drug|TILD|one 1 mL injection of study medication
45807971|NCT04314531|Drug|matching placebo injections|one 1 mL injection of placebo
46075297|NCT02785614|Drug|trazodone hydrochloride tablet|50mg, oral administration 3 times per day
46075298|NCT02859155|Procedure|Multivisceral en bloc resection surgery|Multivisceral en bloc resection for colorectal cancer in advance patients (T4)
45944179|NCT00400257|Behavioral|Early detection of heart failure|Early detection of heart failure
45944180|NCT00419887|Drug|Vildagliptin (LAF237)|
45944181|NCT03690544|Drug|Apremilast 30mg|Apremilast is an oral small-molecule inhibitor of phosphodiesterase (PDE) 4 that works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. PDE 4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells. PDE4 inhibition elevates intracellular cAMP levels, which in turn down-regulates the inflammatory response by modulating the expression of TNF-alfa, IL-23, IL-17 and other inflammatory cytokines. Cyclic AMP also modulates levels of anti-inflammatory cytokines such as IL-10. Apremilast has immunomodulatory activity and, therefore, has the potential to be effective in the treatment of RAS.
45944182|NCT03685591|Drug|PF-06952229|Oral 7 days on / 7 days off - 28 day cycles (Part 1)
45944183|NCT03685591|Drug|Enzalutamide|Prostate Cancer (Part 2). 160mg, capsules, orally, daily
45944184|NCT04299620|Device|Digital Image Analysis|Analysis of images
45944185|NCT04299620|Procedure|Radical Prostatectomy|Undergo standard of care radical prostatectomy
45944186|NCT04299620|Procedure|Transrectal Ultrasound|Undergo transrectal ultrasound
45944187|NCT00123006|Behavioral|Dietary Approaches to Stop Hypertension (DASH)|4 week feeding intervention
45656893|NCT03035539|Other|Cardiac rehabilitation|AF specific cardiac rehabilitation Group education 1 hour each week for 3 months Physical training 1 hour each week for 3 months with physiotherapist
45656894|NCT03035539|Other|Standard treatment|Standard treatment
45807972|NCT04312659|Drug|Infliximab|Participants will be observed who were treated with Infliximab.
45656895|NCT04821973|Device|Radius PPG Tetherless Pulse Oximetry (Masimo)|continuous monitoring by a portable, wireless and stand-alone device
45807973|NCT04309474|Drug|Elezanumab|Intravenous (IV) infusion
45656896|NCT04821973|Device|usual monitoring|usual nurse respiratory monitoring
45656897|NCT04822207|Procedure|acupuncture|Patients undergo acupuncture at the beginning of embryo transfer cycle three times a week until 14 days after embryo transfer. Every acupuncture lasts 20 minutes.
45807974|NCT04309474|Drug|Placebo|Intravenous (IV) infusion
45807975|NCT04304352|Drug|Vinorelbine|Metronomic Vinorelbine 40 mg orally thrice a week
45944188|NCT00123006|Behavioral|Control Diet|4 week feeding intervention
45944189|NCT00314977|Drug|Doxorubicin|doxorubicin (arm A:60 mg/m2) and arm B: 50 mg/m2)
45944190|NCT00314977|Drug|Cyclophosphamide|Cyclophosphamide: (arm A; 6000 mg/m2) an (arm B: 500 mg/m2)
45458057|NCT01139983|Genetic|reverse transcriptase-polymerase chain reaction|
45944191|NCT00314977|Drug|Docetaxel|Docetaxel: (arm A: 100 mg/m2) and (arm B: 75 mg/m2)
45944192|NCT00400296|Drug|RG547|Administered iv on days 1 and 8 of a 3 week cycle at escalating doses to successive groups of patients until MTD is reached.
45944193|NCT00315016|Drug|eplerenone|active comparator
45944194|NCT00315016|Drug|fosinopril|doubling of fosinopril dose
45944195|NCT00315016|Drug|placebo|placebo (double dummy)
46075299|NCT00810615|Other|Hyperbaric oxygen @ 2.4 ATA|Subject will breath 100% oxygen at 2.4 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at 2.4 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
45458058|NCT01139983|Other|laboratory biomarker analysis|
45458059|NCT02305966|Procedure|surgery|All patients will receive a Delta XTEND reverse shoulder implant
45656898|NCT04835233|Drug|Methyldopa 250 MG|maintaining postpartum the use of methyldopa 250 mg 01 tablet every 8 hours, being able to double the dose depending on pressure levels, up to 15 days postpartum
45944196|NCT00419068|Drug|Cholecalciferol|
45944197|NCT00419068|Drug|Migliol Placebo Oil|
45944198|NCT00419146|Drug|Ethyl-eicosapentaenoic acid (EPA)|Capsules, 2 g per day for 16 weeks
45944199|NCT00419146|Drug|Vitamins E + C|RRR-alpha-tocopherol 392 mg + slow-release ascorbic acid 1000 mg per day, for 16 weeks
45944200|NCT00419146|Other|Etyl EPA (placebo)|Paraffin oil. Capsules, each 0.5 g.
45944201|NCT00419146|Other|Vitamins E+C (placebo)|Tablets containing dicalciumphosphate
45944202|NCT00123045|Behavioral|health education|
45944203|NCT04239365|Diagnostic Test|WLE followed by NBI or NBI followed by WLE (crossover design)|EMR scar is inspected using WLE followed by NBI or vice versa
46002172|NCT04557189|Drug|Ondansetron|Ondansetron IV injection
46002173|NCT04557189|Drug|Ondansetron Placebo|Ondansetron placebo-matching IV injection
46075300|NCT00810615|Other|Sham treatment|
46075301|NCT02787018|Drug|Ropivacaine and Normal saline|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 1 ml normal saline
45656899|NCT03035695|Device|Axiostat®|
45656900|NCT03035695|Device|Cotton Gauze|
45656901|NCT04834999|Other|Validation of questionnaires in Kinyarwanda|Four questionnaires, three self-report instruments (Medication Adherence Rating Scale, Internalized Stigma of Mental Illness Inventory - 9-item Version and the Mood Disorder Questionnaire) and one clinical interview (the Young Mania Rating Scale)
45656902|NCT04822051|Other|The Uncertainty Management Psychoeducation Program|The program is conducted in the form of individual psychoeducation. The training was planned to include a total of five sessions, with 60 minutes for each session once a day, and at least two sessions a week. At least two days of a gap was decided between two consecutive sessions.
45807976|NCT04304352|Drug|Capecitabine|Metronomic Capecitabine 500 mg, thrice daily
45807977|NCT04304352|Drug|Cyclophosphamide|Metronomic Cyclophosphamide 50 mg daily
45807978|NCT04298567|Drug|Rivaroxaban (Xarelto,Bay 59-7939)|Rivaroxaban (2.5 mg [BID])
45807979|NCT04298567|Drug|Acetylsalicylic acid(ASA)|ASA (75mg [QD]; dose according to local label.
45807980|NCT04297592|Drug|Cephalexin|500 mg oral tablet, 4 times daily for 7 days
45807981|NCT04297592|Drug|Doxycycline|100 mg oral tablet, 2 times daily for 7 days
45807982|NCT04297592|Drug|Cefadroxil|500 mg oral tablet, 2 times daily for 7 days
45807983|NCT04294459|Drug|Isatuximab SAR650984|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous"
45807984|NCT04294459|Drug|Acetaminophen (paracetamol) or equivalent|"Pharmaceutical form: Tablets~Route of administration: Oral"
45944204|NCT00315094|Behavioral|Caregiving support interventions (FamTechCare)|One set of combined interventions to be tested in this study are nursing interventions for the prevention of catheter-related infection, reactive depression, and HPN home care problem-solving. The other set of combined interventions are for increasing social support and use of a short nap to reduce daily fatigue. Information about all the interventions were incorporated into Internet formats as a booster for reinforcement.
45944205|NCT03426475|Procedure|interprof ACT measures|Definition of common goals between general practitioner and nursing staff, appointment of a contact person, support in assigning medication, use of name badges worn by GPs and nurses during visits, mandatory availability of contact person, standardized procedures for GPs home visits
45807985|NCT04294459|Drug|Ranitidine or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
45807986|NCT04294459|Drug|Diphenhydramine or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
45807987|NCT04294459|Drug|Methylprednisolone or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
45944206|NCT03327532|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion will be performed within 72 hours of admission and before discharge from hospital
45944207|NCT03327532|Procedure|Cardio-pulmonary and peritoneal ultrasound|Cardio-pulmonary and peritoneal ultrasound will be performed within 72 hours of admission and before discharge from hospital
45944208|NCT03327532|Biological|Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed within 72 hours of admission and before discharge from hospital
45944209|NCT03327532|Other|Telephone interview|Telephone interview will be performed 3, 12 and 24 months after discharge from hospital
45944210|NCT03327532|Biological|Urinary sample retrieved for biological assessment and biobanking|Urinary sample collection will be performed within 72 hours of admission and before discharge from hospital
45944211|NCT03327532|Procedure|jugular and renal ultrasound (optional)|optional jugular and renal ultrasound performed within 72hours of admission and before discharge from hospital
45944212|NCT00123084|Behavioral|Voice/Respiration Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort exercises focusing on increased loudness and good voice quality.
45944213|NCT00123084|Behavioral|Speech/Articulation Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort articulation exercises to promote more enunciated speech.
45944214|NCT02965196|Drug|IV Dexamethasone Therapy|
45944215|NCT02965196|Other|IV Normal Saline (NaCl 0.9%)|
45944216|NCT03325426|Device|FitBit|Daily use of physical activity tracker coupled with biweekly provider telemonitoring and feedback for 6 months and then additionally without feedback for an additional 6 months
45944217|NCT00315133|Procedure|Immunosuppression and autologous stem cell transplantation|Immunosuppression and autologous stem cell transplantation: Mobilization of hematopoietic stem cells (HSC) with cyclophosphamide (2 g/m2) and granulocyte-colony stimulating factor (G-CSF, 10 ug/kg/d), followed by collection and cryopreservation of unselected HSC and conditioning with cyclophosphamide (200 mg/kg) plus rabbit anti-thymocyte globulin (ATG 4.5 mg/kg).
45944218|NCT00091611|Drug|IL-2 (interleukin-2)|
45944219|NCT00091611|Drug|OKT3|
45944220|NCT00091611|Drug|Cyclophosphamide|
45807988|NCT04294459|Drug|Montelukast or equivalent|"Pharmaceutical form: Tablets~Route of administration: Oral"
45807989|NCT04291105|Biological|VV1|VV1 is to be administered on Day 1 and every 3 weeks as long as there is clinical benefit
45807990|NCT04291105|Biological|Cemiplimab|Cemiplimab should be given on Day 8 of Cycle 1 (28 days) and then Day 1 of each subsequent 21-day cycle.
45807991|NCT04289571|Diagnostic Test|VR Motility Tool|Participant wears VR goggles and interacts with a visual avatar via a control unit to navigate four courses. Derived parameters automatically recorded by the VR system include number and type of collisions, walking speed, task time, and distance walked.
45807992|NCT04283552|Device|Dynamic PET/CT Imaging|-Will take approximately 60 minutes
45458060|NCT02305966|Device|0.8 mm diameter Tantalum marker beads|At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant,
45458061|NCT02309554|Other|SILCS diaphragm used with ContraGel|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. ContraGel is a clear, water soluble greaseless gel packed in a metal tube.
45807993|NCT04279613|Drug|NNC0361-0041|Recombinant supercoiled plasmid encoding four human proteins: (pre-proinsulin (PPI), transforming growth factor β1 (TGF-β1), interleukin-10 (IL-10), and interleukin-2 (IL-2) is administered s.c. via syringe and needle.
45807994|NCT04279613|Other|Placebo|Placebo
45807995|NCT04276441|Device|Heart healthy Engagement Program with the Apple Watch Series 5 or later|No drug will be given as part of this study. Participants without a diagnosis of AF will be enrolled and a heart healthy Engagement Program delivered via the Heartline app on the iPhone with the Apple Watch Series 5 or later.
45807996|NCT04276441|Device|Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later|No drug will be given as part of this study. Participants with a diagnosis of AF (taking a DOAC for at least 30 days) will be enrolled and an Anti-Coagulation Adherence Module delivered via the Heartline app on the iPhone with an Apple Watch Series 5 or later.
45807997|NCT04273945|Drug|Macitentan 10 mg|Participants will receive macitentan 10 mg film-coated tablets orally.
45807998|NCT04273945|Drug|Macitentan 37.5 mg|Participants will receive macitentan 37.5 mg film-coated tablets orally.
45944221|NCT00091611|Drug|Fludarabine|
45944222|NCT00091611|Drug|Mesna|
45944223|NCT04729478|Device|Drug-induced sleep endoscopy|An intravenous bolus injection of midazolam 1.5 mg will be used to induce sleep. Maintenance of sedated sleep will be obtained by a target-controlled infusion of propofol (2.0-3.0 µg/mL).
45944224|NCT04729478|Device|Natural sleep endoscopy|Endoscopy during natural sleep.
45944225|NCT03195088|Drug|BI 473494|Solution for injection
45944226|NCT03195088|Drug|Placebo|Solution for injection
45944227|NCT00123201|Drug|Dronabinol MDI|
45944228|NCT03031483|Drug|clarithromycin and lenalidomide|"Each treatment course will consist of:~Oral Lenalidomide (Revlimid) once daily for 21 days at a dose 20 mg; in case of drug-related adverse events the dose can be reduced to 15 and 10 mg/day; Oral Clarithromycin 500 mg twice daily for 28 days. Courses will be repeated every 28 days. After the first 3 courses patients with stable disease or better response will be given another three courses. Patients with complete remission or disease progression after 6 courses will be taken off study, while patients with partial response or stable disease will receive 3 further courses of treatment. Again, patients with complete response or disease progression will stop therapy, while patients with partial response/stable disease will receive 3 further courses up to a maximum of 12 courses in total."
46075302|NCT02787018|Drug|Ropivacaine and Dexamethasone|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 4mg (1ml) dexamethasone
45807999|NCT04273945|Drug|Macitentan 75 mg|Participants will receive macitentan 75 mg film-coated tablets orally.
46075303|NCT02787018|Drug|Ropivacaine and Dexmedetomidine|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 50 mcg (1ml) dexmedetomidine
46075304|NCT02858999|Drug|PAD-VCD|12 weeks of induction chemotherapy by liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) alternating with Bortezomib-Dexamethasone-Cyclophosphamide (VCD) for a total of 4 cycles
46075305|NCT00873925|Biological|Autologous UCB|Umbilical Cord Blood stem cells CAN be collected and frozen immediately after birth in private and public cord blood banks. If a child with recent onset T1D has their OWN cord blood in storage they may qualify for this study. The cells would be released to the University of Florida where we would perform a single IV infusion of the cells once they have been thawed and washed. Depending on how the cells are stored, it may be possible to keep some portion of the cells in storage for future use.
46075306|NCT00873925|Dietary Supplement|Omega 3 FA|Omega 3 Fatty Acids commonly found in fish oil may play an important role in preserving beta cell function via their anti-inflammatory actions. Those subjects randomized to treatment will take a daily supplement supplied as a capsule that can either be swallowed whole or opened so the contents can be mixed with food.
45656903|NCT04821427|Behavioral|Brief mhealth intervention + mobile messaging to reduce sexual risk behavior and heavy drinking|The intervention is a brief, motivational video-conferencing intervention followed by four weeks of app-based, interactive mobile messages to reduce heavy episodic drinking and sexual risk behavior (condomless anal intercourse) among Black/African American and Hispanic/Latino men who have sex with men
45808000|NCT04273945|Drug|Placebo|Participants will receive matching placebo film-coated tablets orally.
45808001|NCT04272034|Drug|INCB099318|INCB099318 administered orally in 20 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle.
46075307|NCT00873925|Dietary Supplement|Vitamin D|Vitamin D is important for calcium absorption and bone health but may also play an important role in promoting healthy immune responses. Subjects randomized to intervention will take vitamin D supplied as a liquid in a dropper (1 drop per day added to food) for 1 year.
45656904|NCT05619445|Other|Whole Liquid Egg|Subjects will consume 2 fluid ounces of whole liquid eggs per day for 120 days.
45656905|NCT05619445|Other|Plant-based Egg Substitute|Subjects will consume 2 fluid ounces of liquid plant-based egg substitute (JUST eggs) per day for 120 days.
45656906|NCT04821583|Drug|Hydrocortisone|Hydrocortisone is orally administered.
45656907|NCT04821583|Drug|Placebo|Placebo is orally administered.
45656908|NCT04834921|Device|Ultraflux® EMiC®2|Ultraflux® EMiC®2-CVVHD runs in septic shock patients with AKI KDIGO 3 for 24 hours. and patients were randomised to start Ultraflux® EMiC®2-CVVHD in the first day or in the second day from the RRT start; more precisely, crossover randomized to sequence consists in Ultraflux® EMiC®2-CVVHD (first day)+ HFF-CVVHDF(second day) and HFF-CVVHDF (first day) + Ultraflux® EMiC®2-CVVHD (second day) for 48 h total without washout
45656909|NCT04829149|Other|Observational|Statin therapy group and Rosuzet tablet group
45808002|NCT04271475|Drug|Macitentan|Participants will receive Macitentan film-coated tablets orally od.
45808003|NCT04271475|Drug|Placebo|Participant will receive matching placebo tablets orally od.
45808004|NCT04271254|Diagnostic Test|PET/MR|Patient will be scheduled for a pre-surgery PET/MR within four weeks of scheduled surgery.
45808005|NCT04269902|Procedure|Biospecimen Collection|Undergo collection of blood samples
45808006|NCT04269902|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
45808007|NCT04269902|Procedure|Computed Tomography|Undergo CT
45808008|NCT04269902|Biological|Obinutuzumab|Given IV
45808009|NCT04269902|Other|Quality-of-Life Assessment|Ancillary studies
45808010|NCT04269902|Other|Questionnaire Administration|Ancillary studies
45808011|NCT04269902|Drug|Venetoclax|Given PO
45656910|NCT01668355|Other|Patient Aligned Care Team (PACT)|An integrated healthcare model to coordinate and address physical health needs of people with serious mental illness. This specialized PACT medical home model is designed for individuals with serious mental illness.
45656911|NCT01667731|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
45458062|NCT02309554|Other|SILCS diaphragm used with 3% Nonoxynol-9|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. 3% Nonoxynol-9 (branded as Gynol II) is clear, unscented water soluble greaseless gel packed in plastic tubes with a vaginal applicator.
45656912|NCT01667731|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
45656913|NCT05618119|Drug|[18F]MC225|[18F]MC225 PET scan
45808012|NCT04268121|Drug|Neoadjuvant treatment|4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide followed by surgery or chemoradiotherapy
45656914|NCT04828759|Behavioral|VR-treatment|The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
45656915|NCT04828759|Behavioral|Treatment as usual|The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
45656916|NCT04828525|Drug|Dexamethasone|adjuvant dexamethasone treatment
45808013|NCT04268121|Drug|Adjuvant treatment|Surgery (before study entry) followed by 4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide
45656917|NCT04828525|Drug|normal saline|placebo
45656918|NCT04821505|Behavioral|Health Education|didactic classroom instruction on improving ones lifestyle through healthier diet, exercise and control of substance use.
45656919|NCT04821505|Behavioral|Transcendental Meditation|TM is described as simple technique practiced 20 minutes twice a day for deep rest and relaxation.
45656920|NCT04835155|Procedure|Premature Infant Oral Motor Intervention (PIOMI)|The Premature Infant Oral Motor Intervention (PIOMI), developed by Dr. Brenda Lessen Knoll, was chosen for this study because it is the only oral motor program designed specifically for preterm babies as young as 29 weeks post menstrual age (PMA) and is the only program with a standardized training method and published intervention fidelity. The 5 minute therapy offers assisted movement to activate muscle contraction and movement against resistance to build strength in the perioral structures. The PIOMI has 8 steps where a provider uses a pinky finger to provide gentle stroking and pressure on the cheeks, lips, tongue, gums and palate to strengthen the oral sensory-motor functions and improve feeding efficiency. PIOMI ends with 2 minutes of NNS. NNS and oral stimulation have been found to mature the oral motor sensory system, and improve not only bottle feeding, but also breastfeeding.
45656921|NCT04828915|Other|Machine learning|Machine learning on vital parameters, clinical symptoms and underlying diseases
45656922|NCT04828915|Other|Machine based evaluation|Quantification of the prediction power and identification of the most relevant predictive parameters
45808014|NCT04267848|Drug|Carboplatin|Given IV
45808015|NCT04267848|Drug|Cisplatin|Given IV
45808016|NCT04267848|Drug|Gemcitabine Hydrochloride|Given IV
45808017|NCT04267848|Other|Observation|Undergo observation
46075308|NCT02859233|Other|Lack of hyperhydration|
45656923|NCT04427683|Behavioral|Brief mindful parenting program|Mindfulness exercise include formal and informal mindfulness exercises, and additional exercise for coping with anger and arousing emotions. Psychoeducation includes understanding relationship between thoughts and feelings, fight or flight responses and adaptive coping in parenting relationship.
45656924|NCT04828213|Device|Rapid Maxillary Expansion Treatment with Tooth-borne RME appliance (Hyrax)|The patients were treated with a expansion appliance containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months.
45808018|NCT04267848|Drug|Paclitaxel|Given IV
45808019|NCT04267848|Biological|Pembrolizumab|Given IV
45808020|NCT04267848|Drug|Pemetrexed Disodium|Given IV
45808021|NCT04267848|Other|Quality-of-Life Assessment|Ancillary studies
45808022|NCT04267848|Other|Questionnaire Administration|Ancillary studies
45808023|NCT04266223|Device|Mask-free surface monitoring|Mask-free headrest and couch for patient positioning for radiation therapy combined with a surface monitoring system
45808024|NCT04259632|Behavioral|Time Restricted Eating (TRE)|daily eating window restricted to 8 hours
45808025|NCT04259632|Behavioral|Caloric Restriction (CR)|15% daily caloric deficient
45808026|NCT04256512|Device|Medical Device Usage and Evaluation|Wear Elasto Gel Therapy Mittens and Foot Wraps
45808027|NCT04256512|Other|Questionnaire Administration|Ancillary studies
45808028|NCT04254978|Drug|Bomedemstat|Oral administration
45808029|NCT04252742|Drug|Erenumab|140 mg, 2 consecutive injections of 70 mg
45808030|NCT04252742|Drug|Placebo|2 consecutive injections
45808031|NCT04252612|Drug|Pramlintide|SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide.
45808032|NCT04251156|Drug|Semaglutide|Semaglutide administered subcutaneously (s.c., under the skin) as well as diet and physical activity counselling for 44 weeks. Doses gradually increased to 2.4 mg
46002174|NCT04557189|Drug|TAK-951 Placebo|TAK-951 placebo-matching SC injection
45944229|NCT04135703|Behavioral|Risk Prevention Services + Housing|opioid and related prevention services in addition to 6 months of rental assistance
45944230|NCT04135703|Behavioral|Risk Prevention Services Only|opioid and related prevention services for 6 months
46075309|NCT03870529|Drug|Vitamin A Compound|Participants randomized to this arm will receive 7 consecutive days of of Vitamin A compound without disease progression or unacceptable toxicities. Within 21 days of completion of treatment participants will undergo surgical resection
45656925|NCT04828213|Device|Rapid Maxillary Expansion Treatment with Hybrid hyrax RME appliance|The patients were treated with a Hybrid hyrax RME appliance containing a Hyrax expansion screw positioned parallel to the second premolars and mini-screws. RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months.
45656926|NCT04821193|Drug|Skin antisepsis with 5% NaHCO3 water solution|In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
45656927|NCT04821193|Drug|Skin antisepsis with 2% Chlorhexidine Gluconate solution|In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
45808033|NCT04251156|Drug|Placebo (semaglutide)|Semaglutide placebo administered s.c. as an adjunct to a reduced-calorie diet and increased physical activity regimen for 44 weeks
45656928|NCT04821037|Behavioral|ACT|Acceptance and Commitment Therapy
45656929|NCT05619367|Drug|Odronextamab|
45656930|NCT04820725|Diagnostic Test|Plantar pressure and gait|Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated using Win-Track platform (MEDICAPTEURS Technology, France).
45808034|NCT04249986|Behavioral|The Borg Rating of Perceived Exertion|Participants who satisfy the exclusion criteria and health assessment instrument are categorized in the lowest risk group for cardiac events and does not require medical screening for mild to moderate exercise per ACSM guidelines.
45808035|NCT04243330|Behavioral|Audit and Feedback|The following components will be incorporated into the audit and feedback intervention: i) individualized facility performance data (site level), ii) frequent delivery intervals (monthly), iii) comparisons with other sites, iv) graphical and text form displays of information, v) constructive, non-punitive tone, vi) target performance or benchmark provided, and vii) specific actions or recommendations for meeting the target.
45808036|NCT04243330|Behavioral|External Facilitation|Facilitation will be conducted by a team of facilitators who will employ the facilitation process to improve uptake of VA Risk ID. Trained external facilitators will flexibly deliver the facilitation process utilizing an integrated set of implementation strategies (e.g., stakeholder engagement, identification of barriers and facilitators, education, problem solving, the use of formative data, communication, and ongoing support).
45808037|NCT04242199|Drug|INCB099280|INCB099280 administered orally in 25 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle
45808038|NCT04238676|Drug|PP353|active administered by intradiscal injection
45808039|NCT04238676|Other|Placebo|Sham injection
45808040|NCT04227444|Diagnostic Test|Hologram|"Patient undergoing elective anatomical resection for lung cancer will receive standard preoperative CT scan of the chest (as usual); CT images will be subsequently elaborated by a Holographic computer to generate 3D images (holograms).Two radiologists and two thoracic surgeons will analyze CT images in a standard modality and report number of artery and vein branches for the lobe to be resected, moreover they will report every anatomical variation, according to the normal anatomy.~After that, the same two radiologists and thoracic surgeons will analyze 3D images by the use of Microsoft Hololens and perform the same analysis as quoted above.~For each review of the exam performed will be written a digitally signed clinical report to certify the timing of the evaluation and to be able to trace the analysis and any subsequent modifications of the interpretation of the CT images results."
45808041|NCT04226742|Behavioral|ADAPT Platform (Treatment)|The ADAPT platform consists of 2 modules based on evidence-based strategies from cognitive-behavioral therapy including cognitive restructuring and behavioral experiments. The platform includes didactic material, interactive tools, and crowd-features. Crowd-features are present to increase personal relevance of content and to promote engagement with the ADAPT platform through accountability. Crowd-features include requesting, responding, and exemplars.
45808042|NCT04226742|Behavioral|ADAPT Comparison (Control)|The control platform is a self-guided version of the ADAPT platform that includes no crowd-features. As such it will include only didactic material on cognitive restructuring and behavioral experiments and interactive tools.
45808043|NCT04225715|Drug|Nucleos(t)ide (NUC)|Nucleos(t)ide (NUC) will be administered orally
45808044|NCT04225715|Drug|CpAM (RO7049389)|CpAM (RO7049389) will be administered orally
45808045|NCT04225715|Drug|TLR7 (RO7020531)|TLR7 (RO7020531) will be administered orally
45808046|NCT04225715|Drug|siRNA (RO7445482)|siRNA (RO7445482) will be administered subcutaneously
45808047|NCT04225715|Drug|PEG-IFN|PEG-IFN will be administered subcutaneously
45808048|NCT04225715|Drug|PD-L1 LNA (RO7191863)|PD-L1 LNA (RO7191863) will be administered subcutaneously
45944231|NCT02838979|Dietary Supplement|First Intervention (14 days)|Oral Glutamine or Maltodextrin for 2 weeks
45944232|NCT02838979|Other|Washout (3 weeks)|No study product is taken prior to beginning crossover
45944233|NCT02838979|Dietary Supplement|Second Intervention (14 days)|Oral Glutamine or Maltodextrin for 2 weeks
45944234|NCT00091650|Drug|Olanzapine|
46075310|NCT03870529|Procedure|Therapeutic Conventional Surgery|Participants randomized to this arm will receive surgical resection
45944235|NCT00091650|Drug|placebo|
45944236|NCT02728726|Drug|Sugammadex|Sugammadex will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
45944237|NCT02728726|Drug|Placebo|Placebo will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
46002175|NCT04556461|Drug|Tralokinumab|2 x 300 mg Tralokinumab s.c. loading dose followed by 8 x 300 mg every 2 weeks (Q2W)
45944238|NCT04716517|Other|Alkasite bioactive restorative material.|"Alkasite restorative is a category of filling material, like compomer, and is essentially a subgroup~of the composite resin. Cention N is a urethane dimethacrylate (UDMA)-based, self-curing powder/liquid restorative with optional additional light curing. The liquid comprises of dimethacrylates and initiators, while the powder contains various glass fillers, initiators, and pigments. It is radio opaque and contains alkaline glass fillers capable of releasing fluoride, calcium, and hydroxide ions. Due to the sole use of cross-linking methacrylate monomers in combination with a stable, efficient self-cure initiator, Cention N displays a high polymer network density and degree of polymerization over the complete depth of the restoration."
45944239|NCT04716517|Other|Resin Modified Glass Ionomer|The resin-modified glass ionomer materials are hybrid materials of traditional glass ionomer cement with a small addition of light-curing resin, and hence exhibit properties intermediate to the two, with some characteristics superior to conventional glass ionomer materials
45944240|NCT02662153|Other|Observation only|No intervention.
45944241|NCT00091689|Drug|852A|
46075311|NCT04980651|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
45656931|NCT04828291|Behavioral|Benign Behavioral Interventions|This project will use a Randomized Control Trial (RCT) design and Daily Reconstruction Method (DRM8) to model the effects of the OMI on dynamic changes in first-year undergraduate and graduate students' well-being over time. The intervention will take place over the course of 46 days, with a 7- day follow up assessment taking place one month after the intervention. People will complete surveys through an online link leading to Qualtrics.com.
45656932|NCT04820803|Other|ORAL INTERVENTION WITH CETYLPYRIDINIUM CHLORIDE|one mouthwash containing cetylpyridinium chloride (0.07%) for 60 seconds
45808049|NCT04223934|Other|optima4BP|"optima4BP establishes a no gaps computational framework in determining the most effective treatment change that can optimize a patient's HTN management towards BP Target. All possible drug combination options available through the 16 anti-HTN drug classes and subclasses are quantitatively evaluated in the context of 5 actions: add a drug, remove a drug, replace a drug, increase a drug dose, and decrease a drug dose. The pharmacological intervention efficacy ranking is computed and the highest ranked treatment recommendation is selected for consideration by the treating physician."
45944242|NCT02645149|Drug|Standard therapy or clinical trial|Patients with BRAF V600 mutations detected by standard of care tumour testing will be treated with standard approved therapies or on clinical trials.
45458063|NCT02309554|Other|SILCS diaphragm|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring
45656933|NCT04820803|Other|PLACEBO|one mouthwash containing distilled (placebo) water for 60 seconds
45944243|NCT02645149|Drug|Matched targeted therapy|Patients with tumour found to be non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma will have tumour tested further using the extended molecular testing platform designed for this project. Patients will first receive standard therapy(ies) for non-V600 BRAF, wildtype and NRAS wildtype melanoma until disease progression or intolerable drug toxicities. Followed by a targeted therapy matched to the genetic aberration detected in their tumour on NGS testing.
45944244|NCT02645149|Drug|Trametinib and / or supportive care|Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma for whom there is no actionable genetic aberration found on extended molecular testing, may receive trametinib (if not already administered as part of standard care) and/or supportive care.
45656934|NCT03036787|Behavioral|family based intervention|behavioural advises to family for normal motor development
45656935|NCT04834843|Other|Observational study, no intervention|Observational study, no intervention
46002176|NCT04530838|Biological|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
46002177|NCT04530838|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
46002178|NCT04474054|Device|Catheter ablation to treat paroxysmal atrial fibrillation|A pulmonary vein isolation will be performed using catheter ablation
46075312|NCT04980651|Procedure|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
46075313|NCT04040257|Behavioral|Team-based approach|Team-based participation in the The Perinatal Quality Foundation Fetal Monitoring Credentialing (PQF/FMC) exam.
46075314|NCT03412266|Drug|Cytarabine|RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).
46075315|NCT02786940|Device|Cardiophone|Remote live monitoring for 15 days for detection or exclusion of arrhythmias
45656936|NCT04827511|Other|Refraction measurement with auto-ref-keratometer Canon|Refractive measurement and vitamin D level dosing
45656937|NCT04827667|Diagnostic Test|bronchoalveolar lavage|Bronchoalveolar lavage is performed by instillation and suction of saline in the middle lobe during bronchoscopy. Cytological examination and flow cytometry will be performed to assess PD-1lymphoctes.
45656938|NCT04834609|Procedure|Injection of autologous adipose tissue in anal fistula|
45656939|NCT04834531|Drug|Zhuli capsule|This capsule is made from the exact of Phyllostachys glauca McClure or Phyllostachysnuda McClure, which has the expectorant effects. It is oral used,2 capsules for once, three times a day, for 7 days.
46002179|NCT04451525|Device|MicroVention Mechanical Thrombectomy Devices as first-line treatment|Patient will be treated with mechanical thrombectomy at the direction of the treating physician
46075316|NCT00877591|Drug|Fosamprenavir/Ritonavir|1400/200 mg once daily for 15 days total
45453130|NCT03191630|Behavioral|SystemCHANGE and Fitbit (Intervention)|Study procedures include group sessions with 10-12 participants for 6 months and a 6-month maintenance phase without contact from study personnel until month 12. Study personnel will demonstrate proper Fitbit activity tracker use, and teach participants to sync to their smartphone and retrieve data from their Fitbit. Subjects will be called to encourage them to increase their step goal 5% each month. Fitbit activity tracker reports will be reviewed and participants will be asked to identify what people or things influence their physical activity. Subjects will be asked what they are learning about physical activity, their contentment level with current physical activity, and if they want to make changes. Participants will continue for months, after which time there will be a final group session.
45808050|NCT04223882|Behavioral|Management of Stress|"Psychoeducation:~Coronary artery disease, Percutaneous Coronary Intervention, traditional risk factors and emotional stress.~Stress: physiology, triggers, triad (thinking, emotion, action).~Skills training:~Identify warning signs - signs and symptoms; Monitoring of irrational automatic thoughts generating alternative interpretations of situations or unrealistic thinking patterns (Dysfunctional Thinking Records Sheet).~Self-control for stress management:~Assertiveness training, problem solving. Thought-stopping technique, designed for dysfunctional thoughts, such as, I won't do it, It won't work.~Stress Relief / Control Techniques:~Diaphragmatic Breathing: Expansion of the abdomen rather than the chest when breathing.~Progressive Muscle Relaxation: Maximize tension and alternately relax the muscles (legs, abdomen, chest, arms and face)."
45656940|NCT04834531|Drug|Placebo|The placebo capsule is filled with amylodextrin made with food colour and flavor，with the similar appearance, smell and flavor with Zhuli Capsule. It is oral used, 2 capsules for once, three times a day, for 7 days.
45808051|NCT04223882|Other|Usual care|outpatient medical appointments
45453131|NCT03191552|Device|SPIO|"SPIO (stabilizing input pressure orthosis) 2 hours will receive conventional exercise therapy with the garment on during 2 hours. SPIO 6 hours group wore the SPIO 4 hours more in addition to 2 hours during therapy.~SPIO 6 hours group will wear the SPIO 4 hours more in addition to 2 hours during therapy.~(conventional exercises :range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills"
45453132|NCT03191552|Other|conventional exercises|range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills
45656941|NCT04834531|Other|Standard medical treatment|"Standard medical treatment will be given according to the recent guidelines with the evaluation of the clinicians, include:~if the patient with AECOPD, he or she will be given with oxygen therapy, bronchodilators, glucocorticoid or antibacterial drugs;~if the patient with AECB, he or she will be given with antibacterial drugs or anti-asthmatic drugs for asthma attacks."
45656942|NCT04360135|Drug|Acetaminophen|Preemptive acetaminophen the day before surgery
45656943|NCT04360135|Drug|Placebo|Preemptive placebo the day before surgery
45656944|NCT05617885|Drug|Darolutamide|Tablet administered orally, per protocol, 2 x daily. Darolutamide is an orally administered molecular drug therapy that blocks the action of testosterone, the male sex hormone which can stimulate growth of prostate cancer.
45808052|NCT04221477|Drug|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a dose of 1000 mg at Baseline and Weeks 2, 24, 26, 50 (group 2: placebo), and 52 and subsequently from Week 80 and every 6 months thereafter, based on response.
45656945|NCT05617885|Drug|Abemaciclib|"Tablet administered orally, per protocol, 2 x daily. Abemaciclib is an orally administered molecular drug therapy that is called a CDK4/6 inhibitor. CDK4 and CDK6 are enzymes that are involved in helping healthy and cancerous cells divide and blocking these enzymes can stop cancerous cells from growing."
45656946|NCT05617885|Drug|GNRH-A Leuprolide Acetate|Administered via intramuscular injection, per standard of care. GnRH agonist is a hormonal therapy drug.
45656947|NCT05617885|Drug|GNRH-A Goserelin|Administered via subcutaneous injection, per standard of care. GnRH agonist is a hormonal therapy drug.
45808053|NCT04221477|Drug|MMF|MMF willl be administered at a target dose of 2.0 - 2.5 g/day in divided doses through Week 80.
45656948|NCT05617885|Drug|Degarelix|Administered via subcutaneous injection, per standard of care. GnRH antagonist is a hormonal therapy drug.
45808054|NCT04221477|Drug|Prednisone|Prednisone 0.5 mg/kg/day (maximum 60 mg/day) will be started on Day 2. Beginning on Day 15, prednisone will be tapered to 5 mg/day and continued until Week 80.
46002180|NCT04442919|Drug|Ticagrelor followed with Methoxyflurane|patients who received ticagrelor followed with inhaled methoxyflurane due to unstable angina
46002181|NCT04442919|Drug|Ticagrelor followed with Morphine|patients who received ticagrelor followed with intravenous morphine due to unstable angina
46002182|NCT04442919|Drug|Ticagrelor alone|patients who received ticagrelor without any analgesia due to unstable angina
46002183|NCT04435197|Drug|Pembrolizumab Injection|Pre-operative Pembrolizumab+chemoradiotherapy
46002184|NCT04432532|Other|No intervention|There are no interventions
46075317|NCT00877591|Drug|Darunavir/Ritonavir|800/100 mg once daily for 15 days total
46075318|NCT00877591|Drug|Rifampin|600 mg once daily for 15 days total
45656949|NCT04827823|Other|Retrospective evaluation of amalgam and composite restorations|Multi-surface restorations that were performed by dental students and that are in function for the last five years will be clinically evaluated with mirrors and probes according to the modified USPHS criteria.
45656950|NCT04827589|Drug|Tirabrutinib|Tablets administered orally
45656951|NCT04827589|Drug|Placebo|Tablets administered orally
45656952|NCT04834687|Behavioral|Exercise|Rope-skipping exercise for three times a week (90 minutes each time, and there is a 10 min break after 20 min Rope skipping). Exercise bracelet and smart bracelet would be used to record the energy consumption throughout the study.
45656953|NCT04834687|Behavioral|Diet|"Diet interventions include ten-hour time-restricted eating and a high-fiber diet.~Participants will be instructed to take food from 7:30 AM until 5:30 PM and completely abstain from caloric intake for the remainder of the day (14 hours fast:10 hours eat). Only noncaloric beverages were permitted outside of the eating widow.~According to the dietary recommendation proposed by Chinese Government and the existing dishes in the canteen , participants are instructed to eat following a high-diet recipe weekly from Monday to Friday which includes whole grain wheat rice, vegetables, fruits, and other foods rich in dietary fiber ."
45656954|NCT04827277|Procedure|Reverse Total Shoulder Replacement|Participants will be randomized to a reverse total shoulder replacement
45656955|NCT04827277|Procedure|Anatomic Total Shoulder Replacement|Participants will be randomized to an anatomic total shoulder replacement
45656956|NCT02605837|Drug|Oral Budesonide Suspension (OBS)|Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
45656957|NCT02605837|Drug|Placebo|Oral dose of 10 ml of placebo matched with the experimental drug.
45656958|NCT04820569|Procedure|Resection and chemotherapy|
45656959|NCT05619133|Device|PBM|"In this study, the health benefits of the addition of NIR to the light spectrum of a desk lamp already available in the market will be investigate; Ikea Ypeperlig, to which a module with high power Lumileds NIR-Leds will be attached with beam angle of 90 degrees. They will be attached in such a way that, when the lamp is installed in the right place, a 1sr beam that covers the users face, neck and hands and lower arms on the desk with the required intensity of 5mW/cm2 of NIR at the skin surface.~The device will be equipped with 3 sensors:~A distance sensor connected to the driver of the NIR-leds, such that when the user leans forward or backward, the intensity of the NIR is automatically adjusted such that the intensity on the skin remains 5mW/cm2 (see figure below).~a presence sensor~ambient vertical lux sensor by which amount of light that enters the users' eye will be measured since it is known that these have an effect sleep, mood and performance."
45656960|NCT04819789|Other|Fermotein™ dry powder porridge|At one out of four test days: Fermotein™ dry powder mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
45656961|NCT04819789|Other|Fermotein™ wet porridge|At one out of four test days: Fermotein™ wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
45656962|NCT04819789|Other|Fermotein™ modified wet porridge|At one out of four test days: Fermotein™ modified wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
45656963|NCT04819789|Other|Mycoprotein porridge (matching control)|At one out of four test days: Mycoprotein (Quorn) mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
45656964|NCT04834375|Drug|Weight-based dexamethasone dose|Weight-based dexamethasone dose in COVID-19 patients with hypoxic respiratory failure
45656965|NCT04833985|Procedure|LAAC combined with radiofrequency ablation|Each patient received the same group of patients with simple radiofrequency ablation and LAAC
45808055|NCT04221477|Drug|Placebo|Placebo matching obinutuzumab will be administered by IV infusion at baseline and Weeks 0, 2, 24, 26, 50 and 52 and subsequently from Week 80 and every 6 months thereafter based on response.
45808056|NCT04221477|Drug|Methylprednisolone|Methylprednisolone 80 mg IV will be administered as predmedication prior to infusions.
45808057|NCT04221477|Drug|Acetaminophen|Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
45808058|NCT04221477|Drug|Diphenhydramine|Diphenhydramine 50 mg will be administered as premedication prior to infusions.
45656966|NCT04827121|Procedure|Fascial iliac compartment block|Patients will recieve supra-inguinal approach of fascial iliac compartment block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
45656967|NCT04827121|Procedure|Quadratus lumborum block|Patients will recieve transmuscular approach of quadratus lumborum block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
45656968|NCT04820101|Drug|Dexmedetomidine|administrating dexmedetomidine in order to evaluate the efficacy in achieving sedation for LISA procedure
45808059|NCT04214288|Drug|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally.
45808060|NCT04214288|Drug|Fulvestrant|Dosage formulation: Fulvestrant will be administered via intramuscular (IM) injection.
45808061|NCT04214262|Drug|Atezolizumab|Given IV
45656969|NCT04826887|Other|SOLTIVE Thulium Laser|Use of SOLTIVE Thulium laser for HoLEP
45944245|NCT02645149|Drug|CDK4/6 and MEK inhibitor|"Patients mucosal melanoma and any genetic aberration on NGS testing may receive ribociclib + trametinib initially. After failure of trametinib and ribociclib, actionable genetic aberrations from the NGS testing will be reviewed for the opportunity to use a further targeted therapy off label.~Patients with an NRAS mutation on standard of care tumour testing will also receive ribociclib + trametinib."
45808062|NCT04214262|Procedure|Biospecimen Collection|Undergo blood sample collection
45808063|NCT04214262|Other|Quality-of-Life Assessment|Ancillary studies
45808064|NCT04214262|Other|Questionnaire Administration|Ancillary studies
45808065|NCT04214262|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45808066|NCT04210505|Drug|Povidone-Iodine Topical Ointment|Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing hemodialysis before each session.
45808067|NCT04210505|Other|Standard Care|Control group will receive standard care as provided by the dialysis center
45944246|NCT02645149|Drug|Compassionate Access Targeted Therapy|Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma may have an actionable aberration(s) for which there is no current study-specific drug supply. In this scenario, access will be sought for compassionate use of the off label use of the relevant regulatory approved targeted therapy
45808068|NCT04210219|Drug|JNJ-64264681|JNJ-64264681 capsule will be administered orally.
45808069|NCT04209595|Drug|PLX038|Phase I: Dose escalation will follow the classical 3+3 trial design by Fibonacci sequence. Phase II: MTD identified in phase I. PLX038 will be administered as a 1 hour (-10 minutes / +30 minutes) IV infusion on Day 1 of each cycle (21 days).
45944247|NCT02357719|Device|VistaO2 FLUX device|Full night VistaO2 FLUX device monitoring synchronized with the gold standard polysomnography.
45944248|NCT02958306|Biological|platelet rich plasma|PRP is a portion of the plasma fraction of autologous blood, having a platelet concentration above baseline values
45808070|NCT04209595|Drug|Rucaparib|Phase I: Dose escalation will follow the classical 3+3 trial design by Fibonacci sequence. Phase II: MTD identified in phase I. Rucaparib will be given orally at designated dose twice a day on days 5 to 19 of every 21-day cycle.
45808071|NCT04204408|Drug|NNC0365-3769 (Mim8)|Mim8 administered subcutaneously (s.c., under the skin). The treatment period will consist of 12 once-weekly doses or 3 once-monthly doses
45808072|NCT04204408|Drug|Placebo (Mim8)|Mim8 placebo administered subcutaneously (s.c., under the skin)
45808073|NCT04200937|Device|Tactra Malleable|The Tactra™ Penile Prosthesis is a sterile, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in adult males who are suitable candidates for implantation procedure.
45808074|NCT04200937|Device|Spectra Penile Prothesis|The Spectra Penile Prothesis is a sterile, non-pyrogenic, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in men who are determined to be suitable candidates for implantation surgery.
45944249|NCT04004273|Behavioral|Exercise|24 moderate-intensity exercise training sessions over six weeks (four times per week; ~50 min per session)
45944250|NCT01691833|Dietary Supplement|Vitamin D|Patients that are Vitamin D deficient and randomized to the treatment group will receive a 10,000 IU dose of Vitamin D.
45944251|NCT01691833|Dietary Supplement|Placebo|Patients that are Vitamin D deficient maybe randomized to the placebo group D.
45944252|NCT00123240|Behavioral|Low calorie high carbohydrate diet|65% carbohydrate, 15% protein, 20% fat (7% SFA, 8% MFA, 4% PUFA), P/S 0.63, 152 mg cholesterol/1500 kcal
45944253|NCT00123240|Behavioral|Low calorie high fat/protein diet|High Fat/Protein Diet: 10% carbohydrate, 25% protein, 65% fat (26% SFA, 25% MFA, 9% PUFA), P/S 0.33, 458 mg cholesterol/1500 kcal
45944254|NCT03977402|Other|Biological specimen collection|Collection of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) from patients with cancer or at risk of having cancer. This is not a treatment trial. It is a study designed to create a centralized data and tissue repository.
45944255|NCT00091728|Drug|Depo Medroxyprogesterone acetate|
45656970|NCT04826887|Other|Standard of Care (Holmium Laser)|Use of Holmium laser for HoLEP
45656971|NCT04328311|Other|Watermelon Juice|500 mL watermelon juice (What a Melon), containing ~1 g of L-citrulline.
45656972|NCT04328311|Other|Water|500 mL low nitrate water
45944256|NCT00091728|Drug|Combined oral contraceptives|
46002185|NCT04424901|Drug|Placebo|Daily dose while hospitalized up to 9 days
46002186|NCT04424901|Drug|Dipyridamole Tablets|Daily dose while hospitalized up to 9 days
45656973|NCT04428463|Procedure|Tachosil|tympanic membrane perforation repair using Tachosil patch under local anesthesia
45656974|NCT04428463|Procedure|fascia and cartilage|tympanic membrane perforation repair using fascia and cartilage under general anesthesia
46075319|NCT00877591|Drug|Rifabutin|300 mg once daily for 15 days total
45656975|NCT04819633|Other|Determination of serum sestrin levels|Serum sestrin levels will be determined using venous blood samples obtained from the subjects.
45656976|NCT04819867|Drug|Propolis|propolis is an extract derived from bee hives
45656977|NCT04819867|Drug|Gluma Desensitizer|Gluma is a desensitizer agent
45656978|NCT04827043|Combination Product|Ultrasound guided quadratus lumborum block|prospective randomized comparative study between Group (1) : quadratus lumborum block
45656979|NCT04827043|Combination Product|Ultrasound guided thoracic paravertebral block|PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml, yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10 as a single injection sonar guided.
45656980|NCT02423343|Drug|Galunisertib|Administered orally
45656981|NCT02423343|Drug|Nivolumab|Administered IV
45656982|NCT04909515|Drug|Naxitamab|3.0 mg/kg/day = 9.0 mg/kg/cycle
45656983|NCT04909515|Drug|GM-CSF|250 - 500 microgram/m2/day
45656984|NCT04909515|Drug|Isotretinoin|160 mg/m2/day
45808075|NCT04200937|Device|AMS Ambicor|The AMS Ambicor inflatable penile prothesis intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence) in adult men who are determined to be suitable candidates for implantation surgery.
45808076|NCT04195698|Drug|Upadacitinib|Upadacitinib will be administered oral as tablet
45808077|NCT04194528|Drug|Oxycodone/acetaminophen 5/325 mg|The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
45808078|NCT04194528|Device|Proteus digital medicine program|The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
45808079|NCT04192006|Device|Total Knee Arthroplasty|Surgical implantation of prosthetic knee using robotic-arm assist
45808080|NCT04190446|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45808081|NCT04190446|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
45656985|NCT02605447|Drug|3 months of dual antiplatelet therapy (DAPT)|3 months of P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) plus 15-months of aspirin
45808082|NCT04190446|Other|Quality-of-Life Assessment|Ancillary studies
45944257|NCT04729166|Behavioral|Structured education and follow-up|This structured educational material was developed by the authors on the basis of the literature. Interventions of the study were carried out in the 32nd-42nd week of pregnancy, 3rd-7th day postpartum, and at the 1st month. At first stage, a 15-20-minute education was given to the pregnant women in the study group in the breastfeeding room of the facility, educational booklets were distributed. The main emphasis parts of the education were repeated with a standard summary information form at each follow-up.
45656986|NCT02605447|Device|SYNERGY Stent System|SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
45656987|NCT05617729|Other|Saline applied via swab|sterile saline applied via swab
45808083|NCT04190446|Other|Questionnaire Administration|Ancillary studies
45808084|NCT04189614|Drug|Cofetuzumab Pelidotin|Intravenous (IV) infusion
45808085|NCT04182204|Drug|Polatuzumab Vedotin|Polatuzumab vedotin 1.8 mg/kg for a maximum dose of 240 mg/cycle IV on Day 1 of each 21-day cycle for up to 8 cycles.
45656988|NCT05617729|Other|Povidone-iodine based gel|gel applied via swab
45808086|NCT04182204|Drug|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle for up to 8 cycles.
45808087|NCT04182204|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycles.
45808088|NCT04182204|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycle.
45808089|NCT04181827|Drug|JNJ-68284528|Cilta-cel infusion will be administered at a target dose of 0.75 * 10^6 CAR-positive viable T cells/kilogram (kg).
45944258|NCT00123279|Drug|Microplasmin|25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.
45944259|NCT00091806|Drug|panitumumab (ABX-EGF)|6 mg/kg once every 2 weeks
45944260|NCT00091806|Drug|Panitumumab|9 mg/kg once every 3 weeks
45808090|NCT04181827|Drug|Pomalidomide|Pomalidomide 4 mg will be administered orally.
45808091|NCT04181827|Drug|Bortezomib|Bortezomib 1.3 milligram per meter square (mg/m^2) will be administered subcutaneously (SC).
45808092|NCT04181827|Drug|Dexamethasone|Dexamethasone 20 mg/day (10mg/day for participants >75 years of age) (on bortezomib treatment days and the days following bortezomib treatment) will be administered orally in PVd treatment; and orally or intravenous (IV) at 40 mg weekly (20mg weekly for participants >75 years of age) in DPd treatment.
45808093|NCT04181827|Drug|Daratumumab|Daratumumab 1800 mg will be administered SC.
45808094|NCT04181632|Device|Buzzy Bee with Ice pack|Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used with an ice pack.
45808095|NCT04181632|Device|Buzzy Bee without Ice pack|Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used without an ice pack.
45808096|NCT04181632|Device|Shot Blocker|Shot Blocker is a device that instantly alleviates the pain and anxiety of needle injections when pressed firmly against the skin at the injection site.
45808097|NCT04179396|Drug|Rucaparib|Oral rucaparib will be administered twice daily
45808098|NCT04179396|Drug|Enzalutamide|"Enzalutamide will be administered once daily.~Enrollment into Arm A will be prioritized over Arm B until the objectives for Arm A have been achieved."
45808099|NCT04179396|Drug|Abiraterone|Abiraterone will be administered once daily with prednisone
45808100|NCT04175600|Drug|Selexipag|Selexipag tablet will be administered orally.
45808101|NCT04175600|Drug|Placebo|Matching placebo tablets will be administered orally.
45808102|NCT04174144|Procedure|Single-level TLIF|Transforaminal interbody fusion approach, using polyaxial pedicle screws (Xia®, Stryker Spine, Allendale, NJ, USA), combined with a crescent-shaped interbody cage (T-Plus®, Pioneer Surgical Technology, Marquette, MI, USA), bilateral facet joint removal and laminectomy.
45656989|NCT04317859|Behavioral|Behavioural Activation|Behavioural Activation (BA) is a therapy previously shown to be effective in depressive disorders. This form of therapy involves modification of activities in order to change perceptions of specific situations, thereby improving mood. The BA treatment program will consist of 18 two-hour visits over 14 weeks (twice weekly group visits for the first 8 weeks, followed by two individual visits over 6 weeks).
45808103|NCT04172675|Drug|Erdafitinib|Participants will receive erdafitinib orally beginning on Cycle 1 Day 1 until 2 years of treatment have been completed, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurs first. Each cycle is of 28 days.
45656990|NCT02485899|Biological|BMN 190|300 mg Intracerebroventricular (ICV) infusion administered every other week for up to 240 weeks
45808104|NCT04172675|Drug|Investigator Choice (Gemcitabine)|Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
45808105|NCT04172675|Drug|Investigator Choice (Mitomycin C)|Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
45808106|NCT04170348|Drug|Daily oral vitamin D3, 3,333 IU|Oral vitamin D3, 3,333 IU, will be administered daily.
45808107|NCT04170348|Drug|Bolus oral vitamin D3, 100,000 IU|Bolus oral vitamin D3, 100,000 IU, will be administered monthly.
45808108|NCT04170348|Drug|Placebo oral tablet|Participants randomized to receive once monthly oral bolus of vitamin D3, will receive placebo on all other days of the month.
45808109|NCT04166487|Drug|Pembrolizumab|predetermined dose, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
45808110|NCT04166487|Drug|PEMETREXED|administered per standard practice, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
45808111|NCT04166487|Drug|CARBOPLATIN|administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
45808112|NCT04166487|Drug|PACLITAXEL|administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
45808113|NCT04166487|Diagnostic Test|InVision|Plasma draw for clinical test performed at C1D1 and C2D1; plasma draw for research testing performed at other timepoints per protocol.
45808114|NCT04164199|Drug|Tislelizumab|To be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
45808115|NCT04164199|Drug|Pamiparib|To be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
45808116|NCT04164199|Drug|Pemetrexed 500 mg/m² IV|To be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
45808117|NCT04164199|Drug|Capecitabine 1000 mg/m² PO BID|Day 1 to Day 15 of each 21 day cycle, to be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
45808118|NCT04164199|Drug|Temozolomide 120, 80, 40 or 20 mg PO Once Daily (QD)|To be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
45808119|NCT04164199|Drug|Sitravatinib|To be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
45656991|NCT02485899|Device|Intracerebroventricular (ICV) access device|Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
45656992|NCT04362553|Device|wearable vital signs sensor|vital signs monitoring during standard of care procedures; TTE, swan-ganz catheterization
45808120|NCT04164199|Drug|Ociperlimab|Participants will receive tislelizumab followed by the administration of ociperlimab on Day 1 of each 21-day cycle (ie, once every 3 weeks)
45808121|NCT04164199|Drug|BAT1706|Participants will receive tislelizumab followed by the administration of BAT1706 on Day 1 of each 21-day cycle (ie, once every 3 weeks). If applicable, ociperlimab will be administered after completion of the BAT1706 infusion
45808122|NCT04164199|Drug|Fruquintinib|Fruquintinib will be self-administered orally once daily for 21 days, followed by 7 days off in 28-day cycles with or without food.
45808123|NCT04163094|Drug|W_ova1 Vaccine|Patients will be treated with a W_ova1 vaccine that includes 3 OC TAA RNA-LPX products.
45656993|NCT05619055|Other|Routine treatment|Antibiotics, intravenous fluids and symptomatic supportive treatment.
45656994|NCT04818931|Drug|Cefazolin Injection|cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy
45944261|NCT03944486|Device|Feasibility of OnTrack|Patients to use digital application- study assessed the feasibility of the application for patients and therapists.
45808124|NCT04161287|Procedure|transcatheter arterial chemoembolization|The hepatocellular carcinoma patients (≤5cm）who received SBRT are devided into two groups: with TACE and SBRT alone.
45808125|NCT04159506|Behavioral|mindfulness, emotion didactics, interpersonal skills, experiential learning|mindfulness interventions involve body scanning, deep breathing, and muscle relaxation. Emotion didactics focus on emotion recognition and regulation. Interpersonal skill development looks at how to use emotion regulation to improve social functioning. Experiential learning means learning either through interactions with horses or via team-building activities.
45808126|NCT04158440|Drug|4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab|Biological: Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m^2 by IV infusion Q3W
45656995|NCT02423109|Device|fanfilcon A|contact lens
45808127|NCT04158440|Drug|4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )|Biological: Placebo by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m^2 by IV infusion Q3W
45656996|NCT02423109|Device|enfilcon A|contact lens
45656997|NCT02420691|Other|Laboratory Biomarker Analysis|Correlative studies
45808128|NCT04154774|Drug|Apalutamide|Apalutamide will be administered orally.
45656998|NCT02420691|Other|Pharmacological Study|Correlative studies
45656999|NCT02420691|Drug|Ribociclib|Given PO
45657000|NCT02406651|Drug|Recombinant Human Interleukin-22 IgG2-Fc (F-652)|IV infusion of reconstitution lyophilized F-652.
45808129|NCT04154267|Procedure|Percutaneous renal biopsy.|The biopsy will be performed with a 16 Gauge semi-automatic needle gun for renal biopsy under real-time ultrasound control. After the procedure will be done ultrasound control
45808130|NCT04150887|Drug|Cusatuzumab|Cusatuzumab will be administered as a dose of 10mg/kg or 20mg/kg intravenously.
45944262|NCT01589302|Drug|ibrutinib|Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
45944263|NCT01589302|Other|Correlative laboratory samples|Blood samples will be collected and used for pharmacodynamic testing. Samples will be collected pre-dose on Cycle 1 Day 1 and 2 hours post-dose Cycle 1 Day 1, pre-dose on Day 2 and Day 8 of Cycle 1 and pre-dose on Day 1 of Cycles 2 and 3 and then every 3 cycles thereafter for 1 year (Cycle 15 Day 1). Samples will also be collected at the time of relapse and at any time when bone marrow biopsy is performed.
45657001|NCT02406651|Drug|Systemic Corticosteroids|Prednisone (or equivalent) at the time of the onset of clinical symptoms consistent with GI and/or liver aGVHD, as per the standard of care. Prednisone (or equivalent) will be given at a dose of 2 mg/kg/day and tapered as needed.
45657002|NCT02406261|Drug|Lanabecestat|50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
45657003|NCT02406261|Drug|Simvastatin|20 mg simvastatin will be administered orally as 1 × 20-mg tablet
45657004|NCT02406261|Drug|Midazolam|500 mcg midazolam will be administered orally as 0.25 mL of 2-mg/mL syrup
45657005|NCT02406261|Drug|Midazolam|250 mcg midazolam will be administered intravenous (IV) as 0.25 mL of 1-mg/mL injection solution
45657006|NCT02406261|Drug|Donepezil|5 mg donepezil will be administered orally as 1 × 5-mg tablet
45657007|NCT02406261|Drug|Lanabecestat|50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
45657008|NCT04421001|Device|I-port use|patient will use I-port device fo 2 months
45657009|NCT04420767|Device|tDCS|Individuals undergo 20min daily sessions receiving actual tDCS to the brain (to the right DLPFC: dorsolateral prefrontal cortex)
45657010|NCT04420767|Device|Sham brain stimulation|Individuals undergo 20min daily sessions receiving sham stimulation to the brain (to the right DLPFC: dorsolateral prefrontal cortex)
45657011|NCT04420767|Behavioral|Go-No GO task|During the brain stimulation sessions, all individuals will be asked to perform a 10 min-computerized task related to inhibitory control (Go-No Go)
45657012|NCT02405091|Drug|NBI-98854|
45657013|NCT02485353|Drug|Vosaroxin and Cytarabine|
45657014|NCT02603107|Drug|RTV|100 mg capsule coadministered orally with ATV or DRV once daily with food
45657015|NCT02603107|Drug|ATV|300 mg capsule administered orally once daily with food
45657016|NCT02603107|Drug|DRV|800 mg tablet administered orally once daily with food
45657017|NCT02603107|Drug|COBI|150 mg tablet coadministered orally with ATV or DRV once daily with food
45657018|NCT02603107|Drug|ATV/co|300/150 mg FDC tablet administered orally once daily with food
45657019|NCT02603107|Drug|DRV/co|800/150 mg FDC tablet administered orally once daily with food
45657020|NCT02603107|Drug|FTC/TDF|200/300 mg FDC tablet administered orally once daily without regard to food
45808131|NCT04150887|Drug|Azacitidine|Azacitidine will be administered 75 mg/m^2 subcutaneously or intravenously.
45808132|NCT04150887|Drug|Venetoclax|Venetoclax will be administered orally and the dose will ramp-up to 400 mg.
45808133|NCT04146012|Device|Artegraft® Collagen Vascular Graft™ (Artegraft)|The Artegraft is intended for use distal to the aorta as a segmental arterial replacement, as an arterial bypass, as an arteriovenous shunt where more conventional methods have proven inadequate, or as an arterial patch graft.
45808134|NCT04145622|Drug|Ifinatamab deruxtecan (I-DXd)|A total anti-B7H3 antibody and MAAA-1181a
45808135|NCT04140162|Drug|Daratumumab|"Induction: 16 mg/kg actual body weight IV weekly (weeks 1-8; total of 8 doses) then every 2 weeks (weeks 9-24; total of 8 doses).~Consolidation: 16 mg/kg actual body weight IV every four weeks (weeks 25-36)~Maintenance: 16 mg/kg actual body weight IV every eight weeks (weeks 37-88)~Sites will continue to use IV daratumumab to treat existing study patients until the IV daratumumab stock on site has been exhausted. The sites will then transition existing patient to SQ daratumumab. New patients will be started on SQ 1800mg daratumumab.~Induction- Cycles 1-2 (days 1, 8,15, 22), Cycles 3-6 (Weeks 9-24- two weeks (days 1, 15 ) Consolidation- Every 4 weeks on day 1 Maintenance- Every 8 weeks on day 1"
45808136|NCT04140162|Drug|Lenalidomide|"Induction: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 1-24)~Consolidation: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 25-36)~Maintenance: 10 mg PO once daily, on days 1-21 of each 28-day cycle until progression or intolerance~Maintenance: 10 mg PO once daily, on days 1-21, weeks 37+ until progression"
45453133|NCT03191396|Drug|Semaglutide|Dose gradually increased to 1.0 mg, given s.c. (under the skin), once-weekly for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs (tablets), if any
45453134|NCT03191396|Drug|Liraglutide|Dose gradually increased to 1.2 mg, given s.c. once-daily for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs, if any
45453135|NCT01331798|Device|Cohera TissuGlu Surgical Adhesive|TissuGlu device used prior to closing of the flap in the abdominoplasty procedure.
45453136|NCT01331798|Procedure|Control- Standard of care|Control Arm- no TissuGlu device used. Standard abdominoplasty procedure followed.
45453137|NCT04482140|Device|Genta-Foil resorb|Use of Genta-Foil resorb to prevent adhesions in patients undergoing hand surgery
45453138|NCT03509636|Drug|Fluzoparib|Fluzoparib capsule will be given twice daily orally
45453139|NCT01331876|Behavioral|Cognitive and behavioral Therapy|15 CBT sessions with a psychologist expert in OCD treatment
45453140|NCT03664934|Other|Exercises|Neck-specific exercises for chronic whiplash associated disorders
45808137|NCT04140162|Drug|Bortezomib|Consolidation: 1.5 mg/m2 SQ on day 1, 8, 15 and 22 of each 28-day cycle (weeks 25-36)
45453141|NCT01333670|Device|Prontosan wound irrigation solution|"cleansing wound bed at change with Prontosan Wound Irrigation solution (syringe 20-30 ml, needle 19-20 G)~positioning of sterile gauze dressing impregnated with Prontosan Wound Irrigation solution on the wound for 10 minutes~dressing with Prontosan Wound Irrigation solution"
45453142|NCT01333670|Drug|Isotonic solution (saline or lactated ringer)|"cleansing wound bed at change with isotonic solution (syringe 20-30 ml, needle 19-20 G)~positioning of sterile gauze dressing impregnated with isotonic solution on the wound for 10 minutes~dressing with isotonic solution"
45453143|NCT00007345|Drug|Romidepsin|
45453144|NCT01571102|Behavioral|Therapy|week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 40min.
45657021|NCT02603107|Drug|ABC/3TC|600/300 mg tablet administered orally once daily with or without regard to food
45657022|NCT02603107|Drug|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
45657023|NCT04826263|Other|Home Exercise Program|All patients will be instructed to follow a home exercise program for 3 weeks. Patients will be informed about the exercises by giving an exercise sheet describing the exercises and an exercise diary prepared to mark the days they exercise. The home exercise program will include previously recommended exercises such as Achilles tendon and plantar fascia stretching and toe curl exercises. Patients will be instructed to perform these exercises 10 repetitions each and 3 times per day for three weeks.
45657024|NCT04826263|Other|Low-Level Laser Therapy (LLLT)|Patients in the LLLT group will receive gallium-aluminum-arsenide (Ga-Al-As) low-level laser treatment with Chattanooga Vectra Genisys Transport model (Chattanooga Group) with a wavelength of 850 nm and a power of 100 mW. The LLLT treatment will be applied 3 times a week, a total of 10 sessions. A maximum energy density of 5.6 j/cm2 will be reached by delivering a continuously increasing dose of energy to each tender spot for one minute. The LLLT will be performed with patients in the prone position and will be applied to 5 points on the plantar fascia by positioning the laser head perpendicular to the treatment area.
45808138|NCT04140162|Drug|Dexamethasone|Induction and Consolidation: 40 mg (or reduced dose of 20 mg) PO or IV weekly
45808139|NCT04138030|Procedure|Conventional Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy snare closed over a polyp with electrocautery
45808140|NCT04138030|Procedure|Cold Snare Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy snare closed over a polyp without electrocautery
45808141|NCT04137289|Drug|BI 905711|BI 905711
45657025|NCT04826263|Other|Extracorporeal Shockwave Therapy (ESWT)|Patients in the ESWT group will receive treatment with a radial ESWT system (EMS Swiss Dolor Clast), which transforms kinetic energy into a shock wave, which is then applied to the target tissue with pressure varying from 1 to 10 bar and penetrating up to 40 mm. The ESWT treatment will be administered to the patients once a week for three weeks, for a total dose of 2000 mJ/mm2 pulse per application. ESWT will be applied to the patients in prone position with their foot inverted. Ultrasound gel will be applied to the patient's heel The area of tenderness will be palpated and 1000 shock wave impulses were applied to this area, and 1000 pulses will be applied over the plantar fascia.
45657026|NCT02484729|Drug|AZD9977, oral suspension|Single ascending doses of AZD9977 oral suspension (Part A) Single dose of AZD9977 oral suspension in IntelliCap® capsule in regional absorption part (Part B)
45808142|NCT04133636|Drug|JNJ-68284528|Participants in cohort A,B,C, D, E and F will receive JNJ-68284528 intravenously.
45808143|NCT04133636|Drug|Lenalidomide|Some participants in cohort D and all participants in cohort E will also receive lenalidomide capsules orally.
45808144|NCT04133636|Drug|Daratumumab|Participants in cohort E will also receive daratumumab subcutaneous (SC) injection.
45808145|NCT04133636|Drug|Bortezomib|Participants in cohort E will also receive bortezomib subcutaneously.
45808146|NCT04133636|Drug|Dexamethasone|Participants in cohort E will also receive dexamethasone orally or intravenously.
45808147|NCT04131088|Other|Follow up of midlines|The follow-up data to be collected will be recorded on a monitoring logbook that will follow the patient (Appendix 4). The latter will be involved in the follow-up of his data insofar as he will be able to solicit the various professionals performing care on his midline in order to aim at the exhaustiveness of the filling of the book.
45808148|NCT04129515|Device|NovoTTF-200A|•NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle
45808149|NCT04129515|Drug|Pembrolizumab|Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle
45944264|NCT01589302|Other|quality of life assessment|During screening, sociodemographic information (e.g., age, race, marital status) and reports of recent (last year) stressful events will be obtained. The assessment will consist of measures of emotional distress, depressive symptoms, and quality of life. Quality of life measures will be administered during screening and on Days 1 (±3), 8 (±3),, 15 (±3),, 22 (±3), of Cycle 1, Day 1 (±3), of Cycle 2 and on day 1 (±7) of Cycles 3, 6, and then every 3 months thru month 24.
45944265|NCT00091845|Drug|AVI-4020 Injection|
45657027|NCT02484729|Drug|Placebo, oral suspension|Matching placebo
45657028|NCT02484729|Drug|AZD9977, oral solution|AZD9977, single dose of oral solution in Part B as reference
45944266|NCT01397110|Other|respiratory and exercise therapy|Conventional therapy with specific respiratory and physical therapy plus mental walking training
45944267|NCT00123318|Drug|epirubicin|50mg/m2 IV day 1
45657029|NCT04941729|Device|OR3O™ - Dual Mobility System|OR3O™ Dual Mobility System is comprised of a diffusion-hardened, oxidized zirconium acetabular liner (OR3O™ Liner), and an insert of highly cross-linked polyethylene (OR3O™ XLPE Insert).
45944268|NCT00123318|Drug|cisplatin|60mg/m2 IV day 1
45944269|NCT00123318|Drug|5-fluorouracil|5-FU 200mg/m2/d IV 21 day continuous infusion Cont. infusional 5-FU 225mg/m2/day, 7 days/wk throughout entire period RT via CADD pump through PICC line
45944270|NCT00123318|Radiation|Radiotherapy|45Gy 25 Fractions, 5 days/week for 5 weeks
45944271|NCT01005277|Other|Laboratory Biomarker Analysis|Correlative studies
45944272|NCT00327535|Drug|Darbepoetin alfa|According to the approved local label (6.75 micrograms/kg every 3 weeks, or 2.25 micrograms/kg every week)
45944273|NCT00327535|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|6.3 micrograms/kg every 3 weeks
45944274|NCT00327535|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|9 micrograms/kg every 3 weeks
45944275|NCT00327535|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|12 micrograms/kg every 3 weeks
45944276|NCT00327574|Behavioral|Home heath education +/_ GP training|
45657030|NCT04941729|Device|Conventional|A conventional, single-bearing design Total Hip System comprised of R3™ Acetabular Shell with XLPE liner and a Smith & Nephew Oxinium (Ox) femoral head.
45657031|NCT02601625|Drug|Anifrolumab SC injection (300mg)|300 mg of anifrolumab delivered as 2 separate 1 mL SC injections administered serially on Day 1
45808150|NCT04124939|Drug|OnabotulinumtoxinA 100 UNT|"BOTOX for injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for:~• Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication."
45808151|NCT04124185|Diagnostic Test|Ocular assessments|Complete ocular examination, Axial length and corneal curvature, Optical Coherence Tomography, Visual acuity, Contrast sensitivity
45808152|NCT04119050|Drug|M281|M281 injection administered as intravenous infusion
45657032|NCT02601625|Drug|Anifrolumab IV infusion (300mg)|300 mg of anifrolumab delivered as an IV infusion over 30 minutes on Day 1
45808153|NCT04119050|Drug|Placebo|Placebo administered as intravenous infusion
45657033|NCT02601625|Drug|Anifrolumab SC infusion (600mg)|600 mg of anifrolumab delivered as 4 mL SC by infusion pump on Day 1
45808154|NCT04117035|Procedure|Gamma Knife Radiosurgery (GKRS) personalised procedure|Personalised GKRS treatment
45808155|NCT04117035|Procedure|GKRS standard care|Standard GKRS treatment
45657034|NCT02601625|Drug|Anifrolumab placebo SC injection (300mg)|300mg of placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1
45657035|NCT02601625|Drug|Anifrolumab placebo IV infusion (300mg)|600mg of placebo delivered as an IV infusion over 30 minutes on Day 1
45657036|NCT02601625|Drug|Anifrolumab placebo SC infusion (600mg)|600 mg of placebo delivered as 4 mL SC by infusion pump on Day 1
45657037|NCT04819087|Behavioral|Questionnaires and Rehabilitation Programs|Questionnaires and Rehabilitation Programs
45808156|NCT04111978|Drug|Letrozole 2.5mg|Aromatase inhibitor
45944277|NCT00327652|Drug|CRS-100|Live-attenuated Listeria monocytogenes
45944278|NCT00091923|Device|Eye patch|
45944279|NCT00091923|Device|Spectacles|
45944280|NCT00327691|Drug|Atorvastatin|
45944281|NCT03913832|Device|sirolimus drug coated balloon (SCB)|"Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and Nano based drug delivery technology. Magic Touch SCB is a product of CMI proprietary drug delivery technology Nanolute. It is indicated (CE approved) for ISR, small vessels, bifurcation lesions & de novo lesions."
45657038|NCT04819165|Other|COVID-19|Impact of covid-19 on infections associated with health care devices.
45657039|NCT04819321|Device|CoolSculpting® System|A treatment is comprised of timed segments of cooling and heating; a vacuum treatment may include an optional massage
45808157|NCT04111978|Other|Placebo|Placebo tablet of Femara
45944282|NCT03913832|Device|paclitaxel releasing coronary balloon catheter|SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter.
45944283|NCT00123396|Behavioral|BioCASES and BioTESTS|
45944284|NCT03885401|Behavioral|Enhanced care planning|The intervention includes (1) screening for unhealthy behaviors, mental health needs, and social needs, (2) creation of a care plan, (3) quarterly updates to the plan, (4) a clinical navigator and community health worker to support accomplishing the care plan, (5) registry of community resources and programs, and (6) messaging and video-visit system for team members.
45944285|NCT00327730|Drug|Eperisone|
45944286|NCT04716868|Dietary Supplement|Agave Fructans 5 g|Agave tequilana Weber blue variety 5 g once a day for 8 weeks
45944287|NCT04716868|Dietary Supplement|Agave Fructans 10 g|Agave tequilana Weber blue variety 10 g once a day for 8 weeks
45944288|NCT04716868|Dietary Supplement|Agave Fructans 5 g + Maltodextrin 10 g|Maltodextrin 10 g + Agave tequilana Weber blue variety 5 g once a day for 8 weeks
45657040|NCT03036553|Other|Diagnosis/Prognosis|The present study will be a prospective multi-centric 12-month study that will be conducted between May 2017 and April 2019 in four primary care centers and a hospital in the province of Malaga. Several questionnaires assessing different psychological factors will be administered to these participants. The results will be evaluated at baseline (t1) and at 3-fold follow-up (after 3 (t2), 6 (t3) and 12 months (t4)).
45944289|NCT04716868|Dietary Supplement|Psyllium plantago|Psyllium plantago 15 g once a day for 8 weeks
45944290|NCT00327769|Drug|Fulvestrant|250 mg intramuscular injection
45944291|NCT00327769|Drug|Anastrozole|1 mg tablet
45808158|NCT04110756|Behavioral|ChangeGradients|In the proposed intervention, adolescents at the UCSF clinics who endorse alcohol use on the Health e-Check screen, a 5-minute confidential risk behavior module, will be randomly assigned to either the CHANGEGRADIENTS Intervention or Comparison (no intervention). The CHANGEGRADIENTS system will generate behavior change narrative episodes that are tailored to the adolescent (e.g. level of alcohol use) while also universally addressing a core set of topics related to health behavior change. Shortly following the clinic visit, through 4 weekly, 20 minute episodes, adolescent participants will interact with the CHANGEGRADIENTS health behavior change environment outside of clinic. Adolescents will complete a brief alcohol screening-past 7-day use-at the beginning of each episode. At the end of the final episode, the system will produce an individualized adolescent report that summarizes use of the CHANGEGRADIENTS modules as well as self-reported alcohol use since clinic visit baseline.
45808159|NCT04109066|Biological|nivolumab|Specified Dose on Specified days
45808160|NCT04109066|Drug|paclitaxel (PTX)|Specified dose on Specified days
45808161|NCT04109066|Other|nivolumab placebo|Specified dose on Specified days
45944292|NCT00092001|Drug|Sunitinib|Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
45808162|NCT04109066|Drug|anthracycline|Specified dose on Specified days
45808163|NCT04109066|Drug|cyclophosphamide|Specified dose on Specified days
45808164|NCT04109066|Drug|Endocrine Therapy|Variable endocrine therapy of investigators choice
45808165|NCT04109066|Procedure|Surgery|Surgery for breast cancer
45808166|NCT04108208|Drug|Apalutamide|Apalutamide 240 mg (4*60 mg tablets) will be administrated orally once daily.
45944293|NCT03883919|Drug|5-FU|-Standard of care drug
45808167|NCT04108208|Drug|Placebo|Matching placebo will be administered orally.
45808168|NCT04108208|Drug|Androgen-deprivation Therapy (ADT)|Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.
45808169|NCT04108195|Drug|Daratumumab|Participants will receive daratumumab.
45808170|NCT04108195|Drug|Talquetamab|Participants will receive talquetamab.
45808171|NCT04108195|Drug|Teclistamab|Participants will receive teclistamab.
45808172|NCT04108195|Drug|Pomalidomide|Participants will receive pomalidomide.
45808173|NCT04107766|Device|Microwave Ablation|Patients who meet the eligibility criteria will undergo microwave ablation (MWA) with the NEUWAVE Microwave Ablation System with or without Ablation Confirmation of at least one soft-tissue liver lesion, in accordance with the study site's standard-of-care (SOC) practices.
45808174|NCT04107649|Behavioral|Telephonic Active Coaching (Motivational Interviewing) + Financial Incentives|As part of TAC(MI)+FI, participants speak with a health coach at Brigham and Women's Hospital once a week via telephone for weeks 6-13 following surgery, and once every other week for weeks 14-31 after surgery. Participants in this arm can receive financial rewards for achieving weekly physical activity goals, as well as bonus rewards for achieving goals multiple weeks in a row. Over the course of this 6-month long TAC(MI)+FI intervention period, these participants are able to receive up to $680 for meeting physical activity goals, and up to $95 in bonus rewards.
45944294|NCT03883919|Drug|Leucovorin|-Standard of care drug
45944295|NCT03883919|Drug|Liposomal Irinotecan|-Standard of care drug
45453145|NCT01571102|Behavioral|Exercise therapy|week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 30 min.
45944296|NCT03883919|Drug|Paricalcitol|-Investigational drug
45944297|NCT03883919|Procedure|Serum and plasma blood samples|-baseline, day 1 of each cycle beginning with cycle 2
45944298|NCT03883919|Procedure|Tumor biopsy|"5 patients in each arm will be required to undergo a mandatory tumor biopsy from the primary pancreatic site or metastatic site, if safe and feasible, prior to cycle 1~After Cycle 3 of treatment, all patients who had a baseline biopsy will be required to undergo a mandatory biopsy of the same site if safe and feasible."
45944299|NCT04708366|Drug|NER1006|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
45944300|NCT04708366|Drug|MoviPrep|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
46002187|NCT04415060|Drug|Isoflurane Inhalant Product|Isoflurane will be administered using an inhalation device
46002188|NCT04415060|Drug|Sevoflurane inhalant product|Sevoflurane will be administered using an inhalation device
45944301|NCT04708366|Drug|Macrogol 400|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
45808175|NCT04107649|Behavioral|Wrist based activity tracker wear|Activity tracking data will be collected on a weekly basis. Participants who receive this intervention are eligible to be entered into a lottery to win one of two $25 rewards for every week they wear their wrist-based activity tracker >10 hours for >4/7 days a week, beginning 6-weeks after surgery.
45657041|NCT04834141|Other|FlexiCurve ruler method to assess thoracic kyphosis angle|The determination that the effect of thoracic kyphosis posture on trunk biomechanical alignment may be related to balance may contribute to new treatment recommendations in this area. The aim of this study is to investigate whether the thoracic kyphosis posture has an effect on static balance.
45657042|NCT04826497|Drug|nicorandil|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg nicorandil was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention
45657043|NCT04826497|Drug|Placebo（normal saline）|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg placebo was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of placebo to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention
45808176|NCT04107649|Other|Basic Study Activities|Basic study activities begin two-weeks before TKR and end approximately 24-months after TKR. Basic study activities include: two in-person visits at the local clinic site (2 weeks before TKR and 32-weeks after TKR), having check-in calls with study staff weekly from weeks 1-13 after surgery and every other week for weeks 14-31, completing 6 surveys, and wearing an ActiGraph activity tracker (waist-worn) for five one-week periods throughout the study (2-weeks before-TKR, 32-weeks post-TKR, one-year post-TKR, 18-months post-TKR, two-years post-TKR). All participants will be eligible to receive up to $235 for completing these activities over the course of two years.
45808177|NCT04105842|Device|Delfilcon A|Participants wear delafilcon A contact lenses on a daily disposable basis.
45944302|NCT00327808|Drug|TPI-1020|600 mcg BID x 14 days followed by 1200 mcg BID x 7 days
45944303|NCT00327808|Drug|budesonide|400 mcg BID x 14 days then 800 mcg/day x 7 more days
45944304|NCT00092079|Drug|MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks|
45944305|NCT03719066|Biological|killed whole cell oral cholera vaccine|two week interval
45944306|NCT00327847|Drug|Oral Vitamin D Supplementation|
45808178|NCT04105543|Drug|CLR 131|CLR 131 is a radiopharmaceutical dosed intravenously over a period of approximately 30 minutes, dose will be based on total body surface area calculated from actual body weight and height
45944307|NCT00327925|Procedure|Find Cancer Associated Antibodies|
45944308|NCT00123435|Behavioral|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
46002189|NCT04410445|Biological|Bempegaldesleukin|Specified dose on specified days
45657044|NCT04834219|Procedure|On-Pump CABG|Patients who have undergone on-pump Coronary artery bypass grafting (CABG) surgery are planned by the Department of Cardiovascular Surgery.
45657045|NCT04834219|Procedure|Off-Pump CABG|Patients who have undergone off-pump Coronary artery bypass grafting (CABG) surgery are planned by the Department of Cardiovascular Surgery.
45657046|NCT04819243|Drug|Pabociclib, Endocrine, Talazoparib, Atezolizumab|"Palbociclib 125mg~AI~GnRH agonist~Talazoparib~Atezolizumab"
45657047|NCT04819243|Drug|Pabociclib, Endocrine, Talazoparib,|"Palbociclib 125mg~AI~GnRH agonist~Talazoparib"
45657048|NCT05618821|Drug|Indocyanine Green Tracer|Laparoscopic gastrectomy with lymph node dissection for remnant gastric cancer using Indocyanine Green Tracer
46002190|NCT04410445|Biological|Nivolumab|Specified dose on specified days
46002191|NCT04408664|Drug|Sodium Cromoglycate|Sodium Cromoglicate 10 mg/mL packed in ampulla of 2 mL; Daily dosis of 4X20 mg milligram delivered by aerosol.
45944309|NCT00123435|Behavioral|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
45944310|NCT00123435|Behavioral|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
45944311|NCT00123435|Behavioral|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
45944312|NCT00123435|Device|Simple pedometer|Device to be worn during waking hours to give an objective measure of steps taken each day.
45808179|NCT04103879|Biological|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|"Conditioning: High dose TBI (1320 cGy TBI + Fludarabine 75 mg/m2 + Cyclophosphamide 120 mg/kg) or Intermediate Intensity regimen (400 cGy TBI + Fludarabine 150 mg/m2 + Cyclophosphamide 50 mg/kg + Thiotepa 10 mg/kg).~Single UM171-Expanded CB transplant (CD34+: 2.5-50x10E5/kg, CD3+>1x10E6/kg)~Immunosuppression: Tacrolimus/MMF"
45944313|NCT00123435|Behavioral|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
46002192|NCT04408664|Drug|Placebo|Sodium Chloride 0.9% packed in ampulla of 2 mL; Daily dosis of 4 ampulla delivered by aerosol.
45458757|NCT04802356|Drug|Belantamab mafodotin|"Dose of 2.5 mg/kg/every 8 weeks on day 1, intravenously, Induction: three induction cycles with belantamab mafodotin in combination with VRd.~Consolidation: one cycle after 90 days of transplantation with belantamab mafodotin in combination with VRd.~Maintenance: belantamab mafodotin in combination with lenalidomide until disease progression, patients withdrawal, death or up to two years, whichever occurs first"
45657049|NCT04818619|Diagnostic Test|flow cytometry test|Blood samples will be stained with TIGIT by flow cytometry test
45808180|NCT04102436|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
45808181|NCT04102436|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
45808182|NCT04102436|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg or 72,000 IU/kg (based on total body weight) IV over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
45808183|NCT04102436|Biological|Sleeping Beauty Transposed PBL|Day 0: Cells are to be infused at a dose not to exceed 1.5e11 in 400 mL intravenously on the Patient Care Unit over 20-30 minutes or as clinically determined by an investigator for patient safety (between 2-4 days after the last dose of fludarabine).
45808184|NCT04096014|Dietary Supplement|Ensure Enlive|The subjects in the intervention group will receive two Ensure Enlive supplements per day for 180 days.
45808185|NCT04096014|Other|Standard Of Care|The subjects in the Standard of care group will continue to receive the standard clinical therapy.
45657050|NCT02601469|Drug|DSXS|twice daily for 28 days
45657051|NCT05618743|Procedure|Non Surgical Periodontal Therapy|Scaling and root planing using scalers and periodontal curettes will be done
45657052|NCT04826107|Drug|DP303c treatment|DP303c injection, every 3 weeks.
45657053|NCT04826107|Drug|DP303c treatment（second-line of HER2-positive）|DP303c injection, every 3 weeks.
45657054|NCT04826107|Drug|DP303c treatment （third-line of HER2-positive）|DP303c injection, every 3 weeks.
45944314|NCT00123435|Behavioral|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
45808186|NCT04095923|Behavioral|Social media game|Participants will engage in weekly challenges that require them to take photographs of interesting things they discover during their walks. They will post and discuss these photographs with other participants on a private social media page. They will track their steps using a wearable activity monitor and receive brief standard self-regulatory counseling.
45944315|NCT00123435|Device|Simple pedometer|Device to be worn during waking hours to give an objective measure of steps taken each day.
45944316|NCT00123435|Device|Enhanced pedometer|Simple pedometer with the addition of web-based feedback.
45944317|NCT03709550|Drug|Decitabine|Given IV
45808187|NCT04095923|Behavioral|Standard self-regulation|Participants will track their steps using a wearable activity monitor and receive brief standard self-regulatory counseling.
45808188|NCT04092283|Drug|Carboplatin|Given IV
45944318|NCT03709550|Drug|Enzalutamide|Given PO
45944319|NCT00315172|Procedure|Non-Exercise Activity Thermogenesis (NEAT)|
45944320|NCT00315211|Drug|Intravenous Topotecan|Topotecan 3 mg/m2 IV over 30 minutes on Days 1 and 8 every 21 days
45944321|NCT00315211|Drug|Intravenous Docetaxel|Docetaxel 30 mg/m2 IV over 60 minutes on Days 1 & 8 of a 21 day cycle
45944322|NCT00315289|Procedure|Nasolacrimal balloon catheter duct dilation|
45944323|NCT00315289|Procedure|Nasolacrimal intubation|
45944324|NCT00315289|Procedure|Simple Nasolacrimal duct probing|
45453146|NCT01584271|Device|Natural Ear Comfort(TM), a botanical ear drops product|"Ear Comfort(TM): active ingredients - Thyme essential oil & Camomile extract. Inactive ingredients: anhydrous glycerin and a small quantity of surfactant.~Dex-Otic(R): Dexamethasone sodium phosphate 1mg; neomycin sulfate 5mg; polymixin B sulfate 10,000 units.~Inactive ingredients: propylene glycol, sodium acetate anhydrous, phenyl mercuric acetate, purified water.~Otidin(R): Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin."
45808189|NCT04092283|Drug|Cisplatin|Given IV
45808190|NCT04092283|Biological|Durvalumab|Given IV
45808191|NCT04092283|Drug|Etoposide|Given IV
45657055|NCT04826107|Drug|DP303c treatment（≥second-line of HER2 low expressing）|DP303c injection, every 3 weeks.
45657056|NCT04826107|Drug|DP303c + PD-1/PD-L1 treatment|DP303c injection + PD-1/PD-L1 injection, dose and frequency to be determined.
45808192|NCT04092283|Drug|Paclitaxel|Given IV
45808193|NCT04092283|Drug|Pemetrexed Disodium|Given IV
45808194|NCT04091282|Other|No intervention|No intervention
45944325|NCT02960191|Device|Magnetic resonance imaging (MRI)|
45944326|NCT00123513|Behavioral|Diet|Environmental changes in the food and physical activity environment. Cafeteria and vending machine changes, food brought from home, walking routes, and awareness building.
45944327|NCT00123513|Behavioral|Exercise|Increase routing physical activity, walking routes, stairs intervention, etc.
45944328|NCT00123513|Behavioral|Environment|Cafeteria and vending machine changes and identification of opportunities of physical activity.
45944329|NCT00315367|Drug|Donepezil HCI (drug)|
45944330|NCT00315484|Drug|Epoetin alfa and Darbepoetin alfa|
45944331|NCT00315523|Drug|Levocetirizine|
45657057|NCT04816435|Diagnostic Test|Ultrasound test|Ultrasound evaluation of airway
45657058|NCT05617417|Other|Local applied injectable platelet-rich fibrin in women with stress urinary incontinence|Injectable platelet-rich fibrin was prepared by centrifuging venous blood taken from women with stress urinary incontinence and applied locally to the anterior vaginal wall of the patients.
45657059|NCT02604589|Drug|hydromorphone hydrochloride|Patient-controlled narcotic analgesia pump
45944332|NCT00315562|Procedure|carotid endarterectomy|
45944333|NCT00092196|Drug|MK0869, aprepitant / Duration of Treatment: 3 days|
45944334|NCT00315601|Drug|Telithromycin|800 mg once a day for 5 days
45944335|NCT00315601|Drug|azithromycin|500 mg on day 1, and then 250 mg once-daily on days 2 through 5
45944336|NCT00315601|Procedure|bronchoalveolar lavage|One bronchoscopy with bronchoalveolar lavage with each drug administration
45944337|NCT00315601|Drug|Telithromycin|Telithromycin 800 mg once a day
45453147|NCT03405662|Device|Vielight Neuro Gamma|The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.
45808195|NCT04085458|Drug|Damoctocog alfa pegol (Jivi, BAY94-9027)|The recommended starting dose is every 5 days treatment (45 IU/kg)- An assessment of response to treatment will be performed at the next scheduled visit after 10-15 ED (8-10 weeks). Participants may be assigned to different dosing regimens (every 7 days or 2x/week) or continue with every 5 days regimen, according to individual bleeding tendency and needs at investigator's discretion.
45657060|NCT02604589|Procedure|Infusion catheter placement|Placement of continuous infusion catheter and elastomeric pump into extrathoracic paraspinous space
45657061|NCT02604589|Drug|bupivicaine 0.25%|Low Dose analgesia
45657062|NCT02604589|Drug|bupivicaine 0.5%|High dose analgesia
45657063|NCT04825249|Procedure|traditional suture bridge technique|(A) Limbs of the sutures from the medial anchor were passed through torn tendon (B) the suture limbs were tied in a horizontal mattress suture pattern (C) the lateral row pressed the free tails of the knotted line on the greater tubercle of the humerus (D) the effect after completion of the TSB technique
45657064|NCT04825249|Procedure|modified suture bridge technique|(A) Limbs of the sutures from the medial anchor and 2 tendon sutures were passed through the same position of torn tendon (B) the lateral row pressed free tails of the two tendon lines on the greater tubercle of the humerus (C) after examination of sufficient tension and stable fixation, sutures of medial row was knotted (D) the effect after completion of the MSB technique
45808196|NCT04084678|Drug|Ralinepag|Oral ralinepag
45808197|NCT04084678|Drug|Placebo|Matching oral tablets
45808198|NCT04083976|Drug|Erdafitinib|Participants will receive erdafitinib oral tablets.
45657065|NCT04356859|Drug|Albumin Human|Addition of albumin during acute resuscitation following burn injury
45453148|NCT03405662|Other|Sham Vielight Neuro Gamma|The Sham Vielight Neuro Gamma headset is identical to the active Vielight Neuro Gamma headset and intranasal light emitting diode (LED) except it has a power output of 0.
45453149|NCT02530099|Procedure|CN-group|Time limited simulation based training on camera navigation tasks on a virtual reality-simulator.
45657066|NCT04818307|Other|Macquarie Injury Management group|Group A was treated by MIMG (soft tissue mobilization) with base line treatment (Hot pack for 10 mint, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with extended knee, therapist places both hands on the knee and gently apply soft tissue release. This procedure was applied for 2 to 3 minutes.
45808199|NCT04077580|Drug|Methenamine Hippurate 1000 MG|Methenamine and placebo is taken 1 tablet morning and evening for 180 days
45808200|NCT04077463|Drug|Lazertinib|Lazertinib will be administered orally.
45808201|NCT04077463|Drug|Amivantamab|Amivantamab will be administered as an intravenous (IV) infusion.
45808202|NCT04077463|Drug|Carboplatin|Carboplatin will be administered as IV infusion.
45808203|NCT04077463|Drug|Pemetrexed|Pemetrexed will be administered as IV infusion.
45808204|NCT04076618|Device|Vest|Weighted Vest worn > or = 8 hours per day
45808205|NCT04076618|Behavioral|Resistance Exercise Training|Structured exercise training 3 days a week
45808206|NCT04076618|Behavioral|weight loss program|a 24-week intensive phase (with weekly dietary classes) followed by a 27-week transition phase (with biweekly dietary classes)
45808207|NCT04075591|Device|iDesign Refractive Studio with STAR S4 IR® Excimer laser System|Surgeons will perform wavefront-guided monovision LASIK for the treatment of myopic subjects with presbyopia based upon measurements obtained with an iDesign Refractive Studio.
45808208|NCT04069884|Radiation|regional nodal irradiation|external-beam radiotherapy (XRT)
45808209|NCT04069884|Radiation|WBI|Whole Breast Irradiation
45808210|NCT04069884|Radiation|chestwall XRT|chestwall irradiation
45808211|NCT04068376|Other|Control excercise|Each session will be for 60 minutes, 3 days a week, for 24 weeks. The make-up of each session is 1) 5 minutes of warm-up; 2) 30 minutes of moderate-to-strong intensity aerobic exercise, 3) 5 minutes of aerobic cool-down, 4) 20 minutes of balance-stretching exercise; and 5) 5 minutes of cool-down stretching (this times does not count as activity).
45944338|NCT00315679|Drug|Pentoxifylline (also known as oxpentifylline)|
45453150|NCT02530099|Procedure|Procedure-group|Time limited simulation based training on laparoscopic procedure on a virtual reality-simulator.
45944339|NCT00315718|Drug|Extract from Hintonia latiflora bark|
45944340|NCT00092274|Drug|HuMax-CD20|
45944341|NCT00315796|Device|Biophilic Nature Scene and Sound|
45944342|NCT00315835|Drug|Buprenorphine transdermal delivery system|
45944343|NCT03468686|Device|Bilateral rTMS|The coil will locate on F3 and F4 in accordance with the 10-20 international system. bilateral rTMS include stimulate the right DLPFC at 1 Hz for a 10 seconds train of stimulation, and a total of 150 pulse trains. Immediately after that, the stimulation was carried out on the left DLPFC at 10 Hz, 5 seconds of stimulation, with 10 second inter-train interval and 75 pulse trains.
45944344|NCT03468686|Device|Sham rTMS|The same parameters will use in the sham rTMS. However, the coil adjust at an angle of 90º vertically on the skull in a way that one wing place on the head.
46075320|NCT00877591|Drug|Buprenorphine|"FOSAMPRENAVIR/RITONAVIR Dosing information: 1400 mg fosamprenavir + 200 mg ritonavir once daily for 15 days~DARUNAVIR/RITONAVIR Dosing information: 800 mg darunavir + 100 mg ritonavir once daily for 15 days~RIFAMPIN Dosing information: 600 mg once daily in the morning for 15 days~RIFABUTIN Dosing information: 300 mg once daily in the morning for 15 days"
45944345|NCT03468686|Device|Unilateral rTMS (High frequency)|The coil will locate on F3 in accordance with the 10-20 international system. Unilateral rTMS include stimulate the Left DLPFC at 10Hz for a 5seconds train of stimulation, 10 seconds inter-train interval, and a total of 75 pulse trains. .
45944346|NCT00315874|Drug|Buprenorphine transdermal delivery system|
45808212|NCT04068376|Other|"Mind and Movement for Cognitive Health in the Older Adult"|The T1-GR will consist of 60-minute training sessions delivered three days a week during a 24-week period. Each session will be guided by a health profesional certified to coach SSE. The make-up of each session is: 1) 5 minutes of warm-up; 2) 30 minutes of moderate-to-strong intensity aerobic exercise, 3) 5 minutes of aerobic cool-down, 4) 20 minutes of double-task exercise (mat); and 5) 5 minutes of cool-down stretching (this times does not count as activity).
45944347|NCT00315913|Drug|Propranolol|IV Propranolol 1mg/min for a total of 2 minutes. Total dose 2mg
45944348|NCT00315913|Other|IV Placebo|IV Saline Solution
45944349|NCT00477724|Behavioral|exercise and respiratory therapy|exercise and respiratory therapy for three weeks in-hospital and 15 weeks at home
45453151|NCT02530567|Procedure|Intervention|All patients performing the biopsy will have an MRI to carry out the necessary measures.
45453152|NCT01333748|Genetic|blood collection|blood collection for research quantification of allelic expression in the gene BRCA1.
45944350|NCT00477724|Other|sedentary control group|control group with no specific training
45944351|NCT00092313|Drug|MK0966, rofecoxib|
45944352|NCT00092313|Drug|Comparator: oxycodone and acetaminophen|
45944353|NCT00315952|Drug|Exubera|
45944354|NCT00315991|Behavioral|Blood Glucose Awareness Training for Parents|
45944355|NCT00399971|Procedure|Ex Vivo Immunotherapy|Allogeneic and autologous ex vivo activated immune cells are given intravenously at least once a week
45944356|NCT00399971|Drug|Ex vivo immunotherapy|i.v. infusions, once a week, at least 6 to 12 months
45944357|NCT00316030|Drug|Bexarotene|
45944358|NCT04728867|Other|to compare the educational effectiveness of various educational tools|This prospective, randomized, blinded study is designed to compare the educational effectiveness of various educational tools including the surgical textbook, animation, and cadaveric videos in laparoscopic rectal surgery among board-certificated surgeons.
45944359|NCT00316108|Device|WALLSTENT® Endoprosthesis™|Carotid Artery Stent
46075321|NCT05755425|Device|CPAP|CPAP will be delivered with a CPAP valve with venturi flow system with full-face mask. Treatment will start with CPAP set at 10cmH2O and FiO2 60% to target a SpO2 ≥90% or PO2 ≥60mmHg and then adjusted according to SpO2, respiratory distress and clinical tolerance
45808213|NCT04068376|Other|Double-task exercise by older adults and their caregivers|"In the case of T2-GR, older adults and their caregivers will participate in the same SSE program led by a coach for 12 weeks; older adults will then be asked to continue SSE at home under the supervision and with the active participation of their caregivers for another 12 weeks. They will be asked to practice SSE for 60 minutes, three times a week, and to reach a ≥65% heart rate increase. In the field of sports, the people who perform the above-mentioned activities are called pacers, and they supervise physical activity through active accompaniment of older adults."
45808214|NCT04065399|Drug|SNDX-5613|SNDX-5613 orally
45808215|NCT04065399|Drug|cobicistat|Phase 1 Arm C participants will receive 150 mg cobicistat daily.
45944360|NCT00400010|Behavioral|Expert System Intervention|Questionnaires on motivation to change and alcohol consumption were assessed in a clinical interview. Data were entered in a Computer and a fully automatized feedback letter was generated by an expert system. The printed feedback letter was handed out to patients by study staff the following day.
45944361|NCT00316147|Biological|DTPa-HBV-IPV/Hib vaccine|
45657067|NCT04818307|Other|Mulligan Mobilization with Movement|Group B was treated by Mulligan Mobilization with movement with base line treatment (Hot Pack for 10 mints, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with 30 degree knee flexion, therapist places right hand below the knee and left hand above the knee. Apply the lateral glide on the joint. This procedure was applied for 3 times.
45944362|NCT00123552|Drug|Amodiaquine+Artesunate|Amodiaquine 10 mg/kg on day 1, then 5 mg/kg on day 2 and 3; Artesunate 4 mg/kg/d for three days
45808216|NCT04064827|Drug|Paricalcitol|Paricalcitol oral solution (2.5 mcg/mL) will be administered with an oral dispenser
45808217|NCT04056910|Drug|ivosidenib and nivolumab|"Ivosidenib will be administered orally at a dose of 500 mg (provided as 250 mg strength tablets) daily. The dose may be reduced to 250 mg for patients experiencing more than one event of Grade 2 nausea or vomiting (related or unrelated), or Grade 3 or Grade 4 adverse events.~Nivolumab will be administered at 480 mg IV every 28 days."
45808218|NCT04055792|Drug|Sintilimab|Sintilimab 200mg intravenously on day 1 and Anlotinib 12 mg on days 1-14 once every 3 weeks
45808219|NCT04054752|Biological|Recombinant human IL-7-hyFc (NT-I7)|NT-I7 administered at escalating doses of 720, and 960g/kg to determine OBD of NT-I7
45808220|NCT04054752|Biological|Vaccine sequence 1|Day 1 Immunization Pre-NT-I7:Td and Polio Day 64, Immunization Post-NT-I7: Hep A#1, Hep B#1 Day 106: Hep B#2 (Optional) 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1
45808221|NCT04054752|Biological|Vaccine sequence 2|Day 1 Immunization Pre-NT-I7: Hep A#1, Hep B#1 Day 64, Immunization Post-NT-I7:Td and Polio Day 106: no Vaccine 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1
45808222|NCT04048512|Procedure|Resection with intraoperative use of ECMO/CPB|Patients are operated with the use of intraoperative ECMO/CPB
45808223|NCT04048512|Procedure|Resection without intraoperative use of ECMO/CPB|Patients are operated without the use of intraoperative ECMO/CPB
45808224|NCT04038645|Other|Experimental group (laser)|"The patients will receive infrared LEDs in 6 points using a mask developed for the research . The irradiations will be performed with red LED ( wavelength = 660 nm) with output power of 100 milliwatt. During application of the LED both patient and operator will wear goggles.~The red diode laser will be used. The power of the device is 100 mW and the wavelength used was 660nm (± 10nm). The diameter of the fiber optic of the apparatus has 600 μm, therefore a spot (area) of 0.002826cm2. The energy delivered per point is 1 Joule. 10 seconds of application is required. As 6 points are irradiated, the total energy delivered is 6 Joules. The energy density is 354 J / cm2 and the power density would be 35.4 W / cm2. The points will be determined by the same operator, obeying the protocol."
45808225|NCT04038645|Other|Control group (Placebo)|Patients will receive the LED at the same points recommended for the experimental group, but will be off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of the application of the laser. The questionnaire to assess the impact of treatment on quality of life will be applied at baseline and after 8 days as well as the evaluation of serum CRP.
45944363|NCT00123552|Drug|Amodiaquine+Sulfadoxine/Pyrimethamine|Amodiaquine 10 mg/kg on day 1, then 5 mg/kg on day 2 and 3; S/P at 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine single dose
45944364|NCT00123552|Drug|Artemether+Lumefantrine|Artemether 20 mg + Lumefantrine 120 mg 6 dose regimen at 0 and 8 hours on day 1 and twice daily on days 2 and 3:5 kg to < 15 kg: 1 tab/dose; 15 to 24 kg: 2 tabs/dose; >35 kg:4 tabs per dose
45944365|NCT00316342|Device|Back supports|
45944366|NCT00316381|Procedure|Autologous bone marrow-derived stem cells|
45944367|NCT03352427|Drug|Dasatinib|60 mg/m2 orally twice daily
45944368|NCT03352427|Drug|Everolimus|3.0 mg/m2, with titration of dosing after first cycle to keep trough level of 5-15 ug/ml
45944369|NCT00316420|Drug|Capecitabine (Xeloda)|650 mg/m2 po bid Days 1-14 750 mg/m2 po bid Days 1-14 850 mg/m2 po bid Days 1-14 950 mg/m2 po bid Days 1-14
45944370|NCT00316420|Drug|Gemcitabine|750 mg/m2 IV Days 1 & 8 q 21 days
45944371|NCT00316459|Drug|ERB-041|
45657068|NCT02601001|Drug|Omecamtiv mecarbil|Omecamtiv mecarbil tablets for oral administration
45657069|NCT02601001|Drug|Placebo|Matching placebo tablets
45944372|NCT00092352|Drug|MK0966, rofecoxib|
45944373|NCT00092352|Drug|Comparator: celecoxib, placebo|
45944374|NCT00316498|Drug|OGT918|
45944375|NCT00316537|Drug|ATG002 (study drug)|
45944376|NCT00316576|Procedure|Blood sampling for PCR|
45944377|NCT00316615|Biological|influenza vaccine|
46075322|NCT05755425|Device|HFNO|HFNO will be applied initially at maximal settings: 100% FiO2, flow rate 60 L/min and temperature 37C . Within 1 to 2 h, the HFNO settings should be titrated based on patients respiratory rate (<25-30 per minute), SpO2 (92-96%) and comfort
45808226|NCT04037826|Dietary Supplement|L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475|L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475) at dose of 2x108 Colony Forming Units (CFU) per tablet. One chewable tablet is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.
45808227|NCT04037826|Dietary Supplement|Placebo|Placebo
45808228|NCT04037527|Drug|Gemcitabine|Gemcitabine will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity on a 3+3 escalating dose (100 mg/m² to 300 mg/m²)
45808229|NCT04037527|Drug|Docetaxel|Docetaxel will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity (10 mg/m² to 25 mg/m²).
45808230|NCT04037527|Radiation|Radiation|Radiation is to be done with standard preop dose of 50 Gy but at lower doses per fraction. Thus 50.4 Gy in 28 FX. Radiation will be given for 5 days (Monday - Friday) every week for approx. 6 weeks.
45453153|NCT01333748|Genetic|blood collection|blood collection for research quantification of allelic expression in the gene BRCA1.
45453154|NCT01331954|Device|Ultrasonic ablation device|One or two HIFU procedures
45453155|NCT00031447|Drug|Acyclovir|Oral suspension 300 mg/m^2/dose, 3 times per day (TID), for 6 months.
45808231|NCT04037527|Procedure|Surgical Resection|Upon completing neoadjuvant chemotherapy plus radiation therapy, surgical resection will occur.
45808232|NCT04037527|Other|Blood draws|Before treatment, blood (about 2 tubes of 10 mls each) to better understand some aspects of participants' immune system before chemotherapy.
45944378|NCT00123591|Drug|activated recombinant human factor VII|
45944379|NCT00316654|Biological|Meningococcal C conjugate vaccine|
45944380|NCT00316732|Procedure|IPSS Questionnaire|
45944381|NCT00316732|Procedure|EQ-5D Questionnaire|
45944382|NCT00316810|Drug|Alemtuzumab|Day 0: Campath 30 mg i.v. infusion over 3-6 hours
45944383|NCT00316810|Drug|Rabbit Anti-Human Thymocyte Globulin|Day O: Single shot of a polyclonal antilymphocyte preparation (ATG-Fresenius - 8 mg/kg, or IMTIX-Sangstat ATG 4 mg/kg/day).
45944384|NCT00092391|Biological|Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live|0.5 mL subcutaneous injection of one of three sub-lots on Day 0
45944385|NCT00092391|Biological|Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)|0.5 mL subcutaneous injection on Day 0
45944386|NCT00316849|Other|pharmacological study|
45944387|NCT00316849|Procedure|adjuvant therapy|
45944388|NCT00316849|Radiation|3-dimensional conformal radiation therapy|
45944389|NCT00316849|Radiation|intensity-modulated radiation therapy|
45944390|NCT00316849|Drug|temsirolimus|Given IV
45944391|NCT00316849|Drug|temozolomide|Given orally
45944392|NCT03272477|Drug|Perjeta Injectable Product|Single dose of 840mg (loading dose) day1 cycle 1, 420mg at day1 of each subsequent cycle, every 3 weeks. (The latter cycle is called cycle of treatment and is to be given 4 times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
45657070|NCT04825405|Procedure|hand motor coordination in a sitting position after use TipStim Glove|The next therapy with the use of Tip Stim took place after a week. The duration of each therapy session was 60 minutes. After the first therapy session and after a week, the parameters of movement coordination and handgrip were examined. The study of motor coordination and grip strength was performed in two different starting positions: sitting (no stabilization) and lying (with stabilization), and with a different position of the examined upper limb. The upper limb was examined in adduction, with the bent elbow joint in the intermediate position of the forearm. In each of the starting positions, first, the range of passive motion in the wrist joint (flexion and extension) and fingers (global flexion and extension) was measured, then the active movement was measured, in the sequence as above. Patients were asked to make movements as quickly and as fully as possible. Measurement of the grip force was performed after testing the ranges of motion and speed/frequency.
45808233|NCT04036539|Procedure|Placement of the mini-implant and verticalization|an orthodontic mini-implant will be installed in the retromandibular region. The site will be anesthetized. The region will be pre-drilled by about 5mm with a spear drill attached to an implant motor. Once the mini-implant has been selected, it will be locked into position using a kit-specific digital key. Being threaded clockwise until the intramucosal mini-implant is at the gingival level. After installation, a metallic orthodontic lingual will be glued to the molar mesial to be verticalized. The lingual button will be glued to the inclined molar mesial with orthodontic adhesive. A gray chain elastomeric ligature will attach the head of the mini-implant to the lingual button glued to the molar mesial. A light force of 150gr will be imposed (measured with a tensiometer) in all cases, regardless of tooth position. This chain elastic will be changed every 30 days for a period of 3 months. After 90 days of the experiment time, the mini-implants will be removed.
45808234|NCT04034095|Drug|Androgen-deprivation Therapy (ADT)|Participants enrolled in this study will continue to receive ADT (example- Leuprorelin, Goserelin and Degarelix) alone or in combination with other therapies in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
45453156|NCT00031447|Drug|Placebo|Placebo identical to oral acyclovir suspension in appearance and taste.
45657071|NCT05618665|Other|Asthma Education|Asthma education about asthma disease, its symptoms, diagnosis, treatment, risk factors, use of medication, use of medication apparatus, vaccination treatment, follow-up of the asthmatic child, precautions to be taken in prevention, what to do during an attack, what to do for adaptation to the disease and things to do in school life.
45808235|NCT04034095|Drug|Bicalutamide|Participants enrolled in this study will continue to receive bicalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
45808236|NCT04034095|Drug|Abiraterone|Participants enrolled in this study will continue to receive abiraterone in combination with prednisolone along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
45944393|NCT03272477|Drug|Herceptin|Single dose of 8mg/kg (loading dose) day1 cycle 1; 6mg/kg at day1 of each subsequent cycle body weight every 3 weeks. (This is called cycle of treatment and is to be given four times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
45944394|NCT03272477|Drug|Tamoxifen|20 mg per day for a total of 40 weeks in the adjuvant therapy phase.
45657072|NCT05618665|Other|Delivery of booklets|The booklets, prepared by the researchers, included information about the content of the education.
46075323|NCT02785536|Behavioral|RITCh Treatment|"The RITCh treatment increased the emphasis on stress management, negative affect management and utilized language and activities to foster an internal locus of control. Activities were added to address impulsive decision-making, develop home smoking policies, increase the positive valance of treatment, and address barriers to use of the nicotine patches. The treatment materials were also tailored with numerous examples relevant to lower SES groups and African Americans. For example: stress management components specifically address financial stress, discrimination, and micro-aggressions; treatment utilization components include reinforcing the value of individual contributions to the group, structured positive feedback among group members at every session, sending missed you post cards signed by all group members to participants who miss a treatment session, specifically addressing myths about nicotine patch use, and practicing the application of nicotine patches together."
45657073|NCT04818151|Drug|Warfarin|Warfarin treatment for VTE
45944395|NCT03272477|Drug|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment and is to be given for 12 weeks in neoadjuvant therapy phase.
45944396|NCT03272477|Drug|Epirubicin|12 weeks (4cycles) of max. 90mg/sqm in adjuvant therapy phase
45944397|NCT03272477|Drug|Cyclophosphamide|12 weeks (4cycles) of 600 mg/sqm i.v. on day 1+8 or 12 weeks (4cycles) of 500 mg/sqm i.v. on day 1 in adjuvant therapy phase
45657074|NCT04818151|Drug|Apixaban|Apixaban treatment for VTE
45944398|NCT03272477|Drug|Anastrozole|1mg per day for a total of 40 weeks in adjuvant therapy phase
45453157|NCT00006721|Biological|rituximab|Given IV
45453158|NCT00006721|Drug|cyclophosphamide|Given IV
45453159|NCT00006721|Drug|doxorubicin|Given IV
45453160|NCT00006721|Drug|prednisone|Given orally
45453161|NCT00006721|Drug|vincristine|Given IV
45453162|NCT00006721|Radiation|tositumomab|Given IV
45453163|NCT03949543|Other|Large Lunch Intervention|Participants were asked to consume 60% of their daily energy requirements as lunch, between 12:30 and 13:30. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as dinner.
45944399|NCT03272477|Drug|Letrozole|2,5 mg/day for a total of 40 weeks in adjuvant therapy phase
45944400|NCT03272477|Drug|Exemestane|25mg/day for a total of 40 weeks in adjuvant therapy phase
45944401|NCT03272477|Drug|Leuprorelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
45944402|NCT03272477|Drug|Goserelin|3,6mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
45944403|NCT03272477|Drug|Anastrozole|1mg per day for 12 weeks in neoadjuvant therapy phase; 1mg per day for a total of 40 weeks max. in adjuvant therapy phase
45657075|NCT04817527|Drug|Edaravone Dexborneol|Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 7-14days.
45944404|NCT03272477|Drug|Letrozole|2,5 mg per day for 12 weeks in neoadjuvant therapy phase; 2,5 mg perday for a total of 40 weeks max. in adjuvant therapy phase
45808237|NCT04034095|Drug|Prednisolone|Participants enrolled in this study will continue to receive prednisolone in combination with abiraterone along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
45808238|NCT04034095|Drug|Docetaxel|Participants enrolled in this study will continue to receive docetaxel along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
45944405|NCT03272477|Drug|Exemestane|25mg/day for 12 weeks in neoadjuvant therapy phase; 25mg/day for a total of 40 weeks max. in adjuvant therapy phase
45944406|NCT03272477|Drug|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment an is to be given for 12 weeks in the adjuvant phase
45944407|NCT03272477|Drug|Tamoxifen|20mg per day (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase.
45944408|NCT03272477|Drug|Leuporelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
45944409|NCT03272477|Drug|Goserelin|3,5mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
45944410|NCT03272477|Diagnostic Test|Biopsy|Core biopsy at screening (outside of protocol), at week 4 after randomization, (at week 14 in addition if neoadjuvant phase is prolonged)
45944411|NCT03272477|Procedure|Surgery|Surgery at week 14 after randomization (or later, if neoadjuvant phase is prolonged)
45657076|NCT04357795|Drug|CequaTM (Cyclosporine 0.09%) ophthalmic solution|One drop CequaTM (Cyclosporine 0.09%) ophthalmic solution in each eye twice daily, approximately 12 hours apart.
45657077|NCT05617339|Behavioral|I am (internet approach to migraine)|I AM has a biopsychosocial perspective. Modules 1-3 and 10 are mandatory and for those who are in need of shorter support and module 1-10 is for those who have more frequent and severe migraines and want a long time of support and treatment. The rationale of the treatment assumes that we do not know why we get migraines and instead focus on becoming as good as possible at managing the migraine attacks. The focus area of the treatments cognitive-behavioral interventions is, among other things, psychoeducation, what migraine is and what happens in the body during migraines and pain, interpretation of symptoms and information processing, training to stop through mindfulness and becoming aware of assumptions that guide behavior during pain management, management of grief, worry, guilt and feelings of shame based on self-compassion, challenging avoidances in a valued direction through ACT interventions and physiotherapist-led cardio training and exercises.
45808239|NCT04034095|Drug|Enzalutamide|Participants enrolled in this study will continue to receive enzalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
45657078|NCT02604199|Drug|ARC-520 Injection|ARC-520 Injection was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
45808240|NCT04034095|Drug|Apalutamide|Participants enrolled in this study will continue to receive apalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
45808241|NCT04033445|Drug|Placebo|Participants will receive matching placebo IV or SC.
45808242|NCT04033445|Drug|Guselkumab|Participants will receive guselkumab IV or SC.
45808243|NCT04033159|Drug|DYN101|DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 RNA
45808244|NCT04033146|Device|Strengthening muscle contractions during walking|The investigators will use ankle-exoskeletons to systematically alter the behavior of participant muscle contractions. For example, participants will walk in a robotic device that adds a spring in parallel with their lower limb that will help the participants generate a stronger propulsive push-off and may reduce the effort of walking.
45808245|NCT04032899|Dietary Supplement|Lactobacillus fermentum CECT5716|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.
45808246|NCT04032899|Dietary Supplement|Maltodextrin|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.
45808247|NCT04029233|Device|Occlutech PFO Occluder|The Occlutech PFO Occluder is a medical device for transcatheter closure of PFO.
45944412|NCT02959957|Drug|Temocillin|Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial temocillin administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
45944413|NCT02959957|Drug|Cefotaxime|Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial cefotaxime administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
45657079|NCT02604199|Other|placebo|Placebo was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
45657080|NCT02604199|Drug|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
45657081|NCT02604199|Drug|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
45657082|NCT02604199|Drug|antihistamine|All participants will be pretreated with an oral antihistamine, administered 2 hours (±30 minutes) pre-dose. The antihistamine used should in general be an H1>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
45808248|NCT04026113|Drug|Linaclotide 72 μg (FC Participants)|Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)
45944414|NCT02958033|Radiation|Whole Breast irradiation Plus simultaneous tumor bed Boost|hypo-fractionated irradiation for experimental group and normal fractionated irradiation for comprator group
45944415|NCT00316927|Drug|acetylsalicylic acid|
45944416|NCT00316927|Drug|dexamethasone|
45808249|NCT04026113|Drug|Placebo (FC Participants)|Matching placebo
45944417|NCT00316927|Drug|diethylstilbestrol|
45944418|NCT00316966|Behavioral|Multidisciplinary dietary intervention|
45657083|NCT04807699|Other|Data collection|Clinical and sociodemographic data collected through interview at admission and results of complementary tests performed during hospitalization.
45657084|NCT04817215|Drug|ORMD-0801|Randomized to receive ORMD-0801 8 mg QD or 8 mg BID or matching placebo
45808250|NCT04026113|Drug|Linaclotide 145 μg (IBS-C Participants)|Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)
45808251|NCT04026113|Drug|Linaclotide 290 μg (IBS-C Participants)|Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)
45944419|NCT00317005|Drug|folate treatment|
45657085|NCT04817059|Device|Caseforge headcase|We used a custom-fitted styrofoam head mold designed to reduce head motion during MRI scanning.
45657086|NCT04816903|Diagnostic Test|Gyni|Vaginal discharge collection
45944420|NCT00123669|Drug|500 mg of depot hydroxy-progesterone|An intramuscular injection of 500 mg of depot hydroxy-progesterone 5 to 15 days prior to surgery.
45944421|NCT00317083|Procedure|Cough reflex test|
45944422|NCT00317122|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
45808252|NCT04023526|Drug|Azacitidine|Azacitidine SC or IV will be administered at a standard dose of 75 mg/m^2 on days 1-7 of each cycle.
45808253|NCT04023526|Drug|Cusatuzumab|Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg on days 3 and 17 of each cycle.
45808254|NCT04008407|Procedure|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection (ESD) results in en-bloc resection of LSL, regardless of lesion size. This allows for accurate histopathological assessment of SMIC, R0/R1 resection and depth of invasion. ESD is considered a potentially curative for superficial cancers (T1a).
45808255|NCT04008407|Procedure|Endoscopic Mucosal Resection|EMR is the current standard for treating colonic LSL and has been validated to be safe and efficacious. LSLs => 20mm are frequently resected piecemeal. Recent research show that resection margin soft coagulation reduces recurrence rates to those similar to en-bloc resections.
45808256|NCT04008030|Biological|Ipilimumab|Specified dose on specified days
45944423|NCT00317161|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
45944424|NCT00317200|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV infusion over 1 hour, days 1, 8 and 15 of 28 day cycle.
45944425|NCT00317200|Drug|Bevacizumab|Bevacizumab 10 mg/kg, days 1 and 15 of 28 day cycle
45944426|NCT00317278|Other|massage therapy|massage therapy to stable preterm infants
45944427|NCT00317278|Other|Sham|Sham (placebo) provided to the control group
45944428|NCT00317317|Procedure|Acupuncture|4 acupuncture treatments will be conducted during the IVF cycle. The 1st one is at the beginning of egg stimulation, the 2nd one is before the egg retrieval, the 3rd and 4th one are before and after the embryo transfer
45944429|NCT02960035|Drug|50mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
45944430|NCT02960035|Drug|25mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
45944431|NCT02960035|Drug|placebo|
45944432|NCT03034226|Other|Glucose clamp technique|Hyperinsulinemic euglycemic and hyperinsulinemic hypoglycemic clamp procedure with infusion of insulin and glucose
45944433|NCT00317434|Drug|lapatinib|
45944434|NCT00328120|Drug|Fulvestrant|500 mg intramuscular injection
45944435|NCT00328159|Drug|Oil special 107 and MYGLIOL 810|
45657087|NCT04816045|Procedure|Electrochemotheraoy|Electrochemotherapy (ECT) is endoscopic electroporation in combination with bleomycin
45657088|NCT04816045|Procedure|Electroporation with saline (placebo)|Electroporation in the control group is performed endoscopically with saline
45944436|NCT04716790|Procedure|Ultrasound Debridement|Ultrasounds debridement is performed using an SONOCA 185 device (Söring GmbH, Germany). The ultrasounds device generates an ultrasound low frequency of 25kHz and is equipped with three instruments with different sonotrode shapes. The choice of sonotrode depends on wound depth. The ultrasounds instrument piezoelectrically transforms the electrical energy delivered from the ultrasound device into mechanical oscillations in the sonotrode tip.
45944437|NCT04716790|Procedure|Conventional Treatment|Conventional Treatment based on international guidelines for diabetic foot
45657089|NCT04816123|Drug|[14C]Donafenib|Each volunteers received a single 300 mg dose of [14C]donafenib (toluene sulfonic acid) containing a radioactivity dose of 120 μCi as an oral suspension, in fasting within 5 minutes.
45657090|NCT04807465|Device|G-Premio Bond in etch&rinse mode|The phosphoric acid gel was applied to enamel and dentin washed for 5s and was dried gently with air spray. The adhesive system was applied to enamel and dentin surfaces and leave it in place for 10s.
45944438|NCT00328237|Procedure|Cord Blood Transplant|
46075324|NCT02785536|Behavioral|Standard Treatment|The components of the standard treatment include education and activities in which participants gain an understanding of the biopsychosocial underpinnings of tobacco dependence and the cue-urge-response cycle of smoking. Interventions include self-monitoring, guided scheduled rate reduction, treatment goal setting, medication education, stress management, cognitive and behavioral strategies for managing cravings and cues, problem-solving, conflict management, enhancing social support, relapse prevention, and cigarette refusal training. A participant workbook was provided that corresponded to the activities in the treatment sessions.
46075325|NCT04919265|Other|No intervention - mother-infant cohort study|There are no interventions because it is a mother-infant cohort study
45657091|NCT04807465|Device|G-Premio Bond in selective-etch mode|The phosphoric acid was applied only on enamel for 10-15s then washed and was gently dried with air spray. The adhesive system was applied to enamel and dentin surfaces.
45808257|NCT04008030|Drug|Oxaliplatin|Specified dose on specified days
45808258|NCT04008030|Drug|Leucovorin|Specified dose on specified days
45808259|NCT04008030|Drug|Fluorouracil|Specified dose on specified days
45657092|NCT04807465|Device|G-Premio Bond in self-etch mode|The adhesive system was applied to the enamel and dentin surfaces.
45657093|NCT04807621|Biological|Platelet transfusion|Platelets (10 ml/kg body weight) is transfused.
45657094|NCT04807621|Biological|Fibrinogen concentrate|Fibrinogen concentrate (300 mg/kg body weight) is administered.
45657095|NCT04807543|Drug|17-hydroxyprogesterone caproate|intramuscular injection weekly
45808260|NCT04008030|Drug|Irinotecan|Specified dose on specified days
45944439|NCT00328276|Drug|Sarcosine|
45944440|NCT00092430|Biological|V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks|
45944441|NCT04729283|Procedure|Sigmoidectomy|The sigmoid resection surgery, realized by laparoscopy or laparotomy, with anastomosis.
45657096|NCT04807543|Drug|Castor Oil|intramuscular injection weekly
45657097|NCT05616559|Combination Product|Treatment Package for First-Episode Depression|The outpatient 'treatment package' for first episode depression is a national uniform package designed by Mental Health Services in the Capital Region. The treatment package for first-episode depression is a program with manualized group CBT, psychoeducation of patients and relatives, and relapse prevention. Antidepressant medication and individual psychotherapy are available as needed.
45808261|NCT04008030|Drug|Bevacizumab|Specified dose on specified days
45808262|NCT04008030|Drug|Cetuximab|Specified dose on specified days
45808263|NCT04008030|Biological|Nivolumab|Specified dose on specified days
45808264|NCT04001062|Procedure|Surgical Fixation|For both scissoring and non-scissoring injuries surgical fixation by either pinning, dorsal plate, or lag screws will be considered. This will be determined by surgeon expertise at the time of surgical fixation. Postoperative, a volar short arm splint and immediate AROM at full range with buddy taping to adjacent digit will be indicated. Transition to removable short arm splint at week 2 after suture removal. No strengthening until clinical union.
45808265|NCT04001062|Other|Non-Operative Management|"For non-scissoring injuries: Placement of short-arm cast; immediate AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of <2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union.~For scissoring injuries: Closed reduction in clinic/ER and placement of short-arm cast; immediate full range AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of <2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union"
45944442|NCT00328393|Drug|Pioglitazone|45 mg 8 weeks
45944443|NCT00328393|Drug|Placebo|Placebo
45944444|NCT00328432|Drug|celecoxib 400 mg bid|
45657098|NCT04815811|Other|Blood collection|Blood samples collections to evaluation of the potential role of the sex chromosomes in the innate immune response by analyzing inflammatory cytokine production (IL-1β, IL-6, IL-8, IL-10, TNF-α and IFN-α), studying the cell diapedesis receptor CD99 on PMNs, monocytes, and lymphocytes, analyzing the contribution of X-linked genes of the TLR pathways and the influence of X-linked miRNAs.
45657099|NCT04815811|Other|Stool collection|Fecal sample collection to delineate microbiome contribution, we will study the gut microbiota in faecal samples obtained from the recruited patients.
45657100|NCT04815655|Procedure|Cartilage tympanoplasty|is the reconstruction of the tympanic membrane (TM) by using catilage
45657101|NCT02600845|Device|ACCU-CHEK|ACCU-CHEK Connect Diabetes Management System contains ACCU-CHEK Aviva Connect Blood Glucose Monitoring System, ACCU-CHEK Connect Diabetes Management App, and ACCU-CHEK Connect Online Diabetes Management System.
45944445|NCT00092469|Biological|V441, diptheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), & Haemophilus influenza type b conjugate vaccine|
45944446|NCT00328471|Behavioral|care management|
46075326|NCT04200222|Diagnostic Test|cadmium, lead and vanadium measurements and compare|"The method developed by Aliyev et al. was used for preparing the samples for analysis (1).~The three metals (cadmium, lead and vanadium) were measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).~1. Ovayolu A, Ovayolu G, Karaman E, Yuce T, Ozek MA, Turksoy VA. Amniotic fluid levels of selected trace elements and heavy metals in pregnancies complicated with neural tube defects. Congenit Anom (Kyoto). 2019:10.1111/cga.12363."
46075327|NCT00874003|Drug|mirtazapine|oral tablet, 30 mg daily
45808266|NCT04000360|Other|High-Intensity Aerobic Exercise|The home-based exercise group will receive a Peloton indoor cycle delivered to their home and a heart rate monitor strap. Participants will be asked to cycle 3x/week for 12 months on their bike with their heart rate monitor at an aerobic intensity between 60-80% of heart rate reserve with a target cadence between 80-90 revolutions per minute (RPMs). Additionally, participants (both groups) will receive activity monitors to monitor their daily activity levels.
46075328|NCT00874003|Drug|placebo|oral tablet, 1 daily
45657102|NCT04427995|Device|OMNI surgical system|GATT + viscodilation
45657103|NCT04806997|Diagnostic Test|Vascular occlusion test|The VOT procedure was conducted twice in each patient, before and 15 min after intrathecal injection. An NIRS sensor (INVOSTM 5100C Cerebral/Somatic Oximeter; Medtronic, Minneapolis, MN, USA) was attached to the patient's gastrocnemius muscle. A tourniquet (A.T.S ® 3000 Automatic Tourniquet System; Zimmer Inc., Warsaw, IL, USA) was applied to the thigh and inflated to a pressure value 50 mmHg over the patient's baseline systolic blood pressure in the leg and maintained for 5 min. After a 5-min ischemic period, the tourniquet was rapidly deflated to 0 mmHg. The StO2 data was continuously recorded during the VOT procedure. After confirmation of spinal anesthesia using cold sensitivity, the VOT procedure was repeated in the same manner as mentioned above. The occlusion slope and recovery slope were calculated based on the measured StO2 data.
45657104|NCT04798105|Behavioral|Effects of tDCS of dlPFC on Probabilistic Selection Task|Predictors of Probabilistic Selection Task Performance including anodal tDCS of dlPFC, eye blink rate, extraversion and impulsiveness
45657105|NCT04798183|Diagnostic Test|3-dimensional scan|Facial 3-dimensional scan according to posture
46075329|NCT04232046|Other|Massage|Massage the trigger points in 8 different points for 1 min in circle direction and 3 times a day.
45657106|NCT04806763|Device|Menicon Z Night|To assess the use of Menicon Z Night contact lenses for reducing myopia progression in children
46075330|NCT04915365|Drug|Acetazolamide|Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
45657107|NCT04806763|Device|Control|Distance, single-vision glasses were used as control
45657108|NCT05617261|Other|Conscious sedation|Conscious sedation is a combination of medications to help you relax (a sedative, for example nitrous gas) and to block out pain (commonly known as freezing, for example lidocaine).
45808267|NCT03996915|Device|Pdt Photodynamic Therapy|device irradiation with low intensity laser (wave length = 660 nm) 9 J (Joules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated.
45808268|NCT03996915|Other|tongue scrapper|Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
45808269|NCT03995927|Other|Data collection and analysis|Only radiation oncology patients data from medical records regarding treatment, demographics and follow-up visits will be collected and logged by investigators.
45808270|NCT03995927|Other|Quality of Life Questionnaire|Participants will be asked to complete a set of short forms at first visit and post-treatment visits. If participant has a routine visit about 3 months after treatment, participant will be asked to complete a final form that is optional.
45808271|NCT03989414|Drug|CC-92480|Specified dose on specified days
45808272|NCT03989414|Drug|Bortezomib|Specified dose on specified days
45808273|NCT03989414|Drug|Dexamethasone|Specified dose on specified days
45808274|NCT03989414|Drug|Daratumumab|Specified dose on specified days
45808275|NCT03989414|Drug|Carfilzomib|Specified dose on specified days
45808276|NCT03989414|Drug|Elotuzumab|Specified dose on specified days
45808277|NCT03989414|Drug|Isatuximab|Specified dose on specified days
46075331|NCT04915365|Drug|Placebo|"Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses~1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m."
46075332|NCT03838393|Other|multidisciplinary management|pharmacological and non.pharmacological treatment (specially trained nurses, psychologists and physiologists)
45657109|NCT04797949|Drug|Low-dose aspirin|Women will be prescribed 81 mg of aspirin to take daily during pregnancy.
45808278|NCT03989414|Drug|Carfilzomib|Specified dose on specified days
45808279|NCT03988283|Biological|Personalized neoantigen DNA vaccine|At each vaccination time point, patients will receive one injection of the neoantigen DNA vaccine, one injection into the vastus lateralis.
45808280|NCT03988283|Device|Ichor TDS-IM v2.0|All study injections will be given intramuscularly using an integrated electroporation device (TDS-IM v2.0 device - Ichor Medical Systems).
46075333|NCT00877669|Procedure|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
46075334|NCT00877669|Procedure|Holmium Laser Enucleation of the Prostate|HoLEP using 100W Ho:YAG laser
45808281|NCT03988283|Procedure|Peripheral blood draw|-After trial enrollment and up to 7 days after the first vaccine dose (baseline); 2 weeks after last dose; time of progression or discontinuation (optional); other time points throughout the study if deemed pertinent to assessment of exploratory objectives (optional)
45808282|NCT03978624|Drug|Pembrolizumab|200 mg IV on day 1 and day 22
45808283|NCT03978624|Drug|Entinostat|5 mg given orally on day 1, day 8 and day 15
45808284|NCT03977259|Other|Individually targeted fortification|"Abbott liquid protein and/or medium chain triglyceride are added routinely to ensure that the base milk has protein 1 g/dL and calories 67/dL."
45808285|NCT03974217|Drug|Talazoparib|Talazoparib is a drug that stops the activity of a protein called poly (adenosine diphosphate [ADP]-ribose) polymerase or PARP. PARP is involved in repairing damage to the DNA within the cells. When PARP is turned off by Talazoparib in cancer cells, DNA damage cannot be repaired and leads to the death of the cancer cells.
45808286|NCT03974217|Drug|Decitabine|Decitabine is a drug that is meant to inhibit DNA methylation to restore normal functions to genes and helps to support normal cell production in the bone marrow and the death of abnormal bone marrow cells.
45808287|NCT03973684|Device|pdt experimental group|"G1-40 patients Photodynamic therapy with methylene blue as photosensitizer~device irradiation with low intensity laser (wave length = 660 nm) 9J (Jaules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated."
46075335|NCT04913727|Diagnostic Test|Cardiac magnetic resonance imaging before the procedure|CMR image acquisition with previously mentioned analysis
46075336|NCT04913727|Procedure|Transcatheter mitral edge-to-edge repair.|Included patients will undergo Transcatheter mitral edge-to-edge repair.
46075337|NCT00874159|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
46075338|NCT02785146|Drug|Huaier Granule|Huaier Granule is continuously taken three times per day, 20g per time.
46075339|NCT02785146|Drug|Oxaliplatin|85 mg/m², ivdrip, D1
45808288|NCT03973684|Other|tongue scraper group|Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
46075340|NCT02785146|Drug|Calcium folinate|Calcium folinate 400 mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
46075341|NCT02785146|Drug|5-fluorouracil|400 mg/m², iv, D1; and 2400mg/m², civ, 48h
46075342|NCT00869635|Drug|S-1 Chemotherapy|S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, <1.25m2: 80mg/day, 1.25~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment
45808289|NCT03972930|Radiation|Hypofractionated Radiotherapy|Hypofractionated radiation is delivered using highly conformal technique, allowing for a high dose of radiation to be delivered precisely.
45808290|NCT03971045|Drug|Pembrolizumab|Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle
45808291|NCT03969888|Drug|ABBV-3067|Tablet taken orally.
45808292|NCT03969888|Drug|Placebo ABBV-3067|Tablet taken orally.
45808293|NCT03969888|Drug|ABBV-2222|Capsule taken orally.
45808294|NCT03969888|Drug|Placebo ABBV-2222|Capsule taken orally.
45808295|NCT03968653|Drug|Debio 0123|Debio 0123 will be given as an oral capsule for 3 days during each 21-day cycle, except Cycle 1 which is of 24 days.
45808296|NCT03968653|Drug|Carboplatin|Carboplatin will be given as an IV infusion in combination with Debio 0123 on Day 1 from Cycle 2 onwards in Group A.
45808297|NCT03968653|Drug|Debio 0123|Debio 0123 will be given as an oral capsule for 6 days during each 21-day cycle.
45808298|NCT03968653|Drug|Carboplatin|Carboplatin will be given as an IV infusion in combination with Debio 0123 on Day 1 from Cycle 1 onwards.
45808299|NCT03966716|Device|Arthroplasty|Patients with an undisplaced femoral neck fracture receive a hemi or total hip arthroplasty depending on each hospital's routine for patient age and mobility.
45808300|NCT03966716|Device|Internal Fixation|Patients with an undisplaced femoral neck fracture undergo a closed reduction and internal fixation with 2-3 screws or pins, or sliding hip screw device. Type of fixation depends on each hospital's routine.
45808301|NCT03964415|Biological|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV via IM injection into the deltoid muscle at months 0 (Day 1), 3, 6 and 12.
45808302|NCT03964415|Biological|Clade C and Mosaic gp140 HIV bivalent vaccine|Participants will receive Clade C and Mosaic gp140 HIV bivalent vaccine as IM injection into the deltoid muscle at Months 6 and 12.
45808303|NCT03964415|Biological|Placebo|Participants will receive matching placebo.
45808304|NCT03960983|Device|Treatment with tongue scraper|Treatment with tongue scraper. the evaluation of halitosis will be repeated before this step.
45808305|NCT03960983|Procedure|Hygiene procedures for the mucosa and dentures|Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
45808306|NCT03960983|Radiation|Photodynamic Therapy|Treatment with Photodynamic therapy. The evaluation of halitosis will be repeated before this step
45808307|NCT03960983|Procedure|Hygiene procedures for the mucosa and dentures|Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
45808308|NCT03952585|Procedure|Biopsy|Undergo tissue biopsy
45808309|NCT03952585|Procedure|Biospecimen Collection|Undergo blood sample collection
45808310|NCT03952585|Drug|Cisplatin|Given IV
45808311|NCT03952585|Procedure|Computed Tomography|Undergo CT
46075343|NCT00869635|Procedure|Photodynamic therapy|PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation
46075344|NCT00869635|Procedure|Systemic chemotherapy except S-1|Variable systemic chemotherapy except S-1
46075345|NCT00913965|Drug|Atenolol Tablets 100 mg (Cord Laboratories)|
46075346|NCT00913965|Drug|Atenolol Tablets 100 mg (Stuart Pharmaceutical)|
46075347|NCT02785380|Procedure|laparoscopic surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
45458758|NCT04802356|Drug|Bortezomib|Dose of 1.3 mg/m2, on days: 1, 4, 8 and 11 of every 28-day cycle. Subcutaneous administration Induction: 6 cycles Consolidation: 2 cycles
45657110|NCT04797793|Drug|Adapalene Gel 0.1%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
45944447|NCT02571725|Drug|Olaparib|Olaparib starts concomitantly with the first dose of Tremelimumab
45944448|NCT02571725|Drug|Tremelimumab|3 to 6 patients will be treated at 10 mg/kg depending on RLT observed in the first 3 patients. If 0 out of 3 or 1 out of 6 patients experienced a RLT at 10 mg/kg, then this dose will be considered at the recommended phase 2 dose (RP2D). If 2 out of 6 patients experience RLT at this dose within 56 days, then dose reductions as detailed in the Arm description will be carried out.
46075348|NCT02785380|Procedure|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
46075349|NCT02609451|Procedure|Ileostomy closure|Ileostomy closure at a different time point
46075350|NCT03166332|Behavioral|Mediterranean diet|Mediterranean diet supplemented with extra-virgin olive oil and nuts
46075351|NCT03166332|Behavioral|Mindfulness|Mindfulness-Based Stress Reduction program (MBSR)
46075352|NCT05226481|Other|Trauma-focused cognitive behavioral therapy (TF-CBT)|Trauma-focused cognitive-behavioral therapy (TF-CBT) is an evidence-based method for the treatment of posttraumatic stress among youth.
46075353|NCT02609529|Other|Medical Food|Serum-derived bovine immunoglobulin protein isolate will be supplied by EnteraHealth. The product is manufactured in accordance with Good Manufacturing Practice (GMP) and U.S. Food and Drug Administration (FDA) guidelines for medical food ingredients (21 CFR Part 110). Serum-derived bovine immunoglobulin protein isolate (SBI) is generally recognized as safe (GRAS). The FDA has reviewed the safety dossier for SBI as a medical food product.
46075354|NCT02609529|Other|Placebo|
45657111|NCT04797793|Drug|Placebo Control|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
45657112|NCT04797793|Drug|Differin® Gel (Adapalene 0.1%, Galderma)|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
45657113|NCT04806529|Drug|Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)|Biological/Vaccine: Investigational adjuvanted SARS-CoV-2 Subunit vaccine
45657114|NCT04806529|Drug|Comparator|Biological/Vaccine: A dose of 0.5 mL saline for injection will be administrated to subjects randomized to receive the placebo
45808312|NCT03952585|Other|Fludeoxyglucose F-18|Receive FDG
45808313|NCT03952585|Radiation|Image Guided Radiation Therapy|Undergo IGRT
45808314|NCT03952585|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45808315|NCT03952585|Procedure|Magnetic Resonance Imaging|Undergo MRI
45808316|NCT03952585|Biological|Nivolumab|Given IV
45808317|NCT03952585|Procedure|Positron Emission Tomography|Undergo PET
45808318|NCT03952585|Other|Quality-of-Life Assessment|Ancillary studies
45808319|NCT03952585|Other|Questionnaire Administration|Ancillary studies
45944449|NCT00328549|Drug|Pegylated Interferon and Ribavirin|
45944450|NCT00123747|Procedure|Positron Emission Tomography (PET) scan Imaging|
45944451|NCT00328588|Drug|YM155|IV
45453164|NCT03949543|Other|Large Dinner Intervention|Participants were asked to consume 60% of their daily energy requirements as dinner, between 19:30 and 20:30, each day during their two dietary interventions. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as lunch.
45657115|NCT04796857|Drug|PD-1 Antibody|Tislelizumab will be administered every 4 weeks up to 6 cycles during induction phase if patients get CR or PR after induction phase.
45808320|NCT03952559|Drug|Baricitinib|Administered orally
45808321|NCT03952559|Drug|Placebo|Administered orally
45808322|NCT03952559|Drug|Topical corticosteroid|Administered as standard-of-care
45808323|NCT03952468|Device|Transcranial Magnetic Stimulation|Administration of rapidly fluctuating magnetic field, delivered over the dorsolateral prefrontal cortex.
45808324|NCT03952468|Other|Brief Cognitive Behavioral Therapy|BCBT is a well-established and efficacious treatment that is an extension of Cognitive Behavioral Therapy, a treatment that is widely implemented across VA health care systems.
45808325|NCT03946800|Biological|MEDI1191|Subjects will receive MEDI1191 (at least twice)
45808326|NCT03946800|Biological|Durvalumab|Subject will receive durvalumab every 4 weeks
45808327|NCT03945175|Drug|MYDAYIS|MYDAYIS treatment will be given at a minimum dose of 12.5mg/day and will increase in increments of 12.5mg, up to 37.5mg, based upon clinical response and tolerability.
45808328|NCT03945175|Drug|Placebo|During the two-week, placebo lead-in, all patients will receive 12.5mg of placebo at Visit 1 and Visit 2.
45808329|NCT03942406|Combination Product|BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device|Live attenuated pertussis vaccine administered via the VaxINator(TM) atomization device
45808330|NCT03941743|Drug|Fingolimod|Given PO
45944452|NCT00328666|Behavioral|Iyengar yoga|
45944453|NCT00328666|Behavioral|Enhanced nutritional care classes|
45944454|NCT02215889|Procedure|Liver transplantation|
45944455|NCT00328705|Device|Implantable Cardioverter Defibrillator|
45944456|NCT00328744|Behavioral|Standard|18-month standard behavioral weight loss intervention
45944457|NCT00328744|Behavioral|Limited Variety|Two chosen snack foods
45944458|NCT00092508|Drug|OPC-6535|
45808331|NCT03941743|Drug|Fingolimod Hydrochloride|Given PO
45944459|NCT00092508|Drug|Asacol®|
45944460|NCT00328822|Drug|Quetiapine|
45944461|NCT00328822|Drug|placebo|
45944462|NCT00420043|Drug|imatinib|
45944463|NCT02158793|Procedure|Craniomaxillofacial allotransplantation|Transplantation of donor face
45944464|NCT00420082|Drug|Bilastine|Encapsulated Bilastine 20 mg tablets Q.D.
45944465|NCT00420082|Drug|Fexofenadine|Encapsulated Fexofenadine 120 mg tablets Q.D.
45944466|NCT00420082|Drug|Cetirizine|Encapsulated Cetirizine 10 mg tablets Q.D.
45944467|NCT00420082|Drug|Placebo|Encapsulated Placebo tablets Q.D.
45944468|NCT00123786|Procedure|Positron Emission Tomography|Positron Emission Tomography
45944469|NCT00420121|Procedure|laboratory analysis|blood withdrawal for laboratory analysis
45944470|NCT00420160|Behavioral|Smoking cessation treatment plus moderate intensity exercise|
45944471|NCT00420160|Behavioral|Smoking cessation treatment plus health education|
45657116|NCT04796857|Drug|Lenalidomide|"Phase I: dose escalation phase. Patients will oral dosage as 10mg, 20mg, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral lenalidomide as RP2D up to 6 cycles during induction phase"
46075355|NCT02689752|Drug|fruquintinib|fruquintinib suspension, 5mg ( 100mCi), oral, taken once, fast
46075356|NCT05753865|Drug|SYHX2011|IV infusion, 260 mg/m^2
46075357|NCT05753865|Drug|Paclitaxel for injection (albumin-bound)|IV infusion, 260 mg/m^2
45657117|NCT04796623|Drug|TQB3616 capsules|TQB3616 capsules 180 mg given orally, once daily in 28-day cycle.
45657118|NCT04796623|Drug|Fulvestrant injection|Fulvestrant injection was given at a fixed dose of 500mg on day 1, day 15 of the first cycle and day 1 of each subsequent cycle, and each cycle is 28 days.
45808332|NCT03941743|Other|Questionnaire Administration|Ancillary studies
45808333|NCT03940235|Drug|Androgen deprivation therapy (ADT)|SBRT + ADT
45808334|NCT03940235|Radiation|SBRT|SBRT to all radiological documented lesions (bone or lymphnodes)
45808335|NCT03939156|Other|Completion of questionnaires|Completion of questionnaires at the time of study entry
45808336|NCT03937154|Drug|Romiplostim|This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer
45808337|NCT03937154|Drug|Placebo|Placebo comparator
45808338|NCT03937011|Device|Robotic Suturing of gastric sleeve oversew and vaginal cuff closure|"Robotic Bariatric Sleeve gastrectomy~Robotic Hysterectomy with or without oophorectomy;"
45808339|NCT03935893|Biological|Tumor Infiltrating Lymphocytes (TIL)|TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
45944472|NCT01821833|Dietary Supplement|Omega-3 fatty acid|"Patients receive omega-3 fatty acid capsules orally beginning 1 week prior to paclitaxel treatment.~Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first).~Each 1-gram capsule contains approximately 465 mg eicosapentaenoic acid (EPA) and 375 mg docosahexaenoic acid (DHA)."
45944473|NCT01821833|Dietary Supplement|Placebo|"Patients receive placebo capsules orally beginning 1 week prior to paclitaxel treatment.~Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first)"
45944474|NCT01821833|Drug|Paclitaxel|Patients will receive, as part of their standard of care, weekly paclitaxel at 70 to 90 mg/m2 intravenously for a minimum of 2 months. Treatment 3 out of 4 weeks is allowed.
46075358|NCT00869869|Drug|melatonin|2.5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
46075359|NCT00869869|Drug|placebo|placebo
46075360|NCT04216719|Behavioral|OCM-RISE|OCM RISE will comprise four phases (Exploratory, Preparation, Implementation, and Sustainment). During Exploration, staff will conduct readiness surveys, interviews and system mapping exercises to assess county context. In the Preparation Phase, the needs assessment data will inform county-specific action plans. Guided facilitation during this phase includes court development planning, practice/process improvement strategies, and training on data-driven decision-making to help IACTs operationalize the 10 OCM guidelines, assess performance, and fit the guideline to the local context. In the Implementation Phase, counties will roll out the OCM for 18 months with data feedback, support, and facilitation. Each IACT will receive reports on the performance of its OCM and complete two plan-do-study-act cycles. In the Sustainment Phase, implementation and feedback reports will continue for 6-18 months, but without other external facilitation.
46075361|NCT04213755|Diagnostic Test|ROTEM|ROTEM including INTEM, EXTEM, APTEM, and FIBTEM
45453165|NCT01099345|Procedure|cystometry (CMG)|recording device measuring pressures though catheters placed in bladder and rectum
45808340|NCT03935893|Drug|Fludarabine + Cyclophosphamide combination|Preparative lymphocyte depleting (immunosuppressive) combination regimen consisting of fludarabine and cyclophosphamide administered prior to TIL infusion.
45453166|NCT01099345|Procedure|polysomnography (PSG)|Recording device measuring sleep activity through electrodes attached to the subject
45453167|NCT01103011|Drug|ND0611|Continuous delivery of ND0611
45657119|NCT04815421|Other|the paste group|Patients in the paste group were treated with Nanxing paste on the affected region include shoulder, neck or back and no more than 3 pieces. The paste lasted for 24 hours and then peeled it rested the pasted region for 24 hours and changed another paste on the pain region. The therapy duration was 6 days.
45808341|NCT03933670|Drug|Hyperpolarized Carbon C 13 Pyruvate|Given IV
45808342|NCT03933670|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
45808343|NCT03933670|Procedure|MRI Ultrasound Fusion Guided Biopsy|Undergo MR/US fusion-guided prostate biopsy
45944475|NCT00328900|Drug|Administration of 0,7 mg of atropine|
45944476|NCT00328900|Device|Measurement of skin conductance with Pain detector|
45944477|NCT00328939|Drug|ARIXTRA infusion|
45944478|NCT00328939|Drug|Enoxaparine infusion|
45944479|NCT02965014|Behavioral|Face-to-Face Young Women's CoOp (YWC)|Participants will be offered HIV counseling and testing (HCT) and a two-session face-to-face YWC intervention. The face-to-face sessions will include information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal.
45944480|NCT02965014|Behavioral|mHealth Young Women's CoOp (YWC)|Participants will be offered HIV counseling and testing (HCT) and training on the mHealth application, which will include all content addressed in the face-to-face YWC delivery format. Participants will also be offered a tablet to complete the two-session intervention.
46075362|NCT03120312|Procedure|total hip replacement|primary hip replacement patients during past 5 years．
45657120|NCT04815421|Other|the meridian group|Patients in the meridian group were treated with dredging the same side three yang meridian techniques(include the gliding techniques of deep tissue massage on three yang meridians of back hand (the second, fourth and fifth metacarpal bone); pinching and kneading the second, fourth and fifth phalanges of fingers of the affected side hand; Encourage the patient to try his best to roll his neck to the most tolerable degree during dredging the meridian) and the total time was about 3 to 5 minutes according the tolerance of every patient . The massage will not stop until the meridian route was relatively smooth, soft and thermal or light red. The sequence of massage is Hand Yangming meridian(LI) the first, Hand Taiyang meridian(SI) the second and Hand Sanjiao(SJ) the last. The frequency of massage was once a day.
45944481|NCT02965014|Behavioral|HIV Counseling and Testing|Participants will be offered standard HIV counseling and testing (HCT).
45944482|NCT00328978|Drug|Quetiapine|
45944483|NCT01479608|Procedure|Liver transplantation and liver resection|
45944484|NCT00329017|Procedure|Fine needle aspiration|Fine needle aspiration
45944485|NCT00092859|Drug|MK0557|
46075363|NCT05753787|Other|preservative-free solution of standard post-cataract eye drops|Usage of preservative-free eye drops in comparison to the standard preserved drops with dexamethasone 0.01%.
45808344|NCT03932201|Drug|Damoctocog alfa pegol (Jivi, Bay94-9027)|Follow clinical practice. BAY94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII) product site-specifically conjugated to a single (dual 30-kDa branched) 60-kDa polyethylene glycol (PEG) molecule. BAY 94-9027 is intended for prophylaxis and treatment of bleeds in patients with hemophilia A aged ≥12 years, with a narrow, predictable weekly dose that allows for the treatment regimen to be tailored to individual patient needs.
45808345|NCT03927612|Device|Virtual reality perspective taking training|Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the alternate perspective condition, participants will then experience the scenario again from the counterpart's perspective, including internal thoughts of the virtual counterpart.
45808346|NCT03927612|Device|Virtual reality control perspective|Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the control perspective condition, participants will then experience the scenario again from identical perspective.
46075364|NCT00874315|Other|anti-thymocyte globulin|2.5 mg/kg/day for 4 doses on day -3, -2 , -1 and day +2.
45657121|NCT04815265|Drug|Remimazolam|Remimazolam is used for sedation
45657122|NCT04815265|Drug|Dexmedetomidine|Dexmedetomidine is used for sedation
45657123|NCT04796389|Other|Music|Preferred music of the participant administered using headphones.
45808347|NCT03924908|Behavioral|VRH|Patients will see a 3D film combined with a hypnotic voice during the entire procedure of dressing change
45808348|NCT03924908|Behavioral|VR|Patients will see a 3D film without any hypnotic voice during the entire procedure of dressing change
45657124|NCT04806841|Behavioral|Motivational intervention|Three group meeting of 60 minutes to help create effective goals and methods on maintaining motivation to exercise regularly. These meetings will help participants create effective goals and methods on maintaining their motivation to exercise regularly. They will then receive a monthly phone call follow-up at months 4-6.
45808349|NCT03921515|Other|Blister induction|Blister induction involves creating 8 blisters on the forearm and removing the tops of the blisters for primary cell culture derivation. After blister induction, subjects may have an optional overnight admission to assess cell infiltration in response to autologous serum and/or sterile saline solution.
45808350|NCT03921515|Other|Skin Biopsies|The skin biopsies will involve up to 4 biopsies: 2 initial punch biopsies 2 mm in diameter, followed by a punch biopsy 3 (plus or minus 1) and 7 (plus or minus 2) days later using a 3 mm punch to encompass the initial biopsy sites, capturing the tissue at 3 and 7 days of healing.
45808351|NCT03916510|Biological|Enadenotucirev|Enadenotucirev is a live replicating oncolytic adenovirus; it is considered a BioSafety Level 1 (BSL-1) infectious substance.
45944486|NCT00329056|Drug|MitoQ|Two doses will be compared to placebo: 40 or 80 mg of MitoQ once daily for a period of 12 months.
45944487|NCT00329095|Drug|travoprost, latanoprost, or bimatoprost|
45944488|NCT00329095|Drug|Additional ocular hypotensive medication|
45944489|NCT00329134|Drug|Administration of quinine sulphate taste-masked pellets|
45944490|NCT00329173|Drug|Rosuvastatin|
45944491|NCT00329173|Drug|Atorvastatin|
45944492|NCT00123825|Drug|Gemcitabine|
45944493|NCT00123825|Drug|Cisplatin|
45944494|NCT00329212|Drug|San Huang Xie Jin Tang|
45944495|NCT00329251|Biological|Hepatitis A|
45944496|NCT00329251|Biological|Hepatitis B|
45944497|NCT00329251|Biological|Influenza|
45944498|NCT00329251|Biological|Pneumococcal|
45944499|NCT00329251|Biological|Tetanus-diphteria|
45944500|NCT00329251|Biological|Varicella|
45944501|NCT00329251|Biological|Measles-Mumps-Rubella|
45944502|NCT00329329|Drug|satraplatin and capecitabine|satraplatin and capecitabine dose escalated per the dosing scheme
45944503|NCT00123864|Procedure|Intensity-modulated radiation therapy|
45944504|NCT00329368|Biological|EC90 (KLH-FITC)|1.2mg in combination with adjuvant GPI-0100 administered subcutaneously, weekly for 4 consecutive weeks during the first treatment cycle, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
45944505|NCT00329368|Biological|GPI-0100|3.0mg in combination with EC90 administered subcutaneously weekly for 4 consecutive weeks during the first treatment cycle, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
46075365|NCT00874315|Drug|busulfan|0.8 mg/kg/dose for total of 8 doses.
46075366|NCT00874315|Drug|cyclosporine|1.5 mg/kg/dose every 12 hours.
46075367|NCT00874315|Drug|fludarabine phosphate|30 mg/m2/day for 5 days.
46075368|NCT00874315|Drug|mycophenolate mofetil|15 mg/kg/dose every 8 hours
46075369|NCT00874315|Drug|tacrolimus|0.03 mg/kg/day as continuous infusion or 12 hour divided doses
46075370|NCT00874315|Procedure|allogeneic hematopoietic stem cell transplantation|Donor stem cell transplantation from HLA matched sibling donor or an unrelated donor.
45944506|NCT00329368|Drug|EC17 (Folate-FITC)|0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks followed by 2 observation weeks for each cycle.
45808352|NCT03916510|Drug|Capecitabine|Capecitabine is a chemotherapy drug licensed for use in rectal cancer, it is a non-cytotoxic pre-cursor of the cytotoxic 5-fluorouracil. Due to Capecitabine not being taken on Enadenotucirev dosing days it is considered an investigational medicinal product within this trial.
45808353|NCT03916510|Radiation|Radiotherapy|50 Gy/25#
45453168|NCT01103011|Drug|ND0611|Solution of ND0611 delivered continuously
45657125|NCT04806841|Other|Control intervention|Participants in the control group will be simply encouraged to exercise at the EPIC center and complete the online surveys. Participants in the control group will receive the skills/tactics at the end of the study.
45944507|NCT00329368|Drug|Interleukin-2|Low dose (7-12 MIU) IL-2 administered subcutaneously three times per week (MWF) for 3 consecutive weeks during the first cycle, 4 consecutive weeks during cycle 2 and additional cycles
45944508|NCT00329368|Drug|Interferon-alpha|3.0 MIU administered subcutaneously 3 times per week (MWF) for 3 consecutive weeks during the first cycle of treatment, then 3.0 MIU administered subcutaneously 3 times per week (MWF) for 4 weeks for cycle 2 and additional cycles.
45657126|NCT04815187|Drug|Montelukast|Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.
45657127|NCT04815187|Drug|Placebo|Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.
45657128|NCT05616481|Procedure|Laparoscopic Burch colposuspension|The original Burch procedure will be performed
45657129|NCT05616481|Procedure|Modefied Burch (TOT - like)|more lateral fixation to avoid post-operative voiding dysfunction
45944509|NCT00434408|Behavioral|chx once|4.0% chlorhexidine cleansing of the cord applied once by a project worker visiting the newborn in the home as soon as possible after birth
45944510|NCT00434408|Behavioral|CHX x 7 days|4.0% chlorhexidine cleansing of the cord during home visits by project workers for the first 7 days after birth
45944511|NCT00434408|Behavioral|dry cord care|Household members are instructed to apply nothing to the newborn's umbilical cord stump.
45453169|NCT03948997|Radiation|Pulsed dye laser (PDL)|Pulsed dye laser (PDL, 595nm) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis
45453170|NCT01101139|Drug|Sugammadex|Sugammadex (single intravenous injection 0.25 mg/kg)
45657130|NCT02599129|Drug|Secukinumab|subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.
45657131|NCT02599129|Drug|Placebo|￼subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.
45808354|NCT03915652|Behavioral|Rheum iCMP|Selected iCMP nurses will receive a 4-hour training using unique educational materials already developed by our team that specifically address lupus-related racial, ethnic and socioeconomic disparities, as well as clinical information about lupus. These iCMP nurses will then reach out to high-risk lupus patients to ensure that patients attend scheduled rheumatology appointments, fill prescriptions for lupus-specific medications, and obtain recommended lupus screening labs and preventive care.
45808355|NCT03915587|Device|CardioQ-EDM and CipherOx-CRI|A CardioQ-EDM probe will be placed on the day of surgery after induction of general anesthesia. The anesthesiologist will inform the investigator of plans to provide a fluid or blood bolus per clinical judgement in addition to the protocolized 10 ml/kg bolus provided after induction. While the anesthesiologist is preparing to administer volume expansion, a co-investigator will collect pre-fluid bolus data. Measurements will be recorded for data analysis at the completion of the trial. Additionally, a CipherOx-CRI probe will be placed on the patient's index finger (recorded data will be interpreted post hoc) and a bedside ultrasound will be performed by either the principal investigator (PI) or one of two co-investigators to measure the IVC CI. Ultrasound cine-loops will be recorded, and CI will be calculated post-hoc. Data will be recorded on the Data Collection Form for each fluid bolus administered. The PI and co-investigators will manage all aspects of investigational devices.
45808356|NCT03912428|Drug|Celecoxib|COX-2 inhibitor
45808357|NCT03912428|Diagnostic Test|11C-MC1|PET radioligand for COX-2
45944512|NCT00329446|Drug|Quetiapine Fumarate|
45944513|NCT00329446|Drug|Escitalopram oxylate|
45944514|NCT00329485|Drug|CORvalen (D-Ribose)|
45944515|NCT00329563|Drug|Up to 2 liter infusion of cold 4 degree C normal saline|Patients randomized to field cooling will receive up to 2 liters of 4oC normal saline. Control patients will receive standard of care following resuscitation.
45944516|NCT00092937|Drug|Busulfan|
45944517|NCT00420277|Drug|Hemospan (MP4OX)|250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers
45453171|NCT01101139|Drug|Placebo|Placebo: single intravenous injection Saline 0.9%
45458064|NCT01140763|Device|Sysmex's 5-blade lymph node cutter|"A maximum of 3 dissected sentinel lymph nodes (SLN) per subject will be included in this study. Lymph nodes will be sliced at 1 mm intervals with Sysmex's 5-blade lymph node cutter. Alternate slices will be allocated to either reference histopathology or test histopathology. Three serial sections will be cut every 200 µm (level): the 1st section per level for hematoxylin & eosin (H&E), the middle section of the 3rd level for Immunohistochemistry (IHC)(pan- cytokeratin antibody clone AE1/AE3). All other sections will be blanks in case further analysis is needed."
45458065|NCT03721471|Other|Scoring of frailty|"Patients will be scored by the Clinical frailty Scale~Patients' hand-grip-strength will be measured by a dynamometer."
45944518|NCT00420277|Drug|Voluven (HES 130/0.4)|250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers
45944519|NCT04716751|Drug|Toripalimab|"Neoadjuvant treatment stage: Toripalimab 240mg, Carboplatin AUC5+ paclitaxel 200 mg/m ², iv, 3 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: Patients with tracheal malignant tumor received radical surgery after neoadjuvant therapy, and patients who could not or refused surgical treatment due to various reasons were treated with multidisciplinary discussion.~Adjuvant treatment stage: Toripalimab 240mg, Carboplatin AUC5+ paclitaxel 200 mg/m ²,iv, up to 4 cycles (including neoadjuvant stage)."
45944520|NCT04716673|Other|Down-phase targeted auditory stimulation|The presentation of a soft, brief tone (50 ms of pink noise). The volume will be held low enough to avoid provoking arousals or awakenings. In case of a waking-up-reaction, the volume will be lowered in steps of 5 dB.
45944521|NCT00123903|Drug|metoprolol xl|
45944522|NCT00123903|Drug|carvedilol MR|
45657132|NCT04796545|Device|NG SI IMT 3X implant|The NG SI IMT 3X implant is a visual prosthetic implantable device, which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with bilateral, end-stage age-related macular degeneration.
45657133|NCT04796077|Other|Pop-Up Book|Patients spent 5-10 minutes reading an illustrated pop-up book that promoted active learning about the process of general anesthesia induction.
45657134|NCT04806061|Drug|Sodium bicarbonate|sodium bicarbonate 8.4% to achieve urinary pH >7.5
45657135|NCT04806061|Drug|standard care|standard care
45657136|NCT04805749|Other|Manual Therapy: osteopathy|"Osteopathic protocol applied at week 0, 1, 2 and 3:~Spinal mobilisation of L1, L2 and L3 vertebrae to stimulate the arterial supply of mesenteric attachments of the colon and small intestine.~Visceral osteopathic therapy to address adhesions/ fixations in the presacral fascia, Toldt fascia, posterior peritoneum and caudal peritoneum.~Circulatory techniques to stimulate the celiac plexus, the superior and inferior ganglia.~Cranial osteopathy techniques to address the vagus parasympathetic nerves."
45808358|NCT03912428|Diagnostic Test|11C-ER176|PET radioligand for TSPO
45808359|NCT03909100|Device|CoolSculpting® System|A treatment session is comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage.
45657137|NCT04814797|Other|Capnography data included in Lung Clearance Index measurement|Capnography data included in Lung Clearance Index measurement (a pulmonary function test included in routinely yearly follow-up of cystic fibrosis children) will be collected and analyzed
45808360|NCT03905798|Drug|Lorazepam|"The usual dose of lorazepam in adults is 4 mg administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 4 mg may be added but the dose should not exceed 8 mg as the sum of initial and additional doses.~The usual dose of lorazepam in children aged 3 months or older is 0.05 mg/kg (up to 4 mg) administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 0.05 mg/kg may be added but the dose should not exceed 0.1 mg/kg as the sum of initial and additional doses."
45808361|NCT03901963|Drug|Daratumumab|Daratumumab 1800 mg will be administered by SC injection weekly during Cycles 1 and 2, every 2 weeks during Cycles 3 through 6, and every 4 weeks from Cycle 7 onward until confirmed progressive disease (PD), unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles.
45808362|NCT03901963|Drug|Lenalidomide|Lenalidomide 10 mg will be administered orally from Day 1 to Day 28 (continuously) of each 28-day cycle until confirmed PD, unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
45808363|NCT03901482|Drug|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
45808364|NCT03901482|Drug|Placebos|Placebo for STS101
45944523|NCT00123903|Drug|lisinopril|
45944524|NCT00329680|Dietary Supplement|Eicosapentaenoic acid, Gamma-Linolenic Acid and Antioxidant Vitamins|An enteral diet will be given in accordance with the caloric goal calculated by the Harris-Benedict equation x 1.3. The enteral diet will be provided for a period of 7 days or until death OR start of oral diet OR start of parenteral diet OR discharge from the ICU OR decision from the attending physician/family/patient to no longer participate in this clinical study
45944525|NCT00329680|Dietary Supplement|Standard ICU enteral diet, isocaloric to the study diet|Patients will receive this diet in a blinded way using the same dose regimen specified previously and used in the study group
45944526|NCT00294827|Procedure|Liver transplantation and colo-rectal cancer|Liver transplantation
45944527|NCT00329758|Drug|rosuvastatin|20 mg oral, during 10 days
45944528|NCT00329758|Drug|Placebo|
45944529|NCT00329914|Drug|Progesterone|Vaginal pessaries, 200 mg/day
45944530|NCT00329914|Drug|Placebo|Placebo pessaries containing peanut oil
45944531|NCT04716478|Other|Clinical and radiological data collection|No specific intervention. Data of the usual care will be collected as the demographic data, the medical history, imaging report, etc.
45944532|NCT00092976|Drug|ReFacto|
45944533|NCT00329992|Behavioral|Brief Eclectic Psychotherapy for PTSD|16 weekly sessions (50min) of Brief Eclectic Psychotherapy for PTSD
45944534|NCT00330070|Drug|IPL512,602 20 mg once daily|
45944535|NCT00330070|Drug|IPL512,602 Matching Placebo once daily|
45944536|NCT00083876|Drug|Thalidomide|
45944537|NCT00123942|Drug|MEDI-507|
45808365|NCT03900598|Drug|JNJ-67856633|JNJ-67856633 capsule will be administered orally.
45944538|NCT00330109|Procedure|MRS Imaging|Performed on a 3.0 Tesla Philips Intera MRI Unit (Best, Netherlands). Scout views and T2 transverse images are obtained to locate the tumor in conjunction with any previous diagnostic images.
45944539|NCT00330109|Procedure|PET Scanning|Using an Allegro scanner, the patient will be scanned for approximately 20-30 minutes. All emission scan data is processed by a multi-step procedure.
45808366|NCT03900377|Drug|SyB L-0501RI|The specified dose of SyB L-0501RI and rituximab will be administered by intravenous rapid infusion over 10 minutes on specified days.
45453172|NCT00006409|Behavioral|Trial of Activity for Adolescent Girls (TAAG)|Intervention activities were designed to create (1) environmental and organizational changes supportive of physical activity and (2) cues, messages, and incentives to be more active. The intervention was designed to establish more opportunities, improve social support and norms, and increase self-efficacy, outcome expectations, and behavioral skills to foster greater moderate-vigorous physical activity (MVPA). An innovative feature of TAAG was linking school and community agencies to promote activity programs for girls. Finally, a TAAG Program Champion component was developed to foster sustainability after the 2-year staff-directed intervention. TAAG investigators recruited and trained Program Champions during the staff-directed intervention phase to promote maintenance of the program.
45808367|NCT03896295|Drug|M281|M281 injection administered as intravenous infusion
45944540|NCT00330109|Procedure|Diffusion Tensor Imaging|Subjects will be scanned with a 3T Philips Intera MRI scanner for approximately 26 minutes for anatomical and DTI imaging. Total DTI acquisition time will be 6:06 minutes with 40 contiguous axial slices for full brain coverage.
45944541|NCT00330148|Drug|melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d|
45944542|NCT00330148|Drug|melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d|
45657138|NCT04814641|Biological|hypophosphatemia occurrence in infants with severe bronchiolitis admitted in a pediatric intensive care unit|Serum phosphorus level < 1.55 mmol/L at any time between admission and the 5th day.
45944543|NCT00330148|Drug|nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d|
45944544|NCT00330265|Device|KC-002|Determine the safety and effectiveness of a device (the KC-002 interactive wound dressing) in the promotion of healing in diabetic foot ulcers as compared with a conventional wound therapy regimen for subjects with Type 1 or Type 2 diabetes mellitus.
45944545|NCT00330265|Other|Conventional Wound Therapy|Normal Saline Dressings
45657139|NCT04814719|Drug|Pentosan Polysulphate Sodium|Subcutaneous Injection (100mg/ml)
45657140|NCT04814719|Drug|Placebo (Sodium Chloride Injection, 0.9%)|Placebo to match PPS
45808368|NCT03895658|Device|MRI|Structural and functional neuroimaging pre and post ECT treatment
45808369|NCT03895658|Device|MagPro TMS stimulator and coil|Transcranial magnetic stimulation measurements of cortical excitability pre and post ECT treatment
45657141|NCT04795609|Other|Early mobilization strategy adapted after immediate internal pudendal artery perforator flap reconstruction for abdominoperineal resection (intervention group).|"Early mobilization strategy adapted after immediate internal pudendal artery perforator flap reconstruction for abdominoperineal resection (intervention group).~Trunk control.~Orthostatism.~Walk training.~Aerobic exercises.~Muscle strengthening."
45808370|NCT03895658|Device|MECTA paired with the 4X1 HD-ECT|Multichannel Stimulation Interface (Model 4X1E1)
45944546|NCT00093093|Drug|Viramidine|
45944547|NCT00093093|Drug|Ribavirin|
45944548|NCT00093093|Drug|pegylated interferon alfa-2a|
45944549|NCT04729244|Drug|CBD|Hemp Oil
45944550|NCT00330304|Drug|Isoniazid|isoniazid 10mg/kg orally, daily, for study period
45944551|NCT00330304|Drug|Cotrimoxazole|Cotrimoxazole given 3 times a week or daily, orally, for study period
45944552|NCT00330304|Drug|isoniazid|Isoniazid, 10mg/kg daily for study period
45944553|NCT00330304|Other|placebo|Placebo tablet identicle in appearance to intervention: isoniazid table
45453173|NCT01099423|Procedure|timing of surgery|
45453174|NCT01099423|Genetic|gene expression analysis|
45453175|NCT01099423|Other|biologic sample preservation procedure|
45808371|NCT03892694|Device|RejuvenAir System|Bronchial metered cryospray using RejuvenAir® System.
45808372|NCT03892694|Other|Sham|Sham control procedure
45808373|NCT03882723|Device|Evaluated 4 masks used for NIV with mechanical ventilators|Order of the masks (BiTrac MaxShield™ with standard elbow, BiTrac™ Full Face with standard elbow, Respironics PerforMax with standard elbow, and Respironics AF531 with standard elbow) were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
45808374|NCT03878446|Drug|somapacitan|Somapacitan injected under the skin once a week for a total of 52 weeks
45944554|NCT00330499|Drug|Cisplatin|Weekly Cisplatin 35mg/m2 x 6 doses, IV administration
45944555|NCT00330499|Radiation|External beam radiation treatment|64Gy reference dose in 32 fractions over 6.5 weeks
45944556|NCT00083954|Drug|Quetiapine Fumarate|
45944557|NCT00330577|Drug|timolol maleate 0.5%|
45944558|NCT00330577|Drug|latanoprost/timolol fixed combination|
45944559|NCT00330577|Drug|placebo (artificial tears)|
45944560|NCT00323596|Behavioral|physical activity program of strength and balance retraining|
45944561|NCT00123981|Procedure|Off-Pump Coronary Artery Bypass Grafting|
45808375|NCT03878446|Drug|Norditropin®|Norditropin® injected under the skin once a day for a total of 52 weeks
45944562|NCT00323674|Device|Polysoft Mesh|Polysoft Mesh is used.
45808376|NCT03868124|Combination Product|G2-TR intraocular implant containing travoprost|Provided in Arm/Group descriptions
45657142|NCT04805905|Other|FACE-Q patient reported outcome|"As both interventions of treatment are gold standards and clinical equipoise exists if one intervention is superior to the other, there is no true control group. However, for the purpose of the application, the local flap group will be chosen as the control group.~Skin graft (Experimental): Participants in the experimental group will receive a skin graft and receive the FACE-Q skin cancer questionnaire pre- and post-treatment. There will also be photos taken of the patient's face along with the distributed questionnaires.~Local flap (Control): Participants in the experimental group will receive a local flap and receive the FACE-Q questionnaire pre- and post-treatment."
45944563|NCT00323674|Device|Light Weight Mesh|Light Weight Mesh is used.
45944564|NCT00323713|Behavioral|Very low protein diet|0.3 g of proteins per kilo of body weight per day, supplemented with a mixture of essential aminoacids and chetoacids
45944565|NCT00323713|Behavioral|Low protein diet|0.6 g of protein per kilo of body weight per day
45944566|NCT00083993|Drug|Temsirolimus (CCI-779) for 34 months|
45944567|NCT00083993|Drug|Letrozole for 34 months|
45657143|NCT04805827|Drug|Gabapentin|1 tablet contains 600 mg Gabapentin
45808377|NCT03868124|Drug|Sham surgery + active-comparator eye drops|Sham surgery plus postoperative active-comparator eye drops (Timolol Maleate ophthalmic solution, 0.5%)
45944568|NCT00093171|Drug|rFIX|
45944569|NCT00323752|Procedure|rHuEpo|Subjects will be randomly assigned to either participate in the PAD program or receive the rHuEpo treatment. Subjects in the PAD group will donate 1 unit of blood at -14 and -7 days prior to surgery. A dose of 500 IU of rHuEpo will be administered subcutaneously to subjects in the rHuEpo group at -21, -14, and -7 days prior to surgery.
46075371|NCT05753709|Procedure|Hand sewn end-to-end anastomosis|Hand sewn end-to-end anastomosis (EE) Holding sutures were taken through a seromuscular bite with PDS (Polydiaxonone) 3-0 or Silk 2-0 RB (Round Bodied needle), one each at the mesenteric and antimesenteric ends of the stoma. A posterior layer of Lembert sutures was taken first. The first bite was taken at the anti-mesenteric end and a knot was applied. A Connell stitch was applied at the corner and then the posterior layer was closed using an inverting interlocking continuous stitch till the mesenteric end. Another Connell stitch was applied here to secure the corner and the suture was continued on to the anterior layer which was then closed in a similar manner using a continuous interlocking stitch. The final bite crossed the initial knot and the final knot was applied. An anterior layer of Lembert sutures was taken to reinforce the anastomotic line.
45808378|NCT03861143|Drug|BT-11 (440 mg)|Oral, once daily tablet
45808379|NCT03861143|Drug|BT-11 (880 mg)|Oral, once daily tablet
45808380|NCT03861143|Drug|Placebo|Oral, once daily tablet
45657144|NCT04805827|Drug|Neurontin|2 capsule contains 2*300 = 600 mg Gabapentin
45944570|NCT00323791|Drug|gemcitabine hydrochloride|
45808381|NCT03860844|Drug|Montelukast|Pharmaceutical form: tablet Route of administration: oral
45808382|NCT03860844|Drug|Isatuximab|Pharmaceutical form: Solution for injection Route of administration: Intravenous
45808383|NCT03860844|Drug|Dexamethasone|Pharmaceutical form: Solution for injection or tablet Route of administration: Intravenous or oral
45808384|NCT03860844|Drug|Fludarabine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
45944571|NCT00323791|Drug|imatinib mesylate|
45944572|NCT00323791|Genetic|gene expression analysis|
45808385|NCT03860844|Drug|Cytarabine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
45808386|NCT03860844|Drug|Liposomal daunorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
45808387|NCT03860844|Drug|Daunorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
45808388|NCT03860844|Drug|Idarubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
45808389|NCT03860844|Drug|Filgrastim|Pharmaceutical form: Solution for injection Route of administration: Intravenous
45944573|NCT00323791|Genetic|protein expression analysis|
45944574|NCT00323791|Other|immunohistochemistry staining method|
45944575|NCT00323791|Other|laboratory biomarker analysis|
45944576|NCT00323830|Drug|Capecitabine, cisplatin, Radiotherapy (+/-)|Capecitabine, cisplatin + Radiotherapy (randomized)
45944577|NCT00317512|Procedure|Percutaneous Coronary Revascularization|
45944578|NCT00317512|Drug|Hemoglobin-Based Oxygen Carrier-201 (HBOC-201)|
45944579|NCT00317512|Drug|Voluven|
45944580|NCT00124059|Drug|Seroquel|400mg/day quetiapine
45944581|NCT00124059|Drug|Placebo|400mg/day placebo
45944582|NCT00084032|Behavioral|Structured treatment interruption|Treatment interruption schedule is dependent on the Arm in which participants are enrolled in Step 2
45944583|NCT00084032|Drug|Antiretroviral regimen|Participants will take any combination of FDA-approved ARV medications prescribed by their physician
46002193|NCT04397003|Biological|Neoantigen DNA vaccine|All study injections will be given intramuscularly using an integrated electroporation device (TDS-IM system, Ichor Medical Systems). At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.
46002194|NCT04397003|Drug|Durvalumab|-Supplied by AstraZeneca/MedImmune
45944584|NCT00323947|Drug|Extended Release Methylphenidate (OROS-Methylphenidate)|"Participants will first take either immediate release MPH or placebo A for 1 day. On Day 2 of treatment, participants assigned to receive XR-MPH will begin taking it, and participants assigned to receive placebo will switch to placebo B. This treatment phase will continue for 6 days to 4 weeks, depending on weight, and will then be followed by a 1-week medication washout period. Target dose depends on the weight of the participant. Possible dose forms include 18, 36, 54 mg OROS-MPH."
45808390|NCT03860844|Drug|Mitoxantrone|Pharmaceutical form: Solution for injection Route of administration: Intravenous
45808391|NCT03860844|Drug|Doxorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
45808392|NCT03860844|Drug|Vincristine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
45944585|NCT00317551|Device|Aberration controlled contact lens|
45944586|NCT00317551|Behavioral|Vision training|
46075372|NCT05753709|Procedure|Hand sewn side-to-side anastomosis|Hand sewn side-to-side anastomosis (HSSA) Each end of the stoma was closed using either a single layer of inverting interlocking continuous sutures with PDS 3-0 or Silk 2-0 RB, or a Linear Stapling device. The two closed stumps were then brought adjacent to each other in an anti-peristaltic arrangement. A posterior layer of Lembert sutures was applied using Silk 2-0 RB. The bowel wall was incised using electrocautery close to the suture line. The incision was lengthened up to a width of at least 5-6 cm. The posterior and anterior layer was now closed using the same technique as in HS using PDS 3-0. An anterior layer of Lembert sutures was applied. The mesenteric defect was then closed using a superficial interrupted layer of Silk 2-0 RB.
45944587|NCT00093210|Drug|rFIX|
46075373|NCT05753709|Procedure|Stapled side-to-side anastomosis|Stapled side-to-side anastomosis or Functional End-to-end anastomosis (SSSA/FEEA) The two limbs of a Linear Cutter SR55 are placed into the proximal and distal bowel loops of the stoma, facing as far away from the mesenteric border as possible and then fired. If both lumens are of similar size, traction sutures are applied with Silk 2-0 RB at the anterior and posterior termination ends of the staple line. The two ends are pulled away from each other, and a Linear Cutter SR75 is applied just below the edge of the bowel and fired. However, in case of an ileo-colostomy, after the first linear cutter SR55 is fired, the two suture lines are approximated in such a way that they do not get apposed but rather lie adjacent to each other. The lumen is then clamped in SR75 which is then fired.
45657145|NCT04805359|Behavioral|Normoxic exercise|Trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax)for 30 minutes per day, 5 days per week for 6 weeks
45657146|NCT04805359|Behavioral|Hypoxic exercise|Trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax)for 30 minutes per day, 5 days per week for 6 weeks
45657147|NCT04814329|Other|genetic characteristic|the underlying genetic characteristics that prodicting response
45944588|NCT00093210|Drug|rFIX-R|
45944589|NCT00323986|Drug|azithromycin (drug)|
45657148|NCT02596711|Drug|Nicotine Patch|Participants receive 4 weeks of 21 mg, 4 weeks of 14 mg, and 4 weeks of 7 mg patches.
45944590|NCT00317590|Device|Rapid Diagnostic Test for Malaria (Paracheck®)|
45657149|NCT02596711|Behavioral|Questionnaires|Questionnaires regarding tobacco and alcohol use, culture, religion, and sense of control completed at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
45944591|NCT00324025|Drug|Mycograb|
45944592|NCT00324025|Drug|placebo|
46075374|NCT00874393|Drug|Dopamine|Dopamine
45453176|NCT01099423|Other|laboratory biomarker analysis|
45453177|NCT01099423|Procedure|therapeutic conventional surgery|
45657150|NCT02596711|Other|Carbon Monoxide (CO) Test|Carbon monoxide (CO) test given at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
45657151|NCT02596711|Behavioral|Health Education and Handouts|Participants receive general health education and handouts.
45808393|NCT03860844|Drug|PEG Asparaginase|Pharmaceutical form: Solution for injection Route of administration: Intravenous
45944593|NCT00317629|Drug|controlled nitric oxide releasing patch|daily nitric oxide patch application during 20 days
45944594|NCT00317629|Drug|meglumine antimoniate|20mg/kg daily during 20 days
45808394|NCT03860844|Drug|Cyclophosphamide|Pharmaceutical form: Solution for injection Route of administration: Intravenous
45808395|NCT03860844|Drug|Etoposide|Pharmaceutical form: Solution for injection Route of administration: Intravenous
45808396|NCT03860844|Drug|Methotrexate|Pharmaceutical form: Solution for injection Route of administration: Intravenous
45808397|NCT03860844|Drug|L - Asparginase|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
45808398|NCT03860844|Drug|Hydroxyurea|Pharmaceutical form: Solution for injection Route of administration: Intravenous
45808399|NCT03860844|Drug|L - Asparaginase (Erwinase)|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
45453178|NCT00006289|Drug|Placebo|4 tabs b.i.d.
45453179|NCT00006289|Drug|Neurotropin|4 tabs b.i.d.
45808400|NCT03860844|Drug|Tocilizumab|Pharmaceutical form: Solution for injection Route of administration: Intravenous
45808401|NCT03853317|Biological|Avelumab|For the treatment of adults and pediatric patients 12 years and older with Metastatic Merkel Cell Carcinoma (MCC).
45808402|NCT03853317|Biological|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
46002195|NCT04397003|Device|TDS-IM v2.0 Device|-Integrated electroporation administration system
46002196|NCT04397003|Procedure|Peripheral blood draws|-Pre-treatment, Week 3 (before Cycle 2 chemotherapy), Week 6 (before Cycle 3 chemotherapy), Week 9 (before Cycle 4 chemotherapy), Vaccine Day 1, Vaccine Day 29, Vaccine Day 85, Vaccine Day 141, on even numbers of cycles for durvalumab for one year following completion of vaccine (C8D1, C10D1, C12D1, C14D1, C16D1, C18D1, C20D1)
45657152|NCT02596711|Behavioral|Culturally Tailored Reading Materials|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting.
45944595|NCT00093249|Drug|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion)will be administered intravenously at an initial infusion rate of 0.4 µg/kg/min and will be titrated, as tolerated, at the discretion of the investigator, in doubling increments approximately every 90 seconds up to a maximum of 3.2 µg/kg/min, in order to achieve the desired blood pressure lowering effect. Clevidipine may be titrated upwards or downwards and may be temporarily interrupted and restarted to attain the desired blood pressure effect. The maximum study drug infusion rate of 8.0 µg/kg/min may not be exceeded.
45944596|NCT00093249|Drug|placebo|Placebo (20% lipid emulsion - vehicle) will be administered intravenously in a fashion identical to clevidipine as described above.
45944597|NCT00317707|Drug|N-3 Polyunsaturated Fatty Acids|Each subject assigned to active treatment group will receive 1g/day capsule of n-3 PUFA
45944598|NCT00317707|Drug|Placebo: Olive oil|Each subject assigned to the control group will receive 1 g/day capsule of olive oil.
45453180|NCT01103167|Behavioral|control of ultrafiltration|During the interventional period, dry weight of patients will be adjusted according to the results of body composition.
45657153|NCT02596711|Behavioral|Counseling Sessions|Participants attend 3 counseling sessions during the study.
45944599|NCT00324064|Procedure|GHRH/arginine stimulation testing|GHRH(Geref) 1mcg/kg IVP followed by Arginine 10% solution 0.5mg/kg (maximum of 30 Gm) infused over 30 minutes. Labs drawn 6 times over 2 hours.
45944600|NCT00124098|Drug|Aranesp® (darbepoetin alfa)|
45944601|NCT00324103|Drug|Structured Treatment Interruptions|
45944602|NCT00084188|Behavioral|Behavior Therapy|
46075375|NCT00874393|Drug|Hydrocortisone|Hydrocortisone
46075376|NCT00874393|Drug|Infusion Placebo|Dextrose (D5W)
45657154|NCT04805281|Other|monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime.|wear of the new material of monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime in posterior teeth
45657155|NCT04805281|Other|Lithium Dislicate IPS e.max crown|wear of lithium disilicate IPS e.max crown in posterior teeth
45657156|NCT05616403|Other|No intervention|This is an observational study without any intervention
45657157|NCT04814251|Other|Observationnal cohort|data collection
45808403|NCT03853317|Biological|haNK™|haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).
45808404|NCT03848676|Diagnostic Test|Evaluation of patients resistance to immunotherapies in Multiple Myeloma|There are only collections of the samples.
45808405|NCT03845010|Drug|Sotalol|Patients will be titrated to the maximal tolerated dose of sotalol with a targeted dose of 80 thrice daily (TID)
45808406|NCT03845010|Drug|Flecainide and verapamil|Patients will receive maximal tolerated dose of flecainide and verapamil with titration to a maximal dose of 200 mg of flecainide and 240 mg of verapamil per day
45808407|NCT03845010|Procedure|Catheter ablation|Patients will undergo VPB/VT ablation using a percutaneous transfemoral approach according to standard clinical routine
45808408|NCT03842189|Drug|M281|Participants will receive once weekly intravenous (IV) infusions of M281
45808409|NCT03841617|Drug|Thyrogen|intramuscular injection administered once/day for 2 consecutive days at Week 3; then once annually for subjects who meet criteria.
45944603|NCT00324142|Drug|Oral tinidazole|
45944604|NCT00324298|Biological|bleomycin sulfate|
45944605|NCT00324298|Drug|cisplatin|
45944606|NCT00324298|Drug|etoposide|
45944607|NCT00324298|Procedure|management of therapy complications|
45944608|NCT00124137|Device|Aquadex system|
45944609|NCT00124137|Drug|IV diuretic|
45657158|NCT04814485|Drug|SHR-1020+albumin-bound paclitaxel|SHR-1020 combined with albumin-bound paclitaxel for advanced pancreatic cancer
45944610|NCT00324376|Drug|Sevelamer hydrochloride|
45944611|NCT00084227|Drug|Azithromycin/Chloroquine|
45944612|NCT00084227|Drug|Atovaquone/Proguanil|
45944613|NCT00317746|Drug|Citalopram|
45944614|NCT00317746|Drug|Placebos|
45944615|NCT00317785|Drug|cyclophosphamide|
45944616|NCT00317785|Drug|cyclosporine|
46075377|NCT00874393|Drug|Syringe Placebo|Normal saline
46075378|NCT02786706|Device|Optic nerve ultrasound|All patients will undergo Optic Nerve Ultrasound (ONUS), with measurement of Optic Nerve Sheath Diameter (ONSD) by both an expert investigator as well as by the automated image analysis algorithm.
46075379|NCT05753631|Procedure|non surgical periodontal treatment|"scaling and root planning were applied for non-surgical periodontal treatment i-PRF application: Intravenous blood sample taken from the antecubital vein of the patients was collected in a 10 ml tube and centrifuged at 700 rpm for 3 minutes in a PRF centrifuge device. The PRF obtained from the upper liquid layer formed in the tube was injected subgingival into the deepest point of the pocket after SRP treatment.~Clinical periodontal measurements: plaque index, gingival index, probing depth, clinical attachment level, bleeding on probing, and gingival recession were calculated.~gingival crevicular fluid: Perio papers were placed in the deepest part of the sulcus and left for 30 seconds. After 30 seconds, the paper strips were placed in the periotron device and the volume was calculated."
46075380|NCT04199364|Drug|Poractant Alfa 80 mg/mL Intratracheal Suspension|Exogenous surfactant (Poractant Alfa) administration at a dose of 200 mg/kg.
45657159|NCT04288141|Other|Acquisition of blood samples and tumour tissue samples (biopsies)|Acquisition of blood samples and tumour tissue samples (biopsies) in a sequential manner as participants proceed through HER2-directed therapy as prescribed by their oncologist.
45944617|NCT00317785|Drug|methotrexate|
45944618|NCT00317785|Drug|mycophenolate mofetil|
46075381|NCT00877825|Procedure|dairy food control diet and high- and low- isoflavone soyfood diets|
46075382|NCT04231890|Other|IPI monitoring|Patients in this arm will have IPI monitoring
45944619|NCT00317785|Drug|sirolimus|
45944620|NCT00317785|Drug|tacrolimus|
45944621|NCT00317785|Other|pharmacological study|
45944622|NCT00317785|Procedure|allogeneic bone marrow transplantation|
45944623|NCT00317785|Procedure|allogeneic hematopoietic stem cell transplantation|
45944624|NCT00317785|Procedure|peripheral blood stem cell transplantation|
45657160|NCT04280887|Device|MyPad|Ultrasound bed wetting alarm
45808410|NCT03841617|Radiation|I-131|therapeutic dose administered orally to treat thyroid cancer at Week 8. 5-7 days later, the post-treatment I-131 Whole Body scan w/ SPECT is performed; then administered once annually, if the patient needs to be re-treated
45944625|NCT00317785|Radiation|total-body irradiation|
45944626|NCT00093288|Drug|bupropion XL|
45944627|NCT00324454|Biological|Levetiracetam|Levetiracetam 1500 mg BID
45657161|NCT04280029|Device|SELUTION SLR™ DEB|The SELUTION Sustained Limus Release (SLR)™ drug-eluting balloon (DEB) catheter is a combination product consisting of a standard percutaneous transluminal angioplasty (PTA) balloon catheter coated with a drug (Sirolimus). The drug coating is formulated with Sirolimus microspheres suspended in a phospholipid blend. The balloon catheter component of the SELUTION SLR™ DEB is a conventional single use, sterile, rapid exchange catheter to dilate vascular lesions. The semi-compliant balloon is inflated for 60 seconds (minimum of 30 seconds) to transfer the Sirolimus loaded microspheres to the target vessel wall. The balloon is then deflated and removed from the body.
45808411|NCT03841617|Radiation|I-124|one capsule ingested orally once at Week 3, and Week 8; then administered once annually to subjects who meet criteria.
45808412|NCT03841617|Other|Thyroid hormone withdrawal|withdrawal of thyroid hormone during weeks 4 through 8
45808413|NCT03838978|Device|Calypso Knee System|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
45944628|NCT04729361|Genetic|CGH array analysis|CGH array analysis
45944629|NCT00317902|Drug|Epoetin alfa|
45944630|NCT00317980|Drug|Meglumine antimoniate|Meglumine antimoniate 5mg/kg/d for 20 days
45944631|NCT00317980|Drug|Meglumine antimoniate|Meglumine antimoniate 15 mg/kg/d for 20 days
45944632|NCT00419458|Procedure|inspiratory muscle strength training|
45944633|NCT00124215|Biological|GI-5005|Heat-killed yeast cell transfected with NS3-Core fusion protien.
45944634|NCT00419497|Behavioral|Paleolithic diet vs Mediterranean diet|Prudent diets with or without grains and dairy
45808414|NCT03829371|Drug|Velcade|Subcutaneous use
45808415|NCT03829371|Drug|Melphalan|Oral use
45808416|NCT03829371|Drug|Prednisone|Oral use
45808417|NCT03829371|Drug|Lenalidomide|Oral use
45808418|NCT03829371|Drug|Dexamethasone|Oral use
45808419|NCT03829371|Drug|Daratumumab|Subcutaneous Injection
45808420|NCT03828227|Drug|OPTIMOX-bevacizumab|"Induction Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles (3 months)~Bevacizumab: 5 mg/kg IV (day 1, every 2 weeks [q2w]),~Folinic acid (FA): 400 mg/m² IV/2h (day 1, q2w),~Oxaliplatin: 85 mg/m² IV/2h (day 1, q2w),~5-fluorouracil (5-FU) continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w),~No 5-FU bolus.~then Maintenance Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)~Bevacizumab: 5 mg/kg IV (day 1, q2w),~FA: 400 mg/m² IV/2h (day 1, q2w),~5-FU continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w)~No 5-FU bolus"
45808421|NCT03828227|Drug|Capecitabine plus bevacizumab|"Bevacizumab: 7.5 mg/kg intravenous infusion [IV] (day 1; q3w),~Capecitabine: 1000 mg/m² orally twice a day (day 1 through day 14, q3w)."
45808422|NCT03826264|Procedure|TAVR|transcatheter aortic valve replacement (TAVR)
45944635|NCT00324532|Drug|ProBactrix|
45944636|NCT00318019|Dietary Supplement|OPC Factor(TM)|Evervescent poweder containing oligomeric proanthocyanidins (OPCs)and other nutrients.
45944637|NCT00318019|Other|Placebo|Effervescent powder similar in taste and appearance to the intervention but without the OPCs and nutrients.
45944638|NCT00324571|Drug|Sevelamer hydrochloride|
46075383|NCT00870025|Biological|human chorionic gonadotropin|200 IU, sc, every 5 days, 4 doses
45808423|NCT03816358|Biological|Anetumab Ravtansine|Given IV
45808424|NCT03816358|Procedure|Biopsy|Undergo biopsy
45944639|NCT00324571|Drug|Calcium-based phosphate binder|
45944640|NCT00093327|Procedure|Acupuncture|
45944641|NCT00084461|Drug|romidepsin|Given IV
45657162|NCT04280029|Device|Control|The treating physician may chose to implant a commercially available DES or alternatively may use POBA only to treat the patient. Choice of DES is at the treating physician's discretion, but is limited to ZES and EES devices
45657163|NCT04262401|Behavioral|Standard health coaching|12 weekly sessions of standard health coaching followed by 4 monthly sessions
45657164|NCT04262401|Behavioral|Habit-focused health coaching|12 weekly sessions of standard health coaching followed by 4 monthly sessions
45808425|NCT03816358|Procedure|Biospecimen Collection|Undergo collection of blood
45808426|NCT03816358|Drug|Gemcitabine Hydrochloride|Given IV
45808427|NCT03816358|Biological|Ipilimumab|Given IV
45808428|NCT03816358|Biological|Nivolumab|Given IV
45808429|NCT03816332|Biological|Ipilimumab|Given IV
45944642|NCT00084461|Other|laboratory biomarker analysis|Correlative studies
45944643|NCT00318058|Biological|influenza vaccine Fluarix, Adjuvanted Fluarix|
45944644|NCT00324610|Drug|capecitabine|
45944645|NCT00093366|Biological|etanercept|
45944646|NCT00093366|Drug|arsenic trioxide|
45944647|NCT00084539|Radiation|Radiation therapy|
45944648|NCT00324688|Drug|Viread|
45944649|NCT00324727|Drug|melphalan|Given throug isolated hepatic artery infusion
45944650|NCT00324727|Drug|regional chemotherapy|Patients receive the best alternative therapy
45944651|NCT00324727|Drug|systemic chemotherapy|Patients receive the best alternative therapy
45944652|NCT00324727|Procedure|hepatic artery embolization|Patients receive the best alternative therapy
45944653|NCT00324766|Drug|levosimendan|1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
45944654|NCT00324766|Drug|placebo,|24 h, infusion
45944655|NCT00093405|Drug|tanespimycin|
45944656|NCT00084578|Drug|celecoxib|
45944657|NCT00084578|Drug|rosiglitazone maleate|
45944658|NCT00084578|Procedure|conventional surgery|
45944659|NCT00084578|Procedure|neoadjuvant therapy|
45944660|NCT00318175|Drug|Bosentan (Tracleer)|
45944661|NCT00318253|Procedure|cranberry juice|
45944662|NCT00093444|Drug|lyso-thermosensitive liposomal doxorubicin|
45944663|NCT00093444|Procedure|radiofrequency ablation|
45944664|NCT02965118|Drug|PAC-14028 cream 1.0%|topical application
46075384|NCT00870025|Biological|placebo|diluent, every 5 days, s.c., 4 doses
45453181|NCT01099501|Dietary Supplement|Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.|Oxepa will be administered(enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding
45657165|NCT04795063|Procedure|Total Robotic Distal Gastrectomy|All the surgical procedures are performed using the robot system.
45657166|NCT04795063|Procedure|Robotic-Assisted Distal Gastrectomy|After finishing the lymphadenectomy, the digestive tract reconstruction is performed extracorporal.
45657167|NCT04804501|Device|Blue Light Glasses|Participants will be randomized into an experimental group (blue light glasses) or a control group (no glasses). Participants will perform a computer reading task while either wearing, or not wearing the glasses.
45657168|NCT04804501|Other|Computer Reading Task|Participants will read on a computer until concussion symptoms increase by a score of 3 or more (reading task termination criteria). One or more points will be assigned for each increase in symptom severity, and one point will be assigned for each new symptom that appears.
45808430|NCT03816332|Biological|Nivolumab|Given IV
45808431|NCT03816332|Drug|Prednisone|Given PO
45808432|NCT03816332|Drug|Tacrolimus|Given PO
45657169|NCT04814017|Procedure|Radial Shock-Wave Therapy|Radial shock-wave therapy was applied in 1.0-4.0 bar intensity, 10-15 hz frequency interval. 300-700 pulse for a trigger point, 1500-3000 pulse for a muscle. Intensity, frequency and pulse increased every session regularly beginning from minimal taking patients tolerance into consideration. Trigger points in the upper, middle and lower trapezius, supraspinatus, infraspinatus and levator scapula muscles were treated. Neck and upper back muscle static stretching exercises were teached to patients as home exercise program. The patients were asked to do each stretching exercise given as a home-based program every day, 3 times a day and 3 repetitions. The exercise program consisted of static neck lateral flexors stretching, shoulder posterior capsule stretching and apley stretching exercises. Exercise booklets were prepared and given to the patients.
45657170|NCT04814017|Procedure|Control|Neck and upper back muscle static stretching exercises were teached to patients as home exercise program. The patients were asked to do each stretching exercise given as a home-based program every day, 3 times a day and 3 repetitions. The exercise program consisted of static neck lateral flexors stretching, shoulder posterior capsule stretching and apley stretching exercises. Exercise booklets were prepared and given to the patients.
45657171|NCT04804657|Dietary Supplement|Sage extracts Cognivia|Cognivia is composed of 400 mg of aqueous extract from Salvia officinalis and the remaining 200 mg contained 50 µL of Salvia lavandulaefolia essential oil and encapsulated with gum acacia. It will be administrated the the morning before the endurance test (oral administration).
45657172|NCT04804657|Dietary Supplement|Placebo|Made with maltodextrin. It will be administrated the the morning before the endurance test (oral administration).
45657173|NCT04804423|Drug|38% Silver Fluoride and Potassium Iodide solution (generic name; Riva Star®)|38% silver fluoride will be applied to the surface of the isolated hypersensitive carious lesion followed by application of potassium iodide solution and according to manufacturer's instructions.
45657174|NCT04804423|Drug|Sodium fluoride varnish (generic name; Duraphat®)|22,600 ppm sodium fluoride varnish will be applied on the surface of the affected hypersensitive active carious lesions.
45657175|NCT04804111|Drug|arm 0|placebo group
45657176|NCT04804111|Drug|arm 1|3 mg of the URC102 group
45657177|NCT04804111|Drug|arm 2|6 mg of the URC102 group
45657178|NCT04804111|Drug|arm 3|9 mg of the URC102 group
45808433|NCT03812874|Drug|PTX-9908 Injection|"Proposed dose cohorts:1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, and 16 mg/kg.~Frequency:~Phase I: one dose per day for 4 consecutive weeks (20 doses). Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 4 weeks (Phase I) and 12 weeks (Phase II)."
45808434|NCT03812874|Drug|Placebo|"water for injection~Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 12 weeks (Phase II)"
45453182|NCT01099501|Dietary Supplement|oxepa|A dose determined by a patient's energy expenditure and tolerance of enteral feeding.
45453183|NCT01099501|Dietary Supplement|Control group|Pulmocare or Jevity (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
45458066|NCT03709225|Behavioral|Music-based meditation|The program is designed to incorporate music-based meditation practices and music making activities (e.g., guitar, drums) to help promote relaxation during cancer treatment
45657179|NCT04804111|Drug|arm 4|Febuxostat 80 mg
45657180|NCT04794673|Other|brain damage|Have or not have the brain damage and the location of the damage
45657181|NCT04794049|Drug|Lactulose|In experiment cohort, patients do not use standard bowel preparation regimen, they totally drink 300ml lactulose.
45808435|NCT03811561|Drug|Semaglutide|Participants will get one dose of semaglutide once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
45944665|NCT02965118|Drug|PAC-14028 cream Vehicle|topical application
45944666|NCT00318331|Drug|Glutamine|Group A patients will receive 0.5g/kg/day of enteral glutamine daily while they are receiving tube feeds or at the end of 28 days (whichever comes first)
45944667|NCT00325000|Behavioral|Interpersonal Psychotherapy|
45808436|NCT03811561|Drug|Placebo (semaglutide)|Participants will get one dose of placebo (semaglutide) once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
45808437|NCT03793179|Procedure|Biospecimen Collection|Undergo blood sample collection
45944668|NCT00325000|Drug|sertraline or amitriptyline|
45944669|NCT00318448|Drug|Zolpidem (SL800750)|
46075385|NCT04198974|Behavioral|PreVenture Training (PTtT)|"PreVenture TtT model will involve identifying local expert trainers to be trained to train school-based professionals on the PreVenture program. Steps include:~PreVenture Facilitator certification: Trainers participate in training workshops and deliver the program to eligible youth in Cohort 1 and are rated on quality of implementation using the PIFA.~Reliable use of the PIFA: Each trainer demonstrates convergence with the Montreal Team's ratings on a set of previously-recorded PreVenture sessions.~PreVenture Training Workshop Certification: Trainers participate in a one-day TtT workshop to review the main aims and exercises of PreVenture Training. Trainers then record mock TtT sessions in which key components of the PreVenture Training Workshop are delivered to an audience of 4-10 individuals (e.g., class of graduate students). These sessions are rated by the Montreal Team the PreVenture Implementation Fidelity and Adherence-Trainer Scale (PIFA-T)."
45808438|NCT03793179|Drug|Carboplatin|Given IV
45808439|NCT03793179|Procedure|Computed Tomography|Undergo CT scan
45808440|NCT03793179|Procedure|Magnetic Resonance Imaging|Undergo MRI
45808441|NCT03793179|Biological|Pembrolizumab|Given IV
45657182|NCT04794049|Drug|Polyethylene Glycol (PEG)|In control cohort, patients use the standard split-dose bowel preparation regimen,
45657183|NCT04794127|Drug|Trabectedin|Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
45808442|NCT03793179|Drug|Pemetrexed|Given IV
45808443|NCT03793179|Procedure|Positron Emission Tomography|Undergo PET scan
45808444|NCT03793166|Procedure|Biospecimen Collection|Undergo blood sample collection
45808445|NCT03793166|Drug|Cabozantinib|Given PO
45808446|NCT03793166|Procedure|Computed Tomography|Undergo CT scan
45808447|NCT03793166|Biological|Ipilimumab|Given IV
45808448|NCT03793166|Procedure|Magnetic Resonance Imaging|Undergo MRI
45944670|NCT00124254|Procedure|Silicone metacarpophalangeal joint arthroplasty|Intervention involves reconstructing the metacarpophalangeal joint using the Swanson silastic implant.
45657184|NCT04794127|Drug|Pioglitazone Oral Product|Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
45657185|NCT04804267|Drug|Linaclotide|Manufactured by Jiangsu Hansoh Pharmaceutical Co., Ltd. Drug: Linaclotide 145μg orally once daily
45657186|NCT04804267|Drug|LINZESS®|Manufactured by Almac Pharma Services Limited Drug: Linaclotide 145μg orally once daily
45657187|NCT04804267|Drug|Placebo|Drug: Placebo orally once daily
45808449|NCT03793166|Biological|Nivolumab|Given IV
45808450|NCT03793166|Other|Quality-of-Life Assessment|Ancillary studies
45808451|NCT03793166|Other|Questionnaire Administration|Ancillary studies
45808452|NCT03786198|Behavioral|Activity program|Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks
45808453|NCT03786198|Behavioral|Control|Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy
45808454|NCT03785964|Drug|Nirogacestat oral tablet|Nirogacestat tablet
45808455|NCT03785964|Drug|Placebo Oral Tablet|Sugar pill manufactured to mimic nirogacestat 50 mg tablet
45808456|NCT03783975|Genetic|Simplified Cascade Screening|Screening of the KCNQ1 Thr224Met variant for family members of probands
45808457|NCT03783871|Device|Microwave ablation|Subjects will be treated with microwave ablation.
45808458|NCT03781791|Drug|Active Investigational Treatment ENT-01|ENT-01 will be administered in tablet form, once daily.
45808459|NCT03781791|Drug|Placebo Treatment|Placebo will be administered in tablet form, once daily.
45808460|NCT03779230|Drug|L19TNF|Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.
45808461|NCT03775265|Drug|Atezolizumab|Given IV
45808462|NCT03775265|Procedure|Biopsy of Bladder|Undergo a bladder biopsy
45808463|NCT03775265|Drug|Cisplatin|Given IV
45808464|NCT03775265|Procedure|Computed Tomography|Undergo CT or MRI
45808465|NCT03775265|Procedure|Cystoscopy|Undergo a cystoscopy
45808466|NCT03775265|Drug|Fluorouracil|Given IV
45808467|NCT03775265|Drug|Gemcitabine|Given IV
45944671|NCT00124254|Other|Usual care|Non-surgical usual care
45944672|NCT00325117|Drug|Vildagliptin|
45944673|NCT00084695|Biological|anti-thymocyte globulin|Given IV
45944674|NCT00084695|Drug|busulfan|Given orally
45944675|NCT00084695|Drug|cyclophosphamide|Given IV
45944676|NCT00084695|Drug|fludarabine phosphate|Given IV
45944677|NCT00084695|Drug|melphalan|Given IV
45944678|NCT00084695|Drug|methylprednisolone|Given IV
45657188|NCT04427059|Procedure|Transversus Abdominis Plane (TAP) block|"The laparoscopic-assisted Transversus Abdominis Plane (TAP) block will be done just after the optic trocar placement as follow: as landmarks we use the anterior axillary line, in the middle between the iliac crest and the costal margin. After insertion of the optic trocar the peritoneum is visualized. A 14 Gauge needle is inserted 2 cm cranially respect the taken landmark through the skin until the penetration of the internal and external oblique fascias, identified as sudden lowering of resistance. Laparoscopy allows to confirm that the needle did not pass the peritoneum.~A solution of 20 ml of Ropivacaine (0.25%) is then injected, observing the formation of a bulge posterior to the transversus abdominis muscle.~The procedure is then repeated identically on the contralateral side."
45657189|NCT04427059|Procedure|Port-Site Infiltration (PSI)|The Port-Site Infiltration (PSI) will be performed by infiltrating the subcutis and the skin at the trocar site before the trocar placements with a solution of local anesthetic (Ropivacaine 0.25%), a total of 40 ml will be administered.
45944679|NCT00084695|Radiation|radiation therapy|Patients undergo radiation therapy two times daily on days -7 to -4.
45657190|NCT04793971|Procedure|percutaneous paratenon release|percutaneous paratenon release for chronic midportion Achilles tendinopathy
46075386|NCT04198974|Behavioral|PreVenture Training+Implementation Facilitation|"PreVenture TtT model + Implementation Facilitation Package:~Youth advisors identified the role of older youth to support program implementation. Youth will help promote PreVenture to students and families and help Facilitators optimize attendance at sessions.~Trainer-led coaching sessions will focus on enhancing program fidelity and acceptability by Facilitators. 'Best practice' supervision elements from efficacy trials will be integrated. Fidelity and symptom monitoring will be conducted in real-time during program implementation.~Performance metrics have been developed based on youth qualitative feedback to PreVenture sessions in previous trials. Analysis indicates key responses that are predictive of students most likely to benefit from PreVenture on 12-month substance use outcomes and indicates the extent to which Facilitator's interventions are leaving students with impressions consistent with positive long-term outcomes."
45657191|NCT04794439|Drug|Dentifrices|Dentifrice on plaque
45657192|NCT02596009|Device|Breezhaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
45657193|NCT02596009|Device|Ellipta®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
45808468|NCT03775265|Procedure|Magnetic Resonance Imaging|Undergo CT or MRI
45808469|NCT03775265|Drug|Mitomycin|Given IV
45808470|NCT03775265|Other|Quality-of-Life Assessment|Ancillary studies
45808471|NCT03775265|Radiation|Radiation Therapy|Undergo 3DCRT or IMRT
45808472|NCT03775265|Other|Survey Administration|Ancillary studies
45808473|NCT03775265|Procedure|Transurethral Resection of Bladder Tumor|Undergo a TURBT
45808474|NCT03767244|Drug|Apalutamide|Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) orally once daily.
45808475|NCT03767244|Drug|Androgen Deprivation Therapy (ADT)|Participants will receive a stable regimen of ADT - gonadotropin-releasing hormone analog (agonist or antagonist) (GnRHa). ADT is a kind of hormone therapy for prostate cancer. GnRHa will be administrated to achieve and maintain sub-castrate concentrations of testosterone (50 nanogram per deciliter [ng/dL]).
45808476|NCT03767244|Drug|Placebo|Participants will receive matching placebo oral tablets daily.
45944680|NCT00325273|Dietary Supplement|Lactobacillus rhamnosus GG|use Lactobacillus rhamnosus GG in pregnant women from gestational 26 weeks till newborn 6 months
45944681|NCT00325312|Drug|carbon dioxide, subcutaneous application|
45944682|NCT00325351|Drug|Sagopilone (ZK 219477) + carboplatin|Chemotherapy for recurrent ovarian cancer
45944683|NCT00093483|Biological|filgrastim|Subcutaneously beginning 12 hours after the last dose of chemotherapy and continuing until blood counts recover.
45808477|NCT03765073|Biological|Multivalent Group B streptococcus vaccine|Various formulations at three dose levels
45808478|NCT03765073|Biological|Placebo|Saline control
45808479|NCT03755128|Other|No intervention|No investigational drugs will be administered as part of the study
45808480|NCT03743610|Other|Simulated altitude|Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines
45808481|NCT03743610|Other|Placebo simulated altitude|Participants will exercise at sea level at similar percentage of intensities to the simulated altitude group.
45808482|NCT03743428|Drug|Apatinib Mesylate Tablets|Apatinib combinated with FOLFIRI regimen as the second-line chemotherapy for mCRC
45808483|NCT03743428|Drug|Bevacizumab Injection|Bevacizumab combinated with FOLFIRI regimen as the second-line chemotherapy for mCRC
45944684|NCT00093483|Drug|arsenic trioxide|IV over 1 hour on day 1
45944685|NCT00093483|Drug|cytarabine|IV over 1 hour every 12 hours on days 1-6
45944686|NCT00093483|Drug|idarubicin|IV over 30 minutes on days 2-4 (immediately after doses 3, 5 and 7 of cytarabine).
45458067|NCT03502720|Device|Scaphoid fixation using 3D device|A headless screw inserted percutaneously from the volar aspect of the scaphoid in a retrograde manner using a customised 3D exoesqueleton guide
45944687|NCT00084734|Drug|capecitabine|Oral
45944688|NCT00084734|Drug|cisplatin|IV
45944689|NCT00084734|Drug|docetaxel|IV
45944690|NCT00419185|Procedure|Delamination of the Internal limiting membrane|
45944691|NCT00325390|Drug|clopidogrel (SR25990C)|
45944692|NCT00325429|Drug|Vildagliptin|
45944693|NCT00093522|Biological|autologous tumor cell vaccine|
45944694|NCT00093522|Biological|keyhole limpet hemocyanin|
45944695|NCT00093522|Biological|therapeutic autologous dendritic cells|
46075387|NCT00877981|Procedure|Minimal invasive Parathyroid surgery|
45944696|NCT00093522|Drug|fludarabine phosphate|
45944697|NCT00093522|Procedure|conventional surgery|
45657194|NCT02596009|Device|Handihaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
45944698|NCT00084773|Biological|cetuximab|
45944699|NCT00084773|Drug|fluorouracil|
45944700|NCT00084773|Procedure|neoadjuvant therapy|
45944701|NCT00084773|Radiation|radiation therapy|
45944702|NCT00419224|Biological|inactivated split-virus influenza vaccine|
45944703|NCT00318682|Device|FIBROSCAN|diagnostic examination of the hepato fibrosis
45944704|NCT00325546|Drug|Rimonabant (SR141716)|
45944705|NCT00325546|Drug|Placebo|
45944706|NCT04727580|Drug|HSK7653 10mg Q2W|HSK7653 5mg (2 tablets) and placebo of HSK7653 25mg (1 tablet) Q2W, oral, Day1 to week12
45944707|NCT04727580|Drug|HSK7653 25mg Q2W|HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
45458068|NCT03502720|Procedure|Scaphoid fixation using standard procedure|A headless screw inserted percutaneously from the volar aspect of the scaphoid in a retrograde manner without using the 3D device (standard procedure)
45808484|NCT03741582|Other|TransMiCable|"TransMiCable will have one service line 3.43 km-long with four stations (El Tunal , Juan Pablo II , Manitas , and Paraiso, see highlighted stops in Figure 2). El Tunal is the station that connects to the city's bus rapid transit system. The planned capacity of TransMiCable is 3,600 persons per hour in 163 cabins or gondolas. Each cabin fits ten passengers, with space for wheelchairs and bicycles and will be equipped with free Wi-Fi. The expected travel time reductions from each station to portal El Tunal, through the shortest pathway, are: 26 minutes saved from Juan Pablo II station-from 32 to 6 minutes; 31 minutes saved from Manitas station-from 38 to 7 minutes and 49 minutes saved from Paraiso station-from 62 to 13 minutes 22. In conjunction with TransMiCable, urban projects will be implemented including the construction of parks, outdoor gyms, sport courts, community centers for children and older adults, a market, an administrative, and a tourism offices."
45808485|NCT03740490|Combination Product|Smart-T + NRT|Smart-Treatment App and Nicotine Replacement Therapy
45808486|NCT03740490|Combination Product|QuitGuide + NRT|NCI QuitGuide Treatment App and Nicotine Replacement Therapy
45808487|NCT03739710|Drug|Docetaxel|Docetaxel will be administered.
45808488|NCT03739710|Drug|Feladilimab|Feladilimab will be administered.
45944708|NCT04727580|Drug|Placebo|Placebo of HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
45944709|NCT00325585|Behavioral|Couples HIV counseling and testing|
45657195|NCT02590939|Device|CEFALY Active|Active external trigeminal nerve stimulation
45657196|NCT02590939|Device|CEFALY Placebo|Placebo external trigeminal nerve stimulation
45657197|NCT04793503|Other|conventional complete denture|the complete denture constructed by packing technique
45808489|NCT03739710|Drug|Ipilimumab|Ipilimumab will be administered.
45808490|NCT03739710|Drug|GSK4428859A|GSK4428859A/EOS884448 will be administered.
45808491|NCT03739710|Drug|Dostarlimab|Dostarlimab will be administered.
45808492|NCT03739710|Drug|GSK6097608|GSK6097608 will be administered.
45808493|NCT03734666|Behavioral|Mindfulness Based Relapse Prevention - Smoking and Alcohol|Mindfulness Based Relapse Prevention (MBRP) is a treatment for preventing relapse in addictive disorders that integrates mindfulness meditation with standard relapse prevention practices.
45808494|NCT03734666|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a form of therapy that aims to help individuals modify problematic emotions, behaviors, and thoughts.
45808495|NCT03733067|Drug|abatacept|Double-blind, placebo-controlled, intra-patient dose-escalation trial of abatacept for treating cytopenia in CTLA4 deficiency. Abatacept or placebo will be administered for 3 doses over 30 days, followed by 5 more months of administration at double the initial dose. If the participant s hematologic parameters normalize at Day 120 or onwards, the investigator may taper or discontinue concomitant medications aimed at treating cytopenia.
45944710|NCT00325585|Behavioral|Women's relationship-focused HIV counseling and testing|
45944711|NCT00084812|Drug|cisplatin|
45944712|NCT00084812|Drug|safingol|
45944713|NCT00325624|Device|Bluetooth-enabled Glucometer|blood glucose information provided to health care providers
45944714|NCT00318721|Device|Long Lasting Impregnated Nets (LLIN)|Distribution of LLIN in selected clusters
45944715|NCT00325663|Procedure|Acupuncture|
45944716|NCT02959879|Drug|FOLFOX neoadjuvant chemotherapy|4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient
45944717|NCT02959879|Drug|FOLFIRINOX neoadjuvant chemotherapy|4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient
45944718|NCT02959879|Procedure|curative surgery for resectable pancreatic duct adenocarcinoma|curative surgery for resectable pancreatic duct adenocarcinoma
45944719|NCT02959879|Drug|Standard adjuvant chemotherapy|12 cycles of standard adjuvant chemotherapy are administrated
45944720|NCT02959879|Drug|adjuvant chemotherapy|8 cycles of standard adjuvant chemotherapy are administrated
46002197|NCT04396795|Drug|Autologous Platelet Rich Plasma|Each injection session will consist of a total of 10 mL PRP infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum.
46075388|NCT02786472|Behavioral|Online Bystander Training|Large groups of 120-150 students will complete Haven training via computer; training lasts duration of the online program.
46075389|NCT02786472|Behavioral|Online Substance Abuse Training|Large groups of 120-150 students will complete EverFi training via computer; training lasts duration of the online program.
46075390|NCT02786472|Behavioral|In-Person Bystander Training|In-person training of large groups of 120-150 students; training lasts 3-4 hours
46075391|NCT02786472|Behavioral|In-Person Combination Training|In-person training of large groups of 120-150 students; training lasts 3-4 hours
46075392|NCT00870181|Biological|ADV-TK/GCV|gene therapy
46075393|NCT00870181|Procedure|Surgery|
46075394|NCT00870181|Drug|systemic chemotherapy|
45944721|NCT02965079|Device|ECCO2R|The ECCO2R system was developed from the principle of ECMO systems by underscoring the importance of carbon dioxide elimination rather than direct improvement of oxygenation in some patients. The circuit of the ECCO2R system can be set up in venovenous (VV) or arteriovenous (AV). For VV setup, a low flow pump is used to maintain a low extracorporeal flow rate using only 20-30 % of cardiac output. The ECCO2R system does not provide complete pulmonary function as it can achieve only limited oxygenation but provides predominantly carbon dioxide removal. As neither VV nor AV circuit allows full cardiopulmonary bypass, the system provides respiratory function but no cardiac support
45944722|NCT04717609|Procedure|Saphenous Nerve Block|Preoperative Saphenous Nerve Block for partial Meniscectomy
45808496|NCT03733067|Other|Placebo|Saline packaged identically to abatacept, with volume matching that of the abatacept dosing by weight, and will be administered via IV infusion identically to abatacept
45808497|NCT03729869|Drug|Progesterone|200 mg of exogenous progesterone twice a day
45944723|NCT04717609|Drug|Ropivacaine injection|preoperatively the participant will receive an injection ar the surgical site of 5 milliliters (mL) of 0.5% ropivacaine
45944724|NCT00318760|Drug|Clonidine|0.1 or 0.2 mg oral, one dose
45944725|NCT00318760|Drug|Placebo|oral capsule 1 dose
45944726|NCT00093561|Dietary Supplement|lycopene|
45808498|NCT03729869|Drug|Placebo|One dose of matched placebo twice a day.
45944727|NCT00325702|Behavioral|community-level intervention for young MSM|The community-level intervention includes small media in the form of role model stories, peer outreach and web-based intervention
45944728|NCT00318799|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 824: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
45453184|NCT01099657|Behavioral|Virtual Reality Hypnosis for chronic pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Hypnosis. After VRH, the will again answer Pain and anxiety questionnaires.
45657198|NCT04793503|Other|CADCAM 3D printed denture|The files from the laser-scan will be translated into stereolithography (STL) files and the CDs are virtually designed in ExoCad software
45657199|NCT04793503|Other|CAD/CAM milled denture|Once the complete denture has been virtually designed in CAD software (ExoCad software) a preview will be sent for evaluation using 3D viewing software
45808499|NCT03729830|Device|Boston Scientific Open Irrigated Ablation Catheters|The BSC Open-Irrigated catheters are designed to deliver RF energy to catheter tip electrode for cardiac ablation. The BSC OI catheters incorporate an open-irrigated cooling mechanism through a tip that is partitioned into two chambers. The proximal chamber circulates normal saline (0.9 %) within the tip to cool the proximal electrode and mitigate overheating while the distal chamber allows the fluid to flow through six irrigation holes into the patient's vasculature, thereby cooling the tip/tissue interface.
45808500|NCT03729349|Biological|Golimumab|Participants will receive golimumab as a part of clinical practice.
45808501|NCT03728608|Device|Feeding tube dwell time of 48 hours|Feeding tube dwell time of 48 hours for first 4 weeks of life.
45808502|NCT03728608|Device|Feeding tube dwell time of 7 day|Feeding tube dwell time of 7 days for first 4 weeks of life.
45808503|NCT03723551|Drug|Afabicin|Administered intravenously and orally.
45808504|NCT03723551|Drug|Standard of Care|Administered with SOC in accordance with local practice and applicable treatment guidelines.
45657200|NCT04803565|Device|Custom-made shoe insole|Subjects will receive a custom-made shoe insole designed on the patient's foot and shoes. The subjects should wear the insole for at least 6 hours per day.
45657201|NCT04803565|Device|Sham conventional Insole|Subjects will receive a conventional insole without any specific property (sham insole)
45657202|NCT04793113|Other|FreshlyFit Meals|FreshlyFit meals are low carbohydrate, high protein meals
45808505|NCT03718325|Device|Burst-SCS|The treatment arm used in the study is clinically-effective burst spinal cord stimulation (Burst-SCS). The device used to deliver Burst-SCS is the St. Jude Medical Invisible Trial System.
45808506|NCT03718325|Device|Sham SCS|The placebo control arm used in the study is sham spinal cord stimulation (sham SCS). The device used to deliver sham SCS is the St. Jude Medical Invisible Trial System.
45808507|NCT03715933|Drug|INBRX-109|Tetravalent DR5 Agonist Antibody
45808508|NCT03715933|Drug|Carboplatin|Chemotherapy
45808509|NCT03715933|Drug|Cisplatin|Chemotherapy
45808510|NCT03715933|Drug|Pemetrexed|Chemotherapy
45808511|NCT03715933|Drug|5-fluorouracil|Chemotherapy
45808512|NCT03715933|Drug|Irinotecan|Chemotherapy
45944729|NCT00318799|Drug|SH D01155E|per cycle: Days 1-21: 0.03 mg EE + 0.15 mg LNG; Days 22-28: Placebo
45944730|NCT02959801|Procedure|Percutaneous mechanical thrombectomy|Aspirex catheters(Straub Medical AG, Wangs, Switzerland)
45944731|NCT00084890|Drug|carboplatin|30 minute infusion dosed based on glomerular filtration rate of patient
45944732|NCT00084890|Drug|docetaxel|escalating doses ofstarting at 25 milligrams per meter squared
45944733|NCT04728945|Procedure|lung recruitment|Automatic lung recruitment using the anesthetic machines (with PEEP 15 cmH2O for 30 seconds) will be performed every 30 minutes during laparoscopy.
45944734|NCT04728945|Procedure|Standard ventilatory management|"After tracheal intubation, standard ventilatory management (metered ventilation) should be performed with the following initial settings, and rescue should be performed when hypoxemia occurs, if necessary.~[initial setting] PEEP 4cmH2O, FIO2 0.3 Ventilation rate: 6-8 ml/kg predicted body weight (PBW)"
45944735|NCT00325741|Procedure|Hematopoietic Cell Transplantation|1200 cGy total lymphoid irradiation (TLI) are administered on day -11 through -7 and days -4 through -1 pretransplantation; rabbit ATG at 1.5 mg/kg i.v. on days -11 through -7 pretransplantation; one single infusion of donor CD34+ cells plus selected T cell add back on completion of TLI (day 0); mycophenolate mofetil (MMF) is begun on day 0 at a dose of 15 mg/kg bid and stopped on day +28; cyclosporine (CSP) at initial dose of 6.25 mg/kg and adjusted to maintain trough blood levels of 350-500 ng/ml is begun on day -3 to complete withdrawal by 6 months post-transplantation.
45944736|NCT00318838|Drug|Azimilide dihydrochloride|125 mg azimilide tablet every 12 hours for 3 days followed by 125 mg azimilide tablet every 24 hours for three days
45944737|NCT00318838|Drug|Placebo|Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
45944738|NCT00318877|Behavioral|After school team sports program|
45657203|NCT04348123|Other|Survey|Survey questionnaire seeks to collect data relevant to mammogram completion, barriers, and facilitators
45808513|NCT03715933|Drug|Temozolomide|Chemotherapy
45657204|NCT04348123|Behavioral|Education Session|After the survey, clinic staff will conduct brief, culturally-appropriate educational session about breast health and mammography delivered by a female public health educator with experience in the underserved community. Educational session will explain screening options and address common barriers
45944739|NCT00318877|Behavioral|After school health education program|
45944740|NCT00085124|Biological|oblimersen sodium|Given IV
45944741|NCT00085124|Drug|cytarabine|Given IV
45808514|NCT03714984|Other|Pre operative exercise|After randomization participants will be allocated in two groups. The educational pelvic floor intervention group will receive two months before surgery a physiotherapy visit were will be explain to patients and care giver the pelvic floor anatomy and biomechanics and how perform the exercises to be follow at home focusing on pelvic muscles awareness and contraction.
45808515|NCT03714984|Other|Control Group|The control group will be just informed about the study protocol and will not receive any pre-operative intervention.
45808516|NCT03714373|Drug|DCCR|Once daily oral administration of open-label DCCR tablet(s) during the OLE Period
45944742|NCT00085124|Drug|daunorubicin hydrochloride|Given IV
45944743|NCT00085124|Other|laboratory biomarker analysis|Correlative studies
45944744|NCT00402441|Drug|Risedronate (HMR4003)|
45944745|NCT00325858|Drug|Tramadol HCl ER|
45944746|NCT00318955|Drug|Dexmedetomidine|
45944747|NCT00318955|Drug|Propofol|
45944748|NCT00325936|Drug|Cilnidipine|10~20mg, qd, po for 3 months or 12 months.
45944749|NCT00318994|Drug|Meropenem|
45944750|NCT00093600|Drug|cytarabine|
45657205|NCT04813471|Drug|Endothelial Protocol|Endothelial Protocol
45657206|NCT04813393|Other|Questionnaire Development|To evaluate psychometric the properties of the Compliance of Parents of Children with Cerebral Palsy to Home Program Assesment Questionnaire (CPHP-Q), a caregiver-report for adherence and frequency of home program implementation of parents of children with Cerebral Palsy.
45657207|NCT05616247|Behavioral|ECALC|Expectancy Challenge Alcohol Literacy Curriculum Cognitive Behavioral Intervention
45657208|NCT05616247|Behavioral|ECALC Plus Weekly Boosters|Expectancy Challenge Alcohol Literacy Curriculum Cognitive Behavioral Intervention Plus Weekly Booster Content Delivered by Mobile Device
45808517|NCT03714373|Drug|DCCR|Once daily oral administration of double-blind (DCCR) tablet(s) during the RW Period
45657209|NCT04803175|Drug|Sacubitril-Valsartan|Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
45657210|NCT04803175|Drug|Valsartan|Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
45657211|NCT04793347|Device|shock master (shock waves device)|device produces shock waves
45808518|NCT03714373|Drug|Placebo for DCCR|Once daily oral administration of double-blind (placebo for DCCR) tablet(s) during the RW Period
45808519|NCT03708328|Drug|Lomvastomig|Lomvastomig will be administered intravenously (IV) with a flat dose on the schedule described for each study arm.
45808520|NCT03695081|Procedure|Patient Pathway Pharmacist intervention|"Medication reconciliation at admission to hospital~Medication review post surgery~Optimised list of drugs in the discharge summary, in accordance with hospital procedures~Medication reconciliation, six weeks after discharge~Medication review, six weeks after discharge"
45808521|NCT03691064|Drug|LUTATHERA|Labeled dosing regimen: 7.4 gigaBecquerel (GBq) (200 milliCurie [mCi]) every 8 weeks for a total of 4 doses.
45808522|NCT03690921|Drug|Cisplatin|Given IV
45808523|NCT03690921|Drug|Fluorouracil|Given IV
45808524|NCT03690921|Radiation|Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy|Undergo LET-IMPT
45944751|NCT00093600|Drug|daunorubicin hydrochloride|
45944752|NCT00093600|Drug|midostaurin|
45944753|NCT00319033|Drug|bosentan|
45944754|NCT00085163|Drug|celecoxib|
45944755|NCT00085163|Drug|fluorouracil|
45944756|NCT00085163|Drug|leucovorin calcium|
45944757|NCT00085163|Procedure|adjuvant therapy|
45944758|NCT00319072|Behavioral|TalkToYourDoc(sm) hormone therapy module|
45944759|NCT00326014|Device|iStent|Glaucoma Surgery
45944760|NCT00093639|Drug|everolimus|
45944761|NCT00093639|Drug|imatinib mesylate|
45944762|NCT00319150|Drug|erythropoietin|Decrease dosage by 12.5% q 2 weeks according to an algorithm.
45944763|NCT00326053|Drug|Budesonide/formoterol|
45944764|NCT00400088|Drug|paroxetine|Start at 20 mg po od. Increase dose to 40 mg po od at week 4 if there is less than 20 % reduction in MADRS scores.
45944765|NCT00400088|Drug|lithium|start at 600mg po hs with dose to be flexibly titrated to a serum level of between 0.6 and 1.1 mmol/l.
45944766|NCT04727385|Device|Double Crosslink Microgel|"DXM hydrogel is a pH responsive Double Cross-Linked microgel based on single internally cross-linked microspheres (comprising a methacrylic acid-methyl methacrylate-ethylene glycol dimethacrylate copolymer)~The DXM gel is injected into the intervertebral disc (IVD) space via a standardised procedure similar to the routinely-performed Discography procedure. The disc approach described in the discography procedure has been reported to allow the injection of a solution in the centre of the disc. The injection of the gel takes about 2 min."
45944767|NCT00326092|Drug|Brinzolamide/Timolol|
45944768|NCT00326131|Drug|Oral Taxane|
45944769|NCT00319189|Drug|Nateglinide|
45944770|NCT00319267|Drug|Bosentan|Pediatric oral formulation of bosentan, i.e., 32 mg dispersible and breakable tablets
45944771|NCT00085280|Drug|erlotinib hydrochloride|Given orally
45944772|NCT00085280|Other|laboratory biomarker analysis|Correlative studies
45944773|NCT00326248|Drug|GW679769 (casopitant)|
45944774|NCT04727112|Drug|Usual care versus primary care|RCT study
45944775|NCT00319306|Drug|Budesonide/formoterol|
45944776|NCT00319306|Device|Symbicort® Turbohaler®|
45944777|NCT00085358|Drug|carboplatin|Given intraperitoneally
45944778|NCT00085358|Drug|paclitaxel|Given IV or intraperitoneally
45808525|NCT03690921|Procedure|Quality-of-Life Assessment|Ancillary studies
45944779|NCT00085358|Drug|docetaxel|Given IV
45944780|NCT00085358|Biological|bevacizumab|Given IV
45944781|NCT00326326|Drug|CP-778,875|
45944782|NCT00093678|Drug|celecoxib|
45944783|NCT00093678|Procedure|anticachectic therapy|
45944784|NCT00093678|Procedure|nutritional support|
45944785|NCT00093678|Procedure|pain therapy|
45657212|NCT04793425|Behavioral|Mobile application (afterAMI)|"The rehabilitation process of the patients in the intervention group will be supported by the mobile application (afterAMI) with synchronized, dedicated web page.~Patients in the intervention group will be given an access to educational data regarding their individualized diseases. Additionally every patient will receive regularly messages with notifications regarding lifestyle and adherence to the therapy. All reported vital signs (blood pressure, heart rate, weight and many more) will be analyzed every day and in case of need a short message will be sent to the patient with indication to go to the primary healthcare clinic/hospital.~Additionally, application will send notifications with reminders to take drugs."
45808526|NCT03690921|Other|Questionnaire Administration|Ancillary studies
45944786|NCT00093678|Procedure|supportive care/therapy|
45944787|NCT00319345|Drug|Mannitol, Sodium-Lactate|
45657213|NCT04351087|Device|Platelet Rich Plasma|"Platelet rich plasma: 157cc of whole blood will be collected, processed, and injected into the knee joint under sterile technique using ultrasound-guidance.~Microfragmented adipose tissue: Adipose will be aspirated from the subcutaneous tissue of the buttock or abdomen, processed, and injected into the knee joint under sterile technique using ultrasound-guidance."
45944788|NCT00326365|Drug|Kali bichromicum 10-60 (C30)|
45657214|NCT04803253|Device|ORTHOPUS prosthetic accessory: 0109 - Universal Wrist|"The ORTHOPUS mechanical wrist device is intended to provide an external wrist joint only for external upper limb prostheses with pronation/supination passive motion (activation with external force), a quick connection (with automatic lock) and manual disconnection of the mechanical wrist connectors.~The mechanical wrist connector allows to quickly switch between different type of terminal devices (hand or tools)."
45657215|NCT04803253|Device|ORTHOPUS prosthetic terminal device: 0112 - Hook|The ORTHOPUS body-powered hook is a Voluntary Opening (VO) device made of aluminium intended to provide high grasping capabilities under harsh environments.
45808527|NCT03689543|Drug|ER beta agonist|We propose to evaluate the efficacy of a selective estrogen receptor (ER) beta agonist (Lilly Compound LY500307) to prevent estradiol withdrawal-induced mood symptoms. The effects of estradiol primarily occur through activation of two receptor subtypes, often with opposing outcomes: estrogen receptor (ER) alpha, and ER beta. We focus on ER beta because the beta estrogen receptor is reported to mediate the effects of estradiol on the serotonergic system and mediate the antidepressant-like effects of estradiol in the forced-swim test.
45808528|NCT03689543|Other|Placebo|Placebo
45944789|NCT00419536|Drug|LBH589|
45944790|NCT00319384|Device|Ultrafiltration therapy|
45458069|NCT01236469|Procedure|Echocardiogram|A prospective follow-up Study Echocardiogram will be performed, as applicable, for those subjects who do not have echo data as of January 1, 2009.
45808529|NCT03684889|Biological|SCRI-huCAR19v1|1:1 mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
45808530|NCT03684889|Biological|SCRI-huCAR19v2|Mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
45944791|NCT00319423|Procedure|Patient education and supervised exercise|Patient education: 3 sessions Supervised exercise: 2-3 times/week for 12 weeks
45944792|NCT00124293|Drug|activated recombinant human factor VII|
45944793|NCT00085397|Biological|autologous dendritic cell-tumor fusion vaccine|Given subcutaneously
45944794|NCT00085397|Biological|gp100 antigen|Given IV
45944795|NCT00085397|Biological|therapeutic autologous dendritic cells|Given IV
45944796|NCT00326404|Drug|Desogestrel-Ethinyl Estradiol 21 tablets|The participants in the continuous study arm will be given 4 packs of Marvelon-21, so that they can take the pills continuously for 84 days followed by no medication for 7 days. During these 7 days, the participant will have a withdrawal bleed. This sequence is repeated by the participant for a total of 12 months. Each patient in the continuous arm will have 4 withdrawal bleeds per year.
45944797|NCT00326404|Drug|Desogestrel-Ethinyl Estradiol 28 tablets|The participants in the cyclical arm of the study will be given 3 packs of Marvelon-28 and asked to take all the pills in the packet, including the placebo pills. During the week of placebo pills, these participants will have a withdrawal bleed. Each patient in the cyclical arm will have 12 withdrawal bleeds per year. The duration of study drug treatment for both arms is 12 months.
45944798|NCT00319462|Device|hemoclip|
45944799|NCT00326443|Biological|CVD 909|5 X 10^9 CFU of oral S. Typhi vaccine strain CVD 909 with buffer administered on Day 0.
45944800|NCT00326443|Drug|Placebo|Buffer placebo administered on Day 0.
45944801|NCT00326443|Biological|Vi Polysaccharide|25 micrograms (0.5 ml) of licensed purified Vi polysaccharide vaccine on Day 21.
45944802|NCT00085475|Drug|imatinib mesylate|
45944803|NCT00085475|Procedure|conventional surgery|
45944804|NCT00319618|Drug|Gefitinib|
45944805|NCT00319618|Drug|Docetaxel|
45944806|NCT00326560|Procedure|Pterygium excision and conjunctival autograft|
45944807|NCT00319657|Biological|Hematopoietic cell transplantation|Transplantation of hematopoietic stem cells from the living donor.
45944808|NCT00319657|Radiation|Total lymphoid irradiation|Total lymphoid irradiation is used as part of the conditioning regimen for the hematopoietic stem cell transplant.
45944809|NCT00124332|Drug|Rimonabant (SR141716)|
45944810|NCT00124332|Drug|Placebo|
45944811|NCT00085553|Drug|Erlotinib Hydrochloride|Given PO
45944812|NCT00085553|Other|Laboratory Biomarker Analysis|Correlative studies
45944813|NCT00085553|Other|Pharmacological Study|Correlative studies
45944814|NCT00085553|Drug|Tipifarnib|Given PO
45944815|NCT00326638|Radiation|Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy|"IMRT using Helical Tomotherapy* 7800 cGY/39 Fractions once daily Monday to Friday for 8 weeks~Initial IMRT to Nodes/Prostate + Seminal Vesicles 4,600 cGy/23~Boost IMRT to Prostate 3,200 cGy/16"
45657216|NCT04803253|Device|ORTHOPUS prosthetic terminal device: 0105 - Cosmetic Articulated Hand|The ORTHOPUS cosmetic articulated hand is intended to provide a replacement limb in order to hide the loss of the original one. It is composed of an aesthetic glove (18 colors and 3 sizes, silicone made) and of an internal structure that can be bent to achieve a given position allowing the user to grasp small and light objects.
45808531|NCT03683394|Behavioral|SMARRT Intervention|Interventionists will follow a standard protocol for delivering the SMARRT intervention that allows for personalization of the specific risk reduction action plan; these plans will evolve over time according to participant progress, motivation and preferences or newly identified risk factors. Staff will use a tracking database to record information for each participant, including session dates, identified risk factors, motivational barriers and important values, and the outcome of discussions around developing goals. For each participant, the exact number and mode (phone or in-person) of contacts will differ, but we will aim to have at least 1 contact per month with each participant. Best practice will include in-person meetings twice a year during the 2-year intervention period.
45944816|NCT00326638|Other|Arm A: 3D-Conformal Radiation|"3DCRT 7800 cGY/39 Fractions/ STD Technique* once daily Monday to Friday for 8 weeks~Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23~Boost 6 F 3DCRT to Prostate 3,200 cGy/16"
45944817|NCT00319774|Device|Hemocontrol Biofeedback System|
45944818|NCT00326677|Behavioral|Problem Solving Therapy|6 to 8 Problem Solving Therapy sessions over the course of 6 to 16 weeks followed by 3 booster PST sessions over the course of 2 years
45944819|NCT00326677|Behavioral|Dietary Education|6 to 8 Diet Education sessions over the course of 6 to 16 weeks followed by 3 booster Diet Education sessions over the course of 2 years
45944820|NCT00319813|Behavioral|Education|
45944821|NCT00400335|Drug|Nanomilled testosterone|
45944822|NCT00400335|Drug|commercially available dutasteride|
45944823|NCT00400335|Drug|Nanomilled dutasteride|
45944824|NCT00326794|Procedure|mobilisation (rehabilitation)|
45944825|NCT00319852|Biological|DTaP-IPV combined vaccine|0.5 mL, IM
45944826|NCT00319852|Biological|DTaP vaccine|0.5 mL, IM
45944827|NCT00326833|Drug|vitamin B12|9 µg vitamin B12 three times daily for two days (CobaSorb)
45944828|NCT00319891|Procedure|Computer-based Cognitive Training|
45944829|NCT04728828|Biological|Serological COVID-19 vaccine immunogenicity|Serological test
45944830|NCT00085748|Drug|paliperidone ER|
45944831|NCT00326989|Procedure|intracoronary stem cell therapy|extracorporal shock waves prior to intracoronary cell therapy
45944832|NCT00327028|Drug|Diphenine|
45944833|NCT00319930|Drug|CNF1010 (17-AAG)|
45657217|NCT04803253|Device|ORTHOPUS prosthetic accessory: 0104 - body powered harness|The ORTHOPUS body powered harness is intended to allow the patient to actuate the 0112 - Hook device. It will be installed on the patient's contralateral shoulder and linked to the 0112 - Hook device with a cable.
45657218|NCT04792723|Drug|Sublingual aspirin|Vita Green Health Products sublingual aspirin 80 mg tablet
45808532|NCT03683394|Behavioral|Health Education Intervention|Participants randomized to the Health Education (HE) group will receive mailed materials (typically 1-2 pages) every 3 months. This will include general information on Alzheimer's and dementia risk reduction using materials from sources such as the Alzheimer's Association and educational materials commonly provided as part of routine care at Kaiser Permanente Washington (KPWA).
45808533|NCT03681223|Device|Vertessa® Lite Y mesh|Via randomization, 50 surgical subjects will receive Vertessa® lite Y mesh for the treatment of vaginal vault prolapse. The patient will be blinded as to which mesh they receive.
45944834|NCT00320008|Behavioral|Diet|
45944835|NCT00320008|Behavioral|Exercise|
45944836|NCT00320008|Behavioral|Stop smoking|
45944837|NCT00320008|Drug|Glucose lowering therapy|
45944838|NCT00320008|Drug|Blood pressure lowering therapy|
45944839|NCT00320008|Drug|Lipid lowering therapy|
45944840|NCT04728984|Drug|Nalfurafine Hydrochloride|"Nalfurafine Hydrochloride 2.5μg*2~; Oral administration after dinner, once daily for 14 consecutive days"
45944841|NCT04728984|Drug|Nalfurafine Hydrochloride+Placebo|Nalfurafine Hydrochloride 2.5μg+ A placebo pill; Oral administration after dinner, once daily for 14 consecutive days
45944842|NCT04728984|Drug|Placebo|two placebo pills; Oral administration after dinner, once daily for 14 consecutive days
45944843|NCT00085787|Drug|ARRY-142886, MEK inhibitor; oral|Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
45458070|NCT02313376|Biological|GAP3KO|GAP3KO administered via the bite of 150-200 GAP3KO-infected A. stephensi mosquitoes under controlled conditions.
45944844|NCT04717102|Drug|0.5 MAC desflurane|Following induction of anesthesia by propofol, the patients will be maintained on 0.5 MAC desflurane with remifentanil infusion during spinal surgery.
45944845|NCT04717102|Drug|0.75 MAC desflurane|Following induction of anesthesia by propofol, the patients will be maintained on 0.75 MAC desflurane with remifentanil infusion during spinal surgery.
45944846|NCT04717102|Drug|1.0 MAC desflurane|On completion of the neuromonitoring phase of surgery, the patients will be maintained on 1.0 MAC desflurane with remifentanil infusion.
45944847|NCT00320047|Drug|Baclofen|Participants will take baclofen 3 times a day, before meals, for 10 weeks. Baclofen dosages will be low to begin, followed by a gradual increase over a 2-week period. Upon reaching the maximum tolerated dose of baclofen, participants will continue at this dosage level until Week 11, at which time the dose will be gradually decreased. If any serious side effects occur, baclofen dosage will be decreased to the previous tolerated dosage level.
45944848|NCT04708639|Drug|Alectinib|Use of ctDNA to establish response and resistance to alectinib.
45944849|NCT00085826|Drug|Exisulind|
45944850|NCT04708405|Other|Observation|Follow up and observe under standard of care given
45944851|NCT04708483|Device|Extra DCE-CT scan|DCE-CT of thoracic tumors as an early biomarker for treatment monitoring in comparison with morphologic criteria.
45944852|NCT00124371|Behavioral|a nurse led home-based education and support programme|
45944853|NCT00320125|Dietary Supplement|Orange juice plus calcium|> 1,200mg Ca (four glasses of orange juice plus calcium)per day
45944854|NCT00320125|Dietary Supplement|Dairy products|> 1,200mg Ca (by consuming milk, yogurt, and cheese)
45944855|NCT04708444|Diagnostic Test|CD318|Flowcytometric marker
45808534|NCT03681223|Device|Restorelle® Y mesh|Via randomization, 50 surgical subjects will receive Restorelle® Y mesh for the treatment of vaginal vault prolapse.The patient will be blinded as to which mesh they receive.
45944856|NCT00093873|Drug|Anti-angiogenesis|Anti-angiogenesis
45944857|NCT00093873|Drug|AMG 706|Anti-angiogenesis
45944858|NCT00320320|Drug|Irinotecan|
45944859|NCT00327106|Drug|Tranexamic acid (Exacyl)|15 mg/kg IV (in the vein), just before surgery and 3 hours after surgery
45944860|NCT00327106|Drug|Placebo|NaCl 9‰, 0,15 ml/kg IV (in the vein), just before surgery and 3 hours after surgery.
45944861|NCT00085904|Drug|SB-485232|
45944862|NCT00320359|Drug|Intravenous topotecan/cisplatin|"Topotecan 1 mg/m2 should be administered intravenously over a period of 30 minutes on days 1-5. Then a 30 minute saline flush should be administered followed by the cisplatin on day 5.~Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 5 after topotecan."
45944863|NCT00320359|Drug|Intravenous etoposide/cisplatin|"Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 1. Cisplatin should be given simultaneously to post-hydration to ensure a high volume fluid.~Etoposide 100 mg/m2 should be administered after cisplatin intravenously over a period not less than 30 minutes on days 1 -3."
45808535|NCT03681223|Procedure|Laparoscopic sacrocolpopexy|The subject's surgeon will decide if their patient should have laparoscopic sacrocolpopexy upon their clinical evaluation
45808536|NCT03681223|Procedure|Robotic assisted laparoscopic sacrocolpopexy|The subject's surgeon will decide if their patient should have robotic assisted laparoscopic sacrocolpopexy upon their clinical evaluation
45808537|NCT03680677|Procedure|Bone Marrow or Peripheral Blood Graft (BMT)|Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol.
45944864|NCT00093912|Drug|clevidipine|
45944865|NCT00093912|Drug|sodium nitroprusside|
45944866|NCT00327145|Drug|valsartan|
45944867|NCT00327145|Drug|hydrochlorothiazide|
45944868|NCT00327145|Drug|amlodipine|
45944869|NCT00085943|Drug|LEXIVA (GW433908)|
45944870|NCT00085943|Drug|Ritonavir|
45944871|NCT00085943|Drug|KALETRA|
45944872|NCT00085943|Drug|EPIVIR|
45944873|NCT00085943|Drug|Ziagen|
45944874|NCT00085943|Drug|Abacavir/Lamivudine|
45944875|NCT00085943|Drug|Fosamprenavir|
45944876|NCT00093834|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|The first three patients will receive a dose of 5 X 107 cells, and the next three will receive a dose of 5 X 108 cells. Then, if these two doses of vaccine alone are found to be safe, a fixed vaccine dose of 5 X 108 cells will be tested in combination with chemotherapy based on the safety of the allogeneic breast vaccine alone and the safety and bioactivity of a dose of 5 X 108 cells in the allogeneic pancreatic vaccine trial
45944877|NCT00093834|Drug|cyclophosphamide|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
45944878|NCT00093834|Drug|doxorubicin hydrochloride|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
45944879|NCT00327184|Biological|Haemophilus influenzae type b- and meningococcal serogroup C (vaccine)|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
45944880|NCT00327184|Biological|Infanrix Penta|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
45944881|NCT00327184|Biological|Infanrix hexa|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
45944882|NCT00327184|Biological|Neis-Vac-C|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
45944883|NCT00419302|Drug|Technosphere/Insulin|
45944884|NCT00327223|Drug|imexon|
45944885|NCT00093951|Drug|SGS742|
45944886|NCT00419419|Drug|Topical AmphiMatrix with nitroglycerin (MQX-503)|
45944887|NCT00320476|Drug|Velcade|
45944888|NCT00086021|Procedure|Acupuncture|
45944889|NCT00327262|Drug|Imatinib|
45944890|NCT00093990|Drug|Tipifarnib;Zarnestra; R115777|
45944891|NCT00327379|Drug|Trasylol (Aprotinin, BAYA0128)|Infusion of aprotinin (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
45944892|NCT00327379|Drug|Placebo|Infusion of placebo (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
45944893|NCT00086060|Behavioral|Exercise regimen|Aerobic Exercise is a self-management technique that increases personal control over pain by enhancing physical fitness. Patients will be encouraged to choose activities best suited to their tastes and current lifestyle, incorporating lifestyle physical activities (climbing stairs, household chores, etc) and more traditional exercise activities (walking, cycling, etc.). Subjects will use ratings of perceived exertion (RPE) to guide their effort. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for exercise, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
46002198|NCT04396795|Other|Saline solution|Each injection session will consist of a total of 10 mL saline solution infused slowly over a 2-minute period; 5 mL s each injected to the right and left corpus cavernosum
46002199|NCT04392440|Behavioral|DIAL-SDM|Communication intervention for nephrologists and coaching intervention for patients.
45808538|NCT03680677|Other|Cancer-directed Therapy or Best Supportive Care|"Cancer-directed therapy with intensive regimens (7+3, Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care."
45657219|NCT04792723|Drug|Oral aspirin|Synco (HK) oral aspirin 80mg tablet
45657220|NCT04813081|Procedure|Free Gingival Graft|In the recipient area, a half-thickness flap with two vertical incision widths was removed with a horizontal incision with 15C blades from the mucogingival junction. The recipient site was determined such that one or two teeth or one tooth extends into the mesial and distal regions of the tooth. Muscle attachments were dissected and FGG was placed on recipient bed and non-resorbable monofilament sutures were used for fixing the four corners of the graft.
45657221|NCT04427215|Other|Complementary and alternative medicines|Five types of Complementary and alternative medicines (Music Therapy, Art Therapy, Dance-Movement Therapy, Bibliotherapy, Physical Activity) will be applied twice a week.
45944894|NCT00086060|Behavioral|Relaxation training|Relaxation is a self-management technique that increases personal control over pain by relaxing tense muscles, allowing the body to rest, and improving mental clarity through concentration and attention and has a great deal of empirical research supporting its effectiveness as a means of pain management. A variety of relaxation skills will be taught with some being based on muscle relaxation, and others focused more on cognitive relaxation and imagery. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for relaxation, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
45808539|NCT03680677|Diagnostic Test|Frailty Assessment|Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.
45808540|NCT03678389|Other|ESC|USE OF ENDOSPHENOIDAL COIL (ESC) TO OBTAIN MRI IMAGING OF THE PITUITARY GLAND
45657222|NCT04813237|Other|n a|the participants are not subjected to any type of intervention
45808541|NCT03666273|Drug|Bapotulimab (BAY1905254)|Intravenous administration of escalating doses of Bapotulimab
45808542|NCT03666273|Drug|Bapotulimab (BAY1905254) + Pembrolizumab|Intravenous administration of Bapotulimab of fixed dose (expansion), and of a fixed dose of pembrolizumab
45808543|NCT03661528|Drug|andexanet alfa|Andexanet alfa is a recombinant version of human FXa
45808544|NCT03661528|Drug|Usual Care|Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate.
45808545|NCT03660826|Drug|Capivasertib|Given PO
45808546|NCT03660826|Drug|Cediranib|Given PO
45808547|NCT03660826|Drug|Cediranib Maleate|Given PO
45944895|NCT00086060|Behavioral|Standard Care|Participants in the standard care control group will not receive any additional intervention beyond that which they are receiving from their routine health care professional.
45944896|NCT00320554|Behavioral|Durometer analysis|
45944897|NCT00327418|Drug|Atorvastatin|
45944898|NCT00094029|Drug|Sutent|Sutent, 25, 37.5, or 50 mg daily
45944899|NCT00086099|Drug|Idarubincin and Amufostine (Ethyol)|Starting doses of Idarubincin(12,18 mg/m2 to 21 mg/m2), ara-C, plus amofostine (N-36)
45453185|NCT01099657|Behavioral|Virtual Reality Distraction for Chronic Pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Distraction. After VRD, the will again answer Pain and anxiety questionnaires.
45657223|NCT04427449|Biological|CD44v6-specific CAR gene-engineered T cells|4SCAR-CD44v6 Infusion of 4SCAR-CD44v6 T cells at 10^6 cells/kg body weight
45657224|NCT04803487|Other|robot-assisted cholecystectomy|cholecystectomy was performed for patients using the Chinese Micro Hand S surgical robot.
45657225|NCT04803487|Other|robot-assisted cholecystectomy|cholecystectomy was performed for patients using the da Vinci surgical robot.
45657226|NCT04803097|Diagnostic Test||We took slit-lamp-adapted anterior segmental photography from pediatric cataract eyes at baseline，1 week, 2 weeks, 1 month, 3 months, and 6 months postoperatively.
45657227|NCT05616169|Device|Easy Flype/EasyHiFlype|Patients with stenosis or occlusion of the iliac artery, femoral artery and first third of the popliteal artery, implanted with at least one study device, the Easy Flype or the Easy Hi Flype.
45657228|NCT04812769|Device|eCARE-ID|The intervention, eCARE-ID, consists of: 1) telehealth video clinical consultation services for nursing homes residents; 2) electronic consultation services for healthcare personnel; 3) telehealth video antibiotic stewardship services for healthcare personnel
45657229|NCT04812769|Other|Standard of Care|Standard of care will be delivered to the control home.
45808548|NCT03660826|Biological|Durvalumab|Given IV
45808549|NCT03660826|Drug|Olaparib|Given PO
45808550|NCT03657147|Behavioral|Educational Video and Question Prompt List|A short educational video will be presented on an iPad about the importance of encouraging patients to ask questions and to be involved during glaucoma visits to improve self-management skills. A question prompt list will also be completed where participants check questions of interest to ask the provider.
45808551|NCT03656536|Drug|Pemigatinib|Pemigatinib at the protocol-defined dose administered orally once daily as continuous therapy schedule (a cycle is 3 weeks).
45808552|NCT03656536|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
45808553|NCT03656536|Drug|Cisplatin|Cisplatin 25 mg/m^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
45808554|NCT03647306|Behavioral|Early Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
45808555|NCT03647306|Behavioral|Late Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
45808556|NCT03647306|Behavioral|Extended Overnight Fast|Provide subjects a regimented amount of calories at each meal.
45944900|NCT00086099|Drug|Idarubincin|Idarubincin (12mg/m2) and ara-C(N-18)
45808557|NCT03643939|Device|High Flow Nasal Catheter|"HFNC will deliver through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.~Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize patient´s comfort and SpO2."
45808558|NCT03643939|Device|Noninvasive ventilation|NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 tailored to specific ARF subgroups, according to the protocol. Adjustments of the inspiratory pressure (IPAP) and expiratory pressure (EPAP) and FiO2 according to protocol
45808559|NCT03637660|Drug|Benzathine Penicillin|BPG will be administered as a deep intramuscular injection in the upper, outer quadrant of the buttock.
45808560|NCT03635489|Drug|Paclitaxel|175 mg/m^2 IV infusion on Day 1 of each 21-day cycle.
45808561|NCT03635489|Drug|Bevacizumab|15 mg/kg IV infusion on Day 1 of each 21-day cycle.
45808562|NCT03635489|Drug|Carboplatin|Area Under the Curve (AUC) of 6 mg/ml/min on Day 1 of each 21-day cycle.
45808563|NCT03635489|Drug|Placebo|Placebo matched to bevacizumab IV infusion on Day 1 of each 21-day cycle.
45808564|NCT03634007|Biological|LX1001|LX1001 is a serotype rh.10 AAV gene transfer vector expressing the cDNA coding for human APOE2.
45808565|NCT03633708|Drug|Etelcalcetide|Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling intact parathyroid hormone (iPTH), Ca, and phosphorus and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe
45944901|NCT00327457|Behavioral|Help with physician office and patient management|
45808566|NCT03633617|Drug|Dupilumab|Solution for injection administered subcutaneously
45808567|NCT03633617|Drug|Placebo|Matching placebo
45808568|NCT03631784|Drug|Pembrolizumab 200 mg|Pembrolizumab 200 mg intravenous (IV) infusion on Days 1 of each 3-week cycle for up to 17 cycles
45808569|NCT03631784|Drug|Paclitaxel 45 mg/m^2|Paclitaxel 45 mg/m^2 IV infusion on Days 1, 8, 15 of each 3-week cycle for Cycles 2, and 3 during radiation therapy.
45808570|NCT03631784|Drug|Carboplatin AUC6|Carboplatin AUC6 IV infusion on Day 1 of the 21-day cycle for Cycle 1.
45808571|NCT03631784|Drug|Cisplatin 75 mg/m^2|Cisplatin 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, 3.
45808572|NCT03631784|Drug|Pemetrexed 500 mg/m^2|Pemetrexed 500 mg/m^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, and 3.
45808573|NCT03631784|Radiation|Thoracic Radiation Therapy (TRT)|The target total dose of TRT will be 60 Gy in 30 daily fractions of 2 Gy, prescribed to the planning target volume.
45944902|NCT00327457|Behavioral|Tailored physician recommendation letter|
45944903|NCT00320632|Drug|Desipramine|
45808574|NCT03631784|Drug|Paclitaxel 200 mg/m^2|Paclitaxel 200 mg/m^2 IV infusion on Day 1 of the 21-day cycle of Cycle 1.
45808575|NCT03631784|Drug|Carboplatin AUC2|Carboplatin AUC2 IV infusion on Day 1, 8, 15 for Cycles 2 and 3 during radiation therapy.
45944904|NCT00327496|Biological|DC vaccine|
45944905|NCT00320827|Drug|CS-1008 (humanized anti-DR5 antibody)|
45944906|NCT00320866|Device|syringe driver|
45944907|NCT00320905|Behavioral|Observational|No intervention
45944908|NCT00320983|Drug|Topotecan|Topotecan
45944909|NCT00320983|Drug|Cisplatin|Cisplatin
45808576|NCT03625037|Biological|Epcoritamab|Administered as specified in the treatment arm.
45808577|NCT03618381|Biological|second generation 4-1BBζ EGFR806-EGFRt|Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt
45808578|NCT03618381|Biological|second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG|Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
45808579|NCT03617705|Device|Skyn Monitor Lab Session 1|Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session.
45808580|NCT03617705|Device|Skyn Monitor Field Test with EMA App|After Skyn Monitor Lab Session 1, participants will be instructed to wear Skyn monitor for the rest of the day and the following two weeks. Participants will also enter information on each drinking session during the two week time using a mobile-based ecological momentary assessment (EMA) to collect real-time data in daily life.
45808581|NCT03617705|Device|Skyn Monitor Lab Session 2|Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session. Participant will also complete device acceptability and usability survey.
45808582|NCT03610997|Procedure|Photorefractive keratectomy|
45808583|NCT03607422|Drug|Placebo for Upadacitinib|Tablets taken orally once a day
45808584|NCT03607422|Drug|Upadacitinib|Tablets taken orally once a day
45808585|NCT03604978|Procedure|Biospecimen Collection|Undergo blood sample collection
45808586|NCT03604978|Procedure|Echocardiography|Undergo ECHO
45808587|NCT03604978|Biological|Ipilimumab|Given IV
45808588|NCT03604978|Procedure|Magnetic Resonance Imaging|Undergo brain MRI
45944910|NCT00086177|Drug|8% progesterone vaginal gel|Progesterone 8% Vaginal gel, once daily, maximum duration from 18 07 weeks gestation to 37 0/7 weeks gestation
45944911|NCT00086177|Drug|Placebo Vaginal Gel|Placebo vaginal gel, once daily, maximum duration from 18 07 weeks gestation to 37 0/7 weeks gestation
45944912|NCT05459038|Diagnostic Test|C-Arm Rotational View (CARV)|CARV includes predefined fluoroscopy landmarks of the uninjured side to correct for rotational malalignment of the injured side in which the rotation of the C-Arm Image Intensifier is used
45944913|NCT00321022|Behavioral|Accelerated Diagnostic Protocol Emergency Department Observational Unit|
45944914|NCT05458999|Other|Virtual reality headset during percutaneous coronary intervention|Virtual reality glasses during percutaneous coronary intervention
45944915|NCT00321061|Drug|VRC-HIVDNA016-00, VRC-HIVADV014-00|
45944916|NCT00086216|Drug|Atiprimod|Oral, once a day, 14 days on 14 days off
45944917|NCT00124488|Device|Tomotherapy Treatment Planning|
46002200|NCT04392440|Other|usual care|regular nephrology care
46002201|NCT04381091|Drug|Idebenone 150 MG Oral Tablet|idebenone 900 mg/day
45808589|NCT03604978|Biological|Nivolumab|Given IV
45808590|NCT03604978|Radiation|Stereotactic Radiosurgery|Undergo multi-fraction stereotactic radiosurgery
45808591|NCT03591484|Radiation|Photodynamic therapy|Treatment with Photodynamic therapy. The evaluation of halitosis and the microbiological analysis will be repeated before this step
45657230|NCT04812691|Biological|JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive 1 x 10^8 CAR+T cells (JWCAR029) treatment by intravenous (IV) injection.
45808592|NCT03591484|Device|Treatment with tongue scraper|Treatment with tongue scraper. The evaluation of halitosis and the microbiological analysis will be repeated before this step
45808593|NCT03591484|Procedure|Periodontal treatment|Periodontal treatment will be performed with curettes and ultrassom. The evaluation of halitosis and the microbiological analysis will be repeated before this step
45808594|NCT03591484|Procedure|hygiene procedures for the mucosa and dentures|edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before this step
45808595|NCT03589924|Procedure|Immediate IBBR+TiLoop®Bra|Patients will receive immediate implant reconstruction following mastectomy using TiLoop®Bra
45808596|NCT03589924|Procedure|Immediate-delayed IBBR+TiLoop®Bra|Patients will receive immediate-delayed implant reconstruction following mastectomy using TiLoop®Bra
45808597|NCT03584945|Behavioral|Cognitive Behavioral Therapy|The treatment team will offer a course of up to 12 cognitive behavioral therapy (CBT) (45 minute sessions for 12 to 16 weeks), augmented by medication treatment when clinically indicated based on the clinical treatment standards. Due to Covid, therapy sessions are offered via remote video conference (in clinic sessions made available if clinically indicated). Cognitive-behavioral therapy (CBT) is a treatment based on learning and cognitive theories. CBT for Obsessive-Compulsive Disorder (OCD) involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
45808598|NCT03584945|Other|Community Referral as appropriate|Participants with Obsessive Compulsive Symptoms will be referred to the community for treatment
45808599|NCT03576885|Drug|inhaled nitric oxide|inhaled nitric oxide will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
45808600|NCT03576885|Drug|Placebo|placebo will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
45808601|NCT03576612|Biological|AdV-tk|Given IT
45808602|NCT03576612|Drug|Valacyclovir|Given PO days 1-14; 1-3 days post surgery
45944918|NCT05458882|Behavioral|"living with food allergy educational booklet"|An educational booklet giving information on social and eating out habits as well as reaction rates in food allergy Irish children.
45944919|NCT05458765|Drug|emtricitabine/tenofovir alafenamide|200mg/25mg tablet, once daily dosing for 24 weeks
45944920|NCT05458765|Drug|Emtricitabine / Tenofovir Disoproxil Oral Tablet|200mg/300mg tablet, once daily dosing for 24 weeks
45657231|NCT04792333|Drug|firibastat|Single oral dose of 500 mg administration on Day 1
45657232|NCT04803019|Combination Product|DEB-TACE|"The chemotherapy used in this arm is the Doxorubicin that will be carried into the tumor by Embozene TANDEM® (Boston Scientific) microspheres. TANDEM® embozene microspheres are made of non-resorbable, biocompatible, hydrogel microspheres, subjected to precision calibration and coated with an inorganic perfluorate polymer (Polyzene®-F).~TANDEM® embozene microspheres are available in three different sizes, in 2 ml and 3 ml volumes of product and are supplied in preloaded vials and syringes.The maximum loadable amount on the hydrospheres 50 mg of Doxorubicina for ml. The maximum injectable dose of Doxorubicin for each treatment is 150 mg and therefore the maximum amount of microspheres that can be used for each treatment is 3 ml. The size of microspheres that will be used in this study is up to 100 ± 25 μm."
45808603|NCT03576612|Radiation|Radiation|Undergo RT, 60Gy in 30 daily fractions M-F for 6weeks
45944921|NCT05458687|Other|Chinese herbal medicine decoction、Acupuncture or Laser acupuncture pen treatment、Acupoint Tuina massage、Acupoint application、Nursing/Diet and health education and guidance|"Chinese herbal medicine decoction: prescribed three times a day, seven days a week, and lasts for up to one weeks.~Acupuncture or Laser acupuncture pen treatment: twice a week, once for 20 minutes,up to a total of one week.~Acupoint Tuina massage: once a day for up to 20 minutes each time, for up to a week.~Acupoint application of traditional Chinese herbal medicinal cake: Apply warm navel ointment in our hospital to CV 4 (Guanyuan) point every day, and remove after getting up the next day, seven days a week for up to one week.~Nursing and health education and guidance: teach the patients and their family members the matters needing attention in daily life.~Diet and health education:give personalized Traditional Chinese Medicine diet guidance and recommendations in accordance with Traditional Chinese Medicine physique syndrome."
45944922|NCT00094146|Drug|Sandostatin LAR Depot|
45944923|NCT00086255|Drug|Tiagabine|
45808604|NCT03576612|Drug|Temozolomide|Given PO during RT 75mg/m2 daily during RT Post RT cycle 1: 150mg/m2 days 1-5 150mg/m2 cycle 2-6: days 1-5 (150-200mg/m2)
45808605|NCT03576612|Biological|Nivolumab|day 15 post surgery 240mg IV q2wks x 26 doses , up to 52 weeks
45808606|NCT03576612|Other|Laboratory Biomarker Analysis|correlative studies
45808607|NCT03576105|Combination Product|irrigation /sterile saline|mechanical removal of bacteria with sterile saline
45808608|NCT03576105|Combination Product|Conventional methylene blue as photosensitizer|Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes
45808609|NCT03576105|Combination Product|Methylene blue for oral use as photosensitizer|Irrigation with 0,04mL of photosensitizer(0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes
45808610|NCT03576105|Combination Product|Photodynamic therapy|Red laser for photodynamic therapy (Therapy XT,DMC,Sao Carlos,Sao Paulo,Brazil) Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
45657233|NCT04803019|Device|TAE|"The TAE will be performed with Embozene microspheres (Boston Scientific). Embozene microspheres are spherical particles of hydrogel, precisely calibrated, biocompatible, non-absorbable and coated with a perfluorinated inorganic polymer (Polyzene®-F). This medical device is available in various sizes; in this study, to avoid that the particle size exceeds the one used for the treatment of arm A, it will be possible to use microspheres with dimensions up to 100 μm (range 75 ± 125 μm).~Embozene microspheres are offered in vials containing 1 ml of suspended product in physiological saline solution for apyrogenic sterile transport. The total volume of the Embozene microspheres, including the transport solution, is about 7 ml. To this product it is necessary to add an appropriate amount of non-ionic contrast medium in order to obtain a homogeneous suspension and with good visibility during the injection under fluoroscopy."
45944924|NCT05458570|Other|Breast Cancer positive patients|
45944925|NCT00321178|Drug|SR4 - switch to CR4|switch to oral treatment after 4 weeks SR 'standard' therapy
46075395|NCT00874627|Other|Milk|sublingual administration of milk
45657234|NCT04802785|Drug|Citicoline|Citicoline 500 mg (Vitaae®) per os
45657235|NCT04802785|Drug|Cytochrome C6|Cytochrome10 mg per os
45657236|NCT04802785|Drug|Sodium Chloride Oral Product|Sodium Chloride (NaCl) 2.6 g. per os
45657237|NCT04802785|Drug|Potassium Chloride Oral Product|Potassium Chloride 1.5 g per os
45657238|NCT04802785|Drug|Sodium Citrate Oral Product|Sodium Citrate 2.90 g per os
45657239|NCT04802785|Drug|Dextrose Oral Tablet, Chewable|Dextrose 13.5 g per os
45657240|NCT04802785|Drug|Domperidone Oral Product|Domperidone 1 tablet per os
45657241|NCT04802785|Drug|Simethicone|3-4 capsules per os
45808611|NCT03574038|Device|Transcranial Direct Current Stimulation|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.
45808612|NCT03574038|Other|Sham Stimulation|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the cap and electrodes in place, and sham switch moved but without prolonged delivery of electrical stimulation.
45808613|NCT03568318|Drug|Placebo|Tablets taken orally once a day
45944926|NCT00124527|Drug|Irofulven + capecitabine|
45944927|NCT00086294|Drug|Intravenous Levodopa|
45944928|NCT00086294|Drug|ACP-103|
45944929|NCT05458492|Drug|Sirolimus|"Sirolimus, tablets 2 mg/day with dose adjustment of 1 to 3 mg/day for residual concentrations between 4 and 10 ng/mL~1 dose daily for 16 weeks"
45944930|NCT04717648|Diagnostic Test|Biochemical test|C Reactive protein and sodium
45944931|NCT05458414|Device|Intra-operative Navigation System|In the experimental group，a navigation technology was used to identify tumor margins during the surgery.
45944932|NCT00086333|Drug|SGN-15, Docetaxel|
45944933|NCT00321256|Procedure|human pancreatic islet transplantation|
45453186|NCT05625841|Other|Honey product|Bee products intervention from the first day of radiation to the end of radiation therapy duration 8-12 weeks.
45453187|NCT05625841|Other|propolis|propolis
45453188|NCT05625841|Other|Usual care|Usual care
45657242|NCT04802785|Drug|Acetylsalicylic acid|Acetylsalicylic acid 150 mg per os
45657243|NCT04802785|Drug|Magnesium hydroxide|magnesium hydroxide 30 mg per os
45657244|NCT04802785|Drug|Probiotic Formula|1 capsule per os.
45657245|NCT04802785|Drug|Melatonin 5 mg|Melatonin 5 mg per os.
45657246|NCT04802941|Device|Neoadjuvant Chemotherapy by CDSS (MedicBK)|CDSS (MedicBK) captures the patient-specific data required to determine appropriate care decisions from the EMR and then presents relevant data alongside treatment suggestions to clinicians. MedicBK uses algorithms for presenting treatment suggestions framed by guideline-based therapy and personalized personalized evidence-based therapy. MedicBK consists of three main blocks: database, network meta-analysis, and heterogeneity of treatment effects assessment.
45657247|NCT04802941|Drug|General practice|General practice
45657248|NCT04802317|Diagnostic Test|Identification of the composition of the intestinal microbiota|Identification of the composition of the intestinal microbiota
45657249|NCT02598193|Drug|Nintedanib|Participants with IPF will receive nintedanib at the 200-300 mg/day dose up to 24 weeks.
45657250|NCT02598193|Drug|Pirfenidone|Participants with IPF will receive pirfenidone at 1602-2403 mg/day dose up to 24 weeks.
45808614|NCT03568318|Drug|Upadacitinib|Tablets taken orally once a day
45944934|NCT05458336|Device|Nasal lavages with Tonimer Panthexyl®|At the moment of diagnosis, patients were asked to fill out an ad hoc questionnaire to subjectively evaluate symptoms and comorbidities at the moment of diagnosis and of negativization. Subjects performed a daily nasal swab. When the subjects tested negative for the first time, they had to complete the questionnaire once again. Patients were given nasal washes (Tonimer Panthexyl®) to be performed three times a day, and in any case after nasal swab.
46002202|NCT04379505|Device|Ring gantry kV-CBCT combined with linear accelerator (Halcyon)|-Varian Medical Systems is the manufacturer
46075396|NCT00874627|Other|Milk|placebo
46075397|NCT02786550|Drug|Botulinum Toxin|A total of 7.5U per side of botulinum toxin will be injected to the lateral part of obicularis oculis muscle (3 injections of 2.5 U).
46075398|NCT02786550|Other|Normal Saline|The same amount (3 cc) of Normal saline will be injected to the lateral part of obicularis oculis muscle
46075399|NCT03085212|Behavioral|Stress Free Now|Online stress management program developed by the Cleveland Clinic that uses mindfulness and cognitive-behavioral therapy to help individuals manage their stress.
45657251|NCT04791631|Procedure|Epiretinal membrane surgery|Surgery for epiretinal membrane i.e. standard 3-port pars plana vitrectomy and epiretinal membrane and internal limiting membrane peel. Phakic patients will undergo cataract surgery.
45808615|NCT03568318|Drug|Topical corticosteroids (TCS)|"Topical corticosteroids will be applied in a stepdown regimen, starting with medium potency once daily to areas with active lesions until lesions are clear or almost clear, or for 3 consecutive weeks, whichever is shorter; then low potency topical corticosteroids once daily. If lesions return or persist, this step-down approach will be repeated until lesion resolution or evidence of local or systemic topical corticosteroids toxicity.~Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as low potency topical corticosteroid."
45808616|NCT03550794|Drug|Thiamine Hydrochloride|Thiamine hydrochloride is a water soluble vitamin (vitamin B1). 200mg of thiamine hydrochloride in 50ml 0.9%NACL will be administered twice daily for 3 days.
45808617|NCT03550794|Drug|Placebo|50ml of 0.9% NACL will serve as the placebo
45808618|NCT03539614|Drug|Prazosin|This is an antagonist of the alpha1 receptor for noradrenaline. It is FDA approved for the treatment of hypertension, and has also been used for benign prostatic hypertrophy (BPH). Most recently, it has been found to be helpful for symptoms of PTSD in some but not all participants.
45808619|NCT03539614|Drug|Placebo|This is a capsule containing an inert substance, in order to provide blinding to participants and study staff of when participants are on active medication and when they are not during the later portions of the trial.
45808620|NCT03536572|Behavioral|Sleep Apnea Self-Management Program|Protocol-based sleep apnea and CPAP education and support
45808621|NCT03533673|Biological|ACTUS-101|Adeno-associated virus serotype 8 carrying the human GAA gene under the control of the LSP promoter.
45808622|NCT03532282|Behavioral|ONLINE ONLY|Access to an online cognitive behavioral therapy for insomnia
45808623|NCT03532282|Behavioral|STEPPED CARE|A two step treatment that starts with either an online or therapist led cognitive behavioral therapy for insomnia, depending on a decision algorithm. Those with insufficient progress to the online treatment after 8 weeks are switched to a therapist-led treatment
45808624|NCT03523858|Drug|Ocrelizumab|Ocrelizumab will be administered via intravenous (IV) infusion at an initial dose of two 300-mg infusions separated by 14 days (on Days 1 and 15), and then 600 mg at every subsequent dose every 24 weeks for the remainder of the study treatment period (approximately 192 weeks)
45808625|NCT03519464|Biological|Gardasil 9|Gardasil 9 administered as a 0.5ml intramuscular injection in the deltoid region of the upper arm or in the anterolateral area of the thigh, 3-dose regimen of injections given at month 0, month 2, and month 6.
45808626|NCT03519386|Combination Product|G2-TR intraocular implant containing travoprost|Provided in Arm/Group descriptions.
45808627|NCT03519386|Drug|Sham surgery + active-comparator eye drops|Sham surgery plus postoperative active-comparator eye drops (timolol maleate ophthalmic solution, 0.5%).
45808628|NCT03513302|Dietary Supplement|placebo|2 x 70 mL concentrated beet root juice depleted of nitrate per day for 14 days.
45808629|NCT03513302|Dietary Supplement|nitrate|2 x 70 mL concentrated beet root juice per day for 14 days.
45808630|NCT03506880|Behavioral|MADD Materials|Handbook developed by MADD and the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
45808631|NCT03506880|Behavioral|Surgeon General Materials|Information published by the Surgeon General about teens and drinking
45808632|NCT03506321|Diagnostic Test|chromoendoscopy, high definition white light and narrow band imaging|Chromoendoscopy, high definition white light and narrow band imaging are compared for predicting submucosal invasion within laterally spreading lesions in the colon and determining the presence of residual or recurrent adenoma at the post endoscopic resection scar
45808633|NCT03496181|Behavioral|Multilingual Aphasia Examination|"For patients only prior to MRI scans.~The MAE contains eleven subtests in five categories which may be used to assess both languages in bilinguals and the participant's primary language in monolinguals: Oral Expression, Spelling, Oral Verbal Understanding, Reading, and Rating Scales. Subtests are scored for accuracy of individual items on a three-point scoring system (0, 1, 2). Contained within these domains are The Token Test, Aural Comprehension of Words and Phrases and Visual Naming which naturally parallel fMRI and direct cortical stimulation behavioral assays already in place for clinical use (phonemic fluency, auditory responsive naming and confrontation naming respectively). The MAE is expected to take under 50 minutes."
45808634|NCT03496181|Diagnostic Test|Language paradigms + RS fMRI|10 monolingual patients: 2 language paradigms + RS fMRI = 7x3 = 21 minutes 10 early bilingual patients: 2 language paradigms+ RS fMRI = 7x3 = 21 minutes 10 late bilingual patients: 2 language paradigms+ RS fMRI = 7x3 = 21 minutes
45676334|NCT03887481|Device|"High-definition active tDCS (HD-tDCS) + Repeat After Me (RAM) Treatment"|"Device: Active HD-tDCS & Repeat After Me (RAM) Treatment~Stimulation will be delivered by a battery-driven constant current stimulator. Electrical current will be administered to left supramarginal gyrus (L_SMG). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.~Participants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay."
45808635|NCT03496181|Diagnostic Test|Language paradigms + RS fMRI + one anatomical sequence|"10 monolingual English volunteers: 2 task language paradigms* + 1 Resting State fMRI + one anatomical sequence for a total of approximately 25 minutes.~10 late bilingual volunteers: 4 language paradigms (2 English + 2 Spanish) + 1 Resting State fMRI + one anatomical sequence for a total of approximately 39 minutes.~10 early bilingual volunteers: 4 language paradigms (2 English + 2 Spanish) + 1 Resting State fMRI + one anatomical sequence for a total of approximately 39 minutes."
45808636|NCT03495713|Drug|Nivolumab|Nivolumab 3 mg/kg will be administered on day 1 (pre-response assessment week 0) and on day 1 and continued per standard of care and institutional practices. A
45808637|NCT03491059|Drug|C-11 labeled nicotine|Participants will vape with e-cigarettes radio-labeled with C-11 nicotine.
45808638|NCT03491059|Radiation|PET/CT imaging|After vaping with radio-labeled e-cigarettes, participants will be PET/CT imaged.
45944935|NCT05458180|Drug|Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)|"Drug: Liposomal mitoxantrone hydrochloride (15 mg/m2, 18 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.~Drug: Etoposide (60 mg/ m2) will be administered by an intravenous infusion on day 1-3 of each 21-day cycle.~Drug: Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle."
45657252|NCT04791397|Procedure|Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.|Every patient from control group undergo 15 procedures of IHHT, 5 procedures per week for 3 weeks, 1 procedure lasts 40 minutes. IHHT is a protocol which employs passive (the patient is at rest), short (several minutes) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia, and repeated for 40 minutes. During the initial pretreatment test, the patient inhales air with low oxygen content at atmospheric pressure in a continuous mode through a mask. In the interval therapeutic mode that follows, periods of hypoxia (10-14% O2) are interrupted by periods of reoxygenation by hyperoxia (up to 35% O2). Automatic switching of gas flows (SRT technology). Built-in intelligent software automatically identifies and suggests key treatment parameters for the individual treatment program, by adjusting the starting parameters based upon the results of the pretreatment hypoxic test.
45657253|NCT04791397|Procedure|Simulating Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.|Every patient from group control undergo simulating procedures of interval hypoxic-hyperoxic training, 15 procedures, 5 procedures per week for 3 weeks. 1 procedure lasts 40 minutes, in normoxia. Before the start of the course, each patient undergoes a test procedure for 10 minute (in normoxia) for simulate procedures IHHT.
45808639|NCT03485209|Drug|tisotumab vedotin|Given into the vein (IV; intravenously)
45808640|NCT03485209|Drug|pembrolizumab|200mg or 400mg given by IV
45808641|NCT03485209|Drug|carboplatin|AUC 5mg/mL per minute or AUC 3.3mg/mL per minute given by IV
45808642|NCT03485209|Drug|cisplatin|100mg/m^2 given by IV
45808643|NCT03473795|Behavioral|Questionnaire forms|The questionnaires will include information such as socio-demographic data, risk factors, disease specific data, investigation and treatment details as well as findings during followup. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality.
45808644|NCT03473795|Other|Bio-specimen samples|Samples can include tissue, blood, urine, saliva, hair and nail clipping.
45808645|NCT03467516|Biological|Tumor Infiltrating Lymphocytes (TIL)|TIL infusion intravenously through a central vein catheter over 20-30 minutes. Folowed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
45808646|NCT03459846|Drug|Durvalumab|Durvalumab 1500 mg IV q4w
45944936|NCT00321295|Device|Atrial synchronous bi-ventricular pacing|
45944937|NCT00419653|Drug|Amisulpride|
45944938|NCT00419653|Drug|Olanzapine|
45944939|NCT00419653|Drug|Haloperidol|
45808647|NCT03459846|Drug|Olaparib|Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance.
45808648|NCT03459846|Drug|Placebo|Matching placebo for oral tablet BID
45808649|NCT03456895|Other|Light perception|We will be using Wi-Fi/IP programmable LED lighting systems that will replace conventional lighting systems and may be in canned lights, spot lights, light chains or table lights. These lighting systems can be fully controlled by web based applications on smart phones tablets and computer systems and can be combined with input systems such as switches, motion detection or voice activated. Differences in lighting perception will be explored by varying lighting color and brightness.
45453189|NCT01101217|Drug|Zinc Supplement|in 50 patients zinc sulfate 220 mg per day orally for 6 weeks
45453190|NCT01101217|Drug|placebo|placebo daily for 6 weeks
45808650|NCT03456895|Other|Sound perception|We will be using Wi-Fi/Bluetooth addressable sound systems that will be linked with sound sources such as media players on smart devices or computer systems. Differences in sound perception will be explored by varying sound types (i.e. different music types, ambient noise, etc.).
45808651|NCT03456895|Other|Smell perception|We will explore the use of consumer grade ventilation systems that can be equipped to distribute packaged scents. Differences in smell perception will be explored by varying the types of scents.
45808652|NCT03456895|Other|Vibration perception|We will explore the use of chairs or blankets that enable subjects to perceive vibrations. An initial implementation will be the use of on relaxing/massage chair that enables the experience of vibration sensation in the back or leg area. We may use also potentially vibration blankets in the arm or neck area. Differences in vibration perception will be explored by varying the location, frequency, etc. of vibrations with the subject being placed in a chair on an imaging table/bed.
45944940|NCT00094341|Drug|Etanercept|
45944941|NCT00321334|Procedure|Chemotherapy+Surgery|Docetaxel:75mg/m2 on D1 cycle,3 cycles Carboplatin:AUC=5 on D1 cycle,3 cycles
45944942|NCT00086489|Drug|CP-675,206|pts treated at 10 mg/kg dose level on a monthly regimen
45944943|NCT00086489|Drug|CP-675,206|pts treated at 15 mg/kg dose level on a quarterly regimen
45944944|NCT00321451|Behavioral|Cognitive behavioral therapy for insomnia|4 biweekly outpatient sessions with sleep psychologist
45657254|NCT04802239|Other|Medical hypnosis group|"Hypnotic induction is performed according to a standard protocol and identical for all.~A script will be written to give all the important steps. .Only the pleasant place and the characteristics of the analgesic glove will be different between the subjects .the procedure will follow the following protocol:~State of calm at rest of 3 minutes.~Hypnotic induction by catalepsy of the eyes guided by breathing.~The hypnosis session takes place in safety place , with glove protect by dissociation and confusion techniques."
45808653|NCT03456895|Other|Voice activation|We will explore the use and linkage of voice activation system such as Amazon Echo, Google home or similar devices. Some participants may be asked to use voice activations to verbally select and/or change the environmental settings according to their preferences. We are evaluating the feasibility of voice activation with the imaging environment.
45808654|NCT03456102|Drug|Pravastatin|"Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.~A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated."
45808655|NCT03451448|Diagnostic Test|PET/MRI|PET/MRI with USPIO contrast
45808656|NCT03451448|Diagnostic Test|MRI|MRI with USPIO contrast
45808657|NCT03448666|Combination Product|Pembrolizumab|Electrochemotherapy will be performed with the CLINIPORATOR™ after the first treatment of Pembrolizumab
45808658|NCT03442738|Procedure|Endocuff group|Endocuff Vision cap on Standard colonoscope
45808659|NCT03440398|Procedure|Robotic NSM|Surgical technique conducted using robot to perform nipple sparing mastectomy and breast reconstruction
45808660|NCT03440398|Procedure|Open NSM|Open nipple-sparing mastectomy and immediate breast reconstruction with implant
45808661|NCT03440385|Drug|Ozanimod|Specified dose on specified days
45808662|NCT03440385|Other|Placebo|Specified dose on specified days
45808663|NCT03439865|Drug|Ivacaftor|150 mg tablet PO BID x 14 days
45808664|NCT03439865|Drug|standard of care treatment|topical nasal steroid spray and culture-directed antibiotics x 14 days
45808665|NCT03436654|Drug|Apalutamide|240mg daily orally
45808666|NCT03436654|Drug|Abiraterone Acetate|1000mg daily orally
45808667|NCT03436654|Drug|Prednisone|5mg BID orally
45657255|NCT04802239|Other|calm wake group|healthy volunteers will observe 3 minutes calm waking state before standardized thermal harmful stimulation
45657256|NCT04802551|Other|Sensory integration therapy|Sensory integration disorder is defined as the inability of a person to use the information he / she receives through his / her senses properly in order to continue his daily life properly. Intervention group have some therapy sessions which include sensory integration therapy exercises.
45808668|NCT03436654|Procedure|Radical Prostatectomy|A laparoscopic, robotic-assisted, or open approach to RP is permitted at the discretion of the operating surgeon.
45808669|NCT03436654|Procedure|Extended Pelvic lymphadenectomy|To be performed concurrently with prostatectomy. Bilateral pelvic lymphadenectomy should include complete removal of all pelvic lymph nodes within the broad template described and includes the external iliac, hypogastric, obturator, and pre-sacral lymph nodes
45808670|NCT03436654|Drug|GnRH agonist/antagonist|Physician's choice, for a total duration not to extend beyond the treatment phase of the protocol or 10 months from the start of investigational agent(s)
45808671|NCT03436654|Radiation|Stereotactic Body Radiation Therapy|Subjects undergo SBRT in cycle 4, then salvage radiation therapy in cycles 7-8. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity
45808672|NCT03429582|Device|Standard C02 Cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
45808673|NCT03429582|Device|Single Tip Thermoablation|Thermoablator outfitted with a 19mm conical tip
45808674|NCT03429582|Device|Multiple Tip Thermoablation|Thermoablator outfitted with detachable probes
45808675|NCT03427346|Procedure|Endoscopic mucosal resection|Endoscopic resection is carried out using a double-channel scope. The lesion borders are marked with a coagulator. Saline liquid and sometimes epinephrine are injected into the submucosal layer to swell the area containing the lesion and elucidate the markings. The resected mucosa is lifted, then trapped and strangulated with a snare, and subsequently resected by electrocautery. Another method of EMR employs the use of a clear cap and prelooped snare inside the cap. After insertion, the cap is placed on the lesion and the mucosa containing the lesion is drawn up inside the cap by aspiration. The mucosa is caught by the snare and strangulated, and finally resected by electrocautery.
45808676|NCT03427346|Procedure|Endoscopic submucosal dissection|After circumferential cutting of the surrounding mucosa of the lesion, fluid is injected into the submucosa to elevate the lesion from the muscle layer, and the connective tissue of the submucosa beneath the lesion is dissected subsequently.
45808677|NCT03427125|Drug|Tenapanor|Active Drug
45808678|NCT03427125|Drug|Placebo|Inactive Drug
45808679|NCT03427125|Drug|Sevelamer Carbonate|Active control
45808680|NCT03422302|Device|Biphasic Positive Airway Pressure|Receive BiPAP
45808681|NCT03422302|Procedure|Computed Tomography|Undergo CT simulation scans
45808682|NCT03422302|Procedure|Continuous Positive Airway Pressure|Receive CPAP
45808683|NCT03422302|Procedure|Deep Inspiration Breath Hold|Complete DIBH
45808684|NCT03422302|Radiation|Radiation Therapy Treatment Planning and Simulation|Undergo CT simulation scans
45808685|NCT03422302|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45808686|NCT03420274|Behavioral|NEST|This is a point-of-care shared decision-making instrument.
45808687|NCT03420274|Behavioral|Usual care|This group will utilize usual care with respect to healthcare provider practice for education and counseling.
45944945|NCT00321451|Behavioral|Pseudo-desensitization procedure|4 biweekly outpatient visits with sleep psychologist
45944946|NCT00321451|Other|Usual care|3 outpatient visits with study physician
45944947|NCT00094380|Drug|CTLA4-IgG4m (RG2077)|
45657257|NCT02595073|Drug|DSXS|Active treatment
45657258|NCT02595073|Drug|Placebo|Placebo treatment
45808688|NCT03419637|Other|Mobile app|The mobile app, or app, is installed on the patient's mobile device and is used to document the surgical procedure with before and after photographs, including pre- and post-surgery diagnosis. The app allows patients to view a skin history summary report and a reference on their skin ﬁndings and procedures.
45808689|NCT03414463|Behavioral|TREAT|A 4-week one-to-one intervention between the clinical RA (cRA) and participant. Comprised of eight sessions, it involves psycho-educational lessons and skill-building exercises to achieve objectives based on the characteristics of alexithymia.
45657259|NCT04791007|Drug|OB-002|vaginal or rectal administration
45808690|NCT03412773|Drug|Tislelizumab|200 mg once every 3 weeks (Q3W), intravenous dosing (IV)
45808691|NCT03412773|Drug|Sorafenib|400 mg twice daily (BID), oral dosing
45808692|NCT03409692|Diagnostic Test|Gene Expression Profiling|SkylineDx has previously developed the MMprofiler, a microarray-based diagnostic test that can subtype MM patients and reliably predict MM patient survival (prognosis). In this project, the test's clinical value will be expanded to include the prediction of treatment effectiveness in individual patients based on Gene Expression Profiling.
45808693|NCT03393884|Biological|GEN-1|IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
45808694|NCT03393884|Drug|Carboplatin|AUC 6 IV over 1 hour on Day 1 of each cycle
45944948|NCT00094380|Drug|Cyclophosphamide|
45944949|NCT00321490|Drug|Quetiapine fumarate|
45808695|NCT03393884|Drug|Paclitaxel|175 mg/m2 IV over 3 hours on Day 1 of each cycle
45808696|NCT03377296|Other|Plasmodium vivax infection|Two healthy human volunteers are exposed to the bites of five infectious mosquitoes per participant (by placing their forearms over the pot containing mosquitoes) for 5-10 minutes. Fed mosquitoes (as indicated by the presence of a blood meal in the abdomen) are individually dissected and assessed for sporozoite load (graded 0 to +4; a gland rating of +2 or more, representing 10 or more observed sporozoites, qualifies as being infectious). If, by this method the volunteer is found to have been inoculated by less than five infected mosquitoes, further mosquitoes are allowed to feed on the volunteer until a total of 5 appropriately infected mosquitoes have fed. The bite-challenge procedure continues until the subject has been bitten by 5 infectious mosquitoes.
45657260|NCT04791007|Drug|Placebo|vaginal or rectal administration
45808697|NCT03377296|Procedure|Collection of 250mL blood from each volunteer (N=2)|Collection of 250mL of P. vivax-infected blood from each volunteer when a threshold parasitaemia/ symptoms are met
45808698|NCT03371706|Behavioral|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
45944950|NCT00321490|Drug|Duloxetine|
45944951|NCT00086528|Drug|XL647|Administered orally as a solution with mass-based dosing in early cohorts or as 50-mg tablets at a fixed dose at the MTD. A minimum of 3 subjects was planned for each dosing cohort with dose escalation dependent on subject tolerance of the prior dose. During the Treatment Period, subjects in each cohort were administered a single dose of XL647 on Day 1 followed by a 72-hour period of observation. If there were no XL647-related dose limiting toxicities, subjects received 5 daily doses of XL647 on Days 4-8. Twenty-one days after the initial dose, in the absence of unacceptable toxicity or disease progression, subjects could enter a Treatment Extension Period that consisted of repeated 2-week cycles of five oral doses of XL647 followed by a 9-day observation period.
45944952|NCT05457829|Drug|Doxorubicin Hydrochloride Liposome+Irinotecan|Q3W, 2 cycles.
45944953|NCT05457829|Drug|Temozolomide+Irinotecan+Vincristine|Q3W, 2 cycles.
45944954|NCT00321529|Device|motion analysis by durometer|
45944955|NCT05457751|Procedure|Rocuronium injection pain|1: no reaction, 2: movement only in the ankle, 3: movement or withdrawal only in the arm (shoulder and ankle), 4: diffuse reaction (movement or withdrawal in more than one extremity, coughing and holding breath
45944956|NCT00086606|Drug|Xolair (omalizumab)|
45657261|NCT04802083|Biological|Eculizumab|Eculizumab 900-1200 mg will be administered intravenously.
45657262|NCT02593825|Behavioral|START-Play intervention|The START-Play group is a perceptual-motor approach, which uses self-initiated goal-directed movements to bolster orienting and attending to objects, while understanding basic relationships of cause and effect through manipulation and focused attention. Generally, activities focus on helping the child attend to significant environmental information, which can be correlated to forces useful for controlling posture and movement. Unlike passive movement therapy, the investigator's approach encourages activity and learning to solve problems linked by movement and manipulation of objects, which then scaffold cognitive skill.
45657263|NCT02593825|Behavioral|Business as usual|May include active or passive movement, parent training, positioning, equipment modification, training other team members, functional skill training
45657264|NCT05616949|Behavioral|Treatment as Usual (TAU) (Arm 1)|Treatment as Usual (TAU): The treatment and/or other services received as part of usual care while living in a recovery residence. This arm serves as the active comparator group for the study.
45808699|NCT03371706|Behavioral|Evidence-Based Impairment Focused|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
45808700|NCT03362177|Biological|Romiplostim|This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of gastrointestinal/colorectal/pancreatic cancer.
45808701|NCT03362177|Other|Placebo|Placebo Comparator
45808702|NCT03360708|Other|Laboratory Biomarker Analysis|Correlative studies
45808703|NCT03360708|Biological|Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Given ID
45944957|NCT05457712|Dietary Supplement|protocol|The energy and protein value of the prescribed diet will be followed according to the original protocol considering plans A, B or C, via a hypercaloric formula with a caloric density of 1kcal/ml for infants starting 60 days preoperatively. The return for nutritional monitoring will take place after evaluation: weekly, biweekly or monthly.
45944958|NCT05457712|Other|Control|Afterwards, they will be evaluated through the standard nutritional protocol of the nutrition clinic of the Instituto de Cardiologia de and Hospital Santo Antonio de Porto Alegre, whose standard nutritional prescription is a polymeric formula with a caloric density of 0.67 kcal/ml. Nutritional monitoring will take place through telephone contact for information on the baby's clinical data and in person before the surgery is performed.
45944959|NCT00124566|Drug|Irofulven|Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.45 mg/kg on Days 1 and 8 every 3 weeks.
45944960|NCT00124566|Drug|Prednisone|Subjects will also receive oral prednisone at a dose of 10 mg per day in the morning.
45944961|NCT00124566|Drug|Mitoxantrone|Subjects will receive mitoxantrone in an intravenous (IV) infusion (5 to 15 minutes) at a dose of 12 mg/m^2 per day, once every 3 weeks.
46075400|NCT05139511|Device|Study group|The IPL therapy consists in a polychromatic pulses of light not coherent and not collimated. The therapy leads to a series of processes such as the destruction of superficial blood vessels and thus the reduction of local inflammation, the liquefy of the meibum and an antimicrobial, anti-inflammatory and antioxidant effects. The therapy is performed over the cheeks, nose and upper eyelids.
45944962|NCT00124566|Drug|Capecitabine|Subjects will receive oral capecitabine at a dose of 1000 mg/m^2 twice daily for 15 days every 28 days.
46075401|NCT05139511|Other|Control group|Same procedure but without energy
46075402|NCT05258058|Behavioral|Memory and Adaptation Training-Geriatrics|MAAT-G is a cognitive behavioral therapy-based intervention comprised of 10 workshop sessions as well as a participant workbook. The workshop sessions are delivered one on one by a health professional via videoconferencing technology.
45657265|NCT05616949|Behavioral|Peer Recovery Support Services (PRSS) + TAU (experimental- Arm 2)|Peer Recovery Support Services (PRSS) Intervention: The experimental group for this study that involves the implementation of the PRSS intervention. This study will test the preliminary efficacy of the PRSS intervention on Medications for Opioid Use Disorder (MOUD) retention by evenly randomizing N=50 individuals on MOUD living in recovery residences (RRs) to either a 24-week course of the experimental PRSS intervention layered on top of treatment as usual services
45944963|NCT00124566|Drug|Irofulven|Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.4 mg/kg on Days 1 and 15 every 4 weeks.
45944964|NCT05457634|Other|Combustible Cigarette|Subjects smoke their Usual Brand Combustible Cigarette, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
45808704|NCT03359863|Drug|Pirfenidone|Subjects will receive pirfenidone for 52 weeks, titrated to 2403 mg/day (3 capsules, 3× daily) after a 4-week titration period (1 capsule, 3x daily for 2 weeks, 2 capsules, 3x daily for 2 weeks) for a total of 56 weeks of pirfenidone. Eligible participants will continue pirfenidone beyond 56 weeks.
45808705|NCT03353688|Device|Boston Scientific Vercise PC IPG with directional DBS lead|Deep brain stimulation
45808706|NCT03341273|Drug|Azithromycin|Azithromycin is an azalide antibiotic and is derived from erythromycin used to treat many different types of infections caused by bacteria, such as respiratory infections.
45808707|NCT03341273|Other|Placebo|Placebo will be a matching capsule the same size, weight, and color as the capsules containing Azithromycin tablets.
45808708|NCT03341273|Device|VIDAS B.R.A.H.M.S Procalcitonin Test (PCT)|The VIDAS B.R.A.H.M.S PCT is an automated test for use on the VIDAS instruments for the determination of human procalcitonin in human serum or plasma using the Enzyme-Linked Fluorescent Assay (ELFA) technique.
45808709|NCT03334617|Drug|Durvalumab|Durvalumab given IV at 1500 mg Q4W ±2 days
45944965|NCT05457634|Other|blu Disposable A|Subjects use the blu disposable e-cigarette with flavor A, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
45944966|NCT05457634|Other|blu Disposable B|Subjects use the blu disposable e-cigarette with flavor B, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
46075403|NCT02784054|Drug|Carboplatin|
46075404|NCT02784054|Drug|Etoposide|
45453191|NCT03951259|Drug|SM934|In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.
45453192|NCT03951259|Drug|Placebos|The placebo pills are made identical to the investigating SM934 in appearance.
45458071|NCT02309632|Other|Pancreatic Cancer Screening Pathway 1|Screening with imaging and biomarker testing
45808710|NCT03334617|Drug|AZD9150|AZD9150 given IV at 200mg every other day of a 1-week lead-in period followed by QW
45808711|NCT03334617|Drug|AZD6738|AZD6738 given orally at 240mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
45808712|NCT03334617|Drug|Vistusertib|Vistusertib (AZD2014) given orally at a dose of 125 mg BD on an intermittent dosing schedule of 2 days on, 5 days off
45808713|NCT03334617|Drug|Olaparib|Olaparib (AZD2281) given orally at 300 mg BD
45944967|NCT05457634|Other|blu Disposable C|Subjects use the blu disposable e-cigarette with flavor C, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
46075405|NCT02784054|Drug|Cyclophosphamide|
46075406|NCT02784054|Drug|Bleomycin|
46075407|NCT02784054|Drug|Thiotepa|
46075408|NCT02784054|Drug|Melphalan|
46075409|NCT02784054|Radiation|Reduced dose radiotherapy|
45657266|NCT04790929|Device|Muse|Interaxon markets a head-worn EEG biofeedback device ('Muse') to encourage and aid effective meditation and sleep. This device has been previously shown to improve workplace wellness, fatigue and quality of life, and performance on the Stroop Task. It has also been shown to improve physiological markers associated with improved relaxation. Muse has been shown to have an EEG signal comparable to a clinical grade EEG.
45808714|NCT03334617|Drug|Oleclumab|Oleclumab given at dose level 1 for 2 cycles and then dose level 2 thereafter
45808715|NCT03334617|Drug|trastuzumab deruxtecan|Durvalumab given IV at 1120mg Q3W ±2 days for Module 6 only & trastuzumab deruxtecan given at 5.4 mg/kg via IV infusion Q3W ±2 days
45944968|NCT05457634|Other|blu Disposable D|Subjects use the blu disposable e-cigarette with flavor D, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
45944969|NCT05457634|Other|blu Disposable E|Subjects use the blu disposable e-cigarette with flavor E, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
45808716|NCT03334617|Drug|cediranib|cediranib given orally at 20 mg tablets on an intermittent schedule (5 days on, 2 days off), starting on C1D1
45944970|NCT00321724|Drug|cediranib maleate|Given orally
45944971|NCT00321724|Other|laboratory biomarker analysis|Correlative studies
45944972|NCT00086645|Drug|citalopram hydrobromide|10mg/5ml solution
45657267|NCT04790929|Behavioral|Meditation Coaching|Participants will be asked to use the Muse Meditation system for a minimum of 5 minutes a day (in one or multiple sessions), a minimum of 5 days a week, for 6 weeks and will be coached in how to do so. Coaches will be versed in Mindfulness and how to use Muse. Coaching will take place virtually using Interaxon's Zoom account.
45808717|NCT03334617|Drug|AZD6738 (ceralasertib)|AZD6738 given at 240 mg twice daily for 14 days on treatment in each 28-day cycle, between Days 1 and 14.
45808718|NCT03334617|Drug|AZD6738 (ceralasertib)|AZD6738 given orally at 240mg twice daily for 14 days in each 28 day cycle (starting from Cycle 1) between Days 15-28
45808719|NCT03334617|Drug|AZD6738 (ceralasertib) (240 mg or 160 mg)|AZD6738 given orally at 240mg or 160mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
45808720|NCT03334617|Drug|AZD6738 (ceralasertib) 7 days monotherapy|AZD6738 given orally at 240 mg twice daily for 7 days on Day 1-7 in each 28 day cycle
45808721|NCT03332797|Drug|GDC-9545|GDC-9545 will be administered orally, once daily, on Days 1-28 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
45657268|NCT04802005|Other|Aerobic Interval Training|The aerobic interval training group
45657269|NCT04801303|Drug|Calcitriol|Administration of Calcitrol 0.25mcg/24h for a year in Friedreich's Ataxia patients (n=20)
45944973|NCT00086645|Other|placebo|up to equivalent of 20 mg of active comparator daily
45944974|NCT00321802|Drug|Simvastatin|Patients take 40 mg of simvastatin per day for 6 months.
45944975|NCT00321802|Drug|Placebo|Placebo
45944976|NCT00321880|Procedure|therapeutic touch|administration of healing touch in 30 minute sessions
45944977|NCT00321997|Drug|Pegaptanib sodium|
45657270|NCT04801303|Other|Blood analysis for frataxin's level measurement|"Five blood analysis in Friedreich's Ataxia patients: before starting the treatment, and after fifteen days, 4 months, 8 months and 12 months of the treatment.~To validate the Frataxin's levels measurement, a blood analysis will also be done in two kind of controls for every Friedreich's Ataxia patient, only once at the beginning of the trial.~The control groups will be composed by:~Heterozygous Ataxia's Friedreich controls (a close relative of the patient, either a heterozygous sibling or one of the parents)~Age- and gender-matched controls (supposedly non-heterozygous)."
45808722|NCT03332797|Drug|Palbociclib|Palbociclib will be administered orally, once daily, at the label-recommended dose of 125 mg on Days 1-21 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
45944978|NCT00124605|Drug|pamidronate disodium|Given IV
45944979|NCT00124605|Drug|arsenic trioxide|Given IV
45944980|NCT00124605|Other|laboratory biomarker analysis|Correlative studies
45944981|NCT00124605|Other|pharmacological study|Correlative studies
45944982|NCT02959528|Other|Working memory training|n-back training program
45944983|NCT02959528|Other|perceptual training|visual-perceptual training program
45808723|NCT03332797|Drug|LHRH Agonist|The LHRH agonist will be administered by injection once every 4 weeks on Day 1 of each 28-day cycle, according to the label. The investigator will choose the appropriate LHRH agonist approved for use in breast cancer.
45808724|NCT03330691|Biological|Patient-derived CD19- and CD22 specific CAR|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
45808725|NCT03327792|Drug|Mavoglurant|200 mg Mavoglurant
45808726|NCT03327792|Drug|Placebo|Placebo
45944984|NCT00400127|Device|Silesian suspension belt|
45944985|NCT05457361|Drug|VEN combined with azacitidine plus homoharringtonine|VEN begins at 100 mg on day 1 and increases stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, 400 mg); dosing is continued at 400 mg per day from day 4 through day 14; azacitidine (75 mg/m²) is administered subcutaneously on days 1-7, and HHT (1 mg/m²) on days 1-7.
45944986|NCT05457361|Drug|VEN combined with azacitidine|The use of VEN is just the same as it dose in VAH regimen except lasting for 28 days. The use of azacitidine is exactly the same as VAH group does.
45944987|NCT05456854|Diagnostic Test|Hyperglycemic Clamp|Administration of a hyperglycemic clamp
45944988|NCT05456854|Drug|Kisspeptin-10|Administration of kisspeptin-10 * 16 hr
45944989|NCT05456854|Drug|Placebo|Administration of placebo *16 hr
45657271|NCT04801303|Diagnostic Test|Blood analysis for hypercalcemia's control|Five blood analysis in Friedreich's Ataxia patients for monitoring the hypercalcemia risk (with measurement of Calcium, D Vitamin, renal function, albumin, protein, phosphate, sodium and potassium) Before starting the treatment, and after fifteen days, at 4 months, 8 months and 12 months of the treatment.
45808727|NCT03325062|Behavioral|MOVE|The MOVE program emphasizes movement pattern retraining in conjunction with contemporary rehabilitation. More specifically, the MOVE program promotes symmetry in functional knee motion and loading without postural compensation. Intervention uses pressure-sensing shoe insoles to deliver real-time visual biofeedback during activity performance.
45808728|NCT03325062|Behavioral|Control|The contemporary progressive rehabilitation program consists of progressive resistive exercise to key lower extremity muscle groups, knee range of motion exercise, weight-bearing exercise, as well as education on symptom management strategies.
45808729|NCT03319901|Drug|Venetoclax|"Venetoclax is an inhibitor of Bcl-2. Bcl-2 is critical for keeping cancer cells alive.~By inhibiting Bcl-2, venetoclax promotes cancer cell death."
45808730|NCT03319901|Drug|Standard Chemotherapy|Standard treatment of chemotherapy is administered
45808731|NCT03307785|Drug|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
45808732|NCT03307785|Drug|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
45808733|NCT03307785|Drug|Carboplatin-Paclitaxel|Carboplatin in combination with paclitaxel is a chemotherapy treatment that has been shown to be efficacious against a variety of different tumor types, including non-small cell lung cancer [NSCLC], ovarian cancer, endometrial cancer, and head and neck cancer.
45808734|NCT03307785|Drug|Bevacizumab|Bevacizumab is a chemotherapy treatment that has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. Bevacizumab is in the angiogenesis inhibitor and monoclonal antibody families of medication. It works by slowing the growth of new blood vessels.
45808735|NCT03307785|Drug|TSR-022|"TSR-022 is a monoclonal antibody against TIM-3 (also called HAVCR2), an immune checkpoint receptor. Immune checkpoint proteins are molecules that help to regulate the immune system so it does not mistakenly attack healthy cells. However, they can also keep immune cells from recognizing and killing cancer cells.~TIM-3 is found on the surface of certain T-cells, including tumor-infiltrating T-cells, that have left the bloodstream and migrated into the tumor environment. By binding to and blocking TIM-3, TRS-022 allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce their growth."
45808736|NCT03307785|Drug|Carboplatin-Pemetrexed|Pemetrexed and platinum therapy in combination with pembrolizumab (anti-PD-1 antibody) has proven to be efficacious in a first line setting for nonsquamous NSCLC patients
45808737|NCT03307785|Drug|Carboplatin-Nab-Paclitaxel|Nab-paclitaxel is a formulation of paclitaxel that is indicated for locally advanced or metastatic NSCLC, as first-line treatment in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. Nab-paclitaxel has shown increased ORR and time to progression in metastatic breast cancer compared with solvent-based paclitaxel and has shown antitumor activity and improved ORR compared with solvent-based paclitaxel as first-line therapy in patients with NSCLC.
45808738|NCT03301766|Drug|lidocaine 5% patch|transdermal patch
45808739|NCT03301766|Drug|standard therapy|Drugs prescribed at the discretion of the treating physician (acetaminophen, NSAIDs, muscle relaxants, etc)
45808740|NCT03301766|Drug|Non-medicated patch|non-medicated patch
45808741|NCT03296085|Procedure|Exam for quantity of edema|There is no intervention
45808742|NCT03284710|Biological|ALVAC-HIV (vCP2438)|Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane (TM) anchor sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain); formulated as a lyophilized vaccine for injection at a viral titer ≥ 1 × 10^6 cell culture infectious dose (CCID)50 and < 1 × 10^8 CCID50 (nominal dose of 10^7 CCID50) and reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose
45808743|NCT03284710|Biological|Bivalent Subtype C gp120/MF59|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion); delivered as a 0.5 mL IM injection
45808744|NCT03284710|Biological|Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, admixed with Aluminum Hydroxide Suspension (~625 mcg aluminum content); delivered as a 0.5 mL IM injection
45657272|NCT04790383|Other|Advanced Self-Adhesive resin composite hybrid restorations (Surefil one (Dentsply Sirona)).|Hybrid resin composite that doesn't need bonding system and releases calcium and flouride.
45657273|NCT04790383|Other|Conventional resin composite restoration. (Sphere Tec, (Dentsply Sirona|Conventional Nanohybrid resin composite
45808745|NCT03284710|Biological|Bivalent Subtype C gp120|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with sodium chloride for injection, 0.9%; delivered as a 0.5 mL IM injection
45808746|NCT03276793|Other|MRI scan|Patients will undergo an MRI scan
45944990|NCT05456386|Behavioral|The Circadian Rhythm Approach to Weight Loss (CRAWL)|The Circadian Rhythm Approach to Weight Loss (CRAWL) is a behavioral intervention that is designed to provide support for behavioral change to improve sleep and feeding parameters that will lead to sustainable weight loss.
45944991|NCT00086801|Drug|doxorubicin hydrochloride|given IV
45944992|NCT00086801|Drug|gemcitabine hydrochloride|given IV
45657274|NCT04790461|Other|Pre-post test|Adult Caregiver Quality of Life Questionnaire (AC-QoL) Perceived Stress Scale (PSS) The Stress Coping Styles Questionnaire (SCSQ)
45657275|NCT04790461|Behavioral|face-to-face training + PMR exercise|4 weeks Roy adaptation-based face-to-face training + PMR exercises to be taught, 4 weeks exercise counseling
45657276|NCT04790461|Behavioral|mobile health education + PMR exercise|To provide awareness and exercise with 8 weeks Roy adaptation model-based training and mobile application access with PMR exercise content
45657277|NCT04790461|Behavioral|face-to-face and mobile health education + PMR exercise|4 weeks face-to-face training based on Roy adaptation model + teaching PMR exercises and 4 weeks based training on Roy adaptation model and mobile application access with PMR exercise content
45657278|NCT04801615|Other|Surgery|All patients in the database undergo surgery due to a suspicion of necrotizing soft tissue infections
45808747|NCT03276793|Behavioral|Behavioral testing|Patients will complete a series of cognitive tasks
45808748|NCT03266640|Drug|viral specific cytotoxic t-lymphocytes|CMV specific CTLs will be collected from HLA matched or mismatched donors and manufactured in a GMP facility and administered to patients with refractory CMV infection.
45808749|NCT03265821|Procedure|Healing after treatment|
45808750|NCT03250247|Device|Stents|"US-guided puncture of vein, fluoroscopic monitoring of catheter/guidewire manipulations, baseline venogram of CFV through infrarenal IVC.~Iliac vein should be pre-dilated to at least 12 mm. Bare, self-expanding stents made of elgiloy or nitinol legally marketed in the US for any indication and that are at least 12 mm in diameter should be used to recanalize the entire diseased segment of vein.~The use of devices > 14 mm is highly recommended for the iliac vein and dilated to at least 14 mm, unless compelling patient factors dictates dilatation to a smaller diameter.~Balloon angioplasty of inflow veins.~After successful iliac vein recanalization, patients who continue to be symptomatic beyond 2 weeks follow-up and who have valvular reflux in GSV, accessory GSV, anterolateral thigh circumflex, and/or SSV should be offered endovenous ablation.~Any FDA-approved method may be used including radiofrequency or laser ablation, sclerotherapy or pharmacomechanical ablation."
45808751|NCT03248167|Drug|Cannabidiol|600 mg daily
45808752|NCT03248167|Drug|Placebos|This project aims to determine whether cannabidiol (CBD) is effective in treating alcohol use disorder (AUD) comorbid posttraumatic stress disorder (PTSD). To address this aim, investigators will conduct a clinical trial in which CBD will be administered to 48 individuals with AUD comorbid with PTSD, and assess alcohol intake and PTSD symptoms. The aim is to test the hypothesis that CBD will reduce alcohol drinking in individuals with AUD comorbid with PTSD. To test this hypothesis, 48 otherwise healthy adult participants with moderate or severe AUD and PTSD will be randomized to treatment with either CBD (600 mg daily) or placebo, for a period of 6 weeks, such that both participants and study staff are blind to treatment condition.
45808753|NCT03244306|Biological|Patient-derived CD22-specific CAR T-cells also expressing an EGFRt|Patient-derived CD22-specific chimeric antigen receptor T-cells expressing an EGFRt
45808754|NCT03243552|Drug|L-DOPA versus Placebo|Participants will be randomized in a blocked schedule to yield 1:1 L-DOPA: placebo assignment.
45808755|NCT03243552|Behavioral|Social Skills Training|ASD participants will be enrolled concurrently in a 16-week manualized, structured, group-based, social skills training program (PEERS).
45808756|NCT03242278|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
45808757|NCT03220737|Biological|VAXCHORA (Cholera Vaccine, Live, Oral)|VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.
45808758|NCT03220737|Other|Placebo|Placebo control for this study is normal (0.9%) saline.
45657279|NCT04790539|Drug|SHR-1210|SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
45657280|NCT04790149|Other|Conventional Rehabilitation|Motor Imagery Training combined with Active functional exercises
45808759|NCT03198728|Drug|SOV2012-F1|oral preparation of testosterone undecanoate (TU)
45808760|NCT03198728|Drug|AndroGel|topical testosterone gel 1.62%
45657281|NCT04790149|Other|NEUROM + tDCS|NEUROM combined to tDCS
45657282|NCT04790149|Other|NEUROM|protocol to induce motor recovery
45657283|NCT04789993|Other|No intervention.|There is no intervention needed. It is a retrospective cohort. The usual follow-up of type 1 diabetes is studied from its beginning to the last news of the patient.
45657284|NCT04812301|Radiation|Egg-white sandwich|1 mCi of Tc-99m sodium phytate is added into the egg-white sandwich
45657285|NCT04812301|Radiation|Abbott Vital®|1 mCi of Tc-99m sodium phytate is added into the Abbott Vital®
45657286|NCT04427371|Other|the levels of pyroptosis|Blood samples were taken to detect plasma lncRNA NBR2 levels and GSDMD protein level.
45808761|NCT03198663|Behavioral|POSSE|Popular-opinion leader
45808762|NCT03192852|Other|dental bleaching|dental bleaching can be achieved with light, light+ peroxide carbamide gel, or only with peroxide carbamide gel
45808763|NCT03192852|Procedure|Gingivoplasty|gengivoplasty will be realized to in illuminated tissue an no illuminated tissue to morphometrically evaluate the tissue
45808764|NCT03190590|Device|tDCS-NeuroConn.|tDCS is delivered noninvasively via electrodes applied to the surface of the head, and a mild electrical current is given during motor training.
45808765|NCT03190590|Device|TMS - Magstim.|TMS is delivered noninvasively via a hand-held coil applied to the surface of the head, and a magnetic pulse probes cortical circuitry [this is not repetitive TMS and so does NOT modulate brain excitability
45808766|NCT03190590|Device|Sham tDCS|delivered by briefly turning on and off the stimulator at the beginning of training, which mimics the sensation of true stimulation.
45944993|NCT00086801|Drug|vinblastine|given IV
45944994|NCT00086801|Procedure|fludeoxyglucose F 18 positron-emission tomography (PET) scan|
45944995|NCT00086801|Procedure|CT scan|
45944996|NCT05456113|Biological|Cannabidiol|Urbal Activ Extra Strength CBD Body Strong Balm applied to region of forearm to be stimulated by iontophoresis machine
45944997|NCT00124644|Drug|cytarabine|
45944998|NCT00124644|Drug|daunorubicin hydrochloride|
45944999|NCT00124644|Drug|etoposide|
45945000|NCT00124644|Drug|tipifarnib|
45945001|NCT00124644|Procedure|chemotherapy|
45945002|NCT00124644|Procedure|enzyme inhibitor therapy|
45945003|NCT00124644|Procedure|high-dose chemotherapy|
45945004|NCT05452837|Procedure|FDFG|FDFG is applied to the parotidectomy bed after superficial parotidectomy
45808767|NCT03188965|Drug|Elimusertib (BAY1895344)|Solution or tablet, oral, to be administered until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
45945005|NCT05452837|Procedure|SMAS|SMAS flap is applied to the parotidectomy bed after superficial parotidectomy
45657287|NCT04812145|Radiation|Chemoradiation|Hypofractionated radiotherapy with concurrent Gemcitabine
45808768|NCT03186118|Biological|T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)|Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
45808769|NCT03168672|Device|Global ICON|The study device is the GLOBAL ICON stemless humeral component, consisting of the Anchor Plate and Humeral Head.
45808770|NCT03159624|Other|Biodesign™ SIS graft|2x3 cm Biodesign™ SIS perforated mesentery graft
45808771|NCT03159624|Other|Doyle silastic sheet|Doyle silastic sheet
45945006|NCT05425771|Procedure|Anti Reflux Mucosa Ablation|Mucosa ablation with Argon plasma coagulation performed in inversion at the gastroesophageal junction in a crescent or horseshoe shape over a width of 1.5 - 2 cm in patients with refractory reflux symptoms
45808772|NCT03156114|Drug|BI 754111|Day 1 of 3 week cycle
45808773|NCT03156114|Drug|BI 754091|Day 1 of 3 week cycle
45808774|NCT03153475|Device|ATTUNE Revision Knee System in Revision Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their existing implants need to be removed and replaced.
45808775|NCT03153449|Device|ATTUNE Revision Knee System in Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their anatomy is such that the use of revision components are required to perform primary total knee arthroplasty
45808776|NCT03151811|Drug|Melflufen|Intravenous infusion
46075410|NCT00874861|Biological|Peptide vaccine + Poly-ICLC|"Subcutaneously in right or left upper arms with intact draining axillary nodes. Each will be injected to the same location in the same arm as the previous vaccine was administered. In case of no intact axillary lymph nodes as draining nodes, vaccines will be administered in the upper thigh on the same side with intact inguinal lymph nodes.~Vaccine will be administered on weeks 0,3,6,9,12,15,18 and 21. Poly-ICLC First course(20 mg/kg i.m., up to 1640 µg/injection) will be administered on an outpatient basis in the Clinical & Translational Research Center (CTRC)the day of the first GAA/TT-vaccine and on day 4 after the vaccine. For each of the repeated vaccinations (on Weeks 3,6,9,12,15,18 and 21) poly-ICLC will be administered on day of the vaccine and on day 4 after the vaccine."
45657288|NCT04801069|Device|Nocturnal Ventilation|AirCurve 10CS PaceWave (Resmed)
46075411|NCT00878137|Device|INR by point-of-care instruments and venopuncture|Three fingersticks will be performed and from each one drop of capillary or venous whole blood collected from a fingerstick performed by the primary investigator to measure PT/INR using the CoaguChekXSTM (10 microliters), ProTimeTM (27 microliters), the investigational ProTime, and INRatioTM 15 microliters) point-of-care instruments and one i.v. blood draw (20 mL of blood) will be performed by a phlebotomist.
46075412|NCT02176278|Other|Telephone Reminder|Nurse will provide telephone contact to patients every 3 month to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns
45808777|NCT03151811|Drug|Pomalidomide|Oral capsules
45657289|NCT04426903|Other|webFitForAll|PT training participants use the webFitForAll exergaming computer platform as the physical training component (PT)
45657290|NCT04426903|Other|BrainHQ|CT training participants use the language adapted version of the BrainHQ program as the cognitive training component (CT)
45657291|NCT04812223|Procedure|Delayed umbilical cord clamping|The umbilical cord will be clamped 60 seconds after the baby is born.
45808778|NCT03151811|Drug|Dexamethasone|Oral tablets
45808779|NCT03148418|Drug|Atezolizumab|Atezolizumab will be administered as monotherapy or combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study). Dosing regimen will be in accordance with the parent study and local prescribing information.
45808780|NCT03144804|Drug|Lamivudine|This drug may help prevent the growth and spread of the cancer cells to other parts of the body.
45808781|NCT03142334|Biological|Pembrolizumab|IV infusion
45808782|NCT03142334|Drug|Placebo|IV infusion
45945007|NCT00086840|Drug|temsirolimus|Given IV
45945008|NCT00086840|Other|laboratory biomarker analysis|Correlative studies
45657292|NCT04812223|Procedure|Early umbilical cord clamping|The umbilical cord will be clamped 15 seconds after the baby is born.
45808783|NCT03141034|Drug|Irinotecan|-Irinotecan is commercially available and will be billed to insurance.
45808784|NCT03141034|Drug|Ramucirumab|-Ramucirumab will be provided free of charge by Eli Lilly and Company.
45808785|NCT03141034|Genetic|Blood for angiome profiling|-Before treatment on cycle 1 day 1, cycle 5 day 1, cycle 9 day 1, and end of treatment
45657293|NCT04812223|Procedure|Milking of the umbilical cord|The cord will be milked 5 times with 2 seconds milking, then letting 2 seconds for spontaneous blood flow.
45808786|NCT03141034|Genetic|Blood for cfDNA|-Before treatment on cycle 1 day 1, cycle 3 day 1, cycle 5 day 1, cycle 7 day 1, cycle 9 day 1, and end of treatment
45808787|NCT03135847|Device|Tactor|The tactor is a small robot providing touch and vibration.
45808788|NCT03131024|Dietary Supplement|50% caloric restriction|Meals mimicking participant dietary preferences and matching North American macronutrient guidelines will be provided consisting of 50% of total caloric intake for 48 hours
45808789|NCT03131024|Other|Aerobic exercise|The supervised exercise session will consist of a 10-minute warm-up, 30 minutes performed at 70-75% of heart rate reserve, which corresponds to a vigorous intensity, followed by a 5-minute cool-down
45945009|NCT05392621|Behavioral|Yoga|A single Hatha yoga session designed to support stress management.
45945010|NCT05392621|Behavioral|Deep Breathing|A single deep breathing exercise session designed to elicit relaxation and to assist in stress management.
45945011|NCT05392621|Behavioral|Progressive Muscle Relaxation|A single session of progressive muscle relaxation designed to elicit relaxation.
45808790|NCT03126539|Drug|Sulforaphane|Isothiocyanate sulforaphane (SF), derived from broccoli sprouts, has been known to induce an antioxidant response through the Keap1-Nrf2-antioxidant response element pathway.
45808791|NCT03126539|Radiation|Narrow-band Ultraviolet B exposure|The investigators will use a Lumera ultraviolet B (UVB) light phototherapy device which allows for targeted delivery of controlled doses of UVB radiation (emission spectrum 290-320 nm).
46075413|NCT02176278|Other|Doctor-Nurse Follow Up|Patient will be followed by a doctor-nurse team at least 3 monthly to achieve multiple targets recommended as A1c<7%, BP<130/80 mmHg, LDL-C<1.8 mmol/l, triglyceride<1.7 mmol/l and persistence with RAS inhibitors taking into consideration safety and tolerability (e.g. hypoglycemia, hypotension, changes in electrolytes). Patient report will be given after follow up.
45808792|NCT03126539|Procedure|4 mm skin punch biopsy|All areas will be biopsied using standard punch biopsy tools and following standard clinical protocols, including cleansing the skin with an alcohol wipe and injecting local anesthesia with lidocaine and epinephrine. No more than four total skin biopsies will be obtained from a volunteer over the course of the study. After removal of the tissue sample, one or two sutures are placed to close the circular opening. Sutures are removed and a scar is formed, but typically heals well without complications and blends well with the surrounding skin.
45808793|NCT03125070|Other|Best Practice and Internet site with links to existing resources|Receive usual care
45945012|NCT05392621|Behavioral|Quiet sitting|A single session of quiet sitting.
46075414|NCT02176278|Other|Personalized Risk Report for Patient Empowerment|Patients will be given with personalized risk reports after baseline and 12-month repeat comprehensive assessments.
45808794|NCT03125070|Other|Internet, Mobile app and Telehealth Intervention|Receive INSPIRE and survivorship care plan
45808795|NCT03125070|Other|Survey Administration|Ancillary studies
45808796|NCT03123250|Device|Aquablation|The procedure is performed with the AquaBeam System. It is designed to utilize a high-velocity sterile saline waterjet as the cutting medium, which is projected through a nozzle positioned within the prostatic urethra. The Aquablation procedure integrates real-time ultrasound imaging with a robotically executed surgeon guided high-velocity waterjet to resect prostate tissue.
45808797|NCT03121404|Procedure|Rectus abdominis muscle biopsy|Patients who will already be having either liver transplant surgery or abdominal surgery will have a biopsy of their rectus abdominis muscle during the time of surgery.
45808798|NCT03114319|Drug|TNO155|TNO155 for oral administration
46075415|NCT04038853|Drug|1,25-Dihydroxyvitamin D|1,25-dihydroxy-vitamin D3 1000 IU orally daily for 12 months
46075416|NCT04038853|Drug|Placebo|Placebo identical to the study intervention drug
45453193|NCT02530021|Other|Heart rate monitor|One hour non-invasive ECG heart rate variability monitoring. The results will be blinded and interpreted independantly. Study results will not effect patient management.
45808799|NCT03114319|Drug|TNO155 in combination with EGF816 (nazartinib)|TNO155 for oral administration; EGF816 (nazartinib) for oral administration
45808800|NCT03113435|Other|Oxygen consumption optimization|hemodynamic stability will be achieved through exploration of oxygen consumption need of the patient based on CO2gap/CaO2-CvO2 ratio
45808801|NCT03107923|Diagnostic Test|Dobutamine stress test|Test of myocardial reserve
45808802|NCT03100552|Diagnostic Test|Endoscopic imaging|Analysis of the presence of dysplasia within sessile serrated polyps (SSP) using endoscopic imaging (high definition white light +- narrow band imaging)
45808803|NCT03099096|Drug|Mepolizumab|It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within an autoinjector.
45945013|NCT00124683|Drug|Bupropion|
45945014|NCT00124683|Drug|nicotine transdermal patch|
45945015|NCT04717063|Drug|Peroxyl Oral Product|mouth wash
45945016|NCT04717063|Drug|Placebo|placebo mouth wash
45945017|NCT04717180|Behavioral|aphasia rehabilitation using software program or conventional therapy|Patients were randomized into two groups: group I who received therapy using the software aphasia rehabilitation program and group II who received conventional (traditional) language therapy
45945018|NCT05382910|Drug|MG-K10|MG-K10 Humanized Monoclonal Antibody Injection
45945019|NCT05382910|Drug|Placebo|Placebo
45945020|NCT00086879|Drug|carmustine|
46075417|NCT00878293|Drug|GRT6005|liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days
46075418|NCT00878293|Drug|MS Continus®|60 mg, capsule, once daily
45657294|NCT04356469|Biological|Haploidentical Hematopoietic Cell Transplantation|TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
45945021|NCT00086879|Drug|erlotinib hydrochloride|
45808804|NCT03096782|Biological|Anti-Thymocyte Globulin|Given IV
45808805|NCT03096782|Drug|Busulfan|Given IV
45808806|NCT03096782|Drug|Clofarabine|Given IV
45808807|NCT03096782|Drug|Cyclophosphamide|Given IV
45808808|NCT03096782|Biological|Filgrastim-sndz|Given SC
45808809|NCT03096782|Drug|Fludarabine|Given IV
45808810|NCT03096782|Drug|Melphalan|Given IV
45808811|NCT03096782|Drug|Mycophenolate Mofetil|Given IV or PO
45945022|NCT00086879|Drug|temozolomide|
45808812|NCT03096782|Biological|Rituximab|Given IV
45808813|NCT03096782|Drug|Tacrolimus|Given IV
45808814|NCT03096782|Radiation|Total-Body Irradiation|Undergo total body irradiation
45808815|NCT03096782|Procedure|Umbilical Cord Blood Transplantation|Undergo cord blood transplant
45808816|NCT03092817|Drug|Dexamethasone|Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): dexamethasone for intravenous injection and dexamethasone for oral ingestion
45945023|NCT00124722|Drug|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 0.45 mg/kg prior to intubation.
45945024|NCT00124722|Drug|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 0.6 mg/kg prior to intubation.
45945025|NCT00124722|Drug|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 1.0 mg/kg prior to intubation.
45945026|NCT00322036|Drug|MPC-7869|Oral 800 mg BID
45945027|NCT00322036|Drug|MPC-7869|Oral BID dosing
45945028|NCT05373121|Behavioral|Online Peer Support|Signposting to online peer support groups and forums
45657295|NCT04789759|Device|Socket Preservation - Bond Apatite synthetic bone substitute|"Pre-op CBCT scanner for evaluating bone conditions around hopeless tooth. If 1/3 of the buccal plate is missing, considered a class 2 alveolar socket.~Extraction of tooth and place 2/3 biphasic calcium sulfate cement matrix's with Hydroxyapatite (HA granules) , condensed , and covered with a resorbable membrane suture to the adjacent tissue.~At implant placement ,take bone for histological preparation and histomorphometric analysis of the healing pattern.~At T0, T1 and T2 measure adjacent teeth periodontal status , Probing Depth , bleeding on probing.~Volumetric measurements, will use fixed landmarks (ex. adjacent teeth) to calibrate the STL measurements. Calculate the difference between pre-extraction socket and the post treatment with the alloplastic material.~Primary and secondary stability will be measured by ISQ units with a RFA machine, that will include the machine to measure and the magnetic tip to be screwed in the implant platform."
45808817|NCT03092817|Other|Placebo|"Treatment with matched placebo:~Standard saline for intravenous injection and placebo oral tablets containing cellulose"
45808818|NCT03084081|Device|CO2 standard therapy|Standard therapy using carbon dioxide for freezing of tissue
45808819|NCT03084081|Device|CryoPen|Provides a means of freezing tissue without the use of gases or liquids
45808820|NCT03084081|Device|Thermocoagulator|Thermoablation
45808821|NCT03078010|Drug|Piperacillin-tazobactam|piperacillin-tazobactam (4.5 gm IV q 6 hrs)
45945029|NCT00094614|Drug|Atropine|
45945030|NCT00087035|Drug|docetaxel|Administered as an IV infusion of 60m/m2 over a 1-hour period, once every 21 ± 2 days
45945031|NCT00087035|Drug|erlotinib hydrochloride|Will be taken at a starting daily dose of 150mg
45808822|NCT03078010|Drug|cefepime|(2 gm IV q 8 hrs)
45808823|NCT03065387|Drug|Everolimus|Given PO
45808824|NCT03065387|Drug|Neratinib|Given PO
45808825|NCT03065387|Drug|Palbociclib|Given PO
45808826|NCT03065387|Drug|Trametinib|Given PO
45808827|NCT03064126|Device|RANGER™ Paclitaxel Coated Balloon|"A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries."
45808828|NCT03064126|Drug|Paclitaxel|The RANGER™ Balloon is coated with the drug Paclitaxel.
45808829|NCT03064126|Procedure|Standard Balloon Angioplasty|"A procedure that utilizes an uncoated balloon which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries."
45808830|NCT03047629|Drug|ENT-01|Daily dosing with ENT-01. ENT-01 is an orally administered proprietary substance formulated as a small 25mg coated tablet. Dosing will range from 25-200mg, and the dose will be taken upon awakening on an empty stomach with 8oz water simultaneous to dopamine.
45808831|NCT03047629|Other|Placebo|Daily dosing with a placebo
45808832|NCT03043664|Drug|Lanreotide|Somatuline depot (lanreotide) 90 mg SQ every 3 weeks
45808833|NCT03043664|Drug|Pembrolizumab|Keytruda (pembrolizumab) 200 mg IV every 3 weeks
45808834|NCT03041467|Device|IN.PACT AV DCB|IN.PACT™ AV Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon
45808835|NCT03041467|Device|Standard Balloon Angioplasty|Standard PTA Balloon
45945032|NCT00322075|Drug|insulin glargine|
45945033|NCT00322114|Dietary Supplement|lycopene|Given orally
45945034|NCT00322114|Other|placebo|Given orally
45945035|NCT00322192|Behavioral|Conventional UK Physical therapy|
45945036|NCT00322192|Behavioral|Increased intensity of UK conventional physical therapy|
45945037|NCT00322192|Behavioral|UK conventional physical therapy plus functional strength training|
45945038|NCT00124761|Procedure|Surgery + WBRT|Surgery - complete excision of Solitary Brain Metastasis with 30 Gy in 10 fractions over 2 2 1/2 weeks
45945039|NCT00124761|Radiation|Radiosurgery + WBRT|Radiosurgery - Marginal dose based on maximum tumour diameter
45945040|NCT00087074|Drug|temsirolimus|Given IV
45945041|NCT00087074|Other|laboratory biomarker analysis|Optional correlative studies
45657296|NCT04789759|Procedure|Socket healing - No Filler|"Pre-op CBCT scanner for evaluating bone conditions around hopeless tooth, at extraction day, no flap opening , atraumatic extraction, no biomaterial filler, At T0, T2 measure adjacent teeth periodontal status , Probing Depth , bleeding on probing.~Volumetric measurements will include an intramural scanner from all the stages , we will use fixed landmarks (ex. adjacent teeth) to calibrate the STL measurements. Calculate the difference between pre-extraction socket and the post treatment with the alloplastic material."
45808836|NCT03033992|Device|Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields)|The Optune, a.k.a. Tumor Treating Fields (TTFields), will be worn for a minimum of 18 hours a day, with a recommendation of 22 hours/day for at least 23 days in a 28-day cycle. Cycle 1 includes 7 days training period, followed by 28 days treatment (total 35 days). The patients will receive multiple 28-day cycles of continuous Optune treatment. In the absence of treatment related serious adverse events or disease progression, Optune will continue up to 26 cycles.
45945042|NCT00322270|Drug|Alfimeprase|single-dose of alfimeprase, 10 mg.administered intracatheter to an occluded CVAD
45945043|NCT00332176|Drug|Celgosivir|400mg qd + standard of care for 12 weeks
45945044|NCT00332176|Drug|Celgosivir|600mg qd + standard of care for 12 weeks
45945045|NCT00332176|Drug|Peginterferon alfa 2b + ribavirin|Standard of care for 12 weeks
45657297|NCT04789525|Other|High-intensity aerobic training with high protein diet|High-intensity aerobic training was given with 50 to 70 % of the maximum heart rate. the intervention started with 10 mins of warm-up exercise through stretching of upper and lower limb muscles. Subsequent to stretching, the subjects were asked to do 30 mins of exercises; consisting of 20 mins on the treadmill and 10 mins of cycle ergometer at 50 to 70 % of MHR, then with 10 mins of cool down.
45657298|NCT04801147|Biological|Dendritic Cells Vaccine|"Right after the surgical resection of the tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Immunotherapy will follow radiochemotherapy and will comprise 4 vaccinations every second week (injections I, II, III, IV), 2 further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) 2 months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only. In correspondence to the third vaccine injection (week 13), mTMZ will start.~Vaccine doses will be injected in the forearm of the patient."
45657299|NCT02388165|Biological|Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine|SA4Ag vaccine reconstituted in 0.5mL water for injection. Administered via IM injection, once 10 to 60 days prior to surgery
45945046|NCT05317702|Other|Moderately Painful Massage|Participants will be seated in a chair with his or her shirt on. Participants will receive 60 seconds of manual pressure applied to the myofascial trigger point identified in the participant's upper back. The researcher's thumb or index finger will apply a deep manual pressure such that the participant rates the pain = 50/100 on a 101-point numeric pain rating scale with 0 indicating no pain and 100 indicating the most severe pain imaginable. The participant will be asked to rate his or her pain during the massage so the pressure may be adjusted to maintain the 50/100 related pain. Massage will be applied for 60 seconds, 4 times for a total contact time of 240 seconds. During each 30 second break in which manual pressure is released, Pressure Pain Threshold (PPT) to the foot will be examined. PPT will be assessed 2 times immediately after each of the 4 massage applications.
45657300|NCT02388165|Other|Placebo|Vaccine excipients reconstituted in 0.5mL water for injections. Administered via IM injection given 10 to 60 days prior to surgery
45945047|NCT05315167|Drug|PRJ1-3024|PRJ1-3024 is provided as capsules and is administered orally once a day.
45657301|NCT04811755|Behavioral|Surgical timing from ED admission to surgery|the impact of delay of time between patient admission to ED and surgery for source control on 90-d mortality and postoperative outcomes in patients with gastrointestinal perforation with or without septic shock
45657302|NCT04800679|Drug|receive 4 monthly IVB injections and then rescue IVB|IVB group that receive 4 monthly IVB injections and then rescue IVB
45657303|NCT04800679|Drug|PRP group|PRP group that undergo full PRP in 2 or 3 sessions and then rescue IVB
45945048|NCT00124800|Behavioral|Tinnitus retraining therapy|Sound therapy and counseling
45945049|NCT00124800|Device|Sound therapy|sound therapy and counselling
45945050|NCT00087113|Drug|pemetrexed disodium|
45945051|NCT00332215|Drug|Inhaled Sodium Pyruvate|
45945052|NCT00332254|Drug|Anakinra|150 mg IL1Ra ia x1 vs saline ia x1
45945053|NCT00332293|Drug|Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%|1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
45945054|NCT00332293|Drug|Moxifloxacin hydrochloride ophthalmic solution 0.5% as base|1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
45945055|NCT02964975|Procedure|Percutaneous coronary intervention|Recanalisation of chronic total occlusion of coronary artery
45453194|NCT00005947|Biological|sipuleucel-T|Autologous peripheral blood mononuclear cells, including antigen presenting cells, that have been activated in vitro with a recombinant fusion protein, PAP-GM-CSF. Treatment consist of 3 doses administered approximately 2 weeks apart.
45945056|NCT02964975|Drug|Optimal medical therapy|Medical threatment according to guidelines
45945057|NCT00087191|Drug|EF5|Given IV
45945058|NCT00087191|Drug|motexafin lutetium|Given IV
45945059|NCT00087191|Other|pharmacological study|Correlative studies
46075419|NCT00878293|Drug|Placebo|liquid formulation and capsule, once daily
45945060|NCT05222152|Drug|Chronocort|Hydrocortisone modified-release hard gelatin capsules for oral administration - 5mg and 10mg
45808837|NCT03033992|Combination Product|Concurrent Optune and RT followed by Optune System alone|In Stratum II patients will be treated with standard of care focal RT concurrently with Optune followed by Optune treatment. This study specifies a 1 cm clinical target volume margin.The duration of the first cycle of therapy will be from Day 1 of RT to 14 days after completion of RT (approximately 8 weeks total). Subsequent cycles of therapy will be 28 days in duration. The Optune device will be worn for a minimum of 18 hours/day, with a recommendation of 22 hours/day. For the phase I part, the initial treatment will involve RT delivery with Optune arrays remaining in place but turned off. If this is not tolerated, two treatment de-escalation levels are planned, Specifically, Level -1: remove the Optune arrays during RT delivery and reapply daily after RT; Level -2: initiate Optune therapy after completion of RT. The established safe treatment approach from phase I will be investigated for feasibility and efficacy in phase II. Treatment with Optune may continue for up to 5 years.
45808838|NCT03021031|Other|Observational|Observational study
45808839|NCT03019406|Drug|Avalglucosidase alfa (GZ402666)|"Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV"
45945061|NCT05222152|Drug|Plenadren|Hydrocortisone modified-release tablets for oral administration - 5mg and 20mg
45945062|NCT00094692|Device|Eye patch|
45945063|NCT00094692|Device|spectacles|
45945064|NCT00094692|Drug|atropine|
45945065|NCT05211388|Procedure|RFA controlled using echo decorrelation imaging|"The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, with echo decorrelation imaging providing an additional stopping criterion.~The targeted ablation zone will be subdivided into one or more contiguous control subvolumes encompassing the tumor. An echo decorrelation threshold will be chosen to provide a target specificity (e.g. 90%) for local ablation prediction, based on ROC curve analysis for ablation prediction in clinical RFA and MWA as well as in controlled ablation of ex vivo human liver tumors. Controlled RFA treatments will proceed until the average cumulative decorrelation exceeds this predetermined threshold within each control subvolume.~To avoid compromising patient safety, treatments will not be extended beyond manufacturer-specified end points."
45657304|NCT04800679|Drug|IVB injections and a modified laser|Combination group that receive 2 bimonthly IVB injections and a modified laser (1 session anterior to the equator) and then rescue IVB or laser
45657305|NCT04811911|Radiation|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
45657306|NCT04811911|Drug|Methotrexate|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
45945066|NCT05211388|Procedure|RFA controlled using standard manufacturer-specified algorithms|The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, e.g. based on temperatures measured by thermocouples integrated into the RFA probe. 3D echo decorrelation imaging will be performed in real time during ablation, but will not be used to modify treatments.
45945067|NCT00400166|Behavioral|Recovery Mentor|Provided Recovery Mentor services
45945068|NCT05181007|Drug|Mefanamic Acid|mefanamic acid once every 6 hours on Day 4 and Day 5, Ciprofol on Day 1 and Day 5
45657307|NCT04789291|Drug|BI 1595043|BI 1595043
45808840|NCT03019406|Drug|Alglucosidase alfa (GZ419829)|"Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV"
45808841|NCT03006068|Drug|Upadacitinib (ABT-494)|Upadacitinib (ABT-494) will be administered orally.
45808842|NCT03006068|Drug|Placebo|Placebo will be administered orally.
45945069|NCT05181007|Drug|Valproate|valproate once daily on Day 4 to Day 8, Ciprofol on Day 1 and Day 8
46002203|NCT04379505|Radiation|Quad shot radiation|Treatment of each cycle should ideally take place on two consecutive days. Allowing for holidays, weekends, and other scheduling issues or unexpected delays, treatment may be completed within five calendar days.
45808843|NCT02992522|Drug|Lenalidomide|Given PO
45808844|NCT02992522|Biological|Obinutuzumab|Given IV
45808845|NCT02992522|Drug|Venetoclax|Given PO
45453195|NCT00005947|Biological|Placebo|Approximately one-third of the autologous quiescent antigen presenting cells (APCs) prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
45453196|NCT01103401|Drug|Drug: Tobramycin 0.3% - Dexamethasone 0.1%|one drop four times per day
45453197|NCT01103401|Drug|Drug: Tobramycin-Dexamethasone plus Ketorolac tromethamine|Tobramycin-Dexamethasone one drop four times per day and Ketorolac tromethamine one drop three times per day
45657308|NCT04789603|Other|6-min-walk surgical mask|To walk as fast as possible without running for 6 minutes with surgical mask
45657309|NCT04789603|Other|6-min-walk Fpp2|To walk as fast as possible without running for 6 minutes with Fpp2 mask
45657310|NCT04789603|Other|6-min-walk without mask|To walk as fast as possible without running for 6 minutes without mask
45945070|NCT00332371|Device|CPFA (Coupled Plasma Filtration Adsorption)|"CPFA is a specific method for the treatment of sepsis.~It consists of:~a plasma-filter (polyethersulfone 0.45 m2 with a cutoff of approx 800 kDa)~a hemofilter (polyethersulfone 1,4 m2)~a cartridge (contains approximately 140 ml of hydrophobic styrenic resin)~The kit is lodged in the Bellco Lynda machine (Bellco Mirandola, Italy). The treatment consists of the separation of plasma from the whole blood with adsorption of the inflammatory mediators and cytokines from the plasma, and a subsequent purification step by way of a hemofilter."
45808846|NCT02972593|Biological|Blood and blood products for transfusion|Randomization would not occur until the patient's Hgb dropped below 7 g/dL. If the patient is randomized to the liberal arm, they would be transfused to keep their Hgb >7 g/dL. If the patient is randomized to the conservative arm, they would not be transfused until their Hgb drops below 5.5 g/dL. If the patient's Hgb does not drop below 7.0 g/dL, randomization will not be done.
45808847|NCT02969681|Drug|ascorbic acid|1.5g/kg/day, D1-3, every 2 weeks
45808848|NCT02969681|Drug|Chemotherapy|"mFOLFOX6~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks"
45945071|NCT00124839|Drug|Naltrexone|Daily oral administration (capsules): 50mg naltrexone and placebo or 200mg naltrexone and placebo or placebo and naltrexon 50mg or placebo and 200mg naltrexone
45945072|NCT05160181|Other|Yogatherapy|Description: Retrospective study on medical file of patients seen in consultation for chronic pain with prescription of Yogatherapy
45945073|NCT00087269|Drug|erlotinib hydrochloride|Given orally
46075420|NCT02066220|Radiation|Radiotherapy without Carboplatin|"Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks~LR Arm after Amendment (Protocol version 11- 17 Nov 2014):~Brain - 18.0 Gy in 10 daily fractions of 1.80 Gy Spine - 18.0 Gy in 10 daily fractions of 1.80 Gy Primary tumour boost - 36.0 Gy in 20 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks"
45945074|NCT00087269|Procedure|therapeutic endoscopic surgery|Undergo surgical resection
45657311|NCT04789135|Drug|Ozone|Treatment consists of direct instillation into the bladder of ozone gas, with concentration of 20µg / ml - 60ml via urethral catheter.
45657312|NCT04348669|Other|Tele-yoga|Subjects will undergo 30-minute yoga sessions delivered remotely 2 times/week for 6-weeks. The yoga sessions will be delivered one-on-one. The sessions will include 5-7 minutes of breathing exercises, 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
45657313|NCT04800445|Diagnostic Test|Salivary CRP|Salivary C reactive protein in neonatal sepsis
45657314|NCT02404545|Device|Ethicon Physiomesh|Ethicon Physiomesh will be paced at the time of radical cystectomy and ileal conduit.
45808849|NCT02967107|Procedure|Cold snare polypectomy|Use of a polypectomy snare closed over a polyp without electrocautery
46075421|NCT02066220|Drug|Reduced-intensity maintenance chemotherapy|"Starts 6 weeks after radiotherapy. 6 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15, Regimen B: (cycles 2, 4, 6): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks, for a total duration of 27 weeks.~Cumulative doses of chemotherapy drugs: cisplatin 210 mg/m2, lomustine (CCNU) 225 mg/m2, vincristine 18 mg/m2, cyclophosphamide 6 g/m2."
45945075|NCT00087269|Other|laboratory biomarker analysis|Correlative studies
45945076|NCT05137873|Other|Dunn-2 infant Sensory Profile (PS2-N)|The Dunn-2 infant Sensory Profile evaluates the child's sensory integration process
45945077|NCT05126836|Drug|Cilostazol 100Mg Tab|Cilostazol Twice a Day
45945078|NCT05126836|Drug|Placebo|Placebo
45945079|NCT00124878|Procedure|Male circumcision|Sleeve circumcision
45945080|NCT05020171|Device|Group of strength training|2x a week during 5 weeks, strengthening of weak muscles with the intensity recommended in the literature, i.e. 3-4x15 repetition at an intensity of 50 to 80% of the maximum force combined with serious games to stimulate patient involvement in strength training
45808850|NCT02967107|Procedure|Endoscopic mucosal resection|Use of injected chromogelofusine solution to raise a lesion prior to snare resection with electrocautery
45808851|NCT02956590|Drug|Pitavastatin|Statin
45657315|NCT04788979|Drug|Melatonin 5Mg Oral Tablet|"control without treatment~obese periodontitis patients treated only by scaling and root planning~obese periodontitis patients treated with scaling and root planning with daily dietary supplementation of 5 mg melatonin (NOW-USA)"
45808852|NCT02956590|Drug|Placebo|Placebo
46075422|NCT02066220|Radiation|Radiotherapy with Carboplatin|Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 G Carboplatin 35 mg/m2 5 times/week.
46075423|NCT02066220|Drug|Maintenance chemotherapy|"Starts 6 weeks after radiotherapy. 8 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5, 7): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15 Regimen B: (cycles 2, 4, 6, 8): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks. Duration 36 weeks. Cumulative doses of chemotherapy drugs: cisplatin 280 mg/m2, lomustine (CCNU) 300 mg/m2, vincristine 24 mg/m2, cyclophosphamide 8 g/m2, carboplatin 1050 mg/m2 (in randomized patients)."
45657316|NCT04811209|Other|1.Baseline Measurements Before Surgery|"Baseline demographic data~Baseline physiological variables (blood pressure, heart rate, respiratory rate, oxygen saturation)~Baseline investigations (hemoglobin, coagulation profile, serum electrolytes) if appropriate.~Preoperative pain state using NRS (0-10)~Preoperative functional state using the QoR-15 questionnaire~Pain expectation - patients will be asked preoperatively with the question In a scale from 0 to 10 (where 0 = no pain and 10 = worst pain imaginable), what do you consider is an acceptable pain score for your first (and second) day after surgery?... Two weeks after surgery?~Pain castastrophizing scale"
45945081|NCT05020171|Other|Group of physiotherapy not focus on strength training|2x a week during 5 weeks, active physical therapy treatment based on movement
45657317|NCT04811209|Other|2.Intraoperative Anesthetic Management|All study patients will be managed per routine clinical practice and institutional standard for the performed surgery.
45808853|NCT02956291|Device|Magnetic Resonance Fingerprinting|Non-contrast MRF acquisition will be acquired through the region of tumor in all patients. For patients receiving intravenous gadolinium based contrast, a post contrast MRF acquisition will also be acquired. This acquisition will be skipped in patients who do not receive or are not eligible for receiving IV contrast as a part of their clinical scan. The research scan will take approximately 10-15 minutes
45945082|NCT00087347|Drug|ferumoxytol|
45808854|NCT02949700|Drug|Metformin|Metformin will be administered orally twice daily during treatment with chemo-radiation for head and neck squamous cell carcinoma. This will occur 7 to 11 days prior to chemotherapy and radiation.
45808855|NCT02947087|Drug|Prolastin-C|Patients will receive Prolastin-C at 60mg/kg on day 0, 7, 14, and 21 days of transplantation
45808856|NCT02947087|Drug|Placebo|Patients will receive saline on day 0, 7, 14, and 21 days of transplantation
45945083|NCT00087347|Procedure|magnetic resonance imaging|
45945084|NCT04960930|Drug|FMX101|topically once daily
45945085|NCT00094731|Procedure|Memory Training|
45808857|NCT02944071|Device|Boston Scientific Ranger™ and Ranger™ SL Paclitaxel-Coated PTA Balloon Catheter|
45945086|NCT00087386|Drug|tanespimycin|Given IV
45945087|NCT00087386|Other|laboratory biomarker analysis|Correlative studies
45945088|NCT00419692|Drug|Ropinirole|Subjects will receive ropinirole 0.5 mg for first 7 days, 1 mg from Day 8-14, 2 mg from Day 15-21, 3 mg from Day 22-28, 4 mg from Day 29-35, 5 mg from Day 36-42 and 6 mg from Day 43-51.
45945089|NCT00419731|Drug|Bupropion|"Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks.~Placebo, 25 mg, q.d., for 7 weeks."
45945090|NCT00419731|Drug|Bupropion + Naltrexone|"Bupropion, Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks.~Naltrexone, 25 mg, q.d., for 7 weeks."
45945091|NCT00419809|Drug|SB-681323 oral tablets|
45945092|NCT00419848|Drug|Doxycycline|Cap 100mg- 100mg/daily
45945093|NCT00419848|Drug|Azithromycin|Azithromycin: Cap 250 mg- 500 mg single dose/daily - 3 times per week
45945094|NCT00094848|Drug|TRAIL-R1 mAb (TRM-1; HGS-ETR1)|
45945095|NCT00087425|Biological|rituximab|
45945096|NCT00087425|Drug|bryostatin 1|
45945097|NCT00330655|Drug|memantine|
45808858|NCT02941783|Drug|Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973)|Treatment parameters following the physician's decision based on the summary of product characteristics.
45945098|NCT00330694|Other|ParkNet|Development of a network of dedicated physiotherapist with specific expertise in Parkinson's Disease and structured referrals to these ParkNet therapists by neurologists.
45945099|NCT00330694|Other|Usual Care|No altered organisation of physiotherapy care in Parkinson's Disease
45945100|NCT00330772|Drug|Aspirin|
45808859|NCT02932150|Drug|TAF|Administered orally once daily
45808860|NCT02932150|Drug|Placebo|Administered orally once daily
45808861|NCT02927821|Behavioral|ADS Plus|Contact occurs at a minimum for about 1 hour per month over 12 months (face-to-face/ telephone). Targeted education materials concerning clients' conditions and related matters are shared via email or traditional mail. The goal of each contact is to provide ongoing emotional support, situational counseling, education about importance of taking care of self, referrals/linkages and skills (e.g., stress reduction, behavioral management, how to talk with doctors). The care planning process is collaborative and flexible, reflecting CG fluctuating needs
45808862|NCT02919592|Device|MemoryShape® Breast Implants|MENTOR® MemoryShape™ Breast Implants are devices with shells constructed from medical grade silicone elastomer. The shell is filled with Mentor's proprietary formulation of medical grade silicone gel. The textured shell is constructed of successive crosslinked layers of silicone elastomer, and includes raised orientation marks on the anterior and posterior of the implant intended to help the physician orient the implant and ensure proper placement during implantation. Each MENTOR® MemoryShape™ Breast Implant is provided sterile. MemoryShape Breast Implants are available in sizes ranging from 120 cc-775 cc and 5 styles with various projection and height options.
45808863|NCT02919592|Device|MemoryGel® Breast Implants|MENTOR® MemoryGel™ Breast Implants are round devices with shells constructed from medical grade silicone elastomer. The shell is filled with MemoryGel™, Mentor's proprietary formulation of medical grade silicone gel, and is constructed of successive cross-linked layers of silicone elastomer. There are two styles of shell: smooth and textured. Each MENTOR® MemoryGel™ Breast Implant is provided sterile. MemoryGel Breast Implants are available in sizes ranging from 100 cc-800 cc and 4 styles with various projection and height options.
45808864|NCT02919592|Procedure|Other Aesthetic Surgery|Other aesthetic surgery procedures (for example, liposuction, rhinoplasty, brow lift, rhytidectomy, mentoplasty/genioplasty, otoplasty, or blepharoplasty; may not include silicone implants)
45808865|NCT02879448|Device|Amulet Left Atrial Appendage Occluder|Transcatheter left atrial appendage closure
45808866|NCT02879448|Device|WATCHMAN Left Atrial Appendage Closure|Transcatheter left atrial appendage closure
45808867|NCT02868216|Behavioral|anger management training|
45808868|NCT02864550|Drug|Doxycycline|doxycycline 100mg orally daily
45945101|NCT00330772|Drug|Clopidogrel|
45945102|NCT00094926|Drug|Risperdal Consta|25, 37.5 or 50mg IM injections every 2wks for 52wks
46075424|NCT02066220|Radiation|WNT-HR < 16 years|Brain - 23.4 Gy in 13 daily fractions of 1.8 Gy Spine - 23.4 Gy in 13 daily fractions of 1.8 Gy Primary tumour boost - 30.6 Gy in 17 daily fractions of 1.8 Gy Boost to macroscopic metastases - 21.6 Gy in 12 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
45808869|NCT02864550|Other|Placebo|placebo capsule identical in appearance, taste, and size to the capsule provided to the intervention group
45945103|NCT00094926|Drug|placebo|matching placebo IM injections every 2wks for 52wks
45945104|NCT00087464|Drug|Emtricitabine|
45945105|NCT00087464|Drug|Nevirapine|
45945106|NCT00087464|Drug|Tenofovir disoproxil fumarate|
45945107|NCT00330850|Drug|PRO-513|
45945108|NCT02964702|Device|Thrombectomy Device T-01|
45945109|NCT00331045|Drug|alvimopan|0.25 mg/day
45945110|NCT00331045|Drug|Placebo|
45945111|NCT00331045|Drug|Alvimopan 0.5 mg/day|
45945112|NCT00331045|Drug|Alvimopan 1 mg/day|
45945113|NCT00087503|Drug|Edotecarin|
45945114|NCT00331084|Drug|antibiotic/steroid combination|1 gtt, 4x/day, 15 days
45945115|NCT00331084|Drug|moxifloxacin / dexamethasone|1 gtt 4x/day, 15 days
45945116|NCT00420355|Drug|atazanavir|Atazanavir 300 mg daily on Days 6-12.
45945117|NCT00420355|Drug|lopinavir/ritonavir|Lopinavir/ritonavir 400 mg/100 mg twice daily on Days 6-16, then 800 mg/200 mg daily on Days 17-21.
45945118|NCT00331123|Drug|Testosterone Transdermal System|testosterone patch, 300mcg/day, changed every 3-4 days for up to 52 weeks
45808870|NCT02845258|Procedure|Pancreatic pseudocyst drainage with a plastic or self-expandable metallic stent (SEMS)|"Pancreatic pseudocyst drainage with a plastic or self-expandable metallic stent (SEMS):~This procedure is to be regarded as a clinical routine procedure since a couple of years back. The type of stent (material? length? thickness?), the cyst appearance (large? infected? cyst wall thickness?) and the type of access (transgastric? transduodenal?) may however vary from patient to patient.~In this study we perform EUS-drainage using different types of equipment on a wide range of pancreatic pseudocysts of different appearance and character. All procedures are performed as recommended. The very aim of the study is to investigate which technique and Equipment is to be preferred in different scenarios."
45945119|NCT00331123|Drug|Placebo|placebo patch,changed every 3-4 days for 24 weeks during double blind phase
45945120|NCT00087542|Drug|ACP-103|
45808871|NCT02841995|Drug|Belumosudil (KD025)|Pharmaceutical form: Capsules or Tablets Route of administration: Oral
45808872|NCT02822768|Procedure|Packing|The patient will receive packing as part of their wound care
45945121|NCT00331201|Drug|SAFEstart|
45657318|NCT04811209|Other|3.Postoperative Analgesic Management|"postoperative pain will be managed on the ward using a multimodal analgesic regimen as appropriate. This includes:~acetaminophen 650 - 1,000 mg given orally every 6 hours around the clock~NSAIDs e.g., celecoxib or other agents given orally around the clock per clinical guideline; omit if contraindicated or per surgeon's preference~Opioids e.g., hydromorphone 1-2 mg or oxycodone 15-30 mg given orally every 1-2 hours as required by the patient per standard nurse administered analgesic protocol.~In the event of severe pain refractory to the above treatments, the patient will be offered IV opioid e.g., intermittent doses of 0.2-0.4 mg hydromorphone IV every 10 minutes until pain becomes tolerable"
45945122|NCT00331240|Drug|travoprost/timolol fixed combination|
45945123|NCT00331240|Drug|placebo (artificial tears)|
45657319|NCT04811209|Other|4.Postoperative NRS Pain Assessment|Pain assessment using NRS pain scores (0 = no pain and 10 = worst possible pain) will be performed by an independent research staff, starting immediately in the PACU and serially over the first 48 hours after surgery or until hospital discharge.
45945124|NCT00124956|Drug|Doxorubicin|
45945125|NCT00331279|Drug|Oral Cinnamon Extract|A purified aqueous abstract of cinnamon in a 500mg tablet will be taken by each patient before lunch and dinner, making a total of one gram per day for eight weeks.
45808873|NCT02822768|Other|No packing|The patient will not receive packing as part of their wound care
45808874|NCT02799485|Other|Laboratory Biomarker Analysis|Correlative studies
45808875|NCT02799485|Other|Pharmacological Study|Correlative studies
45808876|NCT02799485|Behavioral|Quality-of-Life Assessment|Ancillary studies
45808877|NCT02799485|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
45945126|NCT00331279|Drug|Placebo|Placebo pills in likeness of the cinnamon extract
45945127|NCT00087581|Drug|Mycophenolate mofetil|Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The initial dose will be at least 1 gram BID in adults and 600 mg/m^2 in pediatrics. In Groups A and B, subsequent doses will be adjusted to maintain blood MPA levels ≥1.3 μg/mL with cyclosporine or ≥1.9 μg/mL with tacrolimus. In Group C, subsequent doses are not to be adjusted, except in the case of unacceptable toxicity.
45945128|NCT00087581|Drug|Cyclosporine|Cyclosporine will be given as 100-mg soft gelatin capsules and dosed to maintain either reduced (Group A) or standard/full (Groups B and C) blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 125-165 ng/mL (reduced) or 250-270 ng/mL (full); Days 90 through end of study, 95-145 ng/mL (reduced) or 190-220 ng/mL (full).
45945129|NCT00087581|Drug|Tacrolimus|Tacrolimus will be given as 1-mg and 5-mg capsules and dosed to maintain either reduced (Group A) or standard/full (Groups B and C) blood concentrations. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 4-6 ng/mL (reduced), 8-10 ng/mL (full); Days 90 through end of study, 3-5 ng/mL (reduced), 6-8 ng/mL (full).
45945130|NCT00094965|Drug|Oxaliplatin (SR96669)|oxaliplatin in combination with FOLFOX4
45945131|NCT00331435|Procedure|Ocular photodynamic therapy with verteporfin|Ocular photodynamic therapy with 6 mg per meter squar of body sarface of verteporfin with PDT lazer application for 83 seconds
45945132|NCT00331474|Biological|BCG delayed|early (birth) and delayed (14 weeks) intradermal BCG vaccination
45945133|NCT00331513|Drug|vorinostat|Given orally
45945134|NCT00331513|Drug|idarubicin|Given IV
45945135|NCT00331513|Other|laboratory biomarker analysis|Correlative studies
45808878|NCT02773030|Drug|CC-220|CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
45808879|NCT02773030|Drug|Dexamethasone|Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle
45945136|NCT00331513|Other|pharmacological study|Correlative studies
45945137|NCT00087620|Drug|XELODA [capecitabine]|
45945138|NCT00124995|Drug|terbutaline|
45945139|NCT00331669|Procedure|deep brain stimulation|high frequency stimulation
45458072|NCT02309632|Other|Pancreatic Cancer Screening Pathway 2|Screening with biomarker testing only
45808880|NCT02773030|Drug|Daratumumab|Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle
45808881|NCT02773030|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle
45808882|NCT02773030|Drug|Carfilzomib|Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1 and C1D2; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle
45945140|NCT00331708|Drug|Artesunate plus sulfadoxine-pyrimethamine|
45945141|NCT00331747|Drug|Glatiramer acetate|
45945142|NCT00087659|Drug|zoledronic acid|
45945143|NCT00331786|Drug|nitric oxide-releasing acetylsalicylic acid derivative|
45945144|NCT00331786|Other|laboratory biomarker analysis|
45945145|NCT00331786|Procedure|biopsy|
45945146|NCT00331825|Drug|Risperidone and Olanzapine|
45945147|NCT00125073|Behavioral|Postoperative nutritional counseling|
45945148|NCT00420394|Procedure|Chemotherapy|
45808883|NCT02771977|Other|Drug-specific alert|A drug-specific alert, informing the provider of the presence of AKI as well as recent exposure to a potentially nephrotoxic agent, will be fired.
45945149|NCT00420394|Procedure|surgery|
45945150|NCT00420394|Procedure|radiotherapy|
45808884|NCT02754596|Drug|Travoprost Intraocular Implant, high elution|Surgical implant placed within the eye to elute travoprost.
45945151|NCT00420433|Procedure|Skeletal Scintigraphy|Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
45945152|NCT00420433|Procedure|Radiography|Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
45945153|NCT00420433|Procedure|CT Scan|CT scan will include your chest, abdomen, and pelvis. Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
45657320|NCT04811209|Other|5.Postoperative Global Rating Scale (GRS) Pain Assessment|Also, the degree of pain relief after treatment is assessed using a subjective 15-point Global Rating Scale (GRS) as mentioned above (Background). This is performed at the same time of each NRS assessment and a minimum of twice daily
45945154|NCT00420472|Drug|mycophenolate mofetil [CellCept]|
45657321|NCT04811209|Other|6.Postoperative Patient Acceptable Symptom State (PASS) Assessment for Pain|"During each NRS pain assessment before or after an analgesic intervention on POD 0, 1 and 2, the patient will also be asked this question- In your opinion, do you consider your current pain state satisfactory after your operation? Patients giving a positive response are considered having an acceptable pain state. The PASS is the 75th centile for the pain NRS score in those with a satisfactory pain state."
45945155|NCT00087737|Drug|DVS-233 SR|
45945156|NCT00087737|Drug|Venlafaxine ER|
45945157|NCT00331981|Drug|Amisulpride|
45945158|NCT00126633|Biological|bevacizumab|
45945159|NCT00126633|Drug|cisplatin|
45945160|NCT00126633|Drug|gemcitabine hydrochloride|
45945161|NCT00332020|Drug|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 35 +/- 4 days
45945162|NCT00332020|Drug|Enoxaparin|40 mg enoxaparin syringe administered for 12 +/- 2 days
45945163|NCT02965274|Drug|Torrent's Fluoxetine Tablets|
45945164|NCT02965274|Drug|Warner Chilcott LLC's Sarafem Tablet|
45945165|NCT00125112|Behavioral|Internet-based intervention designed to reduce binge eating and improve healthy weight regulation|
45945166|NCT00332059|Drug|bimatoprost/timolol fixed combination|
45945167|NCT00087776|Drug|Chemotherapy|
45945168|NCT00332098|Behavioral|Family-Focused Treatment Plus Pharmacotherapy|Participants assigned to FFT will take part in weekly treatment sessions with their families for 12 weeks, biweekly for 12 weeks, monthly for 3 months, and then trimonthly until Month 24. Medications used for the pharmacotherapy portion of the study will include mood stabilizers, such as lithium or divalproex sodium, and atypical antipsychotics, such as quetiapine. Participants will also receive anti-anxiety medications, psychostimulants, or antidepressants as needed.
45808885|NCT02754596|Drug|Travoprost Intraocular Implant, low elution|Surgical implant placed within the eye to elute travoprost
45945169|NCT00332098|Behavioral|Enhanced Care Plus Pharmacotherapy|Participants assigned to Enhanced Care will take part in weekly brief psychoeducation sessions for 3 weeks. The pharmacotherapy treatment will be the same as for the FFT participants.
45945170|NCT00332137|Drug|Tolterodine|
45945171|NCT00126789|Drug|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and will be available in 25, 50, 75 and 100 mcg/hr patches. The patches will be worn on the chest or upper arm and an overlay will be placed over the patch. Patches (and overlays) will be replaced every 3 days by the patient and/or responsible caregiver. If a patient experiences end-of-dose-failure, the dosing interval may be changed by the physician investigator to every 2 days. The maximum dose allowed in this study is 300 mcg/hr.
45945172|NCT02965352|Device|Door handle device|To evaluate the cylindrical grip movement, it was used a door handle, which evaluated all the strength at the arc of motion
45945173|NCT02965352|Device|Linear switch device|To evaluate the pulp-pulp pinch movement, it was used one linear switch, which evaluated all the strength at the motion displacement.
45945174|NCT02965352|Device|Door key device|To evaluate the pulp-side pinch movement, it was used a door key, which evaluated all the strength at the arc of motion
45808886|NCT02754596|Drug|Timolol Maleate Ophthalmic Solution, 0.5%|Instillation of one drop of timolol in the study eye twice daily
45808887|NCT02752035|Drug|gilteritinib|Tablet, oral
45808888|NCT02752035|Drug|azacitidine|Subcutaneous injection or intravenous infusion
45808889|NCT02739295|Drug|recombinant granulocyte - colony stimulating factor|
45808890|NCT02739295|Drug|NaCl 0.9%|
45808891|NCT02728050|Drug|Cladribine|Given IV
45945175|NCT05831969|Drug|Lenalidomide|Lenalidomide: 10mg/d, 1-21d/28d orally; until disease progression or intolerable adverse reactions.
45458073|NCT02309710|Device|ShangRing|ShangRing administered to males seeking medical male circumcision
45808892|NCT02728050|Drug|Cytarabine|Given IV
45808893|NCT02728050|Biological|Filgrastim|Given SC
45808894|NCT02728050|Other|Laboratory Biomarker Analysis|Correlative studies
45808895|NCT02728050|Other|Quality-of-Life Assessment|Ancillary studies
45808896|NCT02728050|Drug|Mitoxantrone|Given IV
45808897|NCT02728050|Drug|Sorafenib|Given PO
45808898|NCT02724371|Device|Mentor Larger Size MemoryGel Ultra High Profile Breast Implant|The Mentor smooth and Siltex® larger size MemoryGel® Ultra High Profile (UHP-L) breast implants are large round silicone gel-filled breast implants. The devices are made with cross linked layers of silicone to provide the prosthesis with elasticity and integrity.
45945176|NCT05831956|Procedure|Laparoscopic colectomy|Patients who under went laparoscopic colectomy
45945177|NCT05831943|Diagnostic Test|Contrast enhanced Kidney CT|"Test group : Patient undergoing CT scan with 80kVP protocol and using low concentration intravascular contrast media ( Iobrix 270 mgl/MI , Taejoon pharm, Seoul, South Korea)~Control group : Patient undergoing CT scan with 120kVP protocol and using high concentration intravascular contrast media ( Iobrix 320 mgl/MI , Taejoon pharm, Seoul, South Korea)"
46075425|NCT02066220|Radiation|WNT-HR >= 16 years|Brain - 36.0 Gy in 20 daily fractions of 1.8 Gy Spine - 36.0 Gy in 20 daily fractions of 1.8 Gy Primary tumour boost - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (cranial) - 14.4 Gy in 8 daily fractions of 1.8 Gy Metastases boost (spinal) - 9.0 Gy in 5 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 50.4 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
45808899|NCT02719847|Procedure|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.
45808900|NCT02713022|Device|DEXA Scan|
45808901|NCT02713022|Behavioral|Godin Leisure Time Exercise Questionnaire (GLTEQ)|
45808902|NCT02702414|Biological|Pembrolizumab|Intravenous (IV) infusion
45808903|NCT02684825|Device|Reveal LINQTM- LNQ11 Internal Loop Recorder plus standard cardiac monitoring|Reveal LINQTM- LNQ11 continuously monitors cardiac electric activity for up to three years.
45808904|NCT02682342|Other|75 g glucose solution|This is the same as the standard oral glucose challenge dose and route given clinically
46075426|NCT02066220|Drug|Induction Chemotherapy|Doxorubicin 37,5mg/m² in 24h-infusion, days 1 and 2 (If administration of doxorubicin is not deemed appropriate, doxorubicin can be substituted by carboplatin 200mg/m²) VCR 1,5mg/m² (max. dose 2mg) in short infusion, days 1, 15, 29, 43 HD-MTX 5g/m²in two doses (0.5g/m² in 0.5h and 4.5g/m² in 23.5h), days 15 and 29 (+ Leucovorin) Carboplatin 200mg/m² in 1h-infusion, days 43, 44, and 45 MTX 2mg intraventricularly, days 1-4, 15, 16, 29, 30, 43-46
45808905|NCT02672449|Radiation|Carbon Ions Boost Followed by Pelvic Photon Radiotherapy|The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, at the Division of Radiation Oncology of the European Institute of Oncology (IEO), Milan, Italy, or at the Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy. The treatment will include a boost phase on the whole prostate with carbon ions performed at CNAO followed by a pelvic photon RT, with IMRT performed with conventional fractionation of 1.8 Gy per fraction up to 45 Gy to the pelvic lymph nodes, prostate and seminal vesicles. The total dose prescribed to the prostate boost with carbon ions will be of 16.6 GyE in 4 fractions (4.15 GyE/fraction).
45808906|NCT02669251|Drug|MPH966|"Phase 1b Cycle= 14 days: Each dose level will increase by 60mg PO BID, up to a maximum of 240mg PO BID~Phase 2 Cycle=28 days: MTD PO BID"
45945178|NCT05831930|Drug|Nituozumab|Nituozumab injection 200mg, administered once a week on the first day, with a duration of at least 60 minutes for a total of 7 times
45945179|NCT05831917|Radiation|Radiotherapy|"Radiotherapy: All patients were treated with Unity MRI Linac intensity modulated radiation therapy, daily imaging of MRI-IGRT and online target delineation, redesign, and total radiation dose: GTV 70Gy/33f, GTVLN 70Gy/33f, CTV 60Gy/33f, CTVLN 54Gy/33f, 5 days per week. Dose limit: The average dose to the upper, middle, and lower pharyngeal constrictor muscles is ≤ 40-50Gy, with oropharyngeal cancer requiring an average dose to the upper, middle, and lower pharyngeal constrictor muscles to be ≤ 50Gy and ≤ 20Gy; Lower pharyngeal cancer requires an average dose of ≤ 40Gy for the upper and middle pharyngeal constrictor muscles, and ≤ 50Gy for the lower pharyngeal constrictor muscles.~chemotherapy: cisplatin 75mg/m2, 21 days per cycle, a total of 3 cycles."
46075427|NCT02066220|Radiation|SHH-TP53 M0|"with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks~clinical target volume (CTV): safety margin along typical spread 10 mm: 23.4.Gy in 13 fractions to CTV.~focal RT boost to tumour bed and residual tumour (GTV) (boost: 30.6 Gy in 17 daily fractions of 1.8 Gy)"
45945180|NCT05831891|Drug|Fruquintinib combined with Serplulimab|Fruquintinib 5mg, qd, 2w on/1w off and Serplulimab 4.5mg/kg, IV drip, d1, q3w
45945181|NCT05831839|Device|RehaCom|computerized cognitive training
45945182|NCT05831787|Other|Patient Reported Outcomes|Patients will be asked to complete baseline, 30-day, and 6-month clinical and patient reported outcome health surveys.
45945183|NCT05831761|Drug|Comparison of analgesic efficacy protocol|Comparison of 4 possible analgesic protocols
45657322|NCT04811209|Other|7.Postoperative Quality of Recovery Assessment|The quality of recovery 15 questionnaire (QoR-15) to measure the dimension of quality of recovery will be administered once in the morning of POD 1 and POD 2. The MCID and PASS for QoR are determined in the same way as for NRS score. The final MCID value will be average of 4 values, 1 generated by the anchor based method and 3 generated by the distribution based method. The PASS for QoR is the 75th centile of the QoR-15 score in those patients who rated their recovery as good.
45657323|NCT04811209|Other|8.Other Postoperative Assessments|Additionally, opioid related adverse effects e.g., nausea, vomiting, itchiness, constipation, sedation (RASS + Ramsay)/ and respiratory depression will be assessed daily.
46002204|NCT04375761|Procedure|Collection of Biological Samples|Biological samples will be collected throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. All biological samples (e.g. nasal swabs, peripheral blood, stool) will be collected by the caregiver at home using materials provided to the family. At the end of study, additional samples (e.g. nasal secretion and/or saliva samples) may be collected by the family or study staff at a site visit, if feasible.
45458074|NCT05000593|Other|normal saline|Intra-articular injection of normal saline
45808907|NCT02667587|Drug|Nivolumab|
45808908|NCT02667587|Drug|Temozolomide|
45808909|NCT02667587|Radiation|Radiotherapy|
45808910|NCT02667587|Other|Nivolumab Placebo|
45808911|NCT02643966|Device|Whole breast ultrasound|Breast cancer screening with whole breast ultrasound
45808912|NCT02640534|Drug|Enzalutamide|Enzalutamide 160 mg od until disease progression
45808913|NCT02640534|Drug|Metformin|850 mg bid until disease progression
45808914|NCT02632409|Biological|Nivolumab|
45808915|NCT02632409|Other|Placebo|
45808916|NCT02629692|Drug|Vodobatinib (K0706) capsules|"Part A: Vodobatinib (K0706) capsules in single ascending doses.~Part B: Oral Vodobatinib (K0706) capsules in multiple ascending doses, once daily.~Part C: Oral Vodobatinib (K0706) capsules at recommended phase 2 dose of 174 mg, once daily."
45808917|NCT02628366|Other|Personalized Dialysate Temperature|Dialysis centres randomized to the intervention will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.
45808918|NCT02626455|Drug|Copanlisib (BAY80-6946)|"Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. For patients on R-B dosing of copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered and then rituximab followed by bendamustine. For patients on R-CHOP dosing of copanlisib will be administered on Days 1 and 8 of each 21-day cycle. Treatment with copanlisib/placebo will be continued up to 12 months.~Copanlisib will be administered before rituximab followed by cyclophosphamide, doxorubicin and vincristine infusions. Prednisone/prednisolone tablets to be taken for 5 days."
45945184|NCT05831735|Behavioral|Physical activity|"The 6-month APA program is supervised via the videoconference platform and/or carried out independently based on a personalized written program that is updated weekly. The program is based on structured sessions alternating 3 types of PA: aerobic sessions, stretching sessions and muscle strengthening sessions (to be practiced following the teacher's oral or written instructions).~The sessions last from 20 minutes to 1 hour and are of low to moderate intensity depending on the initial level of fitness. The sessions are structured, adapted and progressive. During the sessions, the exercises are adapted according to the means and materials available to the patients at home or in their immediate environment.~The patients will be progressively led to practice in an autonomous way (i.e., without supervision) but following an adapted, personalized and structured program. These PA sessions can be declared afterwards to the PA teacher,(duration and the exercises actually performed)."
45808919|NCT02626455|Drug|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered as per copanlisib described above. Applies to the phase III part of the study only.
45808920|NCT02626455|Drug|Rituximab|Rituximab is administered as an infusion at a dose of 375 mg/m2 body surface on Day 1 of each 28-day cycle for patients assigned to R-B and on Day 2 of each 21-day cycle for patients assigned to R-CHOP.
45808921|NCT02626455|Drug|Cyclophosphamide|Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
45808922|NCT02626455|Drug|Doxorubicin|Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
45808923|NCT02626455|Drug|Vincristine|Vincristine is administered as an infusion at a dose of 1.4 mg/m2 body surface (maximum dose 2.0 mg) on Day 2 of each 21-day cycle for patients assigned to R-CHOP
45808924|NCT02626455|Drug|Bendamustine|Bendamustine is administered as an infusion at a dose of 90 mg/m2 body surface on Day 1 and Day 2 for patients assigned to R-B
45808925|NCT02626455|Drug|Prednisone|Prednisone is given as 100 mg tablets daily from Day 2 to Day 6 for patients assigned to R-CHOP
45808926|NCT02625480|Biological|Brexucabtagene Autoleucel (KTE-X19)|
45808927|NCT02625480|Drug|Fludarabine|Administered intravenously
45808928|NCT02625480|Drug|Cyclophosphamide|Administered intravenously
45808929|NCT02622035|Behavioral|Provision of information|Information about fruit and vegetable feeding for children framed in gain vs. loss manner
45808930|NCT02622035|Behavioral|Emotion induction|Film clip designed to induce anger or fear
45808931|NCT02622035|Behavioral|visual perceptual load|visual and interactivity-based load of virtual reality buffet environment
45808932|NCT02616484|Drug|Dichloroacetate (DCA)|"Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr."
45808933|NCT02616484|Other|Placebo|Participants will receive the same volume of placebo in liquid form given during DCA treatment arm. Liquid will be an exact replication of DCA formulation with no DCA added.
45808934|NCT02616484|Genetic|Genotype|Participants will be genotyped to determine GSTZ1 haplotype status.
45945185|NCT05831735|Behavioral|Physical activity and education|"In addition to the intervention in physical activity, the people participating in this program will benefit from 6 months of educational activity (EA). The EA program includes 6 sessions scheduled according to the patients' availability in groups and by videoconference.~Following their entry into the study and their allocation to the programs (1 month maximum), the patients will be invited to a first individual EA session, in order to establish an educational diagnosis (1 hour). This session will allow for an assessment of their needs and the presentation of the workshops. Then, between the second and the sixth month following randomization, patients will benefit from 5 collective EA sessions per group of 6 patients maximum (1h30 to 2h). These sessions will be about PA, nutrition, pain management. An individual session will be held at the end of the intervention and will allow for an educational assessment."
45808935|NCT02598726|Drug|Curcumin|Given PO
45808936|NCT02598726|Other|Laboratory Biomarker Analysis|Correlative studies
45808937|NCT02598726|Dietary Supplement|Piperine Extract (Standardized)|Given PO
45808938|NCT02598726|Other|Quality-of-Life Assessment|Ancillary studies
45808939|NCT02586038|Drug|MLN9708|
45808940|NCT02586038|Drug|Dexamethasone|
45808941|NCT02586038|Drug|Cyclophosphamide|
45808942|NCT02586038|Drug|Thalidomide|
45808943|NCT02581254|Device|Thin Wire Snare|
45808944|NCT02581254|Device|Thick Wire Snare|
45808945|NCT02579811|Drug|Axitinib|The intent is to maximize sustained dose intensity of axitinib based on individual tolerability using dose modification criteria
45945186|NCT05831722|Procedure|Rapid Maxillary Expansion|Rapid Maxillary Expansion consists in the mid palatal suture opening through temporary anchorage mini implants placed in the palatal area.
45808946|NCT02577549|Behavioral|Diet & Exercise|Participants will attend exercise and diet classes.
45808947|NCT02577549|Behavioral|Attention Control|Participants will attend healthy living classes and receive health newsletters and phone calls/emails/texts.
45808948|NCT02554383|Drug|Amoxicillin-clavulanate|Amoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)
45945187|NCT05831696|Other|Powered Microprocessor-controlled Knee (PMPK)|A microprocessor-controlled Knee with standardized commercial prosthetic foot
45945188|NCT05831657|Other|Prevent It 2.0|A free, anonymous, internet-delivered, therapist assisted, cognitive behavioral therapy (CBT) intervention
45945189|NCT05831657|Other|Waitlist|Participants in the waitlist control will wait thirteen weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing problematic sexual behavior.
45945190|NCT05831631|Diagnostic Test|Circulating leukocytes immunophenotype|Blood samples will be tested with flow cytometry in order to characterize leukocyte subpopulations and to evaluate the circulating immunophenotype
45945191|NCT05831631|Diagnostic Test|Tumor sampling|Immunohistochemical analysis will be performed on tumor samples in order to characterize immune T cells distribution within the tumor.
45945192|NCT05831566|Drug|Budesonide/Formoterol fumarate dihydrate|"The Digihaler will measure use of inhalation medication and inhaler technique and will give feedback and reminders. The aim is to improve adherence en inhaler technique. The device/medicinal product will be used for 12 months.~It will be used in both groups, but patients in the intervention group are not able to see their own results and will not receive feedback/reminders."
45945193|NCT05831527|Drug|ARMRA™ Bovine Colostrum|"Participants have the option to choose between unflavoured ARMRA™ Bovine Colostrum or blood orange flavoured ARMRA™ Bovine Colostrum.~Participants took 2 sachets (1g each) of the product mixed with a cold drink daily for 12 weeks."
45945194|NCT05831514|Other|Mobile Application Supported Education Program (G-MUEP)|Parents who meet the inclusion criteria will use the Mobile Application Supported Education Program (G-MUEP).
45945195|NCT05831501|Procedure|Trans abdominis plane block|Ultrasound guided infiltration of local anaesthetic bupivacaine via 22G Quincke needle between internal oblique and trans abdominis muscle layers in abdominal wall.
45945196|NCT05831488|Other|Non-Interventional|Non Interventional
45945197|NCT05831475|Behavioral|Intergenerational Virtual Paired Exercise|Participants will be paired with someone older/ younger and will engage in exercise videos with the ability to simultaneously video chat with their partner while exercising. Participants will log on with their partner twice a week for 8 weeks.
45945198|NCT05831475|Behavioral|Peer Virtual Paired Exercise|Participants will be paired with someone of the same age group and will engage in exercise videos with the ability to simultaneously video chat with their partner while exercising. Participants will log on with their partner twice a week for 8 weeks.
45945199|NCT05831462|Drug|Ticagrelor 60mg|Standard vs Low dose ticagrelor in post PPCI patients
45945200|NCT05831449|Drug|Local anesthetic injection of CPL-01|Local anesthetic injection (either IP, positive control [Naropin], or negative control [saline placebo])
45945201|NCT05831449|Drug|Naropin, 0.5% Injectable Solution|Local anesthetic injection (either IP, positive control [Naropin], or negative control [saline placebo])
45945202|NCT05831449|Drug|Placebo|Local anesthetic injection (either IP, positive control [Naropin], or negative control [saline placebo])
45945203|NCT05831371|Diagnostic Test|TEP FDG|FDG TEP peformed in clinical routine
45945204|NCT05831345|Drug|Methadone Hydrochloride|Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
45945205|NCT05831345|Drug|Sufentanil Citrate|Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
45945206|NCT05831332|Device|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat.
45945207|NCT05831293|Behavioral|Mindfulness Based Stress Reduction Program|In each session, three sections were discussed and reviewed: (1) last week's experiences, (2) training, and (3) practice. Each session usually began with mindfulness and meditation exercises, followed by group discussion, review of homework activities, and introduction to new exercises. Participants were asked to complete 15-30 minutes of daily practice each week.
45945208|NCT05831267|Other|Fibrin Glue|Blood samples were collected from the antecubital vein of the right or left arm of the patient and drawn into sterile Titanium tubes immediately. The tubes were then centrifuged for 12 minutes at 2800 rpm and room temperature
45808949|NCT02554383|Drug|Placebo|placebo made to match the study antibiotic given twice a day orally for 10 days
45808950|NCT02533960|Other|not applicable (observational study)|Observational study without study related intervention.
45808951|NCT02531516|Drug|Apalutamide|
45808952|NCT02531516|Drug|Bicalutamide|
45808953|NCT02531516|Drug|Bicalutamide Placebo|
45808954|NCT02531516|Drug|Apalutamide Placebo|
45808955|NCT02531516|Drug|GnRH (agonist)|
45808956|NCT02531516|Radiation|74-80 Grays (units of radiation)|
45808957|NCT02522871|Device|OCS™ Liver System|
45808958|NCT02522871|Other|Control|
45657324|NCT04800211|Other|Experimental: Test Product 1|Subjects were instructed to completely replace their cigarettes with the Test Product 1 EVP (Nu Mark LLC, MarkTen® XL Bold CLASSIC)
45808959|NCT02519439|Drug|ganaxolone|225 mg capsules 450 mg to 900 mg 2x/day
45945209|NCT05831267|Other|T-PRF|The contents of the two containers (human fibrinogen, human thrombin) will be mixed with distilled water and then aspirated by two syringes after that, the two solutions will be mixed together and injected into the empty compartment around the dental implant under the sinus mucosal lining using auto mixing applicator.
45945210|NCT05831267|Other|Negative control|this group will not receive any material.
45945211|NCT05831254|Other|Health education:Interactive group training|"To introduce e-pulse software, which is a personal health record system, to show its use, to provide training materials such as video-brochures about e-pulse. This program will be done as interactive group training~Six modular interactive group training, each of which includes the steps of the European Health Literacy Scale of 90 minutes."
45945212|NCT05831254|Other|Health education: Individually training|To introduce e-pulse software, which is a personal health record system, to provide training materials such as video-brochures about e-pulse. This education will be done individually.
45657325|NCT04800211|Other|Experimental: Test Product 2|Subjects were instructed to completely replace their cigarettes with the Test Product 2 EVP (Nu Mark LLC, MarkTen® XL Bold MENTHOL)
45808960|NCT02514226|Procedure|supragingival treatment|In G1, all participants will receive supragingival treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil). Supragingival treatment will be performed above the gingival margin.
45808961|NCT02514226|Procedure|periodontal treatment|All participants receive periodontal treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil) in a full mouth manner.
45945213|NCT05831176|Drug|Dupilumab Dose 1|Administered subcutaneously (SC)
45945214|NCT05831176|Drug|Dupilumab Dose 2|Administered SC
45945215|NCT05831176|Drug|Matching Placebo|Administered SC
45945216|NCT05831137|Procedure|shorter cryoanalgesia|duration time of cryoanalgesia
45945217|NCT05831098|Device|Reveal TP (Syphilis) Antibody Test|All subjects tested with both investigational devices and conventional syphilis serology tests.
45945218|NCT05831085|Procedure|State-of-the-Art Percutaneous Coronary Intervention|supported by intracoronary imaging (e.g., intravascular ultrasound (IVUS) or optical coherence tomography [OCT]), intracoronary physiology (e.g., fractional flow reserve [FFR] or instantaneous wave-free ratio [iFR]), contemporary metallic drug-eluting stents (DES), guideline-directed optimal medical therapy [GDMT] with advanced cardiovascular and anti-diabetic medications [e.g., a sodium-glucose cotransporter [SGLT]-2 inhibitors]) in patients with type 2 diabetes and multivessel coronary artery disease (CAD) with involvement of left anterior descending (LAD)
45945219|NCT05831085|Procedure|standard CABG|Coronary-Artery Bypass Grafting
45657326|NCT04811443|Drug|Empegfilgrastim|Extimia®
45657327|NCT04810897|Other|Exercise|Exercise programme is reported in the clinical trial registration number is NCT03473834.
45657328|NCT04788355|Drug|Control group (standard hospital treatment)|Medications defined by the hospital involved in the study
45657329|NCT04788355|Drug|Group Hydroxychloroquine|Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days. In addition, patients in this group will receive standard medication for COVID-19 which is part of the hospital protocol involved in the study.
45657330|NCT04788355|Drug|Group Hydroxychloroquine and apixaban|Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days + apixaban orally 2.5 mg every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.
45657331|NCT04788355|Drug|Group Apixaban|Patients in this group will receive apixaban 2.5 mg orally every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.
45657332|NCT04800289|Other|questionnaires|questionnaires about disease and satisfaction of patient
45657333|NCT02420379|Drug|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.
45808962|NCT02514226|Procedure|periodontal treatment and photodynamic therapy|In G3, the periodontal treatment will be performed identical as G2. PDT will be administered in periodontal pockets > 4mm. Methylene blue will be applied in the deep of periodontal pockets. After 5 minutes of application the red laser diode (λ = 660 nm) will be applied with output power of 100 mW (Therapy XT, DMC, São Carlos, Brazil) with 90 seconds of exposure, i.e. 9J in each point. Applications will be held in six sites around the tooth in all teeth. To finalize, 1 minute of irradiation in scan around each tooth and rinsing with saline solution to remove the FS.
45945220|NCT05831072|Behavioral|Mindfulness-cognitive oriented group program|Mindfulness-cognitive oriented group program is a 4-week program based on the theory of mindfulness-based cognitive therapy (MBCT). The main elements of MBCT such as mindfulness breathing, raisin meditation for mindful eating, body scan and mindfulness walking are included. In addition to the weekly intervention, participants are also required to do the mindfulness practice at home.
45945221|NCT05831059|Radiation|Pulsed radio frequency therapy|Pulse Radio Frequency mode is a high voltage and low temperature Radio Frequency mode formed by discontinuous and pulsed current around nerve tissue
46075428|NCT02066220|Radiation|SHH-TP53 M+ (germline)|craniospinal radiotherapy with boost to tumour bed, residual tumour and metastatic deposits with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks Brain - 23.4 Gy in 13 daily fractions of 1.8 Gy Spine - 23.4 Gy in 13 daily fractions of 1.8 Gy Primary tumour boost - 30.6 Gy in 17 daily fractions of 1.8 Gy Metastases boost (cranial) - 30.6 Gy in 17 daily fractions of 1.8 Gy Metastases boost (spinal) - 21.6 Gy in 12 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
46075429|NCT02066220|Radiation|SHH-TP53 (somatic)|craniospinal radiotherapy with boost to tumour bed, residual tumour and metastatic deposits with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks Brain - 36.0 Gy in 20 daily fractions of 1.8 Gy Spine - 36.0 Gy in 20 daily fractions of 1.8 Gy Primary tumour boost - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (cranial) - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (spinal) - 9.0 Gy in 5 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45 Gy in 25 daily fractions of 1.80 Gy
46075430|NCT02066220|Drug|Vinblastin Maintenance|Weekly VBL (5mg/m², max. 10mg/dose) for 24 weeks
46075431|NCT00879853|Behavioral|Interpersonal Therapy|
45808963|NCT02514226|Other|dental hygiene orientation|Plaque Control through the use of toothbrush and floss
45808964|NCT02500797|Biological|Ipilimumab|Given IV
45808965|NCT02500797|Other|Laboratory Biomarker Analysis|Correlative studies
46075432|NCT00573391|Drug|Velcade, Thalidomide, and Dexamethasone|"Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles~Thalidomide - By Mouth Days 1-28~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles"
46075433|NCT00573391|Drug|Velcade, Melphalan, and Dexamethasone|"Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles"
46075434|NCT00590967|Radiation|IMRT extended field external beam radiation therapy|
46075435|NCT00590967|Radiation|Brachytherapy|
46075436|NCT00590967|Drug|Cisplatin|
45808966|NCT02500797|Biological|Nivolumab|Given IV
45808967|NCT02500797|Other|Quality-of-Life Assessment|Ancillary studies
45808968|NCT02476682|Other|blood or stool samples will be collected|blood or stool samples will be collected
45808969|NCT02470416|Device|Small bowel video capsule endoscopy (VCE) GIVEN/COVIDIEN LTD|Cases and controls will have a standard VCE procedure at our institution.
45808970|NCT02422550|Device|MRI|Participants enrolled on this protocol may undergo multiple MRI examinations periodically over the course of their treatment and follow-up if they are participating in a development project related to tumor response assessment. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.
45945222|NCT05831059|Other|sham operation|The means to achieve double-blind treatment had no practical effect on the subjects
46075437|NCT02783976|Drug|Sovaldi|Sovaldi 400 mg tablets administered orally once daily
45808971|NCT02404870|Drug|Placebo|Placebo
45808972|NCT02404870|Drug|Canagliflozin|Canagliflozin is a new oral drug for the treatment of type 2 diabetes mellitus (T2DM), and is one of two recently FDA approved sodium glucose co-transporter 2 (SGLT2) inhibitors, which target renal glucose reabsorption and offer promising improvement in HbA1C.
45808973|NCT02378038|Drug|PNT2258|
45808974|NCT02371382|Device|Arthroplasty hip|Hip replacement
45808975|NCT02364687|Radiation|Computed tomography late enhancement imaging|
45945223|NCT05831033|Biological|BEN101|"Lymphodepletion regimen：Cyclophosphamide 250mg/ m2/day x 3 days (day -4, -3，-2) , Fludarabine 25mg/ m2/day x 2 days (day-4, -3) , Paclitaxel 100mg/ m2/day -3. The lymphodepletion regimen could be adjusted by the treating physician according to patient's disease condition.~BEN101 infusion： Single dose level between 1x10^9 to 1x 10^11，not lower than 1×10^9 cells, final dose is affected by the starting amount of TILs cells isolated from the tumor tissue sample.~IL-2：Administer 8-16 hr after TIL infusion. 600,000 IU/kg intravenously over 15-20 mins every 12 hours. It is recommended to start with high dose; and de-escalate based on tolerability, up to 5 days. IL-2 administration will be terminated if unacceptable toxicities occur."
45808976|NCT02359175|Drug|Bupivacaine in epidural catheter|Bupivacain to be given in epidural catheter
45808977|NCT02359175|Drug|Fentanyl in epidural catheter|Fentanyl to be given in epidural catheter
45808978|NCT02359175|Drug|Placebo (for Bupivacain and Fentanyl i epidural catheter)|Saline to be given in epidural catheter
45808979|NCT02359175|Drug|Oral Paracetamol|Paracetamol to be given orally
45945224|NCT05831020|Other|VAC and bolster dressing|"Bolster dressing- Moist bulky cotton gauze dressing and wrapped with cotton bandage.~Vacuum assisted closure (VAC) dressing- A fenestrated tube placed between two sheets of sterilized foam secured to the surrounding skin using adhesive dressing (OPSITE)."
45945225|NCT05831007|Genetic|LX102-C01 Injection|Qualified subjects will receive a single unilateral intravitreal injection of LX102-C01 at Day 0 in the trial.
45458075|NCT05000593|Other|Cord Blood Mononuclear Cells (UCB-MNCs)|Intra-articular injection of Cord Blood Mononuclear Cells (UCB-MNCs)
45808980|NCT02359175|Drug|Oral NSAID|NSAID to be given orally
45808981|NCT02359175|Drug|Oral opioids|Opioids to be given orally
45808982|NCT02359175|Drug|Placebo (for oral opioids)|Placebo tablets to be given instead of oral opioids
45808983|NCT02347995|Other|Protein|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl. This group will drink a beverage containing protein after each training session.
45808984|NCT02347995|Other|Placebo|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl.This group will drink a placebo beverage after each training session.
45808985|NCT02339571|Procedure|Biopsy|Undergo tumor biopsy
45808986|NCT02339571|Procedure|Biospecimen Collection|Undergo blood sample collection
45808987|NCT02339571|Procedure|Computed Tomography|Undergo CT scan
45808988|NCT02339571|Biological|Ipilimumab|Given IV
45808989|NCT02339571|Procedure|Magnetic Resonance Elastography|Undergo MRI
45808990|NCT02339571|Biological|Nivolumab|Given IV
45808991|NCT02339571|Biological|Sargramostim|Given SC
45808992|NCT02310139|Procedure|Colonoscopy|
45808993|NCT02306707|Procedure|Endoscopic Mucosal Resection|
45945226|NCT05830994|Procedure|G-POEM|An Endoscopic submucosal tunnel is formed and extended to the first part of the duodenum, followed by a pyloromyotomy, beginning approximately two centimetres proximal to the pylorus and ending in the first part of duodenum.
45945227|NCT05830994|Procedure|Sham|Endoscopy is performed and tissue samples are collected from fundus and antrum as part of the Sham procedure
45945228|NCT05830955|Other|Lullaby group|The preterm newborns who are going to listen a live lullaby from their mothers' voice will be the first group (Lullaby group).
45808994|NCT02306603|Procedure|Endoscopic Mucosal Resection|
45808995|NCT02305290|Procedure|Endoscopic Mucosal Resection|
45808996|NCT02238938|Procedure|en-bloc resection|En- bloc resection after marking by use of different customary endoscopic knifes including combining devices as hybrid knife to cut down the lesion. After submucosal injection of liquid (saline or equivalent) to elevate the tissue it will be dissected and removed by a snare of adequate size solitarily.
45945229|NCT05830955|Other|Breast milk group|The preterms in the second group (Breast milk group) are going to smell their mothers' breast milk.
45808997|NCT02238938|Procedure|piecemeal resection|"Piecemeal resection is done by snare after marking and submucosal injection of saline or equivalent liquids. Small leftover adenoma tissue will be resected thoroughly by snare or forceps.~After three months, an APC therapy will follow any piecemeal resection, if necessary, another resection of leftover adenoma will be done."
45808998|NCT02215980|Drug|Lenalidomide|
45808999|NCT02215980|Drug|Dexamethasone|
45657334|NCT04799743|Drug|Resveratrol|Resveratrol has been used as a food supplement. Its antiviral properties have been well studied including its inhibitory effect against the coronavirus MERS-CoV. Our previous in vitro and in vivo studies found that the compound had other health benefits such as anti-fibrotic effect.The anti-fibrotic effect will add an extra benefit for resveratrol to fight against COVID-19 as lungs are the most affected organs by the coronavirus, which may result in prolonged fibrotic damage of the lungs even when a patient is recovered from the COVID-19 disease.
45809000|NCT02196649|Device|Endoscopic Clip|
45657335|NCT04799743|Drug|Placebo capsules|The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
45809001|NCT02194738|Procedure|Biospecimen Collection|Undergo collection of blood samples
45809002|NCT02194738|Drug|Carboplatin|Given IV
45809003|NCT02194738|Drug|Cisplatin|Given IV
45809004|NCT02194738|Other|Clinical Observation|Undergo observation
45945230|NCT05830955|Other|Control group|The preterms in the third group (Control group) are going to recieve rutin nursing care interventions.
45945231|NCT05830942|Behavioral|Walking Exercise|aerobic walking exercise using complex (cognitively engaging) walking tasks
45945232|NCT05830942|Device|Prefrontal Active tDCS|20 minutes of 2 milliamp transcranial direct current stimulation (tDCS) of prefrontal regions, delivered at each session
45945233|NCT05830942|Device|Prefrontal Sham tDCS|30 seconds of 2 milliamp transcranial direct current stimulation (tDCS) of prefrontal regions, delivered at each session
45945234|NCT05830929|Procedure|Ovarian tissue freezing and subsequent auto-transplantation after thawing|Removal of the ovarian tissue will be retrieved via laparoscopic surgery under general anesthesia. The ovarian cortical tissue obtained will be transferred on ice to the laboratory for cryopreservation. After medical treatment, if the patient would like to start a family but has experienced premature ovarian failure, she will have ovarian tissue auto-transplantation after thawing.
45809005|NCT02194738|Procedure|Computed Tomography|Undergo CT or PET/CT
45809006|NCT02194738|Drug|Crizotinib|Given PO
45809007|NCT02194738|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and tissue
45809008|NCT02194738|Drug|Erlotinib|Given PO
45657336|NCT04788199|Other|Closure of mesenteric defects using glue|Cyano-acrylate glue is a glue known to be used in surgery as tissue adhesive.
45657337|NCT04788121|Drug|Tranexamic acid|The treatment group will receive Injection TXA 1gm intravenous (IV) over 15 minutes infusion dissolved in 100 ml normal saline (NS- 0.9% NaCl), followed by injection TXA 2 g IV over 12 hours infusion dissolved in a 500 ml NS
45809009|NCT02194738|Drug|Gemcitabine Hydrochloride|Given IV
45809010|NCT02194738|Biological|Nivolumab|Given IV
45809011|NCT02194738|Drug|Paclitaxel|Given IV
45809012|NCT02194738|Biological|Pembrolizumab|Given IV
45809013|NCT02194738|Drug|Pemetrexed|Given IV
45809014|NCT02194738|Drug|Pemetrexed Disodium|Given IV
45809015|NCT02194738|Other|Placebo Administration|Given PO
45809016|NCT02194738|Procedure|Positron Emission Tomography|Undergo PET/CT
45809017|NCT02185560|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients treated by Physician with Nexavar under approved local prescriptions
45809018|NCT02181257|Combination Product|Extracorporeal Photopheresis (ECP)|"Procedure:~ECP treatments will be performed using one of two Therakos systems. Both systems use the drug Methoxsalen"
45809019|NCT02101021|Drug|Momelotinib|Tablet (s) administered orally once or twice daily
45809020|NCT02101021|Drug|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once or twice daily
45809021|NCT02101021|Drug|Nab-paclitaxel|Intravenously administered over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
45809022|NCT02101021|Drug|Gemcitabine|Intravenously administered over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
45809023|NCT02088632|Biological|Incobotulinumtoxina|Incobotulinumtoxina (Xeomin) is botulinum toxin type A and is administered via intramuscular injection.
45809024|NCT02088632|Other|Placebo Comparator|Normal saline is sterile sodium chloride without and preservatives.
45809025|NCT02068794|Other|Laboratory Biomarker Analysis|Correlative studies
45809026|NCT02068794|Procedure|Mesenchymal Stem Cell Transplantation|Given IP
45809027|NCT02068794|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IP
45809028|NCT02031536|Drug|everolimus|Given PO
46075438|NCT00878371|Drug|morphine|All patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively
46075439|NCT05753475|Other|renal transplantation|patients undergoing renal transplantation
46075440|NCT04230720|Drug|Systane Complete|1 drop 4 times a day for 14 days
46075441|NCT04054635|Device|silver diamine fluoride|Antibiotic liquid with anti-caries effects. A non-restorative option to manage cavitated caries lesions. Approved for clinical use in Canada in 2017.
46075442|NCT00923299|Drug|cetuximab|Cetuximab at the initial dose of 400 mg/m² (J1S1) as a 2-hour infusion and then at the 250 mg/m² dose as a 1-hour infusion in subsequent weeks.
45809029|NCT02031536|Other|placebo|Given PO
45945235|NCT05830916|Diagnostic Test|Antiphospholipid antibodies|Antiphospholipid (aPL) antibodies are a heterogeneous group of autoantibodies with high affinity for phospholipids such lupus anticoagulant (LA), β2glycoprotien І (β2GPІ), and anticardiolipin (anti-CL). They interfere with physiological mechanisms of coagulation and fibrinolysis, leading the haemostatic balance towards coagulation. Moreover, it seems to affect the physiological function of various cells such as platelets and endothelial cells
45945236|NCT05830864|Drug|Isoflurane|no other intervention
45945237|NCT05830851|Other|tDCS and aerobic exercise|Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with therapeutic parameters or sham tDCS
45945238|NCT05830825|Procedure|Vertebral Body Tethering (VBT)|Vertebral Body Tethering surgery with the Tether™ in UK
45945239|NCT05830812|Diagnostic Test|Invasiveness diagnosis|To predict the invasiveness of patients with small-sized lung adenocarcinoma intraoperatively based on multi-modal information.
45945240|NCT05830786|Device|Immersive virtual reality (IVR)|Using Oculus Quest 2 (Reality Labs, Meta Platforms, United States) headsets the PrecisionOS platform version 3.0 (PrecisionOS Technology, Canada) virtual reality surgical modules will be utilized.
45945241|NCT05830786|Other|Traditional hands on orthopaedic workshop group|Hands-on orthopaedic workshop sessions (including arthroscopy simulators, cadaveric models, and Sawbones®) in differing orthopaedic subspecialties (including sports, arthroplasty, and spine surgery).
45945242|NCT05830773|Other|Resonance Breathing Exercises|This intervention uses the Camera Heart Rate Variability (CHRV) smartphone application, a resonance breathing app that is available for download to iPhones and Android devices. The CHRV app uses Photoplethysmography (PPG) technology to measure heart rate. PPG is a noninvasive technology that uses a light source (the phone's flashlight) and a photodetector (the phone's camera lens) at the surface of one's skin to measure the volumetric variations of blood circulation. The app also has a timer (to allow the participant to see how long they use the app in each session). The iPhone version of the app also has a breathing pacer (a bar that moves up and down to show the participant when to inhale and exhale). Participants are instructed to initiate a resonance breathing session for at least 5 minutes every day and whenever they experience cravings, feel like they are going to relapse, feel anxious or stressed, or just want to feel calm.
45657338|NCT04788121|Other|Standard of care|For management, initial priority will be given to secure airway, breathing and circulation. To ensure hemodynamic stability, crystalloids infusion will be given as and when required. Blood transfusion will be initiated at the threshold hemoglobin (Hb) of 7g/dl, to maintain the target Hb of 7-9g/dl or with signs of hemodynamic instability despite fluid resuscitation. Intra venous (IV) PPI and antibiotic will be started promptly in all cases and IV splanchnic vasoconstrictor will be given in all suspicious case of Variceal hemorrhage before definitive therapeutic and diagnostic endoscopic procedure is done.
45809030|NCT02028455|Biological|Patient Derived CD19 specific CAR T cells also expressing an EGFRt|Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
45945243|NCT05830760|Biological|Myocardium biopsy|The expression of SGLT2 on small myocardium specimens harvested during aortic valve replacement operation in patients with aortic stenosis
45809031|NCT02023996|Radiation|89Zr-DFO-trastuzumab|
45809032|NCT02023996|Device|PET imaging|
45809033|NCT02020720|Procedure|Biopsy|Undergo image-guided biopsy
45945244|NCT05830747|Drug|Prednisone|Pre-operative drug administration before third molar surgery
45945245|NCT05830747|Drug|Placebo|Pre-operative Placebo administration before third molar surgery
46002205|NCT04375761|Procedure|Symptom and Exposure Surveys|Symptom and exposure surveys (questionnaires) will be completed throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. The primary household contact/caregiver will be the designee for ensuring timely questionnaires completion and submission for all household study participants.
45453198|NCT05625763|Diagnostic Test|sonoclot signature analysis|Investigate the value of global hemostasis studies (Sonoclot signature analysis) in cases of pre-eclampsia and if there a correlation between it and the specific traditional assays of hemostasis.
45657339|NCT04811053|Drug|HR021618|Treatment group A: HR021618 injection
45657340|NCT04811053|Drug|Placebo|Treatment group B: Saline injection
45809034|NCT02020720|Procedure|Computed Tomography|Undergo 18F-DOPA-PET/CT
45453199|NCT00005047|Drug|cisplatin|
45453200|NCT00005047|Drug|doxorubicin hydrochloride|
45453201|NCT00005047|Drug|methotrexate|
45453202|NCT00005047|Drug|vinblastine|
45453203|NCT01099891|Drug|rhEGF|rhEGF 50 μg/ml, spray type, twice a day
45453204|NCT01099891|Drug|Placebo|Placebo, Spray type, Twice a day
45458076|NCT01143025|Drug|Ropivacaine 50 mg|Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity
45809035|NCT02020720|Procedure|Diffusion Weighted Imaging|Undergo DTI
45809036|NCT02020720|Drug|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET/CT
45809037|NCT02020720|Other|Laboratory Biomarker Analysis|Correlative studies
45809038|NCT02020720|Procedure|Perfusion Magnetic Resonance Imaging|Undergo pMRI
45809039|NCT02020720|Procedure|Positron Emission Tomography|Undergo 18F-DOPA-PET/CT
45809040|NCT02020720|Procedure|Therapeutic Conventional Surgery|Undergo stereotactic craniotomy
45809041|NCT02020707|Biological|Bevacizumab|Given IV
45809042|NCT02020707|Other|Laboratory Biomarker Analysis|Correlative studies
45809043|NCT02020707|Drug|Nab-paclitaxel|Given IV
45809044|NCT02020707|Other|Pharmacological Study|Correlative studies
45809045|NCT02019641|Other|Aerobic Exercise Training (AET)|walking on a treadmill at vigorous intensity for up to 45 minutes
45809046|NCT02019641|Other|Education|Weekly education
45809047|NCT02000141|Procedure|Endoscopic Mucosal Resection|
45809048|NCT01968200|Drug|Enalapril|Naprilene 5 mg tablets; Dosage: 2.5 to 10 mg/12h Duration of treatment: up to end of follow up
45809049|NCT01964430|Drug|nab-Paclitaxel|nab-Paclitaxel 125 mg/m^2 on Days 1, 8, and 15 of every 28 day treatment cycle by intravenous (IV) administration for a total of 6 cycles.
45809050|NCT01964430|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 on Days 1, 8, and 15 of a 28 day cycle by IV administration for a total of 6 cycles.
45945246|NCT05830734|Other|injection of freshly collected adipose cells|"A small incision is made bilaterally in the lumbar region. 2-300 ml of Ringer's acetate with 1 mg of added adrenaline is introduced with an infusion cannula fan-shaped into the subcutaneous adipose tissue on each side of the region.~Adipose tissue is harvested for a total of approx. 80 ml. 20 ml Bupivacaine 5 mg/ml is distributed on each side of the lower back. The incisions are then closed with Steri-Strips and a compressive dressing is applied to reduce the risk of hematoma.~The harvested adipose tissue then centrifuged in bulks of four at 1000 rpm. minute for 3 minutes. The liquid fraction is discarded. Using a three-way tap system, the adipose tissue is microfragmented between two 10 ml syringes by moving the contents back and forth at least 20 times. The adipose tissue is then distributed in 2 ml syringes for injection. A total of between 25 and 55 ml of usable adipose tissue will be harvested."
45945247|NCT05830734|Procedure|Bascoms Cleft lift procedure|The procedure is carried out according to standardized principles previously decribed by Drs. John and Tom Bascom
46075443|NCT00923299|Drug|trastuzumab|"Two dose levels of trastuzumab will be evaluated for Phase 1:~Level 1: a loading dose of 3 mg/kg as a 90-minute intravenous infusion at J1S1 and then 1.5 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations;~Level 2: a loading dose of 4 mg/kg as a 90-minute intravenous infusion at J1S1 and then 2 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations."
46075444|NCT02783742|Behavioral|Communication coaching|Study coaches will conduct tailored individual sessions with participating providers to teach and improve communication techniques. Coaches will then shadow or audio-record patient encounters and deliver feedback to providers on their communication during these encounters.
45453205|NCT01584427|Dietary Supplement|Healthy Carbohydrate Diet vs. Western Style Diet|Cross over study with two intervention diets. Healthy Carbohydrate Diet with approximally 55 g of dietary fibers (arabinoxylan and resistant starch)compared with western style diet with low content of dietary fibers.
45809051|NCT01934868|Drug|prolotherapy solution of 20% dextrose|After verifying the anatomy of the lumbosacral spine under ultrasound, a 9cm 22 gauge needle will be used to inject the prolotherapy solution to each of the points specified. In order to view the needle under ultrasound, a needle at least as thick as 22G is required. In order for the prolotherapy injections to be safe, bone must be contacted in order to avoid nerve damage. At each point a total of 1cc prolotherapy solution will be injected.
45809052|NCT01934868|Drug|Epidural Steroid Injection|Prior to the epidural injection a local anaesthetic solution of 1% lidocaine will be injected into the relevant subcutaneous and ligamentous interlaminar space. The injectant solution will be comprised of 80mg methylprednisolone combined with 10mg (2cc) 0.5% bupivicaine. The resulting 4cc will be diluted with another 4cc of normal saline giving a total volume of 8cc. A loss of resistance technique will be used and radiocontrast dye will be injected to verify the placement of the needle prior to injecting the steroid solution.
46075445|NCT04030065|Drug|Omega 3 fatty acid|10% Omega-3 fatty acid oil will be supplemented in intravenous form from preoperative day 1, intra-operatively (anytime during surgery before reperfusion of graft) and from post operative day 1 to day 5 in the study group. The preparation used will be 100 ml injection which contains 10 gm of Omega 3 fatty acids.
46075446|NCT02689830|Device|Bead Block|Prostate embolization
46075447|NCT05753397|Drug|Ropivacaine injection|We are testing if single injection Ropivacaine is non-inferior to multiple-injection Ropivacaine when applied within the intertransverse tissue complex (that is: a paraspinal application mimicking the paravertebral block)
45453206|NCT01103557|Procedure|prophylactic selective lateral neck dissection|Level II, III, IV lymph node dissection
45809053|NCT01928394|Biological|Nivolumab|
45809054|NCT01928394|Biological|Ipilimumab|
45809055|NCT01928394|Drug|Cobimetinib|
45809056|NCT01913717|Radiation|External beam radiotherapy|The patients will be treated with extreme hypofractionated radiotherapy with the dose delivery system that will result most fit at the in-silica study. Simultaneous Integrated Boost (SIB) technique will be applied to deliver a total dose of 36.25 Gy in 5 fractions (over 10 days) to the whole prostate (7.25 Gy/fraction) and 37.5 Gy to the dominant intraprostatic lesion DIL (7.5 Gy/fraction), profiting of the high sensibility of prostate cancer to high dose/fraction. Several strategies will be applied in order to reduce the dose to the surrounding organs at risk.
45453207|NCT01103635|Biological|CD40 agonist monoclonal antibody CP-870,893|Given IV
45453208|NCT01103635|Biological|tremelimumab|Given IV
45453209|NCT01103635|Other|laboratory biomarker analysis|Correlative studies
45453210|NCT03948841|Other|magnetic resonance imaging|
45809057|NCT01898494|Procedure|Transoral surgery|Undergo transoral surgical resection
45809058|NCT01898494|Radiation|intensity-modulated radiation therapy|Undergo standard-dose or low-dose IMRT
45809059|NCT01898494|Drug|cisplatin|Given IV
45809060|NCT01898494|Drug|carboplatin|Given IV
45809061|NCT01863901|Device|Treatment with Cryo-Touch III device|
45809062|NCT01863043|Procedure|No aspiration of gastric contents|Infants will not have routine aspiration of gastric contents prior to every feeding to assess residual gastric contents.
45809063|NCT01863043|Procedure|Routine aspiration of gastric contents|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
45945248|NCT05830721|Device|MY01 + Standard of Care|In addition to standard of care, the MY01 device will be inserted by an orthopedic surgeon into the leg on the same side as the ECMO tubing. This will occur within 6 hours of the start of ECMO. Insertion of the device involves a needle, which is removed once the device is inserted. Monitoring of the device will occur as described by the device manufacturer, which includes a mobile application. If at any time the compartment pressures suggest that there may be ACS, an orthopedic surgeon will be called to perform a physical exam. If the physical exam supports the diagnosis of ACS, then an additional pressure measurement with a needle may be also taken to confirm the measurement. If the diagnosis of ACS is made, the decision to proceed with surgery, or fasciotomy, will be a joint decision made by entire team. Monitoring of with the device will be done for 24 hours. The device will be removed after 24 hours or if the diagnosis of ACS is made.
45945249|NCT05830721|Device|14-Gauge Slit Catheter + Standard of Care|For the 14-gauge slit catheter group, the exact same protocol will be followed as the MY01 group. The 14-gauge slit catheter consists of tubing that is 14-gauge in size, which is inserted into the leg with a needle. The needle will be removed once the tubing is inserted. The tubing is then connected to a monitor, which will display the pressure in the leg. Just like the MY01 group, the leg will be numbed and cleaned before the tube is inserted in the leg. Instead of the data being recorded on a mobile device, a nurse or nurse technician will document pressure readings every 4 hours for a total of 24 hours. Once monitoring is finished, the 14-gauge slit catheter will be removed from the leg.
46075448|NCT04230798|Other|Injury prevention program|The intervention program consisted in 16 sessions, performed during eight weeks, twice per week. Intervention group performed 20 minutes sessions before their habitual volleyball training. The structure of the prevention program consisted in a warm up, a lower limb strength exercise; two core exercises; a lower limb plyometric exercise, and a lower limb stability exercise. While the injury prevention program was being performed, both groups continued with their volleyball training sessions.
45657341|NCT04810819|Drug|Methylprednisolone 40 MG Injection;Dihydroxypropyltheophylline;|Before anesthesia induction, 80 mg methylprednisolone and 100 ml saline were given intravenously, and 0.25 g dihydroxypropyltheophylline and 100 ml normal saline were given intravenously.
45657342|NCT04810819|Drug|Placebo|Placebo
46075449|NCT00875173|Drug|Selenium|selenium as a drug according to Brazilian regulation laws
45657343|NCT04799509|Procedure|VATS lobectomy|VATS lobectomy
45809064|NCT01841359|Drug|Pramlintide|See description above (arm description).
46075450|NCT00875173|Drug|Placebo (for Selenium)|Placebo with similar flavor, smell and colour.
45809065|NCT01824875|Drug|temozolomide|Given PO
45809066|NCT01824875|Drug|capecitabine|Given PO
46075451|NCT04039477|Drug|KZR-616|Patients will receive KZR-616 SC once weekly. Patients assigned to Arm A will receive 30 mg for 13 weeks and patients assigned to Arm B will receive 30 mg for 1 week then 45 mg for 12 weeks
45657344|NCT04810663|Radiation|Radiotherapy|Adjuvant Radiotherapy in operated gastric cancer
45453211|NCT01584505|Drug|CHF1535 + CHF5992 dose 1 BID|CHF1535 + CHF5992 dose 1 BID for 14 days
45657345|NCT04810507|Drug|Anagliptin BID Treatment|Continuous Glucose Monitoring with Anagliptin 100mg BID or Sitagliptin 100mg QD treatment for 12 weeks
45657346|NCT04810585|Drug|Aflibercept + FOLFIRI|"Day 1. Aflibercept + FOLFIRI~aflibercept(Zaltrap): 4 mg/kg IV infusion for over 1hr (Do not administer as an IV push or bolus)~Folinic acid: 400 mg/m2 IV infusion for over 2 hours~Irinotecan: 150 mg/m2 IV infusion for over 1 hours~5-FU: 400 mg/m2 IV bolus injection for over 5 minute~5-FU: 2400 mg/m2 IV continuous infusion for 46 hours every 2 weeks until progression disease or death or unacceptable toxicity"
45809067|NCT01806129|Other|Standard practice related to reproductive heath|Patients undergo usual standard practice related to reproductive health.
45809068|NCT01806129|Other|Training modules, algorithm, referral development|Patients undergo reproductive health program comprising didactics, reproductive health assessment and navigating algorithm, and network development.
45809069|NCT01786486|Device|Amplatzer Cardiac Plug|
45657347|NCT04787887|Drug|Abcertin|60IU/kg Single Intravenous Administration
45809070|NCT01724346|Drug|Post-Chlorambucil Therapy Follow-up|Patients remain in this Arm for continued follow-up until PD, unacceptable toxicity, or other reason for treatment discontinuation. All patients in this Arm have completed Chlorambucil therapy. Patients who have progression will exit the study.
45809071|NCT01724346|Drug|Ibrutinib|Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily.
45809072|NCT01724346|Drug|Second-line Ibrutinib|Patients in this arm who were previously eligible to receive Second-line Ibrutinib will exit the study with option to roll-over to another long-term Ibrutinib study, if eligible.
45809073|NCT01724346|Drug|Alternative Anticancer Treatment|Specific therapy and treatment regimen are at the Investigator's discretion.
45809074|NCT01724346|Drug|Alternative Anti-cancer Treatment|Specific therapy and treatment regimen are at the Investigator's discretion. Patients originally randomized to Chlorambucil will exit the study. Patients originally randomized to Ibrutinib will continue on study.
45809075|NCT01683279|Biological|Autologous CD19 CAR+ EGFTt + T cells|Autologous T cell modified to express a CD19 specific CAR and a truncated EGFRt tag
45809076|NCT01660451|Drug|Copanlisib (Aliqopa, BAY80-6946)|"BAY 80-6946 is administered in a normal saline solution, 100 mL, intravenously over 1h. No intravenous glucose preparations should be administered on the days of infusion. Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).~Part A: The individual dose will be 0.8 mg/kg (max. 65 mg) per infusion from Cycle 1 on. The maximum dose of 65 mg should never be exceeded.~Part B: The individual dose will be 60 mg per infusion from Cycle 1 on."
45809077|NCT01601678|Procedure|Peroral Endoscopic Myotomy (POEM)|After lavage, measure gastro-esophageal junction (GEJ) in cm from mouth piece. Determine entry point 12-14cm above GEJ at the lesser curvature site, inject 10ml coloured saline, create entry point. Advance endoscope into the submucosa, dissect the submucosal tunnel up to 2-3cm into the cardia. Dissect the submucosa close to the muscularis and check endoluminally for the direction of the lesser curvature, sufficient extension onto the cardia and mucosal integrity. After tunnel completion flush with gentamycin and saline. Start myotomy from proximally to distally starting 4-5cm below the mucosal entry site; the inner circular muscle layer should be fully dissected especially at the cardia for good symptomatic results. It is vital that the mucosa of the tubular esophagus remains intact. Extend myotomy at least 2cm onto the cardia. After completion check for mucosal integrity and opening of the distal esophageal sphincter. Close the entry point with clips from distal to proximal.
45809078|NCT01601678|Procedure|Laparoscopic Heller Myotomy (LHM)|Use five trocar technique with patient in the French position as for laparoscopic anti-reflux procedures. Establish 12-15 mm Hg pneumoperitoneum. Use left paramedian trocar for camera, two lateral trocars for elevating liver and retraction of stomach and two trocars for dissection and suturing. Use of robotic surgery devices is allowed. Divide phrenoesophageal ligament starting on the right and mobilize distal esophagus on the lateral and anterior side. Identify and spare anterior vagal nerve. Perform myotomy by dividing both muscle-layers extending at least 6 cm above gastroesophageal junction and at least 2-3 cm inferiorly over stomach. Perform extent downwards after dividing epiphrenic fat pad overlying cardia. Measure myotomy length. Peroperative endoscopy check is advisable. Perform anterior fundoplication according to Dor. Only if necessary mobilize fundus of the stomach by dividing short gastric vessels. Suture fundus to both cut edges of myotomy, using non-resorbable material.
45809079|NCT01586065|Device|Continuous Glucose Monitor (CGM)|CGM during 24-hr CRC stay.
45809080|NCT01579734|Drug|Tamoxifen|1 tablet, 5 mg / day for 5 years
45945250|NCT05830721|Other|Standard of Care|If assigned to standard of care, the participant will undergo monitoring within 1 hour of the start of ECMO. For standard of care group, this will involve monitoring the leg with the ECMO tubing with physical exam every 4 hours for the first 24 hours. This will be performed by a trained nurse. If at any time there is suspicion for ACS, the physical exam will be verified by an orthopedic surgeon. The orthopedic surgeon will decide if pressure measurements will be necessary. If so, then a single pressure measurement from each compartment will be taken with a needle device. If the ACS diagnosis is made, any further monitoring of that leg is stopped. The decision to proceed with surgery, or fasciotomy, will be a joint decision made by entire team, which includes surgeons and medical doctors. This is currently the standard of care at the Johns Hopkins Hospital.
45945251|NCT05830708|Dietary Supplement|Lactobacillus sp. probiotic|The probiotic product contains good bacteria Lactobacillus sp. and primarily maltodextrin as carrier. Sachets of products containing the probiotic appear as light-yellow powder. The probiotic products are kept at storage temperature range below 30oC according to the condition recommended by the manufacturer.
46002206|NCT04372498|Drug|Senicapoc (synonyms: ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide)|This study is conducted as open label, with each patient's response determined with an adaptive Bayesian model based on historical and baseline values for the primary endpoints of the trial. 3 monthly dose escalation steps will assess the efficacy of senicapoc in a dose range (10-40 mg/day) which has been used in prior trials for other indications.
46075452|NCT04029831|Drug|Propofol and Ketamine Mixture (Ketofol)|Each group was given Ketofol, but group K61 received mixture of propofol and ketamine in a ratio of 6:1 while K41 received 4:1
45809081|NCT01579734|Drug|Placebo|1 tablet day for 5 years
45809082|NCT01568671|Other|Room temperatures|Room temperature of metabolic chamber set between 16C and 31C
46075453|NCT05753241|Other|no intervention|It's only observational study. No interventions.
46075454|NCT00875251|Device|body composition|Measurements of body composition using 2 differents devices: Bioimpedance measurements will be made with the RJL System (Quantum BIA 101Q equipment) air-displacement plethysmography in the PEA POD System (Life Measurement).
46075455|NCT04230642|Device|The Quantum Surgical device|Robotic platform for needle placement
45809083|NCT01566240|Drug|Paclitaxel|Paclitaxel 80 mg/m2 (capped at 162mg maximum total dose) weekly for 6 weeks i.e. on days 1, 8, 15, 22, 29 & 36.
46075456|NCT04029675|Dietary Supplement|Vitamin C|Vitamin C is a strong antioxidant and has been shown to regenerate other antioxidants such as vitamin E, vitamin C also play an important role in immune function
46075457|NCT00878449|Drug|ABT-263|150mg of ABT-263 is taken daily for 3 out of 21 days. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
46075458|NCT00878449|Drug|etoposide/cisplatin|etoposide = 100 mg/m2 Days 1-3 of each Cycle; Max duration 6 cycles. cisplatin = 75 mg/m2 Day 1 of each Cycle; Max duration 6 cycles
45809084|NCT01566240|Drug|Carboplatin|Carboplatin AUC 2 (capped at 270mg maximum total dose) weekly for 6 weeks i.e. on day 1, 8, 15, 22, 29, & 36.
45809085|NCT01566240|Radiation|Radiotherapy|Radiotherapy comprising external beam 40-50.4Gy in 20-28 fractions plus intracavity brachytherapy to achieve a minimum total EQD2 dose of 78-86Gy.
46075459|NCT02783352|Procedure|arthroscopic rotator cuff repair|arthroscopic rotator cuff repair
46075460|NCT02783352|Procedure|autologous micro-fragmented adipose tissue|injection of autologous micro-fragmented adipose tissue (10 mL) after arthroscopic rotator cuff repair, in dry arthroscopy condition
46075461|NCT00878527|Device|CircuLite Synergy Pocket Circulatory Assist Device|Goal of successful implantation and follow-up for at least three months
46075462|NCT05753163|Combination Product|HAIC-FOLFOX combined with Sintilimab and Regorafenib|HAIC (FOLFOX: oxaliplatin 85mg/m2, 5- fluorouracil 2500mg/m2, calcium folinate 400mg/m2) was given every 4-6 weeks for 2-4 cycles depending on pts' health status, in combination with Sintilimab (200mg, iv, d1) and regorafenib (80mg, po, d1-21) every 3 weeks for up to 6 months .
46075463|NCT04039555|Device|CO2 intimate|Two sessions with CO2 intimate laser for vaginal symptoms treatment
45809086|NCT01566240|Drug|Cisplatin|Cisplatin 40 mg/m2 (capped at 70mg total dose) weekly for five weeks maximum, commencing in the first week of radiotherapy or as soon as blood counts have recovered from induction chemotherapy.
45657348|NCT04787887|Drug|EU-sourced Cerezyme|60IU/kg Single Intravenous Administration
45657349|NCT04799041|Drug|GTX 2/3|There were 15 patients in this group. Each one received only one treatment.
45945252|NCT05830708|Behavioral|Acceptance and commitment therapy|The ACT session is initiated by building good therapeutic rapport with the subject and gather important information such as experiential avoidance, external barriers, fusion past, unworkable actions, and strength of the subject, followed by formulation of the case. The session may began with coaching subjects on acknowledging and accepting their unpleasant thoughts and feelings. The therapy will also focus on defusion to reduce behavioral avoidance of unpleasant thoughts and feelings by acknowledging them but focus on the values identified. Mindfulness is also practice to allow focus onto the present and surrounding to create awareness among the subjects that they are many things in the surrounding which is more enjoyable that we can enjoy rather than making effort to distract or change or avoid the unpleasant thoughts and feelings.
45945253|NCT05830708|Dietary Supplement|Placebo|The placebo are in powder form prepare in sachet which is light-yellow in color and should be stored in temperature at below 30oC, which is similar to the appearance of the probiotic. Nevertheless, it contains only maltodextrin in same amount as in the placebo.
45809087|NCT01556399|Other|Tissue Sampling|A small sample of the duodenal adenoma will be obtained for molecular testing. The remaining adenoma will be sent for regular histological testing.
45809088|NCT01550198|Device|Advanced hemodynamic monitoring|Comprehensive advanced hemodynamic monitoring
45809089|NCT01529047|Behavioral|Personalized Feedback Intervention|Printed or electronic form containing personalized information about health-relevant behaviors
45809090|NCT01390584|Drug|Doxorubicin|IV
45809091|NCT01390584|Drug|Bleomycin|IV
45809092|NCT01390584|Drug|Vinblastine|IV
45945254|NCT05830695|Drug|human treated dentin matrix|human treated dentin matrix is compared with mineral trioxide aggregate in apexogenesis
45945255|NCT05830695|Drug|Mineral Trioxide Aggregate|mineral trioxide aggregate was used as control
45945256|NCT05830656|Behavioral|Exposure to nearby nature|Participants spend a minimum of 20 minutes in their favourite place in nearby nature.
45809093|NCT01390584|Diagnostic Test|PET|fludeoxyglucose F 18 Imaging exam
45453212|NCT01584505|Drug|CHF1535 + CHF5992 dose2 BID|CHF1535 + CHF5992 dose 2 BID for 14 days
45657350|NCT04799041|Drug|Placebo|There were 15 patients in this group. Each one received only one treatment.
45809094|NCT01390584|Radiation|INRT|selective external radiation therapy
45809095|NCT01390584|Drug|Dacarbazine|IV
45809096|NCT01390584|Drug|Etoposide|IV
45809097|NCT01390584|Drug|Cyclophosphamide|May be given orally, IV push, or by IV infusion
45809098|NCT01390584|Drug|Vincristine|IV
45809099|NCT01390584|Drug|Procarbazine|PO
45809100|NCT01390584|Drug|Prednisone|PO
45809101|NCT01385176|Device|Implant of investigational device system|Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.
45809102|NCT01385176|Procedure|Titration during the randomization phase|Amplitude of the chronically delivered vagus nerve stimulation in the experimental arm was adjusted to the highest tolerable by patient value. No chronically delivered vagus nerve stimulation in the control arm during the randomization phase.
45809103|NCT01385176|Procedure|Titration after the randomization phase|Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.
45809104|NCT01385176|Diagnostic Test|Blood Draw|Blood draw before implant and 6 months after implant at the end of the randomization phase.
45945257|NCT05830656|Behavioral|Exposure to virtual nature|Participants spend a minimum of 20 minutes watching virtual nature videos.
45945258|NCT05830617|Device|real tACS|The effect of transcranial alternating current stimulation (tACS) will be investigated in WP3. Patients will undergo standard intensive rehabilitation plus gamma tACS for two weeks.
45945259|NCT05830617|Device|sham tACS|In WP3, patients will undergo standard intensive rehabilitation plus sham tACS for two weeks.
45945260|NCT05830604|Procedure|Occlusal Splint Treatment- Non Invasive treatment|Each patient in the study had temporomandibular disorder. The first-line routine treatment of this disease is an occlusal splint. This treatment was applied to each patient. Surgical intervention was not performed.
46075464|NCT04039555|Device|Erbium-yag|Two sessions with Erbium-yag laser for vaginal symptoms treatment
46075465|NCT04039555|Device|CO2 intimate or Erbium-yag|Two sessions of one of the two lasers with no therapeuthical energy
45453213|NCT01584505|Drug|CHF1535 daily dose|CHF1535 daily dose for 14 days
45657351|NCT02347761|Drug|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
45657352|NCT02347761|Drug|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
45657353|NCT02347761|Drug|Placebo BID eFlow Closed System (CS) nebulizer|Placebo twice daily (BID) eFlow Closed System (CS) nebulizer
45657354|NCT04798807|Diagnostic Test|Nutritional screening|
45657355|NCT04798963|Procedure|On-clamp partial nephrectomy|Partial nephrectomy will performed with renal artery clamping (less than or equal to 25 minutes)
45809105|NCT01374841|Drug|Cyclophosphamide|14.5 mg/kg, IV qd on day -6 and -5 and 50 mg/kg, IV on day +3 and +4
45809106|NCT01374841|Other|Hematopoietic Stem Cell Transplantation,|Hematopoietic Stem Cell Transplantation,
45809107|NCT01368731|Procedure|Prophylactic use of coagulation therapy|The procedure is completed as per usual, and if the patient has been randomized to the intervention group the appropriate coagulation therapy will be applied immediately after standard EMR to visible vessels within the mucosal resection area.
46075466|NCT00875407|Other|Scintigraphy in 123I-IBZM|
46075467|NCT02786628|Other|Physical performance testing and patient-generated health data|All patients will complete cardiopulmonary exercise testing and 6 minute walk distance performance testing prior to a cycle of chemotherapy (or transplant) and wear a Fitbit Charge HR for the duration of one cycle of chemotherapy.
45809108|NCT01319565|Drug|Aldesleukin|Arm 1 and Arm 2 - Days 1 to 4: Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) for up to 5 days (maximum 15 doses).
45809109|NCT01319565|Drug|Cyclophosphamide|Arm 1 and Arm 2 - Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 mL D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
46075468|NCT00878683|Device|silicone catheter boot|silicone device using Dermabond
45945261|NCT05830591|Other|Characterization of the microbiome in oral and fecal samples|The oral and fecal samples are collected during the periodical dental hygiene session at the odonto-stomatology unit and during day hospital for younger children admitted for the first clinical evaluation at Division of Child Neurology and Psychiatry. Procedures will follow standardized protocols.
45945262|NCT05830578|Device|ASUS Blood Pressure Monitor/Oximeter/ECG Monitor|"The ASUS Blood Pressure Monitor/Oximeter/ECG Monitor analyzes data collected by the integrated electrical sensors on a ASUS Vivowatch to generate an ECG waveform similar to a Lead I, calculate average heart rate, and provide a rhythm classification to the user for a given 30 second session. When a user opens the ECG App while wearing the ASUS VivoWatch on one wrist and places the finger of the opposite hand on the digital crown, they are completing the circuit across the heart which begins a recording session.~Once the recording session is complete, the ECG App performs signal processing, feature extraction and rhythm classification to generate a session result."
45945263|NCT05830552|Other|Receving feedback|Receving regular feedback from a health provider
45945264|NCT05830552|Other|No regular feedback|No regular feedback from a health provider
45945265|NCT05830526|Other|Escape Room|"The next day, 55 students, who agreed to participate in the study, were divided into groups of 5, and they had to fill out a 10-question test, which includes the stages of the ERAS Protocol preoperative period, within the scope of the pre-test. A simulation room for students has been set up as an escape room. At the briefing on the theme of the escape room, it was explained that they would have 10 minutes to complete six missions using the clues given to them.~The 6 stations created in the room were numerically numbered from 1 to 6. There were question/answer cards at each station and a clue on the back of the correct answer card to reach the next station. The first clue was given by the observer who made the information in the information room.The student who could not get out of the room within 10 minutes was considered as unable to leave the escape room."
45945266|NCT05830513|Device|Virtual Reality|Women will be randomly allocated to undergo OPU either with the use of virutal reality (group A) or the control group with standard treatment, without analgesia(group B). The participants of group A will wear the Oculus Quest 2 and will be surrounded by a virtual world. They will see objects flying towards themselves. They will be able to interact with the virtual world by hand controllers and can try to catch the objects.
45945267|NCT05830500|Drug|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation simultaneously.
45945268|NCT05830487|Behavioral|Low AGE diet with reduced energy and fat|This group will be given a low AGE diet with reduced energy and fat,.
46075469|NCT02786238|Behavioral|Standard Behavioral Treatment (SBT)|See description of treatment arm.
46075470|NCT02786238|Behavioral|Acceptance-Based Treatment (ABT)|See description of treatment arm. **Cherokee Nation members receive only the ABT intervention as they are in an open, feasibility trial and are not randomized.**
45657356|NCT04798963|Procedure|Off-clamp partial nephrectomy|Partial nephrectomy will performed without renal artery clamping
45657357|NCT04798729|Device|Digital Occlusal Recording with T-Scan|Occlusal contact recordings of all the teeth were obtained digitally under conditions of maximum bite force and centric occlusion only with the T-Scan (T-Scan III, version 9.1, Tekscan Inc., South Boston, USA).
45945269|NCT05830487|Behavioral|Energy and fat-reduced normal diet|This group will be given a diet with reduced energy and fat, and AGE levels will not be interfered with
46075471|NCT00875719|Device|Oxygen concentrators versus constant flow axygen|Each patient performed 2 walking tests, and received oxygen supplementation from a portable concentrator or a liquid oxygen source, in a random order.
46075472|NCT00875719|Device|oxygen concentrator|comparison walk distance and saturation with continuous oxygen compared to intermittent oxygen
46075473|NCT04231812|Device|Laparoscopic Tissue Morcellation working space (bag)|"The LapBox is working space (bag) intended for use as a laparoscopic instrument port and tissue containment system that creates a working space allowing for visualization during power or manual morcellation procedure following a laparoscopic procedure for the excision of benign gynecologic tissue that is not suspected to contain malignancy"
46075474|NCT00875875|Drug|Rifaximin|Rifaximin 200 mg TID for 3 days OR Rifaximin 600 mg Daily for 3 days
46075475|NCT00875953|Procedure|standard neck dissection|standard surgical technique
46075476|NCT00875953|Procedure|Harmonic Scalpel Dissection|harmonic scalpel used for neck dissection after flaps are raised.
46075477|NCT01716312|Drug|Omalizumab|For each subject, treatment with omalizumab will start with a loading dose of 600 mg followed by a maintenance dose of 300 mg every 4 weeks. The study drug will be administered as a subcutaneous injection. On Week 0 and Week 16 the medication or placebo will be administered to subjects via 4 subcutaneous injections; the remaining weeks 2 injections will be administered.Subjects will be given written directions on dealing with adverse reactions. They will also receive an Epi-Pen before discharge and instructions on how to use it.
46075478|NCT00880243|Drug|GM-CSF|"Randomization 1: GM-CSF (5micogram/Kg/d) versus no GM-CSF during induction chemotherapy and all consolidation courses.~Randomiization 2: Consolidation high dose AraC versus consolidation EMA"
45657358|NCT04798729|Device|Digital Occlusal Recording with Cerec Omnicam|Occlusal contact recordings of all the teeth were obtained digitally under conditions of maximum bite force and centric occlusion only with the CEREC Omnicam™ (version 4.2, Sirona Dental Systems, New York, USA).
45809110|NCT01319565|Drug|Fludarabine|Arm 1 and Arm 2 - Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days.
45809111|NCT01319565|Biological|Young TIL|Arm 1 and Arm 2 - Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
45945270|NCT05830474|Procedure|Continuous intra-airway monitoring and intervention during surgey|Continuous monitoring was performed by visual double lumen bronchial catheter. Once sputum or blood gushing into the tracheal carina was found in the distal bronchus on the surgical side, the above secretions were sucked out with a sputum suction tube under video monitoring until the removal was complete
45809112|NCT01319565|Radiation|Total Body Irradiation (TBI)|Arm 2 - Days -3 to -1: Ondansetron 0.15 mg/kg IV x 1 dose pre-TBI. Patients will then receive 2 Gy TBI twice a day for 3 days (total dose 12 Gy) using a linear accelerator in Radiation Oncology.
45945271|NCT05830448|Behavioral|Cognitive Behavioral Therapy|The trial was planned to have a three-month announcement and an eight-week intervention period. Personal information form, Perceived Stress Scale, Coping with Stress Scale, Connor-Davidson Resilience Scale, Quality of Life Scale for Employees will be used in the pre-test phase of data collection. Participants meeting the inclusion criteria will be randomly assigned to the intervention and control groups. In order to support nurses in the intervention group to gain awareness of stress and anxiety and develop positive coping skills, 8 sessions of 40 minutes were planned, including interaction steps based on education and cognitive approach. As of the second week, homework will be given to individuals and they will be asked to submit these assignments to the researcher 2 days before the next interview. Participants who do not submit the assignments given in this study to the researcher on time will be excluded from the study even if they have completed the training.
45809113|NCT01290692|Biological|TVI-Brain-1|Following surgery, tumor tissue is used to generate a cancer vaccine. Patients are vaccinated with neutralized cells to initiate an immune response. Following vaccinations, the patient's white blood cells are collected, the white blood cells are stimulated and expanded, and are then reinfused into the patient's blood.
45809114|NCT01251965|Drug|Ruxolitinib|"Phase I - Starting dose of 50 mg by mouth twice a day for 28 day cycle.~Phase II - MTD reached in Phase I."
45809115|NCT01242800|Procedure|palliative surgery|Undergo standard palliative surgery
45945272|NCT05830448|Behavioral|T.R. Mobile Mental Health Support System produced by the Ministry of Health|No intervention will be applied to the individuals assigned to the control group by the researcher. Participants will be informed about the Mobile Mental Health Support System created by the Turkish Ministry of Health and will be directed to this application.
46075479|NCT02783586|Procedure|Quadratus Lumborum Block type II|Local anaesthetic injection on the posterior border of the quadratus lumborum muscle
46075480|NCT02783586|Procedure|Transversus Abdominalis Plane Block|Local anaesthetic injection between internal oblique and transversus abdominis muscle
46075481|NCT02783586|Drug|Bupivacaine|20 ml of bupivacaine with adrenaline
46075482|NCT02783586|Device|Ultraplex|A non-stimulating echogenic single-shot needle designed for regional analgesia under ultrasound guidance.
46075483|NCT00590577|Drug|Paliperidone palmitate 25 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Day 1 and 25 mg eq. i.m. Days 8, 36, 64
46075484|NCT00590577|Drug|Paliperidone palmitate 150 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Days 1, 8, 36, 64
46075485|NCT00590577|Drug|Placebo|Placebo i.m. Days 1, 8, 36, 64
45657359|NCT04787575|Procedure|Oxygen-ozone therapy|"Oxygen-ozone therapy (group a) will be performed by:~i) Self-haemoinfusion of 200 cc. with concentrations of 40-50 μg/ml, to be performed two/three times a week, for a time of 6 weeks (for a maximum of 15 sessions); ii) Subcutaneous injections in the perilesional site at the dose of 5 cc. with concentrations of 4 μg,/ml, Cleanse wounds with 100 cc of 5-10 ug ozone gas"
45657360|NCT04787263|Biological|CD19-CAR_Lenti T cell|Fresh peripheral blood mononuclear cells are manufactured to obtain CD19-CAR_Lenti T cell, second generation CAR T cells incorporating the 4-1BB costimulatory domain. The fresh product is infused following lymphodepletion chemotherapy at a dose of 1.0-3.0x10^6 CAR+ cells/kg.
45657361|NCT04810039|Other|Predict the outcome of the Glasgow Outcome Scale|Predict the outcome of the Glasgow Outcome Scale (GOS) score at 6 months compared to the actual outcome, in 20 anonymized records.
45657362|NCT04809727|Procedure|Cervical biopsy|4 quadrant biopsy
45657363|NCT04798417|Dietary Supplement|Probiotic supplement|Use of a probiotic sachet
45657364|NCT04798417|Dietary Supplement|Prebiotic supplement|Prebiotic sachets
45657365|NCT04798417|Dietary Supplement|Maltodextrin|Placebo comparator
45657366|NCT04426747|Other|No intervention|No intervention
45809116|NCT01242800|Procedure|therapeutic conventional surgery|Undergo early surgery
45809117|NCT01242800|Radiation|palliative radiation therapy|Undergo standard palliative radiotherapy
45809118|NCT01242800|Radiation|radiation therapy|Undergo radiotherapy
45809119|NCT01226316|Drug|AZD5363|Patients will receive a single dose of AZD5363, administered orally, followed by a 3-7 day wash-out period. Patients will then commence with twice-daily dosing, administered orally, every day, to cessation of therapy.
45945273|NCT05830435|Behavioral|Trier social stress test|TSST-VR-friendly: The assistant behind the desk asks the participant to prepare a small talk on their favourite holiday within 5 minutes. Then the participant is asked to tell about his holiday for 5 minutes. Then the participant is asked to do a simple math task: adding the number 5 to 0 for 5 minutes. The research assistant gives friendly gestures and verbal encouragements. TSST-VR-neutral: The assistant asks the participant to prepare a speech for a job interview in the upcoming 5 minutes. Then the participant is asked to deliver the speech for 5 minutes in front of two panelists and camera. Then the participant is asked to do a math task, subtracting the number 13 from 1022 for 5 minutes. During the performance the two panellist have neutral gestures and give neutral verbal instructions. TSST-VR unfriendly: The procedure of the TSST-VR unfriendly is the same as the neutral TSST-VR, with the addition that the two panellist give unfriendly gestures such as tapping on the table.
45945274|NCT05830422|Other|nothing|Follow-up observation was conducted without any intervention in an outpatient setting.
45945275|NCT05830383|Behavioral|PDCA circular management|"PDCA circular management means PlanDoCheckAction four steps"
45945276|NCT05830344|Device|Placebo Multi Radiance Medical® Super Pulsed Laser|Placebo, without therapeutic dose.
45945277|NCT05830344|Device|Active Multi Radiance Medical® Super Pulsed Laser|Active with a dose of 8.02 J per site.
45945278|NCT05830331|Other|ERASS Pathway|Enhanced Recovery After Spinal Surgery
45809120|NCT01226316|Drug|AZD5363|Patients will be given AZD5363 administered orally as a single dose, followed by a 3-7 day wash-out period. Patients will then receive AZD5363 twice daily on 6 or fewer days per weekly regimen, to cessation of therapy. Parts C,D: Oral AZD5363 twice daily, 4 days on treatment, 3 days off treatment, to cessation of therapy.
45809121|NCT01226316|Drug|AZD5363|Optional additional schedule. Patients will be given AZD5363 administered orally. Regimen to be determined in response to emerging clinical findings.
45945279|NCT05830318|Other|P-STEP Mobile Application|A mobile application that allows you track your walking habits while keeping you up to date with air quality information.
45945280|NCT05830305|Other|Mobile health intervention|A protocol-based intervention via phone calls, which includes anti-hypertensive drug adjustment and reinforcement of lifestyle modification, will be implemented.
45945281|NCT05830279|Genetic|Pharmacogenetic testing|Genotyping for CYP2D6 and CYP2C19
45945282|NCT05830279|Other|Drug-Drug interaction analysis|Evaluating potential drug interactions with CYP2D6, CYP2C9 and CYP3A4 inhibitors and inducers using the Medical Letter.
45809122|NCT01226316|Drug|AZD5363|Patients will receive oral AZD5363 twice daily (4 days on 3 days off treatment)combined with background therapy of fulvestrant at licensed dose of 500mg intramuscularly on days 1,15,29 and once monthly thereafter.
45945283|NCT05830266|Behavioral|"Mindful with your Baby group-based therapist-guided intervention"|"This 8-sessions long intervention is one of very few interventions that actively includes the baby in the therapy sessions. The intervention includes the following sessions: Becoming aware of the autopilot, Practice to really look at your baby, Getting back in touch with yourself, Responding sensitively to your baby, Taking care of yourself in the difficult moments, Distance and proximity: it's both part of it, Dealing with expectations of yourself and the environment and Mindful parenting: trial and error. The intervention is a group-based therapist-guided intervention via a video-conferencing tool (e.g., Zoom)."
45945284|NCT05830266|Behavioral|"Mindful with your baby self-guided online intervention"|"This 8-sessions long intervention includes the following sessions: Autopilot, Fresh view, At home in your body, Responsive versus reactive parenting, Kindness to yourself, Distance and proximity, Boundaries and taking care of yourself and Mindful parenting - day by day. The intervention is an individual self-guided online intervention."
45945285|NCT05830240|Drug|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
45657367|NCT04809649|Drug|SUBA-itraconazole|Participant will receive treatment with SUBA-itraconazole
45657368|NCT04354831|Biological|anti-SARS-CoV-2 convalescent plasma|"SARS-CoV-2 convalescent plasma (1-2 units; ~200-400 mL maximum dose as 7 ml/kg adjusted IBW )~Study drug will be administered as a single intravenous infusion"
45657369|NCT04787185|Radiation|Valutation of toxicity|"Observation of toxicity~All patient with Brain metastases from NSCLC who are candidates for RS or HFSRT in course of immunotherapy"
45657370|NCT04786795|Drug|Compound Azintamide Enteric-coated Tablets|the experimental group takes Compound Azintamide Enteric-coated Tablets.They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
45657371|NCT04786795|Drug|Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets|the control group takes Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
45809123|NCT01216683|Biological|rituximab|Given IV
45809124|NCT01216683|Drug|Bendamustin|Given IV
45809125|NCT01216683|Drug|bortezomib|Given IV
45809126|NCT01216683|Drug|lenalidomide|Given orally
45945286|NCT05830201|Behavioral|No Dog Present|Dog is not present during pin removal
45945287|NCT05830201|Behavioral|Dog is Present|Dog is present during pin removal
45945288|NCT05830188|Behavioral|Coping and Resilience Intervention for Adolescents|It is a school-based resilience enhancement program to help adolescents build skills of positive coping and social support to minimize negative coping and distress by sharing, identifying, and discussing their feelings, thoughts, and actions regarding problems and stressful events.
45945289|NCT05830188|Other|Printing materials of Coping and Resilience Intervention for Adolescents|Printing materials for the CERIA sessions will be given to school counselors who provide school counseling programs in the control group.
45945290|NCT05830175|Other|manual therapy for cervikal region|Joint mobilization: In the stroke individuals included in the mobilization group, Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization was applied with the Maitland method starting from the upper cervical region towards the lower cervical region, in 3 sets, 2 minutes and 1 minute rest.
45945291|NCT05830175|Other|osteopathic suboccipital myofascial release technique|The patient lies comfortably in the supine position. The therapist's forearms are supported on the treatment table, with the metacarpophalangeal and proximal interphalangeal joints flexed to approximately 45 degrees. After the therapist places his hands on the area where the patient's suboccipital muscles connect the occiput, he asks the patient to relax and rest his head on his fingers. Therapist pays attention to positioning the fingertips in suboccipital area No traction is performed during this technique. The position is maintained until the patient is relaxed. This treatment takes approximately 3-4 minutes.
45945292|NCT05830136|Drug|sodium bicarbonate Ringer's solution|Sodium bicarbonate Ringer's solution was used in Group A as intraoperative intravenous fluids. Lactate Ringer's solution was used in Group B as intraoperative intravenous fluids.
45945293|NCT05830110|Device|Active Vibrotactile Coordinated Reset|Gloves providing vibrotactile coordinated reset stimulation
45945294|NCT05830110|Device|Sham vibrotactile coordinated reset|Gloves providing sham vibrotactile coordinated reset stimulation
45945295|NCT05830097|Drug|CBP-1019|Light yellow to yellow loose lumps or powder；50mg/vial; Infusion for 90 minutes (± 10 minutes), once every 2 weeks.
45945296|NCT05830071|Drug|CHF5993|BDP/FF/GB 100/6/12.5 μg pMDI
45945297|NCT05830071|Drug|CHF5259|GB 12.5 μg pMDI
45945298|NCT05830071|Drug|Moxifloxacin 400mg|400 mg Oral Tablets
45945299|NCT05830071|Drug|CHF5993 Placebo|placebo pMDI
45945300|NCT05830058|Procedure|Biospecimen Collection|Undergo blood collection
45809127|NCT01166113|Drug|Pomalidomide, Cyclophosphamide, Prednisone|"Induction~This multicenter phase I followed by a phase II trial will evaluate the safety and efficacy of the combination Pomalidomide-Cyclophosphamide-Prednisone (PCP) in patients (pts) with MM relapsed/refractory to lenalidomide.~In the phase I we assess the maximum tolerated dose (MTD) of PCP in 25% of pts. The first 4 pts are given the second dose level, accrual continues with 4 pts per dose level for a maximum of 24 pts.~The dose level associated with an updated DLT is recommended for the next patient cohort.~Each patient is assigned to a salvage therapy including Cyclophosphamide and Prednisone (both 50 mg every other d), and Pomalidomide at one of the following doses:1 mg/d;1.5 mg/d;2 mg/d;2.5 mg/d~In the phase II a total of 43 pts will be treated with the MTD of PCP. Pts enrolled at the MTD during the phase I will be included in the Phase II trial.~Maintenance (each cycle repeated every 28 d, until PD) Pomalidomide: 2.5 mg/d; Prednisone: 25 mg every other d"
45945301|NCT05830058|Procedure|Computed Tomography|Undergo CT or PET/CT
45945302|NCT05830058|Procedure|Positron Emission Tomography|Undergo PET
45945303|NCT05830058|Other|Questionnaire Administration|Ancillary studies
45657372|NCT04375189|Other|High Risk Clinic|"Subgroup of primary care clinic where patients have longer time slots, supervision by one longitudinal attending, bedside presentations"
45657373|NCT04809337|Other|Exercise|After manuel therapy, the patients were allocated into two groups as Stabilization Exercise Group and Therapeutic Exercise Group randomly.
45945304|NCT05830058|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45945305|NCT05830045|Drug|QLP2117|Specified dose on specified days
45945306|NCT05830032|Dietary Supplement|Soluble corn fibre|As a powdered beverage
45945307|NCT05830032|Dietary Supplement|Inulin|As a powdered beverage
45945308|NCT05830032|Dietary Supplement|soluble corn fibre and inulin|As a powdered beverage
45945309|NCT05830032|Dietary Supplement|Maltodextrin|As a powdered beverage
45657374|NCT04808635|Other|no intervention, this is a cross sectional questionnaire based study.|no intervention, this is an observational cross sectional study
45945310|NCT05830019|Radiation|carbon ion radiotherapy|carbon ion radiotherapy
45945311|NCT05830006|Procedure|Microfat grafting|Microfat grafting in cleft lip nasal deformities
45945312|NCT05829980|Procedure|Laser assisted in-situ keratomileusis|Laser-Assisted In Situ Keratomileusis is a procedure that permanently changes the shape of the cornea using an excimer laser and the mechanical microkeratome (a blade device) used to cut a flap in the cornea.
45945313|NCT05829980|Procedure|Photorefractive keratectomy|Photorefractive keratectomy is a laser refractive procedure used to ablate the corneal stroma to correct refractive errors without cutting flap
45945314|NCT05829954|Other|questionnaire|All questionnaire were obtained via online survey system.
45945315|NCT05829928|Diagnostic Test|Infectious Disease Testing|Participants will undergo infectious disease testing.
45945316|NCT05829928|Procedure|Gonadal Tissue Removal|Removal of gonadal tissue will be done through a surgical procedure.
45945317|NCT05829915|Device|ROXPro© system (A-Champs)|The intervention consisted in 24 sessions (3/week) of a cognitive-multisensory-physical exercise program carried out in the patient's own home. The exercise program was designed by qualified personal trainers and psychologists, and implemented with the ROXPro© system (A-Champs) (https://a-champs.com; accessed on 8 January 2022). This system consists of small devices that provide visual, auditory and vibration stimuli with which the patient interacts. Through its mobile application, it allows the development of numerous sensory-cognitive-motor exercises adapted to the characteristics of the patients.
45945318|NCT05829915|Other|No exercise program|The control group did not received the physical exercise program
45945319|NCT05829902|Other|Herbal extract drink|30 ml drink containing 600 mg of lemon balm extract, tea leaves, brown sugar and flavoring agent, two weeks daily
45945320|NCT05829902|Other|Placebo|30 ml placebo drink containing maltodextrin, tea leaves, brown sugar and flavoring agent, two weeks daily
45945321|NCT05829876|Other|High Frequency ECG Mapping|A high frequency ECG map will be performed to assess the optimum left ventricular pacing site.
45945322|NCT05829876|Other|Q-LV Measurement|Measurement of Q wave on 12 lead ECG to LV stimulus to assess optimum left ventricular pacing site.
45945323|NCT05829863|Behavioral|educational message exposure|Exposing African American young adult vapers to persuasive anti-vaping public service announcements (PSAs) with the goal of reducing their subsequent e-cigarette use.
45945324|NCT05829850|Device|SYNOLIS VA 40/80|Three 2mL injections of SYNOLIS VA 40/80, one week apart
45809128|NCT01160107|Drug|RP followed by MPR|Induction (4 cycles):Lenalidomide 25 mg/die for 21 days followed by a 7 days rest period and Prednisone at 50 mg three times a week continuously . Consolidation (6 cycles): Melphalan 2 mg three times a week, Prednisone 50 mg three times a week, and Lenalidomide 15 mg/die for 21 days followed by a 7 days rest period. According to the results of the first stage the decisions are as follows: 1. Starting a second stage, at the same dose of lenalidomide for MPR cycles, if grade 3-4 adverse events are 25-50% and PR > 50%; 2. The study stop (if PR <40% and grade 3-4 adverse events >25-30%) 3. A new first stage may be started: - Lenalidomide 20 mg/die if grade 3-4 adverse events are < 25-30%, independently from efficacy; - Lenalidomide 10 mg/die if grade 3-4 adverse events are > 50% and PR rate > 50%. Maintenance: Lenalidomide 10 mg/day from day 1 to 21, followed by a 7-day rest period and Prednisone 25 mg three times a week.Each cycle will be repeated every 28 days, until PD.
45453214|NCT03949075|Drug|Enalapril|Participants will be assigned to daily administration of ACE inhibitors (Initially 5 mg Corodil® 'Enalapril' daily followed by up to 20 mg daily dependent on the blood pressure response) combined with an 8-week training period.
46075486|NCT00590577|Drug|Paliperidone palmitate 100 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Day 1 and 100 mg eq. i.m. Days 8, 36, 64
45945325|NCT05829837|Other|Ultrasonographic evaluation|Ultrasonographic evaluation for the thickness of piriformis muscle
45945326|NCT05829824|Behavioral|CareConnect|A combination of the Ask-Advise-Connect (AAC) with an Interactive Voice Response (IVR)
45657375|NCT05614219|Other|Biochemistry interpretive comment on elevated LDL-C levels|The interpretive comment on LDL-C will encourage for excluding secondary dyslipidemia (measuring Hba1C, TSH and checking current drugs and talk about diet). If secondary dyslipidemia ca be excluded we encourage to referral to lipid clinic. Familial hypercholesterolemia should be suspected if LDL-C > 4 mmol/L in persons under the age of 40, or LDL-C > 5 mmol/L in persons over the age of 40. The biochemistry interpretive comment will thus be released to the referring physician if the blood sample meet the criteria above. We advice that in pregnant women to control elevated LDL-C after childbirth.
45945327|NCT05829824|Other|AutoReach|Phone call / SMS Text
45945328|NCT05829824|Procedure|Biospecimen samples|Saliva and breath sample
45945329|NCT05829811|Device|Lifestyle APP and Artificial Intelligence solutions validation|The lifestyle APP will take into account all the psychological aspect linked to the disease, including the social isolation. Lifestyle APP is not a measurement technology but it is a preventive measures against diabetes evolution that provide insights and advices daily, by the collection of structured data of parameters, essential to feed the AI for Risk analysis module. The involvement of Physicians expert in this discipline will evaluate the effectiveness of the psychosocial education.
45809129|NCT01145495|Other|Laboratory Biomarker Analysis|Correlative studies
45945330|NCT05829798|Device|SYNOLIS VA 80/160|Single 4mL intra-articular injection of SYNOLIS VA 80/160
45945331|NCT05829798|Device|SYNOLIS VA 40/80|Single 2mL intra-articular injection of SYNOLIS VA 40/80
45945332|NCT05829785|Other|None (retrospective study)|None (retrospective study)
45945333|NCT05829746|Device|Tubridge|Intracranial stent for wide-necked aneurysms
45945334|NCT05829733|Device|SYNOLIS VA 80/160|SYNOLIS VA 80/160 (hyaluronic acid 80 mg, sorbitol 160 mg)
45945335|NCT05829720|Dietary Supplement|a2 Full Cream Milk|Mothers in this arm will drink a2 Full Cream Milk twice a day, 200ml each time, for 14 consecutive days. Infants in this arm will be fed with mather's breastmilk exclusively.
45945336|NCT05829720|Dietary Supplement|Conventional Milk (Weidendorf)|Mothers in this arm will drink Conventional Milk (Weidendorf) twice a day, 200ml each time, for 14 consecutive days. Infants in this arm will be fed with mather's breastmilk exclusively.
45945337|NCT05829642|Behavioral|Enhanced Care Management|"ECM aims to enable primary health care providers to coordinate care for patients with complex medical needs. It involves the close coordination of services across all treatment modalities and clinical team members, including primary care physicians, specialists, pharmacists, and other healthcare professionals. Providers undertake:~Comprehensive care planning: A comprehensive care plan is developed and updated by all members of the patient's healthcare team, including their primary care physician, specialist, and other providers, to ensure that all aspects of treatment are addressed.~Proactive outreach: Outreach activities, such as phone calls, home visits, and other forms of contact with the patient and their family are also used to promote patient engagement in health management~Monitoring: Close monitoring of patients and their health conditions is essential to ensure that treatments are effective and that any adverse effects are quickly identified and addressed"
45945338|NCT05829629|Biological|FluBHPVE6E7|Intracervical administration for first dose followed by intramuscular administration for subsequent doses at recommended dose level and determined schedule
45945339|NCT05829629|Drug|Placebo|Intracervical administration for first dose followed by intramuscular administration for subsequent doses at determined schedule
46075487|NCT00880321|Drug|GSK2118436|Dose escalation with GSK2118436 may proceed until either a maximum tolerated dose is established, or the toxicokinetic safety limit is reached.
45809130|NCT01145495|Drug|Lenalidomide|Given PO
45809131|NCT01145495|Biological|Rituximab|Given IV
45809132|NCT01124695|Drug|tamoxifen|PO
45809133|NCT01105169|Dietary Supplement|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
45809134|NCT01105169|Dietary Supplement|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
45945340|NCT05829512|Other|Validity and reliability study|Face-to-face questionnaire study
45945341|NCT05828823|Device|Hemodialysis twice weekly|Frequency and duration of hemodialysis is tailored to the patient. Adjuvant pharmacotherapy is prescribed to maintain volume, electrolyte and acid-base homeostasis ( e.g., diuretics, sodium bicarbonate and potassium binding patiromer)
46075488|NCT00880321|Drug|GSK2118436|Part 2 will use the recommended Part 2 dose of GSK2118436 identified during Part 1 of the study. Biologically active doses will be identified by measurement of pharmacodynamic markers in tumor tissue and blood across a range of doses and these doses may be explored in Part 2.
45453215|NCT03949075|Drug|Placebo|Participants will be assigned to daily administration of placebo (5-20 mg CaCO3) combined with an 8-week training period.
45809135|NCT01084083|Biological|cetuximab|Given IV
45945342|NCT05828823|Other|Hemodialysis thrice weekly|Conventional hemodialysis regimen
45945343|NCT05828758|Drug|Amoxicillin|Amoxicillin 10 mg/kg (50 mg/ml concentration) by nasogastric tube 3 times daily (8 hours apart) 10 minutes before bolus gastric feeding for 7 days.
45945344|NCT05828758|Other|Placebo|Distilled water 0.2 ml/kg by nasogastric tube 3 times daily (8 hours apart) 10 minutes before bolus gastric feeding for 7 days.
45809136|NCT01084083|Radiation|intensity-modulated radiation therapy (IMRT)|Patients undergo low-dose OR standard dose IMRT based on their clinical response to induction therapy
45945345|NCT05828082|Procedure|Biopsy|Undergo biopsy
45945346|NCT05828082|Procedure|Biospecimen Collection|Correlative studies
45945347|NCT05828082|Procedure|Computed Tomography|Undergo CT
45945348|NCT05828082|Procedure|Magnetic Resonance Imaging|Undergo MRI
46075489|NCT00880321|Drug|Midazolam|Midazolam will be administered alone and with GSK2118436 in a sub-set of subjects in Part 2 to study the effect of GSK2118436 on CYP3A using midazolam as a probe.
46075490|NCT02784990|Biological|Lipase, amylase and CRP (C-reactive protein) dosages|
46075491|NCT02877498|Other|Adaptive support ventilation|Adaptive support ventilation during invasive mechanical ventilation
46075492|NCT02877498|Other|Volume controlled ventilation|Volume controlled ventilation during invasive mechanical ventilation
45809137|NCT01084083|Drug|Paclitaxel|Given IV, 90 mg/m^2 on days 1, 8 and 15
45809138|NCT01084083|Drug|Cisplatin|Given IV, 75 mg/m^2 on day 1
45809139|NCT01079780|Biological|cetuximab|Given IV
45809140|NCT01079780|Biological|ramucirumab|Given IV
45809141|NCT01079780|Drug|irinotecan hydrochloride|Given IV
45809142|NCT01063179|Drug|Bortezomib, Melphalan, Prednisone, Thalidomide|"Induction therapy:~9 courses with weekly VELCADE (4 doses) in combination with oral Melphalan 9 mg/m2,oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course and Thalidomide 50 mg/day continuously. The dose of VELCADE is 1.3 mg/m2 administered as a bolus IV injection, on days 1, 8, 15, 22.~Maintenance therapy:~Thalidomide 50 mg/day continuously in combination with VELCADE 1.3 mg or maximum dose tolerated/m2/2 weeks. The maintenance will be initiated at the end of the 9th course and will be stopped after progression. The median expected duration of the maintenance treatment is approximately 2 years."
45809143|NCT01063179|Drug|Bortezomib, Melphalan, Prednisone|Induction therapy: 9 courses with weekly VELCADE(4 doses) in combination with oral Melphalan 9 mg/m2 and oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course. No maintenance therapy is scheduled
45809144|NCT01013961|Biological|alemtuzumab|Given IV
45809145|NCT01013961|Biological|rituximab|Given IV
45809146|NCT00980590|Device|Airway Scope|Tracheal intubation by Airway Scope
45809147|NCT00980590|Device|Macintosh Laryngoscope|Tracheal intubation by Macintosh Laryngoscope
45809148|NCT00979680|Radiation|High-Dose radiotherapy|Preoperative radiotherapy of 45 Gy/25 fractions of 1.8 Gy through three fields was delivered to the pelvis over 5 weeks, followed by a 18 Gy/10 fraction boost to the primary tumor over 2 weeks.
45809149|NCT00979680|Radiation|Chemo-radiotherapy|Chemotherapy (5-fluorouracil, 200 mg per square meter of body-surface area per day) was delivered over 5 weeks concurrently with the pelvic radiotherapy.
45945349|NCT05828082|Procedure|Positron Emission Tomography|Undergo PET/MRI or PET/CT
45945350|NCT05828082|Drug|Tuvusertib|Given PO
45945351|NCT05828082|Procedure|Ultrasound Imaging|Undergo U/S
46075493|NCT02608671|Procedure|Skin adhesive tape|
46075494|NCT02786316|Other|HIT program|HIT program for the rehabilitation of persons with NSCLBP
46075495|NCT02786316|Other|conventional rehabilitation program|a conventional rehabilitation program in persons with NSCLBP
46075496|NCT02608437|Drug|SGI-110|SGI-110: start at 30 mg/m2 s.c. on W0, 3, 6, 9 Day 1 - 5 q21 days. Dose level -1: 15 mg/m2; dose level +1: 45 mg/m2
46075497|NCT02608437|Drug|Ipilimumab|ipilimumab: 3 mg/Kg i.v. over 90 minutes on W1, 4, 7 and 10 for a total of 4 cycles.
45809150|NCT00959712|Behavioral|ECA Interaction|The technology uses a computer character (Embodied Conversational Agent (ECA)) that simulates face-to-face conversation. The ECA talks to the patient and the patient responds by tapping a touch-screen.
45809151|NCT00834093|Biological|Epstein-Barr Virus Specific Immunotherapy|
45809152|NCT00783510|Biological|adalimumab|As prescribed by treating physician
45945352|NCT05828030|Procedure|high flow nasal cannula|the patient receives HFNC after randomization. All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
45945353|NCT05828030|Procedure|Oxygen mask|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
45945354|NCT05827133|Other|No intervention|No intervention
45945355|NCT05826834|Device|ball-rolling (Myostorm ball)|the intervention group
46075498|NCT02786160|Dietary Supplement|HMO|
46075499|NCT02786160|Dietary Supplement|Dextropur|
46075500|NCT05753007|Drug|Cannabidiol (CBD)|Custom-formulated full-spectrum solution high in cannabidiol
46075501|NCT05753007|Drug|Placebo|Placebo solution
46075502|NCT04230330|Drug|IV Nivolumab|240mg every 2 weeks.
46075503|NCT04230330|Drug|IV Nivolumab|Initial treatment dose is 240mg every 2 weeks for 4 doses. Dose changes to 360mg every 3 weeks when given with GDP/L-aspa. Maintenance treatment dose is 240mg every 2 weeks.
46075504|NCT04230330|Drug|IV Gemcitabine|800mg/m2 on Days 1 and 8 every 21 days
46075505|NCT04230330|Drug|IV Cisplatin|20mg/m2 on Day 1 to 4 every 21 days
45945356|NCT05826665|Other|Persistent AF ablation assisted with the STAR Apollo Mapping System|This exploratory hypothesis generating data set will be collected during standard AF ablation procedures using FDA cleared technologies as described in their Instructions for Use (IFU). No randomization or experimental protocols will be used during this study, and all follow up will be performed as per the center's standard of care(SOC).
45657376|NCT04241575|Diagnostic Test|Simple fibrosis scores and electronic reminder messages|"For patients in the intervention group, we will calculate the fibrosis scores. For patients with increased fibrosis scores, we will type the following pop-up message in our electronic clinical management system:~This patient has high Fibrosis-4 index (and/or AST-to-platelet ratio index) of xxx suggestive of significant liver fibrosis. Please consider referring the patient to the hepatology clinic or arranging further test such as FibroScan.~The reminder message will pop up when physicians see the patient at the clinic and use the electronic clinical management system. The message will remain active for one year. Although the message is entered manually at this stage, the arrangement mimics an automated computer system. If the study results are positive, the next step is to modify the system to automate the process."
45809153|NCT00783510|Drug|Methotrexate|As prescribed by treating physician
45809154|NCT00779194|Drug|Rapamycin|Rapamycin, is given to this group at a starting dose of 2 mg/day.
45809155|NCT00665600|Drug|Levalbuterol HCl|Levalbuterol 0.63 TID
45945357|NCT05826067|Other|collection of bacterial strains|Urine (and blood) samples will be collected following SOC procedures for diagnostic purposes, at each visit of the patient (initial visit, follow up study or visit for new episode. For patients needing a catheter, urine sample will be collected before the insertion of the catheter, and before renewal of the catheter. Catheter tips will also be collected and sonicated to isolate bacteria. E. coli will be stored for analysis.
45945358|NCT05825911|Diagnostic Test|Rest/Stress MCG scan|All patients enrolled and receiving standard screening tests for CAD will undergo rest/stress MCG scan before CAG.
45809156|NCT00665600|Drug|Levalbuterol HCl|Levabuterol 1.25 mg TID
45945359|NCT05825911|Diagnostic Test|Rest MCG scan|This is an normal adult population with age-, and sex-matched control group. All participants enrolled will undergo rest MCG scan.
45945360|NCT05823805|Other|Community Health Worker|"Physicians will work with a Community Health Worker (CHW) to review the data presented in their Quality Improvement reports, and triage patients for proactive outreach (e.g. No action necessary, Call patient to check-in, Arrange BP, weight and labs, Book for phone appointment, Book for in-person appointment)."
45809157|NCT00665600|Drug|Albuterol Sulfate|Racemic albuterol 2.5 mg TID
45945361|NCT05823688|Device|Electrical Impedance Tomography|Measure of regional ventilation by Electrical Impedance Tomography (EIT) before and during pneumoperitoneum
45945362|NCT05823025|Other|PWV measurement|Patient will have its PWV measured with the reference (the SphygmoCor) and by stepping on Withings bathroom scales WBS08 and WBS12.
45945363|NCT05821725|Device|Hyaluronic acid|Hyaluronic acid and hemostatic sponge
45945364|NCT05821725|Device|Control|Hemostatic sponge
45945365|NCT05820997|Drug|Ropivacaine|Paravertebral at the T7-10 levels bilaterally with 5 cc of 0.5% ropivacaine at each level
45809158|NCT00665600|Drug|Placebo|Placebo TID
45809159|NCT00606294|Radiation|fluorine-18-labeled fluoro-misonidazole (18F-FMISO)|
45809160|NCT00606294|Device|18F-FMISO PET scan|
45809161|NCT00606294|Device|MRI|
45945366|NCT05820581|Behavioral|Mentalisation|Hypomentalisation, hypermentalisation, correct mentalisation, lack of mentalisation
45945367|NCT05820178|Device|tDCS|On the basis of conventional treatment, tDCS was given on day 2 after enrollment for a total of 14 days, once a day.
45945368|NCT05820178|Device|rTMS|On the basis of conventional treatment, rTMS was given on day 2 after enrollment for a total of 14 days, once a day.
46075506|NCT04230330|Drug|IV/PO Dexamethasone|10mg on Days 1 to 4 every 21 days
46075507|NCT04230330|Drug|IV L-asparaginase|6000 Units/m2 on Days 2 to 8 every 21 days
46075508|NCT00914043|Genetic|gene expression analysis|
45453216|NCT03951727|Device|Endovascular treatment for PAD|Long femoropopliteal stenting with SuperA devices
45809162|NCT00606294|Device|FDG PET/CT scan|
45809163|NCT00583596|Device|Device closure with AMPLATZER Duct Occluder|Device closure with AMPLATZER Duct Occluder
45809164|NCT00583596|Other|Objective Performance Criteria|Compare results of device closure to objective performance criteria
45809165|NCT00551928|Drug|Melphalan|High dose Melphalan 200mg/sm with autologous stem cell support
45809166|NCT00551928|Drug|Lenalidomide|Six months of oral therapy with Lenalidomide 10mg/day given 21 days in every 28 days cycle with the combination ofMelphalan and steroids (day 22 to 28), for 6 cycles every 28 days.
45809167|NCT00551928|Drug|Prednisone|Given orally at the dose of 2 mg/Kg for 4 days followed by a 24 day rest period (days 5 to 28), for 6 cycles every 28 days
45809168|NCT00551928|Drug|Melphalan|Melphalan will be given orally at the dose of 0.18 mg/Kg for 4 days, followed by a 24 days rest period (day 5 to 28)for 6 cycles every 28 days
45809169|NCT00503438|Device|Salto Talaris Ankle|Salto Talaris Anatomic Ankle total joint prosthesis
45809170|NCT00500994|Device|MRI|The imaging study will use a block design to (i) optimize amygdala activation to emotionally valenced images, (ii) to optimize analysis of PPI and (iii) to optimize the go/no-task design. G. T2-sensitive functional images will be obtained on a MRI system with a 1.5 Tesla superconducting magnet and a standard head coil. An echo planar image sequence (TR=2500msec, TE=33 msec, 90 flip angle) with 30 contiguous 2mm thick coronal oblique slices with 1 mm interslice gap centered over the amygdala, tilted 30 to the anterior, to improve susceptibility artifact. Three-dimensional anatomical images will be taken for the co-registration of the functional images.
46075509|NCT00914043|Genetic|microarray analysis|
46075510|NCT00914043|Genetic|polymerase chain reaction|
46075511|NCT00914043|Genetic|polymorphism analysis|
46075512|NCT00914043|Genetic|reverse transcriptase-polymerase chain reaction|
46075513|NCT00914043|Other|biologic sample preservation procedure|
46075514|NCT00914043|Other|enzyme-linked immunosorbent assay|
46075515|NCT00914043|Other|laboratory biomarker analysis|
46075516|NCT00914043|Procedure|fatigue assessment and management|
45809171|NCT00477100|Procedure|Biospecimen Collection|Undergo collection of blood, tissue, and stool
45809172|NCT00477100|Other|Interview|Participate in interview
45945369|NCT05819346|Behavioral|Lifestyle|Participants assigned to the intervention group receive access to a lifestyle mobile application for three months after inpatient rehabilitation has finished. The digital program is target group-specific and includes personalization and interactive elements without face-to-face appointments during the intervention. One virtual appointment at the beginning of the intervention (about one week post-rehabilitation) with the study staff ensures that participants familiarize themselves with the mobile application and that they are assigned to a suitable program level. The intervention is mainly based on the following behavior change technique (BCT) clusters: goals and planning, feedback and monitoring, shaping knowledge, and comparison of behavior.
45945370|NCT05818631|Diagnostic Test|fusion cognitive prostate biopsy|A standard transrectal prostatic biopsy will be performed to both groups. To the group with suspicious lesions in the MRI (PI-RADS 3-5), an added directed cognitive fusion biopsy will be performed.
45945371|NCT05818358|Dietary Supplement|black beans|¾ cup of cooked black beans
45945372|NCT05818358|Dietary Supplement|wheat berries|¾ cup of cooked whole wheat grain
45945373|NCT05818358|Dietary Supplement|white rice|¾ cup of cooked white rice
45809173|NCT00477100|Other|Medical Chart Review|Undergo collection of medical data
45945374|NCT05817188|Other|No intervention|No intervention was applied
45945375|NCT05814523|Drug|Ganaxolone|Ganaxolone will be administered as IV solution.
45945376|NCT05814523|Drug|Placebo|Placebo will be administered as IV solution.
45809174|NCT00477100|Other|Questionnaire Administration|Ancillary Studies
45809175|NCT00369499|Device|PFO Closure|
45945377|NCT05814523|Drug|Standard of care|A non-anesthetic medication not previously used for treatment of SE within the current episode and will be administered at a dose sufficient for the termination of SE according to investigator judgment.
45945378|NCT05813678|Drug|Pegvaliase|This is an uncontrolled, single-cohort, Phase 4 observational study not falling under the definition of an Applicable Clinical Trial (ACT) (i.e., non-interventional).
45945379|NCT05807477|Device|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
45945380|NCT05807464|Device|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
45945381|NCT05807126|Procedure|Biopsy|Undergo biopsies
45945382|NCT05807126|Procedure|Biospecimen Collection|Undergo collection of blood samples
46075517|NCT02785068|Drug|MM-151|Oligoclonal antibody
45809176|NCT00330564|Drug|SU011248|50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).
45809177|NCT00316888|Biological|cetuximab|Given IV
45809178|NCT00316888|Drug|cisplatin|Given IV
45809179|NCT00316888|Drug|fluorouracil|Given IV
45809180|NCT00316888|Radiation|radiotherapy|Given once daily 5 days a week for 5 weeks
45809181|NCT00309478|Drug|Cyclophosphamide|Cyclophosphamide 600mg/m2
45809182|NCT00309478|Drug|Methotrexate|Methotrexate 40mg/m2
45809183|NCT00309478|Drug|Fluorouracil implant|Fluorouracil 600mg/m2
45809184|NCT00309478|Drug|Goserelin|Zoladex 3.6mg/28 days for 3 years
45809185|NCT00309478|Drug|Tamoxifen|Nolvadex 20mg/day for 5 years
45809186|NCT00295646|Drug|tamoxifen|20 mg/d
45809187|NCT00295646|Drug|anastrozole|1 mg/d
45809188|NCT00295646|Drug|zoledronic acid|4 mg q6m
45809189|NCT00295646|Other|goserelin|3.6 mg goserelin subcutaneously every 28 days
45809190|NCT00274924|Biological|filgrastim|Given subcutaneously or intravenous bolus.
45809191|NCT00274924|Biological|rituximab|Given IV
45809192|NCT00274924|Drug|carboplatin|Given IV
45809193|NCT00274924|Drug|cyclophosphamide|Given IV
45809194|NCT00274924|Drug|doxorubicin hydrochloride|Given IV
45809195|NCT00274924|Drug|etoposide|Given IV
45809196|NCT00274924|Drug|ifosfamide|Given IV
45809197|NCT00274924|Drug|prednisone|Taken orally
45809198|NCT00274924|Drug|vincristine|Given IV
45809199|NCT00104884|Drug|Depsipeptide|Given IV
45809200|NCT00096174|Biological|cetuximab C225|400 mg/m^2 IV over 120 minutes on Day 1, 250 mg/m^2 IV over 60 minutes on Day 8, then weekly
45945383|NCT05807126|Procedure|Computed Tomography|Undergo CT
45945384|NCT05807126|Procedure|Magnetic Resonance Imaging|Undergo MRI
45945385|NCT05807126|Biological|Magrolimab|Given IV
45945386|NCT05807126|Drug|Olaparib|Given PO
45945387|NCT05805722|Behavioral|Behavioral counseling for tobacco cessation|"Participants can choose to receive behavioral counseling in group v. individual format:~Group Sessions: Participants will be offered the opportunity to attend 6 weekly 60-90 minute sessions Individual Sessions: Participants will be offered the opportunity to attend up to 12 30-45 minute sessions on a schedule mutually agreed upon between interventionist and participant"
45945388|NCT05803382|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
45945389|NCT05803382|Procedure|Biopsy|Undergo biopsy
45945390|NCT05803382|Procedure|Biospecimen Collection|Undergo collection of blood samples
45945391|NCT05803382|Drug|Capecitabine|Given PO
45945392|NCT05803382|Procedure|Computed Tomography|Undergo CT and PET/CT
45945393|NCT05803382|Procedure|Magnetic Resonance Imaging|Undergo MRI
45945394|NCT05803382|Procedure|Positron Emission Tomography|Undergo PET/CT
45945395|NCT05800249|Drug|PE0116|This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients with Advanced Solid Tumor
46075518|NCT02785068|Drug|nal-IRI|Nanoliposomal irinotecan
46075519|NCT02785068|Drug|Leucovorin|folinic acid
46075520|NCT02785068|Drug|5-FU|Chemotherapy
46075521|NCT05752929|Drug|Insulin|correction scheme with Rapid Acting Insulin Analogs according with the Umpierrez sensitive correction scheme
46075522|NCT05752929|Drug|insulin|correction scheme with Rapid Acting Insulin Analogs according with the Davidson correction scheme
45657377|NCT02596945|Drug|Methoxy polyethylene glycol epoetin beta|Methoxy polyethylene glycol epoetin beta is prescribed as per physician's discretion in accordance with the Summary of Product Characteristics (SmPC).
45657378|NCT04761523|Behavioral|Dietary intervention: reduced fat diet|Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 15% fat, 65% carbohydrate, 20% protein content.
45945396|NCT05793905|Combination Product|Buffered lidocaine in inferior alveolar nerve block injection|Buffered Lidocaine 2% with epinephrine 1.80000 mixed with 1.8% sodium bicarbonate in IANB injection in the treatment of bilateral primary mandibular molars
45945397|NCT05793905|Drug|lidocaine 2% in inferior alveolar nerve block injection|Lidocaine 2% with epinephrine 1.80000 in IANB injection in the treatment of bilateral primary mandibular molars
45945398|NCT05793242|Device|Hypervolt|HyperVolt Percussive Massage Device: this will be performed by a physical therapist while the participant is prone. The physical therapist will apply a vibrating device to the back of the thigh with moderate pressure while continuously moving the device for 5 minutes.
45945399|NCT05793242|Device|Body Tempering|Body Tempering:this will be performed by a physical therapist while the participant is prone. The physical therapist will apply a moderately heavy metal device to the back of the thigh while continuously moving the device for 5 minutes.
45945400|NCT05793242|Device|Dry cupping|Dry Cupping: This will be performed by a physical therapist while the participant is prone. The physical therapist will apply several negative pressure devices to the back of your thigh for 5 minutes.
45809201|NCT00096174|Drug|cisplatin|75 mg/m^2 IV over 30-60 minutes starting day 15 every 3 weeks * 3 (Days 1, 22, and 43 of radiation therapy (RT))
45809202|NCT00096174|Radiation|radiation therapy|RT 70 Gy / 35 starting Day 15, 200cGy / d * 7 weeks (35 fractions)
45945401|NCT05793242|Other|Static stretching|Participants will perform a static stretch on their lower extremity. This stretch will be performed by having the participant loop a strap around their heel and grasping it with both hands followed by pulling the strap to raise the fully extended leg into hip flexion. The participant will be instructed to lift the leg until they reach their maximal tolerable point and then to hold the position for 30 seconds. They will then lower the extremity to the table and rest for 15 seconds This self-stretch sequence will be performed for 7 cycles so that the total intervention was equal to the intervention time of the other group (5 minutes).7
45945402|NCT05791591|Dietary Supplement|NUV001 - IR|Daily supplementation with 1000 mg of NUV001 (in two administration orally) immediate release gel capsule formulation for 90 days in total
45945403|NCT05791591|Dietary Supplement|NUV001 - GR|Daily supplementation with 1000 mg of NUV001 (in two administration orally) gastro resistant gel capsule formulation for 90 days in total
45657379|NCT04761523|Behavioral|Dietary intervention: standard healthy diet|Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 30% fat, 50% carbohydrate, 20% protein content.
45809203|NCT00080938|Drug|Temozolomide|Temozolomide (TMZ) to be given at a dose of 75 mg/m2/day for 14 days, starting on D1 of whole brain radiotherapy (WBRT). Three weeks after completion of WBRT, TMZ will be given at a dose of 200 mg/m2/day x 5 days (or 150 mg/m2/day if prior chemotherapy) every 28-days,for an additional two cycles.
45809204|NCT00080938|Radiation|Radiation therapy|Standard whole brain radiation therapy 30 Gy in ten fractions.
45809205|NCT00078949|Biological|rituximab|Given IV
45945404|NCT05791591|Dietary Supplement|Placebo|Placebo containing starch Powder (1000 mg, daily in two administration orally for 90 days)
45945405|NCT05791513|Other|Using the MAP-Knee Tool|Using the MAP-Knee Tool
45945406|NCT05791513|Other|Usual practice|The consultation between clinician and adolescent is conducted as per usual practice.
45945407|NCT05791474|Drug|ATI-2231|Provided by Aclaris Therapeutics, Inc.
45945408|NCT05790252|Drug|Buprenorphine Transdermal Matrix Patch|Buprenorphine transdermal patches will be applied at time of induction initiation and removed at 48 hours.
45945409|NCT05790252|Other|Sham patch|Bandage applied at time of induction initiation and removed at 48 hours.
45945410|NCT05789576|Drug|VTAMA (tapinarof) cream, 1%|VTAMA (tapinarof) cream, 1% applied topically once daily
45809206|NCT00078949|Drug|cisplatin|Given IV
45809207|NCT00078949|Drug|cytarabine|Given IV
45809208|NCT00078949|Drug|dexamethasone|Given IV
45945411|NCT05786924|Drug|BDTX-4933|RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active KRAS or NRAS mutations
45945412|NCT05780957|Other|MCED|multi-cancer early detection (MCED) test
45945413|NCT05776017|Biological|MSP3-CRM-Vac4All/ Alhydrogel®|30 microgram MSP3-CRM-Vac4All protein extemporaneously formulated with Alhydrogel® adjuvant
45945414|NCT05776017|Biological|Anti-Rabies Vaccine|Control vaccine
45945415|NCT05766020|Behavioral|Listen training|Auditory skills with the inclusion of cognitive control.
45945416|NCT05765435|Other|12-week exercise and walking program|The exercise program requires isometric quadriceps contractions in a supine position with a rolled-up towel placed behind the knee. The exercise program will be performed by participants 5 days per week for 12 weeks. The walking program will be performed 3 days per week for 12 weeks. Participants will walk for 10 minutes and then gradually increase walking time to 30 minutes by the end of the study. Participants will wear the device during the exercise and walking program, which may range from 1 minute to 35 minutes per day.
45657380|NCT04786483|Other|Laughter Theraphy|"Laughter therapy will be applied for 60 minutes, 10 sessions, 2 days a week. The therapy, which starts with the stimulation of the acupuncture points in the palm and acquaintance with hand clapping for an average of 10 minutes, continues with deep breathing and breathing exercises that include diaphragmatic breathing. The childish games section, which is played to reveal and trigger simulated laughter, is the section where laughter starts as if and turns into reality. The last part is the part where the group makes eye contact for no reason and for no reason, and laughs for at least 3 minutes unconditionally. In the last part, wish meditation and relaxation sessions are performed."
45657381|NCT04786327|Procedure|Minimal invasive flap technique|contained defect treated with Minimally invasive flap
45657382|NCT04786327|Procedure|Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin|contained defect treated by Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin graft
45809209|NCT00078949|Drug|gemcitabine hydrochloride|Given IV
45809210|NCT00074282|Biological|rituximab|
45945417|NCT05765435|Device|NMES|Sleeve applies neuromuscular stimulation during exercises to help contract appropriate muscles at appropriate times.
45945418|NCT05765435|Device|FES|Sleeve applies functional electrical stimulation as patients walk to help contract appropriate muscles at appropriate times.
45945419|NCT05754775|Behavioral|Calorie restriction via total food replacement|Restricted foods designed by a clinical nutritionist that delivers to home for diabetic patients.
45657383|NCT04786327|Combination Product|minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21S|contained defect treated with Minimally invasive flap with root conditioning (EDTA) and growth factor enhanced matrix application in the defect
45657384|NCT05614141|Device|Lokomat Augmented Performance Feedback|All participants will exercise with Lokomat Augmented Performance Feedback for six weeks. Augmented Performance Feedback has different virtual reality games.
45945420|NCT05754008|Behavioral|AURORA Care Strategy|Participants will be invited to partake in three telemedicine visits with the care navigator during the months following diagnosis. The visits center around proactive and tailored T2D self-management support.
45945421|NCT05750004|Procedure|computer guided immediate implant placement|Atraumatic extraction followed by immediate implant placement using safe angle position computer guided surgical stents, followed by customized healing abutments. after 3 months, Impressions for final prosthesis will be done
45809211|NCT00074282|Drug|cyclophosphamide|
45945422|NCT05749081|Drug|Lacidophilin tablets in combination with vonorazan dual therapy|2400mg lacidophilin tablets three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
46075523|NCT02783118|Other|Self administered online CBT|"The app being tested has two main components: courses and exercises. Courses represent the psycho-educational and therapeutic background of the program, comprising the following topics: information on depression, psychological vulnerability, what is CBT, healthy and unhealthy negative emotions, rational and irrational thoughts, how behaviors contribute to depression, sleep hygiene, social support, and relaxation techniques. Exercises use the information presented in the courses and follow the structure of a regular therapy session and/or therapeutic homework.~The following exercises are included in the app:~The Emotional Pulse exercise~The Sticky Notes exercise~The Find Irrational Thoughts~The Change Irrational Thoughts"
46075524|NCT04039321|Drug|ESPB group|USG probe will be placed in a longitudinal parasagittal orientation 3 cm lateral to T7 spinous process. The erector spinae muscles will be identified hyperechoic transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 21-gauge 10-cm needle was inserted using an in-plane superior-to-inferior approach or an outplane approach. Following confirmation of the correct position of the needle with 5 ml normal saline, a dose of 20 ml %0.25 bupivacaine will be administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine). Standard pain follow up and monitorization will be performed.
46075525|NCT04039321|Drug|Control group|The patients in this group will be performed no block. Standard pain follow up and monitorization will be performed.
45657385|NCT05614141|Other|Conventional Physiotherapy|Conventional physiotherapy includes stretching, strengthening, balance, coordination and walking exercises under the guidance of a physiotherapist.
46075526|NCT00878761|Biological|STX-100|SC, single dose followed by multiple dose
45657386|NCT04808713|Behavioral|Treatment|The treatment is a therapist-assisted self-help online cognitive-behaviour therapy focusing on post-traumatic stress, sleep and mood. It includes 12 sessions of evidence-based psychotherapeutic components, such as psychoeducation about PTSD, sleep and depression; prolonged exposure to avoided situations and memories; sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education); behavioural activation; relaxation and mindfulness exercises; problem-solving strategies; and cognitive restructuring. A small portion of material was unlocked each week, and access to one module was accessible after the completion of a previous one. Supervised graduate psychology students provided brief regular weekly contacts for 12 weeks by video chat or phone, according to the participant's preference. Access to the online material was unlimited in time.
45657387|NCT04153435|Drug|Calcium Chloride|Calcium chloride 5 mmol
45809212|NCT00074282|Drug|pentostatin|
45809213|NCT00074282|Drug|Alemtuzumab|
45657388|NCT04153435|Drug|Sodium chloride 0.9%|Placebo
45809214|NCT00071981|Biological|incomplete Freund's adjuvant|Given by injection
45809215|NCT00071981|Biological|melanoma helper peptide vaccine|Given by injection
45809216|NCT00071981|Biological|multi-epitope melanoma peptide vaccine|Given by injection
45809217|NCT00071981|Biological|sargramostim|Given by injection
45809218|NCT00071981|Biological|tetanus peptide melanoma vaccine|Given by injection
45809219|NCT00070291|Drug|cyclosporine|Cyclosporine doses will be based on actual body weight unless actual body weight is > 15 kg higher than the ideal body weight. Cyclosporine dose will be adjusted to maintain a trough whole blood level of 250-450 ng/mL during the high dose period (weeks 1 -6, starting dose will begin at cyclosporine 3 mg/kg by mouth two times a day (PO BID)) and 150-250 ng/mL during the maintenance period (weeks 7-36, maintenance dose will begin at cyclosporine 2 mg/kg PO BID) in the absence of renal toxicity
45945423|NCT05749081|Drug|Placebo in combination with vonorazan dual therapy|2400mg placebo three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
45945424|NCT05746325|Other|Digital Photography|Digital photographs taken of array placement
45945425|NCT05746325|Procedure|Lumbar Puncture|Undergo LP
45945426|NCT05746325|Procedure|Magnetic Resonance Imaging|Undergo MRI
45945427|NCT05746325|Device|Medical Device Usage and Evaluation|Transducer arrays applied and wear NovoTTF-200T
45945428|NCT05744648|Procedure|Adhesive resin restoration using Titania nanoparticle reinforced bonding agent|Each group will receive Adhesive resin restoration for Class-I and Class-II carious lesion. In group A, titania nanoparticle reinforced bonding agent will be used
45657389|NCT04121845|Device|Coronary Sinus Reducer device|Coronary sinus reducer device (Neovasc, Richomnd, Canada) implantation in the coronary sinus. The procedure is performed in the cardiac catheterization laboratory through right internal jugular vein.
45945429|NCT05744648|Procedure|Adhesive resin restoration without Titania nanoparticle incorporated bonding agen|Adhesive resin restoration without Titania nanoparticle incorporated bonding agen
45657390|NCT04121845|Other|Sham procedure|Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.
45657391|NCT02404389|Drug|Investigational Treatment|Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.
45945430|NCT05742321|Genetic|Genotyping|Genotyping will measure the triple nucleotide repeat in the TCF4 gene and search for other known mutations in other genes Blood sample will be performed (genetic analyses).
45657392|NCT02404389|Drug|Active comparator|Topical treatment with Aldara 3 times per week. The group will be open-label, but however blinded to the efficacy assessor, and followed by 8 week treatment free follow-up.
45657393|NCT01667419|Drug|Vemurafenib|4 tablets of vemurafenib 240 mg each (total 960 mg) were administered orally as per the schedule specified in the respective arm.
45945431|NCT05742321|Diagnostic Test|Histology|Histology will be performed on flat mounted Descemet membrane obtained after Descemetorhexis
45945432|NCT05742321|Other|Collection of data|Collection of data of examination for diagnosis of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
45657394|NCT01667419|Drug|Placebo|Placebo matching to vemurafenib were administered orally as per the schedule specified in the respective arm.
45657395|NCT01408225|Procedure|tissue banking|tissue procurement for this protocol will occur at the time of initial diagnosis, during routine follow-up, or at the time of relapse.
45809220|NCT00064350|Drug|Sorafenib|"Step 1 (induction): Sorafenib was giventwice daily for two cycles to all patients. Patients with progression (PD) discontinued treatment. Those who responded after two cycles continued treatment up to 1 year or until PD. With response after 1 year, patients were given the option to continue treatment until PD. Patients who were stable after the end of induction were then randomized onto Step 2 to either continue sorafenib or receive placebo.~Step 2 (randomization): Patients with stable disease after induction will be randomized in a double-blinded manner to placebo or sorafenib. If a patient has progressed, the arm will be unblinded. Patients on placebo with PD can then crossover to receive sorafenib; patients with PD on the sorafenib arm will be removed from the study.~Step 3 (crossover): If patients on placebo progressed within 1 year from randomization, they crossed over to the treatment arm and receive sorafenib for up to 1 year or until PD, unacceptable toxicity, or death."
45945433|NCT05735366|Drug|SAIL66|SAIL66 as a IV infusion
45945434|NCT05735366|Drug|Tocilizumab|Tocilizumab as a IV infusion
45809221|NCT00064350|Drug|Placebo|Patients randomized to the placebo arm in step 2 continued receiving placebo until disease progression or one year from randomization. Placebo was given orally twice a day (BID).
45809222|NCT00063986|Procedure|Minimally invasive esophagectomy (MIE)|Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
45809223|NCT00060346|Biological|rituximab|Rituximab is given intravenously. The initial rate is 50 mg/hr for the 1st hour. If no toxicity, the rate may be escalated in 50 mg/hr increments at 30-minute intervals to a maximum of 400 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr. If the patient experiences fever and rigors, the antibody infusion is discontinued. The severity of the side effects should be evaluated. If the symptoms improve, the infusion is continued initially at half the previous rate. Following the antibody infusion, the intravenous line should be maintained for medications as needed. If there are no complications after one hour of observation, the intravenous line may be discontinued.
45945435|NCT05735353|Behavioral|High-Speed Circuit Resistance Training|three times per week; 45 minutes per session; 12-weeks
45945436|NCT05735353|Behavioral|High-Speed Multidirectional Yoga|two times per week; 60 minutes per session; 12-weeks
45945437|NCT05730517|Dietary Supplement|CP5HA|Test group 1 will receive investigational product 1 containing collagen (5 g/ 15 mL), hyaluronic acid (30 mg/ 15 mL) and vitamin C (80 mg/ 15 mL); continuous administration of investigational product for 16 weeks.
45945438|NCT05730517|Dietary Supplement|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 25 mL: collagen: 0 mg, MSM: 0 mg, vitamin C: 0 mg; continous administration of placebo product for 16 weeks.
45945439|NCT05730517|Dietary Supplement|CP5|Test group 2 will receive investigational product 2 containing collagen (5 g/ 15 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 16 weeks.
45945440|NCT05723770|Drug|instillation of NOV03|This trial consists of 2 office visits over a period of approximately 2 weeks. At Visit 2, a designated clinical staff member or the investigator will instill 1 drop of NOV03 into each eye.
45657396|NCT04786015|Other|Active Surveillance Reporting System|A system to actively record change in symptoms older adult patients experience following a chiropractic visit.
45657397|NCT04089709|Behavioral|Well-arm Exercise|Patients randomized to the treatment arm will perform these exercises on the contralateral arm once daily for 3 months: wrist flexion and extension, ball or sock squeeze, wrist curls and biceps curls. Participants allocated to this study arm will be provided a print out of the exercises with detailed explanations and pictures of each exercise.
45657398|NCT04088773|Diagnostic Test|blood biomarkers|biomarkers to distinguish fibrotic vs non-fibrotic CD lesions
45458077|NCT01143025|Drug|Ropivacaine 100 mg|Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity
45657399|NCT04088773|Diagnostic Test|stool biomarkers|fecal biomarkers of inflammation, mucosal inflammation
45657400|NCT04088773|Diagnostic Test|MRI imaging|MRI imaging to detect bowel wall fibrosis and to detect inflamed, non-fibrotic from inflamed, fibrotic bowel
45945441|NCT05719675|Behavioral|Intervention|"The general outline of the intervention is divided into three phases:~Dispositional alteration, where the aim will be to obtain precise information on the barriers that patients encounter in carrying out their treatment and thus focus the issues to achieve an awareness of the disease by altering some of the factors that give rise to the realization of behaviors that interfere with treatment adherence.~Alteration of one's own behavior, focused on the development of healthy habits that are consistent with the indications of the health team for the proper management of the disease.~Alteration of the behavior of others, focused on the development of skills in the participants so that they are able to modify the behavior of other people close to them through health promotion strategies."
45809224|NCT00060346|Drug|cyclophosphamide|"Cyclophosphamide will be given at a dosage of 750 mg/m² intravenously on day 1 of each cycle (1 cycle =21 days) for 6 cycles. Dose is based on surface area calculated based on actual body weight.~The drug should be administered as a rapid IV infusion over 5 to 30 minutes."
45945442|NCT05717543|Device|Retro-illuminator|The device Retro-illuminator will be used to photograph the eyes.
45945443|NCT05715281|Biological|Atezolizumab|Given IV
45945444|NCT05715281|Procedure|Biopsy|Undergo tumor biopsy
45809225|NCT00060346|Drug|Doxorubicin|"Doxorubicin will be given intravenously at a dosage of 50 mg/m² on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Doxorubicin should be administered as a continuous infusion into tubing of a freely flowing intravenous line for 5 -15 minutes. Avoid extravasation."
45809226|NCT00060346|Drug|Prednisone|Prednisone will be administered at 100 mg/m² orally, days 1-5 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.
45809227|NCT00060346|Drug|Vincristine|"Vincristine will be administered 1.4 mg/m² intravenously (Maximum dose = 2.0 mg) on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Given as IV push over 1 minute, using extravasation precautions."
45657401|NCT04808791|Drug|Irinotecan|"Irinotecan is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase I inhibitor."
45809228|NCT00057954|Procedure|Extracorporeal Photopheresis|Day -7 to -4: Extracorporeal Photopheresis may be given as an outpatient therapy on two consecutive days any time between days -7 to -4. This must be performed on UVAR or XTS photopheresis machines (Therakos, Inc.) according to standard procedure as per manufacturer's guidelines.
45809229|NCT00057954|Drug|Pentostatin|Day -3, -2: Pentostatin 4 mg/m²/d by continuous IV infusion (Total dose = 8 mg/m²)
45809230|NCT00057954|Radiation|Total body irradiation (TBI)|Day -1: TBI 400 cGy total dose given in two 200cGy doses. Patients who have received TBI for a previous transplant or radiation as part of previous treatment for a lymphoid malignancy will receive only 200 cGy in 1 dose.
45809231|NCT00057954|Procedure|Allogeneic bone marrow transplantation|Day 0: Infusion of unmanipulated allogeneic bone marrow or stem cells. Minimum cell dose of 2 x 106 CD34 cells/kg recipient and no more than 10 x 10^6 CD34/kg
45809232|NCT00057954|Drug|Cyclosporin (CSA)|Cyclosporin A or tacrolimus will be administered according to institutional GVHD prophylaxis protocols. Therapeutic levels will be maintained and patients will be switched to oral agents when they can tolerate
45945445|NCT05715281|Procedure|Biospecimen Collection|Undergo blood sample collection
45809233|NCT00057954|Drug|Mycophenolate mofetil (MMF)|At day 100 MMF will be introduced at a dose of 250 mg po BID and cyclosporine or tacrolimus will be tapered according to the discretion of the investigator. The dosage will be escalated to a maximum of 2 g/d at the discretion of the attending physician and will be tapered and discontinued at 12 months if there is no active cGVHD. Doses should be given on an empty stomach
45945446|NCT05715281|Procedure|Computed Tomography|Undergo CT scan
45945447|NCT05715281|Procedure|Echocardiography|Undergo ECHO
45945448|NCT05715281|Drug|Tiragolumab|Given IV
45657402|NCT04808791|Drug|Oxaliplatin|"Oxaliplatin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Oxaliplatin is classified as an alkylating agent."
45657403|NCT04808791|Drug|TAS 102 (Trifluridine/Tipiracil)|"Trifluridine/Tipiracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an antimetabolite/pyrimidine analog; antimetabolite/thymidine phosphorylase inhibitor"
45657404|NCT04023019|Biological|Nuwiq|Nuwiq is a recombinant FVIII concentrate from a human cell line. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
45945449|NCT05712590|Other|dietary habit|As it is observational study, women that follow three different dietary patterns will be inlcuded .
45945450|NCT05709821|Drug|IMM60|IMM60, every 3 weeks for up to 6 cycles, intravenous (IV) infusion
45945451|NCT05709821|Drug|Pembrolizumab|Pembrolizumab, 200 mg, every 3 weeks for up to 35 cycles or approximately 2 years, intravenous (IV) infusion
45945452|NCT05707793|Other|Evaluating sexual function, quality of life and pelvic floor muscle strength, as well as thickness and force (strength) of voluntary contractions of the core muscles|Evaluation through Vaginal Laxity Questionnaire, Female Sexual Function Index, Short-Form 36 Health Survey, modified Oxford grading scale and ultrasound imaging
45945453|NCT05698602|Device|NivolisMonitor|"NivolisMonitor comprises a sensing element and controller to measure respiratory values, such as pressure and flow optionnally temperature, relative humidity and oxygen concentration, of a patient being treated with a respiratory therapy devices NIV, CPAP or HDN.~NivolisMonitor is inserted between the respiratory assistance device and the mask or cannula inline with the standard patient circuit used routinely with the respiratory assistance device.~NivolisMonitor functions are:~measure the respiratory values from the builtin sensor (Pressure, Flow, Temperature, Humidity, Oxygen fraction),~store the measurements in the embedded memory~extract from the measurement basic respiratory markers:~detect if and when a patient is using the respiratory assist device,~calculate leakage~calculate respiratory frequency~transmit the measured values via the NivolisBox component to NivolisPortal"
45945454|NCT05698602|Device|NivolisAnton|"NivolisAnton device enables wireless and remote communication from tcPCO2 monitors which measure transcuteanously CO2 and O2 partial pressures in the blood (tcPCO2 & tcPO2) .~NivolisAnton device connects to the serial port of tcPCO2 monitor, detects if the monitor is actively measuring blood gas values, collects the measurements from the monitor by following manufacturer's communication protocol and stores the collected values in its internal memory. When applicable per the manufacturer recommendations, NivolisAnton collects the values to apply the drift correction as per the manufacturer recommendations.~NivolisAnton transmits the collected data to external receiving devices, such as Medical Devices (NivolisMonitor or another Medical Device that is granted approved data access by Vivardis) via Bluetooth or data servers (NivolisBox as an example) via WIFI. This data is thereafter transmitted by previously mentioned devices to the NivolisPortal server for archiving."
45453217|NCT05625607|Procedure|Transcatheter mitral valve-in-valve implantation|Transcatheter transfemoral mitral valve-in-valve implantation is an alternative for surgery redo in high-surgical-risk patients with bioprosthetic valve failure. The procedure is performed via femoral vein access. By the transseptal puncture (in the postero-inferior part of the interatrial septum) and balloon septostomy, the bioprosthetic valve is introduced through the degenerative valve into the left ventricle. The valve is expanded in the mitral position during rapid ventricle pacing.
45945455|NCT05691517|Procedure|Biopsy|Undergo tumor biopsy
45945456|NCT05691517|Procedure|Biospecimen Collection|Undergo blood sample collection
45945457|NCT05691517|Procedure|Computed Tomography|Undergo CT scan
45945458|NCT05691517|Drug|pH Low Insertion Peptide-exatecan Conjugate CBX-12|Given IV
45945459|NCT05687123|Procedure|Biospecimen Collection|Undergo a blood sample collection
45809234|NCT00057954|Drug|Methotrexate (MTX)|"The dose of Methotrexate is based on the corrected ideal body weight for patients with > 33% above ideal weight.~Day +1 MTX 15 mg/m² IV push; Day +3 MTX 10 mg/m² IV push (May be omitted if patient develops mouth sores.)"
45809235|NCT00049530|Biological|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
45809236|NCT00045305|Drug|Cyclosporine|Immunosuppressant
45809237|NCT00045305|Drug|Methotrexate|Antimetabolite
45809238|NCT00045305|Drug|Photopheresis|Psoralens
45809239|NCT00045305|Drug|Mycofenolate mofetil|an antibiotic with immunosuppressamt properties isolated from Penicillium spp
45453218|NCT01101529|Drug|Aprepitant (Emend)|Aprepitant will be added to the standard anti-emetic therapy. Emend is given orally, 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after
45657405|NCT04023019|Biological|Octanate|Octanate is a high-purity human Factor VIII / von Willebrand Factor (VWF) concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
45657406|NCT04023019|Biological|Wilate|Wilate is a high-purity human von Willebrand Factor (VWF)/Factor VIII concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
45657407|NCT04023019|Biological|Emicizumab|Emicizumab is a therapeutic antibody which brings activated factor IX and factor X together It is administered via subcutaneous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
45809240|NCT00045305|Drug|Pentostatin|Purine analogue
45809241|NCT00045305|Procedure|allogeneic bone marrow|Unmanipulated allogeneic bone marrow
45809242|NCT00045305|Procedure|peripheral blood stem cell|G-CSF mobilized peripheral blood stem cell
45809243|NCT00045305|Radiation|Total body irradiation|a total of 600 cGy given in 3 200 cGy fractionated doses
45453219|NCT01101529|Drug|Placebo|Placebo will be administered instead of Emend
45657408|NCT04023019|Biological|Recombinant factor VIIa (rFVIIa)|Recombinant factor VIIa (rFVIIa) is a blood factor VII manufactured using recombinant technology. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
45945460|NCT05687123|Procedure|Computed Tomography|Undergo a CT scan
45657409|NCT04023019|Biological|Activated prothrombin complex concentrate (aPCC)|Activated prothrombin complex concentrate (aPCC) is an anti-inhibitor coagulant complex acting on multiple pathways to facilitate coagulation. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
45809244|NCT00033657|Drug|cisplatin|"Days 1 - 35 : Cisplatin 30 mg/m² days 1, 8, 15, 22, 29~Days 63 - 77 : cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
45809245|NCT00033657|Drug|irinotecan hydrochloride|"Days 1 - 35 : Irinotecan 65 mg/m² days 1, 8, 22, 29~Days 63 - 77 : irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
45809246|NCT00033657|Drug|paclitaxel|"Days 1 - 35 : Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29~Days 63 - 77 : paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles"
45809247|NCT00033657|Procedure|conventional surgery|The type of resection (lvor-Lewis, Transhiatal, etc.) was left to the discretion of the operating surgeon. One lymph node dissection was required.
45809248|NCT00033657|Radiation|radiation therapy|The total dose to the prescription point was 4500 cGy given in 25 fractions. The patient was treated with one fraction per day with all fields treated per day. 180 cGy was delivered to the isocenter. If the dose to the supraclavicular fossa (SCF) was less than 4500 cGy, a localized photon or electron boost was allowed in order to increase the SCF dose to 4500 cGy, specified at 3 cm depth from the anterior skin surface.
45945461|NCT05687123|Drug|Lutetium Lu 177 Dotatate|Given IV
45945462|NCT05687123|Procedure|Magnetic Resonance Imaging|Undergo MRI
45945463|NCT05687123|Procedure|Positron Emission Tomography|Undergo a SSR PET/CT scan
45945464|NCT05687123|Drug|Sunitinib Malate|Given PO
45809249|NCT00006421|Drug|2-Fluorodeoxyglucose|
45945465|NCT05680818|Drug|Encaleret|Encaleret is a drug product supplied as a film-coated tablet intended for oral administration
45945466|NCT05680818|Dietary Supplement|Calcium supplements and active Vitamin D (calcitriol, alfacalcidol, falecalcitriol, etc.)|Standard of Care
45945467|NCT05679167|Behavioral|Supervised digital training with focus on core stability|After randomization, Group 1 will be digitally supervised by experienced physiotherapist.
45945468|NCT05679167|Behavioral|Supervised digital training with focus on aerobic exercise|After randomization Group 2 will be digitally supervised by experienced physiotherapist.
45945469|NCT05679167|Behavioral|Non-supervised daily physical activity|After randomization Group 3 will receive training instruction regarding daily physical activity.
45945470|NCT05674344|Device|Masimo Temperature device|Non-invasive temperature device
45657410|NCT04808557|Other|Biorepair Total Protection|Volunteers will use Biorepair Total Protection for home oral hygiene for the following 30 days from the bonding procedure.
45657411|NCT04808557|Other|Sensodyne Repair & Protect|Volunteers will use Sensodyne Repair & Protect for home oral hygiene for the following 30 days from the bonding procedure.
45809250|NCT00003389|Drug|Doxorubicin|given IV
45809251|NCT00003389|Drug|Bleomycin|given IV
45945471|NCT05670379|Combination Product|NPM-119 (exenatide implant)|NPM-119 is a drug:device combination that delivers steady levels of exenatide, a glucagon-like peptide-1(GLP-1) receptor agonist, for an extended period of time following subdermal insertion.
45945472|NCT05670379|Drug|Bydureon BCise (exenatide extended release)|glucagon-like peptide-1 (GLP-1) receptor agonist
45945473|NCT05665270|Drug|Dextenza 0.4Mg Ophthalmic Insert|Group 1 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate drops QID x 1 week, then Dextenza will be inserted at the one-week postoperative evaluation (Day 8). Both groups will receive topical Prolensa Qa.m. x 5 weeks and Moxifloxacin TID x 1 week, per investigators preferential treatment regimen.
45945474|NCT05665270|Drug|Prednisolone Acetate 1%|"Group 2 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate for five weeks with dosing schedule: QID x 2 weeks, TID x 1 week, BID x 1 week, QD x 1 week.~Both groups will receive topical Prolensa Qa.m. x 5 weeks and Moxifloxacin TID x 1 week, per investigators preferential treatment regimen."
45945475|NCT05664477|Dietary Supplement|PhytoSERM|PhytoSERM is a dietary supplement containing equal amounts of genistein (16.7 mg ± 10%), daidzein (16.7 mg ± 10%) and S-equol (16.7 mg ± 10%).
45657412|NCT04808089|Other|Health Lung App. of mobile phone+ezOxygen mobile spirometry|"Subjects can get reminder to use inhaler on schedule, input ACT score to evaluate the asthma control, get education materials about asthma and operate spirometer to access lung function outside of hospital.~The physicians can get the information about control status, lung function, adherence of controller and usage of reliver of patients between each clinical visit, if patients following the instruction of Health Lung."
45809252|NCT00003389|Drug|Vinblastine|given IV
45809253|NCT00003389|Drug|Dacarbazine|given IV
45809254|NCT00003389|Drug|Vincristine|given IV
45809255|NCT00003389|Drug|Mechlorethamine|given IV
45809256|NCT00003389|Drug|Etoposide|given IV
45809257|NCT00003389|Drug|Prednisone|taken orally
45809258|NCT00003389|Drug|Cyclophosphamide|given IV
45809259|NCT00003389|Radiation|Radiotherapy|
45809260|NCT00003138|Biological|Erythropoietin|Administered at 150 units/kg subcutaneously every day. Rotating sites should be used. The dose should be rounded off to the nearest 1000 U. The dose should be adjusted based on hematocrit.
45809261|NCT00003138|Biological|Filgrastim|G-CSF should start at a dose of 1 mcg/kg per day or 2.5 mcg/kg three times a week subcutaneously. Rotating sites should be used The dose should be rounded off to the nearest 10 mcg.
45809262|NCT00003138|Procedure|Transfusion|Red cell and platelet transfusions
45809263|NCT00002525|Drug|fluorouracil|"Perioperative 5-FU: 600 mg/m^2/d x 7 days continuous IV, beginning within 24 hours of surgery~After surgery, 5-FU was given 425 mg/m^2 IV push on days 1-5"
45809264|NCT00002525|Drug|leucovorin calcium|given after surgery at dose of 20mg/m^2 IV push on days 1-5
45945476|NCT05664477|Drug|Placebo|Placebo product with identical shape, size and color will be produced with absence of S-equol, daidzein and genistein. Ingredients include calcium carbonate, comprecel M102, croscarmellose sodium, stearic acid, Zeofree 5162, magnesium stearate, carnauba wax, coating cellulose clear (PEG), coating white (PEG), water.
45809265|NCT00001379|Biological|Interferon|For LYG Grade 1 and 2: Interferon starting at 7.5 million Units subQ 3 times a week and increasing on the following schedule: 10 million U; 15 million U; 20 million U; 25 million U; and increased in 5 million U increments, as tolerated. Patients continue taking interferon for 1 year beyond CR.
45809266|NCT00001379|Drug|Rituxan and EPOCH|For LYG Grade 3: EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituxan) every 3 weeks for 6 cycles.
45945477|NCT05662579|Other|Exercises|"There will be 2 reevaluations of the participants, similar to the initial: at the end of the exercise protocol and in a follow-up of 12 weeks after the end of the protocol.~The contraction phase of each exercise will be 2 concentric seconds, 1 isometric second and 2 eccentric seconds, followed by 1 second of rest; there will be approximately 90 seconds of rest between each set of 10 repetitions, time the other member will be exercising.~At the beginning and at the end of each session, the participants will be asked to point out the pain they feel in the hip at that time. In each of the 8 sessions, the physiotherapist will take note of the presence, lateral pain in the hip at the beginning and end of the therapy (by VAS), number of repetitions performed in each exercise (for the group that will do core exercises, it will be noted the time in seconds of each exercise) and any adverse events. Each series of exercises will be repeated 3 times, all performed bilaterally."
45835811|NCT05371002|Behavioral|Online group nonviolent communication (NVC) interventions|"The primary purpose of NVC as defined by Dr. Marshall Rosenberg is to resolve interpersonal conflict using empathic communication skills. Nonviolence does not refer to the mere absence of physical harm. It is a way of life that helps us to transform old patterns of defensiveness and aggressiveness into compassion and empathy and to improve the quality of all types of relationships. The basic model of NVC consists of four key principles: the separation of observation from evaluation (observation), exploring and expressing the feelings that emerge from observations (feeling), taking responsibility for one's feelings (need), and telling others the need to enrich lives (request). A book on NVC specifically targets parents to improve communication and connection with their children. The NVC model emphasizes the importance of observation and has similarities with the concept of mindful parenting, which refers to a non-judgmental and open parenting style."
45945478|NCT05660447|Drug|Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]|One drop of rho-kinase (ROCK) inhibitor in the vitrectomized eye, once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
45945479|NCT05660447|Drug|Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud|Patients enrolled in the control group will receive a placebo (one drop of artificial tears) once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
45945480|NCT05658289|Procedure|Coracoid Transfer|For patients randomized to the active comparator group, the coracoid process and conjoined tendon will be cut and transferred to the anterior rim of the glenoid through an incision in the subscapularis muscle.
45945481|NCT05658289|Procedure|Distal Tibia Allograft with Bankart repair|For the experimental group, a distal tibia allograft will be prepped, cut (20mm x 10mm x 15mm), and inserted into the anterior aspect of the shoulder through a far medial portal. The distal tibia allograft will be attached to the anterior glenoid using cannulated screws. A soft tissue repair, Bankart repair, is performed above the graft.
45945482|NCT05653973|Drug|Acetylcholine|acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
45945483|NCT05653973|Drug|Endothelin-1|endothelin-1, endothelin-1 + BQ-788 (endothelin receptor type B-inhibitor), and endothelin-1 + BQ-123 (endothelin receptor type A-inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelin-mediated constriction and the role of the receptor subtypes in this response.
45945484|NCT05652790|Procedure|Enhanced Rehabilitation Programme|"The ERP would be offered at least two sessions, each lasting 60-120 minutes per week, delivered in the Manchester Institute of Health and Performance. Interventions may include a combination of the following depending on the individual patient needs.~Manual Therapy Hydrotherapy Exercise Strength and Conditioning Programmes Gait re-education Pilates/ Yoga Cognitive and Vocational Rehabilitation Occupation Therapy Interventions eg. Anxiety Management, Pacing, Cognitive Behavioural Therapy"
45945485|NCT05652790|Procedure|Standard Care|Standard care received at usual NHS facility
45945486|NCT05647200|Drug|Treatment: additional albumin during cardiopulmonary bypass|Treatment group (T): administration of 100 mL Human Albumin (20%), first dose directly after aortic cross clamping and blood cardioplegia administration, second dose after the third blood cardioplegia administration (± 30 min after the first dose).
45945487|NCT05647200|Drug|control: additional ringers during cardiopulmonary bypass|Control group (C): administration of 100 mL of Ringer's solution, first dose directly after aortic cross clamping and blood cardioplegia administration, second dose after the third blood cardioplegia administration (± 30 min after the first dose).
45945488|NCT05646719|Drug|Phentolamine Opthalmic Solution 0.75%|phentolamine ophthalmic solution 0.75% (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
45945489|NCT05646719|Other|Placebo|Vehicle for Phentolamine Ophthalmic Solution
45835812|NCT05371002|Other|Waitlist control group|Waitlist control, but included a short active intervention during the 2nd and 3rd assessments.
45835813|NCT04773756|Drug|Sofosbuvir 400 MG/ Daclatasvir 60mg|Giving these two drugs for treatment of COVID patients
45945490|NCT05646719|Drug|Low dose pilocarpine|Pilocarpine hydrochloride ophthalmic solution 0.4%
45809267|NCT04031911|Device|Hydroposturotherapy|"Hydroposturotherapy combines:~posturotherapy (patient placed upside down with water jets sent to the kidneys)~lumbar percussion~hyperdiuresis: prescribed quantities of water to be absorbed by the patient"
45945491|NCT05646719|Other|Low dose pilocarpine vehicle|Vehicle for low dose pilocarpine
45945492|NCT05644912|Device|Transanal irrigation (TAI)|Transanal irrigation (TAI) with new catheter on subjects experienced in using TAI with balloon catheter.
45945493|NCT05638802|Drug|DS-7011a|20 mg/kg intravenous dose to be administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
45945494|NCT05638802|Drug|Placebo|Saline intravenous solution administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
45945495|NCT05629338|Combination Product|Autologous Spray Dried Plasma|Evaluation of the Safety of Ascending Doses of Autologous Spray Dried Plasma in Healthy Volunteers
45809268|NCT04031911|Device|Standard support in urology|Dispensing of AFU plugs Dietary advice
45945496|NCT05628363|Device|Ethos Varian treatment system|Device that will be used to administer radiotherapy
45945497|NCT05628363|Radiation|Adaptive stereotactic body radiotherapy|Radiotherapy interruptions are acceptable as long as treatments are no more than 16 days apart.
45945498|NCT05628363|Drug|Androgen deprivation therapy|"Androgen deprivation therapy (ADT) will be administered to study patients according to institutional standard. Patients should initiate ADT beginning no sooner than 60 days prior to start of radiation. ADT is defined as a GnRH agonist/antagonist (leuprolide, goserelin, degarelix, or relugolix). Patients treated with leuprolide, goserelin, or degarelix should also receive an androgen receptor antagonist (flutamide or bicalutamide) for 30 days from the start of GnRH agonist/antagonist or until the end of radiation, depending on institutional standard and physician preference.~Agent selection is per treating physician discretion and will be administered per institutional standard and FDA-approved labeling."
45945499|NCT05627440|Dietary Supplement|Ensure Max Protein|Ensure Max Protein, 1 bottle daily (330 mL), 30 grams protein
45945500|NCT05627440|Dietary Supplement|Ensure Original|Ensure Original, 1 bottle daily (237 mL), 9 grams protein
45945501|NCT05626088|Other|No Intervention|This is a non-interventional study.
45809269|NCT05475522|Device|Ultrasound guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection using ultrasound
45809270|NCT05475522|Device|5-aminolevulinic acid fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope
46075527|NCT05295888|Device|Temporal Interference stimulation|TI involves simultaneous delivery of independent currents to the brain at slightly different kHz frequencies, which are individually too high to recruit neural firing. However, the difference ('beat') frequency where the currents overlap (i.e., temporally interfered) is low enough to drive neural activity. The interferometrically derived low frequencies have been demonstrated to activate neurons at a selected focus without activation of surrounding regions in awake mice. The safety of the TI paradigm has been demonstrated in over 60 healthy human volunteers, and finite element modeling of simulations of TI fields in human anatomical models suggests that large subcortical structures such as the hippocampus or SCC could be selectively targeted. However, the precise TI parameters for selective engagement of SCC in healthy participants and in MDD is currently unknown.
45809271|NCT05474274|Other|Machine learning algorithms|Machine learning techniques to rank order physiologic variables obtained via the wearable and handheld devices as well as remove low-importance and redundant variables to accurately determine postoperative pain intensity in outpatients
45809272|NCT05472558|Biological|anti-CD19 CAR-NK|lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19 CAR
45809273|NCT05470374|Procedure|Intraoperative sonography|ultrasound scanning of brain to search tumor remnants
45809274|NCT05646966|Other|one time testing|
45809275|NCT02259348|Drug|Cyclophosphamide|Given intravenously (IV)
45809276|NCT02259348|Drug|Fludarabine|Given IV
45809277|NCT02259348|Biological|G-CSF|Given IV or subcutaneously (SQ)
45945502|NCT05625633|Biological|Human Papillomavirus 9-valent Vaccine, Recombinant|0.5-mL suspension of 9-valent Gardasil administered as intramuscular injection at weeks 0, 4, and 20
45453220|NCT00003907|Drug|cisplatin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
45809278|NCT02259348|Biological|Interleukin-2|Given SQ
45809279|NCT02259348|Drug|Melphalan|Given IV
45809280|NCT02259348|Drug|Thiotepa|Given IV
45945503|NCT05625633|Other|Normal Saline|0.5-mL normal saline administered as intramuscular injection at weeks 0, 4, and 20
45945504|NCT05624125|Other|Beetroot juice|Two 70 ml beetroot juice drinks daily for 4 months.
45945505|NCT05624125|Other|Placebo|Two 70 ml placebo drinks daily for 4 months.
45945506|NCT05621395|Other|E-OJ-01|1 capsule (400 mg) orally to be taken after breakfast daily for 60 days
45945507|NCT05621395|Other|Microcrystalline cellulose|1 capsule (400 mg) orally to be taken after breakfast daily for 60 days
45945508|NCT05611424|Genetic|FT-003|Administered via intraocular injection.
45945509|NCT05609045|Biological|Lyophilized COVID-19 mRNA Vaccine|RH109 is a mRNA-based vaccine encoding the N-Terminal Domain (NTD) - Receptor Binding Domain (RBD) derived from Spike (S) protein of SARS-CoV-2 Omicron variant.
45458078|NCT01143025|Drug|Ropivacaine 150 mg|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
45809281|NCT02259348|Drug|Rituximab|Given IV
45809282|NCT02259348|Biological|Natural killer cell therapy|Given IV
45809283|NCT02259348|Biological|T-cell depleted HPC transplant|T-cell depleted hematopoietic stem cells will be infused on day 0.
45809284|NCT02259348|Biological|CD45RA-depleted HPC transplant|CD45RA depleted stem cells will be infused on day 1.
45809285|NCT04864626|Other|semi-standardized interview|annual collection of the number of consultations and hospitalizations at the center, as well as the number of treatments
45809286|NCT04864626|Other|care experience questionary|questionary with 12 questions to rate the quality of the telephone reception and your feelings during the interview
45809287|NCT00357019|Drug|N-acetyl-aspartyl-glutamate (NAAXIA Sine)|
45945510|NCT05609045|Drug|Sodium chloride|0.9% sodium chloride
45945511|NCT05603312|Genetic|AAV-GAD Dose 1|Bilateral infusion of AAV-GAD Dose 1
45945512|NCT05603312|Genetic|AAV-GAD Dose 2|Bilateral infusion of AAV-GAD Dose 2
45945513|NCT05603312|Procedure|Sham Surgery|Sham infusion
45945514|NCT05591794|Other|Aerobic and resistance exercises|Participants in the study group will be given an aerobic exercise program on the treadmill for 8 weeks, 2 days a week, 20 minutes at a rate of 60-80% of the target heart rate. Participants will work on the treadmill for 20 minutes at 60-70% of the target heart rate for the first four weeks, and at 70-80% of the target heart rate for the last four weeks. Resistance exercises will consist of exercises that will work large muscle groups with rubber bands. According to Borg, the resistance exercises to be applied will be three sets of 10 repetitions for each movement at an RPE of 11-12 during the first four weeks, and 3 sets of 15 repetitions at the same RPE for the last four weeks, 2 times a week for 20 minutes.
45945515|NCT05591794|Dietary Supplement|Diet program|Initially, participants will be educated on healthy eating habits through one-on-one dietitian consultation. A personalized calorie-restricting diet will be given. According to this program, the daily energy intake of the individual will be reduced to provide 0.5-1.0 kg of body weight loss per week.
45945516|NCT05591794|Other|Regular walking program|Regular walking will be recommended as 30 minutes/5 days or 50 minutes/3 days per week.
45945517|NCT05583097|Diagnostic Test|Non-selective cytology|All noduleas are evaluated according to EU-TIRADS. Cytology performed on all nodules larger than 1 cm regardless of ultrasonographic features. Nodules 1 cm or smaller evaluated as EU-TIRADS 5 undergo cytologic examination if possible.
45945518|NCT05580692|Procedure|Biospecimen Collection|Biospecimen Sample Collection
45945519|NCT05579483|Dietary Supplement|Prebiotics|The prebiotics consists of three non-digestible carbohydrates (40% acacia gum, 20% partially hydrolyzed guar gum, and 40% resistant starch). During the 8-week intervention, two sachets (3 g per sachet) will be consumed per day, one in the morning and one in the evening.
45945520|NCT05579483|Dietary Supplement|Placebo|The placebo consists of two digestible carbohydrates (20% maltodextrin and 80% corn starch). During the 8-week intervention, two sachets (3 g per sachet) will be consumed per day, one in the morning and one in the evening.
45945521|NCT05574608|Biological|CD123-CAR-NK cells|CD123-CAR-NK is an allogenic CD123-Targeted chimeric antigen receptor NK-cell (CAR-NK) therapy.
45945522|NCT05574400|Drug|Dextrose Water|Dextrose 5% in water
45945523|NCT05574400|Drug|Caffeine citrate|Low-dose caffeine citrate (1.5 mg/kg)
45945524|NCT05574400|Drug|Caffeine citrate|High-dose Caffeine citrate (3 mg/kg)
45945525|NCT05573685|Device|DiNaMo Study App|Study App to be used in patients with 1 of the 4 indications of rheumatoid arthritis, fibromyalgia Irritable Bowel Syndrome, Diabetic Neuropathy
45945526|NCT05573685|Device|Placebo App|Placebo App to be used in patients with 1 of the 4 indications of rheumatoid arthritis, fibromyalgia Irritable Bowel Syndrome, Diabetic Neuropathy
45945527|NCT05569252|Drug|DS-1211b|DS-1211b tablet administered once daily in the morning either in the fasted state or with a meal
45945528|NCT05569252|Other|Placebo|Placebo tablet administered once daily in the morning either in the fasted state or with a meal
45945529|NCT05564494|Procedure|Bankart Repair|Patients Randomized to Bankart Repair Group
46075528|NCT05295888|Device|Sham stimulation|Electrodes will be placed in the same location on the head as that for the TI intervention; 0 mA of electrical current will be delivered to the brain (compared to 2 mA in the active intervention arm), therefore it is expected to elicit no changes in neural activity.
46075529|NCT00880477|Biological|DTPa-HBV-IPV/Hib vaccine|Vaccination according to a 3-dose schedule at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
45945530|NCT05564494|Procedure|Anatomic Glenoid Reconstruction|Patients Randomized to Anatomic Glenoid Reconstruction Group
45945531|NCT05562167|Drug|KNO3|10 mmol of KNO3 via a single gel capsule to be consumed orally once per day for 6 weeks.
45945532|NCT05562167|Drug|Placebo|10 mmol of placebo via a single gel capsule to be consumed orally once per day for 6 weeks.
45945533|NCT05560763|Device|FlowTriever2 Catheter|The FlowTriever2 Catheter is utilized for the treatment of Pulmonary Embolism
45945534|NCT05556239|Behavioral|Resistance Exercise Training|Supervised resistance training program planned as 3 sessions per week of approximately 60 minutes. The resistance training program comprises 6 exercises for the major muscle groups, starting at 2 sets of 15 repetitions maximum progressing to 4 sets of 8 repetitions maximum. Each session will be supervised by physiotherapist to ensure proper technique, and progression in training load. The participants will choose an exercise ambassador from their network, who during the period will be encouraged to, on a weekly basis, to be in contact with the participant.
45945535|NCT05555862|Drug|Artesunate|artesunate formulated as intra-anal suppositories
45945536|NCT05555862|Drug|Placebo|placebo intra-anal suppository
45945537|NCT05546359|Drug|Amisulpride Injection [Barhemsys]|Dose finding treatment for continuation to phase 3
46075530|NCT00880477|Biological|DTPa-IPV/Hib vaccine|Vaccination according to a 3-dose schedule at at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
46075531|NCT00880477|Biological|EngerixTM-B|The vaccine was administered according to a 2-dose schedule at 1½ and 6 months of age with booster at 15-18 months of age.
45945538|NCT05546359|Drug|Dexamethasone|Standard of care treatment
45945539|NCT05539430|Biological|LB1908|Claudin 18.2-Targeted autologous Chimeric Antigen Receptor T-cells
45945540|NCT05529316|Drug|Botensilimab|An anti-CTLA-4 monoclonal antibody
45657413|NCT04808089|Other|Usual care|The research assistant assess/ teach inhaler technique, offering advice on adherence, delivering patient self-management asthma action plan and education the meaning of asthma control accessed by ACT.
46075532|NCT05293938|Drug|Obeticholic Acid 5 MG|once daily, oral administration
46075533|NCT05293938|Drug|Obeticholic Acid 10 MG|once daily, oral administration
45945541|NCT05529316|Drug|Balstilimab|An anti-PD-1 monoclonal antibody
46075534|NCT05293938|Drug|Standard of Care: UDCA|No study medication is provided by the sponsor or by the investigators. The decision to initiate, continue or discontinue UDCA, or to modify UDCA dosing, is entirely at the discretion of the treating physician as per their standard of care and is in no way influenced by the sponsor or participating institutions. UDCA utilization is recorded and included in the study record.
46075535|NCT00882739|Drug|Clopidogrel 300 mg|Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
46075536|NCT00882739|Drug|Clopidogrel 600 mg|Patients will receive a 600 mg clopidogrel loading dose at first medical contact
46075537|NCT00882739|Drug|Clopidogrel 900 mg|Patients will receive a 900 mg clopidogrel loading dose at first medical contact
46075538|NCT00878839|Device|Toric|AcrySof Toric IOL
46075539|NCT02783040|Drug|Midazolam|
46075540|NCT02783040|Drug|Warfarin|
46075541|NCT02783040|Drug|Omeprazole|
46075542|NCT02783040|Drug|Midazolam|
46075543|NCT02783040|Drug|Digoxin|
46075544|NCT02783040|Drug|BI 425809|
46075545|NCT00882817|Other|Pulmonary Rehabilitation|The intervention group will perform a 6 month pulmonary rehabilitation program which consists of training, patient education, nutrition counseling and psychosocial support. They will be evaluated with some tests for the study.
45657414|NCT04785937|Diagnostic Test|Ultrasound and Magnetic Resonance|liver ultrasound (US), including shear wave elastography (SWE) with liver stiffness measurement and US- fatty liver indicator (US-FLI), and a multiparametric unenhanced liver magnetic resonance examination including MR spectroscopy (MRS), Proton Density Fat Fraction (PDFF) and T2* measurement with Multiecho technique, T1 mapping with Inversion Recovery method, and Intravoxel Incoherent Motion diffusion weighted imaging (IVIM-DWI), measuring different parameters.
45657415|NCT04785547|Drug|Blinatumomab|15 mcg/m2/day for 28 days
45945542|NCT05522153|Drug|Arista|hemostatic powder
46075546|NCT02512926|Drug|Carfilzomib|Carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
46075547|NCT02512926|Drug|Cyclophosphamide|
46075548|NCT02512926|Drug|Etoposide|
46075549|NCT04038775|Behavioral|Volunteering|Subjects recommended volunteer by their provider.
46075550|NCT02786082|Drug|20mg Azilsartan Tablets|Strength: 20mg, oral administration 1 tablet/ day
46075551|NCT02786082|Drug|40mg Azilsartan Tablets|Strength: 40mg, oral administration 1 tablet/ day
46075552|NCT05275686|Drug|Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray|Patients will use two sprays in each nostril twice a day for 6 weeks and additional 6 weeks (open label).
46075553|NCT05275686|Other|Placebo Nasal Spray|The Placebo is made of the following ingredients: Purified Water, Microcrystalline Cellulose RC-591, Dextrose, Anhydrous, EDTA Disodium Dihydrate, Benzalkonium Chloride Solution 50%, Polysorbate 80 (Tween 80, HP-LQ-(MH)), Sodium Hydroxide, and Hydrochloric Acid. Patients will use two sprays in each nostril twice a day
46075554|NCT01503606|Drug|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization for one week
46075555|NCT01503606|Drug|Clarithromycin|clarithromycin 500mg po bid after randomization for one week
46075556|NCT01503606|Drug|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization until delivery
46075557|NCT01503606|Drug|Clarithromycin|clarithromycin 500mg po bid after randomization until delivery
46075558|NCT05082727|Dietary Supplement|KOVIR (TD0068) oral softgel|KOVIR (TD0068) is a softgel containing Allium sativum extract 270mg, Colostrum156.4 mg, fine powder mixed herbs 43.6mg
45945543|NCT05518175|Device|Traditional laparoscopy|Utilizes three or four 5 mm ports for access and retrieval.
45945544|NCT05518175|Device|Single site laparoscopy|One port is placed via a 2 to 3 cm umbilical/fascia incision to accommodate the Gelpoint device, where several laparoscopic instruments are used. With this technique, there is a single incision, hidden in the umbilicus a
45945545|NCT05518175|Device|V-Notes surgery|One port placed trans-vaginally via a 2-3 cm vaginal incision with no abdominal scars
46075559|NCT05082727|Dietary Supplement|Placebo oral softgel|Placebo
45657416|NCT03938389|Drug|Sacubitril-Valsartan Tab 97-103 MG|Participants will take Sacubitril-Valsartan for 26 weeks
45657417|NCT03938389|Drug|Valsartan 160mg|Participant will take Valsartan for 26 weeks
45945546|NCT05515523|Genetic|Adipose Derived (AD) Stromal Vascular Fraction (SVF)|autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain and function associated with OA of the knee joint
46075560|NCT02784522|Device|locking compression plate group|Closed reduction via shoulder lateral approach followed by locking compression plate fixation using minimally invasive technique
46075561|NCT02784522|Device|conventional locking plate group|Closed reduction via shoulder lateral approach followed by conventional locking plate fixation using minimally invasive technique
46075562|NCT05062993|Procedure|caudal epidural pulse radio frequency|A needle is inserted into the caudal epidural space under ultrasound guidance and pulse radiofrequency is administered at 5 Hz using a 5. ms pulse width for 600 seconds at 55 V.
45657418|NCT03938389|Drug|Placebo Oral Tablet|Participant with take placebo for 26 weeks or if blood pressure elevated will receive standard of care blood pressure medication, amlodipine.
45657419|NCT04785157|Biological|serology testing profiles description|SARS-CoV-2 quasispecies detection and associated serology testing profiles description (peripheral blood and cerebrospinal fluid - CSF)
45945547|NCT05510115|Drug|Empagliflozin|Empagliflozin: The chemical name of empagliflozin is D-Glucitol,1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3furanyl]oxy]phenyl]methyl]phenyl]-, (1S). Empagliflozin is a white to yellowish, non-hygroscopic powder. It is very slightly soluble in water, sparingly soluble in methanol, slightly soluble in ethanol and acetonitrile; soluble in 50% acetonitrile/water; and practically insoluble in toluene. Empagliflozin power will be added in white and bovine origin gelatin capsules. Each capsule of empagliflozin will contain 10 mg or 25 mg of empagliflozin (free base) and the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.
45945548|NCT05510115|Drug|Placebo|Placebo capsules will be matched in size and color to empagliflozin capsules. Each placebo capsule will contain the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.
45657420|NCT04785157|Biological|immune response characterization|systemic and central immune response characterization , associated to the assessment of CNS damage biomarkers (peripheral blood and CSF)
45945549|NCT05508022|Behavioral|Breathing exercise|Before the enema is applied, breathing exercises will be applied to the participants in the intervention group.
45945550|NCT05498987|Device|Monopolar 448 kilohertz radiofrequency stimulation|448kilohertz capacitive resistive monopolar radiofrequency will be applied on the dominant Achilles Tendon
45945551|NCT05496452|Dietary Supplement|Beta-lactoglobulin|Beta-lactoglobulin (BLG) will be administered thrice daily during a 7 day period of prehabilitation and 5 day period of immobilisation when the leg is placed in a brace.
45945552|NCT05496452|Dietary Supplement|Carbohydrate|Carbohydrate (dextrose monohydrate) will be administered thrice daily during a 7 day period of prehabilitation and 5 day period of immobilisation when the leg is placed in a brace.
45945553|NCT05495737|Behavioral|Meaning-Centered Psychotherapy/MCP-PC Training|Two-Day MCP-PC Training for Nurses (including mock patient/simulation with actor) with a Pre- and Post-Training Assessment
45945554|NCT05495737|Behavioral|Meaning-Centered Psychotherapy/MCP-PC|3 sessions, completed over the course of 3-6 weeks in the participant's home
45945555|NCT05495737|Behavioral|Treatment As Usual/TAU|"Research team will provide:~feedback about level of distress at time of screening~local referral for psychological care"
45945556|NCT05489523|Drug|Tafamidis 61 MG|Tafamidis 61 mg by mouth daily for 12 months
45657421|NCT04785157|Other|in vivo brain PET-TSPO acquisitions|in vivo brain PET-TSPO acquisitions (Positon Emission Tomography using a radioligand that targets the Translocator Protein, which is upregulated in activated microglia)
45809288|NCT03162211|Other|Feedback Report|There are two types of feedback forms: 1. Patient feedback forms and 2. Clinician feedback forms. Feedback form content has been developed in consultation with a board of clinicians, service providers, and patients living with depression. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals.
45945557|NCT05488145|Other|Best Practice|Receive standard of care
45945558|NCT05488145|Other|Internet-Based Intervention|Receive application intervention
45809289|NCT03994705|Biological|Descartes-11|CAR T-Cells
45945559|NCT05488145|Other|Questionnaire Administration|PROMIS medication adherence questionnaire is a well-defined self-report measure of medication-taking habits used to objectively assess adherence to medication and therapy. At the end of the study period, we will perform data analysis.
46075563|NCT00882973|Drug|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
46075564|NCT00805935|Drug|Menotropin|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
45809290|NCT03994705|Drug|Fludarabine|Pre-conditioning chemotherapy
45809291|NCT03994705|Drug|Cyclophosphamide|Pre-conditioning therapy
45945560|NCT05488145|Other|Survey Administration|Improvement in patient satisfaction will be measured by utilizing Consumer Assessment of Healthcare Providers and Systems (CAHPS) Cancer Care Survey scores. Surveys will be conducted among all participants at baseline and at 12 weeks, regardless of their use of the app, to better understand any barriers to using the app and which aspects of the app were most useful to patients.
45945561|NCT05486546|Procedure|Contoura with Phorcides|Participants that undergo LASIK surgery using Contoura with Phorcides Analytic Engine
45657422|NCT04785157|Other|brain MRI assessment|structural/functional brain MRI assessment (PWI/DWI mismatch imaging, quantification of gray and white matter microstructural integrity, DTI, functional connectivity)
45657423|NCT04785157|Behavioral|neurocognitive assessment|multi-domains neurocognitive assessment
45657424|NCT04785313|Biological|Retrievable Inferior Vena Cava Filters (IVCF)|Analysis anatomopathology of Retrievable Inferior Vena Cava Filters (IVCF) (ALN CF model).
45835814|NCT03012984|Drug|Dexmedetomidine supplemented morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
45945562|NCT05486546|Device|WaveLight Wavefront Optimized|Participants that undergo LASIK surgery using WaveLight Wavefront Optimized
45945563|NCT05484115|Device|endovascular aneurysm repair (EVAR) using the Endurant II/IIs stent graft system|treatment of AAA's with wide proximal neck diameters with Endurant II/IIs endograft system
46075565|NCT00805935|Drug|Progesterone vaginal insert|100 mg inserted vaginally 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
46075566|NCT00805935|Drug|Follitropin beta|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
46075567|NCT00805935|Drug|Progesterone in oil|50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
46075568|NCT00805935|Drug|leuprolide acetate|Daily administration of 0.5mg of leuprolide acetate (depot formulations were not permitted) began on Day 21 following onset of menses, and then decreased to 0.25 mg when gonadotropin therapy was initiated.
45809292|NCT03984487|Behavioral|Surviving and Thriving in the Real World|The STRW intervention consists of 14 weekly concurrent adolescent and parent group sessions. The DLS to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning DLS and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).
45657425|NCT04785313|Other|Demographics data collection|Demographics data : age, gender, thromboembolic risk factors, Retrievable Inferior Vena Cava Filters (IVCF) (indication, dates of insertion and removal), and anticoagulant management during the period with filter.
45453221|NCT00003907|Drug|doxorubicin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
45453222|NCT00003907|Drug|mitomycin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
45453223|NCT00003907|Procedure|embolization|Immediately following delivery of the chemoemulsion, particulate embolization is performed. The particulate embolic material is prepared on a separate table or tray, using absorbable gelatin sponge (Gelfoam, Upjohn, Kalamazoo, MI), in either powder or pledget form. Approximately 1 g of this temporary occlusive agent is dissolved in 20-30 cc of full-strength contrast with 2.4 cc of absolute alcohol.
45453224|NCT00003901|Other|immunohistochemistry staining method|
45453225|NCT00003901|Procedure|biopsy|
45657426|NCT03892915|Combination Product|evidence-based depression treatment|We will use a stepped care approach to depression treatment. Participants with clinical depression (defined as PHQ-9>9) will be offered either Problem Solving Therapy (PST) or Antidepressant Therapy (ADT), but those with moderate to moderately severe depression will be recommended PST, while those with severe depression will be recommended ADT. Participants with subthreshold depressive symptoms (PHQ-9: 5-9) will receive depression psychoeducation and continued depressive monitoring.
45657427|NCT04785235|Procedure|Non-Surgical Periodontal Therapy|
45657428|NCT04807855|Device|The cMLP device|There is only one medical device we are testing, so only one intervention.
45657429|NCT03843853|Drug|Pemetrexed|Pemetrexed 500 mg/m2 d1
45657430|NCT03843853|Drug|S-1|S-1 (20mg、25mg), capsule, 40~60mg, Bid,p.o, d1~14
45657431|NCT03843853|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg d1
45809293|NCT03984487|Behavioral|Program for the Education and Enrichment of Relational Skills|PEERS is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning get-togethers with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
45809294|NCT03960541|Drug|Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein)|Efprezimod alfa will be given as IV infusion, 240 mg per infusion, on Days 0, 14, and 28.
45809295|NCT03960541|Drug|Saline Solution|Sterile saline solution (0.9% sodium chloride) will be given as placebo via IV infusion, 100 ml per infusion, on Days 0, 14, and 28.
45809296|NCT03587207|Biological|MenABCWY vaccine|Two doses administered intramuscularly in the deltoid region of the non-dominant arm.
45809297|NCT03587207|Biological|rMenB+OMV NZ (Bexsero) vaccine|Two doses administered 2 months apart intramuscularly in the deltoid region of the non-dominant arm to subjects randomised to the rMenBOMV+ACWY_S Group, rMenBOMV+ACWY_D Group and rMenBOMV Group
45809298|NCT03587207|Biological|MenACWY (Menveo) vaccine|Two doses administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the rMenBOMV+ACWY_S Group and rMenBOMV+ACWY_D Group and one dose administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the MenACWY Group
45945564|NCT05484115|Device|endosuture aneurysm repair (ESAR) using Heli-FX EndoAnchor system|treatment of AAA's with wide proximal neck diameters with the Endurant II/IIs in conjunction with the Heli-FX EndoAnchor system
45945565|NCT05478837|Drug|Cyclophosphamide|Given IV
45945566|NCT05478837|Drug|Fludarabine|Given IV
45945567|NCT05478837|Biological|Autologous Anti-H3.3K27M TCR-expressing T-cells|Given IV
45657432|NCT04784767|Biological|25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)|SpFN_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial
45657433|NCT04784767|Drug|Sodium chloride, USP, for injection (0.9% NaCl)|Normal saline will be provided in a sterile, single-use 10 mL vial
45945568|NCT05477901|Other|Supplemental cash transfer|Supplemental cash transfer ($40/month)
46075569|NCT04230096|Device|low level laser therapy|apply low level laser therapy on buccal surface of maxillary jaw on anterior segment for three minutes at every three weeks in fixed orthodontic patients in their regular follow up visits
45453226|NCT00003901|Procedure|surgery|
45453227|NCT01584661|Behavioral|Dietary recommendations|
45453228|NCT00003895|Biological|HPV 16 E7:12-20|Given SC
45453229|NCT00003895|Biological|gp100:209-217(210M)|Given SC
45453230|NCT00003895|Other|laboratory biomarker analysis|Correlative studies
45453231|NCT05623891|Drug|177Lu-B5-IgG4|177Lu-B5-IgG4 injection followed by SPECT scan
45453232|NCT01100047|Drug|AZD5069|Oral suspension
45453233|NCT01100047|Drug|Placebo|Oral suspension
45453234|NCT01100125|Drug|sitagliptin|sitagliptin 100mg once daily, orally, for 24 weeks.
45453235|NCT01100125|Drug|insulin dose increase|insulin dose increase
45453236|NCT01100203|Drug|Eplerenone|25 mg once daily 1 week, then 50 mg once daily for another 23 weeks.
45453237|NCT03948685|Drug|Carvedilol SR|blood pressure, heart rate based titrated carvedilol SR for 24 weeks
45453238|NCT03948685|Drug|Placebo|Placebo
45809299|NCT03901261|Procedure|Neuro-imaging, Lumbar puncture|Optional Lumbar Puncture will be performed at inclusion visit Optional Neuro-Imaging (MRI (Magnetic Resonance Imaging) will be performed within 3 months after inclusion visit
46075570|NCT05265390|Other|Adolescents watching an informational video|In the information video; The materials used during the PCR test, how long the process will take, how the sample will be taken, why healthcare professionals wear personal protective equipment, and what adolescents should do are included.
45945569|NCT05474534|Device|Neurofeedback (MUSE 2)|During each at-home treatment session, mothers will place the MUSE 2 on their heads and connect it to the app on their personal device. Their brain activity is monitored by the MUSE 2 and is represented on the app through audio-based feedback (e.g., birds chirping, sounds of waves lapping on the beach) that mothers will listen to with earbuds as they direct their focus on maintaining a calm state of mind during the session; when a calm state is maintained, they are rewarded with calming sounds. The goal is to gain increased conscious control over their own brain activity. The audio feedback, primarily composed of nature-based sounds, is meant to guide their brain activity into a calm state. The session will begin, and the MUSE 2 will provide audio feedback in real time to guide their brainwave activity into an optimal frequency bandwidth range (e.g., as their brain activity reaches the target state, sounds of wind would subside to peaceful waves or other rewarding audio feedback).
45945570|NCT05466370|Biological|Transfusion of Allogeneic Blood|Transfusion of Allogeneic Blood
45945571|NCT05444881|Behavioral|Mindfulness-based Intervention (Headspace TM)|"A commercially available mindfulness mobile phone application (HeadspaceTM) will be used. The use of HeadspaceTM in the current protocol is approved by NYSPI Information Technology Services.~An mHealth mindfulness program such as Headspace provides self-paced, guided mindfulness meditations through a website or mobile app (iOS and Android). The program consists of basic meditation courses as well as courses targeting stress management, anxiety, depression, and parenting. Based on the qualitative interviews with parents in Phase I, psychoeducation will be included on mindfulness practice and mental health, emphasizing basic meditation courses, and asking parents to complete daily assignments of 10 to 20 min a day during the 6-week period. As an engagement strategy, every week participants in the intervention group will receive a call or an email or text message (depends on preference; partisans may opt out to receive email/text messages)."
45945572|NCT05444595|Behavioral|Behavioral plant-based dietary intervention|Participants will meet with community health workers to receive information focused on healthy eating and consuming a traditional plant-based diet in a group format for the first few months followed by individual check-ins.
46075571|NCT00880789|Biological|CMV/AdV specific T cells|CTL Dose Given from Day +30 post SCT (stem cell transplant). For the trial, two patients are allocated in each cohort and are followed for 30 days post IV injection of transduced T-cells for evaluation of DLTs. A maximum 18 patients will be accrued into each group. The final MTD will be the dose with probability closest to the target toxicity rate at these termination points. The trial continues until a minimum of 12 patients have been treated. The trial will stop when the maximum 18 patients have been treated, or when six patients have been treated at the current MTD. We therefore expect to enroll between 12-18 patients into this trial.
46075572|NCT00878917|Drug|Dorzolamide 2 % eye drops solution|1 drop into eye(s) three times a day for the duration of each treatment phase
46075573|NCT03969927|Device|Low-Fidelity PDS|"The principal investigator recently developed a low cost ($10,000) low fidelity portable driving simulator (PDS) in the University of Kansas Laboratory for Advanced Rehabilitation Research in Simulation (LARRS) that measures 25.5 Wide, 32.5 High, and 25 Deep and requires only approximately 4 square feet of space.~This intervention uses the PDS to retrain study participants and improve their driving related skills."
46075574|NCT03969927|Device|High Fidelity Fixed-Base Simulator|This intervention uses the large high-fidelity fixed-base driving simulator to retrain study participants and improve their driving related skills.
46075575|NCT00638118|Drug|Fexofenadine|
45809300|NCT03866785|Diagnostic Test|interview|The goal is to evaluate the needs, the constraints and representations of patients on the practice of physical activity.
45809301|NCT03866785|Diagnostic Test|Adult Physical Activity Questionnaire (APAQ)|The goal of this questionnaire is to evaluate the sedentary lifestyle of patients.
45809302|NCT03866785|Device|Activity actigraph|An activity actigraph will use by the patient for a week. It measures the level of physical activity and the sedentary lifestyle of patients.
45809303|NCT03866785|Other|Peer training|"The goal of the peer training will organize once a week for 3 weeks for a patient.~After this training, they will have :~Skills in physical activity advice~Knowledge of functional signs (symptoms)~Knowledge to examine heart rate and perceived effort rate"
46075576|NCT00805545|Drug|Antibiotic|Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
46075577|NCT00805545|Drug|Antibiotic|Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
45809304|NCT03866785|Other|Physical Activity Program|"During the Physical Activity Program, patients will be supervised by peers and a clubs and sports associations labeled sport-health by Olympic and Sports Committee of the Loire Department.~The peer will coach the patient once a week minimum for 3 months."
45809305|NCT04345159|Other|Questionnaire by phone call|"2 questionnaires : at inclusion and 4 months later. The exposure to hydroxychloroquine and the history of autoimmune disease is determined during the phone call along with other exposure factors. The symptoms presented by the patient are classified in Suggestive of a COVID-19 infection or Not suggestive of COVID-19 infection by a team of internists and infectious diseases specialists, by studying the questionnaires after the completion in a blind-manner regarding the hydroxychloroquine intake."
45809306|NCT05723263|Behavioral|Standard Pay-it-forward|400 men who have sex with men (MSM) at 4 clinics will be enrolled. The standard pay-it-forward arm will include free point-of-care gonorrhea testing, as well as a passive community engagement component (such as viewing postcards and materials written by others encouraging gonorrhea testing).
45809307|NCT05723263|Behavioral|Community Engaged Pay-it-forward|400 MSM at 4 clinics will be enrolled. The community engaged pay-it-forward arm will include free point-of-care gonorrhea testing, as well as an active community engagement component (such as multi-stakeholder co-creation activities to develop essential components of the intervention and implementation strategies; writing postcards; opportunity to donate to support others)
45657434|NCT04784767|Biological|50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)|SpFN_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial
45657435|NCT04784611|Behavioral|Our Peers - Empowerment and Navigational Support (OP-ENS) Peer Health Navigator Intervention|Disability peer health navigator mentored and manualized process of barriers identification, asset mapping, goal setting, and action planning along with on-going social support and information sharing.
45809308|NCT05723263|Other|Control arm|400 MSM at 4 clinics will be enrolled. The control arm will include a fee-based point-of-care gonorrhea testing (approximately 20 USD per test) and no community engagement component
45809309|NCT00357487|Device|peroperative scintillating probe|
45809310|NCT00357487|Device|operative gamma camera|
45657436|NCT04337749|Drug|Chorhexidine scrub|Chorhexidine scrub was given to patients for 2 weeks
45809311|NCT03416621|Behavioral|Cognitive behavioral cessation counseling|Standard smoking cessation plus support text messages
45809312|NCT03416621|Behavioral|Counseling and placebo drug intervention|Enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo
45945573|NCT05444595|Behavioral|Standard care|Participants will meet with community health workers to receive general health information through individual check-ins.
45453239|NCT01585051|Drug|25(OH) vitamin D|300 000 U intramuscularly, one dosage, in subjects with 25 (OH) vit D levels below 80 nmol/L, another dosage of 150 000 U after 3 months if 25(OH)vit D levels continue to be below 80 nmol/L.
45453240|NCT01585051|Drug|0.9 % NaCl|1 ml of 0.9 % of NaCl at the beginning and 0.5 ml of 0.9 % NaCl after three months
45453241|NCT01103791|Drug|Docetaxel-PNP|Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel
45657437|NCT04337749|Device|ZnO-NPs socks|ZnO-NPs socks were given to patients for 2 weeks
45945574|NCT05438147|Other|CT-100 DiNaMo|Active Treatment (Study App)
45945575|NCT05438147|Other|Care-as-Usual|Care-As-Usual control
45945576|NCT05437198|Other|collection of human exhalation|"the collection of the exhalation will be carried out with a non-invasive device manufactured by a Chinese company.~The collection of exhalation consists of the subject inhaling through the nose and exhaling gently through the mouth through a plastic straw for a time set at 5 min in the device"
45945577|NCT05435040|Device|proprioceptive knee brace|the patient will perform the tests with the knee brace
45657438|NCT04337749|Combination Product|Combination of chorhexidine scrub and ZnO-NPs socks|Combination of chorhexidine scrub and ZnO-NPs socks were given to patients for 2 weeks
45945578|NCT05435040|Device|No knee brace|the patient will perform the tests without the knee brace
45945579|NCT05426902|Behavioral|SLE@Duke|SLE@Duke is a set of tools to implement the Type 1 & 2 SLE Model in a clinical setting. The model includes an Electronic Medical Record (EMR) note template, patient-reported outcome measure, and training on how to discuss Type 1 & 2 SLE.
45945580|NCT05426382|Device|A digital care solution for patients with NAFLD|A digital solution that provides remote symptom monitoring and support of healthy lifestyle choices through tasks that are made more attractive with gamification and rewards.
46075578|NCT02845440|Other|Academic Detailing|Academic detailing (AD) is a targeted continuing medical education (CME) strategy that adapts social marketing techniques, using mixed interactive and didactic formats in individual and group settings integrated into the practice setting to promote beneficial changes in medical care. AD helps clinicians understand and adopt targeted evidence-based practices and is one of the few Continuing Medical Education (CME) interventions that has consistently demonstrated improved alignment of physician prescribing behavior with evidence-based practice.
45657439|NCT04337749|Device|Placebo socks|Placebo socks were given to patients for 2 weeks
45809313|NCT03416621|Drug|Counseling and active drug intervention|Enhanced cue exposure treatment (lab-based + interactive SMS texting)+ active DCS. In addition to an in-person, screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.
45809314|NCT03417557|Device|Comfilcon A lens (test)|contact lens
45458759|NCT04802356|Drug|Lenalidomide|Dose of 25 mg/day on days 1-21 of every 28-day cycle. Oral administration. Induction: 6 cycles Consolidation: 2 cycles Maintenance: 10 mg/day on days 1-21 continuously (may increase up to 15 mg/day) until disease progression, patients withdrawal, death, whichever occurs first
45657440|NCT05054179|Drug|Ropivacaine 0.2% Injectable Solution Bolus|20 mL of ropivacaine 0.2% will be injected via parasternal multi-orifice catheters on each side
45657441|NCT05054179|Other|Normal Saline Infusion|3 mL/hour infusion of normal saline for 48 hours via parasternal multi-orifice catheters on each side of the sternum
45809315|NCT03417557|Device|Omafilcon B lens (control)|contact lens
45809316|NCT03459131|Device|Comfilcon A with Digital Zone Optics™ contact lenses|Silicone hydrogel spherical contact lenses with Digital Zone Optics™
45809317|NCT03459131|Device|Comfilcon A contact lenses|Silicone hydrogel spherical contact lenses
45809318|NCT03417713|Device|Fluoroscopic imaging with the OEC Elite Device|Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system in the vascular configuration would be prescribed.
45809319|NCT03592121|Drug|AB-101|Apply approximately 1 hour prior to sexual activity
45809320|NCT03592121|Drug|Placebo|Apply approximately 1 hour prior to sexual activity
45809321|NCT04332809|Procedure|saline-gentamicin irrigation|Layer-by-layer irrigation of the appendectomy wound will be performed using saline-gentamicin solution
45809322|NCT04332809|Procedure|saline irrigation|Layer-by-layer irrigation of the appendectomy wound will be performed using saline solution
45809323|NCT03596723|Drug|KPI-121 1%|eye drops
45657442|NCT05054179|Drug|Ropivacaine 0.2% Injectable Solution Infusion|3 mL/h infusion of Ropivacaine 0.2% for 48 hours via parasternal multi-orifice catheters on each side of the sternum
45657443|NCT04337515|Device|CliniMacs®|CliniMACS® CD34 Reagent System is now indicated for processing hematopoietic progenitor cells collected by apheresis (PBSC) from an allogeneic, HLA-identical MSD to obtain a CD34+ cell-enriched population for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional GVHD prophylaxis in patients with AML in first morphologic complete remission (CR1).
45657444|NCT03688945|Procedure|Art Therapy|Attend art viewing sessions
45657445|NCT03688945|Other|Best Practice|Receive standard of care
45809324|NCT03596723|Drug|Prednisolone acetate|eye drops
45809325|NCT04355117|Drug|Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.|Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.
45809326|NCT04357379|Behavioral|IQOS|Participants will try an IQOS product and then take home the IQOS to sample for one week.
45809327|NCT03463889|Drug|Gallium Ga 68-labeled PSMA-11|Given IV
45809328|NCT03463889|Procedure|Magnetic Resonance Imaging|Undergo MRI in combination with PET
45809329|NCT03463889|Procedure|Positron Emission Tomography (PET)|Undergo PET in combination with MRI
45809330|NCT04484207|Other|A short video intervention|Three minutes video of a veteran that shares his personal story
45809331|NCT04484207|Other|A vignette intervention|A written description of the content of the video
45809332|NCT04485455|Device|iTBS Device/Motor Threshold Coil|Motor Threshold determination, done prior to starting treatments, determines the location and the intensity for the iTBS treatments. A magnetic field is applied with increasing intensity stimulating the motor region of the brain until there is thumb movement; this indicates the intensity of the treatments; the location for treatment is in the sensory area parallel to this location.
45809333|NCT04485455|Device|iTBS Device/Treatment Coil|iTBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz very quickly). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatments lasts approximately 3 minutes, and sessions are provided 20 times (Monday-Friday for 4 consecutive weeks).
45809334|NCT04525079|Drug|CT-P59|CT-P59 will be administered
45809335|NCT04525079|Drug|Placebo|Placebo-matching CT-P59
45945581|NCT05425745|Drug|Obicetrapib|10 mg Obicetrapib tablet
45657446|NCT03688945|Other|Questionnaire Administration|Ancillary studies
45809336|NCT03599687|Other|Training in SALAD technique|The training session will be delivered, and will take around 45 minutes to complete, including time for participant practice. The training intervention will adopt the Advanced Life Support Group/Resuscitation Council 4-stage approach of skills teaching, and is comprised of: A real-time demonstration of the SALAD technique by the researcher; A repeated demonstration with an explanation of the rationale of the steps taken when performing SALAD (not real-time); Another demonstration of the SALAD technique conducted by the researcher, but guided by one of the participants; An attempt by the same participant who guided the researcher in the previous step, followed by a practice attempt by the other participants.
45657447|NCT05612113|Behavioral|Live Supervision + Session Goal Formulation|"Read under Arms"
45657448|NCT05612113|Other|Session Goal Formulation|"Read under Arms"
45657449|NCT05018611|Behavioral|LifeSkills Mobile|A mobile app designed to facilitate the broad reach and impact of the LifeSkills intervention to reduce sexual risk behavior which drives HIV infection. The LifeSkills intervention addresses the specific structural, developmental, and interpersonal challenges to HIV prevention among YTW ages 16-29, with prior evidence of the efficacy to reduce sexual risk.
45657450|NCT05014477|Procedure|Removal or leaving of LAA occluders|After LAA device embolization there are different approaches to dealing with the occluder dislocation. The aim is to find out which way leads to the best outcomes.
45809337|NCT04734509|Device|Silhouette breathing system|The Silhouette is a single-use nasal mask and breathing circuit with lightweight tubing and an adhesive strip across the bridge of the nose to secure the mask in place and create a good seal around the patient's nose.
45809338|NCT03467477|Drug|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
45809339|NCT03467477|Procedure|Brain PET Scan|positron emission tomography (PET) scan of the brain
45809340|NCT04555031|Device|kalifilcon A lenses|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
45945582|NCT05425745|Drug|Placebo|placebo tablet made to resemble active
45945583|NCT05422794|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
45657451|NCT03679585|Other|Internet-Based Intervention|Undergo Talking Pictures social media intervention
45945584|NCT05422794|Procedure|Biopsy|Undergo biopsy
45945585|NCT05422794|Procedure|Biospecimen Collection|Undergo collection of blood samples
45945586|NCT05422794|Procedure|Computed Tomography|Undergo CT
45945587|NCT05422794|Procedure|Magnetic Resonance Imaging|Undergo MRI
45945588|NCT05422794|Drug|Nab-paclitaxel|Given IV
45945589|NCT05422794|Biological|Pembrolizumab|Given IV
45945590|NCT05421858|Drug|PF-07842805|PF-07842805 (IV infusion)
45945591|NCT05421858|Drug|Caspofungin|Caspofungin (IV infusion)
45945592|NCT05421858|Drug|PF-07842805|PF-07842805 oral tablet
45945593|NCT05421858|Drug|Fluconazole|Fluconazole oral capsule
45945594|NCT05421858|Drug|Placebo|Matching placebo (IV infusion)
45945595|NCT05421858|Drug|Placebo|Matching placebo (tablet or capsule)
45945596|NCT05413330|Drug|Triamcinolone Acetonide|Intravitreal injection of 4 mg/0.1 mL preservative-free triamcinolone acetonide at the end of phacoemulsification surgery will be injected at 3.5 mm inferolateral and posterior to the limbus.
45945597|NCT05410145|Drug|D3S-001|Oral
45945598|NCT05398848|Biological|Recombinant two-component COVID-19 vaccine (CHO cell)|Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter
45657452|NCT03679585|Other|Quality-of-Life Assessment|Ancillary studies
45657453|NCT03679585|Other|Questionnaire Administration|Ancillary studies
45809341|NCT04555031|Device|Dalies Total 1|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
45945599|NCT05398848|Biological|Placebo|"Before reconstitution:~Lyophilized powder for reconstitution in single-use vials~After reconstitution with BFA03 adjuvant:~Milk-white solution with no visible foreign matter"
45945600|NCT05396430|Device|Urinary catheter|Duration of planned urinary cathterization following cesarean delivery
45945601|NCT05396417|Procedure|cesarean delivery|Cesarean delivery under any form of anesthesia for any reason and for any indication
45945602|NCT05395715|Procedure|Electrical stimulation|Patients with cubital tunnel syndrome will receive either surgery and sham stimulation, or conditioning electrical stimulation 7 days prior to surgery
45945603|NCT05393180|Device|Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF|"Epicardial linear lesions will be created endoscopically using the EPi-Sense®-AF Guided Coagulation System throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. Posterior and other linear lesions such as a roof lesion and mitral valve isthmus lesion will not be created during the endocardial component of the convergent procedure. This will be done endocardially using an irrigated endocardial ablation catheter.~Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi-Sense®-AF Guided Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation. ."
45945604|NCT05387122|Device|mandibular advancement device (MAD)|mandibular advancement device (MAD) is a removable oral appliance. It is an alternative therapy for patients of Obstructive Sleep Apnea who are non compliant to Continuous positive airway pressure(CPAP) which is the most accepted therapy for Obstructive Sleep Apnea.
45809342|NCT04555031|Device|Precision 1|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
45945605|NCT05386368|Drug|ReCell|"The perioral area of the face will be treated with CO2 laser. Randomization would occur before study initiation with subjects assigned either left perioral or right perioral RECELL treatment based on their subject enrollment number. The study team member who prepares and blinds the RECELL will create the list of subject ID numbers with subject ID number randomly assigned to either left perioral or right perioral treatment group. This will be completed prior to any patient enrollment in the study. Intraoperatively, RECELL and Placebo will be provided to surgeons and assistants in opaque application devices prepared by a trained, designated study team member.~Both the treatment and placebo sides, will be dressed with a standard autologous cell suspension post treatment dressing (Telfa Clear and Xeroform)."
45945606|NCT05377749|Behavioral|FACT|Families Addressing Cancer Together (FACT) is a web-based intervention that provides tailored communication support for parents with cancer.
45945607|NCT05373017|Other|EGS Delirium Recovery Program|Virtual visits with care coordinator to carry out an individualized recovery plan
45945608|NCT05373017|Other|Questionnaires|Physical, cognitive, and psychological assessments
45945609|NCT05368558|Drug|Cariprazine|Oral Capsule
45945610|NCT05368558|Drug|Placebo|Oral Capsule
45945611|NCT05359965|Device|Positive Airway Pressure|Gentle and steady pressure (with or without supplemental oxygen) delivered to the airways of the lungs while subjects are sleeping.
45945612|NCT05354947|Device|Ultrasound Delivery|A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to selectively deliver pulsed ultrasound to both, the portal region of the liver and the superior mesenteric plexus.
45945613|NCT05344859|Behavioral|Weekly Automated Health Coaching|This intervention will involve health coaching delivered by Artificial intelligence (AI). The automated health coaching mechanism will be coupled with AI-based responses, and recent advancements have made the voices generated through the AI, almost human-like voices. Every week participants enrolled in automated health coaching intervention will receive a health coaching and goal-setting call that will help guide the participants in managing their Type 2 Diabetes Mellitus. This technology-driven study group will inform us whether trained human coaches are required or if the automated technologies are sufficient to create clinically meaningful HbA1c improvements.
45945614|NCT05344859|Behavioral|Weekly Human Health Coaching|Every week participants enrolled in human health coaching intervention will receive a health coaching call and goal-setting call from their respective health coaches to guide them in managing their Type 2 Diabetes Mellitus.
45657454|NCT04972825|Behavioral|Mind the Gap|This intervention will help parents with children newly diagnosed with autism or other neurodevelopmental disorders learn how to navigate the system of acquiring services for their child. These parents will be assisted by a coach, an employee at the child's agency, that will help them through this process.
45809343|NCT04555031|Device|Biotrue ONEday|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
45809344|NCT04574297|Behavioral|smoking and alcohol assumption|documenting the change of smoking and drinking status during the follow-up period
45809345|NCT04574297|Diagnostic Test|genetic sequencing|sequencing the susceptibility genes for CP, including serine protease inhibitor Kazal type 1, cationic trypsinogen, cystic fibrosis transmembrane conductance regulator, chymotrypsin C, etc.
45945615|NCT05344859|Behavioral|Adapted Reward Level|In the adapted reward (gamified) variation, participants will receive 25 cents per day for the first week of daily-monitoring calls, 50 cents per day in the second week, 75 cents per day in the third week, and a dollar per day from the fourth week until the end of the study (Aim 2). In the adaptive variation, missing one day of monitoring (in the past seven days), drops the reward value by one level (example: 75 cents becomes 50 cents), two days of missed calls drop the reward level by two levels, and similarly for three days. In the adaptive variation, participants have to continue to daily monitor their behavior to again build up their reward levels.
45945616|NCT05344859|Behavioral|Fixed Gamified Reward Level|In our fixed-reward arm, participants will be awarded 25 cents per day for answering the daily monitoring call - this serves simply as a reward for answering the daily calls. It is important that the rewards are for answering the calls and not for the actual values of the responses provided.
45945617|NCT05338307|Dietary Supplement|R-1,3-Butanediol|Study participants will be taking 35mL of HVMN Ketone-IQ by mouth three times daily, with each dose containing 10 grams of R-1,3-Butanediol.
45945618|NCT05332704|Drug|ONO-4685|-Part A: Single ascending doses of ONO-4685 as a single IV dose (Cohort A1-A11).
45945619|NCT05332704|Drug|Placebo|-Part A: Single ascending doses of placebo as a single IV dose (Cohort A1-A11).
45945620|NCT05332704|Drug|ONO-4685|-Part B: Multiple doses of ONO-4685 as IV doses over a 4-week treatment period (Cohort B1 and B2)
45809346|NCT03468179|Dietary Supplement|Oatmeal|Subjects will be fed a calculated serving of oatmeal.
45809347|NCT03472469|Drug|Acetaminophen IV/PO|Acetaminophen 1g IV/PO every 6 hours
45458079|NCT03502642|Device|wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain)|After peritoneum closure a 16cm multiorifice perforated catheter (Dosi-Pain® Kit, LEVENTON SAU, Spain) was inserted by the surgeon below the fascia used for normal saline continuous infusion in the Placebo group and for continuous ropivacaine infusion (Ropivacaina Molteni®, MOLTENI FARMACEUTICI, Italy) in the ropivacaine group.
45657455|NCT03588637|Other|No intervention|No intervention
45657456|NCT05472727|Other|reaction time test|Reaction time tests consist of 3 sub-parameters as simple reaction time, selective reaction time and distinctive reaction time. Participants will do these tests on the computer.
45809348|NCT03472469|Drug|Acetaminophen PO|Acetaminophen 1g PO every 6 hours
45945621|NCT05332704|Drug|Placebo|-Part B: Multiple doses of placebo as IV doses over a 4-week treatment period (Cohort B1 and B2).
45657457|NCT05472727|Other|Physical fitness test|The physical fitness test will be evaluated with the senior fitness test used for geriatrics and the 8 meter walking speed test.
45809349|NCT03472469|Drug|Ketorolac|Ketorolac 30mg IV once
45809350|NCT03472469|Drug|Celebrex|Celebrex 200mg PO every 12 hours
45809351|NCT03472469|Drug|Naproxen|Naproxen 500mg PO every 12 hours
45809352|NCT03472469|Drug|Tramadol|Tramadol 100mg PO every 6 hours
45809353|NCT03472469|Drug|Pregabalin|Pregabalin 100mg PO every 8 hours
45945622|NCT05332704|Drug|ONO-4685|-Part C: Multiple doses of ONO-4685 as IV doses over a 4-week treatment period.
45945623|NCT05332704|Drug|Placebo|-Part C: Multiple doses of placebo as IV doses over a 4-week treatment period
45809354|NCT03472469|Drug|Gabapentin|Gabapentin 300mg PO every 8 hours
45809355|NCT03472469|Drug|Lidocaine|Lidocaine patch every 12 hours
45657458|NCT05472571|Other|Forest bathing|The intervention consists of 11 consecutive sessions of forest bathing (one session per week), each one lasting about 2 hours. Each session involves an easy walk through a forest area, interspersed with non-intrusive activities of contact with the surrounding nature aimed at fostering mindfulness and the use of the five senses.
45945624|NCT05331989|Other|patient group/ healthy group|Cranio- Cervical Flexion Test, cervical mobility, Pressure Pain Threshold,Functional evaluation of the temporomandibular joint,Pittsburg Sleep Quality Index
45945625|NCT05322954|Drug|Psilocybin|25mg orally followed by 25 mg or 50 mg orally
45945626|NCT05303857|Drug|Semaglutide Pen Injector|Injection of the semaglutide once weekly
45945627|NCT05303857|Drug|Placebo|Injection of placebo once weekly
45945628|NCT05301881|Procedure|Surgery|resection of the oligometastatic lesion(s)
45809356|NCT03472469|Drug|Opioids|Opioid options include: Oral Opioids (Codeine, Tramadol, Hydrocodone, Oxycodone, Methadone, Morphine, Hydromorphone); Transdermal Opioid (Fentanyl); Intravenous Opioids (Morphine, Hydromorphone, Fentanyl)
45945629|NCT05301881|Radiation|Radiotherapy|radiation of the oligometastatic lesion(s)
45945630|NCT05301881|Other|Radiofrequent ablation|radiofrequent ablation of the oligometastatic lesion(s)
45945631|NCT05297071|Device|Orascopic HDL 3.0 Loupes|The loupes will be used during the surgical procedure on half of the subjects. The other half will be performed with a microscope.
45945632|NCT05297071|Device|Semorr DOM3000D Operation Microscope|The microscope will be used during the surgical procedure on half of the subjects. The other half will be performed with loupes.
45945633|NCT05284006|Diagnostic Test|Imaging, gait analysis, growth, joint test, hearing test, questionnaire, etc.|This study includes 15 major assessments: clinical assessment procedures; anthropometric measurements; activity of daily living and quality-of-life questionnaires; gait kinematics and kinetics analysis; pulmonary function tests (PFT); skeletal radiographs and dual-energy x-ray absorptiometry (DXA); MRI in cervical spine, temporal bones, and hip; computed tomography angiography (CTA) for tracheal obstruction; CT for temporal bones; anesthetic encounters; joint mobility; hearing function; biochemical analyses; and pathological analyses.
45945634|NCT05271630|Other|Autologous Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled ASCT recipients receiving Single agent vs doublet maintenance chemotherapy post ASCT
45945635|NCT05271630|Drug|Immunomodulatory Agent|ASCT recipients receiving maintenance therapy consisting of an Immunomodulatory agent (IMID) after ASCT transplant
45945636|NCT05271630|Drug|Proteasome Inhibitor|ASCT recipients receiving maintenance therapy with a proteasome inhibitor in combination with an immunomodulatory drug after ASCT transplant
45945637|NCT05265013|Combination Product|ASP-1929 Photoimmunotherapy|ASP-1929 Photoimmunotherapy with pembrolizumab
46075579|NCT02845440|Other|Community Health Worker|Community Health Worker (CHW) The CHW will offer to support patients and prescribers in health promotion and preventive care in general and specifically to support communication between the primary care provider and patient regarding smoking status, smoking cessation, and to aid implementation of any smoking cessation treatments recommended by prescribers. CHWs will complete the standard CHW certificate training program in general preventive medicine, available through the Boston Public Health Commission. CHWs will then receive the additional specialized training.
45458080|NCT03502642|Procedure|Spinal Anesthesia|Cesarean section was conducted under spinal anesthesia in both groups
45657459|NCT03529669|Device|Cytosponge™|Cytosponge™ is a capsule-sized device which contains an expandable, spherical mesh which is attached to a string. The capsule dissolves in the stomach after swallowing, releasing the sponge which is then retrieved by gently pulling the string after five minutes. As the sponge is pulled out it collects the cells from the lining of the gullet.
45945638|NCT05264675|Procedure|primary suture|Primary suture of the EPL-tendon
45945639|NCT05264675|Procedure|EIP-transfer|transfer of the EIP-tendon to the EPL-tendon
45657460|NCT05472493|Biological|[18-F]CETO|PET/CT will be performed; Non-contrast CT images will be acquired over the adrenals (slice width, ~3 mm). CETO (~2.5 MBq/kg; up to 365 MBq +/- 20%) will be administered as a single dose intravenously and dynamic PET images will be acquired from ~0-90 minutes.
45657461|NCT02588833|Drug|Pegcetacoplan|Complement (C3) Inhibitor
45809357|NCT03472469|Drug|Regional anesthesia|Regional anesthesia
45809358|NCT04926233|Drug|Tiotropium bromide + Olodaterol|Tiotropium bromide + Olodaterol
45809359|NCT04926233|Device|Sp(t)iolto® Respimat®|Sp(t)iolto® Respimat®
45809360|NCT04943159|Drug|Afamelanotide|Group A is administered afamelanotide implant on Days 0, 21 and 42; Group B is administered afamelanotide implant on Days 0 and 28.
45809361|NCT04525157|Drug|Afamelanotide|
45809362|NCT04525157|Drug|Placebo|
45945640|NCT05254639|Drug|DONEPEZIL|5 mg daily for 4 weeks + 10 mg daily for 12 weeks according to tolerance or efficacy
45945641|NCT05254639|Drug|PLACEBO|5 mg daily for 4 weeks + 10 mg daily for 12 weeks according to tolerance or efficacy
45945642|NCT05253586|Procedure|Laparoscopic|Surgeon
45945643|NCT05253586|Procedure|Robotic|Versius system
45809363|NCT04734665|Drug|Niraparib-Bevacizumab|"Niraparib 200mg or 300mg (once daily[QD]) Bevacizumab 15mg/kg every 3 weeks (Q3W)~*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD."
45809364|NCT02259114|Drug|Birabresib|Birabresib 10, 20 and/or 40 mg oral capsules
46075580|NCT02845440|Other|Treatment as Usual (TAU)|Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services.
45657462|NCT03497689|Drug|Intravenous/Subcutaneous Treprostinil; Oral Treprostinil|Short term course of IV/SC treprostinil continuous infusion followed by transition to oral treprostinil extended-release tablets taken three times daily
46075581|NCT00590031|Drug|Cisplatin|pts will receive weekly cisplatin 30mg/m2 after hydration on weeks 8,9,11 and 12
46075582|NCT00590031|Drug|Irinotecan|Irinotecan will be given 65 mg/m2
46075583|NCT00590031|Radiation|External Beam Radiation Therapy|will be delivered with multiple (>2) field techniques using mega-voltage radiation therapy. pts will receive 50.4 Gy and will be treated over a 6 week period.
45945644|NCT05243940|Drug|dexmedetomidine-ketamine-lidocaine (DKL)|"patients will be administered 0.25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1 mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving~1mL/10kg/h of the aforementioned solution."
46075584|NCT02421276|Other|Phlebotomy|White blood cell analysis: Subtypes of white blood cells will be counted by flow cytometry
45657463|NCT05611879|Drug|Tislelizumab|Tislelizumab: 200mg, IV, day 1 of each 21-day cycle, Neoadjuvant therapy : 3 cycles
45657464|NCT05611879|Drug|Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC)|Pemetrexed: 500 mg/m^2, IV, day 1 of each 21-day cycle, 3 cycles. Paclitaxel: 60-75mg/m^2, IV, day 1 of each 21-day cycle, 3 cycles. Nab-paclitaxel: 260mg/m^2, IV, day 1 of each 21-day cycle, 3 cycles.
45657465|NCT05611879|Drug|Carboplatin|AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 2.
46075585|NCT04232514|Drug|HEC74647|Administered HEC74647 200 mg orally once daily in fed state
45657466|NCT05472415|Other|cognicise|"a combination of cognition and exercise training"
45657467|NCT05472415|Device|arch support insoles|The FootDisc insole is designed with curEVA for shock absorption and motion reduction, poron for secondary heel and metatarsal protection, and dynamic arch support for returning energy for propulsion
45657468|NCT05613751|Behavioral|Nudge|Three text messages that are sent four weeks apart reminding to obtain the vaccines
45657469|NCT04884373|Diagnostic Test|Gastric ultrasound|An ultrasound exam will be performed before induction of anaesthesia. GUS results from selected patients will be systematically acquired and assessed following an algorithm (Appendix Ia). The ultrasound results will be collected on a standardized form (Appendix IIa). The technique is performed in the supine and right lateral decubitus position (Appendix Ib) and only by anesthesiologists with sufficient experience with ultrasound and the technique. The patient will be asked to indicate his/her satiety on a predetermined ten-point scale.
45809365|NCT03112603|Drug|Ruxolitinib|Ruxolitinib twice daily at the protocol-defined starting dose.
45945645|NCT05243940|Drug|remifentanil infusion|remifentanil infusion under the Minto model (target controlled infusion-TCI aiming at 4ng/ml blood concentration
46075586|NCT04232514|Drug|HEC110114|Administered HEC110114 800 mg orally once daily in fed state
46075587|NCT02785692|Radiation|Radiation|preoperative Radiotherapy/ IMRT
45657470|NCT05613673|Other|No intervention - observational study only|No intervention - observational study only
46075588|NCT04232436|Other|Survival at discharge|Survival at discharge
46075589|NCT04232436|Other|Survival without severe morbidity|Survival without severe morbidity (IVH, severe BPD, NEC, ROP)
46075590|NCT02783196|Drug|Liraglutide|In the LIR arm, the participants will be provided with instructions in using pre-filled single-use plastic syringes ready for once daily subcutaneous injection of LIR. From day 1 to day 10, with LIR daily dose of 0.6 mg (0.1 ml), followed by other 10 day courses (from day 11 to day 20) with LIR 1.2 mg (0.2 ml), then will be up-titrated to high dose 1.8 mg (0.3 ml) of LIR (from day 21 to day 40). At crossover-day 40, the participants will undergo a 14 days wash-out period, day 41 to day 55.
45657471|NCT05472103|Behavioral|ergonomics surgical workshop|ergonomics surgical workshop
45809366|NCT03112603|Drug|Extracorporeal photopheresis (ECP)|Best available therapy (BAT) will be selected by the investigator for each participant. BAT may not include experimental agents (ie, those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements. The BAT in this study will be among the following treatments currently used in this setting (no other types or combinations of BATs are permitted in this study).
45809367|NCT03112603|Drug|Low-dose methotrexate (MTX)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
45945646|NCT05239494|Device|DT1 Sphere Contact Lenses|Devices: Dailies Total 1 Sphere Contact Lenses
45945647|NCT05238701|Drug|LPM3770164 sustained release tablet|LPM3770164 sustained release tablet will be administrated orally single-dose on day 1
45809368|NCT03112603|Drug|Mycophenolate mofetil (MMF)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
45945648|NCT05238701|Drug|LPM3770164 sustained release tablet simulant|LPM3770164 sustained release tablet simulant will be administrated orally single-dose on day 1
46075591|NCT02783196|Drug|Placebo|In the PLA arm, the participants will be provided with instructions in using pre-filled single-use plastic syringes ready for once daily subcutaneous injection of PLA. Will start with PLA with matched volume saline injections of 0.1 ml PLA during the first 10 days, followed by 10 days, with 0.2 ml PLA, thereafter PLA will be up-titrated to highest volume 0.3 ml placebo for the rest of the PLA treatment period . At crossover-day 40, the participants will undergo a 14 days wash-out period, day 41 to day 55.
45657472|NCT05613595|Behavioral|Positive Psychotherapy|"Positive Psychotherapy is an effective treatment for many mental disorders and depression is primary empirical target. Its primary goal is to build positive emotion, engagement, and meaning in life that will alleviate depression and other mental health disorders. Thus PPT may offer a new way to treat and prevent mental health issues.~Interventions sessions included, Session Records Session One: Positive Introduction and Gratitude Journal Session Two: Character Strengths and Signature Strengths Session Three: Practical Wisdom , Session Four: A Better Version of Me , Session Five: Open and Closed Memories, Session Six: Forgiveness Session Seven: Maximizing versus Satisficing, Session Eight: Gratitude ,Session Nine: Hope and Optimism, Session Ten: Posttraumatic Growth, Session Eleven: Slowness and Savoring, Session Twelve: Positive Relationships, Session Thirteen: Positive Communication, Session Fourteen: Altruism , Session Fifteen: Meaning and Purpose"
46075592|NCT00634608|Other|Health Information Prescription|The patient education materials will consist of approximately 21 topics representing some of the most common conditions seen at the Fairview Internal Medicine Clinic. Twenty-one e-mails, one per topic, will be created by Fairview physicians to be distributed to selected clinic patients. There will be a standard e-mail for each condition with a specific link to MedlinePlus. To create the targeted health information topic email, the physician will review the information available at MedlinePlus. The physician will then select several links of appropriate information and, using the template, will write a short annotation on each link.
45657473|NCT05613595|Behavioral|Counseling Group|Caregivers in control group only regular counseling will be provided (psychoeducation). it will be based upon the insight of cerebral palsy and training based on Adaptive skill functioning of the CP child of the caregivers
45657474|NCT05471869|Diagnostic Test|Aneurysm diagnosis|Intelligent detection and diagnosis of aneurysm diagnosis by CTA
45657475|NCT05613439|Procedure|Day-surgery|Standard surgical procedure but with planned discharge on day of surgery
45657476|NCT05613439|Procedure|High-risk patient|Standard fast-track procedure but with additional perioperative measures dependent on risk-profile.
45657477|NCT05613439|Procedure|Main Group|Standard fast-track procedure according to usual standard of care and discharge when fulfilling functional discharge criteria
45657478|NCT05471713|Other|Autonomic dysfunction|Autonomic dysfunction
45657479|NCT04789057|Drug|Atorvastatin 40 Mg Oral Tablet|p.o., once daily
45657480|NCT04789057|Drug|Placebo|p.o., once daily
45657481|NCT05611723|Other|Exposure to disability|Disability status assessed by functional measures
45657482|NCT05613361|Drug|Colistin|added for infection with multi drug resistant bacteria
45657483|NCT05613361|Drug|Curcumin|added for the possible nephroprotective effect
45657484|NCT03340519|Device|MR Imaging|Novel MR imaging will be performed to provide bowel anatomic and functional data
45657485|NCT05611645|Radiation|Hypofractionated Stereotactic Radiotherapy|Starting with low-dose bevacizumab, 25Gy in 5 fractions of 5 Gy each delivered on consecutive treatment days.
45657486|NCT05611645|Drug|Bevacizumab|Staring within 2 weeks of randomization, IV 5mg/kg (experimental group) or 10mg/kg (comparison group) every two weeks until disease progression.
45657487|NCT05611567|Procedure|POSE2.0 procedure|The POSE 2.0 involves full-thickness plications by suture anchor pairs that shorten and tabularize the stomach along its greater curvature. The POSE 2.0 procedure was carried out using the Incisionless Operating Platform (USGI Medical, San Clemente, CA)
45657488|NCT05611567|Behavioral|Life style and behavioral intervention|The intervention focuses on caloric restriction diet, physical activity, and behavioral modification targeted toward weight loss and administered by a health care professional months for the 12 months duration of the study.
45809369|NCT03112603|Drug|mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
45809370|NCT03112603|Drug|Infliximab|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
45809371|NCT03112603|Drug|Rituximab|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
45809372|NCT03112603|Drug|Pentostatin|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
45945649|NCT05237206|Biological|SUPLEXA|PBMC-derived autologous cellular therapy derived through an ex vivo activation procedure, resulting in a cell mixture comprised predominantly of NK, NK-T, and T cells stored in cryogenic media.
45945650|NCT05231200|Behavioral|QI Team Building|Each NICU will create a core QI team composed of 6-8 multidisciplinary members including a parent advisor, when feasible. This team will lead the QI activities and education, and champion the culture and practice change in the unit.
45945651|NCT05231200|Behavioral|QI education|Each NICU QI team will receive standardized QI education using the 6-hour EPIQ Workshop which involves hands-on approach to enable teams to successfully implement QI projects together. EPIQ 10 Steps and QI Tools will be used to build the team's understanding of QI using realistic improvement opportunities based on the standardized care bundles identified in the trial.
45657489|NCT03267121|Drug|Apatinib Mesylate Tablets|500 mg qd.p.o. every day for 21 days as a cycle
45657490|NCT03267121|Drug|Tegafur Gimeracil Oteracil Potassium Capsules|25mg/㎡ bid p.o. every day for 14 days as a cycle
45945652|NCT05231200|Other|Standardized care bundle- respiratory care|"A care bundle is a small, simple set (3-5 elements) of evidence-based practices that, when performed collectively and reliably, will result in improved patient outcomes. This bundle will aim to implement best practices for stabilization and respiratory care in moderate and late preterm infants (MLPIs) including~establishing effective ventilation in the delivery room~prevention of hypothermia~early diagnosis and management of respiratory distress with continuous positive airway pressure (CPAP)~standardized approach for surfactant indications and administration~standardized approach for early extubation."
45945653|NCT05231200|Other|Standardized care bundle- nutritional care|"A care bundle is a small, simple set (3-5 elements) of evidence-based practices that, when performed collectively and reliably, will result in improved patient outcomes. This bundle will aim to implement best practices for nutritional support in MLPIs including~early initiation of enteral or parenteral nutrition;~standardized tables for feeding initiation and progression~optimizing breastfeeding and use of mother's own milk~standardized approach for a transition from enteral nutrition via tube feeds to oral feeds."
45945654|NCT05231200|Behavioral|QI mentoring|Each NICU in the intervention arm will have one or more assigned members of the study team who are experienced in collaborative QI and EPIQ methods. The mentors will help local QI teams to engage frontline staff in QI and navigate the unit-specific challenges.
45945655|NCT05231200|Behavioral|Collaborative networking|The study team will conduct virtual meetings every 2 months for the NICUs in intervention arm allowing local QI teams to discuss progress, and share data. The investigators will arrange annual in-person or virtual meetings for the NICUs in the intervention arm to present projects, successes, and lessons learned. These NICUs will have continuing access to the data and will receive quarterly reports using statistical process control charts outlining the unit's performance compared to other units and to the group average.
45945656|NCT05231200|Other|Current practice- standard of care|All participating NICUs will be in the control arm during the first year prior to randomization to create a baseline of the current practices and between-units variation. NICUs in the control arm can continue conducting QI activities relevant to current practice, but without receiving the interventions outlined above until they transition to the intervention arm. The investigators will capture these activities and account for them in the analysis.
45945657|NCT05227846|Biological|Human Umbilical Cord-derived Mesenchymal Stem Cells|Human Umbilical Cord-derived Mesenchymal Stem Cells will be administered intravenously.
45945658|NCT05225376|Other|Physical activity sessions for pregnant women|"The physical activity sessions will take place once a week at the Estaing UHC, in the room used for the childbirth and parenting preparation classes of the outpatient obstetrics-gynecology clinic; and twice a week on Zoom. These sessions will be supervised by an APA professional (degree in STAPS and APA).~The measurement of the women's physical conditions will make it possible to adapt and individualize the PA sessions to each woman's level."
45809373|NCT03112603|Drug|Imatinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
45945659|NCT05214768|Drug|CC-93538|Specified dose on specified days
45809374|NCT03112603|Drug|Ibrutinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
45945660|NCT05214768|Drug|Placebo|Specified dose on specified days
45945661|NCT05209347|Device|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
45809375|NCT03611777|Drug|Inhaled corticosteroid|Drug
45809376|NCT04864470|Behavioral|Stroke Odysseys|"The participants will take part in a twelve-week performance programme that takes place online/in a community halls/arts centre. Sessions run for three hours and during these sessions, participants devise a dance and music performance work from their own stories. The culmination of the programme will be a public facing performance to an audience of carers, health care practitioners, friends, family and the wider community, done online through Zoom.~After the performance is completed, participants will be invited to a training programme where they learn to act as advocates for life after stroke - termed 'stroke ambassadors'. The training will be a four-day programme. The programme will take place once weekly and is led by a team of artists supported by a leadership coach, on Zoom.~Following training, ambassadors will support artists in recruitment, befriend the newly discharged stroke survivors and take part in small scale performance tours to challenge the perception of disability."
46075593|NCT02784678|Procedure|closed reduction group|Patients in the experimental group will undergo C-arm fluoroscopy-assisted minimally invasive closed reduction and internal fixation with fully threaded headless cannulated compression screws. In the experimental group, fractures will be reduced and internally fixed with fully threaded headless cannulated compression screws of appropriate lengths (Acutrak plus; Acumed Inc., Beaverton, OR, USA) under C-arm fluoroscopic guidance to restore the radial inclination and ulnar deviation of the distal radius.
46075594|NCT02784678|Device|open reduction group|Patients in the control group will undergo open reduction and internal fixation with a titanium plate (Ningbo Cibei Medical Treatment Appliance Co., Ltd., Ningbo, China).
46075595|NCT02782650|Other|survey and interview|"all participants: survey on prenatal counseling and treatment decisions at the limits of viability.~a selection of participants: focus group interviews to further perform in-depth exploration of prenatal counseling preferences"
45458081|NCT03502642|Drug|intrathecal morphine|Intrathecal morphine was administered during spinal anesthesia in the placebo group but not in the ropivacaine group
45458082|NCT03502642|Drug|Ropivacaine (Ropivacaina Molteni®)|A10ml bolus of ropivacaine 7.5mg/ml were administered in the wound catheter after skin closure then an infusion of ropivacaine 2mg/ml at the rate of 5ml/h was administered as wound infusion via the Dosi-Pain® Kit for 48hours.
45458083|NCT03502642|Drug|Normal saline|A10ml bolus of normal saline were administered in the wound catheter after skin closure then an infusion of normal saline at the rate of 5ml/h was administered as wound infusion via the Dosi-Pain® Kit for 48hours.
45809377|NCT05458362|Behavioral|Brief Enhanced Anxiety Sensitivity Treatment (Group BEAST)|"Group BEAST consists of a 1.5-hour-long intervention session, followed by a 2-week-long EMI. During the intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety and stress), discuss popular misconceptions they may have about anxiety symptoms, and complete exposure exercises (e.g., practicing facing feared physical sensations such as trembling or elevated heart rate). Homework exposure exercises will be completed by all participants. They will receive phone app reminders about completing homework.~Only the EMI group will receive EMI prompts and intervention."
45809378|NCT05458362|Behavioral|Control group Anxiety Sensitivity Treatment|Control group Anxiety Sensitivity Treatment consists of a 1.5-hour-long intervention session, followed by a 2-week-long EMI. During the intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety and stress), discuss popular misconceptions they may have about anxiety symptoms, and complete exposure exercises (e.g., practicing facing feared physical sensations such as trembling or elevated heart rate). Homework exposure exercises will be completed by all participants. They will receive phone app reminders about completing homework.
45809379|NCT05448768|Device|TBS for Amyloid-positive MCI|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
45945662|NCT05204719|Procedure|Prophylactic Delivery Room Continuous Positive Airway Pressure|Prophylactic Delivery Room Continuous Positive Airway Pressure (DR-CPAP) of 5-6 cm H20 will be provided for 20 minutes through the face mask or the appropriate size of nasal prong after the initial steps as per the participating institution's neonatal resuscitation protocol.
45453242|NCT03948607|Other|Electroencephalography during sustained attention task.|"The Continuous Temporal Expectancy Task (CTET) (O'Connell et al., 2009) is a very demanding discrimination task with sustained attention. It consists of the presentation on a computer screen of a visual pattern resembling a checkerboard that changes orientation at regular intervals of time. In this task the subject must respond (pressing a response button) to the appearance of rare target stimuli that have a longer duration (1120 ms) than non-target stimuli (800 ms).~SART (Sustained Attention to Response Task) (Robertson et al., 1997) is a task of inhibition (Go / No-Go task) to evaluate the capacities of sustained attention. It consists in the successive and random presentation on a computer screen of the numbers from 1 to 9. In this task the subject must respond, by pressing a response button, to the appearance of all the numbers (very non-target stimuli frequent), with the exception of the number 3."
45809380|NCT05448768|Device|TBS for Amyloid-negative MCI|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
45809381|NCT03473171|Device|Nasal non-invasive ventilation with RAM cannula|Pediatric Pulmonary Team will be consulted on inpatient or outpatient patients that fail to wean from chronic respiratory support (CPAP, BiPAP, High flow Nasal Cannula) in whom long-term ventilation is considered. Pediatric Pulmonary Team, as a consultant, will consider patient history, physical examination, previous imaging and laboratories and previous attempts to wean from respiratory support and causes of failure to wean. The Pulmonary team will determine which patients would potentially benefit from use of NIV/RAM-NC for long-term respiratory support and will recommend initiation of NIV/RAM-NC.
45453243|NCT03800173|Drug|galidesivir|galidesivir IV infusion
45945663|NCT05198544|Device|Hēlaquis Matrix is a hyaluronic acid matrix (HaM)|Hēlaquis Matrix is a hyaluronic acid matrix (HaM) derived from the American Alligator and indicated for the treatment of chronic wounds. Hyaluronic Acid (HA) is a naturally occurring non sulphated glycosaminoglycan consisting of a linear sequence of D-glucuronic and N -acetyl-Dglucosamine. It is present in connective tissue and plays a role in several biological processes including tissue repair.
45657491|NCT05611489|Procedure|Single port Lap appendectomy|A multiport device will be introducted through a 2-2.5 transumbilical incision. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
45453244|NCT03800173|Drug|placebo|placebo IV infusion
45458760|NCT04802356|Drug|Dexamethasone|Dose of 20 mg on days: 1, 2, 4, 5, 8, 9, 11 and 12 of every 28-day cycle. Oral administration Induction: 6 cycles Consolidation: 2 cycles
45809382|NCT05441514|Drug|Cobimetinib|Given PO
45809383|NCT05441514|Drug|Enasidenib Mesylate|Given PO
45945664|NCT05186818|Drug|CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg)|CK-3773274 tablets administered orally
45657492|NCT05611489|Procedure|Conventional Lap appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
45657493|NCT05467735|Other|Application of compression to bilateral lower extremities of patients using appropriately-sized elastic compression stockings.|Patients in the Compression group would be subject to application of standardized lower extremity, thigh-high, elastic compression stockings within 24 hours of admission. Appropriate size of the stockings would be based on calf circumference, thigh circumference and leg length. The compression would be applied throughout the entire duration of hospitalization, provided the patient is able to tolerate it. Daily thorough skin checks for any cutaneous defects or lesions will be performed, and mobilization encouraged.
45945665|NCT05186818|Drug|Placebo to match CK-3773274|Placebo administered orally
46075596|NCT04231656|Device|CLEARSIGHT and NICCOMO measurements in sequence A|Starting from 0° position, shift to position +20°, then tilt to -20°, and finally back to the 0° position.
45458761|NCT04802356|Procedure|Autologous stem cell transplant (ASCT)|High-dose melphalan (200 mg/m2) and ASCT will be performed as per routine practice
46075597|NCT04231656|Device|CLEARSIGHT and NICCOMO measurements in sequence B|Starting from 0° position, shift to position -20°, then tilt to +20°, and finally back to the 0° position and collect the last group of figures.
45657494|NCT03167671|Device|AposTherapy|AposTherapy® is a home-based exercise program utilizing footwear that causes exercise with normal daily activity
45657495|NCT03167671|Other|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy
45657496|NCT04426513|Other|Kinesiotherapy with magnetotherapy|Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 0-50 Hz, type of impulse: unipolar or bipolar, rectangular pulse
45676335|NCT03887481|Device|"Sham + Repeat After Me (RAM) Treatment"|"Device: Sham Current will be administered in a ramp-like fashion but after the ramping phase the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.~Participants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay."
45676336|NCT03866148|Device|Reveal LINQ|Insertion of monitoring device called Reveal-LINQ (an implantable loop recorder)
46075598|NCT04230174|Drug|11C-PBR28|This study will evaluate, serially, functional and structural tissue changes in the cortex and WM of subjects with RRMS and progressive disease under Ocrelizumab using 11C-PBR28 MR-PET imaging at baseline and at approximately 12-month follow up.
45809384|NCT03613493|Diagnostic Test|HPV self-sampling kit|The HPV self-sampler kit will include the collection swab and the vial for collecting and storing the specimen, and an instructional sheet that visually depicts the steps for self-sampling.
45809385|NCT03613493|Behavioral|Culturally-targeted Fear Appeal Message|Participants will receive culturally-targeted and fear appeal messages in a graphically designed kit.
45809386|NCT03613493|Behavioral|Fear Appeal Message|Participants will receive fear appeal messages (only) in a graphically designed kit.
45809387|NCT03613493|Behavioral|Interview|Participants will be interviewed about experiences using the self-sampling tool (qualitative).
45945666|NCT05186272|Behavioral|Stress reduction program 'A'|Participants will use stress reduction program 'A' app 10-20 min per day for 6 weeks.
46075599|NCT05188170|Drug|Niclosamide|Niclosamide will be administered orally for 14 days. Each dose will be followed by backbone chemotherapy
46075600|NCT04231422|Combination Product|Platelet-rich plasma|12mL of platelet-rich plasma injected into cavernosal bodies bilaterally
46075601|NCT02782572|Other|Exercise|Exercise in acute heart failure in three different groups (conventional medical treatment; exercise with non-invasive ventilation and exercise with placebo of non-invasive ventilation).
45809388|NCT05131789|Procedure|dementia case management information system|The investigators will develop an information system based on the data collected in our previous research, the content and method of dementia case management which will be established by the Delphi method, and then the dementia case management information system will be constructed accordingly.
45809389|NCT04492397|Device|Test Contact Lens|Subjects will be randomized to wear test lenses.
45809390|NCT04492397|Device|Control Contact Lens|Subjects will be randomized to wear control lenses.
45945667|NCT05186272|Behavioral|Stress reduction program 'B'|Participants will use stress reduction program 'B' app 10-20 min per day for 6 weeks.
46075602|NCT02782494|Other|Examination of latent TB by QuantiFERON-TB|Examination of latent TB by QuantiFERON-TB both QFT-plus QFT-GIT
46075603|NCT02784132|Other|Video diversion|The intervention is playing a video on a computer or iPad (using www.youtube.com) while performing fundoscopy.
46075604|NCT02782338|Drug|Voltaren ophtha 0.1%|All study patients will be treated with Voltaren ophtha 0.1% after cataract surgery
46075605|NCT02782260|Drug|Dipyridamole|
46075606|NCT02782260|Drug|Placebo|
46075607|NCT02782416|Other|Examination of latent tuberculosis|
45945668|NCT05185453|Behavioral|Strengthening Connections for Change|Strengthening Connections for Change is a 12-session curriculum designed to strengthen adolescent-adult support networks, build leadership skills, foster community engagement, and challenge attitudes and behaviors that foster violence involvement. During the program, youth ages 13-17 years invite their self-identified key adult supports to jointly participate in programming including youth-focused, adult-focused and jointly focused activities. Towards the end of programming participants design and carry out a community project to strengthen intergenerational connections and promote community engagement.
45657497|NCT02977195|Drug|NP137 DL and RP2D|"DOSE ESCALATION PART: 7 DL: NP137 was administrated every 2 weeks, as single agent by intravenous injection over 90 min with up to 7 ascending dose levels: Dose level 1: 1 mg/kg Dose level 2: 2 mg/kg Dose level 3: 4 mg/kg Dose level 4: 6 mg/kg Dose level 5: 9 mg/kg Dose level 6: 14 mg/kg Dose level 7: 20 mg/kg~EXPANSION PARTS: NP137 was administered every 2 weeks, as single agent by intravenous injection over 180 min at 14 mg/kg (RP2D defined in the Dose escalation part).~FOR ALL PARTS AND COHORT: Treatment will be administered as long as patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
45809391|NCT02258334|Biological|Fluzone® Quadrivalent vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
45945669|NCT05185453|Behavioral|Job Readiness Training|Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth.
45945670|NCT05182866|Combination Product|ASP-1929 Photoimmunotherapy|ASP-1929 640 mg/m^2 IV infusion followed approximately 24 hours later by photoimmunotherapy
45809392|NCT02258334|Biological|Fluzone I®ntradermal vaccine, 2014-2015 formulation|0.1 mL, Intradermal
45945671|NCT05175352|Drug|Cendakimab|Specified dose on specified days
45945672|NCT05175352|Drug|CYP substrates|Specified dose on specified days
45945673|NCT05167734|Drug|Iron Dextran|1000 mg IV
45945674|NCT05167734|Drug|Erythropoietin (EPO)|40,000 units subcutaneous
45945675|NCT05164575|Behavioral|progressive resistance exercise|Progressive resistance exercise program and self-management strategies. Participants will be provided with Theraband to progress exercise intensity, a FitBit to monitor physical activity, an audio-journal to promote self-reflection, and educational materials provided as part of usual OA care.
45945676|NCT05164575|Behavioral|self-management strategies|Progressive resistance exercise program and self-management strategies. Participants will be provided with Theraband to progress exercise intensity, a FitBit to monitor physical activity, an audio-journal to promote self-reflection, and educational materials provided as part of usual OA care.
45945677|NCT05163639|Procedure|Non-invasive pairing of cortical and spinal stimulation|Transcranial magnetic stimulation (TMS) threshold, Transcutaneous spinal cord stimulation (TSCS) threshold, and peripheral and central motor conduction times will be determined. In the active intervention, two TMS pulse intensities will be tested: 90% and 120% of motor threshold. Two conditioning TSCS pulse intensities will be tested: 50% and 90% of response threshold. Single TSCS pulses will be delivered timed to arrive in the cervical spinal cord at a range of intervals from 30ms before to 30ms after the TMS pulse. The control conditions will include TMS only TSCS only and non-convergent pairing latency pairing stimulation.
45945678|NCT05163639|Procedure|Intraoperative pairing of cortical and spinal stimulation|The surgeon will position spinal cord electrodes on the epidural surface one level rostral (typically C4/C5) to the site of myelopathy. Spinal and cortical thresholds will be determined. Investigator will then test the immediate effects of paired stimulation by stimulating the cortex at 120% of threshold and the spinal cord at 90% of threshold at various latencies relative to the time of synchronous convergence. The control intervention will include cortical only (120%) spinal only (90%) and non-convergent latency pairing stimulation.
45657498|NCT04340167|Biological|Autologous humanized anti-CD22 chimeric antigen receptor T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In CD22 T cell clinical trials, CAR-T cells was given once. All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR T-cell infusion to determine the disease status.
45809393|NCT02258334|Biological|Fluzone® Quadrivalent vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
45809394|NCT02258334|Biological|Fluzone High Dose vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
45809395|NCT03478163|Drug|CeFAZolin 1000 MG|Cefazolin 1000 mg every 8 hours for 3 doses
45809396|NCT03478163|Drug|Clindamycin 900 MG in 6 ML Injection|Clindamycin 900 mg every 8 hours for 3 doses
45945679|NCT05163639|Procedure|Non-invasive repeated pairing of cortical and spinal stimulation (SCAP)|Thresholds will be determined as above. Immediately prior to repetitive pairing, a set of 12 TMS pulses will be delivered at 120% threshold to measure the baseline cortical MEP. Likewise, a set of 12 TSCS pulses will be delivered at 120% of threshold to establish the baseline spinal MEP. For each session, baseline maximal pinch dynamometry will be determined. Immediately after the SCAP protocol is completed, response to TMS, TSCS, and maximal pinch dynamometry will be measured again every 10 minutes over the subsequent hour. The control conditions will include TMS only TSCS only and non-convergent pairing latency pairing stimulation.
45945680|NCT05163639|Procedure|Intraoperative repeated pairing of cortical and spinal stimulation (SCAP)|Intraoperative: Spinal and cortical thresholds will be determined. Immediately prior to repetitive pairing, a set of 12 baseline cortical pulses and 12 baseline spinal pulses will be delivered at 120% threshold. SCAP protocol will be applied, both of which have been successful at inducing lasting effects in the rat. After pairing, cortical stimulation at 120% of threshold and spinal cord stimulation at 120% threshold will be repeated every 10 minutes for the duration of surgery. In a subset of patients repeated pairing will be conducted with a latency that investigator does not expect will induce SCAP, or with electrodes placed over the ventral epidural surface. The control intervention will include repeated pairing at a non-convergent latency, as well as pairing of cortical stimulation with ventral epidural stimulation.
45945681|NCT05163639|Procedure|Intraoperative repeated pairing of cortical and spinal stimulation (SCAP) at or below myelopathic region|As per the intervention 'Intraoperative repeated pairing of cortical and spinal stimulation (SCAP)' targeted at or below myelopathic region.
45809397|NCT05440110|Device|active and active TBS|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50- Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
46075608|NCT05342610|Other|Distant reiki|Reiki; It is the transfer of energy to other people by the hands of the person who receives the theoretical training and attunement (initiation) from the reiki master, close or distant. When the hands are brought closer to the body in suitable positions or when the reiki practitioner visualizes the person in his/her thoughts, the energy flow starts spontaneously and the transferred energy is shaped according to the needs of the reiki recipient. The biggest advantage of Reiki; It is an easy and cost-effective method to ensure that the individual restores the balance between body, mind and spirit, has no side effects, has no negative effects on behavior and attitudes.
45945682|NCT05163548|Device|PerQseal Plus Device|Percutaneous closure of femoral artery access site created by 14 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing Percutaneous Transcatheter procedures.
45945683|NCT05157659|Diagnostic Test|[18F]F-AraG PET-scan|[18F]F-AraG PET scans are performed to assess the accumulation of activated T-cells in the tumour and healthy tissue.
45945684|NCT05157009|Procedure|implant placement|autogenous bone reconstruction of damaged socket & simultaneous implant placement
45945685|NCT05147636|Procedure|Extubation with PEEP|No aspiration within the 3 minutes before extubation and extubation with 10cmH2O PEEP
46075609|NCT04229784|Procedure|Radiofrewuency surgery|The research procedure consists of radiofrequency destruction of hemorrhoidal vascular tissue. It consists in delivering a 4 MHz radiofrequency wave current delivered at low temperature by microfibre electrodes using a large disposable needle within the hemorrhoidal vascular tissue
45945686|NCT05147636|Procedure|Endotracheal Aspiration|Aspiration during cuff deflation
45809398|NCT05440110|Device|sham and active TBS|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50- Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min. Sham stimulation applies the same iTBS protocol with the sham coil.
45945687|NCT05145309|Drug|KMgCit|Supplement that provide K, Mg, and citrate
45945688|NCT05145309|Drug|Placebo|Power with identical appearance to KMgCit
45809399|NCT05646810|Diagnostic Test|Lidocaine (10 mg/ml)|Lidocaine (10 mg/ml) will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.
46075610|NCT04229862|Procedure|Laryngeal mask airway insertion|Laryngeal mask airway insertion in patients who undergoing transurethral bladder tumor resection
45809400|NCT05646810|Diagnostic Test|Isotonic saline|Isotonic saline will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.
45809401|NCT04449263|Device|Lens A|Subjects will be randomized to wear Lens A (test) for 2 weeks.
45809402|NCT04449263|Device|Lens B|Subjects will be randomized to wear Lens B (control) for 2 weeks.
45809403|NCT04449263|Device|Habitual Lenses|All Subjects will wear their habitual lenses for 2 weeks prior to randomization of test lens and control lens.
45945689|NCT05145127|Drug|PF-06741086|300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
45945690|NCT05142241|Procedure|Computed Tomography|Undergo CT
45945691|NCT05142241|Drug|Talazoparib|Given PO
45945692|NCT05142241|Drug|Temozolomide|Given PO
45809404|NCT05646732|Device|TMS-fMRI|Participants will undergo simultaneous TMS and fMRI
45809405|NCT04413929|Drug|Ergoferon|Oral administration
45809406|NCT04734743|Other|cystic fibrosis|Evaluation of Upper Extremity Muscle Strength and Endurance, functional capacity, Respiratory Function and Quality of Life
45458762|NCT01239277|Other|protein|20g protein
45458763|NCT01239277|Other|protein and carbohydrate|20g protein and 20g carbohydrate
45945693|NCT05141474|Biological|NEXTGEN-TIL|"NEXTGEN-TIL product is a cellular investigational product comprising a live cell suspension of autologous tumor-infiltrating lymphocytes derived from the patient's own tumor.~Each dose contains at least 5 x 10^8 total viable lymphocytes, and a maximum of 1.11x10^11. It will be administered IV on Day 0 (24h after the last dose of Fludarabine)."
45809407|NCT04960202|Drug|PF-07321332|PF-07321332 (tablet)
45809408|NCT04960202|Drug|Ritonavir|Ritonavir (capsule)
45945694|NCT05141474|Drug|Non-myeloablative Lymphodepletion (NMA-LD) Regimen|Patients will receive a NMA-LD chemotherapy based on Cyclophosphamide 60 mg/kg IV (once daily on Days -5 and -4) and Fludarabine 25 mg/m2 IV (once daily on Days -5 to -1).
45657499|NCT05611333|Behavioral|Physician-Led Remote Exercise Program Intervention|The physician-led remote exercise program intervention consists of three 45-minute walking classes on Zoom per week for 4 weeks.
45657500|NCT04339543|Other|Cognitive dual-task walking|• The task will consist in walking while performing the phoneme monitoring task. The phoneme monitoring task will consist in listening to a text through headphones, and participants will be asked to i) answer ten questions regarding the content of the text after the task, and ii) count how many times two predefined words appeared in the text. During single and dual-task walking, participants will be asked to walk around the track at a speed that they feel would be comfortable while walking through the grocery store or walking to their car, with no instructions regarding the priority to give to each task (walking vs. cognitive task).
45945695|NCT05141474|Drug|Interleukin-2|"Patients will receive sequential doses of 720,000 IU/kg IV IL-2 every 8-24 hours depending on patient tolerance. It will be administered on Days 0 to 2, starting between 3 and 24 hours after the completion of NEXTGEN-TIL infusion.~IL-2 doses may be skipped in case of toxicity. If 2 sequential doses or more than 2 non-sequential doses of IL-2 are skipped due to patient intolerance or the discretion of the investigator, IL-2 administration must be stopped."
45657501|NCT02907697|Behavioral|Life Steps-Drug Use|
45945696|NCT05136963|Drug|Iohexol|5 milliliter of iohexol will be administrated.
46075611|NCT02782728|Behavioral|TIPS-Plus|Patients receive brief psycho-educational messages on a tablet computer following completion of questionnaire about personal experiences of intimate partner violence (IPV), sexual assault (SA), and reproductive coercion (RC). These messages are tailored to each patient and are based on their responses to specific items. The messages serve as prompts to encourage the patient to continue the discussion about various topics (healthy relationships, birth control methods, harm reduction) with their provider during their clinic visit. Simultaneously, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
45945697|NCT05136963|Biological|pharmacokinetics|10 blood samples of 5 milliliter will be performed. sampling time ater administration of Iohexol: 00h30, 1h00, 1h30, 02h00, 03h00, 04h00, 05h00, 06h00, 09h00 and 12h00
45945698|NCT05134727|Drug|AZD5055|Healthy participants will receive AZD5055
46075612|NCT02782728|Behavioral|TIPS-Basic|Patients complete tablet questionnaire about personal experiences of IPV/SA/RC and based on responses, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
45657502|NCT02907697|Behavioral|General Health Education|
45657503|NCT02906215|Behavioral|Care Coordination Intervention|cross-training in HIV/PrEP and substance use, plus a digital health tool to improve evidence-based screening, brief intervention, referral to treatment, and patient management across HIV, PrEP, and addiction treatment providers
45657504|NCT02835079|Drug|Tamoxifen|
45657505|NCT02474095|Other|Quality-of-Life Assessment|Ancillary studies
45657506|NCT02474095|Procedure|Transcutaneous Acupoint Electrical Stimulation|Undergo ALTENS
45657507|NCT05455567|Diagnostic Test|OCTA|Choriocapillary vessel density calculated with OCTA
45657508|NCT05446285|Other|Clinical assessment|All participants will be invited to attend their local research facility to undergo a physical and questionnaire assessment as well as an MRI. Assessments include: Expanded Disability Status Scale, 9-Hole Peg Test, MRI scan, Patient Reported Outcome Measures (MSIS-29, neuroQOL and PROMIS), Brief International Cognitive Assessment for MS)
45809409|NCT04960202|Drug|Placebo|Placebo (tablet or capsule)
45809410|NCT03615911|Biological|vaccine candidate MVA-MERS-S|vaccination with MVA-MERS-S in two escalating dose regimes
45809411|NCT03618017|Behavioral|CCC website|ConnectedCancerCare (CCC) is a web-based guide to support survivorship care for women who have been treated for early-stage (stages 0-II) breast cancer. It encourages patients to utilize team-based care by oncologists and primary care physicians and provides them with the information on cancer surveillance, screenings and preventive healthcare during survivorship.
45809412|NCT03618017|Behavioral|Static care plan|"The control is a static survivorship care plan template in PDF format that includes information similar to what an oncologist currently provides as standard of care."
45809413|NCT03619811|Diagnostic Test|Reflux Band® Upper Esophageal Sphincter (UES) Assist Device|UES augmentation via the UES assist device is effective in true Reflux associated laryngeal symptoms. In our first pilot trial with the UES assist device, patients had significant symptom reduction following 2 weeks of UES assist device use. Based on our preliminary work, we theorize that the UES assist device is effective in Reflux associated laryngeal symptoms.
45809414|NCT03619889|Other|Manual pressure release technique on trigger points.|A specific pressure is applied on trigger points of masticatory and neck muscles between pain pressure threshold and pain tolerance (7-8 visual analog scale).
45809415|NCT03619889|Other|Sham|A simulated pressure release technique is applied around masticatory and neck muscles.
45809416|NCT02959112|Drug|Epinephrine|
45945699|NCT05134727|Drug|Placebo|Healthy participants will receive placebo
46075613|NCT05031936|Procedure|cervical spinal injection with 0.2% ropivacaine|spinal injections performed in cervical pillar area to relieve chronic neck pain
45945700|NCT05134532|Drug|regorafenib|Regorafenib 160 mg orally every day for 3 weeks of every 4-week cycle (i.e. 3 weeks on, 1 week off) plus best supportive care
45809417|NCT02959112|Other|Sterile water|
45809418|NCT02959112|Drug|Indomethacin Rectal Suppository|
45945701|NCT05131139|Device|Continuous Glucose Monitoring System|Eversense 524 CGM System and ROME CGM System.
46075614|NCT03577704|Drug|HLX07+Gemcitabine+Cisplatin|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Gemcitabine and Cisplatin.~HLX07, IV, weekly."
46075615|NCT03577704|Drug|HLX07+Paclitaxel+Carboplatin|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Paclitaxel and Carboplatin.~HLX07, IV, weekly."
45657509|NCT05436145|Behavioral|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver intervention notifications. The intervention notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of two types of message sets: 1) Support, or 2) Consequences. Within each message set the core content is adapted to provide either 1) Emotional Support or Practical Support, or 2) Gain or Loss-Framed Consequences.
45657510|NCT01667107|Drug|Posaconazole|
45657511|NCT01667107|Drug|Calogen®|
45657512|NCT04412239|Behavioral|Patient-centred advice on Telephone Consultation in TB Patients:|The primary aim was to assess the efficiency and the satisfaction of the telephone consultation. The COVID-19 pandemic might be an opportunity to review and refine our practices in TB care. For the follow-up of selected patients, telephone consultations may be efficient and cost effective.
45809419|NCT05154188|Device|Neuro Cochlear Implant system|Patients will be regular candidates for a cochlear implantation surgery, according to the indication criteria of the Neuro Cochlear Implant System and the device will be used according to its intended purpose
45809420|NCT05377034|Combination Product|SIRT-Y90 with Atezolizumab + Bevacizumab|Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by 1200mg atezolizumab + 15mg/kg bevacizumab administered by IV at every 3 weeks for 18 months.
46075616|NCT03577704|Drug|HLX07+mFOLFOX6|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Oxaliplatin, Calcium Folinate and 5-FU.~HLX07, IV, weekly."
46075617|NCT05341206|Drug|Herbal gargle|The treatment group receive Herbal gargle 150ml and are instructed to hold the gargle in the mouth for 30s and then expectorate it twice a day, 5 days a week for 8 weeks.
45809421|NCT05377034|Combination Product|SIRT-Y90 with Placebo (IV)|Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by placebo at every 3 weeks for 18 months.
46075618|NCT05341206|Other|Normal saline|The control group receive Normal saline 150ml and are instructed to hold the normal saline in the mouth for 30s and then expectorate it twice a day, 5 days a week for 8 weeks.
45809422|NCT03481595|Device|HealthLoop mobile application|Patients will utilize the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care.
46075619|NCT05176860|Device|CBCT Imaging|Two research CBCT images will be acquired per subject.
46075620|NCT04229706|Drug|xingjurupining capsule|xingjurupining capsule,8 capsule,tid,3 months.
46075621|NCT04229706|Drug|xiangjurupining capsule, xiangjurupining capsule placebo|xiangjurupining capsule,4 capsules , and xiangjurupining capsule placebo,4 capsules,tid,3 months.
46075622|NCT04229706|Drug|xiangjurupining capsule placebo|xiangjurupining capsule,8 capsule,tid,3 months.
45809423|NCT04957550|Drug|SHR0302 tablets、Placebo|SHR0302 tablets dose 1 for 48 weeks
45809424|NCT04957550|Drug|SHR0302 tablets、Placebo|SHR0302 tablets dose 2 for 48 weeks
45809425|NCT04957550|Drug|Placebo|SHR0302 tablets blank preparation for 24 weeks then SHR0302 tablets dose 1/dose 2 for 24 weeks
45809426|NCT03622619|Other|Optimel Antibacterial Manuka+ Dry Eye Drops|Leptospermum sp Honey 165mg/g
45809427|NCT03622619|Other|Systane Ultra Lubricating Eye Drops|Polyethylene glycol 400 0.4% and propylene glycol 0.3%
45809428|NCT04951778|Drug|CC-91633|Administered orally according to the assigned treatment schedule
45809429|NCT04885244|Procedure|Index or spine revision surgery for complex adult spinal deformity|Surgical interventions will be patient specified by treating surgeon.
45809430|NCT04428359|Drug|Measles-Mumps-Rubella Vaccine|Group A patients will receive intralesional injection of upto 0.5 mL of reconstituted MMR vaccine into a single or a maximum of 5 warts at a time in case of multiple warts. Intralesional injection will be given every three weeks for a maximum of 5 doses or until complete resolution, whichever is earlier.
45809431|NCT04428359|Drug|Vit D|Group B patients will receive a maximum of 0.5 mL Inj. Vitamin D3 (600,000 IU; 15mg/ml) in each session after injection of IL lignocaine with 31 G insulin syringe. In cases of multiple warts, a maximum of 5 warts will be injected at a time. The session will be done at 3 weekly intervals for a maximum of 5 sessions or until complete resolution of warts, whichever is earlier
45809432|NCT02257632|Drug|Ranibizumab 0.5 mg|Administered as an intravitreal injection
45809433|NCT02257632|Drug|Aflibercept 2 mg|Administered as an intravitreal injection
45809434|NCT04943120|Procedure|"Snow-plow technique"|In class II cavities, application of X-tra Base bulk fill flowable composite (VOCO) in 1 mm thickness without curing followed by X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. Polymerization as one unit for 20 seconds.
45809435|NCT04943120|Procedure|Bulk fill technique|In class II cavities, application of 4 mm increment of X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. then the restoration id fully polymerized.
45809436|NCT04942028|Behavioral|Exposure|Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
45809437|NCT04942028|Behavioral|Standardized education|Standardized routine care education for individuals suffering from distress related to somatic symptoms, primarily focusing on healthy lifestyle behaviors such as sleep, diet, and exercise
45809438|NCT04942028|Behavioral|Prolonged assessment|Patients are encouraged to keep a rudimentary symptom diary to track if and how their symptoms interact with mood and lifestyle behaviors
45809439|NCT04415489|Device|Office hysteroscopy|Use of hysteroscopy in the clinical setting to directly visualize the cavity. If pathology amenable to immediate treatment is visualize, removal will be attempted by hysteroscopic graspers.
45945702|NCT05127018|Drug|injection of Botulinum type A|The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.
45945703|NCT05126719|Drug|MRG003|Administered intravenously
45945704|NCT05126719|Drug|Capecitabine tablets|Administered peros
45945705|NCT05126719|Drug|Docetaxel injection|Administered intravenously
45945706|NCT05124925|Biological|Ianalumab|Ianalumab VAY736 150mg/1ml Solution for injection
45945707|NCT05119140|Drug|Hydroxychloroquine|400mg of hydroxychloroquine per oral daily
45945708|NCT05119140|Drug|Mesalamine|the participant will maintain their current standard of care dose which can range from 1.5g to 4.8g of mesalamine per oral daily
45945709|NCT05116020|Other|Usual chiropractic care|Usual chiropractic care in Switzerland can include spinal manual therapy, soft-tissue therapy, use of electric therapeutic modalities (low level laser therapy, therapeutic ultrasound, interferential current), acupuncture, prescription medication, exercise, education and reassurance.
45945710|NCT05112926|Device|Embosphere Microspheres|Embosphere Microspheres are 100-300μm small, compressible, hydrophilic, biocompatible spheres made of acrylic polymer and porcine-derived gelatin used for embolization of geniculate artery.
45945711|NCT05111561|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
45945712|NCT05111561|Drug|Binimetinib|Given PO
45945713|NCT05111561|Procedure|Biopsy|Undergo biopsy
45945714|NCT05111561|Procedure|Biospecimen Collection|Undergo collection of blood samples
45945715|NCT05111561|Procedure|Computed Tomography|Undergo CT
45945716|NCT05111561|Procedure|Magnetic Resonance Imaging|Undergo MRI
45945717|NCT05107050|Device|Normal Saline and Amorphous gel|Saline - sodium chloride and water Amorphous hydrogel dressings are formulations of water, polymers
45945718|NCT05107050|Device|BIAKOS™ Antimicrobial Skin & Wound Cleanser, BIAKŌS Antimicrobial Wound Gel|"Antimicrobial Skin & Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site.~BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel. The gel provides preservative properties through the antimicrobial PHMB. BIAKŌS Antimicrobial Wound Gel: • Resists microbial colonization within the gel during shelf storage. • Provides an amorphous gel covering. • Facilitates autolytic debridement through a moist wound environment. Wounds experience some level of autolytic debridement in which the body's own enzymes breakdown necrotic tissue."
45945719|NCT05097586|Device|active tDCS|2mA of direct current delivered in 15 sessions lasting 30 minutes each over 3 weeks
45945720|NCT05097586|Other|workbook|Self-directed depression in pregnancy workbook completed during each session to control the in-session brain state
45945721|NCT05097586|Device|sham tDCS|Sham stimulation in which the current turns off after 30 seconds in a slow ramp down that mirrors sensory adaptation in ongoing stimulation, delivered in 15 sessions lasting 30 minutes each over 3 weeks
45945722|NCT05097261|Drug|Ketamine|Racemic ketamine® will be administered by continuous infusion in a prefilled 50 ml syringe at a concentration of 50 mg/ml, undiluted. The ketamine dose is 1 mg/kg/h, to a maximum dose of 120 mg/hour, which corresponds to an infusion rate of 0.02 ml/kg/h to a maximum rate of 2.4 ml/h.
45945723|NCT05097261|Drug|Placebo|Placebo (NaCl 0.9%) will be provided in the same type syringes and administered at the same infusion rate as the IMP (0.02 ml/kg/h to a maximum rate of 2.4 ml/h).
45945724|NCT05096988|Dietary Supplement|PKU sphere liquid|PKU sphere liquid will be prescribed by the study dietitian based on the patient's individual requirements.
45458764|NCT01239277|Other|protein and leucine|20g protein, 2.5g leucine
45657513|NCT02410213|Drug|Ferric Carboxymaltose (FCM)|
45657514|NCT05381779|Other|Inspiratory Muscle Training Group|"Patients in the training group will receive inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) at 50% of the maximal inspiratory pressure.~Patients in the training group inspiratory muscle training will be given 2 sets of 15 minutes a day for a total of 30 minutes/per day or a single session for 30 minutes/week, 7 days/week for a total of 8 weeks.~Patients in the training group will be given respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week."
45657515|NCT05381779|Other|High Intensity Interval Training Group|"High-intensity interval aerobic exercise training will be given to training group on treadmill 3 days in a week and 15-45 minutes in a day for 8 weeks with the assistance of a physiotherapist.~The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate or according to Borg scale dyspnea/fatigue 15-18 points.~The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate or according to Borg scale dyspnea/fatigue 11-13 points."
45657516|NCT05381779|Other|Control Group|Breathing exercises will be given to the control group 120 times in a day and 7 days in a week for 8 weeks as a home program. The control group will be followed-up by telephone once a week.
45809440|NCT04872452|Procedure|Skin biopsy|Any combination of the following six 3-6mm skin biopsies may be taken: palm, dorsum of hand, calf, other non-genital and non-face (this last one includes areas for use as negative controls which are not on the distal limbs). No more than 6 biopsies will be taken at one time.The biopsy size 3-6mm and method (punch, shave or wedge) will be done depending on the biologic assay destined for the biopsy. While 3mm will be sufficient for microarray analysis, 6mm will be required for any cell sorting preceding microarray analysis.
45945725|NCT05095454|Device|Percutaneous epidural electrical spinal stimulation|"Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Ripple Neuromed Nomad Neurostimulation System"
45945726|NCT05095454|Device|Transcutaneous electrical spinal stimulation|Digitimer DS8R Bipolar Constant Current Stimulator
45657517|NCT04411615|Drug|Omega 3|rTG form Omega-3
45809441|NCT04937036|Diagnostic Test|Polysomnography|Each of the patients will undergo polysomnography
45945727|NCT05082051|Drug|Part A|"Randomized, double-blind, placebo-controlled dose escalation part to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after single oral dose administration in healthy adult subjects.~Single-dose administration of CDX-7108 at the following anticipated dose levels. 10 000, 50 000, 150 000, 250 000, and 500 000 lipase units will be evaluated in 5 sequential cohorts of 6 subjects each."
45809442|NCT05436054|Drug|Picoprep|200 patients will be randomised to this arm
45809443|NCT05436054|Drug|Plenvu|200 patients will be randomised to this arm
45657518|NCT02405221|Biological|TA-CIN (arm)|TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.
45809444|NCT04864106|Device|Endoscopic Examination|Endoscopic airway grading using a rigid 75-degree angle laryngoscope.
45809445|NCT04932434|Drug|Psilocybin therapy|"Psilocybin administration session 1: 10mg delivered orally with psychological support and monitoring~Psilocybin administration session 2: 25mg delivered orally with psychological support and monitoring"
45657519|NCT02405221|Biological|TA-CIN (thigh)|TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.
45657520|NCT02230501|Dietary Supplement|stringent diet regimen|
45657521|NCT02230501|Dietary Supplement|moderate diet regimen|
45809446|NCT04383665|Device|STN DBS 10Hz|Stimulation of existing DBS device at 100Hz, with other parameters at baseline
45657522|NCT01802203|Device|truFreeze Spray Cryotherapy|spray cryotherapy
45809447|NCT04383665|Device|STN DBS 130Hz|Stimulation of existing DBS device at 130Hz, with other parameters at baseline
45809448|NCT04383665|Device|STN DBS off|Existing DBS device turned off
45809449|NCT02977130|Behavioral|Map group|diabetes shared care plus conversation map intervention
45809450|NCT02977130|Behavioral|Control group|diabetes shared care
45809451|NCT04925882|Procedure|Erector spinae plane block|"After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : Levobupivacaïne 2,5mg/ml."
45657523|NCT04685551|Behavioral|Change in knowledge, motivation, skills, and resources|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to improve survivorship outcomes.
45657524|NCT04638673|Device|Soterix taVNS model 0125-LTE Stimulator - Active-Active Group|Participants will receive active taVNS stimulation for weeks 1-4 of the stimulation portion of this study.
45657525|NCT04638673|Device|Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group|Participants will receive sham taVNS stimulation for weeks 1&2 and active stimulation for weeks 3&4 of the stimulation portion of this study.
45657526|NCT04589611|Drug|amobarbital/Gel-One (one dose)|One dose of amobarbital/Gel-One during the initial surgical intervention
45945728|NCT05082051|Drug|Part B|"Randomized, double-blind, placebo-controlled dose escalation parts to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after multiple oral dose administration in healthy adult subjects.~It will evaluate multiple dose administration of CDX-7108 at an appropriate low (50 000 lipase units), mid (150 000 lipase units), and high dose (250 000 lipase units) 4 times a day (QID) for 6 consecutive days in 3 sequential cohorts of 6 subjects each."
45657527|NCT04589611|Drug|Placebo (single dose)|One dose of placebo during the initial surgical intervention
45657528|NCT04589611|Drug|amobarbital/Gel-One (two doses)|One dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
45657529|NCT04589611|Drug|Placebo (two doses)|One dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
45657530|NCT04535479|Behavioral|Dry Needling|Dry needling is a procedure in which a thin, stainless steel needle is inserted into the skin to produce a muscle twitch response. It is intended to release a knot in a muscle and relieve pain.
45657531|NCT05269849|Drug|Sirolimus|Sirolimus (1, 2, or 5 mg tablets) given for 3 months followed by a washout period of 3 months
45657532|NCT05256199|Behavioral|Multidomain lifestyle intervention|A multidomain lifestyle intervention, including (1) physical activity, (2) cognitive training, (3) cardiovascular risk factor management (Cardiovascular), (4) dietary counselling, (5) Souvenaid, (6) sleep counselling, (7) stress management, and (8) social activities.
45657533|NCT05240131|Drug|GB1211|GB1211 is a galectin 3 inhibitor an orally available small molecular anti-fibrotic. It is administered orally twice a day.
46075623|NCT05176626|Behavioral|Online Lifestyle Behavioral Therapy|Participants will receive access to the WW™ digital application for the duration of their participation. The WW™ digital application can be accessed using a smartphone, tablet or personal computer and includes functions such as food journaling, progress charts, lifestyle coaching , ability to manually enter exercise data or link with a fitness tracking device, incentives for behavior change, recipes, and local restaurant recommendations using GPS. Over the course of 12 clinic visits with an obesity provider, participants will be prescribed a dietary plan based on the WW™ app and will be asked to journal dietary intake.
45657534|NCT05240131|Drug|Placebo|Placebo is administered orally twice a day.
45657535|NCT05240131|Drug|Atezolizumab|Atezolizumab is an PD-L1 inhibitor administered as an intravenous infusion every three weeks at a dose of 1200mg
45657536|NCT05220943|Behavioral|Video|This 5-minute video presents clips with voiceover narration summarizing and highlighting the key safety points in the Center for Surgical Innovation (CSI) location.
45657537|NCT05475145|Procedure|Resin based sealing [RBS]|
45657538|NCT05615155|Other|Platelets Rich Fibrin (i-PRF / C-PRF)|one site of the mouth will be injected with i-PRF and the other site will be injected with C-PRF
45657539|NCT05614999|Other|Endoscopy training curriculum|Eight sessions training in endoscopic tip control using Varix trainer model I.
45945729|NCT05082051|Drug|Part C|"Randomized, double-blind, placebo-controlled, single-dose, 2-way crossover part to assess POC of CDX-7108 in terms of PD as well as its safety, tolerability, and immunogenicity in subjects with EPI.~Approximately 10 subjects with severe EPI from partial/total pancreatectomy or chronic pancreatitis will be enrolled. It is anticipated that Part C (POC study) will commence after completion of the third single-dose cohort from Part A (SAD study) and following SRC review of the data from this cohort."
45657540|NCT05188339|Drug|4% sodium citrate|"Dose of 4% sodium citrate is also according to catheter lumen (LVR) instilled into each lumen of catheter after HD session, eg. 1.6 cc/lumen for LV R 1.6, 1.8 cc/lumen for LVR 1.8.~A prospective, open label, control study. The content of study protocol will be posted in the HD room in the Kaohsiung Chang Gung memorial Hospital, Taiwan. After inform consent obtained, we will categorize enrolled participants randomly into two groups, 4% sodium citrate group(experimental group), heparin group(control group), respectively. The study duration is three months."
45657541|NCT05188339|Drug|heparin group|Heparin dosage is based on volume ratio in catheter lumen (LVR) after each HD session, eg. 8000u/lumen in 1.6 LVR, 9000u/lumen in LVR 1.8.
45657542|NCT05169385|Behavioral|Parent SMART|Parent SMART experimental intervention
45657543|NCT05169385|Behavioral|Treatment as Usual|Residential treatment as usual
45657544|NCT04393909|Behavioral|Diagnostic Uncertainty Educational Curriculum|"A Diagnostic Uncertainty Educational Curriculum will consist of an interactive, one-hour teach-the-teacher workshop delivered to resident-attending pairs early on during their inpatient medicine rotation. During the workshop, we will discuss the motivation behind teaching diagnostic uncertainty, review factors that may predict risk of diagnostic error during hospitalization, introduce the framework. Each resident-attending pair will work through a case-based exercise focused on managing learners' diagnostic uncertainty during rounds. Our research team will also conduct Training for clinical staff working on intervention units and will provide at-the-elbow support during the intervention period of the main trial."
45657545|NCT04393909|Behavioral|Diagnostic Timeout|"A Diagnostic Timeout is a structured pocket guide that clinicians may use to address uncertainty in a step-wise approach for patients who have risk factors for diagnostic error. This tool can be used during or after clinical rounds, inside or outside of a patient's room if the patient is agreeable. The Diagnostic Timeout will be introduced as part of the Diagnostic Uncertainty Educational Curriculum as well as Training."
45809452|NCT04925882|Procedure|Erector spinae plane block|"After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : NaCL 0,9%."
45809453|NCT01642914|Drug|Linaclotide 290 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
45809454|NCT01642914|Drug|Linaclotide 145 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
45809455|NCT01642914|Drug|Matching placebo|oral capsule, taken once daily each morning at least 30 minutes before breakfast
45809456|NCT04381481|Behavioral|Experimental Drink: Nutrition claim on fruit drinks|Fruit drink contains a nutrition claim (task 1)
45809457|NCT04381481|Behavioral|Control Drink: No nutrition claim|Fruit drinks does not contain a nutrition claim (task 1)
45945730|NCT05080842|Drug|AC682|Participants will receive AC682 by mouth daily in 28-day cycles.
45945731|NCT05071092|Behavioral|Dietary counselling|Participants assigned to the intervention group will receive coaching from a dietitian to improve adherence to the Dutch dietary guidelines. Several behavioral change techniques will be used.
45945732|NCT05062291|Device|Merit WRAPSODY Endovascular Stent Graft|Target Lesion Primary Patency (TLPP)
45945733|NCT05060705|Drug|Efesovir|Antiviral therapy of COVID19 with Efesovir oral solution in dose 0.125 ml / kg two times per day. Duration of treatment is 5 - 10 days, depending on the severity of the disease.
45945734|NCT05037032|Drug|Naltrexone Pill|50 mg PO one-time only
45945735|NCT05037032|Drug|Placebo|Matching placebo for naltrexone
45945736|NCT05020418|Other|Chart Review|Intervention sites will receive a multi-faceted implementation intervention, which will include external and internal blended facilitation, education materials for providers and patients, and audit and feedback about practices and outcomes with benchmarking to non-intervention sites.
45945737|NCT05013593|Dietary Supplement|Red Clover Extract (RCE)|Red clover extract containing isoflavones Formononetin and biochanin A together with a heterogenous culture of probiotic lactic acid bacteria, and a natural sugar free raspberry/orange flavor. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening together with a meal)
45945738|NCT05013593|Other|Placebo (PL)|Placebo containing water, brown coloring, and natural sugar free raspberry/orange flavor.
45945739|NCT05005949|Device|Arctic Front™ Cardiac Cryoablation Catheter System|Pulmonary vein isolation will be performed with the Arctic Front™ Cardiac Cryoablation Catheter System
46075624|NCT05176626|Drug|Phentermine Hydrochloride 8 MG|At the randomization visit, participants will be started on 8 mg PO daily of phentermine or placebo, with a recommendation to take the medication in the morning. They will be provided with detailed instructions on how to increase their dose of study drug over the subsequent weeks. After one week, participants will increase to 16 mg daily. After the second week, participants will further increase their dose to 24 mg daily and at the 1-month in-person follow-up, participants who tolerate the 24 mg dose will be maintained on this as the maximum daily dose for a total of 24 months. For participants who do not tolerate an escalation in medication dose due to side effects, adverse events, and/or elevations in blood pressure and/or heart rate, the study clinician may adjust the dose and/or delay dose escalation. Study clinicians will work with participants to achieve and sustain the maximum dose tolerated.
45809458|NCT04381481|Behavioral|Experimental snack: Text warning|The snack contains a text warning (task 2)
45657546|NCT04393909|Behavioral|Patient Diagnostic (Dx) Questionnaire|"We will administer a survey, the Dx Questionnaire, to patients which asks a series of questions on communication regarding diagnosis with the care team. Patients admitted to inpatient units within the prior 24 hours will be approached after asking the patient's nurse to determine whether it is the appropriate time to approach for enrollment. Upon explaining the objectives of the survey and obtaining verbal informed consent, patients will be asked to complete the Dx Questionnaire via REDCap on an iPad. Alternatively, the research assistant administering the survey will go through the Dx Questionnaire with the patient and record their answers in REDCap on their behalf. If patients' answers indicate a gap in communication (i.e., an answer of No on a question), the Research Assistant will ask for permission to follow-up within the next few days and will relay the gap in communication to the patients' care team (i.e., nurse)."
45945740|NCT05001126|Behavioral|HIFT 1x/week|HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 1x/week represents a dose of one HIFT workout per week.
45945741|NCT05001126|Behavioral|HIFT 2x/week|HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 2x/week represents a dose of two HIFT workouts per week.
45945742|NCT05001126|Behavioral|HIFT 3x/week|HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 3x/week represents a dose of three HIFT workouts per week.
45809459|NCT04381481|Behavioral|Experimental snack: Graphic warning|The snack contains a graphic warning (task 2)
45809460|NCT04381481|Behavioral|Control snack: barcode label|The snack contains a neutral barcode label (task 2)
45945743|NCT04981509|Biological|Atezolizumab|Given PO
45809461|NCT04497116|Drug|RP-3500 (camonsertib)|Oral ATR inhibitor
45809462|NCT04497116|Drug|Talazoparib|Oral PARP inhibitor
45809463|NCT04497116|Drug|Gemcitabine Injection|Gemcitabine
45945744|NCT04981509|Biological|Bevacizumab|Given IV
45945745|NCT04981509|Procedure|Biopsy|Undergo biopsy
45945746|NCT04981509|Procedure|Biospecimen Collection|Undergo blood collection
45809464|NCT04486352|Drug|Atezolizumab - 28 Day Cycle|Atezolizumab will be given to participants intravenously at a dosage of 1680 mg on day 1 of each 28-day cycle.
45809465|NCT04486352|Drug|Bevacizumab|Bevacizumab will be given to participants intravenously at a dosage of 10mg per participant kilogram every 2 weeks of the 28-day cycle.
45809466|NCT04486352|Drug|Ipatasertib|Ipatasertib will be given as an orally at a dosage of 400 mg once daily for 21 days of each 28-day cycle.
45945747|NCT04981509|Procedure|Computed Tomography|Undergo CT without contrast
45945748|NCT04981509|Procedure|Computed Tomography with Contrast|Undergo CT with contrast
45945749|NCT04981509|Drug|Erlotinib|Given PO
45945750|NCT04981509|Procedure|Magnetic Resonance Imaging|Undergo MRI
46075625|NCT05338164|Procedure|cervical cerclage|McDonald cervical cerclage will be applied using Mersaline braided tape with double needle. Single stitch (4 bites) will be applied as close as possible to the level of internal os. The Knot will be put either anterior or posterior according to the surgeon desire.
46075626|NCT05341050|Drug|TKI|halve dose of 2G-TKI for 12 months and then withdrawal for 12 months
45945751|NCT04981509|Procedure|Positron Emission Tomography|Undergo PET
45945752|NCT04981509|Drug|Sodium Fluoride F-18|Given F-18 sodium fluoride
45809467|NCT04486352|Drug|Talazoparib|Talazoparib will be given in an orally at a dosage of 1 mg once daily for each day of the 28-day cycle.
45945753|NCT04970901|Drug|Loncastuximab Tesirine|Intravenous (IV) infusion
46075627|NCT02780076|Other|Functional training program|Patients treated for hip fracture participate in a functional training program during their short-term stays at nursing homes. The program is initiated by the nurses 4 times a day for 3 weeks as part of the habitual routine.
45809468|NCT04486352|Drug|Trastuzumab emtansine|Trastuzumab emtansine be given to participants intravenously at a dosage of 3.6 mg per participant kilogram, on day 1 of each 21-day cycle.
45809469|NCT04486352|Drug|Tiragolumab|Tiragolumab will be given to participants intravenously at a dosage of 840 mg on day 1 of each 28-day cycle.
46075628|NCT05030766|Drug|Nicotine Replacement Therapy|6 weeks of Nicotine replacement patches
46075629|NCT05030766|Behavioral|Mindfulness Training Smoking Cessation Intervention|Mindfulness Training Smoking Cessation Intervention administered online via Zoom. Each session lasts 60-90 minutes, twice weekly for 4 weeks for a total of 8 sessions.
45809470|NCT04486352|Drug|Atezolizumab - 21 Day Cycle|Atezolizumab will be given to participants intravenously at a dosage of 1200 mg on day 1 of each 21-day cycle.
46075630|NCT05030766|Behavioral|Contingency Management Smoking Cessation Intervention|Contingency Management Smoking Cessation Intervention includes one orientation session lasting about 60-90 minutes administered via Zoom. Participants will then be required to contact the research associate about their quitting progress three times a week for 4 weeks also by zoom.
45809471|NCT04486352|Drug|Inavolisib|Inavolisib will be given in an orally at a dosage of 9 mg once daily for each day of the 28-day cycle.
45809472|NCT04486352|Drug|Letrozole|Letrozole will be given orally at a dosage of 2.5 mg once daily for each day of the 28-day cycle.
45809473|NCT01642602|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsules.
46075631|NCT05333172|Other|Dual task exercises|Dual tasks, often also referred to as secondary tasks, present an objective-direct measurement in which two tasks are to be performed simultaneously to observe performance drops in either task.
46075632|NCT04228770|Behavioral|Meeting with pharmacist|Meeting with pharmacist to support drug management following their routine surgery.
46075633|NCT04229628|Other|No special intervention|No special intervention
46075634|NCT00615199|Drug|CP-690,550|administration via oral route twice daily
46075635|NCT00615199|Drug|CP-690,550|administration via oral route twice daily
46075636|NCT00615199|Drug|CP-690,550|administration via oral route twice daily
46075637|NCT00615199|Drug|Placebo|administration via oral route twice daily
46075638|NCT04228692|Procedure|Self-catheterization only|Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.
46075639|NCT04228692|Device|Posterior tibial nerve stimulation + self-catheterization|"Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.~Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary."
45657547|NCT04393909|Behavioral|Enhancements to Epic-integrated Quality & Safety Dashboard|"Epic-integrated Quality and Safety Dashboard, currently in operational use at BWH, will be enhanced to include a new diagnostic safety column. Clinical staff will receive Training and at-the-elbow support by the research team upon implementation."
45657548|NCT05474989|Drug|LSD|Moderate to high dose LSD
45657549|NCT05474989|Drug|Active placebo|Low dose LSD
45657550|NCT05474911|Device|Negative pressure therapy|The wound will be cleaned (irrigation with Physiological Serum), the cavity and the perilesional area will be dried with gauze. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing. The cavity will be filled with a sponge. When the depth of the wound is less than 1.5 cm, it will not be necessary to fill the defect. The appropriate dressing will be applied to the size of the incision, reinforcing the edges, and it will be connected to the TPN device, ensuring correct functionality.
45809474|NCT04858412|Dietary Supplement|β-hydroxy β-methyl butyrate (HMB) enriched amino acid|β-hydroxy β-methyl butyrate (HMB) is a non-nitrogenous leucine metabolite with anabolic properties.
45809475|NCT04858412|Dietary Supplement|Balanced amino acid|Balanced amino acid is the balanced mixture of the various essential amino acids.
45809476|NCT03488849|Device|SureCRIC|SureCRIC is intended to be used as an accessory to cricothyrotomy and tracheotomy devices, helping to identify and stabilize anatomical landmarks for establishing an airway.
45809477|NCT03488849|Other|Freehand|Freehand palpation approach to identification of the cricothyroid membrane
45835815|NCT03012984|Drug|Morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml) diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
45835816|NCT01574118|Behavioral|Revisiting the Trauma memories|Patient engages in repeated revisiting of their trauma memory under the guidance of the therapist for about 40 minutes. During each revisiting trial the patient closes their eyes and verbally describes the trauma and the feeling and thoughts experienced during the trauma.
45945754|NCT04970901|Drug|Polatuzumab Vedotin|IV infusion
45945755|NCT04970901|Drug|Glofitamab|IV infusion
45945756|NCT04970901|Drug|Mosunetuzumab|Subcutaneous (SC) injection
45945757|NCT04970901|Drug|Obinutuzumab|IV infusion
45809478|NCT04371419|Behavioral|Messaging|"o The video messages each participant in one of the treatment groups sees will be randomized on the following dimensions. The different versions are clearly demarcated in the US Doctors Scripts document.~Racial or ethnic identity of the doctor delivering the messages: concordant vs. discordant identity to the subject.~Whether the message includes an acknowledgment of elephant in the room issues for each target group: trust in the medical system or fear of deportation.~Whether the social distancing component of the message is delivered by Dr. Birx of the CDC or recorded by the MGH physicians.~Whether individuals are given information about how representative individuals perceive mask wearers of color. This information comes from results of our nationally representative pilot survey.~Some individuals in a control group will see messages later."
45657551|NCT05474911|Other|Conventional wound care|The wound will be cleaned with physiological serum irrigation, the cavity will be dried with gauzes and filled with a dressing made of cellulose and silver. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing.
45809479|NCT04848194|Procedure|skin biopsy and blood sampling|"4 skin biopsies outside the face under local anesthesia: 2 in damaged zone, 2 in non-damage zone.~A blood sample"
45809480|NCT04470518|Other|diagnostic algorithm|"Guidance will be part of a diagnostic algorithm which includes clinically guided point-of-care C-reactive protein testing and safety netting advice to inform parents on what to expect and what to look out for. A selection of clinical features will be assessed and recorded by the physician in the patient's health record and on the e-CRF, including the clinical decision tree (clinician's gut feeling, body temperature, dyspnea).~The safety-netting advice will be supported by a parent information booklet, based on previous research (the When should I worry-interactive booklet (a guide to Coughs, Colds, Earache & Sore Throats), the Mijn kind heeft koorts booklet (Eefje de Bont, www.thuisarts.nl), and the Caring for children with coughs-leaflet (information about how to look after a child who has a cough and when to see the doctor))."
45945758|NCT04920916|Biological|Dupilumab|Participants will receive a loading dose of dupilumab (600 mg, given as two 300 mg subcutaneous injections) on day 0/1. If participants are still hospitalized a second and third dose (300 mg) will be given on days 14 and 28.
45945759|NCT04920916|Drug|Placebo|Participants will receive a loading dose of normal saline (2 ml, given as two one ml subcutaneous injections) on day 0/1. If participants are still hospitalized a second and third dose (1 ml) will be given on days 14 and 28.
45945760|NCT04918225|Radiation|Magnetic Resonance Imaging|"Encephalic (about 30 minutes*)~lesion location assessment: 3D FLAIR, 3DT1, 3DT2 (standard OFSEP protocol)~lesion severity assessment: Axial magnetization transfer imaging (mt0, mt1)~tract location assessment: 30 directions diffusion imaging (standard OFSEP protocol)~B0 and B1 mapping to correct for B0 and B1 inhomogeneities~● Spinal cord (about 50 minutes*)~lesion location assessment: cervical and thoracic sagittal T2 TSE (0.7x0.7x2.5mm3), axial cervical MEDIC T2* (0.7x0.7x3mm3), axial thoracic T2 (0.5x0.5x3mm3)~lesion severity assessment: Axial magnetization transfer imaging (mt0, mt1, 0.7x0.7x3mm3) on the cervical cord and on the thoracic cord~tract location assessment: performed from registration on atlas~B0 and B1 mapping to correct for B0 and B1 inhomogeneities"
45809481|NCT02256540|Drug|Climara|
45945761|NCT04918225|Diagnostic Test|Neurological examination|Global disability will be scored using the Expanded Disability Status Scale score
45809482|NCT02256540|Drug|Placebo patch|Placebo patch designed to match active Climara patches.
45809483|NCT02256540|Dietary Supplement|Resveratrol|
45945762|NCT04918225|Diagnostic Test|Multiple Sclerosis Functional Composite|"Walking disability will be scored using the 25-foot timed-walked test~Arm disability will be scored using the nine-hole peg test"
45945763|NCT04918225|Diagnostic Test|Physiotherapist examination|"American Society Injury. Association motor subscore for each limb~The muscle strength using a dynamometer. Two muscle groups will be tested for the upper (elbow flexors and extensors) and lower limbs (hip flexors and ankle dorsiflexion).~The Ashworth Scale and the Tardieu Scale to assess spasticity.~6 minutes walking test~Fatigue Severity Scale~MFIS : Modified Fatigue Impact Scale"
45945764|NCT04914351|Drug|HY-0102|Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle
46075640|NCT02780232|Behavioral|Cuida tu animo / Care for your mood|"CUIDA TU ÁNIMO is an online program to adolescents that provides information, education and support related to the care of the mood.~Adolescents interact with the program via a monitoring e-mail that they receive every two weeks (Monitoring) and a website which allows them to access a number of links. The website have the following modules:~What is 'CUIDA TU ÁNIMO': Description and definition of the program~Psycho-educational information: Information about depression, its treatment, and opportunities for prevention~How is your mood? (Monitoring): a) Online assessment of symptoms every two weeks during three months with the PHQ-3. b) Feedback~Forums.~Blog.~Appointment (Chat or Phone call).~Contact."
46075641|NCT02780154|Biological|PfSPZ (7G8) Challenge|PfSPZ (7G8) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
46075642|NCT02780154|Biological|PfSPZ (NF54) Challenge|PfSPZ (NF54) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
46075643|NCT00883207|Behavioral|Psychotherapy|Narrative and dialogical approach for couples
45945765|NCT04904588|Drug|Busulfan|Given IV or PO pre-transplant as part of conditioning regimen
46075644|NCT02782026|Device|Exhaled Breath Olfactory Signature (Artificial Nose)|
46075645|NCT05328024|Drug|Immunotherapy|anti-PD1
45657552|NCT05614765|Drug|Statin+Ezetimibe compound|Crezet Tablet, Litorvazet Tablet
45945766|NCT04904588|Drug|Busulfan|Given IV pre-transplant as part of conditioning regimen
45945767|NCT04904588|Drug|Fludarabine|Given IV pre-transplant as part of conditioning regimen
45657553|NCT05613127|Biological|Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL|Dosage and administration: pre-iflled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
45657554|NCT05613127|Biological|HAVRIX 720 Junior 0.5 mL|Dosage and administration: pre-filled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
45657555|NCT05474599|Other|conventional physical therapy|TENS
45657556|NCT05474599|Other|Dry cupping therapy|Experimental group was given Dry cupping therapy along with TENS.
45945768|NCT04904588|Radiation|Total-body irradiation|Administered pre-transplant as part of conditioning regimen
45809484|NCT02256540|Dietary Supplement|Placebo|Placebo tablets designed to match active resveratrol tablets.
45809485|NCT04366583|Device|argon plasma coagulation|Olympus electrosurgical unit/argon plasma coagulation unit (PSD-60/Endoplasma, Olympus Corp., Tokyo, Japan)
45809486|NCT04366583|Device|hemoclipping|clipping device (Olympus HX 110/610, Olympus Corp., Tokyo, Japan)
45945769|NCT04904588|Drug|Cyclophosphamide|Given IV pre-transplant as part of conditioning regimen
45945770|NCT04904588|Drug|Melphalan|Given IV pre-transplant as part of conditioning regimen
45945771|NCT04904588|Procedure|PBSC Hematopoietic Stem Cell Transplantation (HSCT)|Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0.
45945772|NCT04904588|Procedure|Bone Marrow Hematopoietic Stem Cell Transplantation|Bone marrow graft is infused from a mismatched unrelated donor on Day 0.
46075646|NCT00879073|Drug|Bendamustine|Approximately 15-24 study patients will be enrolled in this Phase I trial. Study patients will receive a weekly dose of IV bendamustine with whole brain radiation therapy for 3 weeks and then receive a fourth dose of IV bendamustine one week after completion of whole brain radiation therapy. The first dose of IV bendamustine will be given when whole brain radiation is initiated.
46075647|NCT05342142|Behavioral|Aerobic and ResistanceExercise|Exercise program consisting of 12 weeks of aerobic and resistance exercises
45657557|NCT05610865|Other|Control; Standard-of-care management|Patients will undergo conventional wound care management.
45657558|NCT05610865|Biological|Only PRP injection|Only PRP injected / cm2 intradermally at the border zone & inside of wound surface bed.
45657559|NCT05610865|Biological|PRP + SVF injection|Uncultured cells (SVF) along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone & inside of wound surface bed.
45657560|NCT05610865|Biological|PRP + ASCs injection|Cultured ASCs along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone & inside of wound surface bed.
45676337|NCT03856658|Drug|Floxuridine (FUDR)|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
45809487|NCT05646342|Other|Measure of CO by ECHocardiac Machine|we will realise ETT before and after PLR in all women that eligible of crieria inclusion , in obstetric consultation
45809488|NCT03627299|Drug|300mg glecaprevir/pibrentasivir 120mg|300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant
45809489|NCT05646264|Drug|Agomelatine|Agomepratine is added to a second-generation antipsychotic drug (olanzapine, aripiprazole, risperidone, etc.)
45809490|NCT04841954|Diagnostic Test|hemp prick-test|hemp seed and flower prick-test
45809491|NCT04734431|Biological|Eosinophil count|Evaluation of the eosinophil count from admission to day 7
45809492|NCT01640184|Procedure|Parathyroidectomy|sHPT patients with enlarged glands (≥3)will be randomized into parathyroidectomy group or ultrasonic ablation group. Patients in parathyroidectomy will get parathyroid surgery.
45809493|NCT01640184|Drug|Active vitamin D|CKD patients suffered from sHPT with 1-3 enlarged gland(s) and without indication of parathyroidectomy will be randomized to oral medicine therapy group or ultrasonic ablation therapy group. Patients in oral medicine group will be treated by active vitamin D and other general treatments, such as dietary phosphate restriction and phosphate binders, according to the suggestions in KDIGO guidelines.
45835817|NCT01574118|Behavioral|Processing the trauma memories|The patient and therapist discuss the patient's experience during the trauma revisiting with the goal of helping the patient gain alternative perspectives of the trauma.
45835818|NCT01574118|Behavioral|Psychoeducation|Through patient handouts and didactic instruction, the patient learns about the common reactions to trauma and the rationale for exposure therapy.
45835819|NCT01574118|Behavioral|Trauma Memory Retrieval Trial|Prior to the start of Imaginal Exposure, the patient is asked to recall a threatening element of their trauma memory for 1 minute. This is followed by a 30-minute rest-period prior to beginning imaginal exposure.
45835820|NCT01574118|Behavioral|Exposure to video clips related to the patient's trauma|Patient is seated in front of a computer monitor and instructed to view a 30-min looped video clip that thematically resembles the patient's trauma.
45835821|NCT01574118|Behavioral|Breathing retraining|Patient is seated comfortably in a chair and instructed to breathe slowly and deeply in a relaxed manner.
45835822|NCT01574118|Behavioral|Exposure Homework|Therapist assists the patient in identifying trauma-related situations/activities that the patient is avoiding and encourages the patient to begin to confront these situations between sessions.
45835823|NCT01574118|Behavioral|Compound extinction|The patient repeatedly confronts the truama-related media clip while simultaneously listening to their own trauma script through headphones.
45835824|NCT02938416|Device|Isokinetic strengthening exercise|Isokinetic strengthening exercise provides muscle training throughout the range of motion of a joint at a pre-set constant speed of angular velocity. It can be performed in an eccentric or concentric way in a controlled manner, and is evidenced to be an effective and safe training method in patients with anterior cruciate ligament reconstruction, burn injury, ankle instability, osteoarthritic knee, and chronic stroke in the past literatures.
45835825|NCT02938416|Device|Isotonic strengthening exercise|Isotonic strengthening exercise keeps the tension remained unchanged during the muscle's length changing. As the muscle's force changes via the length-tension relationship during a contraction, an isotonic contraction will keep force constant while velocity changes. There are two types of isotonic contractions: (1) concentric and (2) eccentric. In a concentric contraction, the muscle tension rises to meet the resistance, then remains the same as the muscle shortens. In eccentric, the muscle lengthens due to the resistance being greater than the force the muscle is producing.
45835826|NCT04773990|Device|Biodex Balance System|Subjects will receive several unique training modules using biodex
45657561|NCT05134051|Device|Shockwave® Intravascular Lithotripsy System (Shockwave Medical Inc)|IVL is a novel balloon catheter-based device that utilises pulsatile mechanical energy to disrupt calcified lesions. IVL differs from other types of lithotripsy with respect to depth of penetration. It is a single-use, sterile, disposable balloon catheter. The emitters convert electrical energy into transient acoustic circumferential pressure pulses that disrupt both superficial and deep calcium within plaque. The balloon catheter is connected to the generator, which is programmed to deliver the specified dosage of pulses. The IVL balloon, sized 1:1 to the reference artery ratio, is inflated low pressure (4 atm) with 10 pulses of ultrasound energy of 10s delivered per balloon. The procedure is repeated to provide a minimum of 20 pulses in the target lesion, with interval deflation to allow distal perfusion. Each catheter can emit a max of 80 pulses at a rate of one pulse per second. If the lesion exceeds the 12mm balloon length, the balloon can be repositioned and the IVL repeated.
45809494|NCT01640184|Procedure|Ultrasonic ablation|CKD-sHPT patients with enlarged parathyroid gland(s) randomized into the ultrasonic ablation group will be treated by ultrasound guided percutaneous parathyroid gland radio frequence ablation. According to the indications of parathyroid surgery, the patients will be divided into two sub-groups. The outcomes of these patients will be compared to the oral medicine group and the parathyroidectomy group, respectively.
46075648|NCT00880867|Drug|Poly-ICLC|An accessible site of disease (lymph node, cutaneous, subcutaneous, etc.) will be selected by the principal investigator. Patients will then receive two doses of low dose irradiation (2 Gy per day) to that single site on days 1 and 2. Intratumorally or peritumorally Poly-ICLC will be dosed on days 3 and 4 by the physician during weeks 1, 2, 3, 4, and 8.
46075649|NCT04229550|Behavioral|Festival participation|One week's participation in Roskilde Festival 2016 or living a normal daily life.
46075650|NCT05340660|Radiation|[ 18 F]PSS232|[ 18 F]PSS232 for imaging metabotropic glutamate receptor subtype 5 and comparing expression of the receptor in healthy persons and ALS patients
45657562|NCT05114005|Behavioral|Rhythmic Auditory Stimulation|Rhythmically-entrained sensorimotor activity.
45809495|NCT04904978|Other|Blanx Black Toothpaste|Use of Blanx Black Toothpaste twice a day per at least 2 minutes.
45809496|NCT04904978|Other|Colgate Sensation White|Use of Colgate Sensation White Toothpaste twice a day per at least 2 minutes
45809497|NCT04903574|Behavioral|NEAT!2 sedentary behavior app|This is a smartphone app that reminds you to stand up if you've been sitting for at least 30 minutes.
45809498|NCT04903574|Other|Pregnancy smartphone app|This is a commercially available general pregnancy smartphone app
45809499|NCT03630185|Device|Custom-manufactured compression hosiery (Isobar)|The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.
45809500|NCT03630185|Device|Off-the-rack stockings (Sigvaris)|Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.
45945773|NCT04904588|Drug|Post-transplant Cyclophosphamide|Cyclophosphamide (50 mg/kg) is administered on Day +3 and on Day +4 post-transplant as an IV infusion over 1-2 hours.
45945774|NCT04904588|Drug|Mesna|Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide.
45945775|NCT04904588|Drug|Tacrolimus|Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at 90-100 days post HCT.
45945776|NCT04904588|Drug|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
45945777|NCT04904588|Other|Patient-Reported Outcomes|Survey assessments will be administered to study participants pre- and post-transplant.
45945778|NCT04903197|Drug|VAY736|VAY736 is a fully human IgG1 monoclonal antibody (mAb) which targets the B cell activating factor receptor (BAFF-R) expressed on the surface of differentiated B cells and modulates their function.
45945779|NCT04903197|Drug|lenalidomide|Immune-modulatory agent that enhances activation of NK cells.
45945780|NCT04903197|Drug|CC-99282|Cereblon (CRBN) E3 Ligase Modulator that induces the recruitment, ubiquitination and destruction of key target substrates (e.g. Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3)
45945781|NCT04884113|Device|Motorized Spiral enteroscopy|Small-bowel enteroscopy for diagnosis and intervention
45945782|NCT04883333|Drug|LEO 153339|LEO 153339
46075651|NCT02780934|Other|Pressure Dressing|Patients in this group will receive the standard post-operative bandage: a pressure dressing consisting of high absorbency gauze and retention tape.
46075652|NCT02780934|Other|Simple Adhesive Dressing|Patients in this group will receive the experimental bandage: a simple adhesive dressing consisting of a non adherent pad and transparent dressing.
45657563|NCT05114005|Behavioral|Evidence-Based Exercise|This program consists of information on neuropathy and fall prevention combined with a schedule of 1 hr training (i.e., endurance, resistance, and sensorimotor) performed 2x per week
45809501|NCT05421702|Procedure|laparoscopic conventional colectomy|Laparoscopic colectomy with only lymph node dissection up to level 2 lymph nodes D2.
45809502|NCT05421702|Procedure|laparoscopic complete mesocolic excision|Laparoscopic colectomy with lymphovascular dissection from level 3 lymph nodes or more D3.
45809503|NCT02256384|Device|Respiratory Acoustic Monitor|Examine the reliability and accuracy of the respiratory acoustic monitor.
45809504|NCT03631433|Drug|Ibuprofen 600 mg|identical appearing tablets containing 600 mg of ibuprofen
45809505|NCT03631433|Drug|ibuprofen 600 mg and acetaminophen 650 mg|identical appearing tablets of the combination of ibuprofen and acetaminophen
45809506|NCT04343612|Device|Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
45809507|NCT05417490|Other|PRADO-IC|"The CAM (Health Insurance Advisor) are part of the staff of the Primary Health Insurance Funds (CPAM). They are physically present in the establishments participating in the PRADO.~They are facilitators between city health professionals and the patient for their return home.~They assist the patient in making appointments with their general practitioner, their cardiologist, and the IDE (general care nurses) trained at PRADO-IC who will make the home visits.~After returning home, the CAM verifies, by two telephone calls at 1 week and 2 months, that the patient has initiated his outpatient follow-up.~IDE, trained in the therapeutic education of the IC patient according to the PRADO-IC device, carry out:~for NYHA (New York Heart Association) 1-2 patients: 8 home visits in two months.~for NYHA 3-4 patients: 8 home visits in 2 months, upon confirmation and prescription from the physician, 8 visits in the following 4 months.~The doctor carries out a long consultation at 2 months."
45809508|NCT05417490|Device|Remote monitoring|"Chronic Care Connect is intended for remote medical monitoring of patients suffering from chronic heart failure.~It consists of a web application (named NOMHADChronic™) and non-medical remote human assistance performed by qualified personnel.~Non-medical human assistance allows the following steps to be carried out:~characterization of alerts~structured follow-up of remote patients.~This non-medical human assistance is provided by:~nurses trained in therapeutic education and cardiology, Customer Relations Advisors, and logisticians.~Weight and symptoms (listed in an 8-question questionnaire) are collected respectively using a connected scale and the mobile application.~It allows, via a web browser:~to the personnel constituting the non-medical human assistance, to have access to the health data of the patients~remote monitoring doctors, to have access to the health data of each of their own patients, and to carry out medical remote monitoring procedures."
45809509|NCT03489941|Drug|EM-100|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
45809510|NCT03489941|Drug|Zaditor®|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
45809511|NCT03489941|Drug|Vehicle|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
45809512|NCT03585114|Drug|[F-18] DCFPyL|[18F]DCFPyL will be used for study imaging. It will be administered intravenously on the day of imaging. Subjects will receive a bolus injection of 9mCi (331 MBq) of [18F]DCFPyL through a peripheral IV catheter. 60 to 120 minutes after injection, a whole body (toes to vertex) lowdose CT will be obtained (120 kVp, 80 mA maximum).
45809513|NCT03585114|Procedure|PET/CT imaging|As per standard of care, acquisition will be performed on PET/CT scanner (Siemens, Germany) operating in 3D emission mode with CT-derived attenuation correction.
45945783|NCT04883333|Drug|Placebo|Placebo
45945784|NCT04879342|Behavioral|VIP Program|This intervention will engage the participants with psychoeducational material once a week. This material will include didactic instruction as well as participant engagement in developmentally appropriate activities.
45945785|NCT04878965|Device|Smartwatch|Smartwatch apparatus to measure strong emotions (e.g., anxiety)
45945786|NCT04877756|Drug|OLX10010|Lyophilized cake reconstituted with WFI and injected intradermally
46075653|NCT04413331|Other|Data collection|Medical data collection at M0, M3, M6, M9 and M12 then every 6 months until M60 and at each vascularitis relapse
46075654|NCT04413331|Other|Biological samples and data collection|Biological samples at M0, M6, M12, M24 and at each relapse until M60
46075655|NCT04228926|Drug|ZKY001 eye drops 0.3g:0.006mg|ZKY001 eye drops of 0.002% continuously for up to 14±2 days after Corneal endothelial transplantation
46075656|NCT04228926|Drug|ZKY001 eye drops 0.3g:0.012mg|ZKY001 eye drops of 0.004% continuously for up to 14±2 days after Corneal endothelial transplantation
46075657|NCT04228926|Drug|ZKY001 simulated eye drops|ZKY001 simulated eye drops continuously for up to 14±2 days after Corneal endothelial transplantation
46075658|NCT02781948|Device|Optical Coherence Tomography|
45657564|NCT02590003|Drug|Carboplatin|
45657565|NCT02590003|Drug|Nab-paclitaxel|
45657566|NCT05474521|Device|CODTimer test|The Illinois test times of the participants will be measured with different phone applications that measure the change of direction performance, and each individual will perform the test twice.
45657567|NCT05614531|Genetic|EXG001-307 injection|non-replicating, rAAV vector based on AAV9 containing cDNA encoding the human SMN protein.
45809514|NCT05646186|Dietary Supplement|Personalized dietary intervention based on microbiome analysis|Personalized dietary intervention based on individual microbiome analysis
45809515|NCT05646186|Dietary Supplement|Low-FODMAP diet|Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet
46075659|NCT00883363|Procedure|Precondition|Precondition on a arm in four intervals at start of surgery for ruptured aortic aneurysm
46075660|NCT05324670|Other|Didactic model for suicidal behavior in the framework of impulsivity and ideations|It will be in the form of lectures (Educational approach). Content will be developed one day before the commencement of the session. The Knowledge provided in the form of written material with proper explanation shall not exceed 30 minutes and a Focused group Discussion will be held at the end of each month.
46075661|NCT04377061|Diagnostic Test|Evaluation of anemia|Evaluation of anemia in NCWS patients, and in CD and IBS controls, with both retrospective and prospective method.
45945787|NCT04877535|Device|ML-based report card|PACU and ward providers caring for participants will be notified by Anesthesia Control Tower clinicians before arrival if the patient's report card. The notification will contain a report card of the patient's forecast risk of major adverse events, explanatory machine-learning outputs, most influential pre- and intraoperative data, and predicted treatments.The ML risk profile generated for each patient will include risk of 30 day mortality, risk of respiratory failure, risk of acute kidney injury, and risk of postoperative delirium
45945788|NCT04876781|Drug|Tofacitinib XR|Tofacitinib XR 11mg
45945789|NCT04873050|Drug|Semaglutide Pen Injector [Ozempic]|Start injection of semaglutide 0.25mg subcutaneously (SC) once a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses
45945790|NCT04873050|Drug|Placebo semaglutide pen injector|Start injection of placebo semaglutide 0.25mg subcutaneously (SC) one a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses
46075662|NCT02782182|Drug|FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)|FOLFIRINOX administered preoperatively and postoperatively
45945791|NCT04871568|Procedure|Temporary central dialysis catheterization|Placement of temporary central dialysis catheter
45945792|NCT04870112|Drug|Durvalumab|Anti-PD-L1 antibody
45945793|NCT04870112|Drug|Cisplatin|Chemotherapy
45945794|NCT04870112|Drug|Carboplatin|Chemotherapy
45945795|NCT04870112|Drug|Etoposide|Chemotherapy
45945796|NCT04868656|Other|Implementation Strategy: Foundational REP|The goal is to test implementation intensification approaches for STRIDE sites that have not met implementation adoption benchmarks, specifically Foundational REP vs. Enhanced REP. We propose that low intensity implementation support that promotes adapting STRIDE for context and provides tools for ongoing STRIDE evaluation (defined as foundational REP), will be sufficient for some but not all sites to successfully incorporate STRIDE into routine practice.
45945797|NCT04868656|Other|Implementation Strategy: Enhanced REP|The goal is to test implementation intensification approaches for STRIDE sites that have not met implementation adoption benchmarks, specifically Foundational REP vs. Enhanced REP. We posit that monitoring sites' progress and adding, for sites with low adoption, higher intensity strategies (defined as Enhanced REP) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
46075663|NCT02780778|Drug|Apatinib|Targeted therapy Apatinib：500 mg，po，qd
45809516|NCT02973659|Drug|Oxybutynin|10% oxybutynin gel (one side) Vs placebo aqueous gel (other side) - 2/d application, 1 month
45809517|NCT02973659|Drug|Placebos|
45809518|NCT04443530|Drug|Ultimaster™ Tansei™ stents|Patients receiving Ultimaster™ Tansei™ stents
45809519|NCT04825886|Device|Zotarolimus-Eluting Stent|Percutaneous coronary intervention using zotarolimus-eluting stent
45809520|NCT04439942|Other|cardiac magnetic resonance imaging (MRI)|Cardiac MRI is a mandatory examination for Hypertrophic cardiomyopathy patients as it provides important information about the presence of fibrosis which is also directly associated with sudden cardiac death.
45809521|NCT00377663|Behavioral|AsthmaNet|The AsthmaNet Web site will provide parents of children in the AsthmaNet group with individualized clinical information regarding their child's asthma care and with decision-making aids that they can share with their child's doctor. The web site will also prompt parents to make additional doctor appointments, as needed, to discuss their child's condition.
45809522|NCT04439396|Drug|Ketorolac Tromethamine|nonsteroidal anti-inflammatory drug
45809523|NCT04439396|Other|Saline|saline fluid injection
45945798|NCT04864912|Other|Questionnaires and survey|Questionnaires: Health Utilities Index Mark III, Chronic Otitis Media Outcome Test-15 and Speech, Spatial, and Qualities of Hearing Scale-12 Survey: Client Service Receipt Inventory (adapted version)
46075664|NCT02780778|Drug|Docetaxel|chemotherapy Docetaxel：60mg/m²，vein input 1hour，every 3w
46075665|NCT04327219|Other|CDED diet|examine the microbial, mucosal and immunological changes of the pouch during one year post IPAA, and examine the impact of the CDED on disease activity and dysbiosis in adults suffering from active pouchitis.
46075666|NCT04229082|Other|observational|
46075667|NCT00881101|Drug|Liposomal paclitaxel|All Patients will receive liposomal paclitaxel (starting at a dose of 190mg/m2,3h,ivgtt,at d1)each cycle for 1 cycle.
45945799|NCT04857931|Drug|Colchicine|Patients meeting all inclusion criteria and no exclusion criteria will be randomly assigned to receive either colchicine (0.5mg once daily), colchicine (0.5mg twice daily) or matched placebo (1:1:1 allocation ratio), in addition to standard of care.
45657568|NCT04134325|Biological|Nivolumab|Nivolumab administered at 240mg every two weeks or 480 mg every four weeks as per standard of care after treatment with CD30.CAR T cells
45657569|NCT04134325|Biological|Pembrolizumab|Pembrolizumab administered at 200 mg every three weeks or 400 mg every six weeks as per standard of care after treatment with CD30.CAR T cells
45809524|NCT03493607|Drug|AMO-01|Subjects will receive a single 6-hour intravenous infusion for a total dose administration or 120 mg/m2 of AMO-01.
45809525|NCT02976974|Other|Manual therapy|Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.
45809526|NCT02976974|Other|Therapeutic exercise|"Shoulder extension: Elastic bands.~Shoulder flexion: Elastic bands~Shoulder external rotation: Elastic bands.~Scapulothoracic stability: Movement of scapular adduction guided by the physiotherapist, keeping the position for few seconds ; standing push up on the wall.~Thoracic column movements: Flexion-extension"
45809527|NCT00377039|Drug|AD 337|
45945800|NCT04857931|Drug|Placebo|Patients meeting all inclusion criteria and no exclusion criteria will be randomly assigned to receive either colchicine (0.5mg once daily), colchicine (0.5mg twice daily) or matched placebo (1:1:1 allocation ratio), in addition to standard of care.
45945801|NCT04857502|Drug|99mTc-based PSMA Imaging and Surgery Agent|Given via IV injection
45809528|NCT02255760|Drug|MEDI3902 - Dose 1|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
45945802|NCT04857502|Procedure|Computed Tomography|Undergo SPECT/CT
45945803|NCT04857502|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
45945804|NCT04856189|Biological|Pembrolizumab|Given IV
45945805|NCT04856189|Drug|Selinexor|Given PO
45945806|NCT04851756|Device|CRet|In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (80-100W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (100-120 W) on the hamstrings. Then a 5 min Functional Massage (F.M) with passive anckle dorsiflexion and CRet on resistive mode (110-120 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min F.M with CRet on capacitive mode (180-250VA) on the mentioned area. In supine position, a 5 min F.M with passive knee flexion and CRet on resistive mode (110-140W) will be performed on the rectus femoris, followed by a 4 min F.M with passive knee flexion and CRet on capacitive mode (180-250VA) on the mentioned area. A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes.
45945807|NCT04851756|Device|Sham CRet|"In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (0 W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (0 W) on the hamstrings. Then a 5 min Functional Massage (F.M) with passive anckle dorsiflexion and CRet on resistive mode (0 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (0 VA) on the mentioned area. In supine position, a 5 min F.M with passive knee flexion and CRet on resistive mode (0W) will be performed on the rectus femoris, followed by a 4 min F.M with passive knee flexion and CRet on capacitive mode (0VA) on the mentioned area.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes."
45945808|NCT04840199|Drug|Letermovir 240 MG Oral Tablet|240 mg tablets. Administered orally as two tablets once daily with or without food.
45945809|NCT04840199|Drug|Letermovir 480 MG Oral Tablet|480 mg tablet. Administered orally as one tablet once daily with or without food.
45945810|NCT04840199|Drug|Combination ART|ART (antiretroviral therapy) medications will be prescribed by participants' health care providers. ARV medications will not be provided by the study.
45657570|NCT04131439|Diagnostic Test|Computed Tomography and Magnetic resonance imaging|Preoperative imaging for patients undergoing cochlear implants
45657571|NCT05474443|Other|Myofascial gun with conventional therapy|"MYofascial gun was applied for the duration of 5 minutes over upper trapezius muscle. every week, on first two sessions frequency was set to 1-2 then for next two 3-4 and so on conventional therapy Hot Pack applied at the beginning of session for 10 minutes Muscle stretching of Upper Trapezius, Levator Scapulae and Pectoralis Major applied with holding time 20 seconds and 4 repetitions.~Cold pack was applied at the end of the session for few minutes"
45809529|NCT02255760|Drug|MEDI3902 - Dose 2|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
45809530|NCT02255760|Drug|MEDI3902 - Dose 3|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
45809531|NCT02255760|Drug|MEDI3902 - Dose 4|Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
45945811|NCT04839952|Behavioral|Healthy Lifestyles|12 telehealth sessions. The first 5 visits include psycho/medical education plus a motivational interviewing component. The second 7 sessions include psycho/medical education plus a problem solving training component.
45945812|NCT04839952|Behavioral|Education-Only Control|This control condition includes meeting with a clinician for one telehealth visit to review nutrition and physical activity recommendations.
46002545|NCT00712751|Behavioral|CSI-SH- Cancer Survivorship Intervention|This involves four 1-hour individual sessions with three additional telephone booster/review sessions provided in between the four sessions. Sessions can be completed in person or conducted over the phone. Although every effort will be made to complete the booster session in between counseling sessions, if the patient is unavailable to complete the booster calls they may be skipped. Sessions one and two will focus on rehabilitation techniques and tools will be provided and discussed with participants during these first two sessions.
45809532|NCT02255760|Other|Placebo|Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
45835827|NCT04773990|Other|specific physical therapy exercise program|Subjects will receive recommended PT program
45945813|NCT04836585|Other|eMBC Intervention|"The treating psychiatrist sets a flag in the patient's electronic chart that prompts them to complete self-report scales prior to each appointment:~Edinburgh Postnatal Depression Scale (EPDS) for symptoms of depression and anxiety~PROMIS Neuro-QOL and PROMIS ASCQ-Me Social Functioning Short form for measures of functional capacity~Adapted Frequency, Intensity, and Burden Side Effects Rating (FIBSER) Scale for participants taking antidepressant medication to measure side effects~Patient participants and providers can view the questionnaire results over time in the electronic chart item by item, and/or see them in graphical format. During the clinical encounter, the provider and patient participant review the results of the scales, as part of a collaborative re-evaluation of the treatment plan."
45809533|NCT03497585|Behavioral|Activity pacing framework|The activity pacing framework will be used to structure and standardise the instructions of pacing in existing rehabilitation programmes for adult patients with chronic pain/fatigue. The activity pacing framework has been developed in Stages I and II of this research. Stage I involved an online survey of activity pacing across healthcare professionals in England. The survey findings, together with existing research were used to develop the first draft of the framework. The framework was refined in Stage II: Nominal group technique (consensus method). The activity pacing framework describes the aims, facets and stages of pacing, together with how pacing relates to different behavioural typologies and other pain management strategies.
45809534|NCT05646108|Device|Endovascular treatment|Endovascular treatment
46075668|NCT00879151|Behavioral|Cognitive Behavioral Therapy for Adolescents|The therapist will work with the adolescent to understand triggers to binge eating and purging, such as thoughts, feelings, and interpersonal difficulties. Also, establishing regular eating patterns and eliminating medically harmful behaviors associated with the eating disorder is a primary goal.
46075669|NCT00879151|Behavioral|Supportive Psychotherapy|SPT focuses on having the patient build a relationship with the therapist and explore their unique individual needs within the context of their life and the experience of having an eating disorder.
46075670|NCT00879151|Behavioral|Family Based Therapy for Bulimia Nervosa|FBT helps parents to take an active role in guiding their child through eating disorder treatment. In this therapy, the parents are supported in helping their child stop bingeing, purging and engaging in other harmful weight-control behaviors. The way in which the eating disorder has impacted the family and the adolescent's development is also explored.
45453245|NCT05614687|Behavioral|Community-informed art-based programme|The Community-informed art-based programme is an intervention incorporating art in the form of for example poetry and drawings in addressing trauma and encouraging community attitudes towards the positive reintegration of ex-offenders.
46075671|NCT02779998|Other|non invasive ventilation|non invasive ventilation is delivered by a specific respirator with inspiratory help mode. NIV mask and parameters are adapted to obtains a Tidal volume ≤ to 8 ml/kg/cycle (if possible ≤ 6 ml/kg/cycle) and a SpO2 superior of 94%.
45809535|NCT05414760|Device|Womed Leaf|Womed Leaf™ is a sterile, degradable film of poly(D,L-lactide) (PLA) and poly(ethylene oxide) (PEO). PEO is a biocompatible polymer with anti-adhesion and swelling properties. It is polymerized with hydrophobic PLA to form a degradable film. Womed Leaf™ is inserted in the uterine cavity by a gynaecologist surgeon with a 5 mm diameter flexible inserter. Once released, the film unfolds and grows into the uterine cavity to create a mechanical barrier and keep the uterine walls separated for approximately one week. It is then degraded and discharged naturally through the cervix.
45809536|NCT00360464|Drug|Azithromycin SR|
45809537|NCT05369754|Biological|YBSW015 injection|Prepared YBSW015 injection is intravenously injected by an infusion pump or gravity infusion with intravenous infusion of 250 mL for 60 min±10 min.
45809538|NCT03637517|Drug|DSM265-TPGS 34% SDD, 400 mg fasted|New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.
45809539|NCT03637517|Drug|DSM265-TPGS 34% SDD, 400 mg fed|New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.
46075672|NCT02779998|Other|Standard oxygen therapy with facial mask|
45453246|NCT05614687|Other|Government Media Intervention|Government Media Intervention involving media content from the National Orientation Agency and other media sources
45453247|NCT01103947|Device|EcoAnaesthesia facemask first|The trial facemask will be used before the standard one.
45453248|NCT01103947|Device|Portex Adult (Standard) facemask first|The standard facemask will be applied before the trial device.
45453249|NCT01103947|Device|Portex Adult (Standard) facemask second|The standard facemask will be applied after the trial device
45945814|NCT04835987|Diagnostic Test|Holter ECG|Measurement of the modification of the sympathomimetic balance
45809540|NCT03637517|Drug|DSM265 25% SDD, 400 mg fasted|Reference formulation used in early clinical trials.
46075673|NCT00883441|Other|Insecticide treated curtains and insecticide treated covers|The study is comparing the introduction of two new vector control tools (insecticide treated curtains and insecticide treated covers) through two different distribution strategies. These tools are curently not in use in the routine programmes of the concerned countries.
46075674|NCT05168748|Drug|IMJ995 single agent|Single intravenous administration of IMJ995
45809541|NCT04825496|Genetic|ssCART-19 Cells|"Split-Dose of ssCART-19 cells will be infused, and classic 3+3 dose escalation will be applied."
46075675|NCT04039009|Diagnostic Test|Pelvic Organ Prolapse Quantification system|The Pelvic Organ Prolapse Quantification system assessment tool measures nine anatomical points and distances in the vagina. The hymen is the reference point to which the other points are compared. The prolapsed organs are measured in centimeters to the hymen with an examination ruler.
45453250|NCT01103947|Device|EcoAnesthesia facemask second|The trial facemask will be used after the standard one.
45945815|NCT04835987|Behavioral|Questionary|Lifestyle questionary (time spent in front of television, physical activity)
45657572|NCT05474443|Other|Instrument Assisted Soft Tissue Mobilization with Conventional therapy|Graston's tool was applied over upper trapezius muscle from its origin to insertion kept at the angle of 45 Conventional Therapy Hot pack 10mins Upper Trapezius, Levator scapule and Pectoralis major muscle stretching(20s hold and 4 reps) Cold pack for few minutes
46075676|NCT02779764|Drug|roxadustat|Oral
46075677|NCT04294849|Other|Magnetic Resonance Imaging|A. Phosphorous 31 MR Spectroscopy to evaluate skeletal muscle metabolism via measurement of depletion and recovery of phosphocreatine (PCr) B. Non-invasive arterial spin labeling MRI to evaluate lymphatic flow velocities and venous flow
46075678|NCT04294849|Other|Bicycle Ergometry|To measure peak VO2 as a representation of global aerobic fitness
45657573|NCT04116697|Other|Acupuncture|Acupuncture is a form of alternative medicine in which thin needles are inserted into the body.
45809542|NCT04825496|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
45453251|NCT00003631|Biological|filgrastim|
45453252|NCT00003631|Drug|carboplatin|
45453253|NCT00003631|Drug|carmustine|
45453254|NCT00003631|Drug|cyclophosphamide|
45453255|NCT00003631|Drug|cytarabine|
45453256|NCT00003631|Drug|etoposide|
45453257|NCT00003631|Drug|ifosfamide|
45453258|NCT00003631|Drug|melphalan|
45453259|NCT00003631|Procedure|bone marrow ablation with stem cell support|
45453260|NCT00003631|Procedure|peripheral blood stem cell transplantation|
45453261|NCT00003631|Radiation|radiation therapy|
45453262|NCT00003535|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a recurrent/progressive high grade glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
45657574|NCT04116697|Other|Aromatherapy|Aromatherapy is a form of alternative medicine in which you will inhale aromatic plant extracts and essential oils.
45657575|NCT05474365|Other|Stepwise training|The protocol of stepwise training is mentioned in Detailed description in Study Description.
45657576|NCT05474209|Other|"Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes"|"Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes for 12 months"
45945816|NCT04835987|Diagnostic Test|Pupillometry|Monitoring of nociception and autonomic nervous system by pupillometry in intraoperative.
45657578|NCT05474053|Drug|Ticagrelor 90mg (Brilique)|compare the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers
45657579|NCT05474053|Drug|Ticagrelor 90mg (Ticaloguard)|compare the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers
45809543|NCT04825496|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
45809544|NCT05646030|Diagnostic Test|TAP-II|The TAP-II device will be compared to lancet capillary sampling and the venipuncture
45809545|NCT05646030|Diagnostic Test|Lancet capillary sampling|The lancet capillary sampling will be compared to TAP device and the venipuncture
45809546|NCT05646030|Diagnostic Test|Venipuncture|The venipuncture will be compared to TAP device and the lancet capillary sampling
45809547|NCT05645952|Other|Clinical follow up of hypertrophic cardiomyopathy|Patients diagnosed with hypertrophic cardiomyopathy during study period
45945817|NCT04824248|Behavioral|Pain Neuroscience Education|Increase pain coping skills and educating the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.
45945818|NCT04824248|Behavioral|Cognition-targeted exercise therapy|Daily (physical) activity and exercise therapy. To confront the patient with movements and activities that are feared, avoided and/or painful using a gradual and cognition-targeted approach.
45945819|NCT04824248|Behavioral|Behavioral weight reduction program|Changes in diet, behavior and a physical exercise to reach weight loss. It will include a lifestyle approach, incorporating behavioral theories and constructs to assist and facilitate healthy energy balance related behavior.
45945820|NCT04818541|Device|PPCI|Closure of the femoral access site with PerQseal device at the end of the PPCI index procedure and removal of the Impella pump.
45945821|NCT04818541|Device|Cardiogenic shock|Closure of the femoral access site with PerQseal device after removal of the Impella pump.
45945822|NCT04818138|Device|Narrowband UVB phototherapy|Narrowband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
45945823|NCT04818138|Device|Broadband UVB phototherapy|Broadband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
46075679|NCT04294849|Other|Lab Panel|A. Inflammatory lab panel (IL-6, IL-8, TNF alpha, P-selectin, high sensitivity CRP, IL-6 receptor, TNF R1/R2) drawn at diagnosis B. Thrombin Generation Assay to measure hypercoagulability and Thromboelastography prior to initiating anticoagulation
46075680|NCT04294849|Behavioral|Questionnaires|A. Dalhousie Dyspnea Scale B. Godin Leisure Time Exercise Questionnaire C. Pediatric Venous Quality of Life Questionnaire
46075681|NCT05341986|Other|Clinical Decision Support (CDS) tool|Implementation of an EHR-based CDS tool for providers to use.
46075682|NCT00883519|Behavioral|Interpersonal Psychotherapy for Depressed Adolescents|12 psychotherapy sessions delivered over 16 weeks
45809548|NCT00377117|Procedure|Management|
45809549|NCT00377117|Procedure|Screening|
45809550|NCT05651256|Drug|Botulinum toxin type A injection|The solution for injection was prepared immediately before the intervention, by dissolving the vials of BTX, kept refrigerated at 5ºC, in 1 ml of sterile saline solution at room temperature. Eight injection sites were marked, three located in the masseter muscle, two in the lateral pterygoid muscle, one in the temporomandibular joint (TMJ) and two in the temporalis muscle. A 1 cc marked insulin syringe was used for intramuscular injection of the prepared solution, according to the locations and amounts proposed by Kim et al. and Ho et al. with a total dose of 100 U in each patient.distributed at the different injection sites.
45809551|NCT00377195|Radiation|Involved Field Radiotherapy|"The prescribed dose will be 30 Gy in 15-20 fractions, unless the orbit is to be treated, in which case the dose will be 24 Gy in 1.5 to 2 Gy fractions.~Daily fractions of 1.5-2.0 Gy will be employed. Treatment will be given 5 days per week with the planned duration of treatment not exceeding 28 days."
45809552|NCT04297631|Drug|Tobramycin Powder|Everyone gets tobramycin powder.
45809553|NCT04297631|Device|Vancomyscin|Everyone gets the vancomyscin powder.
45835828|NCT05051202|Other|Sugars from Fiber|Proprietary blend of Sugars from Fiber baked into 50 g flapjack
45945824|NCT04815954|Procedure|Urinary catheter removal|Removal of urinary catheter which was placed during kidney transplantation.
45945825|NCT04815733|Procedure|Mandatory ventilation|Use PCV-VG
45945826|NCT04815733|Procedure|pressure support ventilation|Use PSVpro
45945827|NCT04808947|Procedure|Local infiltration analgesia|Procedure: Local infiltration analgesia performed by surgeons.
45945828|NCT04808947|Procedure|Ultrasound-guided adductor canal block|Procedure: Ultrasound-guided adductor canal and iPACK blocks performed by anesthesiologists preoperatively.
45945829|NCT04800393|Drug|Sevoflurane|induction of anesthesia with propofol, maintenance of anesthesia with sevoflurane during breast cancer surgery
45945830|NCT04800393|Drug|Propofol|propofol-based total intravenous anesthesia during breast cancer surgery
45945831|NCT04773314|Other|PROPESS Cohort|Non-intervention
45945832|NCT04771442|Drug|Stromal vascular fraction|Single dose
46002546|NCT00521222|Drug|Fluticasone with salmeterol|Fluticasone 45mcg, 115mcg, or 230mcg with salmeterol 21mcg, via HFA device, 2 puffs every 12 hrs, over 16 week study period.
46002547|NCT00521222|Drug|Fluticasone HFA|Fluticasone HFA alone at 44mcg, 110mcg or 220 mcg 2 puffs every 12 hrs, over 16 week study period.
45657580|NCT04027465|Dietary Supplement|Egg allergy oral desensitization|Subjects in the treatment will begin treatment by undergoing an egg oral challenge. This will confirm that the subject is still allergic to egg and establish the dose of egg the subject can tolerate. The last dose of egg tolerated during the challenge will serve as the first desensitization dose Subjects will then come to the research center every two weeks to receive their dose increases until they reach the maintenance dose of 300 mg. Subjects will then enter the maintenance phase for one year. During this period they will undergo another oral food challenge one month after attaining the maintenance dose
45945833|NCT04770844|Other|Acquisitions|"Three acquisitions of 1 hours during hospitalization will be realized:~a few days after hospitalization,~in the middle of the hospitalization,~a few days before hospital discharge. The child will be lying on his back in a heated cradle and filmed with a specific camera. The signal will be obtained by 2k ZED 2 stereo camera in order to obtain a three-dimensional location of the child"
45945834|NCT04768881|Drug|Selinexor|Dose and formulation: 80 mg (4 tablets of 20 mg)
45809554|NCT05645874|Diagnostic Test|Skin biopsy|Control skin biopsies from children without a chronic underlying disease are drawn from surgical crop margins during elective orthopedic surgery of the lower leg (n<80). Skin punch biopsies from children with acquired (n<80) or genetic NDD (n<80) or unknown etiology (N<80) are drawn in the setting of elective interventions during sedation or after local anesthesia. IENFD is quantified by immunohistochemistry and compared between the control and NDD group.
45945835|NCT04768881|Drug|Pembrolizumab|Dose and formulation: 400 mg (25 milligrams per milliliter [mg/mL]) Solution
45945836|NCT04768296|Drug|Berzosertib|Participants with advanced solid tumors, for which no effective standard therapy exists, or standard therapy has failed will receive Berzosertib at a dose of 105 milligrams per square meter (mg/m^2) intravenously on Day 2 and Day 5 of each 21-day cycle in DL1 of safety run-in part.
45945837|NCT04768296|Drug|Berzosertib|Participants with relapsed, platinum-resistant SCLC will receive Berzosertib at a dose of 210 mg/m^2 intravenously on Day 2 and Day 5 of each 21-day cycle in DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
45945838|NCT04768296|Drug|Topotecan|Participants who have advanced solid tumors, for which no effective standard therapy exists, or standard therapy has failed or who have relapsed, platinum-resistant SCLC will receive Topotecan at a dose of 1.25 mg/m^2 intravenously on Days 1 through 5 of each 21-day cycle in DL1 and DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
45809555|NCT04296227|Device|The Vital Detect blood pressure monitor|The end goal is to provide Non-invasive Blood Pressure (NIBP) accuracy data to support validation of the Vital Detect blood pressure monitor.
45945839|NCT04765865|Other|SHAKE Package|The SHAKE (Surveillance of salt intake, Harness industry, Adopt standards for labelling and marketing, Knowledge to empower consumers, and Environments to promote health eating) package is a WHO Best Buy and is recently implemented within Nigeria by the Nigerian Agency for Food and Drug Administration and Control (NAFDAC).
45945840|NCT04761588|Dietary Supplement|Tyr sphere|"Tyr sphere is a powdered, low phenylalanine and tyrosine protein substitute, containing a balanced mix of casein glycomacropeptide (cGMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and the long chain polyunsaturated fatty acid (LCP) and docosahexaenoic acid (DHA). It contains sugars and sweetener.~The product is designed to be prescribed based on its protein content, not its energy content."
46075683|NCT00883519|Behavioral|Interpersonal Psychotherapy for Depressed Adolescents and Parents|12 psychotherapy sessions delivered over 16 weeks
45657581|NCT04983511|Diagnostic Test|Electrical Epidural Stimulation Test (EST)|EST measures sensory/motor responses
45809556|NCT04430582|Other|Cognitive Assessment (not diagnostic)|Cognitive testing will assess working memory and attention, verbal memory and delayed memory, executive function, and psychomotor speed.
45809557|NCT04430582|Diagnostic Test|ECG|ECG will take place during screening visit.
45809558|NCT04292639|Device|The Vital Detect Pulse Oximeter|The Vital Detect is a noninvasive device designed for spot-checking physiological parameters, such as Noninvasive Blood Pressure, Oxygen Saturation, Pulse Rate, Body Temperature, and Respiratory Rate. This device is a finger-cuff technology which is applicable for use at-home or in healthcare facilities in/on individuals 18 years of age and older. It may be used by the individual themselves or an operator. The Vital Detect is not intended for continuous monitoring or for use with high frequency surgical equipment. It is non transit-operable. The Vital USA Vital Detect is composed of a sensor head mounted on a base connected to a phone or computer via Vital Detect App which is free to download.
45809559|NCT05393388|Drug|[18F]AV-1451|[18F]AV-1451 has been developed as a positron emitting radiopharmaceutical for in vivo imaging of tau protein aggregates.
45809560|NCT04812470|Drug|Autologous Tumor Infiltrating Lymphocytes|Administered via hepatic arterial infusion
45809561|NCT04812470|Drug|Melphalan|Melphalan will be administered once as an intravenous infusion.
45809562|NCT04812470|Drug|Interleukin-2|After TIL infusion, Interleukin-2 will be administered subcutaneously once daily for up to 14 days.
45945841|NCT04754529|Other|Quality-of-Life Assessment|Ancillary studies
45945842|NCT04754529|Other|Survey Administration|Ancillary studies
45657582|NCT05473897|Device|Catalyst Cryohelmet|The Catalyst Cryohelmet will be used to provide head and neck cooling. It comes in three sizes based on head circumference. Once informed consent is obtained then the patient's head will be measured to provide the correct helmet size. The Cold Packs will be stored in the emergency department freezer and applied to the helmet once the helmet is ready to be applied. The Cryohelmet will be washed between uses. The Catalyst Cryohelmet is registered with the FDA as D344812. It is a Class I (minimal risk) device not requiring pre-marketing or regulatory processes.
45809563|NCT03502265|Other|Otteroo|Otteroo will be provided for 4 weeks of use, to supplement any standard care. Standard care is not provided.
45945843|NCT04754529|Other|Yoga|Receive yoga intervention
45945844|NCT04735458|Other|Procedure/Surgery: Response Inhibition and Deep Brain Stimulation in Parkinson's disease|After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.
45809564|NCT04428554|Radiation|Experimental arm|Consolidative radiotherapy (pelvic irradiation and/or metastases irradiation) + standard of care +/- previous transurethral resection of bladder tumor
45945845|NCT04729270|Procedure|Physiotherapy treatment with physium device.|The intervention for this group consisted of 10 sessions with Transcranial Direct Current Stimulation for a month.
45809565|NCT05651178|Drug|Human CD19-CD22 Targeted T Cells Injection|Autologous genetically modified anti-CD19/CD22 CAR transduced T cells
45809566|NCT02976194|Drug|ranibizumab|Ranibizumab 0.5mg is injected into the vitreous cavity through the pars plana using 30 gauge (or narrower) needle-attached syringe.
45945846|NCT04729270|Procedure|Conventional physiotherapy treatment.|The intervention for this group consisted of 10 sessions with Electrical Nerve Stimulation (TENS) for a month.
45945847|NCT04718220|Diagnostic Test|Antibody testing for SARS-CoV-2 IgG|Women enrolled into the unexposed (SARS-CoV-2 negative) cohort will undergo testing for SARS-CoV-2 IgG antibodies at enrollment, every trimester of pregnancy, and during delivery hospitalization.
45945848|NCT04718220|Diagnostic Test|Testing for SARS-CoV-2 RNA|Women in the exposed (SARS-CoV-2 positive) cohort will undergo testing of placental tissue, umbilical cord blood, amniotic tissue, and neonates for SARS-CoV-2 RNA, as available.
45945849|NCT04718220|Diagnostic Test|Testing for SARS-CoV-2 IgM/IgG|Women in the exposed (SARS-CoV-2 positive) cohort will undergo testing of umbilical cord blood for SARS-CoV-2 IgG and IgM antibodies, as available.
45809567|NCT00360776|Drug|tipifarnib|Given orally
45945850|NCT04712461|Other|SUPPORTS|The SUPPORTS implementation model will be developed and refined based on community feedback. It will likely include a combination of strategies demonstrated to reduce burnout and secondary traumatic stress in the occupational health literature, such as psychoeducation about burnout, mindfulness training, or changes in scheduling or the physical environment. As the most effective interventions have been shown to involve an integration of both individual- and organization-directed strategies supporting each other, SUPPORTS will aim to include both. For example, the model may include provider-directed strategies such as group peer consultation meetings, and organizational-directed strategies such as increasing communication and providers' involvement in organizational decisions. Through this approach, SUPPORTS will aim to target therapist burnout and turnover at the provider and organizational level.
46002548|NCT00521222|Drug|Ipratropium HFA|Primary as-needed rescue medication in all treatment groups
46002549|NCT00521222|Drug|Albuterol HFA|Secondary as-needed rescue medication in all treatment groups
45809568|NCT00360776|Other|laboratory biomarker analysis|Correlative studies
45809569|NCT04800458|Biological|Blood samples|"Thrombopoietin : 7 ml whole blood.~Anti-platelet antibodies free : 14 ml whole blood.~Anti-platelet antibodies bound :~If the platelet count is ≥ 50 G / L : 14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is < 50 G / L and ≥ 20 G / L : 28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is < 20 G / L and ≥ 10 G / L: 42 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is < 10 G / L : 49 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation."
45809570|NCT04343300|Other|Pilates|Intervention of12 weeks of Pilates
45809571|NCT04343300|Other|exercise without Pilates|exercise without Pilates
45809572|NCT04274075|Drug|GDC-9545 Tablet, Fasted: Treatment A|One dose of the GDC-9545 Phase 1 reference tablet formulation (three 10-mg tablets) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
45809573|NCT04274075|Drug|GDC-9545 Capsule, Fasted: Treatment B|One dose of the GDC-9545 Phase 3 capsule formulation (one 30-mg capsule) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
45809574|NCT04274075|Drug|GDC-9545 Capsule, Fed: Treatment C|One dose of the GDC-9545 Phase 3 capsule formulation (one 30-mg capsule) administered orally with approximately 240 mL room temperature water within 30 minutes of eating a high-fat meal.
45945851|NCT04704375|Device|Bio Electro-Magnetic Regulation (BEMER) Therapy|BEMER is a therapeutic modality that deploys a biorhythmically defined stimulus through Pulsed Electromagnetic Field (PEMF). This stimulus has a targeted effect on the microvasculature, and the primary effect is an improvement in tissue microcirculation. The positive effects of vasomotion on the microcirculation has been shown to result in significant increases in arteriovenous oxygen difference, number of open capillaries, arteriolar and venular flow volume, and flow rate of red blood cells in the microvasculature. Therefore, BEMER can potentially be used in the treatment of LBP by improving microcirculation in muscular tissue.
45809575|NCT02976740|Radiation|SBRT|Stereotactic body radiotherapy A type of radiation therapy to the Metastasis lesion
45657583|NCT05473819|Drug|Buffered Local Anesthesia|"Buffered local anesthesia will be administered after being previously prepared just before the injection time.~Buffering Local Anesthetic Solutions Using 8.4% Sodium Bicarbonate in a 19:1 Ratio: Using the REMOVE AND REPLACE hand buffering method~-Under sterile conditions, 0.09 mL of local anesthetic solution will be removed from the cartridge using a 0.5 mL syringe with a 28- gauge, 0.5-inch needle (Kendall Monoject Insulin Syringe [Tyco Healthcare, tyco.com] lot number 027501). Using a separate unused syringe, 0.09 mL of the commercially available 8.4% sodium bicarbonate will be removed from the 50 mL vial and immediately injected into the local anesthetic cartridge. The cartridge will be inverted 5 times to mix the solution, and no precipitation will be present."
45945852|NCT04704375|Procedure|OMT (osteopathic manipulative treatment)|i. OMT Myofascial release (MFR), soft tissue (ST) release, muscle energy (ME), counterstrain (CS), and balanced ligamentous tension (BLT) technique.
45945853|NCT04704375|Procedure|Light touch|Treaters will place their hands lightly on the subject's lumbar paraspinal muscles in the supine and prone positions in the same area as where one would place your hands for lumbar MFR technique for the same amount of time as it would take to perform MFR in this area (approximately 5 minutes). However, no lifting or action will be done. In addition, the subject will lie down on the BEMER mat (as they would do during a BEMER session), but the device will not be activated.
45945854|NCT04683653|Radiation|Hypofractionated Radiation|Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given less often. Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.
46002550|NCT00378482|Drug|CP-675,206 (Tremelimumab)|15 mg/kg IV every 3 months as long as required
45657584|NCT05473819|Drug|Conventional Unbuffered Local Anesthesia|The control group will receive the unbuffered conventional anaesthetic solution
45809576|NCT02976740|Drug|Immunological Agent|Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.
45809577|NCT02976740|Drug|Immunological Factors|Thymosin Alpha 1(1.6mg Biw)will be executed from the fist Week to the 12th Weeks.
45809578|NCT04409288|Drug|Apalutamide|Androgen receptor inhibitor.
45809579|NCT04409288|Drug|Enzalutamide|Androgern receptor inhibitor
45809580|NCT03639857|Device|532nm laser|532nm laser will be used to treat the lesion in this study arm.
45809581|NCT03639857|Device|1064nm laser|1064nm laser will be used to treat the lesion in this study arm.
45809582|NCT03639857|Drug|Topical corticosteroid|The topical corticosteroid will be used to treat the lesion in this study arm.
45453263|NCT00003511|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Multiple Myeloma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45453264|NCT01101607|Procedure|Distal Forearm Fracture Reduction|Fracture reduction
45453265|NCT00003499|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Low-grade non-Hodgkin's lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45453266|NCT00003487|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Adenocarcinoma of the Esophagus will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45657585|NCT04330729|Drug|Acetylsalicylic acid|Se arm description
45809583|NCT04342910|Drug|camrelizumab|200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.
45453267|NCT03950947|Device|Amplatzer vascular plug|See above
45453268|NCT03950947|Other|Sham Controll|Angiography of the RIMA without occlusion
45809584|NCT04342910|Drug|Apatinib Mesylate|250 mg qd
45453269|NCT01101685|Drug|Escitalopram|7 days dosing of 10mg per day
45809585|NCT04342910|Drug|Paclitaxel|80 mg/m^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.
45453270|NCT01101685|Drug|Placebo|7 days dosing at 10mg daily
45809586|NCT04342910|Drug|Irinotecan|180 mg/m^2 administered as IV infusion on Days 1, and 15 of each 28-day cycle.
45809587|NCT03504839|Device|Subcutaneous ICD with same day discharge|Receiving a SICD and discharged the same day
45809588|NCT04714073|Drug|BI 706321|BI 706321
45809589|NCT04714073|Drug|Itraconazole|Itraconazole
45809590|NCT04342676|Device|k ras|K ras
45657586|NCT05473741|Drug|Second Generation Long-Acting Injectable Antipsychotic Medications|Patients who have been stabilized on long-acting injectable formulations of paliperidone palmitate, risperidone and aripiprazole will be followed for 48 weeks to determine the rate of relapse when adherence is established. Blood samples to measure plasma antipsychotic levels and prolactin levels, and urine samples for drug screen will be collected at baseline and at the 24-week and 48-week time points.
45657587|NCT04842721|Drug|Hypertonic Saturated Saline Mouth Rinse Active Arm|Each Patient of this groups will be asked to keep the solution still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the solution will be spit out and mouth will be rinsed with plain water several times. The process will be done twice a day for 2 days.
45657588|NCT04842721|Other|Placebo Plain Water Mouth Rinse Arm|Each Patient of this groups will be asked to keep the water still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the water will be spit out. The process will be done twice a day for 2 days.
45657589|NCT05614375|Procedure|endoscopic surgery|transnasal endoscopic surgery
45809591|NCT04342676|Drug|Panitumumab|vectibex in stage iv
45809592|NCT04269629|Drug|Insect Venom|Patients receive insect venom immunotherapy. The frequency of systemic side-effects is recorded and compared between patients under antihypertensive treatment and patients not taking antihypertensive drugs.
45809593|NCT01641822|Drug|AZLI|Aztreonam for Inhalation Solution (AZLI) 75 mg 3 times daily combined with diluent administered using an eFlow nebulizer
45809594|NCT01641822|Drug|Placebo to match AZLI|Placebo to match AZLI 3 times daily combined with diluent administered using an eFlow nebulizer
45809595|NCT01641822|Drug|Tobramycin inhalation solution|Tobramycin inhalation solution (TIS) 300 mg 2 times daily using a PARI® LC Plus nebulizer and DeVilbiss Pulmo-Aide® air compressor
45809596|NCT04400318|Drug|Dupilumab SAR231893|Pharmaceutical form:solution for injection Route of administration: subcutaneous
45809597|NCT04400318|Drug|Placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
45809598|NCT04250987|Device|SpeediCath(R)|IC SpeediCath ® connected to pressure sensor
45809599|NCT04398368|Drug|Gemcitabine Hydrochloride|Given intravesically
45809600|NCT05651100|Biological|CD19 and CD22 targeted CAR-T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (300 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In sequential CAR-T clinical trials, CAR-T cells will be given.（anti-CD19 CAR-T first, then anti-CD22 CAR-T).
45809601|NCT04393844|Other|turbo-ject PICC set|The turbo-ject PICC set, which will be used in this study, is the set for peripherally inserted central catheterization. In this study, we will see the difference according to the presence or absence of the hydrophilic coated stiffening obturator included in this turbo-ject PICC set.
45809602|NCT05645094|Drug|Envafolimab|Patients will receive single drug therapy of Envafolimab (300mg) once every two weeks. Patients who do not have tumor regression after 3 months of treatment should be judged by the investigator whether to adopt standard chemoradiotherapy plus surgery. Patients with tumor regression should continue to receive Envafolimab therapy until 6 months. For patients who do not reach complete clinical response (cCR) after 6 months of treatment, the investigator shall determine whether to perform standard chemoradiotherapy or radical surgery. For patients who reach cCR, they could receive the observation waiting or local resection which depend on the investigator. Patients should be followed up until reaching cCR or 3 years after surgery.
45809603|NCT04393532|Device|Su2ura Approximation Device|the use of the study device during a laparoscopic surgery
45809604|NCT04393532|Procedure|Laparoscopic hernia repair surgery|repairing primary umbilical hernia in a laparoscopic procedure using the study device.
45809605|NCT03507569|Drug|RO7017773|RO7017773 will be administered orally. The doses to be tested will be determined by review of PET scan, PK, and safety results from the previous dose level.
45809606|NCT03507569|Other|[11C] Ro15-4513|At the start of each PET scan, participants will receive an intravenous dose of the radiolabeled tracer [11C]Ro15-4513.
45809607|NCT05364762|Drug|Cyclophosphamide|Given IV
45809608|NCT05364762|Drug|Itacitinib|Given PO
45809609|NCT05364762|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell infusion
45809610|NCT05364762|Other|Quality-of-Life Assessment|Ancillary studies
45809611|NCT05364762|Drug|Tacrolimus|Given IV or PO
45809612|NCT03508661|Other|SPIN-SSLED Program|The program includes 13 modules that will be delivered live via webinar over the course of the 3-month program. Each module will be delivered in a 60- to 90-minute session. Module topics include (1) the leader's role; (2) starting a support group; (3) structuring a support group meeting; (4) scleroderma 101; (5) successful support group culture; (6 &7) managing support group dynamics I and II; (8) grief and crisis in scleroderma; (9) marketing and recruitment; (10) the continuity of the group; (11) supporting yourself as a leader; (12) virtual support group meetings, (13) support group leader resources. Participants will receive a workbook, be shown filmed vignettes, and will have access to an online resource center.
45458765|NCT03774979|Drug|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
45809613|NCT05358990|Other|Plain Language Recommendation (PLR)|New easy to read COVID-19 recommendations available on the COVID19 Living Map of Recommendations and Gateway to Contextualization (RecMap).
45809614|NCT05358990|Other|Standard Language Version (SLV)|Original recommendation as initially published by the guideline organization.
45835829|NCT05051202|Other|Resistant Maltodextrin|Resistant Maltodextrin baked into 50 g flapjack
45835830|NCT05290974|Other|Self exploring of available online material on supraclavicular brachial plexus block|Potential new method of learning a specific regional anesthesia technique
45835831|NCT05290974|Other|Conventional in-person teaching on supraclavicular brachial plexus block|Conventional method of learning a specific regional anesthesia technique
46075684|NCT02781714|Behavioral|Two-way SMS|"SMS messages will provide tailored and actionable education, counseling, and reminders specific to antenatal/postpartum timing and partner track. Messages will include questions and prompts; women and their male partners have the option of writing back to a nurse with questions or concerns, who will provide real-time responses via text and/or make referrals to a clinic. Message content will be tailored to women and couples, and will range from health benefits of child spacing and an emphasis on contraceptive options, to the hierarchy of effectiveness and information on specific methods, to simple reminders about postpartum visits.~Prior to randomization, each enrolled woman will be asked if she has a male partner, and whether she would like to refer her male partner for recruitment and enrollment into the study. The partner tracks are as follows:~Male partner invited to enroll/enrolled~Male partner not invited to enroll~Unpartnered"
45657590|NCT03910933|Other|elearning patient information|The videos will standardize patient teaching about anticoagulants, warfarin, INR testing, and warfarin safety for Patient Self-Testing, and Patient Self-Management. eKITE, will provide a user-friendly interface to provide health education about anticoagulation. eKITE will teach concepts to the patient, facilitate sustained patient knowledge (6 month evaluation), reduce stress associated with learning, actively engage patients in their anticoagulant management (preference, satisfaction and knowledge).
45945855|NCT04683653|Other|Clinical Follow-Up and Assessments|"At each visit, the subject will be evaluated for any signs of their endometrial cancer or symptoms returning (clinical disease recurrence) and any negative side effects associated with their prior radiation treatment. Study participants will also be asked to fill out a survey regarding bowel/urinary habits and quality of life questionnaires (known as the EPIC questionnaire) during these visits. The data collected during these clinical follow up visits will be used to determine how effective hypofractionated/shortened whole radiation therapy is for treating endometrial cancer."
45945856|NCT04680585|Other|Enhanced Usual Care|A standardized handout with information on what treatment options might be useful to start with based on EPDS score and stage of pregnancy or postpartum.
45945857|NCT04680585|Other|MOVIN Care Platform|Virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.
45657591|NCT05612893|Other|pathogen|"The patients were divided into groups according to the pathogen(bacteria or virus).~The influenza upper respiratory tract infection cohort will be grouped mainly according to age."
46075685|NCT04205383|Other|biological analyses|The histones H3-citrullinated, acetylated histones (Pan-histones), H1 histone as well as the free HMGB1 protein will be quantified. This choice corresponds to the histones involved in inflammation, proliferation, migration or cell differentiation and can be quantified to date.
45945858|NCT04677166|Device|Negative pressure wound therapy coupled with instillation|Use of V.A.C. VeraFlo to treat skin grafts with NPWT coupled with instillation.
45809615|NCT04871958|Device|Continuous glucose monitoring (CGM, Dexcom G6)|"The Dexcom G6 sensor will be placed on the back of the upper arm at admission and changed after 10 days. In the participants randomized to Real-time CGM, glucose values will be transmitted through Bluetooth to a mobile phone at the bedside. From this phone data are transmitted to a tablet in the nursing station.~In the blinded CGM group, sensor readings will be blinded to patient and healthcare providers.~The MDI groups will be managed with basal/bolus insulin regimen, as clinically indicated.~V-Go will be placed on the abdomen each morning. Insulin-naïve patients randomized to the V-Go system will start at the lowest basal rate (20 UI/24h).~On daily basis, expert diabetologists will retrospectively review CGM data and provide indications for insulin therapy adjustments."
45945859|NCT04677166|Device|Standard Negative Pressure Wound Therapy|standard negative pressure wound therapy via V.A.C. Ulta device at 125mmHg suction.
45657592|NCT03882307|Drug|sofosbuvir and daclatasvir|oral tablets
45809616|NCT04342598|Other|Serum Vitamin D|Primary exposure assessed will be serum vitamin D (25(OH)D). Diet will also be assessed via Food Frequency Questionnaire.
45809617|NCT03645785|Dietary Supplement|Normal fluid intake without true lemon|16.9oz water with True Lemon
45809618|NCT03645785|Dietary Supplement|Double fluid intake plus 3 bottles of water with True Lemon|No intervention
45809619|NCT00360854|Drug|erlotinib hydrochloride|
45945860|NCT04672226|Dietary Supplement|PDE MAX|PDE MAX will be prescribed by the study dietitian based on the patient's individual requirement.
45945861|NCT04668300|Biological|Durvalumab|Given IV
45945862|NCT04668300|Biological|Oleclumab|Given IV
45945863|NCT04650178|Other|Quality-of-Life Assessment|Ancillary studies
45945864|NCT04650178|Other|Questionnaire Administration|Complete questionnaire
45809620|NCT00360854|Genetic|mutation analysis|
45945865|NCT04647097|Behavioral|Standard intervention only|Standard intervention (SI) will be a part of standard care in all participating centers, and will be provided for all acute pancreatitis patients, who are hospitalized and their condition is alcohol induced. A specially trained study nurse will deliver the intervention, since they were found to be the most effective regarding the decrease in alcohol consumption and smoking. The cost- effectiveness of the intervention and the feasibility were also taken into account. The Assist-linked brief intervention according to the World Health Organization (WHO) will serve as the base for the intervention, with an avarage of 30 minutes, based on a review containing 69 randomized controlled trials, which concluded that longer intervention do not have additional benefit. The patients will be also educated about the disease course of acute pancreatitis during the standard intervention.
46002551|NCT00195091|Drug|Tetrathiomolybdate|"Induction with Tetrathiomolybdate (TM) Tetrathiomolybdate 40 mg. p.o. TID with meals and tetrathiomolybdate 60 mg at bedtime for a total of 4 doses (180 mg) per day.~Induction goal Total tetrathiomolybdate dose per day = 180 mg until serum ceruloplasmin (Cp) level decreases to 5-15mg/dL.~When target Cp window is reached, then the maintenance phase begins.~Maintenance with Tetrathiomolybdate Total tetrathiomolybdate dose per day = 100 mg~Tetrathiomolybdate 40 mg p.o. BID with meals and tetrathiomolybdate 20 mg at bedtime."
45458766|NCT01142635|Drug|Rocuronium bromide|Rocuronium, iv, 0,6 mg/kg diluted with saline to double volume, bolus, single dose
45809621|NCT00360854|Genetic|polymorphism analysis|
45809622|NCT00360854|Other|laboratory biomarker analysis|
45809623|NCT00360854|Other|pharmacological study|
45809624|NCT00360854|Radiation|radiation therapy|
45657593|NCT03858517|Device|ReUnion TSA System|The ReUnion TSA System is designed as an anatomical total shoulder or hemi-shoulder endoprosthesis to address advanced arthritic disorders affecting the shoulder joint in subjects having intact or repairable rotator cuff function. The ReUnion TSA System consists of a completely modular shoulder platform including a Humeral Stem, Humeral Head and Glenoid. The intended purposes of the ReUnion TSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
45657594|NCT04803799|Other|Training Programme|Cognitive-motor dual task exercises corresponding to associations between different motor tasks and different cognitive tasks.
45945866|NCT04647097|Behavioral|Standard intervention plus repeated intervention|Standard intervention (SI) will be performed as described above. The repeated intervention will be delivered by the former mentioned same nurse and will be structured similarly to the standard intervention. Every visit and intervention will be individually altered according to the motivation of the patient, but they will follow the same structure. The sessions can be divided into three main parts: first, highlighting the harmful effects of smoking and alcohol on the pancreatic functions. Secondly, a discussion about the motivation of the patient will happen. The last portion of the session will focus on the responsibility of the individual to reach the desired goal will be highlighted. To enhance the efficacy of our intervention we wish to provide feed-back for the patient based on laboratory testing: the mean corpuscular volume (MCV) and gamma glutamyl-transferase (GGT) values will be measured right before the interview. The study nurse will not take part in patient care.
45945867|NCT04642079|Biological|20vPnC|20-valent pneumococcal conjugate vaccine
45809625|NCT05650944|Diagnostic Test|Hemogram|Sysmex XN-1000 hematological analyzer
45809626|NCT04783220|Behavioral|Comprehensive structured parent intervention|"Educational sessions and coaching on infants' behavior cues~Skills on motor stimulation~Written instructions for play and stimulation activities at discharge~Multidisciplinary follow-up~Developmental tracking and advice via a mobile app"
45809627|NCT04862208|Dietary Supplement|Maltodextrin supplement|maltodextrin (25g in 12 oz water) 1 hour pre-exercise
45945868|NCT04638491|Drug|Lurbinectedin for injection|On the first day of each cycle, patients with advancedsolid tumors or small cell lung cancer were treated with Lurbinectedin for injection
45945869|NCT04629300|Behavioral|Supportive Care Mobile Application|Tablet computer with application providing modules on skills for managing symptoms and coping.
45945870|NCT04629300|Other|Usual Care|Standard oncology care with monitoring of supportive care services usage
45945871|NCT04616898|Device|Venus Bliss|The Venus Bliss™ system is an aesthetic medical device designed to non-invasively reduce subcutaneous adipose tissue of the abdominal area and flanks. It is intended for use in individuals with a Body Mass Index (BMI) of 30 or less. The device consists of an external treatment component and an internal control component. The treatment console is a 1060nm diode laser applicator and a radio frequency applicator. In addition, a Bliss Belt is provided with the system to properly secure one or more applicators to the patient's body during treatment. Finally, the touchscreen monitor is used by the clinician to control the setting display on the main console. It also keeps the clinician informed of the device's status and operating parameters.
45945872|NCT04616560|Biological|Trastuzumab Deruxtecan|Given IV
45945873|NCT04613505|Behavioral|Semi-structured interview|Participants will be asked a set of questions as applicable to each phase. Researchers will be able to ask additional questions as they arise within each interview.
45945874|NCT04613505|Behavioral|Same day consent questionnaire|A questionnaire (yet to be developed) will be administered to participants.
45945875|NCT04598828|Device|Non-invasive brainstem stimulation|Study participants will self-administer ~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device. The device has been deemed as a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
45945876|NCT04583423|Drug|MK-3655|MK-3655 low, middle, or high dose for injection
45945877|NCT04583423|Drug|Placebo|Matching placebo to MK-3655
45945878|NCT04581785|Biological|hLB-001|hLB-001 via IV infusion
45945879|NCT04572295|Drug|E7090|E7090 oral tablet.
45945880|NCT04572295|Drug|Fulvestrant|Fulvestrant intramuscular injection.
45945881|NCT04572295|Drug|Exemestane|Exemestane oral tablet.
45945882|NCT04571385|Drug|AP30663|Administer by intravenous infusion.
45945883|NCT04571385|Drug|Placebo|Placebo matched to AP30663.
45657595|NCT04800601|Other|Rehabilitation program 1|"Both groups will benefit from a conventional rehabilitation treatment including a repetitive walking.~In addition to this conventional rehabilitation, the experimental group will receive an ankle isokinetic program, 5 times a week, for 6 weeks (with a minimum of 25 sessions)"
45809628|NCT04862208|Dietary Supplement|Whey supplement|whey (25g in 12 oz water) 1 hour pre-exercise
45809629|NCT04862208|Dietary Supplement|Water|non-caloric control (12 oz flavored water) 1 hour pre-exercise
45809630|NCT04862208|Dietary Supplement|Maltodextrin supplement|maltodextrin (25g in 12 oz water) with no exercise
45809631|NCT03511001|Other|E-Cigarette Vs. Smoking as Usual|6 weeks of JUUL e-cigarettes vs. 6 weeks of smoking as usual
45809632|NCT04035356|Device|Aortic valve repair|Use of a HAART Aortic Annuloplasty Device in patients undergoing aortic valve repair surgery
45809633|NCT05650866|Device|Activation of pro-erectile nerves within the pelvic plexus|The study device is an active implantable device. The device activates the cavernous nerves by delivering electrical pulses, to trigger an on-demand erection. The daily delivery of electrical pulses to the cavernous nerves will also allow participants to recover natural erectile function.
46075686|NCT02781636|Device|Device: StimGuard Protect System|Lead implanted adjacent to tibial nerve. Wireless rechargeable system.
45453271|NCT00003475|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a primary malignant brain tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45809634|NCT05650788|Diagnostic Test|NMR spectrometry|"The MRI protocol will be carried out at 3 Tesla (3T) on a Siemens NMR imaging system (Magnetom Vida, Siemens Healthcare, Erlangen, Germany), the emission of radiofrequency waves and the reception of the signal will be done using a resonator in quadrature head (64-channel phase-array antenna). The MRI protocol will take place in two phases:~Realization of a morphological sequence for the identification of the zone of interest.~Acquisition of a 1D NMR spectrum in the ventral striatum (right and left).~Acquisition of a 1D NMR spectrum in the anterior cingulate cortex (right and left).~Acquisition of a 1D NMR spectrum in the prefrontal cortex (right and left)."
45453272|NCT01104181|Device|HC2 collection kit with a swab or brush|We will sample the anal canal for cells with either a swab and swab or swab and brush to determine which is superior
45458767|NCT01142635|Drug|Rocuronium bromide|Rocuronium, iv, single dose, single bolus, 1.2 mg/kg
45657596|NCT04800601|Other|Rehabilitation program 2|"Both groups will benefit from a conventional rehabilitation treatment including a repetitive walking.~The control group will have a supplement in conventional rehabilitation equal to the additional time of the experimental group."
45657597|NCT04762771|Drug|Colchicine|"Colchicine dosing = 0.6 mg bid x 30 days Decrease dose to 0.3-0.6 mg daily or every other day in setting of gastrointestinal intolerance (nausea, diarrhea, emesis, abdominal discomfort) Decrease dose to 0.6 mg daily in the setting of weak or moderate CYP3A4 inhibitor Decrease dose to 0.3 mg daily in the setting of strong CYP3A4, P-glycoprotein inhibitors, or protease inhibitors Decrease dose to 0.3 mg daily in the setting of chronic kidney disease (CKD) stage ≥ 4 (CrCl ≤ 30 ml/min) or liver failure (aspartate aminotransferase /alanine aminotransferase > 3x normal).~Decrease dose to 0.6 mg every 14 days in patients with end stage renal disease (ESRD) or requiring dialysis Route of Administration: oral"
45809635|NCT03647033|Device|iStent implantation|The iStent is a FDA and Health Sciences Authority (HSA) approved micro-bypass stent device that bypasses the trabecular meshwork (filtration membrane of the aqueous fluid exit pathway) and reroutes aqueous from the anterior chamber directly into canal of Schlemm and out of the eye. It lowers the intraocular pressure (IOP) by increasing the outflow of fluid from the eye from the micro-bypass. In angle closure, the lens has to be removed to create enough space for the iStent to be inserted.
45809636|NCT04778930|Other|Physical Therapy|"FACE-TO FACE SESSIONS: approximately 90 minutes of Goal-directed training (activities for the activation of the muscles of the trunk, pelvis and lower limbs; and training of activities will be carried out in a functional and meaningful context, aimed at specific functional objectives, according to the interests of each participant and agreed with the participants and their families) and gait training on the treadmill for 20 minutes.~TELEHEALTH THERAPEUTIC EDUCATION PROGRAM: Session 1: Concept and causes of CP, together with the general objectives and guidelines of the program. Session 2: The family-centered model; Sessions 3, 4 and 5: Actions Observation Therapy; Session 6: Program Evaluation."
45809637|NCT04778930|Other|THERAPEUTIC EDUCATION PROGRAM|TELEHEALTH THERAPEUTIC EDUCATION PROGRAM: Session 1: Concept and causes of CP, together with the general objectives and guidelines of the program. Session 2: The family-centered model; Sessions 3, 4 and 5: Actions Observation Therapy; Session 6: Program Evaluation.
45809638|NCT04871022|Procedure|Double layer closure of the hysterotomy|Double layer closure with a first continuous unlocked suture of the deep portion of the myometrium and a second unlocked continuous suture that approximate the upper portion of the myometrium.
45809639|NCT04871022|Procedure|Purse closure of the hysterotomy|Purse suture of the uterus with a first continuous purse suture of the deep portion of the myometrium and a second unlocked continuous suture including the remaining part of the myometrium
45809640|NCT05314205|Procedure|ligation of inter-sphincteric fistula tract|"The surgical treatment was achieved through identification of the fistula by injecting hydrogen peroxide (H2O2) through the external opening. Probing of the fistulous tract by a metallic probe for proper identification of the fistula in the inter-sphincteric plane.~Perpendicular skin incision (about 1 cm) was done at inter-sphinctric zone, perpendicular to the fistulous tract. Dissection between the internal and external sphincters and identification of the fistula.~Finally, Ligation and transection of the tract in inter-sphinctric space followed by excision of a segment and transferred for histopathology examination. Trans-fixation suture was applied near to the internal mucosal opening of the divided tract to confirm closure using polyglactin suture 2/0. Insertion of a probe to check the closure of the tract segments.~The remaining part of the tract was curetted till external opening and left for spontaneous healing."
45809641|NCT04362254|Drug|Spesolimab|Spesolimab
45809642|NCT03511937|Behavioral|Sugar-Sweetened Beverage Health Warning Label|Labels with a health warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research and on designs described in US and international legislation.
45809643|NCT03511937|Other|Neutral Label|Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
45809644|NCT05641818|Other|Screening tool for vitamin D deficiency|(1) Determination of 25(OH) Vitamin D3 in human serum samples and (2) Question based screening tool with personal (age, gender,...), lifestyle (e.g. sun exposure, outdoor activity) and dietary factors that affect the status of vitamin D in the human body.
45945884|NCT04557956|Procedure|Biopsy|Undergo tumor biopsy
45945885|NCT04557956|Procedure|Computed Tomography|Undergo CT scan
45945886|NCT04557956|Drug|Dabrafenib Mesylate|Given PO
45945887|NCT04557956|Procedure|Magnetic Resonance Imaging|Undergo MRI
45945888|NCT04557956|Drug|Tazemetostat Hydrobromide|Given PO
45945889|NCT04557956|Drug|Trametinib Dimethyl Sulfoxide|Given PO
46002552|NCT00544856|Behavioral|complex cognitive training|
45657598|NCT04339465|Behavioral|CARE-FAM|CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months.
45453273|NCT00003457|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
45657599|NCT04339465|Behavioral|WEP-CARE|WEP-CARE is an online-intervention that addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 12 standardized writing tasks on a secured internet platform
45657600|NCT05466409|Other|Visualization of the hyoid bone|Visualization of the hyoid bone using POCUS of upper airway (probe positioning: transverse plane). Hyoid bone visualization will be assessed as a binary outcome (yes/no).
45809645|NCT05641584|Other|retrospective data review study|Patient information will be scanned retrospectively from the computer environment and patient cards. No intervention will be made to the patients.
45809646|NCT05640258|Diagnostic Test|rotatory chair testing in a velocity step protocol.|Tc was evaluated by the rotational velocity step test using the OtoaccessTM interface (Interacoustics Nydiag 200, Middlefart, Denmark). Subjects were seated on the rotatory chair wearing videonystagmography goggles with their heads supported and tilted 30° forward, thus bringing the horizontal semicircular canals plane perpendicular to the axis of rotation. Standard videonystagmography techniques were employed to record eye-movements. Subsequent to eye movements' calibration, the chair was accelerated about the yaw axis at 30°/sec2 to a maximal velocity of 90°/sec, followed by rotation at a constant velocity. After 57 seconds of constant velocity rotation, the chair was decelerated to zero velocity at 30°/sec2. The described velocity step was conducted both clockwise and counter-clockwise, giving a total run time of 4 minutes.
45809647|NCT00361478|Behavioral|Exercise and education|Weekly exercise and education program for 8 weeks
45809648|NCT00361478|Behavioral|Education|Written educational material
45453274|NCT01100281|Behavioral|Neuropsychological examination|Examination including especially concept formation
45657601|NCT05466409|Other|Visualization of vocal cords|Visualization of the vocal cords through the cricoid cartilage using POCUS of upper airway (probe positioning: transverse plane). Vocal cords visualization will be assessed as a binary outcome (yes/no).
45657602|NCT05466409|Other|Localization of thyrohyoid membrane|Localization of thyrohyoid membrane using POCUS of upper airway (probe positioning: midsagittal plane). Thyrohyoid membrane visualization will be assessed as a binary outcome (yes/no).
45657603|NCT05466409|Other|Visualization of epiglottis and pre-epiglottic space|Visualization of epiglottis and pre-epiglottic space using POCUS of upper airway (probe positioning: midsagittal plane). Epiglottis and pre-epiglottic space visualization will be assessed as a binary outcome (yes/no).
45809649|NCT04018118|Biological|Biological sample|Additional blood samples for biobanking
45809650|NCT01641198|Device|Configuration 1|B placed at sites 2 and 5, SW placed at sites 1 and 4, SC placed at site 3
45809651|NCT01641198|Device|Configuration 2|B placed at site 3, SW placed at sites 2 and 5, SC placed at sites 1 and 4
45809652|NCT01641198|Device|Configuration 3|B placed at sites 1 and 4, SW placed at site 3, SC placed at sites 2 and 5
45809653|NCT02975414|Procedure|rTARUP technique|obot-assisted rTARUP technique
45809654|NCT04214951|Drug|Eltrombopag|Patients will be given eltrombopag 50mg once daily for 6 weeks.
45809655|NCT04214951|Drug|Recombinant human thrombopoietin (rh-TPO)|Patients will be given rh-TPO 300 U/kg once daily for 21 days.
45809656|NCT04012814|Device|Venus Bliss|The FDA cleared device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1060 nm diode laser applicators (60 mm x 60 mm). A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation. The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.
45809657|NCT04770506|Other|Data extraction from medical files|Data extraction from medical files
45809658|NCT05637918|Other|Group 1 (Patients who recorded as Grade 0)|When the gastric contents were evaluated with the upper gastrointestinal endoscopy, the stomach was completely empty in Group 1 that patients who recorded as Grade 0.
45809659|NCT05637918|Other|Group 2 ( Patients who recorded as Grade 1)|When the gastric contents were evaluated with the endoscope, small volume of gastric clear fluid was visible and gastric content aspirated and measured in Group 2 that patients who recorded as Grade 1.
45657604|NCT05466409|Other|Visualization of cricothyroid membrane|Visualization of cricothyroid membrane using POCUS of upper airway (probe positioning: midsagittal plane). Cricothyroid membrane visualization will be assessed as a binary outcome (yes/no).
45809660|NCT04762082|Drug|Tadalafil 10 MG|comparison of tadalafil gummy 10mg and tadalafil oral tablet 10mg
45809661|NCT03514277|Drug|Exparel|1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL
45809662|NCT03514277|Drug|Bupivacaine|30 mL bupivacaine 0.5% w/v solution
45657605|NCT05466409|Other|Visualization of thyroid gland|Visualization of thyroid gland using POCUS of upper airway (probe positioning: transverse plane). Thyroid gland visualization will be assessed as a binary outcome (yes/no).
45657606|NCT05466409|Other|Hyoid bone to skin distance|Measurement of hyoid bone to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
45657607|NCT05466409|Other|Anterior commissure to skin distance|Measurement of anterior commissure to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
45657608|NCT05466409|Other|Epiglottis to skin distance|Measurement of epiglottis to skin distance (mm) using POCUS of upper airway (probe positioning: midsagittal plane).
45945890|NCT04553146|Procedure|Immediate implantation in posterior region with alveolar ridge preservation combined with sealing socket abutment|Twenty BLXⓇ Straumann immediate implants were placed flapless. The gap around the implant was filled with xenogeneic biomaterial. An intra-oral scanner was performed and sent to the dental laboratory to digitally design a customized healing abutment. The abutment was then milled from a block of PEEK and placed a couple of hours later in the clinic. Three months after implantation, the abutment was removed and the final monolithic crown based on the initial IOS was placed. The transmucosal design from the SSA was replicated on the final crown.
45945891|NCT04547374|Other|GaH Intervention|"Patients in this cohort will be referred for management/intervention with GaH.~However, the purpose of this program is not to define, control, or evaluate the specific details of the GaH process or procedure, but to evaluate its effectiveness as an alternative clinical care path in this setting. As such, the specific details and actions of the GaH care team in each patient interaction are left to their medical discretion."
46075687|NCT00883831|Procedure|Individualized manual acupuncture|Acupuncture treatment will be provided according to traditional korean medicine (TKM) theory which focuses on patient's individual symptoms and conditions. 10-12 needles will be inserted into acupuncture point on the body except one arm where arteriovenous fistula is located for hemodialysis access. Needle retention time will be 30 minutes with intermittent manual stimulation to elicit de-qi sensation. Biweekly treatment will be conducted at non-dialysis access day or before hemodialysis at dialysis-access day for 6 weeks.
46075688|NCT00883909|Drug|dutasteride|A follow-up study in adult male subjects who have received investigational product
45453275|NCT01100281|Other|MRI|MRI performed in T1-weighted three dimensional sequence
45657609|NCT05466409|Other|Thyroid isthmus to skin distance|Measurement of thyroid isthmus to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
45657610|NCT05614297|Diagnostic Test|Knee joint laxity test|Patients seen in an outpatient clinic in connection with an ACL injury or in connection with short or long-term follow-up after ACL surgery, will undergo a clinical assessment of their knee injury as part of standard care. This includes an assessment of knee joint laxity using both the Rolimeter and the Lachmeter, to allow for an assessment of agreement between the two methods.
45657611|NCT04754737|Other|No antibiotic|No antibiotics will be given prior to intravesical injection of onabotulinumtoxinA
45657612|NCT04754737|Other|Prophylactic antibiotic|This is the current standard of care, this group of patients will be given a single dose of prophylactic antibiotic prior to the injection of onabotulinumtoxinA via cystoscopy
45657613|NCT04754737|Procedure|cystoscopic injection of onabotulinumtoxinA|cystoscopic injection of onabotulinumtoxinA
45657614|NCT04717141|Other|Selective nerve block|"D0 :~Information, collection of consent, inclusion,~Clinical and instrumental evaluation,~Realization of the selective nerve block,~Post-selective nerve block clinical and instrumental re-evaluation,~Performance of the botulinum toxin injection if indication selected.~D28 (+/-5 days) :~- Clinical and instrumental post-botulinum toxin injection evaluation."
45657615|NCT04705363|Behavioral|Dialectal Features Varied|Participants will randomized to interact with a VHA that speaks either Standardized American English, a low level of African American English, or a high level of African American English
45657616|NCT04705363|Behavioral|Video Intervention|Participants will randomized to either receive a video introduction from the voice actor or receive no introduction
45657617|NCT04705363|Behavioral|VHA with no voice|virtual health assistant that will consist of photos of the computer-generated doctor with text that will guide you through the interaction. No voice will accompany the photos or text.
45945892|NCT04541446|Other|Dynamic Haptic Robotic Trainer (DHRT)|Device trains medical residents to safely perform the needle insertion portion of Central Venous Catheterization.
45945893|NCT04541446|Other|Advanced Dynamic Haptic Robotic Trainer (DHRT+)|Device offers whole procedural training for medical residents to safely perform the procedure of Central Venous Catheterization.
45945894|NCT04541017|Procedure|Biospecimen Collection|Undergo blood sample collection
46075689|NCT04229160|Device|Noninvasive mapping (Cardioinsight® system)|Noninvasive mapping (Cardioinsight® system) of the left atria before the Atrial fibrilation ablation procedure
46075690|NCT04229160|Device|long-term cardiac monitoring (LINQ system)|long-term cardiac monitoring (LINQ system) is used to evaluate recurrence rate following AF ablation procedure
46075691|NCT04229160|Procedure|Atrial Fibrillation ablation procedure|Atrial Fibrillation ablation procedure is done with standard practice
46075692|NCT05341830|Behavioral|Recovery housing|Recovery housing provides housing and other services to individuals who are recovering from substance-use disorders. They provide a substance-free living environment, as well as services to assist residents with life in recovery. These services include connections to employment and educational opportunities, help obtaining documentation such as a driver's license, connection to mutual aid, and assistance building life skills.
46075693|NCT00634686|Dietary Supplement|DHA/EPA|1.2 gram capsule daily for 6 months
45945895|NCT04541017|Procedure|Computed Tomography|Undergo PET/CT or diagnostic CT
45945896|NCT04541017|Biological|Magrolimab|Given IV
45945897|NCT04541017|Biological|Mogamulizumab|Given IV
45945898|NCT04541017|Procedure|Positron Emission Tomography|Undergo PET/CT
45945899|NCT04541017|Procedure|Punch Biopsy|Undergo skin punch biopsy
45657618|NCT05612737|Procedure|Horizontal bone augmentation|"After taking six 9 mL tubes of blood from the patient, advanced (A-PRF) and liquid (S-PRF) PRFs were prepared. A-PRF was chopped, added to the xenogeneic bone substitute (THE Graft; Purgo Biologics Inc.), and then impregnated with the liquid S-PRF, which enabled the particulate bone substitute to become moldable and turned into a block (sticky bone). After local anesthesia, a midcrestal incision was made with one vertical releasing incision at the flap's mesial end. After full-thickness flap elevation, a periosteal releasing incision was made at the flap's apical portion. The alveolar bone was decorticalized on the buccal aspect with surgical burs. Next, the prepared bonded graft matrix was adapted to the ridge. Then, tenting screws (Pro-fix; Osteogenics) were placed to maintain the periosteum in an elevated and tension-free position The bone augmentation material was covered with A-PRF membranes. Finally, tension-free wound closure was performed."
45945900|NCT04521868|Drug|Sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
46075694|NCT00634686|Dietary Supplement|Placebo capsule|daily for 6 months
46075695|NCT00634686|Dietary Supplement|Calcium with vitamin D|1000 mg of calcium with 1000 IU vitamin D daily for 6 months
46075696|NCT05341674|Other|the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner.|the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner.
46075697|NCT05340192|Drug|Octreotide 1 MG/ML|100 mcg (1 ml) of Octreotide
46075698|NCT05107908|Behavioral|Active Implicit Priming|Approximately 10-minute behavioral intervention
46075699|NCT05107908|Behavioral|Control Implicit Priming|Approximately 10-minute behavioral intervention
45809663|NCT04861740|Other|Autism ALERT|Autism Access Link for Early Referral and Treatment [ALERT], the intervention proposed in this application, is a novel state-wide referral and case management platform that PCPs can activate to ensure that a child with suspected ASD receives all necessary ASD diagnosis and treatment resources in a single referral, radically simplifying a complex diagnostic and treatment process.
45809664|NCT04861740|Other|Screening Intervention|Autism screening intervention only.
45809665|NCT04227119|Device|Irrigated ablation catheter|After completion of ablation, the ablation catheter will be serially positioned in the cardiac chambers (either the left or right side of the heart). The stop cock will be turned to the pressure transducer and waveforms will be stored corresponding to each chamber.
45809666|NCT04227119|Device|Balloon tipped PA catheter|After removal of the irrigated ablation catheter, a 5F balloon tipped PA catheter which will be positioned under fluoroscopic guidance in each previously evaluated chamber and the chambers will be measured again.
45809667|NCT04861428|Other|IQOS|IQOS is a heat-not-burn tobacco product (consisting of an electronic heating device and Heatstick tobacco rods).
45809668|NCT04861428|Other|Smoking as Usual|Cigarette smoking
46075700|NCT05107908|Behavioral|Food Exposure Task|Approximately 10-30 minute behavioral intervention
46075701|NCT05340114|Device|CEREBO®|Near-infrared based point-of-care portable intracranial hematoma detector
46075702|NCT02780544|Behavioral|skin-to-skin contact|skin-to-skin contact with parent during eye examination.
46075703|NCT02780544|Device|incubator|staying in incubator during eye examination.
46075704|NCT02780544|Drug|Sucrose|oral sucrose before eye examination
46075705|NCT05341596|Procedure|repeat endotracheal intubation|repeat endotracheal intubation in the PACU after planned extubation of the initial endotracheal intubation for general anesthesia or combined general anesthesia other than that performed in the operating room
45453276|NCT00030901|Drug|L-selenomethionine|Randomization between active L-selenomethionine and placebo
45835832|NCT02866344|Procedure|Microwave ablation|Laparoscopic or robot-assisted laparoscopic microwave ablation of cancerous lesions with a 2.45-GHz microwave generator and a 1.8-mm-diameter transcutaneous antenna.
45835833|NCT02866344|Procedure|Hepatic resection|Laparoscopic or robot-assisted laparoscopic surgical resection of cancerous lesions.
45945901|NCT04521868|Dietary Supplement|placebo|Placebo is made of starch
45945902|NCT04514497|Procedure|Biopsy|Undergo tumor biopsy
45453277|NCT00030901|Drug|L-selenomethionine placebo|Randomization between active L-selenomethionine and placebo
45945903|NCT04514497|Procedure|Biospecimen Collection|Undergo collection of blood samples
45945904|NCT04514497|Procedure|Computed Tomography|Undergo CT
45945905|NCT04514497|Drug|Elimusertib|Given PO
45945906|NCT04514497|Drug|Irinotecan Hydrochloride|Given IV
45945907|NCT04514497|Procedure|Magnetic Resonance Imaging|Undergo MRI
45945908|NCT04514497|Drug|Topotecan Hydrochloride|Given IV
45945909|NCT04514484|Procedure|Biospecimen Collection|Undergo blood sample collection
45945910|NCT04514484|Drug|Cabozantinib S-malate|Given PO
45945911|NCT04514484|Procedure|Computed Tomography|Undergo CT
45945912|NCT04514484|Procedure|Magnetic Resonance Imaging|Undergo MRI
45945913|NCT04514484|Biological|Nivolumab|Given IV
45945914|NCT04501848|Procedure|adenotonsillectomy|adenotonsillectomy surgery
45945915|NCT04495127|Drug|Selumetinib|Selumetinib 25 mg/m2 BID
45945916|NCT04481204|Drug|Cisplatin|Given IV
45945917|NCT04481204|Drug|Fluorouracil|Given IV
45945918|NCT04481204|Drug|Gemcitabine|Given IV
45945919|NCT04481204|Drug|Irinotecan|Given IV
45945920|NCT04481204|Drug|Leucovorin|Given IV
45945921|NCT04481204|Drug|Nab-paclitaxel|Given IV
45945922|NCT04481204|Drug|Oxaliplatin|Given IV
45945923|NCT04481204|Radiation|Radiation Therapy|Undergo RT
45945924|NCT04475536|Device|TANSEI stent|stenting with the TANSEI sirolimus-eluting stent
45945925|NCT04470453|Biological|Blood sample|Blood samples will be collected for measuring PG-MTX blood concentration.
45945926|NCT04470453|Diagnostic Test|CRQ|Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.
45945927|NCT04468932|Device|Repetitive transcranial magnetic stimulation (rTMS)|"Aim 1: To determine the clinical effects of rTMS targeting the cerebellum on postural instability in PSP. The hypothesis to be tested is that TMS augmentation of cerebellar inhibition will improve cerebellum-dependent balance symptoms of PSP for a period of time sufficient to improve rehabilitation outcomes. The investigators will measure a battery of objective posturography metrics and other measures of motor control, including sway and center of pressure changes to backward tilt and forward translation.~Aim 2: We will use functional near infrared spectroscopy (fNIRS) to examine changes in motor and premotor cortical activity after cerebellar rTMS. The hypothesis to be tested is that premotor and motor cortical activity will decrease after cerebellar rTMS compared to sham TMS, reflecting improved cerebellar inhibition of the motor cortex after the intervention."
45945928|NCT04446832|Other|Vaccine immunogenicity|Evaluation of the vaccine immunogenicity by standard approved serological tests
45945929|NCT04445155|Behavioral|Modified DECIDE Parent and Provider Intervention|The parent component will include up to three 60 minutes sessions. Session 1 (Decisions and Agency) is designed to increase awareness of their role in clinical interactions and encourage participation and decision making in care. Session 2 (the Who, How, and Why of Decisions) teach skills for understanding treatment decisions in terms of roles, processes, and reasons involved. Session 3 (Self-efficacy and Consolidation) encourages parents to ask questions about their adolescents' behavioral health and health care and treatment options. The provider component is designed to improve provider communication in three key areas: 1) perspective taking to understand circumstances and perceptions; 2) attributional errors or attributing negative parent behaviors to character traits; and 3) receptivity to parent participation and collaboration.
45945930|NCT04442022|Drug|Selinexor (combination therapy)|Dose: 40 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
45945931|NCT04442022|Drug|Selinexor (combination therapy)|Dose: 60 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
46075706|NCT04038463|Behavioral|EFP|This intervention will take place on day 4 of the participants' menstrual cycle. This will correspond to the mid-point of the early follicular phase (EFP).
45453278|NCT03950869|Behavioral|Positive Expectation Manipulation|Participants are watching a video tape of a trauma expert who provides selective information on the development of intrusive memories. This video tape aims to increase positive expectations.
45945932|NCT04442022|Drug|Selinexor (combination therapy)|Dose: Selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
46075707|NCT04038463|Behavioral|LFP|The intervention will take place on day 8 of the participants' menstrual cycle. This will correspond to the mid-point of the late follicular phase (LFP).
45657619|NCT04680715|Radiation|Per-Operative Radiotherapy technique by Papillon +TM|20Gy Per-Operative Radiotherapy technique by Papillon +TM, on localized breast cancer
46075708|NCT04038463|Behavioral|ELP|The intervention will take place on day 18 of the participants' menstrual cycle. This will correspond to the mid-point of the early luteal phase (ELP).
45453279|NCT03950869|Behavioral|Negative Expectation Manipulation|Participants are watching a video tape of a trauma expert who provides selective information on the development of intrusive memories. This video tape aims to increase negative expectations.
45453280|NCT01104259|Drug|veliparib|Given PO
45453281|NCT01104259|Drug|cisplatin|Given IV
45453282|NCT01104259|Drug|vinorelbine tartrate|Given IV
45809669|NCT03651479|Other|real boxing training|In the real boxing (RB) group in addition to the NDT program, real boxing training will be given. Accordingly, the physiotherapist and the patient will wear boxing gloves and the patients will punch the physiotherapist's glove with a pre-specified treatment protocol. Resistance and frequencies between levels will be increased by the physiotherapist as the sessions progress. The RB group will have 30 minutes of real boxing training for 3 sessions per week for 8 weeks.
45809670|NCT03651479|Other|virtual boxing training|In the virtual boxing (VB) group, in addition to the NDT program, virtual boxing training will be given by using Kinect Xbox Boxing. For the VB group, virtual boxing training will be held for 3 weeks 30 minutes a week for 8 weeks.
45809671|NCT05334108|Drug|Ecopipam|ecopipam HCl ~2mg/kg/day
45809672|NCT05334108|Combination Product|Cohort 1 Probe Substrate Cocktail|dextromethorphan, caffeine, omeprazole, and midazolam
45453283|NCT01104259|Other|laboratory biomarker analysis|Correlative studies
45453284|NCT01104259|Other|pharmacological study|Correlative studies
45453285|NCT01104337|Drug|paracetamol|Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets twice a day along with two matching placebo tablets once daily
45657620|NCT04608721|Other|Postpartum Anxiety|Postpartum anxiety will be assessed at 1-3 days (T1), 1(T2), 3 (T3), 6 (T4) and 12 months (T5) postpartum by using the State-Trait Anxiety Inventory (STAI) with a score ≥40 serving as a positive screen.
45809673|NCT05334108|Drug|Cohort 2 Probe Substrate|bupropion
45809674|NCT05334108|Combination Product|Cohort 3 Probe Substrate Cocktail|dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam
45835834|NCT04773132|Other|Low Protein|Low protein/protein-free diet for 3 days (Day 1, 2 and Day 3) in order to deplete the label protein pool. The diet provided will meet the daily energy requirements of all the subjects.
46075709|NCT04038463|Behavioral|LLP|The intervention will take place on day 25 of the participants' menstrual cycle. This will correspond to the mid-point of the late luteal phase (LLP).
46075710|NCT03955861|Biological|adalimumab|Subcutaneous injection
46075711|NCT03955861|Biological|Certolizumab|Subcutaneous injection
46075712|NCT03955861|Biological|Etanercept|Subcutaneous injection
46075713|NCT03955861|Biological|Golimumab|Subcutaneous injection
46075714|NCT03955861|Biological|Secukinumab|Subcutaneous injection
46075715|NCT04468243|Other|Nurse-led diabetes care|Nurse-led brief diabetes education, instructions on glucometer and Metformin use, patients receive prescriptions for Metformin and blood glucose testing kit
46075716|NCT05014698|Genetic|WGS|Whole Genome sequencing
46075717|NCT00881179|Drug|Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)|
45657621|NCT04426357|Drug|JNJ-64417184|Participants will receive single oral (as film coated tablet) dose of JNJ-64417184 on Day 1.
45835835|NCT01565382|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose (intervention for Study A05 participants, source of scans for this study)
46075718|NCT00881179|Drug|Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)|
45809675|NCT04342832|Procedure|Cryoballoon ablation|If a patient is randomized to early invasive treatment, the ablation is performed within 3 months by an experienced cardiac electrophysiologist using CE-certified equipment. Via the femoral vein a guiding catheter is advanced through the inferior vena cava to the right atrium and into the left atrium via transseptal puncture. Then, the cryoballoon is advanced, inflated, and placed against one of the four PVs. PV occlusion is assessed by selective contrast injection. When adequate PV antral seal is confirmed, ablation of the tissue in contact with the balloon is performed using pressurized liquid nitrous oxide. The cold inflated balloon thus creates circular lesions around the PV. The balloon and tissue interface are then allowed to reach normal temperatures. Depending on local practice, the freeze-thaw cycle may be repeated twice. Electrical isolation is assessed and when it is confirmed, the next PV is treated in the same way. The procedure ends when all PV's are isolated.
45945933|NCT04442022|Drug|Placebo matching for Selinexor (combination therapy)|Dose: Placebo matching for selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
45945934|NCT04442022|Drug|Rituximab (combination therapy)|Dose: 375 milligram per meter square (mg/m^2) on Day 1; Route of administration: intravenous (IV)
45945935|NCT04442022|Drug|Rituximab (combination therapy)|Dose: 375 mg/m^2 on Day 1; Route of administration: IV
45945936|NCT04442022|Drug|Gemcitabine (combination therapy)|Dose: 1000 mg/m^2 on Days 1 and 8; Route of administration: IV
45945937|NCT04442022|Drug|Dexamethasone (combination therapy)|Dose: 40 mg (20 mg if patient is more than 70 years old) on Days 1, 2, 3, and 4; Route of administration: oral or IV
46075719|NCT02781246|Drug|perineural dexmedetomidine|"Children scheduled for arm and forearm surgery underwent supraclavicle brachial plexus blocks with ropivacaine and dexmedetomidine guided by ultrasound visualisation were randomly assigned five groups: Group A (perineural ropivacaine), Group B (ropivacaine plus 0.5 mcg/kg dexmedetomidine), Group C (ropivacaine plus 1 mcg/kg dexmedetomidine), Group D (ropivacaine plus 1.5mcg/kg dexmedetomidine) and Group E (ropivacaine plus 2 mcg/kg dexmedetomidine). In each group, children received a certain concentration of ropivacaine which adjusted by the Dixon up-and-down method for supraclavicle brachial plexus. The first child received 0.2% ropivacaine , and the concentration of ropivacaine varied by 0.1% according to the up-and-down method. The primary endpoint was the minimum local anesthetic concentration (MLAC)."
46075720|NCT00613951|Drug|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
45657622|NCT04603417|Diagnostic Test|Electroencephalography (EEG)/Magnetoencephalography (MEG)/MRI|This cross-sectional study will present the participants with an instrumental pain avoidance learning task, while we record continuous Magnetoencephalography (MEG) brain signals, and other autonomic measurements. All patients will complete behavioral, neuropsychological and pain assessments to rate their current pain, disability, fear, anxiety, and depression using standardized scales.
46075721|NCT00613951|Drug|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
46075722|NCT00613951|Drug|biphasic insulin aspart|Treat-to-target dose titration scheme, injection s.c., twice daily
45657623|NCT05612659|Procedure|Transcranial Electrical stimulation|Noninvasive electrical stimulation of lateral frontal cortex.
45809676|NCT04419792|Other|Assessment of physical performance variables|"Other:~Assessment of physical performance indices using the following outcome measures:~Cardiopulmonary fitness: YMCA submaximal bike test Upper Body: ACSM press up test, Dynamometry Lower body: Wall squat test, Countermovement jump test"
45945938|NCT04442022|Drug|Cisplatin (combination therapy)|Dose: 75 mg/m^2 on Day 1; Route of administration: IV
45945939|NCT04442022|Drug|Selinexor (continuous therapy)|Dose: 60 mg QW for each 28-day cycle until PD; Route of administration: oral
45453286|NCT01104337|Drug|paracetamol|Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets three times a day
45657624|NCT05612659|Procedure|Transcutaneous direct current stimulation|Noninvasive electrical stimulation of the T10 spinal column.
45657625|NCT05421481|Other|home visit, health education, mobile application, group walk, message|"Home visit: Elderly individuals will be visited once at home. During the home visit, training will be given on the slide about physical activity. A brochure will be provided for general health promotion awareness. Counseling will also be provided during the home visit process.~Google Fit Application: During the home visit, the application will be downloaded to the phone of the elderly, and a document will be given about the use of the application after the usage is explained. The researcher will support those who have problems with the application in the following weeks.~Group walking: The walk, which will be done once, will be done in a light paced manner, and the purpose of the walk is to see the number of steps in the mobile application and to increase their motivation with the group.~Message: Message content For your health, you should exercise at least 30 minutes a week for a total of 150 minutes. will be."
45945940|NCT04442022|Drug|Placebo matching for Selinexor (continuous therapy)|Dose: Placebo matching for 60 mg selinexor QW for each 28-day cycle until PD; Route of administration: oral
45945941|NCT04440735|Biological|DSP107|DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
45945942|NCT04440735|Biological|Atezolizumab|Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1
45945943|NCT04439409|Device|Holter electrocardiogram|Holter electrocardiogram will be carried during 7 days to measure heart's electrical activity continuously.
45453287|NCT01104337|Drug|Placebo|Treatment consisted of two matching placebo tablets three times a day.
45453288|NCT01100359|Drug|carboplatin|
45453289|NCT01100359|Drug|liposome-encapsulated doxorubicin citrate|
45453290|NCT01100359|Other|laboratory biomarker analysis|
45945944|NCT04431648|Drug|DEFINITY PERFLUTREN INJECTABLE SUSPENSION|MRI-guided ultrasound-stimulated microbubble-treatment
45945945|NCT04419857|Dietary Supplement|High-calorie formula|Infant randomly assigned to high-calorie formula for 14 days
45945946|NCT04419493|Drug|Alteplase (from modified manufacturing process)|Alteplase, TPA-05
45945947|NCT04419493|Drug|Alteplase (from current manufacturing process)|Alteplase, TPA-02
45945948|NCT04419493|Drug|Heparin-Natrium-5000-ratiopharm (unfractionated heparin)|Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
45945949|NCT04405401|Radiation|SABR|SABR to all oligoprogressive lesions + continuation of current systemic therapy
45945950|NCT04405401|Other|Standard of care|Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.
45945951|NCT04404803|Other|questionnaire|Patients will be asked to complete a questionnaire about the reasons why they agree / decline to take part in research.
45809677|NCT03984656|Drug|lidocaine treatment|The index marks the upper edge of the lower rib of the selected intercostal space to avoid the vasculonervous bundle sitting at the lower part of the overlying rib.Non-targeted subcutaneous infiltration is performed in the drainage area with 5 to 10 mL of Lidocaine 20 mg / mL non-adrenaline, plane by plane, with regular aspiration until air or fluid confirming effusion.
45945952|NCT04401748|Drug|Venetoclax|Tablet: Oral
45945953|NCT04401748|Drug|Azacitidine|Subcutaneous (SC) or Intravenous (IV) injection
45945954|NCT04401748|Drug|Placebo|Tablet; Oral
45945955|NCT04399408|Device|Obstetrics Ultrasound (non invasive)|Participants are instructed to preform 1-3 short (3 minuets) ultrasound scans a day according to pre-defined steps.
46002207|NCT04342494|Behavioral|Enhanced Feedback + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback."
45809678|NCT03984656|Drug|serratus plane block treatment|"The Serratus plane block is located at the level of the 5th rib, on the midaxillary line, on the drainage side, ultrasound guided. The block is performed with a 70 mm needle in the ultrasound plane, and the needle is directed postero-inferior, after visualization of the structures from the surface to the depth: dorsal muscle~anterior serratus large muscle (serratus anterior)~intercostal muscle~4th and 5th ribs~pleura A single injection of 30 mL of Ropivacaine 4.75 mg / mL is performed around the Serratus muscle.~An intravenous injection of 8 mg of Dexamethasone is added to prolong the duration of the block."
45809679|NCT05305872|Drug|Gandouling|The experimental group was given gandouling tablet + zinc gluconate simulant; The course of treatment was 24 weeks.
46002208|NCT04342494|Device|Headspace app + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Headspace is an app designed to train the user in mindfulness practices."
46002209|NCT04342494|Device|Headspace app + Enhanced Feedback + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Headspace is an app designed to train the user in mindfulness practices."
46002210|NCT04342494|Device|SilverCloud + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Silvercloud is an app designed to deliver cognitive behavioral therapy."
46002553|NCT00560001|Behavioral|MD.2 Medication Dispenser|For those subjects receiving an MD.2 Medication Dispenser, the machine organizes medications and provides verbal and auditory explicit reminders for individuals to take their medications. At the scheduled time, the patient gets a series of reminders. The patient is then expected to push a single button to dispense a pre-filled medication cup. An automatic record is kept of the subject's medication adherence. Interviewer-administered surveys of the Geriatric Depression Scale, SF-12 Health Status Inventory, self-reported medication compliance and recent hospitalizations and emergency room visits will be given. Caregivers will complete the Caregiver Burden Interview.
46075723|NCT00613951|Drug|metformin|Tablets, 1500-2000 mg/daily
46075724|NCT05321238|Other|High agency and immediate threat|Participants were asked to make several decisions for the main character in the interactive digital narrative that related to drinking / turning down alcoholic drinks.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from acute alcohol poisoning after ingesting too much alcohol in a short period of time.
45657626|NCT04580563|Drug|OctaplasLG®|Patient receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
45657627|NCT04580563|Drug|0.9% NaCl|Patient receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
45809680|NCT03653351|Device|Active Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a form of neurostimulation (also known as neuromodulation) where very low levels of direct electrical current are delivered to specifically targeted areas of the brain, in order to increase neuroplasticity. The direct current in active tDCS will be of 2 mA (current density = 0.57 A/m2) and will be applied for approximately 30 minutes per day during meditative practices of the MBSR protocol.
45453291|NCT01100359|Procedure|quality-of-life assessment|
45453292|NCT00003199|Drug|tamoxifen citrate|Given orally
46075725|NCT05321238|Other|High agency and distant threat|Participants were asked to make several decisions for the main character in the interactive digital narrative that related to drinking / turning down alcoholic drinks.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from multiple organ failure after ingesting too much alcohol over a long period of time.
46075726|NCT05321238|Other|Low agency and immediate threat|Participants were asked to read a narrative in which the main character turns down alcoholic drinks at a party. The participants can not influence the decisions of the main character and only consume the narrative passively.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from acute alcohol poisoning after ingesting too much alcohol in a short period of time.
46075727|NCT05321238|Other|Low agency and distant threat|Participants were asked to read a narrative in which the main character turns down alcoholic drinks at a party. The participants can not influence the decisions of the main character and only consume the narrative passively.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from multiple organ failure after ingesting too much alcohol over a long period of time.
46075728|NCT00881257|Device|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
46075729|NCT02781402|Procedure|4 weeks of Aerobic Training|The duration of aerobic training was 40 minutes for each session and 3 days per week with the intensity of 75-80% of their maximum heart rate. The participants were needed to walk or jog on treadmill during the first 10 minutes at the intensity of 50-60% of maximal heart rate (HR max). The aerobic training was followed by 4 x 4 minutes intervals at 75-80% HR max. The participants were given 3 minutes active breaks in between the intervals in which they can either walk or jog at 50-60% of maximal heart rate.
45657628|NCT04481035|Drug|N-acetylcysteine (NAC)|The study design is essentially a cross-sectional survey and then longitudinal evaluation of cognition and behavior, motor function, cortical function, and metabolomics profiles in NF1 before and after 8 weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC) or placebo. This is a cross-over double-blind placebo controlled study. Participants in the experimental phase/arm will receive 70 mg/kg/dose (max dose 900 mg) three times per day of NAC for eight (8) weeks.
45657629|NCT04481035|Other|Placebo|The study design is essentially a cross-sectional survey and then longitudinal evaluation of cognition and behavior, motor function, cortical function, and metabolomics profiles in NF1 before and after 8 weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC) or placebo. This is a cross-over double-blind placebo controlled study. Participants in the placebo phase/arm will receive placebo (non-drug) three times per day for eight (8) weeks.
45657630|NCT04471207|Device|Therapist Guided Prolonged Exposure with BioWare Device|Experimental: Intelligent Biometrics - Prolonged Exposure (therapist guided). In the therapist guided group, Study Therapists will use actionable data during IVEs (e.g., HR, GSR, SUDS) to modify the assignments in real-time.
45657631|NCT04471207|Device|Record Only Prolonged Exposure with BioWare Device|In the record-only group, passive data collection will be utilized to collect and store biometric and behavioral data for future offline analyses to investigate predictors of outcome.
45809681|NCT03653351|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a form of neurostimulation (also known as neuromodulation) where very low levels of direct electrical current are delivered to specifically targeted areas of the brain, in order to increase neuroplasticity. The direct current in active tDCS will be of 2 milliampere (mA) (current density = 0.57 A/m2), however, the device is pre-programmed to turn off after 1 minute of active stimulation (and then turn back on briefly at the end of the 30 minutes).
45809682|NCT03966248|Other|Chinese Tuina therapy|"The doctor presses the affected lower limb from the anterior superior iliac spine to the ankle;~The doctor gives the pressure on the Biguan(ST31), Futu(ST32), Heding(EX-LE2), Neixiyan(EX-LE4), Waixiyan(Dubi, ST35), Zusanli(ST36) and Sanyinjiao(SP6) of the affected lower limb;~Massage the spleen and stomach meridians of the affected lower extremes;~Roll the soft tissues around the affected knee;~Relax the gastrocnalis muscle~The doctor gives the pressure on the Xuehai(SP10), Liangqiu(ST34), Neixifeng(medial patellofemoral ligament), Waixifeng(lateral patellofemoral ligament), Neixiyan(EX-LE4) and Waixiyan(Dubi, ST35) at the same time;~Push the patella and do the passive movement of the affected knee;~Strength training of the affected knee.~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
45809683|NCT03966248|Other|Physical Manual therapy|"Manual therapy: Stretching the knee joint, stretching the knee joint with valgus or abduction, stretching the knee joint with varus or adduction is suitable for patients with knee flexion and extension difficulty.Patellar manipulation by bending the knee 5-10 degrees downward is suitable for patients with patellar sliding difficulty.The lower end of the muscle length manipulation is suitable for patients with muscle tension and soft tissue tension.Soft tissue loosening is performed in the suprapatellar and peripatellar regions, medial and lateral capsule joints, and popliteal fossa.~Activity training: Mainly about the knee joint flexion and extension movement training.~Strength training: Mainly about quadriceps muscle resistance exercises~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
45809684|NCT05299944|Drug|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in opioid consumption, opioid craving, pain, peripheral markers of inflammation, and anxiety, as well as changes in sleep, AEA, and cognition.
45657632|NCT04427137|Device|MagPro X100 Stimulator, B70 Fluid-Cooled Coil|Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single LFR treatment, with 360 pulses of LFR delivered in one continuous train of 6 minutes at 1Hz at 120% of the patient's resting motor threshold.
45809685|NCT05299944|Drug|Placebo|Placebo arm
45809686|NCT03515681|Behavioral|Text messages|Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
45809687|NCT04329494|Procedure|Biopsy|Undergo biopsy
45809688|NCT04329494|Drug|Cisplatin|Given via PIPAC
45809689|NCT04329494|Drug|Doxorubicin|Given via PIPAC
45809690|NCT04329494|Drug|Fluorouracil|Given IV
45809691|NCT04329494|Device|Intraperitoneal Chemotherapy|Undergo PIPAC
45809692|NCT04329494|Drug|Irinotecan|Given IV
45809693|NCT04329494|Drug|Leucovorin|Given IV
46075730|NCT00881413|Drug|Esomeprazole|Intravenous esomeprazole (Nexium®, AstraZeneca, Sodertalje, Sweden) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral esomeprazole 40 mg (Nexium®, AstraZeneca, Sodertalje, Sweden) for 2 months
46075731|NCT00881413|Drug|Pantoprazole|After successful endoscopy, intravenous pantoprazole (Pantoloc®, Nycomed GMBH, Konstanz, Germany) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral pantoprazole 40 mg (Pantoloc®, Nycomed GMBH, Oranienburg, Germany) for 2 months
45657633|NCT02404311|Biological|ALVAC-HIV|a lyophilized vaccine for injection at a viral titer ≥ 1 × 10E6 cell culture infectious dose (CCID)50 and < 1 × 10E8 CCID50 (nominal dose of 10E7 CCID50) and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose.
45657634|NCT02404311|Biological|Bivalent Subtype C gp120/MF59®|2 recombinant monomeric proteins, each at a dose of 100 mcg, mixed with MF59® adjuvant (an oil-in-water emulsion) delivered as a 0.5 mL IM injection
45809694|NCT04329494|Drug|Mitomycin|Given via PIPAC
45809695|NCT04329494|Drug|Oxaliplatin|Given via PIPAC
46075732|NCT04229394|Drug|2ccPA|"Four dose cohorts (50 μg, 200 μg, 800 μg, and 2,400 μg) are planned in this study sequentially.~study group: one dose intra-articular on day1"
45809696|NCT04329494|Other|Quality-of-Life Assessment|Ancillary studies
45657635|NCT02404311|Biological|ALVAC-HIV (vCP2438) Placebo|a sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for injection as a single dose IM
45657636|NCT02404311|Biological|Bivalent gp120/MF59® Placebo|Sodium chloride for injection, 0,9% delivered as a 0.5 mL IM injection
45809697|NCT04329494|Other|Questionnaire Administration|Ancillary studies
46075733|NCT04229394|Drug|placebo|"A total of 8 subjects will be recruited and randomized in each dose cohort with a 3:1 ratio (6 subjects in the 2ccPA treatment arm and 2 subjects in the placebo arm).~control group: one dose intra-articular on day 1"
45809698|NCT03655301|Drug|Copanlisib (Aliqopa, BAY80-6946)|"The copanlisib dose for this study is the standard dose recently approved and also used in Phase 1, 2 and 3 studies across the copanlisib development program: 60 mg i.v. infusion administered intermittently on Days 1, 8 and 15 of a 28-day cycle.~In this study subjects will receive a single i.v. dose of 60 mg copanlisib on day 8."
45809699|NCT03655301|Drug|Metformin|Single dose of 1000 mg is administered orally.
45809700|NCT04318106|Device|Precision tinted spectacle lenses|Precision tinted spectacles lenses (Cerium Technologies TM)
45657637|NCT03033043|Device|Relay Pro Stent-Graft|Endovascular treatment of an aortic dissection
45657638|NCT03032107|Drug|T-DM1|-T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle
46075734|NCT00881491|Drug|Double Antibiotic Paste|ciprofloxacin and metronidazole powder mixed at a 1:1 ratio used as a intracanal medicament for disinfection.
46075735|NCT00881491|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection.
46075736|NCT00881491|Drug|Mineral Trioxide Aggregate|standard material providing an apical barrier
46075737|NCT00805467|Drug|Fostamatinib Disodium (R935788)|50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD
45453293|NCT00003199|Drug|busulfan|Given orally
45657639|NCT03032107|Drug|Pembrolizumab|-Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle
45657640|NCT02841163|Drug|Herbal medicine|Herbal medicine was administered 2-3 times daily in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
45657641|NCT02841163|Procedure|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly proximal acupuncture points and Ah-shi points.
45809701|NCT04342988|Drug|Cequa|The effect of Cequa treatment on the accuracy of pre-operative biometry and on corneal higher-order aberrations (HOAs) in cataract patients who have signs of dry eye disease.
45809702|NCT05279430|Behavioral|Inspiratory muscle training|Patients allocated to the IMT arm will be instructed to train at home twice daily, for 20 minutes each session, using a Threshold inspiratory muscle trainer (Respironics Inc., Parsippany, NJ). They will be instructed by a physiotherapist responsible for training intervention and educated to maintain diaphragmatic breathing during the training period. The subjects will start breathing at a resistance equal to 25% to 30% of their maximal inspiratory mouth pressure (MIP) for 1 week. The respiratory therapist will examine the patients at weekly intervals by checking the diary card and measuring the MIP each time. The resistance will be modified each session according to the 25% to 30% of their MIP measured.
45809703|NCT04304846|Other|Questionnaires and interviews|List of questionnaires: ASQ, PSI, PPQ, SDQ, GSA and AMMI score obtained from mother during two separated interviews for the mother and the child at 3 and 5 years old
45809704|NCT04861350|Other|motor imagery with action observation|Standing clamshell exercise with elastic band, sliding, and Romanian deadlift exercise will be instructed to the subjects with video, and they will practice each exercise for 3 times in physical to familiarize with the program. Then, the subjects will mentally simulate each exercise with video 10 times for a set, 3 sets totally. With 2 min interval between each sets, it will take approximately 8 minutes to finish each movement. It will also take 3 min for resting between each program.
45945956|NCT04395183|Drug|5-Hydroxytryptophan 100 MG|5-HTP 100mg PO BID
45945957|NCT04395183|Drug|Creatine monohydrate|Creatine monohydrate 5g PO qday
45945958|NCT04395183|Drug|placebo matched to 5-HTP|placebo matched to 5-HTP
45945959|NCT04395183|Drug|Placebo|Dextrose either as loose powder (matched to creatine) or encapsulated (matched to 5-HTP)
45945960|NCT04394975|Combination Product|Biological : Toripalimab Drug: Axitinib|Biological: Toripalimab, Intravenous infusion Drug: Axitinib, oral tablet
45945961|NCT04394975|Drug|sunitinib|Drug: Sunitinib, oral capsule
45945962|NCT04381910|Drug|LY01610( Irinotecan hydrochloride liposome injection )|LY01610 will be administered via intravenous infusion every 2 weeks on Day 1
45945963|NCT04380610|Diagnostic Test|iohexol GFR|We will perform mGFR in 400 SCA patients
45945964|NCT04369924|Behavioral|Measurement-Based Care|Both study conditions will receive measurement-based care, which is the systematic, ongoing administration of assessment measures to support clinical decision-making.
45809705|NCT04861350|Other|physical training|Standing clamshell exercise with elastic band, sliding, and Romanian deadlift exercise will be instructed to the subjects with video, and they will practice each exercise for 3 times in physical to familiarize with the program. Then, the subjects will physically perform each exercise with supervision of investigator 10 times for a set, 3 sets totally. With 2 min interval between each sets, it will take approximately 8 minutes to finish each movement. It will also take 3 min for resting between each program.
46075738|NCT02608281|Device|CONTRAST ENHANCED DUAL ENERGY (CEDEM)|The CEDEM application requires the intravenous injection of iodide contrast agents. For each projection view (CC, MLO) a low and a high energy x-ray image will be acquired after Iodine based contrast medium administration. Patient will undergo CE MRI procedure.
45453294|NCT00003199|Drug|thiotepa|Given IV
45453295|NCT00003199|Drug|melphalan|Given IV
45657642|NCT02841163|Procedure|Pharmacopuncture|Select herbal ingredients (Eucommia ulmoides cortex, Acanthopanax sessiliflorum cortex, Achyranthis bidentata radix, Saposhnikovia divaricata radix, Cibotium barometz rhizoma, Paeonia albiflora radix alba, Ostericum koreanum radix, Angelica pubescens radix, and Scolopendra subspinipes corpus (Paeonia albiflora twice the proportion of that of other ingredients)) were freeze dried into powder form after decoction, then diluted in water-for-injection and adjusted for acidity and pH. Pharmacopuncture was administered once daily at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
45453296|NCT00003199|Biological|aldesleukin|Given SC
45453297|NCT00003199|Biological|sargramostim|Given SC
45809706|NCT04861350|Other|combine physical training and motor imagery with action observation|Standing clamshell exercise with elastic band, sliding, and Romanian deadlift exercise will be instructed to the subjects with video, and they will practice each exercise for 3 times in physical to familiarize with the program. Then, each exercises will be mentally simulated with video for a set and physically performed with supervision of investigator for 2 sets, 10 times for each set and 3 sets totally. With 2 min interval between each sets, it will take approximately 8 minutes to finish each movement. It will also take 3 min for resting between each program.
45809707|NCT04291898|Device|AMPLATZER™ Septal Occluder.|Implantation of the AMPLATZER™ Septal Occluder in the ASD.
45657643|NCT02841163|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture was administered only after confirming a negative response to hypersensitivity skin tests. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens was injected at 4-5 acupoints proximal to the painful site at the physician's discretion. Each acupuncture point was injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
45657644|NCT02841163|Procedure|Chuna manipulation|Chuna is a Korean version of spinal manipulation that incorporates spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation was administered 3-5 times a week to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
45657645|NCT05388175|Device|Rigid catheter|Participants will be invited to positioning a rigid catheter in the manikin's trachea for surfactant aministration
45945965|NCT04360928|Device|Lake Effect Zero Degree Knee Splint|Specific type of splint which utilizes an inflatable air pocket on the posterior aspect of the leg to provide a combination of bracing and splinting in full extension in the immediate postoperative period.
45945966|NCT04360928|Device|Standard Hinge Knee Brace|Standard knee brace used postoperatively after ACL reconstruction.
45945967|NCT04359901|Biological|SARILUMAB|Single dose of 400 mg subcutaneous sarilumab
45809708|NCT04291898|Device|Occlutech Figulla Flex II®|Implantation of the Occlutech Figulla Flex II® in the ASD.
45945968|NCT04350957|Diagnostic Test|Low-dose Imaging|"We are comparing MRI image quality for diagnostic purposes. We hope to learn whether using a lesser dose (25%) of the FDA approved contrast agent, Gadavist®, is just as effective as a standard or full dose (100%) of the same contrast in a breast MRI.~This research is being done because breast MRI's have repeatedly been shown to represent the most reliable imaging method for breast cancer screening and diagnosis, regardless of personal risk for breast cancer and radiographic breast density. However, there are growing concerns about getting frequent breast MRI examinations due to the deposition of gadolinium, a metal ion that is found in all breast MRI contrast agents. The FDA states that this deposition and retention is not known to have any long term side effects on patient. However, the researchers at the University of Chicago Medicine would like to further investigate this using a lesser dose of contrast agent than the recommended dose for breast MRI examinations."
45945969|NCT04340843|Drug|Belinostat|Given IV
45945970|NCT04340843|Procedure|Biopsy|Undergo biopsy
46075739|NCT00958841|Drug|pasireotide LAR|Investigational drug pasireotide LAR was supplied in vials with 20 mg or 40 mg powder and 2 mL vehicle was supplied in ampoules for reconstitution.
45453298|NCT00003199|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell infusion
46075740|NCT02937116|Drug|IBI308|
45453299|NCT00003199|Radiation|radiation therapy|May undergo radiotherapy after completion of IL-2/GM-CSF
46075741|NCT02937116|Drug|IBI308\Cisplatinum\Pemetrexed|
46075742|NCT02937116|Drug|IBI308\cisplatin\gemcitabine|
46075743|NCT02937116|Drug|IBI308\oxaliplatin\capecitabine|
46075744|NCT02937116|Drug|IBI308\etoposide\cisplatin|
46075745|NCT02937116|Drug|IBI308\irinotecan\5-FU|
45453300|NCT01327261|Drug|Levodopa + benserazide|Single oral dose of either Experimental or Active Comparator. Levodopa 200 mg/benserazide 50 mg tablets,with 200 mL of water.
45458084|NCT01140139|Biological|HIV DNA Vaccine|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
45458085|NCT04667377|Drug|BI 456906|BI 456906
45809709|NCT04291898|Device|GORE® CARDIOFORM ASD Occluder|Implantation of the GORE® CARDIOFORM ASD Occluder or GORE® CARDIOFORM Septal Occluder in the ASD.
45657646|NCT05388175|Device|Soft catheter|Participants will be invited to positioning a rigid catheter in the manikin's trachea for surfactant aministration
46075746|NCT03927105|Drug|Nivolumab|Nivolumab is a human monoclonal antibody (HuMAb; immunoglobulin G4 [IgG4]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.1 Binding of PD-1 to its ligands, programmed death-ligands 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T-cell responses to both foreign antigens as well as self-antigens. Nivolumab will be delivered intravenously at a fixed dose of 240 mg on day 1 of 14 day cycles.
45657647|NCT05700955|Drug|Pembrolizumab and Temozolomide|Characterize the safety and immunologic/genomic/metabolomic effects of neoadjuvant Pembrolizumab and Temozolomide in recurrent glioblastoma.
45809710|NCT05634018|Diagnostic Test|aneurysmectomy with sampling of a segment of the aneurysm wall|"Patients with aneurysms of the abdominal aorta undergo an ultrasound examination of the abdominal aorta to assess the elastic properties of the aortic wall. The accessible wall of the abdominal aortic aneurysm is taken intraoperatively.~In in vitro studies, the strength properties of the aneurysm wall are measured during uniaxial tension on a tensile testing machine, which makes it possible to evaluate the elastic properties of the test sample.~The assessment of the boundaries of the linearity of the surface under study, as well as the yield strength of the vascular wall and thrombotic masses, is evaluated under shear stresses using a rheometer. To correlate the mechanical properties with the structural composition of the aneurysm tissue, spectral analysis of the studied tissues by laser-induced fluorescence and histological examination with staining of the obtained sections for the presence of elastic fibers, fibrous tissues and calcification will be used."
45458086|NCT04667377|Drug|Placebo|Placebo
45657648|NCT01650519|Drug|IV ibuprofen|800 mg intravenous ibuprofen administered intravenously over 10 minutes.
45809711|NCT04740476|Drug|STK-001|STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection.
45809712|NCT05630586|Drug|Semaglutide|Subcutaneous Semaglutide, 0.5 mg weekly for 4 weeks. First dose given at inclusion.
45809713|NCT05630586|Other|Standard care|Treatment according to Danish national clinical guidelines on stroke treatment, including reperfusion therapy if eligible.
45945971|NCT04340843|Procedure|Biospecimen Collection|Undergo collection of blood
45945972|NCT04340843|Procedure|Computed Tomography|Undergo CT
45945973|NCT04340843|Drug|Decitabine and Cedazuridine|Given PO
45945974|NCT04340843|Drug|Guadecitabine|Given SC
45945975|NCT04340843|Procedure|Magnetic Resonance Imaging|Undergo MRI
46075747|NCT03927105|Drug|cabiralizumab|Cabiralizumab is a recombinant, humanized Immunoglobulin G4 (IgG4) monoclonal antibody that binds to human colony stimulating factor 1 receptor (CSF1R; c-fms). Cabiralizumab will be delivered intravenously at a dosage of 4 mg/kg on day 1 of 14 day cycles.
46075748|NCT02781168|Device|use of earmuffs|The earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels. Are devices that have oval and anatomical shape that allow proper positioning of the ears of newborns. They are made with a soft foam and has hydrogel adhesive on the outer edges for attachment to the skin.
46075749|NCT00613327|Drug|Oxybutynin chloride OROS|Participants will receive oxybutynin chloride OROS tablet at starting dose of 10 milligram (mg) orally once daily. The dose will be adjusted by 10 mg every 2 weeks up to first 6 weeks, based on the criteria for evaluation of optimal dose. The optimal dose obtained in first 6 weeks will be continued up to Week 12. Maximum allowed dose will be 30 mg per day.
46075750|NCT04273997|Drug|Metronidazole 10% ointment|Metronidazole 10% ointment
46075751|NCT04273997|Drug|Placebo ointment|Placebo ointment
45458087|NCT02306278|Drug|gabapentin|gabapentin capsules 0.3g
45657649|NCT01650519|Drug|IV ketorolac|30 mg ketorolac for patients < 65 years of age (15 mg ketorolac for patients > 65 years of age) administered intravenously over no less than 15 seconds
45657650|NCT04335487|Behavioral|PSP PTSD Course|A tailored ICBT intervention designed to treat symptoms of PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
45809714|NCT04870866|Drug|Nicotinamide ribonucleoside|Two year intervention
45945976|NCT04337723|Behavioral|ABI/WIFI scoring|The initial ABI training workshop will be coordinated by the non-physician clinic staff champion, and all non-provider clinic staff will be asked to participate. The PI and a research assistant will conduct a 1.5-hour telemedicine training session instructing clinical staff in ABI measurement and WIfI and scoring, using the clinical scoring sheet. Following didactic teaching, participants will perform ABI tests under the guidance of the PI/research assistant and with the support of other participants. During each part of the workshop, specific attention will be directed to pitfalls and technical errors of the test. A pre-post assessment will be used to ensure comprehension of key concepts and performance of the ABI and WIfI tools.
45945977|NCT04334876|Diagnostic Test|SARS-CoV-2 IgG Antibody Testing Kit|A, finger prick, at home test for SARS-CoV-2 IgG Antibodies.
45458088|NCT02306278|Drug|vitamin capsules|vitamin B
45458089|NCT01140841|Drug|Fipamezole ODT|Subjects take three daily doses of Fipamezole ODT, with each dose escalating from 30 to 60, 90, 120, 150 and up to 180 mg over 8 weeks.
45945978|NCT04315389|Device|(1) Mobile Assistant Balance Robot|MRBA: Robotic wheelchair with a planar compliant robotic arm to provide balance assistance to the user at the pelvis and hip, during sit to stand, standing and walking tasks in indoor and controlled outdoor level environments.
45945979|NCT04315389|Device|(2) Transfer Assistive Cobot|TAC: Intelligent powered wheelchair equipped with a robotic arm that is capable of lifting payload up to 110kg, and perform a totally dependent transfer in a semi- autonomous fashion
45458090|NCT01140841|Drug|Placebo|1 to 2 tablets three times per day to be taken according to the same schedule as the active study drug.
45458091|NCT02313610|Drug|Qinbudan|Contains three kinds of traditional Chinese medicine radix scutellariae, radix stemona, liquorice
45809715|NCT04262102|Behavioral|SD_SF|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will be spoon-fed during complementary feeding.
45945980|NCT04310735|Behavioral|Verbal smoking expectancy manipulation|Instructions regarding whether or not participants will have an opportunity to smoke during the experimental session.
45809716|NCT04262102|Behavioral|SD_BLW|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will follow a baby-led weaning approach for complementary feeding.
45809717|NCT04262102|Behavioral|HFV_SF|Women will follow personalized diet, high in fruits and vegetables. And their children will be spoon-fed during complementary feeding.
45809718|NCT04262102|Behavioral|HFV_BLW|Women will follow personalized diet, high in fruits and vegetables. And their children will follow a baby-led weaning approach for complementary feeding.
45809719|NCT05620758|Other|Nd YAG laser|patients from those diagnosed with TMD will receive Nd YAG laser 1064 nm
45809720|NCT05620758|Other|diode laser (980 nm)|patients from those diagnosed with TMD will receive a diode laser (980 nm)
45809721|NCT05620758|Other|diode laser (940 nm)|patients from those diagnosed with TMD will receive a diode laser (940 nm)
46075752|NCT05339802|Combination Product|9MW1411 injection 1 combined with Linezolid|After randomization, 9MW1411 injection, single dose, intravenous infusion, linezolid: 600mg, given intravenously or orally every 12 hours, for a total course of treatment not exceeding 14 days.
45657651|NCT04335487|Behavioral|PSP Wellbeing Course|A tailored ICBT intervention designed to treat symptoms of depression, anxiety, or PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
45809722|NCT05620758|Other|diode laser (660 nm)|patients from those diagnosed with TMD will receive a diode laser (660 nm)
45657652|NCT01650285|Drug|Cabazitaxel|"Dose Level Day 1, 22, 43~5.0 mg/m2~10.0 mg/m2~15.0 mg/m2~20.0 mg/m2"
45809723|NCT05620758|Other|diode laser (635 nm)|patients from those diagnosed with TMD will receive a diode laser (635 nm)
45809724|NCT02976506|Behavioral|Unsupervised exercise program|Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to < 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
45945981|NCT04304495|Other|Fall Prevention|The intervention arm participants will receive a physical therapy and pharmacy consults as well as Apple Watch training and an Apple Watch device to test memory and mobility during the ED visit and during our home visits.
45945982|NCT04302870|Drug|Memantine Hydrochloride Oral Solution|Memantine hydrocholoride taken once daily
45945983|NCT04302870|Drug|Trazodone Hydrochloride oral solution|Trazodone Hydrochloride taken once daily
45458092|NCT02313610|Drug|Qinbudan Placebo|Qinbudan Placebo was the same as therapeutic drug in package,shape,size.
45458093|NCT01143103|Device|Cough assist (Philips,respironics)|
45458094|NCT01143103|Other|Usual respiratory therapy|
45657653|NCT05612503|Other|Traditional physical therapy program|resistance-based diaphragm strengthening exercises, breathing exercises to increase costal or chest breathing, and breathing exercises to relax the breathing muscles.
45657654|NCT05612503|Other|Virtual reality-based exercises|Virtual reality exercise using Nintendo Wii systems. As game interfaces, the Nintendo Wii systems employ haptic sensor-based controllers and a balance board.
45657655|NCT05557981|Behavioral|Coaching|A novel coaching curriculum based in positive psychology with an emphasis on self-reflection, goal setting and adverse event processing.
45945984|NCT04302870|Drug|Placebo oral solution|Placebo taken once daily
45945985|NCT04302870|Drug|Amantadine Hydrochloride Oral Solution|Amantadine Hydrochloride taken once daily
45945986|NCT04301687|Procedure|Femoral Articular Branch Block|Slow injection (3mL aliquots) of local anesthetic solution (20ml of Ropivacaine 0.5%) into the fascia above the iliopsoas muscle (located in the groove between the two bony landmarks - (1)anterior inferior iliac crest and (2)iliopubic eminence).This is done by ultrasound guidance.
46075753|NCT05339802|Combination Product|9MW1411 injection 2 combined with Linezolid|After randomization, 9MW1411 injection, single dose, intravenous infusion, linezolid: 600mg, given intravenously or orally every 12 hours, for a total course of treatment not exceeding 14 days.
45657656|NCT02347527|Behavioral|Active Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of positive or negative valence.
45657657|NCT02347527|Behavioral|Control Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of neutral valence.
45809725|NCT02976506|Behavioral|Physical fitness and quality of life|Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to < 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
45809726|NCT04852614|Diagnostic Test|Pharmacokinetic test|Blood samples will be collected 48 hours after the first dose on day 3 of the observed intake of the study medication at the following time points: t=0 (pre-dose), 1, 2, 3, 4, 8 and 12 hours post ingestion (7 samples) (3 mL each), Breast milk samples will be collected by emptying both breasts at 0, 2, 4, 8 and 12 hours (5 samples).
45809727|NCT02976662|Procedure|Artificial shrinkage|Artificially eliminated blastocoelic fluid before vitrification procedures.
45945987|NCT04301687|Procedure|Placebo Block|Subcutaneous injection of 1ml normal sterile saline
45945988|NCT04294628|Procedure|Biopsy|Undergo biopsy
45945989|NCT04294628|Procedure|Biospecimen Collection|Undergo collection of blood samples
45945990|NCT04294628|Procedure|Computed Tomography|Undergo CT scan
45945991|NCT04294628|Procedure|Magnetic Resonance Imaging|Undergo MRI
45809728|NCT03657407|Drug|Belladonna Opium|Belladonna Opium 16.2-60mg rectal suppository
45945992|NCT04294628|Biological|Trastuzumab Deruxtecan|Given IV
45945993|NCT04267744|Other|Myia Health® remote patient monitoring unblinded treatment arm|"After consenting to the study, the Myia in-home suite of devices will be provided to all recruited patients. The data flowing from the Myia platform will be available to clinicians and patients for the duration of the pilot and utilized to complete study activities.~Device: Myia Health platform and in-home suite of devices®:~Emfit Ballistocardiograph® Withings Connected Scale® VitalScout (VivaLink) ECG Accelerometer® Omron Blood Pressure Monitor® (Sphygmomanometer) Cradlepoint - Hotspot / Adaptor® (LTE Connection) Samsung Galaxy Tab A 8.0® (User Interface)"
45945994|NCT04267731|Dietary Supplement|VMK223|Heat killed and purified Bifidobacterium breve polysaccharide-based extract
45945995|NCT04267731|Dietary Supplement|Cellulose|Bulking agent in food production without probiotic properties
45945996|NCT04267692|Other|HaRTC|HaRT-C participants will attend 8, virtual, adapted, low-barrier, weekly, closed-group Talking Circles-- named Harm Reduction Treatment Circles or HaRTC -- lasting approximately 2 hours each. During the HaRTC, the circle keeper will present the day's harm reduction topic, smudge the space, and allow participants to open themselves up to the circle. Topics presented by the Circle Keeper focus on harm-reduction and improving overall quality of health. Abstinence from alcohol use is not a requirement. We will not limit participants' access to treatment or services in either arm.
45945997|NCT04252690|Device|MOBIDERM® autofit : auto-adjustable compression stocking|"The experimental protocol will require 2 visits during usual reduction phase performed at the hospital (5 days of hospitalization).~Visit 1 will be performed the first day of hospitalization and will consist of inclusion visit and some evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics).~Between visit 1 (D1) and visit 2 (D3), patients will wear Mobiderm Autofit continually.~Visit 2 will be performed the third day of hospitalization and will consist of evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics, satisfaction survey)."
45945998|NCT04242823|Diagnostic Test|Automated visual evaluation|Participants will undergo primary hrHPV testing and if positive will be referred for VIA per Botswana and WHO guidelines. Participants will also undergo colposcopy, image capture for automated visual evaluation and biopsy at the time of VIA.
46075754|NCT05339802|Combination Product|9MW1411 injection placebo combined with Linezolid|After randomization, 9MW1411 injection placebo, single dose, intravenous infusion, linezolid: 600mg, given intravenously or orally every 12 hours, for a total course of treatment not exceeding 14 days.
46075755|NCT04649203|Drug|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)|The study drug will be administered in two phases: intravenous infusion of study drug for 10 days followed by oral administration of study drug for 75 days. Thus, the total duration of the study therapy is 12 weeks.
46075756|NCT04649203|Drug|Placebo|The placebo comparator will be administered in two phases: intravenous infusion of placebo solution for 10 days followed by oral administration of placebo pills for 75 days. Thus, the total duration of the study therapy is 12 weeks.
46075757|NCT00881725|Drug|Metformin|500mg tablets t.i.d. for 4-12 weeks prior to Radical Prostatectomy
46075758|NCT05086224|Drug|Hematoma Local Anesthetic Block Procedure with 1% Lidocaine|Inject anesthetic into the hematoma site, 20 mL of 1% lidocaine without epinephrine.
45458095|NCT02313688|Procedure|gastrectomy|Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 3±0.5 cm lengthen proximal resection margin.
45458096|NCT02313688|Procedure|gastrectomy|Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 5±0.5 cm lengthen proximal resection margin.
45809729|NCT03657407|Drug|Glycerin Suppository|Glycerine rectal suppository
45809730|NCT04243772|Other|Data extraction|Data extraction from medical files
45809731|NCT01639560|Drug|Varenicline|1 mg of varenicline twice per day for 12 weeks and brief behavioral counseling
45809732|NCT01639560|Drug|Placebo|1 placebo tablet twice per day for 12 weeks and brief behavioral counseling
45809733|NCT04243616|Drug|Cemiplimab|350 mg, IV, Day 1 of Cycle 1-2 (3-week cycle)
45809734|NCT04243616|Drug|Paclitaxel|80 mg/m^2, IV, Day 1,8 and 15 of Cycles 1-4 (3-week cycle)
45809735|NCT04243616|Drug|Carboplatin (not mandatory)|Area under curve (AUC)=6, IV, Day 1 of Cycles 1-4 of Paclitaxel cycles (3-week cycle)
45809736|NCT04243616|Drug|Doxorubicin|60 g/m^2, IV, Day 1 of Cycles 1-4 of ddAC (2-week cycle)
45809737|NCT04243616|Drug|Cyclophosphamide|600 g/m^2, IV, Day 1 of Cycles 1-4 of dose-dense Adriamycin (Doxorubicin) and Cyclophosphamide (ddAC) (2-week cycle)
45809738|NCT04209335|Other|isometric core muscle endurance testing|holding previously described isometric positions until fatigue
45809739|NCT00361556|Behavioral|The Back Book|A book on how to prevent back pain
45809740|NCT00361556|Behavioral|The Back Guide|A guide for the prevention of back pain.
45809741|NCT00361556|Behavioral|General health book|A book on general health
45809742|NCT04205669|Drug|Benzyl Benzoate 25% Topical Application Lotion|Applied to skin for the treatment of scabies
45809743|NCT03954314|Drug|Tranexamic Acid|Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
45809744|NCT01601652|Drug|Omegaven|1 g/kg/d iv infusion over 24h
45835836|NCT04773444|Behavioral|Eccentric cycling training|"Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~Each training session: 3 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~Intensity: Firstly, set at 45% Wmax, and progressively increased 5% per week"
45809745|NCT03516227|Behavioral|heart rate variability biofeedback|The HRVBF group received four, one-on-one bedside biofeedback training sessions (20-minutes a day for 4 days), and practiced on their own (10-minutes twice a day) using a FDA-regulated, hand-held mobile biofeedback device (StressEraser, Helico Inc., New York, NY, USA).26 The control group received usual care.Afterwards, all participants were telephoned bi-weekly and encouraged to practice slow breathing (HRVBF group) or to perform self-care (control group) for three months.
45657658|NCT02197039|Drug|esomeprazole or pantoprazole|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis is achieved spontaneously or by gastroscopy. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Because of concern for patient safety with certain drug-drug interactions, patients who take clopidogrel receive intravenous pantoprazole (Pantoloc®, Takeda, Singen, Germany), including an 80 mg loading dose and a 3-day continuous high-dose (8 mg/h) of infusion.
45945999|NCT04241822|Behavioral|Vestibular exercises combined with body awareness exercises and cognitive therapy|The intervention is group based and is a combination of information/education, vestibular exercises (head movements and gaze stability exercises) body awareness exercises and cognitive therapy
45946000|NCT04241822|Behavioral|Exergaming|The intervention consists of different balance exercises using non-immersive virtual reality
45657659|NCT02197039|Procedure|Endoscopic hemostasis|At the index gastroscopy, bleeding ulcers are checked. If the adherent clot is found over the ulcer base, it will be vigorously washed away with water jet. All of the stigmata of recent hemorrhage (SRH) are treated by one or a combination of endoscopic therapies including local injection of diluted epinephrine 1:10000, bipolar heated probe at 20 J per goal consecutively until achievement of coaptive coagulation, argon plasma coagulation, band ligation, or hemoclip therapy. The success of endoscopic hemostasis is defined as cessation of bleeding together with achievement of cavitation at the vessel after application of the heater probe.
45946001|NCT04238910|Behavioral|Maximizing Energy|The intent of the MAX intervention is to personalize OT delivered education to facilitate the implementation of Energy Conservation strategies using the PST framework to address specific fatigue-related problems and then to generalize from these solutions to both similar and new situations in daily life.
45946002|NCT04238910|Behavioral|Health Education|The intent of the health education intervention is to control for the non-specific effects of interactions with an interventionist. Participants received education on a variety of health related topics relevant to individuals with TBI.
45946003|NCT04231214|Drug|Olodaterol-Tiotropium|5µg Olodaterol and 5 µg Tiotropium via the soft mist inhaler Respimat®, administered once on Day 1 or Day 9 and daily from Day 10 to Day 24
45657660|NCT02028559|Device|Propulse 1|Move kidney stones with Propulse 1 device.
45946004|NCT04229095|Drug|Suvorexant 20 mg|Single-dose administration of 20 mg suvorexant given on an inpatient clinical research unit
45946005|NCT04229095|Drug|Placebo oral tablet|Single-dose administration of placebo given on an inpatient clinical research unit
45946006|NCT04223141|Procedure|SIA|As indicated by arm description
45946007|NCT04182451|Device|Meso Wound Matrix|"Subjects who meet eligibility criteria will receive standard of care and Meso Wound Matrix.~The standard of care therapy in this study is offloading of the DFU, appropriate sharp or surgical debridement, and aggressive infection management with the use of appropriate dressings. Total contact casting or fixed ankle walker will be used for off-loading. Wound Matrix is an acellular scaffold to reinforce and repair soft tissue defects. Subjects may receive up to eight applications of Meso Wound Matrix. Subjects whose study ulcer does not heal after eight applications will receive only SOC treatment for 4 additional weeks."
45657661|NCT05557903|Biological|Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection|Single dosing: DLT observation for 7 days after administration; Multiple dosing: 3times/weeks,12 times, 28 days of DLT observation
45657662|NCT04335097|Device|Biosensors|Sensor that detect vital signs
45657663|NCT02386839|Drug|rhIGF-1/rhIGFBP-3|"Participants who received rhIGF-1/rhIGFBP-3 in study ROPP-2008-01 (NCT01096784) will be enrolled to this study. No investigational product will be administered in this study."
45809746|NCT05611476|Behavioral|Cognitive Muscular Therapy for low back pain|Psychologically informed physiotherapy which used biofeedback training to reduce muscle overactivity and improve postural control
45946008|NCT04179149|Behavioral|Environmental enrichment|The experimental group will participate in six modules that mimic and integrate the three hallmarks of EE: social interaction (more animals per cage = support group meetings, online support), novelty (toys and activities = exposure to new hands-on activities), and larger enclosures (larger cages = meetings in open environments). There will be 2 interventions per month, for three months, and a follow up 3 months after the end of the intervention
46002554|NCT04647045|Dietary Supplement|Cultured milk drink|Each bottle contains 109 cfu Lactobacillus acidophilus LA-5 and Lactobacillus paracasei L. CASEI-01. In each 100 ml unit, it contains 4.06 g of fructose, 4.14 g of glucose, 0.29 g of sucrose, less than 0.1 g of maltose and 1.35 g of lactose.
46002555|NCT00544934|Drug|GLY-230|125, 250 0r 375 mg bid for 14 days
46002556|NCT00544934|Other|Placebo|No drug administered
46075759|NCT05086224|Drug|Bier Anesthetic Block Procedure with 1% Lidocaine|Intravenous anesthetic infusion, a maximum lidocaine dosing of 3 mg/kg.
46075760|NCT04998318|Device|Pocket Colposcope|Both arms will receive treatment in order to prevent cervical cancer. However, the intervention using the pocket colposcope device will be used on half the enrolled subjects.
46075761|NCT04998318|Procedure|Standard of Care Colposcopy|VIA and VILI as previously described,
46075762|NCT02837588|Device|Hyperthermy treatment with MJS electrode|30 patients who are diagnosed Pelvic pain with myofascial syndrome by gyneacologist or urologist goes to Pelvic Floor Physiotherapist for 4 session with hyperthermy treatment with MJS electrode at pelvic floor trigger points
45657664|NCT05557825|Radiation|Photobiomodulation Therapy|Focal low-level laser therapy, 2 to 3 Joules per point, depending on the degree of pain, wavelength 633 to 685 nm, transcutaneously on the surface of the tissue injured by radiotherapy, three times a week during radiotherapy treatment and two more applications after the end of radiotherapy
45809747|NCT03520283|Other|Interview|Ancillary studies
45657665|NCT05557747|Other|cervicothoracic junction mobilization in form of Maitland mobilization|Group A: will receive cervicothoracic junction mobilization mobilization in form of Maitland mobilization to the C7-T1 level, according to their primary movement restriction (for flexion-extension restriction- central PA glide, for rotation restrictions (unilateral PA glide) for 3 sessions/week over 4 weeks periods.
45657666|NCT05557747|Other|autogenic muscle Energy Technique|"the technique will applied to neck muscles that are prone to get short including anterior, middle and posterior Scaleni, Sternocleidomastoid, Levator Scapulae and upper fibers of the Trapezius muscle.~The AI MET group will given 3-5 repetitions of post isometric relaxation (PIR) (30-50% isometric contraction of the muscle to be stretched for 7-10 seconds, followed by rest period of 5 seconds and then a stretch of 10-60 seconds hold"
45657667|NCT05557747|Other|conventional physical therapy|conventional physical therapy only in form of: (superficial heat using hot pack for 10 minutes , Isometric Neck Exercises and Dynamic Neck Exercises)) for 3 sessions/week over 4 weeks periods
45657668|NCT01718041|Drug|Experimental: VRS-317|Active treatment arm
45946009|NCT04166227|Procedure|Hip Arthroscopy|Patients in the Hip Arthroscopy group will undergo arthroscopy in the supine position under general anesthesia, with all procedures performed by two subspecialty-trained hip arthroscopists. An algorithmic surgical approach will be utilized to sequentially address pathology in the central and peripheral compartments of the hip based on both preoperative imaging findings and intraoperative findings. Emphasis will be placed on labral preservation and refixation, with osseous decompression under fluoroscopic guidance.
45809748|NCT03520283|Other|Questionnaire Administration|Ancillary studies
45946010|NCT04166227|Procedure|Total Hip Arthroplasty|Patients randomized to the Total Hip Replacement (THR) group will undergo THR via a direct anterior approach. A slightly oblique skin incision measuring approximately 8 cm will be used, starting 3 cm distally and laterally to the anterosuperior iliac spine. The intervals between tensor fascia lata (TFL) and sartorius will be developed superficially, and between rectus femoris and gluteus minimus deeper. Capsulotomy will be performed. A double osteotomy of the femoral neck will be performed to facilitate removal of the head followed by traditional preparation of the acetabulum using an offset reamer and the acetabular component will be inserted. Next, the superior capsule will be released to elevate the femur to allow access to the femoral canal, followed by standard preparation by use of an offset broach and the stem will be implanted
45946011|NCT04164069|Biological|Bevacizumab|Given IV
45809749|NCT03520283|Behavioral|System Support Mapping|Complete MAP
45809750|NCT05107440|Other|BREATHE|A virtual, multidisciplinary, patient-centred self-management program for long COVID. The BREATHE program provides education on Breathing, Rest/recovery, Education, Activity management, Thinking/cognition, Healthy voice strategies, and Eating/nutrition.
45809751|NCT05590494|Procedure|Ultrasonic tenotomy|Ultrasonic procedure as part of standard of care, as clinically indicated, to stimulate healing of the partial tear. The procedure uses ultrasound guidance that allows a needlelike device to gradually break up and remove tendinopathic tendon tissue.
45946012|NCT04164069|Drug|Dasatinib|Given PO
45946013|NCT04164069|Drug|Fluorouracil|Given IV
45809752|NCT04186481|Device|MINITAC Ti 2.0 suture anchor|The MINITAC◊ Ti 2.0 Suture Anchor is intended to provide secure reattachment of soft tissue to bone in the foot and ankle as well as elbow, wrist and hand.
45946014|NCT04164069|Drug|Leucovorin|Given IV
45946015|NCT04164069|Drug|Leucovorin Calcium|Given IV
45946016|NCT04164069|Drug|Oxaliplatin|Given IV
45946017|NCT04164069|Other|Quality-of-Life Assessment|Ancillary studies
45946018|NCT04155281|Other|urine analysis|New Psychoactive Substances research in urine at admission in unit care
45809753|NCT03952130|Drug|LY900014|Administered SC
45946019|NCT04147611|Device|BAHA|Participant's pediatric bone conduction hearing device.
45946020|NCT04147611|Device|Wireless Audio Streaming Accessory|Cochlear Corporation's Mini Microphone 2+ Wireless Audio Streaming Accessory is an accessory used to transmit speech and sound. It consists of a microphone and a transmitter that transfers the signal to a receiver that's connected to a hearing device.
45946021|NCT04147611|Device|Digital Adaptive RM System|Sonova's Roger Digital Adaptive RM system is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
45946022|NCT04147611|Device|Hearing Aid|Participant's unilateral hearing aid with contralateral plug.
45458097|NCT01234753|Other|Physician and nurse consultation|Usual care by a visit to physician at the hospital out-patient clinic and computer-based and individual education and psychosocial support by a nurse-led session.
45809754|NCT03952130|Drug|Insulin Lispro|Administered SC
45946023|NCT04140331|Device|Accelerometer|Patient will wear the accelerometer for 7 consecutive days to measure the level of physical activity.
45946024|NCT04139993|Drug|Microbiota-based Formulation RBX7455|Given PO
45809755|NCT03952130|Drug|Insulin Glargine|Administered SC
45809756|NCT03952130|Drug|Insulin Degludec|Administered SC
45946025|NCT04128644|Behavioral|Thoughts & health|12 sessions of Thoughts & Health. Baseline questionaires and follow up assessments
45946026|NCT04128644|Other|Treatment as Usual|Baseline questionnaires and follow up assessments, intervention as usual, Student Health
45946027|NCT04126837|Other|Diagnosis and treatment|Monocentric, Prospective and Biomedical Research excluding Health Product
45809757|NCT03661541|Drug|Squaric Acid Dibutyl Ester|2% squaric acid dibutyl ester (SADBE) (Supplied by Squarex) is topically applied to the inner aspect of the upper arm of the subject and covered with Tegaderm. Subject is advised to wash it off after 3 hours.
45809758|NCT03661697|Device|Laser Therapy|"Clear and Brilliant Permea is a 1927nm fractional laser with 3 settings; low, medium, high.~All interventions were done at low with four passes to each participant's full face."
45809759|NCT03661697|Other|Basic Skin Care Regimen|Skin Medica brand cleanser, sunscreen, moisturizer as directed for 12 weeks
45809760|NCT03661697|Other|Lytera|cosmeceutical serum applied to face daily for 12 weeks
45946028|NCT04115345|Biological|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
45946029|NCT04102228|Device|1Hz inhibitory rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 coil
45946030|NCT04102228|Device|1Hz sham rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 sham coil.
45946031|NCT04102228|Behavioral|Multi-Modality Aphasia Therapy (M-MAT)|Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
45946032|NCT04098744|Drug|Artesunate vaginal insert|Artesunate formulated as vaginal inserts, 200mg
45809761|NCT02975648|Behavioral|educational model + follow up|Orientation from health professionals at discharge, educational program with explanation of booklets and telephone follow-up (three calls)
45809762|NCT02975648|Behavioral|usual care|Hospital health professionals offered orientation on care after discharge
45946033|NCT04098744|Drug|Placebo vaginal insert|Placebo for artesunate vaginal inserts
45946034|NCT04088604|Drug|LY01610 ( Irinotecan hydrochloride liposome injection )|Part1-Dose Escalation and Part1-Dose Extension : subjects take LY01610;
45809763|NCT05575362|Other|Group A|Group A will receive Epleys maneuver and Cawthorne Cooksey exercise for two weeks.
45657669|NCT05352451|Behavioral|Interventional Survey|Complete the surveys before and after attending coaching sessions. The two interviews each lasting for about one hour and will be done in-person or through video-conferencing meeting (depending on which is more convenient for you) with a study team member. The first interview, will ask about some basic information. In the second and last interview, will ask about experience of the coaching sessions and about how you feel about your decisions regarding your treatment and care. At each of the two time points, you and your caregiver will be interviewed separately. The video-conferencing, will be conducted through Zoom, which is a secure, widely used software which allows people to communicate remotely with computers, tablets, or smart phones. The software is available free of charge to you if you have a computer or other suitable device and internet.
45657670|NCT01494103|Biological|iCaspase9-transduced T cells|Patients will receive the T cells between 30 and 90 days following transplantation. The T cells will be infused through a catheter line.
45946035|NCT04088604|Drug|LY01610 ( Irinotecan hydrochloride liposome injection ) with 5-Fu（Fluorouracil Injection）|Part2-Dose Escalation and Part2-Dose Extension : subjects take LY01610 with 5-Fu;
45946036|NCT04088604|Drug|Irinotecan Hydrochloride Injection（CAMPTO®）|Irinotecan Hydrochloride Injection（CAMPTO®） pharmacokinetics comparative study
45946037|NCT04081779|Other|Survivorship Care Plan|Receive patient-generated SCP
45809764|NCT05575362|Other|Group B|Group B will receive Half Somersault maneuver along with Cawthorne Cooksey exercise for two weeks.
45946038|NCT04081779|Other|Educational Intervention|Receive telephone-based educational counseling session
45946039|NCT04081779|Other|Questionnaire Administration|Ancillary studies
45946040|NCT04078191|Drug|Tc 99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
45809765|NCT04735133|Device|pNBYT|pNPWT device (80mm Hg) was placed in the pNPWT group for seven days The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI.
45809766|NCT03925532|Biological|Denosumab|Given SC
45809767|NCT04851912|Other|Winterlight Apps|Longitudinal speech recordings
45809768|NCT05430828|Drug|Repatha (evolocumab); Praluent (alirocumab)|Dosage form: Injection
45809769|NCT03922490|Device|Lipogems Device PLUS debridement|Lipogems is the name of the technology used to obtain stem cells from the abdomen, which will then be injected into the knee after knee arthroscopy.
45809770|NCT03922490|Procedure|Debridement only|Patients will undergo knee arthroscopy as a standard treatment for their condition but will not receive the fat-derived stem cell treatment nor will undergo any additional procedures.
45809771|NCT04242680|Device|Brainstim DLPFC|"The active tRNS will be delivered to bilateral DLPFC for five consecutive days for two weeks for a total of ten days.~tRNS will be delivered by a battery driven, random-noise current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The electrodes will be placed on the left and right DLPFC, F3 and F4 position according to the 10-20 international EEG system for electrode placement, while participants will receive a usual treatment (cognitive training).~Stimulation intensity will be set at 0.75 milliampere (mA) (100-500 Hz), the duration of stimulation will be 20 min."
45835837|NCT04773444|Behavioral|Concentric cycling training|"Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~Each training session: 3 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~Intensity: Firstly, set at 45% Wmax, and progressively increased 5% per week"
45946041|NCT04078152|Drug|Durvalumab|IV infusion q4w with 1500mg durvalumab until progressive disease
45946042|NCT04075253|Behavioral|VO2 peak testing|Exercise on treadmill starts with ~4km/h at 0% inclination before inclination is increased to 4% and speed kept unchanged. Inclination will then be increased with two percent approximately after each minute until exhaustion.
45946043|NCT04075123|Other|CPAP|The two NRS strategies being compared will be initiated at the time of first extubation (NRS support practices prior to initial intubation will be as per local unit guidelines and practices) and all subsequent extubations (if applicable) until 32 weeks PMA. For instance, a unit adopting post-extubation NCPAP strategy will initiate this mode following the initial and all subsequent extubations until 32 weeks PMA whereas centres adopting post-extubation NIPPV will initiate NIPPV following initial and all subsequent extubations until 32 weeks PMA.
45458768|NCT03947788|Behavioral|OKQ Training Program|The OKQ training program helps clinicians more efficiently meet the needs of women's pregnancy intentions and provide evidence-based care.
45946044|NCT04070300|Behavioral|Interval exercise|Aerobic interval training during 12 weeks 3 times a week: 4 x 4 minutes intervals at an intensity of 90-95% of VO2 peak and active breaks of 3 minutes between intervals.
45809772|NCT04242680|Device|Brainstim PPC|"The active tRNS will be delivered to bilateral PPC for five consecutive days for two weeks for a total of ten days.~tRNS will be delivered by a battery driven, random-noise current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The electrodes will be placed on the left and right PPC, P3 and P4 position according to the 10-20 international EEG system for electrode placement, while participants will receive a usual treatment (cognitive training).~Stimulation intensity will be set at 0.75mA (100-500 Hz), the duration of stimulation will be 20 min."
45946045|NCT04036435|Drug|BMS-986165|Specified dose on specified days
45946046|NCT04021719|Other|Stakeholder feedback|Stakeholders, including OnTrackNY participants, past participants, family members, clinicians, administrators, payors and state leadership, will participate in a variety of activities to provide continuous quality improvement to the OnTrackNY program, including a Stakeholder Workgroup, interviews and focus groups
45946047|NCT04021719|Other|Data infrastructure|Data will be systematically collected as part of CQI activities, within a state-of-the-art data infrastructure that allows for client-level feedback to clients, providers and sites to improve quality of care.
45946048|NCT04018040|Other|Lacto-ovo vegetarian diet|Lacto-ovo vegetarian diet inclusive of dairy and eggs
45657671|NCT01494103|Drug|AP1903|"AP1903 will be administered if there is development of Grade 1 or greater GvHD.~Dose: 0.4 mg/kg by IV over 2 hours.~Up to 3 additional doses may be administered if the GvHD does not respond or gets worse."
45657672|NCT05557669|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is a procedure of removal of the gallbladder and a gold standard in treatment of gallstone disease.
45657673|NCT05347459|Drug|Dapagliflozin|usual and customary doses for type 2 diabetes management
45657674|NCT05347459|Drug|Empagliflozin|usual and customary doses for type 2 diabetes management
45809773|NCT04242680|Device|Brainstim Sham|The same electrode placement will be used as in the stimulation conditions (Brainstim DLPFC or Brainstim PPC), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held five consecutive days for two weeks for a total of ten days.
45809774|NCT04242680|Behavioral|Cognitive Training|"A cognitive training (Vektor; Nemmi et al., 2016) will be adiministered concomitantly to Brainstim DLPFC, Brainstim PPC, Brainstim Sham for 20 min.~The training consisted of math exercises (number line, calculations) and math-related exercises (visuo-spatial working memory, mental rotation)."
45809775|NCT04680260|Other|Standard of care|Patients will be offered adjuvant chemotherapy according to standard of care. Follow up will be performed with imaging according to standard guidelines, equal to the experimental arm. Blood samples will be analyzed retrospectively to evaluate the ctDNA status.
45946049|NCT04013321|Device|SleepScore Max coaching feature|The SleepScore max is a non-contact sleep tracking device. The app has an integrated feedback coaching feature to improve sleep.
45946050|NCT04013321|Behavioral|Online CBTi|Online Cognitive Behavioral Therapy for insomnia is a user guided program to track sleep, receive sleep coaching, and initiate behavioral techniques such as tailored sleep scheduling and sleep hygiene to help improve sleep.
45835838|NCT05217108|Device|FitBit|All participants in each study group will receive a Fitbit. Participants will be asked to wear a Fitbit every day for 8 weeks to record the number of steps you take
45835839|NCT01895556|Other|Information|
45946051|NCT04006288|Drug|Clopidogrel|Patients on aspirin and plavix will be randomized to either continue with aspirin and plavix or to switch to aspirin and rivaroxaban
45946052|NCT04006288|Drug|Prasugrel|Patients on aspirin and prasugrel will be randomized to either continue with aspirin and prasugrel or to switch to aspirin and rivaroxaban
45946053|NCT04006288|Drug|ticagrelor|Patients on aspirin and ticagrelor will be randomized to either continue with aspirin and ticagrelor or to switch to aspirin and rivaroxaban
45946054|NCT04006288|Drug|aspirin|all patients will remain on aspirin
45946055|NCT04006288|Drug|rivaroxaban|Patients on DAPT will be randomized to either continue with DAPT or to switch to aspirin and rivaroxaban
45835840|NCT01895556|Other|Control|
45946056|NCT04003480|Device|FRAME|External support for vein grafts in peripheral bypass surgery
45946057|NCT03979131|Combination Product|Avelumab addition to perioperative chemotherapy in GC and GEJC|Avelumab addition to perioperative chemotherapy in GC and GEJC. Peri-operatory treatment consisting of four cycles (each cycle is 14 days) of neoadjuvant chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) plus avelumab previous to surgery. Surgery is recommended to be scheduled 4 to 6 weeks after the last dose. Afterwards (4 to 10 weeks after surgery), four cycles of adjuvant therapy with the same schema, followed by avelumab up to one year. There will be be a follow-up of 5 years.
45946058|NCT03978663|Radiation|Neoadjuvant radiotherapy|Neoadjuvant radiation therapy delivered to a portion of the index tumour for high-risk breast carcinoma for immune priming prior to neoadjuvant radiation
45458769|NCT01237171|Radiation|Cesium-131 Brachytherapy Seed|85 Gray Dose
45657675|NCT05347459|Drug|Canagliflozin|usual and customary doses for type 2 diabetes management
45657676|NCT05347459|Drug|Sitagliptin|usual and customary doses for type 2 diabetes management
45657677|NCT05347459|Drug|Saxagliptin|usual and customary doses for type 2 diabetes management
45657678|NCT05347459|Drug|Linagliptin|usual and customary doses for type 2 diabetes management
45946059|NCT03975075|Behavioral|Psychophysiological monitoring|30 minutes of one channel (ECG) physiological monitoring with Mindfield eSense Pulse.
45657679|NCT05347459|Drug|Vildagliptin|usual and customary doses for type 2 diabetes management
45809776|NCT04680260|Other|Circulating tumor DNA guided treatment approach|Circulating tumor-marker positivity will lead to escalation with 6 months of intensified chemotherapy consisting of 4 months of FOLFOXIRI followed by 2 months of 5FU monotherapy. Circulating tumor-marker negativity will based on shared decision-making lead to de-escalation i.e. possibilities for observation in patients otherwise eligible for monotherapy or observation/monotherapy in patients, otherwise eligible for combination chemotherapy according to standard of care.
45809777|NCT01640964|Drug|Terlipressin acetate|IV bolus injection
45946060|NCT03975075|Behavioral|Biofeedback training|Traditional resonance frequency training with the Mindfield eSense Pulse smartphone application. Using visual feedback of real time parameters of HRV and the use of controlled breathing, participants are trained to reach a relaxed state.
45809778|NCT01640964|Drug|Serelaxin (RLX030)|Part A2: IV infusion for 2-3 hours; duration of infusion depends on time required for completion of MRA data acquisition; Part B: IV infusion for approximately 2 hours
45809779|NCT04343066|Device|Implant insertion|"In both groups, the implants will be placed using a two-stage surgical approach at the crestal level in previously horizontally augmented bony sites.~A final crown will be placed (screw-retained on multiunit abutment) between 3- and 4-months post-implant placement.~Random allocation of implant type per site will be done by the sealed envelope method.~Follow-up measurements will be done at 6 months and 1-year post-loading. The measurements are done by a blinded investigator. Before starting the study, the examiner will be trained in a calibration process.~Exam sheets are kept confidential and anonymous. Inclusion criteria are: patient aged 20 to 65, no systematic contraindication for implant surgery, smoking < 10 cigarettes, previous horizontal bone augmentation, FMBS <20% and FMPS < 20%. Exclusion criteria are: general contraindication for implant surgery, pregnant/lactating women, uncontrolled diabetics, patients not willing to sign the consent form, active periodontitis."
45809780|NCT03663101|Drug|Lidocaine|0.5 mL (2.5 mg) of lidocaine per injection point will be injected subcutaneously (maximum 10 injection points).
45809781|NCT03663101|Biological|Botulinum toxin type A|0.2 mL of one of three different doses of Dysport per injection point will be injected intradermally (maximum 10 injection points).
45809782|NCT03663101|Drug|Placebo|Part A - 0.5 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected subcutaneously (maximum 10 injection points).
45809783|NCT03663101|Drug|Placebo|Part B - 0.2 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected intradermally (maximum 10 injection points, 2,0 mL maximum).
45809784|NCT05430048|Drug|nasal Desmopressin|compare the effect of nasal desmopressin versus oral bisoprolol for controlling bleeding and improving surgical field clarity during functional endoscopic sinus surgery.
45809785|NCT02975570|Drug|Delamanid|Delamanid is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth.
45809786|NCT02975570|Drug|Linezolid|Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics.
45809787|NCT02975570|Drug|Levofloxacin|Levoflaxacin is an antibiotic used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis.
45809788|NCT02975570|Drug|Pyrazinamide|Pyrazinamide is a medication used in combination with other drugs such as isoniazid and rifampicin in the treatment of Mycobacterium tuberculosis.
45946061|NCT03958045|Combination Product|Rucaparib and Nivolumab|Rucaparib (600mg BID) and Nivolumab (480mg IV q4 wk)
45809789|NCT02975570|Drug|WHO MDR-TB regimen|The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: pyrazinamide; a fluoroquinolone; a parenteral agent (typically amikacin or kanamycin); ethionamide (or prothionamide); and either cycloserine or para-aminosalicylic acid, with preference for cycloserine. Short (9 mos) or longer (20-24 mos) treatment schedules can be used.
45809790|NCT05230602|Dietary Supplement|opuntia (tzabar fruit)|consuming of the tzabar fruit twice a day
45946062|NCT03956680|Drug|BMS-986301|Specified dose on specified days
45946063|NCT03956680|Biological|Nivolumab|Specified dose on specified days
45946064|NCT03956680|Biological|Ipilimumab|Specified dose on specified days
45946065|NCT03952273|Combination Product|PCI with BioMatrix Alpha™ stent|Randomozation between either Sirolimus eluting and endothelial progenitor cell Combo™ stent or Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent
45946066|NCT03952273|Combination Product|PCI with Combo™ stent|Randomozation between either Sirolimus eluting and endothelial progenitor cell Combo™ stent or Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent
45946067|NCT03947827|Drug|Minocycline|Participants will be randomized to receive either Minocycline or placebo added to standard oral antidepressants.
45946068|NCT03927989|Behavioral|Text messaging plus nicotine replacement therapy|Brief advice to quit smoking prior to lung cancer screening (LCS), 8 weeks of gain-framed, LCS-tailored text messages, and nicotine replacement therapy.
45657680|NCT05346445|Drug|Fluoxetine 20 MG|Participants received non-hormonal treatment with fluoxetine.
45946069|NCT03927989|Other|Standard Care at Lung Cancer Screening|Brief advice to quit smoking prior to lung cancer screening
46002557|NCT04638348|Device|New Biofeedback|Conventional biofeedback consists of a electromyography biofeedback device with a vaginal probe.
46002558|NCT00545012|Drug|Levetiracetam|
45657681|NCT05346445|Drug|Citalopram 20mg|Participants received non-hormonal treatment with citalopram.
45657682|NCT05334121|Dietary Supplement|Beta-alanine|The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
45657683|NCT05334121|Other|Control product consumption|Product with identical characteristics to the experimental product. The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
45657684|NCT05612269|Diagnostic Test|interleukin 6|follow up of type 2 diabetes with SGLT2 inhibitors like empagliflozin, canagliflozin, and dapagliflozin for measurement of inflammatory factors like interleukin-6, CRP
45946070|NCT03923725|Drug|Artemether-lumefantrine+ Amodiaquine (AL+AQ)|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days."
45946071|NCT03923725|Drug|Artemether-lumefantrine + placebo (AL+PBO)|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets."
45946072|NCT03923725|Drug|Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate. The weight-based treatment aims for a dosage of approximately.~24 mg/kg/day in patients <25 kg (range 16.0 - 32.0 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day.~18 mg/kg/day in patients ≥25 kg (range 15.0 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day."
45946073|NCT03923725|Drug|Artesunate-mefloquine+placebo (AS-MQ+PBO)|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PBO: Placebo tablets for piperaquine are identical in size, shape and colour to the piperaquine tablets."
46075763|NCT04250012|Behavioral|Internet-based ACT intervention|The Internet-based ACT intervention included a 10-week web-based program consisting of five modules with different themes that the participants were instructed to process during the course of two weeks. The program was based on the processes of ACT and included themes such as life values, mindfulness, defusion, self-as-context acceptance and self-compassion. The content of each module consisted of text, video, exercises with audio files, and homework assignments. In addition, the participants filled in a diary with exercises in paper format. The intervention included also three remote meetings (à 45 minutes) via a videoconferencing tool doxy.me conducted by a psychologist. The remote meetings took place at the beginning, after 4 weeks, and at the end of the intervention.
45946074|NCT03914300|Procedure|Biospecimen Collection|Undergo blood sample collection
45946075|NCT03914300|Drug|Cabozantinib S-malate|Given PO
45946076|NCT03914300|Procedure|Computed Tomography|Undergo CT
45946077|NCT03914300|Biological|Ipilimumab|Given IV
45946078|NCT03914300|Procedure|Magnetic Resonance Imaging|Undergo MRI
45657685|NCT05557201|Biological|Lymphocyte immunophenotyping|If the patient accepts the ancillary study, a blood sample will be taken (1 EDTA tube of 3 ml and 2 lithium heparin tubes of 10 mL each) for lymphocyte immunophenotyping in flow cytometry on fresh blood and for the constitution of the biological collection (plasma/mononuclear cells).
45946079|NCT03914300|Biological|Nivolumab|Given IV
45946080|NCT03896503|Drug|Berzosertib|Given IV
45946081|NCT03896503|Procedure|Biopsy|Undergo a tumor biopsy
45657686|NCT05557123|Device|MEDI-app|MEDI-app based feedback algorithm. The app based feedback algorithm will check and remind the patients of taking medication.
45946082|NCT03896503|Procedure|Biospecimen Collection|Undergo blood sample collection
45946083|NCT03896503|Procedure|Computed Tomography|Undergo a CT scan
45946084|NCT03896503|Drug|Topotecan Hydrochloride|Given IV
45946085|NCT03880422|Dietary Supplement|Dietary Intervention|Receive diet plan
45946086|NCT03880422|Other|Educational Intervention|Attend educational meeting
45946087|NCT03880422|Behavioral|Exercise Intervention|Complete exercise program
45458770|NCT03749746|Behavioral|Home Blood Pressure Monitoring|Each participant will receive 1:1 training by the project staff in all aspects of home blood pressure monitoring (HBPM). Throughout the study, they will be asked to monitor home blood pressures for the first week of each month with Bluetooth-enabled blood pressure cuffs.
45657687|NCT05557123|Device|conventional treatment|conventional treatment with rivoxaban
45946088|NCT03880422|Other|Quality-of-Life Assessment|Ancillary studies
45946089|NCT03880422|Other|Survey Administration|Ancillary studies
45946090|NCT03880019|Procedure|Computed Tomography|Undergo CT
45946091|NCT03880019|Procedure|Core Biopsy|Undergo tumor biopsy
45946092|NCT03880019|Procedure|Magnetic Resonance Imaging|Undergo MRI
45946093|NCT03880019|Drug|Olaparib|Given orally (PO)
45657688|NCT01649271|Drug|Herceptin|3-weekly
45657689|NCT01649271|Drug|afatinib|at MTD level
45657690|NCT01649271|Drug|trastuzumab|3-weekly
45657691|NCT01649271|Drug|Herceptin|weekly
45657692|NCT01649271|Drug|afatinib|at MTD level
45946094|NCT03880019|Drug|Temozolomide|Given PO
45946095|NCT03877276|Dietary Supplement|Breakfast|a prepared meal consisting of pastry and 2 cooked egg whites
45946096|NCT03877276|Dietary Supplement|Spinach smoothie|a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and spinach
45946097|NCT03877276|Dietary Supplement|Kale smoothie|prepared blended kale smoothie, consisting of banana, avocado, orange juice, and kale
45946098|NCT03877276|Dietary Supplement|Blended smoothie|a prepared blended smoothie, consisting of banana, avocado, and orange juice
45946099|NCT03877276|Dietary Supplement|V spinach smoothie|a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and a varying amount (low, medium, high) of spinach
45657693|NCT01649271|Drug|afatinib|escalating dose
45946100|NCT03877276|Dietary Supplement|Sodium oxalate drink|a prepared sodium oxalate drink
45809791|NCT05428644|Behavioral|massage therapy|In addition to the standard nursing care of the hospital, individuals in the reflexology hand massage and placebo hand massage group will be given a 10-minute massage for both hands, a total of 20 minutes, after the extubation procedure.
45946101|NCT03876964|Device|Transcatheter Aortic Valve Replacement|Minimally invasive replacement of the aortic valve through a catheter.
45946102|NCT03861091|Drug|risedronate|Risedronate 150 mg Oral Given once 7 - 21 days prior to initiation of SBRT
45946103|NCT03861091|Drug|Matching placebo|Dose not applicable, given once 7-21 days prior to initiation of SBRT
45946104|NCT03858530|Diagnostic Test|Ultrasound Examination|Grayscale ultrasound, Doppler ultrasound, ultrasound elastography with or without ultrasound intravenous contrast will be performed.
45946105|NCT03854474|Procedure|Biospecimen Collection|Undergo collection of blood samples
45946106|NCT03854474|Procedure|Computed Tomography|Undergo CT
45809792|NCT04184999|Drug|dexamethasone intraocular suspension, 9%|single dose intracameral corticosteroid
45946107|NCT03854474|Procedure|Magnetic Resonance Imaging|Undergo MRI
45946108|NCT03854474|Biological|Pembrolizumab|Given IV
45946109|NCT03854474|Drug|Tazemetostat|Given PO
45946110|NCT03849326|Other|Questionnaires|Quality of life Depression Physical pain Social provisions Quality of sleep
45657694|NCT00521209|Behavioral|Self-Care Stimulating Disease Prevention Program (SCSDPP)|"The SCSDPP development is guided by the following premises: a) patient-directed lifestyle change or self-prescription of behavior change is potentially a more empowering, sustainable, and proactive approach to addressing personal health habits than the more conventional physician-directed approach; b) patient-directed lifestyle change or self-prescription of behavior change is potentially an important predictor of self-efficacy and long-term adherence to healthy habits; c) behavior change in isolation is less sustainable than change that is reinforced by other distinct but related changes (e.g., the potential synergy of improving diet and physical activity concurrently to prevent chronic disease); d) a multi-level change directed at the service delivery system and physician support, however small, has the added benefit of potentially reducing provider and staff burden while maximizing available clinic and community resources; and f) brief physician counseling"
45657695|NCT00521209|Other|Stand procedures, no intervention|
45657696|NCT05700877|Other|CAC-based treatment strategy|The intervention is a combination of screening with a heart CT scan and multifactorial intervention based on the screening results. Participants randomized to CAC-based treatment and with screening results showing high risk of CVD, will receive a multifactorial intervention including the combination of two open label investigational medical products: dapagliflozin 10mg/day and semaglutide 0.25 /week or 0.5 /week or 1.0 /week.
45946111|NCT03849326|Biological|blood test|complete blood count and cytokine concentration
46075764|NCT04250012|Behavioral|Psychoeducation|The psychoeducation group received a self-help booklet and a link to a web-based wellness training program. The program included exercises with MP3 audio files. No personal support during the 10-week intervention was provided.
45657697|NCT05700877|Other|Standard treatment|Participants randomized to standard treatment are recommended to follow updated guidelines for CVD prevention.
45657698|NCT05558917|Procedure|PECS BLOCK 2|With the patient supine, the linear probe will be placed in the sagittal plane slightly lateral to the hemiclavicular line ipsilateral to the surgical site. Once both muscle planes of interest have been identified, in-plane needle insertion will proceed in the cranio-caudal direction. The first local anesthetic administration with Ropivacaine 0.5% will be 20ml between small pectoralis and serratus anterior. Coming out with the needle, 10ml of Ropivacaine 0.5% will then be injected between large and small pectoral.
45809793|NCT04184999|Drug|Prednisolone Acetate 1% Oph Susp|topical ophthalmic steroid drop
45809794|NCT05220384|Behavioral|In-person Motivational Interview combined with Self-Management techniques|"This is an approximately 30 mins in-person, semi-structured, semi-personalized physical activity focused Motivational Interviewing treatment with self-management techniques. (This therapy is an add on to the usual therapy that is given to the adolescents who present at the hospital.) During the interactive treatment a self-management workbook will be filled out by the adolescent for the purpose of further data collection. This in-person therapy at the hospital is followed by two booster sessions via phone at the 1st week post meeting date and 1 month post meeting date."
45809795|NCT05220384|Behavioral|Video-based Motivational Interview combined with Self-Management techniques|"This is a series of three videos comprising a structured activity focused Motivational Interviewing treatment with self-management techniques. The videos' thematic follow the semi-structured interview elements to ensure that it is a true sham of the in-person one. (This therapy is an add on to the usual therapy that is given to the adolescents who present at the hospital.) This first video is going to be watched by adolescents at the hospital. During the interactive video-treatment a self-management workbook will be filled out by the adolescent for the purpose of further data collection. The second video is going to be sent to the participants via e-mail on the 1st week post meeting date and the third video is on the 1-month post meeting date."
45946112|NCT03849326|Other|Maximal effort test|The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.
45946113|NCT03849326|Device|actigraphy|assessment of sleep quality
45946114|NCT03849326|Device|Neuromuscular evaluation|"The maximum isometric force produced by the knee extensors will be measured on the ergometer~the intensity of muscular electrical activity recorded by surface electromyography~Peripheral nerve stimulation~Transcranial magnetic stimulation~Magnetic resonance imaging (optional)"
45946115|NCT03843645|Procedure|general anesthesia|surgical procedure under general anesthesia
45946116|NCT03843645|Procedure|regional anesthesia|surgical procedure under regional anesthesia
45946117|NCT03832985|Genetic|Receive an adult-onset result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have received an adult-onset genomic result.
46075765|NCT02779842|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. formulation number SR15-39-Z12-002.
46075766|NCT00954941|Drug|Ondansetron|8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy.
45809796|NCT03907748|Other|Music Intervention|After training, caregivers will deliver the music intervention to the person with dementia whom they care for. The music intervention will include: a) singing familiar/preferred music followed by discussions facilitated by the caregiver about any associated meanings or memories; b) movement to music (e.g. upper body and arms imitating familiar dance movements to music); c) instrument playing; and d) listening to familiar/preferred relaxing or enlivening music (dependent upon symptoms present in the moment). These methods are known to assist in emotion regulation and increase cognitive reserve (e.g. attention and perceptual-motor function).
45809797|NCT03907748|Other|Reading Intervention|After training, caregivers will deliver the reading intervention to the person with dementia whom they care for. The reading intervention will include: a) the caregiver reading aloud to the person they are caring for; b) the person with dementia reading aloud to their caregiver; and c) discussion of the text and personal responses. Strategies to engage the person with dementia and to create opportunities for meaningful dialogue will be provided, as well as guidance on selecting reading material that is accessible to the person's level of cognitive impairment.
45809798|NCT05369520|Device|TESCoN device - Thoracic stimulation|TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). The stimulation site will be over the thoracic spinal cord (T7-T12, Group 1).
45809799|NCT05369520|Device|TESCoN device - Lumbosacral stimulation|TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). The stimulation site will be over the lumbosacral spinal cord (L1 - L3, Group 2).
45809800|NCT03524339|Drug|Placebo oral capsule|Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.
45809801|NCT03524339|Drug|Tamsulosin|Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.
45657699|NCT05558917|Procedure|ESP BLOCK|Positioning yourself behind the patient, lying on her side with the surgical hemilateral on top, you place the linear ultrasound probe in the sagittal plane and find the lateral margin of the transverse process. At this point, the blocking needle is inserted in the caudocranial direction and 25ml of Ropivacaine 0.5% is injected, taking care to visualize the anesthetic spread in the cranial direction.
45946118|NCT03832985|Genetic|Receive a pediatric-onset result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have received an adult-onset genomic result.
45809802|NCT03895112|Drug|AVID200|dose cohorts of 21-day cycles
45809803|NCT05203302|Other|Single-Electrode Pulse Train|AIM 2 - Stimuli will be presented on one of three electrodes (apical, middle, and basal) at an amplitude between 10 and 100% dynamic range in µAs in 10% dynamic range steps. Stimulation will be delivered at a rate of 1000 pps. The process will be repeated in random order until 20 loudness estimates are obtained for each stimulus (3 electrodes x 2 rates x 10 amplitudes) for each subject. The dynamic range will be determined by measuring the maximum acceptable loudness (MAL) and threshold for each of the stimuli. MAL will be measured by slowly raising the current level for each stimulus until the subject reports that it is as loud as they are willing to accept without becoming uncomfortably loud.
45946119|NCT03832985|Genetic|Control - No Result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have not received an adult-onset genomic result.
45946120|NCT03831217|Procedure|mid urethral sling surgery|patients with clinically and/or urodynamically proven stress urinary incontinence underwent mid urethral sling surgery under general anesthesia.
45946121|NCT03826277|Other|Melanostop peel|"Melanostop peel treatments containing 20% azelaic acid, 10% resorcinol, 6% phytic acid, 3% tranexamic acid. (4 treatments, performed at 2-week intervals), in combination with home care products (twice daily):~a facial tonic and cream containing brightening ingredients: vitamin C, niacinamide, alpha arbutin, kojic acid,~sunscreen protection cream with SPF 50, protecting against UVA, UVB, HEV and IR"
45809804|NCT05203302|Other|Modulation Detection Threshold (MDT) and Gap Detection Tasks|AIM 1 - MDT will be set at 150 Hz. Testing will be conducted in soundfield in a sound booth at 60 dB Sound Pressure Level (SPL) while the participant listens with both implants adjusted to user setting.
45946122|NCT03819764|Behavioral|Aerobic Exercise|Cycling on a recumbent stationary bike with a specialized motor that forces the individual to cycle approximately 30-35% faster than your self-selected speed
45946123|NCT03819764|Behavioral|Upper Extremity Repetitive Task Practice|Repetitive arm exercises
45657700|NCT05370105|Other|blood withdrawal|"10 ml of blood, two 5 ml tubes suitable for serum isolation. Given the nature and objectives of the study, there are no risks and / o inconveniences of particular importance for the patient since the blood samples will be performed according to the common procedure used in all analysis laboratories. At the end of the collection, in the area where the blood sample was taken, a small bruise may form which will disappear in the following hours, in any case during the collection particular attention will be paid to the subjects being treated with antiplatelet and anticoagulants.~The study does not include the execution of interventional treatments or therapies."
45657701|NCT05558839|Behavioral|A 12-week weekly sports and cognitive training intervention.|A 12-week weekly sports and cognitive training intervention was provided to the participants. The training, 2 hours each week, involved 1 hour of sports training and 1 hour of cognitive training.
45946124|NCT03819387|Drug|NBF-006|Intravenous infusion, once-weekly x 4 consecutive weeks, every 6 weeks
46075767|NCT00954941|Drug|Aprepitant|125 mg capsule by mouth every morning while receiving chemotherapy followed by 80 mg capsule by mouth daily while receiving chemotherapy continued till 1 day after last chemotherapy dose.
45657702|NCT04892199|Drug|Semaglutide, 1.34 mg/mL|Semaglutide 1.34 mg/ml, 1.5 ml pre-filled pen-injector is supplied in pens for injection containing 2.0 mg of the GLP-1RA semaglutide in 1.5 ml sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Direction for use will be given together with trial products.The possible doses of semaglutide are 0.25 mg, 0.50 mg and 1.0 mg. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide will remain on 0.5 mg once-weekly. The injection is administered subcutaneously once-weekly.
45676338|NCT03856658|Device|Hepatic Artery Infusion Pump|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. The primary tumor will be resected or ablated with irreversible electroporation at the time of HAI pump placement. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
45946125|NCT03803787|Drug|Inhaled budesonide|Patients will use inhaled budesonide (Numark) with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
45946126|NCT03796702|Procedure|Deileostomy|Deileostomy
45809805|NCT05203302|Other|Sound coding strategy.|Aim3 - Spectral-temporally modulated ripple test (SMRT), Quick Spectral Modulation Detection (QSMD), Modulation Detection, Gap Detection. CNC words will be set in quiet and Az-Bio/BabyBio sentences in quiet and multi-talker babble (+10 and +5 dB SNR) using both the subject's clinical map and the new reduced channels map. Tests will be presented in the soundfield at 60 dB SPL
45946127|NCT03776162|Procedure|ACL Reconstruction (Bone Patellar Tendon Bone Graft)|Standard of care procedure Patellar Tendon Autograft ACL reconstruction, in which a bone-patellar tendon-bone graft from the front of the knee is taken to replace the torn ACL.
45946128|NCT03776162|Device|Bridge Enhanced ACL Restoration (BEAR)|The BEAR technique involves surgically placing a sponge (the BEAR implant) between the torn ends of the ACL, providing a sponge for the ligament ends to group into.
46075768|NCT02837666|Dietary Supplement|Supplementation with Spirulina maxima|Supplementation with Spirulina maxima (4.5 g/d) in capsules during 6 weeks.
46075769|NCT02837666|Other|Washout|2 weeks washout period to each study subject to avoid any possible carryover effect.
46075770|NCT02837666|Other|Supplementation with placebo|Supplementation with placebo (4.5 g/d) in capsules during 6 weeks.
46075771|NCT02837666|Other|Isoenergetic diet|All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 14 weeks
46075772|NCT02837666|Other|Exercise program|Participants are going to exercise five days a week with the following protocol: Between 5 and 10 min of heating exercise, Between 20-30 min anaerobic exercise and 20-30 min of aerobic exercise (cardiovascular exercise): walking, jogging, running and/or cycling, Three days a week aerobic intensities will be between 60% and 80% and two days between 70% and 90% of the maximum heart rate reserve, and five final minutes of stretching.
45657703|NCT04892199|Drug|Semaglutide-placebo|"The semaglutide placebo pens contain XX-vehicle (no active drug) and are administered in the same way and volume as semaglutide. The semaglutide placebo is specially packed for this study and will be used in the study only. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide placebo will remain on 0.5 mg once-weekly. The injection is administered once-weekly. If the lowest tolerated dose is less than 0.5 mg of semaglutide placebo once-weekly, the patient will be excluded from the study."
45809806|NCT05203302|Other|Electric-only spectral resolution|Aim 1- Spectral resolution will be tested using frequency allocations consisting of the full default clinical range as well as the subject's clinical frequency allocation if they differ. For Hybrid electrode users in which electrode contacts are closer in proximity in the cochlea, maps with a frequency allocation of 938-7938 Hz will also be tested in that it will closely approximate the frequency spacing of a Nucleus Contour Advance electrode array. Spectral resolution will be measured with three repetitions of the SMRT and one repetition of the QSMD test. Testing will be presented at 60 dB SPL in the soundfield with the acoustic ear plugged and muffed.
45946129|NCT03771391|Dietary Supplement|PKU Sphere|PKU sphere is a powdered, low phenylalanine protein substitute containing a balanced mix of casein glycomacropeptide (GMP) isolate, essential and non-essential amino acids, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA). With sugar and sweetener.
45946130|NCT03765788|Drug|Secukinumab 300 mg, s.c.|Secukinumab 300 mg was administered by subcutaneous (s.c.) injections using 1 mL pre-filled syringes (PFSs) throughout the study.
45946131|NCT03765788|Drug|Prednisolone|Prednisolone was provided as tablets (1 mg, 5 mg, 10 mg, 20 mg tablets) for daily administration as tapered regimen from a dose of 25 mg to 60 mg at Baseline to 1 mg at Week 26 (last dose)
45946132|NCT03765788|Drug|Placebo|Placebo 300 mg was administered by subcutaneous (s.c.) injections using 1 mL pre-filled syringes (PFSs) throughout the study.
45946133|NCT03765710|Other|Recommended protein intake|Recommended protein intake in a mixed meal contained 13% protein, 54% carbohydrate, and 33% fat.
45946134|NCT03765710|Other|Elevated protein intake|Increased protein intake in a mixed meal contained 26% protein, 44% carbohydrate, and 30% fat.
45946135|NCT03760211|Behavioral|Multilevel Gaming Adherence Intervention|Combination of electronic medication monitoring device with Information-Motivation-Behavior based mobile gaming application tailored for those living with HIV and adherence-based text messages
45946136|NCT03760211|Behavioral|Treatment as Usual +|Combination of electronic medication monitoring device and non-HIV related mobile gaming application
45946137|NCT03728881|Biological|Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine|Given IM
45946138|NCT03728881|Biological|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
45946139|NCT03718858|Procedure|Interscalene Block|15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to C5 and C6 nerve roots.
45946140|NCT03718858|Procedure|Superior Trunk Nerve Block|15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to Superior Trunk Nerve.
46075773|NCT05339646|Drug|SSD8432 dose 1~7 and Ritonavir|"Cohort 1 Period 1 single dose of SSD8432 dose 1 or placebo, on day 1. Period 2: single dose of SSD8432 dose 2 or placebo , on day 7. Period 3: single dose of SSD8432 dose 3 on day 13, ritonavir or placebo, before SSD8432 dose 3 and BID on SSD8432 dosing date~Cohort 2:~Period 1 single dose of SSD8432 dose 4 or placebo, on day 1 Period 2: single doses of SSD8432 dose 5 or placebo , on day 7 Period 3: single dose of SSD8432 dose 6 on day 13, ritonavir or placebo, before SSD8432 dose 3 and BID on SSD8432 dosing date~Cohort 3:~single dose of SSD8432 dose 7 or placebo on day1. ritonavir or placebo, before SSD8432 dose 7 and BID on SSD8432 dosing date."
45657704|NCT05280145|Device|EchOpen ultra-portable ultrasound device|Depending on the clinical picture, the patient is examined with EchOpen to detect the presence or absence of pyelocaliceal dilation or hepatic steatosis
45657705|NCT05280145|Device|Ultrasound device routinely used in the department|Patient who was first examined with EchOpen, is secondarily examined with an ultrasound probe used routinely in the department to detect pyelocaliceal dilation or hepatic steatosis
45809807|NCT05440370|Device|MegaCarti®|MegaCarti® application after microfracture through athroscopic or incision surgery
45809808|NCT05440370|Procedure|Microfracture|Microfracture through athroscopic or incision surgery
45946141|NCT03711253|Drug|Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg|antiretroviral therapy
45946142|NCT03654079|Other|Simulation|Participants assigned to the intervention group will participate in the following simulations: 1) the process that may occur if a baby has a significant drop in heart rate during labor, 2) the process of moving from the labor bed to the transport stretcher and on to the operating room in the event that a woman needs a cesarean delivery, 3) the pushing process after a woman becomes completely dilated
45946143|NCT03646045|Other|Transpyloric feeding|Preterm infant feeding using transpyloric feeding tube (nasoduodenal tube)
45946144|NCT03643822|Drug|Dexamethasone 4mg|To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
45946145|NCT03643822|Drug|Dexmedetomidine|To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
45946146|NCT03643822|Other|Saline|Control/Placebo intervention
46075774|NCT05339646|Drug|SSD8432 dose 8~9|Cohort 4: SSD8432 dose 8 or placebo, on day 1 ~day6. Cohort 5: SSD8432 dose 9 or placebo, on day 1 ~day6.
46075775|NCT05339646|Drug|SSD8432 dose 10~12 and ritonavir|Cohort 6: SSD8432 dose 10 or placebo, on day 1 ~day6. Cohort 7: SSD8432 dose 11 or placebo, on day 1 ~day6. Cohort 8: SSD8432 dose 12 or placebo, on day 1 ~day6 Cohort 9: to be decided
45946147|NCT03641313|Drug|Berzosertib|Given IV
45946148|NCT03641313|Procedure|Computed Tomography Assisted Biopsy|Undergo CT assisted biopsy
45946149|NCT03641313|Procedure|Endoscopic Biopsy|Undergo endoscopic biopsy
45946150|NCT03641313|Drug|Irinotecan|Given IV
45946151|NCT03641313|Procedure|Magnetic Resonance Imaging|Undergo MRI
45657706|NCT05280145|Procedure|Standard ultrasound examination by an independent referent radiologist|In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating.
45946152|NCT03635424|Device|Medtronic TAVR Systems|Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems
46075776|NCT05339646|Drug|SSD8432 dose 13 and Ritonavir|"Cohort 10:~Group A: SSD8432 dose 13, on day1 under fasting condition, on day 6 under fatty food condition, ritonavir, before SSD8432 dose 13 and BID on SSD8432 dosing date.~Group B: SSD8432 dose 13, on day1 fatty food condition, on day 6 under fasting condition ,Ritonavir, before SSD8432 dose 13 and BID on SSD8432 dosing date"
46075777|NCT05339646|Drug|SSD8432 dose 14 and Ritonavir|Cohort 11: to be decided
45809809|NCT04201106|Behavioral|Open Label Placebo with Rationale|In the OLP + rationale group, the participants will be prescribed to take placebos for 2 weeks with the standard 4-point accompanying rationale: (1) the placebo effect is powerful, e.g. in clinical trials placebos are roughly 80% as effective as antidepressants; (2) classical conditioning is a possible mechanism for automatic self-healing - meaning that the body can automatically respond to taking placebo pills like Pavlov's dogs who salivated when they heard a bell; (3) placebo-treated patients who are more compliant have better outcomes, therefore the placebos should be taken faithfully; and (4) positive expectations increase placebo effects, but it is OK to have doubts.
46075778|NCT00630695|Drug|Lanreotide LP 90|Lanreotide LP 90
45657707|NCT04334239|Other|Oncological certification|Oncological certification encompasses a variety of criteria such as treatment according to the clinical guidelines, staffing, technical infrastructure, minimum caseloads, and multidisciplinary care.
45809810|NCT04201106|Behavioral|Open Label Placebo without Rationale|In the OLP without rationale group, the adolescents will be asked to take placebos for 2 weeks but they will be told that the pills contain inert substance and do not have any pharmacological effect.
45657708|NCT02385669|Drug|Ipilimumab|Checkpoint blockade inhibitor
46075779|NCT00630695|Drug|Placebo lanreotide|Placebo
46075780|NCT05339490|Drug|Progenitor Biological Bandages|"The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, PBB will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1. Old PBB will be replaced by new ones according to the local procedure.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality."
45809811|NCT04174313|Diagnostic Test|CT scan|"Mechanical variables and PaO2/FiO2 were registered daily for 14 days or until initiating assisted ventilation. These data were obtained in passive mechanical conditions.~Ventilator-induced lung injury vortex was defined as a progressive increase in driving pressure (ΔP) as Vt remained constant or even decreased.~Refractory hypoxemia was defined as PaO2/FiO2 <100 despite the optimization of mechanical ventilation and prone positioning."
45809812|NCT00362024|Drug|MK0952|
45809813|NCT00362024|Drug|Comparator: Placebo|
45809814|NCT03664193|Radiation|SIBRT|Patients will receive 35 Gy in 5 fractions. Also, patients will receive 0.5-2 Gy per fx for a total dose of 37.5, 40, 42.5, or 45 Gy. Patients will also have an option to have a rectal balloon or a rectal spacer prior to receiving radiation therapy.
45835841|NCT02744430|Drug|Mirabegron|Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus >5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.
45946153|NCT03632863|Behavioral|Electronic Patient Decision Aid|"The electronic PDA is an interactive website with 3 main sections:~Review of depression treatment options (non-pharmacological and pharmacological) along with their respective risks and benefits.~Interactive values clarification exercises to help women determine which risks and benefits are most important to them.~Exercises to help women consider how partners, family, providers and the social context impacts decision-making.~A summary of how a woman feels about each option along with risks and benefits is generated which can be provided to treating clinicians for use in follow-up.~A printable pdf with standard published information and resources is also included."
45657709|NCT02385669|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
45657710|NCT05255965|Diagnostic Test|level of IL-8+ initial T cells|5ml peripheral venous blood was taken before surgery or biopsy, and the levels of initial T cell with IL-8+, PLXND1+, PTK7+ or CR2+ were detected and recorded within 6 hours, respectively.
45657711|NCT05558683|Other|Randomized clinical trial.|Our study will be a Randomized Clinical Trial. It will be held at the Aymara Abreu Physiotherapy Clinic center, with a maximum duration of 1 year. It will consist of two parts. In the first stage of the treatment we will carry out an initial assessment, and in the second stage a final assessment. After that, the corresponding data analysis will be carried out.
45657712|NCT02402907|Device|2% chlorhexidine gluconate (CHG) cloth|administration of a 2% CHG cloth at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
45809815|NCT04668248|Other|Simulation|"The simulation will consist of a one-time, short immersive simulation session at the STRATUS Center for Medical Education at BWH. The session will be conducted for up to one intern at the same time, in accordance with social distancing practices at BWH. This simulation session will consist of one short, hands-on scenario of simulated patient experiences with expert facilitators in the simulated hospital rooms to help providers identify when they are in the hot state and their reactions, and work on improving communication skills, differential diagnoses, and alternative therapeutic options. These scenarios are intended to simulate both in-person and virtual interactions that are common in the inpatient setting. During these trainings, we will use behavioral principles like time pressure and increasing cognitive load to simulate a hot state environment. After the scenarios, the facilitator will perform a debriefing session for the interns."
45809816|NCT04668248|Other|Online educational training|Providers assigned to the control arm will receive online educational training about other poorly-prescribed medications, including albumin, transfusion, and blood product repletion guidelines. This information will be in the form of electronically-delivered links to information already housed and available at BWH, including reviewing BWH guidelines and literature about transfusion reactions. The interns will be asked to answer several clinical questions about optimal prescribing. Albumin and related products are also high-risk medications often overprescribed on twilight shifts.
45946154|NCT03632863|Behavioral|Standard Resource Sheet|A control group aims to isolate the PDA's effects from time and clinical care. Controls login to the study website and receive the same printable pdf as in the PDA so that they can access standard publicly available information/resources, even if they will not receive the PDA.
45946155|NCT03610516|Drug|CFZ533|multiple doses of CFZ533 intravenous infusion
45946156|NCT03610516|Drug|Placebo|multiple doses of placebo intravenous infusion
45946157|NCT03606967|Procedure|Biopsy|Undergo tumor biopsy
45946158|NCT03606967|Procedure|Biospecimen Collection|Undergo blood sample collection
45946159|NCT03606967|Drug|Carboplatin|Given IV
45657713|NCT02402907|Device|Placebo cloth|administration of a cloth with the placebo (commercial cleansing cloth) at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
45676339|NCT03856658|Drug|Heparinized Saline|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
45946160|NCT03606967|Procedure|Computed Tomography|Undergo CT scan
45946161|NCT03606967|Biological|Durvalumab|Given IV
45946162|NCT03606967|Drug|Gemcitabine Hydrochloride|Given IV
45946163|NCT03606967|Procedure|Magnetic Resonance Imaging|Undergo MRI
45946164|NCT03606967|Drug|Nab-paclitaxel|Given IV
45809817|NCT03526055|Device|Algovita Spinal Cord Stimulation System|The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
45657714|NCT05254093|Other|Quadratus lumborum block|quadratus lumborum block, anterior approach using a curvilinear (5-8MHz) transducer. The transducer will be positioned transverse above the iliac crest at the posterior axillary line and slided posteriorly till the Shamrock sign is identified (the transvers process represent the stem and the attached erector spinae, QL and Psoas major muscles represent the three leaves). A 22 G, 100 mm needle will be advanced in-plane from lateral to medial through the QL muscle to reach the inter-fascial plane between the QL and psoas major muscles, posterior to the transversalis fascia. After ensuring negative aspiration, the local anesthetic solution (20 ml of 0.25% isobaric bupivacaine) will be injected anterior to the QL muscle. The procedure will be repeated on the opposite side of the back
45809818|NCT00360932|Device|SCULPTRA (poly-L-lactic acid injection)|Subjects will be treated with SCULPTRA® according to the investigator's judgment, and in accordance with the SCULPTRA® package insert. Details of the exact amount and the time of administration of SCULPTRA® (date, amount, location) will be documented in the CRF at each protocol and non-protocol visit.
45946165|NCT03606967|Biological|Personalized Synthetic Long Peptide Vaccine|Given SC
45946166|NCT03606967|Drug|Poly ICLC|Given SC
45809819|NCT05380050|Behavioral|Goal Management Training plus Attention Training|GMT is a Power Point directed interactive group training to use a five point strategy to plan and execute complex tasks. Attention Training utilizes Brain HQ attention modules and individualized attention goals.
45809820|NCT05380050|Behavioral|Brain Health Workshop and National Geographic Movies|BHW is a Power Point directed interactive training to learn about the brain and cognitive components. National Geographic Movies, participants select movies to watch with the therapists and answers questions regarding the content.
45809821|NCT03667547|Drug|Raltegravir|Raltegravir 600 mg tablet
45809822|NCT00361010|Drug|Levetiracetam|
45809823|NCT05060640|Procedure|Detection of anal HSIL in a routine colonoscopy.|Detection of anal HSIL in a routine colonoscopy by using acetic acid and NBI/BLI.
45809824|NCT00361088|Drug|PS-341|Phase I and II: 1.3mg/m2 iv days 1,4,8,11
45946167|NCT03606967|Biological|Tremelimumab|Given IV
45946168|NCT03603964|Drug|Guadecitabine|Guadecitabine
45676340|NCT03848845|Drug|belantamab mafodotin|belantamab mafodotin will be available as 20 milligrams per millilitre (mg/mL) solution for IV infusion, supplied as frozen liquid. belantamab mafodotin solution will be diluted in normal 0.9% saline to the appropriate concentration for the dose.
45676341|NCT03848845|Drug|Pembrolizumab|Pembrolizumab will be available as 100 mg/4 mL solution that should be stored under refrigeration at 2-8 degree Celsius. Pembrolizumab injection (solution) will be diluted prior to IV administration in 0.9% sodium chloride injection or 5% dextrose injection.
45809825|NCT00361088|Drug|R11577|"Phase I: 100mg po BID days 1014 for Cohort 1, 200mg po BID days 1014 for Cohort 2, 300mg po BID days 1014 for Cohort 3.~Phase II: Maximum Tolerated Dose (MTD)"
45946169|NCT03588702|Device|RF and PEMF treatment|Treatment with Venus Legacy LB2 body applicator
45946170|NCT03575000|Drug|Bromocriptine|This is an open-label study, so there is no comparator group. As such there is only one arm. Subjects will receive bromocriptine at a starting dose of 2.5mg daily which will be increased, if tolerated, to 5mg daily after one week. Bromocriptine will be continued for a total of 6 weeks. Laboratory investigations, telephonic interviews, and face to face visits with subjects will be conducted before, during, and after the time period that bromocriptine will be used as detailed in the study design section.
45946171|NCT03513952|Drug|Atezolizumab|Given IV
45946172|NCT03513952|Procedure|Biopsy|Undergo biopsy of tumor
46075781|NCT05339490|Device|Jelonet|"The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, Jelonet, as standard bandages, will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality."
45809826|NCT02975726|Device|Peritoneal Dialysis Catheter|Peritoneal dialysis catheter insertion in order to drain access fluid within the belly for patients with liver cirrhosis and refractory ascites.
45809827|NCT02975726|Procedure|Large Volume Paracentesis|Insertion of a needle into the peritoneal cavity where ascites accumulates, then attaching the needle to a collection system that drains the ascites by gravity. This procedure is part of the standard care for the treatment of refractory ascites.
45809828|NCT02975726|Biological|25% Human Serum Albumin injection|Patients will be given Human Serum Albumin after the initial drain of ascites fluid: 100cc for 5-10L drainage, 200cc for 10-15L drainage.
45946173|NCT03513952|Procedure|Biospecimen Collection|Undergo collection of blood and stool samples
45946174|NCT03513952|Procedure|Computed Tomography|Undergo CT
45946175|NCT03513952|Biological|Glycosylated Recombinant Human Interleukin-7|Given IM
45946176|NCT03513952|Other|Laboratory Biomarker Analysis|Correlative studies
45946177|NCT03513952|Procedure|Magnetic Resonance Imaging|Undergo MRI
46075782|NCT02843438|Other|Fluorescein angiography|
46075783|NCT02843438|Other|Dilated fundus examination|
46075784|NCT02843438|Biological|Toxoplasmosis serology|
46075785|NCT02843438|Drug|Anti-toxoplasmosis treatment|
46075786|NCT02843438|Drug|Anti-inflammatory treatments|
45946178|NCT03513952|Procedure|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT
45809829|NCT02975726|Procedure|Bloodwork|Monthly bloodwork will be done as part of usual standard of care.
45809830|NCT04160975|Behavioral|Video about safety and effectiveness of adult seasonal flu vaccination|The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination. The content of the video will be the safety and effectiveness of adult seasonal flu vaccination. The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.
45657715|NCT05254093|Other|erector spinae plane block|the block will be given at the level of the 9th thoracic transverse process using a linear 6-13 MHz ultrasound transducer. The transducer will be positioned vertically 3 cm to the side of the midline to visualize the muscles of the back, the transverse process, and the pleura between the two transverse processes. Then, a 22G 10-mm needle will be introduced in the cranial-caudal direction toward the transverse process (T9) using the in-plane method till the needle tip crosses all the muscles. The tip of needle should be in the plane between the transverse process and the erector spinae muscle. After ensuring negative aspiration, the local anesthetic solution (20 ml of 0.25% isobaric bupivacaine) will be injected below the muscle. The procedure will be repeated on the opposite side of the back
45946179|NCT03502733|Procedure|Biopsy|Undergo tumor biopsy
45946180|NCT03502733|Procedure|Biospecimen Collection|Undergo blood sample collection
45809831|NCT04833816|Drug|Administration of drug|Administration of ketamin during the 48h after trauma
45809832|NCT04172402|Drug|TS-1|Intervention is administered to patients in this Arm.
45809833|NCT04172402|Drug|Gemcitabine|Intervention is administered to patients in this Arm.
45809834|NCT04172402|Drug|Nivolumab|Intervention is administered to patients in this Arm.
45657716|NCT02345889|Device|Colonoscopy with EndoCuff™|colonoscopy performed with an EndoCuff™ device at the tip of a standard colonoscope
45809835|NCT04153409|Drug|LAT8881|Two 30 mg capsules of LAT8881
45946181|NCT03502733|Procedure|Computed Tomography|Undergo CT scan
45946182|NCT03502733|Drug|Copanlisib|Given IV
45657717|NCT02345889|Device|FUSE® Colonoscopy|colonoscopy performed with the FUSE® (full spectrum endoscopy) system
45657718|NCT02345889|Device|Colonoscopy with EndoRings™|colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
45809836|NCT04153409|Drug|Placebo|Two capsules of placebo
45809837|NCT01638390|Device|Treatment with the VisuMax™ Femtosecond Laser|The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
45809838|NCT04662242|Drug|Selenium Supplement|Zelnite 400mcg/day in normal saline 100ml iv infusion for 7 days
45809839|NCT04662242|Drug|normal saline|normal saline 100ml iv infusion for 7 days
45946183|NCT03502733|Biological|Ipilimumab|Given IV
46075787|NCT02843438|Other|Puncture in anterior chamber|
45809840|NCT03535571|Dietary Supplement|Salmon Protein Hydrolysate|4g of salmon protein hydrolysate per serving.
45809841|NCT05373342|Device|iCount system assembled with swabs|Designed as single use. Intended purpose - To be used to count swabs and tampons after childbirth in an objective manner. This is intended to be used in women during and after childbirth.
45809842|NCT04658966|Other|administration of a self-questionnaire|Women will have to fill in an online self questionnaire on pre-eclampsia
45835842|NCT02744430|Other|Placebo|Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus >5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.
45946184|NCT03502733|Procedure|Magnetic Resonance Imaging|Undergo MRI
45946185|NCT03502733|Biological|Nivolumab|Given IV
45946186|NCT03498261|Drug|Gabapentin|Gabapentin has been commonly used as an adjuvant in the treatment of neuropathic pain.
45946187|NCT03498261|Drug|Placebos|Placebo
46075788|NCT00954707|Drug|Clopidogrel & Aspirin, Prasugrel & Aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of thienopyridine treatment in addition to aspirin.
45946188|NCT03495921|Biological|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.
45946189|NCT03495921|Drug|Irinotecan|Injectable formulation of irinotecan was distributed from central supplier. 1 Cycle (5 doses of 50 mg/m2 per syringe) was drawn into provided oral syringes and dispenses to the subject with instructions to refrigerate until administration.
45946190|NCT03495921|Drug|Temozolomide|Dose: 100 mg/m2 daily, oral Schedule: Days 1-5, every 21 days Administered at least 1 hour before Irinotecan.
45657719|NCT02345889|Device|Standard Colonoscopy|Current standard of care colonoscopy
45657720|NCT05549947|Drug|SHR1819|Treatment group A：SHR-1819 injection dose 1， Treatment group B：SHR-1819 injection dose 2， Treatment group C：SHR-1819 injection dose 3，
45657721|NCT05549947|Drug|Placebo|Treatment group D：placebo
45657722|NCT05556421|Diagnostic Test|uterocervical angle|uterocervical angles were measured for both groups by transvaginal ultrasonography and investigated whether the uterocervical angle had any effect in predicting the displacement of copper intrauterine devices.
45809843|NCT04332185|Procedure|vestibular socket therapy|(VST) included the following steps. a-traumatic tooth extraction, the socket curetted and rinsed with normal saline thoroughly . One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a micro screw to the alveolar bone apical to the base of the socket .
45809844|NCT05026008|Drug|SR1375|The subject will be orally administered by single and multiple doses of SR1375 capsules with 240 ml water
45946191|NCT03475186|Drug|Ramipril|2.5 - 5 mg oral, 1x daily for 22 weeks
45946192|NCT03467724|Device|fractional radiofrequency|Fractional radiofrequency will be delivered to the area of the surgical scar identified to receive the study treatment.
45946193|NCT03456700|Drug|Auranofin|Given PO
45946194|NCT03456700|Other|Laboratory Biomarker Analysis|Correlative studies
45946195|NCT03456700|Drug|Sirolimus|Given PO
45946196|NCT03453710|Procedure|Bankart Repair plus Remplissage|"Arthroscopic Bankart repair with a minimum of 3 anchors~1 or 2 anchor Remplissage subsequently performed with percutaneous anchor insertion in the base of the Hill-Sachs defect, and sutures passed in a horizontal mattress configuration 1 cm apart, tied in the subacromial space."
45946197|NCT03453710|Procedure|Latarjet coracoid transfer|Coracoid transfer performed via deltopectoral approach with horizontal subscapularis split. Graft placed in the conventional orientation, secured with 2 screws, ensuring the graft is not lateral to the glenoid rim.
45946198|NCT03449680|Procedure|Femoral Articular Branch Block|Slow injection (3mL aliquots) of local anesthetic solution (20ml of Ropivacaine 0.5%) into the fascia above the iliopsoas muscle (located in the groove between the two bony landmarks - (1)anterior inferior iliac crest and (2)iliopubic eminence).This is done by ultrasound guidance.
45946199|NCT03449680|Procedure|Placebo Block|Subcutaneous injection of 1ml normal sterile saline
45946200|NCT03400618|Other|Moderate carbohydrate diet|30 E % carbohydrates included in the diet
46075789|NCT00954707|Drug|Placebo & Aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
46075790|NCT05334992|Behavioral|Mindfulness Based Cognitive Therapy|Individual therapy 12 to 16 weeks
46075791|NCT05334992|Behavioral|Behavior Activation|Individual therapy 12 to 16 weeks
45657723|NCT04328623|Procedure|Hypnosis|"conversational hypnosis technique call the magic glove"
45657724|NCT04328623|Procedure|Infiltration|Ultrasound-guided hand infiltration
45809845|NCT05026008|Drug|Matching placebo|The subject will be orally administered by single and multiple doses of matching capsules with 240 ml water
45809846|NCT04160546|Drug|Ponatinib 15 MG|"Patients will receive ponatinib 15 mg/day for 104 weeks orally. Ponatinib will be self-administered by the patient on a daily schedule.~Acetyl salicylic acid (ASA) (100 mg) will be used such auxiliary medicinal product in order to prevent vascular occlusive events related with ponatinib."
45809847|NCT04160546|Drug|Acetylsalicylic acid 100 MG|Patients will receive acetylsalicylic acid 100 mg/day for 104 weeks orally.
45809848|NCT03675581|Drug|Microgynon|fixed sequence trial
45809849|NCT03675581|Drug|Nintedanib|fixed sequence trial
45835843|NCT05208138|Device|Senhance Surgical System from Asensus|Bariatric operation with the Senhance Surgical System
45946201|NCT03400618|Other|Higher carbohydrate diet|50 E % carbohydrates included in the diet
45946202|NCT03380819|Diagnostic Test|Genome sequencing|Patients will undergo exome or genome sequencing, and their referring provider will receive an interpreted report with the following categories of results: 1) results related to the indication for testing, 2) secondary monogenic results, 3) carrier status, 4) pharmacogenomics results.
45946203|NCT03372148|Diagnostic Test|pHRMi|Pharyngeal High Resolution Manometry and Impedance swallowing function evaluation
45657725|NCT02345811|Device|Sapphire|silicone-hydrogel contact lens
45657726|NCT02345811|Device|senofilcon A|contact lens
45657727|NCT05558371|Other|No intervention.|No intervention administered as part of this study; observational only.
45946204|NCT03539536|Drug|Telisotuzumab vedotin|Intravenous (IV) infusion
45946205|NCT03363919|Device|NeuroStar TMS Therapy® System|The NeuroStar TMS Therapy® System is a computerized electromechanical instrument that produces and delivers brief duration, rapidly alternating (pulsed) magnetic fields to induce electrical currents in localized regions of the cerebral cortex. It is a non-invasive tool used for the treatment of Participants with MDD who have not achieved sufficient clinical benefit from antidepressant pharmacotherapy.
45946206|NCT03363919|Device|NeuroStar XPLOR®|NeuroStar XPLOR® is a clinical research option for the NeuroStar TMS Therapy System that provides features necessary to conduct randomized controlled trials and other TMS research.
45946207|NCT03363165|Drug|VM202|"Participants randomized to VM202 will receive calf muscle injections of VM202 to each leg with evidence of PAD. Injections of VM202 are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Therefore, participants randomized to VM202 will receive 4 mgs of VM202 in each calf muscle on each treatment day. Injections are placed beginning 2 cm below the popliteal crease, and are administered in a pre-designed sequence and pattern, at a measured distance 2 cm apart.~Note: Participants who have a evidence of PAD in only one leg will only receive injections in the leg with evidence of PAD."
45946208|NCT03363165|Other|Placebo|"Participants randomized to placebo will receive calf muscle injections of placebo (the excipient buffer formulation minus the VM202) to each leg with evidence of PAD. Injections of placebo are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Placebo appears identical to the VM202 study drug and is administered in a pattern on the calf identical to that of the VM202 injections.~Note: Participants who have a evidence of PAD in only one leg will only receive injections in the leg with evidence of PAD."
45946209|NCT03360396|Device|Endobronchial Coils|Endobronchial Coil implants
45946210|NCT03327129|Procedure|fMRI|An fMRI scan will be conducted to collect neuroimaging data. The scanning session will consist of a structural MRI, followed by resting state and task-based functional MRI protocol.
45809850|NCT05157438|Behavioral|virtual reality device|The virtual reality device is a 3D head-mounted display which provides a wide field of view and a high-resolution visual display, it has been used to manage cases of phobia and extreme fear through the use of exposure-based treatment programs. The virtual reality system consists of head mounted glasses, a compatible smartphone and headphones. This technology creates a computer stimulated virtual environment into which the child can be entirely immersed. It works to distract the brain from the painful procedure and reduce the perception of pain stimuli
45946211|NCT03321643|Drug|Atezolizumab|Given IV
45946212|NCT03321643|Procedure|Biopsy|Undergo biopsy
45657728|NCT05549869|Diagnostic Test|serum leptin|Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators
45809851|NCT05157438|Behavioral|screen programs|the screens are used for distraction during dental treatments. they could be on tablets, iPads or televisions.
45946213|NCT03321643|Procedure|Biospecimen Collection|Undergo collection of blood samples
45946214|NCT03321643|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
45946215|NCT03321643|Procedure|Computed Tomography|Undergo CT or PET-CT
45946216|NCT03321643|Drug|Gemcitabine|Given IV
45946217|NCT03321643|Procedure|Magnetic Resonance Imaging|Undergo MRI
45946218|NCT03321643|Drug|Oxaliplatin|Given IV
45946219|NCT03321643|Procedure|Positron Emission Tomography|Undergo PET-CT
45946220|NCT03321643|Biological|Rituximab|Given IV
45946221|NCT03317977|Behavioral|Reach for Control|In Phase 1 (weeks 1-4), the CHW conducts an initial intake and then completes a comprehensive functional analysis (FA) of behavior to determine the causes of poor asthma management for each youth regarding asthma management. In Phase 2 (weeks 5-20) is a treatment phase and consists of a combination of mandatory cognitive-behavioral skills training (CBST) modules (received by all families) and flexible CBST modules chosen and individualized based on the results of the Phase 1 FA. This includes but not limited to In-vivo Asthma Skills Training, Improving Family Communication and Behavioral Contracting. Phase 3 (weeks 21-24) involves termination planning and relapse prevention
45657729|NCT05556109|Diagnostic Test|Inflammatory serum biomarkers|Measuring inflammatory serum biomarkers by ELISA
45657730|NCT02586493|Drug|Placebo|Subjects will receive 1 inhalation once-daily until visit 2.
45657731|NCT02586493|Other|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
45657732|NCT05543395|Behavioral|Domestic Violence Questionnaire|Domestic Violence Questionnaire
45657733|NCT02400333|Drug|Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water|90 mg single dose
45657734|NCT02400333|Drug|Ticagrelor OD tablet (90 mg single dose) administered without water|90 mg single dose
45657735|NCT02400333|Drug|Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube|90 mg single dose
45809852|NCT02975960|Biological|injection of autologous stromal vascular fraction|"Acquiring autologous stromal vascular fraction (SVF) from liposuction~purifying SVF from lipoaspirates and making syringe filled with SVF~SVF injection - Inject SVF on fingers subcutaneously."
45809853|NCT05142228|Drug|Erenumab-Aooe|Administered once every 4weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
45809854|NCT05142228|Other|Placebo|Administered once every 4weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
45809855|NCT04154540|Other|Motion analysis|Gait and posture recording
45946222|NCT03317977|Behavioral|MATCH|Managing Asthma Through Case Management in Home (MATCH) is the current intervention provided by WCHAP to youth with poorly controlled asthma and their families.
45946223|NCT03296592|Diagnostic Test|MRI with DBSI technology|The MRI will be done with diffusion basis spectrum imaging
45946224|NCT03278925|Procedure|Biopsy|Undergo biopsy
45946225|NCT03278925|Procedure|Biospecimen Collection|Undergo collection of blood samples
45946226|NCT03278925|Procedure|Computed Tomography|Undergo CT
45657736|NCT02400333|Drug|Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water|90 mg single dose
45657737|NCT02399475|Drug|Levothyroxine|Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L
45657738|NCT02399475|Drug|Liothyronine|Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L
45809856|NCT03678311|Device|Continuous Positive Airway Pressure (CPAP)|If diagnosed with Long QT Syndrome and have Sleep Apnea index >5 pauses per hour then given CPAP to wear for approximately 3 months.
45657739|NCT02399475|Drug|Thyrotropin-Releasing Hormone|200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).
45809857|NCT03821636|Procedure|Standard Roux-en-Y gastric bypass|Standard Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 25 % of total length of the intestine (150 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 65 % of total length of the intestine (400 cm).
45809858|NCT03821636|Procedure|Long alimentary limb Roux-en-Y gastric bypass|Long alimentary limb Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 45 % of total length of the intestine (280 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 45 % of total length of the intestine (280 cm
45809859|NCT00362102|Drug|Cetuximab|
45809860|NCT05122026|Drug|Rifapentine|As included in arm/group description
45809861|NCT05122026|Drug|Isoniazid|As included in arm/group description
45809862|NCT04658498|Other|Procedure: Usual Care (UC)|Intermittent spontaneous breathing periods
46075792|NCT02857517|Drug|conbercept|0.05ml conbercept
45809863|NCT04658498|Other|Procedure: UC + HI-IMT|UC + Supervised daily sessions of training including 4 sets of 6-10 full vital capacity breaths against an external load using a tapered flow resistive device (POWERbreathe KH2, HaB International, UK). The maximum tolerable resistance allowing patients to inhale at least 70% of their inspiratory vital capacity will be chosen and progressively increased throughout the training period.
45809864|NCT04658498|Other|Procedure: UC + LI-IMT (sham IMT)|UC + superrvised daily sessions of training including 4 sets of 6-10 breaths at the lowest external imposable load with the tapered flow resistive device (POWERbreathe KH2, HaB International, UK) (i.e. 3 cmH2O).
45809865|NCT04655430|Other|3-second SDF application|Dosage: 3-second 38% SDF solution application
45809866|NCT04655430|Other|5-second SDF application|Dosage: 5-second 38% SDF solution application
45809867|NCT04655430|Other|10-second SDF application|Dosage: 10-second 38% SDF solution application
45809868|NCT04655430|Other|15-second SDF application|Dosage: 15-second 38% SDF solution application
45809869|NCT04655430|Other|30-second SDF application|Dosage: 30-second 38% SDF solution application
45809870|NCT04655430|Other|45-second SDF application|Dosage: 45-second 38% SDF solution application
45809871|NCT04655430|Other|60-second SDF application|Dosage: 60-second 38% SDF solution application
45809872|NCT04655430|Other|120-second SDF application|Dosage: 120-second 38% SDF solution application
45809873|NCT04655430|Other|180-second SDF application|Dosage: 180-second 38% SDF solution application
46075793|NCT04992390|Behavioral|Brief digital imagery-competing task intervention|"First session guided by a researcher: A memory cue followed by playing the brief digital imagery-competing task with mental rotation instructions.~Option to engage in self-administered/guided sessions after the first session and record their intrusive memories (symptom monitoring)."
46075794|NCT00589797|Device|Activ-L Artificial Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
45657740|NCT04420377|Dietary Supplement|Carnipure|Supplement contains L-carnitine tartrate.
45657741|NCT04420377|Other|Resistance Training|5 weeks of whole-body resistance training, performed 2 times per week.
45657742|NCT02399163|Drug|Fluoride free toothpaste|Brushing with fluoride free toothpaste
45809874|NCT04651296|Behavioral|compassion meditation|manualized compassion meditation training
45809875|NCT04651296|Behavioral|health education|manualized health education group
45809876|NCT02958878|Drug|Tamsulosin|
45809877|NCT02958878|Drug|Placebo Oral Capsule|
45809878|NCT03813524|Device|Cardiovalve Transfemoral Mitral Valve|The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
45809879|NCT03812276|Device|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).
45809880|NCT04154384|Behavioral|Pain Management Strategies|The Life Care Specialist (LCS) teaches evidence-informed behavioral interventions and will work with the patient to develop personalized pain management strategies focused on behavioral education, including progressive muscle relaxation (PMR), the Community Resiliency Model (CRM®), motivational interviewing, and reflective listening.
45946227|NCT03278925|Drug|Defined Green Tea Catechin Extract|Given PO
45946228|NCT03278925|Other|Laboratory Biomarker Analysis|Correlative studies
45946229|NCT03278925|Procedure|Magnetic Resonance Imaging|Undergo MRI
45946230|NCT03278925|Other|Pharmacological Study|Correlative studies
45946231|NCT03278925|Other|Questionnaire Administration|Ancillary studies
45946232|NCT03278925|Procedure|Ultrasound|Undergo ultrasound
46075795|NCT00589797|Device|ProDisc-L Total Disc Replacement or Charité Artificial Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
46075796|NCT05052606|Other|No intervention|This study is an observational study without treatment intervention.
45946233|NCT03258567|Biological|Nivolumab|Nivolumab, 480 mg IV every 4 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment
45657743|NCT02399163|Drug|Fluoride toothpaste|Brushing with fluoride containing toothpaste
45657744|NCT02399163|Drug|Fluoride mouthwash|"Fluoride mouth wash to be followed after brushing with fluoride free toothpaste in Placebo dentifrice/Fluoride rinse arm and in Fluoride dentifrice/Fluoride rinse arm"
45657745|NCT02398227|Behavioral|HOPE|Cognitive Behavioral Treatment for PTSD in Battered Women
45809881|NCT04154384|Behavioral|Life Care Specialist (LCS) Intervention|The Life Care Specialist (LCS) uses a two-arm approach to education by initially assessing participants general understanding of opioids upon which targeted education is tailored and applied and secondly, building a longitudinal relationship with each patient to increase the saliency of administered opioid education during postoperative follow-up. Information includes proper disposal, common symptoms of opioid use, signs of dependence and overdose and use of naloxone. Information is disseminated orally with adjunct physical resource guides including visual representations and literature.
45657746|NCT02398227|Behavioral|PCT|Present Centered Therapy for PTSD
45946234|NCT03258554|Biological|Cetuximab|Given IV
45946235|NCT03258554|Biological|Durvalumab|Given IV
45946236|NCT03258554|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45946237|NCT03258554|Other|Laboratory Biomarker Analysis|Correlative studies
45657747|NCT02397915|Drug|FF nasal spray|FF as a suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose x 4 doses (total dose 110 mcg) administered via a metered side-actuated nasal spray device.
45657748|NCT02397915|Drug|MF nasal spray|MF as a suspension for intranasal inhalation with unit dose strength of 50 mcg per dose x 4 doses (total dose 200 mcg) administered via a metered top-actuated nasal spray device.
45657749|NCT02397837|Drug|Pramipexole|Up to 4.5mg, PO, (by mouth) per day of the 12-week study.
45809882|NCT04154384|Other|Clinical Coordination with Referrals|The Life Care Specialist (LCS) can help arrange a referral for the participant, should a medical or social issue be identified during LCS intervention, including mental health services, addiction medicine services, housing insecurity referrals, food insecurity referrals, and amputee support. When giving referrals, the LCS works closely with physicians and nurses to make sure that the participant is a good fit for the referral program.
45809883|NCT02976116|Drug|Fruquintinib|Fruquintinib will be administered orally once daily from Day 1 to Day 21 per 28-day cycle until disease progression or unacceptable toxicity
45809884|NCT02976116|Drug|Gefitinib|Gefitinib will be administered orally once daily per 28-day cycle or unacceptable toxicity
45809885|NCT01600716|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1 in the onabotulinumtoxinA 100 U arm. After a minimum of 12 weeks, patients in both the onabotulinumtoxinA 100 U arm and the placebo arm could request/qualify for an onabotulinumtoxinA injection.
45809886|NCT01600716|Drug|Placebo (Normal Saline)|Placebo (normal saline) is administered into the detrusor at Day 1.
45809887|NCT02975258|Procedure|Blood draw|Blood will be drawn for plasma, serum, and peripheral blood mononuclear cells.
45946238|NCT03258554|Other|Quality-of-Life Assessment|Ancillary studies
45946239|NCT03258554|Other|Questionnaire Administration|Ancillary studies
45946240|NCT03212274|Procedure|Biopsy|Undergo tissue biopsy
45946241|NCT03212274|Procedure|Biospecimen Collection|Undergo blood sample collection
45657750|NCT02397837|Drug|Placebo|placebo match study drug
45657751|NCT02586415|Procedure|Endovascular Thrombectomy|Patients will be treated with thrombectomy devices (stent-retrievers) and/or suction thrombectomy systems currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke following the published instructions for use for these devices. These devices will be used between 6 and 16 hours following symptom onset in DEFUSE 3 based on an FDA IDE. The devices which will be used are the Trevo Retriever, the Solitaire Revascularization Device and the Penumbra system thrombectomy system.
45657752|NCT02586415|Device|Trevo Retriever|Trevo Retriever is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
45657753|NCT02586415|Device|Solitaire™ FR Revascularization Device|Solitaire™ FR Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
45657754|NCT02586415|Device|Penumbra thrombectomy system|"Penumbra thrombectomy system is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure. The Penumbra System includes:~• Penumbra Aspiration Pump (1115V) Penumbra System 054 Penumbra System MAX Penumbra System 110 Aspiration Tubing Penumbra System [026, 032, 041] Penumbra System Separator Flex [026, 032, 041, 054] Penumbra Pump MAX Penumbra System Reperfusion Catheter ACE64 & ACE68"
45946242|NCT03212274|Procedure|Computed Tomography|Undergo a CT scan
45946243|NCT03212274|Procedure|Magnetic Resonance Imaging|Undergo a MRI
45946244|NCT03212274|Drug|Olaparib|Given PO
45946245|NCT03210714|Procedure|Biospecimen Collection|Undergo blood sample collection
45946246|NCT03210714|Procedure|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
45946247|NCT03210714|Procedure|Bone Scan|Undergo a bone scan
45946248|NCT03210714|Procedure|Computed Tomography|Undergo a CT scan
45946249|NCT03210714|Drug|Erdafitinib|Given PO
45946250|NCT03210714|Other|Laboratory Biomarker Analysis|Correlative studies
45946251|NCT03210714|Procedure|Magnetic Resonance Imaging|Undergo MRI
45946252|NCT03210714|Other|Pharmacological Study|Correlative studies
45946253|NCT03210714|Procedure|Positron Emission Tomography|Undergo a PET scan
45946254|NCT03210714|Procedure|Radionuclide Imaging|Undergo radionuclide imaging
46075797|NCT00630851|Drug|Donepezil (Aricept)|Donepezil (Aricept) 5 mg tablet orally once daily for 30 days, followed by 10 mg tablet orally once daily to complete 6 months of treatment
46075798|NCT00630851|Drug|Placebo|Matching placebo tablets orally once daily for 6 months
45458396|NCT03501160|Other|Face-to face semi-structured in-depth interview|Face-to face semi-structured in-depth interview will be arranged in order to explore the inappropriate social behavior and caregiver stress from caregivers. The interview will be guided by a semi-structured interview guide which specially designed for exploring clinical picture of inappropriate social and affectionate behavior and caregiving distress. The interview guide mainly consisted of specific questions and open-ended questions that encourage the subjects to talk freely in relevant topics during interview. Demographic data was also collected in the beginning of interview. Each interview will be conducted around 60 minutes until data saturated. The interview will be audio-taped with informed consent from subjects.
45657755|NCT02586415|Device|Covidien MindFrame Capture Revascularization Device|Covidien MindFrame Capture Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
45657756|NCT02383173|Other|Basic Implementation Approach|Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using a Basic Implementation Approach with a teleconference to review educational materials and activate PCCTs to educate other providers.
45657757|NCT02383173|Other|Enhanced Implementation Approach|"Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using an Enhanced Implementation Approach with in-person, train-the-champion workshops to prepare PCCT members to be leaders and trainers at their home sites"
45657758|NCT02383017|Dietary Supplement|Shroom Tech Sport|STS will be given every day in accordance to company guidelines for 12 weeks.
46075799|NCT00613171|Drug|STI571|STI571 tablets taken orally once a day
45657759|NCT02383017|Dietary Supplement|Placebo|Placebo will be given in the same fashion as the STS pills guidelines for 12 weeks.
45657760|NCT05556031|Other|Standard care|Standard clinical care
45809888|NCT02975258|Other|Questionnaires|The following questionnaires are administered to participants by study personnel: Gingo Asthma Questionnaire (GAQ) and the Asthma Quality of Life questionnaire (AQL).
45809889|NCT02975258|Procedure|Spirometry|Spirometry is a simple breathing test that measures the amount of air in one's lungs and how well one can move that air by forcefully blowing 3 or more times into a mouthpiece. A series of these maneuvers will be performed under the instruction of a respiratory technician or respiratory therapist.
45809890|NCT02975258|Procedure|Methacholine challenge test|A methacholine challenge is a common test often used to support a diagnosis of asthma. The test consists of inhaling increasing doses of methacholine through a nebulizer to assess how quickly the participant's airways narrow.
45809891|NCT02975258|Radiation|Quantitative CT scans|There will be a standard chest CT and an abdominal CT. The CT scans capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and the abdomen and will be performed during a breath-hold at end-inspiration. The investigators will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized. If the participant has had a research chest CT scan done recently, only the abdomen CT will be done.
45809892|NCT02975258|Procedure|Urine pregnancy test|All female participants with childbearing potential will be asked to provide a urine sample for pregnancy testing. The result of the pregnancy test must be negative in order for her to be in this research study.
45946255|NCT03210714|Procedure|X-Ray Imaging|Undergo an x-ray
45946256|NCT03198650|Drug|Acalabrutinib|Acalabrutinib
46075800|NCT05156892|Drug|SUBA-itraconazole|150 mg BD
46075801|NCT05156892|Drug|Tamoxifen|"Dose Escalation:~Cohort 1: 20 mg OD Cohort 2: 40 mg OD Cohort 3: 60 mg OD~Dose-Expansion: Recommended dose from dose-escalation phase of study"
46075802|NCT03894345|Drug|Prazosin|Competitive alpha-1 adrenergic receptor blocker which has been used to treat PTSD and Benign Prostatic Hypertrophy
46075803|NCT05154006|Behavioral|Information about benefits of the behavior|The women will be informed that the safe carrying behaviors can reduce pelvic strain. She is informed about the benefits reducing pelvic strain may imply [5.1; 5.3.,5.6 Information about health; environmental; social; and emotional consequences, (Michie et al., 2013)]
46075804|NCT05154006|Behavioral|Instruction on how to perform a behavior|"For the target behavior reduce carried weight information on recommended weight limits will be given. The women will be encouraged, that even if these limits may not be feasible for them, any reduction of weight can still reduce the strain on the pelvic floor.~For the target behavior safe lifting techniques, instructions to learn the correct behavior (how to perform safe lifting techniques?) based on leaflets developed and validated by Caagbay et al., (2017, 2020) [4.1 Instruction on how to perform a behavior (Michie et al., 2013)]"
46075805|NCT05154006|Behavioral|Self-efficacy|Self-efficacy will be promoted by the four sources of self-efficacy (Bandura, 1977): 1) Mastery Experiences (experience that one is able to successfully apply the behavior), vicarious experience (observing successful others performing the safe carrying behavior), verbal persuasion (receiving positive feedback when performing the behavior and encouraging messages to do so) and emotional state (e.g. being in a positive emotional state when performing the behavior). [6.1 Demonstration of the behavior; 8.1 Behavioral practice/rehearsal; 15.1 Verbal persuasion about capability; 15.2 Mental rehearsal of successful performance; 15.3 Focus on past success;15.4 Self-talk; 5.4 Monitoring of emotional consequences (Michie et al., 2013)]
45946257|NCT03198650|Drug|Obinutuzumab|Obinutuzumab
45946258|NCT03191864|Drug|APT-1011|APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate
45946259|NCT03191864|Drug|Placebo|Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.
45946260|NCT03176732|Device|Positive Airway Pressure|Participants will use Positive Airway Pressure (PAP) treatment
45657761|NCT05549791|Drug|Remimazolam Tosilate for Injection|Remimazolam Tosilate for Injection
46075806|NCT05154006|Behavioral|Social Support|A self-selected social partner from the same or neighboring household (e.g. husband, mother-in-law) will be involved in the learning process (observational learning, feedback). The partner will participate in the intervention activities and will be instructed to provide emotional social support and practical informational support. [3.2 practical support, 3.3 emotional support; 6.3 Information about others' approval (Michie et al., 2013).]
46075807|NCT02859077|Drug|EGFR-TKI|EGFR-TKI (gefitinib)
46075808|NCT02859077|Drug|Chemotherapy（pemetrexed/gemcitabine）|Chemotherapy (pemetrexed/gemcitabine)
46075809|NCT02859077|Drug|Chemotherapy（carboplatin）|Chemotherapy（carboplatin）
46075810|NCT00896480|Biological|Immunotherapeutic GSK2132231A|Administration by intramuscular injection
46075811|NCT05149794|Other|Calisthenic Exercises|Bunny Jumps, Bear Crawls, Bear Crawls, Bird Dog . these intervention were used
46075812|NCT00879307|Drug|quetiapine|Use of quetiapine for 16 weeks in acute mania and depression
45657762|NCT02382939|Drug|somapacitan|Administered subcutaneously (s.c., under the skin) with an investigational pen once weekly for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
45657763|NCT02382939|Drug|somatropin|Administered subcutaneously (s.c., under the skin) with a prefilled pen (Norditropin® FlexPro®) daily for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
45657764|NCT05549557|Drug|IMM40H|IMM40H is a monoclonal antibody with a molecular generated from ImmuneOnco's antibody platform. IMM40H targets CD70 (a tumor cell marker).
45657765|NCT05543005|Other|maternal voice intervention|maternal voice in terms of lullaby, music, and meaningful words plays near the head of premature infant in the incubator by 30 mins each time after routine care period
45657766|NCT05542927|Diagnostic Test|urine chloride|Serum chloride, urinary chloride & serum creatinine will be requested on the first day of admission in Intensive Care Unit (ICU). 2. Serum chloride & urinary chloride will be requested every 48 hours in ICU with correlation between urinary chloride concentrations, AKI & mortality. 3. Serum creatinine will be requested every 24 hours in ICU. 4. Monitoring of Urinary Output (U.O.P.) every 24 hours
45657767|NCT04425889|Diagnostic Test|COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA)|a blood sample is drained for detection of IgG and IgM antibody
45657768|NCT05555563|Other|MTAD irrigation|Final irrigation protocol was performed using 5 ml MTAD (n=50).
45657769|NCT04426435|Drug|honey based (HB) syrup|"honey-based syrup is prepared according to the documented Persian Medicine manuscripts with some modifications. HB is a mixture of honey, rose water and saffron. Each 100g of HB consisted of 79.87 g honey, 19.97 g rose water, and 0.16 g saffron.~All the ingredients were licensed and approved by The Islamic Republic of Iran Food and Drug Organization (I.R.I.FDO)."
45657770|NCT05549245|Device|high-flow nasal cannula oxygen therapy,|Patients were treated with high-flow nasal cannula oxygen therapy for three nights
45809893|NCT02975258|Procedure|Adipose biopsy|The doctor will obtain a sample of fat cells from the participant's abdomen. Numbing medicine will be applied. A needle is placed through the skin & into the fat pad under the skin. A blunt-tip hollow cannula is then used to aspirate fat tissue through the incision.
45809894|NCT02975258|Procedure|Exhaled nitric oxide measurement|The investigators will measure concentrations of exhaled nitric oxide by asking the participant to inhale deeply, and then exhale very slowly into a mouthpiece for between 10-15 seconds.
45809895|NCT03680105|Drug|RJX|RJX is an IV infusion formulation. The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).
45809896|NCT03680105|Drug|Placebo|Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.
46075813|NCT02857127|Behavioral|Walking program|To encourage people to exercise more through a behavioural and educational intervention during six months and other six months of follow up.
46075814|NCT03851835|Drug|Ondansetron Oral Solution|Six doses of oral ondansetron (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24 hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use).
45458397|NCT01351298|Drug|0.05% xylometazoline hydrochloride with 1% lidocaine hydrochloride|Decongestant with local anesthetic
45458398|NCT01351298|Drug|0.05% xylometazoline hydrochloride|Decongestant
45458399|NCT01351298|Drug|Isotonic normal saline|Placebo
45657771|NCT05549245|Device|CPAP|Patients were treated with CPAP for three nights
45458400|NCT02324686|Drug|vitamin K1|Vitamin K1 400 mcg orally three times a week on dialysis days for four months
45458401|NCT01360034|Drug|Nifedipine|Nifedipine: 20 mg as a single dose upon admission and then 10 mg vo every 8 hours for 48 hours.
45676342|NCT03811847|Drug|Methylphenidate Extended Release Oral Capsule|"Stimulant It can treat ADHD and narcolepsy.~1 capsule 18mg"
45676343|NCT03811847|Other|Placebo|Placebo comparator MPH Matched Placebo Tablet
45809897|NCT05114460|Drug|Naloxone|Intranasal Naloxone
45809898|NCT05114460|Drug|Marijuana|Vaped Marijuana
45809899|NCT04844814|Drug|Anakinra 100Mg/0.67Ml Inj Syringe|Anakinra 100 mg/d subcutaneous injection
45809900|NCT04844814|Drug|Prednisone|Prednisone 30 mg/d
45809901|NCT04844814|Drug|Placebo of Prednisone|Placebo of Prednisone
45809902|NCT04844814|Drug|Placebo of Anakinra|Placebo of Anakinra
45809903|NCT04833270|Other|KM non-pharmacological treatment group|This is a pragmatic setting, and specific intervention is not determined prior to the study. Non-pharmacological treatment including Korean medicine, such as acupuncture, electroacupuncture and chuna, etc, will be chosen by professional physician according to the medical condition of each subject.
45809904|NCT04833270|Other|Pharmacological treatment group|This is a pragmatic setting, and specific intervention is not determined prior to the study. The pharmacological treatment will be chosen by professional physician according to the medical condition of each subject.
45657772|NCT05699005|Drug|Packed Red Blood Cells (PRBCs)|"Patient will recieve PRBCs transfusion only in case of ScVO2 level<65% after assessment of patient for optimisation of SaO2 targeting 100%, volume status, ECMO flow (increase to 20% in relevant), pain, anxiety and fever (body temperature >38°3).~In both groups transfusion may be performed in case massive bleeding according to local protocols, STEMI, Hyperlactatemia >4 that can be related to oxygen demand and supply DO2/VO2 ratio impairement, in all groups, transfusion should be performed in case of hemolobin level <7g/dL or worsening of neurological condition (Increase in Neurological SOFA component of 1 and more) related to DO2/VO2 impairement."
45946261|NCT03147430|Other|Biomarkers|Experimentally discover putative plasma markers for detecting early, stage I breast cancer in the setting of a suspicious mammogram and distinguish those cancers from benign lesions b) verify the putative markers through molecular profiling; and c) validate the markers by mass spectrometry.
45458402|NCT01360034|Drug|Indomethacin|Indomethacin: 50 mg vo as a single dose upon admission and then 25 mg vo every 6 hours for 48 hours.
45946262|NCT03141684|Drug|Atezolizumab|Given IV
45946263|NCT03141684|Biological|Bevacizumab|Given IV
45946264|NCT03141684|Procedure|Biospecimen Collection|Undergo collection of blood and urine
45946265|NCT03141684|Procedure|Computed Tomography|Undergo CT
45946266|NCT03128996|Drug|RIC regimen|Days -60 to -21: hydroxyurea (30mg/kg/day po) >6hrs prior to 1st dose: alemtuzumab (3mg IV) Day -21: alemtuzumab (10mg IV or S/C) Day -20: alemtuzumab (15mg IV or S/C) (10mg if < 10kg) Day -19: alemtuzumab (20mg IV or S/C) (10mg if < 10kg) Days -8 to -4: fludarabine (30mg/m2/day IV) Day -4: thiotepa (8mg/kg IV) Day -3: melphalan (140mg/m2) Days -2 to -1: rest days/no therapy Day 0: bone marrow transplant
45809905|NCT02975102|Device|CBL-101 Eye Drops|CBL-101 Eye Drops 3 to 6 times per day for 3 months.
45809906|NCT02975102|Device|Vismed® Multi|Vismed® Multi 3 to 6 times per day for 3 months.
45657773|NCT05549167|Drug|Sirolimus|Sirolimus 0,8 mg/m2, but <2 mg per day, once a day (QD), per os, oral solution, 1mg/ml, 60 ml Optimal individual dosage of sirolimus will be determined under control of concentration in blood serum. Therapeutic concentration - 5-15 ng/ml. Blood samples will be collected until therapeutic concertation will be achieved in 2 consecutive samples, but no more than 4 samples (on the 4th, 7th, 10th, 14th days of admission).
45657774|NCT05542693|Biological|RNA MCTI CIMATEC HDT 5µg|Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)
45946267|NCT03128996|Drug|GVHD prophylaxis regimen|Day +3 to +4: cyclophosphamide (50mg/kg/day IV) Day +5: Start of tacrolimus & Start of mycophenolate mofetil (MMF) Days +5, +14, +30, +60, +90: abatacept (IND) (10mg/kg/day IV) Days +120 to +390: abatacept (IND) monthly (5mg/kg/day IV)
45809907|NCT05011656|Device|Seraph-100 + State of the Art Care|Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin-coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins. The efficacy, safety, and risk-benefit data of the studies suggest that Seraph 100 is also safe and potentially beneficial by reducing the rate of thrombosis, without its use entailing a risk for patients. The achieved results from the above-mentioned testing and studies support the performance and safety of Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Seraph 100, when used to treat patients with pathogen associated shock, outweigh the known and potential risks when used according to the intended use.
45946268|NCT03123978|Drug|Enzalutamide|Given PO
46075815|NCT03851835|Drug|Oral Placebo|Six doses of oral placebo (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24 hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use).
46075816|NCT00879385|Drug|Dacogen™ (decitabine)|"Dacogen™ (decitabine) is a FDA approved drug (NDA - 021790) for the treatment of myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia).~Decitabine will be given on this study at 45 mg/m2 IV over 2 hrs"
45809908|NCT05011656|Device|State of the Art Care|"State of the Art careis defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock, available at https://www.sccm.org/SurvivingSepsisCampaign/Home"
45809909|NCT04833114|Drug|Polatuzumab Vedotin|Polatuzumab vedotin 1.8 mg/kg will be administered intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
45946269|NCT03123978|Drug|Niclosamide|Given PO
45946270|NCT03117881|Behavioral|DirectCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at a clinic with a therapist. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
45946271|NCT03117881|Behavioral|TeleCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at home via videos. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using the videos.
45458403|NCT02321254|Device|The RehaARM-Robot|Robot therapy by using a 3-Degrees-Of-Freedom (3DOFs) robot to train the shoulder.
46075817|NCT00879385|Drug|Vectibix® (panitumumab)|"Vectibix® (panitumumab) is a FDA approved drug (BLA-125147) indicated as a single agent for the treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. Approval is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival.~DRUG DESCRIPTION Vectibix® (panitumumab) is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). Panitumumab has an approximate molecular weight of 147 kDa. Panitumumab is produced in genetically engineered mammalian (Chinese Hamster Ovary) cells.~Panitumumab will be given on this study at 6 mg/kg, IV over 1 hr"
45657775|NCT05542693|Biological|RNA MCTI CIMATEC HDT 10µg|Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)
45657776|NCT05542693|Biological|Covishield® - AstraZeneca|Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer)
45657777|NCT05542693|Biological|Comirnaty® - Pfizer|Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer and (Covishield - Oxford/Astrazen).
45946272|NCT03117881|Behavioral|rDirectCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks by a therapist via videoconferencing technology. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
45946273|NCT03114072|Device|Blue-blocking glasses|Wear the BB-glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
45946274|NCT03114072|Device|Light grey control glasses|Wear the light grey glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
46075818|NCT04228536|Procedure|Totally ExtraPeritoneal (TEP) repair|
46075819|NCT04228536|Procedure|TransAbdominal PrePeritoneal (TAPP) repair|
46075820|NCT04228536|Procedure|Open anterior mesh repair (OAM)|
46075821|NCT04228536|Procedure|Combined Anterior and Posterior technique (CAP)|
46075822|NCT04228536|Procedure|Open PrePeritoneal Mesh technique (OPPM)|
46075823|NCT04228536|Procedure|Sutured Repair|
45809910|NCT04833114|Drug|Mabthera|Rituximab (Mabthera/Rituxan®) will be administered as per local practice at a dose of 375 mg/m2 intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
45809911|NCT04833114|Drug|Ifosfamide|Ifosfamide 5000 mg/m² will be administered i.v. over a 24 hr period starting on cycle Day 2.
46075824|NCT00914121|Drug|SKI-606|
46075825|NCT00914121|Drug|Placebo|
46075826|NCT00914121|Drug|Moxifloxacin|
46075827|NCT00953225|Drug|vitamin D3|4,000 IU daily for one year
45809912|NCT04833114|Drug|Carboplatin|Carboplatin AUC 5 max 800 mg will be administered i.v. on cycle Day 2.
46075828|NCT00953225|Drug|Placebo daily for one year|Placebo
46075829|NCT00879463|Procedure|Brain tissue oxygen saturation monitoring|Brain tissue oxygen saturation monitoring with infrared spectrophotoscopy
46075830|NCT00879463|Procedure|Transfusion according to the anesthesiologist's judgement|Transfusion if hemoglobin is between 5.5-7 mg/dl
46075831|NCT04249934|Dietary Supplement|Caffeinated Coffee|A single 8 ounce cup of regular starbucks coffee will be given to the participant in the am post operative day two. Participants will have 15 minutes to consume the coffee. Additionally, medical record data will be collected up to 30 days after surgery.
46075832|NCT04249934|Dietary Supplement|DecaffeinatedCoffee|A single 8 ounce cup of decaffeinated starbucks coffee will be given to the participant in the am post operative day two. Participants will have 15 minutes to consume the coffee. Additionally, medical record data will be collected up to 30 days after surgery.
45657778|NCT05549089|Device|Insignia™ twin brackets|it is metal orthodontic twin brackets with customized base and individual arch-wires for each patient
45946275|NCT03108586|Procedure|Dental treatment|Dental treatment of all dental needs present in adults related or not to the dental caries
45946276|NCT03108586|Procedure|Dental treatment|Dental treatment of all dental needs present in adults related or not to the dental caries
46075833|NCT03819231|Drug|Oxytocin|A single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) will be self-administered to each participant. Each 40 IU dose will be transferred into four, 1 ml intranasal atomizers and will be administered in four sprays to each nostril over the course of 15 minutes.
45657779|NCT05549089|Device|Maestro® 3D Ortho Studio software (Discovery, Dentaurum®, Ispringen, Germany)|it is conventional metal orthodontic twin brackets will be customizing the bracket base with adhesive composite, individual arch-wires for each patient and 3D printing indirect bonding tray
45657780|NCT05549089|Device|Ray set® device (Discovery, Dentaurum®, Ispringen, Germany)|it is conventional metal orthodontic twin brackets will be customizing the bracket base with adhesive composite, individual arch-wires for each patient and double-layer vacuum-formed thermoplastic indirect bonding tray
45657781|NCT04323553|Diagnostic Test|Pulsed-field gel electrophoresis and whole genome sequencing|Comparison of the two different techniques
45676344|NCT03811821|Behavioral|Biofeedback|The participant will learn how to improve strength and rectal sensation during five (5) - six (6) visits each lasting 60 minutes.
45676345|NCT03811821|Device|Injection|The participant will have a bulking agent injected into rectal wall to narrow opening. Two visits each lasting 45 minutes at weeks 0 and 6 respectively.
45809913|NCT04833114|Drug|Etoposide|Etoposide 100 mg/m² will be administered i.v. on cycle Days 1, 2 and 3.
45809914|NCT03536819|Device|Votiva|The applicator uses radio-frequency energy to treat the vaginal canal
45809915|NCT00376883|Drug|pamidronate|
45809916|NCT04651868|Other|GLP-2|A 210 mins intravenous infusion with GLP-2 (10 pmol × kg^-1 × min^-1)
45809917|NCT04651868|Other|Placebo|A 210 mins intravenous infusion with isotonic NaCl
45809918|NCT04651868|Other|CCK|A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg^-1 × min^-1)
45809919|NCT04651868|Other|Placebo|A 180 mins intravenous infusion with isotonic NaCl
45946277|NCT03089125|Behavioral|Dyspnea Intervention|"Dyspnea intervention will be administered over two sessions~Patients will receive:~Psychoeducation~Relaxation training for reducing physiological stress~Behavioral techniques for managing acute breathlessness"
46075834|NCT03819231|Behavioral|Mindfulness|Participants will be instructed to listen to and practice a 20-minute guided mediation each day for 7 days prior to the experimental session. The guided mindfulness practices will include body scan and seated stillness meditations.
46075835|NCT03819231|Drug|Saline Solution|A single 40mL doses of sterile saline (0.9% provided by USC pharmacy) will be transferred into four, 1 ml intranasal atomizers and will be self-administered in four sprays to each nostril over the course of 15 minutes.
46075836|NCT03819231|Behavioral|Sham mindfulness|The mindfulness sham group will be required to listen to 20-minutes of Tedtalk podcasts each day that match the attention and time of the mindfulness group. Participants will be instructed to listen to two 10-minutes segments per day in succession between lab visits while in a seated posture.
46075837|NCT02843048|Behavioral|Exercise training program|"Participants allocated to the Exercise training plus standard medical care group will undergo an exercise-training program of 11 months duration, 3 sessions/week, and 60 minutes/session, starting one month after the surgery. Each exercise session will be supervised and will include 5 major components: i) warm-up, ii) multidirectional jumps, iii) balance, iv) strength and, v) cool down. This structure is planned to meet two main objectives: i) enhance bone formation and, ii) reduce fall risk by improving muscle strength, cardiorespiratory fitness and balance."
46075838|NCT02843048|Behavioral|Standard medical care|Standard follow-up medical care following bariatric surgery
45657782|NCT04323553|Other|Data collection|Demographic data (age, gender, hospital admission and discharge date, rooms and wards with dates of admission and discharge, hospitalization prior to current hospital stay, discharge destination, outcome, cause of death, travel history, recent hospitalization in an ESBL-high burden region, admission from another healthcare facility, admission from a long-term care facility, occupational or household contact to animals) Clinical data (date of diagnosis of ESBL-producing E. coli carriage, type of infection/colonization with ESBL- producing E. coli, comorbidities, Charlson Comorbidity Index, infectious diseases after detection of ESBL-PE, active open wounds, indwelling vascular devices, urinary catheterization) Treatment data (Immunosuppression, antibiotic therapy, concomitant medication and surgical therapy prior to and during hospital stay) Microbiological data
45657783|NCT05542615|Drug|Prolonged-Release Pirfenidone|1200 mg / day of Pirfenidone (KitosCell® LP)
45657784|NCT05700721|Drug|Niraparib|Given by PO
45657785|NCT05700721|Drug|Dostarlimab|Given by IV (vein)
45657786|NCT04134559|Drug|Pembrolizumab|Pembrolizumab will be administered every 3 weeks, at predetermined dose with 21 consecutive days defined as a treatment cycle.
45809920|NCT05356416|Other|Ischemic compression|"Ischemic compression technique is a massage technique that consists of moderate compression, typically applied with the fingers, to the MTrP. Application of this technique to an MTrP results in a positive effect on pain-pressure threshold.~Patients in Group B will receive a single session of ischemic compression technique for ischemic compression technique sustained pressure on the trigger points will be maintained for 30 seconds."
45809921|NCT05356416|Other|Dry needling|"Trigger-point dry needling is an invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle.~Patients in dry needling (DN) group will receive a single session of DN of 10 minutes with sterile needles insert on trigger points in scalene muscles as first twitch response will obtained needles will be manipulated in and out of the muscles to get 2 or 3 more local responses."
45809922|NCT04734587|Diagnostic Test|Blood serum Neuron-specific Enolase measurement|The Silent Brain Injury ratio was compared by measuring the Neuron-specific enzyme level with venous blood sampling from both patient groups before and after percutaneous coronary intervention.
45809923|NCT04651010|Other|Multimodal MRI|Multimodal MRI will be realized between 12 and 24 hours after thrombectomy
45809924|NCT04195308|Device|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator."
45809925|NCT04195308|Device|Sham TBS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
45809926|NCT04195308|Device|Open label TBS-DLPFC|"Patients will have the option of receiving active, open label aTBS treatment following sham.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device."
45946278|NCT03089125|Other|Usual Care|Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians
45946279|NCT03063619|Drug|Afimoxifene|Applied topically
45946280|NCT03063619|Other|Laboratory Biomarker Analysis|Correlative studies
45946281|NCT03063619|Other|Placebo|Applied topically
45946282|NCT03063619|Other|Questionnaire Administration|Ancillary studies
45946283|NCT03037931|Drug|Ferric Carboxymaltose|Intravenous Iron
45946284|NCT03037931|Drug|Placebo|Normal Saline Solution
45946285|NCT03030378|Procedure|Biopsy|Undergo a tumor biopsy
45946286|NCT03030378|Procedure|Biospecimen Collection|Undergo collection of blood
45946287|NCT03030378|Procedure|Computed Tomography|Undergo a CT scan
45946288|NCT03030378|Biological|Edodekin alfa|Given SC
45657787|NCT04425967|Radiation|pre-operative radiotherapy|pre-operative radiotherapy
45809927|NCT05314673|Drug|Preoperative Intra-lesional Bevacizumab Injection in primary pterygium|"The surgical technique featured:~subconjunctival anesthetic (lidocaine 2%) injection 5 mm from limbus; excision of the pterygium, starting from its head, followed by pterygium body removal; exposition of a triangular-shaped bare scleral bed (3-4 mm) conjunctival autograft stitched limbus to limbus with 10/0 vicryl suture Any intraoperative complication was noted and was treated accordingly. All patients received dexamethasone + tobramycin eye drops postoperatively 4 times a day in the 1st week. The eye drops were tapered over 4 weeks.~Patients were examined 30 days before bevacizumab injection (D-30), before surgery (day 0: D0) and then at D7, M1, M3, and M6 after surgery."
45946289|NCT03030378|Procedure|Magnetic Resonance Imaging|Undergo a MRI
45946290|NCT03030378|Biological|Pembrolizumab|Given IV
45458404|NCT02321254|Behavioral|Standard rehabilitation therapy|Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities.
45657788|NCT05542537|Behavioral|Brighter Bites (BB) Produce Distribution|For 16 weeks in the school year, teachers in participating program schools will receive distributions of 8-10 different types of produce items.
45946291|NCT03030378|Procedure|Positron Emission Tomography|Undergo a PET scan
45946292|NCT03024827|Drug|CanniMed® 1:20|A cannabidiol (CBD): tetrahydrocannabinol (Δ9 THC) 20:1 ratio product will be provided as an oil-based suspension.
45946293|NCT03002103|Drug|EndoTAG-1|
45946294|NCT03002103|Drug|Paclitaxel|
45946295|NCT03002103|Drug|Gemcitabine Hydrochloride|
45946296|NCT02975882|Drug|Irinotecan Hydrochloride|Given PO
45946297|NCT02975882|Other|Laboratory Biomarker Analysis|Correlative studies
45946298|NCT02975882|Other|Pharmacological Study|Correlative studies
45946299|NCT02975882|Drug|Sirolimus Albumin-bound Nanoparticles|Given IV
45946300|NCT02975882|Drug|Temozolomide|Given PO
45946301|NCT02968810|Procedure|Biospecimen Collection|Undergo collection of blood
45946302|NCT02968810|Procedure|Computed Tomography|Undergo CT
45946303|NCT02968810|Procedure|Magnetic Resonance Imaging|Undergo MRI
45946304|NCT02968810|Other|Placebo Administration|Given PO
45946305|NCT02968810|Other|Questionnaire Administration|Ancillary studies
45946306|NCT02968810|Drug|Simvastatin|Given PO
45946307|NCT02935205|Drug|Enzalutamide|Given PO
45946308|NCT02935205|Drug|Indomethacin|Given PO
45458405|NCT01363310|Drug|Quetiapine XR|Dosage form: tablets Day 1-2: 50 mg Day 3-7: 150 mg Day 8-57: either 150 or 300 mg/day (flexible)
45458406|NCT01363310|Drug|Escitalopram|Dosage form: capsules Day 1-7: 10 mg Day 8-57: 10 or 20 mg/day (flexible)
45657789|NCT05542537|Behavioral|Brighter Bites (BB) Nutrition Education|Brighter Bites Nutrition Education will consist of recipes, food preparation and storage ideas, and tips and tools to budget and plan meals. Teachers will be trained in a nutrition education curriculum, which will be implemented in the program schools as part of the BB program.
45657790|NCT05542537|Behavioral|Create Healthy Futures (CHF) Weekly Wellness Groups|Peer-facilitators will lead virtual weekly group discussions. Penn State Better Kid Care will train the wellness facilitators.
45946309|NCT02898207|Drug|Olaparib|Given PO
45946310|NCT02898207|Drug|Onalespib|Given IV
45946311|NCT02875561|Device|Sonopet Ultrasonic Aspirator|To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
45946312|NCT02875561|Device|CO2 Laser Ablation|To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
45946313|NCT02862275|Drug|Atezolizumab|Given IV
45946314|NCT02862275|Procedure|Biopsy|Undergo tissue biopsy
45946315|NCT02862275|Procedure|Biospecimen Collection|Undergo blood specimen collection
45946316|NCT02862275|Procedure|Computed Tomography|Undergo CT scan
45946317|NCT02862275|Other|Laboratory Biomarker Analysis|Correlative studies
45946318|NCT02862275|Procedure|Magnetic Resonance Imaging|Undergo MRI
45946319|NCT02853474|Behavioral|Early Palliative Care visit|"A PC visit is a visit done by a PC physician. Any kind of visits done by other professionals IS NOT a PC visit.~Five PC visits are scheduled in this arm."
45946320|NCT02853474|Other|EORTC-QLQ-C30 questionnaire|The Quality of Life is assessed with the QLQ-C30 questionnaire at baseline, 12 and 24 weeks after inclusion, as well as every 8 weeks thereafter.
45946321|NCT02853474|Other|HADS score|The depression is assessed with the HADS scale (Hospital Anxiety and Depression Scale) at baseline, and then 12 and 24 weeks after inclusion.
45946322|NCT02849496|Drug|Atezolizumab|Given IV
45946323|NCT02849496|Procedure|Biopsy|Undergo a biopsy
45946324|NCT02849496|Procedure|Biospecimen Collection|Undergo blood sample collection
45946325|NCT02849496|Procedure|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration or biopsy
45946326|NCT02849496|Procedure|Bone Scan|Undergo a bone scan
45946327|NCT02849496|Procedure|Computed Tomography|Undergo a CT scan
45946328|NCT02849496|Procedure|Magnetic Resonance Imaging|Undergo MRI
45946329|NCT02849496|Drug|Olaparib|Given PO
45946330|NCT02849496|Procedure|Positron Emission Tomography|Undergo a PET scan
45946331|NCT02849496|Other|Questionnaire Administration|Ancillary studies
45946332|NCT02849496|Procedure|X-Ray Imaging|Undergo an x-ray
45946333|NCT02825771|Behavioral|Caring Contacts Messages|Text messages expressing care and support are sent following initial meeting on the following schedule: next day, 6 weekly, 9 bi-weekly, 7 monthly; one each on birthday, holiday, and seasonal (total of 25)
45657791|NCT05542537|Behavioral|Create Healthy Futures (CHF) Web-Based Module|Create Healthy Futures Web-Based Module is self-paced and focuses on the following topics: 1) Introduction, 2) Challenges of the food environment, 3) Nutrition and your health, 4) Food culture reform, and 5) Providers' role in creating healthy futures. The Create Healthy Futures module utilizes several educational methods to increase interactivity and engagement, including video footage of content experts, reflection activities, downloadable handouts, and action planning. Each chapter takes approximately 30-40 minutes to complete. The program is delivered on the Better Kid Care On Demand platform, an asynchronous learning management system that provides professional development training for teachers in all 50 states and 69 countries.
45809928|NCT05314673|Procedure|pterygium surgery without adjunctive therapy|"The surgical technique featured:~subconjunctival anesthetic (lidocaine 2%) injection 5 mm from limbus; excision of the pterygium, starting from its head, followed by pterygium body removal; exposition of a triangular-shaped bare scleral bed (3-4 mm) conjunctival autograft stitched limbus to limbus with 10/0 vicryl suture"
45657792|NCT04320667|Diagnostic Test|Flow cytometry analysis of urine samples|"Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326"
45946334|NCT02825771|Behavioral|Usual Care|Usual care consists of services available to the participant in their community to reduce their suicide risk and improve their behavioral health
46075839|NCT02779920|Procedure|per oral pylorotomy|The procedure is endoscopic pylorotomy. The standard procedure consists in the realization of a longitudinal incision of 2 cm at the anterior surface of the gastric antrum at 5 cm from the pylorus after a submucosal injection of a solution containing 85% saline 10% glycerol and 5% fructose. This longitudinal incision serve as an input for producing a submucosal tunnel dissected fibers gastric submucosa step. The internal circular of the pyloric muscle is then severed fiber after fiber over its entire length and its entire thickness. Once the pyloric section completed, the tunnel inlet will be closed by means of hemostatic clips.
45458407|NCT02321332|Procedure|bilateral simultaneous endoscopic thoracic symapthectomy|Patients underwent bilateral simultaneous T2-T3 ganglionectomy using thoracoscopic approach.
45657793|NCT05548933|Procedure|non-surgical periodontal therapy|supragingival scaling,subgingival scaling
45809929|NCT04634318|Other|Respiratory rehabilitation program (RR).|"Patients in the RR group will follow the respiratory rehabilitation program during a 4-week hospitalization in the respiratory diseases department of Renée Sabran hospital (Hyères, France).~The program includes for each week:~One medical consultation Four 40-min sessions of aerobic exercises on an ergocycle Four 1-hour sessions of walking in Renée Sabran Hospital's park Three 1-hour sessions of muscle strengthening exercises One 1-hour session of sophrology One 1-hour session of occupational therapy One 1-hour session of psychomotricity"
45657794|NCT05542459|Drug|Biologics|Infliximab, adalimumab, vedolizumab, ustekinumab, and other biologics approved for IBD
45657795|NCT05548855|Procedure|Heart Transplant|Patients who have undergone a heart transplant as standard of care (SOC) procedure
45657796|NCT05548855|Device|Cardiac Assistive Device|Patients who have undergone a placement of a cardiac assistive device
45809930|NCT04634318|Other|Respiratory tele-rehabilitation program (TRR).|Patients in the TRR group will realize the 4-week respiratory tele-rehabilitation program at home. The TRR program for each week includes the same sessions as RR program. But, medical consultation, sophrology, occupational therapy, psychomotricity and muscle strengthening sessions are carried out through live videoconferences. Additionally, aerobic and walking sessions are carried out outside home. The intensity of each session will be controlled by heart rate monitor.
45809931|NCT04823754|Other|Hospitalized patient with advanced hepatocellular carcinoma receiving systemic therapy.|"Administation of two surveys to included patients, about the perception of the disease and the expectations related to the treatment.~The physician will be asked to complete a survey on his or her perception of the prognosis and information received by the patient."
45809932|NCT05314595|Procedure|bilateral uterine artery ligation|"Spinal anaethesia with intrathecal morphia~Transverse skin incision~Adequate dissection of the bladder.~Incision of the uterus above placental edge.~Delivery of the fetus.~Delayed cord clamping (60 seconds) if the baby appears well.~Exteriorization of the uterus.~Start Oxytocin infusion and uterine massage to ensure good uterine contractions immediately after delivery of the fetus. No trials of placental delivery will be made at this point.~At this point, a gentile trial to deliver the placenta is performed~A catheter is placed in the cervix from above to secure the cervical opening~Compression is applied to the site of bleeding from placenta site~Placental pouch is marked by multiple allies and is closed down to the multiple-8 suture.~Blood loss is measured using the suction device and coated socked towels. In modified PPC, Bilateral uterine artery ligation will be done after exteriorization of the uterus in order to minimize the blood loss."
45809933|NCT03796442|Device|AVR with AVALUS|aortic valve replacement with AVALUS bioprosthesis
45946335|NCT02807805|Drug|Abiraterone Acetate|Given PO
45946336|NCT02807805|Drug|Niclosamide|Given PO
45946337|NCT02807805|Drug|Prednisone|Given PO
45657797|NCT05698849|Other|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
45657798|NCT05555017|Procedure|PSMA-radioguided surgery|Approximately 15-24 hours prior to surgery, 400-600 Megabecquerel (MBq) of 99mTc-PSMA-I&S will be intravenously administered to the patient at the Nuclear Medicine department. Following this injection patients will be allowed to return home, and then present for their 99mTechnetium (99mTc)-based PSMA-radioguided salvage surgery the next day.
45946338|NCT02775383|Other|Therapeutic|Observational Study
45946339|NCT02774746|Other|35-week delivery|Induction at 35 weeks gestational age
45946340|NCT02774746|Other|38-week delivery|Observation to spontaneous delivery or induction at 38 weeks gestational age
45946341|NCT02737046|Drug|Belinostat|Belinostat will be administered as 1,000 mg/m2 IV infusion over 30 minutes on Days 1- 5 every 21 days (Exception as per FDA-approved Package Insert: In patients known to be homozygous for the UGT1A1*28 allele, the starting belinostat dose must be 750mg/m2) for up to 8 cycles.
45946342|NCT02737046|Drug|Zidovudine|Zidovudine shall be administered in the outpatient setting as 300 mg tablets orally (PO), three times daily (TID) for 21 days on cycles 1 to 8, followed by maintenance therapy (+/- IFN-alfa) up to the end of Month 12.
46075840|NCT00613015|Drug|Guanfacine|
45946343|NCT02737046|Drug|Interferon-Alfa-2b|OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
45657799|NCT05555017|Drug|ADT|Standard 6 months of ADT according to current clinical guidelines. ADT consists of one subcutaneous depot of 22,5mg triptorelin (Pamorelin), with 4 weeks bicalutamide 50mg per os from 2 weeks before till 2 weeks after the first Pamorelin administration.
45946344|NCT02737046|Drug|Pegylated Interferon-Alfa-2b|OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
45946345|NCT02713126|Drug|Placebo|administered orally or inhaled, taken every 4 hours or 3 times per day during waking hours for 12 weeks
45946346|NCT02713126|Drug|Sodium Nitrite|administered orally or inhaled, 40 mg, taken every 4 hours or 3 times per day during waking hours for 12 weeks
45946347|NCT02713126|Device|Accelerometer|External triaxial accelerometer is worn externally at the hip during exercise training sessions, and day/night to continuously measure activity levels, removed for bathing only.
45946348|NCT02713126|Other|Cardiac Exercise Training|Cardiac rehabilitation exercise training consisting of supervised endurance and strength exercise training of approximately one hour, 3 times per week for 12 weeks.
45809934|NCT03796442|Device|AVR with CEPME|aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis
45657800|NCT05700175|Diagnostic Test|Transcriptomic, epigenetic and proteomic analysis|"Next-generation sequencing will be used to identify differences in expression of circulating transcripts (protein-coding and not) in patients affected by Marfan Syndrome (MFS), subdivided based on the presence or absence of thoracic aortic aneurysms (TAA) and indication of TAA-surgery (TAA_MFS_signature).~The obtained TAA_MFS_signature will be correlated to fundamental biological parameters by analysing:~Blood-levels of cytokines and chemokines relevant for inflammation. Transcriptomic and epigenetic (Cytosine methylation) changes in aortic aneurysms tissue by Next-generation sequencing.~Progression of biomarkers in surgical-patients before and at 6 and 12 months after surgery."
45946349|NCT02707926|Drug|Anti-HIV Agents|Therapy to treat HIV infection
45946350|NCT02695342|Behavioral|Home balance exercise program|
45946351|NCT02682485|Drug|Cipro, metronidazole, neomycin combo|During endoscopies after imaging, the anastomosis will be lavaged with an antibiotic solution composed of metronidazole, ciprofloxacin and neomycin
45946352|NCT02682485|Procedure|Serial Endoscopic Surveillance|Patients will undergo serial endoscopic surveillance consisting of three endoscopies: one intra-operative endoscopy (POD0) and two post-operative endoscopies (POD3-7, POD12-28). During endoscopies, the anastomosis will be lavaged with saline, the fluid will be collected by suction and images will be taken.
45657801|NCT05554783|Diagnostic Test|Trendelenburg position|Positioning the patient with head 15 degrees down
45676346|NCT03809000|Radiation|Radiation Therapy|Radiation Therapy
45809935|NCT03688685|Drug|CAD-1883|Treatment groups receiving twice-daily oral dosing of CAD-1883 for a treatment period of 14 days.
45809936|NCT04126187|Device|Panoptix|Panoptix trifocal intraocular lens (IOL)
45809937|NCT04633304|Device|EndoAVF System for endovascular AV fistula creation|AV fistula creation
45809938|NCT04823208|Drug|LY3437943|Administered SC
45809939|NCT04823208|Drug|Placebo|Administered SC
45809940|NCT04419636|Drug|Lu AG06466|capsules, orally
45946353|NCT02682485|Drug|Saline|During endoscopies after imaging, the anastomosis will be lavaged with a placebo direct topical saline solution
45946354|NCT02649790|Drug|KPT-8602|Participants will receive KPT-8602 oral tablets.
45946355|NCT02649790|Drug|ASTX727|ASTX727 is a combination drug of 35 mg decitabine and 100 mg cedazuridine.
46075841|NCT00613015|Drug|Modafinil|
46075842|NCT00613015|Drug|Placebo|
46075843|NCT04249856|Diagnostic Test|Dynamic Spectral Imaging (DYSIS)|Women who have a colposcopy exam performed at Randers Regional Hospital were examined by Dynamic Spectral Imaging colposcopy (DYSIS)
46075844|NCT02858765|Other|Application of white polychromatic light for 2h30 at different times of day|
46075845|NCT03811899|Diagnostic Test|18F-DCFPyL|The purpose of this study is to determine whether HG SOC are 18F-DCFPyL (=GCP-II)-avid and to compare the performance of this PET to CT and findings at time of surgery.
46075846|NCT02779608|Drug|intraperitoneal docetaxel|One peritoneal access port will be implanted in subcutaneous space of patients' abdominal wall after laparoscopic exploration.Then intraperitoneal docetaxel in 1litre normal saline will be administered through the port
46075847|NCT02779608|Drug|oral S-1|40mg/m² twice daily on day 1-14 every 3 weeks
46075848|NCT04250480|Dietary Supplement|beta-alanine|beta-alanine tablet
46075849|NCT04250480|Dietary Supplement|placebo|rice powder tablet
46075850|NCT05750589|Drug|IRX-101|IRX-101 is a novel ocular anti-septic
46075851|NCT05750589|Drug|Providone-Iodine|5% Providone-Iodine
46075852|NCT02543671|Other|vitamin D3 enriched, reduced-fat yellow cheese|60 grams of vitamin D3 enriched, reduced-fat yellow cheese provide 5.7 micrograms of vitamin D per day for 8 weeks
45809941|NCT05440292|Device|Transcranial magnetic stimulation|For each stimulation day, low-frequency (1 Hz) ,1800 pulses(intensity of 100% resting motor threshold(RMT), duration 30 min) rTMS stimulation were delivered on the hotspot of unaffected hemisphere(Hotspot-rTMS Group) and the motor task activation poin of unaffected hemisphere(fMRI-rTMS Group). rTMS which guided by individualized navigation delivery 5 days a week for 4 weeks.
45809942|NCT04113785|Device|Klassic Knee System|At present, all TKA available for surgeons to use are asymmetric where there is a distinct femoral and tibial component for the left knee and a distinct femoral and tibial component for the right knee. The Klassic knee system is a symmetrical knee implant, where the same femoral and same tibial component can be used for either the right or left knee
45657802|NCT05698615|Behavioral|Chess training|"The chess training, which takes place as a measure for CRT with the children and adolescents, is carried out by the concept of the Munich Chess Academy. The concept applied here, Chess according to the King's Plan, represents a holistic concept. Especially prepared for children and adolescents, theoretical aspects are illustrated in games and exercises."
45809943|NCT04823130|Drug|Dupilumab SAR231893|Pharmaceutical form: solution for injection Route of administration: subcutaneous
45809944|NCT04112069|Device|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
45809945|NCT04112069|Other|Usual Care|Usual care
45809946|NCT04622046|Drug|ALXN2060|ALXN2060 tablets will be administered twice daily at a dose of 800 milligrams.
45809947|NCT03786692|Drug|Arm A|Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab
45809948|NCT03786692|Drug|Arm B|Carboplatin + Pemetrexed + Bevacizumab
45809949|NCT04603482|Behavioral|Resourcefulness Training|A cognitive-behavioral intervention presented within an audiovisual format that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
45809950|NCT04603482|Behavioral|Biofeedback Training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and to continue to influence behavior."
45809951|NCT04603482|Behavioral|Diversional Activites|An audiovisual format presenting 12 activities for adults including but not limited; crossword puzzles, reading, gardening, exercise, cooking/baking, board games, learning a new language, social activities, online games, etc.
45809952|NCT03544307|Behavioral|Taekwondo training|Exercise group
45809953|NCT03785210|Drug|nivolumab|480 mg IV every 4 weeks
45946356|NCT02649790|Drug|Dexamethasone|Participants will receive dexamethasone oral tablets.
45946357|NCT02638298|Device|Prevana Dressing|negative pressure wound therapy (NPWT) dressing
45458408|NCT02321332|Procedure|unilateral sequential endoscopic thoracic symapthectomy.|Patients underwent unilateral T2-T3 ganglionectomy of the dominant side followed by T2-T3 ganglionectomy of the other side after 2 months interval.
45657803|NCT05548543|Drug|HCP2202|Take it once per period.
45809954|NCT03785210|Drug|tadalafil|10 mg PO daily
45809955|NCT03785210|Drug|oral vancomycin|125 mg every 6-hour (500 mg total daily dose) PO from week 1 to week 3, week 4 off.
45809956|NCT04990596|Biological|additional blood sample|One sample per patient will be taken 1 to 3 hours after clopidogrel administration. Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.
45946358|NCT02638298|Other|Standard Dry Gauze Dressing|Standard Dry Gauze Dressing
46075853|NCT02543671|Other|plain (non-fortified) reduced-fat yellow cheese|60 grams of plain (non-fortified), reduced-fat yellow cheese provide 0 micrograms of vitamin D per day for 8 weeks
46075854|NCT05338710|Other|STELLA-FTD|Behavioral intervention for caregivers for those with FTD
45458409|NCT01363466|Procedure|hysterectomy|
45657804|NCT05548543|Drug|RLD2202|Take it once per period.
45657805|NCT05548543|Drug|RLD2203|Take it once per period.
45676347|NCT03809000|Drug|Enzalutamide|Anti-androgen
45676348|NCT03809000|Drug|Bicalutamide|Anti-androgen
45809957|NCT04086407|Device|Dual-axis inclinometer attached to the subject's forehead with tape|This is the first clinical trial in the industry to address OSA symptom severity and snoring as a direct function of head pitch and roll angle. The head pitch and roll angle can be used with high consistency to predict OSA symptom severity. The apnea equation is based on the gravitational crush forces of the mass of the tongue and nearby tissue on the upper air way and is valid for most OSA sufferers.
45809958|NCT04583514|Behavioral|Control|Weight-stable Control group
45809959|NCT04583514|Behavioral|Overfeeding|30% Overfeeding group
45809960|NCT04411290|Procedure|Total thyroidectomy (TT)|Final total thyroidectomy histopathology report should be available for correlations with preoperatively determined malignancy predictive factors, Bethesda (cytology) and TI-RADS (ultrasound findings)
45809961|NCT04098575|Drug|Empagliflozin|drug
45809962|NCT05350410|Other|HALT-AD|Prior studies have shown that programs that focus on promoting brain health and managing lifestyle risks (such as poor diet, obesity, physical inactivity, sleep issues, loneliness) may help in preventing or lowering the risk of dementia. To address this, we have developed the HALT-AD program. HALT-AD is an educational program designed to teach about dementia and lifestyle changes that can help preserve brain health and lower dementia risk
46002559|NCT04647123|Other|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)
46002560|NCT00545090|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
46075855|NCT02838992|Drug|Rabbit ATG, (Genzyme)|ATG is an infusion of rabbit-derived antibodies against human T cells, which is used in the prevention and treatment of acute rejection in organ transplantation and therapy of aplastic anemia
46075856|NCT02838992|Drug|Cy|Cyclophosphamide is a medication mainly used in chemotherapy. It is an alkylating agent of the nitrogen mustard type
45453301|NCT03950713|Behavioral|Mindfulness-based Stress Reduction Program - Taiwan (MBSR-T)|The MBSR-T is focused on strategies to manage diabetes distress for new residents by three new techniques. Firstly, it involves practicing body and meditation exercises for openness to the awareness and acceptance of transferred life experiences, such as mindful attention exercise, which is assumed to allow the residents to behave in a less reactive and more reflective manner when confronted with transferred life stressors. Second, mindfulness meditation techniques were provided for difficult thoughts and feelings related to diabetes, such as paying full attention to the present moment of life and choosing to respond skillfully rather than reacting automatically to external events, thoughts or emotions as they arise. Third, a specific topic, for example on how to be mindful when life style is changed, or how to pay attention to the present moment within Chinese culture of peacefulness was discussed in each session.
45453302|NCT05478031|Drug|REM0046127 High Dose|"Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~REM0046127 high dose: 1400mg (700mg bid) oral suspension per day for 28 days"
45809963|NCT03776240|Drug|HD201|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
45809964|NCT03776240|Drug|EU-Herceptin|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
45809965|NCT03776240|Drug|US-Herceptin|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
45657806|NCT05542225|Procedure|Strength training|Strength training will be performed with the patient in supine lying position as per FITT guidelines in which resistance will be given with the help of resistance bands on major muscle groups including shoulder flexors and extensors, hip and knee flexors and extensors, hip abductors and adductors,foot plantar flexors and dorsiflexors at an intensity of 8-15 repetitions, 2-3 times per week for 30 minutes.
45657807|NCT05542225|Procedure|Flexibility training|Flexibility training will be performed with the patient in supine lying position as per FITT guidelines. Static stretching will be applied to the major muscle groups( trapezius, latissmus dorsi, gluteus maximus and medius, gastrocnemus, soleus, hamstrings and paraspinals( errector spinae and multifidi. Session will be completed in 10-15 minutes with a hold of 15 secs, 5 times per week. Stop before it becomes painful.
45657808|NCT05542225|Procedure|Standard therapy|TENS at frequency of 2-125Hz for 30 minutes, pharmacological intervention
45946359|NCT02636725|Drug|Axitinib|5 mg tablets twice daily oral dose administered for 7 consecutive weeks on Cycle 1. A safety lead-in consisting of the initial five patients, intrapatient dose escalation of Axitinib will be permitted based on the absence of predefined toxicities. Twice daily oral dose between 2 mg to 10 mg Axitinib tablets will be administered on subsequent 6 week cycles until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
45946360|NCT02636725|Drug|Pembrolizumab|200 mg intravenous infusion administered every 21 weeks beginning week 2 of Cycle 1 for a maximum of up to 2 years or until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
45946361|NCT02631733|Drug|Ferumoxytol|Given IV
45946362|NCT02631733|Drug|Irinotecan Sucrosofate|Given IV
45946363|NCT02631733|Other|Laboratory Biomarker Analysis|Correlative studies
45809966|NCT04832100|Drug|Pregabalin 150mg, imipramine 25mg|Conventional treatment for fibromyalgia was given to patients. Clinical follow-ups with questionnaires and interview were arranged then.
45809967|NCT04106492|Drug|SQ3370|SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin
45809968|NCT04100720|Device|Cardiovalve Transfemoral Tricuspid Valve|The Cardiovalve Transfemoral Tricuspid Valve System is intended for use in patients with severe, symptomatic Tricuspid regurgitation
45946364|NCT02631733|Procedure|Magnetic Resonance Imaging|Undergo MRI
45453303|NCT05478031|Drug|REM0046127 Low Dose|"Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~REM0046127 low dose: 350mg (175mg bid) oral suspension per day for 28 days"
45657809|NCT05554705|Behavioral|Intensive Lifestyle intervention|12 week therapeutic lifestyle change program
45676349|NCT03809000|Drug|GnRH analog|Anti-androgen
45676350|NCT03795454|Behavioral|Singing|Infant-directed singing and singing of self-invented songs, especially songs emerging from the interaction with the infant, are especially encouraged. The families will receive audio material of children's songs, lullabies, and lyrics of the lullabies to support them if they feel unable to accomplish the task otherwise.
45809969|NCT02976272|Other|bortezomib|
45809970|NCT01600326|Procedure|Tenotomy (no injection)|Subjects randomized to this group will fill out a pre-treatment pain survey and have a blood draw They will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti-inflammatory medications for 2 weeks before the study. Two weeks after enrollment subjects see their referring physician to begin physical therapy.
45946365|NCT02631733|Drug|Veliparib|Given PO
45946366|NCT02595866|Drug|Antiretroviral Therapy|Given PO
45946367|NCT02595866|Procedure|Biopsy|Undergo biopsy
45946368|NCT02595866|Procedure|Biospecimen Collection|Undergo blood sample collection
45946369|NCT02595866|Procedure|Computed Tomography|Undergo CT or PET/CT
45946370|NCT02595866|Biological|Pembrolizumab|Given IV
45946371|NCT02595866|Procedure|Positron Emission Tomography|Undergo PET/CT
45946372|NCT02592499|Device|HM III|
46075857|NCT02838992|Drug|CsA|CsA is an immunosuppressant drug widely used in organ transplantation to prevent rejection. It reduces the activity of the immune system by interfering with the activity and growth of T cells
46075858|NCT02838992|Biological|Cord blood|Cord blood is blood that remains in the placenta and in the attached umbilical cord after childbirth. Cord blood is collected because it contains stem cells, which can be used to treat hematopoietic and genetic disorders
46075859|NCT05750433|Dietary Supplement|PreforPro+B. subtilis DE111 probiotics|PreforPro is bacteriophage-based product which was used in combination with Bacillus subtilis probiotics.
46075860|NCT05750433|Dietary Supplement|Placebo|Maltodextrin is rice based powder which was used as placebo.
45809971|NCT01600326|Drug|Ultrasound guided platelet rich plasma injection|"Subjects will fill out a pre-treatment pain survey, then will undergo ultrasound and have blood drawn from their arm.~The blood sample will be separated into blood cells and plasma. The plasma portion of the blood (liquid minus the cells) will be injected into the tendon under sterile conditions. Ultrasound will help guide the injection. This is called Ultrasound guided platelet rich plasma injection.~Subjects will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti inflammatory medications for 2 weeks before the study and 2 weeks after the study.~Subjects will see their referring physician two weeks after treatment to begin physical therapy."
45946373|NCT02592499|Other|OMM, optimal medical management|Patients randomized to OMM will be treated according to international guidelines. All patients should receive a beta blocker, an ACE-inhibitor or an Angiotension II receptor blocker, and a mineralocorticoid receptor antagonist if tolerated and at optimally titrated doses according to guidelines. Loop diuretics should also be used as needed to control fluid retention. Other drugs that may relieve symptoms and improve prognosis can be used (incl ivabradin, digoxin, hydralazine,isosorbiddinitrate, anticoagulant agents). Patients that have an indication for implantable cardioverter defibrillator (ICD) and/or cardiac resynchronization therapy (CRT) should receive such therapy. Surgical interventions that may be indicated for specific underlying or contributing causes of heart failure.
45809972|NCT04082819|Device|Contec CMS50EW|Participants' blood pressure will be measured 3 times with the wearable finger pulse oximeter at their study visit.
45657810|NCT02587819|Drug|Treatment with BSCT|"The study product BSCT (anti-nf-P2X7) 10% Ointment was anti-nf-P2X7 (highly purified sheep IgG) in an ointment formulation for topical administration. The formulation contained 10% weight by weight of the active pharmaceutical ingredient in an anhydrous ointment base.~Fifty (50) to 100 mg of product (an amount the size of a small pea) was applied topically twice a day for 28 days to a 25 cm2 area of skin containing a single BCC lesion. The product was to be applied in the morning and in the evening after washing."
45946374|NCT02573493|Drug|nab-Paclitaxel|
45809973|NCT04082819|Device|Sphygmomanometer|Participants' blood pressure will be measured 4 times manually with a blood pressure cuff at their study visit.
45809974|NCT00361790|Drug|Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg|Tablets, Oral, Escitalopram: 10 mg; Aripiprazole: 10, 15, 20 mg, once daily, 14 days.
45809975|NCT04570332|Drug|BO-112 and Pembrolizumab|Patients will be treated with the combination of BO-112 and pembrolizumab. Order of administration should be pembrolizumab then IT BO-112. BO-112 will be administered IT at a total dose of 1-2 mg at each administration to 1-8 tumor lesions using tuberculin (TB) syringes (or equivalent) with 20- to 25-gauge needles
45809976|NCT04570332|Procedure|Tissue Biopsies|Pre and post (if feasible) treatment tumor tissue biopsies will be used for correlative research.
45809977|NCT04081961|Device|Anamed OEM device; Air Next mobile spirometry device|Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device
45809978|NCT04821102|Biological|JOINTSTEM|JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10^8cells/(saline), 1 time injection under ultrasonic guided
45809979|NCT04821102|Drug|Saline|saline, 1 time injection under ultrasonic guided
45809980|NCT04143438|Procedure|EOS 3D imaging protocol pre- and post-surgery|Patients will undergo a EOS 3D Imaging protocol before and 6 months after undergoing patello-femoral surgery. This protocol is already used routinely in the hospital before every patello-femoral surgery.
45946375|NCT02573493|Drug|Cisplatin|
45946376|NCT02573493|Biological|Cetuximab|
45946377|NCT02573493|Radiation|Intensity-Modulated Radiation Therapy|
45453304|NCT05478031|Drug|Placebo|"Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~Placebo: placebo oral suspension bid for 28 days and during the 14-days run-in phase"
45453305|NCT00030823|Biological|Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine|
45946378|NCT02559752|Other|NIH Toolbox Cognitive Battery|"For ages 4 to 7 years, the NIH Toolbox Early Childhood Battery will be administered. This test includes the Picture Vocabulary, Flanker Inhibitory Control and Attention, Dimensional Change Card Sort, and Picture Sequence Memory measures to evaluate language, executive function, attention, and episodic memory, respectively.~For patients age 8 years or older, the administered battery will consist of the aforementioned tests in addition to Oral Reading Recognition, Pattern Comparison Processing Speed, and List Sort Working Memory tests. Results will include scores for each individual measure. In addition, each cognition battery provides composite scores, which allow for general interpretation/evaluation of overall cognitive functioning."
45453306|NCT00030823|Biological|QS21|
45453307|NCT01101919|Drug|CP-690,550|Days 1 and 6 dose of 10 mg once daily Days 2-5 doses of 10 mg twice daily
45676351|NCT03743844|Behavioral|Compassion-focused psychoeducation group|Attending six 2-hour weekly group-based psychoeducation sessions and participating in mindfulness, meditation, and acceptance-based experiential exercises
45676352|NCT03742102|Drug|Durvalumab|Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
45676353|NCT03742102|Drug|Capivasertib|Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off
45946379|NCT02555280|Device|coflex® Interlaminar Technology|Decompression plus coflex® Interlaminar Technology
45946380|NCT02555280|Procedure|Decompression|Decompression alone
45946381|NCT02542917|Device|IBDoc home test for faecal calprotectin|IBDoc home test for faecal calprotectin
46002561|NCT00545207|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 2 years
46002562|NCT00545207|Drug|Placebo|po monthly for 2 years
45946382|NCT02532439|Device|HR-pQCT|"Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal."
46075861|NCT05750433|Dietary Supplement|B. subtilis DE111|Bacillus subtilis probiotics.
46075862|NCT00879541|Biological|Biostate® [SP]|Single bolus intravenous dose of 50 IU/kg
45657811|NCT04426045|Procedure|Pericapsular nerve group block|A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. A total volume of 20 ml of ropivacaine 0.2% will be injected.
45657812|NCT04426045|Procedure|Supra-inguinal fascia iliaca compartment block|"A linear 6-13-MHz ultrasound probe will be placed in the sagittal plane to obtain an image of the anterior superior iliac spine. The fascia iliaca and sartorius, iliopsoas, and oblique internal muscles will be identified by sliding the probe medially. After identifying the bow-tie sign formed by the muscle fascias, a 22-gauge, 80-mm needle will be introduced 1 cm cephalad to the inguinal ligament. Using an in-plane approach, the fascia iliaca will be penetrated and hydrodissected, separating the fascia iliaca from the iliac muscle. A total volume of 30 ml of ropivacaine 0.2% will be injected."
45809981|NCT00361868|Drug|fenofibrate (F) + metformin (M) hydrochloride fixed combination|First period: F80mg/M500mg - per os - twice a day during 2 weeks and F80mg/M850mg - per os - twice a day during 10 weeks - Second period: F54mg/M850mg - per os - three times a day during 12 weeks
45809982|NCT00361868|Drug|Rosiglitazone|First period: 4 mg - per os - daily during 12 weeks - Second period: 4 mg - per os - twice a day during 12 weeks
45809983|NCT04990362|Dietary Supplement|Pomegranate oil, Mediterranean Diet|Dietary Supplement: Pomegranate oil in a glass bottle of 0.15ml per day +Mediterranean dietary protocol Dietary Supplement: Mediterranean dietary protocol
45809984|NCT04990362|Dietary Supplement|Mediterranean Diet|Dietary Supplement: Mediterranean dietary protocol
45809985|NCT04564872|Drug|HSK7653 10 mg Q2W|HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
45809986|NCT04564872|Drug|HSK7653 25 mg Q2W|HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg (1 tablet) Q2W, oral, week 25 to week 52.
45809987|NCT04564872|Drug|Linagliptin 5 mg QD|Linagliptin 5 mg QD, placebo of HSK7653 25 mg (1 tablet) and 5 mg (2 tablets) Q2W, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
45809988|NCT04079348|Device|Oasis ECM|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of Oasis Extracellular Matrix to their donor site wound.
45809989|NCT04079348|Other|standard wound care|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of standard wound care to their donor site wound.
46075863|NCT00879541|Biological|Biostate® [SP]|The dose is dependent on the reason for use and may consist of repeated bolus doses as required to manage haemophilia condition.
45809990|NCT05416554|Behavioral|Neuropsychological testing|Upon completion of the consent, the subject will be booked into an available 90 minute in-person or remote neuropsychological testing
45809991|NCT04074668|Drug|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
45809992|NCT04074668|Drug|Iohexol Inj 300 milligrams/milliliter (mg/ml)|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
45809993|NCT04074668|Radiation|PET/CT Scan|Imaging used to visualize the kidneys and quantify renal metabolic activity
45809994|NCT04074668|Procedure|Renal Biopsy|Minimally invasive outpatient procedure to obtain renal tissue after ultrasound visualization.
45946383|NCT02532439|Device|DEXA|The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
45946384|NCT02532439|Device|pQCT|Peripheral Quantitative Computed Tomography (pQCT) will be performed and measure bone and muscle parameters.
45946385|NCT02522533|Other|Physical Therapy|6 weeks of an exercise program.
45946386|NCT02521493|Drug|Asparaginase|Given IM or IV
46075864|NCT00879541|Biological|Biostate® [RP]|Single bolus intravenous dose of 50 IU/kg.
46075865|NCT04987944|Drug|Zavegepant|150 mg BID
46075866|NCT04987944|Drug|Placebo|Placebo matching active drug
46075867|NCT05750043|Drug|bi-annual CDTI|"bi-annual community directed treatment with ivermectin (CDTI) and community-based slash and clear vector control intervention"
46075868|NCT02838914|Procedure|radiofrequency ablation (RFCA)|Patients undergo radiofrequency ablation (RFCA)
45453308|NCT03951571|Drug|Anlotinib Hydrochloride|Before breakfast, take an Anlotinib hydrochloride placebo once a day, 12 mg (1 pill) at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
45657813|NCT05542147|Drug|Fenofibrate 145 mg|1 tablet per day
45657814|NCT05542147|Drug|Placebo|1 tablet per day
45453309|NCT03951571|Drug|Placebo Oral Tablet|Before breakfast, take an placebo once a day, 1 pill at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
45657815|NCT05548465|Drug|Remifentanil Hydrochloride|Subjects will receive remifentanil anesthesia for operative analgesia.
45458410|NCT03501004|Device|Sterile acupuncture needles for single use|Sterile acupuncture needles for single use are made by China Beijing Zhongyan Taihe Medical Instrument Limited Company.Acupuncture needles' specifications are 0.25mm*25mm.
45458411|NCT02317588|Dietary Supplement|Flax Oil|Participants will consume capsules containing flax oil at a dose of 4 grams of ALA per day (8 capsules a day) with a meal for 28 days (4 weeks).
45458412|NCT02317588|Dietary Supplement|Fish Oil|Participants will consume capsules containing fish oil at a dose of 4 grams DHA + 0.8 grams EPA per day (8 capsules) for 28 days (4 weeks).
45657816|NCT05548465|Drug|Sufentanil Citrate|Subjects will receive sufentanil and remifentanil anesthesia for operative analgesia.
45657817|NCT04882735|Drug|Acoramidis|TTR stabilizer administered orally twice daily (BID)
45657818|NCT05548387|Drug|HCP2202|Take it once per period.
45657819|NCT05548387|Drug|RLD2202|Take it once per period.
45657820|NCT05548387|Drug|RLD2203|Take it once per period.
45809995|NCT04343144|Drug|Nivolumab Injection|Treatment consists of an infusion of OPDIVO® 3mg/kg on day 1 (D1).
45809996|NCT04075409|Drug|Padsevonil|Padsevonil will be administered in predefined dosages.
45809997|NCT03743246|Drug|JCAR017|JCAR017
45809998|NCT03743246|Drug|Lymphodepleting|Lymphodepleting
45809999|NCT03743246|Drug|Fludarabine|Fludarabine
45810000|NCT03743246|Drug|Cyclophosphamide|Cyclophosphamide
45810001|NCT05415696|Procedure|Prostatic artery embolization|Patients will undergo PAE with 100-300 µm or 300-500 µm Embospheres following standard PAE technique performed by Interventional Radiology at Stanford University
45810002|NCT04581512|Drug|EP0042|EP0042 Oral 20 mg 50 mg capsules
45810003|NCT04579094|Other|Feces sampling at inclusion (J0)|Feces sampling at inclusion (J0)
45810004|NCT04074941|Other|Dietary intervention|Intervention include low sodium or usual sodium diet
45946387|NCT02521493|Drug|Asparaginase Erwinia chrysanthemi|Given IM or IV
45946388|NCT02521493|Drug|Cytarabine|Given IT and IV
45946389|NCT02521493|Drug|Daunorubicin Hydrochloride|Given IV
45946390|NCT02521493|Drug|Etoposide|Given IV
45946391|NCT02521493|Other|Laboratory Biomarker Analysis|Correlative studies
45946392|NCT02521493|Drug|Mitoxantrone Hydrochloride|Given IV
46075869|NCT02514798|Other|Esophageal and gastric balloons|Esophageal and gastric pressures will be measured with an esophageal ballon positioned at the lower third of the esophagus, filled with 0.5 mL of air and a gastric balloon filled with 1 mL of air. The proper position of balloons will be verified using the occlusion test as previously described. Transdiaphragmatic pressure (Pdi) is calculated as the difference between gastric (Pga) and esophageal (Pes) pressure. The pressure time integrals of the diaphragm and the other inspiratory muscles are calculated per breath (PTPdi/b and PTPes/b, respectively) and per minute (PTPdi/min and PTPes/min). Measurements will be collected at baseline, at each randomized HFNC and CPAP settings during the last 4 minutes of each 10 minutes session.
45657821|NCT05554549|Other|Dietary pattern observed|Dietary pattern: regular meat-eater, occasional meat-eater, pescatarian, and vegetarian. There are no interventions in this observational cohort.
45657822|NCT05548309|Device|HFNC|High flow nasal cannula (HFNC) was inserted through specific medium/large nasal prongs . FiO2 was continuously measured by a dedicated system (AIRVO™ 2; Fisher & Paykel Healthcare, Auckland, New Zealand) connected to the HFNC. Starting flow 35 L/min, temperature 31oc. The flow was titrated up to 60L/min with a target SpO2 of ≥94%.
45657823|NCT05548309|Device|Oxygen face mask|Oxygen face mask was applied to patients postoperatively with starting flow 8L/min and titration of flow up to 10 L/min with target SpO2 of ≥94%
45810005|NCT03703778|Procedure|Androgen deprivation therapy - bilateral orchidectomy|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
45810006|NCT03703778|Drug|Androgen deprivation therapy - GnRH agonist|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
45810007|NCT03703778|Drug|Androgen deprivation therapy - GnRH antagonist|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
45810008|NCT05346666|Drug|Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam|Tocilizumab is an immuno-modulatory drug which act as interleukin (IL)-6 receptor inhibitor that blocks IL-6-mediated signal transduction. This drug is known to improve various diseases
45810009|NCT00361166|Drug|ACP-103|
45946393|NCT02521493|Drug|Thioguanine|Given PO
45946394|NCT02502266|Drug|Cediranib|Given PO
45946395|NCT02502266|Drug|Cediranib Maleate|Given PO
45946396|NCT02502266|Procedure|Computed Tomography|Undergo CT
45946397|NCT02502266|Procedure|Magnetic Resonance Imaging|Undergo MRI
45946398|NCT02502266|Drug|Olaparib|Given PO
45946399|NCT02502266|Drug|Paclitaxel|Given IV
45657824|NCT05554471|Device|MYNX CONTROL™ Venous Vascular Closure Device 6F-12F|Mynx Control Venous VCD 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation.
45657825|NCT05542069|Device|Threshold IMT (Inspiratory muscle trainer) by Philips|Apply a resistive load with the IMT device according the maximal inspiratory pressure of each subject.
45657826|NCT05541991|Dietary Supplement|single dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract|coated tablet with a single dose of standardised rhubarb extract
45810010|NCT03694613|Other|Placental/Umbilical Cord Blood sample|After infant is delivered, placenta along with clamped umbilical cord Blood will be obtained from the ObGyn team. One umbilical clamp will be placed at the umbilical end, and the other clamp will be placed on the placental end of the umbilical cord. Then the umbilical cord will be cut between the clamps. The umbilical cord will be cleaned three times with 2% chlorhexidine, plus 70% isopropyl alcohol under sterile conditions (sterile gloves). Cord blood samples will be collected using vacutainer blood collecting system with a sterile 22-gauge needle. We will collect 3 - 4 ml of blood.
45946400|NCT02502266|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
45810011|NCT03674294|Drug|Aprepitant|Aprepitant is manufactured by Merck & Co. for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. It was approved by the FDA in 2003
45810012|NCT03674294|Drug|Palonosetron|Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINV-nausea and vomiting and there are tentative data to suggest that it may be more effective than granisetron.
45810013|NCT03674294|Drug|Dexamethasone|Dexamethasone is a type of corticosteroid medication. It is used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, and along with antibiotics in tuberculosis.
45657827|NCT05541991|Dietary Supplement|placebo coated tablet|coated tablet without active principle
45657828|NCT05541991|Dietary Supplement|double dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract|coated tablet with a double dose of standardised rhubarb extract
45657829|NCT05700097|Drug|Dengzhanxixin Injection|Experimental arms for low, and high dose for the standard protocol
45657830|NCT05700097|Drug|Placebo injection|placebo control arm for the standard protocol
45810014|NCT03674294|Drug|Placebo Oral Tablet|In the current clinical trial, placebo oral tablet is provided as a substance for Aprepitant with no active therapeutic effect.
45657831|NCT05541835|Diagnostic Test|sampling|venous sampling of patient
45657832|NCT05554081|Device|Peezy urine collection device|use peezy collection to obtain urine sample
45657833|NCT05548075|Drug|Psilocybin|Up to 25mg of Psilocybin on 2 occasions.
45810015|NCT05413278|Behavioral|Behavioral|Patient education, information and empowerment
45810016|NCT03669146|Device|Glasses|Partial refractive correction in a pair of glasses.
45810017|NCT00377273|Drug|fluorouracil cream 0.5%|
45810018|NCT03421184|Other|blood sample|25 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
45810019|NCT03421184|Other|urine sample|10 ml
45810020|NCT03421184|Other|food questionnaire|dietary habit enquiry and a 48h dietary
45810021|NCT03421184|Other|hair|lock of hair
45810022|NCT04842864|Behavioral|Fasting|23 hours fasting
45810023|NCT03706313|Drug|15mL 0.25% bupivacaine|Patients will be randomly assigned to either a genicular nerve block with bupivacaine or saline
45810024|NCT03706313|Procedure|Genicular nerve block|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 5mL of a solution containing 15 ml of 0.25% bupivacaine with 2mg dexamethasone or 5mL saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
45946401|NCT02502266|Other|Questionnaire Administration|Ancillary studies
45946402|NCT02502266|Drug|Topotecan|Given IV
45657834|NCT05548075|Behavioral|Therapeutic support|Psychological and physical therapeutic support
45810025|NCT03706313|Drug|Saline|Patients will be randomly assigned to either a genicular nerve block with bupivacaine or saline
45810026|NCT05369364|Drug|Zanubrutinib|Zanubrutinib 80mg qd po, 6 consecutive weeks
45657835|NCT05700643|Dietary Supplement|Montmorency cherry supplement|Montmorency cherry supplement
45657836|NCT05700643|Dietary Supplement|Control|Placebo
45810027|NCT05369364|Drug|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
45810028|NCT03421106|Behavioral|Intervention Food Pantries|Food pantries will receive consulting services to transform their food offerings and environment in order to influence client health behaviors.
45810029|NCT03421106|Other|Control Food Pantries|Normal food pantry use
45810030|NCT04542642|Device|reSET-O|reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.
45810031|NCT04542642|Device|PEAR-008|PEAR-008 is a new, game-based version of reSET-O, a mobile application treatment for opioid use disorder.
45946403|NCT02502266|Drug|Topotecan Hydrochloride|Given IV
45946404|NCT02498613|Other|18F-Fluoromisonidazole|Correlative studies
45946405|NCT02498613|Drug|Cediranib Maleate|Given PO
45946406|NCT02498613|Other|Laboratory Biomarker Analysis|Correlative studies
45946407|NCT02498613|Drug|Olaparib|Given PO
45946408|NCT02498613|Procedure|Positron Emission Tomography|Correlative studies
45458413|NCT01363544|Other|Neurofeedback|30 sessions of theta/beta neurofeedback within 10 weeks.
45946409|NCT02496208|Procedure|Biospecimen Collection|Undergo collection of blood
45946410|NCT02496208|Drug|Cabozantinib S-malate|Given PO
45946411|NCT02496208|Procedure|Computed Tomography|Undergo CT scan
45946412|NCT02496208|Biological|Ipilimumab|Given IV
45657837|NCT05554003|Drug|Temozolomide capsule|Metronomic temozolomide 60 mg/die continuously
45810032|NCT03706469|Drug|TAK-831 T2|TAK-831 T2 Tablets.
45810033|NCT03706469|Drug|TAK-831 T3|TAK-831 T3 Tablets.
45810034|NCT00361244|Drug|SU011248|Given orally in the morning for two weeks followed by a one week rest period (one cycle equals 21 days). Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
45810035|NCT00361244|Drug|Irinotecan|Given intravenously on days 1 and 8 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
45810036|NCT00361244|Drug|Cetuximab|Given intravenously on days 8 and 15 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
45810037|NCT04532034|Behavioral|Peer-Delivered Decision Support Intervention|An intervention provided by a trained peer interventionist to facilitate treatment decision making among emerging adults with early psychosis. Specific components of this intervention may include facilitating access to information, clarifying values, helping a person obtain the needed support to make a decision, and screening for implementation barriers. Due to having lived experience of a mental health condition, the peer interventionist will also be able to provide unique types of information and support within the coaching process.
45657838|NCT05541757|Drug|In vitro heparin|In vitro heparin and in vitro LMWH
45657839|NCT05541601|Other|Blood and Urine samples|The samples will be used to identify a range of tests (including genetic, protein and other biomarkers), which along with the clinical data will hopefully identify those most at risk of developing HCC, and to identify HCC at the earliest possible time points.
45657840|NCT05547997|Other|Stretching exercises|Exercises will be performed in the following order: 1) stretching towards lateral flexion for the upper part of the trapezius; 2) ipsilateral flexion and rotation for the scalene; 3) and flexion for the extensor muscles. Each maneuver will be held for 30 seconds as this is an optimum time to not create alteration in the evoked protentional. Each stretch will be repeated 3 times
45657841|NCT05547997|Other|Two way traction|During the traction, the head halter will be fixed posteriorly to cause slight distraction, retraction, and slight extension and at the same time a front anterior strap had weight will be applied over a pulley that allows transverse traction load to be applied to the apex of the participants cervical curve alteration. Weights will start at 15 lbs. (6.8 Kg) on the anterior strap and will increase over consecutive visits to patient tolerance or a maximum of 35 lbs. (15.9 Kg).
45657842|NCT05547919|Radiation|18F-PSMA PET/CT|Patients with metastasized gastrointestinal tumors, that exhibit histological PSMA expression, receive an additional 18F-PSMA PET/CT to routine imaging.
45657843|NCT05699941|Device|Ectoin® Inhalation Solution|Ectoin Inhalation Solution (Class-IIa Medical Device Directive (MDD) legacy medical device) is an isotonic, aqueous solution containing Ectoin 1.3 % and sea salt 0.6%. It is used for moistening the lung epithelium by the Ectoin hydro complex and supports the barrier function of the lung epithelium. The inhalation solution can be administered with jet, mesh, and ultrasound nebulizers.
45810038|NCT04067232|Diagnostic Test|4D-CT-scan|Both forearms of the subjects with posttraumatic forearm impairment are scanned with a 4D-CT scanning technique, during forearm rotation.
45946413|NCT02496208|Procedure|Magnetic Resonance Imaging|Undergo MRI
45657844|NCT05700565|Other|Extracorporeal photopheresis|ECP consists of the three steps of leukapheresis, photoactivation and reinfusion and has immunomodulatory effects (modulation of dendritic cells, change in cytokine profile, induction of T cell subpopulations). Indications are currently the treatment of Sézary syndrome, Graft-versus-host disease (GvHD), organ transplant rejection and systemic scleroderma.
45657845|NCT05700565|Other|Other immunosuppressive or immunomodulatory drugs|Other immunosuppressive or immunomodulatory drugs
45810039|NCT03381482|Diagnostic Test|CSF drawing during spinal anaesthesia|4mL of CSF by lumbar puncture
45810040|NCT03381482|Diagnostic Test|Fasting blood sample|6x5 mL of fasting blood sample
45946414|NCT02496208|Biological|Nivolumab|Given IV
45946415|NCT02465268|Biological|pp65-shLAMP DC with GM-CSF|
45810041|NCT03381482|Diagnostic Test|Lumbar puncture|10 mL of CSF by lumbar puncture
45810042|NCT03545165|Drug|177Lu-PSMA-617|[1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)]
45810043|NCT03545165|Drug|177Lu-J591|[1.35 GBq/m2 or 36.5 mCi/m2]
45810044|NCT03545165|Drug|68Ga-PSMA-HBED-CC|[185 ±74MBq or 5 ±2 mCi]
45810045|NCT05293860|Other|Connective tissue manipulation|Connective tissue manipulation will be applied to participants' back for 5-20 minutes, 3 times a week for 4 weeks in this group.
45946416|NCT02465268|Biological|unpulsed PBMC and saline|
45946417|NCT02465268|Drug|Td|All subjects will receive a Td booster before study drug dose #1. Subjects in the experimental arms will receive Td skin prep before study drug doses #3, #6, and #9.
45946418|NCT02465268|Drug|Saline|
45810046|NCT05293860|Other|Superficial massage with the head of the therapeutic ultrasound device|Superficial massage with the head of the therapeutic ultrasound device will be applied to participants' back for 15 minutes, 3 times a week for 4 weeks in this group.
45946419|NCT02465268|Biological|pp65-flLAMP DC with GM-CSF|
45946420|NCT02408861|Procedure|Biospecimen Collection|Undergo blood sample collection
45946421|NCT02408861|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
45946422|NCT02408861|Procedure|Computed Tomography|Undergo CT scan
45946423|NCT02408861|Biological|Ipilimumab|Given IV
45946424|NCT02408861|Biological|Nivolumab|Given IV
45946425|NCT02408861|Procedure|Positron Emission Tomography|Undergo PET scan
45946426|NCT02394834|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
45810047|NCT02974946|Device|RenalGuard|
45657846|NCT05698537|Diagnostic Test|EEG|EEG registration performed in PwE to confirm epilepsy diagnosis
45657847|NCT05698537|Diagnostic Test|Neuroimaging|Neuroimaging performed in PwE to diagnose epilepsy etiology
45810048|NCT04968522|Drug|Methylphenidate Hydrochloride|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin 10 will be administered at the child's prescribed dose and may include a half tablet (5mg) increment. Ritalin 10 will be encapsulated in full tablet (10mg) or half tablet (5mg) dose.
45657848|NCT05698537|Diagnostic Test|Blood sample|Blood samples from both PwE and controls will be collected to measure full blood count, IgM and IgG antibodies to parasitic antigens including Taenia solium, Toxoplasma gondii and Plasmodium falciparum, to perform ELISA for HIV1 and HIV2, to measure HIV viral load and to conduct an emmel test.
45946427|NCT02394834|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab|oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
45946428|NCT02392429|Drug|Chemotherapy|Given anthracycline IV
45946429|NCT02392429|Procedure|Computed Tomography|Undergo FLT PET/CT
45946430|NCT02392429|Drug|Cytarabine|Given IV
45946431|NCT02392429|Other|Fluorothymidine F-18|Undergo FLT PET/CT
45946432|NCT02392429|Other|Laboratory Biomarker Analysis|Correlative studies
45946433|NCT02392429|Procedure|Positron Emission Tomography|Undergo FLT PET/CT
45946434|NCT02381561|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45946435|NCT02381561|Other|Laboratory Biomarker Analysis|Correlative studies
45946436|NCT02381561|Other|Pharmacological Study|Correlative studies
45946437|NCT02381561|Drug|Ropidoxuridine|Given PO
45946438|NCT02381535|Drug|Cisplatin|Given IV
45458414|NCT01363544|Behavioral|Exercise|30 sessions of individual sports training during 10 weeks.
45657849|NCT05698537|Other|Risk factor questionnaire|Both PwE and control subjects will complete a structured questionnaire on a wide range of potential risk factors present before the onset of the epilepsy.
45676354|NCT03742102|Drug|Oleclumab|Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1
45810049|NCT04968522|Drug|Placebo|The placebo is Maize Starch and Pregelatinised Maize Starch. The placebo will be encapsulated using the same capsule that is opaque so that participants cannot distinguish the two visually. Where the active mediation amount is small for the capsule, there will be additional Starcke 1500 (Maize Starch and Pregelatinised Maize Starch) added to fill the capsule so that the active drug and capsule also weigh approximately the same. The dose of placebo will be matched to the participants currently prescribed stimulant medication.
45946439|NCT02381535|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45946440|NCT02381535|Other|Laboratory Biomarker Analysis|Correlative studies
45946441|NCT02381535|Drug|Onalespib|Given IV
45946442|NCT02381535|Other|Pharmacological Study|Correlative studies
45946443|NCT02347709|Procedure|Diabetic Foot Ulcer Biopsy|Specimens from both the wound edge and a distal area of skin of patients will be obtained via 3 mm punch biopsy in the Winthrop University Hospital Wound Care Center. Biopsies will be collected from the wound edge prior to routine debridement using the following standard procedures, including the use of anesthetic if needed.
45946444|NCT02347709|Other|Survey|Study subjects from all three groups will be asked to complete a one-page Focused Neuropathy Evaluation. Providers will complete a one-page Focused Neuropathy Evaluation and a complete neurological examination and sensation assessment.
45946445|NCT02347709|Other|Comprehensive Neuropathy Assessment|Standard Monofilament Exam, Vibration Assessment, and Temperature Assessment will be performed on all patients in all study groups.
45946446|NCT02347709|Other|Wound Photography|Digital photographs and wound measurements for patients in Study Group 1 will be obtained per standard protocol at baseline and all subsequent visits.
45946447|NCT02329366|Other|Specimen Collection|. In this study, diabetic patients undergoing DFU debridement under the standard of care will be asked for their permission to collect the debrided tissue for use in scientific research.
45946448|NCT02327078|Drug|Nivolumab|specified dose and dosing schedule
45946449|NCT02327078|Drug|Epacadostat|oral twice daily continuous at the protocol-defined dose
45946450|NCT02327078|Drug|Chemotherapy|Specified dose on specified days
45946451|NCT02314169|Procedure|Biospecimen Collection|Undergo blood sample collection
45946452|NCT02314169|Procedure|Computed Tomography|Undergo CT scan
45946453|NCT02314169|Biological|Ipilimumab|Given IV
45946454|NCT02314169|Procedure|Magnetic Resonance Imaging|Undergo MRI
45946455|NCT02314169|Biological|Nivolumab|Given IV
45946456|NCT02304458|Biological|Ipilimumab|Given IV
45946457|NCT02304458|Other|Laboratory Biomarker Analysis|Correlative studies
45657850|NCT05541523|Behavioral|cognitive behavioural therapy|The three therapists in the cognitive behavioural group therapy condition were two students of master's degree of nursing with formal education in cognitive therapy and one psychological specialist nurse working in a palliative care unit. There was no evidence of significant deviation from the protocol.
45810050|NCT04968522|Drug|Methylphenidate hydrochloride|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin LA will be administered at the child's prescribed total dose. Ritalin LA will be encapsulated.
45946458|NCT02304458|Biological|Nivolumab|Given IV
45946459|NCT02304458|Other|Pharmacological Study|Correlative studies
45946460|NCT02298959|Procedure|Biopsy|Undergo tumor biopsy
45946461|NCT02298959|Procedure|Biospecimen Collection|Undergo blood sample collection
45946462|NCT02298959|Procedure|Computed Tomography|Undergo CT scan
45946463|NCT02298959|Procedure|Magnetic Resonance Elastography|Undergo MRI
45946464|NCT02298959|Biological|Pembrolizumab|Given IV
45946465|NCT02298959|Biological|Ziv-Aflibercept|Given IV
45946466|NCT02270567|Device|NETest|Non-invasive blood test
45810051|NCT04968522|Drug|Methylphenidate Hydrochloride 18 MG|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Concerta (18mg) will be administered at the child's prescribed total dose. Concerta will be encapsulated.
45657851|NCT05541523|Behavioral|mindfulness-based therapy|The two therapists in the mindfulness-based stress reduction condition were one clinical psychologist and one student of master's degree of nursing with formal education in mindfulness.Both interventions were manualized. To assure adherence to the study protocol meetings between the therapists and the researchers were organized regularly and the therapists detailed the content of each group session in clinical records which were frequently monitored by a research assistant.
45676355|NCT03742102|Drug|Paclitaxel|Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off
45946467|NCT02219373|Drug|Gabapentin|Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit >30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit <30% pain reduction, the patient will crossover to the other medication option in the protocol.
45946468|NCT02219373|Drug|Oxcarbazepine|Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit >30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit <30% pain reduction, the patient will crossover to the other medication option in the protocol.
45810052|NCT04968522|Drug|Dexamphetamine sulfate|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Dexamphetamine (10mg) will be administered at the child's prescribed total dose. Dexamphetamine will be encapsulated.
45810053|NCT00421850|Behavioral|UNITED Planned Care|
45810054|NCT03546491|Drug|Preventive Gel|0.4% Stannous Fluoride
45810055|NCT03546491|Drug|Marketed Control|0.243% Sodium Fluoride
45810056|NCT04047810|Biological|Mesenchymal Stem Cells|0.5- 2 million cells/kg, intravenously once
45946469|NCT02219373|Other|Placebo|Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
45946470|NCT02208375|Drug|Capivasertib|Given PO
45946471|NCT02208375|Other|Laboratory Biomarker Analysis|Correlative studies
45946472|NCT02208375|Drug|Olaparib|Given PO
45946473|NCT02208375|Other|Pharmacological Study|Correlative studies
45946474|NCT02208375|Drug|Vistusertib|Given PO
45657852|NCT05541445|Drug|Pembrolizumab|The subjects first receive induction therapy with pembrolizumab combined with chemotherapy for 6 weeks, and then receive sequential therapy with pembrolizumab combined with concurrent chemoradiotherapy for 6 weeks, and receive surgical treatment within 4-8 weeks after neoadjuvant therapy. For patients whose postoperative pathology is confirmed as PCR (pathological complete response), the patients will be observed with long-time follow-up; If the postoperative pathology is confirmed as non-PCR, pembrolizumab will be administrated until 1 year or disease progression or intolerable toxicity.
45810057|NCT00361322|Drug|clindamycin phosphate|
45810058|NCT00361322|Drug|salicylic acid|
46075870|NCT02514798|Other|Respiratory Inductance Plethysmography (RIP) system|Inspiratory tidal volume (VTi), respiratory rate (RR), breath duration (Ttot), inspiratory time (Ti) and fractional inspiratory time (Ti/Ttot) will be determined using a Respiratory Inductive Plethysmography (RIP) system. This will measure the thoracic and abdominal excursion of the subjects via two inductive wires which are sewn into the elastic bands that encircle the thorax and abdomen. The acquired signals represent changes in cross-sectional area and, following calibration to determine the relative contribution of each signal, and volume calibration using spirometry, their weighted sum will reflect VTi. The RIP companion software will be used to derive RR, Ttot, Ti and Ti/Ttot on a breath by breath basis.
45946475|NCT02199769|Other|Clinical Decision Support|Investigators will develop and implement an automated Diabetes Detection Tool (DDT) that does data mining on EMR lab data to systematically identify all primary care patients with elevated RPGs who are at high risk of diabetes and in need of further diabetes testing/screening.
45810059|NCT03714659|Device|Lipogems|Lipogems is a closed-loop system designed to break up adipose tissue into micro-fragmented adipose tissue without additives; therefore, meeting FDA requirements for minimal manipulation. A small volume of adipose tissue is harvested from the abdomen, thigh, or other location. The lipoaspirate is fed into the device through a reduction filter, and is then cleansed of blood and oil residues using a sterile saline solution. This fat-saline solution is then shaken for 30 seconds in a device containing stainless steel ball bearings, which further fragments and washes the lipoaspirate. Once the tissue is purified and fragmented, it is collected in 10cc sterile syringes and subsequently injected into the meniscus and knee joint.
45810060|NCT03648710|Other|Peer Community Health Worker|Participants will be communicating with their CHWs on a weekly basis, which is consistent with other successful community health worker protocols with published efficacy. Community Health Workers will be peers with sickle cell disease, who have successfully transitioned and are under 30 years of age.
45810061|NCT03648710|Other|Mobile Health|A mobile health application created as a resource for young adults transitioning.
45810062|NCT01637142|Drug|LY2140023|Administered orally.
45676356|NCT03742102|Drug|Trastuzumab deruxtecan|Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w
45676357|NCT03742102|Drug|Datopotamab deruxtecan|Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w
45810063|NCT01637142|Drug|14C-LY2140023|Administered IV.
45810064|NCT01637142|Drug|14C-LY404039|Administered IV.
45810065|NCT04055519|Device|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
45810066|NCT04055519|Device|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
45810067|NCT04055519|Device|Multi-purpose disinfection solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
45810068|NCT01636986|Device|Delefilcon A contact lenses|Silicone hydrogel contact lenses for daily wear, daily disposable use
45810069|NCT01636986|Device|Etafilcon A contact lenses|Hydrogel contact lenses for daily wear, daily disposable use
45810070|NCT04055675|Diagnostic Test|Urine dipstick test|A sample of urine will be tested using a Mission Urinalysis Reagent Strip.
45810071|NCT04539392|Other|Questionnaires on sexuality|Panel of questionnaires assessing sexuality, relationship satisfaction, and body image
45810072|NCT04831944|Drug|parsaclisib|parsaclisib will be administered orally after 8 hours of fasting.
45810073|NCT02974712|Drug|Fentanyl|
45810074|NCT02974712|Drug|Saline|
45810075|NCT04526340|Diagnostic Test|Blood sample|2 Blood samples at the beginning and end of the test to analyze; Haptoglobin phenotyping, Haptoglobin concemtration (μmol/l) (serum), Sodium (mmol/l) (serum), Osmolality (mOsm/kg) (serum), Urea (g/l) (serum), Creatinine (g/dl) (serum), Potassium (mmol/l) (serum).
45810076|NCT04526340|Diagnostic Test|Bio-impedance measurement (BIA)|for every 30 minutes for 4 hours
45946476|NCT02198131|Procedure|laser therapy|Undergo pulsed dye laser
45946477|NCT02198131|Other|questionnaire administration|Ancillary studies
45946478|NCT02187224|Drug|Progesterone|
45946479|NCT02187224|Drug|Placebo (for Progesterone)|
45946480|NCT02176226|Behavioral|IntelliCare|Behavioral interventions for depression and anxiety via a mobile phone application, IntelliCare.
45946481|NCT02159066|Drug|LGX818|Combination of LGX818 and MEK162 (Part I)
45946482|NCT02159066|Drug|MEK162|Combination of LGX818 and MEK162 (Part I)
45810077|NCT04526340|Dietary Supplement|Ingestion of testing nutrient/food capsules|The subjects will be tested in fasted and sober state in the morning. No food/drink 6 hours prior to the test. The subjects will be asked to take 2 different dosages of testing nutrient along with 500ml of water and only water for the control, on 3 different test days. The testing nutrients will be prepared in 1g capsules.
45946483|NCT02159066|Drug|LEE011|Combination of LGX818 + MEK162 + LEE011 (Part II)
46075871|NCT02514798|Other|Sentec transcutaneous monitoring system|The oxygenation, the level of carbon dioxide, and the heart rate will be recorded using the Sentec transcutaneous monitoring system: a probe will be placed at the earlobe or on the forehead, and it will measure in a noninvasive way these parameters.
46075872|NCT02514798|Device|High-flow humidified nasal oxygen delivery system|
45657853|NCT05699863|Behavioral|Lifestyle intervention|"Lifestyle intervention in the form of individualised dietitian consultation with the overall goal of weight loss.~Intervention includes one initial consultation with a dietician of 1 hour and 15 minutes where participants receive a personalised diet-plan customised to the participants everyday life. After the initial consultation, the participants attend 10 follow-ups of about 25 minutes that are spread out over 4-5 months."
45657854|NCT05541289|Biological|BBV152|Single Arm; BBV152 (COVAXIN™)
45946484|NCT02159066|Drug|BGJ398|Combination of LGX818 + MEK162 + BGJ398 (Part II)
46075873|NCT02514798|Device|CPAP (Positive Control)|
45657855|NCT04325503|Drug|carbidopa|carbidopa and carbidopa-levodopa standard treatment
45657856|NCT05699785|Other|plasma inflammatory markers|Evolution of different plasma inflammatory markers (CRP, IL6, D-Dimers, CD14s, CD163, IL-1, IP-10, MCP-1, IL-18, IFAB)
45657857|NCT05699785|Other|CD4/CD8 ratio|Evolution of CD4/CD8 ratio
45946485|NCT02159066|Drug|BKM120|Combination of LGX818 + MEK162 + BKM120 (Part II)
46075874|NCT02543515|Procedure|office hysteroscopy|diagnostic procedure
46075875|NCT04029285|Other|Exergaming|The exergaming group played six IREX® exergames. Those in the TGB group performed exercises that were matched to the IREX® exergames for: movement patterns required, physiological demands, sequence, duration and mode of exercise by adopting open and closed kinetic chain movements, in the same range and loading, across both groups. Each IREX® exergame was played for two minutes and was repeated three times within a session. TGB exercise was conducted in sets of two minutes duration, repeated three times within a session. In both groups participants were given rest periods of 10 to 30 seconds, or longer, if required, between exergames or TGB exercise sets.
45676358|NCT03732794|Device|AtriCure CryoICE & AtriClip LAA Exclusion|AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
45810078|NCT04526340|Diagnostic Test|Urine sample|3 Urine samples at the beginning, after 2 hrs and at the end of the test to analyze: Total voided volume, Osmolality (mOsm/kg), Creatinine (g/dl), Sodium (mmol/l), Potassium (mmol/l), Urea (g/l)
45810079|NCT02974556|Procedure|Standard surgical treatment|Standard surgical treatment (open or laparoscopic techniques) containing at least 12 lymph-nodes for accurate pN staging.
45946486|NCT02159066|Drug|INC280|Combination of LGX818 + MEK162 + INC280 (Part II)
45946487|NCT02107586|Procedure|Biceps tenotomy|A biceps tenotomy procedure involves cutting of the long head of the biceps just prior to its insertion on the superior labrum of the glenoid.
45946488|NCT02107586|Procedure|Biceps tenodesis|Biceps tenodesis involves detaching the long head of the biceps from it's superior labrum in the shoulder and reattaching it to the humerus bone just below the shoulder.
45946489|NCT02107547|Procedure|Biceps tenodesis|A biceps tenodesis involves cutting the tendon within the shoulder joint and reattached further down the arm.
45946490|NCT02107547|Procedure|Labral repair|Repair of a Superior Labrum Anterior and Posterior lesion involves placing small anchors in the glenoid to re-attach the torn labrum.
45657858|NCT05547763|Procedure|surgically mandible will be exposed to reduced the fracture anatomically and then fixated with either resorbable or the titanium plates|under general anesthesia , fracture site of the mandible will be exposed and fracture will be reduced anatomically and held together by either resorbable or titanium plates and then the incsion site will be closed with vicryl sutures and patient will be observed on the follow ups clinically and radiographically for the fracture reduction and stability of the fractures with resorbable plates as compared to the titanium plates.
45657859|NCT05540977|Drug|Donepezil|Donepezil 5mg QN
45946491|NCT02099825|Drug|d-cycloserine and mifepristone|All participants will receive a one-time only dose of both, d-cycloserine and mifepristone at Session 2
45946492|NCT02064764|Device|Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter|
45657860|NCT05540977|Other|Usual care|Usual care
45946493|NCT02064764|Device|Arctic Front Advance™ Cardiac Cryoablation System|
45946494|NCT02057978|Procedure|EXCEL DES implatation|Implant DES for CAD cases
45657861|NCT05553535|Diagnostic Test|MRI|retrospective review of shoulder MRI
45657862|NCT05547685|Diagnostic Test|Methylene blue intradermal injection|Methylene blue intradermal injection
45946495|NCT02057978|Procedure|EXCEL-II DES implantation|Implant DES for CAD cases
45946496|NCT02032823|Drug|Olaparib|Patients will be administred olaparib orally twice daily (b.i.d.) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
45946497|NCT02032823|Drug|Placebo|Patients will be administred matching placebo. Two (2) tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
46075876|NCT00633308|Device|NxStage System One (NxStage Medical, Lawrence, MA)|Each patient will be studied on 4 separate occasions. The study sessions are longer than routine daily hemodialysis therapy using the System One.
45657863|NCT05553379|Diagnostic Test|FeNO measurement|FeNO measurement at each visit
45657864|NCT05540821|Diagnostic Test|Hysterosalpingo-contrast sonography and sonoPODography|"Before operation, phloroglucinol 40mg of antispasmolysis was injected intramuscular, and then cervical dilation was performed according to aseptic operation requirements. A 12G double-lumen catheter was inserted into the uterine cavity, and 1.5-1.8ml of normal saline was injected into the sacculus.~Transvaginal 2/3/4D hysterosalpingo-contrast sonography: One operator extracted 2ml of Sonovue and injected 18ml of normal saline through a dual-lumen catheter, and the other operator started the four-dimensional ultrasound mode to collect dynamic volume data.~sonoPODography: Sterile saline was injected into the intrauterine cavity, with an upper limit of 20ml. The normal saline flowed from the intrauterine cavity into the pelvic cavity through the bilateral fallopian tubes, forming a good acoustic window. Pelvic observation was then performed."
45810080|NCT02974556|Procedure|Proactive management|Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure. Simultaneously patients will undergo infracolic omentectomy, appendectomy, exeresis of the liver round ligament and, in women, a bilateral oophorectomy. After positioning three in- and outflow catheters HIPEC perfusion starts with a minimum of 2 L isotonic dialysis fluid at a flow-rate of 1-2 l min and an inflow temperature of 42-43° C with a total of 30 minutes perfusion time. Before the beginning of HIPEC 5-fluouracil and leucovorin will be administrated intravenously to potentiate oxaliplatin activity.
45657865|NCT05547607|Diagnostic Test|advanced cardiac imaging|In all patients with high suspected or confirmed endocarditis at the echocardiography the following information will be collected: 1) endocarditis risk factors, 2) type, size and position of infected valve or prosthesis, 3) echocardiographic data; 4) imaging technique used for diagnosis in addition to echocardiography; 5) management of the case performed by the endocarditis team (including cardiologist, microbiologist, cardiac surgeon, radiologist); 6) Duke criteria verification; 7) management of the case (conservative or invasive); 8) antibiotic therapy prescribed and timing; 9) follow-up at one year (death, cardiac surgery, stroke, re-infection).
45657866|NCT05540587|Drug|Edoxaban|"Patients in the Edoxaban group take Edoxaban 60mg once daily. If any of the following conditions are present, take 30mg once daily.~CrCl 15-50mL/min~Body weight ≤ 60kg~Concomitant use of P-glycoprotein inhibitor (Dronearone, Ciclosporine, Erythromycin or Ketoconazole)"
45810081|NCT02974556|Drug|Standard adjuvant systemic chemotherapy|Adjuvant systemic chemotherapy (according CAPOX or FOLFOX regimens for a total of 6 months) will be reserved in patients with pT3 tumors with poor prognostic factors, in patients with pT4 tumors and when lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT every six months for the first 24 months and later every year for the next three years in both study arms.
45810082|NCT04523142|Drug|CyclASol Ophthalmic Solution|Cyclosporine A solution in vehicle
45810083|NCT04538456|Other|questionnaire and optional interview|Participants will be sent an online or paper questionnaire. If participants have expressed an interest in taking part in an interview, they may be contacted by a member of the research team. The interviews will be conducted over the phone at time suitable for the participant. There will be no study specific hospital visits.
45810084|NCT04819152|Behavioral|Tobacco cessation intervention|Already implemented in-person (including online meetings) tobacco cessation interventions in Sweden
45810085|NCT03557333|Combination Product|INP104|No more than 2 doses within 24 hours, 3 doses within 7 days. 1.45 mg in a divided dose, one actuation per nostril.
45810086|NCT04537520|Device|Kerecis Omega3 Wound|Treatment of the wound with Kerecis Omega3 Wounds matrices
45810087|NCT04527380|Drug|Ixekizumab|Administered SC
45946498|NCT01958021|Drug|LEE011|Ribociclib was administered orally at a dose of 600 mg once daily (three 200 mg capsules).
45946499|NCT01958021|Drug|Letrozole|Letrozole 2.5 mg tablets taken orally.
45946500|NCT01958021|Drug|LEE011 Placebo|Matching ribociclib placebo was the control drug and was administered orally once daily.
45946501|NCT01954316|Drug|CFI-400945|Polo-like kinase 4 (PLK4) inhibitor
45946502|NCT01946477|Drug|Pomalidomide|
45946503|NCT01946477|Drug|Dexamethasone|
45946504|NCT01946477|Drug|Daratumumab|
46002563|NCT04647006|Procedure|thyroid|Conventional Thyroidectomy and Transoral endoscopic thyroidectomy vestibular approach
46002564|NCT04638504|Other|ultrasonography|vascular and adipose tissue measurement by ultrasonography
46075877|NCT00884299|Dietary Supplement|Diet rich in antioxidants|Dietary intervention based on diet with increased consumption of foods containing antioxidants such as fresh fruits, fruit juices and vegetables. Patients are advised by a physician and a specialist nurse during regular scheduled outpatient clinic visits to increase fresh fruit /fruit juices/vegetable consumption of at least one portion per day compared to baseline and to maintain this regime throughout the study period.
45810088|NCT04527380|Drug|Adalimumab|Administered SC
45657867|NCT05540587|Drug|Warfarin|Patients in the Warfarin group take Warfarin 2-10mg once daily, dose adjusted with the target INR 2-3. In the elderly or frail patients, a lower dose administration is allowed at the discretion of the investigator.
45657868|NCT05540509|Behavioral|Community-based intervention|Mothers were given physical activity goals and coping resources to practice at home and were asked to record their experiences on an activity log. Course content was taught from a detailed training manual and was based on concepts and strategies from social cognitive theory that have been effective in increasing physical activity and fitness levels among mothers. In the first month, mothers attended group exercise sessions twice per week (total of eight group sessions) and exercised on their own once per week. In the second month, mothers attended group exercise sessions once per week (total of four group sessions) and exercised on their own twice per week. In the third month, mothers exercised on their own three times per week.
45946505|NCT01853631|Genetic|Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells|"Three dose levels will be evaluated.~Group 1: CD19.CAR/28137ζ at 1×10^6 cells/m^2 and CD19.CAR/28ζ at 1×10^6 cells/m^2~Group 2: CD19.CAR/28137ζ at 5×10^6 cells/m^2 and CD19.CAR/28ζ at 5×10^6 cells/m^2~Group 3: CD19.CAR/28137ζ at 2×10^7 cells/m^2 and CD19.CAR/28ζ at 2×10^7 cells/m^2"
45946506|NCT01853631|Genetic|Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells|The primary goal of the expanded cohort is to further study the safety profiles of CAR-T cells in each of the disease settings, both with or without lymphodepleting chemotherapy given before CAR-T cell infusion.
46075878|NCT00914355|Radiation|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver.You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment.Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
46075879|NCT02543593|Device|Active tDCS or Sham tDCS|tDCS is a painless technique which consists in applying low direct-current through electrodes (one electrode serving as an anode, the other as a cathode) placed on the scalp to target the cerebral cortex. In patients with chronic pain, the anode is commonly placed over the motor cortex (M1) (Valeriani et al., 1999).
46075880|NCT02843126|Drug|Trastuzumab|Pre-dose (0 hours) on Day 1 of Cycles 1 to 8 (cycle length of 21 days)
45657869|NCT05540509|Behavioral|Home-based intervention|The HBI group received information on building social support and reducing physical activity barriers based on materials from the Diabetes Prevention Program. Participants were also given activity logs to record their physical activity each week, which was collected by research staff at each monthly assessment time point to assess how participants were progressing with their physical activity goals. Mothers exercised on their own for three months with the goal of meeting national physical activity guidelines
45810089|NCT04957368|Drug|Nitrous Oxide 99 %|Nitrous oxide will be administered at an inspiratory concentration of 50% with concurrent intravenous saline (100ml) for one hour.
45946507|NCT01742299|Drug|imatinib mesylate|Imatinib will be provided as 100 mg and 400 mg tablets taken orally once daily unless other wise instructed by investigator
45657870|NCT05540431|Drug|Activated Charcoal|RCT
45946508|NCT01621711|Behavioral|Linkage patient activation intervention|"Usual Care plus Linkage encompassed Usual Care with the exception that the six 45-min Linkage patient activation education groups replaced the six 45-min Usual Care medical education groups, plus a linkage phone call (and/or a facilitated email) with the patient, clinician, and Primary Care physician.~The patient activation intervention components -- 1) six 45-min Linkage sessions on activation regarding overall health behaviors and 2) a linkage phone call (and/or a facilitated email) with the patient, clinician, and PC physician -- were delivered by a clinical psychologist."
45946509|NCT01556256|Other|Caregiver-Related Intervention or Procedure|Undergo TMV+P
45657871|NCT05540431|Dietary Supplement|Probiotic|RCT
45657872|NCT05540431|Other|No intervention|RCT
45657873|NCT05700409|Behavioral|Intensive lifestyle consultations|detailed above
45657874|NCT05553067|Genetic|Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody.|Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody and compare levels of expression in different ovarian specimens to detect its potential role in oncogenesis of ovarian carcinoma.
45810090|NCT04957368|Drug|Oxygen + Midazolam|Oxygen will be administered at 50% with intravenous midazolam (0.02mg/kg in 100ml) for one hour
45810091|NCT04050605|Device|somofilcon A toric contact lens|Contact Lens
45810092|NCT04050605|Device|fanfilcon A toric contact lens|Contact Lens
45810093|NCT04818450|Drug|Gabapentin|Gabapentin 100-300 mg is given to the intervention group
45810094|NCT04841148|Drug|HCQ|600 mg tablets twice daily D1-28 of each 28-day cycle
45946510|NCT01556256|Procedure|Music Therapy|Undergo TMV
45946511|NCT01556256|Procedure|Music Therapy|Undergo TMV+P
46075881|NCT02843126|Biological|NK immunotherapy|For each procedure, 10 billion cells will be infused for 4 times
46075882|NCT04201652|Procedure|Superficial local anesthetic infiltration|Superficial infiltration of local anesthetic for carpal tunnel release.
46075883|NCT04201652|Procedure|Deep local anesthetic infiltration|Deep and superficial infiltration of local anesthetic for carpal tunnel release.
46075884|NCT05338476|Drug|Midazolam|Administered orally.
46075885|NCT05338476|Drug|Selpercatinib|Administered orally.
45946512|NCT01556256|Other|Quality-of-Life Assessment|Ancillary studies
46075886|NCT02838758|Device|Cryoablation|A minimally invasive cryoablation device. It delivers focused nitrous oxide to the target tissue via a 22-gauge needle to create an approximately 9.4mm by 5.4mm spherical freezing zone of temperature between -20 to -100° C.
45810095|NCT04841148|Drug|Avelumab|10 mg/kg, IV, D1 and D15 of each 28-day cycle
46075887|NCT02838758|Drug|Lidocaine|Roughly 3cc of lidocaine will be injected near the intermetatarsal neuroma under ultrasound visualization.
45453310|NCT05447533|Other|Comprehensive geriatric assessment (CGA)|"Within 5 weekdays from date of randomization (not included) a standardized CGA with a tailor-made intervention will be performed in the allocated ward or at home by a geriatric team. Bedside Multidimensional Prognostic Index (MPI) will be performed.~A geriatric Clostridioides difficile infection checklist will be performed by local geriatrician and secure an early assessment of CDI and treatment strategy.~When indication: pre-treatment with vancomycin 125 mg x 4. Routine biochemical analyses for patients with Clostridioides difficile infection.~Evaluation of indication for faecal microbiota transplantation (FMT).~Criteria for FMT rely on the geriatric assessment and will be considered for the patient if the patient fulfil one of the following:~Severe index, recurrent or refractory CDI as defined by national clinical guidelines or~High risk patient according to CGA at first visit. High risk patient is defined frailty grade MPI-2 (moderate) or MPI-3 (severe)."
45458415|NCT01363544|Drug|methylphenidate|The medication treatment is based on the MTA study and includes methylphenidate dosages of 5, 10, 15 (only for children with a weight below 25 kg) and 20 mg (only for children with a weight above 25 kg. The optimum dose will be determined by a double-blind placebo-controlled trial.
45657875|NCT04319809|Device|Object recognition subsystem|The object recognition subsystem is an add-on to the Argus II retinal prosthesis system. in the early stage of the study the subsystem will run on a separate processor; in the later stage the subsystem will run in the Argus II user's video processing unit.
45657876|NCT05547139|Other|Protocolized weaning of respiratory support|The protocolized weaning aims to keep babies on CPAP for a longer period of time and will measure how long it takes babies to wean to 2L nasal cannula support or come off all support (room air, RA).
45657877|NCT05547061|Drug|Lu-177-DGUL|Lu-177-DGUL(150mCi, 200mCi) intravenous 4 doses, 6weeks apart
45657878|NCT05547061|Drug|Ga-68-NGUL|Ga-68-NGUL(2MBq/kg) intravenous during screening and every 12 weeks after the first administration of Lu-177-DGUL
45657879|NCT04318249|Behavioral|Assisted Relaxation Therapy|This intervention includes using a smartphone application that helps with breathing techniques and sleep.
45657880|NCT04318249|Behavioral|Modified Assisted Relaxation Therapy|This intervention includes using a smartphone application that is modified to help with breathing techniques and additional sleep instructions.
45810096|NCT04841148|Drug|Palbociclib|125 mg capsule daily, by mouth on D1-21 concurrently with Avelumab. Or 75 mg capsule daily, by mouth on D1-28 concurrently with HCQ.
45946513|NCT01556256|Other|Questionnaire Administration|Ancillary studies
46075888|NCT02838758|Drug|Saline|Roughly 3cc of saline will be injected near the intermetatarsal neuroma under ultrasound visualization.
46075889|NCT04228224|Device|Robot-assisted training with a lower extremity powered exoskeleton (H3 Exoskeleton, Spain)|The H3 is a powered lower extremity exoskeleton with actuated at hips, knees and ankles joints. A novel control software has been design and implemented in this device, which allows selective joint movement and recording of data from each rehabilitation session.
45810097|NCT02974790|Procedure|Echocardiography|Two-dimensional imaging echocardiography
45946514|NCT01556243|Procedure|therapeutic conventional surgery|
45946515|NCT01556243|Radiation|whole breast irradiation|
45946516|NCT01534299|Device|Medtronic Renal Denervation System|The Symplicity renal denervation system is comprised of a single-use, disposable catheter and a reusable radiofrequency (RF) generator. The Symplicity renal denervation system has CE Marking for the intended use of delivering low-level radiofrequency energy through the wall of the renal artery to denervate the human kidney.
45946517|NCT01475786|Biological|Low Dose: 16 mg Engensis (VM202)|"Subjects in the Low Dose Group (8mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)~Day 14 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)"
45810098|NCT04035161|Combination Product|Investigational Product|2%(w/v) Chlorhexidine in 70%(v/v) Isopropyl skin preparation
45810099|NCT04035161|Other|Reference Standard|60% (v/v) 1-propanol skin preparation
45810100|NCT04035161|Combination Product|Active Comparator|ChloraPrep® SEPP® skin preparation
45810101|NCT04035161|Other|Negative Control|0.9% Normal Saline skin preparation
45657881|NCT05540275|Drug|Sintilimab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks
45810102|NCT05369286|Drug|"MAX-40279-01 and Toripalimab"|"MAX-40279-01combined with Toripalimab"
45810103|NCT04037969|Device|Nesofilcon A|Hydrogel contact lens for daily wear
45810104|NCT04037969|Device|Delefilcon A|Silicone hydrogel contact lens for daily wear
45810105|NCT03583814|Behavioral|CASE Program|Controlling Asthma in Schools Effectively (CASE) provides school-based education and environmental assessments. This program takes place over the course of about 4 weeks and involves in-school or remote asthma education for school aged children, after-school or remote education sessions for their parents, asthma care training for school staff, and an evaluation of asthma triggers in the school.
45810106|NCT03583814|Behavioral|HARP Program|Home Asthma Response Program (HARP) is a home-visiting program consisting of 3 home visits or remote sessions (over about 6 weeks). HARP provides individualized asthma education, home-based environmental assessment, and strategies and supplies for controlling environmental asthma triggers.
45810107|NCT04508192|Other|Exercise|Both interventions are simple strength exercises without technical equipment
45810108|NCT03718871|Behavioral|HIV testing at traditional healer practices|HIV 1/2 antigen-antibody POC test (Oraquick©) will be administered to those participants who agree to test. Pre-test counseling will be performed before results are delivered. Clients with positive tests will be provided with detailed contact information for the MUST ISS clinic, and given specific instructions to present to the clinic as soon as possible for confirmatory testing and linkage to care.
45810109|NCT04829760|Dietary Supplement|Psyllium|Participants will consume 10 grams of fiber from psyllium in two doses each day for 8 weeks
45810110|NCT04829760|Dietary Supplement|Coarse wheat bran|Participants will consume 10 grams of fiber from coarse wheat bran in two doses each day for 8 weeks
45810111|NCT04829760|Dietary Supplement|Maltodextrin|Participants will consume maltodextrin in a volume equivalent to the psyllium intervention (~2 tablespoons) in two doses each day for 8 weeks
45810112|NCT05289804|Device|NITESGON|"NITESGON will be delivered by a specially developed, battery-driven, constant current stimulator via a pair of saline-soaked surface sponges on the scalp. One electrode each will be placed over the left and right C2 dermatomes.~NITESGON will first be switched on in a ramp-up fashion over 30 seconds. For active NITESGON, stimulation will occur during the word association task. For sham the current intensity (ramp down) will gradually be reduced (over 5 seconds) as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain."
45810113|NCT05289804|Drug|Lidocaine / Prilocaine Topical Cream|A topical skin anesthetic (lidocaine/prilocaine cream) will be used to reduce any potential contribution from transcutaneous stimulation of peripheral nerves. This lidocaine/prilocaine preparation blocks sodium channels in peripheral nerves in the skin and thereby stabilizes the membrane potential and increases the threshold for firing an action potential.
45810114|NCT05289804|Device|C5/C6 stimulation|The electrodes will be placed over cervical nerves five and six, to mimic the sensation, but change the location.
45810115|NCT05289804|Device|Sham NITESGON|Sham NITESGON
45810116|NCT03719885|Device|TrueTear Intranasal Tear Neurostimulator|This study will evaluate the immediate tear production resulting from use of intranasal tear neurostimulation in patients with Sjogren's disease
45810117|NCT04021368|Drug|RVU120(SEL120)|RVU120(SEL120) will be administered as a single oral dose every other day (q.o.d.) for a total of 7 doses i.e. on Days 1, 3, 5, 7, 9, 11 and 13, in a 3-week treatment cycle.
45946518|NCT01475786|Biological|High Dose: 32 mg Engensis (VM202)|"Subjects in the High Dose Group (16 mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)~Day 14~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)"
45657882|NCT05540119|Procedure|Surgery|Patients who undergo surgery are separately assessed
45657883|NCT05552677|Other|Multicomponent Training|Participants will perform a multicomponent training that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 12 weeks
45657884|NCT05546827|Procedure|Surgical resection|Surgical resection after receiving neodjuvant combination immunotherapy followed by radiation therapy.
45810118|NCT05448872|Drug|Sacubitril/Valsartan|HF patients treated with Sac/Val
45810119|NCT04817826|Drug|Durvalumab|durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).
45810120|NCT04817826|Drug|Tremelimumab|tremelimumab 300 mg single administration (day 1)
45810121|NCT00362258|Drug|Irbesartan (Aprovel)|Aprovel (150 & 300mg) & CoAprovel (300/12.5mg hydrochlorothiazide) one tablet/day per os.
45810122|NCT00362726|Drug|Rosiglitazone maleate|Tablets, Oral, RGZ 4 mg, once daily, 1 day.
45810123|NCT00362726|Drug|Atazanavir Sulphate|Capsules, Oral, ATV 400 mg, once daily, 5 days.
45810124|NCT00362726|Drug|Atazanavir Sulphate + Rosiglitazone maleate|Capsule, Oral, ATV 400 mg + RGZ 4 mg, once daily, 1 day.
45810125|NCT00362726|Drug|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 14 days.
45810126|NCT00362726|Drug|Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate|Capsules/Tablets, Oral, ATV 300 mg + RTV 100 mg + RGZ 4 mg, once daily, 1 day.
45810127|NCT04011774|Other|PLANI-REV|Cognitive remediation program.
45810128|NCT04011774|Other|RELAXATION|Stimulation with no cognitive remediation.
45946519|NCT01475786|Other|Control- Placebo (normal saline)|subjects will receive thirty-two (32) 0.5 mL injections of normal saline on Day 0 and Day 14.
46002565|NCT04684784|Device|Intervention-Dry Needling|Deep Dry Needling into the site of the latent TriggerPoint of the upper trapezius muscle. 1 session in upper trapezius muscle moving the needle up and down ten times.
46002566|NCT04684784|Device|Control-Dry Needling|Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles
45657885|NCT05539885|Procedure|Pre-incisional Ultrasound guided (PIFP) block|Patients in group P will be injected with 0.4 mL/kg of 0.25 bupivacaine in the fascial plane between the internal intercostal and pectoralis major muscles on each side of the sternum after induction of anesthesia and before skin incision under ultrasound guidance.
45657886|NCT05539885|Procedure|Post-incisional Surgeon delivered parasternal block group|"After sternal closure, the surgeon will inject bupivacaine (0.5- to 2-mL aliquots depending on the weight) in the fascial plane under direct vision between the 5 anterior (2nd-6th) intercostal spaces on each side 1 to 1.5 cm lateral to the sternal edge using 25-gauge, 50 mm needle. The surgeon will inject the same dose and concentration of bupivacaine used in the ultrasound technique. This technique was prescribed before by Chaudhary et al (23).~In both techniques, the maximum dose of bupivacaine will never be exceeded (2 mg/kg). In addition, all patients were administered 2 mL of 0.25% bupivacaine at the site of the mediastinal drain location."
45946520|NCT01275716|Behavioral|Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications|Subjects will be randomly assigned (like the flip of a coin) to a study group. One group will be given before and after treatment pictures of their affected heart arteries. The other group will not be shown these pictures. Both groups will still receive written and verbal information about living a heart healthy lifestyle and taking heart medications properly as part of their normal routine care.
45946521|NCT01087073|Behavioral|Patient Activation|Culturally tailored patient activation training classes providing education and communication strategies to empower patients to be proactive in their diabetes self-management behavior. Participants attend a 10 week interactive class. Diabetes support groups after the completion of these classes help patient maintain self-management and adherence to healthy behaviors.
46075890|NCT04228224|Behavioral|Conventional gait rehabilitation|Conventional gait rehabilitation consist in walking and other applicable lower limb exercises performed by participants with assistance of a physical therapist.
46075891|NCT00803595|Drug|CS-8958|CS-8958 powder 20 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
46075892|NCT00803595|Drug|CS-8958|CS-8958 powder 40 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
46075893|NCT00803595|Drug|oseltamivir phosphate|CS-8958 placebo powder to be inhaled one time. Oseltamivir phosphate oral capsules taken twice daily for 5 days.
45453311|NCT05447533|Other|Continued geriatric care|"Continued specialized geriatric care through 8 weeks of follow-up. Minimum of follow-up is 8 weeks from last FMT or start of vancomycin/fidaxomicin treatment.~Tailormade telephone contacts and/or visits in case of clinical exacerbation. Performed by local geriatric teams.~The geriatric department remains responsible for the CDI during 8 weeks of follow-up or until cured."
45657887|NCT05539807|Behavioral|Mindful Eating Conscious Living|"MECL is a 8 week mindfulness-based group intervention. Each session is of 2.5-3 hours duration. During the sessions, theories about eating-related difficulties in general are presented, participants are guided in mindfulness practices and participants who want to share their experiences in the group can do so. Topics include: (1) What is mindfulness, why and how can we use mindfulness in relation to eating (2) slowing down, taking breaks and noticing different types of hunger (e.g. physical hunger and the hunger for comfort - heart hunger) (3) working with satiety and satisfaction (4) becoming aware of patterns associated with one's eating behaviors, (5) awareness of feelings and bodily sensations (6) Food and mood (7) craving, and finally (8) working with heart hunger and emotional eating. Six to 10 participants participated in each group."
45657888|NCT05552599|Procedure|woolen blanket|Woolen blanket: The people in the experimental group were treated with a standard hospital woolen.
45657889|NCT05552521|Diagnostic Test|Echocardiography|Echocardiography in 4 timepoints: 1st 24h + 7th-10th day; 28th-30th day; 6 months Whole exome sequencing at admission
45657890|NCT04426123|Drug|Botulinum toxin type A|Intramuscular injection with Botulinum toxin type A in m.masseter and m.temporalis.
45657891|NCT04426123|Other|saline solution|Intramuscular injection with NaCl in m.masseter and m.temporalis.
45657892|NCT05539651|Drug|RBD5044|Subcutaneously Administered RBD5044 in Healthy Subjects
46075894|NCT02779374|Other|Autologous bone marrow transplantation|Bone marrow aspiration of 10 ml/kg is done from the posterior iliac crest. The sample is put in sterile container with appropriate amount of heparin then filtered to remove bone spicules, fat, and cellular debris. The filtered sample is injected unprocessed in a peripheral vein. The process is done once.
45657893|NCT05539651|Drug|Placebo|Subcutaneously Administered Placebo in Healthy Subjects
45458416|NCT04462354|Procedure|Blumgart Anastomosis|Patients undergoing cephalic duodenopancreatectomy, reconstructing pancreatic-enteric communication by Blumgart anastomosis
45458417|NCT04462354|Procedure|Pancreatogastric anastomosis.|Patients undergoing cephalic duodenopancreatectomy, reconstructing pancreatic-enteric communication by Pancreatogastric anastomosis.
45458418|NCT04462432|Other|no intervention|This is an observation study, with no intervention.
45453312|NCT05447533|Other|Faecal microbiota transplantation (FMT)|When clinical indication for FMT, this will be delivered as 15-25 capsules (~ 50 grams of donor faeces from one thoroughly screened healthy donor). If the patient is not admitted to hospital, FMT will be de-livered as home treatment via regional geriatric team or project manager and project nurse. If the patient has dysphagia diagnosed by dysphagia screening or carries a nasogastric tube, vancomycin and FMT can be delivered by naso-jejunal tube (Bengmark 10 Fr, Nutricia), requiring a referral to the Radiology department for verification of duodenal/jejunal tube placement. If available in the specific department, placement can be controlled via mobile x-ray.
45657894|NCT04425811|Other|kinesiological taping|The kinesiological banding applied to the tibialis anterior muscle was applied to improve walking parameters and compared to sham control.
45657895|NCT01666951|Drug|LCP-Tacro tablets|Tacrolimus
45657896|NCT01666951|Drug|Prograf|Tacrolimus
45810129|NCT04194450|Dietary Supplement|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior to assessment of outcomes.
45810130|NCT04194450|Dietary Supplement|Placebo|Acute ingestion of taste-matched placebo prior to assessment of outcomes.
45810131|NCT04474470|Drug|NT219|Dose escalation of NT219 as a single agent in adult subjects with recurrent and/or metastatic solid tumors
45810132|NCT04474470|Drug|NT219 and ERBITUX® - Dose Escalation|Dose escalation of NT219 in combination with standard dose ERBITUX® in adult subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck and colorectal adenocarcinoma
45810133|NCT04474470|Drug|NT219 and ERBITUX® - Expansion|Expansion cohort of NT219 at its RP2D in combination with standard dose ERBITUX® in adult patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
45810134|NCT03530072|Diagnostic Test|Karius Test|Next Generation Sequencing
45453313|NCT05447533|Other|Standard care|Standard care: Patients are not contacted by the geriatric team. They receive usual treatment at the treating physician's discretion.
45453314|NCT03951415|Drug|PARP inhibitor and Anti-PD-L1|olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks
45657897|NCT05546437|Device|Ion Endoluminal System|Ion Endoluminal dye marking procedure for pulmonary nodule
45810135|NCT04471194|Diagnostic Test|Self-sampling HPV test|Tests for human papillomavirus from cervical cell sample
45810136|NCT04471194|Diagnostic Test|Fecal occult blood test|Tests for human hemoglobin from blood in fecal samples
45657898|NCT05699395|Diagnostic Test|Non interventional|No intervention
45657899|NCT05539339|Other|Individualized intervention based on genomic alterations|Specialized tumor board recommended agents that target the specific recurrence-driving genomic alterations that are determined by serial TISF ctDNA analysis.
45810137|NCT03271034|Dietary Supplement|Weight loss|Participants will lose weight by utilizing a low caloric diet and meeting with a study dietitian and/or behaviorist weekly for ~4 months.
45810138|NCT04467996|Device|Intrauterine balloon tamponade|Intrauterine balloon will be placed in the uterus for postpartum hemorrhage control.
45810139|NCT03261206|Other|5-ASA Withdrawal|Withdrawal of 5-ASA therapy
45810140|NCT05330754|Dietary Supplement|Caffeine intake in mg|"Preanesthetic check-up was done. Average daily caffeine consumption in mg was calculated according to caffeine content in consumed drinks as estimated by Food Data Central."
45810141|NCT04465344|Device|Implantation of trifocal IOL, Isatis TF (device under investigation)|Patients will be implanted with study IOL in both eyes
45810142|NCT04465344|Device|Implantation of monofocal IOL, Isatis (control device)|Patients will be implanted with Control IOL in both eyes
45810143|NCT02374112|Dietary Supplement|Creatine|Creatine supplementation
45810144|NCT02374112|Other|Placebo|Placebo supplementation
45810145|NCT03967158|Device|Xience Sierra stent|Percutaneous coronary intervention with Xience Sierra stent
45810146|NCT04908774|Behavioral|Fasting Mimicking Diet|"The mobile application Salufast provides standardised fasting packages for 5 days of approx. 500 kcal and accompanies the participants during all fasting days."
45810147|NCT03506672|Other|Approach based on the meanings of vocal behaviours|Systematic problem-solving approach involving reflecting, deciding, planning and acting together (family and formal caregivers to reduce vocal behaviours and to increase everyone's well-being.
45810148|NCT03506672|Other|Usual practices|Usual practices of formal caregivers regarding vocal behaviours
45810149|NCT03251378|Drug|Fruquintinib (HMPL-013)|Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.
45810150|NCT03752177|Drug|LY3415244|Administered IV
45453315|NCT05423275|Device|Negative ion therapy|Negative ion generator
45453316|NCT05423275|Device|Light therapy|Fluorescent light box
45453317|NCT03948451|Drug|[14C]AZD5718 Oral Suspension|200 mg dose of [14C]AZD5718 Oral Suspension
45657900|NCT05539261|Device|magnetic resonance image|Imaging data were collected in a strong magnetic field
45657901|NCT05539261|Diagnostic Test|Neuropsychological scale|Multi dimensional neuropsychological test
45657902|NCT05539183|Procedure|Blood withdrawal|Blood withdrawal
45657903|NCT05539105|Procedure|Double tract reconstruction|Double tract reconstruction would be applied after radical proximal gastrectomy.
45810151|NCT02271932|Other|Non-operative|Patients will receive only antibiotics and will not undergo appendectomy unless they do not improve or their appendicitis recurs
45810152|NCT01601496|Device|FUSION Vascular Graft|All subjects who received the FUSION Vascular Graft at the baseline implant procedure.
45810153|NCT03224858|Other|SUMMIT intervention|See description in experimental arm.
45810154|NCT03224858|Other|Enhanced usual care|See description in active comparator arm.
45946522|NCT01087073|Behavioral|Provider Training|Provider patient-centered communication training focuses on cultural competency and communication skills training to aid in shared decision-making and tailoring treatment recommendations to the patient's cultural preferences and readiness. Providers attend 4 1-hour monthly modules and one booster workshop 3 months post-class.
45657904|NCT05539105|Procedure|Gastric conduit reconstruction|Gastric conduit reconstructionn would be applied after radical proximal gastrectomy.
45810155|NCT04839900|Other|Proactive iCCM|CHWs in the proactive iCCM intervention arm will conduct weekly visits of all households in their communities to detect children < 5 years with diarrhea or cough, and people of all ages complaining of fever or history of fever. People with fever or history of fever in the past 48 hours, or any person with symptoms suggestive of malaria (chills, headache, muscle ache, fatigue, etc), will receive an RDT; those with positive results will be defined as confirmed malaria cases, and will receive the first line antimalarial. Any child under 5 years with diarrhea will be treated with oral rehydration solution (ORS) and zinc, and any child meeting diagnostic criteria for pneumonia will receive the first line antibiotic recommended per national iCCM policy. If the CHW does not have the indicated therapy on hand, the patient will be referred for treatment.
45810156|NCT03211832|Other|Dissemination of public health knowledge|Participating local health departments will help develop and choose dissemination strategies they prefer for their staff working in and supporting diabetes and chronic disease prevention and control to receive. Dissemination strategies may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes prevention and control.
45810157|NCT04828668|Dietary Supplement|Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)|Hemp seed oil
46075895|NCT02543359|Behavioral|Training Models of PCIT|Agency participants are trained in one of three training model strategies: Train the Trainer Model (TTT), Learning Collaborative (LC), or Web-Supported Self Study (SS).One third of participating agencies will be randomized to the Train the Trainer training model.One third of participating agencies will be randomized to the Learning Collaborative training model.One third of participating agencies will be randomized to the Web-Supported Self Study.
45810158|NCT04448184|Drug|Tranexamic Acid|"Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.~Tranexamic Acid will start when Platelet count is less than 50 x 109/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions. Subjects unable to swallow oral Tranexamic Acid pills may have the tablets crushed, administered via nasogastric (NG) tube or the medication will be administered intravenously."
45810159|NCT04444128|Diagnostic Test|Cardiac Imaging|Subjects undergo CMR study with contrast agent (gadobutrol 0.1 mmol/kg; mapping, volumes, function, strain and LGE); transthoracic echocardiography and blood testing.
45946523|NCT01087073|Behavioral|Quality Improvement|Participating clinics participate in quality improvement (QI) programs which aim to redesign clinic operations to improve care for diabetes patients. QI initiatives have included instituting group visits, patient medication cards, peer support groups, flow sheets, nurse case management, and patient registries. New initiatives include improving access and tracking of specialists visits, employing community health workers/patient navigators, coordinating care, and implementing other team-based care initiatives. Provider and clinical staff members from all six project clinics attend collaborative quarterly QI sessions with project staff to discuss improvements in QI efforts, share QI methods among clinic teams, and provide brief training sessions.
45946524|NCT01087073|Behavioral|Community Outreach|The project collaborates with many community based organizations and resources to reach out to communities at high risk for diabetes on the South Side of Chicago and facilitate diabetes education, particularly in the area of nutrition and physical activity. We provide monthly health education events, nutrition tours, and frequently participate in community-based health fairs and health promotion events. We also work to promote nutrition through the Food Rx program, which utilizes a prescription to link patients at our clinics with nutrition resources on the South Side of Chicago through a coupon that gives discounts towards healthy purchases at participating stores, and have initiated a 10-week fitness program to promote physical activity among minority patients with diabetes.
45946525|NCT00992303|Other|biologic sample preservation procedure|
45946526|NCT00992303|Other|medical chart review|
45946527|NCT00992303|Other|questionnaire administration|
46075896|NCT02543359|Behavioral|Training Models of PCIT|One-third of administrators are trained in the Learning Collaborative training model. One-third of administrators will be trained to usual treatment (none). One-third of administrators will be trained to usual treatment (none).
45657905|NCT05539105|Procedure|Other reconstructions|Other reconstructions except for double tract and gastric conduit reconstructions would be applied after radical proximal gastrectomy.
45657906|NCT05546281|Other|No intervention|No intervention
45657907|NCT05546203|Other|Ischemic compression|"IC was applied over the detected MTrPs and the participant was asked to describe the pressure and pain she felt . It was started with moderate tolerable pressure (7/10) and then severity was increased. The color of the thumb pulp was observed to control the pressure. The pressure was continued for 90 sec. The patient's pain sensation continued to be questioned and the pressure was controlled to a level at comfortable pain"
45657908|NCT05546203|Device|Low-level laser therapy|LLLT was applied for 90 sec at each MTrPs with a frequency of 2000 Hz (3 J) using a GaAs diode laser instrument (Roland Serie Elettronica Pagani, wavelength 904 nm, the frequency range of 5-7000 Hz and maximum peak power of 27, 50 or 2764 W) . The laser probe was held perpendicular to the MTrPs in skin contact without pressure.
45657909|NCT05546203|Behavioral|Standardized exercise program|The standardized exercise program included stretching and pilates exercises for core stabilization. All exercises were supervised by the same physiotherapist whom certificated by The Australian Physiotherapy and Pilates Institute (APPI). Pilates exercises were selected from APPI's mat-work exercises and performed in accordance with APPI principles. In addition, patients performed stretching exercises for 5 days a week and pilates exercises for 3 days a week at home.
45810160|NCT04427592|Diagnostic Test|ultrasound|trans-vaginal and trans-abdominal ultrasound using different modalities such as grey-scale, Doppler, multi-planer mode
45810161|NCT04427592|Procedure|closure of uterine wall defect|uterine incision above placental bulge by at least 5 mm then complete separation of the placenta starting from areas of least resistance to areas of high resistance leaving a clear defect which will be closed by non locked running sutures from inside the uterus starting from one edge, hitch the bed to the other edge of the defect and controlling placental bed hemorrhage then closing the uterine incision via running sutures in 2 layers with compressing the bed from outwards in the first layer. hemostasis of the abnormal pelvic vasculature if excessive bleeding internal iliac artery may be ligated then insertion of intra-peritoneal drain followed by closing the abdomen.
45810162|NCT04426968|Drug|Hepalatide 2.1mg|2.1 mg/day subcutaneously (s.c.) for 24 week
45810163|NCT04426968|Drug|Hepalatide 4.2mg|4.2mg/day subcutaneously (s.c.) for 24 week
45810164|NCT04426968|Drug|Hepalatide 6.3mg|6.3mg/day subcutaneously (s.c.) for 24 week
45810165|NCT04426968|Drug|placebo 2.1mg|2.1 mg/day subcutaneously (s.c.) for 24 week
45810166|NCT04426968|Drug|placebo 4.2mg|4.2 mg/day subcutaneously (s.c.) for 24 week
45946528|NCT00856947|Dietary Supplement|Cholecalciferol D3|2 tablets of 1200 IU daily from week 24 of gestation to 1 week after delivery
45946529|NCT00856947|Other|Placebo tablet|2 tablets containing no active substance
45946530|NCT00776035|Procedure|PET (positron Emission Tomography)|this is a diagnostic scan that requires the injection of radioactive tracers into an IV placed in the arm.
45946531|NCT00776035|Procedure|Echocardiogram|an ultrasound of the heart
45946532|NCT00776035|Procedure|VO2 peak test|walking on a treadmill during which you will breath in and out through a tube
45657910|NCT05538871|Diagnostic Test|Survey + Physical exam|"Survey:~Demographic data Pain Oswestry disability index International Physical Activity Questionnaire Scoliosis Research Society (SRS-22r) Spinal appearance questionnaire Fear Avoidance and Beliefs Questionnaire Short Orebro musculoskeletal pain questionnaire Work Ability Index~Physical exam:~Repeated movements (MDT) Posture ROM Neuro Updated treatment based classification tests Pathoanatomical classification tests"
45657911|NCT05551507|Drug|IN10018 in combination with PLD|IN10018 in combination with PLD to treat subjects with platinum-resistant recurrent ovarian cancer
45810167|NCT04426968|Drug|placebo 6.3mg|6.3 mg/day subcutaneously (s.c.) for 24 week
45810168|NCT04426968|Drug|Pegylated Interferon|180 ug/week subcutaneously (s.c.) for 28 week
45810169|NCT05278962|Drug|SGLT2i|empagliflozin (10 mg daily) or dapagliflozin (10 mg daily), depending on formulary coverage
45810170|NCT05278962|Other|No SGLT2i|No SGLT2i
45810171|NCT03892824|Device|Vine™ Embolic Protection System|"The system includes the implant and the Vine™ Inserter (inserter) manufactured by Javelin Medical LTD (Israel). The inserter comprises a Motor Unit and a Needle Unit (Needle Unit) available in two sizes. The system is operable when the Needle Unit is loaded with the implant (labeled Loaded Needle Unit) and connected to the Motor Unit. A flag indicating the needle orientation is attached to the needle luer. The implant is automatically deployed from the needle upon activation of the operating button."
45810172|NCT04887948|Biological|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
45810173|NCT04887948|Biological|BNT162b2|RNA-based SARS-CoV-2 vaccine (BNT162b2)
45946533|NCT00776035|Procedure|Body composition Study|a scan of your entire body measuring Body Mass Index, fat percentage etc...
45657912|NCT05538715|Procedure|Split-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a split-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
45657913|NCT05538715|Procedure|Full-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a full-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
45946534|NCT00776035|Radiation|15O water|radioactive tracer used to study blood flow during the PET scan
45946535|NCT00776035|Radiation|11C Acetate|radioactive tracer that helps study heart metabolism
45946536|NCT00776035|Radiation|11C Palmitate|radioactive tracer used to study fatty acid usage in the heart
45657914|NCT05538559|Other|Chemomechanical caries removal by Carie-Care|caries in primary teeth will be removed using Carie-Care™ the chemomechanical agent.
45946537|NCT00776035|Radiation|11C Glucose|radioactive tracer usde to study glucose usage in the heart
46075897|NCT02543359|Behavioral|Parent-Child Interaction Therapy (PCIT) Treatment|Parent-Child Interaction Therapy (PCIT), a parent coaching evidence-based protocol is given to each family from clinicians and supervisors in each training model.
46075898|NCT02843204|Drug|Pembrolizumab|Patients received i.v. pembrolizumab (10 mg/kg) on day 1 of a 21-day cycle, until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
45657915|NCT05538559|Other|Mechanical caries removal by Atraumatic Restorative Technique|caries in primary teeth will be removed using the mechanical caries removal by ART method.
45657916|NCT05538325|Device|Bubble Inclinometer and Digital Pelvic Inclinometer|They are valid and reliable devices to measure the range of motion for the lumbopelvic region.
45657917|NCT05698303|Drug|Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)|CT103A is an BCMA targeted genetically modified autologous T cell immunotherapy product that identifies and eliminates BCMA-expressing malignant and normal cells. CAR specifically recognizes BCMA with a low-immunogenic fully human single chain fragment variable (scFv), promotes CAR-T activation, proliferation, cytokine secretion and target cell killing through the CD3ζ domain, and enhances CAR-T proliferation and persistence through co-stimulatory signaling via 4-1BB.
45657918|NCT05551351|Diagnostic Test|Cardiac CT with photon counting detector|Cardiac CT including the coronary arteries. The cardiac CT is performed in routine care for the included patients.
45657919|NCT02586805|Drug|DX-2930 - 300mg/2wk|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
45657920|NCT02586805|Drug|DX-2930 - 300mg/4wk|300 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
45657921|NCT02586805|Drug|DX-2930 - 150mg/4wk|150 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
45657922|NCT02586805|Drug|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
45810174|NCT04887948|Other|Saline|Normal saline for injection
45810175|NCT05275608|Dietary Supplement|VLCKD diet with replacing meals|Patients will receive an accurate teaching + brochure on VLCKD diet from an expert dietician and freely receive the correct amount of supplements provided from Labotaoire Therascience (4 or 5 meals). The supplements contain (in total) between 600 and 800 kcal, mainly fats, 1,2/1,5 g/body weight of proteins, very low amount of charbohydrates (<30/40g/die), 10-20g fibers, + minerals and vitamins covering the needings of patients. After 6-8 weeks, 1 meal will be replaced with a natural dish rich in proteins.
45453318|NCT00001849|Drug|Pentetreotide|Binds primarily to the somatostatin receptors subtypes (sst) 2 and 5. A high dose (18mCi) was used if the conventional dose (6mCi) was negative and scheduling was available. High doses limited to 3 over the course of the study.
45453319|NCT00001849|Drug|18F-DOPA|18F-DOPA is a radiolabeled amino acid used as a radiotracer in positron emission tomography (PET). Limited to 3 doses over the course of the study.
45810176|NCT05275608|Behavioral|Hypocaloric mediterranean Diet|Patients will receive an accurate teaching + brochure on an hypocaloric Mediterranean style diet (LARN 2014) from an expert dietician. Patients will follow the istructions on grams and foods to eat. The calories will be around minus 400-500 kcal from energy requirement (measured by indirect calorimetry * physical activity score).
45810177|NCT04882800|Device|Lyric extended wear hearing aid device A|Current commercially available extended wear hearing aid
45946538|NCT00740298|Other|sucrose|sweet taste
45946539|NCT00740298|Other|warmth|warmth
45946540|NCT00672880|Behavioral|Self-System Therapy|12 sessions of structured Self-System Therapy
45946541|NCT00672880|Behavioral|Education|12 sessions of spine and muscle education including life style changes and medical treatments.
45946542|NCT00672880|Other|Standard Care|Study participants continue with their usual medical care, no changes.
45946543|NCT00655993|Drug|simvastatin|40 mg po daily
45946544|NCT00567580|Radiation|PBRT|1.8 Gy per fraction once daily, 5 days a week totaling 64.8-70.2 Gy. 3D-CRT or IMRT required.
45946545|NCT00567580|Radiation|PLNRT|1.8 Gy per fraction once daily, 5 days a week, totaling 45 Gy. 3D-CRT or IMRT required.
45946546|NCT00567580|Drug|AA|Antiandrogen (AA) therapy can be either 250 mg flutamide by mouth three times a day or 50 mg bicalutamide by mouth once a day.
46075899|NCT02843204|Biological|NK immunotherapy|Each treatment: about 10 billion cells in all, infusion in 3 times, i.v.
46075900|NCT00885547|Drug|tripterygium wilfordii (TW)|90 mg/d for 6 months
46075901|NCT00953927|Biological|MVA85A/AERAS-485|Attenuated virus MVA vector with insertion. Single dose vaccine, 1 x 10^8 pfu.
46075902|NCT00953927|Biological|Candida Skin Test Antigen|1 test, administered once as a placebo control.
46075903|NCT02606565|Biological|Intervention arm: 4% chlorhexidine|See previous description
46075904|NCT04227990|Drug|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
45453320|NCT00001849|Device|CT scan|CT scan of chest, abdomen, neck and /or pelvis
45453321|NCT00001849|Device|MRI|MRI scan of head/pituitary, chest, abdomen, neck and /or pelvis
45657923|NCT05545423|Other|instrumented assisted soft tissue mobilization|the appropriate Graston technique instrument will be selected to scan, and then treat the affected area for 30 to 60 seconds per treated area. The procedure will be applied to the superficial cervical fascia and invested the layers of deep cervical fascia that surround all the structures in the neck. Strokes will be applied on the sternocleidomastoids and upper fibers of trapezius muscles. The IASTM technique was applied at a 45° angle in a direction parallel to the treated muscle fibers for 20 seconds, following immediately by an additional 20-seconds application at a 45° angle in a perpendicular direction to the muscle fibers, resulting in a total treatment time of approximately 40 seconds.
45810178|NCT04882800|Device|Lyric extended wear hearing aid with fitting modification device B|Extended wear hearing aid with fitting modifications
45453322|NCT00001849|Drug|18-FDG|FDG PET scan of body
45810179|NCT03866460|Diagnostic Test|Distortion product otoacoustic emission measurement (DPOAE)|Hearing will be measured at baseline and 3-9 months after completion of treatment with IA carboplatin chemotherapy.
45810180|NCT04854564|Behavioral|Prehabilitation intervention|The investigators will identify participants' perceived important information to develop a prehabilitation intervention in this study. Prehabilitation intervention consisting of physical activities, nutrition, and stress management.
45810181|NCT04854564|Behavioral|Caregiver intervention|The investigators will provide caregivers with variety of educational resources for patients experiencing ESLD.
45810182|NCT03799289|Behavioral|Behavioral weight loss followed by yoga instruction|12-week standard behavioral weight loss program followed by a 12-week yoga intervention
45810183|NCT03799289|Behavioral|Behavioral weight loss followed by cooking/dietary education instruction|12-week standard behavioral weight loss program followed by a 12-week cooking/dietary education intervention
45810184|NCT04851444|Drug|SI-F019|Single dose is administered IV.
45810185|NCT03810053|Behavioral|Mobile App/Online Module|Short didactic explainer video that will provide information about cancers and benefits of uptake of cancer prevention and early detection measures.
45810186|NCT03829488|Drug|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion is a sterile, clear, non-pyrogenic isotonic solution and when administered intravenously is a source of water, electrolytes and calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water & electrolytes or as an alkalinising agent.
45810187|NCT03829488|Drug|0.9% SODIUM CHLORIDE 9g/L injection BP|Sodium chloride (0.9% saline) infusion is a sterile, non-pyrogenic solution of sodium chloride in Water for Injections. The concentration of sodium chloride is 154mmol/L. Sodium chloride (0.9%) intravenous infusion is indicated for extra-cellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.
45810188|NCT03883607|Drug|Elafibranor 80mg|Once daily oral intake of elafibranor 80 mg during 3 months
45810189|NCT03883607|Drug|Elafibranor 120mg|Once daily oral intake of elafibranor 120 mg during 3 months
45946547|NCT00567580|Drug|LHRH agonist|Luteinizing hormone-releasing hormone (LHRH) agonist can be any analog approved by the FDA (or by Health Canada for Canadian institutions) and may be given in any possible combination such that the total LHRH treatment time is 4-6 months. LHRH analogs are administered with a variety of techniques, including subcutaneous insertion of a solid plug in the abdominal wall, intramuscular injection, and subcutaneous injection.
45946548|NCT00473031|Behavioral|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
45946549|NCT00473031|Behavioral|Caloric restriction; normal protein|Weight loss with recommended level of protein (18%)intake
46075905|NCT04227990|Drug|Pegfilgrastim|Pegfilgrastim is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
46075906|NCT04227990|Drug|Docetaxel, doxorubicin, and cyclophosphamide (TAC)|Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
46075907|NCT04581746|Other|questionnaire|bi-monthly questionnaire and then one visit with questionnaire and covid-19 test
46075908|NCT02606409|Drug|Dexmedetomidine|Dexmedetomidine sedation at a starting dose of 0.2-7.0 µg/kg/hour.
46075909|NCT02606409|Drug|Propofol|Propofol sedation at a starting dose of 10-70 µg/kg/hour.
46075910|NCT00611767|Drug|Thiopental|A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
46075911|NCT00611767|Drug|Placebo|A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
46075912|NCT02857439|Other|Standard diagnostic item list|All consecutive patients are assessed by both examiners, according to a standardized physical examination item list.
45453323|NCT03948217|Other|Circadian Lighting regimen|Circadian lighting regimen with one major fluctuation, high light intensity and color
45453324|NCT03950479|Diagnostic Test|3D and 4D Transperineal Ultrasound|The evaluation of Pelvic Floor Muscles with 3D and 4D transperineal ultrasound using A Voluson E6 system (GE Healthcare, Zipf, Austria) with RAB 8-4-MHz volume transducer for all acquisitions. Measurements will be performed in axial planes. The levator hiatus area (LHA), the antero-posterior (AP) diameter and the left-right (LR) transverse diameter will be analyzed at rest, during pelvic floor contraction and on maximal Valsalva maneuver.
45453325|NCT02530255|Dietary Supplement|cycloastragenol|Oral telomerase activator - cycloastragenol.
45946550|NCT00473031|Behavioral|Counseling|Participants will be asked to attend eight 50-minute diet counseling sessions, with the opportunity to attend a total of approximately 28 diet counseling sessions, during the year.
45657924|NCT05545423|Other|traditional therapy|The exercise program will be in the form of stretching exercises for the sternocleidomastoids (SCM), the scalenes, and upper fibers of trapezius; strengthening isometric exercises for the neck flexors, extensors, lateral flexors, and neck rotators; and postural correction and scapular stabilization exercises
45657925|NCT05545345|Procedure|tympanostomy tube placement|An incision will be made in the the tympanic membrane, through which a ventilation tube will be inserted.
45946551|NCT00472745|Behavioral|Weight Loss|Weight loss participants will consume a reduced calorie diet based on their individual caloric needs to lose 1.5-2 lbs/week, and will attend regular counseling sessions (for about 45 minutes each) with a dietitian for 6 months
45453326|NCT02530255|Dietary Supplement|placebo (for cycloastragenol)|placebo comparator, placebo for cycloastragenol.
45657926|NCT05545345|Procedure|adenoidectomy|The adenoid is resected transorally under a 70° endoscope with microdebrider or coblator until torus tubarius and choanae are completely revealed.
45657927|NCT05545267|Procedure|Angioplasties|Transluminal angioplastie
45657928|NCT05550883|Other|Aerobic exercise|The patients in this group participated in aerobic exercise training for 45 minutes, three sessions per week for 6 weeks. They underwent the proper warm up to minimize the risk of musculoskeletal injury .The training session started by a proper warm up for 5 min in the form of mild stretching for the involved muscle group to prepare the exercised muscles and improve blood supply for skeletal muscle to prevent fatigue or injury. Patients in this study group performed aerobic exercise (in the form of treadmill training) All sessions were supervised to ensure correct technique and monitor the appropriate amount of exercise. The training session ended by a proper cooling down for 5 min to prevent fatigue or injury.
45657929|NCT05550883|Drug|Fibromyalgia Agents|tricyclic antidepressants (low evening doses), and mostly when needed, low doses of: analgesics, muscle relaxants, hypnotics, and tranquilizers.
45657930|NCT05545189|Diagnostic Test|colonoscopy,polypectomy|polyp removal during colonoscopy
45657931|NCT05537779|Device|CT examination|Administration of contrast medium using the power injector
45657932|NCT05698225|Other|Streptococcus pneumoniae serotype 6B|A controlled concentration of streptococcus pneumoniae serotype 6B is placed in both nares of participants
45946552|NCT00472745|Behavioral|Weight Maintenance|Diet for weight maintenance for 6 months
45946553|NCT00268385|Other|Laboratory Biomarker Analysis|Correlative studies
45453327|NCT03947905|Procedure|Virtual visit|Type of visit
45453328|NCT01100515|Other|normobaric oxygen therapy|oxygen therapy was delivered via a full face mask at high flow to achieve 100% of inspired oxygen fraction
45657933|NCT04736017|Device|TSB Axo|The TSB Axo is a wearable biosignal recording device combined with an auditory stimulation. The device consists of pre-gelled biosignal electrodes, headphones integrated in a headband, and a biosignal processing module.
45657934|NCT05545033|Device|Virtual reality|5 to 15 minutes of virtual reality exposure
45657935|NCT05550649|Procedure|embolization|Prophylactic arterial embolization is performed for the artery in the diseased blood supply area. The embolization material: gelatin sponge particles are recommended, and micro-steel ring can be used as an auxiliary if necessary; after operation, symptomatic and supportive treatment such as acid suppression, hemostasis, blood transfusion, and fluid replacement are given according to the condition.
45657936|NCT05544955|Dietary Supplement|isolate whey protein prior to and immediately after resistance training|This arm involved protein ingestion immediately prior to and immediately after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
45946554|NCT00268385|Other|Pharmacological Study|Correlative studies
45946555|NCT00268385|Drug|Temozolomide|Given orally
45946556|NCT00268385|Drug|Vorinostat|Given orally
45946557|NCT00340054|Other|questionnaire administration|
45946558|NCT00340054|Procedure|study of high risk factors|
45946559|NCT00340093|Behavioral|Managing Diabetes|
45946560|NCT00125151|Drug|C1 inhibitor concentrate (C1-esteraseremmer-N)|
45946561|NCT00087815|Drug|dexamethasone|
45946562|NCT00087815|Drug|hyperbaric oxygen|
45946563|NCT00087815|Procedure|cognitive assessment|
45946564|NCT00087815|Procedure|magnetic resonance imaging|
45946565|NCT00087815|Procedure|positron emission tomography|
45946566|NCT00087815|Procedure|quality-of-life assessment|
45946567|NCT00340327|Drug|IMA-638|
45946568|NCT00126828|Procedure|External beam radiotherapy|
45946569|NCT00087854|Drug|Amonafide L-malate (drug)|
45946570|NCT00340483|Behavioral|Smoking cessation|
45657937|NCT05544955|Dietary Supplement|isolate whey protein 3 hours prior to and 3 hours after resistance training|This arm involved protein ingestion 3 hours prior to and 3 hours after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
45946571|NCT04715620|Drug|Niraparib|Niraparib 300mg/day (body weight ≥77Kg and baseline platelet count ≥150,000/µL) or 200mg/day (body weight <77Kg or baseline platelet count <150,000/µL)
45946572|NCT00125229|Drug|Mannitol|
45946573|NCT00125229|Drug|Hypertonic Saline|
45453329|NCT01100515|Other|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy was delivered in a hyperbaric chamber, pressurized at 2 absolute atmosphere (1 hour plateau) and the patient breathed high oxygen concentration via a full face mask followed by 4 hours of normobaric oxygen therapy
45657938|NCT05537545|Procedure|Soft tissue grafting|A pouch is made in the buccal mucosa using microsurgical instruments. Thereupon, a free gingival graft is harvested from the palatal mucosa in the premolar area and de-epithelialized to arrive at a CTG of about 1 mm thickness. Height and length are tailored to the dimensions of the site. Then, the CTG is brought into the pouch and fixed with two single sutures (Seralon 6/0, Serag Wiessner, Naila, Germany) onto the buccal mucosa.
45657939|NCT05544877|Behavioral|Integrated 5-day Gratitude Exercise and Behavioral Activation Program|The 5-day intervention integrates a brief behavioral activation (BA) and a gratefulness exercise (GE) program. BA is composed of a lab-based idea generation and planning phase as well as a home-based performing phase with regard to pleasurable activities. GE is a idea generation task about aspects in life participants are grateful for about. It is performed once lab-based and daily with a home-based diary.
45657940|NCT05550415|Drug|Simvastatin 40mg|The administration of Simvastatin 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
45657941|NCT05550415|Drug|Placebo|The administration of Placebo capsule 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
45657942|NCT02586727|Drug|aflibercept|This study will consist of 2 simultaneous treatment arms of aflibercept: A six week dosing regimen arm and a treat and extend (TAE) dosing regimen arm, total duration 54 weeks. In the TAE arm the patients will receive an intravitreal aflibercept injection first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward.
45810190|NCT04848090|Diagnostic Test|Neonate WGS Testing|"Neonates will undergo whole genome sequencing, and analysis with a targeted panel of genes likely to cause genetic disorders in the first year of life. If no diagnosis is identified, sequenced data will be analyzed using a whole exome filter. Performed in a CLIA-certified lab. Pathogenic, likely pathogenic, and VUS in genes related to the phenotype will be returned to the care team and family.~Parents will be enrolled for the purpose of trio analysis with the child to assist in determining the pathogenicity of variants in genomic sequencing. Pathogenic and likely-pathogenic findings will be reported to the parents in the setting of genetic counseling.~Sibling will be enrolled and have samples collected for use in the genetic analysis only if deemed essential. Results will be reported to the parents in the setting of genetic counseling."
45946574|NCT04715776|Dietary Supplement|Brown seaweed|Uptake of 1650 mg brown seaweed product twice daily
45946575|NCT04715776|Dietary Supplement|placebo|Uptake of 1650 mg placebo twice daily
45453330|NCT01100593|Procedure|length of IV catheter|Subjects will be randomized to one of two IV catheter lengths
45453331|NCT01102075|Device|Electroacupuncture|We used Electrical stimulator(STN-111,Stratek)with a frequency of 24 Hz and intensity of 0.27-1.3mA(tolerable strength), asymmetric interactive pulse with continuous stimulation by the pulse generator. The participants were given treatment twice a week for 30 minutes for 5 weeks(10 sessions) by practitioner.(n=13)
45453332|NCT01102075|Device|Sham electroacupuncture procedure|We used same electroacupuncture device, number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment. Specific details are as described in the arm description.(n=13)
45657943|NCT05537311|Behavioral|Social Engagement|30-45 minutes of social engagement provided to patients in ICU. Social engagement strategies including meaningful conversation, cognitive stimulation, and emotional support
45657944|NCT05699161|Genetic|Adipose-derived stromal vascular fraction cells|Published minimal clinically important differences (MCID) for PDQ-39; MDS-UPDRS; and levo-dopa equivalent dose and changes in the levels of blood proteins (L-1beta, IL-2, IL-6, IL-10, and TNF-alpha) in 10 patients after 12 months of treatment with SVF cells.
45946576|NCT00126906|Drug|Monthly sulfadoxine/pyrimethamine|
45946577|NCT00126906|Drug|2-dose sulfadoxine/pyrimethamine|
45946578|NCT00088049|Drug|Olanzapine|
45946579|NCT00088049|Drug|Aripiprazole|
45946580|NCT00126945|Biological|Meningococcal Vaccine|
45946581|NCT04715815|Other|No intervention (only interview)|Interview
45946582|NCT00088088|Drug|Paclitaxel|
45946583|NCT00088088|Drug|Carboplatin|
45946584|NCT00088088|Drug|STA 4783|
45946585|NCT00125307|Drug|tacrolimus|
45657945|NCT05537155|Procedure|Buccal acupuncture in addition to routine care|"Acupuncture will be performed at a depth of 10 mm, with the needle retaining for 20 min, in addition to routine care. Bilateral acupoints include Tou, Shangjing, Jing, Bei, and Sanjiao. Unilateral acupoints is related to surgical sites and include Kuan in hip joint replacement surgery and Xi in knee joint replacement surgery. Patients with agitation will be treated first until agitation is controlled before acupuncture is performed."
45810191|NCT04846296|Other|Questionnaire|The QLPSD, developed in Spain, was the first questionnaire designed to evaluate HRQoL in adolescents with spinal deformities. It has shown good validity and reliability. English, French and Persian versions of the QLPSD have been developed and validated. Good reliability and ease of use are mentioned in these versions. The QLPSD was designed to examine adolescents with spinal deformities and measure the effect of orthotic and surgical treatments on QoL.
45946586|NCT00341224|Behavioral|Group-mentoring intervention|Group mentoring used to teach social skills to middle school students
45946587|NCT00332566|Biological|DTPw-HBV/Hib Kft vaccine GSK323527A|Intramuscular injection, 1 dose
45946588|NCT00332566|Biological|Tritanrix™-HepB/Hiberix™|Intramuscular injection, 1 dose
45946589|NCT00127023|Biological|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
45946590|NCT00088283|Drug|pegaptanib sodium|
45946591|NCT00332683|Procedure|Maintaining low (15mmHg) ETT cuff pressure|Manipulation of the ETT cuff pressure to hold a lower pressure of 15 mmHg
45657946|NCT05537155|Other|Routine care|Routing care includes the following: (1) remove the precipitating cause and treat the primary disease; and (2) supportive care, including reorientation and cognitive stimulation, sleep enhancement, early mobility and exercise, vision and hearing optimization, family engagement and empowerment, and early oral intake and nutrition.
45810192|NCT03805308|Procedure|Intra-arterial Therapy|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels.
45810193|NCT04826796|Behavioral|WhatsApp peer support|Trained peer supporters will provide breastfeeding and emotional support for participants in the WhatsApp group.
45810194|NCT03926039|Behavioral|sharing decision-making program|Sharing decision-making talks and decision-making assistance tools used in the process
45946592|NCT00332683|Procedure|Maintaining a normal pressure in the ETT cuff|No manipulation to maintain a low pressure of 15 mm Hg in the ETT cuff
45946593|NCT00332761|Drug|Caduet|
45946594|NCT00332800|Drug|Nutritional Supplementation|
45946595|NCT00088400|Drug|TransMID|
45946596|NCT00332878|Behavioral|Stepping Stones|a comprehensive sexual and reproductive health promotion programme lasting about 50 hours comprising 13 content sessions of about 3 hours duration and 4 meetings of peer groups
45946597|NCT00332878|Behavioral|stepping Stones short|3 hour intervention on HIV and safer sex
45657947|NCT05550259|Procedure|protocolized postextubation support|The intervention corresponds to a protocolized use of HFNO or NIV after extubation in accordance with the risk of extubation failure: a) 24H HFNO in patient at low risk of extubation failure b) 48H NIV+/-HFNO in patients at high risk of extubation failure
45657948|NCT05544799|Other|No intervention|No intervension
45657949|NCT05537077|Other|Prolotherapy|DPT was applied as a total of 3 sessions at 0, 3 and 6 weeks. In each session, intra-articular 5 ml and periarticular 10 ml dextrose injections were administered to the knee. Periarticular injection was applied to 10 points as 1 ml in each region. The regions were determined as medial and lateral coronary ligaments, proximal and distal medial and lateral collateral ligaments, pes anserinus region, proximal and distal patellar tendon, quadriceps tendon attachment area.
45946598|NCT00332917|Drug|Pardoprunox|12-42 mg
45946599|NCT00332995|Drug|dapivirine (TMC120) vaginal ring|
45946600|NCT00333034|Drug|Etanercept|
45946601|NCT00333073|Device|Bulkamid|initial injection with option for second (if required)
45946602|NCT00088478|Drug|Intramuscular Olanzapine Depot|
45946603|NCT00088478|Drug|Placebo|
45946604|NCT00125346|Drug|Tobramycin Inhalation Powder|
45946605|NCT00333112|Drug|solifenacin succinate|Oral
45946606|NCT00333112|Drug|tamsulosin|oral
45946607|NCT00333112|Drug|placebo|oral
45946608|NCT00341614|Behavioral|3-month Exercise Training and Diet Education|
45946609|NCT00333151|Drug|liraglutide|
45946610|NCT00333151|Drug|rosiglitazone|
45946611|NCT00333151|Drug|metformin|
45946612|NCT00088517|Drug|[11C]NNC-112|
45657950|NCT05537077|Other|Home based exercise program|Knee ROM, isometric and isotonic quadriceps strengthening exercises were given as 2 sets of 10 repetitions per day for 12 weeks.
45657951|NCT05537077|Other|Hotpack therapy|Hotpack treatment was applied for 20 minutes at 0, 3 and 6 weeks.
45453333|NCT03950089|Device|Optical Coherence Tomography Angiography (OCT-A)|Optical Coherence Tomography Angiography (OCT-A) images were acquired using an Spectral Domain Optical Coherence Tomography device (Cirrus High Definition OCT Model 5000 with Angioplex; Carl Zeiss Meditec, Dublin, California, USA). With an acquisition speed of 68,000 A-Scan per second, the OCT Microangiography Complex algorithm provided OCT-A information for three-dimensional (3D) flow reconstruction. At each visit, each subject underwent a 3 x 3 millimeter (mm) macular 3D cube acquisition in both eyes. FastTrac continuous eye tracking technology was employed to control for eye movements and minimize motion artefacts.
45453334|NCT01102153|Device|Coolgard|invasive cooling via femoral ICY-catheter
45810195|NCT04393662|Diagnostic Test|Measurement of Muscle strength using a dynamometer|"Muscle strength will be measured in the elbow bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). Supination tests will be performed with the forearm in neutral position, 60° pronation and 60° supination. The elbow will be in 90° flexion, and the shoulder in 45° flexion. Constant pressure is applied to lever of device for 3 to 5 seconds. Maximum torque will be recorded automatically. For each position, three repetitions of 3s (to 5s) contractions will be performed with a break of 15 (or 30s) between the repetitions. There will be an additional break of 2 minutes between measurements of the supination strength in the different positions. This parameter will be analysed regarding asymmetry between both limbs.~Isometric endurance of forearm supination will be measured in neutral forearm. Flexion tests will be carried in the same setting as for supination. Flexion tests will be performed with the elbow in 90, 45 and 0° of flexion."
45453335|NCT01102153|Device|ArcticSun|non-invasive surface cooling by saline-cooled thermo-vest
45657952|NCT05544643|Device|Medtronic Extended Mio 30 Infusion Set|Safety and Efficacy of Medtronic Extended Mio 30 Infusion Set
45453336|NCT01104571|Biological|trastuzumab|Trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery
45657953|NCT05550025|Drug|camrelizumab& apatinib|"TACE（transcatheter arterial chemoembolization） combined with Apatinib and Camrelizumab Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.~The cumulative maximum drug use period is up to 1 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
45810196|NCT04393662|Diagnostic Test|Range of motion clinical measurement (shoulder and elbow)|The range of motion parameters (degree) of both shoulders and elbows will be documented. The circumference of the arm will be measured on the line between the medial acromion and the cubital fossa at 1/3 from the cubital fossa
45810197|NCT04393662|Diagnostic Test|Electromyography (EMG)|Electromyographic (EMG) data will be collected using a wireless EMG system (myon AG, Schwarzenberg, Switzerland). Surface electrodes will be placed bilaterally on biceps and triceps following the guidelines of the SENIAM project (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles)
45810198|NCT04000373|Device|Ekso GT™ exoskeleton|The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.
45657954|NCT05544409|Device|MAKv1|1 hour sessions with the MAKv1 exoskeleton, thrice per week during 1 month
45657955|NCT05700253|Device|Cooled Radiofrequency Ablation|Image-guided genicular nerve ablation will be performed with the Coolief System (COOLIEF* CRFA; Avanos Medical).
45657956|NCT05700253|Device|Hyaluronic Acid Injection|Synvisc-One ([Hylan G-F 20]; Sanofi) will be administered as a single intra-articular dose (6 mL).
45810199|NCT04815564|Device|Invisalign|Invisalign clear aligner system
45810200|NCT04049123|Drug|LY900014|Administered SC
45810201|NCT04049123|Drug|Insulin Lispro|Administered SC
45657957|NCT05536765|Procedure|Surgical exposure of impacted tooth|"The therapeutic approach of surgical exposure of impacted teeth is performed by preparing a flap and removing the cortical bone around the crown of the teeth.~This procedure provides optimal conditions for the orthodontist. In fact, surgical exposure allows the orthodontist to bond the impacted tooth in the correct position depending on the intended direction to apply the correct traction forces for alignment."
45453337|NCT01104571|Drug|lapatinib ditosylate|"Part 1: Lapatinib 1500mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery.~Part 2: Lapatinib 1000mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery."
45453338|NCT01104571|Other|laboratory biomarker analysis|
45946613|NCT00125385|Biological|GC1008|0.3 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
45453339|NCT01104571|Procedure|adjuvant therapy|
46075913|NCT05266326|Other|Western medicine conventional treatment +Bloodletting puncture|All acupoints are positioned according to the WHO standard acupuncture point locations in the Western Pacific Region. Operation: The patient is placed in a reasonable position, the acupuncture site is exposed, and the operator uses pushing, rubbing, squeezing and butterfly on or around the acupuncture site to collect blood at the acupuncture site before pricking, and then disinfects the acupuncture site with 75% ethanol. If more bleeding occurs, press with sterile dry cotton balls to stop the bleeding. The treatment was performed once daily for 7 days.
45453340|NCT01104571|Procedure|neoadjuvant therapy|
45453341|NCT01104571|Procedure|therapeutic conventional surgery|therapeutic conventional surgery
45453342|NCT01100671|Other|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship of vascular inflammation assessed by 18FDG-PET and MDCT at the cross section setting
45676359|NCT03725410|Device|Venus Fiore Study Treatment|Study treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (50 - 70% for up to 15 minutes), externally to the labia (10 - 35% for up to 10 minutes) and externally to the mons pubis (10 - 35% for up to 15 minutes).
45810202|NCT03785262|Device|Uroshield|The Uroshield device sends out low-frequency ultrasound waves which run along the surface of the catheter.
45810203|NCT03785262|Device|Sham Uroshield|The sham Uroshield device is identical to the active machine, but it does not send out low-frequency ultrasound waves along the surface of the catheter.
45946614|NCT00125385|Biological|GC1008|1.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
45810204|NCT04382196|Other|Online survey|An online survey will be administered
45453343|NCT03947593|Other|No Intervention|No intervention is being administered.
45453344|NCT01102309|Device|Robot therapy (NeReBot)|Rehabilitation therapy of the affected arm with NeRebot for five weeks, five times weekly for 40 minutes, plus 80 minutes of conventional therapy
45453345|NCT01102309|Other|Conventional therapy|Conventional rehabilitation therapy of the affected arm for five weeks, five times weekly for 120 minutes
45453346|NCT03947047|Diagnostic Test|NA-NOSE|Breath and blood samples for distinguishing biomarkers.
45453347|NCT03950323|Radiation|MRI with Facial nerve tractography|MRI with Facial nerve tractography in addition to T1 imaging, T1 gadolinium imaging and T2 imaging.
45453348|NCT01104649|Drug|riluzole|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
45453349|NCT01104649|Drug|Placebo comparator|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
45453350|NCT01104727|Procedure|4-Ports Cholecystectomy (4PC)|a 12mmHg pneumoperitoeum is created either by a 10mm umbelical Hasson's port or by a Verress needle followed by a 10 mm umbelical port insertion; further one 10mm and two 5mm ports are placed according to the preferred technique. A straight or angulated laparoscope may be used. Laparoscopic graspers, monopolar hook, bipolar forceps, scissors and 10mm clips-applier are used. A plastic bag system might be used for gall bladder extraction if necessary. In both 10 and 12mm accesses, fascia is sutured with resorbable sutures. Skin is secured by either metallic agraffes or interrupted sutures.
45676360|NCT03725410|Device|Venus Fiore Sham Treatment|Sham treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (1% for up to 15 minutes), externally to the labia (1% for up to 10 minutes) and externally to the mons pubis (1% for up to 15 minutes).
45676361|NCT03709472|Behavioral|Computer Assisted CIFFTA|This is a hybrid intervention that includes individual work with the adolescent (e.g., Motivational Interviewing, diary card identification of triggers), computer assisted psychoeducational work, and intensive family therapy interventions.
45676362|NCT03709472|Behavioral|Behavioral: Traditional face-to-face treatment-no technology|Community agencies provide mostly individual counseling but may add some family involvement in treatment planning.
45676363|NCT03698552|Biological|ADCT-602|Starting dose of ADCT-602: 30 μg/kg given by vein.
45810205|NCT04051463|Drug|Netarsudil Ophthalmic Solution|Netarsudil eye drops instilled once daily
45810206|NCT04051463|Drug|Placebo|Placebo eye drops instilled once daily
45810207|NCT04826328|Drug|FX301|FX301 is an extended-release formulation of funapide being developed as a single injection peripheral nerve block for the management of acute postsurgical pain
45810208|NCT04826328|Drug|Normal Saline|Single peripheral nerve injection
45946615|NCT00125385|Biological|GC1008|2.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
45946616|NCT00125385|Biological|GC1008|4.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
45946617|NCT00125385|Biological|GC1008|8.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
45946618|NCT00333190|Device|CD+8 T cell depletion|CD8 depleted product Given through central line after treatment with fludarabine and busulfex intravenously for 4 days
45946619|NCT00088556|Drug|TLK286|Every 3 Weeks with a starting dose of TLK286 @ 400 mg/m²
46075914|NCT05266326|Other|Western medicine conventional treatment|The patients in both groups were given conventional comprehensive treatment such as improving cerebral circulation, neuroprotection, antiplatelet aggregation, lipid regulation and symptomatic management after admission. Patients with hypertension, hyperglycaemia, hyperlipidaemia and coronary atherosclerotic heart disease were given individualised symptomatic treatment and advised to stop smoking, drinking alcohol and other adverse lifestyles as far as possible.
45657958|NCT05536687|Device|FeetMe|"Healthy volunteers will wear the insoles at 2 visits in hospitals (D0 and D8) and 2 visits at home (D1 and D7). The visits at the hospital will be composed of 3 tests of 6 min. in various conditions in a hospital environment :~In degraded conditions, i.e. a 10m corridor, evaluated simultaneously by the FeetMe® system and an evaluator~In degraded condition, a 10m corridor, evaluated simultaneously by the FeetMe® system and an odometer and evaluator~Under the conditions recommended for the 6-minute test (ref), i.e. a 30m corridor, evaluated simultaneously by the FeetMe® system and the evaluator A rest time of 15 min minimum will be respected between each test. The visits at home will be composed of a 6-minute test at home or outdoors (quiet place, flat, hard surface, few or no passages, ideally no obstacles, covered if weather conditions are not suitable) with a 10-meter track that you can define simply with equipment provided by the promoter."
45657959|NCT05544331|Behavioral|Exercise group (written form)|The exercise program will be structUred with core stabilization exercises. Patients will be given the written form of exercises and will be applied as home exercises. Exercise progression will be provided by position changes.
45810209|NCT04054661|Diagnostic Test|SD Biosensor STANDARD G6PD Test|The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.
45810210|NCT04054661|Diagnostic Test|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
45810211|NCT04054661|Diagnostic Test|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
45810212|NCT04128527|Device|Placement of laryngeal mask|All participants are experienced in placement of laryngeal masks and placement will be performed according to standard clinical practice.
45810213|NCT04132973|Behavioral|Compassion for Skin Conditions|Online guided self-help intervention derived from Compassion Focused Therapy (Gilbert, 2010).
45810214|NCT04184297|Drug|Tiotropium and Olodaterol (Tio+Olo)|drug
45810215|NCT04184297|Drug|Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)|drug
45810216|NCT04713839|Other|no intervention|We didn't have an intervention program, we used two questionnaires to evaluate participants.
45810217|NCT04031885|Drug|Abemaciclib|Administered orally
45946620|NCT00088556|Drug|carboplatin|AUC 6 mg/mL/min Once every 3 weeks
45810218|NCT04031885|Drug|Fulvestrant|Administered IM
45810219|NCT04031885|Drug|Standard Chemotherapy|Standard chemotherapy of physician's choice administered according to product label.
45810220|NCT04029545|Device|PN40082|1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
45810221|NCT04029311|Device|Nuance Pro|Study compares Nuance Pro plus Automatic Positive Airway Pressure (autoPAP) vs TAP PAP plus autoPAP
45810222|NCT04029311|Device|autoPAP|autoPAP
45810223|NCT04029311|Device|TAP PAP|TAP PAP
45810224|NCT01638000|Drug|Mirabegron|oral tablet
45810225|NCT01638000|Drug|Solifenacin succinate|oral tablet
45810226|NCT04023695|Drug|Corticosteroid with lidocaine with epinephrine|Trigger finger injection
45810227|NCT04023695|Drug|Corticosteroid with normal saline|Trigger finger injection
45810228|NCT04013789|Device|DACP FreshTech contact lenses|Nelfilcon A soft contact lenses with a modified lens design
45810229|NCT04013789|Device|DACP contact lenses|Nelfilcon A soft contact lenses
45810230|NCT04211909|Drug|SOF/VEL|400/100 mg FDC tablet orally once daily.
45810231|NCT04211909|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet orally once daily.
45946621|NCT00088556|Drug|paclitaxel|200 mg/m² Once every 3 weeks
45946622|NCT00127140|Drug|vorinostat|
45946623|NCT00333268|Drug|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
45946624|NCT00333268|Drug|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
45946625|NCT00333307|Drug|recombinant human relaxin|
45946626|NCT00125424|Drug|AQUAVAN® (fospropofol disodium) Injection|
45946627|NCT00125424|Drug|Midazolam HCl|
45946628|NCT00088673|Drug|3APS|
45946629|NCT00333346|Drug|Administration of tramadol intravenously|
45946630|NCT00333385|Drug|ceftazidime|
46075915|NCT02838446|Procedure|Cognitive Therapy|"Graded Motor Imagery has three stages:~Lateralisation (2 or 3 weeks) Motor Imagery (2 or 3 weeks) Mirror Therapy (2 or 3 weeks)"
46075916|NCT04967508|Drug|Stelara® (Ustekinumab)|Subjects randomised into Stelara® group will receive Stelara® (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.
46075917|NCT04967508|Drug|SB17 (Proposed Ustekinumab Biosimilar)|"Subjects randomised into SB17 group will receive SB17 (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.~Starting at Week 28, subjects transited from Stelara® to SB17 will receive SB17 via subcutaneous injection."
45946631|NCT00127257|Behavioral|Biofeedback|
45946632|NCT00127257|Drug|Diazepam|
45946633|NCT00127257|Behavioral|Pelvic floor retraining|
45810232|NCT03559205|Other|MSK-Tracker|"The intervention is not a treatment, but involves patients and clinicians engaging with the MSK-Tracker software which will facilitate a new care planning approach with the following distinct components:~Pre-clinic preparation.~Clinic dashboard.~Summary action plan.~Personal goal setting.~Follow-up and monitoring."
45946634|NCT00333424|Biological|pHIS-HIV-AE (DNA vaccine) prime and rFPV-HIV-AE (recombinant fowlpox virus boost) vaccine|6mg pHIS-HIV-AE at weeks 0, 4 and 8; 3 x 10e8 pfu/mL rFPV-HIV-AE at week 12
45946635|NCT00333463|Behavioral|Intervention|The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.
45946636|NCT00333541|Behavioral|Using internet/E-mail for follow-up|follow-up via email link to survey
45946637|NCT00127296|Device|FlexPen®|
45946638|NCT00127296|Device|vial and syringe|
45946639|NCT00127374|Behavioral|Dietary and physical activity modifications|
45946640|NCT00088790|Drug|AZD5438|
45946641|NCT00333658|Behavioral|Goal setting and work feedback group|Goal setting and feedback using WBI
45810233|NCT04223843|Drug|Tiotropium + olodaterol|Oral Inhalation
46075918|NCT00803361|Drug|Duloxetine|60 to 120 mg, capsules, oral, once a day for 15 weeks
45810234|NCT04223843|Drug|Placebo|Oral Inhalation
45946642|NCT00420550|Behavioral|Relaxation Response using Guided Imagery|
45946643|NCT00125463|Drug|Candesartan cilexetil|
46075919|NCT00803361|Drug|Placebo|placebo capsules, oral, once a day for 15 weeks
46075920|NCT02299596|Other|Physical activity|The intervention will take place both pre- and postoperatively. During the hospital stay both groups will be treated in the same manner.
45810235|NCT01637922|Drug|BI 201335|BI 201335 for 9 days
45810236|NCT01637922|Drug|BI 201335|BI 201335 for 9 days
45810237|NCT05722951|Drug|Levetiracetam|levetiracetam will be given to 30 patients and monitored for 6 months
45946644|NCT00333697|Other|Comprehensive Duplex Ultrasound (diagnostic study)|A sigle duplex ultrasound examination of the deep venous system of the leg(s) suspected of deep vein thrombosis. Deep veins of the leg are examined for evidence of thrombosis from the inguinal ligament to the level of the malleolus.
45946645|NCT00088868|Drug|alvespimycin hydrochloride|
45946646|NCT00333736|Device|Biojector|All patients received biojector to use with BID enfuvirtide doses
45810238|NCT05722951|Drug|Metformin|metformin + levetiracetam will be given to 30 patients and monitored for 6 months will be given to 30 patients and monitored for 6 months
45946647|NCT00333853|Device|OneTouch(r) UltraSmart(r)|
45946648|NCT00088946|Dietary Supplement|Polyphenon E|4-200mg capsules PO daily for 12 months
45946649|NCT00088946|Drug|erlotinib hydrochloride|100 mg PO daily for 12 months
45946650|NCT00088946|Other|Erlotinib placebo|identical to Erlotinib in look and appearance of dosing.
45946651|NCT00088946|Other|Polyphenon E|identical to Polyphenon E in look and appearance of dosing.
45946652|NCT00421018|Drug|Single corticosteroid inhalers and Singulair|Treatment steps according to preset algorithm
45946653|NCT00421057|Behavioral|Combined Strength Training and Functional Endurance Exercise|Participants will be taught to stretch a Theraband as far as your arms or legs can stretch and the proper posture for walking for exercise. The Estimated Timed-Get-Up and Go test (ETGUPGo) and a 6-minute walk test will be performed to check your level of fatigue and physical ability.
45946654|NCT00421057|Behavioral|Questionnaire|Questionnaires taking approximately 30 minutes total to complete.
45946655|NCT00421096|Drug|Gemcitabine|125 mg/m² at day 1, 8, 15, 21 and 28, 2 hours before radiotherapy.
45946656|NCT00421096|Procedure|Radiotherapy|"45Gy (5 x 1,8Gy/week) on pelvic area +/- boost (10 to 15Gy)~+/- 45Gy (5 x 1,8Gy/week)on lumbo-aortic area"
45946657|NCT00421096|Drug|Cisplatin|40 mg/m² at day 1, 8, 15, 21 and J28 before Gemcitabine and with a hyperhydration
45946658|NCT00421135|Drug|ZIO-201|ZIO-201 as a single dose given once every 21 days. This is a dose escalation arm.
45946659|NCT00089063|Biological|tyrosinase peptide|Given SC
45946660|NCT00089063|Biological|gp100 antigen|Given SC
45946661|NCT00089063|Biological|MART-1 antigen|Given SC
45946662|NCT00089063|Biological|incomplete Freund's adjuvant|Given SC
45946663|NCT00089063|Drug|Montanide ISA 51 VG|Given SC
45946664|NCT00089063|Biological|sargramostim|Given SC
45946665|NCT00089063|Other|laboratory biomarker analysis|Correlative studies
45946666|NCT04716439|Procedure|Spine Surgery|spine decompression and fixation
45946667|NCT00333892|Procedure|leukapheresis|pack of cells as per protocol
45946668|NCT00333931|Drug|Phenytoin|
46075921|NCT05333822|Dietary Supplement|Bashan|a vegetable plant based compound drink add after three meals for 14 days
46075922|NCT05333822|Other|water|water as placebo
46075923|NCT02837198|Drug|FYU-981|
46075924|NCT02837198|Drug|Topiroxostat|
46075925|NCT00611533|Drug|atomoxetine|Subjects will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
46075926|NCT00611533|Drug|placebo|Subjects will receive placebo equivalent for 6 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
46075927|NCT04038307|Drug|paracetamol|1gm
46075928|NCT04038307|Drug|Saline Solution|100ml
45657960|NCT05544331|Behavioral|Exercise group (video based)|The exercise program will be structUred with core stabilization exercises. Patients will be given the exercise videos, which provide visual and auditory feedback, and will be applied as home exercises. Exercise progression will be provided by position changes.
45946669|NCT00333931|Behavioral|Cognitive Behavioral Therapy|
45946670|NCT00089180|Drug|liposomal T4N5 lotion|Given topically
45946671|NCT00089180|Other|placebo|Given topically
45657961|NCT05535673|Drug|ThisCART19A|In this study, allogeneic anti-CD19 CAR-T cell (ThisCART19A) injection is used to treat patients with refractory or relapsed CD19 positive B cell Lymphoma.
45657962|NCT05544253|Procedure|mitomycin C-based hyperthermic intraperitoneal chemotherapy|The patients with srHCC or PM of HCC were randomly allocated to either the HIPEC group or the control group. All of them have received open liver resection and perfusion tubes had been set in the operation. For patients with PM of HCC served operation, we are subject to reach CC score at 0-1 to creating sufficient conditions for HIPEC. Finally, place the HIPEC tubes. Implementation of HIPEC was administered 3times on the 1st, 3rd, 5th days within one week after operation. We used intraperitoneal hyperthermic perfusion device (BR-TRG-IITM, Bao Rui medical corporation, Guangdong, China) to achieve HIPEC. The abdominal temperature was maintained at 43°C (109°F) by circulating heated saline. The perfusion volume was 3000ml of normal saline, and the chemotherapeutic agent of mitomycin C was 10mg for a 1-hour perfusion period.
45657963|NCT05535517|Other|CeraVe SA Smoothing Cleanser|The CeraVe Salicylic Acid (SA) Smoothing Cleanser is formulated with salicylic acid to help exfoliate the skin and remove dirt and dead skin cells on the skin without compromising or striping moisture from the skin's natural barrier, leaving the skin feeling clean, smooth and hydrated. This salicylic acid cleanser is also formulated to include hyaluronic acid to hydrate and retain moisture and 3 essential ceramides to moisturise and help support the skin's barrier.
45810239|NCT05127733|Behavioral|Online Cognitive Behavioural Therapy|Interactive program utilizing cognitive behavioural therapy principles that guides users through its components and provides feedback, which facilitates behavior change (i.e., reduction in alcohol or substance use).
45810240|NCT05127733|Behavioral|Individual Peer Support|Weekly meetings with a trained peer support worker who guides participants through the BFO platform, reviews the platform's content with them, and supports them in the creation of an action strategy based on the platform's suggestions.
45657964|NCT05535517|Other|CeraVe SA Smoothing Cream|The CeraVe Salicylic Acid (SA) Smoothing Cream contains salicylic acid as well as hydrating hyaluronic acid and three essential ceramides.
45657965|NCT05535517|Other|Propaira 20% Lactic Acid Exfoliating Lotion|For smoothing rough skin.
45657966|NCT05535517|Other|Propaira 30% Urea Exfoliating Emollient|30% Urea, 7% Glycerin to smoothen rough skin.
45657967|NCT05535517|Other|KPAI|The proposed score, Keratosis Pilaris Area Index (KPAI), is a 5-point IGA score (0-4) of five main body areas: face, upper limbs, lower limbs, trunk, and buttocks, for a maximum of 20 in two main categories, activity (erythema, skin roughness and papulation) and damage (pigmentation and scarring). The final score will be a maximum of 100.
45657968|NCT05535517|Other|KP-IGA|A standard 5-point IGA score (0-4) defined specifically for KP
45657969|NCT05698069|Diagnostic Test|Pain Modulation Index|A 18 item questionnaire assessing patients' pain characteristics for the detection of disordered pain modulation processes.
45657970|NCT05698069|Other|Pain Detect|A questionnaire that was validated for the assessment of neuropathic pain
45657971|NCT05698069|Other|Central sensitization inventory|A questionnaire developed for the detection of central sensitization.
45657972|NCT05535439|Procedure|EBUS-TBNA using 22 G EBUS-FNB Device OR 19 G EBUS-FNA needle|Both arm will be interventional where mediastinal lymph nodes will be sampled by two typs of needle
45657973|NCT05535361|Device|Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome|The surgeon verifies the intestinal diameter and selects the appropriate device diameter size. The device is introduced into the lumen of the intestine and advanced about 5-10cm. The surgeon uses 4-0 sutures placed in the seromuscular layer to secure the XL1 Coil within the intestine. The surgeon places metal clips on proximal and distal sutures and in the mesentery adjacent to the XL1 Coil ends to mark the location for radiologic evaluation. The surgeon releases the XL1 Coil and closes the enterotomy.
45657974|NCT05536609|Procedure|Epineural suture|2 or three sutures
45810241|NCT05127733|Behavioral|Group Peer Support|Meetings with a group of peers led by a trained peer support worker/volunteer which will offer the participants an opportunity to discuss their experiences in a supportive and open environment.
45946672|NCT00089180|Other|laboratory biomarker analysis|Correlative studies
45946673|NCT00334048|Drug|Ropinirole (Requip)|1 mg extended release formulation given once per day to a maximum of 4 per day
45946674|NCT00334087|Behavioral|feeding habits|
45946675|NCT00127452|Dietary Supplement|margarine spread|Daily use of margarine spread (approximately 20 grams) during 40 months
45946676|NCT00334126|Drug|paliperidone ER tablets, quetiapine tablets, placebo - all over encapsulated|
45946677|NCT00089219|Biological|IFA|vaccine adjuvant
45946678|NCT00089219|Biological|6MHP|melanoma helper peptides
45946679|NCT00089219|Biological|GM-CSF|vaccine adjuvant
45946680|NCT00334165|Procedure|Auricular acupuncture (procedure)|
45946681|NCT00334243|Drug|Microflare protocol for IVF|
45946682|NCT00334243|Drug|Antagonist protocol for IVF|
45946683|NCT00334243|Drug|Demi-halt protocol for IVF|
45946684|NCT00334321|Radiation|IMRT|
45946685|NCT00334321|Radiation|Intracavitary vaginal brachytherapy|
46075929|NCT04985604|Drug|Tovorafenib|Tovorafenib tablet for oral use.
46075930|NCT04985604|Drug|Pimasertib|Pimasertib capsule for oral use.
45946686|NCT00334321|Drug|Paclitaxel|
45946687|NCT00334321|Drug|Carboplatin|
45946688|NCT00334360|Drug|dexmedetomidine|Dexmedetomidine (delivered by a computer-controlled IV infusion to target a plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
45946689|NCT00334360|Drug|buspirone|Buspirone, 60 mg orally, will be given during controlled hypothermia.
45946690|NCT00334360|Drug|Bus and Dex|the combination of 60 mg buspirone and dexmedetomidine (target plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
45946691|NCT00334360|Drug|Control|No drugs given during controlled hypothermia
45946692|NCT00334399|Drug|Miglitol|
45946693|NCT00400244|Procedure|Wheelchair skills traing program|
46075931|NCT05703243|Diagnostic Test|Comprehensive liquid molecular panel test|Lab test
46075932|NCT05703243|Other|EORTC QLQ-30|Quality of life questionnaire
46075933|NCT02420990|Behavioral|Medication Integration Protocol (MIP)|
45946694|NCT00125502|Biological|CMV gB vaccine|CMV gB is combined with a novel adjuvant, MF59, a proprietary oil-in-water emulsion, administered at 0, 1, and 6 months.
45946695|NCT00125502|Drug|MF59 adjuvant|Oil-in-water emulsion
45657975|NCT05536609|Procedure|Non-operative treatment|The injured finger is protected in a plaster cast
45657976|NCT05536531|Device|Neuromuscular electrical stimulation (NMES)|Electrical stimulator (Electrostimulator TRAINFES 6 ADVANCED, Biomedical devices Spa, Santiago, Chile.) to administer NMES
46075934|NCT02420990|Behavioral|Changing Academic Support in the Home for Adolescents with ADHD (CASH-AA)|
46075935|NCT02543125|Device|NIPPV|"For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
46075936|NCT02543125|Device|NHFOV|"For infants in the NHFOV-group who failNHFOV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
46075937|NCT00884533|Drug|Rosi XR|Rosi XR
45453351|NCT01104727|Procedure|Single-Port Cholecystectomy (SPC)|"a 2.5cm long skin incision around the umbilicus is performed. The subcutaneous tissue is dissected, the muscular fascia exposed and incised along the middle line (linea alba) respecting the muscular tissue. Peritoneum is identified and incised. The Single-Port device is inserted and anchored.~In order to retract the gallbladder a transcutaneous suture is placed in the right hypocondrium with a straight needle and a monofilament thread which are passed through the fundus and knotted outside the skin. The following steps reproduce the traditional laparoscopic cholecystectomy. Each centre will be left free to use dedicated instruments and which or traditional laparoscopic ones."
45676364|NCT03675477|Drug|SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a Janus kinase inhibitor).
46075938|NCT00884533|Other|Placebo|Placebo
46075939|NCT00884533|Drug|Moxifloxacin|400mg single dose
46075940|NCT02842814|Other|Drug free|Both Glucocorticoid(GC) and hydroxychloroquine(HCQ) treatment are stopped in stable SLE patients.
46075941|NCT02842814|Drug|HCQ|Glucocorticoid(GC) treatment is stopped in stable SLE patients. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d
45676365|NCT03675477|Drug|Placebo|Placebo Oral Tablet
45676366|NCT03674736|Dietary Supplement|Dietary Intakes|Four levels of methionine or lysine intakes will be provided by the reference protein drinks, 3 levels of methionine from rice and wheat bread and 3 levels of lysine from chickpeas and lentils
45946696|NCT00125502|Drug|Placebo|Normal saline solution
45946697|NCT00334438|Biological|rituximab|250mg/m2, IV, Days 1 and 8
45946698|NCT00334438|Drug|bortezomib|dose escalation 1.0, 1.3, or 1.5, IVP; Days 4, 8, 11, 15
45946699|NCT00334438|Radiation|yttrium Y 90 ibritumomab tiuxetan|Dose dependant upon platelet count (0.4mCi/kg) not to exceed 32mCi; Day 8
45946700|NCT00334438|Radiation|Indium 111 ibritumomab tiuxetan|5cmCi; IV day 1
45946701|NCT00342316|Procedure|Reduced Intensity Conditioning Stem Cell Transplantation|"One of the following conditioning regimens:~Busulphan (orally or IV), fludarabine~Fludarabine, carmustine, melfalan~Cyclophosphamide, fludarabine"
45946702|NCT00423839|Biological|MVA85A (Tuberculosis vaccine)|
45946703|NCT00334477|Drug|tadalafil|
45946704|NCT00127491|Procedure|Placement of an esophageal balloon measurements|In both groups an esophageal balloon will be placed and baseline measurements recorded. In the EP group the mechanical ventilation settings will be determined based on these measurements. In the control group measurements will be recorded but ventilation will be based in the existing standard of care wich is the ARDSnet low tidal volume ventilation study. measurements will be repeated at 24, 48 and 72 hours or as needed.
45946705|NCT00127491|Other|Low tidal volume ventilation|Low tidal volume ventilation strategy (ARDSnet)
45946706|NCT00127491|Other|Transpulmonary pressure-directed ventilation (EPVent)|Transpulmonary pressure-directed ventilation using measurements from the esophageal balloon.
46075942|NCT02842814|Drug|GC+HCQ|Glucocorticoid(GC) is kept no more than 7.5mg/d. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d.
46075943|NCT02543047|Device|Angioshield|Angioshield is applied to vein graft to provide Mechanical Support for Vein Grafts Used in CABG Surgery
46075944|NCT02837354|Other|No intervention|
45946707|NCT04715269|Drug|Alprazolam|Alprazolam 0.5 mg will be given when the patient with acute coronary syndrome would present to the emergency
45946708|NCT04715269|Other|Placebo|Empty capsule
45946709|NCT00423956|Procedure|Repairing Induced tooth root resorption by ultrasound|Repairing Induced tooth root resorption by ultrasound
45946710|NCT04715464|Other|review of surveillance cultures within the past year|"ASC results are reported as positive or negative based on the culture source. Antimicrobial susceptibility testing is performed but not reported; however, physicians may obtain susceptibility information for MDR GNB only if clinically indicated through the microbiology department.~Nasal swab for MRSA~Respiratory specimens~i. Sputum for MRSA, VRE, and Multi Drug Resistant gram-negative Bacteria (MDR GNB) (if not intubated but with productive cough) ii. Endotracheal aspirate for MRSA, VRE, and MDR GNB (if intubated) c. Drainage from any wounds for MRSA, VRE, and MDR GNB d. Rectal/ perianal swab for VRE, and MDR GNB e. Urine for MRSA, VRE, and MDR GNB (from patients catheterized prior to admission only)"
45946711|NCT00125541|Drug|C1 inhibitor concentrate (C1-esteraseremmer-N)|every 5-7 days
46075945|NCT00882193|Drug|Betaine|Betaine 20 gm/day in 2 divided doses for 48 weeks
45657977|NCT05536063|Procedure|bilateral erector spinae plane block in pediatric cardiac surgeries|The ESPB will be performed after induction of anesthesia, endotracheal tube insertion and before the start of operation, with the child in a right lateral decubitus position under aseptic precautions. A high frequency linear ultrasound transducer will be placed over the T4 transverse process lateral to the spinous process. After identifying the muscles above the hyperechoic transverse process image, a 5-cm 22 gauge needle will be inserted in-plane in a cephalo-caudad direction. The endpoint is defined as the needle pointing to the tip of transverse process piercing the erector spinae muscle. The local anesthetic will be deposited at this position, After careful negative aspiration, local anesthetic, according to study groups , The process will be repeated on thecontralateral side
45810242|NCT04838652|Drug|Pembrolizumab plus Chemotherapy (ICE or DHAP)|Pembrolizumab (200mg) alone or in combination with ICE (or DHAP in case of PET positive findings after P-ICE) will be admistered. 6 additional courses of pembrolizumab will be administered after the completion P-ICE or P-DHAP
45946712|NCT04716205|Other|Mulligan Bent Leg Raise Technique|Participant will be in supine lying on a high couch with the resting on the shoulder. A distraction (longitudinal traction force along the long axis of femur) will be investigator in walk stand position lateral to the leg, which to be stretch. Hip and Knee of the side to be stretch will bent at 90˚- 90 ˚. Participant's flexed knee will be placed over the shoulder, the popliteal fossa of the knee applied at the lower end of femur and the participant will ask to push the shoulder with his or her leg followed by voluntary relaxation.The traction will maintained throughout the technique.
45657978|NCT05535985|Device|acupuncture|treatment of pain or disease by inserting the tips of needles at specific points on the skin
45946713|NCT04716205|Other|Static Stretching|It will be given in supine position by performing passive SLR and end range will hold in 30sec.
45946714|NCT00089258|Biological|beta-glucan|
45946715|NCT00089258|Biological|monoclonal antibody 3F8|
45946716|NCT00089258|Biological|sargramostim|
45810243|NCT05722795|Drug|Imatinib 400 MG Oral Tablet|One tablet daily 10 days before surgery.
45810244|NCT03778554|Drug|Metoprolol Succinate|Eligible patients randomized to receive long-term therapy with oral beta-blockade
45810245|NCT03778554|Drug|Bisoprolol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
45810246|NCT03778554|Drug|Carvedilol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
45946717|NCT00089258|Drug|isotretinoin|
45946718|NCT00127569|Drug|Rituximab|
45946719|NCT00334555|Other|different methods of partner notification|comparing patient referral, partner delivered medications and field intervention to treat sex partners
45946720|NCT00334555|Other|partner delivered meds|patient given meds to give to her partner
45946721|NCT00334555|Other|field intervention|health worker finds partners
45946722|NCT00334594|Drug|Cisplatin|Cisplatin 75 mg/m2 i.v. over approximately 2 hours on day 1 every 21 days
45946723|NCT00334594|Drug|Pemetrexed|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 every 21 days
45453352|NCT01327729|Drug|pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg|YPEG-IFN α-2a 180mcg dose form: subcutaneous dosage : 180 mcg frequency every week or ten days or 2 weeks according to the group
45946724|NCT00334594|Procedure|Therapeutic conventional surgery|Extrapleural pneumonectomy
45946725|NCT00334594|Radiation|Radiotherapy|CTV1 will receive 45 or 46 Gy. CTV2 will be treated up to a total dose of 55,9 to 56,2 Gy.
45946726|NCT00334672|Biological|anti-thymocyte globulin|
45946727|NCT00334672|Drug|busulfan|
45946728|NCT00334672|Drug|cyclophosphamide|
45946729|NCT00334672|Drug|cyclosporine|
45946730|NCT00334672|Drug|dexamethasone|
45946731|NCT00334672|Drug|etoposide|
45946732|NCT00334672|Drug|methotrexate|
45946733|NCT00334672|Drug|mycophenolate mofetil|
45946734|NCT00334672|Drug|therapeutic hydrocortisone|
46075946|NCT00882193|Drug|Peginterferon alpha 2a|Peginterferon alpha 2a 180mcg/0.5ml by subcutaneous injection weekly for 48 weeks
46075947|NCT00882193|Drug|Ribavirin|Ribavirin 200mg - weight based, 1000 - 1200 mg/day for body weight < or > 75mg in 2 divided doses
46075948|NCT02838602|Radiation|Carbon ions therapy|External radiotherapy by accelerated carbon nucleus in a specialized hadrontherapy center
46075949|NCT02838602|Radiation|Advanced external radiotherapy by Xrays or protons|Radiotherapy by any appropriate advance procedure of photontherapy (IMRT, Volumetric Modulated Arc Therapy (VMAT), Tomo, etc.) or when possible by protontherapy or even a combination of both types of radiotherapy
45946735|NCT00334672|Other|laboratory biomarker analysis|
45946736|NCT00334672|Procedure|allogeneic hematopoietic stem cell transplantation|
45946737|NCT00334672|Procedure|biopsy|
45946738|NCT00089453|Drug|Dexamethasone|Dexamthasone 40mg every day, days -5 to -1 only will be given.
45657979|NCT05535985|Device|placebo acupuncture|placebo acupuncture
45657980|NCT05535829|Other|Laboratory analysis of samples|Laboratory analysis of samples
45657981|NCT03932773|Device|Active rTMS|"A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be used to deliver 1 hertz (Hz) stimulation to right dorsolateral prefrontal cortex (rDLPFC) at 110% of a participant's rTMS motor threshold. The device passes electric current through a coil generating an alternating magnetic field. When positioned over the skull, the changing magnetic field causes electromagnetic inducted current flow in brain regions subjacent to the coil. Magnetic pulses (1.5-2.0 Tesla) lasting 100-300 microseconds at 1 Hz will be used.~Motor threshold will be defined by the TMS intensity to right motor region required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time."
45657982|NCT03932773|Device|Sham rTMS|"A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be paired with sham coil. The sham coil will induce electrical current flow in the tissue above the skull but will not induce current flow in brain tissue. The sham coil will be placed over the right prefrontal scalp region to target current flow in rDLPFC. Magnetic pulses lasting for 100-300 microseconds at 1 Hz will be used.~For consistency across the rTMS conditions, motor threshold in the sham condition also will be determined by positioning the active rTMS coil over the right motor region and identifying the stimulation intensity required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time."
45810247|NCT03778554|Drug|Nebivolol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
45810248|NCT05119699|Device|MagPro X100/R30 stimulator equipped with the B70 fluid-cooled coil|Subjects will receive 5 consecutive days (always Monday to Friday) of TBS rTMS, administered 8 times daily at 1 hour intervals. Patients will undergo cTBS of the R DLPFC at 110-120% RMT using bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for a total of 600 pulses over 40 seconds, followed by iTBS of the L DLPFC at 110-120% resting motor threshold (RMT) using bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz with a duty cycle of 2 s on, 8 s off for a total of 600 pulses over 3 min 9 s. Participants will be titrated to 110-120% RMT within the first four treatments to aid with tolerability. If patients tolerate the stimulation well, the target will be 120%. Assessments focused on depressive symptoms will be administered at baseline, after final treatment and four weeks post final treatment.
45946739|NCT00089453|Drug|Cyclophosphamide|A dose of 60mg/kg (using calculated body weight - see appendix A.) will be infused on day-3, and -2. Cyclophosphamide is administered by intravenous infusion over 2-4 hrs in 250 mLs of Normal Saline (0.9%) or D5W Standard MESNA (60% or 36mg/kg) protection to prevent hemorrhagic cystitis will be given on day -3, -2 and -1.
45946740|NCT00089453|Drug|Melphalan|Melphalan will be given as a single dose of 140mg/m2 on day -1. Subject weighing more than 60kg will be dosed according to their calculated body weight.Melphalan will be diluted in normal saline(0.9%NaCl) to a concentration of 1.5mg/ml. A dose of 140mg/m2 will be administered intravenously over a period <or= 20 minutes on day -1.
45946741|NCT00089453|Drug|Fludarabine|dose of 1.0mg/m2 on days -8,-5,-2.
45946742|NCT00089453|Drug|Bortezomide|A dose of 1.0mg/m2 will be given as a bolus dose on day-8, day-5 and day-2 as per standard practice
45946743|NCT00089453|Procedure|Leukapheresis|On day 0 to collect donor cells for NK cell isolation
45946744|NCT00089453|Drug|Interleukin|2 at 3x10x6 IU on days +1 to 13.
46075950|NCT00882271|Other|Acupuncture|Ten Acupuncture treatments within six weeks
45946745|NCT00089453|Procedure|Infusion #1|Infusion of donor NK Cells #1 on day 0
45946746|NCT00089453|Procedure|Leukapheresis #2|on day +2
45453353|NCT01104805|Behavioral|Therapeutic Education System (TES)|Participants will received modified treatment-as-usual plus the computerized psychosocial intervention (Therapeutic Education System), including contingency management. Participants will be asked to use the self-directed TES intervention twice weekly and will be asked to complete 2 modules during each session (for a total of 4 modules per week) during the 12-week intervention. Participants will receive incentives contingent primarily upon abstinence from drugs of abuse and, secondarily, upon completion of TES modules.
45946747|NCT00089453|Procedure|Infusion #2|on day +2
45946748|NCT00089453|Procedure|Auto Graft|on day +14
46075951|NCT02778360|Device|Neurofeedback NFT|"The ADHD@Home Device is composed of a software for NF Training deployed on a Windows tablet, and connected to an EEG headset and an amplifier.~The training is personalized according to patient's characteristics."
46075952|NCT02778360|Drug|Methylphenidate MPH|Drug prescribed with a first titration period until an optimal dose.
45946749|NCT00125580|Behavioral|Infant sleep instruction|
45946750|NCT00334711|Drug|Sulfonylurea|
45946751|NCT00334750|Other|There is no intervention in this study.|This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
45946752|NCT00089492|Drug|Optimized Background ARVs|As prescribed
45946753|NCT00089492|Drug|enfuvirtide [Fuzeon]|180mg sc once daily for 48 weeks
45946754|NCT00089492|Drug|enfuvirtide [Fuzeon]|90mg sc bid for 48 weeks
45946755|NCT00127686|Drug|Dextromethorphan|
45946756|NCT00127686|Drug|Buckwheat Honey|
46075953|NCT00953147|Drug|Ciclesonide HFA 80 mcg|Ciclesonide HFA Nasal Aerosol 80 mcg once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
45946757|NCT00334789|Drug|Belinostat|Given IV
46075954|NCT00953147|Drug|Ciclesonide HFA 160 mcg|Ciclesonide HFA Nasal Aerosol 160 mcg once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
45946758|NCT00334789|Drug|Isotretinoin|Given orally
45946759|NCT00334789|Other|Pharmacological Study|Correlative studies
45657983|NCT03932773|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidenced based, trauma-focused treatment for Posttraumatic Stress Disorder (PTSD). CPT is a recommended form of treatment in the Veterans Administration - Department of Defense Clinical Practice Guideline for PTSD. The CPT manual delineates the agenda for each of 12 sessions (60 minutes per session): 1) Introduction to CPT and Patient Education regarding PTSD, 2) Meaning of the Trauma, 3) Identification of Thoughts and Feelings related to the Trauma, 4) Remembering the Trauma, 5) Identification of Stuck points, 6) Challenging Questions about the Trauma, 7) Dysfunctional/Maladaptive Thinking patterns related to the Trauma, 8) Safety Issues, 9) Trust Issues, 10) Power and Control Issues, 11) Self-Esteem Issues, and 12) Intimacy Issues.
45810249|NCT04822740|Device|Control Glucose Monitoring System|"With a sensor, transmitter and display device (receiver and/or compatible smart device).~The CGMS sends glucose readings to a compatible smart device every 5 minutes. In this study the CGMS for all patients with use of the results of the device in real time by the health care team for the Experimental arm and without the use of the results by the health care team for Active Comparator (Conventional strategy ."
45657984|NCT05544097|Other|Recording of the bowel sounds|Recording of the bowel sounds before and after enteral feeding three times a week with an electronical stethoscope
45657985|NCT05592535|Procedure|Coronary revascularization|Coronary revascularization performed by PCI in a vessel investigated with FFR or indication for surgery
45657986|NCT05699083|Other|Body Image/Self-Esteem Questionnaires|Pre-operation and post-operation questionnaires to assess factors including but not limited to body image, quality of life, and self-esteem.
45676367|NCT03653364|Drug|Baloxavir Marboxil|"Participants will receive single oral dose of baloxavir marboxil on Day 1 based on body weight and age.~Participants will be recruited in parallel to the following three cohorts:~Cohort I: ≥ 3 months to < 12 months old (minimum 8 participants): 2 mg/kg~Cohort II: ≥ 4 weeks to < 3 months old (minimum 4 patients): 1 mg/kg~Cohort III: birth to < 4 weeks old (minimum 4 patients): 1 mg/kg"
45810250|NCT05722717|Genetic|Saliva collection at home|Children (with help of their parents) collect their saliva with a saliva collection kit which they send to our research center.
45810251|NCT04810494|Drug|2% Lidocaine HCl topical solution|0.5mL of 2% Lidocaine will be administered intranasally in each nostril with a mucosal atomization device.
45946760|NCT04715425|Procedure|Thoracoscopic pulmonary vein isolation without additional lesion + left atrial appendage exclusion/amputation|Bilateral pulmonary vein isolation using radiofrequency energy
45810252|NCT04810494|Drug|0.9% Sodium chloride|0.5mL of 0.9% Sodium chloride (normal saline) will be administered intranasally in each nostril with a mucosal atomization device.
45810253|NCT05722639|Device|X-Trodes acquisition system|No intervention. The participants will sit passively while electrophysiology signals are captured from two devices in order to evaluate the signal quality.
45946761|NCT04715425|Procedure|Catheter pulmonary vein isolation without additional lesions|Bilateral pulmonary vein isolation using radiofrequency energy
45810254|NCT05270928|Drug|IBI346|IBI346 Antibody and IBI346 CAR-T cell injection
45946762|NCT00334867|Drug|cyclophosphamide|Given IV
45657987|NCT05696197|Behavioral|Targeted touchscreen training|Participants will practice the Swipe Slide Pattern (SSP) task independently at home in both ST and DT condition, offered in a random order. During this task, participants form different pre-defined patterns by moving their finger over a touchscreen, resembling a touchscreen unlock trace. The DT condition includes the SSP-task while counting either red or green lights illuminated on the screen. They will receive 10 training sessions of the SSP-task over a period of two weeks. Each week will consist of 5 consecutive days of training for approximately 10 minutes per session. Participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14 seconds. Instruction and answers are also included. Feedback will be provided by means of knowledge of performance. On each training day, participants will receive a reminder on the training tablet.
45946763|NCT00334867|Drug|dexrazoxane hydrochloride|Given IV
45676368|NCT03647358|Device|PET/CT Scan|Up to four whole-body PET scans (approximately 24, 48, and 120 hours post 124I oral dose) will be performed on one of the GE Discovery 710 or 690 PET scanners.
45946764|NCT00334867|Drug|doxorubicin hydrochloride|Given IV
45946765|NCT00334867|Drug|etoposide|Given IV
45810255|NCT04332588|Drug|[18F]FMISO PET/MRI imaging|[18F]FMISO PET/MRI imaging
45946766|NCT00334867|Drug|ifosfamide|Given IV
45946767|NCT00334867|Drug|topotecan hydrochloride|Given IV
45946768|NCT00334867|Drug|vincristine sulfate|Given IV
45946769|NCT00334867|Procedure|conventional surgery|Patients undergo surgery in week 18
45946770|NCT00334867|Procedure|radiation therapy|Patients undergo radiation therapy in week 19
45946771|NCT00127725|Device|Pulsed electromagnetic field stimulation|
45946772|NCT00089531|Drug|VRC-HIVDNA016-00-VP|
45453354|NCT01104805|Behavioral|Treatment-as-Usual (TAU)|Participants in this condition will receive TAU, consisting of standard treatment offered at each collaborating CTP and will reflect the model of treatment typically provided to most individuals in outpatient, community-based substance abuse treatment settings in the U.S. These sessions will consist of a combination of group and individual counseling.
45810256|NCT02832271|Drug|SUNPHENON EGCg|SUNPHENON EGCg Oral, 400mg, twice per day
45810257|NCT02832271|Drug|Placebo|Placebo
45810258|NCT05109169|Combination Product|FINGER 2.0 multidomain lifestyle-based intervention|"Multimodal lifestyle-based precision prevention intervention, including:~Optimized FINGER multidomain lifestyle intervention (diet, physical activity, cognitive training and cardiovascular/metabolic risk monitoring and social interaction)~Metformin (Glucophage® XR)"
45946773|NCT04715152|Drug|ACB with levobupivacaine and dexamethasone|Patients will receive ultrasound-guided (USG) ACB with levobupivacaine and dexamethasone 30 minutes before spinal anesthesia and sham intra-articular normal saline
45946774|NCT04715152|Drug|IA analgesia with levobupivacaine and dexamethasone|Patients will receive intra-articular levobupivacaine and dexamethasone at the end of surgery and sham USG-ACB with normal saline
45946775|NCT00342706|Procedure|Community based intervention|
45946776|NCT00334906|Drug|memantine HCl|
45453355|NCT01342952|Drug|Ambrisentan|open label, flexible dosing from 2.5 to 10 mg (not to exceed 10 mg/kg) per day
45810259|NCT05109169|Other|Self-guided multidomain lifestyle intervention|Participants build their own healthy lifestyle program based on standard healthy lifestyle advice on diet, physical activity, cognitive training and cardiovascular/metabolic risk
45810260|NCT04291014|Device|SunRay Light Boxes|SunRay light boxes will be used to administer the light therapy.
45810261|NCT05722405|Drug|Ixazomib plus low-dose lenalidomide|Whether Ixazomib combined with low-dose lenalidomide improves the outcome and prognosis of patients with high-risk multiple myeloma as a maintenance treatment option compared to ixazolomib alone
45810262|NCT05722405|Drug|Ixazomib|Ixazomib alone
45946777|NCT00089570|Drug|terlipressin|
45946778|NCT00089570|Drug|Placebo|
45946779|NCT00125697|Procedure|3T MRI Scanning|pre-radiation therapy, week 4 radiation therapy, 2 months post radiation therapy and every 4 months for the first year
45946780|NCT00334984|Drug|glutamine|
45810263|NCT04259658|Combination Product|Calcium electroporation|Patients with cutaneous metastases will be treated with calcium electroporation.
45946781|NCT00334984|Procedure|chemoprotection|
45946782|NCT00334984|Procedure|management of therapy complications|
45946783|NCT00334984|Procedure|therapeutic nutritional supplementation|
45946784|NCT00342862|Drug|Amevive exposure|Observational
45946785|NCT00335023|Other|Red blood cell transfusion|At least one unit of red blood cells will be administered. The target Hb value after transfusion is at least 8.7 g/dL.
45946786|NCT00089687|Drug|GBR 12909|
45946787|NCT00342940|Biological|influenza surface antigen inactivated vaccine|
45946788|NCT00127764|Drug|dexamethasone (50mg 1dd6, 3 consecutive days/month)|
45946789|NCT00343057|Other|Patients' questionnaire|
45946790|NCT00089726|Biological|CG8123|
45946791|NCT00089726|Drug|Cyclophosphamide|
45946792|NCT00335101|Drug|Iodixanol, Ioversol, Iopromide|
45946793|NCT04726995|Other|CHOP and BFM regiments|used CHOP and BFM regiments
45946794|NCT00343096|Drug|Lorazepam|All doses 0.1mg/kg once, repeat after 10 minutes x1
45946795|NCT00335179|Drug|Aldara (imiquimod 5% cream)|Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream
45946796|NCT00335179|Drug|Vehicle cream|Vehicle cream in 250 mg
45946797|NCT00089765|Drug|Ranibizumab|
45946798|NCT00343135|Drug|amoxicillin/clavulanate potassium 1gm|amoxicillin/clavulanate potassium 1gm
45946799|NCT04726644|Procedure|hernia repair|different methods for hernia repair
45946800|NCT00343174|Drug|Ancrod|
45946801|NCT00343213|Procedure|colposcopy|
45946802|NCT00343369|Drug|asparaginase|
45946803|NCT00343369|Drug|cyclophosphamide|
45946804|NCT00343369|Drug|cytarabine|
45946805|NCT00343369|Drug|daunorubicin hydrochloride|
45946806|NCT00343369|Drug|dexamethasone|
45946807|NCT00343369|Drug|doxorubicin hydrochloride|
45946808|NCT00343369|Drug|mercaptopurine|
45946809|NCT00343369|Drug|methotrexate|
45946810|NCT00343369|Drug|pegaspargase|
45946811|NCT00343369|Drug|prednisolone|
45946812|NCT00343369|Drug|teniposide|
45657988|NCT05697913|Other|Continued treatment adapted to the response|Instead of receiving a pre-specified number of treatment cycles, regardless of the result obtained, in the MRDI-driven treatment group patients continue receiving treatment until reaching a complete remission with negative MRD and Image, changing the therapeutic line if it is not obtained with the line current therapy. In this group of the patients the treatment was stopped only when this degree of deep response was achieved.
45810264|NCT04780074|Dietary Supplement|Single dose intervention with Standard product (SP)|2 capsules - 200 mg total CoQ10
45810265|NCT04780074|Dietary Supplement|Single dose intervention with Investigational product (IP1)|2 softgels - 200 mg total CoQ10
45810266|NCT04780074|Dietary Supplement|Single dose intervention with Investigational product (IP2)|2 softgels - 200 mg total CoQ10
45810267|NCT04780074|Dietary Supplement|Single dose intervention with Investigational product (IP3)|2 softgels - 200 mg total CoQ10
45946813|NCT00343369|Drug|thioguanine|
45946814|NCT00343369|Drug|vincristine sulfate|
45946815|NCT00343369|Radiation|radiation therapy|
45810268|NCT04780074|Dietary Supplement|Single dose intervention with Investigational product (IP4)|2 capsules - 200 mg total CoQ10
45946816|NCT00343408|Drug|cediranib maleate|
45946817|NCT00343408|Drug|cisplatin|
45946818|NCT00343408|Drug|fluorouracil|
45946819|NCT00343408|Drug|gemcitabine hydrochloride|
45810269|NCT02826733|Device|Electroencephalogram (EEG)|
45810270|NCT02826733|Device|Near Infra Red Spectroscopy (NIRS)|
45810271|NCT02826733|Device|magnetic resonance imaging (MRI)|
45946820|NCT00343408|Drug|leucovorin calcium|
45946821|NCT00343408|Drug|oxaliplatin|
45810272|NCT05098873|Other|psychodynamic|intervention with adolescents through the presentation of questions to be completed
45946822|NCT02958111|Drug|Capecitabine|Patients will receive capecitabine (650 mg/m2 bid, p.o.，d1-21，q3wks; continued until disease progression, unacceptable toxicity, or over 1 year).
45946823|NCT00343447|Biological|autologous tumor cell vaccine|
45946824|NCT00343447|Biological|rituximab|
45946825|NCT00343447|Drug|cyclophosphamide|
45946826|NCT00343486|Drug|Solabegron|
45810273|NCT04770090|Other|Blood samples|Peripheral blood samples at the beginning of surgery, after pneumoperitoneum creation and uterine pedicles coagulation.
45810274|NCT02767531|Drug|Orlistat|Orlistat is a gastric and pancreatic lipase inhibitor that is approved by the FDA for weight loss. It is available over-the-counter as 60 mg tablets under the trade name Alli, and available by prescription as 120 mg capsules under the trade name Xenical.
45810275|NCT05404932|Drug|Aliquoted allogeneic donor plasma in patient's conjunctiva|1-2 drops of allogenic aliquoted plasma to affected eye every 1-5 hours per day based on disease severity to be weaned down based on clinical response Administration period: Two to Six months. This may be repeated based on recurrence/worsening of conjunctivitis
45810276|NCT05722249|Behavioral|Mindfulness and Sleep Hygiene|Participants will experience demonstrations and explanations regarding sleep hygiene, mindfulness alerts for at work and mindfulness rest for at home.
45946827|NCT00089804|Drug|abetimus sodium (LJP 394) and/or placebo solution|300 mg (50 mg/mL)abetimus sodium (three 2 mL vials of of abetimus sodium plus six 2 mL vials of normal saline) administered i.v. (in the vien) weekly for 52 weeks
45946828|NCT00089804|Drug|abetimus sodium (LJP 394)|900 mg (50 mg/mL) abetimus sodium (nine 2 mL vials) administered i.v. (in the vien) weekly for 52 weeks.
45946829|NCT00089804|Drug|Phosphate-buffered saline|A volume of 18 mL (nine 2 mL vials of normal saline) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly for 52 weeks
45946830|NCT00343525|Drug|bavituximab|
45453356|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 0.3 mg, once daily, 1 day
45946831|NCT00127881|Drug|HuMax-CD4 (zanolimumab)|Monoclonal Antibody, 12 weekly infusions.
45946832|NCT00343681|Biological|Inactivated influenza vaccine (split virion)|0.5 mL, Intramuscular
45946833|NCT00343720|Drug|VELCADE|
45946834|NCT00343720|Drug|Alimta|
45946835|NCT00343759|Drug|Lapatinib|Patients will take 14 days of Lapatinib prior to definitive surgery.
45946836|NCT00127920|Drug|Avastin|Paclitaxel, Carboplatin and Avastin given on day 1 every 21 days
45946837|NCT00343798|Drug|cyclophosphamide|Given IV
45946838|NCT00343798|Drug|fludarabine phosphate|Given IV
45946839|NCT00343798|Drug|cyclosporine|Given IV
45946840|NCT00343798|Drug|mycophenolate mofetil|Given IV or PO
45946841|NCT00343798|Other|ex-vivo umbilical cord blood expansion|Undergo double-unit umbilical cord blood transplantation
45453357|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 1.0 mg, once daily, 1 day
45657989|NCT05543941|Device|XPERIENCE Advanced Surgical Irrigation|The patient will undergo THA, TKA, or HR with irrigation of the deep wound prior to fascial closure consisting of XPERIENCE Advanced Surgical Irrigation (XP). XP solution will be applied prior to fascial closure and left to soak for up to 3 minutes. Remaining product will be suctioned away throughout the procedure. No rinsing should take place after irrigation and surgical site will be closed according to site standard operating procedures.
45676369|NCT03647358|Drug|Iodine-124|Patients will receive 0.9 mg injections of rhTSH on two consecutive days. Twenty-four hours after the last injection of rhTSH each patient will receive approximately 5 mCi (range: 4-7 mCi) of 124I orally as a single dose.
45676370|NCT03600350|Biological|pTVG-HP|Plasmid DNA vaccine encoding Prostatic Acid Phosphatase (PAP)
45946842|NCT00343798|Procedure|double-unit umbilical cord blood transplantation|Undergo double-unit umbilical cord blood transplantation
45946843|NCT00343798|Procedure|biopsy|Optional correlative studies
45946844|NCT00343798|Other|immunologic technique|Correlative studies
45946845|NCT00343798|Other|diagnostic laboratory biomarker analysis|Correlative studies
45946846|NCT00089882|Procedure|APOE Genetic susceptibility testing|
45946847|NCT04715308|Procedure|Urinary diversion|The formation of a stoma to divert urine to the skin because of the need to resect the bladder as part of surgery for advanced pelvic malignancy
45946848|NCT00343876|Drug|aspirin|
45946849|NCT00343876|Drug|clopidogrel|
45946850|NCT00402636|Device|rapamycin plus 17beta estradiolvalerat-eluting stent|rapamycin plus 17beta estradiolvalerat-eluting stent was implanted due to randomisation
45657990|NCT05543941|Device|Dilute Betadine|The patient will undergo THA, HR or TKA with irrigation of the deep wound prior to fascial closure consisting of Dilute Betadine (DB). DB concentration will be standardized at 0.3% povidone-iodine. DB will be prepared by combining 30 mL of sterile 10% povidone-iodine (from a sterile catheter pack) with 1 L of 0.9% saline in a sterile splash basin. Solution will be left to soak for up to 3 minutes and remaining povidone-iodine solution will be suctioned away. Area will then be rinsed with 1L of normal saline. Surgical site will be closed according to site standard operating procedures.
45657991|NCT04425733|Drug|MK-5475|MK-5475 administered at a dose of 180 µg or ≤360 µg QD via inhalation
45810277|NCT05722249|Behavioral|Phyical activity and Sleep Hygiene|All enrolled participants in the inpatient units randomly assigned to Arm B during Study Period 1 will receive written guidelines about physical activity during the nightshift (please see Appendix V). These guidelines will instruct them to achieve the goal of up to 15 minutes of physical activity between midnight and 0500 each nightshift during the 8-week study period. Each enrolled participant will view a video with voice over of the study team physical therapist demonstrating the methods
45946851|NCT00402636|Device|rapamycin-eluting stent|rapamycin-eluting stent was implanted due to randomisation
45946852|NCT00343954|Drug|L-citrulline tablets, 1000 mg|
45946853|NCT00343993|Device|noninvasive positive pressure ventilation|
45946854|NCT00089921|Drug|SCIO-469|60 mg capsule three times daily for 12 weeks
45946855|NCT00089921|Drug|SCIO-469|30 mg capsule three times daily for 12 weeks
45946856|NCT00089921|Drug|Placebo|2 capsules three times daily and one tablet daily
45946857|NCT00089921|Drug|SCIO-469|100 mg tablet once daily for 12 weeks
45946858|NCT00344110|Drug|Aliskiren|
45946859|NCT00402675|Procedure|Timing of percutaneous coronary intervention|Immediate, early or selective invasive angiography
45657992|NCT04425733|Drug|Placebo|MK-5475-matching placebo administered QD via inhalation
45657993|NCT05543863|Diagnostic Test|Platelet function testing|platelet function testing (Platelet function analyzer-100 (PFA-100) collagen epinephrine closure time, VerifyNowⓇ Assays (aspirin, P2Y12)) before surgery and 5 days, 3 months after surgery
45657994|NCT05543473|Other|Vestibular Rehabilitation Therapy|an exercise-based treatment program designed to promote vestibular adaptation and substitution. The goals of VRT are to enhance gaze stability, to enhance postural stability, to improve vertigo, and to improve activities of daily living. VRT facilitates vestibular recovery mechanisms: vestibular adaptation, substitution by the other eye-movement systems, substitution by vision, somatosensory cues, other postural strategies, and habituation
45946860|NCT00344149|Drug|Rituximab (Mabthera)|I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
45946861|NCT00089960|Drug|AMG 706|AMG 706 125 mg daily for 48 weeks, or until progressive disease or unacceptable toxicity.
45946862|NCT00344227|Drug|Lucentis (Ranibizumab)|
45946863|NCT00402753|Behavioral|Ambulatory Physical Exercise Program|supervised exercise, 2 x / week
45946864|NCT00344383|Drug|Norgestimate/Ethinyl Estradiol tablet|
45946865|NCT00335218|Drug|Climodien / Lafamme (BAY86-5027)|1 tablet daily (2 mg EV + 2 mg DNG)
45946866|NCT00335218|Drug|Placebo|1 tablet daily
45946867|NCT00344422|Drug|Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)|
45946868|NCT00335296|Device|PFx catheter|
45946869|NCT00090038|Drug|rituximab|Dose, schedule,and duration specified in protocol
45946870|NCT00402792|Drug|Hydrocodone/Acetaminophen Extended-Release|1 tablet q 12 hours
45946871|NCT00402792|Drug|Hydrocodone/Acetaminophen Extended Release|2 tablets q 12 hours
45946872|NCT00402792|Drug|Placebo|2 tablets q 12 hours
45946873|NCT00335335|Drug|iodixanol|
45946874|NCT00335374|Drug|Pardoprunox|12 -42 mg
45946875|NCT00127959|Drug|tenofovir|
45453358|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 3 mg, once daily, 1 day
45453359|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 10 mg, once daily, 1 day
45453360|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 30 mg, once daily, 1 day
45676371|NCT03600350|Drug|Nivolumab|Nivolumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
45946876|NCT00127959|Drug|emtricitabine|
45946877|NCT00127959|Drug|zidovudine|
45946878|NCT00127959|Drug|efavirenz|
45946879|NCT00344539|Biological|AMA1-C1/Alhydrogel®|AMA1-C1/Alhydrogel malaria vaccine, cloudy suspension, 0.5 mL dose containing up to equivalent of 377 mcg of aluminum as Alhydrogel® (800 mcg of aluminum hydroxide gel per dose) onto which 20 mcg or 80 mcg of recombinant AMA1-C1 is bound. Dosages: 20 mcg and 80 mcg administered via the deltoid muscle by IM injection
45946880|NCT00344539|Biological|CPG 7909 Oligodeoxynucleotide (VaxImmune®)|CPG 7909 is an investigational agent and is supplied in sterile vials at 10mg/mL in phosphate buffered saline for intramuscular administration. Dosage 500 mcg.
45946881|NCT00090077|Drug|GW695634|
45946882|NCT00344578|Device|Restor IOL|
45946883|NCT04715503|Radiation|PET imaging, 18F-FDG|PET-MRI with 18F-FDG
45946884|NCT04715503|Radiation|PET imaging, 68Ga-DOTANOC|PET-CT with 68Ga-DOTANOC
45946885|NCT00344617|Drug|Bevacizumab (tradename: Avastin)|
45946886|NCT00127998|Drug|chloroquine|
45946887|NCT00127998|Drug|sulfadoxine-pyrimethamine|
45946888|NCT00127998|Drug|amodiaquine|
45946889|NCT00127998|Drug|amodiaquine+artesunate|
45946890|NCT00127998|Drug|amodiaquine+sulfadoxine-pyrimethamine|
45946891|NCT00127998|Drug|sulfadoxine-pyrimethamine+artesunate|
45946892|NCT00127998|Drug|artemether-lumefantrine|
45657995|NCT05696041|Other|Static strength training program or/and Dynamic strength training program of the hand|Four of the five exercises included in the static or dynamic training program were based on holding the weight over the edge of the table and maintaining the position for 10 seconds, then resting briefly and changing to the next position. The training was performed in the following assumed positions, pronation, supination, radial and ulnar position. In the fifth and final exercise, you would squeeze an exercise ball as hard as possible without pain. The starting weight was 0.5 kilogram, and each exercise (1-4) was performed in three sets in the first week. The training increased by one set per week for up to eight sets/week if pain or paresthesia got worsened. If the training worked, the OT and the subject could choose to increase the weight to 1 kilogram and start over with three sets/day and gradually increase the training or switch to a dynamic training program.
45657996|NCT05697757|Other|Dynamic Lighting|This will be an eighteen-hour lighting scheme that includes three modes: morning (6:00 - 12:00), afternoon (12:00 - 18:00), and evening (18:00 - 24:00). It mimics natural lighting by providing blue-enriched high-intensity lighting in the morning and neutral white medium-intensity lighting in the afternoon to maintain alertness without exerting substantial circadian effects. The biodynamic lighting will provide yellowish low-intensity lighting in the evening to minimize any circadian effect.
45657997|NCT05697757|Other|Placebo Lighting|We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness from morning to evening. The numbers of CCT and illuminance levels are selected based on the average room lighting
45657998|NCT05557279|Drug|500 mg NDS-446|All participants will receive 500 mg NDS-446 daily for 12 weeks following a baseline assessment
45657999|NCT05592301|Diagnostic Test|Diffusion-weighted Magnetic Resonance Imaging (DW-MRI)|The Diffusion-weighted Magnetic Resonance Imaging (DW-MRI) is used to diagnose perioperative stroke.
45658000|NCT05592301|Diagnostic Test|Transcranial Doppler (TCD)|Used to diagnose PFO
45658001|NCT05592301|Diagnostic Test|Transthoracic Echocardiogram (TTE)|Used to diagnose PFO.
45658002|NCT05695963|Other|Clinical assessment|RLS history, RLS treatments, and International Restless Legs Syndrome Rating Scale (IRLSRS) will be recorded
45658003|NCT05695963|Behavioral|auto-questionnaires|To evaluate sleep quality, daytime somnolence and mood disorders (Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS) and Hospital Anxiety and Depression Scale (HADS)).
45658004|NCT05695963|Device|Ecological Momentary Assessment (EMA)|4 electronic interviews administred per day during 14 days by a study-dedicated Android OS smartphone
45658005|NCT05695963|Device|activity-rest cycle|To further investigate the mutual influence of sleep quality on RLS symptoms and mood, the activity-rest cycle will be monitored by wearable actigraph to be placed on the non-dominant wrist during a period of 13 days and 14 nights.
45658006|NCT05592067|Other|I tape technique|I tape technique described by Dr Kenzo Kase will be applied once a week, a total of 3 times, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
45658007|NCT05592067|Other|Button hole technique|Button hole technique defined by Dr Kenzo Kase will be applied once a week, 3 times in total, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
45658008|NCT05592067|Other|exercises|exercises will be taught to the patient and a total of 21 sessions will be applied once a day
45658009|NCT05498701|Drug|Tafamidis free acid tablet (Test)|12.2 mg tafamidis free acid tablet (Test)
45658010|NCT05498701|Drug|Tafamidis meglumine capsule (Reference)|Commercial 20 mg tafamidis meglumine capsule (Reference)
45810278|NCT04419324|Device|transoral flexible endoscope with magnifying narrow band imaging|To use an esophago-gastroscopy endoscope (OGD) with Narrow Band Imaging (NBI) passed transorally and retroflexed into the nasopharynx to view the nasopharynx with increased magnification and clarity for the diagnosis of nasopharyngeal carcinoma.
45810279|NCT05722171|Biological|gdT cell injection targeting B7-H3 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 1E8, 2E8 and 4E8 CAR-gdT groups in order of sequence. And the subjects will be administered once.
45946893|NCT00127998|Drug|mefloquine|
45658011|NCT05695807|Device|Carboxytherapy|Device generating CO2 gas
45658012|NCT02580877|Drug|67.5 mg oral insulin crystals daily|human insulin crystals in capsules
45658013|NCT02580877|Drug|500mg oral insulin crystals every other week|human insulin crystals in capsules
45658014|NCT03093493|Diagnostic Test|Genotyping|Genotyping by next generation sequencing
45658015|NCT05591833|Procedure|SASI|Single-Anastomosis Sleeve ileal (SASI) Bypass
45658016|NCT05591833|Procedure|SAS-J|Single-Anastomosis Sleeve Jejunal (SAS-J) Bypass
45658017|NCT05688163|Other|programme based on everyday cognition|Will carry out a programme based on everyday cognition, As material for use as for the traditional cognitive stimulation sessions, a training booklet on everyday cognition has been created which includes all the sessions mentioned above. Each day one of these tasks will be worked on.
45658018|NCT05688163|Other|traditional cognitive stimulation|Individual cognitive skills such as attention, memory, executive functions, orientation, praxis, calculation, visual perception and reasoning will be trained. The materials and media used will be a cognitive stimulation notebook created for the study which includes cards in printed paper format to be completed by the participants.
45658019|NCT04316923|Diagnostic Test|ECG|ECG will be performed during each visit in the study group.
45658020|NCT04316923|Diagnostic Test|24-hour ECG monitoring|24-hour ECG monitoring will be performed during each visit in the study group.
45810280|NCT04419246|Other|interscalene block|ultrasound guided ultrasound guided interscalene block 30 minutes before operation. 30 minutes before operation.
45810281|NCT04419246|Drug|tranexamic acid|10 mg/kg intravenous tranexamic acid 10 minutes before the incision.
45810282|NCT04419246|Other|general anesthesia|general anesthesia will be applied in accordance with standard procedures
45946894|NCT00420589|Drug|taranabant|taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
45810283|NCT05722093|Drug|Manzi Guben granules|Administration cycle of Manzhi Guben granules: 1-4 weeks; Usage: 10g once, twice a day, washed with boiling water.
45658021|NCT04316923|Diagnostic Test|Cardio-pulmonary exercise test (CPET)|CPET will be performed during the first and the last visit in the study group.
45658022|NCT04316923|Diagnostic Test|Cardiac biomarkers|Cardiac biomarkers will be assessed during each visit in the study group.
45946895|NCT00420589|Drug|Comparator: placebo|Placebo capsules once daily. Treatment for 52 weeks
45810284|NCT05400174|Diagnostic Test|Tilt table (upright position)|Different versions of cognitive assessments will be administered in the sitting and upright positions.
46075955|NCT00953147|Drug|Placebo|Placebo HFA Nasal Aerosol once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
46075956|NCT02842892|Other|Tissue stiffness|
45946896|NCT00090116|Drug|Neramexane|
46075957|NCT04884750|Behavioral|ECA-ACE Vaccination Promotion Intervention|A smartphone-based embodied conversational agent that educates users and motivates them to obtain vaccinations for SARS-CoV-2 and Influenza, according to Boston Public Health Commission guidelines.
46075958|NCT05333744|Drug|Prednisone|Prednisone po, 20mg per day for 2 weeks, if response (Plt 30-100×100^g/L),gradually taper to the maintenance dose（5-10mg per day）until 6 weeks after delivery; if not response, gradually taper to withdrawal.
45658023|NCT05697601|Diagnostic Test|Artificial-Intelligence Based Screening Tools|Artificial-Intelligence Based Screening Tools build on machine learning models
45658024|NCT05697601|Diagnostic Test|Pathology analysis|Pathology assessment of cells and tissues from respective organs
45810285|NCT04825626|Biological|HB-adMSCs|Hope Biosciences adipose derived Mesenchymal Stem Cells.
45810286|NCT04758312|Behavioral|MY-Skills Mobile|Yoga and Self-Management Education
45946897|NCT00344695|Drug|bupropion SR|
45946898|NCT00128037|Drug|mitomycin C, vindesine, cisplatin and radiotherapy|
45946899|NCT00344734|Drug|Ng-monomethyl-L-arginine (drug)|
45946900|NCT00344812|Drug|LAAM. buprenorphine and methadone|
45946901|NCT00420706|Drug|SCA-136|
45946902|NCT00344851|Drug|metformin, exenatide or combined (metformin & exenatide )|
45946903|NCT00128076|Procedure|All-Arthroscopic repair|joint techniques and repair are both performed entirely through the arthroscope
46075959|NCT05333744|Drug|Recombinant Human TPO|rhTPO im, 300U/kg per day for 2 weeks, if response (Plt 30-100×100^g/L), taper to 300U/kg for twice per week until 6 weeks after delivery; if not response, drug withdrawal.
46075960|NCT04228458|Device|Thermal Imaging|Testing the effectiveness of using a Thermal Imaging camera in participants with Juvenile Arthritis.
46075961|NCT04250246|Drug|Ipilimumab plus nivolumab plus guadecitabine|"Cohort A Melanoma ARM A Guadecitabine: 30-45 mg/m2 s.c./day 1-5 q21 x 4 cycles and from W13 q28 x 6 cycles Ipilimumab: 3 mg/Kg i.v. plus nivolumab 1 mg/Kg i.v. on W1, 4, 7 and 10 and from W14 nivolumab 480 mg i.v. q4 wks for 2 years~Cohort B NSCLC ARM A Guadecitabine: 30-45 mg/m2 s.c./day 1-5 q21 x 4 cycles and from W13 q28 x 6 cycles Ipilimumab: 1 mg/Kg i.v.q 6wks plus nivolumab 3 mg/Kg i.v. q2 wks until W13, then ipilimumab: 1 mg/Kg i.v. q 6wks plus nivolumab 480mg i.v. q4wks for 2 years"
45658025|NCT05697523|Other|Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test|Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
45658026|NCT04425499|Other|Learning running subcuticular sutures on the Gamified Educational Network|Each arm will have 15 participants who will learn how to perform running subcuticular sutures through videos on GEN.
45658027|NCT01905631|Drug|Aurstat Anti-Itch Hydrogel (Aurstat)|Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
45658028|NCT05679115|Behavioral|Lifestyle tool|Regular use of the digital Lifestyle tool
45658029|NCT01808989|Other|Exercise oxymetry|
45658030|NCT05380219|Other|dual task strength training|strength training and dual task
45658031|NCT05316571|Behavioral|One 5-Minute Walking Bout Each Hour|One 5-minute light intensity walking break per hour throughout the 4-hour SB condition
45658032|NCT05316571|Behavioral|One 15-Minute Standing Bout Each Hour|One 15-minute standing break per hour throughout the 4-hour SB condition
45946904|NCT00128076|Procedure|Mini-open repair|repair is performed though a small incision and the arthroscope can be used to address problems within the joint (as per traditional diagnostic procedures)
45946905|NCT00090155|Drug|MK0869, aprepitant|
45946906|NCT00090155|Drug|Comparator: ondansetron IV|
45453361|NCT01105429|Drug|BMS-820132|Oral Solution, Oral , 75 mg, once daily, 1 day
45810287|NCT05721625|Other|Aerobic exercise|The aerobic exercise program will be applied at moderate intensity 3 days a week for 8 weeks. Walking will be recommended as an aerobic exercise
45946907|NCT00420823|Drug|Taurine 4g|
45946908|NCT00344890|Procedure|Anterior Cervical Discectomy and Fusion|1,2,3,or 4 level surgery
45946909|NCT04714957|Other|construction of a database of genetic and epigenetic data on peritoneal carcinomatosis of colorectal or ovarian origin.|Construction of a core database of genetic and epigenetic markers, in order to identify predictive biomarkers and potentially actionable targets for controlling the spread of peritoneal carcinomatosis.
45946910|NCT00128115|Drug|MK0677|
45946911|NCT00335413|Drug|Spironolactone|
45946912|NCT00090194|Biological|Immune Globulin Intravenous (Human), 10%|
45946913|NCT00345007|Procedure|Scleral buckling|
45946914|NCT04716088|Diagnostic Test|Rapid antigen test for SARS CoV2|Defining diagnostic performance of repeated testing regimen in hospital setting
45946915|NCT00345085|Device|Wavefront and Contrast Sensitivity|
45946916|NCT00335491|Behavioral|exercise intervention|12 weeks of 3x/week training on a recumbent eccentric stepper
45946917|NCT00335491|Procedure|complementary or alternative medicine procedure|12 weeks of 3x/week training on the eccentron
45946918|NCT00335491|Procedure|fatigue assessment and management|The visual analog scale will be used to assess muscle soreness from the previous exercise session
45946919|NCT00335491|Procedure|physical therapy|12 weeks of 3x/week training on the eccentron
45946920|NCT00345124|Behavioral|high sodium diet|250-350 mmol
45946921|NCT00345124|Behavioral|Low Sodium Diet|25-35 mmol
45946922|NCT00335569|Drug|hCG-IBSA|
45810288|NCT05721625|Other|Connective tissue massage|Connective tissue massage will be applied by the physiotherapist 3 days a week for 8 weeks. While the patients are in the sitting position, this massage will be applied on whole back.
45946923|NCT00345163|Drug|bevacizumab|Intravenous repeating dose
45453362|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 150 mg, once daily, 1 day
45946924|NCT00345163|Drug|irinotecan|Intravenous repeating dose
45946925|NCT00345202|Drug|HMG-CoA reductase inhibition (atorvastatin)|
45453363|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 300 mg, once daily, 1 day
45453364|NCT01105429|Drug|BMS-820132|Capsule, Oral, (TBD), once daily, 2 days
45658033|NCT05316571|Behavioral|One 5-Minute Walking Bout and One 15-Minute Standing Bout Each Hour|Two breaks per hour throughout the 4-hour SB condition, alternating between a 5-minute light intensity walking break and a 15-minute standing break
45658034|NCT05316571|Behavioral|Uninterrupted Sitting|No breaks will be provided throughout the 4-hour SB condition. This will be used as the control condition
45658035|NCT05591521|Other|Using different survey to evaluate pain|Survey will be at different time of the IVF protocol (at the first medical appointment in the medically assisted department, after stimulation, after oocytes retrieval, after embryo transfer, one month after the IVF protocol)
45946926|NCT00335647|Drug|fluphenazine hydrochloride|
45810289|NCT02649907|Dietary Supplement|nutritional stimulation via different testmeals|nutritional stimulation of hormonal response through different testmeals
45946927|NCT00128154|Drug|Chromium picolinate|
45946928|NCT00345241|Drug|Systane Ocular Drops (OTC)|
45810290|NCT02649907|Other|Nutritional counseling|nutritional counseling for healthy eating behaviour
45810291|NCT02649907|Dietary Supplement|formula diet|formula diet to help weight loss
45810292|NCT02521753|Drug|Metformin|Intervention also includes weight reduction diet and exercise therapy
45946929|NCT00345241|Drug|Placebo - Saline Drops|
45946930|NCT00345280|Procedure|impression cytology, obtain the tear fluid|Vitamin A
45946931|NCT00335686|Drug|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h
45946932|NCT00335686|Drug|Nevirapine (Viramune): 1 comp (200mg)/12h|Nevirapine (Viramune): 1 comp (200mg)/12h
45946933|NCT00128232|Drug|Octreotide LAR|
45946934|NCT00345319|Biological|rabies vaccine|Administration of PCECV according to ESSEN regimen
45946935|NCT00345514|Behavioral|Behavioral Intervention Arm|The arm emphasized individual provider behavior (interactive CME, feedback at the provider, clinic and program levels, expert modeling, academic detailing and opinion leaders)
45946936|NCT00345514|Behavioral|Organizational Interventions Arm|Leadership, team building, benchmarking at the clinic and program level
45946937|NCT04708249|Dietary Supplement|D-chiroinositol|Supplementation with 600 mg of D-chiroinositol, two-times daily on an empty stomach, for 30 days.
45946938|NCT00090272|Drug|MK0826, ertapenem sodium|
45946939|NCT00090272|Drug|Comparator: cefotetan|
45946940|NCT00345670|Biological|MEDI-534|10:4 TCID50 of MEDI-534 intranasal spray Study Day 0
45946941|NCT00345670|Biological|MEDI-534|10:5 TCID50 of MEDI-534 intranasal spray Study Day 0
45946942|NCT00345670|Biological|MEDI-534|10:6 TCID50 of MEDI-534; intranasal spray
45946943|NCT00345709|Behavioral|Questionnaire|65 page questionnaire that contains questions about your ovarian cancer diagnosis, gynecologic history, family history, general medical history, and health risk factors.
45946944|NCT00345787|Drug|Placebo|Corresponding placebo is applied for 12weeks
45946945|NCT00345787|Drug|Buprenorphine Transdermal System|Buprenorphine Transdermal System 5, 10 or 20mg/patch is applied for 12weeks
45946946|NCT00128271|Drug|Bavituximab|
45946947|NCT00090311|Drug|quetiapine fumarate|
45658036|NCT05591287|Procedure|Contrast enhanced harmonic Endoscopic Ultrasound|Solid pancreatic masses suspected for PDAC detected by cross-sectional imaging and confirmed at EUS will be enrolled. The
45946948|NCT02959762|Dietary Supplement|Placebo-Control|two placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
45946949|NCT02959762|Dietary Supplement|Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d)|one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
45946950|NCT02959762|Dietary Supplement|High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)|two 45-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
45946951|NCT00345826|Drug|dasatinib|
46075962|NCT04250246|Drug|Ipilimumab plus nivolumab|"Cohort A Melanoma ARM B Ipilimumab: 3 mg/Kg i.v. plus nivolumab 1 mg/Kg i.v. on W1, 4, 7 and 10 and from W14 nivolumab 480 mg i.v. q4 wks for 2 years~Cohort B NSCLC ARM B Ipilimumab: 1 mg/Kg i.v. q 6wks plus nivolumab 3 mg/Kg i.v. q2 wks until W13, then ipilimumab: 1 mg/Kg i.v. q6 wks plus nivolumab 480mg i.v. q4wks for 2 years."
45946952|NCT00345904|Biological|Fluarix|
45946953|NCT00345982|Drug|Serdolect|16 mg, 12 weeks
45658037|NCT05535205|Other|Digital preoperative assessment|a digital preoperative assessment for patient requiring surgery
45946954|NCT00345982|Drug|placebo|placebo
45946955|NCT00090389|Procedure|Chinese Acupuncture|
45946956|NCT00346021|Behavioral|Increasing hat use|Sun protection intervention that address sun protection knowledge, attitudes, social norms, and perceived behavioral controls. Intervention also provides free wide brimmed hats
45946957|NCT00421213|Drug|Darinaparsin|300mg/m2 of Darinaparsin given daily for five consecutive days to be repeated every 28 days for up to six months.
46075963|NCT02779296|Other|2-Octyl Cyanoacrylate Glue|topical
46075964|NCT04273529|Drug|thalidomide|100mg，po，qn，for 14 days.
46075965|NCT04273529|Drug|placebo|100mg，po，qn，for 14 days.
46075966|NCT05230134|Procedure|Cervical sympathetic block|All participants will get the cervical sympathetic block and catheter under ultrasound guidance.
46075967|NCT05333666|Other|Data collection|This investigation aims to collect and analyze the data from a cohort. During the cohort development, all participants received venous puncturing for NOAC concentration measurement. However, the standard treatment protocol was not changed after study enrollment. In this retrospective cohort study, we only collect data from the cohort without further intervention to the participants.
45453365|NCT01105429|Drug|Placebo|Oral Solution, Oral, 0mg, once daily, 1 day
45453366|NCT01105429|Drug|Placebo|Capsule, Oral, (TBD), once daily, 2 days
45810293|NCT02521753|Dietary Supplement|Magnesium|Intervention also includes weight reduction diet and exercise therapy
45810294|NCT02521753|Dietary Supplement|PUFA|Intervention also includes weight reduction diet and exercise therapy
45453367|NCT04962373|Other|Semi-structured interviews|Each participant will attend a 30-60 minute semi-structured interview conducted by the CI
45453368|NCT01105507|Drug|canakinumab (company code: ACZ885D)|
45453369|NCT01104883|Procedure|Adductor-Canal-Blockade|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
45658038|NCT05535205|Other|Face-to-face preoperative assessment|a face-to-face preoperative assessment for patient requiring surgery
45658039|NCT05275075|Other|Pancreatic cancer microRNA and messenger RNA expression.|Tumor specimens from pancreatic patients will be analyzed for markers associated with muscle loss.
45658040|NCT05679037|Other|Placebo|Inactive capsules
45658041|NCT05679037|Drug|Alpha Lipoic Acid 600 MG Oral Capsule|Universal antioxidant
45453370|NCT01104883|Procedure|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
45658042|NCT05588401|Biological|GenPHSat injection (Safety)|Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the left biceps muscle.
45810295|NCT04411134|Biological|E7 TCR|Approximately 3x10^8 or 1.5x10^9 E7 TCR T cells will be injected on day 0 and 1.5x10^9 E7 TCR T cells on day 31 (2 escalating dose levels)
45946958|NCT00346060|Device|Retinal transplantation instrument|
45946959|NCT00346060|Device|Fetal tissue.|
45946960|NCT00346099|Drug|Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by|
45946961|NCT00346099|Drug|Panitumumab with capecitabine and radiation|
45946962|NCT00125736|Drug|E0671|One 50 mg capsule is orally administered three times daily (150 mg/day)
45946963|NCT00125736|Drug|rabeprazole sodium|One 10mg tablet is administered orally each day
45946964|NCT00125736|Drug|E0671 placebo|One 50 mg capsule is orally administered three times daily (150 mg/day)
45946965|NCT00090428|Behavioral|Gluten- and casein-free diet|Participants will follow a gluten-free and casein-free diet for 18 weeks. All children received individual EIBI interventions to decrease the confound of different types of therapies.
45946966|NCT00090428|Behavioral|Placebo controlled diet|Participants will follow a gluten-free and casein-free diet for 18 weeks. They will receive double blind placebo controlled challenge snacks that contain gluten, casein, gluten+casein or placebo with measurement of response. They remain on the gluten free and casein free diet for the entire study period.
45946967|NCT00346138|Procedure|Corneal transplantation|
45946968|NCT00346177|Biological|Autologous Stem Cells|Intramyocardial injections
45946969|NCT00346255|Drug|BB-10901|dose escalation study, doses will vary per cohort. patients will receive an IV infusion weekly for two weeks every three weeks.
45946970|NCT00346294|Drug|Etanercept|Intervention type was to study the drug delivery method.
45946971|NCT00125775|Biological|Engerix-B|Engerix-B at 0, 1, 6 months
45946972|NCT00346450|Procedure|Cultivated conjunctival transplantation|
45946973|NCT00346489|Drug|5-fluorouracil|
45946974|NCT00346489|Drug|Mitomycin C|
45946975|NCT00090506|Behavioral|Yoga|
45946976|NCT00125814|Drug|Interferon alfa-2b|
45946977|NCT00125814|Procedure|Structured treatment interruptions|
45658043|NCT05588401|Biological|GenPHSat injection (Efficacy)|Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the right biceps muscle.
46075968|NCT02838290|Other|Induction|Participants will be randomly assigned (computer generated straight away after clicking the link to the research) to one of 4 experimental conditions: stress at work, dealing with a patient's death, managing stress at work or all topics together. Each module includes brief reflection parts and quizzes. Participants will be asked to fill in an online survey just before the induction and a week after. The survey is about current occupational distress and organizational factors.
45658044|NCT05588401|Other|Muscle Biopsy (Safety)|Participants undergo muscle biopsy 3 month after safety GenPHSat injection.
45946978|NCT00346528|Drug|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
45946979|NCT00346528|Drug|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
45946980|NCT00346567|Drug|Zidovudine and Lamivudine (Combivir)|
45946981|NCT00346567|Drug|Emtricitabine and Tenofovir (Truvada)|
45946982|NCT00090623|Drug|rhuFab V2 (ranibizumab)|
45946983|NCT00346606|Drug|Denosin® and Xyzal®|
45946984|NCT02957994|Drug|Tenofovir alafenamide fumarate|Patients on TDF will be switched to TAF
45946985|NCT00346645|Drug|Bortezomid (VELCADE®)|
45946986|NCT00346684|Drug|Rituximab|
45946987|NCT04714801|Drug|adipose derived mesenchymal stromal cells|Intravenous infusion of cells
45946988|NCT04714801|Drug|Saline|Intravenous infusion of saline
45453371|NCT01104961|Device|Contact lens packaging solution|These test solutions are the intervention being tested.
45946989|NCT04728932|Drug|Levosimendan|A continuous infusion of Levosimendan over 24h
46075969|NCT02838290|Other|Control group|Participants in the control group will be asked to fill in an online survey, but will not have any task at time-1. However, participants in the control group will be invited to complete induction programme after time-2 (a week time after time-1) in ensure the same expectations in both, experimental and control, groups.
46075970|NCT02776176|Procedure|Enhanced Recovery After Surgery Program|optimized peri-operative protocol
46075971|NCT02776176|Procedure|Traditional Program|traditional standard protocol
45453372|NCT01104961|Device|Balanced salt solution (BSS)|BSS is isotonic to the tissues of the eyes.
45453373|NCT04371380|Drug|Cabotegravir Tablets|Cabotegravir tablets will be white to almost white oval shaped film coated tablets with a unit dose of 30 mg and will be administered orally.
45453374|NCT04371380|Drug|Rilpivirine Tablets|Rilpivirine tablets will be off-white, round, biconvex film coated tablets with a unit dose of 25 mg and will be administered orally.
45453375|NCT04371380|Drug|Cabotegravir extended release suspension for injection (long-acting)|Cabotegravir long-acting will be a sterile white to slightly pink suspension containing 200 mg per mL of GSK1265744 as free acid for administration by intramuscular injection.
45658045|NCT05587465|Device|Lobster Device|The intervention is performed percutaneously using the dedicated instrument set.
45946990|NCT04728932|Drug|Placebo of Levosimendan|A continuous infusion of Placebo of Levosimendan over 24h
45658047|NCT05573737|Other|education|education about ubilical cord care
45658048|NCT05695651|Diagnostic Test|triglyceride glucose index and HOMA IR|"TyG index was calculated as formula: ln[fasting triglycerides (mg/dL) × fasting plasma glucose (mg/dL)/2].~an insulin resistance score (HOMA-IR) was computed with the formula: fasting plasma glucose (mmol/l) times fasting serum insulin (mU/l) divided by 22.5. Low HOMA-IR values indicate high insulin sensitivity, whereas high HOMA-IR values indicate low insulin sensitivity (insulin resistance)."
45658049|NCT05197621|Biological|mRNA COVID-19 vaccine (Pfizer or Moderna)|mRNA vaccine received at any time during pregnancy course
45658050|NCT05678881|Drug|High dose RLS103|8 mg CBD inhaled powder
45946991|NCT00346723|Biological|Influvac® subunit influenza vaccine for i.m./deep s.c.injection|
45946992|NCT00125892|Drug|duloxetine|
45946993|NCT00346762|Behavioral|Education|HIV prevention education and risk reduction counselig
45946994|NCT00346801|Drug|Celecoxib|100 mg by mouth (PO) twice daily for 5 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 7 weeks).
45946995|NCT00346801|Drug|Cisplatin|25 mg/m^2 IV over 60 minutes on Day 1, Weeks 2-8
45946996|NCT00346801|Drug|CPT-11|30 mg/m^2 IV over 90 minutes on Day 1, Weeks 2-8, followed by cisplatin which will be infused for 60 minutes.
45946997|NCT00346801|Radiation|Concurrent Thoracic Radiation Therapy|63 Gy at 1.8 Gy/Fx in 35 Fractions over 7 weeks starting 2nd week of celebrex.
45946998|NCT00346840|Drug|Misoprostol vaginal insert 25 mcg|One hydrogel polymer vaginal insert for up to 24h
45946999|NCT00346840|Drug|Misoprostol vaginal insert 50 mcg|One hydrogel polymer vaginal insert for up to 24h
45947000|NCT00346840|Drug|Misoprostol vaginal insert 100 mcg|One hydrogel polymer vaginal insert for up to 24h
45947001|NCT00346840|Drug|Misoprostol vaginal insert 200 mcg|One hydrogel polymer vaginal insert for up to 24h
45947002|NCT00090701|Drug|AG2037|
45947003|NCT00346879|Drug|fondaparinux|Single 2.5 mg dose of fondaparinux or weight-based 0.03 mg/Kg dose of fondaparinux
45947004|NCT00126009|Drug|Amisulpride|
45947005|NCT00346918|Drug|Sirolimus|Standard plus Sirolimus
45947006|NCT00346918|Other|Standard|Standard
45947007|NCT00346957|Drug|Anecortave acetate 30 mg|0.5ml administered onto the sclera once every six months for 24 months
45947008|NCT00346957|Drug|Anecortave Acetate 15 mg|0.5ml administered onto the sclera once every six months for 24 months
45947009|NCT00346957|Drug|Anecortave Acetate 3 mg|0.5ml administered onto the sclera once every six months for 24 months
45947010|NCT00346957|Other|Anecortave Acetate Vehicle|0.5ml administered onto the sclera once every six months for 24 months
45947011|NCT00346996|Drug|insulin levemir / aspart|for subcutaneous injection
45947012|NCT00346996|Drug|human insulin /insulin isophane|for subcutaneous injection
45947013|NCT00402480|Drug|Hydroxyurea|
45947014|NCT00347035|Drug|brimonidine|
45658051|NCT05678881|Drug|placebo inhaled powder|placebo inhaled powder
45658052|NCT05678881|Drug|Low dose RLS103|4 mg CBD inhaled powder (open label)
45947015|NCT00402519|Radiation|Accelerated partial breast irradiation|APBI with PDR and HDR brachytherapy
45947016|NCT00402519|Radiation|External beam whole breast irradiation|Standard Whole breast irradiation
45810296|NCT04229303|Drug|Voriconazole inhaled|"Part 1 (SAD): eligible subjects received a single ascending inhaled dose (5 mg, 10 mg, 20 mg, and 40 mg) of ZP-059 5mg capsules administered via dry powder inhaler (DPI) on the morning of Day 1.~Part 2 (MAD): eligible subjects received 2 (10mg twice daily [BID]) or 4 [20mg BID]) inhaled doses of ZP-059 5mg capsules administered via DPI BID for 9 days and once in the morning of Day 10, or 8 inhaled doses of ZP-059 5 mg capsules (40mg once daily [QD]) for 10 days. For QD dosing, subjects received QD doses of ZP-059 (at hour 0) on Days 1 to 10.~Part 3 (2-period crossover): eligible subjects received a 4 [20mg BID] inhaled doses of ZP-059 5mg capsules administered via DPI on the morning of Day 1 according to the crossover scheme of the study.~ZP-059 (inhaled voriconazole) was provided in clear, colorless size 3 hydroxypropylmethylcellulose hard capsules, which were individually and manually triggered by a breath actuated inhalation device (RS01 monodose inhaler)."
45947017|NCT00347113|Drug|Albendazole and praziquantel|
45658053|NCT04134091|Drug|LPCN 1144 Formulation A|Oral LPCN 1144 Formulation A capsule, total daily dose of 450 mg testosterone undecanoate administered as BID (225 mg testosterone undecanoate per dose)
45947018|NCT00347152|Drug|Divalproex|Divalproex, 8-20% taper
45658054|NCT04134091|Drug|LPCN 1144 Formulation B|Oral LPCN 1144 + d-alpha tocopherol total daily dose of 450 mg testosterone undecanoate + 476 mg d-alpha tocopherol administered as BID (225 mg testosterone undecanoate + 238 mg d-alpha tocopherol per dose)
45658055|NCT04134091|Drug|Placebo|Oral matching placebo capsule administered as BID
45658056|NCT05672407|Drug|Tranexamic acid|100 mg/mL Tranexamic acid with lidocaine with 1:100,000 epinephrine in 1:1 manner administered subcutaneously
45658057|NCT05672407|Drug|Placebo|Lidocaine with 1:100,000 epinephrine mixed with 1:1 Basal Saline Solution (BSS) administered subcutaneously
45658058|NCT05678725|Device|tACS|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as the stimulation electrode, while the return electrode placed on the right shoulder . The dose was at 2mA, 20Hz for 20 minutes.
45658059|NCT05678725|Device|tDCS|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The dose was at 2mA for 20 minutes.
45658060|NCT05678725|Device|sham|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The dose was at 0mA for 20 minutes with the ramp up and down time of 40 seconds.
45658061|NCT05678569|Diagnostic Test|Dual Energy Xray Absorptiometry|DXA for diagnosis of osteoporosis
45947019|NCT00347152|Drug|Divalproex|Divalproex, 8-20% taper
45947020|NCT00090896|Biological|maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody|
46075972|NCT02858843|Drug|lumacaftor-ivacaftor|Drug given for cystic fibrosis
46075973|NCT00803205|Drug|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
46075974|NCT00803205|Drug|Placebo|Placebo matching to ataluren will be provided.
45658062|NCT02582983|Drug|Enfuvirtide|All participants received enfuvirtide 90 mg SC BID until 4 weeks after commercial availability was established in Thailand.
45810297|NCT04229303|Drug|oral voriconazole|Part 3 (2-period crossover): eligible subjects received a single dose of oral voriconazole (200mg oral film-coated tablet, Vfend) on the morning of Day 1 according to the crossover scheme of the study.
45947021|NCT00402558|Drug|Thymoglobulin|1.5 mg/kg By Vein Daily x 3 Days
45453376|NCT04371380|Drug|Rilpivirine extended release suspension for injection (long-acting)|Rilpivirine long-acting will be a sterile white suspension containing 300 mg per mL of rilpivirine as the free base for administration by intramuscular injection.
45658063|NCT02582749|Drug|LHRH agonist/antagonist|Treating physician will determine LHRH agonist/antagonist, dosage and route of administration, per package insert, during each 28-day cycle.
45658064|NCT02582749|Drug|Bicalutamide|Bicalutamide, 50 mg Oral (PO) will be administered daily in each 28-day cycle.
45810298|NCT04419012|Other|observation|observation
45810299|NCT05721547|Other|Assessment|Assessment
45947022|NCT00402558|Drug|Busulfan|130 mg/m^2 By Vein Over 3 Hours x 4 Days
45947023|NCT00402558|Drug|Fludarabine|40 mg/m^2 By Vein Over 30 Minutes x 4 Days
45947024|NCT00402558|Procedure|Alloreactive NK Infusion|Alloreactive NK infusion from haploidentical donor on Day -8. The alloreactive NK cell infusion given at one of 4 dose levels 10e6, 5 x 10e6, 3 x 10e7 cells/kg and 3 x10e7.
46075975|NCT02836964|Device|Dental Implant|Dental implant
46075976|NCT02779530|Drug|Diclofenac|50 mg po, b.i.d for 6 days
45658065|NCT02582749|Radiation|Radium-223 dichloride|Radium-223 dichloride, 50 kBq (1.35 microcurie) per kg body weight intravenous (IV bolus) every 28 days for 6 injections
45947025|NCT00402558|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 x 109/L for 3 consecutive days.
45947026|NCT00402558|Drug|Tacrolimus|Starting dose of 0.015 mg/kg as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after Day +90 if no GVHD is present.
46075977|NCT02779530|Other|Placebo|Placebo po, b.i.d. for 6 days
46075978|NCT02836730|Procedure|Low back pain surgery|
46075979|NCT00952523|Drug|Tretinoin Facial Gel|A marketed facial gel containing Tretinoin 0.04% is applied to one side of the face daily for three weeks.
45658066|NCT05695495|Drug|N,N-Dimethyltryptamine (5mg)|Intravenous bolus application over 45 seconds
45947027|NCT00402558|Drug|Methotrexate|5 mg/m2 intravenously on Days 1, 3 and 6 and Day +11 post transplant.
45947028|NCT00402558|Drug|Interleukin-2|0.5 million units per day subcutaneously starting on Day -8 (day of the NK cell infusion) to Day -4 only to participants receiving fourth dose level of NK cells.
45947029|NCT00347230|Device|Intacs intracorneal ring insertion for the treatment of keratoconus|
45947030|NCT00347386|Drug|Drug: Zinc (zinc sulphate)|Dissolvable tablet 10 mg. Once daily during the illness
45947031|NCT00347386|Drug|Placebo|Placebo tablet, once daily
45947032|NCT00347425|Drug|Aripiprazole|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
45453377|NCT03950011|Procedure|Enhanced recovery after surgery program|Enhanced Recovery After Surgery Programs (ERP) includes multimodal approaches of perioperative patient's clinical pathways designed to achieve early recovery after surgery and a decreased length of hospital stay (LOS).
45658067|NCT05695495|Drug|N,N-Dimethyltryptamine (10mg)|Intravenous bolus application over 45 seconds
45658068|NCT05695495|Drug|N,N-Dimethyltryptamine (15mg)|Intravenous bolus application over 45 seconds
45658069|NCT05695495|Drug|N,N-Dimethyltryptamine (20mg)|Intravenous bolus application over 45 seconds
45658070|NCT05695495|Drug|N,N-Dimethyltryptamine (25mg)|Intravenous bolus application over 45 seconds
45658071|NCT05695495|Drug|Placebo (saline)|Intravenous bolus application over 45 seconds
45658072|NCT05461261|Drug|Docetaxel|Docetaxel will be given intravenously 75 mg/m2 every 3 weeks for 6 cycles.
45658073|NCT05461261|Drug|Prednisolone Acetate|5mg Prednisolone Acetate will be given orally twice a day during treatment.
45658074|NCT05461261|Drug|Platinum-based drugs|Platinum-based drugs will be given intravenously 70 mg/m2 every 3 weeks for 6 cycles. Cisplatin or carboplatin will be carefully chosen according to each patient's Creatinine Clearance.
45810300|NCT05266092|Other|Observational study|Observational study
45810301|NCT05263986|Drug|MRTX849|"Approximately 18-24 patients to ensure at least 12 PK evaluable patients.~Subjects will be administered a single oral dose of 600 mg MRTX849 in PK lead in D1, and will start the dosing regimen of 600 mg BID orally from C1D1."
45453378|NCT04333784|Other|Exercise training|Exercise with blood flow restriction (with a pneumatic cuff).
45658075|NCT05456035|Behavioral|Cognitive behavioral therapy plus social cognitive training (CBTSCT)|The study has two intervention arms to which depressed adolescents will be randomized: (1) CBTSCT is cognitive behavioral therapy enhanced with training in social cognitive abilities (e.g., social perspective taking), and (2) CBT only is cognitive behavioral therapy without the additional social cognitive training component.
45658076|NCT05453617|Behavioral|Time-restricted eating|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm)
45658077|NCT05453617|Behavioral|The 5:2 diet|Participants will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
45658078|NCT05407051|Behavioral|Family Centered Treatment|In the Family-Centered Treatment Arm, parents would be given the same list of mental health referrals and crisis numbers, but in this condition, they would authorize researchers to share their contact information with the partner agency, Catholic Charities, and would then be linked directly to bilingual adult mental health services there with a behavioral health provider who would provide collateral therapy to parents via telehealth. Although parents will be referred to the community partner for therapy as a part of the research intervention, the behavioral health providers at the community partner will be providing therapy as they usually do for these participants in line with their usual job duties.
45658079|NCT05407051|Behavioral|Treatment as Usual|"All participants (parents) would receive follow-up calls from a MetroHealth research personnel at 3 months and 6 months to measure changes in parent mental health outcomes, as well as satisfaction.~Children of parents in both conditions will receive treatment as usual which includes brief consultation for 3-5 sessions with an integrated MetroHealth behavioral health provider which is already standard practice in the clinic. Sessions typically occur monthly. Teens will be re-administered the Patient Health Questionnaire -9 by the integrated behavioral health provider as a part of clinical practice to measure treatment progress and this information will be obtained at the end of 6 months of treatment via chart review (see data sheet). Repeated measurement of patient's symptoms over the course of several months of treatment is common in clinical practice to measure patient's symptom improvement."
45658080|NCT05383729|Other|learning-curve-based training modality|It is an individual duration of simulation training that is based on the previous performance of FOB on a simulator.
45658081|NCT05383729|Other|fixed-training-time training modality|It is a training duration of 1 hour which is the dominant duration of simulator training in previous studies.[1]
45658082|NCT05339815|Device|SMR shoulder arthroplasty|Data collection of population that underwent a reverse shoulder arthroplasty performed with SMR 36-mm CoCrMo versus 40-mm cross-linked UHMWPE glenospheres
45676372|NCT03600350|Drug|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a growth factor that supports the survival, clonal expansion and differentiation of hematopoietic progenitor cells including dendritic antigen presenting cells.
45947033|NCT00347425|Drug|Olanzapine|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
45947034|NCT00347425|Drug|Risperidone|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
45947035|NCT00347425|Drug|Quetiapine|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
45947036|NCT00347425|Drug|Ziprasidone|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
45947037|NCT00347425|Drug|Aripiprazole|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
45453379|NCT01105585|Device|Tecnis 1-piece Aspheric Acrylic (ZCB00) IOL|Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
45453380|NCT01105585|Device|AcrySof Natural IQ (SN60WF) IOL|AcrySof Natural IQ (SN60WF) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
45676373|NCT03598608|Biological|pembrolizumab|Administered as an IV infusion every 3 weeks (Q3W)
45676374|NCT03598608|Biological|Favezelimab|Administered as an IV infusion Q3W
45810302|NCT00357643|Drug|Calcium 500 mg/day and vitamin D 700 IU/day|
45810303|NCT05072665|Device|HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE|HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE
45810304|NCT04812912|Diagnostic Test|Hormone biomarker analysis|For female patients, hormone biomarker analysis will be performed to measure: anti-Mullerian hormone (AMH), estradiol and FSH in the blood. In male patients, hormone biomarkers of testicular function and spermatogenesis will be monitored: testosterone, inhibin B, steroid hormone binding globulin (SHBG) and FSH. Sperm analysis will also be performed in male patients to monitor changes in sperm count.
46075980|NCT00952523|Drug|Adapalene/Benzoyl Peroxide Facial Gel|A marketed facial gel containing Adapalene .1% and Benzoyl peroxide 2.5% is applied to the other side of the face daily for three weeks
46075981|NCT02836808|Behavioral|CAIPaDi|Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, dentists, psychiatrist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement.
46075982|NCT02779218|Procedure|Paired Associative Stimulation|Patient with Paired Associative Stimulation only
46075983|NCT02779218|Procedure|Paired Associative Stimulation + Motor Imagery exercises|Patient with Paired Associative Stimulation + Motor Imagery exercises
46075984|NCT02779218|Procedure|Placebo Paired Associative Stimulation + Motor Imagery exercises|Patient with placebo Paired Associative Stimulation + Motor Imagery exercises
46075985|NCT02858531|Other|data retrieval|data retrieval with the Hospital Information System
46075986|NCT04249154|Drug|Eligard|Eligard dose of 22.5mg given, 50Gy in 20 treatments of radiation therapy to start 12 weeks after first injection concurrent with second injection of Eligard
46075987|NCT02779140|Biological|NTM-1632|Monoclonal antibody mixture of XB10, XB18, and XB23
45658083|NCT05285761|Behavioral|Provision of extended information on the conduct of complementary feeding|"Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.~In addition to the paper brochure and the generic information, parents in the intervention group will also receive the new recommendations relating to CF through an educational device (in the form of a smartphone application). This app will deliver information and very short videos illustrating various aspects of responsive feeding during CF and taking up the themes of the paper brochure. These 106 messages will be delivered regularly from the 3rd months until the 36th months of the child."
45658084|NCT05285761|Behavioral|Provision of current official information on complementary feeding|Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will also receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.
45676375|NCT03598595|Drug|Docetaxel|Given IV
46075988|NCT02779140|Other|Placebo|Placebo
46075989|NCT00914433|Drug|TPI 1100|1 dose only increasing dose
46075990|NCT04228146|Behavioral|Cognitive Behavioral Therapy for Insomnia|"Immediate access to the self-help CBT-I treatment, content of which is based on the translated Chinese version of a well-established CBT-I treatment manual entitled Insomnia: A Clinician's Guide to Assessment and Treatment. CBT-I aims at changing dysfunctional cognitive beliefs and maladaptive behaviors that contribute to the maintenance of insomnia. The self-help CBT-I treatment is delivered in Chinese language in six consecutive weekly modules via a smartphone application known as proACT-S. Duration of each module is around 45 to 60 minutes."
46075991|NCT04228146|Other|Waitlist Control|Delay access to the self-help CBT-I treatment.
46075992|NCT02857361|Drug|Sublingual ketamine wafers|Two sublingual ketamine 25 mg wafers
46075993|NCT02606175|Other|Taking questionnaires and tests|"At predefined timepoints:~2 tests for health literacy: New Vital Sign-Dutch version (NVS-D) and Functional, Communicative and Critical Health Literacy (FCCHL)~1 test for medication adherence: BAASIS~1 questionnaire about demographic factors (weight, income, sex, age, financial situation,...)~1 test about medication knowledge"
46075994|NCT02778282|Other|MySafeRx™|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
46075995|NCT02857205|Other|Fecal samples|High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
46075996|NCT02778126|Drug|[¹⁴C]Prexasertib|Administered IV Infusion
46075997|NCT02778126|Drug|Prexasertib|Administered IV Infusion
45676376|NCT03598595|Drug|Gemcitabine|Given IV
45947038|NCT00347425|Drug|Olanzapine|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
45947039|NCT00347425|Drug|Risperidone|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
45947040|NCT00347425|Drug|Quetiapine|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
45947041|NCT00347425|Drug|Ziprasidone|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
45947042|NCT00126048|Drug|Atorvastatin|40mg tablet
46075998|NCT02606331|Procedure|Piezosurgery|Corticotomy cuts will be performed by this technique.
46075999|NCT02606331|Radiation|ER:YAG laser|Corticotomy cuts will be performed by this technique.
45947043|NCT00126048|Drug|Placebo|Placebo tablet
45947044|NCT00126087|Drug|dopamine|
45947045|NCT00347503|Drug|ketorolac 0.4%, bromfenac 0.09%|
45947046|NCT00347542|Drug|Vitamin D|
45658085|NCT05204875|Radiation|X-ray Velocimetry|X-ray Velocimetry (XV) technology images the motion of the lungs, determines airway volumes and measures regional lung ventilation during spontaneous breathing.
45947047|NCT00091052|Biological|sargramostim|
45947048|NCT00091052|Radiation|radiation therapy|
45947049|NCT00347581|Procedure|Base-in prism glasses for reading|
45947050|NCT00347581|Procedure|Placebo reading glasses|
46076000|NCT02834702|Device|Sinew acupuncture|The subject is asked to be on sitting posture. The skin around the needling points is disinfected with a 75% alcohol swap. A tube-guided, sterilized, disposal needle is then inserted (at a small angle to the skin) into the acupoint at 0.5-1 cun (depending on point location and body size of the subject). No needle sensation (deqi sensation) is required. A piece of surgical adhesive tape will be applied to the needle immediately after insertion.
45947051|NCT00126165|Procedure|radiotherapy|
45947052|NCT00347620|Device|spectacles|
45947053|NCT00347620|Procedure|Cataract Surgery|
45453381|NCT04321928|Behavioral|Personalized health education|Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive detailed individualized education regarding lifestyle changes based on their current habits.
45453382|NCT04321928|Behavioral|General health education|Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive general health education aiming towards improvement of these factors with general recommendations following the WHO principles.
45458419|NCT03257618|Drug|Temozolomide|"Treatment with TMZ will be given orally according to standard practices. The therapeutic schedule will be left at the investigator's discretion.~Patients will be followed every 3 months during the treatment period, at the end of the treatment with TMZ, 6 months after the end of TMZ, and then annually until tumor progression."
45658086|NCT05678413|Procedure|DVIU with paclitaxel injection|Cystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue. A 23 Fr Wolf (Vernon Hills, IL) injection scope and a standard injection needle was used to inject 30 mg/5mL of paclitaxel vial, 1.5 mL will be injected along the length of each incision into healthier appearing tissue for a total of 5 mL.
45658087|NCT05678413|Procedure|DVIU|DVIU
45658088|NCT05123365|Drug|N-Acetylcysteine|Given PO
45658089|NCT05678335|Drug|Hydroxychloroquine|Oral hydroxychloroquine 200mg twice daily for 12weeks.
45947054|NCT00421252|Drug|clopidogrel 600 mg|Clopidogrel load > 2hrs pre-angiography
45947055|NCT00421252|Device|arterial access sheath|randomize to 5Fr vs 6Fr
45947056|NCT00091091|Other|medical chart review|
45947057|NCT00091091|Other|questionnaire administration|
45947058|NCT00091091|Procedure|management of therapy complications|
45658090|NCT05678335|Drug|Tacrolimus|Oral Tacrolimus 1-2mg twice daily for 12 weeks.
45658091|NCT02582671|Drug|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
45658092|NCT02582671|Drug|Dasabuvir|Tablet
45658093|NCT02582671|Drug|Ribavirin|Tablet
45676377|NCT03598595|Drug|Hydroxychloroquine|Given PO
45947059|NCT00421291|Behavioral|Education|
45947060|NCT00126204|Drug|Doxycycline|
45947061|NCT00421330|Procedure|Open Aneurysm Repair|
45947062|NCT00421330|Procedure|Endovascular Aneurysm Repair|
45947063|NCT00426322|Device|bovine bone mineral particles (Bio-Oss®)|bovine bone mineral particles used for sinus augmentation prior to dental implant placement
45947064|NCT04705402|Drug|Mannitol|"Mannitol (Israeli Brand Name: Osmitrol) is in the osmotic diuretic pharmacologic categoryaccording to the American Hospital Formulary Service (AHFS) database. . During the procedure, volume of 2.8 cc / kg body weight of the solution bag (either mannitol or saline 0.9%) will be given. The bag itself will be covered so it cannot be identified which solution is in it and marked per patient.~Mannitol is injected by intravenous infusion using an I-vac pump and infused over 15 minutes."
45947065|NCT04705402|Drug|Saline|Study participants randomized to this arm will receive a 0.9% saline solution at a dose of 2.8 cc / kg, infused within 15-30 minutes prior to renal artery reperfusion through an existing intravenous access catheter (either through an central or peripheral intravenous infusion).
45947066|NCT00091130|Biological|HspE7|Given SC
45947067|NCT00091130|Other|placebo|Given SC
45947068|NCT00091130|Other|laboratory biomarker analysis|Correlative studies
45947069|NCT00126243|Drug|rituximab|
45947070|NCT00126243|Drug|CHOP|
45947071|NCT00426400|Drug|The cessation of anti-aggregative treatment for 10 days|
45947072|NCT00426439|Drug|Chloroquine|Chloroquine tablets gives as 50 mg/kg divided into 6 doses giver twice a day for 3 days.
45947073|NCT00426439|Drug|Artemether-lumefantrine (Coartem)|Will be dosed according to the recommendations of WHO. Will be given at time: 0 h, 8 h, 24 h, 36 h,48 h and 60 h. The dosage will be according to bodyweight of the child as follows: 5-14 kg: 1 tablet, 15-24 kg: 2 tablets, 25-34 kg: 3 tablets, < 34 kg: 4 tablets.
45947074|NCT00426478|Drug|Valsartan plus Hydrochlorothiazide (80mg/12.5mg)|
45947075|NCT00426478|Drug|Amlodipine (5mg)|
45947076|NCT04705519|Drug|Nab-paclitaxel Combined With Bevacizumab|Nab-paclitaxel 150mg/m2 ，iv drip, d1, Bevacizumab 5mg/kg, iv drip, d1, q2w.
45947077|NCT00126282|Behavioral|behavior therapy|
45658094|NCT05696977|Drug|Cyclosporine Capsule|Determination of the most appropriate weight based dose of Cyclosporine to achieve the target therapeutic drug level and response and its relation with fat percentage and lipid profile
45947078|NCT00126282|Drug|D-Cycloserine|
45810305|NCT04812912|Behavioral|QoL Questionnaires|All participants will respond to protocol questionnaires, which will include both validated questionnaires as well as non-validated ones. This design will allow for basic demographic, psychosocial and sexual-health-related data to be obtained.
45810306|NCT05069389|Other|Data collection|"Some data will be collected for all patients included :~specific treatment administered in COVID unit~dosages of treatment~inclusion in clinical trials~Evolution of French recommendations and the publication of scientific articles"
45947079|NCT04705714|Drug|Frankincense Extract|The phytochemical composition of the volatile components of the extract was identified by GC-MS analysis, Crystal violet assay to test inhibition of biofilm formation by the tested isolates,Light microscope and scanning electron microscope were used to examine the biofilms and they confirmed the reduction of biofilm formation by frankincense extract
45947080|NCT04705285|Device|Erbium Yag Laser|Subjets in the laser arm will undergo 2 sessions of vaginal erbium-yag laser, separated by a month
45947081|NCT04705285|Behavioral|Pelvic Floor Training|Patients allocated to pelvic floor training, are goin to undergo 10 sessions of pelvic floor exercises coached by an expert physiotherapist
45947082|NCT04705129|Drug|Zanubrutinib|160mg Bid, D1-21, po
45810307|NCT04232358|Drug|Corticosteroid injection|Corticosteroid injections are administered ultrasound guided in the bursa adjacent to the achilles tendon insertion every 4 weeks until symptoms resolve with at maximum of 3 injections.
45810308|NCT04232358|Drug|Local anesthesia injections|Local anesthesia injections are administered ultrasound guided in the bursa adjacent to the achilles tendon insertion every 4 weeks until symptoms resolve with at maximum of 3 injections.
45947083|NCT04705129|Drug|Tislelizumab|200mg, D1, ivgtt
45658095|NCT05696899|Other|STILL QuickTAB Medipack blended scent aromatherapy, manufactured by Soothing Scents|A resealable quick-tab dispenser with the 'therapeutic inhaled essential oils' lavender, bergamot, sweet orange, and ylang ylang.
45658096|NCT05051449|Drug|Ketamine Hydrochloride|Ketamine will be administered by a nurse in a 2-week treatment phase, during which participants will receive six IV infusions of 0.5 mg/kg (over 40-50 minutes) ketamine three times per week. Infusion days for patients will be on Mondays, Wednesdays, and Fridays, +/- 1 day. Ketamine infusions will take place at the UMB General Clinical Research Center (GCRC). The GCRC nurse will deliver ketamine within a private exam room. The infusions will last 40-50 min, and the participant will be observed by the GCRC clinical staff for 2 hours post-infusion. Vital signs will be monitored throughout the treatment; specifically, blood pressure, pulse ox and heart rate will be checked prior to treatment, q20 minutes during infusion, and q30-60 minutes after infusion for up to three hours.
45947084|NCT00126321|Drug|cladribine|2-chlorodeoxyadenosine, 2-CdA
45947085|NCT00426595|Drug|Administration of omeprazole suspension|
45658097|NCT05154721|Device|experimental Group - Mila-Learn|Eight tasks are used in Mila-Learn.
45658098|NCT05154721|Device|control Group - Mila-Placebo|Eight tasks similar to Mila-Learn are used in the placebo group
45947086|NCT00426595|Drug|omeprazole administered as a multi-unit-pellet system|
45947087|NCT00426673|Drug|Brivaracetam (ucb34714)|
45947088|NCT00426712|Biological|1018 ISS immunostimulatory oligonucleotide with HBV surface antigen|Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8
45658099|NCT02585713|Drug|Apixaban|Given PO
45658100|NCT02585713|Drug|Dalteparin|Given SC
45947089|NCT00426712|Biological|Hepatitis B Vaccine (Recombinant)|IM (in the muscle) injections on Day 0, Week 4, Week 8 and Week 24
45947090|NCT00091247|Drug|tetracycline hydrochloride|
45947091|NCT00091247|Other|placebo|
45947092|NCT00126360|Drug|Timing of Anastrozole in respect to radiotherapy|
45947093|NCT01058863|Drug|Albuterol Spiromax®|Albuterol Spiromax® delivers 90 mcg albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.
45658101|NCT02585713|Other|Questionnaire Administration|Ancillary studies
45658102|NCT05032495|Other|Surveys|Surveys to evaluate prior experience, opinions and intervention acceptability.
45658103|NCT05032495|Other|Focus group|To answer any questions and discuss topics covered in the standard presentation.
45658104|NCT05078671|Drug|Olaparib|olaparib treatment
45658105|NCT05078671|Drug|Cobicistat|Pharmacokinetic booster
45658106|NCT02579863|Biological|Pembrolizumab|IV infusion
45658107|NCT02579863|Drug|Lenalidomide|oral capsules
45810309|NCT00377507|Dietary Supplement|catechin extracts|catechin extracts solution
45810310|NCT05395494|Drug|D-Cycloserine|"Daily oral D-cycloserine 100mg during TMS treatments (20 days).~Other Names:~Seromycin"
45810311|NCT05395494|Drug|Placebo oral tablet|Daily oral placebo during the TMS treatments (20 days).
45810312|NCT05395494|Device|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
45947094|NCT01058863|Drug|ProAir® HFA|ProAir® HFA delivers 90 mcg of albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.
45947095|NCT01058863|Other|Placebo Inhaler|Placebo delivered in both the Spiromax® and HFA inhalers to maintain the blind and also to support the placebo treatment arm.
45947096|NCT00091286|Biological|HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine|
45947097|NCT00126399|Drug|doxycycline|
45947098|NCT00426790|Procedure|Positive end-expiratory pressure|
45947099|NCT01058395|Drug|Minocycline|Minocycline 800 mg loading followed by 200 mg Q12 or Minocycline 800 mg loading followed by 400 mg Q12 will be delivered in an open-label study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.
45947100|NCT00091325|Dietary Supplement|defined green tea catechin extract|
45947101|NCT00126477|Procedure|cognitive assessment|
46076001|NCT02834702|Device|Sham acupuncture|The procedure in the sham acupuncture group will be as similar to that of the acupuncture group as possible. In the sham acupuncture group, however, a mock plastic needle guiding tube is tapped on the surface of each acupoint (Ashi point and traditional acupoints) to produce some discernible sensation. A piece of adhesive tape is immediately applied to fix the needle on the dermal surface tapped, without needle insertion. In addition, a plastic tube-guided needle is superficially inserted at the sham point at less than 5mm in depth.
45810313|NCT00357721|Drug|Atazanavir Sulphate|Capsules, Oral, 200 mg, twice daily, 7 days.
45658108|NCT02579863|Drug|Dexamethasone|oral tablets
45810314|NCT00357721|Drug|Atazanavir Sulphate|Capsules, Oral, 300 mg, twice daily, 8 days.
45658109|NCT05053555|Device|high dose rate brachytherapy|diagnostic workup, staging, and treatment per the institution standard of care
45658110|NCT05053555|Device|high dose rate brachytherapy|reviewing historical patients who meet the above criteria for group A but did not receive HDRBT between 01/01/2000 and 1/01/2021
45658111|NCT05028517|Other|FMF Connect|The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.
45658112|NCT05028517|Other|Coaching|A text-based coaching module is added to the FMF Connect app. Coaches support continued use of the app and individualized goal setting.
45658113|NCT05678023|Other|Effect on contrast media depending on the time of its administratsion|CM is a common practice when it comes to the management of small bowel obstruction. However there is no consensus as when it should be administered
45810315|NCT00357721|Drug|Atazanavir Sulphate|Capsules, Oral, 400 mg, twice daily, 9 days.
46076002|NCT05052060|Other|Group A|19 patients will be treated with pelvic tilt exercises
46076003|NCT05052060|Other|Group B|19 patients will be treated with pelvic tilt exercises and facet joint manipulation.
45810316|NCT00377585|Biological|Fluarix|
45810317|NCT00377585|Biological|adjuvanted influenza vaccine|
45810318|NCT04227600|Drug|JR-171 (lepunafusp alfa)|IV infusion
45810319|NCT03504410|Drug|CPI-613 + High Dose Cytarabine and Mitoxantrone|CPI-613 + High Dose Cytarabine and Mitoxantrone CPI-613: 2000mg/m2, 5 doses once a day, days 1-5 Cytarabine 1gm/m2, 5 doses every 12hrs starting day 3 through day 5 Mitoxantrone 6mg/m2, 3 doses, once a day following the first, third and fifth doses of Cytarabine
45810320|NCT03504410|Drug|High Dose Cytarabine and Mitoxantrone|Cytarabine 1gm/m2, 5 doses every 12hrs starting day 3 through day 5 Mitoxantrone 6mg/m2, 3 doses, once a day following the first, third and fifth doses of Cytarabine
45810321|NCT03504410|Drug|Mitoxantrone, Etoposide and Cytarabine|"Mitoxantrone, Etoposide and Cytarabine~Etoposide 80mg/m over 60 minutes as a central line IV infusion; 6 doses Day 1 though 6 Cytarabine 1000mg/m2 over 3 hours as a central line IV infusion: 6 doses, Day 1 through 6 Mitoxantrone 6 mg/m2 over 30 minutes as a central line IV infusion: 6 dose, Day 1 through 6"
45947102|NCT00126477|Procedure|management of therapy complications|
45947103|NCT00126477|Procedure|psychosocial assessment and care|
45947104|NCT00126477|Procedure|quality-of-life assessment|
45947105|NCT00091481|Drug|Zemplar|
45947106|NCT00126516|Drug|Angiotensin II Receptor Antagonists|any dosage, frequency, and duration
45810322|NCT03504410|Drug|Fludarabine, Cytarabine, Filgrastim|"Fludarabine, Cytarabine and Filgrastim~Fludarabine 30mg/m2/day over 30 minutes as a central line IV infusion; 5 doses Day 1 though 5 Cytarabine 2g/m2 over 4 hours as a central line IV infusion: 4 hours after Fludarabine: 5 doses, Day 1 through 5 Filgrastim 5µg/kg/day by SQ or as per institutional guidelines starting from Day 1 through Day 5"
46076004|NCT05689281|Behavioral|Peer PrEP Navigation|Ecological momentary assessments to identify and address stressors related to social determinants of health (e.g., housing, substance use, mental health), and motivational interviewing to support participants' health care empowerment and progression along the PrEP continuum.
45810323|NCT03579186|Device|OKS|Optokinetic stimulation
45810324|NCT04243421|Device|Implantation|Soft tissue aesthetics, marginal bone level on CBCT
45658114|NCT05677945|Drug|3Mixtatin paste: Simvastatin mixed with modified triple antibiotic|"Drying the mucosa with gauze,topical anesthesia will be applied.~Administration of local anesthesia with vasoconstrictor.~Rubber dam isolation.~Caries removal & access cavity using a round bur mounted on a high-speed contra with coolant.~Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~Radicular section will be kept untouched,no instrumentation.~Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~Drying the access cavity with sterile cotton pellets.~Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier & condensed over orifices using a moist cotton pellet.~Cavity sealing with RMGI capsules.~Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement."
45676378|NCT03596606|Procedure|Manual Treatment|"The manual treatment will be adapted to each patient at the discretion of the therapist, being able to select all or part of the following osteopathic techniques in each session.~Soft tissue techniques.~Articulatory techniques applied at cervical level~Osteopathic manipulation techniques applied at the affected jaw/s.~Functional Indirect technique at the level of the affected jaw/s: For Type I or II diagnosis."
45810325|NCT02464969|Drug|Apixaban|Tablet or Solution
45810326|NCT02464969|Drug|Standard of Care|Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist. For subjects under 2 years of age, standard of care will be limited to unfractionated heparin or low molecular weight heparin.
45810327|NCT04739982|Device|GuessWhat Mobile App|The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
45810328|NCT05392530|Drug|Macitentan|Macitentan film coated tablets will be administered orally as per assigned treatment sequence.
45810329|NCT03559829|Device|RAPAEL Smart Glove|The RAPAEL Smart Glove is a commercially available, non-invasive biofeedback based system for distal upper extremity rehabilitation. The Smart Glove is very lightweight and allows for easy movement of all distal upper extremity joints. It is made of an elastomer material that is simple to maintain and clean. The Bending Sensor is a variable resistor that changes as it is bent. The sensor is a 9-axis movement and position sensor that consists of 3 acceleration channels, 3 angular rate channels, and 3 magnetic field channels that measure wrist movements. They are connected to a computer system which can accurately compute the amount of individual finger movements.
45810330|NCT03498014|Other|Pharmacogenetic analysis allowing personalized opioid prescription|Genotypic of patient to determine optimal opioid treatment (tramadol, codeine or oxycodone)
45947107|NCT00126516|Drug|Angiotensin-converting Enzyme Inhibitors|any dosage, frequency, and duration
45947108|NCT00091520|Drug|Nesiritide|
45947109|NCT04050462|Drug|Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks|Nivolumab 240 mg IV plus Cabiralizumab 4 mg/kg IV every 2 weeks combination therapy
45947110|NCT04050462|Drug|Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks|Nivolumab 240 mg IV plus BMS-986253 1200mg IV every 2 weeks
45947111|NCT04050462|Drug|Nivolumab 240 mg IV every 2 weeks|Arm 1 (control) Nivolumab 240mg IV every 2 weeks monotherapy
45947112|NCT02965040|Drug|Roxadustat|Oral
46076005|NCT02734719|Device|Bonestim|Bonestim is the multipad electrical stimulation device.
46076006|NCT02778048|Other|MRI (magnetic resonance imaging)|Assessment of the sphincter
46076007|NCT02778048|Other|US (ultra sound)|Assessment of the sphincter
46076008|NCT02778048|Other|FLIP (functional lumen imaging probe)|Assessment of the sphincter
46076009|NCT02778048|Other|HRAM (high resolution anal manometry)|Assessment of the sphincter
45947113|NCT04710888|Drug|use of basil extract gel in treatment of aphthus ulcer|This study aimed to evaluate the efficacy of basil extract (Ocimum basilicum) in the treatment of aphthous ulcers
45947114|NCT04710888|Other|muco adhesive placebo gel|mucoadhesive gel without drug which was used as placebo (contains tragacanth gum, alcohol, sodium benzoate, and distilled water) 4 times per day
45947115|NCT04710888|Other|no treatment|(i) had underlying systemic disease(s) or a history of immunologic disorder(s); (ii) were taking immunomodulatory agents or systemic nonsteroidal anti-inflammatory drugs < 1 month before study commencement; (iii) are smokers; (iv) are pregnant; (v) had a history of abusing drugs or alcohol; (vi) could not provide written informed consent.
45810331|NCT03498014|Other|Standard opioid prescription|Opioid prescription made without reference to patient genetic profile (tramadol, codeine or oxycodone)
45947116|NCT00400283|Drug|NNC 55-0414|
45810332|NCT02460133|Drug|Paritaprevir|
45658115|NCT05677945|Drug|3Mix: Modified triple antibiotic mix in propylene glycol|"Drying the mucosa with gauze,topical anesthesia will be applied.~Administration of local anesthesia with vasoconstrictor.~Rubber dam isolation.~Caries removal & access cavity using a round bur mounted on a high-speed contra with coolant.~Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~Radicular section will be kept untouched,no instrumentation.~Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~Drying the access cavity with sterile cotton pellets.~Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier & condensed over orifices using a moist cotton pellet.~Cavity sealing with RMGI capsules.~Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement."
45658116|NCT05650177|Behavioral|blended Mindfulness-Based Intervention (bMBI)|The blended Mindfulness-Based Intervention (bMBI) is a 24-week online course 'blended' with therapist support via video link. The entire course is completed online and requires no in person contact. The bMBI follows the general structure of Mindfulness-Based Cognitive Therapy (MBCT) with an added emphasis on the cultivation of self-compassion. The bMBI comprises of 9-themed sessions spread out over the 24-weeks. Each session involves: video instructions, written information, psycho-educational exercises, and guided meditation practices. Participants meditate for 30-minutes each day. Additional homework involves short daily activities designed to incorporate mindfulness into daily life and keeping a journal about experiences within and around the practices and exercises. The therapist sessions are every two weeks and last for 45-minutes and help participants overcome any problems they experience.
45658117|NCT04964947|Drug|Tobramycin Injection|80 milligrams of tobramycin diluted in 40 milliliters of normal saline
45658118|NCT05677789|Diagnostic Test|Medical observation|Likely suitable for home treatment
45658119|NCT05677789|Diagnostic Test|Supportive treatment (BSC)|Consider hospital supervised treatment
45658120|NCT05677789|Diagnostic Test|Intensive care management|Manage in hospital as severe pneumonia
45658121|NCT05677711|Device|ultimaster|Subjects who received Ultimaster stent will be included.
45658122|NCT02582515|Drug|D-cycloserine|
45658123|NCT02582515|Drug|Placebo|
45810333|NCT02460133|Drug|Ritonavir|
45810334|NCT02460133|Drug|Dasabuvir|
45810335|NCT02460133|Drug|Ombitasvir|
45810336|NCT02460133|Drug|Ribavirin|In genotype 1b individuals without cirrhosis, treatment will NOT include ribavirin.
45810337|NCT02220452|Other|music listening during anesthesia|In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia
45810338|NCT02220452|Other|absence of music listening during anesthesia|In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
45810339|NCT04735614|Device|Posthorax Thoraxbelt|The patients will be assisted to put on the ThoraxBelt after the surgery by our research member and will be asked to keep it on except for during showering through the whole study period.
45810340|NCT04256603|Drug|Gabapentin|Timing of gabapentin initiation
45810341|NCT04256603|Other|No gabapentin|No gabapentin
45947117|NCT03999138|Diagnostic Test|MRI|MRI studies (non-contrast) will consist of a free-breathing localizer (~10 seconds) followed by a free-breathing yarnball water density scan, for a total MRI time of < 3 minutes.
45947118|NCT01058005|Drug|BG00002 (natalizumab)|300 mg intravenous injection every 4 weeks
45947119|NCT01058005|Drug|interferon beta-1a|44 mcg subcutaneous injection 3 times per week
45947120|NCT01058005|Drug|glatiramer acetate|20 mg subcutaneous injection once daily
45947121|NCT00091559|Drug|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months|
45947122|NCT03952728|Behavioral|Intensive lifestyle intervention|Lifestyle intervention focused on weight loss through diet and physical activity
45947123|NCT03952728|Behavioral|Diabetes support and education|Behavioral intervention focused on diabetes support and education
45947124|NCT00426829|Drug|Bevacizumab|10 mg/kg by vein every 14 days +/- 2 days, starting on day 1.
45947125|NCT00426829|Radiation|Proton Radiation Therapy|3 Gy dose/fraction x 20 fractions.
45947126|NCT00426868|Other|Direct injection of ADRCs into the Left Ventricle|Dose escalation
45947127|NCT00426868|Other|Direct injection of placebo into the Left Ventricle|
45947128|NCT00426907|Procedure|Unlimited postoperative weightbearing|Unlimited postoperative weightbearing
45947129|NCT00426946|Drug|Reboxetine|
45947130|NCT00091598|Drug|Ambrisentan|
45947131|NCT05562336|Device|Optical coherence tomography angiography|Optical coherence tomography (OCT) is a noninvasive imaging method that uses reflected light to create pictures of the back of your eye
45458420|NCT03257618|Other|QoL, neurocognitive and psycholpathological assessment|This assessment will be performed at baseline, at 6 months, 12 months, 18 months, at the end of the treatment with TMZ, 6 months after the end of TMZ
45658124|NCT02579629|Drug|Ropivacaine 0.1%|Ropivacaine 0.1% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.1% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.1% ropivacaine for 72 hours post-operatively.
45947132|NCT00426985|Drug|Ketoprofen Topical Patch 20%|
45947133|NCT00427102|Drug|Oral MRX-1024|
45947134|NCT00427102|Procedure|Standard Fractionation Radiation Therapy|
45947135|NCT00427102|Drug|High-Dose Cisplatin Chemotherapy|
45947136|NCT05562219|Drug|QA108 granules|Take the medication as required for 24 weeks
45947137|NCT05562219|Drug|QA108 granules placebo|Take the medication as required for 24 weeks
45947138|NCT00427141|Drug|GSK580416|
45947139|NCT00091637|Drug|Pexelizumab|Pexelizumab (2 mg/kg) intravenous , bolus for 10 minutes once
45810342|NCT02975180|Device|FES|The MyndMove FES System (MyndTec Inc., Mississauga, ON) is a fully programmable FES device with eight channels. This system allows motor practice of 17 different reaching and grasping protocols. The muscles stimulated may include the anterior, middle and posterior deltoid, biceps and triceps brachii, flexor digitorum superficialis and profundus, extensor digitorum, thenar eminence, lumbricals, and interossei. The sophistication of this system is unique. In contrast, many of the MyndMove stimulation protocols involve activation of small muscles that are used for fine motor control. The second FES device that will be used is the Odstock 2-channel Stimulator (FES Mobility Ltd., Vancouver, BC). While less sophisticated than the MyndMove system, it is smaller and more portable.
46076010|NCT02834858|Biological|Umbilical Cord Mesenchymal Stem Cells|stem cell acquisition, processing and reinfection, to evaluate the efficacy by using umbilical cord mesenchymal stem cells
46076011|NCT02834858|Biological|saline|
46076012|NCT05050500|Drug|Dapagliflozin 10mg/Tab|patients meeting inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 6 months
46076013|NCT05050500|Drug|Placebo|patients meeting the inclusion criteria will be randomized to receive a placebo tablet every 24 hours for 6 months.
45658125|NCT02579629|Drug|Ropivacaine 0.2%|Ropivacaine 0.2% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.2% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.2% ropivacaine for 72 hours post-operatively.
45810343|NCT02975180|Behavioral|Conventional|Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
45810344|NCT03545334|Diagnostic Test|Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD)|Injection of ICG intradermally around the scar of the primary excision of the tumour and transcutaneous assessment of fluorescence with the VS3-3DHD camera (Visionsense™ VS3 - Stereoscopic High Definition Visualisation System ).
45947140|NCT00091637|Drug|Placebo infusion|bolus infusion over a 10 minute period once
45947141|NCT00427180|Device|Retinal Implant System (IRIS)|AIMD - Active Implantable Medical Device designed for artificial electrical neural stimulation of photoreceptor degenerated retina
45947142|NCT00427258|Drug|MOA-728|
45947143|NCT05562102|Biological|Typbar-TCV, Bharat Biotech|Typhoid conjugate vaccine
45947144|NCT00427375|Procedure|local rectal excision|New surgical option in good responders after neoadjuvant treatment for low rectal cancer
45947145|NCT00427375|Procedure|total mesorectal excision|standard surgery
45947146|NCT00427414|Drug|liposomal daunorubicin citrate|40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
45947147|NCT03929718|Drug|Spironolactone|receive spironolactone treatment after CTI ablation
45947148|NCT03929718|Drug|No Spironolactone|no spironolactone treatment
45947149|NCT01056640|Device|Intel Health Guide|The Intel Health Guide is an FDA approved device that is placed within the patient's home and is connected to the health system via broadband internet, 3G network or phone line.
45947150|NCT01056640|Other|Usual Care|The usual care intervention will include appropriate primary care and specialty office practice visits as required.
45947151|NCT03906318|Drug|Iticitinib|
45947152|NCT01056523|Drug|Ribavirin|Dose level 1 = 1000 mg po BID/ Dose level 2 = 1400 mg po BID/ Dose level 3 = 1800 mg po BID
45947153|NCT01056523|Drug|Cytarabine arabinoside|Previous cohorts at 20 mg bid days 1 to 10 of every 28 day cycle. Dosage modified to 10 mg bid days 1 to 10 of every 28 day cycle for more recent cohorts.
46076014|NCT02232737|Other|Very low nicotine content cigarettes|
46076015|NCT04226196|Device|Implantation of an intraocular lens|Implantation of an intraocular lens Zeiss 409 MP into the capsular bag using an injector, after removing of the human crystalline lens.
45458421|NCT02317666|Procedure|Medication Review|A structured 5-step multidisciplinary medication review (STRIP method) as described in the multidisciplinary guidelines by the Nederlands Huisartsen Genootschap (2013) including the objective to reduce the DBI, performed by the pharmacist in collaboration with the general practitioner
45947154|NCT00091676|Biological|FNHLId1|5 monthly vaccinations over a 6 month time period consisting of 0.5 mg ID-KLH s.c. on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
46076016|NCT04272359|Drug|Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas|"Substitution of sulfonylureas with other classes of new hypoglycaemic drugs. In every group, it will be evaluated:~efficacy in terms of glycometabolic compensation (glycemia, HbA1c, lipid profile);~effects on BMI, blood pressure monitoring and hypoglycemic risk;~changes in renal function and microalbuminuria;~tolerability and side effects of the new therapeutic regimes;~therapeutic adherence;~post-prandial glycemic excursion, determined by a 6-point glycemic diary (pre- and 2h post-prandial glucose values) to be performed at home in the week before the scheduled follow-up visit;~effects on chronic complications of diabetes and cardiovascular safety."
46076017|NCT02834468|Drug|DEX Combined With RTX, CSA and IVIG|The investigators are undertaking a multicenter trial of 100 primary ITP adult patients from 5 medical centers in China. All participants receive dexamethasone (given orally at a dose of 40 mg per day for 4 days), rituximab (given intravenously at a dose of 500mg once), cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days) and intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months) for the treatment of adults newly diagnosed ITP patients.
45810345|NCT05721313|Procedure|root resection|It will be carried out under local anestesia. Intra-crevicular or para-marginal gingival incision will be carried out and full-tickness mucoperiostal flaps will be raised to expose the affected roots. Whit the use (if possible) of a surgical stent an incision will be performed on the root to be removed. Biodentine will be used for retrogade obturation. The flaps will be sutured.
45658126|NCT02579629|Drug|Normal saline|Normal saline will be administered as a single bolus dose of 8ml of normal saline followed by an infusion of normal saline using the On-Q® elastomeric pump. The bolus dose of 8ml of normal saline will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr normal saline for 72 hours post-operatively.
45947155|NCT00091676|Biological|KLH + GM-CSF|5 monthly vaccinations at month 1, 2, 3, 4, and 6 consisting of 0.5 mg KLH s.c on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
46076018|NCT02777814|Drug|Entecavir|anti hepatitis B virus
46076019|NCT00914511|Drug|avanafil 200mg|single dose tablet of 200mg avanafil
45947156|NCT00427453|Biological|MVA85A|
45947157|NCT04705207|Procedure|reflexology massage|the patient receive only foot reflexology massage
45947158|NCT04705207|Procedure|sham massage|the patient receive only foot traditional massage
45947159|NCT04704778|Combination Product|Transcutaneus electrostimulation therapies|"Sterile steel acupuncture needles of 0.25x13mm, disposable AcuBEST brand, and portable electro-stimulator equipment KWD- will be used. The superficial area of the skin of the masseter muscle will be cleaned with alcohol.~Two needles will be placed in each masseter muscle, the area to be punctured is the origin of the masseter muscle or superficial area of the mandibular condyle anterior to the atrial tragus approximately 1cm away, insertion of the masseter muscle at the angle of the mandible. The two double alligator cables will be connected to the head of the needles. The positive pole will be connected at the origin of the masseter muscle and the negative pole at the insertion.~The parameters to be used will be are two frequency bands (210Hz-10140Hz.); amplitude 3050 volts, pulse duration: 40100 msec; and the output intensity: 0.70 (for 100Hz). The treatment time will be 20 minutes."
46076020|NCT00914511|Drug|avanafil 200mg|single tablet dose of 200mg avanafil
46076021|NCT04430192|Drug|177Lu-PSMA-617|Patients 1-10 will be given 5GBq of 177Lu-PSMA. Patients 11-20 will be given 2 cycles of 5GBq of 177Lu-PSMA, separated by 6 weeks.
46076022|NCT02778906|Drug|Abatacept|Administration of Abatacept s.c. 125mg/weekly according to the Label for Rheumatoid arthritis
46076023|NCT02778906|Drug|Placebo|Administration of the comparator s.c. weekly in comparable to verum
46076024|NCT00630929|Drug|Ibuprofen|800 mg oral tablet 3 times daily with meals for 6 weeks
46076025|NCT00630929|Drug|Placebo|Matched placebo orally for 6 weeks
45658127|NCT02579629|Device|On-Q ® elastomeric pump|The On-Q® elastomeric pump automatically and continuously delivers a regulated flow of 0.1% or 0.2% ropivacaine or normal saline locally to the surgical site for 72 hours post-operatively. The infusion will be delivered by pre-setting the On-Q® elastomeric pump to deliver at the rate of 8ml/hr for 72 hours post-operatively.
45658128|NCT05677555|Drug|Colchicine 0.5 MG|A total of 25 subjects will be randomized to treatment with COLCHICINE 0.5 mg, three times a week (at the end of each hemodialysis session) over the 3 month study period.
45658129|NCT05677555|Drug|Placebo|A total of 25 subjects will be randomized to treatment with matched placebo, three times a week (at the end of each hemodialysis session) over the 3 month study period.
46076026|NCT00630929|Drug|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
46076027|NCT02508363|Behavioral|questionnaires|
45810346|NCT00362492|Procedure|Bilateral ultrasound examination 7+/- 2 after surgery|
45810347|NCT03560141|Device|LID011121 contact lens|Investigational silicone hydrogel contact lens
45810348|NCT03560141|Device|Comfilcon A contact lens|Commercially available silicone hydrogel contact lens
45658130|NCT04832971|Drug|ARO-ANG3|ARO-ANG3 Injection
45947160|NCT04704778|Combination Product|Percutaneus electrostimulation therapies|"Kendall® MediTrace 100 conductive adhesive ECG electrodes (pediatric) 2.4 cm in diameter, and portable KWD-808 electrostimulator equipment will be used.~The superficial area of the skin will be cleaned, two electrodes will be placed on each muscle (superficial area of the mandibular condyle and at the angle of the jaw). The current leads will then be connected to the KWD-808 electroacupuncturist to the patient.~Current will be transmitted with a square waveform, 210Hz-10140Hz of frequency, 3050 volts of amplitude and 40100 msec pulse time. The treatment time will be 20 minutes."
45947161|NCT04704778|Diagnostic Test|Oclusal splint|"The occlusal splint is worn 24 hours a day, removed for eating and brushing teeth. It is washed with neutral liquid hand soap.~For the preparation, an impression of the maxillary dental arches will be taken with alginate; It is made with acetate .060 and .080.~Relining is done with self-curing acrylic on the occlusal surface of the splint"
45947162|NCT04705090|Drug|YY-20394 treatment|Each treatment cycle is comprised of 28-day consecutive dosing of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if they are benefit from the treatment and the toxicity is tolerable.
45658131|NCT04832971|Drug|Placebo|Sterile Normal Saline (0.9% NaCl)
45658132|NCT05696821|Diagnostic Test|Educational intervention|The educational intervention includes a 3-months training program in the use of point-of-care ultrasound tailored to meet the educational needs of general practitioners. The training programs consists of three teaching seminars over a three month time period, a curriculum of 10 POCUS applications, and an online learning platform providing educational support before, during and after the teaching sessions.
46076028|NCT02838212|Drug|adverse drug reaction|drug-related death
45947163|NCT00091715|Drug|bosentan|65 mg tablet twice a day for 4 weeks followed by 125 mg tablet twice a day until end of study
46076029|NCT02497677|Behavioral|Circle of Security -Parenting|The COS-P manual and video material has been translated to Danish (Tryghedscirklen - Forældreprogrammet, manual, Lier, 2013). Based on standard video material of parent-infant interactions, parents are trained to see and understand infant attachment behavior and especially to learn about infant miscuing attachment signals. In the current study parents will attend 10 sessions of 1.5 hour duration
46076030|NCT02497677|Behavioral|Care as Usual|CAU are different in the three participating districts and vary in content and duration. All three districts offer (a) group interventions for mothers who experience postnatal depressive symptoms and/or (b) extra counselling home-visits by a health nurse. Number and content of extra home-visits vary in accordance with the families' specific needs, and will rarely exceed 12 extra visits per year.
45810349|NCT02199002|Device|multi-pH-impedance manometry catheter|a special catheter will be placed in the esophagus of all study groups. Measurment of pH, impedance and pressure will be performed.
45658133|NCT04906759|Behavioral|Meals plus exercise|Participants will receive 12 weeks of a MOW delivery service that will include 2 meals per day during the weekdays with 4 shelf-stable meals at the end of the week. The MOW driver will visit the participants in-person to ask a series of 5 questions about change in health status, joint/muscle injuries, new pain, falls, and poor appetite twice a week. Participants will also will receive an exercise kit from the MOW driver with their first meal delivery which will contain 2 tennis balls, 2 1-pound hand weights, and one towel. Every week, the driver will give the participants a handout containing 3 exercises from the NIA Go4Life Workout-to-Go book that are designed to help with strength/endurance, balance, and flexibility20. The participants will be asked to do the 3 exercises every day, if possible, on their own. Every 4 weeks during the 12-week study period and at 6 months follow up patients will have blood drawn for frailty and inflammatory biomarkers.
45810350|NCT04418700|Device|Breath Stacking|The patients will perform the maneuver through successive inspiratory efforts for 20 s. Subsequently, the expiratory branch will be unobstructed to allow expiration. This maneuver will be repeated 5 times in each series, with intervals of 30 seconds between them. The technique will be performed with the trunk inclined 30º in relation to the horizontal plane, in 3 series, with interval of 2 min completing 15 min of therapy.
45810351|NCT05721079|Device|ECP (Extracorporeal Photopheresis System)|After the cells have been inoculated with UVADE, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and the infused back into the patient.
45810352|NCT00362570|Drug|Temozolomide|"p.o.(by mouth), 150 mg/m2/d x days 1-7 and 15-21, given every 28 days [i.e., 7 days on/7 days off] using a standardized dosing range.~Administration: Temozolomide will be administered on an empty stomach (i.e., 1 hour before or 2 hours after any oral intake)."
45947164|NCT00091715|Drug|placebo|placebo for 6 months followed by an open-label period
45658134|NCT04906759|Behavioral|Meals only|Participants will receive 12 weeks of a MOW delivery service that will include 2 meals per day during the weekdays with 4 shelf-stable meals at the end of the week. The MOW driver will visit the participants in-person to ask a series of 5 questions about change in health status, joint/muscle injuries, new pain, falls, and poor appetite twice a week. they will be asked to continue their usual level of activity.Every 4 weeks during the 12-week study period and at 6 months follow up patients will have blood drawn for frailty and inflammatory biomarkers.
45658135|NCT04893265|Behavioral|Text Messaging Only|Active Comparator
45658136|NCT04893265|Behavioral|INFORMED|Experimental
45947165|NCT05561946|Device|Owlet OSS 3.0|The Owlet OSS 3.0 is worn continuously for a minimum of 48 hours and the skin where the device is worn is monitored for any skin injury/irritation
45947166|NCT04704817|Other|obsevation|prospective data collection for colonic or rectal surgery
46076031|NCT04204928|Drug|pralsetinib (BLU-667)|Pralsetinib will be administered orally (PO) at a dose of 400 mg once daily (QD) in continuous 28 day cycles
46076032|NCT05212116|Drug|SDI-118|SDI-118 is presented as low dose, and high dose capsules.
46076033|NCT05212116|Drug|Placebo|The Matching Placebo for SDI-118 is mannitol in capsules.
46076034|NCT00952367|Other|Nasopharyngeal swab|Nasopharyngeal swab
45458422|NCT01363778|Drug|tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
46076035|NCT02834546|Biological|Sorafenib plasma concentration 4 weeks after treatment initiation|Sorafenib plasma concentrations will be assessed at 4, 8 and 16 weeks by high performance liquid chromatography. The pharmacology Unit of Bordeaux university hospital (Pr Molimard) is a French Center of reference for the dosage of TKI in the plasma
46076036|NCT02834312|Drug|Estetrol|All treatments (E4 [2.5 mg, 5 mg, 10 mg, 15 mg] capsule) will be administered once daily (QD) per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
45658137|NCT04874857|Other|Lavandula angustifolia, Rosmarinus officinalis L. and Origanum majorana L.|Massage application
45658138|NCT04874857|Other|Baby oil|Massage application
45658139|NCT05677477|Other|simulation training|A mother scenario with a baby with physiological jaundice will be implemented with the intervention group.
45658140|NCT04855357|Behavioral|Resident counselling|One hour, one-on-one counseling for residents
45658141|NCT04855357|Behavioral|Staff Training|A two-hour training for PSH staff on how to provide referrals to smoking cessation programs using materials previously developed from UCSF's 'Rx for change' curriculum for service providers, directed toward empowering PSH staff to provide referrals to local cessation services using the ask, advise, and refer approach. The training will address nicotine addiction, tobacco use among PSH residents, pilot data, brief cessation counseling (ask, advise, and refer), and local resources for cessation. Because PSH resident-PSH staff encounters will take place as part of routine care, the study team will request permission from a random sample of staff and resident dyads (n=40) to record these interactions to assess fidelity.
45658142|NCT05677399|Other|aquatic exercise and peloidotherapy|Treatment group received 30 minutes of aquatic exercise by a physiotherapist in a warmed up to 33° C tap water and 30 minutes of mud pack treatment at 42°C on both knees 5 weekdays for 2 consecutive weeks (totally 10 sessions).
46076037|NCT02834312|Drug|Placebo|1 capsule will be administered QD per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
46076038|NCT04227834|Behavioral|Health hygiene education|A cartoon video explaining the etiology, risk factors, clinical symptoms, treatment and prevention of helminthiasis were given to the school-aged children
46076039|NCT02831738|Dietary Supplement|Polydextrose|Polydextrose 12 g
45658143|NCT02343939|Drug|Entospletinib|Tablet(s) administered orally every 12 hours
45658144|NCT02343939|Drug|Daunorubicin|60 mg/m^2 administered intravenously daily on Days 1 to 3 for up to two 14-day induction cycles
45658145|NCT02343939|Drug|Cytarabine|100 mg/m^2 administered intravenously daily on Days 1 to 7 for up to two 14-day cycles
45658146|NCT02343939|Drug|Decitabine|20 mg/m^2 administered intravenously
45658147|NCT02343939|Drug|Azacitidine|75 mg/m^2 administered intravenously or subcutaneously
45658148|NCT02397447|Drug|Momordica charantia|Momordica Charantia: 2000 mg per day for three months
45658149|NCT02397447|Drug|Placebo|Placebo: 2000 mg per day for three months
45658150|NCT02397057|Drug|Injectafer|
45658151|NCT02397057|Other|Placebo|
45810353|NCT03562559|Other|Measurements Using Ultrasound|Ultrasound measurements will be made in 5 positions. The ultrasound probe will be measuring from a fixed external location of the thigh. The 5 positions include: external rotation, neutral, manual tissue external rotation, straight leg raise at 30 degrees and hip/knee flexion at 90 degrees.
45810354|NCT00357799|Device|VeinViewer|Using the VeinViewer, IV attempts will be made
46076040|NCT02831738|Dietary Supplement|Control Treatment|no polydextrose
46076041|NCT04883502|Biological|Blood sample collection|A blood sample will be collected at enrollment.
46076042|NCT04883502|Biological|Other biological sample collection|"The following biological samples will be collected during the first surgery:~1 blood sample~3 fragments of induced membrane~1 fragment of periosteum"
45458423|NCT02321410|Other|Contrast enhanced ultrasound of the carotid plaque|visual grading of neovessel
45658152|NCT02343549|Device|NovoTTF100A|
45658153|NCT02343549|Drug|Bevacizumab|
45658154|NCT02343549|Drug|Temozolomide|
45658155|NCT02343159|Drug|dimethyl fumarate|120 mg and 240 mg delayed release capsules
45658156|NCT02343159|Device|Medication Event Monitoring System (MEMS)|The MEMS automatically compiles drug dosing history data by electronically recording the date and time of each opening of the medication container
45658157|NCT02343159|Behavioral|Adherence counseling|A telephone call to discuss adherence and individualized strategies based on data collected via smart device (i.e., LCD reader)
45658158|NCT02395653|Drug|fentanyl|An opioid that has been administered parenterally as an anesthetic and analgesic for more than 20 years.
45658159|NCT01664923|Drug|Enzalutamide|160 mg, daily, by mouth.
45658160|NCT01664923|Drug|Bicalutamide|50 mg, daily, by mouth
45658161|NCT04778527|Drug|Dual Prevention Pill|a single over-encapsulated DPP containing a PrEP tablet and a COC
45658162|NCT04778527|Drug|PrEP tablet and a COC as two separate tablets|PrEP tablet and a COC as two separate tablets
45658163|NCT04743583|Device|Endosonography B-mode examination|Endobronchial ultrasound (EBUS) or Endoscopic with bronchoscope (EUS-B) B-mode examination and sampling, when indicated, of lymphadenopathy
45658164|NCT05696665|Other|conventional therapy|Patients will be kept on conventional therapy and no added drugs will be given
45658165|NCT05696665|Drug|Saffron and Chamomile|Patients will be given saffron and chamomile in capsule formulation twice daily
45658166|NCT05696665|Drug|Crocin and Apigenin|Active ingredients of saffron(Crocin) and Chamomile(Apigenin) will be given in capsule formultaion once daily
45810355|NCT04727970|Drug|Tricaprilin|Tricaprilin will be emulsified in infant formula/milk
45810356|NCT03459638|Other|Screening for DM, ASCVD, MetS and OSAS|Finger stick analysis, questionnaires and clinical measurements
45947167|NCT00427492|Drug|Magnesia|Tablet magnesia 500mg. 2 tablet 2 times a day for a week
45947168|NCT00427492|Drug|Placebo|
45947169|NCT00427531|Other|physiologic testing|
45947170|NCT00427570|Biological|BCG vaccine|
45947171|NCT00427570|Biological|biological therapy|
45947172|NCT00427570|Drug|fluorouracil|
45947173|NCT00427570|Drug|semustine|
45947174|NCT00427570|Drug|vincristine sulfate|
45947175|NCT00403299|Procedure|MDCT of the coronary arteries.|
45947176|NCT00427609|Drug|Bicillin L-A|Bicillin L-A administered intramusculary in a dose of 2.4 million units every three weeks or normal saline injection administered intramusculary in a dose of 3 cc every three weeks
45947177|NCT04704895|Dietary Supplement|Total parenteral nutrition|Total parenteral nutrition, TPN also starts from POD 1 and is delivered through a central venous catheter, with a target energy of 1.5 amino acids/kg/day reaching 30 kcal/kg/day
45947178|NCT04704895|Dietary Supplement|Enteral nutrition|NJEEN was defined as providing at least 50% of the nutritional requirements through the nasojejunal tube prior to the 5th day after surgery (POD) and having no parenteral nutrition for 72 hours or more.
45947179|NCT00427687|Drug|AGG-523|
45810357|NCT00357253|Drug|capecitabine|This is a dose escalation study. 375, 500, 650, or 850 mg/m2 capecitabine RDT is given orally daily in two divided doses approximately 12 hours apart beginning at the start of radiation therapy and continuing for 9 weeks. After a two week break, patients receive twice daily oral capecitabine, either 900 mg/m2 or 1250 mg/m2, approximately 12 hours apart for 14 days followed by a 7-day rest period for a total of 3 courses.
45810358|NCT00357253|Radiation|radiation therapy|Participants receive local radiation once daily, 5 days/week for 9 weeks for a total dose of 5580 cGy.
45658167|NCT04697563|Device|Laser|real laser beam administered
45947180|NCT00091910|Drug|Epoetin alfa|
45947181|NCT00427843|Behavioral|home exercise program for the hip abductor muscles|"All patients with knee OA will be taught a home-based exercise program for the hip abductor muscles during the initial visit. Patients will be instructed in the following program: contraction of the gluteus medius muscle during functional activities (gait, stepping sideways up on a step and standing on one leg); and side lying isotonic hip abduction exercises using graded resistance elastic bands positioned around the distal thighs.~The program will be performed 3 times per week for 8 weeks and subjects will record exercise frequency and level of resistance on exercise calendars. Follow-up visits will occur at the end of week 1 and week 4 for review and progression of exercises. A telephone follow-up call will occur for support and participants will be encouraged to call with any questions or concerns."
45810359|NCT05239104|Other|No intervention|This is an observational study with no intervention
45810360|NCT03563027|Behavioral|Social Incentive Gamification|Game-based intervention with points and levels
45810361|NCT03563027|Behavioral|Support Sponsor|Participants select a support sponsor to receive weekly updates on progress in the game
45947182|NCT00427882|Drug|ALFUZOSIN|
45947183|NCT04704622|Drug|Ketamine|ketamine intranasal injection,2 mg/kg, once, 30 min preoperative
45658168|NCT04697563|Device|Placebolaser|no laser beam admitted
45810362|NCT03563027|Behavioral|Financial Incentive|Participants receive a loss-framed financial incentive allocated upfront each week and financial incentives taken away each day the goal is not met
45658169|NCT04465201|Device|Impella CP with Smart Assist (Circulatory Support System)|Subjects will receive the Impella® with the Impella® Hemodynamics Platform prior to High risk percutaneous coronary intervention (HRPCI). Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be consented for follow-up through discharge from the index HRPCI admission.
45658170|NCT04403347|Dietary Supplement|Innovative Dietary Formulation (Patent ID: CN110250417A)|In addition to regular diets and usual care of hypertension, additional innovative natural dietary formulation derived from tartary buckwheat will be orally taken 3 times per day.
45810363|NCT03458546|Drug|Roflumilast|All patients will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days for a total of 6 cycles. All patients will receive a fixed oral dose of one 500 microgram (μg) tablet per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses of roflumilast.
45947184|NCT04704622|Drug|Midazolam|midazolam intranasal injection,0.2mg/kg, once, 30 min preoperative
45947185|NCT04704622|Drug|Dexmedetomidine|dexmedetomidine intranasal injection,1 μg/kg, once, 30 min preoperative
45658171|NCT04403347|Drug|Losartan 50mg per day|In addition to regular diets and usual care of hypertension, antihypertensive medication will be orally taken (Losartan 50mg per day).
45947186|NCT00091988|Behavioral|Lifestyle & Behavioral Change Program|Participants in the weight loss arm will receive an intensive group-based behavioral weight loss program. In the first six months of the intervention, all participants in the weight loss arm will be given skill-based diet and exercise prescriptions for weight loss and will be taught specific cognitive and behavioral skills to assist in the modification of their eating and exercise habits. Participants will meet weekly for 6 months in group sessions led by a nutritionist, exercise physiologist, or behaviorist and will follow a structured protocol. This intervention strategy is modeled on interventions that have been successful in other overweight populations and is similar to the programs implemented in our ongoing studies, such as Look AHEAD. With this intervention, women are expected to lose on average of 7-9% of their initial body weight.
46076043|NCT04883502|Diagnostic Test|Surgical waste collection|The pieces of polymethylmethacrylate surgical cement will be collected during the second surgery.
46076044|NCT04883502|Diagnostic Test|Radiological examination and functional exploration|A radiological examination and a functional exploration will be performed 6 weeks, 3 months and 6 months after the first surgery
46076045|NCT02857049|Other|Oral nutritional supplements (ONS) degustation|
46076046|NCT02831582|Dietary Supplement|Omega-3 Fatty Acid|Given PO.
46076047|NCT02831582|Other|Placebo|Given PO.
46076048|NCT02776332|Procedure|Manual Expression of Breastmilk|Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery
46076049|NCT00948857|Dietary Supplement|Dehydroepiandrosterone|25 mg PO TID
46076050|NCT00948857|Dietary Supplement|Placebo|Blinded placebo
46076051|NCT04227912|Other|Transversus abdominis plane block|Before surgery, Ultrasound-guided TAP block was performed preemptively to Group TAP patients.
45658172|NCT05677009|Device|BUFEO system|In the BUFEO Condition, the subject will receive oxygen through the BUFEO system.
45658173|NCT05677009|Other|Standard of Care|Standard Condition is the baseline apparatus utilized by the subject at the time of enrollment in the study. In the hospital setting, the supplemental oxygen delivery may come from compressed oxygen cylinders or liquid oxygen and is often delivered through a port in the facility wall at the bedside.
45658174|NCT05675761|Drug|Azorubine|Azovudine tablets, 1mg /tablet, 5 tablets, QD+basic treatment (14 days at most)
45658175|NCT05674357|Behavioral|Individualized Evidence-Based Therapy in Cancer (Patients)|"The intervention will mirror clinical care in psycho-oncology in which the therapist, collaboratively with their supervisor, will choose specific components of the following evidence-based treatments to administer based on the clinical presentation of the patient and referring problem.~Cognitive Behavioral Therapy (CBT)~Acceptance Commitment Therapy (ACT)~Mindfulness-Based Cognitive Therapy (MBCT)~Mindfulness-Based Stress Reduction (MBSR)~Meaning-Centered Psychotherapy (MCP)~Cognitive Behavioral Therapy for Insomnia (CBT-I)~CBT for pain~CBT for fatigue~CBT for nausea"
45658176|NCT05674357|Behavioral|Training in Individualized Evidence-Based Therapy in Cancer (Therapists)|Enrolled therapist participants will receive training in evidence-based therapies and deliver therapy to patient participants.
45658177|NCT01664533|Drug|Erlotinib|Erlotinib was supplied as tablets in the retail product Tarceva.
45947187|NCT00091988|Behavioral|Structured Education Program|Women randomized to the Structured Education Program will be invited to participate in hour long group educational sessions at months 1, 2, 3, and 4. At months 6, 9 and 15, the groups will meet again for group support sessions. The content of these education and support sessions will include information about weight loss, physical activity, healthy eating habits and general health promotion. The educational sessions will be delivered primarily in a group format, with individual make up sessions provided for participants who miss group sessions.
45947188|NCT00428155|Device|closure device placement|
45658180|NCT04661293|Biological|Autologous Muscle Derived Cells (AMDCs)|
45658181|NCT05673655|Drug|intraoral trigger point injection by botox|intraoral injection of trigger point of masseter muscle by botulinum toxin
45658182|NCT05673655|Drug|transcutaneous trigger point injection by botox|transcutaneous injection of masseter muscle by botulinum toxin
45658183|NCT05640193|Biological|Lifileucel (LN-144)|A portion of the patient's tumor is resected and serves as the starting material for manufacturing lifileucel. After preparative NMA-LD, patients are infused with their autologous TIL (lifileucel), followed by a short course of high-dose IL-2.
45658184|NCT05692297|Drug|Denosumab|The patients in the denosumab group received subcutaneous injection of denosumab 60mg once every 6 months for 24 months.
45658185|NCT05692297|Drug|Non-denosumab|Taken other medications, such as diphosphonates, active vitamin D and/or active vitamin D analogue, calcimimetics, calcitonin, estrogen receptor agonists, etc.
45947189|NCT00428194|Drug|cisplatin|40 mg/m^2 every 7 days during radiation
45947190|NCT00428194|Drug|erlotinib hydrochloride|Erlotinib escalating dose per schedule - 100, 125 and 150 mg/m^2 by mouth once a day beginning day 1.
46076052|NCT04227912|Other|Local anesthetic infiltration|Before surgery, Ultrasound-guided Local anesthetic infiltration to the surgical incision line was performed preemptively to Group Local patients.
46076053|NCT04227912|Other|Intravenous dexketoprofen|Before surgery, 50 mg intravenous dexketoprofen was performed preemptively to Group dexketoprofen patients.
46076054|NCT04270253|Procedure|Conservative therapy|Conservative therapy including aquatic exercises, land-based exercises, balneotherapy, TENS therapy
46076055|NCT04270253|Procedure|Manual therapy|End-range mobilization
45658186|NCT05696587|Other|Multimodal rehabilitation|"The multimodal rehabilitation program included comprehensive therapy 5 times a week during the 4 weeks between assessments. The therapy consists of:~Individual physical therapy focused on improving range of motion and alleviating pain in the affected limb;~Mechanical desensitization;~Transcutaneous electric nerve stimulation (TENS) electrotherapy;~Aquatherapy (arm or leg whirlpool bath of the affected extremity);~Graded Motor Imagery, including the Recognise™ app and mirror therapy;~Psychoeducation on relaxation and coping with chronic pain."
45658187|NCT05696509|Drug|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor.
45658188|NCT05696509|Drug|Isoflurane|Isoflurane was used as an anaesthetic in a dose of - 1.1-1.2 MAC
45658189|NCT05696509|Drug|Sevoflurane|sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC
45658190|NCT02584855|Drug|Ixekizumab|Administered SC
45658191|NCT02584855|Drug|Placebo|Administered SC
45947191|NCT00428194|Procedure|radiation therapy|standard (fixed) doses of pelvic irradiation (as determined by their radiation oncologist)
46076056|NCT02776254|Other|START|Point of care testing for rapid ART initiation
46076057|NCT02776254|Other|CAG|Community Adherence Group
46076058|NCT02776254|Other|UAG|Urban Adherence Group
46076059|NCT02776254|Other|FAST-TRACK|Prescription refill only
46076060|NCT02834156|Other|LP in a seated position then LP in a lying position|
45658192|NCT05654935|Radiation|Ultrasound for Carotid Arteries|"Cohort A: each subject will undergo two manual ultrasound image acquisitions by two different registered vascular sonographers who will be blinded to one another's images and findings.~Cohort B: each subject in Cohort B will undergo one manual ultrasound acquisition conducted at Rush University Medical Center."
45947192|NCT03769467|Biological|tabelecleucel|Tabelecleucel is an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
45947193|NCT03769467|Biological|pembrolizumab|pembrolizumab IV infusion
45947194|NCT00092183|Drug|MK0869, aprepitant / Duration of Treatment: 3 days|
45947195|NCT00092183|Drug|Comparator: ondansetron / Duration of Treatment: 3 days|
45947196|NCT00428233|Procedure|Leukemia cell harvest|Leukemia cells will be harvested either by: Blood draw, leukapheresis, bone marrow aspiration or surgery to remove the lymph node
45947197|NCT00428272|Drug|Lexatumumab alone|Dose escalation : 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
45947198|NCT00428272|Drug|Lexatumumab in combination|Dose escalation : 1mg/kg, 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
45810364|NCT05053945|Diagnostic Test|Esophagogastroduodenoscopy|"To set up a prospective study and registry (HAR-P) for patients with H. pylori infection, atrophic gastritis or intestinal metaplasia to evaluate their clinical features and outcomes. The objectives include:~Assess the short- and long-term patient outcomes of H. pylori patients~Characterize factors involved in the progression or regression of pre-neoplastic lesions, namely atrophic gastritis and intestinal metaplasia~Gather information for a better understanding on the efficacy and role of surveillance~Potential for the development of new screening/surveillance strategies and tools for better risk stratification of patients~Establish a biobank for H. pylori, atrophic gastritis and intestinal metaplasia patients"
46076061|NCT02834156|Other|LP in a lying position then LP in a seated position|
46076062|NCT02854787|Drug|Phenylephrine|A bolus of 100 mcg
46076063|NCT02854787|Drug|Norepinephrine|A bolus of 0,2 mcg/kg
45453383|NCT01332032|Behavioral|Reminder Letter|A letter sent to women reminding them that they are coming due or overdue for a mammogram. It contains a reminder that their doctor recommends mammography screening every 1-2 years; urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider. For women in the reminder letter only arm, who did not complete a mammogram within 12 months of the first reminder, a booster intervention (I.E. reminder letter) will be sent. The letter requests that a woman call in to schedule a mammogram, and reminds her that her PCP recommends she get one. Booster letters will be sent up to three times at annual intervals for those failing to get a mammogram
46076064|NCT02834234|Genetic|comparative genomic analysis|DNA and RNA extraction will be performed in Lyon University hospital (genomic platform) using commercially available kit. Percentage of tumors cells will be controlled by stained section before extraction. The CGH arrays will be realized on frozen samples in Lille (genomic platform). Pangenomic Agilent array will be used. Micro-array include 180000 probes. Analysis will be performed in Lille (genomic platform / department of BioInformatics) with Marie Brevet. Data will be processed from the log2 transformed data into normalization with the WACA method. Then copy number variation will then be identified with Circular Binary Segmentation. Copy number variations will be called as gain or deletion according to the log2 ratio distribution and the percent of tumoral cells. Using matched tumoral and normal DNA will eliminate Copy Number Polymorphisms. We will construct non supervised hierarchical analyses to study the classification of peritoneal mesothelioma based on copy number variation
45453384|NCT01332032|Behavioral|Reminder Call|A reminder letter (as in the 1st group) is sent. If a woman does not call in to schedule a letter, 2 weeks later, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offers to schedule a mammogram for her. For women in the reminder letter arm who did not complete a mammogram within 12 months of the first reminder, a booster intervention ( I.E.a reminder letter will be sent requesting that they call in to schedule a mammogram. The letter reminds her that her PCP recommends she get a mammogram. Those who do not respond within 7 days, will receive a scheduler call) will be repeated as necessary for up to 3 times.
46076065|NCT02776020|Device|CorrecDose Infrared Monitor|The monitor is attached to patient's wrist and ear in order to measure changes in propofol concentrations in blood
45458424|NCT02321410|Other|Dynamic contrast-enhanced carotid plaque MRI|quantitative analysis of gadolinium enchantment in a region of interest
45458425|NCT04175834|Drug|antihistamine|prophylaxis
45658193|NCT05654935|Radiation|Telerobotic Ultrasound for Carotid Arteries|"Cohort A: each subject will undergo two separate telerobotic acquisitions, in which the robotic arm will be controlled by two separate sonographers from Mount Sinai Medical Center (New York, NY). The sonographers controlling the robotic arm will be blinded to one another's images and to the images from the manual acquisition.~Cohort B: each subject will undergo one telerobotic ultrasound (in random sequence with the manual acquisition also performed for this cohort) acquired by a separate technologist than the technologist that acquired the subject's manual ultrasound. This acquisition will be conducted at Rush University Medical Center by a technologist blinded to the images of the manual acquisition technologist. Robotic acquisition will be manipulated from a different building at Rush University Medical Center using a broadband cellular internet signal (rather than the institutional intranet)."
45810365|NCT02386735|Drug|Placebo|Three days prednisone 40mg, two days placebo
45810366|NCT02386735|Drug|Prednisone|Five days prednisone 40mg.
45458426|NCT02324998|Drug|Olaparib|PARP Inhibitor
45458427|NCT02324998|Drug|Degarelix|Gonadotrophin releasing hormone blocker
45458428|NCT03500926|Device|total hip replacement - standard femoral stem|total hip replacement with standard femoral stem
45947199|NCT00428272|Drug|Interferon gamma 1b in combination|Dosing at the following for each lexatumumab dose level: .75mcg/m2/dose and 25mcg/m2/dose
45947200|NCT00428272|Drug|Gamma 1b potential expansion|Potential expansion (at 10mg/kg lexatumumab): 1.5mcg/m2/dose and 50mcg/m2/dose
45947201|NCT01580254|Drug|IOPIZE© Latanoprost eyedrops|patients will receive in each eligible eye one drop of IOPIZE© Latanoprost eyedrops once a day, in the evening (8pm), for two months
45810367|NCT04711590|Other|Microcirculation examination|Sublingual microcirculation images were recorded using an incident dark-field video microscope
45947202|NCT01580254|Drug|GALAXIA© Latanoprost eyedrops|patients will receive in each eligible eye one drop of GALAXIA© Latanoprost eyedrops once a day, in the evening (8pm), for two months
45947203|NCT01580254|Drug|Latanoprost RATIOPHARM© latanoprost eyedrops|patients will receive in each eligible eye one drop of Latanoprost RATIOPHARM© Latanoprost eyedrops once a day, in the evening (8pm), for two months
45947204|NCT00428311|Drug|Metformin|
45947205|NCT00428311|Drug|Ethynyl-estradiol plus cyproterone acetate|
45947206|NCT00092300|Drug|MK0966, rofecoxib|
45947207|NCT00092300|Drug|Comparator: valdecoxib|
45947208|NCT05561712|Other|Laboratory method validation|Test several sampling conditions
45947209|NCT00428350|Drug|Quetiapine Fumarate (Seroquel)|
46076066|NCT02831426|Device|Two-stage with Acellular Dermal Matrix (CELLIS® Breast)|After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by an ADM (CELLIS® Breast, MECCELLIS BIOTECH, 40 rue Chef de Baie, 17000, La Rochelle FRANCE) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
45658194|NCT02581891|Drug|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by individualized treatment intervals of between 8 to16 weeks based on protocol-defined anatomical criteria
45810368|NCT02975024|Device|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
45658195|NCT02581891|Drug|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by five 8-weekly doses (5 x 2Q8), then by individualized treatment intervals of between 8 to 16 weeks based on protocol-defined anatomical criteria
45658196|NCT04523857|Drug|Abemaciclib|Oral CDK4/6 inhibitor to target bone marrow disseminated tumor cells (DTCs)
45658197|NCT04523857|Drug|Hydroxychloroquine|Oral autophagy inhibitor to target bone marrow disseminated tumor cells (DTCs)
45810369|NCT02975024|Device|wound fluid measurement|Wound fluid at the wound margin is collected using filter strip and volumetrically measured by Periotron 8010 instrument.
45810370|NCT02975024|Device|quantitative determination of VEGF|For the quantitative determination of VEGF in the fourth day wound fluid sample the Human VEGF Quantikine ELISA Kit will be used.
45947210|NCT00428428|Drug|Isoproterenol|ISO 0.1 microgram/ml, 8 ml/min irrigation compared to saline irrigation
45947211|NCT00428467|Procedure|LV Apex Compression|
45947212|NCT00428506|Drug|albumin 4 gr/L ascites removed|albumin 4 gr/L ascites removed
45947213|NCT00428506|Drug|albumin 8 gr/L ascites removed|albumin 8 gr/L ascites removed
45947214|NCT00092339|Drug|MK0966, rofecoxib|
45947215|NCT00092339|Drug|Comparator: valdecoxib, placebo|
45947216|NCT03748017|Dietary Supplement|Placebo-Control Supplement|A once-daily oral dose of the placebo-control supplement will be consumed by adults for 14 consecutive days.
45658198|NCT02581345|Biological|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
45658199|NCT02581345|Biological|Humira|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
45658200|NCT05590507|Behavioral|Mindfulness Audio Recordings|A 5-minute audio file aimed to increase likelihood of experiencing positive affect associated with physical activity. Participants will listen to a mindfulness audio file at the beginning of each physical activity session they choose to engage in during weeks 2-4
45810371|NCT03170648|Device|Acupuncture|Acupuncture has been studied in clinical trials in cancer patients and has been shown to be helpful for management of pain, nerve damage from chemotherapy, and nausea
45810372|NCT03164486|Drug|18F-αvβ6-BP|Subjects will be injected once with up to 10 mCi of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 seconds).
45947217|NCT03748017|Dietary Supplement|Streptococcus-Containing Probiotic Supplement|A once-daily oral dose of the streptococcus-containing probiotic supplement will be consumed by adults for 14 consecutive days.
45947218|NCT00428545|Drug|Bevacizumab|Starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days
45947219|NCT00428545|Drug|Bortezomib|Starting Dose 0.7 mg/m^2 By Vein On Days 1 and 8 Every 21 Days
45947220|NCT01056484|Behavioral|Mindfulness Based Relapse Prevention for Alcohol Dependence|"All subjects receive outpatient standard of care (SOC) therapy for alcohol dependence. Experimental subjects also receive the Mindfulness Meditation Relapse Prevention ('meditation') intervention. The intervention is an extension of existing meditation-based therapies for stress, relapse prevention in addictive disorders, and depression. It has been patterned after Mindfulness Based Relapse Prevention and tailored to the specific needs of alcoholics. Its curriculum includes both meditation and traditional cognitive therapy relapse prevention components. The intervention consists of an 8-week, manualized meditation course (2 hours/week group sessions) guided by trained instructors. In addition, experimental subjects are asked to meditate at-home (30 min/day, 6 days/week) during the study."
45658201|NCT05579509|Drug|Midazolam and Fentanyl|Prior to the start of the nerve block, patients in Arm 1 will receive titrated pharmacological sedation with IV midazolam with a goal of achieving moderate sedation. If pain is felt despite subcutaneous lidocaine, IV fentanyl may be administered with a goal of achieving moderate sedation with analgesia.
45947221|NCT01056484|Other|"Wait-list control"|'Standard of care' (SOC) outpatient therapy for alcohol dependence is provided to all subjects through their outpatient treatment centers and as recommended by their regular providers. Subjects in the control group receive SOC only. Subjects in the experimental arm will receive the study meditation intervention in addition to SOC.
45947222|NCT00092378|Drug|MK0966, rofecoxib|
45658202|NCT05579509|Behavioral|Educational Reassurance|Patients in the nonpharmacologic group will receive intraprocedural education and reassurance without pharmacologic sedation. They will have the option to receive more pharmacologic sedation at any point during the nerve block (cross-over to titrated sedation group).
45658203|NCT04314661|Biological|Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|After Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
45658204|NCT04314661|Biological|Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome|After Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
45658205|NCT04314661|Biological|Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|Without Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
45658206|NCT04314661|Biological|Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome|Without Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
45658207|NCT04029337|Device|HighLife Transcatheter Mitral Valve Replacment|Transcatheter mitral valve replacement
45658208|NCT05696431|Other|Universal adhesives application|The adhesive will be used according to their manufacturer's instructions. Selective etching for enamel will be applied for 15 seconds, followed by rinsing and gentle air drying. Then, the adhesive will be applied to enamel and dentin and light cured using a light-curing unit for 20 seconds. The composite material will be incrementally applied, and each increment will be light cured for 20 seconds. The restoration will be finished and polished using finishing and polishing instruments.
45810373|NCT02068430|Drug|Riboflavin 0.1%|After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber.
45810374|NCT02068430|Other|UV-X™ Illumination System|When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture. The correct aperture setting will be selected for the size of the eye (7.5 , 9.5, or 11 mm), and the eye will be irradiated for 30 minutes, during which time instillation of riboﬂavin will continue (1 drop every 2 minutes). At the end of 30 minutes, the UV light source will automatically switch to the off position. The operator will keep track of irradiation time independently to conﬁrm the actual treatment time.
45810375|NCT03138512|Biological|nivolumab|Specified dose on specified days
45810376|NCT03138512|Biological|ipilimumab|Specified dose on specified days
45810377|NCT03138512|Drug|nivolumab placebo|Specified dose on specified days
45947223|NCT00092378|Drug|Comparator: diclofenac sodium, placebo|
45947224|NCT00092846|Drug|MK0803, lovastatin|
45947225|NCT00092846|Behavioral|Self-Management System|
45947226|NCT03705897|Other|Computerized Risk Stratification Tool|Implement a novel computerized risk stratification tool in Parkland community-oriented primary-care clinics that collects data directly from patients and uses a computerized algorithm system to generate their personalized guideline-based next steps in the screening regimen
45947227|NCT03705897|Other|Algorithmic Risk Stratification Tool|Implement a novel algorithmic risk stratification system in Parkland's endoscopy clinics that, based on test findings entered by colonoscopists, generates personalized guideline-based next steps in the screening regimen for patients with colorectal polyps removed at olonoscopy
45947228|NCT03705897|Other|Step completion assessment|Assess completion of guideline-recommended steps in personalized screening regimens, under-screening, and over-screening
45947229|NCT00092924|Drug|TRAIL-R1 mAb (TRM-1;HGS-ETR1)|
45947230|NCT00093002|Drug|Fulvestrant|250 mg & 500 mg intramuscular injection
45947231|NCT05561322|Other|Consultation involving pain evaluation, questionnaires and the Lasègue Manoeuver|Raising the lower limb with the knee in extension reproduces sciatica pain if there is an impression of discal pain with its origin at the roots of the sciatica nerve L5 and S1. This test is evaluated by the degree of elevation of the lower limb relative to the examination table. During the Lasègue manoeuvre the sciatica pain is improved during dorsal flexion of the foot.The doctor notes whether the Lasègue manoeuvre done on the healthy side exacerbates the pain on the opposite side. It is said that contralateral Lasègue sign is positive.
45947232|NCT05561322|Other|Magnetic Resonance Imaging of the lumbar spine|Sagittal proton density-weighted Dixon sequence on the lumbar spine and axial T2-weighted spin echo sequence on the lumbar discs.
45947233|NCT00093080|Drug|ridaforolimus|12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
45947234|NCT05561283|Diagnostic Test|Self-questionnaires|Self-questionnaires on satisfaction, burn-out, depression, anxiety, relational skills and sleep quality
45947235|NCT00093119|Drug|ABI-007|
45947236|NCT03573882|Drug|Voxelotor|300mg or 500mg Tablet, Oral, With or Without Food
45947237|NCT00093158|Drug|Angiomax (bivalirudin) anticoagulant|
45947238|NCT05561127|Combination Product|GIE Medical ProTractX3 TTS DCB|"The ProTractX3 Drug-coated balloon is a 0.035 guidewire compatible over-the-wire catheter."
45947239|NCT05561127|Other|Control|Standard of Care Endoscopic Dilation
45458429|NCT03500926|Device|total hip replacement - short femoral stem|total hip replacement with short femoral stem
45658209|NCT05696431|Other|universal adhesive with bioactive properties|The adhesive will be used according to their manufacturer's instructions. Enamel and dentin will be cleaned using clean and boost for 10 seconds, rinsed and gently dried. Then, the adhesive will be applied to enamel and dentin and light cured using a light-curing unit for 20 seconds. The composite material will be incrementally applied, and each increment will be light cured for 20 seconds. The restoration will be finished and polished using finishing and polishing instruments.
45810378|NCT03138512|Drug|ipilimumab placebo|Specified dose on specified days
45810379|NCT02440334|Drug|Optison|Optison is an ultrasound contrast agent. The agent is a blood pooling agent administered via catheter and provides improved ultrasound visualization of the vasculature.
45658210|NCT05696431|Other|Fluoride-releasing universal adhesive|Fluoride-releasing universal adhesive
45658211|NCT05696353|Combination Product|In-vehicle Device|The Azūga™ in-vehicle driving feedback technology, which consists of a pager-sized device plugged into the vehicle's on-board diagnostic port (installed in the teen's car) and a smart phone app (downloaded on the teen's smart phone), will be installed/downloaded. Three types of feedback will be provided to intervention teens: 1) Direct audio feedback from the installed device; 2) Detailed cumulative driving data via the smart phone app and study website; and 3) A customized biweekly driving summary report via study website.
45810380|NCT02065700|Drug|Filgotinib|Tablets administered orally
45810381|NCT03127592|Drug|Fixed Dose Combination|Fixed Dose Combination of Etodolac 400 mg + Cyclobenzaprine 10 mg
45810382|NCT03127592|Drug|Etodolac|Individual drug
45810383|NCT03127592|Drug|Cyclobenzaprine|Individual drug
45810384|NCT02974400|Behavioral|Internet-based, CBT-oriented, guided self-help|The self-help program includes sessions regarding (1) cognitive model, (2) sleep hygiene, (3) mindfulness, (4) meta-cognition, (5) coping with voice hearing, (6) persecutory ideation, (7) worrying, (8) self-esteem, (9) depression, (10) social competence, and (11) relapse prevention.
45810385|NCT03102554|Genetic|Return of Genetic Results|The results of testing for genetic causes of DSD/hypospadias will be returned to parents of subjects who elect to receive these results.
45810386|NCT02444234|Drug|Tedizolid PO|Participants will be randomized to receive tedizolid oral 200mg once daily for 3 days and crossed over to IV after a 1 week washout.
45947240|NCT03501498|Drug|Loperamide|Alters intestinal transit time.
45947241|NCT03501498|Drug|Senna|Alters intestinal transit time.
45458430|NCT02325076|Device|Spirodoc|A device to detect the physical condition of the lungs
45810387|NCT02444234|Drug|Tedizolid IV|Participants will be randomized to receive tedizolid IV 200mg once daily for 3 days and crossed over to PO after a 1 week washout.
45810388|NCT02444936|Drug|ZOSTAVAX|Shingles vaccine
45947242|NCT00093197|Drug|KAI-9803 for Injection|0.05 mg
45810389|NCT02445014|Device|MGH SECM Imaging Capsule|Imaging of the Esophagus using the SECM capsule and SECM Imaging system
45810390|NCT02445326|Drug|Dexamethasone|
45810391|NCT02445326|Other|Placebo Vehicle|
45810392|NCT02287831|Biological|umbilical cord mesenchymal stem cells|
45947243|NCT00093197|Drug|KAI-9803 for Injection|0.5 mg
45947244|NCT00093197|Drug|KAI-9803 for Injection|1.25 mg
45947245|NCT00093197|Drug|KAI-9803 for Injection|5 mg
45947246|NCT00093197|Drug|Placebo|
45947247|NCT05561049|Drug|Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens|Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens
45947248|NCT00424034|Drug|GSK1325760A|
45947249|NCT05561010|Drug|Intra-articular injection of bupivacaine in the knee joint|25 participants will be allocated to the bupivacaine arm.
45947250|NCT05561010|Drug|Intra-articular injection of placebo in the knee joint|25 participants will be allocated to the placebo arm.
45947251|NCT05559957|Behavioral|observation of delivery and neonatal outcomes|MONITORING THE DELIVERY MODE EITHER CESAREAN OR VAGINAL, BESIDE THE NEONATAL OUTCOME AND MORBIDITIES IN BOTH GROUPS
45947252|NCT00093236|Procedure|Early Periodontal Treatment|Subjects will receive scaling and root planing at baseline. Three weeks after initiation of the study, they will return and be re-evaluated for the need for periodontal surgery. If indicated, they will then receive definitive periodontal surgery over the next 4 weeks. At the 12-week time point, periodontal surgery will be reevaluated and further therapy provided as needed and make repeated visits as needed to achieve periodontal health.comprehensive periodontal treatment
45947253|NCT00093236|Procedure|Usual Dental Hygiene|Subjects will receive routine oral hygiene visits at the 3 and 12-week time points. After a 12-week period (24 week time point) to allow healing and resolution of a systemic inflammatory state, patients will return for follow-up measurements of periodontal parameters, vascular function and inflammation.
45947254|NCT05559216|Other|Plyometric Training|Plyometric training exercises are being given to the participants to see the changes after the 8 week period
45947255|NCT00093275|Drug|HP184|
45658212|NCT05696353|Behavioral|Expert-Delivered Parent Communication Training|An individualized virtual training in communication strategies about teen driving safety along with a booster session will be delivered by a traffic safety communication specialist to parents in the Feedback and Expert-Delivered Parent Communication Intervention Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
45947256|NCT03448107|Device|Silver Diamine Fluoride|Silver diamine fluoride (SDF)
45947257|NCT03448107|Device|Fluoride Varnishes|Fluoride varnish (FV)
45947258|NCT03448107|Device|Glass Ionomer|Glass Ionomer Sealants (GC Fuji IX)
45947259|NCT00093314|Drug|HuMax-CD20|
45947260|NCT03440970|Drug|Lysine Chloride|Patients will receive the study drug twice a day for 5 days.
45947261|NCT03440970|Other|Placebo|Patients will receive the placebo twice a day for 5 days.
45810393|NCT05721001|Device|Surgical Repair|In Frozen Elephant Trunk procedure, the proximal aortic arch is replaced with a dacron graft, and a thoracic stent graft, sutured to the distal end of the dacron prosthesis, is deployed antegradely into the descending aorta. This mostly one-stage alternative approach eliminates the interval mortality rate related to the conventional elephant trunk procedure. Moreover, it constitutes a solution in fragile patients who cannot safely complete a second major operation after surviving the first.
46076067|NCT02831426|Device|Two-stage with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)|After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by a Titanium Coated Polypropylene Mesh (TiLOOOP® Bra, pfm medical, ag Wankelstraße 60 ,50996 Köln GERMANY) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
45658213|NCT05696353|Behavioral|Peer-Delivered Parent Communication Training|An individualized virtual training in communication strategies about teen driving safety along with a booster session will be delivered by a peer trainer who is a parent of teen with traffic citation and has participated in the Feedback and Peer-Delivered Parent Communication Intervention Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
46076068|NCT02778828|Drug|Linezolid|adjustment of Linezolid of based on the AUC/MIC and % T> MIC for each patient to confirm the appropriateness, in light of the peak and residual, and the interest of the split doses more frequently performed in case of too low residual or toxicity.
46076069|NCT02831270|Procedure|Acute normovolemic hemodilution (ANH)|
46076070|NCT02831270|Drug|hydroxyethyl starch (HES 130/0.6)|
45810394|NCT04344457|Drug|Hydroxychloroquine|200 mg PO BID 7 days
45810395|NCT04344457|Drug|Indomethacin|50 mg PO TID 14 Days
46076071|NCT02831192|Biological|microtransplantation|HLA mismatched donor mobilized prepheral stem cell infusion
45810396|NCT04344457|Drug|Zithromax Oral Product|500 mg PO QD 3 Days
46076072|NCT02778984|Device|QuadraLite masks|The intervention is identical in the two group
45810397|NCT05720923|Device|Analysis with Ergometer|The analysis with the ergometer aims at assessing neuromuscular function
46076073|NCT02778984|Other|standard mask|
46076074|NCT02831114|Other|Acupuncture|Acupuncture uses tiny needles to promote blood flow, nervous system signaling, and brings the body back into homeostasis which the state of optimum functioning. Treatment for taxane induced peripheral neuropathy will consist of traditional acupuncture and will use points located in the foot (SP 3, ST 41, LR 3, K 3, GB 41), knee (SP 9, ST 36, K 10, GB 34), and arm (LI 11). Participants will continue to take their conventional therapy. Each acupuncture treatment will take place at Oriental Medicine Associates with trained acupuncturist, William Hendry. Each session should last about 30 minutes.
46076075|NCT02777736|Drug|Methotrexate|i.v. or intrathecal CNS prophylaxis
46076076|NCT04247360|Device|cuff pressure|maintaining cuff pressure according the groups
45458431|NCT05188430|Device|Medical Device (Kaptufat®)|"140 mg chitosan, 460 mg cellulose and 35.384 mg ascorbic acid for 1 tablet~Oral administration: 3 tablets twice a day before the main meals"
45458432|NCT05188430|Other|Placebo|Oral administration: 3 tablets twice a day before the main meals
45658214|NCT05696275|Behavioral|exercise|20-30 minutes of walking and elastic band exercise per day
45810398|NCT01920932|Drug|brentuximab vedotin|Given intravenously (IV).
45810399|NCT01920932|Drug|etoposide|Given IV.
45947262|NCT00093353|Drug|cefixime|
45947263|NCT00093353|Drug|irinotecan hydrochloride|
45947264|NCT00093353|Drug|temozolomide|
45658215|NCT05578885|Procedure|Bier block|patients in group a (n = 25) received 2% lidocaine3 mg/kg (maximum, 200 mg) for IVRA and 2 mL NaCl 0.9% IV , patients in group b (n = 25) received 2% lidocaine 3 mg/kg (maximum, 200 mg) plus 8 mg dexamethasone for IVRA and 2 mL NaCl 0.9% IV , and those in group c (n = 25) received 2% lidocaine 3 mg/kg (maximum, 200 mg) plus fentanyl IV
45810400|NCT01920932|Drug|prednisone|Given orally (PO).
45810401|NCT01920932|Drug|doxorubicin|Given IV.
45947265|NCT03393039|Behavioral|Negative Affect Task|fMRI stress task
45947266|NCT00093509|Drug|doxorubicin hydrochloride|To be dosed at 75 mg/m2 i.v. push every 4 weeks for 4 cycles. This treatment is optional and will not be used on all subjects.
45947267|NCT00093509|Drug|ifosfamide and mesna|2 gm / m2 ifosfamide mixed in 1000 cc D5W infused continuously over 24 hours daily for 6 days (144 hours); total ifosfamide dose 12 gm/ m2. For the day infusion only MESNA (sodium 2-mercapto-ethanesulphonate) is mixed with ifosfamide as above and given at 2.5 gm / m2 / 24 hours.
45947268|NCT00093509|Procedure|hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator|Patients will receive hyperthermia throughout the course of radiotherapy delivered once weekly for a total of 5 treatments. Each treatment will last 1-2 hours with a goal of delivering a cumulative thermal dose of 10-100 CEM 43˚T90.
45947269|NCT00093509|Radiation|radiation therapy|External beam megavoltage (≥ 4 MV) beams will be used at SSD, SAD ≥ 70 cm at a dose rate of > 100 cGy/min. Fraction sizes of 180 cGy will be used 5 times per weeks in a continuous course. Total dose will be 45 Gy + 10%, consistent with sites being treated.
45658216|NCT05575453|Other|Kvatchii Portal|Online education portal
45810402|NCT01920932|Drug|cyclophosphamide|Given IV.
45810403|NCT01920932|Drug|Dacarbazine(R)|Given IV.
45658217|NCT05629351|Other|Observational Group|"Demographic Data (Blood pressure, subcutaneous fat tissue, height, waist and hip circumference, and body weight, BMI (body mass index) and double product)~International Physical Activity Questionnaire (IPAQ)~Godin-Shephard Leisure-Time Physical Activity Questionnaire~The Dutch Eating Behavior Questionnaire~Pittsburg Sleep Quality Questionnaire~Perceived Stress Scale and Beck Depression Scale"
45810404|NCT01920932|Drug|filgrastim|Given subcutaneously (SQ) as clinically indicated.
45810405|NCT01920932|Other|quality of life assessment|Quality of life assessment will be done at initial clinical visit, and during chemotherapy, completion of therapy, then at 1 year, 2 years and 5 years. It should take no more than 15-20 minutes to complete. Participation is voluntary by participating institution and by participant.
45810406|NCT01920932|Radiation|radiation therapy|At the end of chemotherapy and recovery of blood counts, radiotherapy will be given to any involved nodes (if any) that are not in complete remission.
45810407|NCT05052853|Drug|NMDAE|Use of an NMDA enhancer for the treatment of prodromal schizophrenia .
45810408|NCT05052853|Drug|Placebo Cap|Use of placebo as a comparator
45658218|NCT05628883|Biological|TBio-4101|TBio-4101 is a tumor-infiltrating lymphocyte (TIL) product that involves the use of special immune cells called T-cells. A T-cell is a type of lymphocyte, or white blood cell.
45658219|NCT05628883|Drug|Cyclophosphamide|Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL over approximately 1 hour per day for 2 days.
45658220|NCT05628883|Drug|Fludarabine|Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 15 to 30 minutes for 5 days, prior to T-Cell infusion
45658221|NCT05628883|Drug|Interleukin-2|Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously every 8 to 12 hours beginning within 24 hours after T-cell infusion.
45810409|NCT05720845|Procedure|VESPA|Using Ventilatory strategy of prevent atelectasis for General Anesthesia.
45810410|NCT05720845|Procedure|conventional mechanical ventilation|Conventional mechanical ventilation for General Anesthesia.
45810411|NCT02978599|Drug|AVL-3288|daily for 5 days
45810412|NCT02978599|Drug|Placebo|daily for 5 days
45458433|NCT03497650|Device|Mirror Therapy|Mirror Therapy involved the patient sitting on a chair with a standard mirror placed between both legs with the reflective side of the mirror facing the non-affected leg. The patient is instructed to observe the reflection of the non-affected limb during the sessions. The patient was not given any instruction on the use of the affected limb.
45947270|NCT03200769|Device|CPAP active|CPAP PR1 Philips Respironics with a pression between 4 and 14 mm Hg
45658222|NCT05575219|Drug|Clonidine (without protocolized initiation)|Participants will be observed for dexmedetomidine withdrawal and clonidine will be started at clinician discretion.
45947271|NCT03200769|Device|CPAP placebo|CPAP PR1 Philips Respironics with a constant pression of 4 mm Hg.
45658223|NCT05575219|Drug|Clonidine (protocolized initiation)|"Observe participants without initiating clonidine with dexmedetomidine infusion time of 72-119 hours. To wean off dexmedetomidine, decrease the infusion by 25% of the starting dose every 6 hours.~Begin clonidine at 1 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion time of 120-167 hours. Decrease the dexmedetomidine infusion by 25% of the starting dose 1 hour after each dose of clonidine until off (wean every 6 hours).~Begin clonidine at 2 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion time of >/= 168 hours or with infusion time of 120-167 hours at doses >/= 1.1 mcg/kg/min. Decrease the dexmedetomidine infusion by 25% of the starting dose 1 hour after each dose of clonidine until off (wean every 6 hours)."
45658224|NCT04341571|Dietary Supplement|Probiotics|Probiotics capsules (lactobacillus acidophilus y bifidobacterium lactis) 400 mg 1 time at day before breakfast and one placebo capsule before dinner during 13 weeks. Homologated to the other intervention.
45658225|NCT04341571|Drug|Metformin|"Metformin capsules, 750 mg, two pere day before breakfast and dinner during 13 weeks.~Homologated to the other intervention."
45658226|NCT05568745|Device|Balloon for cervical ripening (Teleflex French Dufour catheter CH20 reference 174000)|Balloon catheter is inserted by a resident or a physician under visual control. The expected volume injected in the balloon probe is 60 mL. No traction is performed on the catheter. The catheter is left in place for a maximum of 12 hours.
45658227|NCT05568745|Drug|Oxytocin|Intravenous oxytocin addition (preceded or followed by epidural analgesia on patient's request) will be performed 6 hours after insertion of balloon catheter. Oxytocin is administered as an intravenous infusion (5 IU of oxytocin in 49 mL of 5% glucose*) at the lowest possible dose with the aim of achieving a maximum of three to four contractions per ten minutes. After appropriate uterine activity has been achieved, the rate of the oxytocin infusion is decreased or stopped.
45810413|NCT05720533|Drug|Disitamab Vedotin Combined With Sintilimab|Disitamab Vedotin injection：2.5mg/kg，IV，Q3W Sintilimab injection：200mg，IV, Q3W
45810414|NCT04744766|Procedure|major duct excision|2 methods of major/central mammary duct excision are compared as regard the outcome
45810415|NCT02145871|Other|standard fluid management|
45810416|NCT02145871|Other|fluid management guided by the EV1000|
45947272|NCT00093548|Biological|alpha fetoprotein adenoviral vector vaccine|
45810417|NCT01897688|Biological|Islet Cell Transplant|
45947273|NCT00093548|Biological|alpha fetoprotein plasmid DNA vaccine|
45810418|NCT02446496|Drug|Cefadroxil tablets manufactured by GSK|Cefadroxil tablets manufactured by GSK contains 1 mg of Cefadroxil
45810419|NCT02446496|Drug|Cefadroxil tablets manufactured by NP|Cefadroxil tablets manufactured by NP contains 1 mg of Cefadroxil
45810420|NCT04344691|Procedure|Rectus femoris stretching|Patient lying prone with the non-implicated leg outside the treatment table resting on the floor. Physical therapist flexes patients knee until tension is felt. In that position 5 seconds' isometric contraction is asked and physical therapist progresses in knee flexion range of motion until new tension is felt. After three contract-relax procedures physical therapist holds the range of motion for 30 seconds.
45810421|NCT00355693|Device|Pump for propofol delivery|
45810422|NCT02448368|Drug|RDEA3170,10 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
45947274|NCT00093548|Biological|sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant|
45947275|NCT05549895|Drug|Dexamethasone|8 mg intrathecally
45947276|NCT05549895|Drug|Bupivacaine Hydrochloride|0.5 % intrathecally
45947277|NCT00093587|Biological|anti-thymocyte globulin|
45810423|NCT02448368|Drug|RDEA3170, 2.5 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
45810424|NCT02448368|Drug|RDEA3170, 5 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
45947278|NCT00093587|Drug|busulfan|
45947279|NCT00093587|Drug|cyclophosphamide|
45947280|NCT00093587|Drug|cyclosporine|
45947281|NCT00093587|Procedure|allogeneic bone marrow transplantation|
45947282|NCT00093587|Procedure|peripheral blood stem cell transplantation|
45947283|NCT00093587|Radiation|radiation therapy|
45947284|NCT05549427|Other|Ventilation|Ventilation in ICU
45947285|NCT00093626|Other|Laboratory Biomarker Analysis|Correlative studies
45947286|NCT00093626|Drug|Sorafenib Tosylate|Given orally
45947287|NCT05543109|Drug|Fentanyl|1 mic/kg during induction of anesthesia
45947288|NCT05543109|Drug|Propofol|3mg/kg during induction of anesthesia
45947289|NCT05543109|Drug|Rocuronium|0.9 mg/kg during induction of anesthesia
45947290|NCT05543109|Drug|Sevoflurane|2-3% during maintanance of anesthesia
45947291|NCT05543109|Drug|Ropivacaine|0.25% Ropivacaine will be used at 1 ml/kg will be injected Ultrasound guided after induction of general anesthesia.
45947292|NCT00093665|Drug|cisplatin|
45947293|NCT00093665|Drug|fluorouracil|
45947294|NCT00093665|Radiation|radiation therapy|
45947295|NCT03144219|Diagnostic Test|Transcranial Doppler (TCD) ultrasound monitoring|TCD monitoring comatose patients in ICU looking for signs of impaired cerebral compliance
45810425|NCT02448368|Drug|RDEA3170, 10 mg|Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
45658228|NCT05568745|Drug|Misoprostol Oral Tablet|Patients will receive misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
45947296|NCT03144219|Diagnostic Test|Non invasive intracranial compliance monitoring|A sensor of cardiac beat by beat cranial dilation will be used for monitoring intracranial compliance, in non-invasive fashion.
45947297|NCT02964806|Dietary Supplement|Ordinary Diet|
45947298|NCT02964806|Dietary Supplement|Modified Atkin's Diet|
45947299|NCT02964806|Dietary Supplement|Ketogenic Diet|
45947300|NCT00093704|Drug|bortezomib + ganciclovir|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.
45947301|NCT01055314|Biological|Cixutumumab|Given IV
45947302|NCT01055314|Drug|Cyclophosphamide|Given IV
45947303|NCT01055314|Biological|Dactinomycin|Given IV
45947304|NCT01055314|Drug|Doxorubicin Hydrochloride|Given IV
45658229|NCT04314895|Drug|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles within a well-characterized particle-size distribution. Following PCA, NanoPac is filled into a clear 60mL Type 1, USP, clear-glass vial (306 mg/vial) as a powder fill of nanoparticulate paclitaxel, closed with a bromobutyl rubber stopper and aluminum crimp seal, and sterilized by gamma irradiation. Prior to administration at the hospital/clinic, NanoPac will be reconstituted with 1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP, to form a suspension. The suspension will be further diluted with 0.9% Sodium Chloride for Injection, USP to achieve the final clinical formulation.
45658230|NCT04302493|Behavioral|Mindfulness Based Stress Reduction (MBSR)|Participants randomized to the MBSR arm will undergo a standard 8 week course of MBSR taught by a psychologist trained in the MBSR protocol and encouraged to engage in additional individual mindfulness sessions using a cell phone application.
45658231|NCT04302493|Behavioral|Stroke Support Group (SSG)|As a control group, participants randomized to the SSG arm will participate in 8 weeks of weekly Stroke Support Group sessions to experience activity and socialization without additional mindfulness training.
45810426|NCT02448368|Drug|RDEA3170, 2.5 mg|Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
45810427|NCT02978365|Other|Questionnaires|Patients will fill self-reported functional shoulder scales (1. Western Ontario Shoulder Instability index - WOSI, and 2. Disabilities of Arm, Shoulder and Hand questionnaire - DASH), as well as a Fear Avoidance Belief Questionnaire (FABQ).
45947305|NCT01055314|Drug|Etoposide|Given IV
45947306|NCT01055314|Drug|Ifosfamide|Given IV
45810428|NCT02978365|Device|Isokinetic Strength Measurement|Isokinetic strength will be measured using a Biodex Isokinetic System 4.0 (Shirley, NY)
45810429|NCT05013307|Other|CASE|The Clinical Assessment for Sports Exertion (CASE) addresses the physical performance of athletes by quantifying physiological and symptomatic responses to dynamic exertion. It was developed by clinicians at the Baylor Scott and White Sports Concussion Program in an effort to identify specific system impairments in athletes who were unable to successfully demonstrate readiness for return to play protocols.
45810430|NCT02448914|Drug|TRIGEL|All patients will receive TRIGEL. Treatment order is determined by randomization.
45810431|NCT02448914|Drug|Duodopa|All patients will receive Duodopa. Treatment order is determined by randomization.
45810432|NCT03496662|Drug|BMS-813160|BMS-813160 will be supplied by Bristol Myers Squibb
45947307|NCT01055314|Drug|Irinotecan Hydrochloride|Given IV
45947308|NCT01055314|Other|Laboratory Biomarker Analysis|Correlative studies
45947309|NCT01055314|Drug|Temozolomide|Given PO
45947310|NCT01055314|Drug|Vincristine Sulfate Liposome|Given IV
45947311|NCT00093743|Drug|fludarabine phosphate|Given IV
45947312|NCT00093743|Drug|cyclosporine|Given IV or PO
45947313|NCT00093743|Radiation|total-body irradiation|Undergo TBI
45947314|NCT00093743|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
45947315|NCT00093743|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplantation
45947316|NCT00093743|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplantation
45947317|NCT00093743|Drug|mycophenolate mofetil|Given PO or IV
45947318|NCT02863926|Biological|Injection of cBMA aspirate into the index leg|Injection of cBMA into the anterior tibialis muscle and upper index leg of subjects scheduled for semi-elective BKA 7-21 days before surgery
45947319|NCT00093821|Drug|tanespimycin|Given IV
45947320|NCT00093821|Other|pharmacological study|Correlative studies
45947321|NCT00093821|Other|laboratory biomarker analysis|Correlative studies
45947322|NCT04704310|Behavioral|Enhancing exercise training for adults with COPD: The roles of peers and functional tasks|A proof-of-concept online 8-week exercise training program for adults with COPD that incorporates both a peer mentorship and a functional tasks component.
45947323|NCT00428623|Procedure|wound dressing|
45947324|NCT05529030|Behavioral|Salience of Omicron variant|The message mentions the Omicron variant, which can be a fear appeal or make salient the reason for the new booster
45947325|NCT05529030|Behavioral|Self-protection message|The message makes a reference to protecting one's self
45947326|NCT05529030|Behavioral|Other-protection message|The message makes a reference to protecting others (patients)
45947327|NCT00428662|Device|drug eluting nonpolymeric nanoporous stent|
45947328|NCT00400322|Drug|Valganciclovir (Valcyte)|
45947329|NCT00400322|Other|Placebo|
45947330|NCT00402870|Device|ProSeal LMA|ProSeal LMA vs Tracheal Tube
45810433|NCT03496662|Drug|Nivolumab|Nivolumab will be supplied by Bristol Myers Squibb
45810434|NCT03496662|Drug|Gemcitabine|Gemcitabine will be given as per routine care from commercial supply.
45947331|NCT00402870|Device|ProSeal LMA, Tracheal Tube|ProSeal LMA vs Tracheal Tube
45947332|NCT00093860|Drug|Propranolol|
45947333|NCT00402909|Drug|Nateglinide|
45810435|NCT03496662|Drug|Nab-paclitaxel|Nab-paclitaxel will be given as per routine care from commercial supply.
45947334|NCT01055197|Radiation|Prophylactic Cranial Irradiation|Prophylactic Cranial Irradiation (PCI) to the brain in ten once-daily fractions of 2.5 Gy, five days per week, for a total of 25 Gy.
45947335|NCT01055197|Radiation|Radiation Therapy|Radiation Therapy (RT) to locoregional and residual metastatic disease in 15 once daily fractions of 3.0 Gy, 5 days per week, for a total of 45 Gy
45947336|NCT00093938|Drug|Cranberry juice|
45947337|NCT02823366|Drug|Fenofibrate|
45810436|NCT03496662|Procedure|Biopsy|Pre-treatment, end of cycle 2, end of treatment for patients who progress or otherwise do not go to surgery, and surgery for patients who do go to surgery
45947338|NCT02823366|Drug|UDCA|
45947339|NCT00093977|Drug|darbepoetin alfa SF|"Frequency of dosing depends on frequency at randomization:~rHuEPO QW = darbepoetin alfa SF Q2W (dosing conversion table in protocol) rHuEPO biw or tiw = darbepoetin alfa SF QW (dosing conversion table in protocol) darbepoetin alfa RB = darbepoetin alfa SF at same dose and frequency PFS 10, 15, 20, 30, 40, 50, 60, 80, 100, 150, 200 or 300 mcg; Hb maintained between 11.0 - 13.0 g/dL"
45947340|NCT00094133|Procedure|hot flashes attenuation|
45947341|NCT00094133|Procedure|hypnotherapy|
45947342|NCT02813889|Device|SmarToyGym|"We aim to develop a SmarToyGym where sensitized, wireless toys are strategically hung and placed within reach of infants to elicit toy-oriented body and arm/hand movements. Each toy will be equipped with sensors capable of measuring the infant's grasping actions such as squeezing, pinching, tilting, etc.~A low-cost 3D motion capture system will be used to collect video data and the infants' reaching and body kinematics in response to the toys. A pressure mat will be used to measure postural changes to detect weight shifts, rolling, crawling and other movements away from the initial posture."
45947343|NCT00094250|Behavioral|Resistance and Aerobic Training|
46076077|NCT05026086|Other|pressure biofeedback|10 patients will be treated with isometric exercises and pressure biofeedback.
46076078|NCT05026086|Other|isometric exercises|10 patients will be treated with isometric exercises
46076079|NCT02836418|Drug|ATYR1940|ATYR1940 at a dose no greater than 3.0 mg/kg administered via IV infusion over 90 minutes once weekly.
45810437|NCT03496662|Procedure|Peripheral blood|-Cycle 1 Day 1 before treatment begins, after 2 cycles of treatment +/- 3 days of mandatory tumor biopsy, end of treatment for patients who progress or otherwise do not go to surgery, and no more than 24 hours prior to time of surgery (if applicable)
45947344|NCT05519007|Other|No-Rinse Solution (NS)|The surgical site will be irrigated with NS prior to closure,
45947345|NCT05519007|Other|Saline irrigation|The surgical site will be irrigated with Saline
45947346|NCT02964962|Device|29 mm LOTUS Edge™ Valve System|Transcatheter aortic valve replacement
45947347|NCT00094289|Drug|Disulfiram|
45947348|NCT02610855|Procedure|Spinal Fusion Surgery|Participants with severe scoliosis curves requiring spinal fusion surgery.
45947349|NCT02610855|Other|Bracing|Participants with scoliosis curves that require brace treatment for at least the next year. Braces include monitors to record hours of brace wear, as is current standard of care.
45947350|NCT02610855|Device|Tri-axial Accelerometers|Four monitors are place on the participant (waist, thigh, both ankles), attached with straps. Periods of static and dynamic activity are measured based on accelerations in three orthogonal directions for 4 day's time while participating in regular daily activities.
45947351|NCT02610855|Other|Shear Wave Elastography (SWUE)|SWUE is an ultrasound technique for noninvasively evaluating the mechanical properties (stiffness) of skeletal muscle tissue. A commercial ultrasound scanner (Aixplorer from Supersonic Imagine, France) with 2D real time SWUE will be used. The Aixplorer uses ultrasonic push beams to produce shear waves in tissue. The shear wave propagation speed is inherently related to tissue mechanical properties and is used to create a quantitative 2D elastogram of the tissue.
45947352|NCT00094367|Drug|Abacavir/Lamivudine|
46076080|NCT02775942|Biological|IMOVAC-POLIO|IMOVAC-POLIO (Sanofi Pasteur), liquid form composition: Type 1 (Mahoney) 40DU, Type 2 (MEF1) 8DU, Type 3 (Saukett) 32 DU, Subcutaneous route 0.5ml/dose, 3 doses, 4-week interval
46076081|NCT02775942|Biological|IPOVAC 1.5:5:5|IPOVAC- POLYVAC Vietnam Composition: Type 1: 1.5DU, Type 2: 5DU, Type 3:5DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
46076082|NCT02775942|Biological|IPOVAC, 3:10:10|IPOVAC- POLYVAC Vietnam Composition: Type 1: 3DU, Type 2: 10DU, Type 3:10DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
46076083|NCT02775942|Biological|IPOVAC, 6:20:20|IPOVAC- POLYVAC Vietnam Composition: Type 1: 6DU, Type 2: 20DU, Type 3:20DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
46076084|NCT02836340|Drug|2-Iminobiotin|The Investigational Medicinal Product (IMP) under study is 2-IB, which is a biotin (Vitamin H or B7) analogue and a selective inhibitor of neuronal and inducible nitric oxide synthase (NOS).
45947353|NCT05513118|Diagnostic Test|Periodontal clinical examination and gingival crevicular fluid, saliva, dental plaque, serum sampling|"Probing pocket depth was defined as the distance in millimeters from the gingival margin to the base of the gingival sulcus measured using a manual probe (Michigan 0 probe with Williams Markings) in all the teeth present except for third molars. Similarly, clinical attachment level (CAL) was measured as distance from cementoenamel junction to the base of pocket and recorded manually to the nearest millimeter marking on probe.~1 mililiter of saliva was obtained by each participant. Subgingival dental plaque was collected with sterile endodontic paperpoints from mesial sides of each natural teeth without a prostethic restoration. Gingival crevicular fluid samples were collected with absorbent paper strips. Serum samples were also collected at the time of visit."
45947354|NCT00094406|Procedure|Bronchoscopy|
45947355|NCT00094406|Procedure|Bronchoalveolar lavage|
45947356|NCT00094406|Drug|Endotoxin|
45658232|NCT02581189|Drug|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
45947357|NCT00094406|Drug|Carbon Monoxide|
45947358|NCT00094484|Drug|Cinacalcet HCl|
45947359|NCT02964936|Drug|roxadustat|Oral administration
45947360|NCT00094523|Drug|Fosamprenavir|Fosamprenavir
45810438|NCT05002309|Behavioral|Cognitive-Behavioural Therapy|"20 sessions of individual CBT are offered over 16 weeks, conducted 1-on-1, with a trained and supervised therapist. Participants will learn about the cognitive, behavioural, emotional, and environmental factors which contribute to maintaining their depression. They will apply skills to interrupt unhelpful cognitive and behavioural patterns and engage in guided exploration to improve self-understanding. CBT is a structured and collaborative treatment. Weekly homework will be used to maximize opportunities for practice and consolidation of new skills. The individual sessions can be combined with optional family/parent/partner sessions, depending on the situation and preferences of the participant. All sessions will be video-recorded to allow high-quality supervision, fidelity- and quality-assurance. This corresponds to evidence available for CBT for adolescents and young adults that is established as the best practice through rigorous trials."
45458434|NCT03497650|Other|Cross-Education of Strengthening.|Cross-education of strengthening involves training one side of the body with the intention of producing strengthening gains on both sides of the body. In this case the strengthening was done on the non-affected leg of each stroke patient.
45947361|NCT01054885|Drug|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
46076085|NCT02775786|Other|MRIs with and without intravenous contrast (up to 2)|Participants will undergo up to two MRIs with and without intravenous contrast. The first MRI will be performed using an extracellular contrast agent and the second 1-14 days later, with a macromolecular contrast agent. If patient cannot undergo the second MRI for any reason eg. not enough time before surgery, one MRI with either contrast agent will still be used for analysis.
45947362|NCT01054885|Drug|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
45947363|NCT01054885|Drug|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
45947364|NCT01054885|Drug|Placebo|Placebo
46002211|NCT04342494|Device|SilverCloud app +Enhanced Feedback +Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Silvercloud is an app designed to deliver cognitive behavioral therapy."
46076086|NCT04196244|Diagnostic Test|Abdominal or body CT with intravenous contrast|Abdominal or body CT with intravenous contrast
45658233|NCT02581189|Drug|Dasabuvir|Tablet
45658234|NCT02581189|Drug|Ribavirin|Tablet
45658235|NCT05569681|Drug|Bemiparin 3500|"Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals"
45658236|NCT05569681|Drug|Bemiparin 5000 IU|"Bemiparin sodium 5000 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals"
45658237|NCT00352027|Drug|Adriamycin®|Given IV on Day 1 of weeks 1, 3, 5, 7, 9 and 11.
45658238|NCT00352027|Drug|Vinblastine|Given IV, Day 1 of weeks 1, 3, 5, 7, 9 and 11.
45658239|NCT00352027|Drug|Nitrogen Mustard|Given IV, Day 1 of weeks 1, 5 and 9. Cyclophosphamide may be substituted if nitrogen mustard is unavailable.
45658240|NCT00352027|Drug|Cyclophosphamide|May be substituted if nitrogen mustard is unavailable. Given on Day 1 of weeks 1, 5 and 9.
45658241|NCT00352027|Drug|Vincristine|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
46076087|NCT04196244|Diagnostic Test|Abdominal or body CT without intravenous contrast (native CT)|Abdominal or body CT without intravenous contrast (native CT)
45658242|NCT00352027|Drug|Bleomycin|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
45658243|NCT00352027|Drug|Etoposide|Given IV on Days 1 and 2 of weeks 1-10.
45658244|NCT00352027|Drug|Prednisone|Given PO every other day of weeks 1-12.
45658245|NCT00352027|Biological|G-CSF|Given subcutaneously days 3-13, 16-26, 29-39, 42-52, 55-65, and 68-78 (as clinically indicated).
46002212|NCT04340921|Biological|COVID-19 exposure|Observation only
45947365|NCT05431374|Drug|Measurement Based Care (MBC)|"Patients in both groups will receive either open-label paroxetine (20-50mg/day) or open-label mirtazapine (15-45mg/day), within the therapeutic dosage range recommended by the US Food and Drug Authority (Paxil -Highlights of Prescribing Medication, 2022; Remeron -Highlights of Prescribing Medication, 2022). Paroxetine, a selective serotonin reuptake inhibitor, is chosen because it has been one of the most commonly prescribed antidepressants, and mirtazapine, an alpha-2 antagonist, is chosen because it has a different mechanism of action. The treating psychiatrists will decide which of the antidepressants and dosages to prescribe, as long as they were within the study's recommended dosage ranges.~patients in the MBC group will receive treatment according to a schedule that includes individualized starting dosages, dosage adjustment, and medication changes to minimize side effects, maximize safety, and optimize the therapeutic benefit for each patient."
45947366|NCT05431374|Drug|Control/Standard-care|Local medical, psychiatric and family medicine services provide routine care according to their clinical judgment and available resources. Standard-care will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of standard-care delivered to each participant. In current practice, MDD patients are not routinely referred for any psychological therapies in Pakistan. Standard-care in Pakistan largely comprises of pharmacotherapy.
46076088|NCT02836184|Drug|Nicotinic Acids|Nicotinic acids is administered at an initial dosage of 50mg four times daily in the first week. If no significant side effects detected, the dosage will be titrated to 100mg five times daily within the second week and last to the end of study.
46076089|NCT02836184|Drug|Calcium Carbonate|Calcium Carbonate 500mg per oral, twice a day
46076090|NCT04824144|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine will be administered by subcutaneous continuous infusion using a Continuous Ambulatory Delivery Device (CADD pump).
46076091|NCT02834078|Dietary Supplement|BGG|
45810439|NCT05002309|Drug|Antidepressant medication|The choice of antidepressants follows best-established evidence for treating depression in adolescents and young adults. We will offer treatment with fluoxetine, starting at 10mg a day, increasing to 20mg a day after 1 week if tolerated; a protocol established as safe and effective in adolescents and adults in multiple trials. Additional increases to 40 or 60mg will be possible based on positive effects and side-effects and clinical judgement, as recommended in this age group. In cases of intolerance or adverse reaction to fluoxetine, we will switch to sertraline (25-200mg) or escitalopram (5-20mg), two antidepressants licensed by the FDA for major depressive disorder in adolescents. Treatment will be optimized over 16 weeks, a time-frame comparable to the CBT arm. Pharmacotherapy will be managed and prescribed by qualified psychiatrists when starting treatment and reviewed after 1 week, 2 weeks and then in 2-weekly intervals for the remainder of the 16 weeks acute treatment period.
45810440|NCT05720065|Drug|Botulinum toxin type A|Randomized double-blind administration
45810441|NCT05720065|Drug|Isotonic saline 0,9%|Randomized double-blind administration
46076092|NCT02834078|Other|Placebo|
46076093|NCT05299268|Behavioral|Pain (hypertonic saline)|A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the dominant vastus medialis muscle 20 cm proximal from the basis of patella before performance of the 1x3 min Seated Isometric Knee Extension.
46076094|NCT05299268|Behavioral|No pain (Isotonic saline)|A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the dominant vastus medialis muscle 20 cm proximal from the basis of patella before performance of the 1x3 min Seated Isometric Knee Extension
45658246|NCT00352027|Procedure|Radiotherapy|Participants receive radiotherapy after completion of 12 weeks of Stanford V chemotherapy.
45658247|NCT05535127|Diagnostic Test|"Palpation with  laryngeal handshake technique"|Information alredy included
45658248|NCT05535127|Diagnostic Test|Palpation strategy plus sequential ultrasound|Information alredy included
45658249|NCT05535127|Diagnostic Test|Identification of the cricothyroid membrane with routine ultrasound|Information alredy included
45658250|NCT05601115|Procedure|Robot assisted therapy|In addition to the conventional treatment for 60 minutes in the RYT group, it was planned to perform robotic rehabilitation with a hand-finger robot [Amadeo (Tyromotion, Graz, Austria)] for 30 minutes, accompanied by a physiotherapist who is trained in the field of robotic rehabilitation and has at least 5 years of experience
45810442|NCT00363272|Drug|ispinesib|Given IV
45810443|NCT00363272|Other|laboratory biomarker analysis|Correlative studies
45810444|NCT00363272|Other|pharmacological study|Correlative studies
45947367|NCT00094562|Drug|Fish oil supplement|
46076095|NCT02775708|Device|Pillcam endoscopy system|
46076096|NCT02779062|Other|Interview|Interview
46076097|NCT02831036|Other|training program|subjects in the trial group will follow a training program which includes 3 times a week running on a treadmill.
46002213|NCT04340895|Other|Faecal Calprotectin Home Test|"A non-invasive, in vitro diagnostic test for the determination of FC levels in human stool samples in combination with the dedicated 'CalproSmart' smartphone application.~This test helps participants to self-monitor their FC levels at their own homes, ensuring an adequate and effective medical treatment regimen performed by the investigator."
46076098|NCT02831036|Other|VO2max test|each subject will perform 4 times VO2max test according to BRUCE protocol in order to evaluate his aerobic fitness.
45658251|NCT05601115|Procedure|Conventional Therapy Group|An exercise program consisting of 45 minutes of range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) and 15 minutes of NMES was planned, accompanied by a physiotherapist experienced for at least 5 years in stroke rehabilitation, in the conventional therapy group.
45810445|NCT04965649|Genetic|Phenotyping of total and innate CD8+T cells by flow cytometry|"Blood samples from patients in the active file of the Clinical Cytology and Cytogenetics Laboratory at Nîmes University Hospital will be analyzed (diagnosis already known). Samples will be representative of the different stages of the pathology.~For patients with a confirmed diagnosis of Chronic Myeloid Leukemia and Philadelphia+ Acute Lymphoblastic Leukemia), the remaining whole blood sample taken as part of the usual management will be sent for phenotyping of CD8+ TL (total and innate) by flow cytometry. Phenotyping will be performed on samples pooled at the end of the recruitment period."
45453385|NCT01332032|Behavioral|Counselor Call|Reminder letter s as above is sent. If subject does not call in to schedule within 2 weeks, second letter is sent with mammography educational booklet. Second letter reiterates reminder that PCP recommends screening. Has number to call to schedule. If subject does not schedule within 2 weeks, counselor will call. Protocol script includes tailored barriers counseling, correction of misinformation and motivational interviewing techniques. For those who did not complete a mammogram within 12 months of the first reminder, a booster intervention will be repeated annually for up to 3 times as necessary.Booster is reminder letter with pamphlet stressing the 4 reasons why women need regular mammograms.
46076099|NCT02831036|Other|spatial orientation test|each subject will undergo 4 spatial orientation tests during the trial (month between 2 tests), each test is composed of 5 following days in which the subject will wear virtual reality glasses (Oculus Rift DK2) and attempt to arrive different destinations in a virtual maze tasks (using xbox one controller). each day will be given 3 attempts, the duration of each attempt is 2 min.
46076100|NCT04193124|Diagnostic Test|transcranial doppler.|Daily monitoring of transcranial doppler until the disappearance of the intracranial vasosparm
46076101|NCT02830802|Other|Dr. Hauschka Med Mundspüllösung Salbei / cosmetics|"Supervised use over 6 weeks 1x/day additional to habitual oral hygiene protocol.~For an application fill the closure cap with the mouthwash. Rinse the mouth vigorously for 30 seconds, for easier timekeeping use the hourglass. Then spit out the mouthwash, do not rinse."
45810446|NCT04341974|Diagnostic Test|Serum creatinine|Will be described: 1) the number of patients actually screened with postoperative serum creatinine and 2) the number of patients actually screened with the same parameter at the long-term after surgery
45453386|NCT04291196|Other|VR-ECT 360o Video|Patients in the VR arm will be immersed in the ECT process in first person utilizing Google Cardboard headsets. Patients will experience in 360 entering the procedure room, IV insertion, pretreatment checks, anesthetic induction followed by induction of seizure, and recovery. The experience will also have voice-over narration simultaneously describing the procedure and its risks and benefits.
45453387|NCT04291196|Other|Standard Treatment|Patients will receive preparation for their ECT as per standard of care, i.e. a discussion with a Psychiatrist.
45658252|NCT05595655|Behavioral|Motivational Interviewing|Motivational Interviewing (MI) is a directive client-centred counselling approach for eliciting behavioral change by helping people to explore and resolve ambivalence. MI considers several critical factors to improving self-care in patients with HF and is based on brief interventions, which are feasible in several healthcare settings.
45658253|NCT04425265|Procedure|Plasma radiofrequency ablation|Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are completely removed through the bilateral nasal cavity. Then investigators use plasma radiofrequency ablation at low temperature to ablate the tumor tissue and normal tissue of the margin along the upper and lower surgical margin until no obvious tumor remained under the naked eye.
45658254|NCT04425265|Procedure|Electrocautery block resection|Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are continuously and completely removed through the bilateral nasal cavity. Then investigators separate the posterior part of the nasal cavity and the top wall of the nasopharynx along the bone of the nasopharyngeal fornix, cut the pharyngeal suture, and cut the two sides along the edge of the carina, and then merge along the anterior vertebral muscle surface to the midline incision. Along the the soft palate under the inferior margin, investigators horizontally cut the mucosa of the posterior wall of the nasopharynx, and completely frees the entire soft tissue of the posterior wall of the nasopharynx.
45810447|NCT02978287|Drug|BAVU Solution|Tissue preservation solution for transplantation
45810448|NCT05719831|Drug|vonoprazan fumarate + high dose amoxicillin（H-10d）|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 10d
45810449|NCT05719831|Drug|vonoprazan fumarate + low dose amoxicillin（L-10d)|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin1000mg/ time, 2 times/day, oral, for 10d
45810450|NCT05719831|Drug|vonoprazan fumarate + amoxicillin（H-14d)|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 14d
46076102|NCT02830802|Other|Placebo|"Supervised use over 6 weeks 1x/day additional to habitual oral hygiene protocol.~For an application fill the closure cap with the mouthwash."
46076103|NCT02775474|Drug|Use of Intraoperative Intravenous Methadone|The intervention group will be given intravenous methadone at a fixed induction dose (0,15 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
46076104|NCT02775474|Drug|Use of Intraoperative Intravenous Fentanyl|The active control group will be given intravenous fentanyl at a fixed induction dose (6 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
45658255|NCT05594641|Other|Remote ischaemic preconditioning|A tourniquet will be applied to the right arm and it will be inflated (3 cycles, each lasting 5 minutes, at a pressure of 200 mmHg); each cycle is followed by 5 minutes of resting
45810451|NCT05719753|Device|Camstent Coated Catheter|The Camstent Coated Foley Catheter is an all-silicone two-way Foley-type urinary catheter, to which a proprietary polymeric coating has been applied.
45810452|NCT05719753|Device|Standard Care|Bard Catheter
45810453|NCT01152541|Drug|Riboflavin/Dextran|Administration of riboflavin/dextran every 2 minutes for the duration of UV exposure
45810454|NCT01152541|Drug|Hypotonic Riboflavin|Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
45658256|NCT05594641|Other|Control|The tourniquet will be applied to the right arm but the cuff will be not inflated
45810455|NCT01638546|Other|Laboratory Biomarker Analysis|Correlative studies
45947368|NCT02530983|Other|Mayo Clinic Conduit Report Card Questionnaires|Patients will be asked to complete the Mayo Clinic Conduit Report Card Questionnaires at their one month surgical follow up visit and then every three months for 1 year after surgery, then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.
45947369|NCT00428701|Drug|Esomeprazole Sodium|
45453388|NCT01333904|Drug|PUR118|inhaled
45453389|NCT01341080|Drug|Varenicline|Varenicline 1mg twice daily for eight weeks after a one week dose escalation period.
45453390|NCT01341080|Drug|Sugar pill|1mg twice daily for eight weeks after a one week dose escalation phase.
45453391|NCT02886884|Drug|20 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
45453392|NCT02886884|Drug|100 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
45453393|NCT01333982|Other|Amoxycillin, Gentamicin|If referral fails, community management of neonatal sepsis according to clinical algorithm.
45658257|NCT05535049|Procedure|Non-surgical periodontal treatment|Full month non-surgical periodontal treatment procedure was applied to the periodontitis group.
45658258|NCT04686253|Other|not appliable|not appliable
45453394|NCT01333982|Other|Counselling|counselling of management of neonatal sepsis in the community according to clinical algorithm.
45458435|NCT05188352|Other|Chest physiotherapy|The program included diaphragmatic breathing exercises, thoracic expansion exercises, incentive spirometer exercises, and coughing techniques.
45810456|NCT01638546|Other|Placebo|Given PO
45810457|NCT01638546|Drug|Temozolomide|Given PO
45810458|NCT01638546|Drug|Veliparib|Given PO
45810459|NCT01000051|Drug|Eltrombopag|Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily.
45810460|NCT01000051|Drug|Placebo|Once a day, orally for 8 weeks.
45810461|NCT04693338|Other|Quality-of-Life Assessment|Ancillary studies
45810462|NCT04693338|Other|Questionnaire Administration|Ancillary studies
45810463|NCT04693338|Other|Supportive Care|Receive ICP tasks
45810464|NCT00709033|Biological|autologous or syngeneic PBTLs and EBV-CTLs|"Three dose levels are being evaluated namely:~GROUP 1~PBTL CD19CAR-28 zeta 2x10exp7 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp7 cells/m2~GROUP 2~PBTL CD19CAR-28 zeta 1x10exp8cells/m2 and EBV-CTL CD19CAR zeta 1x10exp8 cells/m2~GROUP 3~PBTL CD19CAR-28 zeta 2x10exp8 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp8 cells/m2"
45810465|NCT03480282|Other|Prognosis information and Provider Scripts|An individualized report including each patient's prognosis will be calculated by the Lee-Schonberg and will include information on patient life expectancy from Cho et al.'s US life tables. This report will be sent to the PCP three days before the patient visit. Example scripts for PCPs to use with patients when discussing life expectancy and stopping cancer screening will be sent with the patient prognostic information.
45810466|NCT04948489|Drug|norethindrone acetate (NETA)|5mg of the NETA capsule by mouth daily for 12 months
45947370|NCT00428779|Procedure|running during 24 hours without sleep|patients running during 24 hours without sleep
45947371|NCT00428779|Other|no sleeping|patients without sleep during 24 hours
45947372|NCT00428818|Drug|trimethoprim-sulfamethoxazole or doxycycline|
45947373|NCT05426967|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active rTMS
45947374|NCT05426967|Device|Sham rTMS|Sham comparator to active rTMS
46076105|NCT04248374|Other|Taste Intensity|Taste intensity with and without sour adaptation
46076106|NCT05158686|Device|Paclitaxel-coated Balloon dilation angioplasty|Paclitaxel-coated ballon dilation angioplasty proximal to CTO lesion after failed percutaneous recanalization
46076107|NCT05158686|Device|Non-coated Balloon dilation angioplasty|Non-coated ballon dilation angioplasty proximal to CTO lesion after failed percutaneous recanalization
46076108|NCT02835794|Drug|Omacetaxine|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
46076109|NCT02835794|Drug|Azacitidine|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
45947375|NCT01054846|Other|Bicycle helmet from Bell Sports Inc.|As described under the respective arm
46076110|NCT02835794|Drug|G-CSF|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
45947376|NCT01054846|Other|Bicycle helmet education only|As described under the respective arm
45947377|NCT00094640|Drug|Intramuscular Olanzapine Depot|
46076111|NCT02775396|Device|Spectacle lens|Wearing a spectacle lens design with corrective prescription power while playing computer game using an iPad tablet computer. Two lens designs were prescribed for each participant: the conventional single-vision lens and a new progressive addition lens designed for handheld digital device. Primary outcome measures were performed immediately after each lens delivery and one-month of lens wear.
45453395|NCT01334060|Biological|p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine|p.DOM-WT1-37: 1mg/dose/vaccine p.DOM-WT1-126: 1mg/dose/vaccine The DNA vaccine will be administered 6 times at 4 weekly intervals. Responders (Immunological but without molecular progression) may continue vaccination 3 monthly to maximum of 24 months. The vaccines will be injected intramuscularly (im) followed by electroporation (EP) into separate locations.
46076112|NCT02834000|Device|LiDCO rapid™ CNAP monitoring|LiDCO rapid™ CNAP monitoring allows through analysis of the arterial blood pressure trace to acquire information about CO, HR variability, SVR, SV and BIS during general anaesthesia.
45658259|NCT05551039|Other|Retrospective patient chart review|Retrospective patient chart review to be completed by mCRC-treating physicians. Data is collected through an online case report form (CRF); physicians provide case histories of mCRC patients who initiated regorafenib treatment in most recent 3 years (2019-2021).
45658260|NCT04685941|Drug|Drug-mediated hyperemia|Intracoronary bolus of at least 200 mcg of nitroprussiate or 500 mcg of intracoronary adenosine during 2 minutes. Operators are allowed to combine both drugs.
45658261|NCT04685941|Other|Flow-mediated hyperemia|Intracoronary saline infusion at 20 ml/min via dedicated microcatheter (RayFlow; Hexacath, France) during two minutes.
45453396|NCT04253834|Device|Incentive spirometer|The incentive spirometer is a device that measures how deeply a person can inhale (breathe in). It helps with taking slow, deep breaths to expand and fill the lungs with air, which helps prevent lung problems, such as pneumonia. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator to help users control their breathing.
45453397|NCT04253834|Device|GO2 Mouthpiece|The GO2 Mouthpiece is a simple, comfortable, and straightforward silicone rubber-made, bidirectional oxygenation mouthpiece that effectively delivers PEEP with every breath.
45453398|NCT04130828|Drug|Ferrous Fumarate|Ferrous fumarate 200 mg PO PC
45658262|NCT02576977|Biological|Pembrolizumab|pembrolizumab 200 mg IV infusion
45658263|NCT02576977|Drug|Pomalidomide|pomalidomide 4 mg capsules
45658264|NCT02576977|Drug|Dexamethasone|dexamethasone 40 mg tablets
45658265|NCT04421755|Other|Produce delivery|weekly home delivery of fresh fruits and vegetables
45810467|NCT04948489|Drug|Placebo|Placebo capsule everyday for 12 months
45810468|NCT03839953|Behavioral|Supervised Exercise Program|This intervention is a 12-week supervised exercise program at an established cardiac rehabilitation facility.
45810469|NCT03839953|Other|Best Medical Therapy|After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist. This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
45810470|NCT05222802|Drug|ERAS-801|Administered orally
45810471|NCT05719597|Other|PEP (Positive Expiratory Pressure)|Group A containing 12 participants, will perform Positive expiratory pressure (PEP) technique for total 60 repetitions (15 repetitions 2 sets, twice) per a day (5 sessions/week and total 4 weeks).
45810472|NCT05719597|Other|IS (Incentive spirometry)|Group B containing 12 participants, will perform Incentive spirometry technique for total 60 repetitions (15 repetitions 2 sets, twice) per a day (5 sessions/week and total 4 weeks).
45810473|NCT05715697|Procedure|Sham procedure and maintenance of heart failure medications|Sham intervention, maintenance of heart failure medications
45810474|NCT05715697|Procedure|Renal denervation and maintenance of heart failure medications|Renal denervation and maintenance of heart failure medications
45810475|NCT05719519|Procedure|Initial periodontal therapy and 3D intraoral scanning|Initial periodontal therapy using GBT ( guided biofilm therapy) principle and 3D intraoral scanning
45947378|NCT00428857|Procedure|non invasive ventilation|non invasive ventilation
45947379|NCT02415309|Drug|2 mg Melatonin|40 patients will randomly receive 2 mg melatonin
45947380|NCT02415309|Drug|10mg Melatonin|40 patients will randomly receive 10 mg melatonin
45947381|NCT02415309|Other|Placebo|40 patients will randomly receive a placebo/sugar pill
45947382|NCT00094679|Device|Eye patch|adhesive patch to cover the sound eye
45947383|NCT05394714|Biological|Magicell-NK contains NK cells suspended in 100 mL normal saline|Eligible subjects will be assigned into one of the three dose escalating cohorts (3+3 subjects/cohort) according to the time sequence enrolled
45947384|NCT00094718|Biological|WN/DEN4-3'delta30|Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)
45947385|NCT00094718|Biological|Placebo|Placebo for WN/DEN4-3'delta30 vaccine
46076113|NCT02836028|Drug|Talazoparib|Talazoparib monotherapy 1mg/day orally
46076114|NCT02836028|Drug|Temozolomide|temozolomide 37.5 mg/m2 on days 1-5 of each cycle
46076115|NCT02778672|Other|Thermal imaging of infant's chest with a mobile phone|
46076116|NCT01778946|Drug|Low Dose Nicotine (7mg)|
46076117|NCT01778946|Drug|Moderate Dose Nicotine (14mg)|
46076118|NCT04247204|Biological|Platelet-rich plasma intrauterine infusion|For all women, basic transvaginal sonography will be done in the 2nd day of frozen embryo transfer (FET) cycle and they will receive standard hormone replacement therapy (HRT) in the form of estradiol valerate tablets (white tablets of Cyclo-Progynova; Bayer Schering Pharma AG, Germany) at a dose of 4mg for 7 days then 6mg for 6 days. Endometrial assessment will be done on day 15 of FET cycle. Those with endometrial thickness between 8-14 mm will be evaluated for endometrial and sub-endometrial vasculature pattern by 3D power Doppler analysis. Then 1 ml of PRP (prepared from autologous blood) will be infused in the uterine cavity and vaginal progesterone 400 mg twice daily will be prescribed for 3 days. Subsequently, D3 embryos will be transferred. Endometrial, sub-endometrial and uterine arterial vascularity pattern will be re-evaluated on the day of ET. Both estradiol valerate tablets and vaginal progesterone will be continued up to 12th week of gestation in case of pregnancy.
45658266|NCT04421755|Other|Cooking classes|weekly home delivery of fresh fruits and vegetables participants will be invited to participate in a Culinary Medicine cooking series. The OU Culinary Medicine cooking curriculum will involve a 3-part class series designed to build nutrition knowledge and cooking self-efficacy for preparing fresh F/Vs. Each session is ~2 hr. Core nutrition guidelines for blood pressure and blood sugar management will also be emphasized informed by an evidence-based Conceptual Model of Healthy Cooking. Classes will be conducted in small groups (~16 participants) in an established teaching kitchen used by the culinary medicine program. Classes will be facilitated by a professional chef, a healthcare professional (dietitian, medical doctor, or trained medical student), and other support staff, including trained medical, dietetic, and public health students.
45658267|NCT04397185|Device|Breast Cancer Locator (BCL) guided partial mastectomy|The BCL is a patient-specific, plastic, bra-like form which is placed on the breast to localize the tumor during surgery.
45658268|NCT04397185|Device|Wire Localized (WL) partial mastectomy|Standard of care procedure
45658269|NCT05548777|Drug|Andexanet alfa|Andexanet alfa
45658270|NCT05548777|Drug|4F-PCC|Four-Factor Prothrombin Complex Concentrate (4F-PCC)
45658271|NCT05213845|Procedure|Spine flexion/extension active range of motion exercises|Five full active range of motion rehabilitation sessions will be scheduled. Four or the five following full active range of motion exercises will be performed during one rehabilitation session : spine flexion and extension (quadrupedic position), lumbar flexion and extension (sitting position), posterior and anterior pelvic tilt (sitting and standing position), lumbar flexion and extension (standing position) and Jefferson Curl exercise. All five rehabilitation sessions must be performed within 60 days
45658272|NCT05867316|Behavioral|Unified Protocol|Unified Protocol based treatment, modified for use in brief treatment on inpatient units
45658273|NCT05867303|Drug|RC198 Injection|RC198 injection will be administered subcutaneously on Day 1 of Week 1 to Week 4 (inclusive) of each 6-week (42-day) cycle.
45810476|NCT05719363|Device|Inogen One® G5 Portable Oxygen Concentrator|"The Inogen One® G5 POC is designed to provide a flow of high-purity oxygen. Inogen One G5 is a highly versatile and robust concentrator which offers patients the option to use up to 6 different flow settings.~The unit weighs just under 5 pounds. Utilizing an Intelligent delivery technology, the unit can provide patients with required oxygen therapy on a 24/7 basis. The Inogen One® G5 POC will be used for patients with chronic heart failure as an investigational device. It supplies a high concentration of oxygen and is used with a nasal cannula which channels oxygen from the concentrator to the patient."
45810477|NCT05723497|Other|Elderberry juice|Participants will consume elderberry juice 1-week.
45810478|NCT05723497|Other|Placebo beverage|Participants will consume placebo for 1-week.
45810479|NCT03833713|Behavioral|SMS Dialogue|Once-weekly SMS dialogue sessions or micro-interventions and use behavior change techniques (BCTs) including self-monitoring with performance feedback and goal support
45658274|NCT05867290|Behavioral|Mindful music-listening with sleep hygiene|5 week intervention consisting of sleep hygiene (week 1) and daily bedtime mindful music-listening for 30 minutes or until about to fall asleep, if sooner (weeks 2-5)
45947386|NCT05394051|Behavioral|Positive Affect Regulation sKills (PARK)|"The goal of the PARK program is to reduce feelings of anxiety, depression, and social isolation, as well as increase well-being and a sense of meaning and purpose through the practice of positive emotion skills via a self-guided online platform.~The total time involved from the beginning to the end of the intervention portion of the study is approximately 6 months (includes 6-week PARK course, baseline and follow-up assessments. Wait list controls will be assessed at similar time intervals and will be offered PARK at end of follow-up."
45453399|NCT01332110|Device|Knee abduction moment-reducing footwear|Patients in each study group will be asked to run using their assigned footwear at least 3 times per week (minimum 15 km per week) for six weeks. Each patient will document their perceived knee pain each week throughout the six week intervention.
45658275|NCT05867277|Other|music|The students in the intervention group listened to music for 15 min before and during the peripheral intravenous catheter placement skill practice.
46076119|NCT05224544|Device|Nautilus Catheter|The test product is a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
46076120|NCT05224544|Device|Comparator|The comparator is a urinary catheter for bladder drainage through the urethra.
45658276|NCT05867264|Other|Early drinking water|"After passing the evaluation by the anesthesiologist team in PACU, the EOF1 group drank 200ml of water.~The evaluation criteria for the anesthesiologist team are:~Steward's awakening score is ≥ 6 points.~Level of sobriety ≥ 3.~There is no need to wait for intestinal peristalsis, based on the patient's wishes, and the feeding should be completed within 2 hours after the surgery."
45658277|NCT05867264|Combination Product|Early consumption of carbohydrates|"After passing the evaluation by the anesthesiologist team in PACU, the EOF2 group had a drinking capacity of 200ml of 12.5% carbohydrates (100ml containing 12.5g of maltodextrin, fructose, and glucose).~The evaluation criteria for the anesthesiologist team are:~Steward's awakening score is 6 points.~Level of sobriety ≥ 3.~There is no need to wait for intestinal peristalsis, based on the patient's wishes, and the feeding should be completed within 2 hours after the surgery."
45810480|NCT03833713|Behavioral|SMS Assessments|Once-weekly SMS assessments of motor vehicle risks
45453400|NCT01332344|Drug|Fluticasone propionate/salmeterol combination|Asthma subjects newly prescribed fluticasone propionate/salmeterol combination
45658278|NCT05867264|Other|Late feeding group|After observing the vital signs for 30 minutes after surgery, patients in Group C were sent back to the ward to continue fasting and drinking for at least 6 hours. After the anus exhausts, they began to gradually drink and eat
45658279|NCT05867251|Drug|ARTS-021|ARTS-021 is a selective and potent oral inhibitor of CDK2 being developed for the treatment of patients with CCNE1-amplified solid tumors.
45658280|NCT05867251|Drug|CDK 4/6 inhibitor|Antineoplastic agents, cyclin-dependent kinase 4/6 inhibitor
45658281|NCT05867251|Drug|Fulvestrant 50 MG/ML Prefilled Syringe|Antineoplastic agent, estrogen receptor antagonist
45658282|NCT05867251|Drug|Letrozole 2.5mg|Antineoplastic agent, aromatase inhibitor
45810481|NCT05715619|Biological|VRELysin™|A cocktail of lytic Enterococcus-specific bacteriophages orally administered with sodium bicarbonate solution
45947387|NCT00094796|Procedure|Exercise cardiopulmonary metabolic testing|
45947388|NCT00094796|Procedure|Skeletal muscle biopsy|
45947389|NCT00094796|Procedure|Brachial artery reactivity testing|
46076121|NCT04227210|Biological|RSV vaccine MV-012-968 (dosage #1)|Single dose administered intranasally on Day 1
45453401|NCT01332344|Drug|Inhaled corticosteroids|asthma subjects newly prescribed inhaled corticosteroids in clinical practice
45453402|NCT01334138|Other|A 4-week diet, low in sodium.|"Study subjects receive personal advice to decrease sodium consumption and will change his diet for 28 days.~Follow up is performed by measuring blood pressure, a 24-hour urine sample collection, diaries and questionnaires."
45658283|NCT05867251|Drug|Carboplatin|Alkylating agent
46076122|NCT04227210|Biological|RSV vaccine MV-012-968 (dosage #2)|Single dose administered intranasally on Day 1
46076123|NCT02833766|Drug|anti-EGFR-IL-dox|First-line treatment with anti-EGFR-IL-dox, given at a dose of 50 mg/m2 intravenous, on day 1 of each cycle, cycle length is 28 days
45658284|NCT05867238|Other|Training stress management|The stress management training included 1 day and a half day. It was given by a therapist trained in transactional analysis and a trainer from the nurse anaesthetist school. The training was based on cognitive behavioural stress management training and the use of stress management exercises: cardiac coherence, mindfulness meditation, muscle relaxation, mental imagery.
45658285|NCT05867225|Procedure|Laparoscopic hiatal hernia repair|laparoscopic hiatal hernia repair has replaced the traditional laparotomic or thoracotomic approach, and has resulted in a reduction of length of hospital stay and morbidity, and increased patients' acceptance
45658286|NCT05867212|Drug|Cabotegravir Injection [Apretude]|People who want to get the long acting injectable will have the option in participating in surveys after their visit and have their electronic health records reviewed.
45810482|NCT05715619|Other|Placebo|Placebo orally administered with sodium bicarbonate solution
45810483|NCT05723341|Drug|Bupivacain|%0,25
45810484|NCT05723341|Drug|Morphine|In this group, patients will be postoperatively administered patient-controlled analgesia with morphine only.
46076124|NCT04974840|Behavioral|Treadmill training combined with/ without thera-band|Treadmill walking training with thera-band Treadmill walking training without thera-band
45810485|NCT05718583|Dietary Supplement|Butyrate|"Participants will self-administer the oral Short Chain Fatty Acid (SCFA) Butyrate supplement three times daily with meals for up to 2 months. The minimum duration necessary for an evaluable participant will be 2 weeks of SCFA supplementation."
46076125|NCT02830568|Procedure|open donor nephrectomy|open donor nephrectomy
45453403|NCT01240694|Drug|CEP-33457|CEP-33457 will be administered subcutaneously per dose specified in the arm description.
46076126|NCT02830568|Procedure|standard and hand-assisted laparoscopic donor nephrectomy|standard and hand-assisted laparoscopic donor nephrectomy
46076127|NCT02830568|Procedure|laparoscopic robotic-assisted nephrectomy|laparoscopic robotic-assisted nephrectomy
45658287|NCT05867199|Behavioral|Motor Imagery and Action Observation Training|The training consists of watching videos of actions performed with the hand. At the end of the video the subject is subsequently asked to imagine performing the action just seen
45658288|NCT05867186|Behavioral|Exercise training|Exercise training during intensive cancer treatment, maintenance therapy and aftercare. Training mainly consists of age-appropriate and personalised endurance, strength, flexibility, balance/coordination and gait training. Exercise is provided 3 to 5 times a week lasting for 45 to 60 minutes under supervision during inpatient and outpatient stays, as well as at home. At home, patients train independently according to the exercise recommendations of the exercise professionals, receive supervised telemedical exercise sessions and/or combine their training with digital tools.
45810486|NCT00363350|Drug|rituximab (anti-CD20)|2 infusions of 1000 mg
45658289|NCT05867160|Other|ASM as adjunctive therapy|ASM approved as adjunctive therapy
45810487|NCT05717335|Drug|TachoSil|Placement of TachoSil over the ventricular entry point in patients with periventricular lesions in order to avoid complications related to the ventricular entry.
45810488|NCT00363428|Behavioral|exercise intervention|life style
45810489|NCT00363428|Behavioral|smoking cessation intervention|Life style
45810490|NCT00363428|Other|counseling intervention|life style
45810491|NCT00363428|Other|educational intervention|life style
45810492|NCT00363428|Procedure|conventional surgery|life style
46076128|NCT04813380|Other|Sublingual immunotherapy|Sublingual immunotherapy give to allergic rhinitis patients for treatment
46076129|NCT02835872|Other|dietary fiber|Fiber containing drink mixes and crackers to be consumed with meals (1g fiber/serving) three times per day for a total of 3 g fiber.
45453404|NCT03635918|Device|NightOwl HSAT|Patient wears the NightOwl sensor device
45658290|NCT05867134|Behavioral|Removal of postoperative lifting restrictions|"Patients will be randomized into one of two groups: a control group told to practice standard of care at Eastern Colorado VA with return to activity precautions (6 weeks for open surgery, 2 weeks for minimally invasive surgery) and a treatment group told to return to activity as tolerated/comfortable and stop activity if pain present."
45658291|NCT05867095|Procedure|Surgical navigation|Patients will be operated with assistance of a navigation system
45658292|NCT05867095|Procedure|Conventional|Patients will be operated using the conventional technique
45658293|NCT05867082|Other|Neural Mobilization|Radial Nerve Mobilization, Medial Mobilization, Ulnar Mobilization
45658294|NCT05867056|Drug|IMC-I109V-101 Single Ascending Dose|Single dose administration of IMC-I109V-101
45810493|NCT00363428|Procedure|pulmonary complications management/prevention|life style
45810494|NCT05717257|Drug|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg will be added on top of the standard optimized medical therapy for heart failure and reduced ejection fraction
45810495|NCT04341818|Other|Strength Training and Vitamin D monthly|For 4 wks 50.000 IU vitamin D is given as a monthly dose together with daily 400mg of calcium. Both as a supplement, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D and calcium intake remain.
45947390|NCT05393817|Drug|caffeine citrate|caffeine citrate administration, dosage decided by the the physician on duty, within the range of routine management (5mg/kg/day ~ 20mg/kg/day)
45947391|NCT00094874|Procedure|Acupuncture|
45947392|NCT02077725|Other|interdisciplinary polypharmacy clinic visit|
45453405|NCT01112306|Drug|ACT-293987|Tablets, twice daily
45453406|NCT01332422|Drug|Salmeterol and Fluticasone|Collection of safety data
45453407|NCT04493996|Behavioral|Cognitive training|The cognitive training involves a standardized, paper-and-pencil-based cognitive training that will be performed by the patients at home for approximately 40 minutes per day over a preoperative period of 2-3 weeks
45658295|NCT05867056|Drug|IMC-I109V-101 Multiple Ascending Doses|Multidose administration of IMC-I109V-101
45947393|NCT00403338|Device|CYPHER® Bx Velocity™ stent (sirolimus-eluting)|
45947394|NCT00095069|Drug|MK0928, gaboxadol / Duration of Treatment - 1 year|
45947395|NCT00095069|Drug|Comparator: placebo / Duration of Treatment -1 year|
46002214|NCT04340895|Other|PRO-2 Scoring|Monitoring of clinical symptoms will be performed by PRO-2 scoring, which includes rectal bleeding (RB) and stool frequency (SF) assessment obtained within the last 3-days.
46076130|NCT04951362|Drug|intranasal spray ivermectin|intranasal spray of saline
46076131|NCT02830412|Other|Postoperative nausea and vomiting (PONV) reminder|The postoperative nausea and vomiting (PONV) electronic reminder will be programmed to assess the patient risk for PONV according to the risk factors identified by Apfel and Koivuranta. The PONV risk assessment and current guidelines will be displayed electronically for patients randomized to receive the reminder.
46076132|NCT02833610|Drug|Denosumab Q4W|
46076133|NCT02830490|Other|functional tests|Test-retest reliability of physical function in hemodialysis patients
45658296|NCT05867030|Drug|lenalidomide|lenalidomide is administered orally
45658297|NCT05867030|Drug|rituximab|rituximab is administered intravenously
45658298|NCT05867030|Drug|parsaclisib|parsaclisib is administered orally
45810496|NCT04341818|Other|Strength Training and Vitamin D daily|For 4 wks 800 IU vitamin D is given as a daily dose together with daily 400mg of calcium. Both as a supplement, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D and calcium intake remain.
45810497|NCT04341818|Other|Strength Training and no Vitamin D|For 4 wks no vitamin D is administered, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the also no vitamin D is given. Over the whole study period participants get 400 mg calcium/day.
45810498|NCT00362804|Drug|Tetrabenazine|The initial TBZ dose will be 12.5 mg and the dose will be increased to 25 mg at Week 2. Thereafter, the dose can be decreased to 12.5 mg or increased in 12.5 mg increments at weekly intervals, depending on clinical response and tolerability, to a maximum of 75 mg/day. For 37.5 and 50 mg daily, administration will be BID i.e., 25 mg QAM, 12.5 or 25 mg QHS. For 62.5 or 75 mg daily, a TID dosing will be employed i.e., 25 mg QAM, 12.5 or 25 mg QPM, 25 mg QHS
45810499|NCT01516190|Behavioral|Exercise|Supervised exercise sessions and independent exercise
45810500|NCT01516190|Behavioral|Surgical preparation program|Book, tapes, CD
45810501|NCT05715541|Other|"mobile applications with the name Set My INR"|"The relevant software company assisted in developing the phone application. The language of the application created with the name Set My INR is Turkish. The application provided an opportunity for patients to share and communicate with their physician after having the INR value measured in a health institution near their place of residence before coming to the hospital"
45810502|NCT02451488|Drug|GM-CSF|14 days in a dose of 125 µg/m^2
45810503|NCT02451488|Other|Standard of Care|No neo-adjuvant therapy prior to surgical intervention
45810504|NCT05576701|Behavioral|Laughter Therapy|In this study, laughter therapy was applied to the experimental group three times a week (on Mondays, Wednesdays, and Fridays) for a total of 12 sessions. Each session started with other patients in the HD unit while the patient was receiving HD treatment (1 hour after HD started) and lasted 30-45 minutes. The number of patients who will take part in each laughter session is based on the number of patients attending that session in the hemodialysis unit.
45810505|NCT05576701|Other|Control|The patients in the control group, on the other hand, did not undergo any intervention other than their routine treatment and care. Laughter therapy was applied for four weeks to HD patients in the control group who wanted the results of the research.
45810506|NCT04341506|Device|Non-contact ECG|A non-contact ECG will be used to detect a patient cardiac electrical activity.
45810507|NCT05717179|Diagnostic Test|Ultrasound|At baseline and at weeks 12, 24 and 48, patients will undergo an ultrasound examination of 44 joints by one investigator, who is blinded to the strategic arm and all clinical data. The following joints will be assessed: bilateral wrists (distal radio-ulnar joint, radio-carpal, mid-carpal recesses), 1st - 5th MCP, 1st - 5th PIP, elbows, glenohumeral, acromioclavicular, sternoclavicular, knees, ankles and 1st - 5th MTP. At wrists, MCP and PIP joints, palmar and dorsal sites including synovial recess, extensor and flexor tendons will be investigated whereas at feet the dorsal site (plus the lateral aspects of MTP5) including synovial recess and extensor tendons will be evaluated. Further, we will assess the following: at elbows the dorsal and anterior recess, at shoulders the dorsal recess, at knees the suprapatellar as well as the medial and lateral femoro-tibial recess and at ankles the anterior, lateral and medial recess of the tibiotalar joint.
45658299|NCT05867017|Other|Measure of physiologic parameters|Participants will have hepatic muscle and adipose tissue insulin sensitivity tested
45810508|NCT05714527|Device|Close-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
45810509|NCT05714527|Device|Conventional|Conventional FiO2 adjustment by the clinician according to SpO2 values, by using the manual FiO2 knob.
46076134|NCT04225728|Drug|Iron Sucrose IV|"Intervention will consisted of the administration for the IV route.~-The IV route in two doses will be diluted bolus injection of iron or normal saline at day 0 and day 14."
46076135|NCT04225728|Drug|Ferric polymaltose hydroxide complex IM|Intervention will consisted of the administration for the IM route. Drug will be given in two series of injection; the first series will began at day 0 and consist of administration of 300 mg of iron per day in intramuscular injection up to the half of the total dose and the second series will began at day 14 for the administration of the other half with the same scheme than the first.
45658300|NCT05866978|Behavioral|Integrated Approach to Health, Wellbeing, and Productivity at Work (ITASPA)|The intervention investigates the effect of the Australian WorkHealth Improvement Network (WIN) program and the Total Worker Health (TWH) concepts in a Danish context among blue-collar workers.
45658301|NCT05866965|Other|PRF|centrifuge patient's blood to collect 1 block of yellowish condensed fibrin, which is platelet-rich fibrin
45810510|NCT05717101|Other|Electronic Health Record Review|Review of medical records
45810511|NCT03172494|Drug|Insulin degludec/liraglutide|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
46076136|NCT04225728|Other|Saline solution|100 ml i.v. of normal saline administered at Day 0 and at day 14.
46076137|NCT02830646|Other|DFG mesure|Measure the effect of gastric bypass on the report DFG / VEC.
45453408|NCT01334294|Device|ForeseeHome|The ForeseeHomeTM device, was designed to identify central and paracentral irregularities (vision abnormalities) in the visual field, most commonly associated with exudative macular degeneration.
45810512|NCT03172494|Drug|Insulin degludec|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
45810513|NCT03172494|Drug|Liraglutide|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
45810514|NCT02452346|Drug|Tosedostat|120 mg PO once daily continuously for each 28 day treatment cycle
45810515|NCT02959255|Drug|Esomeprazole|dosage difference
45810516|NCT05716945|Drug|Fluorometholone 0.1% Oph Susp|"Year 1: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months.~Year 2: Half the patients in each study arm will use FML 0.1% daily."
45810517|NCT05716945|Drug|Dexamethasone 0.1% ophthalmic suspension|Year 1: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.
45810518|NCT05716945|Other|Stop steroids|Half the patients in each study arm will discontinue steroids.
45658302|NCT05866965|Other|standard third molar surgical removal|standard third molar surgery following surgical protocol of Department of Oral Surgery, University of Medicine and Pharmacy
45658303|NCT05866952|Diagnostic Test|Computed Tomography of the Chest|Quantitative Computed Tomography of the chest in the inspiratory and expiratory phases will be performed to assess regional lung ventilation as well as pulmonary vascular volume and distribution
45810519|NCT03012620|Drug|Pembrolizumab|Treatment
45810520|NCT05716867|Biological|Measurement of salivary cystatin S protein levels in saliva|The human cystatin S enzyme-linked immunosorbent assay (ELISA) kit will be used to measure the amounts of cystatin S in saliva for cases and controls
45658304|NCT05866926|Drug|FAB122|FAB122 Daily dose 100 mg
45810521|NCT04341584|Drug|Anakinra|"Treatment includes the administration of Two IV infusions / day of ANAKINRA KINERET® 200mg (Total 400 mg) at day 1 (D1), D2 and D3, two IV infusions / day of ANAKINRA KINERET® 100mg (Total 200 mg) at day 4 (D4), and one IV infusion of ANAKINRA KINERET® 100mg (Total 100 mg) at day 5 (D5).~In case of absence of improvement at D4 (absence of clinical improvement AND absence of decrease of CRP level > 50%), 3 supplementary days of treatment at 400 mg/day will be done at D4, D5, D6 followed by a decrease at 200 mg/day at D7 and 100 mg/day at D8 and stop thereafter"
45810522|NCT05716711|Other|LAVENDER OIL|IT WILL BE APPLIED TO 60 PATIENTS, 20 IN EACH GROUP, WITH A COLOSTOMY
45810523|NCT05716555|Device|Deep brain stimulation|Electrical stimulation of lateral habenula
45810524|NCT01345136|Drug|RAD001, everolimus|Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily
45810525|NCT04341428|Drug|DWP14012 20 mg|DWP14012 20 mg, tablet, orally, once daily for up to 24 weeks
45810526|NCT04341428|Drug|DWP14012 20 mg placebo|DWP14012 20 mg placebo-matching tablet, orally, once daily for up to 24 weeks
45810527|NCT04341428|Drug|Lansoprazole 15 mg|Lansoprazole 15 mg capsule, orally, once daily for up to 24 weeks
45810528|NCT04341428|Drug|Lansoprazole 15 mg Placebo|Lansoprazole 15 mg Placebo capsule, orally, once daily for up to 24 weeks
45453409|NCT03162224|Drug|MEDI0457|MEDI0457 7 mg will be administered intramuscularly followed by electroporation (EP) using CELLECTRA®5P device.
45658305|NCT05866900|Device|MiniMed 780G with SmartGuard activated|The MiniMed 780G system consists of a MiniMed 780G Insulin Pump connected to Guardian 4 Sensor or Guardian 3 Sensor, using an automated insulin delivery algorithm called SmartGuard.
45658306|NCT05866887|Behavioral|Sleep ALL Night|Sleep intervention program comprised of a sleep action plan tool and interactive psychoeducation website.
45658307|NCT05866861|Drug|CUG252|CUG252 will be administered by subcutaneous injection.
45810529|NCT03171168|Device|AposTherapy|AposTherapy is a home-based exercise program utilizing footwear that causes exercise with normal daily activity that may significantly improve function in patients with knee pain in general, and specifically knee osteoarthritis (OA).
45810530|NCT03171168|Other|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy
45810531|NCT02977975|Other|Raw sauerkraut|Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.
45810532|NCT02977975|Other|Pasteurized sauerkraut|Sauerkraut without live bacteria.
45658308|NCT05866861|Drug|Placebo|Placebo will be administered by subcutaneous injection.
45810533|NCT02978053|Behavioral|Bright light|Bright light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
45810534|NCT02978053|Behavioral|Red light|Red light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
45658309|NCT05866848|Other|Placebo|Flour capsules as a placebo.
45810535|NCT02453360|Procedure|Adductor Canal Block|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
45810536|NCT02453360|Drug|Adductor Canal Block|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
45810537|NCT03140670|Drug|RUCAPARIB|Rucaparib is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1.
45810538|NCT05568901|Behavioral|Lethal means counseling|"Lethal means counseling is a type of safety education that advises securement or removal of potentially hazardous household items such as medications, knives, and firearms. Counseling provided by study team was derived from the Suicide Prevention Resource Center's Counseling on Access to Lethal Means training module and the Store It Safe campaign from the Ohio Chapter of the American Academy of Pediatrics (AAP). Guidance focused on securement of dangerous items in the household, such as medications and firearms, with locking devices-or more preferably removing these items from the home, even if temporarily."
45810539|NCT05568901|Behavioral|Provision of Cable-style gun locks|Caregivers were provided 2 (two) SnapSafe Cable Padlock (Item No. 75281), advised on how to use these devices to store firearms safely (including instructions from within the package of the provided gun locks) and were advised to store keys away from the firearm in a location that children would not have access
45810540|NCT05714137|Behavioral|Evaluation of the Effect of Proximal Massage and Fist Clenching in Reducing the Risk of Phlebitis From Peripheral Venous Catheter|"Proximal massage: For a total of 5 to 10 minutes, twice daily for 4 days, between 30 seconds- 1 minute in sessions of approximately 20 strokes, a light massage is administered utilizing the palm surfaces of the fingers.~Fist Clenching : Under the researcher's supervision, participants in the activity known as palm fisting squeeze a soft palm ball 20 times in each of 2 days a day for four days, lasting between 30 seconds - 1 minute."
45453410|NCT03162224|Device|CELLECTRA®5P device|MEDI0457 7 mg will be administered intramuscularly followed by EP using CELLECTRA®5P device.
45453411|NCT03162224|Drug|Durvalumab|Durvalumab will be administered intravenously at a dose of 1500 mg every 4 weeks.
45810541|NCT05712889|Drug|VIP236|VIP236 will be administered by IV infusion weekly.
45810542|NCT05716399|Device|Transcutaneous electric stimulation pretreatment|Within 30 minutes before spinal anesthesia or 30 minutes after hypotension, TEAS (density wave 10/50Hz, one side of Neiguan and Quchi points connected to two electrodes on the same wire on the electroacupuncture instrument) was continuously performed on both sides of Neiguan and Quchi points, and the current intensity was only as high as the patient could comfortably tolerate (the electrical stimulation intensity was 2-3 times of the sensory threshold, for example, if the electrical stimulation intensity was 5 mA, 10-15 mA was used for stimulation), Record the specific value of current. FTEAS group pastes electrode piece, turns on the power, but there is no current output.
45810543|NCT05716399|Device|Transcutaneous acupoint electrical stimulation treatment|Transcutaneous acupoint electrical stimulation treatment
45810544|NCT05716399|Device|Transcutaneous acupoint pseudo electric stimulation|Transcutaneous acupoint pseudo electric stimulation
45658310|NCT05866848|Other|Anhydrous caffeine (45mg)|Capsules dosed with 45mg of anhydrous caffeine.
45658311|NCT05866848|Other|Anhydrous caffeine (120mg)|Capsules dosed with 120mg of anhydrous caffeine.
45658312|NCT05866835|Other|Manufacture of custom-made IOP|"Manufacture of custom-made unimaxillary and modified unimaxillary intra-oral protection (IOP) with vertical dimensions of 4 mm and 6 mm. 3D modeling of a IOP based on:~digital recording of the maxillary and mandibular dental arches~mandibular wedging performed with an inter-arch piece~digital recording of the inter-arch position"
45658313|NCT05866835|Other|Ventilation tests|"Realization of a ventilation test (VO2max) to determine the Maximum Aerobic Speed (MAS).~Measurement of ventilatory parameters without IOP and with each IOP :~At rest, standing still.~During a 4 minute run on a treadmill at 50% of MAS.~During a 4-minute run on a treadmill, at a speed corresponding to 70% of MAS"
45810545|NCT02453672|Biological|SB8|SB8, proposed bevacizumab biosimilar
45947396|NCT00403377|Behavioral|Intervention|In the intervention arm, photographs are taken of the participants and they then receive sunscreen lotion and sunless tanning lotion and instructions and benefits for using both. Participants also receive an educational pamphlet regarding skin cancer.
45947397|NCT00095108|Drug|Recombinant Human Interleukin-21|
45947398|NCT00403533|Drug|20 mg of atorvastatin daily|
45658314|NCT05866835|Other|Evaluation of comfort level:|Collection from participants (self-questionnaire)
45810546|NCT02453672|Biological|EU sourced Avastin®|EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)
45947399|NCT00095225|Drug|Avastin (bevacizumab)|
45947400|NCT00095225|Drug|Tarceva (erlotinib HCl)|
45810547|NCT02453672|Biological|US Sourced Avastin®|US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)
45658315|NCT05866822|Other|APA|24 APA sessions
45658316|NCT05866822|Other|PAE|8 individuals sessions of PAE
45658317|NCT05866809|Drug|HK-660S|Administered orally
45658318|NCT05866809|Drug|Placebo|Administered orally
45810548|NCT03119064|Drug|Nanoliposomal Irinotecan|Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
45810549|NCT03119064|Drug|Temozolomide|Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
45810550|NCT00358033|Behavioral|Counseling|
45810551|NCT00358033|Behavioral|Interactive Education|
45947401|NCT00095264|Drug|Darbepoetin Alfa|
45947402|NCT01054729|Drug|Sofosbuvir|Sofosbuvir tablet(s) administered orally once daily
45947403|NCT01054729|Drug|Placebo|Placebo to match sofosbuvir administered orally once daily
45947404|NCT01054729|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
45947405|NCT01054729|Drug|RBV|Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
45658319|NCT05866796|Diagnostic Test|GlycoTransplantTest|Determination of serum glycomics in the early posttransplant stage, using an optimal cutoff based on statistic modeling.
45658320|NCT05866783|Diagnostic Test|HCCRecurrencePrognosticScore|Determination of serum glycomics pre-transplant using an optimal cutoff based on statistic modeling
45658321|NCT05866783|Diagnostic Test|HCCRecurrenceDiagnosticScore|Determination of serum glycomics post-transplant using an optimal cutoff based on statistic modeling
45810552|NCT00358033|Behavioral|Group Support|
45810553|NCT00358033|Procedure|Pharmacologic case management|Provided by clinical pharmacists
45947406|NCT00095342|Drug|TMI-005|
45947407|NCT00403611|Drug|Praziquantel 60 mg/kg|Praziquantel (Distocide) 60 mg/kg single oral dose
45947408|NCT00403611|Drug|Praziquantel 40 mg/kg|Praziquantel (Distocide) 40 mg/kg single oral dose
45947409|NCT00428896|Drug|ZD1839|ZD1839 will be given at the dose of 250mg/day for a minimum of 3 months
45947410|NCT00428935|Biological|rAAV2.5-CMV-minidystrophin (d3990)|Recombinant adeno-associated virus (AAV) carrying a truncated human dystrophin gene (mini-dystrophin) expressed from a cytomegalovirus (CMV) promoter.
45947411|NCT00095381|Drug|forodesine hydrochloride (BCX-1777)|
45947412|NCT01990911|Device|Renal denervation|In patients randomized to intervention both renal arteries will be treated with radio-frequency energy as per standard Symplicity protocol.In patients randomized to medical-treatment group only, sham renal denervation will be performed by only injecting contrast agent into both renal arteries.
45947413|NCT01990911|Drug|Medical therapy|Subjects will continue on their standard medical therapy as prescribed by their treating physician
45947414|NCT00429013|Device|Tongue Display Unit|lingual electric stimulation
45658322|NCT05866757|Other|Discontinuation of maintenance treatment|The discontinuation of maintenance treatment in multiple myeloma. Classed as interventional due to treatment being taken away.
45453412|NCT01334372|Behavioral|CAMS|First, as discussed above, suicidality is the focus of treatment rather than one of many symptoms being treated. Second is the emphasis on patient and therapist collaborating on treatment rather than the therapist dictating how therapy progresses. Beyond those two basic tenets, each therapist is free to utilize their current clinical skills to conduct psychotherapy.
45658323|NCT05866744|Other|Early Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet|18 patients with NAFLD will be asked to follow an early 14:10 (14 hours fasting and 10 hours feeding) time-restricted (eating between 08:00-18:00) and individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) for 12 weeks
45453413|NCT00904046|Drug|Pioglitazone|30 mg orally daily for 6 months
45453414|NCT00904046|Drug|Placebo|Placebo taken orally once a day for 6 months.
45658324|NCT05866744|Other|Late Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet|18 patients with NAFLD will be asked to follow a late 14:10 (14 hours fasting and 10 hours feeding) time-restricted (eating between 12:00-22:00) and individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) for 12 weeks
45658325|NCT05866744|Other|Hypocaloric Mediterranean Diet Without Time Restriction In Feeding|18 patients with NAFLD will be asked to follow an individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) without time restriction in feeding (eating throughout the day) for 12 weeks
45658326|NCT05866679|Drug|Hyperpolarized 13-C-pyruvate|Given by PO
45658327|NCT05866666|Device|Cardiac Performance System (NSR)|Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function.
45658328|NCT05866640|Device|F2 filter and delivery system|Placement of F2 device in aorta to cover great cerebral vessels
45810554|NCT02453750|Drug|Hypersaline|Subject will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer. Sputum production (with cough) will be attempted post inhalation. A maximum of 3 hypertonic saline inhalations will be attempted if inhalation does not generate a productive cough. If sputum induction is not successful and the FEV1 falls <10%, the concentration of inhaled hypertonic saline will increase from 3 to 4%. If 5 mls of 4% hypertonic saline inhaled for 7 minutes does not produce a productive cough we will proceed to 5%. If 5 mls of 5% hypertonic saline inhaled for 7 minutes does not produce a productive cough the test is complete and the sample is labelled 'no sputum collected'. If FEV1 falls >10%, the previous step will be repeated.
45810555|NCT02453750|Drug|Bronchodilator Response|A bronchodilator (Salbutamol 200 mcg or 2 puffs inhaled via spacer device) will be administered to all subjects in the pulmonary function laboratory. 15 minutes after administration of the bronchodilator spirometry will be repeated. This is performed routinely in CDH clinic and is not an additional test for this study.
45810556|NCT03831295|Biological|Anti-OX40 Antibody BMS 986178|Given IT or IV
45810557|NCT03831295|Drug|TLR9 Agonist SD-101|Given IT
45810558|NCT03107286|Drug|Tc-99M-MAG3|Participants will be asked to be imaged at an additional time point during a nuclear medicine study using Tc-99m MAG3
45810559|NCT03107286|Other|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
45810560|NCT05215158|Drug|Dexmedetomidine|to compare perineural (peribulbar) dexmedetomidine versus intravenous (I.V.) dexmedetomidine when used as an adjuvant with local anesthesia in adult strabismus surgery.
45810561|NCT02454296|Drug|Paracervical Block with lidocaine|Performance of paracervical block, using 18 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate, prior to laminaria insertion
45810562|NCT02454296|Drug|Sham paracervical block|A capped needle will be placed on the cervix prior to laminaria insertion for purposes of blinding both the participant and research staff assessing outcomes
45810563|NCT03836833|Drug|ABC/3TC/LPV/r granules (30/15/40/10 mgs)|"This is a fixed dose combination. Each capsule contains Lopinavir (40mg), Ritonavir (10mg), Abacavir (30mg) and Lamivudine (15mg) in granules formulation.~Dosage according to patient's weight:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day"
45810564|NCT03836833|Drug|LPV/r Pellets (40/10mgs) plus ABC/3TC (60/30mgs)|"Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets)~Dosage according to patient's weight:~LPV/r Pellets:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day~ABC/3TC:~Between 3 and 5.9kg: 1 tablet twice a day Between 6 and 9.9kg: 1.5 tablets twice a day Between 10 and 13.9kg: 2 tablets twice a day Between 14 and 19.9kg: 2.5 tablets twice a day Between 20 and 24.9kg: 3 tablets twice a day"
45810565|NCT04744142|Drug|Ketone supplementation|Subjects receive either placebo or ketone ester supplementation
45947415|NCT00429091|Drug|ABT-894|Subjects will take 1 mg QD, 2 mg QD, 4 mg QD, 4 mg BID for up to four weeks.
45947416|NCT00429091|Drug|atomoxetine|Subjects will take 40 mg BID or placebo for up to four weeks.
45658329|NCT05866627|Drug|Famotidine|Specified dose on specified days
45658330|NCT05866627|Drug|Afimetoran|Specified dose on specified days
45810566|NCT04744142|Dietary Supplement|Increased protein intake|Subjects receive either normal or increased protein intake
45947417|NCT00429091|Drug|placebo|Subjects will take BID for up to four weeks
45947418|NCT05261178|Other|Evaluation of satisfaction and the level of daily living activities using the prosthesis|Evaluation of satisfaction with using the prosthesis with TAPES (Trinity Amputation and Prosthesis Experience Scale) and the level of daily living activities using the prosthesis with SF-36 (Short Form-36)
45947419|NCT00095459|Drug|Bevacizumab|
45947420|NCT00095459|Drug|BAY 43-9006|
45947421|NCT00429208|Drug|Nicotine|
45947422|NCT04704739|Drug|GLPG1205 film-coated tablets|Single oral dose of GLPG1205
45947423|NCT04704739|Drug|[14C]-GLPG1205 solution for infusion|A 15-minute IV infusion of [14C]-GLPG1205
45947424|NCT04704739|Drug|GLPG1205 capsules|Single oral dose of GLPG1205 as solid formulation
45658331|NCT05866614|Drug|Remsima IV|Patient will be treated with Remsima IV as per the SmPC or
45658332|NCT05866614|Drug|Remsima SC|Patient will be treated with Remsima SC as per the SmPC
45658333|NCT05866588|Behavioral|Physical, psychological and spiritual nursing care (Nursing Therapeutics)|"Follow-up: To make a presentation about the physiological and psychological changes during pregnancy. do dream work~Follow-up: Providing education and counseling for childbirth.~Follow-up: Training and role rehearsal on mother-infant interaction, breastfeeding and infant care.~Follow-up: To provide counseling on the issues needed with the approaching of the birth.~Follow-up: Teaching about conscious parenting and mother-infant, father-infant interaction.~Tracking. To provide education, counseling and social support on the other roles of the mother in life such as wife role, working woman role, social role.~Follow-up: To evaluate the transition to motherhood.~Follow-up: To evaluate the outcomes of transition to motherhood and adjustment to motherhood according to expected completion time."
45658334|NCT05866575|Other|escitalopram|Patients will receive an antidepressant strategy : escitalopram. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
45658335|NCT05866575|Other|vortioxetine|Patients will receive an antidepressant strategy : vortioxetine. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the treatment strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
45810567|NCT05716243|Device|The nociception level index monitorization|The nociception level index (NOL) is one of the nociception monitors and stands out from the others with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives).
45810568|NCT05716243|Device|The nociception level index measurement;postoperative|The nociception level index (NOL) will be used postoperatively
45810569|NCT03098238|Biological|Biological sample|Biological sampling of two citrate tubes (18 ml) during a normal blood
45810570|NCT03398694|Procedure|Radiosurgery|"Stereotactic radiosurgery will be delivered on all patients utilizing gamma knife or linear accelerator based techniques as per RTOG-9005 dosing criteria (Section 11 Table 1) based on tumor diameter with the exception that the largest lesion diameter to be treated with 15 Gy will be 5 cm. All apparent, previously untreated brain metastases will be treated with radiosurgery at this time.~Radiosurgery will be performed 1-4 days prior to surgical resection. Vital signs and MRI Brain planning scan will be performed on the day of radiosurgery prior to the procedure."
45658336|NCT05866562|Drug|Dupilumab|every other week 200 mg or 300 mg (weight-based) SC injections
45658337|NCT05866562|Drug|Placebo|Placebo comparator
45810571|NCT03362502|Genetic|PF-06939926|"Recombinant adeno-associated virus, serotype 9 (AAV9) carrying a truncated human dystrophin gene (mini-dystrophin) under the control of a muscle-specific promoter.~Subjects will receive a single intravenous infusion of one of 2 dose levels."
45810572|NCT05716087|Drug|LP-168|Subjects to take LP-168 orally with 240mL water, without food, Once daily.The treatment will continue until progressive disease, unacceptable toxicity, etc.
45810573|NCT02457260|Drug|14 N Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times daily for 4 weeks
45947425|NCT04704427|Device|Non-invasive BCI training|In the experimental group, the participants receive non-invasive rehabilitative BCI training. The training using the lower limb orthosis targeted the patient's ability to walk.
45810574|NCT05233410|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
45947426|NCT04704427|Other|Traditional Physiotherapy protocol|In the control group，the participants receive the traditional physiotherapy protocol, including muscle strength training, balance training and walking training, etc.
45947427|NCT05244369|Other|Only TENS|Rehabilitation program consisting of joint range of motion, stretching and strengthening exercises for 30 minutes, 5 days a week for only 4 weeks, and application of transcutaneous electrical nerve stimulation (TENS) to the tip of the stump
45810575|NCT05233410|Drug|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
45810576|NCT04602390|Drug|ANK-700|Intravenous (IV) infusion
45810577|NCT04602390|Drug|Placebo|Intravenous (IV) infusion
45947428|NCT05244369|Procedure|Acupuncture+TENS|acupuncture application twice a week - a total of 8 sessions, rehabilitation program consisting of exercises 5 days a week for 4 weeks and transcutaneous electrical nerve stimulation (TENS) to the stump tip.
45947429|NCT00095537|Drug|panHer|Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached.
45810578|NCT05710471|Drug|Brolucizumab|Intravitreal injection
45810579|NCT05710471|Drug|Aflibercept|Intravitreal injection
45947430|NCT00429247|Drug|Trastuzumab|Trastuzumab,first administration at the dose of 8mg/Kg IV, subsequent administrations at the dose of 6mg/Kg IV,every 3 weeks for 6 cycles
45947431|NCT00095654|Drug|Ramipril|
45947432|NCT00095654|Drug|Rosiglitazone|
45947433|NCT05243472|Dietary Supplement|Protein nutritional supplement|Participants in the intervention group will receive protein-enriched soups (24-30g of protein). Protein may come from either soy, bean or milk products.
45947434|NCT00095693|Drug|sorafenib tosylate|Given PO
45947435|NCT00095693|Other|laboratory biomarker analysis|Correlative studies
45947436|NCT00095693|Other|pharmacological study|Correlative studies
45947437|NCT00095693|Radiation|fludeoxyglucose F 18|Correlative studies
45810580|NCT02457728|Device|LiquiBandFix8|Using LiquiBandFix8 for mesh fixation and peritoneal closure following TAPP repair.
45453415|NCT03635840|Device|Intra Aortic Balloon Pump|"Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand."
45658338|NCT05866523|Behavioral|Team Based Inpatient ARTAS|Infectious Disease Team will provide inpatient consultation. Social Work Team will provide 1 session of case management inpatient and up to 5 case management sessions within 90 days post discharge or until the client is linked to medical care as evidenced by visit with HIV specialist within 90 days post discharge.
45658339|NCT05866523|Behavioral|Standard of Care|Subject admitted and seen by routine inpatient medical service.
45810581|NCT00358111|Device|Luma Cervical Imaging System|Colposcopy using LUMA Cervical Imaging System
45947438|NCT00095693|Procedure|positron emission tomography|Correlative studies
45947439|NCT00095693|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Correlative studies
45947440|NCT01054573|Drug|Telaprevir|750 mg orally every 8 hours (q8h) for 12 weeks
45947441|NCT01054573|Drug|pegylated interferon (Peg-IFN) alfa-2a|180 microgram (mcg) by subcutaneous injection once weekly for 48 weeks.
45947442|NCT01054573|Drug|ribavirin (RBV)|1,000 or 1,200 mg/day (weight based) orally twice daily for 48 weeks.
45947443|NCT00095732|Drug|Liprotamase|Administered orally as either Size 2 capsules (20,000 Units lipase; 20,000 Units protease; and 3,000 Units amylase) or Size 5 capsules (5,000 Units lipase; 5,000 Units protease; and 750 Units amylase)
45947444|NCT00095732|Drug|Placebo|Administered orally in either Size 2 or Size 5 capsules
45947445|NCT00429286|Behavioral|Problem Solving Training|A systematic cognitive-behavioral intervention teaching problem solving skills for addressing functional impairment related to breast cancer and its treatment.
45453416|NCT00867464|Other|Cytology Specimen Collection Procedure|Correlative studies
45453417|NCT00867464|Other|Laboratory Biomarker Analysis|Correlative studies
45453418|NCT00867464|Other|Long-term Follow-up|Undergo extended follow-up
45658340|NCT05866510|Drug|Utidelone and anlotinib|"Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to Utidelone iv drip at the first day of each cycle.~Utidelone will be given at 30 mg/m2/d administered intravenously on days 1-5 and Anlotinib 8mg/d took orally on days 1-14 every 21 days."
45810582|NCT02458352|Device|Ultra low dose non-contrast enhanced CT|Non-contrast enhanced CT for CACS and AC using a novel protocol for ultra low dose radiation dose exposure
45810583|NCT02458352|Device|Standard dose non-contrast enhanced CT|Clinically indicated non-contrast enhanced CT for CACS and AC according to routine protocol
45810584|NCT05652894|Drug|HX008|Drug: HX008 200 mg ,Q3W
45810585|NCT05652894|Drug|Investigator's Choice Chemotherapy|"Drug: bevacizumab 5mg/kg given by IV every 14 days. Other Name: Avastin~Drug: cetuximab 400 mg/sqm initial dose, then 250 mg/sqm once weekly thereafter. Other Name: Erbitux~Drug: oxaliplatin 8 5 mg/sqm by IV, day1. Component of mFOLFOX6.~Drug: irinotecan 180 mg/sqm by IV, day1.Component of FOLFORI.~Drug: calcium Folinate 400 mg/sqm by IV, day1.Component of mFOLFOX6 or FOLFORI.~Drug: 5-fluorouracil 400 mg/sqm, day1,followed by 2400 mg/sqm iv infusion over 46~48 h.Component of mFOLFOX6 or FOLFORI."
45810586|NCT00358189|Device|Deep Brain Stimulation|
45810587|NCT04591080|Device|GUMMETAL Orthodontic Wire|Orthodontic archwire made of TiNbTaZr alloy.
45810588|NCT04591080|Device|Stainless Steel (CrNi)|"Stainless steel (18% Chromium and 8% Nickel) used as the control, and linked anteriorly to the GUMMETAL counterpart. Size of archwire is 0.016 x 0.022"
45947446|NCT00095771|Drug|arsenic trioxide|
45947447|NCT00095771|Radiation|radiation therapy|
45947448|NCT01054456|Drug|palonesetron|One dose administered intravenously 30 minutes pre-chemotherapy
45947449|NCT00429442|Drug|Simvastatin|80 mg once daily
45947450|NCT00429442|Drug|placebo|calcium tablets once daily
45947451|NCT00400361|Drug|RG1507|Administered iv, either weekly or 3 weekly, at escalating doses (with a starting dose of 1mg/kg) (7 cohorts).
45947452|NCT00429481|Biological|Rotarix|
45947453|NCT00429520|Drug|Hyaluronic acid filler/IMD1 basic|
45947454|NCT00429559|Drug|Hycamptin|1.75mg/m2 IV on day 1 every week for 3 weeks in cycles of 4 weeks Number of cycles: until progression
45947455|NCT00429559|Drug|Gemcitabine|"Gemcitabine at starting dose of 700 mg/m 2 with increments of 100 mg/m2 IV on day 1 every week for 3 weeks in cycles of four weeks.~Number of cycles: until progression"
45947456|NCT00095810|Drug|aripiprazole|Tablets, Oral, 1-10mg, Once daily, 6 weeks.
45947457|NCT05234112|Behavioral|Community mobilisation for hrHPV self-testing|use of social media, written media, theatre and other sources of communication to reach women, and relatives, to convince them of importance of screening.
45947458|NCT05234112|Diagnostic Test|hrHPV self-testing|use of swabs that women insert in the vagina for taking sufficient material for testing for hrHPV. For women who are not confident to perform this this nurses provide assistance.
45947459|NCT05234112|Behavioral|Follow-up after testing|based on the results of the test, follow-up is offered. In case of hrHPV negative test, retesting after five years. In case of hrHPV positive test, VIA in a nearby clinic. Women have to be motivated to adhere to follow-up
45947460|NCT05234112|Diagnostic Test|VIA|Test offers insight into existence of dysplasia of the cervix by colouring the transition area
45658341|NCT05866497|Diagnostic Test|clinical periodontal measurements|"Periodontal parameters such as PI, GI, BOP, PD, and CAL were measured using the Williams periodontal probe (Hu-Friedy, Chicago IL). PD and CAL were calculated at six surfaces per tooth, whereas PI and GI were measured at four surfaces per tooth.~The periodontal status of patients was determined based on the Classification of Periodontal and Peri-Implant Diseases and Conditions stated in 2017 World Workshop"
45947461|NCT05234112|Procedure|Thermo-ablation or cryotherapy for dysplasia|Women with identified dysplasia lesions are offered immediate therapy to remove the infected superficial surface of the cervix
45947462|NCT05234112|Diagnostic Test|Pap smear cytology|Cytology for identification of abnormal cells in the cervix, and classification of stages of dysplasia or pre-cancerous lesions
45658342|NCT05866497|Diagnostic Test|CAVI measurements|"Arterial stiffness of the participants included in this study were assessed by CAVI index using VaSera (VS-1500N) CAVI device (Fukuda Denshi Co. Ltd., Tokyo, Japan) between both arms and ankles in a supine position.~Right and left CAVI values were calculated separately."
45947463|NCT01054300|Drug|Ertugliflozin 2 mg single dose|Ertugliflozin 2 mg dose (two 1 mg strength tablets), administered as a single dose
45947464|NCT01054300|Drug|Ertugliflozin 2 mg split into twice daily|Ertugliflozin 1 mg dose (1 mg strength tablet) administered twice daily x 1 day
45947465|NCT01054300|Drug|Ertugliflozin 4 mg single dose|Ertugliflozin 4 mg dose (four 1 mg strength tablets), administered as a single dose
45453419|NCT00867464|Other|Questionnaire Administration|Ancillary studies
45453420|NCT01332734|Drug|Magnesium Sulfate|2 gram in 1 hour
45947466|NCT01054300|Drug|Ertugliflozin 4 mg split into twice daily|Ertugliflozin 2 mg dose (two 1 mg strength tablets) administered twice daily x 1 day
45947467|NCT01054300|Drug|Placebo|Placebo to ertugliflozin administered as a single dose
45658346|NCT05866393|Behavioral|Clean Hands Accessible and Manageable for Patients|Use of a patient-smart hand sanitation dispenser that provides reminders that are non-beeping reminders.
45810589|NCT05715853|Other|QSant|QSant™ is a needle free urine test collected in-home or in-clinic to aid in the evaluation and management of kidney transplant recipients' allograft status. QSant evaluates 6 kidney-specific biomarkers.
45658347|NCT05866380|Other|heart failure risk factors|observational study with diabetes patient with heart failure risk factors
45810590|NCT05652816|Procedure|Split-thickness skin graft|Transplantation of autologous skin to burn area
45658348|NCT05866354|Drug|Tisotumab Vedotin|Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF), a protein aberrantly expressed in a wide number of solid tumors including cervical cancer.
45658349|NCT05866341|Dietary Supplement|nitrate-rich lettuce juice|Consumption of a daily dosage of 200 mg nitrate via the consumption of a 300mö of a nitrate-rich lettuce juice
45810591|NCT05652816|Biological|Artificial skin graft|Decellularized amnion membrane formed into 3-D matrix
45810592|NCT05652816|Biological|Artificial skin graft co-culture|Decellularized amnion membrane formed into 3-D matrix seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells
45810593|NCT05702593|Procedure|Static stretching|The participant was positioned supine for static stretching to be applied to the hamstring muscles. The physiotherapist flexed the participant's hip to the point where resistance to the movement was first observed, with the knee extended.At this point, after waiting for 40 seconds, it was returned to the previous position. This application was made on both sides [Bretischwerdt]. The technique was repeated three times, with a 15-second rest interval between each repetition.
45810594|NCT05702593|Procedure|Myofascial Release|For hamstring muscles, the participants were asked to assume a long sitting position on a firm, flat surface with their arms behind their backs and their body weight on their palms. A foam roller was placed under the hamstring muscles and slowly moved the tuberositas ischii popliteus back and forth with pressure for 4 minutes.
45947468|NCT00095888|Drug|triapine|Given IV
45947469|NCT00095888|Drug|gemcitabine hydrochloride|Given IV
45947470|NCT00095888|Other|laboratory biomarker analysis|Correlative studies
45947471|NCT00095888|Other|pharmacological study|Correlative studies
45947472|NCT00429676|Drug|Haloperidol|
45947473|NCT00429715|Biological|Alum-ALM + BCG|Alum precipitated autoclaved L. major
45947474|NCT00429715|Biological|Alum-ALM + BCG|Arm 1=Alum-ALM + BCG Arm 2=BCG Arm 3=Placebo comparator
45947475|NCT00429715|Biological|Alum-ALM + BCG|Alum-ALM + BCG
45947476|NCT00095927|Drug|Amifostine|Given subcutaneously
46076138|NCT02775552|Behavioral|A&T community-based interventions|"Interpersonal communication delivered by health workers and community volunteers at the health post and during home visits to:~- Increase mothers' knowledge about adequate child feeding practices~Interpersonal communication delivered by agricultural extension workers to:~- Increase fathers' knowledge about nutrition-sensitive agriculture and child feeding~Community mobilization activities to:~Raise awareness of child feeding practices among community members, and increase support to mothers (enhanced community conversations)~Increase mothers' knowledge about preparation of complementary foods (cooking demonstrations)~Raise awareness of adequate child feeding during fasting among family and community members (church sermons)~Enhanced training of government health and agricultural extension workers in infant and young child feeding to:~Improve their ability to provide timely and appropriate information and support to mothers and families"
45658350|NCT05866341|Dietary Supplement|nitrate-depleted lettuce juice|Daily consumption of 300 ml of a nitrate-depleted lettuce juice
46076139|NCT02775552|Behavioral|Mass media|Radio campaign - radio drama series, spots, and jingles
46076140|NCT02835716|Drug|roflumilast|DALIRESP is used in adults with severe chronic obstructive pulmonary disease (COPD) to decrease the number of flare-ups or the worsening of COPD symptoms (exacerbations
46076141|NCT02835716|Biological|ustekinumab|STELARA is approved to treat adults 18 years and older with moderate or severe plaque psoriasis that involves large areas or many areas of their body
46076142|NCT02833454|Procedure|direct insertion anterior cruciate ligament reconstruction|ACL reconstruction based on direct insertion of ACL.
45658351|NCT05866289|Other|Prone position|Each prone position session had a minimum duration of one hour and a maximum duration of 12 hours for a minimum of 3 hours per day.
45658352|NCT05866263|Other|green walking and intelligence gam|The randomized controlled study to examine the effects of green walking and intelligence games on the cognitive skills of individuals aged 50-70 years who had COVID-19 on an outpatient basis were completed with 40 individuals, 20 of which were in the green walking and intelligence game group and 20 were in the control group.
45658353|NCT05866250|Diagnostic Test|Doppler-based renal resistive index|The kidney's interlobular or arcuate artery was preferentially selected and measured by pulse-wave Doppler.
45658354|NCT05866237|Device|Patient Engagement tool|The study intervention (PET) aims to increase uptake of vaccines that are already recommended through national guidance.The PET will help educate and inform individuals about the benefits of COVID-19 vaccination through culturally adapted educational support, including content, design, mode and timing of delivery of messages (text, video or voice messages).
45810595|NCT04566042|Behavioral|Acceptance and commitment therapy video game|The intervention is a videogame which teaches the participant about acceptance and commitment therapy.
45810596|NCT00358969|Drug|guanfacine (Tenex)|
45810597|NCT01636362|Device|Mepitel Ag|Mepitel Ag is an antimicrobial, meshed, non-adherent wound contact layer allowing passage of exudate and providing fixation and protection of tissues.
45453421|NCT03423524|Device|Micropure 1.2.3.|"Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per eye will be implanted"
45810598|NCT05370469|Other|Sensus Smartwatch Application|Sensus is capable of administering ecological momentary assessments (EMAs) on a schedule, randomly, or using sensor-triggers. In this way, Sensus will capture both active (patient-initiated) and passive data streams from native smartphone sensors. Passive streams may include, but are not limited to, GPS, accelerometer, gyroscope, and pedometer data. Participants will be able to log data such as their activity, symptoms and medication adherence via user-initiated surveys within the Sensus app. Sensus will also prompt users to record their medication adherence, symptoms, or activity. This will be done either at fixed intervals (e.g., three times daily) or whenever the onboard sensors detect potential changes in a user's physiological state (e.g., shaking / moving around).
45658355|NCT05866224|Other|Telerehabilitation program|The supervised telerehabilitation program will be performed in the home of each patient and supervised by an experienced physiotherapist with more than 4 years of clinical experience in therapeutic exercise for chronic diseases.
45658356|NCT05866211|Other|Previous exposure to SARS-CoV-2|This is an observational study in which no intervention will be applied.
45947477|NCT00095927|Drug|Carboplatin|Given IV
45947478|NCT00095927|Drug|Paclitaxel|Given IV
45947479|NCT00095927|Radiation|radiation|Given once daily for 4 weeks and then twice daily for 2 weeks.
45947480|NCT00429754|Drug|Aprepitant|
45947481|NCT04703881|Dietary Supplement|AYMES ActaGain|AYMES ActaGain is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is designed as a supplement to the diet but can also be used as a sole source of nutrition.
45947482|NCT04703959|Other|polysomnography|polysomnography is already done for all patients
45947483|NCT00429832|Drug|Ondansetron|
45947484|NCT00429832|Drug|promethazine|
45947485|NCT00429871|Drug|Docetaxel|Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
45810599|NCT05370469|Device|RX Cap|The RXCap medication event monitoring device will be used to collect data on participant adherence to their TKI medication. A small computer chip is included in the top of a pill bottle. When the cap is taken off of the pill bottle by turning it or unscrewing it, the cap records the time and date that it was removed.
45810600|NCT05370469|Device|Fitbit Sense|The Fitbit Sense smartwatch will be used to collect data including steps, calories burned, total distance travelled, sleep (e.g. time spent sleeping and quality of sleep), flights of stairs climbed, active minutes, exercise (e.g. minutes spent exercising at various intensities), and average heart rate.
46076143|NCT02833454|Procedure|single bundle anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction using single bundle technique
45810601|NCT05370469|Other|Surveys|Electronic and paper surveys will be administered throughout the study.
45947486|NCT00429871|Drug|Capecitabine|Capecitabine 950 mg/m2 orally twice a day on days 1-14 every 3 weeks for 6 consecutive cycles
45947487|NCT00429871|Drug|Epirubicin|Epirubicin at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
45947488|NCT00429871|Drug|Docetaxel|Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
46076144|NCT02833454|Procedure|double bundle anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction using double bundle technique
46076145|NCT05154162|Diagnostic Test|PSMA PET/CT|PSMA PET/CT (limited to the pelvis)
45658357|NCT05866198|Diagnostic Test|Actigraph CP Insight Watch|"CP Insight Watch (Actigraph, Pensacola, FL) is usually worn on the wrist. The watch captures and records continuous high-resolution raw acceleration data to provide objective, real-world physical activity, mobility, and sleep measures, in near real time. That data is then processed by ActiLife software into what is called Epoch data (i.e. turning it into activity counts so that things such as moderate vigorous physical activity can be found). The device also passively scores every minute of recorded data as Sleep or Wake based on the amount of activity taking place."
45658358|NCT05866185|Behavioral|Therapy|The standard of care procedures for adults with clinically elevated anxiety and/or depression from their mental health provider.
45658359|NCT05866185|Behavioral|Therapy + Adhere.ly|Participants receive therapy as usual enhanced with a simple, HIPAA-compliant, web-based application to help mental health providers implement homework during therapy for adults with elevated anxiety and/or depression. The three major components of the app help providers to (1) Practice interactive, digitized therapeutic exercises with patients in-session; (2) Remind patients to practice exercises for homework, and (3) Review homework during the next session.
45658360|NCT05866172|Procedure|HAIC|hepatic arterial infusion of oxaliplatin, LV and 5-fu (20h)
45947489|NCT00095966|Drug|sorafenib tosylate|Given orally
45947490|NCT00095966|Drug|gemcitabine hydrochloride|Given IV
45947491|NCT01803594|Dietary Supplement|Krill Oil|Neptune Krill Oil Gold
45947492|NCT01803594|Dietary Supplement|Lutein|Jarrow Formulas
45947493|NCT01803594|Dietary Supplement|Nicotinic acid|Natures Way
45947494|NCT01803594|Dietary Supplement|Dairy phospholipids|PC700 manufactured by Fonterra
45947495|NCT01803594|Other|Control|Control shake without dietary supplements
45658361|NCT05866172|Drug|Zoledronic acid|Zoledronic acid 4mg iv.drip
45947496|NCT00429988|Genetic|fluorescence in situ hybridization|
45947497|NCT00429988|Genetic|polymerase chain reaction|
45947498|NCT00429988|Genetic|proteomic profiling|
45947499|NCT00429988|Other|cytology specimen collection procedure|
45947500|NCT00429988|Other|immunohistochemistry staining method|
45947501|NCT00429988|Procedure|breast duct lavage|
45947502|NCT00430066|Drug|Imatinib Mesylate|400 mg/die for 6 months
45947503|NCT00096005|Drug|tanespimycin|Given IV
46076146|NCT05154162|Procedure|Transperineal template prostate biopsy|Transperineal template prostate biopsies will be performed as per treating urologist's usual practice. No specific template for biopsy is prescribed for the purposes of the study. However, template sampling of the prostate is required, with a minimum of 12 cores, dependent on prostate volume. MRI will be available for any additional targeted biopsies required. Transperineal template biopsies must be labelled appropriately and sent for histopathological analysis.
46076147|NCT05154162|Procedure|Transperineal targeted prostate biopsy|If the PSMA PET/CT is normal, transperineal prostate biopsy would be omitted If the PSMA PET/CT is abnormal, transperineal prostate biopsies would be performed targeting the MRI (done prior to study) and PSMA PET/CT images
46076148|NCT04247984|Biological|Bevacizumab|5 mg/kg intravenously administered on day 1 of a 2-week cycle.
46076149|NCT04247984|Drug|Capecitabine|2000mg/m2/day oral on day 1 to day 10 of a 2-week cycle.
46076150|NCT04247984|Drug|Irinotecan|180 mg/m2 intravenously administered on day 1 of a 2-week cycle.
46076151|NCT04247984|Drug|5-FU|400 mg/m2 intravenous bolus on day 1 and 2400 mg/m2 continuous infusion over 44 hours of a 2-week cycle.
46076152|NCT04247984|Drug|CF|300 mg/m2 intravenously administered on day 1 of a 2-week cycle.
46076153|NCT04247984|Drug|Irinotecan|150 mg/m2 intravenously administered on day 1 of a 2-week cycle.
45947504|NCT00096005|Drug|bortezomib|Given IV
45947505|NCT00096005|Other|laboratory biomarker analysis|Correlative studies
45947506|NCT00430105|Drug|cyclophosphamide|
45676379|NCT03596606|Procedure|Myofunctional Motor control exercises|"The protocol is a set of 8 exercises to improve the execution of the function in the stomatognathic and cervical area.~The therapist explains the objectives of the exercises and the patient performs it after each session and at home three times a day.~The first day before performing the myofunctional exercises, will be an explanatory talk prior to the exercises in order to educate the patient. The second day, before doing the exercises, will review the concept of memory of pain and the benefits of doing the exercises"
45810602|NCT00359047|Behavioral|Documentation|Participants will receive written educational material for themselves as well as the Guidelines document for their physician (same written material as in the Educational Video Group). They will be asked to revisit their physician and provide written documentation inviting him/her to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada
45947507|NCT00430144|Drug|Belotecan(CKD-602)|Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
45810603|NCT00359047|Behavioral|Video|Participants will receive a 15-minute educational video on osteoporosis. They will also receive written educational material for themselves and a Guidelines document for their physician. They will be asked to revisit their physician and provide the written documentation inviting her/him to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. Should participants wish to obtain additional information on osteoporosis, they will be provided with a toll-free number (1-866-571-ROCQ) to contact
45810604|NCT05544175|Procedure|NEUROMOdulation pain therapy in combination with intensive physiotherapy|"Neuromodulation: Spinal cord stimulation affects nerve tissues with a defined electrical current. We will use low-voltage electrical stimulation of the posterior roots of the spinal cord in the MRI region of the localized conus medullaris. Electrodes are inserted epidurally from a laminotomy in the lumbosacral region.~Physiotherapy will be based on recommendations for spinal patients."
45810605|NCT00358423|Drug|Pegaptanib Sodium|0.3 mg/0.1 ml intravitreal injection, every 6 weeks, up to a total of 3 injections
45810606|NCT00358423|Drug|Control|Sham injections, every 6 weeks, up to a total of 3 sham injections
45810607|NCT02896712|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT will assist cocaine patients to notice internal cravings and triggers, abandon attempts to manage these triggers via active avoidance, suppression or other control-based strategies, and to make commitments to engage in behaviors consistent with chosen values or goals. ACT encourages clients to experience thoughts and feelings from an observer perspective, and helps clients not to believe distressing thoughts and feelings as if those thoughts and feelings are literally true and in need of action. ACT treatment will be based on the ACT therapy manual developed and tested previously.
45810608|NCT02896712|Behavioral|Drug Counseling (DC)|The investigators will use the manual-guided individual DC modeled after the NIDA Collaborative Cocaine Treatment Study and used as the active control therapy in previous studies. DC approximates clinical practice as it is considered the most common type of evidence-based treatment in the community for patients actively using cocaine.
45810609|NCT02896712|Behavioral|Contingency Management (CM)|The investigators will use the same high-magnitude CM schedule shown previously to be feasible and effective in facilitating initial cocaine abstinence. Subjects will earn vouchers for cocaine-negative urine samples collected at scheduled clinic visits each week. Under an escalating reinforcement schedule, voucher values will begin at $15 and increase by $10 for each consecutive negative urine. Bonus vouchers of $10 will be given for three consecutive negative urines. Provision of a cocaine-positive urine or failure to provide a scheduled sample will result in no vouchers earned and will reset the schedule to the initial value of $15.
45810610|NCT02896712|Drug|Placebo|The placebo capsule will be filled with corn starch and riboflavin.
45810611|NCT02896712|Drug|Modafinil|Modafinil capsules will start at 200 mg (day 1) and increase to the fixed dose of 300 mg (day 2) and will also contain riboflavin.
45810612|NCT05540899|Radiation|Hypofractionated Postoperative Radiotherapy|Hypofractionated Postoperative Radiation Therapy
45947508|NCT05207163|Behavioral|Continuing medical education|Education section about knowledge of transmissions, severity of viral hepatitis B-C and update treatment strategy of the HBV-HCV
45947509|NCT00430261|Drug|sunitinib|50mg po qd x 4 weeks on followed by 2 weeks off for a 6 week cycle.
45947510|NCT00096083|Drug|isolated perfusion|
45453422|NCT00719888|Drug|Cyclophosphamide|Given IV
45947511|NCT00096083|Drug|melphalan|
45947512|NCT00430378|Procedure|Acupuncture|Acupuncture for 20 minutes before the radiation therapy session, 3 days a week for 7 weeks.
45453423|NCT00719888|Drug|Cyclosporine|Given IV and PO
45947513|NCT00430378|Other|Standard Care|No Acupuncture.
45676380|NCT03590054|Drug|Abexinostat|Given orally (PO) twice a day (BID) days 1-4, 8-11 of every 21 day cycle
45947514|NCT00430456|Procedure|Exercise|Treadmill Training
45658362|NCT05866146|Other|Interprofessional rehabilitation program|The interprofessional rehabilitation program includes a comprehensive assessment, intensified physical activities and exercises, pain education, psychotherapy, occupational therapy, ergonomic interventions, and psychosocial counselling in addition to the current treatment standards. The interprofessional rehabilitation program will be delivered in a combination of individual (one-to-one) and group sessions (in groups of 6 - 10 patients). Care providers will apply a combination of lectures and discussions, individual exercises, and group-based exercises and education. All sessions will be delivered face-to-face (in person). The intervention will be provided by a team of healthcare providers with different professional backgrounds and training. The interprofessional team may include experienced physicians (GPs), neurosurgeons, physiotherapists, nurses, occupational therapists, and clinical psychologists.
45947515|NCT00430534|Biological|EBV vaccine (268664)|
45810613|NCT04744064|Dietary Supplement|Protein and carbohydrate|Intake of 2 x 250 ml of either protein (750 KJ, 21.0 g protein (milk protein), 15.0 g carbohydrate, 4.5 g fat ) or carbohydrate ( 750 KJ, 0 g protein, 0 g fat and 49.2 g carbohydrate (2:1 ratio of maltodextrin: fructose))
45810614|NCT05346601|Drug|Chiauranib|50mg po only once
45658363|NCT05866146|Other|Usual standard care|Participants in this group will receive the usual care currently implemented mainly pharmacological treatment (pain medication), and back pain advice. The usual care in rare occasions may also include physical therapy such as exercise and massage.
45810615|NCT04744844|Procedure|blastocoel fluid biopsy|In the present study, blastocoel fluid biopsy (BF-biopsy) and collapse will be performed using a microinjection pipette similar to that used to perform ICSI. The pipette will be pushed gently through the zona pellucida and TE, and up to 90% of the BF will be aspirated.
45810616|NCT02797184|Drug|KNO3, potassium nitrate|Potassium nitrate (KNO3) will be given orally in 2 gelatin capsules, which will be compounded by the Barnes-Jewish Hospital Pharmacy. The doses are 10 mmol and 20 mmol KNO3.
45810617|NCT05336695|Diagnostic Test|PET/MR Imaging|PET/MRI Scan with [64Cu]FBP8 as directed by protocol
45810618|NCT05336695|Drug|64Cu-FBP8|Will be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center
45810619|NCT05330221|Behavioral|PAL2|Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education Other Names: Pragmatic personalized, adaptable approach to lifestyle and life circumstance
45658364|NCT05866120|Other|Physiotherapy on the ground|Physical therapy will be performed on the ground, in 12 weeks, twice a week. The exercises will be based on a protocol developed by the researchers. This protocol has 15 exercises, aimed at muscle function and extensor musculature. All exercises can be adapted according to the severity of the individual, as well as the progression of these exercises will be made according to the adaptation and ease of individuals throughout the intervention.
45810620|NCT05330221|Drug|PHARM-PAL2|"All intervention arm participants will be referred to our study pharmacist who will prescribe a antihypertensive medication as per standard of care medical treatment algorithm to achieve BP control.~Per AHA recommended guidelines, participants with an indication of diabetes mellitus (DM) and/or CKD will be started on SGLT2 inhibitor within the first month of starting the study intervention."
45676381|NCT03590054|Biological|Pembrolizumab|Given IV on day 1 of every 21 day cycle
45810621|NCT02766686|Radiation|Radiotherapy with protons|
45810622|NCT02766686|Radiation|Radiotherapy with photons|
45810623|NCT00708890|Behavioral|Brief motivation to participate in TSG|The intensive intervention will consist of a boost motivational session on follow-up alternatives and particularly on attending TSGs. Efforts will be made to connect the patients with TSG volunteers via the AA/NA contact telephone. The patients are encouraged to invite AA/NA contact persons to visit them on the ward. The patient will then have the possibility to be followed to a meeting after treatment. The patients in the intensive referral group will get a phone call four weeks after discharge. The focus of this call will be on continued motivation to attend TSGs.
45810624|NCT05524285|Device|Intracranial Support Catheter|Endovascular procedure using the intracranial support catheter which approved by NMPA
45810625|NCT05524285|Device|Guide Catheter|Endovascular procedure using the guide catheter which approved by NMPA
45810626|NCT05693155|Behavioral|Voluntary self-exclusion from gambling ('Spelpaus')|Voluntary self-exclusion from gambling, using the government-based, official service 'Spelpaus' (literally 'play break')
45810627|NCT04344379|Drug|hydroxychloroquine|200 mg BID per day
45810628|NCT04344379|Drug|azithromycin|250 mg per day
45810629|NCT04344379|Drug|hydroxychloroquine placebo|200 mg BID per day
45810630|NCT02465216|Other|Placebo|Placebo
45947516|NCT01726452|Drug|Epirubicin|50mg/m2 on Day 1 of each cycle only (i.e. every 21 days)
45947517|NCT01726452|Drug|Cisplatin / Oxaliplatin|Cisplatin, 60mg/m2 on day 1 of each cycle only (i.e. every 21 days). OR Oxaliplatin,130 mg/m2 on Day 1 of each cycle (i.e. every 21 days) The choice between administering Cisplatin or Oxaliplatin is at the discretion of the investigator.
45947518|NCT01726452|Drug|5 Flourouracil/ Capecitabine|5-Flourouracil 200 mg/m2/day every day for 21 days OR Capecitabine 625 mg/m2 twice daily orally). The choice between administering 5 Flourouracil or Capecitabine is at the discretion of the investigator.
45947519|NCT01726452|Radiation|(41.4 Gy/23 fractions)|Patient will receive 4.5 weeks of radiation therapy (41.4 Gy/23 fractions).
45947520|NCT01726452|Drug|Paclitaxel|50mg/ m2 Paclitaxel dose administered on Days 1, 8, 15,22 and 29. Dexamethasone, Chlorphenamine and Ranitidine dose given per local standard practice. NACL infusion per local standard practice. Ondansetron dose given per local standard practice on Days 1, 8, 15, 22 and 29.
45658365|NCT05866120|Other|Aquatic physiotherapy|Aquatic physiotherapy will be performed in 12 weeks, twice a week, in shallow water. The exercises will be based on a protocol developed by the researchers. This protocol has 15 exercises, aimed at muscle function and extensor musculature. All exercises can be adapted according to the severity of the individual, as well as the progression of these exercises will be made according to the adaptation and ease of individuals throughout the intervention.
45947521|NCT01726452|Drug|Carboplatin|Dose determined as per calculation, infused on Days 1, 8, 15, 22 and 29
45658366|NCT05866120|Other|Power training|The individuals will be submitted to the same exercises as the therapy protocol on the ground, but with a focus on power training, with fewer repetitions of the exercises and greater speed of movement in the concentric phase of the movement. As with other therapies, participants will be accompanied by therapists in small activity groups.
45810631|NCT02465216|Biological|ID93 + GLA-SE|ID93 + GLA-SE
45810632|NCT05448703|Other|Blood Samples for Biomarkers|blood sample to be taken at baseline, during radiotherapy, and after radiotherapy
45947522|NCT01726452|Drug|Docetaxel|Docetaxel, 50 mg/m², day 1 of each cycle (i.e. every 14 days)
45947523|NCT01726452|Drug|Oxaliplatin|85 mg/m², day 1 of each cycle (i.e. every 14 days)
45676382|NCT03581123|Behavioral|Supported-Self Management (SSM)|Provides low back pain sufferers opportunities to develop the capacity and motivation to self-manage their pain in an adaptive manner. This includes psychological/behavioral strategies, mind-body approaches, lifestyle advice, pain education and pain coping.
45676383|NCT03581123|Other|Spinal Manipulation Therapy (SMT)|SMT will address the biological and physical aspects of low back pain (e.g. spinal dysfunction) with the intention of restoring maximum movement and functional ability of the spine.
45947524|NCT01726452|Drug|Leucovorin|200 mg/m², day 1 of each cycle (i.e. every 14 days).
45947525|NCT01726452|Drug|5-Fluorouracil|2600 mg/m² Day 1 of each cycle (i.e. every 14 days) Dexamethasone or equivalent, 8mg, twice daily, Day before, day of and day after OR administered as per standard practice
45947526|NCT00096239|Drug|CP-547,632|
45947527|NCT00096317|Drug|ixabepilone|
45810633|NCT02465372|Behavioral|CSPAP|Comprehensive School Physical Activity Program.
45810634|NCT00359125|Drug|mifepristone (RU-486)|RU-486, 600 mg/day for 1 week.
45810635|NCT00359125|Other|Placebo|Placebo, 600 mg/day for 1 week.
45810636|NCT05688709|Behavioral|WhatsApp peer support group|YLHIVA assigned to the WhatsApp group will interact with each other and their peer counsellors through one-on-one private communications and on the group chat. The group chat will allow YLHIVA to ask questions, post comments, and reply to one another at any time. We shall share education videos once a week at a time agreed upon with study participants to optimize assimilation of information. In addition, peer counsellor will engage in private WhatsApp calls with youth once a week, to monitor psychosocial state, medication adherence, identify barriers to adherence and counsel YLHIVA. However, youth may initiate in more private communications' when need arises. The peer counsellor will also engage with YLHIVA daily through WhatsApp messages. We will tailor the messages to young people's treatment schedules, clinic appointments, and psychosocial state. Again, youth may text a peer counsellor whenever they wish to do so.
45810637|NCT05686603|Device|a fractional 1064-nm neodymium-doped yttrium aluminum garnet (Nd:YAG) picosecond laser with MLA handpiece|Picosecond laser is a novel technology characterized by ultra-short, picosecond pulse duration which can be effective for many skin conditions, such as pigmentation, photoaging and wrinkles reduction. When combined with micro-lens array (MLA) optics, high-intensity, micro-injury zones can be generated in the epidermis and dermis, causing optical breakdown of surrounding tissue and stimulating of dermal remodeling with mild side-effects. Previous studies had showed the picosecond lasers with MLA afforded better or similar clinical outcomes as well as fewer side-effects in treating acne scar than non-ablative lasers.
45810638|NCT05686603|Device|a ablative fractional 2940-nm Er:YAG laser|2940-nm erbium yttrium aluminum garnet (Er:YAG) laser is one of the most commonly used treatments for atrophic acne scars, which can remove the damage tissue of the scars and allow collagen remodeling and re-epithelialization.
45947528|NCT00096317|Drug|ketoconazole|
45947529|NCT01687608|Biological|AskBio009|Single dose IV injection
45947530|NCT00096395|Drug|gemcitabine hydrochloride|Given IV
45947531|NCT00096395|Drug|sorafenib tosylate|Given orally
45947532|NCT00096395|Other|laboratory biomarker analysis|Correlative studies
45453424|NCT00719888|Procedure|Double-Unit Umbilical Cord Blood Transplantation|Undergo double-unit UCBT
45947533|NCT00096434|Drug|sorafenib tosylate|Given orally
45947534|NCT00096434|Other|laboratory biomarker analysis|Correlative studies
45453425|NCT00719888|Drug|Fludarabine|Given IV
45453426|NCT00719888|Other|Laboratory Biomarker Analysis|Correlative studies
45676384|NCT03581123|Combination Product|SMT + SSM|Combination Treatment
45947535|NCT00096473|Drug|Donepezil hydrochloride|
45947536|NCT00130494|Drug|Zoledronic acid|
45947537|NCT05189652|Other|Myofascial Release and Exercise Group|"The exercise program will be applied 3 days a week for 4 weeks. Participants will warm up by walking for 5 minutes before exercise. Stretching exercises - Reach forward with sitting and hamstring (3 reps*30 sec).~First 2 weeks:~Squat exercise (3 sets of 10 reps). Standing on one leg with knee flexed and hip-knee flexed at 90 degrees (30 seconds).~Star Excursion balance training (2 rounds to be applied). Foam Roller massage will apply to thoracolumbar posterior chain (1 set of 30 seconds will be applied with a rolling period of 2-4 seconds).~Last 2 weeks:~Squat exercise (3 sets of 15 reps). Standing on one leg with knee flexed and hip-knee flexed at 90 degrees (40 seconds).~Star Excursion balance training (3 rounds to be applied). Foam Roller massage will apply to thoracolumbar posterior chain (2 sets of 30 seconds will be applied to each area with a rolling period of 2-4 seconds)."
46002215|NCT04314817|Drug|Any drug used to treat Covid-19|lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date.
45453427|NCT00719888|Drug|Mycophenolate Mofetil|Given IV and PO
45453428|NCT00719888|Radiation|Total-Body Irradiation|Undergo high-dose or moderate-intensity TBI
45453429|NCT00719888|Procedure|Umbilical Cord Blood Transplantation|Undergo UCBT
45453430|NCT00719888|Drug|Thiotepa|Given IV
45947538|NCT05189652|Other|Exercise Group|"The exercise program will be applied 3 days a week for 4 weeks. Participants will warm up by walking for 5 minutes before exercise. Stretching exercises- Reach forward with sitting and hamstring (3 reps*30 sec).~First 2 weeks:~Squat exercise (3 sets of 10 reps). Standing on one leg with knee flexed and hip-knee flexed at 90 degrees (30 seconds).~Star Excursion balance training (2 rounds to be applied).~Last 2 weeks:~Squat exercise (3 sets of 15 reps). Standing on one leg with knee flexed and hip-knee flexed at 90 degrees (40 seconds).~Star Excursion balance training (3 rounds to be applied)."
45947539|NCT00096512|Drug|sorafenib tosylate|Given orally
45947540|NCT00096512|Other|laboratory biomarker analysis|Correlative studies
45810639|NCT03042468|Drug|177Lu-PSMA-617|177Lu-PSMA-617 [50mCi (1.85GBq) - 300mCi (11.1GBq)] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)
45810640|NCT03042468|Drug|68Ga-PSMA-HBED-CC|68Ga-PSMA-HBED-CC [5 ±2mCi or 185 ±74MBq] intravenous during screening and at 12 weeks with standard imaging
45947541|NCT05168085|Dietary Supplement|Eggs|Providing 1 egg per day fo 6 months to infants
45947542|NCT00096551|Drug|Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM)|
45810641|NCT05158452|Procedure|Discussion|Attend a focus group
45947543|NCT00096551|Drug|Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM)|
45947544|NCT00096551|Drug|Recombinant Fowlpox-GM-CSF|
45947545|NCT00402948|Drug|TPI ASM8|0.25mg, 0.5mg for 14 days, daily dosage
45947546|NCT00402948|Drug|ASM8|inhalation 0.25mg daily for 14 days
45810642|NCT04486326|Drug|Crofelemer|Crofelemer
45810643|NCT04486326|Drug|Placebo|placebo
45810644|NCT05297773|Behavioral|Aerobic Training Group|The participants will perform continuous cycling at 30%-35% of their heart rate reserve for one month (phase 1: adaptive phase). Then, the intensity will increase every 4-5 weeks (± 5%) up to a maximum of 64% of heart rate reserve (moderate intensity), depending on the participant's tolerance. An individualized equation establishing the relationship between heart rate, oxygen consumption, and power output will be determined during the cardiorespiratory fitness assessment and used to determine exercise intensity.
45947547|NCT01053988|Drug|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
45947548|NCT01053988|Drug|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
45947549|NCT01053988|Drug|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
45453431|NCT00582842|Behavioral|Interview|The phone interview will consist of the following items from the follow up questionnaire; 14, 16, 20, 32, 33, 46, 47, 60, and 65. An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
45658367|NCT05866107|Device|self-monitoring of weight using smart body fat scale with high-precision weighing chip (Huawei Scale 2pro), a mobile phone app (Huawei Health), dietary management, and exercise management.|Participants will use a mobile phone app (Huawei Health) to collect data on sleep log, daily activities and calorie consumption. The smart body fat scale with high-precision weighing chip (Huawei Scale 2pro) will be used to collect heart rate, weight, BMI, body type, basal metabolic rate, fat rate, fat free body weight, skeletal muscle mass, bone salt content, visceral fat grade, body water (%), body protein rate and body composition, and all data will be uploaded to the app. Participants could also record their daily dietary intake (for calculation of calorie intake) in the health app; psychiatrists evaluate the patient's condition and conduct laboratory tests; nutrition instructors conduct dietary education and formulate individualized energy-limited balanced diet prescriptions; exercise instructors conduct behavioral ways and sports education, and individualized exercise prescriptions.
45658368|NCT05866094|Behavioral|Nutritional Intervention|"Nutrition training will be provided to home care staff to deliver the intervention via the participating Home Care Providers from two localities (South and North of England).~This phase will involve identification of people with dementia on their caseload, preliminary assessment of potential impact via collection of quantitative data at baseline (pre-intervention), and at 4 months follow-up (4 months after the first visit by trained home care workers, following baseline).~A process evaluation will be conducted to gather data on intervention fidelity and implementation (quantitative and qualitative)."
45810645|NCT05297773|Behavioral|Resistance Training Group|Initially, and during the first two weeks of the adaptive phase (1-month), the resistance training group will perform one set of 8-12 repetitions (40%-repetition maximum) of 8 exercises for upper and lower body (squat, leg extension, leg curl, deadlift, plank, dead bug, seated row, shoulder press). Then, in the last two weeks, the participants will perform 2 sets of each exercise (45%-repetition maximum). After the adaptive phase, three sets of each exercise will be performed. The initial load will be 50% -repetition maximum increasing up to a maximum of 70%-repetition maximum at the end of the study. Every 4-5 weeks the load will be reviewed and adjusted according to individual.
45810646|NCT05297773|Other|Control group|The control group will perform a weekly stretching/relaxation session for 45 minutes.
45810647|NCT05295901|Device|mKOAH application|mobile app installed group
45947550|NCT01053988|Drug|Placebo|Placebo
45947551|NCT00095186|Drug|Recombinant Human Lactoferrin|
45947552|NCT00096590|Other|coagulation study|
45947553|NCT00096590|Other|immunoenzyme technique|
45947554|NCT00096590|Other|laboratory biomarker analysis|
45947555|NCT00096590|Other|physiologic testing|
45947556|NCT00096590|Procedure|study of high risk factors|
45947557|NCT00130572|Drug|Pimecrolimus|
45947558|NCT00096629|Biological|human prostate-specific membrane antigen plasmid DNA vaccine|
45947559|NCT00096629|Biological|mouse prostate-specific membrane antigen plasmid DNA vaccine|
45947560|NCT00430651|Drug|Docetaxel|Docetaxel 50 mg/m2 IV on days 1 and 15 every 28 days for 6 cycles
45947561|NCT00430651|Drug|Carboplatin|Docetaxel 50 mg/m2 IV over 1 hour followed by Carboplatin 4 AUC IV over 1 hour on days 1 and 15
45947562|NCT00430690|Procedure|acoustic startle testing|acoustic startle testing: listening to sounds through headphones while the eyeblink component of the acoustic startle reflex is recorded with small surface electrodes
45947563|NCT00430729|Drug|Roflumilast|
45947564|NCT00130611|Other|BNP measurement|
45947565|NCT00130611|Other|Clinical examination|
45810648|NCT04450836|Drug|Regorafenib then Trifluridine/Tipiracil|"REGORAFENIB 160 mg per day during 3 weeks followed by 1 week off of each 4-week cycle except for cycle 1.~During first cycle: dose is started at 80 mg per day at week 1, 120 mg per day at week 2, 160 mg per day at week 3, followed by 1 week off.~Then TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 4-week cycle."
45947566|NCT00430807|Drug|hydroxychloroquine/placebo|
45947567|NCT00096668|Drug|TOCOSOL(R) Paclitaxel|
45947568|NCT00430846|Drug|SGN-35|Every 21 days. Dose Escalating. 0.1 - 3.6 mg/kg
45947569|NCT00430885|Drug|Octagam (IVIG)|Intravenous immunoglobulin 0.4 g/kg given as infusion
45947570|NCT00430924|Drug|Eplerenone|Once daily administration for 8 weeks and 8 weeks control.
45947571|NCT00096707|Drug|2-deoxy-D-glucose (2DG)|
45947572|NCT00430963|Drug|IncobotulinumtoxinA (Xeomin) (20 Units)|
45947573|NCT00430963|Drug|Placebo|
45947574|NCT05102409|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed once
45947575|NCT05102409|Drug|Xiidra® (5% lifitegrast ophthalmic solution)|Xiidra® (5% lifitegrast ophthalmic solution) dosed once
45947576|NCT01053247|Drug|0416|Topical 0416 test product applied twice daily for 2 weeks
45947577|NCT01053247|Drug|Vehicle of 0416 test product|Vehicle of 0416 test product applied twice daily for 2 weeks
45947578|NCT01053247|Drug|tacrolimus ointment 0.1%|Reference Product for 0416 test product. Apply twice daily for 2 weeks.
45947579|NCT00096746|Drug|LPV/RTV + 2NRTIs|Tablets, Oral, Variable, Twice daily, 48 weeks.
45947580|NCT00096746|Drug|LPV/RTV + 2NRTIs|Tablets, Oral, Variable, Twice daily, 48 weeks.
45453432|NCT00582842|Behavioral|survey instruments using Web-Based Data Collection System (WBDC) survey content|The content of the WBDC questionnaire will be similar to the paper form, no alteration in the wording, the order, or the formate of the items will be done. In addition, at the time of each outpatient clinic visit to MSKCC, these subjects will be able to login to WBDC using a computer located in the patient waiting-area, and enter their responses to the different items of the questionnaire if their clinic visit corresponds to any of the study time points 3, 6, 9, 12, 15, 18, 24, 36, and 48 following treatment). An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
45947581|NCT05089071|Device|Assist by artificial intelligence system for colon polyp detection|Assist by artificial intelligence system for colon polyp detection
45947582|NCT00096824|Behavioral|Neurological assessment|All participants will undergo neurological examinations and neuropsychological assessments.
45658369|NCT05866081|Device|Standard of care stent placement|Participants will have a stent placed per randomization assigned if there are no complications (per protocol) during ureteroscopy that excludes the participant.
45947583|NCT05088603|Device|Clear Mask|The clear mask has a 4.75 x 1.35 inch clear window that allows for clear visibility of the mouth.
45947584|NCT00096863|Drug|Ziprasidone|
45658370|NCT05866081|Other|No stent placement|Participants not have a stent placed per randomization assigned if there are no complications (per protocol) during ureteroscopy that excludes the participant.
45658371|NCT05866081|Other|Surveys|"All participants in the trial cohort and observational arms will be asked to complete survey instruments (evaluating their pain, quality of life, and experiences following ureteroscopy, as well as surveys evaluating their opinions and preferences around ureteral stenting, etc.).~Participants will also have routine clinical data (preoperative, perioperative, and postoperative) to be collected and analyzed for research purposes."
45658372|NCT05866068|Drug|Clomiphene|Clomiphene citrate 100mg daily during IVF stimulation
45658373|NCT05866055|Drug|VX-973|Suspension for oral administration.
45947585|NCT00096863|Drug|Haloperidol|
45947586|NCT00096863|Other|Placebo|
45658374|NCT05866055|Drug|Placebo|Suspension for oral administration.
45658375|NCT05866055|Drug|Midazolam|Syrup for oral administration.
45947587|NCT00130650|Device|Pain Ease|
45947588|NCT00096902|Procedure|Tilt table test|
45947589|NCT01052779|Drug|Ferumoxytol|IV Ferumoxytol
45947590|NCT01052779|Drug|Iron Sucrose|IV Iron Sucrose
45947591|NCT00431002|Behavioral|Resistance training|See Detailed Description.
45947592|NCT00130767|Drug|finasteride|
45947593|NCT00096980|Drug|Raptiva (efalizumab)|
45947594|NCT00431080|Drug|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles
45947595|NCT00431080|Drug|Paclitaxel|Paclitaxel 175 mg/m2 as an IV infusion over 3hrs every two weeks for 4 cycles
45947596|NCT00431080|Drug|Epirubicin|Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
45947597|NCT00431080|Drug|Cyclophosphamide|Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
45947598|NCT00431080|Drug|5-fluoruracil|5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
45947599|NCT00431080|Drug|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
45947600|NCT00431119|Drug|Azathioprine or Mycophenolate mofetil|
45947601|NCT00431158|Other|Different Mechanical Ventilation Protocols|"OLA Group: Open lung approach protocol and recruitment maneuvers~ARDSnet Group: ARDSnet protocol"
45947602|NCT05076708|Other|IQOS|All participants switch from cigarette smoking to IQOS use for a 14-day phase.
45947603|NCT00097019|Drug|bevacizumab|
45947604|NCT00431197|Drug|Ketoconazole, Dexamethesone, Androgel,GnRH|
45947605|NCT00431236|Drug|Oral Casopitant (GW679769)|
45658376|NCT05866042|Device|tDCS|TDCS is a noninvasive neurostimulation technique involving the transcranial application of a low-amperage electric current at a region of the cerebral cortex involved in the pathogenesis of major depression, the dorsolateral prefrontal cortex. In healthy subjects, the administration of excitatory tDCS on the left DLPFC improves the regulation of attention on information characterized by negative emotions, as does the administration of inhibitory tDCS on the DLPFC Right tDCS produces small changes in the neuronal membrane potential, thus increasing or decreasing the excitability of the stimulated tissue. Simultaneous administration to behavioral tasks designed to activate the stimulated cortical region should achieve a synergistic, amplifying the plasticity stimulated by the task.
45658377|NCT05866029|Drug|Denosumab|Active Comparator: 60mg of Denosumab treatment by subcutaneous injection
45658378|NCT05866029|Drug|Teriparatide|Teriparatide was sequentially treated with Denosumab
45810649|NCT04450836|Drug|Trifluridine/Tipiracil then Regorafenib|"TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 4-week cycle.~Then REGORAFENIB 160 mg per day during 3 weeks followed by 1 week off of each 4-week cycle except for cycle 1.~During first cycle: dose is started at 80 mg per day at week 1, 120 mg per day at week 2, 160 mg per day at week 3, followed by 1 week off."
45947606|NCT00431236|Drug|IV Casopitant (GW679769)|
45947607|NCT00431236|Drug|IV ondansetron hydrochloride|
45947608|NCT00431236|Drug|Oral dexamethasone|
45658379|NCT05866016|Behavioral|Skill birth attendant training|It is an intervention targeted to enhance the competencies of Maternal Neonatal Health (MNH) service providers (skilled birth attendants) in Nepal. It is a capacity-building intervention that is expected to contribute to reducing maternal and neonatal morbidities and mortalities by improving the midwifery competencies (knowledge, attitudes, and skills) of MNH service providers.
45947609|NCT00130806|Drug|MK0478 (muraglitazar)|
45453433|NCT01332890|Other|Sequence 1|Period1(A) Period2(B) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
45453434|NCT01332890|Other|Sequence 2|Period1(C) Period2(A) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
45453435|NCT01332890|Other|Sequence 3|Period1(B) Period2(C) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
45453436|NCT01332890|Other|Sequence 4|Period1(C) Period2(B) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
45658380|NCT05865990|Drug|Patritumab deruxtecan|HER3 directed antibody drug conjugate (ADC) that is comprised of a fully human anti-HER3 immunoglobulin gamma-1 (IgG1) monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a stable tetrapeptide-based cleavable linker.
45658381|NCT05865977|Device|diaphragmatic tissue Doppler imaging，dTDI|dTDI was performed at the end of the SBT to assess excursion, velocity, and acceleration.
45658382|NCT05865951|Other|Isometric Exercises|Isometric (same length) strengthening exercises of the neck muscles will be performed.
45810650|NCT04436406|Diagnostic Test|[99mTc]-NM-01 SPECT/CT|Technetium labelled anti-PD-L1 single-domain antibody (NM-01) single-photon emission computed tomography (SPECT)/CT
45658383|NCT05865951|Other|Isotonic Exercises|Isotonic strengthening exercises for the neck muscles will be performed.
45676385|NCT03581123|Drug|Standard Medical Care (SMC)|Guideline based medical care informed by the American College of Physicians' guidelines on noninvasive treatment for low back pain.
45676386|NCT03568097|Drug|Avelumab|10 mg/kg will be given as intravenous infusion (IV) every two weeks (q 2 weeks) until disease progression.
45810651|NCT05679193|Drug|Propranolol|"Propranolol capsules 20mg taken orally~Day: 1-3:~20mg twice daily~Day: 4-19 (25 , In cases of delayed RALP an extension of up to 6 days is allowed.in cases of delayed surgery).~2x 20mg twice daily~Day 20-22 20mg twice daily"
45810652|NCT04795752|Device|TearCare System|TearCare procedures in this study will include an in-office eyelid debridement, 15 minute bilateral thermal session with the TearCare System, immediately followed by manual expression of the meibomian glands using the Clearance Assistant Plus device. Subjects randomized to TearCare will receive one in-office TearCare procedure within 7 days of the Baseline visit and at 5 Months. Beginning at 9 Months, subjects will receive an additional TearCare procedure when TBUT drops lower than Baseline or within 2 seconds of baseline AND/OR if OSDI worsens by at least 1 category.
45947610|NCT00130806|Drug|Comparator: placebo|
45947611|NCT00431275|Drug|CP-675,206|CP-675,206 15 mg/kg iv single dose on Day 1
45947612|NCT00431275|Drug|CP-675,206|CP-675,206 15 mg/kg iv single dose on Day 1
45947613|NCT00431353|Drug|Ganciclovir|5mg/kg iv bid for 21 days
45947614|NCT00431353|Drug|valganciclovir [Valcyte]|900mg po bid for 21 days
45947615|NCT00097097|Procedure|Neonatal Resuscitation|
45947616|NCT00130845|Drug|Octreotide Acetate in Microspheres|
45947617|NCT00130845|Drug|Placebo|
45947618|NCT00431392|Drug|Phenylephrine|
45947619|NCT00431392|Drug|NG-Monomethyl-L-Arginine|
45947620|NCT00431392|Drug|Propanolol|
45947621|NCT00431392|Drug|Atropine|
45947622|NCT00431470|Behavioral|Six classroom based character building education lessons|
45947623|NCT00130884|Drug|levosimendan|
45947624|NCT01052662|Drug|Memantine|30mg/day Memantine orally everyday for 12 weeks
45947625|NCT01052662|Drug|Memantine|15 mg/day Memantine orally everyday for 12 weeks
45947626|NCT01052662|Drug|Placebo|Placebo orally everyday for 12 weeks
45947627|NCT00431509|Procedure|conventional vs. navigated total knee arthroplasty|
45947628|NCT00431548|Drug|100% O2|
45947629|NCT00097214|Drug|Carboplatin|AUC= 6 IV will be given on the first day of each 3-week cycle, beginning on Day 8.
45947630|NCT00097214|Biological|Cetuximab|400 mg/m2 IV on Day 1, followed by weekly doses of 250 mg/m2 IV beginning on Day 8.
45947631|NCT05049057|Drug|Erenumab 140 Mg/mL Subcutaneous Solution|Active erenumab delivered via subcutaneous injection.
45947632|NCT05049057|Drug|Placebo|Placebo delivered via subcutaneous injection.
46076154|NCT05146362|Other|Vermont RETAIN|RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and a control group that is not.
45947633|NCT00431665|Drug|NG-monomethyl-L-Arginine (L-NMMA)|
45947634|NCT00431665|Drug|triglycerides (Intralipid 20%)|
45453437|NCT01332890|Other|Sequence 5|Period1(B) Period2(A) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
45676387|NCT03768063|Drug|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) or comparator agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
45676388|NCT03564691|Drug|MK-4830|MK-4830 will be administered intravenously (IV) Q3W. In Part C, MK-4830 will be administered after completion of pembrolizumab infusion. Dose escalation will proceed based on emerging safety and tolerability data of MK-4830 as monotherapy (Part A and B) and as combination therapy with pembrolizumab (Part C). For each dose level, an assessment will be made of the safety and tolerability data in order to define the next dose level to be tested.
45810653|NCT04795752|Drug|Restasis|Restasis group will be required to self-administer 1 drop twice a day from baseline through the Month 6 visit. At Month 6, subjects will be crossed over to the TearCare group and will receive one (1) TearCare procedure.
45810654|NCT05501353|Other|no intervention|This study is an observational study, which does not affect the routine diagnosis and treatment of patients and only requires the collection of biological samples at specific nodes
45810655|NCT04795128|Biological|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
45810656|NCT02977741|Drug|Olanzapine|
45810657|NCT04334070|Drug|Lamprene®/Clofazimine|All participants will receive Lamprene/clofazimine 50 mg capsules. The recommended dose of clofazimine for this program is 100 mg once daily, administered orally, preferably with meals. Duration of treatment will be decided by the treating physician. When considering clofazimine for the treatment of NTM infection, clofazimine is to be administered as part of a multi-drug regimen.
45810658|NCT05292001|Drug|Iron-Dextran Complex Injection [InFed]|single 1000mg dose
45810659|NCT05292001|Other|Saline Placebo|Normal saline
45810660|NCT01634178|Drug|Apremilast|Tablet for oral administration
45810661|NCT00358267|Procedure|Partial Resection of Inferior Turbinates (PRIT)|PRIT involves surgically removing a small piece off the turbinate, which also reduces its size.
45947635|NCT00431665|Drug|heparin|
45947636|NCT00431665|Drug|somatostatin|
45947637|NCT00431665|Drug|insulin|
45947638|NCT00431665|Drug|glucose|
45947639|NCT00431665|Drug|inulin|
45947640|NCT00431665|Drug|paraamino hippurate (PAH)|
45947641|NCT00431743|Drug|Hydroxyethylstarch 130/0,4|
45947642|NCT00431743|Drug|Lactated Ringer's solution|
45947643|NCT00130962|Drug|ALGRX 4975|
45947644|NCT02957422|Dietary Supplement|1% Milk|1.5 gallons of 1% milk will be delivered to the participant's home weekly. Participants will be asked to drink 3 cups per day for 3 months.
45947645|NCT02957422|Dietary Supplement|Control|Participants will continue on their regular low dairy diet of ≤1.5 dairy serving/day.
45947646|NCT00097331|Drug|SB683699|
45947647|NCT04703530|Other|hot footbath|The experimental group was given a hot footbath with a temperature of 41℃±1℃ for 20 minutes at about 1-2 hours before sleep
45947648|NCT04703608|Drug|Ivermectin|Ivermectin 0.3-0.4mg/Kg daily for 3 days.
45947649|NCT04703608|Drug|ASP|Aspirin 150mg daily for 28 days or until hospital discharge (whichever is sooner)
45947650|NCT04703608|Drug|Placebo|Non-identical placebo
45947651|NCT04703452|Other|Indicators of central sensitisation|Indicators of central sensitisation, assessed by the Central Sensitization Inventory
45947652|NCT00097409|Drug|Ispinesib|
45947653|NCT00431782|Drug|ATI-5923|
45947654|NCT05001789|Other|CogMed|20 sessions of Cogmed working memory training
45947655|NCT00431821|Behavioral|Exercise|Home-based exercise prescriptions with weekly motivational telephone calls.
45947656|NCT00431821|Other|Stroke education|Stroke education program with matched attention phone calls
45947657|NCT00431860|Procedure|Coronary computed tomographic angiography|
46076155|NCT00948389|Drug|Dasatinib|Tablets, Oral, 100 mg, Once or Twice daily (depending on safety cohort), Until progression or toxicity
46076156|NCT00948389|Drug|Lomustine|Tablets, Oral, 110 mg/m², Every 6 weeks, until progression or toxicity
45947658|NCT02964845|Behavioral|WISH with CHW and referral to HFM|6 intervention counseling sessions with a peer CHW, as well as CHW facilitated linkage to primary care and HIV risk reduction.
45453438|NCT01332890|Other|Sequence 6|Period1(A) Period2(C) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
45810662|NCT00358267|Procedure|Radiofrequency Ablation (RFA)|RFA involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
45947659|NCT02964845|Other|Enhanced Treatment as Usual|Linkage to Primary care.
45947660|NCT00431899|Behavioral|fish oil supplementation|
45810663|NCT03832075|Diagnostic Test|Berg Balance Scale|Berg Balance Scale is 14 item scale for detecting balance disorder.
45947661|NCT00131001|Procedure|contrast-enhanced magnetic resonance angiography|
45947662|NCT00431977|Procedure|coronary computed tomography angiography|
45947663|NCT01052116|Drug|Soy isoflavone supplement|Oral soy isoflavone supplement (100 mg/day)
45810664|NCT03832075|Diagnostic Test|Timed Up and Go Test|Timed Up and Go Test assesses mobility, balance, walking ability, and fall risk in older adults.
45810665|NCT03832075|Diagnostic Test|Korebalance Balance System|"Korebalance Balance System evaluates the balance and stability using objective neuro-sensory balance assessment. Static Test requires standing steady & balancing on the platform, keeping the crosshairs of cursor in the center of the test pattern. The Score indicates the deviation of user's center of gravity from the center of the pattern. Dynamic Test offers a moving cursor that the user follows. Four patterns are offered: Circle, Square, Infinity and Random. Each pattern is available in three dimensions: Small, Medium and Large; five speeds; Clockwise and Counterclockwise directions."
45810666|NCT04418934|Device|Hemanext One|Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 56 days at 1-6°C.
45947664|NCT01052116|Drug|Placebo|Placebo
45947665|NCT04727073|Drug|Experimental: Spironolactone|Spironolactone (an aldosterone antagonist) in tablet form taken daily. The initial study drug dose is 25 mg/day (one tablet) and may be titrated up to 50 mg/day (two tablets) within 4 weeks if kidney function at VR was > 30 mL/min/m2 and potassium < 4.5 mmol/L.
45810667|NCT04794894|Behavioral|outpatient rehabilitation|Treatment provided after completion of inpatient, acute rehabilitation.
45810668|NCT05652192|Radiation|SBRT|SBRT was added to systematic treatment (chemo+ PD-1 antibody)
45810669|NCT00359359|Drug|Sagopilone (BAY86-5302, ZK 219477)|Phase 1: dose escalation/deescalation, starting dose 12mg/m² Sagopilone, Phase 2: MTD or RPIID
45810670|NCT00359359|Drug|Cisplatin|75 mg/m² as a 1 h infusion after the sagopilone infusion on Day 1
45947666|NCT04727073|Drug|Placebo Comparator|Placebo of Spironolactone in tablet form taken daily with dosage escalation rules in accordance with dosage of the study drug Spironolactone.
45658384|NCT05865938|Device|PASCAL vs. MitraClip|"transcatheter mitral valve repair of the mitral valve (M-TEER) using the Edwards PASCAL Transcatheter Valve Repair System or the Abbott MitraClip in patients with severe and symptomatic degenerative or functional mitral regurgitation (FMR).~The type of device system used was not randomized but was determined by the operational structuring of the mitral valve program such that patients were scheduled for the next available implantation date with weekly alternating time slots for MitraClip device and PASCAL device."
45658385|NCT05865925|Drug|LY010616|IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter
45947667|NCT00432016|Drug|zidovudine|
45947668|NCT00432016|Drug|amdoxovir|
45947669|NCT00432016|Procedure|pharmacokinetic sampling|
45947670|NCT04993833|Device|NPi-200 and NPi-300 pupillometers|Device which measures PLR.
45947671|NCT01052077|Drug|OPC-34712|Tablets, Oral, 1 - 3 mg OPC-34712
45947672|NCT01052077|Drug|Placebo|Placebo
45947673|NCT01052077|Drug|ADT|
45947674|NCT00097604|Dietary Supplement|Valerian root extract|Valerian root extract, 100 mg softgels, 3 softgels each night for 2 weeks, 30 minutes before bedtime
45947675|NCT00131040|Drug|Aprotinin|
45947676|NCT00400478|Drug|Rituximab|Rituximab 375mg/m2 i every 8 weeks for two years (12 infusions)
45810671|NCT04782804|Drug|Capecitabine|Capecitabine+PD-1 Antibody（Tislelizumab）as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery.
45810672|NCT04782804|Drug|PD-1 Antibody（Tislelizumab）|PD-1 Antibody（Tislelizumab, 200mg） was given q3w iv.
45810673|NCT04418388|Drug|PBK-1801|Administered orally
45810674|NCT04418388|Drug|PBK-1801|Administered orally
45658386|NCT05865912|Combination Product|Mindfulness training + real tDCS|"The MT is an established app-based programme delivered by Headspace®. During MT, participants complete guided meditation sessions which focus on mindful eating and on coping with cravings. Each MT session lasts 15 min. Participants in the MT+ real tDCS and MT+ sham tDCS groups will be given instructions to practice daily mindfulness for 3 weeks. During 10 of these sessions, MT and real/sham tDCS will be delivered concurrently.~TDCS: During tDCS, a constant weak direct current is applied via electrodes (anode and cathode) placed on the scalp. In this study, the anode will be placed over the right dorsolateral prefrontal cortex (dlPFC) and the cathode will be placed over the left dlPFC. In the real tDCS condition, stimulation will be delivered at a constant current of 2 mA with a 10 second fade in/fade out for 20 minutes. In sham tDCS, the stimulator will deliver 60 seconds of active stimulation at the start (ramping up) and end (ramping down) of the 20 minute period."
45658387|NCT05865912|Combination Product|Mindfulness training + sham tDCS|Mindfulness training + sham tDCS
45947677|NCT04990206|Behavioral|TranS-C|"TranS-C will be provided in eight weekly, one-on-one 50-minute sessions delivered remotely by two-way video conferencing. Each week will include goal setting and homework assignments which will be reviewed in the following session.~The sessions will include information on sleep and circadian rhythms, behavioral change and motivation, and goal setting. The topics covered in the sessions include establishing regular sleep-wake times, learning a wind-down route, learning a wake-up routine, improving daytime functioning, correcting unhelpful sleep-related beliefs, and maintenance of behavior change."
46076157|NCT02777112|Other|e-mental health program|This program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking.
45947678|NCT01052038|Drug|Placebo administration|Placebo administration
45947679|NCT01052038|Drug|Dexamethasone 0.05mg/kr administration|Dexamethasone 0.05mg/kr administered in 100ml of sterile saline solution prior to the start of surgery.
45947680|NCT01052038|Drug|Dexamethasone 0.1mg/kg|Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to the beginning of surgery.
45947681|NCT04703374|Drug|CKD-382(formulation I)|1 tablet administered under fasting condition for 7days
45947682|NCT04703374|Drug|CKD-382(formulation II)|1 tablet administered under fasting condition for 7days
45947683|NCT04703374|Drug|D026|1 tablet administered under fasting condition for 7days
45947684|NCT04972071|Other|Knowledge translation (KT) of the CSRS based practice recommendations|The components of the practice recommendations include: 1) evidence-informed systematic clinical evaluation with appropriate history, physical examination and in-ED investigations (e.g., troponin testing, work-up for pulmonary embolism and CT head) for detecting serious underlying conditions and predicting 30-day serious outcomes; 2) application of the CSRS for risk-stratification at the end of ED visit after no serious underlying conditions for the syncope were identified; 3) use of patient information materials to aid in disposition; and 4) the use of 15-day outpatient cardiac monitoring for CSRS medium and high-risk patients upon ED discharge. All the components of the practice recommendations will be applied by the ED physician treating the patient.
45947685|NCT00432055|Drug|Botulinum toxin type A (Botox)|
45947686|NCT00432055|Drug|placebo (saline)|
46076158|NCT02777112|Other|e-mental health program and job coaching|This combines the e-mental health program and interactive job coaching delivered through telephone. The e-mental health program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking. The job coaching can be accessed by appointment.
45658388|NCT05865899|Procedure|valgus producing medial opening wedge high tibial osteotomy|Valgus producing Opening wedge high tibial osteotomy will be performed through a medial incision at the proximal tibia and stabilized with a plate and screws. Hardware will be removed within 10-12 months to avoid soft tissue irritation.
45676389|NCT03564691|Drug|Pembrolizumab|Pembrolizumab will be administered at 200 mg IV Q3W.
45676390|NCT03564691|Drug|Carboplatin|Carboplatin will be administered IV Q3W.
45947687|NCT00432133|Behavioral|Protection Motivation Theory-Based Intervention|Targets perceptions of outcome severity and susceptibility, self-efficacy, response efficacy, response costs, and rewards of physical inactivity. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
45947688|NCT00432133|Behavioral|Environmenta|Targets increased awareness and use of local parks and trials near the home and work environments. Targets increased access by providing membership to a local fitness facility for 12 months. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
45947689|NCT00097643|Behavioral|exercise|
45676391|NCT03564691|Drug|Pemetrexed|Pemetrexed will be administered IV Q3W.
45676392|NCT03564691|Drug|Lenvatinib|Lenvatinib will be administered orally once daily.
45810675|NCT04418388|Drug|PBK-1801|Administered orally
45810676|NCT04781400|Behavioral|Mobile phone support|Mobile phone support (SMS)
45810677|NCT04781400|Behavioral|Remote service delivery model|ART treatment delivery via a courier service
45658389|NCT05865873|Behavioral|Health education|Health education will be delivered for six months, two times per month; one session will take one hour, and an overall 12 sessions will be conducted. One health education session consists of key messages on normal pregnancy and childbirths, ODS during pregnancy, delivery, and the postpartum period, the practice of BPCR, and the benefits of MHSU. The other actions executed by WDT facilitators will be the motivating mother and their families to utilize MHS. One hour will be allocated for each session, from this 20 minutes will be allowed for the pre-recorded an audio-based lecturer and the remaining 40 minutes will be allowed for raising questions and responses (discussion). After the session, some of the women will be selected to carry out role play which is basic to demonstrate the important messages and share experiences.
45810678|NCT02978521|Other|Pulmonary rehabilitation|Session 1: ventilatory pattern training Session 2,3: ventilatory pattern + respiratory training with incentive spirometer Session 4-6: Sessions 1-3 training continues + training with Positive expiratory pressure device (Threshold PEP) and breathing trainer Threshold IMT) Sessions 7-9: Continue respiratory training + resistance training with RECK MOTOmed2 ergometer at a 30% intensity until 60% is achieved Session 10-12: Continue with previous training + treadmill training
45810679|NCT05651880|Drug|Baricitinib 4 MG|4 mg per day for 6 months (For patients with creatinine clearance between 30 and 60 mL/min at baseline or during the study, the dosage of baricitinib will be 2 mg daily)
45810680|NCT05280535|Behavioral|Cue Reactivity Task|In the cue-reactivity task, participants will be exposed to either a combustible cigarette or e-cigarette cue (within-subjects randomized order across laboratory sessions) and a neutral water bottle cue. Participants will report their craving for cigarettes and e-cigarettes.
45947690|NCT00097643|Behavioral|health promotion|
45947691|NCT00432211|Drug|Avotermin|"Complete Excision:- On Day 0,Following wound closure the two outer segments of the wound will receive either Juvista or placebo.100µl of vehicle containing 200ng of Juvista will be injected per linear centimetre into both margins of one segment of the wound,and 100µl of vehicle alone (placebo) will be injected per linear centimetre into the other segment of the wound. There will be a central area (at least 3cm) of untreated wound between the two segments.The treatments will be re-administered to each wound segment (A and B) 24 hours after the first administration.~Staged Excision On Day 0, the two end segments of the scar will be excised.Following wound closure each subject will receive 100µl of vehicle containing 200ng of Juvista per linear centimetre intradermally into one wound, and 100µl of vehicle alone (placebo) per linear centimetre into the other wound.The trial treatments will be re-administered to each wound 24 hours after the first administration."
45810681|NCT05280535|Behavioral|Computerized Visual Dot Probe|In the computerized visual dot probe task, participants will view a series of substance (cigarette or e-cigarette by trial block) versus neutral (water bottle) image trials and then respond to a subsequent image presented behind either the neutral or substance image. Order of block presentation within the task is randomized within-subjects across study sessions (i.e., cigarette OR e-cigarette block first).
45810682|NCT05280535|Behavioral|Choice Task|In the choice task, participants will choose between smoking their usual brand cigarette or their own e-cigarette over ten sequential ad-libbed trials.
45810683|NCT04781166|Behavioral|Calm program|7 online modules designed to teach cognitive behavioral skills
45810684|NCT05674825|Drug|Targeted agent|"The Molecular Tumor Board (MTB) will suggest molecularly targeted matched treatment."
45947692|NCT00432250|Procedure|Cervical length ultrasound|
45947693|NCT04711044|Other|Papain|Papain will be applied using cowhage spicules inactivated by heat
45947694|NCT04711044|Other|Histamine|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied
45947695|NCT04711044|Other|Cowhage|Cowhage spicules are 1-2 mm in length and have a diameter of 1-3 μm. The spicules are inserted by gently rubbing 30-35 spicules into a 1 cm diameter skin area.
45947696|NCT04711044|Other|L-menthol|A 1 mL aliquot is dispensed onto a 2,5 × 2,5 cm cotton pad and placed on a 6 × 6 cm sheet of medical tape.
45947697|NCT00432289|Procedure|Acupuncture|Acupunture treatment 3x per week for 6 weeks.
45947698|NCT00432328|Drug|Avotermin|
45947699|NCT01051960|Drug|Ambrisentan|Ambrisentan 5mg or 10mg once daily
46002216|NCT04312269|Other|Targeted Memory Reactivation (TMR)|Targeted memory reactivation (TMR) refers to the process of playing audio cues associated with specific learned material quietly during sleep in order to strengthen consolidation of specific memories during sleep.
46002217|NCT04307030|Diagnostic Test|Heart Auscultation and Echocardiography|Heart auscultation will be done by cardiovascular pediatrician and echocardiography by echocardiologist
46076159|NCT02777112|Other|No intervention|Receiving generic information about men's depression from the Movember Foundation website: https://ca.movember.com/programs/mental-health
45658390|NCT05865847|Other|Not applicable, this is an observational study|Not applicable, this is an observational study
45810685|NCT05674825|Drug|Standard of care agent|Subjects will receive treating physician's choice of traditional systemic therapy treatment for their malignancy, defined by National Comprehensive Cancer Network (NCCN) guidelines and/or tumor board recommendation(s).
45810686|NCT04227288|Drug|Enstilar Foam|Subjects will be instructed to apply a thin layer on the nail plate, around the nail plate and under the nail plate. The patient will be instructed to apply one application at night immediately before bed and not wash their hands before morning. All subjects who completed the 6-month treatment will be followed for 1 month after discontinuation.
46076160|NCT02830256|Other|NCS-I (Nociception Coma Scale adapted intubated patients)|Every included patient will be assessed by the 3 methods 3 times (before, during, after the procedure fo care) in 3 conditions. There will be 2 painful conditions usually performed in ICU (Nursing and bronchoaspiration) and a painless condition (RASS assessment).
45810687|NCT04807374|Device|Control IQ|We aim to conduct a non-randomized prospective interrupted time series pilot study to investigate the effect of HCL insulin delivery on glycemic control in underserved adolescents with poorly controlled T1D.
45810688|NCT05651802|Radiation|Prophylactic cranial irradiation|Prophylactic cranial irradiation (PCI) is actually a habitual statement. It is a technique used to eliminate tiny metastatic lesions that have already existed in the brain, but can not be found by brain MRI and other inspection methods.
45810689|NCT05651802|Radiation|Thoracic radiotherapy|Thoracic radiotherapy is a local treatment of tumors located in the chest using ionizing radiation.
45810690|NCT05651802|Drug|Chemotherapy|Chemotherapy is the abbreviation of chemical drug therapy. It is a treatment method that uses chemical drugs to prevent the proliferation, invasion and metastasis of cancer cells, and finally kill cancer cells.
45810691|NCT05673967|Other|Non-Interventional|No study treatment will be administered on this study.
45810692|NCT02724228|Drug|BMN 111|BMN 111 will be administered subcutaneously daily.
46076161|NCT02775318|Procedure|Stellate Ganglion Block|Under aseptic conditions, transducer is placed on the surface of the neck at the level of C6 vertebrae. The internal jugular vein, carotid artery, thyroid gland, trachea, C6 vertebrae, transverse process of C6, esophagus , longus colli with its covering prevertebral fascia and esophagus are visualized. A 25-gauge Quincke spinal needle was inserted paratracheal towards the middle of the longus colli muscle. The endpoint of the injection was the ultrasound image of the tip of the needle as it penetrates the prevertebral fascia covering the longus colli muscle. The drug is then injected and spread of drug is visualized in real time.
45947700|NCT00432367|Drug|Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine|"Eligible women will be allocated randomly to one of three groups and treated as follows:~Arm 1 (OptiMAL® antigen screening and treatment with SP plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment if her screening test is positive.~Arm 2 (OptiMAL® antigen screening and treatment with AQ+AS plus LLIN) - a woman in this will receive 300mg of AQ and 100mg co-administered two times a day for 3 days if her screening test is positive. The first dose is observed on enrolment day at the ANC.~Arm 3 (SP-IPTp plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment as recommended by national policy.~All enrolled women will be given one long lasting insecticide treated bed net each for use."
46076162|NCT02775318|Drug|Bupivacaine|10 ml of 0.5% injection bupivacaine is used for giving stellate ganglion block on the side of cerebral vasospasm
46076163|NCT02775318|Procedure|Transcranial Doppler|The principle on which the TCD works is that with arterial narrowing, the blood flow velocity within the vessel increases. A good correlation has been found between the TCD blood flow velocities and vasospasm. The MCA velocity greater than 120 cm/sec indicates mild vasospasm , velocity greater than 130 cm/sec indicates moderate vasospasm and velocity greater than 200 cm/sec indicates severe vasospasm.
46076164|NCT02775318|Procedure|Digital Subtraction Angiography|Digital subtraction angiography is a direct method for the assessment of vessel caliber. It generates high resolution, high contrast and low artifact images using digital subtraction technology. Direct visualization using DSA is the gold standard for the radiographic diagnosis of cerebral vasospasm
46076165|NCT02854709|Behavioral|Sleep extension|Sleep extension by 1 hour for 2 weeks
45453439|NCT03326492|Drug|Antivenom serum Inoserp Pan-Africa® injection|Participation to the study does not change usual follow-up of patients. All medical procedures will be performed and products will be used in a routine manner. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient.
45453440|NCT01524536|Drug|prednisone|Glucocorticoids (GC) are considered the first- line therapy for hypereosinophilic syndrome.
45453441|NCT00537134|Device|Embolization, coiling|Endovascular embolization with platinum coils
45453442|NCT01315418|Other|1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
45453443|NCT01315418|Other|2-Non fermented dairy product (control)|
45810693|NCT05259865|Diagnostic Test|Genetic test for drug response prediction|"There is interest in whether genetic analysis of how a given drug is processed for a patient can help with rational drug choices (i.e. most efficacious, with least side effects/interactions, in the fastest time). This appears to have some early support in cardiac, psychiatric and acute pain studies.~All participants enrolled in the study will provide consent and a buccal cell sample for genotyping and standard patient reported outcomes questionnaires at the beginning of the study."
45947701|NCT00097760|Drug|Natalizumab|Natalizumab 300 mg, IV infusion, every 4 weeks in addition to 20 mg of glatiramer acetate SC, daily, for up to 20 weeks.
45947702|NCT00097760|Drug|Natalizumab|Natalizumab, 300 mg IV infusion, every 4 weeks for up to 20 weeks.
45658391|NCT05865834|Other|A smartphone application|app will have 2 modules: Chill zone and sleep; Chill zone has 9 sub-modules which are meditation, breathing techniques, family time, art time, funny sayings, reframe stress and relax, diet and cooking tips, mini courses and how to become better. The sub-modules of sleep are: wind down, sleep music, storytelling, nature sounds and beautiful nature. These modules will be approved by a clinical psychologist to help people with symptoms of depression and anxiety. Skills learned include emotion recognition, emotional management, behavioral activation (being active), recognizing and challenging unhelpful thoughts and cognitive restructuring to plan for their future.
45810694|NCT05252767|Behavioral|Patient Engagement Tools|Experimental participants will receive the patient engagement tools or the educational guide after randomization. The participants in the experimental cohort will utilize the tools between visits with their clinic providers. During visits, clinic providers will review the completed tools with participants.
45810695|NCT05252767|Behavioral|Educational Guide|Control participants will receive a brief educational guide about pain management.
45810696|NCT05473039|Dietary Supplement|Seidivid Ferty4|The patient will start taking the study treatment (multivitamin supplement with probiotics) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the diatary supplement, without interruption until the day of the GnRH-agonist trigger.
45947703|NCT00097760|Drug|Placebo|Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
45810697|NCT05473039|Other|Placebo|The patient will start taking the study treatment (placebo) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the treatment (placebo), without interruption until the day of the GnRH-agonist trigger.
45810698|NCT05668195|Procedure|systematic aerobic exercise and intelligent monitoring system in executive skill training|This is a closed-loop training initially developed by the research team in conjunction with other teams, adding a systematic aerobic exercise and intelligent monitoring system to the typical executive skill training, and is being further explored in training.
45947704|NCT00432406|Drug|Infliximab|Infliximab 5 mg/kg given at day 1, week 2, week 6
45947705|NCT00432406|Drug|Etanercept|Etanercept 25 mg twice weekly
45947706|NCT00131118|Drug|Zoledronic Acid|
45453444|NCT00533468|Drug|Lidocaine Cream 4%|Topical cream, 2g applied under occlusive dressing for 20 minutes prior to the procedure
45453445|NCT00533468|Drug|Placebo|inactive placebo without LMX4
45947707|NCT02957656|Biological|H7N9 pLAIV|10^7.0 fluorescent focus units (FFU); delivered by an Accuspray device
45947708|NCT02957656|Biological|H7N9 pIIV|Administered by intramuscular injection in the deltoid.
45947709|NCT02957656|Biological|AS03 adjuvant|Mixed with H7N9 pIIV vaccine; administered by intramuscular injection in the deltoid
45947710|NCT00097799|Drug|Tipranavir|500 mg twice daily
45947711|NCT00097799|Drug|Ritonavir|200 mg twice daily
45947712|NCT00432484|Drug|Lingzhi and Sen Miao San|G lucidum and SMS were supplied as capsules, containing 4.0 gm of G lucidum extract, 2.4 gm of Rhizoma atractylodis (Cangzhu), 2.4 gm of Cotex phellodendri(Huangbai), and 2.4 gm of Radix achyranthes Bidentatae(Niuxi). Each patient took either 3 capsules twice daily as recommended by the TCM experts or identical-looking placebo.
45453446|NCT00226070|Procedure|interview and advising|
45810699|NCT05668195|Procedure|executive skill training|The training program, based on Dawson and Guare's (2010) training of executive skills for children, aimed to improve the everyday performance of executive skills among children with ADHD. Qian Y and her team added some culturally adapted information, following the theory of cognitive behavioral therapy, to ensure that the concepts were acceptable to Chinese children.
45947713|NCT00432523|Biological|M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®|
45947714|NCT04909086|Procedure|Standard physical Therapy|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle stretching, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
45947715|NCT04909086|Procedure|Closed Kinetic Chain|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), three sets of 10 repetitions of 60% of one-repetition maximum (1RM) of seated leg press and partial squat exercises, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
45947716|NCT04909086|Procedure|Open Kinetic Chain|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), three sets of 10 repetitions of 60% of one-repetition maximum (1RM) of Quadriceps seated strengthening and Hamstring curl-up exercises, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
45947717|NCT01051921|Drug|CTS-1027|CTS-1027 supplied in 5 and 10 mg tablets, 15 mg taken twice daily, for up to 48 weeks
45453447|NCT00226070|Behavioral|3 follow up interviews and personal advising|
45453448|NCT00226070|Procedure|interview SF-36 self rated health|
45658392|NCT05865834|Other|Pictorial educational leaflets|the control group will receive self-reading educational leaflets, the majority of which are pictorial. These leaflets will be approved by a clinical psychologist to help people with symptoms of depression and anxiety.
45947718|NCT01051921|Drug|Pegylated interferon|Pegylated interferon, 180 micrograms in 0.5 ml of solution injected subcutaneously (SQ) once per week, for up to 48 weeks. Packaged in single use syringes.
45658393|NCT05865821|Procedure|Negative pressure drainage|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter or Redivac is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure
45676393|NCT03564691|Drug|Paclitaxel|Paclitaxel will be administered IV QW on Days 1, 8, and 15 of each 21-day cycle until disease progression or prohibitive toxicity (Arm J) and on Days 1, 8, and 15 Q4W until disease progression or prohibitive toxicity (Arm K).
45947719|NCT01051921|Drug|Ribavirin|Ribavirin, 200 mg capsules taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg for up to 48 weeks.
45947720|NCT02964650|Device|Personalised rate-response settings|Rate response range fixed to limits suggested by force-frequency curve
45947721|NCT02273479|Drug|Asasantin®|Asasantin® extended release (RAD-SP)
45947722|NCT02273479|Drug|Placebo|
45947723|NCT00131157|Procedure|expert support for interpretation of spirometry|
45947724|NCT02273518|Drug|Asasantin ER, new formulation I|
45947725|NCT02273518|Drug|Asasantin ER, new formulation II|
45947726|NCT02273518|Drug|Asasantin ER, present commercial formulation|
45947727|NCT00432640|Procedure|Endoscopic ultrasound staging|Endoscopic ultrasound staging with both EUS-FNA and EBUS-TBNA
45947728|NCT00432640|Procedure|Surgical staging|Surgical staging
45947729|NCT00097838|Biological|AVX101|Alphavirus replicon particle vaccine expressing HIV Gag antigen
45947730|NCT00097838|Other|placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
45676394|NCT03564691|Drug|Cisplatin|Cisplatin will be administered IV Q3W.
45676395|NCT03564691|Biological|MK-4830A|MK-4830A, a coformulation of MK-4830 800 mg + pembrolizumab 200 mg, will be administered IV Q3W.
45947731|NCT00432718|Procedure|Saline Instillation before Tracheal Suctioning|
45947732|NCT00432757|Drug|Ketotifen with a Contact Lens (generic name not yet established)|
45947733|NCT00432796|Drug|Dalteparin|5,000 iu or 200 iu/kg depending on the type of surgery injection will be given subcutaneously, once a day for a minimum of 4 days or until the INR is 2.0
45947734|NCT00432796|Other|Placebo|"patients will be randomized post-operative to receive either active treatment or placebo.~the placebo will be given as a subcutaneous injection once a day. the amount of the placebo will be equivalent to the active treatment depending on the type of surgery.~ie. 5,000 iu or 200 iu/kg"
45947735|NCT00432874|Procedure|wound hydration method|Anterior vs lateral wound hydration
45947736|NCT00097877|Drug|biphasic insulin aspart|
45947737|NCT00097877|Drug|insulin glargine|
45947738|NCT00432913|Drug|Eicosapentaenoic Acid (EPA)|Either 2 x 500mg EPA capsules in the morning and evening (2g per day EPA) or 1 x 500mg EPA and 1 x placebo in the morning and evening (1g per day EPA)
45947739|NCT00432913|Procedure|Endoscopy|At baseline, month 3 and month 6.
45947740|NCT00432913|Procedure|Biopsies taken|9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.
45947741|NCT00432913|Procedure|Clinical chemistry|Full blood count at baseline, month 3 and month 6.
45947742|NCT00432913|Procedure|Haematology|Urea and electrolytes, liver function tests, clotting profile and CRP at baseline, month 3 and month 6.
45947743|NCT00432913|Procedure|Physical examination|Including cardio-respiratory and abdominal examination at baseline, month 3 and month 6.
45947744|NCT00432913|Procedure|Vital signs|Height, weight, heart rate, blood pressure and temperature at baseline, month 3 and month 6.
45658394|NCT05865821|Other|No pressure drain|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter or Redivac is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure
45658395|NCT05865808|Other|cervical spine mobilization|headache SNAGs, 10 repetitions holding for 10 seconds in each glide with a rest time of 30 seconds in between. Eight weeks of treatment session will be provided and assessment of the improvement in cervicogenic headache will done at baseline, after 04, 06 and at the end of 8 week.
45947745|NCT00432913|Procedure|Urine pregnancy test|For subjects of child-bearing potential, urine pregnancy test at baseline, month 3 and month 6.
45947746|NCT00432913|Procedure|Completion of patient diary card|Subjects are requested to complete when study medication is taken and in any new or unusual symptoms are experienced on a daily basis for 6 months.
45947747|NCT04703491|Behavioral|Interactive and full-featured intervention|Participants will go through an automated program. Participants will learn and practice the techniques of CBT through multimedia elements. They will play games based on Cognitive Bias Modification (CBM) paradigms, practice mindfulness, and chat with an automated empathic chatbot.
45947748|NCT04703491|Behavioral|Feature-limited CCBT|Participants will be going through an automated program. Participants will learn and practice the techniques of CBT in a plain-text format with reduced features
45947749|NCT04703491|Other|Waitlist control|Participants will be put on a waitlist for a period of 6 weeks.
45947750|NCT04867590|Device|Endorotor|"The treatment itself is preceded by a sub-mucosa saline and adrenalin solution injection administered by an endoscopic sclerotherapy needle lifting the submucosa and thus reducing the risk of perforation and hemorrhage.~The interventional tool is then applied tangentially to be brought into contact with the lifted mucosa, visual monitored by endoscope. The aspiration and sectioning system is activated by use of a pedal and a generator specially made for the system, used in every procedure. The entire surface area of the targeted mucosa must be covered by the probe. The residual tissue is then removed via the aspiration system and caught by a filter. The specimens are then easily retrievable at the end of the procedure and can be stored in formalin fixing solution for histological analysis."
46002218|NCT04294563|Dietary Supplement|Peanut Protein Powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
46002219|NCT04294563|Other|Standard Care by Surgeon and Physical Therapist|Patient will receive standard care from treating physicians and physical therapists pre- and post-operatively
46002220|NCT04293562|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
45658396|NCT05865808|Other|Rocabado 6x6|The Rocabado 6x6 program includes 6 types of exercises which are- rest position of the tongue, TMJ rotation control, upper cervical distraction, axial extension of cervical spine, shoulder girdle retraction, and rhythmic stabilization technique, which are to be performed 6 times in a day with 6 repetitions of each exercise in each session,
45810700|NCT04806516|Device|Summit RC+S System with ECoG Paddles|"Summit RC+S System with ECoG Paddles consists of:~Olympus RC+S implantable pulse generator (IPG), Model B35300R: 2 per subject x 5 subjects = 10 units~Extension Leads, Model 37087: 2 per subject X 5 subjects = 10 units~DBS Leads, Model 3387: 2 per subject X 5 subjects = 10 units~Patient Therapy Manager (PTM), Model 4NR009: 1 per subject x 5 subjects = 5 units~Recharge Therapy Manager (RTM), Model 97755: 1 per subject x 5 subjects = 5 units~Clinician Telemetry Module (CTM), Model 4NR011: 1 per subject x 5 subjects = 5 units~Research Lab Programmer (RLP), Model 4NR010: 1 unit~Research Software Development Kit (RDK), Model 4NR013: 2 units~Subdural Quadripolar Paddle Lead, Model 09130: 2 per subject x 5 subjects = 10 units"
45810701|NCT04806516|Other|One Month Blinded Discontinuation Period:|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
45810702|NCT05245825|Other|Flaxseed|A total of 30 g of ground flaxseed per day divided into two portions of 15 grams each, subjects will be asked to take 15 g in the morning and 15 g in the night dissolved in 400 ml of water. They will receive a dietary plan with a distribution of 20-30% of protein, 25-30% of lipids, and 40 to 45% of carbohydrates.
45658397|NCT05865782|Behavioral|Schoolyard reconstruction|The current study will be designed as a quasi-experimental stepped-wedge intervention where schools undertaking schoolyard reconstruction will act as both control and intervention schools. By using the stepped-wedge study design, with internal control schools, will enable the control for the seasonal variation in children's physical activity levels and for the age-related decline in physical activity throughout childhood. That is, without control schools we would be unable to attribute a change in physical activity to the reconstruction of the schoolyards - as any difference in physical activity before and after the schoolyard reconstruction in the intervention group could be explained by the natural change in physical activity over time.
45810703|NCT05245825|Other|Dietary plan|Dietary plan with a distribution of 20-30% of protein, 25-30% of lipids, and 40 to 45% of carbohydrates, controlled consumption of alpha-linolenic acid (no more than 6.8 g/day, the amount provided by 30 g of flaxseed).
45810704|NCT05651646|Other|Intervention Arm (STIMFIX)|This is a single-arm prospective multicenter clinical study recruiting 50 subjects who are already undergoing a spinal cord stimulator trial for chronic back pain secondary to failed back surgical syndrome. Each patient who is recruited for spinal cord stimulator trial for their low back pain is informed about the traditional method of managing the leads and the trail lead anchoring system. If the patient agrees for the Stimfix trail lead anchoring clips StimfixTM, then informed consent is taken for anchoring clips usage during the spinal cord stimulator trail.
45810705|NCT05651490|Behavioral|Problem Solving Treatment for Diabetes|"In the introductory session, the structure of and rationale behind PST-D will be explained. The specialist will work with the participant to develop a problem list related to diabetes self-management and smoking cessation, if applicable.~During the weekly sessions, the participant will be taught and guided through the seven steps of problem solving:~Clarifying and defining the problem~Setting a realistic goal~Brainstorming multiple solutions~Generating pros and cons for each solution~Evaluating and choosing a preferred solution~Developing a specific action plan to implement the solution~Evaluating outcomes from the previous session.~Participants will also plan to engage in at least 1 enjoyable activity daily during the week.~The number of sessions will differ based on the specialist's assessment of the participant's problem-solving skills.~Maintenance sessions will be delivered monthly across 3 months in order to follow-up with participants."
45658398|NCT05865769|Other|Balance|measuring pulmonary and vestibular functions in all subjects
45658399|NCT05865756|Other|Acoustic cough features analysis|Acoustic cough features analysis
45810706|NCT05651490|Behavioral|Attention Control Group|During the sessions, the healthcare practitioners will provide general information and recommendations on general health topics such as oral health, hearing loss, sleep, dementia, adult vaccination, influenza, and dengue fever. Participants will also be given handouts adapted from government agencies and/or public bodies, such as HealthHub, National Health Service, National Addictions Management Service, and National Environmental Agency, on these topics. The healthcare practitioners will avoid discussing topics related to diabetes, diet, physical activity, and medication.
45810707|NCT05469607|Device|Vagus Nerve Stimulator|The device consists of implantable (inside the body) and external (outside the body) components. Implantable components consist of a stimulating/recording electrode assembly that is placed around the vagus nerve in the abdomen, between the diaphragm and the stomach, a cable connecting the electrode assembly to an implantable pulse generator (IPG) that generates the stimulus and records nerve responses. The external components include a Clinical Control/Review Tool (used by the study team after implantation to adjust and periodically review the stimulation settings) and a Patient Control Unit and Charger (to turn on/off the system and perform limited adjustment of the stimulation strategy).
45810708|NCT02978443|Drug|Nivolumab|nivolumab administered IV over 60 minutes at 1 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks
45658400|NCT05865743|Drug|SDD|a 10ml suspension containing amphotericin B (50 mg/ml), colistin sulphate (10 mg/ml), and tobramycin (8 mg/ml). Patients take the oral suspension four times daily for one week, starting three days prior to the surgery. On the day of surgery, intake is limited to an early morning and a late evening dose
45947751|NCT04867590|Device|Radiofrequency|"Endoscopic treatment using the HALO® 360 or 90 system is a thermal method for destroying the superficial mucosa. An initial debridement of the mucosal deposits is carried out by application of acetylcysteine in spray form with a spray catheter on the entire mucosal surface to be treated and then rinsed with water after a minute of application time.~For circumferential BEs, a single-use 360 Express® probe is used to make it possible to size the diameter of the esophagus and the treatment used. The length of the treatment area is 5 cm and several points of impact can be achieved by overlapping the catheter at two consecutive heights, with the zone spanned measuring one centimeter, in order to cover the entire pathological area requiring treatment.~For non-circumferential lesions a palette applicator is used in a variety of sizes, and in this context no sizing of the esophagus is required."
45947752|NCT00432952|Behavioral|Intake of rainbow trout from different feeding conditions versus a control poultry meal|
45947753|NCT00097916|Drug|memantine HCl|
45947754|NCT00433069|Drug|Pioglitazone|Increase early virological response to pegylated interferon alpha plus ribavirin by increasing insulin sensitivity
45947755|NCT00433069|Drug|Interferon Alfa-2a|Standard of care for chronic hepatitis C
45947756|NCT00433069|Drug|Ribavirin|Standard of care for chronic hepatitis C
45810709|NCT02978443|Drug|Ipilimumab|ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction)
45810710|NCT04343911|Device|Pink Pad ® (Xodus Medical Inc., New Kensington, PA)|a non-sliding foam mattress
45810711|NCT04150380|Biological|Lactobacillus rhamnosus GG (LGG; ATCC strain 53103; CRMTS #11272; PTS #3766)|See arm descriptions
45947757|NCT01580371|Drug|CKD-581|CKD-581 qd for Day 1, 8 and 15 every 28days/Cycle
45947758|NCT00097955|Drug|aliskiren|
45947759|NCT00433108|Drug|Mitoquinone mesylate (MitoQ)|
45947760|NCT04703218|Other|olfactory rehabilitation|Olfactory rehabilitation consists of smelling 4 scents twice a day using scent sticks, for 12 weeks
45947761|NCT00403026|Drug|Bevacizumab ( Avastin)|
45947762|NCT00131274|Drug|Imatinib Mesylate (Gleevec)|
45947763|NCT00098033|Drug|clofarabine|
45947764|NCT00403065|Drug|dexamethasone|
45947765|NCT00403065|Procedure|quality-of-life assessment|
45658401|NCT05865730|Other|Live Bacterial Product - Akkermansia muciniphila|Oral administration of Oncobax-AK to patients deficient in Akkermansia by stool metagenomic analysis.
45676396|NCT03546582|Drug|Pembrolizumab|Anti-PD-1 targeted immunotherapy
45676397|NCT03546582|Radiation|Stereotactic Body Radiation Therapy (SBRT)|High-precision radiotherapy
45810712|NCT04150380|Other|Placebo|See arm descriptions
45947766|NCT00403065|Radiation|radiation therapy|
45947767|NCT00098111|Drug|azathioprine|
45947768|NCT01051063|Biological|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A|Intramuscular injection
45947769|NCT04702906|Other|standard treatment|Standard treatment if indicated.
45947770|NCT04702906|Drug|"trimetazidine hydrochloride metacardia ® 20 mg tablet"|"trimetazidine hydrochloride metacardia ® (20 mg three times daily produced by Global NAPI Pharmaceuticals-Egypt)"
45947771|NCT00131313|Drug|Nipent, Cytoxan, Rituxan|
45947772|NCT00433186|Drug|Mycophenolate Mofetil|Mycophenolate 3000 mg each day
45947773|NCT00433225|Drug|Prednisolone Acetate|
45947774|NCT00433225|Drug|Ketorolac 0.4%|
45947775|NCT00433225|Drug|Gatifloxacin 0.3%|
45947776|NCT00433264|Procedure|peritoneal dialysis|individualised
45947777|NCT00433303|Behavioral|Correlation between early delivery and coital activity|
45947778|NCT00433342|Drug|Flucloxacillin|500 mg QD oral
45947779|NCT00131391|Drug|Comparator: taranabant|taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule. 52 week treatment period.
45947780|NCT00131391|Drug|Comparator: placebo|Placebo capsule once daily . 52 week treatment period.
45810713|NCT05651412|Other|Dynamic gait index and 5 time sit to stand test|dynamic gait index and 5 time sit to stand test was administered to all sample size of 400
45810714|NCT02465450|Drug|JBT-101 (lenabasum)|Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84.
45947781|NCT00098228|Drug|QAB149|
45947782|NCT00433459|Drug|cyclophosphamide|drug is used in first line treatment in combination (COPP or COPDAC)
45947783|NCT00433459|Drug|dacarbazine|drug is used in first line treatment in combination (COPDAC)
45947784|NCT00433459|Drug|prednisolone|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
45947785|NCT00433459|Drug|prednisone|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
45947786|NCT00433459|Drug|procarbazine hydrochloride|drug is used in first line treatment in combination (COPP)
45810715|NCT02465450|Other|Placebo|Subjects will receive placebo once a day on Days 1-28, placebo q pm on Days 29-84 (with JBT-101 20 mg q am), or placebo bid on Days 29-84.
45810716|NCT04000152|Diagnostic Test|niPGT-A|"Two scenarios should be considered according to the results in the SBM analysis:~The couple decides to transfer the blastocyst selected according to the SBM result (blastocyst prioritization system).~The couple decides to biopsy the blastocysts (if SBM results show low euploidy score). This PGT-A analysis will be offered for free but the outcome of these transfers will be excluded for the analysis per completed protocol. However, all transfers will be included in the intention-to-treat analysis.~In the exceptional case of getting a non-informative result for all the SBM analysed, the niPGT-A could be performed again on new SBM samples collected after an additional culture of the embryos for, at least, 8 hours."
45810717|NCT04000152|Other|Morphology criteria|Embryos for transfer will be selected by the only applicable technique, the assessment of morphology according to Gardner´s criteria, which is the most standardized method.
45810718|NCT04192500|Biological|OVX836|One single administration intramuscularly at Day 1.
45947787|NCT00433459|Drug|vincristine sulfate|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
45947788|NCT00433459|Radiation|fludeoxyglucose F 18|used as a diagnostic marker for metabolically active tumour at staging and response assessment
45810719|NCT04192500|Biological|Quadrivalent seasonal influenza vaccine (Influvac TetraTM)|One single administration intramuscularly at Day 1.
45810720|NCT05662423|Behavioral|Expressive Writing about Childbirth|Participants will write repeatedly about their deepest emotions and thoughts related to their recent childbirth, focusing on the most stressful experiences.
45947789|NCT00433459|Radiation|radiation therapy|part of combination treatment (combined modality between chemo- and radiotherapy)
45947790|NCT00433498|Drug|carboplatin|Should be given according to local practice but suggested doses and schedules are provided in the protocol.
45947791|NCT00433498|Drug|cisplatin|Should be given according to local practice but suggested doses and schedules are provided in the protocol.
45947792|NCT00433498|Drug|etoposide phosphate|Day 1: given by IV, days 2 and 3 given by IV or oral. Dose should be given according to local practice but suggested doses and schedules are provided in the protocol.
45947793|NCT00433498|Drug|pravastatin sodium|40mg daily oral tablet taken for a maximum of 2 years
46002221|NCT04293562|Drug|Asparaginase|Given IM or IV
46002222|NCT04293562|Drug|Asparaginase Erwinia chrysanthemi|Given IM or IV
46002223|NCT04293562|Procedure|Biospecimen Collection|Correlative studies
46002224|NCT04293562|Procedure|Bone Marrow Aspiration|Undergo BM aspiration
46002225|NCT04293562|Procedure|Bone Marrow Biopsy|BM biopsy
46002226|NCT04293562|Behavioral|Cogstate Assessment Battery|Ancillary studies
46002227|NCT04293562|Procedure|Computed Tomography|Undergo CT
45947794|NCT04804098|Procedure|Compression Profile/Schedule: 15 minute Non-Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw)|Patients will be compressed according to the 15 minute non-linear compression schedule on a rotating daily basis. A total of 2 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth. There are multiple patients exposed during the compression profile randomized for that day. The patients are exposed over the course of 4-12 weeks using one of the two compression protocols to be studied on alternating days.
45658402|NCT05865717|Behavioral|Quantitative sampling|A questionnaire asks about demographics, lifestyle (including cigarette smoking) & desk job hours, eating habits, sleep patterns, mental health, and motivation. Data on the frequency and size of regular food consumption will be gathered by completing a survey. Physical activity will be measured using a questionnaire developed by the American College of Lifestyle Medicine and Loma Linda University (Lifestyle Assessment Short Form, 2018).
45947795|NCT04804098|Procedure|Compression Profile/Schedule: 15 minute Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw)|Patients will be compressed according to the 15 minute linear compression schedule on a rotating daily basis with compression. A total of 2 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth. There are multiple patients exposed during the compression profile randomized for that day. The patients are exposed over the course of 4-12 weeks using one of the two compression protocols to be studied on alternating days.
45947796|NCT00433576|Drug|resveratrol|Given orally
45947797|NCT00433576|Other|pharmacological study|Correlative studies
46076166|NCT04246736|Behavioral|Bädda för Kvalitet|"A group-administered preventive programme focusing on beneficial strategies for sleep and recuperation, in relation to work related stress and shift work. The intervention was based on knowledge from previous research on sleep, stress and work hours, as well as on cognitive behavioural therapy (CBT) techniques for sleep and stress management, modified for shift workers. Participants were encouraged to discuss and reflect on personal habits related to sleep and recovery. As homework between sessions, the participants were encouraged to try possibly beneficial strategies for sleep and recuperation. All participants got written material covering the content of the session, during each sessions. In addition, an adapted version of a biomathematical model (ArturNurse) was used to give participants an estimation of expected sleep lengths and fatigue levels together with tips of possible strategies to optimise sleep in relation to different shifts."
45658403|NCT05865717|Other|Qualitative interviews|Thematic analysis will be done dividing into 4 different themes Personal life, professional life, Concept of Healthiness, Improving Lifestyle
45947798|NCT00433576|Other|laboratory biomarker analysis|Correlative studies
45947799|NCT00433615|Drug|R744|100μg(s.c./i.v.)/4 week for 8 weeks, then 25~400μg(s.c./i.v.)/4 week for 40 weeks
46076167|NCT00948155|Drug|Varenicline|Intervention Drug (Varenicline (Chantix) will be administered in standard dosing in pill format: 0.5 mg days 1-3; 0.5 mg bid daily days 4-7; 1.0 mg bid daily days 8-21.
46076168|NCT02775084|Dietary Supplement|Fish Oil|4 capsules twice daily with food for 6 weeks
45658404|NCT05865691|Other|biomarker assay|blood sample on the day of inclusion
45658405|NCT05865652|Diagnostic Test|Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy|Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy
45658406|NCT05865639|Behavioral|Aerobic Exercise|Three weekly, supervised exercise sessions with aerobic exercise. Each session will last for 60-65 minutes, each period will be consist of 5 min warm up, 45 min formal training and 5-10 min relaxation training. Intervention period will be eight weeks.
45658407|NCT05865639|Behavioral|Time Restricted Fasting|Restricted daily window of caloric intake to maximum 8 hours. Intervention period will be eight weeks.
45658408|NCT05865626|Other|VOT with and without cash incentive|Here we are interested in the remote monitoring of TB treatment, and the impact that financial motivation can have on compliance with this monitoring. the cross-over here means that participants in each intervention group will at some point receive VOT without motivation and then VOT with motivation, depending on whether they start with one or the other combination
45658409|NCT05865613|Device|Pulsed electromagnetic field|Participants were randomized into either the PEMF group or sham treatment group by a computer-generated random number. The participants were treated using PEMF (20 G ,7H for 10min) and sham treatment. treatment was delivered for one month.
45658410|NCT05865600|Other|Optimization of guideline-directed medical therapy|Consultation every second week with optimization of guideline-directed medical therapy according to 2019 ESC guidelines on chronic coronary syndrome. Focus will be on risk-factor modification and anti-anginal medication with the treatment aim to achieve freedom from angina and dyspnea with a heart rate at rest ≤ 60 beats/min and systolic blood pressure > 100 mmHg.
45658411|NCT05865600|Diagnostic Test|Immediate referral for invasive coronary angiography|Immediate referral for invasive coronary angiography
45810721|NCT05662423|Behavioral|Neutral Writing|Participants will write repeatedly about neutral daily events/tasks not related to childbirth.
45947800|NCT00433615|Drug|R744|150μg(s.c./i.v.)/4 week for 8 weeks, then 25~400μg(s.c./i.v.)/4 week for 40 weeks
45947801|NCT00098384|Drug|rifaximin|
45658412|NCT05865600|Diagnostic Test|3-months delayed referral for invasive coronary angiography|3-months delayed referral for invasive coronary angiography
45658413|NCT05865600|Other|Standard of care|Standard of care
45658414|NCT05865574|Drug|BAT1706 Injection|1 vial/carton, 400 mg/16 mL/vial
45810722|NCT00608972|Drug|Doxil|Doxil 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
45810723|NCT00608972|Drug|Carboplatin|Carboplatin 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
45810724|NCT00608972|Drug|Bevacizumab|Bevacizumab 10 mg/kg will be administered on Day 1 immediately following chemotherapy and alone on Day 15 of each 28-day cycle.
45947802|NCT04779918|Device|OviTex Reinforced Tissue Matrix|All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.
45947803|NCT00433693|Drug|R744|50μg(i.v.)/2 week until Hb concentration reaches to 11.0g/dL or above, then 25~300μg(i.v.)/4 week
45947804|NCT00433732|Drug|sumatriptan|
46076169|NCT02775084|Dietary Supplement|Olive Oil|4 capsules twice daily with food for 6 weeks
45947805|NCT00433732|Drug|naproxen sodium|
45947806|NCT00433849|Drug|R744|100μg(i.v./p.o.)/4weeks for 8 weeks, then 25~400μg(i.v./p.o.)/4weeks for 40 weeks
45947807|NCT00433849|Drug|R744|150μg(i.v./p.o.)/4weeks for 8 weeks, then 25~400μg(i.v./p.o.)/4weeks for 40 weeks
45947808|NCT00098423|Drug|tanespimycin|Given IV
45947809|NCT00098423|Drug|cytarabine|Given IV
45947810|NCT04778085|Behavioral|Illness management and recovery|Treatment given in groups, weekly for 10-12 months.
45947811|NCT04778085|Other|Semi-structured interviews|Semi-structured individual or group interviews conducted three times with staff on each participating outpatient clinic.
46076170|NCT02777034|Other|ER|"Preoperative protocols：Multidisciplinary patient information、no bowel preparation、no fasting（drink 10% glucose 1000 at 21：30 night before the surgery）.~Intraoperative protocols：Laparoscopic standardized technique、fluid restriction (max 500 ml/h)、no abdominal drains.~Postoperative protocols：no nasogastric tube、early solid dietary intake and mobilization、urinary catheter removal on postoperative day 1、restrictive fluid management（<2000ml/d）."
45658415|NCT05865561|Other|VOC sampling|"Systematic sampling during the day: Samples every 3 hours (9am, 12pm, 3pm, 6pm, 9pm) until the end of the follow-up period.~Sampling in case of epileptic seizure : Sampling during the seizure (from t0 to t+5 min), whatever the time.~The samples will be taken using a compress on the forehead, the palms of the hands and the back of the neck. The compress will then be placed in a freezer bag and the person with epilepsy will be asked to exhale into the bag, if he/she is able to do so, before closing it."
45658416|NCT05865548|Drug|Aspirin 150 mg|Aspirin 150 mg PO daily
45658417|NCT05865548|Procedure|Standard of care|Surgery with or without radiation, palliative chemo as per investigators choice
45947812|NCT01050790|Drug|Azacitidine|Subject will receive Vidaza (azacitidine) and Revlimid (lenalidomide) as treatment for their multiple myeloma. The Vidaza will be given for 5 days as an injection. On day 6 they will receive Revlimid taken by mouth every day for 16 days followed by 7 days of rest. The drug cycle will be repeated 0, 1 or 2 more times depending on how their blood counts recover.
45947813|NCT00433888|Drug|R744|100μg/4 weeks for 8 weeks,then 25~400μg/4 weeks for 40 weeks
45947814|NCT00433888|Drug|R744|150μg/4 weeks for 8 weeks,then 25~400μg/4 weeks for 40 weeks
45947815|NCT00433927|Drug|5-FU|5-FU 400 mg/m² Bolus day 1 5-FU 2400 mg/m² iv over 46 h day 1-2
45947816|NCT00433927|Drug|folinic acid|Folinsäure (racemisch) 400 mg/m² iv, 120 min d 1
45947817|NCT00433927|Drug|irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min day 1
45947818|NCT00433927|Drug|cetuximab|Cetuximab initial 400mg/m² as 120 min infusion, than 250 mg/m² iv as 60 min infusion d 1 + 8
45947819|NCT00433927|Drug|bevacizumab|Bevacizumab 5 mg/kg iv over 30 to 90 minutes d 1
45947820|NCT00131079|Behavioral|Experimental Programme for Physical Activity Promotion|"General practitioner's (GP) physical activity (PA) assessment and advise using a web-based software that prompted open questions to elicit believes about benefits of PA, graphical information about risks of inactivity and examples of type sentences to provide medical advise.~Educational materials summarizing benefits, risks and motivation.~Prescription: 15 minutes educational session in which GP negotiated a goal, addressed possible barriers and anticipated solutions using web-based tools for lack of time, community resources, and health problems. Finally, they designed a 3-month PA activity plan that derived in a standardized printed prescription of frequency, duration, intensity and progression of a selected PA or exercise that included a self-monitoring log."
45947821|NCT00131079|Behavioral|Control|Control general practitioners assessed physical activity and performed recruitment in a similar way but offered usual care
45947822|NCT00131430|Drug|taranabant|
45947823|NCT00098462|Drug|gefitinib|
45947824|NCT00098462|Drug|sirolimus|
45947825|NCT04702633|Other|Results obtained by biopsy and MRI results.|Results obtained by biopsy and MRI results.
45947826|NCT04702633|Other|Clinical data|Clinical data
45947827|NCT00098501|Drug|pelitinib|
45947828|NCT00098501|Drug|temsirolimus|Given PO
46002228|NCT04293562|Drug|Cytarabine|Given IV or IT
46002229|NCT04293562|Drug|Daunorubicin Hydrochloride|Given IV
46002230|NCT04293562|Drug|Dexrazoxane Hydrochloride|Given IV
46002231|NCT04293562|Drug|Etoposide|Given IV
46002232|NCT04293562|Other|Fludeoxyglucose F-18|Undergo FDG-PET
45658418|NCT05865535|Biological|AV-380|AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
46076171|NCT02777034|Other|UR|"Preoperative protocols：Patient information、Mechanical bowel preparation、Fasting since midnight before operation.~Intraoperative protocols：Laparoscopic standardized technique、fluid overload (over 500 ml/h) 、place abdominal drains.~Postoperative protocols：no nasogastric tube、mobilization from postoperative day 1、fluids and solids intake after first passage of stool、Urinary catheter removal on postoperative day 2/3、no restrictive fluid management（>2000ml/d）."
46076172|NCT02854553|Procedure|Transversus abdominis plane block|ultra sound guides Transversus abdominis plane block
46076173|NCT02854553|Procedure|rectus sheath block|ultrasound guided rectus sheath block
45947829|NCT04702594|Behavioral|Music therapy session via tools validated by MUSIC CARE|Use of the MUSICARE tool, a digital space allowing access to different validated methods of music therapy. Music listening times are offered to patients with cognitive impairment with psycho-behavioral symptoms. The sessions are individual or group performed by a psychomotor therapist in UHR and volunteer caregivers trained in SRH. The sessions last on average 20-30min.
45947830|NCT00434005|Drug|N-acetylcysteine, ascorbate|NAC: 600mg twice daily for the day prior to exposure and 1x pre-exposure Ascorbate: 500mg twice daily for 7 days prior to exposure
45947831|NCT00434005|Drug|Placebo|matched appearance to acetylcysteine and ascorbate intervention
46076174|NCT02776956|Drug|atorvastatin group|Patients in atorvastatin group will orally receive 20 mg of atorvastatin per night (Pfizer) for three days before the operation and three months after the operation
45658419|NCT05865509|Other|Escape room|Students were given training on stress response using the escape room method.
45658420|NCT05865509|Other|Storytelling|Students were given training on stress response using the storytelling method.
46076175|NCT02776956|Drug|non-atorvastatin group|Patients in non-atorvastatin group will not receive atorvastatin before the operation and after the operation.
46076176|NCT04226430|Device|Cytokine aphaeresis|The Cytosorb cartridge was either used alone in hemoperfusion mode or, if renal replacement therapy was clinically indicated, inserted proximally into a conventional continuous veno-venous hemofiltration (CVVH) or continuous veno-venous hemodiafiltration (CVVHDF) circuit. Before the start of the Cytosorb therapy, adequate anti-coagulation was confirmed when target partial thromboplastin time (PTT) of 60±80 seconds, or an activated clotting time (ACT) of 180±210 seconds was achieved with systemic heparin. Antibiotics were administered after each Cytosorb therapy whenever possible.
46076177|NCT04910178|Drug|Empagliflozin 25 MG|tablets to be taken orally once a day
46076178|NCT04910178|Drug|Ursodeoxycholic acid|tablets to be taken orally twice a day
45810725|NCT05661097|Procedure|Suture mode|Patients in the small hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture by hernia hook needle.Patients in the large hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture with hernia hook needle, continuous suture with barbed wire+hernia Intermittent full layer crochet suture.
46076179|NCT04910178|Drug|Pentoxifylline 400 MG|tablets to be taken orally twice a day
46076180|NCT04910178|Other|placebo|just starch tablets without any active agents
46076181|NCT02856737|Other|eye masks and earplugs|Materials similar to those offered on long commercial flights
46076182|NCT04888026|Device|Quantitative sensory testing|"The following QSTs are conducted:~The pressure pain threshold on the tibialis anterior~The Cold-pressor test~Repeat of the pressure pain threshold to assess conditioned pain modulation"
46076183|NCT02778594|Drug|BIA 3-202|nebicapone 50 mg tablets; oral use
45658421|NCT05865496|Drug|611|611 subcutaneous (SC) injection.
45658422|NCT05865496|Drug|Placebo|Placebo subcutaneous (SC) injection.
45658423|NCT05864950|Device|MRI|Participants will undergo an MRI scan while performing exercise at two intensities (light and moderate/vigorous) using an MRI-compatible stepper device.
45658424|NCT05864651|Other|Tele-exercise program|The tele-exercise program focused on lunge movement with additional strengthening abdominal and lumbopelvic muscle training while maintaining neuromuscular control. The difficulty of training was adjusted every week according to the five-step mastery program
46076184|NCT02778594|Drug|Placebo|Nebicapone matching placebo tablets
46076185|NCT02778594|Drug|levodopa 100 mg / benserazide 25 mg|Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) capsules; oral use
46076186|NCT02775006|Drug|Docetaxel|75mg/m2
45658425|NCT05864651|Other|Conventional Fencing Exercise|The conventional exercise was based on 'displacement', a basic footwork training in fencing. The Displacement is also basic footwork to approach the opponent. The Displacement consisted of seven movements including 'Marche', 'Retraite & Rompre', 'Passe avant', 'Passe arrière', 'Bond en avant', 'Bond en arrière', and 'Balestra'.
45658426|NCT05864079|Diagnostic Test|Platelet count|Platelet count in study groups
45658427|NCT05864079|Diagnostic Test|Developmental endothelial locus-1 (DEL-1)|Serum DEL-1 in study groups
45658428|NCT05864079|Diagnostic Test|soluble P-selectin (sP-sel)|Serum sP-sel in study groups
45810726|NCT04804722|Device|18F-FDG PET-CT (fluorodesoxyglucose positron emission tomography)|18F-FDG PET-CT exams during 30 minutes with injection of radiopharmaceutical product
45810727|NCT02729714|Drug|Suvorexant|10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
45810728|NCT02729714|Drug|Placebo|10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
45947832|NCT00434044|Drug|Enbrel (etanercept)|
46076187|NCT02775006|Drug|Erlotinib|150mg/day
46076188|NCT00958217|Behavioral|Cognitive Processing Therapy-Modified (CPT-M)|Psychotherapy that focuses on thoughts associated with traumatic experiences with the goal of developing skills to reduce trauma-related symptoms. We have modified this therapy to include substance relapse prevention skills, reduce depression and substance relapse. CPT-M was delivered in individual 1-hour sessions once weekly.
45810729|NCT05230693|Behavioral|Sarcoidosis Patient Assessment and Resource Companion App|"The first group, called the SPARC group will be asked to download the SPARC app onto the participant's smartphone, will be shown how to use the app, and then will be asked to use the app to do guided meditations for ten minutes twice a day"
45810730|NCT05230693|Behavioral|Enhanced Standard Care|Participants will receive education about reducing fatigue associated with sarcoidosis during a normal clinic visit.
45810731|NCT02555982|Drug|BOTOX ® 200 Unités|"Patients eligible for inclusion will be randomized to one of the two groups:~Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
45947833|NCT00434083|Drug|sumatriptan|
45810732|NCT02555982|Drug|Placebo|Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
45947834|NCT00434083|Drug|naproxen sodium|
45810733|NCT05657275|Diagnostic Test|CRP dosage|multimodal algorithm
45947835|NCT00131547|Behavioral|Dietary Counseling|Dietary Counseling, use of a food diary and pedometer
45947836|NCT00098540|Drug|sorafenib tosylate|Given orally
45947837|NCT00098540|Other|laboratory biomarker analysis|Correlative studies
45947838|NCT01050673|Device|VERSAJET|Hydro-surgery debridement
45947839|NCT01050673|Procedure|Scalpel or blade|Conventional Surgical Debridement
45947840|NCT04751409|Procedure|Chest Radiography|Undergo CXR
45947841|NCT04751409|Procedure|Computed Tomography|Undergo CT-chest
45947842|NCT04751409|Procedure|Follow-Up|Undergo intense follow-up
45947843|NCT04751409|Procedure|Follow-Up|Undergo limited follow-up
45947844|NCT04751409|Procedure|Imaging Technique|Undergo imaging
45947845|NCT04751409|Other|Questionnaire Administration|Ancillary studies
45947846|NCT01050205|Behavioral|Current Intervention|"Participants assigned to Current Intervention will receive the intervention described below immediately after randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity.~GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings."
45947847|NCT01050205|Behavioral|Delayed Intervention|"Participants assigned to Delayed Intervention receive the same intervention as Current Intervention Group, 6 months from randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity.~GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings."
45810734|NCT05657275|Diagnostic Test|multiplex PCR|multimodal algorithm
45810735|NCT05657275|Diagnostic Test|chest scan without injection|multimodal algorithm
45947848|NCT00098579|Drug|alvocidib|Given IV
45947849|NCT00098579|Drug|doxorubicin hydrochloride|Given IV
45947850|NCT00098618|Drug|sorafenib tosylate|Given orally
45947851|NCT00098618|Biological|recombinant interferon alfa|Given orally
45810736|NCT04192344|Drug|ABSK021|ABSK021 oral capsule
45947852|NCT00098618|Other|laboratory biomarker analysis|Correlative studies
45947853|NCT00131625|Behavioral|Health education according to WHO recommendations|
45947854|NCT00098735|Drug|FTY720|
45947855|NCT00098852|Drug|rosiglitazone maleate|
45947856|NCT01059448|Drug|AMG 827|AMG 827 210 mg
45947857|NCT00098891|Drug|entinostat|Given orally
45947858|NCT00098891|Drug|isotretinoin|Given orally
45947859|NCT01058434|Drug|TKI258|
45810737|NCT04802382|Drug|Placebo administration|patients will receive the placebo treatment in addition to Standard of Care
45810738|NCT04802382|Diagnostic Test|Confirm SARS-CoV-2 infection|patients will be tested for SARS-CoV-2 on days 1, 14 and 28
45810739|NCT04802382|Procedure|Physical Examination|patients will undergo a physical examination on days 1-14 and day 28
45810740|NCT04802382|Procedure|Vital Signs|patient's vital signs will be measured on days 1-14 and day 28
45810741|NCT04802382|Diagnostic Test|Hematology blood test|patients will provide a blood sample for a hematology blood test on days 1-14 and day 28
45810742|NCT04802382|Diagnostic Test|Biochemistry blood test|patients will provide a blood sample for a biochemistry blood test on days 1-14 and day 28
45810743|NCT04802382|Other|NEWS score|patient's NEWS score will be evaluated on days 1-14 and day 28
45810744|NCT04802382|Diagnostic Test|PK test|PK test will be performed on day 1 only (only in Brazil sites)
45810745|NCT04802382|Diagnostic Test|blood test for inflammatory markers|patients will provide a blood sample for an inflammatory markers blood test (IL-6, IL-1β, IL-12, TNF α, IFN-γ) on days 1-7, day 14, and day 28
45810746|NCT04802382|Diagnostic Test|D-dimer test|patients will provide a blood sample for D-dimer blood test on days 1, day 2, day 7, day 14, and day 28
45947860|NCT02957617|Drug|BIIB074|Participants will receive an initial dose regimen of 350mg orally twice daily (BID), which may be reduced to 200mg based on tolerability for up to 12 months.
45947861|NCT00098969|Drug|resveratrol|
46002233|NCT04293562|Drug|Gemtuzumab Ozogamicin|Given IV
46002234|NCT04293562|Drug|Gilteritinib Fumarate|Given PO or via NG or G tube
46002235|NCT04293562|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
45810747|NCT04802382|Other|VAS scale|patient's VAS scale will be evaluated on days 1-14, day 21, and day 28
45453449|NCT02886338|Device|capsule endoscopy|The magnetic navigated CE would enable detailed investigations of the whole upper gastrointestinal tract, including the esophagus, stomach and duodenum. Using this remote magnetic manipulation, capsule endoscope might improve diagnostic accuracy and extend the examination of specific area of interest in the gastrointestinal tract.
45658429|NCT05863598|Behavioral|Enhancing protective factors|Participants will watch some short movies and infographics, and will be asked to argue for the importance of body image flexibility, body functionality appreciation, etc.
45810748|NCT04802382|Diagnostic Test|Urine pregnancy test for women of childbearing potential|patients will provide a urine sample for a urine pregnancy test on days 1, and day 28
45658430|NCT05863598|Behavioral|Expressive writing|Participants will reflect and write about any cognitions or emotions they can have in relation to their bodies.
45658431|NCT05863247|Other|Patient Reported Outcomes / Biometric data revision|Multivariate statistical analysis will be done to identify the reported biomarkers to characterize patients into the following categories: satisfied without dysphotopsias, unsatisfied with dysphotopsias, satisfied with dysphotopsias, unsatisfied without dysphotopsias.Main outcome measures will be photic phenomena at 6 months of follow-up in correlation with the following pre-surgical parameters: macular ganglion cell complex thickness and/or total ocular and corneal higher-order aberrations (coma, trefoil, spherical aberration). Patients with known contributing factors for the development of dysphotopsias (such as residual refractive error, IOL decentration, posterior capsular opacification) will be excluded from the analyzis.
45810749|NCT04802382|Procedure|ECG|patients will undergo an ECG examination on days 1, and day 28
45810750|NCT04802382|Other|COVID-19-Impact on Quality of Life Questionnaire|patients will answer the COVID-19-Impact on Quality of Life Questionnaire on days 1, 7,14,21 and 28
45947862|NCT04648956|Other|Standard treatment|Participants shall fill the ICOAP-Ar questionnaire three times within one month in addition to other questionnaires including the KOOS/HOOS, and the Global Rating of Change Scale (GRoC). The first two times will be within a time frame of 48-72 hours. The third time will be after one month.
45947863|NCT04702516|Drug|Ozempic|2 mg prefilled pen for subcutaneous injection, 0.25 mg for two weeks then 0.5 mg for two weeks and then 1 mg for another 48 weeks.
45658432|NCT05862935|Other|Supervised Physical Activity (AMRAP -As Many Repetitions As Possible): Phase 2|20-30 min/session, 3 times/week for 4 weeks. After a 5-min warm-up, participants perform a moderate-intensity functional training program. This program is designed in circuit mode consisting of 6 global functional exercises: i) sit and stand, ii) forward lunges, iii) chest press, iv) high row, v) lateral shoulder raises and vi) heel raises. Participants must complete the highest number of repetitions and/or rounds as possible (AMRAP) in 15-min without a designated rest.
45658433|NCT05862935|Other|Supervised Physical Activity: Phase 1|40-60 min/session, 3 times/week for 12 weeks. After a 5-min warm-up, participants performed 6 global functional exercises: i) sit-to-stand; ii) chest press, iii) forward lunges; iv) unilateral shoulder raises; v) unilateral row; and vi) heel raises. The initial volume is 2 sets and 8 repetitions and it will progressively increase until 3 sets and 12 repetitions.
45658434|NCT05862649|Other|NeuraLight|NeuraLight software-based platform
45658435|NCT05862363|Dietary Supplement|Microbiota-directed complementary food (MDCF)-2|Prototypes for nutritional interventions that are composed of locally available, affordable, culturally acceptable complementary foods commonly consumed in Bangladesh have recently been developed.
45658436|NCT05862363|Dietary Supplement|Ready-to-use supplementary food (RUSF)|RUSF is composed of rice, lentil, sugar, soybean oil, and skimmed milk powder mixed with vitamin-mineral premix. MDCF-2 is composed of chickpea flour, peanut flour, soy flour, green banana pulp, sugar, soybean oil, and vitamin-mineral premix. The results from previous studies support the notion that repair of impaired gut microbial community development could represent a new therapeutic concept for restoring healthy growth6. RUSF will be given to one arm of low-BMI women of reproductive age and low-BMI pregnant women.
45810751|NCT04802382|Drug|CimetrA-1|patients will receive the study treatment, CimetrA-1 treatment in addition to Standard of Care
45810752|NCT04802382|Drug|CimetrA-2|patients will receive the study treatment, CimetrA-2 treatment in addition to Standard of Care
45810753|NCT05648916|Other|Celecoxib|Retrospectively comparing patients with and without heterotopic ossification who have been exposed to celecoxib and underwent cementless total hip joint replacement surgery.
45810754|NCT05462587|Drug|AVTX-803 (L-Fucose)|L-fucose crystalline powder
45810755|NCT02508012|Other|Immuno monitoring|treatment optimization
45810756|NCT05458609|Drug|Lemborexant 10 mg|10 mg of Lemborexant
45810757|NCT05458609|Drug|Naltrexone|50 mg of Naltrexone
45947864|NCT04702516|Drug|Placebo|2 mg prefilled pen for subcutaneous injection, 0.25 mg for two weeks then 0.5 mg for two weeks and then 1 mg for another 48 weeks.
46002236|NCT04293562|Procedure|Magnetic Resonance Imaging|Undergo MRI
45810758|NCT05648058|Drug|Nefopam ampule|nefopam ampule 50 mg
45810759|NCT05648058|Drug|diphenhydramine ampule|diphenhydramine ampule 10 mg
45810760|NCT05653609|Device|Cureety TechCare|Weekly adverse event questionnaires completed by the patients using a digital tool called Cureety
45810761|NCT05649085|Device|Cobalt-Chromium (CoCr) prosthetic abutments|Cobalt-Chromium (CoCr) prosthetic abutments in single-unit implant-supported prostheses
45810762|NCT02502318|Procedure|Video-thoracoscopy|
45810763|NCT02502318|Procedure|thoracotomy|
45810764|NCT05218135|Other|Intervention|Learning session 1: explain key interventions, explain BIC methodology, retrospective patient record analysis Learning session 2: feedback report, share best practices, discussion, set priorities, teaching and improvement, retrospective patient record analysis Learning session 3: feedback report, share best practices, discussion, set priorities, teaching and improvement, retrospective patient record analysis Learning session 4: feedback report
45810765|NCT05647902|Diagnostic Test|Serum samples will be collected. Asprosin levels will be determined by biochemical analysis|Serum samples will be collected from both groups for biochemical analysis.
46002237|NCT04293562|Drug|Methotrexate|Given IT
46002238|NCT04293562|Drug|Mitoxantrone Hydrochloride|Given IV
45658437|NCT05862363|Procedure|Esophagogastroduodenoscopy (EGD)|Aim 1A consists of performing EGD to women with low-BMI and normal BMI women with function dyspepsia. In order to enroll 30 participants with normal duodenal mucosal histology, we are planning to perform EGD on 100 healthy women (BMI 20-24.9 kg/m2) of childbearing age who have been referred for evaluation of functional dyspepsia. Undernourished low-BMI (<18.5kg/m2; 18-30 years) women of childbearing age will be enrolled from Bauniabadh and adjacent slum area of Mirpur, Dhaka and EGD will be performed among 60 women. A total of 6-8 biopsy samples from SI and a dry duodenal aspirate will be collected for biopsy, histochemical and immunocytochemical analysis.
45658438|NCT05862363|Behavioral|Counselling and follow-up|Normal BMI pregnant women will be counseled and followed up as per standard guidelines and will be provided routine antenatal care
45658439|NCT05862012|Drug|ISB 2001|Participants will receive escalating doses of ISB 2001
45658440|NCT05862012|Drug|ISB 2001|Participants will receive injection of ISB 2001 at 2 putative recommended Phase 2 doses as determined in Part 1.
45810766|NCT04791306|Other|supervised exercise training|Participates perform once a week for 4 months an in-house supervised endurance and strength training.
45810767|NCT04791306|Other|home-based exercise training|Participants are provided with an application for planning and documentation of their physical activity, together with an expert participants plan their physical activities for their home-based training to reach at least 150 min physical activity per week.
45658441|NCT05861440|Drug|Prednisolone|adjunct steroid per study protocol
45658442|NCT05861440|Drug|standard anti-tuberculosis agents|standard anti-tuberculosis agents
45658443|NCT05860985|Device|ZEISS disposable|a comparison will be done between the present lenses used (reusable RESIGHT lenses and disposable Vitreq contact lens) and the new disposable RESIGHT lenses.
45658444|NCT05860894|Device|Implantable ECG holter device (Biomonitor3, Biotronik)|Subcutaneous implantation of ECG holder device to monitor ECG
45658445|NCT05860673|Procedure|mini invasive scoliosis surgery|"The minimally invasive technique, involves two small median skin incisions that allow the deep structures to be exposed. The muscle fibers are separated from the bony insertion by the process of subperiosteal skeletonization. The Investigators then proceed with the arthrectomy of the levels to be instrumented and the infiltration of pedicle screw pairs of the appropriate caliber according to the free-hand technique. After amplioscopic control of proper screw placement, osteotomies of the posterior elements are performed to facilitate correction of the metameres."
45658446|NCT05860673|Procedure|posterior spinal fusion technique|"The standard open technique involves a longitudinal incision along the midline extended along the entire thoracolumbar spine, the paravertebral muscles are incised and spread apart to expose the posterior vertebral structures, in a stretch extending more than 30 cm. The series of facetectomies are performed first, and then pairs of pedicle screws are infixed freehand.~After performing the osteotomies necessary to mobilize the vertebral metameres at the apex of the deformity, correction by derotation maneuvers is continued, and the obtained correction is fixed with pre-shaped bars that are then connected to the screws and tightened to the nuts by dynamometric technique. Almost all vertebral levels of the thoracolumbar tract are included in the arthrodesis"
45658447|NCT05859074|Biological|MQ719|Patients will receive either multidose monotherapy with MQ710 or multidose combination therapy with MQ710 and pembrolizumab. The applicable dose of MQ710 will be injected directly into the patient's tumor (intratumorally), and standard dosing of pembrolizumab (200 mg) will be administered intravenously at a 3-week interval.
45658448|NCT05859074|Drug|Pembrolizumab|Patients will receive either multidose monotherapy with MQ710 or multidose combination therapy with MQ710 and pembrolizumab. The applicable dose of MQ710 will be injected directly into the patient's tumor (intratumorally), and standard dosing of pembrolizumab (200 mg) will be administered intravenously at a 3-week interval.
45810768|NCT05212831|Device|Inogen One® G4|Inogen One® G4 will be used for a minimum of 3h per day at Setting 3 during the intervention period.
45810769|NCT05639712|Drug|Placebo|The patient is given standardized questions about their well-being and affective state before and after the administration of placebo intravenously. This is carried out on the operating table right before anesthesia
45658449|NCT05858814|Biological|RC1012 injection (allo-DNT cells)|RC1012 injection (allo-DNT cells) are from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.
45658450|NCT05858801|Device|PRIMUS|Peripheral Nerve Stimulator System
45810770|NCT05639712|Drug|Morphine 2.5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of 2.5 mg morphine intravenously. This is carried out on the operating table right before anesthesia
45810771|NCT05639712|Drug|Morphine 5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 5 mg intravenously . This is carried out on the operating table right before anesthesia
45810772|NCT05639712|Drug|Morphine 10 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 10 mg intravenously . This is carried out on the operating table right before anesthesia
45810773|NCT05639712|Drug|Oxycodone 2.5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 2.5 mg intravenously . This is carried out on the operating table right before anesthesia
45810774|NCT05639712|Drug|Oxycodone 5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 5 mg intravenously . This is carried out on the operating table right before anesthesia
45810775|NCT05639712|Drug|Oxycodone 10 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 10 mg intravenously . This is carried out on the operating table right before anesthesia
45810776|NCT05639712|Drug|Fentanyl 0.025 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.025 mg intravenously . This is carried out on the operating table right before anesthesia
45658451|NCT05858125|Other|Social Media Navigation Aid Kit|"The Social media Navigation Aid Kit (SNAK) was created by using search terms, urinary incontinence, urinary leakage, and urogynecology, and querying various websites/blogs, Facebook, Instagram, and YouTube. These social media platforms were chosen based on the top three social media platforms used in Americans aged 50 to >65 years old according to Pew Research Analytics (Pew paper). The experienced reviewer evaluated each platform for users that provided relevant, accurate, and specific content. The department of Urogynecology at UNM independently reviewed the curated pages and users for approval. Once approved, the various users and pages were then collected and a flyer was created. The flyer will be available via hardcopy, email, or text per patient preference."
45947865|NCT04702477|Behavioral|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a well-documented approach to reduce participants' stress level [19], with the existing group-based peer support, self-empowerment, and lifestyle counseling intervention. MBSR is a type of meditation therapy with the goal of actively cultivating conscious attention and awareness to enhance health benefits. This included 10 hours of intervention with groups of 3-5 people.
46076189|NCT00958217|Behavioral|Integrated Cognitive Behavioral Therapy (ICBT)|Psychotherapy that focuses on thoughts and behaviors associated with depression with the goal of developing skills to reduce depression symptoms. We have integrated substance relapse prevention skills. ICBT was delivered in individual 1-hour sessions once weekly.
46076190|NCT02778516|Dietary Supplement|Sodium Restriction|
45658452|NCT05854654|Diagnostic Test|Air Leaks|"The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 8 inserted in the bronchus with the balloon inflated and a silk suture providing an hermetic closure proximal to the balloon.~This setting will allow us to perform several different endoscopic and RAB procedures in emulated physiologic conditions to complete the study."
45658453|NCT05853094|Procedure|Ileostomy|Protective loop ileostomy after low anterior resection
45810777|NCT05639712|Drug|Fentanyl 0.05 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.05 mg intravenously . This is carried out on the operating table right before anesthesia
45947866|NCT00099008|Dietary Supplement|Genistein|oral Genistein twice daily on days 1-84
46076191|NCT04851834|Drug|NTX-301|Oral hypomethylating agent
46076192|NCT04851834|Drug|Platinum-based Chemotherapy|Standard of care for ovarian and bladder cancer
46076193|NCT04851834|Drug|Temozolomide|Standard of care for high-grade glioma
46076194|NCT01880567|Drug|Ibrutinib|Given PO
46076195|NCT01880567|Other|Laboratory Biomarker Analysis|Correlative studies
45458436|NCT05188352|Other|Aerobic exercise training|"A treadmill was used for aerobic exercise. Training intensity was used at 60-75% of maximal VO2.~Each session had a five-minute warm-up and cool-down period. Blood pressure and ECG were recorded during training sessions before exercise, at the third minute of each workload, after exercise, and during each minute of the recovery period."
45658454|NCT05853094|Procedure|Transverse colostomy|Protective loop transverse colostomy after low anterior resection
45658455|NCT05849298|Drug|AAA617|Administration intravenously once every 6 weeks (1 cycle) for 6 cycles
45658456|NCT05849298|Drug|AAA517|Single intravenous dose of approx. 150 Megabecquerel (MBq) prior PSMA-PET scans
45810778|NCT05639712|Drug|Fentanyl 0.1 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.1 mg intravenously . This is carried out on the operating table right before anesthesia
45810779|NCT02978131|Other|Histopathological study|
45947867|NCT00099008|Dietary Supplement|Placebo|oral Placebo twice daily on days 1-84
45947868|NCT00434200|Procedure|long-term intensive exercise|
46076196|NCT01880567|Biological|Rituximab|Given IV
46076197|NCT02776722|Other|fructose, allulose, tagatose, or sorbose|Single-bolus feeding of fructose, allulose, tagatose, or sorbose given together with a reference carbohydrate(s) compared with the same reference carbohydrate(s) alone for acute feeding trials or chronic feeding of fructose, allulose, tagatose, or sorbose provided in substitution for other reference carbohydrates or added to a control diet compared with the reference carbohydrate(s) alone or the control diet alone for chronic feeding trials.
46076198|NCT02776800|Device|Allevyn Life|
46076199|NCT02776800|Device|Foam dressing with an integrated adhesive border|Foam dressing normally used by the home health agency
45810780|NCT02978131|Other|Molecular study (Polymerase chain reaction)|
45810781|NCT05210101|Drug|Sotrovimab|Two intravenous (IV) doses of sotrovimab were administered over the study period, the first 500mg, and the second 2000mg, in light of the reduced antiviral neutralization of sotrovimab against the BA.2 subvariant.
46076200|NCT02776878|Drug|dasatinib|
46076201|NCT02772900|Other|Beetroot-based nutritional gel|100 g of beetroot-based nutritional gel containing approximately 12 mmol of nitrate.
46076202|NCT02772900|Other|Placebo|100 g of apple-based nutritional gel containing approximately 0.02 mmol of nitrate.
46076203|NCT02772822|Drug|SCT400 plus CHOP|
46076204|NCT02772822|Drug|Rituximab plus CHOP|
46076205|NCT04869540|Other|Usual care|Evidence based care for transition-aged youth (TAY) with ASD.
45947869|NCT00434239|Drug|Lenalidomide + Ancestim|Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
45947870|NCT01057147|Drug|rebamipide 2% ophthalmic suspension|Instill one drop in each eye four times daily for 12 weeks.
45947871|NCT01057147|Drug|placebo eye drops|Instill one drop in each eye four times daily for 12 weeks.
45658457|NCT05849298|Drug|Piflufolastat F 18|Single intravenous dose of approx. 333 Megabecquerel (MBq) prior PSMA-PET scans
46076206|NCT04869540|Other|'Got Transition' toolkit and resources|Providers will be trained in the 'Got Transition' toolkit (the systems level component of the intervention) and have access to web-based transition resources.
46076207|NCT04869540|Behavioral|PSE intervention|A family-based problem solving education (PSE) intervention.
46076208|NCT00635076|Other|placebo|Patients continued taking the matching placebo that they were taking when they completed Study A6131002 (oral tablets taken once daily).
45947872|NCT01054807|Device|Galyfilcon A Habitual Lens|Comparison of three soft contact lens designs.
45810782|NCT05208697|Behavioral|Tele-Harm Reduction|THR is telehealth-enhanced, on-demand services including low-barrier access to antiretrovirals, medications for substance use disorder and hepatitis C treatment. It includes mobile phlebotomy, harm reduction counseling, medication management, telehealth mental health/substance use disorder services-- all delivered via an SSP, integrated with the provision of evidence-based naloxone and injection equipment.
45947873|NCT01054807|Device|Galyfilcon A 8.7 BC (Investigational)|Comparison of three soft contact lens designs.
45947874|NCT01054807|Device|Galyfilcon A 8.3 BC (Investigational)|Comparison of three soft contact lens designs
45947875|NCT00099125|Drug|irinotecan hydrochloride|
46076209|NCT00635076|Drug|alprazolam XR|Patients continued taking the same dosage of alprazolam that they were taking when they completed Study A6131002 (oral tablets taken once daily (1-6mg)); patients taking less than 6 mg/day who failed to show a satisfactory clinical response since the previous visit, and who were free of dose-limiting adverse events, could have their dosage titrated upward by 1 mg/day; upward daily dosage titration of 1 mg was allowed every 7 days, up to a maximum daily dosage of 6 mg/day; patients who were unable to tolerate the previous dosage level of alprazolam XR could have their daily dosage reduced.
45658458|NCT05849298|Drug|ARPI|Enzalutamide, Darolutamide, Apalutamide as prescribed by the local investigator
45658459|NCT05849298|Drug|ADT|as prescribed by the local investigator
45658460|NCT05849298|Other|Best supportive care|as prescribed by the local investigator
45810783|NCT05208697|Other|off-site linkage|standard of care linkage to a Ryan White clinic
45810784|NCT05206279|Drug|Ureteral injection of Indocyanine Green Powder (diluted)|The intervention we study is the intraureteral injection of ICG during a laparoscopic deep infiltrative endometriosis resection procedure. Cystoscopy with intraureteral administration of ICG will be performed, after which intervention the ureters will be examined by laparoscopy. ICG is injected cystoscopy-guided into the ureters (cystoscopy-guided) in a dosage of 5 or 10ml (25mg ICG in 5 or 10ml NaCl) per ureter as a bolus injection.
45810785|NCT04344067|Device|Far Infrared Therapy|The WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) was used to conduct FIR therapy in this study. The electrified ceramic plates of the emitter generated electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 milliwatt (mw) /cm2 when the top radiator was set at a distance of 30 and 20 cm above the skin surface respectively.
45810786|NCT02959333|Biological|hAEC|hAEC: human amniotic epithelial cells
45947876|NCT00099125|Drug|temozolomide|
45947877|NCT00099125|Procedure|adjuvant therapy|
45947878|NCT00099125|Radiation|radiation therapy|
45658461|NCT05849051|Behavioral|Newly developed warnings with images at 30% size|On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning developed by the study team that includes an image. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
45810787|NCT02959411|Drug|Tolvaptan|Tolvaptan is a selective vasopressin receptor antagonist that inhibits activation of the V2 receptor and synthesis and insertion of the aquaporin2 channel into the apical membrane of the renal collecting duct. Tolvaptan inhibits the reabsorption of free water, inducing free water diuresis and increasing serum sodium levels without adversely influencing electrolyte levels or stimulating the sympathetic nervous system or renin-angiotensin system.
45810788|NCT02959411|Drug|Standard of care diuretic therapy|Usual standard of care diuretic therapy for patients hospitalized with acute decompensated heart failure
45947879|NCT01052194|Drug|Placebo|tablet, placebo b.i.d. for 12 weeks
46076210|NCT04225182|Device|traditional rehabilitation protocol|muscular strengthening protocol with traditional rehabilitation protocol without orthosis
46076211|NCT04225182|Device|with instrumented Orthosis|8 weeks of muscular strengthening with the orthosis connected to the phone app associated
46076212|NCT04176432|Other|No intervention|Retrospective observational study with no intervention
46076213|NCT00891020|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous every 4 weeks for 24 weeks
46076214|NCT00891020|Drug|tocilizumab [RoActemra/Actemra]|4 mg/kg every 4 weeks for 24 weeks
46076215|NCT00891020|Drug|Nonbiologic DMARDs of investigator's choice|Nonbiologic disease-modifying antirheumatic drugs (DMARDs) As prescribed
45947880|NCT01052194|Drug|VX-509|tablets, 25mg b.i.d. for 12 weeks
45947881|NCT01052194|Drug|VX-509|tablet, 50 mg b.i.d. for 12 weeks
45947882|NCT01052194|Drug|VX-509|tablet, 100 mg b.i.d. for 12 weeks
45810789|NCT05449873|Procedure|Radiofrequency ablation using combined bipolar and monopolar energy deliver with Triple Cooled-Wet electrodes|Radiofrequency ablation will be performed by using triple cooled-wet electrodes. Two or three electrodes will be places around the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF, bipolar mode and switching monopolar mode) will be applied to two of three electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C.
45947883|NCT01052194|Drug|VX-509|tablet, 150 mg b.i.d. for 12 weeks
45947884|NCT00131703|Drug|Amodiaquine|
45658462|NCT05849051|Behavioral|FDA proposed text-only warnings at 30% size|On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning proposed by the FDA which is text only. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
45658463|NCT05841706|Biological|Arm I Packed Red Blood Cell Transfusion (Hgb < 7 g/dL)|Receive conservative transfusion strategy (Hgb < 7 g/dL)
45658464|NCT05841706|Biological|Arm II Packed Red Blood Cell Transfusion (Hgb < 9 g/dL)|Receive liberal transfusion strategy (Hgb < 9 g/dL)
45658465|NCT05841706|Procedure|Computed Tomography|Undergo CT scan
45810790|NCT02977819|Other|Meditation practice|18 months
45810791|NCT02977819|Other|Learning English as a foreign language|18 months
45658466|NCT05841706|Procedure|X-Ray Imaging|Undergo x-ray imaging
45658467|NCT05841706|Procedure|Biospecimen Collection|Undergo blood sample collection
45947885|NCT00131703|Drug|Sulphadoxine-pyrimethamine|
45947886|NCT00131703|Drug|Chloroquine|
45947887|NCT01051414|Drug|BMS-790052|Tablets, Oral, 60 mg, daily, 24 weeks
45947888|NCT01051414|Drug|BMS-650032|Tablets, Oral, 1200 mg, daily, 24 weeks
45947889|NCT00434317|Drug|Zoledronic acid|
45947890|NCT00099164|Drug|17 alpha-hydroxyprogesterone caproate (17P)|Study coded medication is 250 mg of 17P as a 1 ml intramuscular injection (or 1 ml of placebo inert oil). Patients are seen weekly to administer the study drug through 34 weeks 6 days gestation or delivery, whichever occurs first.
45947891|NCT00131742|Drug|telbivudine|
45947892|NCT00131742|Drug|lamivudine|
45810792|NCT05647213|Biological|iPSC-CL|Autologous IPSCL
45810793|NCT05196061|Other|Questionnaire|"Subjects will be asked to complete a questionnaire. The questionnaire will garner demographic data, medical history, medication and supplement history, gut-specific, skin-specific questions; etc. The complete questionnaire is provided with this submission for review. Demographic data includes:~Age~Sex~Race~Ethnicity"
45947893|NCT04621149|Other|chlorine dioxide|chlorine dioxide is an antimicrobial agent used for a variety of purposes including as a water purification product, a disinfectant on food, etc.
45947894|NCT04621149|Dietary Supplement|zinc acetate|zinc acetate lozenges have been suggested to have antiviral properties
45947895|NCT04621149|Drug|Famotidine|famoitidine is a histamine-2 blocker sold over the counter to reduce stomach acid
45947896|NCT04621149|Other|placebo|filtered water
45947897|NCT04621149|Dietary Supplement|lactoferrin, green tea extract|lactoferrin and green tea extract are dietary supplements
45947898|NCT00099203|Drug|ibandronate [Bondronat]|6mg iv on days 1-3, and every 3-4 weeks
45947899|NCT00099203|Drug|zoledronic acid|4mg iv on day 1 and every 3-4 weeks
45947900|NCT00131781|Behavioral|Cognitive Therapy|
45947901|NCT00131781|Behavioral|Supportive Therapy|
45947902|NCT00099242|Drug|rivastigmine transdermal patch|
45947903|NCT04728542|Device|ORIGIN PS System|Group of 70 subjects who will undergo a surgery with the ORIGIN PS System
45947904|NCT04728542|Device|VANGUARD PS System|Group of 70 subjects who will undergo a surgery with the VANGUARD System
45947905|NCT00131820|Biological|Typhoid Vi vaccine|
45947906|NCT00131820|Biological|Hepatitis A (control)|
45947907|NCT00099281|Drug|YMB 1002|
45947908|NCT04586127|Other|AYA NA-SB Questionnaire|Questionnaire identifying cancer needs so that providers can connect subjects with services that might address them.
45947909|NCT00099320|Drug|exenatide|After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer 20 mcg of exenatide (2 units [5 μg] ), twice daily by subcutaneous injection, for the first 4 weeks of therapy, and then 40 μL of study drug (4 units [10 μg] of exenatide) twice daily by subcutaneous injection, for the remaining 12 weeks of therapy.
45947910|NCT00099320|Drug|Placebo|After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer placebo (in equivalent amounts to exenatide) for 16 weeks of therapy.
45810794|NCT05196061|Other|Stool sample|Stool samples will be collected using a specific kit consisting of a ready-to-use package, including a user guide. When stool samples are collected, they will be immediately placed in previously prepared Fast prep tubes (MP, Cat# 5076-200-34340) containing 500 μL glass beads (Sigma-Aldrich G8772-100g) and 1 mL ASL™ lysis buffer (Qiagen DNA Extraction Kit) and transported to the laboratory where assays will be conducted. Samples will be kept in a - 20 degree Celsius freezer until they are analyzed.
45810795|NCT05196061|Other|Skin swab|Skin swabbing is a safe, non-invasive method to sample microbiota on human skin. Areas to be swabbed: Right upper back, Non-dominant ventral forearm or Most representative lesion
45658468|NCT05841706|Other|Survey Administration|Ancillary studies
45947911|NCT04561596|Device|OnComfort autohypnosis|"Participant arrive in our day care clinic and is prepared as any other patient in interventional radiology. The investigator will collect the signed informed consent form and proceed to randomization.~The participant will then fill the pre and post-operative anxiety and pain questionnaire.~The percutaneous vascular procedure will be performed as usual except for the virtual reality mask and autohypnosis software that will run during the whole intervention.~Pain and anxiolytic medication are provided if needed during the intervention. Immediately after the intervention, the participant will fill the post-operative anxiety and pain questionnaire. The participant will be instructed to report anxiety and pain felt during the intervention.~A clinical visit at 3 month is conducted as part of the standard clinical protocol. The participant will fill a 3rd questionnaire about the remembered anxiety and pain during the intervention."
45947912|NCT04561596|Other|Treatment as usual, without the OnComfort autohypnosis system|"The Participant arrive in our day care clinic and is prepared as any other patient in interventional radiology. The investigator will collect the signed informed consent form and proceed to randomization.~The participant will then fill the pre and post-operative anxiety and pain questionnaire.~The percutaneous vascular procedure will be performed as usual. Pain and anxiolytic medication are provided if needed during the intervention. Immediately after the intervention, the participant will fill the post-operative anxiety and pain questionnaire. The participant will be instructed to report anxiety and pain felt during the intervention.~A clinical visit at 3 month is conducted as part of the standard clinical protocol. The participant will fill a 3rd questionnaire about the remembered anxiety and pain during the intervention."
45810796|NCT05196061|Other|Oral rinse|Briefly, 20-25 ml saline will be provided in separately labelled blue capped 50-mL Falcon™ centrifuge tubes (Fisher Scientifics Co.). Each subject will be asked to swish and gargled the saline from the tube into their mouth for 2 minutes and expectorate the rinse into the tube. The tubes will be closed tightly and stored in -80 C until sequencing can be completed. Prior to use, all the tubes with oral wash samples will be completely thawed on ice, then centrifuged at 4000 rpm for 15 minutes and 20-25 ml supernatant transferred into fresh 50-mL centrifuge tubes. The pellet left in each tube will be used to extract DNA for microbiome studies
45810797|NCT00359593|Behavioral|Knowledge translation intervention package|
45947913|NCT00099476|Behavioral|Effects of dark chocolate|
45947914|NCT00403650|Drug|Iloprost|Iloprost 2.5-5 mg inhaled via nebulizer up to 6 times a day
45947915|NCT00403689|Dietary Supplement|Beta-D-Glucan|1,5 g Beta-D-Glucan daily
45810798|NCT05190991|Biological|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
45810799|NCT05183503|Diagnostic Test|DC/TMD examination|Clinical examination by examiners- experienced dentists (minimum 5 years of practice) and trained and calibrated in accordance with the protocol available on the official website of the International Network for Orofacial Pain and Related Disorders Methodology
45658469|NCT05841706|Procedure|Pancreatectomy|surgical removal of all or part of pancreas
45658470|NCT05841615|Other|Renal Denervation operation|RDN: Percutaneous renal artery sympathetic radiofrequency ablation for both sides. For each side, a total of 13 targets were ablated. The ablation power was 8W~12W for 40 seconds
45658471|NCT05841615|Other|Pulmonary vein isolation|PVI: Pulmonary vein isolation was performed until the potential of each pulmonary vein disappeared under the guidance of the CARTO mapping system. Ablation of the top line and the bottom line of the left atrium was performed at the same time.
45810800|NCT05434585|Biological|ABO1009-DP|Vaccine
45658472|NCT05837676|Behavioral|Problem Solving Training for Concussion|PST-Concussion is a combined treatment consisting of brief problem-solving training, standard concussion education, motivational interviewing, goal-setting, and compensatory cognitive strategies.
45658473|NCT05837676|Other|Treatment as usual|Patients assigned to TAU will receive the care that they and their providers determine is necessary to best manage their presenting concerns.
45810801|NCT05434585|Biological|ABO-CoV.617.2|Vaccine
45810802|NCT05434585|Other|Placebo|Placebo
45810803|NCT05427955|Procedure|One-level Erector Spinae Plane Block|One-level Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position. In applications, 30 ml of 0.25% bupivacaine will be injected at the T5 level.
45658476|NCT05834491|Device|minimal shoes and foot strengthening and flexibility exercises|Flexible shoes that do not provide support and exercises aimed at increasing the strength of plantar intrinsic and extrinsic foot muscles along with foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
45947916|NCT00403689|Dietary Supplement|placebo|1.5 g waxy maize starch daily
45947917|NCT00403728|Drug|ciclosporine A|
45947918|NCT00099515|Drug|LY041001 (HIIP)|Inhalation, capsule, TID 3 times per day min 6 IU max 60 IU
45947919|NCT00099515|Drug|LY041001 (HIIP)|Inhalation, Capsule, TID 3 times per day min 6 IU max 60 IU
45658477|NCT05834491|Device|Supportive Footwear, foot orthotic device and foot flexibility exercises|sturdy supportive shoes fitted with supportive foot orthotic devices and foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
45658478|NCT05828992|Other|No intervention administered|Survey only to gather people's experiences, opinions and needs.
45658479|NCT05827068|Biological|mRNA-1011.1|Sterile liquid for injection
45658480|NCT05827068|Biological|mRNA-1011.2|Sterile liquid for injection
45658481|NCT05827068|Biological|mRNA-1012.1|Sterile liquid for injection
45810804|NCT05427955|Procedure|Bi-level Erector Spinae Plane Block|Bi-level Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position. In applications, 15 ml of 0.25% bupivacaine at T4 level and 15 ml of 0.25% bupivacaine at T6 level will be injected.
45810805|NCT05426161|Drug|Botulinum Toxin A|Botulinum Toxin A (10 units per cm2 wound areal) will be injected subcutaneously around the wound (1-2 cm from wound edge) maximum 200 units at each injection time.The total dose of BoNTA is maximum 400 units. Patient will receive one or two treatments in total.
45947920|NCT00403806|Drug|dexamethasone|intravenous dexamethasone 0.05 mg per kg bodyweight
45810806|NCT05426005|Drug|Cadonilimab|Cadonilimab, 6 mg/kg every 2 weeks until disease progression, intolerable toxicity, or duration of treatment for 2 years
45810807|NCT05630833|Drug|Gepotidacin|Gepotidacin will be administered.
45947921|NCT00403806|Drug|Dexamethasone|Intravenous dexamethasone 0.15 mg per kg bodyweight
45658482|NCT05827068|Biological|mRNA-1010|Sterile liquid for injection
45658483|NCT05827068|Biological|mRNA-1010.2|Sterile liquid for injection
45658484|NCT05827068|Biological|mRNA-1010.3|Sterile liquid for injection
45658485|NCT05826353|Drug|Ripasudil|K-321 ophthalmic solution
45658486|NCT05826353|Drug|Placebo|Placebo ophthalmic solution
45658487|NCT05823974|Biological|Flu mRNA|Different formulations of Flu mRNA (GSK4382276A) study intervention is administered intramuscularly in the non-dominant upper deltoid to YA and OA participants in Phase 1 and Phase 2, at Day 1.
45658488|NCT05823974|Combination Product|Control 1|Control 1 vaccine is administered intramuscularly in the non-dominant upper deltoid to participants in Control group from Phase 1, at Day 1 and to participants in Control YA group from Phase 2, at Day 1.
45658489|NCT05823974|Combination Product|Control 2|Control 2 vaccine is administered intramuscularly in the non-dominant upper deltoid to participants in Control OA group from Phase 2, at Day 1.
45810808|NCT05630833|Drug|Nitrofurantoin|Nitrofurantoin will be administered.
45810809|NCT05630833|Drug|Placebo|Placebo will be administered.
45810810|NCT00359671|Drug|MK6592|MK6592 delivered as a 48-hour CIV as monotherapy in Cycle 1; 48-hour CIV of MK6592 in Cycle 2 and subsequent cycles.
45810811|NCT00359671|Drug|comparator: docetaxel|docetaxel, delivered as a standard IV infusion.
45810812|NCT02978209|Device|7.5 %|Patient untreated with moisturizers for 1-2 weeks will start applying moisturizers containing urea at concentration 0 % on one half of the body twice a day while applying the same moisturizer with 7.5 % urea on the other half of the body in the same quantity at the same frequence
45810813|NCT05153863|Device|C Scope Visualization System|The C Scope Visualization System is indicated to be used by a trained physician to provide illumination and visualization in arthroscopic procedures of an interior cavity of the body through a surgical opening.
45947922|NCT00403806|Drug|dexamethasone|Intravenous dexamethasone 0.5 mg per kg bodyweight
45947923|NCT00403806|Drug|Saline|Intravenous saline
45947924|NCT00400556|Drug|ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination|
45947925|NCT00131859|Procedure|Diffusion-tensor imaging|Obtain a Diffusion tensor MRI of brain.
45947926|NCT00400595|Drug|Mupirocin ointment|topical ointment (already in widespread clinical use)
45947927|NCT00400595|Drug|Polysporin Triple|
45947928|NCT04464915|Other|Isopropyl alcohol swab|Treatment will be administered by taking one deep inhalation of an isopropyl alcohol swab held 1-2cm below the nares. Intervals of administration will be every 10 minutes or every 20 minutes for a total of one hour.
45947929|NCT00131898|Procedure|Surgical Resection|
45810814|NCT04744909|Device|SafeTrach for tracheotomy|The navigation system is a forceps-like instrument with an outer and an inner shank. The inner shank serves as a ventilation lumen and stabilizes the orotracheal tube in the midline of trachea. The outer shank acts as a three-dimensional guide for the puncturing needle to the midline of trachea
45810815|NCT03830905|Drug|XC221|Participants will receive 200 mg XC221 once a day during 3 days
45658490|NCT05822648|Behavioral|Project Health|Project Health will be delivered in six 1-hour group sessions that will be held weekly. In addition, participants will be asked to complete 30 mins of response inhibition and attention trainings once per week between the sessions. This program promotes to retain the gradual lifestyle modification designed to bring energy intake into balance with energy output and the food response inhibition and attention training, but will adapt the dissonance-induction activities to focus on the negative effects of developing T2D in addition to the negative effects of obesity, overeating, and a sedentary lifestyle.
45658491|NCT05822648|Other|Educational Video Control|We selected a T2D management psychoeducational comparison condition. To match Project Health, the educational videos will be delivered in 6 1-hour blocks. The educational group will be instructed to watch videos on nutrition, exercise, and how to maintain general health during the lifespan
45947930|NCT00131898|Procedure|Intensity Modulated Radiation Therapy (IMRT)|
45947931|NCT00400673|Behavioral|Two-step remission induction and risk-oriented consolidation|
45658492|NCT05820295|Behavioral|Care coordination delivered based on perceived need|If patients in intervention group report on the survey that they experience difficulty coordinating care among their providers, the patient will be selected for care management services. Those services will attempt to address the problems with care coordination that the proxy reported.
45658493|NCT05820295|Behavioral|Care coordination delivered based on usual care (e.g. discharge from hospital)|If a patient is discharged from a hospital, the patient will be selected for care management services.
45810816|NCT03830905|Drug|Placebo|Participants will receive Placebo once a day during 3 days
45947932|NCT04728698|Drug|COVI-MSC|1 x 10^6 MSCs/kg or 1.5 x 10^6 MSCs/kg, depending on CRP level
45947933|NCT04728698|Drug|Placebo|Equivalent volume of placebo will be administered
45658494|NCT05819710|Drug|TS-142|Single dose of 5 mg of TS-142
45658495|NCT05819710|Drug|TS-142|Single-dose of 10 mg of TS-142
45658496|NCT05819710|Drug|Zopiclone|Single-dose of 7.5 mg of zopiclone
45947934|NCT04447872|Procedure|Timing of injectable gonadotropins|Gonadotropins will with be started in the luteal phase or in follicular phase (preceded by Estradiol patches)
45947935|NCT00099554|Drug|Etanercept|
45947936|NCT00132015|Drug|tanespimycin|
45947937|NCT00099593|Biological|Autologous Dendritic Cell Vaccine|
45947938|NCT04440228|Behavioral|TeamSTEPPS|"TeamSTEPPS is an evidence-based approach for teams that can be adapted for school mental health.~Team Strategies and Tools to Enhance Performance and Patient Safety (TeamSTEPPS), has been widely disseminated in health care settings with promising outcomes. TeamSTEPPS is designed to build competencies in the areas of leadership, situation monitoring, mutual support, and communication and has been associated with improvements in teamwork and communication as well as patient outcomes, such as decreased seclusion in psychiatric hospitals."
45947939|NCT00099671|Drug|Recombinant human interleukin-7|
45658497|NCT05819710|Drug|Placebo|Single-dose of placebo
45658498|NCT05819502|Drug|Restylane line of injectable|Restylane fillers are manufactured by Q-Med AB, part of the Galderma Group.
45658499|NCT05816356|Drug|Decitabine|Oral administration of decitabine as a single dose to healthy male subjects
45658500|NCT05816356|Drug|Tetrahydrouridine|Oral administration of Tetrahydrouridine as a single dose to healthy male subjects
45658501|NCT05816304|Behavioral|Digital Cognitive Behavioral Therapy for Insomnia (dCBTi)|Digital CBTi is a computer-based cognitive behavioral therapy that provides strategies to improve sleep and daytime function (concentration, productivity) and decreases symptoms of sleep-related attributions, night-time thought content in individuals with insomnia. It is easily accessible with any internet-connected device, eg, computer, tabs, and smartphones.
45658502|NCT05815680|Drug|metformin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
45658503|NCT05815680|Drug|digoxin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
45810817|NCT05627323|Biological|CHM-1101 CAR-T cells|Administered via ICT/ICV dual delivery
45810818|NCT05404321|Other|Establishment of ex vivo breast cancer organoid models|This study includes 2 steps: The constitution of a collection of tumor and blood samples and the analysis of the ex vivo response of the tumor samples to the treatments for the development of functional tests and the research of predictive biomarkers of this response
45810819|NCT04343833|Procedure|Immediate dental implants|At the time of operation, the tooth was atraumatically extracted, and the implant was immediately placed following the surgical protocol recommended by the manufacturer. A temporary prosthesis was made without occlusal contact.
45947940|NCT00132054|Drug|amrubicin hydrochloride|
45947941|NCT00132054|Drug|irinotecan hydrochloride|
45947942|NCT00099710|Dietary Supplement|Curcumin C3 Complex|
45947943|NCT04425603|Device|Anthology Hip Replacement System|
45947944|NCT00099749|Drug|FTY 720|
45947945|NCT00132093|Drug|Eplerenone|
45947946|NCT00099788|Drug|Ranolazine|IV to oral transition.
45947947|NCT00099788|Drug|Placebo|IV to oral transition.
45947948|NCT00132171|Drug|Sequential therapy|
45947949|NCT02958449|Device|Test - Standard Closure with TissuGlu Surgical Adhesive|Patients randomized into the Test group, TissuGlu® will be applied to the chest wall after removal of the breast tissue using the custom applicator during a standard mastectomy procedure followed by normal wound closure (suturing technique) without drain placement.
45658504|NCT05815680|Drug|IBI362|Subjects will initiate treatment with 2 mg for the first four weeks followed by 4mg for four weeks and up to a dose of 6 mg for six weeks.
45947950|NCT04387422|Other|Experimental hyperglycemia|Experimental hyperglycemia with MRI
45947951|NCT00099827|Behavioral|Education|Individuals will receive information about depression
45947952|NCT04377009|Device|Sleep Healthy Using the Internet (SHUTi)|Cognitive behavioral therapy delivered via internet-guided program customized for military service members
45658505|NCT05815680|Drug|warfarin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
45947953|NCT04377009|Other|Education Control Program|Online portal designed to inform participants about healthy lifestyle activities and general insomnia information
45947954|NCT00099866|Drug|vildagliptin|
45947955|NCT00099866|Drug|Metformin Comparator|
45947956|NCT00099905|Drug|vildagliptin|
46076216|NCT02776566|Other|Patient Self-Monitoring vs Anticoagulation Clinic|"Patient Self-Monitoring (intervention): entails 3 education sessions of 90-120 minutes each (week 0, week 2, week 4): 2 provided on site in clinic and 1 in the patient's home, during which, self-testing competency and barriers and facilitators to self-monitoring will be evaluated. Subjects will follow with weekly (or sooner, if clinically indicated) in-home self-monitoring and follow-up weekly phone calls over 6 months by clinical pharmacists to guide warfarin dosing and reinforce key educational messages.~Anticoagulation Clinic (control): subjects will have their INR tested in clinic monthly (or more frequently if clinically indicated) via the Coaguchek® point-of-care device (which is the standard of care in the Anticoagulation Clinic) and receive dosing instructions and standardized education related to warfarin by a clinical pharmacist who provides care in the Anticoagulation Clinic."
45658506|NCT05815680|Drug|atorvastatin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
46076217|NCT02772744|Drug|Daclatasvir 60 MG Oral Tablet [Daklinza]|Daclatasvir (60 MG) is a potent, pan-genotypic inhibitor of the HCV NS5A protein
46076218|NCT02772744|Drug|Sofosbuvir 400 MG Oral Tablet [Sovaldi]|Sofosbuvir (400 MG) is a nucleotide analogue HCV NS5B polymerase inhibitor
45658507|NCT05815342|Device|Omnipod 5 Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
45658508|NCT05814588|Other|Anodal TDCS|"RehaCom software is a computer assisted cognitive rehabilitation, it targets six programs of brain including attention, memory, and higher executive function, visuo-motor abilities, visual filed, vocational abilities, each module is divided into further subsections there is 36 total subsections, we will work on 6 subsections in every week.~The aTDCS device is a battery operated, with a pair of rubber conductive electrodes (size 7×5cm) enclosed with sponge saturated pockets (pads)."
45658509|NCT05814588|Other|Sham Anodal TDCS|rehacom cognitive therapy will be provided to this group participants
45658510|NCT05806996|Drug|Magnesium|Intravenous infusion, load 50 mg/Kg with infusion of 15 mg/Kg/hour
45658511|NCT05806996|Drug|Placebo|Equivalent volume of normal saline
45658512|NCT05805345|Device|Delefilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
45658513|NCT05805345|Device|Lehfilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
45810820|NCT05141539|Device|Rehabilitation assessment software|"In phase 2, this software will be tested in occupational therapists, and head and neck cancer patients results for reliability and validity.~In phase 3, the experiment in the oropharyngeal dysphagia specialists results in content validity, the comparison between the developed software, and VFSS and FOIS results in criterion-related validity, and the experiment in head and neck cancer patients results in reliability."
45810821|NCT05141539|Device|VFSS and FOIS|In phase 3, this study applies VFSS and FOIS for the head and neck cancer patients for comparison with the developed rehabilitation assessment software for criterion-related validity.
45947957|NCT00132210|Drug|pegylated interferon|Pegylated interferon alfa-2a or -2b in standard dosage Ribavirin in case of genotype 1 or 4 at 1000 or 1200 mg/d according to body weight ist recommended.
45947958|NCT00099944|Drug|vildagliptin|
45947959|NCT00099944|Drug|Glimepiride|Glimepiride 4 mg qd
45947960|NCT00099944|Drug|LAF237 placebo|
45947961|NCT04352166|Drug|extended-release buprenorphine (BXR)|Three monthly injections will be provided during the course of the 12 week trial.
45947962|NCT04352166|Drug|sublingual buprenorphine (BSL)|On a weekly basis patients will be provided with sublingual buprenorphine to take up to 24 mg daily.
45947963|NCT00100061|Drug|Cranberry juice|liquid juice taken daily
45947964|NCT00100061|Dietary Supplement|Cranberry Juice|Taken orally
45947965|NCT00100061|Dietary Supplement|Placebo cranberry juice|Placebo comparitor
45947966|NCT04333914|Drug|Autophagy inhibitor (GNS651)|Cohort 1 (arm B): 200mg q.d. orally for 10 consecutive days. If for any reason a treatment is not given within the allowed treatment window (± 12h) it will be cancelled (i.e., missed for that time point), and treatment will be resumed at the next dosing day.
45947967|NCT04333914|Other|Standard of care|"In cohorts 1 and 2, patients allocated in the standard of care arms should receive best supportive care, as per the investigator's discretion and the local routine practices. With regards to the respiratory symptoms and medical resoures at investigational site, the following should be given according to the patient's condition: oxygen supplementation, non-invasive ventilation, invasive ventilation, antibiotherapy, vasopressor support, renal replacement therapy, or extracorporeal membrane oxygenation.~Additional care and medications should be administered in the patient's best interest."
45947968|NCT04333914|Drug|Avdoralimab|Cohorte 2 (arm H): 500mg, intravenously, at Day 1 then 200mg once daily every 2 days during 14 Days
45947969|NCT04333914|Drug|Monalizumab|Cohorte 2 (arm G) : 50mg (flat dose),intravenously, single infusion at Day 1.
45947970|NCT00100100|Drug|Modafinil|
45947971|NCT00100139|Drug|Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU)|
45658514|NCT05805345|Device|Lotrafilcon B toric soft contact lens|Commercially available silicone hydrogel contact lens
45658515|NCT05805345|Device|Verofilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
45658516|NCT05804045|Drug|Pimicotinib(ABSK021)|capsule
45453450|NCT01333124|Radiation|chemoradiotherapy with Gemcitabine|All patients will receive gemcitabine 400 mg/m2 as an intravenous 30-min infusion on day 1, 8, 15, 22, and 29 with radiotherapy.After 4-6 week from end date of chemoradiotherapy, patients undergo preoperative evaluation including CT, PET, CA19-9, CEA. If the patient is feasible for resection on this evaluation, the surgery is performed in 1 to 2 weeks. After surgery, patients will receive gemcitabine 1000 mg/m2 as an intravenous 30-min infusion on day 1, 8, and 15 for every 28 days. Subjects will be treated for at least 1 cycle and to a maximum of four cycles of adjuvant chemotherapy unless there is documented relapse, unacceptable adverse events or withdrawal of consent.
45453451|NCT01333124|Radiation|Radiation: chemoradiotherapy with Gemcitabine|Radiation: chemoradiotherapy with Gemcitabine
45658517|NCT05804045|Drug|Placebo|capsule
45658518|NCT05801419|Device|RETI-port/scan 21|Pattern visual event-related potential and pattern electroretinogram on right eye (non-dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
45658519|NCT05801419|Device|Zilia Ocular|Eye fundus tissue oximetry measure on left eye (dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
45810822|NCT05133115|Behavioral|Fostering Resilience in Adolescents at Risk|"The FRAK training was developed according to ecological framework, empirical evidence and contextual information. The contents, components, pedagogy, and technical elements of FRAK were established based on The Individual & Environmental Resilience Model (IERM). Previous to the intervention, a systematic review and a meta-analysis on Resilience Interventions were performed.~Students will follow a training consisting of six 55-minute sessions: (1) introducing resilience, (2) self-esteem, (3) emotional strategies regulation, (4) social skills, (5) solving problems (6) community resources, social and peers' support."
45810823|NCT02977897|Drug|Octreotide Acetate|Octreotide 100mcg SC q12h for 5 days
45810824|NCT05129059|Other|Logotherapy|Logotherapy is a method of finding meaning with three basic principles. The first principle is that life is meaningful in every situation , even in the most desperate moments. The second principle is that the main source of motivation is the desire to find meaning in life. The third is that an individual is free to choose his own attitude even in the worst conditions.
46076219|NCT02772744|Drug|Ribavirin Oral Product|Ribavirin (twice-daily) dosed according to body weight (<75 kg, 1000 mg daily; ≥75 kg, 1200 mg daily)
46076220|NCT04799886|Other|Semi structured interview|Interviews are performed by one research group member and based on beforehand decided questions and sub-questions. The interview material is transcribed and analysed on a theme level.
45453452|NCT03130790|Drug|Varlitinib|300mg, oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
45658520|NCT05801419|Device|OCT-A|Optical coherence tomography angiography measure on left eye (dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
45658521|NCT05801419|Combination Product|Electronic cigarette without nicotine|Vaping using an e-cigarette paired with an e-cigarette liquid vial without nicotine. Inhaling through the mouth and exhaling through the nose ten times. Inhalations must last 5 seconds and the participant has 5 minutes to do the 10 inhalations.
45658522|NCT05801419|Combination Product|Electronic cigarette with nicotine|Vaping using an e-cigarette paired with an e-cigarette liquid vial with nicotine. Inhaling through the mouth and exhaling through the nose ten times. Inhalations must last 5 seconds and the participant has 5 minutes to do the 10 inhalations.
45658523|NCT05795621|Biological|IBI311|10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions for phase II/III.
45658524|NCT05795621|Biological|placebo|4 does of placebo for phase II; 8 does of placebo for phase III.
45658525|NCT05793450|Drug|IBI362|2.0mg, SC, single dose
45658526|NCT05789069|Drug|HFB200603|Participants will be administered HFB200603 as described in the experimental arm.
45658527|NCT05789069|Drug|Tislelizumab|Participants will be administered tislelizumab as described in the experimental arm.
45658528|NCT05786625|Device|Ablation|Bronchoscopy and microwave ablation of lung nodule
45658529|NCT05786573|Drug|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
45658530|NCT05786573|Drug|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
45658531|NCT05786573|Other|Placebo|Placebo
45658532|NCT05786417|Other|Clinician Discretion|Clinician discretion as to which BB or CCB will be used if the participant has a heart rate and blood pressure within normal limits.
45658533|NCT05786417|Drug|Beta blocker|Selection of the specific BB and initial starting dose will be determined by the treating clinician.
46076221|NCT02774382|Drug|Vancomycin|Already incl. in arm description
46076222|NCT02774382|Drug|Fecal microbiota transplantation|Already incl. in arm description
46076223|NCT02774382|Drug|Rectal bacteriotherapy|Already incl. in arm description
45947972|NCT00100139|Drug|Paclitaxel for injection (Taxol)|
45947973|NCT00132288|Behavioral|Motivational support|Participants in the PALS program at SE Seattle Senior Center are assigned a volunteer phone buddy who uses motivational interviewing techniques during bi weekly or monthly phone calls to encourage the participant to become more physically active.
45947974|NCT00132288|Behavioral|PALS - Physical activity for lifetime success|Referral by a primary care provider to a community based support program to enhance uptake or maintenance of physical activity by the participants.
45947975|NCT04307433|Behavioral|Storytelling narrative videos on tablets|The storytelling narrative episodes in the application will feature video clips of the multiple stories of women living with HIV infection, HIV support group leaders, community leaders, and health care professionals and a Learn More video of physician discussing cervical cancer.
45658534|NCT05786417|Drug|Calcium channel blocker|Selection of the specific CCB and initial starting dose will be determined by the treating clinician.
45658535|NCT05782062|Device|Cleaner XT|Wire like device that rotates to allow for wall to wall disruption of thrombus.
45947976|NCT00100295|Drug|Hypericum perforatum|300 mg capsule taken three times a day
45947977|NCT00100295|Other|Placebo|300 mg given three times a day, containing rice protein powder
45947978|NCT00100334|Drug|PPI-1019 (APAN)|
45947979|NCT00100373|Drug|RSV challenge material|
45658536|NCT05782062|Device|Balloon|Use of balloon for disrupting thrombus.
45658537|NCT05781217|Drug|triptorelin, goserelin, leuprorelin|ADT will consist of LHRH analogues (triptorelin, goserelin, leuprorelin) with bicalutamide 50 mg/day started 10 days before the first ADT injection to avoid LHRH-related flare-ups. Bicalutamide will be discontinued after 30 days. The LHRH analogue will be initiated prior to the start of radiotherapy and administered for 6 or 24 months depending on treatment allocation. The maximum time permitted between randomisation and administration of the first LHRH dose is 30 days. The maximum time from the first LHRH dose to the start of SRT is 60 days.
45658538|NCT05777330|Diagnostic Test|Oral glucose tolerance test (OGTT)|"Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in first-degree relatives at moderate, high and very high risk of clinical onset of type 1 diabetes.~OGTT is performed every 6 months (every 3 months in case of dysglycemia) in all participants."
45810825|NCT05128201|Radiation|consolidative radiotherapy|local consolidative radiotherapy for all metastatic lesion (30-45Gy/3-8F)
45947980|NCT00132405|Drug|ALGRX 3268|
45947981|NCT00100412|Drug|Graded dobutamine infusions|
45947982|NCT00100412|Drug|Graded phenylephrine injections|
45947983|NCT00100412|Behavioral|Psychosocial challenge involving socioevaluative public speaking|
45810826|NCT05115019|Biological|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.
45810827|NCT05115019|Biological|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo
45810828|NCT05114941|Device|immunosorbent column|Immunoadsorption treatment regimen: the treatment is performed once every 1-3 days, at least 5 times, and the amount of regenerated plasma for each treatment is 1 to 3 times the plasma volume. The immunosorbent column adopts the protein A immunosorbent column.
45810829|NCT05114941|Drug|intravenous immunoglobulin|Intravenous immunoglobulin treatment regimen: intravenous immunoglobulin therapy, 400mg/kg/d, once a day, for at least 5 consecutive days.
45810830|NCT05102383|Device|Biofinity Toric contact lenses|Monthly replacement contact lenses
45947984|NCT04247958|Procedure|Colorectal resection|Robotic-assisted resection of the colon or rectum in subjects with benign or malignant colon or rectal disease, where SureForm™ Staplers are utilized for transection and/or creation of anastomosis.
45947985|NCT00100451|Procedure|exercise|
45947986|NCT04244058|Drug|Amantadine + L-DOPA|Amantadine 150 mg L-DOPA 375mg/carbidopa 75mg
45947987|NCT04244058|Drug|NMDA blocker|NMDA blocker
45947988|NCT00132444|Drug|topical vaginal application of UC-781 gel|UC-781 gel (arms 1 and 2) or placebo (arm 3) applied vaginally twice daily for 14 days
45947989|NCT00400751|Behavioral|FAMCON (Family Consultation)|
45947990|NCT00132483|Behavioral|Instruction in physical training program|Instruction in physical training program.
45947991|NCT00132522|Drug|EMD 273066|"dose-escalating study and subjects enrolled in the study may receive a maximum of 6 cycles of the assigned regimen over 18 weeks. Each cycle will be 3 weeks (21 days) with cyclophosphamide on Day 1 and EMD 273066 on Days 2 to 4, followed by 17 days with no experimental pharmaceutical product.~Each cycle, cyclophosphamide at 300 mg/m2 given per institutional guidelines 1 day (22-28 hours) prior to 3 consecutive days of EMD 273066 as a 4-hour IV infusion at 1 of 6 planned dose levels of 0.5, 1, 2, 3, 4, or 6 mg/m2."
45947992|NCT00100568|Drug|Efavirenz|600 mg tablet taken orally daily
45947993|NCT00100568|Drug|Lamivudine/zidovudine|150mg lamivudine/300mg zidovudine tablet taken orally twice daily
45947994|NCT00132561|Drug|Sulfadoxine/pyrimethamine and artesunate|
45947995|NCT04181853|Other|exercise|aerobic exercise
46002239|NCT04293562|Procedure|Positron Emission Tomography|Undergo FDG-PET
45658539|NCT05777330|Diagnostic Test|Hyperglycemic clamp test|"Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in first-degree relatives at moderate, high and very high risk of clinical onset of type 1 diabetes.~Clamp test is performed every 12 months in single autoantibody-positive participants and every 6 months in multiple autoantibody-positive participants. Clamp tests are not performed in participants aged between 5-11 years."
45947996|NCT04728659|Drug|Desogestrel 0.075 MG|It will be given orally for 3 to 5 days during FSH administration for ovarian stimulation
46076224|NCT02774460|Drug|Zestril®|Treatment step up: 1-2 weeks (10 mg tablet) Target dose: 5-7 weeks (20 mg tablet)
45947997|NCT04728659|Drug|Orgalutran|It will be given subcutaneously for 3 to 5 days during FSH administration for ovarian stimulation
45947998|NCT00132600|Drug|bacitracin (allergen)|
45947999|NCT04729010|Other|Acupuncture to treat anxiety in Parkinson disease|Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
45948000|NCT00132639|Drug|Preoperative docetaxel-cisplatin combination chemotherapy|Preoperative docetaxel-cisplatin combination chemotherapy
46076225|NCT02774460|Drug|Atacand®|Treatment step up: 1-2 weeks (8 mg tablet) Target dose: 5-7 weeks (16 mg tablet)
45658540|NCT05777330|Diagnostic Test|Continuous glucose monitoring|"Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in first-degree relatives at moderate, high and very high risk of clinical onset of type 1 diabetes.~A 10-day CGM recording is performed every 6 months (every 3 months in case of dysglycemia) in all participants."
45810831|NCT05102383|Device|Precision1 for Astigmatism Daily Disposable contact lenses|Daily disposable contact lenses
45948001|NCT00132639|Drug|Preoperative docetaxel monotherapy|Preoperative docetaxel monotherapy
45810832|NCT00359905|Drug|Silodosin|8 mg daily for 12 weeks
45810833|NCT00359905|Drug|Tamsulosin|0.4 mg daily for 12 weeks
45810834|NCT00359905|Drug|Placebo|once daily for 12 weeks
45810835|NCT05086939|Drug|Autologous MSCs|Intra-articular injection 40 million/4 ml.
45810836|NCT05086939|Drug|Allogenic MSCs|Intra-articular injection 40 million/4 ml.
45810837|NCT05086939|Drug|Hyaluronic Acid|Intra-articular injection 60mg / 3 ml .
45948002|NCT02958371|Procedure|fMRI|
45948003|NCT02958371|Behavioral|fruit-flavored drink ingestion|
45948004|NCT04728386|Other|curcumin solution|2 % curcumin solution as root canal irrigant
45948005|NCT04728386|Other|sodium hypochlorite|2.5% sodium hypochlorite solution as root canal irrigant
45948006|NCT00100607|Drug|AAE581|
45948007|NCT00100646|Behavioral|Structured treatment interruption|Interruptions in treatment will last 2, 4, and 8 weeks in between 16-week periods of ART
45948008|NCT00100646|Drug|Lamivudine|300 mg tablet taken orally daily
45948009|NCT00100646|Drug|Lopinavir/Ritonavir|400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
45948010|NCT00100646|Drug|Stavudine|Dosage dependent on weight
45948011|NCT00100646|Biological|Rabies de novo antigen|Vaccine injected intramuscularly
45948012|NCT00100685|Drug|Volociximab (anti-α5β1 integrin monoclonal antibody)|Volociximab intravenously (Cohort 1: 10 mg/kg every other week or Cohort 2: 15 mg/kg once a week) for up to 104 weeks or until disease progression, whichever occurs first.
45948013|NCT00132756|Drug|Doxil and Estramustine|
45948014|NCT00100724|Biological|rPA102|
45948015|NCT04107558|Device|Virtual Reality|Subjects will undergo painful stimuli without HVR followed by a session with HVR. Subjects are their own control
45948016|NCT00100880|Drug|lenalidomide|Given PO
46076226|NCT02774460|Drug|Norvasc®|Treatment step up: 1-2 weeks (5 mg tablet) Target dose: 5-7 weeks (10 mg tablet)
46076227|NCT02774460|Drug|Hydrochlorthiazide®|Treatment step up: 1-2 weeks (12,5 mg tablet) Target dose: 5-7 weeks (25 mg tablet)
46076228|NCT02774460|Drug|Treatment X|Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
45948017|NCT00100880|Procedure|perfusion-weighted magnetic resonance imaging|Correlative studies
45453453|NCT03130790|Drug|mFOLFOX6|concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
45948018|NCT00100880|Procedure|diffusion-weighted magnetic resonance imaging|Correlative studies
45948019|NCT00100880|Other|laboratory biomarker analysis|Correlative studies
46076229|NCT02774460|Drug|Treatment Y|Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
46076230|NCT02774460|Drug|Placebo|This is an unblinded placebo run-in which we use to generate baseline values. Each patient will initiate their participation with these 2 weeks of placebo treatment, taking 1 capsule daily.
45948020|NCT00132795|Behavioral|Daily monitoring of alcohol & drug use, & therapy skills|Comparison(s): patients completing group CBT for substance abuse will be randomly assigned to two conditions. In one condition, patients will have unlimited access to the therapeutic telephone system for 4 months. The other condition is standard care (i.e., no formal relapse prevention).
45948021|NCT00132795|Behavioral|control group|standard care (no added treatment)
45453454|NCT03130790|Drug|Placebo|oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
45658541|NCT05776823|Behavioral|Pharmacist Narcan Training|A 20-45-minute didactic presentation conducted with a skills training component designed to demonstrate appropriate administration of the Narcan nasal spray.
45948022|NCT00403104|Drug|ONO-2506PO|1200 mg QD / 18 months
45948023|NCT00403104|Drug|ONO-2506PO|0 mg QD / 18 months
45658542|NCT05776823|Behavioral|BIRT|BIRT participants will receive a 30-45-minute session delivered by the pharmacist to introduce and encourage treatment options, MOUD information, OUD information, and treatment facility information (i.e., flyers (RDD study/CAST clinic/State Opioid Response III funded agencies) and educational materials), and a referral to treatment/linkage to service providers.
45658543|NCT05776823|Behavioral|SMC|SMS participants will receive a 5-10-minute counseling session delivered by the pharmacist providing MOUD information, OUD information, and treatment facility information (i.e., flyers (RDD study/CAST clinic/State Opioid Response III funded agencies) and educational materials).
45658544|NCT05776823|Behavioral|Substance Use Counselor Narcan Training|A 20-45-minute didactic presentation conducted with a skills training component designed to demonstrate appropriate administration of the Narcan nasal spray.
45948024|NCT00100958|Drug|indole-3-carbinol|
45948025|NCT00132834|Device|R-Tube or EcoScreen|Device for collection of exhaled breath condensates (EBC) collection (i.e. condensing and collecting breath vapor from a cold, solid surface)
45948026|NCT00100997|Drug|tanespimycin|
45948027|NCT00403143|Procedure|cataract surgery|
45948028|NCT00101075|Drug|Capecitabine|
45948029|NCT00101075|Drug|Oxaliplatin|
45658545|NCT05771025|Procedure|Hepatectomy|Patients in the hepatectomy group receive liver resection.
45658546|NCT05769530|Drug|Nalbuphine，dexmedetomidine|According to the drug use, the subjects were divided into group A, which was continuously injected with normal saline during the operation, and intravenously injected with 5 mL normal saline 30 minutes before the end of the operation. In group B, DEX 0.5μg/kg was injected intravenously during the operation, which was completed in 10 min, and Nalbuphine 0.20 mg/kg (5 mL) was injected intravenously 30min before the end of the operation. After the operation, all anesthetic drugs were stopped and the patient was transferred to PACU with intubation.
45658547|NCT05764278|Other|exercise|exercise group: first bed exercise after 0~24hr onset ; sit at bed after 24~48hr onset control group: first bed exercise after 24~48hr onset ; sit at bed after 48~72hr onset
45658548|NCT05762705|Behavioral|Multilevel Gaming Adherence Intervention|Information-Motivation-Behavior based mobile gaming application tailored for those taking PrEP and adherence-based text messages
45658549|NCT05762705|Behavioral|Treatment as Usual +|non-PrEP related mobile gaming application
45658550|NCT05753189|Drug|Aceclidine+Brimonidine combination ophthalmic solution|Combination ophthalmic solution of Aceclidine and Brimonidine
45810838|NCT00358813|Drug|Casopitant|Casopitant oral tablets will be available with a dose of 50 milligrams.
45810839|NCT02977663|Other|Magnetic Resonance Imaging (MRI)|"Chest MRI during the MRI cerebral~2 tubes of blood taken during the medical visit"
45810840|NCT05387863|Other|Decision Aid (DA) Web Tool|The DA web tool provides information on kidney masses and available treatment options. It uses risk communication, directed teaching, and interactive benefit-harm assessment to present information.
45810841|NCT05387863|Other|Institutional Pamphlet|The institutional pamphlet provides information on kidney masses, but does not use risk communication, directed teaching, or interactive benefit-harm assessment.
45810842|NCT04344223|Device|Balance Shoe|Use of experimental balance shoes for carrying out the tests along the three sessions and one of the two familiarization phases
45948030|NCT00132912|Drug|SCH 530348|
45948031|NCT00403182|Drug|chemotherapy|
45948032|NCT00403182|Drug|letrozole|
45948033|NCT00101114|Drug|sorafenib tosylate|Given PO
45948034|NCT00101114|Biological|recombinant interferon alfa-2b|Given SC
45948035|NCT00101114|Other|laboratory biomarker analysis|Optional correlative studies
45948036|NCT00403221|Genetic|RTVP-1 Gene|"Cohort Level #1 1.0 x 1010vp Cohort Level #2 5.0x1010vp Cohort Level #3 1.0 x 1011vp Cohort Level #4 5.0x1011vp Cohort Level #5 1.0 x 1012vp Cohort Level #6 5.0x1012vp~One dose only followed by a radical prostatectomy 4 weeks later."
45948037|NCT02964819|Other|exercise|
46076231|NCT02772354|Procedure|Radiofrequency catheter ablation|Biosense Webster: NAVI-STAR ThermoCool, NAVI-STAR® RMT ThermoCool
46076232|NCT02772354|Drug|Metoprolol|"Antiarrhythmic therapy of premature ventricular complexes~Metoprolol 12-50 mg"
46076233|NCT02772354|Drug|Verapamil|Verapamil 20-240 mg
46076234|NCT02772354|Device|NAVI-STAR® RMT ThermoCool|
45658551|NCT05753189|Drug|Placebo|Placebo: Proprietary Vehicle Solution
45948038|NCT02964819|Device|Interferential current therapy|
45948039|NCT02964819|Device|Therapeutic Ultrasound|
45658552|NCT05753189|Drug|Aceclidine Ophthalmic Solution|Aceclidine
45948040|NCT00135252|Procedure|nasal cannula oxygen delivery|
45948041|NCT00135252|Procedure|supplemental oxygen delivery by hood|
45948042|NCT00101153|Drug|cytarabine|
45658553|NCT05751473|Behavioral|Prolonged Exposure for Primary Care (PE-PC)|"Treatment will be given by telehealth or in person, depending on the participant preference.~Content is drawn from the Full Prolonged Exposure model and condensed so as to deliver the most efficacious components in a brief format. There will be 4-6 weekly 30-minute sessions. Treatment follows the standardized PE-PC manual and workbook. At the end of the final session, the counselor and participant will review treatment progress and either conclude treatment or refer the participant to outside mental healthcare for more intensive treatment.~Participants will complete surveys and complete homework during and following the study."
45810843|NCT04344223|Device|Personal Shoe|Use of Personal shoes (the same for each session) for carrying out the tests along the three sessions and one of the two familiarization phases
45810844|NCT04344613|Device|ABODpoct device|The device has been developed by a consortium including the Université Libre de Bruxelles, research centers (SIRRIS, CER), a private company (CISEO), and the spin-off Antigon S.A..The device includes a reader and a disposable disk (ABOD disk) for testing one patient et a blood bag. Four blood drops from the patient are deposited on one side of the disk and 4 blood drops from the blood bag one the other side. The disk correctly filled is inserted in the reader and after 2 minutes the result is displayed on the screen as a message GO or No GO. In case of incompatibility or any other problem a red Stop message will appear on the screen.
45948043|NCT00101153|Drug|daunorubicin hydrochloride|
45810845|NCT05603455|Dietary Supplement|Bifidobacterium adolescentis|Supplement with Bifidobacterium adolescentis twice/day in morning and tonight for 6 months
46076235|NCT00611455|Drug|ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two 700mg IV infusions taken 14 days apart. A total of 8 infusions cycles given over a 144 week period
45810846|NCT05603455|Dietary Supplement|Placebo|Placebo
45810847|NCT05071027|Other|Endovascular Neurosurgery|Custom Dual Antiplatelet Therapy reminders for patients receiving endovascular treatment of cerebral unruptured aneurysms. The app utilized to generate reminders is available on the Apple app store.
46076236|NCT00611455|Drug|Placebo|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two IV infusions taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
46076237|NCT04429724|Diagnostic Test|Diagnostic test Covid-19|Three blood samples will be taken at day 1, month 3 and month 6 A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6.
46076238|NCT02772510|Device|Smart glove system with functional electrical stimulation|Game-based virtual reality rehabilitation system (Smart glove system) combined with functional electrical stimulation on distal upper extremity
46076239|NCT02772510|Device|Functional electrical stimulation|Functional electrical stimulation on distal upper extremity
46076240|NCT04246580|Procedure|Indocyanine green-guided systematic pelvic lymphadenectomy|Injection of Indocyanine green within the uterine cervix before to perform laparoscopic/robotic systematic pelvic lymphadenectomy
45810848|NCT00360061|Behavioral|Cognitive Behaviour Therapy|
45810849|NCT04343599|Other|Hypopressive exercises|The first two sessions will have as objective the correct and effective learning of the hypopressive technique. The rest of the sessions will be dedicated to the realization of an exercise protocol based on a progression of postures from standing to supine. Diaphragmatic apneas of approximately 7 seconds will be performed, alternating each apnea with three breaths.
45948044|NCT00101153|Drug|tipifarnib|
45948045|NCT00132951|Drug|Telithromycin|Telithromycin (AECB: 2 tablets per day for Days 1-5; CAP: 2 tablets per day for Days 1-7)
45948046|NCT00132951|Drug|Azithromycin|Azithromycin (AECB: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5; CAP: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5 then 2 placebo tablets per day for Days 6-7)
45948047|NCT00400790|Drug|propofol|Propofol used as the primary anaesthetic agent
45948048|NCT00400790|Drug|desflurane|Desflurane used as the primary anaesthetic
45948049|NCT00132990|Device|Deep brain stimulation|
45948050|NCT00400868|Behavioral|psycho-educational Joint protection education|individualized psycho-educational joint protection education, 4-times over 3 weeks; one additional booster session 2 months later
45948051|NCT00135291|Procedure|Leukoreduced blood transfusion|
45948052|NCT00400907|Other|clinical observation|
45948053|NCT00400907|Procedure|management of therapy complications|
45948054|NCT00133029|Drug|Timing of prophylactic antibiotic administration|
45948055|NCT00135408|Drug|Ipilimumab+ Placebo|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
45948056|NCT00135408|Drug|Ipilimumab+ Budesonide|Solution/Capsule, Intravenous/Oral, 10 mg/kg + 9 mg, 3 weeks (Ipilimumab) + once daily until week 16 (Budesonide), 12 - 48 weeks depending on the response.
45948057|NCT00101231|Drug|alvocidib|Given IV
45948058|NCT00101270|Drug|irinotecan hydrochloride|Given IV
45948059|NCT00101270|Drug|oxaliplatin|Given IV
45948060|NCT00101309|Biological|aldesleukin|
45948061|NCT00101309|Biological|autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine|
45948062|NCT00101309|Biological|therapeutic autologous lymphocytes|
45948063|NCT00133068|Behavioral|Computer|Computer intervention only
45948064|NCT00133068|Behavioral|Reduction in financial barrier|Copay only
46076241|NCT04751058|Genetic|genetic analysis|"Intervention details: sampling in peripheral blood for the Methodology:~Automatic DNA extraction (ChemagicTM 360)~Mass sequencing using SeqCap EZ Choice Library capture technology (NimbleGen) and NextSeq sequencer (Illumina).~Bioinformatic analysis:.~Identification of point mutations and small deletions or insertions~Analysis of CNVs using the BEDtools program package~Search of the identified variants in the following public databases: 1000G, dbSNP, ExAC, EVS, GenomADm CSVS and DGV. Those with a MAF> 1% have been considered benign, in public or private databases of our population.~The analysis process has focused exclusively on the genes described to date as associated with the pathology under study and included in the panel used. The reference sequences used for these genes are: determination of possible mutations, nucleotics, etc."
45948065|NCT00133068|Behavioral|Computer intervention & reduction of financial barrier|computer intervention & copay
45948066|NCT00133068|Behavioral|Control|No intervention
45948067|NCT00101348|Drug|erlotinib hydrochloride|Given orally
45676398|NCT03536585|Device|Vulvovaginal treatment|"Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.~Radiofrequency and pulsed electro-magnetic fields treatment of the labia to maintain an external temperature of approximately 40 C - 45 C for 15 minutes.~Radiofrequency and pulsed electro-magnetic fields treatment of the mons pubis to maintain an external temperature of approximately 40 C - 47 C for 15 minutes."
45810850|NCT04884061|Other|NBI images and/or videos|A library of NBI images and/or videos will be established from previously recorded bronchoscopies in 30 patients (10 with a SARS-CoV2 infection, 10 with a lower respiratory tract infection not related to SARS-CoV2, and 10 in patients with pulmonary nodule). NBI images and/or videos of the bronchial tree will then be analysed by three experimented interventional pulmonologists blinded to the patient ID. Each investigator will describe the vasculature pattern according to a prespecified grid: Normal mucosal vascularity / increased capillary density / presence of capillary loops / presence of dotted vessels / complex vascular networks of tortuous vessels or abrupt ending vessels / dilated longitudinal vessels. In case of discordance between the investigators, images will be reviewed to obtain a consensus.
45810851|NCT04871191|Drug|Rituximab|375 mg/m²/week for four consecutive weeks (Week 0, 1, 2 and 3) Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52.
45948068|NCT00101348|Biological|cetuximab|Given IV
45948069|NCT00101348|Biological|bevacizumab|Given IV
45948070|NCT00101348|Other|laboratory biomarker analysis|Correlative studies
45948071|NCT00135486|Biological|MenC-TT|
45948072|NCT00135486|Biological|Hib-MenC-TT|
45948073|NCT00101387|Other|Lumbar PENS + General Conditioning and Aerobic Exercise|As above
45948074|NCT00101387|Other|Lumbar PENS|As above
45948075|NCT00101387|Other|Control Lumbar PENS|Identical needle placement as with PENS procedure, but only control needles stimulated for 5 minutes.
46076242|NCT02830022|Other|physiological explorations|
45948076|NCT00101387|Other|Control PENS + exercise|as above
45948077|NCT00133107|Drug|efalizumab|
45948078|NCT00101426|Drug|ranirestat, (AS-3201)|
45948079|NCT00133146|Biological|Grass MATA MPL|
45810852|NCT04871191|Drug|Tocilizumab|Subcutaneous injection of 162 mg per week
45948080|NCT00135564|Biological|MenC-TT|
45948081|NCT00135564|Biological|Hib-MenC-TT|
45948082|NCT00133185|Drug|telmisartan 40 mg/hydrochlorothiazide 12.5 mg|
45948083|NCT00133185|Drug|losartan 50 mg/hydrochlorothiazide 12.5 mg|
45810853|NCT04871191|Drug|Abatacept|Subcutaneous injection of 125 mg per week
45948084|NCT00101543|Device|Electrical Stimulation with Intramuscular Electrodes|
45948085|NCT00101543|Procedure|Body Weight Supported Treadmill Training|
45948086|NCT00135603|Drug|amoxicillin/clavulanate potassium|1 gramme, 3 times a day, intra venous initially and then orally for one or two weeks
45948087|NCT00135603|Procedure|appendectomy|ablation of the appendix by laparotomy or laparoscopy
45948088|NCT00101621|Drug|M40403|
45948089|NCT00133224|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
45948090|NCT00133224|Drug|Chemotherapy (docetaxel and prednisone)|Chemotherapy (docetaxel and prednisone)
45948091|NCT00101738|Drug|Myfortic|
45948092|NCT04728464|Procedure|Periodontally Accelerated Osteogenic Orthodontics (PAOO)|Fixed appliance will be placed for every patient, then surgical procedure will be applied after reflecting a full-thickness labial flap.
45948093|NCT00135642|Biological|Subcutaneous Alutard SQ grass pollen (Phleum pratense)|
45948094|NCT00135642|Procedure|Venepuncture: 20 ml blood sample taken on 2 separate visits|
45948095|NCT00133263|Behavioral|Primary Bereavement Care|a standardized bereavement intervention in Primary Care
45948096|NCT00133263|Behavioral|the current bereavement care in primary care|the non-standardized bereavement care that usually provided family physicians in primary care
45948097|NCT00101855|Procedure|An evidence based tailored web site|
45948098|NCT00135681|Drug|nedocromil budesonide|
45948099|NCT00135720|Drug|Enbrel (Etanercept)|
45948100|NCT00101894|Drug|FOLFOX-4|"The FOLFOX-4 regimen will be administered every 2 weeks as follows:~Day 1: oxaliplatin (ELOXATIN™) 85 mg/m2 IV infusion and leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion given over 120 ± 10 minutes at the same time in separate bags using a Y-line, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed by 5-FU 600 mg/m2 IV infusion as a 22-hour ± 2 hours continuous infusion Day 2: leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion over 120 ± 10 minutes, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed"
46076243|NCT02776410|Behavioral|Consumer reactions to tailored messages sent via app|The intervention will take 1 month. Participants from the Intervention group will receive tailored messages every 2-3 days with a push notification. Additionally, interaction with the participants via the use of app is foreseen.
45658554|NCT05751473|Behavioral|EAP Treatment as Usual (TAU)|"Treatment will be given by telehealth or in person, depending on the participant preference and current EAP practices (4-6 weeks). This will be the standard of care practice at each EAP site. Usually, this includes up to six sessions of solution focused therapy, and referrals to an established network of community providers who specialize in PTSD treatment. All PTSD care received during the study will be collected and monitored as TAU. The type of TAU used will reflect the current practice in EAPs and will not be constrained in the study design. EAP staff will monitor and record all EAP care received, including tracking no shows and cancellations. Study team members will document care received outside of the EAP (including psychiatric medications) by self-report.~Participants will complete surveys and complete homework during and following the study."
45658555|NCT05747950|Other|Vibration|Vibration is used as an alternative to physical exercise in various areas to increase muscle performance and flexibility, improve balance and proprioception, reduce spasticity and increase bone density.
45658556|NCT05747950|Other|Modified Constraint-İnduced Movement Therapy|Compulsory use therapy is a form of treatment in which the movements of the healthy side are prevented and the use of the weak side is encouraged in the stroke patient.
45658557|NCT05747950|Other|Conventional Therapy|Conventional exercises
45658558|NCT05747105|Behavioral|Sleep Extension|The 16-week protocol includes 11 total individual visits that integrate applicable elements of Cognitive Behavioral Therapy for Insomnia (CBT-I) and health behavior change theory. The first 6 weeks include weekly sessions (~45 minutes each) focused on psychoeducation about sleep, goal-setting and self-monitoring, stimulus control, addressing cognitive and somatic arousal, sleep hygiene, and challenging negative thoughts about sleep. Sleep restriction will also be used in specific cases where sleep efficiency is low (<85%). The remaining 10 weeks include briefer biweekly visits (5 visits, ~15-20 minutes each) to reinforce health behavior change strategies through topics such as problem-solving barriers, utilizing social support, identifying setbacks and creating an action plan, and relapse prevention. Self-reported sleep diary data and subjective sleepiness will be collected at each visit.
45810854|NCT04871113|Biological|GSK3810109A|GSK3810109A will be available as sterile aqueous solution.
45810855|NCT05024851|Other|Questionnaires|Evaluation of the Psychogenic and Neurogenic Components using questionnaires
45948101|NCT00101894|Drug|AMG 706|AMG 706 is a small organic molecule that has been shown in preclinical pharmacology studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively inhibiting all known VEGF receptors, PDGF receptor, and Kit.
45948102|NCT00101894|Biological|Panitumumab (Part 1a only)|Panitumumab will be administered by IV infusion at a dose of 6 mg/kg on day 1 of each 2-week cycle.
45948103|NCT00101894|Drug|FOLFIRI|Irinotecan will be administered over 90 minutes ± 15 minutes on day 1 of each 2-week cycle. Leucovorin will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing, immediately followed by a 5-FU bolus and a 5-FU 46-hour ± 2-hour continuous intravenous infusion.
45948104|NCT00133302|Drug|Standard CHOP|
46076244|NCT02835482|Procedure|Femtolaser surgery|
46076245|NCT02835482|Procedure|Phacoemulsification|
46076246|NCT02774304|Device|arterial line|In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
46076247|NCT02774304|Device|Cheetah®|In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
46076248|NCT02835560|Drug|Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy|Ilaprazole -based quadruple therapy for 14 days: Ilaprazole 5mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid
45948105|NCT00133302|Drug|Bi-CHOP (dose intensified CHOP)|
45948106|NCT00102050|Drug|NM-702 (phosphodiesterase inhibitor)|
45948107|NCT00135759|Drug|Naltrexone|low dose naltrexone in addition to daily methadone taper
45948108|NCT00135759|Drug|Placebo comparator|1 capsule/day for 6 days
45948109|NCT00135759|Drug|naltrexone|0.125 mg capsule/day for 6 days
45948110|NCT00135759|Drug|naltrexone|0.250 mg capsule/day for 6 days
45948111|NCT00133341|Drug|Goldnatriomthiosulphate, MDBGN, parthenolide|
45948112|NCT00102089|Biological|VRC-HIVADV014-00-VP booster|
45948113|NCT00102089|Drug|VRC-HIVADV014-00-VP|
45948114|NCT00135837|Drug|Verteporfin for injection|
45948115|NCT00102128|Drug|Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation)|
45658559|NCT05745376|Behavioral|Farm to ECE programming|Students and parents at this center will receive program elements described in arm descriptions.
45658560|NCT05740618|Drug|Mannitol Inhalant Product|A sugar alcohol indicated as an add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis.
45948116|NCT00133380|Drug|PPAR alpha|
45948117|NCT00133380|Drug|atorvastatin|
45948118|NCT00133380|Drug|placebo|
45658561|NCT05738746|Dietary Supplement|Pasteurized Akkermansia muciniphila|PAM supplementation; packaging will be given to the subjects every one month during follow-up visits, with the instructions to take one dose every morning on an empty stomach
45658562|NCT05738746|Dietary Supplement|Placebo|PBO administration; packaging will be given to the subjects every one month during follow-up visits, with the instructions to take one dose every morning on an empty stomach
45658563|NCT05736718|Behavioral|Champion Announcement Approach Training|AAT is a one-hour communication workshop that trains clinical staff how to recommend HPV vaccine for children ages 9-12. In the champion arm, vaccine champions will deliver the training using slides and a standardized script. They will also conduct outreach and sustainability planning.
45658564|NCT05736718|Behavioral|Traditional Announcement Approach Training|AAT is a one-hour communication workshop that trains clinical staff how to recommend HPV vaccine for children ages 9-12. In the traditional arm, outside experts will deliver the training using the same slides and script.
45658565|NCT05735600|Behavioral|AyuDa Virtual: Aprender y Utilizar Decisiones Apreciables (Spanish) - Learning and Utilizing Significant Choices (English)|"The intervention was developed based on the Social Learning Theory, considering both environmental and cognitive factors influencing parent behavior and modeling for children. Researchers have modified a five-module virtual intervention from the Cooking Healthy and Delicious Manual (Cocinando Delicioso y Saludable Manual, Spanish version), which incorporates behavior change strategies for improving diet quality, screen time, physical activity/sedentary behavior, socioeconomic status/food security, and sleep duration."
45676399|NCT03536585|Device|Baseline|Subject is acting as their own control. The baseline general appearance photograph will act as the comparator.
45810856|NCT04505371|Behavioral|Wellness Intervention for Smokers with HIV|"WISH is delivered remotely by mobile phone (voice and text message). WISH addresses both smoking and a number of other personally relevant health behaviors (such as treatment engagement, medication adherence, stress and mood management, social support, alcohol use, etc.), making it relevant and engaging to all, not just those ready to stop smoking. For those not yet ready to quit, WISH is designed to build and strengthen motivation and self-confidence for quitting, while smokers also work on other personal health goals.~Once ready to quit smoking, participants receive evidence-based cognitive-behavioral counseling and encouragement to access nicotine replacement therapy (NRT) or other appropriate pharmacotherapy through usual care VA procedures. Medications will not be prescribed or dispensed by the study."
45948119|NCT00102167|Drug|gaboxadol|Duration of Treatment -1 day
45948120|NCT00135876|Drug|dalteparin|
45948121|NCT00102206|Drug|Abacavir sulfate|
45948122|NCT00102206|Drug|Emtricitabine|
45948123|NCT00102206|Drug|Lamivudine|
45948124|NCT00102206|Drug|Lopinavir/ritonavir|
45948125|NCT00102206|Drug|Saquinavir|
45948126|NCT00102206|Drug|Tenofovir disoproxil fumarate|
45948127|NCT00102206|Drug|Zidovudine|
45948128|NCT00403884|Procedure|Selective RPE laser treatment|interventional SRT laser treatment
45948129|NCT00102284|Drug|levodopa|
45948130|NCT00102284|Drug|rivastigmine|
45948131|NCT00102284|Drug|pergolid|
45948132|NCT00102284|Drug|modafinil|
45948133|NCT00403923|Dietary Supplement|Lactose in water|
45948134|NCT00135525|Drug|Paroxetine|"Fixed Dose (20 mg/day): The fixed dose of 20 mg/day was selected, because it is the recommended dose for the treatment of GAD in the US and other countries.~Flexible Dose (20 - 40 mg/day): Overseas, the maximum dose in the treatment of GAD is 50 mg/day. However, 40 mg/day was selected as the maximum dose for this flexible dose session, because overseas clinical studies have indicated that paroxetine is sufficiently effective at doses of 20 - 40 mg/day and this is the dose range approved for depression/depressive episodes in Japan."
45948135|NCT00135525|Drug|Placebo|Placebo
45948136|NCT00102362|Behavioral|Behavior Therapy|
46002240|NCT04293562|Drug|Therapeutic Hydrocortisone|Given IT
46076249|NCT02835560|Drug|Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy|Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid
46076250|NCT02774070|Radiation|Plain X-ray|antero-posterior, lateral neutral, flexion, extension and open-mouth views
46076251|NCT02774070|Radiation|Magnetic resonance imaging|Magnetic resonance imaging sagittal T1W,T2W and STIR, axial T1W and coronal T2W and post contrast sagittal and axial sequences
46076252|NCT02833532|Device|Volus/Powerfill|Maximum: 22ml
46076253|NCT02767752|Dietary Supplement|T-ChOS|
46076254|NCT02767752|Drug|Gemcitabine|
46076255|NCT02767752|Dietary Supplement|Placebo|
46076256|NCT02767752|Drug|Capecitabine|
46076257|NCT00885625|Biological|7-valent pneumococcal conjugated vaccine|7-valent pneumococcal conjugated vaccine is given twice with 4 weeks apart
46076258|NCT02835404|Drug|Nedaplatin|Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle
45948137|NCT02964468|Radiation|3DCRT treatment (sequential boost)|"Radiotherapy:~3DCRT treatment (sequential boost) 25 fractions fraction 1,8Gy by administering a total dose of 45 Gy on tumor and lymph nodes and lymph node chains more pelvic margin determined according to protocol.~3 fractions fraction 1,8Gy by sequentially administering an additional dose of tumor and lymph nodes 5,4Gy on more margin.~Chemotherapy:~According to routine clinical practice of the participating centers."
45810857|NCT05016505|Behavioral|Reduction (relocation and reduction of personal smoking) and cessation|Individual-level. Peer educator to provide reduction/cessation and/or relocation support.
45810858|NCT05016505|Behavioral|Resident Endorsement|Building-level. Peer educator to conduct building-level sessions.
45810859|NCT05015023|Behavioral|Behavioral intervention|A cluster-randomized controlled trial will be conducted.
45658566|NCT05735600|Behavioral|AyuDa Written: Aprender y Utilizar Decisiones Apreciables (Spanish) - Learning and Utilizing Significant Choices (English)|"The intervention was developed based on the Social Learning Theory, considering both environmental and cognitive factors influencing parent behavior and modeling for children. Researchers have modified a five-module virtual intervention from the Cooking Healthy and Delicious Manual (Cocinando Delicioso y Saludable Manual, Spanish version), which incorporates behavior change strategies for improving diet quality, screen time, physical activity/sedentary behavior, socioeconomic status/food security, and sleep duration."
45658567|NCT05733832|Other|Transitional Liver Clinic (TLC)|Participants in this intervention receive additional attention from their Hepatology providers in terms of an additional call/telemedicine visit and more specific/additional attention from their Hepatology APP (advanced practice provider) based on individual patient needs
45658568|NCT05728944|Drug|Aceclidine+Brimonidine combination ophthalmic solution|Aceclidine + Brimonidine combination ophthalmic solution
45658569|NCT05728944|Drug|Aceclidine|Aceclidine ophthalmic solution
45658570|NCT05728944|Drug|Vehicle|Proprietary vehicle ophthalmic solution
45948138|NCT02964468|Radiation|Dose Escalation Intensity Modulated Radiotherapy treatment|"Radiotherapy:~IMRT treatment (concomitant boost technique) 25 fractions fraction 2,15Gy by administering a total dose of tumor and lymph nodes 53,75Gy on more margin. Simultaneously we will proceed to the irradiation of pelvic lymph node chains according to protocol, a division of 1,8Gy per session until a total dose of 45 Gy.~Chemotherapy:~According to routine clinical practice of the participating centers."
45948139|NCT00102401|Behavioral|Internet-based Dyspnea Self-Management Program|
46076259|NCT02835404|Radiation|Pelvic External Radiotherapy|patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X rays (SSD)
46076260|NCT02835404|Radiation|252-Cf Neutron Intracavitary Brachytherapy|total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations
46076261|NCT02767908|Other|Intervention|Participants will receive a tailored support package which will include; Nicotine replacement products, behavioural support, including telephone support, Carbon dioxide measurements, home air quality measurements, signposting to support groups, and self-help materials.For participants who decline a home visit, the above support options will be offered as far as possible through telephone contact and delivered to the extent accepted by the participant. Those who report cessation at 4 weeks and/or three months will be requested to agree to a home visit for CO validation.
46076262|NCT00952289|Drug|Ruxolitinib|Ruxolitinib phosphate tablets 5 mg administered as oral doses.
45658571|NCT05715463|Other|Resource sheets|Arm 1 is the control arm which will receive the standard of care resource sheets. Patients in this arm will receive cultivated resource sheets for any SDoH-related needs that they screen positive for or request additional information on.
45810860|NCT00360139|Device|Sculptra Injection|
45810861|NCT02977429|Other|standardized fluid therapy|The patients with ScvO2 <70% will receive the standardized fluid therapy for 6 hours.
45810862|NCT02977429|Other|conventional fluid therapy|The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.
46076263|NCT00952289|Drug|Placebo|Matching placebo tablets were administered as oral doses in the same manner as active drug.
46076264|NCT00885781|Drug|lipid emulsion for TPN|1-2 g lipid emulsion /kgBW-day, for consecutive 5 days
46076265|NCT02830100|Other|Healthy volunteers|Magnetic Resonance Imaging during intern speech, listening, talking, thinking.
45810863|NCT02976805|Drug|4L PegLyte + 15 mg bisacodyl|Randomized
45810864|NCT02976805|Drug|6L PegLyte + 15 mg bisacodyl|Randomized
45810865|NCT04844281|Device|Precision1® Daily Disposable Toric Contact Lens|Soft, toric contact lens used to correct distance vision and astigmatism.
45810866|NCT04835623|Drug|Cyclosporine 0.09% Ophthalmic Solution|one drop each eye twice daily
45810867|NCT04500613|Procedure|Bilateral Erector Spinae Plane Block with bupivacaine and dexamethasone|Bupivacaine is administered typically to reduce sensation in an area. It acts as a nerve block for surgical procedures. Dexamethasone is a corticosteroid that reduces inflammation.
45810868|NCT04500613|Other|No bilateral Erector Spinae Plane Block (no bupivacaine and no dexamethasone)|Patients who are randomized to this group will not receive a bilateral erector spinae plane block
45810869|NCT04833907|Drug|rAAV-Olig001-ASPA|Intracerebroventricular administration of a single dose
45810870|NCT04833907|Drug|Levetiracetam|Keppra daily dose (20-50 mg/kg/day divided twice daily administered orally or per G-tube) in the post-operative period and continued for 3 months per standard of care to prevent seizure activity.
45948140|NCT00102401|Behavioral|Face-to-face Dyspnea Self-Management Program|
45948141|NCT00403962|Drug|vestipitant/paroxetine|
45948142|NCT00102479|Drug|Aripiprazole|
45948143|NCT00135954|Drug|Cyclophosphamide and steroids|comparison of difference in time of start of therapy
45948144|NCT00102557|Drug|Hydroxychloroquine|
45948145|NCT05449977|Diagnostic Test|Diagnose|First, the participants will be asked to fill out a structured questionnaire containing their sociodemographic characteristics. Then, the 2-minute walk test, the International physical activity questionnaire, the SF-36 short form, and the World health organization quality of life questionnaire will be applied respectively.
46076266|NCT02830100|Device|MRI|
46076267|NCT04725240|Drug|Setmelanotide|Investigational product: Setmelanotide for Subcutaneous (SC) injection.
46076268|NCT00882427|Other|enhanced model predictive control algorithm (eMPC)|eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
46076269|NCT02829866|Device|AMIStem-H|
45658572|NCT05715463|Other|Community Resource Specialist|The CRS will help guide patients to the necessary community-based resources to help address their specific SDoH needs that impact their health and their ability to access sustained, high quality medical care. This may include forms to arrange for subsidized transportation to and from medical appointments or applications for Section 8 housing. The community resource specialist will reach out to patients in Arm 2 a minimum of 2 times per month, with more interactions guided by patients needs. All outreach attempts and contacts will be documented in EPIC. Actions taken by the CRS will be shared with members of the patient's healthcare team as appropriate (with EPIC notes routed to the rheumatologist and primary care provider, and if indicated and relevant, a social worker, nutritionist, prior CRS, nurse or mental health provider if previously involved in the patient's care).
45948146|NCT00102635|Drug|Fenretinide (4-HPR)|Oral 100 mg capsules in two divided doses at least 8 hours apart for 7 days each cycle.
45948147|NCT00102635|Drug|SCH66336|Oral capsules with 50 mg, 75 mg, or 100 mg formulation in two divided doses at least 8 hours apart for 21 days each cycle.
45948148|NCT00133419|Drug|Vitamin + Zinc + micronutrient mixture|
45658573|NCT05715463|Other|Nurse Navigator|The nurse navigator will both work with the CRS to connect the patient with community-based resources, independently connect the patient with relevant resources, and also help coordinate the patient's medical care and mental health needs. The nurse patient navigator will conduct her own needs assessment (the nurse navigator high risk assessment questionnaire at the time of the first conversation with the patient, originally developed as part of the MGB integrated care management program) and her actions will be guided by their responses. She will reach out to patients a minimum of 2 times per month with an increase in communication around patient appointments as reminders, and more frequent communication on a case-by-case basis depending on active illnesses, frequency of outpatient appointments, and needs of the patient. All outreach attempts and contact will be documented in Epic and similar to the CRS, be shared via EPIC with the care team as indicated.
45948149|NCT00133419|Drug|Vitamin A|
45948150|NCT00133419|Drug|Vitamin A + Zinc|
45948151|NCT00102674|Drug|cangrelor|
45948152|NCT00135993|Drug|Rotigotine|
45948153|NCT00102713|Drug|Divalproex Sodium (Depakote Sprinkle Capsules)|
45948154|NCT00136032|Drug|Somatropin|Stratified based on age and estrogen status from 3 to 6 mcg/kg/day
45810871|NCT04833907|Drug|Prednisone|Post-operatively, a 3-month steroid taper is planned to prevent or reduce possible delayed immunological responses. This tapering regimen will consist of 0.5 mg/kg/day prednisone during weeks 1-4; followed by 0.3 mg/kg/day prednisone during weeks 5-8; and 0.1mg prednisone during weeks 9-12, then off. If there is evidence of new inflammation on MRI at 3-months on T2 FLAIR, the steroid taper will be extended for an additional 3 months or we will transition to steroid-sparing immunosuppression.
45810872|NCT04498585|Other|VR Stimulation|Participants in the intervention group will be provided with 30 minutes of relaxing, 360-degree virtual reality stimulation and corresponding sounds, three times a day (morning, midday, evening) everyday during their stay in the ICU, up to a maximum of 14 days.
45810873|NCT02976259|Drug|Dolutegravir|All patients included must have treated by dolutegravir. They will have some exams (plasma samples, sperm samples)
45948155|NCT00136032|Drug|Placebo|Dosage based on age and estrogen status ranging from 3 to 6 mcg/kg/day
45948156|NCT00133458|Drug|Albendazole|
45948157|NCT00102752|Drug|Glufosfamide|
45948158|NCT00102752|Drug|Gemcitabine|
45948159|NCT00136071|Device|Transobturator tape-ARIS|
46076270|NCT02767674|Drug|Rituximab|375 mg/m2 IVD day0
46076271|NCT02767674|Drug|Gemcitabine|Gemcitabine 1 g/m2 IVD day 1
46076272|NCT02767674|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IVD day1
46076273|NCT02767674|Drug|Cyclophosphamide|Cyclophosphamide 400 mg/m2 IVD d1
46076274|NCT02767674|Drug|Epirubicin Injectable Product|Epirubicin 35 mg/m2 IVD d1
46076275|NCT02767674|Drug|Vindesine|Vindesine 2 mg IVP d1
46076276|NCT02767674|Drug|Prednisone|Prednisone 40mg/m2 PO d1-5
46076277|NCT02829788|Other|Non interventional|Peroperative data collection
46076278|NCT02542891|Other|Blended CBT|
46076279|NCT02542891|Other|Treatment as Usual (TAU)|
46076280|NCT02833688|Drug|dexmedetomidine|dexmedetomidine 2mg is diluted in 0.9% sodium chloride with the concentration of 4 ug ml-1 is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
45810874|NCT00360217|Drug|docosahexanoic acid (DHA)|
45810875|NCT00360295|Drug|Azithromycin SR|
45810876|NCT04492345|Other|Isokinetic reeducation|Conventional rehabilitation session and isokinetic during 7 weeks
45810877|NCT04492345|Other|Conventional reeducation|Conventional rehabilitation session during 7 weeks
45948160|NCT00136071|Device|TVT-O|
45948161|NCT00102791|Drug|ICA-17043|
45948162|NCT00133536|Biological|Influenza A/H5N1 Vaccine|Monovalent inactivated subvirion influenza H5N1 vaccine (derived from A/Vietnam/1203/04). Packaged in single-dose vials of 90 mcg/mL (0.7 mL/vial). Dosage 45 mcg/0.5 mL administered intramuscularly.
45948163|NCT00133536|Drug|Placebo|Normal saline administered intramuscularly.
45948164|NCT00102830|Drug|AMG 386|
45948165|NCT00136110|Drug|Sodium Valproate|
45948166|NCT00136188|Drug|Folic Acid|oral administration of folic acid 5mg /d for 4 weeks
45948167|NCT00136227|Behavioral|small media intervention using video, flip chart, and pamphlets and a tailored interactive multimedia intervention|
45948168|NCT00102869|Drug|levodopa|100mg levodopa per day over 10 days/ treatment phase
45948169|NCT04726839|Other|Standard of care for stroke management and evaluation of functionnal outcome at 3 months|Additional tubes at inclusion (maximum 13 mL) Collection of the mRS data during a routine visit if planned at 3 months +/-15 days or, if not during a specific research phone call at 3 months
45948170|NCT00102908|Drug|Zoledronate|Zoledronate infusion
45948171|NCT00102908|Drug|Zoledronate placebo|Zoledronate placebo infusion
45948172|NCT00133614|Procedure|Prone Positioning|
45948173|NCT00401024|Drug|imatinib mesylate|
46076281|NCT02833688|Drug|0.9% sodium chloride|0.9% sodium chloride is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
46076282|NCT02767440|Behavioral|Families on Track Intervention|Parents will receive the standard of care activities at the Healthy Lifestyles clinic at Duke University. They will also receive a modified version of the previously conducted Track intervention, a digital health weight loss intervention for adults in community health centers . The intervention will utilize the Interactive Obesity Treatment Approach (iOTA). iOTA uses a computer algorithm to assign 3 personalized behavioral goals known to create an energy deficit to produce weight loss (e.g., sugary drinks, fast food consumption walk 10,000 steps/day, etc). Participants will track these goals via interactive voice response (IVR) and text messaging technologies each week. They will receive immediate feedback based on self-monitoring data and skills training videos to learn how to make the behavioral changes necessary for weight loss. Intervention participants will also receive an analog bathroom scale and a pedometer to self-monitor daily weights and steps.
46076283|NCT00885859|Device|TENStemeco Schwa Medico [Transcutaneous Electrical Nerve Stimulation (TENS)]|Patients are instructed how to use the TENS device during the two weeks at home.Self-adhesive reusable electrodes are used to deliver the electrical stimulation. The frequency is 100 Hz, pulse duration 250 μ sec. Stimulus intensity is strong but not unpleasant. The TENS electrodes are attached proximally and distally around the maximum pain point/area. Patients use TENS 4 times daily (30 minutes each time).
46076284|NCT00947531|Drug|Cerebrolysin|
46076285|NCT00947531|Drug|0.9% Saline Solution|
46076286|NCT04721262|Device|Hyperfine Portable MRI|The Hyperfine device is a newly developed MRI unit that has multiple potential advantages over standard CT or MRI including portability, easier upkeep, open design, and ease of use. Unlike CT, the Hyperfine device does not use moving parts or X-rays to generate images. Unlike routine MRI, the Hyperfine device uses two permanent magnets with open space between and around them, rather than a super-cooled superconducting magnetic tube. In contrast to CT and routine MRI, the device can be wheeled from place to place and moved into position with the patient remaining on a gurney or hospital bed. Relative to routine MRI, the device uses a very low magnetic field strength of 64 mT compared to 1.5 T or 3 T, making it safer for patients or environments with medical devices having metallic components.
45658574|NCT05710341|Dietary Supplement|Water with added nitrate|Water with added nitrate
46076287|NCT00885937|Drug|Dexpanthenol (Sinecort, BAY81-2996)|1 squeeze of Sinecort cream sufficient to cover the area of the application chamber, (=50 mikro liter)
46076288|NCT00885937|Drug|Positive control, Na-laurylsulfat-solution|50 mikro liter of 0.5 % Sodium-laurylsulfate-solution
46076289|NCT00885937|Device|Untreated skin under application chamber|Application of treatment chamber as in arm 1 and arm 2 on untreated skin
46076290|NCT02771964|Other|Quality of life survey|"All enrolled patients complete a survey of baseline health during their visit to the preoperative assessment clinic and then complete a follow-up survey approximately 30 days after surgery.~The intervention for this study is to compare self-reported quality of life (How would you rate your quality of life now? (better/same/worse)) to the quantitative change in their VR-12 quality of life scores between the baseline survey and 30-day follow-up survey."
46076291|NCT02854397|Other|blood sample|
45658575|NCT05710341|Dietary Supplement|Water without added nitrate|Water without added nitrate
45658576|NCT05705505|Drug|Narazaciclib|Clear, hard, capsules, each containing 40 mg or 60 mg of narazaciclib as narazaciclib monolactate, which is a yellow/orange color
45658577|NCT05705505|Drug|Letrozole 2.5mg|Tablet
45658578|NCT05700552|Behavioral|skin to skin contact|For skin-to-skin contact (TTT), the newborn is placed naked on the mother's bare chest in the prone (prone) position, the newborn's abdomen and chest are in contact with the mother's skin, and the newborn's head is turned to the side so that the airway remains open.
45658579|NCT05698290|Other|HELP Pain Training Program|A training program to teach school providers nonpharmacologic (e.g., cognitive behavioral and mindfulness meditation) strategies to use with students with pain symptoms.
45658580|NCT05694884|Drug|Placebo|Placebo Comparator
45658581|NCT05694884|Drug|ASLAN004|ASLAN004
45658582|NCT05691387|Behavioral|Thera PEP|"Sitting comfortably, patients receiving Thera PEP will be told to place dental cotton swabs between their cheek and gum, and then under their tongue, to absorb saliva and prevent contamination of the collected sputum by the patient's own saliva. The diameter of the opening will be modified to achieve a ventilation rate of 1:4. The patient will be taught to take in a larger than normal breath but not fill the lungs to capacity in order to maintain a tight seal during exhalation. After completing ten PEP breaths, the patient will have the mouthpiece removed and be instructed to do two or three puff coughs. When secretions need to be brought up, a good cough will do the trick. During the duration of the treatment, which will last around thirty minutes, the patient will be asked to complete three cycles of ten breaths each."
45948174|NCT00401024|Other|pharmacological study|
45948175|NCT00401024|Procedure|conventional surgery|
45948176|NCT00136266|Drug|Ferrous sulphate drops with vitamins A, D, and C|
45948177|NCT00136266|Drug|Ferrous fumarate sprinkles with vitamins and minerals|
45948178|NCT00401063|Device|Acupuncture|Acupuncture treatment twice a day for eight weeks
45948179|NCT00136305|Behavioral|Pictorial asthma action plan|
45948180|NCT00136305|Behavioral|Written asthma action plan|
45948181|NCT00102947|Drug|daptomycin (up to 14 days)|
45948182|NCT00136344|Drug|Cefuroxime|
45948183|NCT00136344|Drug|Levofloxacin|
45948184|NCT00102986|Drug|Lopinavir/ritonavir|
45948185|NCT00133653|Behavioral|Observational|
45948186|NCT00103025|Drug|Sodium Nitrite|
45948187|NCT00103025|Drug|Sodium Nitrite Injection|
45948188|NCT00136383|Drug|paroxetine versus duloxetine|
45948189|NCT00103103|Drug|bortezomib|
45948190|NCT00103103|Drug|fluorouracil|
45948191|NCT00103103|Drug|leucovorin calcium|
45948192|NCT00133692|Drug|Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ)|
45948193|NCT00133692|Drug|Atenolol/HCTZ/Trandolapril|
45676400|NCT03531450|Behavioral|Cognitive Behavioral Therapy|Treatment sessions will use active, structured techniques to alter distorted thoughts, with a focus on acquiring and practicing cognitive and emotional modulatory skills. In particular, cognitive restructuring is used to help patients recognize the relationships between thoughts, feelings, and behaviors. Patients learn to identify, evaluate, and challenge negative thoughts. Patients will also learn behavioral strategies to decrease avoidance behavior and increase toleration of physical sensations.
45676401|NCT03511352|Behavioral|Frequent sit-to-stands|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
45810878|NCT04984681|Behavioral|Mindfulness|The traditional mindfulness intervention consists of the following: (1) orientation; (2) a series of eight weekly session of 2.5 to 3 hours; (3) a silent retreat during the between weeks 4 and 6; (4) daily home assignments including formal and informal mindfulness practices; and (5) didactic presentations on stress and the consequences of stress.
45810879|NCT04984681|Other|Usual Care|The control condition will continue receiving usual care or standard of care.
46076292|NCT02772042|Other|Intervention Group|
46076293|NCT02772042|Other|Control Group|
45948194|NCT00103220|Drug|SJG-136|Given IV
45948195|NCT00136422|Biological|autologous tumor cells|
45948196|NCT05443256|Device|Transcranial Magnetic Stimulation|Figure 8 coil stimulation
45948197|NCT00133731|Drug|Otamixaban (XRP0673)|
45948198|NCT00133731|Drug|Unfractionated Heparin|
45948199|NCT00133731|Procedure|Percutaneous Coronary Intervention|
45948200|NCT00103298|Drug|FOLFOX regimen|
45948201|NCT00103298|Drug|fluorouracil|
45810880|NCT02977351|Procedure|Non-surgical periodontal treatment|
45810881|NCT04485013|Drug|TTX-080|Variable dose (Q3W)
45810882|NCT04485013|Drug|TTX-080|Specified dose (Q3W)
45810883|NCT04485013|Drug|pembrolizumab|Specified dose (Q3W)
45948202|NCT00103298|Drug|isolated perfusion|
45948203|NCT00103298|Drug|leucovorin calcium|
46076294|NCT00612313|Drug|Fluoxetine|Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.
45810884|NCT04485013|Drug|cetuximab|Specified dose on specified days
45810885|NCT04482751|Drug|Corifollitropin alfa|AMH will be measured during ovarian stimulation with corifollitropin alfa
45810886|NCT04474015|Device|transcranial electric stimulation|NeuroConn® DC Plus stimulator: the NeuroConn® stimulator can be programmed with specific frequencies of stimulation ranging from 0.5 to 500 Hz. This device is therefore appropriate for the present study to stimulate only at 0.75 or 3.0 Hz. Also, the NeuroConn only allows low current intensities to be chosen. The maximum current intensity that can be delivered with this stimulator is 5 milliamps.
45810887|NCT04975243|Device|GentleMax Pro Plus 755nm and 1064nm laser system|The GentleMax Pro Plus is a 755nm and 1064nm laser system. The GentleMax Pro PlusTM is indicated for stable long-term or permanent hair reduction using varying spot sizes and fluences.
45810888|NCT04814095|Behavioral|QOL|QOL assessments using the ESAS, CPC, EQ5D every 4-8 weeks +/- 2 weeks
45810889|NCT04814095|Diagnostic Test|CT imaging|CT radiographic imaging every 12 weeks +/- 2 weeks
45948204|NCT00103298|Drug|melphalan|
45948205|NCT00103298|Drug|oxaliplatin|
45948206|NCT00136461|Drug|All-trans retinoic acid|
45948207|NCT00136461|Drug|Bryostatin 1|
45948208|NCT00103337|Drug|cilengitide|Given IV
45948209|NCT00103337|Other|laboratory biomarker analysis|Correlative studies
45948210|NCT00133770|Drug|pantoprazole|The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis
45948211|NCT00103415|Behavioral|Endurance training|
45948212|NCT00103415|Behavioral|Weight-lifting training|
45948213|NCT00103454|Drug|GW685698X|
45948214|NCT00133848|Drug|SB-275833 ointment, 1%|
46076295|NCT00612313|Behavioral|Relapse prevention cognitive behavioral therapy (CBT)|After the first 6 weeks of treatment with fluoxetine, some participants will be assigned to additionally receive relapse prevention CBT for the remaining 24 weeks of treatment. These participants will attend 10 to 12 CBT sessions, during which they will learn specific skills to reduce and prevent the occurrence of residual depressive symptoms.
46076296|NCT00890552|Drug|Lenalidomide|"Lenalidomide is a a derivative of thalidomide.~Orally-administered lenalidomide 10 mg will be taken daily on days 1 to 21 of 28-day cycle."
46076297|NCT00890552|Drug|Melphalan|"Melphalan is a phenylalanine derivative of mechlorethamine.~Orally-administered melphalan 0.18 mg/kg will be taken on days 1 to 4 of a 28-day cycle"
46076298|NCT00890552|Drug|Dexamethasone|"Dexamethasone is an anti-inflammatory and immunosuppressant steroid medication.~Orally-administered dexamethasone 40 mg orally once weekly of a 28-day cycle"
45948215|NCT00103493|Behavioral|Motivational interviewing|
45948216|NCT00103493|Behavioral|Targeted DVD-based educational program|
45948217|NCT00133887|Drug|rapamycin|3 to 5 mg/day
45948218|NCT00133887|Drug|ciclosporine|Blood residual level < or = to 125 ng/ml
46076299|NCT02772198|Biological|CD19 CAR T cells|Autologous T cells activated and transduced with a chimeric antigen receptor targeting CD19
45948219|NCT00133887|Drug|tacrolimus|Blood residual level < or = to 8 ng/ml
45948220|NCT00103532|Behavioral|Healthy Choices - Motivational Enhancement Intervention|Participants who are randomized to the intervention group will participate in four sessions (over approximately 3 months) of Healthy Choices; a motivational enhancement intervention specifically designed to target multiple risk behaviors in HIV+ youth. Participants will receive individualized referrals at the fourth session.
45948221|NCT00103532|Behavioral|Standard care|Participants will receive standard care plus referrals at three months post-baseline
45948222|NCT00136539|Drug|Herceptin|Given intravenously once weekly for 12 weeks prior to surgery.
45948223|NCT00136539|Drug|Taxol|Given intravenously every 3 weeks (weeks 1, 4, 7, and 10) before surgery.
45948224|NCT00136539|Drug|Adriamycin|Given every three weeks for 12 weeks after surgery.
45948225|NCT00136539|Drug|Cytoxan|Given every three weeks for 12 weeks after surgery.
45948226|NCT00103571|Drug|Olanzapine|
45658583|NCT05691387|Behavioral|ACBT and PLB|On the day of the ACBT, the patient will be taught to place dental cotton swabs between the cheek and gum, as well as beneath the tongue, to absorb saliva and prevent contamination of the collected sputum by saliva. Throughout the treatment, the patient will be urged to maintain a comfortable sitting position. The patient will then be instructed to perform PLB at a normal tidal volume (for approximately 6 breaths), followed by 3-4 deep inspirations with relaxed exhalation (thoracic expansion exercise), and finally, another period of breathing control, i.e. PLB, followed by FET, i.e. a deep breath in and a huff cough, followed by a medium breath in and a huff cough again. Approximately thirty minutes will pass over the course of this session.
45658584|NCT05684198|Device|subcutaneous NPWT|Following fascia closure, NPWT system will be inserted into subcutaneous tissue, continuous negative pressure of 120 mmHg will be applied.
45948227|NCT00103571|Drug|Aripiprazole|
45948228|NCT00136578|Drug|SB-715992|SB-715992 will be available either as 5 milliliter (mL) vial containing 4 milligram (mg) of SB-715992 or 4 mL vial containing 5 mg of SB-715992 at a concentration of 1 mg/mL OR a 10 mL vial that contains 10 mg of SB-715992 in a 10 mL solution at a concentration of 1 mg/mL.
45948229|NCT00136578|Drug|carboplatin|Carboplatin will be available as sterile, lyophilized white powder available in single-dose vials containing 50 mg, 150 mg, and 450 mg of carboplatin for administration by IV infusion. Each vial will be reconstituted with either Sterile Water for Injection, USP, 5% Dextrose in Water (D 5 W), or 0.9% Sodium Chloride Injection, USP.
45948230|NCT00103649|Drug|xaliproden (SR57746A)|
45948231|NCT00136617|Drug|chlordiazepoxide|
45658585|NCT05684146|Device|Emboliner Embolic Protection|Emboliner Embolic Protection Device will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
45658586|NCT05684146|Device|Sentinel Cerebral Protection|The Sentinel Cerebral Protection System will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
45658587|NCT05682846|Drug|Sodium glycerophosphate pentahydrate solution|Glycophos is a 20 ml vial of Sodium glycerophosphate pentahydrate containing 1 mmol glycerophosphate and 2 mmol sodium per ml
45658588|NCT05682222|Drug|EDP1815|EDP1815 is an essentially non-viable, non-replicating pharmaceutical preparation of a single strain of Prevotella histicola, a naturally occurring human commensal microbe.
45810890|NCT04813783|Other|Mucositis care training to be given in line with MASCC / ISOO 2019|Mucositis care training to be given in line with MASCC / ISOO 2019
45810891|NCT04467619|Device|Functional Proprioceptive Stimulation|Functional Proprioceptive Stimulations (FPS) are applied on the musculo-tendinous junction. FPS mechanically stimulate the muscle spindles, mimicking the sensory signals - Ia fibers of functional movements. This neurosensory trick activates related sensory-motor areas allowing patients to feel natural movements. Because sensory & motor systems are interdependent, the central nervous system then reacts by initiating corresponding movements.
45810892|NCT02976727|Drug|Topical Vitamin D (Calcipotriol) application|Calcipotriol ointment 50 mcg/g (Daivonex, Leo Pharma, Denmark) was applied twice for daily on treatment area for 15 consecutive days.
45658589|NCT05682222|Drug|EDP2939|EDP2939 is a pharmaceutical preparation of extracellular vesicles.
45810893|NCT02976727|Drug|Placebo cream application|placebo cream (indistinguishable from calcipotriol cream by visual and physical appearance and sense of smell) was applied twice for daily on treatment area for 15 consecutive days.
45948232|NCT00103727|Drug|Talnetant|talnetant
46076300|NCT02856503|Drug|Vitamin D3|Weekly oral dose of Vitamin D3 per protocol.
45810894|NCT02976727|Drug|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
45810895|NCT02976727|Device|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
45810896|NCT02976727|Drug|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
45948233|NCT00103727|Other|placebo|Placebo Comparator
45948234|NCT00103727|Other|risperidone|Active Comparator
45948235|NCT00404001|Drug|MD-0727|
45948236|NCT00103766|Drug|Alteplase|
45948237|NCT00133926|Procedure|Treatment of periodontal disease|
45948238|NCT00103805|Drug|levodopa|
45948239|NCT00404040|Drug|Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)|
45948240|NCT00404040|Drug|Lactulose|
46076301|NCT02829632|Behavioral|Group Sessions|Participants will receive a 3-session behavioral lifestyle program for a healthful lifestyle and weight loss.
46076302|NCT02829632|Behavioral|Feedback|Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings.
46076303|NCT02829632|Behavioral|Self-monitoring|Participants will receive an one-time how to self-monitor using the smartphone session.
45658590|NCT05682222|Drug|Placebo oral capsule|Placebo.
45658591|NCT05677295|Drug|duloxetine|Duloxetine 30 mg per day
45658592|NCT05677295|Drug|Imipramine|Imipramine 25 mg per day
45676402|NCT03511352|Behavioral|Stand More|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 8-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
46002241|NCT04284969|Behavioral|PROADAPT program|"A pre-intervention activity by telephone follow-ups every week for 12 weeks and then every month.~Pre-operative physical training including strength, endurance and breathing exercises.~A nutrition activity.~An activity to educate patients (on nutrition, exercise).~The implementation of standardised intervention procedures, established in agreement with the surgeons' representatives.~A pharmaceutical drug conciliation activity: optimization of the patient's different treatments with pharmaceutical expertise.~A transition activity from the hospital to the home, and a telephone follow-up up to 12 weeks after the surgery."
45948241|NCT00133965|Behavioral|Dignity Psychotherapy|At the beginning and at the end of the study, you will be asked to fill out a series of questionnaires.will also receive three visits by a mental health professional over a period of five to seven days. You will be asked to fill out some brief questionnaires during this session which ask about feelings about your illness, symptoms, emotional reactions, and support you have available. The second meeting will be scheduled as soon as you are able to do so, within no more than 24 to 48 hours from your initial session with the Research Staff.The third meeting you will also be asked to fill out several questionnaires,including a specific questionnaire regarding your thoughts about the Dignity Psychotherapy Intervention. Total time commitment for this study should be approximately 120-150 minutes.
45948242|NCT00133965|Behavioral|Supportive Psychotherapy|you will receive the standard care you normally would receive, but will also receive three visits by a mental health professional over a period of five to seven days. The initial visit will take approximately 45 minutes. You will be asked to fill out brief questionnaires (described above) during this session.A second contact will be scheduled as soon as you are able to do so, within no more than 24 to 48 hours from your initial session with the research staff. During this second session, you will have the opportunity to discuss with a supportive research therapist issues or topics relevant to your experience of coping with cancer.The third and final contact,you will be asked you to fill out questionnaires similar to those you filled out at the beginning of the study. Total time commitment for this study should be approximately 120-150 minutes.
45810897|NCT02976727|Other|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by ImageJ program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
45948243|NCT00133965|Behavioral|Standard Palliative Care|"If you are in the Standard Palliative Care group you will receive the standard care that is usually provided here at Memorial Hospital. This can include services such as consultations by physicians, nurses and other healthcare professionals. In addition, referrals to community resources and services can also be made. The study period will be between five and seven days. At the beginning and at the end of the study, you will be asked to fill out a series of questionnaires as described above. Total time commitment for this study should be approximately 60-90 minutes."
45948244|NCT00103922|Drug|cilomilast|
45948245|NCT00103961|Behavioral|Questionnaire|A behavioral questionnaire will occur at Week 8
45948246|NCT00134160|Drug|Olmesartan medoxomil|Olmesartan medoxomil 40mg/Day
45658593|NCT05666102|Behavioral|Transgender men's perspectives on HIV risk and HIV prevention interventions|Investigators will enroll 30 TMSM in 5 focus groups where they will examine the unique contexts in which risk for HIV acquisition occurs for TMSM, and explore participant preferences for HIV prevention services. Focus group questions will focus on five areas: 1) Gathering information related to partner selection and sorting among TMSM; 2) assessing TMSM's perceptions of HIV risk in their lived experiences; 3) exploring the various types of sexual behavior TMSM are engaging in; 4) understanding the various HIV prevention strategies currently being deployed by TMSM; and 5) examine the preferences TMSM have for receiving information related to sexual health and HIV prevention information.
46076304|NCT02542579|Genetic|16S rRNA pyrosequencing analysis|Next generation sequencing analysis will be done for 16S rRNA V1,2 hypervariable regions at Biocore (Seoul, Korea).
46076305|NCT02772276|Drug|MB-102-- single dose|4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.
46076306|NCT02772276|Drug|MB-102-- two doses|4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.
46076307|NCT02772276|Drug|Iohexol|5 mL of a 647 mg/mL solution administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds
46076308|NCT02772276|Device|QuantumLeap|Optical Renal Function Monitor (ORFM)
46076309|NCT02772276|Device|Radiance|Optical Renal Function Monitor (ORFM)
46076310|NCT02772276|Device|Brilliance|Optical Renal Function Monitor (ORFM)
46076311|NCT02834936|Drug|pyrotinib|
45658594|NCT05665387|Drug|0.1% STN1013600 ophthalmic solution|0.1% STN1013600 ophthalmic solution 1 drop BID for 2 months
45658595|NCT05665387|Drug|0.3% STN1013600 ophthalmic solution|0.3% STN1013600 ophthalmic solution 1 drop BID for 2 months
46076312|NCT04280237|Other|Blood samples|Blood samples
46076313|NCT02833376|Other|alcohol antisepsis|
45810898|NCT02976727|Device|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
46076314|NCT02833376|Other|chlorhexidine antisepsis|
45658596|NCT05665387|Drug|Placebo|Placebo ophthalmic solution 1 drop BID for 2 months
45810899|NCT04949737|Biological|Helicobacter Pylori detection|"Biopsies will be sent to the referral anatomopathology laboratory. The search for Helicobacter pylori will be performed by immunohistochemistry. An additional blood sample for serological testing will be taken during the initial workup.~Additional data will be collected through a questionnaire."
45658597|NCT05664750|Drug|TNM002|"Dosage Form: Injection, solution~Route of administration: IM gluteal injection"
45810900|NCT04945447|Other|Systematic pharmacist intervention|Already described in the arm group intervention group for patient level
45810901|NCT02977117|Other|Dialysate magnesium (1.0 mmol/L)|Dialysate magnesium will be increased from 0.5 mmol/L to 1.0 mmol/L for 4 weeks after which subjects will return to dialysate magnesium 0.5 mmol/L for 2 weeks observation.
45810902|NCT02977117|Other|Dialysate magnesium (0.5 mmol/L)|Dialysate magnesium will be maintained at 0.5 mmol/L for the duration of the trial.
45810903|NCT04793269|Other|No intervention|no intervention
45810904|NCT00361465|Other|EMG and Kinematics recording|"The experimental protocol envisages the recording of the movement and the bilateral recording of activity EMG during three types of tasks:~discrete driving tasks: movements of inflection and extension of the wrist car-generated, or produced in answer to an imperative stimulus try driving repetitive: sequence of inflection-extension of the wrist unilateral, bilateral in phase and bilateral in opposition of phase.~try driving complexes: movement of inflection and extension of the wrist with concurrent realization of a driving task controlatérale different, or of a cognitive task.~For the Parkinsonian patients, these various tests will be carried out twice: without antiparkinsonian treatment (off) and under treatment (one)."
45810905|NCT00360841|Procedure|Auricular acupuncture|Subjects will be randomized to one of these arms. The subjects in arm A and B will receive auricular acupuncture. Before subjects receive chemotherapy within one day, they will be treated by auricular acupuncture, sham acupuncture, or control group.
45810906|NCT00360841|Procedure|Sham auricular acupuncture|
45948247|NCT00134160|Drug|Calcium channel blockers (amlodipine, azelnidipine)|Olmesartan medoxomil 20mg/Day with Calcium channel blockers (amlodipine or azelnidipine)
45658598|NCT05664750|Drug|Human tetanus immunoglobulin (HTIG)|"Dosage Form: Injection, solution~Route of administration: IM gluteal injection"
45810907|NCT00360451|Behavioral|Adolescent only Penn Resiliency Program (Adolescent PRP)|In adolescent PRP, students learn both cognitive skills (recognizing the link between beliefs and emotions, challenging negative beliefs with evidence, making accurate attributions for events, and accurately assessing the ramifications of negative events) and behavioral problem-solving skills (decision making, assertiveness and negotiation, social skills, and relaxation).
45810908|NCT00360451|Behavioral|Parent Penn Resiliency Program (Parent PRP)|Parent PRP teaches parents to model and reinforce the skills taught in the adolescent program.
45810909|NCT04343131|Behavioral|Dietary intervention|Crossover dietary manipulation using three different types of diet for 7 days each
45810910|NCT02977273|Other|Thin/100% Portion|Thin textured rice meal (ground rice grains) served in a regular portion size (100 %: 700g)
45658599|NCT05648344|Behavioral|WW|"WW assigns foods to a point value calculated through a proprietary algorithm that accounts for the food's caloric value, saturated and unsaturated fat, sugar, fiber, and protein. Members are encouraged to track their food and beverage intake, with the goal of staying within their personal points targets assigned based in an individual's sex, age height, weight, goals, and activity. The program also has Zero Point Foods (list of healthy foods with no point value) and can be eaten freely. In addition to the personal points, participants will be asked to attend WW coach-led virtual workshops conducted over Zoom, engage with peer- support, and WW-trained behavior change experts via 24/7 chat."
45658600|NCT05648344|Behavioral|Control|Usual care with information from myplate.gov
45658601|NCT05644262|Drug|T2:C100|"The active study intervention, T2:C100, is an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in a digestible oil. T2:C100 is a full spectrum oral solution with five non-reactive ingredients: delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), a pharmaceutical grade medium chain triglyceride (MCT) oil, and two flavoring agents (lemon and peppermint).~During the double-blind treatment period, participants will receive 1mL study drug (T2:C100) twice daily for Baseline - Day 7 (approximately 1 week), and then will increase to 2mL study drug twice for the remainder of the double-blind treatment period (Day 7 - Week 12 (approximately 11 weeks)).~Participants who enter the Open Label Extension will receive 1mL study drug (T2:C100) twice daily for Week 12 - Week 13 (approximately 1 week), and will then increase to 2mL study drug twice daily for the remainder of the Open Label Extension (Week 13 - Week 26 (approximately 23 weeks))."
45676403|NCT03491176|Procedure|Biospecimen Collection|Undergo collection of blood samples
45948248|NCT00136656|Drug|antibiotic|cephalosporine by oral route : cefixime
45948249|NCT00136656|Drug|antibiotics|cephalosporine : ceftriaxone by intra venous route and cefixime by oral route
45948250|NCT00134199|Drug|CP-945,598|
45948251|NCT00134199|Drug|sibutramine|
45948252|NCT04729088|Drug|Isosorbide mononitrate|Intra-anal application performed by the study physician of 2 g of the study drug
45948253|NCT00136734|Drug|Methylphenidate|
45948254|NCT00136734|Other|placebo|placebo
45948255|NCT00104078|Drug|MYO-029|
45948256|NCT00136773|Drug|amlodipine/benazepril|
45948257|NCT00134277|Procedure|Infragenual dilatation|Infragenual dilatation
45948258|NCT00134277|Procedure|Infragenual dilatation with stenting|Infragenual dilatation with stenting
45810911|NCT02977273|Other|Thin/150% Portion|Thin textured rice meal (ground rice grains) served in a larger portion size (150 %: 1050g)
45810912|NCT02977273|Other|Thick/100% Portion|Thick textured rice meal (whole rice grains) served in a regular portion size (100 %: 700g)
46076315|NCT02542813|Drug|IM oxytocin 10 IU|IM oxytocin 10 IU is a colourless and clear sterile solution in a 1 mL ampoule containing 10 IU of oxytocin, which is administered intramuscularly
46076316|NCT02542813|Drug|IH oxytocin 50 mcg|IH oxytocin 50 mcg is a powder blend for inhalation in a hard capsule containing 50 mcg of oxytocin, which is administered by oral inhalation.
46076317|NCT02542813|Drug|IH oxytocin 200 mcg|IH oxytocin 200 mcg is a powder blend for inhalation in a hard capsule containing 200 mcg of oxytocin, which is administered by oral inhalation.
46076318|NCT02542813|Drug|IH oxytocin 400 mcg|IH oxytocin 400 mcg is a powder blend for inhalation in a hard capsule containing 400 mcg of oxytocin, which is administered by oral inhalation.
45810913|NCT02977273|Other|Thick/150% Portion|Thick textured rice meal (whole rice grains) served in a larger portion size (150 %: 1050g)
45810914|NCT04904575|Procedure|Erector spinae plane block|"Procedure : After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : Levobupivacaïne 2,5mg/ml."
45810915|NCT04904575|Procedure|Erector spinae plane block|"Procedure : After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : NaCL 0,9%."
45948259|NCT00134277|Procedure|Infragenual dilatation with cutting balloon|Infragenual dilatation with cutting balloon
45948260|NCT00134277|Procedure|Laser therapy|Laser therapy
45948261|NCT00104117|Drug|XL999|XL999 was to be given biweekly to an initial cohort of subjects at 0.20 mg/kg and to successive cohorts at doses that escalated by cohort according to a design for safely determining an MTD. After determination of the MTD, one or more additional cohorts were to receive XL999 weekly at the MTD or a lower dose, as determined by the CRC on the basis of interim safety and PK data. By a protocol amendment after initiation of the study, subjects were to be enrolled in an additional cohort to receive a weekly XL999 dose of 200 mg.
46076319|NCT02542813|Drug|IH oxytocin 600 mcg|IH oxytocin 600 mcg is a powder blend for inhalation in a hard capsule containing 600 mcg of oxytocin, which is administered by oral inhalation.
46076320|NCT02542813|Drug|Placebo|Placebo is a powder blend for inhalation in a hard capsule containing five inactive components, which is administered by oral inhalation.
45810916|NCT04898647|Other|fundoscopic picture|A central review of numerised fundoscopic picture will be performed.
46076321|NCT02772120|Drug|Vaginal progesterone gel (Crinone® 8%)|Crinone® 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) is administered once 5 days prior to embryo transfer, then twice per day until the pregnancy test is negative or until the 10th week of pregnancy.
46076322|NCT02772120|Drug|Intramuscular Progesterone|Progesterone-25 mg intramuscularly once 5 days prior to embryo transfer, then 50 mg once per day until the pregnancy test is negative or until the 10th week of pregnancy.
46076323|NCT02856347|Other|18F-DOPA|Injection of 18F-DOPA and PET / CT-scan assessment
45948262|NCT00136851|Drug|amlodipine besylate/benazepril hydrochloride|
45948263|NCT00104156|Procedure|External Qigong therapy|
45948264|NCT00136890|Procedure|PET Imaging|Patients randomized to PET staging will undergo FDG-PET or PET-CT as well as some form of cranial imaging (CT or MRI)
45948265|NCT00134316|Behavioral|psychoeducational intervention|three 75 minute long individual psychoeducational sessions
46076324|NCT04248608|Procedure|serratus plane block|ultrasound guided block
45810917|NCT04898647|Biological|blood sample|"Two 10 ml blood vials will be sampled in addition to standard blood sampling for getting 6 to 7 200 μL aliquot.~One 5 ml EDTA vial for GP1bα expression study, only if this sample can be sent to hemostasis laboratory within the 4 hours after sampling"
45810918|NCT04898647|Procedure|bone marrow sample|Five to 10 ml bone marrow sample will be collected in addition to standard bone marrow sampling for getting molecular characteristics of WM
45948266|NCT00104273|Drug|Rasagiline|
45948267|NCT00136929|Drug|Thrombolytic therapy|
45948268|NCT00136929|Procedure|Percutaneous coronary intervention (PCI)|
45948269|NCT00104390|Biological|Grass MATA MPL|
46076325|NCT04248608|Procedure|erector spinae block|ultrasound guided block
45948270|NCT00134355|Drug|PTK787|
45948271|NCT00104429|Drug|GW873140|
45948272|NCT00104429|Drug|Combivir|
45948273|NCT00136968|Drug|Voriconazole|
46076326|NCT04248608|Drug|Morphine Sulfate|intravenous morphine sulfate 0.1 mg/kg
46076327|NCT04783194|Drug|Dexamethasone+ Bupivacaine|Dexamethasone plus bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery.
45948274|NCT00104468|Drug|Troxatyl™ (Cytotoxic Chemotherapeutic)|
45948275|NCT00137007|Drug|Azithromycin|
45948276|NCT00137007|Drug|Ampicillin/sulbactam|
45948277|NCT00104507|Drug|APD356|
45948278|NCT00137085|Drug|ketamine|
45948279|NCT00104546|Procedure|Acupuncture point injection of vitamin K|
45948280|NCT00134394|Drug|Etanercept plus tacrolimus|
45658602|NCT05644262|Drug|Placebo|"Matching placebo in a digestible oil. The placebo contains only three non-reactive ingredients: medium chain triglyceride (MCT) oil and two flavoring agents (lemon and peppermint).~During the double-blind treatment period, participants will receive 1mL placebo twice daily for Baseline - Day 7 (approximately 1 week), and then will increase to 2mL placebo twice for the remainder of the double-blind treatment period (Day 7 - Week 12 (approximately 11 weeks))."
45810919|NCT00421759|Device|Vibrating Insoles|Participants wear vibrating sandals for 3 trials of 6 minutes, during a single lab visit. The sandal vibration is on during either first or second 3 minutes of the 6 minute trial, as they walk. Also, participants wear the sandals for 2 hours while sitting, with vibrations on for one visit and off for the other.
45810920|NCT04895839|Behavioral|Patient Empowerment Program|"The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips."
45810921|NCT00360607|Drug|Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.|
45658603|NCT05639894|Biological|RSV mRNA LNP CL-0059 Low dose|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
45658604|NCT05639894|Biological|RSV mRNA LNP CL-0137 Low dose|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
45658605|NCT05639894|Biological|RSV mRNA LNP CL-0059 Medium Dose|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
46076328|NCT04783194|Drug|Bupivacaine|Bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery.
45810922|NCT00360607|Drug|Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited|
46076329|NCT02854241|Procedure|Biannual ultrasonography|Biannual ultrasonography for HCC surveillance, performed by board-certified radiologists.
45658606|NCT05639894|Biological|RSV mRNA LNP CL-0137 Medium Dose|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
45810923|NCT00360607|Drug|Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.|
45810924|NCT00360607|Drug|Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.|
45810925|NCT00360763|Drug|candesartan cilexetil|
45658607|NCT05639894|Biological|RSV mRNA LNP CL-0059 High Dose|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
45810926|NCT02977039|Other|NDPR diet|nutrient rich plant based diert
45810927|NCT02977039|Other|USDA healthy eating diet|DASH diet
45810928|NCT04886245|Other|Video sequences|"videos will be made of each participant, during the realization of 5 movements that are the simple closure of the eyelids, the forced closure of the eyelids, the labial protrusion on the sound [o], the labial protrusion on the sound [pu] and the wide smile uncovering the teeth.~Then, a video sequence will be realized thanks to the dedicated software Tobii Pro Lab®."
45810929|NCT04061083|Device|Smart Cuff Manager|Participant will be attached to the smart cuff manager within 4 hours after intubation. They will remain attached during the first 48 hours of intubation in the intensive care unit
45810930|NCT04061083|Device|Manometer|Participant will be attached to the manometer within 4 hours after intubation. They will assess 3 times per day during the first 48 hours of intubation in the intensive care unit
45810931|NCT02976025|Other|Longitudinal Remote Consultation|Longitudinal Remote Consultation utilizes video conferencing to efficiently link providers to consultants who provide timely feedback and training in collaborative care. LRC will be provided in addition to standard collaborative care training and support.
45810932|NCT02976025|Other|Collaborative Care|Standard collaborative care implementation training and support.
45810933|NCT04034329|Procedure|ASVAL|Ambulatory Selective Varices Ablation under Local Anesthesia
45810934|NCT04034329|Procedure|EVLA|Endovenous Laser Ablation
45810935|NCT04032301|Drug|Ketamine|Six infusions of intravenous 0.5 mg/kg ketamine hydrochloride solution over 3 weeks.
46076330|NCT02854241|Procedure|Annual noncontrast liver MRI|"Annual noncontrast liver MRI consisted of T2WI, precontrast T1WI, dual-echo image, DWI (single shot, multishot) and T2 map.~DWI using multishot and T2 map are not included for initial MR reading."
46076331|NCT02854241|Procedure|Contrast enhanced liver CT|In patients without report of HCC during surveillance period, contrast CT is performed 6 months after the last MR scan.
46076332|NCT02835248|Other|Fall Detection|All participants will wear a device configured to detect falls.
45658608|NCT05639894|Biological|RSV mRNA LNP CL-0137 High RSV mRNA LNP CL-0137 High Dose Dose|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
45658609|NCT05639894|Other|Placebo|Pharmaceutical Form: Liquid Route of Administration: Intramuscular injection
45658610|NCT05626751|Drug|HZN-825|HZN-825 will be administered BID for 52 weeks
45658611|NCT05626322|Drug|Maplirpacept|Intravenous infusion
45658612|NCT05626322|Drug|Tafasitamab|Intravenous infusion
45658613|NCT05626322|Drug|Lenalidomide|Oral (by mouth)
45658614|NCT05623514|Combination Product|Trans-vaginal ultrasound|Pre-operative trans-vaginal ultrasound in order to evaluate sliding sign between the uterus and the rectum
45658615|NCT05623020|Drug|Elranatamab|Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
45658616|NCT05623020|Drug|Daratumumab|Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
45658617|NCT05623020|Drug|Lenalidomide|Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
45658618|NCT05623020|Drug|Dexamethasone|Randomized
45658619|NCT05622110|Procedure|Adhesive glue closure|Incision closure with adhesive glue
45658620|NCT05622110|Procedure|Subcuticular closure|Incision closure with 3-0 vicryl subcuticular sutures
45948281|NCT00104624|Drug|docetaxel|
45948282|NCT00104624|Procedure|quality-of-life assessment|
45948283|NCT00137124|Drug|L-Arginine|oral administration of L-arginine for 4 weeks
45948284|NCT00104663|Drug|Quinacrine|
45810936|NCT04032301|Other|Normal Saline|Six infusions of intravenous normal saline solution over 3 weeks.
45948285|NCT00134433|Genetic|intramyocardial VEGF angiogenesis (at a dose of 2 mg)|
45948286|NCT00134433|Drug|oral L-arginine supplementation (at a dose of 6 g/day)|
45658621|NCT05622097|Other|0.9% Saline warmed to 37 degrees Celsius|0.9% Saline warmed to 37 degrees Celsius
45810937|NCT04010305|Drug|Sublingual film containing BXCL501 (Dexmedetomidine)|Sublingual film containing BXCL501 (Dexmedetomidine) for the treatment of agitation associated with Schizophrenia
45948287|NCT00137163|Device|Dermafill Dressing|
45948288|NCT00104702|Procedure|adjuvant therapy|
45948289|NCT00104702|Procedure|conventional surgery|
45948290|NCT00104702|Radiation|radiation therapy|
45658622|NCT05622097|Other|0.9% Saline warmed to 24 degrees Celsius|0.9% Saline warmed to 24 degrees Celsius
46076333|NCT04225104|Behavioral|Yogic breathing intervention|Yogic breathing will be completed while following a video provided by the investigative team. Breathing practices consist of slow, deep, relaxation breathing and are led by a certified yoga instructor.
46076334|NCT02835170|Biological|Autologous immunoglobulin|Autologous immunoglobulin (total IgG) aseptically purified from the autologous plasma will be administered to the patients by intramuscular injection, once a week for 7 weeks (total 8 injections).
45658623|NCT05621616|Drug|mirabegron|"Participants will receive mirabegron prolonged-release microgranula-based oral suspension once daily. The initial dose of mirabegron will be based on the participant's weight.~The initial low dose will be up-titrated to a higher dose at weeks 2, 4 or 8 unless the participant is determined to be effectively treated with the low dose, based on urodynamics and the participants'e-diary."
45658624|NCT05608681|Drug|EP-104IAR|Long-acting fluticasone propionate for injection
45810938|NCT04010305|Drug|Placebo film|Placebo film for BXCL501
45810939|NCT02975401|Procedure|rTAPP technique|robot-assisted rTAPP technique
45810940|NCT00361933|Drug|Valganciclovir|valganciclovir open label, two 450mg tablets orally, twice a day
45810941|NCT03987763|Drug|IDP-122 Lotion|Topical
45810942|NCT02975635|Other|Questionnaire|Patients are given a questionnaire with items related to personality and behaviour.
45810943|NCT04786093|Radiation|Stereotactic radiation therapy|Radiation therapy will be delivered using standard SAbR treatment schedule or every 4 weeks on the PULSAR schedule to achieve optimal local control of metastatic cancer and augment the effects of durvalumab.
45658625|NCT05608304|Behavioral|Formal mindfulness induction|The formal mindfulness induction will consist of a 10-minute audio recording of a sitting meditation, guiding the participant to consciously and repeatedly bring their attention to their breath and inner experience with nonjudgmental acceptance.
45658626|NCT05608304|Behavioral|Informal mindfulness induction|The informal mindfulness induction will consist of on-screen instructions guiding participants through the completion of four routine tasks (washing hands, drinking water, laying down, listening to music) with mindful awareness and acceptance over the course of 10 minutes.
45676404|NCT03491176|Procedure|Magnetic Resonance Imaging|Undergo MRI scan
45676405|NCT03491176|Other|Quality-of-Life Assessment|Ancillary studies
45810944|NCT04786093|Drug|Durvalumab|Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
45948291|NCT00134472|Procedure|Therapeutic mild hypothermia|Keeping 32 - 34 degree celsius of core temperature at least for 72 hours.
45948292|NCT00104741|Drug|flutamide|
45948293|NCT00104741|Drug|triptorelin|
45948294|NCT00104741|Radiation|radiation therapy|
45948295|NCT00134511|Drug|Torcetrapib/atorvastatin|
45948296|NCT00104780|Biological|EP-2101|
45948297|NCT00104780|Biological|incomplete Freund's adjuvant|
45948298|NCT00134550|Drug|Atorvastatin (10 mg or 80 mg)|
45676406|NCT03491176|Other|Questionnaire Administration|Ancillary studies
45948299|NCT00104819|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
45948300|NCT00104819|Biological|sargramostim|
45948301|NCT00137202|Drug|Ondansetron (Zofran)|
45948302|NCT00137202|Drug|Diphenhydramine (Benadryl)|
45948303|NCT00401141|Procedure|Blood samples|
45948304|NCT04728503|Behavioral|5-Minute Mindful Movement Video|5 minute video includes a brief verbal introduction to mindfulness and then guides participants through a mindful movement exercise to facilitate grounding in the present moment and activation of the parasympathetic nervous system.
45948305|NCT04728503|Behavioral|Written Educative Materials|1 page written educative material about the benefits of mindfulness to serve as a control.
45948306|NCT00134589|Behavioral|Academic Detailing (Medical Practices)+Decision Aids (Patients)|
45948307|NCT00104897|Drug|tanespimycin|
45948308|NCT00137319|Device|Impedance threshold device|
45948309|NCT00104936|Procedure|adjuvant therapy|
45948310|NCT00104936|Radiation|radiation therapy|
45948311|NCT00104936|Radiation|stereotactic radiosurgery|
45948312|NCT00104975|Biological|alemtuzumab|
45948313|NCT00104975|Biological|therapeutic allogeneic lymphocytes|
45948314|NCT00104975|Drug|fludarabine phosphate|
45948315|NCT00104975|Drug|melphalan|
45948316|NCT00104975|Drug|tacrolimus|
45948317|NCT00104975|Drug|thiotepa|
45948318|NCT00104975|Procedure|peripheral blood stem cell transplantation|
45948319|NCT00134628|Procedure|Hyperbaric Oxygen Therapy|HBO at 2.0 ATA
45948320|NCT00134628|Procedure|Sham treatment|Normal air under pressure (1.1 ATA)
46002242|NCT04255875|Biological|Placebo|Participants will receive matching placebo
46002243|NCT04255875|Biological|PF-07209326|Participants will receive SC or IV single ascending doses
45810945|NCT04785859|Diagnostic Test|BPD prediction|"The following lung ultrasounds will be performed on the patients included in the study: first 24 hours of life, 3rd day of life (DOL) and 7th DOL. At one week of life detection of proteins in nasopharyngeal aspirates will be performed. During the first week of life, an echocardiography will be performed in all patients to evaluate the possibility of a patent ductus arteriosus and its hemodynamic significance.~In the first 20 patients who remain intubated at one week of life, tracheal aspirates will be obtained too, to compare protein determination in both aspirates at the same time."
45810946|NCT02976883|Other|[18F]HX4 diagnostic PET/CT scan|Single intravenous injection of [18F]HX4 and PET/CT scan
45810947|NCT02976571|Drug|Bupivacaine|Sub cutaneous and/or Intraperitoneal Marcaine application
45810948|NCT04733989|Other|Biomarker Data Collection|During this study, a sample of your blood will be collected and you will have a PET scan taken of your brain. Blood sample results will be compared to PET scan pictures to understand how well the markers in the blood predict whether there is amyloid in the brain. Blood samples will also be collected that contain your genes. These genetic samples will also be compared to PET scans to help researchers understand how different people react to medicines and to understand the genetic causes of Alzheimer's disease. Some of the samples will be stored for future analysis.
45948321|NCT00105053|Biological|HyperAcute-Prostate Cancer Vaccine|Before enrollment in the Phase I and Phase II- Arm A studies, the patient must be determined to have measurable disease with biopsies on first recurrence or bone metastases. In the Phase II- Arm B study, patients will be men with non-measurable progressive disease as evidenced by elevated PSA only. Cells will be injected intradermally every two weeks for 12 cycles on a prime-boost regimen. Dosage will vary from 30 million to 500 million HAP cells.
45453455|NCT03130790|Drug|mFOLFOX6|concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
45453456|NCT01333202|Other|Fresh lime|fresh lime were used every time the participants began to crave cigarettes and as often as they needed. To correctly use it, fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible.
46076335|NCT02835170|Other|Placebo|"Saline will be administered to the patients by intramuscular injection, once a week for 7weeks (total 8 injections).~(In addition, autologous immunoglobulin is colorless and odorless, injection volume is same between autologous immunoglobulin and saline)"
46076336|NCT02542345|Procedure|magnetic resonance imaging|
46076337|NCT02771730|Biological|Ad4-mgag|A live replication-competent Adenovirus type-4 vector encoding a mosaic HIV Gag antigen, delivered orally by enteric-coated capsules.
46076338|NCT02771730|Biological|Ad4-EnvC150|A live replication-competent Adenovirus type-4 vector encoding an HIV clade C Env protein (gp150 1086.C), delivered orally by enteric-coated capsules.
45453457|NCT03035630|Drug|Avelumab|Avelumab 10mg/kg IV over 60 minutes on D1 and D15 of every 28 day cycle
45453458|NCT03035630|Drug|Sunitinib|Sunitinib 50 mg once daily from D1 to D14 of every 21 day cycle
45658627|NCT05608304|Behavioral|Active control task|Participants assigned to the active control condition will be prompted to download a single-page document containing 100 letters, numbers, and symbols, and a grid of 100 boxes. Following along with a guided audio, participants will be instructed to place all of the characters in the grid in a specific order over the course of 10 minutes. A version of this task has been used in previous studies by our team (Carsley & Heath, 2019; Petrovic et al., 2022) and has been shown not to impact mindfulness levels, and was thus deemed an appropriate neutral attention task for this study.
45810949|NCT04731025|Drug|Gentamicin, Cefazolin and Vancomycin|The antibiotic solution will contain 1000 mg vancomycin, 80 mg gentamicin and 1000 mg cefazolin in a 500 mL isotonic saline solution. The solution will be used to wash the dissected implant pocket and the implant prior to insertion in the implant pocket.
45658628|NCT05595850|Behavioral|Mindfulness|Online non-meditation mindfulness program
45810950|NCT04731025|Other|Placebo|500 mL of sterile isotonic (9%) saline. The solution will be used to wash the dissected implant pocket and the implant prior to insertion in the implant pocket.
45810951|NCT04730635|Drug|Donepezil|Donepezil 5 mg capsules for a total daily dose of up to 10 mg QD, orally, for Days 1-56.
45810952|NCT04730635|Drug|Placebo|Dose matched placebo capsule QD, orally for Days 1-56.
45810953|NCT04726189|Other|Standard exercises|Consists of a a standard exercise program with range of motion exercises from the third week and elastic band exercise from the sixth week.
45948322|NCT00137358|Procedure|Radiation Therapy|
46076339|NCT02771730|Other|Placebo Comparator|Oral sucrose capsules
45658629|NCT05595850|Behavioral|Mindful Learning|Online learning program
45658630|NCT05588141|Drug|Zotiraciclib|Zotiraciclib will be given orally at the DL1, DL-1, or DL 2 once a day on days 1, 4, 8, 11, 15, 18 of every 28-days cycle (18 cycles total).
45658631|NCT05580770|Drug|Mirdametinib|Mirdametinib administered orally
45948323|NCT00137358|Drug|Cisplatin|
45948324|NCT00137358|Drug|Amifostine|
45948325|NCT00105092|Drug|Enzastaurin HCL|
45453459|NCT01333280|Behavioral|Double Trouble in Recovery|DTR is a 12 Step-based fellowship for individuals with co-occurring problems of substance abuse and mental illness
45453460|NCT01333280|Behavioral|Treatment as usual|Receive usual treatment at the programs
45453461|NCT00004124|Drug|bicalutamide|
45453462|NCT00004124|Drug|goserelin|
45453463|NCT00004124|Drug|mitoxantrone hydrochloride|
45453464|NCT00004124|Drug|prednisone|
45453465|NCT01333358|Drug|Alemtuzumab|Alemtuzumab 12mg given intravenously each day for five days and again twelve months later for an additional three days
45948326|NCT00134667|Drug|Photodynamic Therapy (PDT) with Visudyne (verteporfin)|
45948327|NCT00134667|Drug|Macugen (pegaptanib sodium)|
45948328|NCT00134706|Drug|Docetaxel|Given intravenously over 2-3 hours once every three weeks. Participant can continue to receive treatment as long as there is no disease progression or serious side effects.
45948329|NCT00134706|Drug|Carboplatin|Given intravenously over 2-3 hours once every three weeks. Participant can continue to receive treatment as long as there is no disease progression or serious side effects.
45948330|NCT00105170|Drug|hCBE-11|
45948331|NCT00137397|Drug|Tolterodine ER|
45810954|NCT04726189|Other|Standard exercises plus Early progressive exercises|This exercise program consists of standard exercises plus the early progressive program that initiates early (second week) and continues with resistance exercises with progression of the load according to individual participant toleration. Exercises are isometric exercises from the second week and then gradually progression of load in seated heel-rise and resistance band exercises.
45948332|NCT00137397|Drug|Placebo|
45948333|NCT00134745|Drug|estradiol|tablets, 2 mg day 1 through day 22 of the menstrual cycle for 5 years
45810955|NCT04723225|Other|Cat-Cow Yoga|Cat-Cow is one of the essential postures in yoga for its beneficial reasons. It is an alternate shift of posture from flexion of the back (rounded) to the extension of the back (arched). During each set of movement, inhalation and exhalation will be guided
45948334|NCT00105209|Drug|Aspirin|
45948335|NCT00105209|Drug|clopidogrel|
45948336|NCT00137475|Procedure|Intensity-Modulated Radiation Therapy|
45948337|NCT00105248|Behavioral|patient-centered communication training|
45948338|NCT00134823|Other|weight based dosing decision support|weight based dosing decision support
45948339|NCT00105287|Drug|OraVescent fentanyl (OVF)|
45948340|NCT00137514|Drug|chloroquine|
45453466|NCT02697422|Other|Community-based peer health coach intervention|The focus of the peer health coach intervention will be to deliver brief health messages, discuss goal setting, and action planning around health behavior changes shown to decrease CVD risk (for instance, healthy diet, regular to moderate-intensity physical activity, and quitting smoking).
45453467|NCT01334684|Drug|Metformin|Metformin, pills, 850 mg three times a day for three months
45453468|NCT01334762|Drug|Letrozole/IUI|Patients received 5 mg letrozole daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
45658632|NCT05580770|Drug|BGB-3245|BGB-3245 administered orally
45453469|NCT01334762|Drug|CC/IUI|Patients received 100 mg lCC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
45453470|NCT01341548|Drug|Civamide nasal solution 0.01%|20ug/dose, BID for 7 days 0.1 ml to each nostril
45658633|NCT05580640|Procedure|OMT|For this proof-of-concept study we will use a series of case studies. This will allow us to determine if a single session of OMT can improve gait in subjects with prior knee surgery, whether multiple sessions are required to change chronic compensatory musculoskeletal issues, and whether subtle gait anomalies (or improvements), in patients with knee arthroscopy can be detected with the gait analysis system
45658634|NCT05580523|Drug|Aspirin 75mg|75 mg acetylsalicylic acid (C9H8O4, CAS number 50-78-2).
45658635|NCT05580523|Drug|Metformin 1.5g|up to 1.5 g metformin (C4H11N5, CAS number 657-24-9).
45948341|NCT00137514|Drug|amodiaquine|
45948342|NCT00105326|Drug|paliperidone ER|
45948343|NCT00137553|Drug|Sulfadoxine-pyrimethamine (Fansidar)|
45948344|NCT00105365|Device|Shoe insert|Subjects with knee OA underwent gait analysis and knee pain and function assessment at baseline while wearing walking shoes and after four weeks of wearing walking shoes with lateral-wedged insoles.
45948345|NCT00105365|Other|walking shoes|walking shoes
45948346|NCT00137592|Behavioral|small media, group education (multicomponent)|
45948347|NCT00105404|Drug|Triamcinolone Acetonide|
45948348|NCT00105599|Behavioral|End of life care coordination|
45948349|NCT00105599|Procedure|FairCare System|
45658636|NCT05580523|Drug|Aspirin 150 mg|150 mg acetylsalicylic acid (C9H8O4, CAS number 50-78-2).
45658637|NCT05580523|Drug|Placebo|placebo
45948350|NCT01058707|Drug|MLN0128|MLN0128 capsules
45948351|NCT00105638|Behavioral|educational program, by telephone|
45948352|NCT00134979|Drug|Formoterol|
45948353|NCT00137670|Device|Video-based HIV/STD prevention intervention|
45948354|NCT00135018|Drug|celecoxib and chemotherapy|
45948355|NCT00105716|Behavioral|Telephone behavioral education|
45948356|NCT00105716|Behavioral|Computer behavioral education|
45948357|NCT00137709|Drug|Sodium valproate|Week 1 & 2 - 200mg twice daily Week 3 onwards - 400mg twice daily
45948358|NCT00137709|Drug|Lamotrigine|Week 1 - 25mg mane Week 2 - 25mg twice daily Week 3 - 25mg mane, 50mg nocte Week 4 onwards - 50mg twice daily
45948359|NCT00105755|Device|personal dermal thermometer (DT)|
45948360|NCT00105755|Device|Device|
45948361|NCT00137748|Drug|CMV-Ig|Drug: CMV-Ig
45948362|NCT00105794|Procedure|Psychiatric Advance Directives intervention|
45948363|NCT01054144|Drug|Lenalidomide|"Starting Dose: 25 mg by mouth (PO) days 1-21 of a 28 days cycle;~Dose Level -1: 15 mg PO days 1-21 of a 28 days cycle;~Dose Level -2: 10 mg PO days 1-21 of a 28 days cycle;~Dose Level -3: 5 mg PO days 1-21 of a 28 days cycle;~Dose Level -4: Discontinue"
45948364|NCT01054144|Drug|Prednisone|"Starting Dose: 100 mg PO days 1-5 every 28 days;~Dose level -1: 50 mg PO days 1-5 of a 28 day cycle;~Dose level -2: 25 mg PO days 1-5 of a 28 day cycle;~Dose level -3: Discontinue"
45948365|NCT01054144|Drug|Dexamethasone|"Starting Dose: 40 mg daily on days 1 - 4 every 28 days;~Dose level -1: 20 mg daily on days 1 - 4 every 28 days;~Dose level -1a: 40 mg daily on days 1, 2, and 3 followed by 20 mg on day 4 followed by 12 mg on day 5 followed by 8 mg on day 6;~Dose level -2: 10 mg daily on days 1 - 4 every 28 days;~Dose level -3: Discontinue"
45948366|NCT00105833|Behavioral|Collaborative Care - Depression Decision Support (DDS)|Multifaceted collaborative intervention for depression based in primary care
45948367|NCT03277495|Behavioral|Brief behavioral counseling|Staff will engage in behavioral counseling to identify strategies for reducing combustible cigarette use. All participants in the trial receive this intervention
45948368|NCT03277495|Other|Nicotine present in the SREC device and refills|Nicotine is present in the liquid in the SREC device and all refills. Two-thirds of the sample will receive nicotine in their SREC; one-third will not (placebo)
45948369|NCT00137787|Drug|ciprofloxacin|
45948370|NCT00137787|Drug|cefepime|
45810956|NCT00360919|Behavioral|cheese ingestion|"On study day 1, approximately half of the participants will consume a breakfast of fruits and vegetables, whereas the other half of participants will consume a meal consisting of 9 oz. of cheese.~Blood samples will be collected from participants immediately prior to consumption of the meals, and then again at regular intervals for up to 8 hours following the meals.~At least 3 days later, participants will return for study Day 2. The participants will receive the second meal. Blood samples will then be collected immediately prior to consumption of the test meal and for up to 8 hours after the meal."
45948371|NCT00434395|Drug|MOA-728|
45948372|NCT04702048|Drug|Aflibercept Injection|Patients randomized to Arm A will receive 2 mg IVT aflibercept injections every 4 weeks (Q4W) to Week 20, followed by 2-mg aflibercept injections Q8W to Week 52.
45948373|NCT04702048|Drug|Sham injection|Patients randomized to Arm B will receive sham intravitreal injections every 4 weeks (Q4W) to Week 20, followed by sham intravitreal injections Q8W to Week 52. Sham means eye will be numbed and a syringe with no needle will be touched to the eye.
45948374|NCT00105872|Behavioral|Cognitive-Behavioral Therapy|
45453471|NCT01334840|Dietary Supplement|Bicarbonated mineral water|"Volunteers fasted overnight consumed:~0.5 L of the bicarbonated mineral water without meal or, 0.5 L of the bicarbonated mineral water with meal"
45658638|NCT05572632|Behavioral|COPD Wellness|COPD Wellness consists of 10 weekly sessions led by the COPD Wellness Coach. The intervention was designed to be portable, rely on little equipment, and require limited space (~300sqft). The curriculum was iteratively developed with patient input and builds behavioral capability and self-efficacy through 30 minutes blocks of disease education and self-management skill building, exercise training, and social support.
45810957|NCT04703569|Procedure|Dressing with monolayer high compression elastic bandage|The nurse will be apply the therapy high compression elastic bandage once a week, during 26 weeks
45810958|NCT04703569|Procedure|Dressing with Unna boot|The nurse will be apply the therapy Unna Boot once a week, during 26 weeks.
45810959|NCT04686799|Drug|Doxycycline Hyclate 20 MG|Subjects will receive doxycycline 20 mg BID
45810960|NCT04680481|Device|Transcranial alternating current stimulation|Traveling wave transcranial alternating current stimulation will be applied at 4 Hz and 23 Hz over frontal and parietal brain areas in a randomized counterbalanced order.
45810961|NCT04676035|Drug|Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680|"Experimental: Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680~Midazolam, Warfarin, Omeprazole and VitaminK1 QD on Day 1 and Day 22, SHR3680 240 mg once daily (QD) from Study Day 6 - 27"
45810962|NCT03926299|Device|FotonaSmooth SP® Spectro laser device|dual laser treatment with thermal Nd:YAG and ablative Er:YAG (Fotona medical device), 4 laser sessions 4-8 weeks apart.
45948375|NCT00434629|Drug|Bexxar|"Day 0: Tositumomab, IV (in the vein) followed by test dose of 131I-Tositumomab, IV (in the vein) to determine treatment dose of 131I-Tositumomab.~1-2 weeks after Day 0: Tositumomab, IV (in the vein) followed by therapeutic dose 131I-Tositumomab (in the vein)."
46076340|NCT02771730|Biological|AIDSVAX B/E|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered intramuscularly (IM).
45453472|NCT01334840|Dietary Supplement|Mineral water low in mineral content (control)|"Volunteers fasted overnight consumed:~0.5 L of the control water without meal or, 0.5 L of the control water with meal"
45658639|NCT05572632|Behavioral|COPD Wellness Plus+|Couples COPD Wellness with the ZSFG Health Advocates Program. The HA will help the participant prioritize identified needs and, using an algorithm informed approach to connect the individual to the needed resource, this includes providing referrals to outside social or legal service agencies, help with applications for social benefits, or other services. The HA will use a checklist to track activities including review and prioritization of needs, referrals or resources provided, and contacts/contact attempts.
45810963|NCT03926299|Drug|Clobetasol propionate 0.05% ointment|6 months standard treatment with topical steroid cream (high dose for the first two months, medium dose for the next two months, low dose for the last two months)
45810964|NCT03917797|Biological|MSC treatment|Umbilical cord-derived Mesenchymal Stromal Cell
45948376|NCT00135057|Drug|insulin glulisine|
45948377|NCT00135057|Drug|insulin glargine|
45810965|NCT03917797|Drug|Standard of Care|Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate
45810966|NCT03917797|Drug|Placebo|MSC infusion vehicle
45810967|NCT04342507|Other|conservative treatment|lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days.
45948378|NCT00434668|Drug|cisplatin/docetaxel|
45948379|NCT00434668|Drug|cisplatin/vinorelbine|
45948380|NCT00105911|Behavioral|Cognitive Behavioral Therapy|
45948381|NCT00434746|Drug|ILV-094|Single, ascending doses of 5, 15, 50, 100, 300, and 600 mg IV or SC dose of ILV-094 or placebo
45948382|NCT00137826|Drug|Erlotinib|Taken orally once daily. Participants may continue on study treatment until disease progresses or they experience serious side effects.
45948383|NCT00137826|Drug|Bevacizumab|Given intravenously over 30-90 minutes, on day 1 of each 21-day cycle. Participants may continue on study treatment until disease progresses or they experience serious side effects.
45948384|NCT00434785|Drug|AGG-523|
45948385|NCT00434824|Drug|Oral testosterone undecanoate (Andriol)|treatment for 12 months with oral TU 80 mg/d, oral TU 160 mg/d or oral TU 240 mg/d in divided doses
46076341|NCT02835014|Behavioral|Mental Health Symptoms|Adolescents with T1DM will be asked to complete PHQ9 (depression screening), SCARED (anxiety screening) and UCLA PTSD (trauma screening)
46076342|NCT02835014|Behavioral|Self-efficacy regarding self-care and diabetes management|Adolescents with T1DM will be asked to complete the SEDM to asses self-efficacy for diabetes management
46076343|NCT02835014|Behavioral|Parenting Styles|Parents of adolescents with T1DM will be asked to complete the PSDQ to asses parenting style
45810968|NCT04342507|Dietary Supplement|probiotics|use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of adults chalazia by re-establishing intestinal and immune homeostasis
45810969|NCT03893929|Diagnostic Test|New Biological markers for prostate cancer diagnosis and management|To identify potential new blood and urine markers for the diagnosis, risk stratification and prognosis prediction for prostate cancer in Chinese population.
45658640|NCT05572632|Behavioral|Usual Care|Includes access to comprehensive primary care services that is standardized across the SFHN. Participants randomized to the usual care arm will be offered referral to the Better Breathing Program that is part of SFHN standard care for COPD. At end of study enrollment, usual care participants will be offered the COPD Wellness intervention.
45810970|NCT04359199|Radiation|Radiation Therapy|Routine radiation dosing (approximately 70 Gy in 35 fractions over 6.5 weeks) to the head and neck for the treatment of head and neck cancer
45810971|NCT04359199|Drug|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of head and neck cancer
45810972|NCT04359199|Drug|Chemotherapy|Cisplatin is a chemotherapy medication used to treat a number of cancers, including head and neck cancer
45810973|NCT04359199|Drug|Immunotherapy|"Keytruda or Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface.~Opdivo or Nivolumab is a targeted therapy. It is a human programmed death receptor-1 (PD-1) blocking antibody.~Imfinzi or Durvalumab is an anti-cancer (antineoplastic) drug. This medication is classified as an Anti-PD-L1 monoclonal antibody."
45810974|NCT03875911|Drug|Mitomycin C|Three delivery methods of Mitomycin-C in Trabeculectomy
45810975|NCT00362011|Behavioral|Salba diet|
45810976|NCT03866707|Other|One-time blood draw|"Subjects will have a one-time blood draw of 5-10mL. Quantity of blood drawn for study and routine care will not exceed the maximum safe blood volume for subject size.~Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray. This covers over 850,000 CpG methylation sites and is available in the investigator's Genomics Core Facility. Dr. Langefeld has analyzed numerous methylation studies, both array-based and next generation sequencing.~Metabolomic analysis will be performed by mass spectrometry when funds are available."
45810977|NCT03866707|Other|Evaluation of CpG methylation|Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray.
45810978|NCT03866707|Other|Metabolomic analysis|Metabolomic analysis will be performed by mass spectrometry when funds are available.
45810979|NCT00360997|Behavioral|Conventional UK physical therapy|
45810980|NCT00360997|Procedure|Con UK PT + Mobilisation & tactile stimulation (MTS)|Con UK PT + Mobilisation & Tactile Stimulation (MTS) which is further randomised to 30, 60 or 120 mins/day
45810981|NCT00361075|Drug|transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium)|
45810982|NCT04328857|Device|pseudoelastic orthosis|The subject will be given specific physiotherapy including activities oriented to multimodal exploration and refinement of gross and fine motor skills, customized according to the functional status of the individual patient.
45810983|NCT03844633|Drug|Depo-Provera Injectable Product|Depo-Provera Injectable Product -- Shot administered within 48 hours of childbirth
45948386|NCT00434824|Drug|Placebo|treatment for 12 months with placebo in divided doses
45948387|NCT00105950|Drug|lapatinib|Tyrosine kinase inhibitor administered daily at 1500 mg/kg
45676407|NCT03473756|Drug|Rogaratinib (BAY1163877)|Part A:Rogaratinib will be administered orally until disease progression, unacceptable toxicity or consent withdrawal. The starting dose of 800 mg b.i.d. will be confirmed using a dose selection design.
45453473|NCT00383552|Drug|Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID|MF/F 100/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
45810984|NCT03844633|Drug|Placebos|Placebos -- Shot administered within 48 hours of childbirth
45810985|NCT00362089|Dietary Supplement|Marinol D-40|Marinol D-40, three capsules per day, from 15th week of gestation until 4th month of lactation
45810986|NCT04342741|Device|Foley catheter cervical ripening|Participants were assessed when labour was established or the following morning.
45810987|NCT04666987|Drug|Insulin degludec and liraglutide (IDegLira)|Paricipants will be treated with commercially available Xultophy® according to routine clinical practice at the discretion of the treating physician, following approved label in Italy. The decision to initiate treatment with commercially available Xultophy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
45810988|NCT04328701|Behavioral|Mindfulness-based Cognitive Behavioral Therapy|Mindfulness-based CBT methods are based on pain self-management paradigms, and involve the identification and reduction of maladaptive pain-related cognitions (i.e., catastrophizing), the enhancement of self-efficacy for managing pain, and training in the use of adaptive pain-coping strategies such as relaxation, distraction, and self-talk.
45810989|NCT04660669|Other|ESDM intervention|Early Start Denver Model (ESDM) intervention with remote parental training/ supervision versus intensive ESDM intervention.
45810990|NCT04660669|Other|MOOC|Massive Online Open Course: a teaching and learning intervention based on instrumental and interactive teaching situations
45810991|NCT04318717|Drug|Pembrolizumab|Pembrolizumab is commercially available
45948388|NCT00434863|Drug|botulinum toxin type A|
45948389|NCT00434941|Drug|Capecitabine|
45948390|NCT00434941|Radiation|Radiotherapy|
45658641|NCT05571033|Behavioral|Spinal reflex conditioning|Each participant will serve as their own control. The intervention is 30 sessions. The first 6 sessions are baseline measures of reflexes. The remaining sessions will engage participants in learning how to decrease their reflex activity in their calf muscle on the more-affected leg. Each intervention visit will involve 20 trials in which participants do not get visual feedback about their performance, then 225 trials with visual feedback.
45658642|NCT05569122|Diagnostic Test|Cardiopulmonary Exercise Testing|"Testing with an exercise bicycle that is considered standard of care for determination of exercise capacity. Participants will complete about 20 minutes of pedaling in a stationary exercise bike"
45658643|NCT05569122|Device|pGz Bed|Participants will lay down on a passive exercise (pGz) bed for 45 minutes during which the bed will administer passive exercise through periodic acceleration
45658644|NCT05569122|Device|Gentle Jogger|Participants will have passive exercise delivered through the gentle jogger device for 45 minutes. This may be sitting down (aim 1 participants) or laying down (aim 2 participants)
45453474|NCT00383552|Drug|Mometasone Furoate MDI (MF MDI)|MF 100 mcg via metered dose inhaler twice daily for 26 weeks
45453475|NCT00383552|Drug|Formoterol Fumarate 10 mcg|F via metered dose inhaler 10 mcg twice a day for 26 weeks
45658645|NCT05569122|Device|Exercise Pedal|Participants will exercise while laying down for 20 minutes with an exercise pedal that attaches to the bed
45453476|NCT00383552|Drug|Placebo|Placebo metered dose inhaler twice a day for 26 weeks
45658646|NCT05569122|Drug|Lumason® contrast agent|Contrast agent used during a vascular ultrasound of the upper leg. Will occur at each study visit twice before and after pGz bed, gentle jogger, exercise pedal or CPET. Drug Administration will be through an IV line and take about 5 - 10 minutes.
45453477|NCT01335074|Drug|Temsirolimus + Sorafenib|200mg bid Sorafenib + 15, 20 or 25 mg Temsirolimus
45810992|NCT04318717|Radiation|Hypofractionated radiation therapy|It is preferred to leave at least 48 hours between fractions. Daily imaging to verify accurate set-up is mandatory.
45948391|NCT00434980|Behavioral|Family-Directed Cognitive Adaptation Program|
45810993|NCT03822637|Drug|n-acetylcystine + albuterol|NAC is a mucolytic drug and Albuterol is a bronchodilator.
45810994|NCT03822637|Drug|0.9% saline + albuterol|Normal saline is a placebo agent and Albuterol is a bronchodilator.
45810995|NCT03820687|Other|Clinical Trial Educational Video|Culturally tailored educational video, brochure, and support from a patient navigator to empower new cancer patients to make informed decisions about cancer clinical trials.
45810996|NCT03820687|Other|Clinical Trial Fact Sheet|General Clinical Trial fact sheet with usual care information regarding Clinical Trials.
45810997|NCT03820687|Other|Brochure|A brochure with educational material about clinical trials and services offered by Mays Cancer Center.
45948392|NCT00135096|Drug|insulin glulisine|PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.
46076344|NCT04224948|Device|PET MRI scan|"Standard of care includes a baseline PET-CT and conventional CT after 2 cycles of neoadjuvant chemotherapy, and after 5-6 cycles, of neoadjuvant chemotherapy, as per current practice/ standard of care.~Patients that enroll in the trial will receive two additional PET MRI scans- one at baseline and one after 1 cycle of chemotherapy"
45453478|NCT01337414|Behavioral|VMS diary booklet|
45453479|NCT01337414|Behavioral|Standard of Care|
45453480|NCT05186402|Procedure|Total or subtotal gastrectomy|Gastric resection with digestive continuity according Roux or Bilroth
45658648|NCT05557877|Procedure|Biospecimen Collection|Undergo collection of blood
45810998|NCT03820687|Other|Navigator|Support that will be provided by a patient navigator to empower new cancer patients to make an informed decision about cancer clinical trials by increasing awareness of clinical trials and MCC services, positive attitudes and intentions to consider clinical trials as an appropriate treatment option.
45810999|NCT04298437|Behavioral|Addressing Depression and Positive Parenting Techniques (ADAPT) Program|The intervention is a targeted parenting intervention that has modules that help parents build emotion regulation skills, distress tolerance skills and alternative and more helpful ways of thinking about the causes of their child's EBD. The program also includes behavioral parent training skills building modules.
45811000|NCT05444101|Behavioral|Mindful attention|The Mindful attention treatment component consists of a breathing exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
45811001|NCT05444101|Behavioral|Decentering|The Decentering treatment component consists of a guided imagery exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
45811002|NCT05444101|Behavioral|Values and committed action|The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
45811003|NCT02975089|Dietary Supplement|"multi-nutrient supplement"|"1.3g/d multivitamins & minerals powder~Leaflet content (same as control)"
45811004|NCT02975089|Dietary Supplement|"multi-nutrient & soy protein supplement"|"1.3g/d multivitamins & minerals powder~16g/d isolated soy protein powder~Leaflet content (same as control)"
45948393|NCT00135096|Drug|insulin glargine|POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.
45453481|NCT01337492|Drug|Nexavar|400 mg of Sorafenib
45453482|NCT01337570|Other|Dapivirine|Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months
45658649|NCT05557877|Drug|Low-Dose Aspirin|Given PO
45658650|NCT05557877|Other|Questionnaire Administration|Ancillary studies
45658651|NCT05557877|Procedure|Ultrasound-Guided Biopsy|Undergo ultrasound-guided breast biopsy
45453483|NCT01337570|Other|Placebo|Vaginal Ring containing no drug substance
45453484|NCT01337570|Drug|Dapivirine|
45658652|NCT05543681|Drug|Agitation management in Alzheimer's disease (IGC-AD1-Active)|A non-sterile solution for oral administration.
45658653|NCT05543681|Drug|Agitation management in Alzheimer's disease (IGC-AD1-Placebo)|A non-sterile solution for oral administration similar in color and texture to the Active.
45948394|NCT00435058|Drug|timolol maleate 0,5%|
45658654|NCT05526001|Biological|ELIXCYTE|ELIXCYTE, a new investigational product developed by UnicoCell Biomed, contains allogenic Adipose-derived stem cells (ADSCs). The ADSCs of ELIXCYTE for subjects were obtained from donors, and the Sponsor followed the manufacturing and testing procedures described in chemistry, manufacturing and control (CMC) information in order to assure the quality of final products.
45811005|NCT02975089|Dietary Supplement|Nutrition education on balanced diet & food supplement|"Nutrition education with a designed plate~10g/d mixed nuts (cashews, pumpkin seeds, walnuts, macadamia, pine nuts, and almonds)~25g/d milk powder (skimmed and calcium added)~Leaflet content (same as control)"
45948395|NCT00435058|Drug|brimonidine tartrate 0,2%|
45948396|NCT00435058|Drug|travoprost 0,004%|
45658655|NCT05526001|Drug|Saline|Placebo control used in the study.
45948397|NCT00106067|Behavioral|coping and communication support (CCS) intervention|"Trained clinical nurse specialists with masters� degrees in mental health will serve as CCS practitioners and they will be available to patients and family caregivers on a 24/7 basis to assist with coping and communication challenges as they may arise.~The CCS intervention is tailored to individual preferences over time, and designed to accommodate different age groups, especially older adults and their families."
46076345|NCT00946985|Drug|paliperidone palmitate|50, 75, 100, or 150 mg eq. monthly injection for 2 years
46076346|NCT00946985|Drug|oral risperidone|2, 4, 6, or 8 mg tabs once daily for two years
45811006|NCT04342819|Drug|SGLT2 inhibitor|Sodium-Glucose Like Transporter 2 Inhibitor
45811007|NCT02976493|Other|No Intervention|No Intervention
45811008|NCT02412306|Drug|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
45811009|NCT05628636|Drug|AC-OLE-01-VA|formulation of tricaprilin
45811010|NCT05616468|Biological|BGT007 Cell Injection|BGT007 cells (d0) were infused intravenously once, and the dose group was 5.0 × 10^5cells/kg，1.0 × 10^6cells/kg，3.0 × 10^6cells/kg，6.0 × 10^6cells/kg，1.0 × 10^7cells/kg。
45811011|NCT05616468|Drug|Fludarabine|Fludarabine 25~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
45811012|NCT05616468|Drug|cyclophosphamide|250~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
45811013|NCT02274168|Procedure|Conventional RF catheter ablation|RF catheter ablation will be performed as usually done by each center. No ICD EGMs will be obtained and used during the ablation procedure (do not place the programming head over the ICD generator).
45811014|NCT02274168|Procedure|Investigational RF Catheter Ablation using ICD-EG information|RF ablation procedure will be performed with the programming head over the ICD generator. ICD EGMs will be registered every time VT is induced and during ventricular pacing. ICD EGMs obtained during ablation procedure will be compared with the EGMs of the registered spontaneus VT and used to locate appropriate ablation sites.
45948398|NCT00435175|Drug|estradiol|
45948399|NCT00135135|Drug|Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid|See Detailed Description.
45948400|NCT00135135|Procedure|Radiation therapy, Surgery, Peripheral Stem cell transplant|See Detailed Description.
45948401|NCT03278080|Other|Road-tracking test|Driving with simulator program for SDLP measurement
45948402|NCT03278080|Other|Car-following test|Driving with simulator program for DCV measurement
46076347|NCT02829710|Behavioral|Nurse-driven sedation protocol|The nurse-driven sedation protocol included the COMFORT-B scale. Initial doses were chosen by the physicians then all changes were made by the nurses with the aim of attaining an optimal range of analgesia and sedation, which was defined as values from 11 to 17 on the COMFORT-B score.
45658656|NCT05512039|Drug|Botox 50 Unit Injection|Participants will be randomized to either receive a standard dose (100 units) or low dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief, after 3 months post injection, they may receive repeat injection up to twice during the 12 month follow-up period.
45658657|NCT05512039|Drug|Botox 100 Unit Injection|Participants will be randomized to either receive a standard does (100 units) or low dose (50 units) of botox one time.If a particParticipants will be randomized to either receive a standard dose (100 units) or low dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief, after 3 months post injection, they may receive repeat injection up to twice during the 12 month follow-up period.
45948403|NCT03278080|Other|Harsh-braking test|Driving with simulator program for BRT measurement
45948404|NCT04702282|Diagnostic Test|ropivacain concentration measurements|Free and total plasma concentrations of ropivacaine were measured within 24 hours using liquid chromatography - mass spectrometry. A population pharmacokinetic model was built using non-linear mixed effect models
45948405|NCT00435253|Biological|BLVR Treatment|BLVR Treatment, 10 mL Hydrogel
46076348|NCT00611923|Drug|Flutamide|Participants will take one 125-mg flutamide capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
45676408|NCT03473756|Drug|Atezolizumab|Part A: A fixed dose of 1200 mg atezolizumab will be administered through intravenous (i.v.) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity or consent withdrawal.
46076349|NCT00611923|Drug|Placebo|Participants will take a lactose capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
46076350|NCT04246502|Drug|Capecitabine and Pyrotinib|Pyrotinib 400mg orally daily until progressive disease
46076351|NCT04246502|Drug|Capecitabine,Trastuzumab, and Pertuzumab|as instruction
45948406|NCT00435292|Drug|Naproxen|nonsteroidal anti-inflammatory drug
45948407|NCT00435292|Dietary Supplement|flavocoxid 250 mg|flavonoid mixture
45948408|NCT00435292|Dietary Supplement|flavocoxid 500 mg|flavonoid mixture
45658658|NCT05509842|Device|rTMS|A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be used to apply rTMS to targeted locations marked on the structural MRI using a frameless infrared stereotactic neuronavigation system (Brainsight, Rogue Research).
45948409|NCT00435331|Drug|sapropterin dihydrochloride (6R-BH4)|2.5 mg/kg/day for two weeks, 5 mg/kg/day for two weeks, 10 mg/kg/day for four weeks, then 20 mg/kg/day for two days
45948410|NCT00435448|Drug|Lonidamine|
45948411|NCT00137865|Genetic|EGEN-001 (phIL-12-005/PPC)|
45948412|NCT00435526|Biological|anti-CFA/I bovine IgG, and anti-CfaE bovine IgG|
45948413|NCT00435604|Drug|Hylenex|
45948414|NCT00435643|Procedure|nasal continuous positive airway pressure|After an average interval of three months, 10 patients with severe OSAS (AHI of more than 30 events per hour of sleep) treated with a mean nCPAP pressure of 11.2 ± 0.7 cm of H2O were reassessed and all mentioned measurements above were repeated
45948415|NCT00135213|Behavioral|training in smoking cessation|
45948416|NCT00435682|Drug|Botox (Allergan Inc., US)|
45948417|NCT00435721|Behavioral|Psychoeducation|
45948418|NCT00435760|Drug|Aclidinium bromide|200 micrograms, once daily, 1 day treatment
45948419|NCT00435760|Drug|Placebo Tiotropium|1 puff once daily, 1 day treatment
45948420|NCT00435760|Drug|Tiotropium|1 puff of 18 µg (22.5 µg tiotropium bromide monohydrate) in the morning between 8:00 and 10:00
45948421|NCT00435760|Drug|Placebo LAS34273|1 puff, 1 dat treatment
45948422|NCT00435799|Procedure|corneal cross-linking (CCL)|
45948423|NCT00435799|Drug|Riboflavin/dextran eyedrops|
45948424|NCT00435799|Device|UV-X system|
45948425|NCT00435838|Drug|No Intervention -- Observational study|
45948426|NCT02957734|Procedure|Rehabilitation of severely worn dentitions|Patients with severely worn dentition and functional problems are included in this study. Teeth are rehabilitated using indirect composite resin restorations in an increased vertical dimension of occlusion in order to optimize function and esthetics.
45948427|NCT00142467|Drug|Gemcitabine|
45658659|NCT05502315|Drug|Cabozantinib|40 mg taken orally
45658660|NCT05502315|Drug|Nivolumab|480 mg by infusion
45658661|NCT05499741|Device|Forehead Temperature-Regulating Therapy|A forehead thermal therapy device will be used nightly for the duration of each sleep period for four weeks. This device includes a bedside unit and a pump to transport thermal fluid to a bladder, affixed to the forehead with a headband. The bladder circulates fluid over the forehead at adjustable temperatures ranging from 57-61 °F.
45658662|NCT05485974|Drug|HBI-2438|KRAS G12C Inhibitor
45658663|NCT05483283|Other|Empowerment and Navigation|Empowerment and Navigation
45658664|NCT05483283|Other|SOC|SOC
45658665|NCT05476991|Drug|Colchicine 0.5 MG|Colchicine is a medication used to treat gout and Behçet's disease. In gout, it is less preferred to NSAIDs or steroids. Other uses for colchicine include the management of pericarditis and familial Mediterranean fever.
45658666|NCT05476991|Drug|Ticagrelor 90mg|Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y 12 receptor.
45948428|NCT00142467|Drug|Oxaliplatin|
45948429|NCT00142467|Drug|Bevacizumab|
45948430|NCT02957461|Device|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor assessment. BrainScope Ahead 200iD device will be used to perform EEG.
45948431|NCT00435955|Procedure|High dose chemotherapy with autologous transplantation|
45948432|NCT00435955|Drug|Rituximab|
45948433|NCT04702321|Other|Procedure: Biospecimen Collection|Collection of saliva, buccal swabs, blood, or other sample adequate for germline DNA extraction
45948434|NCT04702321|Other|Procedure: Medical Chart Review|Collection of clinical data
45948435|NCT00137943|Behavioral|Full Parent communication intervention|
45948436|NCT00137943|Behavioral|Brief Parent Communication Intervention|
45948437|NCT00137943|Behavioral|Control Parent Intervention|
45948438|NCT00436033|Drug|milnacipran|
45948439|NCT00436033|Drug|Placebo|
45948440|NCT00436072|Drug|ZD6474|Orally on a daily basis
45948441|NCT00436072|Drug|Cetuximab|Infusion once weekly
45948442|NCT00436072|Drug|Irinotecan|Infusion once the safe dose of ZD6474 and cetuximab is established
45948443|NCT04702399|Device|GEL GROUP|Application of an anti-adhesion gel (HYALOBARRIER® GEL ENDO) in the uterine cavity
45948444|NCT03275857|Drug|Cisplatin|Weekly IV
45948445|NCT00137982|Procedure|Treatment of ectopic pregnancy|
45948446|NCT03270631|Other|FM and MCE|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting.
45948447|NCT03270631|Other|FM and sham-MCE|Treatments (FM) are given individually and as in a normal clinical physical therapy setting. Sham-MCE is general exercises.
45948448|NCT03270631|Other|MCE and sham-FM|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting. Sham-FM is similar to trigger point treatment with treated points randomized.
45948449|NCT03270631|Other|Sham-MCE and sham-FM|Sham-FM is similar to trigger point treatment with treated points randomized. Sham-MCE is general exercises.
45948450|NCT03276052|Drug|Aclidinium Bromide 400 μg|Aclidinium Bromide 400 μg BID inhalation powder. One oral inhalation via Genuair® dry powder inhaler (DPI)
45948451|NCT03273322|Drug|Rivaroxaban 10 mg qd|10mg qd
45948452|NCT03273322|Drug|Rivaroxaban 15 mg qd|15mg qd
45948453|NCT03273322|Drug|DAPT|Aspirin 75 mg qd + Clopidogrel 75 mg qd
46002244|NCT04255875|Biological|PF-07209326|SCD participants will receive a multiple dose of subcutaneous PF-07209326
46002245|NCT04242953|Drug|SCO-120|"Part A: single oral administration~Part B: single oral administration in Period 1 and Period 2 (crossover design)~Part C: multiple oral administration (14 day dosing)"
46076352|NCT02767362|Drug|Atorvastatin|Once enrolled on this pre-operative window study, patients with endometrial cancer will be treated with the standard clinical dose of atorvastatin (80 mg once daily orally) for an average of 2-4 weeks prior to surgical staging. Patients will need to be able to undergo atorvastatin treatment for a minimum of 2 weeks but no more than a maximum of 4 weeks prior to surgical staging.
46076353|NCT04246658|Other|conventional physical therapy program|traditional physical therapy program
45948454|NCT00138021|Device|Computerized cognitive training program|"The cognitive training model used in the McGurk et al. (2005) study is referred to as the Thinking Skills for Work program. The program is a manualized, remediative and compensatory training intervention that is integrated with SE services. The program includes a cognitive trainer, a structured training manual (McGurk & Mueser, unpublished training manual) and a computer-based cognitive training program (described below)."
45658667|NCT05476991|Drug|Aspirin 75-300mg|Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI).
45658668|NCT05471323|Biological|RC1012 injection (allo-DNT cells)|RC1012 injection (allo-DNT cells) from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.
45948455|NCT04702360|Drug|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration.
45948456|NCT04702360|Drug|IVA|IVA monotablet for oral administration.
45948457|NCT04702204|Drug|Denosumab 60 MG/ML|"Denosumab, another antiresorptive agent, is a fully human monoclonal IgG2 antibody that binds to the receptor activator of the nuclear factor-kB ligand (RANKL) with high specificity and affinity. Denosumab inhibits bone resorption by affecting the development, activation, and survival of osteoclasts.~Denosumab 60 mg subcutaneously was administered to the patients whose consent forms were obtained, once every 6 months."
45811015|NCT04790682|Biological|assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.|"At pre-screening NGS analysis on tumor tissue (slides). Only patients with at least 1 mutation at NGS on the tumor tissue will ultimately be enrolled in the main study, to have the possibility to follow the mutation using ctDNA.~Main study will be initiated after results of the NGS and before initiation of pembrolizumab. Blood specimens will be taken with EDTA tubes or streck tubes at the time of puncture for pembrolizumab infusion at baseline before starting treatment, at 3 weeks, 6 weeks and then every 6 weeks (30 ml at Baseline then 20 ml of blood). Blood immunomonitoring will be done before starting the treatment, at 6 weeks and at 18 Week. An additional measurement will be performed if treatment is stopped before the end of the study (18 ml of blood).~Optional blood samples will be realized to analyse the degree of activity of the plasmatic lymphocytes before starting the treatment and at 6 weeks and (18 ml of blood)."
45948458|NCT04702087|Dietary Supplement|OLEP|omega 3 (500 mg), leucine (2,5 g), probiotic Lactobacillus paracasei PS23
45948459|NCT04702087|Combination Product|Placebo|Isocaloric formula
45811016|NCT02199054|Other|wheat-safflower oil pretzels|Each serving (6 pieces) of the wheat-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, safflower oil, sugar, yeast, salt, and ascorbic acid.
45948460|NCT00138060|Drug|irinotecan|180 mg/m² or 260 mg/m² in 90 minutes every 15 days
45811017|NCT02199054|Other|soy-safflower oil pretzels|Each serving (6 pieces) of the soy-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, soy flour, soymilk, safflower oil, sugar, yeast, salt, and ascorbic acid.
45948461|NCT00138060|Drug|5 fluorouracil|400 mg/m² in bolus in day 1 and 2400 mg/m² in 46 hours perfusion
46002246|NCT04242953|Drug|matching placebo|"Part A: single oral administration~Part C: multiple oral administration (14 day dosing)"
46076354|NCT04246658|Other|gait training on platform swing walkway|gait training on platform swing walkway for 30 minute.
46002247|NCT04226898|Biological|Synbiotic Supplement|Synbiotic supplement 1 powder stick by mouth daily
46076355|NCT02854319|Device|LOTUS Edge Valve System|Transcatheter Aortic Valve Implantation (TAVI) with the LOTUS Edge™ Valve System when used with the Lotus™ or iSleeve™ Introducer Set
45948462|NCT04701970|Procedure|relining of mandibular complete denture|Relining of mandibular dentures was performed by reducing one mm of the denture fitting surfaces and borders to make a right-angled border. apply two separate layers of Mucopren adhesive upon the vestibular surface of the mandibular denture and allow each layer to dry for about 40 seconds. then, the lower denture was inserted and molded in patient mouths; while biting in centric occlusion with the opposing maxillary complete dentures.
45811018|NCT02199054|Other|control wheat pretzels|Each serving (6 pieces) of the control wheat pretzel contains 6 grams of vegetable shortening. Ingredients in the pretzel are high gluten wheat flour, vegetable shortening, sugar, yeast, salt, and ascorbic acid.
45811019|NCT05195970|Other|Walnuts|Participants consume 2 ounces of walnuts daily for 21 days
45811020|NCT04285723|Other|alpelisib|Retrospective observational case-only study. There is no treatment allocation. Patients with severe or life-threatening PROS who have received alpelisib as part of a compassionate use program were invited to participate.
45811021|NCT04284553|Other|Order Entry|An alert will display in the electronic health record when the provider orders one of the high-risk medications for an eligible patient.
45811022|NCT04284553|Other|Open Encounter|An alert will display in the electronic health record when the provider opens the chart of an eligible patient.
45811023|NCT04284553|Other|Follow-up booster Alert|Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered
45811024|NCT04284553|Other|Cold State outreach|An in-basket message will be sent to the eligible provider 2 days before the eligible patient is scheduled for an in-person visit.
45811025|NCT04284553|Other|Simplified|The alert language itself will be simplified.
45811026|NCT04284553|Other|Sign-off alert|An alert will display in the electronic health record when the medication is sent to sign-off for providers.
45811027|NCT04284553|Other|Pre-commitment|A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.
45811028|NCT04284553|Other|Different Risks|Risks of the high-risk medications will be framed differently.
45811029|NCT04284553|Other|Standard Epic Basic Alert|This alert will be representative of the alerts currently firing in the Atrius system and not incorporate any functionality.
45811030|NCT04284553|Other|Enhanced Alert|An enhanced alert (known as a Best Practice Advisory [BPA]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.
45811031|NCT02976415|Other|In-Bed Cycling|20 minutes of in-bed cycling, either active, passive or a combination of active and passive.
45811032|NCT02975011|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
45811033|NCT02975011|Procedure|Chuna manipulation|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
45948463|NCT04702009|Drug|Anti-PD-1/PD-L1 Monoclonal Antibody，Chemotherapy|Anti-PD-1/PD-L1 monoclonal antibody (approved anti-PD-1/PD-L1 monoclonal antibody)；albumin paclitaxel/docetaxel + carboplatin (albumin paclitaxel 130mg/m2, d1 d8, Docetaxel 75mg/m2, carboplatin AUC=5, d1, every 21 days, 4 cycles of chemotherapy; immunotherapy no more than 2 years)
45948464|NCT04702009|Device|Bronchoscopy-assisted Interventional Therapy|Bronchoscopy-assisted interventional therapy (1 time before chemotherapy or 2 times before chemotherapy and before the third cycle of treatment)
45948465|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor|Dose escalating beginning with rising dose levels of 300, 450, and 600 mg/day in a continuous dosing schedule.
45948466|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor - 450 mg|Dose 450 mg capsules daily for 28 day cycles.
45658669|NCT05465226|Drug|Oliceridine|see arm description
45658670|NCT05465226|Drug|Historical opioid use|Historical matched, control group in 2:1 ratio
45658671|NCT05464134|Radiation|x-ray|plain radiographs of lower limb anteroposterior and lateral views , lumbar spine plain radiographs (anteroposterior, lateral, lateral in flexion and lateral in extension views )
45658672|NCT05463393|Biological|Xanthohumol - prenylated chalcone extracted from female inflorescences of hop cones (Humulus lupus). Hop-RXn™, BioActive-Tech Ltd, Lublin, Poland; http://xanthohumol.com.pl/|The appropriate dose of Xanthohumol was solved in 1 mL of propylene glycol
45658673|NCT05461599|Device|SparkRx Mobile App|The SparkRx app will be fully self-guided and completed by participants at home. It is designed to be completed over 5 weeks but users may progress through the app at their own pace. The app progresses linearly, i.e., a task must be completed before a participant can progress to the next task. Content for a given week is not expected to take more than 60 minutes to complete.
45676409|NCT03398148|Drug|risankizumab IV|risankizumab intravenous (IV) infusion
45676410|NCT03398148|Drug|placebo for risankizumab|placebo for risankizumab
45811034|NCT02975011|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
45676411|NCT03398148|Drug|risankizumab SC|risankizumab subcutaneous (SC) injection
45811035|NCT02975011|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
45948467|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off|Dose escalating in a repeating intermittent dosing schedule of 3 days on and 4 days off at rising dose levels of 450, 600, 800, 1000, 1200, and 1400 mg/day.
45948468|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor - 1 day on, 6 off|Dose escalating in a repeating intermittent dosing schedule of 1 day on/6 days off at rising dose levels of 600, 900, 1200, 1500, 1800, 2400, 3200 mg/day once weekly and then increase at 33% increments.
45948469|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg|Dose 350 mg capsules daily intermittent 3 days on/4 days off dosing. THIS DOSING SCHEDULE IS NO LONGER UNDER INVESTIGATION
45811036|NCT02975011|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
45948470|NCT04701697|Drug|Recombinant Human Albumin Injection|Participants will receive Recombinant Human Albumin Injection of intravenous infusion
45948471|NCT04701697|Drug|HumanAlbumin|Participants will receive HumanAlbumin of intravenous infusion
45811037|NCT02975011|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
45811038|NCT02975011|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
45948472|NCT02957578|Device|Solo TTD|Placement of tympanostomy tube with Solo TTD
45948473|NCT00142545|Drug|apomorphine HCl injection|
45948474|NCT04701775|Dietary Supplement|Only Lactobacillus rhamnosus GG strains|1x106 colony forming unit (CFU) Lactobacillus rhamnosus GG probiotic capsule
45948475|NCT04701775|Combination Product|Combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis strains|combination of Lactobacillus acidophilus 1x109 CFU and Bifidobacterium animalis subsp.lactis 1x109 CFU probiotic capsule
45948476|NCT04701775|Other|Placebo|Placebo probiotic capsule
45948477|NCT00106223|Behavioral|Cognitive behavioral therapy (CBT)|Participants will receive a total of 22 sessions of individual, manual-based CBT. The CBT sessions will occur weekly during the course of the study. During the sessions, participants will receive education about BDD and CBT, engage in activities that help them confront their BDD, learn new ways of thinking about body image, and learn relapse prevention techniques.
45948478|NCT04701892|Other|Indicators of central sensitisation|Indicators of central sensitisation, assessed by the Central Sensitization Inventory
45658674|NCT05455710|Device|VigiApp|mobile application containing a patient identification module; post-discharge surveillance questionnaire with questions related to signs and symptoms of SSI previously validated; possibility of attaching and sending a photograph of the surgical wound; field for exchanging messages between professional and patient; issuing an alert / reminder to fill in the data in the application; in addition to establishing interoperability with the system used by the hospital's SCIH, containing a login for each health professional, which allows access to the answers, images and messages sent by surgical patients, categorizing risk and issuing alerts in suspected cases of SSI.
45948479|NCT00436150|Behavioral|Interpersonal therapy-based treatment|Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. Both groups will attend weekly 1-hour sessions for 5 weeks.
45658675|NCT05451693|Behavioral|Outreach-ER|The intervention is similar to other care intervention/support programs such as REACH or New York University Caregiver Intervention (NYCUI). The Intervention is designed to be delivered over phone/virtual and in-home and will be conducted by Amplio, LLC consultants.
45676412|NCT03384238|Procedure|Fluorescence Imaging|Undergo fluorescence imaging
45676413|NCT03384238|Biological|Panitumumab|Given IV
45811039|NCT02975011|Other|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
45811040|NCT04779294|Diagnostic Test|STAN ( St wave analysis) and fetal blood sample-lactate|The CTG will be analysed by an expert group additional to the standard procedure that have been done in Labour already. The STAN analysis will be decrypted/ demasked anonymously by the Company producing these machines.
45811041|NCT03654768|Drug|Bosutinib|Given PO
45811042|NCT03654768|Drug|Dasatinib|Given PO
45811043|NCT03654768|Other|Laboratory Biomarker Analysis|Correlative studies
45811044|NCT03654768|Drug|Nilotinib|Given PO
45811045|NCT03654768|Drug|Ruxolitinib|Given PO
45811046|NCT03654768|Drug|Imatinib|Given PO
45811047|NCT01352221|Drug|ST10|30 mg capsules to be taken orally twice a day for 12 weeks in double-blind phase
45811048|NCT01352221|Drug|Placebo oral capsule|Matching placebo capsules for ST10 to be taken orally twice a day for 12 weeks in double-blind phase
45811049|NCT03681769|Device|iTBS to the left dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the Universal Serial Bus (USB) key).
45811050|NCT03681769|Device|Sham iTBS to the left dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
45811051|NCT03681769|Device|cTBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
46002248|NCT04226898|Biological|Inert Compound|Synbiotic supplement identical placebo 1 powder stick by mouth daily
45658676|NCT05450003|Device|Irrigation activation using xp endo finisher file , new sonic eddy tip and conventional needle syringe irrigation|irrigation activation using 3 different irrigation activation systems including xp endo finisher file , new sonic eddy system and conventional needle syringe irrigation
45811052|NCT03681769|Device|Sham cTBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
45811053|NCT03678805|Procedure|Corticotomy|Perforations in the areas close to the impacted canines will be performed in order to accelerate tooth movement.
45811054|NCT03678805|Procedure|Traditional withdrawal techniques|The impacted canines will be withdrawn using elastic modules.
45811055|NCT03671005|Behavioral|Mindfulness-based group therapy|see above
45948480|NCT00436150|Behavioral|Standard care|Participants assigned to receive standard care will focus more on the health issues associated with pregnancy and postpartum. Both groups will attend weekly 1-hour sessions for 5 weeks.
45948481|NCT00142623|Behavioral|Tailored DVDs|Five DVDs aimed at reducing exposure to ETS
45948482|NCT00436189|Procedure|Blood Draw|
45948483|NCT00106262|Drug|Velcade (bortezomib)|
45948484|NCT00106262|Drug|Irinotecan|
45948485|NCT03278977|Biological|Blood sample for specific analyzes|"Standard management of ALTE~Hospitalization in pediatric intensive care unit or pediatric emergencies~Etiologic research~Blood volume, 2.5mL in PaxGene® tube, for specific analyzes (M2R, AchE)"
45948486|NCT03278275|Drug|One injection of 68Ga-NOTA-AE105|One injection of 68Ga-NORA-AE105
45948487|NCT03278275|Device|PET/CT|Following injection of 68Ga-NOTA-AE105 the participants will be subjected to whole body PET/CT
45948488|NCT03270241|Device|Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet|This is an investigator-initiated, single-blinded, ascending dose study of NB-UVB treatment for Vitiligo in adults of 3 treatments for one week. It is designed to measure the molecular changes and re-pigmentation in affected and normal skin of participants with Vitiligo and normal skin in healthy participants.
45948489|NCT00142662|Behavioral|diet|
45948490|NCT00142662|Behavioral|financial incentives|
45948491|NCT00106301|Drug|FK228 (romidepsin)|Patients were continued at the same dose of romidepsin as in the previous study, which could have been 13 mg/m2 or a reduced dose of 10 mg/m2, administered intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
45948492|NCT00436267|Drug|fluorouracil|
45948493|NCT00436267|Radiation|selective external radiation therapy|
45948494|NCT00436267|Radiation|tomotherapy|
45658677|NCT05443321|Other|Health Information Exchange (HIE) platform|An improved health information exchange (HIE) platform will be developed at the start of the study with key stakeholder input. This platform will be implemented for use after baseline data collection, and will allow for improved data exchange between transferring and accepting hospital. We will allow for a 6-month wash-in period prior to intervention data collection.
45676414|NCT03384238|Drug|Panitumumab-IRDye800|Given IV
45676415|NCT03382860|Diagnostic Test|Fundus videos|Recordings of fundus videos
45811056|NCT03671005|Other|Treatment as usual|see above
45811057|NCT03583710|Drug|Cisplatin|Given IV
45948495|NCT00436267|Radiation|yttrium Y 90 glass microspheres|
45948496|NCT00436267|Radiation|yttrium Y 90 resin microspheres|
45948497|NCT04701736|Device|Picture Medication Calendar|
45948498|NCT00436306|Behavioral|Individualized Intervention|Individualized Intervention is a computer-based, stage-matched, tailored intervention to promote the use of dual methods of contraception for STD and unplanned pregnancy prevention.
45948499|NCT00436306|Behavioral|Computer-based contraceptive information|Contraceptive method information is provided on a computer.
45948500|NCT00436384|Procedure|Monitoring-blood samples drawn for CMV testing|
45948501|NCT00138099|Drug|Fragmin (dalteparin sodium)|
45948502|NCT00106379|Drug|Truvada (tenofovir DF + emtricitabine)|
45948503|NCT00106379|Drug|Emtriva (emtricitabine)|
45811058|NCT03583710|Drug|Etoposide|Given IV
45811059|NCT03583710|Drug|Mitotane|Given PO
45811060|NCT03583710|Other|Quality-of-Life Assessment|Ancillary studies
45811061|NCT04418154|Drug|epirubicin hydrochloride|Take epirubicin hydrochloride (90mg/m2, d1) every 14 days as one cycle for 4 cycles with cyclophosphamide, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
45811062|NCT04418154|Drug|Cyclophosphamide|Take cyclophosphamide (600mg/m2, d1) every 14 days as one cycle for 4 cycles with epirubicin hydrochloride, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
45811063|NCT04418154|Drug|Albumin bound paclitaxel|Take nanoparticlealbumin-bound paclitaxel (125mg/m2, d1) per week for 3 weeks as one cycle for 4 cycles with Toripalimab, following epirubicin hydrochloride and cyclophosphamide.
45811064|NCT04418154|Drug|Toripalimab|Take Toripalimab (240mg, d1) every 3 weeks as one cycle for 4 cycles with nanoparticlealbumin-bound paclitaxel, following epirubicin hydrochloride and cyclophosphamide.
45811065|NCT05195034|Drug|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with continuous infusion at a rate of 0.2 µg/kg/hour until the end of dural closure.
45811066|NCT05195034|Drug|0.9% saline|The 0.9% saline is administered with the same volume at the same speed as the other group.
45948504|NCT00106379|Drug|Viread (tenofovir DF)|
45948505|NCT00436423|Drug|gemcitabine, TS-1|
45948506|NCT00436579|Drug|sorafenib tosylate|Given orally
45948507|NCT00436579|Other|pharmacological study|
45948508|NCT00436579|Procedure|assessment of therapy complications|Ancillary studies
45948509|NCT00436579|Other|laboratory biomarker analysis|Correlative studies
45658678|NCT05442840|Combination Product|Behavioral and drugs already approved and available for diabetes management|Pharmacists will review the patients information and medical history as well as drug coverage to discuss preferred treatment options to manage diabetes based on recommendations from Diabetes Canada treatment guidelines; all drugs have been approved and are available on the market; pharmacists will offer frequent follow up and provide basic diabetes education to the patient at each follow up appointment
45658679|NCT05437380|Diagnostic Test|peritumoral microbubbles and contrast-enhanced ultrasonography|Inject 1ml microbubbles around the tumors. Then detect lymph vessel and lymph nodes under contrast-enhanced ultrasonography.
45658680|NCT05424042|Behavioral|In-Person Caloric Restriction|20% CR delivered in-person by dietitian/coach
45658681|NCT05424042|Behavioral|Remote Caloric Restriction|20% reduction in caloric intake, meeting schedule, and physical activity goal delivered remotely.
45811067|NCT04790058|Other|Knowledge translation of the CSRS practice recommendations|The intervention is knowledge translation of the CSRS practice recommendations; the application of the practice recommendations will occur during the patient's ED visit and patients who are eligible for 15-day cardiac rhythm monitoring will have Holter monitor applied at the time of ED discharge. For the secondary objective to validate the accuracy of the ultra-low risk criteria of CSRS and assess for potential improvements in the practice recommendations and the prediction models we will request verbal consent during the index ED visit for addition of cardiac biomarker measurements [troponin and NT-proBNP] for patients who did not have such measurements performed as part of routine clinical care, and a 30-day telephone follow-up for serious outcome assessment. Patients who do not consent will be excluded from these portions of the study but included in the health resource utilization and generic patient safety outcome assessment objectives.
45811068|NCT05193942|Behavioral|Intervention Our Plan|From day 1 to day 120 (i.e., entire 4 month duration) of the trial, participants randomized to the intervention arm will be granted access and instructed to use the Our Plan program as directed. The Our Plan program includes modules covering topics of communication, decision-making, HIV/STI prevention, and stigma and discrimination. Each module contains content, questions, and activities for the participant and couple to complete. One goal of OurPlan is to help both partners of the couple create and use a risk- reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own confidence, intention, and perceived ability to use these strategies.
45948510|NCT00436657|Drug|CHPP of Cisplatin|Starting dose of 100 mg/m^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.
46076356|NCT02773992|Behavioral|The IoT|"For the IoT group, three plus two type pulmonary nodule diagnosis： ① gather information: smoking history, tumor personal and family history, copd history, etc.; ② noninvasive examination: tumor markers, lung function and chest low-dose CT thin layer; ③ information mining in-depth:through the software for three-dimensional reconstruction of pulmonary nodules, depth excavation, accurate calculation of the density of the volume, assessment of the surrounding and infiltration of lung nodules and related vascular growth status; two solutions: ① Pathological diagnosis in highly suspected patients: fiber bronchoscope, ultrasonic bronchoscope, thoracoscope and CT guided percutaneous lung biopsy, etc.; ② Close scientific follow-up to the person who can not be qualitative: doctors follow up and manage patients scientifically in accordance with the follow-up management tables through the Internet of things platform."
45811069|NCT05193942|Behavioral|Internation Informational Control|From day 1 to day 120 (i.e., entire 4 month duration) of the trial, participants randomized to the informational control condition will receive a webpage that contains information about HIV/STI prevention options and resources. This control condition represents the current equivalent of a standard of care for online HIV resources.
45811070|NCT05496894|Drug|Mitoxantrone Hydrochloride Liposome Injection|IV, once every 3 months (Q3M)
45811071|NCT04418544|Device|Device used to record voice for screening|voice recording
45811072|NCT03567954|Diagnostic Test|Ultrasound examination of the rotator cuff tendons|An ultrasound scan of the rotator cuff tendons will be performed to determine the presence of a rotator cuff tear or not
45948511|NCT00436657|Procedure|Abdominal Surgery|Surgical removal of abdominal tumors.
45948512|NCT00106418|Drug|Romidepsin|13 mg/m2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
45948513|NCT00436696|Other|Laboratory Biomarker Analysis|Correlative studies
45948514|NCT00436774|Procedure|assessment of therapy complications|
45948515|NCT00436774|Procedure|quality-of-life assessment|
45948516|NCT00436930|Biological|autologous tumor cell vaccine|Given subcutaneously
45658682|NCT05424042|Behavioral|Time-restricted|8-hour TRE with ad libitum caloric intake. This group will undergo a 9-month dietary intervention targeting consumption of all daily caloric intake within an 8-hour window of time, with no restrictions on caloric intake.
45658683|NCT05422924|Behavioral|Web-based platform. (My Viva Plan)|Participants will use a web-based platform (i.e. My Viva Plan®) to improve physical function, nutrition and mindfulness.
45658684|NCT05419050|Drug|denosumab|monoclonal antibody to receptor activator of nuclear kappa-B ligand (RANKL), a protein involved in regulating osteoclastogenesis
45658685|NCT05402436|Other|A diagnosis of atypia as part of the English screening programme|An atypia diagnosis of either ADH (including AIDEP), LISN (both ALH and LCIS) or FEA
45658686|NCT05397496|Biological|PIT565|Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection
45658687|NCT05393271|Drug|VH4011499|VH4011499 will be administered.
45658688|NCT05393271|Drug|Placebo|Placebo will be administered.
45658689|NCT05393271|Drug|Midazolam|Midazolam will be administered
45948517|NCT00436930|Biological|sargramostim|Given subcutaneously
45948518|NCT00436930|Biological|therapeutic autologous dendritic cells|Given subcutaneously
45948519|NCT00437008|Drug|Benfotiamine 1050mg, 3 days|
45948520|NCT00437008|Behavioral|high-AGE vs. low-AGE meal|
45948521|NCT00437086|Drug|PS-341|1.6 mg/m2 by IV; 4 out of 5 weeks
45658690|NCT05382806|Drug|Flumazenil|During the procedure, continuous infusion of remimazolam dose of 2mg/kg/hr. when procedure ends, infusion remimazolam stops and 0.9% normal saline or 0.2mg of flumazenil according to allocated groups.
45658691|NCT05379972|Drug|Pembrolizumab|Pembrolizumab 200mg IV every 3 weeks starting C2D1
45658692|NCT05379972|Drug|Olaparib|Olaparib 200mg orally twice daily starting C1D1 concurrently with radiation. Starting C2D1, Olaparib 300mg orally twice with Pembrolizumab
45658693|NCT05379972|Radiation|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy Dose 25Gy in 5 fractions daily (M-F) for 5 days starting C1D1 with Olaparib
45658694|NCT05369494|Other|Hydrolyzed protein infant formula with oligosaccharides|Hydrolyzed protein infant formula with oligosaccharides
45811073|NCT05474508|Other|Diaphragmatic breathing|Exercise programs will consist of 1 set of contractions per day and each set will include 30 repetitions for 6 weeks.
45811074|NCT05474508|Other|Aerobic exercises|Exercise protocol consist of at least 150 minutes of moderate-intensity aerobic activity every week dividing the 150 minutes into 30-minute workouts on 5 days of the week or into smaller 10-minute sessions throughout each day will be carried out for 6 weeks.
45811075|NCT02065362|Biological|DNR.NPC-specific T cells|"Each patient will receive 2 infusions, 14 days apart, according to the following dosing schedule:~Dose Level 1:~Day 0: 2 x 10^7 cells/m^2~Day 14: 2 x 10^7 cells/m^2~The doses are calculated according to the total T cell number."
45811076|NCT02065362|Biological|DNR.NPC-specific T cells + cyclophosphamide + fludarabine|"Patients will receive cyclophosphamide and fludarabine for 3 days before receiving the DNR.NPC-specific T cells.~Each patient will receive infusions according to the following dosing schedule:~Dose Level 2:~Cy/Flu on Days -4 to -2 and then 4 x 10^7 cells/m^2 on Day 0, Day 1 or Day 2~Dose Level 3:~Cy/Flu on Days -4 to -2 and then 1 x 10^8 cells/m^2 on Day 0, Day 1, or Day 2"
45948522|NCT00437164|Drug|Insulin|
45948523|NCT00437164|Drug|Oral GW677954 Capsules (15 mg)|
45948524|NCT00437242|Drug|Odiparcil|
45948525|NCT00437320|Procedure|Metvix PDT|Metvix PDT
45658695|NCT05367245|Drug|Cal-Mag Butyrate|Supplements
45658696|NCT05367245|Drug|Placebo|Only Cal-Mag but no Butyric acid
45658697|NCT05366400|Diagnostic Test|ECHO|Conventional routine tests and ECHO will be assessed. Biomarkers will be measured using ELISA The functional capacity was assessed by the COPD assessment test (CAT) questionnaire.
45676416|NCT03381326|Procedure|blood and FFPE sample collection|blood sample and Formalin-fixed paraffin-embedded (FFPE) sample collection
45948526|NCT00437320|Procedure|placebo|placebo
45948527|NCT00106496|Drug|Protopic|topical
45948528|NCT00106496|Drug|Corticosteroid|topical
45948529|NCT00106496|Drug|placebo|topical
45948530|NCT00437359|Drug|Toremifene citrate|Toremifene citrate: 40-mg tablets by mouth once daily.
45948531|NCT00437359|Drug|Anastrozole|Anastrozole: 1-mg tablets by mouth once daily.
45948532|NCT00437437|Drug|Brivanib|Tablet, Oral, Brivanib 800 mg, QD after single dose Pk comparison of food effect, until progression
45948533|NCT00437476|Drug|LPV/r|Lopinavir/Ritonavir 200/50 mg 2 cpr BID monotherapy - 26 weeks (A) or 24 weeks (B)
45948534|NCT00437476|Drug|Nucleoside Reverse Transcriptase Inhibitors|NRTIs for 26 weeks (A) or 24 weeks (B)
45948535|NCT00437476|Drug|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week (48 weeks)
45948536|NCT00437476|Drug|Ribavirin|Ribavirin 1-1.2 g/day (48 weeks)
45948537|NCT00106574|Drug|Placebo|iv every 4 weeks
45676417|NCT03354377|Behavioral|Dietary Intervention Meetings|Participants will attend classes once per week for the first 6 months, bi-weekly for the next 6 months; then once a month for the last 12 months.
45676418|NCT03354377|Behavioral|Physical Activity|Participants will be given the following exercise recommendations: strength training twice per week and ≥75 min of vigorous or ≥150 min of moderate PA per week and will be provided with accelerometers.
45676419|NCT03354377|Behavioral|Podcasts/Mailings|Participants with receive additional support delivered remotely months 13-24 in the form of audio podcasts and email newsletters.
45948538|NCT00106574|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
45948539|NCT02957383|Other|Wavelength|wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)
45948540|NCT02957383|Other|Intensity|Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2
45948541|NCT00437554|Drug|Glimepiride|
45658698|NCT05362435|Behavioral|Physical activity-based wellness programs|Each MKS+ program has 20-25 participants and consists of the following: 12 Week INTENSE PHASE: 1) pre-program information and orientation session, and data collection/testing; 2) core weekly programming with the following three components: a) 45-60 minute exercise class, b) 15-20 minute nutrition and wellness education, and c) 15-30 minute sharing circle; 3) end of program celebration; 4) urban poling sessions; 5) introduction to local healthcare providers as identified as relevant for the group; 6) ongoing online support via private Facebook group; 7) daily pedometer tracking to provide immediate motivational feedback to participants. 6-12 Week FOLLOW-UP PHASE: 1) Program Facilitator contacts participants weekly to encourage healthy activities, address concerns as needed, and record weekly step counts; 2) encourages continued engagement in private Facebook group; 3) 15-30 minute nutrition and wellness education, and c) 15-45 minute sharing circle.
45811077|NCT04789902|Other|SurgeCon|The SurgeCon intervention is a pragmatic ED management platform that includes three distinct intervention components which include 1) Restructuring ED Organization & Workflow, 2) Establishing a Patient-Centric ED Environment, and 3) E-Health Action-Based ED Management that together act to improve ED efficiency and patient satisfaction and value of care.
45948542|NCT00437593|Procedure|ppVE, MP, ICG|surgery with ILM staining
45948543|NCT00437593|Procedure|ppVE, MP, MB|Surgery with ERM staining
45811078|NCT02021604|Drug|Fluorodopa F 18|A dose of Fluorodopa F 18, 3-6 MBq/Kg (0.08-0.16 mCi/kg), will be injected intravenously into the subject under the direct supervision of the radiology sub-investigator. Then, the PET imaging procedure will begin and proceed for up to 70 minutes after injection. An abdominal CT image will be made using intravenous contrast. Both images, PET and CT, will be co-localized by the radiologist for interpretation.
45811079|NCT02016378|Behavioral|Bias retraining|Participants will view pictures of drug (e.g., alcohol) and non-drug stimuli (e.g., soft drinks) on a computer. Participants will then use the computer to make the drug pictures smaller and the non-drug pictures larger.
45811080|NCT02016378|Behavioral|Sham retraining|Participants will view pictures of drug and non-drug related stimuli on a computer. Participants will then use the computer to make the pictures larger or smaller based on the tilt of the picture (slightly to the left or right), but without regard to the content of the picture.
45811081|NCT04192968|Other|Cortical auditory evoked potentials|Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.
45811082|NCT04192968|Other|Additional exams|"Cortical auditory evoked potentials Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.~Recording of cortical auditory evoked potentials in response to a click~Realization of electrical potentials via the implant Followed up once a year during a visit scheduled for usual care, for 3 years, that to say up to 6 years post-implant."
45811083|NCT03518034|Drug|Testosterone|It will be administered topically.
45811084|NCT03518034|Drug|Placebo|A matching placebo to testosterone will be administered topically.
45811085|NCT03489252|Device|Monitoring Device|Wear Fitbit Charge 3
45811086|NCT04776798|Other|Taping|Tape applications will repeat twice per week, for 4 weeks.
45811087|NCT04789668|Drug|Bintrafusp Alfa|Given IV
45948544|NCT00437632|Drug|GSK598809|GSK598809 will be available as 5 and 25 mg capsules. Subjects will receive GSK598809 capsules orally with water.
45948545|NCT00437632|Drug|Placebo|Subjects will receive matching placebo capsules to GSK598809 orally with water.
45948546|NCT00437632|Drug|Caffeine|Caffeine 100 mg will be available as oral solution or tablet and subjects will receive Caffeine 100 mg orally on -1 day. On Day 35 caffeine and GSK598809 will be co-administered.
45948547|NCT00437671|Drug|Tetanus Immune Globulin (Human)|Based on package insert recommendation and recommendations of WHO
45948548|NCT00437671|Biological|Diphtheria-Tetanus Toxoids Adsorbed|Based on package insert recommendations and recommendations of WHO
45948549|NCT00437710|Procedure|cell therapy, bone marrow derived stem cell|
46076357|NCT02771886|Behavioral|Surf the Urge|"The intervention teaches clients to be aware of and accept their feelings, thoughts, and sensations in a non-judgmental manner. Clients learn to remain present within the moment, become aware of their urges, and focus on accepting thoughts and feelings rather than suppressing or changing them. It utilizes visual imagery to assist clients in utilizing more acceptance skills; the client imagines his urges as waves within the ocean and then imagines surfing the waves.~Some interventionists also provide psychoeducation. Clients learn that urges will not last forever; clients are also taught information about reinforcing urges. The interventionist explains that if clients do not reinforce urges (e.g., do not smoke when an urge to smoke arises) they will eventual subside; however, reinforcing urges (smoke when an urge to smoke arises) will produce stronger urges. Emphasis is placed on the belief that clients have the choice to refrain from engaging in urge-related behaviors."
46076358|NCT04246190|Drug|CKD-501 and D759|Reference drug, CKD-501 1T and D759 1T, QD, PO
45811088|NCT04789668|Drug|Pimasertib|Given PO
45811089|NCT04789668|Other|Quality-of-Life Assessment|Ancillary studies
45811090|NCT05180838|Device|BioSticker|The BioSticker is an FDA approved medical device which can be worn on the upper left chest for remote data capture and can provide for up 30 days of continuous vital sign monitoring
45811091|NCT05180058|Other|Wrapping + Breastmilk Group|Interventions applied during orogastric tube insertion
45811092|NCT05179824|Other|Observation|No Intervention
45811093|NCT04789278|Other|Notification|Notification of coronary calcium to the patient and their clinician
45948550|NCT00106613|Drug|FK228 (romidepsin)|Patients receive 13 mg/m2 of romidepsin (FK228) intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
45948551|NCT00437749|Drug|CBT-1|(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
45948552|NCT00437749|Other|Placebo|(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
45948553|NCT00437827|Other|Star*D algorithm|Standard of care based upon the therapies selected in the Star*D study.
45948554|NCT00437827|Other|rEEG-guided therapy|An rEEG report is based upon a process that utilizes a patient's drug-free QEEG to predict successful treatment strategies.
45948555|NCT00437905|Procedure|angioplasty|
45948556|NCT00401180|Drug|docetaxel|administered weekly in 5 escalating doses of 25 to 35 mg/ m(2) as a one-hour bolus intravenous infusion for 3 consecutive weeks.
45658699|NCT05358366|Behavioral|Infeccion de Amor (Love Infection)|"Love Infection is a filmed dramatized story (telenovela/soap opera) Infección de Amor (IA), or Love Infection - culturally tailored for US Latinas and delivered online. IA is a four-episode HIV prevention telenovela co-created with Latinas and a community-based participatory and interdisciplinary. Participants have one week window to watch the 10-minute episodes from their preferred device and location."
45658700|NCT05349487|Device|SpeakFree HME Hands Free Valve|A voice prosthesis, SpeakFree HME Hands Free Valve, achieved with creation of a tracheoesophageal puncture will be placed over the stoma for 1 month.
45453485|NCT01337726|Behavioral|Combined Psychotherapy and Illness Management|Participants will have 10 weekly visits with a study clinician at their home and by phone. They will focus on their self care and illness management as well as how to manage their mood/cope emotionally. Follow up assessments will occur at 26 and 52 weeks.
45453486|NCT01337726|Behavioral|Illness Management Only|Participants in this group will have 10 weekly sessions with a study clinician at home and by phone. They will focus only on how they manage their illness. Follow up assessments will occur at 26 and 52 weeks.
45658701|NCT05349487|Other|Digital Occlusion|Using participant's own fingers, they will be putting their fingers over the stoma.
45811094|NCT05178966|Behavioral|Bp OneDay psychoeducation program|"The BP One-Day Psychoeducation program is based on a single day of psychoeducation . This program was carried out by members of the bipolar expert center network in various hospitals of the network and included :~Representation of BD~Definition, diagnosis and awareness of the disorder~Depressive, hypo / manic symptoms~Vulnerability to BD causes of BD, risk factors for relapses~Drug treatments, drug compliance and non-drug treatments~Early detection of prodromal signs~Communication techniques~Each BP One-Day psychoeducation session welcomes an average of ten participants (5 patients / 5 caregivers). At the end of the day, participants receive a booklet containing the main information of the day.~BP One-Day program is delivered by a nurse and a psychologist specialized in both BD and therapy group facilitation. A specialized psychiatrist intervenes in the section Medication treatments and medication adherence for a period of approximately one hour."
45948557|NCT00401180|Drug|temozolomide|administered orally daily for 3 weeks (escalating doses of 75 to 100 mg/m(2)). Cycles were repeated at 4 week intervals.
45658702|NCT05349487|Device|Digital Depression HME|A digital handheld press-down HME will be placed over stoma.
45948558|NCT03278665|Drug|4SC-202 in combination with Pembrolizumab|4SC-202 in combination with Pembrolizumab
45658703|NCT05336188|Device|Smartphone|Adjunctive Smartphone app for improving MAT outcomes
45658704|NCT05335187|Device|micro-macro electrode implantation|One or a handful of micro-macro electrodes are implanted for 2-4 weeks in patients undergoing epilepsy monitoring with intracranial EEG electrodes.
45811095|NCT03231306|Drug|Binimetinib|Adult subjects (18 years and older) will receive binimetinib by mouth twice daily of 45mg/dose. Pediatric subjects (1-17 years of age) are being treated on the pediatric MTD established by a phase I study (NCT02285439).
45948559|NCT04701541|Device|Diaphragmatic Ultrasound|Diaphragmatic ultrasound is non-invasive, portable, quick to perform, with a linear relationship between diaphragmatic movement and inspired volume. In eligible patients, a preoperative baseline ultrasound evaluation of the diaphragm and lungs is accomplished. Evaluation will be performed by a single operator, blinded to the arterial blood gas analysis values. In a semi recumbent position, patients will be asked to rest and breath quietly. An anterior approach will be carried out applying freehand transducer on abdomen at the right midclavicular line immediately below the costal margin with firm pressure, steering in cranial direction. A B-mode transverse scanning will be performed looking across the liver with gallbladder in the middle. Measurements will be recorded by the M-mode frozen images. The M-mode modality will be used to study DIA. The best sinusoidal curve will be considered for measurements.
45453487|NCT05186246|Drug|Combination cream|Spent Grain Wax, Argan Oil, Shea Butter and Saccharide Isomerate Cream combination (10 gram), were applied on one side of the face twice daily by participants.
45453488|NCT05186246|Drug|Placebo cream|Cream that is identical looking were given to subjects to be applied on the other side of the face twice daily
45453489|NCT03158012|Biological|Autologous Microbial Transplant|Twice-daily application of Active or Placebo comparators to the right and left ventral arms of patients
45453490|NCT01337804|Drug|omeprazole/sodium bicarbonate|Single 20 mg dose of omeprazole/sodium bicarbonate powder for oral suspension
45453491|NCT01337804|Drug|omeprazole magnesium|Single 40 mg capsule of omeprazole given orally
45948560|NCT00401219|Drug|conjugated estrogens/progestin (MPA)|
45948561|NCT04701463|Dietary Supplement|L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate|2 daily sachets (mid morning and mid afternoon) of an oral dietary supplement with L-glutamine and L-arginine and calcium beta-hydroxy-beta-methylbutyrate
45948562|NCT04701463|Combination Product|Placebo|Isocaloric formula
45948563|NCT00438061|Behavioral|Weight loss by dietary restriction|
45811096|NCT05408754|Device|Atrial ablation for subject scheduled for a de novo endocardial ablation of symptomatic, drug-refractory PsAF.|Treatment will include the isolation of pulmonary veins (PVIs), and isolation of the left atrial posterior wall (PWI). A right atrial cavo-tricuspid line for bi-directional block may be performed at discretion and clinical judgment of the investigator
45811097|NCT04801524|Behavioral|Self-benefit|Participants will be reminded that the vaccine helps protect themselves from COVID.
45676420|NCT03338374|Device|Biventricular pacemaker|All subjects will receive a biventricular pacemaker at implantation. Programming will initially be to dual-chamber, dual-function rate-responsive pacing for 12 weeks; following reassessment, device will be reprogrammed to biventricular pacing for a further 12 weeks. Optional study extension: if incremental benefit is shown for biventricular pacing above dual chamber, the mechanism will be sought using echocardiographic evidence and the devices will be optimised according to this mechanism of action to see whether further benefit can be achieved.
45811098|NCT04801524|Behavioral|Prosocial-benefit|Participants will be reminded that the vaccine helps protect their family, friends, and community from COVID
45811099|NCT04801524|Behavioral|Early access|Participants will be reminded that they have early access to COVID-19 vaccine.
45811100|NCT04801524|Behavioral|Fresh start|Participants will be reminded that the vaccine offers the promise of a fresh start and chart a new path forward.
45948564|NCT00438139|Drug|Dronabinol|
45948565|NCT03279913|Device|EEG-neurofeedback training in association with TMS.|EEG-neurofeedback training in association with TMS.
46076359|NCT04246190|Drug|CKD-396|Reference drug, CKD-396 1T, QD, PO
45948566|NCT00438178|Drug|Obatoclax mesylate (GX15-070MS)|
46076360|NCT00609973|Drug|Ciprofloxacin|Ciprofloxacin 500 mg oral bid for 6 months
46076361|NCT00609973|Drug|Placebo|Placebo bid for 6 months
45811101|NCT05178342|Drug|CA-4948|"Patients will be treated orally with CA-4948 at 300 mg BID (2x200mg) over 4 cycles. One cycle consists of 28 days, 21 of which are treatment days, followed by 7 days off.~Patients with erythroid response (HI-E) after 4 cycles who tolerate CA-4948 may continue to receive CA-4948 until loss of HI-E response."
45811102|NCT04448886|Drug|Pembrolizumab|(iv) fixed dose, administered once per cycle
45811103|NCT04448886|Drug|Sacituzumab Govitecan|(iv) fixed dose, administered twice per cycle
45948567|NCT00438217|Drug|Triptorelin (GnRH agonists)|
45948568|NCT00438217|Drug|Leuprolide (GnRH agonists)|
46076362|NCT02767284|Device|UCST-V1|A previously developed device, Uppsala Contrast Sensitivity Tester - UCST-V1, that quickly measures the human CSF in one stimulus.
46076363|NCT02767284|Device|UCST-V2|A refined version of the UCST-V1 that randomizes frequency order.
46076364|NCT02767284|Device|UCST-V3|A version that utilises eye-tracking technology to make the measurements more accurate.
46076365|NCT02767284|Device|Quick-CSF (QCSF)|A fast contrast sensitivity measurement method using a Bayesian algorithm.
46076366|NCT02767284|Device|Pelli-Robson|A standard method developed using a Sloan-letter chart with decreasing contrast.
46076367|NCT02767284|Device|Optec 6500|A standard test using sinusoidal gratings to measure the contrast sensitivity function.
45811104|NCT05172882|Procedure|Wound site infiltration|Block fluids that were prepared as 20 ml 0.25% bupivacaine before the intervention, will be applied through the upper and lower incision lips on the suprainguinal surgical site.
45811105|NCT05172882|Procedure|Transversalis fascia plane block|External, internal oblique, and transversus abdominis muscles will be visualized by the ultrasound device. After transversalis fascia will be seen, transversalis fascia plane block will be performed. As a block fluid 20 ml 0.25% bupivacaine will be applied.
46076368|NCT04246424|Behavioral|Fibit + Coaching|This intervention is a combination of the coaching and fitbit interventions
46076369|NCT04246424|Behavioral|Coaching|"Coaching Participants who are assigned coaching group will receive telephone coaching. Coaches follow a guide developed by Kelly Glazer Baron, Jennifer Duffecy, Kathryn Reid, and Lauren Caccamo. The first session is an approximately 30 minute engagement session, with the purpose of getting to know the participant to increase likelihood for participation. The end goal is to have participants express Desire, Ability, Reason, Need, Can (DARN-C) to make changes in sleep). The remainder calls (week 2-6) are follow-up calls lasting about 5 minutes. The goal of these calls is to keep participants motivated and address any issues with the Fitbit hard or software.~Participants will also receive weekly email lessons to their personal email address for 1-6 weeks."
45676421|NCT03299166|Drug|Troriluzole|Troriluzole, 140 mg capsules once daily (QD) orally for the first 4 weeks and 200 mg (140 mg+ 60 mg capsules QD) for an additional 8 weeks
45676422|NCT03299166|Drug|Placebo|Matching capsule once daily (QD)
45948569|NCT03279835|Other|Classic evaluation of neurocognitive functions|Symbol Digit Modalities Test (SDMT)
45948570|NCT03279835|Other|New evaluation of neurocognitive functions|Cognitive Speed Computerized Test (CSCT)
45948571|NCT00438295|Procedure|temperature control|
45948572|NCT00438334|Device|Programmable directional/omni-directional hearing aid|
45948573|NCT03279757|Drug|AHES 5 minutes|Topical application of AHES with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
45948574|NCT03279757|Drug|AHES 15 minutes|Topical application of AHES with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
45948575|NCT03279757|Drug|AHES 25 minutes|Topical application of AHES with 25 minutes application time After 25 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
45948576|NCT03279757|Drug|LTC 5 minutes|Topical application of LTC with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
45658705|NCT05334420|Behavioral|Healthy Dads Healthy Kids|Group based lifestyle behavioral intervention for weight loss for fathers and increased physical activity for their child. The program meets weekly 90-minute sessions over 10 weeks. Mothers/partners are invited to one session (Week 4). Each meeting consisted of a brief review session with Dads and Kids together (15 minutes), separate break-out discussion for Dads (Dad's Club) and Kids (Kid's Club) (30 minutes); and a joint physical activity component for Dads and Kids (Sports Club) (45 minutes). Each week covers different topics for fathers and a corresponding session for kids. The program encourages fathers to be healthy, positive role models for their children, and teaching fathers weight loss strategies, authoritative parenting strategies and to encourage healthy behaviors in their kids. Fathers and kids are encouraged to eat healthy, reduce their screen time and be more active. If the COVID pandemic prevents in-person meetings, the program will be delivered virtually.
45453492|NCT05182736|Behavioral|TRAIL intervention|The TRAIL program is comprised of a multi-tier system of strategies: Universal strategies impact the entire school via a school-wide social norms marketing campaign and school-climate change activities. School staff trainings and professional development activities focus on enhancing protective factors for students to reduce the effects of stressful life events and trauma, improving classroom management, linking students to resources, and improving the overall school climate for students and staff. Targeted strategies include an in-school curriculum and service learning component, which impact all ninth grade students at the intervention high schools and all eighth grade students at the intervention middle schools. Intensive strategies are intended for a subset of youth and their caregivers with identified increased risk-factors, and they include peer mentoring, after-school running/positive youth development programming, summer programming, and parent workshop support.
45948577|NCT03279757|Drug|LTC 15 minutes|Topical application of LTC with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
45948578|NCT03279757|Drug|LTC 25 minutes|Topical application of LTC with 25 minutes application time After 25 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
45948579|NCT03279757|Device|fractional CO2 laser, 50 mJ, 5% density|Pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
45948580|NCT00438568|Drug|Regular Insulin|administered intra-nasally twice a day for 16 weeks
46076370|NCT04246424|Behavioral|Fitbit|Fitbit Participants in the fitbit group will receive a Fitbit Charge 3 black, and asked to wear it for 1-6 weeks. Participants will monitor their sleep through the sleep section in the Fitbit app on the smartphone. Participants will be provided login information so that researchers can access this data and asked to keep Bluetooth on. After week 6, participants can choose to continue to wear the device for the duration of the study (12 weeks). Though wear at weeks 7-12 is not required, researchers will still use any data that was collected from the fitbit during that time. At the completion of their participation, researchers retain the login information and the device is switched to a personal login of the participants choice.
46076371|NCT02541643|Drug|Elotuzumab|"Elotuzumab will be administered intravenously at a dose of 10mg/kg weekly (Days 1, 8, 15, and 22 of a 4-233k cycle) of the first 2 cycles and every 2 weeks (Day 1 and Day 15) thereafter.~A window of -1 to +3 days is permitted in Cycles 1 and 2. In Cycle 1 and 2, an elotuzumab dose that falls outside of the pre-specified window must be skipped. In Cycles 3 and beyond, elotuzumab dosing may be delayed for up to 1 week as clinically indicated. If unable to administer within 1 week, then the dose should be skipped and resumption of the elotuzumab continues per the guidance document defined schedule. In addition the following premedication must also be administered 30-90 minutes prior to any elotuzumab:~H1 blocker: diphenhydramine (25-50mg PO or IV) or equivalent~H2 blocker: ranitidine (50mg IV) or equivalent~acetaminophen (650-1000mg PO)"
46076372|NCT02773914|Other|Comprehensive Geriatric Assessment|Comprehensive Geriatric Assessment intervention
46076373|NCT02829398|Procedure|CerebroSpinal fluid and plasma samples|CerebroSpinal fluid and plasma samples for biological markers
46076374|NCT04717596|Other|BC4Teens Care|Healthcare providers will be trained in contraceptive counseling and provision.
46076375|NCT00888667|Other|Pacing interventions|10 seconds recording of atrial paced rhythm at 100 ppm in sitting 10 seconds recording of atrial paced rhythm at 150 ppm in supine 10 seconds recording of atrial paced rhythm at 150 ppm in sitting
45453493|NCT01776424|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Tablet, 2.5 mg, twice daily, oral
45658706|NCT05334420|Other|Standard of care control|Families will receive handouts on healthy eating, physical activity and screen media use to promote healthy weight status. Fathers will attend one group session with a focus on dietary changes and increased physical activity to promote healthy weight loss.
45948581|NCT00438568|Drug|Placebo|administered intra-nasally twice a day for 16 weeks
45948582|NCT00106769|Drug|VRC-WNVDNA017-00-VP|
45453494|NCT01776424|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Tablet, 5 mg, twice daily, oral
45948583|NCT00438607|Drug|BIIB014|oral administration of BIIB014 at dose to be specified from Part A, given daily for 8 weeks
45948584|NCT00438607|Drug|Placebo|Matched placebo for MTD or MTD-1
45948585|NCT00438685|Behavioral|Outpatient MST/OPTION-A|
45948586|NCT00438685|Behavioral|Usual Services|
45453495|NCT01776424|Drug|Aspirin|Tablet, 100 mg, once daily, oral
45948587|NCT00106847|Drug|Infliximab|
45948588|NCT00438724|Behavioral|Information, counseling and support|
45948589|NCT00106886|Drug|Folic acid, vitamin B6 and B12 or placebo|
45948590|NCT00438841|Drug|bortezomib|
45948591|NCT00438841|Drug|cyclophosphamide|
45948592|NCT00438841|Drug|dexamethasone|
45948593|NCT00438841|Drug|thalidomide|
45948594|NCT00438919|Device|drug-eluting stent|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
45948595|NCT00438958|Biological|filgrastim|Given on day 0.
45948596|NCT00438958|Procedure|allogeneic bone marrow transplantation|Given on day 0
45948597|NCT00438958|Procedure|peripheral blood stem cell transplantation|Given on day 0
45948598|NCT00107003|Drug|lapatinib ditosylate|
45948599|NCT00107003|Procedure|Adjuvant therapy|
45948600|NCT00107003|Procedure|Conventional surgery|
45658707|NCT05312008|Drug|Intranasal oxytocin|Initial dose 40 IU in 1 ml; 2 booster doses of 24 IU in 0.6 mls each, spaced about 1 hour apart
45948601|NCT00107003|Procedure|Neoadjuvant therapy|
46076376|NCT02771808|Other|biomarker samples|biomarker samples for haptoglobin genotype (RT-PCR) and phenotype (hemoglobin electrophoresis) general markers for oxidative stress (isoprostane f2 alpha, malondialdehyde) markers of inflammation (CRP, IL-1, 2, 6, 10 and TNF) markers of cardiac injury (CPK, troponins and BNP) markers of kidney injury (cystatin C, creatinine, GFR)
46076377|NCT04246268|Device|INVOcell|Female participants undergoing in vitro fertilization (IVF) and/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproduction will be asked to participate.
46076378|NCT00888745|Drug|placebo|Intravenous and subcutaneous ascending dose
46076379|NCT00888745|Drug|PRO283698|Intravenous and subcutaneous ascending dose
45658708|NCT05312008|Drug|Intranasal placebo|Initial volume 1 ml; 2 booster volumes of 0.6 mls each, spaced about 1 hour apart
45811106|NCT02666118|Procedure|Preemptive Interscalene Block - Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
45658709|NCT05307900|Other|Confirmation of feeding tube placement in critically ill patients|Confirmation of feeding tube placement using ultrasonography
45811107|NCT02666118|Procedure|Postoperative Interscalene Block- Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
45948602|NCT00439036|Behavioral|Behavior Therapy|The Act-ODT intervention will consist of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
45948603|NCT00439036|Behavioral|Drug Counseling|
46076380|NCT02833298|Behavioral|Automated reminders|At the time consent is obtained, members of the research team will collect data about how a subject prefers to be contacted for automated reminders (i.e. text messages, postcard, email, MyChart)
46076381|NCT02833298|Behavioral|Patient navigation|The patient navigator will attempt to provide a reminder to the subject one to three days before the scheduled imaging and also offer to accompany the subject to the test.
45658710|NCT05301556|Other|Experimental Product|"Before the surgery: FSMP provides daily target energy needed by participants~1-2 days after surgery: Start FSMP and advance as tolerated to achieve 20% of the daily target energy needed by participants~3rd-5th day after surgery: Gradually increase FSMP intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~6th to 11th day after surgery. FSMP provides daily target energy needed by participants"
45676423|NCT03286504|Behavioral|FANMI - Cohort Care|FANMI includes receiving integrated clinical care, group counseling, and social activities in a single session by the same provider to simplify care and strengthen relationships between peers and providers. FANMI groups consist of 5-10 adolescents meeting once per month.
45948604|NCT00439075|Procedure|CPAP|
45948605|NCT00439075|Drug|standard treatment|
45948606|NCT00439153|Device|Tourniquet instrument capable of measuring LOP in combination with tourniquet cuffs|See Detailed Description.
45948607|NCT00107081|Drug|ciprofloxacin and amoxicillin|
45948608|NCT00107081|Procedure|Outpatient management|
45948609|NCT00107081|Drug|i.v. antibiotics|
45948610|NCT00107081|Procedure|inpatient management|
45948611|NCT00439192|Drug|ELB245|
45811108|NCT02666118|Procedure|Preemptive Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
45948612|NCT00439192|Drug|Tolterodine|
45811109|NCT02666118|Procedure|Postoperative Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
45811110|NCT02635932|Device|Day Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the daily life activities.
45811111|NCT02635932|Device|Night Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the night.
45948613|NCT00439348|Behavioral|Verbal advice|Patients receive verbal advice regarding specific over-the-counter medications.
45948614|NCT00439348|Behavioral|Prescription|Patients receive a prescription for a specific over-the-counter medication.
45948615|NCT00107159|Biological|autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine|
45948616|NCT00439426|Drug|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
45948617|NCT00439426|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle
45948618|NCT00138138|Drug|Ritalin|
45453496|NCT01776424|Drug|Aspirin placebo|Aspirin matching placebo, once daily, oral
45658711|NCT05301556|Other|Control Product|"Before surgery: TPF-T provides daily target energy needed by participants~1-2 days after surgery: Start TPF-T and advance as tolerated to achieve 20% of the daily target energy needed by participants~3rd-5th day after surgery: Gradually increase TPF-T intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~6th to 11th day after surgery. TPF-T provides daily target energy needed by participants"
45658712|NCT05296252|Behavioral|mind-wandering intervention|"Participants in this condition receive a brief introduction to the potential impact of mind-wandering (before learning, proactive), and are redirected to lesson if probe-caught mind-wandering are endorsed (during learning, reactive)"
45811112|NCT05337774|Drug|[18F]PI-2620|The participant will be injected with 5 mCi (185 MBq) [18F]PI-2620 via a short line which will be placed in an intravenous line in an antecubital vein. Subjects will be placed in the scanner after injection and dynamic scans will be acquired for 0 to 60 minutes post injection.
45948619|NCT00439504|Drug|Lobeline|
45948620|NCT00439543|Drug|Iloprost inhalation|
45948621|NCT00439582|Dietary Supplement|vaccenic acid enriched milk fat (VAMF) [Transfact1]|
45948622|NCT00439582|Dietary Supplement|hydrogenated oil|Partially hydrogenated vegetable oils (PHVO) and vegetable oils and fats
45948623|NCT00439621|Biological|RP 01|Active immunotherapy
45948624|NCT00107237|Drug|AEE788|AEE788 was available in the form of a hard gelatin capsule of 50 mg or 100 mg strengths and packaged in bottles.
45948625|NCT00107237|Drug|everolimus|Everolimus was formulated as tablets of 2.5 mg and 5 mg strength and supplied in blister packs.
45453497|NCT01776424|Drug|Rivaroxaban placebo|Rivaroxaban matching placebo, twice daily, oral
45453498|NCT01776424|Drug|Pantoprazole|Tablet, 40 mg, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole
45658713|NCT05296252|Behavioral|mind-wandering comparison|Participants in this condition receive no introduction, and only redirection, and the redirection is random, not in reaction to mind-wandering
45948626|NCT00439660|Biological|Oral Rotavirus Vaccine 116E Live Attenuated|
45948627|NCT00142701|Behavioral|diet|
45948628|NCT00142701|Behavioral|physical activity|
45948629|NCT00142701|Behavioral|stress management|
45676424|NCT03251495|Drug|Vaxchora|Vaxchora is a live attenuated cholera vaccine that provides immunity against V. cholerae serogroup O1. Participants will receive one single oral dose of 100 mL.
45948630|NCT00142701|Behavioral|smoking cessation|
45948631|NCT00439699|Drug|Memantine|Mematine administration
45948632|NCT00439816|Behavioral|Group Visits|
45948633|NCT00439855|Drug|Enoxaparin i.v.|
45948634|NCT00439855|Drug|unfractionated heparin|
45948635|NCT00107354|Biological|aldesleukin|
45948636|NCT00107354|Biological|therapeutic allogeneic lymphocytes|
45948637|NCT00107354|Biological|therapeutic autologous lymphocytes|
45948638|NCT00107354|Drug|cytarabine|
45948639|NCT00107354|Drug|etoposide|
45948640|NCT00107354|Drug|mitoxantrone hydrochloride|
45811113|NCT05291988|Other|Educational Intervention|Receive S2S education
45811114|NCT05291988|Other|Fecal Immunochemical Test|Receive FIT kit
45811115|NCT05291988|Other|Questionnaire Administration|Ancillary Studies
45811116|NCT02508324|Biological|haplo-identical cells (donor)|Treatment: Haplo-identical healthy related donor. i.e. Parent, child, sibling, possibly third degree or further removed relative (cousin, aunt, nephew etc). They will be collected using standard methods and approximately 3 x10^6 CD34 cells/kg will be infused within 72 hours after completion of the treatment.
45811117|NCT02508324|Biological|umbilical cord blood unit (CBU)|Treatment: The CBU unit must supply a minimum of 0.5 x107/kg and a maximum of 2.5x107/kg nucleated cell dose pre-cryopreservation. The unit must match at a minimum of 4 of 6 at HLA-A, -B antigens, -DRB1 alleles with the recipient. Mismatches (0-2) can be at any loci -. Although molecular level typing will be available for the patient and the CBU unit, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1. The CBU donor will also have undergone HLA typing of the mother, thus allowing determination of the CBU-IPA and NIMA. CBU grafts used in this study will be investigational units that meet all criteria for clinical use. Better matching units will be preferred over less matching units as long as the CBU dose exceeds 0.5 x107 nucleated blood cells/kg
45811118|NCT02389218|Device|single ablation (CryoBalloonAblation (CBA)|Cryoablation at entry, after randomization to this group
45811119|NCT02389218|Drug|sequential drug adjustment (propafenone, sotalol or flecainide)|Correct drug dosage at entry, sequential adjustment / titration, in stage 2 amiodarone
45658714|NCT05281874|Behavioral|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. It targets alcohol, sexual assault victimization risk, sexual assault perpetration, and bystander intervention. It is tailored by gender and sexual orientation.
45658715|NCT05281874|Behavioral|A healthy lifestyles attention control|A healthy lifestyles attention control will be used as the control condition. We will match the control and intervention conditions on content (text, pictures, number of pages); type (interactive vs. psychoeducation); and average completion time.
45658716|NCT05281874|Behavioral|Positive Change (+Change) Plus Booster|Positive Change (+Change) Plus Booster
45658717|NCT05280639|Device|Wooden block|Individuals randomized to this group will be given a wooden block at no cost to them and a simplified version of home, self-guided exercises with instructions on how to do the exercises and how often to do so.
45658718|NCT05280639|Other|Formal physical therapy or Home Exercise Program|Individuals randomized to this group will receive the standard formal physical therapy which are sessions run by a physical therapist, usually 2-3 times a week to rehabilitate their ankle OR follow a standardized home exercise program which will be done by yourself with exercise outlined with how they should be performed and how often
45658719|NCT05268276|Other|1-perineal ice-gel pad application|For the study group Immediately after delivery (within 30 minutes to one hour after delivery), an ice gel pad will be applied to perineal trauma. each gel pad will have fixed standardized diameter (an approximately 5 cm width, 23 cm length, and 1.5 cm thickness) and approved by Egyptian ministry of health. It will be kept in the freezer for 45-60 minutes and will be removed when frozen. Then, it will be wrapped in a sterile pad and applied to cover the perineum and anal region.The investigator will provide a clear and concise information through oral and written instructions about the following; 1) The ice gel pad's purpose, benefits, anticipated effects and how to apply it, 2) Apply the ice gel pad on perineum after birth within 30 minutes to an hour, 3) Instruct the women to apply the ice gel pad for about 20 minutes every two hours during the first 24 hours postpartum only
45676425|NCT03239132|Behavioral|Breath-based meditation|The experimental group will receive 4 group sessions of breath-based meditation over 4 weeks.
45676426|NCT03239132|Behavioral|Meditation educational materials|Meditation educational materials
45676427|NCT03234478|Other|cognitive assessments|Cognitive assessments will be performed at baseline, 1 year, and 2 years, depending on subject cohort placement
45811120|NCT02381886|Drug|IDH305|
45811121|NCT01953120|Drug|Belatacept|Subjects will receive intravenous belatacept at 5mg/kg every other week starting from day 1 and continuing with weeks 2, 4, 6, and 8, and then monthly at months 3, 4, 5, and 6. At month 6 patients may elect to continue for an additional six-month period of belatacept administration.
45453499|NCT01776424|Drug|Pantoprazole placebo|Pantoprazole matching placebo, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole placebo
45453500|NCT00642148|Drug|GW856553|Active tablet
45811122|NCT05343858|Dietary Supplement|Experimental: Group 1: Spirulina platensis|16 g/day (two doses of 8g)
45811123|NCT05343858|Dietary Supplement|Experimental: Group 2: Chlorella vulgaris|16 g/day (two doses of 8g)
45811124|NCT05343858|Dietary Supplement|Placebo Comparator: Group 3: Control|16 g/day (two doses of 8g)
45811125|NCT01634100|Drug|Probenecid|Probenecid
45811126|NCT01634100|Drug|Rifampicin|Rifampicin
45811127|NCT01634100|Drug|Empagliflozin|BI Drug
45811128|NCT01634100|Drug|Empagliflozin|BI Drug
45811129|NCT01634100|Drug|Rifampicin|Rifampicin
45811130|NCT01634100|Drug|Probenecid|Probenecid
45811131|NCT01634100|Drug|Empagliflozin (BI 10773)|BI Drug
45453501|NCT00642148|Drug|Placebo|Placebo tablet and inhaler
45453502|NCT00642148|Drug|Seretide|Active comparator inhaler
45811132|NCT03662659|Biological|BMS-986213|Relatlimab + Nivolumab specified dose on specified days
45811133|NCT03662659|Biological|Nivolumab|Specified dose on specified days
45811134|NCT03662659|Drug|XELOX|Oxaliplatin + capecitabine
45948641|NCT00107354|Procedure|allogeneic bone marrow transplantation|
45948642|NCT00107354|Procedure|peripheral blood stem cell transplantation|
45948643|NCT00439894|Procedure|Blood draw|blood draw at baseline, week 12 and week 24
45948644|NCT00138177|Drug|oxaliplatin|Given IV
45948645|NCT00138177|Drug|leucovorin calcium|Given IV
45453503|NCT00767416|Biological|MEDI-559|Cohort 1 (5 to <24 months): N=80 MEDI-559 at 10^5 FFU at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains 10^5 FFU MEDI-559 in a sucrose phosphate glutamate buffer.
45948646|NCT00138177|Drug|vorinostat|Given orally
45948647|NCT00138177|Drug|fluorouracil|Given IV
45658720|NCT05268276|Other|2-performance of pelvic floor exercises (Kegel exercises)|women will receive instructions to practice pelvic floor exercises (Kegel exercises) and will be asked to perform these exercises from 6 hours postpartum and continue at home till one week. Before applying the technique, the investigator will teach the women how to recognize the accurate muscle, whereby she imagines holding passing gases or trying to stop the flow of urine midstream at the same time. The women will be taught to insert a clean finger into the vagina before practicing the exercises and if the women feeling pressure around her finger, she is on the right track, . The investigator will perform vaginal examination while the woman is doing the pelvic floor exercises (Kegel exercises) to ensure correct use of muscles. The investigator will instruct the women to continue contracting the muscles for about 5 seconds and then to loosen them for 5 seconds and repeat it for five times each set, perform at least five sets per day
45948648|NCT04701229|Genetic|somatic cytogenetic and genetic characterization|investigating the presence of some genes allelles (RBM22, SLU7, RBM27, other on chromosome 5) by FISH, and sequencing of a classical panel of myeloid genes including RBM22, SLU7, for somatic identification of genetic alterationss of the blasts.
45948649|NCT03279601|Drug|Capecitabine, Dacarbazine|Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W
45948650|NCT03279601|Drug|Capecitabine, Temozolomide|Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o. bid d10-14 q4W,
46076382|NCT02771652|Behavioral|e-training|The e-training intervention is a home-based aerobic and resistance training program. Resistance training was prescribed twice weekly for a period of 12 weeks. No special equipment was necessary except an elastic exercise band or a large gymnastic ball. In addition, endurance training was to be carried out once a week. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. The form of activity for the endurance training was freely selected, duration (between 10-60 min) was adjusted to individual fitness levels. Therapists aimed at eliciting a BORG Feedback of between 11 (fairly light) and 16 (hard). The exercise training was home-based and supervised via the internet. Participants continued exercise training for another 12 weeks after the 3month assessment.
46076383|NCT02771652|Other|Control|After the initial assessment on entry, those assigned to the control group were instructed to maintain their previous physical activity behaviour. After waiting three months, they received the same e-training intervention as the intervention group had received from the start.
45811135|NCT03662659|Drug|FOLFOX|Oxaliplatin + leucovorin + fluorouracil
45811136|NCT03662659|Drug|SOX|Oxaliplatin + tegafur/gimeracil/oteracil potassium
45811137|NCT05226156|Behavioral|Digitally delivered exercise and education treatment Joint Academy|The Joint Academy® (www.jointacademy.com) program for people with LBP consists of video instructed and progressively adaptable daily exercises, patient education through text lessons and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period. The program also contains three telephone consultations with a physiotherapist that were compulsory, one at the start, one after six weeks and one after three month.
45811138|NCT03661645|Drug|10 mg IV dexamethasone & 6 day oral methylprednisolone taper|"Drug: 6-day oral methylprednisolone (glucocorticoid) taper course The oral methylprednisolone taper course will begin on the day of surgery and will include 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day.~Drug:10 mg intravenous (IV) dexamethasone"
45811139|NCT03661645|Other|10 mg IV dexamethasone|Drug:10 mg intravenous (IV) dexamethasone
45811140|NCT01633944|Drug|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 75-600 mcg twice daily
45811141|NCT01633944|Drug|Placebo|Matching Placebo Buccal Film twice daily
45948651|NCT00107393|Biological|trastuzumab|
45948652|NCT00107393|Drug|capecitabine|
45948653|NCT00138216|Drug|irinotecan hydrochloride|
45948654|NCT00138216|Drug|temozolomide|
45948655|NCT00138216|Drug|vincristine sulfate|
45948656|NCT00105586|Drug|Escitalopram|Participants will either take 10 to 20 mg of escitalopram or placebo. Participants who wish to participate in the open-label extension receive an additional 12 weeks of escitalopram.
46076384|NCT02696694|Other|Progesterone 25-75|Impact of serum progesterone concentrations [25-75] on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
45948657|NCT00439933|Behavioral|low fat and polysaccharide rich diet|
45948658|NCT00439933|Behavioral|specific physical training program for obese children|
45453504|NCT00767416|Other|Placebo|Cohort 1 (5 to < 24 months); N = 80 placebo at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains sucrose phosphate buffer.
45948659|NCT00107432|Drug|sorafenib tosylate|Given orally
45948660|NCT00107432|Other|laboratory biomarker analysis|Correlative studies
45948661|NCT00439972|Drug|Ortho-Cyclen (R)|The first 21 tablets contain 35 micrograms ethinyl-estradiol and 250 micrograms norgestimate per tablet. The last 7 tablets contain no hormones. Ortho Cyclen (R) is taken for 1-2 months during the screening phase and for 2 months during the treatment phase of the study.
45658721|NCT05268276|Other|3- perineal warm compresses application|women will be instructed to apply warm compresses on perineal trauma 48 hours postpartum at home. This will be done by using a clean pad soaked in warm water and squeezed to remove excess water then placed gently on the perineum, the warm compresses will be applied for 15 minutes three times per day (every 8 hours), and water in the bowl will be replaced with every application. Women will be asked to apply warm compresses on perineal trauma from 48 hours postpartum till one week.
45658722|NCT05456880|Biological|BEAM-101|Single dose of BEAM-101 administered by IV following myeloablative conditioning with busulfan
45948662|NCT00439972|Drug|Ortho Evra (R)|Ortho-Evra® contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule is to apply one patch each week for 3 weeks and no patch the 4th week. Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
45948663|NCT00439972|Drug|extended use of Ortho Evra (R)|The extended use regimen of Ortho Evra (R) contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule for Ortho-Evra (R) is to apply one patch each week for 7 weeks and no patch the 8th week. Extended use Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
45658723|NCT05265546|Drug|Psilocybin|The effects of different doses of psilocybin (0 - 14 mg) will be compared.
45811142|NCT04598893|Biological|Teplizumab|Received teplizumab in PROTECT Study
45811143|NCT04598893|Other|Placebo|Received placebo in PROTECT study
45811144|NCT04592419|Drug|KSI-301|Intravitreal Injection
45811145|NCT04592419|Drug|Aflibercept|Intravitreal Injection
45811146|NCT04592419|Other|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
45658724|NCT05251324|Other|Hot Flush Induction|A temperature-controlled, water-circulating heating pad at a constant temperature of 107˚F will be placed on the participant's torso, a microwaved heating neck pad will be placed on the participant's neck, and two warm balloons will be placed in the participant's hands for 30 min. Subjective (verbal start and end point to be marked on LabChart software) and objective (skin conductance and skin temperature) measures of hot flushes will be recorded.
46076385|NCT02696694|Other|Progesterone <25, >75|Impact of serum progesterone concentrations (<25, >75) on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
46076386|NCT05323682|Other|Individualized physical exercise program|An individualized physical exercise program was programmed, monitored remotely by e-mail or the use of an activity wristband
45658725|NCT05246670|Drug|Palmidrol|Given PEA PO
45811147|NCT00589316|Procedure|Allogeneic Bone Marrow Transplantation|Given via central line
45658726|NCT05246670|Drug|Placebo Administration|Given PO
45948664|NCT00440089|Behavioral|Hands-on-Healing|
45948665|NCT00440128|Drug|Docetaxel|Docetaxel
45948666|NCT00440128|Drug|Casopitant/Docetaxel|Casopitant/Docetaxel
46076387|NCT05323682|Other|NO Individualized physical exercise program|Usual medication
46076388|NCT00886093|Drug|PF-04447943|35 mg tablet of PF-04447943 taken in the fed state in Period 1 followed a week later by administration of the same tablet and dose taken in the fasted state in Period 2
45948667|NCT00440167|Drug|Gemcitabine|Gemcitabine 1000 mg/m², d 1, 8 , 15, q d28
46076389|NCT00886093|Drug|PF-04447943|35 mg tablet of PF-04447943 taken in the fasted state in Period 1 followed a week later by administration of the same tablet and dose in the fed state in Period 2.
46076390|NCT02773680|Device|"electrical impedance tomography"|One continous electrical impedance tomography (EIT) measurement per subject of approximately 5 minutes duration (2 min prior to MDCT scanning, during end-inspiratory MDCT acquisition and 2 min after MDCT scanning)
45658727|NCT05246670|Other|Quality-of-Life Assessment|Ancillary studies
45658728|NCT05242432|Biological|Ad26/protein preF RSV Vaccine|Ad26/protein preF RSV vaccine will be administered as an IM injection.
45658729|NCT05242432|Other|Placebo|Matching Placebo will be administered as an IM injection
45453505|NCT00629980|Drug|AzaSite®|ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for ~26 days
45658730|NCT05238883|Drug|HFB200301|Participants will be administered HFB200301 as described in the experimental arm.
45658731|NCT05238883|Drug|Tislelizumab|Participants will be administered tislelizumab as described in the experimental arm.
45658732|NCT05227742|Drug|Psilocybin|Participants will receive oral psilocybin once per week for 5 weeks.
45658733|NCT05227742|Drug|Placebo|Participants will receive inert placebo once per week for 5 weeks.
45676428|NCT03226249|Procedure|Computed Tomography|Undergo FDG-PET/CT
45811148|NCT00589316|Drug|Cyclophosphamide|Given IV
45811149|NCT00589316|Drug|Fludarabine Phosphate|Given IV
45811150|NCT00589316|Radiation|Iodine I 131 Monoclonal Antibody BC8|Given IV (dosimetry dose) or via central line (therapeutic dose)
45811151|NCT00589316|Other|Laboratory Biomarker Analysis|Correlative studies
45811152|NCT00589316|Drug|Mycophenolate Mofetil|Given IV or PO
45811153|NCT00589316|Drug|Tacrolimus|Given IV or PO
45811154|NCT00589316|Radiation|Total-Body Irradiation|Undergo TBI
45811155|NCT01633788|Drug|AGN-195263 0.1%|1 drop of AGN-195263 0.1% instilled in each eye twice daily.
45811156|NCT01633788|Drug|AGN-195263 0.03%|1 drop of AGN-195263 0.03% instilled in each eye twice daily.
45811157|NCT01633788|Drug|AGN-195263 0.01%|1 drop of AGN-195263 0.01% instilled in each eye twice daily.
45948668|NCT00440167|Drug|Capecitabine|"Capecitabine 2 x 1000 mg/m²/ d oral, d 1 - 14 followed by 7 days Pause (Flat Dosing)"
45948669|NCT00440167|Drug|Erlotinib|Erlotinib 150 mg/d oral, daily without break
45948670|NCT00107471|Biological|filgrastim|Given PO
45948671|NCT00107471|Drug|topotecan hydrochloride|Given IV
45948672|NCT00107471|Radiation|radiation therapy|
45948673|NCT00404157|Drug|Rituximab|
45811158|NCT01633788|Drug|AGN-195263 Vehicle|1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
45811159|NCT04263493|Other|Rehabilitation (physiotheraphy)|Time of loading, range of motion exercises, strength training
45948674|NCT02957266|Radiation|Volumetric Arc Radiotherapy|Volumetric Arc Radiotherapy
45658734|NCT05227430|Other|Educational video tutorials|Educational video tutorials (Hysterectomy, Bilateral salpingo-oophorectomy, Bilateral salpingectomy)
45811160|NCT04786860|Procedure|CPR|Cardiopulmonary resuscitation performed on patients with in-hospital cardiac arrest
45811161|NCT02032524|Drug|GZ402666|Pharmaceutical form: lyophilized powder reconstituted for infusion Route of administration: intravenous
45811162|NCT01946100|Genetic|Multifocal Lung Adenocarcinoma|Tissue collection at the time of surgery for genetic testing and blood sample for germ line DNA.
46076391|NCT04038073|Diagnostic Test|Antistreptolysin O Test|Test to evaluate of any histories of streptococcal infections
45811163|NCT00362245|Drug|Systemic and Intra-Thecal Amikacin Therapy|
46076392|NCT04038073|Diagnostic Test|Anti-Deoxyribonuclease B|Test to evaluate of any histories of streptococcal infections
45811164|NCT04786548|Drug|Celecoxib|Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks.
45811165|NCT04245397|Drug|SX-682|Drug: SX-682 SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)
46076393|NCT04038073|Diagnostic Test|TLR, MyD88, IRAK-4 polymorphism|Test to evaluate of the frequency and types of genetic alterations of innate immunity
45658735|NCT05225922|Behavioral|Communication Partner Training|This intervention aims to improve the language, communication, participation and overall quality of life of the Person with Aphasia.
45811166|NCT04786080|Behavioral|Parent Positive|"Parent Positive is a smartphone app delivering information and parenting support aiming to improve wellbeing within the family and reduce pressures on services given the ongoing pandemic-related challenges. It will consist of three zones, providing:~structured advice, support and tips for parents~facilitated parent-to-parent communication platform where parents can post questions of one another and parenting experts~access to carefully selected high-quality, evidence-based online parenting resources."
45811167|NCT00361543|Drug|Raloxifene hydrochloride|120 mg per capsule (1 tablet daily)
45811168|NCT00361543|Other|Lactose Capsules|1 tablet daily for 12 weeks
45811169|NCT00003417|Drug|carmustine|
45811170|NCT00003417|Radiation|radiation therapy|
45811171|NCT04329429|Drug|RC48-ADC|The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.5 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first)
45811172|NCT00003267|Procedure|infection prophylaxis and management|
45811173|NCT00003267|Procedure|management of therapy complications|
45811174|NCT00003267|Procedure|surgical procedure|
45811175|NCT00003423|Drug|asparaginase|
45811176|NCT00003423|Drug|cyclophosphamide|
46076394|NCT04038073|Diagnostic Test|Anti-Basal Ganglia Antibody|Test to evaluate the autoimmune component
45658736|NCT05225922|Other|Usual Speech and language Therapy|This group will receive usual speech and language therapy session.
45658737|NCT05220982|Behavioral|Conversation Training Therapy|Training clear speech in conversation with new vs old voice. Training will occur over four weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
45676429|NCT03226249|Drug|Dacarbazine|Given IV
45676430|NCT03226249|Drug|Doxorubicin Hydrochloride|Given IV
45676431|NCT03226249|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET/CT
45676432|NCT03226249|Other|Laboratory Biomarker Analysis|Correlative studies
45811177|NCT00003423|Drug|cytarabine|
45811178|NCT00003423|Drug|daunorubicin hydrochloride|
45811179|NCT00003423|Drug|dexamethasone|
45811180|NCT00003423|Drug|etoposide|
45811181|NCT00003423|Drug|mercaptopurine|
45811182|NCT00003423|Drug|methotrexate|
45811183|NCT00003423|Drug|prednisolone|
45811184|NCT00003423|Drug|thioguanine|
45948675|NCT02957266|Radiation|Interstitial brachytherapy|Interstitial High Dose Rate Brachytherapy
45948676|NCT02957266|Drug|Cisplatin|Weekly Cisplatin
45948677|NCT02957266|Drug|Gemcitabine|Weekly Gemcitabine
45948678|NCT02957266|Genetic|PIK3CA|PIK3CA mutations rate
45948679|NCT02957266|Genetic|KRAS|KRAS mutations rate
45948680|NCT02957266|Genetic|BRAF|BRAF mutations rate
45948681|NCT02957266|Genetic|RRM1|RRM1 mutations rate
45948682|NCT03279562|Drug|Nalmefene|Educational and behaviorally oriented drug counseling
46076395|NCT05323526|Diagnostic Test|Catquest-9SF questionnaire|Patients complete the questionnaire preoperatively and postoperatively.
45658738|NCT05220982|Behavioral|Global Voice Prevention and Therapy Model|Training of four new voices (i.e., resonant voice in connected speech, falsetto for quiet talking, oral twang for talking over noise, and belt for healthy yelling) defined and trained by the anatomy and physiology of the system (i.e., Estill Voice Training's Figures). Training occurs in a bottom-up speech hierarchy with new vs other or old voice at each step. Additional methods are used in asynchronous telepractice to support the new voices during week 1 (e.g., vocal hygiene and education). Training will occur over three weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
45811185|NCT00003423|Drug|vincristine sulfate|
45811186|NCT00003273|Biological|filgrastim|
45811187|NCT00003273|Drug|carboplatin|
45811188|NCT00003273|Drug|cisplatin|
45811189|NCT00003273|Drug|cyclophosphamide|
45811190|NCT00003273|Drug|etoposide|
45811191|NCT00003273|Drug|leucovorin calcium|
45948683|NCT03279523|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
45453506|NCT00629590|Drug|AzaSite®|ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for ~12 days
45658739|NCT05220982|Behavioral|Modified Conversation Training Therapy|Training clear speech in conversation with no use of new vs old voice. Training will occur over four weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
45811192|NCT00003273|Drug|methotrexate|
45811193|NCT00003273|Drug|temozolomide|
45811194|NCT00003273|Drug|thiotepa|
45811195|NCT00003273|Drug|vincristine sulfate|
45811196|NCT00003273|Procedure|autologous bone marrow transplantation|
45948684|NCT00404196|Drug|Calcipotriol and LEO80122 (LEO19123 cream)|
45948685|NCT00107510|Biological|pegfilgrastim|
45948686|NCT00107510|Drug|carboplatin|
45453507|NCT00766324|Drug|PHA-739358|6-hr IV infusion weekly for 3 consecutive weeks in a 4-week cycle
45453508|NCT00766324|Drug|PHA-739358|24-hr IV infusion every 2 weeks in a 4-week cycle
45676433|NCT03226249|Biological|Pembrolizumab|Given IV
45676434|NCT03226249|Procedure|Positron Emission Tomography|Undergo FDG-PET/CT
45676435|NCT03226249|Drug|Vinblastine Sulfate|Given IV
45676436|NCT03184155|Drug|Nicardipine|200 mcg intracoronary nicardipine injection prior to PCI followed by an additional 2-4 doses of 100 mcg intracoronary nicardipine depending on complexity of PCI
45811197|NCT00003273|Procedure|peripheral blood stem cell transplantation|
45811198|NCT00003273|Radiation|radiation therapy|
45811199|NCT04329585|Drug|flumazenil|EEG is observed in both groups to compare the difference between two groups.
45811200|NCT04329585|Drug|Placebos|Placebo is the normal saline, which is given in the controlled group.
45811201|NCT00003279|Biological|BCG vaccine|
45811202|NCT00003279|Biological|monoclonal antibody BEC2|
45811203|NCT00383487|Drug|Calcitriol|0.5 micrograms/kilogram q weekly
45811204|NCT00383487|Drug|Naproxen-n-butyl nitrate|400 mg BID, oral
45811205|NCT00003429|Procedure|biopsy|
45811206|NCT00003429|Procedure|computed tomography|
45811207|NCT00003429|Procedure|positron emission tomography|
45811208|NCT00003429|Radiation|fludeoxyglucose F 18|
45811209|NCT00003435|Biological|anti-thymocyte globulin|
45811210|NCT00003435|Drug|melphalan|
45811211|NCT00003435|Procedure|antiviral therapy|
45811212|NCT00003435|Procedure|bone marrow ablation with stem cell support|
45811213|NCT00003435|Procedure|peripheral blood stem cell transplantation|
45811214|NCT00003435|Procedure|umbilical cord blood transplantation|
45811215|NCT00003435|Radiation|radiation therapy|
45811216|NCT00003291|Genetic|cytogenetic analysis|
45811217|NCT00003291|Genetic|mutation analysis|
45811218|NCT00003291|Other|laboratory biomarker analysis|
45811219|NCT00003441|Drug|Irofulven (MGI-114)|IV over 5 minutes daily for 5 consecutive days. Courses repeated every 28 days. Minimum treatment period is 2 courses.
45811220|NCT00002805|Biological|filgrastim|
45811221|NCT00002805|Drug|cladribine|
45948687|NCT00107510|Drug|docetaxel|
45948688|NCT00107510|Procedure|conventional surgery|
45948689|NCT02957110|Behavioral|Laughter Frequency|Relationships between laughter frequency, momentary mood state, and pain will be observed.
45948690|NCT00440245|Drug|salbutamol|200 micrograms salbutamol from MDI
45948691|NCT00440284|Drug|conventional vs. flexible, intensive insulin therapy|
45948692|NCT00142779|Drug|Fluoxetine|
45948693|NCT00440323|Drug|SB-649868|SB-649868 tablets will be available with dose strength of 5 and 25 mg.
45948694|NCT00440323|Drug|Zolpidem|Zolpidem capsules will be available with dose strength of 10 mg.
45948695|NCT00440323|Drug|Placebo|Placebo tablet matching SB-649868 or Placebo capsule matching Zolpidem will be available.
45948696|NCT00440362|Biological|AVX502|1 dose at 2e8 IU given at t=0 via IM route
45948697|NCT00440362|Biological|AVX502|1 dose at 2e7 IU given at T=0 via the IM route
45811222|NCT00002805|Drug|cytarabine|
45948698|NCT00440362|Biological|AVX502|1 dose at 2e7 IU given at t=0 via the SC route
45948699|NCT00440362|Biological|AVX502|1 dose at 2e8 IU given at T=0 via the SC route
46076396|NCT05323526|Diagnostic Test|Demographics and clinical parameters|The following clinical parameters are evaluated: age, gender, ocular and systemic comorbidities, educational level, preoperative and postoperative monocular distance uncorrected visual acuity (UVA), distance best spectacle-corrected visual acuity (BSCVA) of the eye for cataract surgery, binocular distance UVA and BSCVA, refraction, spherical equivalent (SE), and intraocular pressure.
46076397|NCT04739592|Drug|alendronate sodium vitamin D3 tablets|once per week for one year
45658740|NCT05220982|Behavioral|Modified Global Voice Prevention and Therapy Model|Training of a new resonant voice in connected speech defined and trained by the anatomy and physiology of the system (i.e., Estill Voice Training's Figures). Training occurs in a bottom-up speech hierarchy with no use of new vs old voice. Additional methods are used in asynchronous telepractice to support the new voices during week 1 (e.g., vocal hygiene and education). Training will occur over three weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
45676437|NCT03184155|Drug|Sterile Saline|Bolus of intracoronary sterile saline injection prior to PCI followed by an additional 2-4 doses of sterile saline depending on complexity of PCI
45676438|NCT03175432|Drug|Atezolizumab|Given IV
46076398|NCT04739592|Drug|Placebo|once per week for one year
45676439|NCT03175432|Biological|Bevacizumab|Given IV
45676440|NCT03175432|Drug|Cobimetinib|Given PO
45676441|NCT03175432|Procedure|Quality-of-Life Assessment|Ancillary studies
45811223|NCT00002805|Drug|etoposide|
45811224|NCT00002805|Drug|methotrexate|
45811225|NCT00002805|Drug|mitoxantrone hydrochloride|
45811226|NCT00002805|Drug|therapeutic hydrocortisone|
45811227|NCT00002805|Procedure|allogeneic bone marrow transplantation|
45811228|NCT00002805|Procedure|autologous bone marrow transplantation|
45811229|NCT00002805|Procedure|peripheral blood stem cell transplantation|
45811230|NCT00002805|Radiation|low-LET cobalt-60 gamma ray therapy|
45811231|NCT00002805|Radiation|low-LET electron therapy|
45811232|NCT00002805|Radiation|low-LET photon therapy|
45811233|NCT00003297|Drug|mitoxantrone hydrochloride|
45811234|NCT00003297|Drug|thiotepa|
45948700|NCT00440362|Biological|AVX502|2 doses at 2e7 IU given at T=0 and 8 weeks via the IM route
45948701|NCT00440362|Biological|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the IM route
45948702|NCT00440362|Biological|AVX502|2 doses of 2e7 IU given at t=0 and 8 weeks via the SC route
45948703|NCT00440362|Biological|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the SC route
45948704|NCT00440362|Biological|Placebo|1 dose of placebo given at T=0 via the IM route
45948705|NCT00440362|Biological|Placebo|1 dose of placebo given at T=0 via the SC route
45948706|NCT00440362|Biological|Placebo|2 doses of placebo given at T=0 and 8 weeks via the IM route
46076399|NCT00888823|Radiation|Stereotactic Radiotherapy|Stereotactic Radiotherapy
46076400|NCT00633386|Drug|Celecoxib|400 mg oral capsule as a single dose 1 hour prior to surgery and 200 mg oral capsule as a single dose as needed post-surgery
46076401|NCT00633386|Other|Placebo|Matched placebo
45948707|NCT00440362|Biological|Placebo|2 doses of placebo given at T=0 and 8 weeks via the SC route
45658741|NCT05213923|Procedure|ED Sepsis Tracking Sheet|Implementation of an ED Sepsis Tracking Sheet. This sheet will track time of patient presentation, time of High-Acuity Medical Response (HAMR) page, time of bilateral 18g or larger IV access, time of initial lactate, time two sets of blood cultures were sent, time antibiotics were administered as well as which antibiotics and what dose, time initial IV fluid bolus was completed, time repeat lactate was sent, timing of post-IV-fluid bolus vital signs, as well as the presence of persistent hypotension following this IV fluid bolus and whether or not vasopressors were applied.
45948708|NCT00107549|Biological|rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)])|Recombinant experimental therapeutic vaccine using the modified vaccinia Ankara vector given at study entry and Week 4
45948709|NCT00107549|Biological|rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])|Recombinant experimental therapeutic vaccine using fowlpox vector given at Weeks 8 and 24
45948710|NCT00440440|Drug|Testosterone gel|Testosterone gel to be applied daily, starting does 5g.
45948711|NCT00440440|Drug|placebo|placebo gel apply daily
45811235|NCT00003297|Drug|topotecan hydrochloride|
45948712|NCT00142896|Drug|Tramadol|
45658742|NCT05209243|Radiation|SBRT|SBRT (all metastatic lesions)
45948713|NCT00142896|Drug|Naloxone|
45948714|NCT00142896|Drug|Morphine|
45948715|NCT00440479|Drug|Bortezomib|dose as determined (observational study) by treating physician
45948716|NCT00440635|Drug|Bortezomib, tradename Velcade|
45948717|NCT00107588|Behavioral|Reinforcement for homework completion|Provides contingent reinforcement for engaging in homework activities designed to enhance coping skills
45948718|NCT00107588|Behavioral|Reinforcement for Abstinence|Provides contingent reinforcement for submitting marijuana-free urine specimen
45948719|NCT00107588|Behavioral|Case Management|Will control for the effect of therapist-client contact by providing supportive case management as an active control condition.
45948720|NCT00440674|Device|CoStar Paclitaxel-eluting coronary stent system|
45948721|NCT00440713|Drug|Aripiprazole|
45948722|NCT00440713|Behavioral|Interpersonal Therapy|
45658743|NCT05209243|Radiation|STANDARD OF CARE|ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
45658744|NCT05203237|Biological|VK2735|Administered SC
45658745|NCT05203237|Biological|Placebo|Administered SC
45948723|NCT00440791|Device|PillCam Colon capsule endoscopy|
45948724|NCT00107627|Other|Caprosyn subcuticular sutures.|Caprosyn subcuticular sutures.
45948725|NCT00107627|Other|Monocryl subcuticular sutures.|Monocryl subcuticular sutures.
45948726|NCT00107627|Other|Skin staples;|Skin staples;
45948727|NCT00440869|Dietary Supplement|N-acetylcysteine|600 mg po bid
45948728|NCT00440869|Dietary Supplement|placebo|bid oral dosing
45948729|NCT00440986|Procedure|Eritrocytoapheresis|
45948730|NCT00441025|Drug|Alemtuzumab|
46076402|NCT02771418|Drug|Propofol|Intravenous induction and maintenance of general anesthesia with propofol is a routine practice for this intervention
46076403|NCT02771418|Drug|Sevoflurane|Volatile induction and maintenance of general anesthesia with sevoflurane is a generally acceptable clinical approach for this intervention
46076404|NCT02771418|Procedure|Elective carotid endarterectomy|
46076405|NCT02542423|Other|Endocan blood test samples|
45658746|NCT05195931|Diagnostic Test|preload challenge|reduction in preload by head-up tilt and increase in preload with saline infusion
45658747|NCT05195931|Diagnostic Test|afterload challenge|reduction in afterload with nitroprusside and increase in afterload with phenylephrine
45811236|NCT00003297|Procedure|peripheral blood stem cell transplantation|
45811237|NCT00002811|Drug|liposomal T4N5 lotion|
45811238|NCT00003447|Drug|gemcitabine hydrochloride|
45811239|NCT00003447|Drug|vinorelbine tartrate|
45811240|NCT00003315|Biological|sargramostim|
45811241|NCT00003315|Drug|liposomal amphotericin B|
46076406|NCT02833220|Device|Single-Pulse Transcranial Magnetic Stimulation|Single-pulse Transcranial Magnetic Stimulation activates neurons within the cortex of the brain by way of electromagnetic induction. This causes a small, focused electric field to become present in the brain, which activates the neurons.
45811242|NCT00002817|Biological|sargramostim|
45811243|NCT00002817|Biological|vaccinia-GM-CSF vaccine|
45811244|NCT00003321|Procedure|psychosocial assessment and care|
45811245|NCT00003321|Procedure|quality-of-life assessment|
45811246|NCT00003465|Drug|temozolomide|
45811247|NCT00002823|Drug|cisplatin|
45811248|NCT00002823|Drug|etoposide|
45948731|NCT00441181|Drug|Travoprost|
45948732|NCT00107666|Drug|CTI-01 (ethyl pyruvate)|
45948733|NCT04700995|Procedure|NiTi instruments|Root canal filling removal
45948734|NCT00441298|Drug|Tenofovir gel|Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, 1% tenofovir gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
45948735|NCT00441298|Drug|Placebo (Universal HEC placebo)|Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, placebo gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
45948736|NCT00441376|Drug|ThermoDox|15 ml vial containing 2mg/ml Doxorubicin HCl, DPPC, MSPC, DSPE-MPEG 2000. Administered as single dose intravenously over 30 minutes. Dose is determined by dose cohort patient enters study.
45811249|NCT00002823|Drug|vinblastine sulfate|
45658748|NCT05195931|Diagnostic Test|contractility assessment|heart rate changes will be made by increasing heart rate with external pacemaker/defibrillator. Contractility will be adjusted by dobutamine infusion. Patients will exercise at a constant pump speed and also with pump speed increases.
45948737|NCT00107705|Biological|Tree MATA MPL|
45948738|NCT00441415|Drug|Adapalene BPO|
45658749|NCT05195528|Drug|Vonoprazan|Orally via capsule
45948739|NCT00441454|Device|Transobturator Tension-free vaginal tape (TVT-O)|tension-free vaginal tape (TVT)
45948740|NCT00441454|Device|Retropubic Tension-free vaginal tape (TVT)|Retropubic Tension-free vaginal tape (TVT)
45948741|NCT00441493|Drug|fluvastatin|
45948742|NCT02964728|Drug|Botulinum Neurotoxin Type A|topical injection
45948743|NCT02964728|Other|Normal saline|topical injection
45948744|NCT00441532|Drug|Lidocaine|
45453509|NCT00626704|Drug|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).
45453510|NCT00626704|Other|Placebo|Inactive dummy AMG 655 (to maintain blind)
45948745|NCT00441571|Drug|177Lu-CYT-500|
45948746|NCT00441610|Drug|Gimatecan|
45948747|NCT00441649|Drug|Methylphenidate|
45453511|NCT00626704|Drug|Doxorubicin|Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of Daunorubicin.
45658750|NCT05195528|Drug|Placebo|Orally via capsule
45948748|NCT00107822|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|
45948749|NCT00441688|Drug|GI265235|
45948750|NCT04700683|Device|Noctrix Health NPNS device v1.0 - Active|Wearable device programmed to deliver electrical stimulation to peripheral nerves of the lower limbs.
45948751|NCT04700683|Device|Noctrix Health NPNS device v1.0 - Sham|Wearable device programmed to deliver sham stimulation.
45948752|NCT04700605|Behavioral|Dual task balance test|Participants will be conducting two dual task tests; an 8m gait test and a Wii Balance Board test with simultaneous various cognitive tests.
45453512|NCT00765700|Drug|Topical Ketoprofen 10% Cream|Topical Administration
45453513|NCT00765700|Drug|Topical Placebo Cream|Topical Administration
45453514|NCT00626236|Drug|SPN-810|capsule taken three times a day
45453515|NCT00626236|Drug|SPN-810|capsule taken TID
45658751|NCT05194358|Drug|Stabilized Isoamyl Nitrite (SIAN)|"SIAN is comprised of isoamyl nitrite (IAN) stabilized with 4% by weight epoxidized linseed oil (ELSO) and administered by intranasal (IN) delivery as a nasal spray.~A syringe-based spray device will be used to administer the SIAN product. This syringe-based spray device, consists of a Hamilton type syringe connected to a tip that functions as an atomizer, to provide an optimal spray plume for nasal absorption while minimizing exposure to lungs."
45658752|NCT05168800|Behavioral|Dialogue-Based Webinar|One-time virtual webinars facilitated by a long-term care worker and a physician expert. The webinars will include provision of the existing COVID-19 vaccine Option Grid(TM) conversation aid. The majority of time will be focused on answering participants' questions about COVID-19 and the COVID-19 vaccines. An additional refresher intervention will be delivered several weeks later that will comprise of an email with links to a pre-recorded, shorter webinar available in video and audio-only formats.
45676442|NCT03172624|Drug|Nivolumab|nivolumab 3 mg/kg every 2 weeks
45811250|NCT00002823|Drug|vindesine|
45811251|NCT00002823|Drug|vinorelbine tartrate|
45811252|NCT00002823|Radiation|radiation therapy|
45811253|NCT00361621|Drug|bortezomib|Given intravenously on day 1 and day 4 of a 21-day cycle for 6 cycles
45811254|NCT00361621|Drug|Rituximab|Given intravenously on day 1 of a 21-day cycle for 6 cycles
45811255|NCT00361621|Drug|Cyclophosphamide|Given intravenously on day 1 of a 21-day cycle for 6 cycles
45811256|NCT00361621|Drug|Doxorubicin|Given intravenously on day 1 of a 21-day cycle for 6 cycles
45811257|NCT00361621|Drug|Vincristine|Given intravenously on day 1 of a 21-day cycle for 6 cycles
45948753|NCT00107861|Drug|Ad.hIFN-β (BG00001, IDEC-201)|
45948754|NCT00441805|Device|Radio Frequency|
45948755|NCT03279484|Device|NAVIGO 4LV lead implant|All patients will be attempted to implant or implanted with NAVIGO 4LV lead
45948756|NCT00107939|Drug|Licarbazepine|
45948757|NCT03279406|Device|Percutaneous Left Atrial Appendage Occlusion|Percutaneous left atrial appendage occlusion in routine care for patients with atrial fibrillation
45948758|NCT03279328|Drug|Topical Steroid Ointment|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
45948759|NCT03279328|Other|Vaseline|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
45948760|NCT03279328|Drug|Skin Barrier Moisturier|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
45948761|NCT00142974|Drug|Tegaserod|
45948762|NCT00441844|Drug|Simvastatin|
45948763|NCT03279133|Drug|Ledipasvir 90mg/Sofosubvir 400mg|Ledipasvir 90mg/Sofosubvir 400mg (LDV/SOF) FDC is to be administered once daily with or without food for12 weeks.
45948764|NCT00108017|Drug|MK0507A, dorzolamide hydrochloride (+) timolol maleate|
45948765|NCT00108017|Drug|Comparator: timolol maleate|
45948766|NCT00108017|Drug|Duration of Treatment: Part 1) 6 wk timolol maleate run in|
45948767|NCT00108017|Drug|Part 2) 6 wk washout pd Part 3) two 8 wk active tx pds|
45948768|NCT00441922|Drug|Docetaxel|Docetaxel at the dose of 38 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
45948769|NCT00441922|Drug|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
45948770|NCT00441961|Drug|methotrexate|methotrexate
45948771|NCT00442000|Procedure|Prostatectomy|Patients undergoing prostatectomy.
45948772|NCT00442078|Device|I-STOP TOMS male sling|Bulbus urethral compression with polypropylene mesh
45948773|NCT00108056|Drug|Enzastaurin (LY317615) monohydronchloride|
45948774|NCT00442156|Procedure|Laser photocoagulation|modified ETDRS focal photocoagulation generally completed in a single sitting on the day of enrollment, but if little or no improvement, may be repeated at 16 weeks
45658753|NCT05168800|Behavioral|Social Media Website|A curated COVID-19 social media website. The website will feature content from different social media platforms. The posts will include information about COVID-19 and the COVID-19 vaccines. Participants will have the ability to like and comment on website content and can re-visit the website as many times as they like. An additional refresher intervention will be delivered several weeks later that will comprise of an email featuring previews and links to a selection of website content.
45948775|NCT00138411|Drug|Ciprofloxacin 500 mg|
45453516|NCT00626236|Drug|SPN-810|capsule taken TID
45948776|NCT00138411|Drug|ETI-204 (Anthim)|
45948777|NCT00442234|Drug|Monteplase|
45948778|NCT03279055|Behavioral|SHUTi|Sleep Healthy Using the Internet (SHUTi) is a publicly available insomnia intervention program. It focuses on 5 treatment components that form the core of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention.
45948779|NCT00108095|Drug|intravenous ondansetron|
45453517|NCT00626236|Drug|SPN-810|capsule taken TID
45811258|NCT00361621|Drug|Prednisone|Taken orally on days 2, 3, 4 and 5 or a 21-day cycle for 6 cycles
45948780|NCT03278938|Drug|bupropion|FDA approved drug for treating depression
45658754|NCT05168800|Other|Enhanced Usual Practice|COVID-19 vaccine information on the Centers for Disease Control and Prevention (CDC) website. An additional refresher will be delivered several weeks later that will comprise of an email with a link to the COVID-19 vaccine information on the CDC website.
45453518|NCT00626002|Drug|ABT-874|100mg ABT-874 administered SQ every 4 wks for approximately 204 weeks
45453519|NCT03134404|Other|No Intervention|No Intervention is required for this study
45658755|NCT05165381|Device|Video PPG|Contactless vital signs and stress measurement using video PPG technology. An iPad will be used to record a video of the participant's, which can then be converted to vital signs using a specialized algorithm.
45658756|NCT05163496|Drug|Psilocybin (Usona Institute)|PAP + psilocybin 25 mg
45658757|NCT05163496|Drug|Active placebo|PAP + niacin 250mg
45811259|NCT00361621|Radiation|Radiation therapy|After 6 cycles of chemotherapy there will be 3 weeks of radiation therapy
45658758|NCT05163301|Behavioral|Relapse Prevention Intervention|2 session intervention to address relapse prevention among people with HIV who have an alcohol use disorder
45658759|NCT05162443|Drug|adagrasib (MRTX849)|adagrasib (MRTX849) will be administered orally twice daily in a continuous regimen
45658760|NCT05150964|Device|Phonak Audeo hearing aid|receiver in the canal devices with custom earmolds
45811260|NCT00003327|Drug|paclitaxel|
45811261|NCT00003339|Biological|gp100 antigen|
45948781|NCT03278938|Drug|citalopram|FDA approved treatment for depression
45658761|NCT05135533|Device|Portable Neuromodulation Stimulation|The PoNS group will receive electrical stimulation. Net direct current to the tongue electrode less than 1 µA (micro ampere) will be administered three times a week for four weeks in-lab setting, followed by three times a week for eight weeks at-home setting.
45811262|NCT00003339|Biological|incomplete Freund's adjuvant|
45948782|NCT03278860|Drug|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
45948783|NCT03278860|Drug|intranasal placebo|an identical amount of placebo nasal spray will be applied to each subject.
45948784|NCT03278860|Drug|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
45948785|NCT03278860|Drug|intranasal placebo|an identical amount of placebo nasal spray will be applied to each subject.
45453520|NCT02280694|Drug|Capecitabine|
45453521|NCT02280694|Drug|Cyclophosphamide|
45453522|NCT02280694|Drug|Methotrexate|
45453523|NCT02280694|Drug|Celecoxib|
45453524|NCT02280772|Dietary Supplement|Glucomannan|
45453525|NCT02280772|Dietary Supplement|Maltodextrin|
45453526|NCT02280850|Drug|Guanxin Shutong Capsule|3 capsules three times a day; Duration: 4 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
45811263|NCT00003339|Biological|recombinant interleukin-12|
45948786|NCT00442273|Drug|Umbilical cord serum eyedrops|
45948787|NCT00442273|Drug|Autologous serum eyedrops|
45948788|NCT00108134|Drug|PEP005|
45948789|NCT00442312|Drug|Combigan Ophthalmic Solutiom|
45948790|NCT00442390|Drug|hydrocortisone substitution therapy versus withdrawal|
46076407|NCT02766972|Procedure|Rapid Ventricular Pacing|Use of Rapid Ventricular Pacing to improve surgical clipping of intracranial aneurysms
46076408|NCT02541721|Device|LabiaStick#01|"This medical device has emollient agents whose main function is to increase the skin hydration, provide physical protection and decrease the symptoms and possibility of recurrence of vulvar dermatoses.~The medical device should be applied once daily, in the evening, after a gentle washing (plain water with no cleansing products), on the affected non-hairy vulvar area."
45453527|NCT02280850|Drug|Placebo Capsule|3 capsules three times a day; Duration: 4 weeks.
45453528|NCT02280850|Drug|nitroglycerine|"Adults: 0.25mg-0.5mg (half pill or 1 pill) once, sub-lingual. One more pill per 5 minutes untill pain relief. If total dose is 3 pills in 15 minutes and the pain is still in, please seek medical advice urgently.~The participators in both arms who have agina symptom will take Nitroglycerine. So the accumulated consumption of participators is the one of the maesuremnts."
45453529|NCT02280928|Other|Balance exercise|Balance activities, using a task-oriented approach, progress participants from body stability, to body stability plus hand manipulation, then body transport, and finally body transport plus hand manipulation.
45811264|NCT00003339|Biological|tyrosinase peptide|
45811265|NCT03620773|Drug|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
45811266|NCT03620773|Drug|Iohexol Inj 300 mg/mL|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
45811267|NCT03620773|Procedure|Vertical Sleeve Gastrectomy|Participants will undergo vertical sleeve gastrectomy surgery, a laparoscopic bariatric surgery procedure designed for weight loss in obese patients
45948791|NCT03278743|Other|Cognitive performance and cognitive decline|Assess the global and domain specific (memory, speed and attention) cognitive function at baseline and over 5 years in the high vs. low/moderate tea consumption groups
45948792|NCT03278704|Other|RE only|8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise.
45658762|NCT05135533|Device|Sham|The Sham group will not receive electrical stimulation.
45948793|NCT03278704|Other|RE + HIIT|8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise. Concurrent training: RE followed by HIIT within the same session.
45948794|NCT00442585|Drug|S(+)-ibuprofen|
45948795|NCT00108173|Drug|Zyban|
45453530|NCT02280928|Other|Cognitive training|Cognitive training involves executive function, attention, and working memory. Examples of cognitive training include finding the exit to a maze, calculation, visual-spatial skills, Sudoku, Stroop color-word task, word search, spot the differences, visual discrimination, and memory scanning skills.
45453531|NCT02280928|Other|Dual-task cognitive-cognitive training|The Dual-task cognitive-cognitive training involves applying two cognitive tasks at the same time.
45658763|NCT05135533|Other|Gait and balance training|During each session participants will receive gait training exercises for 20 minutes, 20 minutes of balance training exercises, and 20 minutes of breathing exercise three times a week for four weeks in-lab setting. This will be followed by 20 minutes of gait training exercises, 20 minutes of balance training exercises, and 20 minutes of breathing exercise three times a week for eight weeks at-home setting
45811268|NCT03620773|Procedure|Renal Biopsy|Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
45658764|NCT05128487|Drug|NDI-101150|NDI-101150 capsules
45658765|NCT05128487|Drug|Pembrolizumab|Pembrolizumab IV infusion
45658766|NCT05125471|Drug|Cobimetinib|Adult dosing (>/= 18 years old) will be 60 mg orally once daily (tablet formulation); Pediatric dosing (<18 years old) will be 1 mg/kg/dose (maximum 60 mg per dose) orally once daily (oral suspension formulation).
45658767|NCT05114668|Drug|EVT801|"Stage 1: Patients will be dosed orally with EVT801 capsules at the dose and schedule to which they are assigned.~Stage 2: Patients will be dosed orally with EVT801 capsules at the MTD / RP2D identified in Stage 1 of the study."
45676443|NCT03172624|Drug|Ipilimumab|ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)
45676444|NCT03101748|Drug|Cyclophosphamide|Given IV
45676445|NCT03101748|Drug|Doxorubicin|Given IV
45676446|NCT03101748|Other|Laboratory Biomarker Analysis|Correlative studies
45676447|NCT03101748|Drug|Neratinib|Given PO
45676448|NCT03101748|Drug|Paclitaxel|Given IV
45811269|NCT00002829|Biological|Recombinant Interferon Alfa|Daily
45811270|NCT00002829|Drug|Cyclophosphamide|Infused intravenously over 2 hours daily on Day -7 and -6.
45948796|NCT00442663|Device|Transcervical Foley Catheter|
45676449|NCT03101748|Biological|Pertuzumab|Given IV
45948797|NCT00442663|Device|Transcervical Foley Catheter with an EASI|
45948798|NCT00442741|Drug|Patupilone|
45948799|NCT00442741|Drug|Patupilone + Omeprazole|
45948800|NCT00108212|Behavioral|Diet|
45676450|NCT03101748|Biological|Trastuzumab|Given IV
45811271|NCT00002829|Drug|Etoposide|Administered intravenously on Day -8
45948801|NCT00442780|Drug|BIIB014|oral administration of BIIB014 per dose, schedule,and duration specified in protocol
45948802|NCT00442780|Drug|Placebo|Oral administration of placebo matched to BIIB014 dose level; placebo to follow same dosing schedule as BIIB014
45948803|NCT00404586|Drug|GW784568X|GW784568X will be delivered as a micronized suspension (50 or 100mcg/spray) via an aqueous nasal spray. Dose planned for treatment groups are 100, 200 and 400 mcg.
45948804|NCT00404586|Drug|Fluticasone propionate|Fluticasone propionate will be delivered 50 mcg/spray and planned dose is 200 mcg.
45948805|NCT00404586|Drug|Placebo|Matching Placebo to GW784568X as aqueous nasal spray.
45948806|NCT00442819|Procedure|Hemodialysis with Polymethylmethacrylate Artificial Kidney|
45948807|NCT00108251|Drug|Eplerenone|aldosterone receptor blocker
45948808|NCT00108251|Drug|Placebo|matching placebo
45811272|NCT00002829|Drug|Mesna|Beginning 1 hour after initiation of the cyclophosphamide treatment.
45811273|NCT00002829|Procedure|Bone Marrow Transplantation|Infusion on Day 0.
45811274|NCT00002829|Radiation|Radiation Therapy|Total body irradiation is received on days -4, -3, -2 , and -1.
45811275|NCT03614221|Drug|Lindioil ointment|Each gram contains 200µg of indirubin. Apply 0.5 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
45811276|NCT03614221|Drug|Protopic ointment 0.1%|Each gram contains (w/w) 0.1% of tacrolimus. Apply 0.1 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
45948809|NCT00442975|Biological|Fluarix|
45948810|NCT00443014|Device|Cognitive, physical and social stimulation|Sessions of 30 minutes daily five days a week for one year
45948811|NCT00138528|Drug|Fluvastatin|
45948812|NCT00443092|Other|proprietary cherry juice blend (food)|2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
45948813|NCT00443092|Other|control juice (kool aid blend)|2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
45948814|NCT00443131|Biological|GSK Malaria vaccine 257049|Three-dose vaccination by slow intramuscular injection. Three different formulations of this vaccine are tested (without adjuvant, with adjuvant AS01B, with adjuvant AS02A).
45948815|NCT00108290|Drug|Chemotherapy|
45948816|NCT00443170|Drug|GSK626616, placebo, midazolam|
45676451|NCT03100331|Other|Neuropsychological testing|Comprehensive neuropsychological assessment and implementation of appropriate support and resources.
45676452|NCT03085147|Drug|Olaparib|For PARRi-FL, imaging patients will first gargle a solution of PARRi-FL for 1 min, then spit out this solution and gargle with a cleaning solution (the solvent used for PARRi-FL) for 1 min. Then fluorescence imaging of the oral cavity and pharynx will be performed with an endoscope. The intensity and extent of the fluorescence signal will be recorded by one of the investigators for the tumor and adjacent normal mucosa.
45811277|NCT00003489|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Advanced Head and Neck Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45811278|NCT00003345|Drug|cisplatin|
45811279|NCT00003345|Drug|irinotecan hydrochloride|
45811280|NCT03596905|Drug|Plecanatide|Taken orally daily for 4 weeks
45811281|NCT03596905|Drug|Matching placebo|Taken orally daily for 4 weeks
45811282|NCT00003495|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV or Recurrent Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45811283|NCT00003501|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Refractory or Recurrent High-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45811284|NCT04563403|Behavioral|Projection-based augmented reality therapy (P-ARET)|"The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
45811285|NCT00002835|Biological|Bleomycin Sulfate (BLM)|
45811286|NCT00002835|Biological|Filgrastim (G-CSF)|Arm 1: Administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover through Course 1 then 2 courses administered before PBSC harvest and same regimen with Course 2, then daily with Day 0 of infusion.
45453532|NCT00667654|Drug|CNTX-4975|Testing a range of dosing configurations to optimize patient tolerability
45453533|NCT00799864|Drug|Rilpivirine|Patients will receive rilpivirine (RPV) tablet 25 milligram dose or an adjusted dose orally once daily in Cohort 1 (adolescents aged >=12 to <18 years) up to 240 weeks. Patients will receive RPV weight-adjusted dose orally once daily in Cohort 2 (children aged >=6 to <12 years) or 25 mg once daily for up to 48 weeks.
45811287|NCT00002835|Biological|Recombinant Interferon Alfa|
45676453|NCT03063944|Drug|STAT Inhibitor OPB-111077|Given PO
45676454|NCT03063944|Drug|Decitabine|Given IV
45811288|NCT00002835|Drug|Carmustine|Arm 1, Course 3, IV over 1 hour on day -6.
45948817|NCT00443170|Drug|omeprazole, caffeine, flurbiprofen, rosiglitazone|
45948818|NCT00404625|Behavioral|Risk factors for infections due to ESBL+ Enterobacteriaceae|
45948819|NCT00404625|Behavioral|Risk factors for inadequate initial antimicrobial therapy|
45948820|NCT00404625|Behavioral|Overall and 30-day mortality in bad first antibiotic therapy|
45948821|NCT00443248|Device|Vaginal Heat Wash-Out Device|No drug administered. Device tested twice with each subject.
45948822|NCT00108329|Behavioral|Weight Loss|
45453534|NCT00799864|Drug|Zidovudine|Type=exact, form= appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
45453535|NCT00799864|Drug|Abacavir|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
45453536|NCT00799864|Drug|Tenofovir disoproxil fumarate|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for 240 weeks (Cohort 1).
45676455|NCT03063944|Drug|Venetoclax|Given PO
45676456|NCT03063944|Other|Laboratory Biomarker Analysis|Correlative studies
45676457|NCT03062631|Drug|3,4-Diaminopyridine|The investigator will prescribe an initial dose of 3,4 diaminopyridine (DAP) by mouth based on the participant's weight. This initial dose may be modified later according to the participant's response to treatment.
45676458|NCT03013309|Behavioral|Family Check-Up 4 Health|A parent-training intervention to improve child health and prevent/manage obesity
45676459|NCT03013309|Other|Treatment as usual|Treatment as usual
45811289|NCT00002835|Drug|Cisplatin (CDDP)|
45948823|NCT04700254|Other|DASS questionnaire|The DASS is a 42-item self report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress
45948824|NCT04700254|Other|EAT-26 questionnaire|The Eating Attitudes Test (EAT-26), is a self-report 26-item questionnaire of symptoms and concerns characteristic of eating disorders.
45811290|NCT00002835|Drug|Cyclophosphamide|
45676460|NCT02979873|Drug|Sirolimus|Sirolimus will be started on day 1 for subjects in the Sirolimus arm. A baseline CBC will be obtained within one week of randomization, or on Day 0. Thereafter, CBC will be monitored on a weekly basis for subjects in both arms. In the event of relapse (see definition of outcomes Section 6.7), the patient shall return to the NIH CRC for evaluation to include bone marrow biopsy and aspirate to exclude clonal evolution to MDS. Assessment will include (i) flow cytometry phenotyping of peripheral blood mononuclear cells for regulatory T-cells (Tregs, e.g. CD4+ CD25high FOXP3+) and regulatory dendritic cells (DCregs) and (ii) proteomics assay (research labs).
45811291|NCT00002835|Drug|Cytarabine (ARA-C)|Arm 1, Course 3, every 12 hours on days -5 to -2.
45948825|NCT04700020|Diagnostic Test|ITT|In the context of this study, we will take two blood samples. In addition to the second blood sample, an insulin tolerance test (ITT) is also performed, even if the result of the blood values is normal. MRI will only be performed if the previous imaging was done more than two years ago or when the quality of the MRI was not good enough to measure the volume of the pituitary gland. This is needed for better analysis of the pituitary gland, as the pituitary volume could be important for the hormonal abnormalities.
45948826|NCT00138567|Drug|vildagliptin|
45948827|NCT04700332|Drug|DCFPyL PET/CT|Prostate Membrane Specific Antigen-specific imaging
45948828|NCT00108368|Drug|Risperidone|
45948829|NCT00108368|Drug|Olanzapine|
45948830|NCT00443365|Procedure|Mitral valve repair|mitral valve annuloplasty
45948831|NCT00443404|Procedure|perioperative epidural catheter|Perioperative epidural catheter in groups 1-4. Pre- and postoperative epidural analgesia in group 1. Preoperative IV PCA Fentanyl and postoperative epidural analgesia in group 2. Perioperative IV PCA Fentanyl in groups 2,3. IM meperidine p.o. codeine/acetaminophen, IV acetaminophen and IV parecoxib in group 5 (control)
45948832|NCT04700293|Dietary Supplement|AYMES AMSTERDAM|AYMES AMSTERDAM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
45948833|NCT00404664|Behavioral|influenza vaccine, reminders letters, raffle prize|
45948834|NCT03278470|Drug|HL237|Experimental
45948835|NCT03278470|Drug|Placebo Oral Tablet|placebo with same properties except for active ingredient
45811292|NCT00002835|Drug|Etoposide (VP-16)|Course 1, IV over 2 hours every 12 hours on days 1-3; Course 3, every 12 hours on days -5 to -2.
45948836|NCT00108407|Behavioral|Integrated Cognitive Behavioral Therapy|
45948837|NCT00108407|Behavioral|Twelve Step Facilitation Therapy|
45811293|NCT00002835|Drug|Idarubicin|
45811294|NCT00002835|Drug|Ifosfamide|During Course 1, IV continuously; Course 2, IV continuously on days 1-3.
45811295|NCT00002835|Drug|Leucovorin Calcium|
45811296|NCT00002835|Drug|Melphalan|
45811297|NCT00002835|Drug|Methotrexate|
45811298|NCT00002835|Drug|Methylprednisolone|
45811299|NCT00002835|Drug|mitoxantrone hydrochloride (DHAD)|Arm 1, Course 2, IV on day 1.
45811300|NCT00002835|Drug|Vincristine Sulfate|
45811301|NCT00002835|Procedure|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
45811302|NCT00002835|Radiation|Radiation Therapy|
45811303|NCT04560673|Drug|Duloxetine|Given PO
45948838|NCT00108446|Drug|dextromethorphan|
45948839|NCT00108446|Drug|naloxone|
45948840|NCT00108446|Drug|fentanyl|
45948841|NCT00108446|Drug|lidocaine|
45948842|NCT00138606|Drug|vildagliptin|
45948843|NCT00443482|Drug|formoterol|
45948844|NCT00443521|Drug|Triamcinolone Acetonide 4 mg intravitreal injection|
45948845|NCT00443521|Procedure|Panretinal photocoagulation|
45948846|NCT00401453|Behavioral|Diet: carbohydrate days. (Name: oatmeal.)|Dietary intervention with two days of oatmeal compared to normal diabetes adapted diet in insulin resistant subjects.
45811304|NCT04560673|Behavioral|Neurofeedback|Receive neurofeedback training
45811305|NCT04560673|Other|Quality-of-Life Assessment|Ancillary studies
45811306|NCT04560673|Other|Questionnaire Administration|Ancillary studies
45948847|NCT03278431|Drug|Albendazole|Albendazole (400 mg) from Janssen, donated by the World Health Organization
45948848|NCT03278431|Drug|Pyrantel Pamoate|Pyrantel pamoate (20 mg/kg), will be purchased by the World Health Organization
46076409|NCT04246034|Procedure|Microvascular Breast Reconstruction with Vascularized Lymph Node Transfer|simultaneous free abdominal flaps with VLNT from groin are transferred on a single pedicle for breast reconstruction and postmastectomy lymphedema
46076410|NCT02766894|Device|EEG monitoring|EEG will be performed. Data obtained will be analyzed using software. Anesthesiologists will enter their assumption in a blinded fashion and data obtained will be compared with EEG data
46076411|NCT04245878|Other|gastric ultrasound|gastric ultrasound for measurement of the antral area
45453537|NCT00799864|Drug|Lamivudine|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
45811307|NCT00003351|Drug|irinotecan hydrochloride|
45811308|NCT00361153|Drug|Colesevelam hydrochloride|Welchol tablet 625mg
45811309|NCT00361153|Drug|placebo|placebo
45811310|NCT00002847|Biological|aldesleukin|
46076412|NCT00888901|Drug|eltrombopag|eltrombopag tablets daily, in increasing dosage, for three months
46076413|NCT00888901|Drug|corticosteroids (Aprednislon)|corticosteroids in decreasing dosage
46076414|NCT02766816|Biological|Part 1 study - BBio bOPV|A single dose of 2 drops (0.1 ml) orally of BBio bOPV to 20 children 60 to 83 months of age.
46076415|NCT02766816|Biological|Part 2 study - BBio bOPV Lot 1|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 1 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
46076416|NCT02766816|Biological|Part 2 study - BBio bOPV Lot 2|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 2 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
46076417|NCT02766816|Biological|Part 2 study - BBio bOPV Lot 3|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 3 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
45811311|NCT00002847|Biological|recombinant interferon alfa|
45811312|NCT00002847|Procedure|conventional surgery|
45811313|NCT04342117|Drug|duvelisib|25 mg BID, 15 mg BID
45811314|NCT04342117|Drug|PI3K inhibitor|FDA approved PI3K inhibitors
45811315|NCT00003357|Biological|GM2-KLH vaccine|
45811316|NCT00003357|Biological|QS21|
45811317|NCT04208139|Diagnostic Test|IVUS|IVUS
45811318|NCT04225585|Behavioral|CST-PSP|skills training and experiential learning exercises
45811319|NCT04225585|Behavioral|General health education|general health education intervention that focuses on improving overall health
45811320|NCT00003513|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Metastatic, Recurrent, or Refractory Neuroblastoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45811321|NCT03576001|Drug|Testosterone Undecanoate|administered through injections by study staff
45948849|NCT03278431|Drug|Oxantel Pamoate|Oxantel pamoate (20mg/kg) will be produced by the University of Basel
45948850|NCT03278431|Drug|Mebendazole|Mebendazole (500 mg) from GlaxoSmithKline, donated by the World Health Organization
45948851|NCT04726332|Drug|XL102|oral doses of XL102
45948852|NCT04726332|Drug|Fulvestrant|fulvestrant 500 mg administered as an intramuscular (IM) injection every 2 weeks for the first 3 doses and then every 4 weeks.
45948853|NCT04726332|Drug|Abiraterone|abiraterone 1000 mg administered orally once daily.
45948854|NCT04726332|Drug|Prednisone|prednisone 5 mg administered orally twice daily.
45948855|NCT04699825|Other|Cardiovascular and immunological changes|performing cardiac ultrasound, vascular doppler, and immunological study on cord blood sample
45658768|NCT05112432|Device|Cognitive and Social Cognitive Training|"The Cognitive Training Module is designed to improve the speed and accuracy of auditory information processing while engaging working memory and cognitive control under conditions of close attention and reward. Exercises continuously adjust difficulty level to user performance to maintain an approximately 80% current performance rate. The goal is to increase the effectiveness by which salient stimuli engage and drive plastic changes in brain systems that in individuals with psychosis exhibit relatively poor temporal response.~The Social Cognition Training Module consists of exercises designed to ameliorate core deficits in social cognition expressed in schizophrenia and Autism Spectrum Disorders. The exercises apply principles of implicit learning to restore the brain's capacity to process and utilize socially-relevant information, and include training to improve affect perception, social cue perception, theory of mind, self-referential style, and emotion labeling and working memory."
45658769|NCT05112432|Behavioral|Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App|The PRIME smartphone-based app is designed to be used for 12 weeks to enhance motivation in people with early psychosis. Participants work towards self-identified goals with the support of the virtual community of age-matched peers, as well as with motivation coaches. Participants discuss their interests and aspirations with each other and with their coach, and the coach sends daily individualized motivational messages. Coaches also provide tailored interventions to enhance motivation, and post daily discussion topics to the PRIME community to encourage interaction between members. Coaches will maintain close communication and feedback on progress with each individual's clinical team.
45811322|NCT03576001|Behavioral|hybrid exercise|hybrid exercise: functional electrical stimulation of lower extremity with leg cycling (FES-LC) and arm ergometry, supervised for two weeks and then home-based
45811323|NCT03568201|Diagnostic Test|Transcutaneous oximetry|Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves.
45811324|NCT04220827|Drug|Paclitaxel|Given IP
45811325|NCT03567109|Other|hand laterality judgment task|participants are asked to identify laterality of the hand presented on the screen
45811326|NCT04159857|Procedure|Fetal head extraction technique during the cesarean section|see above for the description about one-hand and two-hand fetal head extraction technique
45811327|NCT00002865|Biological|filgrastim|
45811328|NCT00002865|Drug|cyclophosphamide|
45811329|NCT00002865|Drug|cytarabine|
45453538|NCT00799864|Drug|Emtricitabine|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
45948856|NCT00443638|Behavioral|nurse home visitation|Nurse home visitation
45948857|NCT00108563|Drug|Citalopram or Placebo|
45948858|NCT00443677|Drug|COPPEBVCAD vs BEACOPP vs ABVD|
45948859|NCT00443716|Drug|estrogen|
45948860|NCT00443794|Drug|Thiazides|Capsule (blinded) oral administration once daily for 12 weeks
45948861|NCT00443794|Drug|Ramipril with Thiazide|Capsule (blinded) oral administration 12 weeks
45948862|NCT00443794|Drug|Thiazide plus atenolol|Caspule (blinded) for oral administration once daily for 12 weeks
45948863|NCT00443794|Drug|Ramipril plus atenolol|Capsule ( blinded) for oral administration once daily for 12 weeks
45948864|NCT00443794|Drug|Ramipril plus atenolol plus thiazide|Capsule (blinded) for oral administration once daily for 12 weeeks
45453539|NCT02272972|Other|Application of knowledge|Educational Intervention has been performed at the treating surgeon (video and poster). The surgeons applies the achieved knowledge when performing the intraoperative fluoroscopy in patients with pertrochanteric fractures.
45453540|NCT02273284|Device|Buzzy|The Buzzy will be applied for 30 seconds over the area that is going to be injected, then during the actual injection the Buzzy will be moved rostrally and continuously used during the injection. When the injection is completed the Buzzy is positioned in the same way over the next injection site.
45453541|NCT02273830|Drug|oxygen|Oxygen administered after adjustment during a waking test or at 3L/min
45453542|NCT03134560|Device|Vein Display Instrument|
45811330|NCT00002865|Drug|dexamethasone|
45811331|NCT00002865|Drug|doxorubicin hydrochloride|
45811332|NCT00002865|Drug|etoposide|
45811333|NCT00002865|Drug|ifosfamide|
45811334|NCT00002865|Drug|leucovorin calcium|
45811335|NCT00002865|Drug|mesna|
45811336|NCT00002865|Drug|methotrexate|
45811337|NCT00002865|Drug|therapeutic hydrocortisone|
45811338|NCT00002865|Drug|vincristine sulfate|
45811339|NCT00002865|Radiation|low-LET cobalt-60 gamma ray therapy|
45811340|NCT00002865|Radiation|low-LET photon therapy|
45811341|NCT04192357|Behavioral|WLM3P|18 months behavioral weight loss program divided into three phases (first and second phase of weight loss, during 1 month and 5 months, respectively; and a third phase of weight maintenance, during 12 months).
45811342|NCT04192357|Behavioral|Low-carb diet|18 months behavioral weight loss program divided in two phases (first of weight loss during 6 months and a second phase of weight maintenance during 12 months).
45948865|NCT00443794|Drug|POLYCAP|Capsule for Oral Administration once daily for 12 weeks
45948866|NCT00443794|Drug|Thiazide + Ramipril+Atenolol+Aspirin|Capsule (Blinded) for oral administration once daily for 12 weeks
45948867|NCT00443794|Drug|Simvastatin|Capsule (Blinded) for oral administration once daily for 12 weeks
45948868|NCT00443794|Drug|aspirin|capsule (Blinded) for oral administration once daily for 12 weeks
45948869|NCT00108602|Drug|acetazolamide|
45948870|NCT03278314|Drug|tezacaftor/ivacaftor|orally administered TEZ/IVA combination therapy
45948871|NCT00138684|Procedure|venesection|Venesection therapy is realised every 7 - 14 days until iron desaturation completion.
45948872|NCT00443950|Drug|Etanercept|
45948873|NCT00138723|Drug|SPM 907|
45948874|NCT00444184|Drug|Travoprost/timolol fixed combination, travoprost|
45948875|NCT00444223|Procedure|fluorine F 18 FEQA + positron emission tomography|
45948876|NCT00444262|Procedure|hemodynamic optimisation guided using esophageal Doppler|hemodynamic optimisation guided using esophageal Doppler
45948877|NCT00444262|Drug|VOLUVEN and others solute|VOLUVEN and others solute
45948878|NCT03278236|Behavioral|TRF|Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
45948879|NCT03278197|Other|Interviews|Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs.
45948880|NCT03278197|Other|Treatmentchoice Decisional Tool|Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
45948881|NCT03278197|Other|Questionnaires|Patients and physicians fill out questionnaires on the usual care, Delphi study
45658770|NCT05112432|Other|Early Psychosis Coordinated Specialty Care|Participants will continue to receive treatment as usual at their early psychosis coordinated specialty care clinics. These clinics may follow the NAVIGATE model, as an example.
45658771|NCT05107960|Drug|Azilsartan (TAK-536)|Azilsartan Tablets, Azilsartan Granules
45948882|NCT03278197|Other|Interviews with stakeholders|Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
45453543|NCT02281006|Drug|Trans-tympanic injection of a sodium thiosulfate gel|A sodium thiosulfate hyaluronate gel will be prepared by mixing 0.55 ml of a 25% solution of sodium thiosulfate pentahydrate (Seacalphyx, DIN 02386666, Seaford Pharmaceuticals Inc.) and 0.55 ml of a hyaluronate gel (Healon 10 mg, Abbott Medical Optics Inc.). On the day before each Cisplatin treatment an otologist will deposit 0.1 ml of the gel exactly on the round window of the middle ear.
45811343|NCT00361309|Drug|SU011248|Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks).
45811344|NCT04154943|Drug|Cemiplimab|Intravenous (IV) infusion every 3 weeks (Q3W)
45811345|NCT00361387|Drug|d-methylphenidate|oral dosing for 8 weeks then cross over to placebo in random order
45811346|NCT04530487|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
45948883|NCT03278158|Drug|Placebo|Subjects in the placebo arm will receive a single oral tablet containing no active drug.
45948884|NCT03278158|Drug|XEN-D0501, 1 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet
45453544|NCT00758290|Drug|Triclosan/Fluoride|Brush twice daily for 3 weeks
45948885|NCT03278158|Drug|XEN-D0501, 2 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet
45811347|NCT04530487|Drug|Cyclosporine|Given IV and PO
45811348|NCT04530487|Drug|Etoposide|Given IV
45453545|NCT00758290|Drug|Fluoride/triclosan|Brush daily for 3 weeks
45453546|NCT02281162|Other|Blood Draw|Blood Draw
45658772|NCT05097599|Drug|lorlatinib|This arm of the Strata PATH trial will assess the clinical benefit of Lorbrena® (lorlatinib) in ALK and ROS1 gene fusion positive solid tumors, as detected by Strata testing, with the exception of NSCLC.
45658773|NCT05097599|Drug|encorafenib + binimetinib|This arm of the Strata PATH trial will assess the clinical benefit of Braftovi® (encorafenib) + Mektovi® (binimetinib) in BRAF p.v600X mutated solid tumors, as detected by Strata testing, with the exception of melanoma and colorectal cancer.
45811349|NCT04530487|Drug|Fludarabine Phosphate|Given IV
45811350|NCT04530487|Biological|Lapine T-Lymphocyte Immune Globulin|Given IV
45811351|NCT04530487|Drug|Melphalan|Given IV
45811352|NCT04530487|Drug|Mycophenolate Mofetil|Given IV or PO
45811353|NCT04530487|Drug|Tacrolimus|Given IV and PO
45811354|NCT04530487|Drug|Thiotepa|Given IV
45811355|NCT00003369|Drug|cisplatin|75 mg/m2 IV as a one-hour infusion after tirapazamine on Day 1 of each 21-day cycle
45811356|NCT00003369|Drug|tirapazamine|260 mg/m2 over two hours prior to cisplatin on Day 1 of each 21-day cycle
45811357|NCT04342351|Drug|sacubitril/valsartan|sacubitril/valsartan will be applied from 25mg/b.i.d for 1-2 weeks,50mg b.i.d for 2 weeks, to target dosage 100mg b.i.d for 3 months unless severe safety outcome occurs
45811358|NCT04342351|Drug|perindopril|Drug: perindopril will be applied from 2mg for q.d for 1-2 weeks, 4mg q.d 2 weeks, to target dosage 8mg q.d for 3 months unless severe safety outcome occur
45948886|NCT03278158|Drug|XEN-D0501, 4 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet
45948887|NCT03278158|Drug|XEN-D0501, 8 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet
45948888|NCT00138840|Drug|STA-5326 mesylate|
46002249|NCT04225312|Drug|Personalized extended interval dosing of natalizumab|Personalized extended interval dosing of natalizumab with a schedule from every 6 weeks, which will be further extended if the trough level exceeds 10 ug/ml.
46002250|NCT04225312|Drug|Standard interval dosing|Standard interval dosing in control group and historic group
46002251|NCT04221542|Drug|AMG 509|AMG 509 administered as an IV infusion (Parts 1, 3, 4 and 5) or SC injection (Part 2).
45811359|NCT04342351|Other|Cardiopulmonary Exercise Test|All patients will undergo a first CPET prior to initiation of treatment, a second one after 3 months, and a third one after 6 months of treatment.
45811360|NCT04342351|Other|Echocardiogram|An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 3 months, 6 months later.
45811361|NCT04342273|Drug|KW-6356|KW-6356 will be administered once daily as therapeutic at Day 1 through Day 7
45811362|NCT04342273|Drug|KW-6356|KW-6356 will be administered once daily as supratherapeutic dose at Day 1 through Day 7
45948889|NCT03278041|Procedure|Submental flap for palatal reconstruction|"Under General Anesthesia the tumor in the maxilla will be resected (partial maxillectomy) with a safety margin, then the defect will be reconstructed immediately by :~Submental artery flap : from submental area with 1 cm distance from inferior mandibular border in paddle shape.~1st step will be identify the facial artery and vein,~2nd step dissection and extend toward midline in subplatsmal plane. The flap contains submental artery and vein.~3rd step creating submucous tunnel between vestibular border of post maxillectomy defect and to extraoral incision .~The flap will be through the oral cavity and will be anchored to the intact remaining hard plate with bone sutures by 2-0 vicryl® suture."
45948890|NCT03278041|Device|maxillary obturator|immediate surgical obturator
45948891|NCT03277963|Device|Pain perception tests (mechanical : VON FREY ELECTRONIQUE or electrical stimulus : PAIN MATCHER®)|From a basal level causing no particular sensation, the mechanical or electrical stimulus is applied with a constant increasing rate of progression.
45948892|NCT03275701|Drug|Triumeq|Open Label, Switch to Triumeq (ABC/DTG/3TC)
45948893|NCT03275467|Other|Faecal microbiota transfer (FMT)|Suspended stool from a healthy donor
45948894|NCT00451165|Procedure|laparoscopic colorectal surgery|laparoscopic colorectal surgery
45948895|NCT00138918|Biological|OGX-011|See Detailed Description, Treatment Plan
45948896|NCT00108758|Drug|activated recombinant human factor VII|
45948897|NCT04698928|Device|Theta burst stimulation|Theta burst stimulation over SMA. 3 section per day, for 5 days, total 15 sections.
45948898|NCT00451360|Drug|diacerein|
45948899|NCT00138957|Procedure|Laparoscopic parastomal hernia repair with mesh|
45948900|NCT00451399|Drug|metformin|
45948901|NCT00451399|Behavioral|lifestyle intervention|
45948902|NCT00108797|Drug|eptacog alfa (activated)|
45948903|NCT00108797|Drug|Feiba VH|
45948904|NCT04698772|Drug|Ketamine|Blinded study group will receive ketamine for pain control (0.3 mg/kg IV over 3-5 minutes)
45453547|NCT03799627|Drug|Vadadustat|Vadadustat Tablets 150 mg
45453548|NCT03799627|Drug|Epoetin Alfa|Epoetin Alfa
45811363|NCT04342273|Drug|Placebo|Placebo will be administered once daily at Day 1 through Day 7
45811364|NCT04342273|Drug|Moxifloxacin|Placebo will be administered once daily at Day 1 through Day 6, followed by Moxifloxacin once daily at Day 7.
45811365|NCT00003525|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Cancer of the Cervix and/or Vulva will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45948905|NCT04698772|Drug|Morphine|Blinded study group will receive morphine 4 mg IV push over 3-5 minutes for pain control
45948906|NCT00138996|Device|automated direct feedback on CPR from defibrillator|
45948907|NCT03275428|Device|transnasal humidified rapid-insufflation ventilator exchange|high flow nasal cannula with humidified oxygen
45948908|NCT04699045|Other|No active intervention|
45948909|NCT00108836|Drug|XBD173|
45948910|NCT00451516|Drug|Herbal medicine (St. John's wort and Kava)|
45948911|NCT00451594|Drug|Dexamethasone|"Pulse high dose dexamethasone (Arm 1)~Patients will receive 40 mg of oral dexamethasone daily for four consecutive days.~Other treatments should be considered if there was a platelet count of 30X109/L or less by day 14~If the patient had a platelet count of more than 30X109/L after four days of dexamethasone treatment, no further treatment will be given.~If the platelet count drops below 30X109/L within the first 6 months, another four-day course of dexamethasone will be given, followed by 15 mg of prednisone daily, with gradual tapering.~Patients whose platelet counts can not be maintained at 30X109/L will be offered other treatments."
45948912|NCT00451594|Drug|Prednisolone|"Conventional dose prednisone (Arm 2)~Prednisone, 1 mg/kg is started at diagnosis. If the platelet count is more than 100X109/L, the dose should be used for 4 weeks minimally and then tapered by 10 mg/1 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/1 wk thereafter. (Ann Intern Med 1997, 126, 307-14). If the platelet count is between 30X109/L and 100X109/L, prednisone 1 mg/kg should be used for 8 weeks maximally and then tapered by 10 mg/2 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/2 wk thereafter.~Guideline of prednisone tapering Duration of prednisone treatment: 3-6 months"
45948913|NCT00139035|Drug|cyclosporine A|
45948914|NCT00451633|Drug|E2007|
45948915|NCT00451672|Drug|bromocriptine|
45948916|NCT00108875|Biological|Survivin peptide vaccine|
45948917|NCT00451711|Drug|Liposomal amphotericin B|
45948918|NCT00139074|Drug|Quetiapine fumarate|oral variable dose
45948919|NCT00139074|Drug|sodium valproate|oral
45948920|NCT00451750|Drug|Cortisol|20 mg for 3 times
45948921|NCT00451828|Drug|Simvastatin|40mg/day
45948922|NCT00108914|Drug|GW685698X|
45948923|NCT00451867|Drug|Mycophenolate Mofetil|
45948924|NCT00451867|Drug|Mycofenolate Mofetil (MMF)|2000 mg per day divided into 2 equal doses.
45948925|NCT00451867|Drug|Placebo|Placebo
45948926|NCT00143091|Drug|CP-316,311|
45658774|NCT05097599|Drug|talazoparib|This arm of the Strata PATH trial will assess the clinical benefit of Talzenna® (talazoparib) in patients with advanced solid tumors harboring deep deletions or deleterious mutations with LOH in BRCA1/2 and PALB2, as detected by Strata testing, excluding HER2 negative breast cancer.
45658775|NCT05097599|Drug|fam-trastuzumab deruxtecan-nxki|This arm of the Strata PATH trial will assess the clinical benefit of Enhertu® (fam-trastuzumab deruxtecan-nxki) in patients with advanced solid tumors harboring HER2 over-expression, as detected by Strata testing (HER2 Expression Score positive [HER2 ES-positive]), excluding breast cancer, gastric cancer, or gastroesophageal junction (GEJ) cancer.
45948927|NCT00143091|Drug|Placebo|
45811366|NCT03504241|Biological|Donor-derived Mesenchymal Stromal Cells|These MSCs are a cellular product derived from bone marrow and propagated ex vivo using FDA-approved, clinically applicable methods. Their use in kidney transplantation has been associated with a good safety profile.
45948928|NCT00143091|Drug|Sertraline|
45811367|NCT03504241|Drug|alemtuzumab|Alemtuzumab, 30 mg, given once intravenously (IV) over three hours. The infusion of alemtuzumab shall begin within 24 hours of transplantation surgery and shall be given prior to the first dose of belatacept.
45948929|NCT00451945|Procedure|biopsy|
45948930|NCT00451945|Device|3d-ultrasound and fusion of UL and PET/CT|
45948931|NCT00451984|Biological|Twinrix|
45948932|NCT00451984|Biological|interleukin-2|
45948933|NCT00452062|Drug|Dexamethasone|
45948934|NCT00452101|Drug|Aquamin F|
45948935|NCT00108992|Drug|Diclofenac, topical|
45948936|NCT00452140|Biological|ertumaxomab|10 µg, IV on day 0 followed by 100 µg every 7 days up to a maximum of 12 infusions.
45948937|NCT00452179|Drug|APD125|
45948938|NCT00143130|Drug|Pregabalin|Pregabalin
45948939|NCT04698733|Device|BEST™ HVPC microcurrent electrical stimulation Pro-Sport Ultra® device|"Participants will receive two (2) 20-minute treatments a week on nonconsecutive days for 6 weeks in the clinic. At the end of 6 weeks, participants will have a 6-week pause in treatment.~Active Avazzia PRO-Sport Ultra® medical device, BEST™ HVPC microcurrent electrical stimulation, FDA cleared for pain relief"
46076418|NCT02766816|Biological|Part 2 study - Licensed bOPV|Three doses of 2 drops (0.1 ml) orally of a licensed bOPV to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
46076419|NCT02766816|Biological|Part 1 study - Licensed bOPV|A single dose of 2 drops (0.1 ml) orally of a licensed bOPV to 20 children 60 to 83 months of age.
45453549|NCT03799627|Drug|Vadadustat TIW|Oral Vadadustat
45453550|NCT02274142|Procedure|Restoration with hand-mixed material|restoration with hand-mixed glass ionomer cement
45658776|NCT05097599|Drug|enfortumab vedotin|This arm of the Strata PATH trial will assess the clinical benefit of Padcev® (enfortumab-vedotin) in patients with advanced solid tumors and are Nectin-4 Expression Score High (Nectin-4 ES-H), as detected by Strata testing, excluding urothelial cancer.
45811368|NCT03504241|Drug|belatacept|Belatacept will be given as an intravenous (IV) infusion of 10mg /kg over 1 hour on transplantation postoperative Day 0, Days 5 and 14, then every 2 weeks (± 2 days) for 5 additional doses.Thereafter, belatacept will be given once every 4 weeks (± 5 days) at 10 mg/kg through 24 weeks post-transplant, then at 5 mg/kg every 4-weeks until the participant is evaluated for belatacept discontinuation.
45811369|NCT03504241|Drug|sirolimus|Rapamune® (sirolimus) (Wyeth Pharmaceuticals Inc., Philadelphia, PA) will be started on transplantation postoperative day 1 at a dose of 2 mg/day orally and adjusted to maintain goal 24-hour trough levels of 8-10 ng/ml. Participants who experience grade 3 sirolimus toxicity will undergo dose reduction.
45811370|NCT03504241|Drug|mycophenolate mofetil|Per protocol, and, only permitted in cases of sirolimus intolerance.
45948940|NCT00109070|Drug|Avastin (bevacizumab)|
45948941|NCT04698694|Device|Electroporation with voltage amplitude of 40 V (corresponding to an electric field strength of 100 V/cm)|The physician will select the voltage amplitude of 40 V to be given to the subject based on a randomization list, while the subject will remain blind to the voltage he/she is assigned to. The electroporation will be performed with a EPS electrode gun.
45948942|NCT04698694|Device|Electroporation with voltage amplitude of 60 V (corresponding to an electric field strength of 150 V/cm)|The physician will select the voltage amplitude of 60 V to be given to the subject based on a randomization list, while the subject will remain blind to the voltage he/she is assigned to. The electroporation will be performed with a EPS electrode gun.
45948943|NCT00452218|Drug|Sorafenib|200 mg daily and dose escalated to a maximum of 400 mg twice daily
45948944|NCT00143169|Drug|Parecoxib and placebo|
45948945|NCT00109109|Drug|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment - Up to 8 Cycles or 6 months|
45948946|NCT03275116|Drug|Tiotropium 'Respimat' 5 mcg|Once daily single bronchodilation
45948947|NCT03275116|Drug|Aclidinium Bromide/Formoterol Fumarate 340/12 mcg|Twice daily dual bronchodilation
45948948|NCT03275077|Device|Thromboelastography|A viscoelastic test of coagulation
46076420|NCT02829476|Biological|Osteoblast sample|culture osteoblasts obtained from vertebrae fragments from 30 patients with AIS and from 10 control patients with secondary scoliosis
46076421|NCT00803049|Drug|Teriflunomide (HMR1726)|Tablet, oral administration QD.
46076422|NCT00884767|Drug|FOLFOX regimen|
46076423|NCT00884767|Drug|fluorouracil|
46076424|NCT00884767|Drug|leucovorin calcium|
46076425|NCT00884767|Drug|oxaliplatin|
46076426|NCT00884767|Genetic|gene expression analysis|
45658777|NCT05097599|Drug|sacituzumab govitecan|This arm of the Strata PATH trial will assess the clinical benefit of Trodelvy® (sacituzumab govitecan) in patients with advanced solid tumors and are Trop2 Treatment Response Score High (Trop2 TRS-H), as detected by Strata testing, excluding triple negative breast cancer, hormone receptor positive/ human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer, metastatic urothelial cancer, non-small cell lung (NSCLC) cancer, small cell lung cancer (SCLC), head and neck cancer, colorectal cancer (CRC), and endometrial cancer.
45658778|NCT05097599|Drug|pembrolizumab|This arm of the Strata PATH trial will assess the clinical benefit of pembrolizumab in patients with advanced solid tumors and are Immunotherapy Response Score High (IRS-H), as detected by Strata testing, excluding approved pembrolizumab indications.
45658779|NCT05097599|Drug|axitinib|This arm of the Strata PATH trial will assess the clinical benefit of Inlyta® (axitinib) in patients with advanced solid tumors and are Angiogensis Inhibitor Treatment Response Score High (Angio TRS-H), as detected by Strata testing, excluding renal cell carcinoma, alveolar soft part sarcoma, and solitary fibrous tumors.
46076427|NCT00884767|Genetic|protein expression analysis|
45658780|NCT05092022|Device|Evalyn Self-Sampling Brush|A self-sampling brush to collect cervical cells for screening purposes.
45658781|NCT05091255|Procedure|Cryotherapy|The procedure involves general or peripheral anesthesia and percutaneous treatment under CT control with probes capable of forming ice spheres of up to 3 cm that will be used in sufficient number to treat the neoplasm completely.
45948949|NCT03275038|Behavioral|Tai-Chi exercise|Behavioral: Tai-Chi exercise
45948950|NCT03275038|Behavioral|Aerobic exercise|Behavioral: Aerobic exercise
45948951|NCT00143208|Drug|Xalacom|
46076428|NCT00884767|Genetic|proteomic profiling|
45453551|NCT02274142|Procedure|Restoration with Encapsulated material|restoration with encapsulated ionomer cement
45658782|NCT05087303|Other|Types of Telemedicine Delivery Models|Each arm delivers standard sickle cell care using a different model based on patient location.
45658783|NCT05085756|Behavioral|Puma|One psychoeducation module followed by two transdiagnostic modules tailored to primary depression or anxiety symptoms, followed by three participant-choice modules, and ending with two transdiagnostic modules.
45658784|NCT05085366|Biological|mRNA-1647|Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline)
45658785|NCT05085366|Biological|Placebo|0.9% sodium chloride (normal saline) injection
45658786|NCT05082012|Device|Treatment of Hallux Valgus|Patients 14 years through 58 years with symptomatic hallux valgus will be eligible to participate based on the inclusion/exclusion criteria established in the study protocol. Anticipated subject duration will be 2 years post index procedure.
45658787|NCT05068791|Drug|Psilocybin|0.36 mg/kg will be administered orally to participants
45453552|NCT02274142|Device|Encapsulated glass ionomer cement (EQUIA - GC Corp).|
45453553|NCT02274142|Device|powder-liquid glass ionomer cement (Fuji IX - GC Corp)|
45453554|NCT00756574|Device|Surgical mask|Surgical mask worn for patients with febrile respiratory illness
45453555|NCT00756574|Device|N95 mask|N95 mask worn for patients with febrile respiratory illness
45658788|NCT05068791|Drug|Dextromethorphan|2.6 mg/kg of active placebo will be administered orally to participants
45658789|NCT05013190|Other|No intervention|This is a non-interventional study.
45811371|NCT03504241|Drug|mycophenolate acid|Per protocol, and, only permitted in cases of sirolimus intolerance.
45811372|NCT03504241|Drug|prednisone|Per protocol, and, only permitted in cases of sirolimus intolerance.
45948952|NCT00109148|Drug|MK0364|
46076429|NCT00884767|Other|laboratory biomarker analysis|
46076430|NCT00884767|Other|pharmacogenomic studies|
46076431|NCT00890084|Drug|Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)|Telmisartan 40mg or 80mg +/- HCTZ 12.5mg or 25mg
46076432|NCT00884845|Drug|PM02734 and erlotinib|PM02734 drug product (DP) 1 mg/vial is a powder for concentrate for solution for infusion
46076433|NCT00884845|Drug|Erlotinib|Erlotinib is provided as 25 mg, 100 mg and 150 mg white film-coated tablets
46076434|NCT02773602|Drug|Dexamethasone|200 μgm/kg of dexamethasone in 1 ml saline
45658790|NCT05011734|Other|Fast Track recovery pathway|Multidisciplinary approach alongside the orthopedic surgeon
45658791|NCT05002465|Drug|68Ga-PSMA-11|Injection of 68Ga PSMA-11
45658792|NCT05002465|Procedure|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
45658793|NCT05000359|Behavioral|text messaging intervention|Ten AYA survivors will be recruited to participate in the expanded 12-week text messaging intervention.
45658794|NCT04996004|Drug|Ontorpacept (TTI-621)|Ontorpacept (TTI-621) will be administered by intravenous infusion.
45811373|NCT00003375|Drug|lomustine|
45811374|NCT00003375|Drug|procarbazine hydrochloride|
45811375|NCT00003375|Drug|vincristine sulfate|
45811376|NCT00003375|Radiation|radiation therapy|
45811377|NCT04329195|Drug|1: discontinuation of RAS blocker therapy|discontinuation of RAS blocker therapy
45811378|NCT04329195|Drug|2: continuation of RAS blocker therapy|continuation of RAS blocker therapy
45811379|NCT03499249|Drug|N-Acetyl cysteine|Intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days
45948953|NCT00452257|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, up to 3 years or until progressive disease
45948954|NCT00452296|Drug|tight insulin treatment in patients hospitalized with COPD exacerbation|treatment with basal plus bolus insulin
45948955|NCT00452296|Procedure|tight glycemic control|treatment with basal and bolus insulin
45948956|NCT00452491|Drug|somatropin|0.2 IU/kg/day 7 days per week given sequentially (alternating periods of 6 months of treatment and 6 months of no treatment) for 3 years
45948957|NCT00452491|Drug|somatropin|0.2 IU/kg/day 7 days per week given continuously for 3 years
46076435|NCT02773602|Drug|Clonidine|2 μg/kg of clonidine in 1 ml saline
46076436|NCT02773602|Drug|Normal Saline|1 ml of saline added to the ropivacaine, 0.2%, 1 ml/kg
45948958|NCT00452569|Drug|Thalidomide|Oral thalidomide (100mg or 200mg or 400 mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 + 36 days (12 cycles of 28 +/- 3 days).
45658795|NCT04996004|Drug|Doxorubicin|75 mg/m^2 by intravenous infusion in 21-day cycles for a maximum of six cycles.
45658796|NCT04972955|Device|Freestyle Libre 2|Participants will wear a continuous glucose monitoring device, the Freestyle Libre 2, for two weeks following delivery.
45658797|NCT04972955|Device|Freestyle Libre 2|Participants will wear a second continuous glucose monitoring device, the Freestyle Libre 2, for two weeks at 4-6 months postpartum and before their standard of care postpartum bloodwork after having gestational diabetes.
45658798|NCT04971681|Device|Low frequency repetitive transcranial magnetic stimulation (rTMS)|Subjects will receive one session of low frequency repetitive transcranial magnetic stimulation (rTMS) targeting the medial prefrontal cortex (mPFC), within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 110% of motor threshold (MT), for a total of 1200 pulses
45658799|NCT04971681|Device|Sham|The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
45658800|NCT04952402|Biological|Study-provided Moderna mRNA-1273 COVID-19 vaccine|Participants received a two-dose series (100 µg (0.5 mL) was administered intramuscularly (IM) at Day 0 and Day 28).
45658801|NCT04952402|Biological|Community-provided Moderna mRNA-1273 COVID-19 Vaccine|Participants received a two-dose series.
45658802|NCT04952402|Biological|Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine|Participants received a two-dose series.
45811380|NCT03498391|Drug|Propofol|Titration of propofol to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.
45811381|NCT03498391|Drug|Ketamine Injectable Product|Titration of ketamine to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.
45811382|NCT00003939|Drug|trabectedin|
45811383|NCT00003543|Biological|monoclonal antibody A33|
45948959|NCT00452569|Drug|Dexamethasone|High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
45948960|NCT00143286|Drug|varenicline (CP-526,555)|
45948961|NCT00109187|Drug|Xolair (omalizumab)|
45948962|NCT00452608|Drug|amido pill|one pill of amido/d by mouth for 10 days
45948963|NCT00452608|Drug|atorvastatina|atorvastatina 80 mg/day by mouth for 10 days
46076437|NCT04248140|Other|radio frequency electromagnetic field|Exposure system delivers emissions comparable to those from WiFi access point close to the bed or sham (nor exposure)
46076438|NCT00886171|Behavioral|Social Skills Training|Social skills group will consist of one session (60 minutes) per week for 8 weeks
46076439|NCT00886171|Behavioral|Physical Activity Training|Physical activity groups consist of one session (60 minutes) per week for 8 weeks
46076440|NCT00886249|Device|Acrysof IQ|Intraocular lens
46076441|NCT00886249|Device|Acrysof Natural IOL|Intraocular Lens
45658803|NCT04941144|Biological|COVID-19 Vaccine|COVID-19 Vaccine Intramuscular Injection
45658804|NCT04938895|Behavioral|Black Respondents Exposure to a Photo|Black survey respondents will be randomly assigned to one of four treatments. In each treatment arm, the subject will view a photo of an NIH investigator. We experimentally vary treatment along two dimensions: whether the investigator is a man v. woman and whether the man is white vs. black. We will survey participants' willingness to participate in a clinical trial and how their initial response is impacted by other characteristics such as perceived trustworthiness and quality.
45658805|NCT04930055|Biological|COVID-19 Vaccination|Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
45658806|NCT04909593|Device|Spinal Cord Stimulation|Spinal cord stimulation at varied electrode, pulse width, frequency and amplitude parameters
45658807|NCT04907227|Biological|Pembrolizumab|IV infusion
45811384|NCT00003543|Drug|carmustine|
45811385|NCT00003543|Drug|fluorouracil|
45811386|NCT00003543|Drug|streptozocin|
45811387|NCT00003543|Drug|vincristine sulfate|
45811388|NCT00003549|Drug|CMF regimen|
45811389|NCT00003549|Drug|cyclophosphamide|
45811390|NCT00003549|Drug|fluorouracil|
45811391|NCT00003549|Drug|methotrexate|
45811392|NCT00002883|Drug|cisplatin|
45811393|NCT00002883|Drug|fluorouracil|
45811394|NCT00002883|Procedure|adjuvant therapy|
45811395|NCT00002883|Procedure|conventional surgery|
45811396|NCT00002883|Procedure|neoadjuvant therapy|
45811397|NCT00002889|Drug|flutamide|
45948964|NCT00109226|Drug|Avastin (Bevacizumab)|
45948965|NCT00452686|Biological|Boostrix|
45948966|NCT00452686|Biological|Chinese DT vaccine|
45948967|NCT00452725|Drug|MAXOMAT ®, biosynthetic growth hormone|2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration
45948968|NCT00452764|Behavioral|Withdrawal of medication|
45948969|NCT00452803|Drug|chemotherapy|Paclitaxel 90mg/m2 + Cisplatin 40mg/m2 on D1 & 8 q 3weeks, Pre-OP & post-op : 2cycles (total 4 cycles)
45948970|NCT00452803|Drug|Concurrent chemoradiation therapy|Paclitaxel 50mg/m2 + Cisplatin 20mg/m2 on D1 & 8 q 3weeks, Pre-OP & post-op : 2cycles (total 4 cycles)
45948971|NCT00452803|Radiation|Concurrent chemoradiation therapy|Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx
45948972|NCT00109265|Drug|Erlotinib HCl (OSI-774)|
46076442|NCT05198726|Device|alpha tACS|2mA α-tACS (based on the IAF) over the prefrontal cortex (PFC)
45658808|NCT04907227|Drug|Docetaxel|IV infusion
45811398|NCT00002889|Drug|goserelin|
45948973|NCT00143364|Drug|varenicline (CP-526,555)|
45948974|NCT00452881|Drug|gemcitabine|Gemcitabine1250mg/m2 iv on day 1 and 15, every 4weeks, maximum 4 cycles
45811399|NCT00002889|Drug|leuprolide acetate|
45811400|NCT00002889|Radiation|low-LET photon therapy|
45948975|NCT00452881|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
45811401|NCT03492463|Drug|Nicotine patch|Participants will wear the nicotine patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
45948976|NCT00452881|Drug|Cisplatin|Cisplatin 40mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
45948977|NCT00452920|Drug|docetaxel|
45948978|NCT00452920|Radiation|cesium Cs 137|
45948979|NCT00452920|Radiation|radiation therapy|
45948980|NCT00109304|Biological|VEE 3526|
45948981|NCT00452998|Procedure|Q-switched fd Nd:yag in Laser Iridotomy|
45948982|NCT00143442|Drug|[S,S]-Reboxetine|
46076443|NCT05198726|Behavioral|Speed of Processing Training|SoP training will have a total of four conditions. In condition 1, participants will be asked to identity objects at increasingly brief exposures. For condition 2, identification of stimulus on the center of the screen will be requested from participants, while a second stimulus will appear somewhere in peripheral vision - stimulus duration, difficulty of the central localization task or the area in which targets may be located are used to change the level of difficulty. Condition 3 is similar to condition 2, but visual distractors are added. Finally, for condition 4, an auditory identification component is superimposed over the visual task (Jobe et al., 2001)
45658809|NCT04907227|Drug|Prednisone|Oral tablets
45658810|NCT04907227|Drug|Placebo|IV infusion
45658811|NCT04907227|Drug|Dexamethasone|Oral tablets
45658812|NCT04892277|Biological|Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563|Given IV
45811402|NCT03492463|Other|Placebo patch|Participants will wear the placebo patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
45948983|NCT00453037|Behavioral|structured educational program|structured education and evaluation of hypertensive patients in a design similar to the DAFNE study design. Behavioural intervention follows the Dusseldorf-educational program
45948984|NCT00453037|Behavioral|participation in the educational program after 6 months|Control group consisting of patients randomly assigned to participate in the educational program 6 months later than the active group
45948985|NCT00109382|Drug|Aspirin|
45948986|NCT00109382|Drug|Clopidogrel|
45948987|NCT00109382|Drug|Simvastatin|
45658813|NCT04892277|Drug|Bendamustine|Given IV
45948988|NCT00453076|Device|Paclitaxel eluting covered metal stent and control covered metal stent|Paclitaxel eluting covered metal stent and control covered metal stent are inserted with standard ERCP technique
45948989|NCT00453115|Drug|Oxaliplatin|oxaliplatin 85mg/m2 iv on D1 and 15, every 4 weeks until disease progression
45948990|NCT00453115|Drug|Gemcitabine|gemcitabine 1250mg/m2 iv on day 1 and 15, every 4 weeks until disease progression
45948991|NCT00143481|Drug|Tolterodine ER 4mg QD|
45948992|NCT03274921|Diagnostic Test|Biological determination|Evaluation of plasma accumulation of the 10 retention solutes with CV complications in CKD patients
45658814|NCT04892277|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
45658815|NCT04892277|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
45658816|NCT04892277|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
45658817|NCT04892277|Procedure|Computed Tomography|Undergo CT
45811403|NCT03492463|Other|E-cigarettes|Participants will use e-cigarettes containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
45948993|NCT02273557|Drug|Asasantin ER (new formulation I - low)|
45811404|NCT03492463|Other|Non-nicotine e-cigarettes|Participants will use e-cigarettes not containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
45811405|NCT00003945|Drug|cisplatin|
45811406|NCT00003945|Drug|topotecan hydrochloride|
45811407|NCT00003951|Drug|exatecan mesylate|
45811408|NCT00003957|Biological|filgrastim|
45811409|NCT00003957|Biological|recombinant human stem cell factor|
45811410|NCT00003957|Drug|cyclophosphamide|
45948994|NCT02273557|Drug|Asasantin ER (new formulation III - medium)|
45948995|NCT02273557|Drug|Asasantin ER (new formulation II - high)|
45948996|NCT02273557|Drug|Asasantin ER (present commercial formulation)|
45948997|NCT00109421|Behavioral|Project ÒRÉ|Community-based adolescent social network HIV/STI intervention tailored to African American culture
45948998|NCT00453232|Biological|bleomycin sulfate|
45948999|NCT00453232|Biological|pegfilgrastim|
45949000|NCT00453232|Drug|cisplatin|
45949001|NCT00453232|Drug|etoposide|
45949002|NCT00453427|Drug|Alemtuzumab (Campath-1H)|The investigational drug is alemtuzumab (Campath-1H). It is a recombinant humanized monoclonal antibody directed against the CD52 antigen on most (> 95%) normal lymphocytes and T-cell and B-cell lymphomas. Alemtuzumab binds to the CD52 antigen on the cell surface, activating antibody-dependent cellular cytotoxicity, complement binding, apoptosis, cellular opsonization, and anti-tumour T-cell activity.
45949003|NCT00143520|Drug|Rivoglitazone|
45949004|NCT00143520|Drug|Pioglitazone|
45949005|NCT00143520|Drug|Placebo|
45658818|NCT04892277|Drug|Cyclophosphamide|Given IV
45658819|NCT04892277|Drug|Fludarabine|Given IV
45811411|NCT00003957|Drug|cytarabine|
45811412|NCT00003957|Drug|etoposide|
45811413|NCT00003957|Drug|melphalan|
45811414|NCT00003957|Drug|mitoxantrone hydrochloride|
45949006|NCT00453466|Behavioral|EBW group intervention to empower battered women|
45949007|NCT00109460|Behavioral|Tobacco Use Disorder|
45949008|NCT00453622|Device|Cardiac Resynchronization Therapy-Defibrillator|Implantation of a CRT-D device
45949009|NCT00453661|Behavioral|Questionnaire|"Intervention Group:~Cancer Screening Assessment (CSA) questionnaire 45-60 minutes annually for 4 years + Exit Questionnaire at end of study.~Comparison Group:~Exit Questionnaire only."
45949010|NCT00453661|Behavioral|Patient Navigator (PN)|Staff member, called patient navigator (PN), who assist with medical care and/or screenings, questionnaires.
45949011|NCT00109499|Drug|AdGVPEDF.11D|
46076444|NCT02770950|Drug|Zushima plaster with high dose|Patients in high dose Zushima plaster group will use Zushima plaster topically on knee(s) for 24h per day.
46076445|NCT02770950|Drug|Zushima plaster with low dose|Patients in low dose Zushima plaster group will use Zushima plaster topically on knee(s) for 12h per day.
46076446|NCT02770950|Drug|Indometacin Cataplasms|Patients in Indometacin Cataplasms group will use Indometacin Cataplasms on knee(s)for 24h per day.
45658820|NCT04892277|Procedure|Magnetic Resonance Imaging|Undergo MRI
45658821|NCT04892277|Procedure|Positron Emission Tomography|Undergo CT/PET
45658822|NCT04890535|Drug|TBAJ-587|oral suspension
45658823|NCT04890535|Drug|Placebo|matching placebo oral suspension for TBAJ-587
45658824|NCT04849000|Drug|SHR-1209|SHR-1209
45658825|NCT04849000|Drug|SHR-1209 Placebo|SHR-1209 Placebo
45811415|NCT00003957|Drug|paclitaxel|
45811416|NCT00003957|Procedure|peripheral blood stem cell transplantation|
45811417|NCT00004833|Drug|Immune globulin|
45811418|NCT00003555|Drug|amifostine trihydrate|
45949012|NCT00453700|Procedure|Trypanosoma cruzi serology|
45949013|NCT00143559|Drug|Systematic chemotherapy and antibodies|"Systemic chemotherapy and antibodies as follows:~Transplant recipients received a reduced intensity conditioning regimen consisting of OKT-3, fludarabine, thiotepa, and melphalan followed by an infusion of a T-cell depleted haploidentical hematopoietic stem cell graft. The antibody Rituximab was administered within 24 hours of the infusion in an effort to prevent PTLPD. In addition to T -cell depletion of the donor product, Mycophenylate mofetil was provided over several months as prophylaxis for GVHD"
45949014|NCT00143559|Procedure|Allogeneic stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device
45949015|NCT00143559|Device|Miltenyi CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
46076447|NCT00885001|Procedure|Short Arc Banding|Lumbar extension on the ATM II from back project. Rehabilitation exercise intervention.
46076448|NCT02828930|Drug|Idasanutlin|Idasanutlin 300 mg tablet orally on Day 1; 400 mg tablet orally on Day 11 and Day 19. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days of 28-day cycle.
46076449|NCT02828930|Drug|Placebo|Placebo matching to idasanutlin aqueous dispersion will be administered orally on Day 11.
46076450|NCT02828930|Drug|[13C]-radiolabeled Idasanutlin|[13C]-radiolabeled idasanutlin 100 mcg will be administered as IV infusion over 15-minute on Day 1.
46076451|NCT02828930|Drug|[14C]-radiolabeled Idasanutlin|[14C]-radiolabeled idasanutlin 100 mg capsule (2, 50 mg capsules containing approximately 100 microcurie of radioactivity) will be administered orally on Day 1.
45658826|NCT04843319|Drug|VERU-100|GnRH antagonist
45658827|NCT04842045|Drug|Psilocybin and Midazolam|"The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.~The midazolam in this study will be administered intravenously. The total dose administered to a given subject is dependent on the individual's level of amnesia, sedation scale score, age, and weight."
45811419|NCT00003555|Drug|paclitaxel|
45811420|NCT00003963|Biological|rituximab|Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Week 5-8: Rituxan given every 2 weeks. Week 9-12: Schedule same as week 5-8.
45811421|NCT00003963|Drug|vinorelbine ditartrate|"Week 1-4: Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.~Week 5-8: Vinorelbine given weekly x3, with one week off. Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated."
45811422|NCT00384423|Drug|PRX-03140|
45811423|NCT00003969|Drug|tanespimycin|
45811424|NCT00384501|Device|Intacs|
45811425|NCT00004845|Drug|Rofecoxib|
45811426|NCT00004845|Drug|Naproxen|
45811427|NCT00003981|Drug|indisulam|
45811428|NCT00385281|Biological|FluMist|
45811429|NCT00003993|Biological|aldesleukin|
45811430|NCT00003993|Drug|bryostatin 1|
45811431|NCT00004857|Biological|alemtuzumab|30 mg subQ injection tiw for 6 weeks
45811432|NCT00004857|Drug|fludarabine phosphate|25mg/sq m/day IV infusion x 5 days Wks 1, 5, 9, and 13
45949016|NCT00453778|Drug|FLIXOTIDE Diskus 500 mcg (Fluticasone Propionate)|
45949017|NCT00109616|Behavioral|Newborn skin cleansing with 0.25% chlorhexidine solution|
45658828|NCT04839302|Drug|Indocyanine green solution|Patients with clinical suspicion of necrotizing fasciitis would receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) with immediate fluorescence imaging of the affected body part and simultaneous imaging of an unaffected region
46076452|NCT02766738|Other|GrACE program|to compare with the GrACE + gait programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention and control group
46076453|NCT02766738|Other|GrACE + gait|to compare with the GrACE programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention and control group
45658829|NCT04810650|Other|Mobility Dynamic Treatment Intervention|"1) Access to a mobility coordinator who will assist with transfers, rescheduling, and out-of-facility refills; 2) Provision of a travel pack with alternative ART packaging options (e.g. ziplock bags, envelopes, pill boxes), a packing list and mobility coordinator phone contact for unplanned travel; 3) Screening at every clinic visit for planned mobility; 4) Mobile number and mobile minutes for unexpected travel; 5) Provision of longer refills (up to 6-months) for planned travel"
45658830|NCT04810650|Other|Health Living Intervention for Heavy Alcohol Users|1) Two in-person alcohol counseling sessions with support from a clinical psychologist; 2) Monthly booster phone calls
45658831|NCT04810650|Other|Hypertension Linkage|1) Travel voucher (financial incentive) conditional on linkage to hypertensive care; 2) Phone call reminders for missed visits
45658832|NCT04810650|Other|PrEP/PEP at Outpatient Clinics|Intervention delivered at Outpatient Clinics: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
45658833|NCT04810650|Other|PrEP/PEP at Antenatal Clinics|Intervention delivered at Antenatal Clinics: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
45658834|NCT04810650|Other|PrEP/PEP at Community Households|Intervention delivered in community by village health team: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
45811433|NCT03476239|Drug|Blinatumomab|"Blinatumomab will be supplied as single-use glass injection vials as a sterile, preservative-free, white to off-white, lyophilized powder for reconstitution and administration by continuous intravenous infusion (CIVI).~A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2 week treatment-free interval. The treatment-free interval may be prolonged by up to 7 days, if deemed necessary by the investigator."
45811434|NCT03476239|Drug|Dexamthasone|Premedication with dexamethasone was intended to prevent cytokine release syndrome (CRS) events associated with blinatumomab treatment. Treatment could start pre-study. Dexamethasone 20 mg IV was administered within 3 hours before start of blinatumomab in each treatment cycle, and within 3 hours before dose step increase.
45658835|NCT04810650|Other|Standard of Care|Local country standard of care protocols
45811435|NCT04074993|Drug|Brigatinib|Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily. A Cycle will be defined as 28-days. Treatment will be continued until disease progression or unacceptable toxicity.
45949018|NCT00109616|Behavioral|Cleansing of umbilical cord with soap and water solution|
45811436|NCT00004863|Drug|GEM 231|
45811437|NCT00004863|Drug|paclitaxel|
45949019|NCT00109616|Behavioral|Cleansing of umbilical cord with 4% chlorhexidine|
45949020|NCT00453817|Drug|ferucarbotran (iron-based MRI contrast agent)|islets will be incubated with ferucarbotran prior to transplantation, for imaging after transplantation
45949021|NCT00453817|Procedure|Islet transplantation|intraportal percutaneous islet transplantation
45949022|NCT00453817|Procedure|Magnetic resonance imaging|Magnetic resonance imaging of the liver before and after islet transplantation (6 days, 6 weeks, 6 months, 1 year)
45949023|NCT00453856|Drug|Sulfadoxine Pyrimethamine|
45949024|NCT00143637|Other|Office dust|airborne office dust spiked with glucan
46076454|NCT02352207|Other|identification of a pulmonary malformation in the fetus|
46076455|NCT00889057|Drug|sorafenib|400 mg bid until progression or inacceptable toxicity
45811438|NCT04073043|Behavioral|Telephone Coaching|Access to Telephone Coaching for a period of 12 weeks
45949025|NCT00143637|Other|clean air|Clean air
45949026|NCT00453934|Device|h-Patch|
46076456|NCT02773290|Biological|Romiplostim|Weekly SC administration
46076457|NCT02832986|Other|Medical Questionary|"The medical questionary will contain :~Date of initial infection by Herpes zoster~Localisation~Severity~Presence of postherpetic pain~Postherpetic pain Intensity~Postherpetic pain duration~Antiviral treatment~History of chronic pathologies~Concomitant treatment"
45811439|NCT00004875|Drug|enoxaparin|
45811440|NCT00004875|Drug|heparin|
45949027|NCT00454012|Procedure|biophysical profile|
45949028|NCT00109655|Biological|Oncolytic adenovirus (serotype 5) - CG0070|Intravesical administration of CG0070 (in suspension) directly into the bladder
45949029|NCT03274843|Other|Activity of everyday life|Kitchen workshop
45949030|NCT02964429|Device|Diacap Pro High-Flux|During dialysis treatment ultrafiltration rate will be changed following a fixed schedule and resulting changes in Transmembrane Pressure (TMP) recorded to generate data for calculation of the in-vivo KUF.
45949031|NCT00454090|Drug|AZD8330|oral tablet
45658836|NCT04810650|Other|Hypertension Community|Hypertension care delivered at home with clinician telehealth, facilitated by lay health worker to measure blood pressure and deliver medications
45658837|NCT04795895|Diagnostic Test|ultrasonography (US)|US evaluation was performed after insertion of the tube via subxiphoid approach for tube passing esophagogastric (EG) junction. The tube insertion procedure will be repeated no more than three attempts if no visualization by US.
45658838|NCT04795895|Diagnostic Test|Standard routine (SR)|Standard routine (SR)
45658839|NCT04781933|Dietary Supplement|Treatment with Combo|Treatment with Combo
45658840|NCT04781933|Other|Treatment with placebo|Treatment with placebo
45811441|NCT04071171|Drug|CVVH with Phoxilium® in the first 48h after randomization|After randomization into the Phoxilium®-group, CVVH will be initiated with Phoxilium® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
45811442|NCT04071171|Drug|CVVH with Biphozyl® in the first 48h after randomization|After randomization into the Biphozyl®-group, CVVH will be initiated with Biphozyl® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
45811443|NCT04071171|Drug|CVVH with Phoxilium® in the second 48h after randomization (after previous 48h with Biphozyl®)|48h post randomization, respectively after the cross-over CVVH will be continued with Phoxilium® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
45811444|NCT04071171|Drug|CVVH with Biphozyl® in the second 48h after randomization (after previous 48h with Phoxilium®)|48h post randomization, respectively after the cross-over CVVH will be continued with Biphozyl® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
45811445|NCT00004881|Biological|MVA-MUC1-IL2 vaccine|
45811446|NCT00003561|Biological|recombinant interferon alfa|
45811447|NCT00003561|Biological|sargramostim|
45811448|NCT00003567|Biological|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
45811449|NCT00003567|Biological|sargramostim|Patients receive sargramostim (GM-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
45811450|NCT00003567|Biological|therapeutic autologous lymphocytes|
45811451|NCT00003567|Drug|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour every 6 weeks for 5 courses. Four weeks after the completion of BG and carmustine, patients receive BG IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
45811452|NCT00003567|Drug|carmustine|Patients receive carmustine IV over 1 hour every 6 weeks for 5 courses.Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
45811453|NCT00003567|Drug|temozolomide|Four weeks after the completion of BG and carmustine, patients receive temozolomide IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
45811454|NCT00003567|Procedure|in vitro-treated peripheral blood stem cell transplantation|Approximately 72 hours after the end of the first course of chemotherapy, patients receive reinfusion of retrovirally-transduced hematopoietic stem cells over 5-10 minutes. Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
45658841|NCT04780815|Other|myBluTM Formulation 1|1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 1, with inhalation of the vapour into the lungs
45658842|NCT04780815|Other|myBluTM Formulation 2|1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 2, with inhalation of the vapour into the lungs
45658843|NCT04754945|Drug|Bortezomib|Given SC
45658844|NCT04754945|Drug|Cyclophosphamide|Given IV or PO
45658845|NCT04754945|Drug|Dexamethasone|Given IV or PO
45658846|NCT04754945|Biological|Isatuximab|Given IV
45811455|NCT00003573|Biological|filgrastim|
45811456|NCT00003573|Drug|cisplatin|
45811457|NCT00003573|Drug|cyclophosphamide|
45811458|NCT00003573|Drug|etoposide|
45811459|NCT00003573|Drug|vincristine sulfate|
45811460|NCT00003573|Radiation|radiation therapy|
45811461|NCT03468985|Drug|Cabozantinib|Given PO
45658847|NCT04754776|Biological|ChAdOx1 RVF|Single dose of ChAdOx1 RVF
45658848|NCT04751942|Device|Non-compressive Bioactive Garment|patients will be assigned to wear the non-compressive bioactive garment following total knee arthroplasty
45658849|NCT04751942|Device|thrombo-embolic deterrent|patients will be randomized to wear the gold standard TED hose following total knee arthroplasty
45658850|NCT04743310|Drug|tozuleristide|tozuleristide 24mg administered intravenously 1-24 hours prior to surgery
45811462|NCT03468985|Biological|Ipilimumab|Given IV
45811463|NCT03468985|Biological|Nivolumab|Given IV
45811464|NCT00003585|Biological|aldesleukin|
45811465|NCT00003585|Biological|recombinant interferon alfa|
45811466|NCT00003585|Drug|fluorouracil|
45658851|NCT04743310|Device|Canvas imaging system|imaging device attached to surgical microscope
45658852|NCT04743310|Procedure|Surgical resection of tumor|Standard of care surgical resection of tumor
45658853|NCT04730037|Drug|Edoxaban|- Edoxaban 30 mg/60 mg tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications
45658854|NCT04730037|Drug|Warfarin Potassium|- Warfarin K 1 mg tablets once daily (Dose adjusted with target PT-INR of 1.5-2.5)
45658855|NCT04730037|Drug|Warfarin Potassium placebo|- Warfarin K 1 mg placebo tablets once daily
45811467|NCT00003585|Drug|isotretinoin|
45949032|NCT00454129|Procedure|cholangiography via double-balloon enteroscopy|
45658856|NCT04730037|Drug|Edoxaban placebo|- Edoxaban 30 mg/60 mg placebo tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications
45658857|NCT04729751|Drug|Maralixibat|"Maralixibat chloride provided in the form of an oral solution (i.e., 5, 10, 15, and 20 mg/mL)~400 μg/kg maralixibat chloride is equivalent to 380 µg/kg maralixibat free base~600 μg/kg maralixibat chloride is equivalent to 570 µg/kg maralixibat free base"
45658858|NCT04729387|Drug|Alpelisib|Alpelisib will be administered at 200 mg orally once daily following food on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle
45811468|NCT00003585|Procedure|surgical procedure|
45811469|NCT00003591|Drug|paclitaxel|
45811470|NCT00003591|Radiation|radiation therapy|
45811471|NCT02975323|Drug|Carvedilol|Single dose of oral carvedilol 12.5 mg and wait till the time there's 20% reduction in hepatic wedge pressure gradient from the baseline.
45811472|NCT00003597|Biological|recombinant human thrombopoietin|
45811473|NCT00003597|Drug|carboplatin|
45811474|NCT00003597|Drug|etoposide|
45811475|NCT00003597|Drug|ifosfamide|
45811476|NCT00003597|Biological|G-CSF|
45811477|NCT04520425|Procedure|Osteopathic manipulative therapy|"Mandibular: the clinician applies gentle pressure bilaterally to the subject's mandible, in the direction of the patient's clavicles.~Frontal: the clinician applies gentle pressure bilaterally to the subject's forehead, in a direction halfway between the parietals and ears.~Temporal: the clinician applies gentle pressure bilaterally to the subject's temples, in the direction of the patient's occiput.~Parietal: the clinician applies gentle pressure bilaterally to the subject's parietal bones, in the direction of the patient's occipital atlanto joint.~Occipital: the clinician applies gentle pressure to the subject's occipital bone, in the direction of the patient's neck."
45811478|NCT04188379|Biological|efgartigimod|Intravenous infusion of efgartigimod
45811479|NCT04188379|Other|Placebo|Intravenous infusion of placebo
45811480|NCT00004005|Drug|fluorouracil|
45949033|NCT00454129|Procedure|MR cholangiography|
45949034|NCT00454168|Biological|PR1 leukemia peptide vaccine|Given subcutaneously
45949035|NCT00454168|Biological|sargramostim|Given subcutaneously
45949036|NCT00454168|Other|placebo|Given subcutaneously
45949037|NCT00109811|Biological|PSA:154-163(155L) peptide vaccine|Given subcutaneously
45949038|NCT00109811|Biological|incomplete Freund's adjuvant|Given subcutaneously
45949039|NCT00109811|Other|laboratory biomarker analysis|Correlative studies
45949040|NCT02964390|Procedure|Balloon Pulmonary Angioplasty|
45949041|NCT03274765|Diagnostic Test|Dosage of oestradiol|"The study is based on a concept using capillary blood tests using lateral flow by migration on membrane similarly to a pregnancy test, patented by a french company (NGBiotech).~This study is therefore a feasibility study of a rapid test for oestradiol dosage during monitoring of ovarian stimulation."
45658859|NCT04729387|Drug|Olaparib|Olaparib will be administered at 200 mg orally twice daily irrespective of meals on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle.
45658860|NCT04729387|Drug|Paclitaxel|Paclitaxel will be administered at 80 mg/m2 as an intravenous infusion weekly during a 28-day treatment cycle, starting on Cycle 1 Day 1, and on Day 8, Day 15 and Day 22 of every cycle thereafter
45658861|NCT04729387|Drug|Pegylated liposomal doxorubicin (PLD)|PLD will be administered at 40-50 mg/m2 (physician discretion) as an intravenous infusion once every 28-days in a 28 day treatment cycle, starting on Cycle 1 Day 1
45658862|NCT04728841|Genetic|Injection of GS001|"Patients will be enrolled sequentially every 3 weeks or more between cohorts. Dose escalation may occur after a single patient has been safely dosed if the resulting FVIII activity at Week 3 is < 5 IU/dL.The dose levels are as follows:~2×10^12 vg/kg~6×10^12vg/kg or other recommended doses~2×10^13 vg/kg or other recommended doses"
45811481|NCT00004005|Drug|irinotecan hydrochloride|
45811482|NCT00004005|Drug|leucovorin calcium|
45811483|NCT00004005|Procedure|conventional surgery|
45811484|NCT00004005|Radiation|radiation therapy|
45811485|NCT00003603|Drug|cyclophosphamide|
45811486|NCT00003603|Drug|dexamethasone|
45811487|NCT00003603|Drug|idarubicin|
45811488|NCT00003603|Drug|lomustine|
45811489|NCT00003603|Drug|melphalan|
45811490|NCT00003603|Drug|prednisolone|
45811491|NCT00004887|Drug|carboplatin|
45811492|NCT00004887|Drug|cisplatin|
45811493|NCT00004887|Drug|ifosfamide|
45811494|NCT00004887|Drug|mitomycin C|
45811495|NCT00004887|Drug|paclitaxel|
45811496|NCT00004887|Drug|vinblastine sulfate|
45811497|NCT00004893|Biological|recombinant interleukin-12|
45811498|NCT04513951|Drug|5Fluorouracil|phase II
45811499|NCT04513951|Drug|L-leucovorin|phase II
45811500|NCT04513951|Drug|Irinotecan|phase II
45811501|NCT04513951|Drug|Oxaliplatin|phase II
45811502|NCT04513951|Drug|Cetuximab|phase II
45811503|NCT04513951|Drug|Avelumab|phase II
45811504|NCT03455569|Behavioral|Behavioral sleep education|This group will receive manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
45811505|NCT03455569|Behavioral|Education only|This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations
45811506|NCT00004011|Drug|carboplatin|
45811507|NCT00004011|Drug|paclitaxel|
45811508|NCT00004011|Procedure|conventional surgery|
45949042|NCT03274648|Dietary Supplement|Oral butyrate|Patients follow the habitual diet supplemented with 2.4g/day of oral butyrate
45949043|NCT03274648|Dietary Supplement|Vegetarian diet|Patients follow a vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
45949044|NCT03274648|Dietary Supplement|Habitual diet|Patients follow the habitual diet
45949045|NCT00454402|Drug|Alfuzosin|
45949046|NCT00109889|Procedure|magnetic resonance imaging|magnetic resonance imaging (MRI)
46076458|NCT05684289|Drug|BMS-986278|Specified dose on specified days
45949047|NCT00109889|Procedure|positron emission tomography|positron emission tomography (PET)
45949048|NCT00454441|Drug|MF101|
45658863|NCT04723667|Behavioral|13-week multimodal intervention|The experimental intervention was a 13-week multimodal intervention consists of five-weekly, 90-minute, face-to-face sessions to be delivered in a group format (six to eight participants per group), followed by two weekly and three biweekly telephone follow-ups. The five face-to-face sessions covered brain health information, booster memory power, reducing stressors, optimizing strength and active lifestyle engagement.
45811509|NCT03453385|Behavioral|Electronic Cigarette|An e-cigarette and four weeks of e-liquid provided to participants.
45949049|NCT00143676|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
45658864|NCT04723667|Behavioral|5-week health education programme|The health education program consisted of three topics (fall prevention, oral care and home hygiene), with two tele-booster follow up
45453556|NCT00752050|Drug|Mentor Purified Toxin Botulinum Toxin Type A|For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 30 U of the Active Comparator Mentor Purified Toxin.
45658865|NCT04715646|Drug|Brivaracetam|"Brivaracetam (BRV) tablets or oral solution will be administered twice daily (bid) in 2 equally divided doses.~Tablet strengths: 10 mg, 25 mg, 50 mg Route of administration: oral~Oral solution Concentration: 10 mg/ml Route of administration: oral"
45658866|NCT04704999|Drug|Tafenoquine|Tafenoquine will be given as 100mg coated tablets. Tablets will be given based on weight bands.
45811510|NCT03448393|Biological|CD19/CD22 CAR T-Cells|CD19/CD22 cells will be infused on Day 0 after induction chemotherapy regimen.
45811511|NCT03448393|Drug|Fludarabine|Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose)
45811512|NCT03448393|Drug|Cyclophosphamide|Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion on Day -2.
45811513|NCT04184635|Device|VA-ECMO|"The ECMO device will be the CardioHelp (MAQUET, GETINGE, Orléans, France) using the veno-arterial setting and percutaneous femoro-femoral cannulation with MAQUET GETINGE HLS cannulae.~Intraortic balloon pump will be MEGA 50 cc or 40cc, (MAQUET, GETINGE, Orléans, France)."
45811514|NCT00004017|Procedure|conventional surgery|
45811515|NCT00004017|Radiation|iodine I 131 monoclonal antibody TNT-1/B|
45949050|NCT00143676|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
45658867|NCT04704999|Drug|Chloroquine|Chloroquine will be given as daily dose over 3 days (25mg/kg total dose divided 10/10/5mg/kg)
45811516|NCT00004905|Biological|filgrastim|
45811517|NCT00004905|Biological|recombinant interferon alfa|
45811518|NCT00004905|Drug|cyclophosphamide|
45811519|NCT00004905|Drug|cytarabine|
45811520|NCT00004905|Drug|etoposide|
45811521|NCT00004905|Drug|idarubicin|
45811522|NCT00004905|Procedure|peripheral blood stem cell transplantation|
45811523|NCT00004905|Radiation|radiation therapy|
45811524|NCT00004029|Biological|recombinant viral vaccine therapy|
45949051|NCT00143676|Drug|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
45949052|NCT00454480|Biological|alemtuzumab|
45949053|NCT00454480|Drug|arsenic trioxide|
45949054|NCT00454480|Drug|azacitidine|
45949055|NCT00454480|Drug|busulfan|
45949056|NCT00454480|Drug|clofarabine|
45949057|NCT00454480|Drug|cytarabine|
45453557|NCT00752050|Drug|Preservative-free Saline|For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
45811525|NCT00004029|Biological|sargramostim|
45811526|NCT04174105|Genetic|AT845|AT845 is an AAV8 vector delivering a functional copy of the human GAA gene, under the control of a muscle-specific promoter
45811527|NCT00004041|Biological|Ad5CMV-p53 gene|
45811528|NCT00004041|Procedure|conventional surgery|
45811529|NCT00362323|Drug|fenofibrate (F) + metformin (M) hydrochloride fixed combination|F80mg/M500mg - per os - twice a day during 24 weeks / or / F80mg/M850mg - per os - twice a day during 24 weeks /or / F54mg/M850mg - per os - three times a day during 24 weeks
45949058|NCT00454480|Drug|daunorubicin hydrochloride|
45949059|NCT00454480|Drug|fludarabine phosphate|
45949060|NCT00454480|Drug|gemtuzumab ozogamicin|
45949061|NCT00454480|Drug|melphalan|
45949062|NCT00454480|Drug|tipifarnib|
45949063|NCT00454480|Genetic|DNA methylation analysis|
45949064|NCT00454480|Genetic|cytogenetic analysis|
45949065|NCT00454480|Genetic|gene expression analysis|
45949066|NCT00454480|Genetic|mutation analysis|
45949067|NCT00454480|Other|diagnostic laboratory biomarker analysis|
45949068|NCT00454480|Other|immunologic technique|
45949069|NCT00454480|Procedure|allogeneic hematopoietic stem cell transplantation|
45949070|NCT00454480|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
45658868|NCT04704999|Drug|Artemether 20 mg-Lumefantrine 120 mg|Artemether-lumefantrine will be given twice daily over 3 days. Whole tablets will be given based on weight bands.
45949071|NCT00110006|Biological|rituximab|Rituximab IV over 3-6 hours. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
45658869|NCT04702178|Biological|COVAC-2|Intramuscular vaccine against SARS-CoV-2
45658870|NCT04702178|Biological|Saline Placebo|Intramuscular injection of saline placebo
45811530|NCT00362323|Drug|Metformin|500mg - per os - twice a day during 24 weeks /or / 850mg - per os - twice a day during 24 weeks /or / 850mg - per os - three times a day during 24 weeks
45811531|NCT00004917|Biological|epoetin alfa|
45811532|NCT00004917|Drug|cisplatin|
45811533|NCT00004917|Radiation|radiation therapy|
45949072|NCT00110006|Drug|cyclophosphamide|Cyclophosphamide IV over 30 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
45949073|NCT00110006|Drug|doxorubicin hydrochloride|Doxorubicin IV over 5 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
45949074|NCT00110006|Drug|prednisone|Oral prednisone once daily on days 1-5. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
45949075|NCT00110006|Drug|vincristine sulfate|Vincristine IV over 5 minutes on day 1. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
45949076|NCT00110006|Procedure|positron emission tomography|Beginning 1 hour after receiving fludeoxyglucose F 18, patients undergo whole-body positron emission tomography (PET) scanning. Patients undergo repeat ^18FDG-PET scanning between days 7-10 of course 1, between courses 3 and 4, and then at the completion of R-CHOP.
45949077|NCT00110006|Radiation|fludeoxyglucose F 18|Patients receive fludeoxyglucose F 18 (^18FDG) IV.
45949078|NCT00454519|Procedure|cytoreductive surgery|the whole abdominal-pelvic cavity is explored and maximal cytoreductive surgery is performed to remove visible tumor burden as much as possible.
45949079|NCT00454519|Procedure|intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin|Immediately after the cytoreductive surgery, cisplatin and mitomycin C dissolved in 12,000 ml of normal saline heated to 42 degrees celsius is infused into the abdominal cavity for a sustained hyperthermic intraperitoneal chemotherapy for 60 to 90 minutes.
45949080|NCT00112749|Biological|infliximab|A single infusion of 1mg/kg will be administered.
45658871|NCT04699188|Drug|JDQ443|KRAS G12C inhibitor
45658872|NCT04699188|Drug|TNO155|SHP2 inhibitor
45458437|NCT03500848|Drug|Tacrolimus|Tacrolimus will be started between 3 and 7 days post-transplantation and continued after randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The tacrolimus trough level is measured twice a week for 1 month, followed by trough level once a month thereafter. Tacrolimus trough levels are targeted to be maintained at 8-15ng/ml until Month 6. After Month 6, the dose will be adjusted over time to maintain steady-state tacrolimus trough blood levels of approximately 5-10 ng/mL.
45949081|NCT00112749|Other|Clinical Assessment|Medical, psychiatric, and immune evaluation.
45949082|NCT00112749|Other|Self-report questionnaires|Fatigue Symptom Inventory, Multidimensional Fatigue Symptom Inventory, Hamilton Depression Rating Scale, Beck Depression Inventory II, Hamilton anxiety Rating Scale, Pittsburgh Sleep Quality Index, Brief Pain Inventory, MOS SF-36.
45949083|NCT00112749|Other|Immune Assessment|Proinflammatory cytokines and markers of cytokine activity and lymphocyte subsets and CBC.
45949084|NCT00454597|Procedure|omentectomy|surgery omentectomy
45949085|NCT00110045|Drug|caspofungin acetate|
45658873|NCT04699188|Biological|tislelizumab|Anti PD1 antibody
45949086|NCT00454714|Drug|single dose Sildenafil|Application of a single dose Sildenafil
46076459|NCT05684289|Drug|Sildenafil|Specified dose on specified days
45658874|NCT04698967|Behavioral|Purposeful Pathways|Purposeful Pathways is a manualized intervention to assist veterans in aspiring and pursuing meaningful employment. Purposeful Pathways is an individual counseling protocol delivered weekly for up to 12 sessions (50 minutes per session) focused on career exploration, goal clarity, job-searching, and self-regulation.
45658875|NCT04698967|Behavioral|Transitional Work Experience|Provides Veterans with immediate access to a non-competitive, paid job contracted by the VA. Positions are typically housed within a VA hospital (e.g., housekeeping, grounds, kitchens, and construction), but are sometimes located in the community. TWE is time-limited. TWE is staffed by vocational rehabilitation specialists (VRS).
45949087|NCT00454714|Drug|Single dose placebo|Application of a single dose placebo
45949088|NCT00454792|Other|Exercise|Back exercise: At home every day. In groups once a week. Duration 10 weeks.
45811534|NCT00421915|Drug|Enbrel (etanercept)|
45811535|NCT00362713|Drug|Ipilimumab|Intravenous Solution, Intravenous, One dose every 3 weeks for four weeks, followed through Week 24
45811536|NCT02384473|Procedure|Real-Time CEUS|Undergo real-time CEUS
45811537|NCT02384473|Procedure|SWE|Undergo SWE
45811538|NCT02384473|Drug|Definity Suspension for Injection|Participant will receive contrast agent by intravenous administration
45811539|NCT02384473|Device|Philips Shear Wave Elastography|Type of equipment used for SWE
45811540|NCT02382601|Radiation|Ultrasound|With 3-D and 4-D high-resolution color Doppler methods it is possible to map out the placental circulation, fetal circulation, fetal brain, and fetal cardiac function. Investigators will collect these data points prenatally.
45811541|NCT02382601|Radiation|MRI|Similar to the Ultrasound data, investigators will collect MRI images of the fetal brain and the placenta. MRI will allow investigators to collect more detailed images of both the fetal brain and placenta, and investigators will be utilizing this technique both prenatally and postnatally.
45949089|NCT00454792|Other|Restitution|Restitution: At home 2 times one hour. Meetings every 2 weeks. Duration 10 weeks.
45658878|NCT04649151|Biological|mRNA-1273|Sterile liquid for injection
45658879|NCT04649151|Biological|Placebo|0.9% sodium chloride (normal saline) injection
45658880|NCT04649151|Biological|mRNA-1273.222|Sterile solution for injection
45658881|NCT04640779|Drug|Choline Salicylate|Given PO
45658882|NCT04640779|Drug|Selinexor|Given PO
45811542|NCT02382601|Procedure|Blood collection|The maternal and cord blood will be collected for the processing of plasma and serum. There may be early biomarkers of IUGR in the maternal circulation that investigators can use to better determine the appropriate strategy for clinical management of care. Collection and subsequent analysis of molecular markers in the umbilical cord blood will be used to further confirm physiological dysfunction as detected by ultrasound and MRI techniques.
45811543|NCT02382601|Behavioral|Neurological Function Assessment|Neurological development tests including a Bayley exam, Mullen exam, Developmental Profile-3, Child Behavior Checklist, and Pediatric Stroke Outcome Measure (PSOM) will be performed.
45811544|NCT02382601|Procedure|Placental Analysis|Placentas will undergo pathological evaluation for placental function.
45811545|NCT02382601|Procedure|Measurement of body fat|The baby's body fat will be measured in a special incubator called a PEAPOD or BODPOD when an infant.
45811546|NCT02382601|Radiation|Pediatric heart ultrasound|Children will have ultrasounds of their hearts during follow-up visits.
45811547|NCT00004047|Drug|exatecan mesylate|
45811548|NCT00003627|Drug|cisplatin|
45811549|NCT00003627|Drug|fluorouracil|
45811550|NCT00003627|Radiation|radiation therapy|
45811551|NCT04160065|Biological|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~Immunomodulatory Agent~Route of Administration:~Intralesional (i.e. injection of cutaneous, subcutaneous or nodal lesions)~Mechanism of Action:~Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses."
45811552|NCT00004059|Drug|7-hydroxystaurosporine|
45811553|NCT00004059|Drug|fluorouracil|
45811554|NCT00003633|Drug|docetaxel|
45811555|NCT00003633|Drug|estramustine phosphate sodium|
45811556|NCT00003633|Drug|mitoxantrone hydrochloride|
45949090|NCT00143715|Drug|Phytonadione (Vitamin K1)|1.25 mg given orally
45949091|NCT00454831|Device|HEP-40 chitosan|Enzymatically Hydrolyzed Polychitosamine-40 kDa
45811557|NCT00003633|Drug|prednisone|
45949092|NCT00110123|Drug|fotemustine|
46076460|NCT05684289|Drug|Placebo|Specified dose on specified days
45658883|NCT04628481|Drug|Ladarixin|Oral ladarixin twice a day for 13 cycles
45658884|NCT04628481|Drug|Placebo|Oral placebo twice a day for 13 cycles
45658885|NCT04612751|Drug|Datopotamab deruxtecan|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
45811558|NCT00003639|Biological|recombinant interferon alfa|
45658886|NCT04612751|Drug|Durvalumab|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
45658887|NCT04612751|Drug|Carboplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle
45811559|NCT00003639|Drug|chlorambucil|
45811560|NCT00003639|Drug|dexamethasone|
45811561|NCT00003639|Drug|idarubicin|
45811562|NCT00004923|Drug|docetaxel|
45811563|NCT00004923|Drug|irinotecan hydrochloride|
45949093|NCT00110123|Drug|isolated perfusion|
46076461|NCT02541799|Procedure|Audio-visual telemedicine|Participants in an emergency department will have their care delivered using telemedicine, then they will be approached for a study by a study investigator using the same telemedicine link
46076462|NCT02541799|Procedure|Standard care|Participants in an emergency department will have their care delivered in person, then they will be approached by a study investigator face-to-face.
46076463|NCT02771106|Other|neuro vision rehabilitation|Neuro vision rehabilitation used to treat vision dysfunction following TBI
46076464|NCT02829008|Drug|low-dose-bevacizumab/pemetrexed|Bevacizumab is administrated at a dose of 2 mg/kg once weekly by intravenous transfusion, which is on day 1, 8 and 15, and pemetrexed is given at a dose of 500mg/m2 once on the first day by intravenous transfusion, and repeated every three weeks, too.
45658888|NCT04612751|Drug|AZD2936|Intravenous infusion prior to Dato-DXd
45658889|NCT04612751|Drug|MEDI5752|Intravenous infusion prior to Dato-DXd
45658890|NCT04596267|Drug|Pitolisant|8.9mg Pitolisant for 5 days
45811564|NCT00004929|Biological|MUC-2-KLH vaccine|
45811565|NCT00004929|Biological|QS21|
45811566|NCT02317783|Drug|[18F]Flutemetamol|Brain scan with imaging tracer that binds to amyloid plaques
45811567|NCT02317783|Drug|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with imaging tracer used for measuring glucose metabolism in the assessment, diagnosis, and staging of patients with cancer
45811568|NCT02317783|Diagnostic Test|Functional Magnetic Resonance Imaging (fMRI)|Brain scan to assess regions of abnormal volume and density
45811569|NCT00004065|Drug|tanespimycin|
45811570|NCT00004071|Drug|leflunomide|
45811571|NCT00004071|Drug|mitoxantrone hydrochloride|
45811572|NCT00004071|Drug|prednisone|
45811573|NCT00004077|Drug|cisplatin|
45811574|NCT00004077|Drug|ifosfamide|
45811575|NCT00004077|Drug|paclitaxel|
45811576|NCT00004083|Drug|cisplatin liposomal|
45811577|NCT00004941|Drug|monoclonal antibody cA2|
45811578|NCT00004983|Behavioral|diabetes self-management education|
45811579|NCT00003657|Biological|filgrastim|
45811580|NCT00003657|Drug|Amifostine|
45949094|NCT00454870|Drug|MEM 3454|
45949095|NCT00455026|Drug|remifentanil|target effect site concentration during induction
45949096|NCT00143325|Drug|varenicline (CP-526,555)|
45949097|NCT00455065|Behavioral|Whole Grain Foods|
45949098|NCT00112983|Biological|eculizumab|
45949099|NCT03274609|Combination Product|Augmented fluoroscopy|Augmented fluoroscopy based virtual navigation combined with use of radial EBUS probe and Rapid On Site Evaluation of Histology for diagnosis of peripheral pulmonary nodules.Controlled by cone beam CT.
46076465|NCT02829008|Drug|Treatment of physician's choice|The clinicians can select any drug or regimen that has been approved in metastatic cancer at present, including monotherapy, combination therapy, target therapy and palliative therapy. Specific agents include taxanes, capecitabine, gemcitabine, vinorelbine, cisplatin,carboplatin, nutrient solutions, and so on. These agents can be administered as monotherapy or in combination.
45453558|NCT02275390|Behavioral|Nurse-led Psycho-education (or SPBB: self-learning program)|"The program was modified from the psycho-educational, motivation-driven and emotionally supportive programs developed and previously tested by the research team in Chinese people with different kinds of serious mental illness, mainly including schizophrenia spectrum disorders and mood disorders by Chien and his colleagues in 2012, and adherence therapy for people with psychotic disorders by Gray et al. (2010).~[Note: SPBB consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the [psychosocial] effects of the illness; and Module 5: Dealing with [physical and mental health] effects of the illness).]"
46076466|NCT05683821|Behavioral|Text message smoking treatment|"Facilitated enrollment in an NCI-sponsored text messaging program:~SmokefreeTXT (if ready to set a quit date in the next 14 days)~Practice Quit (if ready to practice quitting 1-5 days but not ready to quit permanently)~Daily Challenges (if not ready to quit, but willing to make some changes)"
45453559|NCT02275390|Behavioral|Usual Psychiatric Outpatient Care|These services consisted of medical consultation and treatment by the attending psychiatrist (i.e., around every four weeks), brief education sessions (i.e., 3 or 4 one-hour sessions) on mental illness and treatment received by psychiatric nurses, and advices and referrals for community mental health and social welfare services available and/or family counseling by a psychiatric nurse or medical social worker in each clinic.
45658891|NCT04596267|Drug|Placebo|Inert ingredients
45658892|NCT04588740|Drug|concentrated beet root juice|On average, we will expect subjects to ingest the supplement for approximately 5 days minimum depending on their testing schedule. On each testing day subjects will be asked to consume the two bottles of either beetroot juice (BRJ) or Placebo 2.5 hours before testing time. Specifically, for female subjects, they will be asked to start their supplementation on day 1 of menses. On day 3-4 they will take the last 2 shots. Female subjects' wash-out period will go according to their menstrual cycle as we will be controlling for hormone fluctuation (low vs high estrogen phase) know to interact with nitric oxide physiology.
45811581|NCT00003657|Drug|Carboplatin|
45811582|NCT00003657|Drug|Etoposide|
45811583|NCT00003657|Drug|Ifosfamide|
45949100|NCT00110162|Drug|antiandrogen therapy|
45458438|NCT03500848|Drug|Tacrolimus (Tacrolimus elimination)|Tacrolimus will be started between 3 and 7 days post-transplantation at a dose of 1.0 mg twice a day (bid, 2 mg daily dose) for 30 (± 5) days and eliminated when randomization is done.
45658893|NCT04588740|Drug|Placebo beet root juice|This will follow the same supplementation regime as explained above but this supplement taste and looks exactly the same as the nitrate-rich beet root juice. It is provided by the same company that produces the concentrated beet root juice shots (Beet It, UK)
45658894|NCT04583878|Diagnostic Test|Blood draw (Visit 1)|Labs will be drawn at Visit 1, also referred to as screening (within 60 days of diagnosis) with the standard of care labs drawn.
45811584|NCT00003657|Procedure|peripheral blood stem cell transplantation|
45811585|NCT00004089|Biological|filgrastim|
45811586|NCT00004089|Drug|fluorouracil|
45811587|NCT00004089|Drug|hydroxyurea|
45811588|NCT00004089|Drug|paclitaxel|
45949101|NCT00110162|Drug|releasing hormone agonist therapy|
46076467|NCT05683821|Drug|Nicotine replacement therapy sampling|"Participants may request:~Nicotine patches that release nicotine slowly over 24 hours, in either 7 mg, 14 mg, or 21 mg doses~Nicotine gum or lozenges that release medication quickly and can be used every 1-2 hours to prevent and cope with cravings to smoke, in either 2 mg or 4 mg doses"
45811589|NCT00004089|Procedure|conventional surgery|
45811590|NCT00004089|Radiation|radiation therapy|
45811591|NCT00004095|Drug|gemcitabine hydrochloride|
45811592|NCT00004095|Drug|irinotecan hydrochloride|
45811593|NCT00004101|Biological|apolizumab|
45811594|NCT00003663|Biological|rituximab|
45811595|NCT00003663|Drug|dexamethasone|
45811596|NCT00004107|Biological|filgrastim|as prescribed by physician
45811597|NCT00004107|Procedure|autologous bone marrow transplantation|1-2 weeks before treatment
45949102|NCT00110162|Procedure|orchiectomy|
45949103|NCT03274336|Behavioral|questionnaire|questionnaire post preanesthetic interview
45949104|NCT03274336|Behavioral|face-to-face interview|Group A = face-to-face interview
45949105|NCT03274336|Behavioral|brochure|after reading a brochure a face to face interview will take place
45949106|NCT03274336|Behavioral|movie|after seeing a film about the procedure a face-to-face interview will take place
45658895|NCT04583878|Diagnostic Test|Blood draw (Visits 2 and 3)|Labs will be drawn at Visit 2 (12 weeks post-diagnosis with a range of 10-16 weeks) and Visit 3 (12 months ± 30 days) for research purposes only and will be collected at Children's Medical Center and processed at UT Southwestern Medical Center.
45658896|NCT04582669|Drug|Intralesional Triamcinolone 10 mg/mL|Injection of 1 mL intralesional triamcinolone 10 mg/mL in up to 3 anatomic areas.
45811598|NCT00004107|Procedure|peripheral blood stem cell transplantation|1-2 weeks before treatment
45811599|NCT00004107|Radiation|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
45949107|NCT02273674|Device|Left rTMS 5 Hz|The subjects will receive transcranial magnetic stimulation (5 Hz of frequency over left dorsolateral prefrontal cortex . Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
45949108|NCT02273674|Device|Right r TMS 1 Hz|The subjects will receive transcranial magnetic stimulation (1 Hz of frequency over right dorsolateral prefrontal cortex . Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
45949109|NCT00143754|Procedure|Hydration|
45949110|NCT02273713|Drug|Nab-paclitaxel|Nab-paclitaxel added to first line treatment oxaliplatin and capecitabine
45811600|NCT00004107|Radiation|yttrium Y 90 epratuzumab|intravenous infusion over 30 min; single dose
45811601|NCT00003669|Drug|arzoxifene hydrochloride|
45811602|NCT00004113|Drug|temozolomide|
45811603|NCT00003675|Drug|topotecan hydrochloride|1.2 mg/sq m twice a day for 5 days (Arm I) and once a day for 10 days (Arm II)
45811604|NCT00004137|Biological|filgrastim|
45658897|NCT04582669|Drug|Intralesional Triamcinolone 20 mg/mL|Injection of 1 mL intralesional triamcinolone 20 mg/mL in up to 3 anatomic areas.
45811605|NCT00004137|Drug|carboplatin|
45811606|NCT00004137|Drug|paclitaxel|
45811607|NCT00004137|Drug|topotecan hydrochloride|
45658898|NCT04582669|Drug|Intralesional Triamcinolone 40 mg/mL|Injection of 1 mL intralesional triamcinolone 40 mg/mL in up to 3 anatomic areas.
45658899|NCT04582669|Drug|Placebo|Injection of 1 mL sodium chloride 0.9% in up to 3 anatomic areas.
45811608|NCT00003681|Biological|epoetin alfa|
45811609|NCT00003681|Drug|amifostine trihydrate|
45811610|NCT00005001|Biological|HIV-1 Immunogen|
45811611|NCT00005007|Drug|Etanercept|
45811612|NCT04712487|Diagnostic Test|Microbiological culture, viral PCR, histopathological analysis|"Intervertebral disc tissue was sent to the laboratory for further analysis:~Microbiological culture: Detection of bacterial growth Viral PCR: Detection of Herpes-Simplex-Type 1 virus, Herpes-Simplex-Type 2 virus, Cytomegalovirus Histopathological analysis: Inflammation signs of disc tissue"
45811613|NCT00384579|Drug|Botulinum toxin B|Botulinum Toxin B
45949111|NCT00110201|Drug|Nesiritide|
45949112|NCT02273791|Drug|Estradiol valerate|Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is < 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
45811614|NCT00384579|Drug|Placebo|Placebo
45811615|NCT00004149|Drug|arsenic trioxide|
45811616|NCT00384657|Drug|iron sucrose|"Patients in Group I will receive iv iron sucrose, as described in the study protocol.~Patient in Group II will receive conventional treatment for chronic heart failure."
45811617|NCT00005013|Drug|Sertraline|
45811618|NCT00005013|Drug|Hypericum perforatum (St. John's wort)|
45949113|NCT02273791|Drug|Sequential Clomiphene citrate and Gonadotropin|Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle > 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
46076468|NCT05683821|Combination Product|Wisconsin Tobacco QuitLine Referral|Patients will be offered referral to the Wisconsin Tobacco QuitLine that offers phone counseling and nicotine replacement starter kits (2 week supplies) to people ready to quit smoking, in addition to web-based, text messaging, and mailed support, at no cost to Wisconsin residents.
46076469|NCT05683821|Combination Product|Referral to Primary Care Provider|Patients who want to talk to their Primary Care Providers about quitting smoking will be encouraged to make an appointment with their provider to receive smoking cessation counseling and to discuss pharmacotherapy options.
45811619|NCT00004161|Drug|fenretinide|
45811620|NCT00004161|Drug|Placebo|
45811621|NCT00004173|Drug|oxaliplatin|
45811622|NCT00004173|Drug|paclitaxel|
45811623|NCT00005025|Biological|herpes simplex thymidine kinase|
45811624|NCT00005025|Drug|ganciclovir|
45811625|NCT00004179|Biological|rituximab|
45811626|NCT00004179|Drug|CHOP regimen|
45811627|NCT00004179|Drug|cyclophosphamide|
45811628|NCT00004179|Drug|doxorubicin hydrochloride|
45811629|NCT00004179|Drug|prednisone|
45811630|NCT00004179|Drug|vincristine sulfate|
46002252|NCT04221542|Drug|Abiraterone|Abiraterone administered as oral tablets.
46002253|NCT04221542|Drug|Enzalutamide|Enzalutamide administered as oral tablets.
45949114|NCT00455182|Procedure|Acupuncture|Standard medical care plus a single true acupuncture treatment.The needles are strategically inserted into the scalp, trunk, arms or legs (not near the surgical site) and manipulated. The needles are withdrawn between 5 minutes and 30 minutes after insertion.
45949115|NCT00455182|Procedure|Sham Acupuncture|Standard medical care plus sham acupuncture. A single treatment, using a maximum of 9 sham needles, which adhere to the skin but do not penetrate it. The sham needles are strategically placed on the scalp, trunk, arms or legs (not near the surgical site)
45949116|NCT00455182|Procedure|Standard medical care|Standard medical care at Woodwinds Hospital includes guided imagery, essential oils and massage.
45949117|NCT00455221|Biological|Bcr-abl multipeptide vaccine|The first three patients will receive the lower dose of both IL-12 and GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the lower dose of IL-12 plasmid and higher dose of GM-CSF plasmid. If this is well tolerated, then the next three patients will receive the higher dose of IL-12 and lower dose of GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the higher dose of both IL-12 and GM-CSF plasmids. Once assigned to a dose, the patient will receive the same dose throughout their participation in this trial
45811631|NCT00003687|Drug|dextromethorphan hydrobromide|
45949118|NCT00455221|Genetic|Cytokine gene adjuvant|Cytokine gene adjuvant
45949119|NCT00110240|Drug|vildagliptin|
45949120|NCT00455260|Drug|hGH-ViaDerm™ System (hGH or somatropin)|transdermal patch; Group 1: 0.2 mg/day SC hGH during Period I, and 0.5 mg per transdermal patch during Period III (expected equivalent dose to SC 0.2 mg/day) Group 2: 0.4 mg/day SC hGH during Period I, and 2.0 mg per transdermal patch during Period III (expected equivalent dose to SC 0.4 mg/day) Group 3: 1.0 mg/day SC hGH during Period I, and 5.0 mg per transdermal patch during Period III (expected equivalent dose to 1.0 mg/day)
46002254|NCT04221542|Drug|Docetaxel|Docetaxel administered as an IV infusion.
46002255|NCT04209205|Drug|AIN457 6 mg/kg i.v.|AIN457 6 mg/kg delivered by i.v. infusion
46002256|NCT04209205|Drug|Placebo|Matching placebo to AIN457 i.v. infusion
46002257|NCT04209205|Drug|AIN457 3 mg/kg|AIN457 3 mg/kg delivered by i.v. infusion
46076470|NCT05683821|Combination Product|BREATHE 2 Cessation Study|Patients who are interested in participating in a separate randomized controlled trial of smoking cessation treatment will be invited to learn about and complete an eligibility screening and consent process for the trial. Those who enter the study receive both counseling and pharmacotherapy.
45658900|NCT04580498|Drug|SHR-1701+Paclitaxel+carboplatin|Drug: SHR-1701 30mg/kg Drug: Paclitaxel 175mg/m2 Drug: Carboplatin AUC 5
45811632|NCT00003687|Drug|morphine sulfate|
45811633|NCT00004197|Biological|keyhole limpet hemocyanin|
45658901|NCT04580498|Drug|SHR-1701|Drug: SHR-1701 30mg/kg
45658902|NCT04575142|Device|CO2 laser|"the CO2 laser (AcuPulse DUO, Lumenis, Yokneam, Israel) generally ranges from 3 to 10 W in superpulse mode, with 0.05 second on/0.01 second off, depending on lesion size and location of the lesion(s).~The CO2 laser can be used in a continuous, pulsed, or superpulsed mode. The superpulsed mode reduces the exposure time to a few nanoseconds while delivering high energies of 400 to 500 W with each peak. The rest time between each peak allows the tissues to cool and reduces thermal injury to adjacent tissues."
45658903|NCT04574843|Procedure|Embolization of MMA|embolization of MMA with one of following liquid embolic agents (Onyx-Squid-Phil)
45658904|NCT04571619|Behavioral|Pain Coping Skills Training (PCST)|The PCST intervention will focus primarily on reducing pain interference in daily activities and improving pain self-management skills. For participants with recent or current opioid use, the PCST intervention will include motivational interviewing aimed at reducing opioid use. During Weeks 1 - 12 the PCST will be delivered by coaches via telehealth (video). During Weeks 13 - 24, the Interactive Voice Response (IVR) will be delivered via telephone. The telehealth component will consist of weekly sessions, each lasting 45-50 minutes. The IVR content, intended to enhance and sustain the effects of the coach-led session, will be delivered with daily telephone interactions, each lasting approximately 5 minutes. Both components of the intervention will be available in English and Spanish.
45811634|NCT00004197|Biological|sargramostim|
45811635|NCT00004197|Biological|tumor cell-based vaccine therapy|
46076471|NCT05683821|Behavioral|Additional modalities to learn about and request treatment|Participants in Enhanced Outreach arm clinics will have the option to request e-mail and/or text message communication regarding their smoking treatment options, and to initiate treatment via phone or online survey.
46076472|NCT00889135|Drug|droxidopa|Droxidopa (L-DOPS) comes in capsule form, 100 mg or 200 mg strength and is usually administered 2 - 3 times per day. It would be taken indefinitely to improve symptoms of orthostatic hypotension
46076473|NCT04828590|Other|No intervention|Due to observational study
45811636|NCT00004197|Drug|cyclophosphamide|
45811637|NCT00004197|Drug|doxorubicin hydrochloride|
45811638|NCT00004197|Drug|mitoxantrone hydrochloride|
45811639|NCT00004197|Drug|prednisone|
45811640|NCT00004197|Drug|vincristine sulfate|
45811641|NCT00003693|Drug|Dolastatin 10|IV bolus once every 3 weeks.
45811642|NCT00005031|Drug|irofulven|
45811643|NCT00005037|Drug|temozolomide|
45811644|NCT00005037|Drug|Temozolomide|Temozolomide capsule once a day for 42 days every 10 weeks.
45811645|NCT00385047|Biological|Group A FMP2.1/AS01B|
45811646|NCT00385047|Biological|Group B FMP2.1/AS02A|
45811647|NCT00004203|Drug|oxaliplatin|
45811648|NCT00003705|Drug|BMS-184476|
45811649|NCT00004209|Drug|cisplatin|
45811650|NCT00004209|Drug|mitomycin C|
45811651|NCT00004209|Drug|vinblastine sulfate|
45811652|NCT00005049|Drug|carboplatin|
45811653|NCT00005049|Drug|cisplatin|
45811654|NCT00005049|Drug|floxuridine|
45811655|NCT00004215|Biological|filgrastim|
45811656|NCT00004215|Biological|leridistim|
46076474|NCT00889213|Procedure|Falciform patch and fibrin glue application|Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament. Those patients randomized to autologous falciform patch will have the falciform membrane harvested. The falciform patch will be laid over the suture line of the resected pancreatic stump and secured to the pancreatic capsule utilizing #4-0 PDS suture placed at 12, 3, 6, and 9 o'clock positions. Fibrin glue (Vitagel) will be utilized to fill the potential space within this membranous capsule. Fibrin glue will be prepared as per standard instructions. Drains will be placed in the splenic bed and/or adjacent to the stump of the pancreas for postoperative fluid evacuation.
45949121|NCT00455260|Device|hGH-ViaDerm™ System|"The hGH-ViaDerm™ System is a transdermal delivery system for somatropin (hGH, rDNA origin).~The ViaDerm System™ consists of a medical device component and a printed dry hGH patch component. The device component is comprised of two primary elements: a reusable, computer mouse-like electronic controller and a disposable sterile array, which is inserted onto the base of the controller, delivers RF-current to ablate cells and creates microscopic throughways, termed RF-MicroChannels™, across the stratum corneum into the upper epidermis. The drug component consists of a unique circular transdermal dry hGH patch formulated specifically for use with the ViaDerm™ device. hGH is delivered by passive diffusion through the RF-MicroChannels™ into the systemic circulation system."
45658905|NCT04571619|Drug|Buprenorphine|At Week 24, participants who meet the eligibility criteria for the buprenorphine intervention will be encouraged to switch from their current full agonist opioid medication to the partial opioid agonist, buprenorphine. Participants who switch to Buprenorphine will be provided with individualized buprenorphine treatment recommendations. Individualized buprenorphine treatment recommendations will be made by the study buprenorphine physician based on current opioid use and other relevant factors. Participants who do not meet the Phase 2 eligibility criteria will not be offered buprenorphine. All participants will continue to be followed from Week 24 until Week 36 for ascertainment of pain, opioid use, and other outcomes to address durability of the effects of PCST, and, for those who switch to buprenorphine, to assess buprenorphine acceptability, tolerability, and efficacy as exploratory outcomes.
45949122|NCT00455299|Procedure|Laparoscopic ventral hernia repair|
45949123|NCT00455338|Behavioral|Meal Composition|
45949124|NCT00110279|Biological|H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
45949125|NCT00455416|Drug|Omega 3 fatty acids (EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid))|1000mgx5 daily
46076475|NCT00889213|Procedure|standard pancreatic closure|Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament.
46076476|NCT05272748|Other|Conventional Exercise|Before and after the treatment, patients' pain, postural control (static and dynamic balance), functional level and fear of falling will be evaluated. Strengthening and flexibility exercises will be done to the conventional exercise group. Hip and knee isometric and isotonic exercises, terminal knee extension, mini squat, lunge, range of motion exercises for lower extremities, hamstring, quadriceps, gastrocnemius stretching exercises will be performed by the patients. Exercises will be applied 3 times a week.
45658907|NCT04562233|Behavioral|Online-delivered physical activity intervention.|Participants randomized to the intervention arm will engage in 12, weekly, supervised, exercise sessions using Zoom with the exercise trainer.
46076477|NCT05272748|Other|Conventional Exercise + Core Stabilization Exercise|Before and after the treatment, patients' pain, postural control (static and dynamic balance), functional level and fear of falling will be evaluated. In addition to the exercises in the conventional exercise group, patients will perform bridging, lateral bridging, plank, extremity exercises in the crawling position, abdominal crunch, oblique crunch, dead bug, clam exercise. Exercises will be applied 3 times a week.
45658908|NCT04562233|Behavioral|Printed, individualized resistance-based physical activity program.|Without the supervision of an exercise trainer, participants will be given a printed, individualized resistance-based physical activity program to complete over the course of 12 weeks.
46076478|NCT02046135|Drug|Sodium Bicarbonate|
46076479|NCT02046135|Drug|Sodium Chloride|
46076480|NCT02766504|Device|airway ultrasound|airway assessment using ultrasound
45658909|NCT04560998|Drug|Semaglutide|Semaglutide is administered subcutaneously (s.c.; under the skin) once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
45658910|NCT04560998|Drug|Placebo (semaglutide)|Placebo (semaglutide) is administered s.c. once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
45811657|NCT00004215|Drug|cytarabine|
45811658|NCT00004215|Drug|daunorubicin hydrochloride|
45811659|NCT00004221|Drug|Carboplatin|Given IV
45811660|NCT00004221|Drug|Cyclophosphamide|Given IV
45811661|NCT00004221|Biological|Filgrastim|Given SQ
45811662|NCT00004221|Drug|Paclitaxel|Given IV
45811663|NCT00004221|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplantation
45949126|NCT00455416|Drug|Selenium (L-Selenomethionine),|100mcgx2 daily
45811664|NCT00004221|Drug|Topotecan Hydrochloride|Given IV
45811665|NCT00005055|Drug|glufosfamide|
45811666|NCT00003711|Drug|irinotecan hydrochloride|
45811667|NCT00003711|Drug|pemetrexed disodium|
45811668|NCT00004227|Biological|cetuximab|
45811669|NCT00004227|Procedure|conventional surgery|
45811670|NCT00004227|Radiation|radiation therapy|
45811671|NCT00003621|Drug|carmustine|
45811672|NCT00003621|Drug|cisplatin|
45949127|NCT00455416|Drug|Garlic extract (Allicin)|6 garlic pearls daily
45949128|NCT00455416|Drug|Pomegranate juice (ellagic acid)|Pomegranate juice 100%, 660ml /495 ml every second day.
45658911|NCT04560075|Behavioral|Text2Connect|The T2C intervention aims to increase mental health self-efficacy though psychoeducation, self-monitoring of symptoms and stressors, and cues to action for college-bound youth.
45658912|NCT04560075|Behavioral|Psychoeducational Videos (PE) Only|Participants in this group will receive psychoeducation through the PE video library.
45811673|NCT00003621|Drug|etoposide|
46076481|NCT00886327|Procedure|Colonic capsule endoscopy|
46076482|NCT04245488|Other|taste test|rate intensity of sour solutions and fatty acid solutions
45658913|NCT04544462|Other|M2 Test|DNA will be extracted from saliva samples obtained from participants. Genetic testing will be performed to screen for the M2 mutation and determine the carrier status of each patient and partner.
45658914|NCT04528498|Other|Preimplantation Genetic Testing|Embryo biopsies will undergo preimplantation genetic testing for aneuploidies as per standard of care, and polygenic disease risk (PGT-P) will be computed for these samples.
45811674|NCT00003621|Radiation|radiation therapy|
45811675|NCT00385359|Procedure|aerosol drug deposition strategies|
45811676|NCT00385359|Drug|Albuterol|
46076483|NCT00382200|Drug|decitabine|
45949129|NCT00455416|Drug|Grape juice (resveratrol, quercetin)|Merlot grape juice 100%, 660ml /495 ml every second day
45949130|NCT00455416|Drug|Green Tea (Epigallocathechin gallate)|Green Tea. 2 cups daily
45949131|NCT00455494|Drug|AQ-13|
45949132|NCT00143871|Drug|Rituximab|
45949133|NCT00455572|Biological|Immunotherapeutic GSK1572932A|Intramuscular injection, 8 doses
46076484|NCT00382200|Drug|tretinoin|
46076485|NCT00382200|Genetic|DNA methylation analysis|
46076486|NCT00382200|Genetic|cytogenetic analysis|
45658915|NCT04523337|Behavioral|Maintaining Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice|Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice version (MISSION-CJ) programming targets co-occurring substance use and mental health disorders and other related health outcomes faced by justice-involved homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based services. Patients will receive 2 hours of MISSION-CJ services per week during and after their stay in the mental health residential rehabilitation program (total of 6-months). Services are delivered using a Critical Time Intervention stepdown approach.
45658916|NCT04523337|Behavioral|Maintaining Maintaining Independence and Sobriety through Systems Integration Outreach and Networking Peer Support|The MISSION Peer Support Curriculum is rolling entry, and includes 24, one-hour exercises focused on co-occurring substance use and mental health disorders, recovery, and community integration.
45811677|NCT02972619|Other|Structured Multicomponent Intervention (MCI)|Multicomponent Intervention (MCI) includes 1) algorithm-driven antihypertensive treatment for all hypertensive individuals using fixed-dose combination (FDC) and lipid lowering for high risk hypertensive individuals, 2) motivational conversation for high-risk hypertensive individuals and 3) telephone based follow-ups of all hypertensive individuals by a team of physician supervised nurse, and 4) discounts on FDC antihypertensive medications
45811678|NCT00004233|Drug|fluorouracil|
45811679|NCT00004233|Drug|leucovorin calcium|
45811680|NCT00004233|Drug|triacetyluridine|
45811681|NCT00003717|Drug|estramustine phosphate sodium|
45811682|NCT00003717|Drug|paclitaxel|
46076487|NCT00382200|Genetic|microarray analysis|
46076488|NCT00382200|Other|flow cytometry|
45811683|NCT00004239|Drug|Compound 506U78|
45811684|NCT00003723|Drug|gemcitabine hydrochloride|Gemcitabine 1000 mg/m^2 days 1, 8 15 (q 28 days)
45811685|NCT00005061|Biological|bevacizumab|
45811686|NCT00004245|Drug|sodium salicylate|
45949134|NCT00455572|Drug|Cisplatin (CDDP)|Four cycles with doses based on patient's body surface area, intravenous administration
45949135|NCT00455572|Drug|Vinorelbine|Four cycles with doses based on patient's body surface area , intravenous administration
45949136|NCT00455572|Procedure|Radiotherapy|Regimen will be based upon the site's own standard procedures
45949137|NCT00110318|Procedure|Manual therapy and therapeutic exercise|
45949138|NCT00110318|Procedure|Corticosteroid injections|
45811687|NCT00004251|Drug|letrozole|2.5 mg of letrozole per day
45811688|NCT00005067|Drug|motexafin lutetium|Given IV
45811689|NCT00005067|Drug|photodynamic therapy|Undergo photodynamic therapy
45811690|NCT00003729|Drug|cytarabine|
45811691|NCT00003729|Drug|fludarabine phosphate|
45811692|NCT00003729|Drug|idarubicin|
45949139|NCT00455611|Device|CPAP (Continuous Positive Airway Pressure)|
45949140|NCT00113061|Procedure|Exercise|
45949141|NCT00455767|Drug|EPI-hNE4|I.V. injection of 1mg/kg Depelestat (EPI-hNE4) 3 times daily for 7 days
45949142|NCT00455767|Drug|Placebo|Placebo
45949143|NCT00401492|Drug|gemcitabine prolonged continuous infusion|
45949144|NCT00401492|Drug|cisplatin|
46076489|NCT00382200|Other|immunohistochemistry staining method|
46076490|NCT04245566|Procedure|Prostatic Artery Embolization (PAE)|Prostatic artery embolization will be performed under local anesthesia according to well established and standardized techniques.
46076491|NCT04245566|Drug|Pharmacotherapy|Pharmacotherapy will be performed using α1-blockers and 5α-reductase inhibitors in accordance with the EAU recommendations
46076492|NCT00802893|Drug|6R-BH4|6R-BH4 5mg/kg or Placebo BID for four weeks and then 8 week dose-escalation period
46076493|NCT00802893|Other|Placebo|placebo given BID for entire length of study
46076494|NCT02696928|Drug|Artemeter-Lumefantrine and MB (combination therapy)|AL first 3 days MB next 14 days
45658917|NCT04514107|Other|Brazilian National Dengue Control Program|This program has 4 basic principles: 1) Adequate case finding, classification and treatment; 2) Epidemiological surveillance and reporting of all cases; 3) Mobilization and communication of risks to the public; 4) mosquito monitoring and control which consists fundamentally of detection of larva using a rapid larval index (LIRAa) followed by removal of breeding sites and local spraying.
45658918|NCT04514107|Other|Wolbachia-infected Aedes aegypti|Brazilian strain of Aedes aegypti infected with Wolbachia pipientis released into geographic clusters.
45949145|NCT00401492|Drug|vinorelbine|
45949146|NCT00455806|Drug|esomeprazole|
45949147|NCT00455806|Drug|moxifloxacin|
45949148|NCT00455806|Drug|amoxicillin|
45658919|NCT04499079|Other|Learning Health System|This is a system-level intervention designed to improve collaboration among personnel from the juvenile and behavioral healthcare systems.
46076495|NCT02696928|Drug|Artemeter-Lumefantrine (combination therapy)|AL first 3 days
45949149|NCT00143910|Other|observation|
45949150|NCT00455845|Device|Levonorgestrel IUD|levonorgestrel IUD
45949151|NCT00110474|Drug|Glucosamine sulfate|
45949152|NCT00110474|Drug|Acetaminophen|
46076496|NCT02696928|Drug|Artemeter-Lumefantrine and Primaquine (combination therapy)|AL first 3 days PQ next 14 days
46076497|NCT00885157|Biological|Inactivated types 1, 2, and 3 poliovirus, D antigens|0.1 mL, intradermal
46076498|NCT00885157|Biological|Inactivated types 1, 2, and 3 poliovirus, D antigens|0.5 mL, Intramuscular
45949153|NCT00113100|Drug|Topical 17-beta estradiol in ethanol/propylene glycol (ETOH/PG)|
45658920|NCT04493060|Biological|Dostarlimab|Given IV
45811693|NCT00004263|Drug|7-hydroxystaurosporine (UCN-01)|20 mg/m2 IV over 24 hours on days 2-4 of course 1 and over 36 hours beginning on day 2 of subsequent courses. Treatment repeats every 4 weeks for a maximum of 4 courses.
45949154|NCT03274297|Drug|EVRA patch (NGMN+EE) (Treatment A) (Reference)|A single transdermal contraceptive patch of EVRA (NGMN + EE) containing 6 milligram (mg) of the progestin NGMN and 600 microgram (mcg) of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
46076499|NCT02828774|Other|there will be no intervention.|this study is observational, procedure are done in vitro and on animal models.
46076500|NCT02606097|Drug|regorafenib|
46076501|NCT00886405|Drug|Transdermal nitroglycerin|Transdermal nitroglycerin (25mg/day) during 5 days (2 days before and 3 days after chemotherapy) at the beginning of each chemotherapy cycle for a total of 4 cycles
46076502|NCT02773134|Other|Brace Group|"All eligible patients will undergo a Posterior Spine Instrumented Fusion (PSIF) with the use of autologous local and iliac crest bone graft, and all pedicle screw instrumentation. A deep wound drain will be placed in all patients for 48 hours.~All patients will complete the Oswestry Disability Index (ODI) questionnaire, the SF-12v2 General Health Survey and the Visual Analogue Scale (VAS) for back pain at baseline visit (preoperatively) and post-operatively at 6 weeks and 3 months follow up. Clinical and radiographic assessments will be performed by independent blinded observers not involved in patient care."
45811694|NCT00004263|Drug|Cytarabine (Ara-C)|Starting dose 1 g/m2 IV over 24 hours on days 1-4 of each course. Treatment repeats every 4 weeks for a maximum of 4 courses.
45811695|NCT00003735|Drug|topotecan hydrochloride|given by mouth
45949155|NCT03274297|Drug|HMW PIB patch (NGMN+EE) (Treatment B) (Test)|A single transdermal contraceptive HMW PIB (NGMN + EE) patch containing 6 mg of the progestin NGMN and 600 mcg of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
45949156|NCT04698265|Biological|Human amniotic suspension allograft (ASA)|Human amniotic suspension allograft (ASA) intra-articular injection.
45949157|NCT00456157|Drug|Intra-articular Injection of OP-1 to affected knee|
45453560|NCT03798769|Other|Supportive Oncology Care at Home|"Entails the following:~patient-reported symptoms, vital sign, and weight monitoring with appropriate triggers to phone calls and home visits by Medically Home based on a clinician-derived algorithm;~scheduled nursing visits for intravenous (IV) hydration during the course of chemotherapy;~regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care."
45453561|NCT02276014|Dietary Supplement|Beta-carotene|
45458439|NCT03500848|Drug|Sirolimus|Within 24 hours of randomization, sirolimus will be started at a dose of 2.0 mg once a day. The sirolimus trough level is measured twice a week for 1 month, followed by trough level once a month thereafter. The dose will be adjusted over time to maintain steady-state sirolimus trough blood levels of approximately 4-10 ng/mL.
45949158|NCT00110552|Drug|Salvia officinalis (sage)|oral dosage
45949159|NCT03274219|Biological|bb21217|autologous T cells transduced ex-vivo with anti-BCMA CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA, suspended in cryopreservative solution
45658921|NCT04493060|Drug|Niraparib|Given PO
45811696|NCT00005073|Drug|zoledronic acid|
45811697|NCT00004275|Drug|growth hormone|
45811698|NCT00004275|Drug|oxandrolone|
45811699|NCT00003741|Biological|monoclonal antibody HeFi-1|
45811700|NCT00005079|Procedure|conventional surgery|
45949160|NCT00143949|Drug|enalapril|
45949161|NCT00143949|Drug|losartan|
45949162|NCT00456235|Drug|Mycophénolate Mofétil|
45949163|NCT00456235|Drug|Ciclosporine A|
45949164|NCT00456235|Drug|Tacrolimus|
45949165|NCT00456274|Procedure|Frequent baseline blood sampling|3 ml of blood sampled every 10 minutes for a total of 8-12 hours
45949166|NCT00456313|Drug|FLIXOTIDE and SERETIDE|comparator
45949167|NCT00113139|Behavioral|Telephone-based coping skills/stress management|Telephone-based coping skills/stress management: 12 weekly sessions.
45949168|NCT00113139|Other|Usual Care|Usual care participants continued their routine and usual treatments and do not receive the 12 telephone training sessions.
46076503|NCT02773134|Other|Control Group|"All eligible patients will undergo a Posterior Spine Instrumented Fusion (PSIF) with the use of autologous local and iliac crest bone graft, and all pedicle screw instrumentation. A deep wound drain will be placed in all patients for 48 hours.~Bracing will not be prescribed postoperatively for this group. All patients will the Oswestry Disability Index (ODI) questionnaire, the SF-12v2 General Health Survey and the Visual Analogue Scale (VAS) for back pain at baseline visit (pre-operatively) and post-operatively at 6 weeks and 3 months follow up. Clinical and radiographic assessments will be performed by independent blinded observers not involved in patient care."
46076504|NCT02828852|Other|Blood sample|"In washed platelets and whole blood, study shall determine the percentage of aggregation after activation by different agonists and the amount of certain membrane markers of platelet activation. Furthermore, an assay of estradiol plasma will be made.~In whole blood, study will evaluate the percentage of platelet adhesion to collagen matrix or fibrinogen and the volume of thrombies formed."
45811701|NCT00004287|Genetic|H5.001CBCFTR|
45811702|NCT00005085|Drug|becatecarin|
45949169|NCT00456352|Procedure|duodenal exclusion|
45658922|NCT04489719|Procedure|Biospecimen Collection|Undergo collection of blood samples
45811703|NCT00004293|Drug|glucocerebrosidase|
45458440|NCT03500848|Drug|MMF and/or steroids|For patients in both groups, MMF and/or steroids are initiated at or prior to the time of liver transplantation according to local practice. Steroids reduction is encouraged by 3 months post liver transplantation.
45658923|NCT04489719|Other|Questionnaire Administration|Ancillary studies
45811704|NCT00003747|Drug|carboplatin|
45811705|NCT00003747|Drug|temozolomide|
45811706|NCT00004311|Drug|leuprolide acetate|
45811707|NCT00004311|Drug|spironolactone|
45811708|NCT00004317|Drug|Leucovorin calcium|See arm descriptions
45811709|NCT00004317|Drug|Pyrimethamine|See arm descriptions
45811710|NCT00004317|Drug|Spiramycin|Spiramycin is administered before the fetal diagnosis is made.
45811711|NCT00004317|Drug|Sulfadiazine|See arm descriptions
45949170|NCT03274180|Other|Nursing consultation|travel preventive consultation was performed by nurse
45949171|NCT00110630|Behavioral|10-week smoking cessation group therapy combined with NicoDerm CQ|
45949172|NCT00456391|Procedure|Medical history|
45949173|NCT00456391|Procedure|Brain CT scan|
46076505|NCT02766426|Behavioral|Lifestyle change program|"Women attended a multidisciplinary counseling (by both the dietitian and the gynecologist). They were given nutritional advice about lifestyle and physical activity, in agreement with the Italian Guidelines for a healthy diet during pregnancy. The diet given comprised 1500 kcal/day and consisted of 3 main meals and 3 snacks (breakfast, snack, lunch, snack, dinner, and evening snack) that corresponds to the baseline metabolism of a pregnant woman. In view of the physical activity program, the dietitian added an amount of 200 kcal/day for obese or 300 kcal/day for overweight women.~The exercise intervention was focused on increasing walking and developing a more active lifestyle. The recommendation for physical activity was to perform 30 min of moderate intensity activity at least 3 days a week."
45658924|NCT04489719|Drug|Radium Ra 223 Dichloride|Given IV
45658925|NCT04483414|Drug|68Ga PSMA-11 injection|Injection of 68Ga PSMA-11
45658926|NCT04483414|Procedure|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
45658927|NCT04469569|Behavioral|HPV-PROTECT|HPV-PROTECT is a multicomponent provider-focused intervention specifically tailored for use in pediatric oncology settings, addressing important survivor-specific vaccine issues. The intervention is comprised of three components, i) Provider Communication Training; ii) Assessment and Peer Feedback/ Coaching; and iii) Provider Toolkit. The HPV-PROTECT intervention is designed to increase provider knowledge regarding use of the HPV vaccine in the cancer survivor population, enhance provider skills in delivering brief, compelling HPV vaccine recommendations to parents of young cancer survivors, present ongoing feedback to providers regarding clinic- and provider-level survivor HPV vaccination rates, and decrease barriers to receipt of vaccine by survivors through the provision of Vaccine Action Plans, tailored to local context.
45949174|NCT00456430|Drug|Escitalopram|10 mg a day of escitalopram by mouth per day for 4 weeks. Dose may be increased to 20 mg a day after the 4th week depending on tolerance and treatment response.
45949175|NCT00113178|Device|Catheter-based cardiac cryoablation|
45949176|NCT00456586|Drug|KW-6002 (istradefylline)|
46076506|NCT02829086|Other|Relationship Enhancement|Relationship Enhancement is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
45658928|NCT04428385|Other|Testing incentive|A small incentive will be paid to the provider each time they perform a malaria rapid diagnostic test.
45658929|NCT04428385|Other|Conditional artemisinin combination therapy subsidy|An additional discount on WHO-approved quality assured ACTs will be offered to individuals with a positive RDT.
45658930|NCT04378010|Drug|EDP-305 1.5 mg|Tablet
45658931|NCT04378010|Drug|EDP-305 2 mg|Tablet
45658932|NCT04378010|Drug|Placebo|Tablet
45658933|NCT04365114|Diagnostic Test|Breast Screening Mammography with single reader|One clinician examined each woman's mammograms for signs of cancer
45658934|NCT04365114|Diagnostic Test|Breast screening mammography with two readers|Two clinicians seperately examined each woman's mammograms for signs of cancer
45658935|NCT04365114|Diagnostic Test|Test threshold|Threshold used by readers examining the breast screening mammograms, defined using their previous proportion of cases recalled
45658936|NCT04361006|Device|Radiofrequency (RF)|Will be evaluated if percutaneous radiofrequency catheter ablation is superior to cryotherapy as treatment modality of para-hisian accessory pathways.
45658937|NCT04361006|Device|Cryotherapy (CRYO)|Will be evaluated if percutaneous cryotherapy catheter ablation is superior to radiofrequency as treatment modality of para-hisian accessory pathways.
45658938|NCT04349072|Drug|Mavacamten|Mavacamten Capsules Other names: MYK-461
45658939|NCT04349072|Drug|Placebo|Placebo
45658940|NCT04337710|Procedure|Exclusive Enteral Nutrition|Mom's milk or donor milk at 60-80 ml/kg/day after randomization within the first 24 hours.
45658941|NCT04337710|Procedure|Progressive Enteral Nutrition|Mom's milk or donor milk at 20-30 ml/kg/day after randomization within the first 24 hours.
45658942|NCT04319354|Diagnostic Test|Analysis of cfDNA|Analysis of cfDNA through liquid biopsy
45949177|NCT00110669|Drug|Prednisone|"Prednisone and dummy preparations for this study will be obtained from Frank's Pharmacy in Ocala, FL and will be supplied as a tablet containing 2.5mg, 5mg, 10mg, 20mg or 50mg Prednisone. Inactive dummy pills of similar look/taste will be supplied to maintain blinding."
45949178|NCT00456664|Genetic|IE gene|
45658943|NCT04313868|Drug|GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)|GEN2 is an investigational drug combining cytotoxic and immunotherapy.
45658944|NCT04312191|Other|Mantra Meditation|Mantra-based meditation will be taught using a standard one-word mantra (Om). Om is a non-English word that will help with focus as opposed to an English word which may cause distraction based on the word itself.
46076507|NCT02829086|Other|Family Stress and Conflict Management|Family Stress and Conflict Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
46076508|NCT02829086|Other|Financial Management|Family Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
45658945|NCT04277559|Other|Patient preferential music|Patients will listen to their preferred music through the headphones before surgery.
46076509|NCT02766660|Device|Optical Coherence Tomography|All groups were measured by optical coherence tomography.
45453562|NCT02277496|Behavioral|Toolkit Intervention|The toolkit intervention consists of strategies and activities to engage students (student toolkit) and school wellness councils (school toolkit) in addressing the six targeted behaviors of the 2010 Dietary Guidelines based on the principles of participatory action research. The intervention will promote goal setting and school-based food and physical promotion activities led by students as well as school wellness network development.
45453563|NCT01102387|Drug|LAS41003|Once daily, topically
45453564|NCT01102387|Drug|LAS189962|Once daily, topically
45658946|NCT04277559|Other|Classical music|Patients will listen to classical music through headphones before surgery.
45658947|NCT04277559|Other|No music|Patients will not listen to music.
45658948|NCT04275700|Procedure|A-PRP|The cortex of each ovary will be injected with autologous platelet rich plasma. Up to seven different sites will be injected under ultrasound guidance. The patient will be under IV sedation.
45658949|NCT04255303|Other|Integrated clinical prediction rule (iCPR) system (iCPR)|"The iCPR tool consists of an electronic calculator that can be used to determine whether the patient is at low, intermediate or high risk for having the diagnosis and a bundled order set (called a Smartset). The iCPR tool will be made available directly within the Electronic Health Record (EHR) for Registered Nurses (RNs) who are seeing patients fall into the study categories. The iCPR tool through the use of order sets will guide the RN in the patient's care. The order set for patients at low risk for these diseases will recommend supportive care including over the counter cold remedies and pain relievers. The order set for patients at intermediate or high risk of these disease will recommend diagnostic tests (rapid strep antigen or CXR) to help determine if they have the disease. Based on the results of the diagnostic tests new order sets will recommend antibiotics or supportive care"
45658950|NCT04242277|Device|Investigational WF-OCT device|Excised lumpectomy tissue will be imaged on an investigational WF-OCT device
45658951|NCT04240886|Drug|fosmanogepix|IV and oral fosmanogepix
45658952|NCT04240665|Behavioral|Digital Memory Notebook (DMN) Application|Subjects will be taught to utilize the DMN application through 2-hour weekly sessions for 6-weeks.
45658953|NCT04226131|Other|Blood Draw|A study nurse will draw up to 150 mL of blood to measure erythrocyte sedimentation rate (ESR) and measures of immune cell function. ESR is a common hematology test that is a measure of inflammation.
45658954|NCT04226131|Other|Disease Activity (DAS-28) Assessment|Participants in the RA cohort will receive a 28-joint examination by the study physician to assess RA disease activity and report their overall health assessment.
45811712|NCT02973243|Device|Automatic RR Measurement|Different newly developed respiration rate sensors are applied at the bedside during the intervention phase which send data to the IntelliVue Guardian System.
45811713|NCT00005091|Drug|exatecan mesylate|
45811714|NCT00004323|Drug|anti-thymocyte globulin|
45811715|NCT00004323|Drug|cyclophosphamide|
45811716|NCT00004323|Drug|cyclosporine|
45811717|NCT00004323|Drug|mesna|
45811718|NCT00004323|Drug|methotrexate|
45811719|NCT00004323|Drug|methylprednisolone|
45811720|NCT00003753|Drug|dexamethasone|
45949179|NCT00456703|Other|intraoperative fluid management|fluid restriction
45949180|NCT00456703|Other|fluid restriction|restriction of fluids
45949181|NCT00454558|Drug|Riociguat (Adempas, BAY63-2521)|Biweekly uptitration of BAY63-2521 (Oral sGC Stimulator) starting from 1.0 mg TID up to 2.5 mg TID in steps of +0.5 mg according to safety and tolerability.
46076510|NCT04247906|Drug|Narsoplimab|
46076511|NCT00889369|Drug|Duloxetine|Duloxetine, flexible dose, 60-120mg/per day for 8 weeks, following a 2-week placebo lead-in phase to determine study eligibility
45453565|NCT01102387|Drug|LAS189961|Once daily, topically
45811721|NCT00003753|Drug|floxuridine|
45811722|NCT00003753|Drug|irinotecan hydrochloride|
45811723|NCT00003753|Procedure|adjuvant therapy|
45811724|NCT00003753|Procedure|conventional surgery|
45811725|NCT00005097|Drug|Polyphenon E and Placebo|Areas of sun damaged skin with actinic keratoses to be treated will be mapped and photographed on patient's bilateral arms. One of the patient's arms will be assigned to be treated with topical Polyphenon E, the patient's other arm with placebo vehicle in a random, double blind manner. The patient's arm treatment areas will receive daily applications of a premeasured amount of drug or placebo. Patients will be seen every other week for 12 weeks to check for effects of the applications and monitor for compliance or possible side effects.
45811726|NCT00003759|Biological|BCG vaccine|
45811727|NCT00003759|Drug|valrubicin|
45811728|NCT00003759|Procedure|conventional surgery|
45811729|NCT00003765|Drug|O6-benzylguanine|
45811730|NCT00003765|Drug|carmustine|
45811731|NCT00004347|Behavioral|diet|
45811732|NCT00003771|Biological|therapeutic estradiol|
45811733|NCT00003771|Drug|norethindrone acetate|
45811734|NCT00004359|Drug|methoxsalen|
45811735|NCT00004401|Drug|botulism immune globulin|
45811736|NCT00003783|Biological|filgrastim|
45949182|NCT00456781|Device|Augmentation|Rotator Cuff Repair plus Graft Jacket
45949183|NCT00456781|Procedure|Rotator Cuff Repair without augmentation|Rotator Cuff Repair without augmentation
45658955|NCT04226131|Other|Skeletal Muscle Mitochondrial Respiratory Capacity|Near-Infrared Spectroscopy (NIRS) will be used to measure oxidative capacity of forearm flexor digitorum profundus and medial gastrocnemius muscles using the PortaMon device (Artinis Medical Systems, The Netherlands). NIRS is a low-cost, non-invasive method that estimates muscle oxidative capacity by measuring oxygen consumption (mVO2) recovery kinetics via assessment of intramuscular oxy- and deoxy-hemoglobin concentration following a sequence of brief, rapid arterial cuff occlusions. NIRS measures mitochondrial oxidative function as the mVO2 recovery rate constant k. In the absence of blood flow, changes in muscle oxygenation occur via oxygen consumption alone. In persons without RA, this non-invasive approach is highly correlated with muscle respiratory capacity assessed via muscle biopsies using in situ permiabilized fiber bundles and the Oroboros O2k system.
45811737|NCT00003783|Drug|asparaginase|
45811738|NCT00003783|Drug|cyclophosphamide|
45811739|NCT00003783|Drug|cytarabine|
45811740|NCT00003783|Drug|daunorubicin hydrochloride|
45949184|NCT00113256|Drug|Rubitecan|
45949185|NCT00110708|Drug|Oralgam (human immunoglobulin)|
45949186|NCT00456820|Drug|Wellbutrin XL|
45949187|NCT00456859|Drug|Kremezin|
45949188|NCT00456898|Drug|desvenlafaxine sustained release (DVS SR)|
45949189|NCT00456898|Drug|Paroxetine|
45949190|NCT00456898|Drug|Codeine|
45949191|NCT00143988|Behavioral|Treadmill testing|Patients will have a exercise stress test using a Bruce protocol during which time heart rates and blood pressures will be monitored and the patient's percieved exertion level monitored and recorded
45949192|NCT00143988|Behavioral|Ambulatory Blood Pressure and Heart Rate Monitoring|Patients will wear an ambulatory blood pressure monitor and an heart rate monitor during one sexual encounter.
45949193|NCT03274141|Other|Non-Interventional|Non-Interventional
45949194|NCT03274102|Biological|Concomitant administration of EV71 vaccine with EPI vaccines|"The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.； the recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.~The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study"
45949195|NCT03274102|Biological|Single injection of EPI vaccine|"The recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.~The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study"
45658956|NCT04226131|Other|Muscle Biopsy|After local anesthesia (xylocaine, 2%) is injected, a small incision will be made in the thigh. Four to six small pieces of muscle about the size of a pea will be surgically removed. The incision site will be closed using steri-strips and/or derma-bond, and a light dressing applied.
45658957|NCT04226131|Other|Body Composition|Body composition assessments include circumference measurements and the BOD POD®. Minimal waist circumference measurements will be taken using a tape measure.
45811741|NCT00003783|Drug|dexamethasone|
45811742|NCT00003783|Drug|etoposide|
45811743|NCT00003783|Drug|idarubicin|
45811744|NCT00003783|Drug|leucovorin calcium|
45811745|NCT00003783|Drug|mercaptopurine|
45811746|NCT00003783|Drug|methotrexate|
46076512|NCT02766192|Drug|Ketamine|
46076513|NCT02766192|Behavioral|TIMBER Psychotherapy|
46076514|NCT02766192|Drug|Placebo (normal saline)|
46076515|NCT04248062|Other|Survey|Survey: 38 preselected patient and parent reported outcomes; rating scale: 9 point likert scale (1=not at all important - 9=very important)
45811747|NCT00003783|Drug|prednisone|
45811748|NCT00003783|Drug|vincristine sulfate|
45811749|NCT00003783|Radiation|radiation therapy|
45811750|NCT00003789|Drug|isolated limb perfusion|Undergo isolated limb perfusion
45811751|NCT00003789|Drug|melphalan|Given via limb perfusion
45811752|NCT00003789|Biological|recombinant tumor necrosis factor family protein|Given via slow injection into the arterial line
45811753|NCT00003789|Other|pharmacological study|Correlative studies
45811754|NCT00003789|Other|laboratory biomarker analysis|Correlative studies
45811755|NCT00004407|Drug|immune globulin|
45811756|NCT00003795|Procedure|quality-of-life assessment|
45811757|NCT00004419|Drug|insulin-like growth factor I|
45811758|NCT00004431|Drug|L-baclofen|
45811759|NCT00384891|Device|Synergo + MMC|Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
45949196|NCT03274102|Biological|EV71 Vaccine only|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
45949197|NCT00110747|Drug|S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)|S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
45949198|NCT00110747|Drug|Placebo Peel|Peel was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
45949199|NCT00456937|Drug|Escitalopram|
45949200|NCT00456976|Drug|Selegiline|
45949201|NCT00144066|Drug|platinum-based chemotherapy alone (up to six cycles)|
45949202|NCT00144066|Drug|platinum-based chemotherapy followed by maintenance therapy with gefitinib|
45949203|NCT00457054|Drug|Lithium|starting dose 600 mg increase as tolerated
45949204|NCT00457093|Drug|glargine|
45949205|NCT00457093|Drug|detemir|
45949206|NCT00110786|Biological|Ragweed MATAMPL|
45949207|NCT00457132|Device|APOS biomechanical gait system|
45949208|NCT00457171|Drug|GI-270384|
45949209|NCT00144105|Drug|TPV500mg/RTV200mgBID|
45949210|NCT00144105|Drug|TPV500mg/RTV100mgBID|
45949211|NCT00144105|Drug|LPV400mg/RTV100mgBID|
45811760|NCT00384891|Drug|Bacillus Calmette-Guérin|Intravesical instillation with BCG (Bacillus Calmette-Guérin)
45811761|NCT00004437|Device|Multichannel Auditory Brain Stem Implant|
45949212|NCT00457210|Procedure|Brain Radiotherapy/Stereotactic Radiosurgery|
45949213|NCT00110825|Behavioral|Cognitive Behavior Therapy|extended treatment with cognitive behavior therapy
45949214|NCT00457288|Drug|TF 002|
45949215|NCT00457327|Procedure|protective ileostomy|
45811762|NCT00384969|Drug|RAD001 and Sorafenib|RAD001 2.5mg to 10.0mg PO QD Sorafenib 400mg PO BID
45811763|NCT00385437|Behavioral|Driving Simulator Testing|
45811764|NCT00385437|Drug|Mirtazapine Treatment|
45949216|NCT00457405|Drug|dipyridamole|dipyridamole 200mg twice daily
45811765|NCT00004443|Drug|NTBC|
45949217|NCT00457444|Drug|Pollen|
45949218|NCT00457483|Drug|hydrochlorothiazide|12.5 mg once-a-day
45949219|NCT00457483|Drug|valsartan, 80 mg once-a-day|80 mg once-a-day
45658958|NCT04226131|Other|Cardiopulmonary Exercise Test (CPET)|Cardiorespiratory aerobic capacity (VO2 peak), will be assessed using a maximal treadmill test protocol with cardiopulmonary gas exchange. Subjects will be asked to exercise on a treadmill to their perceived maximum ability and effort during which time they will have a mouthpiece in their mouth to determine maximal oxygen use/consumption through breathing. For safety purposes the subject will be monitored by electrocardiogram (ECG) and their blood pressure will be measured at rest and throughout the exercise phase of this test.
45658959|NCT04226131|Other|Strength Testing|Strength assessments will include dynamometry-assessed grip and quadriceps strength (Cybex HUMAC NORM, Comp Sports Med, Inc., Stoughton, MA) tests
45658960|NCT04226131|Other|Questionnaires|Measures include global health, pain, fatigue, physical function, self-efficacy for disease management and sleep.
45949220|NCT00110864|Drug|PN2034|
45811766|NCT00004449|Behavioral|intensive one-on-one behavioral treatment|Up to 40 hours per week of one-to-one intervention based on applied behavior analysis
45811767|NCT00004449|Behavioral|Individualized in home parent training|Offered to subjects at some sites, involved 3+ months of individualized training for parents on applied behavior analysis intervention
45811768|NCT00004467|Drug|N-acetylcysteine (NAC)|Infusion of 5% dextrose with N-acetylcysteine with an initial loading dose of 150 mg/kg/h of NAC over 1 hour, followed by 12.5 mg/kg/h for 4 hours, then continuous infusions of 6.25 mg/kg/h for the remaining 67 hours.
45811769|NCT00004467|Drug|Placebo|Infusion of 5% dextrose
45949221|NCT00110864|Drug|Insulin|
45949222|NCT00113412|Drug|SP01A|
45453566|NCT02277808|Drug|500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%)|
45811770|NCT00003801|Procedure|management of therapy complications|
45811771|NCT00003801|Procedure|quality-of-life assessment|
45811772|NCT00004479|Drug|midodrine|
45811773|NCT00004485|Drug|cyclosporine|
45811774|NCT00004485|Drug|fludarabine|
45811775|NCT00004485|Drug|mycophenolate mofetil|
45949223|NCT00457522|Behavioral|Nurse/community health worker telephone intervention|
45949224|NCT00457600|Procedure|patient-driven health IT product|
45949225|NCT00457678|Drug|Visudyne|
45949226|NCT00457678|Drug|Lucentis|
45949227|NCT00457678|Drug|Dexamethasone|
45949228|NCT00457717|Drug|0.25 % atropine|
45949229|NCT00457717|Drug|0.5 % atropine|
45949230|NCT00457717|Procedure|0.25 % atropine+auricular acupoints|
45949231|NCT00110903|Drug|Etanercept Liquid|
45949232|NCT00457756|Dietary Supplement|BiosLife Complete|
45949233|NCT00457756|Dietary Supplement|Placebo|
45949234|NCT00144144|Drug|Angiotensin II receptor antagonists, Calcium channel blocker|
45949235|NCT00465673|Drug|Liposomal Doxorubicin|40mg/m2 over 1 hour infusion for 21 days
45949236|NCT00465712|Procedure|transabdominal amnioinfusion|transabdominal amnioinfusion performed 4 to 24 hours before the second trial of external cephalic version
45949237|NCT00110942|Drug|Systemic AMG 108|300 mg SC AMG 108 Q4W for 3 doses
45949238|NCT00110942|Other|Placebo|SC placebo injection Q4W for 3 doses
45949239|NCT00144183|Drug|Nevirapine (NVP)|Nevirapine 200mg once daily for 14 days followed by 200mg twice daily thereafter for the remainder of the treatment period. Combivir®, one tablet twice daily.
45949240|NCT00144183|Drug|Zidovudine (ZCV)|
45949241|NCT00144183|Drug|3TC|
45949242|NCT00465751|Drug|chenodeoxycholic acid|chenodeoxycholic acid 500 mg capsules tid po
45949243|NCT00465751|Drug|placebo capsules|placebo capsules containing mannitol tid po
45949244|NCT00110981|Device|NB-UVB|Three times a week (TIW) for 12 weeks
45949245|NCT00110981|Drug|Etanerept|50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
45949246|NCT00110981|Drug|Etanercept|50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
45658961|NCT04226131|Other|Skeletal Muscle Biomechanical Property Assessment|Passive skeletal muscle stiffness and elasticity measurements of bilateral biceps brachii, flexor carpi radialis, vastus lateralis, and tibialis anterior using mechanical deformation with myotonometry using the MyotonPro device.
45658962|NCT04223154|Device|Real iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
45658963|NCT04223154|Device|Sham iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
45811776|NCT00004485|Procedure|Bone Marrow Transplantation|
45811777|NCT00385125|Drug|Bendamustine|
45811778|NCT00385125|Drug|Rituximab|
46076516|NCT05278897|Device|Soft Tissue Adapted Biocompatible Hyaluronic Acid|1% sodium hyaluronate
46076517|NCT04037995|Other|No intervation|No intervation
46076518|NCT04243928|Other|kinesio taping|apply kinesio taping on dorsi flexors muscles
46076519|NCT02771262|Other|Pulmonary Rehabilitation|
45811779|NCT00004497|Drug|UT-15|
45811780|NCT00003819|Biological|QS21|
45811781|NCT00003819|Biological|TF(c)-KLH conjugate vaccine|
45811782|NCT00003819|Biological|Thomsen-Friedenreich antigen|
45811783|NCT00003819|Biological|keyhole limpet hemocyanin|
45811784|NCT00003825|Drug|pentosan polysulfate sodium|
45811785|NCT00003825|Procedure|quality-of-life assessment|
45949247|NCT00113646|Drug|MEDI-507|MEDI-507 0.1 mg/kg on transplant day-8, 0.6 mg/kg on days-7 and -6
45453567|NCT02277808|Device|Respirgard II|
45658964|NCT04188509|Drug|Voxelotor|All participants will receive voxelotor once daily (QD), administered orally as tablets, dispersible tablets, or a powder for oral suspension formulation (powder formulation packaged as stick packs).
45658965|NCT04173065|Drug|VK2809|Capsule
45658966|NCT04173065|Drug|Placebos|Capsule
45658967|NCT04173026|Other|Provider-level intervention|Provider minder is a provider-based scheduling and reminder system for stroke screening in SCD
45658968|NCT04173026|Other|Patient-level intervention|50% of centers are randomized to a single stroke screen coordinator as the point of contact for sickle stroke screen
45811786|NCT00003831|Procedure|conventional surgery|
45811787|NCT00004533|Drug|Adeno-associated virus-CFTR vector|
45811788|NCT00004551|Drug|nicotine replacement patch|
45811789|NCT00004551|Behavioral|mood management|
45811790|NCT00004569|Procedure|Non-invasive technique to diagnose and quantitate sleep-disordered breathing|
45811791|NCT02678312|Drug|LCZ696|LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules)
45949248|NCT00113646|Procedure|Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|Cyclophosphamide 60 mg/kg on transplant days -7 and -6; Fludarabine 25 mg/m2 days -5,-4,-3,-2,-1; MEDI-507 0.1 mg/kg on day -8, 0.6 mg/kg on days -7,-6
45949249|NCT00465868|Procedure|PCI (percutaneous coronary intervention)|Outcome of PCI following AMI
45949250|NCT00465907|Drug|Paclitaxel, Carboplatin and Irinotecan|Paclitaxel-60mg/m2 weekly for 3 weeks Carboplatin - AUC 1.5, weekly for 3 weeks Irinotecan - 60mg/m2, weekly for 3 weeks
45949251|NCT00465946|Behavioral|Salt Supplementation|
45949252|NCT00466024|Behavioral|Health Coach and HEPA Air cleaners|Health Coach for ETS reduction in home and 2 HEPA air cleaners
46076520|NCT02542033|Other|treated apple juice with low sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
45811792|NCT02678312|Drug|Enalapril|Enalapril tablets: 2.5 mg, 5 mg, 10 mg dosage strengths
45811793|NCT02678312|Drug|Placebo of LCZ696|
45811794|NCT02678312|Drug|Placebo of Enalapril|
45811795|NCT02678312|Drug|LCZ696|LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules), tablets: 50 mg, 100 mg, 200 mg dosage strengths
45811796|NCT00003837|Drug|nelarabine|
45811797|NCT00003843|Drug|irinotecan hydrochloride|
45811798|NCT00003843|Genetic|mutation analysis|
45811799|NCT00003843|Genetic|polymorphism analysis|
45811800|NCT00003849|Biological|rituximab|
45811801|NCT00004575|Drug|Miconazole, L-NMMA, Bradykinin|
45811802|NCT02972775|Other|no interventions. observational study|
45811803|NCT00422006|Procedure|biopsy of muscle, of liver, and of adipose tissue|biopsy of muscle, of liver, and of adipose tissue
45811804|NCT00422006|Procedure|clamp euglycemic - hyperglycemic|clamp euglycemic-hyperglycemic
45811805|NCT00422006|Behavioral|diet|diet
45949253|NCT00466024|Behavioral|Health Coach and HEPA air cleaners|Behavioral training and 2 HEPA air cleaners
45949254|NCT00113685|Drug|Hypertonic Saline-Dextran Solution|
45949255|NCT00113685|Drug|Lactated Ringer's Solution|
45949256|NCT00111020|Drug|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor: 400 mg of Sorafenib, orally, twice a day, on a continuous basis as a single agent for the treatment of advanced RCC
45949257|NCT00466063|Drug|Deferasirox|
45949258|NCT00466102|Drug|RAD001|Tablet of 5 mg, 2 tablets (10 mg) are taken once daily during study therapy
45949259|NCT00466102|Drug|Placebo|2 tablets are taken once daily during study therapy
45949260|NCT00144222|Drug|Telmisartan 40 mg/HCTZ 12.5 mg|
46076521|NCT02542033|Other|un-treated apple juice with normal sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
45658969|NCT04160832|Genetic|Multi-Cancer Cancer Panel|Eligible patients will receive genetic testing to determine germline cancer predisposition.
45658970|NCT04154488|Drug|Mavorixafor|Mavorixafor capsules will be administered per dose and schedule specified in the arm.
45658971|NCT04146051|Drug|Descartes-08|Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
45658972|NCT04144127|Behavioral|Soccer|"Soccer drills and other fitness routines (two 1-hour sessions per week)~In person education in Life's Simple 7 to help improve life through Lifestyle changes: smoking status, physical activity, weight, diet, blood glucose, cholesterol, and blood pressure."
45658973|NCT04099511|Behavioral|Usual Care Occupational Therapy-Outpatient|The control group in the proposed study will receive usual care occupational therapy services. The dosage between the experimental group and usual care will be identical with each group receiving ten 45- minute treatment sessions. The treating therapists will be unfamiliar with the experimental group intervention to avoid contamination. Each therapist will be instructed to provide care in the same manner as they typically provide in day-to-day practice for patients with similar characteristics as those in the study. The therapists will be encouraged to provide home action plans to participants. Usual care services will be monitored through a log of number of sessions, time spent in each session, and what activities were the focus of each session. The therapists will be instructed that they can address any participant goals they wish other than transfer goals identified by the participant.
45453568|NCT02277808|Device|Isoneb®|
45658974|NCT04099511|Behavioral|Cognitive Orientation to daily Occupational Performance|The Cognitive Orientation to daily Occupational Performance (CO-OP) approach was developed within the field of occupational therapy and is a performance-based, problem-solving approach to address activity performance limitations. Subjects will be taught to use the global problem-solving strategy of Goal-Plan-Do-Check: identifying a specific goal (Goal), outlining a practical plan for reaching that goal (Plan), accurately performing the plan (Do), and analyzing whether the plan led to achievement of the goal and altering the plan accordingly (Check). The Goal-Plan-Do-Check process will be iteratively applied to each of the activity goals. Therapists will use guided discovery to allow the subject to self-identify their own potential solutions within an activity (develop the plan). The therapists will be instructed that they can address any participant goals they wish other than transfer goals identified by the participant.
45811806|NCT00422006|Other|biopsies for biological and genetic analyses|biopsies for biological and genetic analyses
45811807|NCT00004581|Drug|Lopinavir/Ritonavir|
45811808|NCT00004581|Drug|Nevirapine|
45811809|NCT02466230|Device|Repetitive transcranial magnetic stimulation|Active repetitive transcranial magnetic stimulation for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
45811810|NCT02467166|Device|Circa™ Probe|The Circa™ probe will be used to monitor esophageal temperature and guide ablation power and duration during the RFCA procedure. Following ablation esophagoscopy will be performed to assess for esophageal lesions.
45811811|NCT00003855|Procedure|axillary lymph node dissection|
45811812|NCT00003855|Radiation|whole breast irradiation|
45811813|NCT02468570|Other|Administration of CANTAB and Subject Global Assessment|At designated visits, subject will perform the CANTAB tasks and complete the Subject Global Assessment Questionnaire
45949261|NCT00144222|Drug|Telmisartan 40 mg|
45949262|NCT00466141|Behavioral|Increased Exercise for weight loss maintenance|
45949263|NCT00466141|Behavioral|Daily Self-weighing for weight loss maintenance|
45949264|NCT00466141|Behavioral|Education for weight loss maintenance|
45949265|NCT00466180|Behavioral|Nevirapine from twice-a-day to once-a-day|
45949266|NCT00466219|Drug|Ribavirin|
45949267|NCT00466219|Drug|Pegylated interferon alpha2a|
45949268|NCT00144261|Drug|nevirapine|
45949269|NCT00466258|Drug|R-CHOP|"Cyclophosphamide 750 mg/m2 i.v. day 1~Adriamycin 50 mg/m2 i.v. day 1~Vincristine 1,4 mg/m2 i.v. day 1~Prednisone 100 mg i.v or oral. days 1-5."
45949270|NCT00466258|Drug|Highly active antiretroviral therapy|Combined antiretroviral treatment (TARGA) wich include at lest 3 drugs. The combination should be accepted as an initial or rescue treatment.
45949271|NCT00466258|Drug|Central nervous system (CNS) prophylaxis|methotrexate (12 mg) cytarabine (30 mg) hydrocortisone (20 mg)
45453569|NCT01105663|Other|Pharmacokinetic Sampling and pharmacogenetic analysis|Pharmacogenetic and pharmacokinetic samples will be obtained from a peripheral catheter, central catheter, or venipuncture coordinated with scheduled phlebotomies. Pharmacokinetic and pharmacogenetic analyses will be performed. Pharmacodynamic data will be collected.
45453570|NCT03949699|Other|Resistance training|Participants will engage in strengthening exercises using a cable tower while seated. These movements will include trunk flexion and extension, diagonal trunk rotation, and lateral trunk flexion. The goal for resistance training frequency (Weeks 1-8) will be three times per week, lasting about 30-45 minutes per session including warm-up/cool-down, for a duration of eight weeks. Resistance intensity of each exercise will also be determined based on the initial maximal strength performing that exercise: Weeks 1-4 will be 50-60% of the baseline calculated 1 repetition maximum (RM) values; Weeks 5-8 will use resistive loads equivalent to 50-60% of Week 4 1RM calculations
45811814|NCT02468804|Device|rTMS|TMS: Repetitive TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Stimulator (Magstim, Jali Medical US distributors, Woburn, MA). Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodman area 46) using a frameless stereotactic navigation system and the subject's MRI in Brainsight software. Stimuli will be delivered at 20 Hz at 90% of the subjects resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. The same TMS parameters as active stimulation but with the coil held at 90° to the scalp to induce similar somatic sensations and noise as in the active group with minimal direct brain effects.
45811815|NCT02468804|Device|Sham TMS|Sham TMS will be administered with a Magstim sham coil with electrodes attached to mimic the sounds and sensation of real TMS. The site and frequency of stimulation will be identical to the real TMS described above.
45811816|NCT00004257|Drug|fluorouracil|
45811817|NCT00004257|Drug|oxaliplatin|
45811818|NCT00004257|Procedure|conventional surgery|
45949272|NCT00466258|Drug|Prophylaxis of opportunistic infections and support treatment|Pegfilgrastim
45658975|NCT04092660|Behavioral|Behaviour change Intervention Based on Health Action Process Approach Model|"The Behaviour change intervention based on the Health Action Process Approach model entails delivering interventions in a staged manner. Following are the intervention that will be delivered along with the time point of the delivery.~Health Pamphlet at the initial screening~Sleep Apnoea video highlighting the negative consequences at the day of the fitting of the appliance~Counseling involving motivational interviewing for both the participant and the participant's partner at the day of fitting of the appliance and follow up visits.~Booster phone calls in between the follow-up visits"
45676461|NCT02971046|Other|varying protein intakes|"In healthy school-aged children: Four randomly assigned levels of protein intake in a repeated measured design. The levels of protein intake are 0.95, 1.3,1.55, and 2.0 grams per kilogram of bodyweight per day.~In healthy young and old adults: Up to six randomly assigned levels of protein intake in a repeated measured design. The levels of protein intake are : 0.66, 0.8, 1, 1.2, and 1.5 grams per kilogram of bodyweight per day."
45811819|NCT00004257|Radiation|radiation therapy|
45811820|NCT00004647|Drug|mexiletine|
45811821|NCT02469116|Drug|Docetaxel|
45811822|NCT02469116|Drug|Carboplatin|
45453571|NCT02281240|Drug|thrombopoietin, interleukin-11, heparin,|The hemostatic and antithrombotic (thrombopoietin, interleukin-11, heparin) measures during HSCT.
45453572|NCT01102465|Drug|losartan potassium hydrochlorothiazide|100 mg / 25 mg tablet
45811823|NCT02469116|Drug|Pegylated G-CSF|
45949273|NCT00466297|Behavioral|Face-to-face communication interactions|
45949274|NCT00113724|Drug|TPI 287 Injection|
45949275|NCT00466375|Genetic|Cheek cell samples or blood sample (4mL)|DNA will be extracted from cheek cell or blood samples from parents and child having hemangioma.
45949276|NCT00466375|Genetic|Cheek cell sample or blood sample (4mL)|DNA will be extracted from cheek cell or blood samples of parents and child with a vascular anomaly.
45949277|NCT00466414|Device|Polycaprolactone Scaffold|
45949278|NCT00144378|Drug|Irinotecan|
45949279|NCT00111098|Drug|Darbepoetin Alfa|QM administration for 28 weeks, adjusted as necessary to maintain Hb between 11.0 - 13.0 g/dL PFS concentrations: 20, 30, 40, 50, 60, 80, 100, 150, 200 and 300 mcg.
46076522|NCT02770560|Device|Urokinase locking solution|On basis of the prescription : one single administration of thrombolytic locking solution versus multiple administrations (during 3 consecutive dialysis sessions)
46076523|NCT02541487|Dietary Supplement|Alli-nutritional supplement|Obese participants in the FIT-PLESE clinical trial randomized to the nutritional restriction /AlliTM/physical activity arm that achieve pregnancy.
46076524|NCT02773056|Device|Ischial Ramus Containment (IRC)|Ischial Ramus Containment (IRC) is the standard of care socket
46076525|NCT02773056|Device|Dynamic Socket Ischial Ramus Containment (IRC)|Dynamic Socket Ischial Ramus Containment (IRC) is a comparator study socket
46076526|NCT02773056|Device|Sub-Ischial Interface (Sub-I)|Sub-Ischial Interface (Sub-I) is a comparator study socket
45949280|NCT00347659|Drug|BLVR System|Treatment is administered in a single treatment session.
45949281|NCT00347698|Drug|intravitreal injection of bevacizumab|
45949282|NCT00347698|Procedure|panretinal photocoagulation|
45949283|NCT00347737|Drug|teriparatide|Teriparatide
45949284|NCT00347815|Drug|Buprenorphine|
45949285|NCT00113802|Drug|Epratuzumab (hLL2- anti-CD22 humanized antibody)|
45949286|NCT00111137|Drug|rHuEPO|rHuEPO 40,000U QW for 4 weeks. Dose will be increased to 60,000U/week at week 5 if inadequate response through week 12.
45949287|NCT00111137|Drug|Darbepoetin alfa|4.5 mcg/kg QW for 4 weeks then Q3W starting at week 5 through week 11.
45658976|NCT04092660|Device|Mandibular Advancement Appliance (MAA) or Anti-snoring mouth guard|"Patients with mild-to-moderate sleep apnoea are treated with Mandibular Advancement Appliances [MAA] also known as Anti-snoring mouth guards or Oral appliances. These are best made to fit and use the teeth to hold them in place during sleep. They work by moving (in a gradual fashion) the bottom jaw forward, opening the airway at the back of the throat.~Both the arms- Intervention arm and Standardized arm will be given the anti-snoring mouth guard. The usage of the device will be measured subjectively by providing a sleep diary to the participants to record the hour of the usage and objectively by downloading the data from a micro sensor chip embedded in the device."
45453573|NCT00625612|Drug|Denufosol Tetrasodium (INS37217) Inhalation Solution|Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution, Denufosol 60 mg is administered as an inhalation solution, three times daily for twelve months.
45949288|NCT00347854|Other|Systane Free lubricant eye drops|
45658977|NCT04080427|Drug|Placebo capsule|Placebo is administered just prior to weekly exposure sessions by the oral route and contains only dextrose in opaque capsules.
45658978|NCT04080427|Drug|Dronabinol 7.5 milligram oral capsule|Dronabinol (7.5mg) is administered just prior to weekly exposure sessions by the oral route and is placed in an opaque capsule with dextrose filler.
45658979|NCT04074161|Drug|Semaglutide|Dose gradually increased to 2.4 mg administered once weekly for 68 weeks
45811824|NCT00003861|Other|laboratory biomarker analysis|
45811825|NCT00362960|Drug|Olmesartan medoxomil|
45811826|NCT00362960|Drug|Losartan|
45811827|NCT00004659|Procedure|irradiation|
45949289|NCT00347854|Other|Visine Tears Lubricant Eye Drops|
45811828|NCT00004659|Procedure|radiosurgery|
45811829|NCT00003867|Drug|capecitabine|
45658980|NCT04074161|Drug|Placebo (semaglutide)|Administered once weekly for 68 weeks
45658981|NCT04074161|Drug|Liraglutide|Dose gradually increased to 3.0 mg administered once daily for 68 weeks
45658982|NCT04074161|Drug|Placebo (liraglutide)|Administered once daily for 68 weeks
45658983|NCT04073563|Device|Infuse™ Bone Graft (Infuse™)|(Recombinant human bone morphogenetic protein-2 (rhBMP-2)/absorbable collagen sponge (ACS))
45811830|NCT00003867|Drug|irinotecan hydrochloride|
45811831|NCT00363506|Behavioral|Serotona Plus and dietary behavior management|
45811832|NCT00004665|Drug|dehydroepiandrosterone|
45949290|NCT00347854|Other|Refresh Liquigel Lubricant Eye Drops|
45949291|NCT00347854|Other|Refresh Plus Lubricant Eye Drops|
45949292|NCT00347893|Procedure|Selective laser trabeculoplasty|
45949293|NCT04714684|Device|Fitostimoline proctogel|Medical device for topical use for the treatment of fissures
45949294|NCT04714684|Device|Fitostimoline proctogel + muscle relaxant|medical device for topical use for the treatment of fissures
45949295|NCT00347971|Drug|recombinant human interleukin 21 and rituximab|rIL-21 (30, 100, 150 ug/kg) IV rituximab (375 mg/m2) IV
45811833|NCT00363584|Drug|capecitabine|
45811834|NCT00363584|Other|clinical observation|
45811835|NCT00363584|Procedure|adjuvant therapy|
45453574|NCT00625612|Drug|Placebo|Placebo - 0.9% w/v sodium chloride solution, three times daily for twelve months.
45453575|NCT01105195|Other|DuraPrep|DuraPrep is used for skin preparation prior to surgery.
45453576|NCT01105195|Other|ChloraPrep|ChloraPrep is used for skin preparation prior to surgery.
45453577|NCT05263297|Other|control group|no intervention will be made.
45811836|NCT00003873|Drug|fluorouracil|Given IV or orally
45811837|NCT00003873|Drug|eniluracil|Given orally
45811838|NCT00363116|Drug|Daclizumab|daclizumab 1 mg/kg/dose every 14 days for 5 doses
45811839|NCT00004689|Drug|amithiozone|
45811840|NCT00004689|Drug|clarithromycin|
45949296|NCT00113958|Drug|Cinacalcet|
46076527|NCT00889525|Drug|Cabergoline|Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.
45811841|NCT00004689|Drug|ethambutol|
45811842|NCT00004689|Drug|rifampin|
45811843|NCT00004689|Drug|streptomycin|
45811844|NCT02470910|Device|Magnetic Resonance Imaging|
45811845|NCT00004695|Drug|PEG-interleukin-2|
45811846|NCT02570984|Drug|Omalizumab|anti-ige injection
45811847|NCT02570984|Drug|Placebo|placebo comparator arm, injection similar to active
45949297|NCT00111176|Device|Endovascular repair|Endovascular repair.
45949298|NCT00111176|Procedure|Surgical|Surgical endovascular repair
45949299|NCT00348010|Drug|Tramadol HCl ER|
45949300|NCT00348049|Procedure|Laser in Situ Keratomileusis (LASIK)|
45949301|NCT00348049|Procedure|Photorefractive Keratectomy (PRK)|
45949302|NCT00144417|Drug|Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)|Moxifloxacin 400mg daily, 8 weeks
45949303|NCT00144417|Drug|isoniazid|isoniazid, oral, 300 mg, daily, 8 weeks
45949304|NCT00348127|Device|Neurovision|
45949305|NCT00111215|Drug|Tranexamic Acid|
45949306|NCT00111215|Drug|Desmopressin Acetate|
45949307|NCT00348166|Drug|cyclopentolate|
45949308|NCT00348244|Drug|Ketorolac, Prednisolone Acetate|
45949309|NCT00348322|Drug|Systane Free Lubricant Eye Drops|
45949310|NCT00348361|Drug|Fluticasone Propionate|
45949311|NCT00348400|Drug|Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost|
45949312|NCT00144456|Drug|ED-71|0.75μg/day(p.o.)for 144 weeks
45949313|NCT00144456|Drug|Alfacalcidol|1.0μg/day(p.o.)for 144 weeks
45949314|NCT00144456|Drug|ED-71 placebo|0 μg/day(p.o.)for 144 weeks
45949315|NCT00144456|Drug|Alfacalcidol placebo|0 μg/day(p.o.)for 144 weeks
45811848|NCT00004731|Drug|Coenzyme Q10|
45658984|NCT04073563|Device|Intervertebral body fusion device and Medtronic posterior Fixation Systems|Adaptix™Interbody System, Capstone™ Spinal System, Catalyft™ PL Interbody System
45811849|NCT00003885|Drug|arsenic trioxide|
45949316|NCT00111254|Procedure|Microdermabrasion|Treatment will consist of 3 passes in different directions (horizontal, vertical and oblique) with the microdermabrasion handpiece (Parisian Peel, Prestige model, medical microdermabrasion device).
45949317|NCT00348439|Drug|Plasmin|27 mg of human-derived plasmin to be reconstituted with 0.9% Sterile Sodium Chloride for a single intravitreal injection.
45949318|NCT00348439|Drug|Vehicle|Plasmin formulation, without active ingredient to be reconstituted in 0.9% Sterile Sodium Chloride and administered in a single intravitreal injection.
45658985|NCT04066075|Behavioral|Low Vision Rehabilitation|Low Vision Rehabilitation for use of magnification devices for near reading tasks
45658986|NCT04062981|Drug|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
45658987|NCT04046575|Radiation|Intensity Modulated Radiation Therapy|-15 fractions of treatment
45658988|NCT04046575|Drug|Carboplatin|Begins on day 1 of radiotherapy
45811850|NCT00003891|Drug|lurtotecan liposome|
45811851|NCT02472314|Drug|1.3% Liposomal Bupivacaine|local tissue infiltration of Liposomal Bupivacaine during surgery
45811852|NCT02472314|Drug|0.125% Bupivacaine|Continues nerve block with Bupivacaine during surgery and postoperatively
45811853|NCT00004755|Drug|allopurinol|
45811854|NCT00004755|Drug|glucantime|
45811855|NCT02473718|Other|Fluid minimization protocol|Fluid nonresponsive patients will have continuous infusions concentrated, maintenance fluids discontinued, and carrier fluids minimized. Diuretics and/or ultrafiltration will be utilized to maintain an even to negative fluid balance in patients demonstrating fluid non-responsiveness.
45949319|NCT00348478|Behavioral|water and health education program to improve hygiene|
45949320|NCT00348517|Other|Systane Free Lubricant Eye Drops|1-2 drops per eye four times per day for 42 days
45949321|NCT00348517|Other|Refresh Liquigel Lubricant Eye Drops|1-2 drops per eye four times per day for 42 days
45658989|NCT04046575|Other|MD Anderson Symptom Inventory (MDASI)-Plus module|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
45811856|NCT02473718|Device|Ultrasound|
45811857|NCT00003897|Biological|gp100 antigen|
45811858|NCT00003897|Biological|sargramostim|
45811859|NCT00003903|Procedure|management of therapy complications|
45811860|NCT00003909|Drug|motexafin gadolinium|Given IV
45811861|NCT00003909|Radiation|radiation therapy|Undergo radiation therapy
45811862|NCT00003909|Other|pharmacological study|Correlatives studies
45811863|NCT02474498|Drug|EMD|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland).
45949322|NCT00348634|Drug|Tegaserod|
46002258|NCT04193787|Other|EPIC-P|EPIC-P is a brief, bio-behavioral intervention based on the information-motivation-behavioral skills (IMB) model framework, which integrates i) a biomedical component (i.e., PrEP), ii) behavioral components (i.e., drug- and sex-related primary HIV prevention), and iii) mHealth technology (i.e., text messaging PrEP reminders).
46002259|NCT04193046|Other|Blood Sample|Prevalent (existing) and incident (new) participants who are found to either have PH or not by RHC will provide blood sample for the establishment of a biomarker signature of PH.
45811864|NCT02474498|Device|βTCP/HA|During flap access surgery, the granulation tissue will be removed and the root surfaces were carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
45811865|NCT02474498|Procedure|Flap access surgery|In the furcation sites, during flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments.
45658990|NCT04046575|Other|EuroQol (EQ-5D)|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
45658991|NCT04046575|Other|SF-12|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
45658992|NCT04046575|Other|MOS Social Support Measure|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
45811866|NCT00004767|Drug|Sodium Benzoate|
45811867|NCT00004767|Drug|Sodium Phenylacetate|
45811868|NCT00004767|Drug|Sodium Phenylbutyrate|
45811869|NCT00004767|Behavioral|Dietary Intervention|
45811870|NCT00004779|Genetic|Ad5-CB-CFTR|
46002635|NCT00546221|Behavioral|Psychosocial support exercise programme|The experimental arm will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will comprise: fifteen minutes of psychosocial and motivational support, run by a qualified rehabilitation psychologist and overseen by a qualified health psychologist; a half hour preferred intensity exercise session run by a qualified sports physiotherapist. Participants preferred intensity (chosen exertion level) will be established using the Borg RPE scale (Borg G 1998).
45811871|NCT00004785|Drug|dexamethasone|
45811872|NCT00004785|Drug|methylprednisolone|
45811873|NCT02476448|Drug|Normal saline|Used to distend the bladder for cystoscopic evaluation
46076528|NCT02770872|Other|Observation of SAA on apoB containing lipoproteins|attempting to elicit the conditions by which SAA shifts from apo-A1 containing lipoproteins to apoB containing lipoproteins
46076529|NCT02833142|Drug|BIIB033 (opicinumab)|
46076530|NCT00885313|Drug|DHA250|DHA 250 mg/kg/d
46076531|NCT00885313|Drug|DHA500|DHA 500 mg/kg/d
46076532|NCT00885313|Drug|PLACEBO|placebo
46076533|NCT00885313|Behavioral|Lifestyle intervention|lifestyle intervention [including hypocaloric diet (25-30 cal/kg/d) or isocaloric diet (40-45 cal/kg/d) and physical activity], for 12 months.
45658993|NCT04046575|Other|CES-D|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
45658994|NCT04046575|Procedure|Blood for ctDNA (optional)|-Collected at pre-treatment, every 2 weeks during chemoradiation, every 2-3 weeks during consolidation chemotherapy, completion of therapy, 6-8 week follow-up, 3 month follow-up, 6 month follow-up, and 12 month follow-up
45658995|NCT04046575|Procedure|Blood for SCCA|-Collected at pre-treatment, completion of therapy, and 6 month follow-up
45658996|NCT04046575|Drug|Paclitaxel|Begins on day 1 of radiotherapy
45811874|NCT02476448|Drug|Phenazopyridine|Administered orally preoperatively and assessed during cystoscopy
45811875|NCT02476448|Drug|Dextrose 10%|Used to distend the bladder for cystoscopic evaluation
45811876|NCT02476448|Drug|Sodium Fluorescein|Administered intravenously and assessed during cystoscopy
45811877|NCT00004797|Drug|fructose|
45811878|NCT00004797|Drug|placebo|
45811879|NCT00385749|Device|RV apical vs RV septal defibrillation threshold testing|
45811880|NCT02509520|Dietary Supplement|MPR and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)|The MPR provides strength and cardiopulmonary endurance training, which consist of exercises to promote function movements. Intensity is based on patient's hemodynamic responses and subjective report using Modified Borg Dyspnea Scale. Intensity, duration, or type of activity will be modified each session to achieve a moderately intense physiologic response. The NMES protocol requires self-adhesive surface electrodes be placed on quadriceps muscles and lower leg bilaterally, twice daily. This protocol is based on prior NMES protocols used to stimulate muscle protein synthesis in older diabetic patients, preserve muscle mass in intensive care patients and increase strength in older adults after knee replacement. The HPRO intervention is based on caloric needs, calculated using validated equations to maintain positive nitrogen balance. Protein will be supplemented as isolated amino acids twice/day to deliver ~15g of essential amino acids per serving, with a goal of 1.6 g/kg/day.
45811881|NCT00004809|Procedure|gene therapy|
45811882|NCT00003933|Other|laboratory biomarker analysis|
45811883|NCT02496104|Behavioral|Package n°1 of the APIB|
45811884|NCT00004815|Drug|growth hormone|
45811885|NCT00004827|Drug|docosahexaenoic acid|
45811886|NCT04744610|Diagnostic Test|Add 4-hour delayed radiographs|Normal patients only need to take delayed radiographs 24h after HSG operation. In this study, 4-hour delayed radiographs were added to the 24-hour delayed radiographs, so that the patients had to take one more delayed radiographs .
46002636|NCT00546221|Behavioral|Prescribed exercise|This group will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will be an half hour exercise session, at a typically (GP) prescribed level, designed in accordance with national guidelines and run by a qualified sports physiotherapist.
45658997|NCT04044456|Behavioral|Goal Management Training|"GMT: is a 10-session intervention to improve planning and problem solving. Interactive Power Point modules are administered by a cognitive therapist. Each session builds on the steps of a five-stage planning and problem-solving strategy. Veterans will be taught to generate and verbalize the following five-steps: stop-what am I doing?, define the goal, list the steps, learn the steps; then, check-am I doing what I planned? The five-stage strategy is then incorporated into a variety of activities in the laboratory and in-home assignments."
45658998|NCT04044456|Behavioral|Attention Training|"Attention Process Training (APT-III) will be administered for a second weekly session in addition to the GMT session. Each session will be 2 hours/ week for 10 weeks. Veterans will also engage in BrainHQTM attention training at home for one-hour, five days/ week comprised of selected components of BrainHQ from Posit Science Corporation. This web-based computerized CRT modality of cognitive training is a restorative or bottom-up approach that targets basic cognitive skills such as arousal and vigilance processes, attention and information processing, and directly engages fundamental attention-control skills through repetitive graded exercises."
45658999|NCT04044456|Behavioral|Brain Health Workshop|. BHW was developed specifically for consistency with GMT session length and contact with the facilitator49. BHW is an education presentation on brain function and cognitive principles of learning with homework and quizzes on information covered. To match time and contact of attention training, control participants will meet with the therapist for a separate two-hour session from BHW
45811887|NCT02483468|Behavioral|Cognitive Behavioral Therapy for Pain|Cognitive-behavioral therapy (CBT) for pain management takes an active problem-solving approach to tackling the many challenges associated with the experience of chronic pain. Rather than seeing ones self as helpless and disabled because of pain, CBT encourages individuals to take back control and re-engage in activities.
45811888|NCT02483468|Device|Transcranial Direct Current Stimulation|Electrical stimulation of the prefrontal cortex using 2mA of direct current
45659000|NCT04044456|Behavioral|National geographic movies|participants will select movies to watch and answer a few questions about to equate the time and therapist interaction to attention training in arm 1.
45659001|NCT04006652|Drug|ApoGraft|ApoGraft is a cell based product, manufactured with mobilized peripheral blood.
45659002|NCT03997903|Drug|Imatinib Mesylate|"The starting dose for subjects will be 340 mg/m2/day with a maximum dose of 600 mg daily.~Patients will receive Imatinib orally once daily for 6 months."
45811889|NCT02483468|Device|Sham Transcranial Direct Current Stimulation|Sham stimulation of the left dorsolateral prefrontal cortex
45811890|NCT02279823|Drug|CB-03-01 solution|Investigational drug solution
45659003|NCT03982212|Drug|Copaxone|"Agent: Glatiramer acetate (Copaxone®)~Dose: 40 mg~Route: Intratumoral injection~Schedule: At least 1 dose, up to 3 doses, with each dose being at least 48 hours apart and last dose within 96 hours of standard of care surgery."
45659004|NCT03970096|Radiation|Total-Body Irradiation|Undergo TBI
45659005|NCT03970096|Drug|Thiotepa|Given IV
45811891|NCT02279823|Drug|Minoxidil Solution 5%|FDA approved marketed product
46002637|NCT04646772|Procedure|Multivisceral resection|Multivisceral resection for locally advanced colon cancer.
45811892|NCT02279823|Drug|Placebo solution|Vehicle solution
45811893|NCT02480582|Other|Almonds|Whole raw almonds provided as a mid-morning snack - 0.9g\kg
45811894|NCT02480582|Other|Cheese Savouries|Cheese savoury crackers provided as a mid-morning snack - 0.9g/kg
45811895|NCT02415842|Other|Serum samples|The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.
45811896|NCT04040361|Drug|Pembrolizumab|Pembrolizumab will be administered as a dose of 200mg as a 30-minutes IV infusion, Q3W
45811897|NCT04040361|Drug|Ramucirumab|Ramucirumab will be administered as a dose of 10mg/kg as a 60-minutes IV infusion, Q3W
45811898|NCT04040361|Procedure|Surgery|Surgery to be performed is lobectomy or more extensive lung resection and lymph node dissection
45949323|NCT05595330|Behavioral|Lymphedema prevention protocols|"Coming for surgery: A PPT lecture; 2. A seminar; 3. Patients were given a lymphedema prevention brochure; 4. Diary cards for exercise is given and instruct patients to fill out daily; 5. Establish a WeChat group.~The first chemotherapy:1. Review diary card and provide guidance and education. 2. A PPT lecture; 3. A seminar; 4. Play functional exercise videos in the recovery room; 5. Rehabilitation volunteers come to the ward to form mutual help groups with patients under the guidance of subject team members; 6. Instruct regular exercise and avoid behaviors that can lead to lymphedema. 7. Ask about the exercise and whether there is any swelling and discomfort and give guidance.~The second chemotherapy: 1. A PPT lecture; 2. A seminar; 3. Play functional exercise videos in the recovery room.~The third chemotherapy: 1. Routine nursing; 2. Assess patients' knowledge of lymphedema prevention and exercise compliances; 3. Play functional exercise videos in the recovery room."
45949324|NCT00348712|Drug|rosiglitazone|Tablets, 4 mg once or twice daily.
45949325|NCT00348712|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
46076534|NCT05149196|Other|Targeted blood pressure management|"During anesthesia, mean blood pressure is maintained ≥85 mmHg or above baseline by combining fluid challenge and norepinephrine infusion;~For patients admitted to intensive care unit after surgery, mean blood pressure is maintained ≥85 mmHg or above baseline by combining fluid challenge and norepinephrine infusion;~In the general ward, systolic blood pressure is maintained ≥110 mmHg or within 10% of baseline by delaying antihypertensive resumption, providing fluid challenge, and/or norepinephrine infusion."
46076535|NCT05149196|Other|Routine care|In the general ward, management is performed according to routine practice.
45659006|NCT03970096|Drug|Fludarabine|Given IV
45949326|NCT00348712|Drug|metformin|Tablets, 2000 mg/day.
45949327|NCT00348751|Device|CholGate|
46076536|NCT02762760|Biological|AMPION™|AMPION™, up to 3 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
46076537|NCT02762760|Biological|Saline|Saline placebo, up to 3 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride
46076538|NCT00886561|Behavioral|HIV risk reduction intervention|Education intervention designed to reduce HIV risk behaviors and enhance HIV prevention behaviors among female sex workers in Armenia
45659007|NCT03970096|Drug|Tacrolimus|Given IV
45949328|NCT00113997|Drug|REG1|
46076539|NCT02770794|Drug|Infliximab|Discontinue infliximab; receive Infliximab when relapse
46076540|NCT04245332|Dietary Supplement|Fish oil|Fish oil-derived omega-3 polyunsaturated fatty acids (4g fish oil concentrate: 2g EPA+ 1g DHA)
46076541|NCT04245332|Dietary Supplement|Coconut oil|Coconut oil (4g/d)
46076542|NCT04036513|Procedure|MINST|"For reducing the need of surgical treatment in patients with chronic periodontal disease, we will use specifically designed Hu-Friedy curettes mini five, micro mini five and after five together with piezoelectric device with thin and delicate tips that produce less periodontal trauma than usual Gracey curettes."
46076543|NCT04036513|Procedure|Conventional SRP|Scaling and root planing with conventional instruments.
46076544|NCT04224246|Drug|Gamma Hydroxybutyrate|Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours
46076545|NCT00892567|Biological|9 Peptides from Her-2/neu, CEA, & CTA|Each vaccination will be administered on days 1, 8, 15, 36, 43, and 50. All participants will receive 9 class I MHC-restricted synthetic peptides and a class II MHC-restricted tetanus helper peptide administered in Montanide ISA-51. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.
45659008|NCT03970096|Biological|Allogeneic CD34+-enriched and CD45RA-depleted PBSCs|Given IV
45659009|NCT03970096|Drug|Methotrexate|Given IV
45659010|NCT03970096|Drug|Cyclophosphamide|Given IV
45659011|NCT03970096|Biological|Peripheral Blood Stem Cell|Given IV
45659012|NCT03970096|Drug|Cyclosporine|Given IV
45659013|NCT03970096|Drug|Sirolimus|Given IV
45659014|NCT03970096|Drug|Busulfan|Given IV
45659015|NCT03966157|Device|Nasal Bridle|Feeding tube secured with nasal bridle
45811899|NCT00385905|Device|Excel Drug-eluting stent|
45811900|NCT00385983|Device|Harmonic Scalpel|
45811901|NCT02481206|Device|Wearable Cardioverter Defibrillator|Wearable Cardioverter Defibrillator
45811902|NCT00386061|Drug|rimonabant (SR141716)|
45811903|NCT02415998|Procedure|TEE|Epidural catheter will be placed under guidance of transesophageal echography in specific thoracic spinal segment.
45811904|NCT02481440|Biological|human umbilical cord mesenchymal stem cells (hUC-MSCs)|Four times of intrathecal administrations of hUC-MSCs
46076546|NCT02766270|Drug|Temozolomide|RT with daily temozolomide (75 mg/m2/day, 7 days/week for up to 7 weeks) and adjuvant temozolomide (150-200 mg/m2 PO QD for 5 days, repeats every 28 days for up to 12 courses).
46076547|NCT02766270|Radiation|Radiotherapy|
46076548|NCT04300010|Drug|5% Topical Benzoyl Peroxide Gel|Gel treatment used to treat acne
46076549|NCT04300010|Device|Blue Light Therapy|Blue light therapy treatment for acne
45659016|NCT03913559|Drug|Inotuzumab ozogamicin|dose: 0.5 mg/m2 IV over 60 minutes, days: 1, 8 and 15 every 4 weeks (28 days per cycle) for up to 6 cycles.
45811905|NCT02481596|Behavioral|REACH + FAMS|The intervention consists of REACH individual-focused text messaging, plus family-focused phone coaching sessions, goal-focused text messaging, and the option to invite a family member/support person to receive text messages.
45811906|NCT02481596|Behavioral|REACH|The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, plus text messaging targeting other self-care behaviors (see NCT02409329).
46076550|NCT02766348|Drug|gemcitabine|gemcitabine 1000mg/m2 IV on day 1 an day 8, repeat every 3 weeks
46076551|NCT02766348|Biological|DC-CTL|8×10^9 DC-CTL cells for each infusion, IV(In the vein) for 3 cycles, each cycle received four infusions on day 14,16,30 and 32
46076552|NCT02766348|Drug|cisplatinum|cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
46076553|NCT02762916|Other|Selfmanage with the help of telemedicine program|"The intervention group patients were not followed by the usual protocol, but it used the program CONTECI (and test different directions) to guide the patient monitoring.~Both groups used antiplatelets and statines as usual protocol (these were not the interventions) We did not use drugs or device for the intervention, only a Telemedicine programme"
46076554|NCT02833064|Radiation|Non-contrast magnetic resonance imaging|
45659017|NCT03913559|Drug|Methotrexate|Intrathecal (IT) therapy
45659018|NCT03913559|Drug|Hydrocortisone|Intrathecal (IT) therapy
45659019|NCT03913559|Drug|Cytarabine|Intrathecal (IT) therapy
45659020|NCT03913559|Drug|Diphenhydramine|1 mg/kg (max 50 mg) IV
45659021|NCT03913559|Drug|Acetaminophen|10 mg/kg (max 650 mg) PO x 1
45659022|NCT03913559|Drug|Methylprednisolone|1 mg/kg IV x 1
45659023|NCT03891823|Device|MitraClip|Study participants will be randomized to MitraClip device to determine treatment efficacy in improving LV remodelling or functional capacity.
45811907|NCT02481596|Behavioral|Helpline & A1c results|Participants complete all study assessments, receive text messages advising how to access study A1c results, and have access to a helpline for study- or diabetes medication-related questions.
45811908|NCT00386139|Drug|Aliskiren/HCTZ|
45659024|NCT03891823|Drug|Medical Therapy|Study participants will be randomized to medical therapy to determine treatment efficacy in improving LV remodelling or functional capacity.
45811909|NCT00005553|Procedure|Catheter Ablation|
45811910|NCT00005571|Drug|h5G1.1-mAb|
45811911|NCT00005577|Drug|gemcitabine hydrochloride|
45811912|NCT00386217|Behavioral|Telephone Survey|Telephone interview, about 90 minutes, covering demographic information, medical information, health-related quality of life, emotional distress, and stress related to interrupted childbearing.
45811913|NCT00005583|Drug|cisplatin|
45659025|NCT03888898|Other|Reusable respirator fit test and competency evaluation|Feasibility of rapid conversion to reusable elastomeric respirator use during public health emergency
45659026|NCT03888898|Other|Control fit test evaluation|control comparator for fit testing time threshold
45659027|NCT03847636|Device|CryoBalloon ablation|Endoscopic cryoablation (cryogen is contained nitrous) using a CryoBalloon catheter to ablate up to 4 separate DA.
45659028|NCT03843528|Drug|Vorinostat|Vorinostat will be administered concurrent with low-dose azacitidine post-transplant, on days 1-7 and 15-21 of 28 day cycles. This is an oral medication.
45659029|NCT03843528|Drug|Azacitidine Injection|Azacitidine will be administered on days 1-5 of each 28 day cycle, either by IV or subcutaneous injection. The dose of azacitidine will be fixed, with no dose-escalation.
45811914|NCT00005583|Drug|doxorubicin hydrochloride|
45811915|NCT00005583|Drug|epirubicin hydrochloride|
45811916|NCT00005583|Procedure|adjuvant therapy|
45811917|NCT00005583|Procedure|conventional surgery|
45811918|NCT00005583|Radiation|radiation therapy|
45811919|NCT00005589|Biological|filgrastim|
45811920|NCT00005589|Biological|rituximab|
45811921|NCT00005589|Drug|carmustine|
45811922|NCT00005589|Drug|cyclophosphamide|
45811923|NCT00005589|Drug|cytarabine|
46076555|NCT02833064|Other|Biological sampling|Blood, urine, stool and breath sampling and analysis
45949329|NCT02964689|Drug|Binimetinib|Binimetinib will be administered in combination with pemetrexed and cisplatin (induction therapy), and with pemetrexed only (maintenance therapy), during the first 2 weeks of each cycle. Cycles will be repeated every 21 days.
45949330|NCT02964689|Drug|Pemetrexed|Pemetrexed 500 mg/m2 i.v. is applied on day 1 of each cycle, before cisplatin administration
45659030|NCT03837691|Device|Placement of Snowshoe Suture Anchors|Snowshoe suture anchors from g-Cath EZ Delivery Catheters are placed in the stomach with the aid of a Transport, g-Lix and g-Prox device
45949331|NCT02964689|Drug|Cisplatin|Cisplatin 75 mg/m2 i.v. is applied on day 1 of each induction therapy cycle. The drug must be administered after pemetrexed infusion
45949332|NCT02959567|Device|Aqueduct 100 dilation|
45949333|NCT00348829|Procedure|mitral valve repair|surgical mitral valve repair
46076556|NCT04223700|Procedure|Ultrasound imaging & fluoroscopic confirmation|The researchers use ultrasound to scan the left and right sides of the paravertebral sagittal imaging to identify trapezius, semispinalis, erector spinae muscle, transverse process and rhomboid muscle. The radiopaque marker is attached respectively to the skin of the inferior margin of the rhomboid muscle on the left and right thoracic spinal spines. Then, as the first step for the scheduled nerve block to the patient, thoracic vertebra level verification using C-arm is performed. At this time, left and right level of the transverse process of thoracic spine marked with the radiopaque marker are confirmed and recorded.
46076557|NCT02828306|Other|Patient Specific Implant|Implantation of Patient Specific Implant
46076558|NCT00608569|Drug|Lopinavir/ritonavir|Two tablets (200-mg lopinavir and 50 mg ritonavir in each tablet), taken orally twice daily
46076559|NCT00608569|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine and 300 mg tenofovir disoproxil fumarate in each tablet, taken orally once daily
46076560|NCT00608569|Drug|Tenofovir disoproxil fumarate|300-mg tablet taken orally once daily
46076561|NCT00608569|Drug|Zidovudine|300-mg tablet taken orally twice daily
45811924|NCT00005589|Drug|etoposide|
46076562|NCT00608569|Drug|Emtricitabine|200-mg tablet taken orally once daily
45659031|NCT03837691|Behavioral|Moderate Intensity Diet & Exercise Program|After placement of the snowshoe suture anchors in the stomach, subjects are asked to follow a moderate intensity diet and exercise program
45811925|NCT00005589|Drug|melphalan|
45811926|NCT00005589|Procedure|bone marrow ablation with stem cell support|
45659032|NCT03827824|Device|Hysteroscopy & virtual reality glasses|Hysteroscopy. Virtual reality glasses. VAS. STAI scale.
45659033|NCT03827824|Device|Hysteroscopy|Hysteroscopy. VAS. STAI scale.
45659034|NCT03827460|Behavioral|Abstinence from alcohol|Participants will undergo a laboratory alcohol infusion session that terminates 2 weeks of monitored abstinence from alcohol
45659035|NCT03827460|Behavioral|Usual drinking|Participants will undergo a laboratory alcohol infusion session during a period of usual drinking behavior
45659036|NCT03779789|Drug|Vortioxetine|"Antidepressant classified under the category other antidepressants according to the ATC/DDD index [ATC=Anatomical Therapeutic Chemical Classification System; DDD=Defined Daily Dose]. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-20 mg/day)."
45659037|NCT03779789|Drug|Sertraline|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 50-200 mg/day)."
45676462|NCT02941926|Drug|Ribociclib|Ribociclib is centrally supplied to the investigators and administered orally once a day on days 1-21 of each 28 day cycle at a starting dose of 600 mg daily
45811927|NCT00005589|Procedure|peripheral blood stem cell transplantation|
45811928|NCT00005601|Biological|rituximab|
45811929|NCT00005601|Drug|cisplatin|
45811930|NCT00005601|Drug|cytarabine|
45811931|NCT00005601|Drug|dexamethasone|
45811932|NCT00005601|Drug|sargramostim|
45811933|NCT00005607|Drug|FOLFIRI regimen|
45811934|NCT00005607|Drug|fluorouracil|
45811935|NCT00005607|Drug|irinotecan hydrochloride|
45811936|NCT00005607|Drug|leucovorin calcium|
45811937|NCT00005613|Drug|cyclophosphamide|Cyclophosphamide will be given at a dose of 1500 mg/m2/day IV over 1.0 hour on days -6, -5, -4, and -3.
45811938|NCT00005613|Drug|etoposide|Etoposide will be given at a dose of 600 mg/m2/day over 3.0 hours on days -6, -5, and -4.
45949334|NCT00114036|Behavioral|Quality improvement strategies|
45949335|NCT00348868|Behavioral|enhanced behavioral motivation counseling|
45949336|NCT00348868|Behavioral|Motivational counseling|
45949337|NCT00348868|Behavioral|Standard counseling|
45949338|NCT00348907|Drug|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
45949339|NCT00348907|Drug|late thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam at 2 years
45949340|NCT00348985|Drug|belinostat|
45949341|NCT00348985|Drug|bortezomib|
45949342|NCT00348985|Other|pharmacological study|
45949343|NCT00111332|Behavioral|Progressive resistance and aerobic training|
45811939|NCT00005613|Drug|BCNU|BCNU will be given at a dose of 150 mg/m2/day in 500 cc D5W over 3.0 hours on days -6, -5, and -4
45811940|NCT00005619|Genetic|polymerase chain reaction|
45811941|NCT00005619|Other|flow cytometry|
46076563|NCT02832830|Radiation|IMRT|Intensity modulated Raiotherapy (IMRT) of the involved spinal bone metastasis
46076564|NCT02832830|Radiation|fractionated RT|external beam Radiotherapy of the involved spinal bone metastasis
45811942|NCT00005619|Other|immunohistochemistry staining method|
45949344|NCT05595252|Biological|cervical biopsy|cervical biopsy made during and after pregancy
45949345|NCT00349024|Drug|polyvinylpyrrolidone-sodium hyaluronate gel|
46076565|NCT04699422|Procedure|Serratus anterior plane block|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance,30 cc Bupivacaine 0.25% will be injected in the deep compartment. After the deep component of the SAP is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. 10 cc Bupivacaine 0.25% will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound
46076566|NCT04699422|Drug|PCIA with Piritramide|A patient controlled intravenous analgesia system (IVAC PCAM®, Cardinal Health or CADD pump) with piritramide (Dipidolor®, Janssen) using following settings: bolus 2 mg and lockout interval 15 min.
46076567|NCT02828384|Other|low fodmap diet|dietary teaching
46076568|NCT02828384|Dietary Supplement|Psyllium|7.1g of psyllium daily
46076569|NCT02770482|Biological|spinal fluid collection|
46076570|NCT04245098|Procedure|Carpal tunnel syndrome surgery|Biopsy
46076571|NCT02771184|Device|Lung Sound Recording System|The lung sounds are recorded over the posterior chest in supine position on an examination table. A foam pad with several lung sound transducers is placed under the back of the subjects. During the recording the subjects wear a nose clip and hold a pneumotachograph with both hands. The subjects are instructed to breath at a certain airflow rate during inspiration, with natural breathing during expiration. Therefore, they receive a real-time feedback for the airflow rate. The airflow signal and the lung sounds from 16 lung sound transducers are recorded simultaneously for 30 seconds.
45659038|NCT03779789|Drug|citalopram|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 10-20 mg/day)."
45659039|NCT03779789|Drug|Escitalopram|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-10 mg/day)."
45659040|NCT03779789|Drug|Paroxetine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-40 mg/day)."
45659041|NCT03779789|Drug|Fluoxetine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-60 mg/day)."
45676463|NCT02941926|Drug|Letrozole|Letrozole is procured locally and administered orally once a day on a continuous daily schedule at a dose of 2.5 mg
45811943|NCT00005625|Drug|trabectedin|
45811944|NCT00005631|Biological|filgrastim|
45811945|NCT00005631|Biological|rituximab|
45811946|NCT00005631|Drug|carboplatin|
45811947|NCT00005631|Drug|etoposide|
45811948|NCT00005631|Drug|ifosfamide|
45811949|NCT00005637|Drug|carmustine|
45811950|NCT00005637|Drug|temozolomide|
45811951|NCT00005643|Drug|pegylated liposomal doxorubicin hydrochloride|
45811952|NCT00005649|Drug|capecitabine|
45811953|NCT00005649|Drug|paclitaxel|
45949346|NCT00349063|Device|soft contact lens|
45949347|NCT00349063|Drug|Soft contact lens multipurpose disinfection regimen|
45949348|NCT00349102|Radiation|Free breathing|Free breathing during conformal radiation
45949349|NCT00349102|Radiation|Breath holding|Breath holding during conformal radiation
45949350|NCT00111371|Drug|Levodopa|
45949351|NCT00114075|Procedure|Surgery with gait analysis report|Orthopaedic surgery with access to gait analysis report
45811954|NCT02256631|Biological|VRC01|Administered by subcutaneous injection in the thigh
45949352|NCT00114075|Procedure|Surgery without gait analysis report|Orthopaedic surgery without access to gait analysis report
45949353|NCT00349141|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|
45949354|NCT00349180|Drug|Enoxaparin sodium|
45949355|NCT00421369|Drug|sertraline|
45659042|NCT03779789|Drug|Fluvoxamine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 100-300 mg/day)."
45659043|NCT03747939|Drug|Apremilast (CC-10004)|"Subjects randomized to apremilast will receive dose-titration for the initial 5 days. Apremilast subjects will receive dummy titration at wk. 16 (for early escape subjects) and again at week 24 to maintain the blinding of the original treatment assignments. Investigational product (IP) will be dispensed in blinded dose cards until Week 28. Thereafter, IP will be dispensed in open-label bottles."
45659044|NCT03747939|Other|Apremilast (CC-10004) Placebo|"Subjects randomized to placebo will receive dummy dose-titration for the initial 5 days. Placebo subjects who meet the criteria for early escape at wk. 16 may receive apremilast beginning at wk. 16 and will receive active titration. Remaining placebo subjects will receive active dose titration at week 24. Beginning at wk 24 all subjects will be dispensed active apremilast. Investigational product will be dispensed in blinded dose cards until Week 28. to maintain the blinding of the original treatment assignments. Thereafter, IP will be dispensed in open-label bottles"
45659045|NCT03737539|Diagnostic Test|Multigene methylation detection|Colorectal tumor-specific plasma ctDNA methylation markers detection
45659046|NCT03733210|Drug|Panitumumab-IRDye800|30 mg administered intravenously (IV)
45811955|NCT02256631|Biological|VRC01LS|Administered by subcutaneous injection in the thigh
45811956|NCT02256631|Biological|VRC07-523LS|Administered by subcutaneous injection in the thigh
45811957|NCT00005655|Biological|rh IL-12|rhIL-12 will be administered intravenously on days 2, 4, 6, 10, 12 and 14 of each cycle.
45811958|NCT00005655|Biological|rh IL-2|rhIL-2 will be administered intravenously every 8 hours x 3 doses on days 1 and 9 of each cycle.
45949356|NCT00421369|Drug|triiodothyronine (T3)|
45949357|NCT00421369|Drug|reboxetine|
45949358|NCT00111410|Drug|Anakinra (r-metHuIL-1ra)|
45949359|NCT00421447|Drug|Anastrozole|Group of women with breast cancer
45949360|NCT04729140|Drug|Ivermectin Tablets|Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
46076572|NCT04399928|Device|Total Hip Arthroplasty|Total hip arthroplasty with the R3 Acetabular Hip system.
46076573|NCT00886717|Drug|carboplatin|
45811959|NCT02972697|Radiation|11C-acetate ligand|
45811960|NCT02972697|Radiation|FDG ligand|
45811961|NCT00005673|Drug|Capravirine|
45811962|NCT02247349|Biological|BMS-986012 (anti-fucosyl-GM1)|
45811963|NCT02247349|Biological|Nivolumab|
45949361|NCT04729140|Drug|Doxycycline Tablets|Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
45949362|NCT04729140|Drug|Placebo|Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
45949363|NCT00349219|Drug|erlotinib|erlotinib 150 mg taken orally daily until disease progression
45949364|NCT00349219|Drug|cisplatin|cisplatin 80 mg/m2 IV day 1 every 3 weeks given in second-line therapy
45949365|NCT00349219|Drug|gemcitabine|gemcitabine 1200 mg/m2 IV days 1 and 8 every 3 weeks, given in second-line
45949366|NCT00349219|Drug|cisplatin|cisplatin 80 mg/m2 IV day 1 every 3 weeks for 6 cycles
45949367|NCT00349219|Drug|gemcitabine|gemcitabine 1200 mg/m2 IV days 1 and 8 every 3 weeks for 6 cycles
45949368|NCT00349219|Drug|erlotinib|erlotinib 150 mg orally taken daily as second line therapy (after disease progression on chemotherapy)
45949369|NCT00111449|Drug|Etanercept|
45949370|NCT00349258|Drug|Leuprolide acetate|
45949371|NCT05595174|Biological|self ligating bracket with micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment. Micro-osteoperforations will be formed
45949372|NCT05595174|Biological|conventional bracket with micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment. Micro-osteoperforations will be formed.
45949373|NCT05595174|Biological|conventional bracket without micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel titanium were followed to achieve leveling and alignment
45949374|NCT00349375|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate 145mg and Simvastatin 20mg
45949375|NCT00349375|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40 mg
45949376|NCT00349375|Drug|Simvastatin|Simvastatin 40 mg
45949377|NCT00111488|Device|Flex 4 and Generator|
46076574|NCT00886717|Drug|paclitaxel-loaded polymeric micelle|
46076575|NCT02828696|Device|"No prep treatment of worn dentition with CAD-CAM composite"|Realization of minimally invasive prostheses in PICN (CAD-CAM composite)for worn dentition. Tooth tissues are preserved: no preparation is performed and ultra-thin restorations are CAD-CAM milled.
46076576|NCT00889837|Drug|Inhaled Loxapine|Staccato Loxapine, 10 mg x 2 doses, 10 hours apart
46076577|NCT00889837|Drug|Inhaled Placebo|Staccato Placebo, inhalations x 2 , 10 hours apart
45949378|NCT00349414|Procedure|Micropulse Transscleral Cyclophotocoagulation|
45949379|NCT00349414|Procedure|Conventional Transscleral Cyclophotocoagulation|
45949380|NCT00349453|Drug|Deferiprone (L1)|50-100 mg/kg body weight daily
45949381|NCT00349453|Drug|Deferiprone (L1)|75 mg/kg body weight daily
46076578|NCT02828540|Drug|HT047 High-dose group|HT047 2250mg, three times a day dosing schedule, 3 tablets per dose
46076579|NCT02828540|Drug|HT047 Low-dose group|HT047 1500mg, three times a day dosing schedule, 3 tablets per dose
46076580|NCT02828540|Drug|Placebo|placebo having the same appearance as HT047 Tab. 250mg
46076581|NCT02770404|Drug|Nafithromycin|100, 200, or 400 mg of nafithromycin
46076582|NCT02770404|Drug|Placebo|IV matching placebo
46076583|NCT00889993|Dietary Supplement|Mixed Fiber Supplement|Breakfast Muffin containing 0g, 4g, 8g, and 12g of mixed fiber (total fiber amount as listed).
45659047|NCT03733210|Drug|89-Zirconium (Zr-89) Panitumumab|0.8 to 1.2 mCi (29 to 45 Mbq) administered intravenously (IV)
45659048|NCT03733210|Device|Pinpoint IR IR9000 fluorescence imaging system (FIS)|Handheld fluorescence-imaging endoscope manufactured by Novadaq
45949382|NCT00349453|Drug|Desferrioxamine|35-50 mg/kg body weight on 2 or more days per week
45659049|NCT03733210|Device|SPY-PHI IR9000 fluorescence imaging system (FIS)|Handheld fluorescence-imaging endoscope manufactured by Novadaq
45659050|NCT03733210|Device|Explorer Air camera|Fluorescence camera manufactured by SurgVision
45949383|NCT00111527|Other|Optimized echo-guided CRT pacing|Echo-TDI guided VV-delay optimization
45949384|NCT00111527|Other|normal RV pacing|PM or ICD implant according to patient indication
45949385|NCT00349492|Drug|IP|irinotecan+cisplatin
45949386|NCT00349531|Drug|Pramipexole|
45949387|NCT00401739|Drug|CSL360|Weekly IV Infusion. Dose escalation study.
45949388|NCT00349570|Device|Xtract Aspiration Catheter|
46076584|NCT04243694|Behavioral|Mindfulness training|Participants of the intervention group will receive 6-weeks of mindfulness training.
46076585|NCT00886873|Drug|Mifepristone|
46076586|NCT02766114|Procedure|Carpal tunnel release through Mini Transverse Approach|Carpal tunnel release through a transverse cosmetic small incision over the distal wrist crease.
46076587|NCT04243850|Drug|Empagliflozin 10 MG|Jardiance
46076588|NCT04243850|Drug|Placebo oral tablet|Placebo
46076589|NCT04243850|Diagnostic Test|Caffeine|caffeine iv to investigate wheter the changes in renal hemodynamics are adenosine dependent
45453578|NCT01105819|Procedure|Lactobacillus plantarum 299 for oral care|The study group will be attended in the same manor but the swabs used for cleansing are soaked with carbonated water directly from freshly opened bottles. As the final part of the procedure oral mucosal surfaces are pencilled with a suspension of the probiotic bacterium Lactobacillus plantarum 299 Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day
45659051|NCT03733210|Device|PDE-NEO II camera|Medical infrared camera manufactured by Hamamatsu Photonics KK
45659052|NCT03733210|Device|FIS-00 fluorescence imaging system (FIS)|Fluorescence-imaging system (FIS) manufactured by Hamamatsu Photonics KK
45659053|NCT03733210|Device|Da Vinci Firefly Imaging System|Fluorescence-imaging endoscope, mounted or stand-alone, manufactured by Intuitive Surgical Inc
45659054|NCT03733210|Device|IGP-ELVIS-v4 Macroscopic Specimen Imager|Macroscopic specimen imager manufactured by LI-COR Biosciences
45811964|NCT03434509|Other|Continuous Tai Chi and Mindful Movement classes|"Participants will be enrolled in ongoing Tai Chi and mindful movement classes throughout the year, for 1 hour twice a week.~Class sessions will consist of warm up (yoga- and mindfulness-based practices), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing)."
45811965|NCT03407443|Other|Exposure to Make the Connection messages|Participants are exposed to Make the Connection messages (each approximately 3 minutes in length) weekly for over a four-month study period through the study mobile application.
45659055|NCT03733210|Device|Vevo 3100 LAZR-X|Photoacoustic ultrasound imaging system manufactured by VisualSonics
45659056|NCT03733210|Device|Pearl Triology Imaging System|Near-infrared fluorescent and bioluminescent imaging system manufactured by LI-COR Biosciences
45659057|NCT03733210|Device|Odyssey CLx Imaging System|Infrared fluorescent-imaging system manufactured by LI-COR Biosciences
45659058|NCT03733210|Device|Leica fluorescence microscope|Fluorescence microscope manufactured by Leica
45659059|NCT03733132|Drug|Metformin Hydrochloride|Metformin treatment of 2500mg for 10 months in the Metformin group
45659060|NCT03733132|Drug|Placebo Oral Tablet|Placebo treatment of identical tablets to metformin group
45659061|NCT03698994|Other|Pharmacokinetic Study|Ancillary studies
45659062|NCT03698994|Drug|Ulixertinib|Given PO
45659063|NCT03667820|Drug|Osimertinib|Osimertinib 80mg tablet to be taken once daily.
45659064|NCT03667820|Radiation|SABR|Stereotactic Ablative Radiation (SABR)
45659065|NCT03654053|Drug|Placebo Oral Tablet|Placebo taken once nightly at bed time.
45659066|NCT03654053|Drug|Simvastatin 40mg|Simvastatin 40mg taken once nightly at bed time.
45659067|NCT03648840|Behavioral|Aversive cue|Participants will be exposed to unpleasant pictures and tones during performance of a task to earn alcohol
45659068|NCT03648840|Behavioral|Neutral cue|Participants will be exposed to neutral pictures and tones during performance of a task to earn alcohol
45659069|NCT03635073|Drug|Soticlestat|Soticlestat tablets or mini-tablets.
45659070|NCT03627468|Drug|Sofpironium Bromide Gel, 5%|Sofpironium Bromide Gel, 5%
45659071|NCT03627468|Drug|Sofpironium Bromide Gel, 15%|Sofpironium Bromide Gel, 15%
45949389|NCT00111566|Drug|eptifibatide|
45949390|NCT04714723|Behavioral|Routine education|Routine lifestyle education based on smartphone for six month
45949391|NCT04714723|Behavioral|Programmed smartphone intervention|Interactive programmed lifestyle education based on smartphone for six month
45949392|NCT04714723|Behavioral|Programmed smartphone plus dietitian intervention|Interactive programmed lifestyle education based on smartphone plus dietitians support for six month
45949393|NCT00349648|Procedure|acromioplasty|
45949394|NCT00404703|Drug|bevacizumab [Avastin]|15mg iv on day 1 of each 3 week cycle
45949395|NCT00404703|Drug|Platinum-based chemotherapy|As prescribed
45949396|NCT00349726|Drug|Inositol lower volume|60 mg/kg (1.2ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
45949397|NCT00349726|Drug|Inositol higher volume|120 mg/kg (2.4ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
45949398|NCT00349726|Drug|Placebo lower volume|60 mg/kg (1.2ml/kg) of glucose 5% given intravenously over 20 minutes.
45659072|NCT03620019|Drug|Denosumab|A dose of 120 mg will be administered as a subcutaneous (s.c.) injection every 4 weeks in the upper arm, upper thigh, or abdomen. Another loading dose of 120 mg s.c. denosumab will be administered on day 8. On days when denosumab is administered on the same day as pembrolizumab, the s.c. injection should be given after the infusion of pembrolizumab is completed.
45811966|NCT03407443|Other|Active Control Group|Participants are exposed to VA news clips/segments (each approximately 3 minutes in length) weekly for over a four-month study period through the study mobile application.
45811967|NCT03390673|Drug|HD204|Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
45811968|NCT03390673|Drug|Avastin|Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
45811969|NCT02975791|Other|Marking the cricothyroid membrane after ultrasound|Ultrasonography is applied to the subjects neck in order to identify the cricothyroid membrane - subsequently the membrane is marked with a pen
45811970|NCT02975791|Procedure|Marking of the cricothyroid membrane after Palpation|Palpation is applied to the subjects neck in order to identify the cricothyroid membrane- subsequently the membrane is marked with a pen
45811971|NCT04156945|Behavioral|Behavioural intervention|An online tailored behavioural intervention. The intervention will be developed as part of the project and will be based on the principles of the Information-Motivation-Behavioural Skills (IBM) model for behavioural change. It will consist of four interactive text-based modules, and demonstration and modelling videos addressing information, motivation, and behavioural skills. The intervention will be offered on a website and able to be used on PCs as well as any mobile device. It will be provided to the participants after randomization at month 6 and available for a total period of 18 months.
45811972|NCT04156945|Diagnostic Test|HCV RNA home-based test|An additional patient-initiated home-based HCV testing service. The service offers a maximum of 4 free-of-charge HCV-RNA tests, which involves HCV testing using self-sampled dried blood spots (DBS). The DBS obtained from a finger stick will be used for HCV-RNA testing in the laboratory. DBS test kits, along with instructions and package materials for returning the test kits with the self-collected DBS sample will be provided to the participants after randomization at month 6 and available for use for a total period of 18 months.
45811973|NCT04155775|Other|Computer electronic health record alert (Best Practice Alert - BPA)|Upon ordering platelets in patients with recent platelet count >50,000, a pop-up within the electronic health system will recommend to not continue with transfuse product order and provide clinical exceptions to continue. Importantly, the alert does not trigger in operating areas, emergency medicine treatment areas, for certain specialties like neurosurgery or for massive transfusion orders.
45811974|NCT00005727|Behavioral|Intervention|Classroom-based nutrition education curriculum designed for individuals with low literacy skills.
45811975|NCT04343053|Other|SARS-Cov-2 infection|blood sample withdrawal
45811976|NCT00005739|Behavioral|Community-based directly observed therapy (DOT)|A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
45811977|NCT00005739|Behavioral|Clinic directly observed therapy (DOT)|A traditional self-administered preventive treatment
45453579|NCT01105819|Procedure|Chlorhexidine for standard oral care|"A The control group will receive the standard oral care of the department (general ICU, Lund University Hospital).~This includes suction of secretions, brushing of teeth cleansing of the oral cavity with swabs soaked with a chlorhexidine solution. This procedure is performed twice a day. In between, suction whenever needed and cleansing with swabs soaked with carbonated bottled water is performed Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day"
45811978|NCT02974933|Drug|Apatinib combined with pemetrexed|For those pretreated non-squamous non-small cell lung cancer, treat with apatinib 500mg Qd, po.combined with pemetrexed continue until disease progression
45811979|NCT00005769|Drug|Hormone Replacement Therapy|
45811980|NCT00005775|Drug|Glutamine|Infants randomized to glutamine supplementation will receive glutamine any time that parenteral nutrition is required during the first 120 days of hospitalization.
45949399|NCT00349726|Drug|Placebo higher volume|120 mg/kg (2.4ml/kg) of glucose 5% given intravenously over 20 minutes.
45949400|NCT00111605|Biological|HIV-1 gag DNA|A 0.75 mL intramuscular injection of HIV gag DNA vaccine into the deltoid
45659073|NCT03620019|Drug|Pembrolizumab|Pembrolizumab will be administered as standard of care following the institutional guidelines.The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over approximately 30 minutes (range: 25 - 40 minutes) every 3 weeks until disease progression or unacceptable toxicity.
45811981|NCT00005775|Drug|Placebo|TrophAmine given any time that parenteral nutrition is required during the first 120 days of hospitalization.
45811982|NCT02519036|Drug|ISIS 443139 10 mg|ISIS 443139, 10 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
45811983|NCT02519036|Drug|ISIS 443139 30 mg|ISIS 443139, 30 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
45811984|NCT02519036|Drug|ISIS 443139 60 mg|ISIS 443139, 60 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
45811985|NCT02519036|Drug|ISIS 443139 90 mg|ISIS 443139, 90 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
45811986|NCT02519036|Drug|ISIS 443139 120 mg|ISIS 443139, 120 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
45949401|NCT00111605|Biological|HIV-1 gag DNA plus IL-12 DNA adjuvant|Injection IL-12 DNA adjuvant intramuscularly into the deltoid
45949402|NCT00111605|Biological|CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine)|A 1 mL intramuscular injection in the deltoid
46002638|NCT05037383|Other|Video recordings|The surgery of the patient will be recorded by cameras placed on the top of the displays used by the operating staff. The recordings will be only carried out while the patient is draped for the surgery, thus completely covered.
45453580|NCT00749788|Drug|JTT-302|JTT-302, 100 mg tablets, 200 mg dose, oral, 30 minutes after the start of the morning meal
45659074|NCT03620019|Drug|Nivolumab|Nivolumab will be given every four weeks at a dose of 480 mg to be administered as an IV infusion per institutional guidelines.
45659075|NCT03614949|Radiation|Stereotactic body radiation therapy (SBRT)|SBRT with 24 Gy in 3 fractions to participants with ≥ 2 metastatic sites.
46002639|NCT00560079|Drug|Allopurinol|Allopurinol 600mg/day bid for 28 days
46002640|NCT00560079|Drug|Dipyridamole|Dipyridamole 200mg/day bid for 28 days
45949403|NCT00111605|Biological|Sodium chloride injection (0.9%)|"All placebo groups will receive an intramuscular injection of sodium chloride (0.9%) in the deltoid.~Group 1 will receive a 0.75 mL injection on Days 0, 28, and 84. Group 2 will receive a 0.8 mL injection on Days 0, 28, and 84. Group 3 will receive a 1.0 mL injection on Days 0, 28, and 84. Group 4 will receive a 1.5 mL injection on Days 0, 28, and 84. Group 5 will receive a 0.75 mL injection on Days 0, 28, 84, 168, and 273. Group 6 will receive a 1.5 mL injection on Days 0, 28, 84, 168, and 273. Group 7 will receive a 1.5 mL injection on Days 0, 28, and 84 and a 1 mL injection into the deltoid on Days 168 and 273."
45949404|NCT00349765|Behavioral|higher fat, high polyunsaturated fat diet|
45453581|NCT00749788|Drug|JTT-302|JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
45949405|NCT00349765|Behavioral|higher fat, high saturated and trans fat diet|
45949406|NCT00349765|Behavioral|lower fat diet|
45949407|NCT00349804|Other|cool dry air|cool dry air (0.22-0.28 m3/min at 15-18 Degrees C)
45949408|NCT00349843|Device|Soft contact lens|
45659076|NCT03614949|Drug|Atezolizumab|Atezolizumab 1200 mg intravenously (IV) every 3 weeks.
45949409|NCT00349843|Drug|Marketed soft lens multipurpose disinfection regimen|
45949410|NCT00404742|Drug|Placebo|PO BID
45949411|NCT00404742|Drug|LX211|0.2 mg/kg, twice a day (BID)
46076590|NCT00892801|Drug|RAD001|Taken by mouth once a day, for 15 days, one day prior to initiation of whole brain radiation therapy at 5 or 10 mg/day during the phase I component. One of these doses will be selected as the maximum tolerable dose and will be selected for the phase II component
46076591|NCT00892801|Radiation|whole-brain radiation therapy|Standard whole brain radiation therapy (WBRT) 30 Gy will be given in ten fractions.
46076592|NCT04222842|Drug|CM082|Subjects will receive CM082 orally for two weeks followed by two weeks off in four-week cycles.The total treatment period is tentatively set at 3 cycles (12 weeks).
46076593|NCT02541253|Biological|GC3110A|A single 0.5mL dose intramuscular injection
45453582|NCT00749788|Drug|Placebo|Matching placebo tablets, oral, 30 minutes after the start of the morning meal
45453583|NCT00749632|Drug|oxybutynin|low dose oxybutynin administered daily
45453584|NCT00749632|Drug|oxybutynin|middle dose oxybutynin administered daily
45811987|NCT02519036|Other|Placebo|Placebo was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
45811988|NCT00005787|Biological|epoetin alfa|
45949412|NCT00404742|Drug|LX211|0.4 mg/kg, twice a day (BID)
45949413|NCT00404742|Drug|LX211|0.6 mg/kg, twice a day (BID)
46076594|NCT02541253|Biological|GCFLU Pre-filled Syringe inj.|A single 0.5mL dose intramuscular injection
46076595|NCT04245020|Other|Text message follow up|A text message will be sent to the patient 6-8 weeks following discharge
46076596|NCT04245020|Other|Telephone follow up|The patient will be followed up at 6-8 weeks following discharge with a telephone call
45949414|NCT00349882|Device|soft contact lens|
45949415|NCT00349882|Drug|Marketed multipurpose disinfection regimen|
46076597|NCT04245020|Other|In person follow up|The patient will be followed up at 6-8 weeks following discharge in person in the outpatient department
45453585|NCT00749632|Drug|oxybutynin|high dose oxybutynin administered daily
45453586|NCT01105273|Biological|anti-thymocyte globulin|On days -3 to -1
46076598|NCT02762526|Procedure|Lipoabdominoplasty|
46076599|NCT00890071|Other|Fluid administration|500 ml of synthetic colloid (Voluven®, hydroxyethylstarch 6%; Fresenius, Bad Homburg, Germany) infused over 30 minutes
46076600|NCT02832908|Other|Change from semi-seated position to supine|from semi-seated position (30°) to lying position
45659077|NCT03613116|Dietary Supplement|Vitamin D3|One-half of each diagnostic group will be randomized to treatment with high-dose vitamin D3 or to standard dose Vitamin D
45659078|NCT03595176|Device|Lithotripsy|Deliver Lithotripsy to the target vessel prior to placing a coronary stent.
45453587|NCT01105273|Biological|filgrastim|Beginning on day 4 and continuing until blood counts recover
45453588|NCT01105273|Drug|Fludarabine|30mg/M2 once daily IV on days -6 to -2
45453589|NCT01105273|Drug|Cyclophosphamide|60 mg/kg IV on day-3 and -2
45453590|NCT01105273|Procedure|CD3±CD19 depleted hematopoietic stem cell transplantation|Immunogenetic depletion on CliniMACS
45453591|NCT00748852|Drug|JTT-302|JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
45659079|NCT03588039|Drug|Oraxol|Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets
45659080|NCT03588039|Biological|Pembrolizumab|Intravenously administered
45676464|NCT02941926|Drug|Goserelin|Goserelin is procured locally and administered in men and premenopausal women as an injectable subcutaneous implant administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 3.6 mg (cycle = 28 days)
45676465|NCT02941926|Drug|Leuprolide|Leuprolide is procured locally and administered in men and premenopausal women as an injectable intramuscular depot administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 7.5 mg (cycle= 28 days)
45676466|NCT02933255|Biological|PROSTVAC-V/F|PROSTVAC-V (vaccinia) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 2x10^8 infectious units. PROSTVAC-F (fowlpox) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 1x109 infectious units.
45811989|NCT00005787|Biological|filgrastim|
45811990|NCT00005787|Biological|recombinant flt3 ligand|
45811991|NCT00005787|Biological|recombinant interleukin-3|
45811992|NCT00005787|Biological|sargramostim|
45811993|NCT00005787|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45811994|NCT00005793|Drug|Cytarabine|
45811995|NCT00005793|Drug|Daunorubicin|
45811996|NCT00005793|Drug|Etoposide|
45811997|NCT00005793|Drug|Topotecan|
45811998|NCT00005799|Drug|fludarabine phosphate|Given IV
45811999|NCT00005799|Radiation|total-body irradiation|Undergo low-dose TBI
45812000|NCT00005799|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative HSCT
45659081|NCT03570021|Procedure|total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection|"total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection as defined by the American Thyroid Association [American Thyroid Association Surgery Working Group, Thyroid 2009]. This is a standard treatment recognized by the French Society of Otolaryngology Head and Neck Surgery [French Society of Otolaryngology Head and Neck Sugery].~- The number of lymph nodes resected, the number of metastatic nodes, their size and the presence or absence of extranodal spread will be recorded. Due to the large natural variability of the number of lymph nodes retrieved in a prophylactic neck dissection [Hartl DM, Ann Surg 2012], no patient will be excluded on the basis of number of lymph nodes. Furthermore, the participating surgeons routinely perform complete central neck dissections, and were chosen to participate in this study due to a homogenous technique among these surgeons [Hartl DM, World J Surg 2012]."
45659082|NCT03570021|Procedure|total thyroidectomy alone without neck dissection|This is recognized as a standard treatment by the Francophone Association of Endocrine Surgery
45659083|NCT03553004|Drug|Niraparib Treatment|Niraparib treatment by mouth (oral)
45659084|NCT03539822|Drug|Cabozantinib|by mouth
45949416|NCT00111644|Drug|Ceftriaxone|1000mg iv daily
45949417|NCT00111644|Drug|beta-lactam|750mg iv q 23h for 3-14 days
45812001|NCT00005799|Procedure|allogeneic bone marrow transplantation|Undergo nonmyeloablative allogeneic bone marrow transplantation
45812002|NCT00005799|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
45812003|NCT00005799|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
45812004|NCT00005799|Drug|cyclosporine|Given PO
45812005|NCT00005799|Drug|mycophenolate mofetil|Given PO
45812006|NCT00005799|Other|pharmacological study|Correlative studies
45812007|NCT00005799|Other|laboratory biomarker analysis|Correlative studies
45812008|NCT02418026|Other|hypnosis|Conversational hypnotic induction and therapeutic suggestions
45812009|NCT00386373|Drug|Imatinib Mesylate|Starting dose of 100 mg daily by mouth for first 100 days following bone marrow transplant (BMT) or stem cell transplant (SCT).
45812010|NCT00005805|Dietary Supplement|St. John's wort|
45812011|NCT00005811|Drug|topotecan hydrochloride|Given IT
45812012|NCT00005811|Other|laboratory biomarker analysis|Correlative studies
45949418|NCT00111644|Drug|beta-lactam|1500mg iv q 12h for 3-14 days
45949419|NCT00349960|Drug|NeoRecormon SC once-weekly versus once-every-other-week|
45949420|NCT00350038|Drug|Irbesartan|
45949421|NCT00350038|Drug|Ciprofibrate|
45659085|NCT03539822|Drug|Durvalumab|infusion
45659086|NCT03539822|Drug|Tremelimumab|infusion
45659087|NCT03519178|Drug|PF-06873600|PF-06873600 tablet for oral dosing
45659088|NCT03519178|Drug|Endocrine Therapy 1|Endocrine Therapy 1
45659089|NCT03519178|Drug|Endocrine Therapy 2|Endocrine Therapy 2
45659090|NCT03516617|Drug|Acalabrutinib|Given PO
45659091|NCT03516617|Other|Laboratory Biomarker Analysis|Correlative studies
45659092|NCT03516617|Biological|Obinutuzumab|Given IV
45659093|NCT03516617|Other|Patient Observation|Undergo observation
45659094|NCT03516617|Other|Quality-of-Life Assessment|Ancillary studies
45812013|NCT01689831|Biological|To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.|Comparison of different dosages of Aplisol PPD relative to reference standard PPD-S2.
45812014|NCT01689831|Biological|Reactivity of Aplisol compared to reference standard PPD-S2.|Reference standard PPD-S2 formulated to contain different dose concentrations.
45949422|NCT00350077|Drug|Intravenous Vitamin C|vitamin C IV during 24 hour period following burn
45949423|NCT00350077|Drug|Vitamin C|IV vitamin C
45949424|NCT00114153|Drug|capecitabine|
45949425|NCT00114153|Drug|carboplatin|
45812015|NCT02520518|Drug|Dapagliflozin|
45812016|NCT02520518|Drug|Placebo|
45812017|NCT02520518|Behavioral|Weight maintenance|
45812018|NCT02520518|Behavioral|Ad libitum dietary intake|
45812019|NCT02520518|Behavioral|Dietary restriction|
45812020|NCT01689987|Drug|Cyclophosphamide|Given IV
45812021|NCT01689987|Drug|Dexamethasone|Given PO
45812022|NCT01689987|Drug|Hydroxychloroquine|Given PO
45812023|NCT01689987|Other|Laboratory Biomarker Analysis|Correlative studies
45812024|NCT01689987|Other|Pharmacological Study|Correlative studies
45812025|NCT01689987|Drug|Sirolimus|Given PO
45812026|NCT01680939|Drug|Morphine|0.2-0.5 mg/kg PO q4h
45812027|NCT01680939|Drug|Ibuprofen|10mg/kg PO q6hrs
45812028|NCT01689597|Drug|Morphine|Comparison of different dosages of drug
45812029|NCT01689597|Drug|Placebo|
45812030|NCT01686477|Other|Unfortified Human donor Milk used to make up any shortfall in mother's own milk|
45812031|NCT01686477|Other|Fortified Human donor Milk used to make up any shortfall in mother's own milk|
45812032|NCT01686477|Other|Preterm Formula used when there is a shortfall in mother's own milk|
45812033|NCT05140161|Device|collagen|use of hemostatic device in order to reduce bleeding in nail surgery
45949426|NCT00114153|Procedure|conventional surgery|
45949427|NCT00114153|Radiation|radiation therapy|
45949428|NCT00350116|Drug|topical vitamin B12|
45949429|NCT00350155|Drug|Lumiracoxib|
45949430|NCT00111683|Drug|MK0457|
45949431|NCT00350194|Dietary Supplement|Omega-3 fatty acids|Total of 1.8 grams of EPA +DHA in the form of fish oil capsules (3/day)
45949432|NCT00404781|Drug|cilostazol in addition to aspirin and clopidogrel|
45949433|NCT00350233|Device|ExAblate 2000|
45949434|NCT00350311|Drug|nicotine transdermal patch/lozenge|
45949435|NCT00350350|Device|oxygenated oil|oxygenated oil in spray versus product reference (artificial saliva) dosage : one to two spray 5 times a day
45949436|NCT00350350|Device|medical device. Spray containing essentially oxygenated oil|"protective oral spray containing :~94.4% of oxygenated oil~Silicium dioxide~aspartame artificial flavoring"
45949437|NCT02964611|Behavioral|Observational Study|This is an observational study.
46002641|NCT00560079|Drug|Placebo|Placebo
45659095|NCT03502707|Biological|Placebo|Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.
45949438|NCT00350389|Behavioral|Outdoor use of plain distance glasses with counselling|Provision of single lens glasses, glasses aids, counselling, updated multifocal glasses if required
45949439|NCT00114192|Drug|docetaxel|
45949440|NCT00114192|Drug|thalidomide|
45949441|NCT00350428|Procedure|Laser Preipheral Iridotomy and phacoemulsification|
45453592|NCT05215327|Biological|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
45659096|NCT03502707|Biological|RSV preF Protein 50 mcg|RSV preF will be administered as a solution for intramuscular injection at a dose of 50 mcg.
45659097|NCT03502707|Biological|RSV preF Protein 150 mcg|RSV preF will be administered as a solution for intramuscular injection at a dose of 150 mcg.
45812034|NCT05140317|Procedure|Transcatheter heart valve implantation with or withour predilatatation|long term up to 5 years echographic and clinical follow up
45659098|NCT03502707|Biological|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be administered as a solution for intramuscular injection at a dose of 1*10^11 vp.
45812035|NCT02521766|Device|Harmoni Modular Intraocular Lens|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
45812036|NCT02521766|Device|Commercially Available Intraocular Lens|IOL per investigator's standard of care
45812037|NCT02521766|Procedure|Optic exchange|Removal of one optic and replacement with another for the purpose of improving refractive outcomes
45812038|NCT02163733|Drug|AZD9291 tablets|AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
45812039|NCT02163733|Procedure|Pharmacokinetic sampling - AZD9291|Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
45949442|NCT00350467|Drug|ER OROS paliperidone and Olanzapine|
45949443|NCT00350506|Device|64 Channel VCT|
45949444|NCT00111878|Drug|MEDI-534|
45949445|NCT00350584|Behavioral|Mindfulness Telehealth Intervention|Two in-person sessions and six telephone sessions with a therapist. Focus is on learning mindfulness skills.
45949446|NCT00350584|Behavioral|Psychoeducation Telehealth Intervention|Two in-person sessions and six telephone sessions with a therapist. Focus is on education about PTSD.
45949447|NCT00350662|Drug|Deferiprone (L1)|75 mg/kg body weight daily
45949448|NCT00350662|Drug|Desferrioxamine|In combination with deferiprone: 40-50 mg/kg body weight 2-times weekly As single agent: 40-50 mg/kg body weight 5- to 7-times weekly
45949449|NCT00350818|Drug|Azacitidine|8 mg/m^2 Subcutaneously Once Daily for 5 Days
45949450|NCT00350857|Drug|Extended-Release Carbamazepine|
45949451|NCT00111956|Drug|Etanercept|
45949452|NCT00111956|Drug|Placebo|
45659099|NCT03502707|Biological|Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg|Mixture of Ad26.RSV.preF (5*10^10 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
45659100|NCT03502707|Biological|Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg|Mixture of Ad26.RSV.preF (5*10^10 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
45659101|NCT03502707|Biological|Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg|Mixture of Ad26.RSV.preF (1*10^11 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
45659102|NCT03502707|Biological|Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg|Mixture of Ad26.RSV.preF (1*10^11 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
45659103|NCT03502707|Biological|Selected Regimen|A regimen from Cohort 1 or Cohort 2 will be selected and administered as a solution for intramuscular injection at the selected dose.
45949453|NCT00114270|Drug|letrozole|
45949454|NCT00114270|Drug|zoledronic acid|
45949455|NCT00350896|Device|Thumb orthoses|
45949456|NCT00350935|Procedure|fMRI|One 30 minute session
45949457|NCT00114309|Drug|131-I-TM-601|131I-TM601, in solution, delivered intracavitarily following surgical resection 3 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
45949458|NCT00114309|Drug|131I-TM601|131I-TM601, in solution, delivered intracavitarily following surgical resection 6 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
45949459|NCT00111995|Drug|Aranesp®|
45949460|NCT00421486|Procedure|Oral swabs for HPV-typing and high-risk HPV-determination|Oral swabs for HPV-typing and high-risk HPV-determination
45949461|NCT00351013|Other|Malaria Tropica Nosode D200|5 pellets every four months
45949462|NCT00351052|Drug|Pimecrolimus|Pimecroliums cream 1 % bid.
45949463|NCT00351052|Drug|Placebo|Vehicle control (placebo) bid.
45949464|NCT00401609|Drug|gemcitabine|
45949465|NCT00401609|Drug|vinorelbine|
45949466|NCT00401609|Drug|cisplatin|
45949467|NCT00401609|Drug|etoposide|
45949468|NCT00401609|Drug|carboplatin|
45949469|NCT05595135|Other|Text Message-Based Navigation Intervention|Receive interactive text messaging.
45949470|NCT05595135|Other|Behavioral, Psychological or Informational Intervention|Receive medication reminders via smart pill bottle
45949471|NCT05595135|Other|Survey Administration|Ancillary studies
45949472|NCT05595135|Other|Quality-of-Life Assessment|Ancillary studies
45453593|NCT05215327|Biological|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
45812040|NCT02163733|Other|Dietary Fasted|Fasted from 10 hours prior to dosing with 80mg AZD9291 tablet and 4 hours after dosing
45812041|NCT02163733|Other|Dietary High Fat|Allocated breakfast prior to dosing with 80mg AZD9291 tablet
45812042|NCT02163733|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
45453594|NCT00664378|Drug|CYT997|Intravenous infusion (24h); 202mg/m2 on days 1 and 8 of a 21 day cycle
45812043|NCT01689675|Behavioral|Computer based pain management|
45812044|NCT05140083|Drug|68Ga-NOTA Evans Blue|Each subject receives a single subcutaneous injection of 68Ga-NOTA Evans Blue, and undergo PET/CT imaging within the specific time.
45812045|NCT02482610|Other|Glucose|Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
45812046|NCT02482610|Other|Glucose with Whole Fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of whole fat milk within five minutes.
45812047|NCT02482610|Other|Glucose with Non-fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
45949473|NCT00351091|Drug|RISEDRONATE|
45949474|NCT00351130|Drug|valsartan|
45949475|NCT00351130|Drug|amlodipine|
45949476|NCT00351169|Drug|Quetiapine SR|
45949477|NCT00351169|Drug|Escitalopram|
45949478|NCT00401648|Drug|Brivaracetam|
45812048|NCT04823247|Drug|Tildrakizumab|As provided in real world clinical practice.
45453595|NCT00743938|Drug|BMS-690514|Tablets, Oral, 200 mg, once daily, Until disease progression or toxicity
45453596|NCT00743938|Drug|Erlotinib|Capsules, Oral, 150 mg, once daily, Until disease progression or toxicity
45453597|NCT03947203|Behavioral|Social media|Provided pamphlet and a private Facebook group where informational messages and content relating to oral health will be shared
45812049|NCT02483000|Biological|Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein|Given IV
45812050|NCT02483000|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
45812051|NCT02483000|Drug|Carmustine|Given IV
45812052|NCT02483000|Drug|Clearing Agent|Given IV
45812053|NCT02483000|Drug|Cytarabine|Given IV
45812054|NCT02483000|Drug|Etoposide|Given IV
45812055|NCT02483000|Radiation|Indium In 111-DOTA-Biotin|Given IV
45812056|NCT02483000|Other|Laboratory Biomarker Analysis|Correlative studies
45812057|NCT02483000|Drug|Melphalan|Given IV
45812058|NCT02483000|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
45949479|NCT00114348|Procedure|R-Blocks|
45949480|NCT00114348|Procedure|Protocol II-Ida|
45812059|NCT02483000|Other|Pharmacological Study|Correlative studies
45812060|NCT02483000|Radiation|Yttrium Y 90-DOTA-Biotin|Given IV
45949481|NCT00351208|Device|Medtronic Manufactured Spinal Cord Stimulators|
45949482|NCT00351247|Procedure|Postconditioning|
45949483|NCT00351286|Drug|L-citrulline tablets, 1000 mg|
45949484|NCT00351286|Drug|Placebo tablets matching L-citrulline tablets|
45949485|NCT00351286|Drug|Background simvastatin at a stable dose of 40 mg qHS|
45949486|NCT00351325|Drug|BMS-663513|mg/kg, IV, 0.3, 1, 3, 10 mg/kg, q 3 wks, up to 24 weeks
45949487|NCT00112034|Drug|Methotrexate|
45949488|NCT00112034|Drug|IV methylprednisolone|
45949489|NCT00114387|Drug|DL-alpha-tocopherol|
45949490|NCT00351364|Drug|Montelukast Sodium|100 mg P.O. One time only
45949491|NCT00351403|Drug|Ribavirin|Rebetol 200 mg: applied as hard capsule
45949492|NCT00351403|Drug|Peginterferon alfa 2b|PegIntron (50/80/100/120/150 microgram): applied by injection
45949493|NCT00112190|Drug|Itopride Hydrochloride|100 mg tid
45949494|NCT00112190|Drug|itopride|100 mg three times daily
46002642|NCT04646265|Other|periodontal treatment|non-surgical root debridement
46002643|NCT00560118|Drug|fotemustine|
45812061|NCT02088151|Device|Selective retinal pigment epithelium laser therapy using the R:GEN Laser System|Patients receive selective retinal pigment epithelium laser treatment using the R:GEN Laser System by Lutronic Corporation, Korea.
45949495|NCT05595096|Procedure|General anesthesia with preservation of spontaneous breathing|non-intubation group, thoracic paravertebral nerve block was performed before anesthesia induction,when the BIS value drops to between 40 and 60, laryngeal mask airway(LMA) is placed,and observation of breathing
45812062|NCT04125043|Diagnostic Test|Direct ophthalmoscope|Red reflex test
45812063|NCT01973179|Radiation|Radiation therapy|Radiation therapy with protons
45949496|NCT00351520|Drug|Miltefose|
45949497|NCT00351559|Device|AlloMap molecular expression testing|
45949498|NCT00351559|Procedure|Right ventricular endomyocardial biopsy|
45949499|NCT00112229|Biological|group 1|Melan-A analog peptide + CpG + Montanide
45812064|NCT02279745|Drug|Ralinepag|Active
45949500|NCT00112229|Biological|group 2|Melan-A natural peptide + CpG + Montanide
45949501|NCT00112229|Biological|group 3|Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
45949502|NCT00112229|Biological|group 4|Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide
45949503|NCT00351598|Radiation|Definitive Radiotherapy|60Gy in 6 weeks, 50Gy in 4 weeks. Each individual fraction should not exceed 2.5Gy.
45949504|NCT00351637|Drug|Sublingual Methadone|
45949505|NCT00112268|Behavioral|QuitLink (office support system for quit line referral)|
45949506|NCT00351676|Behavioral|Integration of a team based clinical pharmacist|
45949507|NCT00351676|Drug|Optimizing therapeutic treatments|
45949508|NCT00351676|Behavioral|Optimizing processes of care|
45949509|NCT00114426|Device|non-invasive mechanical ventilation|
45949510|NCT00351715|Drug|Sublingual Methadone|
45949511|NCT00351754|Drug|Isovue|
45949512|NCT00351832|Drug|Vildagliptin|
45949513|NCT00112307|Procedure|Brachytherapy|
45949514|NCT00351871|Drug|PEG-Intron Plus REBETOL|
45949515|NCT00351910|Drug|Quetiapine|
45949516|NCT00351910|Drug|Amitriptyline|
45949517|NCT00351910|Drug|Bupropion|
45949518|NCT00351910|Drug|Citalopram|
45949519|NCT00351910|Drug|Duloxetine|
45949520|NCT00351910|Drug|Escitalopram|
45949521|NCT00351910|Drug|Fluoxetine|
45949522|NCT00351910|Drug|Paroxetine|
45949523|NCT00351910|Drug|Sertraline|
45949524|NCT00351910|Drug|Venlafaxine|
45812065|NCT02484092|Biological|SPK-9001|A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
45812066|NCT02420210|Drug|Bendamustine Hydrochloride|Given IV
45812067|NCT02420210|Biological|Obinutuzumab|Given IV
45949525|NCT00112346|Drug|Cetuximab + platinum + gemcitabine|Solution, IV, Cetuximab: 400mg/m2 on Day 1 then given weekly at 250mg/m2 starting on Day 8 + Gemcitabine given at 1250mg/m2 (Day 1 & Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks. Cetuximab is given weekly, Maximum of 6 cycles (18 weeks) Cetuximab will be continued during the period following discontinuation of chemotherapy, until disease progression or cetuximab intolerance.
45949526|NCT00112346|Drug|Platinum + Gemcitabine|Solution, IV, Gemcitabine given at 1250mg/m2 (Day 1 & Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks, Maximum of 6 cycles = 18 weeks.
45949527|NCT00114465|Drug|VSL#3|VSL#3 1 sachet twice a day
45949528|NCT00114465|Other|Placebo|Placebo 1 sachel twice a day
45949529|NCT00351949|Biological|IMP321|subcutaneous injections of IMP321 every 14 days for three months (6 injections. Doses tested: 50, 250, 1,250, 6,250 or 30,000 µg
45949530|NCT00352066|Drug|apricitabine|
45949531|NCT00112424|Procedure|Diagnostic cardiac MRI|Routine cardiac MRI done under general anesthesia as pre-operative evaluation.
45949532|NCT00112424|Procedure|Cardiac catheterization|Routine cardiac catheterization prior to Glenn operation.
45949533|NCT00352144|Drug|Eszopiclone|Eszopiclone 3 mg
45949534|NCT00352144|Drug|Placebo|Placebo tablet
45949535|NCT00352183|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40mg
45949536|NCT00352183|Drug|Simvastatin|Simvastatin 40mg
45949537|NCT04714255|Other|Trace Image and Coloring for Kids-Book (TICK-B)|A collection of images attractive that need to be colored, created as a book called TICK-B. This book was created with the instructions and recommendations of a pediatric psychiatrist and a professional drawing teacher at a children's school.Distraction with TICK-B began 1-3 min. before the intravenous cannula procedure and lasted until the end of the procedure.
45949538|NCT00112619|Drug|topotecan hydrochloride|Participants receive intraventricular topotecan, .2 mg, administered via an indwelling ventricular reservoir daily for 5 consecutive days during weeks 1 and 3 of the first four weeks of therapy (induction), during weeks 5 and 8 of the next 6 weeks of therapy (consolidation), and during weeks 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, and 51 (maintenance therapy).
45949539|NCT00352222|Device|stent implantation|
45949540|NCT00352261|Drug|Esomeprazole|
45949541|NCT00352261|Drug|Lansoprazole|
45949542|NCT00352300|Procedure|Adjuvant Therapy|
45949543|NCT00352300|Drug|Carboplatin|Given IV
45949544|NCT00352300|Drug|Paclitaxel|Given IV
45949545|NCT00352300|Biological|Pegfilgrastim|Given IV
45949546|NCT00112658|Drug|fluorouracil|
45949547|NCT00112658|Drug|gemcitabine hydrochloride|
45949548|NCT00112658|Drug|irinotecan hydrochloride|
45659104|NCT03488667|Drug|Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab|Pembrolizumab, mFOLFOX Chemotherapy
45949549|NCT00112658|Drug|leucovorin calcium|
45812068|NCT02420210|Drug|Dexamethasone|Given PO
45812069|NCT02420210|Other|Quality-of-Life Assessment|Ancillary studies
45812070|NCT02420210|Other|Laboratory Biomarker Analysis|Correlative studies
45812071|NCT02974777|Drug|DAPT reduction|Reduction of standard dose DAPT due to low platelet reactivity
45949550|NCT00112658|Drug|oxaliplatin|
45812072|NCT02974777|Drug|DAPT on-target|Standard DAPT within the therapeutic window of platelet reactivity
45812073|NCT02974777|Drug|DAPT intensification|Intensification of standard dose DAPT due to high platelet reactivity
45949551|NCT00352339|Drug|Rispridoen and Aripiprazole|Start with risperidone and switch it to aripiprazole. Flexible dose
45949552|NCT00352339|Drug|Risperidne|Start with risperidne and keep it through the end of study. Risperidne:flexible dose
45949553|NCT00352339|Drug|Abilify|Start with abilify and keep it through the end of study
45949554|NCT00114543|Procedure|Aggressive Phototherapy 501-750g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-14.
45949555|NCT00114543|Procedure|Aggressive Phototherapy 751-1000g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-7, and started, stopped, and/or restarted when levels reach 7 mg/dl during days of life 8-14.
45949556|NCT00114543|Procedure|Conservative Phototherapy 501-750g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥8.0 mg/dl during days of life 1-14.
45949557|NCT00114543|Procedure|Conservative Phototherapy 751-1000g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥10.0 mg/dl during days of life 1-14.
45949558|NCT00352378|Drug|Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine|"Patients will be randomized to receive regimen A (AC) and regimen B(TX),preoperatively as follows:~Regimen A (AC): Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1. Regimen B(TX): Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14"
45949559|NCT00352495|Drug|carboplatin|
45949560|NCT00352495|Drug|vinblastine sulfate|
45949561|NCT02964351|Biological|High PSA levels|
45812074|NCT02485964|Other|Blood draw|One time blood draw at time of consent. Blood will be stored until all subjects have been enrolled and then the enzyme-linked immunospot (ELISPOT) assay will be done to measure the antigen-specific interferon secretion.
45812075|NCT04821609|Behavioral|Resistance Training|The resistance training will be for arms and legs, self-loading type, and external weights.
45949562|NCT00112697|Drug|cisplatin|
45949563|NCT00112697|Drug|docetaxel|
45949564|NCT00112697|Drug|fluorouracil|
45949565|NCT00112697|Radiation|radiation therapy|
45949566|NCT02959606|Drug|Sarpogrelate SR 300mg|
45949567|NCT02959606|Drug|Clopidogrel|
45949568|NCT00352651|Drug|Pregabalin|
45949569|NCT00352729|Device|ACell dressing|dressing
45949570|NCT00112775|Drug|dasatinib|
45949571|NCT00112775|Drug|imatinib mesylate|
45949572|NCT00352768|Drug|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
45659105|NCT03488667|Drug|Adjuvant Treatment - mFOLFOX & Pembrolizumab|Pembrolizumab, mFOLFOX Chemotherapy
45659106|NCT03459625|Behavioral|Mindfulness-Based Stress Reduction (MSBR)|MBSR includes eight weekly 2.5-hour group sessions, a day-long (6hr) meditation retreat on the weekend during week six, 45 minutes of daily home practice guided by instructional audio CDs, and an MBSR parent workbook. Formal mindfulness exercises aim to increase the capacity for mindfulness and include a body scan, mindful yoga, and sitting meditation. Participants are also taught to practice mindfulness informally in everyday activities. In session, didactic instruction on stress physiology and using mindfulness for coping with stress in daily life is provided. Participants practice formal mindfulness exercises, break into dyads to discuss their daily homework practice, and meet as a larger group to ask questions related to the practice of mindfulness in everyday life.
45676467|NCT02933255|Drug|Nivolumab|Nivolumab is to be administered as a flat dose over approximately 60-minutes via IV infusion.
45676468|NCT02910700|Drug|Binimetinib|Given PO
45676469|NCT02910700|Drug|Dabrafenib|Given PO
45676470|NCT02910700|Drug|Encorafenib|Given PO
45812076|NCT00361699|Drug|Statin|
45812077|NCT04829799|Drug|1% preservative-free lidocaine|Instillation of intracameral lidocaine after initial paracentesis incision.
45949573|NCT00352768|Drug|Placebo|Placebo
45949574|NCT00352807|Drug|Brimonidine Purite|
45949575|NCT00352963|Biological|Study vaccines: IH+Hib-MenC/NVC; Control: IH+Meningitec|
45949576|NCT00114582|Procedure|family style dinner|
45949577|NCT00112853|Drug|tipifarnib|Given orally
45949578|NCT00112853|Drug|etoposide|Given orally
45949579|NCT00353002|Drug|Ametop (4% Amethocaine cream )|
45949580|NCT00353002|Drug|Maxilene (4% Liposomal Lidocaine)|
45949581|NCT00114621|Drug|Anthrax Vaccine|
45949582|NCT00114621|Procedure|Blood Chemistry|
45949583|NCT00114621|Procedure|Hematology|
45949584|NCT00114621|Procedure|Urinalysis|
45949585|NCT00353041|Drug|lidocaine topical|
45949586|NCT00353080|Drug|risedronate (HMR4003)|
45949587|NCT00112892|Dietary Supplement|selenium|
45949588|NCT00112892|Drug|irinotecan hydrochloride|
46002644|NCT00560118|Genetic|gene expression analysis|
46002645|NCT00560118|Genetic|polymerase chain reaction|
45812078|NCT04829799|Drug|Phenylephrine 1.0%/ Ketorolac 0.3%|Instillation of Omidria irrigation solution after paracentesis incision and in irrigation solution.
45812079|NCT02975947|Device|Humidified, warmed CO2 insufflation of open peritoneum using Fisher & Paykel's HUMIGARD (Fisher & Paykel Healthcare Ltd, Auckland, New Zealand)|The study group will receive warmed (37°C), humidified (98% RH) carbon dioxide into the open peritoneal cavity using the Fisher & Paykel's HUMIGARD system (Fisher & Paykel Healthcare Ltd, Auckland, New Zealand). This will create a local atmosphere of 100% carbon dioxide (warmed, humidified) in the open peritoneal cavity.
45812080|NCT02975947|Device|Standard heating|Standard intraoperative warming measures including heated blankets, heating with forced warmed air, warming of fluids, and insulation of limbs and head
45949589|NCT05594901|Other|Application of a prognostic score|The CRECOOLT score, for the prospective cohort, will be systematically calculated once week, or at the occurrence of complications, until 60 days after OLT. The therapeutic management of all patients, during both retrospective and prospective periods, will be established by the attending physicians according with routine practice and not dictated by study protocol.
45949590|NCT04714450|Behavioral|Experimental: MMST+|The format of the MMST will remain the same; however, the white noise, images and math task will be modified to mitigate habituation effects.
45659107|NCT03459625|Behavioral|Psychoeducational Support Group (PE)|The PE consists of 8-weekly 2.5-hour sessions, a day-long (6hr) Family Resource Fair during week six, daily homework that includes monitoring progress on goals identified at the end of each session, and a workbook for parents of children with special needs that provides parents with information regarding their child's development, disability, and associated considerations. Weekly topics for discussion include Preparing for Individualized Education Plan (IEP) meetings, Communicating with Teachers, Advocacy, Sibling Issues, and Community Resources.
45949591|NCT00353353|Procedure|consumption of fortified bread|
45949592|NCT00353392|Device|Laser Therapy|
45949593|NCT00114660|Drug|Cocoa butter application|
45812081|NCT01789333|Device|UVA Light with irradiance exposure of 9 mW/cm2|"The device's light emitting diode (LED) is used to deliver a metered dose of Ultraviolet A (UVA) light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.~The aperture setting will be set at 10 mm, and the eye will be irradiated for 10 minutes for the high irradiance exposure of 9 milliwatts (mW)/cm2. During the exposure, instillation of riboflavin will continue (1 drop every 3 minutes)."
45812082|NCT01789333|Drug|Riboflavin 0.1% ophthalmic solution|"The speculum is removed and one (1) drop of Riboflavin 0.1% ophthalmic solution will be instilled topically in the eye every 3 minutes for 30 minutes. At the end of the 30 minute riboflavin pre-treatment period, the eye will be examined to assure the presence of a yellow flare in the anterior chamber, indicating riboflavin saturation of the corneal tissue. If the yellow flare is not detected, riboflavin will continue to be instilled until the presence of the yellow flare in the anterior chamber is confirmed.~During UVA irradiation, instillation of riboflavin will be continued every 3 minutes. For a 30-minute pre-treatment and 30-minute irradiation, the total dose of riboflavin solution is approximately 32 drops, or 1.6 ml (1 drop = 0.05 ml; 1.6 mL = 1.6 mg riboflavin)."
45949594|NCT00353509|Device|Device Closure of a Septal Defect|
45949595|NCT00353587|Drug|MBX-102|MBX-102 200 mg once daily for 16 weeks
45949596|NCT00353587|Drug|MBX-102|MBX-102 400 mg once daily for 16 weeks
45949597|NCT00353587|Drug|MBX-102|MBX-102 600 mg once daily for 16 weeks
45949598|NCT00353587|Drug|Placebo|MBX-102 Placebo once daily for 16 weeks
45659108|NCT03428581|Procedure|ALND with ARM +/- LVB|"Subjects will undergo removal of the lymph nodes in the underarm or axilla area. This is referred to as an axillary lymph node dissection (ALND). The procedure for identifying the drainage of the arm lymphatics during an axillary dissection has been coined axillary reverse mapping (ARM). Lympho-venous bypass (LVB) is a technique incorporated along with the ARM procedure that allows preservation of the lymphatics draining the arm while removing the standard lymph nodes and not compromising the extent of the axillary dissection."
45949599|NCT00353587|Drug|Actos|Actos 30 mg once daily for 16 weeks
45453598|NCT01105897|Procedure|Endometriosis surgery|Complete surgical excision of all visible endometriosis by multidisciplinary approach
45453599|NCT00662740|Drug|Tiotropium/Salmeterol QD|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
45453600|NCT00662740|Drug|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
45949600|NCT05594862|Device|Lipogems|Micro-fragmented adipose tissue infiltration
45949601|NCT00113009|Drug|VLTS-934|
45949602|NCT00353665|Drug|Memantine (Ebixa)|10 mg bid
45949603|NCT00353665|Drug|riluzole|riluzole 50 mg bid
45949604|NCT00353665|Drug|Placebo|
45949605|NCT04714606|Other|Sibling support group|The intervention is a novel, 8 session sibling support group which has been created for the purpose of the study.
45949606|NCT04714606|Other|None - control condition|The second arm of the study is a control condition in which participants will be given a tailored booklet to complete at home as it was deemed unethical to provide them with nothing.
45949607|NCT05594784|Drug|Olverembatinib|a third-generation TKI
45949608|NCT05594784|Drug|Venetoclax|a selective inhibitor of B-cell lymphoma 2 (Bcl-2)
45949609|NCT05594784|Drug|prednisone|Glucocorticoids
45949610|NCT05594784|Drug|Vincristine|Anti-tumor alkaloids
45949611|NCT04714528|Other|Physical Exercise|Physical exercise as described before.
45949612|NCT04714528|Other|Relaxation Therapy|Relaxation therapy as described before.
45949613|NCT00113048|Drug|CAMPATH (alemtuzumab)|
45949614|NCT04714489|Other|NO.|NO.
45949615|NCT00114699|Drug|CCR5mAb004|
45949616|NCT00353743|Drug|placebo|placebo
45949617|NCT00353743|Drug|doxycycline plus metronidazole|doxycycline 200mg/day plus metronidazole 500mg/day up to 10 days of treatment (additional to the hospital treatment)
45949618|NCT00113126|Drug|Treatment interruption|
45949619|NCT00353860|Device|SOLEX 300i Stem Cell Selection|
46076601|NCT02762292|Device|Measurement of work of breathing using indirect calorimeter|"Preparation:~Patient baseline characteristics will be collected.~Connection of the Indirect Calorimeter to the respiratory circuit.~Nasogastric tube installation: a specific modified Neurally Adjusted Ventilatory Assist (NAVA) catheter equipped with both microelectrodes for Electrical Activity of the diaphragme (EAdi) monitoring and an esophageal balloon (for esophageal pressure (PES) monitoring) will be installed.~Simultaneous recordings of: Oxygen Consumption (VO2) and Energy Expenditure (EE); Esophageal Pressure (PES), Airway Pressure (PAW), respiratory volume and flow; EAdi during (i) Conventional mechanical ventilation (ii) Spontaneous Breathing Trial in Continuous Positive Airway Pressure and (iii) Second period of Conventional mechanical ventilation with the same ventilator parameters set in STEP 1.~End of the physiological recordings. Collection of Pediatric Intensive Care Unit (PICU) outcome of patients."
46076602|NCT00633542|Drug|thalidomide|100 mg/day orally until progression or severe toxicity
45812083|NCT02524106|Drug|Bococizumab|PF-04950615 is a humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), being developed by Pfizer, Inc for the treatment of primary hyperlipidemia and mixed dyslipidemia.
45812084|NCT02524106|Drug|Placebo|placebo
45659109|NCT03428581|Procedure|ALND|Prospective and retrospective subjects undergoing an ALND.
45659110|NCT03416959|Procedure|intramedullary fixation or endoprosthetic reconstruction|Surgical treatment for long bone metastases with intramedullary nail or endoprosthetic reconstruction
45812085|NCT04827459|Behavioral|Sleep Coach App|Participants will be encouraged to interact with the mobile app daily for as much time as they wish, or for as little as 5 - 10 minutes, over a 7-week period.
45812086|NCT04117477|Drug|Xylitol|Xylitol dental wipes
45812087|NCT04117477|Other|Placebo|Placebo dental wipes
45949620|NCT00354016|Biological|preservative free inactivated split influenza vaccine using the strain composition 2006/2007|
45453601|NCT00662740|Drug|Salmeterol|Salmeterol Inhalation Powder, hard PE capsule
45659111|NCT03406247|Drug|Nivolumab|"Patients in cohorts 1 and 1bis will be administered Nivolumab 240 mg every 2 weeks during 3 first months and then 480 mg every 4 weeks during 3 months Patients in cohorts 2 and 2bis will be administered~- nivolumab 240 mg every 2 weeks during 6 months"
45659112|NCT03406247|Drug|Ipilimumab|"Patients in cohorts 2 and 2bis will be administered~- ipilimumab 1mg/kg IV every 6 weeks during 6 months"
45659113|NCT03399175|Drug|Early high-dose corticosteroid and immunosuppressive therapy|Early high-dose corticosteroid and immunosuppressive therapy
45659114|NCT03371017|Drug|Atezolizumab|"Atezolizumab will be administered, 1200 mg by IV infusion with :~gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle"
45812088|NCT04824027|Procedure|Harmonic motion imaging|Harmonic motion imaging (HMI) is a non-invasive ultrasound elasticity imaging technique that yields a quantitative relative measurement of tissue stiffness suitable for comparisons between individuals and over time. This technique induces dynamic tissue vibrations internally for tissue elasticity characterization. Participants will be asked to lie down on their back, hold still with shallow breathing while pictures/images are taken of the breast where the tumor is located using an ultrasound without any invasive procedures.
45812089|NCT02524418|Procedure|Cholangiopancreatoscopy|An ERCP with cholangioscopy/pancreatoscopy will be performed using the Spyglass DS. Clinical outcomes will be collected and analyzed.
45812090|NCT04820049|Drug|F573|F573 for injection
45949621|NCT00113165|Drug|LAMICTAL extended-release|
45949622|NCT00354094|Drug|[S,S]-Reboxetine|
46076603|NCT00633542|Drug|interferon alpha|3 MU 3 times a week until progression or severe toxicity
46076604|NCT05278585|Procedure|RAP TAVI|All patients undergoing TAVI with no pre-existing pacemaker and in sinus rhythm at the time of the procedure will receive RAP by placing the temporary wire in the right atrium
46076605|NCT02765958|Device|portable ECG devise|
45949623|NCT00114816|Drug|capecitabine|
45949624|NCT00114816|Drug|docetaxel|
45949625|NCT00354133|Device|Kinetra and Soletra (neurostimulator, Medtronic)|Patients in this arm were implanted with a neurostimulator (Kinetra and Soletra from Medtronic) are stimulated. Additionally the get best medical treatment.
45949626|NCT00354133|Drug|Best Medical Treatment|Patients in this arm get best medical treatment only
45949627|NCT00354211|Device|minimally invasive cardiac output system consisting of arterial line sensor and cardiac output bedside monitor (device)|
45949628|NCT05594550|Other|Data collection|"Demographic data:~Age, Sex, weight, height, main history and treatments.~- Biological data: CRP, PCT, albumin, pre-albumin"
45949629|NCT05594550|Other|analysis of thoracic scans|muscle area calculated on the T7 and T12 thoracic slices
45949630|NCT00354250|Drug|ispinesib|Given IV
45949631|NCT00113204|Drug|IPI-504|
45949632|NCT04714294|Drug|HPP737 or placebo|HPP737 or placebo will be randomized to assign to subjects
45949633|NCT00114855|Drug|HYPOCOL®|
45659115|NCT03371017|Drug|Placebo|"Placebo will be administered, 1200 mg by IV infusion with :~gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle"
45659116|NCT03371017|Drug|Gemcitabine|Gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle
46076606|NCT02828150|Dietary Supplement|Parenteral nutrition|Patients will receive a tailored nutritional support (parenteral nutrition) to cover estimated protein-calorie requirements. Energy: resting energy expenditure [Harris-Benedict] multiplied by a factor of 1.5. Protein: 1.5 g/kg/day. In obese patients (BMI >30 kg/m2) support will be calculated on ideal body weight (BMI=23 kg/m2)
45453602|NCT00662740|Drug|Tiotropium/Salmeterol QD+ Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
45659117|NCT03371017|Drug|Capecitabine|Capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle
45812091|NCT04820049|Other|Placebo|Water for injection
45812092|NCT01761877|Drug|Sulindac|
45949634|NCT00354367|Drug|Certolizumab pegol|
45659118|NCT03371017|Drug|Carboplatin|Carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle
45659119|NCT03317535|Procedure|General anesthesia|Patients will be injected with propofol, remifentanil and muscular relaxant with controlled ventilation.
45659120|NCT03317535|Procedure|Local anesthesia/concious sedation|Patients will be injected with propofol and remifentanil.
45659121|NCT03317535|Procedure|Spontaneous breath|Patients will be kept spontaneous breath.
45659122|NCT03317535|Procedure|Controlled ventilation|Patient will be kept with controlled ventilation.
45659123|NCT03313206|Drug|Pembrolizumab|"Neo-adjuvant therapy :~Anti-PD1 antibody will be used (pembrolizumab, Merck®) intravenously at a dose of 200 mg every 3 weeks. The patient will receive 4 injections maximum over 12 weeks. According to the investigator's opinion, the 4th injection might be cancelled in order to perform surgery from week 10 and not after week 13.~Tumor response will be assessed 2 weeks after the last injection both clinically and radiologically (by CT-scan and MRI).~Maintenance therapy by anti-PD1 antibody (pembrolizumab, Merck®) will be then used intravenously at a dose of 200 mg every 3 weeks for a maximum period of one year, starting one month after the end of radiotherapy."
45659124|NCT03313206|Procedure|Surgery|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
45659125|NCT03313206|Radiation|IMRT|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
45659126|NCT03313206|Drug|Lenvatinib|up to 26 evaluable patients will be treated with pembrolizumab combined with orally lenvatinib at a daily dose of 20 mg for 6 weeks started on the day of the first anti-PD1 dose.
45812093|NCT04820595|Diagnostic Test|RASS|Richmond Agitation-Sedation Scale
45812094|NCT04820595|Diagnostic Test|CAM-ICU|Confusion Assessment Method for the ICU
45949635|NCT00354406|Drug|abciximab|standard i.v. bolus of abciximab is administered at time of randomization in arm A, and at time of primary angioplasty in arm B.
45949636|NCT02965001|Drug|68Ga-NOTA-AE105|The patients are refered to an uPAR-PET/CT scan before initiation of the routine radiotherapy and the prognostic efficacy is assessed by registration of recurrence rate and death at routine clinical follow-up.
45949637|NCT00354445|Drug|pegaptanib sodium (Macugen)|
46076607|NCT02766036|Drug|Propolis|Patients will receive 500 mg / day of the propolis extract in the form of tablets split in two daily doses
46076608|NCT02766036|Drug|Placebo|Patients will receive 500 mg / day of the placebo in the form of tablets split in two daily doses
45949638|NCT00354523|Drug|Capecitabine (Xeloda)|Starting Dose 500 mg/m^2 twice a day Days 1-14 of 21 Day Cycle.
45949639|NCT00354523|Drug|DTIC-Dome (Dacarbazine)|Starting Dose 250 mg/m^2 a day on Days 1-3 of 21 Day Cycle.
46076609|NCT00610675|Drug|Org 50081|One tablet daily
46076610|NCT02832752|Procedure|ECPR Protocol|The regional protocol is activated for eligible patients who remain pulseless after 3 cycles of resuscitation, and intubation. The hospital team is activated at this time, which includes the emergency department team, a perfusionist, and a cardiovascular surgeon. A mechanical CPR device (Lucas chest compression device) is applied at this time and the patient is transported to hospital. The goal times from first professional CPR to ECMO flows is < 60 minutes, and from emergency department (ED) arrival to ECMO flows < 30 minutes.
45453603|NCT00662740|Drug|Tiotropium|Tiotropium
45453604|NCT02529865|Biological|Periurethral injection of autologous ADRCs and adipose tissue|1 mL of the isolated ADRC is injected into the region of the external urethral sphincter, and another 4 mL of the ADRC and 16mL autologous adipose cells is injected under the urethral mucosa.
45453605|NCT01584739|Drug|AZD8683|Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients)
45659127|NCT03250377|Drug|Brivaracetam|"Pharmaceutical form: Film-coated tablet~Concentration: 25 mg and 50 mg~Route of administration: Oral use"
45812095|NCT02421146|Device|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
45812096|NCT02421146|Device|Transcranial direct current stimulation - Sham|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
45949640|NCT00354523|Drug|Gleevec (Imatinib Mesylate)|Starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
45949641|NCT00425659|Device|home sleep study|different in algorithm arrangement for diagnosing sleep apnea
45812097|NCT04744519|Other|Collect data|- Controlled ovarian stimulation with GnRH antagonists effected to the patients in order to get their eggs through follicular puncture, which will be trigger by GnRH analogue. The eggs will be isolated and processed according to the standard protocol.
45949642|NCT00425659|Device|home CPAP titration (Autoset)|continuous positive airway pressure device for treatment of sleep apnea
45949643|NCT00425659|Device|CPAP|usual practice
45949644|NCT00113243|Drug|adult stem cells|
45812098|NCT00362791|Behavioral|"Enhanced HIV/STD Counseling: 4 face-to-face, interctive counseling sessions based on the Theory of Reasoned Action & Health Belief Model"|
45949645|NCT00425737|Biological|Rotarix|
45949646|NCT00425776|Device|acupuncture|
46076611|NCT02770092|Other|sip feeding with stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
45659128|NCT03240588|Device|Neurostimulation System|Spinal cord stimulation
46076612|NCT04245254|Dietary Supplement|Collagen Protien Powder|Collegen Protein Powser
45812099|NCT00362791|Behavioral|"Brief Counseling (aka client-centered counseling): 2 brief, face-to-face interactive sessions targeted a patient-identified risk behavior"|
45812100|NCT00362791|Behavioral|"HIV Prevention Education: 2 brief, didactic sessions informing the patient about HIV/STD prevention strategies"|
45659129|NCT03152773|Procedure|MRI Heart guidewire catheterization|to conduct left and right heart guidewire catheterization using real-time MRI fluoroscopy in human research subjects already undergoing medically necessary left and right heart catheterization. We will use only passive MRI-compatible catheters and a specific guidewire shown to be safe under specific conditions. Under the conditions of use, the guidewire is not susceptible to heating.
45812101|NCT02488070|Procedure|Computed Tomography|Part of PET/CT scan
45812102|NCT02488070|Drug|Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)|Intravenously-administered (IV) radioisotope
45949647|NCT00425776|Device|Sham acupuncture|
45949648|NCT00114933|Drug|Stopping nucleosides and continuing lopinavir/ritonavir monotherapy|
45949649|NCT00425815|Drug|Org 24448|Org 24448 is a moderate-potency selective AMPA positive modulator that enhances the glutamate system in the brain.
45949650|NCT00425815|Other|Placebo|Placebo comparison
45949651|NCT00113282|Drug|Interleukin-2 (IL-2)|
45949652|NCT00425893|Behavioral|hand hygiene|alcohol-based hand wash
45949653|NCT00425893|Other|health education|Proper nutrition, etc.
45949654|NCT00425893|Device|face masks|face masks
45949655|NCT00425932|Biological|Rituximab|At Week 24 or any time up to Week 48 if the Patient DAS 28 > 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.
46076613|NCT00886951|Drug|I123MNI388/I123MNI390|Subjects will be dosed by intravenous injection up to 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) 123-I MNI-388 or 123-I MNI-390.
46076614|NCT02828228|Drug|Vitamin D 1200 IU|Vitamin D 1200 IU once a day for 26 weeks
45949656|NCT00425971|Drug|BMEC-1217B|
45949657|NCT00426010|Drug|caffeine/placebo|caffeine or placebo, either overt or covert
45949658|NCT00113477|Drug|Q10|
46076615|NCT02828228|Drug|Placebo|placebo once a day for 26 weeks
46076616|NCT00892879|Device|Laparoscopic cholecystectomy surgery|Single port laparoscopic cholecystectomy surgery versus a standard four port device.
46076617|NCT00890227|Procedure|Traditional technique|All level open instrumented posterior spinal fusions
46076618|NCT00890227|Procedure|Minimally invasive technique|Open surgery for all the levels except the proximal segment (most proximal instrumented level) where minimally invasive technique will be used.
45949659|NCT00113477|Drug|Selen|
46076619|NCT02828072|Other|SKY therapy|slow breathing
46076620|NCT02828072|Drug|usual drug therapy|
46076621|NCT02769936|Drug|D-cycloserine|100 mg D-cycloserine administered orally as encapsulated pill
46076622|NCT02769936|Other|Placebo|Placebo administered orally as encapsulated pill
45949660|NCT04705753|Dietary Supplement|Cretan IAMA|Cretan IAMA (CAPeo) soft gels, 1 ml/day of a 1.5% essential oil combination from three aromatic plants (Thymbra 59 capitata (L.) Cav., Origanum dictamnus L., Salvia fruticosa Mill.) in extra virgin olive oil
45676471|NCT02910700|Other|Laboratory Biomarker Analysis|Correlative studies
45812103|NCT02488070|Procedure|Magnetic Resonance Imaging|Part of PET/MRI scan
45812104|NCT02488070|Procedure|Positron Emission Tomography|Part of PET/CT and/or PET/MRI scans
45812105|NCT02974699|Dietary Supplement|Potato Starch (Bob's Red Mill)|Subjects will be assigned to Potato Starch (active) following assessment of their gut microbiome.
45812106|NCT02974699|Dietary Supplement|Pregelatinized Starch (Resource ThickenUp)|Subjects will be assigned to Pregelatinized Starch (placebo) following assessment of their gut microbiome.
45812107|NCT04116541|Drug|HDM201|HDM201 120mg, Every 3 weeks, Per os
45812108|NCT04116541|Drug|Ribociclib|Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os
45812109|NCT04116541|Drug|Cabozantinib|Cabozantinib, 60 mg /day, continuous, Per os
45812110|NCT04116541|Drug|Alectinib|Alectinib, 600mg twice daily, Per os
45812111|NCT04116541|Drug|Regorafenib|Regorafenib 160mg, once daily, 3 weeks on/1 week off, Per os
45812112|NCT04116541|Drug|Trametinib|Trametinib 2 mg/day, continuous, Per os
45949661|NCT00115011|Drug|Escitalopram|
45949662|NCT04705636|Device|"Connected device named Leo from Ludocare society"|"Connected device named Leo from Ludocare society will be allocated to each child for three-months period. During this time, child will be helped to take all of his medication and specific care by this connected device."
45949663|NCT00113594|Drug|Olanzapine|
45949664|NCT00426049|Drug|Everolimus|
45949665|NCT05594433|Drug|Lenograstim|Injection sub cutaneous of Lenograstim during 4 days, once per day
45949666|NCT00426166|Device|Low Level Laser Therapy|Low Level Laser Therapy on Wound
46002646|NCT00560157|Dietary Supplement|Crucial (enteral tube feeding)|Evaluation of new enteral product, Crucial, in ICU patients
46076623|NCT00887029|Drug|DuoTrav (travoprost-timolol ophthalmic drops)|topical ophthalmic drops instilled 1 drop daily
46076624|NCT00887029|Drug|Xalacom (latanoprost-timolol ophthalmic drops)|topical ophthalmic drops instilled 1 drop daily
46076625|NCT00635310|Procedure|Percutaneous liver biopsy|Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)
45949667|NCT00113633|Behavioral|Intervention Subjects|The subject's family will view a brief educational video about asthma control and therapy developed using provider and patient focus groups; a mailed reminder will be sent to the family to schedule a follow-up appointment.
45949668|NCT00115089|Drug|R926112|
45949669|NCT00115089|Drug|Beclomethasone dipropionate|
46076626|NCT00635310|Procedure|Percutaneous liver biopsy|Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)
46076627|NCT02826980|Other|questionnaire|Patients consultant in gynecology in the service of Doctor Sauvanet, for whom a diagnosis of endometriosis has been established (clinical history and imaging tests confirming the diagnosis) will be offered to fill a self-administered questionnaire during their consultation
46076628|NCT05278429|Device|Myosuit robotic device|The Myosuit is a partially soft, exoskeleton-type, wearable robot that supports the synergistic extension of the hip and knee joints.
45453606|NCT01584739|Drug|Placebo|Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients
46076629|NCT02769546|Other|Surveys|
45659132|NCT03107520|Diagnostic Test|Intraoperative contrast-enhanced ultrasound (CEUS)|An intraoperative CEUS of the dysplastic femoral head will be performed after surgical reduction of the femoral head and during placement of the spica cast.
45659133|NCT03107520|Drug|Lumason|Administration of Lumason contrast agent to improve visualization of epiphyseal vascularity in the femoral head.
45659134|NCT03077542|Procedure|haploidentical stem cell transplant|haploidentical stem cell transplant
45659135|NCT03077542|Drug|sirolimus|conditioning regimen
45812113|NCT04116541|Drug|Dabrafenib|Dabrafenib 150 mg twice daily, Per os
45812114|NCT04824651|Biological|COVID-19 vaccine|Vaccination done as part of France's COVID-19 Vaccination Campaign
45812115|NCT05138913|Drug|TXA|After the arthroscopic operation was completed, a local TXA injection was performed
45812116|NCT05138913|Drug|Saline|After the arthroscopic operation was completed, a local saline injection was performed
45812117|NCT02421224|Behavioral|Usual Care|Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
45812118|NCT02421224|Behavioral|Deposits|Participants will have to deposit a certain amount of their own money at enrollment. Participants will be able to make additional voluntary deposits above the minimum amount during the intervention period. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
45949670|NCT00113672|Behavioral|Increase healthy activity and increase healthy eating|Increase participants to 60 minutes of activity per day and 5 fruits and vegetables per day over a 3 week prescription phase
45949671|NCT00113672|Behavioral|Decrease unhealthy activity and increase healthy eating|Decrease sedentary activity by 90 minutes per day and increase fruits and vegetables to 5 servings per day over the course of a 3 week prescription phase
46076630|NCT02765646|Device|Coronary stent procedure (CSP)|
46076631|NCT02762448|Drug|Daclatasvir+ Asunaprevir|HCV clearance and complete regression of NHL by ASV+ DCV
46076632|NCT02765724|Drug|Pacritinib|Pacritinib 400 mg (4 capsules of 100 mg each), single dose, oral administration
45659136|NCT03077542|Drug|campath|conditioning regimen
45659137|NCT03077542|Drug|pentostatin|conditioning regimen
45659138|NCT03077542|Drug|cyclophosphamide|conditioning regimen
45659139|NCT03077542|Drug|Hydroxyurea|conditioning regimen
45659140|NCT03071406|Drug|Nivolumab|Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks.
45659141|NCT03071406|Drug|Ipilimumab|Ipilimumab 1 mg/kg/dose IV q6 weeks.
45659142|NCT03071406|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy 24Gy in 3 fractions.
45659143|NCT03066648|Drug|Decitabine|Decitabine is a cytidine deoxynucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation.
45659144|NCT03066648|Drug|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2.
45659145|NCT03066648|Drug|MBG453|MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).
45659146|NCT03066648|Drug|Azacitidine|Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation
45812119|NCT02421224|Behavioral|Small Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test.
45659147|NCT03052816|Drug|Ice T|Ice/Tylenol/Toradol with dilaudid for breakthrough
45812120|NCT02421224|Behavioral|Large Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test. The bonus is twice the value of that in the Small Individual Bonus group.
45812121|NCT02421224|Behavioral|Teammate|Each participant will be randomly assigned one teammate to provide social support during the quit attempt. Each participant will be assigned to a participating coworker who speaks the same primary language and works the same work shift as the participant.
45949672|NCT00113672|Behavioral|Increase physical activity and decrease unhealthy eating|Increase physical activity up to 60 minutes per day and decrease saturated fat to an average of 8% per day over the course of a 3 week prescription phase
45949673|NCT00113672|Behavioral|Decrease sedentary activity and decrease unhealthy eating|Decrease sedentary activity by 90 minutes per day and decrease saturated fat to and average of 8% per day over the course of a 3 week prescription phase
45949674|NCT05594394|Behavioral|Orai: Master Public Speaking|"Participants will access the Orai: Master Public Speaking (Sani, Dhamani, & Gupta, 2020) platform with mobile and web-based applications. Communication skill-building moduleswill be assigned using exercises, case scenarios, and AI-assisted feedback debriefing through the Orai application.~Participants will also complete case scenarios created with specific nursing conflict issues a charge nurse may encounter in an acute care facility. Upon completion of the competency development program, participants will complete the CMCSS to determine the effect on confidence levels and a brief survey (Appendix C) to assess the amicability of the program."
45949675|NCT01059643|Drug|LY2523355|Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a 1-hour infusion on Days 1, 2 and 3 of a 21 day cycle; for up to 2 cycles (4 cycles for prostate cancer patients). Additional cycles administered based on patient response assessment.
45659148|NCT03052816|Drug|Motrin/Percocet/Dilaudid for breakthrough|Standard regimen
45949676|NCT01059643|Drug|pegfilgrastim|6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer patients). Additional cycles of LY2523355 administered based on patient response assessment.
45949677|NCT00115128|Drug|filgrastim|Normal donors being treated with filgrastim for PBPC mobilization and collection
45949678|NCT00113711|Behavioral|smoking cessation|
45949679|NCT00113711|Behavioral|reducing diet|
45949680|NCT00115167|Drug|Placebo|Q4W
45949681|NCT00115167|Drug|Darbepoetin alfa|Q4W
45949682|NCT05594316|Drug|Trichloroacetic acid|5. Patients will be subjected to 3 session of trichloroacetic acid 35% one month apart.
45949683|NCT00115206|Drug|Neulasta® (pegfilgrastim)|
45949684|NCT05594160|Behavioral|Psychotherapy|Patients treated at the inpatient psychotherapy unit of a University Hospital receive 8 to 10 weeks of multimodal psychotherapeutic treatment. Treatment consists of individual as well as group psychodynamic therapy. Additionally, patients receive an individual combination of music, art, relaxation and body-oriented group therapy. Therapeutic treatment is provided by a multiprofessional, interdisciplinary team of psychotherapists with either a medical or psychology degree, art and music therapists, specialist nurses, social workers and physiotherapists.
45949685|NCT00115245|Drug|Telbivudine (LdT)|
45949686|NCT00115245|Drug|Adefovir Dipivoxil|
45659149|NCT03029156|Device|Aeroneb nebulizer|"The Aeroneb Nebulizer System is a portable medical device for single patient use that is intended to aerosolize physician-prescribed solutions for inhalation to patients on and off ventilation.~The Aeroneb Adapter is an accessory specific to the Aeroneb Nebulizer. It facilitates intermittent and continuous nebulization and optional supply of supplemental oxygen to adult patients in hospital use environments via a mouthpiece or aerosol mask. The Aeroneb Nebulizer System and Adapter are FDA approved devices for nebulizing solutions including bronchodilators (albuterol and ipratropium)."
45949687|NCT01059565|Drug|AZLI|Aztreonam for inhalation solution (AZLI; 75 mg aztreonam/52.5 mg lysine monohydrate) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
45949688|NCT01059565|Drug|Placebo|Placebo to match AZLI (lactose and sodium chloride) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
45949689|NCT01059526|Drug|ecallantide|30 mg SC
45659150|NCT03029156|Device|Small volume jet nebulizer|The bronchodilators will be administered via small volume jet nebulizer
45812122|NCT02421224|Behavioral|Team Bonus|If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
45949690|NCT00426244|Other|Osteopathic Manipulative Treatment|OMT is a complementary and alternative body-based treatment method in which the patient is evaluated and treated including the musculoskeletal system to improve physiologic functioning and remove impediments to optimal health and functioning.
46002647|NCT00546299|Drug|oxygen|cylinder and concentrator, dosage to maintain SpO2 above 92%, used during exertion
45676472|NCT02910700|Biological|Nivolumab|Given IV
45659151|NCT03005145|Other|7 days of adequate antibiotic treatment|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
45949691|NCT00426244|Other|Placebo Ultrasound|"In addition to controlling for physician attention during the treatment visit, the SUT used a nonfunctional ultrasound therapy unit that was modified for research purposes to provide both visible and auditory cues that could potentially elicit a placebo response. The physician provided the SUT by placing the applicator head over the subject's clothing and applying sufficient pressure for tactile stimulation of the skin and underlying tissues in the same anatomical distributions as would generally be addressed if the subject were being treated with OMT.~The subjects assigned to the UOBC only group did not receive any study treatments beyond conventional obstetrical care; however, they were expected to complete data collection forms on the same schedule as all other trial subjects."
45949692|NCT00444340|Drug|Enbrel (Etanercept)|
45659152|NCT03005145|Other|14 days of adequate antibiotic treatment.|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
45659153|NCT02955940|Drug|Ruxolitinib|5 mg BID
45812123|NCT04113811|Device|Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France)|In this study, we plan to investigate oncological outcome of fusion-guided microwave needle therapy using transperineal (TP) approach
45949693|NCT00444379|Drug|Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir|Lopinavir/ritonavir 200/50mg plus Emtricitabine/Tenofovir 200/300mg versus Efavirenz 600mg plus Emtricitabine/Tenofovir 200/300mg
45949694|NCT00444418|Drug|Naltrexone|Naltrexone, 100 mg. oral dosage, daily for 12 weeks.
45949695|NCT00444418|Behavioral|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
46076633|NCT04223544|Diagnostic Test|Influenza POC and laboratory testing|Participation in the study is voluntary and carried out after the consent of the examined person. The examination consists of: 1) completing the questionnaire and 2) taking the throat swab twice by the researcher. Two throat swab samples will be taken at the same time. Both samples will be used for virological examination to determine the presence of influenza virus material using non-invasive tests: one sample will be analyzed by a quick 'on-site' test - Flu SensDx kit, while the other sample will be transported to the laboratory, where the reverse transcriptase polymerase chain reaction (RT-PCR) - reference method - will be performed to confirm the presence of influenza genetic material. Swabs are planned to be collected during the 2019/2020 influenza epidemic season (January-March).
45659154|NCT02955940|Drug|Capecitabine|Capecitabine at the same dose provided in the parent study at the time of the rollover.
45659155|NCT02955940|Drug|Regorafenib|Regorafenib at the same dose provided in the parent study at the time of the rollover.
45659156|NCT02883062|Drug|Atezolizumab|Given IV
45659157|NCT02883062|Procedure|Biospecimen Collection|Undergo collection of blood samples
45659158|NCT02883062|Drug|Carboplatin|Given IV
45659159|NCT02883062|Procedure|Lumpectomy|Undergo lumpectomy
45659160|NCT02883062|Procedure|Mastectomy|Undergo mastectomy
45659161|NCT02883062|Drug|Paclitaxel|Given IV
45812124|NCT04821219|Other|Treatment prediction PDT platform|PDT will be generated and response to various chemotherapies and radiation will be investigated. Actionable targets will be identified and response to the target drug will be assessed and compared to the conventional treatment options.
46076634|NCT00888134|Drug|Selumetinib|Given PO
45659162|NCT02850406|Drug|Voxelotor|"Part A: Voxelotor will be administered as oral capsules or tablets~Part B: Voxelotor will be administered as oral capsules or tablets~Part C: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension~Part D: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension"
45659163|NCT02742922|Behavioral|Culturally adapted therapy (C-MAP)|C-MAP is a brief problem focused therapy, comprising of six sessions delivered within three months. C-MAP is a manual assisted intervention based on the principles of CBT .In this intervention there is an evaluation of the self-harm attempt, crisis skills, problem solving and basic cognitive techniques to manage emotions, negative thinking and relapse prevention strategies.
45659164|NCT02721732|Other|Laboratory Biomarker Analysis|Correlative studies
45812125|NCT04825353|Procedure|Endoscopic compbined guided PCNL|patient undergo stone removal by ECIRS
45812126|NCT04825353|Procedure|Standard PCNL|patient undergo SPCNL
45949696|NCT00444418|Behavioral|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption
45949697|NCT03277885|Other|chronic pain|work related chronic pain
45949698|NCT00444574|Drug|Methylphenidate Transdermal System|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
46002648|NCT00558402|Behavioral|Meditation|meditation class 1/week for 8 weeks
45949699|NCT00444574|Drug|Placebo|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
46076635|NCT00573157|Drug|Atacicept|Atacicept will be administered at a dose of 150 milligram (mg) subcutaneously (SC) twice weekly for 4 weeks followed by maintenance dose of 150 mg SC once weekly for 48 weeks.
46076636|NCT00573157|Drug|Mycophenolate mofetil|MMF will be administered orally with a starting dose of 500 mg twice daily for 1 week, will be increased to 1000 mg twice daily for 1 week, then it will be adjusted to 1500 mg or lower twice daily as per investigator's discretion.
46076637|NCT00573157|Drug|Placebo|Placebo will be administered at a dose of 150 mg SC twice weekly for 4 weeks followed by 150 mg SC once weekly for 48 weeks.
46076638|NCT00573157|Drug|Corticosteroids|High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be tapered to 7.5 to 10 mg/day up to Week 12.
45659165|NCT02721732|Biological|Pembrolizumab|Given IV
45659166|NCT02721732|Other|Questionnaire Administration|Ancillary studies
45659167|NCT02702596|Other|Measurement-Based Integrated Care|Measurement-Based Integrated Care (MBIC) synthesizes the science of integrated health care and incorporates the strategies of measurement-based care. concept of MBIC for the treatment of depression includes: systematic assessment of symptoms, antidepressant treatment side effects and medication adherence and incorporation of a Depression Care Manager (DCM) to track patients and keep them engaged in care using behavioral interventions
45659168|NCT02702596|Behavioral|Depression Education Fotonovela|"Depression education that uses a unique, culturally adapted depression fotonovela titled Secret Feelings developed by Cabassa, Molina and Baron (2012). The fotonovela is a popular comic-book style pamphlet that portrays a dramatic story using photographs and dialogue bubbles, which has become an effective tool for engaging Hispanic audiences and increasing knowledge about specific health issues"
45812127|NCT04106089|Behavioral|Extended time between vitals check|Participants will have 6 hours protected sleep time (vitals checks moved from every 4 to every 6 hours)
46076639|NCT04627662|Behavioral|Tele-STELLA|Tele-STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias) is a multicomponent videoconference-based intervention designed to facilitate effective management of behavioral and psychological symptoms common to the later stages of dementia.
45659169|NCT02702596|Behavioral|Standard Education|The the use of a pamphlet to educate people about depression.
45676473|NCT02910700|Other|Pharmacological Study|Correlative studies
45812128|NCT03320317|Other|Learning session 1|Learn form international report, Explain key interventions, Explain BIC methodology, Retrospective patient record analysis, Team measures
45812129|NCT03320317|Other|Learning session 2|Feedback report, Share (inter)national best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis
45812130|NCT03320317|Other|Learning session 3|Feedback report, Share best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis, Team measures
45812131|NCT03320317|Other|Learning session 4|Feedback report, Best practice symposium
45949700|NCT00444574|Drug|Concerta|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
45949701|NCT00113750|Biological|TreeMATA MPL|
45949702|NCT00444652|Drug|Enoxaparin|injection of enoxaparin a few time
45949703|NCT00115284|Behavioral|ABIM asthma practice improvement module|
46002649|NCT00558402|Behavioral|Education|Education class, 90 min per week for 8 weeks along with home assignments based on Powerful Tools for Caregivers
46002650|NCT00558402|Behavioral|Respite only|Respite care 90 mins per week for 8 weeks
46002651|NCT00546494|Drug|Effexor® (Venlafaxine)|
45676474|NCT02910700|Drug|Trametinib|Given PO
45812132|NCT03319849|Combination Product|NT-501|Surgery to receive one NT-501 device implant.
45659170|NCT02684058|Drug|Dabrafenib|Dabrafenib was available as 50 mg and 75 mg hard capsules and as 10 mg dispersible tablets for oral suspension. Dabrafenib was administered orally, twice daily, and was dosed based on age and weight Patients < 12 years old and ≥ 16 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥ 12 years old and ≥ 19 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day) Patients < 12 years old and < 16 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥12 years old and <19 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day)
45949704|NCT00444691|Device|ultra-sonography|"o The ultrasonographic evaluation was performed on 38 joints: the 28 joints included in DAS28 (e.g. shoulderx2, elbowx2, wristx2, metacarpo-phalangeal (MCP)x10, proximal inter phalangeal (PIP)x10, kneex2) and also the metatarso-phalangeal (MTPx10). Systematic multiplanar gray-scale (mode B) and Power Doppler examination was carried out with commercially available real-time scanners using multi-frequency linear transducers (7-12 MHz).~The ultrasonographic evaluation was performed at baseline and 1, 2, 3, and 4 months after baseline."
45812133|NCT03319849|Procedure|Sham|Non-penetrating sham procedure to mimic implant procedure.
45949705|NCT00113789|Other|PI Discretion|PI Discretion
45812134|NCT01501201|Procedure|Gastric By-Pass|Bariatric surgery laparoscopic Roux-en-Y Gastric Bypass (RYGBP)
45812135|NCT01501201|Drug|optimized medical management|group receiving an optimized medical management, among patients with obesity and poorly controlled type 2 diabetes
45949706|NCT04699903|Diagnostic Test|POC SARS-Cov-2 IgG Antibody test|All patients will undergo a Point of care (POC) SARS-Cov-2 IgG Antibody test in fingerstick whole blood
45812136|NCT03306979|Drug|N Acetylcysteine|Patients will be randomized to receive N Acetylcysteine (NAC) (four 600 mg capsules given as 2 capsules in the morning and 2 capsules in the evening). The initial NAC dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
45949707|NCT00444730|Procedure|Radical Prostatectomy|Surgical procedure for prostate cancer.
45949708|NCT00444730|Procedure|InterStim Implantation|surgical placement of the interstim
45453607|NCT01105351|Dietary Supplement|folic acid plus B6 and B12|folic acid 400 µg plus vitamin B12 plus B6
45812137|NCT03306979|Other|Placebo oral capsule|Patients will receive four placebo capsules (lactose-based filler) given as 2 capsules in the morning and 2 capsules in the evening, which will be prepared to mimic the weight of the experimental capsules.The initial placebo dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
45949709|NCT00444730|Procedure|Pelvic organ prolapse repair|Surgical pelvic organ prolapse repair
45949710|NCT00115323|Behavioral|Problem Solving|Problem solving intervention
45949711|NCT00115323|Behavioral|Attention Control|Attention control intervention
45949712|NCT00444769|Drug|GW842166|
45949713|NCT00444808|Drug|Intranasal calcitonin|
45949714|NCT00444847|Device|Hyperbaric chamber|
46002652|NCT04637607|Other|Auricular acupoints stimulation|Noninvasive auricular acupoints stimulation with seeds
46002653|NCT00546533|Drug|Etanercept|
46002654|NCT00558441|Device|IVMRI|Intra Vascular Magnetic Resonance Imaging
45949715|NCT00113828|Procedure|Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|"Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7 and 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days-7,-6; fludarabine 25 mg/m2 on days -5, -4, -3, -2, -1.~Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant."
45949716|NCT00113828|Procedure|T-cell depleted peripheral blood stem cell transplant|"Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7, 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days -7, -6; fludarabine 25 mg/m2 on days -5 through -1.~T-cell depleted peripheral blood stem cell transplant ."
45949717|NCT00444886|Drug|Botulinum Toxin Type A injection (BOTOX)|Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
46076640|NCT04224714|Combination Product|FFR|FFR measurement: Pressure guid wire(radianalyzer Xpress 12711) is produced in Switzerland. After the pressure of the aorta and the pressure guide wire is balanced, Send the pressure guide wire to the distal part of the lesion(more than 20 mm away from the lesion) . Adenosine is injected into the vein,then,record the FFR index 3 times and take the average value as the final measurement index.
45659171|NCT02684058|Drug|trametinib|"Trametinib was available as 0.5 mg and 2 mg film-coated tablets and as 5.0 mg powder in bottle for oral solution (0.05 mg/ml after reconstitution with 90 ml water).Trametinib was administered orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on age and weight.~Patients <6 years old and <26 kg were to be administered the trametinib oral solution (dose: 0.032 mg/kg/day) Patients <6 years old and ≥26 kg were to be administered either the trametinib oral solution or trametinib tablets (dose: 0.032 mg/kg/day) Patients ≥6 years old and ≥10 kg < 33 kg were to be administered the trametinib oral solution (dose: 0.025 mg/kg/day) Patients ≥6 years old and ≥33 kg were to be administered either the trametinib oral solution or the trametinib tablets (dose: 0.025 mg/kg/day)"
45659172|NCT02684058|Drug|Carboplatin|"Carboplatin was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Carboplatin was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy. Each maintenance cycle was 6 weeks, and consisted of 4 weeks of chemotherapy with 2 weeks of rest.~Induction: 175 mg/m^2 as weekly intravenous (IV) infusion on weeks 1 to 4, and on weeks 7 to 10, on the same day as vincristine dosing Maintenance: 175 mg/m^2 as weekly IV infusion over 60 minutes on weeks 1 to 4 of each cycle."
45659173|NCT02684058|Drug|Vincristine|"Vincristine was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Vincristine was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy.~Induction: 1.5 mg/m^2 as weekly IV bolus infusion (0.05 mg/kg if child is <12 kg) (maximum dose of 2.0 mg) for 10 weeks.~Maintenance: 1.5 mg/m^2 as weekly IV bolus infusion (0.05 mg/kg if child is <12 kg) (maximum dose of 2.0 mg) on weeks 1 to 3 of each cycle, on the same day as carboplatin dosing."
45949718|NCT00444886|Drug|Botulinum Toxin Type A injection (BOTOX)|Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
45949719|NCT05594121|Drug|Extended Release Subcutaneous Buprenorphine|Monthly subcutaneous injections of long-acting buprenorphine
45949720|NCT05594121|Drug|Immediate Release Sublingual Buprenorphine|Daily sublingual fast-acting buprenorphine
45949721|NCT04699669|Drug|CBL-514, placebo|"One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized.~No PK samples will be collected in this cohort."
45659174|NCT02682238|Drug|BBI-4000, 15%|
45659175|NCT02682238|Other|Vehicle gel|
45659176|NCT02681328|Other|Afirma GEC|Afirma GEC molecular test on collected thyroid tissue
45659177|NCT02681328|Other|ThyroSeq v.2|ThyroSeq v.2 molecular test on collected thyroid tissue
45659178|NCT02681328|Other|Afirma GSC|Afirma GSC molecular test on collected thyroid tissue
45659179|NCT02681328|Other|ThyroSeq v.3|ThyroSeq v.3 molecular test on collected thyroid tissue
45812138|NCT04101955|Procedure|Incisionless Threaded Carpal Tunnel|ultra-minimally invasive thread carpal tunnel release
45812139|NCT04101955|Procedure|Standard Mini-Open Carpal Tunnel|open surgical carpal tunnel release
45812140|NCT04097275|Other|Skin biopsy|The biopsy will be performed by means of punch biopsy (diameter 2.5 mm) under local anesthesia on a forearm. The skin biopsy will be transferred to sterile cell culture Dulbecco's Modified Eagle Medium (DMEM) 1% Penicillin 1% Streptomycin 1% Gentamycin medium 10% FBS.
45949722|NCT04699669|Drug|CBL-514, placebo|"One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized."
45949723|NCT04699669|Drug|CBL-514|Both sides of the abdominal region will receive CBL-514.
45949724|NCT04699708|Device|Carbon dioxide monitoring|Blinded recording of CO2 during preterm resuscitation.
46076641|NCT00890383|Drug|tetrastarch (Voluven)|Goals directed volume therapy for severe trauma resuscitation
46076642|NCT02762058|Device|Virtual Reality Mirror Therapy|Virtual Reality Mirror Therapy system using occulus rift as virtual headset and kinect as motion tracking sensor.
45812141|NCT04097275|Other|Withdraw of blood|"Blood will be collected in:~1 x Ethylene Diamine Tetraacetic Acid (EDTA) tube (7.5 ml) - for further leucocytes extraction that are a potential backup for new iPS cell lines generation~1 x Citrate Phosphate Dextrose Adenine (CPDA) tube (8.5 ml) - for EBV-transformed lymphoblastoid cell lines generation~1 x Dried Blood Spot DBS-filtercard, called CentoCard® - for quality control confirmatory genetic testing"
45812142|NCT04096729|Other|compression stockings|patients will be prescribed compression therapy for varicose veins of the legs using compression stockings
45812143|NCT03299959|Device|Agili-C implant|Agili-C implant
45812144|NCT03299959|Procedure|SSOC|microfracture and/or debridement
45812145|NCT00362869|Drug|Levofloxacin|Administered at a dose of 500 mg once a day for 3 days
45659180|NCT02674711|Behavioral|Educational Video|The content of the education focus on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage. The video is 11 and ½ minutes long.
45659181|NCT02657356|Drug|Placebo capsules|
45949725|NCT04699552|Device|120W Lumenis Holmium:YAG laser 20J|120W Lumenis Holmium:YAG laser 20J
45949726|NCT04699552|Device|120W Lumenis Holmium:YAG laser 40 J|120W Lumenis Holmium:YAG laser 40J
45659182|NCT02657356|Drug|Bardoxolone methyl capsules|
45812146|NCT00362869|Drug|Placebo|Sodium bicarbonate solution
46076643|NCT02762058|Procedure|Traditional Mirror Therapy|Traditional Mirror Therapy system consisting of a mirror in which patients view their healthy limb over the affected to trick brain during dual motion tasks. This therapy has been shown to improve upper extremity function in patients with acquired brain injury.
45812147|NCT00362869|Biological|Enteroaggregative E. coli (EAEC)|Dosages: 1X10^9, 5X10^9, 1X10^10, and 5X10^10 cfu; given in a sodium bicarbonate solution
45812148|NCT04087213|Device|HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
46076644|NCT00887107|Drug|Sorafenib (nexavar)|6 months therapy with Sorafenib 800 mg/day
45812149|NCT03292237|Dietary Supplement|Supplemental parenteral nutrition|Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)
46076645|NCT02769468|Other|The Back|
46076646|NCT02769468|Other|Chest|
46076647|NCT02769468|Other|Left Axilla|
46076648|NCT00887185|Other|Simulator training for temporal bone surgery|Subjects in experimental arm are asked to spend 2 weeks practicing temporal bone surgical procedures using a computer simulation.
46076649|NCT00802737|Drug|Ofatumumab|Eight once weekly infusions (1 x 300 mg + 7 x 2000 mg), then 2000 mg once monthly for two years
46076650|NCT02769390|Drug|Clonidine 1 mcg/Kg|Clonidine 1 mcg/Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
46076651|NCT02769390|Drug|Clonidine 2 mcg/ Kg|Clonidine 2 mcg//Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
46076652|NCT02769390|Drug|Clonidine 3 mcg/ Kg|Clonidine 3 mcg //Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
46076653|NCT00890461|Radiation|CT scan of the chest without contrast|Patients consenting to participate in the study may also undergo a baseline CT scan of the cest without contrast to allow for the geometrical characterization of their intracardiac electrodes from the ICD system in relation to the position of the 12-lead surface ECG electrodes which would be applied to the chest prior to the CT scan. This scan involves a small amount of radiation, a dose of approximately 1 rem. For comparison, radiation workers are permitted, by federal regulation, a maximum annual radiation exposure of 20 rems to the most sensitive organs of their body.
46076654|NCT02765568|Behavioral|High Intensity Interval Training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks
45659183|NCT02606201|Other|Peri sphincter injection Autologous myofibers|"The first step of the procedure consists to harvest a muscle fragment from the lower part of the rectus abdominis muscle of the abdomen approached by a short incision. Injectable myofiber cores will be prepared by hydrodissection of the muscle biopsy.~All myofibers cores will be suspended in autologous serum prepared by centrifugation before the incision.~During the second step of the procedure, the myofibers will be injected percutaneously into the peri-sphincter region under endoscopic and radiographic control."
45659184|NCT02577978|Device|Medacta GMK posterior stabilized prosthesis|
45812150|NCT03257215|Drug|Stoss vitamin D|A single 1.5 mL dose containing 150,000 IU cholecalciferol (100,000 IU/mL) administered on Day 1 (Solution in Olive Oil B.P. )
45812151|NCT03257215|Drug|Daily vitamin D|Daily 0.2 mL dose containing 1000 IU cholecalciferol administered from Day 1 to 90
46076655|NCT02765568|Behavioral|Moderate Intensity Continuous Exercise Training|Participants will complete supervised exercise sessions. Moderate-intensity continuous exercise training will follow cardiovascular rehabilitation guidelines. Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
46076656|NCT02765568|Behavioral|Nordic Walking|Participants will complete supervised exercise sessions. Participants will attend on-site Nordic walking training two times weekly for 12 weeks
45659185|NCT02577978|Device|Medacta GMK Sphere prosthesis|
45659186|NCT02564705|Procedure|Anterior Lumbar Interbody Fusion (ALIF)|
45949727|NCT04699552|Device|120W Lumenis Holmium:YAG laser 60 J|120W Lumenis Holmium:YAG laser 60J
45949728|NCT02956915|Procedure|Transfemoral Transcatheter aortic valve implantation|Transcatheter aortic valve implantation (TAVI): The SAPIEN-3 prosthese are implanted without open heart surgery. The valve delivery system is inserted in the body via the femoral artery.
46076657|NCT04036591|Diagnostic Test|Acute Bronchiolitis Severity Scale (ABSS)|All infants will be assessed using the Acute Bronchiolitis Severity Scale (ABSS) before and after being treated by experienced physiotherapists using the prolonged slow expiration technique and provoqued cough. Before the application of these techniques a retrograde rhinopharyngeal unclogging will be performed in order to clean the nasopharynx.
45812152|NCT03257215|Drug|Stoss placebo|A single 1.5 mL dose administered on Day 1
45812153|NCT03257215|Drug|Daily placebo|A once daily 0.2 mL dose administered from Day 1 to 90
45453608|NCT01105351|Dietary Supplement|folic acid|folic acid 400 µg
45659187|NCT02564705|Procedure|Posterior Fusion|"Posterolateral Fusion (PLF)~Posterior Lumbar Interbody Fusion (PLIF)~Transforaminal Lumbar Interbody Fusion (TLIF)"
45812154|NCT02422940|Drug|dalfampridine-ER 7.5 mg|
45812155|NCT02422940|Drug|dalfampridine-ER 10 mg|
45812156|NCT00361855|Drug|NX-CP105|
45949729|NCT00115362|Drug|venlafaxine|
45949730|NCT00445042|Drug|Sorafenib|The initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily. Intrapatient dose escalation will occur as defined in the protocol, providing no dose limiting toxicity (Grade 3 or 4) is observed.
45949731|NCT00445081|Drug|Prednisolone|
45949732|NCT00445081|Drug|Ciclosporine A|
45949733|NCT02956954|Drug|Enzyme replacement therapy (Agalsidase alpha (Replagal®))|Patient treated with Enzyme replacement therapy as usual (Agalsidase alpha (Replagal®)). The treatment is prescribed in routine and not specially for the protocol
45949734|NCT02956954|Procedure|Magnetic Resonance Imaging|Magnetic Resonance Imaging will be assessed every 6 months during 2 years
45949735|NCT02957188|Other|13C eicosapentaenoic acid and 13C arachidonic acid|Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
45949736|NCT00113906|Drug|melatonin|
45949737|NCT02956993|Drug|vonapanitase|
45949738|NCT02956993|Drug|Placebo|
45949739|NCT00445120|Drug|Lactobacillus Rhamnosus GG|patients are treated with oral Lactobacillus Rhamnosus GG once daily for six months
45949740|NCT00445120|Drug|placebo (sugar)|Placebo will be administered to patients once daily for six months
46076658|NCT02762214|Device|Clermont-Ferrand Uterine Manipulator|"Pelvic cytology is obtained before starting surgical procedures (washing number 1).~After tubal coagulation, Clermont-Ferrand Uterine Manipulator is installed inside the uterus. At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)"
46076659|NCT02762214|Other|No uterine Manipulator|"Pelvic cytology is obtained before starting surgical procedures (washing number 1). None uterine manipulator is used and the cervix is closed with a cross stitch.~Tubal coagulation, At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)"
46076660|NCT05278819|Other|upper extremity elevation|5 repetitions of active upper extremity elevation in a sitting position
45659188|NCT02539771|Other|Polysomnography and blood sample|"Blood collection is a specific intervention of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  Diurnal VOC  and  Slightly symptomatic "
45659189|NCT02393625|Drug|Ceritinib (LDK378)|
45812157|NCT04072549|Behavioral|Free Summer Programming|The summer day camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. To standardize programming, the schools operate their camps on the same daily schedules which are developed by the same district-level personnel, with identical programmatic content delivered across all schools. The schools also provide the same meals to all children enrolled. The meals adhere to the Summer Food Service Program nutrition guidelines and are reimbursed through existing federal food programs.
45812158|NCT02526680|Device|OrCam|The OrCam low vision aid, camera attached to glasses, used by 27 glaucoma subjects for 1 month.
45949741|NCT00113945|Drug|Cinacalcet|
45949742|NCT00445159|Drug|UT-15C SR (treprostinil diethanolamine) 1mg oral tablets|
45949743|NCT00445237|Device|H1 and H2 deep TMS coils|
45949744|NCT00445276|Drug|Diacerein|
46076661|NCT05278819|Other|upper extremity elevation with deep breathing|5 repetitions of active upper extremity elevation with deep breathing in a sitting position
46076662|NCT02762136|Drug|placebo|
46076663|NCT02762136|Drug|Xiang-sha-liu-jun granules|The Xiang-sha-liu-jun granules comprises 10 herbs, Astragalus membranaceus (Huangqi) 15g, Codonopsis pilosula (Dangshen) 15 g, fructus aurantii (Zhiqiao) 15g, fructus amomi(Sharen) etc
45453609|NCT00662506|Drug|Cediranib Maleate|Given PO
45659190|NCT02393625|Drug|Nivolumab|
45659191|NCT02294032|Drug|Immunosuppressive Agents|standard of care for patients post-transplant
45659192|NCT02168829|Drug|Rivaroxaban|
45659193|NCT02168829|Drug|Acetylsalicylic acid|
45659194|NCT02071134|Device|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.
45659195|NCT01961557|Device|EA-KAFO|This study tests a single device that contains multiple potential configurations as outlined in Table 1 of the protocol. Each participant be evaluated in multiple configurations, minimally including the baseline configuration and the motor assist condition at the knee.
45453610|NCT00662506|Procedure|Diffusion Tensor Imaging|Undergo DTI
45453611|NCT00662506|Procedure|Diffusion Weighted Imaging|Undergo T1 weighted DCE-MRI
45949745|NCT00445354|Drug|cinnamon|
45949746|NCT05594004|Device|Oscillating-rotating electric toothbrush|Oscillating-rotating electric toothbrush used twice daily
45949747|NCT05594004|Device|Sonic electric toothbrush|Sonic electric toothbrush used twice daily
45949748|NCT05594004|Device|Manual toothbrush|Manual toothbrush used twice daily
45949749|NCT00113984|Biological|PROSTVAC-V/TRICOM|
45949750|NCT00113984|Biological|PROSTVAC-F/TRICOM|
45949751|NCT00113984|Drug|MDX-010|
45949752|NCT00113984|Drug|Sargramostim|
45949753|NCT00445471|Behavioral|Mifne Approach to PDD|
45949754|NCT00445471|Behavioral|Treatment as usual|
45949755|NCT00445510|Drug|GSK256066|
45949756|NCT00115440|Radiation|Bononophenylalanine (BPA)-based BNCT|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
45949757|NCT00445783|Genetic|gene expression analysis|
45949758|NCT00445783|Genetic|mutation analysis|
45949759|NCT00445783|Other|immunohistochemistry staining method|
45949760|NCT00445783|Other|laboratory biomarker analysis|
45949761|NCT00445783|Procedure|examination|
45949762|NCT00445783|Procedure|mutation carrier screening|
45949763|NCT00445783|Procedure|study of high risk factors|
45949764|NCT00114023|Drug|Imiquimod 5% cream|
45949765|NCT00445861|Biological|cetuximab + docetaxel + cisplatin|Chemoimmunotherapy: Patients receive cetuximab IV over 1-2 hours once weekly in weeks 1-3 and docetaxel IV over 1 hour and cisplatin IV over 1 hour once in week 1. Treatment repeats every 3 weeks for 2 courses.
46076664|NCT00588861|Device|Answer® hip stem|Total hip replacement using Palacos® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
46076665|NCT00588861|Device|Answer® hip stem|Total hip replacement using Simplex® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
45659196|NCT01839396|Device|Deep Brain Stimulation|The Vercise™ DBS system will be implanted in subjects in both study arms. Stimulation parameters will vary depending on the study arm assignment. All subjects will receive therapeutic settings at the end of the blinded period.
45949766|NCT00445861|Biological|Treatment level 1|Treatment level 1: Patients receive cetuximab IV over 1 hour once weekly, cisplatin IV over 1 hour once weekly, and undergo radiotherapy once daily, 5 days a week, in weeks 7-11.
45949767|NCT00445861|Biological|Treatment level 2|Patients receive cetuximab, cisplatin, and radiotherapy as in treatment level 1. Patients also receive docetaxel IV over 1-2 hours once weekly in weeks 7-11.
46076666|NCT00890539|Drug|Methacholine challenge|Clinical and research test used in asthma
45949768|NCT00445861|Procedure|conventional surgery|Between 4-8 weeks after completion of neoadjuvant chemoimmunotherapy and radiotherapy, patients undergo surgery.
45949769|NCT00445900|Drug|cyclophosphamide|
45949770|NCT00445900|Drug|prednisone|
45949771|NCT00445900|Drug|thalidomide|
45949772|NCT00445900|Other|immunohistochemistry staining method|
45949773|NCT00445900|Other|laboratory biomarker analysis|
46076667|NCT02765412|Other|Webinar, Promotion, and Tool Access|All sites will receive a professionally developed, 15-minute webinar that describes the tool's development (e.g., how the algorithm was designed) and a tutorial on how to use the web-site. The investigators will promote the webinar and using the tool through key local leaders. A web-link to use the tool will be placed within the lung cancer screening clinical reminder.
46076668|NCT02765412|Other|LEAP|Sites randomized to intensive implementation will be offered participation in the LEAP program. LEAP (Learn. Engage. Act. Program) is a multi-week, online learning collaborative using systems redesign techniques to help sites identify and overcome barriers to implementation of shared decision making (use of the Decision Precision tool).
46076669|NCT02765412|Other|Audit and Feedback|Providers at all sites will have access to this system. It will provide feedback on the screening and shared decision making process (e.g., number of provider's eligible patients screened for lung cancer, use of the tool, patient knowledge and satisfaction from patient surveys).
45659197|NCT01732120|Procedure|Off-clamp partial nephrectomy|
45659198|NCT01719562|Procedure|Magnetic resonance imaging|Patients undergo MRI scans for left ventricular function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.
45659199|NCT01719562|Other|Physical Activity|Tailored aerobic exercise program onsite and at home.
45949774|NCT00445900|Procedure|biopsy|
45453612|NCT00662506|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
45949775|NCT00115479|Drug|intensive insulin therapy to maintain normoglycemia|
45949776|NCT00114062|Drug|denufosol tetrasodium (INS37217) Intravitreal Injection|
45949777|NCT00446017|Drug|adrenaline|
45949778|NCT00446017|Drug|milrinone|
45949779|NCT03277768|Device|Resonance Raman Spectroscopy (RRS)|Pre and post-ductal RRS measurements will be obtained daily for a maximum of 14 data collection times in infants with and without PDAs.
45949780|NCT00446173|Drug|Busulfan|130 mg/m^2 IV Daily Over 3 Hours x 4 Days
45453613|NCT00662506|Radiation|Fludeoxyglucose F-18|Undergo 18 FDG PET
45453614|NCT00662506|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45659200|NCT01719562|Other|Healthy Living|Healthy living presentations at a centralized meeting place and over the phone.
45659201|NCT01719562|Device|Cardiopulmonary Exercise Testing (CPET)|Performed on the treadmill using the Bruce or Modified Bruce protocol based on current fitness level.
45659202|NCT01719562|Other|Questionnaire Administration|A self-administered 13-item scale to assess fatigue in participants
45659203|NCT01700439|Device|EDWARDS INTUITY valve|Surgical replacement of the aortic valve with the EDWARDS INTUITY valve.
45659204|NCT01647698|Behavioral|Adaptive working memory training task|"The working memory training task will consist of an adaptive working memory computer program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember."
45659205|NCT01647698|Behavioral|Non-adaptive working memory training task (i.e. an active control task)|Active control task will consist of a non-adaptive working memory task.
45949781|NCT00446173|Drug|Cyclophosphamide|60 mg/kg IV Daily Over 4 Hours x 2 Days
45949782|NCT00446173|Drug|G-CSF|10 mcg/kg Subcutaneously Once Daily
45949783|NCT00446173|Drug|GM-CSF|250 mcg/kg Subcutaneously Once Daily
45949784|NCT05590650|Drug|SZKJT(San-Zhong-Kui-Jian-Tang)|The SZKJT samples were made and packed by Kaiser Pharmaceutical Co. Ltd. with lot number of 2019023247.
45949785|NCT00401687|Drug|Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension|The intervention for this study was that all patients received a slow bolus injection of diluted DEFINITY during the contrast-enhanced imaging study.
45949786|NCT00446212|Drug|Propofol|target controlled infusion of propofol
45949787|NCT00446212|Drug|desflurane|Anaesthetic maintenance with desflurane
45949788|NCT00446329|Drug|cinacalcet|Initiation dose of cinacalcet 30 mg/day. Titration every 2-3 weeks with a maximum dose of 180 mg/day.
45949789|NCT00446368|Drug|RAD001|Participant will take RAD001 (Everolimus) 10mg by mouth once a day.
45659206|NCT01647698|Behavioral|No training|No training during the experiment.
45659207|NCT01433289|Drug|Polyphenon E|There will be 3 dose levels and for each dose level, there will be 6 subjects who will receive the study drug and 2 subjects who will be randomized to take placebo. Dosing will be escalated sequentially contingent on the safety profile of previous doses. Safety data from all participants receiving Polyphenon® E in the preceding dose level will be evaluated and considered acceptable prior to escalation to the next higher dose. PK analyses will be also performed as each dose level is completed. It is necessary to confirm EGCG pharmacokinetics in the event that the primary outcome measure of virologic response is not observed for each arm. For each PK visit on Study Days 1 and 14, a total of 10 blood samples will be obtained per subject.
45659208|NCT01433289|Drug|Placebo|
45659209|NCT01413100|Biological|Anti-Thymocyte Globulin|Given IV
45659210|NCT01413100|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
45659211|NCT01413100|Drug|Cyclophosphamide|Given IV
45659212|NCT01413100|Biological|Filgrastim|Given SC
45659213|NCT01413100|Other|Laboratory Biomarker Analysis|Correlative studies
45659214|NCT01413100|Drug|Mycophenolate Mofetil|Given PO
45949790|NCT00401765|Drug|CNTO 328|Patients will receive 6 mg/kg CNTO 328 in treatment phase of cohort 1A and cohort 1B; 9 mg/kg CNTO 328 in treatment phase of cohort 2; and 12 mg/kg CNTO 328 in treatment phase of cohort 3.
46076670|NCT02765412|Other|Academic Detailing|All sites will be offered an academic detailing approach to implementation of Lung Decision Precsion. A trained detailer will travel to all sites who agree to a visit. The detailer will meet with individual primary care providers whenever possible, and groups of providers as necessary. He will present evidence for a risk-based approach to screening and how to use the tool with patients to make tailored screening recommendations.
45659215|NCT01413100|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
45812159|NCT00588523|Drug|temozolomide followed by high dose busulfan and thiotepa|Temozolomide 200mg/m2 PO Days 1-5 recycled every 28 days Day minus -8 thiotepa 250 mg/m2 intravenously Day minus -7 thiotepa 250 mg/m2 intravenously Day minus -6 thiotepa 250 mg/m2 intravenously Day minus -5 busulfan 3.2 mg/kg intravenously over two hours Day minus -4 busulfan 3.2 mg/kg intravenously over two hours Day minus -3 busulfan 3.2 mg/kg intravenously over two hours Day minus -2 rest Day minus -1 rest Day 0 peripheral blood stem cell or bone marrow reinfusion
46076671|NCT00887263|Drug|Budesonide|3 mg TID
45659216|NCT01413100|Drug|Plerixafor|Given SC
45659217|NCT01413100|Other|Quality-of-Life Assessment|Ancillary studies
45659218|NCT01413100|Other|Questionnaire Administration|Ancillary studies
45659219|NCT01345552|Radiation|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size and is up to the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Note that patients can have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met. For example, if two lung lesions, brain, adrenal, and liver sites were being treated both lung sites could be treated Monday, Wednesday, and Friday and the adrenal, liver and brain lesions treated Tuesday, Thursday
45659220|NCT00995475|Drug|Fluticasone propionate|
45659221|NCT00995475|Drug|Placebo|
45659222|NCT00980460|Drug|Cisplatin|Given IV
45659223|NCT00980460|Drug|Dexrazoxane|Given IV
45659224|NCT00980460|Drug|Doxorubicin Hydrochloride|Given IV
45812160|NCT02527694|Device|Flexible EMS stretcher cart|The flexible EMS stretcher cart is an innovative EMS stretcher cart built to be flexible to fit in smaller spaces such as elevators. The flexible stretcher bends at the hip joint as well as at the knee joint, so that the patient can be put in head-up position at 30 degrees elevation with elevated legs.
45812161|NCT02527694|Device|mechanical CPR|
45949791|NCT00401765|Drug|Docetaxel|Patients will receive 75 mg/m2 docetaxel in run-in phase of cohort 1A, cohort 2, and cohort 3; and in treatment phase of cohort 1A, cohort 1B, cohort 2, and cohort 3.
45659225|NCT00980460|Drug|Fluorouracil|Given IV
45659226|NCT00980460|Drug|Irinotecan Hydrochloride|Given IV
45659227|NCT00980460|Other|Laboratory Biomarker Analysis|Correlative studies
45659228|NCT00980460|Procedure|Liver Transplantation|Undergo liver transplant
45659229|NCT00980460|Drug|Temsirolimus|Given IV
45659230|NCT00980460|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45659231|NCT00980460|Drug|Vincristine Sulfate|Given IV
45659232|NCT00945529|Drug|inhaled nitric oxide (iNO)|Inhaled nitric oxide 40ppm for 48 hours followed by a 6-hour wean.
45659233|NCT00921115|Drug|Fulvestrant|Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.
45949792|NCT00446407|Other|Collaborative Stepped Care Intervention|Psychoeducation, interpersonal therapy, fluoxetine (20-40 mg/d), adherence management
45949793|NCT00446407|Other|Enhanced Usual Care|Screening plus Antidepressants based on practice guidelines
45949794|NCT00115518|Drug|cetuximab|After Cetuximab loading dose. weekly cetuximab during RT. 13 weeks cetuximab weekly maintenance
46076672|NCT00887263|Drug|Placebo|0 mg TID
45949795|NCT00446485|Drug|Ginkgo biloba standardized extract 24/6|tablets, 120 mg/day (60 mg two times daily) during 6 months
45659234|NCT00921115|Drug|Anastrazole|Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles
45812162|NCT03255031|Other|1. Ketogenic Diet (KD) / Standard American (SA) Meals and Shakes|1. Ketogenic Diet (KD) / Standard American (SA) Meals and Shakes: Participants will be randomized to a meal plan of either a ketogenic diet (KD) or standard American (SA) diet at the time they sign the consent (day 1 or 2 of admission). For each meal at breakfast, lunch and dinner, the diets will consist of SA meal (carbohydrate rich) or KD meal depending on treatment randomization. Compliance tests are done twice a week with a blood test measuring ketone levels. To ensure that the diet is double blind in both the outpatient and inpatient phases, solid snacks are always ketogenic and shakes are either KD or SA.
45949796|NCT00446485|Drug|Ginkgo Biloba standardized extract 24/6|tablets, 60 mg/day during 6 months
45949797|NCT00446485|Drug|placebo|placebo during 6 months
45812163|NCT02974387|Drug|Fluorometholone(FML)|
45949798|NCT00446524|Drug|Valsartan + Amlodipine besilate|During the run-in period, either Valsartan 80 mg or Amlodipine 5 mg tablet was given once daily. Throughout the Valsartan + Amlodipine treatment period, a Valsartan + Amlodipine tablet 80/5 mg was given once daily at around 8:00 AM in the morning.
45949799|NCT00446602|Drug|Epoetin alfa|Type=exact, unit=units, number=80,000, form=solution for injection, route=subcutaneous use, once every week or once every 2 weeks.
46076673|NCT00415233|Biological|recombinant thyroid-stimulating hormone|Recombinant thyroid stimulating hormone (rhTSH) should be given at a dose of 0.9mg by intramuscular injection on two consecutive days before ablation.
46076674|NCT00415233|Radiation|Radiodine ablation without rhTSH|Patients in this group do not receive rhTSH pre ablation.
46076675|NCT02765334|Device|nBETTER|60 minutes of nBETTER training followed by 30 minutes of conventional therapy occupational therapy. Total of 18 sessions over 6 weeks.
46076676|NCT02769234|Procedure|ERP/EEG test|The testing protocol consists of an auditory oddball ERP paradigm, followed by the collection of 3min of resting EEG. During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 3 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 45-60 minutes.
46076677|NCT02769234|Procedure|Psychometric testing|Subjects that complete ERP/qEEG testing successfully will move on to clinical and neuropsychological evaluation. Demographic information with also be collected.
46076678|NCT00914667|Drug|warfarin|Single Dose Warfarin 25 mg on Day 1
46076679|NCT00914667|Drug|Warfarin plus Fesoterodine|Fesoterodine 8 mg ER tablets QD for 9 Days and Single Dose Warfarin 25 mg on Day 3
46076680|NCT04112706|Drug|CPP-ACP|CPP-ACP WAS APPLIED AFTER TOOTH BLEACHING
46076681|NCT00887978|Drug|UT-15C SR|treprostinil diolamine sustained release tablets
46076682|NCT00887978|Drug|Placebo|
46076683|NCT02761824|Other|Camp Discovery|Activities included physical, social, emotional, sensory and spiritual activities.
46076684|NCT00608023|Drug|Tesamorelin|
46076685|NCT00608023|Drug|Placebo for Tesamorelin|
45812164|NCT02974387|Drug|Loteprednol (Lotemax)|
45812165|NCT02440633|Drug|14C-OPS-2071|Subjects will swallow Single 25 mL of suspension containing 50 mg of 14C-OPS-2071 directly.
46076686|NCT00802659|Radiation|Stereotactic radiotherapy|This study has 4 treatment groups: This will be determined based on what radiation treatment doses have been previously given to the patient on this study, how effective the dose has been with treatment patient's pain, and how many side effects participants before you have experienced.
46076687|NCT02768844|Device|Stochastic Vibrotactile Stimulation (SVS)|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available; designed by Wyss Institute, Harvard University, Cofab Design LLC) to provide gentle vibrations and sounds during mattress stimulations.
46076688|NCT02768844|Other|Control|Absence of mattress Stochastic Vibratory Stimulation (SVS)
46076689|NCT02765178|Other|Children's Motivation Scale|A 16-item questionnaire to evaluate level of motivation in children and adolescents completed by the primary caregiver.
46076690|NCT02765178|Other|Yale Global Tic Severity Scale (YGTSS)|Clinician administered questionnaire given to Tourette patients. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.
46076691|NCT02765178|Other|Studies Depression Scale for Children (CES-DC)|"Clinician administered questionnaire given to Tourette patients. Consisting of 20 items, respondents are asked to indicate how strongly they have felt a certain way during the past week using a Likert-type scale that ranges from not at all to a lot. Only two items on the questionnaire relate specifically to sleep or fatigue. CES-DC is a validated score for assessing depression in children and adolescents"
45949800|NCT05589753|Other|Hyperoxia|The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure.
45659235|NCT00900198|Procedure|Biopsy|Tissue samples will be collected for research purposes from non-surgical procedures, such percutaneous biopsies for the sole purpose of obtaining specimens or biological fluids for the protocol.
45659236|NCT00720785|Drug|Bortezomib|Parenteral formulation. It is supplied as a 3.5 mg single use vial containing a sterile lyophilized powder that requires reconstitution.
45659237|NCT00720785|Biological|NK cells|NK Cell Infusion
45659238|NCT00349830|Procedure|blood draw|
45659239|NCT00130351|Device|formoterol|
45659240|NCT00060541|Procedure|Laboratory tests|
45659241|NCT00060541|Procedure|Radiological exams|
45812166|NCT03211975|Other|To study the evolution of the prognosis of infectious endocarditis on native valves and on prostheses|To study the evolution of the prognosis of infectious endocarditis on native valves and on prostheses
46076692|NCT02765178|Other|Gilles de la Tourette Syndrome Quality Of Life scale|Clinician administered questionnaire given to Tourette patients. Gilles de la Tourette Syndrome Quality Of Life scale (GTS-QOL) is a recently validated score for the assessment of quality of life in patients with Tourette syndrome. Consisting of a 27-item GTS-specific HR-QOL scale (GTS-QOL) with four subscales (psychological, physical, obsessional, and cognitive).
46076693|NCT02765178|Other|Demographic Data|Data will be collected including: age, age at disease onset, gender, current medication regimen and presence of co-morbidities (like a diagnosis of ADHD, OCD, depression or insomnia).
46076694|NCT00887419|Behavioral|Coping Skills Training|Patients meet individually with therapist for 6 sessions to learn coping skills for stress management, behavioral activation, and communication.
45949801|NCT05589753|Drug|Acetazolamide|Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 6 days. On the final 4 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
46076695|NCT00887419|Behavioral|Education|Patients meet individually with a health educator for 6 sessions in a presentation/discussion format to receive basic information on the etiology and treatment of chronic pain.
45949802|NCT00114179|Drug|capecitabine|Given orally
45949803|NCT00114179|Radiation|radiation therapy|Undergo radiotherapy
46076696|NCT04011111|Procedure|Intubation tube and voice analysis|After the ıntubation tube application, done voice analysis early postoperative period
46076697|NCT02765022|Device|Clip closure|Complete clip closure of secondary lesions after the endoscopic mucosal resection
45659242|NCT04028401|Drug|5% benzoyl peroxide|Application of 5% benzoyl peroxide during 5 days before the procedure
46076698|NCT02765022|Procedure|No clip closure|Observation: no clip closure of secondary lesions after the endoscopic mucosal resection
46076699|NCT05674149|Device|camera|photographs using multi-spectral camera
46076700|NCT04224636|Combination Product|Atezolizumab Injection, Bevacizumab Injection|Atezolizumab and Bevacizumab will be administered prior to or in combination with TACE
46076701|NCT00607789|Drug|Duloxetine|30 mg/day - 120 mg/day
46076702|NCT00607789|Drug|Placebo|identical to study drug
46076703|NCT02761512|Drug|CJ-12420 50 mg QD|CJ-12420 50 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 50 mg.
46076704|NCT02761512|Drug|CJ-12420 100 mg QD|CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 100 mg.
45949804|NCT00114179|Biological|bevacizumab|Given IV
45659243|NCT04130893|Behavioral|stimulation of G13 then G15|Study participant randomized into arm A will undergo a stimulation of point G13 at session N°2, then stimulation of point G15 at session N°3.
45659244|NCT04130893|Behavioral|stimulation of G15 then G13|Study participant randomized into arm B will undergo a stimulation of point G15 at session N°2, then stimulation of point G13 at session N°3.
45812167|NCT00534703|Genetic|AAV1/SERCA2a|AAV1/SERCA2a will be delivered by a percutaneous method in the catheter laboratory. Dose: 1x 10^13 DRP (DNase resistant particles)
46076705|NCT02761512|Drug|Lansoprazole 30 mg QD|Lansoprazole 30 mg capsule will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of Lansoprazole 30 mg.
46076706|NCT00893269|Drug|eszopiclone|Oral capsule at dose recommended for adults
45659245|NCT03906565|Drug|utidelone injection|utidelone monotherapy in patients with advanced or metastatic CRC by iv transfusing utidelone injection
45659246|NCT05534659|Device|Programmable valve|Programmable valve used in the study included Medtronic Strata, B-Braun ProGav, Codman Certas.
45659247|NCT05534659|Device|Non-programmable valve|Non-programmable valve used in the study was Medtronic CSF-flow control valve.
45812168|NCT00534703|Drug|Placebo|Placebo aliquots will be of the same composition as the investigational medicinal product with the absence of the active ingredient and will be visually indistinguishable from the medicinal product. Placebo is prepared and handled exactly as above in a blinded fashion.
45812169|NCT00493831|Drug|nicotine polacrilex, transdermal system or inhaler|on label use of NRT
45812170|NCT00430183|Drug|docetaxel|75 mg/m^2 will be administered intravenously over one hour on Day 1 of each cycle, every 21 days
45812171|NCT00430183|Drug|LHRH agonist|Given intramuscularly
45812172|NCT00430183|Procedure|surgery|Patients undergo radical prostatectomy with staging pelvic lymphadenectomy.
45949805|NCT00114179|Procedure|therapeutic conventional surgery|Undergo surgery
45949806|NCT00114179|Drug|gemcitabine hydrochloride|Given IV
45949807|NCT03277651|Diagnostic Test|hemodynamics tests|Hemodynamics tests for intrahepatic blood flow by colour doppler ultrasound
45949808|NCT00446680|Drug|Mannitol|400mg BD for 6 months followed by a 6 month open label period
45949809|NCT00446680|Drug|placebo|placebo BD for 6 months
45949810|NCT00115557|Other|Practice intervention|Performance feedback, academic detailing, practice facilitation, IT support
45949811|NCT00115557|Other|Practice intervention 2|Performance feedback only.
45949812|NCT00114257|Drug|decitabine|
45949813|NCT00114257|Drug|romidepsin|
45949814|NCT00446719|Drug|Rellidep|2000 mg P.O. daily for 8 weeks
45949815|NCT00446758|Dietary Supplement|Zinc|zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children > 12 months.
45949816|NCT03277534|Other|Electrical stimulation|sensory electrical stimulation was applied prior to upper limb functional training
45949817|NCT03277534|Other|Sham electrical stimulation|electrodes were placed on the same location as the Electrical stimulation condition, but no electric current was applied
45949818|NCT00404937|Drug|Tobradex (Antibiotic steroid combination)|
45949819|NCT03277456|Biological|MVA-NP+M1|Intramuscular injection of novel vaccine
45949820|NCT00114296|Dietary Supplement|omega-3 fatty acid|
46002655|NCT05036213|Drug|BEET IT - Concentrate Beet root juice|Each bottle contains 75ml of concentrated beetroot juice with approximately 6.2mmol of inorganic nitrate. The product is provided by BEET IT, James White Drinks, Ipswich, UK.
45659248|NCT05530681|Diagnostic Test|Questionnaire|The survey consists in standardized and validated questionnaires on urinary function (ICIQ-SF, 4 items), bowel function (SMIS, 7 items and PAC-SYM, 12 items), symptoms of prolapse (POPDI, 6 items) and sexual function (Female Sexual Function Index FSFI, 19 items and Female Sexual Distress Scale - Revised FSDS-R, 13 items). questionnaire will be used at recruitment, at the postpartum visit, at the first annual follow-up visit.
46076707|NCT00893269|Drug|Placebo|Participants receive placebo prior to sleep
45659249|NCT05530681|Diagnostic Test|Pelvic floor ultrasound|Pelvic floor ultrasound is the preferred imaging modality for documenting pelvic floor anatomy during pregnancy or after delivery. This examination is routinely performed in the outpatient clinic during patient visits (including the one year check-up after delivery). The technique used to assess the pelvic floor is described in detail in the 2019 practice parameters issued by IUGA.
45812173|NCT04341415|Procedure|Auricular neuromodulation|"The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.~Ear disinfection and sterile neuromodulation needle placement (service protocol with Chlorhexidine) Placement of 4 semi-permanent Classic needles (SEDATELEC®) on each ear flap at the level of the concha (innervated by the vagus nerve) according to an order and a precise location (4 cardinal points conch), i.e. 8 needles per patient.~Compress soaked with Oxygenated water on the concha (to stop potential bleeding).~Placing an opaque dressing on the ear and a non-occlusive Band-Aid"
45812174|NCT04341415|Procedure|Control|"The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.~Ear disinfection and sterile manipulation without needle placement (service protocol with Chlorhexidine) No needle laying but only sterile disinfection and pressure over the 4 putative locations with the sterile plastic tip (without the needle).~Compress soaked with Oxygenated water on the concha. Placing an opaque dressing on the ear and a non-occlusive Band-Aid."
45812175|NCT02443519|Behavioral|MBCT for Migraine|8 75-90 minute individual sessions of the manualized Mindfulness-based Cognitive Therapy plus a manual and homework
45812176|NCT00362947|Drug|LMWH parnaparin subcutaneously|
45949821|NCT04699396|Procedure|Mobilisation With Movement 1|"Application of a sustained passive accessory movement to a joint (talus or fibula) while the patient actively performs a forward lean/lunge that was previously limited.~3 sets of 10 repetitions of a glide applied to the talus were performed, followed by 3 sets of 10 repetitions of a glide applied to the fibula."
45949822|NCT04699396|Procedure|Mobilisation With Movement 2|"Application of a sustained passive accessory movement to a joint (talus or fibula) while the patient actively performs a forward lean/lunge that was previously limited.~3 sets of 10 repetitions of a glide applied to the fibula were performed, followed by 3 sets of 10 repetitions of a glide applied to the talus."
45812177|NCT00362479|Drug|DR-1021|1 tablet daily
45812178|NCT00363025|Procedure|Two post-remission strategies|
45453615|NCT00662506|Other|Laboratory Biomarker Analysis|Correlative studies
45812179|NCT00363025|Drug|Idarubicin versus daunorubicin|
45812180|NCT02444143|Drug|tacrolimus extended release|
45812181|NCT00362557|Device|MRI|Magnetic resonance imaging
45949823|NCT04699396|Other|Placebo|The Placebo group participants performed the same number of sets and repetitions (6 sets of 20 repetitions) of lean/lunge forward into dorsiflexion, without any glide application.
46076708|NCT00893269|Drug|ramelteon|ramelteon
46076709|NCT00893269|Drug|zolpidem|zolpidem
45453616|NCT00662506|Procedure|Perfusion Magnetic Resonance Imaging|Undergo PWI
45812182|NCT02445625|Device|BCI to train joint attention in ASD|The intervention comprehends seven BCI sessions spread over four months. The first four sessions are planned to occur weekly, and the rest monthly. In each session, the subject is asked to identify objects of interest based on the gaze direction of an avatar. The subject response is interpreted from the EEG signal (using the P300 component, as established in our previous work).
45812183|NCT03161431|Drug|SX-682|SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and C-X-C Motif Chemokine Receptor 2 (CXCR2)
45812184|NCT03161431|Biological|Pembrolizumab|Pembrolizumab is a humanized antibody that targets the programmed cell death 1 receptor (PD-1).
45812185|NCT02445859|Drug|Cefuroxime 4 hourly bolus|Cefuroxime loading dose followed by a continuous infusion dosed according to renal function. Dosed to target a serum concentration of 64mg/L.
46076710|NCT05672667|Drug|intravenous oxytocin|Oxytocin given by intravenous route
46076711|NCT05672667|Drug|intranasal oxytocin|Oxytocin given by intranasal administration
46076712|NCT02764944|Procedure|simple non-exposure EFTR|This intervention includes the steps of laparoscopic seromuscular suturing with a barbed suture thread (V-Loc), which results in inversion of the stomach wall; EFTR of the inverted stomach wall from inside the stomach; and finally, endoscopic mucosal suturing with endoloops and clips.
46076713|NCT02605707|Drug|Intravenous stem cell transplantation|Intravenous injection of autologous endothelial progenitor cells transplantation
46076714|NCT00893347|Behavioral|Treatment as usual|Single session with early intervention coordinator for assessment, education about mild traumatic brain injury, and recommendations for symptom management.
45453617|NCT00662506|Procedure|Positron Emission Tomography|Undergo 18 F FDG-PET
45453618|NCT00662506|Drug|Temozolomide|Given PO
45453619|NCT03947359|Diagnostic Test|Fibroscan Touch 502 M probe|Measurement of liver stiffness
45453620|NCT03947359|Diagnostic Test|Fibroscan Touch 502 S probe|Measurement of liver stiffness
45812186|NCT02446483|Drug|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
45812187|NCT02446483|Drug|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
45812188|NCT02447575|Other|Education on Use of MDI|After the subject demonstrated the use of MDI with the electronic flowmeter in place, the intervention was provided- a short verbal education to demonstrate the correct use of MDI.
45812189|NCT00362635|Drug|Clevudine|
45812190|NCT02449291|Drug|APD421|
45812191|NCT02449291|Drug|Placebo|
45949824|NCT03277417|Other|Echocardiography|Imaging of fetal heart and amniotic fluid
45812192|NCT04744753|Drug|Calcium Ionophore A23187|"Calcium Ionophore A23187 is used in laboratories to increase intracellular Ca2+ levels in intact cells. It also uncouples oxidative phosphorylation, the process cells use to synthesize Adenosine triphosphate which they use for energy. In addition, A23187 inhibits mitochondrial ATPase activity. A23187 also induces apoptosis in some cells (e.g. mouse lymphoma cell line, or S49, and Jurkat cells) and prevents it in others (e.g. cells dependent on interleukin 3 that have had the factor withdrawn).~In IVF field, Ca Ionophore can be used in case of low fertilization rate after ICSI procedure, particularly with Globozoospermia (Round Head sperm syndrome), Ca Ionophore will replace absence of sperm acrosom, and plays role in oocyte activation after ICSI. Recommended use is 0.5 microgram/ml twice for 10 min interrupted with fresh media with 30 min incubation, followed with regular injected eggs culture for IVF."
45812193|NCT02420041|Procedure|Active comparator: Fluoroscopic Guided SIJ injection|"Needle entry point is in the lower one-third of the SIJ~Sterile preparation (with chlorhexidine) and draping and 3 mL of 1% lidocaine injected subcutaneously at site of needle entry~Under fluoroscopy guidance, Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle is inserted in a coaxial fashion into the SIJ~1 mL of contrast (iohexol 300 mg/mL) is injected to outline the SIJ and to ensure no vascular uptake~Injection of 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine~Patient observed in recovery bay for 20 minutes and then discharged home"
45949825|NCT05582460|Diagnostic Test|Reporter Gene Assay|Transcription factor reporter gene assay using luciferase
46076715|NCT00893347|Behavioral|Cognitive-behavioural therapy|6-session manualized cognitive-behavioural therapy protocol designed to prevent persistent post-concussion syndrome
45949826|NCT05582460|Diagnostic Test|Flow Cytometry|Flow Cytometry Analysis using the Sysmex UF-4000, analyzing for bacteria, mononuclear and polymorphonuclear cells, and red blood cell and white blood cell count.
45949827|NCT04699474|Device|Leg ergometer|Leg cycling in bed using motorized ergometer
45949828|NCT03277300|Dietary Supplement|dietary supplement|good dietary supplement for critically ill patients
45949829|NCT03277027|Other|interventional study|The participants wear a monitoring equipment (Actigraph) for a week. And parents do Child Health Questionnaire Parent Form 50 (CHQ-PF50), and Korean Parenting Stress Index-Short Form (K-PSI-SF)
45949830|NCT00115596|Other|Formal Curriculum; Low-Fidelity Simulation|The intervention was a formal procedural skills training curriculum consisting of didactic lectures and simulation training.
45949831|NCT00446836|Drug|Paclitaxel polyglumex (Xyotax)|biologically enhanced chemotherapeutic
45949832|NCT00114374|Drug|Escitalopram|
45949833|NCT00446875|Other|Administration of oral Sucrose|Participants received oral sucrose 2 minutes prior to the combind DTaP, IPV, and Hep B vaccine.
46076716|NCT02761434|Other|Hypertonic Saline (3% NaCl)|0.1 ml of 3% NaCl per kg of body weight per minute
46076717|NCT02761434|Other|Isotonic Saline (0.9% NaCl)|0.1 ml of 0.9% NaCl per kg of body weight per minute
46076718|NCT04115475|Device|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous imaging of subcellular muscle components
46076719|NCT00890851|Procedure|Transurethral Needle Ablation (TUNA)|Transurethral needle ablation of benign prostatic hyperplasia by radio frequencies
46076720|NCT02768922|Other|Aphasia telerehabilitation|Speech and language therapy delivered by speech-language pathologist via computer and telemedicine
46076721|NCT02768922|Other|Standard face-to-face aphasia rehabilitation|Speech and language therapy delivered by speech-language pathologist face-to-face (treatment as usual)
45949834|NCT00446875|Other|Administration of oral Placebo|Participants received Placebo 2 minutes prior to the combind DTaP, IPV, and Hep B vaccine.
45949835|NCT00446914|Behavioral|Systems Change (High Blood Pressure Strategy)|
45949836|NCT00446953|Drug|betamethasone|2x12 mg betamethazone c-section at 38 weeks
45949837|NCT00446953|Other|placebo|c-section at 39 weeks
45949838|NCT00447031|Drug|intravitreal bevacizumab and triamcinolone acetonide|
45949839|NCT00114413|Drug|Inhaled corticosteroids|Used for both regular asthma control and as a rescue inhaler
45949840|NCT00114413|Procedure|eNO measurement|measured by Aerocrine® NIOX device
45949841|NCT00447070|Drug|ATAZANAVIR|
45949842|NCT00447109|Device|Closed system suction|
45949843|NCT00447148|Procedure|3-dimensional coronary angiography|3-dimensional coronary angiography
45949844|NCT00115635|Drug|docetaxel|
45949845|NCT00115635|Drug|gemcitabine|
45949846|NCT00447187|Drug|LX201|"LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded."
45949847|NCT00447187|Other|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
45949848|NCT00447304|Drug|moxifloxacin|
45949849|NCT00447304|Procedure|cholecystectomy|
45949850|NCT00447343|Procedure|Decompressive cervical spine surgery|"Treatment group (25 patients) will undergo decompressive anterior cervical spine surgery~Healthy volunteers will ONLY undergo two scans 6 months apart."
45949851|NCT00447343|Procedure|fMRI and MRS scan|A scan pre-op and 6 months post-op.
46076722|NCT04115397|Drug|Zoledronic Acid|Treating seropositive individuals with musculoskeletal symptoms with one infusion zolendronic acid as compared to placebo
46076723|NCT04115397|Drug|Placebo|Placebo
46076724|NCT00891007|Biological|MVA-mBN85B|Low Dose arm, 1x 10E7 TCID50
46076725|NCT00891007|Biological|MVA-mBN85B|Normal Dose arm, 1x 10E8 TCID50
46076726|NCT00891007|Biological|Rouvax|Standard measles vaccine, approved in South Africa
46076727|NCT00887497|Procedure|Angioembolization|Angioembolization
46076728|NCT00887822|Drug|Bevacizumab|7.5 mg/kg IV infusion on Day 1 of every 3-week cycle
46076729|NCT00887822|Drug|Placebo|Placebo matched to bevacizumab on Day 1 of every 3-week cycle
46076730|NCT00887822|Drug|Capecitabine|1000 mg/m^2 orally twice daily on Days 1-14 of every 3-week cycle
46076731|NCT00887822|Drug|Cisplatin|80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
46076732|NCT04222920|Other|Dose reduction to 2mg/L|Adalimumab dose reduction aiming drug concentration of 2mg/L
45949852|NCT00114452|Biological|Provacel|ex vivo cultured adult mesenchymal stem cells
45949853|NCT00114452|Biological|Placebo|Placebo
45949854|NCT00447460|Procedure|Mesenchymal stem cell (MSC)|
45659250|NCT05530525|Diagnostic Test|The Computerized Adaptive Testing system of the Functional Assessment of Stroke|The Computerized Adaptive Testing system of the Functional Assessment of Stroke comprises 58 items. The items were selected from four well-known physical function measures for patients with stroke: 26 items from the Fugl-Meyer Assessment-Upper limb, 11 items from the Fugl-Meyer Assessment-Lower limb, 12 items from the Postural Assessment Scale for Stroke Patients, and 9 items from the Barthel Index. These items evaluate motor control, postural control, and activity of daily living functions in patients with stroke. Results are automatically reported as Rasch scores (i.e., the minimum and maximum values are negative and positive infinity, respectively). A higher score indicates greater physical functions.
45812194|NCT02420041|Procedure|Ultrasound Guided Sacroiliac Joint Injection|"Sterile preparation (with chlorhexidine) and drape~Using ultrasound guidance (SonoSite S-nerve) with a low frequency (2-5 Hz) curvilinear transducer in a sterile cover, the transducer is placed in a transverse plane over the SIJ and needle entry point is chosen at the medial end of the ultrasound transducer~3 mL of 1% lidocaine is injected subcutaneously at site of needle entry~Under ultrasound guidance, a Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle is inserted in a medial to lateral direction and guided into the SIJ. (0.5-2 mL of normal saline may be injected during needle insertion to locate tip of needle and to ensure solution does not spill out onto sacrum).~After using the Doppler function to identify any surrounding vessels (to avoid intravascular injection), 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine is injected.~Patient observed in recovery bay for 20 minutes and then discharged home"
45949855|NCT00447577|Drug|Loteprednol etabonate and tobramycin ophthalmic suspension|Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
45949856|NCT00447577|Drug|Tobramycin and dexamethasone ophthalmic suspension|Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
45949857|NCT00114491|Drug|Rosuvastatin|
45949858|NCT03276988|Drug|Period 1 GX-30, Period 2 THYROGEN®|Part B - Sequence A. GX-30 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, THYROGEN® 0.9mg will be administered in Period 2.
45949859|NCT03276988|Drug|Period 1 THYROGEN®, Period 2 GX-30|Part B - Sequence B. THYROGEN® 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, GX-30 0.9mg will be administered in Period 2.
45949860|NCT00447655|Behavioral|Self-management and peer support|
45949861|NCT00114569|Drug|lorazepam|
46076733|NCT04222920|Other|Dose reduction to 5mg/L|Adalimumab dose reduction aiming drug concentration of 5mg/L
45659251|NCT05530525|Diagnostic Test|The Barthel Index|The Barthel Index has 10 items, and the total score ranges from 0 to 100. Higher score indicates less disability on activity of daily living functions.
45812195|NCT02420041|Device|"Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle"|
45949862|NCT00447733|Behavioral|Integrated mental health and substance use treatment|Psychosocial and drug treatment targeting both the substance use disorder and the psychiatric disorder in an integrated and comprehensive way.
45949863|NCT00447733|Behavioral|Treatment as usual|Non-standardized psychiatric outpatient treatment
45812196|NCT02420041|Device|SonoSite S-nerve|
45949864|NCT00115713|Behavioral|Aerobic Exercise Training|
45949865|NCT00115713|Behavioral|Resistance Exercise Training|
45949866|NCT03276949|Device|Blood glucose measurement|Device used to measure blood glucose levels
45949867|NCT00447811|Drug|MOA-728|
46076734|NCT04222920|Drug|Adalimumab|Adalimumab
46076735|NCT04115163|Drug|Gemcitabine|Given IV
46076736|NCT04115163|Drug|Nab-paclitaxel|Given IV
46076737|NCT02542111|Drug|Bortezomib|Bortezomib IV
46076738|NCT02542111|Drug|Gemcitabine|Gemcitabine IV
46076739|NCT02542111|Drug|Dexamethasone|Dexamethasone IV
46076740|NCT02542111|Drug|Cisplatin|Cisplatin IV
46076741|NCT02768688|Other|Brain connectivity and physiology|MRI to measure glymphactic flow during simulated natural sleep and again on return to wakefulness.
45812197|NCT02420041|Device|iohexol|
45812198|NCT02420041|Drug|triamcinolone/lidocaine|
45812199|NCT02421055|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
45812200|NCT02421055|Procedure|Laparoscopic Sleeve Gastrectomy|
45949868|NCT00447850|Procedure|endometrial biopsy|
45949869|NCT00447889|Drug|gadoteric acid|
45949870|NCT04728074|Other|The Entering Employment and Sustaining Work Program|A structured, motivation and self-awareness based group intervention
45949871|NCT04728074|Other|vocational rehabilitation|An individual based, focused on desired job or occupation, face-to-face intervention
45949872|NCT00447928|Drug|OrthoDerm transdermal nitroglycerin patch|
45949873|NCT00447967|Drug|Irinotecan|Irinotecan 200 mg/m2 IV on Day 1 every 3 weeks for 6 cycles
45949874|NCT00447967|Drug|Oxaliplatin|Oxaliplatin 80 mg/m2 IV on Day 2 every 3 weeks for 6 cycles
45949875|NCT00447967|Drug|Fluorouracil|Fluorouracil 400 mg/m2 infused over 10 min IV and Fluorouracil600 mg/m2 infused over 22 hours IV, Day 1 and 2 (De Grammont regimen)every 2 weeks for 12 cycles
46076742|NCT02768688|Drug|Dexmedetomidine|Administering of 0.5-1.0 mcg/kg/hr of dexmedetomidine to ensure subject's loss of consciousness.
46076743|NCT00891163|Drug|Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine)|30 minute applicable on antecubital fossa
46076744|NCT00891163|Drug|Placebo Patch|placebo
45949876|NCT00447967|Drug|Leucovorin|Leucovorin 200 mg/m2 infused over 1 hour IV on day 1 and day 2 (De Grammont regimen) every 2 weeks for 12 cycles
45659252|NCT05530525|Diagnostic Test|The National Institutes of Health Stroke Scale|The National Institutes of Health Stroke Scale comprises 11 items and was used to monitor the severity in the patients with stroke. The total score ranges from 0 to 42, with a higher score indicating greater severity. A National Institutes of Health Stroke Scale score of 1-5 indicates mild severity; 6-14, mild to moderate severity; 15-24, severe severity; and equal to or greater than 25, very severe severity.
45812201|NCT02450383|Drug|Acellular Dermal Matrix|Placement of acellular dermal matrix (Alloderm®) on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
45949877|NCT00447967|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 as a 4 hour IV infusion, Day 1 every 4 weeks for 6 cycles
45453621|NCT03947125|Drug|Buprenorphine transdermal patch on knee joint|Conventionally buprenorphine transdermal patch had been applied to anterior chest wall or upper arm. But author had applied buprenorphine transdermal patch to painful knee joint in knee osteoarthritic patients. This research is about the effect, adverse effects, and compliance of comparison conventional chest applied buprenorphine transdermal patch group with painful knee joint applied group in knee osteoarthritic patients.
45453622|NCT00658762|Drug|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks, with 2 week taper
45453623|NCT00658762|Drug|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks, with 2 week taper
45453624|NCT00658762|Drug|paroxetine|Capsules, oral, 20 mg q am, 8 weeks, with 2 week taper
45812202|NCT02450383|Procedure|Autologous subepithelial connective tissue graft|Placement of autologous subepithelial connective tissue graft on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
45949878|NCT00448006|Device|Allium Biliary Stent|device
45949879|NCT00448006|Device|allium biliary stent|allium biliary stent
45453625|NCT00658762|Drug|Placebo|Capsules, oral, BID, 8 weeks, with 2 week taper
45453626|NCT04023409|Other|NA: no intervention|NA: no intervention
45453627|NCT05111899|Behavioral|Newborn Health Education|Community influencers will receive training and give community education to women and their families regarding newborn health.
45453628|NCT00658372|Drug|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
45453629|NCT00658372|Drug|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper
45659253|NCT04425187|Drug|Gefitinib|gefitinib 250mg (1 tablet), once a day，PO
45949880|NCT00114608|Device|The Focus™ Neuromuscular Stimulation System|"Electrical foot stimulation was produced by surface electrodes placed on the sole of the foot over the plantar muscle group. Electrical stimulation was delivered by The Focus™ Neuromuscular Stimulation System, Empi, Inc. (St. Paul, MN.) The crucial stimulus parameters were: biphasic symmetrical square wave at 50 pulses per second, phase duration of 300 microseconds, a starting ramp up time of 2 seconds and a finishing ramp down time of 2 seconds per stimulation cycle, and a stimulation cycle of 12 seconds on and 48 seconds off per minute. Stimulation was increased to an intensity just sufficient to create a slight visible muscle twitch. This level of intensity caused no evident discomfort in any of the subjects in our first study. Subjects were continually monitored throughout this study for any indication of discomfort.The Focus™ Neuromuscular Stimulation System created electrical stimulation of the plantar foot muscles."
45453630|NCT00658372|Drug|Paroxetine|Capsules, oral, Paroxetine, 20 mg QD, 8 weeks with 2 week taper
45949881|NCT00401856|Drug|Eplerenone|50mg oral route
45812203|NCT02421211|Drug|Simeprevir (SMV)|Participants will receive 150 milligram (mg) of SMV (Treatment A) once daily in Panel 1 and Panel 2.
45812204|NCT02421211|Drug|Ledipasvir (LDV)|Participants will receive 90 mg of LDV once daily as FDC tablet with SOF (Treatment B) in Panel 1 and Panel 2.
45812205|NCT02421211|Drug|Sofosbuvir (SOF)|Participants will receive 400 mg of SOF alone (Treatment C) in Panel 1 and as FDC tablet with LDV (Treatment B) once daily in Panel 2.
45453631|NCT00658372|Drug|Placebo|Capsules, oral, placebo, BID, 8 weeks with 2 week taper
45453632|NCT01584817|Other|telephone education|A repeated instruction by telephone on the day before colonoscopy was conducted
45659254|NCT04425187|Drug|Bevacizumab Combined With Gefitinib|Bevacizumab Combined With Gefitinib
45659255|NCT03756649|Procedure|Blood Draw|50 ml will be collected
45812206|NCT00363259|Drug|Peginterferon alfa-2b|
45812207|NCT00363259|Drug|Ribavirin|
45812208|NCT02421757|Device|Fischell Transcutaneous Magnetic Stimulation Pain Treatment Device|Transcutaneous Magnetic Stimulation
45812209|NCT02421757|Device|Placebo|The placebo Transcutaneous device
46076745|NCT02827994|Other|neurophysiology of pain education and exercises|"Pain neurophysiology education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. It was delivered in small groups (4 to 7 participants). A total of 4 sessions were delivered over 4 weeks (1 session per week). Each session took between 45 minutes and 1 hour.~Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular muscles delivered over 3 sessions (the first session covered pain neurophysiology education only). Each exercise was performed in 3 series of 10 repetitions. The number of exercises targeting the same group of muscles increased from one in the 2nd session to 2/3 in the 4th session."
46076746|NCT00914745|Drug|Ointment|Each time about 1.5 cm ointment have to be applied on the upper lip and 1.5 cm on the lower lip, twice daily for prophylaxis for e period of 6 month.
45949882|NCT00401856|Drug|Placebo|Placebo is identical to eplerenone but the active ingredient is absent
45812210|NCT02423317|Device|Intubation with Miller's blade|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Miller's blade.
45812211|NCT02423317|Device|Intubation with Airtraq|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Airtraq.
46076747|NCT02764866|Other|Sleep testing|Home sleep testing
46076748|NCT02541331|Biological|ISMIGEN|Tablets of 30 billion organisms/mg - Sublingual use 1 tablet per day over 10 days for 3 successive months.
45812212|NCT02424175|Biological|Fecal Microbiota Transplantation|
45812213|NCT03093259|Drug|ABX464|ABX464 is a new Anti-inflammatory drug
45812214|NCT03093259|Drug|Placebo oral capsule|Placebo matching with ABX464
45812215|NCT03089905|Drug|Sevoflurane|Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.
45812216|NCT03089905|Drug|Remifentanil|Experimental arm: loading dose: 1 mcg/kg, infusion starting at 0.1 mcg/kg/min or greater.
45812217|NCT03089905|Drug|Dexmedetomidine|Experimental arm: loading dose:1mcg/kg, infusion: 1 mcg/kg/hr.
45812218|NCT02528318|Combination Product|Lucinactant for inhalation|Lucinactant for inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
45812219|NCT02528318|Device|nCPAP alone|nCPAP therapy
45812220|NCT02423408|Drug|TNX-201|TNX-201 capsule
45949883|NCT00448045|Behavioral|Manual and mechanical assisted cough|Individuals will be given a pulse oximeter and taught both manually assisted and mechanically assisted coughing techniques to maximize their cough. Manually assisted coughing consists of air stacking to deep insufflations. An abdominal thrust is then applied upon glottic opening to augment the cough. These subjects will also have rapid access to a mechanical in-exsufflator (CoughAssistTM) and will be trained on how to access and use this device. Mechanically assisted coughing (MAC) involves the use of the CoughAssistTM to expand the lungs and then quickly reverse the pressure to rapidly empty the lungs with expiratory (cough) flows of 600 L/m. An abdominal (manual) thrust is applied in conjunction with the negative pressure (exsufflation) to further increase cough.
45659256|NCT03756649|Procedure|Urine Collection|50 ml will be collected
45659257|NCT03756649|Procedure|Stool Collection|Three 25 ml tubes will be collected
45659258|NCT04425109|Behavioral|meal test response|soy fermented versus non fermented meal test
45659259|NCT05530447|Drug|Samelisant|Tablet
45659260|NCT05523505|Device|Sham intervention|Use of the non-invasive brain stimulation device to simulate peripheral experience of stimulation without actually stimulating the brain.
45659261|NCT05523505|Device|RLN real non-invasive brain stimulation intervention|Real non-invasive brain stimulation to the left angular gyrus and left temporal pole using transcranial alternating current stimulation (tACS).
45659262|NCT05523505|Device|CCN real non-invasive brain stimulation intervention|Real non-invasive brain stimulation to the bilateral dorsolateral prefrontal cortex using transcranial alternating current stimulation (tACS).
45659263|NCT05523505|Device|RLN and CCN real non-invasive brain stimulation intervention|Real non-invasive brain stimulation to the bilateral dorsolateral prefrontal cortex and left angular gyrus using transcranial alternating current stimulation (tACS).
45659264|NCT05530135|Other|Exercise program|Exercise program
45659265|NCT05530135|Other|Cognitive behavioural therapy|Cognitive behavioural therapy
45812221|NCT02423408|Drug|Placebo|Placebo capsule
45949884|NCT00448045|Behavioral|Incentive spirometry|These individuals will be given a pulse oximeter and an incentive spirometer (AirLife Company) and taught how to use them.
46076749|NCT02541331|Biological|PLACEBO|Matched tablets without any active substance.
46076750|NCT02828462|Other|CAPRI|
45659266|NCT05530135|Other|Standard clinical care|Standard clinical care
46076751|NCT02605551|Procedure|Osteopathic Manipulative Therapy|"All OMT techniques will be performed by osteopathic physicians who will have received training specific to this protocol prior to study initiation. All used techniques will be slow moving and gentle to augment rest and relaxation, promote autonomic balance, and release fascial contractures. The techniques that will be used in this protocol are:~OM Occipitomastoid release technique~Sub-Occipital Release Technique~Rib Raising Technique~Rotatory stimulation of posterior Chapman's Reflexes~Lymphatic Pumps and Effleurage: (Pedal Pump of Dalrymple)"
45453633|NCT03946657|Drug|Inhalational anesthetic|Oxygen/air (fraction of inspired oxygen (FiO2) of 0.40), inspiratory fresh gas flow of 2 L/min), sevoflurane (1 minimum alveolar concentration [MAC]) and remifentanil IV infusion (0.1-0.25 mcg/kg of LBW/min) were used.Neuromuscular blockade was performed during the operation by rocuronium infusion (0.3-0.7 mg/kg of LBW/h), ensuring that PTC was zero.
46076752|NCT02605551|Behavioral|Lifestyle Modification|Patients will be counseled on healthy behaviors such as regular exercise, weight loss, and a healthy diet
45812222|NCT02528786|Other|No Intervention|No study drug will be administered in this study.
45812223|NCT02424968|Biological|Anti-Thymocyte Globulin|Given per standard institutional practice
45812224|NCT02424968|Drug|Cyclosporine|Given PO
45812225|NCT02424968|Drug|Mycophenolate Mofetil|Given PO
45812226|NCT02424968|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant|Undergo nonmyeloablative allogeneic HSCT
45812227|NCT02424968|Biological|Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells|Receive CD8+ memory T-cells via IV
45812228|NCT02424968|Radiation|Total Nodal Irradiation|Undergo TLI
45812229|NCT02424799|Drug|GSK2646264 0.5% topical cream|GSK2646264 0.5% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
45812230|NCT02424799|Drug|GSK2646264 1% topical cream|GSK2646264 1% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
45812231|NCT02424799|Drug|Placebo|Placebo topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
46076753|NCT00635388|Other|Placebo|oral, placebo, once/day for 12 weeks
45453634|NCT03946657|Drug|Intravenous anesthetic|Propofol infusion (4-8 mg/kg of total body weight/h), oxygen/air (FiO2 of 0.40; inspiratory fresh gas flow of 2 L/min) and remifentanil IV infusion (0.1-0.25 μg/kg of LBW/min) were used.Neuromuscular blockade was performed during the operation by rocuronium infusion (0.3-0.7 mg/kg of LBW/h), ensuring that PTC was zero.
45812232|NCT02492750|Biological|Anakinra|Given SC
45812233|NCT02492750|Drug|Dexamethasone|Given PO
45812234|NCT02492750|Other|Laboratory Biomarker Analysis|Correlative studies
45949885|NCT00448240|Drug|Erlotinib|loading dose of 300 mg on Day 2 followed by 150 mg daily Days 3 - 17 of each cycle of paclitaxel and cisplatin/carboplatin
45949886|NCT00448318|Procedure|Music Therapy|
45949887|NCT00448396|Drug|Patupilone|
45659267|NCT03730207|Device|Xpede™ Bone Cement|Xpede™ Bone Cement will be injected into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body by filling the bony trabeculae.
46076754|NCT00635388|Other|Lactobacillus (Probiotic 1)|oral, Lactobacillus, once/day for 12 weeks
46076755|NCT00635388|Other|Lactobacillus and Bifidobacterium (Probiotic 2)|oral, Lactobacillus and Bifidobacterium, once/day for 12 weeks
46076756|NCT02827916|Device|Assessment of neuropathic pain with theThermotest device|Measure of painful neuropathy with thermotest
46076757|NCT02827916|Device|Assessment of neuropathic pain with SUDOSCAN device|Measure of painful neuropathy with sudoscan Devices
45659268|NCT03730207|Device|Mendec Spine Bone Cement|Mendec Spine Bone Cement will be injected into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body by filling the bony trabeculae.
45659269|NCT03693547|Drug|utidelone injection|utidelone monotherapy in patients with advanced NSCLC by utidelone
45812235|NCT02492750|Drug|Lenalidomide|Given PO
45812236|NCT02492750|Other|Placebo|Given SC
45812237|NCT00363337|Drug|aripiprazole|open label treatment with aripiprazole
45812238|NCT02453347|Device|CES Therapy|Cranial Electrotherapy Stimulation (CES) may serve as an effective complimentary, noninvasive/non-pharmacological treatment for this Veteran population. CES is administered through a therapeutic device (such as Alpha-Stim®) marketed and approved by the FDA to treat insomnia, depression, anxiety, and pain.
45812239|NCT02493452|Drug|Plecanatide|
45812240|NCT02493452|Drug|Placebo|
45949888|NCT00114686|Drug|Quetiapine fumarate|
45949889|NCT00114686|Drug|lithium|
45949890|NCT00114686|Drug|divalproex|
45949891|NCT00448474|Behavioral|Mailed Arthritis Self-Management Education|
45949892|NCT05553678|Drug|Midazolam|Midazolam (0.03 mg/kg/30 min) will administered during UIA clipping through microscope.
45949893|NCT05553678|Drug|Normal saline|Normal saline (0.03 mg/ml/30 min) will administered during UIA clipping through microscope.
45949894|NCT00448513|Dietary Supplement|catechin extracts|comparison with placebo
45949895|NCT00448552|Drug|capecitabine|
45949896|NCT00448552|Drug|oxaliplatin|
45949897|NCT00114725|Procedure|Laser-assisted intracytoplasmic sperm injection|
46076758|NCT02827916|Device|Assessment of neuropathic pain with the Neuropathic Pain Symptom Inventory.|Measure of painful neuropathy with Neuropathic Pain Symptom Inventory.
45659270|NCT05534113|Drug|Almonertinib Envafolimab|"Subjects will receive Almonertinib treatment for 6-8 weeks after enrollment, and receive ctDNA detection and radiography assessment again.~If the EGFR mutation is positive, according to the patient's condition and clinical actual situation, subjects will receive combination therapy scheme, follow-up once every 6 weeks. The treatment will continue until the disease progress assessed by radiography.~If the EGFR mutation turns negative and stable radiographically deep response, stop Almonertinib treatment and receive the relevant assessment before immunotherapy and receive Envafolimab treatment，and follow-up once every 6 weeks. The treatment of Envafolimab will continue until the EGFR mutation is positive again or disease progress assessed by radiography."
45659271|NCT05534035|Biological|PTX-COVID19-B|The vaccine product, PTX-COVID19-B, is a preservative-free, sterile mRNA-lipid nanoparticle (mRNA-LNP) dispersion in an aqueous cryoprotectant buffer intended for IM injection.
45659272|NCT05534035|Biological|Vaxzevria®|The AstraZeneca COVID-19 Vaccine is a colorless to slightly brown solution, clear to slightly opaque with a pH of 6.6. One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S* recombinant) 5 × 1010 viral particles (vp) (corresponding to not less than 2.5 × 108 ifu).
46076759|NCT05662059|Device|RAVANS|Respiratory-Gated Auricular Vagal Afferent Nerve Stimulation
45659273|NCT05530057|Drug|Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar)|"Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle and SB3 8 mg/kg I.V. over 90 minutes on day 1 of cycle 1 . Thereafter, SB3 6 mg/kg will be infused over 30 minutes on day 1 of each subsequent 21-day cycle until progression or unacceptable toxicity.~Dose reductions for eribulin, but not for SB3, is permitted.~Two dose reductions (1.1, 0.7 mg/m2) are allowed for eribulin before consideration of study treatment discontinuation. Eribulin could be continued as monotherapy if trastuzumab-similar was discontinued, and vice-versa."
45659274|NCT05530057|Drug|Eribulin Mesylate|"Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle until progression or unacceptable toxicity.~Two dose reductions (1.1, 0.7 mg/m2) are allowed before consideration of study treatment discontinuation."
46076760|NCT05662059|Device|RAVANS-sham|RAVANS sham device
46076761|NCT02761590|Other|Circuit training protocol|The construction of own model of periodization to be used complies with the biological principle of interdependence volume vs. intensity, and duration of 14 weeks, proposing a week of recuperative exercises after two weeks of stress, gradually increasing the intensity with respective volume settings. This model is based on the concepts described by Turner et al. which concludes in favor of the organization of training adapted to the reality of the public to be trained.
46076762|NCT00893425|Drug|ramipril|
45812241|NCT02428309|Biological|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|
45659275|NCT05533957|Other|Application of different dosages of oxygen therapy|To evaluate the response (vasodilation, neuromuscular fatigue and muscle oxygenation) of the administration of different dosages of oxygen therapy (ie. FiO2) in patients with COPD associated with CRF and LTOT
45812242|NCT02429869|Drug|everolimus|
45812243|NCT02430337|Behavioral|Technology-Assisted SafeCare|A technology-enhanced version of SafeCare
45812244|NCT02430337|Behavioral|SafeCare|SafeCare, an evidence-based home visiting program
45812245|NCT02493608|Device|scalpel|used to cut the abdominal wall.
45949898|NCT03276910|Drug|EPREX|6 doses at 50 IU/kg or 20 IU/kg in subcutaneous use
46076763|NCT04223388|Dietary Supplement|Lactobacillus plantarum 276|5 Billion CFU/dose, serving size = 1 capsule/day
46076764|NCT04223388|Other|Placebo|Placebo product, serving size = 1 capsule/day
46076765|NCT00951665|Drug|paclitaxel|Intravenous repeating dose
45659276|NCT03678181|Behavioral|Information Resources|The investigators will provide a HIV-related content as the attention-control condition.
45812246|NCT02493608|Device|Diathermy|Diathermy used to cut , coagulate the tissue
45812247|NCT02494076|Drug|EzPAP|
45812248|NCT02494076|Other|Standard Care|
45812249|NCT02431273|Drug|TDF IVR|
45812250|NCT02431273|Drug|TDF-FTC IVR|
45812251|NCT02431273|Drug|TDF-FTC-MVC IVR|
45949899|NCT03276910|Drug|sodium chloride AGUETTANT 0.9%|6 injections at 1ml in subcutaneous use
45949900|NCT03276520|Diagnostic Test|ethyl glucuronide|alcohol urine screening with ethyl glucuronide
45949901|NCT03276520|Diagnostic Test|ethanol|alcohol urine screening with ethanol
45949902|NCT00401895|Device|TIPS created with 8 or 10 mm covered stent|creation of a shunt between hepatic vein and portal vein with PTFE-covered stents
45949903|NCT04699318|Procedure|Group B|To release the pediatric hypospadias using Double Dartos Tubularized incised plate (TIP) Urethroplasty
45812252|NCT02428478|Drug|Desipramine|200 mg administered 2 hours before normal sleep time
45812253|NCT02428478|Drug|Placebo|Placebo-matching desipramine administered 2 hours before normal sleep time
45812254|NCT04341493|Drug|Nitazoxanide 500 MG|Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with two drugs
45812255|NCT04341493|Drug|Hydroxychloroquine|Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with one drug
45812256|NCT04341740|Procedure|Bone Marrow Aspirate|bone marrow aspiration
45812257|NCT02431741|Device|Mepilex Transfer Ag|
45812258|NCT02432287|Drug|Metformin|To determine if treatment with metformin (1700 mg/day) will restore the gene expression profile of older, glucose intolerant adults to that of young healthy subjects.
45949904|NCT04699318|Procedure|Group A|To release the pediatric hypospadias using Single Dartos Tubularized incised plate (TIP) Urethroplasty
45949905|NCT00114764|Drug|filgrastim|Filgrastim given daily after induction chemotherapy
46076766|NCT00951665|Drug|pertuzumab [Perjeta]|Intravenous repeating dose
46076767|NCT00951665|Drug|trastuzumab emtansine [Kadcyla]|Intravenous escalating dose
46076768|NCT00951665|Drug|paclitaxel|Intravenous escalating dose
46076769|NCT00951665|Drug|trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
46076770|NCT02764632|Procedure|Digital facilitation|
46076771|NCT00893503|Procedure|colonoscopy|Patients will provide stool and urine samples and will be scheduled to undergo a colonoscopy. The colonoscopy will be done per standard of care - no study specific procedural requirements imposed.
46076772|NCT02769078|Drug|dabigatran|
45949906|NCT00114764|Drug|pegfilgrastim|Pegfilgrastim given once after induction chemotherapy
45949907|NCT04699513|Device|Mechanical Ventilation Mode (airway pressure release ventilation )|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that alternates between two levels of continuous positive airway pressure (CPAP) support and allows spontaneous respiratory effort at either CPAP level. It is considered as an alternative, life-saving modality in patients with acute respiratory distress syndrome (ARDS) that struggle for oxygenation.
45659277|NCT03678181|Behavioral|Social Support|The investigators will provide evidence-based answers to users' health questions, including linkage to care.
45949908|NCT00448786|Drug|AMG 706|Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off
45949909|NCT00448786|Drug|AMG 706|Arm C - 75 mg BID 5-days on, 2-days off
45949910|NCT00448786|Drug|AMG 706|AMG 706 125 mg daily continuously (Arm A)
45949911|NCT05543967|Behavioral|Cognitive assessments|Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Rey Auditory Verbal Learning Test (RAVLT), Boston Naming Test (BNT), Digit Span Test (DST), Trail Making Test (TMT).
45949912|NCT05543967|Other|Olfactory function measurements|Olfactory Threshold, Odor Identification Score, Odor Memory Score.
45659278|NCT03678181|Behavioral|HIV Testing|The investigators will provide opportunities for participants to get tested through HIV home test kits.
45812259|NCT02432287|Drug|Placebo|there is no other name we used for the placebo
45949913|NCT05543967|Other|Functional magnetic resonance imaging|resting-state fMRI, odor-induced fMRI.
45949914|NCT04699084|Other|Mozart music|A 20-minute piece composed by W.A Mozart ( Sonata K. 448 in D Major for 2 pianos) was applied in music group, directly after the arrival of patients in the Post Anesthesia Care Unit (PACU), while they were receiving usual postoperative care.
45812260|NCT02532998|Drug|AZD9977 oral suspension|AZD9977 oral suspension, single dose
45812261|NCT02532998|Drug|AZD9977 placebo oral suspension|oral suspension, single dose
45812262|NCT02532998|Drug|Fludrocortisone, tablets|Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)
45659279|NCT04310917|Other|blood lipoprotein (a) test|research specific blood sample
45659280|NCT02576587|Other|Continuous Positive Airway Pressure|For cases, those found to have moderate sleep apnea (AHI >=15) will be place on CPAP therapy.
45812263|NCT02532998|Drug|Eplerenone, tablets|100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)
45812264|NCT03026101|Other|Nitroglycerin|Intra-arterial adminstration to dilate external carotid artery branches to replicate migraine pain
45949915|NCT00114803|Drug|Calcitonin nasal spray (salmon)|
45949916|NCT03276442|Other|Low-fat dietary intervention|Low-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
45949917|NCT03276442|Other|High-fat dietary intervention|High-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
45949918|NCT03276403|Device|PiCCO Catheter|The PiCCO Catheter is an investigational device intended to measure lung water content in individuals requiring advanced haemodynamic monitoring. The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.
45949919|NCT03276364|Diagnostic Test|Ultrasound|Point-of-care ultrasound examination by pulmonary and critical care fellow
45949920|NCT00114842|Procedure|MR colonography|
45949921|NCT00448825|Drug|Topiramate + Cognitive Behavioral Therapy|Topiramate up to 300 mg per day
45949922|NCT00448825|Drug|Placebo + Cognitive Behavioral Therapy|Placebo twice a day
45949923|NCT00448903|Drug|Bemiparin|Bemiparin sodium
45949924|NCT00448903|Drug|Placebo|Sodium Chloride 0,9%
45949925|NCT00448942|Behavioral|Daily bathing with Chlorhexidine based product|
46002656|NCT05036213|Drug|BEET IT - Concentrate Beet root juice (nitrate depleted)|Each bottle contains 75ml of concentrated beetroot juice with depleted nitrate, thus, no inorganic nitrate is found in thisbeverage. The product is also provided by BEET IT, James White Drinks, Ipswich, UK.
46002657|NCT00558480|Drug|Vitamin A|Vitamin A capsules, as retinol palmitate 200,000 IU at enrollment, 3 and 6 months
45659281|NCT05519839|Drug|CIC Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (CIC Vaccine) on Day 0.
45659282|NCT05519839|Drug|CIC Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV, SARS-CoV-2 rS, and 75 μg Matrix-M1 Adjuvant (CIC Vaccine) on Day 0.
45659283|NCT05519839|Drug|qNIV Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV and 75 μg Matrix-M1 Adjuvant (Influenza Vaccine) on Day 0.
45812265|NCT00363194|Drug|Pazopanib (GW786034)|Pazopanib (GW786034)
45812266|NCT02453581|Drug|OZ439|OZ439 Powder for Oral Suspension
45812267|NCT02533466|Other|Sodium fluoride + potassium nitrate|Marketed toothpaste containing 1450ppm fluoride as sodium fluoride and 5% potassium nitrate
45812268|NCT02533466|Other|Potassium nitrate|Experimental toothpaste containing 5% potassium nitrate
45812269|NCT02454127|Behavioral|Atkins Diet|Dietary counseling for 1 year
45812270|NCT02454127|Behavioral|Zone Diet|Dietary counseling for 1 year
45812271|NCT02454127|Behavioral|Weight Watchers Diet|Dietary counseling for 1 year
45812272|NCT02454127|Behavioral|Ornish Diet|Dietary counseling for 1 year
46076773|NCT02769078|Drug|rivaroxaban|
46076774|NCT02769078|Drug|apixaban|
46076775|NCT02769078|Drug|warfarin|
46076776|NCT04036201|Drug|Bupivacaine|peribulbar block
45949926|NCT00402012|Drug|Pioglitazone|During the double-blind, 12 weeks treatment period, subjects will self-administer study medication (pioglitazone or equivalent volume of placebo) 30 mg/day each morning. The dose of pioglitazone will be increased to 45 mg/day after 4 weeks if the fasting plasma glucose is higher than 100mg/dl or the HbA1C is higher than 7%. This dose has proven tolerability, safety and efficacy for type 2 diabetes and has previously been used at the Pennington Center in studies on pioglitazone.
45949927|NCT00448981|Behavioral|Hand hygiene and educational material|
45949928|NCT00448981|Device|Mask, alcohol and hand sanitizer|
45949929|NCT03276325|Drug|Placebo-nalbuphine|Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
46002658|NCT00558480|Drug|Vitamin A placebo|Vitamin A placebo at enrollment, 3 and 6 months
46076777|NCT04114773|Other|SCARF (Survivors of Cardiac Arrest Rehabilitation focused on Fatigue)|"The intervention will be delivered by a multidisciplinary team. There will be individual testing and feedback on physical capacity and cognitive ability. Group sessions will include education on the consequences of cardiac arrest, promotion of techniques to ameliorate these consequences, for example, increasing physical activity or energy conservation. Additional sessions will cover psychological reactions; family life; work life; intimacy; and existential considerations.~Participants will have a course information book with a physical activity training diary and problem-solving therapy worksheets to use at home for 12-weeks. They will receive one phone call from the clinical team during this period. The 2-day return stay will revisit the subjects from the first 5-day stay.~Participating survivors who have a relative that wishes to attend will be included in all the group sessions and individual feedback but will not take part in the physical capacity or cognitive ability tests."
45659284|NCT05519839|Drug|SARS-CoV-2 rS Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of SARS-CoV-2 rS, Diluent, and 50 μg Matrix-M1 Adjuvant (SARS-CoV-2 rS Vaccine) on Day 0.
45659285|NCT05519839|Drug|Influenza Vaccine|Intramuscular (deltoid) injections of Comparator influenza on Day 0.
45659286|NCT05519839|Drug|CIC Vaccine|Intramuscular (deltoid) injections of co-formulated mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (CIC Vaccine) on Day 0.
45812273|NCT02974244|Drug|exenatide once weekly|exenatide treatment in the customary clinical care in the USA
45812274|NCT02974244|Drug|basal insulin|basal insulin treatment in the customary clinical care in USA
45812275|NCT04743986|Biological|Platelet Rich Plasma (PRP)|RegenLab, Lausanne, Switzerland
45812276|NCT04743986|Drug|Corticosteroid (CS)|40mg/ml triamcinolone in 2 ml 0.5% bupivicaine
45812277|NCT03016897|Other|Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter|Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
45812278|NCT02974322|Drug|GED-0301|GED-0301
46076778|NCT00891241|Drug|LMI 1195-101|Single dose, bolus IV injection of LMI 1195
46076779|NCT02856191|Other|Holter|
45812279|NCT02974322|Drug|Placebo|Placebo
45812280|NCT02436031|Drug|Desipramine|200 mg administered 2 hours before normal sleep time
45812281|NCT02436031|Drug|Placebo|Placebo-matching desipramine administered 2 hours before normal sleep time
45659287|NCT03648073|Drug|[68Ga]DOTATATE-PET/MRI|[68Ga]DOTATATE-PET/MRI
45659288|NCT03622411|Device|speech app|language exercises provided by the speech therapist in hospital + independent practice of language exercises via a tablet and speech app
45659289|NCT03622411|Device|brain games|language exercises provided by the speech therapist in hospital + independent recreational tablet use via brain games
45659290|NCT03622411|Behavioral|aphasia therapy|language exercises provided by the speech therapist in hospital
45659291|NCT05533879|Other|Tele-yoga|Women with chronic low back pain will be taken to group-based Tele-Yoga sessions of 60 minutes three times a week for 4 weeks, in an internet-based telerehabilitation environment.
45812282|NCT02454283|Drug|Vanoxerine HCl|
45812283|NCT02454283|Drug|Placebo|
45812284|NCT02437669|Drug|Hydromorphone|To be administered by intranasal route using mucosal atomization device.
45812285|NCT02430818|Drug|ketamine|
45812286|NCT02430818|Drug|morphine|
45812287|NCT02455453|Drug|18F-FFNP|
45812288|NCT02455453|Device|CTI/Siemens Biograph 40 PET/CT Scanner|"Will include (1) 18-FDG-PET/CT scan~Will include (2) 18F-FFNP-PET/CT scans"
45812289|NCT02455453|Drug|Estradiol|
45812290|NCT02455453|Drug|18F-FDG|
45812291|NCT02997865|Behavioral|Stepped care for depression|Cognitive behavior therapy (CBT), plus referral to the participant's own physician to discuss antidepressant medications if indicated.
45812292|NCT02457403|Device|ROTEM|Assess coagulopathy with ROTEM device compared to conventional laboratory tests. ROTEM will be used on all patients, however, determination of blood products used will be based on patient's randomization group.
45812293|NCT02457403|Other|Conventional Therapy|Assess coagulopathy with conventional laboratory tests (PT/INR, Hemoglobin, Platelet count). Conventional laboratory tests will be obtained on all subjects, however, determination of blood products used will be based on patient's randomization group.
45812294|NCT02533934|Drug|Harvoni|Treatment of Hepatitis C with sofosbuvir based HCC therapy
45812295|NCT02983513|Behavioral|Early Intervention|
45812296|NCT02459119|Drug|Regorafenib|Regorafenib will be packaged as 40 mg tablets in a bottle. Patients will be instructed to maintain a daily medication calendar.
45812297|NCT02956525|Drug|Dexibuprofen|Dexibuprofen 200 mg
45812298|NCT02925949|Behavioral|DuoPACT|6 couple-based intervention sessions are administered weekly by a counselor.
45812299|NCT02925949|Behavioral|LifeSteps|3 individual-based intervention sessions are administered weekly by a counselor.
45949930|NCT03276325|Drug|Dexamethasone-nalbuphine|Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
45949931|NCT00449020|Drug|Carboplatin|CARBOPLATIN (AUC=2) IV in 250 cc NS over 30 minutes, weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
45949932|NCT00449020|Drug|Docetaxel|DOCETAXEL 75 mg/m2 IV over one hour every three weeks for 3 cycles.
45812300|NCT02519023|Drug|Liposomal Bupivacaine|In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side.
45949933|NCT00449020|Drug|irinotecan hydrochloride|IRINOTECAN 30 mg/m2 IV over 90 minutes weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
45949934|NCT00449020|Radiation|radiation therapy|Radiotherapy will start on the first day of scheduled chemotherapy. The daily administered dose will be 1.8 Gy, 5 days a week for 4.4 weeks, 22 fractions, ( 39.6 Gy) to the primary tumor and mediastinum (primary planning target volume: PPTV). After 39.6 Gy, the same targets will be treated by oblique fields at 1.8 GY for 3 fxs to a toal dose of 45 GY. Thereafter, the primary tumor and involved nodal metastasis (secondary planning target volume SPTV) will be boosted at 2 Gy per day to 18 Gy in 9 fractions. The total dose will be 63 Gy in 35 fractions over seven weeks.
46076780|NCT04037449|Procedure|TAP block|With the patient placed in the supine position, after asepsis of the skin with chlorhexidine, bilateral TAP blockage will be carried out under ultrasound control. We will use a high frequency linear transducer (12-15 MHz) on one side of the abdominal wall, at the level of the mid-axillary line, between the costal margin and the iliac crest. At this level we can identify three muscle layers, from superficial to deep: external oblique muscle, internal oblique muscle and transverse muscle of the abdomen. We will move the transducer more laterally to locate the most posterior border of the internal oblique and transverse muscles. It is at this level that we perform the posterior TAP blockade: we administer 10 ml of 2% Mepivacaine plus 10 ml of 0.5% Bupivacaine between the fasciae of the internal oblique muscle and the transverse muscle of the abdomen and observe an appropriate diffusion pattern of local anesthetics
45812301|NCT02519023|Drug|Bupivacaine|Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
45812302|NCT02519023|Device|Ultrasound|An ultrasound, which is a beam of high frequency sound that allows one to visualize images in the body, will be used to aid investigators to observe the local anesthetic being infiltrated into the plane
45812303|NCT02519023|Drug|Epinephrine|TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine.
45812304|NCT02519023|Drug|acetaminophen|all individuals will receive scheduled acetaminophen (1 gram every 6 hours),
45812305|NCT02519023|Drug|ibuprofen|all individuals will receive scheduled ibuprofen (800 mg every 8 hours)
45949935|NCT00115752|Drug|Valdecoxib|
45949936|NCT00115752|Drug|COX Inhibitor|
45949937|NCT00449059|Drug|acute infusion of nitroglycerine into the pulmonary artery|
45949938|NCT00449098|Device|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
45949939|NCT00449098|Drug|Trabeculectomy with MMC|Trabeculectomy with MMC
45949940|NCT00114920|Drug|Resiquimod|
45812306|NCT02519023|Drug|Oxycodone|all individuals will receive PRN oxycodone 5-10mg q4h if pain is rated at more than 5 out of 10 on a numerical pain scale.
45812307|NCT02535572|Device|FEAST|FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.
45812308|NCT02535572|Device|RUL UB|This is right unilateral ultrabrief ECT, the standard of care.
45812309|NCT02497040|Drug|Levobupivacaine|local injection
45949941|NCT00449137|Drug|Arsenic trioxide|ATO will be administered at dose levels determined by the dose escalation scheme (section 4.2). Intra-venous (IV) infusion of ATO (mg/kg body weight) over 1-4 hours will be administered for 5 consecutive days (day 1 to day 5) during the first week, twice a week on weeks 2 and 3 (days 8, 11, 15, and 18), and only one day (day 22) of week 4. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
45949942|NCT00449137|Drug|Fluorouracil|Escalate 5-FU, starting at dose 1600 mg/m2. On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
45949943|NCT00449137|Drug|Leucovorin calcium|On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
45949944|NCT00449137|Other|Plasma levels of elemental arsenic|Pre-Treatment and and one hour post ATO on days 1, 5, 8, 11,15, 18, and 22
45949945|NCT00449137|Genetic|Peripheral Blood Mononuclear Cells (PBMC) for mRNA analysis|Peripheral blood samples (PAXgene Blood RNA tube, Qiagen, USA) will be obtained up to 2 weeks prior to start of treatment (same day as the first FNA) and one hour post ATO on days 1, 5, 8, 11,15, 18, and 22. Along with FNA an additional blood sample will be obtained on day 23 of every odd treatment cycle.
45949946|NCT00449137|Procedure|Tumor Biopsy (Fine-Needle Aspiration)|Pre-Treatment, Day 23 of Cycles 1, 3, 5, 7
45949947|NCT00115791|Drug|RSD1235|IV
45949948|NCT00115791|Drug|placebo|IV
45949949|NCT00449254|Drug|oleoyl-estrone (MP-101)|
45949950|NCT00449293|Behavioral|standard cognitive behavioral therapy|Standard therapy to help participants with smoking cessation.
45949951|NCT00449293|Behavioral|Mindfulness Based Cognitive Therapy|A novel mind body therapy that extends basic CT principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
45949952|NCT00449410|Drug|Atorvastatin|
45949953|NCT00449410|Drug|ezetimibe|
45949954|NCT00449449|Drug|Pertubation with Lidocain Solution|
46002659|NCT05034146|Drug|68Ga-FAPI|68Ga-FAPI was injected intravenously to each subject, and the dose is calculated according to body weight of subject (approximately 1.85-3.7MBq/kg).
45949955|NCT00115115|Drug|Dopamine infusion to brain dead organ donors|Dopamine infusion administered at a dosage of 4µg/kg/min starting after brain death has been proven until to surgical procurement of the kidneys
45949956|NCT00449488|Drug|epoetin alfa|epoetin alfa 60.000 IU one i.v. bolus
45453635|NCT00616798|Drug|RO4917838|10mg po daily
45812310|NCT02497040|Drug|Bupivacaine|local injection
45949957|NCT03276247|Other|observation|observation
45949958|NCT00115830|Drug|Atorvastatin|
45659292|NCT05369845|Other|questionary|the patient will complete validated questionnaires, at three periods (at the time of the initiation of the CPAP, and during the 2 planned follow-up consultations: four months and at 1 year) The validated questionnaires are as follows: Illness Perception Questionnaire (IPQ-R), Beliefs about Medicines Questionnaire (BMQ), Morisky Medication Adherence Scale (MMAS), Hospital Anxiety and Depression Scale (HADS), Rollnick Scale.
45949959|NCT00115830|Drug|Rosuvastatin|
45949960|NCT03276208|Other|Prenatal Massage|We will utilize moderate pressure Swedish massage (SM) that utilizes long slow strokes known as effleurage and kneading strokes known as petrissage. A specific routine will be performed on each participant with focus on low back, upper back, shoulders, and neck musculature. Consistent moderate pressure, which is lighter than deep tissue massage but deeper than brush strokes, will be used.
45812311|NCT02497040|Drug|placebo|local injection
45453636|NCT00616798|Drug|RO4917838|30mg po daily
45812312|NCT02523235|Drug|ropivacaine 0.2%|Perineural ropivacaine 0.2% at 8 mL/h (adductor) or 6 mL/h (popliteal) basal rate infusion and a 4 mL patient-controlled bolus with a 30 minute lockout
45659293|NCT05529745|Other|Neurorehabilitation cerebellar cognitive disorder|Influence of neurorehabilitation treatment lines of physiotherapy and exercise therapy including scheduled occupational therapy to adapt and improve cognitive-affective disorders in cerebellar lesions.
45812313|NCT02498522|Drug|Metformin|83 patients will continue metformin until end of 1st trimester
45812314|NCT02459197|Behavioral|Heat Pain Stimuli A|
45812315|NCT02459197|Behavioral|Heat Pain Stimuli B|
45812316|NCT02459197|Behavioral|Positive Video|
45949961|NCT03276208|Other|Mindfulness|The intervention and control group will be enrolled in the Craving to Quit® program, a 21-day mindfulness-based program delivered via a smartphone application (https://www.cravingtoquit.com/). This program uses a mindfulness-based approach to train people to recognize and be aware of their tobacco cravings. The program includes videos, online exercises to complete, and a virtual support community.
45949962|NCT00115154|Drug|Aldara (imiquimod) cream, 5%|
45949963|NCT03276169|Procedure|Left atrial appendage closure|Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
45949964|NCT03276169|Procedure|Radiofrequency ablation|Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
45949965|NCT03276169|Procedure|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
45453637|NCT00616798|Drug|RO4917838|60mg po daily
45453638|NCT00616798|Drug|Placebo|po daily
45453639|NCT00616798|Drug|Standard antipsychotic therapy|As prescribed
45812317|NCT02459197|Behavioral|Neutral Video|
45812318|NCT02459197|Drug|Administration of T4P1001 capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
45949966|NCT00449527|Drug|Budesonide/formoterol pMDI|
45453640|NCT01106053|Drug|Pramipexole|Pramipexole tablet titrated up to a maximum dosage of 0.5 mg three times daily (1.5 mg/day).
45453641|NCT05626543|Behavioral|Cognitive behavior therapy (CBT) and Mindfulness-based stress reduction (MBSR) programs|Cognitive behavior therapy (CBT) and Mindfulness-based stress reduction (MBSR) programs will be used combinedly. CBT will be constructed based on the CBT model of Beck, (2021) and mindfulness practice will be implemented based on the MBSR program developed by Williams et. al. (2011).
45453642|NCT00616330|Drug|clindamycin phosphate/butoconazole nitrate|semi solid, single dose
45453643|NCT00616330|Drug|clindamycin phosphate|semi solid, single dose
45453644|NCT00616330|Drug|butoconazole nitrate|semi solid, single dose
45812319|NCT02459197|Drug|Administration of Placebo capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
45812320|NCT02431052|Drug|Olumacostat Glasaretil|
45812321|NCT02431052|Other|Vehicle|
45812322|NCT02919787|Drug|5-FU|Neoadjuvant treatment
45812323|NCT02919787|Drug|Oxaliplatine|Neoadjuvant treatment
45812324|NCT02919787|Drug|Irinotecan|Neoadjuvant treatment
45812325|NCT02919787|Procedure|Pancreatic surgery|All patients
45812326|NCT02919787|Drug|5-FU|Adjuvant treatment
45949967|NCT00449527|Drug|Budesonide HFA pMDI|
45453645|NCT03949933|Radiation|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
45453646|NCT00615940|Drug|WX-671|capsules taken per os once daily until progression or toxicity
45812327|NCT02919787|Drug|Oxaliplatine|Adjuvant treatment
45812328|NCT02919787|Drug|Irinotecan|Adjuvant treatment
45812329|NCT02459275|Other|PEP uP Protocol|Semi-elemental tube feeds are started at the hourly goal rate as determined by the 24 hour volume goal. Protein supplements will be started at the initiation of tube feeds to target a daily delivery of 2 g/kg/day.
45812330|NCT02459275|Drug|Metoclopramide|Metoclopramide 10mg Intravenous (IV) every 6 hours (q6h) or 5mg IV q6h for renal failure will be started empirically concomitant with EN initiation. Gastric Residual Volume (GRV) will be checked every 4 hours and will be reinfused to the patient each time it is checked.
45812331|NCT02498834|Behavioral|Educational Video and Question Prompt List|Educational Video and Question Prompt List
45949968|NCT00449683|Drug|terazosin|off-label use of terazosin to treat antidepressant-induced sweating
45812332|NCT02524561|Drug|CEE pill|Conjugated equine estrogens 0.45 mg/day
45949969|NCT00449722|Drug|mesalazine|
45949970|NCT00449800|Drug|ceftriaxone|
45949971|NCT00449839|Drug|Insulin Aspart|"A; CSII without bolus: 8 hours of constant insulin infusion. B; CSII with bolus: 8 hours of a constant insulin infusion starting with a s.c. bolus.~C; CSII with bolus, optional: 8 hours of a constant insulin infusion starting with a different bolus than period B. This period is optional and it will be evaluated after period A and B if period C is conducted."
45949972|NCT00449917|Drug|lutein|
45949973|NCT00449917|Drug|DHA|
45949974|NCT00449917|Drug|vitamins|
45659294|NCT05533723|Procedure|Endoscopic epidural neuroplasty|"EEN catheter, iDolphine S2 (Meta Biomed Co., Ltd, Osong, Korea) was placed in the epidural space through sacral hiatus. EEN was done on the target segments.~During EEN, normal saline was infused into epidural space under epiduroscopic vision. Dexamethasone (5 mg), 0.3% mepivacaine 10 mL, and hyaluronidase (3000 IU) were injected through catheter at the target segments. Holmium-Yag laser was used to cut epidural fibrous bands and for coagulation of epidural bleeding."
45949975|NCT00449995|Procedure|confocal laser microscopy|
45659295|NCT05533723|Procedure|Percutaneous epidural neuroplasty (PEN)|PEN catheter, EDEN-CC (JMT, Yangju, Korea) was placed in the epidural space and neural foramen . PEN was done on the target segments. Dexamethasone (5 mg), 0.3% mepivacaine 10 ml, and hyaluronidase (3000 IU) were injected through the PEN catheter.
45949976|NCT00450034|Procedure|drug - oriented multifaceted intervention|oriented multifaceted intervention
45659296|NCT05529667|Drug|INCB054828, Paclitaxel|"phase 1>~- Approximately 3-12 patients will be enrolled. The dose escalation will be three patients registered for each cohort until the first dose-limiting toxicity appears during the four weeks of treatment and observation.~phase 2> Phase 2 studies will be extended to a total of 30 patients with a two-phase recommended dose. Patients will be treated until the time of disease progression, intolerable toxicity, rejection of the patient, or withdrawal of consent."
45659297|NCT05533645|Other|Questionnaire|These patients complete the food frequency questionnaire in order to validate it for lower sodium consumptions. The experimental group has already received dietary advices regarding salt consumption during during their recent consultations.
45659298|NCT03571633|Drug|Trastuzumab + Paclitaxel|During neoadjuvant period, weekly paclitaxel + trastuzumab (every 3 weeks, Q3W) During adjuvant period, weekly trastuzumab (every 3 weeks, Q3W)
45659299|NCT03571633|Drug|Pegfilgrastim|During neoadjuvant period, weekly pegfilgrastim (every 3 weeks, Q3W)
45812333|NCT02524561|Drug|Estradiol patch|Climara 50 mcg/day
45949977|NCT00450229|Drug|diindolylmethane|Given PO
45949978|NCT00450229|Drug|placebo|Given PO
45949979|NCT00450229|Procedure|therapeutic conventional surgery|Undergo surgical resection
45949980|NCT00450229|Other|laboratory biomarker analysis|Correlative studies
45949981|NCT00450229|Other|pharmacological study|Correlative studies
45949982|NCT00450268|Procedure|blood draw, skin shave biopsy|
45949983|NCT04699279|Drug|Rosuvastatin 10mg|Rosuvastatin 10mg is taken by oral or nasal feeding every day at ang time.
45949984|NCT04698889|Dietary Supplement|natural cow|
45949985|NCT04698889|Dietary Supplement|high protein cow milk|
45659300|NCT03535597|Device|Quikclot Radial Pad|The QuikClot® Radial® pad will be applied over the radial artery access site covered with either a Coban™ bandage or a Tegaderm™ dressing after TRA.
45812334|NCT02524561|Drug|Active Progesterone|Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
45812335|NCT02524561|Other|Placebo tablet|Placebo tablet
45949986|NCT04698889|Dietary Supplement|natural human|
45812336|NCT02524561|Other|Placebo patch|placebo patch
45812337|NCT02524561|Other|Placebo progesterone|placebo progesterone
45949987|NCT04698889|Dietary Supplement|low protein cow milk|
45949988|NCT00450307|Biological|monoclonal antibody 3F8|
45949989|NCT00450307|Biological|sargramostim|
45949990|NCT00450502|Drug|Batracylin|
45812338|NCT02431598|Drug|gadoxetate disodium|
45812339|NCT02431598|Drug|gadoterate dimeglumine|
45812340|NCT02431598|Drug|Saline|
45812341|NCT00363974|Drug|XIAP antisense|2 days loading dose followed by weekly 2hr infusion
45949991|NCT00450541|Behavioral|Questionnaire|Four questionnaires taking 15-20 minutes total to complete.
45812342|NCT04743739|Drug|Rituximab|Rituximab 1000mg, I.V. on Days 1 and 181, and will be retreated or not at Days 15 and 195 according to the CD19+ B cell count.
45812343|NCT04743739|Drug|cyclosporine|cyclosporine (CsA) will be started at a dose of 3mg/kg/d and adjusted according to the blood levels of the CsA. CsA will be tapered after 6 months and discontinued over a three month period.
45812344|NCT02499380|Device|PneumRx Coil System|
45812345|NCT02461693|Drug|Caffeine|200mg delivered as pill; one-time dose
45949992|NCT00450541|Behavioral|Interview|Interview lasting about 30 minutes.
45949993|NCT03276091|Behavioral|Colofit+ intervention|Personnalized phone call, done by the medical student in the name of Adémas-69, organized cancers screening in the Rhône area association. This is a motivational call to encourage patients with an immunochemical fecal test positive, to realized their colonoscopy.
45949994|NCT00115193|Drug|pegfilgrastim|pegfilgrastim 6 mg on day 1 of each cycle (within 4 hours of chemotherapy completion)
45949995|NCT00115193|Drug|pegfilgrastim|pegfilgrastim 6 mg on day 2 of each cycle (at least 24 hours after chemotherapy completion)
45949996|NCT03276013|Drug|Pembrolizumab|pembrolizumab in combination with doxorubicin
45949997|NCT00450736|Drug|celecoxib|
45949998|NCT00450736|Procedure|adjuvant therapy|
45949999|NCT00450736|Radiation|radiation therapy|
45950000|NCT05536362|Drug|TCI Propofol Injection|To decrease postoperative pain after cancer colon surgery
45950001|NCT00450775|Drug|Dermatix Q|Dermatix Q applied twice daily
46002660|NCT05034146|Device|PET/CT|68Ga-FAPI PET/CT scan were performed 20~60 min after 68Ga-FAPI (1.85-3.7MBq/kg) injection intravenously.
45659301|NCT03519685|Behavioral|Contraceptive Training and Education|Staff at the student health center and local health centers where they refer for contraceptive services will receive a CME-accredited education and training session and technical assistance. The one-day session emphasizes evidence-based and patient-centered contraceptive counseling and provision. Students attending colleges assigned to the intervention arm will receive materials and resources designed to educate young people about contraceptive methods and where to access services.
45453647|NCT00615940|Drug|placebo|capsule taken per os once daily until progression or toxicity
45659302|NCT03519685|Behavioral|Placebo Nutrition Education|Students attending colleges assigned to the nutrition education arm will receive materials and resources designed to educate young people about the impacts of sugar on health.
45659303|NCT03473353|Other|Medical Scribe|Trained Medical Scribes will be present in the exam room to take notes on the the electronic medical record so that clinicians can focus all their attention to the interaction with the patient and parent.
45659304|NCT05365477|Behavioral|Empiric Therapy: Diet|Diet: High water intake - at least 2.5 liters daily Reduce sugar-sweetened cola intake to ≤3 cans per week. Reduce salt intake to <2000mg sodium daily Reduce red meat intake to two 4-ounce portions per week Normal calcium intake: 3 servings of dairy products (or their equivalents) per day Increase vegetable and fruit intake to ≥5 servings per day Reduce oxalate intake to <100 mg/day
45950002|NCT04698577|Behavioral|Attention Training|The training was delivered face-to-face in groups of three participants. Participants were involved in a game of table tennis with two players and one spectator. The roles were rotated every 5 minutes so that each participant experienced 10 minutes of play and 5 minutes of observation. The game was played as normal with one point awarded to the player for every score achieved. All 3 players were asked to keep the score of the game in their minds during each 5-minute round. Participants had two objectives 1) to play and win the game and 2) to silently keep the score of the game. The researcher watched the game and accurately kept score, using a notepad. At the end of every 5-minute round, the researcher paused play and asked each child to write down the score they were holding in their mind. The researcher then revealed the true score, asked participants to swap roles and commence another round.
45950003|NCT04698577|Behavioral|Active Control|The control group was the same as the training group except for the core training mechanism; children were not required to mentally keep score. The researcher kept score by continually calling out the updated score as each point was won. The observing child was simply told to wait his/her turn.
45812346|NCT02461693|Drug|Placebo|Lactose-based pill; one-time dose
45659305|NCT05365477|Drug|Empiric Therapy: Drug|Drug(s): indapamide 1.25mg and potassium citrate 15mEq daily.
45950004|NCT00450853|Drug|granisetron|Granisetron SC followed by granisetron IV
45950005|NCT00450892|Drug|docetaxel+lapatinib|3 cycles of docetaxel (100 mg/m²) + lapatinib (1000 mg/d) followed by 3 cycles of FEC
45659306|NCT05365477|Behavioral|Selective Therapy: Diet|"Diet:~Volume <2.5L Increase fluid intake to ≥ 2.5L/d, based on specific urine volume~Calcium >250mg male, >200mg female Reduce red meat intake to two 4-oz portions/wk; reduce sodium intake to<2000mg/d, avoid vitamin D + calcium supplements~Oxalate >40mg Reduce dietary oxalate intake to <100 mg/d; increase fiber intake to 25-35 g/d~Citrate <450mg male, <550mg female Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~pH<5.8 Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~Uric acid >800mg male, >750mg female Reduce red meat intake to two 4- oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~Sodium >150mmol Reduce sodium intake to <2000mg/d~Sulfate > 80mEq or urine urea nitrogen >14g Reduce red meat intake to three 3-4 oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d"
45659307|NCT05365477|Drug|Selective Therapy: Drug|"Drug(s):~For calcium >250mg male, >200mg female: indapamide 1.25mg and potassium chloride 20mEq. At 1 month if persistent, then increase to indapamide 2.5mg and potassium chloride 20mEq. For citrate <450mg male, <550mg female: potassium citrate 15mEq BID. At 1 month if persistent, then increase to potassium citrate 30mEq BID. For pH<5.8: potassium citrate 15mEq BID. At month if persistent, then increase to potassium citrate 30mEq BID. For uric acid >800mg male, >750mg female: allopurinol 300mg.~If both elevated calcium and low pH: indapamide 1.25mg and potassium citrate 15mEq BID If both elevated calcium and low citrate: indapamide 1.25mg and potassium citrate 15mEq BID"
45659308|NCT05529511|Other|Phase 1 - semi-structured interviews|Semi-structured face-to-face or virtual interviews.
45659309|NCT05529511|Other|Phase 2 - consensus meeting|Face-to-face or virtual meeting(s)
45812347|NCT02525263|Biological|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
45950006|NCT00450892|Drug|docetaxel + trastuzumab|3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule followed by 3 cycles of FEC 100
45950007|NCT00450892|Drug|docetaxel + trastuzumab + lapatinib|"3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule~+lapatinib (1000 mg/d) followed by 3 cycles of FEC 100"
45950008|NCT00450931|Other|counseling intervention|
45950009|NCT00450931|Other|educational intervention|
45950010|NCT00115271|Drug|Nutritional supplements|
45950011|NCT05536089|Diagnostic Test|a multi-locus blood-based assay|Colorectal tumor-specific plasma ctDNA methylation markers detection
45950012|NCT04698655|Other|Information on treatment options|"Asked to read two A4 pages of information on treatment options (osteoarthritis treatment options)"
45950013|NCT04698655|Other|Recommendation from general practitioner|Receive a hypothetical general practitioner recommendation for exercise
45453648|NCT01584895|Behavioral|Cardiac Rehabilitation|A standard cardiac rehabilitation program consisting of 3 days per week of supervised exercise and education.
45453649|NCT00612820|Drug|GSK256066|200mcg bd,
45453650|NCT00612820|Drug|fluticasone propionate|200mcg od,100mcg bd
45453651|NCT00612742|Drug|testosterone gel|once daily transdermal testosterone gel, 300 mcg
45453652|NCT00612742|Drug|placebo gel|once daily transdermal placebo gel
45453653|NCT05016895|Drug|Single-dose azithromycin|Bi-annual mass, community-based distribution of single-dose azithromycin to children ages 1 to 11 months.
45950014|NCT04698655|Other|Information on osteoarthritis|Asked to read 1 A4 page of brief information on osteoarthritis
45950015|NCT00451009|Device|Viacell's product Media Kits|
46076781|NCT04037449|Other|Conventional analgesia|"Intravenous dexketoprofen 50 mg / 8 hours, alternate with intravenous paracetamol 1g / 8 hours. If allergy to Nonsteroidal anti-inflammatory drugs (NSAIDs) or in case of renal failure: Intravenous metamizol 2g / 8 hours alternate with intravenous paracetamol 1g / 8 hours.~Rescue Analgesia: intravenous morphine (2 mg every 15 minutes until VAS less or equal to 3)"
46076782|NCT00801099|Drug|Amoxicillin/Clavulanic Acid|single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively
46076783|NCT02761278|Procedure|Endometrial biopsy|
46076784|NCT04017715|Other|Experimental: warm up|"Phase 1 is dynamic stretching and running exercises which includes, A jogging ,B walking lunge and sweeps, C hip in and out running : jog 3 steps stop and do hip in/hip out for Phase 2 is strength and agility which includes A- squat, B- push-ups: wide palmer push-ups. C vertical jumps. D- lateral jump. E- nordic hamstrings,. F (a)- shoulder external rotations, F(b)- modified inverted rows, Phase 3 is balance and core strength which includes A- modified ankle discs, B - planks: standard forward planks 2 repetitions for 30secs. C- side planks: standard side planks on both sides 1 repetition for 20 secs. Da- bird-dog,Db- modified back extensions, Phase 4 is run sprint which includes A- run sprint: 100% speed running between running (20m) with 1 repetition"
45659310|NCT05533489|Other|No intervention|No intervention This study is a retrospective descriptive study.
45453654|NCT04839211|Device|Inspiratory muscle training|Inspiratory muscle training will be performed three sessions per week as one supervised and two unsupervised for 8 weeks using an inspiratory muscle training device (PowerBreath). The inspiratory muscle training session will consist of 7 cycles including a 2:1 ratio of work and rest interval. Resistance will be adjusted to the highest tolerable load and will be gradually increased.
45659311|NCT05529433|Procedure|Atraumatic Restorative Treatment (ART)|Atraumatic Restorative Treatment is highly accepted by the patients as there is no need for local anesthesia. It is a minimal invasive technique which preserves sound tooth structure as caries removal will be done by a sharp spoon excavator. It requires less time during caries removal. There is a chemical bond between the tooth and the glass ionomer adhesive material. So, there is no need for cutting sound tooth structure for retention of the restoration.
45812348|NCT02525575|Behavioral|Project Life Force Group Treatment|"PLF, a 12-session, group psychotherapy intervention, combines Dialectical Behavioral Therapy (DBT) skill based and psychoeducational approaches, to enhance suicide safety planning development and implementation. Veterans revise their plans over several weeks while learning distress tolerance, emotion regulation, and friendship building/interpersonal skills to incorporate into their safety plans and also receive lessons on gun safety and minimizing access to lethal means. Sessions are augmented with 1) training in the use of a suicide safety planning mobile App to promote accessibility and maximize implementation, and 2) didactic information to bolster recovery, including fostering improved connection with the treatment team, and Veteran's family. Importantly, the group format mitigates loneliness and fosters increased belongingness, both key risk factors for suicide."
45812349|NCT02525653|Drug|albumin-bound paclitaxel|
45812350|NCT02525653|Drug|gemcitabine|
45812351|NCT02431754|Drug|Tadalafil|Administered orally
45812352|NCT02431754|Drug|Placebo|Administered orally
45659312|NCT05529433|Procedure|Smart Burs|Smart Bur is a polymer bur which removes only soft infected dentin as the cutting edges become dull in contact with the hard affected dentin.Caries removal will be done by Smart Bur mounted on a low speed hand-piece leaving the affected dentin intact. It requires less time for caries removal.
45812353|NCT02431754|Drug|Alpha1 Blocker|Administered orally
45812354|NCT02499692|Device|SYNERGYTM Coronary Stent System|SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System
45812355|NCT02526277|Device|MMF07 Foot Massager|
45812356|NCT02526277|Device|Heat Therapy|
45812357|NCT02500628|Drug|Metformin|500 mg orally after baseline testing of heart rate
45950016|NCT00451087|Procedure|leg press training|quadriceps muscle strengthening. 30min/ 3times/ week
45950017|NCT00451087|Procedure|isokinetic training|quadriceps muscle training. 30 min/ 3 times/ week
45812358|NCT02526667|Drug|Chlorhexidine gluconate|2% CHG solution on cloth
45812359|NCT02526667|Drug|DynaHex-2|2% CHG solution
45950018|NCT05535426|Device|Tetranite Implant Stabilization Material|Dental adhesive for increased implant stabilization
45950019|NCT00457834|Device|InSync III|Bi-ventricular pacing from leads in LV+RVA or LV+RVOT
45950020|NCT00115310|Drug|NGX-4010|
45950021|NCT00457990|Drug|Oral administration of ferrous sulphate|
45950022|NCT00458029|Behavioral|integrated program of nutrition, activity, behavior, and promotion|implemented across 5 half-year periods: winter/spring 2007, fall 2007, winter/spring 2007, fall 2008, winter/spring 2008
45453655|NCT04839211|Device|Sham inspiratory muscle training|Sham inspiratory muscle training will be performed three sessions per week as one supervised and two unsupervised for 8 weeks using an inspiratory muscle training device (PowerBreath). The inspiratory muscle training session will consist of 7 cycles including a 2:1 ratio of work and rest interval. Resistance will be adjusted to the unloaded.
45950023|NCT00115388|Procedure|Screening for chlamydia using self-taken vaginal swabs|Women in the intervention group will be tested for chlamydia and those found to be infected will be referred for treatment and partner notification
45950024|NCT00458068|Drug|Oral administration of ferrous sulphate|
45950025|NCT00115908|Drug|Albuferon|
46076785|NCT04017715|Other|Experimental: cool down|"Phase 1 is dynamic stretching and running exercises which includes, A jogging ,B walking lunge and sweeps, C hip in and out running : jog 3 steps stop and do hip in/hip out for Phase 2 is strength and agility which includes A- squat, B- push-ups: wide palmer push-ups. C vertical jumps. D- lateral jump. E- nordic hamstrings,. F (a)- shoulder external rotations, F(b)- modified inverted rows, Phase 3 is balance and core strength which includes A- modified ankle discs, B - planks: standard forward planks 2 repetitions for 30secs. C- side planks: standard side planks on both sides 1 repetition for 20 secs. Da- bird-dog,Db- modified back extensions, Phase 4 is run sprint which includes A- run sprint: 100% speed running between running (20m) with 1 repetition"
45659313|NCT05529433|Procedure|Chemo-Mechanical Caries Removal (CMCR)|Selecti-Solve gel is a dental gel which main active ingredient is Papain enzyme which selectively removes the caries without pain and has bacteriostatic, bactericidal and anti-inflammatory properties. The use of CMCR is recommended as an alternative treatment technique in anxious patients. The gel will be applied with a blunt spoon instrument and distributed well into the cavity according to manufacturer's instructions.
45812360|NCT02526667|Other|Vehicle|Excipients of CHG product only
45812361|NCT02535806|Drug|Velcade|4 doses of study drug will be given.
46076786|NCT04017715|Other|No intervention: control|sprint exercise and general stretching as conventional protocol as follows in star club
46076787|NCT02768610|Drug|Dexmedetomidine|
46076788|NCT02768610|Drug|Normal Saline|
46076789|NCT02605629|Other|CG428|The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
46076790|NCT02605629|Other|Placebo|The placebo group will received placebo which excluded active ingredients. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
46076791|NCT02764710|Drug|Amoxicillin-Potassium Clavulanate Combination|"Short course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily for a total of 2 doses.~Long course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily up until and including postoperative day 7."
46076792|NCT00887744|Device|Aperius® Percutaneous Interspinous Spacer|Implantation of the Aperius® device
45453656|NCT01106131|Drug|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with metformin.
45453657|NCT01106131|Drug|Pioglitazone 15mg|Pioglitazone 15mg, orally, 1 tablet or 2 tablet(if confirmed case) once a day for 24weeks with metformin.
45659314|NCT05533255|Other|Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative)|Composite resin at room temperature is used.
45812362|NCT02535806|Drug|Methotrexate|Intrathecal dose For CNS negative patients, Day 1 and Day 8
45812363|NCT02535806|Drug|Methotrexate / Hydrocortisone / Cytarabine|Intrathecal dose for CNS positive patients, Day 1, 8, 15, 22
45812364|NCT02535806|Drug|Dexamethasone|Days 1-5 and 15-19
46076793|NCT00923169|Drug|Anti-Transforming Growth Factor-beta (GC 1008)|
45659315|NCT05533255|Other|Preheated composite resin (3M™ Filtek™ Z350 XT Universal Restorative)|Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative) is preheated to a temperature of 57 degrees Celsius using a composite warmer for 10 minutes is used.
45812365|NCT02535806|Drug|Mitoxantrone|Days 1 and 2
45812366|NCT02535806|Drug|Vincristine|Days 1, 8, 15, 22
45812367|NCT02535806|Drug|Pegaspargase|Days 3 and 17
46076794|NCT02541019|Drug|Ondansetron|4 mg IV, one minute before the anesthesia induction and 4 mg IV three times a day during two days after the surgery.
46076795|NCT02541019|Drug|Palonosetron|75 mcg IV, one minute before the anesthesia induction.
46076796|NCT02832440|Other|Exercise programmes|
46076797|NCT02540941|Other|non|
45453658|NCT00612664|Drug|Anti-CD137 (4-1BB) (BMS-663513)|IV solution, IV, until PD or toxicity
45453659|NCT04743973|Device|Muse S™ Headband system|Brain sensing headband that measures brain activity by detecting electrical impulses created by the brain.
45453660|NCT00612118|Drug|GSK256066|200mcg bd
45453661|NCT00612118|Drug|azelastine hydrochloride|140mcg
45453662|NCT01328197|Device|Treovance Abdominal Aortic Stent-Graft with Navitel Delivery System|Stent-graft implant
45812368|NCT02865343|Device|Non-invasive Ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
45812369|NCT02865343|Device|Sham Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
45812370|NCT02536040|Drug|38% diammine silver fluoride|treatment of cavity with study agent
45812371|NCT02536040|Other|Water|Fluoride free, distilled water
45812372|NCT02536196|Device|Embolic Protection Device|Embolic protection
45950026|NCT00115908|Drug|Ribavirin|
45950027|NCT00115908|Drug|PEG-IFNalfa2a|
45950028|NCT00458107|Drug|SCA-136|
45950029|NCT00458146|Drug|MM-093|60mg MM-093/week as a subcutaneous injection for 3 months
46076798|NCT05297253|Device|telescopic overdenture|fixed implant retained prostheses
46076799|NCT04676880|Device|Left atrial appendage occlusion (Watchman FLX or Amplatzer Amulet)|Currently, there are two devices available on the Dutch market, Watchman and Amulet. After randomization to the intervention arm, additional randomization for type of device will follow. If the amount of procedures is too small to implant two devices, the centre will implant a device of choice.
45812373|NCT02536196|Procedure|Transcatheter aortic valve implantation (TAVI)|Transcatheter aortic valve implantation (TAVI)
45812374|NCT02461771|Drug|Pegcetacoplan|On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.
46076800|NCT02832362|Drug|Carbomer 980|Test product containing 0.5% carbomer 980 gel
45659316|NCT03419689|Procedure|Tumour tissue collection|"Tumour tissue will be taken from samples already removed from surgery or biopsy or by new tumour biopsies:~At the time of diagnosis or progression~Any surgical procedures for management of tumour related medical conditions~At each subsequent relapse or disease progression"
45659317|NCT03419689|Procedure|Blood sample collection|"Blood samples will be taken:~At the time of first diagnosis~About 1 week after starting any treatment~At each radiological response assessment~At each subsequent relapse or disease progression"
45659318|NCT03419689|Procedure|Ascites Collection|"Ascites will be collected if paracentesis is required during any of the following time points:~At the time of diagnosis or progression~Any surgical procedures for management of tumour related medical conditions~At each subsequent relapse or disease progression"
46076801|NCT02832362|Other|Placebo|Reference product containing vehicle without 0.5% carbomer 980 gel
46076802|NCT00893581|Drug|Quetiapine & Placebo|Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
46076803|NCT00893581|Drug|Lithium and Placebo|Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
45659319|NCT03419689|Procedure|Fluid Collection|Additional fluid will be collected at any time a procedure for clinical management that involves the drainage of fluid (i.e. thoracentesis, or drainage of cystic lesion) is required.
45659320|NCT05529355|Drug|Envafolimab plus Endostar and S-1|Immunotherapy combined with chemotherapy and anti VEGFR therapy
45659321|NCT05529355|Drug|Envafolimab plus Endostar|Immunotherapy combined with anti VEGFR therapy
45453663|NCT00743002|Drug|TT223 with Metformin and/or TZD|Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks
45659322|NCT05529355|Drug|Envafolimab plus S-1|Immunotherapy combined with chemotherapy
45659323|NCT05533099|Other|Observational study|Observational study of a device implanted in a previous clinical study
45659324|NCT05533021|Other|Training and Consultancy|In order to facilitate the transition to motherhood, theory-based training and counseling was provided to primiparous mothers on self and infant care.
45659325|NCT03310879|Drug|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
45659326|NCT03244033|Other|Contextual clinical decision support|Incorporation of contextual data into EHR clinical decision support alerts
45812375|NCT02463487|Device|Cardinal Pro +Simultaneous Irrigation (NPWTi)|NPWT with low volume irrigation (15 cc/hr) with 1% polyhexanide biguanide (PHMB), Prontosan®
45812376|NCT02463487|Device|Cardinal Pro (NPWT) Therapy|NPWT 125 mm Hg continuous pressure with foam interface
45812377|NCT02815345|Device|Rhinometry|An acoustic rhinometry device will be used to evaluate the area and the volume of the nasal cavities. Both nasal cavities will be measured except for patients with nasogastric tube.
45812378|NCT04341649|Other|Manual Head Massage|Duration 10 minutes.
45812379|NCT04341649|Device|BREO Helmet Massager|Duration 10 minutes.
45812380|NCT04341649|Device|Low Laser Therapy (LLT)|Duration 7 minutes.
45812381|NCT04341649|Device|Sham LLT|Duration 7 minutes.
45812382|NCT04341649|Device|TENS ear stimulation|Duration 7 minutes.
45950030|NCT04728152|Other|Blood and salivar test|"Saliva samples will be taken (concomitant with a visit carried out as part of routine care):~At the pre-therapy visit (t3),~At the post-treatment visit (at 3-6 weeks).~Blood samples will be taken at two stages (concomitant with a blood test performed as part of routine care):~At the pre-therapy visit (t3),~At the post-treatment visit (at 3-6 weeks)."
45950031|NCT00458185|Drug|etanercept|
45950032|NCT00458224|Behavioral|parental counseling|Group-based family oriented program involving pediatricians, physiotherapists, dieticians, psychologists and nurses with special training
45812383|NCT04341649|Behavioral|Deep and Slow breathing|A full respiratory cycle of 10 seconds with 5 seconds for inspiration and 5 seconds for expiration.
45659327|NCT03244033|Behavioral|Contextual survey|Patients complete a survey asking about red flags that could signal contextual factors relevant to their care
45659328|NCT05528887|Biological|Autologous CAR-T cells|D0: CAR-T cells will be infused intravenously.
45812384|NCT04341649|Behavioral|Relaxed Reading time|Duration 10 minutes.
45812385|NCT02463799|Drug|Radium-223|6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223
45812386|NCT02463799|Biological|Sipuleucel-T|3 infusions of sipuleucel-T alone
45950033|NCT03274063|Other|Supported self-management|Participants will be supplied with urate self-testing kits. Participants will have a mobile phone application installed which will prompt the participant to perform urate self-testing, enable the clinical research team to advise on escalation of urate lowering therapy, and collect quality of life data .
45950034|NCT03274063|Other|Usual care|Participants will have a mobile phone application installed which will allow the research team to collect quality of life data.
45950035|NCT05528328|Device|CACIPLIQ20®|CACIPLIQ20®
45950036|NCT05528328|Drug|Placebo (saline solution)|Placebo (saline solution) administered in identic al vials
45950037|NCT00115427|Drug|Liatermin (r-metHuGDNF)|
45453664|NCT00743002|Drug|Placebo with Metformin and/or TZD|Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks
45659329|NCT05528887|Drug|Fludarabine|D-5 to D-3: Fludarabine (30 mg/m^2/day) will be administered intravenously for 3 days.
45453665|NCT03944863|Drug|Antibiotics|
45453666|NCT00741442|Drug|RDEA806|Uricosuric agent for the treatment of gout
45453667|NCT00741442|Drug|Placebo|Matching Placebo.
45453668|NCT01102699|Drug|Filgrastim, hrG-CSF|Single subcutaneous injection of Filgrastim (hrG-CSF) 300 microg (30 MU)
45659330|NCT05528887|Drug|Cyclophosphamide|D-5 to D-3: Cyclophosphamide (500 mg/m^2/day) will be administered intravenously for 3 days.
45659331|NCT05501821|Drug|KBA1412|Part A, B, C
45659332|NCT05501821|Drug|Pembrolizumab|Part C only
45659333|NCT05528653|Drug|Descovy|HIV infection pre-exposure prophylaxis
45659334|NCT03016975|Device|Edwards Cardioband System|Transcatheter mitral valve repair with the Edwards Cardioband System
45659335|NCT03016975|Drug|Guideline Directed Medical Therapy|GDMT Only
45659336|NCT05532787|Other|Application of acute chest pain risk stratification scores (HEART and EDACS)|Collection of data elements for the HEART Pathway and EDACS-ADP assessments and calculation of scores to risk stratify patients into low risk or high risk
45812387|NCT02537444|Drug|Acalabrutinib|
45812388|NCT02537444|Drug|acalabrutinib and pembrolizumab combination|
45812389|NCT02464033|Drug|GAD-Alum|Recombinant Human Glutamic Acid Decarboxylase (rhGAD65)
45812390|NCT02464033|Drug|Vitamin D|
45812391|NCT02464033|Drug|Etanercept|
45812392|NCT02432300|Behavioral|Emotion Builder|Total of 8 therapy sessions with the Emotion Builder over approximately four (4) weeks (2 sessions a week)
45812393|NCT02432456|Drug|Ketamine|All individuals randomized to the experimental arm of the trial will receive early ketamine therapy (within 6 hours of admission) at a rate of 0.15 mg/kg/hr dosed based on ideal body weight. Individuals in the control arm will receive our standard of care for thoracic trauma patients, however, they will receive an additional placebo infusion of normal saline.
45812394|NCT02432456|Drug|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
45950038|NCT00458263|Drug|Somatotropin growth hormone recombinant human|daily Sub Cutaneous injections
45950039|NCT00458380|Procedure|Controlled ovarian stimulation, perifollicular vascularity assessment, IVF, embryo transfer.|
45950040|NCT04728126|Other|Survey|"The questionnaire will include socio-demographic information (i.e., gender, age, job seniority) and sub-scales for measuring study variables (i.e., menopausal symptoms, social and personal resources, burnout, and work ability).~Menopausal symptoms will be assessed using the Menopause-Specific Quality of Life questionnaire.~Job burnout will be measured through OBI inventory, which consists of 16 items describing the states of emotional exhaustion and detachment - two core dimension of burnout, and were developed to meet different occupational groups.~The menopause and the quality of working environment will be assessed using the Questionnaire developed by National Health Service in England and Wales."
45950041|NCT00458419|Drug|naloxone versus placebo|10 mg of naloxone administered IV or normal saline administered IV in randomized order at different visits
45950042|NCT00458419|Drug|intravenous injection of normal saline or naloxone|Arm A: 10 mg of naloxone given IV in 25 ml of normal saline Arm B: 25 ml of normal saline
46076804|NCT00893581|Other|Healthy Controls|Healthy control (patients given placebo -- sugar pill intended to mimic drug)
45950043|NCT00115466|Procedure|Non-surgical autologous implant of ASCs|
46076805|NCT04114305|Behavioral|ECD Intervention|"Modeled on the Early Learning Resource Unit's Family & Community Motivator home visiting program and Philani Mentor Mothers home visiting program in South Africa. Program provided stimulation in 5 domains: cognitive, receptive and expressive language, gross and fine motor skills, also covered topics in maternal and child health, nutrition and social services.~Comprised primarily of home visits beginning during pregnancy and continuing until the child was 18 months. ECD MM taught the parent/caregiver about ages and stages of growth, helped facilitate responsive parenting and early learning opportunities for their children, demonstrated use of toys and books to stimulate the child, provided families with picture books, and taught caregivers to create toys and books for their child. Community parenting information play groups and educational talks on ECD at the clinic supplemented home visits."
45812395|NCT02432456|Procedure|Intercostal Nerve Block|All individuals enrolled into the trial will undergo an Intercostal Nerve Blockade as a part of the institutional standard of care for rib fractures. This procedure will be performed according to current standard protocols in the Emergency Department or on admission.
45812396|NCT02432456|Drug|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance < 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
45812397|NCT02432456|Drug|Ibuprofen|All patients will be placed on scheduled Ibuprofen or an equivalent NSAID at dosage of 600mg every 6 hours. Patients must have a Glomerular Filtration Rate > 60 ml/min with no contraindications to NSAID therapy (e.g. Aspirin use, allergy/sensitivity, concurrent ACE inhibitor use, other nephrotoxins, etc)
45950044|NCT00458458|Drug|Norethindrone Acetate (NA)|52 weeks of treatment with Norethindrone Acetate
45950045|NCT00458458|Drug|GnRH Agonist (Lupron Depot)|24 weeks of treatment with Lupron Depot then 28 weeks of treatment with Norethindrone Acetate
45950046|NCT00458497|Device|Holofiber fabric|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.
46076806|NCT04114383|Other|D3-Creatine|30mg D3-Creatine to measure muscle mass
45812398|NCT02432456|Drug|Pantoprazole|All individuals on scheduled Non-Steroidal Anti-Inflammatory Drug (NSAID) therapy will receive scheduled pantoprazole at 40mg daily. Individuals unable to take medications orally will be placed on intravenous therapy. Individuals with previous reaction or intolerance to pantoprazole will be placed on an equivalent proton pump inhibitor.
45950047|NCT00458497|Device|PET fabric|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET)fabric.
45950048|NCT00458575|Drug|CNTO 2476|Participant 1 will receive 5.6x100000; Participants 2, 3, 5, 6, and 7 will receive 6.0x10000; Participant 4 will receive 3.0x100000; and Participants 8 and 9 will receive 1.2x100000 of CNTO 2476 as a single dose of viable cells in phosphate buffered saline (PBS) in a total volume of 100 μL injected subretinally.
45812399|NCT02432456|Drug|Methocarbamol|All individuals enrolled in the trial will be placed on scheduled methocarbamol 500 mg orally every 6 hours while admitted. Individuals with previous intolerance to methocarbamol will be placed on a pharmacy directed equivalent.
46076807|NCT04114383|Other|Deuterium Oxide|D2O provided to measure muscle protein synthesis
46076808|NCT04114383|Other|D3-3-methylhistidine|D3-3-methylhistidine is provided to measure muscle protein breakdown
45812400|NCT02432456|Drug|Opioid|"All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending trauma faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment."
45950049|NCT05525637|Drug|YZJ-1139 20mg|YZJ-1139 20mg tablets, once daily in the evening
45950050|NCT05525637|Drug|YZJ-1139 40mg|YZJ-1139 40mg tablets, once daily in the evening
45659337|NCT05345899|Diagnostic Test|Evaluation of vitamin C level in plasma|A protocol-specific blood test wil assess the vitamin C level in plasma
46076809|NCT04672434|Drug|Sym021|Sym021 is a humanized anti-PD-1 antibody.
45453669|NCT04212052|Radiation|split-course radiotherapy|Patients are irradiation at a palliative dose at the initial course: 30Gy/6f to PTV-GTV. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is repositioned and scanned. The residual tumor was then treated with the second course of radiotherapy. A dose of 40Gy/8f is delivered to the residue tumor.
45659338|NCT05345899|Other|Evaluation of quality of life|Several questionnaire will be completed by patients to evaluate quality of life: Analog and visual scale (EVA) pain, Neuropathic pain (DN) 4 questionnaire, EVA fatigue, Short Form (SF) 12 questionnaire and Hospital Anxiety and Depression scale (HAD questionnaire)
45812401|NCT02531971|Drug|Intravenous fentanyl citrate|100 micrograms (2 millilitres) via intravenous injection
45812402|NCT02531971|Drug|Duragesic®|TDDS dosage is 25 micrograms/hour (worn for 72 h)
45950051|NCT05525637|Drug|Placebo|Match placebo tablets, once daily in the evening
46076810|NCT04672434|Drug|Sym024|Sym024 is an anti-CD73 antibody.
46076811|NCT00951509|Other|Power Mobility Road Test (PMRT)|All subjects will underwent the Power Mobility Road Test (PMRT), and the clinicians scored the driving performance within each condition.
45453670|NCT04212052|Drug|concurrent chemotherapy|Concurrent chemotherapy consists of weekly nab-paclitaxel(50mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration, or nab-paclitaxel(30mg/㎡) and nedaplatin(10mg/㎡) twice every week.
45659339|NCT03009019|Drug|DFN-15 Active|
45659340|NCT03009019|Other|DFN-15 Placebo|
45659341|NCT04425343|Genetic|16s RNA Metagenomics sequencing|The subgingival plaque was collected using a sterile curette from the buccal aspect of maxillary molars and lingual aspect of mandibular incisors, in a vial containing 200µl of Buffer CL.
45659342|NCT05340751|Diagnostic Test|Blood drawn|Hemoglobin and Hematocrit Levels
45659343|NCT02575807|Biological|CRS-207|via IV infusion
45659344|NCT02575807|Drug|Epacadostat|PO BID
45659345|NCT02575807|Biological|Pembrolizumab|via IV infusion
45812403|NCT02531971|Drug|Mylan generic fentanyl|TDDS dosage is 25 micrograms/hour (worn for 72 h)
45812404|NCT02464657|Drug|Nivolumab|"Phase I Starting Dose of Nivolumab: 1 mg/kg by vein on Day 24 of a 28 day cycle.~Phase II Starting Dose of Nivolumab: Maximum tolerated dose from Phase I."
45950052|NCT00115505|Other|quality-of-life assessment|Complete Subjective Significance Questionnaire, MOS Social Support Survey, Patient Preferences, CALGB Background Information, and EQ-5D and QOL Assessment Form, EORTC QLQ-C30 and EORTC QLQ-BR23
45950053|NCT00115505|Other|Questionnaire Administration|Complete the Employment and Informal Care Cost Assessment and Peripheral Neuropathy Assessments
45950054|NCT00458614|Drug|Lansoprazole|
45950055|NCT00458731|Biological|bevacizumab|Given IV
45950056|NCT00458731|Drug|cediranib maleate|Given orally
45950057|NCT03274024|Device|Ahmed Glaucoma Implant|Conjunctival Flap Scleral Exposure Insertion of Episcleral Plate Priming of the tube prior to AC entrance Insertion of Tube into the Anterior Chamber Suturing tube Coverage of tube
46076812|NCT04224168|Dietary Supplement|Green Beans|Please see arm group Green beans for description
46076813|NCT04224168|Dietary Supplement|Liquid Pectin|Please see arm group liquid pectin for description
46076814|NCT04114461|Drug|HL-TOF tab. 5mg|HL-TOF
46076815|NCT04114461|Drug|Xeljanz tab. 5mg|Xeljanz
46076816|NCT02768454|Drug|medical review of controlled broad-spectrum antibiotics|medical review of outcome of antibiotics stewardship by pharmacists and infectious disease physicians
46076817|NCT05659719|Other|Recifercept|Patients received recifercept intervention in the phase 2 clinical trial
45659346|NCT04302727|Behavioral|Med-South Weight Loss Intervention|Phase I is a 4-month lifestyle program focused on the basics of healthy eating. Phase II (8 months) focuses on weight loss, followed by a year-long (Phase III) focused on weight loss maintenance. In Phase I, the main counseling sessions happen at monthly visits, with added check-in phone calls. In Phase II, the main counseling sessions will occur weekly for 6-8 weeks. There are also check-in phone calls - number based on weight loss progress. During Phase III, there are 2 main visits and follow-up phone calls. Counseling visits will be in-person with a health counselor and by phone. Of the 14 core counseling sessions, the in-person format will be required for only 4 (the 1st session of each Phase and after 2 months of the weight loss program). The program also includes brief phone calls to check on progress towards goals for lifestyle change. The number of phone calls will depend on success in meeting personal weight loss goals in Phase II or keeping the weight off in Phase III.
45659347|NCT04302727|Behavioral|WW|If participants are randomized to WW™, they will have access to both the workshop and digital components of the WW™ program for 2 years. The workshop component includes the option of attending weekly group meeting at a WW™ studio (local WW™ office). The digital component can be accessed using the WW™ website or the smart phone App. The study research staff will provide basic instructions on how to use the WW™ digital resources.
45812405|NCT02464657|Drug|Idarubicin|Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.
45950058|NCT03274024|Procedure|Trabeculectomy with Mitomycin C|Conjunctival Flap Mitomycin C Application Scleral Flap Paracentesis Excision of Limbal Tissue Peripheral Iridectomy Scleral Flap Closure Conjunctival Flap Closure
45812406|NCT02464657|Drug|Cytarabine|Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.
45812407|NCT02464657|Drug|Solu-medrol|Phase I and Phase II dose of Solu-medrol 50 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
45812408|NCT02464657|Drug|Dexamethasone|Phase I and Phase II dose of Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
45812409|NCT02533063|Device|VibeTech One|"Vibration Training The VibeTech One Rehab Chair allows vibration exercise while seated. A force is applied on a footplate that simulates the weight of standing or partial bodyweight. The participants will train for 10 minutes 3 days per week. In the loading + vibration group (intervention group) vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g."
45950059|NCT03273985|Other|Dry needling|Trigger point deep dry needling
45812410|NCT02467075|Drug|Iopamidol 300 (Contrast)|Patients will be randomized to receive IV iopamidol 300 (1.25 mL/kg, max 125 mL) with their CT scan
45950060|NCT03273985|Other|Ischemic compression|Trigger point ischemic compression
45950061|NCT00458770|Procedure|position emission transaxial tomography|cerebral position emission transaxial tomography using 18Fluorodeoxyglucose
45950062|NCT00115947|Drug|Terlipressin|
46076818|NCT02854085|Behavioral|Art Therapy|The Art Therapy will consist of creating art pieces, narrating thoughts and inner experiences in relation to the pieces produced (2 sessions a month) and guided visits to the art gallery (one session a month) and art museum (one session a month); there will be 12 sessions weekly for 12 weeks. For the next 6 months, sessions will be fortnightly and consist of creating an art piece once a month alternating with a visit to either the art museum or gallery, once a month; there will be 12 sessions in 6 months. Each session will last 45 minutes and will begin with 5 minutes of mindful relaxation to help participants focus on the task ahead.
46076819|NCT02854085|Behavioral|Music Reminiscence Activity|Music Reminiscence activity will be held weekly for 12 weeks and fortnightly for 6 months. Each session will last 45 minutes and will begin with 5 minutes of mindful relaxation to help participants focus on the task ahead. Session will entail listening and watching music videos and discussing activities, events and experiences related to the music; additional prompts such as photographs may be used to facilitate therapy.
46076820|NCT02768376|Drug|Bupivacaine with Fentanyl (Spinal Anesthesia)|Intrathecal injection of 15 mg Bupivacaine 0.5% at L 2-3 level mixed with 20 µ Fentanyl. Patients head will be lowered till sensory level of T 6 is abstained.
46076821|NCT02768376|Drug|General anesthesia|Induction by propofl 1.5-2 mg/kg, Fentanyl 1-2 mic/kg and atracrium 0.5 mg/kg Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..
46076822|NCT00610441|Drug|MK-8777|
46076823|NCT00610441|Drug|Placebo|
46076824|NCT04732806|Behavioral|Mightier video games|Biofeedback video game play in home
46076825|NCT02855723|Other|Surgery: GS strategy|sentinel node biopsy
46076826|NCT02855723|Other|Surgery: Classic strategy|systematic lymphadenectomy
46076827|NCT02854163|Drug|Secukinumab|All eligible patients registered into the study will receive four 150 - 300 mg subcutaneous injections at weekly intervals, followed by regular injections 150mg once a month thereafter for a total of 12 months
45950063|NCT00458809|Drug|oxaliplatin|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin
45950064|NCT00458887|Procedure|management of therapy complications|Undergo hearing tests
45950065|NCT00115544|Drug|Stanate|Intramuscular injection of stannsoporfin at 0.75 or 1.5mg/kg for treatment of severe hyperbilirubinemia to prevent exchange transfusion
45950066|NCT05522049|Device|hyperangulated videolaryngoscope|Intubation using a hyperangulated videolaryngoscope
45950067|NCT05522049|Device|Macintosh videolaryngoscope|Intubation using a Macintosh videolaryngoscope
46076828|NCT02696460|Procedure|N2O/O2 analgesia|Analgesia for ulcer debridement procedure is provided by the inhalation of N2O/O2 gas premix.
45950068|NCT00459004|Drug|rimonabant (SR141716)|
45950069|NCT03273868|Other|High velocity low amplitude manipulation|The researcher manually applies a preload force on the T5/T6 level followed by a single posterior to anterior thrust.
45950070|NCT03273868|Other|Sham manipulation|The researcher manually applies a preload force on the right scapula followed by a single lateral thrust.
45950071|NCT00459082|Drug|Dexmedetomine|
45950072|NCT00459160|Procedure|Intraoperative Hypotensive Resuscitation|Patients will have a target minimum MAP of 50 for the case
45950073|NCT00115583|Drug|Drug Infusion (BQ-123)|
45950074|NCT00115986|Biological|Influenza A/H5N1 Vaccine|
45659348|NCT05334589|Device|Prewarming|When patients in the study group come to the Preoperative Care Unit (PCU), their body temperature will be measured. Patients in the study group will be placed in such a way that the 3M™ Bair Hugger™ Whole Body Blanket covers the patient's body and prewarmed with the 3M™ Bair Hugger™ Warming Unit for 30 minutes before anesthesia is given in the PCU. Heating unit temperature will be adjusted to 43°C in line with company recommendations. After the patients in the study group are warmed up for 30 minutes, the preheating process will be completed and the whole body blanket will be taken and the blankets that the clinic routinely use for each patient will be covered to cover the patients' body.
45950075|NCT00459238|Other|counseling intervention|subjects will receive telephone based counseling
45950076|NCT00459238|Other|educational intervention|subjects will received telephone based education
45950077|NCT00459433|Procedure|Biopsychosocial intervention|Psychosocial versus usual care
45950078|NCT00459472|Behavioral|laparoscopic training curriculum|All general surgery interns and PGY-2-5's already participate in a surgery training curriculum that includes lectures, surgery, laparoscopic training, attending surgeons evaluating performance of residents at the end of surgical procedures, written tests, and skills tests.
46076829|NCT02696460|Procedure|Lidocaine/Prilocaine analgesia|Analgesia for ulcer debridement procedure is provided by topically administered lidocaine/prilocaine cream.
46076830|NCT02858453|Drug|AQX-1125 100 mg|Synthetic SHIP1 activator
46076831|NCT02858453|Drug|AQX-1125 200 mg|Synthetic SHIP1 activator
45659349|NCT05532553|Device|Carotid Doppler U/S|Measurement of carotid intima media thickness by carotid doppler ultrasound
45812411|NCT02467075|Drug|Placebo (Normal Saline)|Patients will be randomized to receive IV normal saline (1.25 mL/kg, max 125 mL) with their CT scan
45812412|NCT02533921|Other|Interdisciplinary outpatient palliative care|Interdisciplinary outpatient palliative care is an approach to caring for individuals with life-threatening illnesses that addresses potential causes of suffering including physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Palliative care approaches have been successfully applied to improve patient-centered outcomes in cancer as well as several chronic progressive illnesses including heart failure and pulmonary disease.
45812413|NCT02533921|Other|Standard of Care|Usual care defined as including both a PCP and neurologist
45812414|NCT02535481|Device|Epidermal grafting|The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts.
45812415|NCT02535481|Procedure|Split thickness skin grafting|Split thickness skin grafting will be performed as per normal clinical practice.
45812416|NCT00363961|Behavioral|Resistance exercise|resistance exercise vs sham comparison
45812417|NCT02535949|Drug|Tranexamic Acid|Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.
45950079|NCT00115622|Drug|fluticasone furoate|
45950080|NCT00459511|Procedure|Blood AM, IL-6, ACTH, Cortisol, Glucose and Insulin|
45950081|NCT05512221|Other|GBAT+I, GBAT+E - Phase I|Phase I is the development phase, which is informed by the study team's previous pilot study and autistic advisors. It will include the development of engagement booster materials. Booster materials will be tested in 2 groups (GBAT+I and GBAT+E) of six participants each. Groups include GBAT+Individual (GBAT+I; individual sessions to supplement the 10 group sessions) and GBAT+Engagement Booster (GBAT+E; supplemental materials). The first 4-6 eligible adults recruited will participate in GBAT+I and the second 6 eligible adults recruited will participate in GBAT+E. Both groups will consist of 10 weekly 60-90-minute GBAT group sessions. Participants in the GBAT+I group will also attend 30-minute individual booster sessions, approximately between Weeks 4-5, 5-6, 6-7, and 7-8. Participants in the GBAT+E group will be asked to use booster materials in between group sessions (e.g., worksheets, goal trackers, interactive learning activities).
46002661|NCT04637100|Other|Mobile or tablet-based gaming applications|Subject will use their own personal smartphone or tablet device to play from a collection of pre-selected gaming applications. The collection is made of puzzle-type games available on both Android and iOS without excessive ads and with clear or self-explanatory instructions. Subject will be instructed to play for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
46076832|NCT02858453|Drug|Placebo|Appearance and weight matched placebo tablets
46076833|NCT02696538|Other|Functional Gait Assessment|Balance assessment
46076834|NCT02696538|Other|mini-Balance Evaluation Systems Test|Balance assessment
45659350|NCT02813785|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
45812418|NCT02535949|Other|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
46076835|NCT02696538|Other|Berg Balance Scale|Balance assessment
46076836|NCT00888043|Drug|CNTO 95 and avastin|"STAGE 1 (Dose escalation) Cohort # subjects CNTO 95 Bevacizumab~2 3-6 2.5 mg/kg IV Q3 weeks 7.5 mg/kg IV Q3 weeks~1 3-6 2.5 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks~3-6 5 mg/kg IV Q3weeks 15 mg/kg IV Q3 weeks~3-6 10 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks STAGE 2 (Biomarker) Cohort # subjects CNTO 95 Bevacizumab~20 Recommended Phase II Dose Recommended Phase II Dose"
46076837|NCT02761356|Other|Tc99-MAA|To evaluate the fisibility of Tc99-MAA injected intra epatic artery to predict uptake of Yttrium-90 SIRT in patients with liver malignancies
45812419|NCT02536105|Drug|Methylphenidate HCl ER tablets 1|
45812420|NCT02536105|Drug|Placebo|
45812421|NCT02536105|Drug|Methylphenidate HCl ER tablets 2|
45812422|NCT02536105|Drug|Methylphenidate HCl ER for suspension|
46076838|NCT02696304|Other|Adipose tissu repartition|absorptiometry,
46076839|NCT02696304|Other|Visceral and liver adipose tissue repartition|MRI,spectroscopy,
46076840|NCT02696304|Other|Preadipocyte quantification and adipose tissue inflamation|biopsy
46076841|NCT02696304|Other|Inflamation blood markers quantification|blood drawn,
46076842|NCT02855801|Other|constant exercise|
46076843|NCT02855801|Other|cryotherapy|
46076844|NCT02855801|Other|intermittent exercise|
46076845|NCT02768220|Drug|empagliflozin|Test to see how 30 days of jardiance changes serum and urinary advanced glycation end product levels
45950082|NCT05512221|Other|Watchful Waiting and Groups - Phase 2|"Phase 2a will include a watchful waiting (WW) condition and assignment to 1 of 2 treatment conditions: GBAT+I or GBAT+E.~Participants will be assigned to WW for 10 wks. They will not receive specific therapeutic services during WW, but a member of the study team will contact them at weeks 1, 2, 4, 6, and 8 to maintain engagement and monitor for clinical deterioration.~After WW, participants will be randomly assigned to one of the treatment conditions (GBAT+I or GBAT+E). All groups will consist of 10 weekly 60-90-minute GBAT group sessions. GBAT+I participants will attend four 30-minute individual booster sessions. GBAT+E participants will be asked to use booster materials between group sessions (e.g., worksheets, goal trackers, interactive learning activities)~WW group size is based on study feasibility and availability of resources. Additional participants will also be recruited at the end of the WW period to supplement group sizes."
45659351|NCT02813785|Drug|Docetaxel|Docetaxel will be administered as 75 milligrams per square meter (mg/m^2) via IV infusion on Day 1 of each 21-day cycle.
45950083|NCT05512221|Other|GBAT+IE|"Phase 2b will include assignment to GBAT+IE, which includes components of both GBAT+I (individual sessions) and GBAT+E (supplemental materials)~All groups will consist of 10 weekly 60-90-minute GBAT group sessions. Participants in the GBAT+I group will also attend 30-minute individual booster sessions, approximately between Weeks 4-5, 5-6, 6-7, and 7-8. Participants in the GBAT+E group will be asked to use booster materials in between group sessions (e.g., worksheets, goal trackers, interactive learning activities). Participants in GBAT+IE will participate in both the individual sessions and use of booster materials."
45950084|NCT00459550|Drug|GSK933776|"Part A planned doses cohort 1 to cohort 3 0.001 mg/kg, 0.01 mg/kg and 0.1 mg/kg.~Part B planned doses cohort 4 to cohort 7 0.1 mg/kg, 1mg/kg, 3mg/kg and 10 mg/kg"
45659352|NCT04302181|Drug|Ropivacaine injection|6.5cc of Ropivacaine HCl 0.5%, one time into the stellate ganglion
45950085|NCT00459550|Drug|Placebo to match GSK933776|Part A first 2 cohorts 5 patients per cohort 2 placebo and 3 active third cohort part A 2 placebo 6 active. Part B 8 patients per cohort 2 placebo 6 active.
45659353|NCT05528341|Biological|NKG2D-CAR-NK92 cells|NKG2D-CAR-NK92 cells will be administered intravenously over 1h. The starting dose of NKG2D-CAR-NK92 cells will be 0.5×10^6-2×10^6/kg, twice a week. The first evaluation of the efficacy after 3 weeks of treatment.
45950086|NCT00459589|Behavioral|nutritional intervention with dietician plus usual nutritional care|nutritional intervention with dietician at each cycle of chemotherapy in 6 first cycles to maintain 30 kcal/kg/d and 1.2 protein/kg/d
45950087|NCT00459589|Behavioral|usual nutritional care|usual nutritional care
46076846|NCT02768220|Drug|linagliptin|Test to see how 30 days of tradjenta changes serum and urinary advanced glycation end product levels
46076847|NCT02853851|Other|interviews|Each subject will be asked to participate in an individual semidirective interview lasting about 40 minutes on the theme of the stress factors encountered in intensive care. All of the interviews will be audio-taped, transcribed and anonymized. The participants will also have to answer a socio-demographic questionnaire (sex, age, socio-professional category, speciality in intensive care, working hours, family situation, training, diplomas, length of time in the service).
45950088|NCT00115661|Drug|Rosiglitazone|
46076848|NCT02760888|Drug|Tramadol|Women will receive a oral Tramadol 100mg 1 hour before the procedure
46076849|NCT02760888|Drug|Diclofenac|Women will receive oral Diclofenac 100mg 1 hour before the procedure
46076850|NCT02760888|Drug|Placebo|Women will receive a Placebo 1 hour before the procedure
46076851|NCT00799617|Drug|AndroGel® (testosterone gel)|Testosterone levels will be measured at regular intervals in order to achieve a testosterone level in the desired range.
45659354|NCT05528185|Other|Direct participation of the family member in the daily rounds|When the team arrives at the participating family member's room, the family member will be invited by a member of the healthcare team to come out of the room. The rounding team and structure will be the same as the usual care group with the following exceptions: (1) the family member will be invited to participate in the rounds outside their relative's room; (2) the family member will be provided with an orientation to the medical team members; (3) the family member will be allowed to engage and participate throughout the rounds; (4) at the end of the rounds, the team will summarize the patient's daily care plan; (5) the family member will be prompted to ask questions.
45659355|NCT05532475|Diagnostic Test|measurement of vitreous level of tumor necrosis factor alpha|measurement of vitreous level of tumor necrosis factor alpha using ELISA technique
45659356|NCT05527951|Other|eMBC|The experimental group will implement eMBC with our WeChat Easy to Recover from Depression Mini-Program, which consists of mood tracking and lay-coached self-management.
45659357|NCT05527951|Other|standard MBC|The control intervention group will implement standard MBC using paper and pencil questionnaires.
46076852|NCT00799617|Drug|Placebo|Testosterone levels will be measured at regular intervals.
45659358|NCT05532397|Drug|QPOP category 1|combination regimens with published data in the setting of gliomas
45950089|NCT00459628|Radiation|Conventional radiotherapy|Radiation treatment delivered by conventional linear accelerator using matching fields
46076853|NCT02760732|Device|drug eluting balloon; cutting balloon|Patients eligible for inclusion criteria were randomised to study group for percutaneous transluminal coronary angioplasty with a strategy of cutting balloon pre-dilation first and then drug eluting balloon.
46076854|NCT02760732|Device|drug eluting stent|with a strategy of drug-eluting stent implantation alone for de novo coronary artery lesions.
45950090|NCT00459628|Radiation|Tomotherapy|CT image guided intensity modulated radiation therapy delivered by the Tomotherapy HiArt system
45950091|NCT04728321|Biological|AK104 lenvatinib|Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months
45812423|NCT02758951|Other|Perioperative systemic therapy|Neoadjuvant systemic therapy should start within four weeks after randomisation. Adjuvant systemic therapy should start within twelve weeks after CRS-HIPEC. In case of unacceptable toxicity or contraindications to oxaliplatin or irinotecan in the neoadjuvant setting, CAPOX or FOLFOX may be switched to FOLFIRI and vice versa. In case of unacceptable toxicity or contraindications to oxaliplatin in the adjuvant setting, CAPOX of FOLFOX may be switched to fluoropyrimidine monotherapy. Dose reduction, prohibited concomitant care, permitted concomitant care, and strategies to improve adherence are not specified a priori, but left to the discretion of the treating medical oncologist. Perioperative systemic therapy can be prematurely discontinued due to radiological or clinical disease progression, unacceptable toxicity, physicians decision, or at patients request.
45950092|NCT04728321|Biological|AK104|Subjects will receive AK104 until disease progression or for a maximum of 24 months
45950093|NCT00459784|Procedure|Dementia Training Program|
45950094|NCT00459823|Drug|E7107|E7107 administered by intravenous infusion (as a 2-5 minutes bolus) on days 1, 8 and 15 every 28 days.
45950095|NCT00459901|Drug|Erlotinib and capecitabine|
45950096|NCT00401804|Drug|Dexamethasone, Bortezomib, Doxorubicin|
46076855|NCT02855879|Other|Collection of biological data|
45659359|NCT05532397|Drug|QPOP category 2|combination regimens where there is published data on intracranial activity and anti-glioma effect of the individual agents either as monotherapy or in combination with other agents, and where there is published safety data on the combination
45659360|NCT02644369|Biological|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
45950097|NCT04728399|Dietary Supplement|Experimental group|Take 1 bag a day with warm boiling water. Intervention: 2g Soybean peptide, 3g CLA and ng protein. They will complete all baseline, 12-weeks, and 24-weeks visits
45950098|NCT04728399|Dietary Supplement|Control group|Take 1 bag a day with warm boiling water. Intervention: 2g+N protein and 3g Soybean oil. They will complete all baseline, 12-weeks, and 24-weeks visits
45950099|NCT00459940|Drug|Pioglitazone|
45950100|NCT00460018|Behavioral|Diet, Exercise, and Breastfeeding Intervention|"Phase I (Pregnancy Program from GDM diagnosis to delivery): One in-person session with the lifestyle coach, two phone calls with the lifestyle coach, and one in-person session with the lactation consultant~Phase II (Early Post-partum Period from delivery to 6 weeks post-partum): Two to four routine phone calls with the lactation consultant~Phase III (Late Post-partum Period 6 weeks to 7 months postpartum): Two in-person sessions with the lifestyle coach, up to 11 phone calls with the lifestyle coach, and two to three routine calls with the lactation consultant~Phase IV (Maintenance Phase 8 months to 1 year postpartum): One newsletter from the lifestyle coaches, two recipe letters and continue calls with the lifestyle coach (optional)"
45950101|NCT00460057|Drug|Alendronate|Take two tablets (alendronate 10 mg) once weekly with a full glass of plain water in the morning after an overnight fast and to refrain from lying down or taking any other beverage or food for at least 1 h thereafter
45950102|NCT00401921|Drug|Minocycline|100 mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
45950103|NCT00401921|Drug|Placebo oral capsule|1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
46076856|NCT02855879|Other|Collection of clinical data|
46076857|NCT02855957|Other|Free α-Hb pool analysis|
46076858|NCT02768142|Other|Natural cesarean delivery|Natural cesarean delivery
46076859|NCT02768142|Other|Standard cesarean delivery|Standard cesarean delivery
46076860|NCT00607087|Drug|Insulin glulisine|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
46076861|NCT00607087|Drug|Insulin lispro|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
46076862|NCT00607087|Drug|Insulin aspart|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
46076863|NCT02854007|Device|Coronary angioplasty with implant of bioresorbable device|Percutaneous coronary intervention
46076864|NCT02764242|Other|Skin prick test|Skin prick tests to local and imported insect sting allergen with different concentration are performed.
46076865|NCT02764242|Other|sIgE measurement|sIgE levels to stinging insect allergen and their recombinant venom allergen are measured
45812424|NCT02758951|Combination Product|Perioperative CAPOX-bevacizumab|Four three-weekly neoadjuvant and adjuvant cycles of CAPOX (130 mg/m2 body-surface area [BSA] of oxaliplatin, intravenously [IV] on day 1; 1000 mg/m2 BSA of capecitabine, orally twice daily on days 1-14), with bevacizumab (7.5 mg/kg body weight, IV on day 1) added to the first three neoadjuvant cycles.
45659361|NCT05527795|Other|Frequency and duration of response to adjuvant immunotherapy according to clinical features|"Frequency of relapse to adjuvant immunotherapy according to clinical features~Duration of relapse as defined by the time (days) between adjuvant immunotherapy onset and relapse date according to clinical features"
45812425|NCT02758951|Combination Product|Perioperative FOLFOX-bevacizumab|Six two-weekly neoadjuvant and adjuvant cycles of FOLFOX (85 mg/m2 body-surface area [BSA] of oxaliplatin, intravenously [IV] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2), with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
45812426|NCT02758951|Combination Product|Perioperative FOLFIRI-bevacizumab|Six two-weekly neoadjuvant cycles of FOLFIRI (180 mg/m2 body-surface area [BSA] of irinotecan, intravenously [IV] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) and either four three-weekly (capecitabine (1000 mg/m2 BSA, orally twice daily on days 1-14) or six two-weekly (400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) adjuvant cycles of fluoropyrimidine monotherapy, with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
45950104|NCT05505396|Other|Sampling of blood and cerebrospinal fluid|Blood HbA1c, insulin, C-peptide and IL-6 measured at admission. Glucose and lactate measured every 4 hours during intensive care stay. Daily sampling of CSV analysed for glucose and lactate in patients with EVD.
45950105|NCT00460096|Drug|Kamada-API|
45950106|NCT00460135|Behavioral|resistance training|2 times a week resistance training
45950107|NCT00460174|Biological|bevacizumab|10 mg/kg every 2 weeks as an intravenous infusion after gemcitabine and before radiation
45950108|NCT00460174|Drug|gemcitabine|1000 mg/m2, 30 minute intravenous infusion, cycle 1 (weeks 1, 2), cycle 2 (weeks 4, 5, 6) and cycle 3 (weeks 8 and 9). During cycle 2, gemcitabine will be delivered prior to radiation therapy
45950109|NCT00460174|Procedure|conventional surgery|If resectable, patients will undergo surgery no less than 6 weeks following last dose of bevacizumab. Unresectable patients will not undergo surgery.
45950110|NCT00460174|Radiation|radiation therapy|2.4 Gy fractions, 5 fractions/week during cycle 2 only (weeks 4, 5, 6). Total dose 36 Gy.
45950111|NCT00460213|Drug|Valsartan 80mg daily|
45950112|NCT00460213|Drug|Valsartan 160mg daily|
45950113|NCT00460252|Procedure|insulin titration applying a computer algorithm|
45950114|NCT00460291|Device|Implantation of the ProVena vein graft during bypass surgery|
45950115|NCT00115817|Drug|Atorvastatin|
45950116|NCT00460369|Drug|sulfadoxine-pyrimethamine|"tablets 1,25/25 mg~1 tablet per 20 kg of body weight Single drug intake"
45950117|NCT00460369|Drug|artemether-lumefantrine|"tablets 20/120 mg~1 tablet twice daily for 3 days below 15 kg of bodyweight~2 tablets twice daily for 3 days below 24 kg of bodyweight~3 tablets twice daily for 3 days below 35 kg of bodyweight"
45659362|NCT05527795|Other|Frequency of each type of relapse (i. e. local, distant, unique or multiple) to adjuvant therapy according to clinical features|Percentages of each type of relapse (i. e. local, distant, unique or multiple) according to clinical features
45950118|NCT00460369|Drug|amodiaquine-artesunate coformulation|"one 25mg/67,5mg tablet, once daily for 3 days below 9 kg~one 50/135mg tablet, once daily for 3 days below 18 kg"
45950119|NCT05502939|Behavioral|Music Program|"The cohort of students entering the program at the Colburn school in Los Angeles will be a part of a traditional strings curriculum. Students will join the program on a full scholarship and will be provided all materials necessary for instruction, including an instrument. Students will attend Colburn twice a week in a group setting and will receive private instruction once a week.~The program will last 2, 15-week semesters (fall, spring) for 2-years. There will be 2 groups of 10 students. Students will undergo group instruction for 1 hour, 2 times a week and private instruction for 45 minutes, once a week."
45950120|NCT05502939|Behavioral|After School Enrichment Program|The afterschool program will be led by instructors and will include visual arts, theater, and general cultural studies. Students attend the program 3 days per week in the afternoon for 1 hour long lessons. Students will take part in an end of the year celebration to share their work with family and community members.
45950121|NCT00460447|Drug|Gemtuzumab Ozogamicin|
45950122|NCT04697953|Drug|brolucizumab|Pre-filled Syringes for intravitreal injection
45950123|NCT00460642|Drug|GnRH Antagonist (Cetrotide)|
45950124|NCT00460681|Drug|Thymopentin|subcutaneously or intramuscular inject at the dosage of 10 mg every second day (twice a week) for consecutive 3 months.
45950125|NCT00460720|Other|Observational treatment compliance survey|Observational treatment compliance survey
45950126|NCT00460759|Drug|Moxifloxacin|
45453671|NCT04720339|Genetic|Molecular monitoring by quantification of cell-free DNA|"Molecular monitoring by quantification of cell-free DNA (absolute value and variation from baseline) of two house-keeping genes (RPP30, TMEM11) by droplet digital PCR, during based-immunotherapy treatments of NSCLC patients.~Cell-free DNA will be extracted from 4 ml of plasma before treatments by immunotherapy, obtained from blood Streck® tubes.~Quantification of house-keeping genes (or mutated genes if some are previously routinely identified in tumor tissue) by ddPCR."
45659363|NCT05527795|Other|Duration of relapse-free survival according to clinical features|Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and relapse date.
45950127|NCT00460759|Drug|Rifapentine|
45950128|NCT00460837|Drug|bowel preparation: senna & gastrofin versus picolax (standard)|The intervention is a bowel cleansing procedure
45950129|NCT00115856|Procedure|Intravascular MRI|Arterial imaging of atherosclerosis
45950130|NCT00460876|Drug|Topotecan|
45950131|NCT02956876|Drug|standard chemotherapy for colorectal cancer|standard chemotherapy for colorectal cancer
45950132|NCT02956876|Other|Nurse practitioner consultation|Nurse practitioner consultation will be done standard chemotherapy for colorectal cancer
45950133|NCT02956876|Other|Medical practitioner consultation|Medical practitioner consultation will be done standard chemotherapy for colorectal cancer.
46076866|NCT02760966|Other|Alcohol 70º|
45812427|NCT02758951|Procedure|CRS-HIPEC, experimental arm|CRS-HIPEC is performed according to the Dutch protocol in all study centres. The choice of HIPEC medication (oxaliplatin or mitomycin C) is left to the discretion of the treating physician, since neither one has a favourable safety or efficacy. CRS-HIPEC should be performed within six weeks after completion of neoadjuvant systemic therapy, and at least six weeks after the last administration of bevacizumab in order to minimise the risk of bevacizumab-related postoperative complications.
45453672|NCT00603616|Drug|Placebo Comparator|Matching oral placebo pills to be taken twice daily for a total of 8 weeks
45950134|NCT00460915|Drug|Lacidipine & Amlodipine|
45453673|NCT00603616|Drug|Rifaximin|Oral rifaximin 550mg to be taken twice daily for a total of 8 weeks
45659364|NCT05527795|Other|Duration of overall survival according to clinical features|Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and the date of death (irrespectively of the cause) 10 years after inclusion in the study. Alive or lost to follow-up patients will be censored at the date of the last follow-up visit.
45950135|NCT00460954|Drug|Sinemet® controlled release (Carbidopa/levodopa)|
45950136|NCT00115895|Drug|Radioactive iodine|Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq
46076867|NCT02760966|Other|Soap|
46076868|NCT05653635|Radiation|Simultaneous-integrated boost with IMRT|Simultaneous-integrated boost guided by FDOPA-PET
46076869|NCT02763930|Other|Control diet|
46076870|NCT02763930|Other|Milk diet|
45453674|NCT04704037|Other|Guideline implementation tool|Family physicians will receive a tailored letter with their patient's mental health screening test results and associated mental health treatment recommendations from the Ontario Neurotrauma Foundation guidelines, as well as a list of mental health treatment resources. In addition, the patient will receive a written information package about mental health problems after mTBI and treatment options to discuss with their family physician.
45659365|NCT05527795|Other|Overall response rate|Response rate to adjuvant immunotherapy and to treatment lines subsequent to relapse. Response rate to adjuvant immunotherapy is defined by the absence of relapse as assessed by the physician following the first year of adjuvant therapy. Response to treatment after relapse is defined as partial or complete response as assessed by the physician following the first year of adjuvant therapy.
45659366|NCT05527795|Other|Frequency of adverse events according to clinical features|Rate of adverse events according to their nature and grade (as defined by CTCAE V 5.0) and according to clinical features
45812428|NCT02758951|Procedure|CRS-HIPEC, control arm|CRS-HIPEC is performed according to the Dutch protocol in all study centres. The choice of HIPEC medication (oxaliplatin or mitomycin C) is left to the discretion of the treating physician, since neither one has a favourable safety or efficacy. CRS-HIPEC should be performed within six weeks after randomisation.
45812429|NCT02752165|Other|TEAM-ED|Facilitation of preventive asthma management through telemedicine assessment and follow-ups in addition to guideline-based provider prompting
45812430|NCT02752165|Other|Enhanced Usual Care|Report of symptoms to primary care physician
45812431|NCT02436668|Drug|Ibrutinib|
45812432|NCT02436668|Drug|Gemcitabine|
45812433|NCT02436668|Drug|Nab-paclitaxel|
45950137|NCT04728009|Dietary Supplement|Longan and lingzhi mushroom syrup|Fresh fruit pulps of longan were stewed in hot water until they softened. No sugar and additives were added. The pulps were removed by filtration in order to obtain concentrated longan juice. After that, spray-dried powder of lingzhi mushroom extract was dissolved in water in the ratio of 1:2. To make the finished product, 99 g of longan juice was mixed with 1 g of the lingzhi extract in water. The sugar content of the syrup was 77 degrees Brix.
45950138|NCT00461071|Behavioral|Guided Self-help for Bulimia nervosa|bibliotherapy
45950139|NCT00461110|Drug|BMS-663513|mg/kg, IV, 0.3, 1,3,6,10 mg/kg, q 3 wks, 12 weeks
46076871|NCT02763930|Other|GABA-rich cheese diet|
45812434|NCT02503982|Drug|prophylactic Valganciclovir|The common practice dose at Schneider Children's Medical Center dosing guidelines of valganciclovir is 17 mg/kg once daily for prophylaxis, with stratified dose reductions for impaired renal function. Max dose was 900 mg.
45812435|NCT02438540|Drug|metformin|metformin tablet 500 mg
45812436|NCT02438540|Other|acupuncture|Electro body acupuncture and auricular acupuncture
45950140|NCT00461149|Drug|Octreotide-LAR|
45950141|NCT00115973|Device|pump|
46076872|NCT00610363|Biological|Rilonacept|Rilonacept 320 mg loading dose on Day 1 followed by Rilonacept 160 mg/2 mL injections qw for 17 weeks.
46076873|NCT00610363|Other|Placebo (for Rilonacept)|Placebo loading dose on Day 1 followed by single placebo injections (2 mL) qw for 17 weeks.
46076874|NCT00887588|Drug|LCZ696|50 mg, 100 mg and 200 mg tablets
46076875|NCT00887588|Drug|Valsartan|40 mg, 80 mg and 160 mg tablets
46076876|NCT00887588|Drug|Placebo|matching placebo to LCZ696 and Valsartan
46076877|NCT04659096|Drug|ION537|ION537 will be administered by IV injection.
46076878|NCT00945893|Biological|MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]|0.5 mL; (intranasal sprayer)
46076879|NCT00945893|Other|Placebo|(intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer)
46076880|NCT00799383|Drug|Calcium and Vitamin D|Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
46076881|NCT00799383|Other|Placebo|
45812437|NCT02506634|Drug|Esomeprazole MUPS, 20 mg|According to the guidelines, the PPI treatment duration would be 8 weeks(Esomeprazole MUPS, 20 mg bid) for patients with reflux esophagitis and 4 weeks (Esomeprazole MUPS, 20 mg bid) for patients with normal findings on endoscopy.
45950142|NCT00115973|Drug|insulin aspart|
45950143|NCT05490264|Biological|[68Ga]Ga-NOTA-SNA002|[68Ga]Ga-NOTA-SNA002（PD-L1 PET Tracer）for Positron Emission Tomography
45950144|NCT00461266|Drug|enfuvirtide [Fuzeon]|90mg sc bid
45453675|NCT04704037|Other|Generic information about concussion management|Family physicians will receive a generic letter drawing their attention to Canadian clinical practice guidelines for mild Traumatic Brain Injury (developed by the Ontario Neurotrauma Foundation). Patients will receive instructions about how to access generic education materials about mTBI (from concussion.vch.ca/), which they should have received anyway as part of usual care.
45950145|NCT00461266|Drug|Antiretroviral therapy|As prescribed
46076882|NCT02763852|Drug|BIA 3-202|"The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods."
46076883|NCT02763852|Drug|Placebo|Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route.
46076884|NCT02763852|Drug|Madopar® 125|Levodopa 100 mg/benserazide 25 mg capsules (Madopar® 125, marketed by Roche products Limited); oral route.
46076885|NCT00893659|Dietary Supplement|wheat bread with beta-glucan|3 g beta-glucan in approximately 200 g of wheat bread per day for 3 months
46076886|NCT00893659|Dietary Supplement|wheat bread without beta-glucan|Approximately 200 g of wheat bread (without beta-glucan supplementation) per day for 3 months
45453676|NCT02280070|Other|Laboratory test|Leukocyte, neutrophil (ANC ：stab + seg), hemoglobin, platlet, albumin, total birrilubin, AST, ALT, LDH, Creatinine, Na, K, CRP, fast blood sugar
45453677|NCT02280070|Other|Medical history and physical examination|medical history and physical examination
45676475|NCT02901860|Other|Sleep, Dietary and Cardio-metabolic Measurements|"At home session: 2-weeks of wrist actigraphy and sleep diaries; a food diary for the three days preceding the lab session; 24-h period of ambulatory blood pressure on a non-work day for participant. Work schedules over a 4-week period will be collected and participants identified as traditional or non-traditional workers.~Subjects will begin the stay in the research unit in the evening and will remain for about 16-20 hr. Saliva samples will be taken every 30 min from admission until bedtime. Bedtime with polysomnography will be from 11:00pm to 7:00am. Questionnaires will be administered; height, weight and waist/hip circumference and bioimpedance measurement; standard 3-h oral glucose tolerance test and blood tests (CBC, electrolytes, renal, liver and thyroid function , hemoglobin A1c, SHBG levels). For individuals with diabetes only fasting blood samples will be taken."
45812438|NCT02506868|Drug|Darbepoetin alfa|Weekly sc administration of darbepoetin alfa
45812439|NCT02541422|Dietary Supplement|N Acetyl Cysteine|
45453678|NCT02280070|Other|BW and height|Body weight (kg) and height (cm)
45812440|NCT02541422|Other|placebo|
45812441|NCT02541812|Device|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
45812442|NCT02542046|Drug|Barium|Administration of barium oral contrast agent prior to CT scan
45812443|NCT02542046|Drug|Diatrizoate|Administration of diatrizoate oral contrast agent prior to CT scan
45812444|NCT02542046|Drug|Iohexol|Administration of iohexol oral contrast agent prior to CT scan
45950146|NCT04727658|Radiation|Radiosurgical thalamotomy on GammaKnife|fractional radiosurgical thalamotomy on an accelerator (3 sessions of 50 Gy at the isocenter )
45950147|NCT00116012|Drug|rNAPc2|
45950148|NCT00461344|Drug|Docetaxel|
45950149|NCT00461344|Drug|Doxorubicin|
45950150|NCT03273634|Drug|Lansoprazole Pill|once daily at night time
45950151|NCT03273634|Drug|Placebo|Placebo
45950152|NCT03273595|Drug|Lapatinib|
45950153|NCT03273595|Biological|Trastuzumab|
45950154|NCT03273595|Drug|Paclitaxel|
45950155|NCT03273595|Drug|Epirubicin|
45950156|NCT03273595|Drug|Cyclophosphamide|
45950157|NCT03273556|Device|Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.) with Lidocaine 0.3%|"The injective treatment was performed, during T0 visit after the basal evaluations, mono-laterally on nasolabial fold,(right or left face side in according to a previously defined randomisation list).~A quantity of Aliaxin® Ev (up to a maximum of 0.5 ml) with Lidocaine 0.3% was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect."
45950158|NCT03273556|Device|Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.)|"The injective treatment was performed on the contralateral nasolabial fold during T0 visit, after the basal evaluations .~A quantity of Aliaxin® Ev up to a maximum of 0.5 ml was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect."
45950159|NCT00116025|Drug|Human acylated ghrelin|
45950160|NCT04728308|Drug|Bupivacain|Before closing the skin incision,Infiltration of 20ml of 0.5% bupivacaine around incision site will be done in the patients of experimental group and 20 ml of distill water will be infiltrated in the pateints of the placebo group
45950161|NCT00461422|Drug|Ganirelix|sc injection of Ganirelix 0.25 mg per day
45950162|NCT00461461|Procedure|meeting nurses / physicians, quality improvement sessions|"For each iatrogenic indicator, the interventions are:~Meeting with the ICU staff to discuss the epidemiology of patients on each theme.~Pocket card with guidelines on the theme and ICU protocol in each study ICU.~Feedback meeting twice a month on errors in the unit, preventability, and appropriate changes in procedures on the subject."
46076887|NCT05278741|Procedure|Surgery for unilateral breast reconstruction|"Before the surgery, patient will be completed two questionnaire DASH and BREAST-Q. Two tests will be performed (isokinetic test and EMG).~After the surgery, at one month : 2 Questionnaires (DASH / BREAST-Q) will be performed At three months and six months : 2 questionnaires + two tests will be perfomed"
46076888|NCT02768064|Device|temporary pacemaker insertion|Insertion of pacemaker electrode (Medtronic flow direct pacing catheter), connect to external pacemaker (Medtronic).
45659367|NCT04128553|Behavioral|Intervention motivational interview group|"Motivational interviewing (MI) a client-centered, goal-oriented method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. Motivational interviewing is underpinned by a series of principles that emphasise a collaborative therapeutic relationship in which the autonomy of the patient is respected and the patient's intrinsic resources for change are elicited by the therapist.~In the present study, an effort was made to help the IG to realize the dilemmas of individuals in the precontemplation stage about exercising, and individuals in the contemplation stage to produce their own solutions. In this direction, techniques such as decision balance, importance, and trust technique were applied, thus enabling them to reveal their feelings, thoughts, and reactions regarding the benefits/harms of doing/not doing exercise. They were supported to raise awareness about the consequences and solutions of the causes."
45453679|NCT02280070|Other|Performance status|ECOG performance status, 0: Fully active, able to carry on all pre-disease performance without restriction, 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work, 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours, 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair, 5: Dead
45659368|NCT05527639|Behavioral|strength training program|12-weeks of strength training consisting of warm ups, dead-lifts, squats and cool down exercises
45812445|NCT02439164|Drug|Midazolam|specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used
45812446|NCT02542280|Procedure|endometrial injury.|Endometrial injury using a pipelle biopsy catheter on day (5, 6 or 7) of the stimulation cycle combined with the intrauterine insemination.
45812447|NCT02542280|Procedure|intrauterine insemination|Placement of washed sperm in the uterus using a catheter, around the time of ovulation.
45812448|NCT02542280|Drug|ovarian stimulation|Inducing ovulation by human menopausal gonadotrophin ampoules given intramuscular starting from cycle day two, till the leading follicle reaches 16 - 18 mm.
45812449|NCT02439710|Other|Quality of life measure (survey)|The QoL tool is a questionnaire
45812450|NCT04341272|Device|Intermittent Pneumatic Compression Device (FDA approved)|Compression Device placed on either upper or lower extremity for DVT prophylaxis following surgery
45812451|NCT02440022|Combination Product|Lutonix DCB|
45812452|NCT02440022|Device|Standard Balloon Angioplasty Catheter|
46076889|NCT04114149|Device|TENS (transcutaneous electrical nerve stimulation)|TENS as first line of treatment. If insufficient pain relief, i.e. postoperative pain intensity according to NRS (numeric rating scale) ≥ 3 after two treatment sessions à 1 minute, the patient receives conventional treatment with iv opioids.
46076890|NCT04114149|Drug|iv opioid|Conventional treatment with iv opioid if postoperative pain intensity according to NRS (numeric rating scale) ≥ 3.
46076891|NCT00891397|Drug|Pregabalin|Dose of 150mg/day divided in two doses. Increased to 300mg/day then to 600mg/day, always divided in two doses for the day.
46076892|NCT00891397|Other|Placebo|Sugar pill
45812453|NCT02440022|Procedure|Percutaneous Transluminal Angiography|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
45812454|NCT02440178|Drug|Micafungin|
45812455|NCT02543840|Other|Replicating Effective Programs plus External Facilitation|Packaging, training and technical assistance according to the Replicating Effective Programs model plus External Facilitation
45950163|NCT04697992|Drug|vitamin c 20%|one eye was treated with vitamin c 20% + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).
45950164|NCT04697992|Drug|Tranexamic acid 5mg/ml|one eye was treated with tranexamin acid 5 mg/ml + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling)
45950165|NCT05483634|Drug|Vaginal estrogen supplement|Daily vaginal estrogen supplement, then twice per week. Continue for three months.
45812456|NCT02543840|Other|Educational Materials|Dissemination of educational materials on the collaborative chronic care model for 4 or 8 months prior to cross-over to REP-F
45812457|NCT05078606|Device|IJV Ultrasonography|"Patient will be in supine position, The linear probe with frequency of 7- 12 M hz; depth of 3 cm. maximum IJV diameter (IJV-D) and area (IJV-A) will be recorded. M-mode will be used to obtain the distance between the 2 walls of the vein during inspiration and expiration.~Then, the patient will be positioned 10° Trendelenburg and similar ultrasonographic measurements will be again performed"
45950166|NCT05483634|Procedure|Platelet-rich plasma injection|Monthly platelet-rich plasma injection for three months
45950167|NCT00461578|Drug|Chlorproguanil-dapsone + artesunate|
45812458|NCT05078606|Device|Carotid Intima Media Thickness|"US Probe is slided superiorly (toward the head) or inferiorly (toward the feet) until the bifurcation of the common carotid artery (CCA) appears on the left side of the screen. This is the ideal location for imaging and CIMT measurements.~IMT is assessed in longitudinal view from the arterial far wall, along a 10mm length. CIMT will appear as two parallel lines (leading edges of two anatomical boundaries) from it: lumen- intima and media- adventitia interfaces perpendicular to ultrasound beams."
45950168|NCT04728269|Other|Lactibiane Topic AD|Application of Lactibiane topic AD twice a day (morning and evening) on one lesional area
45950169|NCT04728269|Other|Placebo|Application of placebo twice a day (morning and evening) on the symmetrical lesional area
45950170|NCT03273478|Device|Endovascular treatment of bifurcation aneurysm with pCONUS2|"Patients suffering from a bifurcation aneurysm will be treated endovascularly with the pCONUS2 device.~The patients do not face any additional risks by participating in the study as the treatment does not differ from the standard of care in any way.~The patients will only be enrolled in the study if they give their written consent.~If they do not wish to participate in the observational study or if they wish to withdraw from it at a later date, they will not have any disadvantages."
45950171|NCT00461617|Drug|Mitiglinide|10mg tablet, 10mg TID
45812459|NCT05078606|Procedure|Spinal anesthesia|Spinal anesthesia will be performed in the sitting position at level of L3-4 or L4- 5 interspaces with a 25-gauge spinal needle. Local infiltration of skin and subcutaneous tissue with 2% lignocaine will be applied. After confirming cerebrospinal fluid flow, 10 mg of 0.5% hyperbaric bupivacaine plus 25 mcg fentanyl will be injected. The degree of sensory block (cold test by alcohol gauze) will be assessed in the study with a goal of T8 dermatomal level block.
45812460|NCT02546570|Drug|Oxytocin|See arm/group descriptions for dosage amount and procedure.
45950172|NCT00461656|Drug|Preoperative conjunctival irrigation with 5% or 1.25% PI|Before initiation of surgery, children will have their conjunctival fornices irrigated with 5 ml PI 5% or with 5 ml PI 1.25%
45950173|NCT00116064|Drug|intranasal lorazepam|
45950174|NCT00116064|Drug|intramuscular paraldehyde|
45950175|NCT04728035|Drug|Irinotecan Liposome Injection|Irinotecan Liposome Injection
45812461|NCT02546570|Drug|Placebo|See arm/group descriptions for dosage amount and procedure.
45950176|NCT00461695|Biological|Vaccination against TBEV (FSME Immun CC)|Intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
45453680|NCT02280070|Other|Creatinine clearance|Creatinine clearance (CCr, mL/min) was estimated by Cockcroft & Gault method using serum creatinine (mg/dL), age and body weight (kg).
45812462|NCT02743351|Biological|ProTmune|Ex-vivo, programmed mobilized peripheral blood (mPB) cells
46076893|NCT02767596|Drug|Lixisenatide|
46076894|NCT02767596|Drug|Basal insulins|patients are on basal insulin treatment
46076895|NCT04113837|Dietary Supplement|food range|"The food range is comprised of:~sausages (1100 g per week) eggs (3 eggs per week), 100 g mushrooms per day, one bread per week, bread rolls, 100 ml ice cream per week, 3x 70 g pasta per week"
46076896|NCT01691729|Device|Ostomy accessory|Wearing each of the devices for 10 days each
45453681|NCT02280070|Other|Biomarker|Carcinoembryonic antigen and carbohydrate antigen 19-9
45812463|NCT02743351|Biological|Control Arm|Untreated mobilized peripheral blood (mPB) cells
45950177|NCT00461890|Drug|Injectable Naltrexone|
45950178|NCT03273439|Device|repetitive TMS|Prior to each TMS administration, motor threshold was determined by stimulating the left motor strip with the lowest possible energy to produce, within 10 stimuli, at least 5 evoked potentials Z0.05 . In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of motor threshold (MT) for 5-s intervals with 30-s intertrain interval. 30 trains were administered each day (MondayFriday) for 4 consecutive weeks (total stimuli=30,000).
45950179|NCT03273439|Device|Sham rTMS|Sham rTMS, without stimulation
45950180|NCT03273400|Other|Lumbar Mobilisations|Please see arm (intervention) description
46076897|NCT02826902|Drug|propofol and remifentanil|Anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil
46076898|NCT02826902|Drug|desflurane and remifentanil|Anesthesia is induced and maintained with desflurane and remifentanil
46076899|NCT00610207|Device|Surgisis Biodesign Anal Fistula Plug (SurgiSIS AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia
45950181|NCT04727723|Drug|Lutathera®|Treatment with Lutathera® will be independent from participation in this observational study and must not be initiated for the purpose of participating in this study. The decision to treat patients with Lutathera® will occur before patients are enrolled in the study.
45950182|NCT02956720|Device|UltraShape Power|non-invasive body contouring procedure
45950183|NCT02956681|Behavioral|Intervention Group|Callers to California's toll-free breast/cervical screening phone service were screened for family history. Callers identified as high risk will be told that a genetic counselor will call them back to offer them a free genetic counseling appointment and that a brochure will be sent. A UCSF/SFGH genetic counseling assistant will call them back within a few days to offer them a free genetic counseling appointment at SFGH.
45950184|NCT02956681|Behavioral|Delayed Intervention Group|This is a randomized delayed intervention control trial in which eligible callers to California's toll-free breast/cervical screening phone service were screened for family history. Callers identified as high risk will be told that they are eligible to speak to a genetic counselor who is available at no charge at SFGH and that they will be sent a brochure with information on where to call.
45950185|NCT02956564|Procedure|intrauterine intervention|choose different surgeries according to different causes
45812464|NCT02548910|Procedure|Phlebotomy|A central venous catheter will be inserted for every patient to measure central venous pressure, as is the standard of care in elective liver surgery. Strict aseptic technique will be maintained. A total volume of whole blood of 7-10 mL per kg of body weight will be removed, as tolerated. The volume of removed blood will not be replaced by intravenous fluid administration. Collected blood will be transfused back at the end of the liver parenchymal transection, or within 8 hours of collection.
45950186|NCT03273361|Behavioral|Compact Cycling Device|Participants pedaled a compact cycling device while simultaneously working at a desk.
45950187|NCT00461929|Procedure|bone marrow aspiration|
45659369|NCT05527561|Behavioral|Latin dance: Rumba|Latin dance is a kind of sports dance, which originated in Latin America, includes the rumba, samba, Cha Cha Cha, bullfighting dances and cowboy dances. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes.
45812465|NCT02548910|Device|Citrated whole blood collection bag|Transfusion Medicine will send the requested number of whole blood collection bags labelled with the patient's name and MRN. These whole blood collection bags are used in standard practice for collection of whole blood.
45812466|NCT02538523|Device|Erchonia FX-635|The Erchonia FX-635 is applied to the lower back and hips area for 20 minutes per treatment administration, 8 times across 4 weeks, 2 times per week.
45950188|NCT00461968|Drug|Ezetimibe and Simvastatin|
45950189|NCT00462007|Drug|Stalevo|Oral 3-4 daily doses for 6 weeks
45950190|NCT00116103|Drug|Tacrolimus Inhalation Aerosol|
45950191|NCT04727879|Procedure|Synovial membrane biopsy with puncture of synovial fluid|The biopsy of the shoulder bursae will be carried out thanks to a device Tru-cut (Tru-Cut Biopsy Needle), minimally invasive, introduced, as during an infiltration, within the bursa serosa.
46076900|NCT00798759|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
46076901|NCT00798759|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
45659370|NCT05527561|Behavioral|Latin dance: Cha Cha Cha|Latin dance is a kind of sports dance, which originated in Latin America, includes the rumba, samba, Cha Cha Cha, bullfighting dances and cowboy dances. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes.
45659371|NCT05532241|Device|fixed metal orthodontic appliance|fixed metal orthodontic appliance (stainless steel brackets (Mini Master MBT 0.022'', American Orthodontics), nickel-titanium archwire (NiTi, American Orthodontics), elastomeric ligatures (Elastomerics, American Orthodontics))
45812467|NCT02538523|Device|Placebo Laser|The Placebo Laser is applied to the lower back and hips area for 20 minutes per treatment administration, 8 times across 4 weeks, 2 times per week.
45812468|NCT02510144|Drug|Skin Prep Chlorhexidine|3 day preoperative skin prep prior to surgery
45812469|NCT02510144|Drug|Skin Prep Benzoyl Peroxide|3 day preoperative skin prep prior to surgery
45812470|NCT02538679|Other|Placebo|The usual intraoperative and postoperative pain control; NO TAP block performed
45812471|NCT02538679|Drug|US TAP Bupivacaine/Epinephrine|Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
45950192|NCT04727879|Procedure|Joint fluid sampling|In case of associated peripheric arthritis, the patient will also be offered a sample of joint fluid during a cortisonic infiltration for analgesic purposes, performed as part of routine care.
45950193|NCT04727879|Procedure|Blood sample|A blood sample taken during routine care and unused will also be collected from patients and controls for immunoassays.
45950194|NCT00462046|Drug|Berberine|
45950195|NCT02956252|Procedure|Spinal anesthesia|Spinal anesthesia was used in patients who underwent LC
45950196|NCT02956252|Procedure|General anesthesia|General anesthesia was used in patients who underwent LC
45950197|NCT00116051|Device|Acetabular implant, Monoblock cup|
45950198|NCT00462241|Procedure|chiropractic treatment|Participants in the therapy group undergo a physical examination by an experienced, primary sector chiropractor, lasting up to one hour. The chiropractors choose an individual treatment strategy based on a combination of their findings, the patient history, and a standardized protocol reflecting routine practice. The standardized treatment protocol includes high velocity, low amplitude manipulation directed towards the thoracic and/or cervical spine in combination with any of the following: Joint mobilisation, soft tissue techniques, stretching, stabilising or strengthening exercises, heat or cold treatment, and advice. The protocol specifies up to ten treatment sessions of approximately 20 minutes, 1-3 times per week, or treatment until the patient is pain free. The chiropractors record the types of treatment rendered at sessions.
46076902|NCT02853773|Other|ingestion of a test meal with sweetener|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with artificially sweetened drinks
46076903|NCT02853773|Other|ingestion of a test meal with sweetener|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with sugary drinks drinks
45812472|NCT02538679|Drug|Lap TAP Bupivacaine/Epinephrine|Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
45812473|NCT02511236|Behavioral|Group Cognitive Behavioral Therapy|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include a functional analysis of smoking patterns, environmental cues, and motivation for change, and cover nicotine addiction and withdrawal, health consequences, benefits of cessation, stress management, negative affect, alcohol use, triggers, coping responses, cognitive restructuring, social support, decision making, weight control, and physical activity.
45812474|NCT02511236|Behavioral|General Health Education|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include didactic information on tobacco-associated morbidities, such as heart disease, diabetes, and hypertension. Content may include Power Point-delivered lectures on the prevalence, etiology, basic pathology, symptom patterns, and treatment of the conditions, and discussion questions designed to facilitate learning and interest. Smoking cessation specific topics will not be addressed, and coping skills will not be provided. Participants will be allowed to share feelings regarding smoking (if they mention them) and general questions will be answered, although no specific behavioral quitting advice will be provided (i.e., they will be encouraged to adhere to the TNP protocol).
45950199|NCT00462241|Other|Self-management|Advice group: Advice is directed towards promoting self-management. The participants are told that their chest pain generally has a benign, self limiting course. The participants receive individual instructions regarding posture and two or three exercises aiming to increase spinal or muscle stretch based on clinical evaluation. They are advised to seek medical attention for re-evaluation (general physician, chest pain clinic or emergency department) in case of severe or unfamiliar chest pain. The session lasts on average 15 minutes. Further, the advice group is also asked not to seek any manual treatment for the next four weeks.
45659372|NCT05532241|Device|fixed non-metal orthodontic appliance|fixed non-metal orthodontic appliance (ceramic brackets (Radiance MBT 0.022'', American Orthodontics), nylon thread, elastomeric ligatures (Elastomerics, American Orthodontics))
45659373|NCT05532241|Procedure|oral hygiene|conducting regular oral hygiene, commonly recommended for orthodontic patients (toothbrush + toothpaste with a low fluoride concentration of 1450 ppm (Parodontax, GSK)
45659374|NCT05532241|Drug|Chlorhexidine mouthwash|0.12% chlorhexidine digluconate mouthwash (Curasept ADS 212, Curaden) daily during one month
45659375|NCT05453461|Diagnostic Test|Validation of new COMs for non ambulant FSHD patients|Monitoring of commonly used and news COMs in non ambulant patients with facioscapulohumeral muscular dystrophy
45659376|NCT02431897|Drug|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for >5 weeks before surgery, then 2x/week for 1 year after surgery.
45659377|NCT02431897|Drug|Placebo Cream|1g applied vaginally nightly for 2 weeks then 2x/week for >5 weeks before surgery, then 2x/week for 1 year after surgery.
45812475|NCT02511236|Drug|Transdermal Nicotine Patch|Participants will be prescribed up to 8 weeks of transdermal nicotine patch therapy, including 21 mg for 4 weeks, 14 mg for 2 weeks, and 7 mg for 2 weeks. Dosages will be adjusted per manufacturer recommendations.
45812476|NCT02467387|Drug|Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|One time infusion Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg.
45812477|NCT02467387|Drug|Lactated Ringer's Solution|One time infusion 1.5mL/kg
45812478|NCT05073068|Behavioral|Timing of exercise|An acute exercise bout of cycling performed in the morning at 9 AM or at 5 PM
45812479|NCT05073068|Behavioral|Control|No exercise
45812480|NCT02974478|Dietary Supplement|Orange juice with meals|orange juice (20% of energy requirement/day)
45812481|NCT02974478|Dietary Supplement|Orange juice between meals|orange juice (20% of energy requirement/day)
45812482|NCT02974478|Dietary Supplement|Sugar sweetened beverage between meals|Sugar sweetened beverage (20% of energy requirement/day)
45812483|NCT02512874|Other|Pulmonary Rehabilitation|Measures of frailty taken before and after pulmonary rehabilitation.
45950200|NCT04726527|Drug|Florbetapir F 18|A single injection of 10 mCi (370 MBq) florbetapir F 18 will be administered by intravenous bolus injection.
45659378|NCT05532163|Drug|Natalizumab|Administered as specified in the treatment arm
45659379|NCT05527249|Dietary Supplement|Dietary Supplement|20g of protein powder + 650mg of pomegranate extracts
45659380|NCT05527249|Other|Placebo of the dietary supplement|20g of protein powder + 650mg of maltodextrin
45659381|NCT05532085|Other|Evaluation of pain during voluntary termination of pregnancy with medication following consideration of predictive factors of pain without an established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anes!thesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
45659382|NCT05532085|Other|Evaluation of pain during a voluntary medical termination of pregnancy following consideration of predictive factors of pain with an established analgesic protocol|"Evaluation of the pain felt by women having a medical abortion following the application of an analgesic protocol indexed on the predictive factors of pain.~The intensity of the pain of patients during a medical abortion will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
45676476|NCT02849548|Drug|suvorexant|First in class orexin antagonist approved by the FDA for the treatment of insomnia
45676477|NCT02849548|Other|placebo|Pill with inactive ingredients
45812484|NCT02512874|Device|Dynamometer|Grip Test
45812485|NCT02512874|Radiation|DEXA|Body Composition Testing
45812486|NCT02512874|Other|Gait Speed Test|15 foot walk test
45812487|NCT02512874|Device|Activity Monitor|Measures energy expenditure and activity
45812488|NCT02512874|Other|Questionnaires|Health-related questionnaires measuring self-reported exhaustion, emotions and disease symptoms.
45812489|NCT02721979|Drug|Apalutamide|Given PO
45812490|NCT02721979|Other|Laboratory Biomarker Analysis|Correlative studies
45812491|NCT02721979|Other|Quality-of-Life Assessment|Ancillary studies
45812492|NCT02721979|Other|Questionnaire Administration|Ancillary studies
45812493|NCT02551094|Drug|colchicine|0.5 mg tablet taken once a day
45812494|NCT02551094|Drug|colchicine placebo|sugar pill manufactured to mimic colchicine 0.5 mg tablet
45950201|NCT04726527|Device|Positron Emission Tomography|PET Scan for brain imaging
45950202|NCT00462319|Behavioral|Education, weight reduction and physical exercise|
45950203|NCT00462358|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
45453682|NCT02280070|Radiation|Contrasting CT|Computed tomography
45950204|NCT00462358|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
45950205|NCT00116181|Drug|Etanercept|"All subjects will administer etanercept 50 mg twice weekly subcutaneously (2 injections of 25 mg etanercept SC within 1 hour twice weekly) for the first 12 weeks of study.~Subjects randomized to the continuous therapy arm will then receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24. Subjects randomized to the intermittent therapy arm will be assessed for response. Those who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24."
45812495|NCT04904822|Procedure|Vaginal bisection|Uterine bisection vaginally by scalpel 24
45676478|NCT02821741|Device|The Twin Stim Plus, 3rd Edition|Mild transcutaneous electrical stimulation will be applied to the cymba conchae of the left ear on day 1 and the left earlobe on day 2 (or vice versa) using a commercially available TENS unit (transcutaneous electrical nerve stimulator) attached to a pair of silver electrodes.
46076904|NCT02853773|Other|ingestion of a test meal with water|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with waters
45812496|NCT04904822|Procedure|Abdominal bisection|Uterine bisection by endokinfe
46076905|NCT00891475|Procedure|Radiofrequency ablation; Interferon-alpha|Patients undergo ablation by radiofrequency energy under CT-guidance. RFA continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. 38 patients will receive following immunotherapy with Interferon-alpha 9 MIU subcutaneously three times per week, 3 weeks on, 3 weeks off till progression. 38 patients will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off till progression. Evaluation for response will be after second cycle.
45453683|NCT02280070|Other|Adverse event|AE was evaluated using Common Terminology Criteria for Adverse Events (CTCAE v4.0).
46076906|NCT00891475|Procedure|Radiofrequency ablation; Sunitinib maleate|Patients undergo ablation by radiofrequency energy under CT-guidance. RFA continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. 38 patients will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off, till progression. Evaluation for response will be after second cycle.
45453684|NCT02280070|Other|HBs antigen and HCV antibody|check for exclusion criteria
45676479|NCT02821741|Device|Medoc Pathway System|Device used to apply Thermal stimulation to both arms.
45812497|NCT02513498|Drug|Ixazomib Citrate|Given PO
45812498|NCT02513498|Other|Laboratory Biomarker Analysis|Correlative studies
45453685|NCT02280070|Other|Endoscopy|Endoscopy for lower digestive tract
45453686|NCT02280070|Other|HBs antibody and HBc antibody|Check according to hepatitis B guideline
45453687|NCT02280070|Drug|S-1|S-1 (80 mg/m2, p.o.) is administered at day 1 -14 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
45453688|NCT02280070|Drug|L-OHP (130mg/m2)|L-OHP (130mg/m2 intravenously) is administered at day 1 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
45453689|NCT02280070|Drug|L-OHP (85 mg/m2)|L-OHP (85mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
45453690|NCT02280070|Drug|l-LV|l-LV (200 mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
45453691|NCT02280070|Drug|5-FU|5-FU (400 mg/m2) by bolus IV administration just after the L-OHP and l-LV administration. 5-FU (2,400 mg/m2) by IV continuous infusion for 46 hours using infuser pump afterwards and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
45453692|NCT05626309|Drug|Qizhu Yuling Prescription|The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after esophageal cancer surgery.
45676480|NCT02815995|Drug|Durvalumab|Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).
45812499|NCT02513498|Other|Quality-of-Life Assessment|Ancillary studies
45812500|NCT02513498|Other|Questionnaire Administration|Ancillary studies
45812501|NCT00363740|Drug|GW685698X Aqueous Nasal Spray|
45812502|NCT04787354|Drug|Oxaliplatin|Oxaliplatin: 130 mg/m2/day
45812503|NCT04787354|Drug|Capecitabine|Capecitabine: 2,000 mg/m2/day
45812504|NCT02514044|Drug|Dexedrine|10 mg immediate release of Dexedrine
45812505|NCT02514044|Device|Active tDCS|1.5 mA tDCS anodal tDCS
45812506|NCT02514044|Behavioral|Speech Therapy|60 min of speech therapy
45812507|NCT02514044|Drug|Placebo|
45812508|NCT02514044|Device|Sham tDCS|
45812509|NCT02515058|Device|PUROS (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
45950206|NCT00462397|Drug|carboplatin|
45950207|NCT00462397|Drug|cisplatin|
45950208|NCT00462397|Drug|paclitaxel|
45812510|NCT02515058|Device|FDBA (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
45812511|NCT02552810|Device|Steam clean|Control group: dental implant abutments underwent cleaning by steam (VAP 1, Zhermark, Cologne, Germany), performed for 5 seconds at 4 megapascal (MPa).
45950209|NCT00462397|Procedure|neoadjuvant therapy|
45950210|NCT00462397|Radiation|brachytherapy|
45950211|NCT00462397|Radiation|radiation therapy|
45659383|NCT05532085|Other|Assessment of pain during voluntary termination of pregnancy by aspiration under local anesthesia following consideration of predictive factors of pain without an established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days.Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
45659384|NCT05532085|Other|Assessment of pain during voluntary termination of pregnancy by aspiration under local anesthesia following consideration of predictive factors of pain with established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia following the application of an analgesic protocol indexed on the predictive factors of pain.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
45950212|NCT00462436|Behavioral|Consumption of Dietary Portfolio|The study involves following an aggressive low fat diet that is high in viscous fiber, nuts and soy protein. The diet is individually tailored to meet individual participants needs.
45812512|NCT02552810|Device|Plasma of Argon|Test group: dental implant underwent argon plasma treatment in a plasma reactor (Diener Electronic, Jettingen, Germany). The treatment conditions were 75 W of power and 1 bar of pressure for 12 minutes.
45659385|NCT02303119|Drug|Rituximab IV|intra-venous, 375 mg/m²
45659386|NCT02303119|Drug|Rituximab SC|sub-cutaneous, 1400 mg
45659387|NCT02302885|Other|Blood collection|Blood Collection
45676481|NCT02815995|Drug|Tremelimumab|Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
45676482|NCT02791685|Behavioral|MULTIFIT Cardiac Rehabilitation|MULTIFIT is a cardiac rehabilitation program delivered by the Movn smartphone application that will provide risk factor modification, prescribed exercises, education and counseling. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
45812513|NCT02553512|Other|Ingestible Sensor and Wearable Sensor|This digital health offering passively acquires and records medication-taking and habits of daily living.
45812514|NCT02553746|Device|Detection of the puncture site by ultrasound scan of the lumbar spine.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by ultrasound scan of the spine. The scanning will be performed as described by Arzola et al. The L3-L4 space will be identified by palpation and identification of the landmarks (Tuffier's line). The ultrasound probe will be placed perpendicular to the long axis of the spine. The spinous process will be identified (bright signal followed by dark triangular area). The probe will be moved to cephalad or caudal to identify the intervertebral space and when the best view of the ligamentum flavum is achieved two marks will be drawn on the skin: one at the center of the upper surface of the probe and one at the center of the right lateral vertical side of the probe. The intersection of the two landmarks will be the puncture site. The distance from the skin to the ligamentum flavum will be measured by the ultrasound caliper.
45812515|NCT02553746|Procedure|Detection of the puncture site by identification of the landmarks.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by the identification of the landmarks. The L3-L4 space will be identified by palpation of the posterior iliac crests and the ideal intervertebral space will be selected after palpation of the spinous processes.
45812516|NCT02554760|Device|The ZELTIQ CoolSculpting System|The CoolSculpting device and CoolCore applicator with and without the Crown Cooling Insert will be used to perform the treatments.
45812517|NCT02555228|Drug|Simethicone|100mg of liquid simethicone is put into 5mls of water and given at least 30 minutes before the gastroscopy.
45812518|NCT02555228|Other|Water|5mls of water is given at least 30 minutes before the gastroscopy.
45950213|NCT00462475|Drug|Recombinant Growth Hormone, Genotropin (Pfizer)|
45950214|NCT00116129|Drug|Ibutamoren Mesylate (MK-0677)|Ibutamoren Mesylate 25 mg/day
45950215|NCT00462553|Drug|sunitinib malate|Given orally
45950216|NCT00462553|Drug|gemcitabine hydrochloride|Given IV
45950217|NCT00462592|Drug|budesonide|inhaled budesonide turbuhaler 200ug taken 1 puff morning & 1 puff evening.
45950218|NCT00462592|Drug|montelukast|montelukast 5 mg ( < 15 years) or 10 mg (and matching placebo)will be taken 1 tab in the evening
45950219|NCT00462592|Other|placebo|placebo
45950220|NCT00405015|Drug|rosiglitazone|Rosiglitazone 4 mg bidaily for 8 weeks
45950221|NCT00462631|Device|Paclitaxel Eluting Balloon|Paclitaxel eluting balloon
45950222|NCT00462631|Device|paclitaxel eluting stent|paclitaxel eluting stent
45950223|NCT00462631|Device|bare metal stent|bare metal stent
45950224|NCT00116246|Procedure|McRobert's manoeuvre|
45950225|NCT00462787|Biological|filgrastim|
45950226|NCT00462787|Drug|clofarabine|
45950227|NCT00462787|Drug|dexamethasone|
45950228|NCT00462787|Drug|thiotepa|
45950229|NCT00462787|Drug|topotecan hydrochloride|
45659388|NCT02006251|Device|Real-time Instrumentation|To prepare the acetabulum and place the implants on the day of surgery, surgeons will receive either parts necessary to create the real-time with a surrogate model of the acetabular surface or standard surgical alignment instruments provided by the manufacturer of the implant. For the experimental group, the surgeon will be provided with 3 parts necessary to create the real-time instrument: (1) a patient-specific surrogate bone model with a built-in guide pin trajectory which was planned in the 3D planning software, (2) a non-specific plastic arm available in different sizes, and (3) bone cement. The real-time instrument is created to position a peripheral guide wire on the acetabular rim to serve as a visual aid for reaming and impacting the acetabular shell using standard reaming tools supplied by the manufacturer. Once the acetabular shell is placed, the procedure is performed in the same manner for both groups, using the standard manufacturer instruments.
45812519|NCT04654130|Other|Neurofeedback|"NFB is a type of brain training in which a person is given real-time information (or feedback) from their own brain activities to help them potentially change how their brain is functioning (i.e., to work in a healthier or more effective manner). In the current study, we will implement at-home, supervised (via teleconferencing) neurofeedback sessions using the Muse headband paired with the Myndlift software application to conduct alpha-down neurofeedback once per week, for 19 weeks."
45950230|NCT00462787|Drug|vinorelbine tartrate|
45812520|NCT02555306|Drug|0.5 mg of DE-122|DE-122 Injectable Solution
45950231|NCT03273244|Device|NeuroSense monitoring and ANI monitoring|From the start of palliative sedation, monitoring of EEG with NeuroSense device (WAVcns: Wavelet Anesthetic Value of the Central Nervous System) and ANI-monitoring (Analgesia Nociception Index) will be initiated.
45950232|NCT00463021|Drug|Hectorol (doxercalciferol capsules)|
45950233|NCT00463021|Drug|Zemplar (paricalcitol injection)|
45812521|NCT02555306|Drug|1.0 mg of DE-122|DE-122 Injectable Solution
46076907|NCT00891475|Drug|Sunitinib maleate|38 patients with unresected primary tumor will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off, till progression. Evaluation for response will be after second cycle.
45812522|NCT02555306|Drug|2.0 mg of DE-122|DE-122 Injectable Solution
45812523|NCT02555306|Drug|4.0 mg of DE-122|DE-122 Injectable Solution
45812524|NCT02555930|Other|No Intervention|No intervention - observational only
45812525|NCT02556554|Device|Dexcom G4 or G5 Platinum CGM system|Intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy
45812526|NCT02556554|Device|Dexcom G4 or G5 Platinum CGM system with Share|Treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™
45812527|NCT02556788|Drug|CD5789 (trifarotene) 50µg/g Cream|CD5789 (Trifarotene) 50µg/g cream applied once daily during 12 weeks.
45812528|NCT02556788|Drug|Placebo Cream|Placebo cream applied once daily during 12 weeks.
45812529|NCT02516150|Drug|Ethanol|IV infusion of ethanol to stabilize BAC (blood alcohol content) at 0.1%
45950234|NCT00116259|Drug|Aripiprazole|
45950235|NCT00116285|Biological|Ragweed MATA MPL|
45950236|NCT00463138|Behavioral|Crisis intervention|
46076908|NCT00887432|Dietary Supplement|Cholecalciferol|Given PO
46076909|NCT00887432|Other|Laboratory Biomarker Analysis|Correlative studies
46076910|NCT00887432|Other|Patient Observation|
46076911|NCT00887432|Drug|Placebo Administration|Given PO
46076912|NCT00887432|Other|Quality-of-Life Assessment|Ancillary studies
46076913|NCT00887432|Other|Questionnaire Administration|Ancillary studies
46076914|NCT02855645|Drug|Trichosanthes root|Trichosanthes root at a rate of 1.5 g two times per day for 84 days.
45659389|NCT02006251|Procedure|Standard Total Hip Arthroplasty|Total hip arthroplasty performed according to standard of care
45659390|NCT02575339|Drug|MLN0128|Phase I Dose Escalation Study Cohort 1 MLN0128 15mg QW; Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW
45659391|NCT02575339|Drug|MLN0128 (RP2D)|"Phase II Arm A:~MLN0128 administered orally at the recommended phase II dose (RP2D) once weekly."
45659392|NCT02575339|Drug|Sorafenib|"Phase II Arm B:~Sorafenib administered at 400mg PO BID daily"
45659393|NCT01712659|Drug|Ruxolitinib|Ruxolitinib 20 mg orally twice daily for 28 days. Subjects may continue to receive treatment until progressive disease (PD) or unacceptable toxicity.
45812530|NCT02516150|Drug|Glucagon|injection of 50 micrograms of glucagon
45812531|NCT04025060|Behavioral|Commercially-available caffeine-free soda|Subjects are asked to consume caffeine-free soda daily for two weeks
45812532|NCT04025060|Behavioral|Carbonated water|Subjects are asked to consume unsweetened, carbonated water daily for two weeks
45812533|NCT04025060|Behavioral|Regular soda|Subjects are asked to consume regular soda daily for two weeks
45812534|NCT04631510|Drug|Gabapentin 300 mg PO at 8 PM|Administer gabapentin 300 mg PO at 8 PM for sleep
45812535|NCT04542434|Drug|Niclosamide Oral Tablet|Niclosamide tablets 400 mg 3 times daily for 14 days
45812536|NCT04542434|Drug|Placebo|Matching placebo tablets 3 times daily for 14 days
45812537|NCT02557178|Behavioral|health coaching|Supportive coaching to encourage compliance with prescribed pulmonary rehabilitation.
45950237|NCT00463216|Behavioral|A multidisciplinary diagnostic evaluation|
45950238|NCT00463255|Behavioral|diet|
45950239|NCT02964156|Other|Supersole|A 4-mm thin, individually customized insole of a malleable plastic material (CI-Core®) with synthetic textile material on the upper side.
45950240|NCT02964156|Other|No intervention|No intervention
45950241|NCT00463294|Procedure|Coronary Artery Bypass Graft with the use of CPB|Coronary Artery Bypass Graft (CABG) using median sternotomy, CPB, cardioplegia and complete cross-clamp and no associated or concomitant surgical procedures
45950242|NCT00463294|Procedure|Coronary Artery Bypass Graft without the use of CPB|Coronary Artery Bypass Graft (CABG) with no associated or concomitant surgical procedures, using median sternotomy and without CPB and cardioplegia
45950243|NCT00116324|Drug|Montelukast|
45950244|NCT00463372|Drug|PF-02545920|
45950245|NCT00405054|Drug|MK0457|IV infusion 32 mg/m2/hour; 5-day continuous infusion every 14 days
46076915|NCT02855645|Drug|Placebo|Trichosanthes root at a rate of 0.15g (10%) two times per day for 84 days.
45950246|NCT00116363|Genetic|investigational drug INGN 241|
45950247|NCT00463450|Drug|Gynodian® Depot (BAY86-5032)|Injection monthly
45950248|NCT00463450|Drug|BAY86-4980|orally
45950249|NCT00463489|Behavioral|Lifestyle intervention|Women randomized to the lifestyle intervention arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals, incorporated into a 2 year standardized, structured telephone and mail-based intervention. In addition to diet and physical activity, the intervention will address behavioural and motivational issues relating to weight management including maintaining motivation, overcoming obstacles to success, relapse prevention, emotional distress, stress and time management.
45950250|NCT00463489|Behavioral|Mail-based|Participants will receive a standardized mail-based intervention focussing on healthy living. This will include mailings at study entry as well as a two year subscription to health magazine.
45950251|NCT05482191|Behavioral|Lifestyle intervention|"This intervention programme will target the influencing factors of childhood obesity to influence the knowledge, attitude and behaviours of school children. Students in the treatment group will receive the following interventions:~Develop and implement school policies related to weight loss~Distribute health education materials on diet and exercise to students~Carry out student health education courses~Diet and exercise instruction by professional nutritionist using internet applet~Take part in sports activities that are organized by the sports health teacher during school hours."
45950252|NCT00116402|Drug|fluticasone and salmeterol|"will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID~will start with salmeterol 50 mcg BID first and then crossover to combination therapy with fluticasone 220 mcg BID."
45950253|NCT03273127|Drug|Abediterol|A β2-adrenoceptor agonists, produce smooth muscle relaxation in the airways and improves lung function.
45950254|NCT03273127|Drug|Placebo|Abediterol matching placebo without any pharmacological activity.
45950255|NCT00463645|Procedure|microdialysis|
45950256|NCT00463645|Procedure|microperfusion|
45950257|NCT00463723|Drug|FK506 0.06% (eye drops)|
45950258|NCT00116441|Biological|Therapeutic Cellular Vaccine, GM-CSF Producing|
45950259|NCT00463762|Drug|CP-75385-02 Cefoperazone/sulbactam|
45950260|NCT00116376|Drug|AEE788|
45950261|NCT04697914|Diagnostic Test|Plantar pressures will be measured in 7 zones using the Footscan® platform following the two-step method. Three plantar pressures measurements were made for each foot.|to protect the metatarsus and prevent the appearance of foot pain.
45950262|NCT04697680|Behavioral|Algorithm 1|A sleep extension algorithm (algorithm 1) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
45950263|NCT04697680|Behavioral|Algorithm 2|A sleep extension algorithm (algorithm 2) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
45950264|NCT04697680|Behavioral|Algorithm 3|A sleep extension algorithm (algorithm 3) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
45950265|NCT00116480|Drug|Misoprostol|600 mcg of sublingual misoprostol
45950266|NCT00463879|Drug|Galantamine|
45950267|NCT00463918|Drug|varenicline|
45950268|NCT00463957|Drug|sildenafil|
45659394|NCT01712659|Drug|Ruxolitinib|Ruxolitinib 30 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
45659395|NCT01712659|Drug|Ruxolitinib|Ruxolitinib: Ruxolitinib 40 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
45659396|NCT01712659|Drug|Ruxolitinib|Ruxolitinib 50 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
45950269|NCT00463957|Drug|tadalafil|
45950270|NCT00463957|Drug|placebo|
45950271|NCT00116519|Drug|PPAR alpha|
45950272|NCT00116519|Drug|placebo|
45950273|NCT00464035|Behavioral|high calcium intake|
45950274|NCT00116454|Drug|131 I-lipiodol|intra-arterial hepatic administration of Lipiocis will occur, 11 to 12 weeks after the initial curative treatment
45812538|NCT04415528|Other|Emotion-Focused Mindfulness Therapy|"EFMT is a group intervention of 8weekly meetings of 2.5 hours with 10 - 12 participants per group. Participants are provided instruction that encourages noting and experiencing bodily sensations and emotions during meditations. Meditations are conducted in silence for between 20 and 35 minutes. Participants are asked to journal their recollection of the meditation and experiences that arise for them as they journal. Each participant then describes their experience in meditation, with the facilitator offering empathic exploration to support transforming negative emotions into adaptive emotions.~The study will be conducted in an online PHIPPA protected platform and has been modified to accommodate electronic delivery. Maximum number of participants per group will be six, and each session will be 1.5 hours. Data will be collected at three points by a research assistant to evaluate the feasibility of EFMT for older adults and determine whether anxiety is influenced by the intervention."
45812539|NCT03943628|Behavioral|Familias Unidas|
45950275|NCT04697836|Procedure|ST|"After a computer-generated randomization list with a 1:1 intergroup ratio, ensuring equal distribution in the two groups, 30 opaque sealed envelopes numbered 1-30 were prepared. The patients were randomly divided into the Group with bilateral CPB with 15 ml 0.5% bupivacaine or the patients with translaryngeal block with 5 ml 2% lidocaine in addition to bilateral CPB.~Following inclusion, two research assistants, with no further involvement in the study, prepared 15mL syringes and 5 ml syringes according to the envelope's specifications. The syringes were marked with the patient's randomization number. All other investigators, staff, and patients were blinded to group allocations. Before surgery, the patients were transferred to the specified block room area monitored with 3-lead electrocardiography, pulse oximetry, and non-invasive blood pressure. All patients had two intravenous cannula lines, and then bilateral CPB block procedures were performed in awake non-sedated patients."
45950276|NCT00464113|Drug|XL228|1-hour IV infusion
45950277|NCT00464191|Drug|escitalopram|
45950278|NCT00464230|Procedure|Bipolar hemiarthroplasty (Charnley/Hastings)|
45950279|NCT00464230|Procedure|Internal fixation with two parallel screws (Olmed)|
45950280|NCT03273010|Procedure|Free gingival graft|Free gingival graft was harvested from palatal donor site
45950281|NCT03273010|Procedure|Cyanoacrylate application|Periacyrl was applied on palatal wounds
45950282|NCT00116597|Genetic|Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes|
45950283|NCT00116597|Biological|Intranodal booster immunizations with synthetic melanoma associated epitopes|
45950284|NCT00464347|Drug|Avastin|
45950285|NCT00464347|Procedure|Photodynamic Therapy (PDT)|
45812540|NCT04186286|Drug|Ivabradine 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of ivabradine.
45812541|NCT04186286|Drug|Propranolol 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of propranolol.
46076916|NCT04222686|Drug|Perindopril Arginine|10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
45812542|NCT04186286|Drug|Placebo 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of placebo
45950286|NCT00464347|Drug|Preservative-Free Triamcinolone Acetonide (TAC-PF)|
45950287|NCT00464386|Device|Continuous Glucose Monitoring|measure glucose levels on burn patients
45950288|NCT00116493|Dietary Supplement|Iron-folic acid and mebendazole|"100 mg iron for pregnant women, 25 mg iron for children~1 mg of folic acid for pregnant women, 100 ug folic acid for children 500 mg of mebendazole for both pregnant women and children"
45950289|NCT00116493|Drug|Mebendazole|100 mg twice a day for 3 days; Iron-folic acid also given
45950290|NCT00116493|Dietary Supplement|Multivitamins|Iron-folic acid also given; Includes vitamins A, C, B12, E, and B2
45950291|NCT00116493|Drug|Mebendazole + Multivitamin|Multivitamins + Mebendazole at 100 mg twice a day for 3 days; Iron-folic acid also given
45950292|NCT00464425|Procedure|Electroacupuncture|EA using sharp needles placed at various acupoints; electrical stimulation at 50 Hz applied to the needles
45950293|NCT00464425|Procedure|Sham Acupuncture|Acupuncture using blunt-tip needles placed 15 mm away from acupoints; no electrical stimulation used
45950294|NCT00464425|Other|No Acupuncture|Control
45950295|NCT00116636|Drug|Kaletra|
45950296|NCT00464503|Drug|Rosuvastatin-Crestor|
45950297|NCT00464503|Drug|Pravastatin-Pravasine|
45950298|NCT03272971|Device|Radio-frequency Ablation|The intervention consists of a bronchoscopic approach to ablate lung tumors with radiofrequency.
45950299|NCT04726488|Procedure|Periareolar Approach in Minimally Invasive Cardiac Surgery (PAMI Technique)|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
45950300|NCT04726488|Procedure|inframammary approach|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
45950301|NCT00464659|Device|Effective CPAP|Auto-titrating CPAP machines (Remstar Auto; Philips Respironics, Murrysville, PA) provided by a home care company (Bastide Medical, France). Pressure was set between 6 and 14 cm of water
45950302|NCT00464659|Device|Sham CPAP|Similar CPAP machine delivering a 4 cm of water pressure that was too low to suppress sleep respiratory events.
45950303|NCT00116675|Drug|Resiquimod|
45950304|NCT00464776|Drug|Aliskiren|
45950305|NCT00464776|Drug|Aliskiren|
45950306|NCT00464776|Drug|Aliskiren|
45950307|NCT00464776|Drug|Aliskiren|
46076917|NCT04222686|Drug|Losartan Potassium|100 mg Losartan tablet will be added to the usual treatment for each patient for a period of 08 weeks.
46076918|NCT04113915|Drug|triple therapy|Effect of treatment on immunity to obtain infection with hepatitis B&C
45950308|NCT03272893|Behavioral|Acceptance and Commitment Therapy|The main component in the treatment is exposure to symptoms and feared situations. The iACT program is adapted from the evidence based face-to-face treatment at the Behavioral Medicine unit at Karolinska University Hospital. The iACT program has a different structure but is equal in content to face-to-face treatment, and is to be completed within ten weeks. Participants receive texts, audio files, movies and exercises and have online contact with their psychologist via an internet platform or a smart phone application. The treatment aims to encourage valued behaviors in the presence of inner discomfort.
45659397|NCT01640587|Drug|Mefloquine+Artesunate|One tablet of artesunate contains 40mg (Guilin Pharmaceutical Company, PRC). One tablet of mefloquine contains 250 mg mefloquine (Eloquine® (Medochemie Ltd., Cyprus) Standard three days regimen of artesunate-mefloquine given as 4mg/kg artesunate/day and 8 mg/kg of mefloquine/day on Days 0, 1 and 2
45659398|NCT01640587|Drug|Dihydroartemisinin-Piperaquine|DHA-Piperaquine (Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China) One tablet contains 40mg of dihydroartemisinin and 320 mg piperaquine. A weight-based regimen containing 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
45659399|NCT05531851|Other|Instrument Assisted Soft Tissue Mobilization|"For IASTM treatment, IASTM soft tissue mobilization blade to apply the treatment used. It is a stainless steel shaped metal tool with beveled edges. The researcher, with a 30° angled tool, at a speed of 120 BPM, in the direction of the fibers of the m.biceps brachii muscle.~He applied it with a light pressure by intervening with his weight. Researcher during treatment used a metronome to ensure consistent speed and adjusted the instrument angle before each subject's treatment.~calibrated with a protractor. The application took 8 minutes and the instrument was comfortable on the skin."
45659400|NCT01610713|Drug|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
46076919|NCT04113915|Drug|Steroids|Oral or parenteral steroid therapy for ITP
45950309|NCT00116532|Drug|Escitalopram|
45659401|NCT05162755|Drug|S095029|S095029 will be administered via IV infusion every 2 weeks. Once the DLT evaluations period at the second dose level is completed and it is deemed as safe, the dose escalation part 1b will be initiated.
45950310|NCT03272815|Device|Percussion Device (PD)|A laboratory prototype of the Percussion Device (PD) has been designed and built; laboratory data collection software, signal analysis and classification algorithms have been developed. It has been designed to detect a pneumothorax.
45659402|NCT05162755|Drug|S95029 and Sym021|Sym021 will be administered at a fixed dose of 200mg. S095029 will be administered via IV infusion every 2 weeks. Once the RP2D dose of S95029 in combination with Sym21 is defined, dose expansion will begin.
45659403|NCT05162755|Drug|S095029 and Sym021 and anti-HER2 therapy|Patients will be administered with S095029, Sym021 and anti-HER2 therapy.
45950311|NCT03272815|Device|Ultrasound (US)|The SonoSite hand help portable ultrasound device.
45950312|NCT00116714|Drug|DMARD|All subjects were required to initiate, add or change DMARD therapy at study entry.
45950313|NCT00464854|Drug|Glargine and insulin aspart or lispro|
46076920|NCT03590821|Drug|Aspirin 81 mg|timed administration of aspirin in the evening
46076921|NCT03590821|Drug|Celecoxib 200mg capsule|daily administration of celecoxib
45659404|NCT05162755|Drug|Dose expansion 2b: S095029 and Sym021 and futuximab/modotuximab|Patients will be administered with S095029, Sym021 and futuximab/modotuximab.
45659405|NCT05527093|Radiation|MRI 3T and MRI 7T|MRI 3T and MRI 7T before and post epilepsy surgery
45659406|NCT01606189|Drug|GW-1000-02|Contains delta-9-tetrahydrocannabinol (THC) (25 mg/ml) and cannabidiol (CBD) (25mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
45812543|NCT02560922|Behavioral|Pain Coping Skills Training (CST)|The pain CST intervention includes 11 individual sessions with a study counselor, delivered via telephone to enhance access and reach. The sessions include the following: general information about why pain coping skills training is important, training in specific pain coping skills (such as progressive muscle relaxation, communication, imagery, and activity pacing), and guided practice with each skill. The CST program will also include information about other behaviors important for OA, such as physical activity and weight management.
45812544|NCT04341038|Drug|Tacrolimus|the necessary dose to obtain blood levels of 8-10 ng / ml
45812545|NCT04341038|Drug|Methylprednisolone|120mg of methylprednisolone daily for 3 consecutive days
45950314|NCT00464893|Drug|Catumaxomab|10 µg intraoperative and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
46076922|NCT04113993|Drug|Bazedoxifene Acetate|Oral Bazedoxifene dosed at 40 mg daily for 12 weeks
46076923|NCT04113993|Drug|Placebo|Identically packaged placebo capsule daily
46076924|NCT04037839|Other|Questionnaire|"Medical records of children aged 0-18 years who were prescribed a HFNC device at Schneider Children's between 2014-2018 for use in the home setting will be reviewed retrospectively. As part of the telephone consent process, parents will be offered to opt out at the beginning of the interview."
45950315|NCT00464893|Drug|catumaxomab|10 µg intraoperatively and 4 ascending doses: 10, 20, 50 and 150 µg
45950316|NCT00464932|Drug|Vasoactive Intestinal Peptide (VIP)|
45950317|NCT00116571|Drug|Lemuteporfin for injection|
45950318|NCT00116571|Device|Transurethral drug delivery system|
45950319|NCT00116571|Device|Transurethral light delivery system|
45950320|NCT00464971|Drug|estradiol, 25 mcg|
45950321|NCT00116792|Procedure|Percutaneous Coronary Intervention (PCI)|
46076925|NCT02758470|Drug|Acetazolamide|250 mg, taken orally three times per day
46076926|NCT02758470|Drug|Methazolamide|100mg, taken orally two times per day. A placebo pill will be taken between each dose of methazolamide to match the timing of doses and the number of pills between study arms.
46076927|NCT02758470|Other|Placebo|A placebo will be taken three times per day
46076928|NCT05652231|Diagnostic Test|caries assessment|the child will examined for dental caries, caries prevalence, caries indices (def and DMF, or DMF)
46076929|NCT04113447|Other|observational|observational
45812546|NCT04743050|Drug|Fatty Acids, Unsaturated|All participants from Experimental Groups will receive supplementation of different fractions of EFAs esters for six months daily. Control Group will be monitored with the same tests, but will not receive any supplementation.
45458441|NCT01351454|Behavioral|ACT HEALTHY|ACT HEALTHY is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001) and Life Steps, an HIV medication adherence intervention (Safren, Otto, & Worth, 1999). ACT HEALTHY is based on the belief that the best way to improve mood, remain sober, increase medication adherence, and make long-term life changes is by changing and increasing one's activity level. Treatment includes 16 individual sessions over a 12-week period.
46076930|NCT02758314|Other|Evaluation of PD-1/PDL-1 expression.|Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations of peripheral blood by flow cytometry and in tumor tissue by immunohistochemistry in NSCLC, free treatment and healthy subjects
45659407|NCT01606189|Drug|GW-2000-02|Contains THC (25 mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
45812547|NCT04743050|Diagnostic Test|Diagnostic Tests|All participants will have laboratory tests marking: CRP, fasting glucose, lipid profile, total blood count, and additional tests, which will include blood pressure measurements and measurements of body mass and composition on a specialized body composition analyzer (InBody 270). All the mentioned tests will be performed at the time of joining the research program, after 3 months (in the middle of the research program) and after 6 months (at the end of the research program).
45950322|NCT00465010|Behavioral|Talking Parents, Healthy Teens|Talking Parents, Healthy Teens is a worksite-based parenting program to help parents of 6th-10th graders learn to promote their adolescents' healthy sexual development. The program is administered in 8 weekly one-hour sessions during the lunch hour to groups of about 15 parents and focuses on parent-adolescent relationships and communication, with an emphasis on promoting sexual health and reducing sexual risk. It is led by a trained facilitator and assistant facilitator.
45950323|NCT00465049|Other|PRIMARY CLOSRE|SUTURE
45950324|NCT00465049|Other|SECONDARY CLOSURE|ALLOW TO HEAL SPONTANEOUSLY
45812548|NCT02561702|Other|Placebo|240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
45812549|NCT02561702|Drug|Mexiletine|150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days
45812550|NCT02563496|Drug|Tafenoquine|Tafenoquine tablet is supplied as film-coated tablet (100 mg, 150 mg, 200 mg and 300 mg) and fast-dispersing film coated tablet (50 mg).
45812551|NCT02563496|Drug|Chloroquine|Subjects may receive chloroquine according to local/national treatment guidelines.
45950325|NCT00465049|Other|SPONTANEOUS HALING|SECONDARY HEALING AFTER I&D
45950326|NCT00116610|Drug|picoplatin|
46076931|NCT04036825|Dietary Supplement|Liquid Nutritional Supplement from Hospital Product|Liquid Nutritional Supplement from Hospital Product is given 2 times daily for 14 days
46076932|NCT04036825|Dietary Supplement|Placebo|Standard nutritional supplement is given 2 times daily as placebo for 14 days
46076933|NCT02763696|Other|Composition of Viginal flora of Child-Bearing women|Use high-throughput sequencing technology to exam Composition of Viginal flora of Child-Bearing women in different menstrual cycle and type of Vaginitis
46076934|NCT00891553|Procedure|DXA|CR9112792 is a follow-up study of CR9108963, in which the effects of ronacaleret (100mg, 200mg, 300mg, 400mg) on bone mineral density (BMD), safety and tolerability were evaluated in comparison with placebo and 2 active comparators, alendronate and teriparatide. In this study we will follow-up subjects between 6 and 12 months after they discontinued treatment with placebo or ronacaleret (200mg, 300mg, 400mg) to evaluate the potential for mineralization of bone following cessation of ronacaleret therapy, evaluating lumbar spine and hip BMD by DXA. There is no administration of drug in this study.
45659408|NCT01606189|Drug|Placebo|Contains peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum daily exposure was set at 48 actuations per day.
45659409|NCT05526859|Other|Kinsiotaping for wrist flexor muscles|The flexor muscles of the wrist area will be targeted.
45659410|NCT05526859|Other|Kinesiotaping for wrist extensor muscles|The extensor muscles of the wrist area will be targeted.
45659411|NCT05525065|Drug|GlucoCorticoid|Glucocorticoid as calculated in prednisone oral equivalents.
45950327|NCT00465166|Procedure|Ultrasound|Lumbar ultrasound from L1-S1, carried out using a portable ultrasound system equipped with a 2-5 MHz curved array probe.
45950328|NCT00116870|Drug|lovastatin|
46076935|NCT04640766|Device|PRISM|"The study will include 12 EEG-NF sessions, administered twice per week for a duration of 6 active weeks in total. Twice weekly sessions will be held on no-consecutive days. Each session will last approximately 30 minutes."
45950329|NCT03272659|Drug|Cysview|250 mL enema containing 1.6 mmol of hexaminolevulinate
45950330|NCT00465205|Drug|Valacyclovir|500mg oral twice daily
45950331|NCT00465205|Drug|Matching Placebo|500 mg oral twice daily
45950332|NCT00465244|Drug|Levetiracetam 1 g IV + Lorazepam 2 mg IV|Levetiracetam 1 g IV + Lorazepam 2 mg IV
45950333|NCT00465244|Drug|Placebo + Lorazepam 3 mg IV|Placebo + Lorazepam 3 mg IV
45950334|NCT00116909|Drug|OSI 7904L|
45950335|NCT00465283|Drug|Donepezil|Tab.Donepezil 5 mg once daily during ECT treatment and the month after the last ECT treatment
45812552|NCT02563808|Other|Standard Decision Aid|Females will receive standard decisions aid for early stage breast cancer.
45812553|NCT02563808|Other|Post-surgical Regret Decision Aid|Females will receive anticipated regret-augmented version for early breast cancer.
45812554|NCT02540161|Drug|Sym004 - 18 mg/kg|Sym004 was dosed at 18 mg/kg intravenously every two weeks.
45812555|NCT02540161|Drug|Sym004 - 24 mg/kg|Beginning in August 2017, the dose was increased to 24 mg/kg intravenously every two weeks.
45812556|NCT02467465|Other|Physical therapy modalities|Massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
45659412|NCT05524987|Behavioral|ANDES INTERVENTION|ANDES intervention group will receive the ANDES implementation package consisting of health agent home visits and a text messaging program for 12 consecutive months
45950336|NCT04726371|Behavioral|Generic Best Practices|GBP consists of (1) Massachusetts Executive Office of Health and Human Services distribution of standard guidelines and policies for public health prevention and management of COVID and (2) standard virtual training of the staff of the group homes in these generic COVID-19 prevention practices including recommended use of hand washing, use of PPE, and symptom-triggered screening. Group homes randomized to this intervention will receive standard recommended and fully vetted best practices with respect to preventing and managing COVID-19 based on recommendations by the CDC and on consultation with leading national experts in infectious disease working with the Commonwealth of Massachusetts. The control condition does not represent inferior or substandard practice. As findings occur and as policy leads to adjustments in recommendations during the course of the study, the GBP condition will incorporate recommendations that are appropriate and up-to-date with CDC and state policy.
46002662|NCT04637100|Other|Stroke-related educational videos|Subject will use their own personal smartphone or tablet device to watch videos from a collection of pre-selected educational videos. These include topics on stroke recognition, stroke recovery process, patient experiences with stroke, rehabilitation after stroke, activities of daily living equipment instructions. Subject will be instructed to watch for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
46002663|NCT00546611|Drug|PEP005|
46002664|NCT04637490|Device|patellar component|patellar resurfacing
46076936|NCT00891631|Behavioral|iSBIRT|Participants will receive the internet/intranet based screening, brief intervention, and referral to treatment program.
46076937|NCT00891631|Behavioral|iSBIRT/TE|Participants will receive the internet/intranet screening, brief intervention, and referral to treatment system along with technological extenders
46002665|NCT04645875|Other|Sit regimen|See Sit regimen arm description
46076938|NCT02541877|Device|Down sizing valve in type-0 BAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Down sizing valve implantation will be used in type-0 BAS.
45659413|NCT01663987|Drug|tiotropium bromide|18 mcg once a day (QD)
45659414|NCT01663987|Drug|Placebo|once a day (QD)
45659415|NCT05111353|Biological|Optimized neoantigen synthetic long peptide vaccine|Neoantigen vaccines will be provided on a patient-specific basis
45659416|NCT05111353|Biological|Poly-ICLC|Poly-ICLC will be supplied by Oncovir, Inc.
45659417|NCT05526781|Device|Clareon monofocal Intraocular lens (toric and non-toric models)|Bilateral implantation of the Clareon monofocal Intraocular lens (toric and non-toric models) with the Monarch IV inserter
45812557|NCT02467465|Device|Invasive Physical therapy modalities|Dry needling added to massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
45812558|NCT02564354|Drug|QR-010|Single-stranded RNA antisense oligonucleotide in isoosmolar solution
45812559|NCT02467777|Device|Bair Hugger|
45812560|NCT02467777|Device|VitaHeat|
45812561|NCT02540629|Procedure|Bundled EMS CPR approach including dispatcher-assisted CPR, 3-person team CPR, and feedback CPR monitoring device|Gold standard EMS CPR refers to our bundled approach to providing high quality EMS CPR through one or more intervention(s) as applicable including 1) dispatcher-assisted CPR, 2) multi-tiered team CPR, and 3) feedback CPR.
45812562|NCT02568644|Dietary Supplement|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerols).
45950337|NCT04726371|Behavioral|Tailored Best Practices|TBP consists of optimized, tailored, and highly specific COVID-19 best practices and training materials specific to the setting, staff, and residents with SMI and ID/DD in congregate living settings based on the comparative effectiveness of different types, intensities, and combinations of COVID-19 prevention practices (screening, isolation, contact tracing, use of PPP, vaccination) specifically modeled for residents and staff of congregate living settings for people with ID/DD and SMI derived by a simulation model. Results from this modeling process will be provided to stakeholders to support decision makers in prioritizing resources and practices with the greatest impact on reducing COVID-19 tailored for people with SMI and ID/DD in congregate living settings. This process to determine the content of TBP will occur as part of this study prior to randomization.
45950338|NCT03272425|Drug|lesinurad/allopurinol 200/300 FDC tablets|Test Drug
45950339|NCT03272425|Drug|lesinurad 200 mg|Comparator 1
45950340|NCT03272425|Drug|allopurinol 300 mg|Comparator 2
45659418|NCT05531773|Other|follow up of COVID-19 Patients|"In each participating center a post COVID-19 outpatient clinic is already working or will be settled up to care COVID-19 patients after the acute phase. At the post COVID-19 clinic patients will undergo routine blood exams and will be visited by Infectious Diseases physicians after recovery from the acute episode of COVID-19 disease. According to the clinical issues of the patients and the procedures of the study, if necessary, the patients will be visited by other practitioners (Pneumologists, Cardiologists, Neurologists, Physiatrist and Psychologists or others).~Patients who have been already visited at the post COVID outpatient clinics from 01/03/2020 and for whom data of the acute phase and the follow up have been collected will be enrolled in the study and retrospectively analyzed."
45950341|NCT03272542|Dietary Supplement|Prebiotic: soluble corn fiber|prebiotic
45659419|NCT05155111|Diagnostic Test|Telemedicine consult|A joint assessment between Neonatologist at bedside and Neurologist by telemedicine will be performed to assess severity of neonatal encephalopathy
45812563|NCT02568644|Other|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose).
45950342|NCT03272542|Dietary Supplement|Placebo: maltodextrin|placebo
45950343|NCT00116948|Device|ReCap, Hip resurfacing system, Biomet|ReCap total hip arthroplasty inserted according to manufactures manual.
45950344|NCT03272503|Drug|Pimozide 2mg/day (current) or 4 mg/day (study initiation)|Pimozide 2mg tablets will be taken once daily.
45950345|NCT03272503|Drug|Placebo Oral Tablet|Identical matching placebo lactose tablets
45458442|NCT01351454|Behavioral|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. In addition, medication adherence is addressed with the Life Steps HIV medication adherence intervention (Safren, Otto, & Worth, 1999). Treatment includes 16 individual sessions over a 12-week period.
45458443|NCT01360190|Drug|fluoxetine|fluoxetine 20 mg. daily
45812564|NCT02568644|Drug|Intravenous ketoprofen|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received intravenous ketoprofen (100mg).
45812565|NCT02541409|Drug|Sofosbuvir|Direct acting antiviral agent used for the treatment of hepatitis C
45812566|NCT02541409|Drug|Pegylated Interferon alfa-2a|Antiviral agent used for the treatment of hepatitis C
45950346|NCT00465322|Drug|fluvastatin|
45950347|NCT00116987|Device|Dual chamber cardiac pacemaker|Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
45950348|NCT00116987|Device|Single chamber cardiac pacemaker|Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
45950349|NCT00465439|Drug|Subcutaneous Lidocaine 2% (Xylocaine) without epinephrine|10 ml subcutaneously
45812567|NCT02541409|Drug|Ribavirin|Antiviral agent (guanosine analogue) used for the treatment of hepatitis C
45812568|NCT02569112|Device|multipolar RF, varipulse|Multi-polar Radio frequency (RF) technology combining pulsed electro magnetic fields (PEMF) and mild suction stimulation (varipulse).
45812569|NCT02569112|Device|cryolipolysis|Cryolipolysis technology uses the sensitivity of fat cells to cold injury, causing them to freeze and undergo cellular apoptosis.
45812570|NCT02569658|Drug|Tranexamic Acid|
45812571|NCT02569658|Drug|Placebo|
45950350|NCT00116727|Drug|ENBREL®|50 mg/wk SC
45950351|NCT00465478|Procedure|Autologous bone marrow mononuclear cell transplantation|
45950352|NCT00465556|Behavioral|Public Health Nurse Home Visit|The perinatal public health nurse home visit intervention also includes a trifold brochure, printed on 8X10 inch paper, with 6 panels, that can be read with the woman in an interactive manner so that the woman is encouraged to describe her experiences and choose her options as they proceed. Participants will receive three prenatal and three postpartum sessions. The first prenatal sessions will be given during the first (enrollment), second, and third trimesters, with at least three weeks between sessions. Women entering the study after the first trimester will receive the initial session at enrollment, with two subsequent sessions spread out over the remainder of the scheduled prenatal home visitation program sessions.
45950353|NCT00465556|Behavioral|Intimate Partner Violence (IPV) Protocol|The current protocol in use by the participating health departments when a women screens positive for intimate partner violence (IPV), current or history within the last year.
45950354|NCT00473551|Drug|Rituximab|375 mg/m^2 intravenously over several hours on Day -13, followed by 1000 mg/m^2 intravenously on Days -6, 1, and 8.
45812572|NCT02541565|Drug|Cyclophosphamide|Given IV
45812573|NCT02541565|Drug|Doxorubicin Hydrochloride|Given IV
45812574|NCT02541565|Other|Laboratory Biomarker Analysis|Correlative studies
45812575|NCT02541565|Biological|Pembrolizumab|Given IV
45812576|NCT02541565|Drug|Prednisone|Given PO
45812577|NCT02541565|Biological|Rituximab|Given IV
45950355|NCT00473551|Drug|Cyclophosphamide|50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine.
45812578|NCT02541565|Drug|Vincristine Sulfate|Given IV
45950356|NCT00473551|Drug|Fludarabine|40 mg/m^2 intravenously over 30 minutes once per day for 4 days, starting Day -6.
45659420|NCT05305651|Drug|Sotrovimab|Sotrovimab dose and administration per standard of clinical care
45812579|NCT04708184|Drug|GLPG3970 oral solution|GLPG3970 for oral administration
45812580|NCT04708184|Drug|GLPG3970 tablet|GLPG3970 for oral administration
45812581|NCT04707950|Drug|Tranexamic Acid 100 milligram/Milliliter|"Participants will be divided into two groups: a study group & a control group. In addition to the standard management, the study group will be given TXA 1 gm (100 mg/ml) slowly intravenous infusion during delivery after clamping of the cord (administered over 10 minutes at 1 ml/minute).~The second dose of TXA 1 g Intravenous can be given if:~Bleeding continues after 30 minutes~Bleeding restarts within 24 hours of completing the first dose While the control group will not be given TXA and we will compare the results in both groups (amount of blood loss during operation to assess the efficacy of TXA in the prevention of PPH and reduction of intraoperative and postoperative blood loss and to assess its safety and benefit in the reduction of incidence of hysterectomy or blood transfusion requirements)."
45950357|NCT00473551|Drug|Mesna|10 mg/kg continuous intravenous infusion for 4 hours for total of 6 doses (24 hours) following Cyclophosphamide.
45950358|NCT00473551|Radiation|Radiation Treatment|2Gy Total body radiation day before transplantation
45950359|NCT00473551|Procedure|Stem Cell Transplantation (SCT)|Allo CD34+ Selected SCT/Infusion of stem cells.
45950360|NCT00473551|Drug|Sirolimus|6 mg by mouth on day -2 followed by 2 mg daily from day -1 through day +7.
45950361|NCT00473551|Procedure|Anti-third Party Cytolytic T-lymphocytes (CTL)|Intravenous infusion of anti-third party CTL.
45950362|NCT00473785|Behavioral|Group-based motivational interviewing|
45950363|NCT00473785|Behavioral|Individual CVD-risk factor feedback|
45950364|NCT00473785|Behavioral|Education for protective health behavior change|
45950365|NCT00473863|Procedure|Coronary Computed Tomographic Angiography|CCTA will be performed
45950366|NCT00117026|Drug|Placebo|Placebo for benfotiamine
45950367|NCT00117026|Drug|Benfotiamine|300mg/day
45659421|NCT05526625|Other|Ultrasound-based measurements of IVC & IJV.|Ultrasound-based measurements of IVC & IJV.
45659422|NCT05524831|Other|KINESIOTAPE|kinesiotape will be applied on orbicularis oris muscle
45659423|NCT05524831|Other|oromotor training|selected oromotor training: Perioral sensory stimulation ,Tapping,Tongue pressure,Jaw exercises andIntraoral stimulation
45659424|NCT05531695|Behavioral|Exercise (either aerobic or flexibility)|
45659425|NCT05526469|Procedure|Serratus anterior plane block|patients in this group will receive ultrasound guided single shot serratus anterior plane block for pain control intra and postoperative
45659426|NCT05526469|Procedure|erector spinae plane blocks|patients in this group will receive ultrasound guided single shot erector spinae plane block for pain control intra and postoperative
45659427|NCT05526469|Drug|Bupivacaine 0.25% Injectable Solution|Patients in both group will receive 0.5 ml/kg bupivacaine 0.25% injected locally in the muscle plane
45659428|NCT05531617|Procedure|Intubation|Study groups Intubated with Macintosh or cmac video laryngoscopes
45950368|NCT00473902|Behavioral|Training|
45659429|NCT05155033|Drug|Pembrolizumab|Pembrolizumab 200 mg IV over approximately 30 minutes on Day 1 of cycles 1 and 2 during Courses 1 and 2.
45659430|NCT05155033|Drug|Aldesleukin|Aldesleukin (IL-2) administration [600,000 IU/kg IV bolus every 8 hours continuing for up to 4 days (maximum 10 doses)] starting on Day 1 of cycles 1 and 2 during Course 1.
45950369|NCT00473902|Drug|Creatine Monohydrate, Conjugated Linoleic Acid|
45950370|NCT00473980|Drug|Indomethacin, celecoxib, esomeprazole|
45950371|NCT05396313|Device|CRT/ICD|The patients received implantation of CRT/ICD.
45950372|NCT00474019|Drug|esomeprazole|IV qd for 4 days
45950373|NCT00117065|Drug|Aranesp®|
45950374|NCT00474136|Drug|Intravenous diclofenac sodium (DIC075V) 18.75 mg|DIC075V 18.75 mg
45950375|NCT00474136|Drug|Intravenous diclofenac sodium (DIC075V) 37.5 mg|DIC075V 37.5 mg
45950376|NCT00474136|Drug|Oral diclofenac potassium 50 mg|Oral diclofenac potassium 50 mg
45950377|NCT00474214|Behavioral|Early hospital discharge facilitated by close nurse practitioner follow-up|
45950378|NCT00116766|Device|anti-mosquito plant use|
45950379|NCT00117104|Drug|Aranesp®|
45950380|NCT03270709|Drug|Vitamin D3 450,000 IU orally|Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.
45950381|NCT04727892|Procedure|epilepsy surgery|Surgical procedures were individually designed according to the presurgical evaluation findings. Standard epilepsy surgery procedures were applied. Generally, surgical procedures were divided into curative and palliative surgery. Curative surgery included resection and disconnection of the epileptogenic zone. Palliative surgery included corpus callosotomy for bilateral synchronous onset and multiple subpial transections for epileptic foci located in the eloquent cortex. For widespread epileptogenic zones, multiple surgical techniques were combined.
45950382|NCT00474409|Drug|Merislon|
45950383|NCT03270592|Other|Service dog|Use of a individualized certified service dog
45950384|NCT03270553|Drug|plazomicin|single intravenous dose
45950385|NCT03270553|Drug|metformin|single oral dose
45950386|NCT00117182|Drug|Dry powder mannitol|
45950387|NCT00117182|Drug|Budesonide 400mcg administered via turbuhaler|
45950388|NCT00117182|Drug|Ipratropium bromide 80mcg|
45950389|NCT00117182|Drug|Salbutamol 400mcg|
45950390|NCT03270202|Behavioral|PAI group|"physical activity defined as 100 weekly PAI during 1 year~smartphone application and a user-friendly activity wristband (Mio PAI Slice)"
46002666|NCT04645875|Other|SitLess regimen|See SitLess regimen arm description
45950391|NCT03270202|Behavioral|Usual care|Participants will be informed about, and encouraged to be active according to current recommendations for physical activity from the health authorities.
45950392|NCT00116883|Drug|GW685698X aqueous nasal spray|
45812582|NCT04707950|Drug|Oxytocin|both groups will be given oxytocin as a standard management
45812583|NCT03681236|Procedure|Alveolar recruitment maneuver|Applying plateau pressure 30cmH₂O for 30 seconds to achieve alveolar inflation
45950393|NCT03270397|Behavioral|"Academic course The group- theory and practice"|"Active participation in the course The group- theory and practice."
45453693|NCT05626309|Drug|Placebo|It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after esophageal cancer surgery.
45950394|NCT03270280|Drug|Nigella Sativa Oil|The individuals will apply 55 drops of Nigella sativa Oil on gingivae twice daily for two weeks
45812584|NCT03593564|Behavioral|KINDER|KINDER is an online course for people assisting an older adult with dementia. It is intended to improve the quality of caregiver's relationship with the care recipient and reduce the chance of risky relationship behavior (e.g., yelling). Courses will cover topics including understanding cognitive impairments, navigating evolving roles, and dealing with frustration. During this course, participants will learn skills to deal with difficult situations caregivers frequently encounter in ways that support a healthy caregiving relationship. Videos will be story-based and represent different types of caregiving relationships and challenges encountered.
45950395|NCT03270280|Drug|Normal saline|The individuals will apply 55 drops of Normal saline on gingivae twice daily for two weeks
45950396|NCT00116922|Drug|Avandamet [Rosiglitazone 2mg/Metformin 500mg] BID|[Rosiglitazone 2mg/ Metformin 500mg] twice daily
45950397|NCT03270358|Procedure|Blood sampling in arterioveinous fistula without stenosis|"Plasmatic osteopontin level (ng/ml) collected in the patient's arteriovenous fistula.~Blood sampling in arterioveinous fistula right before a dialysis session"
45950398|NCT03270358|Procedure|Blood sampling in arterioveinous fistula with stenosis|Blood sampling in arterioveinous fistula right before the surgery for stenosis of the fistula
45950399|NCT03270475|Other|exercise training|subjects complete 4-5 weeks of training
45950400|NCT00474565|Procedure|Placement of an aortic root pigtail catheter.|Seldinger technique for placement of catheter.
45659431|NCT05524519|Drug|Basic treatment|"Health education: Properly explain the causes and precautions of the patient and instruct the patient to rest regularly. In addition, care should be enhanced to avoid accidents.~The basic therapeutic drug is the use of one or more antidepressants, such as oral 5-hydroxytryptamine reuptake inhibitors, dual inhibitors of pentraxin and norepinephrine reuptake, noradrenergic and specific pentraxinergic antidepressants, pentraxin receptor balance antagonists, tricyclic antidepressants, etc. If there is significant sleep disturbance, benzodiazepines may be added temporarily. Dosing and dosage will be adjusted by a specialist."
45812585|NCT04044560|Biological|blinatumomab|Continuous intravenous infusion
45812586|NCT02569892|Device|Pascal Retinal Laser Photocoagulator|Sub-threshold macular laser treatment with Pascal laser Endpoint Management System
45812587|NCT02571218|Device|Substrate+mCPVA|The intervention in the experimental arm includes using a research software (investigational device) to map AF substrate and guide ablation.
45812588|NCT02571218|Device|mCPVA|The intervention in the active comparator arm includes using the commercially available EnSite Velocity mapping and ablation system for modified circumferential pulmonary vein ablation.
45812589|NCT03807440|Drug|Empagliflozin|Empagliflozin
45950401|NCT00116961|Drug|Velcade|
45950402|NCT00116961|Drug|Doxil|
45950403|NCT00116961|Drug|Dexamethasone|
45950404|NCT00474682|Drug|Micronized dispersible ferric pyrophosphate|
45950405|NCT00474721|Drug|ibuprofen|
45950406|NCT00474721|Drug|acetaminophen with codeine|
45950407|NCT00117260|Drug|Seasonale (levonorgestrel and ethinyl estradiol)|
45950408|NCT00474799|Drug|MNS075|MNS075 7.5mg q1h MNS075 15mg q3h
45950409|NCT00474838|Drug|intensive insulin group|Once daily long acting insulin and preprandial rapid acting insulin injection
45950410|NCT00474838|Drug|Oral AntiDiabetic Drug (glimepiride and metformin)|glimepiride and metformin combined therapy
45950411|NCT00474877|Device|Static resting splints|
45950412|NCT04727918|Procedure|Polypectomy of diminutive colorectal polyps will be performed by CBF|All polypectomy procedures will be standardized amongst the study centers. Endoscopists with a minimal experience of at least 50 CBF and CSP performed the polypectomies CBF : The CBF will be performed using a standard biopsy forceps (Gluton Life ® Life Partners). Multiple biopsies bites were taken until complete resection (as many as needed).
45950413|NCT04727918|Procedure|Polypectomy of diminutive colorectal polyps will be performed by CSP|All polypectomy procedures will be standardized amongst the study centers. Endoscopists with a minimal experience of at least 50 CBF and CSP performed the polypectomies CSP : The CSB procedure will be performed using a 9 mm cold snare (Exacto ® Life Partners). One to two mm of normal surrounding mucosa will be ensnared around the base of the polyp, followed by mechanical excision without electrocautery
45950414|NCT04054453|Combination Product|Intra-partum care bundle invoking 4 elements|Care bundle involving all the 4 elements
45950415|NCT00474916|Drug|KRN5500|Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo . The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.
45950416|NCT00474916|Drug|Placebo|Normal Saline given as dose escalation for placebo
45950417|NCT00475072|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
45950418|NCT00475072|Drug|ribavirin|1000/1200mg po daily for 48 weeks
45950419|NCT00475111|Behavioral|Cognitive Behavior Therapy for Pain (CBT-P)|
45950420|NCT00475111|Behavioral|Mindfulness Meditation for Emotion Regulation (MM-ER)|
45950421|NCT00475111|Behavioral|Rheumatoid arthritis education|
45950422|NCT00117299|Drug|PTK787/ZK222584|PTK787/ZK222584 is administered at the dosage of 1250 mg o.d. orally
45950423|NCT00117000|Drug|testosterone undecanoate|
45950424|NCT02956369|Dietary Supplement|Control|Control granulates (maize starch and long-chain fatty acids) with powder
45950425|NCT02956369|Dietary Supplement|SATIOSTAT|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder
45950426|NCT02956408|Dietary Supplement|Vitamin D3|Patients will be prescribed either 2000 IU or 6000 IU of vitamin D3 per day. They will go to a pharmacy and purchase a vitamin D3 supplement in their preferred form (eg gummy, liquid, chew, tablet, capsule)
45659432|NCT05524519|Procedure|PSA|Four PSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20*1.5m or φ0.20*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
45659433|NCT05524519|Procedure|TSA|Four TSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20*1.5m or φ0.20*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
45812590|NCT03807440|Drug|Sodium Glucose Transporter 2 inhibitor|Sodium Glucose Transporter 2 inhibitor
45812591|NCT03807440|Drug|Dipeptidyl-peptidase 4 inhibitor|Dipeptidyl-peptidase 4 inhibitor
45812592|NCT03807440|Drug|Glucagon-like peptide 1 agonist|Glucagon-like peptide 1 agonist
45812593|NCT02573402|Device|Transcutaneous Tibial Nerve Stimulation|10 sessions over a 2 week period of TTNS for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. Current intensity may vary from patient to patient and will be documented and used in the analysis.
45812594|NCT02573402|Device|Control|10 sessions over a 2 week period of TTNS sham stimulation for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode. Current intensity will be set to zero.
45812595|NCT03791060|Drug|Secukinumab|Secukinumab is selective for human IL-17A and potently neutralizes the bioactivity of this cytokine. IL-17A is the central cytokine in multiple autoimmune and inflammatory processes. It is being recognized as one of the principal pro-inflammatory cytokines in autoimmune diseases such as psoriasis, PsA and AS, uveitis and is thought to play a role in other inflammatory conditions.
45812596|NCT00364364|Drug|Radiolabeled humanized PAM4 IgG|
45812597|NCT03256916|Drug|Nelfinavir|Nelfinavir (HIV protease inhibitor) targets proteasome and inhibits AKT phosphorylation and plays an important role in radiosensitization of tumour cells.Nelfinavir will be given to the patient orally with food, because the bioavailability increases under the influence of food.
45812598|NCT03256916|Drug|Cisplatin|Cisplatin will be administered on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT. Patient will be premedicated with I.V Ondansetron to prevent emesis. Pre chemotherapy and post chemotherapy, patient will be administered IV fluids for effective renal clearance of cisplatin.
45950427|NCT00475189|Drug|loestrin 24/4 vs loestrin 1/20|One month of loestrin 1/20 then randomized to Loestrin 24/4 or Loestrin 1/20 x 3 months. After 3 months if randomized to 1/20 will be switched to 24/4 if already on 24/4 will be given a choice which OC they want to continue for 3 more months.
45950428|NCT00475189|Drug|loestrin 1/20|loestrin 1/20 1 tab 21/7 x 3mo and then changed to Loestrin 24 FE
45950429|NCT00117377|Drug|Pimecrolimus|Pimecrolimus cream 1 % bid
45950430|NCT00117377|Drug|Placebo|Placebo application bid
45950431|NCT00475267|Device|Trifecta aortic heart valve|Intended as a replacement for a diseased, damaged, or malfunctioning aortic heart valve.
45950432|NCT02964195|Drug|Rifaximin|ALFA WASSERMANN S.p.A.
45950433|NCT00475345|Behavioral|Bedtime snacks|
45950434|NCT00475462|Drug|metoprolol|
45950435|NCT00475462|Drug|conventional treatment|
45950436|NCT00475579|Procedure|tube with subglottic drainage and polyurethane cuff|
45950437|NCT00475618|Procedure|topical fluoride varnish application.|Vanish application every 6 months in all accesible tooth surfaces
45950438|NCT00475618|Procedure|professional cleaning|Daily use fluoride toothpaste 500 ppm.
45950439|NCT00475618|Procedure|No fluoride toothpaste|Daily use no fluoride toothpaste.
45950440|NCT00117039|Drug|Aranesp®|
45950441|NCT00475696|Drug|Duloxetine|
45950442|NCT00117455|Drug|pegfilgrastim|
45950443|NCT00117455|Drug|filgrastim|
45950444|NCT00475774|Behavioral|Long-chain (C18:2) and medium chain fatty acid (C8 and C10).|
45950445|NCT03270007|Drug|Vinorelbine|different from primary chemotherapy(containing anthracycline or paclitaxel)
45950446|NCT00475813|Drug|FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)|
45950447|NCT00402038|Drug|SC Methylnaltrexone|Dose 1
45659434|NCT05524519|Procedure|CCA|Acupoints: LR3 (Taichong), PC6 (Neiguan), SP6 (Sanyinjiao), and HT7 (Shengmen). PC6 and HT7 will use φ0.20*1.2mm acupuncture needle. LR3 and SP6 will use φ0.20*1.5m acupuncture needles. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
45659435|NCT05524441|Other|Circadian Disruption - Quasi-Experimental|2 conditions: comparing trips with circadian disruption to trips without circadian disruption
45453694|NCT01106365|Device|H-coil (Repetitive deep transcranial magnetic stimulation)|Repetitive deep transcranial magnetic stimulation of prefrontal cortex or motor cortex or sham stimulation
45659436|NCT02380677|Drug|CRLX301|
45659437|NCT02380287|Drug|humanized monoclonal antibody against human IL-17|
45659438|NCT02343003|Device|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe
45659439|NCT02343003|Drug|Corticosteroid injection|Delivery of corticosteroid into knee by injection with needle to reduce knee pain
45659440|NCT04900701|Other|Energy status|Varying conditions of energy intake, thereby manipulating whether participants are in a state of energy restriction, balance, or surplus.
45659441|NCT02394561|Biological|Secukinumab|Secukinumab was supplied as 150 mg solution in pre-filled syringe for subcutaneous injection
45659442|NCT04904913|Drug|IBI362|IBI362 administered subcutaneously (SC) once a week.
45659443|NCT04904913|Other|placebo|placebo administered subcutaneously (SC) once a week.
45659444|NCT02342223|Device|Voluma|
45659445|NCT02393547|Drug|Varenicline|All subjects receive Varenicline
45812599|NCT03256916|Radiation|Pelvic EBRT and Brachytherapy|Pelvic EBRT will delivered by standard 4 field technique using 6MV/15 MV photon beams. Prior to delivery of radiation, patients will be simulated by CT simulator for planning the beam arrangements. Total dose of pelvic EBRT will be 45- 50Gy/23-25 #/5 weeks. The prescribed dose will be specified according to ICRU 50 guidelines. All patients will be treated with 3D conformal external radiation with target delineation and multileaf collimator leaf shaping.
45812600|NCT02579876|Drug|Viaskin Milk 500 mcg|Biological: Viaskin Milk 500 mcg Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
45812601|NCT02579876|Drug|Viaskin Placebo|Biological: Viaskin Placebo Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
45812602|NCT00364052|Drug|oral Valganciclovir vs oral Ganciclovir|
45812603|NCT03169166|Drug|Triptorelin|Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart
45950448|NCT00402038|Drug|SC Placebo|
45659446|NCT02393547|Drug|Lorcaserin|All subjects receive Lorcaserin
45659447|NCT02574637|Drug|Brazikumab IV Infusion|Brazikumab IV infusion as per protocol specified dosing schedule.
45659448|NCT02574637|Drug|Brazikumab SC Injection|Brazikumab IV infusion as per protocol specified dosing schedule.
45659449|NCT02574637|Drug|Placebo|Placebo-matching Brazikumab IV infusion as per protocol specified dosing schedule.
45659450|NCT05531539|Device|WELMO sensors vest|Wearing of a vest equipped with lung auscultation and EIT sensors for signal acquisition and transmission
45659451|NCT05526235|Behavioral|Doing What Matters (DWM)|The original DWM program consists of a self-help guide called 'Doing What Matters in Times of Stress', that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. In this study, DWM will be delivered as an online intervention. The DWM intervention, i.e. both the audio recordings and the self-help guide, has been adapted for use on a smartphone or other device with internet access. The format of DWM is innovative in that it seeks to ensure that key intervention components are delivered as intended through the use of pre-recorded audio, without the burden of extensive training and supervision. In the online application tool a new module is released every week so participants will be asked to go through the entire DWM intervention within 5 weeks with weekly guidance from a helper.
45659452|NCT05526235|Behavioral|Problem Management Plus (PM+)|PM+ is a new, brief, psychological intervention program based on cognitive behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support. Across the five 90-minute sessions participants may talk to trained non-professional. PM+ has four core features, and it is brief. In this study, the delivery mode of the PM+ intervention will be flexible, with remote delivery in phases of the pandemic when physical distancing rules apply. This is a future-oriented attempt towards a more holistic mental health care system that can flexibly switch between modes of delivery (e.g. remotely (e.g. Zoom) or face-to), depending on the needs and the specific containment measures that apply, and the specific preferences and needs of the participant.
45950449|NCT00475930|Drug|2% chlorhexidine gluconate (CHG) impregnated cloths|self applied three times per week
45812604|NCT02787668|Other|Carbohydrate-restricted diet|Participants will be randomized (20 per group) to the carbohydrate restricted diet (i.e., CHO <10%; fat >65%, protein 25%) or a low fat diet (CHO 55%; fat 20%; protein 25%) for 8 weeks. Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
45812605|NCT02787668|Other|Control, low-fat diet|Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
45950450|NCT00475930|Drug|Comfort Bath cloths (placebo cloths)|self applied three times weekly
45950451|NCT00475969|Drug|duloxetine|
45659453|NCT05526235|Behavioral|Psychological First Aid (PFA)|PFA is a brief intervention consisting of a 15-min call that assess the immediate concerns and needs of an individual in order to connect individuals to help and resources.
45659454|NCT05531383|Drug|Memantine Hydrochloride|study the effect of memantine on platelet, platelet/lymphocyte ratio (PLR) and C reactive protein (CRP) & serum NSE levels in patients with moderate to severe TBI as well as their outcome.
45950452|NCT00475969|Drug|placebo|
45950453|NCT05376306|Behavioral|Stress Reduction: MBSR|Four activities, one each week - raising body awareness, sitting meditation, mindful yoga, expanding awareness meditation.
45950454|NCT05376306|Behavioral|Stress Reduction : PMR|Progressively tensing and releasing each muscle group from head to toe in a specific order.
45950455|NCT04727840|Drug|Sodium Zirconium Cyclosilicate Oral Product|"Sodium zirconium cyclosilicate (SZC), a non-absorbed cation exchanger, selectively binds potassium in the intestine. SZC is in a powder form and will be provided to patients in packets containing 5g or 10gm of the medication. Participants will mix the contents of one packet with water (about 45mL). The drink should be stirred and drank immediately. If powder remains in the glass, then water should be added and the remainder of the drink should be consumed. Other medications should be taken 2 hours before or after SZC.~At Day 0 and Day 1, participants will be taking SZC at 10gm three times a day. A serum potassium will be checked on Day 2; if serum potassium is <5.1mEq/L, then the dose will be decreased to the maintenance dose of 5gm per day. At each serum potassium checks, the medication dosage will be adjusted accordingly."
45950456|NCT00476164|Drug|Rituximab|2 doses of 1g 14 days apart
45950457|NCT00476164|Other|Control arm|Continue of optimised oral immunosuppression
45950458|NCT00476203|Behavioral|Yoga|Instructor-led yoga classes 1/time per week + 4 days of home practice
45950459|NCT00476203|Other|Delayed yoga classes|Delayed yoga classes (after 6 months) offered [wait list control group]
45659455|NCT05524207|Procedure|carotid artery stenting|Implantation of stents at the site of carotid artery stenosis for the treatment of carotid plaque with severe stenosis
45659456|NCT05526079|Other|Watchfuf waiting|Careful review of patient response with the hope of avoiding radical surgery.
45659457|NCT05287945|Drug|Orellanine|single intravenous administration of orellanine over 30 (±5 minutes) following hemodialysis
45659458|NCT02392611|Drug|Alobresib|Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle
45659459|NCT02392611|Drug|Exemestane|Tablets administered orally once daily on Cycle 1 Day 1 of 28 days cycle
45950460|NCT00476281|Procedure|Urinary collect|
45950461|NCT00476281|Procedure|Continuous Glucose Monitoring System (CGMS)|
45950462|NCT00402077|Drug|pramlintide acetate|subcutaneous injection, three times a day, 120mcg
45950463|NCT00402077|Drug|sibutramine|oral tablet, once a day, 10mg
45950464|NCT00402077|Drug|phentermine|oral tablet, once a day, 37.5mg
45950465|NCT00402077|Drug|placebo|subcutaneous injection, three times a day
45950466|NCT00476320|Procedure|Magnetic Resonance Imaging|
45950467|NCT00476320|Procedure|Revascularization|
45950468|NCT00476320|Procedure|Echocardiography with myocardial deformation imaging|
45950469|NCT00476359|Drug|Lopinavir/r plus saquinavir|lopinavir/ritonavir 230/57.5 mg/m2 orally twice daily and saquinavir 50 mg/kg orally twice daily
45950470|NCT00117117|Drug|Aranesp|
45950471|NCT00476398|Procedure|Capsule endoscopy|Patient will undergo a capsule endoscopy for the evaluation of their chest pain.
45950472|NCT00476437|Drug|biphasic insulin aspart|
45950473|NCT00476437|Drug|biphasic human insulin|
45950474|NCT00117494|Drug|Pravastatin|
45950475|NCT00117494|Drug|Rosuvastatin|
45950476|NCT03270046|Procedure|Water enema|Addition of water enema in standard PEG preparation in participants scheduled for CRC screening.
45950477|NCT03279952|Drug|CNS Stimulant|Participants will be stabilized by any FDA approved CNS stimulant medication during open label trial.
45950478|NCT00117195|Device|Automated Neuropsychological Assessment Matrix|"This study will evaluate a profile of neurophysiologic tests for potentially predictive signs of PD or PS in individuals with PD or PS, those who may be at risk for PD or PS and in a population of individuals without parkinsonian symptoms or any other neurologic conditions.~In addition, the study will evaluate serum samples for changes in proteins or metabolites that may be indicators of early changes associated with Parkinson's disease or parkinsonian syndrome."
45950479|NCT00117533|Drug|pegylated IFN alfa-2b plus ribavirin|
46076939|NCT02541877|Device|Standard sizing valve in type-0 BAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Standard sizing valve implantation will be used in type-0 BAS.
46076940|NCT02541877|Device|Standard sizing valve in TAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Standard sizing valve implantation will be used in TAS.
45659460|NCT02392611|Drug|Fulvestrant|Administered intramuscularly on Cycle 1 Day 1 of 28 days cycle and every 28 days
45659461|NCT02378961|Drug|VOX|100 mg tablet(s) administered orally once daily with food
45659462|NCT02378961|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily with food
45659463|NCT02378883|Device|Apollo™ Onyx™ Delivery Micro Catheter|
45812606|NCT02582216|Device|3D augmented reality|Each treatment period included a 3DARS (3D augmented reality system)training session.All 3DARS training sessions were performed in the same quiet room under the supervision of the same single investigator.The 3DARS training session protocol included two virtual training procedures. The first virtual training procedure consisted of applying a vertical virtual mirror to the display screen, where the non-affected side of the patient's body (such as the right) was symmetrically duplicated by a vertical axis on the affected side (such as the left).The second virtual training procedure consisted of flipping the 3D image horizontally along a vertical axis. This allowed patients to observe the reflection of their non-affected upper extremity as if it was the affected one.
45812607|NCT02582840|Drug|Dapagliflozin 5mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
45812608|NCT02582840|Drug|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
45659464|NCT05145829|Diagnostic Test|Diagnostic Test: Sentinel node mapping using MRI|Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
46076941|NCT04223076|Drug|Chlorhexidine 0.2%, Corsodyl|Comparison of Corsodyl and Curasept
46076942|NCT04223076|Drug|Chlorhexidine 0.2%, Curasept|Chlorhexidine 0.2% mouthwash with an Anti Discoloring System (ADS)
46076943|NCT00951275|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 months
45659465|NCT05140525|Drug|Macitentan Tablets|10 mg oral once daily
45659466|NCT05140525|Drug|Riociguat|1 mg to 2.5mg oral three times daily
46076944|NCT00951275|Drug|Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)|As prescribed
46076945|NCT00888199|Device|Experimental prosthetic foot (K3 Promoter)|Experimental prosthetic foot
46076946|NCT02764008|Drug|Bupivacaine|20 ml %0,25 bupivacaine
46076947|NCT02764008|Device|Ultrasound|
46076948|NCT00891709|Drug|LEO 29102|First-in-man. Healthy volunteers
45659467|NCT05140525|Device|balloon pulmonary angioplasty|on hemodynamics and RV function (including advanced assessments of RV-PA coupling
45659468|NCT05531071|Device|Biofeedback electrical stimulation|treated with biofeedback electrical stimulation, 3 times a week for 30 minutes for 15 times.
46076949|NCT04222530|Diagnostic Test|Linear EUS first|Linear endoscopic ultrasonography followed by magnifying narrow band endoscopy are used to determine the depth of invasion of early rectal cancer.
45659469|NCT05531071|Procedure|Acupuncture|acupuncture treatment, including Guanyuan, Qihai, Zhongji, Zusanli, Sanyinjiao and Yinlingquan, once a day, Monday to Friday, 30 minutes each, a total of 10 times.
45659470|NCT05531071|Combination Product|Acupuncture combined with biofeedback electrical stimulation|treated with acupuncture combined with biofeedback electrical stimulation.
45812609|NCT02582840|Drug|Placebo tablet|Placebo tablet. Oral dose
45950480|NCT00117234|Drug|darbepoetin alfa|
45950481|NCT00117611|Drug|Anti-IgE antibody omalizumab or placebo|given subcutaneously oce or twice monthly depending on dose
45950482|NCT05374239|Other|Multi-component implementation intervention|The multiple-component implementation intervention will comprise of 3 key components: (1) education, (2) operational process, and (3) audit and feedback
46076950|NCT04222530|Diagnostic Test|ME-NBI first|Magnifying narrow band endoscopy followed by linear endoscopic ultrasonography are used to determine the depth of invasion of early rectal cancer.
45659471|NCT05518591|Behavioral|Compassion Focused Therapy (CFT) combined with Breathing Pattern Retraining (BPR)|Study participants in the experimental arm of the study are being asked to take part in a 6-week, virtual, psychological therapy group involving compassion focused therapy and breathing pattern retraining. This group involves exercises in practicing self-compassion, emotional regulation, and breathing retraining. Each group session lasts less than two hours, per week.
46076951|NCT04037137|Other|Questionnaire|Caregiver Difficulties Scale, Impact on Family Scale, WHOQOL-BREF Quality of Life Assessment, Nottingham Health Profile, Fatigue Severity Scale, Beck Depression Scale
45659472|NCT05518513|Drug|Bupivacain|adductor canal block with 0.25% bupivacaine
45659473|NCT05518279|Drug|Tranexamic Acid Pill|Patients will receive 1950mg of an oral tranexamic acid pill (3 pills total) while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the oral TXA and are medically optimized, they will be taken to the operating room for fracture fixation.
45812610|NCT02583230|Behavioral|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
45812611|NCT00364988|Drug|pioglitazone+losartan|Pioglitazone (30 mg/daily) losartan (100 mg daily)
45812612|NCT00364988|Drug|losartan|losartan (100 mg daily)
45812613|NCT00365222|Drug|Temozolomide|temozolomide 75 mg/m2 /d
45812614|NCT03302156|Drug|PSMA-based 18F-DCFPyL PET tracer|PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer
45812615|NCT03119012|Drug|Clopidogrel|75mg/day
45812616|NCT03119012|Drug|Ticagrelor|120mg/day
45812617|NCT03119012|Drug|Aspirin|100mg/day
45812618|NCT04340804|Behavioral|Kcal labelling|Real-time kcal counter synchronised with the food amount changes
45812619|NCT04340804|Behavioral|PACE labelling|Real-time PACE counter (as minutes needed to walk to burn off the calories) synchronised to the food amount changes
45812620|NCT02580188|Drug|sugammadex|Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block).
45812621|NCT04741958|Diagnostic Test|Ultrasound Guided Peripheral Thoracic Tumors|Transthoracic ultrasonography: Transthoracic US was done using machine Hitachi 5500 in the Diagnostic Ultrasound Unit - Chest Department- Kasr El-Aini Hospital.on 60 patients that had radiographic evidence of thoracic mass suspected of malignancy
45812622|NCT02584790|Device|Laryngoscope with NBI system|All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
45812623|NCT02584868|Drug|Hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution|Peri-operative fluid replacement therapy (max 40ml/kg/day)
45812624|NCT02584868|Drug|Hydroxyethyl starch 130/0.4 in 0.9% sodium chloride|Peri-operative fluid replacement therapy (max 40ml/kg/day)
45812625|NCT02586896|Behavioral|Strengths-based Case Management (SBCM)|The six case management sessions for the proposed trial are based on those described in manuals developed by Dr. Rapp for two clinical trials, one supported by National Institute on Drug Abuse (NIDA) and another by the Centers for Disease Control (CDC). Each session is guided by specific objectives that promote linkage with and retention in substance abuse treatment, particularly pharmacotherapy for opioid dependence in a specialty or primary care setting. Objectives from the earlier trials will be adapted to fit the specific context of this trial, linking with and staying in treatment following an emergency department visit. Initiation of the relationship between client and case manager begins immediately following random assignment and termination takes place when either (1) six sessions have occurred; (2) ninety days have elapsed; or (3) clients discontinue involvement.
46002667|NCT00546650|Drug|Sumatriptan succinate|NP101 iontophoretic transdermal system
46002668|NCT00546650|Drug|Sumatriptan succinate|oral, subcutaneous, and intranasal formulations
45659474|NCT05518279|Drug|Placebo Oral Tablet|Patients in the control arm will receive 3 placebo pills while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the placebo pills and are medically optimized for surgery, they will be taken to the operating room for fracture fixation.
46002669|NCT04637373|Diagnostic Test|Hysteroscopy|adding Hysteroscopy before and after suction curettage for early missed abortion to define the wall of implantation and look for retained products of conception
46076952|NCT04111224|Diagnostic Test|pentraxin 3 marker|Assess the role of pentraxin3 (PTX3) in the early diagnosis of ventilator-associated pneumonia (VAP).
46076953|NCT00798603|Biological|bevacizumab|
46076954|NCT00798603|Drug|carboplatin|
46076955|NCT00798603|Drug|pemetrexed disodium|
46076956|NCT04036981|Drug|Botulinum toxin type A|Injection of botulinum toxin A into the spastic elbow flexor muscle or muscles
46076957|NCT02763618|Other|Neurofeedback|Neurofeedback theta/beta ratio training. See 'Neurofeedback theta/beta ratio training' in detailed study description.
45453695|NCT03949309|Other|Exploring health literacy levels and patients' informal needs or individual relationship between caregivers and patients.|It is a cross-sectional study coupled with a qualitative ancillary study conducted within patients hospitalized for one of the two acute cardiovascular diseases (acute coronary syndrome or acute heart failure). All patients hospitalized at Hospices Civils de Lyon for one of these two diseases and whom are going back home will be enrolled. Few patients will be interviewed during the follow-up visit at 1-month post hospitalisation. Caregivers from cardiology units will also be interviewed.
45453696|NCT05626075|Diagnostic Test|Using Oculus Pentacam® which is s a rotating Scheimpflug camera. The rotational measuring procedure generates Scheimpflug images in three dimensions.|Scheimpflug imaging attains a wide and high depth-of-focus , providing sharp images that include information from an anterior corneal surface through to the posterior crystalline capsule
45659475|NCT05523661|Drug|Dasatinib plus anti-CD19/CD22 CAR-T cells|Dasatinib plus VP chemotherapy was administrated to newly diagnosed Ph-positive patients aged 55-70 years old,if hCR was achieved,autolymphocyte was collected,and anti-CD19/CD22 CAR-T cells infusion was administrated to patients followed by Fludarabine and Cyclophosphamide therapy
45659476|NCT05523583|Other|questionnaire|A trained interviewer (Clinical Research Associate : CRA) will administer a questionnaire soon after the diagnosis on the phone (within 15 calendar days after diagnosis). The participants are followed up during the first year following the diagnosis through 3 follow-up assessments (at 3, 6, and 12 months after the baseline assessment) and hospital record reviews. At each follow-up, a brief questionnaire will be administered by an interviewer (CRA) via telephone.
45812626|NCT02586896|Behavioral|Screening, Assessment, and Referral (SAR)|"The research assistant will provide these participants with an information sheet listing treatment (including both specialty treatment centers and primary care clinics that provide buprenorphine) and self-help resources in their community. The referral sheet includes names, addresses, and phone numbers of local addiction treatment agencies. Because the emergency department does not currently screen or refer systematically, the SAR condition represents a level of care significantly higher than treatment as usual. Participants will also receive an informational pamphlet about drug use and its consequences, addiction, and treatment."
45812627|NCT02586974|Device|Humigard|warmed and humidified CO2 insufflation
45812628|NCT05249504|Other|VIVIFRAIL|"VIVIFRAIL is a set of physical activity programs (designed according to several elderly functional level profiles) aimed to prevent motor disability and improve quality of life. It works endurance, flexibility, balance and strength.~https://web.archive.org/web/20210907041944/https://vivifrail.com/"
45812629|NCT05249504|Other|Nutrition|Sessions to learn about personal nutrition habits, offer nutritional advice, and acquire skills to incorporate simple healthy nutrition guidelines into everyday life. A visit to a supermarket to make it easier to read and understand the basic information on nutrition labels.
45812630|NCT05249504|Behavioral|Psychology|Relaxation techniques to manage mood, a photo-elicitation dynamic to address loneliness, and a dynamic to collectively develop a map of health assets in the neighborhood or territory to obtain information on community resources. Finally, a group visit is planned to a community facility previously agreed upon by the participants.
45812631|NCT05249504|Behavioral|Personal autonomy|Review practical cases on personal autonomy, the proper use of medications, and discover basic cognitive stimulation strategies.
45812632|NCT05249504|Other|Community resources|Learn about community resources
45812633|NCT05249504|Other|Standard recommendations|Usual advice provided at primary care office accompanied to booklets about healthy lifestyles
45812634|NCT05248256|Other|Evidence-based radiation dose limitation to the vertebral bone marrow|The only intervention that will occur during the radiation treatment planning process will be the application of evidence-based radiation dose limitations to the vertebral bone marrow during treatment plan optimization in order to attempt to limit Grade 3 Lymphopenia (G3L) toxicity.
45812635|NCT02983292|Device|PyroTITAN™ HRA|Humeral Resurfacing
45812636|NCT02791568|Procedure|Ultrasound Scan|The research exam is expected to take 30 minutes for blood flow assessments
45812637|NCT02791568|Procedure|MRI Scan|MR imaging will take approximately 30 minutes.
45812638|NCT02791568|Drug|Ferumoxytol|A subset of subjects will complete MRI imaging with ferumoxytol as a contrast agent at the 24-28 week visit. A nurse will administer ferumoxytol in a hospital triage with pulse and blood pressure monitoring and fetal heart monitoring. The pharmacy will prepare the infusion and deliver to triage. Subjects will arrive at the obstetric triage unit for ferumoxytol injection three days prior to their scheduled ferumoxytol MRI study. In the triage, the nurse will obtain baseline vital signs and fetal heart rate. The IV Ferumoxytol infusion will be 30 minutes and atients will be monitored at 5 to 15-minute intervals. Three days after the ferumoxytol infusion, at 24-26 weeks gestation, subjects will have blood/urine collected, undergo a 30 minute ultrasound, a 30 minute MRI, an adverse event review, and medical record review. The MRI scanning procedure will be conducted at WIMR and will last approximately 30-60 minutes.
45812639|NCT02410304|Device|Xrays|Clinical evaluation
45812640|NCT02410304|Device|Ultrasound (B mode )|
45812641|NCT02410304|Device|Ultrasound (D mode)|
45812642|NCT02004704|Drug|GZ402665|"Pharmaceutical form: Powder for concentrate for solution for infusion~Route of administration: intravenous infusion"
45950483|NCT04727684|Drug|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
45453697|NCT03845491|Device|Mechanical Thrombectomy|Treatment of LVO with mechanical thrombectomy
45453698|NCT03944551|Device|Bubble CPAP|Those assigned to the bCPAP group will receive a Total flow oxygen at a rate of 2 liters per kilogram to a maximum of 10 liters per minute using the appropriate nasal prongs for the age and size of the patient. The positive end-expiratory pressure (PEEP) provide by bCPAP will start at 8cm HO2. The FIO2 will be adjusted to obtain a saturation of oxygen of 90% or greater.
45453699|NCT03944551|Other|Standard Therapy|For patients in the standard therapy group, oxygen will be delivery by nasal cannula at a flow rate of 4 Liters per minute. If a patient in the standard group after 1 hour of treatment still has a SpO2 < 90% or meeting criteria of treatment failure the patient will be move from the standard therapy group to the bCPAP group.
45453700|NCT01108783|Drug|Bilastine|20 mg (encapsulated) tablets QD/14 days
45659477|NCT04424953|Device|McGrath videolaryngoscope|A brand of a commonly-used videolaryngoscope which has a camera at the end of the laryngoscope to visualize the vocal cords
46076958|NCT02763618|Other|Placebo Neurofeedback training|The placebo training will be a previously recorded Neurofeedback session of a participant in group A
45453701|NCT01108783|Drug|Desloratadine|5 mg (encapsulated) tablets QD/14 days
45453702|NCT01108783|Drug|Placebo|(encapsulated) Tablets QD/14 days
45453703|NCT03795103|Device|neuromuscular electrical stimulator|A 12-week program of neuromuscular electrical stimulation
45659478|NCT04424953|Device|Direct laryngoscope|Classic direct laryngoscope that depends on visualization of the vocal cords by the operator
45812643|NCT05372432|Other|Handgrip strengths measurements with Jamar-type hand dynamometer and, tip pinch strengths measurements with pinchmeter|The handgrip strength and tip pinch strength of the participants were measured using the Jamar-type hand dynamometer and pinch meter available in our clinic. The handgrip strengths were measured with shoulders in adduction and neutral rotation, elbows in 90 degrees flexion, and forearms and wrists in a neutral position, while the tip pinch strengths were measured by squeezing a pinch meter between the thumb and index finger. Participants took a deep breath and then applied gripping force with maximal force while exhaling. In the analysis, the average of the three measurements made with an interval of five minutes was taken as the basis for the analysis.
46076959|NCT00891787|Dietary Supplement|Probiotic Supplement|
46076960|NCT02758392|Drug|JNJ-61178104 Intravenous|Participants will receive JNJ-61178104 Intravenously on Day 1.
46076961|NCT02758392|Drug|JNJ-61178104 Subcutaneous|Participants will receive JNJ-61178104 Subcutaneously on Day 1.
46076962|NCT02758392|Drug|Placebo|Participants will receive placebo on Day 1.
46076963|NCT00887354|Drug|Teriparatide|Administered subcutaneously
46076964|NCT00887354|Drug|Risedronate|Administered orally
46076965|NCT00887354|Drug|Placebo|"Weekly: Administered orally~Daily: Administered subcutaneously"
46076966|NCT00887354|Dietary Supplement|Calcium|Approximately 500 to 1000 mg/day administered orally throughout study.
45453704|NCT03795103|Other|Walking sessions|A 12-week program of walking sessions performed outdoors and independently
45453705|NCT03795103|Other|Advices|The usual practice associated with an information leaflet outlining tips for active living and walking.
45453706|NCT03778411|Device|VCTE with splenic stiffness measurement|Subjects will undergo vibration controlled transient elastography to measure liver stiffness (LSM) liver steatosis via controlled attenuation parameter (CAP) and splenic stiffness
45659479|NCT05523193|Other|Formal treatment model|Formal treatment model , no further surgery or minimally invasive treatment was performed
45659480|NCT05523037|Drug|Sevoflurane|For the maintenance of anesthesia, the end-tidal concentration of 1 minimum alveolar concentration (MAC) sevoflurane and the concentration was adjusted by 1% stepwise titration
45659481|NCT05523037|Drug|Remimazolam|For the maintenance of anesthesia, 1-2 mg.kg-1.h-1 of remimazolam was continuously infused.
45659482|NCT04625647|Drug|Sotorasib|Given PO
45659483|NCT05122741|Drug|P2Y12 Potent Inhibitor + Aspirin for STEMI patients|Patients will undergo primary percutaneous coronary intervention and DAPT with potent P2Y12 inhibitor (ticagrelor or prasugrel + aspirin)
45812644|NCT05372432|Other|The Nine Hole Peg Test|This test was used to evaluate the hand dexterity of the participants. This test consists of a square area and nine holes in this area, nine cylinders suitable for these holes, and a storage box. Participants quickly took the nine cylinders from the storage box and placed them in the holes, and after placing all the cylinders, they put the cylinders back in the storage box one by one. In the evaluation of the test, the time elapsed during these operations was measured in seconds with a chronometer, and shorter times were considered to indicate better hand dexterity.
45950484|NCT04727684|Drug|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
45950485|NCT04727684|Drug|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
45950486|NCT04727684|Drug|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.
45950487|NCT03277261|Biological|Ublituximab|Administered as an IV infusion.
46076967|NCT00887354|Dietary Supplement|Vitamin D|Approximately 800 International Units per day (IU/day) administered orally throughout study.
46076968|NCT00951041|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections
45453707|NCT02743780|Drug|MGV354 ophthalmic suspension|
45453708|NCT02743780|Drug|MGV354 placebo|Inactive ingredients used as placebo comparator
45659484|NCT05122741|Drug|Clopidogrel + Aspirin for CCS patients|Patients will undergo elective percutaneous coronary intervention and DAPT with non-potent P2Y12 inhibitor (clopidogrel + aspirin)
45659485|NCT05517889|Diagnostic Test|Optical coherence tomography|Optical coherence tomography is a non-invasive scanner which generates real-time in-vivo images of the skin and its adnexal structures. Images are generated by light-interferometry.
45659486|NCT05525767|Drug|Bevacizumab|All subjects enrolled will receive bevacizumab .Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
45659487|NCT05517811|Diagnostic Test|TEG indices|Blood samples
45950488|NCT03277261|Drug|Teriflunomide|Film-coated tablets administered orally.
45950489|NCT03277261|Drug|Oral Placebo|Administered orally.
46076969|NCT00951041|Biological|GSK investigational vaccine GSK2340269A|Two intramuscular injections
46076970|NCT02760576|Drug|BAY 987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
46076971|NCT00894049|Drug|reduced intensity conditionings|comparison of non myeloablative (Flu-TBI) and reduced intensity (FLU-BU-ATG)
46076972|NCT02763540|Procedure|Lung cryobiopsy|Transbronchial cryobiopsy
46076973|NCT04502160|Procedure|Vascular Access Creation|arteriovenous fistula creation
46076974|NCT02541097|Behavioral|Language therapy|Participants will receive semantic and phonological therapy for words they cannot retrieve spontaneously. They will be given an opportunity to practice the words in a group setting.
45950490|NCT03277261|Drug|IV Placebo|Administered as an IV infusion.
46076975|NCT02832596|Drug|Norepinephrine|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
46076976|NCT02832596|Procedure|Maintained blood pressure|Norepinephrine therapy to maintain preanesthesia blood pressure
46076977|NCT02832206|Procedure|hybrid ablation|Surgical thoracoscopic epicardial ablation (box-lesion) and left atrial appendage occlusion , followed (after 2-3months) by electrophysiological examination, and catheter ablation (completion of the box-lesion, cavotricuspid isthmus ablation and other ablation if indicated)
45659488|NCT05522725|Other|Single-use wipes installed at the bedside|
45812645|NCT05248022|Procedure|Drug-eluting beads bronchial arterial chemoembolization|"Drug-eluting beads bronchial arterial chemoembolization generally uses platinum-containing two-drug chemotherapy platinum (cisplatin, carboplatin, nedaplatin) combined treatment, and drug-loaded microspheres can be loaded with vinorelbine, gemcitabine, irinote Kang, raltitrexed. The dose of chemotherapy drugs is set to 75mg/m2 of platinum, and the dose of chemotherapy through catheter infusion is reduced by 25%. The dose of drug-loaded drugs is vinorelbine 25mg/m2, gemcitabine generally 1000mg/m2, irinotecan 80mg/ m2, raltitrexed 4mg. Chemotherapy was perfused first, followed by embolization with drug-loaded microspheres, until the blood flow in the artery supplying the tumor slowed down and approached stagnation. The number of DEB-BACE treatments is determined by the investigator, and is given as needed according to the patient's condition, usually 1-2 times, with an interval of 28±10 days."
45950491|NCT05373147|Biological|αPD1-MSLN-CAR T cells|The safety and efficacy of αPD1-MSLN-CAR T cells will be assessed in a standard 3+3 dose escalation approach. Four doses of CAR T cells will be evaluated in this study: 1×10^5 CAR+ T cells/kg, 3×10^5 CAR+ T cells/kg, 1×10^6 CAR+ T cells/kg, and 3×10^6 CAR+ T cells/kg.
45950492|NCT04727957|Other|Diagnostic and prognostic models for VA-LRTIs|Diagnostic and prognostic models for VA-LRTIs
45950493|NCT02273947|Drug|BMS-955176|Single dose by mouth for each treatment specified
46076978|NCT00891943|Other|Structured lifestyle support|The intervention group will meet with a research nurse on 14 occasions over the 1 year research study, for structured lifestyle support, including dietary, physical activity and behavioral advice. They will also receive a pedometer.
46076979|NCT02758158|Device|Tri-modal imaging|This trimodal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified.
46076980|NCT00610129|Drug|MK-0646|MK-0646 (20 mg/mL) in sterilized solution for IV infusion (12.7 mL to deliver 12.0 mL) will be used for a dose of 10 mg/kg IV weekly administered over 60 minutes.
46076981|NCT02760420|Drug|Amoxicillin|Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
46076982|NCT02760420|Drug|Placebo|Oral placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
46076983|NCT04612530|Device|Irreversible Electroporation (IRE)|Irreversible electroporation (IRE) is a local ablative technique that utilizes electrical pulses to destroy tumor tissue
46076984|NCT04612530|Drug|Nivolumab|Nivolumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells. Binding of the PD-1 monoclonal antibody onto the PD-1 receptor blocks the brake signal on the T-cells, allowing them to attack the cancer cells.
46076985|NCT04612530|Drug|Toll-Like Receptor 9|Toll-Like Receptor 9 (CpG) is an oligodeoxynucleotide that stimulates dendritic cells to release IFN type I, activating natural killer and infiltrating T cells. This creates a more pro-immunogenic tumor environment.
46076986|NCT02763774|Other|Walking exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs, stationary running and walking. The intensity of walk will be determined by the Borg's sujective effort perception scale - (modified from zero to 10). On first postoperative day, participants will perform exercises in supine position. From the second to the fifth postoperative day, they will perform progressive walking.
45659489|NCT04625101|Drug|NBI-827104|Triple T-type calcium channel blocker.
45659490|NCT04625101|Drug|Placebo|Non-active dosage form.
45659491|NCT05522569|Drug|Allogeneic human mesenchymal stem cells (Allo-hMSCs)|Participants will be treated with one intravenous (IV) infusion of 200 million allogeneic human mesenchymal stem cells (Allo-hMSCs), lasting from 40-90 minutes following an acute ischemic stroke within 9 days after stroke symptom onset.
45659492|NCT05025085|Drug|AGEN1777|An immunoglobulin gamma (IgG1) antibody
45659493|NCT05025085|Drug|a PD-1 inhibitor|Anti-programmed cell death protein 1 (Anti-PD-1) antibody monoclonal antibody
45950494|NCT05367336|Drug|Morphine|second group will be receiving morphine
45950495|NCT05367336|Drug|Fentanyl|third group receiving fentanyl
45950496|NCT00476515|Drug|Rituximab|the recommended dosage of Rituximab is 375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22).
45950497|NCT00476632|Behavioral|Questionnaire|50 Minute Interview
45950498|NCT00117689|Biological|Thymoglobulin|Antibody inductions with tacrolimus and corticosteroid sparing maintenance therapy
45950499|NCT00117689|Drug|Corticosteroid|For a minimum of 3 months
45950500|NCT00117689|Drug|Tacrolimus|Between Day 3 the last dose of Thymoglobulin
45950501|NCT00117689|Drug|Mycophenolate Mofetil|for at least 1 month posttransplant
45453709|NCT01106443|Procedure|Total Thyroidectomy + CLND|Total thyroidectomy includes removing all possible thyroid tissue. Central lymph node dissection is a neck level 6 dissection. This includes removal of all central lymphatics from carotid artery to carotid artery and hyoid to sternum/clavicle.
45453710|NCT01106443|Procedure|Total thyroidectomy - CLND|Removal of all possible thyroid tissue without dissection of neck level 6.
45950502|NCT00476671|Procedure|lumbar puncture, MRI, MRS|lumbar puncture, MRI, MRS are only performed in patients with HIV associated dementia
45812646|NCT05248022|Drug|Programmed Cell Death Protein 1 Inhibitor|Programmed cell death protein 1 inhibitor fixation was treated with sintilimab (Xinda Biopharmaceutical Co., Ltd.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.
45950503|NCT00117273|Drug|Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)]|1 tablet daily
45950504|NCT00117273|Drug|Seasonique (LNG/EE and EE)|1 tablet daily
45950505|NCT00117273|Drug|Portia (LNG/EE)|1 tablet daily x 28 days
45453711|NCT01106443|Procedure|Hemi-thyroidectomy + CLND|Removal of one thyroid lobe and ipsilateral central lymph nodes
45453712|NCT01106443|Procedure|Hemi-thyroidectomy - CLND|Removal of one thyroid lobe only. No lymphatic dissection.
45950506|NCT00476710|Drug|Colesevelam HCl|
45659494|NCT05525299|Behavioral|Reminiscence-Based Life Review|"The reminiscence chatting activities covering 6 themes include:~Week 1: Instruction of the 'Life Story Narrative Journal' and My 'Childhood' memories Week 2: My 'Adolesces' memories and Memorable moments spent with my family Week 3: My 'Adulthood' memories and My very first full time job Week 4: My thoughts when I received my cancer diagnosis Week 5: My favourite activities before and after receiving a cancer diagnosis Week 6: When COVID-19 hits, _____ changes and The story goes on! The future pages are more to come!~A 'Life Story Narrative Journal' with six themes to recall subjects' memory through the life review reminiscence activities will be given. The Life Story Narrative Journal is a diary booklet that enables the participant to write down and express their thoughts in a narrative."
45812647|NCT05371730|Drug|NCR300|Intravenous infusion of NK cells（NCR300）
45950507|NCT00117728|Drug|nevirapine|
45950508|NCT05358678|Diagnostic Test|cs niche group|"A niche is formally defined by the European Niche Taskforce as an indentation of the uterine myometrium of at least 2 mm at the site of the CS scars. A niche can be sub classified as follows:~Simple niche~Simple niche with one branch~Complex niche (with more than one branch).~The following measurements will be taken:~Length.~Depth.~Width.~RMT (residual myometrium thickness).~AMT (adjacent myometrium thickness).~Distance between the niche and the VV (vesico-vaginal) fold.~Distance between the niche and the external os. We will also comment on the position of the uterus (AVF or RVF), presence or absence of intra cavitary fluid and its thickness."
45812648|NCT05247944|Procedure|Fenestrated and branched endovascular aortic repair (F-BEVAR)|Fenestrated and branched endovascular aortic repair (F-BEVAR)
45950509|NCT00117767|Drug|Terbinafine hydrochloride (HCl)|Terbinafine hydrochloride (HCl) pediatric formulation (minitablets)o.d. administration
45950510|NCT00117767|Drug|Griseofulvin|Griseofulvin pediatric suspension o.d. administration
45950511|NCT03277066|Drug|Diclofenac Sodium Active Topical Patch 1|HP-5000 Active Topical Patch 1 were applied on subjects with Osteoarthritis of the knee(s)
45950512|NCT03277066|Drug|Diclofenac Sodium Active Topical Patch 2|HP-5000 Active Topical Patch 2 were applied on subjects with Osteoarthritis of the knee(s)
45950513|NCT03277066|Drug|Placebo patch|Topical placebo patches were applied on subjects with Osteoarthritis of the knee(s)
45950514|NCT05357157|Other|Electroacupuncture|Subjects will be administered electroacupuncture as described in the electroacupuncture group description
45950515|NCT05357157|Dietary Supplement|Nutrition|Subjects will be administered the intervention described in the electroacupuncture nutrition and dietary supplement group description
45950516|NCT05357157|Dietary Supplement|Dietary supplement|Subjects will be administered the intervention described in the electroacupuncture nutrition and dietary supplement group description
45453713|NCT03740971|Device|Remote Ischemic Conditioning treatment|Remote Ischemic Conditioning is given twice a day with 200mmHg pressure.
45453714|NCT03740971|Drug|Guideline-based therapy|Guideline-based therapy
45453715|NCT02280148|Procedure|Endoscopy of Intravenous Anesthesia|The dose of intravenous anesthesia drug and time was controlled by the anesthesiologist,endoscopists were responsible for gastroscopy or colonoscopy , nurses assisted endoscopists with biopsy.Each subject's initial dose of propofol were set at 2mg / kg, and were added properly by anesthesiologists additional according to the subjects' intraoperative sedation or surgical time.
45453716|NCT02280148|Device|Driving Simulator|
45453717|NCT02280148|Drug|Propofol|2mg / kg
45950517|NCT00117923|Drug|Resiquimod|
45950518|NCT05339451|Diagnostic Test|Blood biomarkers|Blood biomarkers in plasma and serum.
45950519|NCT00118001|Behavioral|Worry exposure|
45950520|NCT00118001|Behavioral|Applied relaxation|
45950521|NCT00117351|Drug|VELCADE|
45950522|NCT00118196|Drug|arsenic trioxide|
45950523|NCT00118196|Drug|azacitidine|
45950524|NCT00117390|Procedure|Measurement of inulin clearance|
45950525|NCT00118235|Drug|cisplatin|Given IV
45950526|NCT00118235|Drug|irinotecan hydrochloride|Given IV
45950527|NCT00118235|Biological|bevacizumab|Given IV
45950528|NCT00118235|Other|laboratory biomarker analysis|Correlative studies
45453718|NCT00602602|Biological|bevacizumab|
45950529|NCT00117429|Biological|HIV gp120/NefTat/AS02A Vaccine|im injection, 0.6-0.7 ml
45950530|NCT00118313|Biological|incomplete Freund's adjuvant|
45950531|NCT00118313|Biological|multi-epitope melanoma peptide vaccine|
45812649|NCT05247944|Procedure|Open repair|Open surgery for complex abdominal aortic aneurysm
45812650|NCT05247710|Procedure|Punch biopsy|Punch biopsy of basal cell carcinoma tumor and a control biopsy of healthy skin are collected during primary tumor excision surgery from each recruited patient.
45950532|NCT00118313|Biological|sargramostim|
45950533|NCT00118313|Biological|tetanus toxoid helper peptide|
45950534|NCT00118313|Drug|dimethyl sulfoxide|
45950535|NCT00118313|Drug|imiquimod|
45659495|NCT05522491|Drug|Olaparib|All subjects enrolled will receive olaparib.Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
45812651|NCT05247554|Drug|Hydroxychloroquine + low-dose prednisone|Hydroxychloroquine, tablets, 400mg/day for 6 months combined with Prednisone, 20mg/day for 1 month, then 10mg/day for 20 weeks (ie up to M6). The cumulative doses of prednisone during the 6 months of the study will be 1820mg
45812652|NCT05247554|Drug|Prednisone|"prednisone, tablets, 40mg/day for 4 weeks, then 30mg/day for 2 weeks, then 20mg/day for 2 weeks, then 15mg/day for 2 weeks, then 10mg/day for 14 weeks (i.e. up to 6 months ).~The cumulative doses of prednisone during the 6 months of the study will be 2870mg "
45812653|NCT05217368|Other|mandala painting|In addition to routine antenatal education, pregnant women included in the experimental group will be asked to practice at least 1 mandala per day at least 5 times a week during the 6-week pregnancy education under the supervision of a researcher.
45950536|NCT00118313|Procedure|adjuvant therapy|
45950537|NCT03277690|Drug|Levoketoconazole|"During the double-blind Withdrawal Phase, patients will receive up to 1200 mg levoketoconazole daily.~During the double-blind Restoration Phase, patients will receive levoketoconazole plus placebo."
45659496|NCT02340975|Biological|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
45659497|NCT02340975|Biological|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
45659498|NCT02340975|Biological|MEDI4736|MEDI4736 will be administered by IV infusion.
45950538|NCT03277690|Drug|Placebo|"During the double-blind Withdrawal Phase, patients will receive placebo tablets.~During the double-blind Restoration Phase, patients will receive placebo plus levoketoconazole."
45950539|NCT00118391|Behavioral|Cognitive behavior therapy|Receive 8 50-minute sessions of one-on-one cognitive behavioral therapy
45950540|NCT00118391|Behavioral|Contingency management|Receive vouchers that can be spent on rewards for completing activities that support abstinence from gambling
45950541|NCT03271021|Drug|FMX101|FMX101, 4% minocycline foam
46076987|NCT02763774|Other|Stationary cycling exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, they will perform progressive cycling exercise.The intensity of cycling will be determined by the Borg's sujective effort perception scale - (modified from zero to 10).
46076988|NCT02763774|Other|Neuromuscular electrical stimulation|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, quadriceps and gastrocnemius muscles will be percutaneous stimulated with the following parameters: Synchronic mode, 50Hz, 400uS, time on 10s, time off 20s, intensity as tolerated by the patient.
45659499|NCT02340975|Biological|Tremelimumab|Tremelimumab will be administered by IV infusion.
45659500|NCT02340975|Biological|MEDI4736+tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
45950542|NCT03271021|Drug|Vehicle Foam|Vehicle Foam
45950543|NCT00118469|Behavioral|Psychoeducation|
45950544|NCT00118469|Behavioral|Cognitive behavior therapy|
45950545|NCT03279640|Device|rTMS on ipsilesional M1|
45950546|NCT03279640|Device|tDCS on contralesional M1|
45659501|NCT02340975|Biological|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
45659502|NCT02392377|Drug|Paclitaxel|Given IV or IVPB
45659503|NCT02392377|Drug|Carboplatin|Given IV or IVPB
45659504|NCT02392377|Drug|Oxaliplatin|Given IV
45950547|NCT02273986|Drug|Digoxin|
45950548|NCT02273986|Drug|K-877|
45812654|NCT05217368|Other|antenatal education|Routine antenatal education will be given.
45950549|NCT00476866|Device|intermittent positive-pressure breathing (IPPB)|
45950550|NCT00118508|Drug|risedronate (including placebo)|risedronate 35mg weekly
45950551|NCT00476905|Device|Spectral Diagnosis Probe|The device collects two types of tissue spectra: i) laser-induced fluorescence spectra and ii) white light reflectance spectra. This portable reflectance spectrofluorimeter collects spectra in a fraction of a second. Light collection and delivery are achieved via an optical fiber probe. The optical fiber probe is approximately 1 mm in diameter and 3 m long. The same probe collects light emitted from the tissue and delivers it back to the instrument for spectral analysis.
45950552|NCT00476944|Procedure|Percutaneous Coronary Intervention (PCI)|
45950553|NCT00476983|Drug|saquinavir/ritonavir plus truvada|SQV/r 1500/100 mg OD + Truvada OD for 2 years
45950554|NCT00477022|Device|Vasotrain-447|
45950555|NCT00118547|Behavioral|In home monitoring with feedback|Behavioral counseling
45950556|NCT00477061|Drug|Morphine|
45659505|NCT02392377|Drug|Leucovorin Calcium|Given IV
45659506|NCT02392377|Drug|Fluorouracil|Given IV
45659507|NCT02392377|Radiation|Radiation Therapy|Undergo radiation therapy
45659508|NCT02392377|Procedure|Therapeutic Conventional Surgery|Undergo esophagectomy
45659509|NCT02392377|Other|Laboratory Biomarker Analysis|Correlative studies
45659510|NCT02340819|Drug|Teduglutide|0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
45950557|NCT00118625|Biological|Tree MATA MPL|
45659511|NCT04904289|Other|All intervention of real world|We analyzed all data we can obtain from our databases
45659512|NCT02340663|Device|SOVA Bite Splint|Over-the-counter thermoplastic bite splint blank, heated, molded to fit.
45659513|NCT02340663|Device|Michigan Bite Splint|Heat-cured acrylic bite splint fabricated by dentist/dental technician to fit
45659514|NCT02573467|Drug|Bimagrumab|BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
45659515|NCT02573467|Drug|Placebo|Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
45659516|NCT04903899|Combination Product|177Lu-DOTATATE|A weight-based activity of 200 MBq kg-1 will be used for the first dose. The activity of the second dose will be calculated based on whole body activity scans as well as SPECT CT scans to determine the absorbed kidney dose. The aim is to administer 177Lu-DOTATATE corresponding to a whole-body dose of 1,2 Gy, with a cumulative whole-body dose of about 2,4 Gy over two courses, and not exceeding a cumulative renal dose of 23 Gy, in order to avoid renal toxicity.
45659517|NCT05517733|Biological|Platelet Rich Fibrin|"for the preparation of PRF, A well-trained professional nurse drew 10ml of patient blood from the antecubital vein and transferred it to a test tube without anticoagulant. The blood sample was immediately centrifuged for 10-12 minutes at 3000 rpm. L-PRF was ready to use after centrifugation.~PRF membrane was put over the implant and slightly tucked under the soft tissue periphery, then held in place with a figure-of-8 suture by 0.5 proline suture"
45812655|NCT02596022|Drug|CI-581a|a 50 minute infusion 24 hours prior to cocaine self-administration session
45812656|NCT02596022|Drug|CI-581b|a 50 minute infusion 24 hours prior to cocaine self-administration session
45812657|NCT05208320|Behavioral|Adherence|"Patients received interventions as follow:~The health education syllabus included 4 chapters: (1) introduction to hypertension, (2) complications of high blood pressure, (3) lifestyle management, and (4) SCORE - European High-Risk Chart~Home health education by Community Health Workers every month for 6 months"
45812658|NCT00364442|Drug|fluticasone propionate/salmeterol|investigational drug
45812659|NCT00364520|Other|Shanghai workers|
45812660|NCT02597582|Procedure|Neck dissection|The Small Jaw® handpiece (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) was not only used as a dissection forceps but also served as a ligation device.
45812661|NCT00364598|Drug|Anginera, a human tissue replacement therapy|
45812662|NCT05371574|Drug|clonidine group|Each participant will be receive 0.2mg of oral clonidine 60 minutes before surgery and 10mls of sterile water (placebo) 10 minutes after skin incision
45950558|NCT00477217|Drug|Zoledronic acid|
45812663|NCT02599766|Other|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
45812664|NCT02599766|Other|standard therapy|standard physiotherapy, standard speech therapy and standard occupational therapy
45950559|NCT03279367|Diagnostic Test|Objective speech response detection|Changes in brain activity when a speech stimulus is presented will be measured using electro-encephalography (EEG)
46076989|NCT00945815|Biological|epratuzumab|
46076990|NCT00945815|Drug|clofarabine|
46076991|NCT00945815|Drug|cytarabine|
46076992|NCT00945815|Other|laboratory biomarker analysis|
46076993|NCT02758002|Procedure|Firm ablation for transitional AF rotors|Transitional AF rotors will be mapped and ablated as part of this study. All subjects will undergo this ablation after standard PVI and Firm ablation for sustained rotors.
46076994|NCT00606307|Drug|ITF2357|50 mg b.i.d. PO every day. More precisely, ITF2357 was supplied as 50 mg hard gelatine capsules for oral administration.
46076995|NCT04603014|Combination Product|Interdialytic peritoneal ultrafiltration with 10% dextrose solution|Interdialytic peritoneal ultrafiltration with incremental doses of a 10% dextrose solution, after hemodialysis twice weekly for three consecutive weeks
45812665|NCT05371418|Procedure|surgical (guided tissue regeneration)|In group 1 (G1), ten teeth over erupted with angular bone loss were treated by guided tissue regeneration (GTR) followed by Orthodontic intrusion
45812666|NCT05371418|Device|orthodontic intrusion followed by guided tissue regeneration GTR|. In group 2 (G2), ten teeth over erupted with angular bone loss were treated by Orthodontic intrusion (OI) followed by guided tissue regeneration (GTR)
45812667|NCT05371340|Dietary Supplement|Quercetin (500 mg)|Once-daily 500 mg Quercetin
45812668|NCT05371340|Other|Placebo (500 mg)|Once-daily 500 mg methylcellulose 9E4M)
45812669|NCT02601170|Biological|Platelet-Rich Plasma Intra-Articular Injection|
45812670|NCT02601170|Drug|Hyaluronic Acid Viscosupplementation|
45950560|NCT00477256|Behavioral|Questionnaires|5 Paper-and-Pencil Questionnaires: All participants will engage in a one-time completion of all measures.
45950561|NCT00477373|Drug|depakine chrono|Depakine Chrono 500 mg
46076996|NCT00892021|Drug|NSA-789|
46076997|NCT00892021|Drug|Placebo|
45950562|NCT00477646|Behavioral|Prevention Care Management|Telephone support over 18 months to help women become screened for breast, cervical and colon cancer. Includes barriers assessment, patient education and motivation, provider recommendation letter, appointment reminder, and some scheduling of appointments.
45453719|NCT00602602|Drug|fluorouracil|
45950563|NCT00477763|Drug|Restasis, Refresh Endura|"Restasis 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening~Refresh Endura 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening"
45950564|NCT00477802|Biological|Botulinum Toxin Type A|Injected once during the course of the study.
45950565|NCT00477802|Biological|Placebo|Injected once during the course of the study.
45950566|NCT00118781|Drug|iseganan hydrochloride|
45950567|NCT00477841|Procedure|Esophageal stent placement|
45950568|NCT00477841|Procedure|dysphagia scores|
45950569|NCT00477841|Procedure|complications of therapy|
45950570|NCT00477841|Procedure|survival time of therapy|
45659518|NCT05517733|Device|Diode laser|"A 980 nm diode laser device (BIOLASE) was applied in a circular motion to the blood formed at the socket orifice at a power of 1W for 1 minute with a continuous wave mode, the application was done without touching the pooling blood and with a non-activated tip of the fiber optic.~The laser application cycle was repeated 3-5 times to yield a stable fixed blood clot covering the dental implant with no oozing blood from its periphery."
45950571|NCT00477880|Biological|Cetuximab|
45950572|NCT00118820|Drug|IV Preoperative antibiotic or placebo|
45950573|NCT00477997|Device|Physiological Bolus of Growth Hormone|0,5 mg Norditropin
45950574|NCT00402129|Procedure|1064nm Nd:YAG laser at 12 J/cm2, 20 ms and 10mm spot size.|
45950575|NCT00478075|Drug|bortezomib|
45950576|NCT00478075|Other|immunologic technique|
45950577|NCT00478075|Radiation|samarium Sm 153 lexidronam pentasodium|
45659519|NCT05517655|Drug|129Xe|Rapid spatial mapping of lung, liver, and pancreatic structure and function is now possible with a combination of hyperpolarized 129Xe and traditional proton MRI, all absent sedation and ionizing radiation.
45659520|NCT02337387|Biological|Blosozumab|Administered SC
45659521|NCT02337387|Other|Placebo|Administered SC
45950578|NCT00117078|Drug|Aranesp®|
45950579|NCT00478114|Drug|sorafenib|sorafenib in the patients with advanced Renal Cell Carcinoma
45453720|NCT00602602|Drug|gemcitabine hydrochloride|
45453721|NCT00602602|Drug|oxaliplatin|
45659522|NCT04903665|Device|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
45950580|NCT00118859|Behavioral|Integrative care for low back pain|
45950581|NCT00118859|Behavioral|Conventional treatment for low back pain|
45950582|NCT00478270|Drug|ibandronate [Bondronat]|6mg iv on days 1-3
45950583|NCT00478309|Other|counseling intervention|
45950584|NCT00478309|Other|educational intervention|
45659523|NCT02574247|Procedure|Computerized auditory training|10 sessions of computerized auditory training (1.5 hr/session) across a 15-week span.
45659524|NCT02391363|Behavioral|Cognitive behavior treatment|Anxiety management skills with the option to included religious/spiritual beliefs and practices
45659525|NCT02391363|Behavioral|Information and referral|Resource counseling and follow-up for mental health and basic needs
45659526|NCT05522335|Biological|BBV154(Intranasal) & covaxin|Intervention Covaxin
45812671|NCT05371262|Drug|Levothyroxin|Congenital hypothyroidism children received two different doses of levothyroxin within the recommended range to evaluate any differences in long-term outcomes.
45950585|NCT05302752|Other|Magnetic phrenic nerve stimulation|"The intervention consists of bilateral rapid magnetic phrenic nerve stimulation on the neck using different stimulation intensities.~On one visit, the effect of increasing chest wall stiffness and respiratory muscle work by adding incrementally small weights to the chest/abdomen will be investigated."
45950586|NCT00478348|Procedure|Prosthetic repair of abdominal incisional hernia|Rives-Stoppa repair of incisional hernia
45453722|NCT00602602|Other|immunohistochemistry staining method|
45453723|NCT00602602|Other|laboratory biomarker analysis|
45453724|NCT00602602|Procedure|conventional surgery|
45453725|NCT00602602|Procedure|endoscopic biopsy|
45453726|NCT00602602|Procedure|laparoscopy|
45453727|NCT00602602|Radiation|radiation therapy|
45812672|NCT02602496|Other|Fruits and Vegetables|5 servings of fruits or vegetables
45812673|NCT02602496|Other|Whole Grain|3 servings of whole grain
45812674|NCT02602496|Other|Control|3 servings of refined grain
45812675|NCT02603666|Device|Fibroscan|Ultrasound by specific wavelength developed for elastography, repeated measures according to the manufacturer's instructions.
45812676|NCT00366002|Drug|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
45812677|NCT00422240|Drug|Adapalene/Benzoyl Peroxide|
45812678|NCT05371184|Drug|L-Glutamine, Oral Powder for Reconstitution|Glutamine is an essential amino acid. It will be provided in a powder form. It will be dissolved in at least 8 ounces of hot or cold liquid. It can also be mixed with a soft food such as pudding, applesauce, or yogurt. Then it will be Stirred and then eaten or drunken The Glutamine will be as an add on to the Standard of care
45812679|NCT05371184|Other|Standard of care|Hydroxyurea 15-25 mg per kg per day and/ or blood transfusion therapy
45812680|NCT05366972|Device|Ultrasonographic measurements|"Posterior layers of the thoracolumbar fascia ,middle layers of the thoracolumbar fascia thickness and Lumbar interfacial triangle thickness~CSA (cross-sectional area) measurements of erector spinae muscles, quadratus lumborum muscles and the latissimus dorsi muscles"
45812681|NCT00365534|Procedure|MEI|
45812682|NCT02605304|Drug|Ledipasvir/sofosbuvir|Participants were prescribed one fixed dose tablet of LDV 90 mg/SOF 400 mg orally per day.
45950587|NCT00478387|Biological|The current season's trivalent killed influenza vaccine|
45950588|NCT04727801|Device|Verily Patch|The Verily Patch is an investigational wearable temperature sensor that consists of a Patch (Verily Patch), with swappable adhesives, as well as an app (Verily Patch app).
45950589|NCT00478504|Drug|Letrozole|Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
45950590|NCT00478504|Drug|Clomifene citrate|Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
45950591|NCT00117468|Drug|DR-2011|Administered vaginally from Day 14 to Day 31
46076998|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
46076999|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
46077000|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
45950592|NCT00117468|Drug|Progesterone 8% Vaginal Gel|Administered vaginally from Cycle Day 14 to Day 31
45659527|NCT05512429|Other|measured of body composition with computed tomography|Multislice and single-slice computed tomography images were used for assessment of body composition including visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), skeletal muscle mass volume (SMMV)
45659528|NCT05522257|Diagnostic Test|[18F]-JK-PSMA-7 PET/CT scan|A [18F]-JK-PSMA-7 PET/CT scan will be made to assess the level of tracer uptake in the malignant lesion(s). We expect to make a [18F]-JK-PSMA-7 PET/CT scan in 15 out of 60 patients per cohort.
45659529|NCT04903509|Drug|BI 1820237|BI 1820237
45659530|NCT04903509|Drug|Placebo|Placebo
45659531|NCT04903509|Drug|Saxenda®|Saxenda®
45659532|NCT04903509|Drug|Paracetamol-ratiopharm®|Paracetamol-ratiopharm®
45812683|NCT02605304|Drug|Ribavirin|"Based on weight at entry:~For weight <75 kg, participants were prescribed 1000 mg of RBV per day, divided into two doses to be taken orally.~For weight ≥75 kg: participants were prescribed 1200 mg of RBV per day, divided into two doses to be taken orally."
45950593|NCT03271879|Drug|Empagliflozin at a dose of 10 mg/day|Comparing empagliflozin versus placebo on the ventricular arrhythmia burden. This study encompass 4 periods for each study subject: screening period of 8 weeks, first treatment period of 8 weeks, washout period of 4 weeks and a second treatment period of 8 weeks in a cross-over design
45950594|NCT00478543|Drug|Furosemide|
45659533|NCT05522179|Dietary Supplement|NutraHeal|Receive NutraHeal (2 capsules twice a day) as a dietary supplement beginning 1 week prior to surgery and extending to 3 weeks after foot surgery.
45659534|NCT05522179|Dietary Supplement|NutraHeal Plus|Receive NutraHeal Plus (2 capsules twice a day) as a dietary supplement beginning 1 week prior to surgery and extending to 3 weeks after foot surgery.
45659535|NCT04903431|Behavioral|Crisis Response Planning for Suicide Risk|Crisis Response Planning is focused on creating personalized set of steps for individuals to follow in case of a crisis and includes individuals' personal warning signs of distress, behavioral coping strategies, reasons for living, social supports to contact, and contact information for professional services, including emergency services. Personalization of the Crisis Response Plan is encouraged, and individuals are instructed to handwrite each step of the Crisis Response Plan on an index card to review.
45812684|NCT05365880|Drug|Liquid Lidocaine|The investigational treatment is 2 mL of aqueous 2% lidocaine.
45812685|NCT05365880|Drug|Placebo|The active placebo comparator will be provided to participant.
45812686|NCT04741490|Drug|Camrelizumab|PD-1antibodies，200mg ivgtt Q3W
45812687|NCT04741490|Radiation|radiotherapy|45-55Gy/1.8～2.0Gy
45950595|NCT00118937|Drug|Metformin|Tablet Metformin 500 mg, Dosage: 1000 mg two times daily (2000 mg total daily dose).
45950596|NCT00118937|Drug|Placebo.|Tablet Placebo (corresponding to 500 mg metformin). Dosage: 1 tablet per day.
45950597|NCT00118937|Drug|Placebo.|Tablet Placebo (corresponding to 500 mg metformin). Dosage: 2 tablets two times daily.
45950598|NCT00478582|Procedure|Estimation of Hb concentrations with the HemoHue card|
45950599|NCT00478621|Biological|GSK Biologicals' HPV vaccine (GSK1674330A)|Intramuscular administration, 5 different formulations
46077001|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
46077002|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
46077003|NCT00798369|Drug|Triamcinolone acetonide|Randomized patients received triamcinolone acetonide 40 mg i.m. once and placebo matching canakinumab s.c. once, on Day 1.
46077004|NCT00950963|Behavioral|Phone Counseling|Patient were contacted on a periodic basis via telephone to address there diabetes care.
45950600|NCT00478621|Biological|Cervarix TM|Intramuscular administration
45950601|NCT05292807|Behavioral|Imaginal exposure for memories|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a past distressing anxiety provoking scenario multiple times while honing in on the most negative aspects.
45950602|NCT05292807|Behavioral|Imaginal exposure for future events|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a future distressing anxiety provoking scenario multiple times while honing in on the most negative aspects.
46002670|NCT00546767|Behavioral|Mail and Live Phone|This group will receive assessments of all domains by mail, except for the cognitive performance assessment which will be administered via phone by a live, trained evaluator. Medication compliance will be monitored by a written medication log which will be returned by mail with the other mail-in assessments.
46077005|NCT00950963|Other|Standard Clinical Care|Patients in the usual care or control group were contacted at the beginning of the study only if they had not had an LDL level in the previous 12 months. A letter requesting their presentation for an LDL test was sent to their last known address along with a lab slip and a reminder to schedule an appointment with their PCP for follow-up of results. No additional contact was made with them by the study nurses.
46077006|NCT04221360|Drug|CKD-375|Test drug, QD, PO
46077007|NCT04221360|Drug|D390|Reference drug, QD, PO
46077008|NCT02757612|Radiation|laser diode|laser diode
45950603|NCT05292807|Behavioral|Imagery rescripting for memories|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a past distressing anxiety provoking scenarios one time while honing in on the most negative aspects. Afterwards they will insert changes into the script that try to help them cope in the imagery: First imagining the scenario from a different character perspective that enacts changes in the memories. Second, The will imagine the scenario again from the original perspective along with changes done by the additional character.
45950604|NCT05292807|Behavioral|Imagery rescripting for future events|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a future distressing anxiety provoking scenarios one time while honing in on the most negative aspects. Afterwards they will insert changes into the script that try to help them cope in the imagery: First imagining the scenario from a different character perspective that enacts changes in the memories. Second, The will imagine the scenario again from the original perspective along with changes done by the additional character.
45812688|NCT05603468|Drug|platelet rich plasma|Platelet rich plasma group: after the surgery of rotator arthroscopic rotator cuff repair, 3ml PRP (LongTai Biological Company) was injected into the rotator cuff tear under the rotator arthroscope for a time. PRP production process: before anesthesia, 20ml arterial blood was drawn and injected into the PRP tube. The blood was fully oscillated in the tube, and then placed in a centrifuge with 1500g for 9min to remove excess plasma and make 5ml PRP. 3ml is used for injection and 2ml is used for quality control.
46077009|NCT00608959|Drug|omiganan 1% gel|"Omiganan 1% gel will be applied to 6 sites on the chest and/or abdomen.Swab cultures will be obtained at specified timepoints over a period of 3 days (Part1) or 7 days (Part 2).~In addition, subjects in Part 2 will have omiganan 1% gel applied to one intravenous (IV) catheter site."
45659536|NCT05517499|Drug|Dexamethasone|Randomized clinical trial
45812689|NCT05603468|Drug|Corticosteroid|Corticosteroid group: after the surgery of rotator cuff repair under arthroscopy, 1mL prednisone (MSD) + 2mL sodium hyaluronate (biochemical Industry Co., Ltd.) was injected under arthroscopy.
45812690|NCT05603468|Drug|Normal saline|Normal saline
45659537|NCT05450211|Device|Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)|A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in group SFI.
45950605|NCT00478660|Drug|adalimumab (Humira)|
45950606|NCT00402155|Behavioral|Stress on visual discomfort|Effects of visual discomfort are measured by contrast sensitivity, ERGs, and accommodative stability.
45659538|NCT05450211|Device|Patient controlled analgesia|Patient-controlled analgesia will be used for pain control after surgery in both groups.
45659539|NCT05512351|Drug|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.
45659540|NCT04898985|Diagnostic Test|ImmunoSEQ|experiment assay
45812691|NCT02606708|Radiation|Accelerated intensity modulated radiation therapy (AIMRT)|
45950607|NCT00478699|Drug|Docetaxel/Cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
45950608|NCT00478699|Drug|Docetaxel|Docetaxel 75 mg/m2 day 1, 4 cycles
46077010|NCT00608959|Drug|chlorhexidine 2% solution|"Part 1- chlorhexidine 2% solution will be applied to 6 sites on the chest and/or abdomen. All application sites will be covered with semi-transparent dressings.Swab cultures will be obtained at specific timepoints over a period of 3 days.~Part 2: Subjects in Part 2 will have chlorhexidine 2% solution applied to one intravenous (IV) catheter site only."
45812692|NCT05365256|Behavioral|Standard distraction during chemotherapy treatment period|habitual distraction of patients during chemotherapy sessions authorized as part of routine care
45812693|NCT05365256|Behavioral|Virtual distraction during chemotherapy treatment period|A virtual reality headset will be worn for 15 minutes per hour of treatment
45950609|NCT00478699|Drug|Gemcitabine/Cisplatin|Gemcitabine 1250 mg/m2, day 1 and 8 and cisplatin 75 mg/m2 day 1, 4 cycles
45950610|NCT00478699|Drug|Docetaxel/Cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
45950611|NCT00118976|Drug|Lisinopril|
46077011|NCT02763306|Device|Dermal Cooling System|Treatment with dermal cooling system.
46077012|NCT00945659|Device|Continuous Glucose Sensor|Education and medical management to promote optimal therapeutic benefit from adding use of a continuous glucose sensor to daily diabetes management.
45812694|NCT05362994|Device|Selution SLR™ sirolimus-eluting balloon|If the residual stenosis is ≤30% after initial plain old balloon angioplasty, the investigators will perform angioplasty with the Selution SLR catheter, inflated at nominal pressure for at least 120 seconds. After dilatation of the entire target-lesion, biplane angiograms and IVUS imaging will be obtained. Technical success is defined as residual diameter stenosis ≤30% and adequate distal run-off. Bail-out stenting will be performed if residual stenosis is >30%, either after plain old balloon angioplasty or angioplasty with Selution SLR. For lesions with residual stenosis >30% but not suitable for stenting, repeat angioplasty will be performed for at most twice.
45950612|NCT05288361|Diagnostic Test|Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire|"Patients presenting with symptomatic ischemic heart disease (including chronic stable angina or unstable angina) without evidence of myocardial infarction who require elective or urgent cardiac catheterization, and who meet all eligibility criteria will be enrolled.~Participants will undergo routine coronary angiography as well as comprehensive physiologic assessment with intracoronary acetylcholine provocation for diagnosis of vasospastic angina (VSA), coronary thermodilution to evaluate for coronary microvascular dysfunction (CMD), and intracoronary imaging with optical coherence tomography (OCT) or intravascular ultrasound (IVUS) to evaluate for the presence of atheroma, plaque burden, and myocardial bridging."
45950613|NCT00478816|Biological|Fluad H5N1 Pandemic Influenza Vaccine|Two 0.5 mL doses of MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) hemagglutinin (HA) subvirion influenza vaccine, containing 7.5 μg of H5N1 antigen,administered 3 weeks apart, IM in the deltoid muscle, preferably of the non-dominant arm.
45950614|NCT00119054|Behavioral|In Home Health Messaging Device|
45950615|NCT02956174|Device|Co-Cr single crown|
45659541|NCT05517343|Other|Real-time endoscopic optical diagnosis|The participants assigned to real-time notification group will received the endoscopic diagnosis of the resected colorectal polyps and recommended surveillance colonoscopy schedule right after the sedated colonoscopy.
45659542|NCT05517187|Other|no intervention|Regenerative endodontic treatment induced with blood clot in root canal space as a secondary treatment for failed root canal treated incisors
45453728|NCT03946735|Behavioral|Cognitive Behavioural Therapy as an Effective Treatment for Social Anxiety, Perfectionism, and Rumination|Week one involved introducing CBT and assessing the negative effects of perfectionism, rumination, and social anxiety. Week two allowed participants to specify stressful social activities, stressful social situations, and enjoyable activities. Week three to week six allowed participants to identify automatic thoughts and thinking errors (for example, all or nothing thinking, self-criticism, dysfunctional schemas for self-evaluation, and unrealistic standards). Assignments were provided to participants with the content of exposure to anxiety evoking situations in the treatment sessions and at home. Achievable behavioural goals were set for participants in the treatment sessions and at home.
45453729|NCT04177654|Drug|Benzimidazoles|A single dose of benzimidazole drug (400mg Albendazole or 500mg Mebendazole) will be administered as part of routine deworming services.
45812695|NCT05362994|Device|Plain old balloon angioplasty|The investigators routinely start with a balloon catheter with a diameter ≥0.5 mm smaller than the reference vessel and ended with a balloon catheter with the size approximately equal to the reference vessel diameter. Three minutes after balloon predilation, the investigators will obtain an angiogram. If the residual stenosis is ≤30%, no further intervention will be performed in the plain old balloon (POB) group.
45812696|NCT05584904|Other|volunteer anesthesiologists and nurses|18 not expert in electroencephalography digestive endoscopy and operating room nurses, and 8 anesthesiologists interpreting EEGs obtained with a single electrode EEG
45950616|NCT02956174|Other|Periodontal parameters|
45453730|NCT01108861|Device|GORE VIABAHN® Endoprosthesis|GORE VIABAHN® Endoprosthesis
45659543|NCT05517187|Biological|Platelet rich fibrin|Regenerative endodontic treatment with platelet rich fibrin in root canal space as a secondary treatment for failed root canal treated incisors
45812697|NCT02607254|Drug|Pregabalin|Pregabalin will be given to the patients, starting at 75 mg BID and increased weekly to reach 225 mg BID for 8 weeks. During withdrawal phase, dose of pregabalin will be kept the same for patients who are randomized to the pregabalin withdrawal group.
45812698|NCT02607254|Drug|Placebo|Placebo will be given to the patients that are randomized to placebo during withdrawal phase.
45812699|NCT02609204|Diagnostic Test|Diopsys NOVA|Healthy Controls will have both eyes tested by the Diopsys NOVA machine using Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG) modules.
45812700|NCT02611154|Drug|Testosterone|Participants will self-administer 11 mg 3x daily, for 5 consecutive days for 4 weeks.
45812701|NCT05563298|Device|Neuro RX Gamma device|The Neuro RX Gamma device is a portable, wearable, low level light therapy (LLLT) delivery device. The Vielight Neuro RX Gamma delivers a synchronized pulse frequency of 40 Hz from all LED clusters.
45812702|NCT05563298|Device|Sham Neuro RX Gamma device|The Sham device is indistinguishable from the active device. The sham device will not deliver light for the 20 minutes session duration.
45812703|NCT05140538|Other|SRP + toothpaste + mouthwash|Use of domiciliary products twice a day
45812704|NCT05140538|Other|SRP + toothpaste|Use of domiciliary products twice a day
45812705|NCT05548244|Behavioral|Behavioral Activation Therapy|Participants will be seen for a maximum of 16 sessions of therapy focused on increasing rewarding behaviors (16 individual therapy sessions of 1-hour, 2 of which include the BSIS component) over 16 weeks. BA intervention includes monthly booster sessions offered throughout 6-month follow up. If needed, two extra sessions will be allowed during treatment.
45812706|NCT05548244|Behavioral|Baseline assessment procedures|Completion of the K-SADS and CDRS-R to assess MDD, and the Wechsler Intelligence Scale for Children-Short Form to assess IQ.
45812707|NCT02613338|Device|DePuy Attune posterior stabilizing fixed bearing knee system|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system at least three months post-operative.
45812708|NCT02614274|Dietary Supplement|Nutraceutical joint health formulation|A Proprietary Blend
45950617|NCT02956213|Other|HEPA portable air filter|A high efficiency (MERV17) portable air filter (HEPA portable air filter) will be placed in the subject's bedroom and will run 24/7 for the duration of the study.
46077013|NCT00945659|Other|Standard Care|Intensified diabetes management based on either insulin pump or multiple daily injection insulin regimen, employing carbohydrate counting and a bolus dose correction factor for adjusting insulin doses.
45950618|NCT02956213|Other|Sham Control/Active Comparator|A portable air filtering device will be placed with no high-efficiency air filter, but only the basic carbon filter in place. Then at cross over, there will be an active HEPA portable air filter used
46077014|NCT00945659|Behavioral|CGS + Behavior Therapy|Patients in this group will receive 6 scheduled encounters with a behavior therapist who will assist the adolescent and parent in reducing or eliminating common behavioral and psychological barriers to achieving optimal benefit from CGS use in diabetes care.
46077015|NCT04222296|Device|Fitting strategy of cohlear implant of hearing aid|To determine whether new hardware and fitting strategy provides better sound quality or ease of use than generic hardware and fitting methods
46077016|NCT04113369|Device|TENS|30 minutes of conventional antalgic TENS to non-paretic forearm
45950619|NCT00478855|Drug|Tazocin (Piperacillin/Tazobactem)|
45453731|NCT01108861|Device|Plain old balloon angioplasty|Plain old balloon angioplasty
45453732|NCT02281396|Biological|2.5IU/ml in rabies vaccine （MRC-5 Cell) humans aged 10-20 years old|Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
45659544|NCT05522023|Procedure|group treated with aromatic solution|The aromatic solution applied in the experimental group will be obtained by mixing lavender oil and ginger oil into cold drinking water. For this, lavender and ginger oil approved by the Ministry of Agriculture will be used. 3 drops of lavender oil and 3 drops of ginger oil will be mixed into each 100 ml of drinking water, and it will be applied by spraying 4 times in the oral cavity and throat by shaking to ensure homogeneous distribution before each use. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
45659545|NCT05522023|Procedure|group treated with drinking water|In the placebo group, drinking water will be sprayed 4 times in the oral cavity and throat of the patients after the surgery. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
45950620|NCT00119093|Procedure|Laboratory and clinical monitoring regimens|
45659546|NCT05512273|Procedure|Piezosurgery assisted osteotomy|Sequential osteotomy drilling was done using mectron piezosurgery implant drilling protocol
45950621|NCT00479011|Procedure|fluid management based on arterial pulse pressure variation|
45950622|NCT00117546|Drug|alpha methyldopa|500 mg twice a day
46077017|NCT04113369|Procedure|Conventional rehabilitation|40 minutes of lower limb training and 20 minutes of upper extremity training for stroke
46077018|NCT04113369|Device|EMS|20 minutes of EMS to non-paretic forearm with 5 minutes of pre and post warm-up
46077019|NCT03517813|Device|Contrast-enhanced Spectral Mammography (CESM)|Dual energy mammography images obtained after the administration of an intravenous contrast agent
45659547|NCT05512273|Procedure|Conventional drilling osteotomy|bone osteotomy for implant placement was done following the BEGO Semados RS/RSX TrayPlus conventional drilling
45812709|NCT05104658|Other|Patient-targeted rehabilitation offers|In addition to usual rehabilitation services, patients in the intervention arm will receive patient-targeted rehabilitation offers to support the patients' participation and completion of their heart rehabilitation course.
46077020|NCT02605317|Other|WhatsApp|Consultations used WhatsApp Messenger
45453733|NCT02281396|Biological|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans aged 21-60 years old|Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
45659548|NCT05521789|Drug|ESB Thoracic|Erector spinae thoracic block with bupivacaine
45812710|NCT05104502|Behavioral|Dietary Fasting|"The study will consist of two days of eating a controlled habitual diet and one 36-hour period of water-only fasting with glucose monitoring as a measure of compliance. Water intake will be limited to 2 liters/day to prevent electrolyte abnormalities. Subjects will undergo 4 separate blood-draws consisting of an overnight fasted sample (Baseline), a 2-hour postprandial sample (Fed), a 36-hour fasted sample (Fasted), and final 2-hour postprandial sample after the fasting period (Refed)."
45659549|NCT05521711|Other|Food|Commercially available powders or liquids
45659550|NCT05517109|Other|Hemodynamic goal including lower goal of systolic blood pressure|Different hemodynamic goals in different study arms
45659551|NCT05516875|Drug|JM-010|JM-010
45659552|NCT02569957|Drug|Topotecan Hydrochloride|Given IV
45812711|NCT05083988|Device|virtual reality glasses|a system composed of a head-mounted wide view display placed in front of the eyes and headphones placed in ears, it has the ability to block the real-world stimuli. This could distract the patient from the dental environment, which helps reduce anxiety
45950623|NCT00479050|Procedure|chemoembolization ,Radiofrequency ablation|
45950624|NCT00479206|Drug|Artesunate|
45950625|NCT00479245|Other|Set of questionnaires (respondent)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
45950626|NCT00479284|Procedure|Average volume assured pressure support (AVAPS)|
45950627|NCT00119132|Drug|artesunate-amodiaquine|
45950628|NCT00119132|Drug|sulphadoxine-pyrimethamine|
45950629|NCT05279781|Procedure|Non surgical root canal treatment|Complete root canal treatment will be performed followed by direct restoration
45950630|NCT05279781|Procedure|Pulpotomy|Full pulpotomy followed by direct restoration
45950631|NCT02274064|Behavioral|Motivational Interview and Implementation Intention|Telephone call that includes motivational interviewing techniques and develops an implementation intention plan.
45950632|NCT00479323|Biological|Pneumovax 23|Licensed pneumococcal vaccine (Pneumovax 23).
45950633|NCT00479362|Drug|Warfarin|Warfarin is either interrupted or uninterrupted prior to device implantation
46077021|NCT02760342|Drug|peficitinib|Oral
46077022|NCT02760342|Drug|Metformin|Oral
46077023|NCT00894205|Behavioral|strengthening exercise program|"A low intensity strengthening exercise program based on the Tufts University Strong Bones program. Utilizes small free weights and chair exercises. Participants attend community based class 2-3x/wk for 4 wks."
46077024|NCT04113603|Diagnostic Test|Urinary malignancy|Single bolus three phase CTU
45659553|NCT02569957|Drug|Topotecan Hydrochloride|Given IV
45453734|NCT02281396|Biological|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 10-20 years old)|Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
45659554|NCT02569957|Drug|Acetylcysteine|Given IV and PO
45812712|NCT05083988|Device|music|Music can be used to distract patients from the anxiety provoking stimulus. It helps the patient to escape from the stressful reality as it activates imaginary. Psychosocially music can offer peace and comfort to patients during dental treatment as it helps in making the environment less threatening.
45812713|NCT02617784|Drug|Oseltamivir|Oseltamivir will be given as marketed oral suspension, 30 mg after HD or CAPD treatment.
45453735|NCT02281396|Biological|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 21-60 years old)|Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
45453736|NCT03944395|Other|Assisted Partner Notification Services|Three options for partner Notification services; contract referral, provider referral and dual referral
45659555|NCT01649427|Drug|Prograf|Prograf® capsules were supplied as capsules of 0.5 mg, 1 mg and 1.5 mg dose strengths.
45659556|NCT01649427|Drug|Tacrolimus Hexal|"Tacrolimus Hexal® capsules were supplied to the investigators at dose strengths of 0.5 mg,~1 mg and 1.5 mg."
45659557|NCT05521633|Drug|Metformin and Pioglitazone|Every participant in Group-A took tablet metformin 500 mg daily and every participant in Group-B took tablet pioglitazone 30 mg daily.
45812714|NCT05537168|Procedure|Pediatric cardiac surgery under cardiopulmonary bypass|All patients with pediatric cardiac surgery under cardiopulmonary bypass between 2008 and 2018 operated at our institution
46077025|NCT04221282|Drug|Zebinix|ESL will be initiated by the investigator in patients as a first line monotherapy or adjunctive therapy. ESL will be prescribed according to the usual care. Posology and method of administration of ESL are defined by the summary of product characteristics. Then, data on the efficacy of ESL will be collected.
46077026|NCT00894283|Drug|Enoxaparin|Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.
46077027|NCT00894283|Drug|Fondaparinux|Fondaparinux 5mg subcutaneously 6 hours following surgery, fondaparinux 5mg subcutaneously once daily during hospitalization. Patients will be encouraged to ambulate and compression stockings while in bed.
46077028|NCT04113291|Other|DASH Diet|12 Weeks of isocaloric DASH diet <2300 mg Na/day using meals (lunch, dinner, snacks) prepared by the Wake Forest Clinical Research Metabolic Kitchen under the direction of a registered dietician (RD). Participants will prepare their own breakfast from a menu.The subjects will be instructed to drink no more than three caffeinated beverages and no more than two alcoholic beverages per day.
46077029|NCT04113291|Other|Usual diet|12 weeks usual diet <2300 mg Na/day
46077030|NCT02760186|Procedure|Altitude Exposure|Altitude Exposure
46077031|NCT01138709|Device|Vitala|Vitala™ Continence Control Device
45453737|NCT04471480|Drug|TC/PD-1 inhibitor/anlotinib|chemotherapy and immunotherapy plus antiangiogenic therapy
45950634|NCT00479362|Drug|Aspirin|Aspirin is continued without interruption prior to device implantation
45659558|NCT05512195|Radiation|New delineation approach|New delineation approach
45659559|NCT04898829|Dietary Supplement|PKU explore|"For 28 consecutive days, participants will take their usual restricted therapeutic diet, either:~- Replacing their usual second stage concentrated protein substitute with PKU explore~OR~- Commencing PKU explore and gradually reducing their Phe-free formula for infants."
45950635|NCT00479362|Device|Permanent pacemaker|Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
45950636|NCT00479362|Device|Implantable Cardioverter-defibrillator|Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
45659560|NCT05512117|Device|Midline insertion|Midline catheter insertion
45659561|NCT02375373|Other|Observational Chickpea Diet|"Individuals encouraged to maintain increased legume intake and explore new recipes that allow them to maintain a diverse menu of legume based foods.~Fecal samples collected monthly."
45659562|NCT05521555|Procedure|Total knee arthroplasty|First intention total knee arthroplasty
45659563|NCT02336607|Drug|Felodipine tablet (Plendil) alone|Felodipine sustained release tablet single drug therapy (1st week- 2nd week) Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks. If blood pressure is controlled after 2 weeks, then the subjects will continue the treatment until the end of primary therapy stage (14th week).
45812715|NCT00366158|Device|Device: St. Jude Medical Victory dual-chamber pacemaker|Pacemaker implant
45812716|NCT00366158|Device|Ventricular Intrinsic Preference|Programming of pacemaker
45812717|NCT04741724|Device|TEDS|An non-invasive intervention. During the intervention, the electrode was placed on the skin stimulated muscle.
45812718|NCT04955756|Diagnostic Test|mNGS|Participants will be randomized to receive mNGS or multiplex PCR for diagnosis at enrollment.
45812719|NCT04955756|Diagnostic Test|Multiplex PCR|Participants will be randomized to receive mNGS or multiplex PCR for diagnosis at enrollment.
45812720|NCT05732012|Behavioral|Sexual Health Psychoeducation Program|"62 adolescents were included in the study. Adolescents were assigned to intervention and control groups by randomization using simple numbers table. The intervention group was divided into 3 groups of 10 and included in a six-week psychoeducation program that lasted for one hour once a week, and 55 adolescents completed the program. The data on the sociodemographic characteristics of the adolescents constituting the sample were collected with the Participant Information Form. Data on the effectiveness of the psychoeducation program on sexual health knowledge and attitudes were collected with the Sexual Health Knowledge and Attitude Inventory before the psychoeducation, at the end of the training and at the 3rd month of follow-up."
45812721|NCT04936334|Diagnostic Test|68Ga-PSMA-11 PET Scan|Patients will undergo injection of 68Ga-PSMA-11 at the time of their pre treatment PSMA PET scan and followed until 12 months post surgery.
45950637|NCT00119171|Drug|Ispinesib|
45950638|NCT00119171|Drug|Capecitabine|
45950639|NCT00117624|Drug|darbepoetin alfa|
45950640|NCT00479440|Drug|SAM-315|
45950641|NCT00479479|Drug|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|an intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
45950642|NCT00119210|Drug|Bupropion SR|
45812722|NCT05731934|Drug|HX301|At starting dose of 40 mg, followed by 4 dose levels of 80 mg, 120 mg, 160 mg, and 200 mg
45812723|NCT00365612|Drug|Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)|
45812724|NCT02974166|Other|Conventional Group|Rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) were made and prescribed under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions.
45812725|NCT02974166|Other|Osteopathic Group|Same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week during four weeks. The osteopathic treatment consisted in an individualized assessment of mobility restrictions of myofascial tissues and joints and the application of smooth techniques such myofascial release, membranous strain and counterstrain, muscle energy, cranial and high velocity and low amplitude.
45812726|NCT02974166|Drug|Ibuprofen|The medication was prescribed by the dentist as nonsteroidal anti-inflammatory drug if necessary.
45812727|NCT02974166|Drug|Cyclobenzaprine Hydrochloride|The medication was prescribed by the dentist as muscle relaxer if necessary.
45812728|NCT05493098|Other|dry needling|"The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more Dry needling:~The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes."
45812729|NCT05493098|Other|sham (placebo) dry needling:|The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes.
45812730|NCT05731856|Device|Apollo Wearable|Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phones. Participants will use the Apollo for at least 30 minutes after waking up and at least 30 minutes before bed on the corresponding settings for those times of the day. They will be given the Apollo Device TVS (10-200 Hz) to borrow, which they will be instructed to wear daily. They will be asked to wear the device until all study data is collected.
45812731|NCT05731778|Drug|Stannous Fluoride Toothpaste|0.454% stannous fluoride toothpaste
45812732|NCT05731778|Drug|Colgate fluoride toothpaste|0.76 % Sodium MonoFluorophosphate (MFP)
45950643|NCT00119210|Other|placebo|
45950644|NCT00117663|Drug|Cessation of Hormone Replacement Therapy|
45950645|NCT00479596|Drug|Botox|
45950646|NCT00479752|Drug|FOLFOX4 (Oxaliplatin), Cetuximab|"Arm A FOLFOX4:~Oxaliplatin 85 mg/m² d1~Leucovorin 200 mg/m² d1+d2, followed by~Bolus 5FU 400 mg/m², followed by~Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks~Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m².~Arm B FOLFOX4:~Oxaliplatin 85 mg/m² d1~Leucovorin 200 mg/m² d1+d2, followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks~Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks."
45950647|NCT00479791|Behavioral|Test meals rich in different fatty acids|
45950648|NCT00119249|Drug|sorafenib tosylate|Given orally
45950649|NCT00119249|Other|laboratory biomarker analysis|Correlative studies
45950650|NCT00479830|Behavioral|Focus Groups|Eight Focus Groups Consisting of 8-10 Members Each
45950651|NCT00479830|Behavioral|Questionnaire|To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
45950652|NCT00479830|Behavioral|Interview|To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
45950653|NCT00479908|Drug|Sildenafil citrate|
45950654|NCT00479908|Drug|Glyceryl trinitrate|
45950655|NCT00479947|Drug|Probiotics (Natural product)|
45950656|NCT00479947|Drug|Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)|
45950657|NCT00479986|Drug|pioglitazone|
45950658|NCT00479986|Drug|placebo|
45950659|NCT00119444|Procedure|Periacetabular osteotomy|osteotomy of the pelvis to increase acetabular coverage
45950660|NCT05270109|Procedure|BiZact|"In the hot group the peritonsillar space is dissected and sealed in one step by a bipolar instrument (BiZactTM). The instrument uses Valley Lab adjustable bipolar energy. Energy is automatically adjusted and delivered to the tissue in order minimize thermal tissue damage and seal blood vessels less than 3mm in diameter while dividing the soft tissue."
45950661|NCT05270109|Procedure|Cold Steel|"In the cold steel group the peritonsillar space is dissected with metal instruments, and bleeding is typically controlled by ligation or electrocautery."
45950662|NCT00480064|Drug|Lomustine, intermediate dose cytarabine|
45950663|NCT00480103|Device|in vivo (ANECOVA D-1) or in vitro culture in 25-µl droplets of cleavage medium (Medicult®) under paraffin oil|
45950664|NCT00480142|Drug|Oxycodone 10 mg|
45950665|NCT00119483|Drug|Nebido (Testosterone Undecanoate)|
45950666|NCT00480181|Drug|nabilone|Cesamet (nabilone) capsules given at titrating dosages as per protocol.
45950667|NCT00480181|Other|placebo|placebo capsules (identical appearance to Cesamet) given at titrating dosages as per protocol.
45950668|NCT00480220|Procedure|Global care and support program|
45950669|NCT00480259|Behavioral|hyperproteic nutrition|
45659564|NCT02336607|Drug|Felodipine tablet (Plendil)+Hydrochlorothiazide|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with hydrochlorothiazide 12.5mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
45812733|NCT05477264|Drug|Tislelizumab|"Induction therapy: Tislelizumab combined with radiation~Tislelizumab: 200mg, IV at 3-week intervals combined with radiotherapy.~Radiotherapy: 400Gy/20 fractions~Maintenance therapy(after termination of combination therapy)~Tislelizumab: 200mg IV at 3-week intervals for up to 2 years until disease progression or intolerance."
45812734|NCT00422318|Drug|Benzbromarone (drug)|
45812735|NCT00364676|Drug|VLI|Patients are dosed on Day 1 and Day 8 of a 21-day cycle.
45950670|NCT05244876|Behavioral|Back school|Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
45950671|NCT02274103|Behavioral|BFST|Family-based skills training.
45950672|NCT00480298|Drug|Administration of oral methylprednisolone|
45950673|NCT00480337|Procedure|In Vitro Maturation of immature oocytes|
45950674|NCT00480376|Drug|ofloxacin|
45950675|NCT00480376|Drug|gentamicin|
45950676|NCT00119561|Behavioral|Telephone Support|Each telephone support group of 5 caregivers and a group leader met 14 times over a year. The hour calls were semi-structured with an educational component and a support component, led by a trained Group Leader. Topics included knowledge of dementia, safety, caregiver health and well being, communication, managing behavioral challenges and caregiver stress and coping.
45950677|NCT00117702|Drug|Tacrolimus|day 0-100, then taper
45950678|NCT00117702|Drug|Everolimus|day 0-56
45950679|NCT01240018|Dietary Supplement|Probiotic|Parallel, randomized, controlled 2 arms study.
45950680|NCT00480454|Biological|MVA 85A|intradermal vaccine
45950681|NCT00480571|Drug|BL-1020|BL-1020 Low Dose
45950682|NCT00480571|Drug|BL 1020 High Dose|BL 1020 High Dose
45950683|NCT00119600|Drug|AMG 114|
45950684|NCT00480610|Drug|tacrolimus ointment|Topical application
45950685|NCT00480610|Drug|Placebo ointment|Topical application
45950686|NCT00117741|Behavioral|Dialectical Behavior Therapy|Weekly individual DBT, DBT group skills training, as needed phone calls for coaching, team meeting for psychotherapists, suboxone
45950687|NCT00117741|Behavioral|Drug Counseling|Weekly individual counseling and weekly group therapy following guidelines of drug counseling treatment manual,
45950688|NCT00480649|Drug|Salmeterol/ fluticasone propionate|2 active arms (parellel group)
45812736|NCT00364676|Drug|VLI|Patients are dosed on Day 1 of a 21-day cycle.
45812737|NCT00364754|Drug|Tesmilifene (YMB 1002)|
45812738|NCT05731700|Device|Drug Eluting Balloon|PCI of in-stent restenosis
45812739|NCT00366236|Drug|Nitazoxanide|
45950689|NCT00480688|Biological|BCG|
45950690|NCT00119639|Drug|Sorafenib (BAY43-9006, Nexavar)|All subjects were given a open-label, single dose of 400mg sorafenib
45950691|NCT00480727|Procedure|Halo pin re-tensioning|Re-tensiong every 2 weeks with torque driver. Pins are re-tensioned to 8lb/inch
45950692|NCT00480727|Procedure|Placebo Re-tensioning|Pts undergo re-tensioning procedure with torque driver set at zero to elicit the same clicking sensation with no tightening of the pin.
45950693|NCT05238792|Biological|Tumor-associated antigen-specific T cell (TAA-T)|"Patients will receive an infusion of partially HLA-matched TAA-T any time >1 week after completing most recent course of conventional (non-investigational) therapy for their disease. For the lymphodepletion cohort, patients will receive lymphodepletion (LD) chemotherapy >2 weeks from most recent course of conventional therapy and will nadir and recover before beginning TAA-T therapy. Patients will be enrolled to one of the following TAA-T dose levels:~BSA <1.20 BSA ≥1.20 Dose level 1 without LD (low dose) 2x107 cells 4x107 cells Dose level 2 (LD + Low dose) 2x107 cells 4x107 cells Dose level 3 (LD + High dose) 4x107 cells 8x107 cells"
45950694|NCT00480844|Drug|Sertindole|Oral (tablets), 16-24 mg QD (once a day) for 12 weeks.
45950695|NCT00480844|Drug|Risperidone|Oral (tablets), 4-8 mg QD (once a day) for 12 weeks.
45950696|NCT00119717|Device|NeuroFlo™ catheter|45 minute treatment
45812740|NCT04710602|Procedure|Minimally invasive surgical fixation of unstable rib cage|Minimally invasive and muscle sparing surgical fixation of ribs and/or sternum in an unstable segment of the chest wall (flail chest) with titan plates or medullary nails (MatrixRib Fixation System, DepuySynthes).
45812741|NCT04710602|Procedure|Large incision surgical fixation of unstable rib cage.|Surgical fixation of ribs and/or sternum in an unstable segment of the chest wall (flail chest) with titan plates or medullary nails (MatrixRib Fixation System, DepuySynthes). Large non muscle sparing incision with simultaneous thoracotomy.
45950697|NCT00119717|Other|Control|ASA Guidelines
45950698|NCT00480883|Drug|meglumine antimoniate, allopurinol|first drug in injectable, second is in tablet form.
45659565|NCT02336607|Drug|Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with metoprolol succinate prolonged-release tablet (Betaloc ZOK) 47.5mg , once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
45950699|NCT00480883|Drug|meglumine antimoniate|injectable 20 mg/kg/day/intramuscular for 21 days.
45950700|NCT00480883|Drug|meglumine antimoniate, allopurinol|injectable meglumine antimoniate 10 mg/kg/day/intramuscular for 21 days plus tablet allopurinol 300mg/4times a day for 21 days.
45659566|NCT02336607|Drug|Felodipine tablets (Plendil)+Lisinopril (Zestril)|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with Lisinopril (Zestril) 10mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
46077032|NCT00895609|Drug|Sugammadex, Neostigmine, Saline|"Single intravenous injection of either:~Sugammadex 0.0625 mg/kg (Sgx 0.0625) Sugammadex 0.125 mg/kg (Sgx 0.125) Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 1.0 mg/kg (Sgx 1.0) Neostigmine 5 mg/kg (Neo 5) Neostigmine 8 mg/kg (Neo 8) Neostigmine 15 mg/kg (Neo 15) Neostigmine 25 mg/kg (Neo 25) Neostigmine 40 mg/kg (Neo 40) Saline 0.9% (Saline)"
45659567|NCT02374671|Device|VisAbility Micro Insert|Subjects are implanted with the VisAbility Micro Insert (Model SGP-046) and followed for 24 months.
45950701|NCT00480922|Behavioral|Low glycemic load diet|Outpatient behavioral counseling
45950702|NCT00480922|Behavioral|Low fat diet|Outpatient behavioral counseling
45950703|NCT00480961|Procedure|intramiocardiac autograft of autologous stem cells|
46077033|NCT02757690|Device|3-dimensional distal pancreatectomy|3D laparoscopy
46077034|NCT02757690|Device|2-dimensional distal pancreatectomy|2D laparoscopy
45659568|NCT02569801|Drug|Fulvestrant|Fulvestrant at a dose of 500 mg as two intramuscular injections will be administered on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle.
45659569|NCT02569801|Drug|GDC-0810|GDC-0810 will be administered as tablets at a dose of 600 mg orally once daily.
45659570|NCT05521477|Dietary Supplement|SLAB51|One dose of probiotic consists of a bag of probiotic powder to dissolve in a glass of water according to the manufacturer instructions. Each bag contains 100 billion bacteria of the following strains: streptococcus thermophilus DSM 32245, 2 Bifidobacteria lactis DSM 32246 and DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244 and Lactobacillus brevis DSM 27961.
45812742|NCT05731466|Device|CardioMems HF System|"Implantation CardioMems device.~Evaluation of right ventricular-arterial coupling during exercise using a hybrid technique of real-time CMR-derived volume measures and CardioMems-derived pulmonary artery pressure measurements."
45950704|NCT00481000|Behavioral|Dialectical Cognitive Therapy|Dialectical Behavior Therapy in Combination with Traumafocused CBT
45659571|NCT05521399|Diagnostic Test|MRI Sequencing|MRI test-retest (select healthy volunteers) for development of MRI sequence.
45659572|NCT05521399|Diagnostic Test|MRI Testing (pediatric)|Comprehensive cardiac MRI measures will be evaluated for the identification of complications after heart transplantation (ACR, CAV) in children.
45659573|NCT05521399|Diagnostic Test|MRI Testing|Cardiac MRI to improve HTx monitoring for ACR and CAV as well as outcome prediction
45659574|NCT05516719|Other|Positron Emission Tomography (PET) scan using BU99008 tracer|A positron emission tomography (PET) scan produce detailed 3-dimensional images of the inside of the body by showing radiation from tracers used to highlight specific areas of the brain.
45950705|NCT05236998|Drug|SID1903 (FDC)|Single oral administration of SID1903 (FDC) after an overnight fast
45950706|NCT05236998|Drug|Dapagliflozin and Sitagliptin|Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast
45950707|NCT01240096|Drug|Mirtazapine|Mirtazapine 15 mg daily
45950708|NCT00119756|Drug|paliperidone palmitate|
45950709|NCT01240174|Behavioral|Demonstration of near zero antibiotic prescribing for patients with acute bronchitis|A controlled, continuously-monitored, implementation of an EHR-integrated diagnosis and treatment algorithm for acute bronchitis in a large, diverse primary care practice.
45950710|NCT01240252|Drug|Human insulin|U100 Humulin at a rate of 80 mU/m^2 surface area per minute one time over 4 hours
45950711|NCT05233605|Drug|Dexmedetomidine|"Dexmedetomidine will have been administered at the end of sedation in the ICU to prevent or treat delirium after post-COVID-19 ARDS.~This drug was administered in accordance with its MA, as part of care, prior to inclusion in the protocol 24 months (+12 months) and independently of it."
45950712|NCT01240291|Dietary Supplement|Dipeptiven|Intravenous alanyl-glutamine (0.5 g/kg body weight; i.e. 0.35 g L-glutamine / kg body weight; continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks.
46077035|NCT04269317|Device|Tixel C|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide for dermal remodeling and collagen restructuring that promote acne scar appearance improvement.
45950713|NCT01240291|Dietary Supplement|normal saline|0.5 g/kg bod weight /day, continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks
45950714|NCT00119795|Behavioral|Exercise|Increase Physical Activity to 150 min/wk
46077036|NCT04113681|Procedure|Geniculate Artery Embolization|"Conscious sedation : midazolam and fentanyl~Local anesthesia : Lidocaine 2% subcutaneous~Retrograde or anterograde common femoral artery access - 4Fr introducer~Sub-therapeutic anticoagulation (heparin 2000 IU IA)~Lower extremity arteriography~Selective and supra-selective catheterization of geniculate arteries supplying painful region of the knee~If abnormal arterial blushes are demonstrated selective and supra-selective embolization will be performed with Embozene microspheres (100 microns to 200 microns) - cold saline or ice-packs sac to be applied to overlying skin if significant cutaneous arteries are demonstrated at angiography.~Angiographic end-points: embolization of abnormal blush while preserving the parent vessel~Arteriotomy closure (manual compression or closure device)"
45812743|NCT04622540|Procedure|External biliary drainage|Application of external biliary drainage through duct-to-duct anastomosis
45812744|NCT04741880|Drug|Lidocaine IV|"Will be sent to Group L a 10 ml syringe of 2% lidocaine and 200 ml of lidocaine solution at 8mg.ml-1 (80ml of 2% lidocaine associated with 120ml 0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered."
45812745|NCT04741880|Drug|Saline|"Group S will be sent a 10 ml syringe of 1% lidocaine and 200 ml of saline solution (0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered."
45950715|NCT00119795|Behavioral|Weight Loss|Lose 7-10% of body weight and increase physical activity to 150 min/wk
46077037|NCT00894439|Drug|BLI-489/Piperacillin|
46077038|NCT00894439|Drug|BLI-489|
46077039|NCT00894439|Drug|Piperacillin|
46077040|NCT02855489|Behavioral|Attitudes Only|
46077041|NCT02855489|Behavioral|Norms Only|
46077042|NCT02855489|Behavioral|Perceived Behavioral Control Only|
46077043|NCT02855489|Behavioral|Intentions Only|
46077044|NCT02855489|Behavioral|Three Constructs|
46077045|NCT02855489|Behavioral|Four Constructs|
46077046|NCT04113213|Behavioral|Lifestyle Prescription (LRx)|Lifestyle prescription, based on the UK WP10 medicinal prescription form. Includes advice and guidance regarding physical activity, diet, smoking and alcohol consumption.
46077047|NCT04035889|Dietary Supplement|Melatonin|Participants will start with 0.5 mg tablets of melatonin with the option of switching to an 'escalation dose' of 3 mg if no relief after 3 days.
46077048|NCT04035889|Dietary Supplement|Placebo|Placebo
45812746|NCT05447234|Biological|Tcrx T cell|Sequential IV infusion
45812747|NCT05433818|Behavioral|Group A|Skin-to-Skin Contact (SSC) contributes to mother-infant interaction and can increase breastfeeding success
46077049|NCT00895687|Drug|Erlotinib Hydrochloride|Beginning dose of 150 mg taken by mouth daily for 21-day cycle.
45812748|NCT05433818|Other|Group B|education with a structured and expert opinion-based breastfeeding brochure
45812749|NCT04621838|Other|Assigned interventions.|"Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use, with Silicone Foam Dressing and Silicone Foam Lite Dressing.~The patients will be evaluated at each dressing change over a six-week period (per Product) or until the wound is healed to extent that the use of the Silicone Foam and Silicone Foam Lite dressing is no longer indicated from the time that the patient has been recruited."
45950716|NCT00119795|Behavioral|Health Education Control|Lectures on information relevant to successful aging
45950717|NCT00481039|Procedure|Medical history and basic laboratory analysis|Medical history and basic laboratory analysis
45950718|NCT00481117|Drug|LY2405319|
45950719|NCT00481117|Drug|Placebo|
46077050|NCT00895687|Drug|Bortezomib|Beginning dose of 1. mg/m^2 by vein over about 1-5 minutes on Days 1, 4, 8, and 11 of each 21-day cycle.
46077051|NCT02758080|Other|Matching on the basis of molecular analysis|
46077052|NCT02758080|Other|Matching on the basis of physician's choice|
46077053|NCT00894595|Behavioral|Knäkontroll, SISU Idrottsböcker©, Sweden, 2005|The preventive program (Knäkontroll, SISU Idrottsböcker©, Sweden, 2005) consists of six exercises focusing on knee control and core stability and is performed during the warm-up at two training sessions per week throughout the 2009 competitive season.
46077054|NCT02757924|Other|Infant formula supplemented with prebiotics|Sole source nutrition
46077055|NCT00892255|Device|Microwave Ablation|Tumor tissue from the liver is inter-operatively treated with the microwave ablation device to measure the destruction of tissue.
46077056|NCT00798135|Drug|itraconazole|oral itraconazole 200mg a day until disease progression or unacceptable toxicities.
46077057|NCT02762838|Biological|BCD-055|BCD-055 is infliximab biosimilar
46077058|NCT02762838|Biological|Remicade®|
46077059|NCT02762838|Drug|Methotrexate|All patients will receive methotrexate in a dose from 10 to 25 mg per week.
45950720|NCT00117780|Drug|insulin detemir|
46077060|NCT02762838|Drug|Folic acid|All patients will receive folic acid in a dose of 5 mg per week.
45812750|NCT04615130|Other|Rehabilitation|Rehabilitation, exercise training
45659575|NCT05516719|Other|FP-CIT Single-photon Emission Computed Tomography (SPECT) scan|A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
46077061|NCT02752854|Other|pain threshold measurement|pressure algometer
45659576|NCT05516719|Other|Magnetic Resonance Imaging (MRI) Scan|MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain.
45812751|NCT04551326|Other|manual hamstring stretching|Participants' lower limb will be positioned in maximal hip flexion and gradually moved to maximal knee extension by physical therapist. The procedure will take one minute for each lower limb.
45659577|NCT05516719|Other|Lumbar puncture|A lumbar puncture is where a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
45659578|NCT05516641|Dietary Supplement|Soluble Corn Fiber|once daily additive to diet
45812752|NCT04490486|Biological|UCMSCs|100 x 106 (100 million) UCMSCs delivered via peripheral intravenous infusion.
45812753|NCT04490486|Other|Placebo|Placebo, a solution of 1% human serum albumin in Plasmalyte A, delivered via peripheral intravenous infusion
45812754|NCT05421728|Behavioral|ENACT group visit|Participation in two 2 hour group visits about advance care planning.
45812755|NCT05421728|Behavioral|Mailed Resources|Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
45950721|NCT00117780|Drug|insulin aspart|
45950722|NCT00481156|Behavioral|Cognitive Remediation|
45950723|NCT00481156|Behavioral|Cognitive Behavioral Social Skills Training|
45950724|NCT00481156|Other|Retest in Health Controls|Pre/Post test performance and neuroimaging only
45950725|NCT00119834|Device|Mechanical Circulatory Support Device (MCSD)|INTERMACS is an observational registry of adult and pediatric patients with end stage heart failure that receive a legally utilized Mechanical Circulatory Support Device.
45950726|NCT01240408|Drug|HOPE|10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
46077062|NCT00941603|Drug|SCH 900271 15mg|oral tablets; SCH 900271 - 15 mg taken once daily for 8 weeks
46077063|NCT00941603|Drug|SCH 900271|oral tablets; SCH 900271 10 mg taken once daily for 8 weeks
46077064|NCT00941603|Drug|SCH 900271|oral tablets; SCH 900271- 5 mg taken once daily for 8 weeks
46077065|NCT00941603|Drug|SCH 900271|oral tablets; SCH 900271- 2.5 mg taken once daily for 8 weeks
46077066|NCT00941603|Drug|SCH 900271|oral tablets; SCH 900271- 1 mg taken once daily for 8 weeks
45453741|NCT04471948|Device|Fractional picosecond 1064 nm laser|The parameter of laser was 8 mm spot size, 0.8 mJ/CM2, 750 ps, 5 Hz, 2 passes The treatment was done in every 4 weeks for 3 sessions.
45453742|NCT00657826|Device|ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm|Isolated aortic valve replacement with a size 19mm valve
45453743|NCT02880956|Drug|ABBV-8E12|ABBV-8E12 solution for IV infusion
45659579|NCT05516641|Dietary Supplement|Maltodextrin|once daily additive to diet
45676483|NCT02791685|Behavioral|Movn Pulmonary Rehabilitation|Movn pulmonary rehabilitation is a program delivered by the Movn smartphone application that includes targeted educational content and prescribed exercises with mild resistance training in addition to walking and other cardiovascular exercises. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
45812756|NCT04742504|Biological|BENRALIZUMAB|The decision of the patients treatment with benralizumab (Fasenra®, Astra Zeneca) included in the study will not come in any case influenced by their participation in the study but will be made in accordance with the clinical criteria established by the Asthma Multidisciplinary Unit (UMA).
45812757|NCT00365924|Drug|Forteo|Open label single arm study with Forteo as an intervention
45812758|NCT04437914|Diagnostic Test|Electrocardiogram diagnosis|Electrocardiographic diagnosis will be made in a double-blind manner by two specialists in cardiology and cardiac arrhythmias and the results will be compared between the groups studied.
45812759|NCT05731310|Drug|Angong Niuhuang Pill|Take Angong Niuhuang pill half a pill/day； Angong Niuhuang pill combined with music scalp acupuncture group These operations last for 4 weeks
45950727|NCT01240408|Drug|HOPE|10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
45950728|NCT05232786|Other|No treatment given|No treatment given
46077067|NCT00941603|Drug|Placebo|oral tablets; placebo administered once daily during the 5-week single-blind placebo run-in and diet stabilization period and during the 8 week double-blind treatment period.
46077068|NCT02753166|Drug|Dexamethasone|After six (6) hours of the accident, subject will take 5 mg of DEX in the Emergency Department (ED). Within twenty-four (24) hours, the subjects will send in a saliva sample. After sexen (7) days, subjects will participate in a phone interview. After thirty (30) days, subjects will participate in an online assessment and return for a one month follow-up visit. Subjects will then participate in online assessments at months 3,6,9, and 12 months.
45950729|NCT01240447|Biological|racotumomab|Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), subcutaneously, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and a second line therapy is indicated, the patient will only be able to continue in the study if the drug indicated is docetaxel. Vaccination will not be interrupted during docetaxel administration unless criteria for vaccine discontinuation are met.
45950730|NCT01240447|Other|Best support treatment|Patients will receive best support treatment as indicated by the investigator. In case a second line therapy is indicated, docetaxel is the only drug allowed to continue in the study.
45950731|NCT00481234|Device|Heart Rate Variability analysis|
45950732|NCT00119873|Biological|VRC-HIVADV014-00-VP|
45659580|NCT05511961|Behavioral|Healthier Wealthier Families|Budget and debt counselling will involve at least one meeting with a counsellor. Examples of assistance the counsellors can offer include: suggestions on ways to improve a participant's financial situation; checking eligibility and helping to apply for social welfare support; helping to organise finances and develop a budget; and assistance with debt management, threatening letters or harassment by debt collectors, or imminent house eviction. The municipal budget and debt counselling services involved in the trial will receive guidance on how to work preventatively with families, which will align with the content of the 'Your child, your money'. The book covers topics such as planning finances, consumer rights, private insurance, family law, parental leave, pensions, saving, and budgeting.
45659581|NCT05521165|Other|therapeutic exercises|strengthening exercises for gluteus medius and APTA guided program for NSCLBP
45676484|NCT02791685|Behavioral|Standard of Care Cardiac Rehabilitation|Standard cardiac rehabilitation involves a facility's standard rehabilitation practices. Participants will be seen at baseline and during a 12 and 24 week follow-up visit.
45676485|NCT02780310|Drug|Lenvatinib|
45676486|NCT02772367|Procedure|skin punch biopsy|
45812760|NCT05404958|Other|Systems Analysis and Improvement Approach (SAIA)|"What is SAIA? It is a 5-step cycle that is repeated every 4-6 weeks for continuous quality improvement, implemented by Kenyan public health workforce and FP clinic staff, and monitored by Mombasa DOH.~Step 1: Understanding the cascade from FP clinic enrollment to HIV testing to linkage to treatment and prevention services.~Step 2: Use process mapping to identify modifiable bottlenecks. Step 3: Define and implement workflow adaptations to eliminate modifiable bottlenecks.~Step 4: Monitor change in performance. Step 5: Repeat the analysis and improvement cycle (steps 1-4)."
45812761|NCT05360030|Drug|Naloxone|The volunteer received an intravenous bolus followed by a continuous infusion of naloxone, which was continued throughout the pcTBS session
45812762|NCT05360030|Drug|Saline|The volunteer received an intravenous bolus followed by a continuous infusion of placebo (saline), which was continued throughout the pcTBS session
45812763|NCT05360030|Drug|Ketamine Hydrochloride|The volunteer received an intravenous bolus followed by a continuous infusion of ketamine, which was continued throughout the pcTBS session
45812764|NCT05360030|Device|pcTBS of M1|Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left M1 at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
45950733|NCT00481273|Drug|Azacitidine|Physician's discretion
45950734|NCT00481312|Drug|Dexmedetomidine|Continuous Infusion
45950735|NCT00481312|Drug|Midazolam|Continuous Infusion
45950736|NCT05220735|Dietary Supplement|Omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA)|"3 three fish oil capsules providing 2.1 g n-3 PUFA; 1.27 g Docosahexanoic acid (DHA) and 0.86 g Eicosapentanoic acid (EPA) capsules.~The absorption study test meals will consist of white bread with butter and honey, 6mg of labeled iron as ferrous sulfate and 300 g of distilled water. The meal will be given on two days without and with ascorbic acid. The test meals without ascorbic acid will contain 6 mg 57Fe as ferrous sulfate whereas the meals containing ascorbic acid will contain 6 mg 58Fe as ferrous sulfate."
46077069|NCT04112901|Device|Microprocessor-controlled knee joints|Any type of microprocessor-controlled knee joints will be considered; this includes those controlling stance phase only (e.g. Compact C-Leg), swing phase only (e.g. Smart IP), both swing and stance phases (e.g. Reho knee), or power generating knees (e.g. POWER knee Ossur).
46077070|NCT04112901|Device|Non-microprocessor-controlled knee joints|Any non-microprocessor-controlled knee joints such as prosthesis incorporating hydraulic, polycentric, pneumatic mechanisms, friction or locked knees.
46077071|NCT04222140|Combination Product|ERIPTO Protocol|combination biologic treatment
46077072|NCT04222140|Biological|BMAC Only|BMAC treatment only
46077073|NCT02605083|Drug|eFT508|Will be given orally once or twice daily. Each treatment cycle = 21 days.
46077074|NCT02752698|Procedure|Micro Hand S robotic surgery|20-70 patients undergo Micro Hand S robotic surgeries
46077075|NCT02752698|Procedure|laparoscopic surgery|20-70 patients undergo laparoscopic surgeries
46077076|NCT02752698|Procedure|da Vinci robotic surgery|20-70 patients undergo da Vinci robotic surgeries
46077077|NCT04113135|Other|Yoga|Participants will be lead through a series of yoga poses by a licensed physical therapist with advanced training in yoga. Participants in this group will also receive education related to MS as well as SMART goal setting, journaling and guided meditation. Modifications will be offered as needed.
45950737|NCT00119951|Behavioral|Participation on the ACOR Listserv|
45659582|NCT05511805|Other|Visual Analogue Scale (VAS),|The pain levels of the individuals participating in the study will be evaluated with the Visual Analog Scale. According to VAS, in the severity of pain; '0' means no pain, '10' means worst pain imaginable. During the study, the participants will be asked to rate their pain experienced in daily life and pain during evaluation between 0-10 points. Individuals with pain intensity of 3 and above according to VAS will be included in the study.
45950738|NCT00481390|Procedure|Cheek cells sample|Cheek cells sample
45950739|NCT00481390|Procedure|Blood sample|Blood sample
45950740|NCT00481429|Drug|Rosiglitazone|Rosiglitazone 4mg od, increased to 4mg bg at 4 weeks if HbA1C above 7%.
45659583|NCT05511805|Other|Oswestry Low Back Pain and Disability Questionnaire|The Oswestry scale will be used to determine the level of functional disability due to low back pain. In this questionnaire, 10 questions are asked about pain intensity, social life, weight lifting, walking, personal care, sitting, sleeping, sexual life, standing and travel. Each question has 6 options and the patient is asked to choose the statement that best describes his or her condition.
45659584|NCT05511805|Other|Functional Low Back Pain Scale|The Functional Low Back Pain Scale will be used to evaluate how much the low back pain experienced by the people who will be included in the study affects their daily living activities. Evaluated functions; work and school activities, home activities, wearing shoes or socks, leaning forward, lifting an object from the ground, habits, sleeping, walking, sitting, climbing stairs, standing and driving. The questionnaire consists of 12 questions, and each item scores in the range of 0-5 points.
45659585|NCT05511805|Device|Prokin TecnoBody isokinetic balance 2 device|For the one-leg balance test, the subject is positioned on one leg at the origin of the platform. The participant is asked to look at any stationary point or object in front of him. Participants are allowed to experiment on the platform of the meter for approximately 2-3 minutes. The stem sensor apparatus is then attached to coincide with the xiphoid projection. After the torso sensor is attached, the patient is placed in the dominant side position on one foot and the static balance test measurement is started. 30 seconds from the patient in this position. asked to stop.
45676487|NCT02763072|Device|Enlighten Laser|
45676488|NCT02763072|Device|Excel V Laser|
45950741|NCT00117858|Procedure|Anodal DC polarization of left prefrontal cortex|
45950742|NCT00119990|Drug|Icodextrin (dialysate)|2 liter of extraneal are given with one fill for 4 hours.
46077078|NCT04113135|Other|Control|Participants in this group will receive education related to MS as well as SMART goal setting, journaling, and guided meditation.
45950743|NCT00119990|Drug|Physioneal (dialysate) 1.36% and 2.27%|2 liter of Physioneal of 1.36% or 3.86% are given with one fill for 4 hours one two different days.
45950744|NCT00481624|Drug|Epoetin Alfa plus Iron|"One (1) injection of Procrit®, by needle, inserted just under the skin;~125 mg of ferric gluconate (an iron injection product), through an IV injection into a vein.~These injections will take approximately 10-15 minutes to complete. Both will be administered every 3 weeks for a total of 4 cycles, unless the study doctor decides that a change in the amount of Procrit® and iron is necessary once the hemoglobin level rises or is above a certain amount.~In addition to Procrit® and the intravenous iron, the subject will also receive platinum-containing chemotherapy every 3 weeks for 4 cycles as per standard of care for their lung cancer treatment. Radiation therapy will be allowed during this regimen if it is part of the subject's treatment plan."
45950745|NCT00117897|Drug|pegfilgrastim|
45950746|NCT00117897|Drug|Filgrastim|
45950747|NCT00481663|Drug|Sitagliptin|
45950748|NCT00481663|Drug|Placebo to sitagliptin|
45950749|NCT00481663|Drug|Metformin|
46077079|NCT02753088|Drug|BCD-063|
46077080|NCT02753088|Drug|Copaxone-Teva|
46077081|NCT02753088|Drug|Placebo|
46077082|NCT04112979|Behavioral|Music|45 dB SL, normalized, high-frequency sampled W.A. Mozart Symphony n°4 in D K19 and n°5 in B-flat K22 (from Mozart Symphonies Vol. I - Adam Fisher, Dacapo Records, Frederiksberg C., Denmark, 2013)
46077083|NCT04112979|Behavioral|Mother's lap|45 dB SL, normalized and filtered, high-frequency sampled heartbeat sound, 75 bpm tempo, looped
46077084|NCT04112979|Behavioral|Soundproof earplugs|Disposable foam earplugs with a noise attenuation of at least 30 dB
46077085|NCT02605239|Drug|Bleaching teeth|bleaching teeth with carbamide peroxide 10% for 3 weeks
46077086|NCT02757534|Drug|Domperidone|The study drug will be given to relieve the symptoms of gastroparesis, including nausea and vomiting.
46077087|NCT00914901|Drug|inhaled salmeterol|Inhalation of 100 micrograms salmeterol in one dose.
45659586|NCT05511805|Device|EMG|In our study, electromyography (EMG) device will be used to evaluate muscle strength. Electromyography is a method by which electrical activity analysis of muscles can be performed. In the study, the erector spina and multifidus muscles will be measured. Measurements are made with electrodes placed on the skin surface.
45659587|NCT05511805|Device|Algometer|The pressure perception and pain threshold of pain sensitivity are determined and recorded with an algometer. The details of the application will be explained to the participant and it will be emphasized that the feeling of pressure he feels causes pain and that he should give a 'stop' command. The pressure force is increased until the patient receives the 'stop' command in the area to be applied. It is stopped by the command from the patient and the response on the algometer screen is recorded. These measurements are repeated 3 times. The average of these three recorded measurements is determined.
45659588|NCT05511805|Device|Goniometer|Using the universal goniometer's measure of knee joint range of motion, sense of proprioception will be evaluated. For measurement, subjects are asked to lie on a stretcher in the prone position. The pivot point of the goniometer is placed in the center of the lateral knee joint condyle. The fixed arm of the goniometer is fixed in parallel at the level of the thoracantary major, and the movable arm is positioned at the level of the head of the fibula and the lateral malleolus. First of all, starting from the 0° extension position to the knee joint, the angle desired by the physiotherapist is made and the value in the goniometer is recorded. Then, the patient is asked to bring the knee joint, which is still in 0° extension, to the angle brought by the physiotherapist. Then the angle brought by the patient to the knee joint is recorded.
45659589|NCT05511727|Device|single versus double Foley's catheter in pre-induction cervical ripening|The single balloon catheter (i.e. Foley catheter [FC]) and Cook cervical ripening balloon have been the most commonly used mechanical method
45659590|NCT05516407|Drug|FEN164|Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
45812765|NCT05360030|Device|pcTBS of DLPFC|Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left DLPFC at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
45812766|NCT05360030|Device|SHAM stimulation|The Sham stimulation was delivered using the same pcTBS protocol, with the coil being flipped 90◦to the scalp so that the magnetic field would be delivered away from the scalp
45812767|NCT05731232|Dietary Supplement|Vivatlac Synbiotikum|Each capsule of Vivatlac® Synbiotikum contains a total of 4.5 x 10˄9 colony forming units (CFU) of nine different probiotic bacteria. Probiotic bacteria strains and their CFU amount per capsule are: Lactococcus lactis Ll-23, 9.00 x 10˄8 CFU; Lactobacillus helveticus SP 27, 9.00 x 10˄8 CFU; Bifidobacterium longum Bl-05, 6.75 x 10˄8 CFU; Bifidobacterium breve Bb-03, 4.50 x 10˄8 CFU; Lacticaseibacillus rhamnosus Lr-32, 4.50 x 10˄8 CFU; Streptococcus thermophiles St-21, 4.50 x 10˄8 CFU; Lacticaseibacillus casei Lc-11, 2.25 x 10˄8 CFU; Lactiplantibacillus plantarum Lp-115, 2.25 x 10˄8 CFU; Bifidobacterium bifidum Bb-02, 2.25 x 10˄8 CFU. As a prebiotic component each capsule contains 63 mg of fructooligosaccharides.
45812768|NCT05731154|Other|taking periorbital selfie images using smartphones|taking periorbital selfie images using smartphones
45812769|NCT05731076|Behavioral|Self-management support nutrition and exercise intervention|Provide information about different home exercise type(walking, strength training, flexibility training), nutrition knowledge to maintain or improve cancer cachexia syndrome.
45812770|NCT00364910|Behavioral|Cognitive behavioral therapy (CBT)|Participants meet with a therapist for three to five sessions brief exposure-based CBT.
45812771|NCT00364910|Behavioral|Educational session and treatment as usual|Participants assigned to the educational session attend one meeting with a researcher to discuss the results from their evaluation. They could also be referred to a mental health clinic of their choice to help relieve their symptoms.
45812772|NCT05730998|Dietary Supplement|ANTHOCRAN FITOSOMA|The product (Anthocran phytosome or placebo) will be taken in the quantity of 1 capsule of 120 mg, 1 times a day, for 6 months
45812773|NCT05730998|Dietary Supplement|PLACEBO|Placebo will be taken in the quantity of 1 capsule of 120 mg, 1 times a day, for 6 months
45812774|NCT04158362|Drug|Paclitaxel injection|Paclitaxel is administrated at the dose of 80 mg/m² as a 1-hour intravenous infusion every week (i.e., D1, D8 and D15) of a 3-week cycle
45812775|NCT04158362|Drug|Capecitabine tablets|Capecitabine is given orally at a dose of 2000 to 2500 mg/m² daily for 14 days followed by a 7-day rest period every 3 weeks
45812776|NCT04158362|Drug|Letrozole 2.5mg|Letrozole is administered orally at 2.5 mg/day continuous for patients nonsteroidal aromatase inhibitor naïve or relapsing >1 year after the end of adjuvant endocrine therapy.
45812777|NCT04158362|Drug|Anastrozole 1mg|Anastrozole is administered orally at 1 mg/day continous for patients nonsteroidal aromatase inhibitor (NSAI) naïve or relapsing >1 year after the end of adjuvant endocrine therapy.
46077088|NCT04112745|Other|Static magnet|Static magnet with 2,000 Gauss
46077089|NCT04112745|Other|Placebo|Polyvinyl chloride resin material black jewelry
46077090|NCT02759874|Device|specialized breathalyzer w face recognition technology|
46077091|NCT04530318|Other|Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded|The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).
46077092|NCT04530318|Other|Placebo|The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).
45453744|NCT02880956|Drug|placebo for ABBV-8E12|placebo solution for intravenous (IV) infusion
46077093|NCT00797823|Drug|Insulin, Asp(B28)-|Insulin dosing and frequency calculated by Fading Memory Proportional Derivative algorithm
46077094|NCT00797823|Drug|Glucagon|During incipient hypoglycemia, glucagon was given in an attempt to prevent overt hypoglycemia. Dosing and frequency was calculated by the Fading Memory Proportional Derivative algorithm
46077095|NCT00797823|Drug|Placebo|Saline solution 0.9%
45812778|NCT04158362|Drug|Fulvestrant Prefilled Syringe|Fulvestrant is administered at the dose of 500 mg intramuscular on D1-D15-D29 (as a loading dose), and then 500 mg every 28 days (as a maintenance dose) for patients relapsing on adjuvant or less than one year after completion of adjuvant NSAI.
45812779|NCT04158362|Drug|Abemaciclib|Oral 150 mg BID continuous
45659591|NCT05520931|Other|Questionnaire and register-based data assessment|Primary data will be collected via a generic questionnaire from the two groups. Secondary data will consist of register-based socio-economic data and medical charts data collected from the Danish Health Data Authority and Denmark' Statistics.
45659592|NCT05511571|Device|Transcutaneous electrical neural stimulation (TENS)|The TENS group: TENS application was implemented by the researchers in the patient room. The conventional TENS application took 30 minutes per session. The application continued until frequency reached 100 Hz, the pulse width reached 100 μs, and the current impedance reached a point where the women felt needling or tingling according to their tolerance. Before the application, the women were asked to lie in a supine position, and the area/skin where TENS would be applied was cleaned and dried. Two electrodes of TENS were placed 2 cm above the cesarean incision, and the other two electrodes 2 cm below the incision. The women were allowed to rest during the application, and they were accompanied by the researcher. A total of five TENS sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held.
45676489|NCT02758431|Drug|Acyline|Acyline 300ug/kg injection will be administered on Day 0 and on day 14
45676490|NCT02758431|Drug|Placebo Gel|Placebo gel packet applied daily for 28 days.
45676491|NCT02758431|Drug|Placebo Tablet|Placebo oral tablet taken daily for 28 days.
45676492|NCT02758431|Drug|Testosterone Gel|Testosterone Gel applied daily for 28 days
45812780|NCT05341778|Other|Shoulder bridge|The shoulder bridge is great for, strengthening your gluteal muscles, quadriceps, hamstrings, pelvic floor, abdominals and back muscles; most notably the tiny ones which control movement of each individual vertebrae and can weaken after episodes of back pain.
45812781|NCT05341778|Other|Clam shell|Scissors is an abdominal exercise that strengthens the transverse abdominals, helping flatten your belly and strengthen your entire core. Scissors is not only a core strength move, but it is also a great stretch for your hamstrings and your lower back.
45812782|NCT05341778|Other|Scissors|Scissors is an abdominal exercise that strengthens the transverse abdominals, helping flatten your belly and strengthen your entire core. Scissors is not only a core strength move, but it is also a great stretch for your hamstrings and your lower back.
45812783|NCT05341778|Other|Adductor squeeze|Adductor Squeeze exercise The SQ exercise is an isometric hip adduction exercise with the player holding a ball between their knees.
45812784|NCT05341778|Other|Pelvic clock supine|The pelvic clock is a brilliant exercise to help achieve flexibility and strength in the lower back, pelvic floor, and core-in order to prevent pain and injury.
45812785|NCT05341778|Other|urine hold and tummy tuck in|During tummy tuck patients are able to strategically tighten and reinforce the muscles around the pelvic floor, urethra, and other structures. This increased strength and support greatly reduces stress urinary incontinence
45812786|NCT05341778|Other|Bridging|A bridge exercise isolates and strengthens your gluteus (butt) muscles - the gluteus maximus, medius and minimus - and hamstrings, which are the main muscles that make up the posterior chain. It is done by lying on your back with your knees bent, feet flat on the ground and at a comfortable distance from your butt.
45812787|NCT05341778|Other|Split table top|To strengthen your abs, shoulders, arms and legs. The most important part of this move is to contract your abs fully before you start to lower your hips
45812788|NCT05341778|Device|Electrical muscle stimulation|Electric stimulation works by mimicking the natural way by which the body exercises its muscles. The electrodes attached to the skin deliver impulses that make the muscles contract. It is beneficial in increasing the patient's range of motion and improves the circulation of the body.
46077096|NCT02757378|Procedure|Neuroplasticity Explanation (Experimental)|Patients were given an explanation of how the brain uses the information from a manual therapy technique to help it remain sharp in identifying where this input is coming from.
46077097|NCT02757378|Procedure|Biomechanical Explanation (Control)|Patients were given an explanation of how the manual therapy technique affects the anatomy and physiology of the back.
45676493|NCT02758431|Drug|Arimidex|Arimidex Oral Tablet 1mg taken orally daily for 28 days
45812789|NCT04742426|Other|WHO recommended PPE|Uses polycarbonate safety spectacles, fluid-resistant (Type IIR) surgical mask and disposable surgical gown. No head or foot cover.
45812790|NCT04742426|Other|Super-safe setup|Uses surgical cap, FFP3 respirator covered by surgical mask, face shield, whole-body suit (Tyvec), 3 pairs of gloves typed to suit sleeves and disposable foot cover.
45812791|NCT04740944|Behavioral|Salutogenic Approach Based Interview|Salutogenic Approach Based Interview has five basic components. (1) Continuity of health, (2) The story of the person, (3) Health promoting factors, (4) Understanding the health promoting power of tension and strain, (5) Active adaptation In traditional therapy recommended for recovery, more emphasis is placed on negative life events, diagnosis and medication. In the salutogenic approach-based interview, the resources and coping potential of the person are discussed and three healing factors are focused on for the recovery process. These factors are that the participants (1) perceive themselves as more than just a diagnosis and disease, (2) self-discovery and respect for other people's self-discovery, (3) control over their own lives. In the intervention, mental health nurses take part as group leaders. The focus in interviews is therapeutic conversations.
45453745|NCT00656890|Biological|sterile saline for injection|10mg/kg/dose sterile saline injected every other week for a total of 4 doses
45453746|NCT00656890|Biological|MDX-1100|10mg/kg/dose MDX-1100 injected every other week for a total of 4 doses
45453747|NCT01106521|Radiation|Permanent breast seeds implant|Patients are pre-planned using CT simulation. Implant is realised under light sedation and local freezing. Stranded seeds are inserted using a brachytherapy template that is immobilised to the planned target volume using a 'localization' needle. Patients is released the same day and Quality Assurance involves a 2 months post-implant CT
45659593|NCT05511571|Other|Progressive relaxation exercises (PRE)|The PRE group: The PRE application was implemented in the patient room. A quiet and calm environment was prepared in the room for the intervention. The PRE application was implemented by the women under the researchers' instructions. Each session lasted 30 minutes. A total of five sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held. The PRE application includes exercises based on stretching and then the relaxation of different muscle groups, accompanied by deep breathing. The exercises were carried out in the following way: First doing a deep breathing exercise and then stretching all the muscles from feet to face accompanied by breathing in, keeping the breath, and finally relaxing the muscles by breathing out at the same time.
45659594|NCT05511571|Other|Transcutaneous electrical neural stimulation (TENS) and Progressive relaxation exercises (PRE)|The TENS+PRE group: The PRE and TENS applications were carried out together in this group. The administration of the interventions was the same as in groups where only TENS and only PRE applications were carried out. In this group, first, a 30-minute PRE application was implemented, which was followed by a 30-minute-TENS application.
45659595|NCT02573311|Drug|tamsulosin hydrochloride|
45676494|NCT02756000|Procedure|PCI|percutaneous angioplasty and stent implantation in coronary artery with significant atherosclerosis and stenosis
45676495|NCT02756000|Procedure|dobutamine stress echocardiography|Echocardiographic stress test of provoked myocardial ischemia using dobutamine
45812792|NCT05730764|Diagnostic Test|Accurate prediction of fertilization disorders and clinical decision support systems assist doctors in decision-making|With the assistance of accurate prediction of fertilization disorders and clinical decision support systems, clinicians predict and judge the probability and key factors of fertilization disorders of patients, and formulate and implement personalized diagnosis and treatment plans based on the prediction results
45812793|NCT05730764|Diagnostic Test|Clinicians follow a routine protocol|Treatment is performed by the clinician according to the usual protocol.
45812794|NCT05730686|Procedure|Registry of Therapy of patient's diagnosed with FibroLamellar|Registry of Therapy of patient's diagnosed with FibroLamellar
45812795|NCT05297552|Drug|RC48-ADC|Drug: RC48-ADC 2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
45950750|NCT00481663|Drug|Rescue|Patients whose FPG >240 mg/dL from Week 16 or HbA1C >8.5% from Week 25 up to (not including) Week 52 could receive rescue antihyperglycemic therapy with pioglitazone, and remain in the extension study (Extension 1). Participants were eligible for rescue with pioglitazone 30 mg (or rosiglitazone in countries where pioglitazone was not licensed) if they met the following criteria: from Week 16 and during the second extension: FPG consistently >240 mg/dL (repeated and confirmed within 3 to 7 days); from Week 52 up to (not including) Week 70: HbA1C >8%; from Week 70 up to (not including) Visit 21/Week 106: HbA1C >7.5% (Extension 2). Participants placed on rescue therapy with pioglitazone (rosiglitazone where pioglitazone is not available) in the first or second extensions were not eligible for enrollment in the third extension. Rescue therapy was not available in the third extension.
45950751|NCT00120029|Behavioral|weight loss counseling|
45950752|NCT00481702|Drug|Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks|
45950753|NCT00481702|Drug|MK0826, /Duration of Treatment : 8 Weeks|
45950754|NCT00481702|Drug|Comparator: metronidazole / Duration of Treatment: 8 Weeks|
45453748|NCT01111513|Drug|48-hour ropivacaine infusions|Patients receive 20 ml of ropivacaine 0.5 % pre-operation through femoral block catheter, followed by ropivacaine infusions from 0.1 % to 0.1 ml/kg/hour for 48 hours.
45453749|NCT01111513|Drug|Single dose ropivacaine|Patients receive 20 ml of ropivacaine 0.5% pre-operation
45676496|NCT02698254|Biological|Bevacizumab|
45676497|NCT02698254|Other|Quality-of-Life Assessment|Ancillary studies
45950755|NCT00481741|Device|SafeSeal(TM) Hemostasis Patch|
45950756|NCT00481780|Device|plain balloon angioplasty|
45950757|NCT00481780|Device|cutting balloon angioplasty|
45950758|NCT05220423|Other|sms and emails reminders|6 reminders encouraging influenza vaccination on top of the National annual communication campaign organized by the French Health System authorities
45812796|NCT05297552|Drug|JS001|Drug: JS001 3.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
45453750|NCT01111513|Drug|Patient controlled analgesics|Patient controlled analgesics alone, no femoral block
45812797|NCT05272202|Drug|Propofol|STIM-MOTANA is an interventional and prospective study conducted in patients scheduled for surgery under general anesthesia, involving EEG measurements and median nerve stimulation. In this study, 30 patients will undergo surgery under total intravenous anesthesia using a propofol target-controlled infusion pump. The rest of the anesthetic protocol will be at the discretion of the anesthesiologist in charge. After surgery, patients will have a gradual decrease of propofol at different effect-site concentrations (from 4.0 μg/ml to 2.0 μg/ml, in increments of 0.5 μg/ml).
45812798|NCT05272202|Device|Median nerve stimulation|The right-hand median nerve will be stimulated in the same way as for measurement with a conduction velocity or for an evoked potential. Two stimulation electrodes will be placed on the right-hand wrist according to the standards.The stimulation is transcutaneous and painless using the specific Micromed device Sd Ltm Stim Energy (Micromed, Mˆacon, France). The stimulus intensity will range between 3 and 14 mA. The stimulation duration will be 100 ms with a frequency of 0.1 Hz.
45812799|NCT05272202|Device|EEG measurements|Changes in ERD and ERS patterns during median nerve stimulation according to the various propofol concentrations will be continuously monitored by an EEG amplifier. EEG signals will be acquired using the OpenViBE platform with a Biosemi Active Two 64-channel EEG system, arranged in the Biosemi's ABC system covering the entire scalp at 2048 Hz. Among all recorded sites, some of the electrodes will be localized around the primary motor cortex, the motor cortex, the somatosensory cortex, and the occipital cortex.
45812800|NCT01575834|Drug|Romosozumab|Administered by subcutaneous injection once a month (QM)
45812801|NCT01575834|Drug|Placebo|Administered by subcutaneous injection once a month (QM)
45812802|NCT01575834|Drug|Denosumab|Administered by subcutaneous injection once every 6 months (Q6M)
45812803|NCT05251454|Procedure|Brain Stimulation|Participants will receive brief electrical brain stimulation as they perform the study tasks. This will be linked to events occurring on screen and/or to specific changes in their brain activity. The stimulation parameters will be individualized for each participant, but will never exceed safe limits for charge density (30 µC/phase).
45812804|NCT05248802|Drug|Placebo caplet of DLBS2411|1 caplet of placebo DLBS2411, twice daily
45812805|NCT05248802|Drug|DLBS2411|1 caplet of DLBS2411 250 mg, twice daily
45950759|NCT05220423|Other|No reminders|no reminders on top of the National annual communication campaign organized by the French Health System authorities
45950760|NCT00120068|Behavioral|Nursing inservices|
45950761|NCT00120068|Procedure|Academic detailing to MDs; concurrent review and feedback|
45950762|NCT00481819|Drug|FK506MR|oral
45950763|NCT00481819|Drug|Prograf|oral
45950764|NCT00481819|Drug|Mycophenolate Mofetil|oral
45950765|NCT00481819|Drug|Methylprednisolone|oral
45950766|NCT00481819|Drug|Prednisolone|oral
45950767|NCT02958228|Behavioral|Positive Mental Imagery Training (PMIT)|
45950768|NCT02958228|Behavioral|Cognitive Control Training (CCT)|
45950769|NCT02958228|Other|Treatment as Usual|
45453751|NCT01106599|Drug|GDC-0623|Repeating oral dose
45453752|NCT01111591|Drug|Cox2 inhibitor (Celecoxib)|From postoperative third day, administration will be started celecoxib 200mg bid for 6 months for administration group.
45453753|NCT02281474|Drug|Nilotinib|
45453754|NCT04630561|Behavioral|Postural Intervention Program|Dynamic warmup program designed to target several areas of physical and mental wellbeing.
45676498|NCT02698254|Radiation|Radiation Therapy|Undergo radiation therapy with conventional fractionation
45676499|NCT02688985|Drug|Ocrelizumab|Ocrelizumab will be administered as IV infusion.
45676500|NCT02688985|Procedure|Lumbar Puncture|Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.
45676501|NCT02688985|Drug|Methyloprednisolone|Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.
45676502|NCT02688985|Drug|Antihistamine|Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.
45676503|NCT02648334|Device|IN.PACT drug coated balloon|
45676504|NCT02648334|Device|Lutonix drug coated balloon|
45676505|NCT02639273|Drug|Nalmefene|Active Drug
45676506|NCT02639273|Other|Placebo|Single Dose Placebo
45950770|NCT02958059|Biological|Pacetin® (cefoxitin)|1~2g of Cefoxitin (2nd generation cephalosporin) is administered to patients 30 minutes Before ERCP procedure. Cefoxitin is mixed with 10ml of normal saline. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.
45950771|NCT02958059|Biological|Placebo|10ml of normal saline is injected to patients as placebo. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.
45950772|NCT01240525|Other|CD4 DLI|Patients will receive CD4 DLI between day 70 to 115 post transplant
45659596|NCT05520853|Radiation|SBRT combined with PD-1 inhibitors and thoracic hyperthermia|At least one lesion (primary or metastatic) was selected for SBRT treatment, and the radiotherapy dose of each lesion was 32Gy/4Fx. SBRT was combined with thoracic hyperthermia from the first fraction, and hyperthermia was performed 6 times, twice a week. PD-1 inhibitor was used on the second day after the completion of SBRT. The PD-1 inhibitor was administered at a dose of 200mg every time, every 3 weeks for 2 years (35 times total), or until the investigators deem that the patient need to discontinue the drug because of treatment-related toxicity or disease progression.
45812806|NCT04741100|Other|Ex-vivo analysis|Ex-vivo analysis
45659597|NCT05516329|Drug|A single dose of 7±1 mCi (259±37 MBq) IV injection of 18F-Thretide|The patients will be intravenously injected with 18F-Thretide and undergo PET/CT scan at 60~120 min after the injection.
45659598|NCT05511493|Device|fractional Erbium-YAG laser|Platelet-rich plasma with fractional Erbium-YAG laser in localized stable vitiligo
45659599|NCT05511493|Device|microneedling|Platelet-rich plasma with microneedling in localized stable vitiligo
45659600|NCT05516251|Device|Transcutaneous Supraorbital Nerve Stimulator|SNS devices (DJTT-Ib, Hengyang Dajing Medical Instrument Technology Co., Ltd.) Stimulation electrodes are placed on the bilateral forehead, covering the supratrochlear and supraorbital nerves. The stimulus parameters are set as follows: pulse width 300 μsec, frequency 60 Hz, pulse duration μsec, increasing current peaked at 14 min with 16 mA. Patients receive SNS treatment daily for 20 min, no lease than 5 per week, last for 4 weeks.
45812807|NCT04718792|Drug|Psilocybin|A single administration psilocybin (25mg, opaque capsule for oral ingestion). The psilocybin is synthetically manufactured under current Good Manufacturing Practices (cGMP)
45812808|NCT05222126|Procedure|Ultrasound-guided Hydrodissection (HD) with 5 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 5 cc of 5% dextrose.
45812809|NCT05222126|Procedure|Ultrasound-guided Hydrodissection (HD) with 5 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 5 cc normal saline.
45812810|NCT05222126|Procedure|Ultrasound-guided Hydrodissection (HD) with 10 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 10 cc 5% dextrose.
45812811|NCT05222126|Procedure|Ultrasound-guided Hydrodissection (HD) with 10 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 10 cc normal saline.
45812812|NCT05726474|Behavioral|Combined exercise|Patients will exercise for 40 minutes three times a week on an ergometric bicycle at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without ergometer at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without shortness of breathing difficulty. In addition, strength training will be performed (bench press, leg press, leg curl, leg machine, bench press, leg press, leg curl, leg curl, leg machine). leg curls, leg curls, rowing machine, triceps dips, pectoral pull-ups) twice a week. week. Strength training will be performed with 15 repetitions per exercise and per session, with a corresponding workload of 15 repetitions. session, with a workload corresponding to 60% to 65% of the 1-repetition maximum (1RM) measured at (1RM) measured at the beginning and at the end of the intervention.
45659601|NCT05516251|Drug|Topiramate 25Mg Tab|Topiramate 25Mg Tab (Tuotai Pian, Xian Janssen Pharmaceutical Ltd.) are prescribed to participates by one neurologist. Participates are asked to take 25mg oral per day in a fixed time usually in the morning.
45659602|NCT04292743|Biological|Eryaspase|intravenous administration of Eryaspase, starting dose 75 units/kg, dose escalation to 100 units/kg, dose reduction 50 units/kg and 25 units/kg
45659603|NCT04292743|Drug|FOLFIRINOX|intravenous administration of FOLFIRINOX
45676507|NCT02635009|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo PCI using 3DCRT
45676508|NCT02635009|Other|Cognitive Assessment|Ancillary studies
45676509|NCT02635009|Radiation|Intensity-Modulated Radiation Therapy|Undergo PCI with HA using IMRT
45676510|NCT02635009|Other|Laboratory Biomarker Analysis|Correlative studies
45676511|NCT02635009|Other|Quality-of-Life Assessment|Ancillary studies
45659604|NCT04990687|Device|gammaCore™|"Implantable VNS (iVNS), the electrical stimulation of the nervous system to modulate or modify function, has been FDA approved in the United States since the late 1990s. Implantable VNS therapy has been approved for use in epilepsy and depression.~When treating major depression with implanted VNS, the widely held belief is that chronic stimulation is required for therapeutic effect. In trials of implantable VNS in major depression, more patients respond at 12 months than at 3 months. Once depressed patients respond to VNS, the effects have been demonstrated to continue for up to five years with continued stimulation. This finding suggests that VNS gradually changes brain function through neuroplasticity."
45659605|NCT05520697|Behavioral|Nutritional intervention|Nutritional treatment with caloric restriction.
45950773|NCT01240525|Other|No DLI|Patients will not receive DLI as trial treatment
45950774|NCT00481897|Behavioral|low-fat, vegan diet|Diet that excludes animal products (i.e. meat, dairy, eggs) and keeps oils to a minimum.
46077098|NCT02757456|Behavioral|Aerobic Exercise program|The 16-week program will consist of aerobic-type steady-state or interval exercises using a pedals attachable to the dialysis chairs. The purpose will be to slowly increase exercise duration by 5 minute increments to reach the goal of 30 min/treatment. The exercise program during hemodialysis sessions will contain a combination of aerobic and flexibility exercises, about 30 minutes of cycling with 10 minutes of warm up/stretching exercises and 10-15 minutes cool down. The frequency of exercise will be three sessions a week, during the first hour of dialysis treatment for the duration of 16 weeks. Blood pressure and heart continuous monitoring will be carried out during the exercise program. Exercise log sheets will be filled for each session for the 16 weeks.
45659606|NCT05520697|Behavioral|Mental exercise.|Mental exercise.
45659607|NCT05520697|Behavioral|Physical training.|Exercise.
45950775|NCT00120107|Drug|Black Tea|
45950776|NCT00481975|Drug|rimonabant (SR141716)|
45950777|NCT00482209|Drug|Mifepristone, misoprostol|200mg mifepristone followed by 400mcg misoprostol 36-48 hours later
46077099|NCT02757456|Other|Control|No aerobic exercise is offered but baseline and end of study testing of the outcomes occur
46077100|NCT00797667|Drug|Telcagepant 140 mg|
46077101|NCT00797667|Drug|Telcagepant 280 mg|
46077102|NCT00797667|Drug|140 mg telcagepant placebo|
46077103|NCT00797667|Drug|280 mg telcagepant placebo|
46077104|NCT02757144|Drug|DWP14012|DWP14012 tablets
46077105|NCT02757144|Drug|Placebo|DWP14012 placebo-matching tablets, Active control placebo-matching tablets
46077106|NCT02757144|Drug|Esomeprazole|Nexium®
45659608|NCT05086393|Drug|Duloxetine|Patients will be randomized to receive Duloxetine or a placebo.
45659609|NCT05086393|Drug|Placebos|Patients will be randomized to receive Duloxetine or a placebo.
45659610|NCT04886791|Procedure|Vaginal NOTES hysterectomy|Vaginal assited NOTES hysterectomy
45659611|NCT04886791|Procedure|Vaginal hysterectomy|Vaginal hysterectomy
45659612|NCT05516173|Diagnostic Test|Blood Pressure Monitoring, Ambulatory|To monitor the blood pressure during 24 hours.
45659613|NCT02571049|Drug|DFN-11|Sumatriptan 3 mg versus 6 mg
45659614|NCT04597801|Drug|Alcon|Fluorescein sodium is administered intravenously with a bolus injection of 5 mg per kg of bodyweight 20-40 minutes prior to the planned tumor resection.
45659615|NCT04885465|Behavioral|web-based psychoeducational support|Caregivers in the experimental group will have access to psycho-educational support through a web-based plattform during 3 months.
45659616|NCT05520385|Diagnostic Test|blood group and Rh|check of blood group , Rh for patient and control
45950778|NCT00482209|Drug|mifepristone, misoprostol|200mg mifepristone followed by 800mcg misoprostol 36-48 hours later
45950779|NCT00117936|Combination Product|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose|Up to ten intramyocardial injections of low dose FGF 1-141, via a NOGA Injection Catheter, single cath lab session
45950780|NCT00117936|Combination Product|Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose|Up to ten intramyocardial injections of high dose group (FGF-1-141), via a NOGA Injection Catheter, single cath lab session
45950781|NCT00117936|Combination Product|Placebo|Up to ten intramyocardial injections of placebo via a NOGA Injection Catheter, single cath lab session
45950782|NCT00482248|Drug|Omalizumab|
45950783|NCT00120185|Drug|Interleukin-2|
45950784|NCT01240642|Drug|ASA404|
45950785|NCT05202054|Other|mindfulness stress reduction program|Before the program is implemented, in case women forget, they will be called and reminded of the training time, and they will be invited to the program. The women in the experimental group will be administered 150 minutes of BFSAP once a week, lasting 8 weeks, and consisting of 8 times in total. Afterwards, the women will be given an intermediate test. After the midterm test, women will be asked to individually repeat their BFSAP administration in their own home for 8 weeks (weeks 8-16).
46077107|NCT04568616|Drug|Letrozole 2.5mg|Aromatase Inhibitor
46077108|NCT00950807|Drug|Tiotropium|long-acting muscarinic receptor antagonist; 18mcg once-daily
46077109|NCT00950807|Drug|Placebo|Inactive/ excipients only
46077110|NCT00950807|Drug|GSK573179|GSK573179 investigational drug
45950786|NCT01240681|Procedure|FLT PET and BOLD MRI scan|Eligible consenting patients with LABC receiving neoadjuvant chemotherapy (NA CT) will undergo FLT PET, BOLD MRI, and clinical examination of the involved breast including ipsilateral axillary and supraclavicular nodes to assess the treatment response to chemotherapy (CT). The imaging studies will be performed at baseline and after the first cycle of NA CT.
45950787|NCT00482287|Drug|MTR105|Intravenous administration, dose escalating (4 arms), single dose
45950788|NCT00482365|Other|biologic sample preservation procedure|biologic sample preservation procedure
46077111|NCT00797511|Biological|TdcP-IPV vaccine|0.5 mL, Intramuscular
46077112|NCT02752620|Other|Osteopathic Manipulative Treatment|
46077113|NCT02752620|Other|Exercise Therapy|
45950789|NCT00482365|Other|medical chart review|review of patients' medical records at study entry and every 6 months
45812813|NCT05726474|Behavioral|High interval training|Patients will perform three training sessions per week. Each training session begins with a 10-minute warm-up at moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, no shortness of breath) before cycling, four 4-minute intervals at high intensity (corresponding to 85-90% of VO2max, 90-95% of HRmax, 15-17 on the Borg scale, shortness of breath). Each interval will be separated by 3 minutes of active pauses, with a HRmax of 50-70%. The training session will end with 3 minutes of cool down at moderate intensity (corresponding to 50-60%). moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without difficulty). Borg scale, no shortness of breath). The total exercise time will be 40 minutes for the HIIT group.
45812814|NCT04668638|Other|Respiratory rehabilitation|Respiratory rehabilitation includes education, hypoventilation exercises, diaphragmatic breathing exercises, relaxation, retraining, others.
45950790|NCT00482365|Other|Patient interview|Elicit demographic data as well as information about personal habits such as drinking and smoking.
45950791|NCT00117975|Biological|galiximab|given IV
45950792|NCT00117975|Biological|rituximab|Given IV
45950793|NCT00482404|Behavioral|Romantic kissing|
45453755|NCT01111669|Drug|Tranexamic Acid|The bolus of TA is prepared according to patient weight (10mg / kg loading dose). The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the TA or saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation or normal saline for the duration of the operation.
45950794|NCT00120263|Procedure|Plasma Exchange|
45950795|NCT00482443|Other|A software programme in mobile telephone|Use of Mobile phone technology in maintaining Diabetes Interactive Diary.
45950796|NCT00482443|Other|Standard Education Programme.|Control Arm patients will receive a standard education programme designed to help the Type 1 Diabetic manage their condition.
45950797|NCT00482482|Behavioral|psychoeducation|on weekly basis for 8 weeks
45950798|NCT00482482|Behavioral|Yoga|on weekly basis for 8 weeks
45950799|NCT00482521|Drug|CC-4047|Oral CC-4047 once daily on days 1-21 followed by a 7-day recovery period. Cohorts of 3-6 patients receive escalating doses of CC-4047 until the maximum tolerated dose (MTD) is determined.
45950800|NCT00482560|Drug|Sucrose solution 30%1 ml|
45950801|NCT00482560|Behavioral|Breastfeeding|
45950802|NCT00482599|Drug|Sugammadex|2 mg/kg sugammadex administered intravenously at reappearance of T2 after 0.6 mg/kg rocuronium in patients with renal impairment and control patients
45950803|NCT00482638|Drug|MK0493|
45950804|NCT00120302|Drug|Pimecrolimus|Pimecrolimus cream 1 %
45950805|NCT00120302|Drug|Placebo|Matching vehicle cream
45950806|NCT00482716|Biological|epoetin alfa|
45950807|NCT00482716|Biological|epoetin beta|
45950808|NCT00482716|Dietary Supplement|iron dextran complex|
45950809|NCT00482716|Dietary Supplement|iron sucrose injection|
45659617|NCT05516095|Device|Transcranial magnet stimulation|Theta burst stimulation, which is a form of Transcranial magnet stimulation, works by inducing focused magnetic field pulses to make durable changes in the activity of brain regions. The magnetic pulses are transferred to the brain through an electromagnetic coil.
45659618|NCT05516095|Device|Sham Transcranial magnet stimulation|Similar in appearance and give the same sound as the active device, but deliver no magnetic pulse that reach the brain
45659619|NCT04296955|Other|Motivational interview as a new health communication intervention|Same as intervention name
45659620|NCT04979533|Device|Insufflator oxygen tubing|high flow, low pressure oxygen with pressure relief valve and luer Lock connections delivered at 15 L/min through surgeon's laryngoscope.
45659621|NCT05511259|Other|exercise|Square stepping exercise
45659622|NCT05520151|Dietary Supplement|ORAL IMPACT treatment|the group of patients will be received a 7-days course of ORAL IMPACT
45659623|NCT05520151|Other|control|no intervention
45950810|NCT01240720|Drug|131I-F16SIP Radioimmunotherapy (RIT)|"Dosimetric evaluation with 131I-F16SIP or 124I-F16SIP will be performed to assess eligibility for Radioimmunotherapy.~Patients eligible for Radioimmunotherapy will receive 55.5 mCi/m2 as established in the Phase I part of the study. A single dose of 5 to 10 mg of 131I-F16SIP will be administered intravenously (I.V)."
45659624|NCT04297423|Drug|Plenvu|randomization 1:1
45950811|NCT00482755|Drug|sunitinib malate|
45950812|NCT00482755|Other|immunohistochemistry staining method|
45950813|NCT00482755|Other|laboratory biomarker analysis|
45950814|NCT00482755|Other|pharmacological study|
45950815|NCT00482755|Procedure|needle biopsy|
45950816|NCT00482755|Procedure|neoadjuvant therapy|
45950817|NCT00482872|Genetic|gene expression analysis|
45950818|NCT00482872|Genetic|mutation analysis|
45950819|NCT00482872|Genetic|polymerase chain reaction|
45812815|NCT05707442|Procedure|Stent Implantation|Aspirin (100 mg) and clopidogrel (75 mg) were administered 3-5 days before endovascular treatment. The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to > 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure. Postoperatively, all patients received dual antiplatelet medications for 3 months and then received a single antiplatelet (either aspirin or clopidogrel).
45659625|NCT05515939|Device|InPen Insulin Pen|The InPen is a reusable smart insulin pen for people living with diabetes. The device uses Bluetooth technology to send dose information to a mobile application. The InPen can be used to deliver insulin, help calculate insulin doses, and estimate carbohydrates for meals
45659626|NCT05515861|Procedure|Endoscopic ultrasound|Using endoscopic ultrasound (EUS) to observe the diameter and blood flow of residual variceal veins after endoscopic cyanoacrylate injection for gastric varices to evaluate the embolization effect. Endoscopic cyanoacrylate injection is performed again if the diameter of variceal vein is larger than 5 mm and with blood flow signal. After the injection, the blood flow signal is confirmed disappear by endoscopic ultrasound. Patients in the EUS group required endoscopic ultrasound assessment at each stage of the follow-up period.
45812816|NCT05707442|Drug|Acetazolamide-based medical therapy|The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade <1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily.
45950820|NCT00482872|Genetic|polymorphism analysis|
45950821|NCT00482872|Other|flow cytometry|
45950822|NCT00482872|Other|laboratory biomarker analysis|
45950823|NCT00120341|Device|Anodyne Therapy System|
45950824|NCT00482950|Drug|PHX1149T|
45950825|NCT00482989|Biological|MEDI 545|"MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
45950826|NCT00482989|Other|Placebo|"Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
45950827|NCT00120380|Drug|Aerosolized iloprost|
45950828|NCT00120380|Drug|Placebo|
45659627|NCT04295941|Drug|TraZODone Hydrochloride 300 MG|Oral administration of Trazodone once-a-day.
45950829|NCT00483028|Drug|donezepil (Aricept)|
45950830|NCT01240837|Other|Arenga Pinnata Sugar|50 g palm sugar given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
45950831|NCT01240837|Other|Glucose|50 g glucose given orally 3 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
45950832|NCT01240837|Other|Sucrose|50 g sucrose given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
45950833|NCT00118014|Drug|Sertraline|
45950834|NCT00118014|Behavioral|Habit Reversal Training|
45659628|NCT04294771|Drug|ICI|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the ATC following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC3)
45950835|NCT00120419|Drug|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
45950836|NCT01240954|Drug|OSIRIS|OSIRIS current practice
45950837|NCT01240954|Drug|OSIRIS other concentration 1|OSIRIS new concentration 1
45950838|NCT01240954|Drug|OSIRIS other concentration 2|OSIRIS new concentration 2
45950839|NCT05176470|Drug|Cyclophosphamide|Given IV
45950840|NCT05176470|Drug|Fludarabine|Given IV
45950841|NCT05176470|Biological|Lifileucel|Given by IV infusion
45950842|NCT05176470|Biological|Pembrolizumab|Given IV
45950843|NCT05176470|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45950844|NCT01240993|Behavioral|Mothers and Toddlers Program|This intervention is a short-term attachment-based parenting therapy for substance using mothers of young children that emphasizes the development of the capacity for mentalizing.
45950845|NCT01240993|Behavioral|Parent Education|PE was developed to represent parent education and support that is typically available to mothers with substance use problems who are at high risk for neglecting their young children. Mothers enrolled in PEP will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs and a choice of pamphlets on age-related parenting topics.
45950846|NCT01241032|Drug|Udenafil|200mg Single Oral Dose of
45950847|NCT01241032|Dietary Supplement|Alcohol|Alcohol 39g / 240ml
45950848|NCT00120458|Dietary Supplement|Black cohosh|"32 to 128 mg (black cohosh)~1 to 4 capsules daily (placebo)"
45950849|NCT00483067|Drug|2-CdA|12 mg/m^2/day by vein (IV) Continuous Infusion x 5 Days
45950850|NCT00483067|Drug|Ara-C|1 gm/m^2/day IV Over 2 Hours x 5 Days
45950851|NCT00483067|Drug|G-CSF (Granulocyte colony-stimulating factor)|5 mcg/kg/day given under the skin (subcutaneously) starting Day 9
45950852|NCT00483106|Drug|Ritalin|0.25 mg/kg bid, orally for 7 consecutive days
45453756|NCT01111669|Drug|Normal Saline (placebo)|The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of saline for the duration of the operation.
45659629|NCT05510869|Procedure|"Bimanual 1.4 mm microincision cataract surgery (B-MICS) with IOL implantation in a wound-assisted technique. In bimanual MICS group a self-sealing 1.4 mm wide incision was created supratemporally"|microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch & Lomb
45659630|NCT05510869|Procedure|Coaxial 1.8 mm microincision cataract surgery (C-MICS) with IOL implantation with an injector through the 1.8 mm wide incision created temporally.|microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch & Lomb
45812817|NCT05707442|Behavioral|Weight loss|The weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.
45812818|NCT05213078|Other|Educational Intervention|Receive teaching intervention
45812819|NCT05213078|Other|Quality-of-Life Assessment|Ancillary studies
45812820|NCT05213078|Other|Questionnaire Administration|Ancillary studies
45950853|NCT00483106|Drug|Placebo|taken orally twice a day for 7 consecutive days
45950854|NCT00118170|Drug|sorafenib tosylate|Given orally
45453757|NCT02281630|Drug|KWA-0711|
45453758|NCT02281630|Drug|Placebo|
45812821|NCT04604132|Drug|Derazantinib|Derazantinib will be administered orally at a dose of 300 mg once a day and at a dose of 200 mg twice daily as monotherapy in the Substudy 1.
45812822|NCT04604132|Drug|Derazantinib-paclitaxel-ramucirumab|"Derazantinib will be administered at the RP2D for derazantinib-paclitaxel-ramucirumab determined in Substudy 2 in combination with paclitaxel and ramucirumab.~Paclitaxel will be administered intravenously at the RP2D for derazantinib-paclitaxel-ramucirumab determined in Substudy 2 on days 1, 8, and 15 of a 28-day cycle in combination with derazantinib and ramucirumab.~Ramucirumab will be administered intravenously at the RP2D for derazantinib-paclitaxel-ramucirumab determined in Substudy 2 every 2 weeks in combination with derazantinib and paclitaxel."
45812823|NCT04604132|Drug|Derazantinib-atezolizumab|"Derazantinib will be administered orally at a dose of 300 mg once a day in combination with atezolizumab.~Atezolizumab will be administered intravenously at a dose of 1200 mg every 3 weeks in combination with derazantinib."
45950855|NCT00118170|Other|pharmacological study|Correlative studies
45950856|NCT00120497|Drug|somatropin (rDNA)|"Dosage form/strength: 13.8 mg powder in 2-chamber cartridge; reconstitutes to 10 mg/ml~Dosage regimen: 0.48 mg/kg/week~Route/rate of administration: subcutaneous injection, daily dose"
45950857|NCT00483145|Device|Long-pulsed dye laser (Candela) and PDT (methylaminolevulinate)|
45950858|NCT00483145|Device|Long-pulsed dye laser|
45950859|NCT00483145|Device|Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)|
45950860|NCT00483301|Drug|Sorafenib (BAY 43-9006)|dosage
45453759|NCT01108939|Drug|Antimalarial treatment|
45453760|NCT01108939|Other|Observation|
45950861|NCT00483301|Drug|ABI-007(Abraxane)|dosage
45950862|NCT00483457|Drug|enzyme inhibitor therapy|enzyme inhibitor therapy
45453761|NCT00654706|Drug|Sertindole|Once daily oral dose. Day 1-20: 4-16 mg/day (titration period). Day 21-84: 12, 16 or 20 mg/day (flexible treatment period).
45950863|NCT00483457|Genetic|protein expression analysis|protein expression analysis
45950864|NCT00483457|Other|immunohistochemistry staining method|immunohistochemistry staining method
45950865|NCT00483457|Other|laboratory biomarker analysis|laboratory biomarker analysis
45950866|NCT00483457|Procedure|biopsy|biopsy
45950867|NCT05168631|Other|Histologically confirmed neuroendocrine tumor|Patients aged 18 years or older with histologically confirmed neuroendocrine tumor of any grade or site; Metastatic or inoperable disease; Patients with clinical information about the therapies received, including exclusive palliative care;
45950868|NCT00120536|Drug|vildagliptin|
45950869|NCT00483535|Drug|GW273225|GW273225 will be available as 25 milligram tablets.
45950870|NCT00483535|Drug|COC|COC will consist of Microgynon 30 which is available as ethinylestradiol 30 micrograms/levonorgestrel 150 micrograms beige color, sugar-coated tablets.
45950871|NCT00483613|Behavioral|Cognitive-behavioral therapy of Meichenbaum|
45950872|NCT01241071|Other|myofascial treatment|myofascial release techniques of different muscles implicated in low back pain
45950873|NCT01241071|Other|Placebo|A manual sham intervention will be applied to different muscles implicated in low back pain
45950874|NCT00483691|Behavioral|Home Visit|Homw visits scheduled weekly for one year.
45950875|NCT00483730|Drug|Deproteinised hemoderivative of calf blood (Actovegin)|Symptomatic diabetic peripheral polyneuropathy
45950876|NCT00118326|Biological|filgrastim|
45453762|NCT00654706|Drug|Quetiapine|Twice daily oral dose. Day 1-20: 50-500 mg/day (titration period). Day 21-84: 400, 500 or 600 mg/day (flexible treatment period).
45659631|NCT05510869|Procedure|Coaxial 2.4 mm small incision cataract surgery (C-SICS) with IOL implantation with an injector through the 2.4 mm wide incision located temporally.|small incision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch & Lomb
45659632|NCT05515783|Drug|68Ga-FAP-RGD|The dose will be 4-7mCi given intravenously.
45659633|NCT05515783|Drug|68Ga-FAP-RGD|68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) given intravenously at a single time prior to imaging. 68Ga-FAPI-02, the dose will be 1.8 (MBq /kg) given intravenously at a single time prior to imaging; 18F-FDG, the dose will be 3.7 (MBq / kg) given intravenously at a single time prior to imaging.
45659634|NCT05515705|Device|EUS navigation system|Incorporation of the EUS navigation system to the EUS scope
45812824|NCT04604132|Drug|Paclitaxel-ramucirumab|"Paclitaxel will be administered intravenously at a dose of 80 mg/m² on days 1, 8, and 15 of a 28-day cycle in combination with ramucirumab.~Ramucirumab will be administered intravenously at a dose of 8 mg/kg every 2 weeks in combination with paclitaxel."
45812825|NCT05193188|Drug|Anlotinib hydrochloride|Anlotinib 12mg per person per day, continuous medication for 2 weeks and 1 week off, 3 weeks 1 cycle, until disease progression or intolerable toxicity
45812826|NCT05193188|Drug|PD-1 inhibitor|Intravenous injection, once every 3 weeks, until the disease progression or intolerable toxicity
45812827|NCT04799262|Drug|Tofacitinib 5 MG|Oral tofacitinib at the dose of 5mg twice a day was given for 24 weeks. Prednisone (or equivalent oral GCs) of 15 mg daily at baseline willed be tapered to 2.5 mg or less within 20 weeks. Unless specifically considered by patients and physicians, the GC will be tapered followed the predefined taper regimen depending on the response to treatment judged by PMR-AS. The PMR-AS will be determined every two weeks; if<10 the daily GC dosage was decreased by 2.5mg; if>17, the GC daily dosage was increased to the previous dosage; if 10≤PMR-AS≤17, the GC daily dosage was maintained at the previous stable dose.
45812828|NCT01196130|Behavioral|Cancer Symptom Questionnaire|5 minute questionnaire(s) completed at each study visit.
45812829|NCT01196130|Other|Biomarker Testing|Blood draw at each study visit for biomarker and cytokine testing.
45812830|NCT01041534|Other|Survey|Two surveys are sent to patients: Adjustable gastric band (AGB) Health Survey and a quality of life survey (EQ5D)
45812831|NCT05698316|Diagnostic Test|Collection of both retrospective and prospective data collection in 3 visits.|3 clinic visits with multimodal imaging done at least at 6 months interval between 2 visits and meet the inclusion and exclusion criteria. Those with one visit remaining to complete 2 years, images will be acquired prospectively. In addition to the images, routine demographic data (age and sex) and available visual acuity (VA) (BCVA if possible, VA with Pinhole or VA with patient's glasses) will be collected. Multimodal imaging includes mandated macular OCT with or without enhanced depth imaging and infrared imaging. Fundus autofluorescence (AF) and multicolor imaging are optional. All imaging must be done on Heidelberg Spectralis system.
45812832|NCT00851136|Drug|bevacizumab|Intravenous repeating dose
45812833|NCT00851136|Drug|FOLFOX|Intravenous repeating dose
45812834|NCT00851136|Drug|PRO95780|Intravenous repeating dose
45453763|NCT03741049|Device|Scalpel Bougie technique (plastic laryngeal model)|ScalpelBougie Set
45453764|NCT03741049|Device|Seldinger technique (plastic laryngeal model)|Melker Set
45950877|NCT00118326|Procedure|allogeneic bone marrow transplantation|
45950878|NCT00483769|Drug|Glargine|
45950879|NCT04727489|Genetic|DNA from subjects will be stored in the biobank of our study.|Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders.
45950880|NCT00405171|Drug|Nevirapine|
45950881|NCT00483808|Device|Ardian Symplicity™ Catheter|Renal denervation using the Symplicity Catheter
45453765|NCT03741049|Device|Surgical technique (plastic laryngeal model)|Scalpel and speculum
45453766|NCT03741049|Device|Scalpel Bougie technique (porcine laryngeal model)|ScalpelCric Set
45453767|NCT03741049|Device|Surgical technique (porcine laryngeal model)|Scalpel and speculum
45950882|NCT00483886|Drug|Prucalopride|2 mg o.d.
45950883|NCT00483886|Other|Placebo|Placebo o.d.
45950884|NCT00483886|Drug|Prucalopride|4 mg o.d.
45950885|NCT00118443|Behavioral|Question, Persuade, Refer (QPR) training|
45950886|NCT00120575|Procedure|hemofiltration|
45950887|NCT00483964|Drug|Bacopa monnieri|
45950888|NCT00483964|Drug|Nardostachys jatamansi|
45950889|NCT00483964|Drug|Olanzapine|
45950890|NCT00484003|Drug|Pimecrolimus cream 1%|
45950891|NCT00120614|Behavioral|Premature infant behavior and development information|
45950892|NCT00120614|Behavioral|Parental activities to support premature infant information|
45950893|NCT05160129|Device|Selective focal stimulation of ALIC-pathways|DBS will be applied selectively to different electrode contacts/ segments to evaluate clinical, behavioral, and electrocortical responses of specific pathways within the ALIC.
45950894|NCT01241110|Drug|Ofloxacin group A, Azitromycin group B|Group A (treated by Ofloxacin 400 mg. + Metronidazole 500mg) and Group B (a single dose of oral Azitromicine 1gr + Metronidazole 500mg) for 10 days, were compared in terms of side effects and efficacy.
45950895|NCT01241110|Drug|azitromycin|azitromicin vs ofluxacin
45950896|NCT01241149|Procedure|anti-reflux surgery|Anti-reflux surgery (Laparoscopic Nissen Fundoplication)
45950897|NCT01241188|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
45950898|NCT01241188|Biological|2 TU Tuberculin PPD RT 23 SSI|The 2 TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
45950899|NCT00120653|Drug|Metoclopramide|
45950900|NCT00484081|Procedure|Microdissection Testicular Sperm Extraction|
45950901|NCT00484081|Procedure|ICSI|
45950902|NCT05138211|Device|Exoskeleton assisted gait on a treadmill|"The experimental protocol is divided in three sessions. During all of them, the patient will walk on a treadmill for 6 minutes while wearing a safety harness and the robotic exoskeleton in the paretic leg.~- Training session: The patient will wear the robotic exoskeleton to familiarize with the action of the device.~- Ramp Velocity Session: the session will be divided into five trials: (a) Pre, the patient will not wear the device; (b) Free, the patient will wear the robot but it is mechanically decoupled so it will enable the free knee movement; (c) Active, the robot will assist the gait until 75% maximum gait velocity ; (d) MaxActive, the robot will assist the gait until maximum gait velocity ; and (e) Post, the patient will repeat the Pre condition. Velocity will increase from comfortable velocity to the maximum and then come back to the comfortable one.~- Random Velocity session: the session will be divided into the same trials than the Ramp Velocity Session."
45950903|NCT00484120|Drug|3%-Diclofenac-Nano-Emulsion Cream|3%-Diclofenac-Nano-Emulsion Cream
45950904|NCT00484120|Drug|Placebo cream|Placebo cream
45950905|NCT00484237|Drug|etanercept|
45950906|NCT00120692|Drug|Darbepoetin Alfa|
45950907|NCT00120692|Drug|Recombinant Human Erythropoietin|
45950908|NCT00484276|Drug|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
45950909|NCT00484432|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 week until confirmed evidence of disease progression or unacceptable toxicity occurs
45453768|NCT04068454|Device|Virtual reality device|Functional exercises will be done by virtual reality group
45453769|NCT04068454|Other|EBM rehabilitation exercises|scapular exercises will be done
45659635|NCT05515549|Other|Venous blood was collected from patients under fasting state to detect the level of thrombus molecular markers|"The venous blood of the patients in fasting state was collected to detect the level of thrombus molecular markers. Color Doppler ultrasound was used as the gold standard to determine whether VTE occurred. According to the color Doppler ultrasound diagnosis results, the patients were divided into VTE group and non VTE group."
45659636|NCT02573155|Drug|Dose 1, AZD8871 50 μg (Part 1)|50 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
45950910|NCT00484432|Drug|doxorubicin|Doxorubicin: 60mg/m² every 3 weeks, until cumulative dose of 550 mg/m²
45950911|NCT05138055|Other|No intervention|No intervention
45950912|NCT00484510|Drug|Ascorbic acid (Vitamin C)|Eight 500 mg capsules/day of ascorbic acid. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months. (Total 4 gr/day).
45950913|NCT00484510|Drug|placebo|Eight 500 mg capsules/day of placebo. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months.
45950914|NCT00484549|Procedure|Blood sample|Ischemic stroke hospitalized
45659637|NCT02573155|Drug|Dose 2, AZD8871 100 μg (Part 1)|100 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
45950915|NCT00120731|Drug|Potassium Citrate|
45950916|NCT00120731|Drug|Acetazolamide|
45950917|NCT00120731|Behavioral|Diet low in oxalate and purines|
46077114|NCT00608881|Drug|coenzyme Q10|4 - 300 mg CoQ chewable wafers taken orally twice a day
46077115|NCT00608881|Other|placebo|an inactive substance
46077116|NCT04006431|Other|embolization|Retrospective, observational collection with division of patients into two groups according to unilateral or bilateral embolization of the porstatic arteries.
45950918|NCT00484627|Procedure|Use of creatine monohydrate (a dietary supplement)|
45950919|NCT00484627|Behavioral|Progressive resistance exercise training|
45950920|NCT00484705|Procedure|Electroacupuncture|
45950921|NCT00484705|Procedure|Physical exercise|
45950922|NCT00484705|Procedure|Untreated control|
46077117|NCT02752386|Behavioral|Biofeedback Training|Participants will received biofeedback training to reduce arousal and pain
46077118|NCT00914979|Device|AngioSculpt|The AngioSculpt Scoring Balloon Catheter is a standard balloon dilatation catheter with a scoring balloon near the distal tip
45950923|NCT00120770|Drug|Cellulose Sulfate Vaginal Gel (Microbicide)|
45453770|NCT03946345|Drug|Iohexol Inj 300 MG/ML|"Administration of iohexol: each 24 hours one bolus IV (1-5ml) during 72 hours~Blood samples are drawn for analysis of iohexol concentrations and other parameters of renal function at 2, 5 and 7 hours after administration~Urine is collected from catheter between 4 and 6 hours after adminstration to determine urine creatinine and iohexol concentrations"
45453771|NCT02280382|Device|Femmeze®|Femmeze will be used by women in the intervention group for 8 weeks These women will be measuring against their usual care in a linear design; measurement will include validated questionnaires
45659638|NCT02573155|Drug|Dose 3, AZD8871 300 μg (Part 1)|300 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
45453772|NCT03496675|Behavioral|Group Music Therapy|The core intention of GMT is to meet the psychosocial needs of each person living with dementia, which in turn is thought to reduce depressive symptoms and anxiety and to stimulate overall social and emotional wellbeing. It includes active, reciprocal music making with the use of singing and musical instruments. GMT is provided by a trained music therapist, highly skilled as a musician, and registered with the appropriate professional association in his or her country.
45453773|NCT03496675|Behavioral|Recreational Choir Singing|RCS is intended to foster connectedness in a group, wellbeing, and enjoyment of music making in a group. It includes singing familiar songs and providing a familiar musical environment for participants. RCS is provided by a musician with choir leading skills.
45453774|NCT03496675|Other|Standard care|May include pharmacological and non-pharmacological interventions as locally available
45453775|NCT00651508|Drug|KOS-1584|25 mg/m2, IV (in the vein) on day 1 and 8 of each 21 day cycle until progression or unacceptable toxicity develops.
45659639|NCT02573155|Drug|Dose 4, AZD8871 600 µg (Part 1)|600 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
45659640|NCT02573155|Drug|Dose 5, AZD8871 1200 µg (Part 1)|1200 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
45659641|NCT02573155|Drug|Dose 6, AZD8871 1800 μg (Part 1)|1800 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
45659642|NCT02573155|Drug|Placebo, AZD8871 placebo (Part 1)|AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
45659643|NCT02573155|Drug|Treatment A, AZD8871 dose A (Part 2)|AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
45659644|NCT02573155|Drug|Treatment B, AZD8871 dose B (Part 2)|AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)
45812835|NCT02618642|Radiation|Irradiations of the biceps brachii muscle with PILER light. The participants were randomized into 4 groups: group v - no filter/ group x - red filter/ group y - blue filter/ group z - placebo.|"Biceps brachii examination was carried out before (examination 1) and after (examination 2) a series of 10 PILER light treatments. It included a traditional electrodiagnostic examination and the assessment of the pressure pain threshold (PPT).~The electrodiagnostic examination of the muscle was performed using the unipolar stimulation method from the direct motor point. The passive electrode (6 cm x 6 cm) was attached to the side of the distal part of the forearm, and the distal edge of the electrode was adjacent to the proximal edge of the ulnar styloid process. The examination was performed with a Multitronic MT3 electrotherapy apparatus set.~PPT at the direct motor point was determined using an algometer (Algometer commander TM ITECH Medical Industries). A head with a rubber jacket with a surface area of 0.5 cm2 was used to cause pressure pain. Pressure was exerted until the participant reported pain, at which time the force (lbs) marked by the algometer was recorded."
45659645|NCT02573155|Drug|Treatment C, Indacaterol 150 μg (Part 2)|150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule
45812836|NCT04774848|Device|High Frequency Jet Ventilator|HFJV provides short bursts of gas into the respiratory circuit at a rate of 240 to 600/min (4 to 11 Hz) and expiration is passive. It is used in conjunction with a conventional ventilator which provides positive end expiratory pressure (PEEP) and can also provide occasional sigh breaths.
45812837|NCT04774848|Device|High Frequency Oscillatory Ventilator|HFOV uses a piston diaphragm to generate alternating positive and negative pressure changes to give breaths of 300 to 900/min (5-15 Hz) given over a set mean airway pressure. Both inhalation and exhalation are active.
45950924|NCT00484744|Drug|Acetaminophen|
45950925|NCT00484744|Drug|Avicel (placebo)|
45950926|NCT00484744|Drug|Ibuprofen|
45950927|NCT05128656|Other|serology|serology at M3 and serology at M6
45950928|NCT00484783|Procedure|Natural Orifice Transluminal Endoscopic Surgery (NOTES)|Patients will have the standard laparoscopic procedure and the NOTES procedure will be added. The surgical procedure will require two operating teams: one led by a laparoscopic surgeon, the other by an endoscopic surgeon. During the usual course of the surgery, the flexible endoscope will be passed through the mouth urethra top gain access to the peritoneal cavity.
45950929|NCT00484783|Procedure|Natural Orifice Translumenal Endoscopic Surgery (NOTES)|chart review of historical data from control group
45950930|NCT00484822|Drug|Bemiparina Sodica|3.500 UI/día.
46077119|NCT02759796|Procedure|Tailoring the flap according to clinical assessment|After microvascular anastomosis is performed, the investigators clinically assess flap vascularization and the well vascularized tissue is marked by means of a dermographic pencil. Then the investigators administer 0,2mg/kg of ICG intravenously. The vascularization of the flap is also checked by means of the Photo Dynamic Eye (Pulsion Medical System) but finally the decision of discarding the poorly vascularized areas of the flap is made by clinical assessment.
46077120|NCT02759796|Procedure|Tailoring the flap according to ICG Angiography assessment|After microvascular anastomosis is performed, the investigators administer 0,2mg/kg of ICG intravenously. Then the investigators check the vascularization of the flap by means of the Photo Dynamic Eye (Pulsion Medical System) and the poorly vascularized areas of the flap are discarded guided by ICG perfusion test.
45453776|NCT03944473|Drug|Sugammadex|Patients undergoing laparoscopic ambulatory surgery randomized into Sugammadex group will receive a dose of Sugammadex as their reversal agent
45659646|NCT02573155|Drug|Treatment D, Tiotropium 18 μg (Part 2)|18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule
45659647|NCT05045755|Biological|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
45659648|NCT05519761|Device|Implantation of veinous access ports|"The surgeon, anaesthetist and interventional radiologist should be thoroughly familiar with the surgical procedure, instruments, and device characteristics prior to performing the implantation.~The nurse has also to be familiar with the implantable port since he/she intervenes in it at the time of the Huber needle puncture and solution injection."
45812838|NCT05732246|Other|First rib mobilization with balloon breathing exercises|Patient will lie in the supine position, placing the soles of his feet against the wall so that the ankle, knee, and thigh joints are at a 90-degree angle. The subject will place a 3-4-inch ball between his/her knees, which he/she has to maintain through the pressure of the internal thigh muscles during the whole training period and puts his/her back on the bed. Holds the right hand above the head and the left hand with the balloon. Meanwhile examiner would palpate 1st rib with head in left side flexion. Patient will then be asked to inhale through the nose in three-four seconds and then exhales slowly into the balloon. Then, holding the first rib in place, the patient will be asked to inhale and exhale deeply again. The examiner will continue applying pressure to hold the first rib in a position of relative depression during inhalation, and further depress the first rib as able during exhalation.
45812839|NCT00366392|Device|Optical Aids|
45812840|NCT04774458|Procedure|Fluoroscopic-guided cervical epidural access|After identifying the target level of the cervical spine under a fluoroscopy-guided anteroposterior image, an 18-Tuohy needle is inserted through a paramedian approach after local infiltration with 1% lidocaine. When feeling a strong resistance through the needle by a ligamentum flavum, the image intensifier is rotated to 50 degrees contralateral oblique (CLO) direction. After then, the needle is advanced to just before the ventral interlaminar line in CLO view. It is subsequently advanced further until it is in the epidural space using a LOR-to-air technique. Correct epidural access is confirmed by the injection of contrast medium. After identifying epidural space in AP and CLO view without abnormal dispersion of contrast,(vascular uptake, intrathecal spreads, etc.), a 3-4ml mixture of 0.5% lidocaine with dexamethasone 5mg is injected.
45812841|NCT00366470|Drug|A. 100,000 IU Cholecalciferol per dose of 3.3ml|100,000 IU Cholecalciferol in 3.3ml Migliol (Carrier) oil, once every two weeks for 2 Months
45812842|NCT00366470|Other|B. Migliol Oil without Cholecalciferol|3.3 ml Migliol Oil, every two weeks for two months
45812843|NCT04773210|Device|Mini tube system|Mini tube system (FLOW-JAC System, Bogotá, Colombia) orthodontic treatment
45812844|NCT04773210|Device|Conventional ligating brackets|Conventional ligating brackets (Gemini 3M Unitek Orthodontic Products bracket, Calif, USA) with Nitinol Classic or superelastic (SE) archwires 0.014 and 0.016 orthodontic treatment
45812845|NCT00366782|Biological|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10^6 TCID50
45812846|NCT00366782|Biological|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10^5 TCID50
45812847|NCT00366782|Biological|Placebo|Placebo for rB/HPIV3 vaccine
45812848|NCT01116804|Procedure|MRI of the liver before start of treatment|MRI of the liver as classic work out of patients (CT-scan if MRI is contra-indicated)
45812849|NCT01116804|Procedure|MRI after treatment|MRI of the liver after 3 - 6 months of treatment (CT-scan if MRI is contra-indicated)
45812850|NCT01116804|Procedure|PET-scan before treatment start|PET-scan with 2 tracers is performed before treatment start
45812851|NCT01116804|Procedure|PET scan after treatment|PET-scan with 2 tracers is repeated 4 weeks following start of treatment
45812852|NCT04537286|Drug|nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)|Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w
45812853|NCT02620904|Drug|Mifepristone|
45812854|NCT02620904|Drug|placebo|
45950931|NCT00484822|Drug|Heparina Cálcica|10.000 UI/día.
45950932|NCT00405210|Drug|sorafenib (200 or 400mg bid) and taxotere iv|200 mg BID, day 3-19 cycle 1, day 2-19 other cycles 200 mg BID, day 3-21 Cycle 1, day 1-21 other cycles 400 mg BID, day 3-19 cycle 1, day 2-19 other cycles 400 mg BID, day 3-21 cycle 1, day 1-21 other cycles
45812855|NCT00300768|Drug|2 mg moxidectin|Single-dose, tablet encapsulated for blinding
45812856|NCT00300768|Drug|ivermectin 150 mcg/kg|Single-dose, tablets encapsulated for blinding
45812857|NCT00300768|Drug|4 mg moxidectin|Single dose, tablets encapsulated for blinding
45812858|NCT00300768|Drug|8 mg moxidectin|single dose, tablets encapsulated for blinding
45812859|NCT02621060|Drug|Placebo|Placebo: 1200 mg per day for three months
45812860|NCT02621060|Drug|Chlorogenic acid|Chologenic acid: 1200 mg per day for three months
45950933|NCT00120809|Drug|Sulfadoxine-pyrimethamine|
45950934|NCT00484900|Drug|Co-Arinate FDC|
45950935|NCT00484900|Drug|Coartem|
45950936|NCT05062356|Drug|Bupivacaine Hydrochloride 0.25% Injection Solution_#2|40cc
46077121|NCT02852759|Procedure|Selective Cold|The volunteers of intervention group will undergo Selective Cold treatment below 10 degree celsius to neck, supraclavicular interscapular regions for 2 hours daily for 8 weeks. The electroacupuncture is conducted by commercially available device. Hyperinsulinemic euglycemic clamp, glucose tolerance test, blood parameter measurements, and PTC-CT scans will be conducted before and after the intervention. The participants will be instructed to maintain their normal behavior and calorie intake.
45453777|NCT03944473|Drug|Neostigmine|Patients undergoing laparoscopic ambulatory surgery randomized into Neostigmine group will receive a dose of Neostigmine as their reversal agent
45453778|NCT03999424|Biological|autologous human Schwann cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix
45812861|NCT04740788|Device|Monofocal IOL|Patients are already implanted with a monofocal lens
45812862|NCT04740554|Behavioral|Duchenne Muscular Dystrophy group with Deflazacort|Subjects with duchenne muscular dystrophy undergoing drug therapy with Deflazacort
45659649|NCT05510791|Dietary Supplement|Nuun Sport Drink|Subjects will consume a total of 24 ounces water and 1.5 tablets of Nuun SPORT. Specifically, subjects will drink 12 ounces of Nuun drink 15 minutes prior to the 60 min run and 4 ounces of Nuun drink at 15 min, 30 min, and 45 min during the run.
45659650|NCT05510791|Dietary Supplement|Control|Subjects will consume a total of 24 ounces water. Specifically, subjects will drink 12 ounces of water 15 minutes prior to the 60 min run and 4 ounces of water at 15 min, 30 min, and 45 min during the run.
45659651|NCT05515471|Drug|SHR8058 eye drops|SHR8058 eye drops
45659652|NCT05515471|Drug|saline eye drops.|saline eye drops.
45659653|NCT05515315|Drug|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
45659654|NCT05515315|Drug|Albumin paclitaxel|Participants will receive Albumin paclitaxel 260 mg/m2 , day 1 of every 3 weeks
45659655|NCT05515315|Drug|Nedaplatin|Participants will receive Nedaplatin 80 mg/m2 , day 1 of every 3 weeks
45659656|NCT05515315|Radiation|radiotherapy|50-60Gy/25-30f
45812863|NCT04740554|Behavioral|Duchenne Muscular Dystrophy group with Prednisone/Predisolone|Subjects with duchenne muscular dystrophy undergoing drug therapy with Prednisona/Predinisolone
45812864|NCT04740554|Behavioral|Duchenne Muscular Dystrophy group without Corticosteroids therapy|Control group with duchenne muscular dystrophy without the use of corticosteroid drug therapy.
45812865|NCT04740554|Behavioral|Control Group Typically Developing|Control group with tipical development.
45812866|NCT04506086|Drug|Blinatumomab|Participants will receive blinatumomab continuous IV infusion for a maximum of 4 cycles. Each cycle is 6 weeks in duration consisting of 4 weeks of treatment and 2 weeks of rest.
45812867|NCT04506086|Device|Current Wearable Heatlth Monitoring System (CWHMS)|The study will use the CWHMS device to monitor participants' vital signs while they are at home.
45812868|NCT04480736|Drug|Placebo|Matching placebo will be administered orally.
45812869|NCT04480736|Drug|JNJ-64281802 High dose|JNJ-64281802 high dose will be administered orally.
45812870|NCT04480736|Drug|JNJ-64281802 Medium dose|JNJ-64281802 medium dose will be administered orally.
45812871|NCT04480736|Drug|JNJ-64281802 Low dose|JNJ-64281802 low dose will be administered orally.
45812872|NCT04480736|Drug|JNJ-64281802 Dosing Regimen X|JNJ-64281802 dosing regimen X will be administered orally.
45812873|NCT04480736|Drug|JNJ-64281802 Dosing Regimen Y|JNJ-64281802 dosing regimen Y will be administered orally.
46077122|NCT02852759|Device|Electroacupuncture|Electroacupuncture (EA) is an add-on treatment and it is applied when starting the cold treatment at the cold treated region to patients.The device is Huatuo SDZ-II model made by Suzhou Medical Appliance Factory, China.
45453779|NCT03944317|Drug|Sulfadoxine pyrimethamine|SP 1500/75mg tablet orally once starting from 16 weeks, at least at four weekly interval until delivery.
45659657|NCT04869787|Device|Selective Cytopheretic Device|SCD in line with CRRT extracorporeal device
45659658|NCT05510713|Device|Hemodialysis Catheter|We add a dialysis catheter to the patient, i.e., replace single-cannula in femoral venous with dual-cannula in jugular-femoral venous
45659659|NCT05515159|Other|electroconvulsive therapy|electrical stimulation of the brain while the patient is under anesthesia.
45659660|NCT05519371|Drug|Remimazolam|"During induction of anesthesia, the rimazolam group was given rimazolam pumped at a rate of 12 mg/kg/h~During the maintenance phase of anesthesia, the rimazolam group was given 1.0-2.0 mg/kg/h of rimazolam continuously pumped."
45659661|NCT05519371|Drug|Propofol|During induction of anesthesia, propofol 2mg/kg was given, and during the maintenance phase of anesthesia, propofol 6-8mg/kg/h was given as a continuous pump.
45812874|NCT04480736|Drug|JNJ-64281802 Dosing Regimen Z|JNJ-64281802 dosing regimen Z will be administered orally.
45812875|NCT02624180|Drug|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
45812876|NCT02624180|Drug|Placebo|A substance containing no medication
45812877|NCT04339946|Diagnostic Test|Three-dimensional rectal water contrast transvaginal ultrasonography (3D-RWC-TVS)|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
45812878|NCT04339946|Diagnostic Test|Two-dimensional rectal water contrast transvaginal ultrasonography (2D-RWC-TVS)|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution.
45950937|NCT05062356|Drug|EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge|10cc
46077123|NCT05608395|Drug|11C-Methionine PET/CT|11C-Methionine PET/CT will be applied in patients in 11C-Methionine PET/CT Arm, based on planning MRI, prior chemo/radiotherapy (2 weeks prior C1D1)
46077124|NCT02759718|Biological|Chromogranin A|The plasma level of chromogranin A (CgA) was measured in enrolled patients who was diagnosed as PNET in preoperative condition.After surgical resection, the CgA level was only measured in the the patient with PNET. In the PNET group, the CgA level was regularly checked in a 3, 6, 12, and 24 months after surgical resection.
46077125|NCT04221906|Drug|BOS-475|topical cream
45950938|NCT05062356|Drug|Bupivacaine Hydrochloride 0.5% Injection Solution_#2|20cc
45950939|NCT05062356|Drug|Ketorolac|15mg
45950940|NCT00120848|Biological|HPV 16/18 VLP AS04|
45950941|NCT01241383|Drug|Bosentan|Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks
45950942|NCT00484978|Procedure|Stereotactic Radiosurgery|
45659662|NCT05515081|Procedure|blood sample collection|blood sample colletion at regular intervals
45659663|NCT04855201|Drug|Bocidelpar|Oral
45659664|NCT04855201|Drug|Placebo|Oral
45812879|NCT05068232|Radiation|Ablative Radiation|Ablative radiation therapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor or very specific area of the body, while limiting the radiation that affects surrounding organs.
45812880|NCT05068232|Drug|Durvalumab|Durvalumab is an immunotherapy drug -- a drug used to help boost your immune response to fight cancer.
45812881|NCT05068232|Drug|Etoposide|Etoposide is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
45812882|NCT05068232|Drug|Carboplatin|Carboplatin is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
45812883|NCT02625428|Drug|Optison|
45950943|NCT00118521|Procedure|Foot Orthotics|
45950944|NCT00118521|Procedure|Physiotherapy|
45659665|NCT04948645|Drug|ABBV-CLS-7262|Oral
45659666|NCT04948645|Drug|Placebo|Oral
45659667|NCT05515003|Other|Individualized patient education|Patients in the intervention group will be applied one-session individualized patient education by the researcher. Educational session will last between 30 and 60 minutes. Problem-focused education will be applied related to the issues that the patient had difficulty in coping with. The subjects that the patient lacks knowledge about will be determined and the patient will be trained on these subjects and a discussion session will be arranged in the form of questions and answers. The education topics will include; fatigue, diarrhea/constipation, abdominal pain, mental health, nutrition, exercise and sleep.
45812884|NCT02625428|Diagnostic Test|Ultrasound (US)|A routine diagnostic and color-Doppler US. A Doppler ultrasound is a noninvasive test that can be used to estimate the blood flow through your blood vessels by bouncing high-frequency sound waves (ultrasound) off circulating red blood cells. A regular ultrasound uses sound waves to produce images, but can't show blood flow.
45950945|NCT00485017|Drug|THR-4109|THR-4109 maximum dose in study is 115 mg via oral capsule daily in a.m. and 115 mg via oral capsule daily in p.m. for 24 weeks
45950946|NCT00485017|Drug|Placebo|Oral capsules daily in a.m. and in p.m. for 24 weeks
45950947|NCT00485056|Drug|Pioglitazone|45mgs daily
45950948|NCT00120887|Drug|Atorvastatin|
45950949|NCT00485095|Behavioral|Intake of plant sterols|
45950950|NCT00118560|Behavioral|Physical exercise|treadmill walking
45950951|NCT00118560|Behavioral|Physical walking|calf muscle exercise
45950952|NCT00485212|Device|compression bandage|
45950953|NCT00485251|Procedure|hand-assisted laparoscopic right hemicolectomy|using the lap disc that allows the insertion of single and into the abdomen for operation
46077126|NCT04221906|Drug|Active ingredient-free vehicle cream|topical cream
46077127|NCT04221906|Drug|Daivonex cream (calcipotriol 0.005%)|topical cream
46077128|NCT04221906|Drug|Betnesol-V cream (betamethasone 0.1%)|topical cream
45950954|NCT00485251|Procedure|total laparoscopic right hemicolectomy|using laparoscopic instruments for mobilization and dissection inside the abdomen
45950955|NCT00485251|Procedure|hand-assisted right hemicolectomy|hand-assisted right hemicolectomy
45950956|NCT00485251|Procedure|laparoscopic right hemicolectomy|using laparoscopic instruments for mobilization and dissection inside the abdomen
45950957|NCT00485290|Behavioral|meal (food intake)|600 kcal. (16% protein, 49%carbohydrate, 35% fatt)
45950958|NCT00118638|Drug|Darbepoetin alfa - 2.25 mcg/kg|Darbepoetin alfa 2.25 mcg/kg QW dosing/ placebo Q3W
45950959|NCT00118638|Drug|Darbepoetin alfa - 500mcg|Darbepoetin alfa 500mcg Q3W dosing / placebo QW
46077129|NCT04109235|Other|High-Intensity Interval Training Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a High-Intensity-Interval-Training (HIIT) handout (developed based on research from Dr. Martin Gibala) detailing their PA recommendations. Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for Justine Horne who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, Justine will respond to these over the phone.
46077130|NCT04109235|Other|Population-Based Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a CSEP handout (page 4&5 from: http://csep.ca/CMFiles/Guidelines/CSEP_PAGuidelines_0-65plus_en.pdf) detailing their PA recommendations.Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for Justine Horne who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, Justine will respond to these over the phone.
46077131|NCT00945191|Drug|CS-1008|CS-1008 intravenous (IV) infusion 10 mg/kg on Day 1 of Cycle 1 and 8 mg/kg once every 3 weeks (1 cycle) for Cycle 2-6
45659668|NCT04847947|Drug|Cholecalciferol|Oral capsule Cholecalciferol 4000 IU once daily and Calcium Lactate 500 mg once daily for 12 weeks
45659669|NCT04847947|Drug|Placebo|Oral capsule Placebo containing white rice flour in the same identical looking with active drug once daily and Calcium Lactate 500 mg once daily for 12 weeks
45659670|NCT05519137|Device|Active lighting intervention|Lighting intervention designed to impact the circadian system
45659671|NCT05519137|Device|Control lighting intervention|Lighting intervention designed to have no impact on the circadian system
45659672|NCT05510479|Other|Software as medical device|At home measurements of visual acuity through a mobile app
45659673|NCT05518981|Device|Respiratory Remote Patient Monitor (Spire Health Tag)|"The RPM service, tailored to chronic respiratory disease patients, utilizes a system that includes three components: undergarment-adhered cardiorespiratory sensors, in-home data transmission hub, and web-based clinical dashboard. The sensors are a set of six proprietary, skin-safe devices that include sensors for intermittent photoplethysmography, continuous respiratory force, and tri-axis accelerometers for activity. Clinical liaisons monitor deviations from patient-specific baselines and contact subjects for a risk assessment call, including questions about symptoms. If a subject fails the risk assessment, they are escalated to the site to be seen, and potentially treated, by their pulmonologist."
45812885|NCT02625428|Diagnostic Test|Contrast-enhanced ultrasound (CEUS)|Contrast-enhanced ultrasound (CEUS) is the application of ultrasound contrast medium to traditional medical sonography. Ultrasound contrast agents rely on the different ways in which sound waves are reflected from interfaces between substances. This may be the surface of a small air bubble or a more complex structure.
45812886|NCT05055596|Behavioral|Tai Chi|Qigong/Tai Chi Easy is a manualized intervention with formal training for instructors through the Institute of Integral Qigong and Tai Chi (IIQTC). The protocol can be modified based on participant needs and physical abilities. Qigong/Tai Chi Easy uses a series of repeated and simple-to-learn movements (rather than long forms with complicated choreography).
45950960|NCT00485329|Other|Papain|15,000 USP U/ml
45950961|NCT00485329|Other|Papain|30,000 USP U/ml
45950962|NCT00485329|Other|Papain|60,000 USP U/ml
45950963|NCT00485368|Drug|Coversyl (perindopril)|
45950964|NCT00485407|Drug|Atomoxetine Hydrochloride|
45950965|NCT00120926|Drug|Parenteral Nutrition|
45950966|NCT01241500|Drug|ON 01910.Na|The dose of ON 01910.Na will be 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards. Infusion bags must be changed every 24 hours and a new infusion bag must be used for each of the subsequent 24 hours until completion of the total 72-hour infusion time.
45950967|NCT00118677|Procedure|Treatment interruption|
45950968|NCT00485446|Procedure|blood analysis|
45950969|NCT00120965|Device|AutoPulse|Standard device settings
45950970|NCT00120965|Other|Manual CPR|Manual CPR
45950971|NCT01241578|Behavioral|Lifestyle Counseling|Participants receive instructions for making healthy changes to their diet and physical activity habits.
45950972|NCT05058612|Drug|Midodrine|10 mg PO/NG q8h
45950973|NCT05058612|Drug|Placebo|Microcrystalline cellulose PO/NG 18h
45950974|NCT01241617|Device|Duet TRS|Endo GIA stapler with integrated Duet TRS
45950975|NCT01241617|Device|Endo GIA|Endo GIA stapler with Single Use Loading Units
45950976|NCT02274181|Drug|Androxal|
45950977|NCT01241422|Drug|JNJ 40929837|On Day 1: participants will receive 2 tablets of 50 mg JNJ 40929837 in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 tablet of 50 mg JNJ 40929837 in the morning and 1 JNJ 40929837 50 mg tablet + 1 placebo capsule in the evening; and on Day 7: 1 tablet of 50 mg JNJ 40929837 in the morning.
46077132|NCT00945191|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 IV infusion once every 3 weeks (1 cycle) for 6 cycles
46077133|NCT00945191|Drug|Carboplatin|Carboplatin (target area under the concentration versus time curve of 6.0 mg/mL/min using the Calvert Formula) IV infusion once every 3 weeks (1 cycle) for 6 cycles
46077134|NCT04563546|Other|Quality Improvement|A quality improvement intervention including reminders, care protocols, and text messages to improve care of myocardial infarction in the KCMC ED
45659674|NCT05514925|Drug|Bevacizumab Injection [Avastin]|Intravitreal injection of bevacizumab (1.25 mg, 0.05 ml) in the inferior temporal quadrant of the eye, 4 mm behind the limbus in phakic eyes, and 3.5 mm in pseudophakic eyes.
45659675|NCT05514925|Procedure|Peripheral Retinal Cryoapplication|In the operating room under peribulbar anesthesia, four focal conjunctival incisions are made on each quadrant between the muscles insertions. The Tenon capsule is opened with scissors to expose the sclera. Four to six cryo-applications are made per quadrant, at the edge of muscle insertion and a line behind. The exposure time is 4 to 5 seconds. 7-0 resorbable sutures are then put on each quadrant to close the conjunctiva.
45659676|NCT05514847|Drug|Aspirin 81Mg Ec Tab|81 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
45812887|NCT05055596|Behavioral|Health Coaching|The Health Education group will be adapted from a previously developed time and attention control condition used in HIV research. Additional health education material will be based on information learned in the qualitative interviews conducted prior to the start of this study. Examples of session material include the following: sleep hygiene, healthy diet, sun safety, and healthy homes.
45812888|NCT04326764|Drug|Panobinostat|"Panobinostat should be taken orally once on each scheduled day at about the same time, either with or without food. Each dose of panobinostat should be taken with a cup of water.~The capsules should be swallowed as whole. If vomiting occurs during the course of treatment, no re-dosing is allowed before the next scheduled dose. If one dose is forgotten during the morning on a scheduled treatment day then the missed dose should be taken on that same day within 12 hours. After more than 12 hours, that day's dose should be withheld, and the patient should wait to take panobinostat until the next schedule treatment day. The patient should then continue treatment with the original dosing schedule.~Panobinostat will be administered at a dose of 20 mg three times weekly (TIW) every second week and will be dosed on a flat scale of mg/day and not by weight or body surface area.~Panobinostat will be dispensed as a 20 mg capsule or as two 10 mg capsules."
45812889|NCT05187546|Drug|[18F]-PI2620|[18F]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of [18F]PI-2620 at a radioactive dose of 185 megabecquerel (MBq).
45812890|NCT02628236|Drug|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
45812891|NCT02628236|Device|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
45812892|NCT02629094|Drug|Inspra /Eplerenone|Eplerenone is provided as 25- or 50-mg tablets that are to be taken orally. Subjects will be dosed at 25 mg daily for 1 week, and then 50 mg daily for 23 weeks. The total duration of dosing for each subject is 24 weeks.
45812893|NCT02630030|Drug|Ixazomib|Given PO
45812894|NCT04325282|Device|Active rTMS|1Hz rTMS delivered for 15-20 minutes
45812895|NCT04325282|Device|Sham rTMS|sham rTMS delivered for 15-20 minutes
45812896|NCT04289792|Drug|nab-Paclitaxel+Gemcitabine|Drug: nab-Paclitaxel 125 mg/m2 IV over approximately 30-45 min on Days 1 and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 min on Days 1 and 15 of each 28-day cycle for 6 cycles.
45812897|NCT04289792|Radiation|split-course SBRT|Radiation: During the first 1 and 2 cycles of chemotherapy, SBRT was given as a single irradiation of 10 Gy ⅹ 4 times (Days 2 and 16 of each 28-day cycle).
45812898|NCT02631590|Drug|Cisplatin|Cisplatin administered once as intravenous (IV) infusion over 60 minutes. Treatment is on Days 1 and 8 every 21 days.
45812899|NCT02631590|Drug|Gemcitabine|Gemcitabine administered as 30-min IV infusion. Treatment is on Days 1 and 8 every 21 days.
45812900|NCT02631590|Drug|Copanlisib|Experimental Drug: Copanlisib administered as an IV over 60-minutes beginning 1 hour after completing gemcitabine infusion. Treatment is on Days 1 and 8 every 21 days.
45812901|NCT02253654|Drug|Epoetin alfa|Administered intravenously (IV) three times a week (TIW) by appropriately trained healthcare professionals during hemodialysis.
45659677|NCT05514847|Drug|Aspirin 162Mg Ec Tab|162 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
45659678|NCT05510401|Other|SECURIDRAP® SELFIA®|Use of SECURIDRAP® SELFIA® for 15 night
45659679|NCT05510323|Drug|Prednisolone|RAS blockade as much as tolerated or allowed
45659680|NCT05510323|Drug|Prednisolone plus Cyclophosphamide|RAS blockade as much as tolerated or allowed
45812902|NCT02252406|Drug|Ranolazine|Ranolazine 500 mg from baseline to week 3 and 1000 mg thereafter until week 24
46077135|NCT04108923|Device|Ligasure|the vessel sealing device ( ligasure covidien ) which seals vessels by fusing the inner layers of the vessel wall
46077136|NCT04108923|Procedure|Conventional vessel ligation|Conventional vessel ligation either tying and /or clipping of blood vessels
46077137|NCT01082393|Drug|topical tacrolimus treatment|4 applications (day 1,day 3, day 6 and day10)
46077138|NCT01082393|Drug|topical pimecrolimus treatment|4 applications (day 1, day 3, day 6 and day 10)
45950978|NCT01241422|Drug|Placebo|On Day 1: participants will receive 2 placebo tablets in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 placebo tablet + 1 placebo capsule in the evening; and on Day 7: 1 placebo tablet in the morning.
45950979|NCT01241422|Drug|Montelukast|On Day 1: participants will receive 2 placebo tablets in the morning and 1 montelukast capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 montelukast capsule + 1 placebo tablet in the evening; and on Day 7: 1 placebo tablet in the morning.
46077139|NCT01082393|Drug|local mometasone furoate treatment|4 applications (day 1, day 3, day 6 and day 10)
45812903|NCT02252406|Other|Placebo|Matching placebo tablets daily for 24 weeks.
45659681|NCT05514691|Diagnostic Test|iStatis COVID-19 Ag Rapid Test|SARS-Cov-2 tests are performed on all appropriate swab samples from each subject enrolled as a comparator test to iStatis Rapid Test
45812904|NCT00368082|Biological|TGFbeta resistant LMP-specific CTLs|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Group One:~Day 0 2 x 10^7 cells/m2 Day 14 2 x 10^7 cells/m2~Group Two:~Day 0 6 x 10^7 cells/m2 Day 14 6 x 10^7 cells/m2~Group Three:~Day 0 1.5 x 10^8 cells/m2 Day 14 1.5 x 10^8 cells/m2"
45812905|NCT05178186|Procedure|Thyroidectomy|Surgery for thyroid carcinoma
45812906|NCT05101200|Other|High Dose Neural Mobilization Technique|Patients in This Group will receive the high dose neural mobilization along with hot pack, strengthening exercises, Neural mobilization technique (slump, sciatic). Participants in the NMG will be asked to actively perform knee extension, ankle dorsiflexion, and head extension in a slumped posture (body and neck semi flexion) followed by simultaneous ankle plantar flexion together with knee and head flexion, Hot pack for 15 minutes, Strengthening exercises of muscles with 10 /8sets. Strengthening exercises of quadriceps with10 rep/8sets, Static stretching exercise for hamstring muscle with 10 rep/8sets, Group A will be given session of 40 min/day, 2 days/week for 4 weeks.
45812907|NCT05101200|Other|Low Dose Neural Mobilization Technique|Patients in this Group will receive the same treatment as group A but with less intensity and low dosage. Hot pack: 15 minutes, Strengthening exercises of muscles with 10 rep/4sets, Static stretching exercise for hamstring muscle with 10 rep/4sets. Group B will be given session of 40min/day, 2 days/week for 4weeks.
45812908|NCT02246478|Drug|TAS-205|"Single-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step, single oral administration after meals~Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"
45659682|NCT05514691|Diagnostic Test|"COVID-19 RT-PCR Test EUA Number: EUA200011, Company: Laboratory Corporation of America (Labcorp)"|The Labcorp COVID-19 RT-PCR or EURORealTime SARS-Cov-2 tests are performed on all appropriate swab samples from each subject enrolled as a comparator test to iStatis Rapid Test
45659683|NCT05514613|Other|retrospektif study; The effect of tracheostomy tecnique method on complications|retrospektif study; The effect of tracheostomy tecnique method on complications complications and correlation of complications with techniques
45812909|NCT02246478|Drug|Placebo|"Single-dose phase: 3steps (low dose, middle dose or high dose group), 2 patients/step, single oral administration after meals~Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 2 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"
45812910|NCT02252016|Drug|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
45950980|NCT00121004|Behavioral|Advance Directive Selection|
45950981|NCT02274220|Dietary Supplement|Rapid advancement of feeds|Feeding is initiated on first postoperative day. Bolus feeds are started at 1 mL/kg every three hours and up-titrated by 1 mL/kg every feed (Q 3 hours) to a goal of 10 mL/kg/feed (equivalent to approximately 50 kcal/kg/day). Feeding volume will exceed 20 mL/kg/day by 6 hours following protocol initiation and reach target feeds by 27 hours of protocol initiation.
46077140|NCT01082393|Drug|cold cream|4 applications (day 1, day 3, day 6 and day 10)
46077141|NCT02757066|Drug|NPC-15 Granules Lower Dose|NPC-15 granule which contains 1mg melatonin
46077142|NCT02757066|Drug|NPC-15 Granules Higher Dose|Melatonin granule which contains 4 mg melatonin
46077143|NCT02757066|Drug|NPC-15 Placebo Granule|Melatonin placebo granule which does not contains melatonin.
46077144|NCT00894673|Biological|Heparin sodium Hipolabor|Heparin sodium Hipolabor 5.000 UI/mL
45812911|NCT02252016|Drug|Placebo|Placebo tablets matching grazoprevir + elbasvir FDC tablets taken once daily by mouth.
45812912|NCT05066100|Other|Prenatal Use of Supple Cups|For pregnant women identified with FIRN and providing consent to participate in this study, Supple Cup usage will be initiated at 32 weeks gestation to begin to elongate the nipples in preparation for breastfeeding.
45812913|NCT04784442|Drug|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 12 weeks
46077145|NCT00894673|Biological|Heparin sodium APP|Heparin sodium APP 5.000 USP
46077146|NCT04222218|Device|repetitive transcranial magnetic stimulation|Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description
45950982|NCT02274220|Dietary Supplement|Standard advancement of feeds|Feeding is initiated on first postoperative day. Bolus feeds are started at 3 mL every three hours for 24 hours. Bolus feeds then up-titrated by 1 mL/kg every-other feed (Q 6 hours) for 24 hours. Bolus feeds then up-titrated by 1mL/kg every feed for to a goal of 10 mL/kg/feed (equivalent to approximately 50 kcal/kg/day). Feeding volume will reach target feeds by 60-63 hours after protocol initiation.
45659684|NCT05510167|Behavioral|Study arm|Participants will be asked to completely abstain from drinking or consume 2 or less drinks per week for 8 months following catheter ablation
45659685|NCT05514379|Behavioral|cognitive training|Cognitive training focused on executive function, attention and working memory delivered either by the therapist in a group setting (experimental group) or by a specialized software for cognitive training (Rehacom) at home.
45950983|NCT05058417|Drug|Empagliflozin 10 MG|participants will receive 10 mg Empagliflozin for 8 consecutive weeks in addition to the standard therapy
45950984|NCT05058417|Drug|Placebo|participants will receive placebo for 8 consecutive weeks in addition to the standard therapy
45950985|NCT02274298|Behavioral|CKD feedback and tools|people in the intervention arm will receive feedback on ckd quality indicators and tools to help in the detection and management of ckd
45659686|NCT04128397|Device|traditional stimulation site continuous theta burst stimulation (cTBS)|before cTBS treatment, MRI was used to confirm the stimulation site
45659687|NCT04128397|Device|precise stimulation site cTBS|before cTBS treatment, rs-fMRI was used to confirm the stimulation site
45812914|NCT04784442|Drug|120mg of ETC-1002(bempedoic acid)|120mg, tablet, once daily, for 12 weeks
45812915|NCT04784442|Drug|60mg of ETC-1002(bempedoic acid)|60mg, tablet, once daily, for 12 weeks
45812916|NCT04784442|Drug|Placebo|placebo, tablet, once daily, for 12 weeks
45812917|NCT02249832|Device|seated robot-assisted ankle therapy|The MIT anklebot provides over one thousand total dorsi/plantar flexion and inversion/eversion robot-assisted movements of the ankle while in a seated position.
45950986|NCT02274337|Drug|AC0010|patients take avitinib orally once per day at different dose
45950987|NCT00121043|Device|SimpleJectTM|
45950988|NCT00121043|Drug|Kineret® (Anakinra)|
45950989|NCT00485602|Procedure|"orthodontic treatment with Rafenalign appliance"|
45950990|NCT05004441|Drug|Fruquintinib Combined With mFOLFOX6/FOLFIRI|Fruquintinib (3mg) will be given p.o. daily
45950991|NCT00485641|Device|SaeboFlex Dynamic Hand Orthosis|
45950992|NCT00485641|Procedure|Saebo F.T.M. Arm Training Program|
45950993|NCT00485680|Drug|Olanzapine Hydrochloride|
45950994|NCT00485680|Drug|Lithium Carbonate|
45950995|NCT00121121|Biological|Lipopeptides LIPO-4|
45950996|NCT00485719|Drug|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths administered orally
45950997|NCT01241656|Behavioral|DESI for home viewing|Decision support intervention is a 31 minute DVD mailed to the patients in all of the experimental groups. The program explains the function and location of the prostate and the nature of prostate cancer, including its associated mortality. Next, the program describes the different tests that are used to detect prostate cancer including the digital rectal exam, prostate specific antigen (PSA) test and prostate biopsy.
46077147|NCT04035967|Other|Questionnaire|Impact on Family Scale (IPFAM), WeeFIM Pediatric Functional Independence Measurement, Nottingham Health Profile. State-Trait Anxiety Inven¬tory (STAI-I and STAI-II), PEDI (Pediatric Evaulation of Disability Inventory)
45950998|NCT01241656|Behavioral|DESI for viewing at Shared Medical Appointment|Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
45950999|NCT01241656|Behavioral|Option of SMA and DESI or DESI only|Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
45951000|NCT00118794|Drug|Chlorproguanil-dapsone (Lapdap)|
45951001|NCT00118794|Drug|Lumefantrine-artemether (Coartemether )|
45951002|NCT01241695|Dietary Supplement|Oral nutritional supplement, food for special medical purposes|2 servings of 200 ml per day, treatment period: 12 weeks
46077148|NCT04220736|Diagnostic Test|Computation of quantitative flow ratio|Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
46077149|NCT02540551|Procedure|Injection of radioactive tracer combined with Patent Blue|Blue dye and the radioactive isotope will be injected in the remains of the ligamentum ovarium proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), just below the peritoneum. Four syringes containing 0,2 ml patent blue and 0,15 ml (20-MBq) radioactive isotope (99mTc-nanocolloid or Nanocoll®, GE Healthcare, Eindhoven, The Netherlands) will be given. After a 15-minute interval the radioactivity the SN(s) will be identified either by the mobile gamma-camera and /or gamma-probe and / or visually (blue dye) after opening the retroperitoneal space.
45659688|NCT02568475|Behavioral|"Provision of Go to the Hospital or Stay Here?"|Residents and families randomly assigned to the intervention group (one half of the residents and one half of the families enrolled) are given the new Decision Aid to review with an RA trained for this purpose by the investigators. The Decision Aid provides information on risks and benefits of acute care transfer and information on advance care planning, resident and families' right to be involved in the decision. Resident or family member is also asked to re-read it and think about it over the subsequent 14 days.
46077150|NCT02855333|Other|EORTC and QLQ-C30 / QLQ-OES24 questionnaire|EORTC and QLQ-C30 / QLQ-OES24 questionnaire was sent to patients to asses QoL after MER or CON procedure
45453780|NCT03944317|Drug|Azithromycin|A total of 1500mg Azithromycin tablets taken orally as 500mg daily for three consecutive days starting starting from 16weeks of pregnancy and to be repeated once at least after 4 weeks
45453781|NCT02280538|Device|Intra-Articular Hyaluronic Acid|
45453782|NCT02280538|Device|Placebo|
45453783|NCT01111747|Procedure|Platelet-rich plasma|Intra-operative use of platelet-rich plasma in the patellar tendon after harvesting its central third for ACL reconstruction.
45659689|NCT04843579|Drug|Selinexor|Given as 60 mg oral capsule
45659690|NCT04843579|Drug|Clarithromycin|Given as 500 mg oral capsule
46077151|NCT02759406|Device|coronary stent|
45453784|NCT01111747|Procedure|Control group|In this group PRP will not be added to the patellar tendon donor site at the end of ACL reconstruction.
45453785|NCT02281708|Drug|vinorelbine plus cisplatin|"Drugs will be administered for 4 cycles, and should be administered at scheduled day +/- 3 days~vinorelbine 25mg/m2 IV (Day 1, 8) q 3wks cisplatin 75mg/m2 IV (Day 1) q 3wks"
45659691|NCT04843579|Drug|Pomalidomide|Given as 4 mg oral capsule
46077152|NCT00606931|Device|Stereo Navigator Accessory to PEM Flex PET Scanner|For patients with suspicious breast abnormalities seen on high resolution PET image, the patients will be biopsied using commercial vacuum biopsy devices (pre-validated to work with Stereo Navigator) using Naviscan's Stereo Navigator (interventional device) for PET image guidance.
46077153|NCT04220424|Diagnostic Test|MR and Histopathology images based prediction of molecular pathology and patient survival|MR and Histopathology images based prediction of molecular pathology and patient survival in gliomas by leverage artificial intelligence algorithms
45812918|NCT02248974|Other|LVAD Decision Aid|"Decision aids are interventions or tools designed to facilitate shared decision making and patient participation in health care decisions.~This Decision Aid was designed to discuss treatment options for patients in end-stage heart failure (i.e LVAD PLACEMENT, PALLIATIVE and SUPPORTIVE CARE)."
45951003|NCT01241695|Dietary Supplement|Oral nutritional supplement, food for special medical purposes|2 servings of 200 ml per day, treatment period: 12 weeks
45951004|NCT01241773|Drug|raltegravir|One 400 mg tablet twice daily for 7 days
45951005|NCT01241773|Drug|TMC435 + raltegravir|Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days
45951006|NCT01241773|Drug|TMC435|Two 75 mg capsules once daily for 7 days
45951007|NCT01241773|Drug|TMC435 + efavirenz|Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet, once daily for 14 days
45951008|NCT01241773|Drug|TMC435|Two 75 mg capsules once daily for 14 days
45951009|NCT01241773|Drug|efavirenz|One 600 mg tablet once daily for 14 days
45659692|NCT04843579|Drug|Dexamethasone|Given as 40 mg oral capsule
45812919|NCT02246166|Drug|Test tablet|The active tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
45951010|NCT00121160|Behavioral|Cognitive Behavioral Stress Management (CBSM) group intervention|Participants will meet in closed, structured groups of 4 to 6 women for ten weekly, 2-hour group sessions. The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Group members and group leaders are used as role models for effective coping and the use of social support. The groups also encourage emotional expression and provide an opportunity to practice techniques learned in the group and experience social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Each week participants also experience a different relaxation technique. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
45951011|NCT01241812|Behavioral|Lower limb muscle strengthening|Participants in the exercise group will receive a lower limb strengthening program consisting of 6 exercises targeting the quadriceps, hamstrings, and hip abductor groups. They will perform these exercises at home 4 times per week (3 sets of 10 repetitions per exercise). Over the course of the intervention, each participant will consult with the physiotherapist a total of 5 times (once per week in weeks: 1,2,3,5, and 8) to ensure proper performance of exercises and safe progression of resistance.
45951012|NCT00118833|Drug|Hypericum perforatum (St. John's wort)|
45951013|NCT01241851|Behavioral|Aerobic exercise|
45951014|NCT01241851|Behavioral|Resistance exercise|
45951015|NCT00121277|Drug|capecitabine|
45951016|NCT00121277|Drug|vorinostat|
46077154|NCT04220580|Other|Blood samples|3 blood samples, two for RNA and one for metabolites are taken 5 minutes before a Cold Pressor Test and again 1 hour after the Cold Pressor Test.
45659693|NCT05507671|Biological|BCG (Bacillus Calmette-Guérin) vaccine|Application of BCG vaccine (0.1 ml intradermal) in the right arm deltoid insertion
45659694|NCT05507671|Other|Placebo|Application of BCG solvent (0.1 ml intradermal) in the right arm deltoid insertion
45659695|NCT02568397|Drug|Lanabecestat|Administered orally
46077155|NCT00892489|Drug|ER OROS Paliperidone|
46077156|NCT02752308|Drug|Bupivacaine|Injection of Bupivacaine in the epidural space (0.25%, 0.33mg/Kg)
46077157|NCT02752308|Procedure|General anesthesia|Induction with thiopental sodium 5 mg/Kg, atracurium 0.4 mg/Kg and fentanyl 2 mcg/Kg and maintenance with isoflurane and a combination of oxygen and nitrous oxide
45453786|NCT02281786|Drug|Placebo|Matching placebo to RO6926496
45659696|NCT02568397|Drug|Dabigatran etexilate|Administered orally
45659697|NCT02566525|Device|CytoSorb|Cytosorb device use during cardiopulmonary bypass
45676512|NCT02601365|Drug|Sargramostim 0.04 mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.04 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
45812920|NCT02246166|Other|Placebo|The placebo tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
45812921|NCT02706847|Drug|Placebo|Tablet; Oral
45951017|NCT00485797|Drug|Ritalin|The effect of ritalin on postural stability of ADHD childrens will be measured using RCT study design
46077158|NCT02752308|Drug|Dilute epinephrine injection|Injection of 1/100000 epinephrine solution along all incision lines
45453787|NCT02281786|Drug|RO6926496|single, ascending dose, intravenous administration
45812922|NCT02706847|Drug|Upadacitinib|Tablet; Oral
45812923|NCT02245620|Drug|Elamipretide|Elamipretide 0.25 mg/kg/hour administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours
45812924|NCT02245620|Drug|Placebo|Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours
45812925|NCT02244996|Dietary Supplement|Lycium Barbarum|Traditional Chinese Herbs
45812926|NCT02244996|Dietary Supplement|Placebo|Placebo
45951018|NCT00485875|Drug|Atomoxetine Hydrochloride|
45951019|NCT00118872|Drug|LGG yogurt|Lactobacillus GG containing yogurt
45951020|NCT00118872|Other|Placebo yogurt|Yogurt NOT containing the active LGG bacteria
46077159|NCT02752308|Drug|Fentanyl|fentanyl 2 mcg /Kg that is repeated during surgery whenever the heart rate or blood pressure increased more than 20% of its baseline
46077160|NCT02752308|Drug|dextrose plus sodium chloride.|Four mL/Kg/hr of 5% dextrose plus 0.04 mL/Kg/hr of 20% sodium chloride. Each mL of blood loss was replaced by 3 ml of Ringer's solution
45453788|NCT01111903|Drug|Lenalidomide|Phase II: 20 mg/day in continuous regimen Phase I: 25 mg/day 21 days/28 with carboplatine AUC 5 + caelyx 30mg/m2
46077161|NCT02752308|Drug|neostigmine and atropine|Injection of 0.04 mg/Kg of neostigmine and 0.02 mg/Kg of atropine, intravenously at the end of operation.
46077162|NCT02752308|Procedure|Hypospadias repair|Surgical repair of hypospadias, using tubularized incised plate technique
45659698|NCT04764253|Behavioral|Modified Sodium Watcher Program + Digital Self-Monitoring|Participants randomized to the experimental group will be asked to follow the modified Sodium Watchers Program intervention along with goal setting for low salt foods. Each participant will be registered to assign a unique ID in the Connected Health Platform developed by the Center on Smart and Connected Health Technologies at UT Health Science Center San Antonio and each account from the individuals' wireless and wearable devices (Fitbit and BP monitor) will be connected to his or her unique ID through this platform. Participants will be instructed to log their activities in real-time, including food intake and in-home BP monitoring using Fitbit and accompanied mobile app and BP monitor. Through the Connected Health Platform, the Fitbit app and BP monitor will transmit the data of the intervention group to the research team.
45812927|NCT02470741|Drug|Letrozole|
45453789|NCT02281942|Behavioral|Yoga|
45453790|NCT02281942|Behavioral|Education|
45676513|NCT02601365|Drug|Sargramostim 0.2mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.2 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
45812928|NCT02470741|Other|Placebo|
45812929|NCT02661451|Device|SAPIEN 3 THV|
45812930|NCT02661451|Biological|Optimal Heart Failure Therapy|
45812931|NCT02543437|Device|Trident Acetabular X3 Insert|
45812932|NCT02544607|Drug|Ketamine|Ketamine 0.5mg/kg over 40 minutes IV
45812933|NCT02544607|Other|Magnetic Resonance Imaging (MRI)|MRI technology will be used before and after ketamine for patients with depression
45812934|NCT02243280|Drug|ABT-493|Tablet
45812935|NCT02243280|Drug|ABT-530|Tablet
45812936|NCT02549365|Drug|Live attenuated influenza vaccine|Administration of LAIV, with subsequent surveillance (nasal swabbing) during influenza season
45812937|NCT02549365|Procedure|Surveillance (nasal swabbing) during influenza season|
45812938|NCT00363571|Drug|GTN, Diamox|
45812939|NCT02637505|Procedure|Arthroscopic microfracture (MF)|Arthroscopy With microfracture procedure
45812940|NCT02637505|Procedure|Arthroscopic debridement (AD)|Arthroscopy With debridement procedure
45951021|NCT00485914|Behavioral|On-site work evaluation|Researchers will measure the effects of worksite assessment through an on-site work evaluation by an occupational therapist on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The scope of the information will be through one-to-one contact and an individualized work plan. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.
45951022|NCT00485914|Behavioral|Educational material|Researchers will measure the effects of worksite assessment through educational materials on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The scope of the information will be through educational materials to develop strategies to compensate. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.
45453791|NCT02280616|Drug|low dose budesonide tablet|1mg budesonide tablet twice daily AND 5ml placebo suspension twice daily
45453792|NCT02280616|Drug|high dose budesonide tablet|2mg budesonide tablet twice daily AND 5ml placebo suspension twice daily
45453793|NCT02280616|Drug|high dose budesonide suspension|placebo tablet twice daily AND 5ml [0.4mg budesonide/ml] suspension twice daily
45453794|NCT02280616|Drug|Placebo|placebo tablet twice daily AND 5ml placebo suspension twice daily
45812941|NCT04744675|Drug|Triamcinolone Acetonide 40mg/mL|Triamcinolone acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intramuscular, intra-articular, and intrabursal injection.
45812942|NCT04744675|Drug|Saline Injection|Saline is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium chloride and, in some formulations, potassium chloride and potassium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body.
45812943|NCT02471521|Other|Mask ventilation|Mask ventilation is performed after administration of rocuronium or not. Initial inspiratory pressure is set as 10 cmH2O and increased gradually by 2 cmH2O until gastric insufflation is detected by either of two methods. Tracheal intubation is done after detection of gas.
45812944|NCT02471521|Drug|Rocuronium|Rocuronium 0.6 mg/kg is injected before mask ventilation in muscle relaxant group or after finish of study in non-relaxant group.
45812945|NCT02624479|Drug|Sodium thiosulfate|oral administration of thiosulfate
45951023|NCT01241968|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
45951024|NCT01241968|Device|Placebo|Placebo
45951025|NCT00121316|Drug|Pimecrolimus|Pimecrolimus Cream 1 %
45453795|NCT01111981|Drug|Clobetasol Propionate 0.05% Emollient Foam|Clobetasol Propionate 0.05% E Foam to be applied to affected area once a day for 16 weeks
45453796|NCT01109017|Drug|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, and a Quality of Life form is completed by the patient, at visits 1 to 5.
45453797|NCT02283424|Drug|Icotinib|compared with chemotherapy,which is better for lung adenocarcinoma patients with epidermal growth factor receptor gene mutation after surgery
45676514|NCT02601365|Drug|Sargramostim 1 mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 1 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
45676515|NCT02592382|Dietary Supplement|Xylitol spray|xylitol nasal spray will be administered to this arm three times daily for three months
45951026|NCT00121316|Drug|Placebo|Vehicle cream (placebo cream)
46077163|NCT00895999|Behavioral|Interpersonal Therapy for Pain (IPT-P)|IPT-P focuses on improving relationships as a way to improve depression and pain. The patient and therapist work together to improve communication and enhance relationships and social support. Patients choose a problem focus and goal related to both their pain and depression. Up to 8 IPT-P sessions are provided regardless of ability to pay.
45453798|NCT02283424|Drug|chemotherapy (Carboplatin and Docetaxel)|as control group,compared with Icotinib
45676516|NCT02583893|Drug|Sirolimus|Given PO
45676517|NCT02583893|Drug|Mitoxantrone|Given IV
45676518|NCT02583893|Drug|Etoposide|Given IV
45676519|NCT02583893|Drug|Cytarabine|Given IV
45676520|NCT02579889|Device|DDD+CLS|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON
45676521|NCT02579889|Device|DDD(R)|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
45812946|NCT02623075|Biological|Influenza vaccine|Blood samples will be collected at research study visits at 0 and 30 days (+/- 2 days) post-IIV4 (influenza vaccine). Collection will be as follows: 45-50 ml blood at each visit (not to exceed more than three visits over a two month period).
45812947|NCT04341337|Other|interview|questionnaire about ethics in surgery
45812948|NCT02554435|Device|EAM|The monitor provides the participant feedback on their daily steps, active time, idle time, burned calories, and distance traveled through the mobile application (app). Participants can review all of their feedback while in the intervention. If the participants chose, they are also able to monitor their sleep and dietary intake. The app also provides health tips and daily challenges. The participants will also have the opportunity to interact with other participants through the social features of the app.
45951027|NCT00118950|Drug|Metformin|Tablet Metformin 500 mg; Dosage: 1000 mg two times daily. Duration: Four months.
45951028|NCT00118950|Drug|Repaglinide|Tablet Repaglinide 1 mg; Dosage: 2 mg three times daily. Duration: Four months.
45951029|NCT00118950|Drug|Placebo-Metformin.|Tablet Placebo (corresponding to 500 mg Metformin). Dosage: 2 tablets two times daily. Duration: Four months.
45951030|NCT00118950|Drug|Placebo-Repaglinide.|Tablet Placebo (corresponding to 1 mg Repaglinide). Dosage: 2 tablets three times daily. Duration: Four months.
45951031|NCT00118950|Other|Diet-only.|Diet-only treatment. Duration: One month.
45951032|NCT00486109|Device|I-Port(TM) Injection Port|
45951033|NCT00486148|Other|Infant formula (with GOS)|Infant formula supplemented with 0.4 g/100 ml of galacto-oligosaccharides
45812949|NCT02554435|Behavioral|5 A's counseling|Brief counseling to encourage behavioral change. The counseling is intended to be administered by a health care provider. The component of the counseling are assess, advise, agree, assist, and arrange.
45812950|NCT02554435|Device|Pedometer|The pedometer provides the participant feedback on their daily steps, activity time, distance traveled, and calories burned. Participants can review the feedback for the past 7 days.
45812951|NCT02555449|Drug|[¹⁴C]-LY3202626|Administered as solution by mouth
45812952|NCT02248818|Drug|AZD8108|Drug: AZD8108 Single or Multiple doses administered orally as a solution.
45812953|NCT02248818|Drug|Placebo|Placebo to match AZD8108 Single or Multiple doses of matching placebo administered orally as a solution
45951034|NCT00121355|Device|safety glide|
45951035|NCT00121355|Device|autocover needle|
45951036|NCT01242007|Other|Supine spirometry|In addition to the current upright lung function evaluation we performed a supine spirometry
45951037|NCT00118989|Dietary Supplement|Curcuminoids|Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
45951038|NCT00486187|Drug|rosiglitazone|
45453799|NCT01109095|Biological|HER.CAR CMV-specific CTLs|"HER2.CAR CMV-specific CTLs will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The patient will get one of the following doses:~1 x 10^6/m^2~3 x 10^6/m^2~1 x 10^7/m^2~3 x 10^7/m^2~1 x 10^8/m^2"
45812954|NCT02472223|Drug|Betadine 5%|"One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.~Betadine 5% exposure to the ocular surface is limited to 2 minutes in-office administration, followed by saline lavage per labeling instructions."
45951039|NCT00486187|Drug|metformin or sulfonylurea|
45951040|NCT00486304|Other|ADD|The ADD has a composition of 65% carbohydrate, 20% fat, and 15% protein. The diet will be completely depleted of vitamins A, E and beta-carotene; it will have 10 mg of vitamin C (6.5% of RDA) added per person per day
45951041|NCT00486304|Other|Placebo|Jevity 1.5 (1.5 cal/mL) will be used for the placebo patients in this study. This will simulate the standard of care for patients not on the ADD. Jevity 1.5 is an isotonic, fiber-fortified, high-nitrogen liquid formula providing complete, balanced nutrition for patients requiring short- or long-term tube feeding, given once per day
45951042|NCT00121394|Procedure|Chlorhexidine vaginal and infant wash|
45951043|NCT00486343|Drug|Zileuton CR|Zileuton CR tablets 2x600mg BID for 24 weeks
45951044|NCT00486343|Drug|Placebo|Placebo tablets 2x600mg BID for 24 weeks
45951045|NCT00119028|Procedure|Depression Care Quality Improvement Implementation|We will used a randomized design to evaluate long term (18-month) cost effectiveness of TIDES collaborative care in six intervention clinics with fully-implemented collaborative care compared to three matched and randomly-assigned usual care clinics. We used a non-randomized quasiexperimental design (untreated control group with pretest and posttest) to measure impacts on clinician performance, knowledge, and attitudes in 6 newly-implemented collaborative care intervention clinics compared to 6 matched usual care clinics
45812955|NCT02472223|Drug|Artificial Tears|One time in-office administration (4-5 drops) of artificial tears limited to 2 minutes, followed by saline lavage.
45812956|NCT02596087|Other|Problem List Suggestion|Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
45812957|NCT02247960|Drug|Ciprofloxacin|
45951046|NCT00486421|Biological|Rituximab|375mg/m2 IV weekly times 4 (days 1, 8, 15, 22)
45951047|NCT00486421|Drug|Prednisone|1mg/kg/d PO, taper to off by 8 weeks
45951048|NCT00121433|Drug|leptin|
45951049|NCT00486460|Drug|Gemcitabine|
45951050|NCT00486460|Drug|Curcumin|
45951051|NCT00486460|Drug|Celebrex|
45951052|NCT00486499|Procedure|I-125 versus Pd-103 radioactive seed insertion|
45951053|NCT00486577|Procedure|significant chronic primary auditory cortex stimulation during the first two weeks|significant chronic primary auditory cortex stimulation during the first two weeks of the follow up than wash out period followed by two weeks of non significant stimulation
46077164|NCT00895999|Behavioral|Enhanced Support and Connection to Counseling|Research staff connect patients with the Strong Family Therapy Services, Women's Behavioral Health Service, or other appropriate mental health care and reduce potential barriers from making it to the initial appointment. This support includes navigating insurance issues, addressing issues of childcare and transportation, helping to schedule the initial appointment, reminder calls, and follow-up after the scheduled intake. Research staff will also check-in monthly to see if the patients require any additional support to remain in mental health treatment. Up to 8 therapy sessions are covered regardless of ability to pay.
46077165|NCT02752464|Behavioral|Counseling|Up to 12 sessions of behavioral counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 12 week period. Counselors will be guided in their sessions by a computer program called CuesWeight. Participants also receive text messages to enable participants to track their behaviors; this information is relayed to the counselors to inform the counseling sessions.
45951054|NCT00486577|Procedure|non significant chronic primary auditory cortex stimulation during the first two weeks|non significant stimulation during the first two weeks of the follow up than wash out period followed by two weeks of significant chronic primary auditory cortex stimulation
45951055|NCT00119067|Biological|BioThrax or Anthrax Vaccine Adsorbed|
45951056|NCT00486616|Device|electrical impedance tomography|
45951057|NCT00486616|Procedure|double-lumen tube placement|
46077166|NCT02752464|Behavioral|feedback report|All participants receive a brief printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
46077167|NCT00894751|Drug|dexmedetomidine|dexmedetomidine general anesthesia for MRI
46077168|NCT00894751|Drug|propofol|propofol general anesthesia for MRI
46077169|NCT02752230|Procedure|Laparoscopic Roux en Y gastric bypass|Laparoscopic Roux en Y gastric bypass
46077170|NCT02752230|Procedure|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy
45659699|NCT04764253|Behavioral|Usual care + Digital Self-Monitoring|Participants randomized to the control group will be asked to follow usual care which is based on their routine medical and nursing care for hypertension that consists of a recommendation to follow a sodium-restricted diet and take medications as prescribed. The participants will receive wireless and wearable devices (Fitbit wristband, BP monitor). Each participant will be registered to assign a unique ID in the Connected Health Platform at the baseline and each account from the individual's wireless and wearable devices (Fitbit and BP monitor) will be connected to their unique ID through this platform. Participants will be instructed to log their activities in real-time, including food intake and in-home BP monitoring using Fitbit and accompanied mobile app and BP monitor.
45812958|NCT02472457|Other|Crohn Disease Exclusion Diet|The CDED is divided into 4 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase I, and weeks 25-52 maintenance phase II.
45812959|NCT02472457|Other|Free Diet|This diet contains no restrictions.
45812960|NCT02473783|Drug|Sertraline HCl|The regimen of Sertraline HCl will be administered with starting dose from minimum 25 mg/day for 1 week and maintenance dose of at least 50 mg/day up to 200 mg/day for the rest of 5 weeks.
45812961|NCT02473783|Other|I-123-ADAM SPECT|The subjects underwent the SPECT scan after I-123-ADAM (185 MBq, 5mCi) IV injection.
45453800|NCT02283502|Device|MRgHIFU system|Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids
45453801|NCT03946267|Device|Inverted inner limiting membrane flap technique for large full thickness macular holes|The ILM, stained with IFCG or BBG, is peeled off with ILM forceps, usually beginning near the inferotemporal vascular arcade, at least 2 disk diameters from the macular hole, in a circular manner. The peeling is extended up to the edges of the macular hole, the wide ILM flap obtained reduced by trimming with the vitreous cutter, and the annular remnant of ILM hinged to the hole's edge gently inverted upside down facing the RPE. Therefore, the hole is covered with usually more layers of inverted ILM. Attention is paid to avoid insertion and filling of the hole volume with ILM.
45812962|NCT02557555|Other|educational information|patients will receive pamphlet on labor analgesia options.
45812963|NCT02543749|Biological|DC vaccine|Autologous DC pulsed with leukemia-associated peptides+adjuvant
45812964|NCT02632526|Drug|AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A)|Oral suspension single dose
45812965|NCT02632526|Drug|AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A)|Single and multiple doses
45951058|NCT00121511|Drug|Efudex (5-fluorouracil)|
45951059|NCT00486655|Procedure|NOTES-Assisted Cholecystectomy|
45951060|NCT00486694|Drug|Sulfadoxine-pyrimethamine + artesunate|
45951061|NCT00486694|Drug|Chloroquine|
45951062|NCT00486733|Device|DermaGold|The first four follow-up study assessment and data collection points will coincide with scheduled operative interventions on the wound guided by clinical situation and the treating physician's judgment (approximately every 3-4 days). Subsequent follow-up study assessment and data collection points will occur on study days 28 ± 3, 42 ± 3, 60 ± 3, and 90 ± 3.
45951063|NCT04995627|Dietary Supplement|Salt (NaCl)|12 grams of salt (NaCl) per day
45951064|NCT04995627|Other|Placebo|Placebo
46077171|NCT00896077|Drug|Lisofylline|Lisofylline via i.v. administration vs Lisofylline vs s.c. administration
45951065|NCT00486772|Drug|Sevelamer (Renagel), calcium acetate (Phos-ex)|
45951066|NCT00121550|Drug|clarithromycin|
45951067|NCT01242046|Dietary Supplement|Caffeine|400 mg of caffeine in tablet form
45951068|NCT01242046|Dietary Supplement|Placebo|Inert tablet
45951069|NCT00486850|Other|Extubation to Nasal IPPV|Comparison of extubation to NIPPV versus NCPAP
45951070|NCT01242124|Procedure|side-to-side stapled esophagogastric anastomosis|20 patients of distal esophageal cancer receive side-to-side stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
46077172|NCT00792909|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose
46077173|NCT00792909|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 2 doses
46077174|NCT02752152|Behavioral|Computer-assisted counseling|The counselor opens the computer-assisted information/educational interactive counseling program on the tablet computer and invites the participant to use the program.
46077175|NCT02752152|Behavioral|On-demand counseling|The counselor only invites the participants to ask questions about HIV and other STIs.
46077176|NCT02752152|Behavioral|Standard counseling|The counselor gives face-to-face general information/education
46077177|NCT02752152|Behavioral|Appointment + reminder|Has an appointment and receive reminders for further testing
46077178|NCT02752152|Behavioral|Reminder|Only receive reminders for further testing
46077179|NCT02752152|Behavioral|No appointment and no reminder|No appointment and no reminders for further testing
46077180|NCT00896155|Drug|Tamoxifen|260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
45453802|NCT02283580|Other|Single limb|"Low load, high-repetitive resistance training.~single limb at a time (e.g., one arm or one leg)~elastic bands~8 weeks~3 times/week,~each session 60 minutes~seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension~maximal number of repetitions (RM) * 3 sets in each exercise."
45453803|NCT02283580|Other|Two limb|"Low load, high-repetitive resistance training.~two limbs at a time (e.g., both arms or both legs)~elastic bands~8 weeks~3 times/week,~each session 60 minutes~seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension~maximal number of repetitions (RM) * 3 sets in each exercise."
45453804|NCT03942601|Drug|Temsirolimus|Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1
45812966|NCT02632526|Drug|AZD5718 placebo oral suspension|Single and multiple doses
46077181|NCT00896155|Radiation|Radiotherapy|260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
46077182|NCT00896311|Drug|IV Nitroglycerin|IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
46077183|NCT00896311|Drug|Normal saline|IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
46077184|NCT02751996|Drug|SB 9200|SB 9200
46077185|NCT02751996|Drug|Placebo|
46077186|NCT02751996|Drug|Tenofovir|
46077187|NCT00944645|Drug|niacin (+) laropiprant (Source 1)|Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 1 in one of two treatment periods.
46077188|NCT00944645|Drug|Comparator: niacin (+) laropiprant (Source 2)|Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 2 in one of two treatment periods.
46077189|NCT00900991|Biological|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
45812967|NCT02632526|Drug|AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)|Single and multiple doses
45812968|NCT04740866|Radiation|Adjuvant Radiotherapy|Irradiation of both the bladder tumor bed and pelvic lymph nodes using Intensity-Modulated Radiation-Therapy (IMRT) technique. ([50Gy in 25 fractions conventional fractionation including tumor bed & pelvic lymph nodes]
45812969|NCT04340414|Device|Low flow ECMO driving by CVVH machine|With aim to clear CO2 and improve oxygenation, a low flow ECMO treatment(using oxgyenator membrane of kid type ) driving by CVVH machine will be performed in the NCP with severe ARDS
45812970|NCT02247804|Drug|Bimatoprost SR|Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
45951071|NCT01242124|Procedure|circular-stapled esophagogastric anastomosis|20 patients of distal esophageal cancer receive circular-stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
45951072|NCT00121589|Drug|Lutein|
45951073|NCT01242202|Drug|ipragliflozin|oral
45951074|NCT01242202|Drug|alpha glucosidase inhibitor|oral
45951075|NCT00119145|Drug|artesunate-amodiaquine|
45951076|NCT00119145|Drug|coartem|
45951077|NCT00119145|Drug|artesunate-lapdap|
45951078|NCT00487006|Other|Serum Lab testing|Serum Lab testing
46002671|NCT00546767|Behavioral|Interactive Voice Response (IVR)|In this group, participants will be asked to answer questions via an automated phone system using interactive voice recognition (IVR) and key-pad response entry. Medication compliance will be monitored by the same method. A standard large-key telephone and training in the use of the interactive phone system will be provided to all participants.
45951079|NCT04710797|Procedure|Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy|"open or minimally invasive surgical approach~cytologic examinations~All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied~BSO and hysterectomy~For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered~Omentectomy~Para-aortic lymph node dissection should be performed by stripping the nodal tissue from the vena cava and the aorta bilaterally to at least the level of the inferior mesenteric artery and preferably to the level of the renal vessels~The preferred method of dissecting pelvic lymph nodes is bilateral removal of lymph nodes overlying and anterolateral to the common iliac vessel, overlying and medial to the external iliac vessel, overlying and medial to the hypogastric vessels, and from the obturator fossa at a minimum anterior to the obturator nerve"
45951080|NCT04710797|Procedure|Comprehensive staging surgery with no Lymphadenectomy|"open or minimally invasive surgical approach~cytologic examinations~All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied~BSO and hysterectomy~For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered~Omentectomy~In open approach surgery, exploring the pelvic and Para-aortic lymph node with hand. In minimally invasive surgery, the peritoneal above the pelvic and Para-aortic lymph node area should be open and visualized.Biopsy and frozen section of the suspicious lymph nodes"
45951081|NCT00487045|Device|Hem-Avert Perianal Stabilizer|Hem-Avert Perianal Stabilizer, TNP-01L, single-use, disposable, sterile, individually packaged instrument
45951082|NCT00119184|Procedure|External cephalic version|7.5 mg bupivacaine intrathecally
45951083|NCT00119184|Drug|spinal anesthesia|spinal anesthesia
45951084|NCT00487123|Drug|Valsartan+/- Hydrochlorothiazide|
45951085|NCT00487201|Procedure|endoscopic balloon dilatation|
45951086|NCT00487201|Procedure|plastic stent placement|
45659700|NCT05514145|Device|Nance/Transpalatal arch space maintainer|A combined design of both Nance and Transpalatal arch space maintainers as a space maintainer for the maxillary arch in mixed dentition
45659701|NCT05514145|Device|Nance space maintainer|Conventional space maintainer for the maxillary arch used in mixed dentition
45951087|NCT00487357|Behavioral|Supplemental Survey|Questionnaire give during home visit to collect behavioral, risk factors and other smoking status data on MATCh parents/guardians.
45659702|NCT05514067|Procedure|Electro-Acupuncture|A single application of EA at cardiac-related acupoints administered for 30 min prior to CABG surgery.
45659703|NCT05513989|Device|modified Magill forceps|modified pediatric Magill forceps was used to assist nasotracheal intubation.
45951088|NCT00487474|Device|DL6049 (injectable poly-L-lactic acid)|Subjects will be treated with SCULPTRA® every 4-6 weeks in accordance with SCULPTRA® package insert
45951089|NCT00487513|Procedure|Procurement of Follicular B Cell Lymphoma Cells|Participants will undergo the following procedure(s) that are appropriate for collecting their tissue: Blood collection, lymph node biopsy, drainage of an effusion, or bone marrow biopsy
45951090|NCT00487591|Drug|Omacor (omega-3-acid ethyl esters)plus simvastatin|Omacor(omega-3-acid ethyl esters) - 4/g day (4 one gram capsules) simvastatin - 20 mg/day (1 tablet/20 mg)
45951091|NCT00487591|Drug|simvastatin plus placebo|simvastatin 20mg/day (1 tablet 20 mg)plus 4 capsules matching placebo
45951092|NCT04706156|Biological|COVID-19 Vaccine|Receiving coronavirus disease (COVID-19) vaccine e.g. Pfizer-BioNTech, Moderna, Oxford/AstraZeneca, or Sinovac COVID-19 Vaccine
45951093|NCT01242280|Device|Stent|Self-expandable esophageal stent (SX-Danis, Czesc Republic).
45951094|NCT01242280|Device|Tamponade|Sengstaken-Blakemore tube
45951095|NCT01242319|Behavioral|HeartAge intervention|Computerized kiosk in waiting room with HeartAge risk calculator, PDA based decision support tool regarding hyperlipidemia management, website and tool box with coronary risk reduction tools for smoking cessation, diet and exercise, medication adherence
45659704|NCT05513989|Device|Magill forceps|Magill forceps was used to assist nasotracheal intubation.
45951096|NCT01242358|Device|Capnography|Capnographic monitoring
45659705|NCT05513911|Other|Acute Intermittent Hypoxia|Acute Intermittent Hypoxia is administered in 30-60 second bouts of 9% O2 concentration, followed by 60-90 seconds of normoxic air concentrations (21% O2, room air). This procedure is repeated 15 times for a 30 minute session
45659706|NCT05513833|Other|Standard School Screening and Referral|Counties in the control condition will use standard hearing screening and standard referral by school district. Standard referral is typically a letter home from the school to parents/caregivers of children who refer screening.
45659707|NCT05513833|Other|Enhanced mHealth Screening|The enhanced screening protocol will consist of an mHealth-based hearing screen combined with tympanometry.
45951097|NCT01242358|Device|Standard monitoring|Standard monitoring
45659708|NCT05513833|Other|Specialty Telemedicine Referral|The specialty telemedicine referral will include a lay-friendly smartphone or tablet that connects to tools necessary for an ear and hearing evaluation. If a child requires referral from hearing screening, a school nurse/teacher will complete the established protocol for the specialty telemedicine referral and send details asynchronously to an audiologist for consultation.
45659709|NCT05513755|Procedure|cardioneuroablation|Endocardical radiofrequency ablation of vagal ganglia located close to pulmonary veins antra and interatrial septum.
45659710|NCT05513677|Device|M4D|Coated catheter
45659711|NCT05513677|Device|Standard of Care|Standard of Care
45659712|NCT05507593|Biological|DLL3-CAR-NK cells|Patients of Group A will be received 1x10^7 DLL3-CAR-NK cells infusion treatment，of group B will be received 1x10^8 DLL3-CAR-NK cells infusion treatment，and of group C will be received 1x10^9 DLL3-CAR-NK cells infusion treatment.
46077190|NCT00635622|Drug|LACTIN-V|Vaginal application of single-use applicators pre-filled with LACTIN-V (Formulation 1) at 2 x 10^9 cfu/dose or placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
46077191|NCT00635622|Drug|Placebo control substance|Vaginal application of single-use applicators pre-filled with placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
46077192|NCT04018027|Drug|difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg administered twice daily
45659713|NCT05507281|Procedure|Ultrasound-guided Erector Spinae Plane Block|ultrasound-guided ipsilateral Erector Spinae Plane Block (20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg)).
45812971|NCT02247804|Drug|Active Comparator: Timolol 0.5%|Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
45812972|NCT02247804|Other|Sham: Applicator Without Needle|Sham administered on Day 1, Week 16, and Week 32.
45951098|NCT04706117|Device|Self-retaining bicanalicular intubation stent|self-retaining bicanaliculs intubation setII(SRSII) which is the latest innovation in the field as these silicone stent segments traverse both canaliculi till the lacrimal sac. In which each end of this semicircular device has 2 stout angulated wings/flanges which pose no resistance while proceeding forward into the canaliculus, but once they get into open cavity (lacrimal sac), the flanges open up and give resistance to their removal against the common canalicular opening
45453805|NCT03942601|Drug|Temsirolimus and dexamethasone sodium phosphate|Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2
45659714|NCT05507281|Procedure|Retrolaminar Block|ultrasound-guided ipsilateral Retrolaminar Block (20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg)).
45659715|NCT05507281|Procedure|Control|General anesthesia
45812973|NCT02247804|Drug|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
45812974|NCT00366860|Behavioral|Soy bread|
45951099|NCT04969380|Device|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
45951100|NCT00487630|Drug|recombinant alpha-galactosidase A|
45951101|NCT00487708|Drug|canakinumab|
45951102|NCT00487786|Drug|OGX-427|OGX-427 injection at 200mg, 400mg, 600mg, 800mg or 1000mg once a week until withdrawn
45951103|NCT00487786|Drug|Docetaxel|injection - 75 mg/M2 IV on Day 1 every 21 days for cohorts 6 & 7 only, together with appropriate dose of OGX-427 until withdrawn from study
45951104|NCT04705922|Drug|TT-00420 Capsule|TT-00420 capsule formulation, administered orally
45951105|NCT04705922|Drug|TT-00420 Tablet|TT-00420 tablet formulation, administered orally
46077193|NCT04018027|Drug|difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg administered twice daily
45659716|NCT04812379|Drug|Abilify prolonged release aqueous suspension for IM injection (Aripiprazole)|The usual dose in adults is 400 mg of aripiprazole administered intramuscularly in the gluteal or deltoid muscle as a single dose once every 4 weeks. The dose may be decreased to 300 mg based on the patient's symptoms and tolerability.
45812975|NCT02635880|Device|Investigational Enlighten Device|Up to 3 laser treatments, spaced 4 to 6 weeks apart
45812976|NCT04943822|Other|A new APP|A new APP for prevention and treatment of complications of intestinal peristomal skin
45812977|NCT00366938|Drug|Lumiracoxib|
45812978|NCT05026320|Drug|Naproxen gel|10%, bid for 5 days (final application on morning of Day 6)
45812979|NCT05026320|Drug|Diclofenac gel|2.32% bid for 5 days (final application on morning of Day 6)
45812980|NCT05026320|Drug|Placebo gel|bid for 5 days (final application on morning of Day 6)
45951106|NCT00487903|Drug|PB127 for Injectable Suspension|0.062 mg/kg continuous IV (100-250 mL/hr) during echocardiogram, single dose, infusion not to exceed 60 minutes.
45951107|NCT00488020|Procedure|stem cells transplant|
45951108|NCT00488098|Drug|GSK372475|
45951109|NCT00488137|Drug|Prucalopride|2 mg o.d.
45951110|NCT00488137|Other|Placebo|o.d.
45951111|NCT00488137|Drug|Prucalopride|4 mg o.d.
45951112|NCT00488176|Drug|montelukast|montelukast sodium
45951113|NCT00488176|Drug|cetirizine|cetirizine
45951114|NCT00488176|Drug|montelukast and cetirizine|montelukast and cetirizine
45951115|NCT00488176|Drug|placebo|placebo
45951116|NCT00488215|Drug|prucalopride|The dose will be consecutively escalated in 2 mg steps per day, starting from 2 mg up to 20 mg once daily or until severe drug-related adverse events occur (= individual maximum tolerable dose, on decision of the subject and/or investigator).
45659717|NCT05507047|Drug|Enamel Matrix Protein|Enamel matrix derivated is used with transcrestal sinus lifting treatment
45659718|NCT04757857|Drug|Rivaroxaban 10 mg|Rivaroxaban pharmaceutical form will be tablets of 10 mg
45659719|NCT04755283|Biological|Abelacimab|Abelacimab provided as liquid in vial (150 mg/mL)
45951117|NCT00488215|Other|Placebo|During the placebo session, the number of placebo tablets will be consecutively escalated in an identical way as described for prucalopride. This means 1 tablet more every day, up to 10 tablets.
45659720|NCT04755283|Drug|Rivaroxaban|Rivaroxaban 15 mg and 20 mg provided as commercially available film-coated tablets
45812981|NCT00367328|Device|1320nm Nd: YAG nonablative laser|a 4 mm piece of skin tissue (about the size of a pencil-head eraser) from the affected area. This procedure is called a punch biopsy and will be done to confirm your diagnosis. A culture swab similar to a Q-Tip will be used to wipe the affected areas during the first visit to determine any bacteria that may be present. A survey with questions will be given at the first visit, again after 3 months and at the last visit to measure the success of the treatment. Photographs will be taken prior to each treatment and one month following your last treatment. A laser, which is a very powerful light, will be used to treat half of the skin that is affected by your condition.
45951118|NCT00121628|Drug|AMG 706|
45951119|NCT00488332|Procedure|Optical Coherence Tomography|Before radiation treatment and once a week thereafter.
45951120|NCT00488332|Procedure|Fluorescence Spectroscopy|Before radiation treatment and once a week thereafter.
45951121|NCT00488332|Behavioral|Pain Scale Questionnaire|Administered before the examination, OCT, and FS and immediately afterward.
45659721|NCT05506969|Biological|rF1V vaccine and CpG 1018® adjuvant|rF1V vaccine and CpG 1018® adjuvant
46077194|NCT04018027|Drug|difelikefalin 1.0 mg|Oral difelikefalin 1.0 mg administered twice daily
45812982|NCT04771806|Procedure|Magnetic Resonance Imaging|Undergo MRI
45812983|NCT04771806|Other|Neurocognitive Assessment|Undergo neurocognitive testing
45812984|NCT04771806|Other|Quality-of-Life Assessment|Ancillary studies
45812985|NCT04771806|Other|Questionnaire Administration|Ancillary studies
45812986|NCT04170374|Other|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
46077195|NCT04018027|Drug|Placebo|Oral Placebo administered twice daily
46077196|NCT02853617|Biological|AV0328 - Cohort 1|Cohort 1 will receive 15 µg to be given as an IM injection
46077197|NCT02853617|Biological|AV0328 - Cohort 2|Cohort 2 will receive 30 µg to be given as an IM injection
45951122|NCT04710758|Procedure|Laparoscopic total gastrectomy|LTG with D2 lymphadenectomy for patients with locally advanced gastric cancer (clinical stage T2-4aN0-3M0)
45951123|NCT04710758|Procedure|Open total gastrectomy|OTG with D2 lymphadenectomy for patients with locally advanced gastric cancer (clinical stage T2-4aN0-3M0)
45951124|NCT00488371|Biological|Pneumococcal Conjugated Vaccine (Prevnar®)|
45659722|NCT05506969|Biological|rF1V vaccine|rF1V vaccine
45659723|NCT05509621|Other|The Effect of Supine Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
45951125|NCT00488410|Device|Doppler echocardiography|
45951126|NCT00121706|Behavioral|Condition A (see detailed summary)|
45951127|NCT00121706|Behavioral|Condition B (see detailed summary)|
46077198|NCT02853617|Biological|AV0328 - Cohort 3|Cohort 3 will receive 75 µg to be given as an IM injection
46077199|NCT02853617|Biological|AV0328 - Cohort 4|Cohort 4 will receive 150 µg to be given as an IM injection
45659724|NCT05509621|Other|The Effect of Prone Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
45659725|NCT05509621|Other|The Effect of left lateral Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
45812987|NCT04170374|Other|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
45951128|NCT00121706|Behavioral|Condition C (see detailed summary)|
45951129|NCT00488449|Drug|GSK256073A tablets|
45812988|NCT04092686|Drug|SEP-363856 75mg|SEP-363856 75mg tablet dosed once daily
45951130|NCT00488527|Drug|Insulin glargine|Patients will begin with a fixed, subcutaneous dose of insulin glargine, (10 U), in its commercial presentation, which will be adjusted week by week, according to the values of the glycemia when fasting (FBG), adding 2, 4, 6 or 8 units of insulin glargine over the following twelve weeks, during which the therapeutic objective should be attained, namely the glucose goal during fasting of 100 mg/dl (<6.0 mmol/L), and the active treatment is to be continued for three more months.
45951131|NCT00488566|Drug|GSK drug|GSK drug
45951132|NCT00488566|Other|Placebo|Placebo
45951133|NCT00488566|Other|Lamictal|Positive control
45951134|NCT00121745|Genetic|Rexin-G Dose 1|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose I 3- 6 Days 1-7, 15-21 7.5 x 10e9 cfu 500 ml
45951135|NCT00121745|Genetic|Rexin-G Dose 2|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose II 3- 6 Days 1-7, 15-21 1.1 x 10e10 cfu 500 ml
45453806|NCT00598312|Drug|Leuprolide Acetate for Injectable Suspension|Sustained release injectable microspheres, 22.5 mg, one injection every 84 days, 3-month product
45812989|NCT04092686|Drug|SEP-363856 100mg|SEP-363856 100mg tablet dosed once daily
45812990|NCT04092686|Drug|Placebo|Placebo tablet dosed once daily
45812991|NCT04840784|Drug|ETH-155008|"ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form:10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal."
45951136|NCT00121745|Genetic|Rexin-G Dose 3|"Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~III 3- 6 5 days/wk x 4 wks 3.0 x 10e10 cfu 500 ml"
45951137|NCT00121745|Genetic|Rexin-G Dose 4|"Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~IV 3- 6 5 days/wk x 4 wks 8.0 x 10e10 cfu 500 ml"
45951138|NCT00488605|Drug|Prednisone, Vinblastin, 6-mercaptopuroine|Initial Therapy:Prednisone- by mouth 3 times/day daily as a 4-week course, then gradually decreased over 2 more weeks. Vinblastine-IV (into a vein)1 day/week for 6 weeks. Patients w/o evidence of active disease at this time will proceed to continuation therapy. If disease is improved or unchanged, pts. will receive additional therapy with: Prednisone- 3 divided doses by mouth for 3 days every week, from week 7-12. Vinblastine- IV 1day/week for 6 more weeks. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP:by mouth daily until the end of month 12. Prednisone in 3 doses daily day 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12.
45453807|NCT04538833|Drug|monosialic gangliosides|The experimental group received 80 mg of monosialic gangliosides (GM1) on days -1, 1, and 2 of albumin-bound paclitaxel(GM1 is a single infusion).
45812992|NCT02640716|Behavioral|multi-domain internet-based adaptive training program|The cognitive training will be a multi-domain adaptive training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. Specific training paradigms include a time perception task, visual search task, attention blink, delayed mapping task, attention span task, Go-No go task, Stroop task, task switching, and name-face match task, among others. To maintain task difficulty, the tasks will be grouped based on the task difficulty in each domain. Furthermore, each task will have various difficulty levels.
45659726|NCT05509621|Other|The Effect of right lateral Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
45812993|NCT02640716|Behavioral|placebo program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
45812994|NCT04086056|Other|NIRS monitoring|Regional cerebral oxygen saturation (rScO₂) will be collected by NIRS monitoring before anesthesia induction, during surgery and after extubation, in children with craniosynostosis.
45812995|NCT04068272|Drug|Bosentan|Eyedrop
45812996|NCT04068272|Drug|Placebo|Ophthalmic eyedrop with the exact same excipient of the drug arm without the active compound
45812997|NCT04058756|Drug|PDR001|PDR001
45453808|NCT04538833|Other|Placebo|The control group received placebo on days -1, 1, and 2 of albumin-bound paclitaxel (placebo as a single infusion)
45812998|NCT02243202|Drug|Canagliflozin|300 mg capsule, taken once daily, orally for 26 weeks.
45812999|NCT02243202|Drug|Phentermine|15 mg capsule, taken once daily, orally for 26 weeks.
45659727|NCT05509621|Other|The Effect of Quarter prone Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
45951139|NCT00488605|Drug|Leucovorin, Methotrexate, Vinblastine, Prednisone|Initial Therapy:Prednisone-by mouth 3x/day daily as a 4-week course then gradually decreased over 2 more weeks. Vinblastine- IV 1 day/week for 6 weeks. Methotrexate-a 24 hour IV infusion day 1 of weeks 1, 3, and 5, followed by leucovorin.The drug will be given by mouth. Pts w/o evidence of active disease at this time will proceed to continuation therapy. Pts whose disease is improved or unchanged will receive additional therapy w/:Prednisone- 3 divided doses, days 1-3 weekly from week 7-12. Vinblastine IV 1day/week for 6 more weeks. Methotrexate-a 24 hour IV infusion day 1 of week 7, 9, and 11, followed by leucovorin. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP by mouth daily until the end of month 12. Prednisone- 3 doses daily days 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12. Methotrexate by mouth once weekly until the end of month 12.
46002672|NCT00546767|Behavioral|Home-based Computer Kiosk|Participants at entry will receive a special Kiosk-like device for collecting assessment information and will be taught to use this device. The user interface will consist of a monitor with a touch screen and a telephone handset, similar to what is often used in museum displays. Pre-recorded instructions will be delivered through the handset as well as displayed visually on the screen. Data will be collected using the handset's high-quality microphone. Daily activity assessments of timed medication use will be obtained via an automated medication tracking device.
46002673|NCT00546767|Behavioral|Traditional Evaluation Instruments|Evaluation methods typically used in clinical trials
46002674|NCT04645758|Combination Product|Dry needling and Extra corporeal Shock wave therapy|5 mins of dry needling and 1250 pulses of shockwave therapy on dominant forearm muscles
45659728|NCT04291885|Drug|Avelumab|Avelumab IV infusion
45659729|NCT04291885|Drug|Placebo|Placebo IV infusion
45659730|NCT04754191|Drug|Enfortumab vedotin|Cohort A will be treated with enfortumab vedotin on a 28 day cycle for up to 12 months.
45659731|NCT04747327|Behavioral|mandate public|mandate by airlines, bars, restaurants
45813000|NCT02243202|Drug|Matching Placebo to Canagliflozin|Placebo capsules look like canagliflozin but do not contain any active drug, taken once daily, orally for 26 weeks.
45813001|NCT02243202|Drug|Matching Placebo to Phentermine|Placebo capsules look like phentermine but do not contain any active drug, taken once daily, orally for 26 weeks.
45813002|NCT04052828|Device|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)|This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.
45659732|NCT04747327|Behavioral|employer mandate|your employer requires vaccination
45659733|NCT04747327|Behavioral|incentive reward|$1,000 tax credit
45453809|NCT00595426|Drug|YM150|Oral
45453810|NCT00595426|Drug|Warfarin|Oral
45659734|NCT04747327|Behavioral|penalty|$1000 tax penalty
45659735|NCT04747327|Behavioral|incentive lottery small|100,000 smaller monetary amount
45659736|NCT04747327|Behavioral|incentive lottery medium|200,000 mid monetary amount
45659737|NCT04747327|Behavioral|incentive lottery large|1 million dollar lottery
45659738|NCT04747327|Behavioral|cash small|smaller guaranteed cash amount
45659739|NCT04747327|Behavioral|cash medium|mid sized quarenteed cash amount
45659740|NCT04747327|Behavioral|cash large|large quarenteed cash amount
45659741|NCT04747327|Behavioral|invitation for exercise financial incentive study|financial incentives earned when increasing exercise behaviors
45659742|NCT04747327|Behavioral|invitation for exercise social incentive study|social incentives earned when increasing exercise behaviors
45659743|NCT04747327|Behavioral|invitation for sleep social incentive study|social incentives earned when increasing sleep
45813003|NCT04050410|Drug|Moxonidine|active drug given as 1 dose
45813004|NCT04050410|Drug|Placebo|placebo pill given as 1 dose
45813005|NCT02243046|Drug|Control toothpaste|1450 ppm fluoride toothpaste control - Subjects will brush their whole mouth with the control toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
45659744|NCT04747327|Behavioral|invitation for sleep financial incentive|Financial incentives earned when increasing sleep
45659745|NCT05513287|Other|On the period of covid 19|In 2020 and 2021 covid 19 waves in egypt , the effect of this waves in our anathesia in patient wwho undergo cesarean section
45659746|NCT05513209|Procedure|opioid based multimodal anesthesia|elective tonsillectomy or adenotonsillectomy surgery using opioid based multimodal anesthesia.
45659747|NCT05513209|Procedure|pterygopalatine ganglion block based multimodal anesthesia)|elective tonsillectomy or adenotonsillectomy surgery using opioid free pterygopalatine ganglion block based multimodal anesthesia.
45659748|NCT05513131|Drug|Venetoclax；Azacitidine；Homoharringtonine|A cycle every 28 days Treatment with Venetoclax 100mg d1，200mg d2，400mg d3~d14； Azacitidine 75mg/m2/d，d1~d7 Homoharringtonine 2mg/d d1~d7
45659749|NCT04291651|Other|Survey|There are no study-specific interventions, as this is a prospective registry. However, patients will be asked to complete approximately 1-2 hours worth of surveys on things such as demographics, medical and surgical history, and pancreatic cyst-specific questionnaires.
45659750|NCT05509465|Device|Ergonomic chinrest|The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting.
45659751|NCT05509465|Device|Ergonomic chinrest used with a low Super Kun shoulder rest|The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting. The low Super Kun shoulder rest has been adjusted to be in the lowest position for all legs attached to the violin before the violinists received it. All participants was told not to adjust the shoulder rest but adjust the chinrest.
45813006|NCT02243046|Drug|Experimental toothpaste|1450 ppm sodium fluoride/zinc base toothpaste - Subjects will brush their whole mouth with a fluoride/zinc toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
45813007|NCT02243046|Drug|Active Comparator|1450 ppm sodium fluoride/triclosan toothpaste - Subjects will brush their whole mouth with this toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
46077200|NCT04002375|Other|pectouteropexy|The surgical procedure was initiated after adhesiolysis had been performed by opening the peritoneal layer along the round ligament toward the pelvic side wall. Preparation started at the right external iliac vein and was performed in the medial and caudal direction. A segment of area approximately 3- 4 cm2 of the right lateral part of the iliopectineal ligament (Cooper ligament) adjacent to the insertion of the iliopsoas muscle was exposed.The peritoneum of the bladder was dissected, and the anterior parts of the distal uterus were prepared for mesh fixation. The uterus was elevated to the intended tension-free position using the transvaginal probe (POP-Q level 0-1). The mesh was fixed anteriorly to the cervix using four polyester permanent sutures (Ethibond Excel®; Ethicon). Finally, the mesh was covered with peritoneum using a continuous monofilament absorbable suture (Maxon™; Medtronic).
45676522|NCT02538315|Drug|[18F]FDOPA PET/CT|Implantation of fetal dopaminergic stem cell transplantation by neuro-surgeon followed by [18F]FDOPA PET/CT imaging
45676523|NCT02520154|Drug|Carboplatin|Given IV
45676524|NCT02520154|Other|Laboratory Biomarker Analysis|Correlative studies
45676525|NCT02520154|Drug|Paclitaxel|Given IV
45676526|NCT02520154|Biological|Pembrolizumab|Given IV
45676527|NCT02520154|Other|Pharmacological Study|Correlative studies
45813008|NCT04034810|Device|Intracranial aneurysm treated with Silk vista and silk vista baby|Patients with intracranial aneurysm(s) intended to be treated with the silk vista and silk vista baby according to standard of care.
45813009|NCT04452500|Drug|CORT108297|CORT108297- 180mg daily for 7 days
46077201|NCT00915291|Other|Web-based educational modules|Interactive case-based modules that includes video vignettes of clinical interactions between hypothetical patients interacting with physicians
46077202|NCT02855255|Behavioral|NHS 1-1 smoking cessation programme.|Smoking cessation using cognitive behavioural therapy/motivational interviewing
45659752|NCT05506657|Other|State Counselor-Coordinated Services|"A counselor affiliated with the New Jersey State Division of Vocational Rehabilitation Services coordinates services that consider the participant's condition, needs and goals. Services participants may receive include:~Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~Help completing applications for services.~Assistance communicating with my employer about my needs and ways to accommodate them.~Referrals to and services from other health care or technology providers."
46077203|NCT02855255|Behavioral|Group smoking cessation programme|Smoking cessation using Allen Carr's Easyway method being delivered in a spoken form.
46077204|NCT02751918|Drug|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine will be administered on Day 1 of every 21-day treatment cycle.
45453811|NCT03946501|Other|Data collection|
45676528|NCT02411448|Drug|Ramucirumab|Administered IV.
45813010|NCT04452500|Drug|Placebo|Placebo- 180mg daily for 7 days
45813011|NCT04016636|Other|Standard of Care|Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 12 months.
45813012|NCT04436978|Drug|30-day DAPT|DAPT (aspirin + P2Y12 inhibitor) during the first 30 days following PCI. After 30 days, all patients will be treated with edoxaban and a P2Y12 inhibitor.
45813013|NCT04436978|Drug|Guideline-directed therapy|Guideline-directed therapy (edoxaban + P2Y12 inhibitor, aspirin limited to in-hospital use or up to 30 days in selected high-risk patients)
45453812|NCT01112137|Drug|Clopidogrel|
45453813|NCT01112137|Drug|Clopidogrel|
45453814|NCT01112137|Drug|Clopidogrel|
45676529|NCT02411448|Drug|Placebo|Administered IV.
45676530|NCT02411448|Drug|Erlotinib|Administered orally.
45676531|NCT02411448|Drug|Gefitinib|Administered orally.
45813014|NCT02207946|Drug|IncobotulinumtoxinA|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
45813015|NCT02207946|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
45813016|NCT03976076|Drug|JBPOS0101|JBPOS0101 (investigational product)
45813017|NCT04933500|Device|Whitacre spinal needle|25G Whitacre spinal needle
45813018|NCT05588804|Drug|Broncho-munal®|1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
45813019|NCT05588804|Drug|Placebo|1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
46077205|NCT02751918|Drug|Pegylated Liposomal Doxorubicin|Pegylated liposomal doxoribicin will be administered on Day 1 of every 21-day treatment cycle.
46077206|NCT00901069|Drug|Azacitidine with rituximab, vincristine, and cyclophosphamide|Azacitidine cycle days 1-5 Cyclophosphamide cycle days 6-9 Vincristine cycle day 8 Rituximab cycle day 8 Rituximab is only for those patients with CD20+ lymphoma. Azacitidine 25 mg/m2^ Azacitidine 50 mg/m2^ Azacitidine 75 mg/m2^ Azacitidine 100 mg/m2^
45676532|NCT02411448|Drug|Osimertinib|Administered orally.
45813020|NCT05588726|Behavioral|Sleep Hygiene|Once weekly coaching calls with advice on sleep hygiene
45813021|NCT05588726|Behavioral|Mindfulness|Once weekly coaching calls with advice on mindfulness
45813022|NCT04235036|Drug|Rituximab|Rituximab is given IV weekly x 4 weeks (to be started on study day 7 ± 3 days), then IV q3months x 4 doses (months 4, 7, 10, 13).
45813023|NCT04235036|Drug|Ibrutinib|Ibrutinib is given orally every day (28-day cycles) for a total of 12 cycles.
45813024|NCT03875300|Behavioral|Foodwise in Pregnancy|A 7 week programme of nutrition and lifestyle advice, delivered in community venues by trained Healthy Lifestyle Support Workers (HLSWs). Participants must meet study inclusion criteria.
45813025|NCT02560051|Drug|Doxorubicin|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)
45453815|NCT01112137|Drug|Clopidogrel|
45453816|NCT01106755|Device|gait training on ground level using BWS|An A1-B-A2 system was applied in which A1 and A2 corresponded to gait training on ground level using Body Weight Support (BWS). Each training phase was performed during 45 minutes, three times a week, for six weeks.
45453817|NCT01106755|Device|gait training on ground level using BWS associated to FES|An A1-B-A2 system was applied in which B corresponded to the training associated to Functional Electrical Stimulation. Each training phase was performed during 45 minutes, three times a week, for six weeks.
45453818|NCT02282098|Drug|Colchicine|Colchicine 0.6mg twice daily
45453819|NCT02282098|Drug|Placebo|Placebo Colchicine
45453820|NCT01208935|Drug|Nicotine Patch|
45453821|NCT01208935|Drug|Nicotine Gum|
45453822|NCT00584974|Drug|SEP-225289|0.5 mg SEP-225289
45453823|NCT00584974|Drug|SEP-225289|2.0 mg SEP-225289
45453824|NCT00584974|Drug|Venlafaxine|150 mg Venlafaxine
45453825|NCT00584974|Drug|placebo|Placebo
45951140|NCT00145197|Behavioral|Improving the Delivery of Effective Care to Minorities|The intervention consists of: a) reminders to prompt surgeons to refer patients for adjuvant treatment, and b) an individual to track referrals for and receipt of adjuvant treatments. We will recruit all physicians who treat patients with early stage breast cancer. Physicians who agree to participate will identify a point person in their office who will inform the research team if the patient has a follow up appointment with radiation or medical oncologists. Following the appointment date, we will contact each office to confirm the patient's visit. If the patient has connected with radiation and/or medical oncologist, we will let the surgeon's office know and stop calling his/her office. However, if the patient has not made the appropriate visits, we will continue to call the surgeon's office every week for a total of 3 calls to let them know that the patient has not connected with the oncologist.
45951141|NCT00488722|Drug|Zoladex|
45951142|NCT00488761|Drug|Tigecycline|
45951143|NCT00121784|Drug|mycophenolate mofetil [CellCept]|1
46077207|NCT02604147|Device|Inspiratory pressure-threshold muscle training device.|The participants who will be allocated in this simulated intervention group will have to do a simulated inspiratory muscle training protocol through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with a load of 15% of maximal inspiratory pressure without progression. In each session will be requested to the volunteers make 30 slow breaths, which will be constantly supervised by the researchers.
45813026|NCT02560051|Drug|Ketoconazole|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive ketoconazole (400 mg orally 3 times daily for 7 days)
45813027|NCT02560051|Drug|Docetaxel|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive docetaxel (35 mg/m2 intravenously on day 1 of each applicable week)
45813028|NCT02560051|Drug|Estramustine|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive estramustine (280 mg orally 3 times daily for 7 days)
45813029|NCT02560051|Drug|Degarelix|The starting dose (240 mg given as two injections of 120 mg each) is followed by maintenance doses of 80 mg administered as a single injection every 28 days
45813030|NCT03786770|Biological|DaxibotulinumtoxinA for injection|Intramuscular injection
45813031|NCT00367718|Drug|Velcade|velcade 1.3 mg/m2 given at the day 1,4,8,and 11 every 21 days schedule.
45813032|NCT02474407|Drug|diazepam nasal spray|
45813033|NCT02474407|Drug|diazepam rectal gel|
45813034|NCT05588570|Behavioral|CAT|Treatment includes 12 sessions: 2 caregiver teach sessions, 4 caregiver coach sessions in the child-directed interaction (CDI) phase, and 6 caregiver coach sessions in the DADS (Describe situation, Approach situation, give Direct command for child to join situation, provide Selective attention based on child's performance) phase. Throughout the 12 sessions, caregivers are coached through exposures in which the child is given the opportunity to slowly encounter anxiety-provoking factors. In the first session, caregivers are provided psychoeducation on anxiety and parenting practices and taught PRIDE (praise, reflect, imitate, describe, enjoy) skills, which are aimed at increasing approach behaviors and decreasing avoidant behaviors. In the CDI phase, caregivers are coached live via Bluetooth headset through the PRIDE and active ignoring skills. In the last 5 sessions, caregivers are coached through the DADS protocol while working up the Fear Hierarchy with the child.
45813035|NCT05588492|Drug|Rifamycin-containing regimen|Rifamycin-containing regimen
45813036|NCT05588492|Drug|Rifamycin-free regimen|Rifamycin-free regimen
45813037|NCT02475031|Device|TAP-C|TAP catheters with ropivacaine infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
45813038|NCT02475031|Drug|TAP-S|Catheters with saline infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
45813039|NCT03777956|Drug|Lacosamide|Lacosamide (50 mg) and identical placebo are given as capsules and taken orally twice a day, up to 200 mg b.i.d.
45813040|NCT03777956|Drug|Placebo|Identical placebo are given as capsules and taken orally twice a day.
45813041|NCT02476357|Device|Harmonic scalpel|
45951144|NCT01242397|Device|CRT pacing|The chronic effect of CRT pacing on the degree of MR in pts with severe-to-moderate or severe functional MR. The treatment being studied is CRT pacing therapy with standard of care LV lead placement. Patients will be randomized to CRT pacing ON vs. OFF and followed for a total of up to 8 months. This includes two 3-month crossover periods for each pacing modality (CRT ON and CRT OFF) and a 6-week washout period between these periods.
45951145|NCT01242436|Procedure|intravenous contrast administration|"The additional burden is restricted to a WB-DWI scan before and during therapy.~MRI is a technique based on magnetic fields and do not require the use of ionizing radiation. Because of the strong magnetic field, a few precautions should be taken. This means that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductor/prosthesis are for this reason not eligible for the study.~During the examination, an intravenous will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine."
45951146|NCT00145236|Drug|Nebivolol|
45951147|NCT01242475|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
45951148|NCT01242475|Biological|2 TU Tuberculin PPD RT 23 SSI|The 2TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
45951149|NCT01242592|Drug|Anti-Tuberculosis Treatment|
45951150|NCT00121823|Biological|FP9 ME-TRAP|
45951151|NCT00121823|Biological|MVA ME-TRAP|
45813042|NCT02519491|Other|Modified Allen Test|The Modified Allen's Test (MAT) will be performed in a well-lit room on both of the participant's hands. This technique will involve compression of both the radial and ulnar arteries by the investigator to assess patency of the contralateral artery. The participant will then be asked to clench and open their hand several times. The participant will then be asked to maintain their hand in an open position. The investigator will then release the compression over the ulnar artery and observe for palmar blush. The length of time to achieve maximal palmar blush will be recorded. This technique will then be repeated by maintaining compression over the ulnar artery and releasing of the compression over the radial artery.
45813043|NCT02519491|Other|Iphone artery assessment|The iRADIAL iPhone app (Heart Rate, Azumio software) will be used to assess radial and ulnar artery patency. Briefly, the iPhone camera will be placed over the participant's thumb and patency assessed before and immediately following isolated contralateral artery compression for a maximum of two minutes.
45951152|NCT00488800|Biological|pneumococcal conjugate vaccine|
45951153|NCT00145275|Drug|zoledronic acid|
45951154|NCT00488995|Drug|CP-675,206|
45951155|NCT00489034|Behavioral|Quantitative Interview|Index participants will be interviewed every six months (with phone interviews focused on service utilization at each six month interval midpoint) for 18 months while network members will be interviewed at baseline and one year. Interviews will consist of in-depth face-to-face and audio computer-assisted interviews (ACASIs) and a structured diagnostic interview to assess engagement in care (number of clinical visits attended), substance use, attitudes about substance use, friend's substance use, sexual risk behaviors, PTSD (for index participants only), support of index participants care use (network participants only), attitudes about healthcare (network participants only), index participant's adherence (network participants only), own functioning (network participants only), and family functioning (network participants only). At Baseline only, a urine sample will be collected from index participants for drug testing to assess the agreement between urine and ACASI.
45951156|NCT00489034|Behavioral|Ethnographic Interview|Qualitative interviews will be conducted with a small sub-sample of index and identified network participants from each site at least monthly for a period of 18 months. Interviews will be ethnographic in nature and will rely on participants' life stories and narratives of social experience to supply their content and guide their progression.
45951157|NCT00489034|Behavioral|Gender Interview|Qualitative interviews will be conducted with a sub-sample of index participants. These interviews will focus on issues of gender related vulnerabilities and will be used to develop a survey.
45659753|NCT05506657|Other|Center Facilitator-Coordinated Services|"A facilitator affiliated with Kessler Institute for Rehabilitation coordinates services that consider the participant's condition, needs and goals. Services participants may receive include:~Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~Help completing applications for services.~Assistance communicating with my employer about my needs and ways to accommodate them.~Referrals to and services from other health care or technology providers."
45659754|NCT05512975|Dietary Supplement|Dairy protein porridge arm|Regular porridge ingredients with additional delical whey protein fortification
45659755|NCT05512975|Dietary Supplement|Plant protein porridge arm|Regular porridge ingredients with the addition of extruded soya protein fortification and soya milk instead of regular dairy milk
45659756|NCT05512975|Dietary Supplement|Control Porridge arm|Regular porridge ingredients with no additional protein fortification
45951158|NCT04911816|Drug|Hydroxychloroquine sulfate|Hydroxychloroquine, oral, dose escalated (400mg, 800mg, 1200mg) beginning concurrent with mFOLFIRINOX and extending 2 weeks post-operatively. Dose will be assigned to patients using 3+3 Algorithm to identify the Maximum Dose Tolerated.
45951159|NCT00489073|Drug|duloxetine|
45951160|NCT00489073|Drug|placebo|
45951161|NCT00121862|Biological|Leish-111f + MPL-SE vaccine|
45659757|NCT05512897|Procedure|erector spinea plane block|in assistance of ultrasound for visualization anesthetic injection point. 30-40 mL Ropivacaine 0.375% plus 2 mg Dexamethasone administered on each side will be administered between thoracic transversus process and longitudinal spine muscle
45813044|NCT02560753|Drug|T3D-959|The 3mg dosage is supplied as 1mg capsules (three capsules, taken once daily by mouth) The 10mg dosage is supplied as 5mg capsules (two capsules, taken once daily by mouth) The 30mg dosage is supplied as either 5mg or 15mg capsules (six 5mg capsules or two 15mg capsules taken once daily by mouth) The 90mg dosage is supplied as 15mg capsules (six capsules, taken once daily by mouth)
45813045|NCT02481505|Drug|Chloroprocaine HCl 1%|Intrathecal Route
45951162|NCT00489112|Drug|Alfuzocine XL 10 mg once a day|
45951163|NCT00489151|Drug|adefovir dipivoxil|
45813046|NCT02563093|Biological|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular (IM)
45951164|NCT00489151|Drug|lamivudine|
45951165|NCT00145314|Drug|FLOX (5-fluorouracil/folinic acid/oxaliplatin)|FLOX every 2nd week
45951166|NCT00145314|Drug|FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab|FLOX every 2nd week Cetuximab weekly
45951167|NCT00145314|Drug|FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab|"FLOX every 2nd week for 8 cycles. Stop of FLOX until progression then FLOX is reintroduced.~Cetuximab weekly."
45951168|NCT00489190|Drug|Insulin Glulisine|
45951169|NCT04727372|Other|Questionnaire|A structured questionnaire will be served to each participant of study after getting the verbal consent from him for inclusion into the study
45453826|NCT01107067|Drug|Sustanon|250 mg/21 days
45951170|NCT00489229|Drug|Rosiglitazone|
45951171|NCT00489229|Drug|Ramipril|
45951172|NCT00489385|Drug|Albinterferon|
45951173|NCT00489385|Drug|Ribavirin|
45659758|NCT05512741|Other|Feces collection|"Feces will be collected, at home, by the patient., by using a collection kit. The stools are collected in the 2 last days before surgery.~After surgery, the first stool is collected, during the hospitalization, by using the same kit. Stools are conserved in the same condition, before being frozen in our local biologic ressources center."
45951174|NCT00489385|Drug|Albuferon|
45951175|NCT01242631|Drug|Everolimus|Everolimus 10 mg orally per day.
45951176|NCT04726215|Drug|[18F]F AraG|PET imaging agent specific to activated T cells
45453827|NCT03942445|Procedure|Gastrocnemius muscle biopsy|In all groups, a 5 mm large gastrocnemius muscle biopsy will be performed and the samples immediately managed in experimental laboratory.
45453828|NCT02282176|Drug|Azithromycin|Azithromycin IV 10mg/kg daily for 10 days
45951177|NCT00486382|Biological|Leish-111f + MPL-SE Adjuvant|
45659759|NCT05509387|Device|transcranial direct current stimulation and naming training|Participants will receive mild stimulation or no stimulation along with naming training
45951178|NCT00487318|Drug|standard of care|peginterferon/RBV
45951179|NCT00487318|Drug|fluvastatin|Add fluvastatin at 20-40 mg/day to standard of care
45659760|NCT05506501|Procedure|unilateral epidural anesthesia|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia using unilateral epidural anesthesia.
45659761|NCT05506501|Procedure|Ultrasound guided femoro/ sciatic nerve block|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia by femoral/sciatic nerve block using ultrasound guidance.
45659762|NCT05506267|Device|Trachea Sound Sensor (TSS)|Use the TSS and commercial vital sign monitors to develop a diagnostic algorithm that detects and predicts hypoventilation due to opioids and anesthetic medication
45659763|NCT05512663|Device|Irreversible Electroporation (IRE)|The area of the prostate that was positive for cancer based on the transperineal prostate biopsy will be targeted for ablation via the NanoKnife System. An MRI/TRUS fusion device probe will be placed in the rectum and the prostate will be visualized in both sagittal and axial views. The ultrasound grid which was used during the mapping biopsy will be oriented using anatomical landmarks and used to identify the location of the positive biopsy cores. The NanoKnife Single Electrode Probes will be surgically inserted into the prostate through the perineum using MRI/TRUS fusion guidance and the ultrasound grid for guidance.
45659764|NCT05512507|Behavioral|Physical Therapy Program|Physical Therapy Program
45659765|NCT05502913|Drug|Antibiotics|Recipients will undergo bowel preconditioning with antibiotics (Rifaximin) following randomization.
45453829|NCT02282176|Drug|Placebo|Azithromycin placebo (5% Dextrose) daily for 10 days
45453830|NCT01209013|Device|Medlight PDT Balloon|Medlight PDT Balloon will be used once to apply the laser light treatment
45453831|NCT01209013|Procedure|Endoscopy|Endoscopy will be performed to confirm eligibility, apply photodynamic therapy, assess esophageal condition and effectiveness of the therapy
45453832|NCT01209013|Procedure|Endoscopy with biopsy|Endoscopy with collection of esophageal tissue will be performed at screening to confirm eligibility and at Week 13 (final visit) to assess effectiveness
45453833|NCT01209013|Procedure|Electrocardiogram|Resting electrocardiogram will be performed at screening (unless one has been performed within 30 days prior to screening) to measure heart function
45453834|NCT01209013|Procedure|Chest x-ray|A chest X-ray will be performed at screening (unless one has been performed within 90 days prior to screening) to provide several pictures of the chest to rule out any lung abnormalities
45659766|NCT05502913|Other|FMT (Fecal Microbiota Transplantation)|FMT involves the transplantation of fecal bacteria from a screened donor to a recipient. This will be achieved per os in the form of a capsule containing freeze-dried stool obtained from the donor.
45659767|NCT05502913|Drug|Placebo Antibiotics|Recipients in the placebo arm of the study will receive placebo capsules with no active ingredients
45951180|NCT01242670|Biological|Ross River Virus Vaccine|Ross River Virus Vaccine (Formalin Treated, UV Inactivated, Vero Cell-Derived) with Aluminum Hydroxide Adjuvant
45951181|NCT01242826|Drug|biphasic insulin aspart 50|A single dose of 0.3 U/kg BIAsp 50 for subcutaneous (under the skin) injection
45951182|NCT00121901|Drug|glyceryl nitrate|
45951183|NCT00489463|Device|intra-uterine device (TCu 380A)|
45951184|NCT00489502|Behavioral|Brief Counseling|
45951185|NCT00489502|Device|REE Assessment|
45951186|NCT01242865|Behavioral|Attention and Interpretation Therapy|"Participants will receive a copy of the book, Train Your Brain Engage Your Heart Transform Your Life along with three handouts summarizing the contents of the book."
45951187|NCT01242904|Drug|bimodal solution|200 mL of 30% glucose infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
45951188|NCT01242904|Drug|icodextrin|200 mL of icodextrin infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
45951189|NCT00121940|Behavioral|Guided Care|"Specially trained registered nurse (Guided Care Nurse) based in a primary care practice collaborates with two primary care physicians to provide seven services for 40-60 high-risk patients: comprehensive assessment and care planning; best practices for chronic conditions; self-management; healthy lifestyles; coordinating care; educating and supporting unpaid caregivers; and accessing community resources."
45453835|NCT01209013|Procedure|Blood collection|Blood samples for laboratory tests will be taken to assess the overall condition
45453836|NCT01209013|Procedure|Tissue sample collection|Esophageal tissue samples will be collected before the porfimer sodium injection and on four separate occasions after the injection (22-26 hour-, 40-50 hour-, 96-120 hour-intervals, and 13 weeks) to measure concentrations of oligomers in a subgroup of 12 patients.
45659768|NCT05502913|Other|Placebo FMT|Recipients in the placebo arm of the study will receive placebo capsules with no active ingredients
45813047|NCT02563093|Biological|Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation|0.1 mL, Intradermal
45951190|NCT01242943|Drug|131I-L19SIP Radioimmunotherapy (RIT)|"Dosimetric evaluation with 131I-L19SIP will be performed to assess eligibility for Radioimmunotherapy.~Phase I: Patients eligible for Radioimmunotherapy will receive escalating doses of therapeutic 131I-L19SIP administration (intravenously) at the following dosages (expressed in mCi/m2): 111, 139 and 167."
46077208|NCT02604147|Device|nspiratory pressure-threshold muscle training device.|The participants who will be allocated in this intervention group will have to make a inspiratory muscle training protocol with progressive loads through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with an initial load of 50% of maximal inspiratory pressure, progressing to 60% after the fourth week, and 70% after the octave week. In each session will be requested to volunteers who performed 30 maximal and prolonged inspiration, maintaining the diaphragmatic breathing, which will be constantly supervised by the researchers.
45951191|NCT00145353|Drug|Insulin NovoRapid versus Actrapid|
45951192|NCT01242982|Procedure|Closed reduction and fixation with 2 pins|Closed reduction and fixation with 2 antegrade intramedullary Kirschner wires. Cast for 2 weeks. Control after 2 and 5 weeks. Thereafter a control after 3,6 and 12 months
46077209|NCT02853539|Drug|Denosumab|Subcutaneous injection of Denosumab
46077210|NCT02751840|Dietary Supplement|Caffeine|200 mg of caffeine capsule before RMR measurement
45951193|NCT01242982|Procedure|Reduction and Plaster of Paris|Closed reduction in local anesthesia and a Plaster of Paris for max. 3 weeks. Control after 1 and 3 weeks, thereafter control after 3,6 and 12 months
46077211|NCT02751840|Dietary Supplement|Placebo|Placebo capsule (starch) before RMR measurement
45659769|NCT05509153|Drug|NAC|1g of clinical grade N-Acetylcysteine capsules, taken orally twice a day
45659770|NCT05509153|Drug|Placebo|Coated Placebo capsules, manufactured to match appearance and taste, taken orally twice a day
46077212|NCT02751840|Other|Coffee|9 grams of black coffee in boiling water consumed before RMR measurement
45951194|NCT00121979|Drug|Racivir, a non-nucleoside reverse transcriptase inhibitor|
45951195|NCT04888572|Radiation|Peri-Apical X-ray|"Using a PCP UNC 15 Hu Friedy® periodontal probe and a gentle horizontal sweeping motion through the peri-implant tunnel or sulcus the examiner will assess bleeding on probing, the main factor in determining peri-implant inflammation and subsequently possible peri-implantitis. Then, using the same instrument, the author will examine whether there is an increase in the values of pocket depths compared to the initial values, highlighting an installation of peri-implant disease. Radiographically, evidence of bone loss after healing through taking a digital x-ray that will be viewed on DBSWIN® software will help authors make a diagnosis of peri-implantitis as well. It will be required that the digital film be perfectly parallel to the axis of the implant and the X-ray tube perpendicular to them in order to have an orthogonal radiograph."
45659771|NCT05506189|Other|mobile application program with human coach|6-months mobile application program with human coach for life-style modifiation including diet and exercise
45813048|NCT02563093|Biological|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular
45951196|NCT00489580|Device|SaeboFlex Dynamic Hand Orthosis|
46077213|NCT02751840|Other|Decaffeinated|9 grams of decaffeinated black coffee in boiling water consumed before RMR measurement
45453837|NCT00580216|Drug|Idrabiotaparinux sodium|"Pre-filled syringes containing:~0.5 mL for the 3.0 mg dosage;~0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);~0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).~Subcutaneous injection"
45813049|NCT02563093|Biological|Fluzone High-Dose vaccine, 2015-2016 formulation|0.5 mL, Intramuscular
45813050|NCT02564029|Drug|PF-06372865|Single dose
45951197|NCT00489580|Procedure|Saebo F.T.M. Arm Training Program|
45951198|NCT00489658|Drug|Eflornithine plus Nifurtimox combination therapy|
45951199|NCT00122018|Drug|N-acetylcysteine|
46077214|NCT00894829|Biological|heparin sodium - Eurofarma|Heparin sodium 5.000 UI - Eurofarma
46077215|NCT00894829|Biological|heparin sodium - APP|Heparin sodium APP 5.000 USP
45453838|NCT00580216|Drug|Warfarin|"Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration"
45659772|NCT05506033|Procedure|rapid GCs taper|After a complete response was achieved, the GCs dose was halved from the original dose.
45813051|NCT02564029|Drug|Placebo|Placebo for PF-06372865 and placebo for lorazepam
45813052|NCT02564029|Drug|Lorazepam|2 mg single oral dose
45813053|NCT05588336|Drug|Morphine|In the literature, intrathecal morphine doses were applied according to the patients' actual body weight and there is no study comparing intrathecal morphine dose in thoracic surgery patients.
45951200|NCT00122018|Drug|fenoldopam|
45659773|NCT04594837|Device|PTR Physical Therapy while wearing Robot group (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
45951201|NCT00489697|Device|real-time contrast-enhanced ultrasound imaging (CEUS)|Real time contrast enhanced sonography was performed using an ultrasound dedicated system after bolus injection of 1.2 and 2x2.4 ml Sonovue ® (Bracco, Milan, Italy)
46077216|NCT04108845|Biological|15-Valent Pneumococcal Conjugate Vaccine|3/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
46077217|NCT00896467|Other|questionnaire administration|
45659774|NCT04594837|Other|Physical Therapy Only (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks. Subjects perform over-ground mobility tasks of increasing challenge with therapist assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
45659775|NCT04594837|Device|Cross over group for Physical Therapy n Sub-Acute group. (Phase II)|Participants enrolled in the physical therapy only group will be given the option to re-enroll as a cross over participant to receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
45659776|NCT04594837|Device|Chronic Stroke Subjects to receive robotic gait training therapy.|Chronic stroke subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
45659777|NCT05509075|Dietary Supplement|nutraceuticals|antioxidants
45659778|NCT05508919|Device|Biofeedback|EMG, RESP, and TEMP Biofeedback Training
45951202|NCT04873752|Biological|UDI-001|2.5 x 10^6 cells/kg of UDI-001 are administered intravenously. One cycle consists of twice a week administrations.
45951203|NCT00489775|Drug|Duloxetine|
45951204|NCT00489775|Drug|Paroxetine|
45659779|NCT05508919|Other|Writing Sessions|The subjects will be asked to take three 20-minute writing sessions and write about the given control topic about their daily events of the past week
45659780|NCT04741789|Drug|Capmatinib|Tablet for oral use, dose Up to 400mg, twice daily
45659781|NCT04735393|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for six weeks (QID for four weeks then BID for two weeks).
45813054|NCT05588258|Other|Participants were given the 10% urea cream purchased in pharmacy or supermarket as appropriate after randomisation and their foot skin quality was assessed by validated questionnaire.|Participants agreed to the interventions after allocation to each arm according to randomisation and after signing an informed consent form. The creams tested in this study provided to participants are authorised for sale within the European Union but are not considered drugs or medical devices. The main purpose of the interventions was based on the care and assessment of the quality of the skin of the participants' feet.
45813055|NCT02564497|Biological|Process E Belatacept|
45813056|NCT02564497|Biological|Process C Belatacept|
45951205|NCT00489814|Behavioral|Questionnaire|Questionnaires administered within 3 weeks before the beginning of the radiation treatment course, twice during radiation therapy, and upon completion of radiation therapy.
45951206|NCT00122057|Drug|antibiotic treatment|
45951207|NCT00489892|Drug|Modafinil|
45951208|NCT04866888|Procedure|closure of the uterine wall defect|Uterine exteriorization followed by pealing of amniotic membranes to reach an accessible pole of the placenta to detect a plan of cleavage behind it. The independent hand of the surgeon passed through the previous plan from points of least resistance to high resistance. The defect will be repaired from the inner aspect of the uterus via running sutures using Vicryl (1-0) on a round needle, 45mm. the suture will pass from one edge to hitch the bed and pass to the other edge till we completely close the defect subsequently, controlling the bleeding. Uterine scar closure by running sutures in two layers, where the first layer compresses the placental bed defect externally.
46077218|NCT00896467|Procedure|psychosocial assessment and care|
46077219|NCT00896467|Procedure|quality-of-life assessment|
46077220|NCT04109157|Diagnostic Test|20-minute pad test|Our 20-minute modified pad test was described previously proposed first by Hahn and Fall and modified by Sand and Ostergard. Each patient's bladder was emptied with a transurethral catheter and filled to the SD amount of sterile water for test. The catheter was removed, and then the patient returned to a standing position with a pre-weighed perineal pad placed on the underwear. The patient was asked to cough 10 times, bear down 10 times, do 10 deep knee bends, jump up and down on the spot 10 times, wash her hands under cold water for 1 minute, walk up and down five stairs 10 times, walk in the hall for 10 minute, and then return for removal of the pad. The pad was then weighed and the net weight was calculated by subtracting from the original dry weight to achieve a measure of the total urine loss during the 20 minute exercise. The pad weight was measured in grams and the accuracy of the scale was 1 gram. The positive pad weight result was defined as more than 1 gram of leakage.
45659782|NCT04735393|Drug|Placebo Comparator|Vehicle Ophthalmic Solution administered for six weeks (QID for four weeks then BID for two weeks).
46077221|NCT04269941|Other|total or subtotal gastrectomy|resection of the gastric tumor
45659783|NCT04735393|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for one year (QID for four weeks then BID for 11 months).
45659784|NCT04735393|Drug|Placebo Comparator|Vehicle Ophthalmic Solution administered for one year (QID for four weeks then BID for 11 months).
45951209|NCT04866888|Diagnostic Test|ultrasound|"Before the procedure transabdominal and transvaginal ultrasound will be done to diagnose PAS and to map the uterine wall defects.~After 3 months,Transabdominal and transvaginal ultrasound with different modalities to assess the uterine wall, the cavity, endometrium, myometrium and the cervix. Isthmocele will be defined as a defect at uterine wall where residual myometrium thickness and ratio between residual myometrium and total myometrium thickness will be measured and recorded. The shape of the isthmocele will be also recorded."
45951210|NCT04866888|Diagnostic Test|outpatient hysteroscopy|Office hysteroscope will be done after patient consent to evaluate the uterine cavity if the patient is symptomatic or with abnormal sonography. It will be performed in the proliferative phase of the menstrual cycle. Non-steroidal anti-inflammatory will be given one hour before the procedure, then the patient will be in lithotomy position. Following aseptic rules, the rigid 4 mm hysteroscope will be inserted into the uterus through the cervix without using speculum nor tenaculum. Any pathology will be identified, and data will be recorded.
45951211|NCT00489931|Drug|VRC-AVIDNA036-00-VP|
45659785|NCT05508841|Other|tDCS and Cognitive Training|Participants will receive mild stimulation or no stimulation along with cognitive training
45951212|NCT00490048|Procedure|Induced sputum (inhalation of 3.5% saline)|
45951213|NCT00490087|Device|Levonorgestrel intrauterine device (IUD)|
45813057|NCT03957278|Device|DAISe System|The DAISe System is indicated for revascularization of patients with acute ischemic stroke for the removal of fresh thrombi from vessels in the neurovasculature.
45813058|NCT02565901|Drug|Carboplatin|Given IV
45813059|NCT02565901|Drug|Docetaxel|Given IV
45813060|NCT02565901|Other|Laboratory Biomarker Analysis|Correlative studies
45659788|NCT04584853|Drug|Abemaciclib|Abemaciclib used in combination with standard Endocrine Therapy for 2 years from randomisation
45813061|NCT02565901|Drug|Sirolimus|Given PO
45813062|NCT03926624|Drug|DFP-10917|DFP-10917 Powder for Injection. Active ingredient: 4-amino-1-(2-cyano-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone monohydrochloride
45813063|NCT03926624|Drug|Cytarabine|cytosine arabinoside (ara-C)
45813064|NCT03926624|Drug|Azacitidine|Azacitidine
45813065|NCT03926624|Drug|Decitabine|Decitabine
45813066|NCT03926624|Drug|Mitoxantrone|Mitoxantrone
45813067|NCT03926624|Drug|Etoposide|Etoposide
45813068|NCT03926624|Drug|Fludarabine|Fludarabine
45813069|NCT03926624|Drug|Idarubicin|Idarubicin
45813070|NCT03926624|Drug|Venetoclax|Venetoclax
45951214|NCT01243060|Drug|Almorexant|100mg
45951215|NCT01243060|Drug|Almorexant|200mg
45951216|NCT01243060|Drug|Zolpidem 10mg|10mg
45951217|NCT01243060|Drug|Placebo|One-time dose of Placebo
46077222|NCT02756988|Drug|Coppertone (BAY987704)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number: X71-109)
46077223|NCT02855099|Other|Rehabilitation|The duration on the rehabilitation will be 3 month and will be a multidisciplinary program that includes supervised physical activity
45659789|NCT04584853|Drug|Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)|Standard of care endocrine therapy for a minimum of 5 years from randomisation
45813071|NCT03926624|Drug|Cladribine|Cladribine
45813072|NCT02566135|Device|Tracheal Intubation using I-gel and ventilating bougie|Following general anaesthesia I-gel was inserted. After proper placement . ventilating bougie was inserted. Once it's placement is confirmed I-gel was removed keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie then it (v.bouggie) was removed . Proper placement of endotracheal tube was confirmed by bilateral equal chest excursion and air entry on auscultation, absence of gastric insuffflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for I-gel, ventilating bougie and endotracheal tube.
45813073|NCT02566135|Device|Tracheal Intubation using C-LMA and ventilating bougie|Following general anaesthesia C-LMA was inserted. After proper placement of C-LMA, ventilating bougie was inserted. It's placement was confirmed and C-LMA was removed after deflation of cuff keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie. It's placement was confirmed by bilateral equal air entry and chest excursion, absence of gastric insufflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for C-LMA , ventilating bougie and endotracheal tube.
45813074|NCT05588102|Drug|Selective Serotonin Reuptake Inhibitor（SSRIs，Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）|Subjects in the intervention group received SSRIs antidepressants combined with Electronic cognitive training based on mobile phone platform for 52 weeks (once a day, 60min each time)
45813075|NCT03565640|Device|Capio Slim Device|Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Capio Slim Device.
45813076|NCT03565640|Device|Anchorsure Device|Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Anchorsure Device.
45813077|NCT05588024|Device|Head Up CPR based bundle of care|All patients in this registry receive the intervention, a Head Up Cardiopulmonary Resuscitation (CPR) based bundle of care. This bundle of care includes the use of multiple FDA approved devices. The components of the Head Up CPR bundle are 1) a single or combination of CPR methods including manual, active-compression decompression CPR, or automated suction-cup based CPR 2) An impedance threshold device 3) An automated patient positioning device capable of elevating the head and thorax
45813078|NCT04744441|Procedure|CHOLECYSTECTOMY|Surgical treatment
45813079|NCT04744441|Procedure|PERCUTANEOUS CHOLECYSTOSTOMY|Patients treated with a percutaneous cholecystostomy
45813080|NCT04744441|Procedure|EXCLUSIVE ANTIBIOTICS|Patients that are treated only with i.v. antibiotics
45813081|NCT04744597|Behavioral|Real execution of Fitts's law tasks|Children will be training Fitts's law tasks of different difficulties. Once each task will be solved, they will receive a new, more demanding task
45813082|NCT04744597|Behavioral|Motor imagery of Fitts's law tasks|Children will be training Fitts's law tasks of different difficulties, same as RE group but the exception of doing it mentally - motor imagery of Fitts's law tasks with eyes open.
45659790|NCT05502445|Other|educational intervention|"In this group, the steps below are added:on the first day, the delivery of the leaflet on the importance of nutrition in the hospital environment will be added in addition to verbal guidance. On the second day, an educational institutional video with duration of two minutes, will be shown with the title Food Intake and Oral Supplement in Nutritional Rehabilitation via tablet or mobile phone.~When the 24-hour recall will be collected, an assessment of food intake will be performed, mainly of foods that are sources of protein and, when they were less than 75%, strategies must be designed to increase the acceptance or indication of oral nutritional supplements."
45659791|NCT05505877|Drug|BR790+Tislelizumab|"BR790 will be administered orally, variable dose.~Tislelizumab will be administered as an intravenous infusion,fixed dose."
45813083|NCT04744597|Behavioral|Skip counting|Children in SCg will silently count (one number per second) in the same working blocks as both experimental groups with a task of saying the number they reached during each block - control condition to keep them mentally active at very low mental engagement.
45813084|NCT03551210|Drug|Nemonoxacin|Solution for infusion, 500 mg (250 ml)
45813085|NCT03551210|Drug|Nemonoxacin|Capsules, 250 mg
45813086|NCT03551210|Drug|Tavanic|Solution for infusion, 500 mg (100 ml)
45951218|NCT04848909|Radiation|stereotactic body radiotherapy (SBRT)|Stereotactic body or external-beam radiation therapy (SBRT) is a method of delivery of radiation in precision manner to the prostate bed in this study. The SBRT dose prescription will be 3000 cGy in 5 fractions to the prostate bed and 2500 cGy in 5 fractions to the pelvic nodes if elective nodal irradiation (ENI) is used, delivered every other business day.
45813087|NCT03551210|Drug|Tavanic|Film coated tablets (each tablet is placed into a capsule shell (overencapsulated) for blinding purposes), 250 mg
46077224|NCT00606229|Drug|Aripiprazole|oral, 24mg/day
46077225|NCT02756754|Device|Radiofrequency ablation|The radiofrequency system will be used as the RFA generator device standard cycle of ablation will be applied in the patient. During RFA, blood pressure, pulse and oxygen saturation will be continuously monitored.
46077226|NCT04108533|Behavioral|Text-Based Support|Text-based breastfeeding support as described in arm/group descriptions
45813088|NCT03551210|Drug|Placebo (250 ml)|0.9% NaCl (250 ml), solution for infusion
46077227|NCT02756598|Drug|Sufentanil I|bolus dose of sufentanil 1 microgram/kg
46077228|NCT02756598|Drug|Sufentanil II|bolus dose of sufentanil 0.5 microgram/kg
46077229|NCT02756598|Drug|Propofol I|Continued dose of propofol 0.03 mg/kg/min
45813089|NCT03551210|Drug|Placebo (100 ml)|0.9% NaCl (100 ml), solution for infusion
45813090|NCT02482675|Other|Glucose|Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
45813091|NCT02482675|Other|Glucose with Non-fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
45813092|NCT02482675|Other|Glucose with Whey Protein Isolate|Following baseline measurements, participants will consume 75 g glucose and whey protein isolate dissolved in 2 cups water within five minutes.
45813093|NCT02482675|Other|Glucose with Sodium Caseinate|Following baseline measurements, participants will consume 75 g glucose and sodium caseinate dissolved in 2 cups water within five minutes.
45813094|NCT04339088|Other|Questionnaires|Questionnaires to assess quality of life
45813095|NCT00364195|Drug|Tesmilifene (YMB1002)|
45951219|NCT04727450|Behavioral|Cognitive training|Involves participants engaging in selected games which require thinking skills to be played in a group of 2-4 people.
45951220|NCT04727450|Behavioral|physical training|"Involves learning of preselected routines of line dancing taught by a line dance instructor."
45951221|NCT04727450|Behavioral|Combination of cognitive and physical training (CCPT)-BIGMAP|BIGMAP is a program engaging participants in specially designed cognitive/memory games together with physical training (Fu & Chow, 2019).
46077230|NCT02756598|Drug|Propofol II|Continued dose of propofol 0.06 mg/kg/min
46077231|NCT00896545|Behavioral|5-keys counseling|5-session small group intervention
46077232|NCT00896545|Behavioral|Lifestyle counseling|5-session small group behavioral intervention
46077233|NCT04108611|Procedure|hemodiafiltration with endogenous re infusion (HFR)|hemodiafiltration with endogenous re infusion (HFR) for cases 2
45659792|NCT04725721|Behavioral|FIRST|FIRST is built upon five empirically supported principles of change (ESPCs-i.e., feeling calm, increasing motivation, repairing thoughts, solving problems, trying the opposite). Each principle can be applied to treatment of problems spanning depression, anxiety (including OCD and PTS), and conduct problems-thus encompassing a majority of the youths seen in outpatient care. Its design addresses breadth of problem coverage, youth comorbidity, and flux in youth treatment needs during episodes of care. It is used in conjunction with performance feedback via a web-based tracking system that gives clinicians weekly data on youth treatment response. FIRST has treatment and training efficiency, and efficient clinician skill-building is supported by group consultation.
45659793|NCT04725721|Behavioral|Usual Care|Treatment in the usual care (UC) condition will use the clinical procedures therapists consider appropriate and believe to be effective.
45659794|NCT04712851|Biological|Pembrolizumab|Given IV
45659795|NCT05508685|Other|HIIT and Cognitive Reassessment|Participants will receive 40 minutes of high-intensity interval training focusing on the upper and lower limbs associated with a cognitive reassessment strategy during the exercises.
45659796|NCT05508685|Other|HIIT group|Participants will receive high-intensity interval training, lasting 40 minutes, focusing on upper and lower limbs.
45659797|NCT05508685|Other|Emotional regulation strategy group|Participants will be instructed to cognitively reassess the negative emotions they feel or do not feel during the practice of the exercises. Participants will receive instructions on how to reassess.
45659798|NCT05508685|Other|placebo group|Participants in this group will not receive any intervention. Only pre and post experiment will be evaluated.
45659799|NCT05505799|Other|Intubation Checklist|A preprocedure checklist will be made available to clinicians, and they will be educated on proper use of the checklist
45659800|NCT05505799|Other|Standard Care|Clinicians will intubate as per their usual practice
45659801|NCT02567227|Other|Cognitive Remediation|This computerized program has successfully been used by seniors in different settings. It trains a number of cognitive processes including attention and Executive Function.The Cognitive Remediation (CREM) training is constructed based on the program's built in baseline cognitive evaluation.
45659802|NCT02567227|Other|Active Control|Computer, multimedia and group based health education programs.
45813096|NCT03466424|Radiation|preoperative short-course radiotherapy|Patients will be enrolled into Group 1 to 3 according to the time order of entering the study to receive dose from 6Gy×5F to 8Gy×5F using the traditional 3+3 dose escalation design.
45659803|NCT02336451|Drug|Ceritinib|LDK378 is a gelatin capsule, administered orally once daily at a dose of 750 mg (five 150 mg capsules) on a continuous dosing schedule on an empty stomach.
45659804|NCT02374593|Drug|Levothyroxine|Levothyroxine dose will be adjusted at the first clinic visit based on thyroid anatomy on ultrasound.
45659805|NCT02374593|Device|Ultrasound|
45659806|NCT01648101|Drug|Retigabine 900mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 900mg/day over a 4 week Titration Phase). The subject will then continue to receive 900mg/day for the next 12 weeks (Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week transition phase, eligible subjects will start the OLE on retigabine 900mg/day.
45951222|NCT00490126|Other|Laparoscopic Surgery Data Collection|Prospectively and retrospectively collect data on patients who had laparoscopic surgery since January 1, 1990 forward. Data from the initial patient visit note, consultation notes, operative report, discharge summary, and follow-up progress notes will be entered into the database.
45951223|NCT00490204|Drug|Cetirizine|
45813097|NCT02566369|Drug|CD5789 (trifarotene) 50μg/g cream|CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks.
45813098|NCT02566369|Drug|Placebo cream|Placebo cream applied once daily for 12 weeks
45813099|NCT05587790|Behavioral|Weight Management Intervention|Participants attend virtual dietary education sessions and over time create a diet plan that satisfies their individual needs. Participants aim to lose 1-2 pounds weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and anthropometric measures of waist and hip circumference, and body composition.
45813100|NCT02569411|Other|Financial Incentive|money
45951224|NCT00122096|Drug|valdecoxib|
45951225|NCT00490243|Drug|budesonide and montelukast|
45951226|NCT00490243|Drug|budesonide and formoterol|
45951227|NCT00490243|Drug|montelukast|
45951228|NCT00490243|Drug|budesonide|
45951229|NCT00490243|Drug|placebo|
45951230|NCT00490321|Device|VentrAssistTM Left Ventricular Assist Device|
45951231|NCT00490360|Drug|Gemcitabine / Cisplatin|
45951232|NCT00122174|Behavioral|Stress Busting Program for family caregivers|
45951233|NCT00490399|Drug|gemcitabine|
45951234|NCT00490399|Drug|cisplatin|
45951235|NCT04844385|Drug|Toripalimab|Toripalimab 240 mg, d1, Q3w for two cycles
45951236|NCT04844385|Drug|Paclitaxel-albumin|Paclitaxel-albumin 260 mg/m2, d1, Q3w for two cycles
45951237|NCT04844385|Drug|Nedaplatin|Nedaplatin 75mg/m2, d1, Q3w for two cycles
45951238|NCT04844385|Radiation|SMART|Once-daily simultaneous modulated accelerated radiotherapy (PTV-GTV: 60Gy/24f )
45951239|NCT04844385|Drug|Capecitabine|Capecitabine 1000 mg/m2, bid, d1-14, q3w during radiotherapy
45951240|NCT00490516|Drug|ACP-104|200 mg, tablet, BID, 6 weeks
45813101|NCT04743427|Other|hot pack and exercises|20-minute hot pack,and three active exercises: (a) chin tucks in supine lying with the head in contact with the floor, (b) active Standing Shoulder pull back , and (c) scapular plane shoulder elevation. (3 sets of 10 repetitions for all the 3 exercises)
45813102|NCT04743427|Device|body blade(BB)|The Body-blade (Classic, Mad Dogg Athletics, USA), an elastic pole exercise tool with 122 cm in length, 0.68 kg, 4.3 cm in width,based on oscillatory/vibration motions that have been used in training or rehabilitation.The body blade works by rapidly changing directions at a low-frequency rhythm of approximately 4.5 Hz (cycles per second )
45951241|NCT00490516|Drug|ACP-104|100 mg, tablet, BID, 6 weeks
45659807|NCT01648101|Drug|Retigabine 600mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 600mg/day over 2 weeks. The subject will then continue to receive 600mg/day for the next 14 weeks (2 weeks of the Titration Phase and 12 weeks of the Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week Transition Phase (3 weeks on retigabine 600mg/day, 1 week on retigabine 750mg/day) eligible subjects will start the OLE on retigabine 900mg/day.
45813103|NCT02569723|Drug|Carbon C 14 Oxaliplatin|Intravenous infusion
45813104|NCT02569723|Drug|Oxaliplatin|Intravenous infusion
45813105|NCT02570425|Device|Training on BF Spiromax followed by SYMBICORT Turbohaler|Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
45659808|NCT01648101|Other|Placebo|Study drug will be administered three times a day in a double blind manner. Subjects randomised to placebo will receive the same number, size and colour of tablets as the 600mg/day and 900mg/day treatment arms for the duration of the 4 week Titration Phase and the 12 week Maintenance Phase. Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach dose of 750mg/day over the 4 weeks of the Transition Phase. On completion of the Transition Phase eligible subjects will start the OLE on retigabine 900mg/day.
45659809|NCT02336373|Drug|hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the PedsQL™ Sickle Cell Disease Module version 3.0 after 6 months at MTD, compared to entrance scores
45951242|NCT00490516|Drug|Placebo|placebo, tablet BID, 6 weeks
45951243|NCT00490594|Device|ACL Reconstruction (SeriACL™ Device)|Bioresorbable ACL
45951244|NCT00122213|Behavioral|Behavior change on physical activity and diet|
45951245|NCT04841304|Device|Loop recorder (Reveal LINQ, Medtronic)|Implantation of a loop-recorder
45951246|NCT04841304|Device|Continuous Glucose Measurement (G6, Dexcom)|Monitoring with a continuous glucose monitor
45951247|NCT00490633|Behavioral|Ear Loop Procedure Mask|Facemasks were requested to be worn while participants were in the residence hall for year one, and while they were in residence halls for a minimum of six hours per day in year two.
45951248|NCT00490633|Behavioral|62% Ethyl Alcohol Hand Sanitizer|Hand sanitizer was provided to participants in the facemask and hand hygiene arm for year one and year two of the study.
45951249|NCT00490672|Behavioral|No Active Intervention.|Conventional Chronic Disease Management in Malaysia Primary Care
45951250|NCT00490672|Behavioral|Community Based Multiple Risk Factor Intervention Strategies|Multi-faceted Intervention in Chronic Diseases Management i.e. Hypertension, Diabetes Mellitus, Hyperlipidaemia involving Primary Health Care Physicians, Nurse Educators, Dieticians and Pharmacists.
45951251|NCT01243216|Device|Ultrasound|Ultrasound examination of the lumbar spine. The level of the lumbar interspace will be determined by the oblique/sagittal method. The transverse method will be used to determine the best lumbar interspace and the distance from the skin to the target (epidural space or intrathecal space)
45951252|NCT00145548|Device|Intra Bronchial Valve|
45813106|NCT02570425|Device|Training on SYMBICORT Turbohaler followed by BF Spiromax|Training with a placebo comparator: SYMBICORT Turbohaler® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
45951253|NCT00490711|Drug|gemcitabine|
45951254|NCT00490711|Drug|carboplatin|
45951255|NCT00490711|Drug|paclitaxel|
45813107|NCT02571439|Procedure|Surgical TAP block|surgeon administered TAP block
45951256|NCT00490750|Procedure|Dor fundoplication|Subjects are randomized to undergo Heller myotomy followed by Laparoscopic Dor fundoplication
45659810|NCT02372799|Drug|Vilazodone|
45659811|NCT02372799|Drug|Placebo|
45951257|NCT00490750|Procedure|Toupet fundoplication|Subjects are randomized to undergo Heller myotomy followed by Laparoscopic Toupet fundoplication
45951258|NCT00122291|Drug|Capecitabine|
45951259|NCT00122291|Procedure|Pelvic radiation|
45951260|NCT00490789|Drug|sirolimus|daily oral sirolimus with dosage individualised by trough blood levels
45951261|NCT00490828|Drug|Hydrocortisone|Hydrocortisone
45659812|NCT02372799|Drug|Fluoxetine|
45951262|NCT00490867|Drug|Alpha lipoic acid|
45951263|NCT00122330|Drug|eculizumab|
45951264|NCT00490906|Drug|Copaxone|20 mg, subcutaneous injections, taken daily
45951265|NCT00490906|Drug|Interferon-beta 1a|30 mcg injected intramuscularly, once weekly
45659813|NCT02566993|Drug|Lurbinectedin (PM01183)|
45659814|NCT02566993|Drug|Doxorubicin (DOX)|
45951266|NCT00490906|Drug|Interferon-beta 1b|.25 mg/day, taken every other day, subcutaneous injections
45813108|NCT02571439|Procedure|Conventional TAP block|Anesthesiologist administered TAP block
45813109|NCT02571439|Drug|0.5% ropivacaine|20ml of 0.5% ropivacaine is used to perform the TAP block
45813110|NCT02573857|Drug|DSM265|Oral suspension from bulk powder
45951267|NCT00490984|Device|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
45951268|NCT00491062|Procedure|Biopsies|
45659815|NCT02566993|Drug|Cyclophosphamide (CTX)|
45813111|NCT02573857|Drug|OZ439|Oral suspension from powder in a bottle
45813112|NCT02576041|Drug|Bilastine|Bilastine tablets once a day for 7+3 days
45951269|NCT00122408|Dietary Supplement|Ergyphilus|5 pills a day of Ergyphilus or placebo
45951270|NCT00491101|Other|Polish Version of PAQLQ(S) by Juniper|Polish Version of PAQLQ(S) by Juniper
45951271|NCT00491101|Other|spirometry|spirometry
45813113|NCT02576041|Drug|Placebo|Placebo tablets once a day during 7+3 days run in period
45659816|NCT02566993|Drug|Vincristine (VCR)|
45659817|NCT02566993|Drug|Topotecan|
45659818|NCT05508607|Other|CDI-risk Classification Tool|This tool will focus a bundle of antimicrobial stewardship (AMS) CDI prevention recommendations on high-risk patients.
45659819|NCT05508529|Dietary Supplement|Chaga Mushroom|Effect of chaga on immune/mood support
45659820|NCT05508529|Dietary Supplement|Algae Extract|Effect of algae extract on immune/mood support
45659821|NCT05508529|Dietary Supplement|Black Cumin Seed Oil|Effect of black cumin seed oil on immune/mood support
45659822|NCT05508529|Dietary Supplement|Black Cumin Seed Oil + Astaxanthin|Effect of Black Cumin Seed Oil + Astaxanthin blend on immune/mood support
45659823|NCT05508529|Dietary Supplement|Black Cumin Seed Oil + Omega 3|Effect of Black Cumin Seed Oil + Omega3 blend on immune/mood support
45659824|NCT05508529|Dietary Supplement|Placebo|Placebo control
45659825|NCT05505487|Other|integrated care model|The interventions in this study were to implement basic patient care only and did not involve any invasive procedures. On the basis of routine nursing, the content of nursing intervention was integrated, and a standardized nursing model was formed for clinical application to control the severity of pulmonary infection in patients with simple tracheotomy in the non-acute phase of stroke.
45951272|NCT00491140|Genetic|Gene mutations analysis and FISH|FISH and mutation analysis of multiple genes
45951273|NCT00491257|Biological|Inactivated influenza vaccine (split virion) NH 2007-2008 formulation|0.5 mL, Intramuscular
45951274|NCT00122486|Drug|Tenofovir Disoproxil Fumarate|
45951275|NCT00491296|Device|SYNERGO|
45951276|NCT00491296|Device|SYNERGO-intravesical chemotherapy instillation combined with hyperthermia|
45951277|NCT04809753|Device|Eustachian tube dilation|Dilation of the eustachian tube with an endovascular balloon
45951278|NCT01243372|Genetic|mutation analysis|
45951279|NCT01243372|Other|laboratory biomarker analysis|
45951280|NCT00122525|Procedure|Male Circumcision|
45951281|NCT00491413|Drug|epoetin|
45951282|NCT01243489|Other|compliance supporting measures|"Patients will be treated for a total of 12 months, 6 months without and 6 months with compliance supporting measures. Patient can choose between an information service Leben mit CML or the use of a daily diary"
45951283|NCT00122564|Biological|HIV-1 gp 160|
45951284|NCT00122564|Biological|DC-Chol|
45951285|NCT00491569|Drug|Sarcosine and D-serine|
45951286|NCT00145665|Procedure|FLT-PET scan|PET scan using FLT
45951287|NCT00491686|Drug|AZD6765|intravenous infusion
45951288|NCT00491725|Drug|repaglinide|
45951289|NCT00491725|Drug|metformin|
45951290|NCT00491803|Drug|Sildenafil|sildenafil 20 mg orally
45951291|NCT00491803|Drug|Sildenafil|sildenafil 40 mg orally
45951292|NCT00122603|Drug|Fosamprenavir|ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill twice a day) + FPV (700mg: 1 pill twice a day)
45951293|NCT00122603|Drug|Saquinavir|ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill per day) + SQV (500mg: 3 pills per day)
45951294|NCT00491881|Behavioral|no added salt diet|
45951295|NCT00145743|Behavioral|physio,pain,psychotherapy;social,nutrit.counselling&sports|profile and treatment recommendations based on the profile vs. routine psychooncology
45951296|NCT00491920|Drug|cholecalciferol (Vitamin D3)|"20 000 Iu x2/week~+ calcium 500 mg/cholecalciferol 400 IU x2/d"
45951297|NCT00491920|Drug|placebo|Calcium 500 mg/Cholecalciferol 400 IU x2/d and placebo 2/w
45951298|NCT00491959|Procedure|Cultured oral mucosa cell sheet transplantation|Cultivated oral mucosal cell sheets will be transplanted on the denuded corneal surface or the scleral surface of the symblepharon area. Therapeutic contact lenses will be applied after surgery.
45951299|NCT00491998|Drug|V1512|6 doses of IMP at 2-hourly intervals
45951300|NCT00491998|Drug|V1512|3-hourly dosing
45951301|NCT00491998|Drug|V1512 and Entacapone|4 doses of IMP and Entacapone at 3-hourly intervals
45951302|NCT00122642|Procedure|Alcohol-lock|The intervention is the instillation of ethanol 70% solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
45951303|NCT00122642|Drug|placebo-lock|The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
45951304|NCT00492037|Drug|YM087 oral|
45951305|NCT04790565|Biological|FMT|Fecal microbiota in frozen capsules
45951306|NCT00492076|Biological|Pangramin Plus D. pteronyssinus 100%|"Active. Pangramin Plus D. pteronyssinus 100%~Placebo. Pangramin Plus placebo"
45951307|NCT00402272|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
45951308|NCT00492271|Drug|Friulimicin B|Intravenous, once daily, single dose
45951309|NCT00492310|Behavioral|yoga|vinyasa yoga
45951310|NCT00492310|Behavioral|cognitive therapy|cognitive behavioral therapy once weekly
45951311|NCT00492310|Behavioral|yoga|vinyasa yoga twice weekly with smoking cessation once weekly
45951312|NCT00492310|Behavioral|wellness|wellness program with smoking cessation
45951313|NCT00145782|Behavioral|Life style|
45659826|NCT05508451|Procedure|Double jaw surgery|A type of orthognathic surgery
45659827|NCT05508373|Biological|JS019|Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.
45659828|NCT04565899|Other|Practice facilitation implementation intervention|6 months during which practice facilitation is implemented to support the primary care clinic in improving routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs.
45951314|NCT00492388|Drug|PMI-150 (intranasal ketamine)|intranasal dosing
45951315|NCT00492388|Drug|placebo|placebo
45951316|NCT01243528|Other|Laboratory values|Laboratory values which represent nutritional status
45951317|NCT01243645|Behavioral|biofeedback training|
45659829|NCT02311881|Drug|Paracetamol 1000 mg SR tablets|Two paracetamol 1000 mg SR tablets administered orally two times a day plus two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day for 12 weeks.
45659830|NCT02311881|Drug|Paracetamol 665 mg SR tablets|Two paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
45659831|NCT02311881|Drug|Placebo|Two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
45951318|NCT01243684|Device|DTI - Diffusor Tensor Imaging|Radiology intervention
45951319|NCT00492427|Drug|R744|25μg(s.c.)/2weeks until Hb concentration reaches to 10g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above, then 25~250μg(s.c.)/4week for 24~26weeks in total.
45951320|NCT00492427|Drug|Epoetin beta|6000IU(s.c.)/week until Hb concentration reaches to 10.0g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above,then 3000k~12000IU(s.c.)/2week for 24~26weeks in total.
45951321|NCT00492466|Drug|Interferon-beta-1a|dosage and frequency as per label
45951322|NCT00492466|Drug|methylprednisolone|dosage and frequency as per Biogen Idec protocol
45951323|NCT00492505|Drug|cisplatin|
45951324|NCT00492505|Drug|sorafenib tosylate|
45951325|NCT00492505|Drug|tamoxifen citrate|
45951326|NCT00492505|Procedure|adjuvant therapy|
45951327|NCT00492661|Drug|Tacrolimus With Diet and Exercise Intervention|Participants on tacrolimus for immunosuppression will be provided with intensive dietary advice and supervised for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
45951328|NCT00492700|Drug|rosiglitazone|
45951329|NCT00492739|Biological|Vaccination with VZV vaccine|Varicella vaccination 2 doses 2 months apart.
45951330|NCT00402311|Procedure|DOC-PG: integrated multidisciplinary assessment|
45951331|NCT00402311|Procedure|Usual care: assessment by GP or one of the regional services|
45951332|NCT04781712|Behavioral|Modular mHealth for Tailored Rehabilitation|an individually tailored self-management through the mHealth app with a smart band worn on the wrist
45951333|NCT00402350|Drug|Inhaled Placebo|Inhaled Staccato Placebo, same number of doses as active comparator in that arm
45951334|NCT00402350|Drug|Inhaled Fentanyl 25 mcg|Inhaled Staccato Fentanyl, 25 mcg x 1 dose
45951335|NCT00402350|Drug|Intravenous Fentanyl 25 mcg|Intravenous Fentanyl 25 mcg, single dose
45951336|NCT00402350|Drug|Inhaled Fentanyl 25 mcg x 2|Inhaled Staccato Fentanyl, 25 mcg x 2 doses
45951337|NCT00402350|Drug|Inhaled Fentanyl 25 mcg x 4|Inhaled Staccato Fentanyl, 25 mcg x 4 doses
45951338|NCT00402350|Drug|Inhaled Fentanyl 25 mcg x 6|Inhaled Staccato Fentanyl, 25 mcg x 6 doses
45951339|NCT00402350|Drug|Inhaled Fentanyl 25 mcg x 12|Inhaled Staccato Fentanyl, 25 mcg x 12 doses
45659832|NCT02565511|Biological|CAD106 Immunotherapy|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
45659833|NCT02565511|Other|Placebo to CAD106|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
45659834|NCT02565511|Drug|CNP520|CNP520 50 mg capsule p.o. for the duration of the Treatment Epoch.
45813114|NCT02576899|Behavioral|Acceptance and Commitment Therapy for PTSD and Tobacco Use|ACT-PT is an acceptance and mindfulness-based smoking cessation treatment for Veterans with PTSD and tobacco dependence. ACT-PT specifically targets smoking cravings related to PTSD symptoms and memories of trauma, in addition to difficulties managing PTSD symptoms. negative affect and nicotine withdrawal symptoms during quit attempts. ACT-PT includes structured intervention components that guide Veterans to replace smoking as a coping strategy for PTSD symptoms and memories with alternative coping strategies (e.g., mindfulness, acceptance). And healthy living activities (e.g., engaging in work, expanding social networks, engaging in physical exercise) that are consistent with Veterans' values.
45951340|NCT04777149|Other|transcranial Random Noise Stimulation (tRNS)|Two electrodes will be placed over the targeted areas on participant's head. A current of random frequency and intensity will be delivered. TRNS will be applied during the first 20 min of functional task practice.
45951341|NCT04777149|Other|transcranial Direct Current Stimulation (tDCS)|Two electrodes will be placed over the targeted areas on participant's head. A continuous low intensity current will be delivered. TDCS will be applied during the first 20 min of functional task practice.
45951342|NCT04777149|Other|sham-stimulation|Two electrodes will be placed over the targeted areas on participant's head. A continuous low intensity current will be delivered for 1- 2 min.
45951343|NCT00402389|Drug|Omega-3 Fatty Acids (EPA plus DHA)|Four capsules will be taken daily for 8 weeks.
45951344|NCT00402389|Behavioral|Supportive psychotherapy|Supportive psychotherapy will provide education to increase understanding of the condition, guidance on how to cope with depression, and methods on how to improve self-esteem.
45951345|NCT00402389|Drug|Placebo|Four capsules will be taken daily for 8 weeks.
45659835|NCT02565511|Other|Placebo to CNP520|Placebo to CNP520 p.o. for the duration of the Treatment Epoch
45813115|NCT02576899|Behavioral|Freedom From Smoking|The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
45813116|NCT03678428|Drug|Irinotecan|Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and 15.
45813117|NCT03678428|Drug|Oxaliplatin HAI|Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
45813118|NCT03678428|Drug|Floxuridine|0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
45813119|NCT03678428|Drug|Leucovorin|Leucovorin 200mg/m2 IV on Day 1 and 15.
45951346|NCT04766970|Behavioral|ADOS-2 Module 4|Assessment in person using standardized Autism Diagnostic Observation Schedule, 2nd Edition (ADOS-2) Module 4.
45951347|NCT04766970|Behavioral|Adapted Telehealth ADOS-2 Module 4|Assessment via telehealth/teleconference platform using an adapted ADOS-2, Module 4 assessment protocol.
45951348|NCT00122720|Drug|Darbepoetin Alfa|
46077234|NCT02756676|Procedure|Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The duration of each session is about one hour. The first session comprise cardiovascular warm-up activities, relaxation, muscle- stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in daily living activities. The last session includes one hour of speech therapy.
45951349|NCT00492895|Drug|Discontinuation of Azathioprin|Discontinuation of Azathioprin
45951350|NCT00492934|Drug|human menopausal gonadotrophins|Daily subcutaneous injections, dose 37.5 IU or 75 IU, start on day 2 of the menstrual cycle until ovulation
45951351|NCT01243723|Drug|Eductyl suppository|One suppository every morning during 21 days
45951352|NCT01243723|Drug|Placebo suppository|One suppository every morning during 21 days
45951353|NCT02274454|Drug|Oxytocin|Experiments will be conducted with some myometrial strips pretreated with oxytocin, and others without any oxytocin pretreatment
45951354|NCT02274454|Drug|Calcium|Calcium will be applied to the myometrial strips in 3 concentrations; 1.25mM (low), 2.5mM (normal) and 5.0mM (high). Myometrial strips will be either oxytocin pretreated, or non-oxytocin pretreated.
45951355|NCT04760730|Biological|AZD1222|"Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10^10 particles (nominal) per dose (unit dose strength > 0.7 × 10^11 vp/mL).~Solution for intramuscular injection, supplied in vials in a carton box"
46002675|NCT00546806|Other|Programs of Care|Two physiotherapy programs of care for the experimental groups; Physician-based education and activation for the active comparator group.
45659836|NCT02565511|Other|Alum|Alum was mixed with reconstituted CAD106 as adjuvant therapy to maximize the effectiveness of CAD106
45659837|NCT05505331|Radiation|three-Dimensional ultrasonography|transadominal and transvaginal examination
45659838|NCT05505331|Radiation|Magnetic resonance imaging|multiplanar T2-weighted sequences and pre-contrast T1-weighted imaging in either the sagittal or axial plane
45659839|NCT05505331|Procedure|myomectomy|myoma excision
45659840|NCT02561455|Drug|Gilteritinib|oral tablet
45659841|NCT02561299|Device|Peripheral Orbital Atherectomy System|Orbital Atherectomy
45813120|NCT03678428|Drug|5-FU|5-FU 2400mg/m2 CIV in 46h on Day 1 and 15.
45813121|NCT03678428|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 IV over 3 hours on Day1 and 15.
45659842|NCT02561299|Device|014 Drug Coated Balloon|Drug Coated Balloon
45813122|NCT02577601|Drug|Ulipristal Acetate|
45951356|NCT04760730|Biological|rAd26-S|"Component I (Dose 1) - (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10^11 particles per dose (unit dose strength 1 × 10^11 vp/0.5 mL) .~Solution for intramuscular injection, supplied in vials in containers"
45951357|NCT00122759|Drug|ketamine|
45951358|NCT00493051|Biological|GAM501|Ad5PDGF-B formulated in a collagen gel
45951359|NCT00493051|Biological|Placebo|Collagen gel
45951360|NCT00493051|Other|Standard of care|moist dressing changes daily
45951361|NCT00493090|Behavioral|modification of an interactive seminar|
45951362|NCT00493129|Drug|Ontak (Denileukin Diftitox)|9 µg/kg by vein Days 1-5 of a 21 day cycle.
45659843|NCT04549051|Device|Tenex|Local anesthetic plus Tenex into the coracohumeral ligament for adhesive capsulitis
45659844|NCT04549051|Drug|Local anesthetic|Only local anesthetic into the coracohumeral ligament for adhesive capsulitis
45659845|NCT04547413|Behavioral|STI/HIV Intervention Behavioral Intervention Program|In addition to standard of care STi/HIV counselling, participants in the intervention arm will also attend a 2-hour educational class and will receive monthly SMS/text messages to reinforce the content of the class.
45659846|NCT05505253|Drug|Alfacalcidol 0.0005 MG|Alfacalcidol 0.5 mcg is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
45659847|NCT05505253|Drug|Placebo|Placebo drug is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
45951363|NCT04750044|Other|early refeeding|In the early refeeding group, oral diet is started 24 hours after PEP is confirmed. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.
45659848|NCT05505097|Drug|Hydroxymethylquinoxalindioxyde|"Dioxidin (Hydroxymethylquinoxalindioxyde), solution for topical and external use, 0.25 mg/ml, applied as:~A - single rinsing of the oropharynx with 15.0 ml of the drug solution for at least 30 seconds B - single irrigation of the oropharynx by spraying the preparation 4 times with a spray nozzle C - irrigation of the skin on the back by spraying the preparation 4 times from a distance of 10 cm on 1% of the body surface using a spray nozzle and exposing the solution for 30 minutes or D - Dioxidin (Hydroxymethylquinoxalindioxyde), solution for infusion and external application, 5 mg/ml, single intravenous 5 mg/ml in 1 ml"
45659849|NCT05501977|Procedure|thoracotomy|thoracic surgery for pulmonary diseases
45813123|NCT02577601|Drug|Levonorgestrel (LNG)/Ethinyl estradiol birth control pill|
45813124|NCT02577991|Drug|Decadron|10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
45951364|NCT04750044|Other|delayed refeeding|In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.
45951365|NCT00126542|Biological|bevacizumab|Given IV
45951366|NCT00126542|Drug|erlotinib hydrochloride|Given orally
46077235|NCT05278273|Device|NeurotrackerX|At-home participants loaned the necessary equipment (e.g., 3D-glasses, computer equipment) from the research facilities and engaged in 10 training sessions over five weeks (2x per week). Participant recruitment, retention, adherence and experience were used as markers of feasibility. For program validation, twenty participants above 50 years old, who had previously completed at least eight sessions of the in-lab 3D-MOT program, were randomly selected as the control group.
45813125|NCT02577991|Drug|Triamcinolone|40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
45813126|NCT05024227|Behavioral|Experimental: nursing education interventions (including e-health platform assistance)|Nursing education intervention: Researchers use teaching, consultation and other methods to give individual cases planned learning to meet individual needs, providing 1. What is an environmental hormone-plasticizer; 2. Common types of environmental hormones (such as plasticizers) and Uses 3. Environmental hormones-sources of plasticizers 4. Environmental hormones-plasticizers harm to the human body 5. How to avoid the common environmental hormones-plasticizers and other related health education in life, and use the electronic platform to assist nursing education conduct.
46077236|NCT04108377|Drug|Roflumilast|Roflumilast capsule
46077237|NCT04108377|Drug|Placebo|Sugar pill manufactured to mimic look of Roflumilast capsule
46077238|NCT00950651|Drug|Tramadol HCl Contramid® Once A Day|The patients orally self-administered the study medication: either 100, 200, 300 or 400 mg Tramadol HCl Contramid® Once A Day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
46077239|NCT00950651|Drug|Tramadol HCl Twice a day|The patients orally self-administered the study medication: either 200, 300 or 400 mg Tramadol HCl Twice a day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
46077240|NCT02756520|Other|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
45453839|NCT00580216|Drug|Placebo (for idrabiotaparinux)|"Matching pre-filled syringes containing:~0.5 mL for the 3.0 mg dosage;~0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);~0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).~Subcutaneous injection"
45659850|NCT04784377|Other|high intensity laser in addition to traditional physical therapy exercises|"high intensity laser will be used with 1064 nm wavelength and maximum of 25 W power. Analgesic and biostimulant modes were used in the present study.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles."
45659851|NCT04784377|Other|low level laser in addition to traditional physical therapy exercises|"patients will receive low level Laser Therapy in addition to traditional physical therapy exercises.~diode laser device with a wavelength of 850nm, power output of 100mV, continuous wave and 0.07cm2 spot area laser will be used. The laser will be applied with a dosage of 5 joule/cm2 (totally 15-20 joule) at the most 5 painful points for 1 minute at each point over subacromial region of the shoulder.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles."
45659852|NCT04784377|Other|traditional physical therapy exercises|Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles.
45659853|NCT04541095|Other|EX_IMF|Infant formula with large amounts of beta-palmitate (about 60%).
45659854|NCT04541095|Other|ST_IMF|Infant formula with low amounts beta-palmitate (about 10%).
45659855|NCT04697719|Drug|Aspirin 81mg|81mg oral capsule
45659856|NCT04697719|Drug|Aspirin 325mg|325mg oral capsule
45659857|NCT02566759|Drug|TAK-831 Oral Suspension|TAK-831 oral suspension.
45659858|NCT02566759|Drug|TAK-831 Placebo|TAK-831 placebo-matching oral suspension.
45659859|NCT02566759|Drug|TAK-831 Tablet|TAK-831 tablet.
45813127|NCT04956133|Behavioral|Physical Activity|Participants will receive the IMPACT program, which includes a combination of aerobic, resistance, balance, and flexibility exercises conducted 1:1 and delivered online by a physical activity specialist via Zoom. The IMPACT program follows basic physical activity progression principles (i.e., principles of frequency, intensity, time, type, overload and progression). Tailoring will be used to promote fitness and wellness benefits, while ensuring safety. In addition, prominent behaviour change techniques will be provided by physical activity specialists within each 1:1 session. Discussions and worksheets will be provided, depending on participants needs.
45951367|NCT00126542|Other|laboratory biomarker analysis|Correlative studies
45951368|NCT00493324|Drug|alefacept|Intramuscular
45951369|NCT00493324|Drug|polyvalent pneumococcal vaccine|Injection
45951370|NCT01243801|Drug|Ketamine|Intravenous ketamine 0.5mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h Epidural Ketamine 0.5 mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h
45453840|NCT00580216|Drug|Placebo (for warfarin)|"Warfarin matching capsules~Oral administration"
45453841|NCT00580216|Drug|Avidin|"Vial containing 105 mg of lyophilized powder for dilution~Intravenous infusion for 30 minutes"
45453842|NCT00580216|Drug|Placebo (for avidin)|"Vial containing 105 mg of matching lyophilized powder for dissolution~Intravenous infusion for 30 minutes"
45659860|NCT05504863|Drug|Ferric carboxymaltose|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 1 were given a single dose of ferric carboxymaltose between 14 and 17 weeks of pregnancy.
45659861|NCT05504863|Drug|Iron isomaltoside|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 2 were given a single dose of iron isomaltoside between 14 and 17 weeks of pregnancy.
45659862|NCT05504863|Drug|Ferric Sulfate|As part of the RAPIDIRON Trial, maternal participants randomized to the active comparator arm were given 200 ferrous sulfate tablets immediately after randomization (~12 weeks of pregnancy). Participants were instructed to take two tablets a day, with each tablet containing 60mg elemental iron.
45659863|NCT04782349|Other|mulligan mobilization with low level laser therapy and traditional physical therapy exercises|"for mulligan mobilization: for improving the limited range of motion of shoulder joint, the therapist will apply posterolateral mobilization for the shoulder joint. Three sets of painless glides of 10 repetitions will be applied with a rest interval of 30 s between each set.~For low level laser application: Laser specifications is as follows: 850 nm wave length and pulsed application with 8 W applied for 20 minutes. laser will be applied over painful points of the shoulder.~For traditional physical therapy exercises: the patients will receive the following exercise program: self stretching exercises for shoulder joint, pully exercises, back climbing exercises, finger ladder exercises, circumduction exercises and pendulum exercises"
45951371|NCT00126620|Drug|erlotinib hydrochloride|
45951372|NCT00126620|Drug|sorafenib tosylate|
45951373|NCT01243879|Other|Stimuli of food smell and vision|60 hours of starvation (fasting) in the presence or absence of visual and odorous food cues
45951374|NCT01243879|Other|No stimuli of food smell and vision|60 hours of starvation (fasting) in the presence or absence of visual and odorous food cues
45951375|NCT01243918|Other|Oxygen therapy delivery systems|T-60 (minutes) : clinical examination, blood gas, electrocardiogram; T0 / First oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T10 : blood gas; Between T0 and T60 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T60 / Second oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T70 : blood gas; Between T60 and T120 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T120: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2
45951376|NCT00493363|Drug|Artesunate|Artesunate 2 mg/kg/day for 7 days
45951377|NCT00493363|Drug|Artesunate + Mefloquine|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
45951378|NCT00126698|Drug|trimethoprim-sulfamethoxazole|
45951379|NCT00126698|Drug|ciprofloxacin|
45951380|NCT00493402|Procedure|Transarterial chemoembolization (TACE)|drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, plus particle embolization.
45951381|NCT00493402|Procedure|Transarterial chemoembolization (TACE)|drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg.
45951382|NCT00493402|Procedure|Transarterial chemoembolization (TACE)|Drugs and dosage:chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.
45951383|NCT00145938|Drug|sildenafil|
45951384|NCT00493480|Drug|carvedilol|6.25 mg of carvedilol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubled weekly up to a maximum of 25 mg carvedilol daily.
45951385|NCT00493480|Drug|propranolol|80 mg of propranolol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubles weekly up to a maximum of 360 mg propranolol daily
45951386|NCT01243996|Drug|Ibuprofen|Treatment with high (20-10-10 mg/kg/day)or standard dose(10-5-5 mg/kg/day) ibuprofen
45951387|NCT01244074|Behavioral|biofeedback training|
45659864|NCT04782349|Other|low level laser therapy and traditional physical therapy exercises|patients in this group will receive low level laser and traditional physical exercises as described before for group (A)
45659865|NCT04782349|Other|physical therapy exercises|The patients will receive traditional physical therapy exercises only as described before for group (A)
45659866|NCT05507983|Drug|Tranexamic acid|Tranexamic acid 1500 mg
45659867|NCT05507983|Drug|Placebo|Placebo, sodium chloride 0.9%
45659868|NCT05501509|Procedure|Coracoclavicular fixation with acromioclavicular stabilization for the management of an unstable acromiclavicular luxation|Using a 3-hole third plate and high resistance sutures across the acromioclavicular joint to achieve horizontal and vertical stability of the joint
45659869|NCT05501509|Procedure|Coracoclavicular fixation for the management of an unstable acromiclavicular luxation|Isolated coracoclavicular repair using a 3 hole third plate.
45813128|NCT04847167|Procedure|Single balloon enteroscopy assisted ERCP using a mechanistic loop resolution strategy group|The SBE was introduced alternately with an overtube apparatus (ST-SB1S; Olympus Corp., Japan) following the mechanistic loop resolution strategy under endoscopic and fluoroscopic guidance. The overtube was advanced along the enteroscope, by gently pulling the enteroscope, like as ERCP accessory advancement over the guidewire.
45813129|NCT02207634|Biological|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
45951388|NCT04743960|Dietary Supplement|Time-of-day of parenteral nutrition provision|Parenteral nutrition will be provided during the nighttime followed by daytime.
45951389|NCT01244113|Drug|propofol|optimization of propofol dose from 1.5 mg/kg to 2.5 mg/kg using Dixon's up and down method during MRI scanning
45951390|NCT01244152|Behavioral|Intensive diabetes self-management education|18 group classes led by a dietitian and peer supporters, and weekly telephone calls by peer supporters. Intervention focus was on diet and physical activity.
45951391|NCT01244152|Behavioral|Enhanced standard diabetes education|2 3-hour diabetes education classes taught by a health educator at a local clinic
45951392|NCT00493519|Procedure|chocolate cake|
46077241|NCT00901147|Drug|panobinostat and bortezomib|oral panobinostat 30 mg 3 times per week AND intravenous bortezomib 1.3mg/m2 on days 1,4,8,11 per cycle
46077242|NCT02756442|Other|Respiratory disorder assessment during sleep|
46077243|NCT02756286|Other|NAT electroencephalography (EEG) test|Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
46077244|NCT04108689|Behavioral|I-ACT|An internet-based behavioral psychotherapy intervention to enhance athletic performance in elite ice hockey players.
46077245|NCT04268537|Drug|PD-1 blocking antibody+standard treatment|After randomization, PD-1 blocking antibody 200mg iv, one time. Standard treatment is according to the protocol of treatment of 2019-nCoV infection
45813130|NCT02207634|Drug|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
45813131|NCT02207634|Drug|Background Statin Therapy|Participants were required to be on a stable, high- to moderate-intensity statin background therapy consisting of an effective statin dose, ie, at least atorvastatin 20 mg daily or equivalent, and where locally approved, highly effective statin therapy (defined as at least atorvastatin 40 mg daily or equivalent) was recommended.
45813132|NCT04712383|Combination Product|Fitbit Care intervention arm|Entire suite of Fitbit Care.
45813133|NCT02484859|Drug|Remifentanil|Remifentanil infusion will be started with a bolus dose of 0.5 µg/kg before the induction, and will be continued throughout the surgery at a dose of 0.25-0.5 µg/kg/min. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
45813134|NCT02484859|Drug|Tramadol|1 mg/kg tramadol will be added to 100 ml of isotonic fluid, and will be administered intravenously in exactly 30 minutes via a perfusor. The infusion will be started just before the induction.
46002676|NCT04637178|Behavioral|Resistance training|Resistance training sessions twice a week for ten weeks
46002677|NCT04637178|Behavioral|Endurance training (habitual)|Endurance training for ten weeks (habitual routines)
46077246|NCT04268537|Drug|Thymosin+standard treatment|Thymosin 1.6 mg sc qd, last for 5 days. Standard treatment is according to the protocol of treatment of 2019-nCoV infection
45813135|NCT02484859|Drug|Metoprolol|0.1 mg/kg of metoprolol will be administered intravenously within 5 minutes following the administration of neuromuscular blocking agent.
45659870|NCT05501431|Device|Verily Study Watch|The Verily Study Watch is a smartwatch, collecting physiological and/or environmental information. The sensors collect data that include movement and activity, pulse rate, skin impedance, electrocardiogram (ECG), environmental temperature, and ambient light level.
45951393|NCT02957981|Behavioral|Web-based Counseling|The web-based genetic counseling and education intervention will include standard information typically provided in individual genetic counseling. the intervention will be individually tailored based upon key clinical and demographic characteristics of the participant.
45951394|NCT02957981|Behavioral|Standard Care|Standard care includes access to resource list for men from hereditary cancer families plus access to standard clinical genetic counseling
46077247|NCT04268537|Other|standard treatment|Standard treatment is according to the protocol of treatment of 2019-nCoV infection
46077248|NCT02756130|Drug|Birinapant|Given IV
46077249|NCT02756130|Drug|Carboplatin|Given IV
46077250|NCT02756130|Other|Laboratory Biomarker Analysis|Correlative studies
46077251|NCT02756130|Other|Pharmacological Study|Correlative studies
45659871|NCT05490355|Procedure|Radiofrequency Ablation (RFA)|RFA involves heating of periarticular nerves using continuous RFA (80-90C for 60-90 seconds) that results in electromodulation and denervation reducing pain. It can be done under fluoroscopy or CT guidance. CT guidance has additional benefit of better localization of the nerves, as opposed to simple bony landmarks used in fluoroscopy, since nerve branching variations are common and will be used in this study.
45659872|NCT05490355|Procedure|Perineural Steroid Injection|Perineural Steroid Injections involve CT guided injection of Local Anesthetic and Steroid into a nerve root of the spine to provide ongoing pain relief.
45659873|NCT05501275|Behavioral|psychotherapy|Psychotherapy and psychoeducation in patients after stroke.
45659874|NCT05328037|Diagnostic Test|Blood sample collection|Blood sample collection for dosage of vitamin C
45659875|NCT05504785|Device|DexCom G6 continuous glucose monitor|Use of real-time DexCom G6 continuous glucose monitor (CGM or glucose sensor) trend data and an insulin-dosing algorithm to control the glucose levels of diabetic patients undergoing hip/knee orthopedic surgery at Thomas Jefferson University Hospital (TJUH).
45659876|NCT05504629|Behavioral|Concurrent training order 1|atag
45659877|NCT05504629|Behavioral|RT+ET|aetaer
45813136|NCT02485561|Behavioral|Health communication intervention|This study will compare the effects of adding narratives that describe personal experiences with colon cancer screening to educational information alone to explore potential differences in reactions to different role models on individuals' screening intentions and behaviors.
45813137|NCT02485561|Behavioral|Education information|Educational materials such as those from the Centers for Disease Control and Prevention are used to present educational information to participants about colon cancer and screening tests.
45813138|NCT00364039|Drug|AV650|
45951395|NCT00493558|Device|Trabecular Metal Intervertebral Cage with RSA beads|Roentgen Stereophotogrammetric Analysis beads will be inserted at time of implant of the Trabecular Metal Intervertebral Cage.
45951396|NCT04741230|Device|Gebauer Lenticule|The Gebauer™ Lenticule corneal implant device is a custom-made device intended for patients suffering from keratoconus or post-LASIK ectasia. The device is expected to reinforce and stabilize the patient's cornea, so that a more consistent refraction is induced and a penetrating human cornea donor transplantation may be avoided or postponed.
45951397|NCT00493675|Procedure|endoscopic bile duct stenting|
45951398|NCT00493714|Behavioral|Questionnaire|Surveys lasting 30 minutes or more.
46077252|NCT05598723|Drug|IncobotulinumtoxinA (XEOMIN®)|IncobotulinumtoxinA (XEOMIN®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.
46077253|NCT05598723|Drug|OnabotulinumtoxinA (BOTOX®)|OnabotulinumtoxinA (BOTOX®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.
46077254|NCT00605293|Drug|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms iv/month (starting dose)
46077255|NCT00605293|Drug|Epoetin alfa|As prescribed
46077256|NCT02855177|Drug|Placebo|Placebo as suspension administered every 8 hours, with food
46077257|NCT02855177|Drug|PF-06427878|500 mg suspension administered every 8 hours, with food
46077258|NCT00635466|Procedure|laparoscopic surgery for rectal carcinoma|Laparoscopic resection of the rectum with adequate lymphadenectomy is performed according to the General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus edited by the Japanese Society for Cancer of the Colon and Rectum. The extent of lymphadenectomy and site of ligation and division of the inferior mesenteric vessels were decided by the surgeon in charge. Pneumoperitoneal approaches are used to explore the abdomen, mobilize the left side colon, identify critical structures and ligate the vascular pedicle. Mobilization of the rectum, excision of the mesorectum, rectal transection, removal of the specimen, and reconstruction are performed by the pneumoperitoneal approach or the extracorporeal approach via a small incision (<8 cm).
45951399|NCT00126854|Procedure|Magnetic Resonance Spectroscopy Imaging|
46077259|NCT04107987|Dietary Supplement|Reglicem|Reglicem is a nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate
46077260|NCT04107987|Other|Placebo|Placebo
45813139|NCT02486263|Other|Study Arm - acid suppression plus feeding bundle|"Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)~Total fluid volume restriction (120-140 milliliters/kilogram/day)~Feeding duration over 30 minutes~Infant feeds with right side down~Infant is placed on back following feeds"
45951400|NCT00493753|Procedure|Acupuncture|
45659878|NCT05501197|Other|Exercise Therapy via video conference|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch"
45951401|NCT00493909|Procedure|intrathecal opioids and thoracic paravertebral analgesia|
45951402|NCT00493909|Procedure|thoracic epidural analgesia|
45951403|NCT00405249|Drug|elvucitabine|
45951404|NCT00493948|Device|ApneaLink|A two channel sleep screening device for the assessment of Sleep Disordered Breathing.
45951405|NCT00493987|Drug|Testosterone Enanthate|testosterone ester
45951406|NCT00493987|Drug|Dutasteride|5 alpha-reductase inhibitor
45951407|NCT00126893|Drug|CC-401|
45951408|NCT00494065|Other|Home exercise|Patient education will be provided by trained therapists under the supervision of licensed chiropractic clinicians. Patients will attend four, 1 hour, one-on-one sessions.
45951409|NCT00494065|Other|Chiropractic Spinal Manipulative Therapy + Home exercise|The number and frequency of treatments will be determined by the individual chiropractor, based on patient-rated symptoms, disability, palpation, and pain provocation tests. Up to 20 treatments will be provided over the 12 week treatment period, each treatment visit lasting from 10-20 minutes. Treatment will include manual spinal manipulation and mobilization.
45951410|NCT00494104|Dietary Supplement|Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day|Infants receive daily 0.5 ml of code labeled supplement
45951411|NCT00405366|Drug|sorafenib tosylate|Patients will receive treatment with 400mg of sorafenib, orally, twice daily, on a continuous basis as a single agent for at least 4 weeks, but not more than 8 weeks prior to their scheduled nephrectomy
45951412|NCT00494260|Behavioral|Social Learning and Cognitive Behavioral Therapy (SLCBT)|The SLCBT condition consists of 3 main components: 1.) relaxation training, 2.) working with parent and child to modify family responses to illness and wellness behaviors, and 3.) cognitive restructuring to address and alter dysfunctional cognitions regarding symptoms and their implications for functioning through cognitive therapy techniques
45951413|NCT00494260|Behavioral|Education Support (ES)|The ES condition focuses on education about GI system anatomy and function, information about the United States Department of Agriculture nutrition guidelines, and additional food-related information such as how to read food product labels. The ES condition was developed to provide a credible alternative condition that would control for therapist and patient time and attention.
45951414|NCT00494338|Drug|Docetaxel|
45951415|NCT00126932|Device|SonoPrep|
45951416|NCT00494377|Drug|duloxetine|
45951417|NCT00494416|Other|delivery approaches of malaria intermittent preventive treatment in pregnancy|"Health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.~Joint with advanced strategies delivery approach (JAS). In addition to passive delivery at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs)."
45951418|NCT00146016|Drug|Amantadine|
45951419|NCT00494455|Device|continuous subcutaneous glucose monitoring|continuous subcutaneous glucose monitoring for 72h
45951420|NCT00494455|Device|continuous subcutaneous glucose monitoring|continuous subcutaneous glucose monitoring for 72h
45951421|NCT00126971|Drug|chlorproguanil-dapsone|
45951422|NCT01244230|Drug|fexofenadine/Allegra (M016455)|"Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral"
45951423|NCT01244269|Drug|Methylphenidate|Methylphenidate 10mg tablets will be overencapsulated in gelatin capsules for blinding. Subjects will take 1 capsule three times daily for a total of 7 doses.
45951424|NCT01244269|Drug|Methylphenidate|Methylphenidate 20mg three times daily for a total of 7 doses.
45951425|NCT01244269|Drug|Placebo 10|Blind gelatin capsule three times daily for a total of 7 doses.
45951426|NCT01244269|Drug|Placebo 20|Blind gelatin capsule three times daily for a total of 7 doses
45951427|NCT02958189|Behavioral|Tweet4Wellness|A daily, behavior change theory-based intervention message is sent to a private, 25-person online Twitter-support group to prompt peer-to-peer discussion. Participants receive individual text messages to encourage group participation (e.g. 'thank you for participating' or 'please participate tomorrow'). Participants also receive weekly individual messages giving them daily step goals for the week based on their previous week's daily step average, recorded from Fitbit.
46002678|NCT00546845|Device|Balloon angioplasty|Balloon angioplasty. Only stent if PTA fails
45659879|NCT05501197|Other|Exercise Therapy via mobile application|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch"
45813140|NCT02486263|Other|Conventional arm - acid suppression only|-Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)
45813141|NCT00422149|Drug|SUBLIVAC® Grasses/Placebo treatment|SUBLIVAC® Grasses/Placebo treatment
45813142|NCT00422149|Drug|SUBLIVAC® Grasses treatment|SUBLIVAC® Grasses treatment
45813143|NCT00422149|Drug|Placebo treatment|Placebo treatment
45813144|NCT03452228|Drug|evinacumab|Administered by Intravenous (IV)
45813145|NCT03452228|Drug|Placebo|Administered by Intravenous (IV)
45813146|NCT02974231|Radiation|Intensity-modulated radiation therapy|
45813147|NCT04341727|Drug|Hydroxychloroquine Sulfate|anti-rheumatic drug (DMARD)
45951428|NCT02958189|Behavioral|Self-monitoring|A Fitbit is provided to the group which tracks participants' daily steps.
45951429|NCT00127010|Biological|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
46077261|NCT04017637|Behavioral|Resistance Training|Static resistance training including two arm and two leg movements will be performed twice per week for 12 weeks.
46077262|NCT04221126|Device|TMFI|Tixel rapidly transfer thermal energy by a metallic pyramid tip that enable skin contact through integrated pulsed movements. The rapid heating dehydrates he epidermis and superficial dermis and creates micropores with no coagulative damage of surronding tissue.
46077263|NCT04221126|Drug|ALA cream|ALA compounded in a cream
45453843|NCT01209247|Other|Nasal, rectal and pharyngeal swabs|Nasal, rectal and pharyngeal swabs were performed before, during, and one month after the end of FQ treatment.
45813148|NCT04341727|Drug|Azithromycin|Antibiotic
45813149|NCT04341727|Drug|Chloroquine Sulfate|Antimalarial
46077264|NCT04221126|Drug|ALA gel|ALA compounded in a gel
45659880|NCT05504473|Device|NEURO-BLINK Device|The NEURO-BLINK is a class IIa medical device that intends to restore the blink function in patients with facial palsy through the application of transcutaneous electrical stimulation.
45659881|NCT05504317|Drug|AK111|Subjects will receive one of four escalated doses of AK111 (75mg/150mg/300mg/450mg) injection subcutaneously.
45659882|NCT05504317|Drug|Placebo|Subjects will receive corresponding dose of placebo injection subcutaneously.
46077265|NCT04035655|Behavioral|Coma Recovery Scale - revised|"Assessment of the level of consciousness by the dedicated Coma Recovery Scale - Revised, current gold-standard in consciousness level assessment.~Assessment before and after the tDCS session (immediately before and after the electrophysiological assessment, see below)."
45453844|NCT01109251|Procedure|Auto-measure of the tension by an autotensiometer|"All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.~The auto-measures will be performed according the methodology recommended by HAS."
45659883|NCT05504239|Drug|Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet|To be orally administered once daily
45659884|NCT05504239|Drug|Teneligliptin Placebo Oral Tablet|To be orally administered once daily
45659885|NCT04587661|Behavioral|off-the-shelf digital CBT|Cognitive behavioral therapy for depression and anxiety
45659886|NCT04587661|Behavioral|adapted digital CBT|Cognitive behavioral therapy for depression and anxiety for individuals from a minority group with SCD
45951430|NCT00494533|Drug|Remodulin (treprostinil sodium)|
45951431|NCT00494572|Drug|Montelukast|10 mg rapid dissolving granule in sterile water orally once
45951432|NCT00494572|Other|sterile water|sterile water
45951433|NCT00494611|Drug|Peri operative Cetuximab.|Cetuximab will be given immediately preoperative and early post surgery period.
45951434|NCT00146055|Procedure|Reduced intensity conditioning with allogeneic transplant|
46077266|NCT04035655|Diagnostic Test|Electrophysiological recordings|"The electrophysiological assessment consisted of:~a 5 minutes resting state high-density EEG recording~a approximately 6 minutes auditory oddball paradigm These two procedures were administered immediately before and after the tDCS session"
45659887|NCT04578925|Behavioral|Happy, Healthy, Loved|A text message based, mobile-device delivered intervention that provides educational information to primiparous mothers and their partners about breast-feeding and coping with stress.
45659888|NCT05282797|Drug|ANEB-001|Experimental Treatment
45659889|NCT05282797|Drug|Placebo|Placebo comparator
45813150|NCT04320901|Device|Ligasure|Ligasure™ Maryland Jaw Laparoscopic Sealer/Divider 37cm
45813151|NCT04320901|Device|Harmonic|Harmonic ACE 7+
45813152|NCT04272385|Other|Observational|Observational
45813153|NCT04247737|Other|gluten free diet|Participants keep a gluten free diet for six weeks
45951435|NCT00494650|Behavioral|Cognitive behavioral therapy (CBT)|CBT will include 12 to 16 counseling sessions, occurring weekly or every other week. Participants will learn about PTSD and ways to decrease anxiety associated with PTSD by completing homework assignments and practicing skills learned in counseling sessions.
45951436|NCT00494650|Behavioral|Brief PTSD treatment|Brief PTSD treatment will include three weekly meetings with a therapist. Participants will learn about PTSD, how symptoms may be affecting their lives, and a technique for reducing anxiety associated with PTSD.
45951437|NCT00127049|Drug|gemcitabine, ifosfamide, cisplatin, G-CSF|
46002679|NCT00546845|Device|Use of self-expanding Expert stent|Nitinol stent
45813154|NCT03437018|Other|moderate diabetic retinopathy follow-up by tele-expertise|"Consultation by an orthoptist to measure visual acuity, eye tone by pulsed air tonometer, and retinography images after pupillary dilatation (9 photographs: one of the posterior pole and 8 of the peripheral retina) and optical coherence tomography (OCT).~The results are immediately evaluated on site by an ophthalmologist. The results are sent through a secure online medical application to a diabetic retinopathy specialist ophthalmologist for evaluation."
45676533|NCT02368041|Device|InSpectraTM StO2 monitor|InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
45813155|NCT04244227|Device|Empower Neuromodulation System|Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
45813156|NCT04340102|Behavioral|BecomeAnEx|This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
45813157|NCT05587478|Drug|EDP-323|Oral administration
45813158|NCT05587478|Drug|Placebo|Placebo to match EDP-323, oral administration
45951438|NCT04737681|Other|body composition|This is an observational study to determine immune response and skin barrier restoration in individuals with and without obesity.
45951439|NCT00494767|Drug|GW869682|GW869682 tablet with a dose strength of 250 mg will be available for subjects
45813159|NCT03494660|Device|Subchondroplasty Procedure with AccuFill|Injection of the commercially available flowable calcium phosphate (CaP) synthetic bone-void filler, AccuFill®, into subchondral bone defects in the hip (Subchondroplasty (SCP) Procedure).
45951440|NCT00494767|Drug|GSK189075|GSK189075 tablet with a dose strength of 250 mg will be available for subjects
45951441|NCT00494767|Drug|GSK189075-Placebo|Placebo tablets to match GSK189075 250 mg will be available for subjects
45813160|NCT00367094|Drug|Benazepril plus hydrochlorothiazide|
45951442|NCT00494767|Drug|GW869682-Placebo|Placebo tablets to match GW869682 250 mg will be available for subjects
45951443|NCT00494845|Behavioral|Mindfulness|8-week mindfulness program will be compared to an education control group.
45951444|NCT00494845|Behavioral|Control: Health Education Class|8-week education program
45951445|NCT00494884|Drug|vildagliptin|
46077267|NCT05594589|Drug|Lemborexant|Lemborexant oral tablet.
45951446|NCT00127088|Drug|docetaxel|
45951447|NCT00127088|Procedure|laparoscopic radical prostatectomy|
45951448|NCT00146094|Procedure|BMD Measurement|
45951449|NCT00494962|Drug|lecozotan SR|
45813161|NCT02581111|Drug|Naloxone|Naloxone 8-mg IV bolus
45813162|NCT02581111|Drug|Normal saline|
45813163|NCT05587400|Behavioral|passive leg raising|transfer a patient from semi-recumbent position to supine position with a 45° leg lifting
45813164|NCT05587400|Drug|dobutamine test|infusion dobutamine
45813165|NCT05587400|Drug|inhaled nitric oxide|nitric oxide inhalation
45951450|NCT01244464|Biological|IMOVAX Polio™-Inactivated types 1, 2, and 3 poliovirus D vaccine|0.5 mL, at 2, 3, and 4 months; Intramuscular
45951451|NCT00127244|Procedure|Periodontal Treatment|
45951452|NCT01244542|Other|unpleasant stimuli|
46077268|NCT05594589|Other|PBO|Lemborexant-matched PBO tablet.
45951453|NCT02957877|Drug|Nadroparin|A nadroparin infusion regimen (loading dose of 35 IU/kg, followed by 10 IU/kg per hour for 6 hours) is administered as anticoagulation during the 8-hour hemodialysis.
45951454|NCT02957877|Drug|Unfractionated heparin|The individualized unfractionated heparin infusion regimen currently employed by the recruited patients in their home dialysis treatment is administered as anticoagulation during the 8-hour hemodialysis.
45951455|NCT04748874|Procedure|Immediate mNC-FET|In the immediate arm, patients undergo mNC-FET in the menstrual cycle immediately following oocyte retrieval and failed fresh embryo transfer or freeze-all.
45951456|NCT01244581|Drug|Amoxicillin-clavulanate|Amoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days
46077269|NCT02756052|Device|Anodal Transcranial direct-current stimulation|NeuroConn Direct-Current Stimulator. Anodal tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
46077270|NCT02756052|Device|Sham Transcranial direct-current stimulation|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
45453845|NCT01109251|Procedure|Auto-measure of the tension by an autotensiometer|"All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.~The auto-measures will be performed according the methodology recommended by HAS."
45951457|NCT01244581|Drug|Placebo|Placebo mixture in two daily doses for 7 days
45951458|NCT01244659|Drug|Tacrolimus from EMS|Tacrolimus initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
45951459|NCT01244659|Drug|Prograf|Prograf initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
46002680|NCT00546923|Drug|Venlafaxine XR|
46002681|NCT00560196|Other|Observation|
45951460|NCT01244698|Drug|Cefadroxil discontinued early|All patients will receive 24 hours of IV Cefazolin (1g IV every 8 hr), as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics. Clindamycin IV 600mg every 6 hours for 24 hours will be used in penicillin allergic patients.
45951461|NCT01244698|Drug|Cefadroxil until drain removal|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil (500mg 2 times a day) until the final drain is removed. This is the normal postoperative regimen. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin 600mg IV every 6 hours for 24 hours followed by clindamycin 300mg IV every 6 hours.
45951462|NCT00127283|Drug|eptacog alfa (activated)|
45951463|NCT00495118|Drug|risperidone|
45659890|NCT04651699|Device|Active Transcranial Direct Current Stimulation|The Starstim tDCS® stimulator will be used by an experienced physical therapist to transfer direct current by a saline-soak pair of surface sponge electrodes (35cm2). The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1 (32). Regarding the stimulated hemisphere, contralateral M1 will be stimulated in patients with asymmetric pain and the dominant (contrary to the dominant hand determined by the Edinburgh Handedness Inventory) in patients with symmetric pain, due to the widespread changes induced by tDCS in other cortical areas, including contralateral M1. A constant current of 2 milli amps intensity (subthreshold intensity) will be applied for 20 min, with 30 seconds of ramp-up and 30 seconds of ramp-down.
45951464|NCT01244737|Drug|[18F] FLT|[18F] FLT, intravenous, at a dose of 0.15 mCi/kg once before a PET scan
45951465|NCT00146133|Behavioral|diet, exercise|
45951466|NCT00495196|Procedure|Experimental lung function test|Administration of several CO2 gas mixtures
45659891|NCT04651699|Device|Sham Transcranial Direct Current Stimulation|The electrodes will be placed in the same positions as for M1 stimulation, but only applying ramping active current for 30 seconds in the beginning and at the end of the procedure for a reliable blinding.
45659892|NCT02335983|Drug|Carfilzomib|Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
45813166|NCT05587244|Device|Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners|Primary and/or Revision total hip arthroplasty with the G7 Freedom Constrained Vivacit-E Liners
45951467|NCT00495235|Behavioral|Questionnaire|Questionnaire taking about 20 minutes to complete.
45813167|NCT04339868|Drug|Terlipressin|Terlipressin (20-100 mcg/hr) plus norepinephrine and/or epinephrine
45951468|NCT00495274|Drug|Formulation A|Formulation A represents the original formulation. SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing micronized drug substance. Formulation A will be administered in Part A.
45813168|NCT04339868|Drug|Placebo|0.9% NaCl plus norepinephrine and/or epinephrine
45813169|NCT00367172|Behavioral|Directly Administered Antiretroviral Therapy|
45813170|NCT05585216|Drug|platelet-rich plasma|intra-articular combination injections of platelet-rich plasma and hyaluronic acid or intra-articular combination injections of PRP combined with leg swing and quadriceps strengthening exercise
45813171|NCT03334526|Other|physical training|workout on treadmill requiring the muscles of the lower limbs mostly in concentric (ascent) or eccentric (downhill)
45813172|NCT03334526|Other|mental training|The task to imagine for the training group will be an abduction of the thumb
45813173|NCT03334526|Other|electrical stimulation|electrical stimulation of the muscles
45813174|NCT03316196|Behavioral|COGENT COGNITIVE TRAINING|Computer-administered cognitive training program. COGENT is a modified working memory capacity task designed to train cognitive functioning. COGENT was designed to contain high interference across trials. By requiring repeated practice with utilization of interference control across trials, COGENT is thought to enhance plasticity of cognitive systems and improve performance. That is, training is based on the premise that learning-based neural changes will occur via repeated exposure to a task demanding cognitive control resources
45951469|NCT00495274|Drug|Formulation B|Formulation B will represent SB-649868 10 mg film coated tablet containing micronized drug substance (3 tablets to reach 30 mg), but contains additional surfactant. Formulation B will be administered in Part A.
45951470|NCT00495274|Drug|Formulation C|Formulation C will represent SB-649868 10 mg lipophilic capsule (3 capsules to reach 30 mg). Formulation C will be administered in Part A.
45951471|NCT00495274|Drug|Formulation D|Formulation D will represent SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing nanomilled and spray dried powder. Formulation D will be administered in Part A.
45951472|NCT00495274|Drug|Formulation E|Formulation E will represent SB-649868 10 mg capsule (3 capsules to reach 30 mg), containing nanomilled and spray dried powder. Formulation E will be administered in Part A.
45951473|NCT00495274|Drug|Formulation F|Formulation F will represent SB-649868 15 mg liquid filled capsule (2 capsules to reach 30 mg). Formulation F will be administered in Part A.
45951474|NCT00495274|Drug|Formulation G|Formulation G will be the selected formulation of SB-649868 30 mg to be assessed in Part B. The formulation will be administered after a standard FDA High-Fat breakfast
45951475|NCT00495313|Drug|doxycycline|COL-101, QD plus metronidazole
45951476|NCT00495313|Drug|doxycycline|40 mg with metronidazole QD
45951477|NCT01244776|Device|acellular corneal matrix|Efficacy of acellular corneal matrix to restore stroma integrity and treat corneal ulcer after lamellar keratoplasty.
45951478|NCT00495352|Drug|Hihg-doseNRT, Low-dose NRT, bupropion|
46077271|NCT04035733|Drug|rVA576|BP subjects will be treated with 30 mg once daily rVA576 regime for 6 weeks.
46077272|NCT02855021|Other|Explorations|"Imaging tests and neuropsychological assessment are carried out within 60 days following patient enrollment.~Neuropsychological assessment lasts 1:30 to 2:00 hours and is conducted by a psychologist in an interview during which patient will pass several tests on memory, language, attention or orientation in space.~These tests do not require discontinuation of Parkinson's disease treatment."
46077273|NCT00896623|Genetic|mutation analysis|
45813175|NCT03316196|Behavioral|Non training computer condition|The non-training condition requires participants to complete a similar computer task for the same length of time. The non-training is a modified working memory capacity task designed to be inert. The non-training condition was designed to contain relatively less interference demands across trials. Participants are required to remember the same total number of items as in COGENT (i.e., storage requirements were equivalent), but the task contains relatively less interference inherent in the task.
46077274|NCT00896623|Genetic|polymorphism analysis|
46077275|NCT00896623|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
46077276|NCT02755740|Other|receiving age and gender-specific SC advice|"After delivering the AWARD advice, the trained SCRA will seek consent from and refer adult female smokers (aged over 25 years) to our intensive smoking cessation telephone or face-to-face counselling interventions, which has already counselled 509 female smokers with a quit rate of 29.7% at 6-month and 26.7% at 3-year follow up. Female youth smokers will give consent and be referred to our Youth Quitline (5111 4333), a smoking cessation telephone counselling for young people aged 25 or below which has counselled 1257 smokers with a quit rate of 21.9% at 6 months. If necessary, the female smokers can be referred to other smoking cessation services (e.g., the integrated smoking cessation hotline by the Department of Health (1833-183)."
46077277|NCT00602303|Drug|Torsemide|
46077278|NCT02759250|Drug|ARGX-110|
45813176|NCT00367250|Drug|Cetuximab|weekly i.v.
45813177|NCT00367250|Drug|Trastuzumab|weekly i.v.
45951479|NCT00495547|Drug|Azacitidine|Azacitidine
45813178|NCT02489227|Drug|CHS-1420|
45813179|NCT02489227|Drug|Adalimumab|
45951480|NCT00495547|Drug|Beta Erythropoietin|Beta Erythropoietin
45951481|NCT00127361|Behavioral|doula training|
45659893|NCT02335983|Drug|Lenalidomide|Administered orally once daily on days 1-21 of each 28-day cycle.
45659894|NCT02335983|Drug|Dexamethasone|Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.
45659895|NCT04640311|Drug|Daprodustat|Daprodustat will be available as oral tablets.
45659896|NCT05274529|Behavioral|Psychological health and flexibility|A remote coaching programme concentrating on psychological health and flexibility
45951482|NCT00495664|Device|Titan stent and Taxus-Liberte stent|
46077279|NCT00896701|Other|flow cytometry|
46077280|NCT00896701|Other|immunologic technique|
45659897|NCT05274529|Behavioral|Work ability|A remote coaching programme concentrating on work ability
45659898|NCT05274529|Behavioral|Sleep and recovery|A remote coaching programme concentrating on sleep and recovery
45659899|NCT05274529|Behavioral|Healthy lifestyle|A remote coaching programme concentrating on healthy lifestyle
45951483|NCT00495703|Behavioral|Exercise|6-months of regular aerobic exercise
45951484|NCT00495703|Behavioral|Usual Care|6-months of behavioral strategies to aid memory/cognition
45951485|NCT00495781|Procedure|%-hypo (laboratory parameter, functional iron deficiency)|
45951486|NCT00495781|Procedure|CHr (laboratory parameter, functional iron deficiency)|
45951487|NCT00495781|Procedure|RET-HE (laboratory parameter, functional iron deficiency)|
45951488|NCT00495859|Dietary Supplement|Immunonutrition|food for special medical purpose (FSMP)
45951489|NCT00495859|Dietary Supplement|food for special medical purposes (FSMP)|an isocaloric isonitrogenous non-specific nutritional support
45951490|NCT00127400|Behavioral|anger management therapy|
45951491|NCT00405405|Drug|Cisplatin|"Two cycles during neoadjuvant therapy~Response assessment at approximately day 36~Concurrent biochemoradiotherapy"
45951492|NCT00405405|Drug|Docetaxel|"Two cycles during neoadjuvant therapy~Response assessment at approximately day 36~Concurrent biochemoradiotherapy"
45951493|NCT00405405|Drug|Bevacizumab|"Two cycles during neoadjuvant therapy~Response assessment at approximately day 36~Concurrent biochemoradiotherapy"
46077281|NCT00896701|Other|laboratory biomarker analysis|
45951494|NCT00405405|Drug|Erlotinib|"Two cycles during neoadjuvant therapy (dose escalation)~Response assessment at approximately day 36~Concurrent biochemoradiotherapy"
45951495|NCT00405405|Radiation|Radiotherapy|Radiotherapy begins as soon as possible following neoadjuvant chemotherapy, and continues for 7 weeks
46077282|NCT04268225|Procedure|US guided dynamic needle tip positioning peripheral intravenous cannulation|Catheterizations will be performed by one of three pediatric intensivists with vast experience in both traditional and US guided DNTP techniques for peripheral intravenous access. The operator will be allowed to independently choose which peripheral vein to cannulate. If necessary, patients will be given supplemental dose of sedation and analgesia in addition to the already given continuous infusions for invasive mechanical ventilation. Before puncture, the limb will be taped and maintained in an optimal position. A tourniquet will be placed proximal to the planned cannulation site. The site of puncture will be disinfected with Chlorhexidine gluconate 0.5% w/v, Alcohol 70% v/v. The choice of catheter will be left to the discretion of the operator. Available PIV cannulas include : 14 GA, 2X45 mm; 17 GA, 1.4X45 mm; 18 GA 1.2X45 mm; 20 GA 1X32mm BD Venflon™ and 24 GA, 0.7X19 mm; 26 GA 0.6X19 mm BD Neoflon™ (Becton Dickinson Infusion Therapy AB, Helsingborg, Sweden).
46077283|NCT04268225|Procedure|Traditional peripheral intravenous cannulation|For traditional insertion technique insertion attempt will be blind or tactile.
46077284|NCT04107831|Other|Pulmonary rehabilitation|Pre-post test design
46077285|NCT04220346|Other|Tablet group|Children in the Tablet group started to play the game with Tablet about 5-10 minutes before circumcision, and continued to play the game during the whole procedure.
45813180|NCT02490631|Drug|2% chlorhexidine gluconate cloths|Cleansing twice pre-operatively jawline to toes with 2% chlorhexidine gluconate cloths
46077286|NCT02540863|Other|myofascial release protocol and Rocabado exercise therapy|
46077287|NCT02540863|Other|exercise therapy|
45813181|NCT02207556|Drug|Doxycycline|"Doxycycline will be continued until one of the following criteria is met:~Patient has completed 1 year of doxycycline therapy~Patient develops any grade 3-4 toxicity related to doxycycline use."
46077288|NCT04269395|Drug|MAL Cream|No intervention will be administered as a part of this study. Participants who received MAL cream in RD.06.SPR.112199 study will be rolled over in the study.
46077289|NCT04269395|Drug|Vehicle cream|No intervention will be administered as a part of this study. Participants who received vehicle cream in RD.06.SPR.112199 study and achieved complete response, will be rolled over in the study.
45813182|NCT03732638|Drug|Rimegepant|Rimegepant 75 mg tablet EOD
45813183|NCT03732638|Drug|Placebo|Placebo tablet to match rimegepant tablet EOD
45813184|NCT02572609|Drug|Ambroxol hydrochloride soft pastille|
45813185|NCT02572609|Drug|Mucosolvan ® adult syrup|
45813186|NCT02587117|Drug|lycopene|Each capsule contain 2 mg lycopene. Each patient was received two capsules of lycopene (total dose was 4 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
45813187|NCT02587117|Drug|Prednisolone|Each capsule contain 20 mg prednisolone. Each patient was received two capsules of prednisolone (total dose was 40 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
45813188|NCT03266588|Drug|Rimegepant|75 mg oral tablet
45813189|NCT02587351|Drug|Metoprolol succinate|Extended release Metoprolol succinate
45659900|NCT05274529|Other|No coaching|Participants also have the option to choose no coaching for the coming 3 month period.
45813190|NCT02587351|Other|Placebo|Matching placebo
45813191|NCT00364117|Behavioral|Timely Discharge (Remote Presence Technology)|
45813192|NCT05553314|Drug|Carvedilol|patients randomized to carvedilol group will receive carvedilol-SR.
45659901|NCT05264623|Device|TENEO 317 Model 2 excimer laser|TENEO 317 Model 2 excimer laser use for refractive surgery
45659902|NCT04578691|Device|"Anatase Spine Surgery Navigation System"|using navigation system in pedicle screw placement in spine surgery
45659903|NCT04578691|Device|Medtronic Stealthstation S7 Treatment Guidance System|using navigation system in pedicle screw placement in spine surgery
45659904|NCT02334423|Biological|Botulinum toxin, Type A|Botulinum toxin, Type A
45659905|NCT02334423|Other|0.9% sterile, unpreserved saline|Placebo
45659906|NCT02310789|Drug|Ivacaftor|150mg administered orally twice daily.
45813193|NCT05553314|Drug|Placebo|patients randomized to placebo group will receive placebo.
45659907|NCT02310789|Drug|β-Adrenergic cocktail|Administered subcutaneously to induce sweating. Cocktail composed of atropine (280µM), isoproterenol (160µM), and aminophylline (20 mM).
45659908|NCT02310789|Drug|Pilocarpine Nitrate 5%|Administered subcutaneously using Macroduct sweat stimulator device.
45951496|NCT00495898|Device|CYPHER sirolimus-eluting stent|drug-eluting stent
45951497|NCT00495898|Device|uncoated Bx VELOCITY balloon-expandable stent|bare metal stent
45951498|NCT00495976|Other|A commercially produced cordial drink|
45951499|NCT00496093|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|
45951500|NCT00127478|Drug|Atrasentan|
45951501|NCT04667715|Device|Exablate BBBD|Blood brain barrier disruption using ExAblate Type 2 device using microbubble resonators
46077290|NCT02759172|Behavioral|Safety Planning Intervention|Brown and Stanley's Safety Planning Intervention (SPI) is a brief, adjunctive intervention designed to reduce subsequent suicidal behavior in high-risk populations. The core element of SPI is the collaborative development of the Safety Plan, which is a prioritized written list of coping strategies and supports that individuals can use during or preceding suicidal crises. In this study, safety planning will occur during pretrial jail detention, with telephone follow-up in the community to conduct risk assessment, review the Safety Plan, problem-solve obstacles to treatment, and assist with linkage to services.
45659909|NCT02310789|Device|Macroduct sweat stimulator|
45659910|NCT02372253|Drug|Verapamil|
45813194|NCT05249491|Diagnostic Test|Microbiological evaluation of dental plaques with children with or without black tooth stain|Evaluation of the etiological factors of black tooth stain according to the questionnaire
45453846|NCT03944239|Biological|Retinal pigment epitheliums transplantation|Subretinal transplantation of clinical human embryonic stem cell derived retinal pigment epitheliums.
45813195|NCT05538338|Other|Platelet Rich Plasma Intrauterine infusion|an intrauterine infusion of platelet rich plasma (PRP) will be administered to this group of participants
45453847|NCT03944083|Other|Treatment as usual for ADHD|Children are given treatment according to diagnostic conclusion and clinical recommendations.
45813196|NCT05538338|Other|Normal saline Intrauterine infusion|an intrauterine infusion of normal saline will be administered to this group of participants
45951502|NCT00127517|Drug|peptide-nucleic acid solution AVR118|
46077291|NCT02751606|Drug|ferumoxtran-10|ferumoxtran-10 will be administered intravenously one day prior to the MRI scan
46077292|NCT02751606|Device|7 Tesla MRI|Subjects undergo a 7 Tesla MRI scan
45453848|NCT01109329|Biological|HMPV challenge virus|Single dose of 10^6 plaque forming units (PFU) of recombinant HMPV small hydrophobic genes (rHMPV-SHs)
45453849|NCT01107145|Drug|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
45813197|NCT05249413|Procedure|Early 23-gauge pars-plana vitrectomy|pars-plana vitrectomy for management of acute post-operative endophthalmitis.
45813198|NCT03260504|Biological|Aldesleukin|Given SC or IV
46077293|NCT02751606|Device|3 Tesla MRI|Subjects undergo a 3 Tesla MRI scan
46077294|NCT00631085|Drug|gamma tocopherol|Maxi Gamma softgels 1200mg QD
46077295|NCT00572533|Other|ESA Dose Adjustment per standard Anemia Management Protocol|Amount of ESA dose adjustment in Units per week guided by standard Anemia Management Protocol in use at the facility
46077296|NCT00572533|Other|"ESA Dose Adjustment per Smart Anemia Manager Algorithm"|"Amount of ESA dose adjustment in Units per week individualized to subject's dose-response profile guided by Smart Anemia Manager algorithm"
46077297|NCT02759328|Behavioral|Xbox Kinect™ training|Xbox Kinect™ (Xbox 360, Microsoft, United States) game console which is one of the commercial interactive game consoles was used. It was comprised of 3 components; Kinect™ sensor, Xbox 360™ game console and 42 inch Liquid crystal display (LCD) television.
45659911|NCT02372253|Drug|Placebo|
45659912|NCT02559895|Drug|ALD403|
45659913|NCT02559895|Drug|Placebo|
45659914|NCT02371629|Drug|NVA237|NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1
45659915|NCT02371629|Drug|Placebo|Placebo to NVA237
45659916|NCT02371629|Drug|Salbutamol|All patients received salbutamol (100 μg) as only rescue medication
45659917|NCT02559817|Drug|Linaclotide Dose A|
45659918|NCT02559817|Drug|Linaclotide Dose B|
45659919|NCT02559817|Drug|Linaclotide Dose C|
45659920|NCT02559817|Drug|Linaclotide Approved Adult Dose|
45659921|NCT02559817|Drug|Matching Placebo|
45659922|NCT05504005|Device|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
45659923|NCT02564887|Device|Iowa Oral Performance Instrument|the IOPI device is being used to increase tongue strength and endurance
45659924|NCT04517929|Other|Group Psychotherapy|9 week group psychotherapy, given by a psychologist trained in group psychotherapy.
45813199|NCT03260504|Biological|Pembrolizumab|Given IV
45813200|NCT05249335|Drug|OST|The subject will receive Orafang for colonoscopy
45951503|NCT00496288|Radiation|Prophylactic radiation to the contralateral breast|The contralateral breast will be treated with 2 tangent fields, using 1.8-2 Gy/fx to a total dose of 50-50.4 Gy. The whole breast will be treated according to traditional guidelines and as described in the RTOG/NSABP B39 study. The heart should be maximally blocked for left sided breasts, included lung tissue should be reduced to minimum. No overlapping field is allowed on the skin between the two breast fields in the midline. Maximal dose should not exceed 110%
45951504|NCT00146211|Drug|Ethyl-EPA (Miraxion™)|
45951505|NCT00496327|Biological|Varicella Virus Vaccine Live (Oka-Merck)|VARIVAX(TM) (Refrigerated) [Varicella Virus Vaccine Live (Oka/Merck), Refrigerator-Stable Formulation.] Subjects enrolled in the study received one 0.5 mL subcutaneous dose of VARIVAX(TM). Frequency is single dose.
46077298|NCT02759328|Behavioral|Conventional rehabilitation|The conventional rehabilitation program consisted of passive and active range of motion exercises, therapeutic stretching, muscle strengthening, neurophysiologic exercises, sitting, standing, balance and gait exercises, occupational therapy and activities of daily living training such as eating, grooming, dressing, toileting and transfer.
45659925|NCT04577443|Drug|Adenosine|To investigate the role of adenosine on cerebral hemodynamic and headache in healthy volunteers and migraine patients
45659926|NCT04577443|Drug|Saline|To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients
46077299|NCT04107909|Procedure|laparoscopic cholecystectomy|"Both four port and three port LC is performed With the patient in supine position, with the surgeon and assistant on the left side and the monitor on the right side. Head up and right up position is employed during surgery in both the groups. Pneumoperitoneum of 12mmHg is created using open Hassan's method through the umbilical port.~In 3 port a 5.5 mm umbilical visiport for 5 mm lens 30 degree A second 10 mm trocar is placed inferior to the sternum at the midline, while the third 5mm trocar is placed 4-5cm inferior to the right costal margin on the right midclavicular line. For the four port LC, additional 5mm port is placed in the sub costal region at the anterior axillary line. Posterior dissection and delineation of The Calot's triangle is done. Then, the cystic artery and cystic duct are identified, isolated, doubly clipped and divided. The gallbladder is removed through the umbilical port using a 10mm gallbladder extractor."
45951506|NCT00496405|Drug|bevacizumab|
45813201|NCT05249335|Drug|2L-PEG/Asc|The subject will receive 2L-PEG/Asc for colonoscopy
45813202|NCT00422396|Drug|Fenofibrate (drug)|
45813203|NCT04034797|Other|Photography teletransmission|A photography of the trauma is teletransmitted to SAMU's physician
45813204|NCT04034797|Other|No photo|Usual management without photography teletransmission
45813205|NCT03992209|Other|Standard care|Usual operating room practice
45813206|NCT03992209|Other|Protocolized care|Hand washing per protocol
45951507|NCT00127556|Procedure|Label applied to blood bag|
45951508|NCT00496444|Drug|Azacitidine|Starting Dose 20 mg/m^2 administered subcutaneously (under the skin), daily, for ten days (Days 1 -10) of every 4 Week Cycle.
45951509|NCT00496444|Drug|Valproic Acid|Starting Dose 10 mg/Kg once daily by mouth, every day of 4 Week Cycle.
45813207|NCT03704701|Diagnostic Test|Cardiac MRI and contrast-enhanced cardiac CT|Cardiac MRI Contrast-enhanced cardiac CT
45813208|NCT00364273|Drug|GSK159802|GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.
45813209|NCT00364273|Drug|Placebo|Subjects will receive placebo administered using DISKUS inhaler.
45453850|NCT01107145|Drug|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
45453851|NCT01107145|Drug|Chloroquine|Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)
45659927|NCT02333487|Drug|Lu AF35700|5 mg tablets for oral administration
45659928|NCT05503849|Behavioral|Lifestyle modification|This lifestyle modification aiming to provide proactive health management during pregnancy, which contains the following: 1) balanced dietary intake based on the Chinese Dietary Guideline; 2) sufficient physical activity; 3) changes in lifestyles (e.g. sleep, sun exposure etc.)
45659929|NCT05500729|Other|Hamstrings maximal voluntary isometric contraction.|Hamstrings maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
45659930|NCT05500729|Other|Quadriceps maximal voluntary isometric contraction|Quadriceps maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
45813210|NCT00364273|Drug|Salmeterol|Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.
45813211|NCT02495467|Drug|Glyceryl trinitrate|At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
45813212|NCT02495467|Drug|MED Placebo|At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
45951510|NCT00496561|Biological|subcutaneous immunotherapy (House Dust Mites)|subcutaneous immunotherapy (House Dust Mites)
45951511|NCT00496561|Other|placebo of subcutaneous immunotherapy (House Dust Mites)|placebo of subcutaneous immunotherapy (House Dust Mites)
45951512|NCT00146250|Drug|Nitrous oxide|Substitution of Nitrous oxide for Nitrogen as balance gas in inspired gas mixture
45951513|NCT00496600|Drug|Patupilone|RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
45951514|NCT00496600|Drug|RAD001|RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
45813213|NCT03432247|Behavioral|Interactive Music Therapy|Six 45-minute individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing, imagery, or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations based on patient needs. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. The IMT experiences are aimed at facilitating emotional expression, offering support through interactive music making, and strengthening inner resources of creativity. In addition, each week the participant learns music-based techniques for self-management of anxiety, stress, mood, and pain.
45453852|NCT03944005|Procedure|Spinal Anesthesia + ACB continious catheter + iPACK + Sham LIA|"ACB - On identification of adductor canal,10ml ropivacaine 0.5% with 1:400,000 epinephrine will be injected to surround the femoral artery.Following catheter placement, another 10ml of the same solution will be injected. Continuous infusion of 5ml/hr 0.2% ropivacaine will be infused till considered ready to discharge.~Ipack - Posterior knee infiltration will be performed following ACB. On visualization of femoral condyle and popliteal artery, 20ml ropivacaine 0.5% with 1:400,000 epinephrine will be infiltrated in muscular space between popliteal artery and posterior femoral condyle.~Spinal anesthesia will be performed following nerve blocks. All patients will receive 2-3ml of 0.75% preservative-free bupivacaine at the level of L2-3 or L3-4 intervertebral space.~LIA - Patients in Group 1 will receive local infiltration 100ml of normal saline around the knee capsule of 100ml of normal saline by the surgeons as a Sham injection."
45453853|NCT03944005|Procedure|Spinal Anesthesia + LIA + Sham Blocks|"ACB - On identification of adductor canal, 10ml of saline as a sham solution will be injected to surround the femoral artery. Following catheter placement, another 10ml of the same solution will be injected. Continuous infusion of 5ml/hr of saline will be infused till considered ready to discharge.~Ipack - Posterior knee infiltration will be performed following ACB. On visualization of the femoral condyle and popliteal artery, 20ml of saline will be infiltrated in the muscular space between popliteal artery and posterior femoral condyle.~Spinal anesthesia will be performed following the nerve blocks. All patients will receive 2-3ml of 0.75% preservative-free bupivacaine injected at the level of L2-3 or L3-4 intervertebral space.~LIA - Patients will receive local infiltration by the attending surgeon intraoperatively with 300mg of ropivacaine (100ml of 0.3% ropivacaine),30 mg of ketorolac, and 10mg of morphine around the knee capsule."
45659931|NCT04411537|Drug|PD-1 antibody|Before neo-CRT: 2 cycles of PD-1 antibody, 240mg d1 q2w. After neo-CRT: 3 cycles of PD-1 antibody, 240mg d1 q2w.
45659932|NCT04411537|Drug|Capecitabine|During neo-CRT: 625mg/m2 bid Monday-Friday per week
45659933|NCT04411537|Drug|Irinotecan|During neo-CRT: 80mg/m2 qw (UGT1A1*28 6/6) or 65mg/m2 qw (UGT1A1*28 6/7)
45659934|NCT04411537|Radiation|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
45659935|NCT05500573|Procedure|Sperm Sorting|Selection of gender specific spermatozoa using a multilayer density gradient solution
45813214|NCT03432247|Behavioral|Verbal support|Six 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears.
45813215|NCT05249179|Other|Pacifier|Preterm infants in Groups 2 and 3 will suck a pacifier 3 times a day (09:00, 12:00, 15:00) for 3 minutes before feeding and then they will be fed with the O/G feeding tube.
45951515|NCT00127595|Drug|gemcitabine, oxaliplatin|
45659936|NCT05500495|Other|no intervention|no intervention
45659937|NCT05503615|Other|Observational|No application will be made to the control group.
45659938|NCT05503615|Other|IASTM Technique Application|Instrument-assisted soft tissue mobilization will be applied to the legs of the individuals to be treated with ultrasound gel for 2 minutes.
45813216|NCT05249179|Other|Oral stimulation|Infants in groups 1 and 3 will receive a prefeeding oral stimulation program once a day, 15 to 30 minutes before a tube feeding. Oral stimulation programs will be delivered by trained nurses or pediatric physical therapies. Nurses will be trained to deliver the stimulation program to the infants, by a member from the pediatric physical therapies medical staff, before the beginning of the study. Based on Backman's principles, the pre-feeding oral stimulation program consisted of a 12-minute stimulation program that included stroking the cheeks, lips, gums, and tongue.
45813217|NCT05249023|Other|Sodium butyrate bolus|On the test day participants suffering from IBS and healthy participants will undergo a distal colonoscopy procedure for the collection of mucosal biopsy specimens pre- and post-administration of a sodium butyrate solution (100 mM) at a selected area in the descending colon. Biopsies will be obtained from the colon pre- and 90 min post-administration of the intervention solution. Blood samples will be collected before and at six time-points after the intervention solution administration.
45951516|NCT00496639|Procedure|angioplasty|Balloonplasty of the stenotic lesion at the venous anastomosis of the thrombosed AV graft.
45951517|NCT00496639|Procedure|stent placement|Balloonplasty plus stent deployment at the stenotic lesion at the venous anastomosis of the thrombosed AV graft
45951518|NCT00496678|Behavioral|Navigation|Cancer patients are randomly assigned to receive standard of care or the help of a trained person to navigated them through the cancer care system
45951519|NCT00496678|Behavioral|Standard of Care|Cancer patients receive standard of care for their cancer treatment
45659939|NCT05503537|Procedure|post-isometric relaxation technique|Post-isometric relaxation technique will be performed by asking the patient to contract his calf muscles using 20% of his strength. Maintain the contraction for 10 second with 15 second of rest time between each contractions. A total of 4 contractions will be performed.
45659940|NCT05503537|Procedure|Static stretching|Static stretching will be performed by asking patient to perform dorsiflexion till the point of discomfort. The patient will hold the stretch for 15 second and 5 repetitions will be performed.
46077300|NCT04269473|Procedure|Telehealth Gait Retraining|Telehealth gait retraining is a novel approach to train participants to adopt a non-rearfoot foot strike pattern during running via telecommunications. During telehealth gait retraining, video of a participant's running form are sent to clinicians over a mobile device app and running form feedback is given. This process is repeated once a week for four weeks and then every other week until week 8.
46077301|NCT04269473|Procedure|Standard Physical Therapy Treatment|Participants receiving standard Physical Therapy will visit the Physical Therapy Clinic every 2 to 3 weeks to be treated by a Physical Therapist.
46077302|NCT04269473|Procedure|Return to Running Protocol|The Return to Running protocol is a six-phase running volume progression to re-introduce running slowly and safely after experiencing a running-related injury.
45659941|NCT05503537|Procedure|Basic Cardiac Rehabilitation Protocol|Ankle pumps, leg slides, walking
45659942|NCT05503459|Other|Bicycle learning|The 10 intervention sessions were conducted in an identical format, comprising three activities: warm-up (10 min), bicycle learning (40 min), and cool-down (10 min). In the bicycle training activity, participants were asked to ride on a training bicycle with training wheels to gain better control of the bike in a gradual way. Participants then progressed from the training bicycle to a two-wheel bicycle. To keep participants on the learning curve, they were asked to ride through an obstacle course that was progressively more difficult to negotiate. The obstacles were designed by a focus group, which consisted of four physical education teachers from participating schools and one experienced cycling coach with more than five years of coaching experience.
45659943|NCT05503459|Other|Stationary cycling|The 10 intervention sessions were conducted in an identical format, comprising three activities: warm-up (10 min), stationary cycling (40 min), and cool-down (10 min). For stationary cycling activity, they were also asked every 10 mins during exercise to indicate their ratings of perceived exertion (target range: 3-5). Participants were positively reinforced verbally with compliments for their efforts in the training program and their daily improvements were visualized through graphs kept in the child's home.
45659944|NCT04510129|Diagnostic Test|OncoPrism™ assay|OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
45659945|NCT04504435|Drug|GSK3494245|Capsule of 10-250 mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
45659946|NCT04504435|Drug|Placebo|Matching placebo capsules will be provided
45813218|NCT04743037|Behavioral|iSMART|This patient-centered and participation-focused self-management intervention will help individuals develop strategies to manage chronic conditions and support their full participation in meaningful life activities.
45813219|NCT02495623|Drug|SYN-010 21 mg|
46077303|NCT04269473|Procedure|At Home Exercise Program|The At Home Exercise Program consists of 4 lower leg and foot exercises that participants can perform on their own time.
45813220|NCT02495623|Drug|SYN-010 42 mg|
45813221|NCT02495623|Drug|Placebo|
45813222|NCT05248087|Device|The bonded McNamara-type appliance|The patient will be asked to expand twice a day until obtaining an overcorrection of 2-3 mm. Then the expander will be kept in place for three months as a retention period.
45813223|NCT05248087|Device|The removable palatal expansion appliance|The slow maxillary expansion will be applied using a removable palatal expansion appliance with a midline screw. The patient will be asked to expand twice a week until obtaining an overcorrection of 2-3 mm.
45813224|NCT02495779|Drug|emtricitabine/tenofovir|Short-term episodic use for 2-3 weeks.
45813225|NCT02495779|Behavioral|CBT-based counseling|Brief CBT-based counseling to promote adherence
45813226|NCT02502019|Device|HEMOBLAST Bellows|HEMOBLAST™ Bellows is intended for use in surgical procedures as an adjunct to hemostasis when control of bleeding by conventional procedures is ineffective or impractical.
45813227|NCT05247931|Diagnostic Test|TXB2 assay of serum , and 11-dehydro-TXB2 assay of urine|Blood samples are analyzed for the assay of serum TXB2, and urine samples for the assay of 11-dehydro-TXB2
45813228|NCT05247775|Procedure|Profilometry|Profilometry was performed in 43 patients before open retropubic radical prostatectomy.
45813229|NCT03241771|Behavioral|Naloxone Navigator 1.0|Patients on chronic opioid therapy will be outreached via email, mail and phone. Within 1 month of enrollment into the trial, intervention participants will receive a link to the web-based resource to view. This is designed to provide overdose education, increase opioid risk awareness, and encourage patients to obtain naloxone.
45813230|NCT02828839|Procedure|Access needle|The primary purpose of the single-use disposable access needle is to guide the use of a biopsy gun to obtain a tissue sample from the patient's prostate gland through a percutaneous puncture of the perineum. The primary purpose of the disposable needle guide is to stabilize the needle biopsy and better approximate the most direct path to the prostate.
45813231|NCT05217277|Diagnostic Test|Humans ELISA kits|"ELISA (enzyme-linked immunosorbent assay) is a plate-based assay technique designed for detecting and quantifying soluble substances such as peptides, proteins, antibodies, and hormones.~The saliva of the patients included in the study will be examined with ELISA kits after they are taken."
45813232|NCT05216497|Drug|Ingavirin®, 90 mg capsules|90-180 mg/day for 7 days on top of standard therapy
45813233|NCT05216497|Drug|Placebo|1-2 capsules for 7 days on top of standard therapy
45813234|NCT02502487|Procedure|Dorsal Penile Nerve Block|Dorsal penile nerve block with 0.33% ropivacaine using 22-G needle in the sub-pubic space at the base of the penis
45813235|NCT02502487|Drug|Ropivacaine|0.33% Ropivacaine administered around dorsal penile nerve using 22-G needle in the sub-pubic space at the base of the penis
45813236|NCT02502487|Drug|Tetracaine|1% Tetracaine gel instilled into urethra
45813237|NCT03238196|Drug|Erdafitinib|4mg - 8mg
45813238|NCT03238196|Drug|Palbociclib|125 mg
45813239|NCT03238196|Drug|Fulvestrant|500 mg
45813240|NCT02657551|Drug|Regorafenib|Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes.
45813241|NCT05473832|Other|Day Cream cosmetic product compared to untreated side|Applied once daily in the morning
45813242|NCT05473832|Other|Night cream cosmetic product compared to untreated side|Applied once daily in the evening
45659947|NCT04781491|Behavioral|Forest Therapy (Düppeler Forst - Berlin-Wannsee)|Forest Therapy means mindful visits in nature, actively perceiving the flora and fauna
45659948|NCT05500183|Behavioral|Cognitively enriched walking program|The PA+CA program is group-based and will have a duration of six months (i.e. 24 weeks), with a frequency of two group sessions a week. All group sessions will last for approximately one hour and take place in groups of twelve or thirteen people supervised by a certified coach. Participants will be encouraged to do one individual session every week, as well.
45676534|NCT02350465|Behavioral|Eccentric Exercise|Submaximal progressive resistance exercise (PRE) using eccentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
45813243|NCT05473832|Other|Eye cream cosmetic product compared to untreated side|Applied twice daily in the morning and in the evening around the eye area
45813244|NCT05473832|Other|Serum cosmetic product compared to untreated side|Applied twice daily in the morning and in the evening
45813245|NCT02632045|Drug|LEE-011|600 mg capsule (3x 200 mg capsules)
45813246|NCT02632045|Drug|Fulvestrant|500 mg injection
45813247|NCT02632045|Drug|Placebo|600 mg capsule (3x 200 mg capsules)
45951520|NCT04665765|Drug|Carboplatin|Given IV
45951521|NCT04665765|Drug|Etoposide|Given IV
45813248|NCT02503735|Drug|Sofosbuvir/Ledipasvir FDC|12 weeks treatment with Harvoni
45813249|NCT04001881|Other|Transthoracic echocardiography|A standard TTE protocol is used in all patients and included the following views: subcostal 4-chamber (SUBC), apical 4-chamber (4CH), apical 2-chamber (2CH), apical 3-chamber (3CH), parasternal long (LAX) and short axis (SAX).
45951522|NCT04665765|Drug|Ifosfamide|Given IV
45951523|NCT04665765|Drug|Polatuzumab Vedotin|Given IV
45813250|NCT04001881|Drug|Spinal anesthesia|Spinal anesthesia is introduced with a single intrathecal injection of 12 to 18 mg (15 mg average dose) plain ropivacaine (0.75% solution) using a 22 or 25-gauge needle (pencil-point) with the patient in the lateral position.
45813251|NCT02505919|Device|AQUABEAM System|To utilizes proprietary heat-free high-pressure waterjet technology to resect and remove prostate tissue using the AQUABEAM system, which is a personalized image-guided tissue removal system.
45813252|NCT02505919|Procedure|Transurethral Resection of the Prostate (TURP)|Transurethral resection of the prostate (TURP) is a type of prostate surgery done to relieve moderate to severe urinary symptoms caused by an enlarged prostate, a condition known as benign prostatic hyperplasia (BPH)
45951524|NCT04665765|Biological|Rituximab|Given IV
45951525|NCT00496717|Device|Helicoidal fast scann|Each patient will have an computed aortic tomodensitometric scan without contrast injection. This procedure lasts few minutes and irradiation is low. The aortic calcium scoring is calculated using a specific program included in the scan machine
46002682|NCT04645563|Other|Sending thorax ct video images via smartphone applications|Video images of the patients will be sent via smartphone application to infectious disease specialist for consulting.
46077304|NCT04107753|Behavioral|Brief counseling based on the 5As model|"It is a structured brief counselling perfomed by nurse who takes clinical care of the patient and it is performed as follow:~ASK: every patient should be asked whether he/she is or is not a smoker;~ADVICE: the patient is advised to quit in a strong, clear and personalized way;~ASSESS: the patient is asked if he/she would like to quit and the strenght of his/her dependence is assessed.~ASSIST: The smoker interested in quitting are assisted in their attempts, for example by helping them to define a quit date, by advising them about strategies against withdrawal symptoms and by providing them information material; patients are asked whether they want to be contacted by the CTT.~ARRANGE: this step is only addressed to the patients who have started a treatment in the CTT and is expected to prevent or treat eventual relapses."
45659949|NCT05500183|Behavioral|walking program|The PA only program is group-based and will have a duration of six months (i.e. 24 weeks), with a frequency of two group sessions a week. All group sessions will last for approximately one hour and take place in groups of twelve or thirteen people supervised by a certified coach. Participants will be encouraged to do one individual session every week, as well.
46077305|NCT00894907|Other|PiCCO-parameter-guided volume resuscitation|"Insertion of an arterial PiCCO catheter. Resuscitation using crystalloids and/or colloids with the following goals:~ITBI: 850-1000 ml/sqm, if ELWI <=12*ml/kg; ITBI 750-850 ml/sqm, if ELWI >12*ml/kg and/or PaO2:FiO2 <200 (*ELWI<=12ml/kg, if MAP>65mmHg without catecholamines; ELWI<=14ml/kg, if catecholamines required for MAP>65mmHg); SVV<10% (only in controlled ventilation and sinus rhythm); MAP>65mmHg (MAP: Mean Arterial Pressure); IAPP >60mmHg (IAPP: Intra-abdominal Perfusion Pressure)"
46077306|NCT00894907|Other|Control-group|"Haemodynamic management without ITBI and ELWI using any other haemodynamic monitoring tool, with the exception of the PiCCO-system.~Main haemodynamic goals: CVP 8-12 mmHg; MAP >65mmHg;IAPP >60mmHg"
45453854|NCT02910973|Device|Vagus Nerve Stimulation|Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch of the vagus nerve.
45813253|NCT03916159|Procedure|Extrauterine placental transfusion (Intervention group)|At delivery by caesarean section, the infant is born with the placenta still attached via the umbilical cord and placental transfusion is performed at least 1 minute but not more than 10 minutes by holding the placenta ~40-50cm above the babies' heart level while respiratory support by mask continuous-positive-airway-pressure (CPAP) is initiated simultaneously.
45813254|NCT03916159|Procedure|Delayed cord clamping (Control group)|At delivery by caesarean section, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 30 seconds with initiation of respiratory support by mask CPAP after cord clamping.
45813255|NCT03019640|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
45813256|NCT03019640|Drug|Carmustine|Given IV
45659950|NCT05500027|Diagnostic Test|serum test|serum test of sCD58 and TGFbeta1
45659951|NCT04630171|Device|Group #1: VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure|Group #1: VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
45813257|NCT03019640|Biological|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given IV
45813258|NCT03019640|Drug|Cytarabine|Given IV
45951526|NCT00496951|Device|Vagal tone assessment|An EKG will be obtained using a Physio-control EKG monitor (R wave Electronics of Florida) in standard application, with three chest leads. The EKG data is inputted into a vagal tone monitor (Delta Biometrix, Bethesda MD) which computes vagal tone from the EKG signal. This data is then transferred to a disk which is analyzed off-line.
45951527|NCT00127751|Behavioral|Enhance health lifestyle changes and medication compliance|
45951528|NCT00496990|Behavioral|Enhanced care|this group received counseling, contingency management and methadone or detoxification
46077307|NCT04269863|Drug|Aspirin|control - 81mg. treatment - 81-325mg.
46077308|NCT00901381|Drug|Filgrastim|10 µg/kg subcutaneously once daily x 5 days
46077309|NCT00602381|Drug|Lithium|
46077310|NCT02751528|Biological|ETBX-021|ETBX-021 is a HER2-targeting vaccine comprising an Ad5 vector and a modified HER2 gene insert.
46077311|NCT00896857|Genetic|RNA analysis|
46077312|NCT00896857|Genetic|polymerase chain reaction|
46077313|NCT00896857|Genetic|protein expression analysis|
45659952|NCT04630171|Device|Group #2: Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure|Group #2: Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
45659953|NCT04630171|Other|Group #3: Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure|Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
45813259|NCT03019640|Drug|Etoposide|Given IV
45813260|NCT03019640|Biological|Filgrastim|Given SC
45813261|NCT03019640|Drug|Lenalidomide|Given PO
45813262|NCT03019640|Drug|Melphalan|Given IV
45813263|NCT03019640|Biological|Rituximab|Given IV
45813264|NCT02456389|Other|Preoperative risk stratification|Preoperative risk-prediction tool based on patient demographics/co-morbidity and planned procedure
45813265|NCT02456389|Other|Postoperative risk stratification|Postoperative risk-prediction tool based on intraoperative variables
45951529|NCT00496990|Behavioral|control|this group receives the opportunity to participate in a support group
45951530|NCT04603326|Procedure|Lumbar Puncture|Lumbar Puncture for collection of Cerebrospinal Fluids
45951531|NCT00497068|Behavioral|tobacco abstinent contingent|Participants receive vouchers wiht monetary rewards for providing breath samples that show tobacco smoking abstinence
46077314|NCT00896857|Genetic|reverse transcriptase-polymerase chain reaction|
46077315|NCT00896857|Genetic|western blotting|
46077316|NCT00896857|Other|immunoenzyme technique|
46077317|NCT00896857|Other|immunohistochemistry staining method|
46077318|NCT00896857|Other|laboratory biomarker analysis|
46077319|NCT00896857|Procedure|breast duct lavage|
45813266|NCT02456389|Other|Risk-based, escalating levels of care|Postoperative observation in regular unit vs. telemetry unit vs. stepdown unit vs. ICU
45659954|NCT04630171|Device|Group #4: VerTouch utilized for identification of site for lumbar puncture procedure|Group #4: VerTouch utilized for identification of site for lumbar puncture procedure for patients undergoing a therapeutic lumbar puncture
45659955|NCT04630171|Device|Group #5: Ultrasound (US) utilized for identification of site for lumbar puncture procedure|Ultrasound (US) utilized for identification of site for lumbar puncture procedure for patients undergoing a therapeutic lumbar puncture
45813267|NCT02456389|Other|Risk-based, escalating levels of monitoring|Varying frequencies of vital signs monitoring Varying use of telemetry, pulse oximetry, and early warning system
45453855|NCT02910973|Device|Sham Vagus Nerve Stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
45659956|NCT04630171|Other|Group #6: Control group, palpation utilized for identification of site for lumbar puncture procedure|Group #6: Control group, palpation utilized for identification of site for lumbar puncture procedure for patients undergoing a therapeutic lumbar puncture
45659957|NCT05503381|Procedure|Laparoscopic radical resection of low rectal cancer with transanal specimens|According to the standard laparoscopic anterior rectum resection, the rectum was separated 2-3cm below the tumor, the rectum was severed 1-2cm from the lower edge of the tumor, the rectal stump was connected with the tumor through the anus, and the sigmoid colon was severed 10cm from the upper edge of the tumor. The stapler head was placed in the sigmoid colon stump, and then the sigmoid colon stump was closed with a linear cutting closure device. Then, the sigmoid colon stump is returned to the abdominal cavity through the anus, the distal rectal stump is closed with a suture purse or a linear cutting closure device, and the stapler body is inserted through the anus, and then the anastomosis is completed.
45659958|NCT04696081|Other|occurence of atrial fibrillation|all adult patients with an active cancer and experiencing atrial fibrillation will be consecutively include. Active cancers will be defined according Agnelli et al. (NEJM 2020; 382:1599-1607).
45659959|NCT05503147|Drug|Sativex|Sativex® is administered as an oromucosal spray and consists of 2.7 mg tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) per dosis spray (Cannabis sativa L. extract, cannabis leaf and flower). The dose (3 sprays) is administered twice, at breakfast and lunch, respectively, with approximately 4 hours between each administration.
45453856|NCT01209403|Drug|Glucose-infusion|Continuous iv infusion of glucose
45453857|NCT01209403|Drug|Glucose-insulin infusion|Continuous iv infusion of glucose and shortlasting
45659960|NCT04619095|Dietary Supplement|Psyllium|See the information already included in the arm descriptions.
45813268|NCT02456389|Other|Risk-based, escalating levels of co-management|Varying use of Hospitalist co-management
45813269|NCT02456389|Other|Standard postoperative care|Routine postoperative care, as medically indicated
45951532|NCT00497068|Behavioral|non-contingent|Participants receive vouchers regardless of tobacco use status
45951533|NCT00497068|Behavioral|control|this group receives no vouchers
45951534|NCT00497107|Drug|UFT, Calcium Folinate, PSK|
45951535|NCT00497107|Drug|UFT, Calcium Folinate|
46077320|NCT02755428|Biological|retinal pigment epithelium transplantation|Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
46077321|NCT00949715|Device|Medtronic or Vitatron Dual-Chamber Pacemaker|A Medtronic or Vitatron market-approved dual-chamber implantable pulse generator (IPG) with atrial tachycardia/atrial fibrillation (AT/AF) trending ability
46077322|NCT00949715|Device|Medtronic SelectSecure 3830 Lead|Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
46077323|NCT02758938|Other|Urologic biofeedback software|All subjects (end users) will be walked through the urologic biofeedback software training suite. Each end user will follow a protocol that is specific to their role. Upon completing their session(s) with the software, each end user will provide appropriate feedback.
46077324|NCT00901537|Drug|Azacitidine and Cisplatin|We plan to give azacitidine daily as subcutaneous injection at escalated doses (37, 60, 75, 85, 100 and 110 mg/m2) for 5 days from day 1 to day 5, and give cisplatin 75 mg/m2 as intravenous injection on day 8, every 4 weeks as a cycle.
46077325|NCT02853227|Other|digital photography|Photographies with digital cameras were taken postoperatively for the documentation, anonymised and used for evaluation of cosmetic results after surgery.
45659961|NCT04619095|Dietary Supplement|Placebo|See the information already included in the arm descriptions.
45659962|NCT05499949|Diagnostic Test|NASH screening|Evaluate liver steatosis and elasticity using transient elastography in the FONS group
45813270|NCT02339779|Procedure|autologous fat transfer|"Each procedure consists of the transfer of syringe-aspirated fat (form the abdomen, thighs, flanks) to the breast by injection in the subcutaneous planes.~Typically three separate procedures are needed for a complete breast reconstruction:~First session comprises of sub- and intrapectoral fat transfer during the primary mastectomy surgery, providing volume to the deep tissue planes.~Second session is preceeded by wearing an external pre-expansion device to prepare the recipient site for grafting. It aims to give the breast its shape and initial volume.~Third session is also preceded by external pre-expansion and aims to provide extra volume of the breast to achieve symmetry with the healthy breast."
45813271|NCT02339779|Procedure|breast implant|"Implant-based reconstruction typically will occur as follows:~During the primary mastectomy surgery, a tissue expander will be implanted subpectorally.~The tissue expander will be gradually filled with sterile saline during outpatient clinic visits.~When the desired volume is achieved, a second operation will be planned, to exchange the tissue expanded with the definite breast implant.~(Note: in patients who are receiving encapsulectomy and implant exchange, the first 2 steps are skipped.)"
45951536|NCT00146289|Drug|MICARDIS® (telmisartan)|
45951537|NCT04727216|Device|Dorsal Root Ganglion Stimulation (DRG-S)|Dorsal Root Ganglion stimulation will be delivered with continuous dosing and 2 different ON/OFF periods to compare effects for each patient.
45951538|NCT01244854|Behavioral|Life Goals Collaborative Care|LGCC consists of 1) 10 sessions focused on CVD risk reduction through behavioral change within the context of patients' psychiatric symptoms; 2) participant goal setting in diet and exercise; 3) customized ongoing motivational interviewing (MI)-based patient contacts with a health specialist for 6 months, in addition to 4) strategies to increase provider access and support for behavioral change and medical management.
45951539|NCT01244932|Drug|bupivacaine 0.5%|Patients will be given bupivacaine 0.5% in different doses (up-down study).
45951540|NCT01244971|Drug|Acarbose|100mg, 3 times daily
45951541|NCT01244971|Behavioral|Exercise|Moderate combined exercise, 50 minutes 3 times per week
45659963|NCT05499949|Diagnostic Test|Cardiac dysfunction screening|Evaluate cardiac dysfunction in 60 patients from the FONS group with transthoracic echocardiography
45813272|NCT02244463|Drug|MLN0128|This is a non-randomized phase II study to investigate efficacy of MLN0128 in metastatic anaplastic thyroid cancer cases.
45813273|NCT02136901|Device|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
45813274|NCT02136901|Drug|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
45813275|NCT02136901|Drug|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
45813276|NCT02136901|Drug|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
45813277|NCT00585338|Device|Tandem 532/1064 nm Laser|Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser
45951542|NCT01244971|Other|Exercise + Acarbose|See respective monotherapy description
45951543|NCT04727177|Device|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive biological stimulation technique born in the middle of 1980's.
45951544|NCT04599894|Drug|37.5mg Pregabalin + 75mg Pregabalin|37.5mg pregabalin preoperatively + 75mg pregabalin postoperatively
45951545|NCT04599894|Drug|75mg Pregabalin|75mg pregabalin postoperatively
45453858|NCT01112215|Drug|Azathioprine|Initial dose of 2-2.5 mg/kg (according to TMTP levels) for 6 months according the severity of the flare with progressive tapering if complete remission has been obtained
45659964|NCT05499949|Diagnostic Test|Liver biopsy|For participants from the FONS group with an elevated liver fibrosis measurement (≥F2) with TE, a laparoscopic liver biopsy will be performed during the bariatric procedure.
45659965|NCT04490005|Other|pupillometry|evaluation of pupillary reflex by using the Neuroptics Pupillometer every 4 hours during ICU stay
45951546|NCT01245010|Other|Water|Water and education will be provided
45951547|NCT01245010|Other|Education|Education
46002683|NCT04637217|Diagnostic Test|Optical Coherence Tomography|Spectral Domain Optical Coherence Tomography(SD-OCT) examination will be performed for every patient: posterior pole scan, EDI-OCT(enhanced depth imaging-OCT) and peripapillary RNFL(retinal nerve fiber layer)
45813278|NCT00581204|Device|Near-Infrared Diffuse Optical Spectroscopy|Early predictor of hemorrhagic shock
45813279|NCT02506309|Device|TOT - inside-out trans-obturator tape/sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
45813280|NCT02506309|Device|SIS - Innovative fixation single incision sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
45813281|NCT00580892|Device|Optical Coherence Tomography imaging|Optical Coherence Tomography imaging
45813282|NCT00580736|Device|Optical Clearing|Optical Clearing
45813283|NCT02507011|Drug|Carvedilol|Beta-adrenergic receptor blocker
45813284|NCT02507011|Drug|Placebo|Placebo
45813285|NCT05379218|Device|Remote Ischemic Conditioning|"Patients randomized to the RIC arm, cohorts of 4 consecutive patients will receive escalating therapy:~A. 4 consecutive patients will undergo 4 cycles of 3 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia B. Observing no safety events (see below) from patients in group A, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia.~C. Observing no safety events from patients in group B, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1 and 2 of therapeutic hypothermia.~D. Observing no safety events from patients in group C, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1, 2, and 3 of therapeutic hypothermia.~All infants will have an extra 1ml of blood collected."
45813286|NCT02977286|Drug|Naloxegol Oral Tablet|Naloxegol Oral Tablet 25 mg (or 12.5 mg) po (enteral) daily
45813287|NCT02977286|Drug|Placebo Oral Tablet|Placebo Oral Tablet po (enteral) twice daily
45813288|NCT02977286|Drug|Docusate Sodium 100 Mg oral capsule [Colace]|Docusate Sodium 100 mg po (enteral) twice daily
45813289|NCT02977286|Drug|Senna 217 Mg Oral Tablet|Senna 127 mg oral tablet daily if no spontaneous bowel movement >/=3 days after scheduled opioid initiation; increase to two senna 127 mg tables if no no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement >/=5 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement >/=6 days after scheduled opioid initiation.
45813290|NCT02977286|Drug|Polyethylene Glycols|Polyethylene Glycols 17 g daily if no spontaneous bowel movement >/=3 days after scheduled opioid initiation; increase to 34 g daily if no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation.
45813291|NCT02977286|Drug|Bisacodyl 10 mg Suppository|Insert one suppository if no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation.
45813292|NCT02977286|Drug|Magnesium Citrate Oral Liquid Product|Administer one 10 oz bottle if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation.
45813293|NCT02977286|Drug|Methylnaltrexone|Administer 8 mg or 16 mg (depending on subject's weight) subcutaneously x 1 if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation, consult surgery/gastroenterology and discontinue study medication.
45813294|NCT05345210|Drug|Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
45813295|NCT05345210|Drug|Vonoprazan Fumarate+Amoxycillin 14days (VA14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
45813296|NCT05345210|Drug|Vonoprazan Fumarate+Amoxycillin 7days (VA7)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
45813297|NCT05345210|Drug|Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
45813298|NCT05345210|Drug|Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days
45813299|NCT00540566|Device|Optical Biopsy imaging|Optical Biopsy imaging
45951548|NCT00497185|Behavioral|Mindfulness-Based Cognitive Therapy for Functional Disorders|"Mindfulness-based cognitive therapy: A manualized program will be delivered by two instructors who are experienced cognitive therapists in eight weekly 3½-hour group training sessions and one follow-up session after a month involving up to 12 patients with somatoform disorders. The patients must be willing and able to attend and devote up to 1 hour per day for homework.~The therapy is compared with a group of controls receiving shared care defined as: Treatment as usual augmented by psychiatric consultation intervention: The patients are offered a psychiatric consultation after the assessment interview. It is the aim to optimise treatment in the present health care system."
45453859|NCT01112215|Drug|Enteric-Coated Mycophenolate Sodium|Initial dose of 1440 mg/day for 6 months to be tapered progressively if complete remission had been obtained
45813300|NCT02976896|Drug|Apatinib Mesylate|Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.
45951549|NCT00497224|Drug|Erlotinib|Erlotinib starting at 150 mg PO (by mouth) daily. Dose may increase or decrease by the study doctor as per protocol (study plan).
45659966|NCT04482595|Drug|BIO 300 Oral Suspension|Suspension of genistein nanoparticles
45659967|NCT04482595|Drug|Placebo|Matched placebo for BIO 300 Oral Suspension
45951550|NCT00497263|Device|Niti CAR|
45951551|NCT04726982|Drug|Acetazolamide|250 mg once daily
45813301|NCT01810705|Drug|GRASPA|Patients receiving Intervention (experimental group) will be treated with one injection of graspa per cycle of treatment, each cycle during 28 days, for a duration up to 24 cycles maximum
45813302|NCT01712191|Device|NUsurface Meniscus Implant|
45951552|NCT04726982|Drug|Acetazolamide|500 mg once daily
46077326|NCT02751372|Drug|BAY 987517|50 μl/cm*2 or 0.05 gm/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.
45659968|NCT04631185|Drug|Single pre-operative dose of intravenous antibiotics with intraoperative redosing|Intravenous cefazolin, a cephalosporin antibiotic, will be prescribed to all patients before surgery. In case of allergy to cefazolin, intravenous clindamycin will be prescribed. For allergy to both antibiotics, an appropriate antibiotic should be chosen by the surgeon and documented. All patients will receive one dose of antibiotic within 60 minutes prior to incision, and any intraoperative doses of antibiotics according to current recommendations based on the antibiotic's dosing and on operative time.
46077327|NCT02751372|Other|Untreated Skin|This site is patched without treatment as irradiated control
46077328|NCT00894985|Biological|heparin sodium - blausiegel|heparin sodium 5.000UI
45659969|NCT04631185|Drug|One week of post-operative antibiotics|The patients will be prescribed one week of Cephalosporin Antibiotic (Keflex/Duricef/Other) of their surgeon's choice.
45659970|NCT05499793|Dietary Supplement|Zingiber Officinale powder|Ginger powder
45813303|NCT02508103|Drug|Oxytocin|Intranasal Oxytocin spray (40 IU, 3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
45813304|NCT02508103|Drug|Placebo|Intranasal Placebo spray (3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
45813305|NCT02508259|Drug|Suramin|20 mg/kg IV in 50 ml saline over 30 minutes
46077329|NCT00894985|Biological|heparin sodium - APP|heparin sodium 5.000 USP - APP
46077330|NCT02853461|Other|Sonication|Ultrasound bath (40 kHz, 1 W/cm2, 1 min) of bearing components of the prosthesis in sterile conditions.
45659971|NCT05499793|Dietary Supplement|Placebo|Starch powder
45659972|NCT05499715|Biological|ScTIL injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and superamplification factor, and cell number are amplified. The obtained ScTIL is used for one-time intravenous infusion."
45659973|NCT04557553|Dietary Supplement|Lagenbone|Traditional Chinese medicine herbal formula
45659974|NCT05502991|Drug|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks
45659975|NCT02333331|Drug|bimagrumab|Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.
45659976|NCT02333331|Other|placebo|Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.
45813306|NCT02508259|Drug|Saline|50 ml IV over 30 minutes
45813307|NCT02848820|Drug|Augmentin + Gentamicin|Amoxicillin/clavulanic acid (Augmentin) 25/2.5mg 6-hourly (total 100/10 mg/kg daily; maximum 6000/600mg a day) intravenously for 48 hours Oral amoxicillin/clavulanic acid 50/12.5 mg/kg 8-hourly (max 1500/375mg a day) for in total 7 days Gentamicin 7mg/kg once daily for 48 hours
45813308|NCT02848820|Procedure|Appendectomy|Pre-, peri- and postoperative care according to local protocol. No routine postoperative antibiotics
45813309|NCT04707859|Diagnostic Test|Head to head comparison: Rubidium vs 15O-water PET|Head to head comparison with invasive FFR as reference. Adjustment for abnormal microcirculation
45813310|NCT04708093|Device|whole body vibration training|Oscillating platform
45813311|NCT05237180|Other|spatial localisation training|8 spatial localization training sessions MBAA and SSQ tests before and after training sessions.
45813312|NCT02509585|Drug|Tc99m tilmanocept|A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery
45951553|NCT04726982|Other|Placebo|Once daily
45951554|NCT04555941|Device|intermittent theta burst stimulation|active or Sham iTBS will be given to the AD/MCI patient
45951555|NCT00497302|Behavioral|RBT|Contingency management and behavioral counseling including motivational interviewing
45951556|NCT00497302|Behavioral|usual care|receives usual comprehensive care at Center for Addiction and Pregnancy
45951557|NCT00497341|Drug|cefuroxime|cefuroxime is administered at a dosage of 1.5 g before tourniquet inflation and release in experimental arm and only before tourniquet inflation in control arm
45951558|NCT00497341|Drug|placebo|cefuroxime 1.5 g IV before tourniquet inflation + placebo before tourniquet release + cefuroxime 1.5 g IV 6 h after surgery
45951559|NCT00497380|Dietary Supplement|Arginine|Oral nutritional supplement
45951560|NCT00146367|Behavioral|Active Living Every Day|
46077331|NCT02853461|Other|Microbiological analysis|Plating the sonicates on agar plates.
46077332|NCT00791661|Drug|MK-1006|MK-1006 capsules in single oral doses beginning at 15 mg and rising to 45 mg in Panel A, beginning at 60 mg and rising to 80 mg and 60 mg fed state in Panel B, or beginning at 100 mg and rising to 170 mg in Panel C.
46077333|NCT00791661|Drug|Placebo|Matching placebo to MK-1006 in a single oral dose
46077334|NCT00897091|Genetic|comparative genomic hybridization|
46077335|NCT00897091|Genetic|microarray analysis|
46077336|NCT00897091|Genetic|reverse transcriptase-polymerase chain reaction|
46077337|NCT00897091|Other|diagnostic laboratory biomarker analysis|
46077338|NCT04585152|Drug|Rituximab Biosimilar|for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
45453860|NCT01112371|Drug|Contractubex|"Contractubex® Gel, containing 10% extractum cepae, 1% allantoin and 50/U of sodium heparin per one gram of gel.~Active drug group: The gel will be applied twice daily (morning/evening). Approximately 2 cm of the IMP are applied onto the scar by light massage rubbing carefully until the product is worked in."
45453861|NCT02283736|Other|Lactobacillus rhamnosus SP1|Tablet containing Lactobacillus rhamnosus SP1
45813313|NCT02240706|Procedure|Best Supportive Care|At Discretion of the Investigator (Transfusions)
45813314|NCT02240706|Drug|BI 836858|Monotherapy with BI 836858
45453862|NCT02283736|Other|Talc powder|Tablet containing talc powder
45659977|NCT02563561|Drug|Apaziquone|One dose of apaziquone administered by intravesical administration
45453863|NCT02283736|Procedure|Periodontal treatment|Scaling and root planning
45659978|NCT02563561|Other|Placebo|Matching placebo (containing 12 mg FD&C red #40, 15 mg sodium chloride, and 10 mg mannitol was supplied in identical appearing vials) by intravesical administration.
45813315|NCT00534469|Biological|aldesleukin|
45453864|NCT02605369|Behavioral|Intervention arm: An integrated package|See description in previous column
45453865|NCT04473196|Other|weightbearing|immediate weightbearing
45453866|NCT01107223|Other|Experimental: Training to antibiotic prescription|GPs assigned to the intervention group attended a two days didactic educational meeting on evidence-based guidelines for diagnosis and treatment of acute respiratory tract infection.
45659979|NCT05498233|Drug|Doxylamine + Pyridoxine|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
45659980|NCT05499481|Drug|Antibiotic|"The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment:~- SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.~- SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy."
45676535|NCT02350465|Behavioral|Concentric Exercise|Submaximal progressive resistance exercise (PRE) using concentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
45676536|NCT02321514|Device|Tendyne Mitral Valve System|Patients will undergo transcatheter mitral valve replacement using Tendyne Mitral Valve system
45676537|NCT02266134|Behavioral|Tailored Implementation of Measurement Based Care|Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire; the implementation of measurement-based care will be tailored based on clinic specific barriers and facilitators.
45813316|NCT00534469|Biological|filgrastim|
45813317|NCT00534469|Drug|busulfan|
45813318|NCT00534469|Drug|cytarabine|
45453867|NCT01107223|Other|No education on antibiotic prescription rules.|GPs assigned to control group received no specific recommendations on antibiotic prescription.
45813319|NCT00534469|Drug|etoposide|
45813320|NCT00534469|Drug|idarubicin|
45813321|NCT00534469|Procedure|autologous hematopoietic stem cell transplantation|
45813322|NCT00534469|Procedure|bone marrow transplantation|
45813323|NCT00534469|Procedure|peripheral blood stem cell transplantation|
45813324|NCT00534469|Radiation|total-body irradiation|
45813325|NCT03757351|Drug|DNL747|Repeating oral dose
45813326|NCT03757351|Drug|Placebo|Repeating oral dose
45813327|NCT04341805|Procedure|PrevOmega|The intervention consisted of placing a prosthesis at the umbilical trocar level with subsequent application of AGHO depending on the randomization performed.
45813328|NCT04341805|Procedure|Physiological saline|The intervention consisted of placing a prosthesis at the umbilical trocar level with subsequent application of SSF depending on the randomization performed.
45813329|NCT03654859|Other|cardiopulmonary resuscitation|no pre-specified
45813330|NCT01600092|Biological|RotaTeq™ experimental formulation|
45813331|NCT01600092|Biological|RotaTeq™ existing formulation|
45813332|NCT00364975|Behavioral|gourmet cooking workshop|
45813333|NCT02588599|Device|Erchonia LUNULA|Active low level laser light therapy
45813334|NCT02240628|Device|Lidocaine/tetracaine transdermal patch|All patients in arm 1 and arm 2 will receive the Synera Patch.
45813335|NCT02240628|Drug|Saline|Patients in arm 2 will receive Saline with the Propofol.
45813336|NCT02240628|Drug|Lidocaine|Patients in arm 1 will receive Lidocaine with the Propofol.
45951561|NCT00127829|Drug|Gefitinib|Oral tablet
45951562|NCT00497419|Procedure|fast track|
45951563|NCT00497458|Drug|Testosterone|testosterone 40 or 80 mg once a day
45951564|NCT00497497|Drug|bevacizumab|(Only for patients not previously treated with bevacizumab) Intravenous repeating dose
45951565|NCT00497497|Drug|cetuximab|Intravenous repeating dose
45951566|NCT00497497|Drug|FOLFIRI regimen|Intravenous repeating dose
45951567|NCT00497497|Drug|irinotecan|Intravenous repeating dose
45951568|NCT00497497|Drug|PRO95780|Intravenous repeating dose
45659981|NCT05564533|Behavioral|Heart-Smile Training Intensive Introduction Program (HST-IIP)|"Heart-Smile Training (HST) is an interoceptive compassion program designed to develop the qualities of compassion, empathy, and kindness for oneself and others with a focus on interoceptive awareness. It is unique from other compassion trainings in its focus on 1) embodiment of warmth and tenderness of compassionate feeling with a compassionate body scan meditation, 2) development of an authentic presence, characterized by a warm feeling of loosened attachment to ego-based self, and 3) cultivation of joy triggered by genuine smile to oneself. HST-IIP is a 3-day/4-week/1-day interoceptive compassion program that shares the same core elements and practices as HST 3-day intensive program. Unlike HST, the format of the HST-IIP has an extended duration to develop self-regulation through the cultivation of emotional and behavioral regulation."
46077339|NCT00943787|Procedure|Hyperinsulinemic, euglycemic and hypoglycemic clamp|At 21:30h, an overnight insulin infusion was titrated to control the subjects' BG overnight between 100 and 150mg/dL by blood sampling for plasma glucose via a YSI analyzer every 30min and adjusting the rate of insulin infusion as needed. At the beginning of the clamp, the overnight insulin was replaced by an insulin infusion via a Harvard pump given as a 20mU/kg priming over a 10-min period, followed by a constant rate delivery of 1mU/kg/min until the end of the clamp. Blood was sampled for plasma glucose, and glucose was clamped at basal levels for the euglycemic control period of 150min via a variable-rate infusion of 20% dextrose. Then the glucose concentration was lowered at a rate of 1mg/dL/min to a minimum of 50mg/dL, where it was held constant for 30min. Finally, the glucose concentration was increased at a rate of 1mg/dL/min to 90mg/dL, where it was held for an additional 30min. Blood was sampled for epinephrine during euglycemia, hypoglycemia, and recovery.
45659982|NCT04413955|Device|Seraph®-100 Microbind® Affinity Blood Filter|Use of an extracorporeal broad-spectrum sorbent hemoperfusion filter to removed SARS-CoV-2 virus and circulating cytokines from the blood
45951569|NCT01245088|Drug|chondroitin sulfate|400 mg orally three times daily for 8 weeks
46077340|NCT00895063|Behavioral|Vocal Exercise|This project will examine whether or not exercise performed immediately following botulinum toxin injection affects the clinical benefit received from the injection. This is a cross-over study and subjects will be randomly assigned to a group where they will speak continually for one hour or remain silent for one hour following injection. Data on the effectiveness of the exercise will be collected just before each injection and at 2 weeks, 6 weeks, and 3 months following injection.
45659983|NCT05498077|Procedure|Body scan meditation|Subject is placed through a brief body scan meditation to determine whether this intervention affects a person's pain experience
45659984|NCT05497843|Drug|Chiauranib|50mg, orally once daily
45659985|NCT04140955|Procedure|Tapering plan and telephone counselling|Before discharge, a tapering plan is made in collaboration between the patient and one of the investigators. The telephone counselling will include guidance of the patient and/or adjustments of the tapering plan if needed.
45659986|NCT05497765|Dietary Supplement|Silibinin extract, mixed power of pueraria, schisandra and salvia miltiorrhiza|Take 4 tablets with warm water twice a day
45951570|NCT00146406|Behavioral|Project Connect|
45951571|NCT00127868|Drug|oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo|
45951572|NCT00497536|Drug|Insulin Aspart (IAsp)|"IAsp 100 U.~≈ bolus protocol: From 6 pm until 6 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm~1 dose/h + 50 % s.c. (≈ bolus)."
46077341|NCT02751294|Drug|Tafenoquine Control|It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine
46077342|NCT02751294|Drug|Tafenoquine dissolution profile X|"It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine and will be intermediate aged TQ Product."
46077343|NCT02751294|Drug|Tafenoquine SIL|It will be compounded at site and will be administered as 0.3 mg/mL (100mL to be dosed, equivalent to 30 mg) aqueous Solution of SIL Tafenoquine.
46077344|NCT00895141|Dietary Supplement|Saturated Fat Diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat diet (40%E) with 8%E saturated fat
46077345|NCT00895141|Dietary Supplement|Saturated Fat Diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
46077346|NCT04220502|Drug|Magic Shave Powder Gold|Depilatory Cream for facial hair removal
46077347|NCT04220502|Device|Traditional Shaving Methods|Continued facial hair removal using traditional razors
46077348|NCT04107597|Other|Core stabilization exercises|Twelve specific exercises following a standard protocol aiming at an intersegmental stabilization of the spine and strengthening and stabilization of specific muscle groups. The exercises are performed under instruction and supervision by a physiotherapist twice per week for 45 minutes
45951573|NCT00497536|Drug|Insulin Aspart (IAsp).|"IAsp 100 U From 6 pm until 8 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm 50 % increase of basal rate"
45659987|NCT05497765|Dietary Supplement|Silibinin extract|Take 4 tablets with warm water twice a day
45659988|NCT05497765|Dietary Supplement|Placebo|Take 4 tablets with warm water twice a day
45659989|NCT05564143|Procedure|EUS-guided gastroenterostomy (EUS-GE)|Treatment
45659990|NCT05564143|Procedure|Laparoscopic gastroenterostomy (LGE)|Treatment
45659991|NCT05564065|Procedure|Radiofrequency thermocoagulation of sensory branches of hip joint|There are two main nerves that carry the pain sensation of the hip joint. These nerves are the femoral and obturator nerves. The sensory branches of these nerves going to the hip joint will be detected with a radiofrequency device under fluoroscopy and percutaneous ablation will be performed.
45951574|NCT00497536|Drug|Insulin Aspart (IAsp)|"IAsp 100 U From 6 pm until 8 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm 50 % increase of basal rate"
45951575|NCT00497614|Drug|adalimumab|
45951576|NCT00497653|Drug|DCI|D-chiro-inositol 1200mg twicely daily for 6 weeks
45951577|NCT00497653|Drug|Placebo|Placebo, twice daily for 6 weeks
45659992|NCT05564065|Procedure|Intraarticular steroid injection of hip joint|Fluoroscopy guided percutaneous intra articular steroid injection of hip joint will be performed
45951578|NCT00146445|Behavioral|Peer Mentoring Intervention|
45951579|NCT00127907|Drug|epinephrine (1 mg/1 mL)|
46077349|NCT04107597|Other|Core stabilization exercises and paced breathing training|Twelve specific exercises following a standard protocol aiming at an intersegmental stabilization of the spine and strengthening and stabilization of specific muscle groups. The exercises are performed under instruction and supervision by a physiotherapist twice per week for 45 minutes. In addition, the participants practice paced breathing training (before and during the CSE sessions as well as 15 minutes twice per day at home) which has a modulating effect on the autonomic nervous system
46077350|NCT04107597|Other|Myofascial trigger point release|A standard protocol of 12 myofascial and trigger point release grips followed by so-called roll-down maneuvers and manual rhythmical oscillation, applied to specific muscles and muscle groups. The treatment is applied twice per week for 45 minutes
46077351|NCT04107597|Other|Myofascial trigger point release and paced breathing training|A standard protocol of 12 myofascial and trigger point release grips followed by so-called roll-down maneuvers and manual rhythmical oscillation, applied to specific muscles and muscle groups. The treatment is applied twice per week for 45 minutes. In addition, the participants practice paced breathing training (before and during the MTPR sessions as well as 15 minutes twice per day at home) which has a modulating effect on the autonomic nervous system
46077352|NCT00901615|Drug|Lenalidomide and R-CHOP|Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
45659993|NCT04280575|Procedure|Percutaneous coronary intervention|Coronary artery stenting for stable angina
45659994|NCT05497609|Other|no intervention. Care as ususal|No intervention
45659995|NCT04047511|Device|VRTierOne|"As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VRTierOne Stolgraf® provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the lector (therapist) tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient influences the course of this story, becomes an active participant of the therapeutic process and sees the effects his work."
45659996|NCT04047511|Behavioral|Group general fitness training|A single session of general fitness training will be composed of low-intensity, general-fitness exercises. Most of the exercises will be carried out in a sitting position and standing positon. The session will contain aerobic (general warm-up), musculo-articular (strengthening muscles and joints range of motion) and stabilizing exercises (improve spatio-visual coordination). Perception of effort will be monitored using the Borg 6-20 rating the perceived exertion. Conducted by a physiotherapist in group form.
45813337|NCT02589067|Drug|Chlorhexidine gluconate|Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
45813338|NCT02589067|Drug|Saline Placebo|Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
45813339|NCT02511379|Other|Propylene Glycol 0.6% eye drops|
45813340|NCT02207400|Drug|Sodium bicarbonate and sodium fluoride|Experimental toothpaste containing sodium bicarbonate experimental dentifrice plus 1150 parts per million (ppm) fluoride as sodium fluoride
45813341|NCT02207400|Drug|Sodium fluoride|Comparator toothpaste containing 1100 ppm fluoride as sodium fluoride
45813342|NCT02511535|Biological|TBE booster vaccination|
45813343|NCT04341961|Other|Pomegranate Juice|Drinking 8 oz of pomegranate juice daily for 2 weeks.
45951580|NCT00127907|Drug|arginine-vasopressin (40 UI/2 mL)|
45951581|NCT00497692|Drug|Lactoserum|
45951582|NCT00497731|Drug|AZD1152|2-hour continuous intravenous infusion
45951583|NCT00497809|Drug|AVI-014 versus Filgrastim|3 different dose arms of AVI-014 versus Filgrastim for up to 14 days daily
45951584|NCT00146484|Drug|Twice Daily versus Three Times Daily Insulin Injections|
45951585|NCT00402584|Drug|sibutramine|
45951586|NCT00497848|Behavioral|motivational interviewing|"An individual intervention building on the Motivational Interviewing by Miller and Rollnick. Several studies has proved effectiveness of this therapy form in improving drug compliance. Patients will be offered individual motivational therapy"
45951587|NCT00497848|Other|The System-Orientated Intervention|"Principles in this intervention come from Clinical Risk Managing and quality assurance. It focuses on daily problems in drug handling, including dropping out of drug therapy, by looking at the system as a whole.Some cases, where patients dropped out of drug therapy will be carefully analysed in order to identify week points in the system, and subsequently alter the instructions for drug therapy, information, reminders and so on."
45659997|NCT04047511|Behavioral|Group Psychoeducation|A single sesstion will contain mini-lectures about mental well-being and psychohygiene, conduced by a psychotherapist in group form.
45659998|NCT03983707|Device|Purastat®|Use of Purastat®
45951588|NCT00497965|Procedure|Chiropractic Manipulation|
45951589|NCT00497965|Behavioral|Balance Exercises|
45951590|NCT00498004|Drug|Quetiapine, Risperidone|The dose of quetiapine will be titrated over 4 days to 300mg/day (50mg at day 1, 100mg at day 2, 200mg at day 3 and 300mg at day 4) and thereafter flexible dose will be administered depending on the clinical state. The dose of risperidone will be titrated as following 2mg at day 1 and 4mg at day 4 and thereafter flexible dose will be administered depending on the clinical state. The dosage of drugs should be 400-800mg/day of quetiapine and 4-6mg/day of risperidone between 6 and 8 weeks of trial.
45951591|NCT00146523|Drug|Mifepristone|
45813344|NCT03545035|Drug|idelalisib and rituximab|patients with treatment-naïve chronic lymphocytic leukemia (CLL) with TP53 disruption (i.e. 17p- or TP53 mutations) or relapsed/refractory CLL who were treated with idelalisib and rituximab
45951592|NCT00146523|Drug|placebo|
46077353|NCT00949325|Drug|temsirolimus plus liposomal doxorubicin|Patients were treated with temsirolimus (Torisel) weekly by IV and with liposomal doxorubicin (Doxil) (standard dose) by IV once every 28 days. Cohorts of patients receive sequentially increasing dose of temsirolimus until dose limiting toxicity (DLT) occurred and the maximally tolerated dose (MTD) was identified. The MTD dose was the standard dose of temsirolimus used for the remainder of the study. Dose modifications were based on protocol parameters for toxicities.
45813345|NCT03539341|Behavioral|PLH-Thailand parenting programme|Parenting programmes include developing positive caregiver-child interaction through child-led play and emotional communication, praise and rewards to encourage positive child behaviour, limit-setting behaviours such as effective instruction giving and establishing consistent household rules, and non-violent discipline strategies to replace harsh parenting and corporal punishment.
45813346|NCT03539341|Other|Control (care as usual)|The control will be an inactive condition of standard care at the time of the intervention. 'Standard care' may include access to Parent Schools in Mother and Child Health clinics at public hospitals, which are provided in some provinces and districts in Thailand.
45813347|NCT02589847|Biological|RBX2660|suspension of intestinal microbes
45813348|NCT02589847|Drug|Standard of Care Antibiotics|Standard of Care Antibiotics
45813349|NCT02512393|Device|Active tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 20 minutes once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
45951593|NCT00498043|Drug|R-CHOP14 induction regimen|R-CHOP14 induction regimen
45951594|NCT00498043|Drug|R-ACVBP14 induction regimen|R-ACVBP14 induction regimen
45951595|NCT00402623|Dietary Supplement|quercetin|1000 mg quercetin within 24 hours
45951596|NCT00402623|Other|placebo|
45951597|NCT00498121|Device|PROCALCITONIN LEVEL|measuring PROCALCITONIN LEVEL
46077354|NCT02755662|Device|Mandibular Retention Device|
46077355|NCT04107441|Drug|AX-8 Part 1|5, 10, 20, and 40 mg AX-8 orally disintegrating tablets (ODTs), up to 80 mg/day split over 2 time points, 8 hours apart (i.e. Dose 1: 0 hour and Dose 2: + 8 hours). AX-8 ODTs will be administered orally and will be dissolved on the back of the tongue while the subject is in a sitting position. The subjects will be instructed not to suck, chew or swallow the tablet, i.e. to allow it to dissolve on the back of the tongue without any further intervention.
45659999|NCT04424875|Drug|3 mg melatonin|patients will remove impacted third molar and receive 3 mg melatonin into 2 ml hydroxyethyl cellulose gel 2%
45660000|NCT04424875|Drug|Placebo|patients will remove impacted third molar and receive 2 ml hydroxyethyl cellulose gel 2%
45660001|NCT05563519|Procedure|I-PRF with collagen|The products will be applied to the sockets after tooth extractions
45660002|NCT05563519|Procedure|L-PRF|The products will be applied to the sockets after tooth extractions
45660003|NCT05563363|Other|Hospital-like treatment in patients' home|Hospital-like treatment in patients' home. Caregivers, medical doctors and social workers will make several visits per day to the patients' home. 24/7 contact is available.
45660004|NCT05563363|Other|standard inpatient treatment|Inpatient treatment on addiction ward
45951598|NCT00498199|Procedure|visual tests|
45951599|NCT04520490|Behavioral|Family Based Behavioral Treatment|Children with obesity accompanied by at least one parent or caregiver will attend 24 weekly sessions. Most sessions will be held via video-conference and include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. A select few sessions will be held in-person between an interventionist and each child/parent pair with no group session. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 8-12 children/families will be initiated every 3-6 mos. in study yrs. 2-3.
45951600|NCT04520490|Drug|Exenatide 2 mg [Bydureon]|Weekly injections of active drug.
45951601|NCT04520490|Drug|Placebo|Weekly placebo injections
45951602|NCT00498238|Drug|Levothyroxine|
45951603|NCT00498277|Procedure|Magnetic Resonance Imaging|One MRI sequence done to look for relative fat, and a second extra MRI sequence done to look for the diffusion.
45951604|NCT00402662|Drug|everolimus|
45951605|NCT00402662|Drug|Imatinib|
45951606|NCT00498316|Procedure|Cord Blood Infusion|Cord blood transplantation performed on day 0.
45951607|NCT00498316|Drug|Busulfan|32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are >1 and < 55 years old. Patients >55 but < 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
45660005|NCT03961555|Biological|SYN023|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
45660006|NCT03961555|Biological|HRIG (HyperRab)|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
45813350|NCT02512393|Device|Sham tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 30 seconds once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
45951608|NCT00498316|Drug|Fludarabine|"10 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are >1 and < 55 years old. Patients >55 but < 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).~40 mg/m2 by vein on Days -6 to -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.~40 mg/m2 by vein on Days -5 to -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are >1 and < 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3."
46077356|NCT04107441|Drug|AX-8 Part 2|5 and 40 mg AX-8 orally disintegrating tablets (ODTs), 45 mg/day split over 2 time points, 8 hours apart (i.e. Dose 1: 0 hour and Dose 2: + 8 hours). AX-8 ODTs will be administered orally and will be dissolved in the mouth while the subject is in a sitting position. The subjects will be instructed to actively move the tablet around in their mouth (i.e. active oral manipulation of the tablet) until it is fully dissolved.
46077357|NCT02539615|Device|ForeCYTE Breast Aspirator|
46077358|NCT00897169|Other|Oral Glucose Tolerance Test (OGTT)|A 5-hour oral glucose tolerance test (OGTT) is performed at visit 2
46077359|NCT00897169|Other|Euglycaemic hyperinsulinaemic clamp|A 4-hour euglycaemic, hyperinsulinaemic clamp is performed at visit 3
46077360|NCT02853071|Drug|Estramustine|
46077361|NCT02853071|Drug|standard practice|standard practice
46077362|NCT02755506|Device|endobronchial ultrasound elastography|Before endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), patients will undergo the examination of endobronchial ultrasound elastography
46077363|NCT00901771|Device|Provent|This is a non-randomized, single-arm, case series study. All subjects will receive Provent device.
46077364|NCT02852915|Procedure|Laparoscopic surgery|Laparoscopic surgery for T4 cancer
46077365|NCT02603757|Dietary Supplement|cholecalciferol|2,000 IU of Vitamin D3 daily and 50,000 IU Vitamin D3 daily
46077366|NCT02758782|Biological|Golimumab|
46077367|NCT02758782|Drug|Celecoxib|
46077368|NCT00897247|Genetic|microarray analysis|
46077369|NCT00897247|Genetic|protein expression analysis|
46077370|NCT00897247|Genetic|proteomic profiling|
46077371|NCT00897247|Other|laboratory biomarker analysis|
46077372|NCT02852369|Behavioral|Task Oriented Treatment|"The intervention administered during each of the training sessions was modeled after the protocol outlined in Winstein et al. (2013) however implementation was in the participant's home setting and involved tasks in the participant's real world.~The manual entitled, Upper-Extremity Task-Specific Training After Stroke or Disability by Lang and Birkenmeier (2014) was also utilized to give a general overview of task specific training for the upper extremity and to help guide each activity the participant chose to work on."
45660007|NCT03961555|Biological|Rabies vaccine|it should be administered in deltoid muscle
45660008|NCT04277845|Drug|Bortezomib, Lenalidomide, Dexamethasone|Bortezomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone
45660009|NCT03874117|Other|Twice weekly hemodialysis|Effect of hemodialysis prescriptions of twice weekly versus thrice weekly on quality of life will be evaluated. All hemodialysis will be prescribed to achieve adequate treatment based on current National Kidney Foundation guidelines.
45660010|NCT03874117|Other|Thrice weekly hemodialysis|Effect of hemodialysis prescriptions of twice weekly versus thrice weekly on quality of life will be evaluated. All hemodialysis will be prescribed to achieve adequate treatment based on current National Kidney Foundation guidelines.
45660011|NCT04072315|Drug|PLN-74809|PLN-74809
45660012|NCT04072315|Radiation|Knottin tracer|Radiotracer
45660013|NCT05497141|Device|Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System|Subjects who received Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System will be included in this arm. The Neoblazar® is intended for reconstruction of the insufficient tricuspid valve through tissue tissue approximation.
45813351|NCT04743115|Drug|BS HH 002.SA|"The Dose Escalation Part is a 3+3 design dose escalation study to determine the MTD of BS HH 002.SA in up to approximately 30 patients with the protocol AML indication or high risk MDS. Cohorts of 3 patients will be sequentially assigned to receive BS HH 002.SA at escalating DLs following the standard 3+3 dose escalation design, with 3 to 6 patients at each DL.~Cohort Expansion Part: Following determination of the MTD, the study will continue at the MTD and/or a lower DL"
45813352|NCT02592421|Drug|Dapagliflozin|SGLT2 inhibitor (dapagliflozin)
45813353|NCT02592421|Drug|Placebo|Placebo Comparator
45813354|NCT02512783|Drug|Lidocaine|Administration of 1ml of pre-treatment 1% lidocaine 1-minute prior to sedation
45813355|NCT02512783|Drug|Normal Saline|Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation
45813356|NCT02512783|Drug|Propofol|Intravenous administration of propofol according to standard care to sedate patient.
46077373|NCT02603835|Device|SSO2 Therapy|Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter
46077374|NCT00895219|Other|Breathing re-training|Breathing re-training
46077375|NCT00895219|Other|Breathing re-training and musculoskeletal techniques|Breathing re-training and musculoskeletal physiotherapy techniques including mobilisation techniques to normalise muscle and joint restrictions, doming of the diaphragm to enhance contraction and relaxation, and rib raising to free restriction in rib cage motion.
45951609|NCT00498316|Drug|Rituximab|375 mg/m2 by vein on Day -9 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
45951610|NCT00498316|Other|ATG|"1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.~1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are >1 and < 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3."
45951611|NCT00498316|Drug|Cyclophosphamide|50 mg/kg by vein on Day -6 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
45660014|NCT04277689|Procedure|Brain signal data collection|Collection of speech related electrophysiological data at the time of DBS.
45813357|NCT02513095|Drug|Dantrolene sodium for injectable suspension|Ryanodex will be administered as a rapid IV push as a single doses of 2 mg/kg or as 1 mg/kg.
45660015|NCT02559505|Biological|Seasonal IIV 0.25 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
45813358|NCT02592655|Device|Pneumatic Tourniquet|Automated pneumatic tourniquet, applied to middle upper thigh.
45813359|NCT02592655|Device|One Windlass Tourniquet|One Windlass Tourniquet 3.8 cm (1.5 inch) wide. A Special Operations Forces Tactical Tourniquet Wide (SOFTT-W) will be used for the windlass tourniquet. One windlass tourniquet will be applied to the middle upper thigh.
45813360|NCT02592655|Device|Two Windlass Tourniquets|Two Windlass Tourniquets will be applied by applying a second 3.8 cm (1.5 inch) wide windlass tourniquet immediately proximal to the first windlass tourniquet.
45951612|NCT00498316|Drug|Clofarabine|30 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are >1 and < 55 years old. Patients >55 but < 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
45951613|NCT00498316|Radiation|Total Body Irradiation (TBI)|200 cGy at 25 cGy/minute delivered on Day -3.
45951614|NCT00498316|Drug|Melphalan|140 mg/m2 by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are >1 and < 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3.
45951615|NCT00498316|Drug|Tacrolimus|0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present.
46077376|NCT04221672|Drug|Terlipressin plus standard care|All the participants received routine care after surgery. Intraoperative 1 mg, and 1 mg q12h from post-operative day 1 through day 4.
46077377|NCT04221672|Other|Standard care|All the participants received routine care after surgery only.
45660016|NCT02559505|Other|Natural influenza infection|Children enrolled on presentation to their primary care provider with a natural influenza infection
45660017|NCT02559505|Biological|Seasonal IIV 0.5 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
45951616|NCT00498316|Drug|Mycophenolate Mofetil|1 gram by vein twice a day Days -3 through Day 100.
45951617|NCT00498316|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on day 0, and continuing until the absolute neutrophil count (ANC) is > 2.5 x 109/L.
45951618|NCT00498394|Behavioral|Clinical diet trial|
45951619|NCT01245166|Drug|Acarbose|Acarbose 50 mg, per orem, thrice daily
45951620|NCT01245166|Drug|Metformin/Acarbose|Metformin HCl 500 mg plus Acarbose 50 mg Tablets, per orem, thrice daily
46077378|NCT02854865|Other|echocardiography|assess whether GLPSS measured during cardiac surgery using AFI is superior to E/Ea ratio in estimation of LVFP measured as PCWP
46077379|NCT02604069|Device|Continuous Glucose Monitor|
45660018|NCT04471597|Drug|normal saline 0.9%|5ml of normal saline 0.9% topically 15 min will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and the patient will be mechanically ventilated as usual.
45813361|NCT02592655|Device|Tourniquet Tape 5 cm|Tourniquet Tape is 5 cm (2 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
45951621|NCT00402701|Behavioral|Walking School Bus Program|Schoolwide promotion of walk to school. Facilitation of parent-led walking school bus routes.
45951622|NCT00498472|Procedure|Pre-discharge NT-ProBNP based treatment|"Discharge date, treatment and follow-up based also on the knowledge of NT-ProBNP levels measured at 2-3 days before discharge.~Discharge may be postponed and medical treatment may be changed when NT-ProBNP is >3000 pg/ml. Changes in medical treatment will include the following: increase in the diuretic dose, association of a different diuretic; combination of digoxin therapy; increase in the dose of the renin-angiotensin inhibitor; association of an ARB; association of a nitrate; short course of i.v. diuretic, vasodilator and/or inotropic therapy."
45951623|NCT00498511|Procedure|upper gastrointestinal endoscopy, colonoscopy|
46077380|NCT00895297|Drug|Dasatinib (Sprycel)|100mg of Dasatinib will be administered as tablets, by mouth, once a day (or twice in some cases depending on the stage of the disease) consistently either in the morning or evening for 12 months. Dose of Dasatinib will be modified according to the patients response.
46077381|NCT02695914|Drug|Compound Qingre Granule|A kind of Chinese patent medicine, which is developed by Dr.Shuwen Zhang and Dr.Baoen Wang from Beijing Friendship Hospital.
45813362|NCT02592655|Device|Tourniquet Tape 10 cm|Tourniquet Tape is 10 cm (4 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
45951624|NCT00146601|Drug|Fulvestrant|
45951625|NCT00498589|Drug|methotrexate|25 mg per week IM or SC during 24 weeks
45660019|NCT04471597|Drug|Bupivacaine Hydrochloride|5 ml of bupivacaine 0.5% will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and patient will be mechanically ventilated as usual.
45951626|NCT00498589|Drug|placebo|one intramuscular injection per week
45951627|NCT00498745|Drug|neratinib|HKI-272
45951628|NCT04517643|Other|Therasphere Therapy|TheraSphere is a radiotherapy treatment for primary and secondary liver neoplasia. This is an imaging study that will examine 3-5 patients who have been treated for metastatic colorectal cancer in the liver using TheraSphere®. Participation in the study involves an additional post-treatment SPECT/CT or PET/CT scan at (0-6) hours.
45951629|NCT00498784|Drug|Mirena|Mirena 52mg during 1 year
45951630|NCT00127946|Procedure|AMNIOECHANGE|The AMNIOECHANGE consists of a transabdominal infusion of saline (heated to 37 ° C) with a needle 18 or 20 gauge under ultrasound monitoring while avoiding the placenta. In the case of a normal amniotic fluid, it must be replaced volume per volume of saline (eg depending on the tank where the puncture is made, it can be 300 per 300 ml). The total amount of amniotic fluid exchange is 600-900 ml. In cases of oligohydramnios, the AMNIOECHANGE results in a normalized volume of amniotic fluid.
45951631|NCT00498901|Drug|goserelin|
46077382|NCT00943319|Drug|Busulfan|Daily intravenous dosing to target AVC
45660020|NCT04470349|Device|LITOS|Patients who received a LITOS dynamic distraction system after 31.12.2017
45813363|NCT00365131|Drug|Cerezyme (imiglucerase for injection)|
45813364|NCT02513641|Device|Hypoxico Altitude Training Systems|Participants will sleep in a tent (which will fit his/her personal mattress) simulating an altitude of ~2,400 meters for 7-12 hours each night for a period of 14 days. Baseline testing measures will include a oral glucose tolerance test (OGTT) and body composition (iDXA). Post-treatment testing measures will include OGTT only.
46077383|NCT00943319|Drug|Fludarabine|Fludarabine dosing will be based on actual body weight. Fludarabine will be infused over 30 minutes before busulfan treatment dose.
45660021|NCT04470349|Device|Ligamentotaxor|Patients who received a Ligamentotaxor dynamic distraction system after 31.12.2017
46077384|NCT00943319|Drug|Campath|All patients will receive premedication for Campath (daily doses of 20 mg are repeated for up to five times).
46077385|NCT00943319|Procedure|Stem Cell Transplant|Infusion of bone marrow and donors(related/ unrelated).
46077386|NCT02603991|Procedure|PINS Vagus Nerve Stimulator|The stimulators are implanted in the body,with the stimulation of the IPG
46077387|NCT02603991|Drug|Levetiracetam|The best anti-epileptic drugs to patients who participate in this study，Levetiracetam，
46077388|NCT02540785|Procedure|lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully
45660022|NCT05563207|Other|traditional Chinese medicine health education standard path|Both groups of patients were given routine treatment, and were intervened by the same batch of nursing staff.During chemotherapy, the patient's condition was closely observed, patiently listened to the patient's chief complaint, answered their questions, and instructed the patient to follow the doctor's instructions to prevent complications such as infection and bleeding.
45951632|NCT00498901|Drug|letrozole|
46077389|NCT02540785|Procedure|small-incision lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), make a small incision
45660023|NCT05563207|Other|The contents of the health intervention mainly included:Graphic and text education|When the patient was admitted to the hospital, the responsible nurse had a comprehensive understanding of the patient's disease cognition and psychological state, and based on this, an individualized intervention plan was formulated. With the help of publicity boards, brochures and other forms of pictures and texts, to popularize the knowledge and precautions of disease treatment for patients
46077390|NCT04243278|Drug|Low-dose aspirin|81 mg of low dose aspirin PO for 6 months
45813365|NCT02513719|Device|XIENCE PRIME SV Everolimus Eluting Coronary Stent|Patients receiving XIENCE PRIME SV Everolimus Eluting Stent
46077391|NCT04243278|Drug|Placebo oral tablet|placebo PO for 6 months
46077392|NCT00915369|Drug|Nanoxel (Paclitaxel Nanoparticle formulation )|Nanoxel (Nanoparticle Paclitaxel) at 4 different dose levels of 220, 260, 310 and 375 mg/m2. Each patient will recieve upto 6 cycles.
45813366|NCT00363727|Drug|ropinirole controlled-release (REQUIP CR) for RLS|
45660024|NCT05563207|Other|The contents of the health intervention mainly included:Language education|adopt one-to-one method to inform patients of the principles, effects and precautions of chemotherapy, eliminate patients' misunderstandings, and repeat language education for many times during the treatment process to strengthen patients' memory
45813367|NCT05372575|Biological|PCV13 PAC study|To test the serotype-specific IgG geometric mean concentration (GMC) and MOPA geometric mean titers (GMT) for each of the pneumococcal serotypes measured at the time of diagnosis of clinical pneumonia.
45813368|NCT02514889|Behavioral|Calorie-counting|"The Calorie Counting (CC) condition asks obese patients to achieve a daily calorie deficit. For average women consuming 2,000 calories at baseline, the target daily calorie total might be 1,600 calories. Participants are also asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the CC condition. The intervention protocol is adapted from the Diabetes Prevention Program. Behavior change strategies include: self-monitoring (e.g., calorie-counting, self-weighing), stimulus control, and relapse prevention strategies. The health coaching will occur during two home visits, two group health education sessions, and 7 telephone coaching calls."
45951633|NCT00498901|Drug|leuprolide acetate|
45951634|NCT00498901|Procedure|conventional surgery|
45951635|NCT04502043|Other|Exercise therapy|"Education~Hip-specific strengthening exercises~Functional lower limb strengthening exercises~Core stability exercises~Postural balance exercises"
45951636|NCT00498979|Biological|recombinant interferon alfa-2b|recombinant interferon alfa-2b
45951637|NCT00498979|Drug|cisplatin|recombinant interferon alfa-2b
45951638|NCT00498979|Drug|sodium stibogluconate|sodium stibogluconate
45951639|NCT00498979|Drug|dacarbazine|dacarbazine
45951640|NCT00498979|Drug|vinblastine|vinblastine
45951641|NCT01245205|Drug|Akt inhibitor MK2206|Given PO
45951642|NCT01245205|Drug|lapatinib ditosylate|Given PO
45951643|NCT01245205|Other|pharmacological study|Correlative studies
45951644|NCT01245205|Other|laboratory biomarker analysis|Correlative studies
46077393|NCT02854475|Procedure|Venous blood collection|weekly within two weeks
46077394|NCT02854475|Procedure|Raman spectroscopy|weekly within two weeks, on the volar forearm, using a RiverDiagnostics gen2-SCA Skin Composition Analyzer
46077395|NCT00901849|Drug|Tarceva and Rapamycin|Tarceva will be administered once a day for 28 days without interruption. THen Rapamycin will be administered, orally twice daily, in combination with the Tarceva for the remainder of the study.
46077396|NCT04243122|Drug|Apixaban 2.5 MG Oral Tablet [ELIQUIS]|2.5mg twice per day for 6 months Then treated & followed up as per standard of care
46077397|NCT04243122|Drug|Aspirin 81 mg|81mg once per day for 6 months Then treated & followed up as per standard of care
46077398|NCT05381831|Drug|NatestoTM|Administering daily intranasal testosterone, Natesto nasal gel is available as a metered-dose pump. One pump actuation delivers 5.5 mg of testosterone
46077399|NCT00897325|Other|Cytology Specimen Collection Procedure|Correlative studies
45951645|NCT01245244|Drug|Morphine|Morphine oral mixture
45951646|NCT01245244|Other|orange juice|orange juice
45951647|NCT00405717|Drug|atorvastatin,pravastatin|
45951648|NCT00499018|Drug|Rituximab|375 mg/m2 day 1
45951649|NCT00499018|Drug|Ciclofosfamide|1200 mg/m2 day 1
45951650|NCT00499018|Drug|Doxorubicina|70 mg/m2 day 1
45951651|NCT00499018|Drug|Vincristina|1,4 mg/m2 (max 2 mg) day 1
45951652|NCT00499018|Drug|Prednisone|100 mg day g 1-5
45660025|NCT05563207|Other|The contents of the health intervention mainly included:Psychological education|guide patients to express their own emotions, according to the patient's personality, cultural background, etc., after communicating with family members and negotiating, selectively inform the patient's actual condition
45813369|NCT02514889|Behavioral|MyPlate|"The MyPlate approach asks Americans to limit daily calories but emphasizes eating MORE high-satiation foods by making ½ of daily food choices fruits and vegetables,¼ of daily food choices whole grains. All participants are asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the MyPlate condition. MyPlate is adapted from the DASH protocol. Behavior change strategies include: progressive goal-setting, stimulus control, and self-monitoring (e.g., % of food choices that are fruits & vegetables). The health coaching will occur during two home visits, two group health education sessions, and 7 telephone behavior change coaching calls."
45951653|NCT00499018|Drug|Pegfilgrastim|6 mg day +1
45951654|NCT00499018|Drug|Mitoxantrone|8 mg/m2/days 1-3
45951655|NCT00499018|Drug|ARA-C|2000 mg/m2/12h day 1 - 3
45951656|NCT00499018|Drug|Lenograstim|5 μg/Kg/days +2
45951657|NCT00499018|Drug|BCNU|300 mg/m2 day -7
45951658|NCT00499018|Drug|ARA-C|200 mg/m2/12 days -6,-5,-4,-3
45951659|NCT00499018|Drug|VP-16|100 mg/m2/12h days -6,-5,-4,-3
45951660|NCT00499018|Procedure|ASCT|PBSC Reinfusion
45951661|NCT00499018|Drug|Ciclofosfamide|750 mg/m2 day 1
45951662|NCT00499018|Drug|Doxorubicina|50 mg/m2 day 1
45951663|NCT00499018|Drug|Vincristina|1,4 mg/m2 (max 2 mg) day 1
45951664|NCT00127985|Drug|6-methyl-prednisolone|iv, 2 mg/kg/day, qid
45951665|NCT00499057|Radiation|interstitial high dose-rate brachytherapy, PBI|Single arm study Treatment schedule is 4 Gy twice a day, with a time relapse of at least 6 hours between each fraction, for four days, for a total dose 32 Gy.
45951666|NCT00424164|Drug|lapatinib ditosylate|
45951667|NCT00424164|Drug|tamoxifen citrate|
45951668|NCT00424164|Other|pharmacological study|
45951669|NCT00128024|Drug|lipid-lowering treatment|
45951670|NCT00499135|Other|Computed Tomography|Correlative studies
45951671|NCT00499135|Other|Fluorothymidine F-18|Correlative studies
45951672|NCT00499135|Other|Laboratory Biomarker Analysis|Correlative studies
45951673|NCT00499135|Other|Pharmacological Study|Correlative studies
45951674|NCT00499135|Other|Positron Emission Tomography|Correlative studies
45951675|NCT00499135|Drug|Sunitinib Malate|Given PO
45951676|NCT01245361|Drug|Infliximab|Infliximab 3 mg/kg wk 0,2,6
45660026|NCT05563207|Other|The contents of the health intervention mainly included:Dietary education|instruct patients to follow the principles of light, easy to digest and balanced nutrition
45660027|NCT05563207|Other|The contents of the health intervention mainly included:Complication education|Actively inform patients about complications in advance, and guide their prevention methods, such as increasing water intake, avoiding activities of affected limbs after chemotherapy, etc. Patients with vomiting, hair loss and other adverse reactions are prone to negative emotions such as anxiety and depression , timely take corresponding measures and appease the patient, inform them that it is a normal phenomenon, and guide them to maintain a good attitude.
45660028|NCT05563129|Other|First aid lessons|The school children will have first aid training
45951677|NCT01245361|Drug|sodium chloride|Group II : Placebo wk 0,2,6
45951678|NCT01245400|Device|Z-Lig|ACL replacement
45951679|NCT01245400|Device|allograft|ACL replacement
45951680|NCT00424203|Drug|AC regimen|
45951681|NCT00424203|Drug|cyclophosphamide|
45951682|NCT00424203|Drug|doxorubicin hydrochloride|
45951683|NCT00424203|Procedure|adjuvant therapy|
45951684|NCT00424203|Procedure|cognitive assessment|
45951685|NCT00424203|Procedure|management of therapy complications|
45951686|NCT00424203|Procedure|psychosocial assessment and care|
45951687|NCT00424203|Procedure|quality-of-life assessment|
45951688|NCT00128063|Drug|succinylated human serum albumin|
45951689|NCT00499213|Procedure|Home Care Assisted Peritoneal Dialysis|
45951690|NCT01245556|Drug|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, Q 12 h daily, Continuously
45951691|NCT01245556|Drug|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg Q 12 h daily for 3 weeks with 3 weeks interval for 4 cycles, then Q12 h daily for 3 weeks every 12 weeks, Continuously
45951692|NCT01245556|Drug|Ipilimumab|Vial, IV, escalating doses starting at 3 mg/kg, Once every 3 weeks for 6 weeks, then once every 12 weeks, Continuously
45813370|NCT05372497|Other|intervention group|"Participants randomized to this treatment will receive a central nervous system-focused intervention consisting of a 20-session treatment program delivered in 30-45-minute sessions scheduled 5 days a week over a 4-week period and standard physical therapy will be continued.~Chronic pain training will be given according to the needs of the person and 5-10 minutes will be allocated every day for the first week and chronic pain education will be divided into modules.~Right / Left Discrimination Training~Localization Training Level 1- Level 2 Training~Visual imagination Training~Visual Imagery Training~Mirror Therapy~Isometric and functional exercises"
45813371|NCT05372497|Other|control group|"The control group will receive only conventional physiotherapy. Conventional physiotherapy will be 5 days a week.~The conventional physiotherapy treatment session will take place as follows.~Scapular mobilization~Passive stretches~Stick Exercises~Pendulum Exercises~Shoulder flexion, extension, internal rotation, external rotation, horizontal abduction/ adduction strengthening exercises~Conventional physiotherapy intervention is planned for 45-60 minutes a day, five days a week for both groups."
45813372|NCT03230773|Device|Defibrillator model|Comparison of the performance of different public access defibrillators
45951693|NCT01245556|Drug|Ipilimumab|Vial, IV, escalating doses starting at 3 mg/kg, Once every 6 weeks for 4 cycles, then once every 12 weeks, Continuously
45951694|NCT02274532|Device|SoftHand|Biomechanical, ADL, and functional testing.
45951695|NCT00128141|Behavioral|Tactile stimulus|four times a day
45951696|NCT04480671|Procedure|Level III support procedure|A level III support procedure is aimed at repairing the distal support of the vagina with either a posterior colporrhaphy and/or a perineorrhaphy.
45951697|NCT04480671|Procedure|Minimally Invasive Sacrocolpopexy|All study participants are planning with their surgeon a minimally invasive sacrocolpopexy (robotic or laparoscopic) to repair pelvic organ prolapse.
45813373|NCT02515825|Device|CADence|
45813374|NCT03074305|Device|PCI for in-bioresorbable scaffold stenosis|"In patients who have in-bioresorbable scaffold stenosis after bioresorbable scaffold implantation, PCI will performed according to the allocated arms~DEB strategy~DES strategy"
45813375|NCT04340869|Other|Theobromine|Natural extract from Cocoa
45813376|NCT04340869|Other|Remin Pro|Remin Pro
45951698|NCT04480671|Other|Transperineal ultrasound of the Pelvic Floor|Subjects from either arm will be invited to participate in this exploratory arm of the study. If they choose to participate, they will have a preoperative ultrasound performed and an ultrasound performed at the time of their 6 month visit.
45951699|NCT00499525|Drug|paclitaxel|given IV
45951700|NCT00499525|Drug|sorafenib tosylate|given orallly
45813377|NCT05668819|Device|TH-001|TH001 is a software program intended to treat adults with prediabetes.
45458444|NCT03500770|Device|Transcranial Direct Current Stimulator|The tDCS device to be used will be an investigational, battery powered, custom-made stimulator able to deliver a biphasic alternate current. Active stimulation consists of 10 active tDCS sessions with current intensity fixed at 2mA for 20 minutes. It has been safely used in several other research studies. The side effects profile for this type of stimulation include tingling/itching at the site of stimulation, skin irritation/redness at the site of stimulation, headache or dizziness.
45951701|NCT00499525|Other|placebo|given orally
45951702|NCT01245790|Drug|fostamatinib|Oral tablets, single dose
45951703|NCT01245829|Other|Swabbing of observation chart|The observation charts to be studied will be stored on the DMH critical care unit and all existing non-laminated white charts removed for the duration of the study period. The observation charts will thereafter be used in the normal way as defined by nursing practice; blue charts from patient admission (irrespective of time) and white charts for each 24 hour period thereafter commencing at 8 am. On placement and after 24 hours of use, a standardised section of the patient observation area will be swabbed by the data collection researcher. The standardised area is defined as the section of the chart that is most comprehensively completed during the patient episode and is therefore most likely to become contaminated through contact. Use of white charts only is required in order to standardise the length of time each chart is in place between the two points of swabbing (white charts present at 8 am have been in use for exactly 24 hours).
46077400|NCT00897325|Other|Laboratory Biomarker Analysis|Correlative studies
46077401|NCT02758548|Procedure|Blood sample|Fingerprick and venous
46077402|NCT02758548|Device|POCT device|Investigational device
45660029|NCT03806179|Drug|Betalutin|Betalutin 10, 15 MBq/kg; lilotomab 40mg, rituximab 375 mg/m2
45660030|NCT05562739|Dietary Supplement|Postbiotic|multistrain postbiotic in the form of a capsule with a daily dose of 1E+9 Colony Forming Unit (CFU) per day for 6 weeks.
45660031|NCT05562739|Dietary Supplement|Placebo|Matching placebo in a form of a capsule for 6 weeks.
45660032|NCT05497063|Drug|Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine & 500 mg sulfadoxine / 25 mg pyrimethamine|Two tablets of 250 mg sulfadoxine / 12.5 mg pyrimethamine or 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
45660033|NCT05497063|Drug|G-COSPE® tablets|One tablet of G-COSPE® tablets, 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
45660034|NCT05496985|Diagnostic Test|Simplified Evaluation of CONsciousness Disorders (SECONDs)|All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs) and Coma Recovery Scale-Revised (CRS-R)
45813378|NCT00366067|Drug|Phenytoin|
45951704|NCT00128258|Procedure|Injection of bone marrow cells in the heart|Biological implant into the heart
45951705|NCT00128258|Biological|Biological bone marrow cell therapy|Biological implant into the heart
45813379|NCT02460835|Radiation|Adaptive Radiation Therapy|
45951706|NCT00146679|Behavioral|Psychoeducational Telephone counseling (TC)|Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided through telephone sessions
45951707|NCT00146679|Behavioral|Psychoeducational Intervention by Group (SG)|Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided in 4 group sessions
45951708|NCT00146679|Behavioral|Usual Care|Usual Care provided by providers
45951709|NCT00499642|Drug|Lecozotan SR|
45951710|NCT00499642|Drug|Moxifloxacin|
45951711|NCT00499720|Drug|Aztreonam Lysine for Inhalation|75 mg three times a day via inhalation for 28 days followed by 28 days off drug.
45951712|NCT04457076|Drug|LevoCept|Levonorgestrel-Releasing Intrauterine System
45951713|NCT00499759|Behavioral|Resting vitals|The fitness assessments will include the assessment of resting vitals including, blood pressure, heart rate, and hemoglobin saturation (pulse oximeter).
45951714|NCT00499759|Behavioral|Body Composition|Body composition and body circumference measurements (anthropometry) will be the only assessments performed multiple times during the study to monitor possible changes in the body composition and swelling of the patients. Body composition analyses will be performed via skinfold measurements following generalized three-site skinfold equations for male and females as recommended by the ACSM, 2005 and via the utilization of a bioelectrical impedance body fat analyzer device.
45951715|NCT00499759|Behavioral|Timed Get-up and Go test (TGUG).|"The functional mobility of the subjects that will participate in the study will be assessed through the Timed Get-up and Go test (TGUG). The administration of the TGUG includes measuring a distance of 3 meters from the legs of a straight-backed armchair with a seat height of approximately 46 centimeters. The subject will be asked to sit with the back against the chair with the arms on the arm rests. When instructed to begin the test (on the command Go), the subject will have to stand upright then walk at a normal walking pace toward the 3 meters mark placed on the ground, turn around, return to the chair, and sit down. The stopwatch was started on the word Go and stopped when the subject gets back to starting position."
45951716|NCT00499759|Behavioral|Cardiorespiratory assessment|The cardiorespiratory assessment will be performed on a recumbent cycle ergometer. Subjects will be asked to cycle at a target submaximal intensity of 60 % of their percentage of heart rate range until a RPE (Rate of Perceived Exertion) of 7 is reached on the modified Borg Scale or when the subject requests termination. The Borg modified RPE scale is a scale ranging from 0 to 11 where 0 means no exertion at all and 11 equals to an exertion of absolute maximum. The total time cycling and heart rate (HR) at the end of the test will be recorded immediately after the test is completed.
45951717|NCT00499759|Behavioral|Handgrip evaluation|Handgrip strength will be tested using a handgrip dynamometer. Subjects will be asked to stand and hold the handgrip dynamometer in one hand lined with the forearm that will be placed beside the body. Maximum grip strength is then determined without swinging the arm and by squeezing the handgrip dynamometer as hard as possible using one brief maximal contraction with no extraneous body movement. The test will be administered three times for each hand with a one-minute rest in between trials. The best score within the three trials for each arm will be the one that will be used for analysis.
45951718|NCT00499759|Behavioral|Dynamic muscular endurance|Subjects will be asked to squat to a 75 degree knee angle with moderate speed, pressing back against the ball at all times. This is repeated as many repetitions as it takes for the subject to report an RPE of 7 or wishes to stop. The second test is the biceps curl exercise. The biceps curls exercise test will follow a protocol developed at the Rocky Mountain Cancer Rehabilitation Institute (RMCRI), Greeley, Colorado. The protocol involves the administration of the exercise biceps curls, done with dumbbells. Subjects will be asked to perform as many repetitions as possible during an alternated biceps curl exercise using a percentage of their body weight as resistance.
45951719|NCT05562518|Drug|Estrogen|1 vaginal ovule daily for three consecutive weeks, followed by 1 vaginal ovule 2 times per week
45951720|NCT05562518|Drug|dehydroepiandrosterone|1 vaginal ovule daily
45951721|NCT05562518|Drug|Estrogen + probiotics|2 vaginal ovules daily for 5 consecutive days, repeated every 4 weeks
45813380|NCT02343757|Device|PET/MRI|
45813381|NCT01994239|Drug|Degarelix|First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)
45813382|NCT01994239|Radiation|Pelvic Radiotherapy|46 Gy in 23 fractions Prostate only-boost up to 66 Gy
45813383|NCT00364429|Drug|[123]I-CNS 1261|Study Drug
45951722|NCT05562518|Drug|Moisturizer|1 vaginal ovule daily for 10 consecutive days, followed by 1 vaginal ovule every three days
45951723|NCT00499837|Drug|Aerosolized, human, plasma-derived Alpha-1 Antitrypsin|
45951724|NCT00499876|Drug|mefloquine|250mg weekly PO for 6 months
45951725|NCT00499876|Other|placebo|1 tablet weekly PO for 6 months
45951726|NCT00146718|Drug|Amodiaquine and Sulphadoxine/Pyrimethamine|
45458445|NCT01351532|Behavioral|smoking cessation program|cross-theoretical model integrating smoking cessation counseling, smoking cessation drug utilization, physician interview and telephone counseling persuasion,
45458446|NCT01351532|Behavioral|Lifestyle counseling|ross-theoretical model integrating smoking cessation counseling,physician interview and telephone counseling persuasion
45813384|NCT00364429|Drug|Lorazepam|Study Drug
45951727|NCT00499954|Procedure|Microdialysis|
45951728|NCT00499954|Device|Guardian RT|
45951729|NCT00499954|Device|Glucoday S|
45458447|NCT02321566|Device|Epidural Motor Cortex Stimulation|
45813385|NCT00364429|Drug|Risperidone|Study Drug
45813386|NCT00364585|Device|GreenLight Model 120 Laser System|
45813387|NCT02593903|Drug|Septra|
45813388|NCT02596321|Drug|Mitizax|Allergen extract
45813389|NCT02596321|Drug|Placebo|Placebo tablet
45813390|NCT02596867|Drug|propanolol|Participants will take 1.5 mg/kg/day propranolol, twice daily for 3 weeks until surgical resection of the breast tumor is performed
45813391|NCT02597101|Drug|Metformin|background drug
45951730|NCT05562401|Device|Coconut Water|Coconut water is the clear fluid inside the coconut, has natural electrolytes such as potassium, sodium and manganese.
45951731|NCT05562401|Drug|Sport Drink|A type to sport drink is isotonic drink. Is an industrialized drink that containing water, carbohydrates, and 4-8% electrolytes.
45813392|NCT02597101|Drug|saxagliptin|background drug
45951732|NCT00499993|Drug|lanreotide (Autogel formulation), duration of treatment 46-48 weeks|
45951733|NCT00500032|Procedure|blood draw|Blood draw from subjects previously vaccinated in 6108A1-500 trial
45813393|NCT02597101|Drug|AZD9668|study drug
45813394|NCT02597101|Drug|placebo|placebo for AZD9668 to be added to background drugs
45951734|NCT00500188|Drug|Imatinib Mesylate (Gleevec)|300 mg orally twice daily
45951735|NCT00146796|Device|Rapid diagnostic test for malaria|
45951736|NCT04710914|Drug|Prolonged sedation with isoflurane|"Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam"
45458448|NCT01351610|Biological|PTA + Infusion of MSC_Apceth|percutaneous transluminal angioplasty followed by infusion of MSC_Apceth
45458449|NCT01351610|Procedure|PTA|percutaneous transluminal angioplasty only
45951737|NCT04710914|Drug|Prolonged sedation with midazolam|"Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam"
45660035|NCT05496829|Behavioral|Multicomponent Adherence Intervention|The adherence intervention will be comprised of a participant preference approach in which all participants undergo a baseline pharmacist-led medication optimization session and are offered training in how to use the patient portal and freely-available smartphone reminder app.
45951738|NCT00500305|Procedure|Withhold standard INDO dose if BNP < 100 pg/ml|
46077403|NCT04107363|Procedure|Oropharyngeal aspiration before changing the position of the patient|"Patients in the experimental group underwent oropharyngeal aspiration prior to each position change in addition to routine nursing care (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).~Patients in this group underwent oropharyngeal aspiration at least 9 times in 24 hours with a pressure of 100-120 mmHg for 10 seconds prior to routine (2 hours a day, 4 hours a night) and non-routine position changes. After the oropharyngeal aspiration was completed, the patient's position was changed."
45660036|NCT05496829|Other|Usual Care|Receipt of usual care from providers
45660037|NCT03660631|Behavioral|CVRS Intervention|"Evaluate gaps in therapy~Contact patients regularly by email, phone and/or text message~Assess and counsel for medication adherence, side effects, life-style behaviors~Develop an action plan and send recommendations to provider"
45458450|NCT02325232|Device|Capsule endoscopy, double balloon enteroscopy sequential use|Small bowel capsule endoscopy followed by double-balloon enteroscopy with histological sampling in case of mucosal alterations
45458451|NCT01363934|Drug|GC1113|"Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously."
45676538|NCT02266134|Behavioral|Standard Implementation of Measurement Based Care|Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire (PHQ-9); the implementation of measurement-based care will be standardized such that clinicians will be encouraged to administer the PHQ-9 to depressed clients before each session.
45813395|NCT05578261|Device|intermittent theta burst stimulation|stimulatory protocol
45813396|NCT02600611|Drug|iclaprim|Experimental treatment
45813397|NCT02600611|Drug|vancomycin|Active comparator
45813398|NCT02600767|Drug|Artemether-lumefantrine combination|This is the sole arm in this study and it is the use of the standard combination therapy for treatment of P. falciparum malaria.
45813399|NCT00365287|Drug|anti-thymocyte globulin|
45813400|NCT00365287|Drug|cyclophosphamide|
45813401|NCT00365287|Drug|cyclosporine|
45813402|NCT00365287|Drug|fludarabine phosphate|
45813403|NCT00365287|Drug|mycophenolate mofetil|
45951739|NCT00500344|Drug|Lucentis (ranibizumab)|intravitreal injection
45951740|NCT00146835|Biological|Pediarix|1 or more injections
45951741|NCT00146835|Biological|Licensed DTPa containing vaccine|1 or more injections
45813404|NCT00365287|Procedure|radiation therapy|
45813405|NCT00365287|Procedure|umbilical cord blood transplantation|
45813406|NCT00365443|Biological|V502|
45813407|NCT00365521|Procedure|Photodynamic Therapy|
45951742|NCT00146835|Biological|Prevnar®: (Wyeth)|Concomitant vaccination
45951743|NCT01245868|Drug|Lidocaine|
45951744|NCT01245868|Drug|bupivacaine|
45951745|NCT05562362|Drug|RE-021, sparsentan|RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level
45951746|NCT00500422|Drug|Doxil|Starting dose of 20 mg/m^2 IV over 2 hours on Day 1, 21 day cycle
45951747|NCT00500422|Drug|Gemcitabine|500 mg/m^2 IV over 30 minutes on Days 1 and 8, 21 day cycle
45951748|NCT00500422|Drug|Velcade|Starting dose of 0.7 mg/m^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles
45951749|NCT00146874|Device|cardiac resynchronization therapy|
45813408|NCT04743193|Other|2.5 %sevoflurane|for 35 patients after reaching 1 MAK level with 4 lt / min fresh gas flow and 2,5% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 minimum alveolar concentration
45813409|NCT04743193|Other|8% sevoflurane low flow anesthesia|For 35 patients after reaching 1 (MAC) level with 1 lt / min fresh gas flow and 8% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration, targeting 1 MAC. .
45951750|NCT00500461|Drug|GSK233705|GSK233705 will be available as IV infusion and oral solution containing Cellobiose octaacetate.
45676539|NCT02197845|Behavioral|Patient Navigator|A specially trained (SCD knowledgable) Patient Navigator will act as a liaison who assists participants in increasing adherence to HU through disease education, addressing barriers to care and improving adherence to HU. PN utilize various techniques geared toward the individual patients needs. Interventions utilized by a PN include improving disease management skills, educational materials about disease, HU adherence, motivational interviewing, care coordination and social support.
45951751|NCT05562284|Procedure|intra-arterial thrombolysis|IAT introduces rt-PA directly into the ophthalmic circulation by super-selective microcatheterization.
45951752|NCT05562284|Other|conservative treatments|conservative treatments
45951753|NCT00500617|Diagnostic Test|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
45951754|NCT00500695|Behavioral|Motivational Interviewing|Motivational Interviewing
45951755|NCT00500695|Behavioral|Psychoeducation|Psychoeducation
45951756|NCT00500734|Procedure|Blood Sample|One time blood draw of 2 teaspoons.
45951757|NCT05562245|Other|Motivational Interviewing-Based Breastfeeding Education|"Motivational interviewing is basically a directive and client-centered psychosocial intervention used to help individuals discover and analyze ambivalent emotions related to their health behaviors, to learn new skills and to improve their existing skills. One of the main guiding principles in motivational interviewing is self-support and empowerment. The interviews consist of one to four sessions lasting between 7.5-60 minutes.~A total of four motivational interviews will be held with the mothers in the experimental group."
45951758|NCT00500851|Device|Electromagnetic imaging for jejunal tube placement (CORTRAK)|Jejunal feeding tubes are placed using electromagnetic imaging (CORTRAK)
45951759|NCT00500851|Device|Endoscopy|Endoscopic placement of jejunal feeding tubes
45951760|NCT00500929|Drug|CMI X-11S|
45951761|NCT01245946|Procedure|Photodynamic therapy|Photodynamic therapy: 2 sessions separated by 2 weeks of TDF with topical ALA20% for 1.5 hrs, then irradiated with red light (Waldmann lamp) at a fluence of 37 J/cm2 for 7-9 minutes. From the sixth week will begin adapalene 0.1% gel until 12 weeks
46077404|NCT04107363|Other|Control group:|The patients in the control group received routine nursing care in the unit. (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).
46077405|NCT04268927|Drug|GnRH ant/letrozole|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
45813410|NCT05371249|Drug|Vonoprazan-based triple therapy|vonoprazan 20mg+amoxicillin 1000 mg + clarithromycin 500 mg twice daily for seven days
45951762|NCT01245946|Drug|Conventional therapy|Conventional therapy: Topical adapalene gel 0.1% at night for 12 weeks plus doxycycline 100 mg / day for 6 weeks.
45951763|NCT05562206|Device|CGMIS (Continuous Glucose Monitoring Infusion Set)|An integrated combination CGM/insulin infusion system
45951764|NCT01245985|Radiation|carbon ion boost|patients receive induction chemotherapy with TPF for a maximum of 3 cycles followed by radioimmunotherapy with cetuximab as intensity-modulated radiotherapy (IMRT) plus carbon ion boost
45951765|NCT01246024|Device|ERG|scotopic and photopic ERG
45951766|NCT00500968|Procedure|stent|ERCP guided stent insertion before transection of the gland
45951767|NCT00500968|Procedure|Distal pancreatectomy|conventional distal pancreatectomy
45951768|NCT00146913|Drug|Imatinib mesylate 600mg/day|
45951769|NCT00146913|Drug|Peg-Interféron at 90 microg/week|
45951770|NCT00501124|Drug|Clevudine|
45951771|NCT00501124|Biological|Purified hepatitis B surface antigen|
45951772|NCT00501241|Drug|ATI-7505|Tablet,placebo, BID
45951773|NCT00501241|Drug|ATI-7505|ATI-7505 20 mg BID for 4 weeks
45951774|NCT00501241|Drug|ATI-7505|tablet, 40 mg, BID, $ weeks
45951775|NCT00501241|Drug|ATI-7505|80 mg ATI-7505, BID for 4 weeks
45951776|NCT00501241|Drug|ATI-7505|120 mg ATI-7505, BID, for 4 weeks
45951777|NCT00146952|Device|Vibrotactile feedback|
45951778|NCT01246102|Drug|AT13387|Treatment will be administered as a 1-hour IV infusion on 2 consecutive days of every week for 3 weeks, followed by a 1-week period without drug administration.
45951779|NCT00501280|Behavioral|Interview|Interview by telephone or on-site in language of choice (English or Spanish), 60 to 70 minutes to complete the mother's and the child participants' questionnaires
45951780|NCT01246180|Drug|Diclofenac|diclofenac 5% vs placebo (topical application) cutaneous blood flow measurement using laser Doppler
45951781|NCT01246180|Drug|Amiloride|amiloride 1mM vs placebo (intradermal injection) cutaneous blood flow measurement using laser Doppler
45951782|NCT01246219|Drug|GH treatment (Genotropin)|4 years treatment with GH
45951783|NCT01246219|Drug|1 year treatment with placebo followed by optional 3 years of GH treatment|1 year treatment with placebo followed by optional 3 years of GH treatment
45951784|NCT05561972|Device|injectable multifractional intercalated hyaluronic acid [Armonia®, Regenyal, Italy]|Armonia® 2 ml was injected into the vaginal wall with a standardized injection technique called Cannulated Intravaginal Injection Technique®. In this technique, Armonia® was injected as drops at 40 different points on the entire vaginal wall using 8 different entry points
45951785|NCT02274610|Drug|Docetaxel-PNP|Docetaxel Polymeric Nanoparticle Formulation
45951786|NCT02274610|Drug|Taxotere|Docetaxel
45951787|NCT00147108|Device|ExAblate 2000|
45951788|NCT05561855|Behavioral|lifestyle intervention|"During the 3-month lifestyle intervention period, the participants need to complete the weight monitoring, behavioral goal recording, diet and exercise recording, online course learning by using the WeChat official account module of Weight Loss and Glucose Control.They will receive corresponding feedback and integral rewards every week, and receive monthly follow-ups to complete health education, goal review, motivational interview as well as collecting medication changes and blood glucose monitoring data."
45951789|NCT00501397|Drug|ketoconazole|
45951790|NCT00501397|Drug|GSK189075|
45951791|NCT00501475|Drug|NAC Bicarbonate|
45813411|NCT05371249|Drug|Extended sequential therapy|Lansoprazole 30mg + amoxicillin 1000mg twice daily for 7 days, followed by lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg twice daily for 7 days
45951792|NCT00147147|Procedure|Gastrectomy with D2 or greater lymph node dissection|
45660038|NCT04424719|Other|Blood test|"High risk patients are referred for the medical oncology consultation to organize oncological surveillance after general staging of the disease. Signature of the informed consent of SALOME study, inclusion in the study and risk-adjusted surveillance schedule :~(i) Liver MRI every 6 months performed at the expert center for UM (according to guidelines).~(ii) For enucleated patients, a blood sample (3 x 6 ml EDTA tubes) is taken every 6 months according to the schedule below. Plasma and mononucleated cells will be isolated and preserved for bio-markers research.~M0 : during the first medical oncology visit.~At each imaging assessment, every 6 months for at least 5 years (M6 to M60) and 10 years maximum (M120).~At the diagnosis of metastasis.~At each significant event during the metastatic disease (surgery, treatment response or progression)."
45676540|NCT02197845|Behavioral|Recruitment into Specialty Care|A specially trained (SCD knowledgeable) Patient Navigator will act as a liaison to participants in increasing adherence to Hydroxyurea. Interventions utilized by a PN include teaching disease management skills, addressing barriers to care, disease education, HU management, motivational interviewing, care coordination and social support.
45951793|NCT00147147|Drug|Gastrectomy+ chemotherapy|
45813412|NCT05371171|Procedure|skin graft|In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing [Alleyvn, Smith, & Nephew] was placed on the regrafted skin for fixation
45813413|NCT05371171|Procedure|no skin graft|In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing [Alleyvn, Smith, & Nephew] was placed on the regrafted skin for fixation
45813414|NCT05370937|Procedure|ARTROSCOPİC SURGERY WITH ELEVATOR SYSTEM|TRANSTİBİAL PULL OUT REPAİR FOR MEDİAL MENİSCUS POSTERİOR ROOT TEARS
45813415|NCT05370937|Procedure|ARTROSCOPİC SURGERY WITHOUT ELEVATOR SYSTEM|TRANSTİBİAL PULL OUT REPAİR FOR MEDİAL MENİSCUS POSTERİOR ROOT TEARS WITH ELEVATOR SYSTEM
45813416|NCT05366491|Diagnostic Test|Il-38 serum level|measurement of serum levels of IL-38
45951794|NCT01246336|Other|collection of exhaled breath|no intervention
45951795|NCT00501514|Drug|Growth hormone|
45951796|NCT05561816|Drug|Hydroxymethylquinoxalindioxyde|Dioxidin®, 0.025% solution for local and external use (Valenta Farm, Russia).
45951797|NCT05561816|Drug|Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium|Miramistin®, topical solution 0.01% (Infamed K LLC, Russia)
45951798|NCT00501670|Procedure|Herpes zoster sampling procedure for VZV PCR|Four types of HZ lesions will be collected (Swabs of vesicles, Swabs of papules, Swabs of crusts and Crusts), 3 replicates of each.
45951799|NCT00501670|Procedure|Blood sampling|Two blood samples taken, the first at the time of HZ diagnosis and the second one month later.
45951800|NCT00147186|Device|Hylan G-F 20|
45951801|NCT04697134|Behavioral|Conscious Discipline-Based Environmental Enrichment Intervention|Conscious Discipline, a social-emotional skills-based learning program that draws on current brain research and fosters enhanced connections between parents and their children.
45951802|NCT00501748|Drug|Rituximab|Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration. Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials. In this single arm study all subjects are treated with two cycles of rituximab. Each cycle consists of two 1000 mg infusions administered two weeks apart. The cycles of rituximab treatment are administered at baseline and at 9 months.
45951803|NCT00501787|Drug|Metformin|
46077406|NCT04268927|Drug|GnRH ant|"Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
46077407|NCT05569317|Other|primary nursing|The primary responsibility of one nurse for the planning, evaluation, and care of a patient throughout the course of illness, convalescence, and recovery.
45458452|NCT01363934|Drug|Darbepoetin alfa|Each Group volunteers (n=8) will be administered Darbepoetin alfa by IV or SC.
45813417|NCT05572645|Drug|Pyrotinib Plus Trastuzumab|treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
45660039|NCT04277611|Procedure|Subcostal Oblique Quadratus Lumborum Block and Erector Spinae Plain Block.|patients undergo general anesthesia,will be put in prone position.In case of Quadratus Lumborum block 1-3 mL of normal saline is injected to produce hydro-dissection and spread cranially between the QL and kidney. The corresponding ultrasonographic sign is a lunar-shaped hypo-echoic fluid collection observed between the long axis of the kidney and QL muscle. 20 ml Bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is administered. In case of the ESPB The location of the needle tip is confirmed by hydro-dissection and after visualizing the fluid spread lifting the Erector Spinae off the transverse process, 20 ml bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is injected.
45660040|NCT05562583|Behavioral|SAGE LEAF|"SAGE LEAF covers 8 skills and each skill has related home-practice activities that unlock every week. Each week will consist of 1-2 days of didactic material and 5-6 days of real-life home practice. Participants can access the skills at their own leisure and as often as they'd like within that week. Participants cannot skip modules with didactic material and can only progress to the next lesson if they have completed the current one. However, participants can return to old lessons or exercises if they choose to do so at a later time."
45951804|NCT05561699|Drug|Penpulimab Combined With CRT|"Penpulimab: 200mg, intravenous infusion, once every two weeks. After completing two courses of CRT, continue to send Penpulimab 200mg every two weeks on the first and 14th days after the completion of CRT, two courses of treatment, a total of four courses.~Radiotherapy 40gy/20fx, once a day from Monday to Friday, completed in 4 weeks;~PC regimen: Paclitaxel 50mg/m2, intravenous drip, carboplatin AUC=2mg/ml/min, intravenous drip, once a week during radiotherapy, a total of 4 courses, the specific time is D1, 8, 15, 22 days after the beginning of radiotherapy.~Gastrointestinal reactions such as nausea and vomiting should be routinely prevented before chemotherapy. Dexamethasone 10mg should be used 30 ~ 60 minutes before paclitaxel, and intramuscular injection should be stopped immediately in case of drug or infusion reactions."
45951805|NCT00501865|Drug|GW273225|GW273225 will be available as white tablets containing 25 mg GW273225.The study drug will be taken with 240 milliliters of water at room temperature.
45951806|NCT00147264|Drug|Telmisartan (Micardis®) vs. Placebo|
45951807|NCT00147264|Behavioral|Low-Glycemic Index Diet vs. Control Diet|
45951808|NCT00501904|Drug|Metformin|
45951809|NCT00501982|Drug|Poractant alfa (Curosurf®)|
45951810|NCT00502021|Dietary Supplement|Placebo|Manioc powder (placebo) 60 g/day
45951811|NCT00502021|Dietary Supplement|Alpha-linolenic acid/ALA|Flaxseed powder 60 g/day (10 g ALA)
45951812|NCT00502021|Dietary Supplement|Alpha linolenic acid/ALA|Flaxseed oil 30 ml/day (10 g ALA)
45951813|NCT00502021|Dietary Supplement|Placebo|Safflower oil 30 ml/day
45951814|NCT00147303|Drug|MCI-9042|
45951815|NCT00502060|Drug|AZD2171|
45813418|NCT05572645|Drug|Pertuzumab Plus Trastuzumab|treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
45813419|NCT05362591|Procedure|resin bonded bridge with no preparation|resin bonded bridge without enamel preparation
45951816|NCT00502060|Drug|ZD1839|
45951817|NCT00502099|Drug|Pegylated interferon alpha 2a|Injections: 180 ug once per week
45951818|NCT00502099|Drug|Ribavirin|Tablets, 1000-1200 daily
45951819|NCT00502099|Drug|Pegylated interferon alpha 2 b plus ribavirin|Pegylated interferon alpha 2 b injections
45951820|NCT00502138|Drug|Continuous Pramlintide infusion|pramlintide injection, 9 mcg/hr plus 60 mcg premeal boluses
45951821|NCT02958137|Procedure|Arthroscopic Resection Arthroplasty|Surgical removal of the arthritic joint(s) using a minimally invasive technique.
45951822|NCT00405795|Device|Envision® Patient Support System|
45951823|NCT00502177|Behavioral|Questionnaire|QOL Questionnaires taking a total of 10 minutes to complete.
45951824|NCT00502255|Device|Health Buddy system|Patients are followed on distance by the Health Buddy system.
45951825|NCT00502255|Device|Telemonitoring in patients with heart failure|Health Buddy in patients home situation.
45951826|NCT00502294|Drug|Visilizumab (HuM291; Nuvion®)|
45951827|NCT04375917|Device|O2matic|O2matic is a closed-loop-system that controls oxygenadministration according to SpO2. The aim is to maintain SpO2 within a predefined target interval, E.G. 88-92% with the lowest possible supplementation of oxygen by nasal cannula
45951828|NCT00502372|Dietary Supplement|Nutritional Supplement/Amino acids and HMB|Subjects will be randomized to receive enriched dietary supplement (Juven) v arginine only (Argenaid) dietary supplement
45951829|NCT00502372|Dietary Supplement|Juven|comparison of Juven with arginine only product in wound healing
45951830|NCT00502411|Drug|Doxorubicin|17.5 mg/m^2 IV bolus infusion, followed by continuous IV infusion on days 1-4.
45951831|NCT00502411|Radiation|Radiation Therapy|Radiation treatments 5 days a week for 6 - 6 1/2 weeks. 60 Gy in 6 weeks (negative resection margin) to 66 Gy in 6.5 weeks (positive resection margin).
45951832|NCT01246375|Device|Dual energy X-ray absorptiometry|Device which measures bone density
45813420|NCT05362591|Procedure|resin bonded bridge with minimal preparation|resin bonded bridge with minimal preparation of tooth enamel
45813421|NCT02608177|Drug|Linagliptin|Receives 4 weeks of study drug linagliptin
45813422|NCT02608177|Drug|Glipizide|Receives 4 weeks of study drug glipizide
45951833|NCT00502489|Procedure|Closed-loop sytem for5 weaning from mechanical ventilation|
45951834|NCT00502528|Drug|Placebo|Peri-interventional
45951835|NCT00502528|Drug|BQ-123|Peri-interventional
45813423|NCT04742335|Other|Survey|Survey will be applied to the participants.
45951836|NCT02955979|Other|CT scan with iodinated contrast agents|"Before the CT scan, the investigators with iodinated contrast agents, the following data will be collected in the medical record: creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern.~After the CT scan the investigators will collect the characteristics of the injection type, osmolarity and volume of contrast used and the appearance of a possible allergic reaction.~Then 24 and 48 hours and day 7 will collect serum creatinine, urine output and vital replacement therapies may be necessary."
45951837|NCT02955901|Other|3 day low residue diet prior to the colonoscopy|3 day low residue diet prior to the colonoscopy
45951838|NCT02955901|Other|1 day low residue diet prior to the colonoscopy|3 day low residue diet prior to the colonoscopy
45951839|NCT02956096|Device|Transcranial direct current stimulation (tDCS)|The active tDCS and placebo will be applied to anode electrode on left temporal cortex placed on the scalp in the region T3. The cathode electrode on the middle deltoid muscle contralateral to the anode.
45660041|NCT05561881|Other|popliteal artery and the capsule of the posterior knee (IPACK) block|ultra-sound visualization of the popliteal artery and posterior surface of the distal femur then the image of the femoral condyles and popliteal artery will be obtained. A needle with a tip length of 100 mm will be inserted in a medial to the lateral plane parallel to the femur in the middle area between the popliteal artery and femur,20 ml local anesthetic solution will be given into this space with adequate and equal distribution of anesthetic agent
45951840|NCT02956096|Device|training on the running belt|The running in the treadmill will be held on a single training session and the speed of the cardiopulmonary exercise testing and slope from 60 to 80% of the maximum achieved in cardiopulmonary testing, in order that the patient reaches 60% to 70% of the heart rate reserve.
45951841|NCT05561465|Procedure|Pterygomaxillary disjunction with interposition Y-shape plate|All patients will be treated under general anesthesia. The pterygoid plate will be fractured, pried up, and pushed backward. A Y-shape plate will be fixed to the lateral maxillary surface with its vertical limb and the other two limbs are turned to fit into the retro maxillary space preventing the reattachment of the fractured pterygoid plate
45951842|NCT00147381|Drug|Alemtuzumab|"Day 0: Campath-1H 20 mg IV infusion over 3-6 hours~Day 1: Campath-1H 20 mg IV infusion over 3-6 hours"
45676541|NCT02107144|Drug|trimetazidine|After being randomized to Trimetazidin and cardiac medication vs. only cardiac medication, patient will undergo scheduled PCI of single, new, native coronary artery lesion using balloon predilatation and subsequent stenting.
45951843|NCT00147381|Drug|Tacrolimus|"Day 0: Tacrolimus will be given pre-operatively or immediately post transplant surgery. The recommended initial daily starting dose is 0,1 mg/kg/d orally (0,05 mg/kg/bid) to aim at a whole blood level of 8-12 ng/ml.~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
45951844|NCT00147381|Drug|Alemtuzumab|"Day 0: Campath-1H 30 mg IV infusion over 3-6 hours~Day 1: Campath-1H 30 mg IV infusion over 3-6 hours"
45951845|NCT00502567|Drug|AZD2171|oral tablet once daily
45951846|NCT00502567|Drug|FOLFOX|intravenous infusion
45951847|NCT00502567|Drug|Pemetrexed|intravenous infusion
45951848|NCT00502567|Drug|Irinotecan (administered with & without Cetuximab)|intravenous injection
45813424|NCT05555095|Behavioral|digital health delivered multicomponent intervention|The MIC program will have set minimum levels of connectivity for each of the three defined conditions under study.
45813425|NCT02608489|Drug|Diquafosol (Diquas)|Diquafosol group used diquafosol 6 times a day during study period.
45813426|NCT02608489|Drug|Sodium Hyaluronate (Hyalein)|Hyaluronate group used sodium hyaluronate 6 times a day during study period.
45951849|NCT00502567|Drug|Docetaxel|intravenous infusion
45951850|NCT00502645|Device|CS-1 DECISION SUPPORT SYSTEM|
45951851|NCT05561231|Procedure|Intubation with C blade|Intubation with C blade of CMAC videolaryngoscope
45951852|NCT05561231|Procedure|Intubation with D blade|Intubation with D blade of CMAC videolaryngoscope
45951853|NCT00147420|Drug|Zhi Byed 11|
45951854|NCT00502684|Drug|Propranolol, etodolac|propranolol 10 mg X 4 /day, starting on day -3 pre-op, for 6 days, till POD 2 Etodolac 400 mg X2/day, starting on day -3 pre-op, for 6 days, till POD 2
45951855|NCT00502723|Procedure|Radical retropubic prostatectomy|Radical retropubic prostatectomy
45951856|NCT00502723|Procedure|Radical laparoscopy prostatectomy|Radical laparoscopy prostatectomy
45458453|NCT02325310|Biological|Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®|One dose of 0.5 mL vaccine will be administered (intra-muscularly or subcutaneous) in post-partum (before the exit of the maternity) during visit V0. A second dose will be administered at week 8(+/-15 days) during visit V1.
45458454|NCT01351688|Drug|AZD3514|Patients will be given AZD3514 tablets or capsules administered orally as a single dose, and then multiple once-daily dosing following a 7 day washout.
45458455|NCT03132376|Dietary Supplement|Water Preload Drink|Participants were given 275 ml (0 kcal) water to consume in the morning following an overnight fast. This served as the control drink.
45951857|NCT01246492|Dietary Supplement|Artificial Sweeteners|A 400mL drink sweetened with 45g glucose and artificial sweetener will be consumed orally
45951858|NCT05561192|Other|Diaphragmatic breathing exercises|The initial proposal is for the first week to be adaptive, that is, learning to perform the exercises freely. During this period, students will be able to experience the activities and solve any doubts, as well as understand the process of a respiratory cycle, in which they will be initiated through a cycle of 12 times per minute. In the second and third weeks, the exercises will consist of 10 breathing cycles per minute (complete cycle consisting of 6 seconds, 2:2:2). It is important to note that each cycle contains the inspiration time, brief pause and expiration time in seconds. In the last week, each cycle will last 16 seconds, consisting of 4 seconds of inspiration, 4 seconds of pause and 8 seconds of expiration (4:4:8). Thus, the objective is to reduce the number of respiratory cycles per minute, as the intervention progresses.
46077408|NCT05429658|Device|Thrombectomy|The Route 92 Medical Reperfusion System is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease within the internal carotid, middle cerebral, basilar and vertebral arteries.
45813427|NCT05554861|Device|Low Frequency rTMS Protocol|"It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex foot area in the non-lesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.~After the daily rTMS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
45813428|NCT05554861|Device|Intermittent Theta Burst Stimulation (iTBS) Protocol|"It was planned to apply 50 Hz high-frequency stimulation protocol to the primary motor cortex foot area in the ipsilesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.~After the daily rTBS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
45813429|NCT05554861|Device|Sham rTMS Protocol|"It was planned to apply daily sham rTMS to the motor extremity area of the primary motor cortex along a 10 cm thick wood for 10 sessions.~After the daily sham rTMS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
45813430|NCT02609113|Device|Strong Magnetic Wristband|
45813431|NCT02609113|Device|Weaker Magnetic Wristband|
45813432|NCT02611765|Drug|Benzathine penicillin G intramuscular 7.2 million units|Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).
45813433|NCT02611765|Drug|Benzathine penicillin G intramuscular 2.4 million units|A single dose of intramuscular 2.4 million units of benzathine penicillin G
45813434|NCT02612857|Drug|IMO-8400 Dose Group 1|IMO-8400 Dose 1 subcutaneous injections once a week for 24 weeks.
45813435|NCT02612857|Drug|IMO-8400 Dose Group 2|IMO-8400 Dose 2 subcutaneous injections once a week for 24 weeks.
45813436|NCT02612857|Drug|Placebo|normal saline subcutaneous injections once a week for 24 weeks.
45813437|NCT05553769|Other|Resistance training, detraining, retraining|Participants (healthy untrained men and women, age 18-40) start with a 3-week familiarization and baseline measurement period. After that, they are randomized to two intervention groups, where other group will conduct 10-week RT intervention and a 10-week DT period and again the exact same 10-week RT intervention again whereas the other group start with a 10-week non-training period and then continues with a 20-week RT intervention. RT consists of two training sessions per week of total body workouts. Same measurements are conducted for both groups with the same time intervals.
45813438|NCT05552287|Drug|Infliximab|IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks till week 24 (end of study). IFX trough levels will be measured at weeks 4, 12, and 24. During the maintenance, the IFX dose and/or interval adjustments, the IFX discontinuation or the start of a co-medication (i.e., an immunomodulator) will be possible on indication (i.e., primary nonresponse, secondary loss of response, intolerance to study medication) at the physicians' discretion.
45813439|NCT05550571|Device|Nautilus Intrasaccular Bridging System|Patients will be treated with the Nautilus, then followed-up for 12 months
45813440|NCT05226169|Drug|Ferinject|"Patients will receive an IV FCM (1,000 mg iron) infusion on the first day (visit 1) of chemotherapy. FCM (FerinjectTM; Vifor Pharma, Glattbrugg, Switzerland) will be diluted in 250 ml of sterile 0.9% normal saline by an aseptic technique and infused over 15 min under the supervision of a clinician.~Patients with a Hb level ≤ 10 g/dL and ID (serum ferritin < 100 ng/mL or TSAT < 50% and serum ferritin 100-500 ng/mL) will receive an additional dose of 500 mg of IV FCM at 6, 12, 24, 36, and 48 weeks. FCM will be diluted in 100 ml of sterile 0.9% normal saline by an aseptic technique and infused over 6 min under the supervision of a clinician."
45813441|NCT05226169|Other|Conservative management|"Patients with absolute (must be administered) or functional (according to the physician's choice) IDA in the control arm will be received oral iron, administered as Feroba-You 256mg once or twice a day. Advice will be given regarding ingestion without food and with liquid high in ascorbic acid to maximize enteric absorption.~If patients in the control arm still meet the absolute or functional IDA at the end of study (at 48 weeks), they can receive IV FCM (1,000 mg) according to the physician's decision."
45813442|NCT02615743|Behavioral|Daily Text message reminder|Subjects in the intervention arm will receive once daily text messages at the time of their choice or at a default time of 7am. The text message will remind them to give their child their controller medication and provide a helpful information on asthma controller use.
45951859|NCT05561192|Other|Cardiorespiratory and strength exercise|"During the first two weeks, students will complete two laps of the circuit, with a 15-second break between one station and another and a 1-minute break between one lap and another. These first two weeks will focus on adaptation and technical learning of the exercises to be performed. From the third to the sixth week, one lap will be added to the circuit, totaling three laps, maintaining the aforementioned intervals. From week 7 to week 12, progressions will be carried out, reducing the interval time between one lap and another on the circuit to 30 seconds. For the purpose of controlling the intensity of the exercise, a subjective perception of effort scale will be used, composed of values from 1 to 10, the first being equivalent to very light effort activity, and ten, equivalent to maximum effort activity."
46077409|NCT05429580|Drug|Tranexamic acid|given intravenous tranexamic acid
46077410|NCT05429580|Other|5% Dextrose|given placebo.
46077411|NCT00790647|Biological|filgrastim|16 mcg/kg daily beginning 3 days before stem cell collection through day before final stem cell collection
46077412|NCT00790647|Drug|bortezomib|1.0 mg/m2/dose D -6, D-3, D +1, D + 4
46077413|NCT00790647|Drug|melphalan|100 mg/m2/dose D -2, D -1
46077414|NCT00790647|Procedure|Stem Cell Infusion|infusion of previously collected autologous stem cells
45951860|NCT05561192|Other|Cooperative sports activities group|"Intervention with cooperative sports activities will be based on the pedagogical model for teaching sports called Cooperative Learning or Cooperative Learning. This pedagogical model has some predominant characteristics, such as student learning occurring with and through other students, through an approach that facilitates and enhances positive interdependence, where teachers and students act as co-learners. Thus, this teaching model encompasses two key points of cooperative learning: promoting interaction between students and interaction between students and teachers.~Also, in the planning of intervention classes with sports, the five points described as fundamental for learning to be considered cooperative will be considered. These are: face-to-face interaction, positive interdependence, individual responsibility, group processing, and social skills."
45813443|NCT02615743|Device|Inhaled steroid canister monitor|An electronic monitor will be affixed to subjects' inhaled steroid canister and families will be instructed to use the inhaler as directed by their physician. Subjects will not receive daily text messages.The canister monitor, the Propeller sensor (Propeller, Madison, Wisconsin) is an FDA-approved, portable device which affixes to the top of most metered dose inhaler canisters. The devices records the number and time of each inhaler actuation and transmits this information to either a smart phone or cellular modem. Data is then sent via the cellular network to the secure Propeller server. The data will then be downloaded monthly.
45813444|NCT02616523|Drug|Dexmedetomidine|The participants will be given infusion of dexmedetomidine 0,5 mcg/kg/h intravenously.
45458456|NCT03132376|Dietary Supplement|Whey Protein Isolate Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g whey protein to consume in the morning following an overnight fast.
45951861|NCT05561192|Other|Traditional physical education class|The comparator group will take physical education classes normally, following the traditional menu in the discipline, without changes in the conduct of activities.
45951862|NCT00502762|Drug|topotecan|
45951863|NCT00502879|Drug|Enbrel (etanercept)|
45951864|NCT00502918|Device|CLM - HA Continuous Monitoring System Heart Application|
45951865|NCT00502957|Behavioral|Biofeedback|
45951866|NCT00503074|Behavioral|TV modification|Parents receive a health behavior-change intervention consisting of 1 in-person visit from a case manager, followed by phone and e-mail contact at least monthly. The intervention is designed to promote healthy TV viewing, including viewing fewer commercials, by the target child aged 2-5 years old, and uses health behavior change theory and social cognitive theory.
45951867|NCT00503074|Behavioral|safety and injury prevention|Parents receive behavior-change counseling around toddler and preschooler safety and injury prevention.
45458457|NCT03132376|Dietary Supplement|Micellar Casein Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g micellar casein to consume in the morning following an overnight fast.
45660042|NCT05561881|Other|genicular nerves block|ultra-sound transducer placed parallel to the femur shaft and the epicondyle will be identified, the superomedial superolateral and inferomedial genicular arteries, which follow a similar route with each genicular nerve will be visualized close to the periosteal areas, A20G needle with a tip length of 50mm will be directed in the plane of the US probe in the long axis view. After confirming placing of the needle next to each genicular artery a total amount of 20 ml local anesthetic in equal increments at multiple sites.
45660043|NCT05561413|Behavioral|Mindfulness and exercise|The mindfulness and exercise group aims to gradually increase participants exercise levels so that they begin to achieve the recommended levels along with the strengthening exercises for all major muscle groups. Along side this mindfulness will be introduced and built on to help consolidate exercise uptake and help manage symptoms experienced by the participants.
45660044|NCT05561413|Behavioral|Mindfulness|The delivery of this practice will be through the app downloaded by participants. The practice based on mindfulness based stress reduction (MBSR). Will build on practice over the 8 weeks.
45660045|NCT05560945|Drug|0.32% Sodium Fluoride Dentifrice Toothpaste|Toothpaste
45660046|NCT05560945|Drug|1.5% Arginine Dentifrice|Toothpaste
45660047|NCT05560945|Drug|8.0% Arginine Dentifrice|Toothpaste
45660048|NCT05559463|Dietary Supplement|ITIS diet|anti-inflammatory (ITIS) diet for 28 days
45813445|NCT02616523|Drug|Lidocaine|The participants will be given infusion of lidocaine 1,5 mg/kg/h intravenously.
45813446|NCT02616523|Other|placebo|The participants will be given infusion of normal saline intravenously.
46077415|NCT00323141|Device|Ventralex versus Leight Weight Vypro II prothesis|Ventralex and Leight Weight Vypro II prothesis are compared.
45458458|NCT03132376|Dietary Supplement|Egg White Isolate Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white isolate protein to consume in the morning following an overnight fast.
45660049|NCT05559385|Device|Robot-Assissted Therapy|Houston Bionics ExoRehab X brand/model device was used for improving the upper extremity in subacute stroke.
46077416|NCT02755194|Other|No intervention|This is an observational study. The exposure of interest includes taking specific prescribed medications during breastfeeding.
46077417|NCT00286013|Drug|Association of gemcitabine, oxaliplatin and radiotherapy|
46077418|NCT02540473|Behavioral|Manualized Therapy|Relational psychotherapy mothers
46077419|NCT02540473|Behavioral|Control Group|one hour of free time to do with as they wish
45660050|NCT05559385|Procedure|Conventional Rehabilitation|It is an upper extremity rehabilitation program prepared in line with individual needs.
45660051|NCT03603535|Device|sensiTVT|The study is designed as a prospective single arm study. All women with an indication for suburethral tape placement for therapy of SUI and meeting the inclusion criteria will be offered study participation to record the objective outcome after one year.
45660052|NCT05496751|Behavioral|Low amount, low intensity exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
45813447|NCT02616523|Drug|Fentanyl|Fentanyl 2 mcg/kg will be given to all participants for the intubation and during the operation when ANI value drops below 50.
45813448|NCT05732155|Drug|methylenedioxymethamphetamine|The overall objective of this study is to use standard clinical measures to explore the safety and preliminary effectiveness of open-label MDMA-assisted therapy with a flexible dose of MDMA HCl, in participants with PTSD and moral injury, in individual and group treatment settings
45813449|NCT05528419|Drug|Sacubitril-valsartan|sacubitril valsartan 100mg initiated, and titrated to 200mg according to mean clinic blood pressure at 1-month follow-up
45951868|NCT00503152|Drug|Benazepril|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
45951869|NCT00503152|Drug|Valsartan|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
45951870|NCT00503152|Drug|Benazepril/Valsartan|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
45951871|NCT00147459|Biological|HBV vaccine booster|
45951872|NCT00503191|Behavioral|NeuroModulation Technique|NeuroModulation Technique is an informational technique that works by identifying and bringing awareness of the mind-body to incorrect informational states of the nervous system which has led to illness or maladaptive behavior. NeuroModulation Technique then directs the body to correct these information states, thereby helping the nervous system resume more adaptive functioning.
45951873|NCT00503230|Behavioral|Standard Care Intervention (SCI)|Standard Care Intervention (SCI)
45951874|NCT00503230|Behavioral|Culturally Tailored Intervention (CTI)|Culturally Tailored Intervention (CTI)
45951875|NCT00503269|Procedure|Hemorrhoidectomy|Hemorrhoidectomy under local anaesthesia
45951876|NCT00503269|Procedure|Hemorrhoidectomy|General anaesthetic haemorrhoidectomy
45951877|NCT05561114|Combination Product|GIE Medical ProTractX3 TTS DCB|Paclitaxel Coated Balloon
45951878|NCT05561114|Other|Control|Standard Endoscopic Dilation
46077420|NCT02754882|Drug|Bevacizumab|Avastin® 15 mg/kg IV every 3 weeks on Day 1
45660053|NCT05496751|Behavioral|Low amount, high intensity exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
45660054|NCT05496751|Behavioral|High amount, high intensity exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
45660055|NCT04047277|Behavioral|Cognitive Behavioral Therapy|The manualized CBT protocol is five sessions that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
45660056|NCT04224961|Device|Respiratory Muscle Training|Two commercially available pressure-threshold RMT devices that utilize a spring-loaded flange to provide resistance against inspiration and expiration independent of respiratory flow rate will be used to provide the necessary range of resistance. Each participant will use two RMT devices, one for IMT and one for EMT.
45813450|NCT05528419|Drug|Valsartan|valsartan 80mg initiated, and titrated to 160mg according to mean clinic blood pressure at 1-month follow-up
45660057|NCT04424563|Device|ventilators|all patients in both groups will be ventilated if shocked and no recordable blood pressure
45813451|NCT04340713|Other|information support program|According to the established information support program for prostate cancer patients during hormonal therapy, information support and guidance on disease knowledge, symptom management, life care and other aspects are provided to patients through face-to-face communication, telephone, written information, network and other ways.
45813452|NCT05731921|Behavioral|The exercise program with the 'Empathy Dress'|The experimental group will be given an exercise program that includes a total of eight sessions (two months) of 'Empathy Dress' and some exercises (stairs going up and down, sitting up, putting on trousers, tying shoes, etc.), every week and 20 minutes per week, by the researchers.
45813453|NCT04741867|Other|Education|Patients will be educated to determine their level of coping with stress and their adaptation.
45813454|NCT04340791|Behavioral|Increased proportion of lower energy density items|The proportion of lower energy density vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (D and DL) (33% lower - 67% higher). Lower energy density items will be defined as lower energy density ≤ median of energy density distribution within a food category.
45951879|NCT04353804|Other|Treatment Arm: Computerized Cognitive Rehabilitation|Treatment Arm: Computerized Cognitive Rehabilitation
45951880|NCT04353804|Other|Active Control computer games|Active Control computer games
45951881|NCT00503347|Drug|bavituximab|The study drug is a sterile solution administered intravenously weekly for 8 weeks. Each cohort is given 0.3, 1, 3, or 6 mg/kg of bavituximab.
45951882|NCT00503386|Drug|Palonosetron|
45660058|NCT04424563|Drug|aminocaproic acid|4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours.
45660059|NCT04424563|Drug|Novo Seven|200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (>10 gm%) another 2 doses of aFVII received
45660060|NCT04044937|Drug|F-18 Fluoroethyltyrosine (FET)|Patients given an injected dose of 4 to 7 millicurie (mCi) of FET per scan. The radiopharmaceutical will be administered while the patient is in the PET scanner
45951883|NCT00503386|Drug|Granisetron|
45951884|NCT00503503|Drug|Enbrel (etanercept)|
45951885|NCT00147576|Drug|CP-866,087|
45951886|NCT00503542|Drug|Terazol or oral fluconazole for candidal vaginitis|Intravaginal terazol qhs x 5 nights; oral fluconazole 150 mg po x 1
46077421|NCT02754882|Drug|SB8|SB8 15 mg/kg IV every 3 weeks on Day 1
46077422|NCT02754882|Drug|Carboplatin|Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
45951887|NCT00503542|Drug|Metronidazole or Clindamycin for Bacterial Vaginosis|Metronidazole 500 mg bid x 5 days; Intravaginal metronidazole bid x 5 days; intravaginal clindamycin
45813455|NCT04340791|Behavioral|Labelling|"When energy density of an item ≤ median of ED distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions when logging-into the platform will introduce the badges to the participants: In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category."
45813456|NCT05731765|Diagnostic Test|Machine Learning Model|Automated machine learning system for the detection of spontaneous venous pulsations and quantification of intracranial pressure
45813457|NCT02974465|Procedure|Biofeedback Electromyography|protocol of sEMG-BFB that consisted of active movements in glenohumeral abduction guided by the visual signal of the register equipment. The protocol was the following: firstly proof active movements were requested in glenohumeral abduction without feeling any pain in order to teach the visual signal of their muscle activity. The therapist dedicated around 10 minutes in each session for subject learned to control the activation of both muscles in the limits that physical therapist marked with each individual in particular (controlling the activation in the upper trapezius). Once integrated information, shoulder abduction were requested following 4 main principles.
45951888|NCT00503542|Drug|Flagyl for definitively diagnosed vaginal trichomoniasis|Metronidazole 2 gms po x 1
45951889|NCT00503542|Other|Empiric Management|In this arm of the study women are treated for vaginal complaints purely on the basis of their symptoms.
45951890|NCT01246648|Procedure|Biopsy|dental extraction and gingival epithelial biopsy
45951891|NCT01246648|Procedure|biopsy|dental extraction and gingival epithelial biopsy
45951892|NCT01246648|Procedure|Biopsy|dental extraction and gingival epithelial biopsy
45951893|NCT00147615|Drug|Eplerenone|
45951894|NCT05561036|Drug|Liposome doxorubicin|Liposome doxorubicin (50mg/m2) or intravenous placebo with a treatment cycle of once every 28 days
45951895|NCT05561036|Drug|Saline Solution|saline solution
45951896|NCT01246687|Behavioral|e-Intervention|Dietary educational programme developed using Transtheoretical Model of Change and delivered via a website specific for Type 2 Diabetes patients.
45951897|NCT01246726|Procedure|CT SCAN|Prior to radiotherapy + after radiotherapy completion
45951898|NCT01246726|Procedure|MRI scan|Prior to radiotherapy + after completion of radiotherapy
45951899|NCT01246726|Procedure|3D Ultrasound scan|Prior to radiotherapy + after completion of radiotherapy
45951900|NCT01246804|Drug|raltegravir single dose|single dose 400mg raltegravir
45951901|NCT01246804|Drug|ginkgo biloba multiple dose|15 days ginkgo biloba 120mg BID
45951902|NCT05560997|Diagnostic Test|10-year ASCVD risk estimation|High CVD risk was defined as a history of CVD or a 10-year ASCVD risk ≥10%. The 10-year ASCVD risk estimation was carried out according to 2016 Chinese guidelines for the management of dyslipidemia in adults.
45951903|NCT00147654|Drug|Tolterodine ER 4 mg QD|
45951904|NCT00147654|Drug|Tamsulosin 0.4 mg QD|
45951905|NCT01246882|Behavioral|Augmented activity feedback|Feedback about walking speed and amount of physical activity will be provided 3 times per week from data acquired from wireless sensors on each ankle.
45951906|NCT01246882|Behavioral|Speed-only feedback|Feedback about walking speed will be provided 3 times per week.
45951907|NCT01246921|Drug|Fluticasone proprionate 0.05% cream|Fluticasone proprionate 0.05% cream . In each patient a representative target lesion will be selected which will be assessed by digital analysis. Patients will apply Fluticasone proprionate 0.05% cream once daily during the first 3 months. I nthe following 9 months FP will be applied in a scheme of 3 days per week
45951908|NCT04696939|Drug|Atezolizumab|Atezolizumab intravenous infusion was administered at a dose of 1200mg on Day 1 of each 21-day cycle.
45951909|NCT04696939|Drug|Carboplatin|Carboplatin intravenous infusion was administered at a dose of 75mg/m^2 on Day 1 of each 21-day cycle.
45660061|NCT04044937|Procedure|Positron Emission Tomography (PET)|All patients receive single PET imaging lasting for 40 minutes. Acquired PET data will be reconstructed so that three time points are created: (1) Perfusion: 60-second acquisition that starts immediately when activity is noted in the field of view, (2) Equilibrium: 10-minute acquisition acquired between 10 and 20 minutes after injection, and (3) Washout: 10-minute acquisition acquired between 30 and 40 minutes after injection. A repeat PET image will be offered to adult patients.
45660062|NCT04038151|Device|Hybrid Leg|The Hybrid Knee uses an actively variable transmission in combination of a passive spring/damper system. This allows the motor torque output to be adapted to the requirements of active dynamic tasks - changing the effective transmission ration from zero (fully passive) for level ground walking to a maximum value (fully active) for sit-to-stand transfers. This provides physiological knee torque and speed with a small motor and primary transmission system while also maximizing electrical efficiency, which minimized battery weight. The knee prototype weights 1.7kg. The Semi-active ankle can actively reposition during non-weight bearing phases of gait and uses a non back driveable transmission to maintain its set point during weight bearing activities.
45660063|NCT04038151|Device|Prescribed Passive Prosthesis|Participants will participate in training sessions of community skills and advanced ambulation training for their home, prescribed passive prosthesis.
45660064|NCT05496361|Device|Tianyi Revascularization Device|Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
45951910|NCT04696939|Drug|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m^2 on Day 1 of every 3-day cycle.
45951911|NCT05560919|Drug|Dihydroxycholecalciferols|Injection of Dihydroxycholecalciferols solution in the periodontal ligament for lower anterior segment teeth.
45951912|NCT05560919|Other|dimethyl sulfoxide|Injection of dimethyl sulfoxide in the periodontal ligament for lower anterior segment teeth.
45951913|NCT05560919|Other|serum|Injection of serum in the periodontal ligament for lower anterior segment teeth.
45951914|NCT00503620|Drug|Botulinum Toxin A|Injection into the gastrocnemius/soleus muscles for spasticity
45951915|NCT00147693|Behavioral|Diagnosis of caregivers' problems|
45951916|NCT00147693|Behavioral|Professional service: treatment of problems by counseling or practical support|
46077423|NCT02754882|Drug|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
45660065|NCT05496361|Device|Solitaire FR Revascularization Device|Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
45660066|NCT05496205|Drug|iN1011-N17|"This study will be conducted in approximately 104 healthy subjects in up to 13 sequential dose cohorts. Thirteen cohorts will consist of up to 8 subjects, including 2 subjects receiving placebo and 6 subjects receiving iN1011-N17.~Each subsequent cohort will continue to be randomized and dosed until maximum exposure is attained or a stopping criterion has been reached."
45813458|NCT02974465|Procedure|Sham Biofeedback Electromyography|consisted of Sham-EMG biofeedback, in which the electrodes were placed as the same method as the EG (Fig. 2) but the screen emit no signal. The subject performed 3 sequences of 10 abduction contractions (first degrees) without pain feeling and with 5 minutes of rest between sequences.
45813459|NCT02974465|Procedure|Conventional Physical Therapy Treatment|All participants received a conventional daily treatment of neurological physical therapy. Since no evidence has been found about a specific therapy that specially could benefit hemiparesis consequences, the common approach in this center consists of a combination of different specific concepts (Bobath, Brunnstrom, Rood, Johnstone, Propioceptive Neuromuscular Facilitation, Perfetti, Vojta, Motor Relearning Programme,…), exercise programs, electrotherapy, myofascial techniques, etc…
45813460|NCT05485831|Drug|Epidiolex 100 mg/mL Oral Solution|As prescribed in routine clinical practice in Italy.
45951917|NCT00503659|Procedure|Bronchial methacholine provocation|A short five-breath dosimeter protocol using a five-step dilution schedule according to ATS guidelines (0.0625, 0.25, 1, 4, 16 mg/ml methacholine)
45951918|NCT00503659|Procedure|Bronchial methacholine provocation|A five-step protocol using a single dilution of 16 mg/ml methacholine (0.01, 0.1, 0.4, 0.8, 1.6 mg)
45951919|NCT00503737|Behavioral|National Colorectal Cancer Roundtable Toolbox|
46077424|NCT00897403|Other|biologic sample preservation procedure|
46077425|NCT00897403|Procedure|diagnostic colonoscopy|
46077426|NCT02852135|Device|LMA Proseal|After preoxygenation, anaesthesia was induced with propofol, fentanyl and cisatracurium,LMA Proseal was inserted and cuff inflated in each group.
45951920|NCT04063163|Drug|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
45951921|NCT04063163|Drug|carboplatin and etoposide|chemotherapeutics
45951922|NCT04063163|Drug|placebo|placebo
46077427|NCT02852135|Device|LMA Supreme|After preoxygenation, anaesthesia was induced with propofol, fentanyl and cisatracurium ，LMA Supreme was inserted and cuff inflated in each group.
46077428|NCT00790569|Drug|nicotine|Given transdermally and orally
45951923|NCT00503815|Drug|BLI-800|
45951924|NCT00503815|Drug|Polyethylene glycol 3350 based bowel preparation|
46077429|NCT00790569|Drug|varenicline|Given orally
46077430|NCT00790569|Other|placebo|Given orally
45951925|NCT01247038|Device|Metal on ceramic articulation|Metal on ceramic articulation against metal-on-metal articulation using the same Recap Acetabular cup
45951926|NCT01247038|Device|Metal-on-Metal|Metal on Metal articulation
45951927|NCT01247077|Other|selenium|200 ug selenium once daily
45951928|NCT01247077|Other|placebo|
46077431|NCT00939029|Drug|nicotine replacement therapy (nicotine patches)|2- 21 mg patches per day for 8 weeks
46077432|NCT00939029|Drug|placebo NRT|2 placebo patches (containing no active ingredient)per day for 8 weeks
46077433|NCT02603601|Behavioral|Mind-body lifestyle intervention|
46077434|NCT02603601|Behavioral|Standard lifestyle intervention|
46077435|NCT02754804|Device|Biomechanic parameters|recording of biomechanic parameters and surface electromyography at the thigh and calf level throughout the walking period, in PAD patients .
46077436|NCT00602615|Drug|Torsemide|
46077437|NCT04106895|Drug|Fibryga|Fibryga
45660067|NCT05496205|Drug|Placebo|Matching Placebo for each formulations
45660068|NCT05496127|Other|Sensorimotor Exercises and Yoga|Within the content of sensorimotor exercise; oculomotor exercise, laser target exercise and postural stability exercise were applied. 14 yoga poses were applied within the content of Yoga Exercises.
45660069|NCT05496049|Device|Triburter|Patients will have to repeat 50 ventilations (start with 20 repetitions in the first week, 30 in the second, 40 in the four week, and 50 in the last week) five days per day for four weeks. And they have to fill a calendar to ensurance the intervention.
45813461|NCT05483413|Behavioral|progressive relaxation exercises|Progressive relaxation exercises are a cognitive behavioral technique that provides relaxation in the muscles that individuals can do alone.
45813462|NCT05480293|Drug|Ranibizumab|ranibizumab，0.5mg,IVT
45813463|NCT05480293|Drug|SCT510A|SCT510A，1.25mg,IVT
45813464|NCT05731609|Other|Resistance Intensive Personal Training|Personalized power training program focused on participant goals.
45813465|NCT05461417|Device|D-SAD|Patients equipped with Panthera D-SAD® orthosis will be recruited.
45813466|NCT05731531|Device|ELECTROGASTROGRAPHY|Electrogastrography as a new tool to customize choice of Bariatric therapies by determining success or failure based on GMA and WLST results has not been studied. GMA measures the normal or depleted gastric ICCs and the WLST measures gastric capacity, objective measures that may be important to predict success of Bariatric procedures and thus to help with patient selection to maximize efficacy and minimize side effects.
45813467|NCT04901143|Device|Advanced hybrid closed loop system|Phase 1: meals in open loop- 3 weeks Phase 2: closed loop conventional meal announcement- 3 weeks Phase 3: closed loop, pre define universal bolus- 3 weeks
45813468|NCT00365677|Device|The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm|Used with LASIK treatment for the correction of myopia and myopic astigmatism.
45813469|NCT00365677|Device|The Bausch & Lomb Zyoptix Tissue Saving algorithm|Used with LASIK treatment for the correction of myopia and myopic astigmatism.
45813470|NCT05449327|Drug|Rivaroxaban 10 MG|Patients are randomly divided into two groups. One group receives no prophylaxis with an anticoagulant, the other one receives Rivaroxaban. The dosage of Rivaroxaban is 10 mg given orally once daily starting on the day of the surgery and continuing the following 13 days.
45813471|NCT05731375|Diagnostic Test|31-MRS at 7 Tesla (T)|31-MRS imaging at 7T to evaluate mitochondrial function in skeletal and cardiac muscles.
45813472|NCT00365755|Drug|carboplatin|
45813473|NCT00365755|Drug|cisplatin|
45951929|NCT00501319|Behavioral|Interactive Voice Response (IVR)|Phone calls once weekly for the first 3 months after surgery, then every two weeks for an additional 3 months.
45951930|NCT00501319|Behavioral|Questionnaire|Questionnaires taking 20 minutes to complete.
45813474|NCT00365755|Drug|cyclophosphamide|
45660070|NCT05496049|Device|Incentive spirometry|They will repeat 10 ventilations per 5 five times a day. Both interventions will be performed for 4 weeks. They have to fill a calendar to ensurance the intervention.
45660071|NCT04380649|Device|New headset prototype|creation of a new headset prototype for using the P300 Speller, comfortable to use in everyday life by people with disabilities.
45676542|NCT02003222|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic SCT
45676543|NCT02003222|Procedure|Biospecimen Collection|Undergo blood sample collection
45813475|NCT00365755|Drug|etoposide|
45813476|NCT00365755|Drug|melphalan|
45813477|NCT00365755|Drug|vincristine sulfate|
45813478|NCT00365755|Procedure|autologous bone marrow transplantation|
45813479|NCT00365755|Procedure|conventional surgery|
45813480|NCT00365911|Procedure|Taking blood sample|A blood sample will be taken.
45813481|NCT00364741|Drug|Oxygen|During and 2 hours after surgery
45813482|NCT04743817|Device|OtoSet - Ear Cleaning System|Up to five (5) cleaning cycles using the OtoSet - Ear Cleaning System
45813483|NCT05731219|Biological|B7-H3 target, CAR gene modified gdT cell injection|After the subjects who signed the informed consent form were screened by the inclusion/exclusion criteria, the qualified subjects will enter 1.0 in order of priority × 108，3.0 × 108 and 6.0 × 108 CAR gdT groups were administered once.
45951931|NCT04011566|Diagnostic Test|ShuntCheck|The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
45951932|NCT00147732|Radiation|Accelerated radiotherapy|68 Gy over 5.5 weeks
45951933|NCT00147732|Radiation|ARCON|68 Gy over 5.5 weeks Carbogen: 98% oxygen plus 2% carbon dioxide Nicotinamide 60 mg/kg daily
45951934|NCT00503854|Behavioral|Questionnaire|Ancillary studies
45951935|NCT03990467|Biological|Plasma dosage of amikacin, piperacillin and tazobactam|Pharmacokinetic (PK) criteria will be used to judge whether the PK parameters of amikacin are predictive of those of piperacillin and tazobactam
45453868|NCT02286388|Procedure|A one-step partial caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.|"Instruments and procedures:~Soprolife® (Acteon, La Ciotat, France) dental imaging device to detect dentinal infection status. The green-black light indicates infected dentin, red indicates infected/affected dentin and green indicates healthy dentinal tissue.~Sterile round bur under water spray coolant followed by final excavation with hand instruments The clinician will remove the superficial necrotic and demineralized dentin with complete excavation of the peripheral demineralized dentin, avoiding excavation close to the pulp.~Hand instruments will be used for final excavation following clinical criteria guidelines (color of residual dentin and probe resistance) and taking in to consideration the color data obtained by the Soprolife® camera.~The operator will stop excavating when the dentin close to the pulp appears red (for infected dentin)."
45813484|NCT05731063|Procedure|Computer guided simultaneous implant placement with tri-cortical ridge augmentation using chin cortical bone struts|fabrication of surgical guide to aid in chin bone harvesting and another guide to help for accurate placement and simultaneous placement in anterior maxillary defective area.
45660072|NCT05495893|Drug|Cyclophosphamide|The patients will be divided into two groups randomly. Cyclophosphamide for injection, 750mg/m2 each time, 1g at most, once a month for 6 consecutive months. Steroids : intravenous methylprednisolone, 15~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day. The duration of induction therapy: 6 months.
45453869|NCT02286388|Procedure|A complete caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.|"Instruments and procedures:~Idem partial excavation arm.~In the complete excavation arm, the operator will stop excavating when the dentin close to the pulp appears green (for healthy dentin tissue) using the Soprolife® camera, leaving no infected or affected dentin."
45660073|NCT05495893|Drug|Mycophenolate Mofetil|The patients will be divided into two groups randomly. Mycophenolate mofetil, tablets, 30-40mg/ (kg · day), BID, the maximum amount is no more than 2g/d. Steroids : intravenous methylprednisolone, 15~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day. The duration of induction therapy: 6 months.
45676544|NCT02003222|Biological|Blinatumomab|Given IV
45676545|NCT02003222|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
45813485|NCT05730985|Dietary Supplement|Miotrof® formula|1 sachet per day for 4 months
45813486|NCT05730985|Dietary Supplement|Placebo formula|1 sachet per day for 4 months
45813487|NCT05730907|Drug|Levosimendan|examine whether levosimendan could improve in-hospital survival with good neurological outcomes in patients with cardiac arrest supported by E-CPR
45813488|NCT04541875|Other|MAR-Scale|The MAR-Scale is a 20-item questionnaire based on commonly reported reasons for non-adherence to medications.
45813489|NCT05729191|Biological|Anti Covid 19 vaccination campaign for pregnat women|Assessment of vaccine hesitancy and Covid-19 disease knowledge
45813490|NCT05355337|Drug|Pramipexole|9 weeks of treatment with Pramipexole
45813491|NCT05355337|Drug|Placebo|9 weeks of treatment with Placebo
45813492|NCT05728255|Diagnostic Test|ABPM plys SCAFB|24-hour ambulatory blood pressure monitoring (ABPM) and of tilt-table Short Cardiovascular Autonomic Function Battery (SCAFB) which consists in carotid sinus massage (CSM) and head-up tilt test (HUT) performed one after the other in an uninterrupted sequence as a single procedure on a tilt table
45813493|NCT04340401|Drug|SHR-1210|Patients will receive 3 cycles induction CapeOX and SHR-1210
45813494|NCT04340401|Drug|Oxaliplatin|CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
45813495|NCT04340401|Drug|Capecitabine|CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
45813496|NCT04340401|Radiation|Intensity modulated radiotherapy|patients will receive intensity modulated radiotherapy with capecitabine
45813497|NCT04340401|Procedure|Total mesorectal excision|Patients will receive TME (Total mesorectal excision) following TNT+SHR1210 if no metastasis occurs.
45813498|NCT05726149|Device|Real UHCDS a-tDCS|Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
45813499|NCT05726149|Device|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
45951936|NCT00503893|Behavioral|Questionnaire|Questionnaire regarding medical history and family medical history that will take about 1 hour to complete.
45813500|NCT05726149|Device|Sham UHCDS a-tDCS|Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
45813501|NCT05691751|Procedure|primary unilateral total knee arthroplasty with limited application of tourniquet|the tourniquet will be applicated around the proximal thigh in all patients before the incision, all patients will undergo primary unilateral TKA by the same surgeon using the medial para-patellar approach, and the prostheses used in all patients will be cruciate scarifying cemented DePuy Synthes PFC Sigma without resurfacing of the patella, intramedullary guides will be used for the femoral and tibial cuts as seen appropriate by the surgeon, however, the application time of the tourniquet during surgery will be as the allocation of each patient imply.
45813502|NCT05691751|Procedure|primary unilateral total knee arthroplasty with full application of tourniquet|the tourniquet will be applicated around the proximal thigh in all patients before the incision, all patients will undergo primary unilateral TKA by the same surgeon using the medial para-patellar approach, and the prostheses used in all patients will be
45813503|NCT04340635|Other||Without intervention
45951937|NCT00503893|Other|Blood specimen|Blood (about 10 teaspoons) will be drawn from a vein for genetic testing. The blood may be drawn more than one time.
45660074|NCT03542461|Drug|Nivolumab 10 MG/ML Intravenous Solution|240 mg as a 30 minutes IV infusion on Day 1 of each treatment cycle every 2 weeks, until intolerable toxicity or patient refusal or investigator's decision. In case of disease progression the treatment should be discontinued unless documented clinical benefits in the Investigator's judgement (no rapid progression, tolerance of trial drug, stable performance status, treatment maintenance does not delay an imminent intervention to prevent serious complication of PD) and no evidence of further progression at a radiographic assessment performed within 6 weeks. No dose escalations or reduction allowed. Administration delay until 6 weeks as well as resuming dose are allowed according to protocol defined criteria.
46077438|NCT02758704|Other|High stress|Generation of a stressful environment during a neonatal intubation procedure.
45660075|NCT03542461|Other|Best Supportive Care|Care that aims to optimize the comfort, function and social support of the patients and their family at all stages of the illness. Best Supportive Care (BSC)includes the use of analgesics, antibiotics, blood tranfusions, blood products, radiotherapy, corticosteroids, antiemetics, antidiarrheals, vitamins and any intervention aiming the improvement of patient's discomfort. Any chemotherapy, immunotherapy and targeted therapy are not considered as part of BSC.
45660076|NCT04201639|Device|Verofilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
45951938|NCT01247311|Dietary Supplement|Dietary supplement|Placebo given orally 3xweek for six months
45951939|NCT01247311|Dietary Supplement|Vitamin D|5000 IU vitamin D given orally 3xweek for six months
45951940|NCT01247311|Dietary Supplement|Vitamin D|0.5ug 1,25 vitamin D given orally 3xweek for six months
46077439|NCT02758704|Other|Low stress|Absence of stressful stimuli during neonatal intubation procedure
45458459|NCT03132376|Dietary Supplement|Egg White Concentrate Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white concentrate protein to consume in the morning following an overnight fast.
45458460|NCT03973112|Drug|HLX10 3mg/kg|anti-PD-1
45458461|NCT03973112|Drug|HLX04 5mg/kg|anti-VEGF, a biosimilar to Avastin
45813504|NCT04143607|Drug|ASK120067|ASK120067 (80 mg orally twice daily) . A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
45813505|NCT04143607|Drug|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
45951941|NCT00147771|Drug|Imiquimod 5% cream|Treatment will last for 36 weeks. Patients will be instructed to apply Imiquimod three times per week for 4 weeks. If no local side effects are noted at the 4 week- follow-up visit, the frequency of the application will be increased to 5 weekly applications.
45951942|NCT01247389|Procedure|laparoscopic colectomy|Laparoscopic segmental colectomy with planned abdominal extraction site
45951943|NCT03987659|Procedure|Irrigation protocols that promote release of dECMs|Irrigation protocols that promote release of dECMs
45951944|NCT03987659|Procedure|Conventional Irrigation protocols|Conventional Irrigation protocols
45951945|NCT01247467|Other|Breast Tumor Blocks|
45951946|NCT01247545|Procedure|Remote ischaemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
45458462|NCT03973112|Drug|HLX04 10mg/kg|anti-VEGF, a biosimilar to Avastin
45951947|NCT01247545|Procedure|Control|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
45951948|NCT00147810|Procedure|Telephone outreach to enhance asthma care|
45951949|NCT01247584|Genetic|DNA analysis|
45951950|NCT01247584|Genetic|mutation analysis|
45660077|NCT04201015|Device|Heart rate optimisation using force frequency data|Programming heart rate rise according to the force frequency relationship
45951951|NCT01247584|Genetic|polymerase chain reaction|
45951952|NCT01247584|Other|laboratory biomarker analysis|
46077440|NCT02758704|Other|Endotracheal intubation on mannequin|Endotracheal intubation will take place at the simulation centre on a mannequin.
46077441|NCT00902083|Drug|p53 gene with surgery|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
45676546|NCT02003222|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
45951953|NCT01247623|Biological|GV1001|
45951954|NCT00147849|Behavioral|mailing of printed educational materials|
45951955|NCT00147849|Behavioral|a combination of interactive educational meetings, educational outreach visits, and reminders|
45951956|NCT00147849|Behavioral|identification of local opinion leaders and establishment of local consensus processes|
45951957|NCT01247740|Drug|NuTRIflex Lipid peri|parenteral nutrition
45951958|NCT01247740|Drug|compounded monobag|parenteral nutrition
46077442|NCT00902083|Procedure|surgery|remove tumor surgery
46077443|NCT00902083|Drug|p53 with chemotherapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times Chemotherapy: standard chemotherapy
46077444|NCT00902083|Drug|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
46077445|NCT02852291|Behavioral|Parents Make the Difference|10 parent training sessions delivered to groups of caregivers
45951959|NCT01247779|Procedure|gynecologic surgery - standard coelioscopy|lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
45951960|NCT01247779|Procedure|gynecologic surgery - robot assisted coelioscopy|lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
45951961|NCT01247818|Drug|PH-10 (0.002% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
45951962|NCT01247818|Drug|PH-10 (0.005% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
45951963|NCT01247818|Drug|PH-10 (0.01% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
45951964|NCT01247818|Drug|Vehicle|PH-10 vehicle will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
45951965|NCT00503932|Procedure|Proton Therapy|Radiation therapy 1 time a day, for 5 days in a row (Monday-Friday) for 6 -7 weeks (30-35 treatments in all).
45951966|NCT00503932|Drug|Capecitabine|825 mg/m^2 by mouth (PO) twice daily on days receive radiation.
45951967|NCT03981146|Drug|Nivolumab|60 Minute IV Infusion
45951968|NCT01247857|Drug|Ropivacaine 30 mg|"Intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and intraperitoneal nebulization of normal saline 3 ml after surgery.~Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports."
45660078|NCT03329599|Drug|Polycap|Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
46077446|NCT02852291|Behavioral|Parents Make the Difference Plus|10 parent training sessions delivered to groups of caregivers, with 3 home visits
46077447|NCT02603523|Behavioral|Senior Dance|The Senior Dance classes consist of different choreographies, which include rhythmic and simple movements with rhythmic folk songs. During the classes, participants can practice the movements sitting or standing, quickly or slowly, in circles, individually, in pairs or in small groups. The concentration required to learn the choreographies challenges balance, motor coordination and cognitive function.
45660079|NCT04191967|Device|Thermocoagulation|Treatment of positive screening results will be performed using the Liger Thermocoagulator device
45660080|NCT05491291|Other|Patients with chronic wound of the lower limbs|The rating scale will be passed at three different times, day 1, day 15 and day 75.
46077448|NCT00635544|Other|dietary treatment|dietary treatment with a high-glycemic index low-fibre diet (HGI-LF)
45660081|NCT04191733|Device|KINCISE(TM) Surgical Automated System|Uncemented Total Hip Arthroplasty via Anterior Approach with and without the KINCISE(TM) Surgical Automated System
45660082|NCT02556307|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a according to the standard practice in line with current summaries \nof product characteristics (SPCs)/local labeling.
45660083|NCT02556307|Drug|Ribavirin|Ribavirin according to the standard practice in line with current summaries \nof product characteristics (SPCs)/local labeling.
46077449|NCT00635544|Other|dietary treatment|dietary treatment with a low-glycemic index high-fibre diet (LGI-HF)
46077450|NCT00284375|Procedure|Registration of all big toe prostheses in Ghent University Hospital|Registration of all big toe prostheses in Ghent University Hospital.
45660084|NCT05495425|Drug|NPC-12Y gel|NPC-12Y gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
45813506|NCT04143607|Drug|Gefitinib|Gefitinib (250 mg orally, once daily) , A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit acording to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
45813507|NCT04143607|Drug|Placebo ASK120067|Placebo ASK120067orally 80mg twice daily . A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
45951969|NCT01247857|Drug|Ropivacaine 30 mg|"intraperitoneal Nebulization of normal saline 3 ml before surgery and intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) after surgery.~Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports."
45951970|NCT01247857|Drug|Saline|Intraperitoneal nebulization of normal saline 3 ml before and after surgery. Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports.
45951971|NCT04331730|Drug|AKST4290|Oral AKST4290
45951972|NCT04331730|Drug|Placebo|Oral placebo
45951973|NCT04331730|Drug|Aflibercept|Aflibercept intravitreal injection
45951974|NCT01248052|Drug|LY2979165|administered orally
45951975|NCT01248052|Drug|Placebo|administered orally
45951976|NCT01248091|Procedure|Nitroprusside Gel|10 cc nitroprusside gel
46077451|NCT00897481|Genetic|gene expression analysis|
46077452|NCT00897481|Genetic|mutation analysis|
46077453|NCT00897481|Other|diagnostic laboratory biomarker analysis|
46077454|NCT00897481|Other|immunohistochemistry staining method|
46077455|NCT00897481|Procedure|sentinel lymph node biopsy|
45813508|NCT04126291|Behavioral|Evaluation of whiteboard videos|Participants will be provided an internet link via email to access the videos and questionnaires through REDCap (Research Electronic Data Capture), and responses will be tracked. Before viewing, participants will complete a pre-questionnaire to collect demographic and practice data and ratings of perceived self-efficacy/confidence and knowledge in talking about weight-related issues. This pre-questionnaire only needs to be completed once. Participants will then be asked to watch each video. Immediately after watching each video, participants will rate their perceived self-efficacy/confidence and knowledge to help elucidate outstanding educational gaps. For those who consent to do a follow up questionnaire four-six months later, they will be sent an email link to complete a satisfaction questionnaire and rate their perceived self-efficacy/confidence and change in practice to help elucidate outstanding educational gaps.
45813509|NCT04110067|Other|Small Incision Lenticule Extraction (SMILE) with Visumax (Carl Zeiss Meditec, Jena)|Creation of a corneal tissue disk called lenticule and extraction through a minimally invasive incision, utilizing only a femtosecond laser
45951977|NCT01248091|Procedure|Placebo Gel|half of the subjects will receive nitroprusside gel for IUD insertion and the other half will receive a placebo gel.
45813510|NCT04802863|Drug|XNW4107, Imipenem/Cilastatin|Five doses of 250 mg XNW4107 in combination with 500 mg imipenem/500 mg cilastatin
45951978|NCT01248208|Biological|FluMist intranasal influenza vaccine|FluMist intranasal vaccine 0.2 mL will be given 0.1 mL in each nostril per manufacturer's instructions.
45951979|NCT01248208|Biological|"Intramuscular influenza injection (flu shot)"|"Subjects < 2 years or > 49 years or those with asthma symptoms or treatment within the past year will receive the intramuscular flu shot in a single injection.~Age 6-36 months: 0.25 mL IM x 1; Age >36 months: 0.5 mL IM x 1 Boosters: All children aged 6 months-8 years who receive a seasonal influenza vaccine for the first time should be administered 2 doses. Children aged 6 months-8 years who received a seasonal vaccine for the first time during 2009-2010 but who received only 1 dose should receive 2 doses, rather than 1, during 2010-2011. In addition, for the 2010-11 influenza season, children aged 6 months-8 years who did not receive at least 1 dose of an influenza A (H1N1) 2009 monovalent vaccine should receive 2 doses of a 2010-11 seasonal influenza vaccine, regardless of previous influenza vaccination history. For all children, the second dose of a recommended 2-dose series should be administered 4 or more weeks after the initial dose."
45951980|NCT00503971|Drug|Vorinostat plus Erlotinib|"Phase I:~Dose level 1: 300 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2: 400 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2b: 300 mg V d1-7 and 15-21 every 28 days plus 100 mg E daily Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily~Phase II:~Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily"
45951981|NCT04311450|Behavioral|Behavioral Weight Loss (BWL) counseling|This therapy is a weekly treatment which focuses on making gradual and modest lifestyle changes with goals of establishing regular patterns of eating, setting weekly goals, decreasing caloric intake, developing coping skills, and increasing physical activity.
45813511|NCT04756843|Device|Quad-helix|Fixed orthodontic appliance
45951982|NCT00504010|Drug|Arnica Montana|Applied to lower extremity once a day for 3 days
45951983|NCT00504010|Drug|placebo cream|placebo cream applied to leg daily for 3 days
45813512|NCT04738279|Device|Non-Invasive Continuous Remote Patient Monitoring|Continuous remote patient monitoring will consist of continuous collection of physiological data and patient status through a non-invasive wearable solution, connected to a structured cascading escalation management pathway
45813513|NCT04738279|Other|Affective Analysis of Participant Response to Continuous Remote Patient Monitoring|Survey and qualitative interviewing of participants
46077456|NCT04107207|Dietary Supplement|Ginger Kombucha|Craft Ginger Kombucha, a fermented black tea
46077457|NCT04107207|Dietary Supplement|Ginger Water|Placebo
45951984|NCT01248325|Drug|Luffa Operculate Nasal Solution 5mg/mL|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
46077458|NCT00604253|Drug|insulin detemir|
45453870|NCT02286388|Device|The application of an antibacterial dental adhesive (ClearfilTM SE Protect, Kuraray Dental).|"Enamel and dentin will be conditioned according to the manufacturer's instructions. Both antibacterial and conventional adhesives are two-steps bonding systems.~The first step consists of the application of a primer to the enamel and dentin for 20 seconds (which allows the completion of etching and priming procedures). The second step consists of the application of the antibacterial adhesive and its light curing for 10 seconds."
45453871|NCT02286388|Device|The application of a conventional dental adhesive (ClearfilTM SE Bond, Kuraray Dental)|Idem antibacterial dental adhesive arm. A conventional dental adhesive will be used instead of an antibacterial.
45453872|NCT00501202|Drug|placebo|twice daily for 4 weeks
45951985|NCT01248325|Drug|Saline Solution (NaCl 0,9%)|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
45951986|NCT02274883|Dietary Supplement|Enriched Protein Fractions|Enriched protein fractions
45951987|NCT02274883|Dietary Supplement|Protein Fractions|Protein fractions
45951988|NCT04278924|Drug|Placebo|TAK-079 placebo-matching SC injection.
45951989|NCT04278924|Drug|TAK-079|TAK-079 SC injection.
45951990|NCT02274961|Drug|S-pantoprazole 10mg|
45951991|NCT02274961|Drug|Placebo|
45951992|NCT02275000|Other|5 Day Physiotherapy Programme|The experimental group will complete a 5 day physiotherapy programme consisting of education, movement retraining and a self management plan.
46077459|NCT00604253|Drug|insulin NPH|
46077460|NCT02754960|Drug|Thalidomide|Interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
46077461|NCT02754960|Drug|Placebo|Placebo administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
45951993|NCT02275000|Other|Physiotherapy|Treatment as usual physiotherapy. The participant will be referred to their closest NHS outpatient neuro-physiotherapy service.
45951994|NCT02275039|Biological|modified vaccinia virus ankara vaccine expressing p53|Given SC
45951995|NCT02275039|Drug|gemcitabine hydrochloride|Given IV
45813514|NCT04682431|Drug|PY159 Single agent dose level 1|Dose of PY159 as a single agent given in a standard 3+3 design.
45660085|NCT05495425|Drug|NPC-12Y placebo gel|NPC-12Y placebo gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
46077462|NCT00902317|Procedure|Cryoplasty (PolarCath peripheral balloon catheter)|Cryoplasty involves advancing the balloon catheter to the site of the lesion and delivering liquid nitrous oxide into the balloon, where it expands into gas and inflates the balloon.
46077463|NCT00902317|Procedure|Laser Angioplasty (Spectranetics)|The basic concept of laser angioplasty is to apply light energy directly to the arterial plaque, thereby altering the plaque in some helpful way, without damaging the surrounding artery.
45453873|NCT00501202|Drug|RWJ-333369 (carisbamate)|200 mg tablet twice daily for 4 weeks
45453874|NCT00500812|Drug|Cethrin|
45660086|NCT02861521|Device|Shoe lift|Subjects will be given a shoe lift post-knee replacement to correct leg length discrepancy
45660087|NCT02861521|Device|Sham|Sham shoe modification
45660088|NCT05495347|Other|patients diagnosed with OSA|All patients diagnosed with OSA since March 2020 with an indication for treatment with PAP have been telemonitored permanently since the start of therapy and continue to be telemonitored at the present time. Data are sent remotely daily to the telemonitoring platform.
45660089|NCT05491135|Biological|HMB002|The solution containing microbeads will be infused manually into the peritoneal cavity under ultrasound guidance, with usually a 50ml syringe, as a single infusion or several infusions, to achieve in excess of 25 million hepatocytes per kilogram of the body weight.
45813515|NCT04682431|Drug|PY159 Single agent dose level 2|Dose of PY159 as a single agent given in a standard 3+3 design.
45813516|NCT04682431|Drug|PY159 Single agent dose level 3|Dose of PY159 as a single agent given in a standard 3+3 design.
45813517|NCT04682431|Drug|PY159 Single agent dose level 4|Dose of PY159 as a single agent given in a standard 3+3 design.
45813518|NCT04682431|Drug|PY159 Single agent dose level 5|Dose of PY159 as a single agent given in a standard 3+3 design.
45813519|NCT04682431|Drug|PY159 Single agent dose level 6|Dose of PY159 as a single agent given in a standard 3+3 design.
45813520|NCT04682431|Drug|PY159 Single agent dose level 7|Dose of PY159 as a single agent given in a standard 3+3 design.
45813521|NCT04682431|Drug|PY159/Pembrolizumab Combination dose level 1|Dose of PY159 and given in combination with pembrolizumab
45951996|NCT02275039|Other|laboratory biomarker analysis|Correlative studies
45951997|NCT04263051|Drug|UCPVax + Nivolumab|"UCPVax will be administrated at day 1 of week 1 ; 2 ; 3 ; 5 ; 6 ; 7 and then week 13 and every 2 months until months 12.~Nivolumab will be administrated at the dose of 480 mg at day 1 and then every 4 weeks until disease progression or unacceptable toxicity according to label.~At the end of COMBO phase, nivolumab will be continued every 4 weeks for maximum 24 months from the first administration, until disease progression or unacceptable toxicity according to standard of care."
46077464|NCT00902317|Procedure|SilverHawk Atherectomy|Once the catheter is connected to the cutter driver, by retracting the positioning lever this simultaneously turns on the motor and caused the distal portion of the cutter housing to deflect, forcing the device against the target lesion.
46077465|NCT00902317|Device|Viabahn Endograft|The Gore-Viabahn should be positioned across the target lesion using the radiopaque hub and tip markers on the catheter. These markers identify the proximal and distal ends of the device, respectively.
45660090|NCT04185337|Procedure|Fine-Needle Aspiration|Undergo ultrasound-guided FNA
45660091|NCT04185337|Procedure|Lymph Node Biopsy|Undergo ultrasound-guided lymph node biopsy
45813522|NCT04682431|Drug|PY159/Pembrolizumab Combination dose level 2|Dose of PY159 and given in combination with pembrolizumab
45813523|NCT04682431|Drug|PY159/Pembrolizumab Combination dose level 3|Dose of PY159 and given in combination with pembrolizumab
45813524|NCT04682431|Drug|PY159/Pembrolizumab Combination dose level 4|Dose of PY159 and given in combination with pembrolizumab
45813525|NCT04682431|Drug|PY159 Single agent dose expansion cohort|Dose of PY159 as a single agent given for predefined tumor histology
45813526|NCT04682431|Drug|PY159/Pembrolizumab Combination dose expansion cohort 1|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
45813527|NCT04682431|Drug|PY159/Pembrolizumab Combination dose expansion cohort 2|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
45813528|NCT04682431|Drug|PY159/Pembrolizumab Combination dose expansion cohort 3|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
45813529|NCT04682431|Drug|PY159/Pembrolizumab Combination dose expansion cohort 4|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
45813530|NCT04682431|Drug|PY159/Pembrolizumab Combination dose expansion cohort 5|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
45951998|NCT04263051|Drug|standard chemotherapy|Second line chemotherapy at the choice of the investigator
45951999|NCT02275078|Behavioral|COPD self-management using an action plan|"Behavioral: Self-management education on the use of a self-administered prescription for exacerbation.~Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription."
45952000|NCT02275078|Device|Telesystem-Phone self-assessment/reporting system|Phone Self-Assessment/Reporting System. The second component of the intervention is the use of a computer-linked interactive phone assessment/reporting system that can assess respiratory status and notify the nurse case manager as needed
45952001|NCT02275078|Other|Nurse case manager support|Support:Nurse Case Manager Phone Support . The nurse case manager will call patients under two conditions. The first is to provide regularly scheduled follow-up education and support.The nurse case manager will also phone patients in response to answers they have provided to the phone system. i.e Worsening COPD status
45813531|NCT04682431|Drug|PY159/Pembrolizumab Combination dose expansion cohort 6|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
45660092|NCT04185337|Procedure|Photoacoustic Imaging|Undergo ultrasound-guided PAI
45660093|NCT04185337|Procedure|Ultrasound|Undergo ultrasound
45660094|NCT04185337|Device|Multispectral optoacoustic tomography (MSOT) acuity instrument|Use multispectral optoacoustic tomography (MSOT) acuity instrument
45813532|NCT05205031|Device|Intraosseous access|Needle placed in the bone marrow.
45813533|NCT05205031|Device|Intravenous|Needle placed in a vein.
45952002|NCT01248403|Drug|Paclitaxel|Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.
46077466|NCT00902317|Procedure|"Angioplasty/Stent (Guidant Absolute stent)"|A Stent is a metal scaffold that is also delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood flow. The stent remains implanted in the blood vessel, and after a few weeks, the inner lining of the blood vessel will grow over the stent surface.
45453875|NCT02283892|Other|Checklist|3 page checklist with suggestions of possible diagnosis according to clinical presentation of patients presenting with dyspnea or cough; also suggests diagnostic tests that are likely to be useful in each situation.
45453876|NCT02283892|Other|Conventional evaluation|Physician evaluation without the use of checklists
45660095|NCT02232997|Other|Standard Hydration|Sodium chloride hydration was set between 12 hours before coronary intervention (before contrast exposure during coronary angiography), continued during procedure, and 12 hours after procedure at 1 ml/kg/h (0.5 ml/kg/h For patients with congestive heart failure, New York Heart Association class>II, or LVEF < 35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to calculated values for patients weighing 80 kg
45660096|NCT02232997|Other|Simplified Hydration|Hydration with sodium chloride was set 1 hour before procedure (before contrast exposure during coronary angiography), continued during procedure, and 4 hours after procedure at 3ml/kg/h (1.5ml/kg/h For patients with congestive heart failure, New York Heart Association class>II, or LVEF <35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to those calculated for patients weighing 80 kg.
45660097|NCT05491057|Drug|Neratinib|Neratinib standard dose 240 mg once daily for 1 year
45676547|NCT02003222|Drug|Cyclophosphamide|Given IV
45676548|NCT02003222|Drug|Cytarabine|Given IT, IV, or SC
45813534|NCT04677751|Device|Acupuncture intervention|Participants will undergo 12 weeks of acupuncture therapy. There will be one 40 minute-1 hour. session per week.
45952003|NCT01248403|Drug|RAD001|RAD001 10mg (2 x5 mg tablets / day) d1-d28
45952004|NCT01248442|Drug|Cholecalciferol|monthly dose of 140.000 IU of cholecalciferol orally, 3 times.
45952005|NCT01248442|Drug|Placebo|Matching Placebo
45952006|NCT01248481|Drug|Acarbose (Glucobay, BAYG5421)|Adult female and male patients are scheduled to be treated with acarbose will be enrolled after the therapy decision has been made. Physicians should consult the full prescribing information for Glucobay® before enrolling patients and familiarize themselves with the safety information in the product package label.
45952007|NCT02957838|Dietary Supplement|C18:0|Receives 24g of C18:0 in a low-fat banana milkshake.
45952008|NCT02957838|Dietary Supplement|mock|Low fat banana milkshake without C18:0 supplement.
45813535|NCT04652869|Device|Transcranial direct current stimulation|Transcranial direct current stimulation targeting the dorsolateral prefrontal cortex
45813536|NCT04652869|Behavioral|Mindfulness|Mindfulness is a type of meditation in which you focus on being intensely aware of what you're sensing and feeling in the moment, without interpretation or judgment.
45813537|NCT04643899|Device|Muscle Electrostimulation|"Scheduled sessions of 20 minutes per day; 5 days a week~In physiotherapy or in their room for the most dependent patients~Installation and monitoring by a physiotherapist or by the trained clinical research nurse~Modalities:~Device program n ° 1: 20mn (2mn of warm-up, 15mn of work at 75hz, then 3mn of recovery)~4 electrodes (2 per thigh): large model (5 * 10 cm) for better comfort - Dura-Stick Plus model (reference 42200)~Gradual auto-increase of the intensity to the highest possible value tolerated, nevertheless allowing a contraction"
46077467|NCT00587847|Drug|Campath|Campath 30 mg administered subcutaneously at varying intervals for up to 1 year
46077468|NCT00604331|Drug|Pyruvate|sodium pyruvate 300 mmol/L, 360 mL/h i.c. over 30 minutes.
46077469|NCT00638196|Drug|Linoleic Acid/Oleic Acid|Dietary Supplement: Linoleic acid emulsion 30g bid/Oleic acid emulsion 30g bid
46077470|NCT02540239|Drug|2L PEG|
46077471|NCT02540239|Drug|2L PEG+simethicone|
46077472|NCT02540395|Drug|Tacrolimus (for Group B)|Tacrolimus (for Group B) will be administered orally twice a day (bid). Tacrolimus (for Group B) will be initially given at the 0,1mg/kg bid to achieve a stable 12-hour trough level of 8-10 ng/mL during the first month after transplantation to progressively tapper to 6-8ng/ml thereafter.
45952009|NCT02955745|Other|Iodine-129|The present study is an observational study and does not therefore include an investigational product in the proper sense because the used tracer (semi-stable iodine isotope) has no physiological effect on the participants. 129I will be used as tracer to measure appearance in plasma, urine and stools after the oral administered of the 129I-tracer.
45813538|NCT04622839|Other|Tylenol and NSAIDS (Ibuprofen, diclofenac)|"This study will assess an aspect of perioperative care relating to pain control. Subjects will not be aware of which aspect is randomized, but will be given a list of possible aspects which will include the intervention (listed below):~Agents used in nerve block (lidocaine vs ropivacaine)~Location of injection for analgesic~Use of over-the-counter pain management (including but not limited to acetaminophen, ibuprofen, naproxen, etc.)~Type of initial opioid prescribed (including but not limited to oxycodone, tramadol, hydrocodone, etc.)~Number of pills in the initial opioid prescription~Instructions for sling wear (duration of use or type of sling)~Ice usage (duration of use and frequency of use)~Blinding the participant to the randomized aspect of this study will help prevent bias in patient responses for outcome scores and medication usage."
45952010|NCT02955667|Procedure|invivo microscopy group|patients receive invivo micro-colposcopy examination
45952011|NCT02955667|Procedure|normal group|patients receive normal colposcopy examination and the biopsy specimens are sent for pathological HE staining and analysis
45952012|NCT01248520|Other|influenza and general health information|Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver. These messages will contain general health information as well as information regarding influenza and the importance of vaccination during pregnancy.
45952013|NCT01248520|Other|general health information|Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver.
45952014|NCT01248637|Drug|Pimonidazole hydrochloride|Pimonidazole is a 2-nitroimidazole that is selectively reduced and covalently binds to intracellular macromolecules in areas of hypoxia (by definition, p02 <= 10mm Hg) within normal and tumour tissue. Pimonidazole adducts can then be detected by immunolabelling techniques (microscopy, ELISA, flow cytometry etc). In this study, pimonidazole will be administered orally as a one time dose of 0.5gm/m2 24hrs prior to surgery. Since the drug has a half-life of approximately 5 hrs, this time-frame ensures low circulating levels at the time of surgery and therefore reduces the confounding effects of surgical hypoxia on tumour analysis.
45952015|NCT04186923|Other|F-SPOKE|This project includes communicative, emotional, and also organizational support with outreach across different sectors and phases (F-SPOKE - family-centered, cross-sector and cross-phase organizational, communicative, and emotional support).
45952016|NCT01248676|Other|Multi-language Online Patient Education Module in addition to standard Patient Teaching|"Patients are usually be given a 5-10 minute new patient teaching before their radiation therapy simulation and planning appointment and before their first radiation therapy treatment appointment. Patients will be asked to view an online patient education module before their radiation therapy simulation and planning appointment or before their first radiation therapy treatment appointment. Then patients will be asked to participate in an interview session and fill out a survey (attached). They will still receive new patient teaching from the therapists before their radiation therapy simulation and planning or radiation therapy treatment appointment."
45660098|NCT05490901|Diagnostic Test|Exercise hemodynamic test|Assessment of pulmonary hemodynamics during exercise by right heart catheterization and cardiac function during exercise by a simultaneous transthoracic echocardiography
45660099|NCT05495191|Diagnostic Test|Signal intensity gradient|"In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A [Xa] along the arterial contour line) and at the inner point (Φb; signal intensity at position B [Xb]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
45676549|NCT02003222|Drug|Daunorubicin|Given IV
45813539|NCT00366379|Drug|GK Activator (2)|25-200mg po bid for 20 weeks
45813540|NCT02619799|Drug|intrathecal magnesium sulphate,|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
45813541|NCT02619799|Drug|Intrathecal midazolam|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
45813542|NCT04592809|Drug|Ketamine Hydrochloride|infused over a 40 minute period
45813543|NCT04592809|Drug|Midazolam Hydrochloride|infused over a 40 minute period
45952017|NCT01248754|Procedure|Surgical neuronavigation with 18F-DOPA PET imaging|Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
46077473|NCT02540395|Drug|MMF (mycophenolate mofetil) (for Group B)|"MMF (mycophenolate mofetil) will be administered orally to patients in group B at conventional doses (1gr/12h) before transplant procedure and during the first 7 days after transplant. For subjects who develop nausea, diarrhea, or other MMF(mycophenolate mofetil) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to MMF), the MMF(mycophenolate mofetil) dose may be decreased to the maximally tolerated dose.~Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™) or to Myfenax.~From day 8 on, patients will not receive MMF."
45458463|NCT02321644|Drug|CC-90001|CC-90001 Active-ingredient-in-capsule and formulated tablet
45660100|NCT05495113|Device|YMS-201B (Device: Mind STIM)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
46077474|NCT02540395|Drug|6-methyl prednisolone (Steroids) (for Group B)|"At the time of surgery, all patients will receive 500mg of 6-methyl prednisolone (Steroids, Urbason, Methypred).~Patients in group B will receive 250mg of 6-methyl prednisolone (or equivalent) on day 2, 125 mg on day 3, 60 mg on day 4 and 30 mg on day 5. From day 6 on, patients will receive 0.25 mg/kg/d of 6-methyl-prednisolone (Steroids, Urbason, Methypred) until month 1, then tapering until discontinuation on month 2 will be performed."
45952018|NCT01248832|Behavioral|Telephone Counseling|"Counseling is conducted in Mandarin, Cantonese, Korean, or Vietnamese by counselors at the Helpline. The protocol used is similar to that proved efficacious. However, to make the counseling culturally appropriate for Asian language speakers, we: capitalizing on first contact, present the Helpline as a credible quit smoking program staffed by experts, avoid the term counseling since it is associated with mental illness, and assume a more authoritative role and directive counseling style. Counseling is proactive (1st call is made by smoker, then subsequent calls are made by the counselor) to help reduce attrition. Counseling includes a 30-40 minute comprehensive pre-quit session plus up to 5 shorter follow-up calls (about 10 minutes) scheduled according to the probability of relapse."
45952019|NCT01248832|Behavioral|Self-Help Materials|All subjects (both in the telephone counseling group and the materials-only group) receive self-help materials in teh appropriate language. Materials were created in-house, are written in the appropriate language, and cover the essentials of the quitting process such as motivation, physiological and emotional responses to quitting, nicotine in the body, quitting aids, quitting strategies (including those that might be culturally specific such as acupuncture or herbs), setting a quit date, planning, relapse prevention, differentiating between slips and relapse, long-term maintenance, and developing the nonsmoker self-image.
46077475|NCT02540395|Drug|Tacrolimus (for Group A)|"The study group A will receive Tacrolimus (for Group A) (Prograf) to achieve 4-8 ng/ml trough levels during all the duration of the study.~Tacrolimus (for Group A) (Tacrolimus) capsules should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption."
45458464|NCT01364012|Drug|Bevacizumab|Bevacizumab will be administered at 15 mg/kg IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
45660101|NCT05495113|Device|Sham stimulation using YMS-201B|Sham stimulation; only 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
45660102|NCT04364737|Biological|Convalescent Plasma|SARS-CoV-2 convalescent plasma (1-2 units; ~250-500 mL) with antibodies to SARS-CoV-21 per April 13, 2020 directive by the FDA, obtained from New York Blood Center will be administered to eligible candidate
45660103|NCT04364737|Other|Saline solution|Equivalent volume of saline solution (defined as half-,quarter-, or normal saline) will be administered to eligible candidate as a placebo control group.
45660104|NCT02559115|Radiation|68Ga-RM2 (RM2)|
45660105|NCT02559115|Device|PET/CT Scan|
46077476|NCT02540395|Drug|Mycofenolate mofetil (MMF) (for Group A)|"Mycophenolate mofetil (MMF) (Cellcept, Myfortic, Myfenax) (for Group A) will be administered orally to patients in group A at conventional doses (1gr/12h). For subjects who develop nausea, diarrhea, or other Mycophenolate mofetil (MMF) (for Group A) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to Mycophenolate mofetil (MMF) (for Group A), the Mycophenolate mofetil (MMF) (for Group A) dose may be decreased to the maximally tolerated dose.~Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™).~The first dose of Mycophenolate mofetil (MMF) (for Group A) should be administered before transplantation."
45660106|NCT05494957|Drug|New regimen(BdqCfzLzd+XY)|The basic regimen consists of bedaquiline, clofazimine, linezolid, and 2-3 drugs such as amikacin and tigecycline are selected according to the drug use history and in vitro culture drug sensitivity results to form the regimen, and the treatment period is usually more than 12 months, and the doses of various drugs are used for the regular drug use.
45660107|NCT05494879|Behavioral|microkinesitherapy treatment|"The therapeutic session of microkinesitherapy included a seeking of body scares both taking into account somatic dysfunctions as well as psychosomatic disorders. According to the creators of the method, Grosjean and Benini Everything that happens with us in a toxic level, either physically or emotionally, are stored by the brain which keeps memories and generates links that may harm the function of the cells generating a vast array of symptoms and dysfunctions."
45660108|NCT04015921|Other|No intervention|There is no intervention. Participants will be asked to complete a questionnaire and computer-based tasks.
45660109|NCT04003363|Other|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
45458465|NCT01364012|Drug|Carboplatin|Carboplatin will be administered at area under the plasma concentration-time curve (AUC) 6.0 IV on Day 1 of each 3-week cycle, up to 6 cycles.
45660110|NCT04352101|Drug|Bupropion XL|Participants will take 150 milligrams per day (mg/d) of bupropion XL for two weeks, then the dose will be increased to 300mg/d, as tolerated, for the remaining 6 weeks of the study.
45660111|NCT04352101|Drug|Escitalopram|Participants will take 10mg/d of escitalopram for two weeks, then the dose will be increased to 20mg/d, as tolerated, for the remaining 6 weeks of the study.
45660112|NCT05490823|Device|A smartphone app for anemia screening|This app can achieve automatic detection of anemia based on patient-sourced images of fingernails and conjunctivae.
45660113|NCT04424485|Procedure|Total thyroidectomy (TT)|Standard TT procedure for thyroid carcinoma, for both groups
45660114|NCT04424485|Procedure|Central lymph node dissection (CLND)|Standard CLND for thyroid carcinoma, for both groups
45660115|NCT04424485|Diagnostic Test|Sentinel lymph node (SLN) bopsy|Intrathyroidal injection of ICG for SL biopsy, for only experimental group
45660116|NCT04424485|Diagnostic Test|Identification of parathyroid glands (PGs)|Near-infrared (NIR) fluorescence visualization of PGs, for only experimental group
45676550|NCT02003222|Drug|Daunorubicin Hydrochloride|Given IV
45676551|NCT02003222|Drug|Dexamethasone|Given PO
45676552|NCT02003222|Drug|Etoposide|Given IV
45660117|NCT05490745|Behavioral|Skills4Parenting+|Skills4Parenting+ has 6-8 weekly individual online sessions (50 min) + 8-week follow-up. First, an assessment session of parents' positive parenting skills (PPS), based on mother/father-child interaction observation. The following sessions aim to (1) promote parental reflective functioning, enhancing parents' understanding of the child´s problems, and (2) activate PPS to solve the child's problems. Written registers of problematic situations - in which the problems of the child occur, are analyzed (i.e., child's and parents' behaviors, thoughts, and feelings) (intersession activity) - are reflected upon, to understand and solve through PPS. PPS implementations are analyzed to understand the changes in the child and parent. Future situations and activation of appropriate PPS are anticipated, to solve potential upcoming problems of the child's, related to adversity. When the therapeutic goals have not been fully achieved, two additional sessions (total of 8 instead of 6), are added.
45660118|NCT05490745|Other|Waiting-list (nocebo)|Participants wait to receive the psychological intervention (Skills4Parenting+) for eight weeks, after the assessment session.
45660119|NCT05494645|Drug|Exparel|Liposomal bupivicaine
45952020|NCT03929939|Behavioral|Exercise training and healthy eating (overseen by IEEM research team)|"Exercise Training: A personalized training program will be developed for participants. Based on maximal steady state heart rate and resting heart rate, three training zones (recovery, base pace, and maximal steady state) will be determined. The target heart rate for each training zone will be set for each patient. The majority of training sessions during the early phase of the program will be prescribed as base pace with target heart rate equivalent to about 75% of maximal. Initially, patients will train 3 times per week for 20-30 minutes per session by walking, jogging or swimming. As the patients become relatively fit, the duration of the base training sessions will be prolonged, and subsequently sessions of increased intensity (i.e., maximal steady state) will be added.~Healthy Eating: Participants will be provided with dietary advice consistent with the American Heart Association guidelines (D.A.S.H. diet eating plan)."
45952021|NCT04183140|Procedure|primary percutaneous coronary intervention|primary percutaneous coronary intervention via transulnar or transradial access
46077477|NCT02540395|Drug|6-methyl prednisolone (Steroids) (for Group A)|"At the time of surgery, all patients will receive 500 mg of 6-methyl prednisolone (steroids for Group A).~Patients in arm A will receive 20 mg/day of 6-methyl prednisolone (steroids for Group A) (or the equivalent) during the first 2 weeks after transplantation, then tapering to 15 mg from week 3 to week 4 to finally be maintained at 5mg/day."
45660120|NCT05494645|Drug|Peripheral Nerve Block|Peripheral nerve block without Exparel
45813544|NCT05164705|Other|Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and alternate between breathing 9% O2 gas mixture for up to 1 minute, or until the target SpO2 of 85 percent is reached, and normal room air (21 percent O2) until 2 minutes are complete. This cycle will be repeated 15 times, resulting in a 30-minute protocol.
45952022|NCT01248910|Behavioral|Alpine Skiing|
45952023|NCT01248988|Other|Synflorix™ Data collection|Safety monitoring: recording of adverse events during using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
45952024|NCT01247194|Drug|PPI-461|capsule, oral, once daily for 3 days
45952025|NCT01247194|Drug|Placebo|capsules, oral, once daily for 3 days
45952026|NCT03844334|Device|WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 80 years requiring treatment for single ruptured or unruptured intracranial aneurysms.
46077478|NCT05565729|Drug|LY3471851|Administered SC.
46077479|NCT05565729|Drug|Placebo|Administered SC.
46077480|NCT05565729|Drug|Levocetirizine|Administered orally.
45660121|NCT05494567|Drug|Tadalafil 5mg|patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin for 12 weeks in group 1
45660122|NCT05494567|Drug|Tamsulosin Hcl 0.4 mg|patients with BPH/OAB will be treated with combination therapy of tamsulosin plus solifenacin for 12 weeks in group 2
45660123|NCT05494567|Drug|solifenacin 10 mg|patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin in group 1 and tamsulosin plus solifenacin in group 2 for 12 weeks
45660124|NCT04339777|Drug|Busulfan test dose|0.8 mg/kg IV infusion over 2 hours
45660125|NCT04339777|Drug|Fludarabine|40 mg/m2 IV infusion over 30 min once daily for 4 days
45813545|NCT05164705|Other|Sham Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and breathe normal air (21 percent O2) for 30-minutes.
45952027|NCT01249105|Drug|MK-2206|Taken orally once a week
45952028|NCT02957955|Behavioral|High-Intensity Interval Training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks. Participants will complete six-minute walk test, cardiopulmonary exercise test, and six questionnaires: Short Form 36 Health Survey Questionnaire (SF-36), Minnesota Living with Heart Failure Questionnaire (MLHFQ), Beck Depression Inventory II (BDI-II), Beck Anxiety Inventory (BAI), Montreal Cognitive Assessment (MOCA), and Impact of Events Scale-Revised (IES-R) at baseline (week 1) and follow-up (after 12 weeks of intervention).
46077481|NCT04547166|Drug|HLX10|a single fixed dose of 300 mg, intravenous infusion (IV), every 3 weeks (Day 1 of each cycle [D1]), non-reducible.
46077482|NCT04547166|Drug|HLX04、|7.5mg/kg, IV, every 3 weeks (D1 of each cycle), non-reducible.
46077483|NCT00897559|Genetic|gene expression analysis|
46077484|NCT00897559|Genetic|mutation analysis|
46077485|NCT00897559|Genetic|polymorphism analysis|
46077486|NCT00897559|Genetic|protein analysis|
46077487|NCT00897559|Other|flow cytometry|
46077488|NCT00897559|Other|laboratory biomarker analysis|
45676553|NCT02003222|Procedure|Lumbar Puncture|Undergo lumbar puncture
45676554|NCT02003222|Drug|Mercaptopurine|Given PO
45676555|NCT02003222|Drug|Methotrexate|Given PO, IT or IV
45676556|NCT02003222|Drug|Pegaspargase|Given IM or IV
45676557|NCT02003222|Drug|Prednisone|Given PO
45676558|NCT02003222|Biological|Rituximab|Given IV
45676559|NCT02003222|Drug|Vincristine|Given IV
45813546|NCT02621983|Behavioral|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
46077489|NCT00602693|Biological|umbilical cord blood transplantation|Infusion of umbilical cord blood
46077490|NCT00602693|Drug|Allopurinol|Administration begins Day -7 through Day 0, tablet or powder prescribed on an individual basis.
45660126|NCT04339777|Drug|Busulfan|"AUC Targeted Dose based on busulfan test dose PKs, IV infusion over 3 hours once daily (3.2 mg/kg IV per day will be the default dose) per the below time frame: For 10/10 Matched Related and Unrelated Donor Recipients For the High Intensity Arm, the busulfan dose will be given for 4 days (-6, -5, -4, and -3).~For Intermediate Intensity Arm, the busulfan dose will be given for 3 days (-6,-5, and -4).~For Low Intensity Arm, the busulfan dose will be given for 2 days on days (-6 and -5). 9/10 HLA Matched Related or Unrelated Donor Recipients For the High Intensity Arm, the busulfan dose will be given for 3 days (-6,~-5, and -4). For the the Intermediate Intensity Arm, the busulfan dose will be given for 2 days (-6 and -5).~For the Low Intensity Arm, the busulfan dose will be given for 1 day on day (-6)."
45660127|NCT04339777|Drug|Alemtuzumab|Alemtuzumab will be given if there is evidence of immune dysregulation 10 mg/m2 SC divided over three days (-14, -13, and -12)
45676560|NCT02003222|Drug|Vincristine Sulfate|Given IV
45813547|NCT02621983|Behavioral|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
45813548|NCT04741165|Drug|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
45813549|NCT04741165|Drug|Bevacizumab|15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
45813550|NCT04741165|Drug|Lenvatinib|Administered orally once a day during each 21-day cycle
45813551|NCT04741243|Device|Extracorporeal Shock wave|Dietary modifications are changes made during food preparation, processing, and consumption to increase the bioavailability of micronutrients-and reduce micronutrient deficiencies-in food at the commercial or individual/household level
45813552|NCT05142787|Device|Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics|placement of Magseed Pro & localisation with Sentimag Gen3 in axillary lymph nodes and/or breast lesions
45813553|NCT05138497|Other|HILIT|A total of 92 men and women 65 years old, distributed in an experimental group that will receive a 12-week of HILIT program (n = 46); and a control group (n = 46) that will only receive general recommendations on the benefits of physical exercise. The variables will be measured for both groups with the same validated tools and the same researcher to avoid information biases and differential incorrect classification.
45813554|NCT04468399|Other|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
45813555|NCT04468399|Other|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
45813556|NCT02623855|Behavioral|Family outings|Participants will be invited to three weekly outings to local parks, case management and support in getting to nature. Participants will be offered transportation to the outings and s meal at local nature destinations. Programming at the park will include a picnic and walk with nature exploration, and will be facilitated by park and clinic staff.
45813557|NCT02623855|Behavioral|Park prescription|Participants will receive a map of local parks, and the recommendation to be physically active outdoors three days a week in nature.
45813558|NCT02623855|Device|Pedometry|Participants will record their daily pedometry.
45952029|NCT01249144|Device|Intraocular Lens (IOL)|Device for implantation in the capsular bag of the eye for visual correction of aphakia following cataract surgery.
45952030|NCT01249183|Biological|Concomitant administration|1 dose (0.5 mL) of VAXIGRIP and 1 dose (0.5 mL) of REPEVAX in 2 separate injections sites (1 on each arm)
45952031|NCT01249183|Biological|Separate administration|1 dose (0.5 mL) of VAXIGRIP at Day 0 and 1 dose (0.5 mL) of REPEVAX 28 days later
45952032|NCT03829787|Device|Eye tracking|Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology
46002684|NCT04637061|Combination Product|intraoperative near infrared (NIR) indocyanine green (ICG)-induced fluorescence angiography (FA) and air leak testing to assess the integrity and the perfusion levels of the colorectal anastomosis|Extra-luminal (serosa) and Endo-luminal (mucosal) evaluation of the proximal colon and distal rectal stump perfusion based on a semi-quantitative NIR-ICG-induced FA. This will be conducted administering IV a bolus of 3.75 to 7.5 mg of ICG and evaluated using a Fluorescence Imaging System; following after completion of the anastomosis a second bolos of 3.75 to 7.5 mg of ICG will be administered IV and the anastomosis will be visualized by insertion of the system trans-anally. Colon and rectal segments and quadrants will be scored for any defect of perfusion.
46077491|NCT00602693|Drug|fludarabine phosphate|40 mg/m^2 intravenously over 1 hour on Days -6, -5, -4, -3, -2
46077492|NCT00602693|Drug|Cyclophosphamide|50 mg/kg intravenous over 2 hours on Day -6
46077493|NCT00602693|Radiation|Total body irradiation|200 cGy on Day -1
46077494|NCT00602693|Biological|Treg infusion|Infusion of T regulatory cells on Day +1 (also Day +15 for Dose level 5 only). Dose escalation ranges include 1, 3, 10, 30, 100, 300 1000, and 300 x 10^5 Treg/kg.
46077495|NCT00602693|Drug|Sirolimus|Beginning on day -3 and continuing until day +100, patients receive sirolimus intravenously (IV) with 8-12 mg oral loading dose followed by a single dose of 4mg/day with a target serum concentration of 3-12 mg/mL with a taper until day +180.
46077496|NCT00902395|Drug|Midazolam|Oral midazolam 1.0 mg/kg (maximum 20 mg)
46077497|NCT00902395|Behavioral|Protective stabilization|Children will receive a protective stabilization (physical restrain) with sheet fixed with tapes.
45660128|NCT04339777|Radiation|Total body Irradiation|200 cGy Transplant Day -1 (Only for 9/10 HLA Matched Related or Unrelated Donor Recipients )
45660129|NCT04339777|Procedure|Allogeneic HSCT|Stem cell transplant
45660130|NCT04339777|Drug|Tacrolimus (Tacro)|Tacrolimus 0.02 mg/kg IV continuous infusion over 24 hours starting on day +5
45813559|NCT02623855|Behavioral|Case Management|Participants will receive a phone call to list potential barriers to participating in nature outings, and will talk through solutions with an investigator. Participants will be offered assistance with transportation if necessary.
45660131|NCT04339777|Drug|Mycophenolate mofetil (MMF)|Mycophenolate mofetil 15 mg/kg IV over 2 hours three times a day starting on day +5 will continue until Approximately+35 (+/- two days)
45660132|NCT04339777|Drug|Cyclophosphamide (Cytoxan)|Cyclophosphamide: 50 mg/kg IV once daily over 2 hours on days +3 and +4, dosed according to ideal body weight
45813560|NCT04340011|Other|Colposcopy|prospective resident education for colposcopy
45660133|NCT05490667|Drug|Anlotinib|Anlotinib combined with chemotherapy for desmoid tumors
45660134|NCT04331587|Device|BF-P190 4 mm thin bronchoscope|"EVIS EXERA III Bronchofiberviedoscopes~Olympus"
45660135|NCT04331587|Device|BF-MP190F 3 mm ultrathin bronchoscope|"EVIS EXERA III Bronchofiberviedoscopes~Olympus"
45660136|NCT04331587|Device|Radial ultrasound probe (UM S20-17S)|-Olympus
45660137|NCT04331587|Device|PeriView FLEX 21G Single Use Aspiration Needle|"NA-403D-2021~Gyrus ACMI, Inc."
45660138|NCT05494489|Device|EsoGLOVE with Trigno Biofeedback (EMG sensors)|The EsoGLOVE + Trigno subjects will receive EsoGLOVE with Trigno Biofeedback (EMG sensors) training on therapy day for 3 weeks (week 1 to week 3, sessions will be done every Monday to Friday), a minimum of 30 minutes per day in additional to the physiotherapy and occupational therapy as standard care for stroke patients.
45660139|NCT00609115|Device|AMES device (test)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
45813561|NCT04410133|Drug|18F fluciclovine|18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
45813562|NCT02625181|Procedure|Automated recommendation at the start of the case|The first notification is the main notification that informs the anesthesia providers at the start of anesthesia of the risk score for that individual patient and the recommended number of prophylactic interventions. The notification occurs within the anesthesia information management system (AIMS)
45813563|NCT02625181|Procedure|Automated notification at the start of surgery|The second notification within the AIMS will notify the anesthesia providers at the start of surgery when no prophylaxis has been given while three or more interventions were recommended.
45813564|NCT02625181|Procedure|Preoperative recommendations: by email|A recommendation on PONV prophylaxis to anesthesia providers through email at the Vanderbilt University Medical Center.
45813565|NCT02625181|Procedure|Automated notification at the end of surgery|A notification will remind anesthesia providers at the closing of surgery how many prophylactic interventions are required to adhere to the recommended number of interventions.
46077498|NCT00902395|Drug|Midazolam, ketamine|Combined oral midazolam (0.5 mg/kg) and ketamine (3 mg/kg) (MK)
46077499|NCT04213404|Drug|Ribociclib|Ribociclib 400mg, 600mg, or 200mg oral daily, D1-D21, 28 days a cycle
45813566|NCT02625181|Device|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
45813567|NCT02625181|Device|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the preoperative emails.
45676561|NCT02003222|Procedure|X-Ray Imaging|Undergo x-ray imaging
45813568|NCT02625181|Procedure|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
45813569|NCT02625181|Procedure|Elective surgery|Surgical procedures that are scheduled and not an emergency.
45813570|NCT02625181|Drug|Propofol|Anesthetic drug used to maintain general anesthesia
45813571|NCT02625181|Drug|Sevoflurane|Anesthetic drug used to maintain general anesthesia
45813572|NCT02625181|Drug|Isoflurane|Anesthetic drug used to maintain general anesthesia
45813573|NCT02625181|Drug|Desflurane|Anesthetic drug used to maintain general anesthesia
46077500|NCT04213404|Drug|Spartalizumab|Spartalizumab 400mg ivdrip on D1, 28 days a cycle.
46077501|NCT00604409|Radiation|SIRT|Undergo SIRT
46077502|NCT00604409|Drug|capecitabine|Given PO
46077503|NCT00905905|Drug|Simvastatin|Simvastatin 40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
46077504|NCT00905905|Drug|Ezetimibe-Simvastatin|Ezetimibe-Simvastatin 10-40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
45458466|NCT01364012|Drug|Paclitaxel|Paclitaxel will be administered at 175 milligrams per square meter (mg/m^2) IV on Day 1 of each 3-week cycle, up to 6 cycles.
45813574|NCT02625181|Drug|Scopolamine|Prophylactic antiemetic
45660140|NCT00609115|Device|AMES device (sham)|Eighteen treatment sessions for each qualifying subject limb using the AMES device (sham) in which the limb is moved, but no active assistance is provided by the subject and the vibration is delivered at a very low frequency to the shortening (i.e., rather than lengthening) muscle. Each treatment session to provide thirty minutes of the placebo form of AMES therapy.
45660141|NCT00609115|Device|AMES device (crossover)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed as soon as possible after the completion of Arm C-1 Sham Comparator.
45660142|NCT05494411|Drug|Mitomycin for pyelocalyceal solution|
45660143|NCT05490589|Other|EQUIPE Program|"EQUIPE is a manualised group community-based parent education programme. Groups consist of 15 parents who meet with one or two trained group leaders for weekly 2-hour sessions over 10 weeks.~This program promotes skill development in parents, strengthens relationships with children, increases cooperation, and helps solve problems in the home."
45813575|NCT02625181|Drug|Droperidol|Prophylactic antiemetic & rescue antiemetic
45813576|NCT02625181|Drug|Haloperidol|Prophylactic antiemetic & rescue antiemetic
45813577|NCT02625181|Drug|Dexamethasone|Prophylactic antiemetic & rescue antiemetic
45813578|NCT02625181|Drug|Promethazine|Prophylactic antiemetic & rescue antiemetic
45813579|NCT02625181|Drug|Meclizine|Prophylactic antiemetic & rescue antiemetic
45813580|NCT02625181|Drug|Aprepitant|Prophylactic antiemetic & rescue antiemetic
45813581|NCT02625181|Drug|Metoclopramide|Rescue antiemetic
45813582|NCT02625181|Drug|Fentanyl|Analgesic drug / Opioid
45813583|NCT02625181|Drug|Sufentanil|Analgesic drug / Opioid
45813584|NCT02625181|Drug|Alfentanil|Analgesic drug / Opioid
45813585|NCT02625181|Drug|Remifentanil|Analgesic drug / Opioid
45813586|NCT02625181|Drug|Morphine|Analgesic drug / Opioid
45813587|NCT02625181|Drug|Meperidine|Analgesic drug / Opioid
45813588|NCT02625181|Drug|Hydromorphone|Analgesic drug / Opioid
45813589|NCT02625181|Drug|Methadone|Analgesic drug / Opioid
45813590|NCT02625181|Drug|Oxycodone|Analgesic drug / Opioid
45813591|NCT02625181|Drug|Oxymorphone|Analgesic drug / Opioid
45813592|NCT02625181|Drug|Hydrocodone|Analgesic drug / Opioid
45813593|NCT02625181|Drug|Ketamine|Analgetic / Analgesic drug
45813594|NCT02625181|Drug|Ondansetron|Prophylactic antiemetic & rescue antiemetic
45813595|NCT02625181|Drug|Granisetron|Prophylactic antiemetic & rescue antiemetic
45458467|NCT01364012|Drug|Placebo|Bevacizumab matching placebo will be administered IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
45660144|NCT04085887|Drug|Panitumumab-IRDye800|Panitumumab-IRDye800 is an imaging agent prepared as a drug-dye compound from panitumumab (Vectibix), a fully-humanized IgG2 monoclonal anti-epidermal growth factor receptor (EGFR) antibody, and IRDye800CW dye. Panitumumab-IRDye800 delivered intravenous (IV).
45813596|NCT02625181|Drug|Dolasetron mesylate|Prophylactic antiemetic & rescue antiemetic
45813597|NCT02625181|Drug|Palonosetron|Prophylactic antiemetic & rescue antiemetic
45813598|NCT02625181|Drug|Tropisetron|Prophylactic antiemetic & rescue antiemetic
45813599|NCT02625181|Drug|Ramosetron|Prophylactic antiemetic & rescue antiemetic
45813600|NCT05092477|Behavioral|Integrated Intervention for Breast Cancer Survivors with Diabetes|"All pilot participants will be required to have a SMB target to be included in this study. A SMB target will be chosen by the participant after reviewing their 18mo follow-up responses with the Care Coach. Participants may endorse a maladaptive belief or emotional response; however, this is not required to participate in this intervention. At each follow-up session, the Care Coach will review the participant's SMB goal and progress, address participant's challenges and suggest alternatives, and correct further misinformation on the disease(s). Additionally, the Care Coach will reinforce or introduce techniques that could help overcome barriers to reaching SMB goal and recommend participants to continue improving on the same goal or begin action planning towards a new SMB goal.~Just SMB concern~SMB + maladaptive belief + emotional response~SMB + maladaptive belief~SMB + emotional response"
45813601|NCT05092477|Behavioral|Attention Control|Participants in the control arm will receive a brochure to discuss healthy lifestyle behaviors to improve DM management. To control for the potentially confounding effect of personalized attention from the care coach on the relationship between the intervention and outcomes, participants also receive 4 calls to discuss study progress, thoughts and feelings about study/illness/behaviors, remind them about returning their pill bottles, and about scheduling for their upcoming 24mo follow-up study interview.
45813602|NCT04391023|Device|Sham Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation technique in which a very weak electrical current (2 mA) is applied to the scalp at the beginning of the session and then remains at 0 mA for the duration of the session to control for placebo-like effects. The anode and cathode will both be placed over the cerebellum.
45813603|NCT04391023|Behavioral|Balance Training|The balance training protocol will include balance training exercises on both compliant (i.e., foam pad and trampoline) and firm surfaces.
45813604|NCT04391023|Device|2 mA Transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique in which very weak electrical current (2 mA) is applied to the scalp for 20 minutes. The anode and cathode will both be placed over the cerebellum.
45813605|NCT04391023|Device|4 mA Transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique in which very weak electrical current (4 mA) is applied to the scalp for 20 minutes. The anode and cathode will both be placed over the cerebellum.
46002685|NCT04637061|Diagnostic Test|Air Leak test|This will be conducted insufflaying air in the anastomosis through a proctoscope, tube or a flexible endoscope, after filling of the pelvis with saline solution and luminal occlusion of the intestine proximal to the anastomosis. Also, the anastomosis will be checked transanally for the presence of air leak.
46002686|NCT04637061|Diagnostic Test|Evaluation of the anastomotic rings|The assessment of the anastomotic rings following mechanical anastomosis will be recorded as complete/incomplete
45952033|NCT01249222|Procedure|plasmapheresis|Plasmapheresis was done every 24-48 hours and continues up to five times. Blood samples were collected 30 minutes before and after each session of plasmapheresis to determine sequential changes in plasma levels of IL-1β, IL-6 and TNF-α. During each exchange session a volume of 25-30 ml/kg bodyweight of patient's plasma was exchanged with equal volume of 20% human albumin diluted with normal saline solution. Before and after plasmapheresis, prothrombin time, activated partial thromboplastin time (aPTT), platelet count and serum calcium level were checked. calcium gluconate 10% (10 ml) was administered even if patient had normal serum calcium in order to prevent hypocalcaemia due to administration of citrate. All drugs except for vasopressors were stopped during procedure.
45952034|NCT01249222|Other|plasmapheresis|plasmapheresis 5 times every 24-48 hours. the apheresis volume will be 30 ml/kg.
45952035|NCT01249300|Other|No intervention|No intervention
45813606|NCT05442229|Other|establish a new Chinese children's speech and language norm|1063 normally developing children and 96 abnormally developing children will be retrospectively enrolled from the medical records of stratified, randomly selected centers. A total of 4137 children with normal development and 448 children with abnormal development aged from 2 to 6 years old will be selected from 11 hospitals in China by multi-center, stratified, unequal proportion random sampling and face-to-face survey. Children's speech and language development was assessed by the Speech and Language Development Scale for children aged 2 to 6, compiled by the Linguistics and Language Research Centre of the Education University of Hong Kong.
45813607|NCT02625571|Behavioral|Phase-based treatment of sexual behavior problems of children|
45660145|NCT04085887|Device|Pinpoint-IR9000 endoscopic/handheld device|"Novadaq intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
45952036|NCT01249339|Procedure|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
45952037|NCT01249339|Procedure|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
45660146|NCT04085887|Device|Explorer Air camera|"Surgvision intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
45660147|NCT04085887|Device|PDE-NEO-II|"Hamamatsu Photonics KK intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
45660148|NCT05494333|Other|no intervention|NO intervention
45660149|NCT04080895|Drug|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
45813608|NCT05046223|Procedure|The responses to bronchoscopic insertion for bronchoscopic interventions such asTBNA, Cryotherapy, etc.|cough response, the changes of BP, HR, SpO2, Trans dermal CO2 during bronchoscopic interventions
45813609|NCT05046223|Procedure|postoperative recovery|anesthetic recovery in postoperative care unit recovery of swallowing by questionnaire in POD1
45813610|NCT04315363|Behavioral|Motivational MRI and Behavioral Intervention|Motivational messaging delivered during a functional brain MRI scan and with daily messaging
45813611|NCT04315363|Behavioral|Control MRI and Behavioral Intervention|Control messaging delivered during a functional brain MRI scan and with daily messaging
45660150|NCT04080895|Drug|Amodiaquine|Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
45813612|NCT04741321|Other|VascuQol-6 questionnaire Spanish version|VascuQol-6 questionnaire was translated by two professional translators into Spanish.
45813613|NCT04740853|Behavioral|Sensory Integration Therapy+Special Education|Sensory integration is a theory first put forward by Ayres in 1972. It is a neurological process that organizes sensory stimuli from our body and our environment for use in the daily life. When the sensory integrity organization of individuals is provided, it is possible to use their body effectively against the environment. Sensory integration therapy, which is defined as a physiologically based process by Ayres and Dunn, also provides changes in individuals' occupations.
45813614|NCT05028283|Procedure|Fat Grafting|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with atrophic acne scars on the cheeks
45813615|NCT05004727|Drug|Guselkumab|Guselkumab 100 mg 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (month 0 to month 24 for arm 1; week 24 to month 24 for arm 2).
45813616|NCT05004727|Drug|Placebo|• Placebo to Guselkumab 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (Month 0 to Week 20 for Arm 2).
45952038|NCT01249339|Procedure|Buccal Administration of nicotine|Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
45952039|NCT01249339|Procedure|Buccal Administration of nicotine|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
45952040|NCT03809429|Drug|FE 999049 + GnRH agonist (GONAPEPTYL)|Pre-filled injection pen
45952041|NCT03809429|Drug|FE 999049 + GnRH antagonist (CETROTIDE)|Powder and solvent for solution for injection
46077505|NCT00784563|Behavioral|Continuous training|The maximal heart rate (HRmax) in the exercise prescription was based on age[Goldberg, Elliot, and Kuehl1988] and reduced by 20% in participants who used beta-blockers.[Wonisch et al. 2003] The duration of exercise sessions (3x/week) was advanced from 15 to 45 minutes over the first 6 weeks. The goal for continuous training was to remain within 70-80% of HRmax throughout the session.
46077506|NCT00784563|Behavioral|Interval training|Interval trainees alternated every 3 minutes between slower (60-70% of HRmax) and faster (80-90% of HRmax) walking [Wisloff et al. 2007].
45660151|NCT04080895|Drug|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
45660152|NCT04080895|Drug|Artemether-lumefantrine + Amodiaquine|Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2
45660153|NCT04265209|Drug|SPECT|[123I]-FP-CIT SPECT imaging procedure
45660154|NCT04265209|Drug|PET|[18F] LBT-999 PET imaging procedure
45660155|NCT05490433|Procedure|robot assisted nipple sparing mastectomy(RNSM)|Patients receiving RNSM and IBR are enrolled in this group. The RNSM is performed using a robotic surgical system.
45813617|NCT02628223|Procedure|Selective Laser Trabeculoplasty|The procedure uses light energy provided by a neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
46077507|NCT05429190|Radiation|Short MRI surveillance (SMS) protocol|Bi-annual, non-contrast agents, MRI screening consisting of Diffusion Weighted Imaging (b-values of 50 and 800 s/mm2), T2-weighted imaging and T1-weighted in- and out-of-phase imaging
45660156|NCT05490433|Procedure|Conventional nipple sparing mastectomy(CNSM)|Patients who receive CNSM and IBR are enrolled in this group. CNSM uses a robot or endoscopic surgical system.
45813618|NCT02628223|Device|Neodymium:Yttrium Aluminum Garnet (YAG) laser|The procedure uses a 400 μm spot size of light energy provided by a low-energy, Q-switched, frequency-doubled (532 nm) neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser with a short pulse duration of 3 nanoseconds that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
45813619|NCT02630017|Drug|ADHD methylphenidate first, placebo second|double-blind, counter-balanced administration
45813620|NCT02630017|Drug|ADHD placebo first, methylphenidate second|double-blind, counter-balanced administration
45453877|NCT02286544|Biological|Salmonella typhi vaccine (Typhim Vi®)|A peripheral venous catheter will be inserted. This catheter will be used to collect blood sample during the study day. In addition, peripheral oxygen saturation will be measured by pulse oximetry. After baseline venous blood samples have been collected, all study participants will receive 0.5 mL of the Salmonella typhi vaccine as an intramuscular injection (Typhim Vi®, Sanofi Pasteur MSD, injection solution 25 microgram/0.5 mL) Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
45453878|NCT02286544|Drug|Oxygen (Oxymask®)|"As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry.~Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended."
45453879|NCT02286544|Drug|Atorvastatin|As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry. A single dose of Atorvastatin 80 mg will be given immediately prior to start of oxygen. Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
45660157|NCT04077619|Behavioral|Modern pain neuroscience approach|Modern pain neuroscience approach. The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.
45660158|NCT04077619|Behavioral|Usual care physiotherapy|Usual care evidence-based physiotherapy The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
45660159|NCT04251169|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as 30 minutes IV infusion every 3 weeks beginning in Cycle 1
45813621|NCT02630017|Drug|Non-ADHD methylphenidate first, placebo second|double-blind, counter-balanced administration
45813622|NCT02630017|Drug|Non-ADHD placebo first, methylphenidate second|
45813623|NCT00366925|Device|Adacolumn®|
45813624|NCT02630719|Drug|Timolol eye drops|eye drops
45813625|NCT02630719|Drug|Artificial tears|Placebo drop
45813626|NCT04979377|Other|Clinical hyperandrogenism assessment|Modified Ferriman-Gallwey scale
45813627|NCT04979377|Diagnostic Test|Total testosterone (ng/dL)|Circulating total testosterone (LC-MS/MS or IQL-CDC method) at follicular phase
45813628|NCT04979377|Diagnostic Test|A1c (%)|High Performance Liquid Chromatography (HPLC)
45813629|NCT04979377|Diagnostic Test|Total cholesterol|Determined by enzymatic methods
45813630|NCT04979377|Other|Body mass index (BMI) (kg/m2)|Defined as body weight divided by the square of body height, and expressed in kg/m2
45813631|NCT04979377|Diagnostic Test|Frequency of chronic vascular complications [n (%)]|Retinopathy, nephropathy, neuropathy, and macrovascular disease.
45813632|NCT04979377|Diagnostic Test|Polycystic ovary morphology|Sonographic assessment
45813633|NCT04979377|Diagnostic Test|Cardiovascular autonomic reflex tests (CARTs)|Cardioautonomic function assessement by Vital scan HW7-HW6T:
46077508|NCT05429190|Radiation|Bi-annual ultrasonography screening|Bi-annual ultrasonography for screening of HCC in high-risk patients
46077509|NCT04269083|Other|BIRC3|BIRC3-expression directed preoperative chemoradiotherapy in patients with resectable adenocarcinoma of the esophagus and EGJ
46077510|NCT00897637|Other|laboratory biomarker analysis|Correlative studies
46077511|NCT05429112|Device|Flexible Tip Bougie|Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
46077512|NCT05429112|Device|Endotracheal Tube with Stylet|Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with a endotracheal tube + stylet.
46077513|NCT00902473|Drug|Topiramate|25mg tablets
45660160|NCT04251169|Drug|Paclitaxel|Paclitaxel will be administered at the 80 mg/m2 dose via 1-hour IV infusion on Days 1, 8, and 15 of every 21-day cycle (beginning in Cycle 2). On days of scheduled infusions of pembrolizumab and paclitaxel (i.e., Day 1 of every cycle), paclitaxel is to be administered after infusion of pembrolizumab
45813634|NCT04979377|Diagnostic Test|Sex hormone-binding globulin (SHBG) (nmol/L)|Circulating SHBG (IQL) at follicular phase
45813635|NCT04979377|Diagnostic Test|Dehydroepiandrosterone-sulphate (IQL) (ng/mL)|Circulating DHEAS (IQL) at follicular phase
45813636|NCT04979377|Other|Waist circumference (cm)|Waist circumference measurement made at the top of the iliac crest
45813637|NCT04979377|Other|Waist-to-hip ratio|Waist circumference divided by hip circumference (measurement should be taken around the widest portion of the buttocks)
45952042|NCT04697251|Diagnostic Test|FOT measurements in newborns and small infants|Measurements will be performed using the device TremoFlo N-100, at bedside, with the infant in the supine position during quiet natural sleep. After proper cleaning and decontamination, the face mask of the device will be preheated at 37oC (to avoid awakening) and will be placed on infant's face. The duration of each measurement will be predetermined at 10 s. At least 3 technically acceptable measurements will be performed per infant, with 30 s intervals between them. The validity of each measurement will be assessed according to the coherence function (automatically determined by the operating system of the device).
45952043|NCT04151004|Other|Incremental cycling test (ICT)|Incremental cycling test to volitional exhaustion
46077514|NCT05177484|Drug|oral ferric maltol|The intervention group will commence a course of oral ferric maltol provided oral intake has recommenced and the control group will receive standard care. All patients will have blood tests checked again at day 3 and day 5 postoperatively if they remain as an inpatient. If they are found to be anaemic on either of these two blood tests they will, at this stage, enter their allocated treatment pathway. If a patient shows no evidence of anaemia on either day 2, 3 or 5 blood tests they will be withdrawn from the study. Patients will continue treatment according to their randomisation allocation until 12 weeks after the operation, at which point the patient attends a routine surgical outpatient follow-up clinic. During the outpatient visit the participants will undergo their final blood testing and questionnaire completion.
46077515|NCT04104633|Procedure|Blood samples|30 ml of blood collection
46077516|NCT02540317|Behavioral|Internet-based CBT|Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy
46077517|NCT05429034|Behavioral|MIST paradigm|Patients are exposed to psychosocial stress = receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator.
45813638|NCT04979377|Other|Body composition|Vital Scan HW7-HW6T
45813639|NCT04979377|Diagnostic Test|Mean glucose (mg/dL)|Continuous glucose monitoring (GCM) records
45813640|NCT04979377|Diagnostic Test|Time in target range (hours)|Continuous glucose monitoring (GCM) records
45813641|NCT04979377|Diagnostic Test|Time in hyperglycemia (hours)|Continuous glucose monitoring (GCM) records
45813642|NCT04979377|Other|Insulin dose (UI/Kg)|Daily insulin dose divided by body weight
45813643|NCT04979377|Other|Insulin sensitivity|Equation that relies on routine clinical measures: A1c, presence of hypertension, and waist circumference
45813644|NCT04979377|Diagnostic Test|High-density lipoprotein (HDL) (mg/dL)|Enzymatic methods after precipitation of serum with phosphotungstic acid and Mg2+
45813645|NCT04979377|Diagnostic Test|Low-density lipoprotein (LDL) (mg/dL)|Estimated by the Friedewald's equation.
45952044|NCT04151004|Other|Constant load cycling test (CET)|Constant load cycling test to volitional exhaustion.
46077518|NCT05429034|Behavioral|Sham paradigm|Patients are not exposed to psychosocial stress = threat components from the program and/or the investigator are absent
46077519|NCT04104789|Drug|Kovanaze Nasal Spray|Intra-nasal local anesthetic
45813646|NCT04979377|Diagnostic Test|Triglycerides (mg/dL)|Determined by enzymatic methods
45813647|NCT02630953|Behavioral|Original Tailored Intervention|The intervention includes regular mailings: weekly in month 1, biweekly in months 2 and 3, monthly in months 4 to 6, and a maintenance dose. Mailings consist of; 1) Manuals matched to the participant's current level of motivational readiness to change, based on TTM 2) Individually tailored computerized expert system feedback reports based on the participant's answers to monthly questionnaires. The computer expert system draws from a bank of over 330 messages developed from previous studies that address different levels of psychosocial and environmental factors affecting PA. 3) PA tip sheets addressing PA barriers specifically identified by Latinas in our formative research (e.g., caregiving duties, neighborhood safety).
45813648|NCT02630953|Behavioral|Enhanced Tailored Intervention|Participants in the Enhanced Tailored arm will receive all the intervention components of the original tailored intervention, as well as: 1) additional print materials; 2) more in-depth tailored reports; and 3) text-messages. Self-monitoring was an important aspect in increasing PA in our previous trials however, participants were only asked to turn in the self-monitoring logs once a month. Based on the importance of self-monitoring and feedback from participants (R01NR011295; R01CA15994) that they wanted greater accountability and interactivity, we added a text-message component for self-monitoring.
46002687|NCT00558675|Biological|AlloStim|single intravenous infusion of 1 x 10^9 AlloStim cells
46077520|NCT04104789|Drug|Articaine Injection|Local anesthetic
46077521|NCT00938717|Drug|Linaclotide or Matching Placebo|Linaclotide or Matching Placebo, administered orally, once daily, for the duration of the trial
45952045|NCT04151004|Other|Incremental respiratory muscle test (IncRMET)|Incremental respiratory muscle test to volitional exhaustion.
45660161|NCT04073329|Other|post operative measure of reduction|measurement was used to grade quality of reduction according to Matta's system . In accordance with prior studies, adequate (or anatomic) reductions with 0-1 mm of displacement were compared to inadequate (imperfect or poor) reductions with > 1 mm displacement . For the CT-based method, postoperative pre-digital (prior to 2000) and digital CT images were independently assessed in the axial, sagittal, and coronal planes, and residual gap and step displacement were measured along the articular surface at the level of the weight-bearing dome. Adequate reductions on postoperative CT were defined as < 1 mm step and < 5 mm gap displacement and inadequate reductions as ≥ 1 mm step and/or ≥ 5 mm gap displacement.
45660162|NCT04279951|Other|Resistance exercise|High-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)
45952046|NCT04151004|Other|Incremental quadriceps muscle test (IncQMT)|Incremental quadriceps muscle test to volitional exhaustion.
45660163|NCT04279951|Dietary Supplement|Omega-3|1 gram of omega-3 per day for 20 weeks
45660164|NCT04279951|Dietary Supplement|Placebo|1 gram of sunflower oleic oil per day for 20 weeks
45660165|NCT05494099|Procedure|endoscopic maxillary mega-antrostomy|a mucosal sparing technique that facilitates mucus clearance and sinus irrigation in terminally dysfunctional maxillary sinuses. EMMA involves extending the antrostomy through the posterior half of the inferior turbinate down to the floor of the nose, creating a significantly enlarged antrostomy.
45813649|NCT04920175|Other|Novel Real-time Neonatal Sleep Stage Detection Algorithm|Comparison of Novel Real-time Neonatal Sleep Stage Detection Algorithm to gold standard concurrent polysomnogram.
45813650|NCT02633371|Drug|Oxybutynin 3% gel|
45952047|NCT04151004|Other|Respiratory muscle training like interventions|Three different respiratory muscle training like interventions that are usually used for respiratory muscle trainings.
45952048|NCT00504088|Procedure|Bypass|
45952049|NCT00504088|Procedure|Silverhawk Plaque Excision|
45952050|NCT00504127|Drug|Naproxcinod 375 mg bid|Naproxcinod 375 mg bid
45952051|NCT00504127|Drug|Naproxcinod 750 mg bid|Naproxcinod 750 mg bid
45952052|NCT00504127|Drug|Naproxen 500 mg bid|Naproxen 500 mg bid
46077522|NCT00905983|Drug|Gemcitabine and Docetaxel|Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
45660166|NCT05494099|Procedure|Endoscopic Modified Medial Maxillectomy|In this approach, the maxillary sinus is operated upon, while the inferior turbinate and nasolacrimal duct are preserved.
45952053|NCT00504127|Drug|placebo|placebo
45952054|NCT03795818|Behavioral|Interpersonal Psychotherapy for Adolescents|IPT-A is a psychosocial intervention for adolescents that focuses on improving interpersonal relationships that seem to be associated with the psychiatric symptoms.
45952055|NCT04088292|Drug|Alteplase 20 Mg Powder for Solution for Injection Vial|Low dose alteplase delivered IV or bu Ultrasound Assisted Thrombolysis device
45952056|NCT04088292|Device|Ultrasound assisted Thrombolysis|Ultrasound assisted thrombolysis (USAT)
45952057|NCT00504205|Drug|multitargeted receptor tyrosine kinase inhibitor MP470|
45952058|NCT00504205|Other|laboratory biomarker analysis|
45952059|NCT00504205|Other|pharmacological study|
45813651|NCT04159519|Drug|Symbicort®|Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation and Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.
45813652|NCT04159519|Drug|Fasenra®|Participants received Benralizumab 30 mg/mL, 1 mL fill volume via Subcutaneous every 4 weeks for first 3 doses.
45813653|NCT04159519|Drug|Ventolin®|Participants received Salbutamol sulfate 100 μg per inhalation as needed.
45952060|NCT00504205|Procedure|positron emission tomography|
45952061|NCT01249495|Procedure|Sharp debridement|After use of local anestetics a sharp currette is used to debride slough and nonviable tissue from the ulcer surface until a healthy tissue is seen.
46077523|NCT00897793|Procedure|venipuncture|Venipuncture for blood samples. Samples will be tested for TGF-beta.
46077524|NCT00897793|Radiation|radiation therapy|Radiation treatments vary according to type of cancer and by patient per doctors' recommendation
46077525|NCT02602587|Biological|Blood sample|additional samples of blood in acts planned in the prognostic or follow-up protocols.
46077526|NCT02602587|Biological|Bone marrow sample|additional bone marrow sample in acts planned in the prognostic or follow-up protocols.
45813654|NCT04119271|Other|Breathe Easy at Home Kit Products|HEPA filtered upright vacuum cleaner, HEPA-filtered Air Purifier, Hypoallergenic latex free mattress cover, box spring cover, and two pillow covers, Healthier alternative to most household cleaners, Non- toxic glue type pest control devices for rodent control and a combination of safe products to locate and kill roaches.
45813655|NCT04913311|Procedure|Biospecimen Collection|Undergo collection of blood, saliva, stool, and bronchoalveolar lavage samples
45952062|NCT03755999|Other|The premature infant oral motor intervention (PIOMI)|The premature infant oral motor intervention (PIOMI) is an oral motor program that provides assisted movement to activate muscle contraction and provides movement against resistance to build strength in the areas of the mouth necessary for feeding. It is designed to increase the maturation of neural structures, improving their ability to suck and swallow.
45952063|NCT01249534|Other|gastroesophageal cancer surgery|gastroesophageal cancer surgery
45952064|NCT04085250|Other|Neoadjuvant therapy|The neoadjuvant therapy before radiotherapy comprised of Docetaxel 60 mg/m2 for 1 hour + Cisplatin 75 mg/m2+Nivolumab 360 mg, once every 3 weeks (Q3W), for a total of 2 cycles.
45952065|NCT04085250|Other|Chemotherapy concurrent with radiotherapy|Docetaxel 25 mg/m2 for 1 hour +Cisplatin 25 mg/m2, once a week (QW)
46077527|NCT05428878|Diagnostic Test|ANS Watch|"ANS Watch will be used to record the pulse waves~Constitution questionnaire will be used to measure the constitution type"
45952066|NCT04085250|Radiation|Radiotherapy|Hypofractionated radiation technique was used to deliver a definitive radiation dose
45952067|NCT04085250|Drug|Nivolumab|Nivolumab consolidation (360 mg) via iv infusion once every 3 weeks (Q3W)±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy. Administration of nivolumab will commence on Day 1 following randomisation to Nivolumab after confirmation of eligibility and will continue on a Q3W schedule for a maximum duration of 12 months.
45952068|NCT04085250|Other|Observation|Observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
45952069|NCT01249573|Other|fascia therapy or transcutaneous fibrolysis|fascia therapy or transcutaneous fibrolysis as treatment for an acute ankle distortion
45952070|NCT01249612|Other|Thermotherapy|Knee joint icing
45952071|NCT01249612|Other|Thermotherapy|Elbow joint icing
45952072|NCT01249690|Drug|Bortezomib,Pirarubicin,Dexamethasone|Bortezomib:1.3mg/m2,on day 1,4,8 and 11 of each 28 day cycle; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
45952073|NCT01249690|Drug|Thalidomide,Pirarubicin,Dexamethasone|Thalidomide:200mg/d, everyday; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
45952074|NCT03712826|Drug|Anti-TNF Drug|Crohn patient with antiTNF treatment
45952075|NCT03712826|Drug|Ustekinumab|Crohn disease with ustekinumab treatment
45952076|NCT04071366|Drug|Itacitinib|Part 1: Itacitinib 200 mg once daily for 30 days. Part 2: Itacitinib 200 mg twice daily for 30 days.
45952077|NCT04071366|Drug|Immune effector cell therapy|Participants will receive IEC therapy that is approved by the health authority in the country where the study is being conducted for any approved hematologic indication.
45952078|NCT04071366|Drug|Placebo|Participants will receive placebo twice daily.
45660167|NCT05494099|Procedure|Modified endoscopic pre-lacrimal approach|The approach involves making a curved mucosal incision on the lateral nasal wall just anterior to the head of the inferior turbinate. The nasal mucosa was then undermined off the lateral nasal wall. The maxillary sinus was entered with a chisel, and the medial bony wall of the maxillary sinus removed.
45660168|NCT04165837|Drug|FB-101|Part A - Single Ascending Dose study Part B - Multiple Ascending Dose study
45660169|NCT04165837|Drug|Placebo|Part A - Single Ascending Dose matching placebo study Part B - Multiple Ascending Dose matching placebo study
45660170|NCT04163341|Behavioral|Adapted Common Elements Treatment Approach|The intervention is a transdiagnostic cognitive behavioral therapy approach to treating any combination of depression, anxiety, post-traumatic stress, or substance use disorder that has been adapted the needs of adults with HIV and to additionally address HIV care engagement.
45813656|NCT04913311|Procedure|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with BAL
45952079|NCT04071366|Biological|Yescarta|Eligible participants are receiving Yescarta (An infusion of chimeric antigen receptor (CAR)-transduced autologous T cells) for relapsed or refractory larbe B-cell lymphoma or follicular lymphoma intravenously.
45952080|NCT01249846|Drug|PerioChip ®|
46077528|NCT04104399|Drug|XC101-D13H|XC101-D13H supplied as 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules
46077529|NCT04104399|Drug|Placebo|Placebo supplied as matching capsules
45813657|NCT04913311|Other|Chemoradiotherapy|Undergo concurrent chemoradiation per standard of care
45813658|NCT04913311|Procedure|Computed Tomography|Undergo computed tomography scan
45813659|NCT04913311|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
45952081|NCT03694691|Diagnostic Test|Liver Biopsy|For measurement of tissue co-factor levels, we will take needle biopsies of transplanted livers immediately after procurement, immediately prior to implantation (at the end of preservation), 30 minutes after portal vein reperfusion, and 30 minutes after hepatic artery reperfusion. For those livers that have more than 60 minutes between portal vein and hepatic artery reperfusion, an additional biopsy will be performed at 60 minutes after portal vein reperfusion. Post-procurement biopsies will be collected regardless of where the liver was obtained.
45660171|NCT04279561|Procedure|Computed Tomography|Undergo 68Ga-PSMA-11 PET/CT
45813660|NCT04913311|Drug|Immune Checkpoint Inhibitor|Receive CPI per standard of care
45813661|NCT04913311|Procedure|Nasal Wash and Collection|Undergo nasal wash
45813662|NCT04913311|Other|Quality-of-Life Assessment|Ancillary studies
45813663|NCT04913311|Other|Questionnaire Administration|Ancillary studies
45813664|NCT04913311|Procedure|Spirometry|Under lung spirometry tests
45952082|NCT00504244|Drug|switch to Myfortic|Myfortic 2 dd 720 mg
45952083|NCT00504244|Drug|continuation of azathioprine|Azathioprine 2 mg/kg
45952084|NCT00405444|Drug|Fentanyl|The dose of fentanyl that each child will receive will be 2 mcg/kg based on the child's weight. The medication will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
46077530|NCT00906061|Drug|Gemcitabine and Docetaxel|Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
46077531|NCT04104087|Procedure|tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.|enhancing papillary hight and treating gingival recession RT2 by performing tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.
46077532|NCT02754648|Procedure|laparoscopic ovarian endometriotic cyst|
45952085|NCT00405444|Drug|Sterile water|The dose of sterile water that each child will receive will be 2 mcg/kg based on the child's weight. It will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
45660172|NCT04279561|Drug|Gallium Ga 68 Gozetotide|Given IV
45660173|NCT04279561|Procedure|Positron Emission Tomography|Undergo 68Ga-PSMA-11 PET/CT
45952086|NCT00504283|Drug|Toradol|
45660174|NCT01662895|Drug|Deferoxamine|Deferoxamine mesylate(62 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
45952087|NCT00504283|Drug|Morphine|
45660175|NCT01662895|Drug|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
45813665|NCT04079491|Other|questionnaire survey|A web-based questionnaire will be send by the trade union for dental hygienists
45952088|NCT00504322|Genetic|AdcuCD40L|Using Weill-IRB protocol #0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L vector, this dose (likely 10^11 particle units) will be used for all individuals enrolled in this efficacy study. Since there is no evidence that delay of surgery for solid tumors for 15 days following diagnosis alters the prognosis, surgery for removal of the primary tumor will be carried out at either 5 or 15 days after administration of the vector (n= 12/group, including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit assessment of the resulting data (in a randomized, blinded fashion) and the biologic responses to the AdCUCD40L vector over time.
45660176|NCT04159987|Other|Spinraza intrathecal injection|The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA® (Nusinersen).
45952089|NCT00504322|Genetic|Placebo|The placebo will be the salt water-sugar solution used as a vehicle for the vector.
45660177|NCT05494021|Other|Whole-process management software|Enrolled participants will managed by a pre-designed software. The software would provide helpful assistance, such as lung cancer education, decision-making, assisting in making and attending LCS LDCT appointments, arranging follow-up when needed, tobacco cessation support for smokers, treatment assistance if diagnosed as lung cancer.
45660178|NCT05494021|Device|LDCT detection|LDCT were performed in both arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 5 mm
45813666|NCT04871659|Other|Online Survey completion|Eligible participants will complete surveys electronically via Amazon's mTurk platform
45813667|NCT04054375|Drug|Prednisone|Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
45813668|NCT02634073|Drug|Lamivudine|It is a clear, colorless to pale yellow solution with the odour of fruit. It will be provided in a 240 mL bottle with the strength of 10 mg/mL Lamivudine 300 mg (30 mL of solution) will be administered orally to the participants
45813669|NCT02634073|Drug|Sorbitol|It is a clear, colorless, odourless solution. It will be available in 3 dosage levels viz;. 3.2 g (low dose), 10.2 g (medium dose) and 13.4 g (high dose) sorbitol total dose.
45813670|NCT00366613|Procedure|Cataract surgery with Perfect Capsule and Sodium Chloride|
46002688|NCT00558675|Biological|AlloStim|Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7
45660179|NCT05493943|Device|Pulsed ElectroMagnetic Field (PEMF) therapy|Application of PEMF using treatment coils in eproximity to the area where treatment is desired.
45660180|NCT05493943|Other|Pulsed ElectroMagnetic (PEMF) therapy|Control arm.
45660181|NCT05493865|Behavioral|The Parent-Child Single-Session-intervention of Mindset Intelligence, Failure and Emotion (PC-SMILE)|This study will be a two-arm cluster-randomised controlled trial to examine the efficacy of the PC-SMILE for adolescents and their parents by comparing to a no-intervention waitlist control group.
45660182|NCT04318171|Device|3D Imaging.|"When the normal Doppler assessment is done following nationally approved protocol for scanning Carotid arteries, lower and upper limb arteries, AVF and Vein mapping. PIUR tUS infinity system 3D Bluetooth motion sensor which is linked to video transmission box will be used to scan the patient's common carotid artery (CCA), internal carotid artery (ICA) and external carotid artery (ECA) in transverse view to obtain the following measurements:~Plaque volume where detectable.~Max area stenosis.~Volumetric stenosis.~Measured length.~3D GSM. The entire assessment should not take more than 45 minutes."
45660183|NCT05499091|Procedure|Skin biopsy, blood sample, urine sample|blood samples, urine samples, skin samples.
45813671|NCT00366691|Drug|Acular LS|
45813672|NCT00366691|Drug|Lotemax|
45813673|NCT00366769|Device|Wavefront-guided LASIK using CustomVue platform|
45813674|NCT02637427|Biological|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg to a maximum of 5 units)
46002689|NCT00558675|Biological|AlloStim|Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7 and day 14
45660184|NCT05493709|Drug|Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide|All subjects will be pediatric patients with central precocious puberty. They will be injected twice with a depot formulation containing 42 mg of Leuprolide. The first dose on day 0 the second dose on week 24 (six months apart).
46077533|NCT02602509|Drug|Celecoxib|
45813675|NCT04400071|Behavioral|Active Music Engagement|Weekly 45-minute sessions with a board-certified music therapist delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. During the first visit, parent and child will receive information on how they can use music play activities to help manage distress during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During subsequent visits the music therapist will lead parent and child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
45813676|NCT04400071|Behavioral|Audio Storybooks|Weekly 45-minute sessions with a trained provider delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. Each session children/parents will choose and listen to one of three illustrated children's books with audio-recorded narration.
45813677|NCT02638051|Device|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
45813678|NCT02638051|Dietary Supplement|TCM Herbal Decoction (Shi Pi)|Shi Pi Decoction can warm Yang, invigorate the spleen, promote Qi circulation to induce diuresis and treat Foot-Taiyin meridian in Gu Zhang.
46077534|NCT02602509|Drug|Rifampicin|
45813679|NCT02638051|Drug|IPCI (CDDP+5FU)|Intraperitoneal chemoinfusion of CDDP (30-60 mg) and 5-fluorouracil (500-600 mg/sqm).
46077535|NCT02602509|Drug|Pyrazinamide|
46077536|NCT02852837|Drug|Daratumumab|Intravenous (IV) infusion of 8 mg/kg or 16 mg/kg daratumumab.
45660185|NCT04150783|Procedure|Surgical repair for nasal obstruction|Patient reported quality of life questionnaires
45660186|NCT04148989|Other|Code Sepsis protocol (full implementation)|Implementation of a coordinated, structured, multidisciplinary team-based protocol for initial evaluation and treatment of ED patients with suspected sepsis.
45660187|NCT04147195|Drug|LYS006|5 mg LYS006 capsules orally administered 20 mg b.i.d for 12 weeks
46077537|NCT02754414|Procedure|Apheresis platelet collection|A single apheresis platelet unit will be collected from a healthy adult volunteer subject using the Trima Accel® Automated Blood Collection System. Concurrent plasma will be collected.
46077538|NCT02754414|Other|Refrigerated storage of apheresis platelets in PAS/plasma|The apheresis platelet unit will be stored, without agitation, at 4°C, for up to 20 days.
46077539|NCT02754414|Radiation|Infusion of aliquot of autologous radiolabeled platelets|Fresh and stored aliquots will be labeled with Indium-111. We are administering ≤30 microcuries in both infusions for a total dose of 0.8 mSv.
46077540|NCT02754414|Other|In vitro tests|Tests to evaluate platelet function will be performed on the platelet unit on day of collection and end of storage
46077541|NCT02539381|Procedure|Formal Perimetry (Goldman or Octopus visual Field)|
46077542|NCT02539381|Procedure|Albert's visual inattention test|
46077543|NCT02539381|Procedure|Star cancellation visual inattention test|
45813680|NCT00367393|Drug|Pimecrolimus cream 1%|Pimecrolimus cream 1% bid, as needed
45813681|NCT00367471|Drug|lapatinib|Lapatinib (GW572016) is a potent small molecule, reversible inhibitor of both EGFR and ErbB2 tyrosine kinases
45660188|NCT04147195|Drug|Tropifexor|100 ug LJN452 capsules orally administered 200ug once daily for 12 weeks
45660189|NCT05498935|Other|CPB time|Cardiopulmonary bypass time
45660190|NCT05489809|Procedure|Endotracheal extubation with suctioning|General anestheisa is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying suctioning.
45813682|NCT00367471|Drug|carboplatin|An alkylating agent used in the treatment of some cancers
46077544|NCT02539381|Procedure|Visual field assessment to confrontation|
45660191|NCT05489809|Procedure|Endotracheal extubation with positive pressure|General anesthesia is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying positive pressure.
45660192|NCT05493631|Biological|MG1113|MG1113 subcutaneous (SC) injection
45660193|NCT05498857|Drug|Intramuscular ephedrine|Patients will receive prophylactic intramuscular ephedrine plus standard spinal anesthesia
45813683|NCT00367471|Drug|trastuzumab|A monoclonal antibody that interferes with the HER2/neu receptor
45813684|NCT00367471|Drug|paclitaxel|A mitotic inhibitor used in cancer treatment
45813685|NCT03765463|Behavioral|Habit Reversal Training|4 sessions of habit reversal training
45813686|NCT04396483|Procedure|Pomeroy's tubal sterilization|Both Fallopian tubes will be grasped by allis forceps and a kokher forceps will be applied below the allis forceps then excision of tubal part above kokher and transfixation of both ends away from each other during cesarean section
45813687|NCT04396483|Procedure|Salpingectomy|Both fallopian tubes will be completely removed during cesarean section
45952090|NCT03679130|Behavioral|Structured supervised exercise training|EXE contains three weekly one-hour exercise sessions at moderate intensity, more specifically one water exercise session and two land exercise sessions. The training will be supervised, held in teams, and both water and land exercise sessions will consist of a combination of aerobic and resistance training.
45813688|NCT04389853|Procedure|Flexible ureteroscopy|Retograde intrarenal surgery (RIRS) has gained much popularity especially when the role of SWL, in management of LPS, has been significantly diminished in the few last years5. RIRS is dependent mainly on flexible ureteroscopy (fURS). fURS increases the quality and performance of upper urinary tract exploration, allowing for the treatment of the majority of stones at all sites. Moreover, it is associated with no risk of renal parenchymal injuries and a very low risk of bleeding.
45952091|NCT03679130|Behavioral|Motivational counseling supported by health technology|MOT contains four individual and three group counseling sessions taking place from randomization until GA week 33+6 and aim to motivate the participants to increase their physical activity level at moderate intensity. During individual sessions, feedback on physical activity performance will be provided based on activity data acquired from the activity tracker and further, MOT-participants will receive weekly SMS-reminders about physical activity.
45952092|NCT00504400|Drug|Intravitreal injection ranibizumab|Monthly intravitreal injection of of 0.5mg ranibizumab in one eye over one year
45952093|NCT00504439|Drug|SB-656933-AAA|The doses of SB-656933 (20 mg, 50 mg or 100 mg) will be provided as a combination of 10 mg and 50 mg tablets of SB-656933-AAA. The tablets will be administered orally.
46077545|NCT02539381|Procedure|Visual inattention assessment to bilateral stimuli|
46077546|NCT02539381|Device|Digital tumbling E visual accuity assessment|
45660194|NCT05498857|Drug|Placebo|Patients will receive prophylactic intramuscular saline plus standard spinal anesthesia
45660195|NCT04424329|Dietary Supplement|Fibers and probiotics|A blend of fibers and seven probiotics
45660196|NCT05498545|Biological|LUCAR-B68 cells product|Before treatment with LUCAR-B68 cells, subjects will receive a conditioning regimen
45660197|NCT05489497|Procedure|Primary closure with or without omental grafting|Primary closure with or without omental grafting
45660198|NCT05489419|Behavioral|Multimodal Prehabilitation|Physical and cardiopulmonary training, personalized nutrition and treatment of anxiety and depression.
46077547|NCT02539381|Device|Digital visual field assessment|
46077548|NCT02539381|Device|Digital line crossing assessment|
46077549|NCT02539381|Device|Digital shape cancellation assessment|
46077550|NCT04219098|Procedure|Butterfly IQ|10ml of solution with .5cc (or one drop) sterile methylene blue will be injected intra-articularly under ultrasound guidance after a sterile prep. The remaining 20ml will be injected into the periarticular tissues after prosthesis implantation before closure.
46077551|NCT04219098|Other|Standard of Care|The entire volume will be injected into the periarticular tissues after prosthesis implantation before closure.
45660199|NCT05493319|Other|Exercises|Both groups will train three times a week, twice synchronously online and once asynchronously, considering a standardized exercise guideline. In all intervention sessions, conventional exercises will be guided by the standardized exercise guideline previously developed by the study team, for 4 weeks. Hypopresive, strength and resistance exercises group will receive static hypopressive exercise in supine position, with variant of arms in flexion, abduction and extension, consisting of 3 exercises at the end of the intervention with strength and resistance exercises.
45952094|NCT00504439|Drug|Matching placebo|SB-656933-AAA matching placebo tablets will be administered orally.
45453880|NCT02282254|Other|Overnight intervention|Subjects will be admitted at the research facility at 19:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. On dual-hormone closed-loop visits, glucagon will be reconstituted according to the manufacturer's instructions and a MiniMed® Paradigm® Veo™ pump containing the glucagon solution will be installed. At 20:30, a snack containing 20g of carbohydrate will be given. Closed-loop strategy will start at 20:00 until 7:00 next morning. A glucose sensor reading will be entered manually in a tablet every 10 minutes. The tablet will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses (glucagon recommendations will only be generated during the dual hormone closed-loop visits). Pumps' parameters will then be changed manually to implement the tablet generated recommendations.
45660200|NCT05498467|Drug|Anakinra|100 mg Anakinra injections s.c.
45660201|NCT05498467|Drug|Sodium Chloride 9mg/ml Injection|9 mg Sodium Chloride injections s.c.
45952095|NCT00504439|Drug|Simvastatin|Simvastatin will be provided as a 40 mg tablet.
45813689|NCT04389853|Procedure|Mini-percutaneous nephrolithotomy|PCNL has regained popularity thanks to the possibility of using reduced calibers and modern technology, which has reduced the complications without compromising the stone clearance, and more efficient intracorporeal lithotripter modalities. However, PCNL is still a challenging surgical technique and can be associated with significant complications that may compromise its efficacy. In the present time, we have available calibers ranging from 4.8 to 30 French. Many reports advocate that morbidity after PCNL may be reduced by recent modifications, such as mini-PCNL (miniperc). One meta-analysis of mini-PCNL and conventional PCNL demonstrated that mini-PCNL had a greater safety profile with similar stone free rates (SFRs).
45813690|NCT04380883|Device|InnoSEAL+TRB|InnoSEAL is a catecholamine chitosan-based pad (InnoSEAL hemostatic pad, InnoTherapy, Inc.). Chitosan-Catechol in InnoSEAL instantly forms an adhesive barrier upon blood contact. It is intended for use under the care of a healthcare professional. The dressing is indicated for the skin surface puncture sites for vascular procedures, percutaneous catheters/tubes. TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. We will apply InnoSEAL and TRB together.
45813691|NCT04380883|Device|TRB alone|TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. It will be the comparing arm.
45952096|NCT04054830|Drug|Voltaren Ophtha 1 mg/ml, GSK|Voltaren Ophtha 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
45952097|NCT04054830|Drug|Monopex 1 mg/ml, Théa|Monopex 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
45952098|NCT01249924|Device|auto-titrated CPAP|Patients will be treated with auto-CPAP preoperatively for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.
45952099|NCT01249924|Device|Control|Patients in this group will receive routine care, undergo sleep study on the third postoperative night and be monitored by a pulse oximeter for oxygen saturation level for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.
45952100|NCT03652259|Genetic|SRP-9003|SRP-9003 will be administered through a single systemic injection.
45952101|NCT01249963|Dietary Supplement|T-Diet plus Atémpero|T-Diet plus Atémpero is a complete normocaloric and normoproteic enteral nutrition product for the dietary management of patients with mild acute pancreatitis.
46077552|NCT04104009|Other|Education|"Following the randomization process, group education of pregnant women will be conducted through four one-hour meetings.~Education program: teaching about the basics of childbirth physiology, visit to the maternity ward with the aim of reducing the fear of childbirth, applying the deep inhale and exhale exercise in the first birth stage, applying the classical music listening technique that will continue until the end of pregnancy daily (in the evenings before bedtime) (for 15 minutes), teaching and applying techniques for successful breastfeeding, maternal and infant health care after delivery. The training program will be implemented so that after 4 workshops a 5-week break will be taken. At the end of the program, the educator arranges with the respondents a weekly telephone check (for the sake of communication quality) to inform them of adherence to the agreed classical music listening.Pregnant women who do not meet expectations will be excluded from the study."
45453881|NCT00574132|Drug|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
45453882|NCT00574132|Drug|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
45813692|NCT03643003|Behavioral|Music therapy|"Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Dosage: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
45952102|NCT01249963|Dietary Supplement|AlitraQ (Abbott)|AlitraQ is a nutritional product for patients with impaired gastrointestinal function.For oral or tube nutrition. Enriched with glutamine and arginine.
45952103|NCT03622775|Biological|Daratumumab|Given IV
46077553|NCT04104009|Other|No education|In the control group there will be no education, no breathing exercises and no listening to classical music.
45952104|NCT01249651|Drug|esomeprazole 40 mg|esomeprazole 40 mg once daily, 8 weeks
46077554|NCT04103853|Drug|Proxalutamide|Stage1:Dose esclation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.
46077555|NCT00902629|Procedure|Early surgery|Intervention group contains patients randomized to receive surgery for their epiretinal fibrosis, at an earlier point than what the common clinical practice is now.
46077556|NCT04221048|Other|Retrospective observational|Pregnancy scores will be based on information obtained from the relevant clinical letter and clinical notes
45453883|NCT00574132|Drug|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions
45660202|NCT05493241|Behavioral|Behavioral Activation for Independence in Older Veterans (ACTIVaTE)|6 sessions delivered by a psychology trainee by telehealth will cover the core content of an existing BA model, Brief Behavioral Activation for Depression-Revised (BATD-R), including education on BA and rationale for the intervention, activity monitoring, values exploration, and activity selection and planning. ACTIVaTE will include the following key modifications: 1) modifying background and psychoeducation to focus on maintaining functional independence; 2) tailoring content to Veterans; 3) adapting materials for VVC telehealth delivery; 4) incorporating elements of activity and environmental modification from an OT perspective; and 5) adding content on VA and community resources for older Veterans. Each session is structured similarly, consisting of education or review of concepts, review of homework and troubleshooting challenges, discussion of core content (e.g. values exploration or activity planning/scheduling), and assignment of homework for the next session.
45813693|NCT03643003|Behavioral|Non-Music Verbal Interaction (Placebo)|"Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Dosage is the same as for music therapy: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
45952105|NCT03999723|Dietary Supplement|Vitamin C|Oral vitamin C (ascorbic acid) 1000 mg daily will be administered from day 1 in the 1st AZA cycle (D1/C1) and continued until discontinuation of AZA or EOS as combination treatment.
45952106|NCT03999723|Dietary Supplement|Placebo|Placebo capsules (two capsules once daily) will be administered from day 1 in the 1st AZA cycle (D1/C1) and continued until discontinuation of AZA or EOS.
45952107|NCT03611270|Device|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
45952108|NCT03567707|Biological|C-section -Vaginal seeding|Mother-infant pair randomized to vaginal microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the vaginal microbiota soaked gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds. Infants will only undergo the seeding.
45952109|NCT03567707|Drug|C-section - Placebo Seeding|Mother-infant pair randomized to placebo microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the placebo gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds.
45952110|NCT03567707|Other|standard care|Mother-infant pair where mother undergoes spontaneous vaginal delivery, with both receiving standard of care.
45952111|NCT03988062|Device|TrelliX Embolic Coil System|Embolic coil with shape memory polymer
45952112|NCT01249417|Biological|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
46077557|NCT00897871|Drug|carboplatin|
46077558|NCT00897871|Drug|cyclophosphamide|
46077559|NCT00897871|Drug|etoposide phosphate|
45952113|NCT01249417|Drug|Placebo|I.M. injection on day 1 of a single treatment cycle.
45952114|NCT00403325|Drug|rhuFab V2 [ranibizumab] ( Lucentis )|
45952115|NCT04725747|Drug|Midazolam/Ketamine HCl 3mg-50mg sublingual|Single sublingual administration of Midazolam/Ketamine HCl 3mg-50mg sublingually prior to surgery
46077560|NCT00897871|Genetic|gene expression analysis|
46077561|NCT00897871|Genetic|polymorphism analysis|
46077562|NCT00897871|Other|pharmacological study|
46077563|NCT00587223|Device|Apligraf|Up to 3 applications: Day 0, Month 1, Month 2.
46077564|NCT00587223|Other|Standard dressing regimen|Dressing regimen will be comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer
45813694|NCT02207244|Drug|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4, 12, and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon randomized treatment group and PASI response (Group I). 100 mg by subcutaneous injection at Weeks 16 and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon PASI response (Group II). Starting at Week 28, participants will receive guselkumab 100 mg through Week 72 depending upon PASI response (Group III). All participants will receive guselkumab q8w starting at Week 76 through Week 252.
45952116|NCT04725747|Drug|Midazolam 3mg Sublingual|Single sublingual administration of Midazolam 3mg sublingually prior to surgery
45952117|NCT04725747|Drug|Ketamine 50mg Sublingual|Single sublingual administration of Ketamine HCl 50mg sublingually prior to surgery
45813695|NCT02207244|Drug|Placebo for guselkumab|Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending on randomized treatment group and PASI response (Group I), at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response (Group II), at weeks 0, 4, 12, 16, and 20, starting at week 28 through week 72 depending upon PASI response (Group III).
45952118|NCT03546686|Drug|Ipilimumab|Patients will receive ipilimumab 1-5 days prior to core biopsy and cryoablation.
45952119|NCT03546686|Drug|Nivolumab|Patients will receive nivolumab 1-5 days prior to core biopsy and cryoablation and every 2 weeks post surgery for 3 additional doses
45952120|NCT03546686|Procedure|Core Biopsy/Cryoablation|US-guided core biopsy and cryoablation 7-10 days prior to surgery.
45952121|NCT03546686|Procedure|Breast Surgery|Standard-of-care definitive surgery.
45952122|NCT04725942|Drug|Oral Posaconazole tablets|Posaconazole tablets (300 mg Q12h D1) taken orally on the day of transplantation, and followed by 300mg Qd, until 90 days after transplantation.
45952123|NCT03544853|Device|Prosthetic socket for transtibial amputee|To wear a prosthetic socket for evaluation of comfort and biomechanical metrics such as skin loading conditions.
45952124|NCT01249261|Drug|Risedronate|5 mg/day
45952125|NCT01249261|Drug|Placebo/Risedronate|placebo years 1-5 followed by 5 mg risedronate years 6 & 7 and no drug year 8
45952126|NCT03907020|Dietary Supplement|Barley|Assessing the metabolic availability of lysine in barley.
45952127|NCT03463694|Other|Na Cl solution|~2.6% NaCl solution prepared from sea salt
45952128|NCT03890952|Drug|Nivolumab|Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
45952129|NCT03890952|Drug|Bevacizumab|Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
45952130|NCT03456128|Other|CAPABLE|It involves up to 10 in-home tailored interventions of approximately 60 minutes duration each over a 5-month period. The assessment driven interventions are delivered by an Occupational Therapist (OT) (≤ 6 home visits for ≤ 1hour), a Registered Nurse (RN) (≤ 4 home visits for ≤ 1hour), and a handyman (HM) team.
45952131|NCT03873636|Other|Stimulation via noninvasive brain stimulation systems|Active (at or below 2mA) stimulation targeting brain regions engaged in task-switching and dual-tasking for 30-40 minutes. Local IRB has determined the Soterix, Neuroelectrics, & Halo devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
45952132|NCT03285893|Other|oral cell DNA adducts|oral cells will be collected, DNA isolated, and analyzed for adducts
45952133|NCT03868722|Drug|Acalabrutinib|Acalabrutinib 100 mg BID from cycle 1 day 1 for 3 cycles of 28 days.
45952134|NCT03868722|Drug|Venetoclax|Venetoclax, ramp up during the first five weeks starting cycle 1 day 1, 7 days treatment on each dose level (20-50-100-200-400 mg), thereafter 400 mg once daily for a total of 3 cycles of 28 days.
45952135|NCT03833778|Other|intervention group|The CED patients play the tablet-CED-quiz, while they wait for their doctor's appointment, so that gaps in the CED knowledge can be clarified during the doctor's consultation.
45952136|NCT03789201|Device|TMS EEG|attempt to use TMS EEG to measure connectivity between cortical areas
45952137|NCT03789201|Device|TMS fMRI|compare measurements to established functional connectivity measures; e.g., EEG coherence and fMRI
45952138|NCT03786939|Procedure|On-pump CABG.|On-pump coronary artery bypass grafting.
45952139|NCT03786939|Procedure|Off-pump CABG.|Off-pump coronary artery bypass grafting.
45952140|NCT03786939|Procedure|Pump-assisted CABG.|Pump-assisted CABG.
45660203|NCT05493241|Behavioral|Attention control|An attention control (AC) group will be used to control for the social interaction and educational aspects of ACTIVaTE. The AC arm will consist of 6 weekly one-hour VVC-delivered sessions including friendly social conversation plus education on remaining active within the physical, cognitive, and social domains during older adulthood. During each session, the interventionist will review a relevant handout or other educational materials with the participant. AC interventionists will not be trained in the ACTIVaTE intervention, and the investigators will assess whether any key features of ACTIVaTE (activity monitoring/planning, values exploration, problem-solving) are incidentally incorporated into this arm during fidelity assessment.
45660204|NCT05498311|Radiation|Intraoperative Radiotherapy (IORT)|The Intrabeam Photon Radiosurgery System will deliver 20 Gy in the act of breast surgery
45660205|NCT05498311|Procedure|Breast conservative surgery|Breast conservative surgery with the aim of resecting breast tumour and with or without oncoplastic surgery
45952141|NCT03190889|Other|HOME|At home rehabilitation following ACL reconstructive surgery as described in the HOME arm.
45952142|NCT03190889|Other|TNMT|Standard of care, clinical rehabilitation following ACL reconstructive surgery with the addition of specified targeted neuromuscular training as described in the TNMT arm.
45952143|NCT03068780|Drug|Oleogel-S10|10% birch bark extract in 90% sunflower oil
45952144|NCT03068780|Drug|Control gel|Sunflower oil gel
45952145|NCT03761511|Drug|Nicotinamide|Nicotinamide 4 g (capsules) or highest tolerated dose with a minimum of 2 g/d per os once daily
45952146|NCT03761511|Drug|Placebo|Matching Placebo (capsules) once daily
45952147|NCT03008291|Procedure|CRT-D Implantation|Cardiac resynchronization therapy defibrillator
45952148|NCT03008291|Procedure|CRT-P Implantation|Cardiac resynchronization therapy pacemaker
45952149|NCT03008291|Procedure|Dual Chamber Pacemaker Implantation|
45952150|NCT00139113|Biological|hepatitis A vaccine|2 doses of inactivated hepatitis A vaccine manufactured by GSK in licensed pediatric formulation of 720 EL. U. per dose given on 3 different schedules: aged 6 and 12 months, 12 and 18 months, and 15 and 21 months. Within each group, subjects were randomized to achieve a relatively equal number of children born to anti-HAV positive and anti-HAV negative mothers.
45813696|NCT02207244|Drug|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 23.
45952151|NCT02952092|Drug|roxadustat|Oral
45952152|NCT02952092|Drug|Darbepoetin alfa|Intravenous
45952153|NCT00139152|Drug|Placebo|Saline, Sub-Cuteanous (SQ)
45952154|NCT00139152|Drug|Xolair|Xolair, 0.016 mg/kg Immunoglobulions E (IgE) , SQ
45952155|NCT02824523|Drug|aspirin|
45952156|NCT02736422|Other|Hyperpolarised Xenon|Hyperpolarised gas Magnetic resonance imaging (MRI) (3He and 129Xe) has enabled novel methods of in-vivo functional lung imaging that do not rely on the use of ionising radiation.
45952157|NCT03733509|Procedure|Intraoperative Block|One shot adductor canal nerve block with 20ml of bupivacaine 0.25% through surgical incision
45952158|NCT03733509|Procedure|Ultrasound Block|One shot adductor canal nerve block with 20ml of bupivacaine 0.25% mid-thigh
45952159|NCT03733509|Procedure|Intraoperative Placebo|One shot adductor canal nerve infusion with 20ml of saline solution through surgical incision
46077565|NCT05428566|Dietary Supplement|Pulse-based diet|"An isocaloric, balanced diet with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein.~The pulse diet will include two pulse-based meals; each pulse meal will be consisted of about one cup of non-oil seed pulses, different varieties of pulses (dried beans, peas, lentils, lupine and chickpeas) will be used."
46077566|NCT05428566|Dietary Supplement|TLC diet|"An isocaloric, balanced diet with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein.~The healthy TLC diet will be tailored for each participant according to their energy levels in order to achieve the following amount of nutrients: less than 7% of total calories of saturated fatty acids, up to 10% of total calories of polyunsaturated fat, up to 20% of total calories of monounsaturated fat, less than 200 mg a day of cholesterol, at least 5 to 10 grams a day of soluble fiber."
46077567|NCT00902707|Drug|Mucinex 1200mg|Compared to Placebo
46077568|NCT00902707|Drug|Placebo|Compare to active Mucinex
46077569|NCT04478994|Biological|TEPEZZA|TEPEZZA is a fully human anti-IGF-1R mAb. TEPEZZA will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of TEPEZZA must be reconstituted with 10 mL of water for injection. Reconstituted TEPEZZA solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. TEPEZZA will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses > 1800 mg).
46077570|NCT04478994|Other|Placebo|Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses > 1800 mg).
46077571|NCT00906139|Drug|Propofol|Propofol dose: 0.5 mg/kg up to 400 mg
46077572|NCT00906139|Drug|Midazolam|Midazolam dose: 0.1 mg/kg
45458468|NCT02317900|Biological|TV005|TV005 is a live attenuated recombinant tetravalent dengue virus vaccine. It will be administered as a 0.5 mL dose containing 10^3 plaque forming units (PFUs) of each component (10^3.3 PFUs/mL of rDEN1∆30, 10^4.3 PFU/mL of rDEN2/4∆30(ME), 10^3.3 PFU/mL of rDEN3∆30/31-7164 and 10^3.3 PFU/mL of rDEN4∆30). It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
45813697|NCT02207244|Drug|Placebo for adalimumab|Placebo for adalimumab [two 0.8 milliliter (mL) injections] at week 0 followed by one 0.8 mL injection at weeks 1, 3, 5, and every 2 week (q2w) through Week 23 (Group I and II).
45952160|NCT03733509|Procedure|Ultrasound Placebo|One shot adductor canal nerve infusion with 20ml of saline solution mid-thigh
45952161|NCT02714387|Other|Collection of medical data|A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
45952162|NCT03721497|Drug|Testosterone Undecanoate|The patients will be randomly assigned to either testosterone or placebo.
45952163|NCT02685098|Biological|Allogeneic bone marrow derived mesenchymal stem cells|Injection of HLA-A2+ and/or gender mismatched allogeneic MSCs above the site of amputation and into the anterior tibialis muscle (ATM) of patients scheduled for semi-elective lower extremity major amputation at 7 days before amputation.
45952164|NCT00139191|Procedure|C-11 acetate PET scan|
45952165|NCT02457338|Dietary Supplement|Bifidobacterium|
45952166|NCT03682029|Dietary Supplement|Vitamin C (ascorbic acid)|Monotherapy with oral vitamin C supplementation to elevate plasma vitamin C level to the upper end of the physiological range.
45952167|NCT03682029|Other|Placebo|Placebo
45952168|NCT02426255|Other|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
45952169|NCT02087072|Other|Collaborative visit with provider and pharmacist|
45952170|NCT00139230|Drug|Taxotere|
45952171|NCT00139230|Drug|Cisplatin|
45952172|NCT00139230|Drug|5-Fluorouracil|
45952173|NCT00139230|Drug|Leucovorin|
45952174|NCT00139230|Drug|G-CSF|
45952175|NCT00139230|Drug|Ciprofloxacin|
45952176|NCT03648996|Other|Low-fructose diet, isocaloric|6 month of consumption a low fructose diet
45952177|NCT03648996|Drug|Allopurinol|6 months of allopurinol treatment with the goal of decreasing uric acid compared to control group
45952178|NCT03648996|Drug|Placebo|6 months of placebo treatment
45952179|NCT03648996|Other|Low-fructose, hypocaloric|6 month of consumption a low fructose diet with a 500 Calorie/day energy restriction
45952180|NCT02086175|Drug|Imprime PGG|
45952181|NCT02086175|Drug|Rituximab|
45952182|NCT00139269|Drug|Docetaxel|
45952183|NCT00139269|Drug|Cisplatin|
45952184|NCT00139269|Drug|5-Fluorouracil|
45952185|NCT02065154|Drug|Cyclophosphamide|
45952186|NCT00139308|Device|high frequency stimulation|
46077573|NCT00906139|Drug|Fentanyl|Fentanyl dose: 0.05 mg
45952187|NCT00403364|Drug|Placebo amoxicillin pantoprazole clarithromycin tinidazole|
45952188|NCT00139347|Biological|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
45660206|NCT05498311|Radiation|External Beam Hypofractionated Radiotherapy (EBRT)|A External Beam Hypofractionated Radiotherapy will be administered after surgery. y. The dose per fraction will be 2.67 Gy per session. EBRT will be performed daily from Monday to Friday for fifteen fractions.
45952189|NCT00403442|Device|Verteporfin Therapy/ Drug: Bevacizumab|
45453884|NCT01337882|Other|Forearm venous occlusion plethysmography study|Forearm venous occlusion plethysmography to measure forearm blood flow during unilateral intrabrachial infusion of endothelium-dependent (bradykinin [100, 300 & 1000 pmol/min]; acetylcholine [5, 10 & 20 µg/min]) and -independent [sodium nitroprusside [2, 4 & 8 µg/min]; verapamil [10, 30 & 100 µg/min]) vasodilators. Each drug to be infused for 6 mins at each dose in increasing concentrations. 0.9% sodium chloride will be infused for 20 min between each individual drug to allow washout.
45453885|NCT01338116|Other|antibiotic treatment of by TREAT/PCR|Management by TREAT/PCR. The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly. On day 2, when results of blood cultures and other cultures become available TREAT will be re-consulted and will issue a new recommendation based on the full microbiological investigation (negative and positive results).
45453886|NCT01335152|Behavioral|Coping with Breast Cancer web-based workbook|10 chapter web-based workbook that teaches stress management, cognitive behavioral coping skills and relaxation training.
45453887|NCT00384904|Drug|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, Once daily, 10 days.
45952190|NCT00139386|Drug|Candesartan|Candesartan Cilexetil (4-12 mg per day)
45952191|NCT00403520|Drug|Experimental 1|Drug: Donepezil Hydrochloride 10 mg orally for 12 months
45952192|NCT00403520|Drug|Placebo Comparator|Drug: Placebo Matching placebo orally for 12 months
45660207|NCT05493007|Procedure|Sandbag motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation.
45660208|NCT05493007|Procedure|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine.
45660209|NCT05489341|Diagnostic Test|Histopathology and Magnetic Resonance Imaging with Follow-Up|Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) with follow-up (≥ 3 years) confirmed cases of indolent PCa or benign tissue as negatives.
45660210|NCT05489341|Diagnostic Test|Histopathology and Magnetic Resonance Imaging|Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) confirmed cases of indolent PCa or benign tissue as negatives.
45660211|NCT05489263|Other|No intervention|No intervention
45813698|NCT02638207|Drug|NewGam|In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding
45813699|NCT04863222|Device|Biodentine|During a patients procedure, one tooth will receive Biodentine instead of MTA.
45813700|NCT04863222|Biological|mineral trioxide aggregate (MTA)|mineral trioxide aggregate (MTA)
45813701|NCT04363879|Procedure|Endometrial scratch with Pipelle curette|For patients in the Pipelle curette group, physicians inserted the Pipelle curette into the uterus and removed an adequate endometrial sample using vigorous motion.
45813702|NCT04363879|Procedure|Endometrial scratch with Shepard catheter|For patients in the Shepard catheter group, physicians performed a four-quadrant scratch technique by inserting the Shepard insemination catheter into the uterus at 12:00. The catheter was then turned one-quarter turn and withdrawn. This was repeated two more times so that four endometrial quadrants were touched by the catheter at 12:00, 3:00, 6:00, and 9:00.
45813703|NCT02207088|Drug|ombitasvir/paritaprevir/ritonavir|tablet
45952193|NCT00139425|Behavioral|Disease Management Assessment|
45952194|NCT00402974|Drug|menaquinone 7|
45952195|NCT00139542|Other|One shock per minute AED protocol|Single shocks; No post-shock pulse checks; 60 sec CPR before first shock; 30 sec CPR between rhythm analysis and shock delivery.
45952196|NCT00139542|Other|Guidelines 2000 AED protocol|Up to 3 consecutive shocks in a stack; No initial CPR prior to the first shock; Post-shock pulse checks after each non-shockable rhythm analysis; 60 sec CPR after each non-shockable rhythm analysis.
45952197|NCT01731236|Dietary Supplement|Carnitine|Group 1: Carnitine supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)
45952198|NCT01731236|Dietary Supplement|Choline|Group 2: Choline supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)
45952199|NCT01731236|Drug|Antibiotics|Group 3: Carnitine or Choline for 2 months, antibiotic cocktail (Ciprofloxacin, Flagyl, Vancomycin, and Neomycin) for 1 week
45813704|NCT02207088|Drug|dasabuvir|tablet
45660212|NCT05486221|Other|Extensive cardiologic work-up|Specific 3D and 2D echocardiography measuring left ventricule and left atrial dimensions as well as longitudinal strain. 30 day prolonged ECG monitoring.
45660213|NCT05489107|Other|Ziverel|Within a first flexible rectoscopy (Day 1) the product will be applied transanally. Then the patients will apply it as enemas twice daily for 7 days. On day 8 (after treatment completion), and on day 31 (after 23 days of no treatment) follow-up flexible rectoscopies will be performed.
45660214|NCT05492929|Other|The deep breathing group|The deep breathing group
45660215|NCT05492929|Other|4-7-8 breathing technique|4-7-8 breathing technique Group
45813705|NCT02207088|Drug|Ribavirin|tablet
45813706|NCT02638597|Drug|Gemfibrozil|FDA Approved Drug(s)/Biologic(s) (study use is not an FDA-approved use)
45813707|NCT02638597|Behavioral|smoking cessation counseling|smoking cessation counseling
45813708|NCT03585595|Other|Blood pressure lowering strategy|The proposed trial will test a treatment strategy of different systolic BP goals and not specific medications. It remains unclear whether a particular class of antihypertensive drug offers an advantage over others in secondary stroke prevention. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications. However, we will emphasize the use of drugs best demonstrated to be effective in lowering CVD in outcome trials and recommended in current clinical guidelines.
45813709|NCT04333615|Behavioral|Exercise|Three conditions will be tested: self-selected exercise, walking with pain exercise, and control session.
45813710|NCT04339699|Device|NobleStitch EL Suture Mediated Closure System|Percutaneous closure of Patent Foramen Ovale (PFO) using NobleStitch EL suture Medicate Closure System
45813711|NCT04339699|Device|Amplatzer PFO Occluder|Percutaneous closure of Patent Foramen Ovale (PFO) using Amplatzer PFO Occluder
45813712|NCT03527485|Diagnostic Test|11UCB-J PET Scan|11UCB-J PET Scan
45813713|NCT04339309|Procedure|Non-surgical periodontal treatment with interdental hygiene devices|
45813714|NCT04339309|Procedure|Non-surgical periodontal treatment without interdental hygiene devices|
45813715|NCT02206620|Drug|Donepezil|
45813716|NCT02239926|Drug|Ranolazine|On January 31, 2006, ranolazine was approved for use in the United States by the Food and Drug Administration (FDA) for the treatment of chronic angina pectoris.
45813717|NCT02239926|Drug|Placebo|
45813718|NCT02239692|Drug|PICOPREP|Sodium Picosulfate, Magnesium Oxide and Citric Acid as PICOPREP powder for oral solution
45813719|NCT00367705|Dietary Supplement|VSL#3®|1-2 sachets/day per os, 6 months
45813720|NCT00367705|Dietary Supplement|Placebo|1-2 sachets/day per os, 6 months
45813721|NCT04340089|Behavioral|squatting on the toilet|the patients could go to squatting on the toilet at any time as they want to after taking the capsule
45813722|NCT04783506|Other|Observational Study|There is no intervention provided by this study. Observed for 12-month period using questionnaires and study visits.
45813723|NCT02641249|Device|Vibration|A device providing vibrations is placed on the subject and vibration is turned on and off in a 6 hour on/off sequence. Heart rate, respiratory pauses and oxygen saturation are compared during vibration (intervention) and without vibration (no intervention) in the same subject.
45813724|NCT04860414|Biological|Blood sampling|Fasting blood glucose, dosage of acylated and non-acylated ghrelin, leptin, insulin and serotonin.
45813725|NCT04860414|Other|Cognitive Assessment|QPC Cognitive complaint questionnaire, CDR functional autonomy scales and IADL 4 items, MMSE cognitive scores, Dubois 5-word test, clock test, BREF, Isaacs test, BARD naming battery and MADRS depression scale
45813726|NCT04860414|Other|Subjective taste tests|Scales of taste perceptive intensity, taste pleasure, hunger sensation (visual analogue scales from 0 to 10 cm) and food preferences on the one hand, and on the other hand, subjective tests of taste threshold determination by triangular tests of increasing sugar solution concentrations.
45660216|NCT02557399|Drug|Duac® fixed dose combination gel|Duac® fixed dose combination gel containing clindamycin phosphate 1.2% and benzoyl peroxide 3%.
45813727|NCT04860414|Other|Objective taste tests|Recording of gustatory evoked potentials
45813728|NCT00367783|Drug|CP-741,952|
45813729|NCT04853238|Other|Prospective observational cohort study|Prospective observational cohort study
45813730|NCT02641561|Drug|Indomethacin|Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) which is commonly used to reduce inflammation caused by gout, osteoarthritis and rheumatoid arthritis. It acts by blocking the cyclo-oxygenase 1 and 2 (COX) receptors. It has also been implicated to prevent post-ERCP pancreatitis
45813731|NCT02641561|Drug|Lactated Ringer's Solution|Lactated ringer's solution (LR), is an intravenous fluid (IVF) used commonly during endoscopic procedures and operative procedures. It's composition is similar to that of humans including sodium, chloride, potassium, calcium and lactate. Studies have implicated the use of this fluid in pancreatitis treatment and prevention of post-ERCP pancreatitis
45453888|NCT00384904|Drug|Atazanavir/Ritonavir + Famotidine|Capsules/capsules + Tablets, Oral, 300/100 mg + 40 mg, Once daily + Twice daily, 7 days.
45813732|NCT02641561|Drug|Normal Saline|standard IVF would include 0.9% normal saline (NS) solution used during all endoscopic procedures. 0.9% NS includes equal parts sodium and chloride.
45952200|NCT01731236|Drug|Choline and Aspirin|Group 4: Choline supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
45952201|NCT01731236|Drug|Carnitine and Aspirin|Group 5: Carnitine supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
45952202|NCT03510078|Drug|Insulin|Insulin for glycemic control according to the allocation
45952203|NCT00139581|Drug|Pimecrolimus|Pimecrolimus cream 1 % applied twice daily (b.i.d.)
45952204|NCT00139581|Drug|Pimecrolimus|Pimecrolimus cream 1 % applied once daily (o.d.) and placebo applied once daily (o.d.)
45952205|NCT03500913|Drug|Growth Hormone|Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
45952206|NCT00740753|Device|Yttrium 90 (TheraSphere)|Y-90 embedded glass microspheres
45952207|NCT00139620|Drug|Tarceva, erlotinib, OSI-774|
45813733|NCT02641561|Drug|Placebo|Placebo would be a suppository 50 mg x 2
45952208|NCT00130481|Drug|Atorvastatin 20 mg daily for 3 months|
45952209|NCT03497481|Biological|Samples|Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis
45952210|NCT00130559|Procedure|BNP guided diagnostics and initial therapy|BNP guided diagnostics and initial therapy
45952211|NCT00130598|Drug|NaCl 0.9% i.v. or NaBic 1.4% i.v. or NaBic 1.4% i.v. + NaBic p.o. (Nephrotrans®)|"control group: preventive hydration with 154mEq/l saline at 1ml/kg per hour of 12 hours prior and after the procedure.~7h-sodium bicarbonate: before contrast 3ml/kg NaHCO3 166mEq/l for one hour, followed by NaHCO3 166mEq/l (1ml/kg per hour until 6h after contrast).~short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg) as a bolus 20 minutes before contrast; ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl non-sparkling mineral water at the start of the infusion. Ingestion of non-sparkling mineral water in the first 6 hours after contrast."
45952212|NCT00139698|Drug|olmesartan alone or in combination with hydrochlorothiazide|
45952213|NCT00130676|Drug|Mifepristone|daily for 7 days
45952214|NCT00130676|Drug|matching placebo|daily for 7 days
45813734|NCT02206152|Drug|N-acetyl cysteine|N-acetyl cysteine (or saline) IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
45813735|NCT02206152|Drug|Placebo|
45813736|NCT00367081|Drug|TMX-SMX (Bactrim(R))|
45813737|NCT00367081|Drug|Pyrimethamine plus Sulfadiazine plus leucoverin|
45813738|NCT00367159|Procedure|endoscopic treatment of vesico-renal reflux|Autologous Adipocytes Graft (lipostructure)
45813739|NCT04146571|Drug|Ensartinib|Oral, ALK inhibitor
45952215|NCT00404274|Drug|Casopitant (GW679769) oral tablets|Casopitant will be available in the dose strength of 20,30 or 50 mg
45952216|NCT00404274|Drug|Warfarin oral tablets|Warfarin will be available in the dose strength of 5 mg
45952217|NCT00130715|Device|Seprafilm Bioresorbable Membrane|
45952218|NCT00130754|Drug|Thymoglobuline|IV 7.5 mg/kg
45952219|NCT00130871|Drug|levosimendan|
45453889|NCT00384904|Drug|Atazanavir/Ritonavir + Famotidine|Capsules/capsules + Tablets, Oral, 300/100 mg + 20 mg, Once daily + Twice daily, 7 days.
45453890|NCT00384904|Drug|Atazanavir/Ritonavir|Capsules/capsules + Tablets, Oral, 300/100 mg, Once daily, 10 days.
45453891|NCT00384904|Drug|Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine|Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 40 mg, Once daily + Twice daily, 7 days.
45660217|NCT02557399|Drug|ADA 0.1% gel|ADA 0.1% gel containing 0.1% of adapalene.
45660218|NCT02557399|Drug|CLDM 1% gel|CLDM 1% gel containing clindamycin phosphate 1.2% (1% as clindamycin).
45660219|NCT05485909|Other|Radiofrequency ablation|For multiple intrahepatic lesions, select 1 to 2 lesions for radiofrequency ablation
45660220|NCT05485909|Drug|Regorafenib and Toripalimab Combination|Toripalimab 200 mg, iv drip, d1, d15, q4w, Regorafenib 80mg, po, d1-d21, Q4w.
45813740|NCT04121221|Drug|GA Depot|Long acting intramuscular injection of glatiramer acetate, once every 4 weeks
45813741|NCT04121221|Other|Placebo|IM injection once every 4 weeks
45813742|NCT02204982|Drug|Duvelisib|PI3K Inhibitor
45813743|NCT02204982|Drug|Placebo|Matching Placebo (25 mg BID) administered orally in 28-day continuous treatment cycles.
45813744|NCT02204982|Drug|Rituximab|IV infusion of rituximab (375 mg/m2) once weekly for 4 weeks during Cycle 1, then once on Day 1 of Cycles 4, 6, 8, and 10.
45952220|NCT00404313|Drug|MK0633|Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks. There will be 2 week period during which all patients will receive placebo to MK0633
45952221|NCT00404313|Drug|Comparator: placebo|Placebo to MK0633 10 mg, 50 mg, or 100 mg tablets once daily for 6 weeks
45952222|NCT00130910|Drug|Albendazole|Albendazole 400mg x 3 first dose observed
45952223|NCT00130910|Drug|Placebo|Albendazole Placebo 400mg x 3 first dose observed
45952224|NCT00130949|Drug|ALGRX 4975|
45952225|NCT04710953|Device|Continuous positive airway pressure machine|CPAP device set at 6-8cmH2O for several hours
45952226|NCT03226821|Drug|Tesamorelin|Patients will be treated with tesamorelin 2 mg by subcutaneous injection daily
45952227|NCT00130988|Behavioral|DEPENAS cognitive and behavioural techniques|
45952228|NCT00139815|Drug|Fondaparinux|fondaparinux 2.5 mg, s.c. injection once daily x 8 days or Hospital Discharge if earlier and placebo-enoxaparin 1mg/kg s.c. injection twice daily x 2-8 days or until clinically stable
45952229|NCT00139815|Drug|enoxaparin|enoxaparin 1mg/kg s.c. injection twice daily x 2 to 8 days
45952230|NCT00131027|Drug|Cyclophosphamide|
45660221|NCT04139395|Drug|68Ga-Citrate PET/MRI|Participants will be injected intravenously (IV) with 370 MBq of 68Ga Citrate. 45 -60 minutes after the radiopharmaceutical IV administration, whole body data acquisition at the PET/MRI suite will begin.
45952231|NCT00131027|Drug|Daunorubicin|
45660222|NCT04139395|Drug|67Ga-Citrate SPECT|67Ga-Citrate will be used as the radiotracer for a regular medical care SPECT scan
45952232|NCT00131027|Drug|Vincristine|
45952233|NCT00131027|Drug|Prednisolone|
46077574|NCT02538835|Behavioral|Metacognitive therapy|Group format, 10-12 participants in each group. 8 weekly sessions of two hours each.
46077575|NCT02538835|Behavioral|Mindfulness based cognitive therapy, group|Group format, 10-12 participants in each group. 8 weekly sessions of two hours each following the manual described by Williams, Zindel & Segal.
46077576|NCT02538835|Behavioral|Support groups|Group format, 10-12 participants in each group. The sessions will only be of supportive character and will not focus on changing or restructuring thoughts, scripts or thought patterns. The format will follow a manual but compared to the other intervention groups the format allow participants to suggests themes for discussions.
46077577|NCT05428410|Other|IL-4R|IL-4R was injected subcutaneously.
46077578|NCT05428410|Other|Placebo|Placebo was injected subcutaneously.
46077579|NCT00898027|Other|laboratory biomarker analysis|laboratory biomarker analysis
45660223|NCT04139395|Device|Positron Emission Tomography|Imaging with 68Ga-Citrate PET/MRI
45660224|NCT04139395|Device|Magnetic Resonance Imaging|Imaging with 68Ga-Citrate PET/MRI
45660225|NCT04139395|Device|SPECT|Imaging with 67Ga-Citrate radiotracer. SPECT scan will be conducted as part of regular medical care.
45660226|NCT02555371|Biological|Mepolizumab 100mg|Mepolizumab is a fully humanised Immunoglobulin (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be provided as a lyophilised cake in sterile vials for individual use.
45813745|NCT05342376|Drug|Dexmedetomidine Hydrochloride|The parturients will receive 10 micro-gram Dexmedetomidine diluted in 02 ml normal saline to be administered intravenously over 10 minutes after umbilical cord is clamped..
45813746|NCT05342376|Drug|Normal Saline|The parturients will receive 02 ml normal saline as placebo, to be administered intravenously over 10 minutes after umbilical cord is clamped.
45813747|NCT03954535|Behavioral|Free2b|The intervention will consist of a website and 9 sessions. The intervention sessions will facilitate youths' acquisition of personal and social cognitive-behavioral skills. The intervention will focus on goal setting, decision making, enhancing self-worth, coping with stress, combating distorted thinking, communication skills, using alcohol and other drugs and a review session. Each session will require approximately 20 minutes and must be finished in a single sitting. Sessions will be delivered on a weekly basis. The website will include entertainment features and resources.
45813748|NCT03954535|Behavioral|Attention-Placebo|Access to the website with entertainment features and resources - but no session content.
45813749|NCT02239536|Procedure|hot snare polypectomy|hot snare polypectomy using electrosurgical snare with application of electrocautery for eligible polyps
45813750|NCT02239536|Procedure|hot snare polypectomy after saline injection|hot snare polypectomy after saline injection using electrosurgical snare with application of electrocautery for eligible polyps
46077580|NCT00938639|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
46077581|NCT00938639|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
45813751|NCT02239224|Biological|Placebo|Concentrate for solution for infusion
45952234|NCT00131027|Drug|L-asparaginase|
45952235|NCT00131027|Drug|Cytarabine|
46077582|NCT05428332|Device|Tri-Compartment Unloader Brace|Knee brace that is designed to reduce compressive forces on all three compartments of the knee.
46077583|NCT05428254|Other|Capacitive and Resistive Radiofrequency therapy|"TECAR or CRRT is electromagnetic waves produced by high frequency electrical current that are able to penetrate very deep and produce a long-lasting heat which stimulates the superficial and dep tissues and produce a potent long-lasting pain-relieving effect. Mild intensity of heat produced by the long wave diathermy may be used to promote proliferation (Hernández-Bule et al., 2014) and improve the vascularization of skin and muscles.~The integration of two operational modes, Capacitive (CAP) and Resistive (RES), makes it possible to combine sub-thermal (electric) and thermal effects. Indiba radiofrequency has output frequency: 448kHz ± 1 kHz with Maximum output power in RES mode: 100 W and in CAP mode: 350 VA. The capacitive used an isolated metal coated electrode acts as a dielectric surface which concentrate the electrical charges near the capacitive electrode While the resistive electrode causing the diffusion of electrical charges which accumulate near bone and soft tissues."
45660227|NCT02555371|Drug|Placebo|The placebo will be 0.9% sodium chloride solution and will be provided by the study site.
45813752|NCT02239224|Biological|ATYR1940|Concentrate for solution for infusion
45952236|NCT00131027|Drug|Etoposide|
45952237|NCT00131027|Drug|Dexamethasone|
45952238|NCT00131027|Drug|Methotrexate|3 g/sqm (high dose)
45952239|NCT00131027|Drug|Mercaptopurine|
45660228|NCT05489029|Other|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
45660229|NCT04122235|Other|LETSGO follow-up|Nurse-led follow-up in 50% of the consultations Access to the LETSGO-app
45660230|NCT02555215|Drug|dimethyl fumarate|administered orally
45952240|NCT00131027|Drug|Doxorubicin|
45952241|NCT00131027|Drug|Methotrexate|0.5 g/sqm (intermediate dose)
45952242|NCT00405483|Procedure|Standard exposure|Minimal invasive vs standard exposure of the joint is the difference between a small incision, smaller equipment for less tissue damage vs large incision (standard is greater than 10cm)and subsequent more tissue damage.
45952243|NCT00405483|Procedure|Minimally Invasive|Minimally invasive surgical technique (minimal incision)
45952244|NCT00131066|Other|Follow up from previous treatment with MEDI-507|There will be no investigational drugs administered under this protocol.
45952245|NCT00139854|Drug|Alprazolam orally disintegrating tablets|
45952246|NCT00131105|Behavioral|The Stanford Active Choices program|
45952247|NCT00405561|Drug|AMT2003|
45952248|NCT00131144|Drug|Octreotide Acetate in Microspheres 20 mg|
45453892|NCT00384904|Drug|Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine|Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 20 mg, Once daily + Twice daily, 7 days.
45660231|NCT05485597|Device|Myosuit-based gait training|In a period of four weeks participants will undergo eight individual task-specific overground gait training sessions with the Myosuit. The sessions will be started with a therapist, and if possible and as soon as possible, the patient will train with an assistant. During the therapy sessions, the patient will be asked to perform various task-specific exercises with the Myosuit, such as Sit-to-stand-, Balance- and walking exercises. Depending on the individual skill level of the participant, a higher level of difficulty in task-specific exercises can be performed. The training sessions are set to last 45 minutes. All training sessions will be accompanied by a certified (physio)therapist or trained assistant and a study investigator.
45660232|NCT05492305|Drug|GLP-1 receptor agonist|Treatment with any GLP1 receptor agonist e.g. liraglutide, semaglutide, dulaglutide for either obesity or type 2 diabetes mellitus
45660233|NCT02555683|Drug|QAW039|QAW039 150 mg once daily
45660234|NCT02555683|Drug|QAW039|QAW039 450 mg once daily
45660235|NCT02555683|Drug|Placebo|Placebo once daily
45660236|NCT04424095|Diagnostic Test|In-office vascular visit|The patient will be examined to search for signs or symptoms of chronic venous disease (teleangiectasia, reticular veins, varicose veins, skin changes, pain, itching, heavy legs, ankle edema)
45813753|NCT01600014|Drug|Ingenol mebutate gel, 0.015%|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
45813754|NCT01600014|Drug|Vehicle gel|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
45813755|NCT02237196|Biological|AMG 157|AMG 157 will be administered once every 4 weeks at dose of 700 mg intravenously. Each AMG 157 dose will be administered at least 1 day before immunotherapy through week 24, then on the same day as immunotherapy thereafter.
45813756|NCT02237196|Biological|Cat Immunotherapy|A standardized allergen extract licensed in the United States for allergen immunotherapy, and is formulated as a long-acting suspension for subcutaneous injection
45813757|NCT02237196|Biological|Cat Immunotherapy Placebo|Placebo for allergen-specific immunotherapy administered subcutaneously
45813758|NCT02237196|Biological|AMG 157 Placebo|Placebo for AMG 157 administered intravenously
45813759|NCT03953755|Procedure|Tricuspid valve repair|Tricuspid valve repair
45813760|NCT04740619|Procedure|Natural Orifice Specimen Extraction|Natural Orifice Specimen Extraction via transanal
45813761|NCT04418310|Procedure|Lay open and curettage|Lay open and curettage
45813762|NCT04418310|Procedure|Endoscopic (E.P.Si.T) method|Endoscopic (E.P.Si.T) method
45813763|NCT04776096|Drug|Bepotastine Besilate 1.5% PF|Bepotastine besilate 1,5% Preservative free ophthalmic solution
45813764|NCT04776096|Drug|Olopatadine Hydrochloride 0.2% BAK|Olopatadine hydrochloride 0.2% with BAK as preservative
45813765|NCT02237118|Device|Mepitel One|
45813766|NCT02237118|Device|UrgoTul|
45813767|NCT04765488|Procedure|WashIn /WashOut|"According Wash In / WashOut procedure in study group we stop the supply of sevoflurane to the first signs of awakening and record the level of sevoflurane , then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and stop the supply of sevoflurane to the first signs of awakening again, then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and finally ( the third time) stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness."
45952249|NCT00131144|Drug|Octreotide Acetate in Microspheres|
45952250|NCT00131144|Drug|Placebo|
45952251|NCT00139893|Drug|Reglan ODT|
45952252|NCT00131183|Drug|Nebido|
46077584|NCT05428254|Other|Exercise therapy|Stretching of the neck extensor, upper fibers of trapezius, levator scapulae and scalenus muscles. stretching is applied for at least 15 seconds and repeated ten times in each session.
46077585|NCT00906295|Other|Allowed drop in hemoglobin to 4.5-5.5 mmol/L|Transfusion with red blood cells to hemoglobin between 4.5-5.5 mmol/L (Transfusion threshold of 4.5 mmol/L)
45458469|NCT02317900|Biological|Placebo|The placebo vaccine will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
45813768|NCT04684212|Device|LAmbre PlusTM Left Atrial Appendage Closure System|The LAmbre Plus device is a self-expanding occluder, composed of a distal Umbrella and a proximal Cover laser welded together, delivered percutaneously via femoral venous access and trans-septal puncture. The distal Umbrella consists of an elastic nitinol frame and outer PET membrane, and has circumferential anchors to secure the occluder to the left atrial appendage (LAA) wall. The proximal Cover is a disc of elastic nitinol mesh, which seals the orifice of the LAA and minimizes thrombus formation, and includes a PET membrane to prevent the passage of blood into the LAA after implantation.
45813769|NCT04684212|Drug|Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)|Continuation of market approved OAC drug.
45813770|NCT02234622|Behavioral|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
45813771|NCT02234622|Behavioral|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity walking with didactics about wellness topics.
45813772|NCT03755245|Other|[68Ga]Ga-DOTA-Siglec-9|Vascular Adhesion Protein 1 (VAP-1) targeted radiopharmaceutical
45813773|NCT05588947|Other|Take Charge session|A 'talk therapy' session designed to harness the person's self-determination, re-establishing purpose, identity, autonomy, and skills to Take Charge of their recovery after stroke
45952253|NCT00131222|Procedure|Food supplement: fortified spread|
45952254|NCT00131222|Procedure|Food supplement: maize and soy flour|
45952255|NCT00139932|Drug|formoterol fumarate|
45952256|NCT00131261|Drug|PXD101|
45952257|NCT00131261|Drug|Dexamethasone|
45952258|NCT00131300|Device|Synvisc (hylan G-F 20)|
45453893|NCT05182424|Behavioral|Myndlift BPT App & As-Needed Therapist Support|"BPT is based on social learning and operant conditioning principles in which parents are instructed to utilize methods to facilitate positive behaviors in their child and reduce challenging behaviors. Myndlift BPT translates established content and processes into a digital format to be delivered through a mobile app. Myndlift content consists of 10 components, designed to be completed in a self-directed manner by parents, over the course of approximately 10 weeks (total weeks depends upon parent's pace through the program).~In this project, trained and supervised doctoral- and masters-level students will serve as study therapists and meet with parents via a secured, password-protected Zoom platform to introduce parents to the Myndlift BPT (first session before start of the BPT), to support and problem solve BPT skills acquisition (during the Myndlift BPT), and at the end of the Myndlift BPT (to review the intervention content and consider the maintenance of skills)."
45453894|NCT00569062|Drug|GW856553X|GW856553X 7.5mg BID for 6 weeks
45453895|NCT00569062|Other|Placebo|Placebo to match GW856553X
45952259|NCT00131339|Behavioral|Cognitive behavioral therapy|
45952260|NCT00131339|Drug|D-cycloserine|
45952261|NCT00139971|Drug|gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6|
45952262|NCT00139971|Drug|UFT 250mg/m2, daily for 1 year|
45453896|NCT01335386|Drug|KLYX|
45453897|NCT01335386|Drug|Glycerine|
45453898|NCT00568594|Drug|APL180|
45453899|NCT00568594|Drug|Placebo|
45453900|NCT01338350|Drug|AZD5423|Inhalation, suspension
45453901|NCT01338350|Drug|Placebo|Inhalation, solution
45453902|NCT05182268|Procedure|endoscopic ear surgery|a ear surgery via endoscopic
45813774|NCT05588947|Other|Active Control|Life After Stroke educational video
45952263|NCT00131417|Drug|ready-to-use therapeutic food|
45952264|NCT00140010|Drug|erythropoietin beta|30,000 units in 6 mL of 0.9% saline IV for 15 minutes every other day for 3 doses within 72 hours after aneurysmal subarachnoid hemorrhage
45952265|NCT00131495|Drug|Testosterone (transdermal patches)|Testosterone patch (300mcg/day, changed twice a week for one year
45952266|NCT00131495|Drug|Placebo patch|placebo patch changed twice a week for one year
45952267|NCT03128268|Device|Imaging software for 4 dimensional images for Cardiac MRI|All enrollees will receive Cardiac MRI scans using Imaging software for 4 dimensional images for Cardiac MRI
46077586|NCT00906295|Other|Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L|Transfusion with red blood cells to between hemoglobin 5.6-6.5 mmol/L (Transfusion threshold of 5.5 mmol/L)
46077587|NCT04219488|Other|Radial nerve mobilization|
46077588|NCT04219488|Other|Supervised home program|
45453903|NCT05182268|Procedure|microscopic ear surgery|a ear surgery via microscopic
45453904|NCT00496132|Drug|PRO131921|Escalating doses by IV infusion
45952268|NCT04726826|Diagnostic Test|Diagnostic and prognostic biomarkers|Observational study of biomarkers predictive of morbidity and mortality in febrile children
45453905|NCT05182190|Dietary Supplement|White bread|Toasted white bread
45453906|NCT05182190|Dietary Supplement|Black beans whole boiled|Whole boiled black beans with spaghetti sauce
45453907|NCT05182190|Dietary Supplement|Knife Mill pasta|Black bean pasta (KM) with spaghetti sauce
45453908|NCT05182190|Dietary Supplement|Combo Flour Pasta|Black bean pasta (Combo) with spaghetti sauce (medium protein flour)
45453909|NCT05182190|Dietary Supplement|Cyclone Flour Pasta|Black bean pasta (Cyclone) with spaghetti sauce (low protein flour)
45453910|NCT00384358|Drug|rhBMP-2/CPM|one time injection of 3-5 mL test article at time of internal fracture fixation
45453911|NCT00384358|Drug|rhBMP-2/CPM|one time injection of 3-5 mL test article at time of internal fracture fixation
45813775|NCT03271489|Other|Elagolix Placebo|Tablets
45813776|NCT03271489|Drug|E2/NETA|Capsules
45813777|NCT03271489|Other|E2/NETA Placebo|Capsules
45813778|NCT03271489|Drug|Elagolix|Tablets
45813779|NCT03260491|Drug|U3-1402 (FL-DP)|U3-1402 (frozen liquid drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a).
45952269|NCT00140049|Drug|Xalacom|
45952270|NCT00140049|Drug|Cosopt|
45952271|NCT00131534|Behavioral|Individual therapy|Stage-based individual therapy for trauma survivors
45952272|NCT00131534|Behavioral|Group therapy|Stage-based group therapy for trauma survivors
45952273|NCT00140088|Drug|ALGRX 3268|
45952274|NCT04726631|Drug|Basal insulin analogue|Analogue insulin is a sub-group of human insulin
45952275|NCT04726631|Drug|rapid acting insulin|Rapid acting insulins are usually taken just before or with a meal. They act very quickly to minimise the rise in blood sugar which follows eating.
45952276|NCT04726631|Drug|Neutral Protamine Hagedorn|is an intermediate-acting insulin
45952277|NCT04726631|Drug|regular insulin|is a type of short-acting insulin.
45952278|NCT02957760|Drug|Hydroxycarbamid|20 mg/kg milligram(s)/kilogram per day during 6 month, oral administration (coated tablet).
45952279|NCT00131612|Drug|FEC 100|5-fluoruracil, epirubicin and cyclophosphamide every three weeks for six treatments
45952280|NCT00131651|Drug|ATN-161|
45952281|NCT03117309|Drug|Nivolumab 240 mg|PART A Nivolumab 240 mg IV every 2 weeks x 6 then initial disease assessment
45952282|NCT03117309|Drug|Ipilimumab 1mg/kg|Ipilimumab 1 mg/kg every 3 weeks x 4
45952283|NCT03117309|Drug|Nivolumab 3mg/kg|In combination with Ipilimumab
45952284|NCT03117309|Drug|Nivolumab 360mg|Continue Nivolumab 360 mg IV every 3 weeks
45952285|NCT00131690|Drug|Nescafé Gold Blend (exposed)|
45952286|NCT00131690|Drug|Nescafé Decaffeinated (controls)|
45952287|NCT00140166|Drug|niacinamide|
45952288|NCT00140166|Drug|pyridoxine|
45952289|NCT00140166|Drug|ascorbate|
45813780|NCT03260491|Drug|U3-1402 (CTM-1 Lyo-DP)|U3-1402 (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the clinical manufacturing sites.
45813781|NCT03260491|Drug|U3-1402 (CTM-3 Lyo-DP)|U3-1402 (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the commercial manufacturing sites.
46077589|NCT02538601|Behavioral|CBT-A|"CBT-A was an 8-session (1.5 hours/session) group treatment for quitting smoking comprised of an optimized protocol that incorporated all elements of the CBT-S treatment plus skills for reducing PTSD/anxiety symptoms and improving tolerance to withdrawal. The CBT-A intervention included skills based on a transdiagnostic approach: (1) repeated interoceptive exposures to feared bodily sensations (e.g., dizziness, racing heart); (2) corrective information about anxiety and cognitive restructuring of catastrophic misinterpretations of somatic sensations (e.g., I will lose control.); and (3) use of graduated in-vivo exposure to feared and avoided situational experiences related to anxiety, WTC-related PTSD triggers, and smoking (e.g., going to lower Manhattan; driving without smoking)."
45813782|NCT03250273|Drug|Entinostat|Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).
45813783|NCT03250273|Drug|Nivolumab|After both lead-in doses of entinostat, nivolumab (240 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).
45453912|NCT00384358|Other|surgical intervention alone|surgical internal fixation of fracture defines the standard of care group
45813784|NCT03250273|Drug|Entinostat|Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).
45813785|NCT03250273|Drug|Nivolumab|After both lead-in doses of entinostat, nivolumab (240 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).
45453913|NCT01338428|Behavioral|Enhanced AAA Sexual Assault Resistance Education|Resistance Program: 4x3-hour units. Unit 1 (Assess) accurate assessment of sexual assault risk. Provides: empirically-based information on situational and (male) behavioural danger cues; practice identifying risk and counteracting it. Unit 2 'Acknowledge[ment]' of risk when present. Includes: women's sexual rights; emotional barriers; tactics used by coercive men; practice. Unit 3 (Act) includes: assessing whether or not an escape is possible; research evidence on the effectiveness of resistance strategies; physical self-defense training. Unit 4 applies content to longer term relationships covering: comfort talking about sexuality, identification of sexual values, practices beyond intercourse, and articulation of relationship goals.
45660237|NCT04424095|Diagnostic Test|Echo Duplex of lower limbs|The venous system of lower limbs will be checked in order to detect any vein dilation and reflux.
45660238|NCT04107181|Device|"Introducer calla device"|The research introducer will be used after the patient consents prior to the annual pap smear.
45660239|NCT04107181|Behavioral|Interviews only|Healthy volunteer interviews
45813786|NCT02203032|Drug|Ustekinumab|45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.
45813787|NCT02203032|Drug|Guselkumab|100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.
45813788|NCT02203032|Drug|Placebo for ustekinumab|Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.
45813789|NCT02203032|Drug|Placebo for guselkumab|Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.
45952290|NCT00131729|Behavioral|Educational programme|
45952291|NCT03095274|Drug|Durvalumab|Durvalumab, 1500 mg Q4W for 12 months.
45952292|NCT03095274|Drug|Tremelimumab|Tremelimumab 75 mg Q4W for up to 4 doses/cycles.
45952293|NCT00131768|Device|Synvisc (hylan G-F 20)|
45952294|NCT01248949|Drug|MEDI3617|Participants will receive MEDI3617 via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
45952295|NCT01248949|Drug|Bevacizumab|Participants will receive bevacizumab via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
45952296|NCT01248949|Drug|Paclitaxel|Participants will receive paclitaxel via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons.
45952297|NCT01248949|Drug|Carboplatin|Participants will receive carboplatin via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons.
45813790|NCT03587701|Drug|Anakinra 100Mg/0.67Ml Inj Syringe (Period 1)|pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
45660240|NCT03989011|Diagnostic Test|Carotid Artery Reactivity test (CAR test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celsius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved.
45813791|NCT03587701|Drug|Placebo injection (Period 1)|pre-filled matching placebo injections will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
45660241|NCT03989011|Diagnostic Test|Arterial stiffness|"The SphygmoCor device will be used to non-invasively measure arterial stiffness parameters using applanation tonometry. For Pulse Wave Analyses (PWA), the radial waveform will be recorded. Approximately 10 waveforms are averaged, resulting in several non-invasive parameters:~Peripheral pressure parameters~Central and abdominal aneurysm pressure parameters (derived using a transfer function)~Cardiac output parameters (SEVR, ED)~Pulse wave velocity will be performed by recording the waveforms of the carotid and femoral artery sequentially. The travelled distance will be measured according to the current guidelines and entered in the program. The program will calculate the PWV based on 10 ECG triggered waveform of each artery."
45813792|NCT03587701|Drug|Anakinra 100Mg/0.67Ml Inj Syringe (Period 2)|pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
45813793|NCT03587701|Drug|Placebo injection (Period 2)|pre-filled matching placebo injections will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
45660242|NCT05485441|Other|Digital Educational Intervention|"The educational intervention will be provided (at T1) in two ways:~(I) a video lecture in e-learning mode lasting about an hour, aimed at adolescents, using the School Institute's platform for distance education (II) the promotion of 2-minute videopills on the social channels most frequently used by students (dedicated youtube channel/school portal)"
45813794|NCT02169414|Drug|BIA 9-1067 5 mg|OPC, Opicapone
45813795|NCT02169414|Drug|BIA 9-1067 25 mg|OPC, Opicapone
45813796|NCT02169414|Drug|levodopa/carbidopa 100/25|immediate (standard) release levodopa/carbidopa 100/25
45813797|NCT02169414|Drug|Placebo|PLC, Placebo
45813798|NCT02169414|Drug|levodopa/benserazide 100/25 mg|immediate (standard) release levodopa/benserazide
45813799|NCT03213457|Drug|Estradiol/Norethindrone Acetate|Tablets
45813800|NCT03213457|Drug|Placebo for Elagolix|Tablet
45813801|NCT03213457|Drug|Elagolix|Tablet
45813802|NCT03213457|Drug|Placebo for E2/NETA|Tablets
45813803|NCT02201940|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
45813804|NCT02201940|Drug|Placebo|Tablet administered orally once daily
45813805|NCT05588869|Other|observation of the adverse outcomes of Cyclosporine in steroid dependent and frequent relapsing nephrotic syndrome in children|The interventions that will be done include collection of the following data : age at disease onset, disease duration, type of steroid response, age at the start of CsA treatment, dose and duration of CsA treatment, mean values of the maintenance doses of CsA and their trough blood levels and observation of the side effects. serum creatinine at regular intervals before and after CsA treatment and renal biopsy for those who are on CsA for more than 2-3 years would be done.
45813806|NCT03568435|Other|Non-Interventional|Non-Interventional
45813807|NCT05588791|Diagnostic Test|whole-body computed tomography|whole-body computed tomography prescription in the emergency department : an identification tool for low risk patients
45813808|NCT03085069|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
45813809|NCT03485365|Drug|GSK3858279 IV|GSK3858279 will be available as solution for injection to be administered via IV route.
45813810|NCT03485365|Drug|GSK3858279 SC|GSK3858279 will be available as solution for injection to be administered via SC route.
45813811|NCT03485365|Drug|Placebo matching to GSK3858279 (SC or IV)|Placebo will be available as sodium chloride solution to be administered via SC or IV route.
45813812|NCT03485365|Drug|Placebo matching to GSK3858279 (SC)|Placebo will be available as sodium chloride solution to be administered via SC route.
45813813|NCT04188288|Device|Experimental feedback|Participants provided with feedback of target brain activation patterns (for example, in the form of a line graph) and will be instructed to try to make the line go up or down.
45813814|NCT04188288|Device|Control feedback|Participants provided with control type of feedback (for example, in the form of a line graph) and will be instructed to try to make the line go up or down.
45813815|NCT03059407|Behavioral|Dog therapy only|Canine assisted therapy only during echocardiogram
45813816|NCT03059407|Behavioral|Dog plus standard distraction tech|Canine assisted therapy plus standard distraction techniques during echo
45952298|NCT03085173|Biological|EGFRt/19-28z/4-1BBL CAR T cells|Cohorts of 3-6 patients will be infused with escalating doses of EGFRt/19-28z/4-1BBL CAR T cells to establish the maximum tolerated dose (MTD). There are 4 planned dose levels: 1 x 10^5, 3 x 10^5, 1 x 10^6, and 3 x 10^6 CAR T cells/kg.
45952299|NCT00131807|Procedure|Blood Pressure Measurement|
45660243|NCT02554981|Drug|Cyclosporine 0.05% Ophthalmic Emulsion|Cyclosporine 0.05% Ophthalmic Emulsion (RESTASIS®) 1 drop instilled in each eye twice a day.
45813817|NCT03059407|Behavioral|Standard distraction techniques only|Standard distraction techniques (such as watching a movie) only during echocardiogram
45952300|NCT00131807|Procedure|Questionnaire|
45952301|NCT02275234|Other|Psychological intervention|Psychological support via clinic visit, helpline and telephone calls
45952302|NCT03030495|Device|Comprehensive physiologic evaluation|Comprehensive physiologic evaluation using pressure-temperature sensor wire to measure fractional flow reserve, coronary flow reserve, index of microcirculatory resistance
45952303|NCT03030495|Device|Intravascular imaging devices|Intravascular ultrasound or optical coherence tomography
45952304|NCT00504478|Dietary Supplement|omega-3 fatty acids|omega-3 supplement will be given in addition to high complex carbohydrate diet.
45952305|NCT00504478|Other|high complex carbohydrate diet|
45660244|NCT02556775|Biological|A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment|To be determined by the physician
45660245|NCT02556775|Biological|HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
45660246|NCT01662505|Drug|Volasertib|Patient to receive volasertib
45660247|NCT05485363|Diagnostic Test|ultrasonographic measurement of the optic nerve sheath diameter|Assessing the optic nerve sheath diameter as an indicator of intracranial pressure during different positions and on specific time intervals in patients undergoing laparoscopic sleeve gastrectomy
45813818|NCT02169336|Drug|Intranasal Dexmedetomidine|
45660248|NCT04080739|Drug|ropivicaine 0.2%|2-8 cc/hr of 0.2% ropivicaine given as a regional block via US-guided ipsilateral sciatic nerve block for fibula free flap patients or US-guided infraclavicular brachial plexus nerve block for forearm free flap patients.
45660249|NCT05491993|Diagnostic Test|Sky Medical™ Rapid Antigen Test|Rapid Antigen Diagnostic Test device performance comparative to RT-PCR.
45660250|NCT03986749|Procedure|Doppler ultrasonography after bursa augmentation|Dynamic ultrasound examination with Grading of blood vessels using the modified Ohberg Score in the longitudinal scan in dynamic ultrasound of the rotator cuff tendon - primary to surgery and 3 weeks later.
45660251|NCT04074733|Diagnostic Test|Patient undergoes a ULD scan|"The following doses will be applied:~6 mGy.cm for the extremities 50 mGy.cm for the dorsal spine 130 mGy.cm for the lumbar spine 130 mGy.cm for the pelvis"
45660252|NCT04074733|Diagnostic Test|Patient undergoes a standard X-ray|"The following doses will be applied:~For the pelvis : front view and profile for the hip. For the dorsal spine : front and profile. For the lumbar spine : front and profile For the extremities : front and profile"
45813819|NCT02169336|Other|Intranasal Placebo|
45813820|NCT03043807|Drug|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
45813821|NCT03043807|Drug|Docetaxel|75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles. Dose may decreased in the following intervals: 65 mg/M2, 55 mg/M2, 35 mg/M2.
45952306|NCT00403637|Drug|indacaterol maleate|
45458470|NCT02317900|Biological|rDEN2∆30-7169|rDEN2∆30-7169 is a live recombinant attenuated DENV-2 candidate vaccine virus. It will be administered as a 0.5 mL dose containing 10^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
45458471|NCT03497494|Procedure|2 cm away from the pylorus edge|2 cm away from the pylorus edge
45660253|NCT04074733|Diagnostic Test|Patient undergoes a classic-dose scan|"The following doses will be applied:~6 mGy.cm for the extremities 50 mGy.cm for the dorsal spine 130 mGy.cm for the lumbar spine 130 mGy.cm for the pelvis"
45660254|NCT05485285|Other|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
45813822|NCT03043807|Drug|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
45813823|NCT03043807|Radiation|Radiation|Radiation will be delivered in 1 to 5 fractions, and the dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints in accordance with AAPM Task Group 101 recommendations. Typical doses include 16 - 24 Gy in 1 fraction, 48 - 50 Gy in 4 fractions, and 50 - 60 Gy in 5 fractions.
45813824|NCT03043807|Drug|Abiraterone Acetate|Abiraterone acetate 1000 mg / day may be given at the investigator's discretion.
45813825|NCT02609828|Drug|Tanezumab|Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.
45813826|NCT03039751|Drug|AdvVEGF-D|AdvVEGF-D will be injected into 10 sites of the myocardium
45813827|NCT03039751|Drug|Control Rx|Placebo (buffer solution without gene) will be injected into 10 sites of the myocardium
46002690|NCT00558675|Biological|AlloStim|Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7, day 14 and day 21
45952307|NCT04696666|Device|INSTYLAN (Sodium Hyaluronate 80mg/50ml)|The bladder instillation with INSTYLAN is a treatment involving a sterile solution of Sodium Hyaluronate (80mg/50ml) inserted into the bladder through a catheter and released after a short period of time.
45813828|NCT05588635|Other|Identification of predictive factors|Evaluation of the following variables : mother age (years), father age (years), serum progesterone (ng/ml), mother body mass index (kg/m2), serum Antimüllerian hormone (AMH) (ng/ml), infertility etiology (yes/no): 4 categories: idiopathic etiology, mixed origin infertility, male infertility, female infertility; smoker status among mothers (yes/no).
45813829|NCT05588557|Drug|Marcaine® 100mg/20mL (0.5%) bupivacaine solution for Injection|"Subjects in this arm will receive a single administration of Marcaine® at the 150 mg.~Marcaine® will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee)."
45813830|NCT05588557|Drug|ND-340 (Bupivacaine Microsphere), 300 mg/vial bupivacaine for extended-release injectable suspension|"Subjects in this arm will receive a single administration of ND-340 at the specified dose (90-320 mg).~ND-340 will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee)."
45952308|NCT00140283|Procedure|Educational interactive intervention|
45952309|NCT01248793|Drug|Placebo|Placebo subcutaneous (SC) injections at Weeks 0, 4, 8, 12, 16, and 20
45952310|NCT01248793|Drug|Golimumab|Golimumab 50 mg SC injection every 4 weeks for 48 weeks
45952311|NCT01248793|Drug|Golimumab (placebo group)|Golimumab with early escape at Week 16, 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48
45952312|NCT00403676|Other|Follow up bu a nurse|Follow up bu a nurse
45952313|NCT00403676|Other|Follow up by a medical doctor|Follow up by a medical doctor
45458472|NCT03497494|Procedure|4 cm away from the pylorus edge|4 cm away from the pylorus edge
45952314|NCT00140322|Behavioral|Exercise, fall risk reduction|
45952315|NCT00403715|Drug|diquafosol tetrasodium (INS365) Ophthalmic Solution|
45952316|NCT03025932|Procedure|repair of giant hiatal hernia with mesh and anterior fundoplication|
45952317|NCT00403832|Device|intraocular lenses: Two foldable, acrylic, sharp edged IOLs: AcrySof™ (AcrySof SA60AT, Alcon), and Akreos adapt™ (Bausch & Lomb)|
45952318|NCT01248364|Drug|BI 10773|BI 10773 tablets once daily high dose
45952319|NCT00140361|Drug|Sulfadoxine-pyrimethamine|
45952320|NCT00140361|Drug|sulfadoxine-pyrimethamine plus artesunate|
45676562|NCT01943643|Procedure|multislice CT angiography|Study patients will undergo MSCTA on Toshiba Aquilion CXL 128 slice CT scanner using predefined protocol. The procedure will include calcium scoring (Agatston) then CT angiography using Ultravist 370 contrast agent ((iopromide concentration 370 mg/ml, Bayer Health Care, Germany). MSCTA angiograms will be analyzed using dedicated software Vital Vitrea Advanced 6.2, Vital Images, Minnetonka, Minnesota, US. The bifurcation lesion analyses will include: the measurement of the angle between MB and SB, measurement of the lesion length, reference diameter of the vessel, degree of stenosis, atherosclerotic plaque analysis 10 mm proximal and distal in the MB, and 5 mm from the ostium of the SB, and at the level of maximum stenosis (minimal lumen diameter).
45676563|NCT01864109|Drug|Cyclophosphamide|
45676564|NCT01864109|Device|Doxorubicin|
45813831|NCT01632306|Drug|LY2090314|LY2090314 administered IV
45813832|NCT01632306|Drug|FOLFOX|FOLFOX administered IV
45952321|NCT00140361|Drug|lumefantrine plus artemether|
45952322|NCT00140361|Behavioral|Sleeping under insecticide-treated bednet|
45458473|NCT03497494|Procedure|6 cm away from the pylorus edge|6 cm away from the pylorus edge
45458474|NCT03497494|Procedure|LRYGB|laparoscopic Roux-en-Y gastric bypass
45952323|NCT00131846|Drug|Thiazide diuretics|Any dosage, frequency, and duration
45952324|NCT00131846|Drug|No diuretics|Any antihypertensive regimen other than diuretics
45952325|NCT01248130|Drug|Omega-3 Fatty Acid|Children with Autism Spectrum Disorders will be randomized to receive either 1500mg (3 capsules) omega-3 fatty acids or placebo. Each 500mg capsule contains 350mg EPA and 50mg DHA. Omega-3 fatty acids dosing will be on a forced titration schedule to 3 capsules per day. All subjects will start with 1 capsule per day with an increase to 3 capsules per day by week 2. Subjects will be maintained at 3 capsules per day thereafter until the end of the trial (completion/discontinuation). During the 12 weeks of the study period, participants will be evaluated at weekly intervals during the first three weeks of the trial (baseline, weeks 1-3) and tri-weekly thereafter till the end of the trial (weeks 6, 9 and 12). At each visit, measures of safety and effectiveness will be administered and subjects will be evaluated for response and side effects to the treatment. Study medications will be prescribed under double blind conditions.
45952326|NCT02830620|Other|Dosage of chimiokines|
45952327|NCT01248013|Behavioral|gut focused hypnotherapy|7 session hypnotherapy protocol designed for irritable bowel syndrome
45952328|NCT02955550|Drug|rhIL-2|Human recombinant Interleukin-2
45952329|NCT02955550|Biological|PNK-007|PNK-007 is a culture-expanded cell population derived from human cord blood hematopoietic stem/progenitor cells.
45952330|NCT00131963|Drug|cyclophosphamide|Given IV
45952331|NCT00131963|Drug|doxorubicin|Given IV
45952332|NCT00131963|Drug|paclitaxel|Given IV
45952333|NCT00140400|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
45813833|NCT01632306|Drug|Gemcitabine|Gemcitabine administered IV
45952334|NCT00132080|Drug|Steroids|This study evaluates the efficacy and safety of pulse steroid therapy, when added to conventional treatment with IVIG plus aspirin, in treatment of children with acute Kawasaki disease.
45952335|NCT00140439|Behavioral|Emergency Department based asthma follow-up clinic|"The clinical activities of the intervention followed a fully specified protocol and provided education and care in three domains:~Asthma self-monitoring and management: Educators first reviewed the basic physiology of asthma with emphasis on its chronicity. After evaluating asthma severity and treatment history, the physician completed an individualized medical action plan (MAP) and provided any necessary device teaching.~Environmental modification and trigger control: After evaluation of potential environmental triggers in the home, each family was educated on their control. Each child was provided hypoallergenic bed encasings.~Linkages and referrals to ongoing primary care: Clinic staff stressed the importance of longitudinal asthma care by a PCP. A full report of the clinic visit was mailed to each child's PCP. In addition, the asthma educator scheduled a follow-up appointment with the PCP within 4 weeks"
45952336|NCT00132119|Drug|nalmefene HCl|Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.
45952337|NCT00132119|Other|Placebo|Placebo tablet
45952338|NCT00132158|Drug|Irinotecan (Camptosar), Gefitinib (Iressa)|See Detailed Description for treatment plan.
45952339|NCT00140478|Drug|Mifepristone|200mg orally once daily
45952340|NCT00132197|Behavioral|Cognitive Behavioral Therapy|1. Specialised treatment includes cognitive groups therapy in 9 modules of 3,5 hours within 3½ months, in all 31,5 hours, consultancy over the phone to the patients' GPs and tuition in groups headed by an experienced social worker. Detailed treatment manuals are worked out separately for each module. Experienced psychotherapists (clinical psychologists and psychiatrists), who also function as consultants, will do the treatment. The Ph.D.-student functions as co-therapist.
45952341|NCT00132197|Procedure|Recommendation of care (letter to general practitioner [GP])|After the diagnostic assessment the patient does not receive any treatment offers at the research clinic, but the patient and the GP will be informed about the diagnosis, and the GP will receive advice on further treatment possibilities.
45952342|NCT00140517|Drug|sulphadoxine-pyrimethamine|
45952343|NCT00140517|Drug|chloroquine|
45952344|NCT01247350|Drug|LY3009104|Administered orally
45952345|NCT01247350|Drug|Placebo|Administered orally
45952346|NCT00132236|Drug|nicotine sublingual tablets|
45952347|NCT00132236|Behavioral|low and high behavior support|
45660255|NCT05488717|Other|art-based mandala application|"Patients who are routinely scheduled for bone marrow transplantation are admitted to the unit one week before the transplant and treatment is started and transplantation is performed a week later. All patients in the intervention and control group will be filled out forms upon hospitalization after receiving their informed consent at the beginning of the study. Subsequently, patients in the intervention group will be given art-based mandala painting, which is sampled below, for 30 minutes for a week, accompanied by instrumental music featuring natural sounds in a room with light-heat control. Mandala painting templates and crayons will be provided by the researcher. The researcher will not intervene in any way other than time management during the preparation and painting of the environment. The researcher participated in training on art-based mandala and made preliminary preparations.~No intervention will be made to the control group except for routine clinical applications."
46077590|NCT02538601|Behavioral|CBT-S|CBT-S was an adapted group-based CBT smoking cessation treatment delivered in 8 sessions (1.5 hours/session) based on the most recent clinical practice guidelines from the United States Department of Health and Human Services (USDHHS), Treating Tobacco Use and Dependence. Standard cessation elements included psychoeducation on reasons for smoking and barriers to quitting, enlisting social support, monitoring and tapering cigarette use, and counseling regarding high-risk smoking situations and unhelpful ways of thinking about smoking and abstinence. The treatment was similar to protocols used in other smoking cessation research.
45458475|NCT05188274|Dietary Supplement|T92|T92 granules (5g/sachet) will be taken BID for 8 weeks, the dosage will be calculated by individual's body weight.
45660256|NCT05491681|Biological|intravenous delivery of allogeneic bone marrow-derived MSCs|MSCs
45660257|NCT05485207|Drug|Transvaginal botulinum toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
45458476|NCT05188274|Dietary Supplement|Placebo|The placebo matched to T92 granules will be taken BID for 8 weeks.
45676565|NCT01864109|Drug|Vincristine|
45676566|NCT01864109|Drug|Ifosfamide|
45676567|NCT01864109|Drug|Etoposide|
45676568|NCT01864109|Procedure|Surgery|
45813834|NCT01632306|Drug|Nab-paclitaxel|Nab-paclitaxel administered IV
45813835|NCT02346565|Procedure|Exercise ECG|
45813836|NCT02346565|Procedure|Stress Echocardiography|
45813837|NCT02600065|Other|Blood draw and MRI|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy.
45813838|NCT02201784|Drug|Levobupivacaine|Comparison of Equipotent doses
45813839|NCT02201784|Drug|Ropivacaine|Comparison of equipotent doses
45952348|NCT04710849|Diagnostic Test|Serum metabolic markers|Ultraperformance liquid chromatography / mass spectrometry (LC-MS) and gas chromatography / mass spectrometry (GC-MS) methods for analysis of the metabolites in AECOPD patients and compare the metabolites profiles between patients with systemic glucocorticoid treatment success and treatment failure.
45952349|NCT00132275|Drug|Amoxicillin potassium clavulanate|
45952350|NCT01246999|Biological|Live attenuated Influenza vaccine|0.2 mL dose delivered through nasal spray, 0.1 ml in each nostril, 2 doses separated by 28 days
45952351|NCT01246999|Biological|Trivalent Influenza Vaccine|.25 mL given intramuscularly to children 24 to 36 months of age, 2 doses given 28 days apart, .5 mL given intramuscularly to children 37 months to 9 years of age, 2 doses given 28 day s apart.
45952352|NCT01246999|Biological|TIV followed by LAIV|TIV .25 mL given intramuscularly to children 24 to 36 months of age or .5 mL given intramuscularly to children 37 months to 9 years of age, followed by FluMist 0.2 mL delivered by nasal spray (.1 mL in each nostril)28 days later
45952353|NCT01246999|Biological|LAIV followed by TIV|LAIV .2 mL given through nasal spray (.1 mL in each nostril) Followed by TIV .25 mL given intramuscularly to children 24 to 25 months of age or .5 mL given intramuscularly to children 36 months to 9 years of age 28 days later
45952354|NCT00140595|Drug|rituximab|
45952355|NCT00140595|Drug|doxorubicin|
45813840|NCT04340479|Diagnostic Test|Ultrasound lung imaging as part of FAST+ evaluation|"FAST+ evaluations will expand on the traditional FAST exam to systematically survey bilateral lung fields. Traditional FAST evaluation will survey the perihepatic, perisplenic, pelvic, and pericardial areas. Representative images will be saved by the performing provider for further evaluation. Up to sixteen areas in total will be included in FAST+ evaluation:~Anterior midclavicular right and left (apical, medial, basal)~Posterior paraspinal right and left* (apical, medial, basal)~*Posterior lung evaluation will be omitted if patients are at risk for further traumatic injury from repeated side rolling.~Lateral axillary medial right and left (apical and basal)~Specifically, we will document the presence or absence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts in these lung fields by ultrasound and will record these findings."
45660258|NCT03897907|Other|Psychologically Informed Education Video|"The education session will teach participants how the body processes nociception and experiences pain, and pain does not mean tissues are being damaged. Additionally we will use the framework called the Common Sense Model of Self-Regulation which advocates for education to address five cognitive dimensions: (1) identity (the effort to evaluate symptoms and label the illness); (2) cause (the subjectively formulated belief of what is causing the symptoms); (3) time-line (the patient's perception of how long the problem will last); (4) consequences (the patient's predictions of how the illness will affect them in different areas of their life); and (5) controllability (the patient's belief regarding their outcome and personal ability to change it)"
45676569|NCT01864109|Radiation|Radiation Therapy*|If local control includes RT, RT should be given concurrently with chemotherapy cycles
45952356|NCT00140595|Drug|cyclophosphamide|
45952357|NCT04696783|Drug|Esomeprazole Magnesium Enteric-coated Tablets|Nexium taken once every 2 days plus lifestyle adjustment
45952358|NCT04696783|Behavioral|Lifestyle adjustment|Lifestyle adjustment
45676570|NCT01864109|Drug|Temozolomide|
46077591|NCT05423184|Other|Exercise Therapy For Lower Extremities|Participants who have inclusion criterias after ACL reconstrontion pos-op 8. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their standardize exercises pragram with telerehabilition during 6 weeks and 18 sessions. This program includes four directions single leg raise with theraband, squat, lunge walk and static balance exercises. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
45952359|NCT00140634|Biological|Carticel (autologous cultured chondrocyte) implantation|Each Carticel vial of autologous cultured chondrocytes contains approximately 12 million cells implanted into the defect and secured with a periosteal flap.
45813841|NCT02201472|Device|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
45952360|NCT00132392|Drug|ALGRX 4975|
46077592|NCT05423184|Other|Exercise Therapy For Myofascial Chains|Participants who have inclusion criterias after ACL reconstrontion pos-op 8. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their structered exercises pragram with telerehabilition during 6 weeks and 18 sessions. This program includes four directions single leg and arm raise with theraband, squat with arm participation using theraband, lunge walk with arm participation using theraband and static balance exercises with arm participation using theraband. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
46077593|NCT00135161|Procedure|FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).|FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).
46077594|NCT00902785|Other|no drug|observational no drug
45952361|NCT02443623|Biological|Vaccination with ACAM2000|In this study (VA-008), healthy adult male and female volunteers who meet the requirements for source plasma donors and study entry criteria will be vaccinated with the ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacture of VIGIV. There are possible risks associated with ACAM2000 vaccination. To ensure the safety of plasma donors, risk factor screening procedures and the collection of post-vaccination safety data will be assessed throughout the study.
46077595|NCT02754336|Behavioral|Cogmed Robomemo, working memory training|
45458477|NCT03497416|Other|No intervention|No intervention
45952362|NCT00132431|Drug|Sensipar|
45952363|NCT00140673|Biological|Rotavirus|
45952364|NCT00132470|Drug|AX200 (G-CSF)|
46077596|NCT02754336|Behavioral|Othmer, neurofeedback|
46077597|NCT00898183|Genetic|gene expression analysis|
46077598|NCT00898183|Genetic|polymorphism analysis|
46077599|NCT05381519|Biological|DXP604|1800mg，IVgtt
45676571|NCT01864109|Drug|Irinotecan|
45952365|NCT00132509|Drug|DFIL|Alteplase : 0.8mg/kg over 90 minutes
45952366|NCT00132509|Drug|NINDS|Alteplase : 0.9mg/kg over 60 minutes
45952367|NCT00140712|Drug|Ropinirole Immediate Release|Ropinirole Immediate Release
45952368|NCT00132548|Drug|Pyrimethamine/sulfadoxine|
45952369|NCT00132548|Drug|Amodiaquine|
45952370|NCT00132548|Drug|Artesunate|
45952371|NCT00140751|Drug|Lopinavir/ritonavir (drug)|
45952372|NCT00132587|Device|cement Palacos R40 and LV40|
45952373|NCT00140790|Drug|valsartan|valsartan 40 or 160 (80) mg per day
45952374|NCT01245751|Biological|Zoster Vaccine, Live|Single approximately 0.65-mL subcutaneous injection of Zoster Vaccine, Live on Day 1 of the study
45952375|NCT00132626|Drug|[123I]ß-CIT and SPECT imaging|
45952376|NCT00132665|Procedure|A: Radiotherapy alone|Procedure/Surgery: A: Radiotherapy alone
46077600|NCT02754102|Other|Sunscreen Spray- Liquid (BAY987516)|50 μl/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.
45952377|NCT00132665|Drug|B: CBDCA and Radiotherapy|Drug: B: CBDCA and Radiotherapy
45952378|NCT01245673|Biological|Prevnar- Pneumococcal Conjugate Vaccine (PCV)|After study enrollment, patients will receive Prevnar- Pneumococcal Conjugate Vaccine (PCV). At Day #14, Day #42, and Day #90, Day #120 and Day #150, patients will receive a booster immunization with Prevnar- Pneumococcal Conjugate Vaccine (PCV).
46077601|NCT00902863|Behavioral|YOGA|Patients with chronic pain will undergo a six week course of YOGA
46077602|NCT00134303|Drug|Metformin|Metformin is used.
46077603|NCT00902941|Drug|Azilect 1mg|1 mg daily orally for 120 days
46077604|NCT00902941|Drug|Placebo|1 mg daily orally for 120 days
46077605|NCT02754258|Drug|MPH|60 days on oral methylphenidate administered 2 times daily before lunch and supper.
46077606|NCT02754258|Drug|Placebo|60 days on oral placebo administered 2 times daily before lunch and supper
46077607|NCT04267991|Drug|Tacrolimus ointment|Patients were treated with 0.03 % tacrolimus ointment twice daily for 6 months.
46077608|NCT04267991|Procedure|phototherapeutic keratectomy|Patients underwent transepithelial PTK for subepithelial infiltrates.
46077609|NCT02539069|Device|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
45660259|NCT03897907|Other|Anatomy Education Video|Participants in the control group will watch three videos equal in length to the psychologically-informed videos. The control videos will discuss anatomy of the lower extremity, basic instruction in proper lower extremity biomechanics, and simple lower extremity exercises. The control videos will provide no psychologically-informed education or positive reinforcement about the condition.
46077610|NCT02754024|Procedure|Total shoulder arthroplasty (TSA)|stemless humeral head implant: Eclipse™ (Arthrex Inc., Naples, FL, USA)
46077611|NCT02754024|Procedure|Hemi shoulder arthroplasty (HSA)|stemless humeral head implant: Eclipse™ (Arthrex Inc., Naples, FL, USA)
45660260|NCT05488639|Other|Registration of football exposure and occurrence of injuries and illnesses only|"Injury & illness registration~Data on injury and illness is gathered following the recommended methodology in the football extension of the International Olympic Committee consensus statement on methods for recording and reporting of epidemiological data on injury and illness in sport. This includes characteristics such as mode of onset, injury mechanism, diagnosis and classification according to body area, tissue, and pathology type, and illness categories for organ system and etiology. Time-loss will be counted in number of days."
45813842|NCT02162329|Behavioral|Questionnaires|"Participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete.~Meditation Group and Wait-List Group also complete questionnaires at follow up visit."
45813843|NCT02162329|Procedure|Electroencephalography (EEG)|"Meditation Group and Wait-List Group: Electroencephalography (EEG) performed at baseline and at follow up visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.~Healthy Control Group: Electroencephalography (EEG) performed at study visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions."
45813844|NCT02162329|Procedure|Magnetic Resonance Imaging (fMRI|"Healthy Control Group: Magnetic resonance imaging (fMRI) scan performed.~Meditation Group and Wait-List Group: Magnetic resonance imaging (fMRI) scan of brain performed at baseline and at follow up visit."
46077612|NCT02754024|Device|Eclipse™ (Arthrex Inc., Naples, FL, USA)|stemless humeral head implant
46077613|NCT02852681|Drug|15 mg E4/3 mg DRSP|All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (Sequence AB), or Treatment B followed by Treatment A (Sequence BA)
45813845|NCT02162329|Behavioral|Meditation Classes|Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
45952379|NCT01245673|Other|Activated/costimulated autologous T-cell|For all patients, the cells will be expanded ex vivo for up to 12 days and then prepared for infusion ~day 2 post-transplant. The target number of costimulated T-cells for infusion will be ~ 5 x 10e10 T-cells total in 100-500 mL total volume.
45952380|NCT01245673|Drug|Revlamid® (Lenalidomide)|At about day 100 post-transplant, after completion of post-transplant immunological assessments and myeloma restaging studies, patients will be eligible to receive low-dose Revlamid® (Lenalidomide) 10 mg/day for maintenance therapy (10 mg/day) until progression of myeloma or development of intolerance.
45952381|NCT01245673|Biological|MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)|After study enrollment, patients will receive both MAGE-A3/GM-CSF [+ coinjection of 2mg of Hiltonol®(Poly-ICLC)]. At Day #14, Day #42, Day #90, Day #120 and Day #150 patients will receive an additional immunization with MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC).
45952382|NCT01245283|Other|normal activities and clinical care|Subjects will continue to participate in their normal activities and clinical care during the four month study. Telephone contact will be made weekly to encourage adherence to the knee management guidelines
46002691|NCT04637139|Drug|Vebicorvir (VBR)|300mg Vebicovir containing 2 µCi [14C]VBR.
46002692|NCT00547001|Drug|Estradiol|1mg during stabilization & then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.
46077614|NCT00898261|Genetic|microarray analysis|
46077615|NCT00898261|Genetic|reverse transcriptase-polymerase chain reaction|
46077616|NCT00898261|Other|flow cytometry|
46077617|NCT02753868|Behavioral|exercise|Participants will be asked to cycle at mild to moderate intensity for 30 minutes during either 1-st hour of 3-rd hour into treatment
46077618|NCT02753868|Procedure|Hemodialysis treatment|Participants will receive a standard hemodialysis treatment during the study period
46077619|NCT00903019|Behavioral|Tele-Problem-Solving Therapy|Six sessions of tele-PST
46077620|NCT00903019|Behavioral|In-Person PST|Six sessions of in person PST
46077621|NCT00903019|Behavioral|Attention control|Six weekly telephone calls
46077622|NCT02754180|Drug|Gemcitabine|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles
46077623|NCT02754180|Radiation|TS-1 with radiation|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.
46077624|NCT00602849|Drug|Sertraline|
45952383|NCT01245283|Other|Concentric Focused Resistance Exercise|Two resistance exercise sessions per week; 1 set of 10-12 repetitions of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
45952384|NCT01245283|Other|Eccentric Focused Resistance Exercise|Two resistance exercise sessions per week; 1 set of 10-12 repetitions of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
45952385|NCT02261415|Drug|Tranexamic acid (TXA)|1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours
45952386|NCT02261415|Drug|Normal saline|1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
45813846|NCT02647346|Device|Daily use of podimetrics smart-foot mat|
45952387|NCT00132704|Radiation|Ionizing radiation (IR) therapy|Tumors will be sliced into 0.5cm fragments, incubated in culture medium and then irradiated to evaluate the kinetics and dose-dependencies of the endothelial apoptotic response. We will irradiate tumor fragments ex vivo at 0, 7, 13, 15, 17, and 25 Gy.
45952388|NCT00132704|Radiation|Ionizing radiation (IR)|Tissue fragments of a total quantity of at least a 4x4x4 cm3 will be required. For each tumor a paraffin block will also be made for routine staining and IHC. Endothelial cell populations (at least 500 cells) will then be exposed to radiation at 0, 7, 11, 13, 15, 17, and 25 Gy and harvested at 4, 5 and 8 hours post IR.
45660261|NCT05488561|Diagnostic Test|CBC with differential ,ESR ,CRP, Amyloid level , FMF gene|leucocytosis , high ESR and CRP ,amyloid level indicates inflammation positive FMF gene indicates having the disease .
45813847|NCT05441995|Other|Cryotherapy|Ice packs were applied in the buccal mucosa related to the tooth for 5 minutes after IANB administration
45952389|NCT02254863|Biological|DUOC-01|Intrathecal administration of DUOC-01
45813848|NCT02554838|Other|Physical activity|Participants receive a weekly individual session of physical activity during 8 consecutive weeks conducted by a licensed physical therapist and focusing on muscle strengthening, flexibility, gait and balance retraining.
45952390|NCT01245049|Biological|Boostrix PolioTM|Single dose, intramuscular administration.
45952391|NCT01245049|Biological|RepevaxTM|Single dose, intramuscular administration.
45952392|NCT01245049|Biological|PriorixTM|Single dose, intramuscular or subcutaneous administration.
45660262|NCT03879109|Drug|Chemotherapy FOLFIRINOX, 6 cycles|"oxaliplatin: 85 mg/m2~irinotecan: 180 mg/m²~folinic acid: 400 mg/m2~5FU : 400 mg/m2 (bolus)~5FU : 2400 mg/m2 (continuous infusion)"
45660263|NCT03879109|Radiation|Radiochemotherapy|Reirradiation consists in conformational intensity modulated external irradiation (Intensity-modulated radiotherapy Volumetric Modulated Arc Therapy or tomotherapy) delivering a 30.6 Gy dose with high-energy photons in fractions of 1.8 Gy per day (17 fractions) 5 days a week With Concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week.
45952393|NCT00132743|Device|Stent|Stent
45952394|NCT00132743|Behavioral|Supervised Exercise Therapy|Supervised exercise therapy, three times per week
45952395|NCT00132743|Drug|Cilostazol|Cilostazol, 100 mg twice a day
45952396|NCT02087592|Behavioral|Structured exercise training plus mediterranean diet|
45952397|NCT01244893|Device|Acuvue Advance Plus prePQ|silicone hydrogel contact lens manufactured prior to equipment process qualification activities.
45660264|NCT03879109|Procedure|Surgery|"Surgery will be performed at:~Arm A: 8 weeks (±1) after the end of treatment~Arm B: 6 weeks (±1) after the end of treatment~Surgical procedures are defined into three categories:~Total mesorectal excision (TME)~Extended-TEM (e-TME)~Pelvic exenteration (PE)"
45660265|NCT05485129|Device|BIORICS|Wearing BIORICS in their ear and perform mental arrhythmic test, relaxation exercises and Stroop test
45813849|NCT02554838|Other|Home assessment and modification|Two home-based sessions of modification of the home environment by a licensed rehabilitation therapist, in order to increase the aera of mobility, the frequency of moving in this aera and the independence to move.
45813850|NCT02554838|Behavioral|Cognitive behavioral therapy|Participants receive during 8 consecutive weeks a weekly individual sessions of CBT and a booster session one month later conducted by a psychologist specialized in CBT focusing on : functional analysis, education about treatment and anxiety, relaxation training and progressive exposure in imagination then in vivo.
45952398|NCT01244893|Device|Acuvue Advance Plus postPQ|silicone hydrogel contact lens manufactured after equipment process qualification activities.
45952399|NCT00132821|Drug|Bupropion|Days 1-3, 150 mg Bupropion in am; days 4-63, 300 mg Bupropion (150 mg in am and 150 mg in pm)
45952400|NCT00132821|Drug|Transdermal Nicotine Patch|21-mg nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg patch applied in AM for 2 weeks; 7-mg patch applied in AM for 1 week
45660266|NCT04032535|Drug|CHF6523|CHF6523 is a PI3K inhibitor (phosphoinositide3-kinase)
45952401|NCT00132821|Drug|Placebo Bupropion|Days 1-3, 150 mg placebo Bupropion in am; days 4-63, 300 mg placebo Bupropion (150 mg in am and 150 mg in pm)
45660267|NCT05488327|Drug|Lenalidomide|All subjects will be treated with lenalidomide 5mg/day with a regular follow-up of 24 weeks.
45952402|NCT00132821|Drug|Placebo transdermal nicotine patch|21-mg placebo nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg placebo patch applied in AM for 2 weeks; 7-mg placebo patch applied in AM for 1 week
46077625|NCT00906451|Drug|Simvastatin|Simvastatin
45660268|NCT05488171|Drug|Methylone|Single oral dose of 200 mg of methylone.
46077626|NCT00898417|Biological|bevacizumab|
45660269|NCT05488171|Drug|3,4-methylenedioxymethamphetamine|Single oral dose of 100 mg of MDMA.
45952403|NCT00132860|Drug|azithromycin|
45952404|NCT01244815|Drug|asenapine|Asenapine tablets, administered sublingually twice daily at one of three dose levels (2.5 mg, 5.0 mg, or 10.0 mg)
45952405|NCT01244815|Drug|Placebo to match asenapine|Placebo tablets to match asenapine tablets, administered sublingually twice daily
46002693|NCT05034107|Other|Aromatherapy|Approximately 6-7 drops of Ylang-ylang essential oil will be diffused in a common area estimated to be about 300 square feet with temperature of around 25 - 26 degree Celsius and humidity of 50% - 60%. Water and essential oil will be diffused twice a day, each for a duration of 20 min during the respective phases.
46077627|NCT00898417|Drug|carboplatin|
46077628|NCT00898417|Drug|paclitaxel|
46077629|NCT00898417|Genetic|proteomic profiling|
46077630|NCT00898417|Other|laboratory biomarker analysis|
45952406|NCT01244815|Drug|Rescue medication|For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
45952407|NCT00132899|Drug|Methotrexate|Methotrexate and infliximab combination
45660270|NCT05488171|Drug|Placebo|Single oral dose of placebo.
45952408|NCT00132899|Drug|Placebo|Placebo and infliximab combination therapy.
45952409|NCT00140868|Device|Luminal stents|
45813851|NCT05140226|Behavioral|Physical Training|Eight weeks of home-based physical exercise training. Aerobic training will be performed 5 times per week using a foot peddler for a minimum of 30 minutes at a moderate intensity (Borg Exertion Scale: between 4 and 6; pedaling speed: 50 RPM). Strength training will be performed 2 times per week, with 1-3 sets of 10-12 repetitions per exercise. Strength exercises will include training with resistance bands and bodyweight exercises. Participants will be instructed to reduce the intensity of their training if they reach a score of 7 on the Borg Exertion Scale, if oxygen saturation is less than 85%, or if they experience any symptoms. Exercise prescriptions will be developed and monitored by an exercise professional with weekly follow-up meetings and supported with a web application (Physiotec) that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials.
45952410|NCT00140868|Procedure|Minimally Invasive Surgical Bowel Diversion|
45952411|NCT00132938|Drug|telithromycin|
45952412|NCT02955706|Drug|Acetyl-L-Carnitine|TID
45952413|NCT02955706|Drug|Placebo of Acetyl-L-Carnitine|TID
45952414|NCT00132977|Device|Cardiac Resynchronization Therapy|
46077631|NCT00898417|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
46077632|NCT05381363|Drug|Inhaled Interferon α2b|Drug: Inhaled Interferon α2b; 1-2 years old: 1 dose, three times per day; 3-7 years old: 1 dose, four times per day; 7-18 years old: 2 doses, four times per day
45660271|NCT05480137|Procedure|NSE scoring balloon and plain balloon angioplasty|Using NSE scoring balloon or plain balloon in BPA surgery.
46077633|NCT05381363|Other|Standard of Care|Standard of care treatment will be provided based on the New Coronavirus Pneumonia Prevention and Control guideline (9th edition), published by National Health Commission of China
45660272|NCT05480059|Other|A questionnaire|A Questionnaire-based Assessment of the Psychiatric Co-morbidities and Health-related Quality of life in Patients with Irritable Bowel Syndrome
46077634|NCT02753634|Behavioral|Square-stepping exercise|Participants are asked to remember and repeat stepping patterns across a gridded mat as shown to them by an instructor.
46077635|NCT00906529|Drug|Levemir (Detemir) and Novolog (Aspart) Insulin|Will use individualized doses of levemir (detemir) and novolog (aspart) insulin to reach blood glucose goal
46077636|NCT02851589|Biological|PCAR-019 (anti-CD19 CAR-T cells)|
46077637|NCT02851667|Behavioral|Resident training programs|A total of 24 resident training programs such as talks, day camp and thematic activities were delivered in the intervention estate by CFSC from June to November 2011. Each program included an introduction to the concepts of Learning Family and family 3Hs as well as how to promote family 3Hs through learning and communicating with family, delivered by interactive games and workshops.
46077638|NCT00898495|Genetic|loss of heterozygosity analysis|
46077639|NCT00898495|Genetic|polymerase chain reaction|
45660273|NCT05485051|Other|2% chlorhexidine digluconate solution with surface-active agents|Bathing will be performed at least daily using 2% chlorhexidine digluconate solution with surface-active agents on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.); These areas will be bathed according to each center current practice.
45952415|NCT01432041|Behavioral|tailored health education|Health Information via a computer kiosk in the pediatric emergency department
45952416|NCT00133016|Procedure|Amniotomy|
45952417|NCT00141024|Biological|EP HIV-1043|"Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag.~The vaccine is provided in single-use 1.1-mL vials."
45952418|NCT00141024|Biological|EP HIV-1090|DNA plasmid vaccine containing the genes Gag, Pol, Vpr, Nef, Rev, and Env. The vaccine is provided in single-use 1.1-mL vials.
45952419|NCT01244425|Drug|Fibrin Sealant (FS) VH S/D 500 s-apr|Dosage form: spray application; dosage frequency: single application
45952420|NCT01244425|Other|Manual compression|Dosage form: surgical gauze swab; dosage frequency: single application
45952421|NCT00133055|Behavioral|Self-help treatment booklet and telephone support|The Parenting Matters treatment program consisted of a self-help treatment booklet and two telephone coaching calls from a paraprofessional telephone coach at Weeks 2 and 5 of the program. Two booklets were used in the three trials; one addressed sleep issues and the second discipline problems.
45952422|NCT00133055|Behavioral|Usual care by a family physician|Parents in the usual care condition were told to continue with care from their family physician and/or any other treatment recommended by the physician.
45952423|NCT00141063|Drug|Focalin XR|
45952424|NCT00133094|Drug|Simvastin|
45952425|NCT00133094|Procedure|Computer-based decision support technology|
45952426|NCT01154439|Drug|cytarabine|Remission induction therapy: by short i.v. infusion on days 1 and 7. Consolidation therapy: by continuous infusion on days 1-5.
45952427|NCT01154439|Drug|etoposide|Remission induction therapy: by short i.v. infusion, on days 1-7. Consolidation therapy: by short i.v. infusion, on days 1-5.
45952428|NCT01154439|Drug|everolimus|"Remission induction therapy: test dose once a day by mouth, on days 1-21 (21 days).~Consolidation therapy: dose as defined by the cohort once a day by mouth, on days 1-10."
45952429|NCT01154439|Drug|idarubicin|Consolidation therapy: by short infusion i.c. on days 1, 3 and 5.
45952430|NCT01154439|Drug|mitoxantrone hydrochloride|Remission induction therapy: by short i.v. infusion on days 1, 3 and 5
45952431|NCT00133133|Drug|ALGRX 4975|
45952432|NCT01057173|Procedure|Transcatheter Aortic Valve Implantation|Retrograde trans-femoral or trans-subclavian aortic valve implantation with the Medtronic CoreValve System(TM) bio-prosthesis (third generation system, 18 Fr, CE mark approved)
46077640|NCT00898495|Genetic|polymorphism analysis|
45660274|NCT05485051|Other|Usual Baths|Bathing will be performed at least daily using soap and water (performed according to the current practice in each center) on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.); These areas will be bathed according to each center current practice.
45660275|NCT05484973|Device|AMMA Portalbe Scalp Cooling System|AMMA Portalbe Scalp Cooling System AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center andat home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
45952433|NCT01057173|Procedure|Surgical Aortic Valve Replacement|Conventional surgical aortic valve replacement with a bio-prosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest
45952434|NCT00133172|Drug|Tacrolimus|IV
45660276|NCT05479903|Procedure|acupuncture|Manual acupuncture or electro-acupuncture by experienced acupuncturists for patients
45660277|NCT05479903|Behavioral|computerized cognitive training system|One-on-one cognitive training by an experienced cognitive therapist, combined with an existing computerized cognitive training system
45813852|NCT05140226|Behavioral|Cognitive-Physical Training|Eight weeks of home-based cognitive and physical training. Cognitive training sessions will be performed 5 times per week using the Brain HQ platform (Posit Science; San Francisco, CA, USA) and will have a duration of approximately 60 minutes. The cognitive training program will be tailored by using the Personal Trainer function which presents an automated sequence of exercise levels to participants based on selected exercises. Participants will have identical sessions initially, but schedules will diverge as participants progress and as the algorithm considers their individual performance history. The Personal Trainer program will be customized to the abilities of each user and will include a focus on the following domains: sustained attention, executive function, short and long-term memory, and anxiety and depression. Participants in this group will also engage in the same exercise training intervention as participants in the Physical Training group.
45952435|NCT00133172|Drug|mycophenolate mofetil|IV
45952436|NCT00133172|Drug|Prednisone|IV
45813853|NCT05588089|Other|Training group|"For the experimental group, Personal Information Form for Fathers and Infant Care Questionnaire were applied to the fathers in the clinic after birth as a pre-test. In the clinic, baby care training was given to fathers practically in 30-35 minutes. After the applied training, the Baby Care Training Program Content prepared by the researchers was given to the fathers."
45952437|NCT00842283|Other|skin tissue sample|skin tissue sample
45813854|NCT05588011|Device|Terumo|A low pressure oxygenator (Terumo) will be used during cardiopulmonary bypass.
45813855|NCT05588011|Device|LivaNova|A high pressure oxygenator (LivaNova) will be used during cardiopulmonary bypass.
45952438|NCT00133211|Procedure|Radiofrequency ablation|Pulmonary vein isolation
45952439|NCT00141141|Drug|Atorvastatin|
45660278|NCT05479903|Behavioral|aerobic exercise|Patients are trained by experienced physical therapists with the help of elastic bands and physical therapy devices
45660279|NCT05479903|Behavioral|tranditional cognitive training|One-on-one cognitive training with an experienced cognitive therapist, combined with traditional cognitive training methods (e.g., balls, cards, counting, daily conversation, etc.)
45660280|NCT05479903|Other|Conventional treatment|Treatment of underlying disease and stroke according to guidelines, as well as necessary care and rehabilitation
45660281|NCT05484817|Diagnostic Test|Assessment of cardiovascular risk factor, endocrine hormones and related biomarker|Cardiovascular risk factors: glycated hemoglobin/C-peptide/continuous glucose monitoring/blood pressure, blood lipids, uric acid, microalbumin test, etc. Endocrin hormones: bone metabolism, sex hormones, adrenal and pituitary hormones, and related biomarkers
45660282|NCT05479825|Procedure|inflation- deflation line combined with ICG fluorography|Identification of the intersegmental plane using inflation- deflation line combined with ICG fluorography under the status of tubeless
45660283|NCT05484583|Drug|Durvalumab + carboplatin/cisplatin + etoposide|Induction period (3 weeks as a cycle, 4 cycles of administration): Durvalumab + carboplatin/cisplatin + etoposide, intravenous drip
45813856|NCT05587933|Procedure|cholecystectomy|cholecystectomy
45952440|NCT00141141|Drug|Simvastatin|
45952441|NCT00133250|Drug|Abciximab|Abciximab bolus and infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 10 mg abciximab. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
45952442|NCT00133250|Other|Placebo Heparin Sodium|Placebo bolus plus infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 3000 U Heparin. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
45952443|NCT00144495|Drug|recombinant human erythropoietin|3600IU(s.c.)/week for 7 weeks and 54000IU(s.c.)/week for 5 weeks
45952444|NCT00144495|Drug|recombinant human erythropoietin|36000IU(s.c.)/week for 12 weeks
45952445|NCT00133289|Device|Pacemaker with Automatic Capture|
45952446|NCT00144534|Drug|MRA (Tocilizumab)|8mg/kg/4 weeks
45952447|NCT00133328|Drug|valsartan|
45952448|NCT00141180|Drug|CP-481,715|
45952449|NCT00133367|Drug|Tacrolimus|Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
45952450|NCT00133367|Drug|Sirolimus|Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
45952451|NCT00133367|Drug|G-CSF|Given starting on day 5 after transplant until the subjects white blood cell count recovers.
45952452|NCT00133367|Drug|Antithymocyte globulin|Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
45660284|NCT05484583|Radiation|Consolidation radiotherapy|Consolidation radiotherapy period: radiotherapy for primary chest lesions + oligometastatic lesions.
46077641|NCT02753478|Other|intracoronary infusion with saline on 22 and 4°C|"Routine primary percutaneous intervention will be commenced. Patient will be asked to participate in the study.~Before reperfusion, saline on room temperature will be infused though the occlusion in the infarct related artery using an over the wire balloon catheter during 10 minutes. The balloon will be inflated to prevent reperfusion in that phase. After 10 minutes the balloon will be deflated allowing reperfusion and infusion with saline on 4°C will be continued for 10 minutes. After this, a coronary stent will be placed."
45660285|NCT05484583|Drug|Durvalumab|Maintenance phase (administered every 4 weeks): Durvalumab intravenous infusion
45813857|NCT05587933|Drug|Antispasmodic|Antispasmodic
45952453|NCT00133367|Drug|Thymoglobulin|Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
45952454|NCT00133367|Drug|Fludarabine|Given intravenously for six days prior to transplant (days 8,7,6,5,4,3).
45952455|NCT00133367|Drug|Melphalan|Given intravenously on day 2 before transplant.
45952456|NCT00141258|Drug|pregabalin|
45813858|NCT02200705|Device|Ice-Sense3TM/ ProSenseTM|
45952457|NCT00403910|Drug|Canrenone|
45952458|NCT00141336|Drug|Pregabalin|
45952459|NCT00133406|Drug|Glutamine|0.8gm/kg, ie up to a total daily dose of 16.2gm/day,with juice daily for 10 days
45952460|NCT00133406|Drug|Vitamin A|100,000 IU for children under 12 months of age (or placebo) and PO 200,000 IU for children at least 12 months of age (or placebo), both q months for 1 year at 0, 4 and 8 months.
45952461|NCT00133406|Drug|glycine|0.4gm/kg; ie up to 8.3gm/d, with juice daily for 10 days
45952462|NCT00133406|Drug|zinc|40 mg twice weekly for 12 months
45952463|NCT00144573|Drug|MRA(Tocilizumab)|
45952464|NCT00133445|Biological|DTaP-Hep B-IPV Vaccine|U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.
45952465|NCT00133445|Biological|Monovalent Hep B Vaccine|U.S. licensed monovalent hepatitis B vaccine; each 0.5 mL dose contains 10 mcg of hepatitis B surface antigen absorbed on 0.25 mg aluminum hydroxide. The vaccine is given to infants as a 0.5 mL dose intramuscularly.
45952466|NCT00133445|Drug|Placebo|Commercially prepared normal saline. The dose will be 0.5 mL administered intramuscularly.
45952467|NCT00141375|Drug|Pregabalin|
45952468|NCT00133484|Biological|Anthrax vaccine absorbed made from Bacillus anthracis (AVA)|
45952469|NCT00133484|Biological|Recombinant protein antigen (rPA) made from Bacillus anthrax|
46077642|NCT00783705|Other|placebo|Given orally
46077643|NCT00783705|Drug|inositol|Given orally
45660286|NCT05479747|Drug|post operative analgesics|post-operative pain killer
45660287|NCT05487937|Other|Use of Toleriane Ultra to relieve face allergic skin|The product developed to restore the natural skin barrier and rebalance skin immune system is a white cream and is applied on the face by a slight massage under normal conditions of use twice daily for 28 days.
45660288|NCT05487781|Combination Product|Tirfostina/L-Carnitina|Estudio clínico fase 1 para describir la seguridad biológica y la farmacocinética de la tirfostina AG-17
45660289|NCT05487469|Drug|Thymosin Alpha1|Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead
45660290|NCT05487469|Other|Blank Control|the Control group did not receive Thymosin alpha 1 or any placebo.
45660291|NCT05479669|Diagnostic Test|Echocardiography|Transthoracic echocardiograms will be performed at inclusion. Echocardiographic parameters that will be evaluated are measures of atrial size (including left atrial volume, right atrial dimensions, left ventricular function and dimensions (including left ventricular dimensions, septal wall thickness, posterior wall thickness, systolic function, Simpson biplane left ventricular ejection fraction), parameters of diastolic dysfunction (including E, A, E/A ratio, deceleration time, E' and E/E' ratio) and valve (dys)function.
45676572|NCT01864109|Drug|Mesna|Mesna 2,100 mg/m2 (or 70 mg/kg if < 10 yrs of age) administered intravenously in concordance with institutional pediatric administration guidelines.
45813859|NCT02018263|Drug|Cocaine hydrochloride|
45813860|NCT02018263|Behavioral|Exercise|
45952470|NCT00133484|Biological|Recombinant protein antigen (rPA) made from Escherichia coli|
45952471|NCT00144612|Drug|MRA(Tocilizumab)|8mg/kg/2weeks
45813861|NCT02018263|Drug|Nicotine|
45813862|NCT05442073|Other|PEEP adjustment|adjusting PEEP about 3-5cmH2O (increase or decrease)
45813863|NCT02649608|Drug|0.04 mg Lu AE04621|0.04 mg dose group
45813864|NCT02649608|Drug|0.08 mg Lu AE04621|0.08mg dose group
45813865|NCT02649608|Drug|0.2 mg Lu AE04621|0.2 mg dose group
45952472|NCT00133523|Biological|Cold-adapted live attenuated influenza virus vaccine, trivalent|Live-attenuated influenza vaccine; single annual dose administered as an intranasal spray.
45952473|NCT00133523|Other|Placebo|Physiological saline administered as an intramuscular injection.
45952474|NCT00133523|Biological|Trivalent inactivated influenza vaccine|Inactivated influenza vaccine; single annual dose administered as an intramuscular injection..
45952475|NCT00133523|Biological|Trivalent inactivated influenza vaccine|Inactivated influenza vaccine; single annual dose administered as an intramuscular injection.
45952476|NCT00133523|Other|Placebo|Normal allantoic fluid administered annually as an internasal spray.
45952477|NCT00144651|Drug|MRA(Tocilizumab)|8mg/kg/4 weeks for 1 year
45952478|NCT00133562|Drug|Alanyl-glutamine|
45952479|NCT00133562|Drug|Glycine|
45952480|NCT00144690|Drug|E2007 (perampanel)|
45952481|NCT00144690|Drug|Placebo|
45952482|NCT00404391|Drug|Hydrocodone/Acetaminophen Extended Release|1 tablet every 12 hours
45952483|NCT00404391|Drug|Hydrocodone/Acetaminophen Extended Release|2 tablets every 12 hours
45952484|NCT00404391|Drug|Placebo|2 tablets every 12 hours
45952485|NCT00144729|Procedure|Bone marrow transplant|
45952486|NCT04726904|Procedure|Sacral neuromodulation in conventional implantation technique|Sacral neuromodulation is implanted with the patients in a prone position, then the insert point of the needle is decided according to anatomical landmarks; afterwards, the lead will be inserted.
45952487|NCT00404469|Procedure|peritendinous corticosteroid injections|1 ml of40mg/ml methylprednisolone acetate at 0 and 4 weeks. 2 week observational
45660292|NCT05479669|Diagnostic Test|24 hour Holter monitoring|24-hours Holter monitoring will be used to determine markers of increased risk of ventricular arrhythmias, such as non-sustained ventricular tachycardias, and ventricular premature beats and doublets. Also the presence and pattern of AF and runs of supraventricular tachycardias are determined.
45660293|NCT05479669|Diagnostic Test|Cardiac Magnetic Resonance Imaging|Multiple short-axis cine images will be acquired throughout the entire LV with a steady-state free precession sequence. Left ventricular volumes, ejection fraction and myocardial mass will be measured on the short-axis stacks at end diastolic and end systolic frames. Ten to 15 minutes after an intravenous bolus injection of a gadolinium-based contrast agent late gadolinium enhancement will be performed with a segmented inversion recovery gradient-echo sequence, using the same image orientation as in the short-axis stacks. The presence, location and morphology of myocardial fibrosis will be described. The extent of myocardial scar will be quantified using computer-assisted planimetry and expressed as a percentage of left ventricular mass. Pre- and post-contrast T1 measurements will be obtained using a single-shot modified Look Locker inversion recovery sequence. Extracellular volume (a measure of diffuse myocardial fibrosis) will be quantified.
45676573|NCT01864109|Drug|Dexrazoxane|Dexrazoxane 375 mg/m2 intravenously over approximately 15-30 minutes and as clinically indicated. To be administered immediately prior to doxorubicin.
45952488|NCT00404469|Procedure|eccentric decline squat training|eccentric decline unilateral squats performed twice daily. for 12 weeks
45676574|NCT01864109|Drug|G-CSF|G-CSF-to be administered after the completion of appropriate chemotherapy cycles as per institutional guidelines.
45813866|NCT02649608|Drug|0.4 mg Lu AE04621|0.4 mg dose group
45813867|NCT02649608|Drug|0.6 mg Lu AE04621|0.6 mg dose group
45813868|NCT02649608|Drug|0.8 mg Lu AE04621|0.8 mg dose group
45813869|NCT02649608|Drug|1.0 mg Lu AE04621|1.0 mg dose group
45813870|NCT02649608|Drug|1.2 mg Lu AE04621|1.2 mg dose group
45813871|NCT02168946|Drug|Vabomere|Vabomere for IV injection, administered as a 2 g/2 g dose
45813872|NCT02168946|Drug|Best Available Therapy|Antibiotic(s) chosen by Investigator
45952489|NCT00404469|Procedure|heavy slow resistance training|Heavy slow resistance training for knee extensors. 3/week. total of 12 weeks
45952490|NCT00133601|Behavioral|Cognitive Behavioral Therapy|CBT-I including sleep restriction, stimulus control, sleep hygiene instructions and one session of cognitive therapy devoted to catastrophic thoughts about the consequences of insomnia.
45952491|NCT00144768|Drug|laronidase|dose of 0.58mg/kg body weight IV every week
45952492|NCT00144807|Drug|rituximab|
45952493|NCT00144807|Drug|doxorubicin|
45952494|NCT00144807|Drug|cyclophosphamide|
45952495|NCT00144807|Procedure|autologous stem cell transplantation|
45952496|NCT00133640|Drug|cholecalciferol|
45952497|NCT00133640|Behavioral|Physiotherapy|
45952498|NCT04726917|Behavioral|Pulmonary rehabilitation|Patients qualified for rehabilitation were assessed for stress levels as well as symptoms of anxiety and depression before rehabilitation began
45952499|NCT00133718|Drug|Combined lifestyle intervention and optimisation of pharmacological treatment|"6 months non-pharmacological treatment, 18 months with polypharmacy for glucose control (metformin, repaglinide/glimepiride, pioglitazone or insulin)~standard care"
46077644|NCT04268459|Device|Provox prosthesis exchange|Each patient post laryngectomy will be randomly assigned to one arm of intervention. The voice prosthesis exchange in all patients will be performed in local anaesthesia. The microbiological samples with cotton swabs will be collected from tracheoesophageal fistula on prosthesis exchange. The clinical evaluation and patients satisfaction from prosthesis usage will be performed on each exchange.
45676575|NCT01862315|Drug|Floxuridine (FUDR)|
45676576|NCT01862315|Drug|dexamethasone|
45676577|NCT01862315|Drug|Gemcitabine|
45676578|NCT01862315|Drug|Oxaliplatin|
45676579|NCT01862315|Other|MRI|
45676580|NCT01862315|Other|Research blood draws|These are optional
45813873|NCT02649842|Device|TECNIS Toric Models ZCT450, ZCT525 or ZCT600|Approved toric intraocular lens
45813874|NCT02650856|Drug|Group 1 Tranexamic Acid|2 gr of tranexamic acid will be applied on the surgical site.
45813875|NCT02650856|Biological|Group 2 Platelet rich plasma|16ml of platelet rich plasma will be applied of the surgical site
45952500|NCT01244191|Drug|Tivantinib|Tivantinib 720 mg daily as 3 x 120 mg oral tablets given twice a day
45952501|NCT01244191|Drug|Placebo|Tivantinib Placebo tablets given twice a day
45952502|NCT01244191|Drug|Erlotinib|Erlotinib 150 mg oral tablets, given once a day
45952503|NCT00404508|Drug|Hydralazine and magnesium valproate|
45952504|NCT00133757|Drug|Bupropion SR|
45952505|NCT00144846|Drug|albuterol sulfate inhalation aerosol|
45952506|NCT00133796|Drug|Herceptin|IV
45952507|NCT00133874|Drug|SB-275833 ointment, 1%|
45952508|NCT00144885|Behavioral|Modification of therapy|Modification of the surgery date if adapted, modification of the antibiotics if adapted, based on RMI results
45952509|NCT00141414|Drug|Pregabalin|
45813876|NCT02168478|Drug|Neo-Synalar Cream|Approximately 0.2 g of test material is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
45813877|NCT02168478|Other|Sodium Lauryl Sulfate Aqueous Solution (0.40%)|Approximately 0.2 ml of the positive , 0.40% aqueous solution of sodium lauryl sulfate is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
45952510|NCT00133913|Procedure|Phlebotomy|Peripheral blood draws for testing of circulating tumor cells
45952511|NCT00145002|Drug|VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis|
45952512|NCT00145002|Drug|biweekly-CHOP with G-CSF and intrathecal prophylaxis|
45952513|NCT00141492|Drug|Androgel (testosterone gel)|
46077645|NCT05136222|Other|Intervention polysomnography|Please refer to 'Arms: Intervention' section.
45952514|NCT00141531|Drug|Apaziquone|"Apaziquone (EOquinTM) 4 mg/40 mL was administered by intravesical instillation once a week for 6 consecutive weeks.~In addition, patients with CIS were to receive further maintenance therapy of 3 weekly apaziquone (EOquinTM) instillations at 3, 6, and 12 months from the date of histological diagnosis."
45952515|NCT01244035|Drug|Treatment A|MK-8266 1.3 mg orally twice daily (BID, 1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
45952516|NCT01244035|Drug|Treatment B|MK-8266 0.1 mg orally administered every 2 hours as frequent divided dosing (FDD, total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
45952517|NCT01244035|Drug|Treatment C|Placebo to match MK-8266 Treatments A and B orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
45952518|NCT01244035|Drug|Treatment D|MK-8266 orally twice daily (1 mg in the morning and 0.4 mg 8 hours later) plus placebo to match Treatment E on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
45952519|NCT01244035|Drug|Treatment E|MK-8266 0.2 mg orally every 2 hours (total dose of 1.4 mg) plus placebo to match Treatment D on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
45952520|NCT01244035|Drug|Treatment F|Placebo to match MK-8266 Treatments D and E orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
45952521|NCT00134069|Drug|sorafenib tosylate|Given orally
45952522|NCT00134069|Drug|cetuximab|Given IV
45952523|NCT00134069|Drug|irinotecan hydrochloride|Given IV
45952524|NCT00141570|Drug|esterified estrogens 0.625 mg and methyltestosterone 1.25 mg|
45952525|NCT00134108|Behavioral|Cognitive Behaviour Therapy|
45952526|NCT00141609|Drug|Slow Sodium|
45952527|NCT00134147|Drug|Inhaled Insulin|
45952528|NCT00145080|Behavioral|Disease Management Assessment|
45952529|NCT00403988|Drug|Oxaliplatin|
45952530|NCT00403988|Drug|vinorelbine|
45952531|NCT00405600|Procedure|Device used in surgery with or without instrumentation|Infuse Bone Graft BMP-2, Large Kit will be used in all surgeries. Spine surgeries will be either instrumented or uninstrumented.
45952532|NCT00134186|Drug|motexafin gadolinium|
45458478|NCT01351844|Behavioral|Education and exercise intervention|An occupational therapist who has clinical experience in hand therapy for breast cancer patients with arthralgia syndrome, will review 4-5 exercises which improve hand range of motion and reduce hand stiffness.
45660294|NCT05479669|Diagnostic Test|99mTc-HDP scan|Patients will receive a 99mTc-HDP scan. 3 hours after the technetium 99m-hydroxymethylene diphosphonate bolus injection, imaging will be performed using a gamma-camera equipped with a collimator which guides individual gamma-rays emitted by the radionuclide. For planar imaging, a collimator will be used to transfer only those gamma-rays which pas in a perpendicular course. Sequentially, a SPECT-CT will be performed in the same session to improve sensitivity. SPECT/CT will be performed on a SPECT/CT dual head gamma camera system. SPECT images will be acquired using a 128 x 128 matrix, 180 degrees of rotation, 64 views, 15s per view. Visual image analysis will be performed by two blinded and experienced nuclear medicine physicians. Data will be scored according to a routine scoring system on a scale from 0 (no cardiac uptake of 99m technetium and normal bone uptake) to 3 (high cardiac uptake, higher than bone uptake).
45813878|NCT02168478|Other|Saline|Saline is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
45813879|NCT00367874|Drug|Buprenorphine|
45952533|NCT00141648|Drug|Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.|Given intravenously on days 1,11,43: Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2. Given orally on days 1-5,22-27: Pednisolone 50mg/m2
45952534|NCT00141648|Radiation|Radiotherapy|Total 45 Gy in 25 fractions
45660295|NCT05479669|Diagnostic Test|ECG|A 12-lead electrocardiogram will be performed at the 1-year and 2-year follow-up visit to determine the heart rhythm and heart rate.
45660296|NCT05484427|Other|Telemedicine|Replacement of the regullar meeting with diabetologist by remote communication only
45660297|NCT05484271|Procedure|Rotator cuff repair|The patients received the arthroscopic rotator cuff repair.
45813880|NCT00367874|Drug|Valproate|
45813881|NCT05100836|Device|Impella 5.5|Impella 5.5 mechanical circulatory support
45813882|NCT00367562|Drug|ENALAPRIL VALSARTAN METHYLPREDNISONE|
45813883|NCT02302976|Drug|cocaine hydrochloride|
45952535|NCT00134225|Device|Muscle Pattern Recognition (MPR)|
45952536|NCT00405678|Behavioral|Exercise Training|Subjects receiving chemo with exercise training
45952537|NCT00405678|Behavioral|Chemo only|Subjects receiving chemo only
45952538|NCT00134342|Other|T-SPOT TB ELISPOT test|ELISPOT test for detecting T cell responses to tuberculosis antigens.
45813884|NCT02302976|Drug|exenatide|
45813885|NCT02302976|Drug|placebo|
45813886|NCT05075564|Drug|Part 1 ES002023|ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
45952539|NCT00141687|Procedure|Early ECV between 34 0/7 and 35 6/7 weeks|Early external cephalic version between 34 0/7 and 35 6/7 weeks of gestation
45952540|NCT00141687|Procedure|Delayed ECV at or after 37 0/7 weeks|Delayed external cephalic version at or after 37 0/7 weeks of gestation
46002694|NCT04645485|Biological|Nebulization of autologous non-hematopoietic peripheral blood stem cells (NHPBSC).|Participants received the investigational therapy through compressor (jet) nebulization, in two doses divided on Days 0 and 1. Each dose contains 10 mL of peripheral blood-derived stem cells CD45-/CD90+/CD133+.
46002695|NCT05030792|Other|Attention-restorative therapy (ART)-based virtual reality (VR)|The ART-based VR intervention will be provided using an Oculus Go™ which is a commercially available, all-in-one VR headset with a handheld controller.
46002696|NCT04636866|Other|NO intervention|NO intervention
45453914|NCT01338428|Behavioral|Brochure|Current 'standard of care' at Canadian universities. Invitation to take and read brochures on sexual assault selected from those available on their Canadian university campus. All sites' brochures include general information on sexual assault and 'date-rape' drugs and post-rape legal and medical advice. The research assistant (RA) will ask the participants to take brochures, read them over, and to ask any questions they may have. Questions will be answered in a group setting and the participant will take home any brochures that she selected. Interaction between participants and the RA on the topic will be limited to 10-15 minutes and will be audio recorded for verification.
45813887|NCT05075564|Drug|Part 2 ES002023|ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
45813888|NCT05073692|Drug|SU|Exposure to the class of drugs known as Sulfonylureas (SU)
45813889|NCT05073692|Drug|DPP4|Exposure to the class of drugs known as Dipeptidyl peptidase-4 inhibitors (DPP4)
45813890|NCT05073692|Drug|SGLT2i|Exposure to the class of drugs known as Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
45813891|NCT05073692|Drug|GLP-1RA|Exposure to the class of drugs known as Glucagon-like peptide-1 receptor agonists (GLP-1RA)
45813892|NCT05073692|Drug|SGLT2i or GLP-1RA|Exposure to either SGLT2i or GLP-1RA
45813893|NCT05073692|Drug|Linagliptin (DPP4)|Exposure to agent Linagliptin (DPP4)
45813894|NCT05073692|Drug|Exenatide (GLP-1RA)|Exposure to agent Exenatide (GLP1-RA)
45813895|NCT05073692|Drug|Liraglutide (GLP-1RA)|Exposure to agent Liraglutide (GLP-1RA)
45813896|NCT05073692|Drug|Empagliflozin (SGLT2i)|Exposure to agent Empagliflozin (SGLT2i)
45813897|NCT05073692|Drug|Glimepiride (SU)|Exposure to agent Glimepiride (SU)
45813898|NCT05073692|Drug|Glipizide (SU)|Exposure to Glimepiride (SU)
45813899|NCT05073692|Drug|Glimepiride (SU) or Glipizide (SU)|Exposure to agent Glimepiride (SU) or Glipizide (SU)
45952541|NCT04710810|Other|umbilical cord blood mononuclear stem cells|UCB samples (70-130 ml of initial volume) were aseptically drained in blood-collection bags with 35 mL of citrate phosphate dextrose (CPDA-1) anticoagulant. Red blood cell-depleted/plasma-reduced nucleated cells were isolated by sedimentation in dextran-40, resuspended in autologous plasma with 10% dimethylsulfoxide and 1% dextran-40, and aliquoted in 3.8 ml vials with target doses of 3.0±0.2 x 10⁶ cells per vial. Vials were cooled to -90⁰C, quarantined in the vapor phase of liquid nitrogen. Tested for HIV-1/2, hepatitis B and C, HTLV-1/2, HSV-1 and -2, CMV, syphilis, and sterility. Characterized by AB0/Rh, CD34/CD45-positive cell content. Before injection sample thaws in the water bath at +37⁰C and washes from an excess amount of DMSO in 40 mL of physiological saline containing 2.5% human serum albumin and 5% dextran-40. After centrifugation and supernatant withdrawal, the UCB resuspends in 40 ml of the same solution at a target dose of 250±10 x 10⁶ viable cells per sample.
46002697|NCT05016674|Device|LipoLife system|Abdominal Laser-Assisted Liposuction
45453915|NCT00383578|Drug|Vildagliptin 100 mg qd|
45453916|NCT00383578|Drug|Metformin 1500 mg daily|
45813900|NCT05073692|Drug|SU or DPP4 (excluding saxagliptin and alogliptin)|Exposure to either SU or DPP4 excluding Saxagliptin and Alogliptin
45813901|NCT05073692|Drug|Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)|Exposure to either Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
45813902|NCT02244164|Drug|Incretinomimetics|
45813903|NCT02244164|Drug|DPP-4 inhibitors|
45813904|NCT05071976|Diagnostic Test|ICG-NIR angiography|Capture NIR video of flap site beginning at time of ICG injection. At time of subjective peak intensity, capture video of flap and recipient wound bed. Measure rate of ICG egress from the global flap at 60, 120, and 180 seconds after initial dye injection from intraoperative video
45813905|NCT02152670|Drug|Methylphenidate|
45813906|NCT02152670|Drug|Alpha Methyl Para Tyrosine (AMPT)|
45813907|NCT02152670|Other|[11C]PHNO|
45813908|NCT02152670|Other|[11C]raclopride|
45813909|NCT02652416|Drug|BI 1026706|oral administration
45813910|NCT02652416|Drug|Placebo|placebo
45813911|NCT02028806|Drug|mFOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
45813912|NCT01756118|Drug|BEZ235|A minimum of 3 dose levels
45813913|NCT04339712|Drug|Anakinra|In case of diagnosis of MAS treatment with anakinra
45813914|NCT04339712|Drug|Tocilizumab|In case of diagnosis of immune dysregulation treatment with tocilizumab
45813915|NCT04909970|Other|Self-hypnosis|Self-hypnosis training during 8 weeks and one daily self-hypnosis session during 8 weeks
45952542|NCT00134420|Drug|Nutropin AQ|Growth Hormone (Nutropin AQ) treatment given to Group 1 immediately Growth Hormone (Nutropin AQ) treatment given to Group 2 after one year observation
45813916|NCT04909970|Other|Control (Waiting list)|Usual practice during the first 16 weeks. At the end of study, the participant will practice Self-hypnosis training during 8 weeks and one daily self-hypnosis session during 8 weeks
45813917|NCT02656160|Drug|Placebo|Placebo 3 hrs before sleep
45952543|NCT00134420|Procedure|Arginine and Clonidine Stimulation Testing|This testing was done to determine growth hormone status prior to starting treatment.
45952544|NCT00134420|Procedure|Growth Factors Laboratory Testing|This involved assessment of growth factors such as IGF#1 before treatment was initiated.
45813918|NCT02656160|Drug|Dalfampridine|Dalfampridine 10 mg extended release 3 hrs before sleep
45952545|NCT00134420|Procedure|Neuropsychological Testing|This testing was done prior to treatment and at the end of treatment.
45952546|NCT00152256|Drug|Asoprisnil|Asoprisnil 10 mg Tablet, oral Daily for 6 months
45952547|NCT00152256|Drug|Asoprisnil|Asoprisnil 25mg Tablet, oral Daily for 6 months
45952548|NCT00152256|Drug|Placebo|Placebo Tablet, oral Daily for 6 months
45952549|NCT00134459|Drug|Bifeprunox|
45813919|NCT02684396|Drug|TAK-648|TAK-648 Solution
45813920|NCT02684396|Drug|TAK-648 Placebo|TAK-648 placebo-matching solution
45813921|NCT02657252|Drug|Glucose|Sclerotherapy of telangiectasis in one lower limb.
45813922|NCT02657252|Drug|Polidocanol with Glucose|Sclerotherapy of telangiectasis in one lower limb.
45813923|NCT02657564|Drug|Polyethylene glycol (PEG)|Participants receive blood tests for serum creatinine and electrolytes (Ca, P, Cl, Mg, Na, K) before and after taking polythylene glycol.
45813924|NCT04740086|Procedure|Calcium alginate hydrogel|"The external and internal fistulous orifice and fistulous tract were explored without applying any product, including hydrogen peroxide or povidone-iodine.~The seton was removed and FT cannulation was performed using a needle for cleaning with a gauze impregnated with saline.~Calcium chloride was applied through the EFO until it exits through the IFO, and then the IFO was obturated.~Alginate was applied, and the pressure at the IFO was stopped, until the alginate solution partial exits through the IFO.~The IFO was closed with a 3/0 braided resorbable suture.~The EFO was removed with an electric scalpel and closed with a 3/0 braided resorbable suture."
45952550|NCT00134459|Drug|Placebo|
45952551|NCT00141804|Drug|Sirolimus|
45952552|NCT00134498|Drug|torcetrapib/atorvastatin|
45952553|NCT00134498|Drug|atorvastatin|
45813925|NCT04857008|Device|BNT001|BNT001 is a commercially-available, prescription-only, software / medical device in the form of a digital application (digital app) for use on the participant's mobile device which delivers 10-sessions on cognitive behavioral therapy for cancer patients.
45813926|NCT04796246|Other|Leap Motion Controller|Training with the Leap Motion Controller instrument will be carried out first for 5 minutes, for a presentation and interaction of the virtual immersion with it, in the initial meeting. After the second meeting, the attendance protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games it was adopted about 2 minutes of rest.
45952554|NCT00141843|Genetic|ReFacto AF|
45952555|NCT00141843|Genetic|B-Domain deleted Recombinant Factor VIII|
45952556|NCT00141843|Genetic|BDDrFVIII|
45952557|NCT00134537|Device|Interspinous process and dynamic stabilization|Interspinous process and dynamic stabilization
45952558|NCT00134537|Device|Conservative Care|Medication, exercise and spinal injections
45952559|NCT00141882|Drug|memantine|
45952560|NCT00134576|Behavioral|Computer Assisted Education for Behavioral Change|TLC-Detect will provide subjects in the intervention group with information about each diagnosed mental health disorder. TLC-Detect will then give the Treatment Module and will tell the intervention subjects that it will call back in one month for a follow-up or the next week if a subject is comorbid with other disorders.
45952561|NCT00152295|Drug|Asoprisnil/Premarin|10 mg (2-5mg tablets) asoprisnil and 0.625 mg Premarin tablets, oral daily for 6 months
45952562|NCT00134615|Behavioral|RQP patient health education module|
45952563|NCT00152373|Drug|Levetiracetam|
45952564|NCT00134654|Drug|Premarin|Group A: 1.25mg once a day Group B: 1.25mg three time a day Group A has been closed and participants have been given the option of enrolling in Group B. Treamtment can continue until disease progression or serious side effects.
45952565|NCT00141960|Drug|Famotidine|
45952566|NCT00141999|Biological|hepatitis B vaccine|
45952567|NCT00134693|Drug|Prednisolone|
45952568|NCT00134693|Drug|SB-681323|
45952569|NCT00152412|Drug|Levocetirizine oral solution|
45952570|NCT00134732|Biological|Live attenuated human rotavirus vaccine|
45952571|NCT00142038|Drug|Docetaxel|
45952572|NCT00142038|Drug|Capecitabine|
45952573|NCT00134771|Drug|Nutrient enriched infant formula|
45952574|NCT00152451|Drug|Seletracetam (ucb 44212)|
45952575|NCT00134810|Biological|Botulinum toxin type A|
46077646|NCT05136222|Other|Sham polysomnography|Please refer to 'Arms: Control' section.
46077647|NCT04047420|Drug|TAF/EVG Insert|TAF/EVG Insert (20/16 mg) administered rectally by study staff
45453917|NCT01341704|Biological|MSP3-LSP/AlOH|"30 µg of test vaccine MSP3-LSP/AlOH, administered by subcutaneous route according to the following schedule:- Primary administration: Three doses administered at 4 weeks interval: D0, D28 (± 2 days), D56 (± 4 days)~Secondary administration (Boost):~Year 1: One dose 3 months after the third dose Year 2: Two doses, given exactly one year after the date corresponding to the third dose and the first boost given during Year 1"
45453918|NCT01341704|Biological|Verorab Vaccine|The Verorab rabies vaccine will be given as control for the primary series of the experimental vaccine. It consists of inactivated rabies virus produced in vero cells (Wistar Rabies PM/W138 1503-3M (inactivated). Manufacturer SANOFI PASTEUR SA. Presentation is 0.5 ml per dose in a pre-filled syringe.
45660298|NCT05479435|Behavioral|Blue Prescription Exercise Program|After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. It will be followed up with the blue prescription program once a week for 12 weeks and will be re-evaluated at the end of the 12th week. Motivation and support will be provided according to the blue prescription philosophy, home exercise program, physical activity selection, obstacles to the activity are discussed, the participant will be asked to determine the appropriate program and keep an activity diary. Throughout the study, the participant will be able to communicate with the physiotherapist by any method (phone, SMS, email).
45660299|NCT05479435|Behavioral|Video Based Home Exercise Program|After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. A video exercise program will be given in the format and method desired by the participant. It will be evaluated again at the end of the 12th week.
45660300|NCT05479435|Behavioral|Supervised Group Exercise Program|DM and physical activity training will be given after the assessment, the benefits of the exercise will be explained and these will be given as a brochure. Exercises will be done with a physiotherapist for 12 weeks 3 days a week and will be evaluated again at the end of the 12th week.
45660301|NCT05479357|Drug|Oxytocin|10 iu will be given intravenously.
45660302|NCT05479357|Drug|Carbetocin|100 micrograms will be given intravenously.
45660303|NCT05487391|Drug|QL1706 injection|QL1706(5mg/kg Q3W IV) concomitantly with Platinum-based chemotherapy
45813927|NCT04796246|Other|Conventional Physiotherapy|The conventional physiotherapy intervention will be based on the same activities developed (MMSS movements) of the IG: - First, attach pins with magnets with moving disc and after 1 minute and 25 seconds remove flower petals from inside a tube. The movements performed will be fine motricity, related to the tweezers handling (thumb and forefinger), alternating hands after 2 minutes and 30 minutes of play; - Hitting your hands on suddenly raised rulers, performing bilateral flexion / extension movements of the wrist simultaneously and alternating hands after 2 minutes and 30 minutes of play.
45813928|NCT04339400|Drug|TQ05105|TQ05105 is a JAK2 inhibitor.
45660304|NCT05487391|Drug|Vinorelbine Tartrate|Vinorelbine 25mg/m2（D1、D8）Q3W IV, 2-4 cycles
45660305|NCT05487391|Drug|Paclitaxel|Paclitaxel 175mg/m2（D1） Q3W IV, 2-4 cycles
45660306|NCT05487391|Drug|Cisplatin|Cisplatin 75mg/m2（D1）Q3W IV, 2-4 cycles
45813929|NCT04693832|Device|5inD|Interactive Mobile Application which is includes five different game (mandala, puzzle, tetris, music, breath exercise)
45813930|NCT02684630|Device|Trima Accel System|Platelet Apheresis Procedure
45813931|NCT04670042|Device|SPRINT® Peripheral Nerve Stimulation (PNS) System (510k Cleared)|Same as Arm Description.
45813932|NCT04739618|Drug|Keytruda Injectable Product|PD-1 inhibitor antibody
45813933|NCT04739618|Drug|Yervoy Injectable Product|Anti-CTLA-4 antibody
45813934|NCT04739618|Drug|GM-CSF|1 mL injected into each non-ablative cryosurgical freezing zone. Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days after each treatment.
46077648|NCT04034953|Diagnostic Test|Faecal Immunochemical Test|Faecal Immunochemical Test detects if there is any hemoglobin presents in stools, so even tiny amount of blood in stool can be found.
45453919|NCT01341704|Other|0.9% NaCl/Normal Saline|0.5 ml per dose; to be given as control for the secondary/booster doses of experimental vaccine
45813935|NCT04739618|Procedure|Non-ablative Cryosurgical freezing|To induce immediate necrosis and necroptosis and a rim of injured cancer cells, thereby exposing a complete range of patient-specific tumor antigens that are specific to the treated subject.
45813936|NCT02684942|Drug|Meperidine|Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
46077649|NCT04034953|Diagnostic Test|Prostate-Specific Antigen Test|PSA blood test is used to measure the level of PSA in blood. When the PSA level is higher than normal, it may represent prostate cancer or benign prostate hyperplasia. Patient who have high PSA level should receive additional tests.
46077650|NCT04034953|Diagnostic Test|Mammogram|Each sides of breast will be taken imaging in 2 different views.The breast will be pressed between 2 plastic plates to flatten and spread the breast tissue for clear imaging.
45660307|NCT05487391|Drug|Carboplatin|Carboplatin AUC=5（D1） Q3W IV, 2-4 cycles
45660308|NCT05487391|Drug|Pemetrexed|Pemetrexed 500mg/m2（D1） Q3W IV, 2-4 cycles
45813937|NCT02684942|Drug|Fentanyl|Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
45813938|NCT02685566|Device|FFDM Plus DBT|FujiFilm Aspire Cristalle System
45813939|NCT02685566|Device|FFDM|FujiFilm Aspire Cristalle System
45813940|NCT04339010|Other|Hypopressive exercise|The hypopressive exercise is performed mainly via transversus abdominis (Tra) activation. The exercise relaxes the diaphragm, decreases intra-abdominal pressure and may activate the abdominal and PFM simultaneously.
45813941|NCT04339010|Other|Pelvic floor muscle contraction|Pelvic floor muscle contraction (PFMC) is performed through a sequence of contraction and relax the PFM. It will improve PFM strength and is effective for treating urinary incontinence.
45813942|NCT04739774|Drug|CHF6001 DPI|Single dose of CHF6001
45813943|NCT04739774|Drug|Itraconazole|Repeated doses of oral Itraconazole
45813944|NCT02685956|Device|Vela Sentosa SA HSV1/2 Qualitative PCR Test|medical device test using Vela Sentosa SA HSV1/2 Qualitative PCR Test
45813945|NCT02660918|Drug|Bupivacaine|Paracervical injection of 20 mL 0.25% Bupivacaine at the completion of the procedure
45813946|NCT02660918|Other|Normal Saline|Equal volume injection of normal saline with the same paracervical technique
45813947|NCT02687126|Device|Central Venous Catheterization|Ultrasound guided internal jugular venous catheterization
45813948|NCT04564196|Procedure|Breath Sample|breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.
45813949|NCT02688218|Behavioral|Aerobic Exercise|Exercise for three 15 minute periods, with 10 minute rests between each period, and exercise intensity will vary between periods to achieve different energy expenditures, which may be determined based on VO2 measurements.
45813950|NCT02688218|Behavioral|Resistance Exercise|Subjects will perform 5-15 minutes of up to 7 different activities of daily living, followed by 20 minutes of resistance exercise, such as straight leg raises.
45813951|NCT00367315|Drug|Lumiracoxib|
45813952|NCT02662244|Device|Nd:YAG laser|Long-Pulsed 1064 NM ND:Yag Laser Treatment Of Basal Cell Carcinoma
45813953|NCT01328587|Drug|Eltrombopag|Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 150mg/day (East Asian ancestry 75mg /day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.
45813954|NCT01192555|Biological|Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells|"1x10^7cells/m2 each of unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells will be given by subcutaneous injection while suspended in Ringers solution with 5% HSA in a single syringe in a volume of up to 1 ml.~Vaccines will be given on day 0 of week 0 and then on day 0 (+ 72 hours) of weeks 2, 4, 6, 9, 12, 16, 20.~Cells will be administered as a subcutaneous injection over 1 minute using a 21-gauge needle. Procedural pain control methods may be used per institutional protocol."
45952576|NCT00142077|Device|Electronic health record and messaging system|
46077651|NCT04268381|Other|Biochemical analysis|aMMP-8 is measured by immunofluorometric assay (IFMA).
46077652|NCT02755350|Drug|Truvada|Daily oral PrEP will be provided to a cohort of 2100 participants (female sex workers, men who have sex with men and young women at high HIV risk) in Kenya. Baseline data will be collected from all participants at enrolment. PrEP users will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period and in between these visits, they will return to the pharmacy for PrEP refill, adherence counselling and assessment of side effects.
45453920|NCT00383422|Drug|Arzoxifene|20 mg, oral, tablet, once a day for 52 weeks
45453921|NCT00383422|Drug|Raloxifene|60 mg, oral, tablet, once a day for 52 weeks
45660309|NCT05487391|Drug|Placebo|Placebo
45660310|NCT05484193|Drug|GnRH agonist|GnRH agonist alone for luteal phase support in fresh IVF embryo transfer cycles
45660311|NCT05484193|Drug|Progesterone|vaginal progesterone for luteal phase support
45813955|NCT01192555|Drug|Cytoxan|Metronomic oral cytoxan will start 72 hours prior to the first vaccination at a dose of 50 mg/m2/day. Cytoxan will be held on the day of vaccine administration and for the next 96 hours. After the first vaccine, patients will take 25 mg/m2/day as outlined on the roadmap.
45813956|NCT02087449|Device|E1-Hip Bearing|Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty. In vitro research and development studies have shown that this material has improved wear performance, retention of mechanical properties, and a high resistance to oxidation due to the anti-oxidative properties of Vitamin E.
45952577|NCT02964455|Drug|Docetaxel|5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation
45952578|NCT02964455|Drug|Nedaplatin|5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation
45952579|NCT02964455|Radiation|chest radiation|continuous chest radiation at 64 Gy/32f
45952580|NCT00142155|Drug|Rituximab|
45660312|NCT05479279|Other|Neck Stabilization Training Program|3 times a week stretching exercises approximately 10 mins dumb bell exercises - 2 sets of 15 reps with weights varying from 1 to 2 kg cranio-cervical isometrics for 10 sec with 15 sec breaks between holds with 10-15 reps Tens 5-10 mins Hotpack 5-10 mins neck stretches home plan - 5 reps/set, 3 sets/ day
45660313|NCT05479279|Other|Conventional physical therapy|Tens 5-10 mins Hotpack 5-10 mins neck stretches home plan - 5 reps/set, 3 sets/ day
45660314|NCT03796195|Drug|.5% Bupivacaine|Ultrasound guided right sided stelate ganglion block using .5% bupivacaine (5mLs)
45813957|NCT05441761|Drug|liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin|"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: gemcitabine (1000 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: dexamethasone (40 mg) will be administered on day 1-4 of each 21-day cycle.~Drug: cisplatin (75 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle."
45813958|NCT02685007|Other|Tachosil|TachoSil is a collagen matrix that is coated with human fibrinogen and human thrombin.
45813959|NCT05587699|Drug|CKD-843 A 45mg(Multiple dose)|1 Injection/3 Month, 3 times Injections
45813960|NCT05587699|Drug|CKD-843 A 45mg|Single Injection
45813961|NCT05587699|Drug|CKD-843 A 55mg(Multiple dose)|1 Injection/3 Month, 3 times Injections
45813962|NCT05587699|Drug|CKD-843 A 55mg|Single Injection
45813963|NCT05587699|Drug|CKD-843-R|0.5mg/day, 9 Month
45813964|NCT00581503|Device|diagnostic|oct imaging
45813965|NCT05587621|Drug|statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran|dietary advice for low cholesterol food
45813966|NCT04739215|Drug|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg / day oral
45660315|NCT05484037|Other|CANATEXTS|Canadian Asthma Text Messaging (CANATEXTS) is a TH intervention facilitating access to an electronic AAP (eAAP) via a mobile device.
45660316|NCT04274179|Other|Modified Atkins Diet|Low carb (20g/day), high fat, moderate protein diet. Started as an outpatient in clinic.
45660317|NCT04274179|Drug|Absence epilepsy medications|At neurologist's discretion
45660318|NCT04273867|Other|Chronic Hypersensitivity Pneumonitis Health Related Quality of Life Survey Instrument|This survey has been developed and revised from prior qualitative research with CHP patients and will be used to better evaluate disease status and quality of life with CHP.
45813967|NCT04739215|Drug|Placebo|One Placebo capsule daily oral
45813968|NCT02665364|Biological|IFNα-Kinoid|
45813969|NCT02665364|Other|Placebo|
45813970|NCT02665364|Other|ISA 51 VG|
45813971|NCT02688829|Device|Rapamycin target-eluting Coronary Stent System|Implantation of the rapamycin-eluting coronary stent system
45813972|NCT00556309|Device|Optical Coherence Tomography|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
45813973|NCT02688842|Device|Rapamycin target-eluting coronary stent systems (38mm)|
45813974|NCT02689063|Drug|Maxigesic IV|IV acetaminophen 1000 mg and IV ibuprofen 300 mg /100 mL solution for infusion, 100mL, every 6 hours for 48 hours
45813975|NCT02689063|Drug|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
45813976|NCT02689063|Drug|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
45813977|NCT02689063|Drug|Placebo IV|Placebo IV- 100 mL intravenous saline for infusion, 100mL, every 6 hours for 48 hours
45813978|NCT02690935|Drug|2LALERG|Homeopathic drug
45813979|NCT02690935|Drug|Placebo|Placebo
45813980|NCT00367861|Drug|interruption of Glivec®|interruption of Glivec®
45813981|NCT02666846|Drug|Ibuprofen|
45813982|NCT02666846|Drug|Diclofenac|
45813983|NCT02666846|Drug|Methyl-salicylate / Menthol|
45813984|NCT02666846|Drug|Placebo|
45813985|NCT02643979|Drug|Ketofol|50mg of Ketamine mixed with 100mg of Propofol
45813986|NCT02643979|Drug|Propofol|100mg of Propofol
45813987|NCT02643979|Drug|Saline|1mL of saline
45952581|NCT00142155|Drug|monoclonal antibodies|
45952582|NCT00152490|Drug|Certolizumab Pegol (CDP870)|
45952583|NCT00134888|Drug|Buprenorphine/naloxone|
45952584|NCT00152529|Behavioral|Screening (Behavior)|
45952585|NCT00134966|Drug|capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)|
45952586|NCT00152568|Behavioral|Car Seat Check (behavior)|At time of well child visit, family receives the services of a certified child passenger safety technician, including assessment, car seat distribution if needed and training.
45952587|NCT00135005|Drug|AMN107, STI571|
45952588|NCT00142233|Dietary Supplement|ANTOX (vers.)1.2|"300 µg organic selenium, 720 mg vitamin C, 228 mg vitamin E, 2880 mg methionine per day (for patients of 10 years and older)~150 µg organic selenium, 360 mg vitamin C, 114 mg vitamin E, 1440 mg methionine per day (for patients aged between 5 and 9 years)"
45952589|NCT00142233|Drug|Magnesium|"15 mmol per day (for patients of 10 years and older)~7,5 mmol per day (for patients aged between 5 and 9 years)"
45952590|NCT00142233|Other|Placebo ANTOX (vers)1.2|Placebo ANTOX (vers)1.2
45660319|NCT05479201|Diagnostic Test|Home based sleep test|Home based sleep test to calculate apnea hypopnea index (AHI) for evaluation of sleep apnea, sleep quality (SQI) and sleep duration (SD)
45660320|NCT05479123|Drug|Propranolol three times a day|"Patients with larger (>2cm) or multiple (>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided TID Week 2: 1 mg/kg/day divided TID Week 3: 2 mg/kg/day divided TID. Patients will stay on this dosage until their 3 month follow up visit."
45813988|NCT02667392|Procedure|Gait Training with Biofeedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Biofeedback Group: Biofeedback (external-focus feedback) will be provided as an adjuvant to therapist-provided feedback during the intervention. Participants will be instructed that a tone will sound when they push off with their (paretic) leg to swing it forward when the participant-specific pre-programmed threshold is exceeded."
45813989|NCT02667392|Procedure|Gait Training with Verbal Feedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Verbal Feedback Group: Therapist-provided internal-focus feedback (directed towards components of body movement) will be used to instruct participants on achieving and/or maintaining appropriate movement patterns that contribute to propulsion generation."
45813990|NCT05587231|Drug|Dextenza 0.4Mg Ophthalmic Insert|The experimental group will have the Dextenza Insert implanted immediately after surgery
45813991|NCT05587231|Drug|Topical Fluorometholone|Steroid drops will be administered by the subject according to the standard of care taper
45813992|NCT02667704|Drug|Bosentan|
45813993|NCT02667704|Drug|Nintedanib|
45813994|NCT02645617|Drug|Varnish|Topical application to the teeth
45813995|NCT02668952|Drug|0.9% Normal Saline (0.9% Sodium Chloride) injection|
45813996|NCT02668952|Drug|Isolyte S injection|
45813997|NCT02648971|Procedure|Single Portal Knee Arthroscopy|Patients in Group 1 will undergo knee arthroscopy using a single portal.
45813998|NCT02648971|Procedure|Two Portal Knee Arthroscopy|Patients in Group 2 will undergo knee arthroscopy using two portals.
45813999|NCT02689154|Device|W8Loss2Go|The participants will proceed through all parts of the app program (problem food withdrawal, snacking control and withdrawal from excessive portions) and receive weekly phone calls from the study coordinator, who will be monitoring app usage and providing motivation. Subjects will return to the EMPOWER clinic for a three month weight check and face-to-face meeting with their mentor. After the study period, participants will again complete the EBQ, and be offered continued enrollment in the EMPOWER clinic or continued home use of the mHealth technology.
45814000|NCT02694445|Other|observation|The study is non-interventional.
45814001|NCT02690168|Behavioral|Fasting|72 hour fasting
45814002|NCT02694601|Dietary Supplement|Control|4-hour visit with no caffeine is given during a standardize breakfast follow by repeated blood sampling.
45814003|NCT02694601|Dietary Supplement|Caffeine low dose|4-hour visit with a dose of 2.5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
46077653|NCT04103541|Behavioral|IP-Colombia|The IP-Colombia program is a multi-component intervention carried out in the context of therapeutic camp, based on EDMR therapies and mindfulness-based interventions. Alongside the interventions, activities are done to facilitate healthy lifestyles, empathy, [and] the recognition and expression of emotions through exercise, art workshops, musical creation, dance and theater.
46077654|NCT04034875|Other|Questionnaire|questionnaire
46077655|NCT00604487|Device|ARD (Atad Ripener Device)|Atad double balloon ripener device
45453922|NCT03635528|Device|Test Lens 1|EMO-114
45453923|NCT03635528|Device|Test Lens 2|EMO-116
45660321|NCT05479123|Drug|Propranolol twice a day|"Patients with larger (>2cm) or multiple (>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided BID Week 2: 1 mg/kg/day divided BID Week 3: 2 mg/kg/day divided BID. Patients will stay on this dosage until their 3 month follow up visit."
45660322|NCT05479123|Drug|Timolol|Patients with a small (<2cm) isolated infantile hemangioma are prescribed timolol 0.5% ophthalmic drops, a topical beta-blocker(1 drop BID directly onto the hemangioma).
45814004|NCT02694601|Dietary Supplement|Caffeine high dose|4-hour visit with a dose of 5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
45814005|NCT02694835|Device|Delefilcon A contact lenses with UV Absorber|
45814006|NCT02694835|Device|Delefilcon A contact lenses|
45814007|NCT02696083|Device|Provant Therapy System|
45814008|NCT05585203|Behavioral|Contingency management|"The investigators will implement a prize-based contingency management protocol in which residents will complete three pre-planned recovery-oriented activities each week for a period of up to 12 weeks. Upon verified completion of the activities each week, participants may earn prize incentives through drawing from a prize fishbowl or spinning a virtual prize wheel.~Prizes will be money added to a debit card. On the first week and individual has completed pre-planned activities, s/he can receive up to 1 draw per activity completed (3 total), and each week the number of prize draws per activity will escalate by 1. If a participant fails to complete any activities, he/she will not receive the draws for the uncompleted activities, and the prize draws would be reset to 1 in the next week. Participants can earn up to $75 in incentives in total."
45814009|NCT05585203|Behavioral|Usual Care|Participants in this arm will receive usual care that they would normally receive at the recovery houses. Recovery residences vary considerably, this form of housing benefits individuals in recovery by reinforcing a substance-free lifestyle and providing direct connections to other peers in recovery, mutual support groups and recovery support services.
45952591|NCT00142233|Other|Placebo Magnesiocard (2.5 mmol)|Placebo Magnesiocard (2.5 mmol)
45952592|NCT00135044|Procedure|intravenous taurine in nutritional supplement|
45952593|NCT00135083|Drug|insulin glulisine|"Once Daily Insulin: Subjects will receive insulin glulisine administered once daily 0-15 minutes before the greatest glycemic impact meal of the day starting at one-tenth the total dose of insulin glargine with maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~Twice Daily: Subjects will receive insulin glulisine administered twice daily 0-15 minutes before the 2 greatest glycemic impact meals of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~Three Times Daily: Subjects will receive insulin glulisine administered 3 times daily 0-15 minutes before each meal of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units for each meal and additional monitoring as shown in the table below."
45952594|NCT04725357|Drug|Meloxicam 15 mg|Participants will receive a prescription of 20 pills of 15 mg Meloxicam after surgery
46077656|NCT00604487|Device|AID (Atad double balloon Instillation Device)|Double balloon instillation device and continuous extra-amniotic instillation of NS 50 Ml/hour
45453924|NCT03635528|Device|Test Lens 3|EMO-118
46077657|NCT00604487|Device|folly catheter|folly catheter (40 ml NS in the balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
46077658|NCT04219410|Procedure|Fully minimally invasive esophagectomy|Esophagectomy using a novel fully minimally invasive approach
46077659|NCT04103697|Drug|Capecitabine|2000 mg/m2, bid, per os, days 1-14, 4 cycles
45453925|NCT03635528|Device|Test Lens 4|RMY-100
45453926|NCT03635528|Device|Test Lens 5|Biofinity multifocal D Lens
45660323|NCT05478967|Procedure|IVA injection before vitrectomy|Patients in IVA group received an IVA (0.5 mg/0.05 ml) injection before surgery (1 to 5 days before surgery)
45660324|NCT05483959|Other|BIPAP mode/SIMV PC mode|BIPAP is a mode of ventilation recently used in ARDS
45660325|NCT04268641|Other|Arm 1|"Materials used for the course :~: Standard Wheelchair~: Standard Wheelchair + Seat back + Positioning cushion~: Standard Wheelchair + Seat back + Positioning cushion + Belt"
45660326|NCT04268641|Other|Arm 2|"Materials used for the course :~: Standard Wheelchair~: Standard Wheelchair + Seat back + Positioning cushion + Belt~: Standard Wheelchair + Seat back + Positioning cushion"
45814010|NCT02650219|Genetic|genetic analyses|
45814011|NCT05574439|Behavioral|TCOC treatment|The TCOC protocol is a chronic care, family-based and multidisciplinary childhood obesity treatment program involving behavior-changing techniques, based on current guidelines for best-practice and authoritative recommendations involving a multidisciplinary tertiary team of health care professionals.
45952595|NCT04725357|Procedure|Preoperative Interscalene Nerve Block|Preoperatively participants will standardly receive an interscalene nerve block
45952596|NCT04725357|Procedure|arthroscopic labral repair|participant will have their standard surgical procedure done
45660327|NCT04268641|Other|Arm 3|"Materials used for the course :~: Standard Wheelchair + Seat back + Positioning cushion~: Standard Wheelchair + Seat back + Positioning cushion + Belt~: Standard Wheelchair"
45660328|NCT04268641|Other|Arm 4|"Materials used for the course :~: Standard Wheelchair + Seat back + Positioning cushion~: Standard Wheelchair~: Standard Wheelchair + Seat back + Positioning cushion + Belt"
45660329|NCT04268641|Other|Arm 5|"Materials used for the course :~: Standard Wheelchair + Seat back + Positioning cushion + Belt~: Standard Wheelchair~: Standard Wheelchair + Seat back + Positioning cushion"
45814012|NCT05574439|Drug|Semaglutide 3 mg|Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.
45952597|NCT00135122|Drug|prednisolone|Prednisolone 60mg day 1 and 2 , 40mg day 3 and 4 , 20mg day 5 and 6
46002698|NCT04645641|Device|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
46002699|NCT04636476|Procedure|Modified Nesbit's procedure and dorsal dartos flap|Modified Nesbit's procedure to correct the penile curvature and dorsal dartos flap to correct the associated penile torsion
46077660|NCT04103697|Drug|Oxaliplatin|130 mg/m2 iv day 1, 4 cycles
46077661|NCT04103697|Drug|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
46077662|NCT04103697|Radiation|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor
45453927|NCT03635528|Device|Control Lens 1|EMO-117
45453928|NCT03635528|Device|Control Lens 2|Proclear 1 day
45453929|NCT02286622|Drug|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite 21-desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone
45814013|NCT02698033|Drug|Peanut flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
45814014|NCT02698033|Other|Toasted oat flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
45814015|NCT02690948|Biological|Pembrolizumab|Given IV
46002700|NCT04645407|Drug|Fuzheng Huayu tablet|Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time)
46077663|NCT04103697|Procedure|Rectal cancer surgery|Laparoscopic or open partial or total mesorectal excision (based on exact tumor location and surgeons discretion)
46077664|NCT00898573|Drug|lapatinib ditosylate|
45660330|NCT04268641|Other|Arm 6|"Materials used for the course :~: Standard Wheelchair + Seat back + Positioning cushion + Belt~: Standard Wheelchair + Seat back + Positioning cushion~: Standard Wheelchair"
45814016|NCT02690948|Drug|Vismodegib|Given PO
45814017|NCT02698735|Drug|Gentamicin|Gentamicin was either formulated into a 0.1% ointment or solutions for injection were purchased directly from suppliers.
45814018|NCT02698735|Drug|Placebo|There are two placebos used in this study. The ointment vehicle (same as used to formulate gentamicin) and vehicle solution for injection.
45952598|NCT00135239|Procedure|Study care|All study patients will be assessed initially by a physician in the CNOSP outpatient clinic to confirm that they meet the inclusion/exclusion criteria of the study. Patients receiving the EBC intervention will then receive re-assurance, advice to avoid passive treatments, acetominophen (except where contraindicated) for a period of 2-4 weeks, a four week course of lumbar spine spinal manipulative therapy administered by a CNOSP Chiropractor and advice to return to work in some capacity within eight weeks following the start of treatment. Patients randomized to the UC treatment arm will undergo the treatment(s) recommended by their family physicians.
45952599|NCT00135239|Procedure|Usual care|Patients randomized to the UC treatment arm will undergo the treatment(s) recommended by their family physicians.
45952600|NCT00152607|Procedure|donor right hepatic lobectomy|
45952601|NCT00135278|Procedure|CSF Drainage|See Detailed Description
45952602|NCT00135278|Procedure|No CSF Drainage|See Detailed Description
45952603|NCT00142350|Drug|continuous infusion of 5-fluorouracil|
45952604|NCT00142350|Drug|combination of irinotecan and cisplatin|
45952605|NCT00142350|Drug|oral administration of S-1|
45952606|NCT00135317|Drug|darbepoetin alfa|
45952607|NCT00152646|Drug|placebo, aspirine, clopidogrel|
45660331|NCT04268407|Drug|Amoxicillin Clavulanate|compare the duration of antbiotic use: 2 day versus 7 day
45814019|NCT02691260|Behavioral|incentives for dietary self-monitoring|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application.
45814020|NCT02691260|Behavioral|incentives for interim weight loss|Participants will receive intermittent financial incentives for losing an expected amount of weight based weight obtained weekly.
45952608|NCT00135434|Drug|Atazanavir/Ritonavir/Lopinavir/ritonavir|
45952609|NCT00142389|Biological|pneumococcal polysaccharide and protein conjugate vaccines|
45952610|NCT00135473|Drug|10% Hemohes® (10% Hydroxyethyl starch)|
45952611|NCT00135473|Drug|Sterofundin® (Ringer lactate solution)|
45952612|NCT00135473|Drug|Actrapid® (Insulin)|
45952613|NCT00142428|Drug|Cetuximab|The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
45453930|NCT00486538|Drug|ABT-869|One oral dose daily.
45453931|NCT01338584|Behavioral|Pelvic floor muscle training 3 weeks before radical prostatectomy|Participants in the intervention group need to attend the nurse-led clinic 6 times for practising pelvic floor muscle preoperatively instead of starting the exercise one day before surgery (usual management).
45814021|NCT02691260|Behavioral|incentives for both|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application and for losing an expected amount of weight based on weight obtained weekly.
45814022|NCT02691416|Drug|propofol postconditioning|administrated Target Controlled Infusion(TCI) of propofol (Cp 1.2ug/ml) and decreased sevoflurane with a Bispectral index (BIS) value of 40-60 to maintain anesthesia after clamp removal
45814023|NCT02691416|Drug|sevoflurane|0.5%-2% sevoflurane with BIS 40-60
45814024|NCT02650999|Drug|Pembrolizumab|200mg intravenously (IV)
45952614|NCT00135551|Drug|Angiotensin receptor blockers|benidipine+angiotensin receptor blocker, titlation scheme
45952615|NCT00135551|Drug|β-blockers|benidipine+β-blockers, titlation scheme
45952616|NCT00135551|Drug|thiazide diuretics|benidipie+thiazide diuretics, titlation scheme
45952617|NCT00152685|Drug|human serum albumin|
45952618|NCT00135590|Dietary Supplement|Protein pulse-feeding|Dietary protein (80% of daily intake) was consumed in one meal (12.00h)
45952619|NCT00135590|Dietary Supplement|Spread diet|Dietary protein was spread over the four meals.
45952620|NCT00152724|Device|pressure strain system, iontophoresis|
45952621|NCT00152724|Drug|scopolamin|
45952622|NCT00152724|Drug|emla|
45952623|NCT00152724|Drug|capsaicin|
45952624|NCT00152724|Drug|aspirin|
45952625|NCT00152724|Drug|clopidogrel|
45952626|NCT00152724|Drug|celecoxib|
45952627|NCT00152724|Drug|indomethacin|
45952628|NCT00152724|Drug|acetylcholine|
45952629|NCT00152724|Drug|sodium nitroprusside|
45952630|NCT00152724|Drug|brethyllium|
45952631|NCT00152724|Device|general and local heating|
45952632|NCT00135629|Biological|Sublingual Alutard SQ grass pollen tablets (Phleum pratense)|
45952633|NCT00135629|Procedure|Venepuncture: 100ml blood sample taken on 12 separate visits|
45952634|NCT00158964|Device|EASYTRAK 4 STEERABLE LV lead|
45952635|NCT00135668|Drug|nitroprusside|nitroprusside IV infusion 0.3-3 mcg/kg/ min
46077665|NCT00898573|Genetic|fluorescence in situ hybridization|
45660332|NCT04014751|Other|Symptom Monitoring Intervention|This study involves a cancer care delivery process improvement component where all cohort participants, at specified timepoints, are assessed for psychological distress, pain, fatigue, physical function, practical and supportive needs, and dietary and nutritional needs. Patients with severe elevations in psychological distress, physical symptoms or those who endorse supportive care and/or dietary needs are triaged in real time to appropriate providers within the health system (i.e., social work, nursing pool, nutrition services) to address elevated scores and/or stated needs. As such, within the context of this process improvement care delivery project, real time referrals function as interventional processes within the health system to route patients to relevant points of care based on their needs.
45814025|NCT02691962|Device|Xen Matrix AB|Xen Matrix™ AB Surgical Graft is an acellular, sterile, non-pyrogenic porcine dermal matrix packed dry for use in the reconstruction of soft tissue deficiencies. The device surfaces are coated with the antibacterial agents Rifampin and Minocycline in a bioresorbable L-Tyrosine succinate polymer carrier.
45814026|NCT05542303|Drug|ZB001 for injection|Dose Cohort1 (3mg/kg) ZB001 of single IV injection
45814027|NCT05542303|Drug|ZB001 for injection|Dose Cohort2 (10mg/kg) ZB001 of single IV injection
45814028|NCT05542303|Drug|ZB001 for injection|Dose Cohort3 (20mg/kg) ZB001 of single IV injection
45814029|NCT02701387|Device|Megagen AnyRidge dental implant|AnyRidge is an approved dental implant with a knife edge, thin thread design available in various thread widths (depth).
45814030|NCT02701387|Device|Megagen EZ Plus dental implant|EZ Plus is an approved dental implant with a standard thread design (width and depth) and that is comparable to many other dental implants currently available on the market.
45814031|NCT02693132|Behavioral|Supervised (SUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of supervised moderate-to-vigorous intensity physical activity.
45814032|NCT02693132|Behavioral|Unsupervised (UNSUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of unsupervised moderate-to-vigorous intensity physical activity.
45814033|NCT02693132|Behavioral|Step-based (STEP)|"Weight loss intervention that involves an energy restricted diet plus the inclusion of physical activity in the form of 10,000 steps/day with 2,500 brisk steps/day."
45814034|NCT05502211|Drug|Fentanyl|induction of anaesthesia using fentanyl
45814035|NCT05502211|Drug|Lidocaine IV|induction of anesthesia using lidocaine
45814036|NCT04339244|Other|RALRP under lower mean BP|RALRP under regulation of lower mean BP
45814037|NCT04339244|Other|RALRP under lower mean BP|RALRP under regulation of highly normal mean BP
45814038|NCT02673944|Device|Peritron+|Peritron+ will be connected to a standard urodynamic analyzer system to measure vesical pressure
45814039|NCT02674412|Drug|Buspirone|
45814040|NCT02674412|Drug|Placebo|Placebo Pill Manufactured by the Investigational Pharmacy at Cleveland Clinic
45814041|NCT00367952|Drug|apricitabine|800mg apricitabine twice daily orally for 96 weeks
45814042|NCT04708106|Other|RELX ENDS Tobacco Flavor|Ad libitum use of the RELX ENDS Tobacco Flavor product
45814043|NCT04708106|Other|RELX ENDS Menthol Flavor|Ad libitum use of the RELX ENDS Menthol product
45814044|NCT04708106|Other|RELX ENDS Tobacco and Menthol Flavors|Ad libitum use of the RELX ENDS Tobacco and Menthol Flavor products
45814045|NCT02697188|Drug|Testosterone undecanoate|Single-day dose as QD or BID for 3 of 5 crossover periods
45814046|NCT02697188|Drug|Testosterone enanthate|Single-day dose for 2 of 5 crossover periods
45660333|NCT05489653|Behavioral|mixed music|Learn about the effects of listening to music and doing activities with it on sleep.
45814047|NCT04707560|Procedure|EUS fine needle biopsy with heparin wet suction|"EUS FNB with Heparin wet suction:~Investigator will remove stylet from the FNB device and then infuse Heparin 1ml (5000IU) into device before procedure. The syringe will pre-loaded with 10 ml negative pressure and attach to device upon needle tip insertion into mass lesion.~EUS FNB with Dry suction:~Investigator will remove stylet from the FNB device. Syringe will be pre-loaded with 10 ml negative pressure in syringe and attach to needle tail upon needle tip inserted into target lesion."
45814048|NCT05421104|Other|Ruxolitinib|PV patients who were resistant to or intolerant of HU (as defined on the index date) and switched to RUX in the post-index period.
45814049|NCT02652481|Device|ImageReady MR Conditional Defibrillation System|"ImageReady MR Conditional Defibrillation System Components:~Device Name Device Model Number Pulse Generators Phase I and II Phase II Only * CRT-D (IS1/DF4/IS4) VR ICD (DF4) DR ( dual chamber) ICD (IS1/DF4) ORIGEN™ MINI ICD ORIGEN EL ICD ORIGEN X4 CRT INOGEN™ MINI ICD INOGEN EL ICD INOGEN X4 CRT DYNAGEN™ MINI ICD DYNAGEN EL ICD DYNAGEN X4 CRT-D AUTOGEN ™ MINI ICD* AUTOGEN EL ICD* AUTOGEN X4 CRT-D* Right Atrial Leads and Accessories FINELINE™ II Sterox FINELINE II Sterox EZ Suture Sleeves for FINELINE II Leads INGEVITY™ MRI* Suture Sleeve for INGEVITY MRI* IS-1 Lead Port Plug 7145 Right Ventricular Leads and Accessories RELIANCE 4-FRONT™ (DF4)* Suture Sleeve for RELIANCE 4-FRONT leads*; ENDOTAK RELIANCE™ (DF4) Left Ventricular Leads and Accessories ACUITY™ X4 (IS4) Suture Sleeve for ACUITY X4 leads~* May only be used internationally outside the US"
45814050|NCT05420714|Device|Dexcom Professional Continuous Glucose Monitoring|Patient will be asked to wear the Dexcom Pro-CGM device (small device that can be applied to either the arm or abdomen) for 10 days. They will have 30 minutes initial visit with CDCES to apply the device and review its use and 60 minute final session to review the blood sugar data from the CGM with CDCES and diabetes clinic provider.
45814051|NCT02697890|Device|FDBA (MinerOss®) + Mucograft® seal|Collagen matrix membrane for soft-tissue regeneration
45814052|NCT02697890|Device|FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)|Standard of Care
45952636|NCT00152802|Biological|The polysaccharide vaccine Pneumovax (Merck-Frosst)|
45952637|NCT00152802|Biological|The conjugate vaccine used will be Prevnar (Wyeth vaccines)|
45952638|NCT00135746|Drug|nicotine transdermal system|
45952639|NCT00135785|Drug|Bupropion|
45952640|NCT00135785|Drug|Placebo|
46077666|NCT00898573|Genetic|gene expression analysis|
46077667|NCT00898573|Genetic|mutation analysis|
45952641|NCT00159081|Drug|Haloperidol, Risperidone (drug)|targeted dose of 2-4 mg/day over 1 year
45952642|NCT00152841|Drug|Iron supplement 300-600 mg/day|
45952643|NCT00152841|Drug|Vitamin E 800IU|
45952644|NCT00159120|Other|maintained antipsychotic treatment vs. stepwise drug discontinuation|maintained antipsychotic treatment (in low dose) vs. stepwise drug discontinuation; both supplemented by prodrome-based early intervention; 1 year
45952645|NCT00159159|Drug|Ciclosporine 130 µg/l < T0 ciclosporinemia < 200 µg/l|
45814053|NCT05419154|Procedure|Early pain dependent weight-bearing without immobilization|Patients are advised to conduct pain-dependent full weight-bearing starting at the day of study inclusion. In case of severe swelling, a splint or below knee cast can be applied until the initial swelling subsides, but no longer than 14 days. Otherwise, no immobilization is applied. The use of crutches is allowed per the individual patients demands. The physiotherapists at the individual study centers are informed prior to study initiation and are briefed about each patient enrolled in the study. Each patient is handed an information sheet for their outpatient physiotherapist.
45952646|NCT00159159|Drug|Ciclosporine 200 µg/l < T0 ciclosporinemia < 300 µg/l|
45952647|NCT00135824|Drug|Povidone K25 eye drops (povidone)|
45952648|NCT00135863|Drug|tinzaparin|
45952649|NCT04724616|Other|Educational Program (CARTOON)|CARTOON is an interdisciplinary psychoeducational intervention program. It consists of five teaching sessions: 1) hand hygiene, not grasping the face, 2) sneezing etiquette, 3) wearing a mask, 4) social distancing, and 5) theoretical knowledge about the coronavirus. Using special exercises and games, information about the coronavirus is conveyed in a child friendly manner.
45814054|NCT02653183|Device|Active Comparator: Aquacel Surgical|Post-operative all-in-one self-adherent soft silicone coated foam dressing. Duration of treatment: Total 5 days included the day of surgery and 4 post-operative days.
45814055|NCT02653183|Device|Experimental: Mepilex Border Post-Op|"Aquacel Surgical is a sterile, one piece post-operative dressing.Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
45952650|NCT00135902|Drug|17 alpha-Hydroxyprogesterone Caproate and Omega-3 supplement|Participants receive a weekly progesterone injection (17 alpha hydroxyprogesterone caproate) up to 37 weeks gestation and take daily Omega-3 supplements.
45952651|NCT00135902|Drug|17 alpha-hydroxy progesterone caproate and Placebo supplement|Participants receive a weekly progesterone injection (17P) up to 37 weeks gestation and take daily placebo supplements
45952652|NCT04726670|Other|Evaluation of postoperative pain|"A participant voluntary consent form was obtained from each patient. Ninety patients were numerically coded in computer environment by someone who was not included in the study for randomization (www.random.org).~A single clinician performed retreatment on each of the 90 teeth during a single visit."
45660334|NCT05487001|Procedure|dexamethasone group|"1) Arm l (dexamethasone group) Ultrasound-guided femoral nerve block with 1% lidocaine 15 ml after the end of surgery Postoperative femoral nerve patient controlled analgesia~Total volume 250 ml (0.375% ropivacaine 60 ml + normal saline 188 ml + dexamethasone 10 mg (2 ml))~Basal rate 4 mL/hr, Bolus volume 2 mL, Lock-out time 15 min"
45660335|NCT05487001|Procedure|sham group|"2) Arm ll (sham group) Ultrasound-guided femoral nerve block with 1% lidocaine 15 ml after the end of surgery Postoperative femoral nerve patient controlled analgesia~Total volume 250 ml (0.375% ropivacaine 60 ml + normal saline 190 ml~Basal rate 4 mL/hr, Bolus volume 2 mL, Lock-out time 15 min"
45660336|NCT05483725|Biological|Booster dose of mRNA vaccine|Administration of SARS-CoV-2 mRNA vaccine.
45660337|NCT05486845|Other|survey|We are planning a questionnaire survey. We combine our own questions with validated, official questionnaires. Validated forms ask for an assessment of the extent of low back pain and the quality of experienced stress.
45814056|NCT05418920|Procedure|left-opening single-flap technique|left-opening single-flap technique
45814057|NCT05418920|Procedure|double-flap group technique|double-flap group technique
45814058|NCT02701400|Biological|Durvalumab|Given IV
45814059|NCT02701400|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
45952653|NCT00135941|Drug|insulin glargine|Sequence 1 (Lantus + Apidra first, then Premix): Subjects randomized to this sequence will receive ApidraTM administered three times per day 0-15 minutes before main meals using a fixed bolus regimen following titration based on preprandial blood glucose values; as well as Lantus qd for 12 weeks. After the first 12 weeks, subjects will cross over to the premix insulin for a further treatment of 12 weeks.
45952654|NCT00135941|Drug|insulin glulisine|Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.
45952655|NCT00152919|Drug|Meloxicam|
45952656|NCT00135980|Behavioral|professional audit and feedback|
45952657|NCT00135980|Behavioral|integrated care programmes|
45952658|NCT00159237|Procedure|blood test|
45952659|NCT00159276|Procedure|Induced Sputum|
45952660|NCT00136019|Drug|SPM 927|
45952661|NCT00406146|Drug|amodiaquine+artesunate/artemether-lumefantrine|
45952662|NCT00136058|Procedure|bone densitometry (DEXA)|
45952663|NCT00136058|Drug|alendronate or risedronate|
45952664|NCT00136097|Device|Placement of a silver impregnated central venous catheter|
45952665|NCT00152958|Drug|Pramipexole|
45952666|NCT00159315|Procedure|Inhalation Challenge with ATP|
45952667|NCT00159315|Procedure|Inhalation Challenge with AMP|
45952668|NCT00136175|Drug|Paclitaxel|
45952669|NCT00136175|Drug|Carboplatin|
46077668|NCT00898573|Genetic|polymerase chain reaction|
45660338|NCT05478889|Procedure|Minimally invasive pancreatoduodenectomy|Whipple's procedure using minimally invasive (laparoscopic/robotic) techniques
45660339|NCT05478811|Device|Er,Cr:YSSG laser|NaOCl, Er,Cr:YSSG will be activated by laser during the final irrigatio
45814060|NCT02701400|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45814061|NCT02701400|Biological|Tremelimumab|Given IV
45814062|NCT00368173|Drug|rhIGF-I/rhIGFBP-3|
45660340|NCT05478811|Device|Control|Routine final irrigation procedure will be done, NaOCl will not be activated by any method)
45660341|NCT04009291|Combination Product|TransCon PTH|TransCon PTH drug product is supplied as a clear solution containing TransCon PTH with a nominal PTH(1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection.
45814063|NCT05403710|Drug|Botulinum toxin|Standard-of-care administration of botulinum toxin (50 units/axilla injected intradermally) will be performed for routine treatment of Hidradenitis Suppurativa
45814064|NCT05400824|Diagnostic Test|Blood, DNA, feces, urine, hair and skin microbiota collection|See above
45952670|NCT00136175|Drug|Gemcitabine|
45952671|NCT00159354|Drug|predisolone|
45952672|NCT00136253|Behavioral|Help dietitians and patients address specific nutritional barriers|
45952673|NCT00152997|Drug|Pramipexole 0.125 mg tablets|
45952674|NCT00152997|Drug|Pramipexole 0.125 mg tablets Placebo|
45952675|NCT00159393|Other|registry and database|data collection
45952676|NCT00136292|Drug|daptomycin|
45952677|NCT00153075|Device|Berodual Respimat|
45952678|NCT00153075|Device|Berodual HFA-MDI|
45952679|NCT00136331|Biological|Pandemic influenza vaccine|
46077669|NCT00898573|Genetic|reverse transcriptase-polymerase chain reaction|
46077670|NCT00898573|Other|cell sorting|
45660342|NCT04009291|Combination Product|Placebo for TransCon PTH|Placebo is supplied as a clear solution containing the formulation buffer for TransCon PTH in a pre-filled pen intended for subcutaneous injection.
45952680|NCT00159471|Drug|capecitabine, gemcitabine, docetaxel|
45952681|NCT00136370|Drug|Chlorhexidine|
45952682|NCT00136370|Procedure|Birth canal wipe|
45952683|NCT00136370|Procedure|sterile water external genital wipe|
45952684|NCT00159510|Drug|Methylene blue|Injection bolus of 2 mg/kg PBW and infusion of 0.2 mg/kg/hr
45952685|NCT00159510|Drug|Nitric oxide|An inhalation of NO via ETT at 10 ppm, partially weaned by 72 hrs of therapy
45952686|NCT00159510|Drug|Methylene blue & nitric oxide|See the dosage in the previous arms
45660343|NCT03781141|Procedure|Wound closure|Comparison of two wound closures
45814065|NCT04738994|Dietary Supplement|whey protein-enriched nutritional supplement|Standard hospital diet + 80 g/die (two servings) of whey protein-enriched nutritional supplement dissolved in 125 ml of water
45814066|NCT04738994|Other|Control group|Standard hospital diet
45814067|NCT02653417|Drug|RAD1901|RAD1901
45814068|NCT02653417|Other|Placebo|Placebo
45814069|NCT02677766|Other|occupational therapy|an intervention phase in the period of hospitalization for rehabilitation in the hospital, aimed mainly at achieving objectives related to the area of self-care and, secondly, the objectives in the areas of productivity and leisure, identified at T0; plus an intervention in the post-discharge at the patient's home, aimed primarily at achieving objectives related to the areas of productivity and leisure time and, secondly, to possible targets in residues of self-care, identified in T0.
45814070|NCT02677766|Other|Usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
45952687|NCT00136409|Drug|Imatinib mesylate|400mg orally once daily until disease progression or unacceptable side effects
45952688|NCT00153114|Drug|polyethyleneglycol3350|
45952689|NCT00136448|Drug|cytosine arabinoside (ara-C)|
45952690|NCT00136448|Drug|daunomycin|
45952691|NCT00136448|Drug|interleukin-2|
45952692|NCT00153153|Drug|polyethyleneglycol3350|
45952693|NCT00136487|Drug|Celecoxib|
45952694|NCT00153192|Drug|Marinol (dronabinol)|
45952695|NCT00136526|Drug|Docetaxel and Diethylstilbestrol (DES)|Subjects receive docetaxel 36 Mg/m2weekly for ten cycles (3 weeks out of every 4) and DES 1 mg daily for 40 weeks or until there is evidence of disease progression, whichever occurs first.
45952696|NCT00136565|Drug|Velcade|1.5 mg/m², D1, D5, 4 cycles
45952697|NCT00136565|Drug|Doxorubicin|75 mg/m², D1, 4 cycles
45952698|NCT00136565|Drug|Prednisone|60 mg/m², D1-D5, 4 cycles
45952699|NCT00136565|Drug|Cyclophosphamide|1200 mg/m², D1, 4 cycles
45952700|NCT00136565|Drug|Vindesine|2 mg/m², D1, D5, 4 cycles
45952701|NCT00136565|Drug|Bleomycin|10 mg, D1, D5, 4 cycles
45952702|NCT00153231|Device|IVS|Infracoccygeal sacropexy
45952703|NCT00153231|Procedure|Sacrospinofixation|
45952704|NCT00159549|Behavioral|education and training program|
45952705|NCT00404105|Procedure|PRK|
45952706|NCT00404105|Procedure|LASIK|
45952707|NCT00159627|Drug|KW-3902IV|
45952708|NCT00136643|Drug|Invisible Condom®|
45952709|NCT00159666|Drug|pregabalin|
46077671|NCT00898573|Other|immunohistochemistry staining method|
46077672|NCT00898573|Other|laboratory biomarker analysis|
46077673|NCT02852525|Device|Confocal laser endomicroscopy (pCLE)|Patients agreeing to participate in the research study will receive an additional intravenous injection during endoscopy. This dose of 2.5 mg of IV fluorescein will be administered during their EGD. Probe-based microscopy will be used to evaluate the mucosa of the esophagus and GE junction
46077674|NCT04321668|Device|Synvisc-One|SYNVISC-ONE® (Hylan G-F 20), 10 mL single-injection viscosupplement Status : CE marked (CE 0086) class III Medical Device The IP is used according to its usual dosage, administration and indication
45952710|NCT00136682|Drug|patient-controlled epidural analgesia (PCEA)|During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
45952711|NCT00136682|Drug|patient-controlled intravenous analgesia (PCA)|During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
45453932|NCT01338584|Behavioral|Intensive preoperative pelvic floor muscle training|Patient started to learn pelvic floor muscle 3 weeks before surgery
45453933|NCT00564928|Drug|IPI-504|IPI-504 at 400mg/m2, IV, 2 times a week for 2 weeks with 10 days off treatment. Twenty-one (21) day cycle
45453934|NCT00564226|Drug|SSR240600C|oral administration
45952712|NCT00153270|Drug|Sodium Valproate|
45952713|NCT00159705|Drug|pregabalin|
45952714|NCT00136799|Drug|Fluvastatin|
45814071|NCT04338997|Drug|IZD174|Small molecule inhibitor of NLRP3
45660344|NCT05486767|Diagnostic Test|Transient elastography|Both tests belong to the group of non-invasive tests for liver fibrosis (transient elastography belongs to the imaging-based tests and FIB-4 to the blood-based tests)
45814072|NCT02705365|Other|Patient Navigation|One to one patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
45814073|NCT02705365|Other|Usual Care|Usual care during the study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
45814074|NCT02703350|Drug|LY900014|Administered subcutaneously (SC)
45814075|NCT02703350|Drug|Insulin Lispro|Administered SC
45814076|NCT02682056|Device|Microneedle patch|The microneedle patch will collect interstitial fluid to be tested for glucose level. The microneedles are made from biocompatible polymers or metal. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
45952715|NCT00153309|Behavioral|People with Arthritis Can Exercise|
45952716|NCT00136877|Procedure|(adeno)tonsillectomy|
45952717|NCT00407004|Device|MARS (Molecular Adsorbents Recirculating System)|
45952718|NCT00407004|Device|Prometheus (FPSA, Fractionated Plasma Separation and Adsorption)|
46077675|NCT04103463|Other|Interactive stepping exercise|An exercise intervention based on the principle of square stepping exercise
46077676|NCT04103463|Other|Home exercise|Home exercise
46077677|NCT00903253|Drug|LNK-754|
46077678|NCT02851745|Drug|Linagliptin|
46077679|NCT02851745|Drug|Placebo|
45676581|NCT01860170|Drug|Cohort 1-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
45814077|NCT02682056|Device|Intravenous (IV) catheter|The intravenous (IV) catheter will collect venous blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
45952719|NCT00136994|Drug|Ziprasidone|
45952720|NCT00153348|Behavioral|Women's health|
45952721|NCT00153387|Behavioral|Women's health|
45952722|NCT00137033|Drug|Celecoxib|
45952723|NCT00137033|Drug|Naproxen|
45952724|NCT00137033|Drug|ASA|
45952725|NCT00153426|Behavioral|West Virginia WISEWOMAN|Print-based tailored health communications and computer-based interactive nutrition program
45952726|NCT00137072|Drug|Viagra (Sildenafil Citrate) 100 mg|
45952727|NCT00153465|Behavioral|Motivational intervention, parent training|
45952728|NCT00137150|Procedure|Placement of implants|
45453935|NCT00564226|Drug|tolterodine|oral administration
45453936|NCT00564226|Drug|placebo|oral administration
45453937|NCT03635684|Drug|Acetaminophen|"Subcutaneous infusion of Acetaminophen over 20 to 30 minutes, with evaluation of:~local side effects;~pain and/or fever;~at time of infusion, after 30 minutes, 60 minutes and 180 minutes."
45453938|NCT05185700|Behavioral|post covid 19 symtoms|observation
45453939|NCT00563680|Drug|AMG 479|AMG 479 is a fully human monoclonal antibody (IgG1) against the insulin-like growth factor receptor-1 (IGF-1R). IGF-1R signaling has been shown to play a critical role in the survival of cancer cells. AMG 479 inhibits the binding of both IGF-1 and IGF-2 to IGF-1R, thus inhibiting ligand-dependent receptor activation. Inhibition of IGF-1R signaling with AMG 479 provides a potential mechanism for inhibiting tumor growth and survival.
45952729|NCT04724538|Radiation|99mTc-pertechnetate aerosol|99mTc-pertechnetate is 99mTc-labeled carbon ultrafine aerosol
45952730|NCT04724538|Drug|99mTc-pertechnetate aerosol|99mTc-pertechnetate is 99mTc-labeled carbon ultrafine aerosol
45952731|NCT00137189|Procedure|Resource-oriented music therapy|
45453940|NCT00092690|Drug|MK0653A, ezetimibe (+) simvastatin|
45453941|NCT00092690|Drug|Comparator: atorvastatin|
45952732|NCT00137189|Procedure|Standard care|
45952733|NCT00159900|Drug|Sildenafil Citrate|
45952734|NCT00137228|Procedure|figure-of-eight hand measurements|
45952735|NCT00137228|Procedure|water volumetry hand measurements|
46077680|NCT02602197|Drug|Paracetamol|After anesthetic induction, the first I.V bolus injections of 1 gr paracetamol (total amount of 100 ml) were given during 15 minutes and then repeated every 6 h until 24 h postoperative period.
46077681|NCT02602197|Drug|Dexketoprofen|After anesthetic induction, the first I.V bolus injections of 50 mg Dexketoprofen (premixed with 0.9 % sodium chloride to total amount of 100 ml) were given during 15 minutes and then repeated every 8 h until 24 h postoperative period.
45814078|NCT02682056|Device|Lancet|The lancet will collect capillary blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
45453942|NCT02286700|Drug|Desonide Cream|Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
45952736|NCT00159939|Procedure|prone positioning|prone positioning
45952737|NCT00137306|Procedure|Facilitate evidence-based treatment for depression|
45952738|NCT00159978|Procedure|18F-FLT and 18F-MISO-PET|18F-FLT-PET-images will be acquired one hour after injection of 250 MBq FLT. 18F-MISO-PET: 400 MBq FMISO will be injected intravenously. Marker administration: The day before surgery (≤ 24h) pimonidazole (500 mg/m2) will be administered intravenously in 100 ml saline over 20 min. IdUrd (200 mg) will be administered as bolus injection 20 min before surgery.
45952739|NCT00137345|Drug|sirolimus|
45952740|NCT00160017|Behavioral|Breakthrough collaborative|Participants (professionals) participate in a Breakthrough Collaborative to improve diabetes care
45952741|NCT00153504|Behavioral|Housing and Health Study housing rental assistance|
45952742|NCT00153504|Behavioral|Standard local practice housing assistance|
45814079|NCT02706925|Drug|BI 443651|
45952743|NCT00137462|Drug|torcetrapib/atorvastatin|
45952744|NCT00137462|Drug|atorvastatin|
45952745|NCT00153543|Biological|Pneumococcal polysaccharide vaccine|
45952746|NCT00153543|Biological|Pneumococcal conjugate vaccine|
45814080|NCT02706925|Drug|Placebo|
45814081|NCT05378438|Other|Microbe literacy Program in the form of workshop|Two to Three hours of workshop on microbe literacy will be conducted as an intervention. Workshop includes discussion on various common microorganisms causing diseases, their sources, relationship with surroundings and management. Prime focus of the session will be on management via treatments and risk reduction via vaccination.
45952747|NCT00153582|Biological|WT1 126-134 peptide|
45952748|NCT00137501|Drug|Nifedipine|"Arm A:~Nifedipine 20 mg sublingual, repeated after 30 minutes if contractions do not decrease in intensity. Maintenance of 120-160 mgs of slow-release nifedipine daily for 48 hours.Once contractions cease, nifedipine will be maintained at 80-120 mg daily in divided doses up to 36 weeks.~Arm B:~Nifedipine 10 mg sublingual crushed, then 10 mg in 15 min, followed by 10 mg PO Q 15 mins PRN to a maximum of 40 mg in the first hour. Maintenance of 60-80 mgs of slow-release nifedipine daily for 48 hours. Once contractions cease, nifedipine will be maintained at 60 mg daily in divided doses up to 36 weeks."
45952749|NCT00160056|Procedure|Hypoglycemia|
45952750|NCT00137540|Device|RF ablation|
46077682|NCT04035343|Behavioral|Face down positioning|See description of the face down positioning group
45453943|NCT02286700|Other|Amino Acid Moisturizing Cream|Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
45453944|NCT01315964|Dietary Supplement|plant stanol ester|3 gr of plant stanol esters per day in a margarine product as part of daily diet for a period of 6 months
45453945|NCT02286778|Dietary Supplement|Acetogenins|Acetogenins BID for 12 months
45453946|NCT02286778|Dietary Supplement|Placebo|
45952751|NCT00137540|Drug|anti-arrhythmic drug therapy|
45952752|NCT00137579|Procedure|Influenza vaccine intramuscular administration route|
45952753|NCT00137618|Behavioral|Educational Intervention to Increase Informed Decision Making for Prostate Cancer Screening|
45952754|NCT00153660|Drug|Celecoxib(drug)|Celecoxib 100 mg bd
45952755|NCT00153660|Drug|Naproxen(drug)|Naproxen 500 mg bd
45952756|NCT00160134|Drug|SLV320|
45952757|NCT00137657|Drug|Cotrimoxazole (trimethoprim sulfamethoxazole)|
45952758|NCT00153699|Drug|Topiramate|
45952759|NCT00137696|Biological|Vaccination with inactivated polio vaccine|
45952760|NCT00137696|Procedure|Collection of serum|
45952761|NCT00160212|Drug|Daglutril|
45952762|NCT00153738|Drug|phytosterol|
45952763|NCT00160290|Drug|Lactulose|15 mL / 12 hours
45952764|NCT00160290|Drug|Plantago ovata|3,5 g / 12 hours
45952765|NCT00137735|Drug|Gabapentin|300mg tds
45952766|NCT00137735|Other|placebo|tds
45952767|NCT00153777|Drug|Cellulose Sulfate gel (6%)|
46077683|NCT04035343|Behavioral|Supine positioning|See description of the supine positioning group
46077684|NCT02753712|Drug|Fluticasone/Formoterol BAI|
46077685|NCT02753712|Drug|Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)|
46077686|NCT00898885|Procedure|oral biopsy|oral mucosa and salivary gland biopsy after bone marrow transplantation
46077687|NCT00938327|Biological|Rotarix™|Two doses of oral vaccine.
45952768|NCT00137774|Drug|Bevacizumab|Given intravenously every other week. Participants can continue to receive study drug as long as there is no disease progression or serious side effects.
45952769|NCT00137774|Drug|Temozolomide|Given once daily for one week followed by a one week rest period. This one-week on/one-week off scheduled will be continued as long as there is no disease progression or serious side effects.
45952770|NCT00160329|Drug|Atazanavir|300 mg with ritonavir boosting or 400 mg without
45952771|NCT00137813|Drug|Docetaxel|Given intravenously once a week for 3 out of four weeks for a minimum of 8 weeks and maximum of a year and a half
45952772|NCT00137813|Drug|Bevacizumab|Given intravenously once a week for every other week for a minimum of 8 weeks and a maximum of a year and a half
45952773|NCT00137852|Drug|Cisplatin|Given weekly on weeks 1, 2, 4 and 5 during radiation therapy.
45952774|NCT00137852|Drug|Irinotecan|Given weekly on weeks 1, 2, 4 and 5 during radiation therapy
46002701|NCT00547040|Other|no intervention|no intervention
46077688|NCT04220892|Drug|Pembrolizumab|200 mg intravenous (IV) every 3 weeks
46077689|NCT04220892|Drug|Pemetrexed|900 mg/m^2 IV every 3 weeks. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
45453947|NCT01338896|Drug|Rotigotine transdermal patch|8 mg/24 h, transdermal patch 8 mg/24 h, 2 days
45453948|NCT00560482|Drug|ABR-215050, tasquinimod|Gelatin capsules containing 0.25mg, 0.50mg, 1.0mg ABR-215050; 0.25mg/day taken orally once daily for 2 weeks, 0.50mg/day taken orally once daily for 2 weeks (dose-titration), and 1.0 mg/day taken once daily for 5 months (+6 months continuation)
45453949|NCT00560482|Drug|Placebo|Identical appearing gelatin capsules containing placebo
45453950|NCT05185544|Other|Neoadjuvant pemetrexed and cisplatin chemotherapy|neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma
45660345|NCT05486689|Other|Pulmonary Rehabilitation|"The enrolled subjects will receivePR program. The 3 weeks inpatient PR will include education, exercise training, nutritional and psychological counselling.~Education: individualized session of 20 minutes each and group session of 45 minutes each. Endurance training: at least twelve 30-minute daily sessions of supervised incremental exercise training according to Maltais, continuous cycling at 50-70% of the maximal load calculated on the basis of the baseline 6MWT according to Hill. Strength training: twelve 30-minute daily sessions of peripheral limb muscle strength training: 2 set of 8 repetitions during the first week, increased at 12 from the second. The initial load will be set at 30/50% of maximal voluntary isometric strength (MVS). Psychological intervention: individual tailored intervention will be offered when the Hospital Anxiety and Depression Scale (HADS) score is >10 or judged necessary by clinicians, after verifying the subject's motivation."
45814082|NCT04739228|Behavioral|Guided Written Disclosure Protocol Group|The writing task consists of three sessions of 20 minutes each, with an interval of one week between each other. In the first session, patients were asked to describe the onset of illness, describing chronologically and detailed places, images, sounds and actions, as they are followed and detached from the emotions. In the second session, the patients were asked to write about thoughts and emotions felt during the illness experience, talking about the impact that illness had on their daily lives and how it had changed their personal attitude to life itself. In the third and final session, the patients were asked to analyze subjective new skills acquired.
45814083|NCT04739228|Behavioral|Active Control Group|The writing task also consists of three sessions of 20 minutes each, with an interval of one week between each other. In all three writing sessions, patients were asked to report the daily activities during the last week, without focusing on the emotional aspects.
45814084|NCT05470465|Drug|Placebo and Oxycodone|Participants will receive placebo on days 1-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
45814085|NCT05470465|Drug|Paroxetine and Oxycodone|Participants will receive 40 mg paroxetine (2 x 20 mg tablets) on days 1-6 and 60 mg paroxetine (3 x 20 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
45814086|NCT05470465|Drug|Escitalopram and Oxycodone|Participants will receive 20 mg escitalopram (2 x 10 mg tablets) on days 1-6 and 30 mg escitalopram (3 x 10 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
45814087|NCT00368030|Drug|Eszopiclone|Eszopiclone 3 mg QD
45814088|NCT00368030|Other|Placebo|Placebo tablet
45453951|NCT00382096|Drug|Vildagliptin|
45814089|NCT02656069|Drug|G-Pen (glucagon injection)|1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
45814090|NCT02656069|Drug|Lilly Glucagon (glucagon injection [rDNA origin])|1 mg of Lilly glucagon reconstituted from lyophilized powder
45814091|NCT00368186|Biological|Pneumo 23|
45814092|NCT05419063|Behavioral|weight loss strategies|Participants will receive recommendations on how to decrease caloric intake, monitor their weight and track the related behaviors and progress.
45814093|NCT05419063|Behavioral|text-based and email feedback|Participants will receive weekly text-based feedback based on dietary strategy tracking and weight tracking. Participants will receive tailored email support and synchronous problem solving sessions as needed.
45814094|NCT02707172|Behavioral|handwashing with soap|handwashing with soap by a standardized 6-step handwashing technique
46077690|NCT04220892|Drug|Abemaciclib|150 mg twice a day, by mouth.
46077691|NCT02696148|Drug|liraglutide|For subcutaneous (s.c., under the skin) injection once daily.
45453952|NCT00382096|Drug|Metformin|
45814095|NCT02707172|Behavioral|handwashing with water|handwashing with water by a standardized 6-step handwashing technique
45814096|NCT05351762|Drug|Nimotuzumab Combined With Neoadjuvant Chemotherapy|The study arm received nimotuzumab (400mg, every three weeks, for 2 weeks) combined with TPF chemotherapy
46077692|NCT02696148|Drug|placebo|For subcutaneous (s.c., under the skin) injection once daily.
45453953|NCT00382096|Drug|Vildagliptin + Metformin|
45453954|NCT05172284|Other|Questionnaires|This is a collection of data from normal clinical routine: patients will be asked to record the assessments they undergo during their course of treatment, without changing clinical practice in any way. Data inherent to the following procedures will be collected: examinations, laboratory tests, imaging tests, questionnaires and rating scales.
45453955|NCT00482092|Drug|Prochymal®|Prochymal® IV infusion
45453956|NCT00482092|Drug|Placebo|Prochymal® Placebo-matching IV infusion
45952775|NCT00137852|Drug|Celecoxib|Given twice daily 3 days prior to radiation and up until one week prior to surgery. It will then be started again once the participant is released from the hospital following surgery for 26 weeks.
45952776|NCT00137852|Procedure|Radiation Therapy|5 days a week for 5-6 weeks
45952777|NCT00137852|Procedure|Esophagectomy|Within 4-8 weeks of chemoradiation therapy
45952778|NCT00160368|Behavioral|Potassium supplementation|
45952779|NCT00137891|Drug|Modified Release rhTSH|
45952780|NCT00160407|Drug|Orlistat (Xenical)|
46077693|NCT00887198|Drug|Abiraterone acetate|1000 mg per day (4 x 250-mg tablets) taken orally.
45453957|NCT01338974|Genetic|gene expression analysis|
45453958|NCT01338974|Genetic|proteomic profiling|
45453959|NCT01338974|Other|flow cytometry|
46077694|NCT00887198|Drug|Placebo|4 placebo tablets per day taken orally.
46077695|NCT00887198|Drug|Prednisone|5 mg tablet orally twice daily.
46077696|NCT04342585|Drug|Micronised vaginal progesterone|A diary will be given to participants to ensure compliance.
45660346|NCT05478655|Other|visual analog scale|VAS was studied: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital and further 1, 3, 6, 12 months after the injury; 5) at the rehabilitation stage. Intervals between analgesia were also studied.
45952781|NCT00160407|Behavioral|1400 kcal diet (30% fat)|
45660347|NCT03753607|Other|No intervention|No intervention
45952782|NCT00137930|Biological|Live attenuated rotavirus vaccine|
45952783|NCT00153894|Behavioral|Strength training|One-on-One training with a personal trainer for 50 minutes twice a week using Nautilus machines for 16 weeks.
45952784|NCT00153894|Behavioral|Endurance training|Cardiovascular training at home for 30 minutes three times per week for 16 weeks.
45952785|NCT00138008|Drug|endocrine therapy|Drug: endocrine therapy
45952786|NCT00138008|Procedure|radiotherapy|Procedure/Surgery: radiotherapy
45952787|NCT00160446|Drug|Asoprisnil|5mg Tablet, oral Daily for 12 weeks
45952788|NCT00160446|Drug|Asoprisnil|10 mg Tablet, oral Daily for 12 weeks
45952789|NCT00160446|Drug|Asoprisnil|25 mg Tablet, oral Daily for 12 weeks
45952790|NCT00160446|Drug|Placebo|Tablet, oral Daily for 12 weeks
45952791|NCT00138047|Drug|zinc supplementation|
45453960|NCT01338974|Other|laboratory biomarker analysis|
45814097|NCT05346536|Other|Detection of circulating tumor cells expressing Axl: CTC-AXL(+)|"Detection of CTC-AXL(+) using 2 techniques:~CellSearch®, FDA-USA approved technology~EPIDROP System~CellSearch® (Menarini Company) The current gold-standard CellSearch® technique requires the use of CellSave tubes. This technique allows the isolation of fixed CTCs. This technique uses a positive (CellSearch® Epithelial Cell Kit) enrichment method from total blood using magnetic beads coupled to an EpCAM capture antibody. CTCs are then detected (anti-panCK antibodies, DAPI, anti-CD45 and characterized (anti-AXL antibody) by immunofluorescence (IF).~EPIDROP It requires the use of EDTA tubes. This technique is based on a method of negative enrichment of CTCs from total blood using a cocktail of tetrameric antibodies to eliminate unwanted blood cells and to preserve only purified tumor cells (RosetteSep - StemCell Technology).Then, cells are loaded in a microfluidic chip. The detection and characterization is done by IF to the single cell in micro-droplets."
45952792|NCT00153933|Drug|Bortezomib|Given intravenously on days 1, 2, 8, 11 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
45952793|NCT00153933|Drug|CC-5013|Orally on days 1-14 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
45952794|NCT00138086|Drug|Zevalin plus BEAM|
45952795|NCT00138164|Biological|denileukin diftitox|
45952796|NCT00153972|Drug|Cabergoline|
45952797|NCT00153972|Drug|Levodopa|
45952798|NCT00404144|Device|Drug Eluting Balloon|PCI of small vessels single arm study
45453961|NCT01335776|Behavioral|Mindfulness-Based Stress Reduction|This intervention is provided over the course of eight, weekly, 90 minute sessions, plus one 6 hour silent retreat.
45453962|NCT01335776|Behavioral|Cognitive Behavior Therapy|This treatment is delivered to small groups over the course of 8 weekly, 90 minute sessions
45453963|NCT00379990|Drug|GW274150|60 mg /day
45453964|NCT00379990|Drug|Prednisolone|7.5 mg/day
45453965|NCT00379990|Other|Placebo|Placebo
45814098|NCT02683772|Device|Astral|Astral ventilator
45814099|NCT02708641|Drug|pembrolizumab|200 mg IV given every three weeks
45952799|NCT00160485|Drug|Glyburide|dosage required to obtain adequate glucose control
45952800|NCT00160485|Drug|Insulin|variable dosage to obtain glucose control
45952801|NCT00404183|Drug|Extended-Release Hydrocodone/Acetaminophen|2 tablets BID
45952802|NCT00404183|Drug|Placebo|2 tablets BID
45952803|NCT00154011|Drug|rosiglitazone (drug)|
46077697|NCT04342585|Device|Vaginal pessary|The internal diameter size will be decided based on the clinical assessment of the cervix.
46077698|NCT05402904|Diagnostic Test|nerve conduction study|Routine nerve conduction study on both lower limbs as well as F- wave , Hoffman reflex and somatosensory evoked potential.
45952804|NCT00404222|Drug|Hydrocodone/Acetaminophen Extended-Release|2 tablets x 1
45952805|NCT00404222|Drug|Hydrocodone/Acetaminophen Immediate Release (NORCO®)|1 tablet q 4 hours x 3
45952806|NCT00404222|Drug|Placebo|q 4 hours x 3
45952807|NCT00160602|Drug|Certolizumab Pegol|
45952808|NCT00138242|Drug|carboplatin|
45952809|NCT00138242|Drug|docetaxel|
45952810|NCT00138242|Procedure|adjuvant therapy|
45952811|NCT00154050|Drug|candesartan (drug) or quinapril (drug)|
45952812|NCT00138281|Biological|FluMist|
45952813|NCT00138281|Biological|Fluzone|
45952814|NCT00160719|Procedure|retrieve blood samples|blood samples obtain pre-op, 6 and 12 months post-op
45952815|NCT00154089|Drug|EM-1421|EM-1421 administered intravaginally every 3 weeks as 45 mg (1% w/w) EM-1421 or 90 mg (2% w/w) EM-1421
45952816|NCT00138359|Drug|Niclosamide|
45952817|NCT00154128|Device|occlusal appliance|
45952818|NCT00138398|Biological|Commercial TriValent Split Influenza Virus|
45952819|NCT00154167|Drug|NV-101 (phentolamine mesylate solution)|
45952820|NCT00160758|Procedure|retrieve massive allograft|Allograft constructs removed because of infection or cancer complications will be retained for biomechanical testing
45952821|NCT00138476|Drug|Placebo|120 mL of the sodium bicarbonate solution, followed by 82 mL of sterile water, United States Pharmacopeia (USP) without virus; followed by 500 mg of sodium bicarbonate aqueous solution taken 5 minutes after placebo inoculation.
45952822|NCT00138476|Biological|Norwalk Virus|Prepared and packaged from liquid feces (DC544) by clarification, centrifugation, and serial dilutions; desired doses [reverse transcription polymerase chain reaction (RT-PCR) Units] 4800, 48, 4.8, 0.48.
45814100|NCT02657629|Other|Continuous Feeding Regimen|Nocturnal continuous enteral feedings given from 8pm-8am with intermittent bolus feedings every 3 hours between 11am and 5pm. Continuous feedings given via gavage (nasogastric tube, orogastric tube or gastrostomy tube) and intermittent bolus feeds via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
45814101|NCT02657629|Other|Intermittent Bolus Feeding Regimen|Intermittent bolus enteral feedings given after 3 hours for entire 24 hours period. Feedings given via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
45952823|NCT00160797|Device|MIS™ Minimally Invasive Solutions™ TKA System|
45952824|NCT00138515|Drug|vildagliptin|
45952825|NCT00154206|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
45952826|NCT00138554|Drug|vildagliptin|
45952827|NCT00138554|Drug|pioglitazone|pioglitazone 45 mg qd
45952828|NCT00160836|Device|"Tissue sampling (G.I.U.M. catheter)"|
45952829|NCT00138593|Drug|vildagliptin|
45952830|NCT00154245|Drug|Enteric-Coated Mycophenolate sodium (EC-MPS)|
46077699|NCT00903643|Other|Physical examination|Physical examination and multiple questionnaires will be administered
46077700|NCT05399706|Diagnostic Test|CTA Aorta|Computed Tomography Angiography - Aorta Whole
46077701|NCT04219644|Device|Breatheasy device|
45453966|NCT01339130|Behavioral|Computerized tests and Electrophysiological measurements|"Computerized tests: used to evaluate the empathy The participant observes a computer screen on which appears different types of images or words that can evoke an emotion. The participant responds by pressing the screen with his finger. This is a choice between several answers and respond as quickly as possible.~Electrophysiological measurements: provide a measure of autonomic response to emotional stimuli: galvanic response (GSR) and electromyographic activity (EMG) of facial muscles (corrugator supercilii and zygomatic major).~Neuropsychological assessment includes an assessment of intellectual efficiency, perceptual and visual-constructive abilities, memory, executive and an assessment of behavior and mood from questionnaires."
45453967|NCT00377182|Drug|Copegus|1000/1200mg po daily for 4 weeks
45660348|NCT03981445|Behavioral|ARTAS Adapted Patient Navigation|Patient navigation will provided by trained patient navigators to participants randomized to the off-site referral to specialized care arm. Patient Navigators will actively coordinate and link participants to available clinics and community resources by scheduling appointments, arranging transportation, and assisting the participant with completing any paperwork that a clinic or service agent may require. The intervention will include up to five, 30-45 minute face-to-face meetings between the patient navigator and participant. These meetings will be tailored around each participant's needs. Additionally, the patient navigator assists the participant in identifying and utilizing informal and formal sources of support to move along the PrEP and/or HCV care continuum.The patient navigator will help the participant inform off-site physicians of the trial and of the availability of PrEP and HCV medication, should the physician and patient decide to initiate one or both treatments.
45814102|NCT02683928|Biological|GBR 830|
45814103|NCT02683928|Biological|Placebo|
45814104|NCT02708186|Drug|Nelotanserin|once daily, oral, 20-mg tablets
45814105|NCT02708186|Drug|Placebo|once daily, oral, matching tablets
45814106|NCT02710591|Drug|Rimeporide|"Cohort 1:~50 mg TID in patients with a body weight ≤ 30kg at Baseline and 75 mg TID in patients with a body weight > 30kg at Baseline~Cohort 2:~100mg TID in patients with a body weight ≤ 30kg at baseline and 150 mg TID in patients with a body weight > 30kg at Baseline~Cohort 3:~150 mg TID in patients with a body weight ≤ 30kg at baseline and 200 mg TID in patients with a body weight > 30kg at Baseline~Cohort 4:~200 mg TID in patients with a body weight ≤ 30kg at Baseline and 300 mg TID mg TID in patients with a body weight > 30kg at Baseline"
45453968|NCT00377182|Drug|PEGASYS|180 micrograms sc weekly for 4 weeks
45453969|NCT00377182|Drug|RO5024048 1500mg|1500mg po bid for 4 weeks
45814107|NCT04339322|Other|Follow up|Follow up to assess the outcome until complications, improvement, death or being transferred to another quarantine hospital.
45952831|NCT00138632|Drug|PTK787|Visudyne® + PTK787, 500 mg/day
45952832|NCT00138632|Drug|PTK787|Visudyne® + PTK787 1000 mg/day
45952833|NCT00138632|Drug|Placebo|Visudyne® + Placebo
45952834|NCT00160875|Drug|Irinotecan hydrochloride trihydrate|Irinotecan (65mg/m2) weeks 1-2, 4-5, 7-8
45952835|NCT00160875|Drug|Cisplatin|Cisplatin (30 mg/m2) weeks 1-2, 4-5, 7-8
45952836|NCT00138710|Drug|Letrozole (Femara)|
45952837|NCT00160914|Behavioral|Identification/management of childhood obesity (behavior)|In this project, we plan to conduct a national survey of pediatricians to assess common strategies for identification and management of childhood obesity, along with pediatricians' attitudes and beliefs about childhood obesity.
45952838|NCT00138749|Drug|SS-RBX|
45952839|NCT00160953|Procedure|Endorectal Coil Magnetic Resonance Images|
45952840|NCT00138788|Procedure|Radiotherapy, dose fractionation|
45952841|NCT01243762|Drug|dalotuzumab|Administered intravenously (IV) once weekly in 28-day cycles for a maximum of 6 months of study therapy
45952842|NCT01243762|Drug|MK-0752|Administered orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy
45952843|NCT01243762|Drug|ridaforolimus|Administered PO daily for 5 consecutive days per week in 28-day cycles for a maximum of 6 months of study therapy
45952844|NCT01243762|Drug|MK-2206|Administered PO weekly in 28-day cycles for a maximum of 6 months of study therapy
45952845|NCT00154323|Drug|Oxcarbazepine|
45952846|NCT00138827|Drug|Biotene (mouth care)|
45952847|NCT00160992|Biological|Melan-A analog peptide|
45952848|NCT04696705|Biological|Ex-vivo expanded allogeneic γδT cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
45660349|NCT03981445|Behavioral|Adherence Counseling|Counseling for PrEP initiation and adherence and, if necessary, HCV treatment will be provided by the clinical counseling staff of the on-site integrated care arm. Adherence counseling will include, but not be limited to, the indications, advantages, and disadvantages (e.g. side effects) of PrEP and HCV treatment in order to help the participant with his/her decision. The counselor will provide any necessary information to the participants and help them to address health and social needs. If required, the counselor will help the patient and physician with insurance-related issues. Adherence counselling will be carried out in a motivational style. The intervention will include five 30-45 minute face-to-face meetings with the participant and the adherence counselor over 6 months.
45814108|NCT02710981|Drug|clomiphene citrate|Clomiphene citrate only arm: Patients received Clomiphene citrate induction ( (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Sonographic assessment of endometrial thickness together with Uterine artery Doppler evaluation were done in the late proliferative phase ( Day of HCG injection).
45660350|NCT05483647|Procedure|Local infiltrative anaesthesia|In prone position, before the skin incision, patients in G1 underwent local infiltrative anaesthesia et the level of incision. The skin, subcutaneous tissue and muscles up to the foramen intervertebral were anesthetized by the surgeon employing forty millilitre solution of Lidocaine 1% with Dexamethasone 0.02% and Epinephrine 0.00018%.
45814109|NCT02710981|Drug|Sildenafil vaginal gel|In addition to clomiphene citrate treatment as the previous group, women in the second arm were prescribed sildenafil vaginal gel in a dose of 5 g gel applied vaginally twice daily from cycle day 8 to the day of HCG injection. The sildenafil vaginal gel consists of sildenafil acetate as a medicament loaded on an in situ gelling system based on two polymers: Pluronic p-127, and Hydroxy Ethyl Cellulose.The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 10 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel.
45814110|NCT04193228|Device|Carbon Fibre Ankle Foot Orthosis|Off teh shelf carbon fibre ankle foot orthoses worn bilaterally
45814111|NCT04193228|Behavioral|Exercise|Ankle muscle strength training
45814112|NCT04189796|Dietary Supplement|Cheese|Daily oral intake of cheese
45814113|NCT02711839|Dietary Supplement|Commercial diabetic formula|The formula were supplied 1500~1800 kcal daily depend on the patient's individual situation
45814114|NCT02711839|Dietary Supplement|White sweet potato formula|The formula were supplied 1500~1800 kcal daily depend on the patient's individual situation
45814115|NCT04738838|Drug|Oxytocin nasal spray|Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
45814116|NCT04738838|Drug|Placebo nasal spray|Intranasal treatment with placebo via nasal spray
45814117|NCT04738916|Device|Whole-body vibration training|Whole body vibration (WBV) is a form of treatment that has been shown to have an important role in increasing neuromuscular performance, improving muscular strength, balance. The technique involves standing and holding positions, or performing prescribed exercises, on a platform that is vibrating at a programmed frequency, amplitude, and magnitude of oscillationWhole-body vibration (WBV) is a therapeutic method that exposes the entire body to mechanical oscillations while the patient stands or sits on a vibrating platform.
45814118|NCT05362123|Other|non interventional|Online google form questioner
45814119|NCT05331404|Radiation|PET examination|PET examinations with auditory stimuli such as human voice and environmental sounds.
45814120|NCT05331404|Other|Quality of life assessment|"quality of life assessment by :~Speech, Spatial and Qualities of Hearing~Hearing Handicap Inventory For The Elderly Screening~Short Form Health Survey"
45814121|NCT04739917|Biological|Vaccine PvCS N+C+R 150 mcg|Vaccine PvCS N+C+R 150 mcg (Montanide ISA-51), freeze dried powder.
45814122|NCT04739917|Other|Placebo SSN Montanide ISA-51 1 mL|SSN Montanide ISA-51 1 mL
45453970|NCT00377182|Drug|RO5024048 3000mg|3000mg po bid for 4 weeks
45814123|NCT05315726|Other|Dynamometer|Measurement of elbow/wrist spasticity
45814124|NCT05315726|Other|Muscle vibrations|1 session of 10 minutes
45814125|NCT05315726|Other|Muscle vibrations|3 times/week for 6 weeks
45814126|NCT05315726|Other|Placebo muscle vibration|3 times/week for 6 weeks
45814127|NCT02713711|Radiation|phototherapy|Twelve sessions of phototherapy (UV-B) according to individual initial evaluation of Minimal Erythema Dose (MED).
45814128|NCT02713711|Procedure|balneotherapy|Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L).
45814129|NCT02713711|Procedure|balneophototherapy|Twelve sessions of both balneotherapy and phototherapy treatments.
45814130|NCT02659501|Drug|Liposomal bupivacaine|Liposomal Bupivacaine is an aqueous suspension of multivesicular liposomes containing bupivacaine. After injection into soft tissue, bupivacaine is slowly released from the multivesicular liposomes, extending this drug's duration of action.
46002702|NCT04645056|Other|Stretching and Mobility exercises for neck and shoulder|9 specific stretching and mobility exercises performed 3 times every day the first 4 weeks after surgery.
46002703|NCT04684316|Other|Electronic survey with selective consultations|Participants complete an online questionnaire, after which the 20% employees that mostly need contact with the occupational physician (based on their survey score) are invited to a consultation with the occupational physician.
46077702|NCT02826668|Other|Ultrasound|A baseline lumbar ultrasound in a standardized lateral position (by bed markings) will be performed with the midline and L3-L4 interspace marked, and estimated depth to the epidural space recorded. A second lateral lumbar ultrasound will be performed immediately prior to placement at the time of epidural request. The bed position will be standardized with lines drawn down the back, at the flexion of the knee, and heel of the foot. The sonographic measurements will include the midline, the L3-4 interspace, (both marked at the skin surface), and the measured depth to the ligamentum flavum (in centimeters).
45660351|NCT05483647|Procedure|Erector spine plane block|The transverse vertebral process of the required level of spine was identified using the mobile C-arm X-ray System. When the tip of the 22G needle reached to the transverse vertebral process 3 cm lateral to the spinous process, a solution of 40 millilitres of Lidocaine 1% with Dexamethasone 0.02% and Epinephrine 0.00018% was injected under the erector spinae muscle bilaterally.
45660352|NCT05478577|Other|Motor rehabilitation|Treatments for upper limb recovery (e.g. occupational therapy, technology devices, conventional therapy)
45660353|NCT05486299|Procedure|Robotic assisted single-port general surgery|Robot assisted single-port rectal resection, colectomy, partial gastrectomy, appendectomy and cholecystectomy via the single-port configuration
45660354|NCT05478421|Procedure|Collagen sponge|The bone cavity will be filled with collagen sponge.
45660355|NCT05478421|Procedure|GBR|The bone cavity will be applied with guided bone regeneration with deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG) .
45660356|NCT05478421|Procedure|CS/GBR|The bone cavity will be applied with guided bone regeneration with collagen sponge and deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG) .
45814131|NCT02659501|Drug|Bupivacaine with epinephrine|Bupivacaine, like other local anesthetics reduces the flow of sodium in and out of nerves. This decreases the initiation and transfer of nerve signals in the area in which the drug is injected. This leads first to a loss of sensation of pain, temperature, touch, and deep pressure. This drug is the current standard of care for local, postoperative local anesthesia following breast reconstruction. Epinephrine, a vasoconstrictor, is included in bupivacaine formulations to improve the duration of local anesthesia.
45814132|NCT02659501|Drug|Morphine sulfate|Morphine is an opiate pain medication administered intravenously for severe, breakthrough post-operative pain.
45814133|NCT02659501|Drug|Hydrocodone/acetaminophen|Hydrocodone acetaminophen is a combination of an opiate pain medication (hydrocodone) and a non-steroidal anti-inflammatory drug (acetaminophen) given orally to patients for moderate post-operative pain.
45814134|NCT02659501|Drug|Diazepam|Diazepam is a benzodiazepine medication that is administered orally to treat muscle spasms in patient's following expander and implant-based breast reconstruction.
45814135|NCT02718157|Device|Comparison between GenePOC PCR and Reference Method|Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
45814136|NCT00367939|Drug|valsartan + amlodipine|
45814137|NCT05303701|Drug|GV1001 Placebo|0.9% normal saline
45814138|NCT05303701|Drug|GV1001 0.56mg|Lyophilized peptide from hTERT
45814139|NCT05303701|Drug|GV1001 1.12mg|Lyophilized peptide from hTERT
45814140|NCT02720107|Drug|fingolimod|
45814141|NCT02662387|Device|External nasal dilator (END)|Applying External nasal dilator as adjuvant to high flow oxygen
45814142|NCT02662387|Other|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
45814143|NCT02722837|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
45814144|NCT02710526|Drug|CAM2038|Long-Acting Subcutaneous Injectable Depot of Buprenorphine
45814145|NCT04339231|Procedure|sphenopalatine ganglion block|"The block of the sphenopalatine ganglion will be performed bilaterally, using a cotton bud soaked with 1% ropivacaine, placed in the mucosa of the posterior wall of the nasal cavity, through both nostrils.~Once placed in the proper position, the swab will remain for about 20 minutes to absorb the local anesthetic from the mucosa."
45814146|NCT02724787|Behavioral|Manage Emotions to Reduce Aggression (MERA)|MERA is a 3-session group treatment that teaches Veterans the purpose of emotions, how trauma and combat can increase emotions, and how to better regulate them. The skills use cognitive-behavioral and mindfulness techniques to help Veteran better regulate their emotions. These skills are commonly used in clinical practice, but have not been delivered in 3 sessions.
45814147|NCT02725645|Other|loading conditions|Different backpack loading conditions 0%, 10%, 15% and 20% allocated randomly
45814148|NCT02664961|Drug|TRC105|Subjects will begin by receiving TRC105 weekly. Subjects who achieve a complete response on single agent TRC105 may transition to every two week dosing.
46077703|NCT02826590|Other|Neck passive mobilizations|Passive mobilizations performed to the neck of the participant by a Physiotherapist
45660357|NCT05483569|Other|Complex Decongestive Physiotherapy|Complete or complex decongestive physiotherapy (CDP) is a treatment for lymphedema, a condition in which excess fluid (lymph) collects in a part of the body. Damage to the lymph nodes or vessels, or a blockage leading to chronic swelling, usually causes lymphedema.
45660358|NCT05483569|Other|Multidimensional Diaphragmatic Breathing Exercises|Diaphragmatic breathing is an exercising technique to help strengthen your diaphragm and fill your lungs with air more efficiently.
45814149|NCT02664961|Drug|Bevacizumab|Bevacizumab will be dosed every two weeks.
45814150|NCT02725801|Device|Allergen one-port tissue expander placement|patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
45814151|NCT02725801|Device|AlloX2 two-port tissue expander placement|patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
45814152|NCT02665273|Procedure|Greater occipital nerve block|Bilateral greater occipital nerve block
45814153|NCT02665273|Drug|Bupivacaine|0.5 cc of 0.5% bupivacaine injected intradermally
45814154|NCT02713178|Drug|bupivacaine liposome injectable suspension|bupivacaine liposome injectable suspension 133 mg expanded with normal saline to 20 mL or 266 mg in 20 mL
45814155|NCT02713178|Drug|Placebo|Normal saline.
46077704|NCT02826590|Other|Manual contact|Manual contact applied to the neck of the participant by a Physiotherapist
46077705|NCT05110794|Drug|LY3502970|Administered Orally.
45814156|NCT02665741|Device|Olympus transparent cap|distal colonoscope attachment
45453971|NCT01341938|Drug|Commit® nicotine lozenges (4 mg) & self-help materials|"Participants provided with instructions on standard use of lozenge for nicotine replacement therapy (NRT) & instructed to use the lozenge any time they have a craving or urge to use ST or tobacco. Dosing: weeks 1-6 one lozenge every 1-2 hours/16 per day, weeks 7-9 one lozenge every 2-4 hours/8 per day, weeks 10-12 one lozenge every 4-8 hours/4 per day + The Enough Snuff video and printed guide providing strategies for tobacco cessation."
45814157|NCT02665741|Device|Medivators Endocuff|distal colonoscope attachment
45814158|NCT02665741|Device|Control|No distal colonoscope attachments
46077706|NCT02832128|Drug|AUT00063|4 capsules of 200 mg AUT00063, to take orally with food for 4 weeks
45453972|NCT01341938|Behavioral|Commit® nicotine lozenges (4 mg) & phone counseling & self-help materials|"Three phone counseling sessions to assist in cessation from use of all tobacco + lozenge nicotine replacement therapy (NRT) + The Enough Snuff video and printed guide providing strategies for tobacco cessation."
45453973|NCT01341938|Behavioral|Phone counseling & self-help materials|"Three phone counseling sessions to assist in cessation from use of all tobacco + The Enough Snuff video and printed guide providing strategies for tobacco cessation."
45660359|NCT05483569|Other|Facial Release Technique|Fascial release is a manual therapy method that is applied holistically to the muscles and surrounding fascia through mechanical stimulation. It is a comprehensive approach to the evaluation and treatment of the muscular and fascia system in the body.
45660360|NCT04273087|Other|Observation|Clinical signs and symptoms
45660361|NCT05478343|Biological|IM21 CAR-T cells|IM21 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
45660362|NCT05478187|Device|QWalk Study Group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the new wearable cueing system (QWalk)
45660363|NCT05478187|Other|Traditional visual cues - Control group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the traditional cues (stripes on the floor)
45660364|NCT05478109|Drug|[14C]XZP-3287|360 mg suspension containing 50µCi of [14C] XZP-3287
45660365|NCT05475535|Behavioral|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy
45660366|NCT05475535|Behavioral|Self-Compassion|Self-Compassion focused exercises
45814159|NCT05267756|Device|(kurki-application),VR glasses|it is virtual reality immersive based-exercise game
45814160|NCT04130438|Drug|Nebivolol|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
46002704|NCT04636788|Procedure|Venous sampling|venous sampling of 12ml
46077707|NCT02832128|Drug|Placebo|4 capsules of placebo, to take orally with food for 4 weeks
45814161|NCT04130438|Drug|Diltiazem|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
45952849|NCT04696588|Other|Complex set of kinesiotherapy of cervical spine and delicate massage|"Intervention:- A complex neck therapy.Treatment comprises 10 sessions performed on consecutive working days, includes four parts.~Active exercises of the neck, 5 minutes, first demonstrated by the physiotherapist and next the patient performs them under supervision, 5 repetitions of each of the following: cervical flexion, rotation to the left and to the right, side bending to the left and to the right, torsion to left and right.~Massage of cervical interspinales muscles performed by therapist 3 minutes.~Post Isometric Relaxation (PIR) performed by physiotherapist. 15 minutes.~Active neck exercises - the same as mentioned in step 1. 5 minutes. Total duration of one treatment session is around 30 minutes."
45453974|NCT02284048|Drug|ticagrelor|compare the effect of ticagrelor and control on the Coronary Flow Reserve in patients with microvessel angian
45453975|NCT05185232|Other|Impact of gaps in care/loss to healthcare follow-up|There will not be a discrete intervention as part of this study but study investigators will be examining a set of primary and secondary outcomes in patients who have followed recommended cardiac care vs. those who have not.
45453976|NCT00374296|Drug|MGCD0103|MGCD0103 administered orally three-times per week
45952850|NCT00138866|Drug|Risedronate|
45952851|NCT00154362|Drug|Oxcarbazepine|
45952852|NCT01243411|Biological|AA4500|2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)
45952853|NCT00138905|Device|UMTS mobile basestation radiation|
45952854|NCT00161031|Drug|Atomoxetine|
45453977|NCT00547066|Biological|veltuzumab|hA20 will be administered intravenously in two doses over two weeks
45814162|NCT04130438|Other|Placebo|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
45814163|NCT02726971|Drug|Femoston|Femoston is a Complex Packing Estradiol Tablets and Estradiol and Dydrogesterone.
45814164|NCT04121936|Other|There will be no intervention|There will be no intervention
45814165|NCT04048850|Drug|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]|Daily medication
45453978|NCT01315496|Drug|Immunoglobulin G|Immunoglobulin 1.5-2g/Kg/3days
45458479|NCT01351844|Behavioral|Education and General Exercise|A physical therapist with experience in treating breast cancer patients with lymphedema will demonstrate a series of 4-5 general stretching and toning exercises.
45814166|NCT02727751|Drug|Tenapanor|
45814167|NCT05165329|Combination Product|PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations|PROBIOTIC: The probiotic to be used is Lactobacillus rhamnosus GG, supplied as a freeze-dried powder. Probiotic will be prepared under strict Food Manufacturing Regulations. The daily dose of 2x10^10 cfu will be packed individually in sachets. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic must be stored at 4 degrees Celsius
45814168|NCT05165329|Combination Product|PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations|PROBIOTIC PLACEBO: Probiotic Placebo is maltodextrin. The daily dose will be measured using a standardised scoop. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic should be stored at 2-8 degrees Celsius.
45952855|NCT02964533|Other|thunder-fire moxibustion therapy|burn moxa stick and heat shenque acupoint
45952856|NCT02964533|Other|common moxa-stick moxibustion|burn moxa stick and heat shenque acupoint
45952857|NCT00154401|Drug|liraglutide|
45952858|NCT00138944|Drug|placebo|od
45952859|NCT00138944|Drug|eplerenone|50mg od
45952860|NCT00161070|Drug|anticoagulation|
45952861|NCT00161070|Drug|aspirin and dipyridamole|
45952862|NCT00161070|Drug|aspirin alone|
45952863|NCT00138983|Drug|Alendronate versus alfacalcidol (1-alpha OH vitamin D)|
45952864|NCT01243177|Drug|Lacosamide|"Lacosamide:~Strengths: 50 mg / 100 mg~Form: tablets~Dosage: total daily target dose of 200 mg, 400 mg or 600 mg. 1 dose reduction was allowed from either 600 mg to 500 mg or from 400 mg to 300 mg total daily dose~Duration: up to 118 weeks"
45952865|NCT01243177|Drug|Carbamazepine-Controlled Release|"Carbamazepine-CR:~Strengths: 200 mg~Form: tablets~Dosage: total daily target dose of 400 mg, 800 mg or 1200 mg. 1 dose reduction was allowed from either 1200 mg to 1000 mg or from 800 mg to 600 mg total daily dose~Duration: up to 118 weeks"
45952866|NCT00139022|Device|Continuous Positive Airway Pressure|
45952867|NCT00154440|Drug|proton pump inhibitor|
45952868|NCT00154440|Drug|clarithromycin|
45952869|NCT00154440|Drug|amoxicillin|
45952870|NCT00154440|Drug|metronidazole|
45952871|NCT00154440|Procedure|radiation therapy|
45952872|NCT00139061|Drug|Torcetrapib/Atorvastatin|
45952873|NCT00139061|Drug|Fenofibrate|
45952874|NCT00504517|Other|Evaluating Educational Models|Evaluating various forms of educational models for physicians.
45952875|NCT00139100|Drug|antimicrobial agent in soap|
45952876|NCT00161148|Drug|Probiotics|
45952877|NCT00161187|Biological|therapeutic allogeneic lymphocytes|The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/kg +/- 1.0 x 108 CD3+ cells/kg. Up to 6 cycles.
45952878|NCT00139178|Drug|Different HAART regimens|
45952879|NCT04705584|Drug|Prednisolone (as Acetate)|Standard treatment protocol includes Topical steroids for 8 weeks with gradual dose tapering.
45952880|NCT04705584|Drug|CycloSPORINE Ophthalmic Suspension|This treatment arm includes the use of topical cyclosporine A after 2 weeks of topical steroid use.
45952881|NCT04705584|Drug|LTacrolimus Topical|This treatment arm includes the use of topical Tacrolimus after 2 weeks of topical steroid use.
45952882|NCT00139217|Drug|iNO|
45814169|NCT05165329|Combination Product|PEANUT PLACEBO: Peanut Placebo is maltodextrin powder with food colouring and peanut essence that has similar appearance, taste and smell to the active product.|PROBIOTIC PLACEBO: Probiotic Placebo is maltodextrin. The daily dose will be measured using a standardised scoop. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic should be stored at 2-8 degrees Celsius.
45952883|NCT00139217|Procedure|Non-invasive nitric oxide|
45952884|NCT00161226|Device|Levonorgestrel intrauterine system|
45952885|NCT00139256|Drug|Betamethasone|Betamethasone injection
45952886|NCT00161265|Procedure|tissue procurement|tissue procurement
45952887|NCT00139295|Device|Hylastan|
45660367|NCT05475535|Behavioral|Active Control|Engagement in a mobile application (Cooperation skills)
45660368|NCT05475457|Behavioral|R3|Training, consultation, and fidelity-monitoring to supervisors in the child welfare system to reinforce (1) effort, (2) relationships and roles, and (3) small steps toward goal achievement.
45952888|NCT00161304|Drug|Testosterone Enanthate|Testosterone Enanthate
45952889|NCT00161304|Other|Placebo|placebo
45952890|NCT00139334|Biological|Rotavirus|
45952891|NCT04705389|Other|Samples|blood samples
45952892|NCT01242748|Drug|Degarelix|The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. In the main CS35 trial, a starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the degarelix treated participants continued to receive degarelix 480 mg s.c. treatment every three months.
45453979|NCT02286856|Behavioral|diet intervention|The dietary intervention implies optimizing the diet based on individually calculated energy and protein requirements, while for remaining nutrients advise in line with recommended daily amounts (RDA) will be provided. This nutrients will be translated to food products and lifestyle advice is added. Individual diet counseling will be part of the intervention to improve compliance.
45660369|NCT05475379|Biological|Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)|"Typhoid Vi-polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT) Typhocon will be manufactured by Incepta Vaccine Limited"
45453980|NCT01339208|Other|Telemedicine diabetes intervention|3 month duration telemedicine consultation and diabetes education
45660370|NCT05483257|Device|Multigene panel for next-generation sequencing|HLA-I genotyping based on next-generation sequencing for prognosis evaluation
45660371|NCT05475223|Diagnostic Test|End Tidal Carbon Monoxide Value|A noninvasive ETCO value will be obtained by inserting a soft silicon cannula placed in the baby's nostril for a few minutes to measure exhaled end tidal carbon monoxide; a value corrected for ambient ETCO value will be recorded.
45814170|NCT02713256|Drug|CFZ533|CFZ533 intravenously over approximately one hour
45952893|NCT01242748|Drug|Goserelin acetate|The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. In the main CS35 trial, an initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the goserelin treated participants continued to receive goserelin acetate 10.8 mg s.c. implants every three months.
45952894|NCT00139373|Drug|donepezil|
45952895|NCT00139451|Drug|Pediasure|With the assistance of a research dietician, we will prescribe and monitor the use of a liquid food supplement (Pediasure). Adjustments to the supplementation will be made based on weight measurements in the clinic with subjects wearing paper gowns at 2 and 4w, and monthly thereafter, and repeat dietary intake and TEE assessment at 6 and 12mo.
45453981|NCT00544960|Drug|AT-101 and docetaxel|AT-101 30 mg bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
45453982|NCT00544960|Drug|placebo and docetaxel|placebo 3 tabs bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
45814171|NCT05153551|Other|Play-based assessment (RITA-T)|"The RITA-T is a play-based assessment that involves nine different activities that can be done safely with a child seated in the exam room. After scoring the RITA-T, the PEARS PCP will immediately provide feedback to the parent regarding results and next steps.~In addition, parents will complete certain assessments/surveys during the study to evaluate the program."
45952896|NCT00139451|Drug|GH|Growth Hormone will be 0.3mg/kg/week, given SC once daily.
45952897|NCT00161343|Behavioral|Health Improvement Project for Teens on HIV Prevention|Comparison of 2 facilitator-led intervention groups: (1) HIV prevention, and (2) general health promotion. Outcome measures: sexual risk behaviors in adolescent girls
45952898|NCT04705740|Other|ERCP|ERCPs performed annually by an endoscopist
46002705|NCT00547235|Biological|therapeutic allogeneic lymphocytes|
46002706|NCT00547235|Procedure|allogeneic bone marrow transplantation|
45453983|NCT01339286|Drug|atomoxetine|Atomoxetine will be titrated to optimal dose, beginning with 0.5mg/kg.d, then increasing to 1.2mg/kg.d in two weeks and maintaining for 4 weeks. If the optimal dose does not achieved, the dose can be increased further to 1.4mg/kg.d and maintained for 4 weeks.
45660372|NCT03699553|Behavioral|LARKSPUR; Online Positive Emotions Skills for Individuals with Chronic Musculoskeletal Pain|8 positive emotion skills taught over 5-6 weeks to help individuals cope with chronic pain and stress.
45814172|NCT05261672|Drug|Midazolam/ bupivaciane|20 ml bupivacaine 0.25% will be injected + 2 mg midazolam in 1 ml saline on each side.
45814173|NCT05261672|Drug|Bupivacain|20 ml bupivacaine 0.25% will be injected + 1 ml saline on each side
45814174|NCT05152849|Drug|AXA1125|AXA1125 administered BID with or without food
45814175|NCT05152849|Drug|Placebo|Matching Placebo administered BID with or without food
45814176|NCT02714504|Drug|Voriconazole or posaconazole|Azole with activity against molds
45814177|NCT02665975|Behavioral|CBT-based internet-intervention for tinnitus|Tinnitus e-learning programme
45814178|NCT02665975|Behavioral|Face-to-face clinical tinnitus care|Hospital tinnitus counselling
45814179|NCT02718248|Device|CHESS Mobile Health smart phone application|A smart phone application designed to reduce intentional self-harm through problem solving e-therapy.
45814180|NCT02718248|Behavioral|Problem solving therapy|Face to face problem solving therapy every week for six weeks.
45814181|NCT02668003|Behavioral|Cognitive Behavioural Therapy|The CBT intervention, delivered by telephone, will consist of an initial assessment, 6 weekly sessions, and then booster sessions at 3 and 6 months. The intervention will be delivered by trained and accredited therapists. Participants will be supported by a self-management CBT manual. There will be a patient-centred assessment by the therapist for problem identification, risk assessment and development of a shared formulation of the current health problem. The sessions will involve education about musculoskeletal pain, somatic symptoms and specific CBT techniques such as pacing of activity, behavioural activation, diary keeping, identifying and challenging negative and unhelpful thinking patterns and the development of a longer term management plan.
45814182|NCT05221502|Drug|Delamanid + Bedaquiline + OPC-167832 10 mg|Delamanid (300 mg once daily [QD]) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg thrice-weekly [TIW]) + OPC-167832 (10 mg QD) for 17 weeks
45814183|NCT05221502|Drug|Delamanid + Bedaquiline + OPC-167832 30 mg|Delamanid (300 mg once daily [QD]) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg thrice-weekly [TIW]) + OPC-167832 (30 mg QD) for 17 weeks
45453984|NCT01339364|Other|Didactic Lecture|2 sessions of didactic lecture with PowerPoint presentations each delivered by a special lecturer. whole education period lasts 3 hours.
45453985|NCT01339364|Other|Interactive Lecture|2 sessions of brief interactive lectures followed by case discussion sections.
45453986|NCT01339364|Other|Lecture plus Small Group Education|A 1.5 hours session of didactic lecture followed by a session of small group education with 3 simulated patients.
45453987|NCT00468442|Biological|Allogeneic Pancreatic Islet Cells|transplant of islet cells injected into the portal vein of the liver
45660373|NCT03699553|Behavioral|Emotion Reporting Control Group|Attention matched control condition, participants will report their daily emotions over 5-6 weeks online.
45660374|NCT03684811|Drug|FT-2102|FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.
45660375|NCT03684811|Drug|Azacitidine|Azacitidine will be administered per the site's standard of care.
45660376|NCT03684811|Biological|Nivolumab|Nivolumab will be administered per the site's standard of care.
45660377|NCT03684811|Drug|Gemcitabine and Cisplatin|Gemcitabine and cisplatin will be administered per the site's standard of care.
45660378|NCT03655015|Procedure|Lung Tumor Resection|Lung Tumor Resection
45814184|NCT05221502|Drug|Delamanid + Bedaquiline + OPC-167832 90 mg|Delamanid (300 mg QD) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg TIW) + OPC-167832 (90 mg QD) for 17 weeks
45814185|NCT05221502|Drug|RHEZ|RHEZ for 8 weeks followed by 18 weeks of rifampin and isoniazid (for a total of 26 weeks)
45814186|NCT00368576|Drug|SB 480848, tablets|
45814187|NCT03947684|Device|Transcranial Magnetic Stimulation Device|The TMS device electrically stimulates the intended parts of the brain. In this study, the investigator plan to target the part of the brain cortex that is responsible for the voluntary motion of the leg muscles, whose functions are under investigation.
45814188|NCT02724800|Behavioral|CBTI|28 Veterans with chronic insomnia will be randomized to CBTI. The intervention will be delivered in 5 face-to-face session within an 8 week time period. The intervention will be delivered at the VA Pittsburgh Healthcare System. Treatment visits will last approximately 45 minutes.
45814189|NCT02724800|Behavioral|BBTI|28 Veterans with chronic insomnia will be randomized to BBTI. The intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3 (option for telephone), and telephone appointments on Weeks 2 and 4. Interventions will be delivered at the VA Pittsburgh Healthcare System. The duration of the first treatment visit is approximately 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
45814190|NCT02730247|Drug|ramucirumab|it is administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.
45814191|NCT02730247|Drug|nab-paclitaxel|it is administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle.
45814192|NCT03889106|Drug|Ribavirin|Standard of care: Intravenous administration of ribavirin at currently recommended dosages. Loading dose of 30 mg/kg (maximum 2 g), followed by 15 mg/kg (maximum 1 g) intravenously QDS for four days, followed by 7.5 mg/kg intravenously (maximum 500 mg) TDS for six days.
45814193|NCT04738604|Other|Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany|The prepared cavities will be restored with Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 20 seconds according to manufacturer's instructions.
45814194|NCT04738604|Other|Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany)|The prepared cavities will be restored with Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 40 seconds according to manufacturer's instructions.
45814195|NCT00369200|Drug|AFP464|Given IV
45814196|NCT00369200|Other|laboratory biomarker analysis|Correlative study
45814197|NCT00369200|Other|pharmacological study|Correlative study
45453988|NCT00468442|Biological|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
45814198|NCT02730403|Other|Treatment As Usual|
45814199|NCT05207618|Dietary Supplement|ARBOX (QUEBRACHO AND CHESNUT EXTRACT)|ARBOX TWICE A DAY FOR 60 days
45814200|NCT02669329|Device|CoolSculpting device with vacuum applicator.|The CoolSculpting device with a vacuum applicator will be used to perform the treatments.
45814201|NCT02727842|Device|CP950 Sound Processor|An off-the-ear processor configuration with identical functionality to the commercially approved CP910/920 processor
45814202|NCT02727842|Device|Wireless programming pod|The CP950 Sound Processor will be programmed by the wireless programming pod, which is needed as the interface to commercially approved programming software
45814203|NCT00368329|Drug|Capecitabine (Xeloda)|PO bid daily on RT days: 500mg & 150mg tabs for dose 825mg/m2 bid AM/PM (total daily dose 1650mg/m2)
45814204|NCT00368329|Drug|[18-F] Fluorodeoxyglucose (FDG)|5-10 mCi IV administration
45814205|NCT00368329|Drug|5-Fluorouracil (5-FU)|200mg/m2 continuous venous infusion
45814206|NCT00368329|Drug|Carboplatin|AUC 2, based onCalvert formula IV infusion
45814207|NCT02670343|Drug|Oral Testosterone Undecanoate|Subjects will receive a single dose containing 158 mg of testosterone undecanoate, equivalent to 200 mg testosterone.
45814208|NCT02730260|Behavioral|Nondirective smoking cessation coaching|Quitline coach allows participant to set agenda for each call.
45814209|NCT02730260|Behavioral|Directive smoking cessation coaching|Quitline coach follows a pre-specified agenda for each call, and does not allow participant to deviate from the agenda.
46002707|NCT00547235|Radiation|total-body irradiation|
45453989|NCT00468442|Biological|Daclizumab|Will replace antithymocyte globulin in all islet transplantations after the first one
45453990|NCT00468442|Biological|Rituximab|Depletes transient B-cells
45453991|NCT00468442|Drug|Sirolimus|Maintenance immunosuppressive therapy
45453992|NCT01339442|Drug|BKM120|
45453993|NCT01339442|Drug|Fulvestrant|
45453994|NCT01339442|Procedure|biopsy|Correlative studies
45453995|NCT02286934|Drug|Carvedilol|"Day 1 to 3 : Carvedilol 12.5 mg qd~Day 4 to 8 : Carvedilol 25 mg qd~Day 9 to 11 : Carvedilol 12.5 mg qd"
45453996|NCT02286934|Other|Isoproterenol Sensitivity Test|Day 0, 1, 8 : Isoproterenol Sensitivity Test
45453997|NCT02282410|Drug|ADVATE|The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2-3 times one week with ADVATE for 1 year.
45660379|NCT03937921|Drug|Gadavist 15Ml Solution for Injection|Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as contrast agent. The contrast agents will be administered at a flow rate of 5.0 ml/s for both groups. In this study aim, all imaging protocols will comply with standard of care and only the perfusion data will be post-processed and analyzed.
45660380|NCT04542733|Drug|Everolimus|Everolimus will be given with tacrolimus.
45660381|NCT04542733|Drug|reduced dose tacrolimus|Reduced dose tacrolimus will be given with or without leflunomide
45453998|NCT01339520|Behavioral|Scorecard|Points were assigned for blood pressure, HbA1c level, LDL-cholesterol level, aspirin use and exercise level.
45453999|NCT01339520|Behavioral|Control|Standard of care for diabetes subjects
45454000|NCT02287012|Other|Time/Motion evaluation of actual apheresis|The actual apheresis events will be measured in consecutive patients scheduled to be candidates for peripheral blood stem mobilization in the apheresis area of the hospital. Each apheresis will be considered as one event . Should the patient receive more than 1 apheresis, each apheresis will be considered as one different event.
45454001|NCT02287168|Procedure|pre-gastrectomy peritoneal washing cytology|sampling of peritoneal washing fluid before gastrectomy
45660382|NCT05474755|Drug|GP681 40mg|2X20mg tablets taken orally
45660383|NCT05474755|Drug|Placebo|Placebo tablets matching GP681 40mg
45660384|NCT05474677|Procedure|closure of the abdominal fascia|The abdomen will be closed in intervention group with continuous PDS 2\0 sutures and size zero in control group.
45814210|NCT00368407|Device|308-nm excimer laser|
45814211|NCT00367549|Dietary Supplement|Energy-containing soft drink|Commercial energy/sports drink
45814212|NCT05128370|Other|Visual observation of arm swing during walking|The gait pattern of the stroke patients will be scored based on a visual observation scale. Additional components concerning the arm swing have been added to an existing scale.
45814213|NCT02670811|Dietary Supplement|Fermented milk|150 mL daily of fermented milk with Lactococcus lactis NRRL-B50571
45814214|NCT02670811|Dietary Supplement|Acidified milk|150 mL daily of artificially acidified milk
45814215|NCT03697850|Drug|Atezolizumab|Atezolizumab after adjuvant radio-chemotherapy for the treatment of patients with muscle-invasive bladder cancer not eligible for radical cystectomy
45814216|NCT02730884|Drug|Rigosertib|Participants take 560 mg Rigosertib by mouth in the morning (two 280 mg capsules) and 560 mg Rigosertib in the afternoon.
45814217|NCT02730884|Behavioral|Questionnaire|Quality of life questionnaire completed on Day 1 of Cycle 1. It should take about 10-15 minutes to complete.
45814218|NCT02732587|Drug|Saracatinib|Subjects will receive 125 mg Saracatinib for 8-11 days followed by an alcohol interaction lab session
45814219|NCT02731820|Dietary Supplement|Potassium citrate|Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
45814220|NCT02731820|Dietary Supplement|Placebo|Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
45814221|NCT02731820|Dietary Supplement|Vitamin D3|400 IU/die Vitamin D3 daily by mouth
45814222|NCT02731820|Dietary Supplement|Calcium carbonate|500 mg/die calcium carbonate daily by mouth
45814223|NCT02732899|Drug|Sirolimus|
45814224|NCT02732899|Drug|EYLEA|
45814225|NCT04339153|Behavioral|Parent Training for Disruptive Behaviours|Critically, PT also involves education about autism during the initial sessions, and thus benefits of PT are inferred to come from the specific training.
46002708|NCT04636749|Device|Erbium laser|Vaginal laser therapy
46002709|NCT04636749|Device|Sham laser|Sham laser therapy
46002710|NCT00547274|Drug|MK0767|
45952899|NCT00139490|Behavioral|Health Education Program|The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.
45660385|NCT04424017|Biological|Specific anti-SARS-CoV-2 antibodies|"A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples.~All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA)."
45660386|NCT05477797|Drug|Ixazomib DX/Lenalidomide DX|After assessment of risk stratification，patients will be assigned to Id or Rd group randomly for maintenance therapy. Then they will be reviewed the efficacy monthly.
45952900|NCT00139490|Behavioral|Basic Group|"The basic information and referral intervention will deliver key just-in-time information to nurses, patients and patients' physicians while the patient is receiving post-acute home care services. The basic intervention relies on care provided by home health nurses during the routine home health stay."
45952901|NCT00139490|Behavioral|Control Group|Usual Care
45952902|NCT00406224|Drug|breathing 100% oxygen|
45952903|NCT00139529|Behavioral|Motivational Interviewing Telephone Counseling|Participants will receive up to 5 phone calls.
45952904|NCT00139529|Behavioral|Educational Intervention|Educational intervention will be completed during pregnancy.
45952905|NCT00161421|Drug|Oral Testosterone|200 mg (Formulation A) Day 1 400 mg (Formulation A) Day 2, fasting; Day 3, with food 200 mg (Formulation B) Day 8, fasting 400 mg (Formulation B) Day 9, fasting; Day 10, with food
45952906|NCT00161421|Drug|Leuprolide (Lupron)|7.5 mg injection into muscle (once) (Day -14)
45660387|NCT05483179|Diagnostic Test|CPET|Cardiopulmonary exercise test
45660388|NCT04267315|Procedure|Trigger point injection|1mL injections of 1% lidocaine in the muscles identified active trigger points at the day of intervention (pectoralis major, serratus anterior, levator scapulae, latissimus dorsi, infraspinatus).
45660389|NCT04267315|Procedure|Subcutaneous saline injection|0.2mL subcutaneous saline injections superficial to the muscles identified with active trigger points at the day of intervention (pectoralis major, serratus anterior, levator scapulae, latissimus dorsi, infraspinatus).
45814226|NCT03647462|Device|Continuous Positive Airway Pressure|CPAP is an FDA approved therapy machine for patients diagnosed with OSA. CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep. CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether CPAP can improve clinical outcomes in patients with COPD. Therefore, our investigators want to initiate CPAP therapy in patients hospitalized for COPD to investigate whether there is an improvement in cardiac function and clinical outcomes (i.e. mortality).
45814227|NCT02733757|Drug|Clonidine|Clonidine 1 µg/kg plus 2% lidocaine
45814228|NCT00368264|Drug|infliximab|azathioprine (2 mg/lkg) plus four infusions of infliximab (5mg/kg)
46077708|NCT04243460|Procedure|Xenogeneic collagen matrix (XCM) graft augmentation|"12 months after gingival augmentation Measurement of marginal bone level and soft tissue thickness were done. STT (soft tissue thickness) was measured using ultrasonography with a Pirop® dental, ultrasound device (Echoson Company, Poland). The patients underwent a clinical and ultrasound examination before, 3 and 12 months after gingival augmentation (GA) respectively to evaluate TKT at two points using ultrasound equipment (Pirop®, Echoson).~Intraoral radiographs were taken using a paralleling technique with a Rinn-type film holder in high resolution mode (Visualixe HD®, Gendex®, USA). Two images of each region were selected to calculate the marginal bone changes:"
45660390|NCT04267315|Other|Comprehensive Rehabilitation program|Patients in both groups will undergo standard of care rehabilitation delivered by a Physiatrist, which may include Physical Therapy, Occupational Therapy, Exercise Physiologist, Rehabilitation Nurse, Psychologist, as per Physiatrist's prescription. Both the comprehensive rehabilitation program and pain medications will continue to be managed by participant's Physiatrist, who will be blinded to patient's allocation. The researchers will be responsible for TPI and for data collection.
45660391|NCT03643705|Other|Multi-component intervention|4 components as described
45660392|NCT03643705|Other|General prevention education|General education as described
45814229|NCT00368264|Drug|placebo|azathioprine (2 mg/kg) plus four placebo infusions
45814230|NCT05086406|Other|Combination of Video and Virtual Pre-operative Counseling|Intervention will be a pre-operative counseling video followed by a virtual visit with a gynecologic surgery provider, using standard and secure communications.
45814231|NCT02734147|Drug|Ascorbic Acid|
45952907|NCT00161421|Drug|Dutasteride|24.5 mg load (3.5 mg x 7 capsulesDay -14 only) 0.5 mg daily (Day -13 to day -1)
45952908|NCT00139568|Drug|Tegaserod|
45952909|NCT00406263|Procedure|Scheimpflug crystalline lens photographs|scheimpflug photographs
45952910|NCT00139607|Drug|Paracoxib|
45952911|NCT00161460|Behavioral|colorectal cancer screening intervention|Enrolled subjects receive tailored education from a registered nurse who also facilitates ordering and completion of screening tests
45814232|NCT02734147|Other|Normal Saline|
45814233|NCT00368342|Drug|Erythromycin, Azithromycin , Clarithromycin|
45952912|NCT00139646|Drug|Parecoxib|
45952913|NCT00139646|Drug|Diclofenac|
45952914|NCT00406302|Drug|Docetaxel|75mg/m², day 1,22
45952915|NCT00406302|Drug|oxaliplatin|40mg/m², d1,2,22,23
45952916|NCT00406302|Drug|cetuximab|400mg/m² (day1), 250mg/m² (day 8,15,22,29,36)
45952917|NCT00406302|Procedure|surgery|28 days after end of induction chemotherapy
45952918|NCT00139685|Drug|Depo-Provera Contraceptive Injection - DP150CI|
45952919|NCT00161538|Device|Pacing leads to be implanted according randomization.|
45952920|NCT00161538|Device|Selection 9000 prevent AF an Diagnose AF|
45952921|NCT04726943|Procedure|Radiofrequency Energy Applications|RF energy applications to the atrial edge of a leak resulting from incomplete LAA occlusion
45952922|NCT00406341|Drug|Difluprednate Ophthalmic Emulsion|
45952923|NCT00139724|Drug|tolterodine extended release capsule|
45952924|NCT00161577|Drug|Ketorolac|Intravenous ketorolac every 6 hours for 24 hours
45952925|NCT00161577|Other|Placebo|Placebo Comparator
45952926|NCT00404261|Drug|Fluticasone/Salmeterol HFA|Fluticasone/Salmeterol HFA, 2 puffs twice daily
45952927|NCT00406380|Drug|Bevacizumab|
45952928|NCT00406380|Procedure|Intravitreal injection of Bevacizumab|
45952929|NCT00404300|Drug|Optivate|Plasma-derived Factor VIII
46077709|NCT04243460|Procedure|Connective tissue graft augmentation (CTG)|12 months after gingival augmentation Measurement of marginal bone level and soft tissue thickness were done. STT (soft tissue thickness) was measured using ultrasonography with a Pirop® dental, ultrasound device (Echoson Company, Poland). The patients underwent a clinical and ultrasound examination before, 3 and 12 months after gingival augmentation (GA) respectively to evaluate STT (soft tissue thickness) at two points using ultrasound equipment (Pirop®, Echoson).
45660393|NCT05473663|Device|Radiofrequency Ablation|Genicular nerve RFA is a standard outpatient procedure using fluoroscopic guidance to ensure accurate placement of the radiofrequency cannula. After placement of the radiofrequency cannula, nerve stimulation is performed to confirm proper position and ensure that the cannula is not too close to motor fibers. One mL of 2% lidocaine is placed at each of the cannulas. The RFA treatment is then proceeded by rhizotomizing each genicular nerve at 80°C for 90 seconds with a 15-second ramp-up.
46077710|NCT00633620|Device|Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test)|colonoscopy withdrawal with NBI mode
46077711|NCT02753322|Other|Dual task training|Balance and walking exercises with simultaneously engaging in attention demanding tasks
45660394|NCT05473663|Device|Sham|Is performed identically to the active treatment but without the application of the RFA current
45814234|NCT02673541|Device|AXIOS™ stent|Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum.
45814235|NCT02673541|Device|Double Pigtail Stents|Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity.
45952930|NCT00406497|Drug|Difluprednate Ophthalmic Emulsion|
46077712|NCT02753322|Other|Single-task training|Balance and walking exercises and and attention demanding task performed separately
45454002|NCT02287168|Procedure|post-gastrectomy peritoneal washing cytology|sampling of peritoneal washing fluid after gastrectomy
45454003|NCT02287168|Procedure|post-lavage peritoneal washing cytology|sampling of peritoneal washing fluid after peritoneal lavage
45454004|NCT01339598|Device|Transcranial direct current stimulation (Eldith DC Stimulator)|Eldith DC Stimulator (NeuroConn GmbH, Germany)
45454005|NCT00092612|Drug|MK0653, ezetimibe|
45454006|NCT00092612|Drug|Comparator: ezetimibe, placebo|
45454007|NCT00540358|Drug|gemcitabine/carboplatin|Gemcitabine and carboplatin administered according to instructions in the package inserts.
45952931|NCT00404339|Biological|mutant p53 peptide pulsed dendritic cell vaccine|
45952932|NCT00404339|Biological|tetanus toxoid helper peptide|
45454008|NCT00540358|Drug|iniparib|"Body weight adjusted dose~1 hour intravenous infusion"
45454009|NCT04469504|Other|Prehabilitation program|4-week trimodal prehabilitation program: Exercise, nutritional supplementation, and psychological support
45454010|NCT04469504|Dietary Supplement|Oral Impact|perioperative immunonutrition by ORAL IMPACT
45454011|NCT00462202|Drug|sulodexide|
45454012|NCT01335854|Behavioral|Web-based Access to CPAP Data|Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the study, and then as frequently as they choose after the first week.
45952933|NCT00404339|Procedure|adjuvant therapy|
45952934|NCT00161655|Drug|Etanercept|
45952935|NCT00161655|Drug|Methotrexate|
45952936|NCT04726865|Other|Naser Al-Husban|voluntary completion of an online questionnaire
45952937|NCT00161694|Dietary Supplement|sucrose solution|
45952938|NCT00139763|Procedure|Educational Materials|
45952939|NCT00139802|Device|Coronary Stent Implantation|
45952940|NCT00161733|Drug|Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D)|
45952941|NCT00161733|Drug|TISSEEL VH fibrin sealant|
45952942|NCT00139841|Drug|Bendamustine HCl|Dose of 120 mg/m2 on Day 1 and Day 2 of each treatment cycle (every 21 days). Patients who are continuing to experience clinical benefit at Cycle 6, as assessed by the investigator, may receive up to 2 additional cycles, to a maximum of 8 cycles.
45952943|NCT00154518|Procedure|Orthodontic treatment|
45952944|NCT00139880|Drug|Parcopa|
45952945|NCT04724187|Drug|Misoprostol|it is prostaglandin E1 .
45952946|NCT04724187|Drug|Oxytocin|it stimulates uterine contractions
45952947|NCT04727021|Drug|20 mg tablet rivaroxaban|Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions
45952948|NCT04727021|Drug|20 mg rivaroxaban, granules for oral suspension|Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions.
45952949|NCT00154557|Behavioral|elite judo athletes program|
45952950|NCT00139919|Drug|Bifeprunox|
45952951|NCT04724226|Drug|Camrelizumab; Apatinib|"Cryoablation~Drug: Camrelizumab and Apatinib Camrelizumab (200mg), iv, Q3W; Apatinib (250mg), po, QD"
46077713|NCT02753322|Other|Limbs exercise|Stretching and strengthening exercises
46077714|NCT02831894|Drug|0% Hypnotic Medication Taper|Participants will not have their soporific hypnotic medication dosage changed during a 20 week blinded tapering period
46077715|NCT02831894|Drug|25% Hypnotic Medication Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 20 week blinded tapering period.
46077716|NCT02831894|Drug|10% Hypnotic Medication Taper|Participants will have their soporific hypnotic medication dosage reduced by 10% every two weeks during a 20 week blinded tapering period.
45952952|NCT04724343|Drug|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
45952953|NCT04724343|Drug|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
45952954|NCT04724343|Drug|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
45952955|NCT04724343|Drug|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
45660395|NCT05482945|Other|Noble gas Argon|Ventilation with Ar 70%/O2 30% in comatose patients resuscitated from OHCA with the use of an experimental mechanical ventilator.
45660396|NCT05473351|Other|Questionnaire|Visual Analogic Scale
45952956|NCT00140036|Procedure|Blood draw|
46077717|NCT00782067|Drug|Midostaurin (PKC412)|Midostaurin was provided as 25 mg soft gelatin capsules for oral administration.
45952957|NCT00161772|Biological|Tick-borne Encephalitis Vaccine|
45952958|NCT00140075|Drug|Epirubicin with Cyclophosphamide, followed by a Taxane|"Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2~Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2"
45814236|NCT02732366|Behavioral|Group-based exercise and peer coaching|Group-based exercise and peer coaching will take place over 6 weeks plus one booster visit after 3 months, and include physical therapist-led 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions) to include: progressive strengthening, balance and mobility exercises; patient goal setting; peer coaching training activities to teach group members ways to help each other to meet their exercise goals during and after classes are over. There will be an individualized home program including flexibility, strengthening, walking, and balance, as well as activity monitoring.
46077718|NCT02753244|Other|Motion Based Cognitive Video Games Software|Intendu FBT motion based cognitive video games software
45814237|NCT02732366|Other|Usual PT and attention control grp class|The usual PT and attention control group class will receive standard one-on-one PT strength, balance, gait and education intervention, and group classes to provide valuable information about healthy living, including nutrition, relaxation, and stress management. The attention control - healthy living group classes will take place over 6 weeks plus one booster visit after 3 months, and include 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions).
45660397|NCT05477641|Procedure|Pericapsular Nerve Group Block with Lateral Femoral Cutaneous Nerve Block|Local anesthetic will be deposited along the lower pelvis to block 3 nerves that innervate the anterior hip capsule
45952959|NCT00140075|Drug|Epirubicin with a Taxane|"Epirubicin = 75 mg/m2 per cycle~Taxane = paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2"
45952960|NCT00140114|Drug|Misoprostol (Cytotec®)|50 micrograms of sublingual or vaginal misoprostol every 4 hours for a maximum of 5 doses
45952961|NCT04724382|Behavioral|Culturally tailored healthy eating advice|Culturally-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
45952962|NCT04724382|Behavioral|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips for general dietary recommendations
45952963|NCT01242514|Drug|Fostamatinib|Fostamatinib 100mg twice daily
45952964|NCT01242514|Drug|Fostamatinib|Fostamatinib 150mg once daily
45952965|NCT01242514|Drug|Fostamatinib|Fostamatinib 100mg once daily
45952966|NCT00140153|Drug|testosterone gel (Androgel)|
45952967|NCT04710966|Procedure|arthroscopic debridement|For the arthroscopic debridement, only stump refreshing and surrounding soft tissue cleaning were performed.
45952968|NCT04710966|Procedure|arthroscopic repair|For the arthroscopic repair, we converted partial tears into full-thickness tears and sutured them.
45952969|NCT00140192|Drug|creatine|
45952970|NCT00154635|Drug|DCB-AD1|
45952971|NCT00140270|Behavioral|PEP program|
45660398|NCT05477641|Procedure|Fascia Iliaca Compartment Block|Local anesthetic is deposited between the fascia iliaca and the internal oblique muscle in an attempt to block 3 nerves that innervate the hip.
45660399|NCT05482633|Other|Inspiratory muscle training (IMT)|Treatment group will perform IMT every day for eight weeks. Initial load is going to be set as the 60% of maximal inspiratory pressure (PImax) and is going to be increased by %10 of the initial load every two weeks.
45814238|NCT03609320|Behavioral|The STOP-HPV Trial 5: Bundle Intervention|This intervention will implement a 3-component bundle intervention (communication skills training, performance feedback and prompts) together in practices that previously received standard of care.
45814239|NCT03609008|Drug|Levcromakalim|Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
45814240|NCT03609008|Drug|Saline|Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
45952972|NCT01242085|Procedure|trumatch group|these patient will have CT based customized knee instruments used for surgery
45952973|NCT01242085|Procedure|control group|these patients will have standard instrumentation used for for knee replacement
45952974|NCT00154674|Device|ICY catheter, Thermoguard device|
45952975|NCT00140309|Drug|moxifloxacin (with isoniazid, rifampin, pyrazinamide)|
46002711|NCT00547352|Drug|tadalafil|20 mg tadalafil tablets taken by mouth, as needed, no more than once a day for 8 weeks.
46077719|NCT02753244|Other|iPad Apps|Commercially available iPad game applications
46077720|NCT02832050|Behavioral|Play therapy|See previous description of play therapy intervention arm.
46077721|NCT02832050|Behavioral|Standard of care|See previous description of comparator arm.
46077722|NCT05521269|Drug|ANX1502|ANX1502 is a prodrug of ANX1439.
46077723|NCT05521269|Drug|Placebo|Placebo comparator.
46077724|NCT02752932|Other|Drug testing on PDX per Investigator's choice (upto 4)|Drug of Investigator's choice (upto 4 Ontario funded Chemotherapeutics) will be tested on PDX (Patient Derived Xenografts)
46077725|NCT00886340|Behavioral|Enhanced standard care|One appointment with nurse practitioner (20 minutes) One appointment with nutritionist (45 minutes)
45952976|NCT01241461|Drug|LY2584702|"Dose escalation starting at 50 milligram (mg). On Day 1, subjects will receive a single oral dose. After a two-day observation period, subjects will receive oral doses twice daily for a 28-day cycle.~Patients may continue 28-day cycles of twice daily dosing until discontinuation criteria are met."
45454013|NCT01335854|Behavioral|Web-based Access to CPAP Data with Financial Incentive|Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the the study, and then as frequently as they choose after the first week. There will be a payment of $30 during the first week for each day a participant uses CPAP for more than 4 hours the previous night and logs on to the website.
45454014|NCT02287246|Drug|Extended-Release liposomal bupivacaine (Exparel)|20mL
45454015|NCT02287246|Drug|Normal saline|20mL
45952977|NCT00161811|Biological|Vero Cell-derived Influenza Vaccine|
45952978|NCT00161811|Biological|Egg cell-derived Influenza Vaccine|
45454016|NCT02682836|Behavioral|Walk with Ease|
45454017|NCT04470544|Drug|Camostat Mesilate|Given PO
45952979|NCT01240135|Device|FID 114675A multi-purpose disinfecting solution (MPDS)|Daily regimen, 14 days: Thoroughly wet and rub each side of study contact lens for 10 seconds, rinse each side of the lens for 10 seconds, and soak contact lens for at least 6 hours.
45952980|NCT01240135|Device|renu fresh Multi-Purpose Solution (MPS)|Daily regimen, 14 days: Wet study contact lens with 3 drops and rub each side of the lens for 20 seconds, rinse each side of the lens for 5 seconds, and soak contact lens for at least 4 hours.
45952981|NCT01240135|Device|Galyfilcon A contact lenses (Acuvue Advance)|A fresh pair of contact lenses matching subject's pre-study lenses, including parameters, dispensed at the beginning of each period for daily wear, minimum 8 hours per day, 14 days.
45454018|NCT04470544|Other|Standard of Care|At Investigator discretion
45454019|NCT00535366|Drug|Tiotropium|Oral inhalation by HandiHaler® device
45454020|NCT00535366|Drug|Salmeterol|Oral inhalation from Diskus®
45454021|NCT00535366|Drug|Fluticasone|Oral inhalation from metered dose inhaler (MDI)
45660400|NCT03386929|Drug|Avelumab|A human antibody of the immunoglobulin gamma-1 isotype that specifically targets and blocks the Programmed Death ligand (PD-L1) for PD-1.
45660401|NCT03386929|Drug|Axitinib|A selective oral (tablet) inhibitor of tyrosine kinases Vascular Endothelial Growth Factor (VEGF) receptors 1, 2, and 3. These receptors are implicated in pathologic angiogenesis, tumor growth and cancer progression.
45814241|NCT02732600|Other|Facilitated Implementation|Facilitated Implementation sites will receive one year of support based on the i-PARIHS implementation model which includes training, implementation planning, ongoing external facilitation, feedback and consultation
45814242|NCT02734238|Drug|Sesame Oil|200 mg sesame oil by intramuscular injection weekly on days 15, 21, 28, and 35
45814243|NCT02734238|Drug|testosterone enanthate|200 mg testosterone enanthate by intramuscular injection weekly on days 15, 21, 28, and 35
45952982|NCT01245634|Drug|Placebo|iv infusion every 4 weeks, 32 weeks
45814244|NCT02734849|Drug|AK001 low dose|25 mg AK001 will be administered as multiple doses
45814245|NCT02734849|Drug|AK001 high dose|250 mg AK001 will be administered as multiple doses
45952983|NCT01245634|Drug|RO4905417|20 mg/kg iv infusion every 4 weeks, 32 weeks
45952984|NCT00140348|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
45454022|NCT00535366|Drug|Ciclesonide low|Oral inhalation from MDI
45454023|NCT00535366|Drug|Ciclesonide high|Oral inhalation from MDI
45814246|NCT02734849|Drug|Placebo|Placebo will be administered as multiple doses
45660402|NCT03386929|Drug|Palbociclib|A selective, reversible oral (capsule) inhibitor of cyclin-dependent kinases (CDK) 4 and 6. The inhibition of CDK 4/6 blocks DNA synthesis by prohibiting progression of the cell cycle from G1 to S phase.
45660403|NCT05472337|Drug|Colchicine|Oral colchicine (1 mg loading dose followed by 0.5 mg 1 hour later, administered 6 to 24 hours before angioplasty, followed by 0.5 mg (1 comp.) per day for 6 weeks.
45660404|NCT05472259|Drug|Nanoliposomal irinotecan|In the control arm (Naliri) a dose of 70mg/m² is administered in combination with 5FU and leucovorin In the investigational arm (Nalirinox) a dose of 50mg/m² is administered in combination with 5FU, leucovorin and oxaliplatin
45814247|NCT04707547|Biological|immunotherapy with Nivolumab|After subjects had received radiofrequency ablation for two weeks, they were performed by immunotherapy with Nivolumab 200mg.
45952985|NCT00154713|Biological|CEA pulsed dendritic cells|
45952986|NCT01240876|Drug|CEP-37247|0.5-, 1-, 3-, 6-, and 12-mg doses of CEP-37247 will be administered by the transforaminal epidural route.
45952987|NCT01240876|Drug|Placebo|Matching placebo vials will be filled with the buffered solution for CEP-37247.
45952988|NCT01240759|Drug|S-707106 Dose A|One S-707106 A tablet
45952989|NCT01240759|Drug|S-707106 Dose B|One S-707106 B tablet
45952990|NCT01240759|Drug|S-707106 Dose C|Four S-707106 4 X B tablets
45952991|NCT01240759|Drug|Placebo A tablet|Up to 4 Placebo A tablets
45952992|NCT01240759|Drug|Metformin|The standard of care dose of metformin for each patient
45454024|NCT00535366|Drug|Placebo|Oral inhalation from MDI
45454025|NCT02282488|Other|Low protein formula|
45454026|NCT02282488|Other|High protein formula|
45454027|NCT00369070|Biological|Bevacizumab|15 mg/kg bevacizumab, delivered via intravenous (IV) infusion once every 3 weeks
45454028|NCT00369070|Drug|AMG 706|subjects in Arms A and B will take AMG 706 orally in one of two dosing regimens over each 21-day cycle: •Arm A: 125 mg once daily (QD) •Arm B: 75 mg twice daily every 12 ± approximately 1 hour for 5 days followed by a 2 day treatment free period every 7 days
45454029|NCT00369070|Drug|Paclitaxel|All subjects will receive a paclitaxel chemotherapy regimen (paclitaxel 200 mg/m2) on day 1 of each 3-week cycle for a maximum of 6 cycles.
45454030|NCT00369070|Drug|Carboplatin|All subjects will receive carboplatin chemotherapy regimen (carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3-week cycle for a maximum of 6 cycles.
45454031|NCT02284204|Drug|Midazolam, Ketamine and Sevoflurane|The combination of these three drugs were administered for the children of the intervention group in a attempt to improve the behavioral control. Midazolam and ketamine orally, sevoflurane inhaled.
45454032|NCT02284204|Drug|Midazolam and Ketamine|The combination of these two drugs were administered orally for the children of the control group.
45454033|NCT01352416|Drug|Ranolazine|Ranolazine 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
45814248|NCT04707547|Procedure|Radiofrequency Ablation|The most commonly used local ablation is radiofrequency ablation. In this operation, a radio frequency probe is used to insert the liver cancer under ultrasound or computer tomography guidance, and then the radio frequency waves generated by the current oscillations locally heat the high temperature, causing the liver cancer cells to die.
45814249|NCT02735551|Drug|Long Acting Reversible Contraception (LARC)|Same day LARC placement (intervention) of Mirena, Skyla, Paragard, Implanon
45814250|NCT02735551|Other|Referral for Long Acting Reversible Contraception (LARC)|Referral to local clinic for LARC placement of choice (Mirena, Skyla, Paragard, Implanon, etc.)
45814251|NCT02735551|Other|Prescription for Short-Acting Hormonal Contraception|Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice
45814252|NCT03535376|Drug|Valsartan|Patients are tested for their normal prescription valsartan medication
45814253|NCT02736175|Drug|Dexamethasone|
45814254|NCT02736175|Other|Placebo Vehicle|
45814255|NCT02735174|Device|Sensor cap system for inhalers|All subjects will be given a commercially available inhaler cap with monitoring sensor on clinically prescribed asthma inhalers.
45814256|NCT02735174|Other|App for SmartPhone|All subjects will be given smart phone with mobile software management platform to motivate and record medication adherence.
45814257|NCT02735174|Behavioral|Motivational interviews|All subjects will have motivational telehealth visits to assess adherence and promote problem-solving skills
45814258|NCT02735174|Other|Telehealth clinic visits|All subjects will have asthma medical visits via telehealth technology to assess asthma control.
45814259|NCT02735642|Behavioral|SMART Randomization 1 - Referral|Participants will be randomized to receive standard referral to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
45814260|NCT02735642|Behavioral|SMART Randomization 1 - Referral and SMS|Participants will be randomized to receive referral plus SMS to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
45814261|NCT02735642|Behavioral|SMART Randomization 2 - SMS|Those that have not linked to care after the first randomization, will be re-randomized to receive an SMS message. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
45814262|NCT02735642|Behavioral|SMART Randomization 2 - Incentive|Those that have not linked to care after the first randomization, will be re-randomized to receive a one-time economic incentive. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
45814263|NCT02735642|Behavioral|High Risk Negative Cohort (N=185)|A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185). They will receive an SMS health promotion message with survey at 6 and 12 months. At 12 months, they will be re-tested for HIV and an exit interview completed.
45814264|NCT02735642|Other|All participants. Approximately (N=1200)|"HIV testing approaches that females can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).~All participants will receive a behavioral CAPI survey at baseline visit, an SMS HIV test experience satisfaction survey, and for those who choose the self-testing option, a staff-administered questionnaire."
45814265|NCT03449576|Other|Trauma Management Therapy|Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.
45814266|NCT03449576|Other|Exposure Therapy with Psychotherapy group|Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.
45814267|NCT05446610|Other|Fermented product of Pleurotus eryngii mushroom|I Stimulation of human colonic biopsies with the fermented product of Pleurotus eryngii mushroom
45814268|NCT02736955|Drug|Valbenazine|
45952993|NCT00161850|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
45952994|NCT02955784|Device|Sinasprite Mobile App|Mobile App
45952995|NCT01241734|Drug|Revlimid|"Stage I:~Cohort 1: RICE + Lenalidomide 10mg days 1-7 Cohort 2: RICE + Lenalidomide 15mg days 1-7 Cohort 3: RICE + Lenalidomide 20mg days 1-7 Cohort 4: RICE + Lenalidomide 25mg days 1-7~Stage III:~Lenalidomide 25mg days 1-21 every 28 days"
45952996|NCT00140387|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
46002712|NCT00547352|Drug|sildenafil|Current users of sildenafil citrate for a minimum of 6 weeks prior to visit 1 will continue with an individual dosage to be taken no more than once a day for an additional 4 weeks.
45660405|NCT05472259|Drug|5 FU|In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin
45660406|NCT05472259|Drug|Leucovorin|In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin
45660407|NCT05472259|Drug|Oxaliplatin|Only administered in the investigational arm (Nalirinox): a dose of 60 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and Leucovorin
45814269|NCT00369356|Drug|Prednisone|Bare metal stenting with administration of oral prednisone as described in the protocol
45814270|NCT00369356|Device|Drug eluting coronary stent|Stenting with DES (Cypher or Taxus)
45814271|NCT00369356|Device|Bare metal coronary stent|Stenting with BMS only
45814272|NCT03409562|Behavioral|motor control training|Exercises to strengthen the lumbar musculature and control the posture.
45814273|NCT03409562|Behavioral|pain neurophysiology education|Educational sessions to improve patient's neurophysiology of pain knowledge.
45814274|NCT05446441|Procedure|Endoscopic surgery;|Endoscopic thyroidectomy group is the papillary thyroid carcinoma patient group who underwent endoscopic thyroid surgery using a gasless, trans-axillary approach.
45814275|NCT03375164|Genetic|SRP-9001|Single IV infusion of SRP-9001.
45814276|NCT04947085|Drug|Ketamine via Intravenous|Ketamine administration in sub-dissociative doses
45814277|NCT04947085|Drug|Ketamine via BAN|Ketamine administered via Breath-Actuated Nebulizer (BAN)
45952997|NCT02955862|Other|Vietnam Cryptococcal Retention in Care Study (CRICS)|"Drug: Fluconazole HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.~Other Names:~• Fluconazole"
45952998|NCT00161889|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
45952999|NCT00504634|Drug|Bortezomib|1 mg/m^2 IV On Days 1, 4, 8, and 11.
45953000|NCT00140465|Drug|Clopidogrel|after PCI
46077726|NCT00886340|Behavioral|Lifestyle counseling|Enhanced standard care Six appointments with nurse practitioner (20 minutes)
46077727|NCT05520723|Drug|Sacituzumab govitecan|"Upon meeting all selection criteria, patients enrolled in the single-arm study will receive the combination of: sacituzumab govitecan and prophylaxis (loperamide and G-CSF).~Sacituzumab govitecan :10 mg/kg, intravenously (IV) on Days 1 and 8 every 21-day cycle . This treatment will continue until disease progression, unacceptable toxicity, or physician's/patient's decision."
45660408|NCT04266145|Drug|intravenous dexmedetomidine|adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL normal saline while, the intravenous solution; consists of 0.5µg.kg-1 dexmedetomidine diluted in 20 mL normal saline
45660409|NCT04266145|Drug|adductor canal block dexmedetomidine|adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL of 0.5µg.kg-1 dexmedetomidineline while, the intravenous solution;consists of 20 mL normal saline
45660410|NCT05477329|Device|Lenses|The test lens is manufactured in a standard FreeForm technology (exactly like a standard progressive addition lens which is similar in terms of the graduall power profile induced in both lens). It does not demand any special manufacturing processes.
45814278|NCT03357224|Drug|Atezolizumab|Patients will receive atezolizumab 1200 mg IV Q3w for 1 year.
45814279|NCT02677753|Radiation|Fluoroscopy|
45814280|NCT04958798|Behavioral|Culturally Centered MOUD Implementation Intervention|Support clinical sites to culturally center the delivery of medications for opioid use disorder through evidence-based implementation strategies tailored to local needs
45814281|NCT04947020|Drug|Metformin|Metformin use before operation due to previously diagnosed diabetes.
45814282|NCT04940221|Behavioral|Shared Decision Making|Telephone delivered non-persuasive shared decision-making for lung cancer screening.
45814283|NCT02679469|Drug|nalmefene hydrochloride 10 mg|
45814284|NCT04915508|Drug|Hormone Therapy|Receive hormonal therapy
45814285|NCT04915508|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45814286|NCT05445973|Procedure|Percutaneous Radiofrequency Ablation|In brief, ablation was performed using a 200-W multichannel generator and a switching monopolar technique with separate clustered electrodes. Tumor targeting was done under the guidance of CEUS-CT/MRI FI, and the ablation procedure was monitored with US-FI. The ablation procedure was terminated when the operator expected to complete the ablation of the index tumor with a minimum 5-mm ablative margin on the US-FI images.
45814287|NCT05445986|Procedure|flap elevation and guided bone regeneration|to rebuild the alveolar ridge convexity
45814288|NCT05445986|Procedure|gap filling|to use biomaterials to fill the jumping gap
45814289|NCT05445986|Procedure|connective tissue graft|to change the soft tissue phenotype by connective tissue graft
45814290|NCT05445908|Drug|SKB264|SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle (5mg/kg)
45814291|NCT05445908|Drug|KL-A167|KL-A167 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle (900mg Q2W)
45814292|NCT02681809|Drug|ocriplasmin 0.0625mg|Up to 3 intravitreal injections of ocriplasmin 0.0625mg approximately 1 month apart
45814293|NCT02681809|Drug|ocriplasmin 0.125mg|Up to 3 intravitreal injections of ocriplasmin 0.125mg approximately 1 month apart
45814294|NCT02681809|Drug|Sham injection|3 sham injections approximately 1 month apart. No actual injections. No medication is used.
45814295|NCT05445661|Device|injectable poly-L-lactic acid|Injectable biostimulant for volume loss
45814296|NCT05445661|Other|Normal Saline|Sham Comparator
45814297|NCT05445271|Diagnostic Test|Optic nerve sheath diameter measurement with linear ultrasound|In this study, we aimed to show whether endotracheal intubation or LMA applications with optic nerve sheath diameter measurement, which is a completely non-invasive method, have effects on intracranial pressure.
45660411|NCT05477251|Procedure|microwave ablation|MWA procedures were performed under local anesthesia and CT guidance (GE Discovery CT750 HD) was used for the guidance. Using the coaxial system, MWA was performed by the combining of a 17G sharp-tip guide trocar needle and a 15-cm cooled-shaft electrode (18-gauge) with a 1.5-cm expandable blunt-tip (MTC-3CA-II3, Vison Medical Inc.). Firstly, the sharp-tip guide trocar needle was used to puncture through the pleura and then the blunt-tip MWA electrode was advanced into the GGO lesion through the guide needle lumen. Once the target was reached, ablation was performed at a power of 40 watts. Once the lesion was covered by the ablation zone, the ablation completed.
45660412|NCT05477251|Procedure|lobectomy|lobectomy for GGOs located in hilar regions
45660413|NCT02554513|Device|EPG Tx|behavioral intervention that incorporates a device that provides visual biofeedback
45660414|NCT02554513|Behavioral|SPT|A treatment hierarchy involving integral stimulation
45660415|NCT05477173|Behavioral|The Strengths and Difficulties Questionnaire (SDQ) Parent Version Parent : It consists of 25 questionnaires used to screen for behavioral problems in children aged 4-17 years.|screen by using psychometric scales
45660416|NCT04570969|Procedure|Erector spinae plane block|Insertion of bilateral catheters in the intersfacia space of erector spinae muscle
45660417|NCT05471635|Biological|COVID-19 Vaccine|All COVID-19 vaccines approved by national or international regulatory agency, despite the vaccine technology, manufacturer, and regulatory agency that granted marketing authorization.
45660418|NCT05482399|Other|Statin discontinuation|Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
45660419|NCT03383419|Drug|Epclusa|If and when these recipients develop confirmed viremia by HCV PCR, Epclusa® therapy will be administered for a 12-week course.
45660420|NCT05482321|Drug|Definity Suspension for Injection|"DEFINITY is administered as per manufactures instructions~1 vial of DEFINITY is allowed to warm to room temperature and activated by 45s shaking on a VIALMIX~Withdraw the activated milky white suspension using the provided Dispensing Pin, PINSYNC or 18-20 gauge syringe needle, from the middle of the liquid in the inverted vial.~Deliver a dose of 10 μl/kg of 'milky white suspension' IV as a bolus, delivered over 30seconds.~Following imaging, provide a 10 mL flush of preservative-free saline~Wait at least 30minutes until second dose (if provided)."
45660421|NCT05477017|Drug|SGLT2 inhibitor|Selective inhibitors of the sodium and glucose co-transporter 2 (SGLT2) originated as antidiabetic drugs thanks to their hypoglycemic and glycosuric effect.
45660422|NCT02554279|Drug|menotropin|
45814298|NCT04805125|Biological|Moderna COVID-19 Vaccine, mRNA-1273 (100 μg)|intramuscular injection, proposed as a series of two doses (0.5 mL each), dosing is 100 microgram on day 0 and day 28
45814299|NCT04805125|Biological|Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)|intramuscular injection, proposed dosing is 30 microgram of the diluted vaccine solution (0.3 mL each) on day 0 and day 21
45814300|NCT04803955|Drug|16mg，KB|16mg,Q8h±3min,Day1-Day7
45814301|NCT04803955|Drug|Placebos|16mg,Q8h±3min,Day1-Day7
45814302|NCT04339075|Other|Questionnaires|Questionnaires to access the quality of life (EQ5D, VCSS, CVVQ, CIVIQ, Patient satisfaction survey)
45814303|NCT05445115|Device|Mollie device|medical device
45814304|NCT05444959|Dietary Supplement|HMB supplementation|Group taking oral HMB free acid supplementation in a blinded liquid form.
45953001|NCT00140465|Drug|Clopidogrel|after PCI
45953002|NCT00504673|Drug|insulin detemir|
45953003|NCT00504673|Drug|insulin NPH|
45660423|NCT02554279|Drug|recombinant FSH|
45814305|NCT05444959|Dietary Supplement|Placebo treatment|Group taking oral supplementation with placebo (in a blinded liquid form).
45660424|NCT02554903|Drug|Macitentan 10mg|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
45660425|NCT02554903|Drug|Placebo sugar pill|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
45953004|NCT00504673|Drug|insulin aspart|
45953005|NCT01245517|Other|Education|Dietary Phosphorus Education Program
46077728|NCT05520723|Drug|Loperamide|Loperamide : 2 mg orally (PO), twice a day (BID), or 4 mg once a day (QD) during three consecutive days after administration of sacituzumab govitecan, (D2, D3, D4 and D9, D10, D11) during the first two cycles (consider extending to the next cycle at the discretion of the physician).
45814306|NCT04685473|Drug|T-1101 (Tosylate)|T-1101 (Tosylate) Capsule
45814307|NCT00368017|Drug|pioglitazone|30 mg once a day for 12 weeks
45814308|NCT00368017|Drug|placebo|1 pill once a day for 12 weeks
45814309|NCT04672447|Dietary Supplement|L-Citrulline|Four weeks of oral L-Citrulline (2 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
45814310|NCT04672447|Dietary Supplement|L-Citrulline|Four weeks of oral L-Citrulline (6 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
45814311|NCT04672447|Dietary Supplement|Placebo|Four weeks of oral placebo (6 grams/day maltodextrin) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
45814312|NCT04672447|Dietary Supplement|Glutathione|Four weeks of Glutathione (200mg/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
45814313|NCT00367627|Drug|Albendazole|
45814314|NCT05444647|Procedure|stool and blood collection|Patients will collect fecal and blood samples prior to treatment and at the time of response evaluation, and completion of therapy using a standard stool-collection-kit. At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.
45953006|NCT00161928|Biological|Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT)|
45953007|NCT02955628|Drug|Ibrutinib-RICE|Ibrutinib will be added to RICE regimen for patients not achieving a complete remission at interim PET-2. Ibrutinib will be continued for up to 1 year after autologous transplantation.
45660426|NCT03337399|Other|Stepped PC|"Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer"
45953008|NCT00140504|Other|Medcheck message|Participants selected at random will receive one email message asking them questions about their prescription which will be forwarded to their physician
45953009|NCT00154752|Procedure|CCRT, Pelvic lymphadenoectomy.|
45953010|NCT01247701|Drug|Busulfan|Busulfan dosing will be as follows: Patients < 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients > 12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses. It will be given on Days -9, -8, -7 and -6.
45660427|NCT03337399|Other|Early Integrated PC|"Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer"
45660428|NCT03329131|Device|Cryotherapy|An Elasto gel™ frozen (4°C) glove and sock
45660429|NCT03328195|Device|Neuro RX Gamma synchronous|Twenty minute treatment, six days per week for 12 weeks
45660430|NCT03328195|Device|Sham|Twenty minutes, six days per week for 12 weeks with sham device
45814315|NCT04739137|Diagnostic Test|DDiVAT Testing|Participants will self examine his/her distance visual acuity via application in a simulation room of our department with certain predetermined environmental lighting conditions using the same smart devices.
45814316|NCT04739137|Diagnostic Test|Distance visual acuity assessment via ETDRS chart|The distance visual acuity of each participant will be measured with the conventional method via ETDRS chart
45814317|NCT05444335|Device|Wearable cardiac monitor -Zio patch|Women older than 70 years old will be asked to wear a cutaneous cardiac monitor for 2 weeks.
45814318|NCT00368485|Device|Neurally Controlled Mechanical Ventilation|A new mode of mechanical ventilation controlled by the electrical activity of the diaphragm (NAVA) will be used before and after extubation.
45814319|NCT00368563|Drug|Helioblock SX|
45814320|NCT04633759|Other|Blood Flow Restriction Exercise|Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg and dosed following standard BFR guidelines: 1 set of 30 reps, then 3 sets of 15 reps at 20-30% 1RM with up to 80% limb occlusion. Exercises will target bilateral 1) knee and hip extension, 2) hip abduction, and 3) ankle plantarflexion, as these muscles are important for functional mobility in people with MS.
45814321|NCT05436223|Drug|Human CD19Targeted T Cells Injection|A single dose of predetermined level CAR-positive T cells will be infused.
45814322|NCT04536103|Diagnostic Test|MRI|Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in healthy patients and patients with ACL injury.
45814323|NCT05444179|Behavioral|Mommies can Eat & Exercise with No Stress (MomEENS)|This intervention involving behaviour modification, incorporates nutrition and physical activity modification. The intervention encourages participants to consume a healthy diet and active lifestyle during postpartum period. For nutrition modification, a general advice on healthy nutrition were given and several nutrients are highlighted which evidenced can reduce postpartum depression. While for physical activity, the mothers are encouraged to do exercise, targeting aerobic, flexibility, and strength type of exercise. The exercise protocol is progressive. During the first month, the participants will be advised to conduct flexibility and strength exercises for 8 repetitions (1 set), at least 3 days per week for both aerobic and flexibility exercise. While during the second month, participants are asked to increase repetitions and frequency of exercises, up to 16 repetitions (2 set) for each flexibility exercise, and conduct exercise at least 5 days per week.
45814324|NCT04738903|Procedure|Femtosecond laser assisted LASIK eye surgery|FS-LASIK eye surgery includes corneal flap creation with femtosecond laser using the Femtosecond laser WaveLight FS200 followed by excimer laser vision correction of the patient's refractive error using excimer laser WaveLight EX500.
45814325|NCT05434897|Drug|AK3280 Cream|Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use
45814326|NCT05434897|Drug|Placebo cream|Active Substance: Placebo, Pharmaceutical Form: Cream, Route of Administration: External use
45814327|NCT05443789|Behavioral|Proton pump inhibitor education|A 15 minutes (preferable) one-on-one educational visit about deprescription of proton pump inhibitor
45953011|NCT01247701|Drug|Cyclophosphamide|Cyclophosphamide (50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.
45953012|NCT01247701|Drug|Fludarabine|Fludarabine will be given IV daily over 1 hour for 3 days. Dosing will be as follows: for patients ≤ 10 kg: 1.3 mg/kg; for patients > 10 kg: 40 mg/m^2.
45953013|NCT01247701|Procedure|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on Day 0.
45660431|NCT03328195|Device|Neuro RX Gamma asynchronous|Twenty minutes, six days per week for 12 weeks with sham device
45660432|NCT05482087|Drug|XZP-3621|ALK inhibitor-treated ALK-positive NSCLC treatment
45660433|NCT02332707|Drug|Grazoprevir|One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.
45660434|NCT02332707|Drug|Uprifosbuvir|Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.
45660435|NCT02332707|Drug|Elbasvir|One EBR 50 mg tablet (Part A), taken q.d. by mouth.
45814328|NCT05443789|Behavioral|Other education|A 15 minutes (preferable) one-on-one educational visit about another topic (NOT asthma).
45953014|NCT00140543|Drug|sirolimus versus mycophenolate mofetil|
45953015|NCT00154791|Drug|oxaliplatin|
45953016|NCT00154791|Drug|gemcitabine|
45953017|NCT00154791|Drug|5-FU/LV|
45953018|NCT00140582|Drug|Rituximab|rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment
45953019|NCT00154830|Behavioral|cerebral palsy|
45953020|NCT00154830|Behavioral|crouch gait|
45953021|NCT00154869|Drug|Peginterferon Alfa-2a plus Ribavirin|
45953022|NCT00161967|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive one vaccination with either FSME-IMMUN 0.25 ml or FSME-IMMUN 0.5 ml, depending on their age.
45953023|NCT00140660|Drug|rituximab|375 mg/m2 on D1
45660436|NCT02332707|Drug|Ruzasvir|Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.
45660437|NCT02332707|Drug|Uprifosbuvir (+) Grazoprevir (+) Ruzasvir|Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.
45660438|NCT02332707|Drug|Ribavirin|RBV 200 mg capsules taken b.i.d. at a total daily dose of 800-1400 mg based on participant body weight.
45660439|NCT02370615|Drug|TAK-272|TAK-272 tablet.
45660440|NCT02370615|Drug|Digoxin|Digoxin tablet.
45660441|NCT02370615|Drug|Itraconazole|Itraconazole oral solution
45814329|NCT04738747|Behavioral|WHOOP fitness tracker|WHOOP is a device that uses a wristband or arm band to track heart rate, heart rate variability (HRV), and sleep to calculate proprietary strain and recovery scores for its users. Heart rate variability is an important metric for correlation with acute stress
45814330|NCT05443477|Dietary Supplement|Hericium Erinaceus Mycelium|participants received two oral capsules containing Hericium erinaceus Mycelium every day for the 3 months.
45814331|NCT05443477|Dietary Supplement|Probiotic|participants received two oral capsules containing Probiotic powder every day for the 3 months.
45814332|NCT05443477|Dietary Supplement|control|participants received two oral capsules containing control powder every day for the 3 months.
45814333|NCT05424523|Drug|Omalizumab|Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab
45814334|NCT05443243|Procedure|Total Hip Arthroplasty|Patient were operated, a Total hip arthroplasty was performed
45814335|NCT04164277|Behavioral|Caregiver Component.|Facebook-based program including four new habit-formation tasks/week. Three face-to-face or virtual caregiver meetings: Meeting 1: Study orientation and healthy cooking education will be offered, and each family will receive a small bag of groceries to facilitate preparation of a recipe at home. Each caregiver will also receive an intervention cookbook containing affordable slow-cooking recipes, quick-fix recipes, and healthy snack ideas. Meeting 2: Study interveners will demonstrate how to spend less and shop healthy and how to read nutrition fact labels to promote healthy purchasing behaviors. Meeting 3: Study interveners will present healthy eating and PA community resources (e.g., farmer's markets, community gardens, nearly parks or other free or affordable PA facilities) and provide caregivers a resource booklet.
45814336|NCT04164277|Behavioral|Caregiver-Preschooler Learning.|Preschoolers, using stickers, will create two letters each week regarding a food or activity presented in the center-based program that they liked or want to try at home. Letters will be sent by the PM privately to each caregiver via Facebook messenger on two weekdays. Caregivers will be asked to answer two Facebook multiple-choice questions related to the letters each week by Sunday midnight (e.g., what foods listed in the their child's letter did the participant provide? and what activities listed in the their child's letter did the participant's family try?). Caregiver responses to the questions will be summed to indicate caregiver responses to child requests. Each preschooler's letters will be kept in his/her intervention binder with other intervention materials to present to his/her caregiver at Meeting 3. Weekly preschooler activities, with pictures or videos, will be shared with caregivers via the Facebook private group every week.
45814337|NCT04164277|Behavioral|Center-based Preschooler Component.|"Built on previous research, preschoolers will receive weekly, age-appropriate, participatory learning co-delivered by teachers and MSU student educators. Session duration will be 20 minutes because children's normal attention span is 3-5 minutes per year of age, and 20 min/session is recommended for preschoolers. The already developed Eat & Walk My ABCs curriculum will be implemented. The curriculum includes four components: healthy eating learning, taste-testing activities, movement skill training, and fun physical activity."
45814338|NCT05413759|Other|Pharmaceutical care in multiprofessional collaboration|"In addition to usual practices: medication reconciliation and pharmaceutical motivational interviews with patients (discharge, 2 & 6 months).~Objective of medication reconciliation (admission): to detect and resolve unintended medication discrepancies between home medication list and treatment and hospital admission medication orders. Objective of medication reconciliation (discharge): to obtain an exact list of medication, to explain the medication modifications during hospitalization.~Objective of the Disease-Modifying Antirheumatic Drugs information interview (discharge): to provide information and to answer questions on the management of treatment, to deal with practical situations to assess patients' self-management skills.~Objective of interviews (2 & 6 months): to evaluate medications and their daily management, benefits and problems that patient may encounter, to assess the patient's ability to manage the treatment."
45814339|NCT04147039|Behavioral|MINISTOP 2.0|The MINISTOP 2.0 is a behavioural change program aiming to promote healthier diet and physical activity among 2.5-year-old children. The program consists of features such as information, monitoring and feedback (dietary key variables, physical activity, screen time) and it is built around 13 themes during the 6-month period.
45814340|NCT04338607|Procedure|Subtalar (Talocalcaneal) arthrodesis|Subtalar (Talocalcaneal) arthrodesis with a novel sustained dynamic compression intramedullary nail
45814341|NCT04338607|Device|DynaNail Mini|Utilization of a novel sustained dynamic compression pseudoelastic intramedullary nail
45953024|NCT00162006|Drug|Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution|
45953025|NCT00140699|Behavioral|Balance|
45660442|NCT02370615|Drug|Midazolam|Midazolam syrup.
45660443|NCT02307513|Drug|Apremilast|Tablets for oral administration
45660444|NCT02307513|Drug|Placebo|Tablets for oral administration
45660445|NCT02332239|Behavioral|iDOVE Intervention (ED+text)|"In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention~Eight-week longitudinal tailored text-message program"
45660446|NCT02332239|Behavioral|Control (EUC)|"In-ED brief session, discussing home safety & nutrition~Eight-week longitudinal home safety & nutrition text-message program"
45660447|NCT02370537|Drug|Epanova® (omega-3 carboxylic acids)|4 g (administered orally as 4 x 1 g capsules)
45660448|NCT02370537|Drug|Omacor® (omega-3-acid ethyl esters)|4 g (administered orally as 4 x 1 g capsules)
45660449|NCT02330055|Procedure|Forty-five degrees elevated upper body position|
45660450|NCT02330055|Procedure|non-elevated upper body position|
45660451|NCT02330055|Device|Noninvasive wrist pulse oximeter (WristOx Model 3150)|The noninvasive wrist pulse oximeter (WristOx Model 3150) is used to measure the SpO2 and the pulse rate of the patient in the first night after delivery.
45953026|NCT00162045|Drug|Technetium Tc99m Sestamibi|Rest and/or stress SPECT imaging study
45660452|NCT02330055|Other|Stop-Bang questionnaire|"The Stop-Bang questionnaire is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient. The STOP Bang questionnaire includes snoring, tiredness, observed apneas, blood pressure, Body Mass Index, age, neck circumference and gender.~The investigators will ask the patient to answer the questionnaire and measure the neck circumference."
45953027|NCT00140738|Biological|GSK Biologicals' 719125|Patients receive six vaccinations at two-week intervals
45953028|NCT00162084|Drug|apadenoson|
45953029|NCT00154986|Procedure|immunohistochemical staining, transfection, invasion assay|
45814342|NCT05442931|Drug|Pregabalin 150mg|The oral tablet half an hour preoperative 150 milligrams
45814343|NCT05442931|Drug|Magnesium Sulfate|Intravenous administration half an hour preoperative 2 grams
45814344|NCT05442931|Drug|Nitroglycerin|measure total dose of nitroglycerine in milligrams using a syringe pump
45814345|NCT05442931|Other|surgeon satisfaction|surgeon satisfaction measured according to Likert's scale
45953030|NCT02964572|Drug|Glimepiride|In accordance with the standard treatment guidelines of diabetes, glimepiride as a drug of active comparator will be administered to improve blood sugar in patients with poorly controlled blood sugar.
45953031|NCT02964572|Drug|Empagliflozin|Empagliflozin as a drug of experimental will be administered to improve blood sugar in patients with poorly controlled blood sugar.
45953032|NCT00162201|Drug|Abatacept|Parenteral, IV, 500 mg if < 60 kg; 750 mg if > 60 & < 100 kg; 1000 mg if > 100 kg, Monthly, 4 months.
45953033|NCT01248247|Drug|Erlotinib|150 mg by mouth each day of a 28 day cycle.
45953034|NCT01248247|Drug|AZD6244|100 mg by mouth daily of a 28 day cycle.
45660453|NCT02330055|Other|Epworth Sleepiness Scale|"The Epworth Sleepiness Scale is a well-established clinical tool to quantify daytime sleepiness. It is clinically used for the diagnosis of sleep disorders.~The investigators will ask the patient to complete the questionnaire and will specify that the questionnaire pertains to the patient's pre-admission condition."
45660454|NCT02330055|Other|P-SAP Score|"The P-SAP Score is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient.~The investigators will ask the patient to answer the questionnaire and will assess the Mallampati Score. The investigators will also measure the neck circumference and the Thyromental distance."
45660455|NCT02330055|Other|self-reported pain|A verbal numerical rating scale is used to asses the pain during the study-night.
45660456|NCT02306265|Device|FFDM|2D imaging of the breast using Full-Field Digital Mammography (FFDM) device
45660457|NCT02306265|Device|DBT|3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device
45660458|NCT02329743|Drug|RX-10045|topical therapy
45660459|NCT04896567|Diagnostic Test|Cell isolation|Tissue from kidney biopsy will be used to isolate Cluster Differentiation 34+ cells.
45814346|NCT05442541|Behavioral|not included any interventions(Evaluation of menstrual well-being in women of reproductive age, field survey study)|This is a prospective cross-sectional analytical study conducted through a questionnaire.
45814347|NCT05393479|Behavioral|Thinking Healthy Programme|The Thinking Healthy Programme (THP) is a psychological treatment recommended by the World Health Organization for perinatal depression. The THP is based on the basic tenets of cognitive behavioural therapy (CBT) that aims to identify unhealthy thoughts and the vicious effects it has on the emotions and behaviour of a person and transform to healthy thinking style that ultimately impacts one's emotions and behaviour, too. The intervention aims to bring positive outcomes in three areas - a) mother's health, b) the mother-baby relationship, and c) the mother's relationship with others. A randomized controlled trial (RCT) showed that the intervention was effective in reducing depressive symptoms and disability and improving functioning. Additionally, women receiving THP had higher rate of exclusive breastfeeding, and engaging more with their infants. Similarly, infants of these women were also less likely to have diarrhoeal episode and more likely to complete immunization.
45814348|NCT05442385|Other|Evidence based management|clinical patterns , laboratory investigations , radiology , lines of managements and outcome of each modality of treatment
45814349|NCT05442307|Behavioral|asthma education|A 15 minutes (preferable) one-on-one educational visit about asthma treatment. The main points being: Every person with asthma should be treated with inhaled corticosteroids (ICS). Most patients with asthma should be treated with Bufomix Easyhaler either as needed and/or regularly. Patients should not use short-acting bega2-agonist (SABA) unless they use a medium-ICS-dosis.
45814350|NCT05442307|Behavioral|Other education|A 15 minutes (preferable) one-on-one educational visit about another topic (NOT asthma).
45953035|NCT01248247|Drug|MK-2206|100 mg by mouth every week of a 28 day cycle.
45953036|NCT01248247|Drug|Sorafenib|400 mg by mouth twice a day for a 28 day cycle.
45953037|NCT01248247|Drug|Erlotinib|150 mg by mouth daily of a 28 day cycle.
45953038|NCT01248247|Drug|MK-2206|135 mg by mouth every week of a 28 day cycle.
45953039|NCT00140816|Behavioral|Increased intake of dairy products|
45953040|NCT04518241|Behavioral|MI sessions|"Three counseling sessions lasting less than 60 minutes each to identify goals, factors that promote or impede goals, and increase readiness for ART with high adherence"
45953041|NCT04518241|Behavioral|TMQQ|Weekly text messages with health information as well as motivational messages. Two days later a true/false quiz question is sent. Participants earn 4 points for answering correctly, 2 points for answering incorrectly, and 0 points for not answering. Participants earn $1 for each point. Messages are sent over 21 weeks.
46077729|NCT05520723|Drug|Granulocyte Colony-Stimulating Factor|G-CSF : 30 MU subcutaneously (SC) QD during two consecutive days, 48 hours after administration of sacituzumab govitecan (D3, D4 and D10, D11) during the first two cycles (consider extending to the next cycle at the discretion of the physician).
46077730|NCT02753010|Procedure|Gastric emptying of carbohydrate-rich beverage|Old women with acute hip fracture with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied for retention in the elderly with acute trauma.
45660460|NCT02329431|Behavioral|activation curriculum|psychosocial activation curriculum
45660461|NCT02329431|Behavioral|support group|parent directed support group
45660462|NCT02328105|Drug|Carboplatin|Dosing: AUC = 6; on Day 1
46077731|NCT02753010|Procedure|Gastric emptying of carbohydrate-rich beverage|Old women on waiting list for hip joint replacement with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied as comparator in the elderly without acute trauma..
45660463|NCT02328105|Drug|Abraxane|100 mg/m^2; Days 1, 8, 15
45660464|NCT04896021|Diagnostic Test|Cardiovascular disease risk assessment|Intervention in which the addition of guideline-recommended absolute cardiovascular disease risk assessment is embedded into point-of-care blood collection services for cholesterol measurement and results (including risk score) are reported to referring doctors.
45660465|NCT04896021|Diagnostic Test|Usual care assessment|Usual care in which blood cholesterol results are reported to referring doctors
45660466|NCT02305797|Drug|Extended-release lorazepam|Extended-release lorazepam capsules
45814351|NCT05440513|Device|Renal Pelvic Denervation (bilateral)|Using the natural orifice of the urethra, the ureters are accessed (bilaterally and in sequence), to allow for an ablation device to be placed into the renal pelvis where RF energy is delivered to ablate renal nerves.
45814352|NCT05439967|Other|Augmented and Virtual Reality Gait and balanceTraining|C-Mill VR+ device used for training. The training was carried out 3 days a week for 6 weeks, with each exercise session lasting approximately 1.5 hours, accompanied by a physiotherapist. Training started with conventional exercises, continued with C-Mill VR+ training, and ended with stretching and relaxation exercises. The patients in the intervention group were applied the exercises with the same principles with conventional training, except the exercises performed in standing and walking. Patients performed 10 exercises in AR and VR gait training for 4 minutes and resting the individuals by sitting for 1 minute between exercises.
45814353|NCT05439967|Other|Conventional Training|Conventional training was applied to the patients in the control group. Conventional training was planned taking into account the following goals: increasing mobility by improving the impaired kinesthetic sensation; improving axial rotation, coordination, flexibility of soft tissues, mobility in and out of bed; increasing body image perception by improving upright and proper posture; and improving balance and gait. The training was applied 3 days a week for 6 weeks, with each exercise session lasting 40-50 minutes, accompanied by a physiotherapist. Each of the exercises was done in 2 sets of 10 repetitions. In gait training, each exercise was performed for 4 minutes.
45660467|NCT02305797|Drug|Placebo|Placebo capsules
45814354|NCT05439811|Procedure|Swan-Ganz Catheter|Swan-Ganz Catheter
45814355|NCT05439499|Drug|FCN-437c, Letrozole or anastrozole, Goserelin acetate|FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach. 200mg once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment until progressive disease。Letrozole or anastrozole：Letrozole 2.5 mg or anastrozole 1 mg once daily；Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
45814356|NCT05439499|Drug|Placebo, Letrozole or anastrozole, Goserelin acetate|"Placebo：available in 25mg and 100mg capsules, and is administered in the same way as FCN-437c。~Letrozole or anastrozole：Letrozole 2.5 mg or anastrozole 1 mg once daily；~Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。"
45814357|NCT04018261|Drug|Activated T-Lymphocytes|Activated T-Lymphocytes will be infused intravenously in a single-dose
45953042|NCT04518241|Behavioral|Type of compensation|Participants who achieve HIV viral suppression at 21 weeks will receive either fixed compensation of $275 or be entered into a lottery where they have a 3/10 chance of winning $500, and a 7/10 chance of winning $175. Those who do not achieve HIV viral suppression receive a $50 participant incentive.
45953043|NCT04518943|Behavioral|Walking|Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.
45953044|NCT00504790|Drug|GSK923295|anti-mitotic compound
45953045|NCT00140894|Drug|MK0966; rofecoxib / Duration of Treatment: 24 weeks|
46077732|NCT02753010|Procedure|Gastric emptying of carbohydrate-rich beverage|Young healthy women with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied as comparator in young women.
46077733|NCT02826746|Drug|Magnesium Sulfate|adminstration of intravenous magnesium as bolus of 50 mg/kg, followed by continuous infusion at rate of 10 mg/kg/h
46077734|NCT02826746|Drug|Normal saline|the same bolus and infusion volumes of normal saline
46077735|NCT02750904|Behavioral|Experimental plus Nicotine Replacement Therapy|"Behavioral: Experimental plus Nicotine Replacement Therapy will be built to specifically address challenges of smoking cessation for individuals with bipolar disorder.~Includes four in person and four phone visits.~Therapy information is withheld to protect the integrity of the study."
46077736|NCT02750904|Behavioral|Control plus Nicotine Replacement Therapy|Includes four in-person and four phone visits
46077737|NCT04103307|Procedure|Dialysis cooling|Cooling the blood in the CRRT circuit during delivery
46077738|NCT02831972|Drug|AG120|
45660468|NCT01646073|Biological|Adalimumab|adalimumab eow
46077739|NCT02831972|Drug|Itraconazole|
45660469|NCT01646073|Biological|placebo|placebo
45660470|NCT05438199|Device|Toilet seat that measures waste output|Participants will use a toilet that includes a apparatus designed to measure waste output.
45660471|NCT02328027|Drug|99mTc-rhAnnexin V-128|1 single intravenous bolus administration of 250 MBq, at Day 1 and at Day 42.
45660472|NCT02551159|Biological|MEDI4736|Anti-PD-L1 antibody
45660473|NCT02551159|Biological|Tremelimumab|Anti-CTLA-4 Antibody
45660474|NCT02551159|Biological|MEDI4736+Tremelimumab|
45660475|NCT02551159|Biological|Cetuximab|Monoclonal Antibody
45660476|NCT02551159|Drug|5-fluorouracil (5FU)|Chemotherapy Agent
45814358|NCT04003987|Drug|Liposomal bupivacaine|20ml
45814359|NCT04003987|Drug|bupivacaine, 0.125%|60ml
45953046|NCT00140894|Drug|Comparator: placebo / Duration of Treatment: 24 weeks|
45953047|NCT02275429|Procedure|Blood test|blood will be drawn the day before the race (day 0), upon completion of the race (between 27 and 67 hours after departure), and on days 7 and 28
46077740|NCT05279508|Behavioral|Make My Day - stroke prevention program|A stroke prevention program within primary healthcare
45953048|NCT02481154|Drug|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
45953049|NCT00155064|Drug|captopril, Losartan (drug)|
45953050|NCT02483260|Drug|Ribavirin|"Loading dose, 33 mg/kg (maximum dose: 2.64 g)~Followed in 6 hours by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses)~Followed by a dose of 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 6 days (18 doses)."
45953051|NCT00140933|Drug|MK0966; rofecoxib|
45953052|NCT00140933|Drug|Comparator: diclofenac, placebo|
45953053|NCT04515628|Drug|Rosuvastatin|Specified dose on specified days
45814360|NCT03984331|Device|Fish skin|One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive fish skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
45953054|NCT04515628|Drug|Branebrutinib|Specified dose on specified days
45953055|NCT04511845|Drug|SPYK04|SPYK04 capsule
46077741|NCT02827760|Dietary Supplement|Synergy1|Inulin type fructans
46077742|NCT02827760|Dietary Supplement|Maltodextrin|
45660477|NCT02551159|Drug|Cisplatin|Chemotherapy agent
45660478|NCT02551159|Drug|Carboplatin|Chemotherapy Agent
45660479|NCT05482009|Other|Traditional Chinese Medicine Treatment Combined with Western Medicine Basic Treatment|The cumulative observation and treatment (including Chinese patent medicine, Chinese medicine decoction, Chinese medicine granule, Chinese medicine injection, and western medicine) were more than 5 months, and the follow-up was 1.5 years.
45953056|NCT00407043|Drug|Lotemax|
45953057|NCT00407043|Drug|Restasis|
45953058|NCT00141011|Drug|Ancrod (Viprinex)|0.167 IU/kg/hr (0.6 mL/kg/hr) IV for 2-3 hours
45953059|NCT00141011|Drug|Placebo|0.6 mL/kg/hr
45814361|NCT03984331|Device|Cadaver skin|One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive cadaver skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
45953060|NCT00504907|Drug|BTA9881|Single oral escalating doses
45953061|NCT00504907|Drug|Placebo|
45953062|NCT00504946|Drug|prednisone, lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone+ 0.3mg lactose"
45953063|NCT00504946|Drug|prednisone, colecalciferol, lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone + 1000j colecalciferol + 0.3mg lactose"
45953064|NCT00504946|Drug|lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~0.3mg lactose"
45953065|NCT00504946|Drug|montelukast sodium|Allergen immunotherapy (build-up phase)premedication with montelukast sodium. Children 6-14 years received 5 mg of montelukast and children > 14 years old received 10mg oral tablet once daily at bedtime
45953066|NCT00504946|Drug|lactose|Allergen immunotherapy (build-up phase)premedication with 0,3mg lactose once daily at bedtime
45953067|NCT00141050|Drug|Focalin XR|
45953068|NCT00505024|Behavioral|Interactive Voice Response System|Calls twice weekly, where the system will ask you to rate types of symptoms on a scale from 0 to 10.
45953069|NCT00505024|Other|Symptoms Report|A report of severe symptoms will be sent to your doctor or nurse.
45953070|NCT04511416|Drug|Metformin XR, 500-2000mg nocte|anti diabetic medication
46077743|NCT02695758|Procedure|Interscalene brachial plexus block|
46077744|NCT02695758|Procedure|bupivacaine extended-release liposome injection|
46077745|NCT04200950|Device|Previse|Machine learning algorithm for early acute kidney injury (AKI) prediction.
46077746|NCT00605215|Drug|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
46077747|NCT00605215|Drug|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
46077748|NCT00605215|Drug|Avonex®|Avonex® will be administered per dose and schedule specified in the arm description.
46077749|NCT04197830|Procedure|Thrombectomy for stroke|Patients who have had thrombectomy for acute stroke.
46077750|NCT05660564|Procedure|DIGU Dorsal inlay preputial graft urethroplasty|"Using a scalpel, a midline incision is made from the meatus to the end of the plate .~The edge of the distal glans should not be incised to avoid meatal stenosis. The depth of this relaxing incision depends on the plate's width and depth, but in all cases, it extends down to the corpora cavernosa. Degloving of the penile skin to the penoscrotal junction If a minimal chord is present, it should be corrected.~From the inner prepuce, a free graft was measured, harvested, defatted, and stitched to the UP. With interrupted 6/0 polyglactin sutures running from the old meatus to the tip of the glans, the graft was secured to the medial edges of the incised plate. Depending on the location of the meatus, the characteristics of the UP, and the depth of the midline incision, the graft width and length varied in each case."
45953071|NCT04517695|Device|BVA-100|The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin.
45814362|NCT05448001|Drug|JP-1366 20mg|JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal
45953072|NCT04517695|Device|Transpulmonary Thermodilution (TPTD)|TPTD consists of placing a thermistor-equipped catheter in a central artery (usually the femoral or axillary artery) and injecting cold saline solution into a central vein through a central venous catheter.
45953073|NCT04517695|Device|Sublingual Microcirculation|With incident dark field imaging, the CytoCam device can record digital image sequences using a handheld camera. In the current study the camera will be used to non-invasively record images of the sublingual microcirculation.
45953074|NCT00407082|Drug|fluocinolone acetonide intravitreal implant|Fluocinolone acetonide ocular implant 0.59mg
45953075|NCT00407082|Drug|Fluocinolone acetonide 2.1mg|Fluocinolone acetonide ocular implant 2.1mg
45660480|NCT03557905|Device|RM 0.5|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse.
45953076|NCT04517617|Other|The level of air pollution|The intervention measure is the level of air pollution, it is a non-human interventional measure based on the weighted average of various air pollutants monitored by air pollution monitoring stations during different period of pregnancy.he perinatal period.
45953077|NCT00141089|Drug|Tegaserod|
45953078|NCT00141128|Drug|SS-RBX|
46077751|NCT02827682|Device|Angel-6000D Multiparameter Anesthesia Monitor (IoC)|The Angel-6000D Multiparameter Anesthesia Monitor, Shenzhen Weihaokang Medical Technology Co., Ltd, Guangdong, China
46077752|NCT02827682|Device|BIS VISTA Monitor (BIS)|BIS VISTA Monitor, Covidien, Changchun city shi jia trade co., Ltd, Changchun, China
46077753|NCT04877262|Other|weight maintenance diet (WMD)|A diet meeting the participant's weight maintenance energy needs will be provided.
46077754|NCT04244474|Drug|A single one ml injection|All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 [18], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) or placebo which is 1 ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code. (only office secretary aware of randomization codes).
45814363|NCT05448001|Drug|Lansoprazole 30mg|JP-1366 20 mg placebo 1 capsule, Lansoprazole 30 mg 1 capsule before meal
45814364|NCT05366257|Other|CAR-T|infusion of CAR-T therapy among patients with r/r DLBCL
45814365|NCT05366257|Other|Allo-HSCT cohort|Patients received allogeneic hematopoietic stem cell transplant
45953079|NCT00407121|Drug|Bevacizumab|
45953080|NCT00407121|Procedure|Intravitreal Injection of Bevacizumab|
45953081|NCT00141167|Drug|varenicline|
45953082|NCT00141206|Drug|varenicline (CP-526,555)|
45953083|NCT00141245|Drug|Pregabalin|
45953084|NCT00155220|Device|Low Stretch Bandage and Kinesio Tape|
45953085|NCT00141362|Drug|Pregabalin|
45953086|NCT00155259|Drug|Docetaxel , Cisplatin , Capecitabine|
45953087|NCT04519216|Behavioral|Telesimulation|Telesimulation educational intervention
45660481|NCT03557905|Device|RM 0.3|The patient will be ventilated with volume control mode with tidal volume 6 ml/kg, PEEP 3 cmH2O, an inspiratory expiratory ratio of 1:1.5, respiratory rate 20-25 breaths per minute depending on the patient's age and FiO2 of 0.3.
45660482|NCT05481853|Procedure|One Anastomosis Gastric Bypass|
45660483|NCT04539379|Drug|Magnesium sulfate|intravenous infusion
45660484|NCT04539379|Drug|Labetolol|intravenous infusion
45660485|NCT04529473|Dietary Supplement|Eubacterium hallii|Eubacterium hallii, ≥ 1x10^9 live bacterial cells (per capsule)
45953088|NCT04518124|Drug|Propranolol|Propranolol will be administered as monotherapy in a dose of 40-80 mg 2-3 times a day, if tolerated. The study consists of a single arm.
45953089|NCT00141401|Drug|Pregabalin|
45953090|NCT04517344|Other|Initial Flow Rate|Patients placed on High Flow Nasal Cannula by treating physician will be randomized to initial flow rates of 1 L/kg/min, 1.5 L/kg/min, or 2 L/kg/min
45953091|NCT00162240|Drug|Muraglitazar|
45953092|NCT00505102|Drug|Everolimus|cyclosporine dose reduced of 50% after introduction of everolimus
45660486|NCT04529473|Other|Placebo|Placebo capsules are identical to the active treatment
45814366|NCT05301751|Drug|AG-73305|AG-73305 Ophthalmic Solution
45814367|NCT05447845|Diagnostic Test|Computerized visual acuity assessment program|Each subject underwent visual acuity assessments using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and the computerized program
45814368|NCT05447767|Device|KIT BMAC AND at-SVF FIDIA|intra-articular infiltration or intra-articular and intra-osseous infiltration
45953093|NCT04696237|Other|Questionnaire|a questionnaire to provide data about the management of cleft lip and palate patients in Egypt will be designed
45953094|NCT00404378|Drug|ketoconazole|Ketoconazole tablets will be available with dose strength of 200 mg. The dose of ketoconazole 400 mg will be comprised of two 200 mg tablets. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
45953095|NCT00404378|Drug|casopitant 100 mg|Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive two 50 mg tablets for the dose of 100 mg. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time
45953096|NCT00404378|Drug|Casopitant 50 mg|Casopitant tablets will be available with dose strength of 50 mg and will receive single dose. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
45953097|NCT04511728|Drug|HSK3486|The initial Induction dose of HSK3486 is 0.4 mg/kg. The initial maintenance dose of HSK3486 is 0.8 mg/kg/h
45814369|NCT05447455|Procedure|Transversus Abdominis Plane Block|A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
45660487|NCT05470153|Device|Continuous Positive Airway Pressure|For each patient with Obstructive Sleep Apnea, titration of Continuous Positive Airway Pressure (CPAP) pressure will be performed by conventional polysomnography or using auto-CPAP equipment using a validated protocol. The CPAP device should have an hour meter recording system, so that machine-on time hours could be checked at each clinical visit.
46077755|NCT05271474|Device|ANNE ONE Platform|ANNE ONE is one most advanced digital platforms that are gradually becoming more available to enable providers to help patients manage their condition. It integrates soft and flexible sensors for comprehensive vital signs monitoring. This platform creates objective transparency by automatically recording data from the sensor on the patient, lessening the need for patients to consciously track their COPD exacerbation events, enabling providers to proactively manage their patients' condition, and creating actionable reports for providers to review with their patients.
45953098|NCT04511728|Drug|Propofol|The initial Induction dose of propofol is 2.0 mg/kg. The initial maintenance dose of propofol is 5.0 mg/kg/h
45953099|NCT04510987|Drug|BAY2433334 single dose in treatment groups 1-4 and 6 as well as on the dialysis free day of treatment 5|Tablet, oral
45660488|NCT05470075|Drug|HR18042 tablets|Drug: HR 18042 tablets 175mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
45953100|NCT04510987|Other|BAY2433334 on dialysis treatment day|Tablet, oral
45953101|NCT04519996|Procedure|US Internal Jugular Vein Collapsibility Index measurment|"Machine~A sonosite M-Turbo ultrasound machine will be used for all the examinations. A curvilinear USG probe for IVC imaging (1-5 MHz, 21 mm).~The US transducer will be placed on the right side of the neck in the transverse plane over RIJV 2 cm above the sternoclavicular joint. The IJV will be identified by the color flow Doppler and compressibility. Care will be taken not to compress or obliterate the vein by applying minimal pressure. When the whole circumference of the vein will be visible the measurements were done. The recordings will be done for four respiratory cycles. The maximum, minimum AP diameters, and cross-sectional area will be estimated and, from this, corresponding CI will be derived (Maximum diameter or cross-sectional area (CSA)-minimum diameter or CSA/maximum diameter or CSA) ×100%. All the above measurements will be repeated with the head end of patients elevated to 30° position."
45953102|NCT04519996|Procedure|US Inferior Vena Cava Collapsibility Index measurment|"Machine~A sonosite M-Turbo ultrasound machine will be used for all the examinations. A linear vascular transuder for IJV imaging (7-13 MHz, 38 mm) will be used.~The transducer will be placed in the subxiphoid region in a longitudinal position. IVC measurements will be made just distal to the IVC-hepatic vein junction, approximately 3 to 4 cm distal to the right atrium. The IVC will be identiﬁed by Doppler waveform, compressibility and phasic collapse with respiration. The maximum (IVCD) and minimum (IVCD) internal anteroposterior (AP) diameters of the IVC at the end of expiration and inspiration respectively over the same respiratory cycle will be measured. The IVCCI is derived from the equation, IVCCI= (IVCD max -IVCD min)/IVCD max × 100."
45953103|NCT00162318|Drug|Cetuximab + Gefitinib|IV solution + tablet, IV + oral, ERB (100 mg/m2, 200 mg/m2 + 250 mg/m2 IV) +GEF 250 mg tablet, ERB weekly/ GEF once daily, Until disease progression.
45953104|NCT00404417|Drug|Botulinum Toxin A / Placebo|Botulinum Toxin A at first injection / Placebo at second injection
45660489|NCT05470075|Drug|HR18042 tablets|Drug: HR 18042 tablets 225mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
45660490|NCT05470075|Drug|HR18042 tablets|Drug: HR 18042 tablets 275mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
46077756|NCT05660876|Procedure|standard fistulotomy|in a standard manner fistula tract was identified and laid open without doing marsupialization
45814370|NCT05447455|Procedure|Local anesthetic wound infiltration|40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
45660491|NCT05470075|Drug|Tramadol hydrochloride SR Tablets|Drug: Tramadol hydrochloride SR Tablets 100mg and placebos match to HR18042 tablets Dosing frequency: single dose; Route of administration: oral
46077757|NCT05660876|Procedure|fistulotomy with marsupialization|in this arm fistulotomy was done in a standard manner and marsupialization was done
45660492|NCT05470075|Drug|Placebos|Drug: Placebos match to HR18042 tablets and Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
45660493|NCT05476627|Diagnostic Test|Biomarkers|Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.
46077758|NCT04243382|Biological|Autologous umbilical cord blood|Single infusion of autologous umbilical cord blood cells
46077759|NCT04243382|Biological|Placebo|Placebo
45660494|NCT05481619|Drug|Vedolizumab|"Recommended dose in patients with UC: 300 mg intravenously at weeks 0, 2, and 6 and every 8 weeks thereafter.~Discontinue vedolizumab at week 14 in patients who do not show treatment benefit."
46077760|NCT04218942|Device|Exime is the name of the single use temporary prostatic stent used instead of the Foley catheter|"Insertion after instillation of a local lubricant anesthetic gel in the urethra like for Foley insertion. Calibration of the urethral meatus with a 22F Bougie. Insertion of the Bougie until abutment against the posterior wall of the bulbous urethra just below the striated sphincter. Note depth of abutment on the scale of the Bougie. Retrieve the Bougie and glide the device to the same depth until abutment against the posterior wall of the bulbous urethra. At this stage the stent is correctly positioned. Stent release: unlock the Luer connection between pusher tube and stylet . Retrieve pusher tube, stylet and flattener tube.~Control of correct positioning: ask patient to stand up to verify the absence of any urine leak. Ask patient to void immediately to control clear urine output."
46077761|NCT00903799|Device|Implantation of ENTERRA therapy|Gastric electrical stimulation using Enterra Therapy
46077762|NCT00636012|Procedure|verum acupuncture|acupuncture at St36 and Pe6
46077763|NCT00636012|Procedure|sham acupuncture|superficial needling at sham points
46077764|NCT02826200|Drug|Acenocoumarol|Standard of care plus oral anticoagulant therapy (acenocoumarol)
46077765|NCT02826200|Other|Standard of care|Standard of care
46077766|NCT02750982|Other|Laughter Therapy|Laughter Therapy (LT) involves simple exercises using playfulness, eye contact and chanting in forms of laughter. LT will be taught by a certified LT instructor in a group session. There will be 8 sessions per group with each session attended by 8-12 participants and lasting 60 minutes
46077767|NCT04754802|Drug|PH94B Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
45660495|NCT03276559|Behavioral|EMPOWER|"EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment."
46077768|NCT04754802|Drug|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
46077769|NCT04244708|Drug|Radiotherapy plus temozolomide|undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks, for a total dose of 54 Gy, plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
46077770|NCT04244708|Other|Radiotherapy plus placebo|undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks, for a total dose of 54 Gy, plus placebo
45814371|NCT05447377|Biological|SII Yellow Fever Vaccine|"SII YF vaccine:~Live attenuated Yellow Fever Virus (17D-213 Strain) not less than 1000 IU/dose propagated in specific pathogen-free chick embryos.~SII-YFV contains the 17D-213 vaccine strain, a derivative of 17D-204 strain which is used in many currently produced yellow fever vaccines. SIIPL imported the YF WHO Primary Seed Virus lot 213-77 from National Institute for Biological Standards and Control (NIBSC) for preparation of the master seed virus, working seed virus and the vaccine.~After reconstitution, 1 dose (0.5 mL) contains:~Yellow fever virus 17D-213 strain (live, attenuated) not less than 1000 IU propagated in specific pathogen-free chick embryos~Excipients with known effects:~This product contains approximately 5 mg of sorbitol per dose."
45953105|NCT00404417|Drug|Botulinum Toxin A / Botulinum Toxin A|Botulinum Toxin A at first injection / Botulinum Toxin A at second injection
45454034|NCT01352416|Drug|Placebo|Placebo 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
45660496|NCT03276559|Other|Enhanced Usual Care|Enhanced usual care consists of standard ICU psychosocial support for caregivers like social work, chaplaincy, or palliative care team visits as charted in the patient's medical record. Participants assigned to EUC will also receive a general information guide for caregivers as well as a site-specific list of caregiver resources.
45660497|NCT03276481|Diagnostic Test|Oral microbiota assessment|Whole mouth microbiota will be assessed by having participants swish in their mouth 10 ml of sterile water for 30 sec and then expectorate in a sterile container. Specimens will be immediately placed on wet ice and transferred to the laboratory for processing or for storage at -80° C until they are ready to be prepared for sequencing.
45953106|NCT00404417|Drug|Placebo / Botulinum Toxin A|Placebo at first injection / Botulinum Toxin A at second injection
45953107|NCT00404417|Drug|Placebo / Placebo|Placebo at first injection / Placebo at second injection
46077771|NCT02750748|Drug|Naltrexone|
46077772|NCT02750748|Other|Intravail|
46077773|NCT00604279|Drug|Paliperidone palmitate (R092670)|Paliperidone palmitate suspension for intramuscular injection at a dose of 150 milligram equivalent (mg eq.) at baseline, 100 mg eq. on Day 8, flexible dose, either 50 or 100 mg eq on Day 36 and 50, 100, or 150 mg eq.on Day 64 depending on investigator's discretion.
46077774|NCT00604279|Drug|Risperidone|Risperidone LAI intramuscular at a dose of 25 mg on Day 8 and Day 22; flexible dose of either 25 or 37.5 mg on Day 36 with same dose on Day 50; and either 25, 37.5, or 50 mg on Day 64 with same dose on Day 78; along with oral risperidone 2 mg tablet on Day 1, flexible doses (1-6 mg/day) for first 28 days; and 1-2 mg/day during Day 36-57 and Day 64-85 if the dose of risperidone LAI was increased on Day 36 and Day 64.
46077775|NCT02826122|Device|Pai APP|Prescription: Target 100 PAI Points per week
46077776|NCT02826122|Device|FitBit APP|Prescription: Target daily 10.000 steps
46077777|NCT00635856|Drug|Gefitinib|Iressa
45454035|NCT00531622|Drug|saredutant (SR48968)|oral administration, capsules
45454036|NCT00531622|Drug|escitalopram|oral administration, capsules
45953108|NCT04519918|Behavioral|AOA|AOA represents an invasive non-physiological technique.
46002713|NCT04645095|Device|Transcutaneous electrical nerve stimulation|All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.
45660498|NCT03276481|Diagnostic Test|Comprehensive chemical gustometry|Chemical gustometry assessments will be performed by a trained clinician on the study team, including a Registered Dietitian, Physician's Assistant, or Research Nurse. The test solutions and gradients will be formulated in house using sterile water and the following constituents: Sweet taste; 0.05, 0.1, and 0.2 g/ml sucrose, sour taste; 0.05, 0.09, and 0.165 g/ml citric acid, salty taste; 0.016, 0.04, and 0.1 g/ml NaCl and bitter taste; 0.0004, 0.0009, and 0.0024g/ml quinine-HCl. Umami will be tested with MSG at 25, 50, and 75 mM.
45953109|NCT04519606|Procedure|Optimal lung compliance during OLV|Stepwise increase of tidal volume from 4 ml/kg PBW to 7 ml/kg PBW during OLV to determine the optimal tidal volume at the level the the pressure-volume loop reaches upper refection point where the peak airway pressure at or just below 30 cmH2O
45953110|NCT04519762|Drug|Glycophos (Sodium Glycerophosphate)|Management of hypophosphatemia via Glycophos Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
45814372|NCT05447377|Biological|STAMARIL®|"STAMARIL® contains the 17D-204 vaccine strain, which is used in many currently produced yellow fever vaccines. STAMARIL® is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF vaccine virus.~STAMARIL® will be used as a comparator in the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with solvent.~After reconstitution, 1 dose (0.5 mL) contains:~Yellow fever virus 17D-204 strain (live, attenuated) not less than 1000 IU propagated in specific pathogen-free chick embryos~Excipients with known effects:~This product contains approximately 8 mg of sorbitol (E420) per dose."
45814373|NCT00369109|Other|biologic sample preservation procedure|
45953111|NCT04519762|Drug|Antibiotics|Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
45814374|NCT00369109|Other|immunohistochemistry staining method|
45953112|NCT04519762|Drug|Inotropes|Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
45953113|NCT00162357|Drug|Technetium Tc99m Sestamibi|
45953114|NCT04519723|Device|Assess the safety and efficacy of light-laser therapy using the Harmony XL and Dye-VL (500-600nm), Q-Switched 1064nm, Er:YAG 2940nm modules in combination .|
45814375|NCT00369109|Other|laboratory biomarker analysis|
45953115|NCT00404456|Drug|Melatonin|Melatonin 3 mg once-daily
45953116|NCT02275468|Drug|Fu-zheng-qu-zhuo (FZQZ) oral liquid|FZQZ oral liquid is a herbal medicine, composed of astragalus, angelica root, rhubarb, etc, with the effect of reinforcing Qi and activating blood, dissolving dampness and downbearing turbid.
45953117|NCT04519450|Device|Mindray TE7 ultrasound machine|The study was performed using a Mindray TE7 ultrasound machine with the depth of the linear probe at 70 mm and gain of 90 dB; settings remained unchanged during the study. Measurements of the right m. sternocleidomastoideus, the right m. trapezius, and the right upper leg were taken, with the final value being the average of three measurements for each. The probe was set at the musculoskeletal ultrasound setting.
45953118|NCT00155337|Procedure|photodynamic therapy|
45953119|NCT00404534|Drug|Amoxicillin, Clarythromycin, Omeprazole for ten days|Amoxicillin 1000 mg BID, clarythromycin 500 mg BID for ten days in the experimental group and placebo of Amoxicillin 1000 mg BID and placebo of clarythromycin 500 mg BID in the placebo comparator. Both groups receive omeprazole 20 mg bid for 10 days.
45953120|NCT04519060|Device|phototherapy eye shield|Phototherapy eye shields will be applied to the eyes of infants dilated for scheduled eye exam. They will be worn until four (4) hours after the last dose of dilating eye drops.
45953121|NCT02955472|Drug|GLA5PR GLARS-NF3 tablet 150mg|A new formulation(3rd.) of Pregabalin CR tablet
46077778|NCT02827292|Other|music|"A standard music with a standard volume as per the protocol will be played with headphones during the entire duration of the surgery starting from the point of induction to the time of extubation.~A proper silent operative room environment will be maintained."
45953122|NCT02955472|Drug|GLA5PR GLARS-NF1 tablet 150mg|A new formulation(1st.) of Pregabalin CR tablet
45953123|NCT00505258|Drug|ceftobiprole medocaril|
45953124|NCT00162396|Drug|Albuterol|
45953125|NCT04519333|Procedure|drug(intradermal injection)|"The mesotherapy was performed by an experienced and trained physician using a disposable 4 mm and 6 mm long, 30 Gauge needles. Initially, a pharmacological mixture of 1 cc (2 mg) thiocolchicoside, 1 cc (16.2 mg) lidocaine and 1 cc (5 mg) tenoxicam was prepared for each treatment session, and 0.1-0.2 cc of this mixture was applied to each injection point with a depth of 1-3 mm using point by point intradermal method without causing papules.~In the systemic therapy group, we applied a 50 mg dexketoprofen (Revafen, Haver Pharma Pharmaceutical Co., Turkey) in 100 cc isotonic solution intravenously for 5 minutes."
45814376|NCT00369109|Procedure|biopsy|
45814377|NCT00369187|Drug|large protein molecule|
45814378|NCT03831139|Behavioral|TIM&SARA|
46002714|NCT04645095|Device|Hot pack|All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.
46077779|NCT02827292|Other|No music|Silent Headphones (Without music) will be applied to the patient from the point of induction of anaesthesia to the time of extubation.
45814379|NCT05447221|Diagnostic Test|The diagnosis of Artificial Intelligence and pathologists|Pathologists and AI will assess the severity of intestinal metaplasia and judge the tumor area of whole slide images of gastric biopsy specimens independently. In addition, the pathologists can not see the diagnosis of AI.
45814380|NCT05446987|Other|Position change and back massage|Changing the patient's position every two hours as follows in the same order: supine position with a head angle of 15°, semi-fowler position with a head angle of 30°, lateral right or left position with a head angle of 15°. Also, the researcher applied a simple stroke of lower back massage for 5 minutes every 2 hours
45814381|NCT05446987|Other|Early ambulation|The patient ambulated after 3 hours of complete bed rest in the supine position with a zero head of bed elevation angle
45814382|NCT05446909|Behavioral|IBMT mindfulness|IBMT is an effortless mindfulness technique; health education is a class including health-related topics - exercise, sleep, nutrition, lifestyle, stress management
45814383|NCT05446909|Behavioral|health education|Health education includes health-related topics - exercise, sleep, stress management, nutrition, lifestyle
45814384|NCT05247541|Drug|Definity|Definity (Lantheus Medical Imaging, N Billerica, MA) in 50 mL of saline infused over 5-10 minutes
45660499|NCT03276481|Diagnostic Test|Measurement of salivary flow|Both stimulated and un-stimulated salivation will be assessed by saliva collection in pre-weighed plastic containers. Participants will be seated with their back at a 90 degree angle and asked to swallow everything in their mouth. They will then be asked not to swallow and spit the accumulated saliva in the plastic container every 30 seconds for two minutes (unstimulated flow). For measurement of stimulated saliva, we will follow the same procedure except that after the initial swallow, participants will have their tongue swabbed twice with a cotton swab dipped in ascorbic acid solution or lemon juice.
46077780|NCT02827292|Procedure|Laparoscopic Surgery|Patients will undergo Laparoscopic Surgery as per the set protocol
45660500|NCT03276481|Behavioral|Surveys assessing taste disturbances|Surveys will be administered and examine taste disturbances pre and post HCT.
45660501|NCT05481463|Drug|Surufatinib|250mg, qd, po, 28 days for a cycle
46077781|NCT00906685|Drug|bevacizumab|Intravitreal injection of 1.25 mg bevacizumab
46077782|NCT00906685|Drug|Sham bevacizumab injection|Sham intravitreal injection
46077783|NCT00938015|Other|Questionnaire|This is a non-interventional study
45454037|NCT00531622|Drug|placebo|oral administration, capsules
45660502|NCT05481463|Drug|TAS-102|35mg/m2, po, d1-5, d8-12, bid, 28 days for a cycle
45660503|NCT05476471|Behavioral|multicomponent exercise training program|One supervised 60 minutes training sessions per week were organized combining warm-up, speed-walking, resistance exercise, static and dynamic balance. Supervised walking sessions were for 10-20 minutes at a target intensity of 13-15 on the Borg scale. Thereafter, 10 resistance exercises targeting lower body, trunk and upper body muscles were performed with elastic band. In addition, participants were instructed to accumulate 150 minutes per week of moderate intensity aerobic activity in bouts of at least 10 minutes, and at least 2-3 days all major muscle groups training.
45660504|NCT05481385|Behavioral|Reference preparation-Reference preparation-Test Preparation|Under fed conditions, subjects randomly divided into RRT group were given one tablet of reference preparation first, and then one tablet of reference preparation after cleaning period, and then one tablet of test preparation after cleaning period.
45814385|NCT05446753|Dietary Supplement|Animal-based meats|Animal-based meats from beef, pork and chicken
45814386|NCT05446753|Dietary Supplement|Plant-based meat alternatives|Plant-based meat alternatives of beef, pork and chicken
45814387|NCT00369733|Drug|Darbepoetin alfa|Darbepoetin alfa adminstered SC every other week to acheive a Hb not to exceed 12 g/dL
45953126|NCT00141440|Procedure|mechanical ventilation|evaluated the effect of two different cycling off criteria on breathing pattern, respiratory effort, and gas exchange in patients with chronic obstructive pulmonary disease
45660505|NCT05481385|Behavioral|Reference preparation-Test Preparation-Reference preparation|Under fed conditions, subjects randomly divided into RTR group were given one tablet of reference preparation first, and then one tablet of test preparation after cleaning period, and then one tablet of reference preparation after cleaning period.
45953127|NCT04518904|Other||
45953128|NCT04518826|Device|fractional flow reserve|FFR is a physiological functional parameter indicating the severity of ischemic myocardium perfused by a diseased coronary artery. It is measured by a pressure wire placed in the coronary artery and calculated by the ratio of pressures distal and proximal to the stenosis.
45953129|NCT02955589|Drug|HBI-8000|Oral, twice weekly
45953130|NCT00162435|Drug|Warfarin|
45953131|NCT00141479|Drug|Bifeprunox|
45953132|NCT04518709|Procedure|Posterior Mitral Annulus Elevation Technique|Posterior mitral annulus elevation technique is performed using a large pledget and non-absorbable braided suture starting from the subvalvular section of the posterior mitral valve sutured to the ring annuloplasty (if in the process of repairing the mitral valve, ring implantation is performed; if without the use of ring annuloplasty, the suture is placed in the left atrial wall / supravalvular of PML), so that the posterior annulus is slightly attracted upward toward the cranial and the PML moves toward the center.
46077784|NCT00938015|Other|Questionnaire|This is a non-interventional study
46077785|NCT04244318|Behavioral|Video-feedback ODISEA 2.0|Video-feedback intervention which ODISEA 2.0 (Gómez & Maureira, 2017), which incorporates an attachment theory framework, this intervention was constructed within the ODISEA's comprehensive and formative model of parenthood which was developed in Chile.
46077786|NCT00898963|Genetic|gene expression analysis|
46077787|NCT00898963|Genetic|microarray analysis|
46077788|NCT00898963|Genetic|polymorphism analysis|
46077789|NCT00898963|Other|diagnostic laboratory biomarker analysis|
45454038|NCT02282644|Biological|Bone marrow sampling|
45454039|NCT00364546|Drug|CG 5503;tapentadol|
45454040|NCT00361582|Drug|CG5503 IR; tapentadol|
45454041|NCT00359476|Drug|Vinflunine|solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
45814388|NCT05234281|Other|Interdisciplincary concentrated group rehabilitation|"All arms receive a concentrated interdisciplinary rehabilitation with similar focus and structure:~Three phases:~Pre-intervention preparation (1-2 months): mobilize the patients' resources for change~Concentrated group intervention (2-5 days): (further described below)~Post-intervention follow-up (1 year): digital follow-up~The core intervention is based on the concentrated rehabilitation format:~Initiate treatment when the patient is ready for change~Focus on the behavioral patterns which maintain the disorder, identify situations where they can break the patterns (micro-choices).~Assist the patient when breaking the patterns.~Use long sessions to ensure that they face a broad range of potential micro-choices~Work side-by side with others going through an analogous pattern of change~Prepare them for taking responsibility for integrating the change into every-day living"
45814389|NCT05222737|Device|medency diode laser|intra pocket application of diode laser
45814390|NCT05222737|Drug|spirazole forte|adminstration of spirazole forte with a dose 17 mg per kg
45814391|NCT05446675|Procedure|Endoscopic eTEP|Endoscopic extended view totally extraperitoneal prosthesis repair.
45814392|NCT05446675|Procedure|Open Rives-Stoppa|Open Rives-Stoppa repair with retromuscular mesh placement.
45814393|NCT05217979|Device|Transcutaneous pulsed radiofrequency|single treatment with transcutaneous pulsed radiofrequency, for a duration of 15 minutes, at a strength of 800 mA.
45814394|NCT05217979|Device|Sham|Sham treatment by turning on the device in demo mode. No treatment delivered, but indistinguishable by sound or visual signals or sensations felt by the study participant
45454042|NCT04470466|Device|short pulse and Q-switched ND-YAG laser with topical carbon|application of topical carbon cream, followed by two passes of short pulse 1064 ND-YAG, then one pass of Q-switched 1064 ND-YAG on one side of the face
45660506|NCT05481385|Behavioral|Test Preparation-Reference preparation-Reference preparation|Under fed conditions, subjects randomly divided into RTR group were given one tablet of test preparation first, and then one tablet of reference preparation after cleaning period, and then one tablet of reference preparation after cleaning period.
45953133|NCT04518709|Procedure|Conventional Mitral Valve Repair|Conventional mitral valve repair in the pediatric patient using annuloplasty, leaflet resection and plication, sliding-plasty of chordae technique
45953134|NCT04518865|Device|Herbst appliance|The bottom line of the study is to investigate the changes after Herbst appliance treatment and relate it to the pubertal status of the skeletal class II patients using CBCT.
45660507|NCT02305563|Drug|BMS-936564|
45660508|NCT02305563|Drug|Cytarabine|
45660509|NCT02327325|Behavioral|Physical Activity|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
46077790|NCT00898963|Other|immunohistochemistry staining method|
45660510|NCT02327325|Behavioral|Cognitive Behavioral Therapy|Telephone-based training in multiple skills for managing low back pain.
46077791|NCT00898963|Other|immunologic technique|
46077792|NCT04679532|Other|Gx sweat patch|Adhesive-backed flexible epidermal wearable regional sweat patch to collect and analyze sweat via microfluidics and colorimetric assay
45660511|NCT02304705|Drug|Sildenafil|20 mg three times daily by mouth for 90 days
45814395|NCT05445739|Behavioral|The effect of an online exercise course on the increase of elders' regular exercise intention|The intervention of an online exercise course which 2 days a week for 4 weeks to increase the elders' regular exercise intention.
45814396|NCT00368719|Drug|Tacrolimus|Participants will be followed for 10 years to study the effects of Tacrolimus.
45660512|NCT02304705|Drug|Placebo|One capsule three times daily by mouth for 90 days
45660513|NCT02553499|Biological|MK-1248|IV infusion
45814397|NCT05445193|Behavioral|PEaters Choice Module|There will be nine sessions conducted throughout the intervention period, which include module activity, assessment sessions and follow-up sessions. This module will have four primary sub modules (SM): SM1- An overview of picky eaters, SM2-Healthy eating for children, SM3-Parental Strategies and SM4- Sensory perception.
45814398|NCT00369811|Drug|Oxycodone, fentanyl|
45814399|NCT03647761|Device|Tetra-grip|Tetra-grip is a tubular elastic bandage that provides both compression and support
45660514|NCT02553499|Biological|pembrolizumab|IV infusion
45660515|NCT04507009|Device|Ozone|topical gaseous ozone application
45814400|NCT03615547|Drug|Clomifene Citrate|"After randomization, the andrologist will give a prescription with the first three months of treatment (Clomifene Citrate or placebo) to be collected to the local hospital pharmacy. The andrologist will be blind of the treatment arm.~Treatment unit and their shipment to local pharmacy will be provided and organized by the East group pharmacy of the Hospices Civils of Lyon which is the coordination pharmacy for this study. Prescription and delivery will be renewed for three months at the 3 month and 6 months visit.~The experimental treatment consists in a daily dose of 50mg of Clomifene Citrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The dose level was set according to Chua et al 2013 (cf 1.2.2). One capsule containing 50 mg of CC will be orally administered in the morning every day."
45953135|NCT04518982|Drug|Sintilimab and lenalidomide|Drug: Sintilimab 200mg ivgtt on day 1. Drug: lenalidomide 10mg orally once a day, day 1-14.
45953136|NCT04518982|Drug|Sintilimab placebo and lenalidomide placebo|Drug: Sintilimab placebo ivgtt on day 1. Drug: lenalidomide placebo orally once a day, day 1-14.
45953137|NCT00155376|Drug|morphine and glucagon|
45660516|NCT04507009|Other|CGF|concentrated growth factor (CGF) application
46002715|NCT00547391|Procedure|Tonsillectomy|Tonsillectomy under general anesthesia as a day surgery using diathermy or blunt dissection. Follow up started from the day of surgery.
46002716|NCT00547391|Other|no intervention|No intervention (controls). Follow up started from the day of randomization.
46002717|NCT04636827|Biological|sIPV+DTaP+HepA|sIPV+DTaP+HepA at the age of 18 month old
46077793|NCT04679532|Other|Reference sweat patch|Adhesive Tegaderm with absorbent pad regional sweat patch to collect sweat, followed by standard benchtop gravimetry and ion chromatography methods to analyze sweat
46077794|NCT02826278|Other|External genitalia measurements in female newborns|
46077795|NCT00906763|Dietary Supplement|Chocolate|A single oral application of 200 grams of chocolate (85% cocoa for arm #1; 0% cocoa for arm #2).
46077796|NCT02746926|Drug|tafamidis|
45454043|NCT04470466|Device|fractional CO2 laser|single pass of fractional CO2 laser on the other side of the face
45660517|NCT04507009|Other|Traditional treatment|Alvogyl application
45660518|NCT04468789|Other|Six-month ARV dispensing|Patients in the intervention group who meet eligibility criteria will receive a six-month supply of antiretroviral medications, rather than the standard of care supply which is typically 2-3 months.
45953138|NCT04518631|Behavioral|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
45953139|NCT00141557|Drug|esterified estrogens 1.25mg and methyltestosterone 2.5mg|ESTRATEST® administered orally QD
45953140|NCT00141557|Drug|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
45953141|NCT00162474|Drug|Warfarin|
45953142|NCT00162474|Drug|Phenytoin|
45953143|NCT04518553|Drug|active comarator using antiviral drug of nucleoside analogues|using antiviral drug of nucleoside analogues without additional active interference to control Hepatitis B virus.
45953144|NCT04518553|Device|HA+purification|Based on antiviral drug of nucleoside analogues, plasma purification is added to control hepatitis B virus every three months. After three months, plasma purification will continue if hepatitis B virus DNA titer is still higher than cut-off normal value. plasma purification process lasts 2.5-3 hours each session.
45953145|NCT00505336|Drug|Eplerenone|oral Eplerenone titrated to 50mg for duration of 12 months
45953146|NCT00505336|Other|No additional treatment|normal disease modifying therapy for heart failure i.e. ACE-I, beta blockers
45953147|NCT00505336|Drug|Atorvastatin|oral Atorvastatin 40mg
45953148|NCT04518514|Device|TAPE-Software|Telemedical Risk Assessment and Preoperative Evaluation prior to anaesthesia via personal computer
45660519|NCT05481307|Drug|RLD2202|Take it once a day per period
45454044|NCT00450970|Drug|Oral Satraplatin|The SPERA protocol states that satraplatin may be continued until evidence of disease progression (at the discretion of the investigator), intolerable toxicity, withdrawal of informed consent, or non compliance. The treatment consists of satraplatin 80 mg/m2 administered by mouth once daily for five consecutive days (days 1-5) plus prednison 5 mg po twice daily. The treatment cycle is repeated every 35 days.
45454045|NCT00449878|Drug|Liprotamase|Administered orally
45660520|NCT05481307|Drug|RLD2203|Take it once a day per period
45814401|NCT03615547|Other|Placebo|The placebo treatment consists in a daily dose of 50mg of lactose monohydrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The capsule containing the placebo will have the exact same size, weight, color, taste and will be delivered in the exact same condition as the experimental treatment capsule.
45814402|NCT00422539|Drug|70% trichloroacetic acid|
45814403|NCT05443711|Other|No intervention, observational study|No intervention, observational study
45814404|NCT05443633|Behavioral|individualized speech-language training|Language treatment might include lexical, semantic, and interactive treatment. During treatment, patients may be trained to name words by attempting to self-cue lexical retrieval. The therapy moves incrementally through semantic cuing. The semantic treatment will be implemented using the methods described in (Edmonds et al., 2009, 2014).
45814405|NCT05443633|Behavioral|standard language intervention|Participants will undergo standard speech-language naming therapy
45814406|NCT05166655|Behavioral|Movement task|Computer task with experimental conditions manipulating sensory and motivation cues for movement.
45814407|NCT05440825|Device|VRelax|Virtual Relaxation relaxation, VRelax, includes a collection of high quality 360° degrees videos of nature environments with 3D audio and interactive elements, created for relaxation, stress-reduction and improving sleep. When activated, the participant can choose specific 360° videos from a menu. The 360° videos include among other things a coral reef with an interactive game element of popping air bubbles, a scuba diving experience with dolphins, a mountain meadow with cows, and a session of Tibetan sound bowls.
45814408|NCT05440825|Other|Relaxation exercises|Relaxation exercises consisting of audio-guided breathing exercises, muscle relaxation exercises, and body scan exercises
45814409|NCT03573583|Behavioral|Resistance Training|The intensity, volume, tempo, and progression will be based on the Federal Physical Activity guidelines. The resistance training exercises will include mainly multi-joint exercises using selectorized machines. Each session will include upper body exercises (Chest Press, Shoulder Press, Seated Rows, Bicep curls, and Tricep Extensions) and lower body exercises (Leg Press, Leg Extension and Leg Curls, and Calf raise) that will be tailored to the participant needs.
45953149|NCT04518202|Drug|lidocaine patch|5% lidocaine patch applied at 6 hours before the scheduled office hysteroscopy.
45953150|NCT04518202|Drug|Sham patch|Sham patch containing no study medication applied at 6 hours before the scheduled office hysteroscopy.
45953151|NCT04517890|Drug|lidocaine patch|5% lidocaine patch applied at 3 hours before the procedure
45953152|NCT04517890|Drug|Sham patch|Sham patch containing no study medication applied 3 hours before the procedure
45953153|NCT00141596|Drug|Cardura XL 4 mg bd|
45953154|NCT00141596|Drug|Amiloride 5 mg bd|
45454046|NCT00449878|Drug|Placebo|Administered orally
45660521|NCT05476315|Other|Emergency surgery during covid-19 pandemic|Patients undergoing emergency surgery during the covid period and compared with emergency interventions before the pandemic
45660522|NCT02553421|Device|ivWatch Model 400|The ivWatch Model 400 is placed next to the subject's PIV site. All subjects will receive standard care for their IV sites including the normal routine assessments of the IV site by the bedside registered nurses.
45660523|NCT04270591|Drug|Glumetinib|The investigational product will be orally administrated when fasting at dose level of 300mg QD
45953155|NCT00141596|Drug|Furosemide 40 mg bd|
45953156|NCT04517812|Other|Exercise-based games via the VirtualRehab platform|A 12-week exercise-based home rehabilitation intervention delivered via the VirtualRehab platform. A personalised exercise-based rehabilitation plan will be created for each participant.
45953157|NCT04724811|Procedure|Open reduction and internal fixation (ORIF)|"Approaches used:~Intrapelvic approach +/- iliac window~Kocher-Langenbeck approach"
45953158|NCT04517968|Other|immediate implant with customized healing abutment|"All patients will be operated under local anesthesia.~Atraumatic extraction of the remaining root or tooth will be achieved.~A careful curettage of the socket will be performed if any granulation tissue is present.~Sequential drilling of the osteotomy site with copious irrigation will be done~The Implant is secured in place using a torque wrench.~Fabrication of the customized abutment with flowable composite by first placing a rubber dam between the abutment and the implant to prevent leakage of composite into the socket then start adding the composite in a manner to seal the socket.~Finishing the composite outside the patient's mouth will be done to ensure the borders are smooth with no sharp ends.~The abutment will be attached to the implant."
45814410|NCT03573583|Behavioral|Successful Aging|The successful aging will attend stretching and health lectures as a group . The topics might include, medication management, disease management (e.g. blood pressure, diabetes, arthritis, dementia, pain management, diet) and other health related matters.
45814411|NCT05120791|Dietary Supplement|Placebo vegetable bouillon|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1,3g)
45953159|NCT02275507|Device|Masimo Rainbow Sensor|Non-Invasive Hemoglobin Measurement
45454047|NCT02282800|Genetic|Vitamin D receptor|50-100mg gingival tissue samples were collected from both test and control group for immunohistochemical staining to assess the number of vitamin D receptors in nucleus as well cytoplasm and also for RNA isolation to check the presence of VDR gene.
45953160|NCT00141635|Behavioral|physio,pain,psychotherapy;social,nutrit.counselling&sports|
45660524|NCT02549287|Behavioral|SafeCare|An evidence-based home visiting program
45660525|NCT02549287|Behavioral|Supportive Case Management|Child welfare services as usual
45660526|NCT05469451|Procedure|Low level laser therapy|Irradiated with a low power density laser of 940 (nm), 100 megawatt, which will be calibrated and the result of the calibration will be checked with the use of the power meter. The equipment used will be a diode laser (BIOLASE™), the area to be irradiated will be the anterior segment of the lower arch, each tooth will be irradiated for a time of 10 seconds on the vestibular surfaces of the teeth and 10 seconds on the lingual surfaces of the teeth, both at gingival level and at apical level in scanning mode.
45953161|NCT02275585|Other|Event of portal vein thrombosis|There is no intervention over patients. They are followed during 3 years to look after any event of portal vein thrombosis
45953162|NCT00162513|Biological|Allogeneic tumor cell vaccine|
45953163|NCT02275663|Drug|Azacytidine|
45953164|NCT02275663|Drug|Fludarabine|
45953165|NCT02275663|Drug|Cytarabine|
45953166|NCT02275663|Drug|Filgrastim|G-CSF
45953167|NCT02275702|Drug|Dexamethasone IV|It will be administered at the induction of the anesthesia
45953168|NCT02275702|Drug|Saline solution|
45953169|NCT00141674|Procedure|Blood Transfusion|This is a single centre randomized trial in severely head injured patients requiring a blood transfusion. Randomization will be by computer generated random numbers paced in sealed envelopes. Patients would be randomized to receive either blood less than 5 days old or greater than 20 days old. The decision to transfuse and all other intensive care management will be unaltered by enrolment in the study.
45814412|NCT05120791|Dietary Supplement|microalgae phaeodactylum|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae Phaeodactylum
45953170|NCT04517773|Other|writting test|Patients will be invitated to fill a questionary about self-autonomy
45953171|NCT00155415|Behavioral|Different timing of taking polyethylene glycol(PEG)|
45953172|NCT04518163|Drug|Tranexamic Acid|Intravenous 1 gm tranexamic acid in 100 ml saline by slow infusion before skin incision
45953173|NCT04518163|Drug|placebo to TA|Intravenous 110 ml saline by slow infusion before skin incision
45953174|NCT04518163|Device|Bakri Balloon|Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
45953175|NCT04517227|Drug|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer.
45953176|NCT04517227|Procedure|Transcatheter Hepatic Arterial Chemoembolization (TACE)|TACE techniques have been described in the NCCN and ESMO-ESDO guidelines, including cTACE and DEB-TACE.
45953177|NCT04517227|Procedure|Ablation|In this study, thermal ablation could be conducted with radiofrequency (RFA) or microwave (MWA).
45660527|NCT04505527|Behavioral|Lateral stepping|Subjects will step laterally, changing direction every 10 m, thus alternating lead and lag limbs.
45814413|NCT05120791|Dietary Supplement|From the Microalgae phaeodactylum the extracted beta-Glucan (especially chrysolaminarin)|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), Beta-Glucan (1.8g)
45953178|NCT00141713|Drug|Etanercept|Patients enrolled on the study will receive etanercept at 0.4 mg/kg per dose up to a maximum of 25 mg per dose subcutaneously twice a week. Etanercept must be initiated within 72 hours of starting solumedrol.
45953179|NCT04517188|Drug|Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP|Single topical administration
45953180|NCT04516837|Drug|Eltrombopag|Eltrombopag 25-75 mg oral daily according to platelet response.
45953181|NCT04516837|Drug|rhTPO|Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
45953182|NCT00155454|Procedure|Intravitreal long acting gas (10% C3F8)|At the end of surgery, fluid-gas exchange with 10% C3F8 were done in the eye of study group
45953183|NCT04516954|Biological|Convalescent COVID 19 Plasma|A total of 500 ml of convalescent COVID 19 plasma will be transfused intravenously per subject
45814414|NCT05120791|Dietary Supplement|A combination of the vegetable bouillon, the microalgae and the beta-Glucan|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae, Beta-Glucan (1.8g)
46002718|NCT04636827|Biological|sIPV|sIPV at the age of 18 month old
45660528|NCT04505527|Behavioral|Forward walking|Subjects will have a typical forward walking
45660529|NCT05476159|Drug|Indocyanine green solution|"Adequate perfusion was defined as the direct and clear visualization of the fluorescence along the gastric tube, relative to the excised specimen, after an estimated time of 150-180 s after i.v. administration injection"
45454048|NCT02287324|Procedure|Manipulation|
45660530|NCT05476159|Device|Gastric bypass|Roux and Y Gastric bypass
45454049|NCT02287324|Procedure|Manual Contact|
45814415|NCT03562897|Dietary Supplement|Ocoxin-Viusid|Ocoxin-Viusid group (Experimental): Oral solution Ocoxin-Viusid (30 ml vials) were used at a rate of 60ml / day (1 vial every 12 hours), preferably administered after breakfast and dinner. The treatment will start a week before start Chemotheray treatment (CT) and, It will maintenance until 3 weeks after finished the last cycle of CT (3 cycles of CT of Carboplatin/Paclitaxel or Cisplatin/ Paclitaxel with neoadjuvant intent).
45814416|NCT03559543|Dietary Supplement|Ocoxin-Viusid|"An oral solution of Oncoxin® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT up to 3 weeks after finishing the treatment.~The treatment with Oncoxin®-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously for approximately 29 weeks from the patient's inclusion in the study."
45814417|NCT05431309|Diagnostic Test|Coronary Computed Tomography Angiography|Intervention strategies were selected according to CCTA results
45814418|NCT05431309|Other|Standard Treatment|Traditional cardiovascular disease prevention strategy based on Chinese guideline
45814419|NCT05429047|Biological|Tozinameran|Tozinameran during pregnancy
45814420|NCT05429047|Other|COVID-19|SARS-CoV-2 infection during pregnancy
45814421|NCT05429047|Other|No SARS-CoV-2 exposure|No SARS-CoV-2 exposure during pregnancy
45814422|NCT05423119|Behavioral|conventional therapy|upper limb rehabilitation with and without technologies
45814423|NCT05119387|Other|Observation|Observation of genetic characteristics
45814424|NCT03475147|Device|eyeFusion|Smartphone app based flicker fusion test.
45814425|NCT05069467|Device|Acupuncture|For the active acupuncture group, the acupuncturist chose standard points depending on subjects' preferred positions. In addition, up to four acupuncture points were chosen on the basis of subjects' other presenting symptoms (such as fatigue, insomnia, or erectile dysfunction). The needles (30 or 40 mm and 0.25 mm gauge; Soochow, Hwato) will be inserted and manipulated until De Qi, a sensation of soreness and tingling.
45814426|NCT05069467|Device|Sham Acupuncture|Treatment will be the same for the sham acupuncture, except for the following: the acupuncturist selected the same number of nonacupuncture, nontrigger points. Instead of eliciting De Qi, the needles will be minimally manipulated to avoid eliciting sensations other than initial contact with skin.
45814427|NCT03443167|Behavioral|Training on emergency telephone numbers and mnemonics|"The intervention will consist in carrying out an initial theoretical training on how to act in case of attending an emergency, with graphic support of slides (power-point) during 5 minutes, followed by a practical part with the projection of the video of a song and with a role play activity for 15 minutes, to remember the helpline number for emergencies (112) and relate it to the mnemonic mouth-nose-eyes. At the beginning and at the end of the theoretical-practical activity, the evaluation questionnaires will be administered to each one of the students."
45814428|NCT03443167|Behavioral|Sham generic formation on the cardiopulmonary arrest.|The sham intervention for the control group will consist in providing a generic formation on the cardiopulmonary arrest, with graphic support of slides (power-point) during 10 minutes, without specifying the telephone number of assistance for emergencies or the mnemonics mouth-nose-eyes. At the beginning and at the end of the theoretical activity, the evaluation questionnaires will be administered to each one of the students.
45953184|NCT00141752|Device|Toronto Bedside Swallowing Screening Test (TOR-BSST)|Toronto Bedside Swallowing Screening Test
45953185|NCT02955277|Other|TECH: Tablet Enhancement of Cognition and Health|TECH protocol - cognitive training using touchscreen tablet gaming applications
45454050|NCT02282878|Dietary Supplement|High/Low Sodium Diet|All patients will receive 2 weeks of the high sodium diet followed by a 1 week washout and then 2 weeks of the low sodium diet
45660531|NCT02553265|Drug|Carbidopa Low-Dose|300 mg/day
45660532|NCT02553265|Other|Placebo|A placebo containing an inert substance, in capsule form that does not contain an active drug ingredient.
45660533|NCT02553265|Drug|Carbidopa High-Dose|600 mg/day
45953186|NCT00505453|Biological|Fluviral®|
45454051|NCT05208034|Drug|Methotrexate|Two-doses of intramuscular methotrexate as 50mg/m2.. One at at day-zero and 2nd at day 7.
45660534|NCT04269967|Other|Receiving routine rehabilitation care via tele-rehabilitation system|Drain care education, self-massage techniques and exercise (PT and OT)
45660535|NCT05480839|Procedure|M-IBCS|Manual Cataract Surgery - Phacoemulsification: removal of the eye lens and insertion of an intraocular lens implant
45953187|NCT02955238|Behavioral|Special Intervention|"Participants randomized into the SI group will participate in four group health education classes and seven clinical visits per year with the patient care team. The patient care team will be comprised of a mid-level clinician and a Community Health Worker (CHW).~Content and materials utilized in the group health education classes are derived from the validated and translated curriculum Pasos Adelante , developed and refined by the CDC. Methods for training CHWs will be derived from the Pasos Adelante Curriculum."
45953188|NCT00162552|Drug|pentoxifylline|Patients with severe cirrhosis treated with Pentoxifylline
45953189|NCT00162552|Drug|PLACEBO|Patients with severe cirrhosis treated with a placebo
45660536|NCT05480839|Procedure|ReLA-IBCS Early|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with early administration of anesthesia
45660537|NCT05480839|Procedure|ReLA-ISBCS|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with standard administration of anesthesia
45814429|NCT05066737|Procedure|lateral suspension via V-NOTES surgery|pop-q, pisq-12 assesment of patients with pelvic organ prolapse before and 6 or 12 month after lateral suspension surgery performed via V-NOTES technique.
45814430|NCT05023993|Other|Exercise Intervention|Complete home exercise
45953190|NCT04516681|Drug|Ascorbic acid|1.5g/kg/day, D1-3, every 2 weeks
45953191|NCT04516681|Drug|FOLFOXIRI Protocol|CPT-11 165 mg/m² d1 concurrent with Leucovorin 400 mg/m², followed by Oxaliplatin 85 mg/m² d1 followed by Bolus 5FU 400 mg/m² , followed by Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks with or without bevacizumab 5mg/kg, every 2 weeks
45953192|NCT00141791|Drug|Etanercept|
45953193|NCT04516330|Genetic|miRNA|miRNA's expressed in breast cancer
45953194|NCT04516603|Drug|Fampridine SR|Fampridine is an inhibitor of voltage-gated potassium (Kv) channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
45953195|NCT04516603|Drug|Placebo|no active component
45953196|NCT00162591|Drug|remifentanyl|
45953197|NCT00505492|Drug|Carboplatin|AUC 5 by vein once every 28 Days
45953198|NCT00505492|Drug|Cisplatin|40 mg/m^2 by vein (IV) Weekly Over 4 Hours
45814431|NCT05023993|Dietary Supplement|Nicotinamide Riboside|Given PO
45660538|NCT03514459|Other|Systems Analysis and Improvement Approach|SAIA has five steps. The first step uses an Excel-based tool to quantify drop- offs, or people who did not progress, in each step of a process (Figure 1). This tool also allows the user to see the downstream effect when improving one step in the cascade, and holding the other steps constant. Step 2 involves process flow mapping with clinic staff to identify modifiable bottlenecks in the process. Step 3 develops and implements a workflow modification to address a bottleneck identified in step 2 (continuous quality improvement [CQI] step). Step 4 assesses impact of the modification and recalculates the cascade analysis in step 1 (CQI step). Step 5 repeats the cycle for CQI. SAIA draws from systems engineering in the Toyota Production Systems and from research in LMICs. Studies in quality improvement in LMICs highlight that CQI processes led to more sustainable, effective, and appropriate interventions (42-44).
45660539|NCT03495427|Drug|F-DCFPyL Injection|F-DCFPyL Injection is a radioactive diagnostic imaging agent indicated for imaging of patients with recurrent prostate cancer.
45814432|NCT05367583|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation
45953199|NCT00505492|Drug|Paclitaxel|135 mg/m^2 by vein (IV) Once Every 28 Days
45454052|NCT02284282|Drug|Spinal injection bupivacaine/morphine|Spinal injection bupivacaine/morphine in laparoscopic surgery
45814433|NCT03105128|Drug|placebo for risankizumab|Placebo for risankizumab administered by intravenous infusion
45454053|NCT02284282|Drug|subcutaneum injection lidocaine|placebo injection
45814434|NCT03105128|Drug|risankizumab IV|Risankizumab administered by intravenous infusion
45814435|NCT03105128|Drug|risankizumab SC|Risankizumab administered by subcutaneous (SC) injection
45814436|NCT03331393|Other|Non-interventional|Non-interventional
45953200|NCT00141830|Drug|Methotrexate plus ERB-041 for 12 weeks|
45953201|NCT00141830|Drug|Placebo for 12 weeks|
45953202|NCT04516174|Procedure|Transversus abdominis plane block using ropivacaine|Before anesthesia, the ultrasound-guided bilateral transversus abdominis plane block using 0.25% ropivacaine was perdormed by anesthesiologist who is not involved in intraoperative management and postoperative follow-up and evaluate the effect after the block completed.
45814437|NCT05005819|Drug|[18F] APN-1607|Subjects will undergo PET imaging using [18F]APN-1607.
45814438|NCT05359081|Drug|SEP-363856|SEP-363856 50 mg or 75 mg, flexibly dosed once daily tablet for 52 weeks
45814439|NCT04963777|Dietary Supplement|Prebiotic|Chicory root derived inulin-type fructan (13.2 kcal/day for ages 8-13 years; 26.4 kcal/day for ages ≥14 years)
45953203|NCT04516174|Drug|Dexmedetomidine|After finished the transversus abdominis plane block, then perform tracheal intubation and start the infusion of dexmedetomidine.
45953204|NCT04516174|Procedure|Transversus abdominis plane block using saline|Before anesthesia, the ultrasound-guided bilateral transversus abdominis plane block using saline was perdormed by anesthesiologist who is not involved in intraoperative management and postoperative follow-up and evaluate the effect after the block completed.
45953205|NCT04516174|Drug|Saline|After finished the transversus abdominis plane block, then perform tracheal intubation and start the infusion of saline, dosage and infusion method of saline are consistent with dexmedetomidine.
45953206|NCT00155493|Procedure|obtain surgical specimen for analysis|
45953207|NCT04516213|Other|Enteral Formula With (PHGG)|Pediatric subjects will be fed a Peptide-based Enteral Formula With Partially Hydrolyzed Guar Gum (PHGG)
45953208|NCT04515979|Drug|Vactosertib 300 mg BID and pembrolizumab 200 mg IV|Vactosertib 300 mg orally (PO) BID(5 days on/2days off) and pembrolizumab 200 mg IV (Q3W).
45953209|NCT00162630|Procedure|Fascia Iliaca Compartment Blockade|
45953210|NCT04515706|Drug|Iguratimod|Iguratimod is an anti-rheumatic drug that approved for treating rheumatoid arthritis in East Asia. Recent data reveal its independent anti-fibrosis effect.
45953211|NCT04515706|Drug|Placebo|Placebo of Iguratimod
45953212|NCT00505531|Drug|Tramadol Extended Release Oral Capsule|Tramadol ER- up to either 200 mg or 300 mg based on randomization
45953213|NCT00505531|Drug|Benadryl|Placebo group will take up to 25 mg of Benadryl
45953214|NCT00505570|Device|AMPLATZER® PFO Occluder Device|PFO device closure
46002719|NCT04636827|Biological|DTaP|DTaP at the age of 18 month old
45660540|NCT03495427|Diagnostic Test|PSMA PET|PSMA PET imaging (for men with high GC >0.45) will be done after 2 years post-treatment, then yearly up to 5 years.
45814440|NCT04963777|Dietary Supplement|Placebo|Maltodextrin (isocaloric; 13.2 kcal/day for ages 8-13 years; 26.4 kcal/day for ≥14 years)
45953215|NCT02964299|Device|Mandibular advancement bite block|Mandibular advancement bite block that provides mandibular advancement by 3 mm, 6 mm, or 9 mm from neutral position
45953216|NCT00155532|Procedure|3 mm-punch biopsies of the skin|
45953217|NCT04515355|Behavioral|Ready for MS|Receive 'ready for MS' programme in addition to standard care.
45814441|NCT03122509|Drug|durvalumab|1500 mg durvalumab via IV infusion
45814442|NCT03122509|Drug|tremelimumab|75 mg tremelimumab via IV infusion
45814443|NCT03122509|Radiation|Radiotherapy (RT)|Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice.
45814444|NCT03122509|Procedure|ablation|Ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice.
45953218|NCT04515277|Dietary Supplement|40 g Gum acacia (FibregumTM)|Applied in 300 mL of orange juice with breakfast (single use at visit)
45953219|NCT04515277|Dietary Supplement|20 g Gum acacia (FibregumTM)|Applied in 300 mL of orange juice with breakfast (single use at visit)
45814445|NCT04956289|Drug|Viltolarsen|Received during weekly intravenous infusions
45814446|NCT03113695|Drug|Obinutuzumab|obinutuzumab 1000 mg x 8 doses (first dose split on Cycle 1 days 1 100mg and 2 900mg; then day 8 and 15 of cycle 1; then day 1 of cycles 2-6, each cycle being 28 days long)
45953220|NCT04515277|Dietary Supplement|0 g Gum acacia (FibregumTM)|300 mL of orange juice with breakfast (single use at visit)
45953221|NCT00141908|Drug|17-alpha Hydroxyprogesterone Caproate|250 mg IM weekly
45953222|NCT00141908|Drug|Castor oil|weekly IM injections
45953223|NCT00162669|Drug|bevacizumab|
45953224|NCT04515160|Diagnostic Test|Clinical Frailty Scale|Clinical fragility scale will be recorded in the first 24 hours of intensive care admissions.
45953225|NCT04515160|Diagnostic Test|Modified Frailty Index|Modified Frailty Index will be recorded in the first 24 hours of intensive care admissions.
45953226|NCT04515043|Drug|INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study.|blood sampling will be drawn once in order to analyse long term memory immune response to INVAC-1 vaccine
45458480|NCT02325388|Device|ForeSite PT™ system|"XSENSOR Technology Corporation's ForeSite PT™ Patient Turn System (referred to as the ForeSite PT™ system) continuously monitors interface pressure and provides CPI that quantifies real-time interface pressure information. It also provides patient turn tracking to assist with management of the patient turn schedule by alerting healthcare providers and/or caregivers to the location of body areas that have experienced the greatest exposure, and when the next turn/repositioning is due as per pre-set alerts."
45660541|NCT03490357|Procedure|Control - Transversus Abdominus Plane Block|Abdominal fascial plane block - regional anesthesia
45953227|NCT04514614|Drug|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of arthritis by PET/CT.
45953228|NCT04724889|Diagnostic Test|blood test|Blood test to check high sensitivity troponin. Additional blood biomarkers maybe added in light of new research
45660542|NCT03490357|Procedure|Quadratus Lumborum Block|Abdominal fascial plane block - regional anesthesia
45660543|NCT05480683|Diagnostic Test|CT exam|Noncontrast CT of the pelvis with specific penile anatomical positioning for coverage and with the protocol optimized for application of Agatston calcium scoring post processing.
45660544|NCT03215095|Drug|Durvalumab (Medi4736)|durvalumab 1500 mg IV every 4 weeks
45953229|NCT00141947|Drug|bexarotene (Targretin)|
45953230|NCT04514770|Drug|Misoprostol|rupture of membrane early and late
45953231|NCT04514809|Other|human milk analized|After birth (24-72 hours) 15 ml, and end of the first month of birth 30 ml of milk from the mother will be milked in the appropriate way and put into the sterile milk collection container. The milk taken into the milk transport container will be delivered to the Nutrition Lab for analysis (moisture, protein, fat, lactose) by the researcher who arrives at the TUBITAK Mam Research Center as fresh within 3 hours
45953232|NCT02955433|Other|Rideshare-based transportation|
45953233|NCT00141986|Dietary Supplement|vitamin D3|2000 IU per day
45953234|NCT00141986|Dietary Supplement|vitamin D3|400 IU per os once daily
45660545|NCT03215095|Radiation|Radioiodine (RAI)|100 mCi (+/- 10 mCi) of 131I will be administered a day after Thyrogen injections have been administered for two consecutive calendar days.
45953235|NCT04514731|Drug|Magnesium sulfate|Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of isotonic saline over 15 minutes after spinal anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/hour) until the end of surgery.
45953236|NCT04514731|Drug|Isotonic Saline|Isotonic saline group receives the same volume of isotonic saline, administered according to the same methods as in the magnesium group.
45953237|NCT04514419|Drug|HS627|Prior to surgery: trastuzumab, HS627, and docetaxel for 4 cycles (1 cycle = 21 days).
45953238|NCT04514419|Drug|Pertuzumab|Prior to surgery: trastuzumab, Pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days).
45953239|NCT04514380|Other|Carbohydrate fluid|400 mL carbohydrate fluid
45953240|NCT04514380|Other|Non-carbohydrate fluid|0 mL carbohydrate fluid
45953241|NCT00155610|Device|intravesical current perception test|
45660546|NCT02561195|Biological|Clostridium difficile Vaccine|0.5 mL intramuscular injection.
45814447|NCT03113695|Drug|lenalidomide|lenalidomide PO daily. The starting dose of lenalidomide is 5 mg PO daily. Starting on C2D1, the dose increases every 2 weeks in 5 mg increments to a maximum of 25 mg PO daily. Patients will continue lenalidomide until disease progression, unacceptable toxicity, or subsequent therapy.
45814448|NCT03113695|Drug|HDMP|methylprednisolone 1000 mg/m2 (ie HDMP) on days 1-5 of cycles 1-4
45814449|NCT04892329|Other|Artificial intelligence assistant system|The endoscopists in the experimental group will be assisted by EndoAngel, which can assist in identifying important anatomical structures adjacent to the pancreas in real time. The system is an non-invasive AI system .
46002720|NCT04636827|Biological|HepA|HepA at the age of 18 month old
46002721|NCT00547469|Drug|DDP733|
46077797|NCT04266743|Device|FeetMe Monitor|"For gait parameters' evaluation, the investigator asks the participant to move in a straight line over a 10-meter mat. The participant had to start the feet in line and then start walking at a comfortable speed. During this time, the investigator records the gait parameters from the FeetMe Monitor® and Gaitrite® system.~An operator asked the patient to repeat 3 trials. The same sequence was repeated by three other operators. The same measurement is done 7 days later.~A questionnaire is given to assess the ergonomics of the device"
45660547|NCT02561195|Biological|Placebo|0.5 mL intramuscular injection
46077798|NCT05660720|Drug|Orelabrutinib and placebo (orelabrutinib tablet simulator)|Orelabrutinib will be administered as 3 tablets (150mg) and placebo as 5 tablets (250mg)
46077799|NCT05660720|Drug|Orelabrutinib|Orelabrutinib will be administered as 8 tablets (400mg)
45660548|NCT04558775|Other|Observational|no intervention
45953242|NCT00505609|Behavioral|Standard Days Method|The Standard Days Method is a fertility awareness-based method of family planning. Users avoid unprotected intercourse during cycle days 8 to 19. Study participants were for up to 13 cycles of method use.
46077800|NCT05660720|Drug|Placebo (orelabrutinib tablet simulator)|Placebo will be administered as 8 tablets (400mg).
45953243|NCT00142025|Drug|Oxcarbazepine|
45814450|NCT03032029|Device|Adaptive Servo-Ventilation|Adaptive Bi-Level positive airway pressure with a targeted minute ventilation and auto-adjusting expiratory pressure level.
45814451|NCT05315947|Drug|brivaracetam|Study participants will receive a single-dose of brivaractam tablet (reference - Treatment A) administered orally.
45953244|NCT00505648|Drug|Tegeline®|2g/kg in IV on 2days 2g/kg in IV on 4days for patients with renal insufficiency or 65 years old.
45953245|NCT04514263|Other|OHIP-14 Administration|All patients fulfilled the OHIP-14 questionnaire three times: six hours, seven days and twenty-one days after the biopsy
45953246|NCT04514263|Other|VNS Administration|All patients fulfilled the VNS scale three times: six hours, seven days and twenty-one days after the biopsy
46002722|NCT04636515|Drug|F520|200mg，Q3W
46002723|NCT04636593|Drug|Almonertinib|All enrolled patients underwent positioning CT scans before the initial treatment, a radiotherapy plan was made for each patient, and the lung V20 of each patient was calculated. Patients with lung V20 ≥ 28% were enrolled in group A: Almonertinib induction therapy was given for 2 months firstly, followed by Almonertinib combined with radiotherapy; patients with lung V20<28% were enrolled in group B: Almonertinib was synchronized with radiotherapy initially.
45660549|NCT05390723|Behavioral|Communciation intervention|The investigators cannot reveal the manipulated communication as this might influence participant outcomes.
45660550|NCT05389163|Device|Giomer based injectable resin composite|Giomer material has been introduced as the true hybridization of glass ionomer and resin composite, containing surface pre-reacted glass ionomer (S-PRG) filler particles within a resin matrix. Giomer combines caries protection through fluoride release and recharge of glass ionomers and the esthetics, physical and handling properties of resin composite
45660551|NCT05389163|Device|Resin modified glass ionomer|Resin modified glass ionomer (RMGI) have been developed to combine the advantages of both resin composite and glass ionomer; the good mechanical properties, esthetic of resin composite added to anticariogenic activity and chemical bonding to tooth structure of glass Ionomer.
45660552|NCT01663103|Drug|Rilonacept|12 weeks of treatment with rilonacept (subcutaneous injection with a loading dose of 320 mg, followed by 160 mg/wk)
45660553|NCT01663103|Drug|Placebo|Twelve weeks of treatment with placebo (subcutaneous injection of normal saline with a loading dose of 320 mg, followed by 160 mg/wk)
45660554|NCT05509673|Other|Lipofilling (sublesional fat grafting)|
45814452|NCT05315947|Drug|brivaracetam|Study participants will receive a single-dose of brivaractam dry syrup (test - Treatment B) administered orally.
45814453|NCT05445050|Diagnostic Test|Application and measurement of tumor vascularization using diagnostic contrast enhanced ultrasound (CEUS)|"Part A: performing CEUS with the contrast agent SonoVue® at two different doses and two different injection speeds in participants with primary breast cancer~Part B: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants undergoing neodajuvant chemotherapy~Part C: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants with lesions of unknown dignity"
45814454|NCT00369434|Drug|Desvenlafaxine succinate sustained-release (DVS SR)|
46002724|NCT02277275|Dietary Supplement|BCAA|Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months
46077801|NCT05660720|Drug|Moxifloxacin hydrochloride|Moxifloxacin hydrochloride will be administered as 1 tablet (400mg)
46077802|NCT05277883|Radiation|CT scan|CT of the lower limb
46077803|NCT02695212|Drug|Apremilast|"Investigational Product: Apremilast~Doses: Period A:~10mg Per day, day #1, 10mg Twice Per day, day #2 10mg qAM, 20mg qHS day #3 20mg Twice per day, day #4 20mg qAM, 30 mg qHS day #5 30mg Twice per day, day #6~Period B:~30mg Twice per day, day #7 through week #24~Period C:~Week 28 (4 weeks off therapy), for final evaluation Mode of Administration: Oral"
46077804|NCT00903955|Other|7% hypertonic saline|Administered via jet nebulizer to subjects in specific aim 3
45953247|NCT04514536|Device|Health monitors|"The connected scale (iHealth HS2) measures weight from 5 to 180kg and BMI.~The connected actimeter (iHealth AM4) monitors activity (number of steps, distance, calories), sleep (automatic sleep recognition, effective sleep time, number of awakenings) and swimming (automatic activity recognition, session duration, swim type recognition and number of laps).~The connected blood pressure monitor (iHealth Track KN-550BT)is a medical device that measures blood pressure and pulse rate.~The activity monitor (manufactured by RF Track) consists of a housing that can be positioned as a pendant or at the hip. It includes an accelerometer, gyroscope, magnetometer, barometer, radio transceiver, and led. The sensor records the raw signals.~The touchpad allows the subject to connect to the Calliope app. This app allows the data recovery, storage, analysis, visualization, and all the required settings for the platform to work together."
45660555|NCT05501951|Other|tDCS stimulation|The transcranial direct current stimulation (tDCS) method has emerged in the recent years as a non-invasive, safe, cheap, convenient and effective means to modulate brain functions and behaviours
45953248|NCT02275858|Device|Stiffening wire|Stiffening wire
45660556|NCT05501951|Other|Sham stimulation|For the sham group, the electrode positioning will be randomly allocated to be identical to either the DLPFC or the OFC group, and active stimulation will be delivered for the first 30 seconds only
45814455|NCT05287867|Biological|Platelet-rich plasma (PRP), Platelet lysate (PL), and Platelet Poor Plasma (PPP)|Approx 161-420cc autologous blood is drawn and processed into PPP, PRP, and PL, amount dependent on condition. Using sterile technique with patient sedated, US or x-ray is used to guide needles bilaterally into multifidus, specifically LM, TF, IAF. Once the lamina is reached the physician injects 2.5 cc of PPP into the multifidus muscle on one side and then repeat this on the opposite side for each level. The physician guides a needle into the supraneural transforaminal space to perform an epidural injection with 2cc of 4x PL and 1 cc of 0.5% ropivacaine. Next, a needle will then be guided into the facet joint to perform an intra-articular injection with 1cc of 14x PRP. Any tendon insertion areas will be injected using ultrasound guidance with platelet lysate dextrose. The supraspinous/interspinous, SI ligaments at the involved degenerative levels will be injected with 4x PL/12.5% dextrose/0.125% ropivacaine. If L5/S1 is involved, the iliolumbar ligaments will also be injected.
45814456|NCT05287867|Other|Sham procedure|"Approximately 161-420 cc of autologous blood is drawn to maintain patient blinding. While lying prone, the patient's back will be exposed and prepped sterilely.~Provider puts patient in conscious sedation and several needles are placed into the low back. The provider inserts needle into the facet joint and then removes. Then inserts the needle midline to ligament and removes (1 needle per level) mimicking normal needle placement, but not injecting anything."
45953249|NCT02275858|Device|Placebo wire|Placebo wire
45953250|NCT00142064|Behavioral|observed levels of pain|
45953251|NCT00162708|Procedure|Radiotherapy 62-64 Gy in 5 W (31-32 f. of 2 Gy BID)|
45953252|NCT00162708|Procedure|Radiotherapy 62-64 Gy in 22-23 D (31-32 f of 2 Gy BID)|
45953253|NCT00162708|Drug|CDDP, 5 Fu|
45953254|NCT02275897|Procedure|Slow Speed of spinal injection|Speed of injection over 60 seconds
45953255|NCT02275897|Procedure|Fast Speed of spinal injection|Speed of injection over 15 seconds
45953256|NCT04514185|Device|Passive industrial exoskeleton for the upper limb|The goal is to compare the human response to the simulated industrial tasks
45953257|NCT04514185|Other|The protocol will be performed without exoskeleton|The protocol will be performed without exoskeleton
45953258|NCT04514068|Procedure|Acupuncture|In each session, acupuncture are applied unilaterally or bilaterally on P6 acupoint. Each acupuncture needle will be stimulated by transcutaneous electric device.
45953259|NCT04514068|Procedure|Sham acupuncture|Sham acupuncture
45953260|NCT00142103|Drug|CPG10101|CPG10101 subcutaneous, 0.20mg/kg, weekly, 12wks
45814457|NCT05286385|Device|CP1150 Sound Processor|Speech perception tests whilst the subject is fitted with the CP1150 Sound Processor
45814458|NCT05286385|Device|CP1150 (modified firmware)|Speech perception tests whilst the subject is fitted with the CP1150 modified firmware.
45953261|NCT00142103|Drug|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks
45953262|NCT00142103|Drug|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Ribavirin, oral, 800-1400mg, daily, 12wks
45953263|NCT00142103|Drug|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
45953264|NCT00142103|Drug|Control|Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
45953265|NCT00142103|Drug|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
45953266|NCT00162747|Drug|Aquaphor|
45953267|NCT00162747|Drug|Sunflower Seed Oil|
45953268|NCT04513873|Device|Equipment to divert the focus of children|The equipment was placed in an area where the children would be able to see easily during the blood collection process. It was turned on as soon as the children sat on to the chair where the process would take place to divert the focus of the children at the equipment.
45953269|NCT00505726|Procedure|Reflectance Confocal Imaging|Microscopic images taken during routine colposcopy where disinfected probe inserted into vagina and placed against cervix, 1-3 regions imaged (2 abnormal and one normal), and each taking about 1-2 minutes.
45953270|NCT00162786|Drug|Rupatadine|
45953271|NCT00162786|Drug|Hydroxyzine|
45953272|NCT00162786|Drug|Placebo|
45953273|NCT04513600|Diagnostic Test|Cardiac MRI|Lab work: Hs- Troponin, Serum N-terminal-proBNP CMR: Native T1, Native T2, extracellular volume, strain and strain rate.
45953274|NCT00142181|Drug|Campath-1H|Participant will receive three test doses of Campath-1H (3, 10, and 30mg). If this is tolerated then they will receive Campath-IH three times a week for 6 weeks.
45660557|NCT05303753|Other|fermented dairy protein with prebiotic fiber|During the intervention period, the participant will consume a new product and will reduce the amount of protein in their normal diet reflecting the protein content of the new product.
45814459|NCT05286385|Device|CP1150 + FF|Speech perception tests whilst the subject is fitted with the CP1150 Sound Processor with ForwardFocus.
45814460|NCT05286385|Device|CP1110|Speech perception tests whilst the subject is fitted with the CP1110 Sound Processor.
45660558|NCT04281797|Diagnostic Test|Intestinal microbiome new generation sequencing|Fecal samples collected at baseline pre-transplant and post-transplant, new generation 16s RNA sequencing performed.
46077805|NCT05381207|Drug|Montelukast Oral Tablet|Subjects in group A (study) will be treated with Fluticasone Furoate nasal: (50 micrograms/spray) 100 micrograms (2 sprays) in each nostril twice daily plus oral montelukast (montelukast 10 mg, once a day) for 3 months. Subjects group B (control) will receive only topical steroids in an identical regimen
45660559|NCT05509517|Diagnostic Test|Photoplethysmography based smartphone application for heart rhythm analysis (FibriCheck™)|Heart Rhythm assessment using the FibriCheck™ application with the patient's proprietary smartphone, three times daily, from discharge until follow-up consultation (day 21-91 after discharge).
45660560|NCT05501639|Drug|tiotropium|tiotropium
45814461|NCT04828928|Procedure|electromyogram|Patients meeting the criteria will be seen in consultation with standardized interview and clinical examination. An electromyogram will be then carried out to check for the presence of neuropathy. Finally, for patients diagnosed with neuropathy, a biological check-up to look for another cause of neuropathy will be performed. In patients who already had an EMG as part of their medical follow-up, the examination will not be repeated if it strictly meets the conditions of the minimum protocol and if it was done within the year prior to inclusion. In patients who already had an identical biological assessment in the year prior to inclusion, the sample will not be taken.
45814462|NCT00368797|Drug|XRP0038 (NV1FGF)|
45814463|NCT04828304|Device|PLASOMA|Treatment with cold plasma device
45814464|NCT04847323|Device|V-bend Bonded Retainer|Traditional stainless steel retainer commonly bonded in the anterior teeth of the mandibular arch to maintain their alignment after orthodontic treatment.
45953275|NCT04513756|Behavioral|Community Reinforcement Approach|Community Reinforcement Approach (CRA) as an intervention consisting of nine sessions (each session consists of 45-minutes). Treatment is primarily based upon the guidelines by Robert Meyers and William Miller (2001). The techniques included in the sessions are functional analysis, sobriety sampling, behavioral skills, and relapse prevention techniques. The first three sessions of the intervention are based upon rapport building, induction of the rationale of CRA and Functional analysis of usage and non-usage behavior.
45660561|NCT05501639|Drug|long-acting β2-agonists (LABA)|long-acting β2-agonists (LABA)
45660562|NCT05501639|Drug|inhaled corticosteroids (ICS)|inhaled corticosteroids (ICS)
45660563|NCT05284643|Radiation|Intensity Modulated Proton Therapy (IMPT)|Participants will receive radiation therapy delivered via intensity modulated proton therapy (IMPT) simultaneous integrated boost technique over a period of 10 days, 5 days per week for approximately 2 weeks.
45660564|NCT05284643|Drug|Bevacizumab|Bevacizumab will be administered intravenously (IV), beginning at a dose of 10 mg/kg every 2-3 weeks until disease progression.
45660565|NCT05501405|Other|Electroencephalogram and eye-tracking recordings|"Participants will perform two tasks: recognize the expression (explicit recognition of the expression) or detect the change in color of the cross (implicit processing of the expression). Each participant will perform two tasks x 6 models x 5 expressions, i.e. 60 stimulations, for a stimulation duration of approximately 30 minutes.~Recognition of the emotional facial expression with a choice among 5 possibilities. Two neutral faces of the same person will be presented side by side. When the participant has looked at the central fixation cross for one second, one of the two faces will produce an expression. The participant will have to indicate as quickly as possible which expression it is, while his or her eye movements are recorded. Each participant will have to recognize 5 expressions x 8 models, i.e. 40 trials for a duration of approximately 5 to 10 minutes"
45953276|NCT02954926|Drug|IVIG|IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
45953277|NCT02955121|Other|Prescriber Access to Genetic Information|
45953278|NCT00505804|Drug|dexmedetomidine|Dexmedetomidine IV infusion of 0.0 to 0.7 mg/kg/min for as long a deemed necessary by the treating clinician.
45953279|NCT00505804|Drug|haloperidol|Haloperidol IV loading dose of 2.5mg, followed by a continuous infusion of 0.0 to 2mg/hr for as long as deemed necessary by the treating clinician
45953280|NCT00142220|Drug|Defined percentage of omega-3-fatty acids|
45660566|NCT05509361|Biological|AK101 injection SC|AK101 is supplied as 135 mg doses, provided in 1 mL prefilled syringes.
46077806|NCT02824640|Behavioral|Patient Navigation|The study will follow a PN model (Check Hep C) developed by NYCDOH in collaboration with Montefiore and the community. HCV PNs will provide the following interventions to those randomized to the PN arm: coordination of HCV treatment; health promotion; assisting patients to overcome barriers; and psychosocial support.
45458481|NCT01360346|Procedure|Enteral Sedation (EN)|Intravenous propofol or midazolam administration at the ICU admission and stopped within 48h. Melatonin by enteral route (3mg x 2/die) from admission to discharge. Hydroxyzine by enteral route from ICU admission (600mg/die), decreased and stopped as soon as possible. Lorazepam supplementation (maximum 16mg/die) if hydroxyzine is inadequate.
45660567|NCT05501327|Drug|SLI-F06|Skin injection of SLI-F06 at each wound edge after closure of punch biopsy excision.
45814465|NCT04847323|Device|Vacuum-formed Retainer|Removable retainers made of plastic and derivatives. Currently gaining popularity due to the increased use of esthetic aligners. These clear retainers have the objective to maintain stable the results obtained after orthodontic treatment. They cover all the surfaces of the teeth up to the first or second molars.
45953281|NCT04513093|Other|Aromatherapy Massage|The elderly individuals in the intervention group underwent aromatherapy massage with ginger and lavender oils for a period of five days and 15 minutes on weekdays for four weeks according to the abdominal massage application protocol.
45814466|NCT05282173|Behavioral|Siyakhana CHW Training|Please see arm description.
45814467|NCT04796558|Other|AVAS Classification|Validation of AVAS classification
45953282|NCT04512898|Drug|Triple therapy for H.pylori|Triple therapy of proton pump inhibitors, clarithromycin and metronidazole.
45953283|NCT00142259|Device|Deep brain stimulation of the internal globus pallidus|
45953284|NCT04512820|Device|TRUCLEAR tissue removal system|evacuation of POC using the TRUCLEAR tissue removal system
45953285|NCT00505843|Drug|MK0657|7mg MK0657 capsules
45953286|NCT00505843|Drug|Comparator: Placebo (unspecified)|7mg MK0657 Pbo capsules
45953287|NCT00505843|Drug|Comparator: levodopa|levodopa >/=1.0 mg/kg/hr dose of levodopa. levodopa infusions will occur over a 2 hour period
46077807|NCT02824640|Behavioral|modified Directly Observed Therapy|Subjects will be observed taking medications, a minimum of 5 times a week for those enrolled in the OAT setting, and a minimum of 3 times a week for those enrolled in the community health clinic setting.
45953288|NCT00505843|Drug|Comparator: carbidopa|carbidopa 25mg administered 3 times: at 1 hour before levodopa infusion and at 1 and 3 hours after the start of levodopa infusion.
45953289|NCT00505882|Drug|Pramlintide|Pramlintide will be started at 15 mcg (2.5 units) subcutaneously immediately prior to major meals and it will be increased by 15mcg every 3 days as tolerated (i.e. nausea, vomiting, upset stomach) to a maximum dose of 60 mcg (10 units) before meals. If significant nausea persists at 45 or 60 mcg level, the dose should be decreased to 30 mcg (5 units) before meals. If the 30 mcg dose is not tolerated, investigator will evaluate for possibility of withdrawing the pramlintide. The dose of preprandial short acting insulin (eg: Novolog/Humalog) will be reduced by 30 to 50% at the start of pramlintide 15 mcg (2.5 units) and then will be adjusted every time the dose of pramlintide is increased by 15 mcg (2.5 units) as needed based on blood glucose readings.
45953290|NCT00505882|Drug|Glargine|
45953291|NCT00505882|Drug|Lispro|
45953292|NCT00505882|Drug|Aspart|
45953293|NCT00142337|Drug|Zidovudine (ZDV)|Zidovudine 300 mg, twice daily, for one month postpartum. Note: after July 03, 2005, all women received 200 mg, twice daily, for the same duration.
45953294|NCT00142337|Drug|Didanosine (ddI)|250 mg ddI-EC (400 mg if body weight >60 kg) once daily, starting at the onset of labor and for one month postpartum
45458482|NCT01360346|Procedure|Control group: Intravenous Sedation (IV)|Propofol or midazolam from ICU admission to discharge at the compatible lowest level with harsh ICU environment.
45458483|NCT03494218|Diagnostic Test|Nociception Coma Scale (NCS)|Patients have been assessed with both the Nociception Coma Scale (NCS) and the FLACC.
45660568|NCT05501171|Behavioral|DREAMLAND|"DREAMLAND is self-administered psychological app for patients with AML that includes four modules, focused on:~Supportive psychotherapy strategies to help patients deal with the initial shock of diagnosis, cope with the loss of independence and abrupt life disruptions, and provide validation and reassurance.~Psychoeducation to manage expectations and enhance preparedness for extended hospitalization and mobilize social support.~Psychosocial skill-building to promote effective coping strategies and facilitate acceptance while living with uncertainty.~Self-care to promote positive health behaviors and enhance patients´ sense of control especially as they transition from the hospital to outpatient care.~Each module takes 20 minutes to complete. DREAMLAND also includes three optional models that also take 15 minutes to complete.~Other names BNT200"
45660569|NCT05501171|Behavioral|CERENA|"CERENA is a self-administered physical health app that includes 4 modules focused, focused on:~Education about general wellness.~Nutrition.~Exercise.~Cancer prevention.~Each module takes 20 minutes to complete. CERENA also includes three optional modules that also take 15 minutes to complete."
45660570|NCT04577963|Drug|Fruquintinib|Oral VEGFR inhibitor
45660571|NCT04577963|Drug|Tislelizumab|PD-1 inhibitor
45660572|NCT05145335|Device|Autoregulated Blood Flow Restriction Cuff (smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training|This group will undergo 2 sessions consisting of a low load leg extension exercise combined with a pressurized tourniquet which autoregulates so when the quadriceps muscle contracts, the total amount of pressure doesn't increase, as the tourniquet will lower the pressure to keep the total amount of pressure constant.
45814468|NCT04784234|Dietary Supplement|GlaucoCetin|GlaucoCetin, a medical food in capsule form, is FDA regulated and includes ingredients that have been shown to support and protect mitochondrial function of retinal ganglion cells. GlaucoCetin consists of a mixture of Curcumin, N-Acetyl Cysteine, Ginkgo Biloba Extract, Alpha-lipoic Acid, Citicoline, Grape Seed Extract, Green Tea Extract, and Coenzyme Q10. Additional ingredients include L-Taurine, Niacinamide, Biotin, Natural Astaxanthin, Fisetin, Quercetin, Luteolin, Proprietary Dragonberry Flavor Complex, Monk Fruit, Bitter Blocker Natural Flavor, Citric Acid, Silica Dioxide, Fibersol-2, L-Leucine. Many of these are known anti-inflammatory and antioxidant ingredients. A 6 month supply of capsules, made for this study, will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.
45953295|NCT00505960|Behavioral|Diabetes Care for Korean Americans|Intervention group participants receive a 6-week in-class education offered by trained nurses, followed by home glucose monitoring with monthly nurse telephone counseling.
45953296|NCT00505999|Behavioral|Questionnaire|Questionnaire taking 30-40 minutes to complete.
45953297|NCT04512859|Procedure|Stellate Ganglion Block|Stellate ganglion block under ultra-guide will be administered using 0.25% ropivacaine 10mL
46077808|NCT02750670|Drug|Obinutuzumab|Type II anti-CD20 monoclonal antibody
45953298|NCT04512859|Procedure|Placebo|Stellate ganglion block under ultra-guide will be administered using 0.9% saline 10mL
45953299|NCT00162864|Drug|montelukast sodium|
45458098|NCT03643861|Radiation|1-3 Fraction Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) has gained favor in the treatment of select central nervous system, lung, and abdominal malignancies due to its ability to deliver highly conformal doses of radiotherapy while using sharp dose gradients to deliver comparatively lower doses to the surrounding normal tissue. Utilization of SBRT is more labor intensive than conventional fractionation and requires precise immobilization and localization techniques with daily image guidance with direct physician and physicist oversight for all treatments. While more labor intensive and often utilizing more advanced technologies, SBRT allows the advantage of reducing setup margins compared to conventionally fractionated treatment while being able to shorten overall treatment times due to the ability to safely dose escalate high risk areas
45814469|NCT04784234|Other|Placebo|The placebo is an identical capsule to the GlaucoCetin, made for this study, with no nutritional value. A 6 month supply of capsules will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.
46077809|NCT02750670|Drug|Gemcitabine|Antineoplastic agent
45953300|NCT04512508|Diagnostic Test|Self test sample|Self test sample, DNA analysis, Biopsy and Anoscopy
45953301|NCT04512625|Biological|Desensitizers|The main aims and objectives of the present study were to evaluate and compare the effectiveness of three commercially available desensitizing agents: Gluma (Hareus Kulzer), Sheildforce Plus (Tokuyama), and Telio CS (Ivoclar Vivadent) desensitizer in reducing the pre- and post-cementation sensitivity for full coverage restorations.
45953302|NCT04512664|Other|cold application|cold application with gel pacs
45953303|NCT00506038|Procedure|fine needle technique|
45953304|NCT04512391|Procedure|Ultrasound guided Erector Spinae Plane Block (ESPB)|Ultrasound guided ESPB is applied at T4 vertebrae level, 3 cm lateral to mid-line where transverse process lies. After identification of transverse process, needle is advanced in plane and real time visualisation on ultrasound screen. When bonny contact is encountered, normal saline is injected for verification of placement, then, 25 ml %0,25 bupivacaine is injected plane between transverse process and erector spinae muscles.
45814470|NCT04835935|Other|microbiome pattern|microbiome pattern in neonatal period
45814471|NCT04774796|Other|Cognitive Behavioural Therapy|Participants will take part in a one day, or two half-day group CBT workshop for parents of children with food allergy. The workshop will included understanding difficulties using a CBT model, psychoeducation on common psychological issues (e.g. anxiety) and the development of skills to help deal with maladaptive cognitions and behaviours relating to managing a child's food allergy.
46077810|NCT02750670|Drug|Dexamethasone|Corticosteroid
45814472|NCT05444738|Drug|oral lollipop with oxytocin (24IU)|Immediately before drug administration, a blood sample (5ml) is collected. For drug administration, participants will be instructed to suck the lollipop medicated with 24IU oxytocin for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after drug administration.
45953305|NCT04512313|Drug|Rocuronium 0,3mg/kg|Rocuronium 0,3mg/kg at induction
45953306|NCT04512313|Drug|Rocuronium 0,9mg/kg|Rocuronium 0,9mg/kg at induction
45953307|NCT00142493|Drug|Propofol|1.2ug/ml
45953308|NCT00142493|Drug|Thiopental Sodium|2.0ug/ml
46077811|NCT02750670|Drug|Cisplatin|Antineoplastic Agent
45953309|NCT00142493|Drug|Dexmedetomidine Hydrochloride|0.5ng/ml
45953310|NCT00142493|Drug|Midazolam Hydrochloride|60ng/ml
46077812|NCT00605891|Drug|carmoterol (CHF 4226)|"carmoterol pMDI 2.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of carmoterol 1.0 mcg)"
46077813|NCT00605891|Drug|carmoterol (CHF 4226)|"carmoterol pMDI 1.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of placebo pMDI))"
45953311|NCT00142493|Drug|placebo|intralipid, saline, saline with multi-Vit solution
45953312|NCT04512352|Other|Online curriculum|"The psychologist and our advisory team had successfully developed a total of 100 hours of parenting curriculum.~The adopted curriculum had focused on using play to facilitate parents in promoting their children's development in cognitive, motor, emotional and social aspects. Play-based activities are instrumental in improving children's development. Given that parents in poverty had difficulties spending time and money travelling back-and-forth to the training site and their homes, the research team decided to use e-learning as the medium of learning for our parenting programme. Web-based learning has the advantage of cutting time and travelling costs, which are luxuries to many parents in poverty."
45953313|NCT04511689|Device|gene-activated bone substitute mixed with autobone|gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene mixed with autobone
45953314|NCT04511884|Diagnostic Test|Next-generation sequencing|The patient who may be diagnosed with cryptogenic organizing pneumonia will be detected through next-generation sequencing.
46077814|NCT00605891|Drug|carmoterol (CHF 4226)|"carmoterol pMDI 4.0 μg once a day, in the morning~(1 puff of carmoterol 2.0 mcg + 1 puff of carmoterol 2.0 mcg)"
46077815|NCT00605891|Drug|salmeterol|Salmeterol 50 μg DPI, in the morning and in the evening (1 blister BID)
46077816|NCT00605891|Drug|placebo|Placebo pMDI once a day, in the morning (1 puff of placebo pMDI + 1 puff of placebo pMDI)
46077817|NCT05007704|Behavioral|Global Experts Consensus opinion using Delphi Methodology|The Investigators will conduct iterative Delphi Rounds with Global experts to achieve consensus on Competencies required for Anesthesiologists to manage critically ill medical and surgical patients in ICU
45814473|NCT05444738|Drug|oral lollipop with placebo|Immediately before drug administration, a blood sample (5ml) is collected. For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after placebo administration.
45814474|NCT04772755|Device|Buzzy® and Electronic Game|Buzzy® will be applied according to manufacturers directions and an electronic game will be played. The participant will be observed for 20 minutes post vaccination.
45814475|NCT04746638|Diagnostic Test|whole body study and SPECT with 99mTc-RM26|One single intravenous injection of 99mTc-RM26, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
45953315|NCT00142532|Procedure|Acupuncture and Questionnaires|"Acupuncture 30 day treatment BL12 - 19 and extra point Wei Guan Xia Shu Each side of the spine,1.5 cun (~2.5cm) lateral to the lower border of spinous process of the T2 - 10 spinal vertebrae respectively 4 weeks ST36, Below the knee, 3 cun (~7.5cm) inferior to the lower border of the patella, one finger breadth lateral to the anterior crest of the tibia. One week following removal of epidural.~Shenmen, bilaterally. At the lateral 1/3 of the triangular fossa in the auricle.One week following removal of epidural.~Questionnaires 30 / 60 / 90 Day and 12 Month Follow-up-Numerical rating scale of pain; total opioid use; Medication Quantification Scale; length of stay; Brief Pain Inventory"
45814476|NCT05253859|Other|No intervention|Registry study: No intervention
45814477|NCT04734158|Other|corneal imaging|corneal imaging using AS-OCT
45953316|NCT00142532|Procedure|Placebo Acupuncture, Questionnaires|"The back studs will be placed halfway between the upper and lower border of spinous processes T2 to T10, approximately 0.5 cun (~1.25cm) from the spine. The leg studs will be placed at 2 cun (~5cm) posterior to GB34 on the posterior of the lower leg. No studs will be placed in the ear; rather studs will be placed on the anterior arm, 3 cun (~ 5cm) proximal and 3 cun (~ 5cm) medial to the midpoint of the antecubital crease.~Pain will be assessed by a 0 - 10 point numerical rating scale (NRS) marked no pain at one end and worst pain at the other."
45953317|NCT04511923|Drug|Nebulised heparin|Nebulised unfractionated heparin 25000 units administered 6 hourly for 10 days
45953318|NCT04511611|Drug|Rivaroxaban (BAY 59-7939, Xarelto) in ODT form|10 mg as 1 x 10 mg orally disintegrating tablet (ODT)
45953319|NCT04511611|Drug|Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form|10 mg as 1 x 10 mg film-coated tablet
46002725|NCT02277275|Dietary Supplement|Placebo|Placebo will be provided to the other two arms for six months
45814478|NCT05243953|Drug|Levcromakalim|Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min (20 ml of 50 mg/ml) levcromakalim.
45814479|NCT05243953|Drug|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
45814480|NCT04715984|Other|Neurophysiology recordings|Neurophysiology recordings will be performed during deep brain stimulation surgery and their relationship to performance on a working memory task evaluated
45814481|NCT04715984|Procedure|Neural stimulation|Neural stimulation will be delivered during a working memory task and its impact on task performance quantified
45458099|NCT03505918|Other|No referral for rehabilitation|Intervention is that some patients will not be refered for postoperative physiotherapy.
45814482|NCT02741258|Device|Mepitel Film|Placement of Mepitel Film to prevent skin toxicity
45814483|NCT02741258|Drug|skin cream|cream to treat skin erythema due to radiotherapy
45814484|NCT02757313|Drug|Low dose THC marijuana|
45814485|NCT02757313|Drug|High dose THC marijuana|
45814486|NCT02757313|Drug|Placebo marijuana|
45814487|NCT02596802|Device|FETO therapy|Fetoscopic surgery at 27 to 31 weeks and 6 days gestation.
45814488|NCT02672293|Drug|Phoslax|Oral sodium phosphate solution (monobasic sodium phosphate 2.4 g and dibasic sodium phosphate 0.9g / 5 mL).
45814489|NCT02514278|Drug|Neoadjuvant chemotherapy Folfirinox, 4 cycles|"oxaliplatin: 85 mg/m2~irinotecan: 180 mg/m²~folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)~5FU: 2400 mg/m2"
45814490|NCT02514278|Radiation|50 Gy, 2 Gy/session; 25 fractions|Radiochemotherapy 5 weeks
45814491|NCT02514278|Procedure|Local excision in good responders|"If local excision:~Surveillance if ypT0-1 or ypT2Nx/cN0 (no lymph node at baseline imaging)~Complementary rectal excision if ypT2Nx/cN1, ypT3 or R1."
45814492|NCT02514278|Procedure|Rectal excision in bad responders|
45814493|NCT02514278|Drug|Capecitabine|1600 mg/m2 daily 5 days/7
45814494|NCT04738591|Device|DIABE-TEXT|Participants will receive daily (from monday to friday) text messages in their mobile phones during three months.
45458100|NCT04645771|Procedure|Questionnaires|Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
45458101|NCT02309866|Genetic|Genetic testing|Genetic testing for mutations in known and novel genes underlying RP and allied diseases
45814495|NCT02379806|Drug|Enoxaparin|
45814496|NCT02379806|Drug|Placebo|
45814497|NCT02636647|Biological|Fecal transplant|
45814498|NCT05227027|Behavioral|Game Module|Receive access to the the game module through the free, 'Smoke Free' smartphone application
45814499|NCT05227027|Behavioral|Smoke Free smartphone application|Receive educational intervention through the free 'Smoke Free' smartphone application (core version of the app)
45814500|NCT02358356|Drug|octreotate|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV)
45814501|NCT02358356|Drug|Capecitabine|oral capecitabine 750mg/m2 b.i.d.
45814502|NCT02358356|Drug|Temozolomide|temozolomide 75mg/m2 b.i.d.
45814503|NCT04700761|Procedure|Opioid-free anesthesia|Anesthesia induction: thiopental, rocuronium, desflurane + single dose of alfentanil for endotracheal intubation Anesthesia maintenance: desflurane (without any opioid) Rescue for hypertension, tachycardia: desflurane and beta blocker/calcium channel blocker
45814504|NCT04700761|Procedure|Opioid-using anesthesia|Anesthesia induction: thiopental, rocuronium, desflurane + continuous infusion of remifentanil (TCI, Minto model) Anesthesia maintenance: desflurane, remifentanil Rescue for hypertension, tachycardia: desflurane, remifantanil and beta blocker/calcium channel blocker
45814505|NCT05206201|Drug|ZY19489 Capsule|Two part study with single and multiple dose
45814506|NCT05206201|Drug|Placebo Capsule|Two part study with single and multiple dose
45814507|NCT04689776|Behavioral|Dual-Task Training|The programs are based on dual-task trainings which contain cognitive training and exercise simultaneously. For physical exercise, we will design the programs that involve balance or strength training components in the aerobic exercises. In terms of cognitive training, we will design self-made teaching aids and board games to train different domains of cognitive functions. We plan to assess the participants before and after the intervention programs. We expect that elders receiving dual-task training will improve on outcome measures, and the group with more frequency will have better performance. The results of the study will provide evidence of interventions for elderly with cognitive decline, thereby reducing the burden on their caregivers and the cost of medical resource.
45814508|NCT05194033|Dietary Supplement|Probiotics daily|Probiotics 1 time/day for 7 consecutive days
45814509|NCT05194033|Dietary Supplement|Placebo daily|Placebo 1 time/day for 7 consecutive days
45814510|NCT04668391|Procedure|Ultrasound-guided anterior quadratus lumborum block at the lateral supra-arcuate ligament|Bilateral single-injection 20 ml 0.56% ropivacaine. Intravenous analgesia was started postoperatively and consisted of 1ug/ml sufentanil，2 ml/h with a 5-minute lockout period, a limited 12 ml/h dose.
45814511|NCT04668391|Procedure|Thoracic epidural analgesia|A thoracic epidural at the level of T7-10. Epidural infusion was started postoperatively and consisted of sufentanil (0.6ug/mL) and ropivacaine（0.2%） at 3ml/h.
45814512|NCT04658888|Device|Evalyn Self-Sampling Brush|A self-sampling brush to collect cervical cancer cells for screening purposes.
45814513|NCT05192551|Other|Bowel-prep (Plenvu as experimental arm)|In this study we will investigate the efficacy and patient satisfaction of the,in Sweden recently approved and introduced low-dose, Peg-based bowel-prep Plenvu in comparsion with the standard bowel-preps used i today's clinical routine
45814514|NCT05192395|Drug|DWJ1525|DWJ1525
45814515|NCT05192395|Drug|DWP16001|DWP16001
45814516|NCT05192395|Drug|DWC202101|DWC202101
45814517|NCT04651088|Drug|Potassium citrate|Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.
45814518|NCT04651088|Drug|Sodium bicarbonate|650mg tabs. Take 3 tabs twice daily.
45814519|NCT04651088|Dietary Supplement|Litholyte|One packet is taken with 170ml of water. Two packets daily.
45814520|NCT04651088|Dietary Supplement|Crystal Lite|The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
45814521|NCT04651088|Drug|Potassium Bicarbonate|20 mEq tablets, one tablet twice daily
45814522|NCT02315768|Drug|GA101|
45814523|NCT02315768|Drug|ibrutinib|
45814524|NCT02350699|Device|Nautilus BrainPulse|A noninvasive device to detect concussion utilizing headset and sensors
45814525|NCT04595617|Biological|Antibodies screening|All included GT patients will be enrolled from different national centres during a 6 months period. Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months.
45814526|NCT02162810|Drug|Prednisolone|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
45814527|NCT02162810|Drug|placebo-controlled|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
45814528|NCT00368498|Drug|teicoplanin|
45814529|NCT02108899|Behavioral|Retrieval practice effect using descriptive stories and free-call tests without feedback|"In the first phase (encoding), people study 2 short prose passages covering general scientific topics.~In the second phase (initial test), they recall one text or restudy the other one.~In the third phase (final test) which takes place 2 days later, they recall both texts."
45814530|NCT05176873|Drug|DZD8586|Single dose of DZD8586. Starting dose of DZD8586 is 20mg. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
45814531|NCT05176873|Drug|Placebo|A single oral dose of placebo will be given.
45660573|NCT05145335|Device|Non-autoregulated blood flow restriction cuff ((smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training)|This group will undergo 2 sessions consisting of a low load leg extension exercise combined with a pressurized tourniquet which does not autoregulate so when the quadriceps muscle contracts, the total amount of pressure will increase, as the tourniquet will not lower the pressure to keep the total amount of pressure constant.
45814532|NCT05444270|Other|Standard salvage therapy|Subjects will continue to receive current salvage treatment suitable for subjects at the discretion of their doctor, considering the location and size of recurrence, and the patient's comorbidities.
45953320|NCT04511260|Device|NuEra Tight VRF Handpiece|"The VRF is a Model that belongs to the NuEra Tight RF Family, specific for the treatment of small areas.~The NuEra is FDA cleared (K151296) for a wide range of indications including but not limited to, selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation. The NuEra Tight VRF with the small area handpiece is CE marked in Europe and currently under review by the FDA. The system and its accessories, are intended to be use for a wide range of indications including, but not limited to:~· Provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation of soft tissue."
45953321|NCT04511299|Other|SMOFlipid 20%|Fish oil-enriched intravenous lipid emulsion
45814533|NCT05444270|Radiation|Standard salvage therapy + SABR|Subjects receive SABR for lesions found in imaging studies. Before or After SABR, standard salvage treatment continues as planned at the discretion of the doctor.
45814534|NCT05172817|Drug|Advixa (Adalimumab)|Injection Advixa(Adalimumab) 40 mg/ 0.4 ml will be administered subcutaneously to the participants by trained medical personnel. Single dose for phase 2 and biweekly for 3 months for phase 3.
45814535|NCT04600622|Behavioral|Rural Diabetes One-Day Education and Care program (R-D1D)|One time, 5.5-hour multi-disciplinary diabetes self-management education and support intervention delivered via telehealth.
45814536|NCT04600622|Behavioral|Diabetes Education Materials|Diabetes Education Materials
45953322|NCT04511299|Other|Lipofundin 20%|MCT/LCT standard intravenous lipid emulsion
45953323|NCT00142571|Drug|Gemcitabine|
45953324|NCT00142571|Drug|Docetaxel|
45953325|NCT00155766|Biological|HPV16 E7 peptide-pulsed autologous DCs|
45953326|NCT04511221|Dietary Supplement|Bifidobacterium animals subsp. lactis BL04+PreforPro|One 15mg capsule taken orally each day
45953327|NCT04511221|Dietary Supplement|Bifidobacterium animals subsp. lactis BL04|One 15mg capsule taken orally each day
45953328|NCT04511221|Other|Placebo|One 15mg capsule taken orally each day
45953329|NCT04511182|Behavioral|Exercise-based cardiac rehabilitation|"Exercise program is based on aerobic exercise and supplemented by strength training following the principle of gradual improvement. The type of exercise, such as walking, jogging, cycling, and the intensity of exercise which is recommended to use a cardiotach or pedometer to detect, are both defined by the results of CPET, such as METs value. Participators must be prepared for about 5-10 minutes to warm up and recover before and after exercise. 30-50 minutes a day, 5 days a week, with a total exercise time of not less than 150 minutes per week. It can be carried out in different stages according to the physical condition. After 1-3 months, the exercise prescription will be re-adjusted according to the results of reexamination.~All patients will undergo Cardiopulmonary Exercise Test, SF-36, echocardiography and laboratory examination prior to initiation of the trial, and which will be checked again after 3 months, and 6 months."
45953330|NCT04511104|Other|Exercise|Resistance and aerobic exercise in addition to standard of care rehabilitation
45953331|NCT04511104|Other|Standard of Care|Standard of care rehabilitation
45953332|NCT00142610|Dietary Supplement|Vitamin|This is designed as a placebo controlled study of 500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks, on airway antioxidant levels in asthmatics.
45458102|NCT03505840|Diagnostic Test|Ultrasound with Doppler and 3D technology|ultrasound will be made to pregnant females in 3rd trimester with doppler and 3D technology
45660574|NCT04286243|Other|Community-based HPV screening strategy|Offering HPV self-collection for cervical cancer screening in the community
45953333|NCT04510870|Drug|Ferric Carboxymaltose Injection|Infusion prior the start of IVF/ICSI cycle. Dosing according to the summary of product characteristics (SmPC) chart. Placebo infusion before frozen embryo transfer if needed.
45458103|NCT04961515|Drug|Orelabrutinib|Orelabrutinib dose escalation will occur using a standard 3+3 dose-escalation approach to determined the maximum tolerated dose(MTD) of orelabrutinib dose in combined regimen, beginning at dose level I (150 mg daily) and potentially escalating to dose level 2 (200mg) and dose level 3 (250mg) with rules for escalation and de-escalation. If the DLT is not found, the dose of 250mg qd will be used for phase II trial.
45458104|NCT04961515|Drug|Orelabrutinib|Orelabrutinib: orally maximum tolerated dose from phase 1b daily (150 mg or 200 mg or 250mg)
45660575|NCT04286243|Other|Clinic-based HPV screening strategy|Offering HPV self-collection for cervical cancer screening in the clinic
45660576|NCT05092373|Biological|Atezolizumab|Given IV
45660577|NCT05092373|Drug|Cabozantinib S-malate|Given PO
45953334|NCT04510870|Drug|NaCl infusion|Placebo infusion prior the start of IVF/ICSI cycle. Ferric Carboxymaltose infusion before frozen embryo transfer if needed. Dosing according to the summary of product characteristics (SmPC) chart.
45953335|NCT00406536|Dietary Supplement|Lym-X-Sorb powder|Lym-X-Sorb is an organized matrix of lyso phosphatidylcholine (LPC), free fatty acid (FFA) and monoglyceride formulated at 20wt% with flour and sugar. A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
46077818|NCT02695602|Procedure|Microdebrider-Assisted Inferior Turbinoplasty (MAIT)|
45660578|NCT05092373|Drug|Nab-paclitaxel|Given IV
45814537|NCT05145907|Biological|TJ107 +Pembrolizumab|TJ107 injection:1200ug/Kg, Q12W, IM; Pembrolizumab: 200mg, Q3W, IV
45814538|NCT04563325|Drug|Oral co-amoxiclav or oral dicloxacillin only|High dose oral treatment followed by standard dose oral treatment
45814539|NCT04563325|Drug|IV ceftriaxon followed by oral co-amoxiclav or oral dicloxacillin|IV treatment followed by standard dose oral treatment
45953336|NCT00406536|Dietary Supplement|Placebo powder|The placebo is composed of soybean oil, sunflower oil, fully hydrogenated cottonseed oil and flax seed oil dispersed at 16wt% on flour and sugar. The placebo is >99% triglycerides with no trans fatty acids. The fatty acid composition and caloric content is designed to match the active supplement (Lym-X-Sorb). A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
45953337|NCT00142649|Behavioral|diet|
45953338|NCT00142649|Behavioral|physical activity|
45953339|NCT02955160|Biological|Multivalent|Pneumococcal conjugate vaccine
45953340|NCT02955160|Biological|Tdap|Tetanus, diphtheria, and pertussis vaccine
45953341|NCT02954965|Behavioral|Reward|Brief behavioral intervention (administered during a 45-minute phone call) that is designed to improve graduate student burnout by helping participants to identify activities that are rewarding and pleasurable and to integrate these activities into their schedule.
45953342|NCT02954965|Behavioral|Approach|Brief behavioral intervention (administered during a 45-minute phone call) that is designed to improve graduate student burnout by helping participants to identify activities that are challenging, but important to their long-term goals and values, and to integrate these activities into their schedule.
45953343|NCT00506116|Behavioral|Videotape, routine care, PME instruction|A 40 minute videotape about non-directed, spontaneous pushing and/or a videotape of antenatal perineal massage and pelvic muscle exerise (PME) at intake visit. The control women received routine care and PME instruction at intake visit.
45814540|NCT05142163|Other|Intraoperative SVV Guided Fluid Therapy|Patients will receive intraoperative maintenance Fluids as crystalloids to maintain SVV <11%, for values >11%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
45953344|NCT00506116|Behavioral|PME practice and record keeping (in diaries)|
46077819|NCT02695602|Procedure|Submucous Resection with non powered instrument|
45814541|NCT05142163|Other|Intraoperative PVI Guided Fluid Therapy|Patients will receive intraoperative maintenance Fluids as crystalloids to maintain PVI <10%, for values >10%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
45458105|NCT04961515|Drug|Sintilimab|The dose of sintilimab is fixed dose. 200 mg intravenously every 3 weeks
45458106|NCT03508336|Diagnostic Test|Coma Recovery Scale-Revised|"Patients with disorders of consciousness were assessed by Coma Recovery Scale-Revised (CRS-R). In addition, we selected four stimuli: 1) only a command (as recommended in CRS-R), which was open your mouth; 2) only a spoon without a command; 3) a spoon and a command, the command was there is a spoon and open your mouth; 4) a spoon with water and a command, the command was there is a spoon with water and open your mouth. In brief, we presented these stimuli orderly in front of the patient's mouth and presented any one of them over 4 trials at 15 second intervals."
45660579|NCT05092373|Procedure|Tumor Treating Fields Therapy|Receive TTF
45660580|NCT05076929|Diagnostic Test|ultrasound|Ultrasonographic measurement of Inferior Vena Cava Collapsibility Index
45660581|NCT05509205|Other|Turkish Validity and Reliability of The PSS Scale|This study is about validation of the Pound Satisfaction Scale to Turkish. The level of satisfaction with the rehabilitation service and treatment of 130 stroke patients undergoing stroke rehabilitation will be evaluated with the Pound satisfaction scale.
45660582|NCT04285697|Other|infection prevention bundle|"The infection prevention bundle (IPB) implemented items:~Preoperative counseling and questionnaire: patient counseling and preparation instructions, screening questions for signs of infection, and presence of open or nonhealing wounds.~Nasal methicillin-resistant and methicillin-sensitive Staphylococcus aureus decolonization: preoperative 24 hours ago twice-daily application of 2% mupirocin ointment to bilateral nares with final application on the morning of surgery.~Body decolonization: Cleansing with 4% chlorhexidine gluconate shower the evening before surgery and the morning of surgery.~Preoperative weight-based antibiotics within 60 minutes of incision~Strict draping and surgical techniques the standardization Irrigation of the surgical site with warm Isotonic NaCl solution before skin closure Postoperative wound care education to patient and family"
45953345|NCT00506116|Behavioral|Non-directed or directed,spontaneous or sustained pushing|Non-directed, spontaneous pushing (experimental group) with perineal massage vs. directed, sustained pushing during delivery.
45953346|NCT00506116|Procedure|Data collection|Baseline at 20 weeks gestation; longitudinal at 35 weeks gestation, 6 weeks postpartum, 6 months postpartum, and 12 months postpartum
45953347|NCT04510558|Device|Stoma closure with non-resorbable mesh (ULTRAPRO Advanced Mesh, Ethicon, Johnson & Johnson) in the sublay position|"Antibioprophylaxis using cefuroxime and metronidazole~Standard disinfection and sterile draping~Circular incision around the stoma using the scalpel blade~Dissection around the stoma until entering the abdominal cavity~Closure of the stoma using a linear stapler~A midline laparotomy may be performed or not~Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~Application of an ULTRAPRO Advanced Mesh, Ethicon, Johnson & Johnson, with +2cm on the edges, secured by 4 stiches of Maxon 2-0~Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~No subcutaneous stitches~Partial purse string skin closure using Monocryl 3-0~Standard wound dressing"
46077820|NCT05122208|Drug|Famotidine Tablets|160 mg/day Famotidine
45814542|NCT04559737|Other|Case Management|"Population management platforms capable of automatically risk stratifying patients (eg, automatically identifying poor users) may be another cost-effective technology-based tool by enabling a management by exception (MBE) follow-up intervention. This intervention concentrates provider effort on patients most at need by allowing providers to passively observe successful users and actively intervene only in CPAP strugglers. Therefore, in addition to Usual Care we will implement this population management process by identifying CPAP strugglers only and further follow-up encounters will be triggered for these select patients for troubleshooting. Additionally, throughout the 1-year period, Q1 window of <70% nights >4 hours will trigger a phone call and at the discretion of the sleep provider convert to video or in-person encounter for troubleshooting. CPAP Follow-Up Questionnaire will also be delivered to patient at 3 months and 1 year."
45814543|NCT04545151|Drug|Verapamil SR 120 mg|"For use as a test product in this blinded study, the IMP will be modified by re-packaging. The film-coated tablets will be squeezed from their blisters and filled into HDPE Twist-Off bottles. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~from Day 0 to Week 4: 120 mg once daily~from Week 4 to Week 8: 240 mg once daily~from Week 8 to Month 12: 360 mg once daily"
45814544|NCT04545151|Drug|Placebo|"The matching placebo will be filled into HDPE Twist-Off bottles, in the same way as the verum. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~from Day 0 to Week 4: 120 mg once daily~from Week 4 to Week 8: 240 mg once daily~from Week 8 to Month 12: 360 mg once daily"
45814545|NCT01438034|Drug|kisspeptin 112-121|0.24 nmol/kg
45814546|NCT01438034|Drug|GnRH|75 ng/kg
45814547|NCT05443958|Other||
45814548|NCT04543903|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
45814549|NCT00961142|Drug|Fludarabine, Thiotepa, Melphalan, Thymoglobuline (ATG)|Conditioning with Fludarabine 30 mg/m2/24h day-8 to -4, Thiotepa 2x5 mg/kg day -3, Melphalan 60 mg/m2 day -2 to -1 and Thymoglobuline (ATG)1.5mg/kg/day day -9 to -6. PBSC depleted of CD3 and CD19 cells by immunomagnetic depletion on CliniMACS.
45814550|NCT04523701|Drug|"white test (= the administration of SMOFlipid retrograde through the cystic duct)"|"white test (= the administration of SMOFlipid retrograde through the cystic duct)"
45814551|NCT05443646|Drug|HLX10|"HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W"
45814552|NCT05443646|Radiation|hypofractionated radiotherapy|45Gy/1.5F/3week
45814553|NCT05443646|Radiation|Prophylactic Cranial Irradiation (PCI)|25Gy/2.5Gy/2week
45814554|NCT04338373|Combination Product|"0.01% Atropine sulfate solution in Comfort Drops (AVIZOR S.A., Spain)"|"nightly instillations of 0.01% Atropine sulfate solution in Comfort Drops (AVIZOR S.A., Spain) in both eyes for 12 months"
45814555|NCT00059930|Drug|FOLFOX regimen|
45814556|NCT00059930|Drug|dexamethasone|
45814557|NCT00059930|Drug|floxuridine|
45814558|NCT00059930|Drug|fluorouracil|
45660583|NCT05501015|Other|Ice chips|Consuming small amounts of ice chips with supervision
45660584|NCT04535531|Drug|SB206 10.3% berdazimer|Topically once daily
45660585|NCT04535531|Drug|vehicle gel|Topically once daily
45660586|NCT04532645|Drug|Olaparib|Olaparib
45660587|NCT02560025|Drug|Alisertib|
45660588|NCT02560025|Drug|Cytarabine|
45814559|NCT00059930|Drug|leucovorin calcium|
45814560|NCT00059930|Drug|oxaliplatin|
45814561|NCT00059930|Procedure|adjuvant therapy|
45814562|NCT00059930|Procedure|conventional surgery|
45814563|NCT00368953|Device|Yukon Choice stent system|coronary stent implantation
45814564|NCT00368953|Device|Taxus Liberté stent system|coronary stent implantation
45660589|NCT02560025|Drug|Idarubicin|
45660590|NCT02560025|Drug|Daunorubicin|Can be used in place of idarubicin
45660591|NCT05500937|Drug|UDCA|UDCA vs. placebo together with statin in ASCVD patients
45814565|NCT00900055|Genetic|microarray analysis|
45814566|NCT00900055|Genetic|polyacrylamide gel electrophoresis|
45814567|NCT00900055|Genetic|polymerase chain reaction|
45814568|NCT00900055|Genetic|protein expression analysis|
45814569|NCT00900055|Genetic|reverse transcriptase-polymerase chain reaction|
45814570|NCT00900055|Genetic|western blotting|
45814571|NCT00900055|Other|chromatography|
45814572|NCT00900055|Other|high performance liquid chromatography|
45814573|NCT00900055|Other|immunoenzyme technique|
45814574|NCT05443412|Diagnostic Test|Diagnostic test for prostate cancer|All recruited patients will undergo investigations including urine for spermine, blood for miRNA, TRUS, and MRI prostate. Patients with high suspicion of Clinically significant prostate cancer in any one step (urine, blood, ultrasound, OR MRI) will be offered an image-guided prostate biopsy.
45814575|NCT02200614|Drug|Darolutamide (Nubeqa, BAY1841788)|Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.
45814576|NCT02200614|Drug|Placebo|Matching placebo 2 tablets twice daily with food.
45814577|NCT00369031|Biological|Human Immunodeficiency Virus glycoprotein 140 (vaccine)|Human Immunodeficiency Virus glycoprotein 140 (vaccine) alone nasally
45814578|NCT00369031|Biological|HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant|Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant nasally
45814579|NCT00369031|Biological|Labile Toxin mutant LTK63 adjuvant|Labile Toxin mutant LTK63 adjuvant alone
45814580|NCT05452382|Procedure|Partial colecctomy|Segmental resection of appendiceal adenocarcinoma including terminal ileum and cecum
45454054|NCT02284360|Drug|APOSEC™ for cutaneous use|"On day 0, a blinded and randomized test treatment with Verum and Placebo is performed on intact skin. If the subject does not reveal any adverse events, the actual treatment phase is initiated 24h later.~Following baseline evaluation on day 1, two punch biopsies (4mm) on the inner upper side of the non-dominant arm are set under local anesthesia. One wound on the upper arm (proximal or distal) will be treated with placebo and the second wound will be treated with the allocated concentration of Verum according to previous randomization scheme set for test treatment. Approximately 1ml of Verum vs. placebo will be applied on the artificial wounds.~From day 2 to 6, artificial wounds will be cleaned with 0.9 % NaCl and then allocated treatment will be administered. Wound dressing will be done daily and will cover the whole area of application.~On day 7 the treatment is terminated and the wound is evaluated with respect the extension of wound closure."
45454055|NCT00359086|Drug|MGCD0103|MGCD0103 given orally three times per week
45454056|NCT02284438|Device|Endotracheal tube|Three endotracheal tubes with different surfaces will be used
45454057|NCT04471558|Other|Music|A part of the RCT will be performed with music in the room. The music will be switch on just before anesthesia and off after the postoperative rest.
45660592|NCT05500859|Other|Data collection at Baseline, 3 months after baseline (BL), 1-year follow-up, Telephone follow-up and questionnaire 3 years and 5 years after BL|Data collection (Patient characteristics including medical history, current medication, cardiovascular risk factors, routine laboratory analysis (including lipids, Hb1c, NT-proBNP), clinical status, electrocardiogram, echocardiography data from latest echo, cardio pulmonary exercise testing (CPET), questions on general health behavior (diet, weekly exercise load), Quality of Life and questions on socio-economic parameters)
45454058|NCT03133780|Drug|Ketamine|Patient will receive IV ketamine 0.5 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
45454059|NCT03133780|Drug|Midazolam|Patient will receive IV midazolam 0.03 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
45660593|NCT04744025|Device|Microfluidics chamber|Unwashed sperm will be placed into the inlet chamber of the microfluidics device. The most motile sperm will swim to the outlet chamber, and these sperms will be used for intracytoplasmic sperm injection (ICSI) into the eggs.
45814581|NCT05452382|Procedure|Hemicolectomy|Formal right hemicolectomy including terminal ileum, cecum, and ascending colon
45814582|NCT05443178|Drug|Nivaquine ® (Chloroquine)|dose escalation and extension trial
45814583|NCT05064319|Drug|Gabapentin|After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive gabapentin 2-3 times a day for a total of 17 days.
45814584|NCT05064319|Drug|Placebo|After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive placebo 2-3 times a day for a total of 17 days.
45814585|NCT05061901|Drug|Lisinopril tablet 20 mg|Lisinopril is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 20 mg of lisinopril.
45814586|NCT05061901|Drug|Zestril® tablet 20 mg|Zestril® is manufactured by Avara Reims Pharmaceutical Services, France. Each tablet contains 20 mg of lisinopril.
45814587|NCT04398056|Drug|Chemotherapy plus radiotherapy and Toripalimab|"Chemotherapy:~The PF regimen included 5 g/m2 5-fluorouracil via a continuous intravenous infusion over 120 h and an intravenous administration of 100 mg/m2 cisplatin on day 1 for a maximum of six cycles.~Radiotherapy, intensity-modulated radiation therapy (IMRT), PTVnx:66-70Gy/30-33F; PTVnd:66～70Gy/30～33F; PTV1:60～64Gy/30～33F; PTV2:50～54Gy/30～33F, 5 fractions per week, for 6 weeks~Toripalimab 240mg every three weeks (Q3W) began on the first day of radiotherapy until an intolerable toxicity, or disease progression, or withdrawal of consent, or the investigator determines that he or she has to withdraw from treatment, or has been treated for up to 2 years."
45814588|NCT04383145|Device|endovascular repair|Endovascular repair of thoracoabdominal aneurysm using stent grafts.
45814589|NCT00368888|Device|Urine collection bag for infants|
45814590|NCT05054803|Drug|WJ-MSC (XCEL-UMC-BETA)|Administration of 2 Intrathecal infusions of WJ-MSC at day 1 and at 3 months
45814591|NCT05054803|Drug|Placebo|Administration of 2 Intrathecal infusions of placebo at day 1 and at 3 months
45814592|NCT05443100|Other|Whole-body cryostimulation (WBC)|Multidisciplinary rehabilitation program consisting of 10 WBC sessions.
46002726|NCT00547508|Drug|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
46002727|NCT00547508|Drug|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
45454060|NCT02282956|Drug|Ropivacaine 0,75%|Ropivacaine injection
45454061|NCT02282956|Procedure|posterior tibial nerve block|ultrasound guided posterior tibal nerve block
45454062|NCT02282956|Drug|morphine and droperidol|i.v PCA
45953348|NCT04510558|Procedure|Stoma closure without mesh|"Antibioprophylaxis using cefuroxime and metronidazole~Standard disinfection and sterile draping~Circular incision around the stoma using the scalpel blade~Dissection around the stoma until entering the abdominal cavity~Closure of the stoma using a linear stapler~A midline laparotomy may be performed or not~Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~No subcutaneous stitches~Partial purse string skin closure using Monocryl 3-0~Standard wound dressing"
45953349|NCT00142688|Behavioral|Physical activity|Tailored print-based intervention in which participants complete questionnaires and receive tailored feedback based on responses to the questionnaires. The intervention is delivered monthly during the first month, bi-monthly during months 2 and 3, and monthly during months 4-6. The intervention is completed through the mail.
45953350|NCT00142688|Behavioral|Wellness|Participants receive wellness materials delivered through the mail on the same schedule as the experimental condition. Physical activity materials are given to this group upon completion of the study.
45660594|NCT04744025|Other|Density Gradient Centrifugation|Sperm will be washed and centrifuged according to standard protocol, and these washed sperm will be used for ICSI.
45814593|NCT05443100|Other|Rehabilitation program|Multidisciplinary rehabilitation program consisting of diet and physical exercise.
45814594|NCT05452603|Device|96-hour off IBP wireless pH monitoring capsule|The endoscopic pH measurement capsule will be placed 6cm above the squamocolumnar junction, determined endoscopically, in the sedated patient. Then the plot will be read.
45814595|NCT05451992|Dietary Supplement|Placebo|The group will have to consume a jar every day (approx. 75 ml) which contain (water, malt-dextrins, 0.1% starch, 0.1% guar gum, flavorings and colorants)
45814596|NCT05451992|Dietary Supplement|SuperFood|The group will have to consume a jar of superfood (vegetable smoothie) every day. The jar will be filled with approx. 75 ml which corresponds to about 75 g. The superfood formulated by the University of Bolzano on the basis of the results and evidence acquired in collaboration with the Istituto Superiore di Sanità. Composition: pomegranate, walnuts, moringa, broccoli, according to the proportions indicated in Annex 2. This mixture has been analyzed by an external laboratory and authorized for human use
45953351|NCT02275936|Drug|N91115|S Nitrosoglutathione Reductase Inhibitor
45660595|NCT05500781|Behavioral|Coaching HER|The CoachingHER coach education program is a six-module online program aimed at upskilling coaches in [the effectiveness, feasibility, and acceptability of the Coaching HER; the first online program aimed at reducing gender stereotypes for coaches]. Each module will take approximately 20 minutes to complete and consists of educational content, interactive elements (quizzes, checklists, opinion polls, reflective exercises), and additional resources.
45953352|NCT00406575|Drug|Placebo|Placebo was the diluent used for preparation of the 100 µg/kg/day dose of active study medication.
45953353|NCT00406575|Drug|Recombinant human relaxin (rhRlx)|Recombinant human relaxin (rhRlx) diluted for continuous IV infusion.
45953354|NCT02275975|Drug|K-877|
45953355|NCT02275975|Drug|Fluconazole|
45953356|NCT02276092|Other|antimicrobial stewardship|A member of the antimicrobial stewardship program will prospectively review the patient's medical record and make recommendations to the most responsible physician in the care of that patient
45953357|NCT00142727|Drug|Methadone|
45953358|NCT00142727|Drug|Full opioid agonist|
45953359|NCT00142727|Drug|Partial opioid agonist|
45953360|NCT00142727|Drug|Opioid antagonist|
45953361|NCT02276131|Device|Vigilant Diabetes Management Application|Human factors and usability assessment of the device in the hands of diabetes subjects and caregivers
45953362|NCT00163059|Drug|NMDA Antagonist, CP-101,606 (traxoprodil)|
45953363|NCT04510402|Drug|Povidine iodine nasal swabs|Daily versus twice daily nasal application
45953364|NCT00506194|Drug|Insulin|
45454063|NCT02282566|Other|Protein-nutrition beverage|Intervention involves consumption of one protein-nutrition beverage after exercise bout and 2 times per day for 5 days thereafter
45454064|NCT02283034|Device|The CPRmeter|Feedback device - 1
45660596|NCT04524455|Drug|Blinatumomab|Blinatumomab will be administered as a continuous intravenous infusion (cIV).
45660597|NCT04524455|Drug|AMG 404|AMG 404 will be administered as an intravenous infusion (IV).
45660598|NCT04524455|Drug|Dexamethasone Premedication|Dexamethasone will be administered orally or intravenously prior to blinatumomab treatment, as needed.
45660599|NCT04692155|Drug|Ublituximab|Ublituximab (900mg) will be administered as an intravenous infusion through a dedicated line.
45660600|NCT04692155|Drug|Umbralisib|Umbralisib(800mg)will be administered orally once daily within 30 minutes of starting a meal.
45953365|NCT00506194|Drug|OAD|Gliclazide-MR, Metformin, Glimepiride
45454065|NCT02283034|Device|The PocketCPR|Feedback device - 2
45454066|NCT02283034|Device|Standard BLS|Standard basic life support = chest compressions without any feedback device (manual resuscitation)
45454067|NCT02283034|Device|The CPREazy|Feedback device - 3
45953366|NCT00506233|Behavioral|Questionnaire|Completion of questionnaires at 3 different times (when joining this study, 3 months later, and 6 months later). Each should take about 20-30 minutes to complete.
45814597|NCT05443022|Radiation|Photobiomodulation|Participants will receive an application of low intensity light directly in the region of the three pairs of salivary glands. The ArGaAl diode laser, DMC 808nm 4J/point equipment will be used. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.
45814598|NCT05443022|Radiation|Simulation of Photobiomodulation|The placebo group will have a simulation of the application of the laser, following the same technique as the active group, but with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off.
45660601|NCT05508893|Radiation|CT Angiography|A CTA will be performed on asymptomatic individuals
45660602|NCT05508893|Diagnostic Test|Exercise stress test|A routine exercise stress test will be performed on a bicycle
45660603|NCT05500625|Procedure|Endoscopic ultrasound-guided coil embolization combined with endoscopic cyanoacrylate injection|Standard diagnostic endoscopy will be done and Fundal varices will be assessed. EUS procedures will be performed using linear endoscope under general anesthesia. Use EUS to assess the anatomy of gastric varices, observe the blood flow, scan the portal venous system, left renal vein, confirm the location of the shunt, and measure the diameter of the shunt. Puncture the gastric fundal variceal vein at the lower esophagus near the cardia and place the coil into the shunt and immediately inject with sclerosant and cyanoacrylate under the guidance of EUS using a sandwich method (cyanoacrylate, sclerosant and cyanoacrylate) via endoscope. Use color Doppler ultrasound to observe the blood flow in the variceal veins to evaluate the embolization effect.
45660604|NCT05500625|Procedure|Ballon-occluded retrograde transvenous obliteration|A balloon occlusion catheter will be inserted into the venous end of the gastro-renal or gastro-caval shunt via the right femoral vein or internal jugular vein. Balloon-occluded retrograde venogram will be done to evaluate degree of retrograde filling of the gastric varices and presence of collateral veins. Any significant large collateral veins seen will be occluded with coils using microcatheter to prevent leakage of the sclerosant into the systemic circulation. Then, sclerosant agent (ethanol-amine oleate, Sodium tetradecyl sulphate, or polidocanol) will be injected into the portosystemic shunt till complete filling of the gastric varices and part of the feeding veins. Finally, the balloon left in place for 2-12 hours then gradually will be deflated when complete occlusion of blood flow of the target shunt is achieved.
45814599|NCT04338919|Procedure|Percutaneous coronary intervention|PCI with stent implantation
45660605|NCT04789889|Radiation|intraoperative radiotherapy|intraoperative radiotherapy
45660606|NCT04789889|Radiation|postoperative radiotherapy|postoperative radiotherapy
45660607|NCT04640519|Other|Usual care|Usual care patients will be seen by a primary care nurse practitioner and a stroke neurologist.
45660608|NCT04640519|Other|TASC intervention|TASC patients will receive a BP monitoring kit and electronic tablet with patient tailored BP infographics. They will be scheduled with 5 telehealth visits over 3 months, including primary care nurse practitioner, pharmacy and stroke neurologist.
45660609|NCT04411901|Drug|Cholecalciferol (vitaminD3)|Theraputic vitamin D3 for CF and non CF bronchiectasis children
45814600|NCT04338919|Drug|Ticagrelor plus aspirin|Ticagrelor plus aspirin
45814601|NCT05442944|Procedure|Physiotherapeutic procedures|As part of the rehabilitation program, the patients performed two exercises in the Universal Therapeutic Rehabilitation Room (UTRR) system. The patient's task was to perform simultaneous abduction and adduction of the upper and lower limbs. The duration of the procedure was 10 minutes, the patient performed the exercises at a comfortable pace. In the second exercise - the patient's task was to alternately bend and straighten the opposite lower and upper limbs. The duration of the exercise was 10 minutes. The combined duration of both procedures used was 20 minutes. In addition, each patient underwent three physical therapy treatments. The procedures were carried out 5 days a week (Monday to Friday) for three weeks.
45660610|NCT05500547|Other|"US Public Health Service USPSH criteria for assessment of success of resin composite restorations"|"US Public Health Service USPSH criteria for color match, marginal adaptation, surface texture, retention, recurrent caries and others after 1, 3, 6 and 9 months."
45953367|NCT00404573|Drug|RGH-188|
45953368|NCT00506272|Procedure|Self blood glucose monitoring and insulin administration|Patients will monitor blood glucose using a hand-held blood glucose monitor, and self-administer insulin
45953369|NCT00506272|Procedure|Standard care|finger-stick blood glucose values to be obtained and all insulin administration to be delivered by nursing staff
45953370|NCT00163098|Drug|UK-369,003|
45953371|NCT00506311|Drug|Fibrin Sealant|Tisseel applied externally to the dissected groin area.
46002728|NCT00547508|Drug|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
46002729|NCT00547508|Drug|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
45814602|NCT05451758|Other|Mindfulness-based stress reduction (MBSR)|The participants were asked to attend a brief version of the MBSR programme lasting six weeks. The intervention was a structured 6-week programme with groups of between 6 and 10 participants. Each weekly session lasted one hour and included mindfulness meditation/exercises and group discussion led by a qualified mindfulness instructor.
45953372|NCT04513327|Device|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to anterior cruciate ligament reconstruction post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 2 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 2 to 12 weeks post surgery."
45953373|NCT04513327|Other|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
45953374|NCT00142766|Behavioral|Nurse Implemented Goal-Directed Comfort Algorithm|See description
45953375|NCT04511377|Device|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to rotator cuff repair post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 6 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 6 to 12 weeks post surgery."
45953376|NCT04511377|Other|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
45953377|NCT02276248|Radiation|Intensity-modulated radiation therapy|total dose: 50 to 56 grays per fraction: 2 grays
45953378|NCT02276248|Drug|GDP chemotherapy|gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
45953379|NCT04519645|Drug|Lacosamide intravenous|Study participants will receive lacosamide (LCM) as an intravenous (iv) infusion during the Treatment Period.
45660611|NCT05508737|Drug|Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)|Single arm: Pembrolizumab 400 mg every 6 weeks (Q6W), trifluridine/tipiracil at 35 or 30 mg/m2 twice daily (BID) for 5 days a week (D1-5, D8-12) with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks (Q4W)
45660612|NCT04281329|Procedure|Magnetic resonance imaging|Cardiac magnetic resonnance imaging before catheter ablation.
45676582|NCT01860170|Drug|Cohort 2-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
45814603|NCT04351009|Procedure|sentinel lymph node mapping|Through on-table colonoscopy indocyanine green solution will be injected in the submucosa at 2-4 points around the tumor for laparoscopic surgeries. Dye will be injected in the subserosa at 2-4 points for open surgeries. Lymphatic flow from the tumor will be mapped in real time with near-infrared fluorescence imaging scope and sentinel lymph nodes will be identified.
45953380|NCT04519645|Drug|Lacosamide oral|Study participants may receive lacosamide (LCM) as an oral solution during the Extension Period.
45953381|NCT04519645|Other|Active Comparator|Active Comparator treatment will be chosen and dosed based on StOC (per local practice and treatment guidelines).
45454068|NCT02283034|Device|The CPR PRO APP|Feedback device - 4
45953382|NCT00406614|Behavioral|Health Literacy-Focused High Blood Pressure Intervention|Participants assigned to the intervention group will attend a weekly 2-hour educational session for 6 weeks that will cover topics such as learning medical terminology, understanding the content of prescription and appointment slips, and blood pressure (BP) management strategies. Upon completion of the educational sessions, participants will submit BP measurements via telephone monitoring system for 12 months and Community Health Worker (CHW) will conduct telephone counseling once every month during the same 12-month period for support and follow-up counseling. Participants will continue to monitor BP measurement by logging BP data on BP diary book for another 12 months. Control group participants will receive the same intervention education following the completion of the study.
45953383|NCT04516018|Other|Cold exposure|Subjects will be exposed to shivering thermogenesis for at least 1 hour for 10 days
45953384|NCT00142805|Drug|Tricaprilin|Powder formulation will be mixed in a liquid (approximately 8 oz).
45814604|NCT05451680|Device|Negative pressure device|Negative-pressure therapy postoperatively on the full-thickness skin graft
45814605|NCT05451680|Procedure|Conventional care|Conventional dressing postoperatively on the full-thickness skin graft
45814606|NCT02231892|Device|TMS|HAC coil (real rTMS or sham rTMS)
45953385|NCT00142805|Other|Placebo|Powder formulation will be mixed in a liquid (approximately 8 oz).
45953386|NCT04510831|Other|Refined maize with extrinsic addition of labelled FeSO4|Porridge prepared with refined maize flour with extrinsic addition of FeSO4 (isotopic iron 54)
45953387|NCT04510831|Other|T.molitor native chitin|Porridge prepared with dried intrinsically labelled T.molitor (isotopic iron 57) native chitin, refined maize flour and extrinsic addition FeSO4 (isotopic iron 58)
45953388|NCT04510831|Other|T molitor reduced chitin|Porridge prepared with dried intrinsically labelled T.molitor (isotopic iron 57) reduced chitin, refined maize flour and extrinsic addition FeSO4 (isotopic iron 58)
45454069|NCT02283034|Device|The CardioPump|Feedback devices - 5
45454070|NCT02283034|Device|Standard BLS|Chest compressions without CPR feedback device (manual resuscitation)
45454071|NCT02284594|Behavioral|text message|series of text messages regarding influenza vaccination
45454072|NCT04470856|Diagnostic Test|End-expiratory occlusion test (EEOT)|An occlusion manoeuvre during the end of expiration for 20 seconds
45454073|NCT02287558|Drug|Pomalidomide|
45660613|NCT05500235|Behavioral|Smart phone based training|The study team will acquaint headmasters with the Tobacco Free Teachers-Tobacco Free Society (TFT-TFS) program and the smartphone training app. Headmasters will receive six monthly trainings on their phones, including brief videos followed by quizzes with feedback, discussion forums to promote peer learning, demonstration of techniques, and the ability to review the content as needed. Headmasters will implement TFT-TFS at monthly school meetings with teachers and parents. TFT-TFS consists of four program components: (1) six group discussions with teachers, (2) cessation support and referrals to government resources, (3) posting six thematic tobacco control posters in the school, and (4) implementing a school tobacco policy. These four components incorporate the program's six themes: Teachers as Role Models; Health Effects of Tobacco; Motivation to Quit Tobacco Use; Skills to Quit Tobacco and to Help Others Quit; Dealing with Withdrawal; and Maintenance and Celebration.
45814607|NCT05442476|Other|Kinesiotaping|For the KT application, participants will be asked to stand with keeping their feet at shoulder level in a comfortable manner. The patient will be in a standing position with lumbar spine flexion. A 5 cm wide long I-shaped piece of tape will be applied with 80% tension transverse to the patient's painful area and the bilateral SIJ region, with no tension applied to the ends of the tape. Another short piece of tape will be applied with 80% tension at an angle from the painful point to the hip, and no tension will be applied to the ends of the tape. An identical application will be performed on the other side of the sacroiliac region
45814608|NCT05442476|Other|Muscle Energy Technique|The subject will be asked for the sitting on the treatment table, back towards the therapist. Then the subject will be taken into flexion, rotation and side bending. When the subject will reach the tolerated limit of flexion, the therapist will ask him to perform extension, sidebending and rotation to the opposite side while holding the breath for 7-10 seconds and rest for 2-3 seconds, then the patient will be asked to release the breath. The therapist will wait for the participant's full exhalation and then will take her further in all the directions of restriction, towards the new barrier. MET will be performed for 10 repetitions.
46077821|NCT04629066|Behavioral|Remote Cardiac Rehabilitation (CR)|"Patients randomized to remote CR will be asked to use an app for cardiac rehabilitation a minimum of 3 times a week. Patients will be given an exercise prescription provided by a certified exercise physiologist.~The exercise prescription will change each week based on refreshed data from the prior week.~Instructional videos for each exercise are provided in the app. Patients will not be told to perform the exercise at a particular time. Instead they will be asked to complete a certain amount of exercise per week at whatever time is convenient for them. Patients randomized to remote CR will also receive App based reminders to take their medications, resources to guide healthy eating habits, and other behavioral health advice as is done as standard of care in both remote based and clinic based CR."
45454074|NCT04470076|Drug|Neoadjuvant treatment: Afatinib, pemetrexed, gemcitabine, cisplatin, carboplatin|"① Eligible patients with non-squamous cell lung cancer will receive pemetrexed 500mg/m2, IV on day 1 and cisplatin 75mg/m2 or carboplatin area under curve (AUC) =5, on day 1 of a 3-week schedule for 3 cycles.~② Eligible patients with squamous cell lung cancer will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 or carboplatin AUC =5 on day 1 of a 3-week schedule for 3 cycles .~③Patient will take afatinib at dosage of 30mg per day 48 hours after chemotherapy and will stop 24 hours before next cycle of chemotherapy."
45454075|NCT04470076|Procedure|Surgical treatment|The patients who respond to neoadjuvant treatment (CR+PR) and the patients who do not respond to therapy but could still undergo surgery (SD and PD) will receive radical lung resection 3-4 weeks later after neoadjuvant.
45454076|NCT04470076|Drug|Adjuvant treatment:afatinib|The CR, PR and SD patients who have been treated surgically will take afatinib at a dosage of 30mg per day for 2 year.
45814609|NCT05442476|Other|conventional physiotherapy|conventional physiotherapy
45814610|NCT05451290|Drug|Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur|Perioperative treatment: camrelizumab plus apatinib in combination with GEMOX 2-4 cycles (neoadjuvant); camrelizumab plus tegafur up to 1 year (adjuvant).
45814611|NCT05452135|Other|Observation of visual, audotory and motor reaction time|Visual, auditory and motor reaction time will be measured as a result of the measurements made during the dual task evaluation.
45814612|NCT04284865|Other|Web Platform|The intervention involves the use of the web platform for 12 months combined with a monthly phone follow-up.
45953389|NCT00406731|Drug|NG-monomethyl-L-arginine (L-NMMA)|bolus 6 mg/kg over 5 minutes followed by a continuous intravenous infusion of 60 µg/kg/min over 12 minutes; twice on 1 study day
45953390|NCT00406731|Drug|Endothelin-1 (ET-1)|5 ng/kg/min intravenous infusion over 17 minutes; twice on 1 study day
45953391|NCT00406731|Drug|Physiologic saline solution (placebo control)|intravenous infusion over 20 minutes; twice on 1 study day
45953392|NCT00406731|Device|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
45953393|NCT00406731|Device|Goldmann applanation tonometer|Intraocular pressure measurements
45814613|NCT05452057|Behavioral|Prehabilitation|"A Registered Kinesiologist will provide your exercise prescription during your first visit for the study. Your exercise sessions will consist of moderate-intensity cardiovascular (or aerobic) exercise, like brisk walking, for 30 minutes. You will also perform resistance exercises (weight lifting) for 30 minutes that will help strengthen your muscles with a focus on muscles that may be affected by your surgery. To complete your exercises, you will receive resistance bands, exercise ball, and exercise manual.~You will also meet with a Registered Dietician within a week of consent to receive information on healthy eating and you will receive protein to improve your nutritional health.~A consult with an expert in psychology to discuss ways to reduce your stress within a week of consent. Some strategies to help reduce your stress may include breathing exercises, being mindful, or other relaxation methods."
45676583|NCT01860170|Drug|Cohort 3-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
45814614|NCT04322162|Other|ASAP Intervention Quality Improvement Protocol|The intervention program includes: (1) a systems redesign Virtual Collaborative, and; (2) data monitoring and is designed to aid each of the 6 participating VAMCs in developing, implementing, and evaluating the implementation of an acute OSA testing and treatment protocol for ischemic stroke/TIA patients. The sites will choose a diagnostic strategy (i.e., unattended polysomnography [PSG]/home sleep test [HST], in-laboratory PSG, direct to auto-titrating [auto]-PAP) and a therapeutic strategy (i.e., in-laboratory PAP titration, auto-PAP). The intervention will employ 3 implementation strategies: (1) local adaptation; (2) external facilitation, and; (3) audit and feedback.
45814615|NCT00369889|Drug|bevacizumab|iv every 21 days
45814616|NCT00369889|Drug|Erlotinib|oral daily
45814617|NCT00369044|Drug|prednisone|
45953394|NCT00406731|Device|HP-CMS patient monitor|blood pressure and pulse rate measurements
45953395|NCT00406731|Procedure|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
45953396|NCT00142844|Drug|Naltrexone|
45953397|NCT00142844|Drug|Disulfiram|
45953398|NCT00142844|Drug|Placebo|
45953399|NCT04511026|Drug|Lymphoseek|Radioactive diagnostic agent
45953400|NCT04511026|Device|Single Photon Emission Computed Tomography (SPECT)|Imaging test
45676584|NCT01847274|Drug|Active comparator: Niraparib|Niraparib vs placebo 2:1 ratio
45814618|NCT00370045|Drug|Bivalirudin with and without eptifibatide|
45814619|NCT05442320|Device|Biodent Toothpaste (Ilirija d.d., Ljubljana, Slovenia)|Toothpaste with 500 or 1000 ppm of fluoride
45814620|NCT04249141|Behavioral|Survey and concept mapping|ICU providers who participoated in SCCM ICU Liberation Collaborative will be invited to participate in surveys and a concept mapping excercise
45814621|NCT05451056|Drug|sotorasib|Sotorasib will be given 960mg daily PO until disease progression or unacceptable toxicity.
45814622|NCT04304690|Other|blood sample|2 blood samples at T0 and 3 months
45814623|NCT05451979|Device|MedBIKE HIIT|Participants will complete a high intensity interval training exercise program 3 times a week for 12 weeks (36 sessions total)
45814624|NCT02231580|Drug|BN82451B|BN82451B capsule
45814625|NCT02231580|Drug|Placebo|Placebo capsule
45953401|NCT04511026|Drug|Indocyanine Green (ICG)|Cyanine dye used in medical diagnostics manufactured by Akorn Inc.
45953402|NCT04511026|Device|Neoprobe Gamma Detection System NPB11L(Model1102)|Neoprobe Gamma Detection System NPB11L(Model1102) made by Devicor Medical Products, Inc.
45953403|NCT00163137|Drug|lasofoxifene|lasofoxifene 0.25mg
45953404|NCT00163137|Drug|raloxifene|raloxifene 60 mg/day
45953405|NCT00163137|Drug|Placebo|0 mg/day
45953406|NCT04516096|Drug|AMX0035|Tauroursodeoxycholic Acid and Sodium Phenylbutyrate orally given twice a day
45953407|NCT00142883|Drug|Pregabalin|pregabalin compared to placebo
45953408|NCT00142883|Drug|placebo|sugar pill compared to pregabalin
45676585|NCT01847274|Drug|placebo|
45814626|NCT05442242|Procedure|Unicompartmental knee arthroplasty|Medial Unicompartmental knee arthroplasty
45814627|NCT05442242|Procedure|High tibial osteotomy|Medial open wedge high tibial osteotomy
45814628|NCT05451823|Device|Post auriclar-frontal|"Frontal sensors will be applied with lead 1 at the center of the forehead; lead 2, 2.8 cm lateral to lead 1; and lead 3 at the temporal area between the lateral canthus and the hairline.~Post auriclar sensors will be applied to the same side of the face, with lead 1 approximately 2.5 cm medial to the mastoid area, post-auricularly next to the hairline. Lead 2 will be attached at the mastoid area and lead 3 will be attached on the same side at the temporal area between the lateral canthus and the hairline."
45814629|NCT05441150|Drug|Low dose ketamine infusion|Administering low-dose ketamine infusion to the patient under general anesthesia for Ketamine Group.
45814630|NCT05441150|Drug|0.9% NaCl infusion|Same dose of 0.9% NaCl infusion as the dose of ketamine for Control Group.
45814631|NCT05439980|Other|Knowledge questionnaire|Completion of a questionnaire at baseline
45814632|NCT05439980|Other|Focus groups|structured interviews
45814633|NCT04270214|Drug|Dysport Injectable Product|Dysport injections optimized using kinematics
45814634|NCT05018689|Other|Aevidum curriculum|The Aevidum curriculum will be delivered to 9th grade students at participating high schools in both study arms. All school staff who plan to deliver the curriculum will participate in a web-based training workshop with the Aevidum Executive Director.
45814635|NCT05018689|Other|Club|Schools will identify ten students interested in participating in an Aevidum club. Following training of interested students, schools are asked to commit to running two Aevidum club activities during the school year.
45814636|NCT04238624|Drug|Dabrafenib|Participants will receive dabrafenib 150 mg orally twice a day
45814637|NCT04238624|Drug|Trametinib|Participants will receive trametinib 2 mg orally once a day
45814638|NCT04217707|Behavioral|Pre- and Post-Surgical Transgender Therapeutic Support Group|Participants will be patients drawn from already-existing therapeutic support groups for transgender patients who are hoping to undergo or have undergone gender-affirming surgeries. Participants will be assured that there will be no changes to their care or decisions about their surgeries if they elect not to participate in the research portion of the groups, but would still like to attend groups as a non-research participant. Prior to their first group session, participants will be arrive early to go over consent again and allow participants to sign the consent form and fill out baseline measures of the outcomes of interest. Following this, research participants will participate in the groups as usual, and after each of their first 8 attended sessions, will be asked to fill out outcomes of interest again. Length of time for them to attend 8 sessions will be capped at 6 months, and participants will be asked to fill out measures again at six months following their enrollment.
45814639|NCT04747405|Other|therapy group|therapy group of maximum 8 people repeated twice
45814640|NCT05144022|Behavioral|Bungee jump|Bungee jump from a cran
45814641|NCT04746859|Other|Prevention Visit|Patients will have a one-on-one, approximately one-hour long visit with a specially trained Prevention Practitioner. During this visit, they will discuss the patient's health history, their risks for developing chronic diseases, including cancer, and possible steps they can take to reduce those risks. The Prevention Practitioner will also assist the patient to develop and articulate specific goals the patient would like to work on to reduce their risk of chronic diseases.
45814642|NCT04746859|Behavioral|Peer health coaching|Patients will be invited to register with the software platform used to facilitate peer health coaching. Once they have registered, they will be matched to a peer health coach who will connect with the patient to initiate the process. The coach will work collaboratively with the patient to help her follow through on a step-wise, personalized plan to achieve health goals that were developed with their prevention practitioner. The coach's approach will be informed by principles of brief action planning and motivational interviewing. Coaches will also provide social support, help to navigate to relevant information and community resources, and advise about options for self-monitoring. Coaching will occur over 12-16 sessions via phone calls, text messages, video calls and/or in-person meetings as desired/convenient and in accordance with local public health guidelines.
45814643|NCT05450510|Other|Accelerated (ACCEL) protocol group|After randomization and initial evaluations, patients will be referred to Physiotherapy and Rehabilitation clinics for a 8-week-long Phase 2 and Phase 3 trainings.
45953409|NCT04518085|Behavioral|Medical hypnosis|Single session 20 minutes hypnosis session originally developed and tested by Montgomery et al. (2007) in a similar setting. Delivered by an experienced clinical psychologist.
45953410|NCT04518085|Behavioral|Internet-based Acceptance and Commitment Therapy (iACT)|Access to an online platform developed to this study containing video clips and audio files with ACT consistent material
45953411|NCT04518085|Behavioral|Mindfulness session|Single session mindfulness session delivered by audio file
45953412|NCT04518085|Behavioral|Treatment as Usual (TAU)|Treatment as usual as part of post-surical care
45676586|NCT01802788|Device|St Jude Medical Portico replacement aortic valve|
45676587|NCT01802788|Procedure|Transcatheter Aortic Valve Implant|
45676588|NCT01736592|Drug|Long term follow up in all patients who received SAR422459 in previous study TDU13583|Blood draw for the laboratory assessment
45676589|NCT01712620|Drug|Spironolactone|Initial dose, 25 mg (pink capsule) orally, daily. If well tolerated at 7-9 wks then increased to 50 mg (brown capsule) daily.
45676590|NCT01712620|Drug|Placebo|Initial dose, pink sugar capsule, daily. If well tolerated at 7-9 wks then changed to brown sugar capsule, daily.
45814644|NCT05450510|Other|Slow (SLOW) protocol group|After randomization and initial evaluations, patients will be referred to Physiotherapy and Rehabilitation clinics for a 14-week-long Phase 2 and Phase 3 trainings.
45953413|NCT04512196|Drug|Superoxidized Water|Super-oxidized solution contains hypochlorous acid (HOCl) which exhibits bactericidal activity. These reactive species create an imbalanced osmotic gradient which damages the cell membrane integrity of single celled organisms, and subsequently denaturing its lipid and protein content. Multicellular organisms including host tissue are not susceptible to such changes in osmolarity hence spared from damage.
45953414|NCT04512196|Drug|Normal Saline|Normal saline contains 0.9% sodium chloride.
45953415|NCT00142922|Behavioral|Breaking Down Barriers|completed
45953416|NCT04517851|Biological|Elotuzumab|Given IV
45660614|NCT05500235|Behavioral|In person training|Headmasters will receive three face-to-face trainings, each 60-75 minutes long and held at convenient locations. The study team will introduce headmasters to the TFT-TFS program and teach them how to use paper-based materials. The trainings will encourage participants to discuss successes and come up with solutions to overcome challenges. Headmasters will implement TFT-TFS at monthly school meetings with teachers and parents. TFT-TFS consists of four program components: (1) 6 group discussions with teachers, (2) cessation support and referrals to government resources, (3) posting six thematic tobacco control posters in the school, and (4) implementing a school tobacco policy. These four components incorporate the program's six themes: Teachers as Role Models; Health Effects of Tobacco; Motivation to Quit Tobacco Use; Skills to Quit Tobacco and to Help Others Quit; Dealing with Withdrawal; and Maintenance and Celebration.
45814645|NCT04746703|Radiation|Magnetic Resonance Imaging|Pancreatic MRI will be performed in severe-obese patients with a planned bariatric surgery, before and 6 months after bariatric surgery.
45660615|NCT04333511|Device|TPS (NEUROLITH)|6 treatments of TPS over 2 weeks
45814646|NCT05438810|Drug|FCN-437c,Fulvestrant,Goserelin acetate|FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach. 200mg once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment until progressive disease。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles ； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
45814647|NCT05438810|Drug|Placebo,Fulvestrant,Goserelin acetate|Placebo：available in 25mg and 100mg capsules, and is administered in the same way as FCN-437c。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
45814648|NCT04738513|Procedure|Vertical preparation technique|Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using vertical preparation technique.
45814649|NCT04738513|Procedure|Conventional Preparation technique|Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using conventional preparation technique.
45814650|NCT04338854|Procedure|Restorative Treatment|9 groups were formed as 6 restorative and 3 protective applications. The restorative treatment groups included procedures with- and without-local anesthesia (LA). Procedures with LA included the groups as root canal treatment, pulpotomy, two-surface restoration and one-surface restoration. Procedures without LA included the groups as two-surface restoration and one-surface restoration. The protective application groups included the groups as fluoride application (by disposable arch tray or by cotton roll) and fissure sealant.
45814651|NCT02166606|Device|ImageReady MR Conditional Pacing System Implant|Implant according to standard-of-care. No study-specific interventions in that registry.
45814652|NCT04730401|Biological|Convalescent plasma from COVID-19 donors|Convalescent plasma from COVID-19 donors
45814653|NCT04730401|Biological|Placebo|200mL saline
45814654|NCT04747496|Drug|Edoxaban|This is a non-interventional, observational study.
45814655|NCT05451121|Drug|Propofol|patient sedation with a propofol (sedative agent) after cardiac surgery
45814656|NCT05451121|Drug|Dexmedetomidine|patient sedation with dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist) after cardiac surgery
45814657|NCT05451121|Drug|Propofol and dexmedetomidine|Patients sedation with a drug combination: propofol and dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist)
45814658|NCT04967443|Drug|Prazosin HCl 2mg|Prazosin HCL 1 X 2 mg capsule.
45814659|NCT04967443|Drug|Prazosin HCl 1 mg|Prazosin HCl 2 X 1 mg capsule.
45814660|NCT04967443|Drug|Prazosin HCl 5 mg|Prazosin HCL 1 X 5 mg capsule.
45814661|NCT04724317|Procedure|Steroid Group|Ultrasound guided shoulder intra-articular steroid injection
45814662|NCT04724317|Procedure|Ozone Group|Ultrasound guided shoulder intra-articular Ozone injection
45814663|NCT04724317|Procedure|PRF Group|Ultrasound guided shoulder intra-articular pulsed radiofrequency application
45953417|NCT04517851|Other|Questionnaire Administration|Ancillary studies
45953418|NCT04515238|Drug|Bendamustine|Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.
45814664|NCT04697017|Other|The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births|The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births
45814665|NCT04943419|Diagnostic Test|Level of Myeloid-Derived Suppressor Cells|Establishing of levels of all MDSC, PMNMDSC, MMDSC, EMDSC, M/PMN MDSC ratio on the day before operation.
45814666|NCT02230956|Biological|onabotulinumtoxinA|onabotulinumtoxinA (botulinum toxin Type A) injection into the intra-articular space of the study knee.
45814667|NCT02230956|Drug|Normal Saline|Normal Saline (placebo) injection into the intra-articular space of the study knee.
45814668|NCT05450887|Drug|Obeticholic Acid Tablets（OCA）|Obeticholic Acid：Once a day (QD) by mouth (PO).
45814669|NCT05450887|Drug|UDCA|UDCA：13~15 mg/kg/day
45814670|NCT05450887|Drug|Placebo|Placebo：Once a day (QD) by mouth (PO).
45814671|NCT05450042|Device|SELUTION SLR DCB|Sirolimus DCB
45814672|NCT05450042|Device|Paclitaxel DCB|Paclitaxel DCB
45814673|NCT02230410|Device|CryoBalloon Focal Ablation|
45814674|NCT05447936|Dietary Supplement|Jarlsberg cheese|Jarlsberg cheese is a regular cheese for free sale in grocery stores. The allotted amount of cheese was taken orally each day
45814675|NCT04739384|Drug|Ticagrelor 90mg|Ticagrelor 90 mg followed by Ticagrelor 60 mg
45814676|NCT04739384|Drug|Ticagrelor 60 mg|Ticagrelor 60 mg followed by Ticagrelor 90 mg
45814677|NCT05450575|Drug|Amosartan Q tablet|Amlodipine, Losartan, Rosuvastatin
45814678|NCT04704596|Device|anesthesia ventilator machine|dynamic lung compliance measurements will be used for detection of the optimum PEEP after alveolar recruitment
45814679|NCT04704596|Device|lung ultrasound|lung ultrasound views will be used for detection of the optimum PEEP after alveolar recruitment
45814680|NCT05450497|Drug|Propofol|comparing sedative agents
45814681|NCT05450497|Drug|Dexmedetomidine|comparing sedative agents
45814682|NCT05450497|Drug|Dexmedetomidine and propofol|comparing sedative agents
45814683|NCT02230332|Drug|Alendronate|
45660616|NCT04333511|Device|Sham-TPS (NEUROLITH)|6 treatments of Sham-TPS over 2 weeks
45660617|NCT04324619|Other|Online interactive learning activities|"3-hour video-storyline-based interactive learning program~Micro-learning activities that can be completed on mobile devices (eg, smartphones)"
45814684|NCT02230332|Drug|Placebo|
46077822|NCT00631241|Procedure|Single Photon Emission Computed Tomography|First 3 Patients = Performed 30-45 minutes, 2-3 hours, and 20-24 hours after injections of the radioactive material or just before surgery; Remaining 17 Patients = Performed only one at a time as was found to be best based on the scans from first 3 patients.
45814685|NCT05447858|Other|SWEA|Managers with one or several l staff experiencing WRNP will be educated in the Prehab guide. The manager should read and listen to all modules and a 1-h lecture recorded by the research team before participating in two workshops (4 h each), together with other managers and an experienced expert in work environmental health and rehabilitation. In the workshops, different themes will be discussed, such as physical, psychological, and organisational work-related health, prevention, and rehabilitation, how to lead problem-solving dialogue, how work-related adaptations can be performed related to WRNP, and questions about the Prehab guide. The Prehab guide will be used to deliver managerial support in the work with the Swedish Work Environment Authority's regulations regarding SWEA and the prevention of ill health, sick leave, and accidents, work adaptations, and workplace-oriented rehabilitation.
45454077|NCT00445198|Drug|ABT-263|"Phase 1 dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.~- 50 patients with SCLC and non-hematologic malignancies. Enrollment is closed in this arm of the study.~Phase 2a dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.~- 40 patients with SCLC"
45953419|NCT04515238|Biological|Obinutuzumab|"Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v."
45660618|NCT04274465|Diagnostic Test|digital PCR (dPCR) assay|It is a highly sensitive and specific droplet digital PCR assay for absolute quantification of circulating tumor HPV DNA for the most prevalent HPV types that will determine if a woman has cHPVDNA
45660619|NCT04231799|Procedure|Bathing|Traditionally, it is the process of washing the newborn in the first hours of life to remove blood, meconium, varnish and other infectious substances.
45660620|NCT05508659|Drug|Duvelisib|Duvelisib PR2D bid po. until progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial.
45660621|NCT05508659|Drug|SG001|240mg, each two weeks,iv,until progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial.
46077823|NCT00631241|Procedure|Intraoperative Lymphatic Mapping|Isosulfan Blue and India ink will be injected into the cervix to help the surgeon identify the sentinel nodes by their blue color and their level of radioactivity.
46077824|NCT00781911|Biological|Cixutumumab|Participants will receive cixutumumab IV 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
45660622|NCT05508581|Procedure|microwaves ablation of varicose veins|"Microwave ablation is an endovenous treatment. This is a similar treatment approach as laser ablation and radiofrequency ablation. Endovenous means that the treatment device is inside the vein during treatment."
45660623|NCT05500157|Procedure|aspiration sclerotherapy versus laparoscopic fenestration|See arm description
45660624|NCT05499923|Device|Debonding|Debonding of orthodontic brackets with wing or base method with a conventional debonding plier
45660625|NCT05508425|Diagnostic Test|oral glucose tolerance test using water at room temperature|The use of water at room temperature to solve the 75g glucose.
45660626|NCT05508425|Diagnostic Test|oral glucose tolerance test using hot water|The use of hot water to solve the 75g glucose.
45660627|NCT05508425|Diagnostic Test|oral glucose tolerance test using cold water|The use of cold water to solve the 75g glucose.
45660628|NCT05508425|Diagnostic Test|oral glucose tolerance test using hot water with tea bag|The use of hot water with tea bag to solve the 75g glucose.
45660629|NCT05508425|Diagnostic Test|oral glucose tolerance test using room temperature water with tea bag|The use of room temperature water with tea bag to solve the 75g glucose.
45660630|NCT05508425|Diagnostic Test|oral glucose tolerance test using cold water with tea bag|The use of cold water with tea bag to solve the 75g glucose.
45660631|NCT05508425|Diagnostic Test|Oral glucose tolerance test using bubble water at room temperature|The use of bubble water at room temperature to solve the 75g glucose.
45660632|NCT05508425|Diagnostic Test|Oral glucose tolerance test using bubble water|The use of cold bubble water to solve the 75g glucose.
45814686|NCT05447858|Other|Neck-specific exercise|NSEs will be performed based on a well-structured framework of evidence-based exercises for facilitation of deep neck muscles, improved interaction between the different muscle layers of the neck, increased neck muscle endurance, and improved postural control .
45953420|NCT04515238|Biological|Zanubrutinib|"Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 160mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 160mg p.o"
45953421|NCT04515238|Biological|Venetoclax|"Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o."
45953422|NCT00142961|Drug|Atomoxetine|atomoxetine
45953423|NCT00142961|Other|placebo|
45953424|NCT00506428|Behavioral|chronic sleep restriction|5.6 hours of sleep per 24 hours for 3 weeks
46077825|NCT00781911|Drug|depot octreotide|Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
45953425|NCT00506467|Procedure|Vibration Response Imaging|Lung function test performed using the VRI system immediately before or after the standard lung function test.
46077826|NCT00605917|Drug|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501092, the duration of the investigation for findings regarding safety and efficacy of a panic disorder patient is from the first drug administration to the 16 weeks after the first administration."
46077827|NCT04609410|Procedure|Neuromuscular blockade|Neuromuscular blockade will be achieved via rocuronium intravenous administration and level will be monitored with train of four/post tetanic count monitoring
45454078|NCT00443326|Drug|AMG 714|Dosing Regimen is 6 Doses over 3 Months
45660633|NCT05508347|Drug|Nituzumab/placebo|"Test group: 3 cycles of induction chemotherapy combined with 9 times of nituzumab targeted therapy followed by 2-3 cycles of synchronous radiotherapy and chemotherapy combined with 7 times of nituzumab targeted therapy, a total of 16 times of nituzumab targeted therapy, equivalent to the whole course targeted therapy.~Control group: 3 cycles of induction chemotherapy combined with 9 times of placebo treatment followed by 2-3 cycles of concurrent chemoradiotherapy combined with 7 times of nituzumab targeted therapy, a total of 7 times of nituzumab targeted therapy, only targeted therapy during concurrent chemoradiotherapy"
45660634|NCT04280471|Drug|Fecal Microbiota Transplantation Capsule|Receive OpenBiome FMT Capsule DE PO
45814687|NCT04934995|Other|Blood Pressure Cuff|"After obtaining consent and confirming eligibility, Blood Pressure cuffs will be used as specified below:~Cuff size: large BP cuffs will be the default size for both arm and ankle measurements, but can be changed as clinically indicated based on circumferences of limbs Cuff location: BP cuffs will be placed on the contralateral arm to the main peripheral IV following standard procedures. Left ankle cuff will be placed underneath intermittent pneumatic compression cuffs Ankle blood pressure monitor screen will be covered. Thus, anesthesia providers will not be able to make any clinical decisions based on ankle blood pressures but arm blood pressure (standard) instead."
45953426|NCT04513288|Dietary Supplement|Experimental treatment L-citrulline (Protéocit®)|Enteral administration of citrulline for 5 days.
45814688|NCT04928989|Other|convergence dialogue meeting|Digital counceling with convergence dialogue tripartite meeting. will be conducted in accordance with work dialogue for return to work. Workplace dialogue among employee with neck problems, an expert in the work environment, and the immediate manager. The purpose of the conversations is, in open dialogue, to reach a common understanding of the situation and identify possible interventions to maintain or improve the employee´s work ability.
45953427|NCT04513288|Other|Placebo treatment|Enteral administration of iso-nitrogenous placebo for 5 days.
45814689|NCT02230254|Device|Percutaneous coronary intervention PROMUS PREMIER|PROMUS PREMIER
45953428|NCT00163254|Drug|abciximab|
45953429|NCT00163254|Device|stent and drug eluting stent|
45454079|NCT00345748|Drug|Abatacept|Injection, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
45814690|NCT04927819|Device|BTI Implant|BTI Dental implants are non-active medical device, single use, non resterilizable, biocompatible and sterile devices made of alloplastic materials (Titanium) intended to be surgically implanted into alveolar and/or basal bone of the mandible or maxilla to provide support and a means of retention for a dental prosthesis (e.g. bridge, single-tooth, overdenture).
45454080|NCT00345748|Drug|Placebo|Injectio, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
45454081|NCT00439738|Drug|HCTZ + Amlodipine|"12.5 mg HCTZ capsules~25 mg HCTZ capsules~5 mg amlodipine capsules~10 mg amlodipine capsules"
45660635|NCT05499845|Diagnostic Test|butanol threshold test and smell identification tests|no additional intervention
45660636|NCT04476953|Drug|Placebo|Placebo looks exactly like the study drug, but it contains no active ingredient.
45660637|NCT04476953|Drug|Fisetin|~20 mg/kg/day oral, NG or D tube course for 2 consecutive days
45660638|NCT05508113|Other|ozone autohemotherapy|After autologous blood is mixed with ozone in vitro, the blood is injected into the patient through intravenous infusion
45660639|NCT05499533|Procedure|implant site preparation|a hole were created in the edentulous ridge area before implant placement
45676591|NCT01697566|Drug|Metformin|"Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg."
45814691|NCT05447546|Drug|HT-6184|Oral capsule
45814692|NCT05447546|Drug|HT-6184 Placebo|Oral capsule
45814693|NCT04616287|Other|Neuropsychological assessment and Multimodal brain MRI|Neuropsychological assessment and Multimodal brain MRI
45953430|NCT04512937|Device|Computer-assisted navigation surgery|Computer navigation-assisted surgery has two main elements; the pre-procedural planning to create accurate 3D images of the pelvis allowing the surgical team to achieve an accurate perception of the operative field, and intraoperative navigation where these images are used for anatomical guidance to enhance surgical precision. Accordingly, computer software is used in this study to outline the tumour and other pelvic organs on pre-operative images which are subsequently used for intraoperative navigation.
45953431|NCT00143000|Drug|Peginterferon alfa-2a 40KD and Ribavirin|
45953432|NCT04517578|Other|Survey|Participants will be asked to fill in an online survey that will be anonimized.
45953433|NCT04514029|Drug|Simvastatin|Simvastatin 40 mg started 2 weeks (+/-5 days) prior to apheresis through day +30
45953434|NCT04514029|Drug|Dexamethasone|Intrathecal dexamethasone 8 mg on days -1, +6, +13 (+/-2 days)
45953435|NCT00143039|Procedure|Tandem MS test for inborn errors of metabolism|Tandem MS spectrometry test will be done on all maternal blood, amniotic fluid and newborn blood samples for both groups.
45454082|NCT00439738|Drug|Valsartan/HCTZ|"160 mg film-coated valsartan tablets~320 mg film-coated valsartan tablets~12.5 mg HCTZ capsules~25 mg HCTZ capsules"
45454083|NCT00435916|Drug|SGN-40|1-8 mg/kg IV (in the vein) on Days 1, 4, 8, 15, 22 and 29 of Cycle 1; 8 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 for Cycles 2-12.
45660640|NCT05508035|Drug|Sacubitril / Valsartan|The participants will be randomized to either ramipril 5 mg twice daily plus placebo for sacubitril / valsartan 200 mg twice daily or sacubitril / valsartan 200 mg twice daily plus placebo for ramipril 5 mg twice daily in 1: 1 ratio using the IT randomization module. All patients eligible for randomization will receive their first dose of double-blind drug plus placebo the day after randomization visit. After assigning a randomized treatment, patients will continue at the target dose and attend a 2-week telephone follow-up followed by site visits after one month, four months, eight months and in the final visit after 12 months.
45660641|NCT05508035|Drug|Ramipril|The participants will be randomized to either ramipril 5 mg twice daily plus placebo for sacubitril / valsartan 200 mg twice daily or sacubitril / valsartan 200 mg twice daily plus placebo for ramipril 5 mg twice daily in 1: 1 ratio using the IT randomization module. All patients eligible for randomization will receive their first dose of double-blind drug plus placebo the day after randomization visit. After assigning a randomized treatment, patients will continue at the target dose and attend a 2-week telephone follow-up followed by site visits after one month, four months, eight months and in the final visit after 12 months.
45660642|NCT04411355|Dietary Supplement|control by dietitian|
45660643|NCT04411355|Other|Exercise programs|In line with the address information of the intervention patients, purpose/content of the study was discussed with the gyms of municipalities and patients were made to benefit from these facilities for free. For the patients preferring private gyms, it was ensured that discounts were made for the patients.
45660644|NCT04411355|Behavioral|control by psychiatrist|The psychiatrist assessed the suitability of the patients to the study, assessed the patients having adaptation problems with respect to lifestyle changes in monthly controls and also played roles in teaching the coping methods to patients and applying and interpreting the hospital anxiety and depression scale.
45660645|NCT04390139|Drug|XCEL-UMC-BETA|Administration on top of the standard administered treatment
45660646|NCT04390139|Other|Placebo|Administration on top of the standard administered treatment
45814694|NCT05447468|Other|Strength of lower trapezius|Ask the patient to raise arm above the head with upper extremity in line with lower trapezius muscle fibers in prone position with the shoulder joint at 135 degrees. The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks.
45814695|NCT05447468|Other|Strength of middle trapezius|Shoulder external rotation with the shoulder abducted 90ₒ and elbow flexed 90ₒ in prone position with elbow supported on the table. The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks.
45814696|NCT05447468|Other|Strength of serratus anterior|"Ask the patient to raise the arm on a wall in the plane of the scapula in standing position.~The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks."
45814697|NCT05447468|Other|Pulsed ultrasound|With a 20% duty cycle, frequency of 1 MHz and intensity of 1.5 w/cm² for 5 minutes 3 times per week for 6 weeks.
45814698|NCT05447468|Other|Stretching of extensor carpi radialis brevis muscle|Put the elbow in extension, forearm in pronation and wrist in flexion with ulnar deviation. Hold for 30s and repeat 3 times with 30s rest in between. Three times per week for 6 weeks.
45814699|NCT05447468|Other|Eccentric exercises of wrist extensors|Ask the patient to extend elbow, pronate forearm, extend wrist and then flex the wrist slowly until full flexion is achieved. Patients should apply 3 sets of 10 repetitions 3 times per week for 6 weeks.
45814700|NCT04587739|Combination Product|Surgery with Neoadjuvant stereotactic body radiation therapy|Stereotactic hypofractionated robotic radiation therapy (24-45 Gy / 3 fractions) followed after 4-6 weeks by conventional hepatectomy (either anatomical liver resection, or non-anatomical liver resection with intention to achieve a minimal 2 cm margin).
45814701|NCT05449652|Other|To prescribe exercise prescription for CVD patients|To prescribe exercise intensity, frequency, session duration, program duration, and exercise type (endurance or strength training) for the same three patient cases
45814702|NCT05449574|Diagnostic Test|Scale for the Assessment of Sensory Integration in Adults|In people with MS and people with health of similar age, a test was performed to assess sensory integration in adults
45814703|NCT04579159|Device|Preventicus heartbeat app in combination with wearables|CE certified devices
45814704|NCT05447390|Diagnostic Test|Handgrip strength test|The Jamar Hydraulic Hand Dynamometer device is used for measuring the handgrip strength test
45814705|NCT04577287|Device|Transcranial direct current stimulation|Cathodal/Anodal tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
45814706|NCT04903015|Diagnostic Test|MRI|"The following sequences of the MRI will be acquired during the inclusion visit:~3D T1 gradient echo (GRE): anatomy; registration; cerebral, white matter, and grey matter volumetry; and cortical thickness;~multiecho 3D T2 GRE: quantitative susceptibility mapping (QSM), iron overload quantification;~continuous arterial spin labeling (ASL) 3D: cerebral perfusion;~resting-state fMRI: functional connectivity;~64-direction DTI (b=1000 and 2500): alterations in white matter and its microstructure, anatomic connectivity;~monovoxel spectroscopy of the mesencephalus with short echo time (TE)."
45953436|NCT04519177|Behavioral|Sleep Health Education Program (SHEP)|Sleep Health Education Program (SHEP) including screening for common sleep disorders
45953437|NCT04515433|Device|Gamma tACS (40 Hz) over the superior parietal cortex|Single session of gamma tACS (40 Hz) over the superior parietal cortex
45660647|NCT04381637|Device|NIPE monitor|NIPE monitor connected to the anesthetic station. No part of the device in contact with the patient. No action on patient or anesthesia. Automatic recording of Heart rate and NIPE index during the study period.
45660648|NCT04381637|Procedure|Tetanic stimulations|"Three tetanic stimulations will be performed (10-30 and 60 milliamps) under general anesthesia, before surgical incision.~Stims performed via the muscle relaxation monitor (used in standard practice in this population) Each stim lasts for 5 seconds. Interval between two stims : 3-5 minutes Order on intensities randomized by a latin square of order 3."
45814707|NCT05449184|Procedure|Balloon Eustachian Tuboplasty with Tympanostomy Tube Insertion|Under local or general anesthesia, insert a balloon into one Eaustachian tube and inflate it for up to two minutes. The balloon is then removed. Subsequently, pierce the tympanic membrane in the front and lower quadrants, suck the tympanic effusion, and then insert a tympanic ventilation tube. The tube will be removed 6 months later.
45814708|NCT05449184|Procedure|Tympanostomy Tube Insertion|Under local or general anesthesia, pierce the tympanic membrane in the front and lower quadrants, suck the tympanic effusion, and then insert a tympanic ventilation tube. The tube will be removed 6 months later.
45814709|NCT04569175|Other|3D Flair sequence|Optimized 3D FLAIR sequence before and 4 hours after the usual care MRI (with contrast product). All patients will have the same intervention as each patient is its own control
45814710|NCT04338542|Genetic|Tumor biobsies analysis|Analysis on archived tumor biopsies
45814711|NCT05449951|Other|Dry needling|In dry needling filiform needle without a bore is used to mimic acupuncture t beyond the use of medicines. On the basis of purpose process and skill level it differs from acupuncture. DN is frequently used to treat pain caused by musculoskeletal structures, including as myofascial pain disorders
45814712|NCT05449951|Other|sustained stretching|sustained stretching is a treatment protocol in which muscle goes into a stretch position for period of time which reduce spasticity
45814713|NCT02198664|Biological|AR101 - Peanut protein capsule|Study product provided as peanut protein in pull-apart capsules at 5 dosage strengths (0.5, 1, 10, 100, and 475 mg) or sachets at 2 dosage strengths (300 and 1000 mg)
45814714|NCT05449028|Drug|H. pylori eradication scheme A|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 8/8h, for 14 days
45814715|NCT05449028|Drug|H. pylori eradication scheme B|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h, for 14 days
45814716|NCT05449028|Drug|H. pylori eradication scheme C|Esomeprazole 40mg bid + bismuth subsalicylate 420mg 6/6h + metronidazole 375mg 6/6h + tetracycline 375mg 6/6h, for 10 days
45814717|NCT05449028|Drug|H. pylori eradication scheme D|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
45814718|NCT05449028|Drug|H. pylori eradication scheme E|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
45814719|NCT04543825|Device|Cardiopulmonary exercise testing|Subjects will perform cardiopulmonary exercise testing which consists of biking on a cycle ergometer (recumbant stationary bicycle) while breathing through a mouthpiece or mask to measure the oxygen and carbon dioxide in the subject's breath.
45814720|NCT04338841|Other|HOME-CoV rule implementation|"HOME-CoV rule is an easy-to-use clinical rule aiming to help emergency physicians in hospitalisation or outpatient management decision making. The definition of the rule is performed using the Delphi method to reach a consensus of a large panel of experts.~Between before and after period, educational lectures, posters, and pocket cards showing and explaining HOME-CoV rule are communicated to participating Emergency Departments."
45814721|NCT04538287|Device|AtaCor StealthTrac Lead|Subjects are assigned non-randomly to receive one of the four AtaCor StealthTrac leads being evaluated in the study.
45814722|NCT04338464|Behavioral|Psychosocial therapy for South Asian women experiencing mood disorders|"The 12 week intervention has four major components:~Relational theory (Belgrave, 2002) & South Asian identity development (Inman et al., 2001). These foundational components focus on strengthening cultural identity through the exploration of values, navigation and reconciliation of two cultures.~Transdiagnostic treatment of mood disorders (Ehrenreich-May et al., 2017). This component will focus on skill building in the areas of emotion awareness, resilience, adaptability, self-compassion and healthy coping strategies (Farchione et al., 2012; Bilek & Ehrenriech-May, 2012; Ritschel, Noriel & Lindsay, 2015).~Psychoeducation on mental health, sexual health, and substance use.~Peer support is a critical component of the intervention and will be provided by the peer researcher on the team. Participants will have access to optional individual peer support for 30 minutes to one hour per week for the duration of the intervention, this can be in person or telephone support."
45814723|NCT04495699|Other|None - observational|If the patient elects to have their stone treated, it will be treated in the usual most clinically appropriate fashion (Shockwave lithotripsy, ureteroscopy, or percutaneous nephrolithotomy). All types of treatment will be analyzed together.
45814724|NCT05448794|Other|injection|ultrasound-guided hydrodilatation with hypertonic Dextrose
45953438|NCT04514575|Biological|Plasma transfusion|Transfusion of allogeneic fresh frozen plasma or cryoprecipitate
45660649|NCT02566889|Drug|Infliximab|Participants in the dose escalation group will escalate dose from infliximab 5 mg/kg q8w to 10 mg/kg q8w at the time of loss response. Participants in the reference group will be maintained on infliximab 5 mg/kg q8w.
45660650|NCT05564585|Other|Kinesio Taping|Kinesio tape was applied over the calf muscle of either leg.
45660651|NCT05564585|Other|Sham Taping|The sham tape was applied over the calf muscle of either leg.
45676592|NCT01697566|Other|Placebo|Placebo taken by mouth twice daily for 4, 30 day cycles.
45676593|NCT01697566|Procedure|Endometrial Biopsy|Endometrial biopsies obtained at baseline and after 4 months.
45676594|NCT01697566|Behavioral|Lifestyle Intervention|Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
45953439|NCT04510909|Other|COMMIT mHealth application|The investigators will develop Community-based mHealth Motivational Interviewing Tool (COMMIT) using iterative design and testing with frequent, structured input from the key stakeholders: community health workers (CHWs), their supervisors and adult depression patients.The tool will be used by community CHWs in Dolakha, Nepal to: 1) obtain decision-support to deliver motivational interviewing (MI) for patients in their communities, and 2) capture consented audio recordings of client interactions for review and feedback by their supervisors, allowing CHWs to maintain MI skills beyond the initial training period.
45953440|NCT00404612|Drug|Placebo|PO BID
45953441|NCT00404612|Drug|LX211|0.2 mg/kg, twice a day (BID)
45953442|NCT00404612|Drug|LX211|0.4 mg/kg, twice a day (BID)
45953443|NCT00404612|Drug|LX211|0.6 mg/kg, twice a day (BID)
45953444|NCT04510441|Other|Nil intervention|Nil intervention; retrospective cohort study
45953445|NCT04513990|Procedure|Biospecimen Collection|Undergo collection of nasopharyngeal, oral, saliva, and nasal samples
45953446|NCT04513990|Other|Questionnaire Administration|Demographic information, sample collection type preferences; clinical outcome information
45953447|NCT02955199|Behavioral|Mothering From the Inside Out (MIO)|Mothering from the Inside Out (MIO) is a 12 session individual parenting therapy designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. MIO aims to promote their capacity for parental reflective functioning (the capacity to recognize and make sense of their own and their child's difficult emotions during challenging parenting situations).
45953448|NCT02955199|Behavioral|Parent Education|Parent Education (PE) is a 12 session individual parent counseling intervention designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. PE provides psycho-education about child development and parenting strategies typically available at community agencies on parenting. PE is designed to control for active treatment, treatment dose, and individualized intervention approach.
45953449|NCT00404690|Procedure|Bedside Silo|silo placed at bedside on admission
45953450|NCT00404690|Procedure|Operative attempt at closure|go the operating room to attempt closure
45953451|NCT02955004|Procedure|Electrical cardioversion|Transthoracic direct current electrical cardioversion
45953452|NCT02594917|Procedure|Right Heart Catheterization|Some participants (i.e., those that are willing and able) will undergo a Right Heart Catheterization to check Cardiopulmonary function.
45953453|NCT02594917|Other|Blood draw|Test and control group will be asked to give 20 ml of blood samples
45953454|NCT02590393|Combination Product|E-cigarettes|Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks.
45676595|NCT01697566|Behavioral|Questionnaires|Completion of questionnaires about diet and exercise at baseline, during treatment and at end of study. Questionnaires take about 30-40 minutes to complete.
45814725|NCT05448638|Procedure|the combination of transversus thoracic muscle plane and pectoral nerves blocks|For the pectoral nerves block, 0.375% ropivacaine , 10ml was injected between the pectoralis major and pectoralis minor and 20 ml above the serratus anterior muscle. For the transversus thoracic muscle plane block, ropivacaine 0.375%,15ml was injected between the transversus thoracic muscle and the internal intercostal muscle.
45953455|NCT02591563|Other|procedures|Nasopharyngeal swab, nasopharyngeal wash, tympanocentesis (if acute otitis media occurs), venipuncture
45953456|NCT00506506|Drug|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily x 48 hours
45953457|NCT00506506|Drug|Placebo|
45953458|NCT02597803|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
45953459|NCT02597803|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
45953460|NCT02594254|Drug|C16G2 Gel|Antimicrobial peptide
45676596|NCT03193190|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.
45676597|NCT03193190|Drug|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
45676598|NCT03193190|Drug|Oxaliplatin|Oxaliplatin will be administered as per the schedule specified in the respective arm.
45814726|NCT05448638|Procedure|the pectoral nerves block only|For the pectoral nerves block, 0.375% ropivacaine , 10ml was injected between the pectoralis major and pectoralis minor and 20 ml above the serratus anterior muscle.
45953461|NCT02594254|Other|Placebo|Placebo
45953462|NCT00143117|Drug|UK-390,957|
45953463|NCT00163332|Drug|Ciclesonide|
45953464|NCT00163371|Drug|Ciclesonide|
45953465|NCT00143156|Drug|pregabalin|
45953466|NCT00163410|Drug|Ciclesonide|
45953467|NCT00143195|Drug|Amlodipine|
45676599|NCT03193190|Drug|Leucovorin|Leucovorin will be administered as per the schedule specified in the respective arm.
45814727|NCT04845685|Device|Continuous Glucose Monitor (CGM)|A device that measures blood sugar levels every 1-5 minutes
45953468|NCT00143195|Drug|iso- 5 - mononitrate|
45953469|NCT00143195|Procedure|Blood tests|
45953470|NCT00143195|Procedure|Exercise Stress Test|
45953471|NCT00163449|Drug|Ciclesonide|Efficacy and Safety of Ciclesonide
45953472|NCT00163449|Drug|Placebo|Placebo
45953473|NCT00143234|Drug|Amlodipine/atorvastatin single pill|
45953474|NCT00163488|Drug|Ciclesonide|
45953475|NCT00143273|Drug|lasofoxifene|0.05 mg tablets
45953476|NCT00143273|Drug|Placebo|0 mg
45953477|NCT00143273|Drug|Lasofoxifene|0.25 mg tablets
45953478|NCT00143273|Drug|Lasofoxifene|0.5 mg tablets
45953479|NCT00163527|Drug|Roflumilast|
45953480|NCT00143351|Drug|Ziprasidone|
45953481|NCT00163605|Device|Macroporous Biphasic Calcium Phosphate-Fibrin Sealant Vapor Heated Solvent/Detergent Treated 4 IU/ML Thrombin (MBCP-FS)|
45953482|NCT02598583|Biological|ALXN1210|Participants were administered ravulizumab as an IV infusion every 4 weeks.
45953483|NCT00143429|Drug|Xalatan|
45953484|NCT00163644|Procedure|aereobic plus resisted exercise|
45953485|NCT00163644|Procedure|aerobic plus active exercise|
45953486|NCT00163644|Other|No formal exercise plus phone calls|
45953487|NCT02598895|Drug|Carboplatin|Given IV
45953488|NCT02598895|Drug|Docetaxel|Given IV
45454084|NCT03134170|Other|Pharmacist review of therapy|Patients who are randomized to the pharmacist group will have their treatment reviewed by a pharmacist
45814728|NCT05446922|Other|Diffusion MRI|All procedures will be performed during a single visit. Subjects will be invited to lie on the scanning bed that will be moved head first into the scanner such as the head lie under the scanner magnets. Hearing protection will be provided to each subject to muffle the noise produced by the MRI scanner. Subjects will also be provided with pillows and blankets to keep them comfortable. They will also be given a call button that they can push to stop the procedure at any time. MRI acquisition will be performed on 1.5T or 3.0T MRI scanners depending on centre's equipment. Acquisition protocol will include the following sequences with the best parameters chosen by local radiologist and technical BrainTale team.
45814729|NCT04845139|Drug|Nivolumab|Nivolumab given intraventricularly
45814730|NCT05446844|Other|A nurse caring behavior protocol|"Nursing interventions based on caring behaviors protocol was provided as follows:~Caring behaviors during ICU admission and orientation processes included orienting patients to time, place, and person.~Caring behaviors during physical care informing patients regarding the purpose and expected duration of mechanical ventilator use.~Caring behaviors during psychological care included offering religious sound meditation.~Caring behaviors during social interaction included maintaining eye contact during nurse-patient interaction.~Caring behaviors during health teaching included providing health teaching for patients.~Caring behaviors during maintaining a safe healing environment included providing patients with an explanation regarding nursing activities."
45814731|NCT05446844|Other|Routine nursing care|Routine nursing care was concentrated mainly on hard skills of physically demanding care such as monitoring vital signs.
45814732|NCT04738669|Other|mHealth|The mHealth intervention includes telephonic call and SMS.
45814733|NCT04738669|Behavioral|Teach-back|While the teach-back includes counselling session related to discharge instruction including medication adherence.
45814734|NCT05446688|Drug|6MW3211|6MW3211 injection, 45mg/kg, Q2W
45814735|NCT04563806|Device|Magnetic Resonance Imaging|Undergo MRI-guided surgery
45814736|NCT04563806|Procedure|Therapeutic Conventional Surgery|Undergo spinal surgery
45814737|NCT04738526|Other|lithium disilicate (IPS e-max) ceramic crown|monolithic lithium disilicate ceramic crown
45814738|NCT04738526|Other|New gradient technology zirconia (5Y-TZP\ 3Y-TZP) IPS e.max ZirCad Prime ceramic crown|conjunction with the two zirconium oxide raw materials 3Y-TZP and 5Y-TZP is responsible for producing a continuous, seamless progression of the shade and translucency within the material
45814739|NCT04738526|Other|natural tooth|natural tooth is composed of enamel. Enamel is on the surface of every tooth and it has a natural hue of white. However, the underlying dentin layer has a slightly yellowish color. This yellowish hue shows through the enamel in almost everyone
45814740|NCT05446376|Drug|68Ga-citrate PET/CT|PET/CT Imaging with 68Ga-citrate PET/CT injection
45814741|NCT04488055|Behavioral|Crisis Line Facilitation (CLF)|CLF is a motivational interviewing-based intervention
45814742|NCT04488055|Behavioral|Enhanced Usual Care (EUC)|In addition to receiving the brochure, EUC condition participants will meet with a therapist (in-person or remotely) for approximately 15 minutes for a descriptive overview of the brochure.
45814743|NCT05449483|Drug|tislelizumab+ Paclitaxel + Cisplatin|tislelizumab combined with chemotherapy
45814744|NCT05448482|Procedure|Transobturator tape|Mid urethral sling for treatment of female stress urinary incontinence
45814745|NCT05448404|Drug|18F-PSMA-1007|Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-PSMA-1007.
45814746|NCT05448404|Drug|18F-FDG|Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-FDG.
45814747|NCT05449093|Other|Periodontal clinical measurements and gingival crevicular fluid sampling|"Periodontal clinical meaurements including the probing depth, clinical attachment loss, the dichotomous recording (present/absent) of bleeding on probing, gingival index, and the plaque index at six sites (distobuccal, buccal, mesiobuccal, distopalatinal/lingual, palatinal/lingual, mesiopalatinal/lingual) on all teeth, except third molars, were performed using manuel periodontal probe.~Standardized absorbent paper strips were used for gingival crevicular fluid sampling. A sterile paper strip was gently inserted into the gingival sulcus/periodontal pocket until mild resistance was felt and were kept in place for 30 seconds. The absorbed fluid volume was measured by a precalibrated electronic device."
45814748|NCT05448326|Other|Questionnaire to assess expectations of a diagnosis|Duration 45 minutes
45814749|NCT05448326|Other|Questionnaire to assess understanding of previously reported results and expectations of a diagnosis|Duration 30 minutes
45814750|NCT05448326|Biological|Blood sample +/- skin biopsy|8 ml of blood biopsy: size 3 to 5 mm
45814751|NCT04338308|Device|new-DES|with ot without embolic protection device
45953489|NCT02598895|Other|Laboratory Biomarker Analysis|Correlative studies
45953490|NCT05147272|Drug|RP-6306 (oral PKMYT1 inhibitor)|RP-6306 in combination with gemcitabine
45953491|NCT00143468|Behavioral|mechanical ventilation|measurement of specific lung elastance during mechanical ventilation
45660652|NCT05564507|Diagnostic Test|TEE simulation-based training|"All participants of the TEE simulation-based training group received:~a traditional didactic training using e-learning with a national free-access online course;~two teaching sessions using a TEE simulator for 2 hours per session. The simulation session will involve standardized initial teaching of normal cardiac, including anatomy of mitral valve with some mitral regurgitation cases, aortic valve, tricuspid valve, interatrial septum, and left atrial appendage, and demonstration of image acquisition by the teacher (time duration: 30 min). The duration of each session was 2 h with a 6:1 student to instructor ratio. Each subject had a dedicated 20 min of hands-on to manipulate the probe and undertake a sequential TEE examination under the supervision of the teacher. Other participants could watch their colleagues working on the TEE simulator."
45676600|NCT03193190|Drug|Fluorouracil|Fluorouracil will be administered as per the schedule specified in the respective arm.
45676601|NCT03193190|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
45814752|NCT04338308|Device|BMS|with ot without embolic protection device
45953492|NCT00163683|Behavioral|Dietary Therapy|
45454085|NCT00524056|Drug|Carisbamate|two 100 mg tablets twice per day
45454086|NCT00524056|Drug|Placebo|two placebo tablets twice per day
45953493|NCT05144932|Device|Stroke Alarm|The patients are in this clinical trial instructed to use the device continuously for 1 month.
45660653|NCT03787589|Behavioral|Exercise Prescription|"Participants in the intervention group will be given an exercise prescription to increase their baseline steps by 1200 and 2000 steps per day at least 3 days a week over the first 3 months. If tolerated and accepted, the participants will increase their step counts by an additional 600 to 1000 steps per day at least 3 days a week for the next 3 months.This will be followed by a 6-month maintenance phase. The research coordinator will instruct the participants on the proper use of the Nordic walking poles which can be used to help participants achieve their prescribed number of steps.~All participants will be encouraged to wear the pedometer throughout the trial in order to follow the step-count prescription and monitor adherence."
45814753|NCT04438759|Device|Oncomfort, commercially available Virtual Reality headset|Virtual Reality headset, consisting of headphones with smartphone glasses - see oncomfort.com/en, CE approval conform 93/42/EEC and 2007/47/EEC
45814754|NCT05448170|Drug|Linerixibat|open label investigational product
45814755|NCT04793659|Drug|Oral Fasudil 90 mg/day|Oral tablet
45814756|NCT04793659|Drug|Oral Fasudil 180 mg/day|Oral tablet
45814757|NCT04793659|Drug|Oral Placebo|Oral tablet
45814758|NCT05448937|Procedure|Lesion sterilization and tissue repair|Pulp therapy for necrotic primary molars
45814759|NCT05448937|Procedure|zinc oxide and eugenol pulpectomy|Pulp therapy for necrotic primary molars
45814760|NCT00370201|Drug|colchicine|
45814761|NCT00422552|Drug|Indacaterol (QAB149)|
45814762|NCT00370279|Procedure|scleral buckling, primary vitrectomy|Four different surgical techniques were performed(one in each arm); 1- scleral buckling, 2- primary vitrectomy without encircling band, 3- primary vitrectomy with encircling band, 4- triamcinolone assisted vitrectomy
45814763|NCT03217058|Behavioral|Clinic-based screening and behavioral interventions|As part of routine HIV primary care visits, patients will complete self-administered computerized substance use, anxiety and depression screening measures. Results will be integrated into the electronic health record. A behavioral health specialist on the clinic staff will contact patients who screen positive for high-risk substance use, anxiety or depression, and offer behavioral interventions including motivational interviewing and cognitive behavioral therapy.
45814764|NCT05448859|Procedure|intracytoplasmic sperm injection|injection of sperm into an oocyte in assisted reproductive technology
45814765|NCT03203954|Behavioral|Standard Learning|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
45814766|NCT03203954|Behavioral|Guided Learning: Instructed statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
45814767|NCT03203954|Behavioral|Guided Learning: Changing statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
45814768|NCT05448781|Drug|Endostatin|Eligible patients with advanced NSCLC were treated with endostatin combined with Tirelizumab and platinum-containing two-drug chemotherapy.26 cases of non-squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Pemetrexed+Carboplatin. and 12 cases of squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Paclitaxel/Albumin paclitaxel+Carboplatin,The maintenance treatment phase was continuous treatment with Endu combined with Tirelizumab
45953494|NCT05148286|Drug|Treatment|For the treatment group, 200cc of 20% human albumin with 15 cc per kg of crystalloid will be administered over 1~2h for initial fluid resuscitation. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.
45953495|NCT05148286|Drug|Placebo|For the control group, 30 cc per kg of crystalloid will be administered according to the usual practice. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.
45953496|NCT00143546|Drug|Defibrotide|Defibrotide to be administered approximately every 6 hours at an initial dose of 6.25 mg/kg/dose. Subsequent doses will be escalated with a plateau of 15 mg/kg/dose (or 60 mg/kg/day total). For patients with persistent VOD, the dose may be escalated by 10 mg/kg/day as needed to a maximum of 110 mg/kg/day total.
45953497|NCT05147779|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
45953498|NCT00155883|Drug|Taxteral|
45953499|NCT00155883|Drug|5-Fluorouracil|
45953500|NCT00155883|Drug|Leucovorin|
45953501|NCT00506545|Drug|SCH 619734|SCH 619734 50-mg capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
45953502|NCT00506545|Drug|Placebo Dose 1|Matching placebo capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
45814769|NCT03187652|Diagnostic Test|CT Perfusion Study|Brain and cardiac CT perfusion scan
45814770|NCT03187652|Diagnostic Test|Echocardiogram|Speckle tracking Echocardiography
45814771|NCT03187652|Diagnostic Test|neuro-cognitive assessment|Cambridge Brain Sciences neuro-cognitive assessment
45814772|NCT03187652|Diagnostic Test|MRI|MRI to assess white matter changes
45814773|NCT05448625|Device|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
45814774|NCT03182426|Drug|Plerixafor|Systemic CD34+ stem cell mobilization for beta-cell repair
45814775|NCT03182426|Drug|Alemtuzumab|T-cell depletion
45814776|NCT03182426|Drug|Anakinra|Anti-inflammatory
45814777|NCT03182426|Drug|Etanercept|Anti-inflammatory
45814778|NCT03182426|Drug|Liraglutide|Beta-cell regeneration
45814779|NCT05448079|Other|Sexual counseling according to the PLISSIT model, randomized pretest-posttest|experimental and control ,a randomized pretest-posttest study to examine
46002730|NCT00547508|Drug|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
46002731|NCT00547508|Drug|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
46002732|NCT00560274|Drug|Pegasys|As prescribed
46002733|NCT00560274|Drug|Ribavirin|As prescribed
46002734|NCT00560274|Drug|epoetin beta [NeoRecormon]|30,000 IU sc/week (starting dose)
45814780|NCT03233347|Drug|Brentuximab Vedotin|Given IV
45814781|NCT03233347|Drug|Dacarbazine|Given IV
45814782|NCT03233347|Drug|Doxorubicin|Given IV
45814783|NCT03233347|Other|Laboratory Biomarker Analysis|Correlative studies
45814784|NCT03233347|Biological|Nivolumab|Given IV
45814785|NCT03233347|Drug|Vinblastine|Given IV
45814786|NCT04506008|Radiation|Hypofractionated Radiotherapy|Treated over the course of 1-2 weeks
45814787|NCT04502966|Biological|Dupixent®|An initial dose of 600 mg (two 300 mg injections), followed by 300 mg administered every other week (biweekly), by subcutaneous injection.
45814788|NCT04502966|Biological|Grazax®|"One Grazax® tablet daily, by sublingual administration.~Grazax® is formulated as a freeze-dried oral lyophilisate/orally disintegrating tablet for oromucosal use. The active pharmaceutical ingredient is a standardized allergen extract derived from extraction and purification of grass pollen from timothy grass (Phleum pratense). The biological activity of the allergen is expressed in Standardized Quality Tablet units (SQ-T) units. The Grazax® dosage is one oral lyophilisate (75,000 Standardized Quality Tablet units (SQ-T) or approximately 2800 Bioequivalent allergy units (BAU), a measure of Phleum pratense SQ total biological potency defined by the FDA."
45814789|NCT04502966|Drug|Dupixent® Placebo|"Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose followed by a single injection administered every other week.~Dupixent® placebo is a subcutaneous injection whose composition is identical to the active Dupixent®, with the exception of the active pharmaceutical ingredient."
45814790|NCT04502966|Drug|Grazax® Placebo|"One tablet of Placebo (for Grazax®) daily, by sublingual administration.~Grazax® placebo is a tablet whose composition is identical to the active Grazax® tablet with the only exception being exclusion of the active pharmaceutical ingredient, Phleum pratense Standardized Quality Tablet (SQ-T) units."
45814791|NCT03219697|Behavioral|Parenting education program|8-week parent/caregiver education program, followed by two booster sessions. You and/or your partner will attend weekly parenting sessions which will take place either at the office of your child's primary care provider or virtually. Our Toronto Public Health Nurse, will arrange 2 home visits/virtual visits with you and your family along with 4 coaching calls during the 6 months. This first home visit will include learning more about your routines at home, and what is available in your neighbourhood. The home visits will focus on helping to apply the messages and skills from the group sessions for your family, and making connections in your community that you find helpful such as recreational or nutrition programs or other supports for your family.
45814792|NCT03133208|Procedure|Blood draws|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72 (7 draws total). Each draw would be up to 20 mL of blood (but no less than 10 mL).
45814793|NCT05442788|Biological|HB0017 150mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
45814794|NCT05442788|Biological|HB0017 300mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
45814795|NCT05442788|Biological|HB0017 450mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
45814796|NCT03182101|Behavioral|Exposure Therapy|Exposure Therapy is a form of Cognitive Behavioral Therapy. There is strong evidence for exposure as a necessary and primary ingredient for treating anxiety and OCD, and exposure is the most common practice element in treatment protocols for anxiety.
45814797|NCT04498598|Device|A/Z Supraglottic airway|Patient receive supraglottic airway for general anesthesia which can be converted to endotracheal ventilation reversibly
45814798|NCT03134755|Drug|Inhaled corticosteroid (mometasone)|The investigators are not measuring the effect of the intervention (ICS), but rather the effect of stress (which is not being intervened on), and this is thus an observational study. The ICS is given to children with asthma in whom an ICS is clinically indicated
45814799|NCT05442164|Behavioral|DANAKIR support network|"The DANAKIR intervention will consist of:~Structured written discharge information~Invitation to the DANAKIR monthly information meeting DANAKIR meetings The monthly meetings are a core component of the support network. One time each month, a meeting will be held at Herlev Hospital with the participation of an emergency surgeon, an emergency surgery dedicated nurse, a dietician, and a physiotherapist. Each professional (surgeon, nurse, dietician, physiotherapist) will host an informative 15 minute session regarding the postoperative course after major emergency surgery. Following the presentations time for questions in plenum and private with the different experts will be held. Furthermore, there will be an opportunity for networking at the DANAKIR meeting. Each meeting is planned to last 2 hours. At the end of each meeting the patients will be asked to evaluate the meeting and content."
45814800|NCT03123835|Procedure|Endoscopic Intervention|After reviewing all therapeutic options the patient will be offered the best therapeutic option to treat their condition. Surgical interventions include open laparotomy, diagnostic/therapeutic laparoscopy or endoluminal therapies. After the patient is consented for the related surgical intervention the patient will be given the option to participate in the clinical study to measure outcomes after surgery.
45814801|NCT03036488|Biological|Pembrolizumab|On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion.
45953503|NCT02964143|Device|Cellular Matrix / A-CP HA|Treatment with 2 injections of Cellular Matrix / A-CP HA Kit, administered 2 months apart; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.
45454087|NCT00523042|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
45660654|NCT03713255|Procedure|PVB group|Patients in this group will receive preoperative ultrasound-guided thoracic paravertebral block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
45660655|NCT03713255|Procedure|MTP block group|Patients in this group will receive preoperative ultrasound-guided mid-point transverse process to pleura block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
45660656|NCT03713255|Procedure|Control Group|Patients in this group will receive preoperative ultrasound-guided sham block with subcutaneous local anesthetic injection using lidocaine 1%, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
45660657|NCT05564351|Other|eye mask and ear plug|black eye mask and silicon ear plug
45660658|NCT04283201|Other|Physical activity|Moderate activity 150 min per week
45660659|NCT04283201|Other|Macronutrient modification|Insoluble dietary fiber 15 g per day (Vitacel wheat fiber); sugar limitation
45660660|NCT03673553|Other|Multimodal treatment of patients with FM|The intervention group took part in 2.5-hour sessions of MRT once a week for 10 weeks. This intervention combined physical exercise with stretching. Health education was geared towards pain management, the pathology itself, healthy habits, insomnia, postural correction and ergonomics. The psychological approaches used in the MRT were problem-solving therapy, cognitive behavioural therapy and sophrology. Given the diversity of the sessions, they were directed by a rheumatologist, a nurse, a psychologist, and a physiotherapist. If the patient needed their pharmacological treatment to be altered, they were offered an appointment with the rheumatologist.
45660661|NCT03673553|Other|Association of people with fibromyalgia|The control group attended the activities organised by the association of people with FMS. These consisted of a weekly 1-hour session of group psychology and a weekly 2-hour session of handicrafts for 10 weeks.
45660662|NCT05507957|Diagnostic Test|direct reporting of time to positivity of blood culture to ICU to know its effect to patients managment|-Disinfection using povidone-iodine, alcohol preparation or chlorhexidine gluconate ethanol (CHG-ALC ), so that each type was used on 40 patients
45814802|NCT03036488|Drug|Carboplatin|On Day 1 of Cycles 1-4 of the neoadjuvant phase of the study OR on Days 1, 8, 15 of Cycles 1-4 of the neoadjuvant phase of the study; IV infusion.
45814803|NCT03036488|Drug|Paclitaxel|On Days 1, 8 and 15 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.
45814804|NCT03036488|Drug|Doxorubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
45814805|NCT03036488|Drug|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
45953504|NCT02964143|Device|Ostenil® Plus|Treatment with 2 injections of Ostenil® Plus, administered one week apart; Ostenil® Plus is a solution of sodium hyaluronate obtained by fermentation, containing 0.5% mannitol, a free radical scavenger, which helps to stabilize the chains of sodium hyaluronate. The product is intended to be used for pain and restricted mobility in degenerative and traumatic changes of the knee joint.
45953505|NCT02964143|Device|RegenKit-BCT-1|Treatment with 2 injections of RegenKit-BCT-1, administered 1 month apart; RegenKit-BCT-1 is designed for the safe, rapid and extemporaneous preparation of autologous platelet-rich plasma. RegenKit-BCT-1 is a single-use medical device including an hematology tube (Regen BCT tube), designed for blood collection and PRP preparation after 5 min centrifugation, and all necessary material for venipuncture and PRP injection. The Regen BCT tube contains a gel acting as a cell separator and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components.
45953506|NCT05147467|Drug|APG2575|APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.
45953507|NCT00143585|Procedure|intramyocardial delivery of either VEGF165 or placebo|
45660663|NCT04282109|Drug|Nivolumab + Paclitaxel|"Combination treatment: Nivolumab 240 mg will be administered via IV infusion every 2 weeks. Paclitaxel 80mg/m2 will be administered via IV infusion weekly. After 12 weeks from the start of the combined treatment paclitaxel will be stopped.~Maintenance treatment with nivolumab 480 mg every 4 weeks will start two weeks after the last administration of nivolumab 240 mg. Once nivolumab is administered at 480 mg, paclitaxel can no longer be administered.~Nivolumab will be continued alone until disease progression, unacceptable toxicity or withdrawal of consent up to a maximum of 24 months."
45660664|NCT04282109|Drug|Cetuximab + Paclitaxel|"Combination treatment: Cetuximab 250 mg/m2 (first dose of 400 mg/m2) administered via IV infusion weekly plus weekly paclitaxel (80 mg/m2) administered via IV infusion.~After 12 weeks from the start of the combined treatment paclitaxel will be stopped and weekly cetuximab will be continued alone until disease progression, unacceptable toxicity or withdrawal of consent up to a maximum of 24 months."
45676602|NCT03193190|Drug|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm.
45814806|NCT03036488|Drug|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.
45814807|NCT03036488|Drug|Placebo|normal saline solution or dextrose: On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; IV infusion
45814808|NCT03036488|Biological|Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim|For prevention of neutropenia, filgrastim 5 μg/kg/day via subcutaneous (SC) injection administered per standard of care after chemotherapy OR pegfilgastrim 100 µg/kg (individualized) or 6 mg (general approach) via SC injection administered per standard of care.
46077828|NCT04242056|Drug|18F-PM-PBB3|"18F-PM-PBB3 brain PET studies will be conducted for 38 subjects. Dynamic PET/MRI studies will be collected by PET/MRI scanner for 100 minutes (4×15 s, 8×30 s, 960 s, 2×180 s, 8300 s, 3×600 s). Volumes of interest (VOIs) will be delineated from corresponding MR images by manual including bilateral frontal, parietal, mesial temporal, lateral temporal, hippocampal, occipital, anterior cingulate, posterior cingulate, cerebellum areas, and genu region of white matter. The DVRs will be computed from Logan graphic analysis by using cerebellum as reference input.~SUVR of every cortical VOI to the gray matter of cerebellum will be calculated from nine 10-min dynamic image sets."
46077829|NCT05381129|Other|Detection of Pain, Quality of Life, Sleep and Functioning|All patients will be evaluated for allodynia, quality of life, headache-related disability, and sleep quality.
46077830|NCT05381129|Other|Temporomandibular joint dysfunction|Patients with jaw complaints will be evaluated for temporomandibular joint dysfunction.
46077831|NCT04919096|Drug|SCB-420|Subjects randomised to SCB-420 arm will receive a total of 3 doses of SCB-420 as an intravitreal injection of 2 mg into the study eye every 4 weeks on Day 1, Week 4, and Week 8.
45660665|NCT02566577|Biological|Fresh red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from fresh (<10 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
45660666|NCT02566577|Biological|Storage-aged red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from storage-aged (>21 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
45660667|NCT02566577|Device|Electronic infusion pump|A programmable, electronic infusion pump (Baxter, Inc) will be used for intravenous transfusion of units of packed red blood cells (RBC). The pump will be programmed to deliver 1 unit of packed RBC per hour.
45660668|NCT04377971|Behavioral|SOC education|Standard participant education from researcher
45676603|NCT03193190|Drug|PEGPH20|PEGPH20 will be administered as per the schedule specified in the respective arm.
45676604|NCT03193190|Drug|BL-8040|BL-8040 will be administered as per the schedule specified in the respective arm.
45814809|NCT04360213|Device|Advanced multimodal wireless vital signs monitor|Investigators have developed a lightweight, stretchable 'skin-like' membranes, called skin sensors. These small, paper-thin monitors were created by matching the mechanical properties of skin, and can be applied to the skin's surface without skin disturbance. Each patch is encapsulated using medical grade materials and applied using single use medical grade skin adhesive integrated with eco-fused fabric (moisture wicking layer between adhesives). The adhesive may be changed between uses, and the device itself can be cleaned with Super Sani-Cloth®, commonly used in the hospital setting.
45814810|NCT02958943|Behavioral|On-screen electronic alert|On-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation. Providers may then 1) access a template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence based clinical practice guidelines, or 3) proceed onto order entry after providing an explanation for why anticoagulation was not prescribed.
45814811|NCT04475822|Behavioral|Intermittent fasting|Intermittent fasting group:During the three-month intervention period, participants were allowed to eat for eight consecutive hours and fast for 16 hours a day.The eating time can be freely chosen in the following two periods: 8:00 -- 16:00;12:00 -- 20:00.No specific restriction shall be made on the type and quantity of food.
45814812|NCT04475822|Behavioral|Low carb diet|Low carb diet:The daily carbohydrate intake of participants in this group was limited to 130g/ D, and the recommended diet was formulated according to the standard and combined with the local eating habits in Xi 'an, and dietary habit education was conducted. Participants could eat according to the recommended diet.
45953508|NCT04696627|Other|Questionnaire|Participants from all 3 groups will be interviewed
45953509|NCT04696393|Drug|Mitapivat tablet|Oral tablets
45953510|NCT05143723|Drug|Gonadotropin-releasing hormone agonist|luteal phase support with gonadotropin-releasing hormone agonist
45953511|NCT05143684|Procedure|Left Lateral Uterine Displacement|a wooden wedge wrapped with cotton, to make it comfortable, and medical sheets with a measured angle of 15° under the right flank of the laying down patient
45953512|NCT00143624|Drug|Rosiglitazone maleate|See Detailed Description.
45953513|NCT00143624|Drug|Placebo|See detailed description.
45953514|NCT05143645|Other|Plasma vancoymcin measurements|
45660669|NCT04377971|Behavioral|Ask-tell-ask education|Participant education using the ask-tell-ask method. First the researcher will ask a question about participant understanding of wound care and after hearing the participant's answer, the researcher will then proceed to tell the patient how to best take care of their wound using a standardized script. After the educational portion, the researcher will then ask the patient to repeat the information that was shared. If the participant's answer is wrong or incomplete, the researcher will then explain the instructions again to ensure that the participant understands the steps needed.
45660670|NCT04377971|Other|Participant satisfaction survey|Participant satisfaction survey using components of the 16 item Skindex questionnaire and the 18 item version Patient Satisfaction Survey, adapted for treatment of skin cancer to characterize patient experience administered at two weeks post-operatively in person
45660671|NCT04377971|Other|Wound care adherence survey|Wound care adherence survey administered at one week over the phone and at two weeks in person
46077832|NCT04919096|Drug|Aflibercept|Subjects randomised to Aflibercept arm will receive a total of 3 doses of Aflibercept as an intravitreal injection of 2 mg into the study eye every 4 weeks on Day 1, Week 4, and Week 8.
46077833|NCT04585386|Other|Visual analog scale|to measure the lumbar and radicular pain felt by the patient.
45660672|NCT05481229|Other|nutritional interventions|Nutritional intervention will be initiated in patients at risk of overweight and obesity. A targeted nutritional intervention will be carried out, which will include consultation on dietary habits and physical activity as determined by diet and physical activity records. Consultations will be aimed at improving lifestyle and maintaining an adequate body weight.
45676605|NCT03193190|Drug|Selicrelumab|Selicrelumab will be administered as per the schedule specified in the respective arm.
45676606|NCT03193190|Drug|Bevacizumab|Bevacizumab will be administered as per the schedule specified in the respective arm.
45814813|NCT04475822|Behavioral|Low carbon diet and intermittent fasting group|Low carbon diet and intermittent fasting group:Participants fasted for 16 hours a day and ate for eight consecutive hours on the same diet as the low-carb group.
45814814|NCT04338451|Other|Music during the first part of ESWL|Music listening during first part of ESWL
45814815|NCT04338451|Other|Music during the second part of ESWL|Music listening during second part of ESWL
45814816|NCT02992574|Radiation|Post Mastectomy Radiation therapy|Post mastectomy radiotherapy to the chest wall and ipsilateral supra-clavicular fossa to a dose of 40 Gy in 15 fractions over 3 weeks
45814817|NCT02848027|Biological|Regenexx SD® procedure|Correlate patient outcomes 6 months after receiving the Regenexx SD procedure with measurements of synovial fluid collected before and after procedure.
45814818|NCT04298593|Device|Cardiostat|This is a prospective observational study including patients accepted by the heart team for a TAVI procedure. There will be no restriction regarding the type of valve and approach used for the TAVI procedure. Following the TAVI procedure, the patients will be under telemetry until hospital discharge and, at hospital discharge, they will be monitorized up to 4 more weeks using the CardioSTAT® device.
45814819|NCT02829229|Behavioral|Community-based obesity treatment (PP)|Participants in the treatment (PP) arm will receive a 5-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; 4)Video testimonials & 5)Interpersonal counseling. Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
45814820|NCT05439044|Other|Data collection|Anti SARS-CoV-2 Monoclonal Antibodies: casirivimab-imdevimab (Ronapreve) OR bamlanivimab-etesevimab OR tixagevimab-cilgavimab (Evusheld) OR regdanvimab OR sotrovimab (Xevudy) OR adintrevimab
45814821|NCT04256083|Biological|Biological analysis|Two blood samples of 4 ml each (total: 8 ml) for IGFBP1 assay and metabolic phenotyping and proteomic analysis.
45814822|NCT04475432|Drug|TP-03, 0.25%|TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
45814823|NCT04475432|Drug|TP-03 Vehicle|Vehicle of TP-03 ophthalmic solution, administered twice a day
45814824|NCT00370825|Drug|Combination therapy with AmBisome and miltefosine|
45814825|NCT04450316|Drug|Naltrexone|4.5mg tab (low-dose) nightly
45454088|NCT00523042|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
45814826|NCT04450316|Drug|Placebo|1 tab nightly
45814827|NCT05431010|Device|electroacupuncture|Participants are required to be in the supine position. Routine disinfection first. Participants are then subjected to acupuncture and achieve deqi sensation at all acupuncture points. Four paired of acupuncture points (i.e. Biguan acupoints and Futu points; Yanglingquan acupoints and Zusanli acupoints, identical on both sides) are connected to the EA devices. EA parameter is set as sparse wave and frequency is 2Hz. The intensity of the EA is determined by the patients' tolerance. Needles will be left in place and each session of EA will last 30 minutes. Participants will undergo a total of 36 EA sessions, with the frequency of 3 sessions every week for 12 weeks.
45953515|NCT05143528|Drug|Nilotinib BE 84mg|84 mg capsule
46077834|NCT04585386|Other|Mac Gill Pain Questionnaire|self-questionnaire that allows a qualitative assessment of chronic pain
45454089|NCT00338104|Drug|insulin glargine|Insulin glargine given at 40% of prior stable drip rate.
45953516|NCT05143528|Drug|Nilotinib BE 112 mg|112 mg capsule
45953517|NCT05143528|Drug|Placebo|placebo capsule
45953518|NCT00156000|Device|Fetal Fibronectin|fFN test done during pregnancy
45953519|NCT00156000|Device|Salivary Estriol|Salivary Estriol done during pregnancy
45953520|NCT05143060|Dietary Supplement|Cereal powder|Eat or drink oral glucose (reference) the valley of fiber powder upgrade formula, perfect meals, by extraction shu cereal bars, light appearance suits (by extraction shu compound dietary fiber powder, feeding combination 1:1) and 17 extraction enzyme 6 kinds of food respectively in different periods.
45953521|NCT05143060|Dietary Supplement|Pure glucose powder|Pure glucose powder
45953522|NCT05142982|Radiation|Radiotherapy|A dose of 30-36 Gy in conventional fractionation of 1.8-2.0 Gy per fraction using 3-dimensional conformal technique. Radiotherapy will be delivered five days a week.
45953523|NCT00143663|Drug|Lapaquistat Acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 12 weeks
45953524|NCT00143663|Drug|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks
45953525|NCT00156039|Behavioral|Follow-up Strategy for Breast Cancer|
45660673|NCT03401489|Device|PACESETTER|Patients will be given a Viaca electronic pill tray & blue-toothed UA-767 Plus BT BP device and the PACESETTER app installed on their smart phone for automatic relay of BP data. The Vaica tray emits a blinking light for 30 minutes when it is time to take the meds. If the compartment is not opened and emptied, an intermittent chime ensues for 30 minutes. If the compartment is not opened and emptied, the subject /caregiver receives an automated SMS. PACESETTERs will be given a questionnaire. Responses will be used to generate personalized motivational & reinforcement messages guided by self-determination theory constructs of competence & autonomous regulation. In addition to personalized messages, PACESETTERs will receive text messages 2 times per week on HTN/stroke facts, importance of med adherence, and tips on expressing questions/concerns with a physician. We will calculate medication possession ratios, on all subjects' HTN medications at each evaluation.
45660674|NCT05507801|Other|High Protein Milkshake|A milkshake with high protein level; including whey protein, fat free strawberry yogurt and whole milk - 337 kcal, 27 g carbohydrate, 57 g protein, 16 g fat.
45814828|NCT05431010|Behavioral|Rehabilitation Training|"The rehabilitation training group will be only treated with the Otago exercise program(OEP). Otago Exercise combines resistance exercise, balance training and aerobic walking and is an exercise prescription for elderly patients with sarcopenia.~Exercise: including warm-up exercise (5 minutes) + resistance exercise (20 minutes) + balance training (5 minutes). Training intensity: 30 minutes a day, 3 times a week, once every other day, 12 weeks of training period; resistance exercise gradually increases the load.~Walking program: Take a walk. Activity intensity: 30 minutes each time, 2 times a week, combined with exercise (walking during the interval between exercise sessions), 12 weeks of training period"
45814829|NCT05428046|Behavioral|MHL intervention|The current MHL intervention is a brief online intervention and comprises two modules. The first module is a short video introducing a teenage girl with bulimia nervosa. The second module is an online lecture comprising information about eating disorders including the prevalence, symptoms, type, cause, treatment, a related symptom checker, and sources of help. The above two modules are implemented in a single session lasting approximately 2 hours.
45814830|NCT05428046|Behavioral|Waiting list|Participants assigned to the waiting list group will not receive any intervention until the end of the 12 weeks follow-up. They received the same intervention as the MHL intervention group after the 12 weeks follow-up test.
45814831|NCT04445870|Other|data record|Data record on registers without medical files
45814832|NCT04040101|Device|smartphone-based balance training system|use smartphone application to training balance
45814833|NCT00370136|Drug|ultrasound contrast|
45814834|NCT02602093|Procedure|Transforaminal Endoscopic Discectomy|Local anaesthesia is to be administered. Verification of the site to be performed by an image intensifier and depending upon the patient's posture, a line is to be drawn from the center of the herniation. The needle is to be set and position checked. After the needle has reached the correct position, a guidewire is inserted. Following that, a series of conical rods are introduced, subsequently a drill is introduced through the cannula. After drilling, the instruments are removed, but the guidewire is to remain in place. The endoscope with the working channels are introduced via an 8mm cannula. Following removal of the hernia, the cannula and endoscope are removed. The patient is to be treated on an outpatient basis.
45814835|NCT02602093|Procedure|Open Microdiscectomy|General or spinal anaesthesia is to be administered. Verification is to be performed using a Carm and the patient is to be positioned prone or in the salaam position. A paramedian incision is to be performed and the level is to be indicated. Loupe or microscope magnification is to be used. Laminotomy as well as foraminotomy is to be performed, if necessary. The amount of degenerative disc material to be removed is at the discretion of the attending surgeon. Post-operative policy will be followed and it is expected that the duration of recovery in the hospital may vary from 2-7 days, but the patient will be discharged as soon as medically responsible.
45814836|NCT05422820|Diagnostic Test|Diagnostic high-definition white-light (HDWL) colonoscopy|All participants will undergo to colonoscopy examination performed by competent/junior or expert/senior endoscopists (>150-400 or >400 previous colonoscopies, respectively). Bowel preparation was performed using different solutions, according to the clinical discretion of the attending, who indicated colonoscopy. After deep sedation by intravenous propofol with or without fentanyl or midazolam administration, a water-assisted colonoscopy was performed using a high-definition (HD) scope with white light (WL). Colonoscope trademark differs among participant centres.
45814837|NCT05419778|Device|Osteogen plug®|A type I bovine Achilles tendon collagen with bioactive resorbable calcium apatite crystals (CCAC)
45814838|NCT05419778|Device|MInerOss®|A cortico-cancellous bone chips mix with polytetrafluoroethylene (dPTFE)(Cytoplast) barrier membrane.
45814839|NCT00370357|Drug|3% w/w SPL7013 Gel (VivaGel™)|
45814840|NCT05417282|Drug|MW151|Females: 20 mg MW151 daily (10 mg capsule BID), for 28 days; Males: 10 mg MW151 daily (10 mg capsule QD), for 28 days.
45953526|NCT05142865|Drug|Camrelizumab|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6) and maintenance phase ,until PD.
45953527|NCT05142865|Drug|Etoposide|100mg/m2 IV continuously on Day 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6)
45953528|NCT05142865|Drug|Carboplatin|AUC 5 mg/mL/min IV on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6)
45953529|NCT05142865|Drug|Cisplatin|25mg/m2，continuously on Day 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6)
46077835|NCT04585386|Other|Roland and Morris Disability Questionnaire|functional disability scale for assessing low back pain
46077836|NCT04585386|Other|Quebec questionnaire|To access the patient's perception of incapacity
45454090|NCT00338104|Drug|insulin glargine|Insulin glargine given at 60% of prior stable drip rate.
45454091|NCT00338104|Drug|insulin glargine|Insulin glargine given at 80% of prior stable drip rate.
45454092|NCT00519142|Drug|placebo for mitiglinide|three times a day with meals
45454093|NCT00519142|Drug|mitiglinide|three times a day with meals
45454094|NCT00519142|Drug|mitiglinide|two times a day with meals
45454095|NCT02284672|Drug|Dexmedetomidine|
45454096|NCT02284672|Drug|Normal saline|
45454097|NCT03134014|Dietary Supplement|Breakfast|If randomized to a breakfast consuming group, participants will be given breakfasts to consume between 6:00-8:00 am.
45660675|NCT05507801|Other|Normal Milkshake|A milkshake with normal protein level; including nesquik (strawberry), fat free strawberry yogurt, whole milk, double cream, whey protein and sweetener - 331 kcal, 64 g carbohydrate, 17 g protein, 19 g fat.
45814841|NCT02808962|Procedure|Cooled RFA of sacral lateral branches|A single target will be identified at the junction of the sacral ala and S1 superior articular process, corresponding to the location of the L5 dorsal ramus. Then, utilizing a stainless steel Epsilon Ruler (Kimberly Clark, Irving, TX, USA), three targets will be localized 8-10 mm lateral to the S1 and S2 posterior sacral foramen at the 2:30, 4:00, and 5:30 positions. Two targets will be localized at the S3 level. Local infiltration with 1% lidocaine and minimal sedation with IV midazolam will be utilized. Once suitable sensory and motor stimulation are verified and impedance is acceptable, each target will be anesthetized with 1 mL of 1% lidocaine prior to each lesion being created at 60 degrees centigrade for 2 minutes and 30 seconds.
45814842|NCT05398094|Drug|Sotorasib|AMG510 (Sotorasib) is small molecule that specifically and irreversibly inhibits the KRAS-G12C mutant protein. AMG510 (Sotorasib) finished product is presented as tablets containing 120mg and will be packaged in bottles of 120 tablets.
45953530|NCT05142865|Drug|Apatinib|250 mg given orally, once daily in 21-day cycle
45953531|NCT00506584|Dietary Supplement|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
45953532|NCT00506584|Dietary Supplement|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier is initiated when nutrition volume reaches 40 mL/kg/day
45953533|NCT00506584|Dietary Supplement|Human milk fortifier (bovine-based), pre-term formula|Bovine-based human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
45953534|NCT00506584|Dietary Supplement|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier initiated when nutrition volume reaches 100 mL/kg/day
45953535|NCT00506584|Dietary Supplement|Pre-term/term formula|Bovine milk-derived nutrition formulated for very low birth weight infants
45953536|NCT00143702|Drug|d4T|See Detailed Description.
45953537|NCT00143702|Drug|Abacavir|See Detailed Description.
45953538|NCT00143702|Drug|Riboflavin and Thiamine (Supplementation)|See Detailed Description.
45953539|NCT00156078|Drug|pregabalin|
45454098|NCT00336934|Dietary Supplement|pomegranate juice|Given orally daily.
45454099|NCT00336934|Other|placebo|Given orally daily.
45660676|NCT03300713|Other|MOCITRAINING program|The program is clinical and psychometric tools for screening for interactions and postpartum psychiatric disorders. The program will expose the existing care arrangements and the different possible orientations of the families according to the identified problem.
45660677|NCT03300713|Other|usual follow-up|usual follow-up
45953540|NCT05142592|Drug|IPG7236|The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.
45953541|NCT05146531|Device|McCoy laryngoscope|Patients scheduled for general anesthesia were intubated with McCoy laryngoscope.
45953542|NCT05146531|Device|C-MAC D-blade video laryngoscope|Patients scheduled for general anesthesia were intubated with C-MAC D-blade video laryngoscope.
46077837|NCT02690285|Drug|Dichloroacetate (DCA)|Dichloroacetate (DCA) 25 mg/kg oral solution will be administered daily for 5 days.
45660678|NCT05563883|Other|event occurence|occurence of an event of interest: (AF, cancer, thromboembolism, bleeding, mortality...
45953543|NCT00506623|Drug|Capecitabine, Irinotecan|
45953544|NCT05146492|Procedure|MRI|MRI with gadolinium contrast media injection
45953545|NCT00143741|Drug|Atorvastatin (Lipitor)|20mg every day, taken by mouth. Dose could be increased up to 60mg every day during the course of the trial if tests indicate this is needed.
45953546|NCT00156156|Drug|Asoprisnil|Asoprisnil 10 mg Tablet, oral Daily for up to 2 years
45953547|NCT00156156|Drug|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for up to 2 years
45953548|NCT05146375|Biological|TGFBR2|"TGFBR2 mutation correlation with severity of the aortic disease. Blood sampling. Serum will be analysed by DNA sequencing to detect specific mutations involved in aneurysms.~Cutaneous biopsy. Fibroblast culture will be done to assess the transcriptome analysis."
46077838|NCT02690285|Other|GSTZ1 haplotyping|One teaspoon of blood is collected by standard phlebotomy. Cheek cells are collected by standard brushing. Samples will be analyzed at two independent laboratories to validate methods for GSTZ1 haplotype analysis.
46077839|NCT02746848|Biological|Amniotic Membrane Extract Eye Drop|Amniotic Membrane Extract use as eye drop for patients with corneal injury.
46077840|NCT02824484|Behavioral|GWDP|"In each writing session participants are asked to:~Describe memories concerning cancer illness in a chronological order, with an objective and detached attitude~Describe: (a) thoughts and emotions perceived during the illness experience; (b) the impact of illness on their daily lives, and how it has changed their attitudes toward life.~Focus on their actual situation, think about the entire illness experience, and report on the following aspects: -Their present thoughts and feelings, and how those differ from the ones felt during the illness experience. -To what extent they have come to terms with, understand and appreciate themselves to have dealt successfully with the illness."
46077841|NCT02824484|Behavioral|Control|Participants are requested to write about events of their daily routine happened during the past week; they are also asked to focus on facts, with an objective and detached attitude.
45660679|NCT05563805|Device|Virtual Reality-based physical activity intervention|The V-RATE intervention will be delivered through a 360-degree non-mobilized treadmill in a university clinical laboratory for 8-weeks (3 days/week, 30 minutes/session) totaling 24 sessions. The V-RATE program will be focused on creating a safe and immersive environment supportive of physical activity. The treadmill enables an individual can walk and run at self-paced speed, moving in 360-degrees (i.e., forwards, sideways, and backwards) without risk of falling. The core feature of the self-paced treadmill is a concave walking platform with an adjustable waist hardness that enables a safe, smooth, natural gait while adults with elevated BMI engage in an immersive walking and running motion. During the V-RATE intervention, participants will self-pace their locomotor action (walking/running/bending/ jumping) while they wear the VR headset and experience immersive VR adventure games using the Omniverse VR system.
45660680|NCT03150173|Behavioral|Onsite treatment|Participants will see a buprenorphine treatment provider who will assess for clinical criteria for opioid use disorder and write a prescription for buprenorphine treatment, which will be filled in a community pharmacy.
45660681|NCT03150173|Behavioral|Enhanced referral|Participants will receive an expedited appointment at a community health center for evaluation for buprenorphine treatment
45660682|NCT03150173|Drug|Buprenorphine|all participants will receive buprenorphine
45660683|NCT05498207|Behavioral|Maya App|Participants will utilize the Maya App for at least 20 minutes per day, 2 days per week, for 6 weeks. Additionally, participants will complete assessments at baseline, 3 months, 6 months, 9 months and 12 months (this includes specimen collections, interviews, and surveys). Participants will also be asked to wear a Fitbit for 12 months.
45660684|NCT04424693|Drug|Tdap Vaccine Administration|Tdap vaccinations are routinely given during pregnancy between weeks 27 and 36 per guidelines of American College Obstetrics and Gynecology (ACOG) -- but this study uniquely is trying to establish that the earlier Tdap vaccinations reduce preeclampsia by more than 50%
45660685|NCT05563571|Drug|Methylprednisolon, Lidocaine|Intra-articular cortisone injection
45660686|NCT05563571|Other|Pulsed radiofrequency, Lidocaine|pulsed radiofrequency of shoulder joint and suprascapular nerve
46077842|NCT00781599|Drug|Chantix|Chantix 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7, and 1 mg twice daily on day 8 through end of treatment at month 3
46077843|NCT00781599|Behavioral|Adherence Counseling|Induction Support counseling on days 8, 12, 20 and months 1 and 2. Adherence counseling based on the Information-Motivation-Behavioral Skills model of adherence behavioral change.
45660687|NCT02717507|Drug|Carvedilol|Given PO
45660688|NCT02717507|Other|Laboratory Biomarker Analysis|Correlative studies
45660689|NCT02717507|Other|Pharmacogenomic Study|Correlative studies
45660690|NCT02717507|Other|Pharmacological Study|Correlative studies
45660691|NCT02717507|Other|Placebo Administration|Given PO
45660692|NCT02717507|Other|Quality-of-Life Assessment|Ancillary studies
45660693|NCT02717507|Other|Questionnaire Administration|Ancillary studies
45953549|NCT05146102|Other|"ethics communication in group, in line with the one to five-step method"|"Healthcare professionals working as ethical representatives at the current ward (n=5) have recently gone through a basic ethics program. They will continue by going through an education program for facilitating ethics communication in group, in line with the one to five-step method~The education program has a theoretical and practical approach, which includes the theoretical base of the ethical communication in groups and practicing the one to five method Thereafter, each ethical representative will facilitate interprofessional sessions at a clinical ward, once a month, for six months at their workplace. Gathering meetings for feedback will be offered for the ethical representatives once a month."
45454100|NCT02287714|Procedure|Instep without gastrocnemius recession|Patient will receive an instep plantar fascial release without gastrocnemius recession.
45660694|NCT02489903|Drug|RRx-001|
45660695|NCT02489903|Drug|Cisplatin|
45660696|NCT02489903|Drug|Etoposide|
45660697|NCT02489903|Drug|Carboplatin|
45660698|NCT02489903|Drug|Irinotecan|
45660699|NCT02489903|Drug|Vinorelbine|
45660700|NCT02489903|Drug|Doxil|
45660701|NCT02489903|Drug|Gemcitabine|
45660702|NCT02489903|Drug|Taxane|
45660703|NCT02489903|Drug|Paclitaxel|
45660704|NCT02489903|Drug|Nab-Paclitaxel|
45953550|NCT05146063|Diagnostic Test|Take the patient's subcutaneous fat tissue to detect the expression of LNK|Take the patient's subcutaneous fat tissue to detect the mRNA and protein expression levels of LNK by RT-qPCR and western blot.
45660705|NCT02489903|Drug|Pemetrexed|
46077844|NCT00781599|Behavioral|Standard Counseling|Visit with counselor on Day 8 to develop a plan to quit smoking. Discuss strategies to quit, risks of continued smoking and discuss strategies for coping with withdrawal and craving.
46077845|NCT04266899|Device|Foot Drop Stimulator - Neuro Orthosis|The WalkAide system is a self-contained functional electrical stimulation device with a built-in tilt sensor and attaches with a cuff to the leg below the knee. The device stimulates the peroneal nerve provides active dorsiflexion of muscle during the swing phase of gait.
46077846|NCT04266899|Device|Treadmill|Gait training on a treadmill
45660706|NCT05563493|Other|Treatment group, Chair-Based Exercise Training|"The weights of the elastic bands to be used in the exercises will be determined by the physiotherapist according to the abilities and development of the participants.~The intensity of the exercise will be adjusted according to the dyspnea or fatigue patients feel according to the Modified Borg Scale.~During the exercises, heart rate and oxygen saturation will be measured with a pulse oximeter, and blood pressure will be measured with a sphygmomanometer.~Chair-based exercise training will be applied to the patients every day they are hospitalized."
45660707|NCT05563493|Other|Control group, Breathing exercise|Breathing exercise will be applied to the patients every day they are hospitalized.
45660708|NCT02104349|Behavioral|Mindfulness meditation|One hour training with mindfulness instructor. Listening to mindfulness CD twice a day for 2 weeks prior to spine surgery. Post-operative practice will be at least 1 track per day.
45660709|NCT01815281|Device|Foot Mechanical Stimulation (GONDOLA)|
45660710|NCT01678547|Device|Robot-assisted walking|The practice will included an add-on robot-assisted walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h and the BWS % will be decreased.
45953551|NCT00143780|Biological|The polysaccharide vaccine used is Pneumovax (Merck vaccines)|
45660711|NCT01678547|Device|Treadmill Training|The practice will included an add-on treadmill walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial comfortable treadmill speed and the speed will be increased to a range of 1,0 to 2.5 km/h and the BWS % will be decreased.
45953552|NCT00143780|Biological|The conjugate vaccine used is Prevnar (Wyeth-Ayerst vaccines)|
45660712|NCT01678547|Other|Ground treatment|The practice will included ground walking therapy s for 40 min with therapist support.
45660713|NCT01658111|Device|Robot Group|"The MIT-MANUS/InMotion2 (Interactive Motion Technologies, Inc., Watertown, MA, USA) system has two translational degrees of freedom (dof): shoulder abduction-adduction (ab-ad), elbow flexion-extension (flexext).~The robotic system supports the execution of reaching movements in the horizontal plane through an assist as needed control strategy. The robot can guide the movement of the upper limb of the patients and record end-effector physical quantities such as the position, velocity, and applied forces. The device is designed to have a low intrinsic end-point impedance (i.e., be back-drivable to easily carry the weight of the patient's arm, to execute movements without constraint and offer minimal resistance. A 3-dof force transducer is placed at the robots end-effector, as well."
45660714|NCT01658111|Procedure|Traditional physiotherapy|Active or passive exercises.
45953553|NCT00156195|Drug|Asoprisnil|10 mg Tablet, oral Daily for 12 months
45660715|NCT01174199|Drug|vorinostat|Given orally
45814843|NCT04359446|Procedure|NC ( Non- Compliant) Balloon dilatation|NC Balloon dilatation at pressure > NC-RBP (18-20 atm) with > 1 long inflation (> 20 minutes each)
45814844|NCT04359446|Procedure|Laser Excimer + NC Balloon|Laser Excimer + NC Balloon dilatation at pressure > NC-RBP (18-20 atm) with > 1 long inflation (> 20 minutes each)
45953554|NCT00156195|Drug|Asoprisnil|25 mg Tablet, oral Daily for 12 months
45953555|NCT05145946|Behavioral|Video Game Training Group 1|Closed-loop audiomotor game. Home-based training sessions for 3.5 hours per week over an 8-week.
46077847|NCT02826044|Drug|SP2086|The study has 3 doses groups and the 30 subjects were administrated SP2086 50mg,100mg,200mg respectively.
46077848|NCT00899041|Procedure|Total Knee Arthroplasty (TKA)|28 subjects will receive the standard Sigma FB knee prosthesis. 28 subjects will receive the high flexion Sigma RP-F knee prosthesis.
46077849|NCT04468074|Device|Virtual Reality Therapy for Chronic Pain|"A 1 1/2 PowerPoint-based education session on the science behind chronic pain and a basic overview of the VR therapy~Virtual Reality Therapy: a virtual reality therapy consisting of different psychological training exercises"
46077850|NCT04266587|Biological|Blood sampling|blood sampling is done on healthy volunteers
45454101|NCT02287714|Procedure|Instep with gastrocnemius recession|Patient will receive an instep plantar fascial release as well as gastrocnemius recession.
45660716|NCT01174199|Drug|temsirolimus|Given IV
45660717|NCT01174199|Other|laboratory biomarker analysis|Correlative study
45814845|NCT05377424|Drug|Consume 20mg of istradefylline|Consume a single 20 mg istradefylline tablet
45814846|NCT05377424|Other|Low Oxygen therapy|Breathing short periods of low oxygen, consisting of 15 episodes of 1 minute of breathing 10% oxygen, with 2 minutes of breathing 21% oxygen. 45 minutes total.
45814847|NCT05377424|Drug|Placebo counterpart to the istradefylline drug|Consume a single microcrystalline cellulose
45953556|NCT05145946|Behavioral|Video Game Training Group 2|Auditory memory game. Home-based training sessions for 3.5 hours per week over an 8-week.
46077851|NCT04241588|Device|3D Printed Upper-limb Prosthesis|The fingers and thumb were made of polylactic acid polymer manufactured using industrial 3D printers. The palm, socket, forearm brace, and leveraging the structure were made of polylactic acid which has properties similar to thermoplastic that facilitate post-manufacturing adjustments. Elastic cords placed inside the dorsal aspect of the fingers provided passive finger extension. Finger flexion was driven by non-elastic cords along the palmar surface of each finger and was activated through 20-30 degrees of wrist or elbow flexion. The device will be given to participants so that they may practice using the device at home.
46077852|NCT04103151|Device|Single lead ECG|Heart Rate Variability will be monitored using a single lead electrocardiogram
45454102|NCT00334828|Drug|eritoran tetrasodium|Intravenous infusion at a total dose of 105 mg.
45454103|NCT00334828|Drug|Placebo|Matching placebo; intravenous infusion.
45814848|NCT05377424|Other|SHAM counterpart to low oxygen therapy.|Breathing short periods of sham low oxygen, consisting of 15 episodes of 1 minute of breathing 21% oxygen, separated by 2 minutes of breathing 21% oxygen. 45 minutes total.
45814849|NCT02165826|Drug|Roflumilast|Roflumilast tablets
45814850|NCT02165826|Drug|Roflumilast Placebo|Roflumilast placebo-matching tablets
45814851|NCT02165826|Drug|Standard of Care COPD Treatment|The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.
45814852|NCT02728154|Other|Blood Sample|One tablespoon of blood will be drawn once during the study.
45814853|NCT02728154|Other|Stool Sample|One stool sample will be collected.
45953557|NCT02276365|Drug|BI 10773|
45953558|NCT02276365|Drug|Pioglitazone|
45953559|NCT05145712|Diagnostic Test|Bowel readiness|"During the examination, the endoscopic physician required to stay in place while rinsing, and the lens could only be withdrawn after rinsing.~During the examination, the recorder should record the time points of the right colon, transverse colon, and left colon, as well as the time of irrigation.~If both are considered to be properly, then second colonoscopy was performed immediately.~If both results agree or either side agrees that the gut is not well prepared, the review will be carried out within a year"
46077853|NCT00605839|Device|GlucoPak|We will be giving participants Glucopak devices and monitoring them closely over the 6 month period.
46077854|NCT00605839|Device|Cell Phone|We will provide cell phones and access to the clinic to facilitate communications
46077855|NCT00605839|Other|Usual Care|This intervention was usual care, without either device.
46077856|NCT05380973|Other|Short fiber resin composite|resin composite reinforced with short glass fibers
45660718|NCT01174199|Procedure|positron emission tomography/computed tomography|PET scan
45660719|NCT04475549|Drug|IW-6463 Tablets|IW-6463 tablets administered orally (daily)
45660720|NCT05497895|Biological|5% thymoquinone (TQ) gel|Mode of Administration In Group I patients, the lipid based TQ gel (5%) will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performing the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior and after its application. The patients will be instructed to not eat for 30 minutes following its application.
45660721|NCT05497895|Biological|SRP and placebo|In Group II patients, the placebo gel will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performs the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior to and after its application. The patients will be instructed to not eat for 30 minutes following its application
45953560|NCT00143858|Device|Pulse Volume Measurement|patients will wear a newly designed calf monitor that will be hooked up to a computer that will monitor leg peripheral pulse volumes which will then be correlated to pressures obtained with Swan Ganz monitoring. The calf monitor is gut two bands with sensors that are wrapped around the ankle and below the knww
45660722|NCT05497895|Procedure|Only SRP-one stage prophylaxis|The Group III patients will be subjected to one-stage oral prophylaxis.
45660723|NCT04472897|Drug|GSK2556286|GSK2556286 will be administered.
45454104|NCT00425464|Device|Standard Monofocal Intraocular Lens|"The control (active comparator) arm is comprised of patients who meet all study eligibility criteria and will be implanted with a standard monofocal intraocular lens.~Each study patient will undergo standard extracapsular cataract extraction through a clear corneal or limbal incision and circular continuous curvilinear capsulorhexis."
45660724|NCT04472897|Drug|Placebo|Placebo will be administered
45660725|NCT04471337|Drug|BAY1817080|BAY1817080 will be administered orally as tablet.
45660726|NCT04356599|Other|Early dynamic 18F-FDG PET/CT assessment of cerebral glucose uptake|The intervention will consist in a dynamic cerebral 18F-FDG PET study performed at D2+/-1. Kinetic modeling will be performed using in-house software at the global, regional, and voxel level. In addition, cerebral perfusion and blood-brain-barrier permeability will be assessed at D4+/- 1 using perfusion MRI and permeability MRI.
45660727|NCT05562869|Drug|Belatacept 250 Milligram Intravenous Powder for Solution|"Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15,30, 45, 60 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)"
45660728|NCT04085237|Drug|Ropivacaine injection|30ml of 0.375% ropivacaine with 5mcg/ml of epinephrine will be injected into the fascial plane on the anterior spinae muscle.
45660729|NCT04085237|Other|Sham|Saline will be used at the same amounts as the ropivacaine arm.
45660730|NCT05497661|Other|448kilohertz Capacitive Resistive Radiofrequency Stimulation in a Sporty Population.|448kilohertz Capacitive Resistive Radiofrequency Stimulation on Patellar tendon in a Sporty Population.
45660731|NCT05497661|Other|Placebo comparator|To simulate a 448kilohertz capacitive resistive monopolar radiofrequency application on the non dominant patellar tendon
45660732|NCT04080869|Drug|retinyl palmitate|topical retinyl palmitate loaded ethosomes
45660733|NCT04080869|Drug|Tretinoin|topical tretinoin
45814854|NCT02535247|Drug|MK-3475|
45814855|NCT02535247|Drug|Copanlisib|
45814856|NCT00370916|Behavioral|Physician-initiated medication reconciliation|Physician house staff performed and documented medication reconciliation after hospital admission with the assistance of a CPRS template
45814857|NCT00370916|Behavioral|Pharmacist-initiated medication reconciliation|Pharmacist performed and documented medication reconciliation
45953561|NCT05145673|Other|Placebo (OGTT)|The control group was given an glucose solution to oral glucose tolerance test (OGTT) The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.
45953562|NCT05145673|Other|Cinnamon (OGTT plus aqueous cinnamon extract)|The intervention group was given an glucose solution to OGTT followed by a cinnamon aqueous extract. The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.
45953563|NCT00156234|Behavioral|One-knee extension ergometer|
45660734|NCT05562791|Drug|[68Ga]PSMA|68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
45660735|NCT05562791|Diagnostic Test|PET/CT imaging|68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
45660736|NCT05562635|Combination Product|5% polymer gel with CBD application|Bilateral application of 5% polymer gel with CBD intraorally, on the masseter muscle
45660737|NCT05562635|Combination Product|10% polymer gel with CBD application|Bilateral application of 10% polymer gel with CBD intraorally, on the masseter muscle
46077857|NCT05380973|Other|Polyethylene ribbon fiber|resin composite reinforced with polyethylene ribbon fiber
46077858|NCT02746614|Other|Psychomotor Therapy|Psychomotor Therapy
45660738|NCT05562635|Combination Product|Placebo intervention|Application of placebo without CBD
45660739|NCT04078061|Behavioral|MABA|Adaptive, modular, behavioral intervention.
45814858|NCT02509897|Other|Hypoxic training|Hypoxic training 3 times per week four four weeks
45814859|NCT02509897|Other|Normoxic training|Normoxic training 3 times per week four four weeks
45814860|NCT04337996|Diagnostic Test|COVID-19 diagnostic test|COVID-19 diagnostic tests performed at day 1 (antigen in blood serum, SARS-Cov2 PCR, antibodies in blood serum) COVID-19 diagnostic test performed at day 21 (antibodies in blood serum)
45814861|NCT02676206|Other|Classical music|Classical music will be played over the headphones
45814862|NCT03855787|Procedure|Ureteroscopy|Ureteroscopy for 1.5cm or less renal stones.
45660740|NCT04078061|Behavioral|EIBI|Early Intensive Behavioral Intervention
45953564|NCT05145634|Other|Patient education related oral anticoagulants (OACs)|The interventions administered to the experimental group were one-on-one instruction and Health Belief Model (HBM)-driven strategies, health information technology system, monthly telephone follow-ups, and providing medication cards. Patient education related oral anticoagulant: each subject in the experimental group was taught individually according to investigators' App in the outpatient department (OPD) by researchers. Every months, participants received a follow-up phone call to clarify any questions related to the knowledge of anticoagulants. The contents of the teaching material consisted of: the purpose of taking anticoagulant, side effects, adjustments to daily diet, and precautions (i.e.how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure and medical card after pretest and routine care in the OPD. All participants completed posttest at 3-month follow-up.
45454105|NCT00425464|Device|Synchrony® Dual Optic Intraocular Lens|"The Synchrony® Dual Optic Intraocular Lens (experimantal) arm is comprised of patients who meet all study eligibility criteria and will be implanted with a Synchrony® Dual Optic Intraocular Lens.~Each study patient will undergo standard extracapsular cataract extraction through a clear corneal or limbal incision and circular continuous curvilinear capsulorhexis."
45660741|NCT00560495|Drug|ammonium tetrathiomolybdate|4 times daily for up to 3 weeks
45660742|NCT00560495|Other|immunoenzyme technique|
45660743|NCT00560495|Other|laboratory biomarker analysis|
45660744|NCT00560495|Radiation|Tc 99m sestamibi|
45660745|NCT00560495|Radiation|radiation therapy|once daily, 5 days a week, for 6-7 weeks
45660746|NCT05497505|Device|Pacmed Critical|For patients in the On-period, Pacmed Critical will be available as decision support after initial eligibility screening for ICU discharge by treatment team
45660747|NCT05499299|Behavioral|Google ads|Individuals who googled COVID-19 information in Hong Kong were randomized to see one of the seven ads and, if they clicked on the ads, the corresponding vaccine message on our website
45660748|NCT05499221|Device|Carriere motion appliance|The CMA will be bonded on the permanent maxillary canine and first molar, and the correct size is chosen according to the manufacturer's instructions.
45660749|NCT02559713|Drug|Vedolizumab|Vedolizumab IV infusion
45660750|NCT05492201|Drug|LY3873862|Administered orally.
45660751|NCT05492201|Drug|Placebo|Administered orally.
45814863|NCT04417920|Procedure|Express implant device|"Operative technique in group I (Express implant) was as in group II (trabeculectomy) except with no sclerectomy or peripheral iridectomy , the steps included conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of a pilot hole is fashioned using a sapphire blade (Alcon laboratories,USA) then Express shunt 3 mm long device and external diameter 400 microns was implanted followed by closure of scleral flap and conjunctiva.~While in group II, Trabeculectomy with Mitomycin-C was done in superior-temporal region away from the fibrotic bleb at 12 o, clock."
45814864|NCT02626130|Procedure|Cryosurgery|Undergo cryoablation
45814865|NCT02626130|Other|Laboratory Biomarker Analysis|Correlative studies
45953565|NCT00143936|Behavioral|Low- Carbohydrate -Atkins Diet|Low Carbohydrate Diet
45953566|NCT00143936|Behavioral|Low Calorie Diet|Maintain a low calorie diet
45953567|NCT05145244|Other|NO intervention|No intervention
45953568|NCT05145205|Procedure|Sleeve gastrectomy|"Bougie was applied over the lower curvature to adjust the gastric tube then longitudinal amputation of the stomach was performed for about 4 to 6 cm per pecker of the pylorus to the corner of His. No supportive materials were used, and over-suturing of the basic line performed only over the points of bleeding.~All resected specimens were sent to histopathology laboratory for examination."
45953569|NCT05145205|Procedure|Laparoscopic Roux-en-Y gastric bypass|An antecolic and antegastric RYGB become executed with a 150 cm alimentary limb with both a linearly or circularly kink (25 mm) gastrojejunostomy in step with the desire of the surgeon. A 50-cm-lengthy biliopancreati
45953570|NCT05145166|Biological|Safety group|All of the participants(N=10000) received one dose of live attenuated mumps vaccine.Vaccine will given by single intramuscular injection(0.5 ml) on day 0.
45953571|NCT05145088|Behavioral|submaximal exercise testing according to ACSM guidelines|For Moderate-intensity exercises includes either 30 min a day for five days a week or a total of two hours and 30 min per week using 50% to 70% of maximum heart rate
45953572|NCT00143975|Drug|Cytarabine|3 g/m2 bid. i.v day 1-3
45953573|NCT00143975|Drug|Mitoxantrone|12 mg/m2 i.v. day 2 and 3
45953574|NCT00143975|Drug|Gemtuzumab Ozogamicin|3mg/m² i.v. day 1
46077859|NCT00906841|Drug|90Y-DOTA-hLL2|Consolidation : Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)
46077860|NCT00605969|Procedure|Motion analysis|Participants will undergo a motion analysis procedure: a dynamic assessment of the movement in their hip.
46077861|NCT00605969|Diagnostic Test|Computed Tomography|Participants will undergo computed tomography (CT) scan of their hip.
45660752|NCT04049825|Drug|OPB-111077|OPB-111077+bendamustine
45660753|NCT04049825|Drug|OPB-111077|OPB-111077+rituximab+bendamustine
45660754|NCT01358981|Drug|LY2881835|Administered orally
45660755|NCT01358981|Drug|Placebo|Administered orally
45660756|NCT05499065|Procedure|Fluorescence guided detection of tumor positive margins|To test if the fluorescence can guide the location for fresh frozen section sampling intra-operatively
45660757|NCT05499065|Drug|Cetuximab-IRDye800|Administrate 75mg cetuximab + 15mg cetuximab-800CW for fluorescence visualization
45660758|NCT04317599|Other|Non Interventional study|Non Interventional study
45660759|NCT04230161|Other|Standard long-lasting insecticidal net|Yahe LN (Yamei Industry) contains a pyrethroid insecticide.
45660760|NCT04230161|Other|Chlorfenapyr insecticide treated net|Interceptor G2® (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.
46077862|NCT02746770|Other|Experimental: Cawthorne and Cooksey exercises group|Experimental: intervention group. Patients assigned to the experimental group will perform the Cawthorne and Cooksey exercises for vestibular rehabilitation in addition to their habitual treatment.
46077863|NCT04971200|Drug|Tildrakizumab|2 100mg subcutaneous injections Q4W
45814866|NCT02626130|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45814867|NCT02626130|Biological|Tremelimumab|Given IV
45814868|NCT02198040|Other|Manual Therapy|"5 minutes. Termotherapy shalow to 50 cm away from the elbow, using a bulb of 250w.~15 minutes. Joint traction of elbow, in submaximal mobility amplitude with distal fixation of humerus and proximal fixation of radius and ulna in neutral position of forearm. Joint traction in I-II degree of flexion and extension submaximal of elbow.~15 minutes. Passive muscle stretching (within the limits of mobility).~15 minutes. Proprioceptive neuromuscular facilitation (PNF) of upper limb, from the abduction, flexion and external rotation of shoulder.~10 minutes. Local cryotherapy with ice bag and protection between it and the skin"
45953575|NCT00143975|Drug|All-trans-Retinoid Acid|45 mg/m2 p.o. day 4-6 15 mg/m2 p.o. day 7-28
45953576|NCT00156312|Drug|Docetaxel|
45953577|NCT00156312|Drug|Capecitabine|
45953578|NCT00506701|Drug|Tadalafil|40 mg tablet
45953579|NCT05147857|Device|Dilapan s|"is an osmotic hygroscopic dilator produced from a patented Aquacryl® hydrogel that guarantees consistency of action.~It is a rigid gel rod that increases in volume by absorbing fluids from the cervical canal, so it gradually dilates the cervix The thin 4 mm rod can expand up to 15 mm over a 12-24 hours period. This allows it to dilate and soften the cervix gradually."
46077864|NCT02539147|Biological|blood samples|Isolation and stimulation of monocytes, preparation of cell lysates, measurement of cytokine production, Western blot
46077865|NCT02746692|Other|Fit15|"Group-based high-intensity circuit training based on functional movement patterns (e.g. squats, push-ups, burpees, jumps, ropeskipping).~Total duration 15 minutes circle training: 20s workout, 10 rest"
45454106|NCT02283190|Drug|Erwinase|Six doses of Erwinase, given Monday-Wednesday-Friday for 2 weeks. Dosage levels to be used are: 20,000 IU/ m2 /day, 25,000 IU/ m2 /day, 30,000 IU/ m2 /day.
45660761|NCT04230161|Other|Indoor residual spraying|Fludora Fusion (Bayer Vector Control) is a spray containing two active ingredients: clothianidin, a neonicotinoid insecticide, and deltamethrin, a pyrethroid insecticide.
45660762|NCT04227977|Device|JuxtaFlow System|The JuxtaFlow System consists of proprietary ureteral catheters deployed endoscopically over the wire to deliver mild controlled negative pressure into the renal pelvis.
45660763|NCT05498909|Other|Multidisciplinary joint diagnosis and treatment mode|Multidisciplinary joint diagnosis and treatment mode,break down barriers and treat the heart and brain together
45660764|NCT04038437|Drug|CPX-351|CPX-351 will be administered on Days 1 and 3 of each cycle
45660765|NCT04038437|Drug|Venetoclax|Venetoclax will be adminstered on Days 2 to 21 of each cycle
45660766|NCT04277741|Dietary Supplement|RS4 bar|The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW containing 20g fiber.
45660767|NCT04277741|Dietary Supplement|Control bar|The control group will consume one native wheat starch bar per day.
45953580|NCT05147857|Drug|Misoprostol|Misoprostol is a synthetic prostaglandin medication used to prevent and treat stomach and duodenal ulcers, induce labor, cause an abortion, and treat postpartum bleeding due to poor contraction of the uterus. Misoprostol is taken by mouth when used to prevent gastric ulcers in persons taking NSAIDs.
45953581|NCT05147740|Drug|B/F/TAF|50/200/25 mg fixed-dose combination administered orally once daily without regard to food.
45953582|NCT05147623|Procedure|Any surgery/procedure|Any surgery/procedure in all adult patients that were performed in an operating room
45953583|NCT00156351|Behavioral|Physical activity promotion|
45953584|NCT00144053|Drug|Cisplatin+Vindesine+MMC/ concurrent radiation|
45953585|NCT00144053|Drug|Irinotecan+Carboplatin/concurrent radiation|
46077866|NCT02746692|Other|Endurance|Moderate intensity ergometer training. Total duration 50 minutes
46077867|NCT00603005|Device|Use of TravAlert dosing aid with or without drop guider|Each patient will use a dosing aid and/or drop guider for 6 months
45454107|NCT00333502|Drug|Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer|Subjects who meet inclusion/exclusion criteria will receive CRLX101 every other week.
45660768|NCT05491577|Other|Filling in the SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire|The SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire will all be filled in by the patients.
45676607|NCT03193190|Drug|RO6874281|RO6874281 will be administered as per the schedule specified in the respective arm
45676608|NCT03193190|Drug|AB928|AB928 will be administered as per the schedule specified in the respective arm.
45953586|NCT00144053|Drug|Paclitaxel+Carboplatin/concurrent radiation|
45953587|NCT05147194|Drug|Trimetazidine|Oral，35mg bid
45953588|NCT05147155|Biological|Mepolizumab|This will be a 2-year prospective study. Patients with uncontrolled severe asthma will receive mepolizumab according to standard of care and best clinical practice, which will be administered as a 100-mg subcutaneous dose every four weeks.
45953589|NCT00147888|Procedure|Acoustic rhinometry (procedure)|Acoustic rhinometry is a procedure that uses sound waves to measure the cross-sectional area and volume of the nasal cavity.
45953590|NCT00144092|Procedure|stem cell source|
46077868|NCT04244006|Drug|Dupilumab Prefilled Syringe|administration of dupilumab corresponding to dupilumab arm
46077869|NCT04244006|Other|Placebo Prefilled Syringe|administration of placebo corresponding to placebo arm
46077870|NCT02750436|Device|Ultrasound guided|This group will be treated using an ultrasound imaging device
46077871|NCT02750436|Device|Fluoroscopy guided|This group will be treated using a fluoroscopy imaging device
46077872|NCT00899119|Procedure|leukapheresis|
45660769|NCT05498675|Drug|Sacubitril / Valsartan Oral Tablet [Entresto]|There is no treatment allocation. Patients administered sacubitril / valsartan oral tablet (Entresto) 200mg 1/day by prescription that have started before inclusion of the patient enrolled into the study and defined as sacubitril/valsartan group.
45953591|NCT04696276|Other|ERAS protocol|special approaches in three phases preoperatively, intraoperatively and postoperatively, by an interdisciplinary team comprising of the surgeon, the anesthesiologist and the nurse. The combination of these techniques reduces the reaction to postoperative stress, relieves acute postoperative pain, restores the patient immediately to their original feeding and mobilization habits, thus reducing the time required for their complete recovery.
45660770|NCT05498675|Drug|ACEI/ARB|"There is no treatment allocation. Patients administered angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI/ARB group.~Including:~benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan."
45660771|NCT04282733|Behavioral|Mindfulness Rounds|"Throughout the 8-week study period, a different mindfulness practice will be introduced weekly in 3 separate 15-minute live sessions. Posters describing the particular practice of the week will be placed around the Unit as visual reminders to encourage actual practice."
45953592|NCT05149924|Drug|QL1012|Subcutaneous injection,starting dose within 75IU ~ 300IU determined by the age , maximum daily dose 450IU
45953593|NCT05149924|Drug|Gonal-f ®|Subcutaneous injection,starting dose within 75IU ~ 300IU determined by the age , maximum daily dose 450IU
45953594|NCT05149885|Device|SenseGuard monitoring|All subjects that recruited to the study will undergo MCT as usual with the addition of SG measurement after each Methacholine dose and spirometry test.
45953595|NCT00144131|Drug|Aranesp®|
45953596|NCT00147927|Behavioral|Sequential emails and web support|
45953597|NCT05149729|Procedure|Shortened hip arthroplasty|Crowe type 3 and 4 patients who underwent shortened hip prosthesis
45953598|NCT05149651|Drug|Totalfill|Totalfill® Bioceramic Root Repair Material -Fast Set Putty is a pre-mixed, bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
45953599|NCT05149651|Drug|MTA|ProRoot White MTA® is a bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
45953600|NCT05149612|Other|Heat Therapy|Patients in the intervention group will be treated with hot water bags twice, 20 minutes in the morning and 20 minutes in the evening, starting four hours after the operation until discharge. In accordance with the literature, the water bag filled with 55 ± 2°C hot water will be wrapped with 2 towels. The water bag will be applied to the shoulder area while the patient is in the fawler or semi-fawler position. After 20 minutes, the hot application will be terminated. Pain and physiological parameters of the patients will be evaluated at the 0th minute, 30th minute, 4th hour, 12th hour, 24th hour and 48th hour postoperatively. At the same time, when individuals have pain, analgesics will be administered at the request of the physician.
45953601|NCT00144209|Drug|pramipexole|
45953602|NCT00144209|Drug|levodopa in combination with benserazide|
45953603|NCT05149339|Drug|Cholecalciferol 2800 I.U. ml oral drops|"(Cholecalciferol 2800 I.U. ml) Oral Drops 15 ml. supplied with a dropper.~Composition:~Each 1 ml (= 28 drops) of oral solution contains: Vitamin D3 (Cholecalciferol) 2800 I.U., (each drop contains 100 IU of vitamin D3)."
45953604|NCT00156468|Behavioral|Provider Prompt|
45953605|NCT00144248|Drug|nevirapine|
45953606|NCT05149183|Other|cervical stability training|cervical stability training will be contain three phases, each phase has six positions ( supine, forearms, sidelying, four point kneeling, sitting and standing position)
45953607|NCT05149183|Other|traditional treatment|TENS, hot packs, stretching exercise of superficial neck muscles, and postural advice.
45953608|NCT05149066|Behavioral|#KindGirlsInACTion|9-session weekly cognitive-behavioural intervention to promote psychological well-being and prevent body image and eating-related disordered behaviours.
45454108|NCT00332956|Biological|rFIV vaccine|rF1V vaccine 80 mcg given by intramuscular (IM) injection into the arm on study Days 0, 28, 182
45454109|NCT00332956|Biological|rF1V vaccine|rF1V 80 mcg vaccine given by intramuscular (IM) injection into the arm on study Days 0, 56, 182
45454110|NCT00332956|Biological|rF1V vaccine|rF1V 160 mcg vaccine given by intramuscular (IM) injection into the arm on Study Days 0, 28, 182
45660772|NCT05491343|Drug|MedroxyPROGESTERone Injection [Depo-Provera]|The drug-induced endometrial changes would likely to prevent the shedding of endometrium, in turn preventing the exposure of AVM.
45814869|NCT02198040|Other|Educational group|"Theory: Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of elbow; Anatomy of elbow musculature. Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations and treatment; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~Practice: exercises in favor of gravity; isometric and isotonic exercises of elbow; active exercises for mobility and pain management; elbow proprioception exercises; and swimming technique."
45814870|NCT02618720|Drug|ornidazole|
45814871|NCT02618720|Drug|Placebo|
45814872|NCT04338139|Procedure|bone regeneration|bone regeneration using bio-oss collagen
45953609|NCT00148005|Procedure|Questionnaire and micturition and drinking diaries|
45953610|NCT00148005|Procedure|Clinical and functional examination (uroflowmetry, bladder scan and video-urodynamic examination)|
45953611|NCT00148005|Behavioral|Adaptation of the drinking scheme|
45953612|NCT00148005|Drug|Anticholinergic therapy|
45953613|NCT00148005|Behavioral|Micturition clock|
45953614|NCT00506740|Device|Ultrasonic scalpel|A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
45953615|NCT00506740|Device|monopolar electrosurgery generator and tip|
45454111|NCT00332956|Biological|rF1V vaccine 160 mcg given on Study Days 0, 56, 182|rF1V 160 mcg vaccine given by Intramuscular (IM) injection into the arm on Study days 0. 56, 182
45953616|NCT00144287|Drug|Tipranavir/Ritonavir|
45953617|NCT02276404|Behavioral|relaxation training|"The relaxation sessions comprise an introduction in 3 relaxation techniques conducted by a mind-body therapist: Body Scan, mindfulness meditation and imagination. Patients also receive a CD with different relaxation exercises and the instruction to exercise daily at home for at least 15 minutes."
45953618|NCT02276404|Other|acupuncture|The acupuncture treatment comprises needling of 6 standardized acupoints: Pericardium 6, Stomach 36, Large intestine 4, Spleen/Pancreas 10, Dumai 20, Liver 3, Shenmen. Additional points can be chosen individual.
46077873|NCT04254497|Diagnostic Test|EGFR mutation detection kit|A microsieve membrane filter device to effectively isolate circulating tumor cells from whole blood sample has been developed by the Institute of Bioengineering and Nanotechnology. The device exploits the size difference between cancer cells and blood cells to achieve the cancer cell capture on a microsieve filter with > 85% recovery rate from 4.5-ml whole blood within 10 min, demonstrated with cancer cells spiked into whole blood samples. The device contains a densely packed pore array (> 8000 pores/mm^2) with an optimized pore diameter of 10 µm. Fluid regulation and cell counting are achieved by a simple vacuum pumping and laboratory fluorescence microscope. The captured cells are stained with anti-EpCAM-PE for CTCs, anti-CD45-FITC for white blood cells, and 4',6-diamidino-2-phenylindole (DAPI) for cell nuclei. The CTCs are identified with anti-EpCAM positive, anti-CD45 negative and DAPI positive, characterized using a fluorescence microscope.
45953619|NCT05149027|Drug|HBM4003 and Triprilimab|Subjects will be treated with HBM4003 and Toripalimap on Day 1 during each 21-day cycles.
45953620|NCT05148988|Diagnostic Test|EchoPIV|All patients will undergo an echoPIV measurement 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair. These measurements will take place at the Vascular Center of Rijnstate Hospital. A venous cannula will be inserted to enable contrast administration. Ultrasound data will be collected at the caudal renal artery, infrarenal neck, aneurysm sac and both iliac arteries.
45953621|NCT05148988|Diagnostic Test|4D flow MRI|A 4D phase-contrast magnetic resonance imaging (4D flow MRI) scan of the abdominal aorta will be obtained 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair.
45660773|NCT05491343|Device|Other|Follow up using US
45953622|NCT00156507|Behavioral|Asthma education for parents of very low birth weight infants|Asthma education is provided to parents of children in the experimental group prior to nicu discharge.
45953623|NCT02954731|Behavioral|UP-CBT|"Psychotherapy in groups based on the Unified Protocol a third generation CBT-type psychotherapy"
45953624|NCT02954731|Behavioral|Standard-CBT|Psychotherapy in groups based on diagnosis specific, manualized, cognitive behavior therapy
45953625|NCT00144326|Drug|Tiotropium Bromide|
46077874|NCT00904111|Drug|Lidoderm®|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
46077875|NCT00904111|Drug|Placebo Topical Patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
45660774|NCT05498441|Device|High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|High-Definition Transcranial Direct Current Stimulation (HD-tDCS) is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each HD-tDCS treatment, the electrode field is generated by a 4*1 ring montage which is placed over the scalp on the brain region of interest with an electrical current induced to modulate brain activity.
45660775|NCT05498441|Drug|Quetiapine, lithium and divalproate|During the HD-tDCS treatment period, all the participants will maintain the stable medication regimen including first-line pharmacological therapy (quetiapine, lithium and divalproate) according to clinical practice guidelines.
45660776|NCT05498285|Behavioral|UPSCALER app|Usage of mobile app to guide rehabilitation after surgery
45660777|NCT04275557|Other|Blood Sample collection|Participants will be asked to donate blood at baseline (+/- 30 days of diagnosis date), 4-6 weeks post-surgery, if applicable, and at the time of follow-up (approximately 1 year and approximately 2 years after baseline).
45660778|NCT04275557|Other|Tissue sample collection|At the time of tissue biopsy and surgical resection (if applicable), pancreatic tumor tissue, muscle, fat, tissue from site of metastasis, and cyst fluid (if applicable) will be collected.
45953626|NCT00144326|Drug|Placebo|
45953627|NCT02954692|Drug|INSULIN GLARGINE (U300)|"Pharmaceutical form: pen for injection~Route of administration: subcutaneous"
45953628|NCT02954692|Drug|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
45953629|NCT02954692|Drug|sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
45953630|NCT02954692|Drug|meglitinides|"Pharmaceutical form: tablet~Route of administration: oral"
45953631|NCT02954692|Drug|thiazolidinediones|"Pharmaceutical form: tablet~Route of administration: oral"
45953632|NCT02954692|Drug|alpha-glucosidase inhibitors|"Pharmaceutical form: tablet~Route of administration: oral"
45953633|NCT02954692|Drug|GLP1 Receptor Agonist|"Pharmaceutical form: pen for injection~Route of administration: subcutaneous"
45454112|NCT04471324|Device|EBUS cryo probe|patients receive a transbronchial cryo biopsy with the EBUS cryo probe from ERBE and an ultra thin bronchoskope
45660779|NCT04275557|Other|Data collection|Participants will be asked to complete questionnaires at baseline and at 1 year and 2 year follow-ups.
45660780|NCT05498363|Biological|Bacteriophage therapy|Difficult-to-treat bacterial infections were treated with bacteriophages (selected from a collection of 25 individual bacteriophages and 6 bacteriophage cocktails), which were shown to target the patient's infecting bacterial strain (in vitro)
45953634|NCT02954692|Drug|Dipeptidyl peptidase-IV (DPP-IV) inhibitors|"Pharmaceutical form: tablet~Route of administration: oral"
45953635|NCT02954692|Drug|Sodium-glucose transport-2 (SGLT-2) inhibitors|"Pharmaceutical form: tablet~Route of administration: oral"
45953636|NCT00506818|Other|Multifactorial vascular-risk-factor-intervention|
45953637|NCT00148044|Procedure|Blood sampling for determination of uremic toxins|
45953638|NCT00506896|Drug|intraarticular injection|Triamcinolone hexacetonide 60mg(3ml)by intraarticular injection Triamcinolone acetonide 60mg (3ml)by intramuscular administration
45953639|NCT00506935|Drug|GVG|5 grams GVG
45953640|NCT00506935|Drug|placebo|placebo
45953641|NCT00144365|Drug|Antiretroviral therapy|
45953642|NCT00506974|Drug|sodium oxybate|3.5 g of sodium oxybate or placebo on two of the five overnights.
45953643|NCT00156546|Drug|antibiotic to reduce the recurrence of infection|
45660781|NCT05491265|Behavioral|Intermittent Kangaroo mother care|Skin to skin contact between mother and preterm newborn between gestational age 28 weeks to 36+6 weeks for three sessions per day ,each contact session of two hours .
45953644|NCT00507013|Device|QuickClose device|
45953645|NCT00507052|Drug|N-acetylcysteine|
45953646|NCT00507091|Drug|ZD6474 (vandetanib) 100mg|once daily oral tablet
45953647|NCT00507091|Drug|Irinotecan|intravenous infusion
45660782|NCT05497193|Drug|perampanel|China's state food and drug administration approved indications for adults and children aged 4 or more focal epileptic hair company or not with secondary comprehensive seizures of epilepsy, adding treatment, in July 2020 to monotherapy without clinical approval, the current domestic perampanel monotherapy clinical effectiveness and safety of focal epilepsy in children have not been reported.
45660783|NCT05486195|Drug|SDI-118|SDI-118 Powder in Capsule
45660784|NCT05486195|Drug|Placebo|Matching Placebo
45953648|NCT00507091|Drug|5-Fluorouracil|intravenous infusion
45953649|NCT00507091|Drug|Leucovorin|intravenous infusion
45953650|NCT00507091|Drug|ZD6474 (vandetanib) 300mg|once daily oral tablet
45953651|NCT05148910|Device|Silver and copper IUD (TCu380Ag)|An intrauterine device containing 380mm² of copper with a silver core.
45953652|NCT05148910|Device|Copper IUD (TCu380A)|An intrauterine device containing 380mm² of copper.
45953653|NCT00148083|Drug|Risperdal Consta (drug)|
45953654|NCT00148083|Behavioral|Social Skills Training|
45953655|NCT04726436|Other|Dextrose 5% in water|One hour before operation, patients were given dexrose 5%100/hour only for 2 hours to end at about middle of surgery
45814873|NCT03758989|Drug|Rituximab Prednisone|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
45660785|NCT05486039|Behavioral|Changing behaviour|Changing the lying position and mattress system
45814874|NCT03758989|Drug|Cyclophosphamide|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
45814875|NCT03758989|Drug|Doxorubicin|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
45814876|NCT03758989|Drug|Vincristine|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
45814877|NCT03758989|Drug|Prednisone|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
45953656|NCT04726436|Other|Dextrose 10%|One hour before operation, patients were given dexrose 10 %100/hour only for 2 hours to end at about middle of surgery
46077876|NCT02750280|Device|MatriStem® [Urinary Bladder Matrix (UBM)]|Porcine derived urinary bladder extracellular matrix
46077877|NCT02750280|Device|Mepilex® [Silicone foam dressing]|primary wound dressing
46077878|NCT00781365|Other|Telemonitors and pharmacy management|Patients in the intervention arm will receive home blood pressure monitors, and will have individual hypertension case management from a medication therapy management pharmacist.
46077879|NCT00604643|Device|TALENT Aortic Cuff Abdominal Stent Graft|Endovascular Aneurysm Repair
45814878|NCT05359562|Behavioral|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD. This is a brief protocol consisting of 8 sessions of exposure and Response Prevention (EX/RP). This protocol includes two psychoeducation/planning sessions, followed by six exposure sessions.
45814879|NCT05359328|Device|Pulse Oximeter, Respiratory Rate, Heart Rate and Arterial line|Measurement of physiological parameters
45814880|NCT03733249|Drug|Rimiducid|Rimiducid is administered to treat chronic graft versus host disease
45953657|NCT04726436|Other|Saline placebo|One hour before operation, patients were given normal saline100/hour only for 2 hours to end at about middle of surgery
45814881|NCT03733249|Biological|rivogenlecleucel|donor T-cells modified with iCasp safety switch
45814882|NCT02197806|Drug|AGN-199201|1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.
45814883|NCT02197806|Drug|AGN-190584|1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.
45953658|NCT05148676|Other|Residual Symptoms and the Quality of Life in Individuals Recovered from COVID-19 Infection: A Survey from Pakistan|An anonymous online survey was administrated in Pakistan from November 2020 to April 2021 in COVID-19 survivors. The questionnaire used the 12-Item Short Form Health Survey (SF-12) to assess mental and physical QoL. Multivariate linear regression was used to explore factors associated with mental and physical QoL scores.
45953659|NCT05148520|Behavioral|5A's model|"(1) Ask - ask youth smokers about their smoking habit, (2) Advise - advise youth smokers to quit smoking, (3) Assess - assess youth smokers about their willingness to quit smoking, (4) Assist - assist youth smokers who are willing to make a quit attempt, and (5) Arrange~- arrange for follow-up."
45953660|NCT00406770|Device|Light therapy|
45953661|NCT05148442|Drug|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody
46077880|NCT03912636|Behavioral|Diaphragmatic breathing|Subjects will perform Diaphragmatic breathing after the test meal.
46077881|NCT03912636|Behavioral|Deep Slow Breathing|Subjects will perform Deep Slow Breathing after the test meal.
45660786|NCT05497739|Drug|Intraperitoneal chemotherapy|5-Fu 1 g/m^2 on Days 1, 8, 15, and 22; Albumin-paclitaxel 80-100 mg/time on Days 1, 8, 15, and 22; Cisplatin 25 mg/m^2 on Days 4, 11, 18, and 25; Interleukin-2 2 million units/time on Days 4, 11, 18, and 25.
45814884|NCT02197806|Drug|AGN-199201 Vehicle|1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.
45953662|NCT05148442|Drug|HMA|Azacitidine is a chemical analogue of the nucleoside cytidine, which is present in DNA and RNA. It is thought to have antineoplastic activity via two mechanisms - at low doses, by inhibiting of DNA methyltransferase, causing hypomethylation of DNA,and at high doses, by its direct cytotoxicity to abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA, resulting in cell death. Decitabine is a hypomethylating agent.It hypomethylates DNA by inhibiting DNA methyltransferase.
45953663|NCT05148403|Drug|glibenclamide|Glibenclamide was given orally or by nasal feeding
45953664|NCT00144443|Behavioral|Basic home repair|
45953665|NCT00144443|Behavioral|Asthma Trigger Education|
45953666|NCT05148325|Drug|BAT4706|The administration cycle was proposed to be 3 weeks (Q3W), i.e., 21 days in a cycle, and the first 4 cycles were administered on the first day of each cycle.
45953667|NCT05148208|Device|Creatine supplementation to dialysate|Creatine supplementation to dialysate
45953668|NCT05148169|Drug|SSRIs|One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.
45953669|NCT05148169|Dietary Supplement|SSRI plus Sulforaphane|"One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.~The oral dose of SFN (ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.) is based on weight. The usage and dosage are as follows: 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day (containing 411μmol of glucosinolates). Take it once in the morning and evening."
45953670|NCT05148130|Diagnostic Test|oral glucose tolerance test|GDM should be diagnosed at any time in pregnancy if one or more of the listed criteria are met following a 75-gram glucose load: fasting plasma glucose ≥5.1 mmol/l; 1-hour plasma glucose ≥10.0mmol/l; 2-hour plasma glucose 8.5-11.0 mmol/l. Those women diagnosed with diabetes or pre-diabetes (impaired fasting glucose or impaired glucose tolerance) before pregnancy were excluded from the study.
45953671|NCT00144482|Drug|recombinant human erythropoietin|36000IU（0.5mL）s.c./week for 8 weeks
45953672|NCT00144482|Drug|recombinant human erythropoietin placebo|0 IU(0.5mL)s.c./week for 8 weeks
45953673|NCT02276599|Procedure|Volume expansion|Fluid bolus of 0.9% normal saline 10 mL/kg over 10 minutes
45953674|NCT05148754|Drug|Elsulfavirine|Elsulfavirin 200 mg tablets.
45953675|NCT00404729|Drug|Citicoline|Ten OAG patients will be untreated (NT-AOG, 10 eyes), while 20 OAG patients (T-AOG, 20 eyes) and 15 NION patients (T-NION, 14 eyes) were treated with Citicoline (oral treatment:1600 mg/die per 60 days)
45953676|NCT05146687|Other|Aflibercept|intravitreal injection
45953677|NCT05146687|Other|Ranibizumab|intravitreal injection
45660787|NCT05497739|Drug|Adjuvant systemic chemotherapy|Oxaliplatin 85 mg/m^2 on Day 1; S-1 depends on Body Surface Area (BSA), 40 mg Bid, Days 1-10 (BSA < 1.25 m^2), 50 mg Bid, Days 1-10 (BSA 1.25-1.50 m^2), 60 mg Bid, Days 1-10 (BSA > 1.50 m^2).
45660788|NCT04276727|Drug|MINT study IMP|Application of gel for 6 weeks.
45660789|NCT05485883|Drug|Tislelizumab Lenvatinib|Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects
45814885|NCT03660085|Behavioral|PC-PEP|"The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips."
45953678|NCT05146687|Other|Bevacizumab|intravitreal injection
45953679|NCT05141929|Behavioral|web based education|In addition to routine care, web-based education was offered to pregnant women with Gestational Diabetes Mellitus.
45953680|NCT05141578|Behavioral|Luci Coach Assisted Intervention|"The Luci intervention is a personalized behaviour change program delivered via an interactive mobile platform with the online support of a coach. It targets 3 lifestyle domains: physical activity, healthy diet and cognitive engagement.~Participants in this group will be encouraged to adopt a healthy lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and by assisting participants outlining goals to progressively adopt and maintain a healthier lifestyle.~Coaching sessions will be held on a weekly basis from week 1 to 12, and every 2 weeks from week 13 to 24."
45953681|NCT00404807|Device|CPAP(Continuous Positive Airway Pressure)|
45953682|NCT05144659|Procedure|Double faced transverse preputial onlay island flap|A well-established one-stage repair of penile hypospadias called Double faced transverse preputial onlay island flap
45953683|NCT05144659|Procedure|Transverse inner preputial onlay island flap|A second well-established one-stage repair of penile hypospadias called Transverse inner preputial onlay island flap
45953684|NCT00156624|Drug|Balloon Angioplasty with or without drug administration|
45953685|NCT05141422|Drug|SHR2150 tablet、efavirenz|SHR2150 tablet single dose, Efavirenz single dose.
45953686|NCT00404846|Procedure|Hyperbaric Oxygenation Therapy|
45953687|NCT00156663|Behavioral|Caring for Women Veterans|
45953688|NCT05141461|Procedure|Group C|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, a 50 mm block needle will be advanced into the interscalen area using the in-plane method. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area. 100 ml of NACI will be given intravenously within 15 minutes.~General anesthesia will be performed using 2 mg/kg of propofol and 1-2 µg/kg of fentanyl. Tracheal intubation will be facilitated with 0.6mg/kg rocuronium. Anesthesia will be maintained using 50% oxygen and 2% sevoflurane. Patients will be extubated into the operating room after reversing residual muscle relaxation. A multimodal analgesia regimen will be applied postoperatively."
46077882|NCT03912636|Behavioral|Normal breathing|Subjects will perform Normal Breathing (as a control) after the test meal as a control.
46077883|NCT03240211|Drug|Pembrolizumab|Pembrolizumab 200 mg IV
46077884|NCT03240211|Drug|Pralatrexate|Pralatrexate 20 or 30 mg/m2 IV push
46077885|NCT03240211|Drug|Decitabine|Decitabine 10 mg/m2
45660790|NCT05485727|Other|The Lokomat® Pro Hocoma USA & Conventional physical therapy|Lokomat Consists of robotic gait orthosis and an advanced body weight support system, combined with a Treadmill. (used for gait training) and Conventional Physical Therapy
45660791|NCT05485727|Other|Conventional Physical Therapy|Balance Exercises , Gait training, Trunk control, Range of motion exercises for lower limbs
45660792|NCT05496959|Drug|Lutetium Lu-177 PNT2002|Given IV
45660793|NCT05496959|Other|Quality-of-Life Assessment|Ancillary studies
45660794|NCT05496959|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
46077886|NCT04103229|Procedure|The use of different types and volumes of solutions to inflate the catheter balloon|In catheterization procedure, catheter balloon was inflated according to the type and amount of fluid appropriate to the group to which the patient was assigned.
45454113|NCT04471012|Other|Individual counselling program|"An individual counseling program that was based on TM and included motivational interview techniques was given to the experimental group which involved general information about the importance of weight control, healthy diet, and exercise.~Benefits of Healthy Diet and Physical Activity in PCOS Training Booklet was given during their first counseling session."
46077887|NCT04278144|Drug|BDC-1001|Immune stimulating antibody conjugate (ISAC), consisting of an anti-HER2 monoclonal antibody conjugated to a TLR 7/8 dual agonist
45660795|NCT04273607|Drug|Subcutaneous Heparin|The intervention group will receive prophylactic heparin instead of standard of care therapeutic intravenous heparin
46077888|NCT04278144|Drug|Nivolumab|Programmed death receptor-1 (PD 1)-blocking antibody
46077889|NCT00899197|Drug|tamoxifen citrate|
46077890|NCT00899197|Genetic|gene expression analysis|
46077891|NCT00899197|Genetic|protein expression analysis|
45660796|NCT02548585|Drug|MEDI0382|MEDI0382 administered subcutaneously.
45660797|NCT02548585|Drug|Placebo|Placebo administered subcutaneously.
45660798|NCT05480605|Behavioral|Occupational Therapy|Children with autism will receive 6 - 8 weeks of regularly scheduled occupational therapy at Nationwide Children's Hospital outpatient centers. The intervention consists of one-hour weekly sessions with a licensed occupational therapist.
45454114|NCT00324220|Drug|MGCD0103|MGCD0103 Oral administration 3 times per week.
45660799|NCT05480371|Device|Conventional tracheal suctioning|"Group 1 allocated to conventional tracheal suctioning,all patiemts will be followed up until discharge from ICU or death~Tracheal suctioning will be performed following the American Association for Respiratory Care recommendations."
45660800|NCT05480371|Device|Mechanical insufflation/exsufflation|Group 2 will be allocated to mechanical insufflation-exsufflation which will be performed with the which will be applied 5 times in 5cough cycles in automatic mode, with insufflation and exsufflation pressures of + 40/-40 cmH2O, respectively. The duration of each phase was 3 s, without pause. Hyperoxygenation (100% O2) will be performed for 1 min before applying each technique and a 20 s interval will be allowed between repetitions.
46077892|NCT00899197|Other|immunoenzyme technique|
46077893|NCT00899197|Other|laboratory biomarker analysis|
46077894|NCT00603083|Drug|Ropivacaine, Ketorolac and Adrenalin|The local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg is given 10 and 22 hours after the operation. The medicine solution is administrated in a catheter, which is placed in the hip at the end of the operation.
45660801|NCT05476081|Drug|Aspirin|Aspirin (100-300 mg) administered for 21-90 days in combination with another antiplatelet treatment
45660802|NCT05476081|Drug|Clopidogrel|Clopidogrel (75-600 mg) administered for 21-90 days in combination with another antiplatelet treatment
45660803|NCT05476081|Drug|Ticagrelor|Ticagrelor (90-180 mg) administered for 21-90 days in combination with another antiplatelet treatment
45660804|NCT05480215|Device|Cala Device|transcutaneous afferent patterned stimulation (TAPS)
45660805|NCT04479553|Drug|Qizhi Tongluo Capsules|Qizhi Tongluo Capsule, a Chinese patent medicine composed of 26 Chinese herbs, has been approved by China Food and Drug Administration for treating recovery period of ischemic stroke (drug approval numbers: B20171001).
45814886|NCT05353322|Behavioral|Sedentary Break (Walking) Condition|For the sedentary break (walking) condition, participants will be randomized to 1 of 25 combinations of frequency (5 doses: sedentary break every 30, 45, 60, 90, or 120 minutes) and duration (5 doses: sedentary break duration of 1, 3, 5, 7, or 10 minutes). Participants will complete a 9-hour study visit and will remain seated throughout the lab visit and will take regular sedentary breaks by walking on a treadmill at 2.0 mph and 0% incline at specific frequency and duration (as determined by the randomization method) for the entirety of the visit.
45814887|NCT05353322|Behavioral|Sitting (Control) Condition|While completing the sitting (control) condition, participants will complete the 9-hour study visit by remaining seated and only standing up/walking to use the restroom at specified times.
45454115|NCT02283346|Radiation|HDR brachytherapy + hypofractionated EBRT|"Single Fraction High Dose Rate (HDR) Brachytherapy One fraction with 10-15 Gray (Gy) (depending on normal tissues constraints).~+ Hypofractionated External Beam Radiotherapy (EBRT) The treatment will be held with fractions 2.5 Gy per day, with a final dose between 25 and 50 Gy (depending on normal tissues constraints)."
45814888|NCT05353322|Behavioral|Controlled Diet|Participants in both the experimental and control groups will eat a controlled diet (breakfast, lunch, dinner, snacks) for two full days before each lab visit. They will also eat a controlled diet (breakfast, lunch) during each of the two lab visits. Participants will choose 1 of 3 dietary menus to eat for the study duration. Each meal will be individualized to meet 33% of daily estimated energy requirements. Target macronutrient profile will be 12-15% energy from protein, 55-58% from carbohydrate and 29-31% from fat; as well as 55 mmol of sodium and 24 mmol of potassium.
45953689|NCT05141461|Procedure|Group Dex|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, a 50 mm block needle will be advanced into the interscalene area using the in-plane method. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area. 5 mg dexamethasone intravenously will be given in 100 ml NACI within 15 minutes.~General anesthesia will be performed using 2 mg/kg of propofol and 1-2 µg/kg of fentanyl. Tracheal intubation will be facilitated with 0.6mg/kg rocuronium. Anesthesia will be maintained using 50% oxygen and 2% sevoflurane. Patients will be extubated into the operating room after reversing residual muscle relaxation. A multimodal analgesia regimen will be applied postoperatively."
45953690|NCT05140135|Behavioral|Recovery Oriented Cognitive Therapy (CT-R)|The CT-R that will be implemented in the present study will focus on strengthening aspirations and focusing on activities that can bring about one's desired life. In CT-R, clinicians use techniques to engage the patient in the adaptive mode, which includes cognitions, affects, motivation, and behaviors that are activated when the individual is engaged in personally meaningful activities.
45676609|NCT03193190|Drug|Tiragolumab|Tiragolumab will be administered as per the schedule specified in the respective arm.
45953691|NCT05140135|Other|Treatment as Usual|All patients enrolled in the study who are randomized to the continued care as usual condition will continue to receive the treatments from their physician/treatment team at the Community Mental Health Center; however, they will not receive the adjunctive CT-R treatment.
45676610|NCT03193190|Drug|Tocilizumab|Tocilizumab will be administered as per the schedule specified in the respective arm.
45953692|NCT00404885|Drug|Placebo|PO BID
45953693|NCT00404885|Drug|LX211|0.2 mg/kg, twice a day (BID)
45676611|NCT01611168|Other|Treatment Algorithms|subjects in the intervention group will receive diabetes care from a well-trained registered nurse (RN) who will follow approved treatment algorithms/protocols for glycemia, high blood pressure, lipids and microalbuminuria.
45953694|NCT00404885|Drug|LX211|0.4 mg/kg, twice a day (BID)
45953695|NCT00404885|Drug|LX211|0.6 mg/kg, twice a day (BID)
45953696|NCT05148832|Drug|Administration of Systemic Corticosteroid|10 mg of systemic corticosteroids were prescribed weekly to patients to observe taste and smell sensation recovery.
45953697|NCT05145985|Diagnostic Test|Senior Fitness Test|"Senior Fitness Test is comprised of 6 individual test items and for a description of the trials. All fitness tests (1-6) were selected for analysis:~Arm Curl (AC) - measurement of upper body muscle endurance - numbers of arm curls as possible in 30 seconds (n)~30-second Chair Stand (30SCS) - measurement of lower body strength; numbers of chair stand as possible in 30 seconds (n)~Back Scratch Test (BST) - measurement of upper-body flexibility; the best score to the nearest centimeter (cm)~Chair Sit and Reach Test (CSRT)- measurement of lower-body flexibility (specifically hamstring flexibility); the best score to the nearest centimeter (cm)~8-Foot Up and Go (TUG) - measurement of agility (dynamic balance) and aerobic endurance; the best time of the two trails to the nearest 1/10th second (s)~2-Minute Walk Test (2MWT) - measurement of (aerobic) endurance; the total number of times the right knee reaches the tape level in two minutes (n)"
45454116|NCT02284750|Procedure|Percutaneous coronary intervention|
45814889|NCT02323165|Other|Molecular Detection of Bacteria in the Bloodstream|Extracted nucleic acid will be tested by Polymerase Chain Reaction (PCR) with universal bacterial 16 S amplifiers from known 16 S sequences that routinely contaminate reagents. Polymerase Chain Reaction (PCR) will be performed with both TaqMan assays to provide quantitative copy numbers, as well as traditional PCR that can produce products that can be sequenced to confirm bacterial species identification.
45814890|NCT02171845|Other|surgical biopsies|
45953698|NCT00148239|Behavioral|Caregiver Only Intervention|A multi-component psycho-educational intervention designed to reduce the negative emotional and behavioral responses of the caregiver and reduce the risk of mental and physical health problems.
45953699|NCT00148239|Behavioral|Dual Treatment|Complements the caregiver only intervention by targetting both caregiver and SCI person with multi-component psycho-educational intervention
45953700|NCT00148239|Behavioral|Control|Participants given written educational materials at beginning of study; no treatment beyond this
45953701|NCT05140213|Device|Anti-infectious prescription support tool|"implementation of a pocket notebook with current anti-infectious recommendations in the emergency department Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
45953702|NCT00156702|Behavioral|Feedback and Motivational Interviewing|
45953703|NCT00156702|Behavioral|Smoking Prevention Video|
45953704|NCT05142943|Other|Visual illusion|the patient will be seated in a chair with a table in front of it. The front part of the trunk will be covered with a black blanket that will be attached to the table. On the table, you will see arms and hands projected performing different types of functional manual activities that will include mobility and strength tasks. The projected arms will be adapted to the dimensions of each subject so that the patient can recognize the projected arms as theirs. This program will last 10 minutes.
46077895|NCT00603083|Drug|Placebo|This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, which is placed in the hip at the end of the operation.
46077896|NCT02827058|Device|G25 pencil point needle|
45814891|NCT05340296|Behavioral|Acute Youth Connect|This intervention is being piloted will be revised with feedback from the first 5-10 patients who complete it. At the time of registration, the protocol is as follows: Roughly one week prior to discharge, the patient and a parent/caregiver will together nominate 3-4 trusted adults in the patient's life to serve as their post-discharge support team. Consenting nominees will then attend a 45-90 minute training on how to provide social support to the patient. Each adult support will also receive weekly (3-15 minute) check in calls from study staff to monitor progress and concerns. Each patient will also attend 3 interactive sessions with a study interventionist, and will be encouraged to bring an adult from their support team. These sessions will be evenly spaced throughout the post-discharge intervention period. Adolescents will receive weekly reflection-prompting text messages to practice skills taught in the interactive sessions.
45454117|NCT00323518|Drug|velafermin|administered intravenously as 100mL single dose over 15 minutes on day 1
45953705|NCT05142943|Other|Physical exercise|"General mobility and warm-up: flexion-extension joint movements, rotations, deviations, abduction-adduction, etc.~Gross mobility and coordination: ball games.~Fine mobility and coordination: writing tasks, puzzles, abacus ...~Strength exercises: shoulder, elbow, wrist, fingers.~Stretching."
45953706|NCT05142943|Other|Sham Visual illusion|only the placebo visual illusion
45953707|NCT05594966|Diagnostic Test|multimodal MRI|patients are diagnosed with cerebral small vessel disease preoperatively using multimodal MRI
45953708|NCT05148637|Drug|Maintenance of general anesthesia by Sevoflurane|Anesthesia was maintained by inhalational anesthesia (sevoflurane) titrated by monitoring of patient sensitivity index of the Masimo
45454118|NCT00323518|Drug|placebo|administered intravenously as 100mL single dose over 15 minutes on day 1
45660806|NCT05476003|Procedure|Ultrasound-guided Bilateral superficial cervical plexus block|"This nerve block is typically performed in the supine or semi-sitting position, with the head turned slightly away from the side to be blocked to facilitate operator access.~Under strict aseptic condition, the linear ultrasound transducer should be placed on the lateral neck, overlying the sternocleidomastoid muscle at the level of its midpoint (approximately the level of the cricoid cartilage). Once the sternocleidomastoid muscle has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.~Once the plexus has been identified and using In-Plane approach, the needle is passed from medial to lateral through the skin, platysma and investing layer of deep cervical fascia and the tip is placed adjacent to the plexus.~Following negative aspiration, 1 mL of local anesthetic is injected to confirm the proper injection site. The remainder of the local anesthetic (5ml) is administered to envelop the plexus."
45953709|NCT05148637|Drug|Maintenance of general anesthesia by Desflurane|Anesthesia was maintained by inhalational anesthesia (desflurane) titrated by monitoring of patient sensitivity index of the Masimo
45953710|NCT05148637|Drug|Anesthesia was maintained by inhalational anesthesia (total intravenous anesthesia by lidocaine, propfol and fentanyl infusions)|Anesthesia was maintained by inhalational anesthesia (total intravenous anesthesia by lidocaine, propfol and fentanyl infusions) titrated by monitoring of patient sensitivity index of the Masimo
45953711|NCT00148278|Drug|norepinephrine and dobutamine|continuous infusion of norepinephrine titrated to maintain a mean arterial pressure at 70mmHg or more and dobutamine could be added as a continuous infusion when cardiac index was of less than 2.5 liters per squared meter of body surface
45660807|NCT05476003|Drug|Midazolam|All patients will be premedicated with Midazolam (0.02mg/Kg).
46077897|NCT02827058|Device|G27 pencil point needle|
46077898|NCT00906919|Behavioral|Regular diabetes patient education|Professionally-led diabetes patient education delivered by health professionals over a two day period
45660808|NCT02547649|Biological|V114-A|Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).
45814892|NCT05306756|Diagnostic Test|Fetal Blood Sampling (FBS)|Vaginal examination, insert amnioscope through cervix, visualise fetal scalp, clean fetal scalp, apply ethyl chloride spray, wipe scalp with petroleum gel, small scalp scratch with sharp instrument, collect sample in heparinised capillary tube, analyse sample.
45953712|NCT00148278|Drug|epinephrine plus placebo of dobutamine|epinephrine was titrated to maintain a mean arterial pressure at 70mmHg or more and placebo of dobutamine was titrated in case of a cardiac index lower than 2.5 liters per squared meters of body surface
45953713|NCT05148091|Biological|SCTV01C|A Recombinant Trimeric S Protein Vaccine against SARS-CoV-2 Alpha and Beta Variants
46077899|NCT00906919|Behavioral|Augmented diabetes patient education|Professionally-led diabetes patient education led by nurse and dietitian over a two day period augmented by participation in the Stanford Chronic Disease Self-Management Program. This program takes place for 2 1/2 hours per week for six consecutive weeks.
46077900|NCT05379257|Combination Product|Random dosage and time of furosemide|Random dosage and time of furosemide, using a designated app
45454119|NCT02287792|Procedure|18-FDG PET/CT scan|Whole body 18-FDG PET/CT to assess cardiac and extracardiac complications in infective endocarditis
45454120|NCT00417118|Drug|Saredutant|oral administration (capsules)
45454121|NCT00417118|Drug|Escitalopram|oral administration (capsules)
45454122|NCT00417118|Drug|Placebo|oral administration (capsules)
46077901|NCT02695836|Other|Initial face-to-face dissemination workshop|Managers and directors of care will receive a printed report (tailored to their facility) on their facility's performance and performance of each unit (microsystem) within that facility. The workshop will include a presentation of the feedback reports with a particular focus on the core set of actionable context targets (Formal Interactions, Evaluation, Social Capital, Organizational Slack (OS) - Time) in the face-to-face workshops. Following the presentation, participants will discuss their reports in facilitated, round-table group discussions to a) help with interpretation of the results overall, b) draw attention to elements of context that are modifiable, c) encourage microsystem teams to work on improving the more modifiable areas
45454123|NCT02883452|Biological|CT-P13|CT-P13 (5 mg/kg) by IV infusion administered as a 2-hour IV infusion per dose every 8 weeks (Part 1)
45454124|NCT02883452|Biological|CT-P13|CT-P13 (120 mg) by single SC injection every 2 weeks (Part 1)
45660809|NCT02547649|Biological|V114-B|Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).
45660810|NCT02547649|Biological|Prevnar 13®|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), and 6B (4.4 mcg) in each 0.5 mL dose.
45660811|NCT03209479|Drug|Glatiramer acetate|Copaxone subcutaneous injection syringe
45660812|NCT05460949|Other|HOLD RELAX STRETCHING OF ILIOPSOAS|"10 second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20 second static stretch, 5 repetitions.~• The stretching exercise was performed 2 times a week for 8 weeks. 10 second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20 second static stretch, 5 repetitions.~The stretching exercise was performed 2 times a week for 8 weeks."
45660813|NCT05460949|Other|WILLIAM'S PROTOCOL|Pelvic tilt Single Knee to chest Double knee to chest Partial sit-up Hamstring stretch Hip Flexor stretch Squat Each group performed special trainings for 8 weeks, 2 sessions per week; each session took about 1 hour. Duration of each exercise was 8 to 10 seconds in each set. Protocols were started with 1 set of 10 repetitions at starting baseline and by improving performance and patients' compatibility with trainings, all eventually finished with 3 sets of 20 repetitions at the end of protocols.
45660814|NCT03097081|Other|No orthosis|The intervention consists of a deviation of the standard protocol; patients do not receive a post-operative orthosis
45660815|NCT03097081|Device|Orthosis|Patients receive post-operative care following the standard protocol and wear an orthosis for 10-12 weeks.
45953714|NCT05148091|Other|Adjuvant|SCT-VA02B is the adjuvant of SCTV01C VACCINE applied as one of the control in the trial
45953715|NCT05148091|Other|Saline|Saline is used as the other control in the trial
45953716|NCT05594849|Drug|Budesonide Orodispersible Tablets (Jorveza)|Patients that swith to Budesonide Orodispersible Tablets (Jorveza)
46077902|NCT02695836|Other|Face-to-face goal setting workshop|Sessions will build on the dissemination workshops and will be held three months after. Feedback reports on Formal Interactions, Evaluation, Social Capital, and Organizational Slack (OS) - Time will be discussed. Small group activities will take place including: a) reflecting on context data, b) performance goal setting using the 'tell and sell' method, which capitalizes on the workshop leaders' perceived expertise about what goals are achievable, c) establishing a series of proximal learning goals that will provide teams with explicit strategies for attaining performance goals set in (b). An action plan and instructions for reporting back at the Virtual Support Workshop will be provided.
45814893|NCT05306756|Diagnostic Test|digital Fetal Scalp Stimulation (dFSS)|Vaginal examination, insert one or two fingers through cervix onto fetal scalp, rub fetal scalp digitally for approximately 30-60 seconds, withdraw fingers and observe CTG for 5-10 minutes.
45814894|NCT04109599|Behavioral|PlaySmart|Participants played the developed PlaySmart game over the course of a week.
45660816|NCT03079297|Drug|L-Leucine|L-leucine is an essential amino acid which will be provided as an effervescent powder mixture to participants.
45953717|NCT00507169|Drug|SVT-40776|
45953718|NCT05143333|Other|DANA app|The Defense Automated Neurobehavioral Assessment (DANA) is a battery of cognitive tests delivered via an electronic tablet or smartphone. The platform allows higher temporal precision and frequency of measurement than traditional neuropsychological methods while including previously standardized cognitive tests and allowing individuals to repeatedly self-administer the battery in their own homes without examiner supervision. Hence, the DANA battery bypasses several of the major limitations associated with in-person cognitive exams.
45953719|NCT00156741|Device|Vitatron C50 D Model C50A2 of Vitatron C60 DR model C60A2|
45814895|NCT04109599|Behavioral|PlaySmart Storyline|Participants played through one PlaySmart Storyline during one 1-1.5 hour session.
45953720|NCT00156741|Procedure|Required pacemaker setting|
45953721|NCT00507247|Drug|Daptomycin|6mg/kg/day IV for at least 10 days.
45953722|NCT05594810|Behavioral|TAU + Addiction focussed - eye movement desensitization and reprocessing (AF-EMDR)|A total of six 45-90 min. sessions of AF-EMDR therapy with an average frequency of twice per week added to a SCP embedded in CRA. AF-EMD therapy consists of a rationale, installating a treatment goal, desensitasing mental video's, installation of positive cognition, future template and positive ending.
45953723|NCT05594810|Behavioral|TAU only: Community Reinforcement Approach (CRA) + SCP|"CRA is a comprehensive cognitive behavioural treatment that focuses on helping people discover and adopt a pleasurable, social and healthy lifestyle that is more rewarding than a lifestyle including substance use.~Within CRA a regular smoking cessation program is embedded."
45953724|NCT00507286|Drug|combination of various doses of sildenefil and alprostadil|
45814896|NCT04109599|Behavioral|Play Smart Mini-Game|Participants played through all levels of the PlaySmart Risk Sense mini-game during one 1-1.5 hour session.
45814897|NCT02229864|Device|Coronary artery stenting: Absorb BVS|"Scaffold diameters: 2.5, 3.0 and 3.5 mm~Scaffold lengths: 8, 12, 18, and 28 mm"
45953725|NCT05143762|Drug|paracetamol|patients will receive intravenous paracetamol 30mg/kg (max 90 mg/kg/day)
45953726|NCT05143762|Drug|Dexamethasone|patients will receive dexamethasone 0.5mg/kg IV.
45953727|NCT05143762|Drug|normal Saline|patients will receive placebo 10 ml normal saline IV.
45660817|NCT03079297|Other|Maltodextrin|Maltodextrin is a nonsweet carbohydrate which will be provided as an effervescent powder mixture similar in taste and appearance to the L-leucine containing effervescent powder mixture
45660818|NCT05475847|Biological|Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection|C-TIL052A injection followed by injection of IL-2
45953728|NCT05143450|Other|Manual Pressure|In the experimental group manual pressure will be applied to the injection site with the thumb for 10 seconds to the infants by the researcher before the procedure. Manual pressure reduces pain within the framework of the gate control theory. According to the gate control theory, when pressure is applied to an area, a fiber transmits the feeling of pressure instead of pain and ultimately the pain sensation is alleviated.
45953729|NCT00148356|Device|ZoMaxx™ Drug-Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
45814898|NCT04273802|Drug|CPX-351 in cohort A|"Treatment by CPX-351 via intravenous infusion over 90 minutes.~Induction treatment with CPX-351 100 Units/m²/D on days 1, 3 and 5.~If response after this induction treatment, 4 courses of consolidation therapy with CPX-351 100 Units/m²/D on day 1.~If no response after this induction treatment, a second induction course of CPX-351 100 Units/m²/D on days 1 and 3. If response is achieved after this salvage course, 3 courses of consolidation therapy with CPX-351 100 Units/m²/D on day1."
45953730|NCT00148356|Device|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
45953731|NCT05594771|Procedure|epidural needle|the loading dose for labor analgesia administrated via epidural needle before the catheter insertion
45953732|NCT05594771|Procedure|epidural catheter|the loading dose for labor analgesia administrated via epidural catheter
46077903|NCT02695836|Other|Virtual support workshops|On virtual support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges.
45660819|NCT02535715|Drug|ORMD-0801 capsules- 2x8mg|Participants who receive this intervention first, then receive either ORMD-0801- 3x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
45814899|NCT04273802|Drug|CPX-351 in cohort B|"Treatment by CPX-351 via intravenous infusion over 90 minutes.~This will be a dose-finding study : CPX-351 100 Units/m²/D on days 1, 3 and 5 or CPX-351 100 Units/m²/D on days 1 and 3 or CPX-351 60 Units/m²/D on days 1 and 3.~In response after induction treatment, 4 monthly courses of consolidation therapy with CPX-351 at the same dose on day 1."
45814900|NCT02229552|Other|Standardized Assessments|Children were asked to attend appointments without consuming study foods 24 hours previously, as habituation measurements are sensitive to recent consumption. Children were provided access to snack prior to completing questionnaires or cognitive assessments. Habituation to food, questionnaires and cognitive assessments were re-measured at 1-year and 2-year follow up.
45953733|NCT02954614|Behavioral|Active play in after school programs (ASP)|"A 15 hour training-program for ASP-staff aimed to increase active play and physical activity among children in ASPs. The program includes lectures, guided discussions and practical tasks focusing on increasing the staffs competence in how to support active play and PA among all children in the ASP~A 8 hour course for local physiotherapists enabling them to guide ASP-staff during parts of the intervention period"
45953734|NCT02954809|Device|Morning bright light therapy|Exposure to morning bright light therapy delivered with Green-Blue Re-Timer glasses for 30 minutes in the morning during one week.
45953735|NCT02954809|Device|Dim light|Exposure to dim light with Red-Yellow Re-Timer glasses for 30 minutes in the morning during one week.
45953736|NCT05140993|Behavioral|extended emotional and orientation support|extended emotional and orientation support
45953737|NCT00156780|Drug|AI-700|
45953738|NCT00507364|Drug|Local injection of activated macrophages to anal fissure|
45953739|NCT05145751|Other|Simple inflammatory biomarkers measurement|In patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection the values of simple inflammatory biomarkers such NLR will be measured
45953740|NCT00424281|Drug|Arixtra (fondaparinux), 2.5 mg/day-what is bioavailability|
45953741|NCT05144503|Device|SpherePVI™ Catheter|SpherePVI™ Catheter with the Affera Mapping and Ablation System
45953742|NCT05142631|Drug|Fruquintinib|To observe the efficacy and safety of Fruquintinib in the first-line treatment of desmoplastic small round cell tumor, epithelioid hemangioendothelioma, solitary fibroma or second-line and posterior line treatment of angiosarcoma.
45953743|NCT05146960|Other|Temporal summation|Temporal summation will be evoked in each predetermined area
45953744|NCT05146960|Other|Placebo|PPTs will be assessed once in each predetermined area
45953745|NCT00148395|Drug|Gemcitabine|
45953746|NCT00148395|Drug|Navelbine|
45953747|NCT00148395|Drug|Carboplatin|
45953748|NCT00148395|Drug|Cisplatin|
45953749|NCT00148395|Drug|Mitomycin|
45953750|NCT00148395|Drug|Ifosfamide|
45953751|NCT00405834|Device|Envision® Patient Support System|
45953752|NCT05140759|Device|automated continual water removal system|The device removes excess fluids in heart failure patients with diuretic resistance
45953753|NCT02964260|Drug|Chemotherapy drug|Doxorubicin/Platinum agents
45953754|NCT02964260|Drug|Embolic agents|Lipiodol/Gelatin sponge/PVA/Blank microspheres
45953755|NCT02964260|Procedure|Simultaneously|1-3 days
45953756|NCT02964260|Procedure|Sequentially|1 month
45953757|NCT02964260|Device|Ablation|Radiofrequency ablation/Microwave ablation
45953758|NCT05149105|Procedure|Argon plasma coagulation|On D0, in the operating room, argon plasma coagulation will be performed around the perimeter of the anastomosis for a period of 5 to 10 min under general anesthesia. The removal of the catheter and the endoscope will be carried out under control. Patients will be kept under surveillance the night following the procedure. A liquid diet will be prescribed for 10 days. The follow-up will be carried out on an outpatient basis with a control endoscopy at 2 months, followed by a new procedure in the event of an anastomosis larger than 1.5 cm. A new endoscopic check will be carried out at 4 months if an argon plasma coagulation was performed during the previous check, with a third and last argon plasma coagulation if an anastomosis of more than 1.5 cm persists. The number of procedures will therefore be a maximum of 3. A control endoscopy will be performed at one year for the final control of the anastomosis.
45953759|NCT02276677|Drug|Oxytocin|Single dose, intranasal
45953760|NCT02276677|Drug|Placebo|Single dose, intranasal
45953761|NCT02276716|Dietary Supplement|Phosphatidylserine|Phosphatidylserine will be titrated starting at 300mg/day dose for two months to 600mg/day dose for 2 months, then 800 mg/day dose for a final 2 month period.
45953762|NCT05144113|Behavioral|Survey subjects to discover their motivations, preferences and challenges pertaining to participation in physical activity in general and FES-rowing.|"The following questionnaires will be answered by subjects:~Questionnaires:~Barriers to Physical Activity Questionnaire for People with Mobility Impairments (BPAQ-MI): measures barriers to physical activity across the intrapersonal, interpersonal, organizational, and community domains.~Physical Activity and Disability Survey (PADS): measures physical activity for people with chronic neurological conditions.~Demographic and Mobility Questionnaire: Important information to inform on user and design needs and potential market for at home FES-row system.~Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0)-(FES-row participants only): measures satisfaction with current FES-row system used in the ExPD Program."
45660820|NCT02535715|Drug|ORMD-0801 capsules- 3x8mg|Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
45953763|NCT04696003|Combination Product|Continuous amnioinfusion with Amnion Flush Solution through the intraamniotic catheter|The amniotic cavity will be punctured with a 18 gauge needle under ultrasound control. The intraamniotic catheter (0.65 mm Diameter, CE 0481, PakuMed GmbH, Essen, Germany) will be placed under local anesthesia with Xylocaine 1% 10 ml. and the amnioinfusion (about 100 ml/h, 2400 ml/day) with artificial amniotic fluid (Amnion Flush Solution, CE 0483, Serumwerk AG Bernburg, Germany) will be carried out with an infusion rate of 100 ml/h under periodic ultrasound using the standard i.v. pump.
45953764|NCT05141344|Drug|Melatonin 3 MG Oral Tablet|it will be given orally one hour preoperatively
45814901|NCT04104217|Behavioral|Music therapy|Music therapy sessions may last 20-60 minutes, with length and frequency to be determined mutually (generally 1-3 times per week). Music therapy sessions are done at the patient's bedside, where the music therapist plays live music on a guitar, keyboard, harp, or percussion instrument, sometimes as accompaniment to singing.
45953765|NCT05141344|Drug|Placebo|sugar-coated tablets will be given one hour preoperatively
45953766|NCT03452293|Device|Stent Peripheral System|Peripheral PTA with Supera Stent implantation
45953767|NCT00156858|Drug|intravenous busulfan|
45953768|NCT03456271|Other||
45814902|NCT04104217|Behavioral|Interviews|Each interview will be conducted in person in a private setting (with the exception of caregivers, who have the option to conduct interviews over the phone if it is not feasible to take place in the hospital). Each interview will follow a semi-structured interview guide and will ask for consent to audio record the interviews .
45814903|NCT05284058|Other|Cardiac Magnetic Resonance Imaging (MRI)|Patients will undergo 2 MRI exams: 1 MRI before surgical intervention (maximum 21 days before) and 1 MRI three months after surgery (+/- 14 days), with intravenous administration of gadolinium.
45814904|NCT02042989|Drug|MLN9708|"Dose Escalation Phase - Starting Dose of MLN9708: 3 mg by mouth on day 1, 8 and 15.~Dose Expansion Phase Starting Dose of MLN9708: Maximum tolerated dose from Dose Escalation Phase."
45953769|NCT03451123|Drug|FET PET/MRI|FET PET/MRI scan before and after surgery
45953770|NCT03450733|Device|Wright Medical Technology Metal-on-Metal Total Hip System|Subjects in Group 1 previously implanted prior to the study start date will be identified from Investigator records. Collected data will be evaluated in aggregate and cross-sectioned by year of implantation. Subjects will be cross-sectioned by the time that has elapsed between implantation and the initial visit (e.g. 5 years, 6 years) using contiguous visit windows (number of years + 6 months). Subject data will be grouped in order to create cross-sectional epochs of ≤ 8 years and > 8 years.
45814905|NCT02042989|Drug|Vorinostat|"Dose Escalation Phase - Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.~Dose Expansion Phase Starting Dose of Vorinostat: Maximum tolerated dose from Dose Escalation Phase."
45953771|NCT05594498|Device|StrataXRT|StrataXRT is a silicone-based film-forming topical gel that may help in reducing radiation dermatitis.
45953772|NCT03451825|Drug|Avelumab|Subjects will receive avelumab administered intravenously (IV) once every 2 weeks.
45953773|NCT03451825|Drug|Avelumab|Subjects will receive avelumab at a recommended phase II dose (RP2D) adjudicated by a safety monitoring committee (SMC) from phase I part of the study.
45953774|NCT00156897|Drug|ATL-962|
45814906|NCT04267874|Procedure|Biospecimen Collection|Undergo collection of nasal swabs, blood, urine, and stool
45953775|NCT00156897|Drug|Orlistat|
45953776|NCT03450187|Drug|TP-271|multiple oral doses of TP-271 or placebo, randomized 6:2, doses escalating 50 mg, 100 mg, 200 mg, 300 mg, 400 mg once daily for 7 days.
45953777|NCT03459859|Drug|Pevonedistat|Administered intravenous (IV) infusion over one hour on Days 1, 3 and 5 of each cycle, after administration of LDAC per protocol.
45953778|NCT03459859|Drug|Cytarabine|Low dose Cytarabine (LDAC) administered subcutaneously (SC) daily for 10 days of every 28-day cycle.
45953779|NCT05594459|Procedure|Mini invasive analgesic technique|patients will be treated with early interventional neuromodulatory techniques, before high opioids dosages.
45953780|NCT05594459|Drug|high opioids dosages|patients will be treated with high opioids dosages
45953781|NCT00148434|Behavioral|Patient-held guideline for hypertension|
45953782|NCT00507403|Drug|infliximab|
45953783|NCT03454204|Other|Pharmacokinetic|Analysis of blood samples
45953784|NCT05594420|Procedure|Mitral valve replacement|Mitral valve replacement through median sternotomy and minimally invasive approach
45953785|NCT00156975|Drug|Capecitabine|
45953786|NCT00156975|Drug|Oxaliplatin|
45814907|NCT04267874|Dietary Supplement|Nutritional Supplementation|Given black raspberry nectar PO
45814908|NCT04267874|Drug|Placebo Administration|Given PO
45814909|NCT04267874|Other|Questionnaire Administration|Ancillary studies
45814910|NCT02014675|Device|SD01 ICD lead|
45953787|NCT03451162|Drug|DHES0815A|DHES0815A will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle.
45953788|NCT02955043|Behavioral|Behavioral techniques|"Improve nighttime sleep: Participants will receive a modified form of cognitive-behavioral therapy for insomnia with a primary focus on stimulus control, a set of techniques to strengthen the association between bed and sleep and weaken its association with stimulating behaviors.~Increase daytime activity: Participants will receive instruction in activity management strategies including prioritizing activities, planning activities during peak energy, activity pacing, and alternating between rest and activity. Participants will be provided with a basic step-count pedometer to enhance ability to self-monitor activity and increase motivation for activity.~The intervention will be adapted to individual needs based on assessments of sleep and activity patterns."
45953789|NCT02954419|Other|No intervention|No intervention
45814911|NCT02214134|Genetic|Tumour markers testing|
45814912|NCT04248686|Behavioral|CoED Online Intervention|Online, guided self-help ED intervention that offers cognitive behavioral therapy (CBT) based tools to improve ED symptoms, while also teaching the healthy methods of behavioral WL, for individuals with clinical/sub-clinical binge-type EDs with comorbid overweight/obesity
45814913|NCT02151032|Behavioral|Booklet|Participants read a booklet about colorectal cancer screening tests.
45814914|NCT02151032|Behavioral|Audio CD|Participants listen to an audio CD that will narrate the colorectal cancer screening tests booklet.
45814915|NCT02151032|Behavioral|Video with Non-Moving Images|Participants watch a video with non-moving images about colorectal cancer screening tests on an iPad.
45814916|NCT02151032|Behavioral|Video with Animated Images|Participants watch a video with animated images about colorectal cancer screening tests on an iPad.
45814917|NCT02151032|Behavioral|Questionnaires|Questionnaire completion before and after viewing the program.
45814918|NCT02072642|Device|active light therapy : Light therapy: DayVia lamp 10000 lux|4 weeks of active light therapy with DayVia lamp 10000 lux
45953790|NCT05594381|Drug|Sintilimab|"Neoadjuvant treatment method: Sintilimab 200 mg, i.v., d1 + oxaliplatin 130 mg/m2, d1, i.v., + Tegafur 40 mg po, bid, d1-14; 3-week course; Neoadjuvant therapy: 3 courses of preoperative SOX chemotherapy (oxaliplatin+Tegafur) + PD-1 monoclonal antibody (Sintilimab).~After the 2nd and 3rd cycles of neoadjuvant therapy (6-9 weeks from the start of treatment), imaging effects and feasibility of radical surgery were performed respectively; The operation time is arranged within 2-6 weeks after the last administration of neoadjuvant therapy, and the operation method is selected by the surgeon according to the actual needs; The postoperative treatment plan is the same as the preoperative neoadjuvant treatment plan, and the SOX+Sintilimab will continue to be given until the full 8 cycles (including the preoperative 3 cycles)."
45953791|NCT00148473|Drug|Misoprostol|
45953792|NCT00507520|Procedure|Full dose almonds|
45953793|NCT00507520|Procedure|Half dose almonds+half dose muffin|
45953794|NCT00507520|Procedure|Full dose whole wheat muffin|
45953795|NCT00507598|Other|No intervention|Correlative study collecting serum and tissue samples
45953796|NCT00507637|Drug|NT 201|Injection of up to 50 Units NT 201 (incobotulinumtoxinA/Xeomin®) per eye and injection visit (8 injections visits in total).
45953797|NCT05594342|Drug|Ivabradine 7.5Mg Tab|Patients will receive ivabradine 7.5 mg twice daily via oral route after dobutamine infusion by 30 minutes.
45814919|NCT02072642|Device|Placebo light therapy|4 weeks with Placebo light therapy
45660821|NCT02535715|Drug|ORMD-0801 capsules- 1x16mg|Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 3x8mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
45660822|NCT03949465|Device|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks
45660823|NCT05460247|Dietary Supplement|Protein|Participants will receive a diet supplemented by the above protein
45660824|NCT02336815|Drug|Selinexor|Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)
45660825|NCT02336815|Drug|Dexamethasone|20 mg was given with each dose of Selinexor.
45660826|NCT05467423|Dietary Supplement|Iron|4 weeks of daily oral iron therapy. The subjects administer the therapy themselves.
45660827|NCT05466643|Drug|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
45660828|NCT05466643|Drug|DWP16001 Placebo|1 tablet, Orally, Once daily single dose
45814920|NCT04093531|Drug|Ustekinumab|Up to 15 subjects will receive an infusion loading dose of 6 mg/kg of ustekinumab at baseline, and 90 mg of ustekinumab subcutaneously at week 4, week 12 and week 20. Subjects will be followed for 24 weeks.
45814921|NCT05272670|Behavioral|A digital foot self-management program|A 4-week digital foot self-management program based on Bandura's Self-Efficacy model. The proposed functions include checking conditions of foot, cleaning, cutting or removing corns and calluses, trimming, clipping nails, foot exercise, dietary related to foot care, foot care logs, etc. Which was developed for older adults with diabetic foot self-management by the study team. Week 1 one-hour face-to-face training session after participant recruitment and allocation. The outline session is 30 min to introduce key topics and function in the app platform, 15 min to install the app and to demonstrate the use of the app, 15min to discuss and practice. Week 2 to week 4 following phone call once per week at the end of week and LINE messages 3 times per week.by research nurse, who will encourage and monitor participant's compliance with the program at home by using the digital platform. Participants are informed that technical phone support is available during the trial.
45814922|NCT04065841|Drug|Tropifexor|Tropifexor is a highly potent, specific and orally available non-bile acid agonist of the bile acid receptor FXR.
45814923|NCT04065841|Drug|Licogliflozin|Licogliflozin is a selective and potent inhibitor of the sodium glucose co-transporters (SGLTs) 1 and 2
45814924|NCT04065841|Other|Placebo|licogliflozin placebo + tropifexor placebo
45814925|NCT05269316|Drug|IMP9064|IMP9064 Monotherapy administered for 21 days
45814926|NCT04186520|Biological|8/12-Day Production of Car-T Cells|A fixed dose of 2.5 x 10^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
45814927|NCT04186520|Biological|8/12-Day Production of Cryopreserved Car-T Cells|A fixed cryopreserved dose of 2.5 x 10^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
45814928|NCT04186520|Biological|12-Day Production of Car-T Cells|A fixed dose of 2.5 x 10^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
45660829|NCT02543203|Biological|Reconnect|Topical Essential Oils mixture and aromatic method
45660830|NCT02543203|Biological|Coconut oil Comparator|Topical Essential Oils mixture and aromatic method
45660831|NCT05434039|Other|diclofenac phonophoresis|the patients will be in comfortable position and apply diclofenac phonophoresis on upper trapezius and suboccipital muscle by ultrasound device. diclofenac gel was applied circularly with a thickness of 2-3 mm. Then ultrasound with was applied with 1 MHz frequency and 1.5 Wt/cm2 power over the trigger points on the trapezius and suboccipital muscle, for 10 min.
45953798|NCT05594342|Drug|DOBUTamine Injectable Solution|Dobutamine infusion by a dose that is titrated according to blood pressure Ranging from 5 to 20 ug/kg/minute
45953799|NCT00157053|Drug|Antihemophilic factor, recombinant, manufactured protein-free|
45953800|NCT00507715|Drug|Plantago ovata husk|5 g of effervescent powder (3.5 g pf plantago ovata husk) t.i.d. during 14 days
45953801|NCT00507715|Other|hemicellulose crystalline|5g effervescent powder t.id. during 14 days
45953802|NCT00507754|Other|T-SPOT TB test|Extra blood draw, followed by ten minutes rest and the injection of Tuberculin subcutaneously on forearm.
45953803|NCT00507793|Drug|Sirolimus|
45953804|NCT00507793|Drug|Cyclosporine|
45953805|NCT05594303|Biological|Autologuos transplantation of bronchial basal cells|Autologuos transplantation of bronchial basal cells
45953806|NCT00507832|Drug|Pimecrolimus|twice daily topical
45953807|NCT00507832|Drug|Hydrocortisone|twice daily topical
45953808|NCT00507832|Drug|Pimecrolimus|topical application as a cream twice daily
45953809|NCT00148512|Drug|1. Tesofensine (NS 2330)|
45953810|NCT00507949|Drug|Megestrol acetate|Sachets of 160 mg of granulated. Dosage 160 mg /b.i.d. Duration 8 weeks.
45953811|NCT00507949|Drug|placebo|sachets of granulate of 160 mg. Dosage 160 mg b.i.d. Duration 8 weeks.
45660832|NCT05434039|Other|high power pain threshold ultrasound|the patients will be in comfortable position and The frequency was set to 1 MHz, and the intensity will be increased from 0.5 to 2 until the patient reported an unpleasant sensation. The probe was held there for 4 s; then, the intensity was reduced by 50%, and the probe will be moved over and around the trigger point. This process is done several times for three minutes
45814929|NCT04172948|Device|Oculus go headset/virtual reality headset|10 minute virtual reality tutorial on diaphragmatic breathing, a game in practicing diaphragmatic breathing, and two scenarios in which the patient can also practice diaphragmatic breathing.
45814930|NCT04172948|Behavioral|Diaphragmatic breathing|10 minute tutorial on diaphragmatic breathing by a medical professional.
45660833|NCT05434039|Other|conventional therapy|the patient will receive an active range of motion exercise, stretching and strengthening of all cervical muscles
45660834|NCT05433571|Device|Test Lens|Multifocal Toric Contact Lenses manufactured in Senofilcon A (C3) material with UV/HEV filter
45660835|NCT05466175|Drug|Olverembatinib|Given PO
45814931|NCT04059757|Biological|Fecal Microbiota Transplantation (FMT)|1 dose = 30 capsules on day 1 of Fecal Microbiota Transplantation
45660836|NCT05466175|Drug|Prednisone|Given Intravenous
45660837|NCT05466175|Drug|Vincristine|Given Intravenous
45814932|NCT04164680|Diagnostic Test|Multimodal Neuroimaging|fludeoxyglucose (FDG-)PET/MR imaging
45953812|NCT02954263|Drug|TD-1439|
45953813|NCT02954263|Drug|Placebo|
45953814|NCT02954302|Procedure|PrPD with proximal Roux-en-y gastrojejunal anastomosis|the distal antrum was divided about 1 to 2 cm proximal to the pylorus ring, preserving more than 95% of the stomach. The proximal jejunum was divided approximately 2 to 4 cm distal to the duodeno-jejunal junction. After completion of the resection, the proximal end of the first loop of jejunum was then brought through the transverse mesocolon, and the gastrojejunal anastomosis (GJA) was performed in two layers by using 3-0 PDS sutures and 4-0 silk sutures in an end-to-side fashion. The jejunum was then divided 35 to 40 cm distal to the GJA, and the distal limb was brought separately through the transverse mesocolon to be placed in the duodenal bed for reconstruction of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA).
45953815|NCT02954302|Procedure|conventional PrPD|After completion of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA), a hand-sewn, isoperistaltic GJA was performed 25 to 30 cm distal to the HJA in two layers by using 3-0 polydioxanone (PDS) sutures and 4-0 silk sutures.
45953816|NCT00148551|Drug|Triamcinolone Acetonide|
45953817|NCT02954185|Other|WellClub|
45953818|NCT02954185|Behavioral|Standard Therapy|
45953819|NCT05594186|Drug|Tranexamic acid, Oral contraceptive pills and the Levonorgestrel-releasing intrauterine system.|Comparing three different nonsurgical management options for abnormal uterine bleeding caused by cesarean scar niche.
45953820|NCT02954380|Device|Zio|long term continuous monitoring
45953821|NCT00507988|Behavioral|Complex Problem Solving Training|10 sessions of 45 minutes complex problem solving training over 3 weeks (including 30 minutes of computerized planning and problem-solving training with Plan-A-Day and 15 minutes group session for transfer to everyday situations)
45953822|NCT00507988|Behavioral|Basic Cognitive Training|10 sessions over 3 weeks of 45 min basic cognitive training (including 45 min computerized training of attention, processing speed, memory)
45953823|NCT00157092|Drug|Aerosolized, Recombinant Alpha 1-Antitrypsin|
45660838|NCT05459077|Behavioral|Hypertension control through education and monitoring|Enrollment of 60 PLWH ≥18 years old receiving care at the Duke ID clinic who have achieved HIV viral suppression who take antihypertensive medication and have uncontrolled blood pressure. Subjects will have be given educational materials, blood pressure monitors to use and report findings, follow up with study coordinator and communication with subject's HIV provider in order to maximize blood pressure control..
45660839|NCT02546323|Drug|Rosuvastatin|20mg tablets, orally once daily for the duration of the 104-week treatment period
45660840|NCT02546323|Drug|Placebo|Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.
45660841|NCT02545933|Drug|Prasugrel|Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
45814933|NCT05224076|Other|Home Air Quality|This study will assess the feasibility and usability of ecological momentary assessment (EMA) to capture the context of real time behaviors and environmental exposures that impact indoor environments. In addition, the study will assess the feasibility and usability of providing participants with a readily available indoor home air quality monitor to continuously capture total volatile organic compounds (VOCs) and particulates (PM2.5).
45814934|NCT05208944|Drug|6-Thio-2'-Deoxyguanosine|small molecule telomere targeting agent
45814935|NCT05208944|Drug|Cemiplimab|programmed cell death protein 1 (PD-1) inhibitor
45814936|NCT01809379|Drug|chemotherapy with doxorubicin and cisplatin|intraperitoneal chemotherapy applied as an aerosol and under pressure
45814937|NCT01802840|Dietary Supplement|biscuits supplemented with soy fiber|Thirty nine overweight and obese college adults (19-39 y of age) were randomly assigned to consume control biscuits or biscuits supplemented with soy fiber for 12 wk (approximately 100g/d).
45814938|NCT01723969|Genetic|Tumour markers testing|Tumour markers testing in patients advanced or metastatic colo-rectal cancer.
45814939|NCT04140110|Other|Intensive BP lowering|The aim is to achieve a systolic BP level of <120mmHg within 1 hour after randomisation and to maintain this BP level for the next 72 hours (or until hospital discharge or death if this should occur earlier).
45953824|NCT02954107|Other|MRI|
45953825|NCT02954107|Other|24h-EEG + video|
45953826|NCT02954107|Other|Neuropsychological tests|
45953827|NCT00508222|Drug|Kaletra Tablets|Kaletra 800/200 OD
45953828|NCT05594108|Diagnostic Test|ultrasonography|transabdominal ultrasonography
45814940|NCT01666808|Drug|FACBC|FACBC is given intravenously prior to PET scan
45814941|NCT01666808|Radiation|Radiation therapy|External beam radiotherapy to prostate bed +/- pelvic lymph nodes; final dose of 66.6 Gy.
45953829|NCT02953951|Other|blood transfusion|blood transfusion different sources
45953830|NCT02953912|Procedure|Reciproc single-file|The Reciproc is a single-file nickel-titanium systems , made of a special nickel-titanium (NiTi) alloy called M-Wire created by innovated thermal treatment process which increases flexibility and improved resistance to cyclic fatigue
45953831|NCT02953912|Procedure|One Shape single-file|One Shape is one of the few single file made of austenite 55- NiTi alloy characterized by different cross sectional designs ,it is used in continuous clockwise rotation for a quick and safe root canal preparation due to its flexibility and minimal fatigue.In addition to , the electropolished safety tip instrument for enhanced cutting efficiency and it is delivered in a sterile blister for single use.
45814942|NCT02229396|Drug|Exantide with Dapagliflozin|2 mg weekly suspension injection and 10 mg Dapagliflozin
45814943|NCT02229396|Drug|Exentide|2 mg
45953832|NCT02954146|Behavioral|Connectd mobile application|Connectd is a mobile application that collects and automatically analyzes input from patients with PTSD/TBI, as well as their families, for clinician review. The app will aggregate patient and family input on current issues, relationship stressors, and situational stressors to better focus (personalize) treatment as well as to more efficiently and accurately understand key factors and root causes. In addition, the app provides informational resources for veterans and family regarding treatment options and mental health supports.
45953833|NCT00148590|Drug|Memantine|Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
45660842|NCT02545933|Drug|Vorapaxar|Vorapaxar will be administered at the dose of 2.5mg once daily
45660843|NCT02545933|Drug|Aspirin|Aspirin will be administered at the dose of 81mg once daily
45660844|NCT02545933|Drug|Ticagrelor|Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
45814944|NCT02229396|Drug|Dapagliflozin|10 mg once daily Dapagliflozin
45660845|NCT05432323|Behavioral|Multi-family therapy|8 sessions of Multi-family therapy of 3 hours each during 24 weeks
45814945|NCT05202158|Procedure|Addition of gentamicin to irrigation fluid during RIRS|During the RIRS, the access sheath is placed first for security. Then, the stone in the kidney is detected with flexible URS and fragmented with a holmium laser. In this group of patients, 80 mg of gentamicin will be added to 3 liters of irrigation fluid while the stone is being fragmented.
45660846|NCT01661179|Drug|Vandetanib 300mg|300 mg oral dose once daily (100 mg x 3 tablets)
45660847|NCT05465239|Device|SurePace Powered Walker User|Participants will be asked to perform one baseline 5-minute trial with the lab's instrumented walker in passive mode (no powered locomotion) and two 5-minute trials with the walker in active mode (powered locomotion).
45660848|NCT05457517|Drug|YL-13027，Sintilimab|"YL-13027 combined with Sintilimab will be used as a cycle for 21 days. YLl-13027 is administered orally twice a day. Starting dose of YL-13027 is 240mg/d，with escalation to 360mg/d in phase Ib, and RP2D was administered orally twice a day in phase II.~Sindilizumab is administered intravenously 200mg every three weeks"
45660849|NCT02545543|Biological|Seqirus QIV|"Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
45814946|NCT05202158|Procedure|Only irrigation fluid during RIRS|During the RIRS, the access sheath is placed first for security. Then, the stone in the kidney is detected with flexible URS and fragmented with a holmium laser. In this group of patients, only irrigation fluid will be used while the stone is fragmented.
45814947|NCT00370370|Drug|bevacizumab|Injection of intravitreal bevacizumab
45814948|NCT00370370|Drug|bevacizumab + triamcinolone acetonide|Injection of bevacizumab + triamcinolone acetonide
45814949|NCT04001179|Other|Pulmonary embolism diagnosis by nuclear medicine imaging|nuclear medicine imaging
45953834|NCT00148590|Drug|Placebo|Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
45953835|NCT02954068|Drug|IV Oxytocin + IM placebo|
45953836|NCT02954068|Drug|IM Oxytocin + IV placebo|
45953837|NCT02953990|Behavioral|MOMS Program|
45953838|NCT00508339|Behavioral|Questionnaire|Toronto Extremity Salvage Score (TESS) questionnaire.
45953839|NCT00157131|Biological|Fibrin Sealant, ARTISS 4IU/ml VH SD|FS 4IU VH S/D, a two-component fibrin sealant with 4 IU/mL human thrombin, vapor heated, solvent detergent treated, provided in a frozen, ready-to-use formulation. Administration by a topical spray application using the TISSOMAT device and Spray Set.
45953840|NCT00157131|Other|Staples|Administration by mechanical/multiple point fixation.
45953841|NCT00508378|Behavioral|Interview|Interview regarding side-effects of chemotherapy, 30-45 minutes.
45953842|NCT00508378|Behavioral|Questionnaire|Quality of life survey and symptom assessment questionnaire, 15 minutes.
45953843|NCT02954029|Device|ezClot (hemostasis pad)|ezClot pad uses chitosan, a deacetylated complex carbohydrate derived from the naturally occurring substance chitin, to accelerate blood clotting.
45814950|NCT04096040|Device|μCor|μCor consists of the following components: A) Patch B) Sensor C) Charger D) Data transmission device (Gateway) E) Server Once activated, the wearable Sensor automatically acquires ECG, RF readings, heart rate, respiration rate, activity, and posture measurements.
45953844|NCT02954029|Device|BloodSTOP ix pad|BloodSTOP® pad is an etherized and oxidized regenerated cellulose matrix that achieves hemostasis by activating the intrinsic coagulation pathway.
45953845|NCT02954029|Device|Rotary compression device|Rotary compression device consists of a plastic arch and a rotary screw to deliver local pressure by moving the silicone compression pad.
45953846|NCT05594069|Other|triple pre-rehabilitation|The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out from the time of enrollment (T0). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
46077904|NCT02695836|Other|Face-to-face support workshops|On face-to-face support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges. Workshops will be attended by all participating teams from a region, to maximize opportunities for teams to learn from one another and trouble-shoot together with the support of workshop leaders.
45953847|NCT05594069|Other|triple rehabilitation|The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out at the time of the beginning of radiotherapy (T1), and the middle stage of radiotherapy (T2). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
45953848|NCT02957721|Other|Usual Care|Patients will not be given the intervention but receive usual care for T2D.
45953849|NCT00508456|Drug|Temodar (Temozolomide)|150 mg/m^2 orally once a day for 7 consecutive days (days 8 through 15).
45953850|NCT00508456|Dietary Supplement|Hominex-2|"Methionine free diet during Days 1 - 7 and Days 15 - 21 by consuming only shakes containing Hominex-2®."
45953851|NCT00508495|Drug|Paracetamol (acetaminophen)|Four 100 mL, 15 min IV infusions at six hour intervals
46077905|NCT02695836|Other|On-demand email and telephone support|Participants can contact the research team if needed with requests for support in defining or implementing improvement strategies or dealing with barriers towards improvement.
45953852|NCT00508495|Drug|Paracetamol 1% solution|Four 100 mL, 15 min IV infusions at six hour intervals
45953853|NCT00508495|Drug|0.9% sodium chloride solution|Four 100 mL, 15 min IV infusions at six hour intervals
46077906|NCT04241900|Behavioral|Shuttle run test|At the shuttle run test, participants were required to run between two lines 20 meters apart, while keeping pace with audio signals emitted from a pre-recorded CD. The frequency of the sound signals increases in such way that running speed was increased by 0.5 km h-1 each minute from the starting speed 8.5 km h-1.
46077907|NCT00899509|Other|laboratory biomarker analysis|correlative studies
46077908|NCT04241744|Drug|Vancomycin 125 MG po BID|prevention to develop CDI during hospitalization
46077909|NCT00906997|Procedure|Immunochemical fecal occult blood test|Biennial, without diet restriction, 1 stool sample. Positive cut-off level: 75 ng/ml.
46077910|NCT00906997|Procedure|Colonoscopy|Every 10 years, with sedation.
46077911|NCT02746536|Other|Slow chest compression|"During the SCC, the patient will remain in the sitting position; a bimanual slow compression on his/her upper chest will be performed always by the same evaluator, who will stand behind the patient. This compression will be done only in the expiratory phase, during one minute, in all respiratory cycles, respecting the chest mobility of each patient.~A standardized verbal command will be given: Exhale all the air."
46077912|NCT02746536|Other|No slow chest compression|"The patient will remain seated at rest for one minute after the 6MST. A standardized verbal command will be given: Exhale all the air."
46077913|NCT02824094|Drug|crizotinib|Crizotinib, 250 mg BID, will be administered orally on a continuous daily dosing schedule
45660850|NCT02545543|Biological|Comparator QIV|"The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
45660851|NCT02542267|Device|Gore VIABAHN Endoprosthesis|
45660852|NCT02545075|Drug|Ipilimumab|
45660853|NCT02545075|Drug|Dacarbazine|
45660854|NCT05456815|Other|Standardized diet|During 9 weeks all food products will be standardized and provided by the Research Unit. The standardized diet is based on the average food composition in the Netherlands.
45660855|NCT03007537|Drug|Erythropoietin|10000 IU erythropoietin, subcutaneous injection
45660856|NCT03007537|Drug|0.9% sodium chloride|0.9% sodium chloride 1ml, subcutaneous injection
45660857|NCT03007537|Procedure|cardiac surgery|included valve, coronary artery bypass graft or surgery for congenital heart diseases
45660858|NCT03004183|Biological|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
45660859|NCT03004183|Drug|Valacyclovir|Prodrug of the antiviral drug acyclovir
45660860|NCT03004183|Radiation|SBRT|Low-dose SBRT
45660861|NCT03004183|Drug|Pembrolizumab|Humanized immunoglobulin G4 anti-programmed death-1 (PD-1) monoclonal antibody
45953854|NCT00508534|Drug|SB-751689|
45953855|NCT00157170|Behavioral|supervised exercise|
45953856|NCT00508573|Behavioral|Questionnaire|Follow-up questionnaire done once a year for five years.
45953857|NCT00508612|Behavioral|Williams LifeSkills Stress and Anger Management Workshop|Williams LifeSkills Stress and Anger Management Workshop
45953858|NCT00508612|Behavioral|High school classes|The control group will attend regular high school classes.
45953859|NCT00508690|Drug|cefmetazole|Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
45953860|NCT00508690|Drug|kanamycin/metronidazole|2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
45660862|NCT02544763|Drug|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
45953861|NCT00148707|Drug|CT-2103 (Xyotax)|
45953862|NCT02953756|Radiation|Gamma Knife radiosurgery|Gamma Knife radiosurgery will be performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the tumor volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target
45953863|NCT05591144|Drug|Prednisone tablet|The dose selection of oral prednisone is the maximum daily dose for 5 days, followed by a taper every 2 days
45953864|NCT05591144|Drug|Ginkgo Biloba Extract|Ginkgo biloba extracts are traditional Chinese medicine, which can improve microcirculation and provide good ameliorating effects for the treatment of tinnitus
45953865|NCT02953522|Other|191 mcg/day of Folate|Diet containing 191 mcg / day of Folate
45953866|NCT02953522|Other|90 mcg / day of Folate|Diet containing 90 mcg / day of Folate
45953867|NCT00157287|Procedure|Evidence based weaning protocol|
45953868|NCT02953483|Other|Red blood cells|Packed red blood cells to final hematocrit of 14%
45953869|NCT05572541|Diagnostic Test|Fonseca questionnaire|Fonseca questionnaire for the evaluation of temporomandibular dysfunction
45953870|NCT02953600|Dietary Supplement|Standard Dose Spirulina Platensis|As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg.
45953871|NCT02953600|Other|Zero Spirulina Platensis|the zero pill-taken group is a comparison for two other groups.
45953872|NCT02953600|Dietary Supplement|Double Dose Spirulina Platensis|As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg. Hence, the investigators would like to see if the investigators could improve sero-conversion rates much faster by taking double dose of Spirulina platensis.
45953873|NCT00508729|Drug|Qingyi granules|
45953874|NCT02953444|Other|Thirty-Second Mindfulness Practice|
45953875|NCT02953444|Other|Three-Minute Mindfulness Practice|
45953876|NCT00148746|Drug|Pimecrolimus|
45953877|NCT00148746|Drug|Tacrolimus|
45953878|NCT00148746|Drug|Prednisolone|
45953879|NCT00148746|Drug|Ciclosporin A|
45660863|NCT02544763|Drug|Placebo|Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
45660864|NCT05464771|Procedure|Surgery for hip and knee replacement|Elective inpatient surgery for hip and knee replacement
45660865|NCT02556203|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10mg OD (once-daily)
45660866|NCT02556203|Drug|Acetylsalicylic Acid (ASA)|75-100mg OD
45814951|NCT01457833|Device|EBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
45953880|NCT00148746|Drug|Dermatop|
45953881|NCT00466453|Behavioral|knowledge-adaptive Web-based instruction|
45953882|NCT05566847|Other|Physician Education|The physician education session delivered to primary care physicians in Arms 2 and 3 will provide an educational update from the regional clinical leader for diabetes regarding guidelines for diabetes treatment and addressing therapeutic inertia.
45953883|NCT05566847|Other|Accountable Population Manager outreach|Patients will be referred to an Accountable Population Manager (APM) for proactive outreach, including supporting medication adherence and educational and overall support for T2D management. An APM is a non-physician clinician (for example, a clinical pharmacist) supporting diabetes management.
45953884|NCT03272152|Genetic|Genome-wide DNA methylation|Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.
45953885|NCT03272230|Behavioral|ECOCAPTURE|45 minutes observational session for tracking goal directed behavior into a waiting room equipped with video and sensor-based data acquisition system
45953886|NCT03272230|Behavioral|Cognitive and Behavioral experimental tasks|Cognitive and Behavioral experimental tasks to explore additional frontal cognitive and behavioral dimensions and functions
45953887|NCT03272230|Diagnostic Test|Neuropsychological assessment|MMS / MADRS / EBI / NART / Mini-SEA / BREF / HAD / MATTIS / HAYLING / STROOP / STARKSTEIN / DAS
45953888|NCT03272230|Behavioral|ICM_APATHY_TASKS|Apathy experimental task
45953889|NCT03272230|Other|MRI|T1 MRI / T2 MRI / Resting state fMRI / Multi-shell diffusion-weighted MRI
45953890|NCT03272230|Biological|Neurohormonal mechanisms|Hormonal dosage / Diabetic dosage / Ionogramme dosage / Inflammatory dosage / Hepatic dosage / Lipidic dosage / Thyroid dosage
45953891|NCT03272230|Diagnostic Test|Supplementary Neuropsychological Assessment - Parkinson's Disease|ACDD / QUIP / BIS-11 / ECMP / QUIP-RS
45953892|NCT00148785|Drug|Indinavir/Ritonavir/Fosamprenavir|
45454125|NCT02883452|Biological|CT-P13|CT-P13 (180 mg) by double SC 90 mg injections every 2 weeks (Part 1)
45660867|NCT02556203|Drug|Clopidogrel|75mg OD
45660868|NCT02556203|Drug|Rivaroxaban (Xarelto, BAY59-7939)|In case of NOAF, 20/15 mg OD (once-daily)
45660869|NCT02556203|Drug|Vitamin K antagonist (VKA)|In case of NOAF, Open-label VKA therapy to target international normalized ratio (INR) 2-3, according to guidelines
45953893|NCT03272191|Procedure|Liposuction and stem cell implantation|The adipose tissue specimen will be collected mainly from the patient's abdomen using a liposuction cannula. The adipose tissue may be collected from other areas if necessary The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred to an injection/infusion catheter for delivery into the akinetic myocardial scar in the region of a previous infarct
45814952|NCT01457833|Device|IBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
45660870|NCT05485571|Device|derma pen|"Group 1: Taking aseptic condition, 15 Patients were subjected to therapy with microneedling, patient will take session weekly for 12 weeks.~Group 2: Taking aseptic condition, 15 patients were subjected to combined therapy with Microneedling and methotrexate After microneedling we applied methotrexate topically (25mg/ml) at dose 0.02ml/cm2 , A maximum of 0.1-0.2ml (2.5-5 mg) on the affected areas and rub it gently then Microneedling again, patient will take session weekly for 12 weeks"
45814953|NCT00370435|Drug|GW274150|
45814954|NCT01107613|Behavioral|Opinion leader educational letter|All patients will receive prednisone X 10 days and antibiotics X 5 days, as well as an opinion leader educational letter sent to the primary care provider outlining the needs of this patient.
45814955|NCT01269164|Procedure|Surgical Procedure Composite Facial Transplant|Single Center Prospective Clinical Study to Document the Safety and Feasibility of the Surgical Procedure for Composite Facial Allograft Transplantation
45814956|NCT00370513|Drug|pazopanib|Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.
45814957|NCT00966979|Device|Triathlon PKR|Triathlon PKR is a unicondylar knee resurfacing system designed to replace a single osteoarthritic compartment of a patient's natural knee.
45814958|NCT05179382|Other|Control protocol|I.10 minutes of initial rest in the supine position; II. 90 minutes of treadmill aerobic exercise at an intensity of 60% of the vo2 peak; IV. 60 minutes of passive recovery in the supine position.
45814959|NCT05179382|Other|Hydration protocol|I.10 minutes of initial rest in the supine position; II. 90 minutes of treadmill aerobic exercise at an intensity of 60% of the vo2 peak; IV. 60 minutes of passive recovery in the supine position. V. Water ingestion distributed in 10 equal portions, administered at regular intervals of 15 minutes from the 15th minute of exercise until the end of the recovery period.
45814960|NCT02197416|Drug|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
45814961|NCT00370591|Drug|Salmeterol/fluticasone propionate and fluticasone propionate|
45814962|NCT05166044|Biological|EV71 Inactivated Vaccine|The EV71 vaccine was manufactured by Sinovac Biotech Co,And inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
45814963|NCT00598988|Procedure|traditional Chinese acupuncture|10 treatments over 6 weeks
45814964|NCT00598988|Other|standard medical care|standard care as provided by primary physician
45814965|NCT03956173|Other|Hypoglycemic combined with either normo or hyperglycemic clamp.|Twenty-four patients with type 1 diabetes has been recruited for a cross-over study including two experimental days, a combined hypo- and hyperglyemic clamp and a combined hypo- and euglycemic clamp, respectively. Patients will be randomised 1:1 to start with either the combined hypo- and hyperglycemic or the hypo- and euglycemic clamp. The hypo- and hyperglycemic or the hypo- and euglycemic clamp are estimated to last 255 minutes. The two clamp days will be separated by at least 30 days.
45814966|NCT03080311|Drug|APG-1252|Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
45814967|NCT00371527|Drug|ipratropium|
45814968|NCT00392756|Drug|gonadotropin releasing hormone (GnRH)|pulsatile GnRH is delivered to adult men (18+ yrs) via portable microinfusion pump. A small dose (30 microliters) is delivered subcutaneously every 120 minutes. The initial dose is 25 ng/Kg which is increased until normal serum testosterone levels are achieved.
45814969|NCT03908593|Drug|Pantoprazole|Pantoprazole (40mg qd) will be concomitant used with DAPT
45814970|NCT05143658|Procedure|LLS versus LP|Procedure: Laparoscopic repair of anterior and apical pelvic organ prolapse Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
45814971|NCT04027322|Drug|Budesonide 0.25 MG/ML Inhalant Solution|"Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8)."
45814972|NCT04027322|Drug|Dexamethasone|"Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8)."
45814973|NCT04027322|Drug|Normal saline|Placebo for the control group.
45814974|NCT00371215|Biological|rThrombin|1000 U/mL applied topically
45953894|NCT03272386|Other|Observational study|Completing a questionnaire
45660871|NCT05485415|Behavioral|Multimodal intervention|Participants in the intervention group will receive personalised advice on sleep, light exposure, meal times and physical activity.
45660872|NCT05485415|Behavioral|Control|General sleep advice
45660873|NCT05485337|Other|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
45660874|NCT05496881|Other|Exercise Group 1|Prescribed exercises will focus on mobility and balance.
45953895|NCT00148824|Biological|7-valent pneumococcal conjugate vaccine (vaccine)|
45953896|NCT00148824|Biological|23-valent pneumococcal conjugate vaccine (vaccine)|
45953897|NCT00466492|Procedure|Sedation or no sedation during mechanical ventilation|No sedation to critically ill patients
45953898|NCT00466570|Drug|gatifloxacin, moxifloxacin|
45953899|NCT04726202|Other|Standard procedure|Coding of cases follows the standard procedures established at the hospital
45953900|NCT04726202|Other|precoding|"Standard coding will be reviewed by dedicated physicians and corrected or extended if necessary.~Coding will compared to the written OP report for consistency. Dedicated physician visits patients daily (in addition to routine visits). Dedicated physicians review discharge report and will make changes and additions. DRG coding will be adapted to results from visits and discharge report."
45953901|NCT00466609|Drug|Clomipramine (fluoxetine plus clomipramine)|Clomipramine at maximum dosage of 75mg per day plus fluoxetine at maximum dosage of 40mg per day
45953902|NCT00466609|Drug|Quetiapine (fluoxetine plus quetiapine)|Quetiapine at maximum tolerated dosage of 200mg per day plus fluoxetine at maximum dosage of 40mg per day
45953903|NCT00466609|Drug|Placebo (fluoxetine plus placebo)|Placebo plus fluoxetine at maximum dosage of 80mg per day
45953904|NCT00466648|Procedure|Tissue adhesive|
45953905|NCT00157326|Drug|tadalafil|
45660875|NCT05496881|Other|Exercise Group 2|Prescribed exercises will focus on physical fitness.
45660876|NCT05496881|Other|Exercise Group 3|Prescribed exercises will focus on flexibility, range of motion, and muscle tone.
45660877|NCT05496803|Other|routine education plus digital video disk|Parents receiving routine education plus digital video disk before their children receiving congenital heart disease catheterization. The DVD content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
45814975|NCT03845257|Diagnostic Test|Blood sampling, FeNO, bronchoalveolar lavage, bronchoscopic tissue sampling|Blood sampling (eosinophil count; eosinophilia is defined as >300/µl (or >150/µl during oral glucocorticosteroid treatment); FeNO: Measurement of fractional nitric oxide (NO) concentration in exhaled breath; Bronchoscopy: BAL: total leukocyte counts and leukocyte differential counts including eosinophils, PSB sampling: eosinophil count/100 cells, endobrochial biopsy: tissue eosinophil count/100 cells.
45814976|NCT05138588|Device|rTMS|For each subject, a verum condition and a control condition will be programmed. We will use the QPS-5 method (4 pulses, Inter-Stimulation Interval; ISI: 5 seconds).
45814977|NCT05454475|Other|Change the water injection temperature|Water injection is a routine procedure for endoscopy of small probe ultrasound, and our intervention is to change the water temperature and observe the effects of different water temperatures on patient safety and comfort.
45814978|NCT00371072|Procedure|trabeculectomy with mitomycin-C|
45953906|NCT00466804|Procedure|Heart transplant|People in this study will have a heart transplant and be monitored for signs of rejection
45953907|NCT00466843|Drug|Antithymocyte globulin (ATG)|ATG 2.5 mg/kg/day via IV will be given for 4 doses. Each participant will receive only one cycle of therapy. The daily infusion will be administered over at least 6 hours and slowed as necessary to minimize infusion-related symptoms.
45953908|NCT00466843|Drug|Prednisone|All participants will be pre-treated with prednisone (1 mg/kg/day by mouth) 2 days prior to the first ATG does and continuing for 14 days after the final dose to prevent serum sickness
45953909|NCT00466882|Device|Inamed Lap-Band System|Patient's will be seen in the physician's office one week post surgery and once a month thereafter. The device can be gradually adjusted by the insertion of a needle into the port and saline is added or removed to inflate or deflate the LAPBAND. This can be conducted in the physician's office setting to enable the patient to lose 1-2 pounds per week over two years.
45953910|NCT02964221|Other|Cognitive Testing|Computerized CogState Brief Battery (CBB), Cognigram, assesses changes in four cognitive domains including psychomotor function, attention, learning and memory, and working memory. The CBB is a computerized test based on card games that can be administered online. .
45953911|NCT00148863|Drug|Peg-interferon alpha 2a (drug)|
45953912|NCT00148863|Drug|Ribavirin (drug)|
45953913|NCT00148863|Drug|Interferon gamma (drug)|
45953914|NCT03272113|Behavioral|SKIP-IT|A theory-based intervention using narrative, images and embedded behaviour change techniques, delivered via text-messaging.
45953915|NCT00466999|Drug|misoprostol|single dose of 400 mcg misoprostol administered sublingually
45953916|NCT00466999|Procedure|surgery|standard surgical treatment (dilation and curettage or manual vacuum aspiration)
45953917|NCT00467116|Biological|cetuximab|400mg/m2 initial dose week 1; followed by 250mg/m2/weekly starting week 2 with gemcitabine at fixed dose rate (10 mg/m2/min) + XRT. Cetuximab will start 1 week prior to all other treatment.
45953918|NCT00467116|Drug|gemcitabine hydrochloride|"Dose Level Gemcitabine dose Gemcitabine infusion~-1 150mg/m2 15 Minutes 0 200mg/m2 20 minutes~300mg/m2 30 minutes~400mg/m2 40 minutes"
45454126|NCT02883452|Biological|CT-P13|CT-P13 (240 mg) by double SC 120 mg injections every 2 weeks (Part 1)
45953919|NCT00467116|Radiation|radiation therapy|"50.4 Gy, 28 fractions, 5.5 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to encompass gross disease with a margin of 1-1.5 cm.~The prescription point will be designated at the intersection of the multiple beams.~There are no planned interruptions > 3 days."
45953920|NCT00157482|Drug|Ezetimibe|
45953921|NCT00157482|Drug|Simvastatin|
45454127|NCT02883452|Biological|CT-P13|CT-P13 (120 mg) by single SC injection every 2 weeks in patients with body weight less than 80 kg, and CT-P13 (240 mg) by double SC 120 mg injections in patients with body weight at or above 80 kg based on body weight at Week 6 (Part 2)
45454128|NCT02883452|Biological|CT-P13|CT-P13 (5 mg/kg) by IV infusion administered as a 2-hour IV infusion per dose every 8 weeks up to Week 22. From Week 30, CT-P13 (120 mg) by single SC injection every 2 weeks in patients with body weight less than 80 kg, and CT-P13 (240 mg) by double SC 120 mg injections in patients with body weight at or above 80 kg based on body weight at Week 30 (Part 2)
45454129|NCT03793426|Biological|Fibryga|Human plasma-derived fibrinogen concentrate
45454130|NCT00508066|Drug|Bupivacaine|Bupivacaine 0.25 - 0.5% @ 4ml/hr for 72 hours
45454131|NCT00508066|Drug|Normal Saline|Normal Saline, 4ml/hour for 72 hours.
45454132|NCT01336010|Drug|Peginterferon alfa-2a|PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
45660878|NCT05496803|Other|routine education|Parents receiving routine education before their children receiving congenital heart disease catheterization
45660879|NCT05496725|Drug|Micafungin|Pharmacokinetic study under fasting conditions
45814979|NCT03056365|Procedure|Advanced Nurse (AN)|Protocoled AN-based management of detox
45814980|NCT03056365|Procedure|General Practitioner (GP)|'As usual' medical management of detox
45814981|NCT00370448|Behavioral|school-based social support system|Training gatekeeper recruited from students and tutors and counselors for group 1; training counsellors for group 2; No special intervention for group 3
45814982|NCT00371228|Procedure|Delay of umbilical cord clamping|Umbilical cord delayed until pulsation stops.
45814983|NCT05454644|Other|Person-Centred Prescription Model|"Step 1: Identify patients with advanced chronic condition and limited life expectancy.~Step 2: Interview with patients or closes caregiver.~Step 3: Medication Review~The clinical pharmacist conduct a structured medication review based on the medication appropriateness index (MAI):~Indication/effectiveness: Product information, STOPPFrail (Screening Tool of Older Persons' Prescriptions in Frail adults with limited life expectancy) criteria and Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.~Dosage adjustment: Product Information and Lexi-Comp's Geriatric Dosage Handbook.~Correct and practical directions: Medication Regimen Complexity Index (MRCI).~Drug-drug interactions: Bot Plus/Beers Criteria and drug burden index (DBI), which measures dose-dependent anticholinergic and sedative loads.~Drug-disease interactions: Beers Criteria.~Duplication, duration and cost-effectiveness: Product information.~Step 4: Treatment Plan"
45814984|NCT05118698|Drug|Gynostemma|Patients in the high-dose group and low-dose group will take gynostemma powder with a saponin content of 12% and 8% respectively, 3 times a day for 3 months.
45660880|NCT05490719|Drug|QL1706|QL1706 is a humanized anti-PD1 IgG4 and anti-CTLA-4 IgG4 antibody.
45660881|NCT04424459|Drug|opioid withdrawal|The data retrieved from the patient will be encrypted and there will also be written data or written in binary form. They will be used to create an Excel table which allows me to list the data on D1 then on M + 3 then on M + 6 in order to evaluate the evolution of these data over a time interval of 6 months and this is which will be used as support in my thesis in pharmacy.
45814985|NCT05118698|Other|Spinach|For the spinach powder group, each patient will take spinach powder with nearly no saponin content, 3 times a day for 3 months.
45814986|NCT00370526|Procedure|Acute hemodynamic assessment using PV Loops (CD Leycom, The Netherlands) during LV lead placement|
45814987|NCT03999164|Drug|[18F]DPA-714 Positron Emission Tomography Scan|All patients will undergo a [18F]DPA-714 PET scan of the brain 2 weeks and 2 months following moderate to severe traumatic brain injury to quantify neuroinflammation.
45814988|NCT05454397|Other|Observational study, no intervention|Observational study, no intervention
45953922|NCT05519345|Behavioral|Operant Conditioning|Active encouragement and feedback to increase motor evoked response during stimulation.
45953923|NCT05519345|Behavioral|Control|Absence of active encouragement and feedback to increase motor evoked response when stimulated.
45953924|NCT03272074|Other|Egg and egg white|Participants will consume either one large eggs or equivalent amount of egg white (3/4 cups) for 12 weeks. Participants will maintain their regular diet and physical activities.
45953925|NCT00467194|Drug|Rapamycin|
45953926|NCT00467194|Drug|Bevacizumab|
45953927|NCT00148902|Drug|lapatinib|lapatinib
45953928|NCT00148902|Drug|docetaxel|docetaxel
45953929|NCT00467428|Drug|NS2359|
45953930|NCT00467428|Drug|Placebo|
45953931|NCT05507645|Drug|Recombinant Human Prourokinase for Injection (rhPro-UK)|15mg of rhPro-UK intravenous bolus within 3 minutes, and the remaining 20mg intravenous drip within 30 minutes.
45660882|NCT05496569|Drug|TQB3616 capsule|TQB3616 capsule is a cyclin-dependent kinase 4/6 kinase inhibitor
45660883|NCT05496569|Drug|TQB3616 placebo|Placebo
45953932|NCT05507645|Drug|standard medical treatment|Standard antiplatelet or anticoagulant treatment at the discretion of local investigators.
45953933|NCT03271918|Drug|Cabergoline|
45953934|NCT00467467|Drug|Alfuzosin Hydrochloride|
45953935|NCT00406887|Drug|Difluprednate Ophthalmic Emulsion|
45953936|NCT00467506|Drug|bispecific antibody and di-DTPA-131I|
45953937|NCT00467545|Drug|telbivudine|
45660884|NCT04179383|Other|Constitution of a biobank|"We are collecting additional blood and CSF samples for patients (during RCVS episode and after resolution of RCVS episode) and for control subjects to constitute a biobank, in order to compare different biologic parameters between RCVS patients and healthy volunteers. A specific agreement will be asked to patients and control subjects before collection of samples.~This is why this study is classified as 'interventional' rather than 'observational'."
45953938|NCT00467662|Drug|Acyclovir 5%|
45660885|NCT05485259|Dietary Supplement|DL-alpha lipoic acid|Treatment group recieves 600 mg of DL-alpha lipoic acid daily, per os, for 3 months.
45660886|NCT05485259|Other|placebo (rice starch)|Placebo group recieves 600 mg (2x300 mg) of placebo (rice starch) daily, per os, for 3 months
45953939|NCT00467662|Drug|Docosanol 10%|
45953940|NCT00467662|Device|Superlysine gel|
45953941|NCT00148980|Device|DBM for creation of bone marrow microenvironment|
45953942|NCT03271957|Procedure|Manual rotation|Rotation of the fetal head to an anterior position at time of fuel dilation that is part of routine care
45953943|NCT05497310|Drug|Arsenic trioxide|Patients will receive ATO 0.3mg/kg/day for days 1-5 (5 doses) and then 0.25 mg/kg/day every other day twice a week for the next 3 weeks (6 doses).
45953944|NCT05497310|Drug|all-trans retinoic acid|Patients will receive ATRA 25/mg/m2/day for 28 continuous days without interruption.
45953945|NCT00467935|Drug|intravitreal injection Lucentis (ranibizumab)|intravitreal injection Lucentis (ranibizumab)
45953946|NCT00149019|Drug|Cell therapy with bispecific antibodies|
45953947|NCT00467974|Procedure|TEA with LEM|Transarterial ethanol ablation (TEA) with Lipiodol-ethanol mixture (LEM)
45953948|NCT00467974|Procedure|TACE|Transarterial chemoembolisation (TACE)
45953949|NCT05486273|Other|interviews with coachs, semi-structured interviews and questionnaires|You will be offered 6 coaching sessions at a rate of one session per month and the first interview will be conducted on the day of inclusion or within one month of inclusion, the others will take place at R6 and R12. Questionnaires will be administered on the day of inclusion and then at R1, R6, R9 and R12. RO is the day of inclusion and it corresponds to M3 (3 months post transplant)
45953950|NCT05486273|Other|semi-structured interviews and questionnaires|The first interview will be conducted on the day of inclusion or within one month of inclusion, the others will take place at R6 and R12.Questionnaires will be administered on the day of inclusion and then at R1, R6, R9 and R12. RO is the day of inclusion and it corresponds to M3 (3 months post transplant)
45953951|NCT00468013|Behavioral|Resilience Building Exercises|Weekly exercises for 6 weeks
45953952|NCT00468013|Behavioral|Journaling|Weekly exercises for 6 weeks
45953953|NCT00468091|Drug|exendin(9-39)amide|
45953954|NCT00468091|Drug|atropine|
45953955|NCT00406926|Drug|Somatropin|
45953956|NCT00468247|Device|Navigator|Navigator circulatory mgt system
45953957|NCT00468247|Other|Conventional care|Conventional haemodynamic care
45953958|NCT00404963|Drug|placebo|
45953959|NCT00404963|Drug|GSK376501|
45953960|NCT00468325|Procedure|Multi-slice computed tomography|Patient receives a CT scan (multi-slice computed tomography) of the heart.
45953961|NCT00468325|Procedure|Rest-stress Nuclear Myocardial Perfusion Imaging|Patient receives the standard of care for emergency room admitting diagnosis of low to intermediate chest pain. A rest-stress nuclear myocardial perfusion imaging test is performed per the standard of care at each institution.
45953962|NCT00468325|Procedure|Multi-slice Computed Tomography|Patients admitted to the emergency department with low to intermediate chest pain receive a multi-slice computed tomographic test of the heart.
46077914|NCT04218630|Other|Reformer pilates exercises|The program consisted of 10 minutes warm-up exercises, reformer pilates exercises for 40 minutes and 10 minutes cool-down exercises. The exercises were started with 6-8 repetitions, increased to 1-2 repetitions each week and applied to be 12-15 repetitions in the last week. Increasing the resistance of the springs and adding different positions were used for progression of exercises.
46077915|NCT04218630|Other|Home mat pilates exercises|The program consisted of 10 minutes warm-up exercises, clinical pilates-based exercises on mat for 40 minutes and 10 minutes cool-down exercises. The exercises were started with 6-8 repetitions, increased to 1-2 repetitions each week, and applied to be 12-15 repetitions in the last week.
45953963|NCT00468364|Drug|insulin glargine|
45953964|NCT00468364|Drug|NPH insulin|
45953965|NCT00149058|Drug|Erythropoietin|
45953966|NCT00468520|Drug|low dose oxytocin|
45953967|NCT03271801|Behavioral|child health education|10, 60-minute sessions with a family-based obesity treatment program implemented for the first 40-minutes of each session followed by 20 minutes of education about a child health topic.
45953968|NCT03271801|Behavioral|skills training|10, 60-minute sessions with a family-based obesity treatment program implemented for the first 40-minutes of each session followed by 20 minutes of experiential learning about stimulus control strategies (portion size, energy density, variety).
45814989|NCT05454332|Drug|Early Caffeine administration|Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
45953969|NCT00406965|Drug|HAE1 (PRO98498)|
45953970|NCT00405002|Procedure|Helium dilution technique, lung CT scan|Helium dilution technique and lung CT scan
45953971|NCT03271723|Other|Observational study|No intervention
45953972|NCT03271450|Drug|Dabigatran: extended treatment (e.g at least 90 days)|90 days
45953973|NCT03271450|Drug|Dabigatran: extended treatment (e.g at least 180 days)|180 days
45953974|NCT03271450|Drug|Dabigatran: extended treatment (e.g at least 270 days)|270 days
45953975|NCT03271450|Drug|Apixaban: extended treatment (e.g at least 90 days)|90 days
45953976|NCT03271450|Drug|Apixaban: extended treatment (e.g at least 180 days)|180 days
45953977|NCT03271450|Drug|Apixaban: extended treatment (e.g at least 270 days)|270 days
45953978|NCT03271450|Drug|Rivaroxaban: extended treatment (e.g at least 90 days)|90 days
45953979|NCT03271450|Drug|Rivaroxaban: extended treatment (e.g at least 180 days)|180 days
45953980|NCT03271450|Drug|Rivaroxaban: extended treatment (e.g at least 270 days)|270 days
45953981|NCT03271450|Drug|Edoxaban: extended treatment (e.g at least 90 days)|90 days
45953982|NCT03271450|Drug|Edoxaban: extended treatment (e.g at least 180 days)|180 days
46077916|NCT00780975|Drug|Aplidin (plitidepsin)|Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.
46077917|NCT02824250|Behavioral|MBSR|Mindfulness-Based Stress Reduction (MBSR) is an 8-week classroom based program of mindfulness meditation and gentle yoga.
45660887|NCT05490485|Drug|Camrelizumab|Camrelizumab combined with cisplatin for advanced cutaneous squamous cell carcinoma
45660888|NCT04027049|Device|Supine cycle ergometry of the lower extremities|The cycle ergometer allows for movement of the lower extremities by a motor if a patient is experiencing a disorder of consciousness or is otherwise unable to move one or both legs. If a patient is able to cycle actively the device allows the patient to move patient's legs without support of the motor.
45660889|NCT05485103|Drug|Polyethylene Glycols|Take asol as total enteral nutrition, and take polyethylene glycols and glycerin enema as bowel preparations
45660890|NCT05496491|Radiation|Neoadjuvant Chemoradiotherapy|5-week neoadjuvant radiotherapy regimen (28 x 1.8 Gy) combined with Capecitabine (bid 800 mg/m2, twice daily, on days 1-33-38)
45953983|NCT03271450|Drug|Edoxaban: extended treatment (e.g at least 270 days)|270 days
45953984|NCT03271450|Drug|Warfarin: extended treatment (e.g at least 90 days)|90 days
45953985|NCT03271450|Drug|Warfarin: extended treatment (e.g at least 180 days)|180 days
45953986|NCT03271450|Drug|Warfarin: extended treatment (e.g at least 270 days)|270 days
45953987|NCT00157521|Drug|L-arginine|
45953988|NCT03271606|Combination Product|ERAS|The investigators mainly used enhanced measures perioperatively in mediastinal surgery as these used in other surgery
45953989|NCT03271606|Combination Product|Traditional measures|The investigators mainly used traditional measures perioperatively in mediastinal surgery as these used in other surgery
45953990|NCT00405041|Dietary Supplement|Dietary supplement GVG 2|2.670 g/day for 14 days
45953991|NCT00468754|Device|Insulin pumps|
45953992|NCT00468793|Procedure|Intravenous fluid|The same intravenous fluids will be used in both arms but the volume will be different
45953993|NCT00468871|Drug|fluocinolone acetonide intravitreal implant|surgical intravitreal implant of fluocinolone acetonide
45953994|NCT00468871|Drug|corticosteroids and immunosuppressants|Systemic corticosteroids alone or combined with immunosuppressants
45953995|NCT00468988|Drug|Travatan® Z|
46077918|NCT04204031|Behavioral|Presentation of the adherence record|Adherence record will be presented to participants with an actual time of use less than prescribed. The participant will also be asked about the presence of possible barriers concerning the use of oxygen therapy. The collaborator in charge of home visits will attempt to resolve these barriers as much as possible.
46077919|NCT04217460|Behavioral|Intervention for fluency difficulty|Children are required to speak materials they hear on recordings. The materials are not words, but contain sound sequences that occur in their language and English.
46077920|NCT00899587|Drug|enalapril|enalapril 5 mg every night
45814990|NCT05454332|Other|Control Group|Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
45814991|NCT03977714|Device|Zirconia implants with G3-coated abutments (test implants and abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
45953996|NCT00468988|Drug|Xalatan®|
45953997|NCT00469027|Biological|eNOS transfected EPCs will be delivered via a PA line|incremental dosing over 3 days
45454133|NCT01336010|Drug|Ribavirin|Genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing <75kg and 1200mg for patients weighing ≥ 75kg) Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients
45953998|NCT00149136|Drug|imatinib|
45953999|NCT00469105|Behavioral|Literacy/Numeracy oriented educational intervention|Receives comprehensive literacy/num sensitive diabetes care
45954000|NCT00469105|Behavioral|Control Group|Receives standard diabetes disease management
45954001|NCT00469222|Procedure|hypofractionated external beam|
45954002|NCT00469261|Drug|Doxycycline|Doxycycline 100 mg bid for seven days after enrollment
45954003|NCT00469261|Drug|Current medical therapy for AMI|Current medical therapy for AMI
45954004|NCT00157560|Drug|Chemotherapy, multiple agents|
45954005|NCT00469300|Drug|Iontophoretic delivery of acyclovir|
45954006|NCT05457140|Genetic|Genetic: Genomic sequencing and molecular diagnostic results, if any.|Genomic sequencing results may be used for diagnosis and treatment of participants.
45954007|NCT05457140|Diagnostic Test|Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)|Whole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.
45954008|NCT00469378|Drug|firategrast|900 (females) or 1200 (males) mg twice daily for 24 weeks
45954009|NCT00149175|Other|Blood sampling, skin biopsy|Blood sampling, skin biopsy in the field of the medical follow-up
45954010|NCT04697641|Drug|Clarithromycin 500mg|Clarithromycin 500 mg twice a day for two weeks
45954011|NCT04697641|Drug|Amoxicillin 1000 MG|Amoxicillin 1000mg twice a day for two weeks
46077921|NCT00899587|Other|oxygen|oxygen 10 lit/min 1 hour twice a day at the first month, once a day at the second month and every other day at the third month
45454134|NCT00321412|Drug|AST-120|oral, sachet, 2 grams three times daily for 8 weeks
45454135|NCT01336088|Drug|ADX48621|oral administration
45954012|NCT04697641|Drug|Pantoprazole 40mg|Pantoprazole 40 mg or equivalent for eight weeks
46077922|NCT00899587|Drug|placebo|
46077923|NCT04268069|Drug|PL9643 Ophthalmic Solution|PL9643 Ophthalmic Solution as topical ophthalmic drops administered bilaterally for 12 weeks.
45954013|NCT04697641|Drug|Levosulpiride|Levosulpiride 25 mg as and when required before meals
46077924|NCT04268069|Drug|Placebo Ophthalmic Solution|Placebo solution as topical ophthalmic drops administered bilaterally for 12 weeks.
45454136|NCT01336088|Drug|Placebo|oral administration
45454137|NCT02549144|Dietary Supplement|Low fat/cholesterol diet|The low fat/cholesterol diet had 10% calories from fat and 150-200 mg of cholesterol per day.
45454138|NCT02549144|Dietary Supplement|High fat/cholesterol diet|The high fat/cholesterol diet had 40% calories from fat and 250-300 mg of cholesterol per day
45454139|NCT02207504|Drug|Crizotinib|Crizotinib is an ATP-competitive small-molecule inhibitor of the ALK, c-Met/HGFR, RON, and ROS receptor tyrosine kinases.
45454140|NCT02207504|Drug|Enzalutamide|Enzalutamide is an androgen receptor signaling inhibitor.
45660891|NCT05496491|Drug|Adjuvant Chemotherapy|8 cycles of CAPOX (Capecitabine bid 1000 mg/m2, twice daily, day 1-14, every 3 weeks and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively, 12 cycles of folinate, fluorouracil and oxaliplatin (FOLFOX)
45660892|NCT05496491|Drug|Consolidation Chemotherapy|CAPOX (Capecitabine bid1000 mg/m2 and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively FOLFOX
45660893|NCT05490407|Drug|Carboplatin|Patients will receive neoadjuvant chemotherapy according to ESGO guidelines
45660894|NCT04137731|Device|Interferential Current Therapy|IFC treatment after Total Knee Arthroplasty
45954014|NCT04697641|Drug|Acotiamide|Acotiamide 100mg as when required before meals
45954015|NCT04697641|Drug|Itopride|Itopride 50mg as when required before meals
45954016|NCT00469417|Procedure|Cryotherapy or Photodynamic therapy with methyl aminolevulinate cream|
45954017|NCT00469495|Drug|Anti-helminthic|
45954018|NCT00469495|Drug|meglumine antimony|
45954019|NCT00157599|Procedure|various diagnostic measures for DVT (e.g., CUS)|
45660895|NCT04424849|Diagnostic Test|CT-Scan|Chest CT scan on admission to the intensive care unit
45660896|NCT05490173|Other|Exosomes derived from mesenchymal stromal cells (MSCs)|Exosomes derived from mesenchymal stromal cells (MSCs) will be administered intranasal in ELBW infants
45954020|NCT00469534|Procedure|IMRT|
45954021|NCT00469573|Drug|1. Optive|Optive 15ml- (in the eye) Instill one drop twice daily in each eye
45954022|NCT00469651|Biological|MSP 3 Long Synthetic Peptide|Lyophilized MSP3 vaccine adjuvanted in Aluminium hydroxide
45814992|NCT03977714|Device|Zirconia implants with control abutments (test implants, negative control abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
45814993|NCT03977714|Device|Titanium implants with G3-coated abutments (control implants, test abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
45954023|NCT00469651|Biological|MSP3 vaccine|Lyophilized vaccine adjuvanted in Aluminium hydroxide
45954024|NCT00469651|Biological|Hepatitis B vaccine|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
45954025|NCT00469651|Biological|MSP3 candidate vaccine|Lyophilized MSP3 adjuvanted in Aluminium hydroxide
45954026|NCT00469651|Biological|Hepatitis B control vaccine|Hepatitis B vaccine adjuvanted in Aluminium Hydroxide
45954027|NCT05430035|Drug|HIPEC|Heated Intra-Peritoneal Chemotherapy (HIPEC) HIPEC will be performed at the time of the index operation if a cancer is known pre-operatively, at the time of re-operation for incidentally discovered cancers already treated with cholecystectomy that are undergoing central hepatectomy and portal lymphadenectomy as part of standard of care, or independently if no other procedures are indicated. A closed technique will be utilized to deliver mitomycin C (MMC) over the first 60 minutes followed by an additional smaller dose over an additional 30 minutes. Perfusate will be heated to obtain a tissue temperature of 42°
45954028|NCT00149253|Drug|a single-dose of Etoricoxib before induction of anesthesia|
45954029|NCT00469690|Drug|Acular, Xibrom|"Acular 5ml (in the eye)Instill one drop into the eye to be operated on four times a day at (6am, 12pm, 6pm, 12am)~Xibrom 5ml (in the eye) Instill one drop into the eye to be operated on two times a day (8am and 8pm)"
45954030|NCT00469729|Drug|StemEx®|The stem/progenitor cell based product composed of ex vivo expanded allogeneic umbilical cord blood cells, which is infused to subject at a rate of 1-3 ml/min in combination with non-manipulated cells derived from the same cord blood unit.
45954031|NCT00469768|Drug|dapivirine reservoir intravaginal ring|a silicone elastomer reservoir ring containing 25mg of dapivirine
45454141|NCT00151372|Behavioral|Treatment Adherence Intervention|The care management intervention aims at facilitating adherence to a treatment algorithm based on the Agency for Health Care Policy and Research (AHCPR) guidelines. The investigators hypothesize that this intervention, in comparison to usual care, will increase the prescription of adequate antidepressant treatment by physicians, enhance treatment adherence by patients, and reduce depressive symptoms, suicide ideation, and disability.
45454142|NCT00151372|Behavioral|Enhanced Care|For subjects in the Enhanced Care group, physicians providing aftercare will receive no clinical instructions by the research team, but will be informed in writing of the patients' diagnosis and will be provided with a copy of the Agency for Health Care Policy and Research (AHCPR) guidelines for the treatment of depression in primary care with an addendum updating the tables describing Selective Serotonin Reuptake Inhibitors (SSRI) side effect and dosage profiles. The investigators expect that these physicians will continue to base their practice on clinical judgment about how best to treat depression in chronic obstructive pulmonary disease patients.
45454143|NCT01342016|Drug|tacrolimus capsule|oral
45454144|NCT01342016|Drug|tacrolimus placebo|oral
46077925|NCT02538913|Behavioral|Exercise training|Daily pelvic floor muscle training and individualized regular exercise training (aerobic and strength exercise) three days per week.
46077926|NCT02538913|Procedure|Usual care|Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training
46077927|NCT04218474|Procedure|Evaluation Of Cross Mental Nerve Transfer In Restoration Of Chin &Lip Sensation Post Inferior Alveolar Nerve Injury|-sural nerve harvest ,and use it as conduit between injured mental nerve and the normal one
46077928|NCT02824406|Drug|Acetazolamide|Acetazolamide is administered to all participants to induce vasodilation, in order to assess the physiologic response on cerebral blood flow.
46077929|NCT04267679|Drug|Cannabidiol|25 mg full-spectrum CBD soft gel capsules
46077930|NCT04251312|Other|Oral Hygiene Education and Oral Hygiene Packets|Patients will be educated on oral hygiene and will be given packets containing toothpaste, mouth rinse, floss and a toothbrush
46077931|NCT00899665|Genetic|fluorescence in situ hybridization|
45814994|NCT03977714|Device|Titanium implants with control abutments (negative control implants and abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
46077932|NCT00899665|Genetic|microarray analysis|
45954032|NCT00469768|Drug|dapivirine matrix intravaginal ring|a silicone elastomer matrix intravaginal ring containing 25mg of dapivirine
45954033|NCT00469768|Other|placebo intravaginal ring|a silicone elastomer intravaginal ring containing no dapivirine
45954034|NCT00157638|Behavioral|integration of pharmacist into primary care|
45954035|NCT00157638|Drug|optimizing therapeutic treatments|
45954036|NCT00157638|Behavioral|optimizing processes of care|
45954037|NCT05429645|Procedure|setting up of the pace maker|Setting up of a pace maker using a 3-dimensional (3D) guidance technique
46077933|NCT00899665|Genetic|molecular diagnostic method|
45954038|NCT00469846|Procedure|L-arginine supplementation in a medical food|
45954039|NCT00469846|Procedure|Vitamin C and E supplementation in a medical food|
45454145|NCT01342016|Drug|leflunomide tablet|oral
45454146|NCT01342016|Drug|leflunomide placebo|oral
45660897|NCT05485025|Behavioral|Tai chi training|Tai chi, also called tai chi chuan, is an ancient Chinese form of exercise originally created as a fighting art. It is a kind of gentle physical exercise and stretching, which involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
45660898|NCT05485025|Behavioral|Group activity|A organizer will lead the subjects to participate in group activities once a quarter. In group activities, there will be popular science lectures and interactive games.
45660899|NCT05484947|Diagnostic Test|Elisa HIV testing|HIV testing on a voluntary basis
45954040|NCT00469885|Drug|Nicotine replacement|For reduction
45954041|NCT00469885|Behavioral|Motivational counseling|No drugs
45954042|NCT04725669|Diagnostic Test|ELISA IgG Testkit|All samples will be tested for IgG antibody level to pertussis toxin using a commercial Bordetella pertussis ELISA IgG Testkit in accordance to the manufacturers' protocol in the laboratory at the University Hospital for Infectious Diseases in Zagreb.
45954043|NCT03271567|Diagnostic Test|Nanodisk-MS assay|Nanodisk-MS assay is a recently reported novel assay for quantitative detection of various MTB antigen peptides, using nanotechnology and mass spectrometry that showed remarkable sensitivity and specificity in diagnosing active pulmonary and extrapulmonary TB. This assay detected MTB-specific antigens, CFP-10 and ESAT-6, in patients' serum samples.
45954044|NCT03271411|Behavioral|EMDR-based Flash technique|Initial EMDR session (with Flash technique) of up to three hours; about one week later, follow-up session of up to one hour
45954045|NCT03271411|Behavioral|PC-based Flash technique|Initial PC session (with Flash technique) of up to three hours; about one week later, follow-up session of up to one hour
45954046|NCT00469924|Procedure|Real Time Clinical Alerting|
45954047|NCT00157677|Procedure|D-dimer testing|Uniform D-dimer use
45954048|NCT00157677|Procedure|D-dimer testing|Selective D-Dimer use
45954049|NCT00469963|Procedure|quality-of-life assessment|quality-of-life assessment
45954050|NCT00469963|Radiation|yttrium Y 90 resin microspheres|radiation therapy
45954051|NCT05425979|Drug|Mepivacaine|Up to two 30 ml vials of mepivacaine 1.5% via ultrasound-guided nerve blockade of the tibial and deep peroneal nerves
45954052|NCT05425979|Drug|Bupivacaine|Up to two 30 ml vials of bupivacaine 0.5% via ultrasound-guided nerve blockade of the tibial and deep peroneal nerves
45954053|NCT00470002|Drug|Somatropin|
45954054|NCT00470041|Drug|administration of two anti-viral drugs (lamivudine and zidovudine) from a new oral formulation|
45954055|NCT00470080|Procedure|venepuncture|venepuncture
45954056|NCT00157716|Drug|(MC-1) Pyridoxal-5'-phosphate|
45954057|NCT00470119|Behavioral|behavioral dietary intervention|A group based modification of the DPP and LookAHEAD lifestyle programs with a goal of 10% weight loss
46077934|NCT00899665|Other|immunohistochemistry staining method|
46077935|NCT00899665|Other|laboratory biomarker analysis|
46077936|NCT00899665|Procedure|biopsy|
46077937|NCT00899665|Procedure|immunoscintigraphy|
46077938|NCT04951388|Biological|MVC-COV1901(S protein with adjuvant)|Approximately 330 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
46077939|NCT04951388|Biological|MVC-COV1901(Saline)|Approximately 55 participants will receive 2 doses of MVC-COV1901(Saline) at Visit 2 (Day 1) and Visit 4 (Day 29) via IM injection in the deltoid region
45814995|NCT03977714|Device|Zirconia implants and titanium implants, for histological and histomorphometric evaluation.|"6 implants (3 tests and 3 controls) will be used to evaluate and compare osseointegration, via histological and histomorphometrical analysis, in the area of the wisdom teeth (non useful sites that will not interfere with the rest of the study or the patient's life) - it can only be performed in patients who no longer have these teeth. The procedure will match that described for Groups A-B-C-D. In this case, implants will only remain in the mouth for 2 months, after which they will be removed for analysis. The extraction will be performed with local anesthesia. A flap will be raised to expose the implant and, using a trephine bur (1 mm wider than the implant diameter), a bone cylinder containing the implant will be extracted. The resulting bone defect and regeneration process will be similar to those following a normal molar extraction. The flap will be sutured and primary curing is expected. A new implantation will not be carried out since in this area it is totally unnecessary."
45814996|NCT03924518|Drug|Granisetron Hydrochloride|Granisetron will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
45814997|NCT03924518|Drug|Placebo（Normal saline）|therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
45814998|NCT03777709|Behavioral|FAITH! App|Participants allocated to the intervention arm will complete a 10-week, individual-tailored intervention program utilizing the FAITH! App to promote the AHA LS7 through health education and to increase awareness and skill development while enhancing self-efficacy, self-regulation, and social support for healthy behavior change.
45814999|NCT05454163|Other|SNOT 22 questionnaire|22 items, score between 0 and 5; sum, minimum = 0, maximum = 110; higher score = higher impact on quality of life)
45815000|NCT05037344|Behavioral|Cognitive-behavioral psychotherapy|The goal is to develop an internet and smart phone delivered CBT (iCBT) for the treatment of pediatric OCD on the bases of our feasibility study. This group will start directly with therapy of 16 weeks. The waiting group gets the same intervention after 16 weeks of waiting.
45815001|NCT05454085|Dietary Supplement|Bisphenol-A|measurement of BPA levels in maternal blood and amniotic fluid
45815002|NCT05453786|Drug|SID1903|Single oral administration of SID1903 after an overnight fast
45815003|NCT05453786|Drug|SID1903-R1/SID1903-R2|Single oral administration of SID1903-R1 and SID1903-R2 after an overnight fast
45815004|NCT03893396|Device|Coronary angioplasty|Procedure used to open clogged heart arteries. Involves the insertion of a tiny balloon and/or a stent to widen the artery.
45954058|NCT00470119|Behavioral|Exercise intervention|Facility based and home-based exercise designed to increase moderate-to-vigorous aerobic activity in participants to 45 mins/day 5 days/week
46002735|NCT00547547|Dietary Supplement|high-selenium Brassica juncea|Dose Level A: 3200 mcg orally day -7 through duration of treatment. Dose Level B: 4800 mcg orally day -7 through duration of treatment. Dose Level C: 6400 mcg orally day -7 through duration of treatment. Dose Level D: 7200 mcg orally day -7 through duration of treatment. Dose Level E: 8000 mcg orally day -7 through duration of treatment.
46077940|NCT04205526|Device|Active rTMS|Patients randomized to receive actual rTMS treatment will receive 1Hz rTMS applied over contralesional M1 at an intensity of 120% resting motor threshold once daily for 30 minutes (approximately 1800 pulses) for a total of 15 sessions.
46077941|NCT04205526|Device|Sham TMS|For sham-stimulation, the TMS coil will be placed over the inter-hemispheric fissure at the vertex and stimulation will be performed with low intensity (10% resting motor threshold). This will cause similar skin sensations as real stimulation but will not induce currents in motor relevant areas.
46077942|NCT04035265|Procedure|Blood test|Carpus and fingers of non-dominating hand MRI with gadolinium contrast
46077943|NCT04242914|Drug|Ketamine|Intravenous Ketamine, dose 0.5mg/kg in 100ml Sodium Chloride 0.9% over 40 minutes.
46077944|NCT04242914|Drug|Midazolam|Intravenous Midazolam, dose 0.03mg/kg in 100ml Sodium Chloride 0.9% over 40 minutes.
46077945|NCT00780273|Device|Ankylos Implants|ANKYLOS Implant System vs Certain PREVAIL Implant
46077946|NCT00780273|Device|Biomet 3i Prevail Implants|
46077947|NCT00904501|Procedure|Bone marrow harvest|Implantation of placebo
46077948|NCT00904501|Procedure|Bone marrow harvest|Implantation of bone marrow - mononuclear cells
45454147|NCT01342016|Drug|prednisone|oral
45454148|NCT00318214|Drug|MRE0094|Gel, 500 mcg/g once each day
45454149|NCT00318214|Drug|Vehicle gel|Gel administered once per day
45815005|NCT00369902|Procedure|acupuncture|
45815006|NCT03886922|Drug|Levcromakalim|Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
45815007|NCT03886922|Drug|Saline|Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
45815008|NCT00370058|Procedure|ECT treatment|
45815009|NCT03864224|Behavioral|GLA:D Back|GLA:D Back is a 10-week program based on first-line recommendations of patient education and structured exercise taught in a group format.
45815010|NCT04738370|Other|Sample collection|Bloods +/- urine +/- vaginal swabs taken
45815011|NCT05453552|Drug|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
45815012|NCT05453552|Drug|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
45815013|NCT05453552|Drug|Busulfan|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group.
45815014|NCT05453552|Drug|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
45815015|NCT05453552|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
45815016|NCT05453552|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group.
45815017|NCT05453474|Genetic|Whole genome amplification|DNA is amplified by whole genome amplification
45954059|NCT05393570|Behavioral|Healthy Lifestyle Behavioral Intervention (MBS -supported intervention)|After patient/parent consent is completed, participants will begin the pre-MBS intervention phase. A minimum of 6 1- hour sessions will occur pre-MBS, and 26 will occur post-MBS.Dr. Klement, MBS coordinator and a diabetes educator will manage session delivery to adolescents/parents. All content will follow the Diabetes Prevention Program (DPP)-adapted curriculum flow. After that the research assistant will perform outreach, reminder calls, and follow-up for missed appointments. Pre-and post-MBS intervention delivery (based on adapted curriculum/model) may consist of a combination of 1-on-1 and group sessions (in-person or virtually), and online support tools, dependent upon adolescent/parent qualitative feedback on delivery method preference.
46077949|NCT02827136|Drug|Lidocaine patch and hypafix|Appliance of Lidocaine patch and hypafix on both shoulder tip after anesthetic induction
46077950|NCT02827136|Drug|hypafix|Appliance of hypafix on both shoulder tip after anesthetic induction
46077951|NCT04102995|Drug|Sepranolone injection low dose|Subcutaneous (SC) administration
45815018|NCT05453318|Procedure|Treatment of cervical neoplasia by thermal ablation|Women screened for cervical cancer by VIA presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
45815019|NCT05018624|Behavioral|Alcohol brief intervention|At baseline, subjects will receive face-to-face or online alcohol brief intervention developed based on the guideline by the World Health Organisation in 5-10 minutes
45815020|NCT05018624|Behavioral|12-page health warning leaflet|Nurses will provide information about the consequences of drinking using a 12-page health warning booklet. Benefits of reducing and quit drinking will be emphasized by focusing on improving their perception towards the impacts on health, social problems, risky behaviors, academic performance and financial issues.
45954060|NCT00470197|Drug|alvocidib|Given IV
45954061|NCT00470197|Drug|cytarabine|Given IV
45954062|NCT00470197|Drug|mitoxantrone hydrochloride|Given IV
45954063|NCT00470197|Other|pharmacological study|Correlative study
45954064|NCT00470314|Drug|L-Ornithine L-Aspartate|
45954065|NCT00149292|Drug|LY2140023|
45815021|NCT05018624|Behavioral|Regular messages through Instant Messaging (IM)|A total of 26 e-messages will be scheduled: once daily for the first week, 3 time/week for subsequent 4 weeks and 1 time/week for the remaining 7 weeks. The frequency will be adjusted according to IM Apps conversation and subject's requests.
46077952|NCT04102995|Drug|Sepranolone injection high dose|Subcutaneous (SC) administration
45454150|NCT01336166|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 adults were assigned to receive 1 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
45954066|NCT00149292|Drug|olanzapine|
45954067|NCT00149292|Drug|placebo|
45454151|NCT01336166|Biological|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|120 adults were assigned to receive 1 dose of 30μg split-virion, non-adjuvanted H1N1 vaccine.
45954068|NCT00470353|Dietary Supplement|calcium carbonate|
45954069|NCT00470353|Dietary Supplement|cholecalciferol|
45954070|NCT00470353|Other|immunohistochemistry staining method|
45954071|NCT00470353|Other|laboratory biomarker analysis|
45954072|NCT00470353|Other|pharmacological study|
45954073|NCT00470353|Procedure|biopsy|
45954074|NCT05391893|Drug|Oral|Diltiazem 0.25mg/kg injection, give over 2 minutes, max dose 30mg
45954075|NCT05391893|Drug|Intravenous drug|these patients will receive traditional treatments at provider discretion. They must receive at least one intravenous medication for atrial fibrillation with rapid ventricular response. This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.
45954076|NCT00470509|Drug|Adalimumab|2 subcutaneous injections on day 0 and 7
45954077|NCT00470509|Drug|Placebos|2 subcutaneous injections on day 0 and 7
45954078|NCT05378906|Drug|DRV/COBI FDC|Participants will receive a single oral dose of DRV/COBI FDC tablet dispersed in water as per assigned treatment sequence.
45954079|NCT05378906|Drug|COBI|Participants will receive a single oral dose of COBI tablet as per assigned treatment sequence.
45954080|NCT05378906|Drug|DRV|Participants will receive single oral dose of DRV suspension as per the assigned treatment sequence.
46077953|NCT04102995|Drug|Placebo injection|Subcutaneous (SC) administration
46077954|NCT04189770|Device|Accelerometer|Wear accelerometer
46077955|NCT04189770|Other|Ecological Momentary Assessment|Complete EMA questionnaire
46077956|NCT04189770|Other|Questionnaire Administration|Complete questionnaire
46077957|NCT04189770|Other|Survey Administration|Complete survey
46077958|NCT00899743|Genetic|polyacrylamide gel electrophoresis|polyacrylamide gel electrophoresis
46077959|NCT00899743|Genetic|western blotting|western blotting
46077960|NCT00899743|Other|immunologic technique|immunologic technique
46077961|NCT00899743|Other|laboratory biomarker analysis|laboratory biomarker analysis
45954081|NCT00157794|Device|Search AV+ algorithm|
45954082|NCT00470665|Drug|Rapamune|
45954083|NCT00470743|Drug|Ibuprofen|
45954084|NCT00470743|Drug|Indomethacin|
45954085|NCT05370482|Device|Focal laser ablation|MRI-guided focal laser ablation for prostate cancer
45954086|NCT00149331|Behavioral|Structured education program|
45954087|NCT00470821|Drug|Oral melatonin 3mg BID|Identical tablets containing melatonin 3 mg. Nurses are requested to give two tablets daily, at 8 PM and 12 PM
45954088|NCT00470821|Drug|Placebo|Identical tablets without the active principles. Each evening nurses are requested to give 2 tablets at 8 PM and 12 PM
45954089|NCT00335881|Biological|hepatitis B vaccine|
45954090|NCT00149370|Procedure|Breast reduction surgery|
45954091|NCT05367830|Behavioral|the Bone@BC app|The bone@BC app is a diary for patients with breast cancer that they can use if they want to.
45954092|NCT00470860|Behavioral|Participation in LOFTS online tutorial|
45954093|NCT00335920|Drug|Dexamethasone-dihydrogenphosphate (4mg/ml)|
45954094|NCT00470899|Procedure|drainage of placenta of fetal blood|
45954095|NCT00149409|Dietary Supplement|Omacor|
45954096|NCT00470938|Device|SpineForce Reactive Neuromuscular Trainer|
45954097|NCT00335998|Drug|triapine|Given IV
45954098|NCT00335998|Other|laboratory biomarker analysis|Correlative studies
45954099|NCT00335998|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
45954100|NCT00335998|Radiation|brachytherapy|Undergo intracavitary or interstitial brachytherapy
45954101|NCT00335998|Drug|cisplatin|Given IV
45954102|NCT00335998|Other|pharmacological study|Correlative studies
45954103|NCT00470977|Drug|ranibizumab injection (0.5 mg)|ranibizumab 10mg mg/ml. , 0.3ml/vial, 0.05 ml./injection intravitreally for 3months then prn for the next 21 months.
45954104|NCT00471016|Behavioral|Guided intervention|
45954105|NCT00149448|Behavioral|TB Contact Priority Model|
45954106|NCT05350592|Drug|Tocilizumab|Single bolus
45954107|NCT05350592|Drug|Dobutamine|Continous weight-adjusted infusion
45954108|NCT05350592|Drug|NaCl 0.9%|Placebo comparator and diluent
45954109|NCT03271216|Device|No intervention|no intervention
45954110|NCT00471055|Drug|"0.0125% Capsaicin gel CAPSIKA gel"|
45954111|NCT00471055|Drug|Placebo|Placebo
45954112|NCT00471094|Drug|Ilaprazole|Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks.
45954113|NCT00471094|Drug|Ilaprazole|Ilaprazole 20 mg, capsules, orally, once daily for up to 8 weeks.
45954114|NCT00471094|Drug|Ilaprazole|Ilaprazole 40 mg, capsules, orally, once daily for up to 8 weeks.
45954115|NCT00471094|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
45954116|NCT00157833|Drug|Artekin / Coartemther|
45954117|NCT05344313|Dietary Supplement|Ensure Plus Advance|as in the arm description of the intervention
45954118|NCT00471133|Biological|Xenogeneic Tyrosinase DNA Vaccine|
45954119|NCT00471133|Device|TriGrid Delivery System for Intramuscular Electroporation|
45954120|NCT00471172|Behavioral|Face-to-face counseling by a dietitian (months 1-3: weekly, months 4-6: every other week)|
45954121|NCT00471172|Behavioral|Face-to-face counseling by a dietitian (monthly)|
45954122|NCT00471172|Behavioral|Counseling by a dietitian via telephone (months 1-3: weekly, months 4-6: every other week)|
45954123|NCT00471172|Behavioral|Counseling by a dietitian via e-mail (months 1-3: weekly, months 4-6: every other week)|
45954124|NCT00471172|Behavioral|Self help|
45954125|NCT00157872|Drug|MK0966; rofecoxib|
45954126|NCT00157872|Drug|Comparator: naproxen tablet 500 mg|
45954127|NCT00471211|Drug|PBT2|
45815022|NCT05018624|Behavioral|Real-time chat-based support through IM Apps|The chat-based IM support is the extension of baseline ABI and regular e-messages, which aims to provide real-time behavioral and psychosocial support to reduce or quit drinking. It will be personalized according to the subjects' characteristics (gender, drinking pattern and alcoholic drinks preferences), intention to drink and specific questions regarding drinking. Through real-time chatting (text and/or voice), drinkers can acquire information on consequences of drinking and gain social support immediately to reduce intention to drink and alcohol consumption.
45815023|NCT05018624|Behavioral|General health through IM Apps|After baseline, they will receive regular e-message through IM Apps with similar frequency to Intervention group with content on general health and the reminding the importance of participating in the follow-up surveys.
45454152|NCT01336166|Biological|split-virion, non-adjuvanted H1N1 vaccine of 45 μg|120 adults were assigned to receive 1 dose of 45μg split-virion, non-adjuvanted H1N1 vaccine.
45815024|NCT05018624|Behavioral|AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong|"a diagram explaining drinking behaviour and potential health risks, definitions of alcohol unit and binge drinking, and advise on limiting daily drinking to 2 alcohol units for men and 1 unit for women"
45815025|NCT03851120|Dietary Supplement|Probiotics and LC-PUFA (480 mg DHA)|Probiotics and LC-PUFA (480 mg DHA)
45815026|NCT03851120|Dietary Supplement|Placebo probiotics and control LC-PUFA (120 mg DHA)|Placebo probiotics and control LC-PUFA (120 mg DHA)
45815027|NCT03851120|Behavioral|Psychosocial stimulation and healthy eating education|Psychosocial stimulation and healthy eating education
45815028|NCT05011838|Other|1. Health Services Redesign|"1.1. Healthy Hearts service: a nursing station providing blood pressure measurement, cardiovascular risk assessment, preventive counselling and effective follow-up in extended opening hours.~1.2. Hypertension screening: All adults attending health care facilities who did not have their blood pressure measured in the previous year will be referred to the Healthy Hearts Service for screening.~1.3. Clinical management: 1.3.1. Creation of the cardiovascular risk team: a group of doctors supervising hypertension management and coordinating improvement.~1.3.2. Guideline-based standardized diagnostic and treatment protocols: a simplified diagnostic and treatment algorithm will identify a core set of primary and secondary antihypertensive medications.~1.3.3. Availability of antihypertensive medications: it will be assured through procurement mechanisms and its availability will be communicated to clinicians at the beginning of each week and ad hoc in case of stock-outs."
45815029|NCT05011838|Other|2. Clinical Staff Training|"2.1. Training on good clinical management of hypertension: focused on correct blood pressure measurement, use of evidence-based guidelines, cardiovascular risk assessment, use of a standardized diagnostic and treatment algorithm, correct prescription of pharmacological and non-pharmacological treatment, patient counselling, and how to tackle clinical inertia.~2.2. Training on communication skills and patients' needs assessment for all health workers involved in hypertension care. This training will be designed under the patient-centred medicine framework, aiming at equipping health providers with tools for understanding patients' feelings and experience of illness, and to improve their capacity to address social, psychological, and behavioural dimensions of hypertension care."
45815030|NCT05011838|Other|3. Patient and Community Engagement|"3.1. Patient empowerment: expert hypertensive patients , under the supervision of a social worker, will provide support and transmit their know-how to other patients in need, particularly those newly diagnosed or non-adherent to treatment or presenting uncontrolled hypertension.~3.2. Community engagement: a Community Hypertension Outreach Group will be set up, composed of existing voluntary community health workers, who will be trained and certified. This group will conduct blood pressure measurements in selected public areas of the commune, referring those with positive screening to the nearest health facility for diagnosis confirmation. It will also provide health information with emphasis on healthy lifestyles. Existing local communication channels such as the community radio and the local newspaper will be engaged."
45815031|NCT03811964|Other|Specific light exposures|Specific light exposures using light in a wide range of intensities or different light/dark regimens
45954128|NCT00336076|Other|Collection of blood and bone marrow|5-8 cc blood or bone marrow was additionally collected for analysis during diagnostic procedures. No assigned interventions.
45954129|NCT03271255|Drug|Apatinib Mesylate Tablets|Apatinib combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
45454153|NCT01336166|Biological|Placebo control|120 adults were assigned to receive 1 dose of placebo.
45815032|NCT04976972|Device|NAVIO/CORI Surgical System|Total knee replacement with robotic assistance
45815033|NCT04976972|Procedure|Non-robotic conventional instrumentation|Total knee replacement with non-robotic conventional instrumentation
45815034|NCT04976738|Drug|Cybis™ 10:25 THC:CBD oil|Cybis™ 10:25 containing 10 mg/mL of D9-THC and 25 mg/mL of CBD, formulated in medium chain triglycerides (MCT)
45815035|NCT04951934|Device|EmoLED|This treatment consists of irradiation with the blue light emitted by the device for one minute on the injured area. If the wound has a greater extension than the irradiated area, multiple repeated applications will be performed on adjacent areas, until the entire wound is covered.
45815036|NCT04951934|Procedure|Standard treatment|"The standard treatment consists of: cleansing and possible debridement of the wound, application of the topical treatment indicated for that phase of the wound, intended as the standard of care of the structure, and subsequent bandaging."
45815037|NCT05453084|Behavioral|Exercise Program|The intervention includes an individualized exercise program in terms of Frequency, Intensity, Time, Type, Volume and Progression (FITT-VP).
45815038|NCT04950296|Other|Group I: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
45815039|NCT04950296|Other|Group II: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
45815040|NCT04950296|Other|Microcrystalline cellulose|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
45815041|NCT03787082|Drug|Nitrates|1,000 mg/11.18 mmol, oral
45815042|NCT03787082|Drug|Chlorhexidine Gluconate Mouthwash|chlorhexidine gluconate 0.12% (15mL) mouth rinse for 1 minute
45815043|NCT03787082|Drug|Placebo Mouthwash|sterile water (15mL) mouth rinse for 1 minute
45815044|NCT05451524|Behavioral|Insomnia prevention program|Youths in the intervention group will receive 4 weekly insomnia prevention program. Each session will last for about 60-90 mins.
45815045|NCT05451524|Behavioral|General health education|Youths in the control group will be provided with group-based general health education with same dosage (4 weeks) as intervention group.
45815046|NCT03738098|Behavioral|Standard of Care|Participants will receive traditional genetic counseling (GC) for the Baseline and Return of Results (ROR1) visits.
45815047|NCT03738098|Behavioral|GUÍA|GUÍA for the ROR1 visit.
45815048|NCT05451134|Other|Catecholamines|Focus on whether catecholamine exposure is associated with dysglycemia in patients with pheochromocytoma and paraganglioma
45815049|NCT05449886|Procedure|TVC|Tidal volume challenge from 6ml/kg to 10ml/kg for 1 min.
45815050|NCT04945304|Procedure|magnetic bariatric surgery|Perform a roux-en-y gastric bypass, sleeve gastrectomy, nissen-sleeve or revisional bariatric procedure with magnetic assistance
45815051|NCT04945304|Procedure|Magnetic gastric bypass|Using the magnetic assistance to perform a gastric bypass
45815052|NCT02165202|Drug|Rilpivirine|Rilpivirine (TMC278), a non-nucleoside reverse transcriptase inhibitor (NNRTI) is a substituted diaryl-pyrimidine (DAPY) derivative with potent antiviral activity against HIV. It is approved by the US FDA for once daily oral administration and is effective as part of treatment for ARV-na'ive HIV-infected patients as rilpivirine 25 mg capsules. It is also co-formulated with TDF and FTC for use as a once- daily single fixed-dose combination (Complera™).
45815053|NCT02165202|Drug|Placebo|Participants randomized to the placebo arm will receive oral placebo capsules prior to injection of saline solution (0.9%NaCI). Participants will be observed while taking the study product by site staff on approximately six occasions during the first two weeks of the oral run-in at Week 0 (Enrollment), at Week 2 (Oral Run-in Safety Visit), and on four separate DOT visits between Weeks 0 and 2. Cervicovaginal and rectal fluid will be collected for PK studies at a single follow-up visit.
45954130|NCT03271255|Drug|Bevacizumab Injection|Bevacizumab combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
45954131|NCT00149526|Behavioral|Shared Decision-Making|
45815054|NCT01628874|Device|J-Tip|Used once for both arms prior to lumbar puncture. The Experimental arm will receive 0.5 mL (5mg) of 1% Lidocaine. The Active Comparator arm will receive normal saline. This will occur after the cream has been placed for 30 minutes and wiped away and prior to the lumbar puncture.
45815055|NCT01628874|Drug|EMLA|In the Active Comparator arm, lidocaine 2.5% and prilocaine 2.5% cream placed over area where lumbar puncture will occur for at least 30 minutes. This same procedure will occur for the Experimental arm with a placebo cream instead. This will occur once prior to the J-Tip injection and lumbar puncture.
45815056|NCT01628874|Drug|Lidocaine|5 mg given via J-Tip once, repeat dosing as needed in the Experimental group. A placebo will be given in the Active Comparator group.
45954132|NCT00471289|Device|PTA with placement of paclitaxel-eluting stent|PTA with placement of paclitaxel-eluting stent
45954133|NCT00471289|Device|PTA|PTA
45954134|NCT05331209|Other|Acupuncture|Weekly acupuncture treatments, for 8 weeks (8 treatments)
45454154|NCT04470310|Drug|Glimepiride|
45815057|NCT04891718|Biological|MVC-101|Intratumoural microdose injection by the CIVO device.
45815058|NCT04891718|Biological|Nivolumab|Intratumoural microdose injection by the CIVO device.
45815059|NCT04891718|Combination Product|MVC-101 + Nivolumab|Intratumoural microdose injection by the CIVO device.
45815060|NCT05336864|Other|NIRS based autoregulation monitoring|Continuous bilateral frontal cerebral near-infrared spectroscopy (NIRS) monitoring will be performed in all patients for the entire duration of general anesthesia (including induction and extubation). Intraoperative parameters including NIRS and invasive blood pressure will be collected and recorded in real-time using the software ICM+. NIRS monitoring will be continued postoperatively in a subset of patients.
45954135|NCT05331209|Other|Acupuncture-Acupressure|Weekly acupuncture, for 8 weeks, with daily self-acupressure by the patient at home.
46077962|NCT02825498|Device|Contact force guided RFA|Contact force guided RFA during Atrial Flutter ablation procedure.
45454155|NCT04470310|Drug|Alogliptin 25Mg Tab|
45454156|NCT04470310|Drug|Alogliptin-Pioglitazone 25 Mg-15 Mg Oral Tablet|
45660900|NCT05484791|Other|The Lumbar Rotational Spinal Mobilization Technique|Patients included in the study underwent the lumbar rotational spinal mobilization(LRSM) technique during two sessions per week. The LRSM technique is applied while patients are lying on their side. The uppermost hip and knee are placed in 90 degree flexion, this is to assist rotational stress, and the lower leg is placed in extension. The lower shoulder is strongly pulled; thus, the upper shoulder is positioned toward the posterior and the pelvis moves anteriorly. The clinician stands in front of the patient. They stabilize the upper shoulder with one hand, and place the palm of the other hand behind the hard part of the ilium wing, with forearm horizontal and fingers turned toward the clinician. A rotational force is applied with pressure in the horizontal direction by pulling the hand on the ilium toward the clinician. In this position, 30 slow repeated movements are performed. The same practice is performed on both sides
45815061|NCT05336864|Other|additional perioperative blood sampling|Main study (all patients): Creatinine, high-sensitivity troponin (T hs-cTnT), Growth/Differentiation Factor-15 (GDF-15), Hemoglobin Neurological injury substudy: C-reactive protein (CRP), S100 calcium-binding protein B (S-100B), Glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE), Matrix metalloproteinase (MMP-9), Neurofilament Light Chain (NFL), GDF-15
45815062|NCT05336864|Other|clinical & telephone assessments|Main study (all patients): Telephone follow-up (1-year MACE). Neurological injury substudy: Mini Mental Status (MMS), Geriatric Depression Scale (GDS), Confusion Assessment Method (CAM), Confusion Assessment Method for the ICU (CAM-ICU)
45815063|NCT03770689|Drug|Peposertib 50 mg|Participants received peposertib 50 milligram (mg) once daily 5 days per week up to 5.5 weeks.
45815064|NCT03770689|Drug|Peposertib 100 mg|Participants received peposertib 100 mg once daily 5 days per week up to 5.5 weeks.
45815065|NCT03770689|Drug|Peposertib 150 mg|Participants received peposertib 150 mg once daily 5 days per week up to 5.5 weeks.
45815066|NCT03770689|Drug|Peposertib 250 mg|Participants received peposertib 250 mg once daily 5 days per week up to 5.5 weeks.
45815067|NCT03770689|Drug|Capecitabine|Participants received capecitabine at a dose of 825 milligram per square meter (mg/m^2) twice daily 5 days per week up to 5.5 weeks.
45954136|NCT04715971|Diagnostic Test|portable ultrasound bladder scan|A post-void residual volume was measured using a Verathon BladdersScan BVI 3000.
45954137|NCT00157989|Procedure|Controlled tidal volume resuscitation|
45954138|NCT00471367|Drug|AZD4877|intravenous infusion administered twice a week for 2 weeks
45954139|NCT00336115|Biological|Tetanus and Diphtheria Toxoids Adsorbed Combined with Acellular Pertussis (Adacel)|
45954140|NCT00336154|Drug|tetracyclin|
45954141|NCT00336193|Behavioral|Home visitation|Home visitation to improve maternal health and well-being and parenting practices
45954142|NCT00158028|Drug|Risperidone|The dosage of risperidone was titrated upward in a stepwise design, beginning with 0.25 mg/d for the first week, 0.5 mg/d for weeks 2 and 3, 1.0 mg/d for weeks 4 and 5, 1.5 mg/d for weeks 6 and 7, and 2.0 mg/d for the remaining weeks.
45954143|NCT00158028|Drug|Placebo|placebo match in identical tablets
45954144|NCT00471406|Procedure|Photodynamic Therapy with Verteporfin|
45954145|NCT00420862|Procedure|Spiral Computed Tomography|
45954146|NCT05309720|Procedure|Glyaderm|All included patients will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. Next, the dermal substitute Glyaderm followed by a split thickness skin graft will be transplanted on the wound.
45454157|NCT02083250|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
45454158|NCT02083250|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
45454159|NCT02083250|Biological|Anti-Thymocyte Globulin|Given IV
45454160|NCT02083250|Drug|Busulfan|Given IV
45454161|NCT02083250|Drug|Clofarabine|Given IV
45454162|NCT02083250|Drug|Fludarabine Phosphate|Given IV
45815068|NCT03770689|Radiation|Radiotherapy (RT)|Participants received RT 50 to 50.4 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks.
45815069|NCT00371306|Drug|Insulin versus glucovance (glyburide/metformin)|
45815070|NCT00371384|Procedure|massage|UP to 10 massages over 10 weeks
45815071|NCT02196714|Drug|Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
45815072|NCT02196714|Drug|Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
45954147|NCT03271177|Device|7F sheathless Guide Catheter|Transradial PCI will be performed with a 7F sheathless Guide Catheter
45954148|NCT03271177|Device|6F Sheath/Guide Catheter Combination|Transradial PCI will be performed with a 6F Sheath/Guide Catheter Combination
45954149|NCT03271294|Device|Exair Transvaginal Mesh|Exair transvaginal mesh system for the treatment of pelvic organ prolapse
46077963|NCT04102683|Behavioral|Therapeutic recreation activity program|The experimental recreation program, which consisted of two sessions per week and lasted approximately 1 hour each session, lasted for 8 weeks between March 2019 and May 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions.
46077964|NCT00899821|Biological|aldesleukin|
45454163|NCT02083250|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
45454164|NCT02083250|Other|Pharmacological Study|Correlative studies
45454165|NCT02083250|Drug|Vorinostat|Given PO
45454166|NCT00412828|Drug|CR011-vcMMAE|administered as an intravenous infusion of 250 mL over 90 min
45454167|NCT01336244|Drug|GLPG0778|capsules containing 50 or 100 mg of GLPG0778
45815073|NCT02196714|Drug|Glycopyrronium (GP) Dose 1|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
45815074|NCT02196714|Drug|Glycopyrronium (GP) Dose 2|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
45815075|NCT03620474|Drug|PRI-724|twice a week for 4 hours continuous intravenous administration of PRI-724
45815076|NCT04337905|Device|ADHD-VR diagnosis tool|"Since that time and in accordance with the application area, several definitions have been formulated: for example, Fuchs and Bishop (1992) defined VR as real-time interactive graphics with 3D models, combined with a display technology that gives the user the immersion in the model world and direct manipulation; Gigante (1993) described VR as The illusion of participation in a synthetic environment rather than external observation of such an environment. VR relies on a 3D, stereoscopic head-tracker displays, hand/body tracking and binaural sound. VR is an immersive, multi-sensory experience; and Virtual reality refers to immersive, interactive, multi-sensory, viewer-centered, 3D computer generated environments and the combination of technologies required building environments."
45815077|NCT03582566|Behavioral|Phonological Awareness|Earobics training
45815078|NCT03582566|Behavioral|Working Memory|Cogmed training
45815079|NCT03582566|Behavioral|Phonological Awareness + Working Memory|Earobics + Cogmed training
45815080|NCT03582566|Behavioral|Active Control|Spashmath
45954150|NCT00149565|Drug|IFN-α2b|
45954151|NCT00471484|Biological|recombinant interferon alfa-2b|
45954152|NCT00471484|Drug|doxorubicin hydrochloride|
45954153|NCT00471484|Drug|fluorouracil|
46077965|NCT00899821|Biological|recombinant interleukin-12|
45454168|NCT01336244|Drug|placebo|multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
45454169|NCT00315640|Drug|Anecortave Acetate Sterile Suspension, 6 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
45454170|NCT00315640|Drug|Anecortave Acetate Suspension Depot, 30 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
45954154|NCT00471484|Drug|oxaliplatin|
45954155|NCT00471484|Other|diagnostic laboratory biomarker analysis|
45954156|NCT00471484|Other|immunoenzyme technique|
45954157|NCT00471484|Other|immunohistochemistry staining method|
45454171|NCT00315640|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
45454172|NCT00315640|Other|Anecortave Acetate Vehicle|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
45454173|NCT05161130|Procedure|Lumbar Spinal Fusion|Lumbar Spinal Fusion with or without posterior stabilization
45454174|NCT00411892|Drug|pioglitazone|Tablets, 45 mg/day.
45954158|NCT00471484|Procedure|adjuvant therapy|
45954159|NCT00471484|Procedure|biopsy|
45954160|NCT00471484|Procedure|neoadjuvant therapy|
45954161|NCT00471484|Procedure|therapeutic conventional surgery|
45954162|NCT00471523|Drug|Clomiphene citrate|
45954163|NCT00471523|Drug|Metformin|
45954164|NCT00471562|Biological|therapeutic angiotensin-(1-7)|sequentially increasing doses 50-1000 mcg/kg
45954165|NCT00471640|Drug|dexamethasone|4 days 5 mg
45954166|NCT00471679|Drug|ethanol|
45954167|NCT00149604|Drug|conjugated estrogens|
45954168|NCT00149604|Drug|Raloxifene|
45954169|NCT00149604|Behavioral|exercise plus mild caloric restriction for weight loss|
45954170|NCT00471796|Behavioral|Biofeedback|
45954171|NCT00471835|Procedure|computed tomography|
45954172|NCT00471835|Procedure|positron emission tomography|
45954173|NCT00471835|Radiation|stereotactic body radiation therapy|
45954174|NCT00149682|Behavioral|6-month educational program|
45954175|NCT00149682|Behavioral|6-month standard care program|
45954176|NCT00471913|Device|Femoral Nailing with Different Entry Points|See Detailed Description.
45954177|NCT00471952|Drug|Maxalt 10mg MLT plus Caffeine 75mg|One migraine attack will be treated
45954178|NCT00471952|Drug|Maxalt 10mg MLT plus Placebo|One migraine attack will be treated with Maxalt 10mg plus placebo
46077966|NCT00899821|Biological|sargramostim|
46077967|NCT00899821|Other|immunologic technique|
46077968|NCT00899821|Procedure|biopsy|
46077969|NCT04389450|Biological|PLX-PAD|PLX-PAD, allogeneic ex vivo expanded placental mesenchymal-like adherent stromal cells
46077970|NCT04389450|Biological|Placebo|Placebo solution for injection
46077971|NCT02602275|Drug|Neurexan®|There are two experimental conditions; in one condition participants receive Neurexan® and the second condition they receive Placebo for oral administration (three tablets) in a cross over design. In the experimantal arm participants will receive verum on DAY1/PERIOD 1 and will receive placebo on DAY2/PERIOD 2.
46077972|NCT02602275|Other|Placebo|There are two experimental conditions; in one condition participants receive Neurexan® and the second condition they receive Placebo for oral administration (three tablets) in a cross over design. In the comparator arm participants will receive placebo on DAY1/PERIOD 1 and will receive verum on DAY2/PERIOD 2.
46077973|NCT00005112|Drug|Human recombinant growth hormone|
46077974|NCT02602041|Other|Literature search and semi-structured interview|We will do a literature search and perform semi-structured interviews with cancer patients and their partners in order to explore knowledge, attitudes, barriers and facilitators regarding health behavior change following cancer treatment.
46077975|NCT04034641|Drug|Bifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapy|On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Probiotic: Bifidobacterium tetrad live bacteria tablets should be taken at noon once a day (30 min after meal ), 9 tablets per time. On day 15-28: Probiotic: Bifidobacterium tetrad live bacteria tablets, taken at noon once a day (30min after meal), 9 tablets per time.
46077976|NCT04034641|Drug|Bifidobacterium tetrad live bacteria tablet placebo plus Helicobacter pylori quadruple eradication therapy|On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Placebo: Bifidobacterium tetrad live bacteria tablet placebos should be taken at noon once a day ( 30 min after meal ), 9 tablets per time. On day 15-28: Placebo: Bifidobacterium tetrad live bacteria tablet placebos, taken at noon once a day (30min after meal), 9 tablets per time.
45660901|NCT05496413|Device|STARSTIM|In order to evaluate the working memory ability of schizophrenic participants, a task was designed that needs to be performed by them. Firstly, a stimulus of six different color circles of same size in a gray background would be given for 500ms. This would be followed by 2000ms delay phase and then a test array would be appeared. The test array would be exactly same to the stimulus array but with or without change in color of only one circle. The test array would appear on the screen till the participants record their response and they would be asked to respond if the test array matches to the stimulus or not.
45815081|NCT03566264|Other|Non-Interventional|Non-Interventional
45815082|NCT05453929|Drug|Rocuronium for deep NMB|Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.
45815083|NCT05453929|Drug|Rocuronium for moderate NMB|Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
45660902|NCT05496257|Other|direct pulp capping in primary molars|caries will be removed, and if the pulps are exposed, the material will be place directly over the exposed pulp.
45660903|NCT05490095|Drug|SVG101 (T)|5mg of SVG101
45815084|NCT00370760|Drug|oral colchicine, dexamethasone, low molecular weight heparin, 5-FU|
45815085|NCT00370760|Drug|placebo|
45815086|NCT05227508|Dietary Supplement|BRIZO|A capsule containing 400 mg. SC012 (unique soy extract)
45815087|NCT05227508|Other|placebo|Comprecel microcrystalline cellulose
45815088|NCT03737461|Drug|Allogenic BM-MSCs Injection|Cell dose will be 20±5 million cells suspended in 2 ml of HypoThermosol isotonic transport solution
45815089|NCT03737461|Other|Sham Procedure|sham-maneuver as in the cell-treated patients are added, consisting in anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment.
45815090|NCT05203562|Procedure|Suction evacuation|both groups underwent complete mole evacuation using suction curettage.
45815091|NCT05203562|Drug|Letrozole tablets|Group II Patients received 5mg(2tablets 2.5gm) daily letrozole for 10 days after complete mole evacuation
45815092|NCT05453773|Other|Questionnaire Administration|Ancillary studies
45815093|NCT05453773|Behavioral|Tobacco Smoking|Smoke waterpipe tobacco
45660904|NCT05490095|Drug|Afinitor (R)|5mg of Afinitor
45660905|NCT05484635|Procedure|Diagnostic laparoscopy and inguinal mesh removal|Surgical examination and treatment of groin pain following inguinal hernia surgery by surgical exploration with a laparoscope or removal of mesh laparoscopically
45660906|NCT04424381|Drug|Rivaroxaban 20 MG Oral Tablet [Xarelto]|The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet [Xarelto].
45815094|NCT05087888|Procedure|Biospecimen Collection|Undergo collection of blood samples
45815095|NCT05087888|Procedure|Magnetic Resonance Imaging|Undergo functional MRI
45815096|NCT05087888|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo multiparametric MRI
45815097|NCT05087888|Other|Questionnaire Administration|Complete questionnaires
45815098|NCT03713125|Behavioral|Reading Tutoring|20 hours of 1:1 reading tutoring intervention over 6 weeks
45815099|NCT04844138|Behavioral|Overcoming Anxiety in Pregnancy and Postpartum Online Self-Directed Program|The investigators will administer the Overcoming Anxiety in Pregnancy and Postpartum program in an online self-directed format. This program is grounded in Cognitive Behavioural Therapy and will teach participants strategies to manage their anxiety. Participants will complete six modules that will be released to them on a bi-weekly basis.
45815100|NCT05453383|Drug|Anlotinib;Toripalimab|Anlotinib Hydrochloride;Toripalimab injiection
45815101|NCT04830488|Behavioral|e-learning didactic module|Participants utilize e-learning
45815102|NCT04830488|Behavioral|Personal reflection activities|Participants complete questionnaires
45815103|NCT05453305|Procedure|Control group: Traditional venipuncture, on the stretcher.|The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial assessment of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child pain and stress using FLACC and Groningen scale and will record it. Next, the companion will place the child on the stretcher in supine position with the limb to be punctured in decline. During the technique, the companion will be present, being able to participate by establishing links of consolation or distraction, as is usually done in the hospital. Simultaneously, a professional from the service will be in charge of holding the chosen extremity, as well as the opposite one. The responsible nurse will perform the venipuncture and/or collecting samples. The observer will assess child's pain and stress and caregiver's STAI during the intervention with the same scales.
45835844|NCT05204706|Other|MyManis app|The women will receive a brochure outlining the app features and step guide on how to download the app which will be available in both Bahasa Melayu and English languages. A link to download the app via text message will also be sent to participants for convenience. Once the app has been downloaded, participants will be invited to set up an account. Once completed this will give them full access to the MyManis app. The key component of MyManis app content presented under six main tabs which are homepage, information, diet, exercise, wellbeing and GDM monitoring. The women will be invited to join group peer support through WhatsApp facilitated by a dietitian trained in motivational interviewing. The women will be notified via text message if an update of the app is required. If there's women who have not accessed the app for over a two-week period will be flagged and a notification will be sent via the app to motivate app engagement.
45954179|NCT00471952|Drug|Placebo + Placebo|One migraine attack will be treated with double placebo
46002736|NCT00547547|Drug|capecitabine|Dose Level 1: 750 mg/m2, 2x daily x 14 days every 21 days. Dose Level 1.5: 850 mg/m2, 2x daily x 14 days every 21 days. Dose Level 2: 1000 mg/m2, 2x daily x 14 days every 21 days.
45660907|NCT04424381|Drug|Rivaroxaban 20 MG Oral Tablet|The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet.
45660908|NCT05496179|Drug|Prucalopride|Prokinetic
45660909|NCT05496179|Drug|Metoclopramide|Prokinetic
45660910|NCT04157621|Device|Active taVNS|Patients will be masked to transcutaneous stimulation of the auricular branch of the vagus nerve at the tragus
45660911|NCT04157621|Device|Sham Stimulation|Sham stimulation involves identical perceptual threshold finding and stimulation parameters as active stimulation, with the exception of stimulation target. Sham stimulation will be delivered to the left earlobe, a target believed to have little to no vagal nerve innervation.
45835845|NCT04772976|Other|Observational study, not applicable|Observational study, not applicable
45954180|NCT00471991|Drug|SH T04769G|The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.
45954181|NCT00471991|Drug|Ethinyl estradiol / dienogest (SH D00659 AF)|The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.Volunteers have to undergo a series of blood sampling during the 2nd treatment cycle to evaluate the pharmacokinetic (liberation, absorption, distribution, metabolization and excretion) of the new oral contraceptive.
45454175|NCT00411892|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
45454176|NCT01336322|Drug|Metformin|Metformin 850 mg bid
45454177|NCT01336322|Drug|Sitagliptin|Sitagliptin 100 mg qd
45454178|NCT01336322|Drug|Sitagliptin + Metformin|sitagliptin 100mg + metformin 850mg
45660912|NCT05496101|Procedure|Intraoperative CLI + FAR LightPath imaging|"Imaging System: The LightPath Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post marketing study).~Radiopharmaceutical:~18F-FDG is a routinely used Positron Emission Tomography (PET) / Computed Tomography (CT) radiopharmaceutical"
45660913|NCT05496023|Device|Percutaneous coronary intervention|"Pre-PCI angio-FFR was calculated and virtual pullback was generated~Automated algorithm to calculate delta angio-FFR per unit length and co-registered onto coronary angiogram was developed~PCI was performed using 2nd generation DES"
45835846|NCT00054756|Drug|TRH (Thyrotropin Releasing Hormone)|
45835847|NCT04772430|Radiation|snow globe|"Control group; The baby whose height and weight measurements will be taken will be taken to the stretcher, and the vaccine will be administered after the pain score is measured before the procedure. Pain scores will be recorded during and after the procedure.~Experimental group; The baby whose height and weight measurements will be taken will be taken to the stretcher, after the pain score is measured before the procedure, the snow globe will be operated and the vaccine will be applied. The snow globe will continue to work until the application is completed. Pain scores will be recorded during and after the procedure."
45954182|NCT03271099|Other|Navigator|Patient Navigation services will be provided to try to eliminate barriers in pursuing survivorship surveillance
45954183|NCT00158067|Device|external Responsive Neurostimulator (eRNS) System|
45954184|NCT00472069|Procedure|transplantation of the squeletic muscular cells|transplantation of the squeletic muscular cells
45954185|NCT00472108|Procedure|PDT with Metvix 160 mg/g cream|
45954186|NCT00472108|Procedure|PDT with placebo cream|
45954187|NCT00472147|Procedure|shock efficacy|
45954188|NCT03271060|Procedure|Posterior lumbar interbody fusion|Lumbar fusion by screws and inter vertebral cage
45954189|NCT03271060|Procedure|Inter transverse bone grafting|Inter transverse process bone grafting by bone graft from illiac crest or other sites
45954190|NCT03271138|Dietary Supplement|Bifidobacterium infantis NLS super strain (Natren LIFE START®2)|2 capsules, 3 times per day, for daily total of 12x10^9 CFU Bifidobacterium infantis NLS super strain
45954191|NCT03271138|Other|Placebo|2 capsules, 3 times per day, containing rice flour, hydroxypropyl and methylcellulose
45954192|NCT03270865|Device|PAF (Positioning And Fixation device)|"Up to 60 Subjects will be evaluating for positioning accuracy and comfort by comparing different methods utilizing the PAF device. Some methods of positioning will be applied and compare for each usability factor X, Y, Z location, and fixation.~The patient will be evaluated before pupil dilation. VA and ophthalmic diagnoses will be recorded.~Pupil position will be recorded using 3 commercial off the shelf cameras when the subject is performing simple ergonomic tasks while looking at a screen presenting images. Each testing session will be limited 20 min long. Subjects will be able to rest within the testing session if required. Total session time per patient will not exceed 30 minutes."
45454179|NCT01033916|Other|LIBERAL|The LIBERAL arm of the study will have a target Blood Glucose level ranging from 121-180 mg/dL. As opposed to the standard of less than 120 mg/dL.
45454180|NCT01339676|Drug|Colecalciferol|Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D
45454181|NCT01339676|Drug|Placebo capsules|Identically appearing once weekly peroral placebo capsules
45954193|NCT00336310|Drug|Repaglinide|
45954194|NCT00336349|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A
45454182|NCT00315250|Drug|[123I]β-CIT|"Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI."
45454183|NCT04848428|Behavioral|Online mindfulness-based cognitive therapy|The first session will first focus on providing feedback regarding post-surgical pain. The second session will focus on teaching mindfulness strategies. The third session will focus on practicing one of the two strategies. Of note, sessions 2 and 3 will start with cognitive restructuring strategies for the moderate-high risk profile patients. The 4th session consists in a booster providing feedback and reminders about cognitive reactions to pain and mindfulness meditation. The participants will be asked to practice meditation 5 days a week, for a total of 4 weeks
45454184|NCT04848428|Behavioral|Online standardized education|One 15-minute educational session on postoperative pain, the relationship between pain, thoughts and emotions and brief overview of strategies.
45835848|NCT04772508|Procedure|Scaling and root planing|15 sites with periodontal pockets ≥ 5mm received only SRP
45835849|NCT04772508|Biological|Amnion membrane|15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane.
45954195|NCT00472225|Drug|Rituximab|"Rituximab Induction: Rituximab 375 mg/m2 weekly IV for 4 consecutive weeks~Rituximab Maintenance: Rituximab 375 mg/m2 monthly IV for 4 consecutive months"
45954196|NCT00336388|Device|Paracheck Device|
45954197|NCT00472264|Procedure|PET imaging|Medical imaging assessment
45954198|NCT00472342|Behavioral|exercise prescription|
45454185|NCT00407914|Device|Aquamid|Subcutaneous injection
45454186|NCT00407914|Device|Restylane|Injection in dermis
45835850|NCT04772508|Drug|Taurine|15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane hydrated with taurine.
45835851|NCT01896960|Drug|Bupivacaine with 15 micrograms of fentanyl|Testing 2 doses of Bupivacaine (12.5 mg and 15 mg) with 15 micrograms fentanyl
45835852|NCT02091102|Device|755nm Alexandrite Laser|755nm Alexandrite Laser for the treatment of Wrinkles
45954199|NCT00336466|Drug|Human recombinant erythropoietin|
45954200|NCT03270787|Drug|Placebo|Drug: Placebo Placebo,10pills,tid,treat 1 weeks.
45954201|NCT03270787|Drug|Compound danshen dripping pills|Drug: Compound danshen dripping pills Compound danshen dripping pills,10pills,tid,treat 1 weeks.
45954202|NCT03270904|Device|Moleculight i:X™ fluorescence imaging|Moleculight i:X™ is a hand held device that emits violet blue light. By controlling distance from the wound and ambient light, Moleculight i:X™ identifies bacteria above a pre-determined concentration by identifying natural fluorescence in the bacteria cell wall.
45954203|NCT00336622|Device|Splint fabricated by an OT versus an off-the-shelf splint|"Experimental:~Custom-made splint and tendon-nerve gliding exercises Custom-made splint and no tendon-nerve gliding exercises~Control:~Control: Off-the-shelf splint and tendon-nerve gliding exercises Off-the-shelf splint and no tendon-nerve gliding exercises"
45954204|NCT00472381|Drug|Insulin|Insulin
45954205|NCT00336661|Device|PerioWave|
45954206|NCT00472459|Procedure|Photodynamic therapy with Metvix 160 mg/g cream|
45954207|NCT00336739|Drug|cinacalcet|
45954208|NCT05279924|Drug|Prophylaxis with Emicizumab|Prophylaxis with Emicizumab in Ivoirian boys with severe hemophilia A
45954209|NCT00472537|Procedure|Retromuscular Mesh repair of midline incisional hernia|
45954210|NCT00472537|Procedure|Laparoscopic repair of midline incisional hernia|
45954211|NCT00336778|Drug|3TC, TDF, NLV|3TC 300 mg PO once daily+ TDF 300 mg PO once daily+ NLV 1250 mg PO twice daily (after 12 week lead-in period)
45954212|NCT00158106|Procedure|Speech and Language therapy for dysarthria and/or aphasia|
45954213|NCT00424151|Drug|Rituximab|
45954214|NCT00472771|Drug|INNO-206|
45954215|NCT00472810|Device|ologen collagen matrix in glaucoma filtering surgery|If ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
45954216|NCT00472810|Drug|MMC in glaucoma filtering surgery|If mitomycin -C is applied, a single cellulose sponge soaked with MMC (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
45954217|NCT00149721|Procedure|Ventriculo-peritonal shunting|
45835853|NCT00055692|Biological|bevacizumab|Given orally
45954218|NCT00337051|Drug|Sevoflurane|General anesthesia using Sevoflurane (inhalation) as hypnotic
45954219|NCT00337051|Drug|Propofol|General anesthesia with propofol TCI
45954220|NCT05262803|Genetic|CYP2C19*2/*3|"Non-carriers of CYP2C19*2/*3 loss-of-function alleles: DAPT with clopidogrel and ASA~Carriers of CYP2C19*2/*3 loss-of-function alleles: DAPT with prasugrel (or ticagrelor) and ASA"
45954221|NCT05262803|Other|Shorter DAPT duration|Duration of DAPT is shortened to 3 months
45954222|NCT00472927|Drug|Premarin/MPA 0.45 mg/1.5 mg|
45954223|NCT00149760|Behavioral|Augmented Standard Medical Care|Participants' physicians will receive a letter making specific treatment recommendations for primary care treatment.
45954224|NCT00149760|Behavioral|Cognitive-Affective Behavior Therapy|Individually-administered cognitive-behavioral therapy with an emotional focus in addition to augmented standard medical care
45954225|NCT04054492|Biological|Sabin-IPV+bOPV+bOPV|202 subjects were vaccinated with 1 dose of Sabin-IPV and 2 doses of bOPV at their age of 2/3/4 months old, respectively
45954226|NCT04054492|Biological|Sabin-IPV+Sabin-IPV+bOPV|197 subjects were vaccinated with 2 doses of Sabin-IPV and 1 dose of bOPV at their age of 2/3/4 months old, respectively
45660914|NCT05489939|Drug|The compound methyl salicylate liniment|The compound methyl salicylate liniment (Ammeltz) has been developed by Japan Sendai Kobayashi Pharmaceutical Co. and has been listed in Japan for many years. It is composed of various components, such as methyl salicylate, menthol, camphor, chlorpheniramine maleate, and thymol.
45660915|NCT05484323|Other|Glucose as reference food|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
45660916|NCT05484323|Other|White bread|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
45660917|NCT05484323|Diagnostic Test|Cookie containing 0 g spirulina|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
45660918|NCT05484323|Other|Cookie containing 2.5 g spirulina|TThirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
45454187|NCT01339754|Drug|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks
45454188|NCT01339754|Drug|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks until progression
45454189|NCT00313768|Drug|paclitaxel + carboplatin + bevacizumab|paclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles
45815104|NCT05453305|Procedure|Intervention group: DAK method venipuncture, simulating a hug|The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial evaluation of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child's pain and stress using the FLACC and Groningen scale and record it. Subsequently, the caregiver will sit in a chair placing the child on top in front of him, with one leg on each side and the arms resting on the shoulders of the companion. The patient's head will rest on the adult's shoulder, contralateral to the limb to be punctured. Simultaneously, the responsible adult patient will hold the simulating a hug. A professional will take care of immobilizing the chosen limb. The responsible nurse performed the venipuncture and collecting samples. The observer will assess the child's pain and stress during the intervention, and will deliver the STAI to the caregiver, to be completed with their perceived sensations during the technique.
45815105|NCT04766762|Procedure|Acupuncture combined with placebo|This group will include 48 patients. Patients in this group will receive acupuncture combined with placebo. Participants are in the supine position. The bilateral Tianrong (SI 17) acupoints are needled for 1-1.5 inch with the direction tilted back 45±5 degrees. The bilateral Fengchi (GB 20) acupoints are needled for 0.5-1 inch with the direction tilted to nose. The bilateral Neiguan (PC 6) acupoints are also needled for 0.5-1 inch with the straight direction. In addition, 4-6 additional acupoints can be identified according to different syndrome types of patients. The needles are kept for 30 min, the treatment frequency is 3 times per week, and the treatment duration lasts 8 weeks. Meanwhile, the dosage of placebo is 1 capsule twice a day and the treatment duration also lasts 8 weeks.
45835854|NCT05043012|Device|flexible AIR coil|mpMRI scan
45835855|NCT05043012|Device|endorectal coi|mpMRI scan
45835856|NCT04772352|Drug|febuxostat treatment|According to NAFLD guidelines, participants accept febuxostat treatment (40mg, once a day, orally)
45954227|NCT04054492|Biological|Sabin-IPV+Sabin-IPV+Sabin-IPV|205 subjects were vaccinated with 3 doses of Sabin-IPV at their age of 2/3/4 months old, respectively
45954228|NCT00337090|Drug|YM178|
45954229|NCT05262452|Device|ALPIUS 900, an ultrasound-guided high intensity focused ultrasound system|Device to deliver mechanical stress and force to enhance drug delivery, using focused ultrasound
45954230|NCT05262452|Drug|FOLFIRINOX regimen|"a chemotherapy regimen for treatment of advanced pancreatic cancer~FOL : folinic acid (leucovorin), a vitamin B derivative that enhances the effects of 5-FU~F : 5-FU, a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis~IRIN : irinotecan (eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis.~OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis"
45954231|NCT04715854|Device|Mask|addition of the mask above the nasal cannulas
45954232|NCT00337246|Biological|rituximab|
45954233|NCT00337246|Drug|cyclophosphamide|
45954234|NCT00337246|Drug|fludarabine phosphate|
45954235|NCT00337246|Drug|mitoxantrone hydrochloride|
45954236|NCT05210972|Radiation|Cardiac catheterization|All the study population will be exposed to diagnostic coronary angiography and invasive coronary intervention as per standard guidelines.
45815106|NCT04766762|Procedure|Sham acupuncture combined with flunarizine hydrochloride|This group will include 48 patients. Participants in this group will receive sham acupuncture plus flunarizine hydrochloride. Participants are in the supine position and sham acupuncture is conducted. The bilateral Tianrong (SI 17) acupoints, Fengchi (GB 20) acupoints and Neiguan (PC 6) acupoints are selected, and 4-6 additional acupoints can be identified according to the syndrome type of the participants. The needles are kept for 30 min, the treatment frequency is 3 times per week, and the treatment duration lasts 8 weeks. Moreover, the dosage of flunarizine hydrochloride is 5mg twice a day and the treatment duration also lasts 8 weeks.
45660919|NCT05495945|Device|Low-intensity focused ultrasound pulsation (LIFUP)|LIFUP will be used to stimulate specific brain regions and assess their causal involvement in the control of conscious state and contents.
45660920|NCT05495945|Combination Product|Functional Magnetic Resonance Imaging (fMRI) using Propofol|Propofol will be administered by intravenous infusion. All anesthesia equipment, supplies, and drugs will be provided by anesthesiologists from the University of Michigan Health System. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations
45815107|NCT04750304|Behavioral|Application ARTHe|Patient will use ARTHe Application for 3 months
45660921|NCT05495867|Procedure|implant placement|implant placement in edentulous area
45815108|NCT04330040|Drug|Olaparib|Tablet
45815109|NCT02737891|Drug|Tesofensine/Metoprolol|Tesofensine 0.5 mg + Metoprolol 100 mg
45815110|NCT02737891|Drug|Placebo|
45815111|NCT05055050|Drug|UGN-201|Intravesical 200 mg /50 ml x 1 dose
45954237|NCT00158301|Behavioral|Cognitive behavioral therapy (CBT)|CBT sessions will focus on teaching participants skills to manage depressed moods and to identify situations which might put them at risk for a relapse in depressive symptoms.
45954238|NCT00158301|Drug|Drug therapy|All participants will receive 12 weeks of treatment with antidepressant therapy. Responders to initial treatment will continue medication during the continuation phase (both treatment arms).
45954239|NCT00473005|Drug|Capecitabine|825 mg/m2 bid, Oral
45954240|NCT00473005|Drug|RAD001|2.5mg QOD, 2.5mg QD, 5.0mg QD, Oral
45954241|NCT00473044|Behavioral|Sisters in Motion|
45954242|NCT04716049|Other|Powerade©, CHP, CJ, FR, CWI|"Combination of recovery strategies including dietary, neuromuscular and physiological as follows:~Powerade©: players will drink 500 mL during the game~Carbohydrate and protein (CHP): players will drink 250 mL of water with CHP within 30 minutes after the end of the game.~Tart cherry concentrate (CJ): players will drink 30 mL of CJ within 30 minutes after the end of the game.~Foam roller (FR): players will follow FR protocol using a polyvinylchloride pipe roller. They will begin with the FR at the most proximal portion of the muscle and to roll as much body mass as tolerable back and forth at a cadence of 1 second superior and 1 second inferior for 45 seconds followed by a 15-second rest for each muscle group (quadriceps, adductors, hamstrings, abductors and calf) in each extremity and repeated once.~Cold Water Immersion (CWI): will be the last strategy used. Players will immerse their lower body to the level of hips for 10 minutes in cold water (13-14°C)."
45954243|NCT04716049|Other|Powerade©, CHP, STR, ICWI|"Combination of recovery strategies including dietary, neuromuscular and physiological as follows:~Powerade©: players will drink 500 mL of Powerade© during the game~Carbohydrate and protein intake (CHP): players will drink 250 mL of water with CHP within 30 minutes after the end of the competition.~Stretching (STR): players will perform 10-min of static stretching, involving 2 unilateral repetitions of 30 seconds held stretches to the quadriceps, adductors, hamstrings, abductors and calf muscles.~Intermittent Cold-Water Immersion (ICWI): will be the last strategy used. It will consist of five 2 min intermittent immersions of the lower limb (up to the iliac crest) in a cold-water bath (13-14ºC), separated by 2 min rest in ambient air. Ice will be added to the bath at regular intervals to maintain water temperature at 13-14ºC. Players will be instructed to stand in the bath, with as little movement as possible."
45954244|NCT05206838|Procedure|Surgical reconstruction of gluteus medius with Achilles tendon allograft|Achilles tendon allograft i fixed between the gluteus medius muscle and the greater trochanter
45954245|NCT00473122|Procedure|Delayed-Immediate Breast Reconstruction|Immediate reconstruction surgery if no XRT required; or reconstruction surgery delayed until XRT complete.
45954246|NCT00149877|Drug|Tegaserod|
45954247|NCT00473161|Device|surface EMG biofeedback|
45954248|NCT00337324|Device|Frequency-modulated electromagnetic neural stimulation|
45954249|NCT00473200|Dietary Supplement|S-adenosylmethionine|1200 mg daily
45954250|NCT05201339|Procedure|Standard method|Insert I-gel™ according to the manufacturer's instruction. Take the sniffing position and gently move the i-gel™ along the hard palate to the soft palate and the posterior oropharynx.
45954251|NCT05201339|Procedure|Hean and Neck Rotation|After rotating the patient's head and neck to the left maximally, insert the i-gel™ from the right side of the tongue to the midline. When the tip reaches the soft palate and oropharynx positions, turn the head and neck back to the neutral position.
45954252|NCT00473239|Drug|cholecalciferol.|100,000 IU of Vitamin D
45954253|NCT00149916|Drug|Mycophenolate sodium (enteric coated)|
45954254|NCT00473317|Behavioral|Sun Exposure|Each subject will wear a swimming suit and be exposed to sunlight for 30 minutes total (15 minutes lying on back, 15 minutes lying on stomach).
46002737|NCT00547547|Drug|irinotecan hydrochloride|Dose Level 1: 100 mg/m2 on day 1 and day 8 every 21 days. Dose Level -1: 75 mg/m2 on day 1 and day 8 every 21 days.
46002738|NCT00547625|Drug|tadalafil|Treatment phase 1 includes 5 mg tadalafil tablet taken by mouth once a day for 6 weeks then treatment phase 2 which includes 20 mg tadalafil tablet taken by mouth once a day for 6 weeks.
46002739|NCT00547625|Drug|placebo|Placebo tablet run in followed by placebo treatment period with one tablet taken by mouth once a day for twelve weeks.
45660922|NCT05484089|Device|CapFlex PIP implant|Patients receive the CapFlex PIP implant based on regular care. During surgery tantalum markers are placed in the bone surrounding the implant.
45815112|NCT05007548|Drug|Ga68-Dolacga Injection|Ga68-Dolacga Injection, 2.0±1.0 mCi, single dose, iv bolus
45815113|NCT04994834|Dietary Supplement|Probiotics|Once a day daily intake of probiotics for at least 28 consecutive starting within 24 hours after birth
45954255|NCT05195762|Drug|NFX-179 Gel 1.50%|"Stanford University (Stanford) is studying a selective mitogen-activated protein kinase kinase (MEK) inhibitor (NFX-179) that has been chemically engineered for topical application to treat epidermal nevus syndromes (ENS).~Preclinical studies evaluating topical application of NFX-179 to human nevus sebaceous explants demonstrated that NFX-179 can penetrate the tissue and suppress the p-ERK biomarker.~It was also determined that NFX-179, when incubated with the tissues in medium, also suppressed ERK phosphorylation in human keratinocytic epidermal nevi. This clinical study is designed to evaluate the safety, tolerability, and clinical effect of NFX-179 Gel in Subjects with Epidermal Nevi."
46077977|NCT05660330|Behavioral|Holistic semi-tailormade well-being intervention|The holistic well-being intervention consists of a mandatory basic package that will take 2 half days and 1 full day to complete. In the first half day, the conclusion of the baseline measurement will be discussed, as well as the specific outline of the well-being thay. On the well-being day, three trained professionals from an HR service company, called Liantis, will guide these interventions (consisting of training and workshops) in the workplace. Only a small proportion of the company employees, called the ambassadors, will attend the well-being day. In the second half day, the ambassadors will be coached to disseminate the obtained information to the entire workplace. This information will be personalized according to the problems, needs and context of each company. Besides the basic package, an optional expertise package will be offered during this second half day. In the period afterwards, the ambassadors are followed every 2 months by means of a semi-structured interview.
45954256|NCT00473356|Dietary Supplement|receive amino acid supplement|Receive amino acid supplement
45954257|NCT00158340|Behavioral|Guided self-help cognitive behavioral therapy (CBT)|Participants receive eight sessions of guided self-help CBT.
45954258|NCT00158340|Behavioral|Usual clinical care|Control group participants receive treatment as usual.
46077978|NCT04163406|Dietary Supplement|ferrous fumarate|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate
45660923|NCT05489861|Behavioral|M-AM|To examine the effects of affirmation and infant massage taught to their parents on their infants' sleep quality and parent-infant attachment.
45815114|NCT03690661|Behavioral|Intervention Video Game|"The intervention game employs evidence-based serious game mechanics (e.g., storylines, long-term goals, scaling difficulty) to design a learning environment that maximizes opportunities for adolescents with ASD to discover the functional utility of eye gaze cues."
45954259|NCT00473473|Drug|Potassium Dichromate (Homeopathy)|twice daily with an interval of 12 hours, for a period of up to 14 days
45954260|NCT00473473|Drug|Placebo homeopathic remedy|identical to treatment without active component
45954261|NCT00337441|Drug|Epoetin Alfa (drug)|
45660924|NCT05489861|Behavioral|F-AM|To examine the effects of affirmation and infant massage taught to their parents on their infants' sleep quality and parent-infant attachment.
45954262|NCT00405873|Drug|AMT2003|
46077979|NCT04163406|Dietary Supplement|ferrous fumarate + GOS|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate and GOS (3g)
46077980|NCT04163406|Dietary Supplement|ferrous fumarate + HMOs|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate and HMOs (2'-FL (2g) + LNnT(1g))
45454190|NCT00313768|Drug|carboplatin + paclitaxel + bevacizumab + PF-3512676|carboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles
45815115|NCT03690661|Behavioral|Placebo Control Game|The placebo game will have all the elements of the serious game mechanics of the intervention game (narrative storylines, long-term goals, scaling difficulty), but will not provide the learning opportunities regarding eye gaze cues.
45454191|NCT01339988|Drug|Busulfan/Cyclophosphamide|"Conditioning regimen:~Cyclophosphamide 50mg/kg/day for 4 days + Busulfan 0.8-1.0mg/kg/day for 4 days."
45954263|NCT00337480|Behavioral|education|education of acute coronary syndrome patients, mostly about nicotinic weaning, weight loss and physical activity
46077981|NCT00899899|Genetic|microarray analysis|
45454192|NCT05160350|Drug|Probiotic|Each probiotic capsule contained combination of lactobacillus and Bifidobacterium species.
45660925|NCT05489627|Procedure|Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement|"Medial knee instabilities will be addressed in this arm as described in the published technique: K. Malinowski, K. Hermanowicz, A. Góralczyk, R.F. LaPrade, Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement for Medial and Anteromedial Rotatory Instability of the Knee, Arthrosc. Tech. 8 (2019) e807-e814. https://doi.org/10.1016/j.eats.2019.03.019.~Due to the fact that isolated injury of medial stabilizers of the knees is very rare, included will be patients with concomitant ACL QTB reconstruction and abovedescribed MCL reconstruction. Any accompanying intraarticular injuries such as meniscal lesions will be addressed as well."
45660926|NCT04423991|Device|COViage|Machine learning intervention
45660927|NCT05483699|Other|Squeezing a ball|The children in the squeezing soft ball group were given the ball before the procedure. They were told to squeeze and loosen the ball with the hand that was not used for the procedure while intravenous cannula was being inserted.
45815116|NCT05453227|Drug|Zinc|To test the effect of a novel zinc-containing vaginal topical on GSM/VVA symptoms.
45815117|NCT02196558|Drug|E6011|
45815118|NCT04941092|Other|no intervention|no intervention, retrospective comparison
45835857|NCT04772352|Behavioral|lifestyle intervention|According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
45835858|NCT00056472|Drug|Olanzapine|10-20mg/day
45835859|NCT00056472|Drug|Sertraline|150-200mg/day
45835860|NCT00056472|Other|placebo|tablet that ressembles sertraline but contains no medication
45954264|NCT05183048|Drug|[89Zr]Panitumumab Tracer|All patients entered into the study will have [89Zr]Panitumumab-PET/MRI imaging.
45954265|NCT00337519|Procedure|allogeneic stem cell transplantation|see detailed description
45954266|NCT00337519|Drug|Alemtuzumab|alemtuzumab is given as cytoreductive pre-treatment with the last application of alemtuzumab scheduled for day 14
45954267|NCT00337558|Drug|Solifenacin succinate|tablet
45815119|NCT05453149|Behavioral|Integrated Physical Activity and Behavioural Change Intervention|"Physical Activity (PA) Component: A group-based PA program geared to the level of injury and mobility delivered through web conferencing software. Participants select at three sessions weekly over 10 weeks. Sessions include 45 mins of exercise (i.e boxercise; aerobics; yoga) and 15 mins of social interaction with the group.~Behavioural Change Component: Participants will also receive synchronous 1:1 sessions (approximately 20 mins/week) with a trained clinician on behavioural strategies to initiate and maintain engagement in PA over the 10-week period. Content of the sessions includes: providing information on PA and the self-management of impairments and related symptoms; evaluating barriers to engagement (e.g. fear of injury); and behavioural strategies."
45954268|NCT00337558|Behavioral|Simplified bladder training|Instructions
45954269|NCT00508963|Drug|sodium stibogluconate (Pentostam)|20 mg/kg IV every day for 20 or 28 days
45954270|NCT00158418|Procedure|Cemented Humeral Stem|
46077982|NCT00899899|Genetic|reverse transcriptase-polymerase chain reaction|
45660928|NCT05483699|Other|Blowing bubbles|The children in the blowing bubble group were shown the bubble blower before intravenous cannulation and they were told how bubbles were formed and how they would blow. During intravenous cannulation, the child blew the blower
45660929|NCT05483699|Other|Kaleidoscope|Children in the Kaleidoscope group were given the kaleidoscope before intravenous cannulation and they were shown how to use it. The children were told to look at the kaleidoscope during the procedure until the procedure ended
45954271|NCT00158418|Procedure|Uncemented Humeral Stem|
45954272|NCT02964104|Drug|Insulin icodec|Administered once weekly subcutaneously (s.c., under the skin) for 35 days
45660930|NCT04134767|Behavioral|Health Linkage|Research staff will: 1) help participants set goals and reduce their health risks by helping them to reflect on personal drug use, sexual relationships, and their consequences in the context of personal values and goals; 2) help link participants to services that they need and want; 3) offer participants the option of HIV and hepatitis C testing, provide the test result, and provide post-test counseling; and 4) provided participants nasal spray naloxone (Narcan) to carry with them in case they encounter someone who has an opioid overdose or in case they have an opioid overdose and a friend can use the naloxone to respond.
45954273|NCT02964104|Drug|placebo|Administered once daily subcutaneously for 35 days
45815120|NCT04902404|Other|First Pathways Game|The First Pathways Game is a free, online parenting education program. Parents watch short videos (approximately 30 seconds) on the First Pathways Game website to receive neuroscience knowledge and ideas for age-appropriate game ideas to play with their child. The game ideas employ common household items, such as measuring cups and paper.
45954274|NCT02964104|Drug|insulin degludec|Administered once daily subcutaneously for 35 days
45954275|NCT02964104|Drug|placebo|Administered once weekly subcutaneously for 35 days
45954276|NCT00337597|Other|Glucose 5%|
45954277|NCT00337597|Other|NaCl 0.9%|
45954278|NCT00337636|Procedure|Surgery to implant human CNS stem cells (HuCNS-SC)|single dose
46077983|NCT00899899|Other|laboratory biomarker analysis|
45660931|NCT04134767|Behavioral|Overdose Education|Participants will complete a 10-minute overdose education training video on preventing, recognizing, and responding effectively to an opioid OD.
45660932|NCT05489315|Device|Positioning with peanut ball|If participants are randomly selected to receive a peanut ball, the intent is for the patient to remain on the peanut ball during their labor progression.
45954279|NCT00337636|Drug|Medication to suppress the immune system|Immunosuppression for 12 months post transplant
45954280|NCT00158457|Drug|Tenofovir (TDF)|
45954281|NCT00158457|Drug|Emtricitabine (FTC)|
45954282|NCT00158457|Drug|Efavirenz (EFV)|
45954283|NCT00509158|Biological|arm I: PfLSA-3-rec with aluminium hydroxide as adjuvant|
45954284|NCT00509158|Biological|arm 2: PfLSA-3-rec with Montanide Isa 720 as adjuvant|
45954285|NCT00509275|Drug|W0027|capsule
45954286|NCT00509275|Drug|Placebo|Placebo
45954287|NCT00509314|Behavioral|melanocyte self-assembly and functional analysis|
45954288|NCT00405080|Drug|GW679769 (Casopitant) oral tablets|Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive three 50 mg tablets for the dose of 150 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
45954289|NCT00405080|Drug|Rifampin oral capsules|Rifampin capsules will be available with dose strength of 300 mg. Subjects will receive two 300 mg capsules for the dose of 600 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
45954290|NCT00337714|Procedure|CVC impregnated with silver nanoparticles (AgTive®)|insertion of medicated silver nanoparticles CVC
45954291|NCT00337714|Procedure|CVC cannulation|placement of conventional trilumen CVCs
45954292|NCT00158496|Drug|pegylated interferon alpha2a|
45954293|NCT00158496|Drug|ribavirin|
45954294|NCT00337753|Behavioral|Cognitive Behavioral Therapy|5-weeks of Cognitive Behavioral Therapy
45954295|NCT00337753|Behavioral|Wait-list|subjects assigned to wait-list condition for six-weeks
45954296|NCT00337792|Drug|oxycodone + lorazepam versus fentanyl + midazolam|
46077984|NCT04102605|Device|Nunap Vision|Participants receive visual perceptual training using the Nunap Vision software
46077985|NCT04102605|Device|Nunap Vision-C|Participants receive sham training using the Nunap Vision-C software
46077986|NCT00900133|Other|immunoenzyme technique|Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.
46077987|NCT00900133|Other|laboratory biomarker analysis|Blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B.
46077988|NCT04218552|Drug|AD209|PO, Once daily(QD), 8weeks
45954297|NCT00509353|Drug|irinotecan hydrochloride|
45954298|NCT00509353|Drug|vincristine sulfate|
45815121|NCT04338217|Device|Bionator|This is a functional appliance that is used to overcome the functional problems and to correct the open bite deformity
45815122|NCT04338217|Device|Removable Appliance with Posterior Bite Planes|This is a one-jaw appliance that is used in conjunction with a tongue crib to control the faulty positions of the tongue and to help in closing the open bite through the use of posterior bite planes.
45660933|NCT05489315|Other|Traditional positioning|If participants are randomly selected to NOT receive a peanut ball, the intent is for the patient to undergo traditional positioning/use wedge pillows during their labor progression.
45454193|NCT01342250|Biological|conventional therapy plus low dose hUC-MSCs treatment|patients will receive the conventional therapy plus low dose hUC-MSCs treatment
45454194|NCT01342250|Biological|conventional therapy plus medium dose hUC-MSCs treatment|patients will receive conventional therapy plus medium dose hUC-MSCs treatment
45660934|NCT03999749|Drug|Ipilimumab|4 induction doses (during the 2 treatment cycles) at a dose of 1 mg/kg intravenously (IV) every 3 weeks, 4 times during the 12-week induction period, concurrent with nivolumab at 3 mg/kg administered at the same interval
45660935|NCT03999749|Drug|Nivolumab|administered first at a dose of 3 mg/kg;
45815123|NCT04885322|Device|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (~20 minutes) to stimulate the targeted brain area. The targeted brain area is determined by the Study Arm.
45815124|NCT05452993|Device|Analysed Retinophotography|taking 2 retinophotographs per eye, and then analysed by AI software to detect Diabetic retinopathy
45454195|NCT01342250|Biological|conventional therapy plus high dose hUC-MSCs treatment|patients will receive conventional therapy plus high dose hUC-MSCs treatment
45454196|NCT00406588|Drug|Levodopa (Pardoprunox)|12-42mg
45660936|NCT03999749|Drug|Tocilizumab|Administered intravenously for each 42-day induction treatment cycle.
45660937|NCT03997643|Radiation|Radiotherapy to all dissected areas|Post operative radiation therapy +/- chemotherapy based on historic treatment volumes (including the primary site, dissected areas +/- elective areas
45660938|NCT03997643|Radiation|Omit radiation to pN0 neck|post operation radiation therapy +/- chemotherapy that avoids targeting the dissected pN0 neck
45815125|NCT02740153|Other|No Intervention Given|
45815126|NCT04809662|Drug|Imiquimod|"Patients with a diagnosis of actinic keratosis or warts that would be prescribed imiquimod as standard of care will be asked to apply 2 packets (or 2 full pumps) of imiquimod once daily before bedtime for two weeks and then leave on overnight for ~8 hours.~(a) A biopsy will be performed at the baseline visit on the pre-treatment skin and the skin where the medication will not be applied. The skin where the medication will not be applied will act as the negative control. A biopsy will then again be performed on day 10 of imiquimod treatment on the treated skin only, where the study drug was applied."
45815127|NCT02196324|Drug|serlopitant|NK1 receptor antagonist
45815128|NCT02196324|Drug|Placebo|Placebo
45815129|NCT03618979|Biological|PPP treatment|The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of PPP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PPP. The physician will then repeat the procedure on the opposite side.
45815130|NCT03618979|Biological|PRP treatment|The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PRP and remove the needle. The physician will then repeat the procedure on the opposite side and at the next level if indicated.
45954299|NCT00509353|Radiation|iobenguane I 131|
45954300|NCT00337831|Procedure|Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration|Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration is followed.
45954301|NCT00337870|Behavioral|PAT|Cognitive-Behavioral/Relaxation Intervention
45954302|NCT00405119|Drug|AH23844 (lavoltidine)|
46077989|NCT04218552|Drug|Amlodipine low|PO, Once daily(QD), 8weeks
45454197|NCT00406588|Drug|Placebo Comparator|Placebo
45454198|NCT05184686|Other|noise expose|simulate noise expose environments
45454199|NCT05184686|Other|RF expose|simulate RF expose environments
45454200|NCT01342328|Other|Normal saline infusion|Normal saline infusion
45458107|NCT04947787|Behavioral|Physical activity referral scheme (PARS)|Participants of the intervention group will receive brief physician advice and be referred to an exercise professional (e.g., physiotherapist, sports therapist) for a more intensive counseling intervention. The counseling intervention consists of an initial assessment, individual physical activity counseling (360'), a final assessment after 12 weeks, and a follow-up assessment after 24 weeks.
45954303|NCT00405119|Drug|NEXIUM (esomeprazole)|
45954304|NCT00405119|Drug|ZANTAC (ranitidine)|
45954305|NCT04715737|Drug|Vasopressin|Administration of vasopressin (20IU) intranasally
45954306|NCT04715737|Drug|Oxytocin|Administration of oxytocin (24IU) intranasally
45954307|NCT04715737|Drug|Placebo|Administration of placebo intranasally
45954308|NCT00337909|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
45954309|NCT00337909|Other|Educational DVDs|
45954310|NCT00509431|Drug|Erlotinib + Sirolimus|In arm I of dose escalation phase,starting dose of erlotinib is 150 mg daily. Starting dose of sirolimus includes a 15 mg loading dose, followed by continuous dosing at 5 mg daily.Dose escalation will proceed according to protocol Phase II of the study was not conducted only Phase I
45954311|NCT00509470|Drug|telmisartan plus hydrochlorothiazide|Combination therapy with telmisartan (40 mg/day) plus hydrochlorothiazide (12.5 mg/day): If blood pressure is not reach to lower than 140/90 mmHg, dose of telmisartan can be increased to 80 mg/day
45954312|NCT00509470|Device|Amlodipine|
45954313|NCT00405158|Procedure|Acupuncture treatment|
45954314|NCT00405158|Procedure|Administration of oxytocin nasal spray|
46077990|NCT04218552|Drug|Amlodipine high|PO, Once daily(QD), 8weeks
46077991|NCT04218552|Drug|Telmisartan|PO, Once daily(QD), 8weeks
46077992|NCT04102761|Procedure|Intradiscal PRP & BMC Injections|The intervention to be studied is the intradiscal delivery of autologous Platelet Rich Plasma (PRP) or bone marrow concentrate (BMC) into the nucleus pulposus of the disrupted disc(s).
46077993|NCT05107154|Behavioral|Dialectical Behavioural Therapy|DBT skills training is organized into 5 specific modules designed to support skills needed to control emotional reactivity, including: Mindfulness, Distress Tolerance, Walking the Middle Path (a family-based module developed by our co-investigators specifically for teens), Emotion Regulation, and Interpersonal Effectiveness.
46077994|NCT00907075|Behavioral|NES With Energy Restriction|The NES will be administered based upon the individual's calculated daily energy requirement, with an energy deficit of approximately 500 kilocalories.
46077995|NCT00907075|Behavioral|NES Without Energy Restriction|The NES will be administered based upon the individual's calculated daily energy requirement.
46077996|NCT00904657|Drug|sunitinib (Sutent)|50 mg capsule Sutent, one application a day for five days
46077997|NCT04196504|Device|Echocardiograghy, ECG|transthoracic echocariography, 12 lead ECG
46077998|NCT04034407|Procedure|Damage control surgery|"All patients with clinical and radiological suspicion of colonic perforation and generalized Peritonitis with indication for emergency surgery were included in the study.~Randomisation was performed intraoperatively in all patients after the performing surgeon confirmed a colonic perforation with generalized peritonitis."
45458108|NCT04947787|Behavioral|Physical activity advice (PAA)|Participants of the control group will only receive brief physician advice regarding the promotion of physical activity and as an information sheet with tips on how to adopt a more physically active lifestyle.
45815131|NCT03618979|Biological|PRP and PL Combo treatment|The day prior to or the morning of the procedure patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP and 5 or 10 cc of PL and 2 or 4 cc of 14x PRP depending on if there will be one or two levels injected. Using sterile technique, under ultrasound visualization into the lumbar multifidus and onto the lamina, the physician will inject the PRP and remove the needle. Under intermittent x-ray, epidural flow is confirmed with contrast, the physician will inject 2cc of the PL and 1cc of 0.5% ropivacaine into the epidural space. Once flow is confirmed for the epidural injection and facet with contrast, 1cc of the 14x PRP is injected into the facet joint. Procedure repeated on the opposite side and next level if indicated.
46077999|NCT02746146|Other|Systematic use of a prognostic score|The prognostic score is given in Dusseux et al 2015. It will be used as soon as possible after the initiation of dialysis.
46078000|NCT04242836|Diagnostic Test|MNREAD testing|One randomly selected eye is included for each study participant. Participants respond to the near vision chart with defined environmental circumstances at 40cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
46078001|NCT00904735|Drug|hydroxyurea|Given orally
46078002|NCT00904735|Drug|imatinib mesylate|Given orally
46078003|NCT02823626|Drug|Spironolactone and patiromer|High dose spironolactone with or without patiromer based on the patient's baseline potassium
46078004|NCT00900211|Genetic|microarray analysis|
46078005|NCT00900211|Genetic|molecular diagnostic method|
46078006|NCT00900211|Other|biologic sample preservation procedure|
46078007|NCT04887038|Drug|SRT-015|Each study part (A,B and C) will be completed sequentially, but with partial overlapping. The first cohort of Part B (Cohort B1) may be initiated after safety, tolerability and available PK data are assessed and deemed suitable to continue for a single dose on Part A that is equal to or greater than the total exposure of cohort B1. Part C (Cohort C1 & C2) may be initiated after safety, tolerability and PK data are assessed and deemed suitable to continue for a single dose in part A that is at least double the specified dose from part C.
46078008|NCT04887038|Other|Matching Placebo for SRT-015|Matching Placebo
46078009|NCT02750046|Procedure|total hip arthroplasty or proximal femoral nails|Bone samples from Hip fracture were collected when total hip arthroplasty or proximal femoral nails was performed.
45660939|NCT03977129|Device|QFR-guided strategy|In this study, the QFR-guided strategy will be applied to in the QFR group in which calculation of the QFR values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to CABG revascularization will be carried out. If QFR ≤ 0.80, then simultaneous CABG revascularization of target blood vessels will be carried out. If QFR > 0.80, then no CABG revascularization of target blood vessels will be carried out.
45660940|NCT03977129|Other|CAG-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and suited for CABG revascularization will undergo CABG revascularization.
45454201|NCT01342328|Drug|Dexmedetomidine|"Infusion of Dexmedetomidine will be administrated during the overnight sleep study. An initial target concentration of 0.25 ng/ml will be selected. After 5 min, the sedative point will be assessed and the concentration will be adjusted stepwise by increments and decrements of 0.05 ng/ml. This process will be repeated until the target sedative state is achieved. Using the Richmond Agitation Sedation Scale (RASS) infusion rates, using known pharmacokinetic parameters will be adjusted to achieve equivalent levels of sedation (RASS -3) for both DEX and propofol sessions.~We aim to achieve an RASS of -3 so that the subjects are moderately sedated. This state of sedation will be maintained for 3-4 hours."
45458109|NCT02310022|Drug|Drug Omega 3|4 g (4 capsules) once a day, administered with food
45458110|NCT02310022|Drug|Drug Omega-3 Comparator|4 g (4 capsules) once a day, administered with food
45458111|NCT01234129|Drug|zoledronic acid|zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years
45458112|NCT03505684|Dietary Supplement|CTP|1,000 mg of CTP was orally administered per day for 12 weeks.
45954315|NCT00405158|Procedure|Improved breast milk removal|
45660941|NCT05495477|Device|EIT|Evaluation of ventilation distrinution during deep sedation through EIT
45815132|NCT03448016|Radiation|[C-11]|Radiolabel
45954316|NCT00405158|Procedure|Warmth applied to breasts|
45954317|NCT00405158|Procedure|Breast massage|
45660942|NCT04140149|Behavioral|Living with Hope|12-week, CBT-based, psychoeducational skills class
45458113|NCT03505684|Dietary Supplement|placebo (starch)|placebo (starch)
45815133|NCT03448016|Drug|NOP-1A|Tracer
45815134|NCT03390530|Drug|Thyroxine|8 µg/kg/day divided into two doses intravenous every 12 hours
45815135|NCT03390530|Drug|Placebo|Placebo
45815136|NCT03534739|Other|Pain Inducing Massage|Participants will receive 60 seconds of manual pressure applied to one myofascial trigger point so the participant rates the pain = 5/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
45815137|NCT03534739|Other|Light Touch Massage|Participants will receive 60 seconds of light touch applied to one myofascial trigger point so the participant rates the pain = 0/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
45815138|NCT03534739|Other|Coldpressor|Participants will place their non-dominant hand into water cooled by a refrigeration unit temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times.
45815139|NCT05450419|Dietary Supplement|Vitamin D3|8pc (576,000 IU/40ml) vitamin D3 on week 1, then 1pc (72,000 IU/5ml) vitamin D3 on week 2, week 3 & week 4.
45815140|NCT05450419|Dietary Supplement|placebo|8pc placebo on week 1, then 1pc placebo on week 2, week 3 & week 4.
45954318|NCT00405158|Drug|Anti-pyretic medication, paracetamol|
45954319|NCT00405158|Drug|cefadroxil|
45954320|NCT00405158|Drug|penicillin|
45954321|NCT00405158|Drug|flucloxacillin|
45954322|NCT00150072|Drug|imatinib|
45954323|NCT00509548|Drug|TG100801|Eye drop, twice a day, 30 days.
45954324|NCT00509626|Behavioral|exercise intervention|
45954325|NCT00509626|Other|questionnaire administration|
45954326|NCT00509626|Procedure|CAM exercise therapy|
45954327|NCT00509626|Procedure|management of therapy complications|
45954328|NCT00509626|Procedure|psychosocial assessment and care|
45954329|NCT00509626|Procedure|quality-of-life assessment|
45954330|NCT02953366|Drug|EMS Mometasone gel|The patient should administer 1 spray in each nostril once daily.
45954331|NCT02953366|Drug|Mometasone spray nasal|The patient should administer 1 spray in each nostril once daily.
45954332|NCT02953327|Biological|Bacille Calmette-Guerin|Vaccine against tuberculosis
45954333|NCT02953327|Biological|BCG solvent|Simple solvent
45954334|NCT00405197|Behavioral|Isocaloric diet high in MUFA or Mediterranean diet|
45954335|NCT00150111|Drug|Methimazole|
45954336|NCT00150111|Drug|Rituximab|
45954337|NCT00150111|Biological|Immunization with various vaccines|
45954338|NCT02953210|Drug|dexter ketamine|multimodal anesthesia without opioids ketamine as induction drug
45954339|NCT02953210|Drug|Lidocaine Hydrochloride|continuous infusion intravenous
45954340|NCT02953210|Drug|Fentanyl Hydrochloride|intravenous
45954341|NCT02953210|Drug|Clonidine Hydrochloride|clonidine intravenous pre induction
45954342|NCT02953210|Drug|Midazolam Hydrochloride|premedication
45954343|NCT02953210|Drug|Isoflurane Volatile Liquid|maintenance of general anesthesia
45954344|NCT02953210|Drug|Rocuronium Injectable Solution|induction of general anesthesia
45660943|NCT05495399|Procedure|Spondylectomy|Patient will be randomized to treated by spondylectomy or debulking surgery. Spondylectomy implied total resection of involved spine; while debulking surgery means partial resection of involved spine.
45660944|NCT05495399|Radiation|SBRT|Patient received debulking surgery will be randomized to receive SBRT or conventional RT. SBRT means high dose per fraction compared to conventional RT.
45660945|NCT05483621|Drug|Beta-hCG|Treatment of spermatogenesis
45815141|NCT03507049|Procedure|iFuse|ifuse will be implanted as described in section on the active comparator arm of the study.
45815142|NCT03507049|Procedure|sham group|sham surgery will be performed as desrcribed in section on sham comparator.
45815143|NCT03507049|Radiation|fMRI study|Quantitative sensory testing, cerebral MRI and functional MRI will be done to examine pain mechanism and activation in the central nervous system.
45954345|NCT02953210|Drug|Propofol 1 % Injectable Suspension|induction of general anesthesia
45954346|NCT02953210|Drug|Dexamethasone-21-Sulfobenzoate, Sodium Salt|at the end of the procedure 4mg IV
45660946|NCT05483543|Drug|Pamiparib|Patients will receive Pamiparib 40 mg bid every 3 weeks after cCRT up to 1 year or disease progression according to RECIST v1.1 occur.
45660947|NCT04139213|Drug|buprenorphine/naloxone oral product|To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly or monthly basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
45660948|NCT04139213|Drug|injectable naltrexone|To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
45815144|NCT03345446|Diagnostic Test|Cardiac MRI|Cardiac MRI is a test that allows us to look at how the heart muscle works and the amount of scar tissue in your heart. Screening questions will be asked to make sure that patients are not pregnant, and that they have kidney function tests to confirm that IV contrast used (gadolinium) during the MRI is safe for them.
45815145|NCT05443009|Drug|Lidocaine|A buccal infiltration injection followed by palatal injections and interpapillary injections of 2% lidocaine with 1:100,000 epinephrine will be administered.
45815146|NCT05443009|Drug|Articaine|A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered.
45815147|NCT02195700|Drug|SD-809|SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.
45815148|NCT02195700|Drug|Placebo|Placebo tablets taken twice daily for 12 weeks.
45815149|NCT00370669|Drug|bevacizumab|
45815150|NCT00370669|Drug|triamcinolone acetonide|
45954347|NCT02953210|Drug|Ranitidine Hydrochloride|at the end of the procedure
45954348|NCT02953210|Drug|Ondansetron Hydrochloride|at the end of the procedure
45954349|NCT02953210|Drug|Ketorolac Injectable Solution|at the of the procedure
45954350|NCT02953210|Drug|Bupivacaine Hydrochloride|at the end of the procedure for infiltration of trocar wounds
45954351|NCT05151692|Drug|Nipocalimab|Nipocalimab will be administered as an IV infusion.
45954352|NCT00158535|Procedure|liver transplantation|
45954353|NCT02953132|Drug|MT-4129|
45954354|NCT02953132|Drug|Placebo|
45815151|NCT04738214|Other|Neoadjuvant CCRT+operation +/- adjuvant treatment|Patients receive neoadjuvant CCRT and operation. Adjuvant treatment after operation is performed depending on pathologic response. The patients showing pathologic complete response after neoadjuvant CCRT are not treated with any adjuvant treatment.
45815152|NCT05421793|Other|Fermented product of carrot derived rhamnogalacturonan I|Stimulation of human colonic biopsies with the fermented product of carrot derived rhamnogalacturonan I
46078010|NCT00904891|Behavioral|Cognitive-behavioral group|Six sessions of cognitive-behavioral depression prevention group intervention
46078011|NCT00904891|Behavioral|Cognitive-behavioral bibliotherapy|"Cognitive-behavioral bibliotherapy, delivered from the book Feeling Good"
45454202|NCT01342328|Drug|Propofol|"For propofol, an initial concentration of 0.75 ng/ml will be targeted. Depending on the score achieved, the infusion rate will be increased or decreased every 5 min by 0.2 ng/ml until the target sedative state is achieved.~Note that the target sedative state (RASS score of -3) is the same for both DEX and propofol sessions, with the investigator being unaware of which drug is being administered. To ensure the investigator is not aware of the type of drug being administered, all drug delivery systems will be covered.~Intravenous drug delivery will be continued throughout the scanning period for 3-4 hours to maintain equivalent levels of sedation for both DEX and propofol."
45454203|NCT05184608|Other|Cycling exercise|20 minutes of cycling (90 rpm).
45815153|NCT03254576|Other|Functional MRI|
45954355|NCT02953054|Drug|DMTS|DMTS applied before surgery and worn for 72 hours
45815154|NCT05378971|Drug|Pomalidomide|Pomalidomide, 2mg/d, d1-21; treatment cycles every 28days
45954356|NCT02953054|Drug|Placebo|Matching patches that have no active drug applied before surgery and worn for 72 hours.
45954357|NCT05110352|Diagnostic Test|Polysomnography|A polysmnography is planned for every patients in order to evaluate the Apnea-Hypopnea Index (AHI).
45815155|NCT04337450|Drug|Dolutegravir (DTG) and lamivudine (3TC)|Children randomised to the DTG/3TC arm will receive once daily DTG/3TC fixed dose combination dispersible or film-coated tablets dosed using WHO weight bands criteria
45815156|NCT04337450|Drug|SOC|2 nucleos(t)ide reverse transcriptase inhibitor (NRTI) and a third (anchor) drug (either an integrase strand transfer inhibitor (INSTI), a protease inhibitor (PI) or a non- nucleoside reverse transcriptase inhibitor (NNRTI)
45954358|NCT05110352|Diagnostic Test|Pharyngeal ph-metry Restech|Pharyngeal ph-metry Restech over 24 hours (night and day)
45954359|NCT05110352|Procedure|Peptest|Saliva sample to look for an association between pharyngolaryngeal reflux and obstructive sleep apnea syndrome
45954360|NCT05110352|Behavioral|Questionnaire RSS-12|Questionnaire with 12 items about quality of life. Score between 0 and 5.
45454204|NCT05184608|Other|Cognitive tasks|20 minutes of cognitive tasks based on the different domains of the UPDRS scale.
45454205|NCT00313222|Drug|bosentan|
45458114|NCT02313844|Biological|Viralym-B|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-B infusion. If a patient has multiple Viralym-B infusions the schedule resets again at the beginning so follow up relates to the last Viralym-B infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
45458115|NCT02313922|Drug|etanercept combined with methotrexate or etanercept combined with placebo|
45660949|NCT04139213|Other|Pharmacy maintenance addiction care|Patients randomized to the pharmacy study arm and on a stable dose of buprenorphine/naloxone or naltrexone will receive maintenance care at the pharmacy for up to three months. Patients will visit for check-ins with a pharmacist on a monthly, weekly, or more frequent basis, depending on the individual treatment plan. Patients on buprenorphine/naloxone will be dispensed their medication at study visits, whereas patients taking injectable naltrexone will be dispensed it monthly by the pharmacist. All patients will visit the pharmacy at least monthly for addiction care (assessment, toxicological testing).
45954361|NCT05110352|Procedure|Reflux Sign Assessment|RSA score about anatomy and morphology of the mouth
45954362|NCT00150150|Procedure|Interstitial laser photocoagulation|
45954363|NCT00509743|Drug|Intravenous diclofenac sodium (DIC075V)|High dose Diclofenac
45954364|NCT00509743|Drug|Intravenous diclofenac sodium (DIC075V)|Low Dose Diclofenac
45954365|NCT00509782|Drug|ZIO-101|Starting Dose 78 mg/m^2 intravenously daily for 5 consecutive days repeated every 4 weeks.
45954366|NCT00509860|Drug|Irinotecan|16 mg/m2 by vein Daily Over 1 Hour x 5 Days
45954367|NCT00509938|Drug|human lactoferrin peptide 1-11|Each subject will receive a single intravenous dose of hLF1-11 given in a volume of 20mL given over 20 minutes i.e. 1mL/per minute.
46078012|NCT02746224|Procedure|Initially dissection of inferior mesenteric vein|Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1A the surgical technique initially dissects the inferior mesenteric vein (IMV)
46078013|NCT02746224|Procedure|Initially dissection of inferior mesenteric artery|Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1B the surgical technique initially dissects the inferior mesenteric artery.
46078014|NCT02746224|Procedure|Latero-terminal colorectal anastomosis|The patients who will undergo a colorectal anastomosis will be included in the study 2 and will be randomized to group 2A and group 2B: in group 2A the patients will have a latero-terminal colorectal anastomosis and in group 2B a termino-terminal colorectal anastomosis.
46078015|NCT02746224|Procedure|Termino-terminal colorectal anastomosis|The patients who will undergo a colorectal anastomosis will be included in the study 2 and will be randomized to group 2A and group 2B: in group 2A the patients will have a latero-terminal colorectal anastomosis and in group 2B a termino-terminal colorectal anastomosis.
45815157|NCT05349344|Other|Aerobic circuit training|Aerobic Exercise Training, 3 times a week for 8 weeks, (Tuesday, Thursday & Saturday, 24 sessions Total) 30 min each time, at 60-80 % of HR max (moderate intensity).
45454206|NCT01336400|Other|single cell haplotyping|We aim to collect single blastomeres from spare IVF embryos of 30 couples to optimize and test methods for single cell haplotyping. We aim to collect 20 and 10 couples coming to the fertility centre for FISH- or PCR-based PGD respectively. In both groups, at least 5 different indications for PGD will be collected. Per couple, we will perform 10 SNP-arrays: 2 for the couple donating the embryo, 4 for family members (often parents of the couple) and 4 for blastomeres since we aim to pick 2 cells from 2 embryos per couple. For five couples, 2 blastomeres of all available embryos will be aspirated to validate and optimize the phasing methods. Finally, for some embryos, all blastomeres will be picked to be able to prove the reproducibility of single cell haplotyping.
45815158|NCT05349344|Other|Outdoor walk|30minutes Walking outside below 40% of HR max for 2 months.(3 times per week for 8 weeks).
45954368|NCT05086016|Device|Catheterized Stenting|Catheterized stenting of vascular narrowings.
45454207|NCT01336478|Procedure|Infusion of donor derived ex-vivo selected NK cells to patients after transplant|Infusion of donor derived ex-vivo selected NK cells to patients after transplant
45454208|NCT01336478|Procedure|Haematology / Blood chemistry sampling|Haematology / Blood chemistry sampling, collection of blood for ancillary lab research
45815159|NCT02740543|Drug|Fluticasone propionate HFA 220|Subjects will take two (2) puffs of Fluticasone propionate HFA 220 twice a day.
45815160|NCT02228460|Drug|GZ/SAR402671|Pharmaceutical form: Capsule; Route of administration: Oral
45815161|NCT05349266|Biological|ThisCART19A|each patient will receive a dose level per body weight(kg) for only once.
45454209|NCT01340222|Biological|biological samples|4 blood sampling will be made at J0, J2, J4, J6 befor delivery and 1 blood sampling 3 days after delivery
45954369|NCT00337948|Drug|Epoetin alfa|
45954370|NCT00150189|Behavioral|Sucrose|
45954371|NCT00338026|Drug|ECO-4601|Continuous IV infusion for 14 days with 7 days recovery (21 day cycle)
45954372|NCT03459937|Behavioral|Hatha Yoga Intervention|Hatha Yoga will focus on a restorative style of Hatha yoga. Total duration will begin at 100 minutes per week and will gradually progress in 4-week intervals until achieving the prescribed dose of 300 min/wk (5 days per week for 60 minutes per day). While attending the behavioral group sessions the participants will also engage in a supervised yoga session with a trained yoga instructor. To facilitate the additional 4 days of unsupervised yoga, we will provide yoga videos that mimic the asanas (poses) and flow patterns that are taught in the supervised yoga sessions. The intervention includes prescribed dietary recommendations based on the participants' baseline body weight, and self-monitoring diaries, meal plans, and sample recipes will be provided. Intervention lessons will also include information related to behavior strategies for achieving the recommended calorie and fat intake goals. Participants will also be provided weekly group intervention sessions across the study period.
45954373|NCT03459937|Behavioral|Vinyasa Yoga Intervention|Vinyasa Yoga will focus on a more vigorous form of yoga. Total duration will begin at 100 minutes per week and will gradually progress in 4-week intervals until achieving the prescribed dose of 300 min/wk (5 days per week for 60 minutes per day). While attending the behavioral group sessions the participants will also engage in a supervised yoga session with a trained yoga instructor. To facilitate the additional 4 days of unsupervised yoga, we will provide yoga videos that mimic the asanas (poses) and flow patterns that are taught in the supervised yoga sessions. The intervention includes prescribed dietary recommendations based on the participants' baseline body weight, and self-monitoring diaries, meal plans, and sample recipes will be provided. Intervention lessons will also include information related to behavior strategies for achieving the recommended calorie and fat intake goals. Participants will also be provided weekly group intervention sessions across the study period.
45954374|NCT02958215|Drug|Phenylephrine|it will be given as a prophylaxis for prevention of hypotension after spinal anesthesia in pregnant patients undergoing cesarean section
45954375|NCT02958215|Other|Placebo|5 ml normal saline will be given before spinal anesthesia
45954376|NCT00338143|Drug|efalizumab|
45454210|NCT00312364|Drug|MRE0094|
45454211|NCT05184530|Drug|Evolocumab 140 MG/ML|140 mg per two weeks, subcutaneous injection
45815162|NCT00370747|Drug|Ecabet|ophthalmic solution 2.83%
45815163|NCT00370747|Drug|Ecabet|ophthalmic solution 3.70%
45815164|NCT00370747|Drug|Placebo|
45815165|NCT02752256|Drug|Tissue Plasminogen Activator|
45815166|NCT05368909|Dietary Supplement|Sleep Supplement|Proprietary sleep formula containing Tri Factor, Ashwagandha root extract, Lavender, Pyridoxal-5-Phosphate, Melatonin, gamma aminobutyric acid (GABA) and Magnesium.
45815167|NCT05368909|Dietary Supplement|Placebo|Placebo product
45835861|NCT00056550|Biological|Recombinant Human Antithrombin (rhAT)|Biological/Vaccine: Recombinant human antithrombin(rhAT) Phase III clinical trial.
46078016|NCT02824172|Other|cast immobilization group|Patients in this group will have their knee locked with a resin going from the ankle to the top of the thigh for 4 weeks, followed by 4 weeks without cast but with rehabilitation through physiotherapy.
46078017|NCT02824172|Other|complete sport rest.|Patients included in this group will follow the current standard procedure for this disease that is to say complete sport rest during 8 weeks including rehabilitation through physiotherapy, following the exact same technic as the experimental group .
46078018|NCT00900289|Genetic|DNA methylation analysis|
45815168|NCT03454555|Behavioral|Shared Decision Making|The Shared Decision Making (SDM) intervention is a patient-provider communication intervention to explore and compare treatment options, assess a patient's values and preferences, and reach a shared decision about chronic pain treatment. The intervention will have both clinician and patient educational components. The content of the clinician component will be based on the Agency for Healthcare Research and Quality (AHRQ) SHARE Approach, which is a 5-step process for shared decision making that includes exploring and comparing the benefits, harms, and risks of each option through meaningful dialogue about what matters most to the patient (Agency for Healthcare Research and Quality, 2017). Participants randomized to Arm 1 will have their study visits and opioid use managed by an SDM-trained clinician at their practice.
45815169|NCT03454555|Behavioral|Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain|The Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain (MI+CBT-CP) intervention is an empirically based behavioral pain management behavioral therapy intervention (Monticone et al., 2015), including MI to enhance motivation for active participation in the CBT-CP, and the use of CBT-CP to enhance pain coping skills. One individual MI session will focus on patient engagement and enhancing a patient's own intrinsic motivation for CBT-CP participation. MI will also be woven into the group CBT-CP sessions. We will deliver 8 sessions of CBT-CP, as is standard in a group setting, in-person or virtually.
45454212|NCT05184374|Drug|Gonadorelin|GnRH pump pulse subcutaneous injection of gonadorelin in a month
45815170|NCT04104542|Behavioral|Mindfulness based stress reduction|on-line training on the website = www.palousemindfulness.com
45815171|NCT04104542|Behavioral|Healthy Lifestyle|Diet and Exercise
45815172|NCT02227446|Drug|Vancomycin antibiotic powder|At the time of fracture fixation 1000 mg of Vancomycin powder placed into the wound during wound closure.
45954377|NCT02953171|Other|Raw, lacto-fermented sauerkraut|Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.
45954378|NCT02953171|Dietary Supplement|Mutaflor|The probiotic Escherichia coli Nissle 1917, registered in Germany as the medicinal product Mutaflor, possesses a unique combination of fitness and survival factors.
45954379|NCT02953171|Other|Pasteurized sauerkraut|Sauerkraut without live bacteria.
45954380|NCT02953171|Other|Placebo capsule|Capsules without probiotics
45954381|NCT00158574|Drug|sulphadoxine-pyrimethamine|
46078019|NCT00900289|Genetic|microarray analysis|
45954382|NCT00158574|Drug|mefloquine|
45954383|NCT00158574|Drug|Chlorproguanil-dapsone|
45954384|NCT00158574|Drug|Placebo|Placebo
45454213|NCT00312286|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
45454214|NCT00312286|Drug|851B|851B 1.5% formulation, gel, topically, twice a week for 1 cycle.
45454215|NCT00312286|Drug|851B|851B 1.5% formulation, gel, topically, twice a week for 2 cycles.
45454216|NCT00312286|Drug|851B|851B 3.0% formulation, gel, topically, once a week for 1 cycle.
45454217|NCT00312286|Drug|851B|851B 3.0% formulation, gel, topically, once a week for 2 cycles.
45454218|NCT00312286|Drug|851B|851B 3.0% formulation, gel, topically, twice a week for 1 cycle.
45660950|NCT04139213|Drug|oral naltrexone|To augment care for patients receiving injectable naltrexone for the treatment of OUD and treat cravings that may arise before their scheduled injection, patients prescribed injectable naltrexone may be provided a several day supply of oral naltrexone by a study pharmacist under a collaborative pharmacy practice agreement. The expected dose of oral naltrexone will be approximately 25-50 mg daily.
45660951|NCT05495165|Other|Therapeutic education for patients in nutrition|Stakeholders give preventive therapeutic education recommandations in their specific expertize
46078020|NCT00900289|Genetic|polymerase chain reaction|
45454219|NCT00312286|Drug|851B|851B 3.0% formulation, gel, topically, twice a week for 2 cycles.
45454220|NCT00312286|Drug|851B|851B placebo-matching gel, topically, once a week for 1 cycle.
46078021|NCT00900289|Other|immunohistochemistry staining method|
46078022|NCT00900289|Other|laboratory biomarker analysis|
45660952|NCT04112849|Diagnostic Test|Measurement of S3 heart sound|S3 heart sound to be measured by Nanowear Congestive Heart Failure Management System device.
45454221|NCT00312286|Drug|851B|851B placebo-matching gel, topically, twice a week for 1 cycle.
45454222|NCT00312286|Drug|851B|851B placebo-matching gel, topically, once a week for 2 cycles.
45454223|NCT00312286|Drug|851B|851B placebo-matching gel, topically, twice a week for 2 cycles.
45660953|NCT05495009|Other|Standard of care+virtual reality glasses|At the beginning of the active and transitional phases of labor, videos were watched with virtual reality glasses.
45660954|NCT05494931|Procedure|corneal neurotomy|Classic Gunderson conjunctival flap surgery adjuncted by corneal neurotomy
45660955|NCT04071587|Device|Brain Computer Interface training|Training with RecoveriX system.
45954385|NCT00158574|Drug|Sulphadoxine-pryrimethamine|IPTi doses 1 and 2, at ages 2 and 3 months, sulphadoxine 250mg, pyrimethamine 12.5mg IPTi doses 3, at 9 months of age, sulphadoxine 500mg, pyrimethamine 25mg
45660956|NCT04071587|Behavioral|Control|Standard physiotherapy and occupational therapy according to clinical routines.
45660957|NCT05494775|Drug|Anti-vascular endothelial growth factors (Anti-VEGFs)|Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).
45660958|NCT03937037|Procedure|Saline irrigation|100ml saline irrigation after CBD stone removal with routine ERCP procedure
45954386|NCT00158574|Drug|IPTi mefloquine|IPTi doses 1 & 2 at ages 2 & 3 months, mefloquine 125mg IPTi dose 3 at 9 months, mefloquine 250mg
45954387|NCT00158574|Drug|Chlorproguanil dapsone|IPTi doses 1 and 2 at ages 2 and 3 months, doses 15mg chlorproguanil and 18.75mg dapsone IPTi dose 3 at 9 months of age, doses 22.5mg chlorproguanil and 28.13mg dapsone
45660959|NCT05483153|Behavioral|Infant-Directed Singing Coaching|At-risk mothers will receive four, 30-minute, in-person infant-directed singing coaching intervention sessions that take place over two weeks. Mothers will learn how to better read infant cues and respond with sensitive singing. Infants will gain experience in self-regulation of arousal states.
45660960|NCT04272827|Procedure|Liposuction|"Liposuction treatment will be performed according to the study protocol using the wet technique depending on the amount of fat to be removed, if necessary in several sessions."
45815173|NCT00371371|Procedure|Bone marrow punction|A total volume of 100 ml bone marrow will be aspirated from the iliac crest under local anaesthesia (lidocaine) according to local routine. To maximise the patients comfort, 5-10 mg midazolam and 50 ug fentanyl will be administered intravenously.
45954388|NCT00338182|Drug|AZD1152 part A|48-hour continuous intravenous infusion
45954389|NCT00338182|Drug|AZD1152 part B|2-hour intravenous infusion
45660961|NCT04272203|Drug|ABBV-184|Intravenous (IV) infusion
45660962|NCT03929159|Procedure|Biospecimen Collection|Undergo blood biospecimen collection
45660963|NCT05482997|Dietary Supplement|Whey Protein Concentrate|whey-based protein powder 32g powder mixed with 8-12 oz water
45660964|NCT05482997|Dietary Supplement|Pea Protein Isolate, Rice Protein Concentrate, Hemp Protein|plant-based protein powder. 32g powder mixed with 8-12 oz water
45660965|NCT05482841|Diagnostic Test|Lung ultrasound score|To evaluate the incidence of pulmonary atelectasis in the post-anesthesia care unit (PACU) using lung ultrasound.
45815174|NCT00371371|Procedure|BM-MNC infusion|Repeated intra-arterial infusion of autologous BM-MNC into the common femoral artery
45815175|NCT00371371|Procedure|Placebo infusion|Repeated intra-arterial infusion of placebo (PBS/4% HAS/heparin, coloured with autologous erythrocytes to match the colour of BM-MNC suspension) into the common femoral artery.
46002740|NCT04645368|Drug|bovhyaluronidase azoxymer|3000 IU intramuscularly once every 5 days with a course of 15 injections
45454224|NCT01336556|Procedure|Oral appliance|Anterior mandibular repositioner: used for two months
45458116|NCT03627013|Drug|Custodiol-N Solution|Perfusion
45458117|NCT03627013|Drug|Custodiol HTK Solution|Perfusion
45660966|NCT05494463|Device|Miller blade|After laryngoscopy with Macintosh blade patient will be evaluated in laryngoscopy with Miller blade
45660967|NCT05488925|Drug|Vitamin E|Evion, 400 mg
45660968|NCT05488925|Drug|Diclofenac Sodium|Voltral SR100, 100 mg
45660969|NCT05488925|Drug|Piroxicam|Feldene, 20 mg
45660970|NCT05488925|Drug|Tramadol|Tramal, 50 mg
45660971|NCT05494385|Drug|Preoperative Gabapentin/Postoperative Placebo|Postoperatively, this group will receive scheduled acetaminophen and ibuprofen every 6 hours, in addition to placebo every 12 hours. The placebo is encapsulated to appear identical to the active drug. This group will have oxycodone 5 mg every 6 hours as needed for pain.
45954390|NCT04695886|Other|Community-delivered Integrated Malaria Elimination (CIME) intervention model|"Malaria: Malaria Diagnosis using RDT, treatment, referral and reporting; Prevention interventions (Behavioral Change Communication, net and repellent distribution); assisting in case and foci investigation and larval source management.~Dengue: Assisting in dengue prevention; Referral of cases. Tuberculosis (TB): Detection and referral of suspected cases; Contact tracing; Directly observed treatment, short-course (DOTS) providers; defaulter tracing; follow-up sputum examinations; assisting in TB health education talks and active case detection activities.~Childhood diarrhea: Prevention; Health education and Water, sanitation and hygiene (WASH) promotion; Diagnosis and dehydration assessment; Treatment and referral; Rehydration therapy using Oral Rehydration Solution (ORS) and oral Zinc tablet; assisted referral.~RDT-negative fever: Prevention and health education; Symptomatic treatment with antipyretics and immediate assisted referral."
45954391|NCT00509977|Procedure|Light Treatment|Light treatment applied to half of the face at each study visit
45954392|NCT00509977|Procedure|Laser Treatment|Laser treatment applied to half of the face at each study visit
45954393|NCT00338221|Drug|alanyl-glutamine|
45954394|NCT00338221|Drug|glycine|
45954395|NCT00338299|Drug|Epoetin alfa|
45954396|NCT00510016|Drug|Clonidine HCL|Duraclon 1 microgram/kg every 4 hours given p.o. as per algorithm
45954397|NCT05065580|Procedure|Osteopathic Manipulative Treatment|Individuals will receive the following techniques during weekly OMT (osteopathic manipulative techniques) for a duration of 8 weeks: 1. Suboccipital release 2. Vault hold. 3. Soft tissue techniques at the cervical and shoulder region 4.There will be NO high velocity low amplitude (HVLA) techniques
45954398|NCT00150228|Drug|CP-526,555 (varenicline)|
45954399|NCT00338338|Drug|Lacidipine 4 or 6 mg (oral)|
45954400|NCT00338338|Drug|Amlodipine 5 or 10 mg(oral)|
45954401|NCT00338416|Drug|Epoetin alfa|
45954402|NCT04695964|Diagnostic Test|ICG-NIRF Imaging plus ingress and egress analysis|intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3) Additional ingress and egress analysis (inflow and outflow analysis) of specificities regions of interest at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3)
45954403|NCT00158613|Biological|Carticel (autologous cultured chondrocyte) implantation|Each Carticel vial of autologous cultured chondrocytes contains approximately 12 million cells implanted into the defect and secured with a periosteal flap
45954404|NCT00338494|Drug|Clofarabine|The starting dose of clofarabine will be 10 mg/m2 once a week for 3 weeks repeated every 4 weeks with dose escalations to 15, 20 , 30 and 40 mg/m2/week.
45954405|NCT00338533|Device|endoscopic goniotomy|The goninotomy is performed through an endoscope; allowing the physician a better view of the structure within the eye
45954406|NCT02953015|Behavioral|Manipulative articulatory (ART) and myofascial techniques|Three manipulative articulatory (ART) and myofascial techniques will be performed to improve cervical and thoracic spine joint mobility and reducing soft tissue stiffness in the cervico-thoracic spine. ART technique is a low velocity to high amplitude technique where each joint is carried through its full motion to increase range of movement. The activating force is either a repetitive springing motion or repetitive concentric movement of the joint through the restrictive barrier. Myofascial technique is directed at the muscle and fascia treatment. It engages continual palpatory feedback to achieve release of myofascial tissues. During each treatment session, each technique will be carried out for 10 minutes including 2 minutes of resting.
45954407|NCT02953015|Device|Transcutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation (TENS) of the upper trapezius muscle will be applied by a portable machine Master 932 (Elettronica Pagani SRL, Milan, Italy) that generates symmetric, bi-phasic rectangular pulses with 140μ sec duration. The current frequency will be set at 150 Hz and intensity will be increased up to patient's perception of paresthesia. The negative electrode will be placed on the active TrPs of the upper trapezius muscle and the positive one was on acromial tendon insertional site. The total duration of each application will be 20 minutes. Treatment frequency and duration will be the same of the EG treatment (1 session/week for 4 weeks). Each session will consist of 20 min of TENS and 10 min of resting in sitting position with the head lean on a pillow.
45954408|NCT02953015|Drug|OnabotulinumtoxinA (Prophylaxis therapy)|Prophylaxis therapy with OnabotulinumtoxinA according to the PREEMPT protocol (155U every three months into 31 injection site).
45954409|NCT05020730|Drug|PTM-001|PTM-001 (400 mg) every day for 12 weeks
45954410|NCT05020730|Drug|Placebo|Matching placebo every day for 12 weeks
45954411|NCT00158652|Procedure|Conventional radiotherapy 70 Gy in 7 weeks|2 gy per fraction, 1 fraction per day, 5 fractions per week
45954412|NCT00158652|Procedure|middle accelerated radiotherapy 70 Gy in 6 weeks|5 x 2gy/week until 40 Gy in 20 fractions and 4 weeks, then 2 fractions of 1.5Gy per day for 30 additional Gy in 2 weeks
45954413|NCT00158652|Procedure|very accelerated radiotherapy 64.8 Gy in 3.5 weeks|2 fractions of 1.8 Gy per day for 64.8 Gy in 3.5 weeks
45954414|NCT00158652|Drug|5FU, Paraplatin|5FU 600mg/m²/D, Paraplatin 70mg/m²/D In arm 1: D1-4, 3 cycles during Rth (D1, D22, D43) In arm 2: D1-5, 2 cycles during Rth (D1, D29)
45660972|NCT05494385|Drug|Preoperative Gabapentin/Postoperative Gabapentin|Postoperatively, this group will receive scheduled acetaminophen and ibuprofen every 6 hours, in addition to gabapentin every 12 hours. The gabapentin is encapsulated to appear identical to the placebo. This group will have oxycodone 5 mg every 6 hours as needed for pain.
45660973|NCT05482763|Drug|Terbinafine Topical Gel|Topical application of terbinafine
45660974|NCT05482763|Drug|Itraconazole 200 mg|systemic itraconazole pulse therapy
45815176|NCT04738058|Drug|Bovine Lactoferrin Supplement|Bovine lactoferrin or placebo will be given to both arms with each feed for 30 days or till discharge from NICU the Lactoferrin dose 100mg/day Then determin is effect by serum zonulin level
46078023|NCT04136496|Device|Black-Eye Ink|There are two proposed studies utilizing the Ink during differing timepoints.Both will identify patients with breast cancer, with a biopsied metastatic axillary lymph node(LN) with a tissue marker clip placed, as is current practice. In Study A, 0.5mL of Black Eye Ink will be placed in the metastatic LN after neoadjuvant therapy. In Study B, 0.5mL of Black Eye Ink will be placed before neoadjuvant therapy. In both studies, the LN containing the tissue marker clip will be the one to have the radioactive seed and Ink inserted. The seed will still be inserted, in the event the dye is not well-visualized. In both studies, the surgeon will attempt to find the LN by direct visualization and then confirm the appropriate LN has been removed by using the Gamma probe and intra-operative radiographs. If the seed is not within the tattooed node, the LN containing the seed will also be removed. All lymph nodes injected with Ink will be removed by the surgeon;no Ink-injected node remains in body.
46078024|NCT00779259|Drug|Theophylline 300mg|Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
46078025|NCT00779259|Drug|Quinine 648 mg|648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
46078026|NCT00779259|Drug|Theophylline 300 mg|Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
46078027|NCT00779259|Drug|Quinine 648 mg|648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
46078028|NCT02824016|Biological|biological sample|T4, thyrotropic-stimulating hormone (TSH) and Thyroglobulin antibody were systematically measured
46078029|NCT02824016|Radiation|supraclavicular irradiation|Irradiation of the homolateral supraclavicular area delivering 46 Gy in 23 fractions
45454225|NCT05187494|Other|Conventional local palatine injection|Conventional palatal injection with anesthetic (lidocaine HCL2% with Epinephrine 1:80000, Korea) Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness
45815177|NCT04738058|Drug|placebo|placebo
45815178|NCT02227368|Drug|Ticagrelor|Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
45954415|NCT00338572|Behavioral|Exercise Program|Participants in the exercise group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day.
45954416|NCT00338572|Behavioral|Combined Exercise and Diet Program|Participants in this group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day. They will meet with a dietician and will be encouraged to reduce their caloric intake by incorporating low-fat, high-fiber foods into their diet.
45954417|NCT00338611|Behavioral|Home-based Pencil Push-Up Therapy|Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose
45954418|NCT00338611|Behavioral|Home-based Pencil Push-ups with Computer Vision Therapy/Orthoptics|Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose combined with additional computer vision therapy
45454226|NCT05187494|Drug|EMLA cream only|Emla cream will be applied at a distance of 1 mm from the palatine gingival edge by cotton buds for 3 minutes within the application area 14*14 mm and the mouth will be open throughout the procedure and the saliva will be controlled by a saliva absorbent. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
45660975|NCT05482763|Drug|Terbinafine 250 mg|systemic terbinafine
45660976|NCT05482763|Drug|Ciclopirox Topical Gel|Topical application of ciclopirox
45660977|NCT05482763|Drug|Amorolfine 50 MG/ML|Topical application of amorolfine
45660978|NCT05482685|Behavioral|Questionnaire|Conduct a 10-minute survey
45660979|NCT05482529|Other|Integrative omics|Integrative omics such as RNA-sequencing,ATAC-seq(Assay for Transposase-Accessible Chromatin using sequencing), CUT&Tag（ Cleavage Under Targets and Tagmentation）to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.
45660980|NCT05482373|Dietary Supplement|Oleuropein from olive tree|The capsules intake will last for a total of 4 months.
45660981|NCT05482373|Dietary Supplement|Placebo|The capsules intake will last for a total of 4 months.
45660982|NCT05482295|Biological|Hepatitis B vaccine lot 1|3 doses of Hepatitis B vaccine lot 1
45815179|NCT02227368|Drug|Comparator|Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures
45815180|NCT05336383|Drug|Radiation Therapy|Given by Infusion
45954419|NCT00338611|Behavioral|Office-based Vision Therapy/Orthoptics|Weekly hour-long sessions of office-based vision therapy with a trained therapist and performed at-home reinforcement exercises
45660983|NCT05482295|Biological|Hepatitis B vaccine lot 2|3 doses of Hepatitis B vaccine lot 2
45660984|NCT05482295|Biological|Hepatitis B vaccine lot 3|3 doses of Hepatitis B vaccine lot 3
45660985|NCT05482295|Biological|Hepatitis B vaccine (registered)|3 doses of Hepatitis B vaccine (registered)
45660986|NCT05482217|Behavioral|Psychoeducation, problem solving and rehearsal (cognitive behavioural intervention)|"The highlights of the intervention.~Session 1: Rapport building and knowledge of HIV~Session 2: Identifying and Dealing with barriers to good adherence~Session 3: Identifying and dealing with problems in relation to depression and adherence:~Session 4: Identifying and dealing with negative cognitions, handling privacy, accessing social Support, and adjusting to HIV and antiretroviral treatment~Session 5: Rehearsal of practical tips on adherence, handling slips, and strategies to improve quality of life.~All sessions involved brief periods of relaxation, homework, and a homework review. The last session was concluded with the assessment of satisfaction with the program. The programs were conducted for 60 minutes weekly for five weeks.~They were delivered by a trained lay counselor and supervised by the principal investigator for five weeks."
45815181|NCT05291299|Behavioral|Anti-inflammatory diet|Patients randomized to the intervention group will work with a registered dietitian to create an individualized diet program to help reduce inflammation and Rheumatoid arthritis related symptoms.
45815182|NCT05291299|Other|Control/Standard of Care|Patients randomized to the control group will be following standard of care where their doctor will instruct them to follow a Mediterranean diet and provides them with an instructional sheet.
45954420|NCT00338611|Behavioral|Placebo Office-based Vision Therapy/Orthoptics|Vision activities designed to simulate office-based therapy
45815183|NCT02162862|Behavioral|Behavioral Counseling|
45815184|NCT02162862|Drug|bupropion-SR|
45815185|NCT02752490|Drug|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by ACOG10 at the discretion of the primary nurse or physician
45954421|NCT00338650|Drug|adalimumab|
45954422|NCT05015660|Device|Left bundle branch pacing lead (Select Secure 3830 lead)|Implantation of a left bundle branch pacing lead via sheath, to perform selective or non-selective pacing
45954423|NCT05015660|Device|Right ventricular active fixation lead|Active fixation lead (standard)
45954424|NCT00158691|Drug|Ethyol|
45660987|NCT05482139|Procedure|Incisional hernia repair with mesh|open or laparoscopic repairs of incisional hernia with mesh
45660988|NCT04245839|Drug|Fludarabine|Fludarabine
45660989|NCT04245839|Drug|Cyclophosphamide|Cyclophosphamide
45660990|NCT04245839|Drug|JCAR017|JCAR017
45815186|NCT02752490|Drug|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
45954425|NCT04715698|Other|ICG-guided drug selection|anti-hypertensive drug selection based on patient's hemodynamic profiling and physician's experience
45954426|NCT04715698|Other|empirical drug selection|anti-hypertensive drug selection based on physician's experience only
45954427|NCT05004740|Other|Vaccinated Pregnant or Lactating persons|vaccinated lactating persons from Sinai Health System or the general public
45954428|NCT00338767|Behavioral|Directly Observed Therapy (DOT)|DOT includes storefront directly observed therapy of prescribed anti-depressants. Participants will meet with a study psychiatrist, who will prescribe an appropriate antidepressant medication. Subsequent meetings with the psychiatrist will occur weekly for the first 3 weeks, and then monthly for the duration of the study. Additionally, participants will have DOT visits every weekday morning for 1 month to take their antidepressant medications. After the first month, DOT visits will occur weekly or biweekly, depending on the medication regimen.
45954429|NCT00338767|Drug|Fluoxetine|Medication treatment includes flouxetine for treatment of depression.
45954430|NCT00150267|Drug|Xalacom|
46078030|NCT05629884|Other|COPERIA-REHAB|"After the randomization of the patient there will be some preliminary sessions where the means of self-monitoring training and the Borg 1/10 effort scale will be explained and training videos will be shown. Doubts will also be answered.~Afterwards, training will start through the COPERIA-REHAB platform, which will last 8 weeks (6 days per week)."
46078031|NCT02746302|Drug|HS-20004|
46078032|NCT02746302|Drug|Placebo|
46078033|NCT00779025|Device|PD-F-5254|Female Personal Lubricant (MINE)
46078034|NCT00779025|Device|10855-096|Male Personal Lubricant (YOURS)
45660991|NCT04069091|Behavioral|'Enjoy your Bump' (iloodottaa.fi) online self-help intervention|"The intervention employs elements of cognitive behavioral therapy: empathic, clear and sensitive communication with women and their families, problem self-formulation of solutions to problems, behavioral activation, identification and changing negative automated negative thoughts, addressing low confidence, and promoting problem- solving and relapse prevention.~The Enjoy your Bump intervention has been adapted to the Finnish culture and healthcare setting (ilodottaa.fi)."
46078035|NCT02823860|Other|Collection of biospecimens and Quality of Life (QoL) assessment|Serum, plasma, buffy coat and formalin-fixed-paraffin-embedded (FFPE). Biospecimens are collected at various stages of diagnostic and therapeutic care.All patients fill out questionnaires of Health related quality of life (QLQ-C30 + QLQ-CR29/STO22, Hospital Anxiety and Depression scale - HAD) and social-demographic survey (Medical Outcome Studies - Social Support Survey- MOS-SSS).
45660992|NCT05494307|Drug|Terbutaline|Orally terbutaline at a dose of 2.5 mg three times daily for 16 weeks
45954431|NCT00338845|Behavioral|Share Safer Sex program|The Share Safer Sex intervention will consist of a single, 30 to 40 minute, one-on-one counseling session designed to increase personal awareness of the participant's current unsafe behaviors and the associated risks, help her understand her motivation to change, and increase her knowledge about how to practice safe sex. Demonstrations and practice exercises will be used to improve participants' attitudes about, as well as intentions to practice, condom use. The counseling session will include the following activities: assessing readiness for change; building motivation for change; and performing exercises in decisional balance, identification of problem and problem-solving, and knowledge and skill-building.
45954432|NCT00338845|Behavioral|Standard didactic safer-sex counseling program|The standard counseling program will be based on a sexual risk reduction counseling program developed by the Centers for Disease Control and Prevention, and will focus on personal risk assessment and strategies for risk reduction. Additionally, it will incorporate risk reduction materials provided by CENSIDA, Mexico's National Center for AIDS Studies.
45954433|NCT00510094|Behavioral|Friend to Friend program|Friend to Friend arm is a social information processing group treatment to help aggressive girls learn better social problem solving and decision making choices. Participants will learn how to identify signs of physiological arousal, evaluate others' intentions, react to a potential conflict situation, and generate and evaluate alternatives. Treatment sessions are twice per week (30 to 40 minutes per session) for ten weeks.
46078036|NCT02746380|Drug|LBAL|Adalimumab
46078037|NCT02746380|Drug|Humira®|Adalimumab
46078038|NCT04241354|Biological|Leukocyte-poor platelet rich plasma|Platelet rich plasma was prepared using PurePRP Supra Physiologic Protocol A preparation [EmCyte Corp. Fort Myers FL].
46078039|NCT04102917|Diagnostic Test|QFR assessment|The quantitative flow ratio (QFR) is a novel angiography-based method for noninvasive functional assessment of intermediate coronary lesions.
46078040|NCT02745990|Drug|Recombinant human erythropoietin|rhEPO is administered 500IU/kg, intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.
46078041|NCT02745990|Drug|Normal saline|Normal salin is administered the same volume with rhEPO intravenously within 72h after birth, and every other day up to 32 weeks of corrected age..
46078042|NCT02538289|Behavioral|Teaching talks|Two teaching talks specifically addressed to medical staff which concerns the adequate treatment and needs of dyspneic patients, including pharmacological and non-pharmacological treatment.
46078043|NCT02823782|Other|MRI|MRI and neuropsychological assessment planned for the study for patient and volunteers
46078044|NCT02823782|Other|neuropsychological assessment|
46078045|NCT04102839|Other|Interview|Qualitative Interview
46078046|NCT00900367|Other|high performance liquid chromatography|
46078047|NCT00900367|Other|laboratory biomarker analysis|
46078048|NCT00900367|Procedure|spectroscopy|
45660993|NCT05494307|Drug|Danazol|Orally danazol at a dose of 200 mg twice daily for 16 weeks
45660994|NCT05488379|Other|Group well child care|Beginning with the 1-month well child care visit, mother-infant dyads will participate in well child care together, with subsequent visits occurring at the American Academy of Pediatrics recommended intervals (2, 4, 6, 9, 12, 15, and 18 months of age).
46078049|NCT00915915|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|Transdermal patch: 0.55mg Ethinylestradiol (EE+2.1mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
46078050|NCT00915915|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|Transdermal patch: 0.55mg Ethinylestradiol (EE+1.05mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
45660995|NCT05494151|Diagnostic Test|Investigation of the metabolic substrate|A blood sample will be received from each patient to assess novel metabolomic biomarkers' levels at the time of acute myocardial infraction
45660996|NCT05482061|Other|visual analog scale (VAS).|The basic tool for pain intensity research was the VAS: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital; 5) at the rehabilitation stage. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the diagnostic DN4: military mobile hospital, a military medical clinical center, then at the time of discharge from a military medical clinical center. Study of the presence of an acute stress reaction - anamnesis + The Hospital Anxiety and Depression Scale. Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
45815187|NCT03402607|Procedure|Percutaneous Local Ablation|Microwave Ablation (MWA) is a form of percutaneous localized ablation using thermal ablation techniques to treat cancer via direct coagulative necrosis. Microwaves can generate high temperatures in a short period of time; MWA has the potential to improve treatment efficacy over radiofrequency ablation as it can be used to treat larger lesions and has less susceptibility to heat-sink due to vessel proximity. MWA uses electromagnetic waves (300 MHz to 300 GHz) to produce oscillation of polar molecules within tissue; this generates tissue necrosis through frictional heating. For HCC, one or more microwave antennae are inserted into the liver, usually under the guidance of ultrasonography or computed tomography (CT). Frequency and length of treatment is determined on a case by case basis depending on tumor size and proximity to vessels or other organs at risk.
45815188|NCT03402607|Radiation|Hypofractionated Image Guided Radiation Therapy|HIGRT represents the only non-invasive curative modality in the management of HCC. HCC patients typically have a host of other medical comorbidities complicated by underlying liver dysfunction that makes the implementation of liver-directed therapy challenging. Presently HIGRT is typically offered only after alternative surgical (transplantation/hepatectomy) and non-operative approaches (PLA/embolization) have been exhausted.
46078051|NCT05659862|Behavioral|Digitally assisted behavioral physical activity intervention|"Digitally Assisted Behavioral Physical Activity Intervention Each week, the step count target will be renewed and an average of 20 minutes of phone calls will be made, including motivational interviews guided by Social Cognitive Theory. Motivational interviews will last 8 weeks.~Outcome Expectations - Informing about the positive results when the physical activity level is increased and the dose-effect relationship Self Efficacy - Individuals' previous physical activity/exercise experiences will be evaluated and discussed.~Social Support - A WhatsApp group will be created. Self Regulation - Self-monitoring ; Goal setting; Feedback, Self-reward"
45660997|NCT04051619|Drug|intranasal oxytocin, 40 IU, twice a day for 7 days|Adjunct therapy
45815189|NCT02752880|Drug|YH1 group|Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
45815190|NCT02752880|Drug|placebo group|Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
45815191|NCT05277727|Dietary Supplement|Fucoidan 500mg|1 capsule to be taken twice daily with food (morning and evening).
45815192|NCT05277727|Dietary Supplement|Placebo|1 capsule to be taken twice daily with food (morning and evening).
45815193|NCT04054232|Other|High PAD risk Alert|"In this message sent via the electronic health record, a participant's primary care physician will receive a message that details the following:~Participant flagged as having a high risk of peripheral artery disease based on their electronic health record data~What peripheral artery disease is and why diagnosis may be important~Recommendation to refer to a vascular medicine specialist or order ankle brachial index for definitive diagnosis~The option to opt out if the potential participant is not deemed a candidate for inclusion in the study with a short explanation of why the potential participant should not be included."
45815194|NCT03241537|Radiation|Intensity modulated radiotherapy|
45815195|NCT02226198|Drug|Rosuvastatin 20mg|Active drug will be taken taken orally, QD, either in the morning or in the evening
45815196|NCT02226198|Drug|Placebo|Will be taken taken orally, QD, either in the morning or in the evening
45815197|NCT02754518|Drug|Entresto|
45815198|NCT05177029|Drug|Lu AG06466|Lu AG06466 will be administered per schedule specified in the arm.
45815199|NCT05177029|Drug|Placebo|Placebo matching to Lu AG06466 will be administered per schedule specified in the arm.
45815200|NCT05169307|Drug|CPX-351|This is a retrospective, non-interventional, observational study. No study drug will be administered in this study.
45815201|NCT02751385|Drug|Microgynon|
45815202|NCT02751385|Drug|Nintedanib|
45954434|NCT00510094|Behavioral|Psychoeducational attention control intervention|Psychoeducational attention control group also meets two times per week for 10 weeks to control for nonspecific factors of treatment. Participants learn homework, study skills, and organizational skills.
45815203|NCT05349032|Dietary Supplement|Curcumin|Oral supplement
45954435|NCT04997915|Other|Observational study exploring the epidemiology and outcomes of AKI in critical COVID-19 patients admitted to the ICU|Critical COVID-19 patients admitted to the ICU
45954436|NCT00338923|Drug|HO/03/03|
45954437|NCT00339001|Drug|erythropoietin and early iron supplements|
45954438|NCT00150306|Drug|Zoloft (Sertraline)|
45954439|NCT00510172|Drug|Prostacyclin, PGI2|10 ng/kg/min of epoprostenol (stable PGI2)
45954440|NCT00510172|Drug|Placebo|NaCL 0,9%
45954441|NCT00420901|Drug|sildenafil|
45954442|NCT02952976|Device|Abthera|ABThera group technique the dressing will be done according to the description and the manufacturer's instructions (Acelity, San Antonio, TX).
45660998|NCT05488301|Other|chest physiotherapy|"chest physiotherapy session including:~nasal ventilation~decrease of respiratory rate without increasement of Tidal volume~abdomino-diaphragmatic ventilation"
45660999|NCT05481983|Other|Walk exercise|The control group will be recommended to walk 5 days a week, 30-45 minutes (min.) (at least 150 minutes of physical activity per week), as recommended by ACOG for pregnant women. Exercise intensity will be given as 4-6 units for moderate-intensity exercise according to the Modified Perceived Difficulty Level (RPE).
45815204|NCT05057689|Drug|Intranasal Dexmedetomidine (4 mcg/kg)|Dexmedetomidine 100 mcg/mL (concentration of 200 mcg/2 mL) will be atomized for intranasal administration at a dose of 4 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 200 mcg.
45815205|NCT05057689|Drug|Intranasal Fentanyl (2 mcg/kg)|Fentanyl 50 mcg/mL (concentration of 100 mcg/2 mL) will be atomized for intranasal administration at a dose of 2 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 100 mcg.
45815206|NCT05057689|Drug|Intranasal Midazolam (5 mg/kg)|Midazolam 5 mg/mL (concentration of 10 mg/2 mL) will be atomized for intranasal administration at a dose of 0.3 mg/kg (0.06 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 10 mg.
45661000|NCT05481983|Other|One-on-one clinical exercise training|One-on-one clinical exercise training will be given by a specialist physiotherapist who has received special training in antenatal exercise. The program is designed to be 2 days a week for 8 weeks.
45815207|NCT05348954|Other|EX-PLISSIT MODEL|The content of the program will include information about the anatomy and physiology of the male-female reproductive system, sexuality and sexual cycle physiology, factors affecting sexuality, postpartum changes, hormonal changes, breastfeeding and their effects on sexuality, and methods of contraception.
45815208|NCT05032183|Drug|Cyclophosphamide|Given IV
45815209|NCT05032183|Drug|Cytarabine|Given IT
45815210|NCT05032183|Drug|Dexamethasone|Given IV or PO
45815211|NCT05032183|Biological|Filgrastim-sndz|Given SC
45815212|NCT05032183|Drug|Leucovorin|Given IV
45815213|NCT05032183|Drug|Mercaptopurine|Given PO
45815214|NCT05032183|Drug|Mesna|Give IV
45815215|NCT05032183|Drug|Methotrexate|Given IT
45815216|NCT05032183|Biological|Pegfilgrastim|Given SC
45815217|NCT05032183|Drug|Prednisone|Given PO
45815218|NCT05032183|Biological|Rituximab|Given IV
45815219|NCT05032183|Biological|Tagraxofusp-erzs|Given IV
45815220|NCT05032183|Drug|Vincristine|Given IV
45815221|NCT02754674|Procedure|type of anterior cruciate ligament reconstruction|comparison of different types of anterior cruciate ligament reconstruction. transportal technique is double bundle graft using flexible reamer, outside-in technique is single bundle graft with remnant preservation
45815222|NCT04737980|Drug|Liposomal bupivacaine|Injection of 10 ml of liposomal bupivacaine 1.3% (133 mg) for ultrasound guided interscalene block
45954443|NCT02952976|Device|Barker|In Barker Group a fenestrated plastic will be used and that will be in contact with viscera followed by four pads with a suction drain and an adhesive finishing layer.
45454227|NCT05187494|Drug|chemical permeability enhancer DMSO with EMLA cream|Adding 10 g of EMLA cream 5%, 1,026 g of DMSO 100% and it will be applied with cotton bud for a period of 3 minutes while the child is opening his mouth and the saliva is controlled by saliva absorbent. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
45815223|NCT04737980|Drug|Bupivacaine Hcl 0.5% Inj|Injection of 10 ml of 0.5% bupivacaine hydrochloride as admixture for ultrasound guided interscalene block
45815224|NCT04737980|Drug|Ropivacaine 0.5% Injectable Solution|Injection of 30 ml of ropivacaine 0.5% injectable solution for ultrasound guided interscalene block
45954444|NCT00420940|Device|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
45954445|NCT00420940|Device|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
45954446|NCT00150384|Drug|Amlodipine/Atorvastatin|
45954447|NCT00425191|Drug|Docetaxel and Gemcitabine|Docetaxel: 40 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 8 immediately followed by Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8
45454228|NCT05187494|Drug|Oral patches with EMLA Cream|EMLA cream 5% will be applied at a distance of 1 mm from the palatal gingival edge using an oral patch 14*14 mm for 3 minutes and the Mouth will be closed throughout the procedure. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness
45815225|NCT04737980|Drug|Dexamethasone|Injection of 8mg (2ml) dexamethasone injectable as admixture
45815226|NCT00371696|Drug|diclofenac|
45815227|NCT00371696|Drug|paracetamol|
45815228|NCT00371696|Device|heat retaining knee support|
45815229|NCT00371696|Device|standard knee support|
45815230|NCT03459170|Biological|BPX-501 T cells|Biological: T cells transduced with CaspaCIDe® safety switch
45815231|NCT03459170|Drug|rimiducid|administered to eliminate BPX-501 cells in the event of GVHD
45815232|NCT05348798|Other|Web based survey|Web-based survey on exercise addiction and personality traits
45815233|NCT02756624|Drug|AC-170 0.24%|
45815234|NCT02756624|Drug|AC-170 Vehicle|
45454229|NCT05187494|Drug|Micro-needle patches dissolved with EMLA Cream|EMLA cream 5% will be applied at a distance of 1 mm from the palatal gingival edge using an micro-needle patch 14*14 mm, 0,25 micron for 3 minutes and the Mouth will be closed throughout the procedure. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
45954448|NCT00425191|Drug|Docetaxel and Gemcitabine|Docetaxel: 50 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 15 immediately followed by Gemcitabine: 1600 mg/m2, administered IV over 30 minutes on day 1 and 15.
45454230|NCT00312052|Drug|E5555|50 mg or 100 mg E5555 tablets
45661001|NCT05488223|Dietary Supplement|AGPI ω-3 (Triple Strength Fish Oil®)|The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
45954449|NCT00425191|Drug|Gemcitabine cisplatin followed by docetaxel|Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8 followed by Cisplatin 75 mg/m2, administered IV over 30-60 minutes on day 2
45954450|NCT00339118|Drug|doxorubicin, cytoxan|
46078052|NCT05659862|Behavioral|Education|"Patient Education~Definition of fibromyalgia syndrome~Symptoms of fibromyalgia syndrome~Exercise and physical activity~Recommendations to improve the quality of life~Sleep quality and sleep hygiene~Pain management~Fatigue and energy conservation techniques All patient education content will also be available on the website."
46078053|NCT02538367|Drug|YH12852 IR 0.05mg|
45454231|NCT00312052|Drug|Placebo|50 mg and/or 100 mg placebo tablets
45661002|NCT05488223|Dietary Supplement|AGPI ω-3 + MUFA (avocado oil)|AGPI ω-3 (0.9g) + MUFA (avocado oil) (0.9g) The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
45661003|NCT05488223|Dietary Supplement|MUFA (avocado oil) (1.8g)|MUFA (avocado oil) (1.8g) The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
45815235|NCT02753413|Biological|RSV vaccine GSK3003891A|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
45815236|NCT02753413|Biological|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
45954451|NCT04995926|Procedure|Labial mucosal epithelium grafting for corneal limbus substitution|Labial mucosa epithelium grafting for corneal limbus substitution will be used to treat limbal stem cell deficiency by way of corneal surface re-epithelization
45454232|NCT01342562|Drug|spinal anesthesia|0.4% bupivacaine(normal saline 0.3ml with dexmedetomidine 3 mcg)
45454233|NCT01342562|Drug|spinal anesthesia|0.4% bupivacaine(normal saline 0.3 ml with 0.5% bupivacaine 1.2 ml)
45954452|NCT02952937|Drug|GLA5PR GLARS-NF3 tablet 300mg|A new formulation(3rd.) of Pregabalin CR tablet
45954453|NCT02952937|Drug|GLA5PR GLARS-NF1 tablet 300mg|A new formulation(1st.) of Pregabalin CR tablet
45954454|NCT00339157|Drug|Anakinra|
45954455|NCT00339157|Biological|Pneumo23|
45954456|NCT00339196|Drug|5 azacytidine - VALPROIC acid- Retinoic acid|5 azacytidine - VALPROIC acid- Retinoic acid
45954457|NCT00158730|Drug|AmBisome|
45954458|NCT04993391|Drug|JS111(AP-L1898 Capsules)|40 mg, QD
45954459|NCT04993391|Drug|JS111(AP-L1898 Capsules)|80 mg, QD
45954460|NCT04993391|Drug|JS111(AP-L1898 Capsules)|160 mg, QD
46078054|NCT02538367|Drug|YH12852 IR 0.1mg|
46078055|NCT02538367|Drug|YH12852 IR 0.3mg|
45454234|NCT00404014|Drug|AL-208|1 dose of 300 mg
45454235|NCT00404014|Drug|Placebo|1 dose of placebo
45454236|NCT01315652|Behavioral|Comorbidities treatment|" Comorbidities treatment:Number of actions initiated in order to treat or prevent Rheumatoid Arthritis comorbidities during the 6 months follow-up"
45454237|NCT01315652|Behavioral|Auto-DAS|"Auto-DASNumber of patients with a modification in their treatment between baseline and 6 months visits"
45454238|NCT01315730|Device|Tactile Stimulation|See Arms
45454239|NCT00116116|Drug|efavirenz, stavudine extended release, lamivudine|
45954461|NCT04993391|Drug|JS111(AP-L1898 Capsules)|240 mg, QD
45954462|NCT04993391|Drug|JS111(AP-L1898 Capsules)|320 mg, QD
45954463|NCT00510211|Drug|olanzapine|
45954464|NCT00150423|Drug|Pregabalin|
45954465|NCT02952547|Drug|Co-administration of DWC20155 and DWC20156|
45954466|NCT02952547|Drug|DWJ1366 Tab.|
45954467|NCT04988282|Drug|Methylprednisolone Tablet|Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks
46078056|NCT02538367|Drug|YH12852 IR 0.5mg|
46078057|NCT02538367|Drug|YH12852 IR 1mg|
46078058|NCT02538367|Drug|YH12852 IR 2mg|
46078059|NCT02538367|Drug|YH12852 IR 3mg|
46078060|NCT02538367|Drug|YH12852 DR1 0.5mg|
46078061|NCT02538367|Drug|YH12852 DR1 1mg|
46078062|NCT02538367|Drug|YH12852 DR1 2mg|
46078063|NCT02538367|Drug|YH12852 DR1 4mg|
45954468|NCT00510250|Drug|Sorafenib|200mg PO BID x 7 days prior to Radiation and Cisplatin for Low-Risk Patients or 200mg PO BID x 7 days prior to, and 35 days during Radiation and Cisplatin for High-Risk Patients
45815237|NCT04335422|Device|Robotic group (Upper extremity robot-assisted training plus routine physical and rehabilitation medicine program)|"Upper extremity robot-assisted training will include facilitated shoulder flexion-extension, internal-external rotation, abduction-adduction, elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, ulnar-radial deviation, hand finger flexion-extension movements by means of visual feedback with a 3-dimensional virtual environment in which the patient is asked to perform various tasks such as object reaching, grasping, holding, dropping activities by playing computer games.~Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given."
45815238|NCT04335422|Behavioral|Control group (routine physical and rehabilitation medicine program)|Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given.
45954469|NCT00510250|Drug|Cisplatin|40mg/m2 administered weekly via IV, with Radiation
45954470|NCT00510250|Procedure|Radiation|Administered for 30-40 days.Combination of external beam radiotherapy followed by intra-cavitary brachytherapy.
45954471|NCT00158769|Drug|Intravenous GR270773 - Phospholipid emulsion|GR270773 (lipid emulsion) is a sterile, white to off-white, semi-translucent liquid for intravenous injection.
45954472|NCT04981067|Other|Maintain the concentration of ropivacaine as same as those used in the previous participant|Maintain the same concentration of ropivacaine used in the previous participant with an 89% chance through a random assignment
45954473|NCT04981067|Other|Decrease the ropivacaine concentration by 0.05% from the concentration used in the previous participant|Decrease ropivacaine concentration by 0.05% from the concentration used in the previous participant with an 11% chance through a random assignment
45954474|NCT04981067|Other|Increase the ropivacaine concentration by 0.05% from the concentration used in the previous participant|Increase ropivacaine concentration by 0.05% from the concentration used in the previous participant.
45954475|NCT00510328|Device|Whole Body Vibration|
46078064|NCT02538367|Drug|YH12852 DR2 8mg|
46078065|NCT02538367|Drug|Prucalopride 2mg|
46078066|NCT02538367|Drug|Placebo|
46078067|NCT03994809|Other|Okada Purifying Therapy|The practitioner raises his/her hand forward towards the recipient with the palm directed toward the recipient. The practitioner uses his/her hands alternately during the administration of Okada Purifying Therapy. The distance between the palm and the body is usually 1-2 feet, with each session typically lasting 30 to 60 minutes.
46078068|NCT02750124|Device|Cobas PCR Female swab sample Packet|The cobas® PCR Female Swab Sample Kit is used to collect and transport vaginal swab specimens self-collected.
46078069|NCT02750124|Other|Routine practice|The standard, annual renewed invitation to cervical screening.
45954476|NCT00339469|Dietary Supplement|LIFE|We are evaluating the effects of a legume enriched, low glycemic index, high fermentable fiber diet, on CRP, and C-peptide participants with four possible combinations of the risk factors insulin resistance and history of adenomatous polyps. In a randomized crossover design controlled feeding study each participant consumed the above experimental diet and a control diet for four weeks with a two week washout period between diets. 65 male participants were recruited and randomized into four groups. A secondary objective is to assess whether these endpoints change by IR status or a history of adenomas. In addition, potential fecal markers of CRC risk are being measured to assess changes in gastrointestinal inflammation, including mRNA from exfoliated fecal colonocytes. To our knowledge this is the first controlled feeding study: 1. to examine the effects of legumes or a low GI diet on markers of inflammation
45661004|NCT05481905|Drug|ENX-101|Adjunctive treatment to current antiseizure medication
45661005|NCT05494073|Procedure|ACL Reconstruction with Hybrid Remnant Repair|The intervention includes the incorporation of the host ACL remnant into the graft. The intervention hopefully
45661006|NCT05494073|Procedure|ACL Reconstruction without Hybrid Remnant Repair|ACL reconstruction without preservation or incorporation of host ACL remnant
46078070|NCT04241432|Device|vibrating platform|Use of two different types of vibrating platform
46078071|NCT03994575|Other|Guideline recommended feedback|The ACS Reflective III Pilot program is a quality assurance program where the decision to follow the recommendations and all treatment decisions related to patient care are left to the physician's discretion and feedback to the physician with their aggregate and individual patient data is intended as a quality assurance undertaking
46078072|NCT00900445|Drug|Daunorubicin Hydrochloride|Given IV
46078073|NCT00900445|Other|Pharmacological Study|Correlative studies
46078074|NCT00900445|Drug|Prednisolone|Given orally
46078075|NCT00900445|Drug|Prednisone|Given orally
46078076|NCT00900445|Drug|Vincristine Sulfate|Given IV
46078077|NCT04217538|Other|clinical exam|clinical oral examination
46078078|NCT04240964|Other||
46078079|NCT03994419|Procedure|Anaesthesia for surgery|Observational study observing proportion of obese and overweight children attending for surgery. Observing adverse events following general anaesthesia for surgery in obese versus healthy weight children.
45661007|NCT05493917|Biological|an inactivated SARS-CoV-2 vaccine named BBIBP-CorV|Completed 2 doses of an inactivated SARS-CoV-2 vaccine more than 6 months ago and received a third dose of the vaccine
45661008|NCT05481515|Device|Pulse oximetry|Pulse oximeters will be evaluated against routine arterial blood gas measurements
45454240|NCT02287870|Drug|Chloroprocaine|60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 3% chloroprocaine.
46078080|NCT02825810|Behavioral|Cervical motor control|Intervention will consist in a tailored exercise training following a previous published motor control protocol
45954477|NCT00158808|Biological|Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib|
45954478|NCT02952703|Behavioral|brief pre-delivery smoking cessation counseling|
46078081|NCT00936065|Drug|Etanercept|Etanercept at a dose of 50mg twice weekly for 12 weeks followed by 25mg twice weekly for 12 weeks
46078082|NCT00936065|Drug|Etanercept + Acitretin|Combination of etanercept at a dose of 25mg twice weekly and acitretin 10mg BID for 24 weeks
46078083|NCT00936065|Drug|Acitretin|Acitretin at a dose of 10mg BID for 24 weeks
45454241|NCT02287870|Drug|Lidocaine|60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 2% lidocaine.
45661009|NCT05481515|Device|Spectrophotometry|Spectrophotometry will be used to measure skin tone
45661010|NCT03906227|Device|ENUMERATION OF CD5+ B Cells|A blood test is done to assess what percentage of CD5+ is present within CD19+. The result is then used to guide choice of arm.
45661011|NCT05481437|Drug|Brentuximab Vedotin|Brentuximab Vedotin injection, 50 mg, once every 2 weeks
45815239|NCT02958800|Other|Intervention|"The intervention will be 12-weeks in duration consisting of four blocks resulting from a 1:1 randomization of two different three-week treatment courses of a patient's existing antipsychotic medication. For example, the intervention ABAB means that a participant would undergo three weeks of treatment A, followed by three weeks of treatment B, followed by three weeks of treatment A, and lastly three weeks of treatment B.~Treatment A block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose.~Treatment B block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose and the dose in Treatment A."
45954479|NCT02952703|Behavioral|additional pre-delivery smoking cessation counseling|
45954480|NCT02952703|Behavioral|post- delivery smoking cessation counseling|
45454242|NCT05157230|Behavioral|exercise|volunteers in the exercise arm instructed to do three basic deltoid muscle exercises 3 times daily at least 20 repetitions for each exercise for five days. exercises were side lateral shoulder raises, front shoulder raises with hyperextension and mid range arm circles.
45458118|NCT03508180|Behavioral|INTERVIONNAL|"Foot reflexology session (30 minutes) each course of chemotherapy (total 4 courses) during the 4 hours following the first 2 hours of injection + auto-massage done by the patient between each course.~During a session focused on the treatment of nausea / vomiting, the reflexologist will stimulate the reflex zones related to the digestive system in order to calm and stimulate all areas for deep relaxation of the patient."
45661012|NCT04239989|Drug|Itacitinib|Given PO
45661013|NCT04239989|Drug|Itacitinib Adipate|Given PO
45661014|NCT05487521|Drug|Methylprednisolone and or prednisolone|we gave methylprednisolone and or prednisolone to patients with EEG activity and follow up the effect of the drug on language
45661015|NCT05481281|Drug|Dexmedetomidine|I/V bolus of dexmedetomidine 0.1 mg/kg as a 20 ml solution, followed by 0.04mg/kg/hr infusion
45661016|NCT05481281|Drug|Ketamine|0.2 mg/kg iv of ketamine diluted to 20 ml followed by 0.1 mg/kg/hr infusion
45661017|NCT05487443|Drug|Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors|Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors for first-line treatment of advanced biliary malignancies
45815240|NCT04937491|Device|New medical device (ReBalans)|Body worn, battery powered bioimpedance measuring patch device.
45815241|NCT00372086|Drug|Rosiglitazone|
45815242|NCT04852471|Behavioral|Standard Post-Operative Counseling + FACT-G|Counseling at discharge + FACT-G at enrollment, at 15-18 and at 30-32 days post-operative.
45815243|NCT04852471|Behavioral|PROM symptom tracker|A 12-item symptom tracker adopted from the Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (NCI-PRO-CTCAE), delivered via text, on days 4, 6, 8, 12, 18, 24, and 30 post surgery.
45815244|NCT04850521|Other|Remote monitoring|patient-facing app + connected spirometer + connected pulse oximeter + clinician view portal
45954481|NCT02952703|Behavioral|incentives|
45954482|NCT00510367|Drug|5-Fluorouracil|500 mg/m^2 By Vein Daily x 2 Days
45954483|NCT00510367|Drug|Cyclophosphamide|500 mg/m^2 By Vein On Day 1
45954484|NCT00510367|Drug|Doxorubicin|50 mg/m^2 By Vein Over 72 Hours
45954485|NCT04980716|Drug|"Multiple cardiovascular drugs related to Golden Triangle"|Based on impedance cardiography results at each timepoints, cardiovascular drug treatment and exercise plan will be given in the intervention group.
45954486|NCT00158847|Drug|fluticasone 500 mcg|
45954487|NCT00158847|Drug|fluticasone 500 mcg + salmeterol 50 mcg|
45954488|NCT00339586|Drug|Erlotinib|
45954489|NCT04976894|Other|open|open
46078084|NCT04241276|Drug|ATRA|45 mg/m2 orally (in two divided doses) from days 1 to 15 of each cycle
46078085|NCT04241276|Drug|Gemcitabine|1000mg/m2 IV on days 1, 8 and 15 of a 28 day cycle
46078086|NCT04241276|Drug|nab-paclitaxel|125mg/m2 IV on days 1, 8 and 15 of a 28 day cycle
46078087|NCT04023513|Other|High protein intake|6 weeks of high protein intake mainly via food (additional 1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.
46078088|NCT04023513|Other|Control, no intervention|No Intervention, control
46078089|NCT04023513|Other|Low protein intake|6 weeks of low protein intake (1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains
46078090|NCT04023513|Other|Strength training|6 weeks of different protein intake followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains
45954490|NCT00339625|Other|low fat, high fiber, high fruit and vegetable eating plan|Participants were randomized to a low fat, high fiber, high fruit and vegetable (intervention arm) or their usual diet (control arm)
45954491|NCT00158886|Drug|Topotecan|Topotecan will be provided as capsules for oral administration and will be administered at least 3 hours before radiation therapy.
46078091|NCT00905047|Drug|XELODA|"XELODA, 2500 mg/m²/bid, with approximatively an interval of 12 hours, 30 minutes after breakfast and dinner - during 14 days.~Cycle treatment duration : 21 days"
46078092|NCT00905047|Drug|TEGAFUR URACIL - FOLINIC ACID|"Tegafur 300 mg/m2/tid with folinic acid 75 mg/tid during 28 days.~Duration of treatment cycle : 35 days."
45661018|NCT05481203|Behavioral|The Kaleidescope|During the nasopharyngeal swab collection process, the researcher held a kaleidoscope to each child's eye, leisurely turning it and asking about the colors and shapes seen within it.
46078093|NCT04023357|Other|PEEK|New polyetheretherketones material
45458119|NCT03508180|Other|CONTROL|None intervention.
45815245|NCT03380000|Drug|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
45815246|NCT03380000|Drug|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
45815247|NCT02754427|Behavioral|Prospective Surveillance Group|Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the surveillance group underwent the same arm assessment at 3, 6, and 9 months post-surgery. If arm morbidity was detected at any of those time points, then the participant was referred to individual physiotherapy treatment until the issue was resolved.
45815248|NCT02754427|Behavioral|Education Group|Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the education group were asked to attend three patient education sessions on nutrition, stress management, and fatigue management of approximately 1 hour, delivered at 3, 6, and 9 months by study staff.
45815249|NCT02973932|Behavioral|Cognitive-bahavioral psychotherapy|
45815250|NCT04777669|Other|Noise Reduction|In within subject design, listeners will have background noise removed by a noise reduction algorithm
45815251|NCT03169010|Other|laboratory biomarker analysis|Laboratory results will be analysed to identify disease related biomarkers.
45815252|NCT03169010|Genetic|Genetic analysis|Gene sequencing results will be analysed to identify disease related mutations.
45954492|NCT00158886|Radiation|Radiation therapy|For radiation therapy, subjects will receive 180 centigray (cGy) per fraction to a total dose of 4500 cGy to the pelvis using a 3 or 4 field technique and high energy photons (>=6 megavolt [mv]).
45954493|NCT03459586|Other|9zest app facilitated exercise|The purpose of this study is to determine if the 9zest app for Parkinson's disease is feasible, safe, and efficacious when used independently by individuals with Parkinson's disease
45954494|NCT04965428|Behavioral|Fear-focused Self-Compassion Therapy|The Fear-focused Self-Compassion Therapy will be delivered as a group format. The intervention consists of eight group face-to-face sessions (60-90 minute for each session) and will be delivered by three trained therapists for eight weeks (sessions are weekly). Each intervention group involves 10 patients.
45954495|NCT00150540|Drug|Lanthanum carbonate|
45954496|NCT00510406|Drug|tamsulosin hydrochloride|Alphablocker
45954497|NCT00510406|Drug|solifenacin succinate|antimuscarinic
45954498|NCT00510406|Drug|Placebo|Placebo
45954499|NCT04943666|Other|Hemorrhoid Disease Questionnaire|a new patient specific questionnaire (HDQ) with appropriate sensitivity and specificity to use for screening of patients with haemorrhoids in Russia in clinical practice for wider screening of haemorrhoids in population and for increasing patients' awareness of the disease and prompting them to seek professional advice.
45661019|NCT05481203|Behavioral|The visual illusion cards|Just before the nasopharyngeal swab participants were allowed to check the cards andwere askedwhat they saw in them.
45661020|NCT04051229|Behavioral|6-week exercise training program|Participants will walk at 50% Heart Rate Reserve (HRR) 3 to 5 days per week for 6 weeks at the Department of Health and Exercise Science Clinical Research Center under the supervision of study staff.
45815253|NCT04759885|Drug|Phase II: NTC015 low dose|Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
45954500|NCT00165555|Drug|Cisplatin|Given as a heated one-hour lavage to the hemithorax after surgery.
46078094|NCT04023357|Other|Emax|standard etchable glass ceramic used for Endocrowns
46078095|NCT02540005|Other|ROTEM analysis|
46078096|NCT02823938|Other|existing database on data collection.|This is an observational study on an existing database.
46078097|NCT04023201|Other|Nocturnal symptoms|Parkinson's disease patients with or without nocturnal symptoms
46078098|NCT04102449|Drug|Apremilast|Single arm receiving Apremilast and ultrasound examinations
46078099|NCT00905203|Other|exercise|exercise training
45815254|NCT04759885|Drug|Phase II: NTC015 medium dose|Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
45954501|NCT00165555|Drug|Sodium Thiosulfate|Given intravenously over 6 hours after the cisplatin lavage.
45815255|NCT04759885|Drug|Phase II: NTC015 high dose|Participants should self administer the preparation within 60 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
45954502|NCT02952664|Behavioral|PUMP Monitoring|A video camera will be placed in each subject room for recording the repositioning events to correlate the monitor signals with the actual subject repositioning captured by the video.
45815256|NCT04759885|Drug|Phase III: NTC015 selected dose|Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
45954503|NCT02952625|Other|Imaging|Single arm Imaging (PET/MR) study
45954504|NCT00150579|Drug|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate|
45954505|NCT02952859|Other|Irreversible electroporation|
45954506|NCT02952196|Drug|drug administration|administering drug to patient with amphetamine addiction
45954507|NCT00511732|Drug|Technosphere Insulin|Technosphere Insulin Inhalation Powder
45954508|NCT00511732|Drug|Technosphere Placebo|Technosphere Inhalation Powder
45954509|NCT00510445|Drug|Imetelstat Sodium (GRN163L)|"The starting dose of GRN163L for this study will be 3.2 mg/kg. Subsequent dose levels will be 4.8, 6, 7.5, 9, 11, and 13.5 mg/kg. The maximum dose to be administered will not exceed 13.5 mg/kg.~Paclitaxel and carboplatin will be administered on Day 2 of each 21-day cycle."
45954510|NCT00150657|Drug|bevacizumab|
45954511|NCT00150657|Drug|carboplatin|
45458120|NCT04629781|Drug|Docetaxel micellar|There will be three dose levels, 1-3, with each level consisting initially of a cohort containing 3 patients. One additional dose level, dose level -1, shall be allowed in the event that dose level 1 is considered too toxic
45954512|NCT00150657|Drug|gemcitabine|
45954513|NCT04937387|Drug|FF/VI|FF/VI will be administered.
45954514|NCT04937387|Drug|FF/UMEC/VI|FF/UMEC/VI will be administered.
45954515|NCT04937387|Device|ELLIPTA|FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.
45954516|NCT00510523|Device|Whole Body Vibration machine|
45954517|NCT00511771|Drug|Tegaserod|Tegaserod maleate
45954518|NCT00510562|Procedure|Cranial osteopathic manipulation|This treatment is performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
45954519|NCT00510562|Procedure|Sham/Placebo|A laying on of hands with no treatment being performed.
45954520|NCT00165594|Drug|E7070|
45954521|NCT00510601|Device|Kaneka Liposorber|LDL-apheresis on a bi-weekly basis
46078100|NCT00900523|Genetic|protein expression analysis|protein expression analysis
46078101|NCT00900523|Other|immunohistochemistry|immunohistochemical staining of tumor tissue to measure COX-1 and COX-2 levels
46078102|NCT02825108|Drug|Intra uterine injection of tissue culture medium containing HCG+ET|40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
45954522|NCT00511849|Drug|carboplatin + SU011248 (sunitinib) + paclitaxel|AUC of 6 mg*min/mL administered as a 30-minute infusion, every 21 days for 4 cycles or until progression/unacceptable toxicity. 25 mg, 37.5 mg, or 50 mg (depending on the dose level assigned) orally taken every day or for 2 weeks and 1 week off without for 4 cycles or until progression/unacceptable toxicity. 175 mg/m2, 200 mg/m2, or 225 mg/m2 (depending on the dose level assigned), administered as a 3-hour infusion every 21 days for 4 cycles or until progression/unacceptable toxicity.
45954523|NCT00510640|Drug|Sunitinib|Capsule, 12.5 or 50 mg, starting dose level 50 mg daily
46078103|NCT02825108|Drug|Intra uterine injection of tissue culture medium +ET|) only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
46078104|NCT02825108|Procedure|ET|the embryo transfer ( ET) is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
46078105|NCT00905281|Other|Action Group|"On inclusion, a visit will be organized between the patient and at least 2 members of the DISSPO staff. It will allow an evaluation of supportive care needs and the proposition of a personalized care plan.~Then, a consultation between the referring oncologist and the DISSPO will be organized once a month, so that the personalized care plan could be adapted if necessary."
45815257|NCT04759885|Drug|Phase III: Polyethylene glycol plus ascorbate solution (2L PEG ASC)|"The instructions for product administration are followed according to the Summary of Product Characteristics.~One treatment consists of two litres of Moviprep® taken according to split-dose regimen.~The first litre of Moviprep® is prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution. The reconstituted solution must be drunk over a period of one to two hours the evening before colonoscopy. About half a litre of clear liquid should be drunk in the next hour to prevent dehydration according to local practice at the centre. This process should be repeated with a second litre of Moviprep® prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution in the early morning of the day of the procedure."
45954524|NCT04912739|Behavioral|Targeted health dialogues|"Before the targeted health dialogue, the participants fill in a questionnaire about health behaviors, background characteristics and self-rated health. Samples for blood glucose and total cholesterol are taken. BMI, waist-to-hip ratio and blood pressure are measured. The results are summoned in a health curve, which is discussed with specially trained healthcare personnel in a Targeted heath dialogue. In a sub-group, blood samples are collected for molecular analyses."
45815258|NCT02754661|Device|COLON Capsule endoscopy|
45815259|NCT02754661|Device|Computed Tomographic Colonography|
45954525|NCT00150696|Drug|Risedronate|
45954526|NCT00510679|Behavioral|Health worker supports (supervision, job aids, incentives)|
45954527|NCT03459508|Diagnostic Test|Ophthalmological examination|Detailed anterior segment examination using slit-lamp biomicroscopy for signs of anterior uveitis, and detailed fundus examination using slit-lamp fundus biomicroscopy with + 90 diopter lens searching for signs of vasculitis and posterior uveitis.
45954528|NCT00165633|Drug|Menatetrenone|45 mg capsule, orally, three times a day, after meals.
45954529|NCT00165633|Drug|Menatetrenone|90 mg capsule, orally, three times a day, after meals.
45954530|NCT00165633|Drug|Placebo|Placebo capsule, orally, three times a day, after meals.
45954531|NCT02952469|Drug|(68Ga)PSMA-HBED-CC|Experimental radiotracer for imaging prostate cancer
45954532|NCT03459430|Other|Core stability training|Effect of different core stability programs using diverse training intensities
45954533|NCT04907591|Device|mHealth App and wearable device|an intervention group (App+IoT device) uses a smart care application tailored to gastric cancer patients created by reflecting the treatment process immediately after surgery and a wearable smart band worn on wrist for 12 months.
46078106|NCT00905281|Other|Standard care|No specific intervention
46078107|NCT02822534|Drug|SP2086|the study has 3 doses groups and the 24 subjects were administrated SP2086 50mg,100mg,200mg respectively.
46078108|NCT02822300|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-74_R84-086)
46078109|NCT00900679|Behavioral|telephone-based intervention|
45454243|NCT02287948|Device|Nintendo Wii Fit Balance Board|"Clinical and instrumental evaluations carry out on the same day.~1) Instrumental evaluations~All subjects (healthy + MS) will ask to perform the following tasks both on force platform and Wii Fit Balance Board:~Open eyes, monopodalic balance for 20 seconds~Closed eyes, monopodalic balance for 20 seconds~Open eyes, balance on both feet for 60 seconds~Closed eyes, balance on both feet for 60 seconds~During trials subjects can leave arms in the most comfortable position they prefere~Subjects will perform every task for 5 times; they can rest for 30 seconds between every trials."
45454244|NCT01340456|Drug|Rifampicin treatment|induction of CYP3A4 with one of three rifampicin doses (10, 20, 100 mg QD)
45454245|NCT00110422|Drug|Irbesartan|Tablets, Oral, 150 mg. titrated to 300 mg, once daily, 28 weeks.
45454246|NCT00110422|Drug|Hydrochlorothiazide|Tablets, Oral, 12.5 mg. titrated to 25 mg, once daily, 28 weeks.
45458121|NCT03505606|Diagnostic Test|Visual acuity tests|Participants to have visual acuity tested with the three modified vision tests.
45954534|NCT00510796|Behavioral|Interview|Interview regarding perception of pain and the benefits and barriers to the combined screening.
45954535|NCT00165711|Drug|Mecobalamin|
45954536|NCT02952781|Device|EKG Patch monitors (Zio and Carnation)|Each patient will be provided with both a Zio-XT Patch monitoring system and the CAM system and will be instructed to wear both simultaneously for 7 days.
45954537|NCT02952742|Drug|Black Cohosh|Vital Nutrients Black Cohosh Extract
46078110|NCT00900679|Other|counseling intervention|
46078111|NCT00900679|Other|educational intervention|
46078112|NCT00900679|Other|medical chart review|
45954538|NCT02952742|Other|Placebo|Inactive comparator resembling the Black Cohosh formulation in appearance. Ingredients include: cellulose; caramel color; powdered yellow dye; and powdered red dye.
46078113|NCT00900679|Other|questionnaire administration|
46078114|NCT00900679|Procedure|psychosocial assessment and care|
46078115|NCT00900679|Procedure|quality-of-life assessment|
46078116|NCT02823548|Drug|Droglican|Chondroitin Sulfate 1,200mg + Glucosamine Hydrochloride 1,500mg
46078117|NCT02823548|Drug|Placebo|Placebo
46078118|NCT04441788|Drug|ION-827359|ION-827359 administered by oral inhalation
46078119|NCT04441788|Drug|Placebo|Placebo administered by oral inhalation
46078120|NCT04441788|Drug|ION-827359|ION-827359 administered by oral inhalation
46078121|NCT02823236|Drug|Topical Pirfenidone|Pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.
46078122|NCT02823236|Drug|Triamcinolone + Pirfenidone|Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months. And pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.
45954539|NCT00510913|Drug|tacrolimus|
46078123|NCT02823236|Drug|Intralesional Triamcinolone|Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months.
46078124|NCT00633698|Drug|Nicotinic acid (niacin)|oral medication Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
45454247|NCT05156528|Biological|S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine|Single intramuscular dose contains 10 µg of S. flexneri 2a polysaccharide and S. sonnei polysaccharide respectively.
45454248|NCT05156528|Biological|Placebo|Single intramuscular dose contains 0.15~0.25 mg of aluminum ion
45954540|NCT04903301|Procedure|Contoura Vision LASIK|Topography-Guided LASIK using Phorcides Analytic Software
45954541|NCT00150735|Drug|LEVETIRACETAM|
45954542|NCT03459391|Drug|XC221 60 mg|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
45954543|NCT03459391|Drug|XC221 200 mg|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
45954544|NCT03459391|Drug|Placebo|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
46078125|NCT00633698|Drug|Placebo|Placebo Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
46078126|NCT03931512|Device|transcranial direct current stimularion|aplication of direct current stimulation on the scalp wiht sponge electrodes
46078127|NCT02825342|Drug|Citalopram|
46078128|NCT02749812|Device|Constant Continuous Positive Airway Pressure|
46078129|NCT02749812|Device|Automatic continuous Positive Airway Pressure|
46078130|NCT02823158|Procedure|Deep brain stimulation (DBS) of Globus Pallidus internus (GPi) and Best medical treatment (BMT)|"Patients in the GPi group will be implanted with DBS-electrodes within 6 weeks after randomisation. The stimulation parameters and the medical treatment are adjusted for optimal control of motor and non-motor signs and symptoms according to published guidelines using a specified algorithm. The stimulation parameters are recorded at the beginning and at the end of each post-surgical assessment.~Best medical treatment is applied in combination with GPi-DBS."
46078131|NCT02823158|Procedure|Best medical treatment|Patients will receive optimized medical treatment according to published evidence based guidelines.
45954545|NCT03459352|Other|ePRO|"Patients will be instructed to log symptoms with an ePRO app using their own personal devices, and prompted once per month for 12 months to log symptoms.~These participants will be sent an Adverse Event Questionnaire (AEQ) via the Noona tool that summarizes their symptoms and distress once per month and one week prior to any medically indicated oncology clinic visit.~Symptoms designated as clinically severe either during regular symptom logging or via the AEQ will trigger a prompt to contact the clinical team for immediate follow-up. Participants will complete a follow-up questionnaire at 6 months and 12 months following enrollment that includes a self-report of symptom burden, HRQOL, and satisfaction."
45954546|NCT02952274|Device|mandibular overdenture retained with single midline implant using locator attachment|
45954547|NCT02952274|Device|mandibular overdenture retained with single midline implant using ball attachment|
46078132|NCT02749890|Drug|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
46078133|NCT02749890|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
46078134|NCT02749890|Drug|Oral anti-diabetic drugs|"Pharmaceutical form: tablet~Route of administration: Oral"
46078135|NCT04242758|Drug|Dapagliflozin 10 MG|SGLT2-inhibitor: Diabetic oral drug with diuretic properties
46078136|NCT04242758|Drug|Hydrochlorothiazide 12.5mg|Best known thiazide class diuretic.
46078137|NCT04192604|Other|WMSDsQ|Work-related MusculoSkeletal Disorders Questionnaire
45454249|NCT00305656|Drug|cediranib maleate|Given orally
45454250|NCT01342718|Dietary Supplement|Herbal extract granule and probiotics|"The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)~The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule [7✕100,000,000 viable cells/strain]), 2 capsules per day (2 hours after morning and evening meal)"
45954548|NCT04892342|Drug|ESG401|Administered via intravenous (IV) infusion
46078138|NCT02745912|Drug|Naltrexone/Bupropion|Naltrexone/Bupropion extended-release tablets.
45661021|NCT04051229|Behavioral|Standardized isoenergetic high fat diet|Prior to the submaximal exercise testing visits, all participants will be provided with 3 days of a standardized isoenergetic high fat diet (20% of kcals from carbohydrate, 65% fat; 15% protein) to promote lipid oxidation. The meals will be prepared and provided by the Clinical Research Unit of Wake Forest Baptist Health. Participants will pick up 3 days' worth of food and snacks 4 days prior the testing visit. For the 3 days leading up to the visit, participants will eat the provided foods and complete a compliance assessment.
45954549|NCT04695925|Drug|Osimertinib 80 MG [Tagrisso]|osimertinib 80 mg po qd until disease progression
45954550|NCT04695925|Drug|Pemetrexed 500 MG Injection|pemetrexed 500 mg/m2 intravenously every 3 weeks until disease progression
45954551|NCT04695925|Drug|Carboplatin|carboplatin area under curve 5 intravenously every 3 weeks for four cycles
45954552|NCT00510991|Device|nippv|
45954553|NCT00511069|Drug|Bortezomib|
45954554|NCT00165750|Drug|DONEPEZIL HYDROCHLORIDE|One 5mg table, once daily. (After 4 weeks treatment, the dose can be increased 10mg once daily.)
45954555|NCT04888949|Biological|Mesenchymal stem cell|1*10^8 cells are administered once a week, total four times intravenously.
45954556|NCT04888949|Biological|Placebo|Commercially available saline.
45954557|NCT00511186|Drug|Placebo|placebo is administered intravenously over 48 hours. An initial loading dose of over 10-minutes is followed by continuous infusion over 48h.
45954558|NCT00511186|Drug|BIAP|AP is administered intravenously over 48 hours. An initial loading dose of 67.5U/Kg body weight over 10-minutes is followed by continuous infusion of 132.5U/Kg/24H administered over 48H
45954559|NCT00511225|Dietary Supplement|cholecalciferol|10,000 IU weekly
45954560|NCT00511225|Dietary Supplement|placebo|placebo capsule
45954561|NCT00150774|Drug|Levetiracetam|
45954562|NCT04864067|Drug|Oxaliplatin|Consolidation Chemotherapy
45954563|NCT04864067|Drug|5-Fluoracil|Consolidation Chemotherapy
45954564|NCT04864067|Drug|Leucovorin|Consolidation Chemotherapy
45954565|NCT04864067|Drug|Capecitabine|Consolidation Chemotherapy
46078139|NCT02745912|Drug|Metformin|Metformin immediate-release tablet.
46078140|NCT02746068|Drug|AXS-02|
46078141|NCT02746068|Drug|Placebo|
46078142|NCT02825186|Drug|Loteprendol etabonate 0.5%|Steroid eye drops used after strabismus surgery.
46078143|NCT02825186|Drug|Dexamethasone 0.1%|
46078144|NCT00604825|Drug|Other: Placebo|
46078145|NCT00604825|Drug|GSK232802|
46078146|NCT00604825|Drug|PREMARIN|
46078147|NCT04239560|Drug|Boron-based Gel (Fibore)|During each radiotherapy session, 15 minutes before radiotherapy, the gel used and patients followed up.
46078148|NCT04239560|Drug|Placebos|During each radiotherapy session, 15 minutes before radiotherapy, the Placebo gel which be free of any chemical used and patients followed up.
46078149|NCT05380817|Other|Remote Monitoring Program|Participants receive remote monitoring while engaging in a theory-based, multi-component, multi-level, multi-setting (MMM) community team sports program designed specifically for children
45661022|NCT05493527|Device|noninvasive high frequency oscillatory ventilation|"A time-cycled, pressure-limited, and continuous-flow neonatal ventilator (SLE6000; SLE) was used for neonates assigned to the NHFOV group. The settings were as follows:~a frequency of 10 Hertz ( range, 8-12 Hz);~an inspiratory time of 50% (1:1)~an oscillation amplitude of 35 centimeter of water column (cmH2O) (subsequent regulation range, 20-40 cmH2O) Oscillation amplitude would be regulated according to the level of carbon dioxide(CO2). Visible chest oscillation was not necessary because elimination of CO2 during NHFOV could also occur in the upper respiratory airway dead space~Mean airway pressure (MAP) of 10 cm H2O ( range, 7-15) MAP was regulated according to an open lung recruitment strategy~fraction of inspired oxygen (FIO2) regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter."
45815260|NCT02757092|Other|Home-based Pulmonary Rehabilitation|(1) breathing exercises (pursed-lip and diaphragmatic breathing) and coughing exercises, (2) aerobic exercises (upper and lower limb exercises and walking), (3) incentive spirometry training (Triflo-II), and (4) threshold load training of the inspiratory muscle. In the first stage (0-2 weeks), the aerobic exercise intensity was targeted to reach 10-11 points on the 20-point Borg rating of perceived exercise (RPE) scale. Patients raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min; in addition, they walked at a comfortable speed for 15 min twice per day. Incentive spirometry training (Triflo-II) was performed 8-10 times per hour. We used a threshold load trainer for inspiratory muscle training (30 breaths each time, twice per day) with the initial pressure set at 25%-30% of the maximum inspiratory pressure.
45815261|NCT04728295|Device|Exablate 4000|Exablate Pallidothalamic Tractotomy
45815262|NCT04738045|Drug|Remdesivir|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily.
45815263|NCT04738045|Drug|Lopinavir/ Ritonavir and Remdesivir combination|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days
45954566|NCT04864067|Radiation|5x5 Gy|Neoadjuvant Radiotherapy
45954567|NCT04864067|Behavioral|Quality of Life Questionnaires|Quality of Life Evaluation (LARS Score, IIEF, FSFI, I-PSS and EORTC QLQ-C30)
45954568|NCT04864067|Procedure|DRE/ Endoscopy|Flexible Sigmoidoscopy and Digital Rectal Exam
45954569|NCT00511303|Drug|STI571|
45954570|NCT00511381|Genetic|No intervention|No intervention
45954571|NCT00511420|Dietary Supplement|Cocoa product type 1|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks.
45954572|NCT00511420|Dietary Supplement|Cocoa product type 2|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
45954573|NCT00511420|Dietary Supplement|Cocoa product type 3|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
45954574|NCT00511420|Dietary Supplement|Cocoa product type 4|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
45954575|NCT00165828|Drug|Zonegran|Intravenous injection; initial daily dose of 50 mg zonisamide (2x25 mg) in both treatment groups; following a prospective or retrospective baseline phase of 8 weeks the study drug will be administered twice daily during 16 consecutive weeks.
45954576|NCT00511498|Drug|Sildenafil|50 mg daily at bedtime
45661023|NCT05493527|Device|noninvasive positive pressure ventilation|"NIPPV will be delivered by ventilator generating the targeted pressures. Infants will be on:~Peep ranging from 5 to 10 cmH2O,~Peak inspiratory pressure range 15-25 cmH2O~Rate range 40-50 breath/minute~FIO2 regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter."
45661024|NCT02558231|Drug|Macitentan|Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.
45661025|NCT02558231|Drug|Tadalafil|Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.
45954577|NCT00511576|Drug|MGCD0103 & Docetaxel|"In both Parts 1 and 2, subsequent doses of MGCD0103 will be escalated in 25 mg increments until the MTD of MGCD0103 in combination with each fixed dose (60 mg/m2 or 75 mg/m2) ofIV docetaxel is determined.~In both parts 1 and 2, MGCD0103 will be administered orally TIW for 3 weeks beginning on Day 1 at 1 hour prior to the start of the IV docetaxel infusion.~There will be no scheduled break between cycles and no limit to the number of cycles a subject can receive provided they do not have disease progression as defined by RECIST, or a clinically significant drug-related adverse event (AE) that does not resolve or respond to treatment intervention with 3 weeks."
45954578|NCT00511615|Procedure|Loop Electrosurgical Excision Procedure (LEEP)|Tissue sample removed from cervix using LEEP and contrast agent.
45954579|NCT00511654|Drug|GW823296 tablet|GW823296 immediate release tablets will be available as white film-coated tablets containing 5 milligrams (mg) and 20 mg of GW823296 for oral administration.
45954580|NCT00511654|Drug|GW823296 matching placebo|Matching placebo tablets will be identical in appearance to the GW823296 tablets.
45954581|NCT00511654|Drug|Midazolam|Midazolam will be administered as 5 milliliter (mL) of an intravenous solution for oral application (5 mg/5 mL, Dormicum).
45954582|NCT00150852|Drug|Vancomycin|
46002741|NCT00547664|Drug|Hylenex recombinant , morphine, saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with or without the preceded co-injection of Hylenex. Hospice patients include both home-bound patients as well as those under intensive care in hospice houses.
46078150|NCT04218162|Drug|Lasmiditan 50mg|Lasmiditan 50mg
46078151|NCT04218162|Drug|Lasmiditan 100mg|Lasmiditan 100mg
46078152|NCT04218162|Drug|Placebo|Placebo
46078153|NCT02690324|Behavioral|cognitive stress (serial 7)|
46078154|NCT03901404|Procedure|Myomectomy Operation|Patients undergoing myomectomy for myoma uteri
46078155|NCT00604799|Device|Talent Thoracic Stent Graft|TEVAR
46078156|NCT02821988|Device|External fetal monitor for Nonstress test|
46078157|NCT02821988|Device|Ultrasonography for Biophysical profile|
45454251|NCT01342718|Dietary Supplement|Herbal extract granule and placebo probiotics|"The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal).~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
45661026|NCT02558231|Drug|Selexipag|Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.
45676612|NCT01603316|Behavioral|surveys|Each survey will take about 45 minutes.Surveys will include questions on medical treatment, health insurance, work-related information, overall health and well being, eating habits, and satisfaction/use of the food program provided. 3 and 6-month follow-up. All participants will be asked to complete the study contact form. Need Assessment surveys will be administered via telephone or in person. The content of the needs assessment questionnaire has been informed by themes generated through IHCD's ongoing research and community outreach and service activities with the cancer patient population at our participating institutions. The survey will ask participants about the impact on their cancer care and their socioeconomic needs of the COVID-19 crisis.
45815264|NCT02755129|Other|Walking Exercises-Six Minute Walk (6MW) Test|The Six Minute Walk (6MW) Test measures the distance an individual is able to walk over a total of six minutes on a flat surface. The goal is for the individual to walk as far as possible in six minutes. The Six Minute Walk (6MW) test will be performed within the Computer Assisted Rehabilitation Environment (CAREN) system system environment - single arm
45815265|NCT02755129|Other|Walking Exercises-4 Meter Gait Speed (4MGS) Test|"The 4 Meter Gait Speed (4MGS) Test measures the gait speed an individual is able to walk over 4 meters on a flat surface. The goal is for the individual to walk as fast as possible over 4 meters.~It will be repeated 3 times within the aforementioned 6MW test (after approximately 1, 3 and 5 minutes) to get variability due to subject tiredness. The test will be performed within the CAREN system environment. - single arm"
45815266|NCT02755129|Other|Walking Exercises-Five Times Sit to Stand (FTSTS) Test|The Five Times Sit to Stand (FTSTS) Test measures the time a subject takes to stand up from an armchair 5 times in a row, without stopping in between. It is a short test which measures dynamic balance and functional mobility - single arm
46078158|NCT03886350|Other|blood and sputum samples|Blood and sputum samples for research purpose collected during routine tests performed at steady state and acute exacerbation
46078159|NCT05659706|Other|cognitive evaluations and non cognitive evaluations|Mini Mental State Examination Charlson Comorbidity Index Katz Index ICOPE step 1 The 15-item geriatric depression scale (GDS-15) Medical Outcomes Study Short Form 36 (SF-36) Short Physical Performance Battery ( SPPB)
46078160|NCT05380739|Behavioral|Working Memory Training|A 10-session working memory (WM) training program
46078161|NCT03842124|Other|Force gauge|The investigators postulate that use of bidirectional traction (superior and inferior directions) and feedback from a digital force gauge is associated with minimal lead displacement compared to conventional lead extraction.
46078162|NCT00606125|Drug|Nexavar (Sorafenib, BAY43-9006)|The purpose of this study is to: 1)evaluate how your body reacts to sorafenib when taken daily in combination with paclitaxel and carboplatin, 2) measure your blood levels of sorafenib, paclitaxel and carboplatin at specific times after taking the medication, and 3) to determine the safety of sorafenib.
45815267|NCT02755129|Other|Walking Exercises-Expanded Timed Get-Up-and-Go (ETGUG) Test|The Expanded Timed Get-Up-and-Go (ETGUG) Test measures the time it takes a subject to stand up from an armchair, walk a distance of 10 m, turn, walk back to the chair, and sit down. It is a short test of basic mobility skills for frail community-dwelling elderly. - single arm
45815268|NCT02755129|Other|Reveal LINQ accelerometer|Walking exercises test
46078163|NCT04242212|Behavioral|Misoprostol sourced from clinics|One cohort of women using misoprostol sourced from clinics
46078164|NCT04242212|Behavioral|Misoprostol sourced from PMVs|One cohort of women using misoprostol sourced from PMVs
45458122|NCT03551977|Behavioral|iCanCope with Pain|The participants are free to use the Norwegian iCanCope with Pain app as much as they want during the 8 week intervention period. The only support available is technical support.
45815269|NCT02755129|Other|3D accelerometer|Walking exercises test
45815270|NCT03106376|Other|16% O2 gas in breathed air|"Inspiratory gas mixtures: Hypoxic inspiratory gas will be obtained by adding nitrogen (N2) to normobaric, normoxic air with medical N2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
46078165|NCT02851433|Drug|total anaesthesia and postoperative inhaled sedation with Sevoflurane|
46078166|NCT02851433|Drug|total intravenous anaesthesia with Propofol.|
46078167|NCT05629806|Drug|Metformin plus pioglitazone|After the screening period, eligible subjects were admitted to two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. Then the subjects were titrated onto the alternative treatment of 50mg acarbose three times daily for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.
45954583|NCT00511693|Behavioral|centralized osteoporosis coordinator|The regional osteoporosis coordinator will phone fracture patients and counsel them about their risk of osteoporosis, reiterating messages in the print material. The coordinator will also follow-up with family physicians by phone and send them a patient-specific reminder that informs them that their patient has experienced a fracture and they are at high risk for future fracture. As part of the reminder, a set of evidence-based recommendations about appropriate BMD testing and treatment based on the recent Canadian guidelines will be included. If the patient does not have a family physician, the regional osteoporosis coordinator will facilitate referral to the MOP.
45954584|NCT00511693|Behavioral|fall prevention|Fracture patients from hospitals receiving falls prevention advice will also be called by the osteoporosis regional coordinator. The patient will receive educational material and telephone counseling regarding fall prevention. During the call, patients will be encouraged to visit their family physician for fracture follow-up. They will not receive counseling or educational materials about osteoporosis at this time. Patients in the falls prevention group will receive the physician and patient osteoporosis program six months post-fracture.
45954585|NCT02952235|Other|SPF50+|Sun protection
45954586|NCT02952235|Other|SPF100+|Sun protection
45954587|NCT02952391|Other|[18F] FEOBV PET scan|Cholinergic PET scan with the tracer [18F]Fluoroethoxybenzovesamicol
45815271|NCT03106376|Other|26% O2 gas in breathed air|"Inspiratory gas mixtures: Hyperoxic inspiratory gas will be obtained by adding oxygen (O2) to normobaric, normoxic air with medical O2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
45815272|NCT04670263|Device|Tear Film Imager|Tear Film Imager recording
46078168|NCT05629806|Drug|Acarbose|After the screening period, eligible subjects were admitted to 50mg acarbose three times daily for 12 weeks. Then the subjects were titrated onto the alternative treatment of two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.
45454252|NCT01342718|Dietary Supplement|Placebo herbal extract granule and probiotics|"The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).~The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule [7✕100,000,000 viable cells/strain]), 2 capsules per day (2 hours after morning and evening meal)"
45815273|NCT02755285|Device|Single Endoscopy Procedure|All subjects will have 1 endoscopy procedure, in which they will have a white light examination followed by FICE and BLI imaging on a maximum of two (2) anatomical sites per subject.
45815274|NCT02226120|Drug|LCZ696|Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
45954588|NCT00165867|Drug|E7070|
46002742|NCT00547664|Other|Saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with the preceded co-injection of saline.
46078169|NCT04239482|Dietary Supplement|L-arginine + Nitrate / Nitrite|Longer-term supplementation (8 weeks)
46078170|NCT04239482|Dietary Supplement|Placebo|Longer-term supplementation (8 weeks)
46078171|NCT05277649|Other|Exercise programme|Performing a programme of warm-up and stretching exercises for the cervico-mandibular region aimed at improving mobility and muscle condition.
46078172|NCT02745834|Other|Gait analysis|Gait will be analysed while participants will walk on a treadmill at different self selected speeds, using the OPTOGait system. Spatiotemporal measures are collected without the use of any markers.
46078173|NCT04242290|Diagnostic Test|Lateral radiography|The lordosis angles were measured on the lateral cervical graphs of all patients.
45954589|NCT03459274|Device|VR-Biofeedback|The intervention uses a smart phone with a virtual reality app; a headset that connects to the phone and has goggles that contribute to the 3 dimensional, interactive, and surrounding aspects of the experience; headphones through which subjects hear calming sounds and guiding voices from the experience; an attached microphone that allows subjects to monitor their breathing and interact with their environment through their breath; and a heart rate monitor whose realtime data on variability has an affect on the virtual environment. The virtual reality experience guides subjects through deep breathing exercises. Subjects will attempt to match a certain slow breathing rate, and pulse and breathing rate will cause non-stressful changes to the environment.
45454253|NCT01342718|Dietary Supplement|Placebo herbal extract granule and placebo probiotics|"The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
45454254|NCT00103558|Drug|Lumiliximab with FCR|Dose, schedule, and duration specified in protocol
45454255|NCT01336946|Behavioral|Psycho educational and behavioural group sessions|10 psycho educational and behavioural group sessions on topics like the Food Triangle, healthy eating, the importance of physical activity, healthy eating on a limited budget, implementing physical activity into the daily life, the influence of advertisements...
45454256|NCT01336946|Behavioral|Walking session|A weekly supervised walking session (30 minutes) in a 10-week period.
45454257|NCT05725954|Behavioral|GUT LINK SmartPath|A virtual care delivery and referral support tool for primary healthcare providers.
45954590|NCT02952430|Procedure|Emergency laparotomy|Patients already undergoing emergency laparotomy - groups divided pre-operatively into frail and not frail based on modified Rockwood score. Then outcomes observed.
45454258|NCT02284984|Drug|Rituximab with belimumab|Rituximab treatment on dag 0 and 14, 1000mg iv Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks through 72 weeks.
45454259|NCT01337102|Procedure|Physician Receives QoL results|Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician receives the print out of the results.
45454260|NCT01337102|Procedure|Physician Does not receive the results|Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician does not receive the print out of the results.
45454261|NCT00305188|Drug|Xaliproden (SR57746A)|oral administration
46078174|NCT02745756|Procedure|Autologous Hematopoietic Progenitor Cell Transplant|Autologous Hematopoietic Progenitor Cell (HPC) Transplant (HPCT). Blood stem cells will be collected by apheresis during the induction phase as part of standard treatment. During apheresis, the participant's blood is collected into a machine that filters out the stem cells and the filtered blood is returned to their body. The stem cells will be separated by the type of protein within the cells. Only the stem cells with a protein called CD34 will be used for the stem cell transplant.
45661027|NCT05487365|Device|Comunicare Solutions Smartphone Application|The Comunicare patient support solution is specifically designed for digital support of HF. It consists of an application for patients and a dashboard for the caregivers. The application is a class 1 certified medical device. It includes different modules for patient education, medication adherence, symptoms tracking, electronic patient-reported outcome (ePRO), appointments, and video consultation. Caregiver dashboard application: this web-based application enables caregivers to administrate the care flow and review all patient-reported data and the alarm generated by the system. Security and Privacy: the application complies with strict security and privacy-related regulations. All data storages are encrypted on the patients' smartphone and a server located in an ISO-certified data center located in Belgium, and all information exchanges are highly secured. A GDPR-compliant privacy notice defines how patient personal data is processed and how data protection principles are applied.
45661028|NCT05487365|Other|Completing a quality of life (QOL)-questionnaire|Patients refusing to use Comunicare app will also be asked to complete a quality of life (QOL)-questionnaire at 0, 6 and 12 months which will be answered online.
45661029|NCT05487287|Device|Kinematic computational analysis of the hand (Leap Motion device)|"Kinematic computational analysis exercises:~Finger extension~Wrist extension~Finger separation~Finger clamp"
45454262|NCT00305188|Drug|Placebo|oral administration
45815275|NCT02973919|Behavioral|Eye Movement Desensitization and Reprocessing Therapy|In 1989, Shapiro discovered that while talking about negative life events or thoughts, rhythmic eye movements on a horizontal axis can alleviate the associated vividness and burden (Shapiro, 1989). She established the psychodynamic-behavioral Eye Movement Desensitization and Reprocessing (EMDR) Therapy, which includes the induction of rhythmic eye movements as a central feature. EMDR is regarded as an efficient treatment tool. Several times it has also been successfully applied in the field of specific phobias (de Jongh, ten Broeke, & Renssen, 1999; de Jongh, Holmshaw, Carswell, & van Wijk, 2011; Lapsekili & Yelboga, 2014; Muris, Merckelbach, van Haaften, & Mayer, 1997) and there is a standard protocol for using EMDR on specific fears and phobias (de Jongh, 2015).
45954591|NCT04797728|Drug|Elacestrant|Elacestrant continuously at 400 mg given orally (PO), once a day, in a continuous schedule (QD) for 4 weeks (+/- 2 days)
45954592|NCT02951806|Drug|(R) Rapid spinal fentanyl injection|Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 20 seconds then 10 mg hyperbaric bupivacaine.
46078175|NCT02745756|Biological|KLH and Tumor Lysate Pulsed DC Vaccine|Keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine. Post-transplant vaccine days: +14, +28, +56 (± 10 days), +84 (± 10 days). Vaccines will be administered by intradermal injection of 0.5 mL at two nodal basins.
45454263|NCT00305188|Drug|Oxaliplatin|IV administration
45454264|NCT00305188|Drug|5-Fluorouracil|IV administration
45454265|NCT00305188|Drug|Leucovorin|IV administration
45454266|NCT01340534|Device|Supplemental oxygen 80% FIO2|Use of oxygen 80% FIO2 during surgery and 2 hours after the procedure. For this purpose an oxygen mask with reservoir will be used (to guarantee the supply of 80% oxygen during and after surgery)
45454267|NCT01340534|Procedure|Use of air (no oxygen during surgery)|No use of oxygen during surgery or in the 2 hours after the procedure.
45454268|NCT01340612|Device|endovascular coiling with any type of currently approved coil (first or second generation)|Standard procedure for endovascular coiling.Coils may be bare Platinum coils or any so-called second generation coils such as but not restricted to Hydrocoil or Cerecyte
45454269|NCT01340612|Device|endovascular stenting with or without coiling. The stent may be any of the currently approved stents for intracranial aneurysms.|Standard procedure for stenting. Addition of coils to the stent is left to the judgment of the treating physician
45454270|NCT02285218|Other|serum blood sampling|
45661030|NCT04269785|Device|Cryoballoon ablation|Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using cryoballoon catheter (cold therapy)
45815276|NCT02973919|Behavioral|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facili- tates the practice of exposure-based treatments especially for situations or places diffi- cult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been con- ducted or only in a limited manner (Mühlberger & Pauli, 2011).
45815277|NCT04587973|Procedure|Group Dexmedetomidine|Ropivacaine plus dexmedetomidine group
45815278|NCT04587973|Procedure|Group Ropivacaine|Plain ropivacaine group
45954593|NCT02951806|Drug|(S) Slow spinal fentanyl injection|Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 90 seconds then 10 mg hyperbaric bupivacaine.
45954594|NCT00512980|Drug|prednisone|
45954595|NCT00512980|Drug|vinblastine|
45954596|NCT00512980|Drug|doxorubicin|
45954597|NCT00512980|Drug|gemcitabine|
45954598|NCT00150891|Procedure|Kidney transplantation|
46078176|NCT04242368|Drug|Isotonic saline|Nasal isotonic saline irrigation (240 mL, 0.9% NaCl) administered through nasal rinse bottle.
45815279|NCT04587973|Procedure|Group Control|Control group
46078177|NCT04242368|Drug|Hypertonic Nasal Wash|Nasal hypertonic saline irrigation (240 mL, 1.8% NaCl) administered through nasal rinse bottle.
46078178|NCT04242368|Drug|Fluticasone Propionate|Fluticasone nasal spray administered two sprays to each nare twice a day
46078179|NCT00900835|Other|educational intervention|
46078180|NCT00900835|Other|questionnaire administration|
46078181|NCT00900835|Other|study of socioeconomic and demographic variables|
46078182|NCT00900835|Procedure|assessment of therapy complications|
46078183|NCT00900835|Procedure|fatigue assessment and management|
46078184|NCT00900835|Procedure|quality-of-life assessment|
46078185|NCT00900835|Procedure|standard follow-up care|
45454271|NCT05183906|Diagnostic Test|Next generation sequencing|Evaluation of microbiological culturing versus next generation sequencing for ribosomal DNA
45454272|NCT00297310|Drug|tacrolimus|
45454273|NCT01340690|Dietary Supplement|ω-3 fatty acids suspension|2 bags of Esprico(R) suspension given orally once daily in the morning for 84 days
45454274|NCT01340690|Dietary Supplement|placebo suspension|suspension to mimic verum Esprico (R) suspension. 2 bags of Esprico(R) placebo suspension given orally once daily in the morning for 84 days
45661031|NCT04269785|Device|Radiofrequency ablation|Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using radiofrequency catheter (heat therapy)
45661032|NCT05487209|Diagnostic Test|MRI,SCC-Ag|Magnetic Resonance Imaging examination,serum squamous cells carcinoma antigen
45954599|NCT00150891|Drug|cyclosporine A|
45954600|NCT00150891|Drug|tacrolimus|
45954601|NCT00150891|Drug|azathioprine|
45954602|NCT00150891|Drug|mycophenolate mofetil|
45954603|NCT00513058|Drug|Lapatinib|Dose level (DL) 1 : 750 mg/d DL2, DL3, DL4: 1000 mg/d DL5, DL7, DL8: 1250 mg/d DL6: 1500 mg/d
45954604|NCT00513058|Drug|vinorelbine|DL1, DL2: 20 mg/m2 DL3: 22.5 mg/m2 DL4, DL5, DL6: 25 mg/m2 DL7: 27.5 mg/m2 DL8: 30 mg/m2
45954605|NCT04782284|Other|Comprehensive swallowing rehabilitation|The treatment time per session is 30 minutes. Total 12 sessions are provided for 6 weeks.
46078186|NCT02745600|Device|RFA therapy simulator|Computer assisted RFA of liver tumors: Planning, simulation, and follow up,
46078187|NCT00905593|Drug|Nilotinib|
45954606|NCT04782284|Other|Swallowing education|The education is 30 minutes. Total 1 session is provided immediately after baseline evaluation.
45676613|NCT01603316|Behavioral|Focus groups|Prior to conducting the updated RCT design with the expanded cohort, we will conduct 4-6 focus groups (to saturation) with underserved breast cancer patients to optimally tailor the written materials, via mail, MSK Secure email, or in person and nutrition education sessions.
45954607|NCT00513097|Behavioral|Smoking Prevention Program|Interactive internet, computer-based activities (like games) with questions about thoughts on smoking and tobacco.
45454275|NCT00095290|Drug|Ramipril + Irbesartan|Tablets + Capsules, Oral, 10mg Ramipril + 300mg Irbesartan target dose, Once daily, 20 weeks.
45954608|NCT00513097|Behavioral|Focus Group|A total of 24 focus groups will be held relating to the topics of smoking prevention and cessation.
45954609|NCT00513097|Behavioral|Survey|On-line evaluations and questionnaires
45954610|NCT00513136|Behavioral|Group based mind body medicine intervention|Small groups of women (5-15) will participate in 10 weekly sessions that will include learning relaxation and yoga techniques, principles of exercise and nutrition, cognitive behavioral therapy and exploration of common issues and concerns
45954611|NCT00513136|Behavioral|Group-based mind body medicine intervention + family focus|In addition to the 10 weekly group-based sessions, women and their key family members will meet twice with a cognitive therapist and family members will participate in selected aspects of the 10 week program.
45454276|NCT00095290|Drug|Ramipril + Placebo|Tablets + Capsules, Oral, 10mg Ramipril + 300mg Placebo target dose, Once daily, 20 weeks.
45954612|NCT00405990|Behavioral|Voluntary counselling and HIV testing in ANC for PMTCT|VCT for 30 minutes in ANC
45954613|NCT00405990|Behavioral|VCT|HIV VCT for PMTCT
45954614|NCT02951962|Drug|Twynsta 80/5mg|Hypertension
45954615|NCT02951962|Drug|Crestor 20mg|Hyperlipidemia
45676614|NCT01566695|Drug|Oral Azacitidine|300 mg daily, days 1 to 21 of each 28-day treatment cycle
45676615|NCT01566695|Drug|Placebo|Identically matching placebo tablets on day 1 to 21 of each 28-day treatment cycle.
45815280|NCT02756689|Other|Inpatient cervical ripening|Subjects will undergo cervical ripening in the inpatient setting.
45815281|NCT02756689|Other|Outpatient cervical ripening|Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
45815282|NCT04766580|Behavioral|Placebo and nocebo effect|The intervention focuses on the speech and instructions given with each placebo (positive for the placebo effect and negative for the nocebo effect)
45954616|NCT02952040|Drug|ASP1517|Oral dose
45954617|NCT02952040|Drug|Lanthanum carbonate hydrate|Oral dose
45954618|NCT02952118|Device|Forrest Snoring device|
45454277|NCT05183750|Procedure|High tibial osteotomy|Opening wedge high tibial osteotomy will be done according to the measurement preoperatively and fixation will be by plate and screws.
45454278|NCT05183594|Dietary Supplement|TSupport (a Traditional Chinese Medicine)|TSupport is made up of 11 Chinese medicinal herbs.
45454279|NCT01340846|Drug|Warfarin|Warfarin dosed at 15mg on Day 1 and Day 22
45454280|NCT01340846|Drug|Ketoconazole|Ketoconazole dosed at 400mg daily on Days 19 through 22
45954619|NCT00513214|Drug|XOMA 052|"Part 1, Single IV infusion at one of six dose levels (mg/kg).~Part 2, Single SC injection at one of three dose levels (mg/kg).~Part 3, Three biweekly SC injections at one of two dose levels (mg/kg)."
45954620|NCT00513214|Drug|Placebo|"Part 1, Single IV infusion at one of six dose levels (mg/kg).~Part 2, Single SC injection at one of three dose levels (mg/kg).~Part 3, Three biweekly SC injections at one of two dose levels (mg/kg)."
45454281|NCT01340846|Drug|Gemfibrozil|Gemfibrozil dosed at 600mg twice daily on Days 19 through 22
45454282|NCT01340846|Drug|GSK2118436 150mg|GSK2118436 dosed at 150mg twice daily
45454283|NCT01340846|Drug|GSK2118436 75mg|GSK2118436 dosed at 75mg twice daily
45454284|NCT02285296|Other|personalized support program|"interview of the primary caregivers to identify their needs and expectations, the implementation of a personalized support program, including telephone follow-up"
45454285|NCT00398710|Drug|Perifosine|150 mg daily (100 mg daily in case of dose reduction)
45661033|NCT04275011|Other|Progressive Resistance and Impact Exercise|Full body resistance and impact exercises will be performed twice a week for 30-45 minutes over a 6 month period. There will be at least one day of rest between scheduled exercise sessions. Participants will be individually prescribed variations of push, pull, squat, lift and carry movements targeting major muscle groups that they can safely complete, and accessory exercises to help develop movement patterns. Exercises will challenge both the upper and lower body using functional movement patterns. Each muscle group will be trained twice a week. During the first month, participants will focus on completing exercises with good form at a low intensity. Once form is mastered, exercises will be progressed (by increasing load, or challenge of the movement) to a moderate to high exercise intensity (80-85% 1RM) so that the participant can complete a maximum of 8 (~80% 1RM) or 6 (~85% 1RM) repetitions with 1-2 repetitions in reserve for 3 sets at a rating of perceived exertion (RPE) of 8-9.
45676616|NCT01566695|Other|Best Supportiv Care (BSC)|BSC included and was not limited to packed RBC (packed red blood cell [pRBC] and whole blood), platelet transfusions (single donor or pooled donor), antibiotic, antiviral and/or antifungal therapy, nutritional support, and granulocyte colony stimulating factors (G-CSF) for participants who experienced neutropenic fever/infections.
45954621|NCT00513253|Drug|lapatinib|
45454286|NCT01342874|Dietary Supplement|Inositol|inositol exposure in early GDM
45454287|NCT00397696|Drug|[123I] 5-IA|All subjects will undergo written informed consent and a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations using the MMSE, the ANAM computerized cognitive battery, and other tests of executive function. All subjects will be evaluated with United Parkinson Disease Rating Scales (UPDRS) following an overnight withdrawal of anti-parkinson medication. Subjects will be asked to undergo an injection of [123I] 5-IA followed by SPECT imaging as described below. A second [123I] 5-IA and SPECT imaging study will be obtained for reliability testing between 2 weeks and 2 months following the initial [123I] 5IA imaging session.
45454288|NCT01337258|Drug|Dutasteride|dutasteride 0.5mg daily.
45454289|NCT01337258|Drug|Placebo|Men taking placebo daily
45454290|NCT00397228|Drug|ALTROPANE®|ALTROPANE® SPECT imaging
45454291|NCT02603809|Drug|Aprocitentan 5 mg|One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
45454292|NCT02603809|Drug|Aprocitentan 10 mg|Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.
45454293|NCT02603809|Drug|Aprocitentan 25 mg|One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
45454294|NCT02603809|Drug|Aprocitentan 50 mg|One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
45454295|NCT02603809|Drug|Lisinopril 20 mg|One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan
45454296|NCT02603809|Drug|Placebo|One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.
45454297|NCT01341002|Procedure|Transfusion|Red Blood Cells (RBC) Transfusion if SCVO2 < 70% and guidelines
45454298|NCT01341002|Procedure|Transfusion|transfusion based on guidelines
45454299|NCT00396448|Drug|CP-945,598 Treatment B|Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
45954622|NCT00513331|Procedure|Endoscopy|Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports. Repeat Endoscopic assessments are based on initial and follow-up assessments.
45954623|NCT00513331|Procedure|Radiofrequency ablation protocol|Ablation using the HALO 360 system according to protocol established by BARRX, Inc.
45954624|NCT00513331|Procedure|Endoscopic mucosal resection protocol|Excision of lesion using DUETTE, marketed by Wilson-Cook
45954625|NCT00150930|Device|narrowband UVB phototherapy at home|
45954626|NCT00513448|Other|Group wellness intervention|
45954627|NCT00513448|Other|Individualized physical rehabilitation|
45454300|NCT00396448|Drug|CP-945,598 Treatment A|Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
45454301|NCT00396448|Drug|Placebo|Subjects receive placebo plus dietary, physical activity, and behavioral counseling.
45454302|NCT01341158|Drug|human interferon-α|Neoadjuvant treatment: Multiferon is given as flat dosages (3 - 9 - 18 MIU) 5 days per week, subcutaneously for 4 weeks
45815283|NCT04558177|Device|Direct current stimulator|HDCprog connected to a direct current stimulator, controls the number of stimulations (maximum 99), the intensity (up to 1.5mA per channel), the duration (maximum 20min), and the minimum interval between two consecutive simulations (max 1168 hours). A sham condition is also available which will ramp the stimulation to a preset maximum level and then immediately reduces the stimulation to 0.
45815284|NCT04516915|Drug|IMU-838|IMU-838 twice daily at 22.5mg doses for 14 days
45815285|NCT04516915|Drug|Oseltamivir|Oseltamivir twice daily at 75mg doses for 14 days
45815286|NCT02757326|Drug|Opaganib|Opaganib, [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (N-(Pyridin-4-ylmethyl)pyridine-4-carboxamide) amide, hydrochloride salt] is an orally available inhibitor of the enzyme SK2.
45815287|NCT02757950|Biological|Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]|Subjects were included in the Exposed cohort if they received Refortrix as part of the maternal immunization program in Brazil.
45815288|NCT05348408|Drug|platelet rich plasma|perineural PRP injection under ultrasound guidance in addition to medical treatment
45815289|NCT02753881|Drug|whole liver lobe cTACE doxorubicin|Doxorubicin CTACE administered in a whole liver lobe manner.
45815290|NCT02753881|Drug|superselective cTACE doxorubicin|Doxorubicin CTACE administered in a super-selective (close to the tumor) manner.
45815291|NCT00425360|Biological|sargramostim|
45815292|NCT00425360|Biological|telomerase peptide vaccine GV1001|
45815293|NCT00425360|Drug|capecitabine|
45815294|NCT00425360|Drug|gemcitabine hydrochloride|
45815295|NCT05349253|Dietary Supplement|Garlic extracts|One intake in total
45815296|NCT05349253|Dietary Supplement|Placebo|One intake in total
45815297|NCT04337437|Drug|Genakumab|150 mg/1ml/bottle, single subcutaneous injection.
45815298|NCT04337437|Drug|Placebo for this trial|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.
45815299|NCT05348096|Drug|Low-dose ibrutinib|Daily ibrutinib (140mg QD) and itraconazole (100mg BID) for six months.
45815300|NCT04337359|Drug|Ruxolitinib|5 mg. Tablet
45815301|NCT04337606|Drug|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance; Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
45815302|NCT04337606|Drug|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
45815303|NCT04337606|Drug|Camrelizumab|Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
45454303|NCT00393952|Drug|Fluticasone propionate/Formoterol fumarate 250/10|FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
45454304|NCT00393952|Drug|Placebo|Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
45454305|NCT00393952|Drug|Fluticasone propionate/Formoterol fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
45815304|NCT02759354|Other|Blood Sample|Blood sample at approx. 4 years of age
45815305|NCT01190306|Device|The VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
45815306|NCT01190306|Drug|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
45815307|NCT02759575|Drug|Pembrolizumab|200mg every 3 weeks starting 3 weeks prior to chemoradiotherapy. Maximum of 4 doses
45815308|NCT02759575|Radiation|Radiation Therapy|70 Gy in 35 fractions over 7 weeks
45815309|NCT02759575|Drug|Cisplatin|100 mg/m2 every 3 weeks starting on day 1 of chemoradiotherapy. Maximum of 3 doses.
45815310|NCT02760056|Drug|Liothyronine sodium|Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.
45815311|NCT02760056|Drug|Placebo|Patient will receive a matching placebo to take twice daily for one week.
45815312|NCT02764970|Drug|Ivabradine 7.5mg orally|additive use to the standard medication with bisoprolol
45815313|NCT05336006|Other|High-intensity aerobic training with high protein diet|"High-intensity aerobic training (HAT) was given at 50 to 70 percent of maximum heart rate. Subsequent to stretching, the subjects were asked to do 30 mins of HAT exercises; consisting of 20 mins on the treadmill and 10 mins on a cycle ergometer at 50 to 70 % of MHR, lastly, 10 mins of cool down was performed.~Next the participants, in this group A were prescribed with strength training exercises with resistance depending upon each subject's individual muscle assessment.~In addition to these physical training exercises, this group also received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (>1 g/kg aBW/d), as prescribed by a qualified nutritionist."
45815314|NCT05336006|Other|Control group|This group is considered a control group and they were allowed to follow their regular physical activities and dietary pattern.
45815315|NCT05320718|Drug|Ropivacaine|20 ml of 0.5% ropivacaine as bolus and a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery
45815316|NCT05314166|Other|meditation practice|Description: meditation practice
45954628|NCT02951611|Procedure|Acupuncture stimulation|Transcutaneous electrical acupoint stimulation on SI3, SJ6, PC6 and LI4
45954629|NCT02951611|Procedure|Sham stimulation|Put electrodes on SI3, SJ6, PC6 and LI4 without stimulation
45815317|NCT05302544|Other|Mixed Reality training|Mixed Reality training: Mixed Reality game with appearance of virtual balloons in the game area that the subject must find and pierce with finger
45815318|NCT05302544|Other|motor activities|motor activities usually performed
45815319|NCT02739698|Drug|Paclitaxel|
45815320|NCT02739698|Procedure|Radical surgery-peritonectomy|
45815321|NCT00371618|Procedure|Fluoroscopy|
45954630|NCT04759547|Device|handheld ultrasound-assisted technique|Ultrasound with 3D navigation function is used to determine the needle insertion point and the insertion angle.
45954631|NCT04759547|Other|conventional palpation-guided technique|The interspinous space is detected by palpation
45954632|NCT04695496|Device|Theta bust stimulating|Theta burst stimulation with Magstim super rapid 2, over SMA. 3 section per day, for 5 days, total 15 sections.
45954633|NCT02951689|Dietary Supplement|Probiotic|
45954634|NCT02951689|Dietary Supplement|Placebo|
45954635|NCT00513487|Drug|Dust mite extract, Fluticasone, Methacholine|Dust mite extract, Fluticasone, Methacholine
45454306|NCT00393952|Drug|Fluticasone propionate 250|Fluticasone 250 is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
45454307|NCT00393952|Drug|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
45454308|NCT01341236|Other|different nutrional regimen|compare bolus versus intermittent nutrition
45454309|NCT01341236|Other|comparison of different feeding regimens|compare intermittent versus bolus nutrition
45454310|NCT02285374|Drug|Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir|Arm 1: Switch efavirenz to dolutegravir immediately (at baseline) for 12 weeks Arm 2: Continue on pre-study regimen (unchanged) for 4 weeks and then switch efavirenz to dolutegravir for 12 weeks
45454311|NCT00391066|Drug|FCR + Lumiliximab|Dose, schedule, and duration specified in the protocol
45454312|NCT00391066|Drug|FCR|Dose, schedule, and duration specified in protocol
45454313|NCT01112449|Other|Placebo|no active medication
45454314|NCT01112449|Dietary Supplement|selenomethionine|200 µg/day of selenomethionine (SM)
45954636|NCT02951572|Device|NIV|
45954637|NCT00405236|Drug|tiotropium|
45954638|NCT00513565|Drug|single dose|Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.
45954639|NCT00403949|Drug|Azelaic acid 15% gel|gel, applied once daily, for 6 weeks
45954640|NCT00403949|Drug|Non-active base from azelaic acid 15% gel|gel, apply once daily for six weeks
45954641|NCT00513643|Drug|insulin aspart|6, 12, 24 U s.c.
45954642|NCT00513643|Drug|human regular insulin|6, 12 and 24 IU sc
45954643|NCT00151008|Drug|Bexarotene/NBUVB vs placebo NBUVB|
45954644|NCT00513760|Dietary Supplement|Grapefruit juice|Coingestion of 240 ml of grapefruit juice with 10 mg of montelukast.
45954645|NCT00513760|Dietary Supplement|Orange Juice|Coingestion of 240 ml of orange juice with 10 mg of montelukast.
45954646|NCT00513760|Dietary Supplement|Gatorade|Coingestion of 240 ml of Gatorade with 10 mg of montelukast.
45954647|NCT00513877|Drug|bortezomib|
45954648|NCT00513877|Procedure|quality-of-life assessment|
45954649|NCT00405314|Device|Continuous positive airway pressure ventilation mask|
45954650|NCT04695613|Drug|Aminoacid|amino acid infusion 150 ml/kg/hr starting preoperative
45954651|NCT04695613|Drug|Magnesium sulfate|magnesium sulphate bolus and infusion 60 mg/kg starting preoperative
45954652|NCT00151047|Drug|Capecitabine|
45954653|NCT00151047|Drug|Docetaxel|
45954654|NCT00513916|Dietary Supplement|soy isoflavones|High or low dose of soy isoflavones in the diet.
45954655|NCT00513955|Drug|bortezomib|
45661034|NCT04275011|Other|Static Balance and Postural Exercise|Participants in the attention control group will perform static posture and balance exercises (e.g., low intensity yoga poses) and will be given the same attention as the participants in the intervention group. The small group exercises will be performed twice a week, 30-45 minutes per session, over 6 months, with at least one day of rest between each session. The exercise program will be supervised by a certified personal trainer and yoga instructor who is BoneFit trained.
45815322|NCT02766374|Behavioral|Heart rate variability biofeedback|"Biofeedback teaches voluntary control of physiological functions by providing instantaneous feedback of variations in that bodily activity. Feedback usually is given in the form of visual and/or auditory signals derived from physiological recording devices. Among its salutary effects is a sense of medical self-efficacy, i.e., less dependency on medical professionals for maintaining personal health.~The HRV-BF protocol we have developed and propose to examine herein works by a different pathway. It involves teaching the individual to increase the amplitude of heart rate accelerations during inhalation and de-celerations during exhalation, thus increasing the amplitude of respiratory sinus arrhythmia (RSA)."
45815323|NCT02766374|Behavioral|Placebo|"The method consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate."
45815324|NCT05284760|Drug|Soticlestat|Soticlestat T4 tablets.
45815325|NCT05284760|Drug|Soticlestat|Soticlestat T3 mini-tablets.
46078188|NCT04217226|Device|Perfusion index derived parameters|"The PVI and PI will be recorded in the supine position by an anaesthesiologist who was not involved in the further intraoperative monitoring of the patient using Masimo SET (MightySat 9900, Masimo Corporation, Irvine, CA, USA). This device allows bluetooth radio for transfer of parameter data to a smart device. The device will be applied on the index finger of the dominant hand of each patient. It will be applied on the hand that neither contains the venous line nor the blood pressure cuff. Three measurements of PVI and PI on one minute interval will be recorded. We will use the average of these readings.~Dicpleth is defined as the ratio of the height of the dicrotic notch to the height of the systolic peak, measured at end-expiratory time."
46078189|NCT04034563|Procedure|1) Risk of metachronous advanced neoplasia at 3-year, beyond 3 years surveillance colonoscopy|"3-year group: High-risk subjects who have baseline colonoscopy done in 2014, 2015 and 2016 and will be eligible for 3-year surveillance colonoscopy in 2017-2019.~Beyond 3 years group: High-risk subjects who had screening colonoscopy prior 3 years, but not received or scheduled for a surveillance colonoscopy- either due to non-adherence or limited access to surveillance colonoscopy will be eligible for surveillance colonoscopy in 2017-2019.~For the surveillance interval beyond 3 years group, recruitment will be prioritizing to subjects who had the screening colonoscopy at the earliest date. This will in part ensure that subjects in this group will consist those with the longest surveillance interval, leading to an applicable estimation of the risk of metachronous advanced neoplasia beyond 3 years surveillance interval."
45661035|NCT05481047|Device|HPI|based on HPI values, clinicians will administer drugs or fluids in order to avoid arterial hypotension
45815326|NCT05284760|Drug|Soticlestat|Soticlestat commercial tablets.
45954656|NCT00513955|Drug|cyclophosphamide|
45954657|NCT00513955|Drug|doxorubicin hydrochloride|
45954658|NCT00513955|Drug|prednisolone|
45954659|NCT00513955|Drug|vincristine sulfate|
45954660|NCT00513955|Other|questionnaire administration|
45954661|NCT00513955|Procedure|quality-of-life assessment|
45954662|NCT04735796|Drug|Drug：LM-102|Traditional '3+3' escalation design will be used. Dose escalation consists of five ascending dose levels of LM-102 (3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg and 40 mg/kg). All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-102 as a 2 h (120±10 min) intravenous (IV) infusion until the disease progression, intolerance, subject discontinuation/informed consent withdrawal, or at the discretion of the investigator in consultation with sponsor, at most till by one year.
45954663|NCT00513994|Drug|Nitroglycerin|MQX-503 1%, a topical microemulsion of nitroglycerin 1% and Nitroglycerin Ointment 2%, USP
46078190|NCT00937391|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-6661)|For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist. Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
45454315|NCT01112449|Dietary Supplement|low dose selenized-yeast|200 µg/day of SY
45676617|NCT01560819|Drug|Gut Microbial Transplantation|Each participant received Gut Microbial Transplantation (GMT) as retention enema over a period of 1 hour (60mL enema every 15 minutes) daily for 5 days. Although 240mL of GMT solution was prepared for each participant, the final administered dose was dependent on the subject's comfort and willingness to proceed with the next enema, which was assessed after each enema infusion. Subjects were monitored for 30 minutes after GMT for any immediate adverse events and discharged.
45815327|NCT04336904|Drug|Favipiravir|"Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction"
45815328|NCT04336904|Other|Placebo|"Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction"
46078191|NCT04217148|Drug|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
46078192|NCT04217148|Drug|ATRA|ATRA, po,10mg bid, for 12 weeks
46078193|NCT00905671|Device|LipiScan Coronary Imaging Catheter|Intravascular near infrared spectroscopic imaging of the coronary artery with a fiberoptic catheter.
46078194|NCT04195802|Other|Salt and potassium Diet|Self-administration questionnary to evaluate the salt and potassium consumption
45661036|NCT05480969|Other|Heart failure educational intervention|Educational intervention constitutes of a face-to-face session delivered before hospital discharge and outpatient sessions on regular intervals for a total of 6 months. Outpatient sessions in Intervention group 1 constitute of two home-based sessions on months 1 and 3, combined with weekly telephone calls during month 1 and bi-weekly calls during months 2-6. Outpatient sessions in Intervention group-2 constitute of weekly telephone sessions during month 1 and bi-weekly calls during months 2-6. The pre-discharge session will address self-monitoring and health awareness. Education will be provided by in-person discussion and through printed supporting material. Caregiver education will include understanding heart failure and advice on how to support their patient, manage their own health and well-being and how to get help when needed. During outpatient sessions, repeat education will be done and evaluation of implementation of self-care activities.
45661037|NCT05480813|Device|Automated KINCISE™ impaction system versus handheld traditional mallet|The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument.
45661038|NCT05480813|Other|Efficiency and ergonomics analysis and physical assessments|Operational efficiency, ergonomic impaction, cognitive/physical/stress level evaluations,
45454316|NCT01112449|Dietary Supplement|high dose selenized-yeast|285 µg/day of SY
45454317|NCT01341392|Drug|CKD-501|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
45454318|NCT01341392|Drug|amlodiopine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
45454319|NCT01341392|Drug|CKD-501 amlodipine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
45454320|NCT03946189|Diagnostic Test|Obtaining arterial blood gases|Obtaining arterial blood sample
45661039|NCT05480579|Biological|placebo|Dose4 placebo of single IV injection
45661040|NCT05480579|Biological|IBI311|Dose2 IBI311 of single IV injection
45661041|NCT05480579|Biological|IBI311|Dose4 IBI311 of single IV injection
45661042|NCT05480579|Biological|placebo|Dose3 placebo of single IV injection
45661043|NCT05480579|Biological|placebo|Dose1 placebo of single IV injection
45661044|NCT05480579|Biological|IBI311|Dose1 IBI311 of single IV injection
45661045|NCT05480579|Biological|IBI311|Dose 3 IBI311 of single IV injection
45661046|NCT05480579|Biological|placebo|Dose2 placebo of single IV injection
45661047|NCT05480501|Biological|IM19 CAR-T cells|IM19 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
45661048|NCT05493371|Drug|Empagliflozin 10 MG|10 mg once daily empagliflozin oral tablets for 12 weeks
45661049|NCT05486819|Drug|Propofol Injection|adding lignocaine or sodium bicarbonate to propofol to reduce pain during injection
45815329|NCT02767934|Other|Laboratory Biomarker Analysis|Correlative studies
46078195|NCT04191720|Other|Weighted blanket|Patients that were randomly assigned to the intervention group received a weighted blanket to use at their will to reduce anxiety
46078196|NCT00900913|Drug|ropivacaine (Naropin)|intravenous infusion 1 mg/kg bw
46078197|NCT04216836|Dietary Supplement|Magnesium oxide|Magnesium capsule
46078198|NCT04216836|Dietary Supplement|Placebo|Cornflour capsule manufactured to mimic the 166.6 mg magnesium capsule.
45454321|NCT05186792|Other|Test:mycoplasma|Retrospective analysis of records of recruits to a previous mycoplasma study.
45454322|NCT03635762|Behavioral|Be In Charge|comparison of pre and post-program weight and calorie intake
45454323|NCT04390958|Drug|nab-paclitaxel|125mg/m2 ivgtt d1、d8
45815330|NCT02767934|Biological|Pembrolizumab|Given IV
45661050|NCT05480423|Behavioral|Mindfulness-based intervention|1. Psychoeducation video on mindfulness and mindful parenting. 2. Audio files of mindfulness exercises including mindfulness of breath, body scan, mindful stretching, mindfulness of soles of the feet, befriending exercises. 3. Informal mindfulness exercises by applying mindfulness in daily lives
45815331|NCT02194998|Drug|Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)|PTV/r/OBT: 150/100/25 mg (two 75/50/12.5 mg fixed-dose combination tablets) orally once a day
45661051|NCT05480345|Diagnostic Test|Impedance cardiography|Transthoracic impedance cardiography recorded with ICG monitor (niccomoTM; Medis, Ilmenau, Germany): electrodes attached to both sides of the patient's neck (4 electrodes in total) and along the midaxillary line of the left and right sides of the chest (4 electrodes in total), employing the xyphoid process as a reference line.
45454324|NCT04390958|Drug|Cisplatin|60mg/m2 ivgtt d1 or d1-2
45661052|NCT02554877|Drug|PF-06291874|study drug to be given as an oral tablet at 30, 60 or 100 mg
45454325|NCT04390958|Drug|Capecitabine|1750mg/m2 po bid d1-14
45454326|NCT03946033|Diagnostic Test|Immunoscore Colon Test|Immunoscore Colon is a CE-marked in-vitro diagnostic test, allowing the quantification of CD3 and CD8 positive cells in formalin-fixed paraffin-embedded (FFPE) tissue samples of primary colon cancer. The test uses immunohistochemistry, digital pathology techniques and a dedicated software.
45454327|NCT02285452|Drug|Zingiberis Rhizoma plv.|
45454328|NCT02285452|Drug|Sinapis nigrea semen|
45454329|NCT02285452|Drug|Placebo|
45661053|NCT02554877|Drug|Placebo|oral tablet
45661054|NCT05486741|Other|Optical cehernce tomography|OCT macula and disc
45661055|NCT05493137|Other|No intervention will be provided|No intervention will be provided, this is an observational study
45661056|NCT05480267|Procedure|surgical treatment for lumbar spondylolisthesis|There are two surgical treatments for lumbar spondylolisthesis; one is UBE, and another is MIS-TLIF
45661057|NCT05480189|Other|Non-intervention|Non-intervention,with real world study
45815332|NCT02194998|Drug|Dasabuvir (DSV)|DSV: 250 mg orally twice a day
45815333|NCT02194998|Drug|Ribavirin (RBV)|RBV: 1,000 or 1,200 mg (weight-based) dosed in two divided doses orally twice a day (all participants (version 1); only participants with HCV genotype 1a (version2))
45954664|NCT00514033|Biological|Poliomyelitis vaccine (inactivated) -PoliorixTM|Deep intramuscular injections for the primary vaccination and booster vaccination.
45954665|NCT00166062|Procedure|Screening patients for IPV|
45454330|NCT05136950|Procedure|Secondary in-the-bag IOL fixation|The experimental group with secondary IOL fixated in the capsular bag
45454331|NCT05136950|Procedure|Secondary ciliary sulcus IOL fixation|The control group with secondary IOL fixated in the ciliary sulcus
45954666|NCT00514072|Biological|BCG vaccine|given intradermally
45954667|NCT00514072|Biological|prostate cancer vaccine ONY-P1|given intradermally
45954668|NCT00514072|Other|placebo|given intradermally
45954669|NCT04735640|Behavioral|nurse-led teleconsultation|Patients assigned to this group will receive personalized dietary and physical activity advice during 9 months. Behavioural goals and action plans will be developed in a stepwise manner in accordance with baseline levels of nutritional and physical activity adherence to recommendations.
45954670|NCT04735640|Behavioral|SMS|Patients assigned to this group will receive a total of 150 text messages (4 to 5 messages per week during weekdays) throughout the intervention period (9 months). The content of the text messages includes advice on diet and exercise.
45954671|NCT02951650|Device|Cyberonics VNS|Vagus nerve stimulation
45661058|NCT05493059|Other|Data collection|o Retrospective data collection in database from medical records (clinical, parasitological and therapeutic data)
45661059|NCT05493059|Other|Questionnaires|"o Administration of two standardized questionnaires by telephone in prospective:~Dermatology Life Quality Index (DLQI)~Treatment Satisfaction Questionnaire for Medication (TSQM)"
45815334|NCT05263232|Other|Natural or artificial office light exposure|Over 4.5 days, participants will stay at our research facilities under different light conditions. Over these days different measurements will take place, including 24h continuous glucose monitoring, 24h blood and saliva sampling, 24h blood pressure and heart rate assessments, 24h core and skin temperature assessments, 24h energy expenditure and whole-body substrate metabolism, and a skeletal muscle biopsy and a mixed meal tolerance test with indirect calorimetry will be performed on the respectively last test day.
45954672|NCT00514111|Drug|pegylated-interferon, conventional-interferon, ribavirin|Genotype 1: pegylated-interferon 2a or 2b plus ribavirin for 48 weeks. Genotype 3: conventional-interferon 2a or 2b plus ribavirin for 24 weeks.
45954673|NCT00151086|Drug|Estramustine|
46078199|NCT00937157|Drug|Copaxone|12 MS patients will be enrolled on GA (Copaxone®) monotherapy (20mg/day sc). Initial intravenous steroid treatment will be given on day 0. 1.5T and 3T scans will be obtained and according to the following schedule: 1 gm Solumedrol i.v. daily for three days. Intravenous steroids will be also allowed for treatment of MS attacks according to the following schedule: 1 gm Solumedrol i.v. daily for three days.
46078200|NCT00907309|Behavioral|iMET|Participants will receive the iMET intervention
45458123|NCT03551977|Behavioral|iCanCope with Pain control|The participants are free to use the Norwegian iCanCope with Pain control app as much as they want during the 8 week intervention period. The only support available is technical support.
46078201|NCT00907309|Behavioral|iMET/TE|Participants will receive the iMET intervention and also receive TEs (Technological Extenders)
45661060|NCT05492981|Behavioral|Enhanced (intervention) education|See arm description
45661061|NCT04235465|Other|Dynamic Gait Index|The Dynamic Gait Index (DGI) measures functionality and dynamic balance in walking and stair climbing. The DGI consists of 8 items including normal gait on flat ground, gait with speed changes, gait with horizontal head movements, gait with vertical head movements, gait and pivot turn, gait and step over an obstacle, gait around obstacles and steps up and downstairs. The performance on each item is rated on a 4-point scale ranging from 0 (severe disorder) to 3 (independent walking). The total score is 24.
45661062|NCT05486429|Combination Product|Abdominal ultrasound and lipid profile|"All patients will be subjected to: -~Complete history taking with stress on:~Age, sex, comorbid conditions (diabetes, hypertension, ischemic heart disease)~History of intake of lipid lowering drugs.~Thorough clinical examination:~General examination, vital sign, height, weight, body mass index. Abdominal examination (hepatomegaly, splenomegaly, ascites)~Laboratory Investigation:~1.Lipid profile (total cholesterol, triglyceride, HDL, LDL, VLDL (~.2Liver function tests (ALT, AST, Albumin, Bilirubin, PT, PC, INR) 3.Complete blood picture. 4.Serology for HBV, HCV. 5.Serum creatinine. 6.Fasting and postprandial blood sugar.~Radiological Investigation:~1.Abdominal ultrasound.~FIB - 4 it combines platelets count, ALI, AST and age.~AST/Platelets ratio index is calculated as (AST/upper limit of normal range) /Platelets count (10^9/L) ×100."
45954674|NCT00151086|Drug|Vinorelbine|
45954675|NCT00514150|Drug|Sodium Bicarbonate plus normal saline 0.9%|IV sodium bicarbonate 8.4% solved in 154 mEq/ L NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
45954676|NCT00514150|Drug|normal saline 0.9%|IV 154 mEq/L solution of NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.)
45815335|NCT05257850|Device|High-flow nasal therapy|A high-flow nasal therapy for 30 minutes.
46078202|NCT05659472|Behavioral|Combination mindfulness spiritual-based cognitive therapy plus hypnosis|The intervention was divided into eight components in eight sessions, namely (1) psychoeducation and intention, (2) awareness of breathing mindfulness, (3) body scan, (4) comfort training through daily activity/comfort exercises, (5) self-compassion / having a great soul with acceptance, gratitude, and sincerity, (6) planning happiness through independent healthy behavior targets, (7) independent healthy behavior (8) independent healthy behavior evaluation. Each therapeutic component of each session is further divided into three sub-components, namely psychoeducation, training, and hypnosis.
45815336|NCT05257850|Device|Airflow directed to face by a fan|A fan directed to the face for 30 minutes
45815337|NCT02194062|Drug|fluticasone nasal spray|use 2-50 mcg sprays to each nostril two times per day
45661063|NCT05492903|Behavioral|COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP)|A peer-led and supportive group program (10 weekly sessions) designed to address the needs of HCWs with chronic or elevated pain. The intervention will integrate work-based injury protections with pain education and cognitive-behavioral therapy strategies for pain self-management.
45661064|NCT05486351|Other|Observation|Patients are observed for stroke or systemic embolism and haemorrhagic transformation
45661065|NCT05475587|Other|Routine care|Both two groups received the same routine care.
45661066|NCT03862781|Procedure|Right Hemicolectomy|Minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis.
45815338|NCT02194062|Drug|Budesonide head upright|(0.5 mg/2mL) to instill into each nostril in the upright position two times per day
45661067|NCT03860987|Drug|goserelin|Goserelin will be administered SC at 10.8 mg every 12 weeks
45815339|NCT02194062|Drug|Budesonide head forward|(0.5 mg/2mL) to instill into each nostril in the head forward position two times per day
45815340|NCT02768558|Radiation|Radiation Therapy (RT)|2 Gy fractions once a day, 5 days per week, for a total of 60 Gy in 30 fractions.
45815341|NCT02768558|Drug|Cisplatin|Concurrently with radiation therapy, 50 mg/m2, IV, on days 1, 8, 29, and 36, to begin with day 1 of radiation therapy.
45815342|NCT02768558|Drug|Etoposide|Concurrently with radiation, 40 mg/m2, IV, on days 1-5 and 29-33, to begin with day 1 of radiation therapy.
45815343|NCT02768558|Drug|Nivolumab|Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
45815344|NCT02768558|Other|Placebo|Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
45815345|NCT00372164|Procedure|American Society of Interventional Pain Physician Guidelines|
45815346|NCT00372242|Behavioral|Prospective Longitudinal Interventional Stury|
45815347|NCT02193828|Biological|Collagenase clostridium histolyticum|Single injection into nodule
45815348|NCT02193828|Biological|Placebo|Single injection into nodule
45815349|NCT04738136|Drug|S-1226|S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in vapour form within a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8%, or 12% CO2
45815350|NCT02772302|Device|mindBEAGLE EEG-based brain-computer interface|
45815351|NCT05196776|Device|Portable, handheld point-of-care ultrasound device|The patient will have an ultrasound performed using a handheld, portable device.
45815352|NCT05196776|Device|Cart-based point-of-care ultrasound device|The patient will have an ultrasound performed using a traditional cart-based model.
45815353|NCT02192970|Drug|Bevacizumab|
45815354|NCT05173532|Other|Balance Training|static and dynamic balance and gait stability exercises
45815355|NCT05173532|Other|Breathing and Stretching Exercises|static stretching while performing diaphragmatic breathing
45815356|NCT05162144|Procedure|Proximal Medial Gastrocnemius Recession|Patients will be operated with PMGR as described by Barouk. No additional procedures will be performed. The surgery will be performed with the patients in a prone position under local anaesthetics. A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied. Patients will be instructed to continue the stretching exercises and fully weight-bear from the first postoperative day. If needed, the patients will be allowed to use crutches during the first 2 weeks after surgery. Sutures are removed 2-3 weeks after surgery.
45815357|NCT05149352|Behavioral|Treatment as usual (TAU) for depression|TAU for depression will be largely determined by the Dutch multidisciplinary practice guideline on depression (Spijker et al., 2013). This means that patients with CT-related depression will receive good clinical care, e.g. evidence-based psychotherapeutic interventions, such as cognitive behavioral therapy (CBT) or interpersonal therapy (IPT) combined with/or pharmacotherapy. Therapists who give TAU are not allowed to provide a trauma-focused intervention aimed at CT during the 12-week intervention period.
45835862|NCT04752930|Diagnostic Test|ctDNA monitoring|Patients who undergoing radical surgery for colorectal cancer for 6~12 months and with 2 consecutive positive ctDNA testing results within 1 month will be enrolled, and diagnostic laparoscopy will be performed immediately after enrollment. Patients with positive peritoneal metastasis (PCI score <20) will be treated with CRS+HIPEC. Tumor markers, endoscopic and imaging examinations, and ctDNA monitoring will be performed every 3 months in patients with negative peritoneal metastasis. Laparoscopy will be performed when imaging suggested peritoneal metastasis (oligometastases). Re-diagnostic laparoscopy will be performed 24 months after radical surgery when there is no radiographic evidence of recurrence or metastasis. Follow-up time will up to 36 months after colorectal cancer surgery.
45954677|NCT00514189|Biological|Autologous Dendritic Cells|The first vaccination will be given once your blood counts have recovered from the final dose of chemotherapy. The remaining 3 vaccinations will be given every 28 days (+/- 7 days).
45661068|NCT03860987|Drug|Enzalutamide|Enzalutamide will be given orally at 160mg once daily
45661069|NCT03860987|Drug|Abiraterone|Abiraterone will be taken orally at 1000 mg once daily
45661070|NCT03860987|Drug|18F-DCFPyL|18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
45661071|NCT03860987|Drug|Prednisone|Prednisone will be taken orally at 5mg twice a day for each dose, or 10 mg once a day. Doses should be taken about 12 or 24 hours apart
45661072|NCT03860987|Procedure|Radical Prostatectomy|Radical Prostatectomy
45661073|NCT05480111|Drug|Local anesthesia at incision site|20 ml of 0.25% Bupivacaine will be given at incision site
45676618|NCT01497184|Procedure|HSCT|Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures
45458124|NCT03508102|Drug|remifentanil|the effects of remifentanil on the average value of BIS at the time period of before induction , induction , intubation , skin incision, peritoneum incision, uterine incision, and delivery
45661074|NCT05480111|Drug|Sham QL|20 mls of normal saline given at QL.The QL block will be administered on both the right and left sides. The transducer is placed transverse immediately cranial to the iliac crest and at the level of the posterior axillary line. The needle is then inserted inplane from the lateral edge of the transducer and advanced through the quadratus lumborum (QL) muscle until the needle tip penetrated the epimysium of the anterior part of the QL muscle. The anesthetic is injected after repeated negative aspiration tests for blood in the fascial interspace between the QL and psoas major (PM) muscles posterior to the transversalis fascia
45661075|NCT05480111|Drug|Sham Local|20 mls of normal saline given at incision site
45954678|NCT00514228|Drug|sunitinib malate|"Starting dose: 37.5 mg 3 x 12.5 mg capsule~Reduced dose: 25 mg 2 x 12.5 mg capsule"
45954679|NCT04695418|Dietary Supplement|Rice Germ|The rice germ was taken every day (25 g in the morning with breakfast and 25 g in the afternoon as snacks) for four weeks
45954680|NCT04695418|Combination Product|Placebo|An isocaloric wheat germ-based supplement was taken every day (25 g in the morning with breakfast and 25 g in the afternoon as snacks) for four weeks
45954681|NCT00514306|Drug|OSI-906|Oral OSI-906 administered on an intermittent schedule at increasing doses until disease progression or unacceptable toxicity
45954682|NCT00514345|Genetic|gene expression analysis|
45954683|NCT00514345|Genetic|polymorphism analysis|
45954684|NCT00514345|Procedure|management of therapy complications|
45954685|NCT00514423|Other|Psychoeducation by professonals|
45954686|NCT00514423|Other|Psychoeducation by peer-moderators|
45954687|NCT00514423|Other|Video-education|
45954688|NCT00514423|Other|Noneducational video group (control group)|
45954689|NCT00514462|Device|diode laser|wavelength at 830nm, 9.7J/cm2 for 10 min
45954690|NCT04695574|Procedure|Some clinical evaluation performance tests together with procedure of Closed Kinetic Chain Lower Extremity Stability Test|Clinical evaluation methods
46078203|NCT05659472|Behavioral|Mindfulness-based cognitive therapy|The program curriculum consists of the automatic pilot; living in our heads; gathering the scattered mind; recognizing aversion; allowing and letting be; thoughts as thoughts; kindness in action; maintaining and extending new learning.
46078204|NCT03975660|Device|Pain Measurement Device|When participants request labor analgesia, the sensors of the pain measurement device (ROPA System [CereVu Medical, Inc. San Francisco, CA] and Edwards Foresight device) will be applied to the forehead and connected to the device. Data recording is then started.
46078205|NCT04034173|Drug|Panitumumab|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion* D1~*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes."
46078206|NCT04034173|Drug|Irinotecan|Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1
46078207|NCT04034173|Drug|Folinic acid|Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1
45458125|NCT03505528|Drug|Nanoparticle albumin-bound paclitaxel|Abraxane is administered intravenous at a constant dose of 100mg/m2
45676619|NCT01497184|Genetic|DLI|Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10^6/m^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.
45815358|NCT05149352|Behavioral|Trauma-focused therapy (TFT)|The content of TFT, delivered by another therapist than the therapist that will provide TAU, depends on the type of CT the patient reports. If the patient predominantly reports experiences of abuse, there are often clear memories of this abuse ('target images') present and Eye Movement Desensitization and Reprocessing (EMDR) is recommended as the treatment strategy. If the patient predominantly reports experiences of neglect, memories are often less identifiable, although these experiences can have a big impact on the development of maladaptive schemas. In this case, imagery rescripting (ImRs) is recommended as treatment strategy. If the patient reports both experiences of abuse and neglect, the therapist will discuss with the patient which type of CT has the greatest impact on the current depressive symptoms and starts with the indicated therapy. If indicated, the therapist can switch between EMDR and ImRs after a minimum of 4 sessions.
45815359|NCT05457296|Drug|Hydrocortisone (capsule)|salivary cortisol measurement at baseline and at one, two, and four hours after hydrocortisone intake.
45954691|NCT00151125|Drug|recombinant interleukin-11|25 mcg/kg subcutaneously daily for seven days
45954692|NCT00151125|Drug|recombinant interleukin-11|50 mcg/kg subcutaneously daily for 7 days
45954693|NCT00151125|Drug|recombinant interleukin-11|10 mcg/kg subcutaneously daily for 7 days
45954694|NCT00514579|Procedure|Cord blood transplantation|Myeloablative preparative regimen of chemotherapy and radiation followed by double unit umbilical cord blood transplantation
45954695|NCT00514618|Drug|Misoprostol|patients will be treated with misoprostol 50 mcg PO q day for two days (days 1 and 4)
45954696|NCT00514618|Dietary Supplement|Placebo|patients will receive placebo (vitamin C) q day for two days (days 1 and 4)
45954697|NCT00514657|Drug|Trafermin (genetical recombinant of human basic Fibroblast Growth Factor)|
45954698|NCT00514696|Drug|GCS-100|GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle
45954699|NCT00514774|Drug|ursodiol|"ursodiol 300 mg twice daily for study days 0 through 28~ursodiol 600mg twice daily on study days 0 through 28"
45954700|NCT00514774|Drug|placebo|placebo 600mg twice daily for study days 0 through 28
45954701|NCT02951221|Drug|BIIB074 Treatment A|Lower dose RCF fasted
45954702|NCT02951221|Drug|BIIB074 Treatment B|Lower dose DCF fasted
45954703|NCT02951221|Drug|BIIB074 Treatment C|Higher dose DCF fasted
45954704|NCT02951221|Drug|BIIB074 Treatment D|Higher dose DCF fed
45954705|NCT02951260|Drug|Metformin|17 days treatment with metformin
45954706|NCT02951260|Other|Placebo|17 days treatment with placebo
45954707|NCT00151164|Procedure|donor bone marrow cell injection into thymus gland|
45954708|NCT02951299|Drug|Pentoxifylline 400Mg Tablet|Investigators with AKI will received oral pentoxifylline (400 mg) three times a day for 14 days or no pentoxifylline according to their decision.
45454332|NCT02285608|Other|PIMM/SAM|The PIMM program will include education to improve patients' knowledge regarding their medication's purpose, dosage, benefits, and side effects. The program will also include tools like a checklist or alarm clock to remind patients of when and how to take their medication. Furthermore, the program will contain an interactive listening period where healthcare professionals involved in medication dispensing will listen to patients' concerns, questions and thoughts regarding their medications.
45815360|NCT04336514|Device|Semi-compressed felt pad (SCF)|Participants with forefoot callus will receive routine treatment of debridement of callus. Along with the debridement, a Plantar Metatarsal Pad (PMP) made of Semi-Compressed Felt (SCF) with appropriate cut outs will be placed in their shoes. The thickness of the SCF would be selected based on the patient weight, and appropriateness of the thickness would be confirmed by the Medilogic pressure measurement. A 50% pressure reduction is the desired outcome.
45815361|NCT04336592|Behavioral|Non-pharmacological Options in post-operative Hospital and Rehabilitative Management (NOHARM)|Gathers patient preferences for non-pharmacological pain management strategies through medical record and inform clinicians (via prompts, orders, etc.) of these preferences and encourages conversation about these preferences throughout their routine pre- and post-surgical interactions with patients. Resources will be provided to bedside clinicians as they assist patients in identifying a personalized post-discharge pain management strategy.
45676620|NCT01471106|Drug|Dasatinib|"Group 1: 40 mg by mouth once a day.~Group 2: 80 mg by mouth once a day."
45835863|NCT04752930|Diagnostic Test|Imageology|Patients who undergoing radical surgery for colorectal cancer for 6~12 months and with 2 consecutive positive ctDNA testing results within 1 month will be enrolled. and there will be no need to conduct endoscopic exploration immediately after enrollment. Tumor markers, endoscopic and imaging examinations, and ctDNA monitoring will be performed every 3 months until imaging suggested peritoneal metastasis (oligometastases). Patients with positive peritoneal metastasis (PCI score <20) will be treated with CRS+HIPEC. Re-diagnostic laparoscopy will be performed 24 months after radical surgery when there is no radiographic evidence of recurrence or metastasis. Follow-up time will up to 36 months after colorectal cancer surgery.
45954709|NCT02951065|Other|Tooth brush without nylon bristles|Subjects will use a bristle-less tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
45954710|NCT02951065|Other|Tooth brush with soft nylon bristles|Subjects will use a soft bristled tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
45954711|NCT02951026|Other|Not applicable (no therapy is administered as part of this study)|"No experimental therapy or placebo is being administered in this study. All subjects in this observational study received a single intra-articular injection of SM04690 or placebo in a prior parent study."
45954712|NCT00166218|Device|near-infrared spectroscopy|
45954713|NCT00514891|Biological|Vitamin A|The effect of vitamin A given with different vaccines will be studied
45954714|NCT00514930|Device|Hexablate|
45954715|NCT00514969|Drug|Imatinib (STI571)|
45954716|NCT00515125|Behavioral|Dietary Advice|Dietary Advice sheet
45954717|NCT00515125|Dietary Supplement|Oral Nutritional Supplements (Fortisip)|"These products are classified as non-medicinal, borderline substances, foods for special medical purposes.~A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 12 week period."
45954718|NCT00515164|Drug|Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel|20 mL Hydrogel
45676621|NCT01445509|Drug|Bevacizumab|Once the MTD of dasatinib with bevacizumab 5 mg/kg IV every two weeks is determined, one final dose level will be accrued with that MTD dose of dasatinib with bevacizumab at 10 mg/kg IV every two weeks in order to determine if we can safely escalate bevacizumab to full dose with dasatinib concurrently.
45676622|NCT01445509|Drug|Dasatinib|We will start dasatinib at 50 mg PO QD which is less than half the recommended Phase 2 dose as well as bevacizumab at 5 mg/kg IV every two weeks, which is half the single agent dose. If this is well-tolerated, study drugs will be escalated per schema to maximize the dose of dasatinib when given concurrently.
45954719|NCT02950948|Drug|Progesterone|Progesterone will be administered subcutaneously once a day for 14 days/month, for 12 months.
45954720|NCT02950948|Drug|Placebo|A placebo solution will be administered subcutaneously once a day for 14 days/month, for 12 months.
45954721|NCT00515242|Behavioral|massage|therapeutic massage
46078208|NCT04034173|Drug|5-FU|5-FU 400 mg/m² BSA, bolus, D1 5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2
46078209|NCT00606203|Drug|milnacipran|taking milnacipran(50) 1#bid after stoke to prevent the occurence of depression
46078210|NCT00606203|Drug|placebo|placebo
46078211|NCT02749734|Procedure|Subretinal transplantation|Transplant hESC-RPE into subretinal space of patients with macular degeneration
46078212|NCT00604877|Behavioral|Treadmill Exercise|3 times per week for 6 months, with target of 45 minutes at 60-70% heart rate range
46078213|NCT00604877|Behavioral|Stretching/ROM|3 times per week for 6 months, passive and active stretching and range of motion (ROM) exercises for the upper and lower extremities
46078214|NCT02539849|Dietary Supplement|FOS|
46078215|NCT02539849|Drug|Adalimumab|
46078216|NCT02749578|Drug|Atorvastatin|
46078217|NCT02749578|Drug|MGL-3196|
45454333|NCT03943459|Drug|Quercetin|Quercetin 250 mg BID
45454334|NCT04832438|Drug|9-ING-41|15 mg/kg as intravenous infusion on Days 1 and Day 4 of a 21-day cycle
45454335|NCT04832438|Drug|Carboplatin|Carboplatin AUC 5 intravenously on Day 1 of a 21-day cycle
45458126|NCT03505528|Drug|Phenelzine Sulfate|Nardil is administered orally from a starting dose of 15mg/d to a maximum of 90mg/d
45954722|NCT00515242|Behavioral|thermotherapy|heat therapy
45954723|NCT00515242|Behavioral|relaxing environment|time in a relaxing environment
46078218|NCT02825030|Drug|Coppertone (BAY 987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation-SR15-78_Y73-167).
46078219|NCT00927199|Dietary Supplement|High-Oleic Canola Oil|Diets contained 35% energy as fat; of which 70% was provided by high-oleic canola oil (high in monounsaturated fat (oleic acid))
46078220|NCT00927199|Dietary Supplement|High-Oleic Canola/Flaxseed Oil Blend|Diets contained 35% energy as fat; of which 70% was provided by a 1:1 blend of high-oleic canola oil and flaxseed oil (high in monounsaturated fat (oleic acid) and omega-3 polyunsaturated fat (alpha-linolenic acid))
46078221|NCT00927199|Dietary Supplement|Western Dietary Control|Diets contained 35% energy as fat; of which 70% was provided by a blend of oils typical to the Western diet (high in saturated fat and omega-6 polyunsaturated fat (linoleic acid))
46078222|NCT05378867|Biological|TRS003|"TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 until end of treatment due to PD, intolerability or other cause for stopping treatment. Intensive PK sampling will be performed after 7 cycles of this TRS003 switch period"
46078223|NCT05378867|Biological|China-approved Bevacizumab|• Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle
46078224|NCT05378867|Drug|mFOLFOX6|"The mFOLFOX6 regimen is:~Oxaliplatin, 85 mg/m2 administered IV over 2 hours~LCV, 400 mg/m2 administered over 2 hours concurrent with oxaliplatin~5-FU, 400 mg/m2 given as a slow IV push (bolus) over 5 minutes administered immediately after LCV~5-FU, 2400 mg/m2 administered IV over 46 hours by infusion pump beginning immediately after FU IV bolus."
45661076|NCT05480111|Drug|QL|QL block involves injection of 19 ml of 0.25% Bupivacaine and iml(4mg) of Decadron in a fascial place formed partly by the posterior surface of the quadratus lumborum muscle.The QL block will be administered on both the right and left sides. The transducer is placed transverse immediately cranial to the iliac crest and at the level of the posterior axillary line. The needle is then inserted inplane from the lateral edge of the transducer and advanced through the quadratus lumborum (QL) muscle until the needle tip penetrated the epimysium of the anterior part of the QL muscle. The anesthetic is injected after repeated negative aspiration tests for blood in the fascial interspace between the QL and psoas major (PM) muscles posterior to the transversalis fascia
45815362|NCT04338230|Other|Progressive muscle relaxation exercise|"Relaxation Exercises CD Audio Records prepared by Turkish Psychological Association is used. Before starting the PMR exercises, the woman in the intervention group is provided to lie on a comfortable seat or bed, stretching the muscles of the face and all body for about 10 seconds starting from the hands to the foot in line with the sound recordings of the PKG exercises and then holding the deep breath while each muscle group is stretching, It is applied as a slow release of this breath during relaxation. In this way, the muscle groups in the hands, arms, neck, shoulders, chest, abdomen, hips, feet and fingers, the face and the whole body are tensioned and relaxed, and the woman is relaxed. During the eight-week period, the women are called by the researcher once a week and the exercises are reminded. Home visit There are 2 home visits at week 1 and at week 8. In case of need, repeated home visits are provided to ensure the continuity of the application."
45815363|NCT04336436|Behavioral|Mindfulness training|Mindfulness training
45815364|NCT04336436|Behavioral|Nutritional consult|Nutrition counseling and development of a personalized nutrition plan
45815365|NCT05456906|Other|No intervention|No interventions
46078225|NCT02749656|Drug|0.25% Desoximetasone cream (Topoxy®)|apply on the scalp psoriasis lesion twice a day
45815366|NCT04336358|Other|Telemedicine|Telemedicine consultation online
45815367|NCT04335266|Drug|SHR2554|SHR2554
45815368|NCT05456438|Other|İntervention 1|Group 1 applied coconut oil to the nipple
45954724|NCT00515320|Drug|Fluoxetine|Once daily oral dispersible tablet 2mg 9mg or 18mg
45954725|NCT00515320|Drug|Placebo|Oral dispersible tablet placebo
45954726|NCT00515359|Procedure|Intermittent Propofol Sedation|Intermittent versus continuous dosage
45815369|NCT05456438|Other|İntervention 2|Group 2 applied tea tree oil to the nipple
45835864|NCT04271826|Procedure|laparoscopic appendectomy|cases with normal CT underwent laparoscopic appendectomy
45835865|NCT04771884|Drug|meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid|The use of antimicrobial agents depends on the clinical practice
45954727|NCT00515359|Procedure|Continuous Propofol Sedation|intermittent vs continuous dosage
45954728|NCT00515398|Other|Observation|Ex vivo administration of AT2220
45954729|NCT00515476|Behavioral|physical exercise|8 weeks of regular exercise training
45954730|NCT00515554|Drug|Rituximab|addition of Rituximab to BEACOPP escalated
45954731|NCT00515554|Drug|BEACOPP escalated|chemotherapy with BEACOPP escalated
46002743|NCT04644939|Other|Phone calls|Patients undergoing outpatient colonoscopy will receive the standard bowel preparation instructions and a telephone call one day before the procedure to re-explain the instructions and the importance of bowel preparation
45454336|NCT01209481|Behavioral|nutritional education group action|The educational group activities will consist of two-hour group dynamics and cooking workshops once a week and for five weeks.
45454337|NCT05182970|Drug|Metformin|Individualised target dose of 2000 mg daily depending on tolerability.
45661077|NCT05475431|Drug|The sequential therapy|Proton pump inhibitors and amoxicillin for the first 5 or 7 days and sequent proton pump inhibitors, clarithromycin, and metronidazole for the next 5 or 7 days
45661078|NCT05475431|Drug|The triple therapy|Proton pump inhibitors, amoxicillin, and clarithromycin for 7, 10, or 14 days.
45661079|NCT05475431|Drug|The hybrid therapy|Proton pump inhibitors and amoxicillin starting from the 1st day and for a total of 10 or 14 days, and clarithromycin, and metronidazole starting from the 8th day and for a total of 7 days .
45661080|NCT05475431|Drug|The concomitant therapy|Proton pump inhibitors, amoxicillin, clarithromycin, and metronidazole for a total of 7 or 14 days
45954732|NCT00151203|Drug|Clarithromycin, Lenalidomide, Dexamethasone|"Dexamethasone (Decadron®) will be given orally at a dose of 40 mg on days 1, 2, 3, 8, 15 and 22 during the first cycle and once a week on days 1, 8, 15, and 22 for each subsequent cycle.~Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day beginning on day 2 of cycle 1.~Lenalidomide (Revlimid®) will be given orally at a dose of 25 mg daily beginning on day 3 and ending on day 21 of cycle 1 and on days 1-21 of subsequent cycles."
45954733|NCT04620200|Drug|Nivolumab|3mg/kg
45954734|NCT04620200|Drug|Ipilimumab|1mg/kg
45954735|NCT00515593|Drug|Parathyroid hormone (PTH) (Preotact)|Patients with severe postmenopausal osteoporosis
45954736|NCT00515632|Drug|Balaglitazone|One arm balaglitazone 10mg, one arm balaglitazone 20mg, one arm placebo, one arm pioglitazone (Actos®) 45mg, orally taken once daily.
45954737|NCT02950909|Procedure|Static exercise for emphasized neck extensors|Emphasized activation of the deep neck extensors was searched for applying a localized resistance with the thumb and index finger at the level of the vertebral arch of C4 while pushing into flexion in a ventral-cranial direction, approximately parallel to the surface of the zygapophyseal joint, asking the patient to resist maximally during 6 seconds in sitting position
46078226|NCT02749656|Drug|0.25% Desoximetasone cream (Topicorte®)|apply on the scalp psoriasis lesion twice a day
46078227|NCT02749656|Drug|Placebo|apply on the scalp psoriasis lesion twice a day
45454338|NCT01315886|Drug|SL fentanyl|SL fentanyl will be administered during 7- 15 BTcP episodes during a maximum period of 21 days, following a baseline period with standard BTcP treatment. The start dose of SL fentanyl is selected individually according to a standardized conversion ratio. The maximum start dose is limited to 400 μg. For a single BTcP episode no more than two (2) tablets or a maximum dose of 800 μg should be given.
46078228|NCT02822066|Procedure|Electroporation|Effectivity and safety of irreversible electroporation for refractory neoplasms in liver and pancreas
45454339|NCT04441294|Behavioral|ACE-Plus|
45454340|NCT04441450|Drug|[14C]ICP-022|150mg suspension containing 100μCi of [14C]ICP-022
45454341|NCT03942367|Device|Active Device (vPatch)|Electrical stimulation inducing motor response at the pelvic-floor muscles. Stimulation will be delivered by vPatch device configured to motor intensity.
45661081|NCT05475431|Drug|Bismuth-based quadruple therapy|Proton pump inhibitors, bismuth, tetracycline, and metronidazole for a total of 10 or 14 days
45661082|NCT03853109|Drug|AMG 404|AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.
45661083|NCT05480033|Behavioral|Imagery Technique|The stages of the imagery technique included preparation of a suitable environment, preparation of the students, setting the background music (ney sound), relaxation, focusing on the technique, visualising the situation to be imagined, loading positive and constructive expressions on the individual, distracting the student from the imagined situation, relaxation and ending the session.
45661084|NCT05479955|Other|5 minutes skin to skin contact|Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. The women in this group received 5 minutes of skin-to-skin contact as a clinic routine.
45661085|NCT05479955|Other|60 minutes skin to skin contact|Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. In line with the recommendation of the World Health Organization, 60 minutes of skin-to-skin contact was applied to the women in this group.
45661086|NCT05479877|Drug|sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India|Collagen based pulpotomy will be applied (sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India)according to the manufacturer's instructions and gently placed over the pulp stumps to a thickness of 2 mm
46078229|NCT00603317|Drug|Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo|Amoxicillin : 2g twice daily Clavulanic acid : 125 mg twice daily
46078230|NCT00603317|Drug|Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid|Amoxicillin : 2g twice daily Clavulanic acid : 125mg twice daily seven consecutive days
46078231|NCT02745522|Drug|Oxytocin|
46078232|NCT02745522|Drug|Placebo|
46078233|NCT02823392|Other|DBMV|the occurrence of at least two following events which were requiring application of CPAP with opening airway maneuvers, requiring oropharyngeal airway, requiring two-person bag mask ventilation, unable to perform bag mask ventilation or presence of desaturation (SpO2 < 95%).
45454342|NCT03942367|Device|Sham Device (vPatch)|Electrical stimulation inducing sensory response at the perineum.Stimulation will be delivered by vPatch device configured to sensory intensity.
45454343|NCT05251142|Other|Plyometric training|"Jumps in place. Some examples include multiple vertical jumps while reaching an overhead object, squat jump, pike jump, or tuck jump.~Standing jumps. Examples include the single leg jump, maximal vertical jump ,standing long jump or lateral long jump.~Multiple hops and jumps. Examples would include multiple long jumps or cone hops performed in succession, such as 5 hops in a row~Box drills. Examples of these drills include box jumps ,repeated box jumps, and single leg box jumps.~Depth jumps. Examples include stepping off the box and landing, stepping off the box and jumping vertically immediately after landing, or stepping off the box, landing, and sprinting."
45954738|NCT02950909|Procedure|Dynamic exercise for emphasized neck extensors|The patient was asked to fix his gaze at an object lying between both elbows hoping to in order to emphasize extension in the lower cervical spine and consequently activation of the extensors in this region.
45954739|NCT02950909|Procedure|Static exercise for general neck extensors|Emphasized activation of all neck extensors was searched for applying the resistance with the therapist's hand or a wall respectively a towel at the occiput in sitting position
45954740|NCT02950909|Procedure|Dynamic exercise for general neck extensors|. The patient was asked to fix his gaze at an object lying between both hands. Extension consequently occurred in the entire cervical spine.
45954741|NCT02957565|Behavioral|Baseline Questionnaires|Participant completes 5 questionnaires during an already-scheduled office visit. Questionnaires ask about symptoms, physical and emotional health, and trust in the medical profession. These questionnaires should take about 17 minutes to complete.
45454344|NCT05251142|Other|General exercises|Dumbbell Squat: 3 sets of 15 reps, Dumbbell Alternating Bench Press: 3 sets of 15 reps, Straight Arm Pulldowns: 3 sets of 15 reps, Dumbbell Front Raises: 3 sets of 15 reps, Reverse Flyes: 3 sets of 15 reps, Overhead Tricep Extensions: 3 sets of 15 reps, Dumbbell Bicep Curls: 3 sets of 15 reps, Jackknife Crunches: 3 sets of 20 reps, Oblique Crunches: 3 sets of 20 reps, External Rotation: 3 sets of 15 reps
45454345|NCT01209637|Behavioral|exercise training|exercise training min. 4 times a day for at least 30 min
45454346|NCT01209637|Behavioral|Intensive exercise training|Intensive exercise training for 4 times / day incl. interval training at 95% individual threshold
45454347|NCT01343654|Behavioral|Text messaging plus EMA|Personalized, tailored text messaging to prompt medication adherence, with EMA random queries about nonadherence and drug use, and two-way messaging for participants to report critical events
45954742|NCT02957565|Other|Videos|Participant watches 2 short videos that show actors playing doctor and patient roles, discussing different cancer-related symptom treatment options. Each video is about 4 minutes long and discusses the same content, but setting of each video is different.
45954743|NCT02957565|Behavioral|Assessment Questionnaires|"After viewing first video, participant completes assessment questionnaire to evaluate their opinion of the physicians behavior. These questionnaires should take about 5 minutes to complete.~After viewing second video, participant completes the same 3 assessment questionnaires. Participant also completes 2 additional questionnaires asking which physician participant would prefer as a primary physician and the satisfaction with health information technology use in their care."
45454348|NCT01343654|Behavioral|Treatment as usual|usual care in one of the three participating ID clinics, along with usual care (if any) in the community for problematic drug and alcohol use
45454349|NCT03133468|Drug|AJM347|Oral administration
45661087|NCT05479877|Drug|Biodentine (Septodont, Saint-Maur-des-Fossés, France)|Biodentine (Septodont, Saint-Maur-des-Fossés, France) will be applied according to the manufacturer's instructions and placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet.
45954744|NCT04576130|Device|Implantable cardioverter defibrillator|Implantation of an ICD for secondary prevention
45954745|NCT00515788|Drug|DepoCyt|Starting dose of 50 mg Intrathecal on Day 1 every 14 days for a total of 12 weeks (6 treatments). After the first 12 weeks, 50 mg Intrathecal on Day 1 every 28 days for 40 weeks (10 treatments).
45954746|NCT00515788|Drug|Temozolomide|100 mg/m^2 (capsules) by mouth daily for 7 consecutive days every 14 days.
45954747|NCT02950870|Drug|Ombitasvir-Paritaprevir-Ritonavir|The patient will be treated daily with Ombitasvir-Paritaprevir-Ritonavir 25/150/100 mg total dose
45454350|NCT03133468|Drug|Placebo|Oral administration
45454351|NCT03943615|Drug|Voxelotor|
45454352|NCT01343732|Device|Deep TMS|deep transcranial magnetic stimulation
45454353|NCT00065728|Drug|Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL|One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months
45454354|NCT03945877|Other|No interventions|No interventions
45954748|NCT02950870|Drug|Dasabuvir|The patient will be treated daily with Dasubavir 500 mg total dose
45954749|NCT02950870|Drug|Ribavirin|Patients will be treated with ribavirin if necessary.
45954750|NCT02950792|Device|ViewRay MRI|ViewRay Magnetic Resonance Imaging
46002744|NCT04644939|Other|Standard bowel preparation|Patients undergoing outpatient colonoscopy will receive the standard bowel preparation instructions
46002745|NCT04644939|Other|Colonoscopy|Patients will undergo colonoscopy
46002746|NCT00547742|Procedure|PET/CT Scan|
45454355|NCT00064714|Drug|AC2993 (exenatide)|Dose-escalation beginning with 2.5 μg administered subcutaneously twice per day (BID); then to 2.5 μg four times a day (QID); then to 5 μg four times a day; then to 10 μg four times a day.
45454356|NCT00064714|Drug|daclizumab (immunosuppressive)|2 mg/kg intravenously infused over 30 minutes every month for 12 months
45954751|NCT02950792|Radiation|Stereotactic Body Radiation Therapy Boost|In the (week 5), all patients will have a week 5 MRI and Four-dimensional computed tomography (4D CT) for purposes of planning Phase II boost. Gross tumors < 5 cm will receive a MR-based adaptive replanning Stereo boost of 80 Gy - 90 Gy (20 Gy-30 Gy in 5 fractions). Gross tumors < 5cm will receive an MR-based adaptive replan fractionated boost to 74 Gy at 2.4 Gy/day. Individualized radiation therapy prescription to primary tumor will maintain organs at risk (OAR) constraints to lung including mean lung dose (MLD) < 20 Gy with V20 < 37%. Simultaneously, MRI-based adaptive replanning boost of 12 Gy in 5 fractions (2.4 Gy/day) will be given to gross lymph nodes. Final doses prescribed will be limited by doses to all OARs.
45954752|NCT00515866|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
45954753|NCT00515866|Drug|Gemcitabine|intravenous injection
45661088|NCT05492747|Other|Kangaroo Care an Effect|Researchers evaluated vital signs and oxygen saturation of preterm infants in the kangaroo care group 15 minutes before kangaroo care. After the baby's mother was admitted to the NICU, she was assisted by the researcher for hand hygiene and they went to the incubator together. The mother was seated in a comfortable chair next to the incubator. After the researcher covered the head and back of the preterm baby with a baby blanket, she took it from the incubator and placed it between the mother's breasts, with the head up and upright. The baby was supported not only by the neck and shoulders, but also by the whole body. Skin contact between mother and baby was ensured at the highest level. The baby was positioned so that its lips were touching the mother's nipple. The researcher waited until the baby opened its mouth.
45661089|NCT05492669|Drug|Lidocaine Hydrochloride, Injectable|In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
45954754|NCT02950714|Other|LIN_NOW|The Lupus interactive navigator (LIN) was developed to facilitate and support engagement and self-management for persons with lupus. It is a web-based program that provides access to relevant information, resources, support, and other tools to help them manage their illness. It is accessible by the Internet and compatible for use with computer, tablet, and mobile device. The content for the LIN was based on the results of focus group discussions and web-based surveys of persons with lupus and health care providers. Medical researchers, writers, designers and programmers worked with clinical experts affiliated with the Canadian Network for improved outcomes in Systemic Lupus Erythematosus (CaNIOS) and persons with lupus to provide the written content and interview videos.
45815370|NCT04737824|Procedure|"An adaptation of the balloon-blowing exercise"|The participants were positioned in supine, on a semi-rigid surface, with the upper limbs placed above the level of the head, at rest. Their feet were also placed at a resting position on a wall and with their hips and knees at 90o of flexion. The cervical was placed in a neutral position and the pelvis was maintained in a posterior pelvic tilt, both structures corrected by the researcher. The participants were asked to contract the adductors, maintaining a bilateral and symmetric pressure between 10 and 15 mmHg on two sphygmomanometers placed between the knees. Also, an isometric contraction of the hamstrings and gluteus was requested. A Threshold®, with a minimum resistance of 5 cmH2O, and they were instructed to close their lips around the mouthpiece, to avoid air leaks. To start the exercise, it was transmitted to the participants to make a maximum inspiration through the nose, for two seconds. Subsequently, a maximum exhalation throughout the threshold was made for three seconds.
45954755|NCT02950714|Other|LIN_WAIT|Usual care for three months prior to access to the LIN
45661090|NCT05492669|Drug|0.9% normal saline|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
45954756|NCT00515905|Drug|Sevoflurane/propofol|Sevoflurane/propofol
45661091|NCT05492591|Drug|Peginterferon α1b|Injecting different doses of the peginterferon α1b into different groups of subjects.
45954757|NCT00166257|Device|Percutaneous closure of patent foramen ovale|Percutaneous implantation of an AMPLATZER® PFO Occluder
45661092|NCT05492591|Drug|Peginterferon α1b with valacyclovir|Both valacyclovir tablets and different dose of peginterferon α1b plan to be used in different groups of subjects.
45661093|NCT05492591|Drug|Valacyclovir|Valacyclovir is a positive control drug.
45954758|NCT00166257|Drug|Medical antitrhombotic treatment|Investigator's choice: Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d
45954759|NCT00515944|Drug|Botulinum neurotoxin type A, free of complexing proteins|
45954760|NCT00515983|Biological|DC/Apo-Nec|
45954761|NCT00516022|Drug|Mistletoe extract|The drug will be administered 3 times a week at home.
45954762|NCT00151242|Drug|Cytarabine|100mg/m² kont. i.v. day 1-7 (induction therapy) 3g/m² 2x/die i.v. day 1,3,5 or day 1,2,3
46002747|NCT00547742|Procedure|phlebotomy|
45954763|NCT00151242|Drug|Idarubicin|12mg/m² i.v. day 1,3,5 (first induction cycle) 12mg/m² i.v. Tag 1,3 (second induction cycle)
45954764|NCT00151242|Drug|Etoposide|100mg/m² i.v. day 1-3 (induction therapy)
45954765|NCT00151242|Drug|All-trans retinoic acid|45mg/m² p.o. day 6-8 (induction therapy) 15mg/m² p.o. day 9-21 (induction therapy) 15mg/m² p.o. day 6-21 (consolidation therapy)
45815371|NCT04737824|Procedure|"An adaptation of the balloon-blowing exercise for seven weeks, three times a week, at home"|The participants were positioned in supine, on a semi-rigid surface, with the upper limbs placed above the level of the head, at rest. Their feet were also placed at a resting position on a wall and with their hips and knees at 90o of flexion. The cervical was placed in a neutral position and the pelvis was maintained in a posterior pelvic tilt, both structures corrected by the researcher. The participants were asked to contract the adductors, maintaining a bilateral and symmetric pressure between 10 and 15 mmHg on two sphygmomanometers placed between the knees. Also, an isometric contraction of the hamstrings and gluteus was requested. A Threshold®, with a minimum resistance of 5 cmH2O, and they were instructed to close their lips around the mouthpiece, to avoid air leaks. To start the exercise, it was transmitted to the participants to make a maximum inspiration through the nose, for two seconds. Subsequently, a maximum exhalation throughout the threshold was made for three seconds.
45661094|NCT02554721|Drug|Cilostazol|
45661095|NCT02554721|Drug|Acetylsalicylic acid|
45815372|NCT02743442|Device|da Vinci® Si™|
45815373|NCT02760277|Drug|Vamorolone 0.25 mg/day/day|Oral administration of 0.25 mg/kg/day daily for 24 weeks.
45954766|NCT00151242|Drug|Pegfilgrastim|6mg s.c day 10 (cohort 1), 6mg s.c. day 8 (cohort 2)
45954767|NCT02950636|Other|Yoga|Restorative Yoga
45954768|NCT02950597|Device|Observational Study to Evaluate Utility of Non-invasive Hemodynamic Monitoring|
45954769|NCT02950519|Other|monitoring of cuff pressures|Cuff pressure will be checked per standard and additionally a minimum of every 8 hours.
45954770|NCT02950402|Other|Two Dried Plums per day|Subjects will consume Two Dried Plums per day
45954771|NCT02950402|Other|Six Dried Plums per day|Subjects will consume Six Dried Plums per day
45954772|NCT00166374|Procedure|balloon kyphoplasty|
46078234|NCT00603395|Device|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
46078235|NCT00908401|Other|Breastmilk|Breastmilk: 0.2 ml
45661096|NCT02554721|Drug|Clopidogrel|
45815374|NCT02760277|Drug|Vamorolone 0.75 mg/day/day|Oral administration of 0.75 mg/kg/day daily for 24 weeks.
45954773|NCT03459118|Behavioral|Function Focused Care|The intervention in the parent study involves the use of a participatory implementation approach as delineated in the Evidence Integration Triangle. Prior to implementation, we meet with the administrator, service coordinator, delegating or oversight nurse or setting contact designee to identify the setting champion and stakeholder team members. In addition to the champion, we recommend the following individuals be included in the stakeholder team: an administrator in a leadership position (e.g. assisted living manager, delegating/overseeing nurse); a direct care worker; a family member; an activity staff member if available; and a resident. FFC-AL-EIT is implemented by a Research Nurse Facilitator working with the stakeholders using our four step approach: (I) Environment and Policy Assessments; (II) Education; (III) Establishing Resident Function Focused Care Service Plans; and (IV) Mentoring and Motivating.
45661097|NCT03810911|Drug|Darbepoetin|Used to treat anemia. In the group labeled no intervention, the intervention is simply delayed 12 weeks after randomization as noted in the description.
45954774|NCT04695184|Diagnostic Test|ICG-NIRF Imaging|intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3)
45954775|NCT04694989|Drug|CKD-386|QD, PO
45954776|NCT04694989|Drug|D013, D326, D337|QD, PO
45661098|NCT03801005|Biological|Blood and Marrow sample|"Twenty patients will be included in a prospective way over a period of nine months. No additional medullary or serum samples will be carried out in addition to those required for the clinical routine. Only an additional blood sample taken during a routine blood test will be recovered as part of the research. Just as some leftover bone marrow, taken as part of a usual unused follow-up will be recovered as part of this trial.~The persons concerned will be recruited on the occasion of their hospitalisation in one of the hematology services participating in the research, or during their consultation with one of the hematologists of the corresponding service (or services). On this occasion, detailed information on their pathology and research will be given, as well as the information document on the proposed research protocol."
45661099|NCT03799523|Other|Temporary skin markings|To use temporary markings in lieu of localization tattoos.
45954777|NCT00516100|Drug|bortezomib|MTD of bortezomib administered Days 1 and 8 plus 500 mg/m2 pemetrexed on day 1, every three weeks.
45954778|NCT00166413|Drug|CC-5013|40 mg/day orally on days 1-4 and 15-18 of each 28-day cycle
45954779|NCT00516178|Drug|Fish oil emulsion|0.2 g/kg FO, 3 times in 24 hours, infused over 3 hours each in cardiac surgery, or continuous infusion of 0.6 g/kg post PTCA
45954780|NCT00516178|Drug|Saline|3 infusions, perioperative or post-PTCA
46078236|NCT00908401|Other|Oral Sucrose|oral sucrose: 0.2 ml one time 1 minute before the painful procedure with a pacifier
45661100|NCT03799523|Other|Surface imaging|To use light-based surface imaging for patient positioning during radiation treatment.
45661101|NCT02552225|Drug|Amitriptyline|Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
45815375|NCT02760277|Drug|Vamorolone 2.0 mg/day/day|Oral administration of 2.0 mg/kg/day daily for 24 weeks.
45815376|NCT02760277|Drug|Vamorolone 6.0 mg/day/day|Oral administration of 6.0 mg/kg/day daily for 24 weeks.
45815377|NCT02776904|Other|Immediate Post-concussion Assessment and Cognitive Testing|Computerized assessment that provides information related to visual reaction time and visual memory.
45815378|NCT02776904|Other|Gait with single and dual task|Walking alone and then walking while performing a memory task on a tablet.
45815379|NCT02776904|Other|Y-Balance test|Dynamic balance test measuring reaching of the leg to the anterior,postero- lateral, and postero-medial directions.
45815380|NCT02776904|Other|Psychomotor Vigilance Task|Assessment measuring reaction time based on auditory cues.
45815381|NCT02744534|Drug|FACBC PET-CT Scan|"One hour prior to scanning, participants will drink one glass (450 ml) of oral contrast to allow for better pictures of abdomen and pelvic organs. The participants will have their temperature taken before and after the injection of the FACBC. Blood pressure and pulse will be taken every 15 minutes during the PET scan.~Participants will lie on a scanning bed and the bed will move slowly through the PET/CT scanner. This portion usually takes about one minute. Following this the FACBC will by administered by an intravenous (IV) catheter and the PET scan portion of the exam will begin. The table moves slowly through the scanner and many sets of PET-CT images are produced. When the imaging is complete, the scanner will send the results to a computer. The computer then generates a number of images that will be reviewed by a specially trained radiologist."
45815382|NCT02744534|Procedure|Three-dimensional ultrasound-guided biopsy|"A lubricated rectal probe will be inserted and a local anesthetic to numb the prostate will be administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images. The probe connects to a computer that will link to the FACBC PET-CT scan results that the participant has already had performed. These combined images will provide a three-dimensional (3D) image from the FACBC PET-CT scan previously obtained as well as real-time, 2D ultrasound images, resulting in an improved visualization tool to target the biopsy needle to a suspicious lesion.~The needle tip position for each biopsy sample will be recorded on the real-time ultrasound images; this information allows the physician to either re-biopsy the same area for a follow-up examination or not to re-biopsy the same region if the original biopsy was negative.~This biopsy process is estimated to take about 10 minutes."
45815383|NCT02744534|Procedure|Standard transrectal ultrasound (TRUS) guided biopsy|A lubricated ultrasound probe of about 2.5 cm in diameter is gently inserted into the rectum and a local anesthetic to numb the prostate is administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images and allows for the placement of a biopsy needle that collects samples of the prostate. Usually, a total of 12 biopsy specimens are collected. The procedure takes about 20 minutes. This TRUS-guided biopsy is considered as the standard method for prostate cancer diagnosis.
45815384|NCT04335565|Other|sugar replacements|Participants will receive a solution of stevia before being administered a fixed meal (lunch). Glucose and insulin levels, and Visual analogue scale data will be collected.
45815385|NCT04335409|Diagnostic Test|Questionnaire|The patients are asked to complete a questionnaire (paper version) once a week during the period of radiotherapy and up to 24 weeks following radiotherapy. In this questionnaire, the patients are asked to state and rate their symptoms potentially associated with pneumonitis. Scoring points are assigned to the severity of the symptoms (symptom scores), and the resulting sum score (patient score) will be used for identification of radiation pneumonitis.
45815386|NCT04335409|Other|Mobile Application|In 10 patients, the paper version of the symptom-based scoring system (questionnaire) will be supplemented by a mobile application (app) asking the same questions regarding symptoms potentially associated with pneumonitis.
45815387|NCT00371852|Drug|lactoserum|
45815388|NCT04337125|Other|Neuropsychological and attachment/parenting assessment|"Children assessments:~Mental health assessment, Intellectual functioning assessment, Sleep patterns assessment, Behavior assessment, Severity of ADHD symptoms assessment, child attachment assessment, parenting practices assessment, emotional regulation assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment~Parents assessments:~Mental health assessment, Intellectual functioning assessment, ADHD symptoms assessment, Depression symptoms assessment, Attachment style assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment."
45661102|NCT02552225|Other|Placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
45661103|NCT05474339|Other|Cardiac rehabilitation|Using Cardiac rehabilitation for patients after coronary artery bypass graft
45815389|NCT02744846|Drug|Antibiotics exposure|
46002748|NCT00560430|Drug|telmisartan|80 mg per day, orally, weeks 1-14
45661104|NCT05474261|Procedure|Valsalva maneuver|Valsalva maneuver: increase intrabdominal pressure
45661105|NCT05473949|Drug|Profofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients|Use of 1% Propofol (Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
45661106|NCT05473949|Drug|Ketofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients|use of Ketofol (1% Propofol + 5% Ketamine with a ratio 1/4) Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
45954781|NCT04515290|Drug|TSG-01|Two tablets of TSG-01 (0.35g/tablet) were given by oral with 3 times a day for 12 weeks; High dose group.
45954782|NCT04515290|Drug|TSG-01 and Placebo|One tablet of TSG-01 (0.35g/tablet) and one tablet of placebo (0.35g/tablet) were given by oral with 3 times a day for 12 weeks; Low dose group.
45954783|NCT04515290|Drug|Placebo|Two tablets of placebo (0.35g/tablet) were given by oral with 3 times a day for 12 weeks.
45454357|NCT03943771|Other|Anxiety, renal anatomy and surgery questionnaires|"The day before surgery, all the patients will be visited by a member of the investigator team for preoperative consultation and will be given a questionnaire evaluating their anxiety based on STAI and VAS scores. The two experimental groups will be offered their renal modelization to be manipulated (virtually or physically) before the questionnaire.~A second survey assessing basic renal anatomy and surgery understanding will also be completed by the patients.~Anxiolytics prescription prior to surgery will be collected inside the medical file."
45454358|NCT04771598|Other|Breathing exercise with the phone application|"Respiratory Control:~Pursed Lip Breathing~Diaphragmatic Breathing Respiratory exercises will be instructed to the individuals forming the intervention group and participants will be asked to do 3 times a day during one month and the exercises will be done by the researchers together with the individuals by establishing a connection with the phone application (zoom, watsapp) once a week from home."
45661107|NCT05479565|Diagnostic Test|venous blood sample for determining the value of highly sensitive C-reactive C protein from serum|The non-invasive oscillometric device Arteriograph (TensioMedTM Kft, Budapest, Hungary) will be used to measure the arterial stiffness. In a quiet room at room temperature, the subjects will lie relaxed for 15 minutes before the start of the measurement. After that, the distance between the jugulum and the symphysis, which represents the approximate length of the aorta, will be measured with a gynecological compass, and the resulting value will be entered into the device.
45661108|NCT04424069|Procedure|Refractive surgery|Myopic patients seeking refractive surgery will be assigned to the study groups to assess the change in myopic and papillary perfusion in these different prodecures
45661109|NCT05492279|Dietary Supplement|sheep ghee|natural sheep ghee, given to patient in a commercial box and intervention group 10 gr per day from sheep ghee
45661110|NCT05492279|Dietary Supplement|sunflower oil|natural sunflower oil, given to patients in a commercial box and patient use 10 gr of it
45661111|NCT02552147|Drug|Transdermal nicotine|
45661112|NCT02552147|Other|Transdermal placebo|
45661113|NCT05479487|Drug|Fluzoparib+Apatinib|Fluzoparib 100mg bid+ Apatinib 375mg qd
45815390|NCT02762071|Drug|Liposomal bupivacaine|Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.
45815391|NCT02762071|Drug|Interscalene Nerve Block|Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
45815392|NCT05456282|Device|Automated mechanical peripheral stimulation|Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles
45815393|NCT05456282|Device|SHAM|Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
45661114|NCT05479487|Drug|Fluzoparib Monotherapy|Fluzoparib 150mg bid
45661115|NCT05479409|Radiation|Neoadjuvant radiotherapy|radiation therapy combined with chemotherapy prior to surgery
45661116|NCT05479253|Diagnostic Test|Artificial intelligence assistant system|The artificial intelligence assistant system can automatically capture images, prompt abnormal lesions and the parts covered by the examination (the stomach is divided into 26 parts).
45661117|NCT03403283|Other|15 subjects with Non Proliferative Diabetic Retinopathy(mild, moderate and severe). 15 subjects with Proliferative Diabetic Retinopathy|
45954784|NCT00516256|Behavioral|CHESS System|Internet-based computer program for 6 months.
45954785|NCT00516256|Behavioral|Cancer Information Mentor|Phone calls to the patient for 6 months.
45954786|NCT00166452|Drug|Lenalidamide|
45954787|NCT02950441|Dietary Supplement|Nicotinamide Riboside|
45954788|NCT02950441|Other|Placebo|
45954789|NCT02950207|Genetic|miRNA|miRNA extraction
45954790|NCT02950246|Procedure|perineural catheterization implementation|Skin preparation (disinfection) with 10 ml of 2% alcoholic Chlorhexidine Perineural catheterization implementation Ultrasonography use
45954791|NCT02950246|Drug|2% alcoholic chlorhexidine|
45954792|NCT02950246|Drug|povidon iodine|
45954793|NCT00151359|Device|SoleSensor|
46002749|NCT00560430|Drug|telmisartan|80 mg per day; orally, weeks 1 and 2; 160 mg per day; orally, weeks 3-14
46002750|NCT00560430|Drug|placebo|placebo; orally weeks 1-14
45815394|NCT05350046|Device|Ear-worn prototype devices|Hearing instrument including sensors to track movement and estimations of biological information.
45815395|NCT04336891|Drug|Testosterone gel|Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day) for 6 months
45954794|NCT02950324|Behavioral|Prehabilitation|Patients in the intervention, 'Prehabilitation', arm of the study will be enrolled into a multimodal programme that involves 15 weeks of exercise, nutritional support and psychological prehabilitation in the form of 'Medical Coaching'. This will take place during neo-adjuvant treatment prior to oesophagectomy or gastrectomy for cancer.
45954795|NCT02950324|Behavioral|Standard care|Patients in the 'standard care' arm of the study will not receive the study intervention. The patients will continue to be offered theatients in this arm of the study will not receive the study intervention. The patients will continue to be offered the standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care.
45954796|NCT02950129|Other|SIJ pain diagnostic tests|The subjects will undergo a specific physical exam of tests reported to be diagnostic of sacroiliac joint (SIJ) pain prior to receiving the routine injection in the SIJ; all tests will be repeated after the SIJ injection
46078237|NCT04218318|Device|phototherapy|Phototherapy will be commenced for neonates in both groups according to AAP guidelines.Neonates will be treated with intensified overhead blue LEDs phototherapy if they have a TSB level at or above phototherapy threshold. Neonates will be started on intensified 360◦ LED phototherapy if they have TSB level within 50µmol/L below the exchange threshold. The administration of IVIG is indicated in infants with isoimmune hemolytic disease if TSB lies within 34 to 51 micromol/L of the threshold for exchange transfusion and not responding to initial intensified phototherapy.Infants with a TSB concentration above the thresholds for exchange should have immediate intensified 360◦ LED phototherapy, and preparation for exchange transfusion will be started.Infants showed clinical signs of acute bilirubin encephalopathy will have an immediate exchange transfusion.
45954797|NCT00151437|Drug|Pegvisomant treatment|
45954798|NCT00151437|Procedure|Medical History, demographics|
45954799|NCT00151437|Procedure|Sign and symptoms: questionnaire|
45954800|NCT00151437|Procedure|Blood tests: IGF-1, AST/ALT/ALP/TBIL, GTT|
45954801|NCT00151437|Procedure|MRI|
45954802|NCT02950168|Procedure|Edoxaban|Edoxaban according to Summary of Product Characteristic (SMPC)
45815396|NCT04336891|Drug|Estradiol ovules|Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
45661118|NCT03403283|Other|Healthy Controls 15 age matched control subjects|
45815397|NCT04336891|Drug|Moisturizer|Local non-hormonal moisturizers applied regularly every 2-3 days and lubricants as needed
45815398|NCT04336891|Drug|Testosterone gel + Estradiol ovules|Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day), plus Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
45954803|NCT04510688|Drug|Cabozantinib|Observation of treatment with Cabozantinib
45661119|NCT05479175|Drug|Ibuprofen|Ibuprofen
45954804|NCT04695223|Drug|Arsenic Trioxide|Refractory cancer patients without standard-of-care harboring TP53 mutation received Arsenic Trioxide Injection (0.16mg/kg,d1-5,ivgtt,28days as a duration)
45954805|NCT00508768|Drug|Oral SCIO-469 capsule|
46078238|NCT02823314|Device|Cure Tape™ covering T 7 and T 8 dermatomes|The intervention group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 20 x 5 cm and they will have to be placed on the T7-T8 dermatome area.
46078239|NCT02823314|Device|Cure Tape™ away from dermatomes T 7 and T 8|The control group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 5 x 4 cm and they will have to be placed near the greater trochanter area.
45661120|NCT05479175|Device|Diode laser|Diode laser
45661121|NCT05479175|Device|Nonactive Diode laser|Nonactive Diode laser
45815399|NCT05456048|Drug|VAH regimen|VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-14; AZA was used at the dose of 75 mg/m2, day 1-7; HHT was given at a dose of 1mg/m2, day 1-7. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
45815400|NCT05456048|Drug|VEN+HMA regimen|VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-28; AZA was used at the dose of 75 mg/m2, day 1-7 or DEC 20mg/m2 day 1-5. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
45815401|NCT05348707|Other|epidemiology|To review medical records to describe diagnosis and severity of the disease.
45954806|NCT00166491|Drug|Insulin|
45954807|NCT00508807|Drug|RTA 402|5 mg by mouth (PO) daily for 21 days
45954808|NCT00508846|Behavioral|Questionnaire|Two-part telephone questionnaire lasting about 60 minutes total.
45661122|NCT05479019|Behavioral|Visual stimuli|Stimuli will be shown to participants and they will be asked to perform a visual task.
45661123|NCT05472857|Biological|Claudin 18.2 CAR-T|treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
45954809|NCT00508885|Drug|Niacinamide|Niacinamide 250 mg twice daily titrated up to 750 mg twice daily
45954810|NCT00508885|Drug|Placebo|Placebo
45954811|NCT02953405|Drug|Clopidogrel|
45954812|NCT00516802|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
45954813|NCT00516802|Drug|dacarbazine|intravenous injection over at least 20 minutes
45954814|NCT05861466|Drug|intra-vitreal injection of Ranibizumab|The intravitreal injection will be performed with ranibizumab (0.5 mg/0.05 mL through a 27-gauge needle that will be inserted into the sclera 3.5 mm from the corneal limbus in pseudophakic patients, and 4 mm in phakic patients.
46002751|NCT00547781|Procedure|PGD|
45954815|NCT05861466|Procedure|anterior chamber paracentesis|A 27-gauge needle on a 1-mL syringe will be inserted into the anterior chamber of the eye, and approximately 0.05 mL of aqueous humor will be withdrawn.
45954816|NCT05861453|Drug|Epeleuton|Participants will receive 2000mg Epeleuton (DS102) capsules twice daily.
45954817|NCT05861427|Drug|Atogepant|Oral Tablet
45954818|NCT05861427|Drug|Placebo for Atogepant|Oral Tablet
45954819|NCT05861414|Behavioral|EWM-T|"This paradigm was adapted from the n-back program described by Jaeggi et al. (2009) and comprised an affective dual n-back task consisting of a series of trials, each of which simultaneously presented a face (for 500 ms) on a 4 × 4 grid on a monitor. Intermediate interval 2500ms, during which, Participants press a button to determine if the current face or position is consistent with the first n. If the position is the same, press F; if the face is the same, press J; if the face and position are not the same, do not react.~The faces used in this training were selected from the Chinese Facial Emotional Picture System (CFAPS), and 12 faces (six male and six female) with fear, anger, disgust, and sadness were selected as n-back experimental materials."
45954820|NCT05861401|Genetic|Janus Kinase 1 and 2|Under complete sterile precautions, 3mL of blood will be withdrawn by venipuncture and put in EDTA tube; DNA extraction will be done after centrifugation and used for genotyping assay of (JAK 1 and JAK2) gene with the polymerase chain reaction(PCR).
45954821|NCT05861388|Procedure|implant placement|2 implants were placed at position of lower 2nd premolar and 2nd molar
45954822|NCT05861375|Diagnostic Test|Fibroscan|Fibroscan is a non-invasive device that allows liver exploration painlessly, quickly (a few minutes) and with immediate results. A probe placed on the skin generates an elastic wave completely painlessly and the device measures its speed of propagation in the liver. Liver stiffness is calculated from this speed.
45815402|NCT05348707|Other|epidemiology|To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.
45954823|NCT05861362|Radiation|Curative radiotherapy|Curative radiotherapy as indicated by the patient's disease and prescribed by the treating radiation oncologist
45954824|NCT05861362|Behavioral|5:2 intermittent fasting|Two nonconsecutive days of fasting per week that could be chosen freely according to the patient's weekly schedule.
45954825|NCT05861349|Diagnostic Test|Nerve conduction study|Nerve conduction study of median and ulnar nerve together with sensory comparative methods on the affected side (sides).
45954826|NCT05861349|Diagnostic Test|Ultrasound|Ultrasound of the median nerve on the affected side (sides).
46078240|NCT05380271|Drug|sequential DEB-BACE and Arotinib and Tirelizumab|DEB-BACE+Arotinib + Tirelizumab
45815403|NCT02745626|Device|Appliance|Orthodontic appliance to carry out orthodontic tooth movement.
45815404|NCT02763865|Device|MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil|"Active rTMS administration (1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total.~Resting motor threshold assessment the TMS machine will initially be set to 50% of its maximal output."
45815405|NCT02763865|Device|eSHAM system|implemented in conjunction with the Cool-B65 A/P coil to effectively blind participants to rTMS treatment (active or sham)
45815406|NCT04337528|Other|Osteopathic manipulation type thrust|The osteopathic manipulation type thrust is applied to solve the sacroiliac joint dysfunction. This technique applies a high velocity and intensity push in a specified direction to correct the dysfunction produced by a not correct position or movement of one joint.
46078241|NCT05380271|Drug|DEB-BACE alone|DEB-BACE alone
46078242|NCT00927277|Device|Erchonia(R) LipoLASER PL; Erchonia(R) EML Laser|The Erchonia(R) EML Laser is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.
46078243|NCT00927277|Device|Erchonia(R) LipoLASER PL|
46078244|NCT02745678|Drug|Thermosensitive gel rectal formulation|
46078245|NCT02824718|Drug|Teriparatide|human recombinant parathormone
45661124|NCT05478941|Combination Product|Progressive Muscular Relaxation via Zoom, and Exposure to a Virtual Reality scenarios deployed by an Head mounted tool (Oculus Quest 2).|"Four individual PMRT sessions via Zoom.~In vivo PMRT relaxing session and Virtual Reality exposure (T1; day 7).~Follow-up phase (T2; day 14), after two weeks. Recovering the virtual reality scenario based on an in-imagination session, and the PMRT session."
45661125|NCT05478941|Combination Product|Progressive Muscular Relaxation via Audio-track, and Exposure to a Virtual Reality scenarios deployed by an Head mounted tool (Oculus Quest 2).|"Four individual PMRT sessions via Audio-track.~In vivo PMRT relaxing session and Virtual Reality exposure (T1; day 7).~Follow-up phase (T2; day 14), after two weeks. Recovering the virtual reality scenario based on an in-imagination session, and the PMRT session."
45835866|NCT02538744|Drug|Doxazosin|Participants will be randomized into two groups: placebo and doxazosin 8 mg/d. The doxazosin dose will be increased every 4 days over 11 days, starting with 1mg on the first study day and and ending with 8mg 11 days later. Participants will receive one capsule daily that will contain either placebo or doxazosin.
45954827|NCT05861336|Drug|Losartan|Losartan will be administered at the dose of 25 mg PO qd starting on Cycle 1 Day 1. If this dose will be tolerated during week 1, escalation to 50 mg PO qd at Cycle 1 Day 8
45954828|NCT05861336|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 on days 1, 8 and 15 every 28 days
46078246|NCT02824718|Drug|Thiazide|Diuretic
46078247|NCT02824718|Drug|Potassium sparing diuretic|Diuretic
46078248|NCT02824718|Drug|Alfacalcidol|Belongs to the class of vitamin D and analogues
45954829|NCT05861336|Drug|Nab paclitaxel|nab-paclitaxel 125 mg/m2 on days 1, 8, and 15
45954830|NCT05861336|Radiation|Stereotactic Body Radiation Therapy|7 consecutive fractions for a total dose of 35-42 Gy
46078249|NCT00908479|Behavioral|Leg Exercise Program|Participants will engage in an extra 45-60 minutes per day of self-managed lower extremity homework exercises focused on improving strength, balance and walking ability.
46078250|NCT00908479|Behavioral|Leg Management group|Therapist provides educational information about leg pain, recovery, bone density, and fall risk.
45661126|NCT05478941|Behavioral|Progressive Muscular Relaxation via Zoom, and Exposure to a Guided Imagery Exposure.|"Four individual PMRT sessions via Zoom.~In vivo PMRT relaxing session and Guided Imagery conducted by the Psychotherapist (T1; day 7).~Follow-up phase (T2; day 14), after two weeks. Recovering the in-imagination relaxing scenario and PMRT session."
45661127|NCT05491889|Biological|trans arterial chemoembolization|trans arterial chemoembolization in patient with partial portal vein thrombosis
45661128|NCT02534935|Biological|rLP2086 vaccine|60 mcg or 120mcg at 0, 2 and 6 months
45815407|NCT04337528|Other|Osteopathic manipulation type muscle-energy|The muscle-energy manipulation is applied to solve the sacroiliac joint dysfunction. This technique applies a movement with an intermittent resistance in a specified direction to correct the position or movement of one joint. The therapist applies the movement in the correct direction since he feels a limitation of movement. When he feels the limitation he requests to the participant pushing in the contrary direction without movement. After five or seven seconds the participant finishes the contraction and the therapist continues the correct movement since he feels once again the limitation, and he request to the participant contraction another five or seven seconds. The therapist request to the participant only three times, when he finish the three contraction and the therapy applies the last movement to correct direction the intervention finishes.
45815408|NCT04337528|Other|Placebo technique|The therapist simulates a false technique. The therapist applies movement in the sacroiliac joint without dysfunction, he applies movement since ninety degrees of pelvic flexion, and he wait sixty seconds. Whit this placebo technique the sacroiliac joint with the dysfunction is not altered.
45815409|NCT02746406|Device|Peritron+|Peritron+ device to measure intravesical pressure
45815410|NCT04337918|Drug|NORS (Nitric Oxide Releasing Solution)|NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.
45815411|NCT04337918|Drug|NORS (Nitric Oxide Releasing Solution)|"Up to ten volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.~Any participants enrolled in the Prevention study who meet the criteria for the sub study will roll over into the Treatment Sub-Study but must remain in their randomly assigned group."
45815412|NCT02765269|Device|Intelligent Pain Management System|A mobile phone application which can record the pain the cancer patients have and can deliver these records to doctors in order that doctors give patients prescriptions promptly.
45815413|NCT02747186|Drug|Lidocaine|Intraoral maxillary field block
45815414|NCT05349968|Drug|Lipovirtide for injection|Multiple dosing of Lipovirtide
45815415|NCT02766517|Drug|Capsaicin|Administered topically
45815416|NCT04335344|Other|Observation of suPAR plasma and salivary levels|Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease
45815417|NCT04336046|Procedure|erector spinae block|will receive real bilateral ultrasounded guided erector spinae block by bupivacaine at 1 mg /kg in a total volume of 20 ml for each side after induction of anaesthesia in prone position
45815418|NCT04336046|Procedure|sham bilateral ultrasounded guided erector spinae block|will receive sham bilateral ultrasounded guided erector spinae block using 1 mg /kg normal saline in a total volume of 20 ml for each side after induction of anaesthesia in prone position after induction of anaesthesia in prone position.
45815419|NCT04336046|Drug|normal saline|using 1 mg /kg normal saline
45815420|NCT04336046|Drug|Bupivacaine|bupivacaine
45835867|NCT02538744|Drug|Modafinil|After titrating doxazosin to the target dose, study procedures will be completed three times, once during treatment with each dose of modafinil (0 [placebo], 200, and 300 mg/d), in pseudo-random order such that 200 mg precedes 300 mg).
45835868|NCT02538744|Drug|cocaine|On the 5th day of study medication treatment participants will receive non-contingent doses of cocaine (placebo, 20, 40 mg, IV) and participate in cocaine self-administration sessions.
45835869|NCT02538744|Drug|Placebo|
45835870|NCT00060528|Drug|Recombinant Fowlpox-GM-CSF|
45835871|NCT00060528|Drug|Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)|
46078251|NCT04169958|Other|safe mood|A tablet application that developed for this study. In addition, sensors are used to examine the possibility of using the system to assess the risk of suicide
46078252|NCT05378711|Drug|Fluoxetine|Children will receive a placebo or fluoxetine at different times dependent upon random assignment to a treatment schedule.
46078253|NCT00777153|Drug|Cediranib|30 mg/day, oral, until progression
46078254|NCT00777153|Drug|Cediranib|20 mg/day, oral, until progression
46078255|NCT00777153|Drug|Lomustine Chemotherapy|110 mg/m2 / Q6W, oral, until progression
45661129|NCT02534935|Biological|Pediatric HAV vaccine|0.5-mL dose at months 0 and 6. Normal saline at month 2.
45661130|NCT05430295|Procedure|phacoemulsification|cataract extraction followed by bilateral implantation of Eyhance intraocular lens in 10 patients and bilateral implantation of Tecnis 1 piece IOL in 10 patients
45661131|NCT05430295|Procedure|monofocal intraocular lens implantation|implantation of monofocal intraocular lens in the capsular bag at the end of phacoemulsification surgery
46078256|NCT00777153|Drug|Placebo Cediranib|Oral, until progression
46078257|NCT04240730|Procedure|Transvaginal natural orifice endoscopic surgery for endometrial cancer staging|Cases of extreme obese patients with early stage endometrial cancer who underwent v-NOTES
45954831|NCT05861323|Behavioral|Comfort Measures Only Time out (CMOT)|This is a brief intensive care unit team (nurse, physician, advanced practice provider, respiratory therapist) intervention to improve communication and care of patients at end of life in the intensive care unit setting.
45954832|NCT05861310|Drug|Metronidazole 1% Cream,Top|Cream that has an active ingredient in the form of metronidazole with a content of 1%. At the beginning of the study visit, anamnesis and examination of the skin status were carried out. Skin status includes examination of the degree of erythema with a Clinician Erythema Assessment Scale (CEA) score, examination of skin scrapings for demodex examination, dermoscopy examination, and TEWL (Transepidermal Water Loss) examination. Then the participants were given metronidazole 1% cream which was to be used twice a day in the morning and at night. Evaluation of the therapeutic response will be carried out on days 28 and days 56.
45954833|NCT05861310|Drug|Placebo|Cream that has not medicine. At the beginning of the study visit, anamnesis and examination of the skin status were carried out. Skin status includes examination of the degree of erythema with a Clinician Erythema Assessment Scale (CEA) score, examination of skin scrapings for demodex examination, dermoscopy examination, and TEWL (Transepidermal Water Loss) examination. Then the research subjects were given Placebo cream (without the drug substance) which was to be used twice a day in the morning and at night. Evaluation of the therapeutic response will be carried out on days 28 and days 56.
45815421|NCT05348239|Drug|Sodium Copper Chlorophyllin|Sodium-copper-chlorophyllin (CHL) is a phytopharmaceutical drug obtained from green plant pigment, chlorophyll. Chlorophyllin scavenges radiation-induced free radicals and reactive oxygen species. It is used as a food colorant and OTC in the USA, Japan, Australia and China for many years for a variety of health benefits including prevention of body odour in geriatric patients, enhanced wound healing, antibacterial action, prevention of cancer in the high-risk populations exposed to hepatocarcinogen aflatoxin B1, treatment of faecal incontinence etc. Studies have shown that CHL has immunostimulatory, anti-inflammatory and antiviral effects in addition to antioxidant and radioprotective properties. It increases the expression of a transcription factor (protein) Nrf2 which improves lymphocyte survival and enables efficient detoxification after exposure to radiation. The duration of therapy will be up to 6 months depending upon the response of participants.
45954834|NCT05861297|Drug|Dexamethasone|Patients were initiated with High Dose-Dexamethasone with a dose of 40 mg/m2 daily for four days per week immediately after the diagnosis of ITP for 6 months
45954835|NCT05861297|Drug|Prednisolone and Azathioprine|the second group received 20 mg of Prednisolone three times daily and 1 mg/kg of oral Azathioprine once daily for two weeks, then tapering the Prednisolone dose through the subsequent weeks (6 weeks). While continuing treatment with Azathioprine for a total of six months.
45954836|NCT05861297|Drug|Rituximab|The third group received 500 mg/m2 intravenously of Rituximab once weekly for one month
45954837|NCT05861297|Drug|Eltrombopag|The fourth group received 50 mg of Eltrombopag four hours before or after meals as oral daily doses for 6 months
45954838|NCT05861297|Drug|Romiplostim|The fifth group received 3μg/kg subcutaneous injection of Romiplostim once a week for 6 months
45954839|NCT05861271|Drug|Capecitabine，Pyrotinib|Pyrotinib and Capecitabine for half a year
45954840|NCT05861245|Radiation|5-fraction hipofractionated protontheray|"The therapeutic schemes that will be proposed to patients based on clinical criteria such as tumor size and relationship of the tumor with adjacent critical organs are:~For chordomas: 37.5 Gy in 5 consecutive sessions of 7.5 Gy per fraction.~For chondrosarcomas: 35 Gy in 5 consecutive sessions of 7 Gy per fraction."
45954841|NCT05861219|Behavioral|water immersion|mild physical activity then water immersion in tub
45815422|NCT02766673|Drug|Albuterol Sulfate|Subjects will receive a dose of study medication every 4 hours for 24 total hours
45815423|NCT02766673|Drug|Sterile Saline|Subjects will receive a dose of study medication every 4 hours for 24 total hours
45954842|NCT05861206|Other|GT-MW group (5% Green tea), WT-MW group (5% White tea),EO-MW group (Listerine mouthrinse)|Subsequently, each patient was instructed to use 15 mL of the mouthwash (5% Green tea, 5% White tea or Listerine mouthrinse) delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for a week. For the next 3 weeks, at the beginning of each week (8th, 15th and 22nd days), patients were invited to the clinic, oral hygiene instruction was repeated, and the mouthwashes to be used the following week were delivered to them.
45815424|NCT05455736|Other|Stereotactic salvage radiotherapy for macroscopic prostate bed relapse|Stereotactic prostate salvage radiotherapy administered on prostate bed macroscopic recurrence. Different techniques will be allowed provided that treatment respects doses and fractionation indicated per-protocol (35 Gy in 5 fractions)
45661132|NCT05429359|Other|CPET: CardioPulmonary Exercise Test for CSII users|"Baseline~VO2peak measurement~Breakfast~100% bolus insulin~CSII users: 100% basal"
45835872|NCT00060528|Drug|Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)|
45835873|NCT00060528|Drug|Recombinant Human GM-CSF|
45835874|NCT02255838|Device|Bronchoscope reusable (Storz 8402 2x)|Bronchoscopy and alveolar lavage
45835875|NCT02255838|Device|Bronchoscope disposable (aScope 4)|Bronchoscopy and alveolar lavage
45661133|NCT05429359|Other|AEX1: Aerobic Exercise Test 1 for CSII users|"90min~40-45% VO2peak~Breakfast~50% bolus insulin~CSII users: -2h target 150 mg/dL"
45661134|NCT05429359|Other|AEX2: Aerobic Exercise Test 2 for CSII users|"90min~40-45% VO2peak~Breakfast~50% bolus insulin~CSII users: -1h target 150 mg/dL"
45661135|NCT05429359|Other|CPET: CardioPulmonary Exercise Test for MDI users|"Baseline~VO2peak measurement~Breakfast~100% bolus insulin~MDI users: 100% basal"
45661136|NCT05429359|Other|AEX1: Aerobic Exercise Test 1 for MDI users|"90min~40-45% VO2peak~Breakfast~50% bolus insulin~MDI users: 50% basal"
45661137|NCT05429359|Other|AEX2: Aerobic Exercise Test 2 for MDI users|"90min~40-45% VO2peak~Breakfast~50% bolus insulin~MDI users: 80% basal"
45815425|NCT05455580|Behavioral|Nurses Taking On Readiness Measures (N-TORM)|The intervention will begin with instructing the participant to complete the Family Disaster Plan booklet. The principal investigator will talk about the different sections of the booklet and instruct the participants how to fill out their emergency plans. Participants will write their medical history, medications, physician, next of kin, pharmacy contact information, evacuation plan information, family communication plan, and insurance policy numbers and contact information. The booklet includes household emergency preparedness recommendations, evacuation zone information, a disaster supply kit contents list, local utility company contact information, shelter locations, and special needs and priority utility restoration registry information. The participants will be provided with a disaster supply kit after successful completion of the booklet. The disaster supply kit is part of the intervention and is not considered compensation.
45815426|NCT02766907|Device|cryopreserved amniotic membrane|placement of cryopreserved amniotic membrane after routine debridement procedure for EBMD
45815427|NCT00372320|Genetic|Gene Transfer|
45815428|NCT00372320|Drug|AdhAQP1|
45815429|NCT00371930|Procedure|application of a dye suspension followed by a laser intervention|
45815430|NCT02767609|Device|Magnetic Resonance Imaging|All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.
45954843|NCT05861206|Other|CHX-MW group (0.12% CHX, as a positive control group)|Subsequently, each patient was instructed to use 15 mL of the mouthwash (0.12% CHX) delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for a week. For the next 3 weeks, at the beginning of each week (8th, 15th and 22nd days), patients were invited to the clinic, oral hygiene instruction was repeated, and the mouthwashes to be used the following week were delivered to them.
46002752|NCT04644588|Diagnostic Test|Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.|Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.
46002753|NCT00547820|Other|placebo|
45815431|NCT00372008|Drug|Testosterone|
46002754|NCT00547820|Device|Urinary sensor|
46002755|NCT00560469|Other|Administration of 70% deuterated water|Subjects will drink 70% deuterated water daily for 8 weeks.
45661138|NCT05428735|Procedure|Embolization|Portal Vein embolization with Glue by a transhepatic approach vs. PVE and Hepatic Vein Occlusion with Vascular plugs via a transjugular or transfemoral approach in the same session as the PVE procedure
45661139|NCT02723773|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
45661140|NCT02544451|Drug|LUM/IVA|"Lumacaftor (LUM) 200 mg every 12 hours (q12h)/ivacaftor (IVA) 250 mg q12h (for 6 through 11 years of age).~LUM 400 mg q12h/IVA 250 mg q12h (for 12 years and older)."
45661141|NCT02544451|Drug|LUM/IVA|LUM 200 mg q12h/IVA 250 mg q12h (for 6 through 11 years of age).
45661142|NCT05455333|Other|Questionnaires|Sends and returns questionnaires to families.
45954844|NCT05861193|Procedure|Treatment of the abfraction with BOPT technique|"The steps to follow for the treatment of abfraction using composite resin and the B.O.P.T. technique will consist of:~Selection of the color of the composite, placement of the retraction cord and chamfering of the coronal margin of the lesion;~Application of 37% phosphoric acid etching and adhesive in 3 steps; placement of the composite by layers, following the conventional obturation technique.~Execution of an overfilling with the composite at the level of the cervical emergence profile of the tooth, with the aim of emphasizing said anatomical particularity.~Removal of the retraction cord.~Diamond milling with red rim flame diamond bur and contra-angle, positioned from the most apical point of the restoration at an angle of 45º without touching the restored dental portion, with the aim of performing a level rotary gingival curettage from the margin of the restoration.~Polishing with a fine-grain flame bur, and polishing discs of decreasing granulometry."
45815432|NCT05348161|Procedure|Samples including blood and tissue collection|Tissue and peripheral blood sample of 100 gastric cancer patients will be collected at the baseline and time point response of therapy.
45954845|NCT05861180|Device|inclinometer, smart phone goniometer and laser beam|devices to objectively assess proprioception of the neck
45954846|NCT05861167|Biological|selective intensive induction therapy based on ustekinumab clinical decision-making tools|At week 0 and week 8, UST was induced intravenously twice (stratified according to body weight, see instructions for dosage), and at the third time, intravenous or standard subcutaneous injection regimen was used according to CRP standard
45954847|NCT05861154|Device|Photobiomodulation|"A diode laser (Sirolaser blue laser system, Sirona Dental Systems GmbH, Fabrikstraße 31, 64625 Bensheim, Germany) of Wavelength 660 nm will be used and the laser parameters will be set as follows: Power 0.1 W, energy 6 J, Continuous wave, Irradiation time 60 Seconds; energy Tip area 0.5 cm2, fluence 12 J/cm2 will be applied at the site of needle penetration.~It should be noted that before each application, the output of the laser device will be checked using the aiming beam on flat surface; both the patient and the operator will wear safety goggles during the irradiation."
45954848|NCT05861154|Drug|Benzocaine Gel|a 20% Benzocaine topical anaesthetic gel will be applied. To increase the absorption of the topical anaesthetic gel, soft tissues will be dried with (2 x 2 cm) gauze. Topical anaesthetic gel will be applied at the site of needle penetration and left in contact with the soft tissues for one minute in order to to maximize its effect.
45954849|NCT05861141|Other|Selected physical therapy program|"Patients will receive a selected physical therapy program for 1 hr, 3 times per week, for 3 successive months in the form of:~Balance and postural control exercises for 15 minutes, including the following:~Standing on balance board.~Stoop and recovery.~Gait training for 45 minutes, including the following:~Forward, backward, and sideways walking.~Walking with obstacles using wedges and rolls with different diameters and heights."
45661143|NCT02544373|Device|PAP therapy|Positive airway pressure treatment for obstructive sleep apnea
45661144|NCT02551991|Drug|nal-IRI|
45815433|NCT05348161|Procedure|CTC detection|Peripheral blood collected from patients will be administrated to CTC detection.
45815434|NCT05348161|Procedure|ctDNA detection|DNA extraction from patients' peripheral blood will be measured by 741 panel DNA sequence.
45815435|NCT05348161|Procedure|10×genomics single cell RNA sequence|Tissue collected from patients will be digested into single cell suspension and administrated to 10×genomics single cell RNA sequence.
45815436|NCT05348161|Procedure|Whole exon sequence|DNA will be extracted from patients' tissue and administrated to whole exon sequence.
45815437|NCT05348161|Procedure|Proteomics detection|Peripheral blood collected from patients will be administrated to proximity extension assay .
45661145|NCT02551991|Drug|5 fluorouracil|
45661146|NCT02551991|Drug|Leucovorin|
45661147|NCT02551991|Drug|Oxaliplatin|
45661148|NCT04268615|Other|Covert Saccades and Virtual Reality|During this intervention, patients will undergo head impulse testing while wearing virtual reality Headsets. During the head impulse tests the visual information will be modified in order to create a conflict between head rotation and rotation of the visual scene. Recording of head and eye movement will be done during these head impulses in order to verify if visual information modifies compensatory eye movements during head impulses.
45661149|NCT04268615|Other|Actives versus passives Head Impulses|Patients will undergo classic passive head rotation as well as active head rotation in order to compare latencies of covert saccades in both conditions.
46078258|NCT03697980|Device|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
45661150|NCT04268615|Other|Visually guided saccades|Patients as well as healthy control subjects will undergo testing of visually guided saccades in different conditions (step, gap, overlap) in order to compare latencies of covert saccades between both groups.
45661151|NCT05472389|Other|Video-electroencephalography|All patients will be monitored 24 hours. Whenever possible, duration of the long-term monitoring will be extended to 48 hours, including a second full night polysomnography. These recordings will also allow us to assess sleep architecture and to capture seizures in some patients video , EEEG, EKG, respiration and other polysomnography data will be centralized at Hospices Civils de Lyon. A copy of the EEG-EKG data required to address the objectives related to cardiac features will then be electronically transferred to Partner 2 (Bonn) Evaluation will be performed blind to other data by the Partner 1 (Lyon) for the respiratory data and by the Partner 2 (Bonn) for the EKG data All primary outcomes and secondary outcomes will be assessed with respect to duration of epilepsy and frequency of convulsive seizures during the baseline period.
45661152|NCT05472389|Other|Blood Samples|Blood samples will be collected at V2 in all patients. A total of seven blood samples of 4 ml each will be collected, including five EDTA and two dry. Samples EDTA plasma and serum will then be prepared after centrifugation. In children < 10 kg, only 5 samples of 4 ml each (22 ml in total), including four EDTA and one dry.
45661153|NCT05491811|Drug|Ensartinib|Participants will receive Ensartinib 225 mg oral once daily from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
45661154|NCT05491811|Drug|Bevacizumab|Participants will receive 7.5 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks) from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
45815438|NCT05349578|Diagnostic Test|swab RUT|rapid urease test using swab instead of biopsied tissue
45815439|NCT02973763|Drug|Alflutinib|
45815440|NCT04335734|Procedure|Nissen Fundoplication with wrap fixation|Firstly, we performed left crural dissection, division of the short gastric vessels, right crural dissection, and esophageal mobilization. Then repair of HH were made by simple cruroraphy if the size of the defect was less then 10 сm² otherwise mesh for reinforcement of cruroraphy was used. Creation of the wrap was made by passing posterior fundus behind the esophagus from left to right, followed by stitching the edges of the stomach with three interrupted sutures. Wrap was fixated to both diaphragmatic crura or to the body of stomach using two non-absorbable stitches on each side.
45815441|NCT04335734|Procedure|Nissen Fundoplication without wrap fixation|Firstly, we performed left crural dissection, division of the short gastric vessels, right crural dissection, and esophageal mobilization. Then repair of HH were made by simple cruroraphy if the size of the defect was less then 10 сm² otherwise mesh for reinforcement of cruroraphy was used. Creation of the wrap was made by passing posterior fundus behind the esophagus from left to right, followed by stitching the edges of the stomach with three interrupted sutures.
45815442|NCT02767843|Device|continuous negative external pressure (cNEP)|soft silicone collar placed on the anterior neck, to which a negative pressure is introduced
45815443|NCT04337593|Drug|Basiliximab|20mg d1,8, repeated every 3 weeks
45815444|NCT04337593|Drug|Pegaspargase|2500IU/㎡, d1,repeated every 3 weeks
45815445|NCT04790864|Behavioral|Online large-group one-session treatment with post-treatment exercise targeting expectancy violation|The treatment is aimed at reducing public speaking anxiety by using cognitive and behavioral techniques. Following a psychoeducation phase, different speaking tasks are conducted to expose the individuals to their feared situation on the one hand and to address common cognitive processes characterizing public speaking anxiety, e.g. self-focused attention, on the other hand. The exercises will be conducted in smaller groups. After treatment, participants receive a worksheet with questions aimed at enhancing the processing of what was learned during treatment in terms of expectancy violation. For example, they are asked if what they were most worried about occured and what actually happened compared to what they predicted to happen. This should highlight the discrepancy between anticipated and actual outcomes. The intervention is conducted in an online group format via videoconference with a duration of approximately 5 hours.
46078259|NCT00907543|Other|Preoperative treatment of chemotherapy and radiation|Cisplatin + 5FU with concurrent radiation followed by surgery
46078260|NCT00907543|Other|Postoperative treatment of chemotherapy and radiation|Surgery followed by cisplatin + 5FU + epirubicin as indicated by pathological stage with extended beam radiation
46078261|NCT00606359|Biological|Inactivated, split-virion influenza virus|0.1 mL, Intradermal. 2 vaccinations 12 months apart
46078262|NCT00606359|Biological|Inactivated, split-virion influenza virus|0.5 mL, Intramuscular. 2 vaccinations, 12 months apart
45661155|NCT05472233|Procedure|Suture removal after Coronally Positioned Flap|Sutures are removed after different healing period post coronally positioned flap surgery, this latter is a procedure that aims at surgically advancing the gingiva in order to cover dehiscences of the soft tissues uncovering dental roots.
45815446|NCT04790864|Behavioral|Online large-group one-session treatment with post-treatment control exercise|The treatment is aimed at reducing public speaking anxiety by using cognitive and behavioral techniques. Following a psychoeducation phase, different speaking tasks are conducted to expose the individuals to their feared situation on the one hand and to address common cognitive processes characterizing public speaking anxiety, e.g. self-focused attention, on the other hand. The exercises will be conducted in smaller groups. After treatment, participants receive a worksheet that addresses basic contentual information concerning the treatment without a specific attempt to highlight the discrepancy between anticipated and actual outcomes. For example, participants will be asked how they would explain public speaking anxiety and exposure therapy to a friend and what advantages they see in conducting treatments like this in groups. The intervention is conducted in an online group format via videoconference with a duration of approximately 5 hours.
45954850|NCT05861141|Device|Aerobic training|"Patients will receive the same selected physical therapy program as the control group for 15 minutes in addition to treadmill training for 45 minutes, 3 times per week, for 3 successive months.~Treadmill training: Will be practiced according to the following stages:~A- Warm up: 5 minutes.~B- The exercise phase: 35 minutes (three-minute stages), the speed will be increased gradually every 3 minutes intervals until the child no longer be able to walk at the current stage.~C- Cool down: 5 minutes."
45661156|NCT04266041|Diagnostic Test|High-density electroencephalogram (HD-EEG)|This study will focus on obtaining a special type of high-density scalp electroencephalography (HD-EEG) recordings in patients with neurological disorders (i.e., epilepsy, brain tumor, stroke, etc.) and appropriately matched controls. HD-EEG is a scalp EEG which uses up to 256 channels compared to the standard 21 channels used for routine clinical applications. The reason for using more channels to record is for more precise localization of epileptogenic foci and/or more precise mapping of brain functions. This type of EEG requires the use of patient's own MRI scan to precisely localize activity. Therefore, all patients and controls getting an HD-EEG will require a structural MRI scan.
45661157|NCT05491733|Drug|APX001|Low-load oral tablet
45661158|NCT05491733|Drug|APX001A|High-load oral tablet
45661159|NCT05478785|Drug|Cisplatin micelle injection (HA132)|HA132 will be administered intravenously (IV), once per 3 weeks.
45661160|NCT05471297|Other|There is no intervention|There is no any intervention
45954851|NCT05861128|Drug|Jaktinib|Participants will receive 100 mg Jaktinib orally twice daily for 32 weeks
45661161|NCT05478395|Other|Questionnaires set|Participants will be asked to respond to the demographic information，the Depression Anxiety Stress Scale（DASS-21）and the Internet Addiction Test（IAT）.
45954852|NCT05861115|Device|"Chang Gung Ventricular Systolic Dysfunction Screening Software"|This software is suitable for 12-lead ECG signals of adults over 20 years old, and assists doctors in screening patients for left ventricular systolic dysfunction.
45661162|NCT05478317|Procedure|ECL- mPZ|"Flapless Technique using Piezoelectric (PZ):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. However, no flap will be reflected the osseous recontouring will be carried using special piezoelectric tip below gingival margin. The required distance between the bone crest and the gingival margin will be checked by inserting a periodontal probe into the incision below gingival margin."
45661163|NCT05478317|Procedure|ECL-OF|"Open Flap Technique (OF):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. Full mucoperiosteal flap will be elevated to preform ostectomy and/or osteoplasty until the desired distance achieved between the bone crest and the gingival margin. After achieving the new supracrestal distance, the flap will be sutured."
45661164|NCT02880293|Drug|melphalan|melphalan (140 mg/m2 IV on day -7)
45661165|NCT02880293|Drug|fludarabine|fludarabine (40 mg/m2/d on days -5 through -2)
45661166|NCT02880293|Drug|thiotepa|thiotepa (5 mg/kg IV on day -67)
45661167|NCT02880293|Drug|Cyclophosphamide|cyclophosphamide (50 mg/kg IV on day +3 and +4)
45661168|NCT02880293|Drug|Mesna|
45661169|NCT02880293|Drug|Mycophenolate Mofetil|(15 mg/kg PO/IV TID)
45815447|NCT04737902|Procedure|Erector spinae plane block|Unilateral ESP block was performed between T3 and T7 levels depending on the thoracic surgical incision. The patient is placed in lateral decubitus position, under sterile conditions, a high frequency (6-15 MHz) linear-array transducer (Sonosite® Edge II, Bothell, USA) was placed in a longitudinal parasagittal orientation 2 cm from the posterior midline to visualise the tips of the transverse processes deep to the erector spinae muscle (ESM). A 21 G, 50 mm or 100 mm needle (Pajunk UniPlex NanoLine; Germany) was advanced in-plane with the ultrasound beam. The needle tip was directed to the plane between the transverse process and the posterior fascia of the ESM. Correct needle tip location was confirmed by ultrasound visualisation of linear fluid spread in the fascial plane. The injection of 0.5 to 1 ml of bupivacaine was 0.5% with epinephrine 5 µg/ml; then, a total of 20-30 ml of the same local anaesthetic was administered.
45815448|NCT04336813|Other|Audience Response system|In the lecture hall, G1 was separated from G2, and both groups completed an assessment of written multiple-choice questions (MCQs) scored out of 20, before the lecture. During L1, phone based (ARS) questions (PB-ARS) secretly displayed on the smart phones of the students in G1, and they were allowed to read the question and answer it, while those in parallel arm of the trial (G2) were blinded to those questions and answers. At the end of L1, both groups completed the same written MCQs assessment
45815449|NCT04707638|Other|No intervention used|No intervention used
45815450|NCT04337671|Other|Moderate intensity aerobic training|"The exercise program consisted of 5 minutes warm-up, 15-30 minutes of moderate aerobic exercises and 10 minutes cool-down, respectively.~Frequency: 3 sessions/week , and Duration:12 weeks."
45815451|NCT04337047|Other|questionnaire assesment|questionnaire assesment
45815452|NCT05339581|Radiation|intensity-modulated radiotherapy|Neoadjuvant IMRT will be initiated at the third treatment cycle, and the dose prescription of IMRT is for planning target volume (PTV). The prescription dose to 95%PTV should be ≥50 Gy and ≤60 Gy, and been given in daily dose fractions of 2 Gy, 5 days per week. And the final prescription dose is determined according to dose constraints for organs at risk.
45815453|NCT05339581|Combination Product|Pembrolizumab|Participants receive PD-1 Blockade (Pembrolizumab 200mg，Sintilimab 200mg， Camrelizumab 200mg，Tislelizumab 200mg) 100-200 mg intravenously on day 1 of a regular treatment cycle until >42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until >7 days before liver transplantation.
45815454|NCT05339581|Drug|Sintilimab|Sintilimab is a recombinant anti-human PD-1 monoclonal antibody.
45815455|NCT05339581|Drug|Camrelizumab|Camrelizumab is a humanized anti-human PD-1 monoclonal antibody.
45815456|NCT05339581|Drug|Tislelizumab|Tislelizumab is a recombinant anti-human PD-1 monoclonal antibody.
45815457|NCT05339581|Drug|Lenvatinib Mesylate Capsule|Lenvatinib (Lenvima®, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.
45815458|NCT04336579|Behavioral|Diaphragmatic Breathing|Simple diaphragmatic breathing exercise
45954853|NCT05861102|Drug|Jaktinib|Participants will receive 100 mg Jaktinib orally twice daily for 16 weeks
45954854|NCT05861102|Drug|Placebo|Participants will receive matching placebo orally twice daily for 16 weeks
45954855|NCT05861089|Diagnostic Test|end-tidal CO2 measurement|Measurements will take place day before surgery, under resting conditions (while sitting in a quiet room with no disruptions) using the Capnography monitor from Nonin Medical (breath by breath data will be recorded and analyzed). Patients will be allowed to get used to the nasal cannula for the first two minutes. Mean end-tidal CO2 value will then be calculated from the following two minutes of spontaneous breathing.
46078263|NCT02821520|Drug|conbercept|At baseline conbercept injection is administered.And thereafter is administered based on re-treatment criteria from month 1 to 11.The PRN conbercept re-injection should be monthly.
46078264|NCT02821520|Procedure|Initial PDT|At baseline PDT with verteporfin is administered initially.And thereafter PDT is administered based on re-treatment criteria from month 3 to 11.The PRN PDT retreatment intervals should be no less than 3 months.
46078265|NCT02821520|Procedure|Delayed PDT|PDT is administered based on re-treatment criteria from month 3 to 11.The PRN PDT retreatment intervals should be no less than 3 months.
46078266|NCT00604955|Drug|Paromomycin sulfate|Paromomycin will be administered intramuscularly at 11 mg/kg, once a day, for 21 consecutive days
46078267|NCT04217070|Other|Questionnaire|Questionnaire including demographic data, data regarding poisoning substance and outcomes of suicidal attempts
45661170|NCT02880293|Drug|Filgrastim|
45661171|NCT02880293|Drug|Tacrolimus|
45676623|NCT01425528|Drug|Sapropterin|Sapropterin will be taken daily for 12 or 24 weeks. Starting dose will be 20mg/kg/day and will increase at the 8 week visit to 30 mg/kg/day. Dosing may be further increased to as high as 40 mg/kg/day in attempt to normalize BH4 levels in CSF. Starting dose for Cohort 2 will be determined from data analysis in Cohort 1.
45815459|NCT05335525|Device|Closure of the femoral arterial puncture site|Patient will undergo a diagnostic or interventional endovascular procedure, compatible with the use of Angio-Seal™ VIP VCD.
45815460|NCT04064684|Drug|Budesonide|Enrolled patients will be treated with Pulmicort Respules® (Budesonide inhalation suspension), at a dose of 0.5 mg, nebulized twice daily through the mechanical ventilator. The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
45815461|NCT04064684|Drug|Placebo|Enrolled patients will be treated with normal saline.The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
45815462|NCT04064684|Device|Nebulizer|The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit.
45815463|NCT05334199|Device|Biodegradable stent|Bronchoscopic placement of biodegradable stent in patients with airway complications after lung transplant
45815464|NCT05325385|Other|There are no interventions - this is a database study only|There are no interventions - this is a database study only
45815465|NCT04715906|Behavioral|UP-Caregiver|The Unified Protocol (UP) is a telehealth group session using Zoom with each session lasting approximately 60-90 minutes. The sessions will focus on a variety of Cognitive Behavior Therapy techniques. These sessions may include teaching coping skills, goal setting, parent-child problem solving and communication, and motivation during this pandemic.
45815466|NCT02192190|Drug|LY2951742|Administered subcutaneously (SC)
45815467|NCT02192190|Other|Placebo- oral|Administered orally
45815468|NCT02192190|Other|Placebo - SC|Administered SC
45815469|NCT02192190|Drug|Celecoxib|Administered orally
45815470|NCT03911726|Radiation|Single PET/MR-measurement|A single PET/MR-measurement using [18F]Fallypride with a duration of 180min. Within this measurement, the dopamine receptor agonist apomorphine is applicated.
45815471|NCT02748889|Drug|Carboplatin|Standard chemotherapy
45815472|NCT02748889|Drug|Etoposide|Standard chemotherapy
45815473|NCT02748889|Biological|MPDL3280A|Experimental biologic
45815474|NCT04334798|Other|Active exercises of the pelvic floor muscles & Electrostimulation & Biofeedback|See information included in arm/group descriptions.
45815475|NCT04334798|Other|Active exercises of the pelvic floor muscles & Biofeedback|See information included in arm/group descriptions.
45815476|NCT04334798|Other|Active exercises of the pelvic floor muscles & Transabdominal US Biofeedback|See information included in arm/group descriptions.
45815477|NCT04334798|Other|Active exercises of the pelvic floor muscles & Electrostimulation &Transabdominal US Biofeedback|See information included in arm/group descriptions.
45815478|NCT02749201|Device|Gastrisail|Light Intensity and gastric wall thickness assessment
45815479|NCT05402228|Diagnostic Test|temporomandbular joint disorders|no intervention
45815480|NCT04334720|Other|Comprehensive treatment of tumor|According to the pathologic types and TNM stage of tumor，specialists chose one or more of the interventions in surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy.
45815481|NCT02224638|Device|TheraHoney HD|Honey
45954856|NCT05861063|Device|Fractional CO2 laser|All patients were given oral administration of 0.5mg paronosetron hydrochloride and lidocaine cream 1 hour before surgery. After cleaning and disinfection, fractional CO2 laser treatment was given. Among them, the fractional CO2 laser laser (American Medical Laser company) selected relatively constant energy parameters in the treatment
45954857|NCT05861063|Drug|Dezocine|Desocine injection was injected intravenously half an hour before surgery (10ml normal saline was added for more than 30 seconds)
45954858|NCT05861050|Procedure|Biopsy|Undergo tumor biopsy
45954859|NCT05861050|Procedure|Biospecimen Collection|Undergo collection of blood samples
45954860|NCT05861050|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
45815482|NCT02224638|Device|SkinTegrity|Hydrogel
45815483|NCT05390528|Drug|HLX301|HLX301 will be administered as a single intravenous (IV) infusion on Day1 in each 14-day cycle.
45815484|NCT04334642|Other|A mindfulness based intervention|It is a pilot study of feasibility and preliminary effectiveness composed of a longitudinal intervention that uses as a baseline measure a Mindfulness Training of 2 cycles (each cycle is formed by 4 days of intervention); two follow-up measures (1 and 6 months after the 2nd cycle); and a final measurement (12 months after the start of the study).
45815485|NCT04690868|Drug|AD-213-A|1 tablet administered before the breakfast during 5 days
45815486|NCT04690868|Drug|AD-2131|1 tablet administered before the breakfast during 5 days
45815487|NCT04654988|Drug|Prednisone|Prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months
45815488|NCT04654988|Drug|Azathioprine|Azathioprine: 2 mg/kg daily for 12 months
45815489|NCT04654988|Drug|Placebo Prednisone|Placebo Prednisone
45815490|NCT04654988|Drug|Placebo Azathioprine|Placebo Azathioprine
45815491|NCT02749903|Drug|enzalutamide|oral
45815492|NCT04631432|Diagnostic Test|Pre-screening|Document upload of Autism diagnosis certificate. Participants can request to show their certificate via a Zoom meeting with the researcher instead of uploading it.
45954861|NCT05861050|Procedure|Computed Tomography|Undergo CT scan
45954862|NCT05861050|Biological|Glofitamab|Given IV
45661172|NCT01661933|Biological|Necator americanus|Previously inoculated subjects will be further inoculated as previously undertaken with 20 3rd stage infective Na larvae (10 + 10 over 4 weeks). Four weeks after the 2nd inoculation, each participant will receive a micro-dose of gluten (10 mg daily) as pasta for 8 weeks, to be followed by a low-dose of gluten (50 mg daily) for 8 weeks. After this, a detailed assessment involving upper endoscopy and duodenal biopsy will be performed before deciding on an individual case basis that it is safe for the participant to proceed to challenge. A gluten challenge of 1 G (15-20 G of pasta or a ½ slice of standard white bread) twice weekly for 12 weeks will commence.
45954863|NCT05861050|Drug|Lenalidomide|Given PO
45815493|NCT04631432|Behavioral|Task session|"The Iowa Gambling task- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, displaying the gain and the loss for that trial. Through contingent feedback, participants are expected to learn that some deck are better than others.The task will include 120 trials.~Block of trials without feedback- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, but the gain and the loss for that trial are not displayed. The task will include 30 trials.~Social Responsiveness Scale, 2nd Edition (SRS-2; adult-self report):(Constantino & Gruber, 2012) The brief autism quotient scale:(AQ10; Baron-Cohen et al., 2001) Brief intelligence test (Similarities-MAB + Raven Set 1)"
45954864|NCT05861050|Biological|Obinutuzumab|Given IV
45954865|NCT05861050|Procedure|Positron Emission Tomography|Undergo PET scan
45954866|NCT05861050|Drug|Venetoclax|Given PO
45954867|NCT05861037|Other|Video-Assisted Thoracoscopy with blebectomy and pleural abrasion|Thoracoscopic management of pneumothorax
45954868|NCT05860946|Device|Remote ischemic conditioning|The RIC intervention included five cycles of 5 min inflating tourniquets with the pressure of 200 mmHg and 5 min deflating with pressure of 0 mmHg alternately
45954869|NCT05860907|Drug|Huaier Granule|20g each time, three times a day
45954870|NCT05860868|Drug|2 cycles induction chemotherapy|"Drug: 2 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week)."
45954871|NCT05860868|Drug|3 cycles induction chemotherapy|"Drug: 3 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week)."
45954872|NCT05860855|Procedure|Augmentative craniotomy|Expansion of the skull
45954873|NCT05860855|Procedure|Decompressive craniotomy|Standard hemicraniectomy
46078268|NCT02824796|Behavioral|Schema Parent Behavioral Training|A novel protocol for parent whose children suffer from ADHD and comorbidities. The protocol combines elements from Schema Focus Therapy (SFT) and Parent Behavioral Training (PBT)
45954874|NCT05860842|Other|exercise|Six months of supervised combined exercise training program, consisting of 2 sessions/wk of 75 min each, followed by a six-month period of follow-up. Each session will comprise a 5-min warm-up, 30-min endurance exercise, 30-min resistance exercise, 5-min flexibility and 5-min cool-down.
46078269|NCT02824796|Behavioral|Parent Behavioral Training|A state of the art Parent Behavioral Treatment (PBT) for Children who suffer from ADHD symptoms
46078270|NCT04266509|Drug|PF-06651600|50 milligram (mg) tablet
46078271|NCT04266509|Drug|Rifampin|600 mg provided as two 300 mg capsules.
46078272|NCT00567541|Device|Battery Powered Microneuromodulator (BBPM)|The Battery Powered Microneuromodulator (BBPM) is programmed to deliver bursts of electrical stimulation to deliver therapeutic stimulation beginning with a frequency of 30Hz, current of 5mA, for 200 microseconds. These settings were applied to deliver greater or lesser intensity based on study arm (active vs placebo).
46078273|NCT02749500|Other|Conventional Occupational Therapy (OT)|Standard of care occupational therapy for stroke recovery
46078274|NCT02749500|Device|m2 BAT|Conventional OT plus 1 hour additional bimanual-to-unimanual device-assisted therapy.
46078275|NCT02824874|Drug|Duvie Tab. 0.5mg|Duvie Tab. 0.5mg*1T/day for 5days, QD, PO
45661173|NCT01661933|Biological|Necator americanus|After completion of the previously planned challenge, volunteers will be invited to extend the gluten challenge. The extension is for 4 weeks total. The gluten challenge is stepwise: gluten 10 mg daily for one week, 50 mg daily for one week and finally 3 grams daily for 2 weeks. The outcome measure is serum tissue transglutaminase to be compared before and after the intervention.
45815494|NCT02224560|Drug|GWP42003-P|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 10 or 20 mg/kg/day.
45815495|NCT02224560|Drug|Placebo control|Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
45954875|NCT05860829|Behavioral|Educational|Caregivers of children with ASD will be sampled that are enrolled in Autism specialized Schools or centers. Tools and group education sessions will be developed in Urdu, English and Sindhi language. A caregiver education program session will be conducted by a practicing dentist and a registered dietitian in Urdu1 and English. Considering the ease of caregivers, cost-effectiveness and managing flexible hours, tele-health will be practiced for education program. A post-test will be conducted to assess the impact of the educational program on the knowledge of caregivers.
45954876|NCT05860816|Other|Survey|Survey aimed at finding out the barriers and facilitators that Spanish primary care physiotherapists have to implement pain neuroscience-based education programmes in patients with chronic pain.
45954877|NCT05860803|Device|LungTrainers|A training device that provides a variable resistance against which users breathe out. Users breathe through a plastic mouthpiece that is connected to an acrylic cylinder via rubber tubing. The mouthpiece has several small holes of various diameters and up to three stainless steel weights (half-weight increments) can be inserted into the acrylic tube. With each breath-out, the user exhales against the resistance provided by the weight inserts, and each inspiration (i.e., breath-in) is unresisted. During each resisted exhalation, the weight inserts are 'lifted' within the acrylic tube depending on the level of expiratory pressure generated by the participant.
45815496|NCT00372710|Drug|Zoledronic acid|
45815497|NCT02973776|Drug|LEO 90100 aerosol foam|
45954878|NCT05860803|Behavioral|LungTrainers Pulmonary Rehabilitation regime|Series of different exercises using the LungTrainers device 3-5 days per week for approximately 10 weeks. Exercises complete in one long session (20-30 minutes) or be broken down into multiple shorter sessions (e.g., 3 x 10 minutes). A health coach will be assigned to guide participants through the LT-PR program.
45954879|NCT05860790|Diagnostic Test|Clinical Prediction Model for Venous Thromboembolism Following Neurosurgery|This is a clinical prediction model that uses perioperative clinical indicators and laboratory tests to predict the occurrence of VTE after neurosurgery.
45954880|NCT05860777|Other|Complexity score and implementation|AI machine learning model to identify patients with complex care needs and implementation with active reaching out to clinicians to offer interpreter services
45815498|NCT02973776|Drug|Dermoval®/Dermovate®|
45954881|NCT05860751|Behavioral|Home Exercise Program|Comprised of four exercises aimed to improve postural strength, postural stability, and trunk range of motion; 3 sets of 10 repetitions, 5 days a week
45954882|NCT05860751|Procedure|Dry Needling|Administered for a total of 4 sessions at a frequency of once per week. The target muscles to be needled will include the upper trapezius, infraspinatus, cervico-thoracic junction multifidus, and cervical erector spinae.
45954883|NCT05860738|Other|sterilization|autoclaving using the rapid cycle (4 mins, 134 oC) and the universal cycle (20 mins, 121 oC). The autoclave used in this study is (Anthos A-17 Autoclave, Italy).
46078276|NCT02824874|Drug|Duvie Tab. 0.5mg + Januvia Tab. 100mg|Duvie Tab. 0.5mg + Januvia Tab.100mg*1T/day for 5 dyas, QD, PO
45815499|NCT02973776|Drug|Diprosone|
46078277|NCT04102215|Device|HEARO|Robotic system for otological procedures
45661174|NCT02865551|Device|Foley catheter|Extended bladder catheterization after epidural anesthesia.
46078278|NCT04102215|Device|OTOPLAN|Otological surgical planning software
46078279|NCT04204265|Device|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose in a 5-mL glass syringe.
46078280|NCT03972150|Drug|BI 836880|Solution for infusion
45661175|NCT02865551|Device|Short term catheter|Intermittent catheterization every 4 hours after epidural anesthesia.
45815500|NCT02973776|Drug|Elocon|
45661176|NCT02865551|Drug|Epidural anesthesia|Performance of epidural anesthesia by a certified anesthesiologist.
45815501|NCT02973776|Drug|Locoid|
46078281|NCT03972150|Drug|BI 754091|Solution for infusion
46078282|NCT00908557|Other|readability improvement and good practice redaction|improvement using Flesch readability index and good practice in redaction of informed consent documents.
45661177|NCT02797769|Drug|Other Biologics|Exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. There are no protocol-specified biologic agents, although the analyses will be stratified by TNFi and non-TNFi targeted therapies. The drug selection and regimen are at the discretion of the prescribing physician.
46078283|NCT00908557|Other|Control|information based on the classic informed consent document
45661178|NCT02797769|Drug|Tocilizumab|Tocilizumab exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. The regimen is at the discretion of the prescribing physician.
45815502|NCT02973776|Other|LEO 90100 foam vehicle|
46078284|NCT02820662|Other|RETCAM|
46078285|NCT02820662|Biological|Blood samples|
45954884|NCT05860725|Behavioral|PSA Development|Health sciences students from a regional community college in Appalachian Virginia will be asked to to develop and submit a public service announcement (PSA) and to watch virtual training webinars that support the development of the PSAs. They will also be asked to complete surveys at three time points: before the PSA contest starts, after the PSA contest ends, and upon submitting a PSA.
45815503|NCT02161458|Drug|Escitalopram 20mg for 2 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 2 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
45815504|NCT02161458|Drug|Escitalopram 20mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
45815505|NCT02161458|Drug|Escitalopram 30mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
45815506|NCT02161458|Drug|Placebo|Additionally, 30 cognitively normal adults aged 60-85 will receive a placebo; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., placebo) administration.
45815507|NCT05214716|Diagnostic Test|FilmArray Pneumonia panel|A rapid molecular diagnostic test designed to detect 27 bacterial and viral species and 6 major resistance genes from respiratory specimens.
45815508|NCT04336657|Other|Questionnaire|Survey to identify number of people who got unusual severe flu- like illness in last October- November
45815509|NCT04336657|Diagnostic Test|IgG|Measure the past immunity of the disease (if possible)
45815510|NCT05144828|Device|Intercostal Nerve Cryoablation|Patients will receive intraoperative intercostal nerve cryoablation using CryoICE® CRYOS-L cryoablation probes (AtriCure, Inc) to intercostal spaces 4th to 10th in thoracoabdominal aortic repairs and 4th to 8th in descending thoracic aortic repair cases prior to wound closure.
45815511|NCT05144828|Drug|Patient-controlled analgesia (PCA)|Patients will have access to the standard PCA (patient-controlled analgesia) offered at Froedtert Hospital. This includes tylenol 650 mg oral, robaxin 500 mg oral, and tramadol 25-50 mg oral. All patients will have the first two ports placed at which time an intercostal nerve block of nerves 4-9 will be performed using 0.5% Marcaine with Epinephrine.
45815512|NCT05455255|Other|Experimental|FL was applied by Jonathan Bergmann and Aaron Sams in 2007 for high school students who had to be absent from chemistry class. Bergmann and Sams published all the learning activities they used during the lesson as videos. Bergmann and Sams (2012) stated that in this model, which they developed over time, it is not compulsory for the trainer to explain the entire course content in the videos, and the important thing is to allocate time to active learning methods during the course. In the FL model, the summary of the course content is presented to the individuals outside the classroom with tools such as video and power point presentations. In the lesson, activities are carried out for the active participation of the student. The student performs the course content outside of the classroom, and the homework and learning the course in the classroom.
45815513|NCT02223858|Behavioral|Positive Activities (PA) Program|6-week program of at-home activities (1 per week) that have been shown to increase positivity. Activities were delivered via activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist oriented participants to the booklets and reviewed the first activity at the end of an in-person baseline visit. Booklets contained all instructions patients needed to complete the full program. Interventionists also provided support via weekly calls in which they assessed completion of the previous week's activity, reviewed instructions for the next activity, and helped participants trouble-shoot anticipated barriers.
45815514|NCT02223858|Behavioral|Attention Control (AC) Program|6-week program of at-home activities (1 per week) based on affectively neutral activities from control conditions in studies of positive activities interventions. Activities were delivered via activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist oriented participants to the booklets and reviewed the first activity at the end of an in-person baseline visit. Booklets contained all instructions patients needed to complete the full program. Interventionists also provided support via weekly calls in which they assessed completion of the previous week's activity, reviewed instructions for the next activity, and helped participants trouble-shoot anticipated barriers.
45815515|NCT04336501|Biological|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later
45815516|NCT05041400|Other|Evaluation of the strength of knee flexors and extensors|Each participant will benefit from a clinical evaluation and an evaluation of the strength of knee flexors and extensors using an isokinetic dynamometer after a 10-minute warm up.
45815517|NCT05455021|Combination Product|Vessel Restoration System (VRS)|"The VRS includes the following components:~VRS 10-8-10 Dimer Coated Balloon Catheter~VRS Light Fiber~VRS Light Source The VRS will collectively refer to all the components used to perform the procedure. Their specific product name will identify individual elements."
46078286|NCT04267913|Drug|Dexamethasone|Given IV
46078287|NCT04267913|Drug|Docetaxel|Given IV
46078288|NCT04267913|Biological|Ramucirumab|Given IV
46078289|NCT04267913|Drug|Sapanisertib|Given PO
45676624|NCT01330446|Drug|Armodafinil|50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
45676625|NCT01330446|Other|Placebo|1 by mouth every morning for a 28 day cycle.
45676626|NCT01330446|Behavioral|Questionnaires|Series of questionnaires completed at different time points before, during, and at study completion.
45676627|NCT01300832|Procedure|Duplex scan of lower extremities|Lower extremities will be duplex scanned pre and post-operatively
45676628|NCT01258933|Drug|Ofatumumab|300 mg Dose 1, then 1,000 mg weekly x 7, (treatment) then 1,000 mg every 2 months beginning on week 12
45676629|NCT01150487|Procedure|bone marrow aspirations|A bone marrow aspiration from each hip bone of the patients.
45676630|NCT00866554|Drug|administration of a LHRH agonist and Bicalutamide|3-month treatment with an LHRH agonist chosen by the treating radiation oncologist and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
45954885|NCT05860725|Behavioral|HPV vaccination focused social marketing campaign|Community members who use a regional health services focused non-profits rideshare buses and/or view their social media pages will be exposed to a 12-week social marketing campaign that uses PSAs developed in Phase 1. Community members will also complete surveys at three time points: before the start of the social marketing campaign, during the social marketing campaign, and after the social marketing campaign.
45954886|NCT05860712|Other|Irrigation|Cinnamon to be prepared were mixed with 50% ethanol and this suspension was placed on the magnetic stirrer for 4 hours.Whitman's filter paper was used to obtain the filtrate which was then dried to obtain the extract. The extract was dried to evaporate the solvent to prevent the influence of extracting agent (ethanol) on the final extract. Cinnamon extract was obtained using cinnamon bark which was pulverized into medium coarse granules. The extracting agent and the procedure to obtain the final extract.These extracts were stored in dark coloured bottles at 4 degree Celsius until use.
45954887|NCT05860699|Drug|Placebo|Placebo made by the same manufacturer to look like the active pills
45954888|NCT05860699|Drug|Half dose|add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 10 days during their inpatient stay
45454359|NCT04771598|Other|Breathing exercise|"Respiratory Control:~Pursed Lip Breathing~Diaphragmatic Breathing Breathing exercises will be explained to the control group and visual material will be given. The participants will be asked to do 3 times a day during one month. In terms of physical activity, the patient will be encouraged to participate in the program by suggesting exercises such as walking and cycling at least three times a week for 20 minutes per week"
45954889|NCT05860699|Drug|Full dose|add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 10 days during their inpatient stay
45954890|NCT05860686|Other|Monoject syringe|monoject syringe is used to clean the wound
45954891|NCT05860634|Procedure|Catheter self-discontinuation|Self-discontinuation of a transurethral catheter
45954892|NCT05860621|Behavioral|Brief Physical Activity Counselling|The brief physical activity counselling program will comprise 8 sessions (120 minutes each), every fifteen days, addressing the following themes: reasons to change, an introduction to the PAC-WOMAN program and principles, types of physical activity and their benefits, strategies on how to become more active and less sedentary, how to safely practice exercise at home, the importance of social support for doing more physical activity, barriers and facilitators for becoming more active, development of coping plans and strategies to overcome those barriers, establishing SMART goals, self-monitoring, medical aspects related to symptom management in breast cancer survivors, body image and self-acceptance, sharing experiences with role models, and re-evaluating action plans. It will be delivered in a need-supportive interpersonal climate, according to Self-Determination Theory principles.
45954893|NCT05860621|Behavioral|Structured Exercise Program|The structured exercise program was informed by the most recent guidelines for exercise prescription and safe practice in cancer populations. A supervised program of 32 sessions (over 4 months), lasting 90 min each, and taking place twice a week, was developed. The program combines aerobic, strength and mobility exercises, and is organized in four mesocycles, with progressive intensity, always adapted according to participants' initial assessments and evolution throughout the weeks. Once every 15 days, a thematic group class will be offered to participants, so that they can experiment and discover new physical activities, and more easily maintain regular practice in the future.
45954894|NCT05860608|Device|Us2.ai (AI-enabled report) handheld echocardiogram|NT-proBNP will be performed in all individuals randomized to the ACTIVE arm at the same visit as informed consent, and those with elevated NT-proBNP (≥125pg/ml) will be invited to attend a visit for an Us2.ai (AI-enabled) echocardiogram which will be controlled with a standard echocardiographic study if the AI-echo is non-diagnostic.
45454360|NCT01109485|Drug|Olopatadine hydrochloride ophthalmic solution 0.1%|1-2 drops 4 times per day
45454361|NCT00292396|Drug|Anti IL-12 monoclonal antibody/ABT-874|Please see Arm Description for intervention description and details.
45454362|NCT00292396|Drug|placebo|12 doses
45454363|NCT03942289|Other|The role of the noradrenergic system across the life span (Healthy Subjects)|A sample (n=90) of balanced distribution of healthy males and females within a continuous segment of the adult life span from 20 to 80 years old will be recruited, with approximately 7 males and 7 females subjects for each decade of age. Each participant will undergo 1) a neuropsychological examination, 2) an olfactory screening and 3) a 90 min 11C-Yohimbine positron emission tomography (PET)/magnetic resonance imaging (MRI) scan in a resting state.
45661179|NCT05471219|Other|Primiparous pregnant women who will undergo vaginal examination by focusing on visual traces|Informed consent was obtained from the mothers to take pictures of newborns who were delivered in the delivery room, routinely cared for, dressed and breastfed by the researcher. A 10-minute visual track was created to be turned into a slide from approximately 70 photos. Vaginal examination was performed between the 4th and 6th minutes while focusing on this visual trace.
45661180|NCT05478083|Drug|Leuprorelin|Treatment consist of leuprorelin 3.75 mg once monthly for the first 3 months followed by 3-monthly injections of 11.25 mg. The direct start group will use leuprorelin for 36 months. The delayed start group will use standard of care in the first 18 months.
45661181|NCT02750657|Genetic|Molecular Profiling|Whole Genome Sequencing
45661182|NCT02544217|Drug|KH176|
45661183|NCT02544217|Drug|placebo|
45954895|NCT05860582|Drug|[14C]GB491|A single 150mg dose of GB491 containing approximately 50 uCi of [14C]GB491.
45815518|NCT03564236|Device|Nasal High Flow Therapy|Nasal High Flow Therapy (nHFT) is an innovative therapy for patients with respiratory diseases. It supplies heated, humidified, and oxygen-enriched air at high flow rates through a nasal cannula. Because the air is provided through an open system with a nasal cannula, it is relatively easy to apply and suggested to be very comfortable for patients. The technique has been shown to be effective in the treatment of hypoxemic respiratory failure, mainly in neonates[2] and patients with acute hypoxemic respiratory failure on intensive care units (ICU).[3]
45815519|NCT03564236|Other|Standard care|Standard regular care of a COPD exacerbation
45954896|NCT05860569|Genetic|GC304|Self-complementary adeno-associated virus serotype 5 (AAV5) carrying a codon-optimized LPL coding sequence(coLPL) driven by a liver-specific promoter (LP)
45954897|NCT05860543|Diagnostic Test|C2i-WGS-MRD Test|The C2i-WGS-MRD Test (hereinafter referred to as C2i-Test), a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS) based whole-genome sequencing (WGS) data for detecting molecular residual disease (MRD) in patients diagnosed with muscle-invasive bladder cancer (MIBC) and histopathologically classified as stage II-IIIA
45954898|NCT05860491|Other|dietary fiber|Retrospective analysis of the relationship between patient dietary fiber intake and hyperkalemia
45954899|NCT05860478|Device|Wearable device|The wearable device includes a motion sensor, and is worn around the wrist, and the device records a participant's physical activity .
45815520|NCT02223390|Behavioral|Improving AIDS Care after Trauma (ImpACT)|
45954900|NCT05860413|Behavioral|Intermittent energy restriction (IER)|During Phase 1 (Weight Loss), participants will follow a very-low energy diet (VLED; 550-800 kcal/d) 2-3 days per week. On other days, participants do not have a specific kcal goal (non-fasting days). After Phase 1, IER participants will be instructed to follow a VLED 1-2 days per week as needed for weight maintenance.
46078290|NCT04216758|Drug|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
45815521|NCT05454865|Dietary Supplement|Jin Si Herbal Tea|Jin Si Herbal Tea 1 pack PO bid for 2 treatment cycles (1 cycle = 3 weeks)
45815522|NCT05454865|Dietary Supplement|Placebo|Placebo 1 1pack PO bid for 1 treatment cycle (1 cycle = 3 weeks) and followed by Jin Si Herbal Tea 1 pack PO bid for the 2nd treatment cycle
45815523|NCT04507646|Other|True auricular acupuncture|The participant in experimental group will receive acupuncture on ear Shenmen point, ear zero point, and Salivary glands.
45815524|NCT04507646|Other|sham auricular acupuncture|The participant in control group will receive acupuncture on ineffective point at ear.
46078291|NCT04216758|Drug|Gemcitabine|Patients receive gemcitabine 1000 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
46078292|NCT04216758|Drug|tegafur|Patients secondly receive tegafur Body surface area < 1.25 m^2, 60 mg/d;Body surface area ≥ 1.25 m^2 to < 1.5 m^2, 80 mg/d;Body surface area ≥ 1.5 m^2, 100 mg/d (po) on days 1-21 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
45661184|NCT05427565|Other|caffeine|The investigators will ask participant to only intake 200 mg of caffeine one hour before the experiment (no other caffeine intake since the wake-up) or avoid caffeine intake at all before the experiment
45815525|NCT02973841|Device|Sono-ease device|insertion of US guided IJV using sono-ease device
45661185|NCT05427565|Other|Experimental time|The investigators will ask participant to attend the experiment in the morning or afternoon
45661186|NCT02533999|Device|PEAK® Plasma System|Surgical method for tonsillectomy and adenoidectomy.
45661187|NCT02533999|Device|Electrosurgery|Surgical method for tonsillectomy and adenoidectomy.
45954901|NCT05860413|Behavioral|Time Restricted Eating (TRE)|Participants will eat within an 8-hour period most days (at least 5 days per week). All foods and beverages containing calories will be restricted to this 8-hour period but calorie-free beverages (coffee, tea, diet soda, etc.) are allowed at any time. TRE participants will follow healthy eating guidelines for weight loss during Phase 1 but not follow a specific kcal prescription or restrict intake thereafter.
45954902|NCT05860374|Drug|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
45954903|NCT05860348|Device|Barostim™ System|Implantation of the Barostim™ System
45661188|NCT02306551|Other|Biological and psycho-social risk and resilience factors|Naturalistic study, no active intervention or exposure is administered
45815526|NCT04507022|Drug|Estradiol Valerate|2mg three times daily
45815527|NCT04507022|Drug|Progesterone|100 mg daily intramuscular
45815528|NCT04507022|Drug|Aromatase inhibitor|2.5 mg twice daily for 5 days
45815529|NCT05272579|Other|Fecal Filtrate Transfer|Treatment with donated fecal samples filtered to contain practically no bacteria and mainly viruses, including bacteriophages
45815530|NCT05272579|Other|Placebo|Saline solution
45815531|NCT00372788|Drug|AZD6244|oral vial
45815532|NCT00372788|Drug|Pemetrexed|oral
45954904|NCT05860335|Drug|Cisplatin/Nedaplatin, albumin paclitaxel|During induction chemotherapy, triplelimab JS001 was administered before cisplatin/Nedaplatin and albumin paclitaxel. JS001 Intravenous infusion of cisplatin/Nedaplatin was administered 60 minutes after the end of infusion and beginning on day 1 of each cycle 40mg/m 2, D1, D2 albumin paclitaxel 230 mg/m 2; Chemotherapeutic drugs are administered in accordance with the drug label and local prodrome and other standard protocols for prophylactic use, every 3 Once a week (Q3W) for 2 cycles
45454364|NCT03942289|Other|The role of the noradrenergic system across the life span (Parkinson's Disease Subjects)|Three groups of Parkinson Disease (PD) patients (each of them n=15) will be studied according to the duration and stage of the disease: early stage (the same group in Task 2); mid stage (5-7 years of disease duration; Hoehn and Yahr in Off 2-3); late stage (7-10 years of disease duration; Hoehn and Yahr in Off 3-4).
46078293|NCT00776997|Device|Magnetic Sphincter Augmentation|The area of the lower esophageal sphincter (LES) is accessed using a standard laparoscopic approach. The tubular esophagus, in the area of the LES, is sized and the appropriately sized sphincter augmentation device is placed circumferentially around the esophagus in the area of the LES. After confirming proper placement, the ends of the device are secured. At this point, the implant procedure is complete, laparoscopic instruments are withdrawn and access points are closed.
46078294|NCT02821598|Other|Upper Limb pattern with flexion - abduction - external rotation|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
46078295|NCT02821598|Other|Lower Limb pattern with flexion - adduction - external rotation with knee flexion|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
46078296|NCT02821598|Other|Lower Limb pattern with flexion - abduction - internal rotation with knee flexion|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
46078297|NCT02821598|Other|Lifting to the right|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
45454365|NCT02285764|Other|Nutritional Supplement|Modified carbohydrate
45454366|NCT02285764|Other|Standard of Care|As determined by the study site
46078298|NCT02821598|Other|Sit to Stand|"Subjects will be sitting on a chair without armrests with ankles positioned at approximately 10 degrees of dorsiflexion. Knees will be kept at approximately 100 degrees of flexion. During the task, the participant will be instructed to stand from the sitting position while keeping their arms crossed over the chest. The examiner will give the command ready - set - go. The task will be performed three times."
46078299|NCT00927433|Behavioral|Psychoeducational intervention for cancer-related fatigue|Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions
46078300|NCT02749266|Other|Chiropractic adjustment|Participant will receive a chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
45454367|NCT03976999|Other|Biological collection|"Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)~Tissue samples (tumor tissue and healthy tissue) collected during the surgery"
45454368|NCT00284128|Drug|AVE7688|oral administration (capsules)
45454369|NCT00284128|Drug|Losartan-potassium|oral administration (capsules)
45454370|NCT01107691|Other|Amount of resistance offered in training|to determine the impact of the volume (1 vs. 3 sets) of a progressive resistance training protocol for inducing muscular hypertrophy
45454371|NCT00035542|Drug|Glucovance (metformin HCl/glyburide)|
45954905|NCT05860322|Dietary Supplement|Inulin|"Inulin is a water soluble non-digestible carbohydrate, and it is available in more than 36,000 species of plants. It is often used as dietary fiber and has obtained the Generally recognized as safe status (GRAS) by the Food and Drug Administration (FDA)."
45454372|NCT00035542|Drug|metformin HCl|
45454373|NCT00035542|Drug|glyburide|
45454374|NCT03941977|Device|Percutaneous introduction of cannula|An 8 gauge cannula is introduced at the site of the bone marrow lesion. The introduction of the cannula is guided by fluoroscopy.
45454375|NCT03941977|Diagnostic Test|Magnetic resonance imaging|MRI scans will be performed on a 1.5 T (Signa Excite HD, GE Healthcare, Waukesha, WI, USA) and a specific knee coil (HD TRKnee 8 Ch High Resolution Knee Array) will be used.
45954906|NCT05860322|Other|Placebo|Placebo control
45954907|NCT05860309|Other|quadratous lumborum block|The patient will be placed in the lateral position, after sterilization.. QLB will be done using ultrasound, The probe will be positioned superior to the iliac crest, in the transverse orientation, at the posterior axillary line. The Shamrock sign will be identified at the L4 level, and the insulated nerve block needle will be advanced from posterior to anterior, through the QL muscle, until the needle tip is visualized in the interfascial plane between the QL muscle and psoas muscle. As the correct needle placement is confirmed with 2-3 mL of saline, 20 mL of 0.25% bupivacaine will be injected ensuring that the psoas muscle will be pushed deeply.
46002756|NCT04979546|Other|Intensive Use of Patient Reported Outcome Measures and Open PROM Availability to Treating Neurologist|"Baseline, 6 months, and 12 months administration of HADS, EQ5D, MFIS, PDDS, PHQ-9 questionnaires in addition to Open ended text response to (limit 280 characters) What are the top 3 things you would like your MS Neurologist to know about you right now?~Additionally, the treating neurologist will be prompted to view the text response to the 3-item prompt in addition to the PROM questionnaire scores for participants in the interventional group."
46078301|NCT02749266|Other|Sham chiropractic adjustment|Participants will receive a simulated chiropractic adjustment with a handheld adjusting instrument called an Activator.
46078302|NCT04200794|Behavioral|musical instrumental training|Learning to play a string instrument in a group setting (school class)
46078303|NCT04200794|Behavioral|sensitization to music|sensitization to music via listening, theory, moderate practice on small percussive instruments and choir singing in a group setting (school class)
46078304|NCT04216914|Device|Hand outline|A simple outline of a hand, to which the child tried to match their own hand on order to improve positioning.
46078305|NCT00907699|Genetic|DNA analysis|DNA is extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways.
46078306|NCT00907699|Genetic|RNA analysis|RNA is extracted from tumor samples. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
45815533|NCT04957316|Device|Triple-effect blood purification filter|Blood purification using the oXiris filter to remove endotoxin, cytokines, and uremic toxins.
45815534|NCT02774941|Device|Jet Nebulizer|Standard single patient-use small volume JN (AirLife™ Sidestream® High-Efficiency Nebulizer, CareFusion, Yorba Linda, CA)
45815535|NCT02774941|Device|Vibrating Mesh Nebulizer|Vibrating Mesh Nebulizer (Aerogen® Solo with Ultra adapter, Aerogen Ltd, Galway, Ireland)
45815536|NCT04334018|Device|conventional CRT|"Conventional CRT or biventricular pacing resynchronizes left ventricular contraction by pacing the right and left ventricles (LV) simultaneously"
45815537|NCT04334018|Device|MPP CRT|CRT with Multipoint pacing (MPP) where pacing can occur from more than one LV site simultaneously
45815538|NCT05253001|Device|smartphone|Use the mobile chatbot approach for intervention groups to improve prenatal education.
46078307|NCT00907699|Genetic|fluorescence in situ hybridization|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
45815539|NCT05441293|Procedure|flap reconstruction|received flap reconstruction over sacrum, back, trochanter, ischium, elbow, and lower extremities
45815540|NCT04759794|Diagnostic Test|Cytology staining|"Two stainings will be performed in cytology specimens obtained from the same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography~conventional cytology staining method~new cytology staining method using the antibody of aminoacyl-tRNA synthetases"
45815541|NCT03515564|Behavioral|Dance/Movement Therapy, Art Therapy, Mindful Yoga|Utilizing deep breathing, exercise modalities, and social support in all settings
45815542|NCT04336423|Diagnostic Test|Obtain samples from sputum and feces|Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
45815543|NCT04759716|Other|Health Literacy-based Weight Control Intervention|intervention arm will be applied to receive health literacy-based mobile Health App, smart sports watch Fitbit versa during the 12 months weight control program
45815544|NCT05211505|Device|WO 2707|Intravaginal application once daily for 1 week, then twice per week until visit 3 (day 38).
45815545|NCT00372151|Dietary Supplement|L-Theanine|400 mg/day, caps.
45815546|NCT00372151|Other|Placebo|caps.
45815547|NCT04336267|Device|Transcranial direct current stimulation (tDCS) group|Patients randomized to the tDCS group were treated with the following parameters: duration of stimulation of 20 minutes per session with a 2 mA intensity of anodal stimulation.
45815548|NCT04336267|Device|Sham group|In the sham group, the stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session.
45815549|NCT00372476|Drug|Imatinib and Vinorelbine|
45815550|NCT04457492|Other|Application of FES to the Face|Functional electrical stimulation (FES) for facial paralysis is a technique in which muscles are electrically stimulated.
46078308|NCT00907699|Genetic|gene expression analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
46078309|NCT00907699|Genetic|mutation analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
45661189|NCT05455177|Other|Digital first-line intervention for osteoarthritis including exercise and education|The digital OA management programme was delivered by a smartphone application, including education and exercises based on a face-to-face osteoarthritis self-management programme provided nationwide in Sweden and designed according to national and international guidelines. Over 12 weeks, which is the recommended minimum duration of a self-management intervention for OA, a total of 163 exercise sessions and 31 educational sessions are provided.
45661190|NCT02533531|Device|1-Lead Patch|The 1-Lead Patch will record and transmit ECG data to a gateway, which will then transmit the data to a central database.
45661191|NCT05452915|Diagnostic Test|Neuropsychological (NPA)|"The neuropsychological assessment consists of following tests and questionnaires:~Wechsler Adult Intelligence Scale (WAIS)-III: Digit-Symbol-Coding (Coding)~WAIS-IV: Digit Span, Matrix reasoning~Delis-Kaplan Executive Function Scale (D-KEFS): Color-Word Test, Word Fluency Test~Ruff 2 & 7~MapCog Spectra~Questionnaires:~EuroQoL five dimensions questionnaire (EQ5D)~Hospital Anxiety and Depression Scale (HADS)~Insomnia Severity Index (ISI)~Multidimensional Fatigue Inventory-20 (MFI-20)~Multidimensional Pain Inventory (MPI)~Screening questions on physical activity~Visual analogue scale on fatigue (VAS-f) before and after NPA~Visual analogue scale on fatigue (VAS-f) and pain before and after the fMRI scanning.~Pain level, experienced during the NPA, will be rated (0-10) at the end of the session"
45815551|NCT04334096|Behavioral|quality of life pathway|The first quality of life (QoL) measurement is conducted in the hospital after surgery via a digital questionnaire (EORTC QLQ-C30, QLQ-BR23) on a tablet computer. Further QoL measures are accomplished via paper-pencil in the practice of the patient's physician during aftercare (3, 6, 9, 12, 18, 24 months after surgery). Paper questionnaires are transferred by fax to a local server, automatically processed, digitized and stored in a database, and transferred back to the physician's practice (email or fax depending on preference) in form of a QoL profile. The immediate response enables patient and physician to discuss the QoL profile right away. Specific therapeutic options for the treatment of QoL have been defined: psychotherapy, social counseling, pain therapy, physiotherapy, nutrition counseling, fitness. To provide continuous medical education, quality circles for each therapeutic option have been founded. Physicians receive a list with addresses of all quality circle members.
45661192|NCT05452915|Other|Imaging|"Imaging (24 patients + 22 controls):~BOLD resting-state before and after 20-min vigilance task (e-prime). During the vigilance task, fMRI is performed.~Clinical protocol:~High-resolution T1-weighted.~High-resolution T2-weighted Scan (FLAIR)."
45661193|NCT05452915|Diagnostic Test|Inflammatory biomarkers|Blood samples from inflammatory biomarkers will be taken on 36 patients and 36 controls. Everyone who undergoes imaging will undergo blood tests.
45661194|NCT05427019|Procedure|Distal adductor canal block|All catheters were inserted under a full aseptic technique using a real-time ultrasound-guided in-plane approach by an experienced anesthesiologist. The adductor canal catheter is inserted 2cm above the adductor hiatus.
45661195|NCT05427019|Procedure|Distal adductor canal block and Periarticular block|All catheters were inserted under a full aseptic technique using a real-time ultrasound-guided in-plane approach by an experienced anesthesiologist. The adductor canal catheter is inserted 2cm above the adductor hiatus.The periarticular injection solution contained 20mL of 7.5 mg/mL ropivacaine, 30mg of ketorolac, and 0.3mL of 1.0 mg/mL epinephrine. These agents were mixed with normal saline to a combined volume of 50mL. The surgeon injected this mixture into the tensor fascia lata, subcutaneous tissues, abductors, short external rotators muscles, and structures in the capsule.
45661196|NCT05426707|Device|RIC|RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
45815552|NCT04737967|Drug|Venlafaxine|Patients will receive will receive Venlafaxine extended release (37.5 mg) tablets once daily(Zimmerman et al., 2016)
45815553|NCT04737967|Drug|Memantine|Patients will receive memantine (10 mg) once daily (Morel et al., 2016)
45954908|NCT05860283|Device|Core stabilization exercise using pressure biofeedback unit|"From crook lying:~1st and 2nd weeks LEVEL 1: ADIM and hold for 10 seconds LEVEL 2 : Hold for 5 sec. Repeat 10 times. Opposite lower extremity on plinth; bent leg fall out.~3rd and 4th week LEVEL 3 : Opposite lower extremity on plinth a)Lift bend leg to 90˚ hip flexion b)Slide heel to extend knee c)Lift straight leg to 45˚.~5th and 6th weeks LEVEL 4 : Hold opposite lower extremity at 90˚ of hip flexion a)Lift bend leg to 90˚ hip flexion b)Slide heel to extend knee c)Lift straight leg to 45˚.~From prone lying:~Extension of each lower extremity. The exercise progression each week will be evaluated.Each exercise session lasted 20 min. The patients had to hold each exercise for 10 seconds, three sets per session and each set 10 repetitions."
45954909|NCT05860283|Procedure|Diaphragmatic release technique|This technique will be given 3 days per week for 6 weeks with total technique duration of 45 minutes. The maneuver will be repeated in 4 sets per session, each set will consist of 5 deep breaths with 2-min intervals in between sets.
45954910|NCT05860244|Drug|Salbutamol|Salbutamol for 6 months
45954911|NCT05860244|Drug|Placebo|Placebo Syrup for 6 months
46078310|NCT00907699|Genetic|polymerase chain reaction|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
45815554|NCT04441892|Device|QTc Meter|Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.
45815555|NCT05350111|Behavioral|lifestyle education|education on healthy lifestyle through group sessions and telemedicine tools
45815556|NCT03464630|Behavioral|Mom & Baby Net|CBT skills based mobile intervention targeting maternal depression and sensitive responsive parenting practices for optimizing infant social-communication promotion and provision of community resources and referral
45661197|NCT05426707|Device|Sham-RIC|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
45661198|NCT02533453|Biological|Bydureon|exenatide once weekly
45815557|NCT03464630|Behavioral|Depression & Developmental Awareness System|Supportive, person-centered mobile intervention targeting maternal awareness of maternal depression symptoms, infant developmental milestones, and provision of community resources and referral (active control condition)
45815558|NCT04334629|Drug|Ibuprofen|Lipid ibuprofen 200 mg
45815559|NCT04766918|Procedure|Sono-guided injection with high molecular weight hyaluronic acid|Sono-guided injection with hyaluronic acid (Aragan Plus, 20 mg/2 ml, 3000kDa) between carpal tunnel and median nerve
45815560|NCT04766918|Procedure|Sono-guided injection with low molecular weight hyaluronic acid|Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2 ml, 600-1200kDa) between carpal tunnel and median nerve
45815561|NCT04334564|Drug|Ginkgo biloba capsule|Ginkgo biloba capsule may improve visual function of primary open-angle glaucoma by repairing of the optic nerve.
45815562|NCT04334564|Drug|Placebos|Placebos were controls.
45815563|NCT04334551|Drug|Doravirine|switches from etravirine to doravirine, in experienced HIV patients
45815564|NCT04334785|Device|cryo-ablation|Under the guide of ultrasound, cryo-ablation for the lump of early invasive breast cancer will be conducted.
45815565|NCT05179447|Radiation|Vaginal brachytherapy|"Internal radiation of the vaginal vault using a vaginal cylinder. For brachytherapy administered alone it is recommended: suggested dose is either 3 fractions of 7 Gy or 5 fractions of 6 Gy.~For brachytherapy administered after completion of External beam radiotherapy (EBRT):~Total dose should aim to be 65 Gy, and suggested dose is 2-3 fractions of 5-6 Gy"
45815566|NCT05179447|Radiation|External beam radiotherapy|External beam pelvic radiotherapy on a linear accelerator, 45-50 Gy in 25-28 out-patients sessions
45815567|NCT05179447|Other|Observation|No adjuvant therapy, but active follow-up and quality of life questionnaires as in the groups who have adjuvant treatment
45815568|NCT05179447|Combination Product|Chemoradiation therapy|4 adjuvant cycles carboplatin and paclitaxel followed by External beam pelvic radiotherapy (45-50 Gy )
45661199|NCT05426083|Other|Physiological Assessment|Observational only
45815569|NCT03365414|Biological|Albumin (Human) 5%, USP|Albumin (Human) 5%, USP. Intravenous Solution. Plasma Substitute/Blood Derivative
45661200|NCT05424835|Drug|SHR-A1811|SHR-A1811
45661201|NCT05424835|Drug|Pyrotinib in combination with Capecitabine.|Pyrotinib in combination with Capecitabine.
45661202|NCT05424601|Behavioral|Rethink game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
45661203|NCT05424601|Behavioral|PsyPills|PsyPills is a mobile app designed to provide personalized psychological pills
45661204|NCT02533375|Drug|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
45815570|NCT03365414|Drug|Normal Saline 0.9% Infusion Solution Bag|Placebo Normal Saline 0.9% Infusion Solution Bag.
45815571|NCT00373022|Behavioral|exercise intervention|
45815572|NCT00373022|Other|flow cytometry|
45815573|NCT00373022|Other|laboratory biomarker analysis|
45815574|NCT00373022|Procedure|management of therapy complications|
45815575|NCT00373022|Procedure|psychosocial assessment and care|
45815576|NCT00373022|Procedure|quality-of-life assessment|
45815577|NCT04367090|Drug|Docetaxel, trastuzumab|Docetaxel and trastuzumab once per cycle
45815578|NCT04367090|Drug|Pyrotinib|Pyrotinib 400/320 mg orally daily
45815579|NCT05131399|Device|Phase A1|Plastic standard ankle foot orthosis
45815580|NCT05131399|Device|Phase B1|carbon medical device ankle foot orthosis
45815581|NCT05131399|Device|Phase A2|Plastic standard ankle foot orthosis
45815582|NCT05131399|Device|Phase B2|carbon medical device ankle foot orthosis
45661205|NCT05410951|Diagnostic Test|Illumina panel|"Determination of germline mutations using a recent panel including 113 genes from the Illumina protocol"
45661206|NCT05410873|Drug|MitoQ Compound|Mitoquinol mesylate
45815583|NCT03305588|Device|Unframed Virtual Cone|The patient will undergo stereotactic radiosurgery. Radiosurgery is a single non-surgical radiation treatment and will be done as an outpatient procedure. High-energy radiation will be delivered to a small, precise area of the patient's brain using a linear accelerator. A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. During the procedure, the study doctor will confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on a small area in the thalamus of the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is 30 to 60 minutes. The face mask will be removed after the treatment.
46078311|NCT00907699|Genetic|reverse transcriptase-polymerase chain reaction|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
45661207|NCT05410873|Drug|Placebo|Placebo
45661208|NCT05410795|Diagnostic Test|Magnetic resonance imaging|Enrolled subjects will be examined with MRI of pancreas, and the volume, length and thickness of coronal plane of pancreas will be measured by software.
45661209|NCT01553149|Drug|Lenalidomide|Given PO
45815584|NCT03233594|Other|Chiropractic Group|Participants will receive approximately 8 weeks of chiropractic care.
46078312|NCT00907699|Other|laboratory biomarker analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
45661210|NCT01553149|Other|Pharmacological Study|Correlative studies
45661211|NCT02551055|Drug|MLN1117|MLN1117 Tablets
45661212|NCT02551055|Drug|TAK-659|TAK-659 Tablets
45661213|NCT02551055|Drug|Alisertib|Alisertib Tablets
46078313|NCT00606437|Procedure|Total Body Irradiation with Fludarabine in UCB Transplants|Administration of the preparative regimen, infusion of the stem cell graft, inpatient care during the immediate post-transplant period and outpatient follow-up for the first 3 months after transplant and at 6, 12, 24 and 36 months. Patients will have human leukocyte antigen (HLA) serologic typing and DNA typing. Bags of UCB are thawed, and diluted by 1:1 volume using a 5% albumin/dextran solution. The thawed and diluted umbilical cord blood unit (UCBU) is next weighed and centrifuged. Specimens are obtained for cell count and viability, culture, clonogenic assays, and phenotype. The UCB is infused at a rate of 1-3 ml/min. Furosemide (0.5-1.0 mg/kg/dose) may be given if volume overload or decreased urine output occurs. Each UCB infusion shall be tested for sterility, CFU content, number of CD34+ cells, cell count and viability.
46078314|NCT02821442|Device|Acupuncture|Acupuncture points selected on the arms and legs using both acupuncture and electroacupuncture to assess effectiveness in alleviating neuropathic pain caused by chemotherapy in breast cancer patients
46078315|NCT02821442|Device|Sham Acupuncture|Placebo needles appear to penetrate but do not actually penetrate the skin
45454376|NCT03941977|Biological|Bone Grafting|A bone substitute consisting of calcium phosphate will be injected through the cannula, previously inserted, filling the area of the bone marrow lesion. GRAFTYS HBS® (Graftys, Aix en Provence, France) will be used.
45454377|NCT01209715|Drug|Placebo|participants will be assigned to 3-weeks treatment of inhaled placebo twice a day
45661214|NCT02551055|Drug|Paclitaxel|Paclitaxel intravenous infusion
45661215|NCT02551055|Drug|Docetaxel|Docetaxel intravenous infusion
45815585|NCT03233594|Other|Healthy Control Group|Participants will not receive any interventions.
45661216|NCT05470673|Procedure|Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF loaded with metronidazole|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and processed with injectable platelet rich fibrin. The injectable PRF will be mixed with 5mg/ml metronidazole first then added to the particulate demineralized dentin graft forming sticky demineralized tooth graft with slowly released metronidazole then inserted in the extraction socket and covered then suturing
45815586|NCT05107609|Behavioral|Acute Self-Compassion Intervention|Participants will be guided through a 30-minute behavioural self-compassion intervention that seeks to mitigate their psychobiological responses to the subsequent weight stigma induction. The intervention is intended to induce a flexible self-compassionate mindset that will facilitate more adaptive psychological responding to stress and activate affiliative/self-soothing physiological systems that can dampen psychobiological stress reactivity. This acute self-compassion intervention will employ a multimodal, experiential approach that is regularly utilized in self-compassion training, drawing from approaches developed in Compassion-Focused Therapy and Mindful Self-Compassion.
45815587|NCT04328558|Other|Clavipectoral fascia plane block group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
45815588|NCT05350033|Device|tDCS - tDCS|active-tDCS administered during 10 sessions, in Phase 1 and Phase 2
45815589|NCT05350033|Device|tDCS - Sham|active-tDCS administered during 5 sessions, in Phase 1
45815590|NCT05350033|Device|Sham - tDCS|active-tDCS administered during 5 sessions, in Phase 2
45815591|NCT05350033|Device|Sham - Sham|sham-tDCS administered during 10 sessions, in Phase 1 and Phase 2
45815592|NCT04853888|Behavioral|ATTACH™ Parenting Program|"ATTACH™ parenting program offers an innovative, novel approach to early intervention, focusing on improving parent-child relationship quality by targeting parents' underlying reflective function (RF)-the ability to better understand one's own and one's child's thoughts and feelings. RF is essential for high quality parent-child relationships and secure parent-child attachment, both tied to child development and health, especially cognition, communication and inflammation.~."
45815593|NCT05457127|Device|Automatic Positive Airway Pressure (APAP)|"If eligible, participants will be given a clinical Automatic Positive Airway Pressure (APAP) device for up to 3 months, while they are waiting for their clinical evaluation from a sleep physician. The APAP device will we will be using is the ResMed Airsense 11 Autoset. APAP is a smart positive airway pressure (PAP) device, where the pressure changes as needed to provide optimal pressure to splint the upper airway. Dr. Lee and Dr. Schmickl will oversee management of the device.~During the first month of APAP use, individuals will participate in weekly phone calls or in-person visits to ensure optimal adherence and troubleshoot any issues (improper mask fitting, discomfort, etc) that may arise."
45954912|NCT05860218|Other|advices|"The following advice will be given to the patients :~Walking as flexibly (normally) as possible~Advise when lifting ;~avoid twisting and bending.~for heavy objects use thighs with a vertical back.~at other times, use the back and flex it.~Heat application for 20 mins twice /day .~Avoid sitting or standing for prolonged period and change position every 15 mins.~Sitting: Sit with a back support~Driving: Use a back support (lumbar roll) at the curve of your back.~Sleeping and lying down: Select a firm mattress and box spring set that does not sag. If necessary, place a board under your mattress. You can also place the mattress on the floor temporarily if necessary."
45954913|NCT05860218|Other|exercises plus advices|"In addition to the same advice of group A, a suggested functional exercise will be performed for this group.~Sidestepping against band resistance:~The quadriped opposite arm leg aganist resistance .~Squat row on a balance board with band resistance:~Front raise single leg support with band resistance:~The Advanced Prone Bridge:~Side sliding on a fitter board (lateral lunge with band):"
45954914|NCT05860205|Behavioral|Multiple Component Mobile-Aid Pain Reduction Intervention|1.Posture training through the wearable device, UPRIGHT GO. The participant wears the device on their neck. The device provides biofeedback to poor posture with vibrations and tracks posture. 2. A daily core muscle training and stretching exercise program including trunk rotation, lumbar rotation, hip flexor stretch, side plank, glute bridge, suitcase carry, and palloff press. 3. Participants will practice stress reduction through breath focus which will help them to concentrate on deep breathing to help them ignore distracting thoughts and sensations. 4. Strategies to improve daily level of activity including wearing a Garmin device that tracks their daily physical activity and reminds them to walk and the use of the communication principle to assist participants in overcoming barriers to physical activity.
45954915|NCT05860205|Other|Osteopathic Manipulation Treatment|Osteopathic Manipulation Treatment (OMT) will be conducted by putting pressure on certain muscles in the back and performing OMT exercises on the patient. The physician will treat participants with OMT twice during month 1 and once during month 2 and 3.
45954916|NCT05860205|Other|Sham Osteopathic Manipulation|The sham osteopathic manipulation treatment (OMT) will be performed by the medical team. Hands will be placed on the patient as if the OMT is being performed. The physician will treat participants with sham OMT twice during month 1 and once during month 2 and 3.
45954917|NCT05860192|Device|Virtual Reality|Use of this virtual reality headset to deliver a single mindfulness session
45954918|NCT05860192|Other|application for mindfulness|Application used to realize mindfulness in virtual reality
45954919|NCT05860153|Drug|Levetiracetam|Group with oral levetiracetam at a dose of 15-20 mg/kg/day
45954920|NCT05860153|Drug|Diazepam|Group with diazepam at a dose of 0.3 mg/kg/dose
45954921|NCT05860114|Drug|Givinostat|Drug: ITF2357 Givinostat 10mg/mL Dose: 10mg/mL; Dosage form: oral suspension
45954922|NCT05860101|Other|Compassion-Focused Therapy|Compassion Focused Therapy (CFT) is based on the premise that we have three emotion regulation systems, the threat, drive and soothing systems. It has been suggested that our psychological wellbeing is dependent on maintaining a balance between these three systems, and if we lose this balance, e.g. the threat or drive systems become more dominant, then we start to experience emotional difficulties (Gilbert, 2009). In this study, participants are given various exercises to develop their soothing system, and help them to balance overactive threat.
45815594|NCT04247672|Device|Total Knee Arthroplasty (uncemented rotating platform ATTUNE)|All patients receive an uncemented ATTUNE rotating platform knee system.
45954923|NCT05860088|Other|Beef Diet|Controlled-Feeding Diet Intervention
45954924|NCT05860088|Other|Vegetarian Diet|Controlled-Feeding Diet Intervention
45954925|NCT05860075|Drug|IMM01|IMM01 will be administered once a week for 4 weeks.
45815595|NCT04336111|Procedure|retrolaminar block|will receive real bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position. The total desired volume used in the whole injection will be 40 ml containing 3mg / kg bupivacaine with adrenaline 2.5 2 µg/ml. The total 40 ml volume will be divided into 10 ml for each injection.
45815596|NCT05456971|Device|Art Filler Volume|Midface correction with injectable hyaluronic acid based-filler
45815597|NCT05456971|Device|Art Filler Lips|Lipscorrection with injectable hyaluronic acid based-filler
45815598|NCT04737590|Device|Bioactive glass|Comparison of bioactive glass to allogenic bone in pediatric bone cysts
45954926|NCT05860062|Dietary Supplement|Vitamin D|Patients with prophylactic treatment (amitriptyline, topiramate) + 0.266 mg of calcifediol (15,960 IU of vitamin D)
45815599|NCT04737434|Device|Extremely low frequency electromagnetic field device|with extremely low frequency electromagnetic wave deliver or not to participants during sleep.
45815600|NCT04737434|Device|electromagnetic field with no wave|electromagnetic field with no wave
45954927|NCT05860062|Other|Calcium|3: Patients with prophylactic treatment (amitriptyline, topiramate) + and Calcium: 1 Tablet every 24 hours containing: Calcium Carbonate 300 mg + Calcium Lactate Gluconate 2.94 g (500 mg of calcium).
45954928|NCT05860049|Device|istrument assisted soft tissue mobilization|"Each subject in group (A) will receive 12 sessions of physical therapy 3 sessions per week for 4 weeks).~Each subject in group (B) will receive 8 sessions of physical therapy(two sessions per week for four weeks)."
45954929|NCT05860036|Biological|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0 x 10^6 anti-BCMA CAR+T cells/kg.
45954930|NCT05860036|Drug|VRD|Bortezomib, Lenalidomide and Dexamethasone
45954931|NCT05860023|Other|Exercise|Individuals in the experimental group will be asked to perform aerobic exercise or pelvic floor muscle strengthening exercises.
45954932|NCT05860010|Drug|Epinephrine injection|patients will be placed on left lateral position and drug will be given the caudal space
46078316|NCT02749344|Other|FET after endometrial preparation|Patients included in the protocol will begin progesterone supplementation 48 hours before scheduled embryo transfer once it has been established that the endometrium is at least 7 mm and there is a leading follicle.
45815601|NCT05349877|Behavioral|Expressive writing|Write, continuously for 20 minutes, about deepest emotions and thoughts concerning experiences of minority stress, exploring a particular event and how it has affected the participant.
45954933|NCT05860010|Drug|Dexmedetomidine|patients will be placed on left lateral position and drug will be given the caudal space
45454378|NCT01209715|Drug|Fluticasone /salmeterol|Participant will be assigned to a 3-weeks treatment with inhaled fluticasone/salmeterol or matching placebo
45815602|NCT05349877|Behavioral|Self-affirmation|Write, continuously for 20 minutes, about values the participant think is important to overcome experiences of minority stress.
45815603|NCT05349877|Behavioral|Placebo|Write, continuously for 20 minutes, about their daily routine, without expressing feelings and deep thoughts about it.
45815604|NCT02590640|Device|Repetitive transcranial magnetic stimulation, MagStim Rapid2|"This study plans to learn more about the way an experimental technique called transcranial magnetic stimulation (TMS) affects a specific part of the brain, called the insula. Some research suggests that this part of the brain plays an important role in craving. The investigators plan to study the effects of TMS using standard surveys and magnetic resonance imaging (MRI) of subjects' brain."
45954934|NCT05860010|Drug|Bupivacaine|patients will be placed on left lateral position and drug will be given the caudal space
45954935|NCT05859997|Biological|BRL-301|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
45454379|NCT01112761|Device|Transcranial direct current stimulation|Each type of stimulation will be administered with a time interval of a week in between to prevent any carryover affects.
45661217|NCT05470673|Procedure|Alveolar ridge preservation using autogenous demineralized dentin graft alone|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid inserted in the extraction socket as particulate demineralized dentin graft
45954936|NCT05859984|Drug|recombinant human interferon ω spray|8 ml/bottle（contain 2 million IU recombinant human interferon ω）
45954937|NCT05859919|Drug|"The drug Rutan 0.1."|"Active ingredient: (3,6-bis-O-galloyl-1,2,4-tri-O-galloyl-β-D-glucose). Active substance: Rutan 0.1 100mg. Excipients: potato starch, calcium stearate, lactulose."
46078317|NCT02538211|Biological|Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine|All subjects will be given an oral dose of the rotavirus vaccine, RotarixTM, and intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.
45661218|NCT05470361|Procedure|stellate ganglion block (SGB)|The protocol for the SGB plus SCGB will be followed, wherein participants are given right-side procedures followed by left-side procedures on a different day if no initial improvement is seen. This procedure is carried out by injecting a local anesthetic into the neck to target the Stellate Ganglion and Superior Cervical Ganglion nerve bundles.
45815605|NCT02590640|Device|Sham repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
45815606|NCT04233476|Drug|99mTc-3PRGD2|Volunteers were injected intravenously and then scanned by SPECT/CT. Drugs use generic name：Technetium [99mTc] Hydrazinonicotinamide PEGylated Bicyclic RGD Peptide Injection dosage form:Injection dosage:0.3mCi/kg
45815607|NCT00371995|Drug|Liposomal amphotericin B and Miltefosine|"Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)"
45815608|NCT04193306|Drug|Alirocumab|Alirocumab 150 mg s.c. every 2 weeks
45815609|NCT04193306|Other|Placebo|Placebo s.c. every 2 weeks
45815610|NCT05456737|Other|assessment|Application of various assessment methods to determine the foot characteristics, foot posture, functional activity, balance levels and quality of life of the determined groups.
45815611|NCT04333940|Procedure|periapical surgery|clinical signs and symptoms, probing depth, Clinical attachment level (CAL ), dimensions of lesion, distance from the defect and apex of tooth to the anatomical structures will be measured
45815612|NCT04335877|Other|Private sector component + modified BCC|Intervention group will be exposed to the private sector component + modified BCC and will receive current standard care
45815613|NCT02303678|Drug|D2C7-IT|D2C7-IT is a single-chain fragment variable (scFv) monoclonal antibody (Mab) fragment immunotoxin with high binding affinity for both EGFRwt- and EGFRvIII-expressing glioblastoma multiforme (GBM) cells.
45815614|NCT05297539|Other|Point light display|Visualization of point-light human actions
45815615|NCT05284903|Other|Beamformer Benefit: Speech intelligibility and Listening effort|Confirm the improvement in terms of speech intelligibility (measured by OLSA, Oldenburg Sentence Test) and the reduction in terms of listening effort (measured by ACALES) of the I-BF (investigational Beamformer) compared to the R-BF (reference Beamformer), when speech is not coming from the front.
45815616|NCT05284903|Other|Speech Enhancer benefit: Speech intelligibility, Listening effort and Subjective Speech intelligibility|"Confirm the improvement in terms of speech intelligibility (measured by Oldenburg Sentence test) and the reduction in terms of listening effort (measured by ACALES) when the Speech Enhancer is on (SE ON) compared to Speech Enhancer is off (SE OFF) for distant speech or speech from adjacent room.~Confirm the improvement in terms of subjective level to follow a conversation in quiet when SE ON compared to SE OFF for distant speech or speech from adjacent room. Measured by a subjective assessment."
46078318|NCT04760990|Other|data collection|clinical data collection regarding COVID-19 suggestive symptoms or confirmed SARS-CoV-2-infections (medical events), recorded comorbidities (concomitant diseases relevant to MS and COVID-19) and recorded vaccinations (other treatments). This information is systematically collected during the routine clinical visits of the patient within the SMSC every 6-12 months.
46078319|NCT04760990|Other|analysis of blood samples|analysis of archived serum samples collected every 6-12 months within the SMSC for measurement of anti-SARS-CoV-2 antibodies in pre-pandemic reference samples and prospectively determine the anti-SARS-CoV-2-serostatus during the study period.
46078320|NCT02745366|Procedure|BFPSC+FDBA+PRF|
46078321|NCT02745366|Procedure|FDBA+PRF|
45815617|NCT05284903|Other|Hearing aid benefit: Speech intelligibility in noise (unaided vs aided condition)|Confirm the improvement in terms of speech intelligibility (measured by OLSA) in noise with the investigational device (aided condition) compared to the unaided condition.
45954938|NCT05859919|Other|Basic treatment|"Basic treatment without the drug Rutan 0.1."
45954939|NCT05859906|Other|mechanical power measurement|"Mechanical power values of the patients;~Before insufflation (baseline value),~0 min after insufflation,~15th min after insufflation,~30 minutes after insufflation,~45th minute after insufflation (if insufflation continues),~60th minute after insufflation (if insufflation continues),~Intraoperative after insufflation It will be measured with the following formula in the specified periods. MP = 0.098 x minute ventilation x [Peak inspiratory pressure - 0.5 x (Plateau pressure - Positive end-expiratory pressure)]"
46078322|NCT04267835|Procedure|MIDCAB|Surgery: MIDCAB
46078323|NCT04267835|Procedure|thoracotomy OPCABG|Surgery: thoracotomy OPCABG
46078324|NCT02821676|Procedure|PECI/SPB Block with Active Anesthetic + Placebo Multilevel Intercostal Nerve Block followed by Latissimus Dorsi Flap Breast Reconstruction|30mL of 0.5% Ropivacaine with 1:200,000 epinephrine preoperatively via an ultrasound guided PECI/SPB regional block and 5mL of Normal Saline intraoperatively as an intercostal nerve block to each of the T2-T7 nerve segments
45454380|NCT02288104|Device|needle based confocal endomicroscopy|real time imaging of living tissue at microscopic scale, through a needle.
45454381|NCT01207375|Behavioral|memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
46002757|NCT04979546|Other|Conservative Use of Patient Reported Outcome Measures and Blinded PROM Availability to Treating Neurologist|"Baseline and 12 months administration of HADS, EQ5D, MFIS, PDDS, PHQ-9 questionnaires in addition to Open ended text response to (limit 280 characters) What are the top 3 things you would like your MS Neurologist to know about you right now?~Additionally, the treating neurologist will only be prompted to view the text response to the 3-item prompt, and will not be able to access the PROM questionnaire scores for participants in the control group."
46002758|NCT00560547|Drug|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms / 4 weeks iv (starting dose)
45661219|NCT03305627|Other|Short PAP|Perioperative antibiotic prophylaxis for 24h
45661220|NCT03305627|Other|Extended PAP|Perioperative antibiotic prophylaxis for >48h
46078325|NCT02821676|Procedure|Placebo PEC/SPB Block + Multilevel Intercostal Nerve Block with Active Anesthetic followed by Latissimus Dorsi Flap Breast Reconstruction|30mL of Normal Saline via an ultrasound guided PECI/SPB block and 5mL of 0.5% Ropivacaine with 1:200,000 epinephrine as an Intercostal nerve block to each of the T2-T7 nerve segments
46078326|NCT02745054|Other|mgt of bleeding concerns/complications of oral anticoagulants|observational study of clincians' management of patients taking oral anticoagulants and having acute significant bleeding or requiring management of bleeding risk before an emergent procedure; observation limited to index hospitalization only
45661221|NCT05459285|Biological|14028 injection|14028 injection, single dose, s.c. injection
46078327|NCT00907933|Drug|SB-705498|0.5mg intranasal SB-705498
46078328|NCT00907933|Drug|SB-705498|1.5mg intranasal SB-705498
45454382|NCT01207375|Behavioral|placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 placebo control sessions.
45661222|NCT05459285|Biological|dulaglutide injection|dulaglutide injection(TRULICITY®), single dose, s.c. injection
46078329|NCT00907933|Drug|SB-705498|3mg intranasal SB-705498
45815618|NCT05284903|Other|Hearing aid benefit: Speech intelligibility in noise (aided condition)|Confirm the improvement in terms of speech intelligibility (measured by OLSA) with the Reference binaural beamformer compared to the fixed directional.
45815619|NCT00372307|Drug|Application of pimecrolimus|
45815620|NCT04137133|Diagnostic Test|collection|bronchial secretions, blood, stools, superficial skin sample, dental plaque sample and urine
45815621|NCT04647110|Drug|crizotinib|as provided in real world practice
46078330|NCT00907933|Drug|SB-705498|6mg intranasal SB-705498
45661223|NCT02542943|Device|Experimental Oral Rinse 1|(1.5% w/w KOX, pH 4.5)
45661224|NCT02542943|Device|Experimental Oral Rinse 2|(1.5% w/w KOX, pH 7)
46078331|NCT00907933|Drug|SB-705498|12mg intranasal SB-705498
46078332|NCT00907933|Drug|Placebo|Placebo '498
46078333|NCT00907933|Drug|SB-705498|6mg intranasal SB-705498 for 14 days bid
46078334|NCT00907933|Drug|SB-705498|12mg intranasal SB-705498 14 days bid
46078335|NCT00907933|Drug|Placebo|Placebo
46078336|NCT02851199|Device|Electroencephalography|Electroencephalograph recording following hyperventilation in different participant's body postures
46078337|NCT00908089|Drug|Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab|methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and infliximab 3 mg/kg during first 6 months
45661225|NCT02542943|Other|Placebo Oral Rinse|(0% w/w KOX, pH 4.5)
45661226|NCT02542943|Drug|Standard fluoride toothpaste|1000ppm fluoride as sodium monofluorophosphate
45661227|NCT03284957|Drug|Amcenestrant|"Pharmaceutical form: capsule~Route of administration: oral"
45661228|NCT03284957|Drug|Palbociclib|"Pharmaceutical form: capsule~Route of administration: oral"
45661229|NCT03284957|Drug|Alpelisib|"Pharmaceutical form: tablet~Route of administration: oral"
45661230|NCT03284957|Drug|Everolimus|Pharmaceutical form: tablet
45661231|NCT03284957|Drug|Abemaciclib|Pharmaceutical form: tablet
45661232|NCT02542865|Dietary Supplement|Fortified malt based food|Fortified malt based food
45661233|NCT05469893|Drug|Teclistamab|Intravenous (IV) dosage and timing per protocol design
45661234|NCT05469893|Drug|Lenalidomide|Oral, dosage and timing per protocol design
45661235|NCT05469893|Drug|Dexamethasone|Oral, dosage and timing per protocol design
45661236|NCT05477927|Biological|Dual-targeting VEGFR1 and PD-L1 CAR-T cells|"In the dose escalation part, the dose levels will be escalated following a traditional escalation scheme for 3+3 design.~In the dose expansion part, patients will be assigned to different groups based on pleural or peritoneal metastases condition."
45815622|NCT04647110|Drug|alectinib|as provided in real world practice
45815623|NCT04647110|Drug|brigatinib|as provided in real world practice
45815624|NCT04647110|Drug|ceritinib|as provided in real world practice
45815625|NCT04647110|Drug|lorlatinib|as provided in real world practice
45815626|NCT05455957|Other|exercise|neuromuscular and vestibulo-ocular training
45815627|NCT04061785|Other|Judo4Balance - 12 week judo inspired exercise program|12 weeks x 45 minute judo inspired exercise in lead by instructor in a group setting.
45815628|NCT05455801|Device|negative preassure wound therapy|wound treated with negative pressure therapy dressing
45815629|NCT04061330|Drug|Ketamine|Initial bolus of ketamine 0.3 mg/kg IV (maximum 30 mg) followed by ketamine infusion of 0.25mg/kg/hr (maximum 25mg/kg/hr) for 6 hours or until patient leaves the emergency department (ED),whichever occurs first.
45815630|NCT04061330|Drug|Morphine|Bolus doses of morphine 0.1 mg/kg (maximum 8 mg) intravenously every 2 hours for 6 hours or until patient leaves the ED, whichever occurs first.
45815631|NCT00372632|Drug|Sulfadoxine-Pyrimethamine|The intervention group receives 1500mg of sulfadoxine and 75mg of pyrimethamine at enrollment and in the third trimester.
46078338|NCT00908089|Drug|Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo|methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and placebo infusion during first 6 months
46078339|NCT05378633|Radiation|SRS|Stereotactic Radiotherapy (SRS)
46078340|NCT05378633|Radiation|Whole Brain Radiotherapy|Whole Brain Radiotherapy (WBRT)
46078341|NCT02745444|Dietary Supplement|low-calorie formula diet|
46078342|NCT02745444|Dietary Supplement|protein-restricted diet|
46078343|NCT04758416|Procedure|biopsy or surgical pathology in metastases|biopsy or surgical pathology in extrahepatic/liver/brain metastases
45815632|NCT00372632|Drug|placebo|The control group receives placebo similar in taste and appearance to to the experimental arm
46078344|NCT04758416|Drug|68Ga-HER2 affibody,18F-FDG, 18F-FES|68Ga-NOTA-MAL-MZHER2 (68Ga-HER2) affibody is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
45815633|NCT05455723|Procedure|Tracheal Intubation|Inflation-Deflation Technique Versus Magill Forceps Technique for Nasal Intubation by Video-assisted Laryngoscope
45661237|NCT05477771|Procedure|Arthroscopic rotator cuff repair|The rotator cuff tears were repaired under arthroscopy. A subacromial decompression was performed in all patients. Then the long head of the biceps with severe lesions were treated by tenotomy while the others were reserved according to the surgeon's judgment during the surgery.
45661238|NCT04469855|Drug|semaglutide|Patients will be treated with commercially available Ozempic® according to routine clinical practice at the discretion of the treating physician. The treating physician's decision to initiate treatment with Ozempic® is independent of the decision to include the patient in the study.
45661239|NCT03644927|Behavioral|Progressive exercise training|The 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12,. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing..
45815634|NCT05455645|Other|targeted intrinsic foot muscle exercises|4 targeted intrinsic foot muscle exercises
45815635|NCT03964454|Behavioral|WIC support + home-based individual support + Breastfeeding Incentives (SC+BFI)|Participants randomized into SC+BFI will receive the same services as the Standard Care Control (SC) group (standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving) plus financial incentives (Breastfeeding Incentives, BFI) contingent on observed breastfeeding.
45815636|NCT03964454|Behavioral|WIC support + home-based individual support (SC)|Participants randomized into SC will receive standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving.
45815637|NCT04525352|Biological|RP-L401|CD34+ enriched hematopoietic stem cells from pediatric subjects with infantile malignant osteopetrosis transduced ex vivo with lentiviral vector carrying the TCIRG1 transgene
45815638|NCT03991195|Dietary Supplement|Probiotic supplemented intervention|In this project, taking the method of random, double blindness and control, the probiotic supplemented group with aMCI will take Bifidobacterium for three months. After that, cognitive changes will be test to investigate the effectiveness of probiotic supplementation.
45815639|NCT03991195|Dietary Supplement|Placebo|In this project, taking the method of random, double blindness and control, the placebo group with aMCI will take placebo for three months. After that, cognitive changes will be test.
45815640|NCT05125237|Drug|Amiloride|Amiloride claim is used as the exposure group.
45815641|NCT05125237|Drug|Triamterene|Triamterene claim is used as the reference group.
45815642|NCT04821115|Device|Low intensity choc waves therapy (active applicator)|At each of the 4 sessions, 4000 shockwaves will be delivered at level 8 (EFD = 0.133 mJ/mm2), over a period of 15 to 20 minutes. The probe will be applied directly to the plaque, on the flaccid penis. The device will stop automatically after the 4000 shock waves.
45815643|NCT04821115|Device|Sham (sham applicator)|At each of the 4 sessions, a sham applicator will be used. The sham applicator has an internal foam pad that disperses the shockwave energy, but is not visible from the outside. The sham applicator will look, feel and sound the same as the active, but no measurable energy is emitted.
45815644|NCT04333693|Procedure|Vascular surgery|Open vascular, endovascular or hybrid procedures
45815645|NCT04809883|Diagnostic Test|Endoflip measurement of gastric and pyloric function|Endoflip device to measure gastric and pyloric functions
45815646|NCT04792021|Drug|N-acetylcysteine|Oral formulation: 600 mg sachets of N-acetylcysteine
45815647|NCT05093413|Behavioral|Sleep deprivation|Fully slept: Sleep habitual amount (i.e., go to sleep at habitual bedtime and wake up at habitual wake time) Sleep deprived: Reduce sleep by 50% (i.e., go to sleep at habitual bedtime and wake up early)
45815648|NCT03905629|Other|None (retrospective observational study)|"This multi-centric retrospective observational cohort study is conducted using the PMSI. Predictive ability of HFRS estimated on the basis of 3 binary outcomes: 30-day in-patient mortality (main outcome), 30-day emergency and potentially avoidable readmission, length of stay >15 days. Odds ratios (ORs) and c-statistics calculated and compared to the original UK results in order to validate the use of the HFRS in France. Other secondary objectives include:~Evaluate agreement between HFRS and Charlson or Elixhauser comorbidity indices~Evaluate ability of HFRS combined with comorbidity indices (Charlson on one hand, and Elixhauser on other hand), to predict 30-day in-patient mortality, 30-day emergency and potentially avoidable readmissions, and long length of stay~Identify specific risk associations in France of a high risk of frailty (as assessed by the HFRS) with individual, organizational and territorial factors"
45815649|NCT04334161|Combination Product|Administration of glucose and controlled induction of hypoglycaemia.|Functional metabolic test involving a 15g oral glucose load (enriched with 1.5% U-13C glucose) and subsequent controlled 20min hypoglycaemic clamp period. Neuroendocrine response will be assessed using frequent blood samples for hormones and metabolites, continuous heart rate monitoring and evaluation for hypoglycaemic symptoms.
46002759|NCT04644510|Device|Lung ultrasonography|Standardized eight-point Lung ultrasonography
46002760|NCT04975607|Behavioral|Music Therapy|The three live music therapy sessions will be provided after lung transplant. All three music therapy sessions will employ a variety of data-based interventions to address pain, anxiety, and improve relaxation. Music therapy interventions may include patient preferred live music, active music listening, singing or other active music-making, and guided breathing and relaxation.
46002761|NCT04636047|Other|The method of gene mutation detection|All samples were detected by NGS CGP panel.
45815650|NCT04978285|Other|Anemia|Depends on Day 3 Hb result
45954940|NCT05859893|Behavioral|Classical Turkish Music Sessions|The participants attended an interactive livestreamed music performance. In selecting the mode, tempo, and songs to be performed, recommendations were obtained from the Applied Music Therapies Association, and the pieces with copyrighted recordings presented by the Edirne State Turkish Music Ensemble, under the leadership of the General Directorate of Fine Arts of the Ministry of Culture and Tourism. As part of the project, examples of traditional Turkish songs were presented to the elderly. The recommended genres and songs consist of vocal and instrumental works belonging to major and minor scales from the Classical Period, which spans from the 14th to the 20th century. In this respect an assembly of eight-musican consisting of five artists playing kanun, tanbur, ney, classical kemençe, and bendir, as well as two vocal soloists performed.
45954941|NCT05859841|Other|Music listening|Music listening under instruction by music therapist, min 3 hours daily
45954942|NCT05859841|Other|Control|Standard treatment, care and rehabilitation
45954943|NCT05859815|Behavioral|Physical Therapy|As part of their normal care, participants will receive any combination of the following interventions to address their specific needs identified during the initial evaluation: cervical spine repeated movements (active range of motion), cervical spine stabilization exercise, aerobic exercise, motor control training, oculomotor/vestibular rehabilitation, stretching, soft-tissue mobilization, joint mobilization, and postural re-education activities.
45954944|NCT05859802|Drug|Dalfampridine Pill|Subjects were blinded and randomized into 2 groups; Group 1 received physical therapy 2 x a week for 12 weeks while taking dalfampridine 10 mg two times day
45661240|NCT03644927|Behavioral|Waitlist Control|Participants will be screened for eligibility and if randomized into the waitlist control group. Wait list participants will wait for 12-weeks before they can participate in the progressive exercise training program. The 12 week progressive exercise program is identical to the one used in the intervention group. Specifically, the 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing.
45954945|NCT05859802|Drug|Placebo|Subjects were blinded and randomized into 2 groups; Group 1 received physical therapy 2 x a week for 12 weeks while taking a placebo pill two times day
45661241|NCT03629171|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
45815651|NCT04957303|Device|sublingual microcirculation video recording|The sublingual microcirculation videos were recorded by video microscope
45815652|NCT00372463|Behavioral|6-week Online Diabetes Self-Management Educational Program|
45661242|NCT03629171|Drug|Venetoclax|Given PO
45661243|NCT03611153|Drug|AZD4831 Oral Myeloperoxidase Inhibitor|A single administration dose of 30 mg oral MPO inhibitor given orally following baseline, resting and exercise testing in patients during right heart catheterization.
45661244|NCT03611153|Drug|Placebo oral capsule|A single administration dose of 30 mg placebo given orally following baseline, resting and exercise testing in patients during right heart catheterization.
45815653|NCT04634773|Radiation|Low-dose CT|"A low-dose, or quantitative (q) CT scan will be performed on the shoulder. This CT scan will be done to assess the bony structure of the shoulder, as well as bone strength, which can influence the health of the cartilage.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years."
45815654|NCT04634773|Other|T1Rho MRI|"A T1Rho MRI will be performed on the shoulder. This imaging technique uses a special sequence and will be used to assess the muscles and tendons around the shoulder.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years."
45815655|NCT04634773|Other|Motion Analysis|"Motion analysis is the study of how joints move and which muscles fire during specific movements. In the lab, participants will be asked to perform movements that they might do during a typical day or when exercising.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years."
45815656|NCT03713437|Diagnostic Test|Measurement of differentially methylated insulin DNA|A serum sample will be drawn to measure differentially methylated insulin DNA.
45815657|NCT04625023|Other|Observational|Retrospective cohorts and Prospective observation of standard clinical practice
45815658|NCT04926961|Device|Sham transcranial magnetic stimulation (TMS)|Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.
45815659|NCT04926961|Device|Real transcranial magnetic stimulation (TMS)|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil.
45815660|NCT04737811|Other|Turkish Version of Swallowing Disturbance Questionnaire|The Turkish Version of Swallowing Disturbance Questionnaire consists of 15 questions related with dysphagia.
45815661|NCT04540003|Other|Access to School Based Health Centre|The SBHC will be staffed by a family physician, two pediatricians and a developmental pediatrician, each with at least one half-day of clinic time per week from September through June. The SBHC is also staffed by a clinic coordinator who is responsible for booking appointments on a first-referral, first-serve basis.
45815662|NCT04333927|Drug|Chemotherapy|Capecitabine (1,330 mg/m2 per day, in divided doses twice daily, 7 days per week).
45815663|NCT04333927|Other|Observation|Patients in observation group will not receive any anti-cancer therapy.
45661245|NCT02542631|Device|Bolus Insulin Patch (Calibra Finesse)|
45661246|NCT02542631|Device|Insulin Pen (Novo-Nordisk FlexPen®)|
45661247|NCT05459051|Diagnostic Test|Rest-angina physiological assessment|The degree of stenosis required to cause angina at rest will be measured under double-blinded placebo controlled conditions using sequential intracoronary balloon inflations. This will then be correlated with various physiological indices, including FFR and iFR.
45954946|NCT05859789|Procedure|kegel exercise|"Each female will be asked to Try to squeeze her pelvic floor muscles as much as possible. She was instructed that the numbers she saw at the top of screen indicated the activity of the muscle (electrical activity), in microvolt (mv).~The therapeutic session will be repeated 3 sessions /week for 12 weeks for each female in both groups (A&B).~Each female will be instructed to Tighten her pelvic floor muscles. Hold tight and count 3 to 5 seconds, relax the muscles and count 3 to 5 seconds, then repeat 10 times, 3 times a day at least three sets of 10 to 15 repetitions a day as a home program~They will be instructed not to use abdomen, thighs or buttock muscles during the contraction, avoid holding breath. Instead, breathe freely during the exercises."
45661248|NCT05459051|Diagnostic Test|Exercise-angina physiological assessment|The degree of stenosis required to cause angina during exercise will be measured under double-blinded placebo controlled conditions using sequential intracoronary balloon inflations. This will then be correlated with various physiological indices, including FFR and iFR.
45661249|NCT02549573|Drug|APOKYN|Subjects in the APOKYN+ group will administer his/her usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit.
45815664|NCT04333927|Procedure|Immunotherapy|Camrelizumab 200mg intravenously every 3 weeks until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal.
45661250|NCT02549573|Behavioral|Physical Therapy|All subjects will participate in a standardized PT intervention
45815665|NCT04333927|Radiation|Radiotherapy|45 Gy to regional lymph nodes and 54 to 59.4 Gy to preoperative tumor bed.
45661251|NCT02542397|Genetic|Pharmacogenomic Testing|Pharmacogenomic test results to guide drug/dose modifications
45661252|NCT05457491|Biological|Human platelet extract (cosmetic product)|A leukocyte depleted allogeneic product derived from human U.S. sourced pooled apheresed platelets (derived from screened healthy donors). Applied to face twice daily for 12 weeks.
45661253|NCT05457491|Other|Vanicream Gentle Facial Cleanser|A mild cleanser specifically formulated for daily facial use. Applied to face twice daily for 12 weeks
45815666|NCT04334005|Dietary Supplement|Vitamin D|The intervention group will receive a single dose of 25000 UI of vitamin D supplement in addition to prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations. Vitamin D supplementation will be taken in the morning together with a toast with olive oil to facilitate its absorption.
45815667|NCT04486261|Other|High-intensity strength training|The high-intensity strength training protocol will consist of 2 training sessions per week. The first two weeks will be familiarisation training, where each exercise will be performed in three sets of 10 repetitions at an intensity of 15 repetitions maximum (RM). At week three each session will consist of 3 sets of each exercise corresponding to 10 RM, which will be kept for the remaining part of training intervention. The weights for each exercise will be adjusted throughout the intervention period, so the training load will correspond to 10 RM for each exercise in the entire intervention period.
45815668|NCT03879512|Drug|depletion of regulatory T cells|oral metronomic cyclophosphamide
45815669|NCT03879512|Procedure|reoperation|resection of relapsed tumor in order to improve clinical condition of the patient and to acquire tumor tissue for vaccine generation
45954947|NCT05859789|Other|Mediterranean diet regimen for 12 weeks.|kegel ex in addition to mediterrian diet . The recommended composition of the dietary regimen was the following: carbohydrates 50-60%, proteins 15-20%, total fat o30%, saturated fat 10% and less than 300 mg of cholesterol consumed per day. Moreover, subjects Will be advised to consume at least 250-300 g of fruits, 125-150 g of vegetables and 25-50 g of nuts per day.
45954948|NCT05859776|Drug|AXT107 Low Dose|Single suprachoroidal injection of AXT107 (0.125 mg/eye)
45458127|NCT04913077|Other|removal of submucosal gastric tumor preferably by Full Thickness Resection Device (FTRD)|FTRD (Ovesco company) in tumors up to 10 mm and predominantly intraluminal growth directly by sucking into the cap, at 10-20 mm and/or intramural/extramural growth by prior circumcision and lateral preparation, so that the lesions can be better pulled into the cap. The procedure depends on the endosonographic extent of the findings. The lesions are pulled into the cap with grippers and other instruments and, if necessary, with a snare and then resected with FTRD
45676631|NCT00866554|Drug|administration of Bicalutamide, Dutasteride and Tamoxifen|"Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered."
45815670|NCT03879512|Biological|cancer vaccine|4 weekly intradermal injections of lysate-loaded dendritic cells, followed by 3 monthly boost vaccines with tumor lysate and further boost vaccines every three months
45458128|NCT02314234|Drug|sugammadex (Bridion)|single dose of sugammadex at skin incision
45458129|NCT03542227|Other|First-void urine collection|Collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) during visit at the Centre for the Evaluation of Vaccination.
45661254|NCT05457491|Other|EltaMD UV Daily Broad-Spectrum SPF 40|A daily moisturizer with a lightweight formula that provides broad-spectrum sunscreen protection. EltaMD UV Daily Broad-Spectrum SPF 40 provides powerful protection against the sun's harmful UV rays, as it hydrates and is gentle enough for post-procedure skin. Powered by hyaluronic acid, this face sunscreen plumps the skin with lightweight moisture, while micronized zinc and octinoxate shield skin from UVA/UVB rays to prevent the visible signs of environmentally caused aging. Applied to face once daily for 12 weeks.
45815671|NCT03879512|Biological|checkpoint blockade|Immediately one week after the DC-induction vaccines, patients will receive four applications of Nivolumab/Ipilimumab double checkpoint blockade in threeweekly intervals, followed by Nivolumab monotherapy every month for a total duration of one year.
45954949|NCT05859776|Drug|AXT107 Mid Dose|Single suprachoroidal injection of AXT107 (0.250 mg/eye)
45954950|NCT05859776|Drug|AXT107 High Dose|Single suprachoroidal injection of AXT107 (0.500 mg/eye)
45954951|NCT05859763|Drug|99mTc-HFAPI|Each patient receive a intravenous injection of 99mTc-HFAPI, and undergo SPECT/CT scan within specified time.
45661255|NCT05457491|Other|EltaMD PM Therapy Facial Moisturizer|A fortifying face moisturizer to repair elasticity and vitality. EltaMD PM Therapy Facial Moisturizer restores youthfulness while strengthening the skin's natural moisture barrier. Niacinamide blends with antioxidants to boost the skin color and tone, as it speeds up the skin's repair processes. Rice protein peptides aid in encouraging cell growth, promoting collagen formation and improving elasticity. Applied to face once daily for 12 weeks.
45661256|NCT05457491|Other|Vanicream Lite Lotion|Lotion to restore and maintain a normal moisture level. Applied to face twice daily for 12 weeks.
45815672|NCT04445233|Device|COVID-19 IgM-IgG Rapid Test|Used to detect the IgG and IgM antibodies of the novel coronavirus in human whole blood (capillary or venous), serum, or plasma.
45954952|NCT05859750|Drug|AK104|AK104 (6mg/kg) on day 1, IV, Q2W
45661257|NCT05477615|Drug|Lazertinib|- Lazertinib 240mg (3 tablets, 80mg/1tablet) once a day, oral, before disease progression
45954953|NCT05859750|Drug|AK104|AK104 (10mg/kg) on day 1, IV, Q2W
45954954|NCT05859750|Drug|Gemcitabine|Gemcitabine (1000mg/m2) on days 1, 8 and 15, IV, Q4W
45954955|NCT05859750|Drug|Nab-Paclitaxel|Nab-Paclitaxel (125mg/m2) on days 1, 8 and 15, IV, Q4W
45954956|NCT05859711|Drug|thyme honey mouth rinse|oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy. (Charalambous et al.,2017)
45954957|NCT05859711|Drug|saline mouth rinse|saline mouth rinse 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy
45954958|NCT05859646|Dietary Supplement|Probiotic use|Probiotics were used for 3 months and all participated patients were followed for 6 months.
46078345|NCT04218396|Device|Virtual Reality use during painful bedside procedure|Virtual reality (VR) will be used in addition to standard analgesic practices during painful bedside procedures. A head mounted display (HMD, Oculus Go Model #1KWPH812PN8354) and noise-cancelling headphones (Sony Model #MDRZ110B) will be provided to the patient during the procedure. This unit involves the patient wearing VR goggles, noise-cancelling headphones, and using a smartphone-based program with various applications the patient can choose from for analgesia/relaxation (eg: calming imagery/scenery of nature, activities involving mindfulness, interactive games or guided imagery, music and imagery, exercise imagery...etc). There are numerous, standard applications available for the patient to choose from, and the choice of most optimal application for analgesia, distraction, or anxiolysis will be left to the decision of the patient prior to their procedure.
46078346|NCT04218396|Drug|Standard Treatment during painful bedside procedure|Pharmacologic sedation or high dose opioids (e.g. nurse-administered IV opioids, anxiolytics and sedatives, patient-controlled analgesia, anesthesiologist administered sedation, general anesthesia if required)
45458130|NCT03542227|Other|Blood draw|Blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccination.
45661258|NCT05477615|Drug|Pemetrexed|- Pemetrexed 500mg/m2 is administered on the 1st day every 3 weeks. One cycle of treatment is defined as continuous administration for 21 days. Pemetrexed and carboplatin can be administered in reduced doses according to the principles of each institution.
45676632|NCT00739362|Device|Transcranial Direct Current Stimulation (TDCS)|Active tDCS (anodal left DLPFC)
45676633|NCT00739362|Other|Sham/no-stimulation|Sham tDCS
45815673|NCT00373009|Behavioral|Traditional Army training|As usual training for Soldiers
45815674|NCT00373009|Behavioral|Core stabilization exercise only|Core stabilization exercise
45815675|NCT00373009|Behavioral|Psychosocial education class only|Psychosocial education class
45815676|NCT00373009|Behavioral|Core stabilization and psychosocial education|Includes both core stabilization training and psychosocial education class
45815677|NCT00966914|Drug|Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Tavocept(BNP7787) 18.4gm/m2 IV every 3 weeks
45815678|NCT00966914|Drug|Placebo in combination with cisplatin and docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Placebo IV every 3 weeks
45954959|NCT05859633|Diagnostic Test|Neutrophil/Lymphocyte Ratio in acute pancreatitis|role of Neutrophil/Lymphocyte Ratio in acute pancreatitis
45954960|NCT05859620|Other|Patient assessment and follow-up|There is no study-specific intervention. The investigators will record data generated by clinical activity before, during and after implementation of the PMI-screening. Follow-up data and the final PMI event adjudication will be the only data generated specifically for this study.
45954961|NCT05859607|Procedure|laparoscopic cholecystectomy|conventional laparoscopic cholecystectomy with calculation of difficulty scorings
45954962|NCT05859594|Other|Laughter yoga|Although the history of laughter yoga dates back to ancient times, its use in medicine has become widespread in the 21st century, while it is used to reduce pain, anxiety, stress, depression and fatigue, it is also a method that can be used to accelerate immunity, quality of life, happiness, sleep quality and recovery.
46002762|NCT00547937|Device|nasal continuous positive airway pressure (CPAP) therapy|Nocturnal ventilation through a nasal mask to avoid sleep apneas
46078347|NCT05378555|Drug|Ketamine Hydrochloride|All patients in this study will receive oral ketamine for the treatment of pain from vaso-occlusive crisis. Patients will receive 0.5 mg/kg ketamine Q8hrs for 48 hours.
45954963|NCT05859581|Procedure|Beyond complete mesocolic excision surgery|If the participants were diagnosed with positive retroperitoneal resection margin (RPRM), they underwent beyond complete mesocolic excision surgery to ensure the R0 resection.
45954964|NCT05859568|Device|Pinna-located microphone|Sound processors using a pinna-located microphone
45661259|NCT05477615|Drug|Carboplatin|- Carboplatin AUC x 5 mg/mL.min is administered on the 1st day every 3 weeks. One cycle of treatment is defined as continuous administration for 21 days. Pemetrexed and carboplatin can be administered in reduced doses according to the principles of each institution.
45661260|NCT05477537|Other|Adapted physical activity program|subjects with Anorexia Nervosa (AN) involved in a day hospital or an inpatient program following HAS guidelines for anorexia nervosa treatment (treatment as usual) who will receive in addition an adapted physical activity program (one lesson per week, during 8 weeks) Adapted Physical Activity program, including psychoeducation on both problematic physical activity and consequences in terms of physical activity good practice leads to a better outcome among persons suffering from anorexia nervosa.
45954965|NCT05859568|Device|Pinna-simulated microphone algorithm|Sound processors using a pinna-simulated algorithm
45954966|NCT05859555|Other|Thematic quality circles - Deprescription|Thematic quality circles on benzodiazepines and analogues with a pharmacist (practical cases)
45954967|NCT05859542|Device|Videolaryngoscope first|started the session with 3 intubations using the videolaryngoscope
45954968|NCT05859542|Device|Direct laryngoscope first|started the session with 3 intubations using the Direct laryngoscope
45954969|NCT05859516|Diagnostic Test|Ultrasound|Every time checking pulse, evaluate the carotid artery compressibility and blood flow of peripheral arteries by ultrasound，compared with EtCO2.
45954970|NCT05859490|Biological|17D|Vaccine administration in subjects previously vaccinated with 17D.
45954971|NCT05859477|Drug|Nivolumab|360 mg, i.v., every 3 weeks
45954972|NCT05859477|Drug|Capecitabine|capecitabine 1000 mg/m², orally, twice a day, days 1-14 of each cycle
45661261|NCT05477537|Other|Treatment as usual group|Subjects with Anorexia Nervosa involved in a day hospital or an inpatient program following HAS guidelines for AN treatment (treatment as usual)
45954973|NCT05859477|Drug|Oxaliplatin|30 mg/m², i.v., day 1, every 3 weeks
45954974|NCT05859438|Other|Communication aid support|Support to use voice input voice output communication aids
45954975|NCT05859412|Other|Neurodynamic exercises|The neurodynamic exercises will consist of a home-based exercise programme performed over a period of 6 weeks. Patients will attend a single session with an investigator who will instruct them the home exercise programme consisting of nerve and tendon gliding exercises which will be adjusted with pre-specified progressions over the 6 weeks intervention period. Patients will receive a leaflet and a video link detailing these exercises.
45661262|NCT02549339|Drug|LEO 43204 gel|
45661263|NCT02549339|Drug|Vehicle gel|
45661264|NCT05469503|Dietary Supplement|TOTUM-854|12 weeks of TOTUM-854 supplementation
45661265|NCT05469503|Dietary Supplement|Placebo|12 weeks of placebo supplementation
45661266|NCT02549027|Drug|MK-1064|Oral MK-1064 tablets (10 and 50 mg strengths)
45661267|NCT02549027|Drug|MK-6096|Oral MK-6096 tablets (5 mg strength)
45661268|NCT02549027|Drug|Placebo|Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
45661269|NCT05477303|Other|taking a picture of a painful facial expression|Immediately after surgery, the patient's facial expression and the NRS score and ANI score reported by the patient are checked together.
45661270|NCT03593525|Other|SPARK|see above
45661271|NCT05478629|Other|Survey|Questioning through google forms
45661272|NCT02710097|Drug|Active inhaled cannabis|"~450 mg of active cannabis, which is roughly equivalent to smoking 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer."
45954976|NCT05859412|Drug|Steroid injection (Depomedrone 40mg)|Steroid injection (Depomedrone 40mg) into the carpal tunnel as per standard practice in patients with carpal tunnel syndrome
45954977|NCT05859412|Other|Advice|Group receiving advice but no additional treatment
45954978|NCT05859399|Other|Laughter yoga|Although the history of laughter yoga dates back to ancient times, its use in medicine has become widespread in the 21st century, while it is used to reduce pain, anxiety, stress, depression and fatigue, it is also a method that can be used to accelerate immunity, quality of life, happiness, sleep quality and recovery.
46002763|NCT04644900|Other|chewed mint gum|In the preoperative waiting area before transferring to the operating room,patients in group G chewed mint gum for 2 minutes and then spit it out.
46078348|NCT02538445|Other|Memorization of the verbs by miming the action|The participant reads aloud the verbs that appear on the screen, by performing the corresponding action verb.
46078349|NCT02538445|Other|Memorization of the verbs by imagining the action|The participant reads aloud the verbs that appear on the screen, by imagining the corresponding action verb.
46078350|NCT02538445|Other|Memorization of the action verbs by means of another word|The participant reads aloud the verbs that appear on the screen. Then, he reads, without memorizing it, a word associated with the action verb to be learnt to favor the memorization of that one. The word is written near the action verb.
45954979|NCT05859386|Behavioral|Mindfulness maintenance program|"Four-week course to strengthen and extend skills learned in 8-week MBCT course. This will consist of four 2-hour sessions, occurring weekly for four weeks.~Monthly 1.5 hour meeting sessions. These will be led by an experienced MBCT teacher and will consist of a group meditation practice, a check-in time, and discussion of a topic relevant to the MBSR course.~Monthly check-in survey. This will be a brief (5 - 10 minute) survey (using Qualtrics) with questions about mood (PROMIS Depression and Positive Affect scales) and recent meditation practice."
45954980|NCT05859373|Combination Product|TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation|TQB3728 is an inhibitor of apoptosis protein. TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
45954981|NCT05859373|Combination Product|TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation|TQB3728 is an inhibitor of apoptosis protein. TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
45454383|NCT01109563|Behavioral|Marijuana Check-Ins|The MCI, an MET intervention, will include the provision of personalized feedback with a motivational interviewing style. The focus of these sessions will be individualized to participants based on recent marijuana use and related experiences. Feedback given to participants during the MCI session will review progress toward goals as self-reported in percent days abstinent, normative data regarding marijuana use, review of reported consequences of marijuana use, review of abuse and dependence criteria reported, comparison of consequences and abuse and dependence symptoms reported over time, review of the positive outcomes from reductions in use, and review of immediate and long-term life goals and how their marijuana goal will affect these. HEs will offer particular encouragement to take advantage of CBT sessions to participants who feel they currently need treatment.
45954982|NCT05859373|Combination Product|TQB2450 injection, sequential or concurrent chemoradiation|TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
45954983|NCT05859347|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive neuromodulatory technique that applies alternating magnetic fields to the scalp to induce electric currents in localized cortical tissue. The intervention (LF or HF rTMS) will be administered daily 5 days/week for 4 weeks, using the MagVenture MMC-140 circular coil, with the brain regions targeted as the bilateral prefrontal cortex and the insula.
45661273|NCT02710097|Drug|Placebo|Approximately 4 drinks of orange juice or ginger ale covered with a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
45661274|NCT02710097|Drug|Active Oral Ethanol|0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
45661275|NCT02710097|Drug|Placebo|No active cannabinoids. Administered over 20 minutes via a vaporizer.
45661276|NCT02709395|Device|Navina Smart|Transanal irrigation at the same frequency as subject used before enrollment.
45676634|NCT00713492|Drug|Alcohol|human laboratory alcohol consumption.
45676635|NCT00648635|Behavioral|Questionnaire|Questionnaires taking 30-60 minutes to complete every 3 months.
45676636|NCT00645931|Behavioral|protein and calorie controlled diet and self-hypnotic relaxation|daily
45954984|NCT05859334|Procedure|Biospecimen Collection|Undergo collection of blood samples
45676637|NCT00633633|Other|Usual Care|Monthly visits with the cardiology team and a booklet about coping with heart failure.
45676638|NCT00633633|Behavioral|Exercise Training|Exercise training 3 times a week.
45954985|NCT05859334|Drug|Erdafitinib|Given PO
45954986|NCT05859334|Procedure|Magnetic Resonance Imaging|Undergo MRI
45954987|NCT05859308|Other|Virtual Reality Pixel Plucker|A virtual reality task where participants wear the Virtual Reality headset and respond to targets.
45954988|NCT05859308|Other|Rock Steady Boxing|An in-person boxing class designed for individuals with Parkinson's disease.
45954989|NCT05858918|Drug|Clopidogrel|Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with clopidogrel 75 mg PO daily
45954990|NCT05858918|Drug|Ticagrelor|Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with ticagrelor 90 mg PO twice daily
45954991|NCT05858840|Other|Urinary Artificial Sphincter (UAS) in Children|Patients aged under 18 years old with UAS
45954992|NCT05858658|Other|Robot-Assisted Pyeloplasty|Pyeloplasty in Children using robotic surgery
46078351|NCT02538445|Other|Simple memorization of the verbs|The participant reads aloud the verbs that appear on the screen, without additional instructions (control condition).
46078352|NCT03553446|Drug|children receiving sevoflurane|Children receiving pre-determined sevoflurane concentration using modified Dixon's up-and-down method
46078353|NCT04266119|Behavioral|Online HOPE intervention|Online HOPE intervention to increase mental health literacy
46078354|NCT00908167|Drug|Sorafenib|Please see detailed description.
45676639|NCT00633633|Behavioral|Dietary Counseling|Food log, booklet, and a cookbook to help decrease the salt content in your diet.
46078355|NCT00908167|Drug|Cytarabine|Please see Detailed Description.
46078356|NCT00908167|Drug|Clofarabine|Please see Detailed Description.
46078357|NCT02749188|Other|Bladder stimulation|Bladder stimulation as a noninvasive technique of urine collection. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes
46078358|NCT04267757|Procedure|rectovaginal fistula repair with Martius flap|rectovaginal fistula repair with Martius flap
45954993|NCT05858281|Behavioral|Survey|Black adolescent girls (aged 12-17) will participate in an online survey and will be asked questions regarding their strengths, family, school and community experiences, sexual education knowledge, physical health and mental wellbeing, etc.
45661277|NCT05468957|Device|Perclose|Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
45661278|NCT05468957|Drug|Statseal|Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
45954994|NCT05858281|Behavioral|Interviews|Parents/guardians of Black girls (aged 12-17) and Black emerging adult women aged 18-22 will participate in individual interviews and will be asked questions about their understanding of Black girls' strengths and resources.
45954995|NCT05858281|Behavioral|Focus group|Black adolescent girls (aged 12-17) will participate in a focus group and will be asked questions regarding their strengths, family, school and community resources, etc.
45954996|NCT05857332|Drug|SG1906|Phase 1a will use an accelerated titration-Bayesian optimal interval (AT-BOIN) design with 7 dose cohorts: 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 9 mg/kg, and 12 mg/kg by IV infusion. Accelerated titration (i.e., 1 patient each) will be applied to the first 2 cohorts.
45954997|NCT05856942|Other|Health service - home-based PrEP monitoring|Home-based PrEP care
45954998|NCT05856890|Biological|HepB mAb19|"HepB mAb19 is a human mAb of IgG1kappa isotype that specifically binds to the a determinant of the extracellular loop of the HBV surface antigen (HBsAg)."
45954999|NCT05856890|Other|Sterile Saline|Placebo will be normal sterile saline (NaCl 0.9%).
45661279|NCT02529553|Drug|LY3076226|Administered IV
45955000|NCT05856877|Other|Human nasal insulin|single dose of 160 U of human insulin as nasal spray
45955001|NCT05856877|Other|Placebo|Single dose of placebo solution as nasal spray
45661280|NCT02547935|Drug|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks.
45955002|NCT05856864|Drug|Cadonilimab Injection|Cadonilimab Injection, 10mg/kg, intravenous drip ,q2w,
45955003|NCT05856864|Drug|Ramucirumab Injection|Ramucirumab Injection，8mg/kg, intravenous drip ,q2w,
45955004|NCT05856760|Drug|Sparsentan|Target dose of 400 mg daily
45955005|NCT05856279|Procedure|mulligan SNAG and mulligan lion position|manual therapy techniques for lumbar spine
45955006|NCT05853315|Procedure|Surgery|Surgical Excision
46078359|NCT02821052|Drug|insulin degludec/insulin aspart|Enrolled patients will be treated with Ryzodeg® under routine clinical practice.
45454384|NCT00006262|Drug|becatecarin|
45955007|NCT05852327|Other|Observation only|Observation only
45955008|NCT05852158|Drug|Cefazolin 2 GM Injection|Single pre-op dose of 2g IV cefazolin
45955009|NCT05852158|Drug|Cefazolin Injection|Pre-op dose of 2g IV cefazolin along with 3 post-op doses of 2g IV cefazolin every 8 hours
45955010|NCT05851924|Drug|NALIRIFOX|"Patients will receive NALIRIFOX for a total of 4 months. NALIRIFOX will be administered on days 1 and 15 of a 4-week cycle for 4 cycles, until intolerable toxicity, or until the development of criteria for removal from the study.~Liposomal irinotecan: 50 mg/m2 IV over the course of 90 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Oxaliplatin: 60 mg/m2 IV over the course of 120 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Leucovorin: 400 mg/m2 IV over the course of 30 minutes (±5 minutes) on days 1 and 15 of every 4-week cycle.~5-FU: 2400 mg/m2 IV over the course of 46 hours (±60 minutes) on days 1 and 15 of every 4-week cycle"
45955011|NCT05851924|Combination Product|AD-XRT and Capecitabine|The interval between completion of induction chemotherapy and initiation of AD-XRT will be 2-6 weeks. The patient will be concurrently treated with capecitabine 825 mg/m2 BID PO Monday to Friday with radiation, as chemoradiotherapy is the standard approach at MSK.
46078360|NCT00908245|Procedure|Control|Surgery without preconditioning surgery
46078361|NCT00908245|Procedure|Preconditioning ischemia|Surgery with a preconditioning ischemia
46078362|NCT05659628|Combination Product|CD19-7×19 CAR-T combined with Tislelizumab|Participants will receive 2×106/Kg CD19-7×19 CAR-T cells infusion and Tislelizumab 200mg every 21 days for 6 cycle on the 31st day after CAR-T infusion.
46078363|NCT03481686|Device|Patients with injections of ESA|Patients will perform ASE injections themselves or by their spouses
45955012|NCT05850741|Device|Cardiokit|The CardioKit prototype used in the study can monitor cyclical heart-beat motion, cyclical respiratory motion and non-cyclical heart position changes while the patient is lying in supine position.
45815679|NCT03229057|Drug|OCP + Metformin|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
45955013|NCT05850286|Biological|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, double infusion intravenously at a target dose of 2.0 x 10^6 anti-BCMA CAR+T cells/kg.
45955014|NCT05850286|Drug|Selinexor-VRD|Selinexor Plus Bortezomib, Lenalidomide and Dexamethasone
45454385|NCT00277810|Drug|lecozotan SR (SRA-333)|one of 3 doses of lecozotan sr dose for 6 months as an extension to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr
45661281|NCT02547935|Drug|Saxagliptin 2.5 mg|Tablets administered orally once daily for 24 weeks.
45661282|NCT02547935|Drug|Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks.
45661283|NCT04258111|Biological|IBI310 (anti-CTLA-4 antibody)|Specified dose on specified days
45661284|NCT04258111|Biological|Sintilimab(anti-PD-1 antibody)|Specified dose on specified days
45955015|NCT05849194|Diagnostic Test|POCUS examination|Point of care ultrasound examination
46078364|NCT00606515|Drug|Liposomal paclitaxel|Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
45454386|NCT01107847|Procedure|low flow pressure volume manoeuvre|In all patients a standard low flow pressure volume manoeuvre is applied by a respirator with a constant gas flow of 4 l/min starting at a zero end-expiratory pressure up to a tidal volume of 2 l or until a maximum airway pressure of 35 cm H2O was reached.
45458131|NCT02306356|Behavioral|Internet-delivered Cognitive Behavior Therapy|
45661285|NCT02554019|Biological|BT063|Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)
45661286|NCT02554019|Biological|Placebo|Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)
45661287|NCT05468411|Other|Oral application of miracle fruit pill|Miracle fruit has a taste modifying function from sourness to sweetness when it is exposed to an acidic environment. To activate the miracle fruit's function, a miracle fruit pill should be orally administered to coat taste buds prior to eating sour food. Thus, participants are instructed to place a miracle fruit pill is on their tongue, and roll the pill around their mouth to allow full contact of the pill with the surface of the oral cavity without chewing until the pill completely dissolved. A miracle fruit pill is administered prior to eating.
45661288|NCT05468411|Other|Oral application of sugar candy|To simulate the miracle fruit's function as a placebo, a chewable sugar candy that has a similar appearance to miracle fruit pill is orally administered. The same protocol that is used in miracle fruit intervention is followed in this placebo intervention but with a chewable sugar candy. Participants are instructed to place a sugar candy is on their tongue, and roll the candy around their mouth to allow full contact of the candy with the surface of the oral cavity without chewing until the candy completely dissolved. A sugar candy is administered prior to eating.
45661289|NCT05476835|Combination Product|respiratory exercises - incentive spirometer - walking|respiratory exercises (in form of diaphragmatic breathing, pursed lip breathing exercise and incentive spirometer), rehab exercise program and walking exercise.
45661290|NCT02327169|Drug|MLN2480|MLN2480 tablets.
45661291|NCT02327169|Drug|MLN0128|MLN0128 capsules.
46002764|NCT04644900|Other|Mouthwash|Patients in the mouthwash group took 15 ml honeysuckle antibacterial mouthwash in their mouths, and vomited them out after 2 minutes
46002765|NCT00547976|Drug|[C-11]PBR28|
46078365|NCT00606515|Drug|Paclitaxel|Patients will be given paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
46078366|NCT00908323|Biological|JS7 DNA vaccine|
46078367|NCT00908323|Biological|MVA/HIV62 vaccine|
46078368|NCT04240418|Other|Survey|The objective is to evaluate the eligibility of the responders, as defined by NELSON criteria and PLCOm2012 scoring, and their willingness to participate to a lung-cancer screening with low-dose computed tomography.
45955016|NCT05848154|Diagnostic Test|ctDNA detection|Blood samples are collected from patients at different time points during the monitoring process before treatment, after treatment, after surgery, and after adjuvant therapy/chemotherapy. ctDNA detection is performed on blood samples of all enrolled patients. WES and RNA-seq of samples from patients before and after treatment are performed to reveal the mechanisms of drug resistance.
45955017|NCT05842343|Other|Stool sample|Purification by affinity of the IgA coated bacteria from a fecal solution. Genomic analysis of the bacteria for diversity and richness
45955018|NCT05842343|Other|Food intake evaluation|Measure (by survey) of food group intake for : lipids /proteins / fibers / carbohydrates
45955019|NCT05842083|Behavioral|On-site supportive communication training|On-site supportive communication training
45955020|NCT05832450|Other|Red cell concentrate transfusion|Perioperative data of patient undergoing elective brain tumor resection with requirements of red cell concentrate transfusion.
45955021|NCT05832424|Behavioral|UPLIFT program|The telehealth group intervention will be delivered using Zoom. Participants will attend facilitated weekly, 1-hour sessions for 8 weeks. The sessions follow a standardized, manualized program based on cognitive-behavioral therapy (CBT) and mindfulness-based practice (MBP)-therapies widely accepted and used by mental health providers for the treatment and prevention of depression and substance use. The study team have tailored this intervention for use in a pregnant population.
45955022|NCT05829187|Drug|Dihydroartemisinin|dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days
45955023|NCT05829187|Drug|Piperaquine|piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
45955024|NCT05829187|Drug|Primaquine|Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
45955025|NCT05829187|Drug|Momordica Charantia Extract|Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
45661292|NCT02327169|Drug|Alisertib|Alisertib tablets.
45661293|NCT02327169|Drug|Paclitaxel|Paclitaxel IV infusion.
45661294|NCT02327169|Drug|Cetuximab|Cetuximab IV infusion.
45661295|NCT02327169|Drug|Irinotecan|Irinotecan IV infusion.
45661296|NCT02327013|Drug|vortioxetine 10 mg tablet|Oral tablets, once daily
45661297|NCT02327013|Drug|vortioxetine 20 mg tablet|Oral tablets, once daily
45661298|NCT02327013|Other|Placebo tablet|Oral tablets, once daily
45955026|NCT05825183|Procedure|Ultrasound-guided manual vaccum|"For managing with miscarriage or termination of pregnancy (TOP) in first trimester loss, ultrasound-guided manual vacuum aspiration (USG-MVA) is one of the treatment options.~The USG-MVA device works by aspirating the uterine content via the cannula into the syringe. Furthermore, product of conception derived from USG-MVA can be sent for karyotyping analysis.~POCs obtained from MVA procedure were rinsed in normal saline thoroughly in the kidney basin to minimize maternal blood. Chorionic villi were considered as a proxy of fetal genetics, appeared to be yellowish in color and tree-projection-like in appearance, floating on the surface of the waterline. Decidua are originated from the mother, appeared substantive in structure and sank in the basin. The two different types of tissues are separated from each other for different testing."
45955027|NCT05823233|Other|Cold application+Deep friction+Home exercise+Eccentric stretching|In our study, deep friction massage will be performed by the researcher with the tip of the thumb, maintaining the pressure for 3-5 minutes in the posterior direction to the tenoosseous junction. The application will be performed 3 times a week for a total of 12 sessions for 4 weeks. After the deep friction massage, cold application will be made for 15 minutes. Simultaneously with the electrical stimulation of the affected arm, the patient will be asked to stretch for 5 seconds and rest for 5 seconds, and doing this 15 times will be considered 1 set. After 1 minute of rest, he will be asked to do this practice for 2 more sets, so 3 sets of 15 repetitions will be completed in total. A total of 12 sessions will be applied 3 days a week for 4 weeks. In our study, a home exercise program consisting of passive stretching and strengthening (concentric and eccentric) exercises will be applied.
45955028|NCT05823233|Other|Cold application+Deep friction+Home exercise|In our study, deep friction massage will be performed by the researcher with the tip of the thumb, maintaining the pressure for 3-5 minutes in the posterior direction to the tenoosseous junction. The application will be performed 3 times a week for a total of 12 sessions for 4 weeks. After the deep friction massage, cold application will be made for 15 minutes. In our study, a home exercise program consisting of passive stretching and strengthening (concentric and eccentric) exercises will be applied.
45661299|NCT02301975|Drug|Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler|FF/Vilanterol 100/25 mcg inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device and 100/25 mcg per actuation.
45661300|NCT02301975|Drug|Placebo inhalation powders via ELLIPTA inhaler|Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.
45661301|NCT02301975|Drug|Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler|FP/Salmeterol 250/50 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250/50 mcg per actuation.
45955029|NCT05822765|Drug|Epinephrine concentration of 1:1000000|Tumescence fluid contained Epinephrine concentration of 1:1000000 (one ampoule 1 mg per liter) lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter
45955030|NCT05822765|Drug|Epinephrine concentration of 1:500000|Tumescence fluid contained Epinephrine concentration of 1:500000 two ampoule 2 mg/liter with same lidocaine and bicarbonate dose. lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter
45955031|NCT05818384|Behavioral|Wakaya: Rising Up for Choctaw Youth Curriculum|An experiential, outdoor, nature-based program grounded in Choctaw values. It is a multi-level intervention that increases individual motivation and leadership skills to make healthy behavioral choices for behavior and exercise.
45955032|NCT05816252|Drug|SKB264|intravenous (IV) infusion (Q2W)
45955033|NCT05816252|Drug|Pembrolizumab|intravenous (IV) infusion (400mg, Q6W)
46078369|NCT02749032|Other|Mixed meal test|Mixed meal test were performed in the morning after an overnight fast. The standardized mixed meal was composed of 2 eggs (100 g), 1 slice (50 g) of whole grain rye bread, 1 slice (50 g) of rye flour bread, 10 g of fat-reduced margarine, 20 g of boiled ham, and 25 g of diet jam, amounting to 450 kcal, 50 % carbohydrate, 20 % protein, and 30 % fat (based on calorie count). Patients were allowed to drink tea (black or fruit-based) or de-caffeinated coffee ad libitum.
45815680|NCT03229057|Drug|OCP + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
46078370|NCT02749032|Drug|Vildagliptin|Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.
45815681|NCT03229057|Drug|Metformin + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
45815682|NCT00505544|Behavioral|Questionnaire|Questionnaires that ask about your sleep, symptoms, and mood.
45815683|NCT00505544|Device|Actigraph|Wear actigraph to collect information on activity levels and sleep patterns for one week.
45454387|NCT01207609|Procedure|Laparoscopic Gastric Plication|The procedure is performed laparoscopic. The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3-5 cm from the pylorus and ending at the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected. At least two rows stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. A calibration tube or endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure.
45955034|NCT05816252|Drug|Carboplatin|intravenous (IV) infusion (AUC5, Q3W)
45955035|NCT05816252|Drug|Osimertinib|80mg, QD
45661302|NCT02301975|Drug|Placebo inhalation powder via ACCUHALER/DISKUS inhaler|Placebo inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device.
45661303|NCT02301975|Drug|Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler|FP 250 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250 mcg per actuation.
45661304|NCT02301897|Drug|Telapristone Acetate|Telapristone acetate, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
45661305|NCT02301897|Drug|Placebo|Matching placebo, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
45661306|NCT02301429|Device|Model 20105|implant and follow-up of study device
45661307|NCT04883385|Other|medical data collection|collection of medical data from patients' medical records
45676640|NCT00618553|Other|Questionnaire|Questionnaire regarding quality-of-life that lasts about 30 minutes.
45676641|NCT00618553|Behavioral|Pulmonary Rehabilitation|Rehabilitation treatment given over about 3-4 weeks.
45676642|NCT00452023|Drug|IFN-alpha2a|Starting dose 90 microgram (mcg) injection under the skin once a week
45955036|NCT05811117|Diagnostic Test|There will be no intervention as we will study patients that undergo autopsy after CAR T cell infusion.|We will study patients that undergo autopsy after CAR T cell infusion.
46002766|NCT00548015|Behavioral|state-of-the art strategy and extented strategy|state-of-the art: education, reminders, performance feedback, extented:state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
45661308|NCT04883229|Device|Halo Neuroscience Neurostimulator|"Experimental: Neurostimulation of 2 milliamps anodal (active) tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework.~Active comparator: Experimental: Sham tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of neurostimulation of 2 milliamps anodal (active) sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks."
45661309|NCT04882839|Combination Product|psychotherapy assisted psilocybin|psychotherapy for patients while under the influence of psilocybin
45955037|NCT05798078|Behavioral|Cognitive Bias Modification for Interpretation (CBM-I)|The CBM-I intervention is based on the interpretation training paradigm developed by Mathews and Mackintosh (2000). It comprises a series of training scenarios describing different (mostly everyday) socially-relevant situations, structured so they start ambiguously but always have a positive ending. The positive ending is presented as word fragment, which participants are instructure to complete. In about 25% of trials, participants are further requested to respond to comprehension questions about the scenario presented. Each CBM-I session comprises 45 trials presented in 5 blocks of 9 scenarios.
45955038|NCT05798078|Behavioral|Sham Training Control Condition|The sham training is in an identical format to the CBM-I training, except that the scenarios are all entirely neutral, with no reference to social situations and no emotional ambiguity.
45661310|NCT02300259|Drug|LY2623091|Administered orally
45661311|NCT02300259|Drug|Itraconazole|Administered orally
45661312|NCT02300259|Drug|Simvastatin|Administered orally
45661313|NCT02300259|Drug|Tadalafil|Administered orally
45661314|NCT02300259|Drug|Diltiazem|Administered orally
45661315|NCT02367885|Drug|TAK-850 0.5 mL injection|TAK-850 injection
45815684|NCT04432285|Device|DBS-device, implanted in GPi bilaterally|Chronic/continuous bilateral GPi-DBS
45815685|NCT04432285|Drug|Botulinum toxin|Repeated intramuscular injections at regular intervals of around 3 months
45815686|NCT04431674|Drug|Definity Suspension for Injection|MRI-guided ultrasound-stimulated microbubble-treatment
45815687|NCT04430959|Drug|Candesartan|Candesartan 4 mg, tablets, orally, once daily for 4 weeks
45955039|NCT05779696|Other|No-intervention|This is a non-intervention study.
45955040|NCT05779644|Drug|Liraglutide|Liraglutide is injected once a day.
46078371|NCT02749032|Drug|Sitagliptin|The dosage of sitagliptin depended on the stratum defined by the background diabetes medication. In patients treated with diet and exercise (no other glucose-.lowering medication), sitagliptin was given as one 100 mg in the morning (15 minutes prior to breakfast or the test meal, on the last day of the treatment period), and a corresponding placebo tablet was administered in the evening (no temporal relation to dinner required).
45661316|NCT02367885|Drug|TAK-850 0.25 mL injection|TAK-850 intramuscular injection
45661317|NCT02367729|Device|Neurostimulator|Non-invasive, battery operated neurostimulator of the external ear worn for 5 days each week x 4 weeks.
45661318|NCT02367729|Device|Sham|Inactive neurostimulator device pre-programmed to be inactive. To be worn for 5 days each week x 4 weeks.
45661319|NCT02366637|Drug|Placebo|Orally inhaled placebo twice a day (BID) for 4 weeks
45661320|NCT02366637|Drug|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 4 weeks
45661321|NCT02300103|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
45661322|NCT02300103|Drug|RBV|Tablet (s) administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45661323|NCT02326467|Drug|Chlorhexidine gluconate|Bi-weekly chlorhexidine baths
45661324|NCT02299635|Drug|PF-03084014|Tablet, 10 mg, twice a day.
45661325|NCT02299635|Drug|PF-03084014|Tablet, 50 mg, twice a day
45661326|NCT02299635|Drug|PF-03084014|Tablet, 100 mg, twice a day
45815688|NCT04430959|Drug|Placebo|Candesartan placebo-matching tablets, orally, once daily for 4 weeks
45955041|NCT05779644|Drug|Semaglutide|Semaglutide is injected once a week.
45955042|NCT05779644|Drug|Metformin|Metformin is taken orally daily.
45955043|NCT05776381|Other|Shared Decision Making using a Patient Decision Aid.|The intervention comprises the surgeon actively using the tailored PtDA and SDM with the patient when deciding on the management of an unexpected malignant colorectal polyp.
45955044|NCT05775016|Behavioral|Exercise|12 week resistance and cardiovascular exercise program
45661327|NCT02366091|Drug|Methotrexate|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease
45661328|NCT02366091|Drug|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
45661329|NCT02366091|Drug|Placebo|Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.
45815689|NCT03821870|Diagnostic Test|Inditreat|Tumoroid formation and drug sensitivity analysis
45815690|NCT03821870|Drug|Experimental drug|Second line treatment based on drug sensitivity analysis
45815691|NCT04430101|Procedure|Minimally invasive stabilization of Lisfranc injuries|Patients with positive weightbearing radiographs will be operated by minimally invasive stabilization (eg, isolated homerun screw)
45815692|NCT04430101|Procedure|Conservative treatment|Patients with negative weightbearing radiographs will be treated conservatively
45815693|NCT04820413|Other|Faecal microbiota transplantation|FMT by daily enema with donor faeces
45815694|NCT03045289|Behavioral|Plant-Based Diet|Women will be provided with 3 meals daily, delivered to their home, for 8 weeks, along with a multivitamin, and will attend weekly office visits.
46002767|NCT04636125|Drug|Doxycycline 100 MG Oral Tablet|Patients that are undergoing a single stage revision total shoulder arthroplasty will be enrolled in this study. As is standard of care, routine cultures will be taken from predetermined areas in the shoulder. All patients will be treated with 13 days of oral Doxycycline pending culture results.
45955045|NCT05774197|Behavioral|Cognitive Behavioral Therapy for pain|Patient participating in this study will have survey assessments at baseline, 4 weeks (end of 4-week intervention period), and 6 weeks (end of 2-week post intervention period) assessing patient reported concerns, quality of life outcomes and usability of STAMP+CBT app. During this time, Patient will receive algorithm-based advice in response to their daily pain and mood surveys. These patients will be introduced to the extensive multi-media library of educational content covering medication support (e.g. using short and long-acting opioids, managing side effects, opioid safety); pain psychology (e.g. pain perception, pain and the stress response); health behaviors and pain (e.g. sleep hygiene); and skills training (e.g. activity pacing/ relaxation recordings).
45661330|NCT02299167|Drug|Dixon's up-and-down method|using a modified Dixon's up-and-down method (using 0.5 mg as a step size) (16). The first patient was tested at a dose 1.5 mg bupivacaine, if patient responded with failed block then the next patient received an increment of 0.5mg bupivacaine, if patient responded with successful block, then the next patient received a decrement of 0.5mg bupivacaine. The research continued until we obtained seven crossover midpoints.
45955046|NCT05766904|Biological|4CMenB vaccine|Four-component MenB vaccine
45955047|NCT05766904|Other|Placebo|0.9% Sodium Chloride Inj. B.P.
45955048|NCT05764161|Drug|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the continuous and open label treatment period.
45661331|NCT01647711|Drug|Dose escalation followed by treatment with MTD|Fixed 3+3 dose escalation; expansion of MTD cohort
45955049|NCT05764161|Drug|Vehicle Cream|Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle-controlled period.
45454388|NCT02286232|Behavioral|Stretching exercise|This program begins with 10 stretches/exercises over 15 minutes on the initial class and incrementally increases by 1 stretch/exercise each session for a total of 21 stretches/exercises over 30 minutes on the 12th session. The program is designed to stretch/exercise the major muscle groups, emphasizing the neck and arms, trunk, and legs. In addition to the stretches, each class will include breathing exercises and guided imagery for relaxation. Classes will be taught by Physical Therapists who are trained to lead classes through the protocol.
45955050|NCT05760781|Drug|STSG-0002 Injection|Intravenous infusion
45454389|NCT02286232|Behavioral|Self-care book|The Back Pain Helpbook which provides information on the causes of back pain and advice on exercising, making appropriate lifestyle modifications, and managing flare-ups.
45661332|NCT02540993|Drug|Finerenone (BAY94-8862)|Oral tablet; starting dose at 10 mg for subjects with an eGFR between 25 to < 60 mL/min/1.73m² at the Screening Visit; starting dose at 20 mg for subjects with an eGFR ≥ 60 mL/min/1.73m² at the Screening Visit; dose could be up-titrated from Month 1 onwards or down-titrated at any time during the study; once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
45955051|NCT05760703|Drug|STSG-0002 Injection|Intravenous infusion
45955052|NCT05749211|Drug|Huaier granule|Oral administration, 20 g once, 3 times a day, continued until progression or intolerance of toxicity
45955053|NCT05748093|Drug|Cobicistat|Feasibility of pharmacokinetic boosting using cobicistat for personalized treatment strategies for osimertinib.
45955054|NCT05741645|Other|Kinesiotaping|During the kinesio taping of the erector spina vs multifidus muscles, the patient is in a standing position. Kinesiotape is applied with 50% tension and stays in the patient for 30 minutes.
45955055|NCT05741645|Other|Sham Kinesiotaping|The elastic taping will be randomly applied to a place outside the area to be measured, without stretching, and without causing any effect.
45955056|NCT05731596|Drug|Rosuvastatin 20 Mg Oral Tablet|Rosuvastatin 20 mg will be administered orally once daily for 3 Months
45955057|NCT05731596|Drug|Coenzyme Q10 100 MG Oral Capsule|Coenzyme Q10 100 mg will be administered orally once daily for 3 Months
45955058|NCT05730543|Drug|Volbella or Juvederm Ultra XC filler|Hyaluronic acid filler
45955059|NCT05730270|Behavioral|Stress reduction program 1|Participants will receive daily online lessons
45955060|NCT05730270|Behavioral|Stress reduction program 2|Participants will receive daily online lessons
45955061|NCT05726006|Other|No Intervention in This study|No Intervention in This study
45454390|NCT03942133|Procedure|ultrasound-guided short-axis placement of catheter at the entrance of the adductor canal|Ultrasound probe is placed at the entrance of the adductor canal in short axis ，insertion of a PAJUNK Contiplex S catheter with the tip of the catheter located at the entrance of the canal
45661333|NCT02540993|Drug|Placebo|Matching placebo, oral tablet, once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
45676643|NCT00442104|Drug|Ganaxolone|
45955062|NCT05722782|Drug|Piroxicam|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 20 mg piroxicam per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
45955063|NCT05722782|Drug|Acetaminophen|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 1000 mg Acetaminophen per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
45955064|NCT05722782|Drug|Placebo|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
45955065|NCT05719350|Other|Exercises for Knee|Four exercises for strengthening and mobility of the knee joint two in a sitting position and two in a standing position for a total of 20-25 minutes
45955066|NCT05714852|Behavioral|Healthy eating|Promotion of healthy eating
45955067|NCT05713318|Drug|HH-120 nasal spray|Nasal spray daily doses of HH-120 4 times added on SOC for 6 consecutive days.
45955068|NCT05713318|Drug|HH-120 nasal spray|Nasal spray daily doses of HH-120 8 times added on SOC for 6 consecutive days.
45955069|NCT05713318|Drug|Placebo Comparator|Nasal spray daily doses of placebo 4 times added on SOC for 6 consecutive days.
45955070|NCT05713318|Drug|Placebo Comparator|Nasal spray daily doses of placebo 8 times added on SOC for 6 consecutive days.
45955071|NCT05711095|Dietary Supplement|Fortified plant-based protein blend|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
45955072|NCT05711095|Dietary Supplement|Plant-based protein blend|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
45955073|NCT05711095|Dietary Supplement|Whey protein|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
45955074|NCT05710328|Drug|Chemotherapy|Receive standard of care chemotherapy
45955075|NCT05710328|Procedure|Computed Tomography|Undergo PET/CT
45955076|NCT05710328|Other|Fludeoxyglucose F-18|Given IV
45955077|NCT05710328|Procedure|Positron Emission Tomography|Undergo PET/CT
45955078|NCT05710328|Procedure|Surgical Procedure|Undergo standard of care surgery
45955079|NCT05709990|Drug|Solifenacin Succinate 5 MG Oral Tablet [Vesicare]|These patients will receive solifenacin 5-10 MG daily (combined with standard urotherapy) for 8 weeks.
46078372|NCT02749032|Drug|Placebo|Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).
45454391|NCT03942133|Procedure|ultrasound-guided long-axis placement of catheter at the middle of the adductor canal|Ultrasound probe is placed at the middle of the adductor canal in long axis with the caphelad end of the probe aligned with the entrance of the canal. insertion of a PAJUNK Contiplex S catheter with the tip of the catheter located at the middle of the canal
45661334|NCT03171545|Behavioral|Patient Activation|Patients in clinics assigned to this group will be offered peer mentoring and digital resources.
45661335|NCT03171545|Behavioral|Provider Education|Staff in clinics assigned to this group will receive team training and a checklist.
45661336|NCT05476757|Biological|rDEN2Δ30-7169|rDEN2Δ30-7169 will be inoculated at Study Day 0. After 6 months of the inoculation, the participants will be vaccinated with Dengvaxia® until completion of 3 doses with 6-month interval between each dose.
45955080|NCT05709990|Drug|Vitamin D3|These patients will receive high dose vitamin D supplementation (more than 2000IU daily) (combined with standard urotherapy) for 8 weeks.
45661337|NCT02547233|Drug|LEO 43204 gel|
45661338|NCT02547233|Drug|Vehicle gel|
45661339|NCT05476679|Drug|RZL-012|50mg/ml drug formulation
45955081|NCT05709990|Behavioral|Standard urotherapy|These patients will receive standard urotherapyfor 8 weeks.
45955082|NCT05699707|Dietary Supplement|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone monoester|Participants will consume a ketone monoester drink (0.75 k/kg body mass) with venous blood samples obtained before and after (30, 60 and 90 minutes) drink consumption.
45955083|NCT05697146|Other|ribociclib + ET|There is no treatment allocation. Patients administered ribociclib + endocrine Therapy (ET) by prescription will be enrolled.
45955084|NCT05696158|Device|MHNA-003|6-week digital therapy program designed to reduce the severity of tinnitus symptoms
46078373|NCT02749032|Drug|Metformin|For patients continuing with pre-existing metformin treatment, 1000 mg film coated tablets from commercial sources. In half of the patients (stratum: metformin as background medication), metformin was administered orally twice daily at 1000 mg of active compound during of after breakfast and dinner.
46078374|NCT02749032|Other|Diet and exercise|Patients treated their diabetes mellitus type 2 with diet/exercise only
45661340|NCT05476679|Drug|RZL-012+Lidacaine injection prior treatment|5ml lidocaine will be injected 10 minutes before RZL-012 treatment
45661341|NCT05476679|Drug|RZL-012+Medrol|oral Medrol dose pack (8 mg (2 tablets) on Day 1 before treatment followed by 16 mg after treatment (as per Instructions for Use)). From Day 2, a daily tapering off by 4 mg until Day 6 will be administered per Rx Instructions for use
45661342|NCT05476679|Drug|RZL-012+Celecoxib+Zyrtec|200 mg Celecoxib BID and 10 mg Zyrtec BID on Days 1, 2, 3, 4, 5 and 6
45661343|NCT05476679|Drug|RZL-012+facial and neck wrap|Universal Facial Band
45661344|NCT02546765|Drug|IV acetaminophen & IV propofol|use of IV tylenol and IV propofol for pain and sedation (respectively)
45955085|NCT05694624|Drug|Para Aminohippurate|Measurements of renal plasma flow and glomerular filtration rate
45955086|NCT05687825|Procedure|pancreaticoduodenectomy procedure|Pancreaticoduodenectomy operation
45955087|NCT05686265|Drug|Oxygen|Physiological intervention consisting of 1 hour of mild hypoxia (PaO2 9-10 kPa), 1 hour of mild hyperoxia (PaO2 13-14 kPa), and in healthy subjects also 1 hour of an inspired oxygen fraction of 100%.
45955088|NCT05684744|Drug|Roflumilast|The patients will receive oral roflumilast in a dose of 500 mcg per day for 12 weeks
45955089|NCT05684744|Drug|Methotrexate|The patients will receive methotrexate in a dose of 0.2- 0.4 mg/kg/week for 12 weeks
45955090|NCT05680623|Diagnostic Test|PPAP diagnosis|"Serum amylase (total or the pancreatic isoform) and/or lipase activity will be systematically measured at least on postoperative days 1 and 2.~A CT with pancreas protocol iv contrast infusion will be performed in the postoperative course when clinically required, facing patients' clinical worsening, suspicious of abdominal complications."
45955091|NCT05679986|Other|no intervention|no intervention
45955092|NCT05678790|Other|Passive Stretching|Sustained passive stretching of hamstring, tendo-achilles, and adductors 10 (30 s, with three repetitions, five times per week)
45955093|NCT05678790|Other|Mobilization|Grade four mobilizations is a stretching motion performed at the talocrural joint with anterior-posterior gliding. Mobilization was performed once a day, 6 times a day, and 5 times a week, only on both deformed feet of the older sibling
46002768|NCT04684628|Drug|68Ga-PSMA PET/CT|Administration of 68Ga-PSMA-11 followed by a PET/CT scan at 45 min after injection.
45955094|NCT05678790|Other|Muscle strengthening|Abdominal muscle strengthening exercises were given to both siblings once a day, 10 times a day, 5 times a week. In the supine position, the patients were asked to lie on their knees with the knees flexed. The hip extensors were trained in the prone position on the bed by resisting hip extension
45955095|NCT05678790|Other|Balance and Coordination|"The following exercises were applied 5 times a week, with 1o repetition once a day.~Standing on one leg in front of the mirror,~Tandem walking,~Rhythmic Dynamic Stabilization,~Swiss ball sitting (eyes open and closed),~Counting the alphabet or numbers while marching"
45955096|NCT05678114|Dietary Supplement|Myo-inositol|Myo-inositol (4g/die)
45955097|NCT05676827|Diagnostic Test|Diagnostic Criteria for Temporomandibular Disorders Clinical Examination|Clinical examination made by experienced dentists (minimum 5 years of practice) and trained and calibrated in accordance with the protocol available on the DC/TMD.
45661345|NCT02546765|Drug|IV acetaminophen & IV dexmedetomidine|use of IV tylenol and IV dexmedetomidine for pain and sedation (respectively)
45955098|NCT05676827|Diagnostic Test|Blood test|Blood samples will be tested to investigate two polymorphisms of genes encoding proteins for serotonin receptors HTR2A - rs4941573 in intron 3 and dopamine DRD3 - rs6280 (Ser9Gly) and levels of serotonin, dopamine, C-reactive protein, cortisol, sodium, potassium, and calcium.
45955099|NCT05675787|Drug|Medroxyprogesterone acetate + Atorvastatin|MPA (at a dosage of 250-500 mg/day,) + Atorvastatin (at a dosage of 20 mg/day), by mouth,
45955100|NCT05668013|Drug|TEV-48574 Dose Regimen A|Subcutaneous (sc) administration using a commercial sc infusion system
45955101|NCT05668013|Drug|TEV-48574 Dose Regiment B|Subcutaneous (sc) administration using a commercial sc infusion system
45454392|NCT03740893|Drug|AZD6738|"PART 1: Pre-operative exposure of 160mg AZD6738 to be administered orally twice daily on Days 5 -14 of the WOP.~PART 2: 12 months post-operative exposure to 160mg AZD6738 to be administered orally twice daily on Days 1 - 14 of a 28 day cycle."
45815695|NCT04737655|Drug|TRIMBOW® pressurised inhalation solution: Beclometasone dipropionate / formoterol fumarate /glycopyrronium 87/5/9 µg per inhalation|Evaluate Trimbow associated with the standard of care in comparison with the standard of care alone.
45815696|NCT05063396|Procedure|opioid free anesthesia|Instead of use of large amount of opioids for intraoperative stress response and postoperative pain controlling, during the whole perioperative period patients received no opioid at all. intravenous local anesthetics and thoracic epidural were used.
45815697|NCT05063396|Procedure|Opioid-sparing anesthesia|patients will receive opioid-sparing anesthesia protocol with minimal intraoperative sufentanil, remifentanil and epidural hydromorphone.
45955102|NCT05665166|Genetic|Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII|Autologous CD34+ haematopoietic stem cells from MPS II patients will be genetically modified ex vivo using CD11b.IDS-ApoEII Lentiviral Vector (LV), a self-inactivating (SIN) LV expressing the human codon-optimized IDS gene tagged with ApoEII and regulated by a human CD11b myeloid-specific promoter. These transduced CD34+ HSCs will then be cryopreserved until the time of infusion back to the patients
45955103|NCT05662527|Drug|Pembrolizumab|One dosage of 4mg/kg (maximum of 400mg)
45661346|NCT02546765|Drug|IV propofol & placebo|use of IV propofol for sedation and morphine, the drug of choice for cardiac pain
45661347|NCT02546765|Drug|IV dexmedetomidine & placebo|use of IV dexmedetomidine for sedation and morphine, the drug of choice for cardiac pain
45661348|NCT05476523|Other|NeuraLight|NeuraLight is an investigational software-based platform used for measuring eye movements in response to visual stimuli and captured using a simple webcam
45661349|NCT02553629|Drug|Rocuronium|
45661350|NCT03555851|Drug|Cyclophosphamide|Pharmacogenomics of candidate genes and pharmacokinetic analyses of cyclophosphamide administered as part of a reduced intensity conditioning (RIC) regimen and as post-transplant GVHD prophylaxis will be examined.
45676644|NCT00441896|Drug|Ganaxolone|
45815698|NCT04737499|Behavioral|CASCADe|Culturally tailored diabetes self-management and education sessions with mHealth integration
45815699|NCT03675152|Other|Soft spinal brace|Soft thoracolumbar brace worn 23 hours a day.
45955104|NCT05661812|Diagnostic Test|Quationnaires and symptom registration|Used to collect data about symptoms potentially characterising the allergy of MB. A shortened version of the MeDALL questionnaire (mechanisms of the development of allergic diseases) will be used to collect data about allergic diseases and symptoms. POEM questionnaire (Patient-Oriented Eczema Measure) will be used to evaluate atopic eczema once in the season of MB and once outside MB and pollen seasons. The participant will also register symptoms during two periods, preferably 6 weeks during MB season autumn (August-September) 2022 and 2 weeks outside MB and pollen seasons in January/February 2023. During the 8 weeks of symptom registration the participants will receive an e-mail every other day with questions regarding symptoms and medication.
45955105|NCT05661812|Diagnostic Test|PNIF and spirometry|To clarify and verify the symptoms registered by the participants we will perform measurements of Peak Nasal Inspiratory Flow (PNIF) and spirometry. PNIF and spirometry will be used to assess airway obstruction through the nose and lungs, and will be performed in and outside the seasons of MB and pollen. Spirometry will be performed pre and post inhalation of bronchodilating medicine (reversibility test). Some of the participants (patients and controls) will be randomised to nasal provocation test (NPT), performed outside the seasons of MB and pollen, and for those PNIF and spirometry will be carried out before and after NPT.
46002769|NCT04636242|Procedure|Skin Biopsy|A Biopsy of the skin where the arthroscopic instrument will be placed, will be taken and sent to the microbiology lab for analysis
46078375|NCT02820740|Device|NeuroBlate System|Laser Interstitial Thermal Therapy
45661351|NCT03555851|Other|Specimen collection|Buccal swabs will be obtained from donors for pharmacogenomics.
45661352|NCT05453981|Behavioral|Transdiagnostic Sleep and Circadian Intervention|Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy. It targets common sleep disturbances in disorders and has improved disorder-focused symptoms and sleep and circadian functioning in patients with Severe mental illness (SMI).
45815700|NCT03675152|Other|thoracolumbar orthosis|Hard thoracolumbar orthosis done individually molded, Worn 23 hours a day.
45661353|NCT05453513|Other|MRI study - everyone scanned.|This is an observational study without an intervention.
45955106|NCT05661812|Diagnostic Test|SPT, spesific IgE, pBAT and NPT|To evaluate the symptoms as specific for allergy the participants will be tested with skin prick test (SPT) with MB and common airway allergens, serum specific IgE (sIgE) to MB and common airway allergens, nasal provocation test (NPT) with MB and passive basophil activation test (pBAT) with MB. Blood samples for the sIgE and pBAT will be performed in MD season, while SPT and NPT will be performed outside seasons of MB and pollen. We will compare the results from SPT, sIgE and pBAT with the results from NPT to calculate sensitivity and specificity of SPT, sIgE and pBAT. All those tests demand that we are able to develop MB extracts that are suitable for those tests.
45955107|NCT05660629|Other|Mulligan Mobilization|Mobilization with movement (MWM) is the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.
45955108|NCT05656664|Dietary Supplement|Folic Acid|Folic acid supplementation to assess for increased arsenic metabolite excretion
45955109|NCT05656664|Other|Placebo|Placebo group to assess arsenic metabolite excretion
45955110|NCT05652738|Device|Passive cooling application|Passive cooling application for asphyxiated neonates and their effect on myocardial function and hemodynamics
45955111|NCT05652738|Device|cooling using Blanket roll III|standard care using Blanket roll III in asphyxiated neonates and their effect on myocardial function and hemodynamics
45955112|NCT05646797|Drug|ASP2074|intravenous (IV) infusion
45955113|NCT05643183|Other|Astmakompas|The Astmakompas platform consists of a patient app, a portal for HCPs, and a wireless spirometer connected to the patient app. The patient app combines monitoring with self-management tools, and provides a portal to present these data as well as to communicate with their HCP. Patients' monitoring data is linked to their personalized digital action plan, including self-management strategies and treatment recommendations based on the latest international treatment guidelines. The action plan aims to increase patients' awareness of their symptoms and/or the severity of their symptoms, as well as their corresponding adverse effects. When patients' monitoring results show a deterioration of asthma control, HCPs receive smart notifications. Patient data can thereby serve as direct input in the consultations with the HCP, or they can proactively offer as-needed support. Patients are able to ask non-critical asthma-related questions to their HCP through a chat function of the application.
45955114|NCT05642533|Other|No treatment given|No treatment given
45661354|NCT03073031|Device|Tablet: Samsung Galaxy Tab A|
45661355|NCT05476445|Procedure|Control|Root canal treatment
45661356|NCT05476445|Procedure|Laser|Root canal treatment+Laser application
45815701|NCT03675152|Other|Excersice restriction|Patients are only allowed to do isometrical excersices adviced by a physiotherapist.
45815702|NCT04378699|Other|SMR (12-15 Hz)|SMR training sessions (12-15 Hz) C4 unipolar placement, central region
45815703|NCT04378699|Other|alpha band (8 -12Hz)|3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region
45955115|NCT05642208|Drug|Dupilumab step-down|step down dupilumab injections
46078376|NCT00908713|Drug|methylprednisolone|methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days
46078377|NCT00908713|Drug|Placebo|Sodium chloride 0.9% 10 mL every 12 h for 5 days
46078378|NCT02749110|Device|Vaginal self-sampling brush|Self-collection by unscreened women aged from 30 to 65 of a vaginal sample with the device. After collection, the whole device is mailed in a normalized for biological samples package to the virology lab of the University Hospital of Lille where a HPV test is conducted using a Cobas 4800 technique.
46078379|NCT02820896|Drug|Placebo|Participants will receive single or multiple doses of RO7105705 matching placebo IV.
46078380|NCT02820896|Drug|RO7105705|Participants will receive single or multiple doses of RO7105705 IV or SC.
45661357|NCT05476445|Procedure|Cryotherapy|Root canal treatment + Cryotherapy application
45661358|NCT05466461|Procedure|Beautifil Flow Plus X.|Class V cavities will be prepared, Selective etching technique will be used with phosphoric acid etching gel for 15 seconds on enamel.Single Bond TM Universal will be applied to cavity walls and margins with agitation for 20 seconds.The adhesive will be light-cured for 20 seconds. Then Beautifil Flow Plus X composite will be placed
45661359|NCT05466461|Procedure|Activa bioactive restorative|Class V cavities will be prepared, Selective etching technique will be used with phosphoric acid etching gel for 15 seconds on enamel. Bonding agent will be applied on the entire cavity and light-cured for 20 seconds then Activa bioactive restorative composite will be applied and cured for 20 seconds.
45815704|NCT05055752|Drug|Pharmaceutical-lipid aspirin (PL-ASA)|Subjects receive the first drug, followed by a 7-day washout period, then receive the second drug.
46078381|NCT00940823|Device|Ahmed FP7 Valve|Implantation of Ahmed FP7 Valve to lower intraocular pressure in refractory glaucoma.
45661360|NCT02546609|Drug|Leu-Met-Sil 0.5|NS-0200 low dose
45955116|NCT05638854|Drug|ZB002|ZB002 Single doses administered subcutaneously as solution
45955117|NCT05638854|Drug|Placebo|Placebo Single doses administered subcutaneously as solution
45955118|NCT05638672|Drug|Huashi Baidu Granule|Granule is produced by Guangdong Yifang Pharmaceutical Co., Ltd. with a specification of 5g × 12 bags, twice a day, take 2 sachets each time with boiling water.
46078382|NCT00940823|Device|Baerveldt-350 Tube|Implantation of Baerveldt-350 Tube to lower intraocular pressure in refractory glaucoma.
45955119|NCT05638672|Drug|Monapiravir|Monapiravir, manufactured by Merck, an American pharmaceutical company, with the specification of 200mg × 40 capsules, 800mg each time, twice a day.
45955120|NCT05637840|Other|Urine sample|Collection of 36-84 urine samples over a 14 consecutive day period.
45661361|NCT02546609|Drug|Leu-Met-Sil 1.0|NS-200 high dose
45955121|NCT05637840|Other|Sleep restriction|Participants will be asked to limit their sleep to 4 hours within a 24-hour period for 2 days in a row.
45955122|NCT05634044|Device|eNose Device|Participants will place the e-Nose device in their bathroom to record VOCs from the ambient air after they have a bowel movement. In addition to this, all participants will complete 2 blood draws 3 stool collections and questionnaires over the course of 3 visits during a 2-week period.
45661362|NCT02546609|Drug|Placebo|Placebo
45661363|NCT02534909|Biological|LFG316|"LFG316 will be administered to all patients enrolled in the study~LFG316: Treatment periods 1-3 and first 4 weeks of period 4. LNP023: Treatment Period 4"
45661364|NCT02534909|Drug|LNP023|LNP023 will be administered in period 4 to patients who participate in period 3 of this study and are willing to join long term extension study with LNP023.
45661365|NCT03030755|Other|Optical coherence tomography|
45676645|NCT00441896|Other|Placebo|
45815705|NCT05042492|Device|gekoTM|The gekoTM device is a small, transcutaneous nerve stimulator that is placed non-invasively on the skin, whereby the surface electrodes will be attached close to the peroneal nerve. Activation of the peroneal nerve causes contraction of the calf muscle pump, which will increase blood circulation that corresponds to 60% of walking. The increased blood circulation reduces the pressure difference between capillaries and the surrounding tissue and transfers the tissue fluid back into the veins and lymph fibers
45815706|NCT05441059|Drug|Mepolizumab 100 MG|Treatment with mepolizumab for severe asthma
45815707|NCT00373100|Drug|Zinc acetate|
45815708|NCT00373100|Drug|Placebo|Placebo
45815709|NCT04223323|Dietary Supplement|Almonds|Participants in the intervention group will consume 2oz of almonds daily over the course of 12 weeks.
45676646|NCT00362843|Drug|[15-O]water|
45815710|NCT04223323|Dietary Supplement|Pretzels|Participants in the control group will consume an isocaloric amount of pretzels daily over the course of 12 weeks.
45815711|NCT04960748|Behavioral|WOMEN FIGHTING TO STOP CERVICAL CANCER|The group intervention draws on theories of social diffusion, cognitive consistency, and social influence, and our own recently developed and tested group intervention that mobilized people living with HIV in Uganda to successfully act as change agents for HIV prevention within their social networks. The intervention actively targets internalized stigma, disclosure decision making, healthy living, and advocacy communication skills. The ultimate goal of the program is to encourage female social network members to get screened for cervical cancer.
45815712|NCT04943510|Other|Physical exercices|"surface EMG: surface electrodes will be positioned on the muscles to evaluate the level of muscle activation~non invasive muscular neurostimulations : application of a percutaneous electrical stimulation of the motor nerve of the considered muscle and a direct electrical stimulation of the muscle"
45815713|NCT04115527|Procedure|Extended Lymphadenectomy|Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 16 17a 17b lymph nodes
45815714|NCT04115527|Procedure|Standard Lymphadenectomy|Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes
45815715|NCT02973698|Other|chin-down posture maneuver|it was performed the training of Chin-down postural maneuver with saliva and water. Besides, the subjects received instructions regarding feeding.
45815716|NCT02973698|Other|Orientations about swallowing|The instructions about feeding were performed. The individuals received all the instructions on a written document.
45815717|NCT02973698|Other|Control|No intervention will do
45815718|NCT04209140|Drug|lithium treatment|"Decisions relating to treatment are also considered the clinician's responsibility to be made according to bipolar treatment guidelines and international standards of care (e.g. discontinuation, co-prescriptions, and according to SmPC in force). After the clinician has confirmed the indication of Lithium treatment as well as the absence of contra-indicated concomintant medication (NSAIDs and Diuretics) and after pre-~Lithium evaluations confirm the absence of contra-indication, Lithium is initiated following standard of care:~progressive titration to reach therapeutic plasma levels. Clinicians will use the therapeutic range provided by the laboratory they use in their usual clinical practice and according to the type of Lithium they prescribe."
45815719|NCT00372541|Drug|ceftriaxone|
45815720|NCT04334486|Other|Super Smash Brothers Melee (Gamecube)|10 minutes of participation in Super Smash Brothers Melee prior to Eyesi Surgical Simulator evaluation of skills.
45815721|NCT04334473|Procedure|phacoemulsification and Intraocular lens implantation|Standartd surgical procedure with small incision to remove catarct using ultrasound waves. it can be done by topica, local or general anaesthesia acoording to patients general fitness and preference.
45955123|NCT05628285|Device|Sentio 1|Sound processor
45955124|NCT05627011|Behavioral|Improving Pediatric Obesity Practice Using Prompts (iPOP-UP)|EHR-based CDS tools refined through a formative evaluation and user-centered design process that immediately preceded this study.
45676647|NCT00254423|Drug|Dasatinib|Given PO
45676648|NCT00254423|Other|Laboratory Biomarker Analysis|Correlative studies
45676649|NCT00254423|Other|Pharmacological Study|Correlative studies
45815722|NCT04334473|Diagnostic Test|Ultrasound Biomicrosopy (UBM)|A diagnostic test using ultrasound waves to evaluate the anterior chamber depth, angle and lens vault.
45955125|NCT05605353|Diagnostic Test|Faecal microbiota sampling and blood sampling|There is no intervention in this study. We will obtain faeces and blood from the recruited patients and assess the microbiota and their metabolites therein. This is an observational work
45955126|NCT05604404|Other|Supine|The patient will be positioned supine with head-of-bed at zero degrees.
45955127|NCT05604404|Other|Semi-Recumbent|The patient will be placed in a semi-recumbent position with head-of-bed at thirty degrees.
45955128|NCT05604404|Other|Semi-Recumbent with Legs Flexed|The patient will be placed in a semi- recumbent position with head-of-bed at thirty degrees and legs flexed.
45955129|NCT05600725|Other|novel atrial pacing approach|See US Patent #10987516. An atrial pacing method that preserves atrioventricular and interventricular synchrony to reproduce an exercise-typical envelope of heart rate.
45955130|NCT05600725|Other|sham pacing approach|A pacemaker/ICD interrogator/programmer will be used to simulate changes in pacing rate over the same time period as the intervention group but the programming changes will not actually be implemented and not change in paced heart rate will occur.
46002770|NCT04636242|Drug|5 Aminolevulinic Acid + Phototherapy|5 aminolevulinic acid solution will be placed on the skin of the shoulder and the participant will receive Photodynamic therapy on the morning of surgery
45815723|NCT03522740|Other|Decision Aid for Renal Therapy|DART is a web-based decision aid that informs older adults with advanced kidney disease of kidney disease treatment options and prompts them to consider their preferences and raise questions to discuss with their kidney disease providers.
45661366|NCT02553317|Biological|Caplacizumab|"First day of treatment: 10 mg intravenous (i.v.) injection prior to plasma exchange (PE) followed by a 10 mg subcutaneous (s.c.) injection (in the abdominal region) after completion of PE on that day.~Subsequent days of treatment during PE: daily 10 mg s.c. injection (in the abdominal region) following PE.~Treatment after PE period: daily 10 mg s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
45815724|NCT04762381|Drug|Dexamethasone phosphate|24 mg dexamethasone infused peroperatively
45815725|NCT04762381|Other|Placebo|Saline
45815726|NCT01547468|Procedure|Femoral Nerve Catheterization|A femoral nerve catheter will be placed prior to surgery in this group.
45815727|NCT01547468|Procedure|Intravenous Opioids|Intravenous opioids will be given after surgery to provide pain relief to subjects assigned to this group.
45815728|NCT04749433|Drug|[11C]CPPC Injection|A single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
46078383|NCT00908869|Drug|Vinorelbine, Cyclophosphamide and Interferon alpha 2b|"Level 1: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 2: Oral Vinorelbine (Navelbine®)20mg x 3/week; oral Cyclophosphamide (Endoxan®) 50mg/day;SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 3: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 5/week.~Level -1 (in case of toxicity at level 1): Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/every 2 days; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week ."
46078384|NCT02820428|Other|Healthy participants|Semi-structured interview
45815729|NCT04717687|Procedure|Irreversible electroporation|Device: NanoKnife The aim of the treatment is to surround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
45815730|NCT04333628|Drug|chloroquine|oral treatment of chloroquine
45815731|NCT04333628|Other|standard care|Currently, there is no specific treatment for novel coronavirus. The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.
45815732|NCT04696315|Diagnostic Test|Multiple features extraction|"In the present study, the gold standard of preclinical AD is amyloid PET. SCD with positive amyloid is the target population for early AD intervention. The investigators aim to extract the diagnostic features from multiple parameter MRI, genetic, blood and clinical data using Max-Relevance and Min-Redundancy (mRMR) algorithm. Then, based on support vector machine (SVM), random forest (RF) and multi-kernel learning (MKL) classification methods, the investigators will construct predicted diagnostic model of preclinical AD."
45815733|NCT04333771|Drug|SHR0302|The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
46002771|NCT00548054|Biological|Bivalent killed oral cholera vaccine|Oral, 1.5 ml, given 2 times at least 14 days apart
46002772|NCT00548054|Biological|Killed Escherichia coli K12 placebo|oral, 1.5 ml per dose
45676650|NCT00254423|Other|Quality-of-Life Assessment|Ancillary studies
45676651|NCT00254423|Other|Questionnaire Administration|Ancillary studies
45454393|NCT03740893|Drug|Olaparib|"PART 1: Pre-operative exposure to 300mg of olaparib to be administered orally twice daily on Days 1-14 of the WOP.~PART 2: 12 months post-operative exposure to 300mg olaparib (2 x 150mg tablets) to be administered orally twice daily on a continuous schedule Day 1-28 of a 28 day cycle."
45661367|NCT02553317|Biological|Placebo|"First day of treatment: i.v. injection prior to PE followed by a s.c. injection (in the abdominal region) after completion of PE on that day.~Subsequent days of treatment during PE: daily s.c. injection (in the abdominal region) following PE.~Treatment after PE period: daily s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
45815734|NCT04333771|Drug|Placebo|The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
45815735|NCT00373412|Biological|VCL CT02 pDNA vaccine|
45815736|NCT00373412|Biological|Towne CMV vaccine|
45815737|NCT03409328|Behavioral|HIV and substance use prevention|The intervention content will be developed through formative research during the initial phase of the study. However, the intervention will address: bisexual-inclusive sexual health education, unique influences of risk behavior among bisexual adolescents, and skills to cope with bisexual stigma and to increase acceptance of one's bisexual identity.
45815738|NCT02241967|Device|4 Real sessions of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp.
45815739|NCT02241967|Device|2 Real Sessions of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp. 2 real sessions of tDCS and 2 sham.
45815740|NCT02241967|Device|1 Real Session of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp. 1 real sessions of tDCS and 3 sham.
45815741|NCT02241967|Device|Sham Transcranial Direct Current Stimulation|Four sessions of sham tDCS; control intervention.
45815742|NCT03315728|Other|Quality Improvement Strategy|Quality improvement strategy The 18 month Quality Improvement Strategy includes 3 months preparation, 12 months intervention, 3 months local knowledge translation. The intervention includes Readiness Consultations to assist in understanding available resources to address and adopt diabetes and chronic disease prevention and care strategies. Community teams receive a series of 3 workshops (in-person/virtual) followed by action periods where the team carry out and evaluate PDSAs they develop to improve diabetes care. Coaching is provided by Western during the 3-4 month action periods. FNDSS is a webbased secure community portal system for communities to develop a diabetes registry/surveillance system and generate reports and plan QI initiatives.
45815743|NCT02088931|Biological|Treg infusion|At the time of Treg infusion (day 0), maintenance immunosuppression will remain unchanged which consists of TAC, MPA and steroids. On follow-up biopsy 2 weeks after Treg infusion, the inflammatory load will be assessed by computer assisted image analysis looking at the number of infiltrating cells per square mm as well as the percentage of renal cortex infiltrated with lymphocytes. If the inflammatory load has decreased by ≥50% and infused Tregs are observed in the allograft, everolimus will be started at 1.5 mg bid and the dose of tacrolimus will be decreased by 50%. After 2 weeks, tacrolimus will be discontinued. These patients will remain on everolimus, mycophenolic acid and prednisone through the end of the study and the follow-up period. If on the 2-week follow-up biopsy, there is no decrease in the inflammatory load or there is a decrease <50%, no change will be made to the maintenance immunosuppressive regimen consisting of TAC, MPA and prednisone.
45815744|NCT00373178|Drug|rosiglitazone|
45815745|NCT00373178|Drug|metformin|
45815746|NCT00373178|Drug|Anti-diabetic medications|
45815747|NCT04095247|Device|Vagus nerv stimulator|pulse triggered autostimulation
45815748|NCT03254732|Drug|ADI PEG20|ADI is a recombinant protein cloned from M. hominis and produced in E. coli, and conjugated with PEG of 20,000 mw. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
46078385|NCT02745288|Procedure|inferior alveolar nerve block|"A long acting local anaesthetic agent Inj Bupivacaine hydrochloride 0.5% (2 ml) will be given after induction by open mouth technique by landmark method.~The mucobuccal fold will be palpated and traced till coronoid notch. The finger will be moved medially across the retromandibular trigone on internal oblique ridge. The 25G needle will be inserted till bone is felt. 2 ml of 0.5% bupivacaine will be injected slowly after withdrawing needle by 1mm and confirming negative aspiration of blood."
45454394|NCT03740893|Drug|Durvalumab|"PART 1: Pre-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of the WOP.~PART 2: 12 months post-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of a 28 day cycle."
45454395|NCT00005788|Biological|aldesleukin|
45661368|NCT03029351|Drug|Exenatide Extended Release for Inj Susp 2 MG|Exenatide extended release treatment weekly for 1 year in T2DM patients with micro- and macroalbuminuria
45661369|NCT03029351|Drug|Placebo|placebo treatment weekly for 1 year in type 2 diabetes with micro-and macroalbuminuria
45815749|NCT03254732|Drug|Pembrolizumab|Pembrolizumab is a PD-1 blocking antibody indicated in the USA for the treatment.
45815750|NCT01163383|Drug|131 I-Metaiodobenzylguanidine (131 I-MIBG)|131 I-MIBG 1-18mCi/kg given intravenously on day 1. Subjects may receive multiple courses every 4-8 weeks depending on the dose given.
45815751|NCT01163383|Drug|131 I-MIBG|131-I-MIBG will be infused intravenously over 60-90 minutes once per course. The dose will be determined by the treating physician.
45815752|NCT04611451|Other|classic lumbar home exercise|classic lumbar home exercise
45815753|NCT04611451|Device|Whole body vibration|Whole body vibration (WBV), which is a new treatment method and applied through the device, is defined as mechanical repetitive motion or oscillatory motion occurring around a balance point
45815754|NCT04611451|Other|Whole body vibration exercise|Whole body vibration exercise
45815755|NCT02923466|Biological|VSV-IFNβ-NIS|Intratumoral injection of a single dose of VSV-IFNβ-NIS
45815756|NCT02923466|Biological|VSV-IFNβ-NIS and avelumab|Intratumoral injection of a single dose of VSV-IFNβ-NIS and intravenous infusion of avelumab
45815757|NCT01052168|Other|skills training|participants will train using different performance goals (based on different metrics)
45815758|NCT00813566|Drug|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with metabolic imaging tracer that aids in assessment, diagnosis, and staging of patients with cancer.
45815759|NCT00813566|Drug|3'-deoxy-3'-[18F]fluorothymidine (FLT)|Brain scan with a radiolabeled imaging agent for investigating cellular proliferation of tumors
45815760|NCT00813566|Drug|[15O]-H2O|Brain scan with imaging agent to determine tumor blood flow
45661370|NCT03010163|Other|Health Fair|Testing includes weight, height, waist and blood pressure testing. In the event that the participants are unable to meet in person for health measurements, the staff will accept self-reported measurements over the phone.
45815761|NCT00813566|Drug|[11C]Acetate|Brain scan with imaging agent to determine growth activity of tumor
45815762|NCT03908359|Procedure|traditional cataract surgery|ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
45661371|NCT03010163|Other|Pedometer|The Fitbit One/Alta/Inspire wireless tracking pedometers measures steps taken, calories burned, distance traveled and sleep pattern. The Fitbit Alta/Inspire also sends reminders to move, which are notifications that remind the wearer to walk at least 250 steps each hour. If the wearer has not walked 250 steps within the hour, the device will vibrate and send an on-screen reminder 10 minutes before the hour. The reminders to move will be turned off during baseline and will be turned on at randomization for all participants.
45661372|NCT03010163|Other|Text Messaging|Daily healthy living advice and encouraging messages about walking through text messages
45815763|NCT03908359|Procedure|minimal invasive lens surgery|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
45815764|NCT03879733|Behavioral|Thrive by Three|"The intervention consists of the following components:~Measurement of daycare quality with CLASS (Classroom Assessment Scoring System) 3 times during the intervention period~Feedback to group staff on 8 CLASS-quality dimensions~Monthly supervision of staff on two levels: supervision of daycare staff, and supervision of supervisors~Competence building with all staff: 3 full training days, plus 2 extra training days for pedagogical leaders/supervisors~Written material to parents, supervisors, and staff~Web page for staff and parents: tf3.no"
45815765|NCT03879733|Behavioral|Treatment as usual (TAU)|The wait-list control group will continue with their daily activities and work in the childcare as usual. The wait list control group will have received general information about the study prior to consenting, however no materials or are provided by project. The child-care centers in the control conditions will receive a gift certificate of 3000 Norwegian Crones (NOK) by the end of the intervention period.
45815766|NCT02885012|Drug|Ambrisentan|At entry to the study following the screen visits, patients will be switched from bosentan to ambrisentan to complete a 24 week trial. The only study intervention will be ambrisentan.
45815767|NCT04555915|Other|Monitoring of cerebral oxygenation|Modify cardio-respiratory support to avoid cerebral hypoxia
45815768|NCT02885246|Other|Data collection|The ICGES database of Panama will be checked for all seasonal influenza A and/or B positive cases reported via influenza surveillance programs from 2010 to 2015.
45815769|NCT03802435|Procedure|two-sessions of ultrasound-guided PIT|two-sessions of ultrasound-guided PIT with 10cc D5W (3 months interval)
45815770|NCT03802435|Procedure|One-sessions of ultrasound-guided PIT|One-session of ultrasound-guided PIT with 10cc D5W and 10cc normal saline separately (3 months interval)
45815771|NCT03802435|Procedure|Placebo ultrasound-guided injection with nerve hydrodissection|Two-sessions of ultrasound-guided PIT with nerve hydrodissection with 10cc normal saline (3 months interval).
45815772|NCT05005663|Other|surgical management of incisional hernia|surgical repair of the incisional hernia
45815773|NCT00372853|Drug|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
45815774|NCT00372853|Drug|SU011248|SU011248 administered at a dose of 37.5mg/day every day.
45815775|NCT00372853|Drug|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
45815776|NCT00372853|Drug|SU011248|SU011248 administered at a dose of 50mg/day for 4 weeks followed by 2 weeks off, repeated every 6 weeks.
45815777|NCT02885636|Drug|Albuterol|": Experimental: Inhaled albuterol~2.5 mg inhaled albuterol through a high efficiency nebulizer as a single dose"
45815778|NCT02885636|Other|Saline placebo|Saline inhaled through a nebulizer as a single dose
45815779|NCT03691129|Behavioral|Participation in the elderly yoga program|Yoga participant groups will practice elderly yoga for four months.
45815780|NCT03625921|Behavioral|Powered device with physical therapy|Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in a device-specific physical therapy (PT) program.
45815781|NCT03625921|Behavioral|Powered device with standard of practice|Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in the current standard of practice training, which includes basic device education and prosthetic training.
45815782|NCT00373087|Drug|entacapone|entacapone
45815783|NCT00373087|Drug|l dopa versus placebo|l dopa versus placebo
45815784|NCT03619213|Drug|Dapagliflozin|10 mg tablets given once daily, per oral use.
45815785|NCT03619213|Drug|Placebo|Placebo matching dapagliflozin 10 mg
45955131|NCT05593835|Device|METHIS Platform|The METHIS platform is a digital healthcare platform, supported by three databases using PostreSQL (based in relational SQL). One of the databases allows adequate internal testing before production. Another database of production (secured with unique access codes) will be created to retrieve data from the practices' and the last database for the research data, where pseudonymised production data can be analysed for research purposes. The platform is integrated (via FCCN Scientific Computation Unit of the Portuguese Fundação para a Ciência e a Tecnologia) with the Software Zoom® to allow encrypted teleconsultations, with a guarantee that each patient connection is unique. The digital platform is web-based, and it can be used in multiple devices.
45955132|NCT05593835|Other|Goal-Oriented Care Training Program|The training program will have three stages: initial face-to-face training, which will happen before the data collection, followed by remote, asynchronous training during a 12-month period, and a final seminar to discuss the results and inquire about the usability of the GOC model and the METHIS platform. The course will be offered to the intervention group one month before the start of patient recruitment, and for the control group at least one month after the end of data collection.
45955133|NCT05589116|Other|Online Compassionate Imagery Intervention|The intervention comprises 14 pre-recorded, 10-15 minute videos. Participants will be asked to watch one video per day over a two-week period. The videos initially focus on providing psychoeducation about what self-compassion is, before delivering a series of guided Compassion Focused Therapy (CFT) informed exercises to cultivate self-compassion. The first week of the intervention will teach key compassion skills, with the second week focusing on skill consolidation.
45955134|NCT05588128|Drug|18F-DCFpyL|Administered to Cohort.
46002773|NCT04644822|Diagnostic Test|[18F] PSMA-1007 Injection|a novel [18F] PSMA radiotracer that is highly selective for PSMA.
46078386|NCT05277415|Biological|Ghrelin|Ghrelin infusion
46078387|NCT05277415|Biological|Placebo|Placebo
46078388|NCT02820584|Biological|GSC-loaded autologous dendritic cells|
46078389|NCT00605111|Drug|biphasic insulin aspart|
46078390|NCT00909025|Drug|Claudiximab|"Patients receive Claudiximab as intravenous infusion over 2 hours on day 1. Cohorts of 3-6 patients receive escalating doses of Claudiximab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no dose-limiting toxicity (DLT) is diagnosed in 3 patients or no more than 1 out of 6 patients exhibits a DLT.~After completion of study treatment, patients are followed for 4 weeks."
46078391|NCT02745132|Other|Neuropsychological evaluation and Brain MRI|"This is a prospective study. The only intervention planned will consist of performing neuropsychological tests and cerebral MRI that will be carried out on a single group cohort at different times.~Notwithstanding, we will record the exposure to DAA to assess any change in neurocognitive function and MRI imaging.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
45815786|NCT02892110|Drug|Varenicline|2 mg daily
46078392|NCT02744820|Drug|GMC-252-L-Lysine Salt|1 dose by oral route, once a day, 28 days
45454396|NCT03945955|Dietary Supplement|Melatonin|Participants will be randomized into two groups (Group A and Group B). Group A will initially be treated with 3 mg melatonin supplements over a 4-week period while Group B will initially receive placebo supplements over a 4-week period. After a 4-week washout period, Group A will receive placebo supplements while Group B will receive 3 mg melatonin supplements.
45661373|NCT03010163|Other|Social Network Support|Family or friends will provide encouragement and remind participants to maintain in a healthy lifestyle and increase daily walking activities
45661374|NCT02325219|Drug|CNTO 1959 50 mg|Participants will receive subcutaneous injection of CNTO 1959 50 mg.
45661375|NCT02325219|Drug|CTNO 1959 100 mg|Participants will receive subcutaneous injection of CNTO 1959 100 mg.
45815787|NCT02892110|Drug|Placebo|2 mg daily
45815788|NCT02778152|Device|Laser depilation|Laser depilation of natal cleft (pilonidal region)
45815789|NCT02779166|Drug|Celecoxib|Received 400mg celecoxib prior to surgery
45815790|NCT02779166|Drug|placebo|
46078393|NCT02744820|Other|Placebo|Matching doses by oral route, once a day, 28 days
45661376|NCT02325219|Drug|Placebo 50 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.
45661377|NCT02325219|Drug|Placebo 100 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.
45661378|NCT02297841|Device|Experimental: Novel lubricant Miami Fragrance|
45661379|NCT02297841|Device|Experimental: Novel lubricant Miami no Fragrance|
45815791|NCT03597607|Behavioral|Intensive Smoking Cessation Group|This group will meet with the pharmacist more frequently and for longer periods than other groups.
45815792|NCT03597607|Behavioral|Abbreviated Smoking Cessation Group|This group will meet with the pharmacist less frequently and for shorter periods in comparison to the intensive group.
45815793|NCT02898740|Behavioral|Structural exercise|Exercise instruction and encouragement
45815794|NCT02898740|Behavioral|Health education|Provision of general information about a variety of health topics
45815795|NCT03406273|Radiation|Cerebral Spinal (CS) radiation|Surgery plus Cerebral Spinal (CS) radiation
45815796|NCT03406273|Radiation|Focal radiotherapy (SRS)|Surgery plus focal radiotherapy (stereotactic radiosurgery to the tumor bed [SRS])
45815797|NCT00373165|Drug|Ganciclovir|
45955135|NCT05586906|Device|Multiple Breath Washout (MBW) tests|LCI measurements (EXHALYZER® D with Nitrogen Washout System, ECO Medics AG) will be performed every month during follow-up beginning 3 months after lung transplantation.
45955136|NCT05586490|Device|Multifunctional RehabilitationDevice (MRD)|Multifunctional rehabilitation device to treat mobility and cognitive problems in PwP
45955137|NCT05586490|Device|existing standard rehabilitation device|existing standard rehabilitation device to be used for in-home comparison testing for aim 3
45955138|NCT05582343|Behavioral|MINDBODYSTRONG™|"Digitalized MINDBODYSTRONG™ is designed for self-paced weekly use via an online platform.~MINDBODYSTRONG© Session Content~Thinking, feeling, & behaving, The ABCs of CBT, Mindfulness Skills Building: Positive self-talk/The ABCs~Self-esteem & positive self-talk, Intentional gratitude, Managing change Skills building: Self-esteem & positive self-talk~Stress, Healthy coping, Abdominal breathing Skills Building: Managing stress~Problem solving, Setting goals, Steps to problem solving Skills building: Strategies to overcoming barriers~Dealing w/ emotions in healthy ways, Using guided imagery, Coping strategies, Effective communication Skills building: Dealing with emotions~Coping w/ stressful situations/valuable sleep Skills building: Coping w/ stressful situations~Distress tolerance & added emotional regulation skills Skills bulding: RAIN practice, Self-love skill, Distracting using ACCEPTS~Putting it all together for a healthy YOU!"
45955139|NCT05581199|Drug|Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
45955140|NCT05581199|Drug|Batoclimab 340 mg SC weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
45955141|NCT05581199|Drug|Placebo|Matching placebo SC
46078394|NCT04267523|Behavioral|Web parenting intervention|Parents participate in the self-delivered web-based parenting intervention for 6 modules. Treatment includes abilities of psychological flexibility (to be open, aware and active), emotion regulation, and positive parenting strategies.
46078395|NCT04267523|Behavioral|Group parenting intervention|Parents participate in face-to-face a weekly 2-hour group for 4 sessions. Treatment includes abilities of psychological flexibility (to be open, aware and active), emotion regulation, and positive parenting strategies.
46078396|NCT05658770|Behavioral|5 days/ week|"The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1.~The exercises to be carried out in phase 1 are:~Supervised Aerobic Training intervention (AT): Perform 50 minutes/day, 3 days/week, totalling 150 min/week at moderate intensity, as recommended by WHO, in a range of 65-75% HRMax.~Supervised Aerobic Training plus Resistance Training intervention (AT+RT): Perform 50 minutes/day, 3 days/week, starting with 50% of 1-repetition maximum (1-RM) and follow a progression of increasing loads up to 75% of 1-RM for optimal gains in strength and insulin action.~Supervised High Intensive Interval Training intervention (HIIT): To be considered high intensive the heart rate needs to be above ≥85%. Perform 25 minutes/day, 3 days/week, totalling 75 min/week at a vigorous intensity, as recommended by WHO."
46078397|NCT05658770|Behavioral|3 days/ week|The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1. The exercises to be carried out in phase 1 are the same as described in the first intervention.
46078398|NCT05658770|Behavioral|2 days/ week|The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1. The exercises to be carried out in phase 1 are the same as described in the first intervention.
46078399|NCT03465774|Drug|Doxycycline|Receive via IPC
46078400|NCT03465774|Device|Indwelling Catheter|Receive IPC
45661380|NCT02297841|Device|KY Liquid lubricant|
45661381|NCT02297841|Device|Astroglide Gel lubricant|
45661382|NCT02365467|Device|Valiant Mona LSA Thoracic Stent Graft System|
45661383|NCT02324361|Other|Physical Activity|The Fitbit Zip is a wireless physical activity monitor that will be worn by the index child during waking hours, and will be used to assess daily active time for the duration of the study.
45661384|NCT02324361|Behavioral|Evidence-based information on healthy family routines|Educational dimensions include nutrition, frequency of family meals, child's screen time, bedtime routines, physical activity, and sleep hours.
45815798|NCT02898974|Behavioral|Medical Marijuana|To investigate the effects of medical marijuana usage on physical function we will employ an observational case-control design
45815799|NCT04400227|Other|Family Talk|"Family Talk is an evidence-based, parent-youth dyadic approach that uses psychoeducation and skills building to help families make meaning of a parent's adversity, increase resilience, and improve family functioning.~The Family Talk model comprises two components: the first involves a series of cognitive-behavioral techniques to bolster problem solving and communication skills among family members; the second involves a facilitated family meeting to develop a shared narrative for discussing each family member's experience of the parent's illness."
45815800|NCT00372931|Drug|AL-37807|
45815801|NCT02901080|Device|Alpha Stim AID cranial electrotherapy stimulation|- 60 minutes of cranial electrotherapy stimulation via Alpha Stim AID once per day, for a minimum of 6 and maximum of 12 weeks.
45815802|NCT02901080|Behavioral|Pregnancy test|- Pregnancy test x 1 (day 1)
45815803|NCT02901080|Other|Anxiety questionnaire|- GAD-7 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
46078401|NCT03465774|Procedure|Quality-of-Life Assessment|Ancillary studies
45661385|NCT02365233|Drug|DPP4 inhibitor|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
45815804|NCT02901080|Other|Quality of life questionnaire|- EQ-5D-5L questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
45955142|NCT05576883|Behavioral|Transdiagnostic emotion regulation intervention|"The intervention under study includes 5 therapeutic approaches, namely: Positive psychology [PP], Mindfulness, Acceptance and Commitment Therapy [ACT], Breathing and relaxation, and Self-compassion [SC].~The intervention consists of 4 core features:~(i) monitoring through filling in EMAs assessing participants emotional states~(ii) feedback through visualization of participant emotional states upon every completion of the EMAs~(iii) exercises targeting different emotion regulation skills [i.e., upregulation of positive affect, mindfulness, cognitive defusion, breathing and relaxation, self-compassion) and health facts (i.e., control intervention) describing health information including nutrition, exercise, sleeping habits.~(iv) psychoeducative articles describing the 5 therapeutic approaches (PP, ACT, Mindfulness, Breathing and Relaxation, SC)"
45661386|NCT02365233|Drug|Pioglitazone|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
45661387|NCT02365233|Drug|Lantus insulin|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
45661388|NCT05369871|Device|Closed-loop system|Closed-loop system consisting of a terminal including the Diabeloop algorithm that is associated with the Dexcom G6 CGM and the Accu-Chek Insight insulin pump.
45815805|NCT02901080|Other|Work and social questionnaire|- WASA questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
45815806|NCT02901080|Other|Sleep questionnaire|- Athens questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
45815807|NCT02901080|Other|Depression questionnaire|- PHQ-9 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
45815808|NCT02901080|Other|Quality of life and financial questionnaire|- CSRI questionnaire x 3 (day 1, week 12 and week 24)
45955143|NCT05576792|Other|Ranibizumab|Prospective observational study. There is no treatment allocation. Patients prescribed with ranibizumab 0.2 mg in the commercial setting are eligible to enroll into this study.
46078402|NCT03465774|Other|Questionnaire Administration|Ancillary studies
45815809|NCT04866589|Behavioral|Distribution of free face masks|"Corona hosts will be placed at the entrance of the intervention stores, and hand out face masks to customers entering the store."
45815810|NCT04333550|Drug|Deferoxamine|Intravenous infusion of Deferoxamine
45815811|NCT04737733|Other|The dementia friendly program|Implementation of a systematic screening and risk modification and management plan, to identify and enhance the management of patients with cognitive impairment and risk of delirium.
45815812|NCT04863625|Behavioral|a peer-led educational intervention based on theory of planned behavior on substance use intentions and behaviors|The intervention will be a peer led education process on substance use (smoking, drinking and chewing) prevention based on the Theory of Planned Behavior (TPB).The intervention aims to encourage anti-substance attitudes and beliefs; foster perceptions of normative support for anti-substance behavior; increase perceptions of control/self-efficacy to resist substance use, increase knowledge and risk perceptions on substance and decrease in intention to use substance and actual substance use behaviors. Six education sessions will be delivered, with one session occurring each week. Each session will be lasted 40-55 minutes. The intervention will be conducted in 30 groups of selected students from grade 9-12, a pair of peer educators will educate a 30 sized group weekly (30 students /group)/ classrooms at pre-assigned time during class periods. The six sessions will be guided by four student training modules.
45815813|NCT02827838|Biological|Durvalumab|Given IV
45815814|NCT02827838|Other|Laboratory Biomarker Analysis|Correlative studies
46078403|NCT03465774|Other|Survey Administration|Ancillary studies
46078404|NCT02538133|Biological|99mTc-Exametazime (HMPAO)-labeled leukocytes|Hybrid tomoscintigraphy with labeled leucocytes for patients with suspected vascular prosthesis infection
46078405|NCT02818634|Procedure|Harvesting rib cartilage|
46078406|NCT02818790|Behavioral|Intervention 1|Bodyguard + Precious App. Short onsite training session on how to use the system.
46078407|NCT02818790|Behavioral|Intervention 2|Bodyguard + Precious App + Motivational Interviewing. Face to face counseling session followed by a short onsite training session on how to use the system.
45454397|NCT03945955|Other|Placebo|Placebo
45661389|NCT05369871|Device|Open-loop system|Open-loop system consisting of a terminal without the Diabeloop algorithm that is associated with the Dexcom G6 CGM and the usual insulin pump.
45661390|NCT02324205|Device|DBT and FFDM|Subjects underwent breast imaging using each device: DBT and FFDM.
45661391|NCT02324049|Drug|SBC-103|
45661392|NCT02364999|Drug|Bevacizumab-Pfizer|Bevacizumab-Pfizer: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles, followed by the assigned blinded bevacizumab monotherapy.
45815815|NCT02827838|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45815816|NCT00373243|Drug|GW406381|GW406381 will be available as 10 mg hard gelatin capsules. Subjects will receive two capsules of 10 mg to make 20 mg dose.
45815817|NCT02758184|Device|ROTEM-based coagulation monitoring|
45815818|NCT02758184|Procedure|Spine surgery|
45815819|NCT03099733|Other|text message|Participants will receive text message assessment and tailored intervention messages daily over the 14-day/two-week study period.
45955144|NCT05576467|Behavioral|Telephone|Classes follow MBCT protocol delivered via telephone by a master's level or higher mental health provider under the supervision of a licensed clinical psychologist, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.
45955145|NCT05576467|Behavioral|Video|Classes follow MBCT protocol delivered via video by a master's level or higher mental health provider under the supervision of a licensed clinical psychologist, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.
45815820|NCT02915185|Procedure|strength training intervention|The strength training program will last 4 weeks (3 times/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb, which are the wrist extensors and the elbow and shoulder flexors. In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Participants' maximal grip force will be determined and used to dose the training of the hand muscles and its progression. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
45815821|NCT02915185|Device|tDCS|An anodal montage over the ipsilesional hemisphere will be used where the anode will be placed over the ipsilesional M1 area whereas the cathode will be placed on the contralateral supra-orbital region.For the tDCS real group, a direct current will be generated by a tDCS stimulator and gradually increased in a ramp-like fashion over the first 8 seconds until a maximum intensity of 2 mA is achieved. The tDCS will be applied for 20 minutes during each training session for a total of 12 sessions. For the group receiving sham tDCS, the protocol will be similar to the tDCS real group although the stimulation will be applied for the first 30 seconds only; a duration long enough to induce similar perceived sensation as real tDCS (tingling), to keep participants' blind to the tDCS type.
45661393|NCT02364999|Drug|Bevacizumab-EU|bevacizumab-EU: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles followed by the assigned blinded bevacizumab monotherapy.
45815822|NCT00373477|Procedure|Generalist Care Manager vs Usual Care|
45815823|NCT02909647|Procedure|Preoperative planning|preoperative planning using 3D digital planning software or conventional template
45815824|NCT02909647|Procedure|Osteosynthesis|osteosynthesis using volar locking plate
45815825|NCT02887885|Drug|Gynoflor|1 vaginal tablet daily for 12 days, followed by 3 vaginal tablets per week as maintenance therapy (Monday-Wednesday-Friday) for 6 weeks
45815826|NCT02902172|Drug|Acetaminophen|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
45815827|NCT02902172|Drug|NSAID|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
45815828|NCT04233229|Device|t:slim X2 with Control-IQ|closed-loop in patients at home for three months
45815829|NCT04233229|Other|home healthcare services|home healthcare services from Air Liquide in patients at home for three months
45815830|NCT04233229|Other|usual care for daily insulin treatment|multiple daily injection insulin regimen with family nurse's daily assistance at home for performing insulin injections and/or glucose monitoring
45815831|NCT02663102|Other|Data collection|Safety monitoring and evaluation: - Recording of all AEs during the study period using diary cards, follow-up contact via telephone or email. - Recording of SAEs throughout the study period for each subject.
45815832|NCT04208347|Drug|Apatinib 250mg|Apatinib 250mg
45815833|NCT04208347|Drug|Camrelizumab|Camrelizumab 200mg
45815834|NCT04208347|Drug|S-1, Oxaliplatin|S-1, Oxaliplatin, q3w
45815835|NCT04208347|Drug|Apatinib 500mg|Apatinib 500mg
45815836|NCT02784548|Other|Virtual Reality|Using a VR headset, motion sensors, and VR software, the investigators will create a customized VR treatment for each participant that engages them in movements and exercises involving their missing limb in a game-like environment. For example, participants may use the headset to engage in activities such as driving a race car around a course requiring both arms, ski down simulated slopes, or manipulate objects.
45815837|NCT02402894|Other|no intervention|
45815838|NCT02777749|Drug|Bupivacaine|15 cc's of 0.5% bupivacaine or 50 cc's of 0.25% short-acting bupivacaine (SB), intramuscular injection
45815839|NCT02785172|Drug|IDP-118 Vehicle Lotion|Vehicle
45815840|NCT02785172|Drug|IDP-118 Vehicle Cream|Vehicle
45815841|NCT02785172|Drug|IDP-118 Lotion|Lotion
45815842|NCT02785172|Drug|Ultravate Cream|Cream
45815843|NCT02754115|Other|Hyperthermic intraperitoneal chemotherapy|Perioperative data of all the patients posted for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be collected prospectively
45815844|NCT02582125|Drug|ONO-4538|
45815845|NCT02906696|Drug|Bosutinib|Given PO
45815846|NCT02906696|Other|Laboratory Biomarker Analysis|Correlative studies
45815847|NCT02503657|Drug|tipelukast|A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity
45815848|NCT02503657|Drug|Placebo|Excipients of MN-001/tipelukast
45815849|NCT02779543|Device|Fitbit|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
45454398|NCT00005608|Drug|leucovorin calcium|
45661394|NCT02364999|Drug|Paclitaxel|Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
45661395|NCT02364999|Drug|Carboplatin|carboplatin AUC =6.0 via IV infusions on Day 1 of a 21-day cyclefor each of at least 4 and no more than six (6) 21-day cycles.
45955146|NCT05576467|Behavioral|Online|Weekly online modules follow migraine and behavior principles delivered via web portal developed by a team of licensed clinical psychologists, neurologists, and mental health providers.
45661396|NCT02322879|Drug|First Treatment Period|(duration: 14 days) Subjects will be randomized to receive either of the 2 interventions (4 grams of solid acetaminophen formulation for two weeks vs. 4 grams of solid acetaminophen formulation + 70 mg/kg/day of liquid propylene glycol)
45661397|NCT02322879|Other|Washout|(duration: 14 days) At the end of the First intervention period all participants will enter a washout period.
46078408|NCT02748954|Behavioral|Thoughts|"Thoughts. Increasing helpful thoughts consisted of two psychoeducational segments (i.e., thoughts affect emotions, and how to manage harmful thoughts), and a list of helpful thoughts that participants could choose to use to increase their mood for the next week."
45661398|NCT02322879|Drug|Second Treatment Period|(duration: 14 days) At the end of the washout period, participants will receive the alternative intervention.
45661399|NCT02322411|Device|Isometric Progressive Resistance Oropharyngeal Therapy|Isometric Progressive Resistance Oropharyngeal Therapy is an approach to oropharyngeal strengthening. This particular use of I-PRO therapy will be facilitated by the Swallow Strong device.
45661400|NCT02322411|Behavioral|Compensatory approaches|
45815850|NCT02779543|Device|Jawbone UP|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
45815851|NCT02779543|Device|Microsoft Band|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
45815852|NCT02785406|Drug|suvorexant|Subjects will receive suvorexant capsules (10 mg week 1, 20 mg week 2), once daily at 10 PM.
45815853|NCT02785406|Drug|Placebo (for suvorexant)|Subjects will receive placebo capsules once daily at 10 PM.
45815854|NCT02307331|Device|Optivac|A vacuum mixing system for cement with mixing and collection under vacuum but open initial mixture of powder and monomer. Has been used since 1993 with excellent results
45815855|NCT02307331|Device|Optipac|A vacuum mixing system for cement with mixing and collection under vacuum but with a pre-packed mixing system allowing for an all closed system minimizing exposure for monomer fumes. This is a relatively new mixing system
45815856|NCT02307331|Device|Arcom (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The first is the 'classic', long term proven ArCom, a conventional polyethylene
45815857|NCT02307331|Device|E1 (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The new is a highly cross linked polyethylene with infusion of vitamin E1 to remove free radicals in order to reduce wear.
46078409|NCT02748954|Behavioral|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated"
45454399|NCT00005608|Drug|tegafur-uracil|
45661401|NCT02322021|Drug|E2609|Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
45661402|NCT02322021|Drug|Placebo|Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
45661403|NCT02363439|Drug|IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly|IMO-8400 at 0.6 mg/kg/wk or 1.2 mg/kg twice weekly as defined per Protocol 8400-401
45661404|NCT02363283|Drug|Glembatumumab Vedotin|Given IV
45661405|NCT02363283|Other|Laboratory Biomarker Analysis|Correlative studies
45661406|NCT02363283|Other|Pharmacological Study|Correlative studies
45661407|NCT02321319|Drug|Hydromorphone HCl ER Tablets|Hydromorphone hydrochloride (HCl) extended release tablet
45661408|NCT02294175|Device|Larval Debridement Therapy|small sterile mesh bags containing live maggots placed into an open chronic wound to remove necrotic tissue and bacterial biofilm
45955147|NCT05574673|Other|Standard of care|Patients receive standard of care treatment according to local and national guidelines
45955148|NCT05574517|Procedure|Without reverse insertion of a ureteral catheter|Traditional tubeless percutaneous nephrolithotomy usually need retrograde ureteral catheter insertion. Our intervention is that the tubeless percutaneous nephrolithotomy is executed without reverse insertion of a ureteral catheter.
45955149|NCT05569395|Other|Neuro mobilization|"For median nerve stretching, the participants' dominant forearms will be in the supination position while the shoulder will be depressed and abducted 90 degrees.~In this position, while the participant's head is lateral flexed to the opposite side, the wrist and finger will be extended and median nerve stretching will be performed. After staying in this position for 30 seconds, the participants will relax by placing the wrist and head in the neutral position. Thus, a set for median nerve stretching will be completed. For median nerve gliding, the dominant side of the individuals' forearms will be in supination, while the shoulder will be placed in a depression and 90 degree abduction position. In this position, the participant will flex the wrist and fingers while lateral flexing the head to the opposite side, and extend the wrist and fingers while the head is lateral flexed to the same side."
45955150|NCT05569395|Other|Sham neuro mobilization|Sham neuromobilization will be applied to the nondominant side upper extremities of the participants.
45955151|NCT05564689|Procedure|Intracoronary flow and pressure|Measurement of absolute coronary flow and resistance
45955152|NCT05555875|Behavioral|IntelliCare Plus|Mobile-app-based digital mental health intervention for individuals struggling with depression and/or anxiety. The app reflects components of evidence-based psychological treatments such as cognitive-behavioral therapy.
45661409|NCT02294175|Procedure|Bedside Sharp Debridement|The use of a sharp clinical instrument (currette, scalpel, scissors, forceps) by a qualified clinician to remove necrotic tissue and bacterial biofilm from an open chronic wound
45815858|NCT02307331|Device|Sirius stem|A polished tapered stem
45454400|NCT01209793|Biological|REGN846|5 IV cohorts (Dose 1, 2, 3, 4, 5)
45454401|NCT02288338|Drug|1 (Lipitor®)|atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
45815859|NCT02062489|Drug|Tamoxifen|20 mg(2#)/day, PO, daily
45955153|NCT05547048|Behavioral|Decision Aid|Decision aid for PrEP tailored for justice-involved women with opioid use disorder
45454402|NCT02288338|Drug|1 (Ezetrol®)|After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
45661410|NCT02088541|Drug|Selinexor|Selinexor oral tablet.
45661411|NCT02088541|Drug|Hydroxyurea|
45661412|NCT02088541|Drug|Ara-C|Ara-C Subcutaneous Injection.
45661413|NCT02294019|Drug|Ibuprofen 400 mg caplet|400 milligram (mg) caplet according to Drug Facts label
45661414|NCT02320149|Drug|Sarecycline|1.5 mg/kg/day taken orally at the same time each day,
45661415|NCT02320149|Drug|Placebo|Placebo-matching sarecycline tablets taken orally at the same time each day.
45661416|NCT05407909|Drug|SYHX2001|SYHX2001 tablets, oral
45815860|NCT02062489|Drug|Placebo|2#/day, PO, daily
45815861|NCT02786810|Drug|Sulfur hexafluoride type-a lipid microspheres|Used as a contrast to enhance renal ultrasound
45815862|NCT02908178|Procedure|Sentinel lymph node biopsy (SLNB)|Intervention is defined as that the DCIS patient has undergone SLNB. Patients in each cohort (group) include those who underwent SLNB (intervention) and those who did not (control).
45815863|NCT02780869|Device|HEMOBLAST Bellows|
45815864|NCT02780869|Device|Absorbable gelatin sponge, USP with thrombin|
45815865|NCT02908490|Drug|Sildenafil|Sildenafil 50 mg once daily
45815866|NCT02908490|Other|Placebo|Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill
45815867|NCT00374036|Drug|ECC|capecitabine
45815868|NCT00374036|Drug|FOLFIRI|Irinotecan
45815869|NCT02345018|Procedure|Mechano-chemical ablation|Treatment with mechano-chemical ablation
45955154|NCT05547048|Combination Product|Athena strategy|eHealth for integrated PrEP/medications for opioid use disorder + decision aid
45955155|NCT05546333|Device|Electrical impedance tomography|Non-invasive measure of electrical impedance in the body, with data collected on electrodes on the surface of the body
45955156|NCT05542420|Other|No treatment given|The study will be based on data already recorded in the medical record
45955157|NCT05539378|Behavioral|Auditory Stimulation|enhancement of sleep slow wave activity through acoustic stimulation
45955158|NCT05539378|Behavioral|Sham (no stimulation)|Playing no tones during sleep but still recording brain activity
45955159|NCT05531565|Drug|BIIB059 (litifilimab)|Administered as specified in the treatment arm.
45955160|NCT05531565|Drug|Placebo|Administered as specified in the treatment arm.
45955161|NCT05527171|Behavioral|Virtual Reality Mindfulness Meditation|Participants will be immersed in a virtual environment of their choosing. While in the virtual environment, participants will follow a guided mindfulness meditation script. Participants will complete the intervention 3 times a week over the course of 8-weeks.
46078410|NCT02748954|Behavioral|Assertiveness.|Increasing assertiveness, consisting of tips for communicating assertively, and an example of an assertive statement. Participants were asked to describe a recent conflict and apply the intervention's assertiveness techniques to address the conflict.
45955162|NCT05527171|Behavioral|Virtual Reality Sham|Participants will be immersed in a virtual environment of their choosing, such as at a beach, forest, or lake.
46078411|NCT02748954|Behavioral|Sleep hygiene|"Increasing sleep hygiene included a description on how sleep can affect mood. Participants were also asked to select from a list of helpful sleep hygiene suggestions to be practiced within the next week such as, Don't take naps during the day and Use the bed/bedroom for sleep or sex only."
45661417|NCT05407363|Procedure|ABB and ATG with simultaneous implant placement|Ridge augmentation using ABB and ATG as a graft material with simultaneous implant placement
45661418|NCT05407363|Procedure|XBB and ATG with simultaneous implant placement|Ridge augmentation using XBB and ATG as a graft material with simultaneous implant placement
45661419|NCT05407363|Procedure|ABB and ABG with simultaneous implant placement|Ridge augmentation using ABB and ABG as a graft material with simultaneous implant placement
45661420|NCT05423509|Other|Dynamic myofascial manipulation|Dynamic myofascial manipulation of the muscles in the back to improve the scoliosis appearance/flexibility/rotation
45815870|NCT02910362|Device|Alcon phacoemulsification equipment|cataract surgery with Alcon phacoemulsification equipment.
45815871|NCT02910362|Device|AMO phacoemulsification equipment|cataract surgery with AMO phacoemulsification equipment.
45815872|NCT02910674|Device|Dario Blood Glucose Monitoring System|Accuracy with usability assessment
45815873|NCT02911844|Drug|Fulvestrant|Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.
45815874|NCT02911922|Device|Endorectal Balloon|"Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
45815875|NCT02911922|Device|Rectal Spacer|"Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
45955163|NCT05525494|Behavioral|Text Fixed R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
45955164|NCT05525494|Behavioral|Text Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period.
45955165|NCT05525494|Behavioral|Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive a pre-commitment prompt message by portal in September. Tailored R/R messages will be sent monthly by portal based on time and place selected by patients (up to 3). R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
45955166|NCT05525494|Behavioral|Portal Fixed R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
45955167|NCT05525494|Behavioral|Portal Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment via portal when they schedule a visit during the study period.
45661421|NCT05423509|Other|Standard AIS treatment with observation or bracing|Observation with radiographs and bracing of curves greater than 20 degrees
45661422|NCT05450965|Drug|Onvansertib|Onvansertib at a dose of 15 mg/m2 orally on Days 1-14 of a 21-day cycle. Treatment will continue until disease progression or intolerable toxicity.
45661423|NCT05422417|Device|Prolonged intermittent theta burst stimulation (piTBS)|Participants in the prolonged dosage (1800 pulse) of intermittent TBS (iTBS) active stimulation group will receive 2-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to the bilateral DMPFC, twice a day. Stimulation will be delivered to the DMPFC using a stimulator.
45661424|NCT05422417|Device|20Hz rTMS|Participants in the 20 Hz rTMS (2000 pulse) active stimulation group will receive 2-week 2s- and-10s off, total 50 cycles at each hemisphere/session, at an intensity of 100% resting motor threshold (MT) to the bilateral DMPFC, twice a day. Stimulation will be delivered to the DMPFC using a stimulator.
46078412|NCT02748954|Behavioral|Own Methods|wherein participants were asked to identify four of their own personal strategies that have helped them improve their mood in the past.
45955168|NCT05524610|Behavioral|Sexual Function Screening Approach|"The screening approach will consist of:~Standardized use of the PROMIS SexFS Brief in a clinic setting. This tool assesses sexual interest/desire, arousal, discomfort/pain, climax, and satisfaction, among other SD concerns and has comparable sex-specific versions. It has been validated in adult cancer populations.~An implementation package to aid in successful implementation. The implementation package will be finalized in the non-trial portion of this study, which will include iterative intervention adaptation. The protocol will be amended as needed to include any relevant updates to the screening approach. Some components may vary per site."
45955169|NCT05520554|Other|Development of the Telerehabilitation Satisfaction Questionnaire|This study will be examined the development, validity, and reliability of the Telerehabilitation Satisfaction Questionnaire in patients with MS.
45955170|NCT05516381|Device|Optetrak Logic CR Knee System|The OPTETRAK® Comprehensive Knee System consists of the OPTETRAK® Total Knee System and the OPTETRAK Logic® Total Knee System. The OPTETRAK Comprehensive Knee System comprises both non-porous and porous knee prostheses for use in total-knee joint replacement procedures. (In the USA, the OPTETRAK Comprehensive Knee System is indicated for cemented use only, except for the OPTETRAK Logic PS and CR Porous Femoral Components, which are indicated for cemented or cementless use.) The system includes various sizes and types of modular femoral components, tibial components, patellar components, and accessories for use in primary and revision applications.
45955171|NCT05515224|Other|5-Cog Paradigm (5-Cog battery coupled with clinical decision tool)|A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. If cognitive concerns are endorsed the 5-Cog battery will be conducted. The 5-Cog battery includes the Picture Memory Impairment Screen, Motoric Cognitive Risk Syndrome diagnosis, and Symbol Match. The simple, <5-minute cognitive assessment will reliably identify older persons with cognitive impairment in primary care settings, and flag them for further evaluation.
45955172|NCT05515224|Other|Enhanced usual care|A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. The results will be provided to primary care physicians.
45955173|NCT05507684|Other|Nature-based social prescribing group intervention|"Groups of 5-12 persons will formed from one assisted living facility. All of them will undergo an individual interview to assess their wishes for the nature-based activities.~Participants meet in a closed group for 9 times once a week for 10 weeks. All 2-4 hour sessions will include nature-based activities and mutual discussions about the experiences of nature and loneliness.~2 professionals will facilitate and observe the group more thoroughly, give feedback to each other, and make use of group dynamics. They write diaries on each session and receive feedback from their trainers. The groups are objective oriented (aiming to alleviate loneliness, to improve participants' self-efficacy), client oriented and aim with favorable group dynamics to mature, self-directing group in which the participants have made friends with each other and want meet with each other without the facilitators after the official group intervention is over."
45955174|NCT05501665|Procedure|Biospecimen Collection|Correlative studies
45955175|NCT05501665|Drug|Carboplatin|Given carboplatin
45955176|NCT05501665|Procedure|Computed Tomography|Undergo PET/CT
45955177|NCT05501665|Other|Fludeoxyglucose F-18|Given IV
45955178|NCT05501665|Drug|Nab-paclitaxel|Given nab-paclitaxel
45955179|NCT05501665|Biological|Pembrolizumab|Given pembrolizumab
45955180|NCT05501665|Drug|Pemetrexed|Given pemetrexed
45955181|NCT05501665|Procedure|Positron Emission Tomography|Undergo PET/CT
45955182|NCT05501665|Radiation|Radiation Therapy|Undergo radiation therapy
45955183|NCT05501665|Other|[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan|Undergo PET scan
45955184|NCT05500079|Device|Wrist splint|A wrist splint is a It stabilizes your wrist. Wearing a wrist splint minimizes pressure on the median nerve.
45955185|NCT05500079|Other|Pulsed radiofrequency current|Pulsed rf current is delivered to the median nerve trace via transcutaneous pads. Pain expression is suppressed in the dorsal horn of the spinal cord.
45815876|NCT02911922|Radiation|Radiation therapy|Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days.
45815877|NCT02790788|Drug|Methylprednisolone; hydrocortisone|Methylprednisolone 40 mg during resuscitation and stress-dose hydrocortisone for postresuscitation shock
45815878|NCT02790788|Drug|Saline Placebo|Saline placebo during resuscitation and during the postresuscitation phase.
45955186|NCT05499975|Other|Self-reported online geriatric assessment (CHAMP)|The CHAMP tool is a self reported online tool that has been developed to increase patients' accessibility to geriatric assessment and improve treatment decision making. The tool includes questions about function, mobility, cognition, nutrition, social support, depression substance use disorders, and miscellaneous items. Based on usability testing in the previous phase of this study, the tool can be completed in approximately 10-15 minutes. The tool generates a summary report with recommendations for patients and clinicians.
45955187|NCT05496283|Other|denture adhesive|After 1 month of using the complete denture with no denture adhesives, patients fill up satisfaction and quality of life forms and given 1 of 3 types of denture adhesive to use for month to compare satisfaction and quality of life forms
45955188|NCT05494398|Drug|N-acetylcysteine|12 week administration of N-Acetylcysteine to target restricted repetitive behavior severity.
45955189|NCT05491278|Drug|Fospropofol disodium for injection|Fospropofol disodium for injection continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
45955190|NCT05491278|Drug|Propofol|Propofol for injection continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
45955191|NCT05491148|Other|work conditions|an increased degree of responsibility for the life of newborns, high psycho-emotional stress, intellectual stress, an irrational work and rest regime, in connection with the COVID-19 pandemic, also using personal protective equipment against biological factors
45661425|NCT05422417|Device|sham control|Half of the patients in the sham group received 2-week the same prolonged iTBS parameter stimulation (sham- prolonged iTBS), and the other half received the same 20 Hz rTMS parameter stimulation using a sham coil (sham-20 Hz rTMS), which also improved the blinding process
45955192|NCT05488249|Diagnostic Test|Cardiac imaging tests|"2D transthoracic echocardiography~128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).~Shear stress evaluation via computational fluid dynamics."
46078413|NCT00909259|Device|Phrenic stimulation device|In Stage 1, a stimulation lead will be introduced via standard access methods and positioned to provide stimulation. A second lead may also be placed for sensing purposes. The proximal portions of the implanted lead(s) will remain externalized such that stimulation and observation can be made using external stimulation and recording equipment. Study subjects will be observed and stimulation will be performed for up to 2 nights of sleep in a clinically supported environment. In Stage 2, a stimulation device and lead will be permanently implanted.
45661426|NCT05450653|Device|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the delivery Microcatheter (BALTACCI-BDPE100)|A Goldballoon Detachable Balloon (GOLDBAL2) will be inserted in the airway of the fetus with severe congenital diaphragmatic hernia (o/e LHR <25% with liver up) during the FETO procedure between gestational age 27 weeks 0 days and 29 weeks and 6 days. The fetal tracheal balloon will be removed at between 34 weeks 0 days and 34 weeks 6 days gestation or earlier as indicated.
45661427|NCT05422105|Drug|[18F]FPSMA-1007|[18F]FPSMA-1007 PET/CT
45955193|NCT05488249|Diagnostic Test|Venous blood sample collection|Venous blood sample collection during CCTA image acquisition for evaluation of serum levels of hsCRP, IL-6, matrix metalloproteases - MMP9, Adhesion molecules (VCAM, ICAM, e-selectin, p-selectin) periostin.
46078414|NCT04240496|Other|Determination of plasma concentration of clozapine/ Genotyping|Determination of trough plasma concentration of clozapine (C0) Genotyping of CYP1A2 & CYP2C19
46078415|NCT03450018|Drug|SLC-0111|Oral SLC-0111
45454403|NCT02288338|Drug|1 (Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
45661428|NCT05405725|Biological|ENZ215|Enrolled women with postmenopausal osteoporosis will receive ENZ215 (60mg)
45661429|NCT05405725|Biological|Prolia|Enrolled women with postmenopausal osteoporosis will receive Prolia
45815879|NCT02793674|Device|Fisher & Paykel high flow nasal cannula|Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.
45661430|NCT02540083|Device|DBT and FFDM|Subjects underwent FFDM breast imaging followed by DBT breast imaging
45815880|NCT02793674|Device|Vapotherm high flow nasal cannula|Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.
45955194|NCT05485935|Device|Investigational device - intermittent catheter with micro-hole zone|Intermittent male catheter with micro-hole zone for urinary drainage
45955195|NCT05485935|Device|Comparator - standard intermittent catheter|SpeediCath Flex, VaPro Pocket, VaPro Plus and VaPro Plus Pocket.
46078416|NCT03450018|Drug|Gemcitabine Injection|1000 mg/m^2 IV
46078417|NCT02537977|Biological|CD19-directed CAR-T cells|CD19-directed CAR-T cell infusion will be given by vein
46078418|NCT04815044|Other|Pregnancy|Experiences from being pregnant when having a history of eating disorder
46078419|NCT04815044|Other|Post-Partum|Experiences from the post-partum period when having a history of eating disorder
45661431|NCT05421169|Diagnostic Test|diastolic hyperemia-free ratio (DFR)|diastolic hyperemia-free ratio uses the mean Pd/Pa calculated over the period in diastole defined as that during which arterial pressure is negatively sloped and below the mean arterial pressure
45815881|NCT03001778|Other|Usability Testing|"Usability testing of ready made workouts in a group format."
45815882|NCT02888665|Drug|Doxorubicin Hydrochloride|Given IV
45955196|NCT05484713|Diagnostic Test|Cardiac imaging|Baseline - 2D transthoracic echocardiography, 128-multislice CT coronary angiography, CCTA of peripheral lower limbs vessels 12-months follow-up - 128-multislice CT coronary angiography with transthoracic echocardiography
45955197|NCT05484713|Device|3D printing of the aortic valve|3D printing of the aortic valve based on CCTA image acquisition
45955198|NCT05480527|Device|Transcutaneous pulsed radiofrequency current|Active treating group: 80 volts, 2Hz, 20 ms pulsed radiofrequency current will be applied to the tibial nerve trace in the ankle with electrodes. Sham group: Elelctrodes will be attached but radiofrequency current will not be applied.
46078420|NCT04265807|Device|Active Remote Ischemic Conditioning|A standard non-invasive blood pressure cuff (e.g., American Diagnostics Corporation, Hauppauge, NY but any one can be used off the shelf) and disposable plastic clamp (e.g.,Medline Industries Incorporated, Mundelein, IL) can be used to apply RIC in patients resuscitated from OHCA via three cycles of 5-mins. inflation to 200 mmHg followed by 5-mins. deflation of a blood pressure cuff on a upper extremity. The cuff occludes the artery; the clamp maintains pressure in the air bladder of the cuff during the inflation periods.
45661432|NCT02293863|Drug|MHAA4549A|Participants will receive a single dose of MHAA4549A by IV infusion on Day 1
45661433|NCT02293863|Drug|Oseltamivir|Participants will receive oseltamivir capsule either 75 mg or 150 mg BID orally for minimum of 5 days. Dosage and administration should follow local prescribing information for oseltamivir.
45661434|NCT02293863|Drug|Placebo|Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1
45661435|NCT02293395|Drug|Acetylsalicylic acid|ASA 100 mg enteric-coated tablet once daily orally.
45815883|NCT02888665|Other|Laboratory Biomarker Analysis|Correlative studies
45661436|NCT02293395|Drug|Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally.
45661437|NCT02293395|Drug|Clopidogrel|Clopidogrel 75 mg once daily orally.
45661438|NCT02293395|Drug|Ticagrelor|Ticagrelor 90 mg twice daily orally.
45815884|NCT02888665|Biological|Pembrolizumab|Given IV
45815885|NCT02918396|Device|Scar-Based Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and 3D-volumes of the atrial anatomy with superimposed dense LGE maps will be generated. Prior to the PVI, a dense voltage map of the left atrium will be performed (>1000 points) iin sinus rhythm. After PVI, low voltage areas (defined as <0.3 mV) which are superimposed on dense LGE on the MRI will be targeted by radio frequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
45815886|NCT02918396|Device|Rotor Anchors Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and the LA shell, along with the LGE-MRI will be sent to the biomedical engineering team who will generate a 3D-model of the LA along with rotor anchor sites predicted by modeling. After the PVI, the 3D models will be displayed and the rotor anchor sites will be targeted by radiofrequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
45815887|NCT02918396|Device|Conventional PVI by Radio-frequency Ablation|Conventional wide area circumferential ablation (WACA) pulmonary vein isolation will be performed using a contact-force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
45815888|NCT02781571|Drug|SOF/VEL|400/100 mg tablet administered orally once daily
45955199|NCT05478239|Drug|ArtemiCoffee|3 cups of Artemisia annua (Aa) coffee per day (1350mg) for 24 weeks.
45454404|NCT02288338|Drug|2 (Ezetrol®)|ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
45454405|NCT02288338|Drug|2(Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
45661439|NCT02025985|Drug|Selinexor|"Route of administration and dosage form: Oral tablet; Doses: 35 mg/m^2 BIW, 35 mg/m^2 QW, 50 mg/m^2 BIW, 50 mg/m^2 QW, 60 mg/m^2 BIW, 60 mg/m^2 QW.~Treatment cycles were 4 weeks each i.e., 28 day cycles."
45955200|NCT05472064|Other|Persona: Primary care doctor|The chatbot persona is a Black woman who is a primary care doctor.
45955201|NCT05472064|Other|Persona: Breast cancer survivor|The chatbot persona is a Black woman who is a breast cancer survivor.
45661440|NCT05450341|Device|rTMS over right frontal target|Low frequency (1 Hz) rTMS over right inferior frontal gyrus
45661441|NCT05450341|Device|rTMS over right temporal target|Low frequency (1 Hz) rTMS over right posterior superior temporal gyrus
45955202|NCT05472064|Other|Communication Style: Direct|The chatbot messages are characterized by commands and direct addresses (''you'').
45661442|NCT04263181|Procedure|Peripheral blood draw|"All cohorts will have peripheral blood drawn at baseline no more than 4 days prior to the first dose of chemotherapy and must also occur before the first dose of chemotherapy~Cohort 0 or 1 - peripheral blood draw on Day 2~Cohorts 0, 2, 3, 4 and 5 - peripheral blood draw on Day 3~Cohort 0 or 1 - peripheral blood draw on Day 35 (at count recovery)~Cohorts 0, 2, 3, 4, and 5 - peripheral blood draw on Cycles 2 or 3 and 4 or 5, Day 28"
45661443|NCT04263181|Procedure|Bone marrow aspirate|"Cohort 0 or 1 - bone marrow aspirate on Day 14~Cohort 0 or 1 - bone marrow aspirate on Day 35 (at count recovery)~Cohorts 0, 2, 3, 4, and 5 - bone marrow aspirate on Cycles 2 or 3 and 4 or 5, Day 28"
45955203|NCT05472064|Other|Communication Style: Indirect|"The chatbot messages are characterized by subjunctive modal verb forms (''would like'') and cooperative addresses (''we, let's)."
45661444|NCT04263181|Procedure|Buccal swab|"Cohort 0 or 1 - buccal swab on Day 35 (at count recovery)~Cohorts 0, 2, 3, 4, and 5 - buccal swab on Cycle 2 or 3 and 4 or 5, Day 28"
45454406|NCT02288338|Drug|2 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
45661445|NCT04423081|Other|EXIT scale|completion of EXIT scale translated in french
45661446|NCT02528305|Other|High-intensity Interval Training|2 minute warm-up at 50rpm, then increase to 100rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 5 sprints in sessions 1-3, 6 sprints in session4, 7 sprints in sessions 5&6, 8 sprints in sessions 7&8, 9 sprints in sessions 9&10 and 10 sprints in sessions 11&12.
45661447|NCT05450263|Behavioral|Interoceptive exposure|A pilot study addressing the efficacy and feasibility of an interoceptive exposure technique.
45661448|NCT05403775|Other|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in TFESI combined with dorsal root ganglion PRF to help to reduce intra-operative radiation.
45661449|NCT05403775|Other|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy.
45815889|NCT02918630|Drug|Nicotine Patch|Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
45815890|NCT02918630|Drug|E-cigarette|The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
45815891|NCT02781649|Drug|Zepatier|Fixed dose Grazoprevir 100 mg/Elbasvir 50 mg by mouth daily for 12 weeks
45815892|NCT02781649|Drug|Ribavirin|Ribavirin 1200 mg/d (> 75 kg) or 1000 mg/d (< 75 kg) by mouth daily in two divided doses
45815893|NCT02781649|Drug|Sofosbuvir|Sofosbuvir 400 mg daily
45815894|NCT02794766|Drug|Inulin+SS|Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
45815895|NCT02794766|Drug|S salivarius|Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
45454407|NCT02288338|Drug|3(Lipitor®, Ezetrol®)|atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
45661450|NCT05420701|Procedure|TEE|Patients in the surgical arm (LAAC) will be arranged to do TEE, which is not considered standard of care.
45661451|NCT05420311|Other|MedDiet Arm|A balanced hypocaloric diet in macronutrients (MedDiet)
45661452|NCT05420311|Other|KetoDiet Arm|A very low carbohydrate diet (KetoDiet).
45661453|NCT05420311|Other|IF Arm|An intermittent fasting (IF) approach
45676652|NCT00202800|Drug|Gemcitabine, Etoposide|Pancreatic cancer is a devastating disease. Previous research shows a correlation between a specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination for locally advanced and metastatic pancreatic cancer
45815896|NCT02794766|Drug|Placebo|Placebo 1 gum each 12 hours for 10 days
45955204|NCT05463783|Drug|Biktarvy|microRNA profiles of subjects on Biktarvy, will be compared with those who are on Symtuza, at various time points.
45955205|NCT05463783|Drug|Symtuza|microRNA profiles of subjects on Symtuza, will be compared with those who are on Biktarvy, at various time points.
45955206|NCT05457582|Drug|Placebo plus high-intensity statin|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
45955207|NCT05457582|Drug|PCSK 9 Inhibitor plus high-intensity statin|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
45955208|NCT05438862|Procedure|State of art aortic valve surgery|Optimal surgical treatment (aortic valve-sparing surgery, aortic valve replacement, Ross procedure).
46078421|NCT04265807|Device|Sham Remote Ischemic Conditioning|The control group will have a sham package opened at the bedside as soon as feasible after ED arrival. This will be identical in size, weight and appearance as that in the intervention group, but will contain a sham device. Upon identification that the patient has been randomized to the control group, the care team will proceed with all other resuscitative measures as in the the intervention group.
46078422|NCT00909337|Drug|Bosentan|2x62.5mg for 4 weeks, then 2x125mg
46078423|NCT02822456|Procedure|VFSS|VFSS using assignment of tube type among the interventions such as individual 3D printed guiding tube, traditional IOE tube, levin tube
46078424|NCT02748876|Other|His-Ventricular (HV) optimisation|Optimisation of atrioventricular pacing interval
46078425|NCT03317418|Other|ATR-FTIR Spectrophotometry|Spectrometry imaging
46078426|NCT00909493|Other|Network Access|Primary Care Physicians in this treatment group will have access to a pain specialist at the Pain Management Unit.
45955209|NCT05436626|Procedure|Early BDI reconstruction without abdominal sepsis control|BDI reconstruction within 6 weeks after the injury without abdominal sepsis control
46078427|NCT04267445|Procedure|Embolization of prostatic artery under ultrasound guidance|Ekobi Embolization MIcrospheres is administered via selective angiography and Prostatic Artery Embolization (PAE), a minimally invasive technique for reducing symptoms from Benign Prostatic Hyperplasia (BPH) to achieve near stasis in the target vasculature. Contrast Enhanced Ultrasound (CEU) and angiographic runs will be used to confirm anatomy at the time of embolization.
46078428|NCT02822690|Other|Hospice care at UMCG|introduction of hospice care facilities on the wards at the UMCG
46078429|NCT02538055|Behavioral|Living Healthy|This intervention tested the effects of a community health worker delivered lifestyle modification program based on cognitive behavioral therapy on diabetes and pain outcomes in individuals with diabetes and chronic pain.
46078430|NCT02538055|Behavioral|General Health Program|Participants in this arm worked with a Community Health Worker (CHW) who provided a general health program that consisted of didactic information of unrelated general health information. Participants received the same number of contacts with their CHW as the intervention arm. Participants and CHW interacted by telephone 8 times over 3 months.
46078431|NCT02748720|Other|RFM (device) Visible|Will measure the expire tidal volume, end tidal CO2 and peak pressure changes according to clinical improvement and tidal volume
46078432|NCT05378243|Device|Robotic Gait Training|Use of a walker adapted with robotic components to promote proper walking gait
46078433|NCT05378243|Behavioral|Functional Clinical Therapy|Personalized program of physical therapy targeted to improving walking gait
46078434|NCT04200716|Behavioral|Moderate intensity continuous training - session|Moderate exercise continuous exercise 30 minuts session
45454408|NCT02288338|Drug|3 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
45454409|NCT02288338|Drug|3 (Ezetrol®)|After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
45661454|NCT05402761|Behavioral|Nurse-guided BBTi group|On the arrival for the baseline appointment, participants will receive workbooks which include an outline and content of BBTi. In the end of week 1 and 3, nurse interventionist will meet participants to review their sleep diary data and negotiate their bedtime and wake-time schedule. During the weeks 2 and 4, participants will receive planned follow-up phone calls to assess their adherence and review progress and challenges.
45661455|NCT05402761|Behavioral|Mobile-delivered BBTi group|They will use the app in conjunction with the standard BBTi procedures provided by the app, such as stimulus control, sleep restriction and audio-guided relaxation techniques (suggest to use before bedtime).
45661456|NCT05447065|Dietary Supplement|Vitamin D supplement|Only the experimental group (D) received the vitamin D supplement.
45676653|NCT00194714|Biological|HER-2/neu Peptide Vaccine|Given ID
45676654|NCT00194714|Other|Laboratory Biomarker Analysis|Correlative studies
45815897|NCT02794844|Drug|Genotype Guided PPI Dosing|Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.
45815898|NCT01709539|Procedure|Diagnostiskt Centrum|Patients who are suspected of having cancer after investigation at the primary care center will be referred to Diagnostiskt Centrum. Each patient who is referred to Diagnostiskt Centrum will undergo the following: (1) clinical chemistry/microbiology tests; (2) medical history; (3) objective clinical examination; and (4) taking of blood samples for analysis of biomarkers. If necessary, patients will also undergo the following: (5) additional laboratory tests; (6) biopsy; (7) X-ray of painful joints; (8) CT scan of the neck, thorax, abdomen, and/or pelvis; (9) mammography and gynecological examination; (10); gastroscopy and/or colonoscopy; and (11) further investigation (e.g., PET-CT scan).
45955210|NCT05436626|Procedure|Early BDI reconstruction with abdominal sepsis control|BDI reconstruction within 6 weeks after the injury with abdominal sepsis control
45955211|NCT05436626|Procedure|Delayed reconstruction|BDI reconstruction after 6 weeks after the injury
45955212|NCT05434234|Drug|YL201|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
46002774|NCT04644432|Drug|Medication (A specification is listed under each arm)|Study drugs and dosages are listed in the description of arms.
46078435|NCT04200716|Behavioral|High intensity interval training - session|The high intensity interval exercise sessions are isocaloric to the moderate intensity continuous exercise, therefore, the necessary exercise time equivalent to 30 minutes of the moderate exercise continuous exercise session was calculated.
46078436|NCT02748642|Drug|BITS7201A|BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.
46078437|NCT02748642|Drug|Placebo|Placebo matched to BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.
46078438|NCT00909571|Drug|FK506E (modified release tacrolimus)|oral
46078439|NCT00909571|Drug|Prograf (tacrolimus)|injection
46078440|NCT05659550|Device|Honeywell HT-900 Turbo Force Air Circulator|This is a basic, portable, household fan with a single cost of CDN$21.99.
46078441|NCT02850731|Device|plate-forme Hu360®|the innovative technology (plate-forme Hu360®) will be used in the experimental arm
46078442|NCT04216992|Device|Cone beam computed tomography|The contrast agent (Omnipaque, GE Healthcare, Ireland) was instilled to conﬁrm the epidural space. With use of a calibrated angiographic C-arm system and a postprocessing workstation, we acquired volume data sets from two dimensional digital projection images obtained to reconstruct the 3D-RE during a C-arm rotation around the patient axis.
46078443|NCT04015375|Drug|Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical gel
46078444|NCT04015375|Drug|ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)|Topical gel
46078445|NCT04015375|Other|Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical gel
45955213|NCT05429892|Behavioral|Smoking cessation counseling and food delivery|"The community health workers will delivery five 30-minute sessions during intervention months 1 through 5 to provide interpersonal level support for smoking cessation. The community health workers will conduct real-time video motivational counseling to clients. The community health workers will implement the 5As (Ask, Advise, Assess, Assist, Arrange) and support smokers in quitting, if ready, and build confidence toward quitting if they are uncertain about change.~Smokers enrolled in the TRTsocialmot1 arm will be provided with monthly delivery of food boxes in accordance with the number of persons in the household and caloric intake needed to support one week's worth of family meals. Healthy meal preparation instructions will be included and delivery by project staff will reduce transportation barriers to food access rural counties.~Participants will receive educational materials."
45815899|NCT01689103|Behavioral|Cognitive-behavioral treatment|Cognitive-behavioral treatment of alcohol use disorders
45815900|NCT01689103|Behavioral|Cognitive-behavioral treatment|Cognitive-behavioral treatment for alcohol use disorders
46078446|NCT04239794|Drug|Propofol|General anesthesia during the laparoscopic colorectal surgery is achieved by using a target-controlled intravenous infusion of propofol.
46078447|NCT04239794|Drug|Sevoflurane|General anesthesia during the laparoscopic colorectal surgery is achieved by using an inhalation agent (Sevoflurane).
46078448|NCT02850887|Other|general endotracheal anesthesia|sedation with the use of endotracheal intubation
46078449|NCT02850887|Other|deep sedation without endotracheal intubation|deep sedation without endotracheal airway management.
45815901|NCT02795780|Drug|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
45815902|NCT02795780|Procedure|PET Scan|positron emission tomography (PET) scan
45815903|NCT02783443|Other|General anesthesia|General anesthesia
45815904|NCT02783443|Other|Regional anesthesia|Regional anesthesia
45815905|NCT02796092|Device|Fibered platinum coils|
45815906|NCT02796092|Device|Vascular plugs|
45815907|NCT02889289|Other|Xbox One Kinect Gaming|"The Veteran completed 15 sessions of supervised VR training. Each session lasted between 50 and 60 minutes in total. The intervention utilized 2 commercially available Xbox One Kinect games called Shape Up and Kinect Sports: Rivals to challenge both cardiovascular and balance systems. Each game is composed of mini-games (MG). Each MG lasted between 1:30 minutes to 4:00 minutes. Both games were played for approximately 25 minutes during each session. Rest breaks were allowed as the participant required them. Guarding by a therapist was provided dependent on the challenge of the game and the participant's abilities."
45815908|NCT02784613|Drug|Ospemifene|FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia
45815909|NCT00373568|Drug|miltefosine: 2.5 mg/kg/day for 42 days|
45815910|NCT02890303|Device|Zepto System|Anterior Capsulotomy using the Zepto System.
45815911|NCT03002012|Drug|Sertraline|sertraline 400mg/day
45815912|NCT03002012|Drug|Placebo Oral Tablet|matched placebo tablet
46078450|NCT02744664|Procedure|Cryotherapy|After entering the group subject receive Cryotherapy on lung cancer
46078451|NCT02744664|Drug|Icotinib|After Cryotherapy, subjects begin Icotinib administration
46078452|NCT00909805|Device|cutaneous suture (Surjet)|cutaneous surjet suture
46078453|NCT00909805|Device|2-octyl-cyanoacrylate (Dermabond® glue)|the cutaneous suture is made with glue only
46078454|NCT04653038|Drug|MGD013|A fixed dose of MGD013 600mg IV Q2W will be administered to subjects
45815913|NCT03002012|Drug|Fluconazole|Standard of Care Fluconazole per World Health Organization and Ugandan Guidelines (800mg/day x 2 weeks, 400mg/day x10 weeks, 200mg through 6 months).
45815914|NCT02798354|Behavioral|Quality Improvement Collaborative|1)Every 8 month 1-2 day interactive webinar learning sessions 2)Monthly webinars sharing best practices 3)Monthly team interactions with dedicated QI coach 4)Monthly data submission on both process and outcome measures 5)Monthly data feedback both at aggregate level with full inter-team transparency as well as at institutional level 6)Monthly mini root cause analyses performed on 1 error at each site 7)Multidisciplinary teams consisting of at least a physician, nurse, and office practice associate 8)Instruction on best practices from content area experts in QI, diagnostic errors, hypertension, mental health, leadership, behavior change, Model for Understanding Success in Quality (MUSIQ) and EHRs 9)Ongoing sharing of best ideas and barriers/issues among institutional teams
45815915|NCT02890381|Biological|RSV LID cp ΔM2-2 Vaccine|10^5 plaque-forming units (PFUs); administered as nose drops
45815916|NCT02890381|Biological|Placebo|Isotonic diluent, administered as nose drops
45815917|NCT00373646|Drug|Thalidomide, Pharmion|200 mg p.o. daily
45661457|NCT05402605|Procedure|ICSI with AOA|"Step 1: All post-ICSI oocytes will be added in the medium drop in AOA dish, these oocytes will be placed in the incubator at 37oC, 6% CO2, and 5% O2 for 20 minutes.~Step 2: After 20 minutes, calcium ionophore stock (Sigma-Aldrich - USA) will be diluted into 10µM drops in AOA dish.~Step 3: After 10 minutes of incubation, all post-ICSI oocytes will be moved to the AOA drop, then this dish will be put back in the incubator for 10 minutes.~Step 4: After 10 minutes, all the oocytes in drop AOA will be moved to another drop for rinsing and then put back in the incubator for 20 minutes.~Step 5: After 20 minutes, the oocytes will be moved into drop AOA and then put back in the incubator for 10 minutes.~Step 6: After 10 minutes, all post-ICSI oocytes will be added in the medium drop, then divided into drops with maximum 3 oocytes per drop for culturing. After that, the culture dish will be put in the K-system G185 incubator at 37oC, 6% CO2, and 5% O2"
45661458|NCT05402605|Procedure|ICSI without AOA|Conventional ICSI procedure will be performed without the application of AOA.
45661459|NCT01351909|Drug|Cyclophosphamide|Given PO
45661460|NCT01351909|Other|Laboratory Biomarker Analysis|Correlative studies
45661461|NCT01351909|Drug|Veliparib|Given PO
45661462|NCT05401903|Other|Chiropractic Maintenance Care|"Subjects will receive high-velocity, low amplitude (HVLA) chiropractic manipulations to areas of defined restriction in the upper cervical spine, thoracic spine, lumbar spine, and pelvis. The clinician will use motion palpation to determine spinal segments with joint restrictions. Subjects will schedule weekly chiropractic visits.~The clinician will not use passive care modalities. The exclusions of passive modalities include heat and cold therapies, electric stimulation, massage, acupuncture, and cupping therapies. Subjects will be encouraged to maintain normal exercise activity levels throughout the study. The clinician will provide instructions on homecare exercises as needed to promote range of motion of spinal segments between chiropractic visits. A single clinician will deliver the HVLA chiropractic manipulations to ensure consistency of chiropractic care throughout the study."
45661463|NCT05401357|Drug|Test - Bimatoprost 0.01% Ophthalmic Solution|Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 1 hour for 42 days.
45815918|NCT03005054|Biological|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
45815919|NCT03005054|Procedure|Autograft|The current standard of care procedure for the treatment of severe complex skin defects. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original wound.
45815920|NCT02891629|Device|EyeControl device|Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences
45661464|NCT05401357|Drug|Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)|Subjects in the other arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm for 42 days.
45454410|NCT02288338|Drug|4 (Lipitor®)|atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
45661465|NCT05401279|Drug|Tislelizumab|Tislelizumab 200mg will be administered on Day 1 of each 21 day cycle for 8 21-day cycles.
45661466|NCT05401279|Drug|Gemcitabine|Gemcitabine 1000mg/m^2 will be administered on Days 1 and 8 for four to six 21-day cycles.
45661467|NCT05401279|Drug|Cisplatin|Cisplatin 70mg^m2 will be administered on Day 1 for four to six 21-day cycles.
45661468|NCT05400655|Drug|L9LS|Administered subcutaneously.
45661469|NCT05400655|Other|Normal Saline|Administered subcutaneously.
45955214|NCT05429892|Behavioral|Smoking cessation counseling|"The community health workers will delivery five 30-minute sessions during intervention months 1 through 5 to provide interpersonal level support for smoking cessation. The community health workers will conduct real-time video motivational counseling to clients. The community health workers will implement the 5As (Ask, Advise, Assess, Assist, Arrange) and support smokers in quitting, if ready, and build confidence toward quitting if they are uncertain about change.~Participants will receive educational materials."
45955215|NCT05429892|Behavioral|Food delivery|"Smokers enrolled in the TRTsocial2 arm will be provided with monthly delivery of food boxes in accordance with the number of persons in the household and caloric intake needed to support one week's worth of family meals. Healthy meal preparation instructions will be included and delivery by project staff will reduce transportation barriers to food access rural counties.~Participants will receive educational materials."
45955216|NCT05424146|Dietary Supplement|Prebiotic Bar +CPT|Participants will be instructed to consume 1 prebiotic bar once daily for 1 week CPT. Starting week 2 they will be asked to consume 1 prebiotic bar twice daily.
45955217|NCT05424146|Behavioral|Non-Prebiotic Bar +CPT|Participants will be instructed to consume 1 non-prebiotic bar once daily for 1 week while receiving CPT. Starting week 2 they will be asked to consume 1 non-prebiotic bar twice daily.
45661470|NCT05400577|Drug|Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)|Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
45661471|NCT05420077|Biological|RVM-V001 10 µg|Low Dose
45815921|NCT02891863|Device|LEVER Acute Study System|The LEVER Acute Study System is an acute pacing and shock delivery system intended for investigational use only. The LEVER Acute Study System is intended for acute conversion testing of monomorphic ventricular tachycardia by one of three different VT conversion methods.
45661472|NCT05420077|Biological|RVM-V001 30 µg|Mid Dose
45661473|NCT05420077|Biological|RVM-V001 60 µg|High Dose
45955218|NCT05419024|Other|Acute Treatment Interruption|Participants randomized to ATI will halt their ART medications starting 2 weeks (more or less 3 days) after the first imaging visit. This plan will be discussed with participants during the baseline visit. Patients will be contacted 1-3 days prior to ATI initiation. ATI may be delayed or cancelled if there are new safety concerns. HIV plasma viral levels and CD4 counts will be monitored every week during the ATI phase. If a participant meets any of the ART restart criteria during the ATI phase, then they will discontinue ATI and restart ART. Participants who do not meet restart criteria will remain off ART and continue to be monitored weekly until they have been on ATI for 90 days, and then will restart ART.
45955219|NCT05415033|Other|BREAST-Q|arabic version of breast questionnaire
45661474|NCT02532517|Device|CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System|
45661475|NCT05418595|Other||
45661476|NCT02545049|Drug|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily.
45661477|NCT02545049|Drug|Placebo|Matching placebo to be taken orally, once daily.
45661478|NCT05451095|Drug|BI 474121|BI 474121
45661479|NCT05451095|Drug|Placebo|Placebo
45661480|NCT05451095|Drug|Ketamine hydrochloride|Ketamine hydrochloride
45661481|NCT05476133|Other|Executive functions training-elementary and Promoting executive function in in the classroom|evidence based practice that target executive function skills in early elementary years.
45661482|NCT05476055|Genetic|NGS|In the conbentional NBS+/NICU/premature infants, NGS was conducted to investigate whether NGS can accelerate diagnosis and improve prognosis in these children
45815922|NCT03001453|Drug|Liposomal Bupivacaine|266mg liposomal bupivacaine
45815923|NCT03001453|Drug|0.25% Bupivacaine with epinephrine|0.25% bupivacaine with epinephrine
45815924|NCT03001453|Drug|Saline|Normal saline
45815925|NCT03001843|Drug|Ketamine|Anesthesia of only Ketamine
45815926|NCT03001843|Drug|Narcotics|The narcotic group will receive no ketamine but rather a more standard anesthetic
45815927|NCT03001843|Behavioral|pain scale|0-10 pain scale. 0 = no pain and 10 = worst pain
45815928|NCT03003793|Diagnostic Test|Hyperinsulinemic euglycemic clamp|Hyperinsulinemic euglycemic clamp to detect insulin sensitivity
45815929|NCT02784925|Device|Ultrasound (US) B mode image|"Ultrasound (US) B mode image is an alternative method to measure tissue structure~and has proven to be an accurate technique to measure subcutaneous fat thickness."
45815930|NCT02785159|Drug|IDP-118 Lotion|Lotion
45815931|NCT02785159|Drug|Tazorac Cream|Cream
45815932|NCT02785159|Drug|IDP-118 Vehicle Lotion|Lotion
45815933|NCT02785159|Drug|IDP-118 Vehicle Cream|Cream
45661483|NCT04423835|Procedure|Paley's Principle osteotomy|. The osteotomy line of all patients was designed according to Paley's principles. The lateral incision was applied in all patients and the osteotomy lines were marked on the humerus with the assistance of C-arm radiographs. An isosceles triangle template was used for osteotomy, and the medial cortex was left intact. K-wires were used to fix the osteotomy laterally.
45815934|NCT02786719|Drug|Topotecan|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
45815935|NCT02786719|Drug|Cyclophosphamide|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
45955220|NCT05411367|Drug|SI-614|1 drop in each eye
45661484|NCT05450705|Biological|9vHPV vaccine|A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.
45955221|NCT05411367|Drug|Vehicle|1 drop in each eye
45955222|NCT05406011|Dietary Supplement|Pelleted sour cherry (anthocyanin) containing chewing gum usage.|Dietary Supplement usage (daily 3 times for 2 weeks) with salivary sampling on fixed days (1., 4. and 7.) and daytime (between 12:00 and 14:00) of the week. Procedure: Scaling after a control period without sour cherry chewing gum usage (1 week).
46078455|NCT02744586|Behavioral|Strengthening Our Vows (SOV)|"Participants, led by a counselor, will discuss options to keep HIV from entering their relationship including both sex partners remaining monogamous, using condoms every time they have sex with outside partners, and being tested together with outside partners to ensure they are HIV negative (Together HIV Free Plan). Participants will discuss options in the event of an outside exposure to HIV including abstaining from having sex with their spouse or by using condoms every time they have sex with their spouse until they can be retested for HIV after 30 days (Protecting my Spouse Plan).~Participants will be screened for hypertension, diabetes, schistosomiasis, HIV, syphilis, and trichomonas vaginalis and the presence of sperm (women only). Health problems will be treated or referred. Couples will be administered questionnaires that record self-report of sexually transmitted infections, number of outside partners, and reports of sex without a condom with outside partners."
46078456|NCT02744586|Behavioral|Good Health Package Plus (GHPP)|Participants, led by a counselor, will discuss how to prevent, screen, and treat neglected tropical diseases (helminths and schistosomiasis), non-communicable diseases (hypertension and diabetes) and diarrheal diseases through basic hygiene and sanitation. The facilitator will demonstrate proper handwashing techniques and chlorination of water and discuss diet and lifestyle changes. Participants will be screened for hypertension, diabetes, schistosomiasis, HIV, syphilis, and trichomonas vaginalis and the presence of sperm (women only). Health problems will be treated or referred. Couples will also be administered questionnaires that record self-report of sexually transmitted infections, number of outside partners, and reports of sex without a condom with outside partners.
46078457|NCT00931567|Biological|Autologous platelets gel|"Application of autologous platelets gel (Platelet Rich Fibrin) after the  open palm  surgical treatment of Dupuytren's disease."
46078458|NCT00931567|Device|Vaselitulle|"application of standardized wound dressing after the  open palm  surgical treatment of Dupuytren's disease."
45661485|NCT02954081|Drug|Phase I: Fumaric acid esters. Phase II: Apremilast|Apremilast
46078459|NCT02820272|Procedure|NPWT with cold water|Each of dressing change would be treated with NPWT and injection of cold sterile water kept in 4°C temperature into sponge 10 minutes before dressing change
45661486|NCT02517125|Device|Transoral robotic-assisted surgery with Da Vinci Xi|
45454411|NCT02288338|Drug|4(Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
46078460|NCT02820272|Procedure|NPWT with normal saline room temp|Each of dressing change would be treated with NPWT and injection of room temperature sterile water kept in room temperature into sponge 10 minutes before dressing change
46078461|NCT02820272|Procedure|NPWT without other intervention|Each of dressing change would be treated with NPWT without injection of any liquids into sponge before dressing change
46078462|NCT03290508|Diagnostic Test|Prolaris Testing|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
45454412|NCT02288338|Drug|4 (Ezetrol®)|After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
46078463|NCT00931645|Procedure|Autologous stem cell transplantation|TBI (10 grays, d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
45661487|NCT02532283|Drug|JNJ-63623872|Participants will be administered JNJ-63623872 600 milligram (mg) tablets orally twice daily for 7 days.
45661488|NCT02532283|Drug|Placebo|Participants will be administered placebo tablets orally twice daily for 7 days.
45661489|NCT02532283|Drug|Oseltamivir|Participants will be administered oseltamivir 75 mg capsules orally twice daily for 7 days.
45661490|NCT01807897|Device|Continuous positive airway pressure|Nocturnal continuous positive airway pressure, titrated to minimize apnea-hypopnea index
45661491|NCT01807897|Device|Nocturnal supplemental oxygen|Nocturnal supplemental oxygen, titrated to 2-4 liters/minute with target of eliminating nocturnal hypoxemia
45955223|NCT05406011|Dietary Supplement|Pelleted chewing gum for stimulated saliva sampling.|Stimulated saliva sampling after chewing a pelleted gum without active ingredient (used only before stimulated saliva sampling), during the whole experimental period (control and parallel with sour cherry chewing gum usage) with sampling on fixed days (1., 4. and 7.) and daytime (between 12:00 and 14:00) of the week.
45955224|NCT05406011|Procedure|Scaling|Scaling after a 1-week control period without chewing the sour cherry gum.
45955225|NCT05405257|Drug|Oxytocin|IV 1IU Oxytocin in 200 ml 0.9%NaCl over 40 minutes. Total of three infusions in three consecutive days (one per day).
45955226|NCT05405257|Other|Placebo|IV, 200 ml 0.9%NaCl over 40 minutes. Total of three infusions in three consecutive days (one per day).
45955227|NCT05402202|Other|Healing abutment with scan peg (Neoss implant system, Harrogate, England)|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of healing abutment with scan peg
45955228|NCT05402202|Other|Customized healing abutment|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of customized healing abutment fabricated by intraoral scanning by scan body
45815936|NCT02786719|Drug|Cisplatin|Cycle 3+5 (given daily x 4 days)
45815937|NCT02786719|Drug|Etoposide|Cycle 3+5 (given daily for 3 days)
45454413|NCT02288338|Drug|5 (Ezetrol®)|ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
45661492|NCT01807897|Behavioral|Healthy Lifestyle and Sleep Education|A 60-minute educational intervention with slide show and printed materials, educating the patient in healthy sleep habits and heart-healthy lifestyle
45661493|NCT05399875|Other|Augmented reality virtual ruler|Use of augmented reality virtual ruler to measure catheter length
45661494|NCT05446831|Drug|Baricitinib|Oral baricitinib was given at a dose of 4 mg daily. The decision to initiate rescue therapy was made after assessment of the extent of bleeding, patient preferences, lifestyle and activity, the complications of specific therapies, comorbidities that predisposed patients to bleeding and the tolerance of side effects. If a platelet count over 300,000/μL was observed for two consecutive tests at least 2 weeks apart, baricitinib treatment was interrupted.
46078464|NCT00931645|Procedure|DHAP rescue and Autologous stem cell transplantation|DHAP :IV cisplatin 100 mg/sqm d1, IV cytarabine 2 g/sqm d2,, IV dexamethasone 40 mg/sqm d1-4, TBI (10 grays d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
45661495|NCT02431351|Drug|Selinexor|60 mg on Day 1 of each week for a 4 week cycle, given for ≥6 cycles.
45815938|NCT02786719|Drug|Vincristine|Cycle 4+6 (given daily for 3 days)
46078465|NCT00931645|Procedure|DHAP rescue and F+C|DHAP :IV cisplatin 100 mg/sqm d1, IV Cytarabine 2 g/sqm d2, IV dexamethasone 40 mg/sqm d1-4, Followed by 3 monthly cycles with IV d1-3 fludarabine (25 mg/sqm) & cyclophosphamide (300 mg/sqm)
46078466|NCT05658692|Device|protective ventilation|Patients with moderate to severe ARDS received ventilation treatment according to predicted body weight(PBW) and controlled plateau pressure.
46078467|NCT05658692|Behavioral|prone position ventilation|patients with moderate to severe ARDS who don't have contraindications were given prone ventilation for over 12 hours.
46078468|NCT05658692|Drug|glucocorticoid therapy|"Dexamethasone: Patients received intravenous dexamethasone 20 mg daily from days 1 to 5, reduced to 10 mg daily from days 6 to 10.~Hydrocortisone：For septic ARDS patients, 50 mg of hydrocortisone was given as an intravenous bolus every 6 hours for 7 days; For patients with COVID-19-related ARDS, The corticosteroid field randomized participants to a fixed 7-day period of intravenous hydrocortisone (50 mg or 100 mg every 6 hours)."
45661496|NCT01349959|Drug|Azacitidine|Given SC
45661497|NCT01349959|Drug|Entinostat|Given PO
45661498|NCT01349959|Other|Laboratory Biomarker Analysis|Correlative studies
45815939|NCT02786719|Drug|Cyclophosphamide|Cycle 4+6 (given daily for 2 days)
45815940|NCT02786719|Drug|Doxorubicin|Cycle 4+6 (given daily for 3 days)
45815941|NCT02786719|Drug|Sargramostim|Granulocyte macrophage colony stimulating factor (rhu GM-CSF, rGM-CSF, GM-CSF)
45815942|NCT03003949|Drug|Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release|Transdermal Estradiol worn daily for 16 weeks (patch changed every 7 days).
45815943|NCT03003949|Drug|Placebo Patch|Matching placebo patches to be worn every day for 16 weeks (patch changed every 7 days).
45955229|NCT05399615|Diagnostic Test|VOX|Breath biopsy
45955230|NCT05398029|Drug|VERVE-101|Intravenous (IV) infusion.
45955231|NCT05389683|Behavioral|Elimination Diet|An 'elimination diet' devoid of the reaction-inducing foods will be suggested for 4 weeks.
46078469|NCT05658692|Other|restrictive fluid resuscitation|"without other organ dysfunction patients: Minimize fluid was given;~other ARDS patients: In the resuscitation phase, controlled fluid replacement combined with vasoactive drugs was given; multiple measures were taken, like lactate and so on, to utilizedto guide fluid resuscitation therapy; diuretics or diuretics in combination with albumin to achieve fluid balance."
45454414|NCT02288338|Drug|5 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
45661499|NCT01349959|Other|Pharmacological Study|Correlative studies
45661500|NCT01349881|Drug|Eflornithine placebo & sulindac placebo|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years
45661501|NCT01349881|Drug|eflornithine & sulindac placebo|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years.
45815944|NCT03003949|Drug|Progesterone Capsule|Micronized progesterone (200 mg) will be administered every day for 12 days during the 9th week of randomization and again following randomization at the 17th week
45815945|NCT03003949|Drug|Placebo Oral Capsule|Matching placebo capsules will be administered orally every day for 12 days during the 9th week of randomization and again following randomization at the 17th week.
45815946|NCT02896075|Other|30 Minute Comedy Video|The intervention is a 30 minute video of a comedy
45815947|NCT02896075|Other|30 Minute Documentary Video|The intervention is a 30 minute video of an uninteresting documentary
45815948|NCT02787655|Behavioral|Aerobic exercise + Cognitive Training Group|stationary bicycling
45815949|NCT02787655|Behavioral|Cognitive training Only|20 minutes of cognitive training using Mindfit program
45815950|NCT02798978|Drug|GSK1795091|GSK1795091 will be supplied as solution for injection vial. Each 5 mL vial contains 0.001 milligram/mL (mg/mL; 1000 ng/mL) or 0.0001 mg/mL (100 ng/mL)of GSK1795091 and will be administered as IV bolus over 2-5 minutes (min) followed by a IV bolus of 10 mL normal saline.
45955232|NCT05388734|Other|alternative medicine education consultation|The intervention will consist in a 1h30 individual consultation with a GP physician. Patients will be able to ask any questions they have regarding treatments for their breast cancer delivered outside of the hospital. Topics such as benefit-risk ratios, placebo effects and expectancies from CAM will be discussed with the patients. This consultation will promote a shared-decision model to help patients better discuss these matters with their healthcare providers.
45955233|NCT05383859|Behavioral|Intervention|"Dietary and/ or physical activity: face to face plus written material (at baseline)~3 months later: motivational phone call."
45955234|NCT05383586|Other|Creative Music Therapy|Creative Music Therapy is provided during kangaroo-care. It is an individualized, family- centered approach offering infant-directed humming and singing accompanied with the monochord.
45955235|NCT05379712|Other|Resource® Support Plus|Nestlé Resource Support Plus® is a high energy- and protein-density Medical Food enriched with omega 3 polyunsaturated fatty acids. This is a nutritionally complete formula, in an easy to swallow, palatable, concentrated low volume, available in 2 flavours optimized for cancer patients undergoing chemotherapy and/or radiation in taste tests. It provides in a 125 mL serving: 250 kcal, 11.5 g protein and 0.95g of omega-3 fatty acid (eicosapentaenoic acid, EPA).
45661502|NCT01349881|Drug|Eflornithine placebo & sulindac|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
45955236|NCT05378620|Behavioral|Project Dulce + Dulce Digital|Project Dulce will consist of a group diabetes self-management program consisting of a 5-week curriculum delivered by a peer educator in Tagalog. The curriculum provides new knowledge as well as skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complication, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants will learn and practice self-management skills, and help one another address family, cultural, or health system barriers to managing your diabetes. Following the 5-week curriculum, participants will be enrolled in the digital texting platform, Dulce Digital, in which they will receive on-going support via text messages derived from the curriculum, medication reminders, and blood glucose monitoring prompts in Tagalog.
45815951|NCT02798978|Drug|Placebo|Matching placebo will be supplied as a solution for injection vial and will be administered as IV bolus over 2-5 min followed by a IV bolus of 10 mL normal saline
45955237|NCT05375916|Drug|Hydromorphone|Sustained-release hydromorphone is a long-acting preparation opioid
46078470|NCT05658692|Biological|Thymosin Alpha|People received thymosin Alpha subcutaneous injections, twice a week.
46078471|NCT05658692|Drug|Muscle relaxant therapy|Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
46078472|NCT05658692|Other|Integrated Chinese and Western Medicine Treatment|"ventilation;~conventional western medicine treatment；~Chinese herbal medicine（Determining medication based on syndrome differentiation）"
46078473|NCT05658692|Drug|statin therapy|"Simvastatin: 80mg qd po for not more than 28days;~Rosuvastatin: 20mg qd po (40mg for the first time) for 28days or 3 days after transfer out of the ICU, or the patient died."
46078474|NCT05658692|Combination Product|anti-infective treatment|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
45815952|NCT02898103|Device|Percutaneous peripheral nerve stimulation|Active electrical stimulation for 5 minutes in the recovery room
46078475|NCT05658692|Device|Extracorporeal Membrane Oxygenation（ECMO）|"For severe ARDS patients with refractory hypoxemia within 7 days of onset;~(Inspiratory oxygen concentration) ≥ 0.80, tidal volume 6ml/kg (PBW), positive end-expiratory pressure [PEEP] ≥ 10 cmH2O;~V-V Model."
46078476|NCT05658692|Genetic|stem cell therapy|A single injection of bone marrow stem cells, doses of 1, 5, 10*106 cells/kg was taken according to the previous clinical studies.
46078477|NCT05658692|Drug|Sedative analgesia/muscle relaxant therapy|Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
45815953|NCT02898103|Device|Sham stimulation|Sham (placebo) stimulation for 5 minutes in the recovery room
45815954|NCT02898103|Device|Percutaneous peripheral nerve stimulation|Active electrical stimulation for 2-4 weeks at home
45815955|NCT03005041|Other|Biotene mouthwash|Participants will rinse their mouth with 15 mL of Biotene mouthwash swishing for 30 seconds.
45815956|NCT03005041|Other|Bottled mineral water|Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds.
45815957|NCT03007225|Drug|Trans-arterial chemoembolization (TACE)|"TACE procedures were performed by experienced radiologists by fluoroscopy. The femoral artery was catheterized under local anesthesia, with a 4F catheter with Copra head configuration. Conventional angiography of the Coeliac and Hepatic arteries to delineate the feeding arteries of the tumors and to exclude portal venous shunting. Then vascular catheter was inserted super-selectively into the branch of the hepatic artery that is the main feeder of the tumor. Chemoembolization then was performed.~Ten milliliters of Lipiodol was mixed with 100 mg of Doxorubicin hydrochloride and 5ml of Urografin emulsified to create a milky solution. The emulsion slowly was infused into the tumour Gel foam embolization was performed by cutting gel foam sheets into small pledges mannully then mixed with a contrast material and an impirical antibiotic (gentamycin 80 mg). Injection of the mixture slowly under fluoroscopy guidance till complete stasis was achieved."
45955238|NCT05369559|Combination Product|Mini bolus 50|"receiving a mini-bolus A:50 ml of crystalloid solution, regularly infused over 30 seconds"
45955239|NCT05369559|Combination Product|MINI bolus100|"receiving a mini-bolus A:100 ml of crystalloid solution, regularly infused over 30 seconds"
45955240|NCT05368467|Combination Product|The clinical course and disease management|The clinical course and disease management of pulmonary hypertension patients
45955241|NCT05368129|Procedure|Balloon dilation|Balloon dilation was performed after DES implantation.
46078478|NCT05658692|Drug|inotropes therapy|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
45661503|NCT01349881|Drug|Eflornithine plus sulindac|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
45955242|NCT05360901|Behavioral|IntelliCare with automated motivational messaging|Digital mental health intervention with automated motivational messaging
45955243|NCT05360446|Drug|Inclisiran sodium 300 mg|Subcutaneously administered on Days 1, Month 3 (Day 90), and every 6 months thereafter.
46078479|NCT05658692|Drug|Vasoactive drug therapy|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
45661504|NCT05464277|Other|Oxygen|Oxygen to achieve assigned SpO2 (or FiO2) targets will be administered to study subjects. The treating clinician can alter oxygenation targets at any time if deemed necessary. The oxygenation goal will be based on SpO2 rather than arterial oxygen saturation (SaO2) or arterial pressure oxygen (PaO2) from arterial blood gases. However, PaO2 can be used instead in situations where the treating clinician considers that peripheral perfusion is poor or SpO2 readings are unreliable. Assigned SpO2 targets will apply to the study subjects for a total duration of 6 hours from intubation or until death or until transfer to the operating theater (whatever comes first).
45661505|NCT05417971|Other|Fludarabine|Reduced-intensity fludarabine with intermediate-dose TBI
45815958|NCT03007225|Drug|TACE with Drug Eluting Beads procedure|"The same was done as cTACE till the super selective catheterization of the feeding artery.~Loading of the beads with Doxorubicin hydrochloride (100-150 mg) was done in vitro an hour before the beginning of catheterization. The loaded beads were then aspirated from the vial into a syringe filled with nonionic contrast medium. Once the feeding artery was identified and catheter was in placement, the loaded beads were infused slowly under fluoroscopic guidance. Two different sizes of DC beads were used, 100-300 μm and 300-500. Starting with the smaller sized beads to occlude the tumoral bed followed by the larger sized one to embolize the proximal vessels. The injection of the loaded beads was performed as selective as possible using either a4F diagnostic catheter (Cobra head catheter; Cordis, USA) or 2.7F microcatheter (Progreat; Terumo, Japan)."
45815959|NCT02799290|Biological|ADIPOSE TISSUE EXTRACT|Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration
45815960|NCT02799290|Biological|PLATELET-RICH PLASMA GEL|Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions
45955244|NCT05360446|Drug|Placebo|Subcutaneously administered on Day 1, Month 3 (Day 90), and every 6 months thereafter.
45955245|NCT05360082|Other|[11C]UCB-J|11C-labeled SV2A binding PET radioligand
45955246|NCT05360082|Other|[18F]SynVest-1|18F-labeled SV2A binding PET radioligand
45661506|NCT05446363|Device|Medimonitor|A digital solution consisting of web based portal gathering data from mobile fundus camera and intraocular tonometer provided to the physicians located remotely to the University hospital that provides consults and analyses of on-site gathered data.
45955247|NCT05359354|Biological|Personalized neoantigen tumor vaccine|Biological: neoantigen tumor vaccine with or without PD-1 In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with PD-1
45955248|NCT05357976|Procedure|Thoracic Paravertebral Block|Thoracic paravertebral block will be applied to the patients under real-time ultrasound guidance.
45955249|NCT05353595|Dietary Supplement|Insect protein|Insect protein concentrate retrieved from lesser mealworms.
45955250|NCT05353595|Behavioral|Running exercise|40 minutes of running on a treadmill at 70% heart rate corresponding Vo2peak
46078480|NCT03638713|Behavioral|colonoscopy first|Received water exchange colonoscopy followed by EGD
46078481|NCT03638713|Behavioral|EGD first|Received EGD followed by water exchange colonoscopy
46078482|NCT02744508|Drug|palonosetron|
46078483|NCT02744508|Drug|palonosetron with dexamethasone|
45815961|NCT02800148|Drug|Azelaic acid foam|
45815962|NCT02800148|Drug|Azelaic acid foam|
45815963|NCT02800148|Drug|Azelaic acid foam - Placebo|
45955251|NCT05353530|Biological|Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells|Single dose of 8R-70CAR T cells administered IV
45815964|NCT03008707|Procedure|Laparoscopic Peritoneal Lavage|LPL is done by irrigation with at least 6 L of warm saline throughout the abdominal cavity and after that, putting a drain in Douglas cavity through the port sites
45955252|NCT05491421|Drug|ZT002|"Participants will receive a single subcutaneous (SC) ZT002 dose of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under fasted conditions.~Participants will MAD Cohorts will receive a single subcutaneous (SC) ZT002 in following doses under fasting conditions-~Cohort 1: 7.0mg, 10mg, 20mg;~Cohort 2: 10 mg, 20mg, 40mg;~Cohort 3: To be decided post safety review meetings"
46078484|NCT00927511|Drug|Fulvestrant|Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity vs Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity
46078485|NCT04637594|Drug|Pembrolizumab|Given IV
45661507|NCT01295125|Device|XenMATRIX mesh|Use of XenMATRIX mesh in the repair of contaminated ventral hernia repair
45955253|NCT05491421|Other|Placebo|"Participants will receive same volume as of the study drug of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under the fasted condition.~Participants in MAD cohorts will receive same volume as study drug in the following cohorts under fasted condition-~Cohort 1: 7.0mg, 10mg, 20mg;~Cohort 2: 10 mg, 20mg, 40mg;~Cohort 3: To be decided post safety review meetings"
45955254|NCT05352243|Behavioral|Expressive Disclosure|Prior to each writing session, participants will receive general instructions for completing the writing (e.g., write continuously for 20 minutes, do not worry about grammar, sentence structure, repetition), and be reminded that their writing will remain confidential. Three writing sessions will be spaced 1-2 weeks apart. A weekly writing prompt will instruct participants to write about their deepest thoughts and feelings surrounding their bereavement experience.
46078486|NCT04637594|Drug|Nivolumab|Given IV
46078487|NCT04637594|Drug|Atezolizumab|Given IV
46078488|NCT04637594|Drug|Durvalumab|Given IV
46078489|NCT04637594|Drug|Avelumab|Given IV
46078490|NCT02748486|Behavioral|Metacognitive Training Jumping to Conclusion|Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - jumping to conclusion.
46078491|NCT02748486|Behavioral|Group discussion|Group discussion of current events
45955255|NCT05352243|Behavioral|Expressive Helping|Prior to each writing session, participants will receive general instructions for completing the writing (e.g., write continuously for 20 minutes, do not worry about grammar, sentence structure, repetition), and be reminded that their first two writing will remain confidential, and their final essay will be de-identified before being provided to newly bereaved young adults. Three writing sessions will be spaced 1-2 weeks apart. In the first two writing sessions, participants will receive a writing prompt that will instruct them to write about their deepest thoughts and feelings surrounding their bereavement experience. For the final writing session, participants will receive a writing prompt instructing them to provide advice and support for a newly bereaved young adult.
45955256|NCT05352243|Behavioral|Fact-Writing|Prior to each writing session, participants will receive general instructions for completing the writing (e.g., write continuously for 20 minutes, do not worry about grammar, sentence structure, repetition), and be reminded that their writing will remain confidential. Three writing sessions will be spaced 1-2 weeks apart. A weekly writing prompt will instruct participants to write objectively about different time frames (e.g., routine for getting up in the morning, routine for going to sleep at night).
45955257|NCT05352230|Device|Free style libre-2|A cross-over design will allow estimation of feasibility and acceptability of patients using CGM vs patients using blood glucose meter monitoring (conventional therapy). The study will consist on two phases, the first will last three months, then it will be a two months of washout period followed by the crossover, then the second phase will last another three months. Patients in the conventional therapy group will also use masked CGM (CGM professional) during the first two and last two weeks of their study phase with the purpose of collecting CGM-parameters information. The cross over randomization will be stratified by donor type (live vs deceased) using a web-based randomization tool. During the washout period the patients will continue using blood glucose meter monitoring
45955258|NCT05352100|Diagnostic Test|Therapeutic Vibration Device|The Therapeutic Vibration Device is capable of applying force through the axial skeletal spine, through bidirectional compression loading (or prestressing) between the shoulder and the plantar surfaces of the feet. It is placed around the body like a mobile frame so that the applied vibration can affect the whole body. The vibration actuators (drivers) are mobile and can vary in size, frequency response, and force. The design minimizes the possibility of mechanical interference for ventilated/intubated patients.
45955259|NCT05346562|Dietary Supplement|Cannabidiol|Cannabidiol tablets
45955260|NCT05346562|Dietary Supplement|Placebo|Cannabidiol-matched placebo tablets
45955261|NCT05344469|Other|ofatumumab|There is no treatment allocation. Patients administered ofatumumab by prescription that have started as routine medical treatment will be enrolled.
45955262|NCT05344469|Other|glatiramer acetate|There is no treatment allocation. Patients administered glatiramer acetate by prescription that have started as routine medical treatment will be enrolled.
45955263|NCT05344469|Other|interferon β1|There is no treatment allocation. Patients administered interferon β1 by prescription that have started as routine medical treatment will be enrolled.
45815965|NCT02801006|Device|stenfilcon A|contact lens
45955264|NCT05344430|Procedure|cone beam computed tomography (CBCT) for percutaneous transthoracic needle biopsy|We will be conducting cone beam computer tomography for percutaneous transthoracic needle biopsies.
45955265|NCT05344326|Other|Cognitive Analytic Therapy - Guided Self Help (CAT-GSH)|CAT-GSH is a novel intervention designed to help those with depression by focusing on the relationships within their life. GSH is used in step two of IAPT services and is typically six fortnightly sessions where the PWP helps the service user complete the self help manual.
45955266|NCT05340972|Diagnostic Test|MEESSI score|The score aimed to predict the AHF patient's future in the month following management for ED
45955267|NCT05328934|Device|SoftHand Pro|Performance assessments utilizing the SoftHand Pro over an 8-week period.
45955268|NCT05328934|Device|Ossur i-Limb|Performance assessments utilizing the i-Limb over an 8-week period.
46078492|NCT02748486|Behavioral|Metacognitive Training To Empathize|Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - Theory of Mind deficits.
46078493|NCT04015063|Other|Anti-Aging Skin Care product|Primary Subjects will use P29429-01 as an anti-aging skin care product on full face twice a day for 12-week.
45661508|NCT01295125|Procedure|Open abdominal ventral hernia repair|Abdominal ventral hernia repair with native tissue
45661509|NCT05398705|Drug|Cepharanthine|Low-dose: Day 1~5: 20mg, Q8H X 5 days (60mg/day)+SMT
46078494|NCT03211338|Biological|Culture with progesterone|Progesterone, a steroid hormone will be cultured with placental IMC cells or peripheral blood CD14+ monocyte cells
46078495|NCT03211338|Biological|Culture without progesterone|Culture of placental IMC cells or peripheral blood CD14+ monocyte cells without progesterone
46078496|NCT03211338|Biological|Culture with growth factors|Culture of placental IMC cells with growth hormones only and analysis
45661510|NCT05398705|Drug|Placebo|"Day 1~5: placebo+SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor, antiviral drug and Chinese medicine treatment, etc."
45815966|NCT02801006|Device|etafilcon A|contact lens
45815967|NCT02790463|Behavioral|Pharmacist-Led Intervention|Pharmacists will conduct outreach primarily via an automated telephone interactive voice recognition system and direct (telephone) contact
45815968|NCT02791399|Behavioral|ISOP Intervention with the Nurse Care Manager|A Nurse Care Manager (NCM) will maintain a registry of enrolled patients, track opioid medication-related events from the medical record, and provide decision support to Primary Care Providers for issues related to prescription opioid safety. The NCM will also meet individually with enrolled participants in the intervention group to discuss strategies for preventing/reducing opioid side effects, preventing diversion, and providing rationale for screening for prescription opioid misuse.
45815969|NCT02902081|Drug|Cannabidiol|
46078497|NCT00927667|Procedure|No Drug|Patients have received primary FVIII prophylaxis (started < 2 years of age)
46078498|NCT00927667|Procedure|No Drug|Patients have received secondary FVIII prophylaxis (started 2 - < 6 years of age)
46078499|NCT00927667|Procedure|No Drug|Patients have received secondary FVIII prophylaxis (started 6 - < 12 years of age)
45955269|NCT05327374|Diagnostic Test|calculation of the inferior vena cava collapsibility index|the ΔIVC was calculated by the emergency physician who was blinded from the patient's medical history using the formula ((IVCmax-IVCmin)/IVCmax) X100.A cutoff of 15% was used to define the presence(<15%) or absence(>15%) of heart failure
45955270|NCT05321459|Other|Neurological prognosis|"In usual practice, in intensive care unit, evaluating the neurological prognosis of comatose patients after cardiac arrest requires a multimodal approach combining standardized clinical examination, serum biomarkers, imaging and classically electrophysiological examinations (among them auditive evoked potentials or AEP).~An algorithm (PRECOM tool) which has been previously developed from the signal extracted from AEP allows to visually classify the patients after processing signal by the algorithm in a cluster of points with a high specificity into good neurological prognosis and bad neurological prognosis.~The AEP signals recorded in the 1st and 2nd week of patient inclusion are to be collected by the neurophysiologist. At the end of the patient's participation in the study, these data will be encrypted, anonymized and transmitted to the mathematician to be processed by the PRECOM tool."
45955271|NCT05320367|Drug|Cannabis, placebo|Eligible participant will be randomize 1:1:1:1:1 to receive placebo, CBD (5mg, 17mg, 50mg and 100mg). Only one research product will be inhaled for each visit. The sequence will depend on the assigned randomization group.
45955272|NCT05313529|Drug|Liraglutide|Liraglutide will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study
45955273|NCT05313529|Drug|Empagliflozin|Empagliflozin will be initiated and maintained at 10mg/ day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
45955274|NCT05313529|Drug|Linagliptin|Iinagliptin will be initiated at 5mg/ day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
45955275|NCT05305430|Device|Synergy Cervical Disc System|motion preservation disc
45955276|NCT05298098|Drug|Hypertonic Saline Solution|Patients receive intravenous infusion of HSS (50ml of 10% NaCl) + Furosemide ( 250mg of furosemide) administered over one hour twice a day.
45955277|NCT05298098|Drug|Placebo|Patients receive intravenous infusion of 5% Dextrose Solution (50ml of Dextrose 5%) + Furosemide (250mg of furosemide) administered over one hour twice a day.
45955278|NCT05287633|Drug|Esomeprazole|Patients are given a box of capsules of which they take 1capsule/day during the month of ramadan
45955279|NCT05287633|Drug|Placebo|Patients are given a box of capsules of which they take 1capsule/day during the month of ramadan
45955280|NCT05285449|Dietary Supplement|Cannabidiol (CBD) powder formulation|30 mg CBD in the form of 300 mg of 10% CBD isolate
45955281|NCT05285449|Dietary Supplement|Matching Placebo Cannabidiol (CBD) powder formulation|Matching Placebo
45955282|NCT05282693|Dietary Supplement|ReMag|300 mg of ReMag dissolved in lemon flavor liquid
46078500|NCT00927667|Procedure|No Drug|Patients have received secondary VIII prophylaxis(started 12 - 18 years of age)
46078501|NCT00927667|Procedure|No Drug|Patients have received on-demand therapy
46078502|NCT00936611|Drug|LBH589|
46078503|NCT00927745|Device|AutoFlow mode on Evita 4 Dräger ventilators|Activation of AutoFlow mode during assist-controlled ventilation
46078504|NCT00927745|Device|Evita 4 Dräger ventilators|Assist-controlled ventilation without activation of AutoFlow mode
46078505|NCT03123822|Device|Glasses|Glasses traditionally prescribed for refractive error
45661511|NCT05398705|Drug|Cepharanthine|"High-dose: Day 1~5: 40mg, Q8H X 5 days (120mg/day) +SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor and Chinese traditional medicine, etc."
45661512|NCT05398627|Behavioral|Amygdala Neurofeedback|real-time feedback on the hemodynamic response of the amygdala during positive autobiographical memory recall
45661513|NCT02540291|Drug|E7046|E7046 will be administered as a single agent orally once daily (QD) continuously in 21-day cycles. In the dose escalation part, increasing doses of E7046 ranging from 125 mg to 750 mg will be administered to cohorts of 6 participants. In the cohort expansion part, participants will be treated at the RP2D.
46078506|NCT04267289|Behavioral|Beating the Blues|Automated, cognitive behavioral therapy delivered via a website. There are 8 sessions, each taking one to 1.5 hours to complete. Sessions are prerecorded and sequenced. Sessions are based on the principles of cognitive behavioral therapy and include techniques such as cognitive restructuring and behavioral activation. The entire program takes about 8 to 12 weeks to complete.
46078507|NCT04265729|Dietary Supplement|Neocate Infant and Junior marketed products|use of Neocate Infant and Junior marketed products
46078508|NCT02748252|Other|stroke center referral|
46078509|NCT00606749|Drug|KC706|300 mg once daily (QD) for 12 weeks.
45661514|NCT05397769|Drug|Envafolimab Plus Chemoradiotherapy|Envafolimab was administrated with 300mg each time, every three weeks for a total of 22 cycles since the first day of induction chemotherapy.
45661515|NCT04468061|Drug|Sacituzumab Govitecan|Intravenous Infusion
45661516|NCT04468061|Drug|Pembrolizumab|Intravenous Infusion
45815970|NCT02902081|Drug|Placebo|
45815971|NCT02801942|Procedure|Inguinal lymph node fine needle aspirate biopsy|Inguinal lymph node will be localized by ultrasonography and sampled by 21-gauge needle and a 5 mL syringe using to and fro needle movement while applying 1 mL suction with the syringe. Up to 2 fine needle aspirate passages will be obtained, to derive immune cells.
45815972|NCT02801942|Procedure|Inguinal lymph node core biopsy|Inguinal lymph node will be localized by ultrasonography and following fine needle aspirate, an incision will be made. Up to five core biopsies will be obtained, to derive immune cells.
45815973|NCT02801942|Procedure|Peripheral blood collection|Blood sample (30 mL) will be collected, to derive immune cells.
45815974|NCT02801942|Other|Pre- and post-biopsy questionnaire|All subjects will be asked to complete a questionnaire about their expectations/experiences of undergoing the biopsy procedures.
45815975|NCT02791945|Behavioral|Medical Management Counseling|Brief alcohol counseling
45955283|NCT05282693|Dietary Supplement|Placebo|Lemon flavored liquid
45955284|NCT05279144|Other|Ventroguleal|Vastus Lateralis
45815976|NCT02791945|Drug|N-acetylcysteine|Experimental supplement
45815977|NCT02791945|Drug|Placebo|Placebo comparator
45955285|NCT05269862|Device|Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature|Implant and initial programming of the Infinity DBS system for this cohort are conducted according to the sites standard of care. After initial programming, all follow-up programming for the first 3 months is conducted in-clinic (not using the Virtual Clinic feature).
45955286|NCT05269862|Device|Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)|Implant and initial programming of the Infinity DBS system for this cohort are conducted according to the sites standard of care. After initial programming, all follow-up programming for the first 3 months is conducted using Virtual Clinic or in-clinic as appropriate.
45955287|NCT05267652|Other|Preoxygenation with Non-Invasive Positive Pressure Ventilation|The delivery of oxygen and ventilation by non-invasive mechanical ventilation via a tight-fitting mask from the initiation of preoxygenation until the initiation of laryngoscopy. Trial protocol will not dictate the brand or type of mechanical ventilator that will be used to deliver non-invasive ventilation.
45661517|NCT04259983|Other|Maximal exercise test|The maximal exercise test will be performed on an electronically braked bicycle ergometer.
45661518|NCT04259983|Other|Endothelial dysfunction assessment|Endothelial dysfunction will be determined by blood samples. Blood samples will be collected and analyzed for the responses of ICAM-1, VCAM-1, E-Selectin, VEGF, ET-1.
45955288|NCT05267652|Other|Facemask Oxygen|The delivery of supplemental oxygen via a non-rebreather mask or bag-mask device without manual ventilation from the initiation of preoxygenation until induction. Trial protocol will not dictate the brand or type of facemask. The decision between use of a non-rebreather mask and use of a bag-mask device will be made by treating clinicians. The decision of whether to provide manual ventilation with a bag-mask device between induction and laryngoscopy will be made by treating clinicians.
45661519|NCT04259983|Other|Arterial stiffness assessment|Arterial stiffness, oscillometric pulse wave velocity (PWV) and augmentation index will be evaluated by recorded brachial pulse waves with automatically with the oscillometric device.
45661520|NCT05475977|Diagnostic Test|MSCT chest|Multi slice Computed Tomography of the chest
45661521|NCT05445037|Device|hemodynamic continuous monitoring|Continuous monitoring will be done with clearsight continuously assessing blood pressure, cardiac output and heart rate; NIRS electrode to assess cerebral O2 saturation, peripheral O2 saturation, BIS value and axillary temperature.
45815978|NCT02793817|Drug|KPI-121 1% Ophthalmic Suspension dosed BID|
45815979|NCT02793817|Drug|Vehicle of KPI-121 Ophthalmic Suspension dosed BID|
45815980|NCT02804594|Drug|N-acetyl cysteine|1250 mg of N- acetyl cysteine taken three times daily
45815981|NCT02804594|Drug|Placebo|placebo taken three times daily
45815982|NCT00374114|Procedure|cervical conization|
45661522|NCT05445037|Device|Standard Monitoring|Standard monitoring will be done with non-invasive blood pressure, heart rate, NIRS electrode to access cerebral O2 saturation, peripheral O2 saturation, axillary temperature, BIS value. In addition, patients will use Clearsight, but the device will be blind to the anesthesiologist. Pressure monitoring will be every 5 min.
45661523|NCT05464043|Diagnostic Test|evaluation of second line glucose homeostasis|blood samples, urine samples, genetic test, peptide C stimulation test, OGTT, continuous glucose monitoring and questionnaires
45815983|NCT00374114|Procedure|ultrasonic surgical aspiration of the cervix|
45815984|NCT03007394|Drug|Lorcaserin|Lorcaserin Capsule
45815985|NCT03007394|Drug|Placebo Oral Capsule|sugar pill to mimic lorcaserin 10mg capsule
45815986|NCT00374192|Drug|Eszopiclone|3 mg per day
45815987|NCT00374192|Drug|Placebo|Placebo
45815988|NCT00374270|Behavioral|Lifestyle Counselling; Opinion Leader Influence Statements|
45815989|NCT02806544|Drug|Tamoxifen|Tamoxifen 20mg by mouth daily
45815990|NCT03008174|Other|Early one-way speaking valve (OWSV) assessment|The OWSV assessment by speech language pathologists will be completed at 12-24 hours following percutaneous tracheostomy procedure, which is earlier than the current standard of care of 48 hours or later.
46002775|NCT04644432|Other|Patient reported outcomes measurement|"PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events.~The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital.~For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish."
46002776|NCT00548288|Drug|pamidronate|
45815991|NCT02809430|Device|Continuous Positive Airway Pressure|Auto-titrating Continuous Positive Airway Pressure (APAP) among patients admitted to a rehabilitation unit after ischemic or hemorrhagic stroke for 3 month treatment period.
45815992|NCT00374348|Drug|Aripiprazole|Abilify, 5mg; 10mg; 15mg; 20mg; 30mg
45815993|NCT03014492|Device|Q Collar|Collar designed to mitigate slosh in the brain
45815994|NCT02928380|Device|Experimental Denture Adhesive|Participants received a single application of test denture adhesive with a Flat Ribbon Nozzle as 3 Continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture which were placed in the mouth.
45815995|NCT02928380|Device|Reference (Marketed) Denture Adhesive|Participants received a single application of marketed denture adhesive with a flat ribbon nozzle as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture, which were placed in the mouth.
45815996|NCT02928536|Other|no intervention|This is an observational study. No intervention is considered
45815997|NCT02930174|Device|noninvasive positive pressure ventilation|Application of various levels of positive pressure
46002777|NCT04644354|Drug|Nifedipine 10 mg|For both groups, when preterm labor is diagnosed, 10 mg capsule will be given sublinguially and if it is not effective in 1 hour, the same dose will be repeated again, and the same regimen will be repeated every day till preterm labor ends or proceed to a preterm birth.
46002778|NCT00548366|Other|Sodium restriction|4 gram sodium diet
45661524|NCT05416411|Behavioral|Inspiratory muscle training|Patients will do inspiratory muscle training via a flow resistive device. Priorly, maximum inspiratory pressure will be measured. Afterwards, the training device will be set to 10% increased value of maximum inspiratory pressure (MIP), and the training will be completed two times and 30 repetitions a day during preoperative 7 days. Meanwhile patients will be advised to walk 5000 steps a day during the intervention period.
45661525|NCT05475899|Device|Instrument assisted soft tissue mobilization|Application of IASTM on the plantar fascia with 10-15 strokes followed by stretching
45661526|NCT05416255|Diagnostic Test|Measuring synovial fluid components|Using speialized techniques to measure S.F. components
45815998|NCT02933372|Drug|Varenicline|Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized for both Parkinson's disease participants and healthy volunteers were 0.25mg once a day, 0.25mg twice a day, and 0.5mg twice a day. A fourth dosing group of 1 mg varenicline twice a day was studied in Parkinson's disease participants, but not in healthy volunteers.
45815999|NCT02933450|Drug|Patiromer 25.2 g|Single dose of Patiromer 25.2 g
45816000|NCT02902237|Biological|tTF-NGR|tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
45661527|NCT02540213|Device|MIRCERA|Methoxy polyethylene glycol epoetin beta (0.6 mcg/kg q2w) will be administered using MIRCERA ready-to-use-syringes up to 9 months.
45661528|NCT05450549|Drug|DNL919|Single doses
45816001|NCT02903407|Drug|Midazolam|IV midazolam will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
46002779|NCT00548366|Other|Sodium restriction|2 gram sodium diet
45661529|NCT05450549|Drug|Placebo|Single doses
45661530|NCT05444413|Biological|ultrasound-guided platelet rich plasma nerve block|selected persons are treated by ultrasound-guided platelet rich plasma nerve block and the regular medicine
45661531|NCT05416021|Drug|dapivirine|dapivirine vaginal ring
45816002|NCT02903407|Drug|Propofol|IV propofol will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
45816003|NCT02903407|Drug|Dexmedetomidine|IV dexmedetomidine will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
45661532|NCT02544503|Device|Single-pulse Transcranial Magnetic Stimulation (TMS)|Single-pulse Transcranial Magnetic Stimulation (TMS) is a brief magnetic pulse that is applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Single-pulse transcranial magnetic stimulation (TMS) will be administered at study visits.
45661533|NCT02544503|Device|Paired-pulse Transcranial Magnetic Stimulation (ppTMS)|Paired-pulse Transcranial Magnetic Stimulation (ppTMS) is two brief sequential magnetic pulses that are applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Paired-pulse transcranial magnetic stimulation (ppTMS) will be administered at study visits.
46002780|NCT04644081|Behavioral|LTP|LTP is a low-literacy, sustainable programme that will provide depressed mothers with valuable skills on parenting, improve mother-child relation and mental health self-care. This is a research-based activity that enhances postpartum mental health while simultaneously promoting attachment security through building parents' ability to monitor and be sensitive to their children's cues, and thereby, actively involves in their children's mental and physical development.
46002781|NCT04644081|Behavioral|CaCBT|CaCBT adopts 'here and now' problem-solving approach, which involves collaborating with families, active listening techniques, changing negative thinking, and depressive symptoms associated with postnatal depression and other forms of parenting distress.
46078510|NCT02920476|Drug|TAS-102|"Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5. TAS-102 is to be taken within 1 hour of completion of morning and evening meals.~Days 6 through 7: Rest~Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Rest"
46078511|NCT03865524|Device|Total knee arthroplasty implanted with GPS navigation system|Obese patients undergoing Total Knee Arthroplasty, GPS achieved alignment
46078512|NCT03865524|Device|Total knee arthroplasty implanted with standard guides.|Obese patients undergoing Total Knee Arthroplasty, alignment achieved by using standard guides
46078513|NCT02850653|Biological|PCR : 16S ribosomal DNA and real-time targeted PCR|
45816004|NCT04333303|Other|Implementation of a complex regional Advance Care Planning program|"Sustainable implementation of ACP at micro- (qualification of professional ACP facilitators to lead conversations in cooperation with family physicians), meso- (qualification of relevant co-actors, organisational development of participating institutions) and macro-level (regional ACP steering group and network), ensuring that valid ACP is encouraged, facilitated, documented, known and honored.~Core of the intervention is a modular 9-day-training for ACP facilitators. These will be preferably located in regional pools, serving more than one nursing home, and reimbursed, if certified, by German sickness funds based on recent legislation (§ 132g Social Code Book [SGB] V: 1 full-time facilitator for 400 residents). ACP conversations will be offered to all residents. Regional intervention at meso- and macro-level comprises various formats of specific ACP training and information for leadership and staff, and aims to support professional change management."
46078514|NCT02850653|Biological|Sampling of aqueous humour|
45816005|NCT02811302|Device|Capnostream Monitor|Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
45816006|NCT02905981|Drug|Fer-In-Sol|Fer-In-Sol is an over-the-counter oral iron supplement. It will be administered during Period 1 at a dose of 3 mg/kg body weight.
46002782|NCT04644081|Drug|TAU|TAU is the routine care currently available for the treatment of postnatal depression at the primary health care sites of intervention (e.g. antidepressants and other forms of mental health care).
46002783|NCT00548444|Biological|MVA85A|Vaccine. Dose: 1 x 10^8 plaque-forming units (pfu) given by intradermal injection into the deltoid region of the upper arm.
46078515|NCT04217928|Procedure|Arthroscopic Debridement|Arthroscopic debridement will be performed under portal site local anaesthesia.
46078516|NCT04217928|Procedure|Arthroscopic Hemi-Trapeziectomy with Mini TightRope|Anaesthesia, position and arthroscopy will be performed in the same way as for arthroscopic debridement, except the distal part of the trapezium will be resected to a depth of 3-4mm together with protruding osteophytes.
46002784|NCT00548444|Other|Deuterated glucose infusion|6,6D2-glucose given as a timed intravenous infusion. The total dose of deuterated glucose will be 1g/kg volunteer body weight (up to a maximum of 60g).
46002785|NCT04636359|Behavioral|Acupuncture stimulation|The intervention is about acupuncture treatment, which has 4 weeks acupoint stimulation and the frequency is 30 minutes each times for 3 times per week. The acupoints include SJ23 (Si Zhu Kong, unilateral), GB8 (Shuai Gu, unilateral), EX-HN5 (Tai Yang, unilateral), GB20 (Feng Chi, unilateral), LI4 (He Gu, bilateral), GB41 (Zu Lin Qi, bilateral), GB34 (Yang Ling Quan, bilateral) and SJ5 (Wai Guan, bilateral).
46078517|NCT02744274|Other|Verum acupuncture|"Patients will lay supine. The acupuncture physicians will disinfect the selected acupuncture points with alcohol and then needle them (30 gauze, 1.5-inch, Yuguang, Taiwan) with a plastic device is fixed needle body, so that the patient achieves a de qi sensation, which is often described as a pressure or achiness feeling. The acupuncture point will be bilateral Quchi, Waiguan, hegu, baxie, Zusanli, Yanglingquan, Sanyinjiao, Taichong, bafeng. Acupuncture needles will be left in place for approximately 30 minutes, and every 10 minutes twisting stainless steel needle to get a de qi."
46078518|NCT04203719|Drug|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
46078519|NCT04203719|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
45661534|NCT02544503|Device|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS)|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) is a sequence of brief magnetic pulses that are applied at 0.1 Hz frequency at low intensity through an air-cooled coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Low-frequency repetitive transcranial magnetic stimulation (rTMS) will be administered at study visits.
46078520|NCT02744196|Biological|Acellbia|Acellbia is rituximab biosimilar, monoclonal antibody which binds CD20.
46078521|NCT02744196|Drug|Placebo|Placebo solution will look identical to the Acellbia solution.
46078522|NCT02744196|Drug|Methotrexate|
46078523|NCT02139852|Dietary Supplement|Capsaicin|
46078524|NCT02744118|Other|5A's Model|"The adapted 5A's model will include the following elements:~Ask the patient about their marijuana use~Advise every patient to quit/reduce marijuana use using clear, specific personalized advice~Assess factors affecting choice of behavior and behavior change~Assist abstinence/reduction in in marijuana use using behavior change techniques to aid the patient~Arrange follow-up for ongoing assistance and support, and to adjust treatment plans"
46078525|NCT02744118|Other|Healthy Internet Use Model|"The Healthy Internet Use Model provides a framework for conversations between pediatric practitioners and their adolescent patients. It focuses on 3 key areas of social media behavior:~Balance~Boundaries~Communication"
45816007|NCT02905981|Drug|Shohl's solution|Shohl's solution will be supplied as 500-milliliter (mL) bottles containing citric acid United States Pharmacopeia (USP) 640 milligrams per 5 milliliters (mg/5 mL) and hydrous sodium citrate USP 490 mg/5 mL. It will be administered during all Periods at a dose of 0.67 mmol/kg body weight.
45816008|NCT02905981|Drug|Triferic|Triferic is an iron salt that is approved by the Food and Drug Administration (FDA) for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients with IRIDA. It will be administered during Period 1 at a dose of 3 mg/kg body weight. In Periods 2 and 3 the dose may be adjusted based on lab results.
45816009|NCT02907073|Drug|BF4|Single IV dose of 9-11 millicurie (mCi) sodium [Fluorine-18] radiolabeled B4^F
45816010|NCT02812160|Device|Spatz3 Adjustable Balloon|An adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed
46078526|NCT02743884|Device|Esophageal Warming|30 minutes of warming from circulating water at about 42 degrees C through an esophageal heat exchanger.
46078527|NCT02743884|Device|Esophageal Cooling|30 minutes of cooling from circulating water at about 7 degrees C through an esophageal heat exchanger.
46078528|NCT05379647|Drug|QN-019a|Experimental Interventional Therapy
45816011|NCT00374023|Drug|Zinc, or Vitamin A or both|
45661535|NCT02544503|Device|Sham Motor Cortex Stimulation|Sham motor cortex stimulation will be applied at study visits.
46078529|NCT05379647|Drug|Rituximab|Monoclonal Antibody
46078530|NCT05379647|Drug|Cyclophosphamid|Lympho-conditioning Agent
45661536|NCT05415865|Combination Product|Alkalinized Lidocaine|20 ml of Lidocaine Hydrochloride and 10 ml of Sodium hydrogen carbonate will be pulled up and mixed in a syringe on site, and 30 ml mixed solution in total will afterwards be installed in the bladder with a catheter.
45661537|NCT05415865|Drug|Placebo Sodium Chloride 0.9% Inj|20 ml of Sodium Chloride 9 g/L and 10 ml of Sodium Chloride 9 g/L will be pulled up and mixed in a syringe on site, and 30 ml solution in total will afterwards be installed in the bladder with a catheter.
45661538|NCT05415787|Other|Blood sample|2 tubes Cell free DNA are taken during a blood sample already planned in the patient's care.
45955289|NCT05266209|Other|Coconut oil skin care group|No special technique was used for sample selection, random sample selection will be made. In the evaluation made according to the large effect size, the number of samples determined for Power: 0.80, :0.20 and :0.05 was determined as 66, with a minimum of 22 for each group. Calculations were made in computer environment using Power analysis (G*Power 3.1.9.2) program. Random selection method will be used while creating research groups. Coconut oil, sunflower oil and control groups will be formed according to the order of admission to the unit. E.g; Coconut oil is planned for the first hospitalized newborn, sunflower oil for the second newborn, and third hospitalized newborn control group. This order will be repeated until a sufficient number of cases is reached when the newborns are included in the groups.
45955290|NCT05256901|Drug|Sugammadex|Participants will receive 4mg/kg for a TOF 0-1 and 2mg/kg for a train of four (TOF) 2 or greater.
45955291|NCT05256901|Drug|Neostigmine/Glycopyrrolate|Participants will receive 0.07mg/kg of Neostigmine and 0.01mg/kg of Glycopyrrolate, administered by anesthesia once at least two twitches are present.
45955292|NCT05256576|Other|Implementation of an innovative multi-modal peri-operative care pathway|The innovative multi-modal care pathway includes the implementation of the ERAS pathway, as well as the introduction of a patient-specific tri-modal prehabilitation program. This consists of a physical fitness, nutrition, and patient empowerment intervention.
45955293|NCT05256277|Drug|CT101a|cytokine-induced memory-like NK cells
46078531|NCT05379647|Drug|Fludarabine|Lympho-conditioning Agent
46078532|NCT05379647|Drug|VP-16|Lympho-conditioning Agent
46078533|NCT02748330|Drug|Ticagrelor|Ticagrelor
46078534|NCT02748330|Drug|Clopidogrel|Clopidogrel
46078535|NCT02748330|Drug|Aspirin|Acetylsalicylic acid
45661539|NCT05415787|Other|Urine sample|Urine sample is taken during the consultation carried out for the patient's care
45661540|NCT05463887|Behavioral|Individualized preventive care recommendations (decision tool)|Providers will receive individualized preventive care recommendations (decision tool) for eligible patients, and discuss them with patients using shared decision-making
46078536|NCT04265417|Procedure|Robotic Assisted Rectal Cancer Resection Alone|participants in this group underwent robotic assisted rectal cancer resection alone, the specimens were extracted through the incision on the abdominal wall.
46078537|NCT04265417|Procedure|Robotic Assisted Rectal Cancer Resection With Natural Orifice Specimen Extraction|participants in this group underwent robotic rectal cancer resection，the specimens were extractd through anus and vagina.
45661541|NCT05415709|Drug|Carboplatin|Given IV
45816012|NCT02812238|Dietary Supplement|Nicotinamide riboside (NR)|NR at dose of 1000mg/day will be given for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of placebo pills.
45816013|NCT02812238|Drug|Placebo|Placebo capsule daily for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of NR at a dose of 1000mg/day.
45955294|NCT05255952|Procedure|Electrical stimulation|Electrical stimulation of the cardiac plexus
45955295|NCT05251090|Drug|ADVATE|50 international units (IU)/kg, a single dose.
45955296|NCT05251090|Drug|FRSW107|50 IU/kg, a single dose.
45955297|NCT05246735|Diagnostic Test|MR-guided Near Infrared optical tomography|
45955298|NCT05240417|Procedure|"Pontic-shield technique"|A 1mm thick fragment of the vestibular aspect of the root will remain after extraction (partial extraction)
46078538|NCT00606827|Drug|Sodium Bicarbonate|Patients in the sodium bicarbonate group (154 mEq/L) received 3 ml/kg for 1 hour before contrast medium, followed by an infusion of 1 ml/kg/h for 6 hours after the procedure
46078539|NCT00606827|Drug|Isotonic Saline|Patients assigned to the isotonic saline group received 1 ml/kg/h 0.9% sodium chloride for 12 hours before and after the procedure
45661542|NCT05415709|Drug|Cisplatin|Given IV
45661543|NCT05415709|Procedure|Cytoreductive Surgery|Undergo CRS
45661544|NCT05415709|Drug|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
45661545|NCT05415709|Drug|Paclitaxel|Given IV
45661546|NCT05415709|Other|Quality-of-Life Assessment|Ancillary studies
45661547|NCT05415709|Other|Questionnaire Administration|Ancillary studies
45661548|NCT05463575|Drug|Ketohexokinase inhibition|participants will be asked to take 300 mg of the KHKi in tablet form daily for 6 weeks in either period 1 or 2.
45816014|NCT03015649|Device|SAVI SCOUT Surgical Guidance System|SAVI SCOUT Surgical Guidance System is a non-wire system, which uses nonradioactive light-activated radar, to provide breast surgeons with real-time guidance to locate and remove the target lesion in the breast and/or axillary tissue.
45816015|NCT03015961|Drug|EXPAREL and bupivacaine HCl|"Drug: EXPAREL EXPAREL and bupivacaine HCl~Other Name: bupivacaine liposome injectable suspension Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl"
46078540|NCT05379569|Drug|Fludarabine|The combination of fludarabine and cyclophosphamide has synergistic effect, which can better kill B lymphocyte, and can enhance the killing effect of pretreatment regimen on B lymphocyte tumor.
45816016|NCT03015961|Drug|Bupivacaine HCl|"Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl"
45816017|NCT02814656|Drug|AZD8871|Multiple inhaled doses of AZD8871 will be administered via single dose dry powder inhaler (DPI). Each subject will receive a single inhaled dose of AZD8871 on Day 1 and then single once daily inhalations of AZD8871 will be administered for 12 days from Day 5 until Day 16.
45955299|NCT05240417|Procedure|Alveolar ridge preservation|Particulate deproteinized bovine bone and porcine collagen membrane will be placed after tooth extraction
45955300|NCT05238597|Drug|A197 Ophthalmic Solution|A197 Ophthalmic Solution
45955301|NCT05238597|Drug|A197 Vehicle Control|A197 Vehicle Control
45955302|NCT05238597|Drug|Active Comparator|Active Comparator
45955303|NCT05233852|Other|"Do not do recommendation"|A drug prescription or procedure included in 'do not do' recommendations
45955304|NCT05226598|Biological|Pembrolizumab/Vibostolimab|Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 35 administrations
45661549|NCT05463575|Other|Placebo|participants will be asked to take 300 mg of the placebo in tablet form daily for 6 weeks in either period 1 or period 2.
45661550|NCT04262843|Drug|Cyclophosphamide|Given IV
45955305|NCT05226598|Drug|Carboplatin|Carboplatin 10 mg/ml administered as IV infusion Q3W for 4 administrations
46078541|NCT02748174|Behavioral|Audio Files|Patients will be given a link to download audio files. They consist of breathing techniques, imaging, progressive relaxation, and more. Patients will be asked to perform 20 minutes of relaxation therapy at least 3 times per week. Patients will record their headache frequency and intensivy, in addition to other symptoms, and the frequency of practiving the behavioral therapy using Curelator Headache.
46078542|NCT04217772|Device|Optical Coherence Tomography Angiography|A device testing the vascular density in the retina
45816018|NCT02814656|Drug|Placebo|Multiple inhaled doses of placebo powder will be administered via single dose DPI. Each subject will receive a single inhaled dose of placebo on Day 1 and then single once daily inhalations of placebo will be administered for 12 days from Day 5 until Day 16.
45661551|NCT04262843|Drug|Fludarabine|Given IV
45955306|NCT05226598|Drug|Cisplatin|Cisplatin 1 mg/ml administered as IV infusion Q3W for 4 administrations
45955307|NCT05226598|Drug|Paclitaxel|Paclitaxel 6mg/ml administered as IV infusion Q3W for 4 administrations
45955308|NCT05226598|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/vial administered as IV infusion Days 1, 8, and 15 of each 21-day cycle for 4 administrations
46078543|NCT02820350|Device|SCD-F40|CRRT with SCD
45955309|NCT05226598|Drug|Pemetrexed|Pemetrexed 500 mg/vial administered as IV infusion Q3W until progression, intolerable adverse event (AE), or participant or physician decision
46078544|NCT01995708|Biological|CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs)|Patients receive CT7/MAGE-A3/WT1 mRNA-electroporated autologous Langerhans-type dendritic cells ID on days 12, 30, and 90 after autologous stem cell transplant. Patients on the vaccine arm of the study will receive a total of 3 vaccinations, comprising a primary immunization on day +12 after ASCT followed by two boosters at days +30 and +90. Vaccines will be dosed at 9x10^6 LCs per vaccine x 3.
46078545|NCT01995708|Other|Standard of care|No vaccines
46078546|NCT02818556|Drug|Restalyne Silk|
46078547|NCT02818556|Drug|Belotero Balance|
45955310|NCT05226598|Biological|Pembrolizumab|Pembrolizumab 25 mg/mL administered as IV infusion Q3W for up to 35 administrations
45955311|NCT05221320|Drug|Ulixertinib|small molecule ERK 1/2 inhibitor
45661552|NCT04262843|Drug|Fludarabine Phosphate|Given IV
45661553|NCT04262843|Biological|Granulocyte Colony-Stimulating Factor|Growth factor therapy
45661554|NCT04262843|Procedure|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
45661555|NCT04262843|Procedure|Intensity-Modulated Radiation Therapy|Undergo TMLI
45661556|NCT04262843|Drug|Mycophenolate Mofetil|Immunosuppressive therapy
45955312|NCT05221320|Drug|Hydroxychloroquine|Autophagy inhibitor
45955313|NCT05218005|Diagnostic Test|Research-based genetic test for Familial Hypercholesterolemia|Next-generation targeted sequencing assay to identify DNA variants in genes known to cause Familial Hypercholesterolemia
45955314|NCT05216913|Behavioral|Lifestyle modification|Could include all/some of the following: weight loss, increased physical activity, smoking cessation and reduction in alcohol intake
45955315|NCT05216913|Drug|Cardiovascular Agents, Other|Could include all/some of the following: statins, antihypertensives, diabetic medication, levothyroxine
45955316|NCT05216913|Other|QRISK 3 Score|Could include a combination of lifestyle measures and/or cardiovascular agents as described above
45955317|NCT05216900|Radiation|Neoadjuvant radiotherapy|"The study examines the delivery NART.~In case of neoadjuvant chemotherapy, RT will start 4 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions per week, or a biologically equivalent dose will be applied.~A mastectomy and a direct breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment. Breast reconstruction can be separated in the types of reconstruction, either reconstruction with a silicone implant or with only autologous tissue, of which the most common flap used is the Deep Inferior Epigastric Perforator (DIEP) flap."
45661557|NCT04262843|Drug|Tacrolimus|Immunosuppressive therapy
45955318|NCT05211323|Biological|Atezolizumab|Given IV
45955319|NCT05211323|Biological|Bevacizumab|Given IV
45955320|NCT05211323|Procedure|Biospecimen Collection|Undergo blood specimen collection
46078548|NCT04171128|Behavioral|antibiotic stewardship efforts|The local antibiotic team plan to implement procalcitonin use among the hospital physicians. the interventions are not ready yet.
45661558|NCT01631851|Behavioral|Cognitive-Behavioral Therapy (CBT) for Irritability|CBT is an individually administered behavioral interventions aimed at reducing irritability and disruptive behavior. There are 10 to 12 weekly sessions that are conducted with the child and the parent. During these sessions children are taught to recognize antecedents and consequences of problem behavior and to use emotion regulation and problem-solving skills to reduce irritability, aggression and noncompliance.
45661559|NCT05415553|Procedure|IOBT|Surgery of inferior oblique muscle belly transposition for treatment of primary position hypertropia with inferior oblique overaction
45661560|NCT05415553|Procedure|IO-Rec|Surgery of inferior oblique muscle recession for treatment of primary position hypertropia with inferior oblique overaction
45661561|NCT05475743|Other|Multidimensional intervention|The treatment protocol was 6 weeks in duration with two visits per week. One of the two visits was 1.5 hours long and was in a group format. During these group sessions patients received pain and self-management education. The second session was an individual session lasting 45 minutes. This second session was tailored specifically to each patient. Its main objective was to develop a global mobility program adapted to the physical capacity of each patient. In addition, this second session supported the implementation of self-management.
45661562|NCT05475743|Other|Control intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
45661563|NCT05394649|Device|Intravascular Lithotripsy|"A new device has been designed by Shockwave Medical Inc. for the treatment of calcified vascular lesions to support stent delivery: the C2 Shockwave Medical® (IVL), Inc. coronary lithotripsy system. The system is based on lithotripsy to induce microfractures in the calcified plaque before low-pressure balloon dilation. The C2 Shockwave Medical® coronary lithotripsy (IVL) system consists of an IVL Catheter with two lithotripsy emitters enclosed within an integrated balloon, an IVL Generator, and an IVL Connector Cable."
45816019|NCT03018223|Drug|Fludarabine|Myeloablative conditioning: 40 mg/m^2 daily for 4 days. Dose will be adjusted for estimated creatinine clearance. Reduced intensity conditioning: 30 mg/m^2 daily on days -6, -5, -4, -3 and -2. Dose will be adjusted for estimated creatinine clearance.
45816020|NCT03018223|Drug|Busulfan|Myeloablative conditioning: IV dosing targeted for a daily total area under curve (AUC) 5300 mmol*min/L for 4 days. Busulfan AUC will be pharmacokinetically targeted. An AUC 3500 mmol*min/l may be considered in patients over 60 years of age or with multiple comorbidities. Chemotherapy may start on day -6 or day -5 depending on the day of admission (-6 for Wednesday admission, -5 for Sunday admission).
45816021|NCT03018223|Drug|Cyclophosphamide|Reduced intensity conditioning: 14.5 mg/kg/day on days -6, -5. GVHD prophylaxis: 50 mg/kg ideal body weight (IBW) daily dose will be given on days +3 and +4 post-transplant as an IV infusion over 1-2 hours.
46078549|NCT04238936|Diagnostic Test|Serum amyloid A values|Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
46078550|NCT04238936|Diagnostic Test|Interleukin-1 (IL-1) receptor antagonist values (A-SAA and IL-1Ra)|Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
46078551|NCT04627142|Drug|BI 1701963|Tablet
45955321|NCT05211323|Drug|Cisplatin|Given IV
45955322|NCT05211323|Procedure|Computed Tomography|Undergo CT
46078552|NCT04627142|Drug|Camptosar®|Solution for infusion
45955323|NCT05211323|Procedure|Conventional Magnetic Resonance Imaging|Undergo MRI
45955324|NCT05211323|Drug|Gemcitabine Hydrochloride|Given IV
45955325|NCT05208905|Device|Esprit BTK Device|Participants will receive Esprit BTK Device
45955326|NCT05207657|Drug|Lentiviral vector transduced CD34+ cells|Gene therapy for p47 AR-CGD will be performed by introduction a normal copy of the NCF-1 gene into the blood forming stem cells (CD34+ cells) of the patient's bone marrow by using a type of gene delivery system (in this trial called a lentiviral vector). The gene corrected cells are then transplanted back into the patient
45955327|NCT05194072|Drug|SGN-B7H4V|Given into the vein (IV; intravenously)
45955328|NCT05190705|Drug|Loncastuximab Tesirine|Administered by intravenous infusion
45955329|NCT05190705|Drug|Dexamethasone|Taken orally or administered by intravenous infusion
45955330|NCT05188118|Drug|Cabozantinib|60mg oral once daily for 12 weeks
45955331|NCT05188118|Drug|Ipilimumab|1mg/kg intravenous once every 3 weeks over 12 weeks
45955332|NCT05188118|Drug|Nivolumab|3mg/kg intravenous once every 3 weeks over 12 weeks, then 480mg once every 4 weeks after
45661564|NCT05394649|Device|Rotational Atherectomy|Rotational Atherectomy is a technique of calcic coronary plaque preparation based on the debulking of superficial calcium by a high-speed burr in order to improve vessel compliance and immediate vessel lumen gain before stenting.
45661565|NCT02552303|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia.
45661566|NCT02552303|Drug|Armodafinil|Active medication
45661567|NCT02552303|Drug|Placebo|Placebo for Nuvigil (armodafinil)
45661568|NCT01660711|Drug|5 Fluorouracil|2400 mg/m2 by continuous intravenous infusion over 46 hours
45661569|NCT01660711|Drug|Leucovorin|400 mg/m2 by IV infusion over 2 hours
45661570|NCT01660711|Drug|Irinotecan|180 mg/m² IV infusion on Day 1 over 90-120 minutes (infusion via a Y connector during the infusion of leucovorin)
45816022|NCT03018223|Radiation|Total body irradiation (TBI)|Reduced intensity conditioning: 200 centigray (cGy) on day -1.
45816023|NCT03018223|Procedure|Peripheral Blood Hematopoietic Cell Transplantation (HCT)|On day 0, patients will receive a peripheral blood hematopoietic cell graft.
45816024|NCT03018223|Drug|Sirolimus (SIR)|GVHD prophylaxis: SIR will be administered as a 9 mg oral loading dose on day +5, followed by maintenance. SIR levels will be monitored and maintenance dosing adjusted as needed for a target trough level 8 to 14 ng/ml, per Moffitt BMT program standard practice. In the absence of acute GVHD, sirolimus taper will start on day +90 (+/- 10 days) and it is suggested to finish by day +180.
45816025|NCT03018223|Drug|Mycophenolate mofetil (MMF)|GVHD prophylaxis: MMF will start on day +5 at a dose of 15 mg/kg every 8 hours IV with the maximum daily dose not to exceed 3 gm. MMF will be changed to orally (PO) and discontinued on day +35 (without taper) in the absence of acute GVHD.
45955333|NCT05188118|Drug|Lenvatinib|18mg oral once daily for 12 weeks
45955334|NCT05188118|Drug|Everolimus|5mg oral once daily for 12 weeks
45661571|NCT01660711|Drug|Oxaliplatin|85 mg/m² IV infusion on Day 1 over 2 hours
45661572|NCT05475665|Drug|Irbesartan/Amlodipine|Irbesartan/Amlodipine once daily for 8 weeks
45661573|NCT05475665|Drug|Irbesartan|Irbesartan once daily for 8 weeks
45661574|NCT05443087|Other|Blood sampling to build population pharmacokinetics model|"Determine for each drug plasmatic exposure (Css, trough) through the PopPK model.~Concentrations measured at the following time points:~1 month after the first treatment administration~2 months after the first treatment administration~In case of progression~In case of severe toxicities (AESI) related to the drug received"
45661575|NCT02544113|Drug|Thymoglobulin|Treatment with thymoglobulin and delayed CNI post OLT
45661576|NCT02544113|Drug|Placebo|Normal transplant immunosuppression
45661577|NCT05442697|Device|PEMF treatment|Patient will receive a PEMF treatment. The involved leg will be exposed to PEMF for 30 minutes per session, and the treatment regime will run three times a week for eight weeks, summing up 24 sessions of PEMF exposure in total.
45661578|NCT05442697|Device|Placebo treatment|Patient will receive a placebo treatment. The involved leg will be exposed to placebo treatment for 30 minutes per session, and the treatment regime will run three times a week for eight weeks, summing up 24 sessions of placebo exposure in total.
45816026|NCT03018223|Drug|Granulocyte-colony stimulating factor (G-CSF)|Growth factor support: G-CSF will be given beginning on day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose), until absolute granulocyte count (ANC) is > 1,000/mm^3 for three consecutive days. G-CSF may be given IV or subcutaneously.
45816027|NCT03018925|Drug|Golimumab|The treatment followed was an induction of 200 mg of Golimumab at week 0, and 100 mg at week 2. Under 70 Kg, the follow-up treatment dose would be 50 mg/month, and 100 mg/month in patients above 70 Kg asindicated in standard clinical practice.
45955335|NCT05185934|Dietary Supplement|Food supplement Endocalyx|Patients with COVID-19 infection will be randomized to receive food supplement Endocalyx for 4 months.
45955336|NCT05185934|Dietary Supplement|Placebo|Patients with COVID-19 infection will be randomized to receive placebo for 4 months.
45955337|NCT05184699|Dietary Supplement|Food supplement Endocalyx|Patients with psoriatic disease will be randomized to receive food supplement Endocalyx for 4 months.
45955338|NCT05184699|Dietary Supplement|Placebo|Patients with psoriatic disease will be randomized to receive placebo for 4 months.
45955339|NCT05182099|Diagnostic Test|Liver MRI|Gd-EOB-DTPA enhanced MRI consists of T2-weighted image (T2WI), diffusion weighted image (DWI) and precontrast T1-weighted image (T1WI), dynamic T1WI (arterial, portal and transitional phases), and hepatobiliary phase.
45955340|NCT05172908|Drug|Dexamethasone|"5 mg dexamethasone in a 50 ml syringe containing normal saline will be infused within 15 minutes.~The syringe will be prepared by a nurse outside the research team and the Study participants, care providers, and data collectors will be blinded to the allocation throughout the study.~Global Quality of Recovery- 15 score and standard pain follow-up scores will be noted."
45955341|NCT05172908|Drug|Saline|"A 50 ml syringe containing normal saline will be infused within 15 minutes. The syringe will be prepared by a nurse outside the research team and the study participants, care providers, and data collectors will be blinded to the allocation throughout the study.~Global Quality of Recovery- 15 score and standard pain follow-up scores will be noted."
45816028|NCT02814890|Procedure|Video-assisted Pneumonectomy|Video-assisted Pneumonectomy under general anesthesia.
45454415|NCT02288338|Drug|5 (Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
45816029|NCT02814890|Procedure|Thoracic paravertebral block|The procedure is guided by ultrasound combined with nerve stimulator at T3-4, T4-5, T5-6, T6-7 of surgical side.
45955342|NCT05156320|Drug|Apitegromab|Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 will be administered every 4 weeks by intravenous (IV) infusion.
45955343|NCT05156320|Drug|Placebo|Placebo will be administered every 4 weeks by intravenous (IV) infusion.
45816030|NCT03019783|Drug|Atazanavir|The active group will switch from a non-atazanavir regimen to an atazanavir-based regimen.
45816031|NCT03019783|Other|Placebo|The control group will stay on their baseline regimen
45955344|NCT05140512|Drug|LY01005|LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
46078553|NCT04238858|Biological|Platelet rich plasma|blood is drawn from the patient's antecubital vein and inserted into four 3.0 ml vacutainer tubes that contain trisodium citrate. These four tubes were placed in a centrifuge machine, and centrifugation was carried out at 2500 rpm (580×g) for 8 min within a 30-min blood collection period. As a result of centrifugation, the plasma was separated in the vacutainer tubes from the remaining blood components. Three different layers formed in the tubes: red blood cells at the bottom, aPRP in the middle layer, and aPPP in the top layer. A total of 1.5 ml of the middle layer (which mainly contained platelets) was withdrawn by syringe, and it was immediately injected into the subtenon space of each eye.
45816032|NCT02815982|Behavioral|NOURISH-T|Overweight/obesity family intervention
45955345|NCT05140512|Drug|ZOLADEX® 3.6 mg|ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
46078554|NCT02818166|Procedure|Mitral valve surgery|Right mini-thoracotomy mitral valve replacement/repair.
45454416|NCT02288338|Drug|6(Lipitor®, Ezetrol®)|atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
45454417|NCT02288338|Drug|6 (Ezetrol®)|After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
45454418|NCT02288338|Drug|6 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
45454419|NCT01109641|Device|diagnostic electrophysiology catheter|electrical measurements through a diagnostic electrophysiology catheter
45454420|NCT00388960|Drug|Amrubicin|"Amrubicin 45mg/m<2> IV days 1, 2 3 of each 21-day cycle until disease progression.~Amrubicin 40mg/m<2> IV days 1, 2, 3 plus cisplatin 60mg/m<2> day 1 of each 21-day cycle until disease progression."
45454421|NCT00388960|Drug|Cisplatin|"Amrubicin 40mg/m<2> IV days 1, 2, 3 plus Cisplatin 60mg/m<2> day 1 of each 21-day cycle until disease progression.~Cisplatin 75mg/m<2> IV day 1 plus etoposide 100mg/m<2> IV day 1 and 200mg/m<2> orally days 2, 3 or etoposide 100mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression."
45816033|NCT02815982|Behavioral|Enhanced Usual Care|Publicly available overweight/obesity materials
45816034|NCT03019939|Drug|Isavuconazole|Given PO or IV
45816035|NCT03017924|Device|Q collar|q-collar concussion prevention device
45816036|NCT03020095|Drug|Ravidasvir|Ravidasvir 200mg tablet administered orally once daily
45816037|NCT03020095|Drug|Danoprevir|Danoprevir 100mg tablet administered orally twice daily
45816038|NCT03020095|Drug|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
45816039|NCT03020095|Drug|Ribavirin|Ribavirin(RBV)1000/1200 mg/day (bodyweight<75/≥75 kg)administered orally
45816040|NCT02818244|Device|Fit Bit Blaze Heart Rate Monitoring Device|
45816041|NCT02818244|Device|Garmin Forerunner 235 Heart Rate Monitoring Device|
45816042|NCT02818244|Device|Tom Tom Spark Cardio Heart Rate Monitoring Device|
45816043|NCT02818244|Device|Apple Watch Heart Rate Monitoring Device|
45816044|NCT02818244|Device|Scosche Rhythm + Heart Rate Monitor|
45955346|NCT05139927|Behavioral|Motivational interviewing (MI) counseling|Those assigned to receive Component A will engage in a MI single session lasting approximately 30-45 minutes. The overall goal of the session is to increase participants' motivation and readiness to test for COVID-19 in various circumstances.
46078555|NCT02818478|Other|Reporting of patient reported outcome measures|Electronic reporting of patient reported outcome measures from home, compared to reporting of patient reported outcome measures at the outpatient clinic
45661579|NCT02538965|Drug|Lenalidomide|Lenalidomide will be administered orally once daily for the first 21 days of every 28-day cycle. The starting dose will be 2 mg/kg/day with a maximum dose of 70 mg/day. Number of cycles: 12, or until evidence of progressive disease. Participants will also be discontinued if unresolved toxicities as described in the protocol occur, or if dose reductions are required and subject does not tolerate minimum dose level of 1mg/kg/day.
45816045|NCT02934698|Drug|Ivacaftor|Subjects will be treated with ivacaftor for 6 months and followed for 7 months and will undergo assessments along the way to measure sweat chloride and sputum amounts.
45955347|NCT05139927|Behavioral|Text messages (TMs) and quiz questions (QQs)|"This intervention lasts 6 weeks. This component is grounded in principles of behavioral economics. Its main goal is to add interest and excitement to the goal of COVID-19 testing, serve as a reminder that COVID-19 testing is recommended in a number of scenarios, and nudge participants toward testing and creating a habit of serial screening and COVID-19 testing as needed. Participants first receive a brief orientation to the component (15 min.), and the participant will put the study phone number into his/her phone and a test TM and QQ will be sent. TMs and QQs are programmed into the Telerivet program and sent automatically. Twice a week participants will receive a TM with information about COVID and COVID-19 testing followed by a true/false question about that TM two days later, for which they earn 10 points for a correct answer, and 5 points for an incorrect answer. Participants earn modest prizes based on their points."
45816046|NCT03019796|Drug|MEDICATION AND EXERCISE TRAINING|"PARTICIPANTS WILL BE (IN A RANDOMIZED BLINDED FASHION) WITHDRAWN OF THEIR HYPERTENSIVE MEDICATION (I.E., PLACEBO) IN ONE OCCASION AND TESTED WITH THEIR MEDICATION IN ANOTHER, WITH A WEEK WASHOUT PERIOD.~THIS TESTING WILL BE REPEATED AFER 4 MONTHS OF EXERCISE TRAINING (48 SESSIONS OF 43 MIN EACH ONE)."
45955348|NCT05139927|Behavioral|Peer education|This component has two aspects: Participants are trained to educate their peers on core messages about the importance of COVID-19 testing that address social norms about COVID-19 testing and highlight COVID-19 testing as an altruistic act (15-20 min. training). Then, participants are given the opportunity to educate three peers who are Black and Latino/Hispanic frontline essential workers on the core messages. These peers contact the study directly and receive a brief assessment and referrals to testing, but are not enrolled in the study.
45816047|NCT03020719|Drug|Oral Glutathione|Oral Glutathione oral powder
45816048|NCT03020719|Drug|Placebo|Placebo oral powder
46078556|NCT05658614|Biological|Sm14 recombinant vaccine+ GLA-SE adjuvant|rSm14 - recombinant protein (GMP produced) - 50ug / injection GLA-SE- synthetic Glucopyranosyl lipid A in stable emulsion: 2.5ug / injection
45816049|NCT02935088|Device|Fractional Flow Reserve|Measurement of physiologic parameters
45816050|NCT03021343|Drug|Colchicine|colchicine given as per trial protocol
45816051|NCT03022435|Biological|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
45955349|NCT05139927|Behavioral|Access to COVID testing|Component D is an adaptive intervention component that avoids unnecessary costs; it is only provided if needed. Level 1: Over a 2-3 week period, navigation includes a brief needs assessment and guidance to assist participants in prioritizing, accessing, and completing COVID-19 testing sequences in a timely fashion and resolving barriers such as transportation or the possible need to take off work if diagnosed with COVID-19. Level 2: 1 month after enrollment, participants will be contacted by phone. If they have not been tested, we will provide them with a BinaxNOW test kit which can be picked up or mailed to them.
45955350|NCT05131113|Other|Physical exercise|Physical exercise
46002786|NCT00548483|Drug|dexamethasone (Oradexon, Nederland)|dexamethasone 5mg was administered every 6 hour for 1 day in group 1 and dexamethasone 10mg was administered every 6 hour for 1 day in group 2
46002787|NCT04635813|Procedure|Thyroidectomy|Thyroidectomy
46002788|NCT04635852|Drug|Fentanyl|
45661580|NCT02543801|Drug|Liposomal Bupivacaine|Periarticular injection
46002789|NCT04635852|Drug|Immediate release morphine|
46002790|NCT00548561|Drug|Dexrazoxane|
46002791|NCT04635657|Other|Long-term Cognitive testing|These patients will undergo their standard of care cognitive testing at baseline, six weeks post-operatively and one year post-operatively.
46078557|NCT02818322|Device|telemedical monitoring ( T)|
45661581|NCT02543801|Drug|Ropivacaine|Periarticular injection
45661582|NCT02543801|Drug|Bupivacaine|Included as an element of the Liposomal bupivacaine intervention periarticular injection
45661583|NCT02543801|Drug|Clonidine|Included as an element of both interventions as a standard of care periarticular injection
45661584|NCT02543801|Drug|Ketorolac|Included as an element of both interventions as a standard of care periarticular injection
45661585|NCT02543801|Drug|Epinephrine|Included as an element of both interventions as a standard of care periarticular injection
45661586|NCT02481635|Drug|Gemcitabine|
45661587|NCT02481635|Drug|Nab-paclitaxel|
45661588|NCT02481635|Radiation|Radiation Therapy|
45661589|NCT02481635|Procedure|Surgical Resection|
45816052|NCT03022435|Biological|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe
45955351|NCT05128682|Diagnostic Test|Urodynamic testing with and without pudendal nerve stimulation|A urodynamic test (UDT) for eligible subjects with and without acute PNS will be conducted. Prior to introducing the acute PNS, the subject's original stimulation properties will be turned off. The implanted neurostimulator device will be programmed to deliver acute PNS per individual tolerance level with the objective of increasing external urethral sphincter pressure. The LPP during Valsalva maneuver or forceful coughing will be assessed with and without acute PNS. The LPP will be assessed at increasing bladder volumes until major detrusor instability, significant leakage (more than drops, stream) or subject discomfort (strong desire to void) is observed. Finally, a UPP with PNS set in an on/off cycling regimen will be conducted to observe the effect on pressures along the length of the urethra.
45661590|NCT02470091|Biological|Denosumab|Given SC
45816053|NCT03022435|Biological|LAIV|Live, attenuated influenza vaccine for Intranasal Spray
45955352|NCT05115929|Procedure|Decompressive Laparotomy|As described in the study protocol a long midline laparotomy is performed and open abdomen therapy using negative pressure dressings initiated to lower abdominal pressure and thereby improve venous return from the brain to lower intracranial pressure.
46078558|NCT02818322|Device|classic monitoring|
45661591|NCT02470091|Other|Laboratory Biomarker Analysis|Correlative studies
45661592|NCT02470091|Other|Pharmacological Study|Correlative studies
45661593|NCT02362503|Drug|BMS-663068|BMS-663068
45661594|NCT02362503|Other|Placebo|Placebo
45661595|NCT02914535|Drug|Filgotinib|Tablet(s) administered orally once daily
45816054|NCT02936648|Other|quality improvement intervention|The intervention activities included: assessment, planning, stakeholder engagement, education, ongoing process monitoring, program adaptation, problem identification and problem solving, data audit/feedback, program marketing, network development, among others.
45661596|NCT02914535|Drug|Placebo|Tablet(s) administered orally once daily
45661597|NCT05432999|Device|Extracorporeal Shockwave Therapy|Shockwaves are high pressure sound waves that interact with tissues to elicit a biological response. The shockwave probe will be placed on the skin with ultrasound gel and the muscle will be stimulated for a few minutes.
45661598|NCT02535065|Device|Zenith Low Profile AAA Endovascular Graft and ancillary components|Treatment of patients with abdominal aortic, aortoiliac, or iliac aneurysms having morphology suitable for endovascular repair
45661599|NCT05461313|Other|Constrained Liner|Subjects in this arm will receive a constrained liner (Freedom or G7 Freedom Constrained Acetabular Liner, Zimmer Biomet)
45661600|NCT05461313|Other|Dual Mobility|Subjects in this arm will receive a dual mobility cup (Avantage Dual Mobility Liner, Zimmer Biomet)
45816055|NCT03023683|Biological|FluMist®|Influenza Virus Vaccine Live, Intranasal Spray
45816056|NCT03020498|Biological|Fluzone|Influenza Virus Vaccine Suspension for Intramuscular Injection
46078559|NCT04238312|Device|RESPeRATE™|Fifty-five anxious pediatric dental patients received a breathing session of 10 minutes, using the RESPeRATE™ device.
46078560|NCT04238312|Behavioral|Tell, Show and Do technique|Fifty-five anxious pediatric dental patients received a traditional behavior management technique (Tell-Show-Do).
46078561|NCT02817386|Other|interview|Trained clinical research assistants interviewed the patients on the first and second day post surgery. The interview included the Confusion Assessment Method (CAM) and MDAS. CAM is a diagnostic algorithm used to determine the presence or absence of delirium.
45816057|NCT03020498|Biological|FluMist|Influenza Virus Vaccine Live, Intranasal Intranasal Spray
45816058|NCT03025945|Drug|Nepafenac 0.3%|
45816059|NCT03025945|Drug|Saline Solution|
45816060|NCT02937194|Behavioral|Personal oral health instruction + pamphlets distribution|Personal oral health instruction (OHI) and oral health pamphlets distribution
45816061|NCT02937194|Behavioral|Pamphlets distribution|Oral health pamphlets distribution
45816062|NCT02937506|Drug|Propofol|The intervention is to use propofol as anesthesia during a colonoscopy.
45816063|NCT02937506|Drug|Fentanyl Plus Midazolam|The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
45816064|NCT03026803|Drug|Oxaliplatin|Given IV
45816065|NCT03026803|Drug|Capecitabine|Given PO
45816066|NCT02938052|Behavioral|PP-based health behavior intervention|The positive psychology exercises include 3 modules: Gratitude-based activities, Strength-based activities, and Meaning-based activities. The goal setting exercises include 3 modules: Physical activity, Heart-healthy diet, and Medication adherence.
45816067|NCT03027661|Drug|Bupivacaine|Inject 10 mL of 0.5% bupivacaine into cervical stroma
45816068|NCT03027661|Drug|0.9% Sodium Chloride|Inject 10 mL of 0.9% NaCl into cervical stroma
45816069|NCT03022526|Procedure|CSE|
45816070|NCT03022526|Procedure|Epidural|
45955353|NCT05115929|Procedure|Decompressive Craniectomy|As described in the study protocol a sufficiently sized hemi-craniectomy is performed and the skin closed over the bony defect to allow cerebral swelling and thereby lower intracranial pressure.
45955354|NCT05111548|Device|tDCS (Active)|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function. Participants in the experimental arm will receive a steady current delivery through the device.
45816071|NCT03022526|Drug|Bupivacaine / fentaNYL|
45816072|NCT02794441|Drug|Dexamethasone|Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
45816073|NCT02794441|Other|Placebo|Matched oral solution
45816074|NCT02941640|Procedure|E group|The securing the base of appendix by endoloop.
45816075|NCT02941640|Procedure|S group|The securing the base of appendix by Stapler.
45816076|NCT02941640|Procedure|H group|The securing the base of appendix by Hem-o-lok clip.
45955355|NCT05111548|Behavioral|BrainHQ|BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
45955356|NCT05111548|Device|tDCS (Inactive)|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function. Participants in the sham arm will wear the device but will not receive a steady current delivery.
45454422|NCT00388960|Drug|Etoposide|Cisplatin 75mg/m<2> IV day 1 plus etoposide 100mg/m<2> IV day 1 and 200mg/m<2> orally days 2, 3 or etoposide 100mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
45816077|NCT02941640|Procedure|DS group|The securing the base of appendix by DS clip.
45816078|NCT02941640|Device|Endoloop|
45816079|NCT02941640|Device|Stapler|
45816080|NCT02941640|Device|Hem-o-lok clip|
45816081|NCT02941640|Device|DS clip|
45816082|NCT02794597|Behavioral|SHINE intervention group|Includes all substance treatment services as well as the brief peer-led behavioral intervention focused on contraceptives, reproductive needs, and motivational interviewing: Sexual Health Initiative for Navigation and Empowerment (SHINE).
45816083|NCT00373555|Procedure|Bronchoscopy|
45816084|NCT02822612|Device|Binocular OCT prototype|Testing will begin using a prototype binocular OCT system. Subjects will undergo the full suite of diagnostic assessments offered by the system at that time (i.e., visual acuity, ophthalmic history, pupillometry, ocular motility, perimetry, anterior segment and posterior segment OCT imaging).
45816085|NCT03028363|Drug|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
45816086|NCT03028363|Other|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
45816087|NCT02823080|Drug|Cetrorelix|study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.
45816088|NCT03028987|Biological|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine)
45816089|NCT03028987|Biological|FluMist®|FluMist® Intranasal Spray (quadrivalent, live, attenuated influenza vaccine)
45661601|NCT05411159|Procedure|Opioid-Free Anesthesia (OFA)|"Opioid-free general anesthesia protocol:~After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.), dexmedetomidine (0.5ug/kg i.v. in 15min), and ultrasound-guided T4-5 paravertebral nerve block (0.5% Ropivacaine 20ml).~Induction of anesthesia with lidocaine (1.5mg/kg i.v.), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v.).~Intraoperative anesthesia was maintained by desflurane (0.5-1MAC), continuous intravenous infusion of dexmedetomidine (0.5ug/kg/h), and lidocaine (1.5mg/kg/h).~Flurbiprofen (50 mg i.v.) given at the time of skin suture."
45816090|NCT03022916|Drug|Nail Polish + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish
45816091|NCT03022916|Other|Nail polish|Application of nail polish only to both big toe nails
45816092|NCT03022916|Drug|Base Coat + Nail Polish + Top Coat + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish with layers of top coat and base coat
45454423|NCT03941899|Other|Levobupivacaine in QLB II|Quadratus Lomborum Block II type will be performed by injecting levobupivacaine 0.375% 20 ml between latissimus dorsi and quadratus lomborum muscle.
45454424|NCT02288416|Other|educational intervention|Undergo video-based intervention
45454425|NCT02288416|Other|questionnaire administration|Ancillary studies
45816093|NCT03022916|Drug|Nail Polish + Top Coat + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish with layer of top coat
46078562|NCT02817308|Other|samples of blood, saliva and urine|Spot samples of Blood, urine and saliva
45816094|NCT03031795|Drug|Ketorolac|Oral Tablet
45816095|NCT03031795|Drug|Placebo|Oral Tablet
45816096|NCT02942654|Drug|LY900014|Administered subcutaneously (SC)
45816097|NCT02942654|Drug|Insulin Lispro|Administered SC
45816098|NCT02825966|Device|AUDICOR then LifeVest then AUDICOR|Wearable Cardioverter Defibrillator to record acoustic cardiograph signals.
45816099|NCT03028220|Device|Dexcom G5 Continuous Glucose Monitor|Real time continuous glucose sensor connected to monitor providing data and alarms and alerts for glucose trends and values
45816100|NCT03028220|Device|Abbott Freestyle Libre|Continuous glucose recording device which reports glucose concentration and trend on demand, along with a retrospective review of the last 8 hours glucose data
45816101|NCT02909959|Drug|Sulforaphane|The investigational medicinal product is an uncoated tablet containing both glucoraphanin and myrosinase, the enzyme that converts glucoraphanin to sulforaphane in vivo. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
45816102|NCT02909959|Drug|Placebo|Placebo tablets are uncoated and matched in appearance to the investigational medicinal product, containing inert components. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
45816103|NCT00373724|Procedure|radiofrequency denervation|
46078563|NCT02817230|Drug|Statin|
46078564|NCT00936221|Drug|AZD6244|oral capsules, 75mg twice daily
45816104|NCT00373802|Drug|Phenylephrine|
45816105|NCT04333394|Dietary Supplement|Probiotic|The probiotic capsules will be administrated once a day. medication with Ritalin starts at the onset of the study in a dose-dependent manner and simultaneous with probiotic supplementation.
45955357|NCT05110170|Drug|LY01005|LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, tamoxifen (10 mg/tablet, 1 tablet/time) was orally administered twice per day during the whole study period.
45955358|NCT05110170|Drug|ZOLADEX® 3.6 mg|ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, tamoxifen (10 mg/tablet, 1 tablet/time) was orally administered twice per day during the whole study period.
45955359|NCT05098145|Biological|FCR001|Enriched hematopoietic stem cell infusion
46002792|NCT00548600|Procedure|Iridium Implant|Temporary iridium implant of the prostate will be done and a dose of 3000 cGy will be delivered in the next 48-72 hours. Two weeks later 20 fractions of external beam radiation at a dose of 4000 cGy will be administered over a period of 4 weeks.
46078565|NCT00936221|Drug|Dacarbazine|1000 mg/m2 iv infusion over at least 60 min. on day 1 of each 21 cycle
45454426|NCT02288416|Other|quality-of-life assessment|Ancillary studies
45454427|NCT02288416|Other|Best Practice|
45454428|NCT03945331|Device|Transcutaneous spinal cord stimulator|DS8R Electrical Stimulator For Human Research
46078566|NCT00936221|Drug|Placebo|Placebo
46078567|NCT00776919|Drug|clindamycin / benzoyl peroxide gel|Once a day application to the face
46078568|NCT00776919|Drug|clindamycin gel|Once a day application to the face
46078569|NCT00776919|Drug|BPO gel|Once a day application to the face
46078570|NCT00776919|Drug|vehicle gel|Once a day application to the face
46078571|NCT00247728|Drug|PI-88|Once-daily SC injection for four consecutive days per week, for 3 weeks out of every 4 weeks
45454429|NCT03945331|Device|Epidural spinal cord stimulation system|Spectra WaveWriter Epidural Spinal Cord Stimulator System with CoverEdge 32 Electrode Surgical Lead
45955360|NCT05082922|Behavioral|Hybrid treatment|Transdiagnostic emotion-focused treatment provided by a psychologist with, when needed, support of a medical doctor (ensuring adherence to medical guidelines) and a physiotherapist (providing assessment and treatment support in exposure for physical activities). Depending on the length of the waiting period (randomly assigned to be either 4, 5 or 6 weeks), the treatment period varies between 14-16 weeks and contains 10-15 sessions.
45955361|NCT05078164|Behavioral|Bridging the Gap (BTG)|"Bridging the Gap: Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.~Firearm Counseling Program: The firearm counseling program was developed to be administered in the hospital alongside the 6-step intervention program, as well as in the patient's home after hospital discharge. The firearm safety counseling program includes 3 components aimed at understanding patient risk, reducing firearm-related violence risk-factors, and helping patients increase firearm safety practices."
46078572|NCT05657678|Drug|Vitamin D3 - 750 000 IU|a single administration of 750,000 IU of vitamin D3
46078573|NCT05657678|Drug|Vitamin D3 - 500 000 IU|a single administration of 500,000 IU of vitamin D3
46078574|NCT05383157|Behavioral|Brief mindfulness|Training in mindfulness focused on breathing and pain sensations to enhance decentering, meta-awareness, and interoceptive awareness.
46078575|NCT05383157|Other|Usual care|Usual pain care as delivered in the clinic involving pain assessment and prescription of analgesics.
46078576|NCT02747940|Drug|flunarizine and/or pregabalin|
46078577|NCT04238702|Drug|Empagliflozin 10 MG|Empagliflozin 10 MG 7 days intervention period
46078578|NCT04238702|Drug|Losartan 50Mg Tab|Losartan 50 MG 7 days intervention period
46078579|NCT04238702|Other|Placebo|Placebo 7 days intervention period
46078580|NCT00603785|Drug|Placebo|Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (>30 and <700 IU/ml) will be randomized to receive placebo treatment for 6 months.
46078581|NCT00603785|Drug|Xolair|Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (>30 and <700 IU/ml) will be randomized to receive Xolair treatment for 6 months.
46078582|NCT02743650|Dietary Supplement|Sodium bicarbonate|The initial dose of sodium bicarbonate is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d.
45661602|NCT05411159|Procedure|Standard general anesthesia (OA)|"Standard general anesthesia protocol:~After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.).~Induction of anesthesia with lidocaine (1.5mg/kg i.v.), sufentanil (0.3-0.4ug/kg), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v. ).~Intraoperative anesthesia was maintained by desflurane (0.5-1MAC) and continuous intravenous infusion of remifentanil (0.1-0.2ug/kg/min).~Flurbiprofen (50 mg i.v.) given at the time of skin suture."
45661603|NCT05431907|Drug|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
46078583|NCT00633776|Drug|formoterol fumarate|Nebulized formoterol fumarate 20 mcg one-time treatment; aerosolizer dry powder formoterol fumarate 12 mcg one-time treatment
46078584|NCT05382923|Behavioral|Bright Light|3 consecutive days of 1 hour bright light
46078585|NCT05382923|Behavioral|Bright Light + Exercise + Melatonin|3 consecutive days of bright light, exercise, and melatonin
45454430|NCT02286310|Other|Kinetic Chain Exercises|Exercises include kinetic chain segments.
45454431|NCT02286310|Other|Traditional Exercises|Stretching, strengthening exercises.
45454432|NCT03945487|Biological|umbilical cord-derived mesenchymal stem cell|Taken a dose of 1.0*10E6 UC-MSC/kg body weight intravenously three times at 3-week intervals, in addition to comprehensive treatment.
45661604|NCT05431751|Dietary Supplement|Whole Algae|Whole Euglena gracilis algae, produced by proprietary fermentation.
46078586|NCT05382923|Behavioral|Control|3 consecutive days of dim red light + light stretching + placbo
45661605|NCT05448911|Procedure|Intraoperative navigation combined with Catheter screw technique|It uses minimally invasive small incisions, physiological access to the pelvis, and hollow screws for Pelvic and Acetabular fractures
45454433|NCT03945487|Other|Comprehensive treatment|"All patients received anti-HBV treatment with NAs (entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF)).~Strategies based on targeting abnormalities in gut-liver axis by antibiotic administration (i.e. rifaximin), improving the disturbed systemic circulatory function (i.e. longterm albumin administration), decreasing the inflammatory state (i.e. statins), and reducing portal hypertension (i.e. beta-blockers)."
45661606|NCT05448911|Procedure|Open reduction and internal fixation with steel plate|Open reduction and plate internal fixation is the most commonly used method to treat pelvic fracture, which can achieve anatomical reduction and rigid fixation. However, this method requires extensive dissection of the surrounding soft-tissue fracture and is invasive
45661607|NCT02530619|Drug|Alisertib|Given PO
45661608|NCT02530619|Other|Laboratory Biomarker Analysis|Correlative studies
45816106|NCT04333394|Other|Placebo|The placebo capsules will be administered once a day. medication with Ritalin starts at the onset of the study in a dose-dependent manner and simultaneous with placebo supplementation.
45955362|NCT05075967|Other|Health Equity|This community-level structural component will use a standardized, nationally replicable community coalition model (Black Treatment Advocates Networks [BTAN]) to implement an enhanced program model geared to 1) facilitate the effects of the other HPTN 096 interventions by minimizing barriers to HIV testing, PrEP use and viral suppression through sensitizing a local network of service providers (e.g., social, legal, economic sectors) to the needs of Black MSM and maintaining an online platform for exchanging information about the local network that can be used to link Black MSM to resources and services, and 2) amplify the effects of other HPTN 096 components by increasing Black MSM's receptivity to those activities through the integration and promotion of HPTN 096 into the activities of the community coalition model.
46002793|NCT00548600|Radiation|Standard external beam irradiation|Standard external beam irradiation at a dose of 6400 cGy in 32 fractions over 6 and a half weeks will be administered.
46002794|NCT04635618|Behavioral|Cognitive Behavioral Brief-Telepsychotherapy|Four sections of Cognitive Behavioral Brief-Telepsychotherapy plus personalized pre-recorded videos
46002795|NCT04635618|Behavioral|Brief Interpersonal Telepsychotherapy|Four sections of Brief Interpersonal Telepsychotherapy plus personalized pre-recorded videos
46002796|NCT04635618|Behavioral|Telepsychoeducation|A single session psychoeducation group plus weekly personalized pre-recorded videos for 4 weeks
45454434|NCT00004912|Drug|megestrol acetate|
45661609|NCT02530619|Other|Pharmacological Study|Correlative studies
45661610|NCT02530385|Other|Placebo Capsules|Placebo capsules contain powdered cocoa and gelatin
45661611|NCT02530385|Biological|FMT Capsules|Capsules will be generated as per FDA-approved procedures
45661612|NCT02362425|Drug|N-acetylcysteine|
45661613|NCT02362425|Drug|Placebo|
45661614|NCT02362269|Dietary Supplement|Vitamin D|Gelcaps containing 1000, 2500, and 4000 IU of vitamin D3 will be obtained from Tischon corporation (Westbury, NY). The gelcaps will be protected from light and not stored above 25° C. Participants will be instructed to take their vitamin D3 gelcaps with supper daily. Compliance with study supplementation will be documented by pill count at the time of each study visits.
45816107|NCT00373633|Procedure|Thoracic Epidural|Gold standard for post thoracotomy pain
45816108|NCT00373633|Procedure|Extrapleural Intercostal Catheter|Continuous extra-pleural intercostal local anesthesia
45454435|NCT00004912|Procedure|physical therapy|
45454436|NCT02529787|Drug|Doxirazole|1 capsule contains 60 mg Dexlansoprazole
45454437|NCT02529787|Drug|Dexilant|1 capsule contains 60 mg Dexlansoprazole
45454438|NCT05725642|Other|Polysomnography|Polysomnography
45816109|NCT02945150|Drug|elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)|"Elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor~Subjects receive first dose on-call to operating room, and continue daily for 12 weeks. Treatment length is extended to 16 weeks and ribavirin (daily dose 1000 mg for those <75 kg and 1200 mg for those ≥75 kg) if subject receives a kidney from a donor who is infected with HCV containing resistance-associated variants (RAV)."
45661615|NCT02529995|Drug|AZD9291 40 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
45661616|NCT02529995|Drug|AZD9291 80 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
45816110|NCT02911753|Other|Mediterranean Lemonade|All participants will be advised to consume all of the beverage assigned (mediterranean lemonade) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
45816111|NCT02911753|Other|Green Tea|All participants will be advised to consume all of the beverage assigned (green tea) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
46078587|NCT02743572|Other|iron sucrose-1|iron sucrose-1 group with PN of iron supplementation of 100μg/kg/d
45816112|NCT02911753|Other|Flavored Water|All participants will be advised to consume all of the beverage assigned (flavored water) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
45816113|NCT02829320|Drug|GSK1278863|GSK1278863 will be provided as round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, 4 mg or 6 mg of GSK1278863 as active ingredient.
45955363|NCT05075967|Behavioral|Social Media Influencers|"In this community-level component, social media influencers (SMI) will be defined for the purposes of this study as users on social media who have established credibility, trust and access to a large audience of Black MSM, and who can persuade them by virtue of their authenticity and reach. SMI will provide tailored messaging for Black MSM in intervention communities on the topics of:~HIV/sexually transmitted infections (STI) testing promotion~PrEP (and general HIV prevention) awareness and promotion~Definition and benefits of viral suppression.~Messages may include direction towards health care facilities (HCFs) involved in the intersectional stigma reduction component and information about the virtual peer support platform or BTAN+ events."
45955364|NCT05075967|Behavioral|Intersectional Stigma Reduction|This organizational-level component will take place in HCFs and is designed to improve cultural responsiveness in the provision of HIV prevention and health care services to Black MSM. It is expected to contribute to a reduction in HIV incidence by creating an affirming and autonomy-supportive healthcare environment that supports Black MSM engagement in HIV-related care and services and that promotes increased HIV/STI testing, PrEP uptake and viral suppression rates.
46078588|NCT02743572|Other|iron sucrose-2|iron sucrose-2 group with PN of iron supplementation of 200μg/kg/d
46078589|NCT02743572|Other|iron sucrose-3|iron sucrose-3 group with PN of iron supplementation of 300μg/kg/d
46078590|NCT02743572|Other|iron sucrose-4|iron sucrose-4 group with PN of iron supplementation of 400μg/kg/d
46078591|NCT04238468|Procedure|Intradermal stromal vascular fraction injection|After flank liposuction, lipoaspirate will be processed by enzymatic digestion, thus stromal vascular fraction will be isolated. Just after the wound is closed the stromal vascular fraction diluted in normal saline (5ml) will be injected intradermally on one site.
46078592|NCT02751216|Other|EEG recording + pain protocol|
46078593|NCT04238156|Other|Hypopressive abdominal exercises|Three sessions per week during four consecutive weeks (Total: 12 sessions). Each session time: 30 minutes.
46078594|NCT00775983|Device|laminaria|place device in cervix for dilation
46078595|NCT00775983|Device|Dilapan-S|Place in cervix for dilation.
46078596|NCT02820116|Drug|Icotinib|In the neoadjuvant treatment phase, eligible patients will receive 125mg of Icotinib three times per day for 8 weeks (56 days). In the post-surgery phase, Icotinib 125mg/three tims/day taken orally for 2 years or till disease progression or unacceptable toxicity.
46078597|NCT02747706|Behavioral|Parent-to-parent mentoring|phone, SMS/text, and smartphone-based support
46078598|NCT02817152|Procedure|Periodontal ultrasonic debridement|Periodontal pockets received periodontal ultrasonic debridement intervention.
46078599|NCT02817152|Device|Debridement plus low-level laser therapy|Ultrasonic debridement plus low-level laser therapy.
46078600|NCT02747784|Behavioral|Cognitive training program RehaCom®|Cognitive training program RehaCom®
46078601|NCT00775593|Drug|clofarabine|"Patients will receive one course of low-dose Clofarabine in combination with Temsirolimus (CloTor regimen) for remission induction.~Induction therapy~- Clofarabine 20 mg/m2/day, administered by iv infusion over 1 hour on days 1 through 5"
46078602|NCT00775593|Drug|temsirolimus|"Those who achieve morphologic CR and morphologic CRi will receive maintenance treatment with Temsirolimus monthly for 12 months, or until relapse.~Those who achieve a PR will receive one additional course of CloTor and, if a CR/CRi is obtained, maintenance treatment with Temsirolimus as above.~Induction therapy:~- Temsirolimus 25 mg (flat dose) administered iv over 30 minutes on days 1, 8 and 15.~Maintenance therapy:~- Temsirolimus 25 mg (flat dose) administered iv over 30 minutes on days 1 and 8 of each month for 12 months, or until relapse."
46078603|NCT00939809|Biological|Urokinase-Derived Peptide A6|Given SC
46078604|NCT00939809|Other|Laboratory Biomarker Analysis|Correlative studies
46078605|NCT05658926|Behavioral|Mindfulness|Patients will learn how to use diaphragmatic breathing with mindfulness
45661617|NCT05431517|Procedure|Analysis of ERCP records|Data will be extracted from ERCP records of stenting, mainly including: 1) Age at the time of ERCP; 2) Gender; 3) Indication; 4) Papilla selection (major or minor); 5) Whether endoscopic sphincterotomy (EST) was performed; 6) Presence of nipple diverticulum; 7) Morphology of the pancreatic duct; 8) Status of pancreatic duct stones; 9) Number, shape, material, diameter and length of the stent; and 10) Operation of the bile duct. Additional data were extracted from the pertinent ERCP records of stent migration: 1) Shape, material, diameter and length of the displaced stent; 2) Type of migration; and 3) Removal tools.
46002797|NCT04684355|Other|Real-time colonoscopic optical diagnosis for colorectal neoplasm|Colonoscopic optical diagnosis by image enhanced technology has been validated as an excellent tool to predict the histology of colorectal polyps and to differentiate the invasion depth of colorectal cancer.
45661618|NCT04260425|Other|Serving of oatmeal made from low avenanthramides oats and water|One serving size (40 grams dry weight) of low avenanthramides oats flakes will be used to make oatmeal. One cup of water and a dash of salt (0.72 g) will be added into the treatment and microwaved on high for 3 minutes. It will be stirred before serving. Ingredients and cooking time will be consistently maintained throughout.
45816114|NCT02829320|Drug|Iron|Subjects will receive supplemental iron therapy if ferritin is <=100 ng/mL and TSAT is <=20%. The investigator (or subinvestigator) will choose the route of administration and dose of prescription iron.
45816115|NCT03032263|Device|Video Laryngoscopy for nasal intubation|The anesthesia provider will use a video laryngoscope to facilitate the nasal intubation for the procedure.
45816116|NCT03032263|Device|Direct Laryngoscopy|These patients will be nasally intubated for their procedure via direct laryngoscopy
45816117|NCT03032965|Drug|Adenosine|"Subject will receive 6-24 mg of intravenous adenosine given rapidly for each PV in order to assess dormant PV conduction.~Subjects in this group will also receive isoproterenol to assess inducibility of AF with re-isolation of PVs and targeting non PV sources of AF if necessary.Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate."
46078606|NCT05658926|Other|Education|Patients will be provided with education regarding the Gate Control Theory of Pain.
46078607|NCT02818010|Other|Global Physical Activity Questionnaire|The practice of physical activity is measured by the GPAQ 2 questionnaire (Global Physical Activity Questionnaire) developed by the World Health Organization.
46078608|NCT02747550|Procedure|LM with TESTO|In subjects allocated to the experimental group, the temporary simultaneous two-arterial occlusions (TESTO) procedure was performed to minimize operative blood loss during laparoscopic myomectomy.
45816118|NCT03032965|Drug|Isoproterenol|Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate. The isoproterenol infusion will be discontinued upon induction of AF, a decrease in systolic blood pressure to<85 mmHg, complaints of severe chest tightness, electrocardiographic changes suggestive of ischemia, or upon completion of the infusion protocol.
45816119|NCT02948426|Biological|Autologous Monocytes + ACTIMMUNE + SYLATRON|The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design including an expansion cohort at the maximum tolerated dose (MTD).
45816120|NCT03030638|Drug|Olodaterol|Drug
46078609|NCT02747550|Procedure|LM without TESTO|In the control group, no intervention for the temporary simultaneous two-arterial occlusions (TESTO) procedure was made during laparoscopic myomectomy
45661619|NCT04260425|Other|Serving of oatmeal made from high avenanthramides oats and water|One serving size (40 grams dry weight) of high avenanthramides oats flakes will be used to make oatmeal. One cup of water and a dash of salt (0.72 g) will be added into the treatment and microwaved on high for 3 minutes. It will be stirred before serving. Ingredients and cooking time will be consistently maintained throughout.
45816121|NCT03030638|Drug|Indacaterol|Drug
46002798|NCT00548639|Other|Statin Choice Decision Aid|Paper based instrument with pictures indicating level of risk.
46002799|NCT00548639|Other|Control Pamphlet|ADA Diabetes Sheet
46002800|NCT04635696|Drug|Ethyl chloride|Pressurized vapocoolant developed for acute, mild pain relief.
46002801|NCT04635696|Other|Tissue culture grade water|Pressurized water mist
46078610|NCT00606983|Drug|Tamsulosin|oral administration of Tamsulosin
46078611|NCT02817932|Drug|Ranolazine|
46078612|NCT02818088|Behavioral|n-Back (Cognitive Training)|
46078613|NCT02743260|Drug|pitavastatin|
46078614|NCT02743260|Drug|Metformin|
46078615|NCT02743260|Drug|digoxin|
45661620|NCT05448209|Behavioral|walking exercise|Intervention Group Afterwards, patients taking paclitaxel-paclitaxel-herceptin will be given a nurse-led Motivational Interview about CIPN, physical activity and regular physical activity-walking. Patients will be instructed that the goal is to beat the previous number of steps each time. If he/she has problems/shortness of breath, chest pain, palpitation complaints during walking, he/she will be told to take a break from walking and rest. The study will be conducted under the supervision of a Medical Oncology specialist throughout the study, as well as the controls of patients with ongoing symptoms. Participants will be given a pedometer for regular follow-up, its use will be explained, and it will be told to mark it on the walking tracking chart. It will be emphasized that rhythmic walking is important for the pedometer to count correctly. Motivational Interview sessions will be conducted face-to-face at the beginning, week 4 and week 8.
46002802|NCT04959890|Other|Retroviral Insertion Site Analysis|Shearing extension primer tag selection ligation-mediated polymerase chain reaction (S-EPTS/LM-PCR) retroviral insertion site (RIS) analysis on samples previously collected from subjects treated with Strimvelis
46078616|NCT02743260|Drug|Adefovir|
46078617|NCT02743260|Drug|sitagliptin|
45661621|NCT05408897|Diagnostic Test|liquid biopsy|A test that enables the diagnosis or analysis of tumors using only a blood or fluid sample rather than a solid tissue biopsy.
45816122|NCT02949518|Other|Enhanced Recovery Pathway (ERP) for Spine|The study team emphasizes that all components of the ERP are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the ERP will receive these standard of care components.
45816123|NCT02949674|Drug|Ropivacaine|It will be used as a analgesic dose in surgical site before surgery.
45816124|NCT02949674|Drug|Bupivacaine|It will be used as a analgesic dose in surgical site before surgery.
45816125|NCT03033511|Drug|Placebo for dexamethasone|Placebo for dexamethasone PO twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
45816126|NCT03033511|Drug|Placebo for rovalpituzumab tesirine|Placebo for rovalpituzumab tesirine administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
45816127|NCT03033511|Drug|Rovalpituzumab tesirine|Rovalpituzumab tesirine 0.3 mg/kg administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
45816128|NCT03033511|Drug|Dexamethasone|Dexamethasone 8 mg administered orally (PO) twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
45816129|NCT03033134|Device|BSJ003W|BSJ003W implant
45816130|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 25mg|25 μg oral inhalation via eFlow Nebulizer, once daily
45816131|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 75mg|75 μg oral inhalation via eFlow Nebulizer, once daily
46002803|NCT04644120|Drug|ABBV-47D11|Intravenous (IV) infusion.
46002804|NCT04644120|Drug|Placebo for ABBV-47D11|Intravenous (IV) infusion.
46002805|NCT04644120|Drug|ABBV-2B04|Intervenous (IV) Infusion
46002806|NCT04644120|Drug|Placebo for ABBV-2B04|Intervenous (IV) Infusion
46078618|NCT00607061|Procedure|Blood sample collection|Blood of the umbilical cord will be collected after delivery. A mother blood sample will be also collected in the few hours preceding delivery to determine glutathione and cysteine concentrations.
46078619|NCT02817854|Procedure|Measure PCT, CRP and WBC at admission|Measure PCT, CRP and WBC at admission after diagnosis of acute diverticulitis with CT scan has been done
46078620|NCT02817854|Procedure|Measure PCT, CRP and WBC 1 day after admission|Measure PCT, CRP and WBC at one day after admission for acute diverticulitis
46078621|NCT02817854|Procedure|Measure PCT, CRP and WBC 2 days after admission|Measure PCT, CRP and WBC at 2 days after admission for acute diverticulitis
45816132|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 200mg|200 μg oral inhalation via eFlow Nebulizer, once daily
45955365|NCT05075967|Behavioral|Peer Support|"Peer support workers will be trained and compensated to provide emotional and practical support services. These peer support workers will have shared lived experiences with those whom they are supporting, be self-reflective of those experiences, and know when to share those experiences with others in an appropriate and supportive manner. Once trained, the peer-support workers will have demonstrated competencies in the following domains:~HIV, PrEP, nPEP, other HIV prevention options and ART education~Adherence to PrEP, ART and medical care~HIV/STI testing~New HIV diagnosis~Addressing intersectional stigma (anti-Black racism, sexual stigmas, HIV-related stigma)~Self-care~Information about national and local resources and assistance programs, Black MSM-centered health services, and the cost and insurance coverage of medications and medical care~Multicultural competency (as it relates to the HIV epidemic for Black MSM in the southern US)"
45955366|NCT05075967|Other|Standard-of-care|Black MSM living in standard-of-care communities will have access to standard HIV prevention and care services available in their communities.
45454439|NCT01328275|Drug|standard regimens according to the Thai Ministry of Public Health national guidelines|Participants may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
45816133|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 200mg Jet|200 μg oral inhalation via inhalation via jet nebulizer, once daily
45816134|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 500mg|500 μg oral inhalation via eFlow nebulizer, once daily
45816135|NCT02951312|Drug|Glycopyrrolate Inhalation Solution1000mg|1000 μg oral inhalation via eFlow nebulizer, once daily
45955367|NCT05072717|Procedure|Perfusion with Indocyanine green|Infusion of Indocyanine green to determine perfusion in meniscal tear tissue.
45955368|NCT05072613|Other|Malaria screening|Participants are screened for malaria and a dried blood spot is collected from malaria positive cases
45955369|NCT05060978|Behavioral|Watch your Weight During the Holidays Program|Participants in this group will have two video call individual sessions and one video call group session. This intervention will include self-monitoring strategies (self-weighing, diet monitoring and physical activity), and nutrition counseling and education. In addition, participants in this group will receive a weighing scale to achieve self-monitoring of body weight from the beginning of the study intervention until the end of the 52-weeks follow-up.
45955370|NCT05060978|Other|Relative 5:2 Fasting|Participants in this group will will have two video call individual sessions and one video call group session. This intervention will receive eating recommendations to follow a 5:2 intermittent fasting. They will be given low-calorie menus of 550 kcal and 660 kcal, for women and men respectively, which the participants in this group will apply on fasting days. The fasting will be held twice a week and on the remaining five days, the participants will not have any type of caloric restriction (it will be ad libitum). They will only have the general recommendation to adhere to a healthy dietary pattern.
45955371|NCT05060978|Other|Control Group|Participants in this group will receive online information and a PDF file brochure during an individual video call session at the beginning of the 8-week period. This information will be about leading a healthy eating based on the norm for health promotion and education for healthy eating in Mexico (NOM-043-SSA2-2012).
45816136|NCT02951312|Drug|Placebo|Placebo 0.5 mL oral inhalation via jet nebulizer, once daily
45816137|NCT02796625|Other|Painful Stimuli|warm or painful heat administration
45816138|NCT03035929|Drug|Dexamethasone|A single dose of dexamethasone IV 4 mg will be administered.
45955372|NCT05044676|Other|patients with hepatocellular carcinoma|The response of the hepatocellular carcinoma to treatment will be evaluated as part of the care
45955373|NCT05042323|Behavioral|TF-CBT-Short|Participants receive either 4-5 sessions of TF-CBT-Skills or TF-CBT-Narr. If the participant still has significant PTSS they are provided with step two which is the components provided in the arm they did not receive.
45955374|NCT05041023|Other|Relative section|"Relatives are assessed by phone calling with an experienced psychologist at 3 and 6 months after patient's death. Relatives answer to self-questionnaire and 3 scales.~Furthermore, 20 of them are offered to participate in a semi-structured interview with an experienced psychologist, within 6 months to 1 year following the patient's death."
45454440|NCT00267592|Drug|Talampanel|Talampanel administered orally TID beginning the first day and continued until there is talampanel-related toxicity or tumor progression.
45454441|NCT00267592|Radiation|Radiation Therapy (RT) 5 days a week +|
45454442|NCT00267592|Drug|temozolomide(TMZ) 75mg|temozolomide(TMZ) 75mg 3 times daily (TID) for 6 weeks
45454443|NCT00267592|Drug|adjuvant TMZ 200mg|adjuvant TMZ 200mg TID for 5 consecutive days each month for a total of 6 months.
45454444|NCT04269889|Drug|Eltrombopag|150 mg/day starting dose (titration and adjustments for age and ethnicity)
45816139|NCT02951702|Drug|Vancomycin Oral|"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician"
45816140|NCT02911909|Device|Delfi|Patients will receive standard of care post-operative ACL reconstruction rehabilitation plus the Delfi moderated blood flow restriction therapy.
45816141|NCT02911909|Other|Standard rehabilitation|Patients will receive standard of care post-operative ACL reconstruction rehabilitation
45816142|NCT02952872|Behavioral|Brief Tablet-based Intervention to Address Heavy Alcohol Use|The intervention will be be tablet-based and take approximately 20 minutes to complete. Content will focus on heavy alcohol use.
45816143|NCT02799667|Device|Standard Dressing|Patients are randomized to the standard dressing at the time of fascial closure.
45661622|NCT05447819|Procedure|Reverse shoulder arthroplsaty|Patients with the diagnosis of rotator cuff arthropathy (degeneration of the glenohumeral joint and wear or tear of at least one rotator cuff tendon) or degeneration of the glenohumeral joint with severe posterior wear with an indication of a reverse total shoulder arthroplasty
45816144|NCT02799667|Device|Negative Pressure Wound Therapy Dressing|Patients are randomized to the NPWT at the time of fascial closure.
45816145|NCT02914795|Other|diagnostic analysis of platelet function|analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique
45816146|NCT02953418|Device|Radiofrequency ablation|RFA
45454445|NCT01328353|Other|telehealth plus aprn triage|aprn using either telephone or telephone plus video conferencing will provide triage for CCHCN
45816147|NCT02915029|Other|Educational and lifestyle coaching|"Educational lifestyle and patient activation is a CHR lead home visits every other week to provide education on healthy lifestyles (diet, exercise, alcohol abuse and smoking) as patient preference; Education provided on management of diabetes, hypertension and hyperlipidemia POC testing for A1C and microalbuminuria conducted at patient homes. Lifestyle and diet related Motivational messaging carried out regularly. Patient will receive group session at the clinic every quarters.~Control arm will receive their usual care provided by IHS. The control group will receive a health evaluation at the initiation of the study and at the 6-month and 12-month."
45955375|NCT05041023|Other|Caregiver section|"Caregivers are self-evaluated within 72 hours after death by questionnaire survey, whose results will remain confidential to the center that included the situation.~Furthermore, 20 of them (10 medical staff and 10 paramedical staff and / or until saturation) are offered to participate in a semi-structured interview with an experienced psychologist."
45955376|NCT05040815|Radiation|chemo-radiation treatment|Radiotherapy (RT) with concurrent 5-fluorouracil and mitomycin-C (5FU/MMC) combination is the treatment of choice for non-metastatic locally advanced anal squam
45955377|NCT05039710|Drug|JNJ-75220795|JNJ-75220795 will be administered as SC injection.
45955378|NCT05039710|Other|Placebo|Matching placebo will be administered as SC injection.
45955379|NCT05026281|Device|Quantra analyzer|one additional tube will be collected during the usual blood test at two different time and analyzed by Quantra ®
45955380|NCT05022511|Behavioral|Screening status|Women are offered check-up on screening status in both CCU and CRC screening. If a woman is not up to date in one or both screening programmes, she will be offered a self-sampling device and/or a FIT kit.
45816148|NCT02831660|Drug|idarucizumab|
45955381|NCT05000021|Behavioral|Cognitive Behavioral Therapy for Diabetes Distress (CBT-DD) with Continuous Glucose Monitoring|CBT-DD consists of approximately 10 individual sessions of CBT delivered virtually by trained protocol therapists, conducted over the course of approximately 12 weeks. The CBT-DD consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. CBT-DD sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.
46002807|NCT00558909|Drug|BI 44847|
46002808|NCT00558909|Drug|placebo for BI 44847|
46078622|NCT05629260|Drug|ATG|Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT, with G-CSF/ATG based protocol.
45816149|NCT02831816|Drug|ZuraPrep|Apply topically.
45816150|NCT02831816|Drug|ChloraPrep|Apply topically.
45816151|NCT02831816|Drug|ZP Vehicle|Apply topically.
45816152|NCT02832284|Device|iNod System|The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.
45454446|NCT04469998|Drug|AXR-270 Low Dose|AXR-270 Topical Eyelid Cream
45816153|NCT03036163|Drug|PBTZ169 - 40 mg|40 mg of PBTZ169 (1 capsule) orally once in fasting state
46002809|NCT04942145|Device|virtual reality in dental patients|"The behavioral anxiety response of dental patients (with and without virtual reality) related to psychological factors is studied.~Participants self-complete the questionnaires"
46078623|NCT05629260|Drug|Post-transplantation cyclophosphamide|Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT with PT-Cy based protocol.
46078624|NCT02819648|Drug|Prednisolone|40 mg prednisolone (two tablets Prednisolone 20 mg, Aventis Intercontinental, Paris, France)
46078625|NCT02819648|Other|Control|Milk Tablet
46078626|NCT00934661|Drug|Extended Release Epidural Morphine (EREM)|A single Four mg (0.4 ml)dose of EREM will be administered into the epidural space and flushed with 1 ml of saline
46078627|NCT00934661|Drug|Placebo|A single epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
45661623|NCT05447585|Device|Coronary atherectomy system of Shanghai MicroPort Rhythm|Coronary Atherectomy System utilizes a diamond-coated eccentric crown to expand the lumen diameter via centrifugal forces while rotating over an atherectomy guide wire.
46078628|NCT02743182|Drug|Pegylated interferon alfa-2a|
45816154|NCT03036163|Drug|PBTZ169 - 80 mg|80 mg of PBTZ169 (2 capsules 40 mg) orally once in fasting state
45816155|NCT03036163|Drug|PBTZ169 - 160 mg|160 mg of PBTZ169 (4 capsules 40 mg) orally once in fasting state
45816156|NCT03036163|Drug|PBTZ169 - 320 mg|320 mg of PBTZ169 (8 capsules 40 mg) orally once in fasting state
45454447|NCT04469998|Drug|AXR-270 High Dose|AXR-270 Topical Eyelid Cream
45454448|NCT04469998|Drug|AXR-270 Vehicle|AXR-270 Topical Eyelid Cream Vehicle
45661624|NCT05447585|Device|Rotablator Rotational Atherectomy System|The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console
45661625|NCT05447117|Procedure|Micropulse laser|532 nm green subthreshold micropulse laser (GSML) as a treatment for acute central serous chorioretinopathy (CSCR).
45816157|NCT03036163|Drug|PBTZ169 - 640 mg|640 mg of PBTZ169 (16 capsules 40 mg) orally once in fasting state
45816158|NCT03036163|Drug|PBTZ169 - 320 mg (multiple administration)|320 mg of PBTZ169 (8 capsules 40 mg) orally once per day in fasting state for 14 days
45816159|NCT03036163|Drug|PBTZ169 - 640 mg (multiple administration)|640 mg of PBTZ169 (16 capsules 40 mg) orally once per day in fasting state for 14 days
45955382|NCT05000021|Device|Continuous Glucose Monitoring (CGM)|Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing diabetes distress, along with self-management information and treatment options to discuss with providers will also be provided.
45955383|NCT04998331|Other|No Intervention|This is a non-interventional study.
45661626|NCT05429021|Drug|IMM-BCP-01|Single dose of IMM-BCP-01
46078629|NCT05655962|Other|STARS|STARS is a structured framework for assessment of rehabilitation and sicklisting, applied by primarily the rehabilitation coordinators working at the primary health care centers.
45816160|NCT02832674|Device|Percutaneous Radiofrequency single treatment|Percutaneous Radiofrequency single treatment' under controlled temperature conditions based on pre-defined amounts of energy as controlled by the device internal algorithm, and investigator expertise. Additionally, Hunsted solution will be infused in the treatment area to eliminate the electrode/fiber to touch inner layers of the skin. External temperatures (skin surface) will be monitored using a temperature reading camera to ensure the external temperature stays within acceptable levels during the procedure Ice packs will also be used as needed to cool the treatment area based on the Thermal Camera Reading where the . heat delivery may be exceeding the threshold.
45816161|NCT02973607|Procedure|Nephrectomy|This is observational in design.
45816162|NCT03034928|Device|Contact lens with investigational coating 1|Contact lens with investigational coating 1 pre-cycled in OPTI-FREE® RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)
46078630|NCT00775437|Drug|Adalimumab|Adalimumab solution for injection for subcutaneous use.
46078631|NCT03924336|Procedure|Advanced- platelets rich fibrin (A-PRF+) + Open flap debridement (OFD)|Elevation of flap.Thorough debridement of the defects using curettes and ultrasonic scalers. Clinical measurements will be then recorded , A-PRF+ of the required size will be filled into the intraosseous defect. The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures
46078632|NCT03924336|Procedure|Open flap debridement (OFD) alone|Elevation of flap.Thorough debridement of the defects using curettes and ultrasonic scalers. Clinical measurements will be then recorded. After debridement and intraoperative recordings, interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
45661627|NCT05429021|Drug|Placebo|Placebo matching single dose of IMM-BCP-01
45661628|NCT02319759|Drug|Guselkumab|In the guselkumab group, Guselkumab 100 mg subcutaneous injection will be administered at Weeks 0, 4, 12, 20, 28, 36 and 44. In the placebo group, guselkumab 100 mg subcutaneous injection will be administered at Weeks 24, 28, 36 and 44 for participants remaining on placebo at Week 24.
45661629|NCT02319759|Drug|Ustekinumab|In both placebo and guselkumab groups, if the participants qualify for early escape, they will switch to receive ustekinumab 45 mg or 90 mg subcutaneous injection at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
45661630|NCT02319759|Drug|Placebo|In placebo group, Placebo subcutaneous injection will be administered at Weeks 0, 4, 12, and 20. In guselkumab group, placebo subcutaneous injection will be administered at Week 24 to maintain the blind.
45661631|NCT05428709|Behavioral|Acute Exercise|Participants will be asked to walk or jog on a treadmill for a maximal exercise test.
45661632|NCT02293005|Drug|Alisertib|50 mg twice a day on Days 1-7 of each 21-day study cycle.
45955384|NCT04983862|Drug|Illuminare-1|Illuminare-1 at 3 dose levels in patients undergoing minimally invasive radical prostatectomy and bilateral pelvic lymph node dissection. Three dose levels will be used: 0.25mg/kg, 0.5mg/kg, and 1.0mg/kg. Once the imaging dose of Illuminare-1 is established at a no-DLT level, an expansion cohort of 20 patients will be evaluated at this dose.
45955385|NCT04983862|Device|Karl Storz D-Light C photodynamic diagnostic (PDD)|The Storz PDD system will be used as the hardware system in this phase 1 study due to its proven safety profile.
45816163|NCT03034928|Device|Balafilcon A contact lens|Balafilcon A contact lens pre-cycled OPTI-FREE® RepleniSH® MPDS
46078633|NCT05370833|Device|transcranial direct current stimulation|Anodal, 2mA, tDCS session applied on M1 for 20 minutes.
46078634|NCT04238078|Drug|Contraceptive|Oral contraceptive pill
46078635|NCT02743416|Other|ECG screening (Zenicor-ECG) for atrial fibrillation|Determination of the biomarker NT-proBNP together with single-lead ECG screening for silent atrial fibrillation.
46078636|NCT04238000|Device|repetitive transcranial magnetic stimulation|Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description
45955386|NCT04975620|Device|Fine needle biopsy|Taking biopsy from solid pancreatobiliary mass lesions with 8 back and forth movement of the needle within the lesion with slow withdrawal of the stylet
45955387|NCT04971499|Drug|Dapansutrile|500 mg tablet
45816164|NCT03034928|Device|OPTI-FREE® RepleniSH® MPDS|Multipurpose contact lens solution
45816165|NCT03034928|Device|Contact lens with investigational coating 2|Contact lens with investigational coating 2 pre-cycled in OPTI-FREE® RepleniSH® MPDS
45816166|NCT03038815|Device|VACOped|restriction of ankle joint motion
45816167|NCT03038815|Device|Ortho Tri|restriction of ankle joint motion
45816168|NCT02800213|Device|Modified Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with a supplemental external handle
45816169|NCT02800213|Device|Conventional Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
45955388|NCT04971499|Drug|Pembrolizumab|Single-use vial containing 100 mg/4 mL of pembrolizumab
46078637|NCT02747394|Other|Working Memory Training|
46078638|NCT02816918|Device|Extraluminal use of Univent bronchial Blocker|"Patients assigned to the Extraluminal use of Univent Blocker group were first inserted Univent bronchial Blocker into the glottis via direct laryngoscopy then advanced the Blocker to the target bronchus until slight resistance was encountered.A conventional tracheal tube with appropriate size was intubated via direct laryngoscopy into the appropriate depth, inflating the tracheal tube cuff, and fixing the tube firmly at the patient's mouth with cloth tape .~So the Univent Blocker Extraluminal of the endotracheal tube,then the fibreoptic bronchoscopy was inserted into the tracheal tube and guided bronchial blocker cuff to the target main bronchus under direct vision"
46078639|NCT02816918|Device|Innerluminal use Univent bronchial Blocker|Patients in Innerluminal use of Univent Blocker group: When the endotracheal tube had been intubated via direct laryngoscopy, the bronchial blocker was advanced Innerluminal of the endotracheal tube and directed into the right or left mainstem bronchus, then the fibreoptic bronchoscopy was inserted into the tracheal tube. After further pushing and twisting, the bronchial blocker tube will move into the mainstem bronchus under direct vision by FOB.the tracheal tube cuff is inflated with the tube being fixed firmly at the patient's mouth with cloth tape
46078640|NCT05369507|Behavioral|Virtual Care Coordination|Participants randomly assigned to the virtual care coordination group will use a mobile app to assist in HCV treatment care coordination.
45816170|NCT02953886|Device|Silver Diamine Fluoride (SDF)|No caries removal will take place. Bacterial samples will be collected using Gracey curettes at the initial visit before application of SDF and one month after. The tooth will be dried and SDF will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet
45661633|NCT02319525|Other|Computerized patient decision-aid|The decision-aid contained information regarding lupus and lupus nephritis, its impact on patient lives and benefits and harms of lupus nephritis treatments, focused on immunosuppressive medications compared to each other. The content of the decision-aid allowed individualization based on patient preference for details on certain aspects, as well as the desire to view additional, optional sections of the decision-aid.
45816171|NCT03035318|Device|DePuy Global® Anchor Peg Glenoid Instrumentation|Placement of glenoid component will be performed using DePuy Global® Anchor Peg Glenoid Instrumentation.
46078641|NCT02742168|Radiation|99mTc-3PRGD2|"Diagnostic group：For patients in suspicion of breast cancer, single intravenous bolus injection of nearly 0.3 mCi/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and lesions SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.~Efficacy evaluation group：patients firstly diagnose with malignant lesions ,and prepare to chemotherapy(including neoadjuvant chemotherapy) or radiotherapy.the same dose of 99mTc-3PRGD2 will be intravenously injected into the patients before treatment ,the second period,the sixth period( almost three months after the initial treatment)，whole-body planar and lesions SPECT/CT to assess the value of 99mTc-3PRGD2 in evaluation of cancers."
46078642|NCT05382845|Diagnostic Test|Manual pain provocation tests|Validated and empirical pain provocation tests of the pelvic joints will be performed, both to exclude ongoing symptoms, and to diagnose one or several dysfunctions. The participants will be asked questions regarding previous symptoms, traumas, type of profession etc.
45661634|NCT02319525|Other|Usual care (lupus pamphlet)|Patient received the standard handout/pamphlet from a non-profit organization (American College of Rheumatology [ACR]) regarding lupus and its treatments, that explained risks and benefits of various treatments
45816172|NCT03035318|Device|DePuy Global® Anchor Peg Instrumentation with SmartBone™|Placement of glenoid component will be performed using DePuy Global® Anchor Peg Instrumentation with SmartBone™.
45816173|NCT03035318|Device|IRI with SmartBone™|Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBone™.
45816174|NCT03035318|Device|RTI with SmartBone™|Placement of glenoid component will be performed using Real Time Instrumentation (RTI) with SmartBone™.
45816175|NCT03035318|Device|IRI with SmartBase|Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBase.
45816176|NCT02802241|Drug|placebo|
45816177|NCT02802241|Dietary Supplement|peppermint oil|
45816178|NCT03035708|Drug|Varenicline|1 mg BID
45816179|NCT03035708|Drug|Placebo oral capsule|1 mg BID
45816180|NCT00374426|Drug|sertraline|
45816181|NCT03040154|Other|"Video Documentary entitled, Para Sa Kinabukasan ng Mga Anak (For Our Children's Future)"|
45955389|NCT04918017|Drug|Treatment based on subtypes: Esomeprazole or Itopride|"Esomeprazole 40mg OD for EPS and Itopride 50mg TDS for PDS~In overlapped EPS/ PDS: treat with Itopride 50mg TDS first and then add Esomeprazole 40mg OD (if partially responded- assessed at week 4) or treat with Itopride 50mg TDS first and then change to Esomeprazole 40mg OD (if not responded- assessed at week 4)"
45955390|NCT04918017|Drug|Treatment with proton pump inhibitor regardless of subtype: Esomeprazole|Esomeprazole 40mg OD
46078643|NCT05654168|Diagnostic Test|Imaging|The thickness of the musculature to be studied will be measured with ultrasonography
46078644|NCT04266821|Other|Experimental Arm|"First, these providers will receive educational materials (e.g. a slide deck, mock test result and FAQ handout) meant to mimic what physicians will receive in the real-world market as they learn about the Ethos technology.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the Ethos test at the clinically-appropriate point in each case."
45955391|NCT04906980|Drug|JNJ-64281802|JNJ-64281802 will be administered orally.
45955392|NCT04906980|Drug|Placebo|Matching placebo (PEG400) will be administered orally.
45955393|NCT04902352|Procedure|No Periadventitial dissection of the SMA|lymphoneural tissue around SMA left intact
45955394|NCT04902352|Procedure|Periadventitial dissection of the SMA|"For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from angle of the artery to the level of inferior border of the uncinate process. In the presence of an accessory or replaced right hepatic artery the peri-adventitial dissection should also be carried out around this vessel as well."
45955395|NCT04898231|Drug|Infliximab|Infliximab will be administered as a single IV dose of 10 mg/kg over 2 hours.
45955396|NCT04898231|Drug|Anakinra|Anakinra will be administered at a dose of 8 mg/kg/day IV or SQ with 100 mg every 6 hours as the max dose. This is discontinued with a taper during the hospitalization over 2-4 days once a patient is stable with significantly improved clinical course and laboratory profile.
46078645|NCT02695134|Other|Healing Touch|Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and energy centers which control the flow of energy to the physical body.
46078646|NCT02819414|Drug|Paracetamol drops|15 mg/kg/dose x 4/day diluted 1:15 yielding dose of 2.25 ml/kg/dose to be given for three days
46078647|NCT02819414|Other|Placebo|2.25 ml/kg/dose x 4/day of sterile water to be given for three days
46078648|NCT04265339|Other|Smoking cessation|Participants are required to quit smoking
45816182|NCT03040154|Other|Usual Care Video that is publicly available|
45955397|NCT04898231|Drug|Methylprednisolone|Methylprednisilone (steroids) will be administered as 2 mg/kg IV or orally divided every 12 hours. At the time of hospital discharge the patient will be given a steroid taper that will take at least 3 weeks to complete.
45955398|NCT04898114|Drug|Magnesium sulfate|Nebulized magnesium sulfate (4 ml of 6.4% solution) every 15 minutes
45955399|NCT04898114|Drug|Sildenafil Citrate|Oral sildenafil citrate at an initial dose of 1 mg/kg, with incremental increases by 0.5 mg/kg every 6 hours till reaching a target dose of 2mg/kg every 6 hours.
45955400|NCT04898114|Other|Isotonic saline|Nebulized isotonic saline (4 ml) every 15 minutes
45955401|NCT04892017|Drug|DCC-3116|Oral Tablet Formulation
45955402|NCT04892017|Drug|Trametinib|Oral Tablet Formulation
45816183|NCT02916745|Drug|Porfimer sodium|After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). A light dose of 200 J/cm of diffuser length will be delivered.
46078649|NCT02816762|Device|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
45816184|NCT02916745|Device|Fiber optic|A fiber optic diffuser length matching the tumor length will be placed in the lesion under fluoroscopy guidance.
45816185|NCT02954198|Drug|Tacrolimus|goal trough level 5-12ng/mL
45955403|NCT04892017|Drug|Binimetinib|Oral Tablet Formulation
45955404|NCT04892017|Drug|Sotorasib|Oral Tablet Formulation
45955405|NCT04890119|Diagnostic Test|tenosynovial tissue biopsy|Biopsy of tenosynovial tissue during surgery for amyloid aggregate search
45955406|NCT04889430|Drug|Iptacopan|Iptacopan 200mg twice daily oral
46078650|NCT02816762|Drug|Pharmacological treatment|Conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.
46078651|NCT02816762|Other|Diet|Conventional anti-diabetic diet recommendations
46078652|NCT02742012|Other|the study is observational|the study is observational
46078653|NCT02743104|Drug|Ketamine|
46078654|NCT02743104|Drug|Propofol|
46078655|NCT02743104|Drug|midazolam and atropine|
45816186|NCT02954198|Drug|Prednisone|goal dose 5mg QD
45816187|NCT02954198|Drug|Mycophenolate mofetil|goal dose 1g BID
45816188|NCT02954198|Drug|Everolimus|goal trough level 3-8ng/mL
45955407|NCT04887558|Combination Product|Smart-T Mental Health and NRT|Smart-Treatment Mental Health App and Nicotine Replacement Therapy
45955408|NCT04887558|Combination Product|Smart-T Mental Health+ and NRT|Smart-Treatment Mental Health App+NRT adherence messages and Nicotine Replacement Therapy
45955409|NCT04887558|Combination Product|QuitGuide + NRT|NCI QuitGuide Treatment App and Nicotine Replacement Therapy
45955410|NCT04886258|Drug|DFV890|DFV890
45955411|NCT04886258|Drug|Placebo|Placebo
45955412|NCT04863898|Behavioral|Drug-use stigma reduction intervention for HIV care and treatment clinics|We will adapt the HP+ health facility HIV stigma-reduction intervention to focus on drug stigma in HIV CTCs. The intervention will address key stigma drivers, including fear, awareness of stigma, and stigmatizing attitudes and beliefs, through a participatory training approach that involves all levels of staff and is grounded in social cognitive theory principles. The approach seeks to reduce stigma through fostering empathy, interpersonal interactions (contact strategies) and building efficacy for stigma reduction through awareness, skills, and knowledge building. The intervention consists of five-2.5 hour participatory training sessions.
46002810|NCT04643964|Behavioral|Entrée: Cognitive skills|In this condition, participants view a video-based intervention covering cognitive emotion regulation skills. This intervention asks participants to respond to questions and practice identifying and evaluating their own thoughts using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
46078656|NCT02743104|Drug|Lidocaine|
46078657|NCT02816528|Behavioral|Training program|Physicians will be given informations regarding antibiotic consumptions and bacterial resistance in their activity area every 3 months during 12 months.
46078658|NCT00775203|Drug|Trazodone Hydrochloride (HCl) Extended-Release Tablets|
46078659|NCT00775203|Drug|Placebo|
45661635|NCT02292927|Behavioral|Post-intervention arm = Prehabilitation|Introduction of a physical exercise training programme, psychological counselling and smoking cessation advice
45816189|NCT02956070|Drug|Dexamethasone acetate|The volunteers in the Dexamethasone acetate group (experimental group) will receive six capsules of dexamethasone 8 mg each to be administered orally, initially two days before the first bleaching query as follows: 8 mg (1 capsule) 9 am two days before the first clinical session whitening; 8 mg (1 capsule) the 9 am to 1 day before session whitening, 8 mg (1 capsule) to 9 am on the day of the first session of whitening.Clinical intervention: 1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A placebo gel will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
45955413|NCT04856215|Drug|90-Yttrium-labelled anti-CD66 monoclonal antibody|"The Investigational Medicinal Product (IMP) consist of 1) 111Indium- and 2) 90Yttrium-labelled anti-CD66 (BW250/183) monoclonal antibody.~The anti-CD66 is a murine IgG1 monoclonal antibody originally developed as an in vivo leucocyte and bone marrow imaging agent (Boßlet 1985, Thomsen 1991). BW 250/183 anti-CD66 is a murine IgG1 kappa monoclonal antibody, originally produced as an anti-CEA antibody.~The batch of antibodies required for treatment will be radiolabelled by Royal Free Hospital radiology team with Indium 111 and Y90 for patient."
45955414|NCT04851210|Other|No intervention|No intervention
45661636|NCT02292849|Behavioral|Peer to Peer|12 weekly sessions of peer-delivered behavioral activation
45661637|NCT02292849|Other|Standard Mental Health Referral|Standard mental health referral to a community agency
45955415|NCT04849026|Drug|Clozaril 100 mg (Clozapine)|2 Doses/Day for 10 days
45955416|NCT04849026|Drug|WID-CLZ18|2 Doses/Day for 10 days
45955417|NCT04847258|Other|Standard rehabilitation|Patients follow standard municipal rehabilitation
46078660|NCT02816684|Behavioral|Pegasys-VR|Pegasys-VR uses artificially intelligent avatars and serious game technology to assist children in the acquisition and use of social skills.
46078661|NCT02816684|Behavioral|Social Effectiveness Therapy for Children|Group social skills training, peer generalization sessions, individual exposure therapy
45661638|NCT05396443|Behavioral|Black Girls for Wellness|Weekly for 12 weeks, adolescent participants will attend 1) a live stream group Wellness session (90 min/wk), 2) a home cooking experience using ingredients sent to participants' home (60 min/wk), and 3) one live stream group dance classes via Zoom (60 min/wk); participants will also be encouraged to attend 2 other dance classes during the week at their own convenience. Enrolled caregivers and others in the home (e.g., siblings) will be encouraged to participate in activities.
45955418|NCT04841980|Drug|Rifaximin|Administration route: PO Rifaximin 400mg TDS for 2 weeks
45955419|NCT04841980|Other|Low FODMAP diet|Low FODMAP diet under dietitian guidance for 4 weeks
45955420|NCT04831736|Drug|Ketamine|Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
45955421|NCT04831736|Drug|Placebo|Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
45955422|NCT04830462|Drug|Rifampicin 300 Mg Oral Capsule|Rifampicin 600 mg orally once daily for 4 months
45661639|NCT05396443|Behavioral|Control|Weekly newsletter for adolescent and caregiver participants to attend public events in New York City for 12 weeks. After post endpoint data collection: recording of Black Girls for Wellness lessons, weekly groceries sent to home to create program's recipes, access to dance classes for 12 weeks.
45661640|NCT05396443|Behavioral|Black Girls for Wellness Caregivers|Caregivers of adolescents participating in Black Girls for Wellness will be encouraged to participate in the program's activities with their child. For example, they may help adolescent cook, or participate in the dance classes along with their child.
45454449|NCT01109797|Behavioral|Transition Social Behavioral Intervention|"If you are assigned to the first group, you will have two all-day Saturday sessions four weeks apart on the KU campus in Lawrence. The objectives of the Saturday programs are to promote positive behavior change with respect to taking ownership of diabetes and its demands by providing transition-specific information, enabling participants to practice the life skills needed to successfully manage diabetes as an adult, and fostering peer-to-peer social networking over the 6-month period of the intervention (and beyond). You will continue to see your current provider of diabetes care outside of the parameters of this study."
45454450|NCT01109797|Behavioral|Diabetes Transition Clinic|Patients who participate in the transition clinic arm of the study will be seen six times during a six-month time period, as well as receive psychological assessment and intervention, as necessary, prior to the first clinic visit (intake) and as part of visits 2 and 4. Three of the six visits will be standard of care medical visits with either a pediatric or adult provider or both. Three will be individual or group education sessions with diabetes educators focused on transition issues such as, managing the adult health care system, talking with your care provider,and dealing with adult issues (pregnancy, genetic concerns, etc).
45661641|NCT05396443|Behavioral|Control Caregivers|Weekly newsletter for adolescent and caregiver participants to attend public events in New York City for 12 weeks. Caregivers of adolescents in control group are encouraged to take their children to said events.
45661642|NCT02318667|Biological|Golimumab|Golimumab 50mg/0.5 mL in a single-use, ready-to-use autoinjector. Golimumab is a fully human anti-TNF (tumor necrosis factor) alpha monoclonal antibody that will be administered SC.
45661643|NCT02292771|Drug|Retosiban|Solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram/milliliter (mg/mL) in 56% volume/volume ethanol/acetate buffer concentrate supplied in 5 mL vial containing 75mg retosiban.
45816190|NCT02956070|Drug|Potassium Nitrate|The volunteers in the Potassium Nitrate Group (Placebo group) will receive 6 placebo capsules, who contained the same components of de dexamethasone drug except the active ingredient (starch [50%], lactose monohydrate [35%], dibasic calcium phosphate [14%], and magnesium stearate [1%]).Clinical session:1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A desensitizing gel containing 6% potassium nitrate will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
45816191|NCT02956616|Drug|ketorolac|Ketorolac, sold under the brand name Toradol among others, is a nonsteroidal anti-inflammatory drug in the family of heterocyclic acetic acid derivatives, used as an analgesic. It is considered a first-generation NSAID. Ketorolac acts by inhibiting the bodily synthesis of prostaglandins.
45454451|NCT03530644|Device|WM3.4NR|The investigational medical device will collect spectral Raman data from tissue.
45816192|NCT02956616|Other|Chewing Gum|Xylitol chewing gum will be provided to patients immediately after the procedure and will be provided 3 times per day for a duration of 30 minutes at each time, based on a metanalysis and systematic review. Patient's will be encouraged on its use for return of bowel function.
45454452|NCT03530644|Device|P0.1|The investigational medical device will collect spectral Raman data from tissue.
45816193|NCT02956616|Procedure|Enhanced Recovery Protocol|enhanced recovery protocol (detailed previously) will include several evidence-based recommendations including early ambulation, early diet initiation, early removal of urinary catheter, early removal of postoperative dressing and standing ketorolac for 24 hours postoperatively.
45816194|NCT02809183|Drug|Placebo|oral suspension
45816195|NCT02809183|Drug|TRC101|oral suspension
45816196|NCT02958956|Drug|Pioglitazone|Participants with diabetes who were members of the KPNC registry, and had received at least 2 prescriptions for pioglitazone within a 6-month period were followed up to 15.5 years (1997-2012) in this observational study 1.
45816197|NCT02833922|Behavioral|Women using Dot to avoid pregnancy|Women who have chosen to use Dot to prevent pregnancy will be followed for 13 cycles to assess perfect and typical use of the Dynamic Optimal Timing method.
45816198|NCT02917447|Behavioral|DESTRESS-WV|This is an online intervention for PTSD tailored for women Veterans. The intervention is based on cognitive behavioral therapy (CBT). The goal of CBT is to help people recognize and address their thoughts and behaviors in positive ways with the aim of improving their ability to function as well as possible in their lives. Participants will be asked to log on to the website twice per week for about 30-60 minutes each time. Homework assignments will include stress management skills that participants will be asked to practice and apply. A study coach will call each participant once a week for 8 weeks for about 15 minutes to review their progress with the program.
45816199|NCT02917447|Behavioral|Phone Monitoring|A study coach will call participants once a week for 8 weeks for approximately 15 minutes. The coach will assess participants' PTSD symptoms and safety. She will encourage participants to use the time on the call to discuss any current life issues or problems that they would like. Active listening and rephrasing will be used, while teaching cognitive-behavioral strategies will be avoided.
45816200|NCT05829616|Drug|QLS12004|Subjects will be treated with different dose groups of QLS12004 according to the frequency and periodicity of administration as specified in the protocol, until disease progression or unacceptable toxicity.
45816201|NCT05829603|Drug|Dimethyltryptamin (DMT) & Harmine|Six varying doses of a fixed-combination formulation of Dimethyltryptamin (DMT) and harmine
45816202|NCT05829590|Diagnostic Test|Artificial intelligence assistant system|The artificial intelligence assistant system can automatically capture bowel segment images and prompt abnormal lesions based on speech recognition and deep learning.
45816203|NCT05829551|Drug|RAY1216 dose 1|RAY1216 dose 1 or Placebo
45816204|NCT05829551|Drug|RAY1216 dose 2|RAY1216 dose 2 or Placebo
45955423|NCT04830462|Drug|Isoniazid 300 Mg ORAL TABLET|Isoniazid 300 mg daily for 6 months
45816205|NCT05829551|Drug|RAY1216 dose 3|RAY1216 dose 3 or Placebo
45816206|NCT05829551|Drug|RAY1216 dose 4 &ritonavir|RAY1216 dose 4 &ritonavir or Placebo
45454453|NCT04258579|Behavioral|PROTECT with Technology Augmentation|PROTECT is a therapeutic intervention focused on treating victims of elder abuse who are experiencing depression. PROTECT therapy will be delivered through video. Participants will be provided with a mobile device (iPhone), and a wearable device (smart watch) that will track sleep, mood, steps, and heart rate.
45816207|NCT05829551|Drug|RAY1216 dose 5|RAY1216 dose 5 or Placebo
45816208|NCT05829551|Drug|RAY1216 dose 6|RAY1216 dose 6 or Placebo
45816209|NCT05829551|Drug|RAY1216 dose 7|RAY1216 dose 7 or Placebo
45816210|NCT05829551|Drug|RAY1216 dose 8|RAY1216 dose 8 or Placebo
45955424|NCT04829851|Device|PROTEIN Mobile App|All recruited user groups will be expected to use the PROTEIN app. During this study the subjects will be asked to visit the lab followed by at least 4 weeks usage of the PROTEIN app and then a final lab visit.
45955425|NCT04829851|Device|Expert Dashboard|Health care professionals (HCP) will be contacted via email and will also be invited to either attend the lab or meet with the researchers utilizing Zoom/ Microsoft teams to discuss the usage of the expert dashboard within the PROTEIN application.
45955426|NCT04827251|Dietary Supplement|Coffee|"Participants will receive Nespresso coffee maker Essenza model. The coffee Nespresso blend voluto will be provided (caffeinated and decaffeinated). The patients will have to take four cups of espresso per day (three cups a day for patients aged 65 and over)."
46078662|NCT02743026|Behavioral|FOXY|This study will evaluate an arts-based HIV prevention program, Fostering Open eXpression among Youth (FOXY) in the NWT, Canada that works with Northern and Indigenous youth to promote sexual health and reduce exposure to HIV/STI. FOXY explores sexual health, HIV/STIs, sexuality and healthy relationships with young women in the NWT. The program's goal is to use arts-based methods and peers to facilitate education and foster more open expression and communication regarding sexual health and sexuality. FOXY uses arts-based approaches in program delivery; for example, drama techniques are used to facilitate discussion and learning about healthy relationships and making positive choices in realistic sexual scenarios.
45816211|NCT05829551|Drug|RAY1216 dose 9|RAY1216 dose 9 or Placebo with high fat meal
45816212|NCT05829551|Drug|RAY1216 dose 10|RAY1216 dose 10 or Placebo with high fat meal
45816213|NCT05829538|Behavioral|SuJok|Data were obtained by applying the Su Jok Efficiency Visual Analog Scale (VAS), Functional and Emotional Dysmenorrhea (Painful Menstruation) Scale, and SF-36 Quality of Life Scale.
45816214|NCT05829538|Behavioral|Massage|Data were obtained by applying the Su Jok Efficiency Visual Analog Scale (VAS), Functional and Emotional Dysmenorrhea (Painful Menstruation) Scale, and SF-36 Quality of Life Scale
45816215|NCT05829525|Other|Evaluation of sleep quality, sleep duration, heart rate and step count|Evaluation of sleep quality with the Pittsburgh Sleep Quality Index Evaluation of sleep duration, heart rate, and step count with the Fitbit® Inspire 2 (Fitbit, Inc., San Francisco, California, USA) Evaluation of quality of life with the Nottingham Health Profile
45955427|NCT04804813|Drug|Cabozantinib|Cabozantinib tablets
45955428|NCT04797767|Drug|Cladribine|Given IV
45955429|NCT04797767|Drug|Cytarabine|Given IV
45454454|NCT03530566|Other|PnK® Method|A multidisciplinary program of weight loss based on diet (initially very low ketogenic diet), physical activity and emotional support
45454455|NCT03530566|Other|standard diet|standard low calorie diet for weight loss
45955430|NCT04797767|Drug|Mitoxantrone|Given IV
45955431|NCT04797767|Biological|Recombinant Granulocyte Colony-Stimulating Factor|Given subcutaneously
45955432|NCT04797767|Drug|Venetoclax|Given PO
45661644|NCT02292771|Drug|Atosiban|Clear, colorless solution for injection in a 0.9-mL vial containing 6.75 mg of atosiban. Clear, colorless concentrate for solution for infusion in a 5-mL vial containing 37.5 mg atosiban.
45816216|NCT05829486|Procedure|gastroscopy|anaesthetic management of ambulatory endoscopic procedures
45816217|NCT05829473|Other|Breathing Exercise Group|A total of 1 times day diaphragmatic breathing exercise will be made on 3 consecutive days (5 minutes diaphragmatic breathing exercise, 5 minutes relaxation exercise). Diaphragmatic breathing exercises will be performed at least 4 hours after the use of antiemetic drugs in the service. 20 minutes from the diaphragmatic breathing exercise application. Afterward, post-test data will be obtained using the Nausea-Vomiting Severity Evaluation Test During Pregnancy and Pregnancy-Related Anxiety scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
45955433|NCT04797403|Behavioral|Stepped-care protocol adapted from the SPRINT intensive-treatment algorithm|The core component of the intervention is protocol-based treatment using the SPRINT intensive BP management algorithm. Implementation strategies include dissemination of SPRINT study findings, team-based collaborative care and shared-decision making, blood pressure audit and feedback, home blood pressure monitoring, and health coaching.
45955434|NCT04787341|Drug|Regorafenib|"regorafenib administered until progression, unacceptable toxicity or patient's refusal followed after progression by panitumumab until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics:~previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept);~RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment;~RAS and BRAF wt ct-DNA at the time of screening."
45661645|NCT02292771|Drug|Placebo matching retosiban|A placebo infusion containing 0.9% sodium chloride (NaCl) matched for retosiban loading (bolus) dose and continuous infusion.
45661646|NCT02292771|Drug|Placebo matching atosiban|A placebo infusion containing 0.9% NaCl matched for the atosiban loading (bolus) dose and continuous infusion.
45661647|NCT04880187|Drug|AXA1125|AXA1125 administered BID with or without food
45661648|NCT04880187|Drug|Placebo|Matching Placebo administered BID with or without food
45661649|NCT02291913|Drug|Everolimus|
45661650|NCT02291913|Drug|Exemestane|Anti-estrogen therapy
45661651|NCT02291913|Drug|Tamoxifen|Anti-estrogen therapy
45661652|NCT02291913|Drug|Fulvestrant|Anti-estrogen therapy
45661653|NCT02291913|Drug|Anastrozole|Anti-estrogen therapy
45816218|NCT05829473|Other|Guided Imagery Group|10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service.10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service. Afterward, 20 minutes from the application post-test data will be obtained by using the Nausea-Vomiting Severity Assessment Test in Pregnancy and Pregnancy-Related Anxiety Scale-R2 scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
45816219|NCT05829460|Drug|Semaglutide|This medication is self-administered as a subcutaneous injection in the abdomen, thigh, or upper arm; injection site should be rotated when using the same body region.
45816220|NCT05829460|Drug|Placebo|This medication is self-administered as a subcutaneous injection in the abdomen, thigh, or upper arm; injection site should be rotated when using the same body region.
45816221|NCT05829460|Drug|Progestin|Released via the levonorgestrel-releasing IUD.
45816222|NCT05829460|Behavioral|Telemedicine behavioral weight intervention|Weekly telephone calls during the first month, biweekly during the next 5 months, and then monthly for the last 7 months (13 months total). Each telephone session will be 30 minutes long.
45816223|NCT05829447|Device|G-EYE 760 R endoscope|The G-EYE 760 endoscope consists of a standard last-generation colonoscope with a permanently integrated balloon, placed at the bending section of the endoscope, which can be gradually insufflated on-demand by the endoscopist through a pedal control. During the endoscope withdrawal the balloon flattens haustral folds, centralizes the colonoscope's optics and reduces bowel slippage, thus facilitating mucous inspection and polyp detection.
45661654|NCT02291913|Drug|Letrozole|Anti-estrogen therapy
45661655|NCT02291913|Drug|Toremifine|Anti-estrogen therapy
45661656|NCT02291679|Drug|Linaclotide|
45661657|NCT02291679|Drug|Matching Placebo|
45661658|NCT02291601|Drug|Chlorhexidine Gluconate|comparison with other CHG products
45661659|NCT02291601|Other|Vehicle|Excipients of CHG product only.
45661660|NCT02291601|Drug|DynaHex-2|2% CHG solution
45661661|NCT02360475|Biological|RSV vaccine GSK3003895A (formulation 1)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
45661662|NCT02360475|Biological|RSV vaccine GSK3003898A (formulation 2)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
45661663|NCT02360475|Biological|RSV vaccine GSK3003899A (formulation 3)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
45661664|NCT02360475|Biological|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
45661665|NCT02360397|Drug|ranolazine|Ranolazine 1000 mg tablet twice daily for 30 days
45816224|NCT05829434|Drug|Magrolimab|Patients will receive magrolimab on day 1; 4: IV 1 mg/kg; day 8: IV 15 mg/kg; day 11, 15 and 22: IV 30 mg/kg (plus 30 mg/kg for 5 weeks weekly and then q2w until the end of consolidation)
45454456|NCT03942055|Device|Sonosite Edge II Ultrasound|Certified by UAB Biomedical and Clinical Engineering Dept- certification #9365 Mechanism of Action: Point of Care Bedside Ultrasound
45454457|NCT03133702|Other|Forensic cases|Forensic cases which were admitted to the Emergency Department
45454458|NCT01112839|Behavioral|Less Intensive|Participants in this group would receive print materials on diet and exercise and two individual counseling sessions; one at the beginning of the study and another 6 months later.
45454459|NCT01112839|Behavioral|Intensive Group|Participants in this group would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
45454460|NCT00267280|Drug|torcetrapib/atorvastatin|
45454461|NCT00267280|Drug|simvastatin|
45454462|NCT03943069|Procedure|Thoracoscopic bullectomy alone|Thoracoscopic stapling of emphysematous like changes (ELCs) to control the air leak from the lung bullae.
45454463|NCT03943069|Procedure|Thoracoscopic bullectomy with pleurodesis|Thoracoscopic stapling of emphysematous like changes (ELCs) to control the air leak from the lung bullae.in addition to mechanical pleurodesis.
45454464|NCT04252495|Drug|Aprocitentan|A single oral dose of 25 mg.
45816225|NCT05829434|Drug|7+3|"Patients will receive during Induction cycle 1: cytarabine at 100 mg/m² on study days 1-7 as a continuous infusion over 22-24 hours and daunorubicin at 60 mg/m² on study days 3, 4, 5~optional during Induction cycle 2: cytarabine at 100 mg/m² on days 1-7 of the second induction cycle (i.e. study days 29-35) as a continuous infusion over 22-24 hours and daunorubicin at 60 mg/m² on days 3, 4, 5 of the second induction cycle (i.e. study days 31, 32, 33)~optional during Consolidation cycle: cytarabine at 1 g/m² administered on days 1, 3, 5 of each consolidation cycle as an infusion for 2 hours every 12 hours (for patients < 60 years up to 3 CONS cycles and for patients ≥ 60 years up to 2 CONS cycles)"
45454465|NCT01109875|Other|blood test|Dry blood spots (DBS) analysis of a- galactosidase-A activity will be used for male patients' diagnosis. Males and females with enzymatic activity bellow the test's cut-off will be further diagnosed by gene sequencing. Since females are heterozygote and may have high residual levels of active enzyme, female patients with a- galactosidase-A activity of 30% bellow averaged normal range will also be further diagnosed by gene sequencing as described before (8).
45661666|NCT02317809|Drug|Liquid pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Liquid Pergoveris) as subcutaneous injection using a disposable pen-injector on Day 1 in either first intervention period or second intervention period.
45955435|NCT04787341|Drug|Panitumumab|"panitumumab administered until progression, unacceptable toxicity or patient's refusal followed after progression by regorafenib until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics:~previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept);~RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment;~RAS and BRAF wt ct-DNA at the time of screening."
45955436|NCT04781972|Drug|Methylphenidate|single dose of 10 mg or 15 mg
45955437|NCT04781972|Drug|Placebo|Matching placebo
45955438|NCT04779684|Other|Advance care planning by proxy for health care proxies of people without medical decision making capacity|Two discussions between a trained health professional and a health care proxy of an RACF resident who no longer has decision making capacity. First discussion focuses on life story, values, previous experiences with medical treatments, illness and death. Second discussion also includes treating physician and focuses on establishing general goals of care and medical orders in case of emergency.
45955439|NCT04776473|Procedure|Open treatment|Open (i.e. surgical) treatment will be performed following the usual practice of the including centre adopting a pragmatic approach.
45454466|NCT03530488|Drug|Lidocaine|intrauterine and intracervical instillation of 4 ml of lidocaine 2% diluted in 15 ml normal saline
45454467|NCT03530488|Procedure|Office hystroscopy|A rigid 3.5 mm hystroscope with an optic of 30 degrees was used. Normal saline solution was used as distension media, with 120 mmHg intrauterine pressure, Vaginoscopic approach, nocervical tenaculum or dilators used.
45454468|NCT02529709|Other|High-Protein Condition|The participants will be fed a high-protein meal
45816226|NCT05829434|Drug|CPX-351|"Patients will receive during Induction cycle 1: CPX-351 with daunorubicin 44 mg/m² and cytarabine 100 mg/m² on days 1, 3, 5~optional during Induction cycle 2: CPX-351 with daunorubicin 44 mg/m² and cytarabine 100 mg/m² on days 29 + 30~optional during Consolidation cycle: CPX-351 with daunorubicin 29 mg/m² and cytarabine 65 mg/m² on days 1, 3"
45816227|NCT05829395|Other|metaverse- based education|"The nursing process course will be conducted in a metaverse environment. A virtual classroom is designed in the metaverse space for the execution of this course.~Starting from the week following the pre-test application, online training will continue according to the Metaverse-based for a total of 3 weeks, two hours a week, for the intervention group. At the end of the 3 weeks, the Instructional Materials Motivation Scale and Self-Confidence Scales will be re-administered as a post-test."
45454469|NCT02529709|Other|High-Monounsaturated Fat Condition|The participants will be fed a high-monounsaturated fat meal
45454470|NCT05202028|Other|Reflexology|After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
45955440|NCT04776473|Other|Closed treatment|Closed (i.e. conservative) treatment will be performed following the usual practice of the including centre adopting a pragmatic approach.
45955441|NCT04776291|Radiation|4D PET-CT Scan|The recruited patients will have a 4d PET-CT scan that is additional to the usual care.
45955442|NCT04775381|Drug|Vitamin D|Patients will receive a cholecalciferol supplementation added to a fruit juice.
45955443|NCT04770181|Device|Alpha-Stim AID CES (Active Comparator)|The Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
45661667|NCT02317809|Drug|Freeze-dried pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in either first intervention period or second intervention period.
45661668|NCT02359851|Biological|Pembrolizumab|Given IV
45661669|NCT02359851|Other|Laboratory Biomarker Analysis|Correlative studies
45816228|NCT05829382|Dietary Supplement|DailyColors™|Capsule containing active ingredient administred daily by the participant during the trial period
45661670|NCT01607905|Drug|Selinexor|Participants in this study will receive selinexor orally at dose levels specified for their respective dose cohorts. Dosing will begin at 3 mg/m^2 twice a week and will escalate until the MTD or RP2D is determined. Cycles will be repeated in 4-week (28 days for schedule 1 to 7) and 3-week (21 days for schedule 8) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
45661671|NCT01607905|Drug|Acetaminophen|Oral 500 mg (in Cycle 1, Week 1) to 1000 mg (in Cycle 1, Week 2 and onwards) of acetaminophen will be administered 1 hour prior to each selinexor dose up to 8 doses per cycle (28 days per cycle)
45661672|NCT02389543|Drug|Selinexor|Two different dosing schedules will be tested, once weekly and twice weekly. If the selinexor 80 mg dose is tolerated, the dose will be increased to 100 mg.
45661673|NCT02389543|Drug|Lenalidomide|In both arms, lenalidomide will be started at 15 mg/day (Dose Level 1) and, if tolerated per DLT criteria, will be escalated to 25 mg/day (Dose Level 2).
45661674|NCT02389543|Drug|Dexamethasone|"Dexamethasone will be given in combination with each dose of selinexor on the once weekly treatment arm.~For the twice weekly arm dexamethasone will be given in combination with each dose of selinexor and will also be given without selinexor on Days 22 and 24."
45661675|NCT02536963|Device|Pediatric Vision Scanning device|The Pediatric Vision Scanner (PVS) performs a 3-second, non-invasive scan of both eyes simultaneously while a child looks at a single target. The scan will measure the frequency of the light waves that reflect off of the participants' eyes to determine the fixation state of the eye.
45661676|NCT02536963|Other|Reference examination|Reference examination of the eyes will be performed by a fellowship-trained pediatric ophthalmologist.
45661677|NCT05441605|Other|Effects of Chlorhexidine Solutions with Different Concentrations in Preventing Peripheral Venous Catheter-Associated Infections|Chlorhexidine solution in different concentrations (1%, 2%, 4%) will applied to the 3 determined experimental groups, and 70% alcohol solution will applied to the control group. Its effects in preventing peripheral venous catheter-associated infection will compared.
45661678|NCT00843037|Drug|Sunitinib|50 mg oral dose daily for 4 weeks, 2 week rest period (repeating 6 week cycles)
45816229|NCT05829382|Dietary Supplement|Placebo|Capsule containing placebo administered daily by the participant during the trial period
45816230|NCT05829369|Other|Intrinsic foot muscle strengthening exercises|participants will perform specific toe and foot motions that recruit plantar intrinsic foot muscles, 3 sets of 10 for each exercise, 5 days per week
45816231|NCT05829369|Other|Minimal footwear with prescribed walking|Participants will be provided minimal footwear. They will walk 30 minutes per day, 5 days per week, and be prescribed a gradual increased time in minimal footwear during daily activities (up to a maximum of 7.5 hours per day).
45816232|NCT05829369|Other|Control|Participants will perform seated upper and lower extremity active range of motion activities 5 days per week. They will also be given a brochure on fall prevention tips.
45816233|NCT05829343|Procedure|Laparoscopic Left colectomy|Patients are treated with a laparoscopic approach as the standard of care for the treatment of left-sided colonic diverticular disease, depending on the experience of the surgeon or institution.
45816234|NCT05829343|Procedure|Robotic left colectomy|Patients are treated with a robotic approach as the standard of care for the treatment of left-sided colonic diverticular disease, depending on the experience of the surgeon or institution.
45816235|NCT05829330|Other|Outpatient|Outpatient Initiation of noninvasive mechanical ventilation
45454471|NCT05202028|Other|Connective Tissue Massage|After the physical therapy applied to the patient by the physiotherapist in the special education center, 3 days a week for 8 weeks, once a day for approximately 15-20 minutes. Connective tissue massage will be applied. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
45816236|NCT05829330|Other|Hospitalization|Initiation of non-invasive mechanical ventilation during hospitalization
45816237|NCT05829317|Drug|Magnesium sulfate|Intravenous Magnesium sulfate
45816238|NCT05829317|Drug|Placebo|0.9% NaCl
45454472|NCT05202028|Other|Classic abdominal massage|After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
45661679|NCT05392543|Other|Brunnstrom movement therapy.|"Group A: Will be treated with Brunnstrom movement therapy for three days in a week for four weeks (1 h) approximately 12 sessions to every subject.~Subjects received Brunnstrom hand manipulation (BHM) and conventional occupational therapy for the upper extremity and lower extremities. The detailed BHM is applied on hand. The major goal of the BHM was the acquisition of mass grasp and mass release of objects. Once the goal was achieved, more prehensile activities were focused. Reflexive, passive, synergistic and active movements were used sequentially to enhance the hand recovery."
45661680|NCT05392543|Other|Mirror Therapy|"Group B: Will be treated with Mirror therapy 45 minutes, for three days in a week for four weeks approximately 12 sessions to every subjects.~First 30 minutes therapy consists of conventional therapy as given conventional tasks only with the affected upper extremity. 15 minutes were continued with mirror. Mirror is placed in front of the midline of the patient so that the affected limb is fully covered by the mirror and the reflection of the unaffected limb is fully visible. The affected limb positioned in a safe and comfortable position behind the mirror. The non-affected limb should be positioned in a similar position as the affected limb, as this facilitates the intensity of the mirror illusion. Patients in the experimental group received 45 minutes of consecutive session."
45661681|NCT00602641|Other|Laboratory Biomarker Analysis|Optional correlative studies
45661682|NCT00602641|Drug|Lenalidomide|Given PO
45661683|NCT00602641|Drug|Melphalan|Given PO
45816239|NCT05829304|Other|MTA based pulpotomy|The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A&B will be at the same patient.
45816240|NCT05829304|Other|Collagen based pulpotomy|The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A&B will be at the same patient.
45816241|NCT05829291|Device|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
45955444|NCT04770181|Device|Alpha-Stim AID CES (Sham Comparator)|The Alpha-Stim® AID CES sham device is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
45955445|NCT04760275|Drug|Fluoxetine|"This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of the medication fluoxetine in upward-titrated dosages. In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with fluoxetine. All participants who do not remit will be randomized (1:1) to either (1) optimization of fluoxetine (increasing the dose of fluoxetine as tolerated), or (2) optimization of fluoxetine and addition of Cognitive Behavioral Therapy (CBT)."
45816242|NCT05829278|Procedure|Acupuncture|Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu), ST36(Zusanli ), KI3 (Taixi), and etc.
45454473|NCT03945253|Drug|ASP8374|Intravenous
45454474|NCT00262990|Drug|EPO906 (Patupilone)|
45454475|NCT00262990|Drug|doxorubicin|
45454476|NCT01108159|Procedure|Blood Draw|
45661684|NCT00602641|Drug|Prednisone|Given PO
45955446|NCT04760275|Behavioral|Cognitive Behavioral Therapy (CBT)|"This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of weekly CBT implemented with Coping Cat (CC). In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with CBT. All participants who do not remit will be randomized (1:1) to either (1) optimization of CBT (intensifying exposure practice and skills review), or (2) optimization of CBT and addition of the medication fluoxetine."
45955447|NCT04742491|Drug|Immediate Intervention Arm Truvada in the US|Truvada in the United States
45955448|NCT04742491|Drug|Deferred Intervention Arm Truvada in the US|Truvada in the United States
45454477|NCT01108159|Procedure|Skin Biopsy|
45454478|NCT01112995|Dietary Supplement|Lactobacillus rhamnosus|1 pill formulation to be given once a day for 4 weeks
45454479|NCT01112995|Dietary Supplement|Sugar pill (placebo)|placebo identical to the active product will be given
45454480|NCT01207843|Behavioral|Imaging|CT image validation and lesion measurement, as well as comparison of different CT phases
45661685|NCT00602641|Other|Quality-of-Life Assessment|Ancillary studies
45661686|NCT00602641|Drug|Thalidomide|Given PO
45454481|NCT03942523|Behavioral|Behavior Change Communication to promote hygiene behavior|"Behavior Change Communication sessions will be used to promote knowledge and practices among young children and to prevent communicable diseases.~This will include, capacity building of teachers and students, health awareness sessions at the school and improving school physical environment"
45454482|NCT01108315|Other|Report symptoms via web or phone-based system|The participant reports their symptoms at least twice a week via the phone or web-based prototype system.
45454483|NCT03941821|Drug|Glecaprevir/Pibrentasvir|Chronic hepatitis C patients will be given Glecaprevir/Pibrentasvir treatment
45454484|NCT01210183|Drug|Dextrose intraarticularly administered|9 ml of 12.5% dextrose
45454485|NCT01210261|Device|Compumedics Somnilink SPAP - Auto-titrating CPAP|"Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carryover effect.~Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.~All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment."
45661687|NCT05414773|Other|measurement of axial length and keratometry by sonographers with a topographic module|measurement of axial length and keratometry by sonographers with a topographic module
45661688|NCT05441527|Device|MI Paste, then, Biotene Dry Mouth Gel|1 milliliter of product will be applied daily to the intaglio (i.e., underside) of the patient's removable prosthesis and seated intraorally.
45661689|NCT05441527|Device|Biotene Dry Mouth Gel, then, MI Paste|1 milliliter of product will be applied daily to the intaglio (i.e., underside) of the patient's removable prosthesis and seated intraorally.
45661690|NCT05391919|Other|Multimodal technology (MT)|"Patients will receive a course of rehabilitation with multimodal correction using BOS-stabilometric training, cognitive-motor training with double and triple tasks once a day for the affected hand, virtual reality, functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator SensoRehab, in moderate paresis of the upper limb, the neurointerface Exokist-3 with EEG registration will be used. The program for IS patients includes 15 sessions with the MT: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours."
45955449|NCT04742491|Drug|Immediate Intervention Arm Truvada in Brazil|Truvada in Brazil
45454486|NCT01210261|Device|Resmed Autoset S8 - Auto-titrating CPAP|"Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carry-over effect.~Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.~All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment."
45454487|NCT01109953|Other|Breath-Hold PET/CT image set|In addition to the standard clinical PET/CT images, we will provide a breath-hold PET/CT image set, using the same PET data for both. In order to spatially match PET, and therefore improve attenuation correction in the PET images, we will acquire a Breath-Hold CT at 310 mA over the same region covered by PET. The normal-organ doses accumulated from the additional 30 mA CT. The patient's breathing signal during CT and the whole body PET will be recorded using a video camera and in house developed software. We will compare the clinical PET/CT and Breath-Hold PET/CT in regards to lesion detection, lesion volume, and SUV quantification.
45454488|NCT01110031|Biological|Ofatumumab|Anti-CD20 monoclonal antibody
45661691|NCT05391919|Other|Conventional rehabilitation (CR)|The patients will recieve Conventional rehabilitation technology (physiotherapy, kinesiotherapy, occupational therapy. The program for IS patients includes 15 sessions with the CR: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours.
45816243|NCT05829265|Behavioral|A digital social intervention by primary care clinicians.|"The intervention in this study will involve a structured consultation with a primary care clinician (e.g. a general practitioner (GP) or practice nurse) to promote online peer support, followed by engagement with the OHC of the Asthma + Lung UK (ALUK) charity. The intervention will either be delivered in person (in the general practices) or virtually. The aim is for the intervention to involve a face-to-face, one-off consultation, lasting approximately 30 minutes, during which a primary care clinician will:~Signpost and sign patients up to the ALUK OHC, by thoroughly explaining terms of conditions of use and providing log in details.~Introduce norms and values for passive (just reading) and active (writing OHC posts) participation.~Encourage seeking and offering self-management information and support, by emphasising that the OHC could be used ad hoc (e.g. when feeling unwell, or when there are information or emotional needs)."
45816244|NCT05829239|Biological|ADI-PEG20|Intramuscular injection weekly for 8 weeks
45816245|NCT05829239|Other|Placebo|Intramuscular injection weekly for 8 weeks
45955450|NCT04742491|Drug|Deferred Intervention Arm Truvada in Brazil|Truvada in Brazil
45955451|NCT04742491|Drug|Immediate Intervention Arm Descovy in the US|Descovy in the United States
45955452|NCT04742491|Drug|Deferred Intervention Arm Descovy in the US|Descovy in the United States
45955453|NCT04733053|Other|Diet plus exercise|"The diet program has two phases: 1) intensive weight loss through a ketogenic very low calorie diet VLCD, and 2) transition from ketogenic VLCD onto a healthy eating plan for weight maintenance. Meal replacements will be provided to participants free of charge from the start of the trial to a maximum of 14 weeks (12 weeks for the ketogenic diet and 2 weeks for transition). If a participant does not wish to transition off the ketogenic diet after 14 weeks but wants to continue or if they wish to recommence the ketogenic diet any time after week 14 they will need to purchase meal replacements themselves at their own cost.~Participants will be encouraged to aim to lose at least 10% body weight."
45955454|NCT04733053|Other|Exercise|The trial coordinator will have provided participants with educational material about OA, handouts of home exercises including photographs and descriptions, a logbook for recording home program completion and resistance exercise bands ahead of their first appointment. Physiotherapists will prescribe 5-6 strengthening exercises from a pre-determined list to be performed at home three times/week, including two quadriceps exercises, one each for hip abductors, hamstrings and calf, and any other as appropriate. Review and modification will occur at each consultation to maintain moderate intensity (effort of ≥5 out of 10 (hard) on a modified Borg Rating of Perceived Exertion scale). The physiotherapist will also prescribe a personalised physical activity plan in collaboration with the participant that is supported and progressed over time.
45661692|NCT05440435|Diagnostic Test|digital radiography (DR)|Patients with bone injury received routine and mobile DR sequential examination.
45661693|NCT05413447|Combination Product|Digital consult|Consultations will be prepared digitally using the Mychart patient portal, an elearning and questionnaires. The consultation takes place via Teams.
45661694|NCT05440045|Drug|6MW3211|6MW3211 injection, 30mg/kg, Q2W
45661695|NCT02531035|Drug|Sotagliflozin|Sotagliflozin, once daily, before the first meal of the day
45661696|NCT02531035|Drug|Placebo|Placebo, once daily, before the first meal of the day
45661697|NCT05389657|Behavioral|Web-based training|Web-based training will be divided into training modules that will be completed by participants over the course of 6-8 weeks. Training will include didactic training videos, knowledge checks, example sessions, and a library of resources.
45661698|NCT05389657|Behavioral|Live training|The live training will be delivered by two trainers over the course of two days via Zoom.
45816246|NCT05829213|Procedure|"arch-bridge-type esophagogastric reconstruction after proximal gastrectomy"|"The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines~Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.~Creating the seromuscular flap (arch-bridge)~The remnant stomach is then inserted into the abdominal cavity, and pneumoperitoneum is re-established to perform the intracorporeal anastomosis."
45816247|NCT05829200|Device|Transcranial Doppler (TCD)|All individuals who are consented for elective or urgent carotid endarterectomy would be eligible to participate. If patient gives consent, they would undergo an approximately 30-60 minute TCD study. We will collect the number of high intensity transient signals (HITS). The patient would undergo surgery regardless of the TCD result.
45955455|NCT04721873|Drug|Phentermine-Topiramate|Patients will be randomized to either once-daily, oral phentermine-topiramate 15-92mg or placebo, in a 1:1 fashion, for 22 weeks, with clinic visits with an obesity medicine specialist, for intensive counseling for diet and lifestyle intervention. All patients will be dose-titrated within the first 4 weeks, starting at phentermine-topiramate 3.75-23mg, or placebo. Dose titration will be performed as follows 3.75-23mg x 1 week --> 7.5-46mg x 1 week --> 11.25-69mg x 1 week --> 15-92mg. Patients who experience side effects would undergo slower titration, and dose would be down-titrated and capped at highest tolerated dose.
45955456|NCT04721873|Drug|Placebo|Matching placebo, titrated as active intervention
45661699|NCT05389111|Other|Internal discourses|This intervention will take place following the randomization performed at the V1 visit. It will be held in videoconference, will be led by a professional of the training field, specialist of the trail activity and trained in the use of mental strategies
45955457|NCT04721015|Drug|ABBV-637|Intravenous (IV) Infusion
45661700|NCT05389111|Other|Non internal discourses|This intervention will take place following the randomization performed at the V1 visit. It will be held in videoconference, and will be conducted by a professional of the training field, specialist of the trail activity and coach of mountain guide
45661701|NCT05387395|Other|NO intervention|no intervention
45955458|NCT04721015|Drug|Docetaxel|Intravenous (IV) Infusion
45661702|NCT05386771|Dietary Supplement|Whey/collagen protein blend|Ingestion of 30g of protein dissolved in 300ml water consumed after an exercise session
45955459|NCT04721015|Drug|Osimertinib|Oral Tablets
45955460|NCT04717388|Other|acoustics tests, Questionaries,|"acoustics tests at V1 Questionaries at V1~cognitive~emotional~auditory"
45955461|NCT04717388|Radiation|MRI|Anatomical and functional MRI at V2
45955462|NCT04707248|Drug|DS-6000a|Intravenous administration at doses starting at 1.6 mg/kg on Day 1 of Cycle 1
45661703|NCT05386771|Behavioral|Resistance exercise|A single resistance exercise session of the leg press and leg extension exercise
45816248|NCT05829161|Behavioral|no intervention|no intervention
45955463|NCT04707248|Drug|DS-6000a|Intravenous administration at RDE on Day 1 of Cycle 1
45955464|NCT04701086|Device|Cationorm Pro|Eye Drops
45955465|NCT04701086|Device|Vismed|Eye Drops
45955466|NCT04685109|Device|Alocross 0.2% Unit Dose|Eye Drops
45955467|NCT04685109|Device|Vismed|Eye drops
45955468|NCT04681274|Device|Image features extraction and clustering|"The image processing operations required for local content-based image feature extraction consist of two main tasks: 1) tiling the images in smaller VOIs, typically a small cube, whose size depends on the modality, on the image resolution and on the purpose of the content-based query, and 2) performing feature extraction operations on the VOIs.~The Feature Extraction Engine performs totally unsupervised, automatic and asynchronous extractions of features from the images, organizes and indexes them in a no-SQL database based on unique similarity metric. The results of this phase are a series of clusters of phenotype signatures."
45661704|NCT05004805|Drug|Methylene Blue|MB administered topically as a 0.02% solution nasal spray in COVID-19 patients requiring hospitalization.
45661705|NCT05004805|Drug|Saline nasal spray|Saline administered topically as nasal spray in COVID-19 patients requiring hospitalization.
45955469|NCT04681274|Device|Phenotype signature database building|Since the clusters are self-organizing their pathophysiological meaning is not readily apparent and requires further analysis. The characterization of each cluster is performed by analyzing representative samples and their respective correlation with histopathology results. After a series of iterations, the clusters are organized to correlate with distinct tissue subtypes identified by their signature similarity. The final number of clusters is not known a priori and depends on the heterogeneity of the underlying imaging phenotypes.
45661706|NCT05412745|Device|Kaloidon Plus|topical application; twice daily
45955470|NCT04679389|Drug|Placebo|administered orally or enterally
45955471|NCT04679389|Drug|Acetazolamide|administered orally or enterally
45955472|NCT04645589|Drug|Myfortic|There is no treatment allocation. Patients administered Myfortic by prescription that have started before inclusion of the patient into the study will be enrolled.
45955473|NCT04644016|Drug|Clofarabine|Clofarabine 30 mg/m2
45955474|NCT04644016|Drug|Fludarabine|Fludarabine 10 mg/m2
45816249|NCT05829148|Drug|Dexmedetomidine|Comparison the effect of Dexmedetomidine, Melatonin and Pregabalin on hemodynamics, recovery profile and postoperative pain in patients undergoing Functional endoscopic sinus
45816250|NCT05829148|Drug|Melatonin|Melatonin
45955475|NCT04644016|Drug|Busulfan|Busulfan per PK
45955476|NCT04644016|Drug|Cyclosporine-A|GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.
45816251|NCT05829148|Drug|Pregabalin|Pregabalin
45816252|NCT05829148|Drug|Placebo|Placebo
45816253|NCT05829122|Procedure|Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage Pupilloplasty|In this study, patients with various causes of pupillary dilatation were recruited, and medical records and ophthalmology examinations, including slit-lamp examination, visual acuity, corrected visual acuity, intraocular pressure, pupil diameter, pupil area, corneal endothelial cell count fundus examination, and photophobia score, were collected. Those who met the recruitment criteria underwent modified iris cerclage. The modified iris cerclage was performed by making four clear corneal incisions, suturing the iris 3-4 times consecutively between each two incisions, completing 360 degrees of iris suturing in sequence, and finally tying the knot intraocularly to complete the iris cerclage.
45816254|NCT05829109|Drug|Fecal Microbiota Transplant (FMT)|"The intervention consists of the following steps:~Step 1: Vancomycin 125 mg orally every 6 hours and metronidazole 250 mg orally every 6 hours for 5 days.~Step 2: Bowel preparation with 10 ounces of magnesium citrate.~Step 3: Two FMT doses will be administered via enema one week apart using stool from donors with a durably healthy pouch."
45955477|NCT04644016|Drug|Mycophenolate Mofetil|GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.
45955478|NCT04644016|Biological|Cord Blood Graft|The CB graft will be infused on day 0 per standard practice
45955479|NCT04634916|Device|EndoAVF Creation|Subjects will have an endoAVF created using the WavelinQ EndoAVF System
45661707|NCT05412745|Device|silicone gel|topical application; twice daily
45661708|NCT04261387|Drug|LUT014 Gel|Topical application qd for 28 days
45661709|NCT04261387|Drug|Placebo for LUT014 Gel|Matching placebo for qd topical application for 28 days
45661710|NCT05412199|Device|Percussion Massage Therapy|Individuals in the percussion massage therapy group will get 3 minutes of percussion massage therapy on the hamstring and gastrocnemius muscles along the origo-insertion in the mid-frequency range.
45661711|NCT05412199|Device|Graston|Instrument-assisted soft tissue mobilization will be used on the hamstring and gastrocnemius muscles along the 5-minute origo insertion line in the Graston group.
45955480|NCT04634162|Drug|Cangrelor|Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The duration of cangrelor/placebo infusion will be 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
45661712|NCT05412199|Other|Dynamic Stretching|Dynamic stretching exercises for the hamstring and gastrocnemius muscles will be performed in the dynamic stretching exercise group.
45454489|NCT02741596|Drug|DX-2930|Participants who rollover from the DX-2930-03 study will receive 300 milligram (mg) DX-2930 subcutaneous injection at Day 0 followed by second dose following the first HAE attack and then once in every 2 weeks until the end of the treatment period (up to 924 days). A wash-out period of a minimum of 10 days and a maximum of 18 days is required between subsequent administrations.
45661713|NCT05411965|Drug|BR3003(T)|"Test drug (T):BR3003 Boryung Pharmaceutical Co., Ltd."
45661714|NCT05411965|Drug|BR3003B(R1)|"Reference drug 1 (R1): BR3003B of Celltrion Pharm, Inc."
45454490|NCT02741596|Drug|DX-2930|Participants who were not participants in DX-2930-03 will receive 300 milligram (mg) DX-2930 subcutaneous injection once in every 2 weeks until the end of the treatment period (up to 924 days).
45816255|NCT05829096|Other|The COMBINED approach|"Patient-level intervention:~Assessment of existing lifestyle factors (smoking status, physical activity levels, and weight) that may be relevant to shoulder pain;~Brief intervention to support health behaviour change: smoking cessation, increasing physical activity levels and consuming a healthy diet~Supporting tools for behaviour change, including an activity workbook for goal-setting and a diary for self-monitoring.~Clinician-level implementation toolkit:~Training package including a face-to-face workshop, training manual, recorded role play simulations and an online follow-up training session~Additional supporting resources; a step-by-step guide to The COMBINED approach, scripts, patient signposting information to support services and a lay summary infographic to explain the links between the health behaviours and RC disorders to patients~Audit and feedback via observations of consultations to address any 'drift' from the intervention delivery as intended"
45454491|NCT01110265|Behavioral|attention training|
45454492|NCT01110265|Behavioral|placebo training|
45661715|NCT05411965|Drug|BR3003C(R2)|"Reference drug 2 (R2): BR3003C of AstraZeneca Korea"
45454493|NCT03941665|Device|Gelronate|Gel for topical use
45816256|NCT05829083|Device|Asymmetric nasal cannula - DUET|"DUET asymmetric nasal high flow interface that fits best to the patients' nostrils (size: one nostril of the patient should be fully occluded)~Patients will be crossed-over between the 2 interventions"
45454494|NCT03941665|Other|Aloevera|Gel for topical use
45661716|NCT04261075|Biological|IPH5201|Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years
45661717|NCT04261075|Biological|durvalumab|Durvalumab Q3W for a maximum of 2 years
45661718|NCT04261075|Biological|oleclumab|Oleclumab Q3W for a maximum of 2 years
45661719|NCT04452019|Device|Use of standard standing frame|Two training sessions in a standard standing frame, max 30 min. pr. session
45661720|NCT04452019|Device|Use of a new device; Innowalk Pro|Two training sessions in Innowalk Pro, max 30 min pr. session
45661721|NCT04451473|Procedure|Enhanced Recovery After Surgery (ERAS )|the treatment of procedure according to Guidelines for enhanced recovery after lung surgery: recommendations of the ERAS Society and the ESTS
45816257|NCT05829083|Device|Conventional nasal high flow cannula|"Well-established conventional nasal high flow cannula (size: medium)~Patients will be crossed-over between the 2 interventions"
45955481|NCT04634162|Drug|Placebo|Normal saline will be infused for 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
45955482|NCT04630860|Drug|LY03003|Rotigotine,extended-release microspheres
45454495|NCT05720728|Diagnostic Test|collection of blood samples|For each patient, a serum sample collected at the time when candidemia is suspected (time of execution of blood cultures) will be examined. For patients with candidemia, all serum samples taken during infection follow-up will also be examined.
45454496|NCT01210339|Drug|Clopidogrel|Clopidogrel
45454497|NCT01210339|Drug|Esomeprazole/ASA|20 mg/81 mg once daily for five days (Day 5-9)
45454498|NCT03684694|Drug|Loncastuximab Tesirine|Intravenous (IV) infusion.
45661722|NCT04451473|Procedure|Traditional perioperative management without Enhanced Recovery After Surgery (ERAS )|the treatment of procedure not abiding Guidelines for enhanced recovery after lung surgery
45661723|NCT05438485|Other|Registry|Observational (Registry)
45661724|NCT05438017|Device|Dreem 3 System vs PSG|Dreem 3 System to be worn by each participant while undergoing in-lab sleep study with PSG.
45454499|NCT03684694|Drug|Ibrutinib|Oral capsule.
45454500|NCT03147248|Biological|CT-P13|CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks
45454501|NCT03147248|Biological|CT-P13|CT-P13 (90 mg) by single SC injection every other week
45454502|NCT03147248|Biological|CT-P13|CT-P13 (120 mg) by single SC injection every other week
45454503|NCT03147248|Biological|CT-P13|CT-P13 (180 mg) by double SC 90 mg injections every other week
45454504|NCT03147248|Biological|CT-P13|CT-P13 (120 mg) by single SC injection every other week with placebo IV at Weeks 6, 14 and 22.
45454505|NCT03147248|Biological|CT-P13|CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks with placebo SC at Week 6 and every other week thereafter up to Week 28
45816258|NCT05829070|Behavioral|CHAT-S|The CHAT-S intervention will include 4 videoconference sessions over a 2-month time period that is delivered by a patient navigator. Session 1 will include content to educate participants about survivorship care and common types of follow-up care required for their specific cancer, as well as, basic insurance terms and concepts. Session 2 will teach participants about their own insurance plan (e.g., coverage, benefits, breakdown of bills, and explanation of benefits) so they can better navigate both the medical and insurance systems. Session 3 reviews health insurance laws (e.g., ACA, FMLA, No Surprises Act) and how to proceed with an appeals process. Session 4 explains how to manage the costs through budgeting and cost-of-care conversations with their medical providers.
45816259|NCT05829070|Behavioral|Usual Care|Usual care will consist of a resource list that describes organizational and community resources available on insurance, financial burden, and survivorship care. Further, we will track whether participants were referred or engaged in services using the follow-up surveys and via the EHR/claims data.
45955483|NCT04617522|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
45454506|NCT03945097|Behavioral|preK|Subjects enter and education program that either focuses on learning letters and their corresponding sounds or on language comprehension skills.
45816260|NCT05829057|Biological|Intravenous injection of P-IL-2|Ia :Single dose intravenous injection of P-IL-2；
45454507|NCT01113073|Other|ventilatory protocol|Ventilatory protocol for short period with four different tidal volumes (12 min)
45454508|NCT01113073|Other|Elastic band|Placement of an elastic band around thorax to reduce thorax compliance
45454509|NCT01113073|Other|passive leg raising test|performing the passive leg raising test
45661725|NCT05436769|Drug|Klaribact 500 mg Clarithromycin Tablet|A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
45661726|NCT05436769|Drug|Klaricid 500 mg Clarithromycin Tablet|A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
45661727|NCT05378737|Drug|BAT8006 for Injection|Intravenous infusion, once every 3 weeks (Q3W), the recommended infusion time of the first cycle is ≥90 minutes, if no infusion reaction occurs, the subsequent cycle can be completed within 30~120 minutes.
45661728|NCT05436379|Device|Theta Burst Stimulation|TBS, a next-gen form of transcranial magnetic stimulation (TMS), requires shorter duration and frequency of stimulation and provides comparable clinical efficacy to traditional repetitive TMS for depression. Thus it is an appropriate technique for use with young adults with depression. TBS can be delivered safely and effectively on an accelerated schedule with two sessions/day. Based on an earlier (ongoing) study of TBS to dorsomedial prefrontal cortex, investigators will administer TBS to dmPFC over 2 weeks in young adults with depression. Addressing the behavioral aspects of anhedonia and reward processing, a subset of participants will also receive positive affect training. Magnetic resonance imaging will guide the personalized location of TBS and will be used to examine change in frontostriatal circuitry with TBS. This study has the potential to influence development of new treatments for depression and anhedonia, with possible mechanisms in frontostriatal brain function.
45661729|NCT03937999|Drug|Bezlotoxumab|Injection: 1,000 mg/40 mL (25 mg/mL) solution in a single-dose vial.
45816261|NCT05829057|Biological|P-IL-2 plus Anti-PD-1 Monoclonal Antibody|Ib：P-IL-2 plus Anti-PD-1 Monoclonal Antibody；
45816262|NCT05829044|Device|Pupillometry|Pupillometer measurement of pupil size in response to different light stimuli
45454510|NCT02288494|Other|stewart approach|Prospective study, for ICU patient with severe hypoalbuminemia < 20g/L, determining biological parameters from Stewart approach for acid base disorders (pH, SIDe, SIDa, SIG, Atot, PaCO2) before, and at 1hour, 2hours and 24 hours after a 200mL 20% human al Clinical parameters (respiratory, haemodynamic, neurologic) were also collected at the same times.
45816263|NCT05829044|Device|Melatonin Suppression Test|Exposure to dim light on night1 and bright light on night2 to determine suppression of melatonin
45816264|NCT05829031|Behavioral|Targeted music listening|Participants listen to self-selected relaxing music. They can choose between a duration of either 10 minutes or 20 minutes.
45816265|NCT05829018|Diagnostic Test|Mixed meal test|Nutridrink 270 mL 405 kcal, 49 Energy% carbohydrates, 35 Energy% fat, 16 Energy% protein, vitamins, and minerals
45816266|NCT05828966|Drug|human chorionic gonadotropin (hCG)|H.C.G. will be given in Group A and in a dose of 5000units intramuscular injection followed by a drip of 10,000 units in 500ml of dextrose 5%, at the rate of 20 drops per minute.
45816267|NCT05828966|Drug|Magnesium sulfate|4gm of MgSO4 will be given in Group B as intravenously as continuous dose followed by 2gm/hr till uterine quiescence is achieved.
45816268|NCT05828953|Drug|Anlotinib|"Drug: Anlotinib The dose of nintedanib hydrochloride is 8mg per dose, taken orally once daily before breakfast. The drug is taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.~Drug: Placebo Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up."
45955484|NCT04616196|Drug|NKTR-255|NKTR-255 IV every 21 days
45955485|NCT04616196|Drug|Cetuximab|Cetuximab will be given at specified doses on specified days
45955486|NCT04613518|Drug|BMS-986165|Specified Dose on Specified Days
45955487|NCT04613518|Other|Placebo Comparator|Specified Dose on Specified Days
45955488|NCT04609904|Drug|BGF MDI 320/28.8/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
45955489|NCT04609904|Drug|BGF MDI 320/14.4/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
45955490|NCT04609904|Drug|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler
45955491|NCT04609904|Drug|BFF pMDI 320/9 μg|Budesonide/formoterol fumarate pressurized metered dose inhaler
45454511|NCT05251064|Device|Suture|Standard suture wound closure device.
45454512|NCT05251064|Device|Clozex|Interlaced adhesive wound closure device.
45454513|NCT05251064|Device|Zipline|Adhesive wound closure device using zip-tie like strips.
45454514|NCT05719012|Biological|UC-MSCs|Intravenous injection three times with one-month interval
45661730|NCT05436067|Device|Vestibular rehabilitation app|Delivery of vestibular rehabilitation through an app on a tablet or other portable device. The app takes patients through their rehabilitation session that has been prescribed by a clinician. Exercises are presented in the forms of games that are controlled by head or torso motion via a motion sensor that is placed on that body part. Data on the motion of the patient are calculated from sensor data and sent over the cloud for the clinician to access remotely.
45661731|NCT03929029|Drug|Nivolumab|Nivolumab is an antibody that prevent cancer cells from suppressing the immune response so that the body can attack and kill the cancer
45454515|NCT05250986|Device|GoCheck Kids (iOS)|"Visual Acuity method is used to measure of the sharpness or clearness of vision.~Device: GoCheck Visual Acuity in Office (Windows) Photorefraction method is used to screen amblyopia risk factors."
45661732|NCT03929029|Biological|NeoVax plus Montanide|Montanide® is an activator of immunity that enhances response to vaccination through slow release of the peptides from the injection site and its ability to create an inflammation and stimulate the recruitment of specific cells of your immune system. Montanide® will be mixed with the personalized neoantigen vaccine
45661733|NCT03929029|Drug|Ipilimumab|Ipilimumab is an antibody that prevent cancer cells from suppressing the immune response so that the body can attack and kill the cancer
45661734|NCT05435209|Drug|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|Gardasil
45816269|NCT05828953|Drug|Placebo|Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.
45816270|NCT05828875|Other|questionnaire investigation|Conduct a questionnaire survey on patients' quality of life, nutrition, and psychology
45816271|NCT05828862|Procedure|hypotension prediction index guidance|using hypotension prediction index guidance to prevent intraoperative hypotension
45816272|NCT05828862|Procedure|no hypotension prediction index guidance|silencing hypotension prediction index guidance during surgery
45955492|NCT04603859|Procedure|Elective induction of labor at 39 gestational weeks and 0 to 3 days|Elective induction of labor (eIOL) according to local policies
45955493|NCT04602949|Diagnostic Test|Breath Biopsy Analysis|Analysis of a single breath Biopsy
45955494|NCT04601948|Behavioral|mHealth Activity Intervention|Eligible participants will receive a Fitbit activity monitor and access to our mHealth physical activity intervention for 6 weeks. The intervention will include regular motivational messages to encourage activity, a social media thread to provide social support, and a series of fun virtual walking races.
45454516|NCT05250986|Device|GoCheck Kids (Windows)|Visual Acuity method is used to measure of the sharpness or clearness of vision.
45816273|NCT05828849|Behavioral|Navigation, compensation, and personalization|The study intervention is composed of navigation, compensation, and personalization. Navigation refers to reducing barriers posed by fragmentation of health and social systems. Compensation refers to reimbursement of out-of-pocket expenses to offset dependent care, time costs, and travel expenditures necessary to access care for the different conditions and goals of the intervention. Personalization refers to preventative interventions that are personalized based on individual for potential benefit.
45955495|NCT04589650|Drug|Alpelisib|"Adult participants (group 1) will receive 125 mg of alpelisib oral tablets once daily. Pediatric participants (Group 2: 6 to 17 years old) will receive 50 mg of alpelisib oral tablets once daily. Pediatric participants (Group 4: 2 to 5 years old) will receive 50 mg of alpelisib oral tablets once daily, Pediatric participants (Group 3: 2 to 5 years old) will receive alpelisib granules at dose determined based on the primary analysis for efficacy, safety and PK of alpelisib in Groups 1 and 2 in addition to the data from Group 4 as available.~Pediatric participants (Group 5: 6 to 17 years old) will receive 125 mg of alpelisib oral tablets once daily."
45955496|NCT04589650|Drug|Placebo|Participants will receive matching placebo once daily up to week 16.
45955497|NCT04588506|Procedure|Lower Trapezius Tendon Transfer Technique|Lower Trapezius tendon used in repairing cuff tear
45816274|NCT05828836|Drug|Allopurinol Tablet|allopurinol300mg once daily
45816275|NCT05828836|Drug|Placebo|placebo once daily
45816276|NCT05828810|Drug|surgical antiseptic skin preparation with either chlorhexidine or iodine-based solution|"Patients will be randomized to receive surgical antiseptic skin preparation with either chlorhexidine or iodine-based solution.~Specifically, the first treatment arm will undergo skin antisepsis with 4% chlorhexidine gluconate pre-wash, followed by 2% chlorhexidine gluconate with 70% isopropyl alcohol skin preparation.~The second treatment arm will undergo skin antisepsis with 7.5% povidone-iodine detergent pre-wash, followed by 10% povidone-iodine skin preparation."
45955498|NCT04588506|Procedure|Latissimus Dorsi Tendon Transfer Technique|Latissimus Dorsi tendon used in repairing cuff tear
45955499|NCT04588506|Procedure|Pectoralis Tendon Transfer Technique|Pectoralis tendon used in repairing cuff tear
45661735|NCT05377567|Behavioral|TAU + FIBRO-On|Group treatment protocol of 12 weekly 60 minute sessions (virtual intervention)
45955500|NCT04583956|Other|Placebo|Risankizumab placebo will be given at an equal volume at the same schedule.
45955501|NCT04583956|Drug|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
45955502|NCT04583956|Biological|Risankizumab|Risankizumab is a humanized immunoglobulin (Ig) G1 antagonistic monoclonal antibody (mAb) directed against the p19 subunit of the human cytokine interleukin-23. Risankizumab is formulated in a buffer of 4.4 mM disodium succinate hexahydrate/succinic acid, 225 mM sorbitol, 0.2 mg/mL polysorbate 20, and WFI in a 6R vial.
45816277|NCT05828784|Device|Intersomatic arthrodesis|"Arthrodesis is an operative modality also used in the treatment of multiple recurrences of herniated discs, stenosis (narrowing) of the spinal anal, degenerative and malformative spondylolisthesis.~The procedure can be performed with different surgical techniques, but in all cases it aims to achieve the same goal: to re-establish, through the use of spacers, the correct distance between two vertebral somes, in cases of disc degeneration, that are no longer able to fulfill their function; that is, they no longer absorb mechanical stresses and/or compress the nerve structures of the spine causing almost always unbearable (disabling) pain."
45955503|NCT04575025|Drug|Tabrecta tablets|There is no treatment allocation. Patients administered Tabrecta by prescription that have started before inclusion of the patient into the study will be enrolled.
45955504|NCT04562987|Behavioral|Physical Activity|Mobile app intervention delivered during chemotherapy for breast cancer that combines goal setting, behavioral monitoring, and goal achievement badges with telecoaching to achieve physical activity prescriptions.
45955505|NCT04562987|Behavioral|Attentional Control|Mobile app intervention delivered during chemotherapy for breast cancer that includes telecoaching on general and cancer-related health topics and basic physical activity monitoring.
45816278|NCT05828771|Procedure|THIN FREE FLAP|Flap design will be performed on the basis of the preoperative perforator mapping. Freestyle flap elevation will be performed under loupe magnification from one of the incisions until the perforators are reached
45816279|NCT05828745|Drug|CB06-036|CB06-036 capsule
45955506|NCT04562207|Diagnostic Test|Screening for respiratory virus infection|Nasopharyngeal swab for screening for respiratory virus infection before surgery
45955507|NCT04544358|Behavioral|BAILAMOS©|BAILAMOS© includes a 4-month, twice-weekly dance program. The PI and a professional dance instructor co-developed an extensive BAILAMOS© Dance Manual and class-by-class schedule.
45661736|NCT05377567|Behavioral|TAU + FIBRO-Out|Group treatment protocol of 12 weekly 120 minute sessions (outdoor intervention)
45816280|NCT05828745|Drug|Placebo|Placebo capsule
45661737|NCT05377567|Other|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients with fibromyalgia.
45661738|NCT05377177|Device|Accelerated Theta Burst Stimulation|B65 magnetic coil stimulation applied to the dorsal lateral prefrontal cortex.
45661739|NCT01659853|Drug|CD07805/47 gel 0.5%/CD07805/47 Vehicle|"To maintain masking, CD07805/47 gel 0.5% will be administered along with CD07805/47 gel vehicle.~During each treatment period (baseline to Day 15):~CD07805/47 gel 0.5%, topical, once daily and CD07805/47 gel vehicle, topical, once daily"
45454517|NCT05250986|Device|GoCheck at Home (iOS)|Visual Acuity method is used to measure of the sharpness or clearness of vision.
45454518|NCT05250986|Device|GoCheck at Home (Windows)|Visual Acuity method is used to measure of the sharpness or clearness of vision.
45816281|NCT05828732|Other|Using a mobile app that integrates with wearable devices|Using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis.
45454519|NCT03796039|Behavioral|Standing|Standing for an additional 100 minutes per week; 20 minutes Monday-Friday
45454520|NCT00250822|Drug|Gemcitabine and Oxaliplatin|"Dose:~Gemcitabine 1000 mg/m2 - IV in about 60 minutes on days 1 & 15. Oxaliplatin 100 mg/m2 - IV over 2hr on days 2 & 16"
45454521|NCT01343810|Behavioral|Mindfulness Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
45661740|NCT01659853|Drug|azelaic acid gel 15%|During each treatment period (baseline to Day 15): azelaic acid gel 15%, topical, twice daily
45816282|NCT05828719|Procedure|Percutaneous coronary intervention|"Revascularization indication~Diameter stenosis >90% by visual assessment~Functionally significant stenosis (FFR≤0.80 or non-hyperemic pressure ratios≤0.89)~Chronic total occlusion with substantial ischemic territory. The below locations will be judged as having substantial ischemic territory.~Left main artery~Proximal to mid left anterior descending artery~Proximal left circumflex artery in left dominant coronary arterial system~Proximal to distal right coronary artery in right dominant coronary arterial system"
45816283|NCT05828693|Behavioral|SysLife©|Use of the SysLife© application, with 2-, 4-, 6- and 8-month follow-up.
45816284|NCT05828693|Behavioral|SysLife©, as intervention after closing the RCT-design|Use of the SysLife© application after 4-month waiting period, with 2- and 4-month follow-up.
45458132|NCT03502564|Behavioral|CBT for ED|Cognitive behavior therapy (CBT) for eating disorders (ED) is a 16-session individual therapy protocol which will focus on maintaining improvements in eating following intensive treatment, as well as addressing overconcern with weight/shape. Interventions will be adopted from the Enhanced CBT for ED manual.
45458133|NCT03502564|Behavioral|Concurrent CBT for ED and PTSD|The concurrent ED and PTSD intervention will consist of 16 sessions of CBT for both PTSD and for ED (ED interventions described above). CBT for PTSD will be based on interventions in the Cognitive Processing Therapy (CPT) manual.
45458134|NCT02310178|Procedure|Bariatric surgery|all of the current bariatric surgeries are allowed in this prospective cohort study
45816285|NCT05828680|Other|Observation|No intervention
45816286|NCT05828576|Diagnostic Test|MRI|Patients will be asked for two additional control visits in the hospital. Overview of measurements: Included subject will visit the UMCU at two occasions. The first MRI scan will be the baseline MRI, and the second MRI will take place after 2 years of follow-up. Additional follow-up data will be collected through medical records reporting on regular follow-up.
45661741|NCT05434741|Behavioral|Weekly Group Skills|The topics covered in group CBT sessions are: 1.) Domains of Healthy Aging; 2.) Stress and anxiety; 3.) Adherence and Engagement in Primary/Preventative Care; 4.) Depression and Distress; 5.) Physical Activity; 6.) Stigma/Self-Compassion; 7.) Substance Use; 8.) Acceptance of Uncertainty and Uncomfortable Emotions; 9.) Diet; 10.) Behavioral Activation; 11.) Frailty and Memory/Cognition; and 12.) Wrap-Up and Maintaining Gains.
45661742|NCT05434741|Other|"One-time Trifold Brochure titled HIV: 50 Years or Older"|"Participants in the education only group will receive a one-time trifold brochure titled HIV: 50 Years or Older. This brochure contains information on the prevalence of HIV among people aged 50 and older, defines medication adherence and drug resistance, encourages physical activity and proper nutrition, and addresses the health risk behavior of tobacco-smoking for people living with HIV. Participants receive one brochure in the information-only group."
45661743|NCT05376631|Procedure|Fresh gas flow of 5 L/min|A fresh gas flow of 5 L/min is used during emergence from general anesthesia.
45816287|NCT05828563|Diagnostic Test|Blood sample test|Blood sample will be taken to determine immunological indices
45816288|NCT05828550|Diagnostic Test|antibiotic sensitivity|"The resistance pattern of the isolates will be detected by disc diffusion method.~Detection of efflux pump genes responsible for the resistance ( norA , norB , norC ) by PCR"
45661744|NCT05376631|Procedure|Fresh gas flow of 10 L/min|A fresh gas flow of 10 L/min is used during emergence from general anesthesia.
45816289|NCT05828511|Drug|Linvoseltamab|Linvoseltamab will be administered by intravenous (IV) infusion
45661745|NCT05376553|Drug|Cemiplimab|350mg intravenous infusion over 30 minutes
45661746|NCT05376553|Drug|Cisplatin|"100mg/m² intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline~Schedule: Day 1, every 21 days (+ 2 days)"
45661747|NCT05376553|Drug|Docetaxel|"75 mg/2 intravenous infusion over 60 minutes, mixed as described in~Schedule: Day 1, every 21days (+ 2 days)"
45816290|NCT05828498|Dietary Supplement|THE Mediterranean diet|The Mediterranean diet was applied to the patients with bacterial vaginitis selected randomly. diet content and application techniques were explained to the patient.
45816291|NCT05828485|Drug|MY008211A tablets|A single dose of MY008211A tablet was administered after fasting and high-fat, high-calorie feeding
45816292|NCT05828472|Drug|MY008211A tablets|MY008211A tablets, low/moderate/high dose orally, for 7 days
45816293|NCT05828472|Drug|MY008211A tablets matched placebo|MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days
45816294|NCT05828446|Device|MRI|To compare the diagnostic performance of US+/- Constrast-enhanced US and AMRI for HCC detection in an at-risk population
45816295|NCT05828433|Other|Epley-Canalith Repositioning|Epley-Canalith Repositioning The intervention was given for approximately 15min, for 2 times in a week, for 4 weeks.
45816296|NCT05828433|Other|Vestibular Rehabilitation Therapy|"Vestibular Rehabilitation Therapy Habituation exercises: The patients were asked to repeat the exercises 5 -10 times for 5 to 10 min, for 2 days in a week, for 4 weeks.~Gaze stability exercises and balance training: The exercises were performed in 3 sets or 5 repetitions, for 2 days in a week, for 4 weeks."
45816297|NCT05828420|Other|White noise|Each baby was listened to white noise 10 minutes before, during and 20 minutes after the painful attempt.
45816298|NCT05828420|Other|Heart sound|Each baby listened to heart sounds at an average rate of 70 beats 10 minutes before, during and 20 minutes after the painful procedure.
45816299|NCT05828420|Other|Music|Each baby was listened to the music that the mother listened to the most during pregnancy restriction 10 minutes before, during and after the painful attempt.
45816300|NCT05828394|Procedure|DFGG|Depithelised free gingival graft harvesting technique
45816301|NCT05828394|Procedure|SCTG|Subepithelial connective tissue graft harvesting technique
45816302|NCT05828381|Drug|Envafolimab|300mg,sc,d1,q3w; for a total of 2 cycles.
45816303|NCT05828381|Drug|Abraxane|100mg/m2,ivgtt, D1、D8,q3w ,for a total of 2 cycles
45661748|NCT05385367|Other|Regional anesthetic|Patient having just the nerve block for surgery
45816304|NCT05828381|Drug|Cisplatin|75 mg/m2 vigtt D1 , q3w , for a total of 2 cycles
45661749|NCT05385367|Other|General anesthetic|Patient having just general anesthetic ie. 'go completely under' for surgery
45661750|NCT05385367|Other|Combined general anesthetic and regional anesthetic|Patient having a combination of a nerve block and general anesthetic for surgery
45661751|NCT05434351|Other|vaginal dehydroepiandrosterone|the clinical outcome in Chinese women with moderate to severe symptoms of GSM treated with vaginal DHEA for 12 weeks will be evaluated
45661752|NCT05610553|Other|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in percutaneous disc decompression surgeries to help to reduce intra-operative radiation, puncture time, etc..
45816305|NCT05828355|Other|Knee Care@Home Programme|During the first 24 weeks after surgery to repair the anterior cruciate ligament, patients in the intervention group will be monitored and guided on their home exercises through remote sessions.
45816306|NCT05828342|Procedure|Endotracheal tube cuff inflation with the loss of resistance syringe method|The cuffs of the endotracheal tubes will be inflated with the epidural loss of resistance syringe, the syringe piston will be released, the syringe piston will be pushed back with oscillation, and then the cuff pressures will be measured and recorded with a cuff manometer (VBM Cuff Pressure Gauge) and an electronic injector that measures cuff pressure (AG Cufill). A three-way vein valve will be used when making this measurement. During the measurement, an epidural resistance loss injector will be attached to one valve, a cuff manometer attached to another valve, and an electronic injector (AG Cufill) measuring cuff pressure to the third track. With this technique, the possibility of leakage due to insertion and removal during measurements will be eliminated.
45955508|NCT04541407|Drug|Temozolomide plus Osimertinib|Temozolomide is an oral alkylating chemotherapy which has good CNS penetration and has demonstrated CNS responses in both primary brain tumors (e.g., glioblastoma and anaplastic astrocytoma) and in small cell lung cancer (SCLC) brain metastases. Preclinical data from glioblastoma suggests potential synergy of concurrent ALK or EGFR inhibition with temozolomide and early phase trials in glioblastoma are ongoing investigating such combinations. It is felt that combining temozolomide with osimertinib or lorlatinib may be beneficial for patients with progressive CNS disease on either of these TKIs because of the high CNS penetration of temozolomide, good CNS activity of temozolomide in other tumor types and preclinical data from glioblastoma suggesting a potential enhanced effect of concurrent EGFR and ALK/ROS1 inhibition with temozolomide.
45661753|NCT05610553|Other|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
45458135|NCT03431467|Device|Impella-CP LV Vent|Patients randomised to the experimental arm will have an Impella-CP implanted in addition to VA-ECMO within a maximum of 10 hours of institution of VA-ECMO
45458136|NCT02310256|Other|Five plus exercise training|calf raise exercise
45661754|NCT05384353|Other|[18F]-SynVesT-1|PET radioligand binding to synaptic vesicle protein 2A as a proxy for synaptic density
45661755|NCT05593393|Device|Endoscopic ultrasound|The EUS follow-up will be conducted at baseline and every 12 months thereafter. For patients with new WF or HRS in the evaluation, the follow-up physician and the patient can jointly decide whether to perform EUS evaluation in the 6 or 3 month intensive follow-up.
45661756|NCT05376163|Other|Survey Study|Headache Disabilty Index (HDI) will be applied.
45955509|NCT04541407|Drug|Temozolomide plus Lorlatinib|Temozolomide is an oral alkylating chemotherapy which has good CNS penetration and has demonstrated CNS responses in both primary brain tumors (e.g., glioblastoma and anaplastic astrocytoma) and in small cell lung cancer (SCLC) brain metastases. Preclinical data from glioblastoma suggests potential synergy of concurrent ALK or EGFR inhibition with temozolomide and early phase trials in glioblastoma are ongoing investigating such combinations. It is felt that combining temozolomide with osimertinib or lorlatinib may be beneficial for patients with progressive CNS disease on either of these TKIs because of the high CNS penetration of temozolomide, good CNS activity of temozolomide in other tumor types and preclinical data from glioblastoma suggesting a potential enhanced effect of concurrent EGFR and ALK/ROS1 inhibition with temozolomide
45955510|NCT04815356|Biological|CD22CART cell infusion|The treatment regimen will consist of lymphodepleting chemotherapy followed by CD22CART infusion: Days -4 to -2: fludarabine 25 mg/m2/dose Day -2: cyclophosphamide 900 mg/m2/dose Day 0: CD22CART infusion (starting at dose level 1 [DL1]: 1 x 105 transduced CAR-T cells/kg) on Day 0 Subjects will be evaluated for response at Day 28 post-CD22CART infusion.
45955511|NCT04552795|Drug|3TC|12 subjects will be administered 3TC, 300mg once daily, via an oral tablet for 24 weeks.
45955512|NCT04522336|Drug|Docetaxel|Given IV
45955513|NCT04522336|Drug|Fluorouracil|Given IV
45955514|NCT04522336|Drug|Oxaliplatin|Given IV
45955515|NCT04522336|Biological|Pembrolizumab|Given IV
45955516|NCT04522336|Radiation|Radiation Therapy|Receive radiation therapy
45661757|NCT05374369|Diagnostic Test|SDC2 Gene Methylation Test and Q-FIT Test|Stool specimens were collected by the subjects for SDC2 Gene Methylation Test and Q-FIT Test
45955517|NCT04497376|Procedure|upgraded '2C3L'|Patients randomized to the upgraded '2C3L' arm will first undergo EI-VOM, followed by the '2C3L' ablation step including bilateral circumferential PV antral ablation and linear ablations across the left atrial roof, MI, and CTI. Any organized AT observed during the procedure will be targeted as well. EI-VOM procedure: An 8.5-French-long sheath or a steerable long sheath is sent to the coronary sinus (CS) via the femoral vein. A JR4.0 catheter is inserted into the CS to identify the ostium of the VOM. Subsequently, a BMW wire supported by an OTW balloon catheter is advanced into the VOM. The balloon is inflated with 6 to 8 atm in the VOM. A selective venogram of the VOM is obtained by slowly injecting 1 mL of contrast medium. Then, 2-4 mL of ethanol is slowly injected into the distal VOM and selective venography of the VOM is repeated. In the same way, another injection is performed for the middle part and then the proximal part. A total of 6 to 12 mL of ethanol will be used.
45816307|NCT05828316|Behavioral|Resilience-based intervention|resilience-based intervention is a curriculum that offers a careful selection of evidence-based exercises to build coping skills and promote thriving. The resilience-based intervention philosophy is that there are many routes to achieving greater resiliency. Each participants choose from a menu of exercises in the areas of goal-setting, emotional skills, social connection, health, meaning, and self-talk. The ability to choose exercises that fit their specific goals, interests, and schedules is important, because the most effective strategies are the ones that people actually do, which tend to be the ones that are most enjoyable and personally relevant. No single practice is going to work for everyone regardless of its proven benefits. resilience-based intervention makes improving well-being accessible, manageable and fun, by introducing a variety of bite-sized, exercises that participants can experiment with and find what works for them.
45661758|NCT05374369|Procedure|Colonoscopy and/or pathological examination|Subjects underwent colonoscopy and/or pathological examination.
45661759|NCT04136587|Other|Colonic fluid collection during endoscopy for analysis of the bacterial secretome|Colonic content will be collected by suction during routine colonoscopy including the residual fluid in the colon and stool contents and also suction of washing fluid (sterile physiologic H2O solution)
45816308|NCT05828264|Behavioral|Quantum touch|this group by the nurse who is included in the study and who has a practice certificate before vascular access is established. In this process, the treatment process of the patient will continue and will not create an obstacle. While the child is in a comfortable position (lying or sitting position) during the application, the child's back/shoulder/head will be touched by the practitioner and guantum touch energy will be applied. Then, vascular access will be performed by the nurse included in the study. The child will be asked to rate the level of pain during the procedure with 'FPS-R', the level of fear with 'CDS', and the level of anxiety with 'ÇAS-D'.
45816309|NCT05828251|Procedure|Vitrectomy (Sequential phakoemulsification and vitrectomy)|Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.
45816310|NCT05828251|Procedure|Combined phako-vitrectomy|Phakoemulsication and pars plana vitrectomy are performed in the same setting. This procedure is normally only offeres to selected cases at our department.
45816311|NCT05828251|Procedure|Phako (Sequential phakoemulsification and vitrectomy)|Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.
45816312|NCT05828238|Drug|[18F]SF-DEVD-2|Patients will receive a tracer dose of 18F (2-4mCi) labelled SF-DEVD-2
45816313|NCT05828238|Drug|[18F]-FDG|Patients will receive a tracer dose of 18F (5-10mCi) labelled FDG
45816314|NCT05828225|Drug|CD19 CAR-T cells injection|CD19 CAR-T in the Treatment of Refractory Myasthenia Gravis
45816315|NCT05828212|Drug|CD19 CAR-T cells injection|CD19 CAR-T cells in the treatment of R/R neuromyelitis optica
45816316|NCT05828199|Drug|Ketamine Hydrochloride|Comparing between dexmedetomidine versus low dose ketamine infusion in patients undergoing nasal and paranasal sinus surgery as regard, intraoperative hemodynamic stability, blood loss, perioperative opioid requirements, Stress response evaluation through the measurement of serum level of cortisol, IL-6, blood glucose and CRP.
45816317|NCT05828199|Drug|Dexmedetomidine|bolus dose of dexmedetomidine 0.5-1 μg/kg in 100 mL of normal saline over 10 minutes then, continuous infusion dose of dexmedetomidine 0.2 ug/kg/hr
45816318|NCT05828121|Behavioral|POINT1|Receiving treatment
45955518|NCT04497376|Procedure|pulmonary vein antral isolation|After reconstructing the left atrial geometry, PVI will be performed (the right PV antrum (PVA) will be ablated first, followed by the left PVA. ) in a wide area circumferential pattern. Complete PVI will be achieved when all PV potentials within each antrum recorded by the high-density mapping catheter are abolished. The endpoint of the circumferential PVA ablation procedure is to achieve electrical bilateral PV isolation, that is, the PV potentials associated with atrial electrical activity cannot be recorded during sinus rhythm or CS pacing (entrance block). A waiting period of at least 20 min (after the last PV is isolated) will be used during which spontaneous PV reconnection will be related. , and tDemonstration of exit block (he by pacing in the PV cannot be and proving the absence of transmitted conduction to capture the atrium) may be performed but is not mandatory. Any organized AT observed during the procedure will be targeted as well.
45955519|NCT04497025|Other|Immersive Virtual-based vestibular rehabilitation|Vestibular rehabilitation based on virtual environment using a head mounted display
45955520|NCT04497025|Other|Conventional vestibular rehabilitation protocol|"Cawthorne-Cooksey vestibular rehabilitation exercises."
45955521|NCT04478162|Other|Supporting parents who have premature babies to be ready for discharge with the training given within the scope of FICare model.|At least 1 week of FICare training for parents At least 4 hours of training on FICare for health professionals Trainings will be held between 13:30 and 15:30 in a training room with heat, light and seating arrangement (for parents who are not able to participate in the training during the week, trainings will be held at the appropriate time interval on the weekend .) Premature baby dummy on oral care, eye care, nose care, ear care, skin care, bath, attired in clothes,/removal, safe sleeping baby, safe transport, kangaroo care (physical contact), non-invasive drug application will be shown and the parents also will be asked to implement,
45955522|NCT04472884|Behavioral|mWACh-PrEP|Participants randomized to mWACh-PrEP will be registered into the system, in addition to receipt of SOC services. Women registered into the mWACh-PrEP platform will indicate their preferences for message delivery including a preferred name for messaging, language (English or Kiswahili or Dholuo), and day of the week and time for SMS delivery. Once registered, women will receive weekly automated push messages on the day/time of their choice from enrollment through 6-months postpartum. All automated push messages will include participant nickname, clinic and nurse name, an educational message or actionable advice targeting PrEP adherence and continuation and/or maternal and child health (MCH) topics, and a question related to the content. SMS topics will include adherence encouragement, PrEP efficacy and safety, self-efficacy for prevention of HIV, support for potential PrEP side effects, behavioral skills (tips for remembering PrEP medications) and visit reminders.
45955523|NCT04472884|Other|Standard of Care|All participants will receive SOC services for MCH and PrEP that will include health education, clinical assessments, laboratory safety monitoring, STI (syphilis, gonorrhea, and chlamydia) screening and treatment (including expedited partner treatment for
45816319|NCT05828056|Device|Wearable activity tracker|Garmin smartwatch will record features, such as activities, heart rate, sleep, through smartphone App
45816320|NCT05828004|Behavioral|Whole-Course Multidisciplinary Care Intervention|On the basis of standard treatment, all patients were evaluated by senior practice nurses in the Department of Oncology in person at the time of enrollment (before radiotherapy) and once every week during radiotherapy, and once in person/over the phone at 1, 2, 3, and 6 months after radiotherapy.
45816321|NCT05827991|Device|1565nm Non-ablative Fractional Laser|1565nm Non-ablative Fractional Laser is used for treatment once every 2 weeks, a total of 10 times. 1565nm Non-ablative Fractional Laser uses square and rectangular light spots, and the size is adjusted according to the treatment area, which is about 8-16mm, 250-300spot, 10J/cm2.
45816322|NCT05827991|Drug|5% minoxidil external use|The method of use of 5% minoxidil tincture is for topical use on the scalp, 1 ml per time, 2 times per day.
45816323|NCT05827991|Device|1565nm Non-ablative Fractional Laser combined with 5% minoxidil|The two treatment mentioned above
45816324|NCT05827965|Behavioral|education and drug adjustement|education of the patients (lifestyle) and adjustement of glucocorticoid replacement schedule
45816325|NCT05827952|Behavioral|behavior modification-Atomic Habit by hybrid|Atomic Habits (20-minute audiobook format), a role structure, and a game structure, online schedule reminders more than twice a week, and individual counseling sessions (online and physical) with one to two total interventions. The content of the online schedule reminders consisted of a total of four concepts for each of the four major habits, and a total of 16 sessions of the online audiobook interventions were adapted for the caregivers' relationship-building habits with the children.
45816326|NCT05827939|Other|Covid19 Vaccination dose|Participants above or below 2 dose Covid19 Vaccination
45816327|NCT05827926|Biological|Fluarix|quadrivalent seasonal influenza vaccine
45816328|NCT05827926|Biological|mRNA-1083.1|Sterile liquid for injection
45816329|NCT05827926|Biological|mRNA-1083.2|Sterile liquid for injection
45816330|NCT05827926|Biological|mRNA-1083.3|Sterile liquid for injection
45816331|NCT05827926|Biological|mRNA-1010.4|Sterile liquid for injection
45816332|NCT05827926|Biological|mRNA-1283.222|Sterile liquid for injection
45816333|NCT05827926|Biological|mRNA-1273.222|Sterile liquid for injection
45816334|NCT05827926|Biological|mRNA-1010|Sterile liquid for injection
45816335|NCT05827926|Biological|Fluzone HD|quadrivalent seasonal influenza vaccine
45661760|NCT05345197|Drug|emicizumab|This study design uses emicizumab as a prophylaxis treatment to prevent bleeding for all participants, bypassing agents (with the exception of aPCC) and treatment of concomitant diseases will be given as clinically indicated. All eligible subjects with AHA will receive the same study medication consisting of: two loading doses of the emicizumab on day 1 and 2 followed by once weekly subcutaneous emicizumab injections. Immunosuppressive therapy (IST) will be given concurrently as per investigator discretion.
45816336|NCT05827913|Device|Polylevolactic Acid Injection|The patient was placed in a flat recumbent position and subjected to topical anesthesia with lidocaine cream for those who were unable to tolerate pain. According to the location and degree of indentation of the atrophic stria, a conventional disinfection towel is placed and injected into the subcutaneous and deep dermis. Use left thumb and index finger to press or tighten the skin from both sides to the middle. Depending on the location of the SD, determine the injection direction. During linear injection, the injection starts from the distal end of the SD, and then the injection is withdrawn until the SD subsides. Apply uniform force and withdraw the needle at a uniform speed. Stop the injection before the needle is pulled out of the skin, To avoid too shallow an injection.
45955524|NCT04463680|Drug|Rifampin 600 MG|Administered daily for 2 weeks
45955525|NCT04459000|Behavioral|STARS + maternal Attachment Biobehavioral Catchup home visiting model|Mothers receive up to 12 home visits from a licensed therapist focused on attachment and positive parenting in substance exposed babies. This includes 1 prenatal home visit and up to 11 postnatal visits.
45816337|NCT05827913|Device|1565nm Non-ablative Fractional Laser|M22-ResurFx laser (Lumenis Medical Company, USA) was used for treatment, with a wavelength of 1565 nm, a selected energy of 45 mJ, and a lattice density of 200 dots/cm2. The end point reaction was erythema and wind masses at the treatment site.
45816338|NCT05827913|Device|Polylevolactic Acid Injection combined with 1565nm Non-ablative Fractional Laser|combination of the two treatments described above
45816339|NCT05827900|Behavioral|Metacognitive Training|Minimum of 6 sessions; but planned 10-12 sessions of metacognitive group training
45955526|NCT04459000|Behavioral|STARs Only|Participants receive prenatal care in the STAR clinic (a clinic specifically designed to support mothers with substance abuse who are at risk of losing their children to child welfare at birth).
45955527|NCT04454970|Device|Urethrotech Urethral catheterisation device (UCD)|Urethral indwelling catheter
45955528|NCT04454970|Device|Bardia Aquafil long term catheter|Urethral indwelling catheter
45955529|NCT04449029|Drug|GSK3228836|GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.
45955530|NCT04449029|Drug|Placebo|Placebo will be available as a clear colorless solution for injection to be administered subcutaneously once weekly.
45955531|NCT04449029|Drug|Nucleos(t)ide therapy|Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleotide therapy for the duration of the study.
45955532|NCT04446650|Drug|Fedratinib|Oral
45955533|NCT04438655|Drug|Oral antibiotic drugs|"Oral antibiotic drugs:~- Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI: h. 8-16-24 the day before surgery if the procedure takes place in the morning; h. 16-24-8 if the procedure takes place in the afternoon."
45955534|NCT04438655|Drug|Parenteral prophylaxis|"Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg."
45955535|NCT04438031|Behavioral|Navigation Intervention Prenatal 1.0 (intervention discontinued, modified to 2.0. Data will not be used)|This program recruits mothers in OB/GYN (prenatal) offices, provides up to three Navigation visits (using prenatal navigation version 1.0), establishes connections between the family and primary health care or other community providers, and then follows up one month later to confirm these referrals. Navigators will assess and support family needs across multiple developmentally-appropriate domains at each age. Prenatally, the domains include support for (1) health and access to healthcare, (2) adjustments to pregnancy, (3) household and material needs, and (4) family safety. At 12, 24, and 36 months, the domains include support for (1) child basic needs, (2) parenting and child behavior, (3) child health and development, and (4) parent health and well-being.
45955536|NCT04438031|Behavioral|Control Intervention|Brief information will be provided about pregnancy prenatally and child development at 12, 24, and 36 months.
45955537|NCT04438031|Behavioral|Navigation Intervention Prenatal 2.0|This program recruits mothers in OB/GYN offices. Mothers are offered visits from a Navigator prenatally and postnatally (12-, 24-, and 36-months). During visits, the Navigator works with the mother to identify family needs, establishes connections between the family and community providers, and follows up one month later to confirm these referrals. Navigators assess and support family needs across 13 factors: caregiver health, infant health, healthcare plans, childcare plans, parent-child relationship, management of infant crying/behavior, household safety/material supports, family/community violence, history of parenting difficulties, parent well-being, substance use, parent emotional support, and other needs not related to first 12 factors. Navigation 2.0 is a revision of 1.0 in which adjustments to the protocol were made to improve guidance for Community Navigators and aid their assessments of family needs.
46002811|NCT04643964|Behavioral|Entrée: Behavioral skills|In this condition, participants view a video-based intervention covering behavioral emotion regulation skills. This intervention asks participants to respond to questions and practice scheduling activities that might give them a sense of pleasure or accomplishment using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to schedule and engage in behaviors in line with the intervention skills.
45661761|NCT05610475|Diagnostic Test|blood cell analysis, blood gas surveillance, chest radiograph and echocardiography|Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
45816340|NCT05827861|Behavioral|HeartAge|HeartAge is a phenotypic age-based risk presentation which is a modified tool for CVD risk communication based on the Framingham risk Score. The Heart-Age risk presentation is the age at which an individual of the same sex would be expected to experience the same absolute risk as the individual, had their risk factors been 'normal' based on the clinical guidelines.
45955538|NCT04433351|Device|Enriched rehabilitation|"The enriched rehabilitation is based on the use of sensory-motor integration in addition to conventional speech therapy. The sensory-motor integration method is based on the Ultraspeech-player software. This software allows therapists to display movements of speech articulators (tongue and lips) recorded on a reference speaker during production of vowels or consonants (isolated or combined). Sagittal movements of the tongue are recorded using ultrasound and front views of lip movements are captured through video imaging.~During rehabilitation with the Ultraspeech-player software, patients will be seated in front of a computer screen, observe articulatory movements and listen to phonemes. Then, they will be required to repeat each of them five times and move on to the next phoneme, with the agreement of the experimenter."
45955539|NCT04433351|Device|Simple rehabilitation|The simple rehabilitation is based on conventional speech therapy. The conventional speech therapy will be provided by the speech therapist. Classically, the speech therapist uses word production with repetition and naming exercises. The therapist will show the patient series of pictures associated or not with written words, and the patient is required to name them and/or read aloud the word. In case of impossibility to perform the task, the therapist may can help the patient by using the indexing method or by asking the patient to repeat after him/her. According to patient's competencies and progress, the difficulty of reeducation can increase progressively.
45955540|NCT04428333|Drug|Feladilimab|Humanized anti-inducible T cell co-stimulatory receptor (ICOS) immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
46078663|NCT02817542|Device|percutaneous coronary intervention|Percutaneous coronary intervention. Procedures include: Implantation of stents The thrombus aspiration (TA) will be started before crossing the coronary atherosclerosis lesion. A minimum of two syringes (40 mL) of aspirate will be recommended. The guide catheter will be engaged with the coronary ostia when removing the thrombectomy catheter. The guide catheter will be aspirated after thrombectomy to avoid embolisation of air or thrombus. PCI procedure will be done without thrombectomy as per the investigator. Direct stenting will not be mandated in either treatment group. Bailout thrombectomy will be allowed after a failure of the initial PCI alone strategy. The decision about bailout thrombectomy will be made by the interventional cardiologist performing the initial PCI.
45661762|NCT05344339|Procedure|Distal gastrectomy|Reconstruction after Distal Gastrectomy
45661763|NCT05382637|Drug|Somatropin|Daily growth hormone at a starting dose of 50 mcg/kg/day and escalating
45661764|NCT05576389|Drug|Camrelizumab+Fluzoparib|Fluzoparib：150mg was given orally twice daily Camrelizumab：200 mg IV drip on Day 1 of each cycle
45816341|NCT05827861|Behavioral|HOPE-CVD Mobile App|The HOPE-CVD mobile app is an evidence-based behaviour change platform that runs for 24 weeks. The programme supports behavioural modification through seven self-care behaviours (active living, exercise, weight management, blood pressure-friendly diet, cholesterol-friendly diet, medication adherence and smoke-free lifestyle). To adopt a digital delivery of Motivational Interviewing and Cognitive Behavioural Therapy, the HOPE-CVD platform incorporates interactive decision aids, dramatic vignettes, expert content, peer videos and behaviour tracking.
45816342|NCT05827861|Behavioral|Genetic Risk Score|Participants will undergo genetic testing from which a genetic risk score for CVD will be estimated. they will receive a genetic risk communication which indicates which quartile of genetic risk they are at in comparison to the rest of the population. The report also contains information on what this risk means for their chances of developing cardiovascular disease in the future.
45955541|NCT04428333|Drug|Pembrolizumab|Humanized anti- programmed cell death receptor1 (anti-PD-1) IgG4 mAb
46078664|NCT00607217|Biological|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
46078665|NCT00607217|Biological|placebo for influenza vaccine|Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
46078666|NCT00607217|Biological|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
45955542|NCT04428333|Drug|Placebo|Sterile normal saline
45955543|NCT04428333|Drug|Platinum based chemotherapy|Cisplatin/carboplatin
45955544|NCT04428333|Drug|Fluorouracil (5FU)|5-fluorouracil
46078667|NCT02742714|Device|PillCam SBC system|The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
45661765|NCT05343793|Other|Enhanced Monitoring and Feedback (EMF)|Enhanced Monitoring and Feedback consists of performance data (reach, adoption, effectiveness, implementation) gathered and reported by the program on a quarterly basis. Data summaries for each program and in comparison to the entire sample, will be reflected back to participants, via dashboards, within one-month of data submission.
45661766|NCT05343793|Other|NIATx/MAT Academy|This two-day workshop will provide participating clinics with rationale, clinical practice and program integration with MOUD (Day 1), and an overview of NIATx principles and tools (Day 2).
46078668|NCT02601807|Device|ActiPatch (active)|Active version of the ActiPatch pulsed shortwave therapy device. Emits shortwave radiofrequency pulsed energy.
46078669|NCT02601807|Device|ActiPatch (placebo)|Placebo version of the ActiPatch pulsed shortwave therapy device. Emits no radiofrequency energy but otherwise appears identical to the active device.
46078670|NCT02817620|Dietary Supplement|Spirulysat®|
46078671|NCT02817620|Dietary Supplement|Placebo|
46078672|NCT02742792|Other|Resistance training|Twenty-four strength training sessions consisted in exercises of extension and flexion knees, lat pull-down, elbow extension and flexion, sitting bench press and hip abduction.
45955545|NCT04428281|Drug|RO7248824|In the Multiple Ascending Dose part RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration. In the Long Term Extension part RO7248824 will be administered up to 10 doses as IT injection of selected dose levels with a minimum of approximately 16 weeks between each dose administration.
45661767|NCT05343793|Other|NIATx-Internal Facilitation (NIATx-IF)|Internal facilitators will receive training (in-person or online) on how to provide coaching within their organization. For 9-months, Internal Facilitators (IFs) will: a) support teams to harness resources toward systemic change and improvement; b) employ a range of concepts and tools to provide individualized support to teams; c) help teams to practice and hone their skills to optimize performance, and d) focus on team relationships and communications. IFs will participate in group coaching calls involving IFs from other NIATx-IF clinics and moderated by NIATx expert to discuss common change-related issues, progress, and successful tactics.
45661768|NCT05343793|Other|NIATx-External Facilitation (NIATx-EF)|For 9-months, organizations in the NIATx-EF study arm will work with one of 4 experienced consultant NIATx External Facilitators (EFs). The EF meets with clinic staff to plan change projects, review ongoing change efforts, discuss successes, and offer guidance on planning future change projects using PDSA cycles. The EF makes a 1-day site visit during the 1st quarter of the implementation period and leads monthly 1-hour phone calls.
45816343|NCT05827848|Device|Percutaneous peripheral nerve stimulation system|All subjects underwent a 7-day baseline assessment (VAS score for at least 4 days) during the screening/baseline period. Eligible subjects underwent PNS surgery and implanted electrode leads and entered the 7-day test period. During the test period, subjects with an average VAS score improvement of ≥30%(VAS score for at least 4 days) will be randomly assigned to the experimental group (on state) or the control group (off state) in a 1:1 ratio for 7 days observation. All subjects were enrolled in the observation period until 28 days after implantation. Safety assessment was performed at a 14-day follow-up after removal of the device.
45661769|NCT04252807|Behavioral|Intervention arm|In addition to the routine care delivered by Lady Health Workers (LHWs), the participants in the intervention arm will receive common elements based integrated intervention. The providers of the intervention are lay health workers who will be trained in the intervention using an online course. The lay health worker will complete the online training course in a group, with interactive group activities and role plays. Lay health workers will be supported online and in-person by the trainers in monthly supervision meetings. The lay health workers will deliver intervention to distressed mothers in 15 monthly sessions. The intervention consists of three modules including 1) mothers' well-being, 2) infant nutrition,early stimulation and breastfeeding and 3) mother-infant interaction.
45816344|NCT05827835|Drug|CD7 CAR-T cells injection|CD7 CAR T cells treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
45816345|NCT05827835|Other|Allogeneic hematopoietic stem cell transplantation|In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
45816346|NCT05827822|Device|Sober Time ACT|Mental health assessment (regular assessment and reporting feedback), daily clock-in (reporting alcohol use and providing encouragement and reinforcement), mental knowledge base (Tips for the Day based on cognitive behavioral techniques, popular alcohol withdrawal courses, alcohol health education manuals) and self-assistance tools (mindfulness meditation training and emergency help buttons)
45816347|NCT05827796|Drug|IN10018|IN10018 orally once daily at approximately the same time each day, to ensure a dosing interval of approximately 24 hours.
45816348|NCT05827796|Drug|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel will be administered as per the schedule specified in the respective arm.
45816349|NCT05827796|Drug|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
45816350|NCT05827796|Drug|KN046|KN046 5 mg/kg on Day 1 of each 21-Day Cycle.
45955546|NCT04415944|Procedure|Second look laparoscopy reassessment surgery (SLLRS)|Performed less than 12 weeks after intravenous chemotherapy cycles are completed.
45955547|NCT04415944|Drug|HIPEC with Carboplatin|"Patient receives HIPEC with CBDCA 800 mg/m2 for 90 minutes.~Patients who exhibit the following will not receive the HIPEC procedure:~Extraperitoneal disease noted at the time of the second look procedure~Macroscopic intraperitoneal disease which is not resectable to R1~Technical problems which prevent continuous, adequate flow to maintain intraperitoneal temperature to 41°C during perfusion~Intraoperative complications such as cardiac or pulmonary instability precluding HIPEC~Participation will consist of completing surveys regarding their cancer and allowing researchers to use information from their medical records for research."
45955548|NCT04415944|Other|FACT-O Quality of Life Questionnaire|Participants will be asked to do this three times (pre-study, 3 months and 6 months). Surveys will be given at follow up visits for surgery. They should take about 10-15 minutes to complete.
45955549|NCT04409236|Behavioral|Quit2Heal|Use Quit2Heal app
45955550|NCT04409236|Behavioral|QuitGuide|Use QuitGuide app
45955551|NCT04409236|Other|Survey Administration|Ancillary studies
45955552|NCT04395989|Drug|A1: Pyrotinib with Capecitabine|A1: pyrotinib(EGFR-TKI) 400mg qd and capecitabine 1000mg/m2 bid (d1-d14)
45955553|NCT04395989|Drug|A2: nab-paclitaxel|A2: nab-paclitaxel 100mg qw (three week on one week off)
45955554|NCT04395989|Drug|B1: everolimus with nab-paclitaxel|B1: everolimus 10mg qd combined with nab-paclitaxel 100mg qw (three week on one week off)
45816351|NCT05827783|Procedure|Implementation of Bee Buzzy|"Implementation of Bee Buzzy It is defined as the use of a device called Bee Buzzy, which applies cold and vibrates in the form of a toy bee, by the researcher for fear and pain during phlebotomy in children.~Nurse performs phlebotomy on pediatric patients in the pediatric phlebotomy unit. During this application, the researcher puts the Bee Buzzy device on the child's arm just above the area from which blood was taken, and remains attached to the arm during the phlebotomy procedure. This device applies cold and vibrates. Pain and fear during the procedure are evaluated by the researcher, the nurse, and the child's parent."
45816352|NCT05827783|Procedure|Implementation of Puppet Zuzu|"Implementation of puppet zuzu It is defined as the use of a puppet that is seized and made to talk by the researcher for fear and pain during phlebotomy in children.~Nurse performs phlebotomy on pediatric patients in the pediatric phlebotomy unit. During this practice, a puppet is seized by the researcher and made to talk, and the child's attention is tried to be drawn. While this procedure is in progress, the researcher, the nurse, and the child's parent evaluate the pain and fear during the procedure."
45955555|NCT04395989|Drug|B2: nab-paclitaxel|B2: nab-paclitaxel 100mg qw (three week on one week off)
45955556|NCT04395989|Drug|C1: PD-1 with nab-paclitaxel and famitinib|C1: PD-1 antibody SHR1210 200mg q2w and nab-paclitaxel 100mg qw (three week on one week off) and famitinib 20mg qd
45955557|NCT04395989|Drug|C2: nab-paclitaxel|C2: nab-paclitaxel 100mg qw (three week on one week off)
45816353|NCT05827770|Drug|Toripalimab combined with Temozolomide|Toripalimab combined with Temozolomide
45816354|NCT05827757|Biological|autologous adipose-derived mesenchymal stem cell transplantation|Transplant 100 million autologous adipose-derived mesenchymal stem cells at Day 0 and Day 90
45816355|NCT05827744|Other|Isokinetic evaluations|Peak torque and total amount of work of hip flexors and extensors will be determined by the Cybex 6000 model computer-aided isokinetic system.
45955558|NCT04395989|Drug|D1: VEGFR and nab-paclitaxel|D1: VEGFR BP102 10mg/kg q2w and nab-paclitaxel 100mg qw (three week on one week off).
45816356|NCT05827744|Other|Ultrasonographic evaluations|Ultrasonographic evaluations will be performed with a 5-12 MHz linear probe (Logic e portable; GE Healthcare, China). The thicknesses of the hip flexor (psoas major) and extensor (gluteus maximus) muscles will be measured while the patient is in the prone position, in accordance with the literature.
45816357|NCT05827731|Behavioral|cesarean section|According to the different outcomes of pregnancy, the patients were divided into natural delivery group and cesarean section group
45955559|NCT04395989|Drug|D2: nab-paclitaxel|D2: nab-paclitaxel 100mg qw (three week on one week off)
45955560|NCT04395989|Drug|E1: Everolimus with nab-paclitaxel|E1: Everolimus 10mg qd with nab-paclitaxel 100mg qw (three week on one week off)
45955561|NCT04395989|Drug|E2: nab-paclitaxel|E2: nab-paclitaxel 100mg qw (three week on one week off)
45955562|NCT04393454|Drug|Sirolimus 2Mg Tab|Sirolimus (oral) will be started at 2 mg daily. Sirolimus dosing will be titrated to meet serum trough levels of >8 ng/ml, assayed at 7 days after starting a new dose, by chromatography/nmass spectrometry. Once adequate serum levels are met (≥8 ng/ml), the same dosing will be continued until progression of disease as evidenced by imaging, or unacceptable toxicity.
45955563|NCT04392193|Radiation|Proton Particle Therapy|Proton therapy will be delivered in a single fraction using the Probeat-V system
45955564|NCT04389632|Drug|SGN-B6A|Administered into the vein (IV; intravenously)
45955565|NCT04389632|Drug|pembrolizumab|200mg every 3 weeks or 400mg every 6 weeks, given by IV
45955566|NCT04384250|Diagnostic Test|Whole Exome Sequencing|Genetic study of patients
45955567|NCT04362826|Biological|Novel probiotic|Investigational novel probiotic
45955568|NCT04362826|Other|Placebo|Placebo for probiotic
45955569|NCT04357288|Other|Patient Decision Aid|The Patient Decision Aid (PDA) is an interactive website designed for use by a participant without the need of their clinician present. It provides information about the atrial fibrillation diagnosis, possible treatments, the effect of this diagnosis on daily life, and how to prepare for a discussion about medications with a clinician. Participants may interact with the website by inputting their health information into the stroke risk calculator or answering questions about their values, goals, thoughts, etc. that they would like to discuss with their clinician.
46078673|NCT02742792|Other|Advice on Lifestyle|Patients receive advice on lifestyle. Patients will be asked to participate in the elderly group meetings the basic health unit linked to the hospital.
46078674|NCT05382767|Drug|CKDB-501A|Muscle Spasticity
46078675|NCT05382767|Drug|Botox®|Muscle Spasticity
46078676|NCT05650814|Device|ButterfLife|On day 1, the investigator delivers the ButterfLife device at home and explains its use. The patient is recommended to take the measurement once a day, preferably in the morning and to repeat the measurement of parameters during the day if necessary. The doctor will check the data recorded by the patient every day and the trend of the parameters over time by a graphical representation on the electronic medical record (Vitaever®, Nethical S.r.l.). Daily telemonitoring will be conducted in addition to standard home care.
46078677|NCT05650814|Other|Control|Patients will receive standard home care: visits will be planned according to the patient's needs. In case of an unstable clinical condition, worsening of symptoms, and alteration of vital parameters, patient can contact by phone the physician or the nurse, who will decide how to intervene.
45816358|NCT05827692|Behavioral|Intervention group A|The forest bath sessions will be led by a specialized guide and will be conceived as a silent walk of about 3 km along a path and forest track with an average gradient of 3%, with three 10-minute stops (at the beginning, in the middle and at the end) to practice deep breathing and awareness of the 5 senses.
45661770|NCT04252807|Other|Treatment as Usual|The participants in the control arm will receive the routine visits by LHWs of their respective areas. The LHWs are trained to provide antenatal care and referral, immunization services and support to community mobilization, provision of family planning and basic curative care via door to door visits to the households of their allocated areas.
45816359|NCT05827666|Dietary Supplement|2% milk beverage|Protein provided at 0.3 g/kg fat-free mass. All other conditions (almond, soy and rice milk alternative beverages) will be matched to the same energy content (i.e., isoenergetic). Macronutrient content of beverage (per 100 g): Calories: 52 kcal; Fat: 2.25 g; Carbohydrates: 4.8 g; Protein: 3.3 g.
45661771|NCT05341921|Behavioral|Alternate Nostril Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
45661772|NCT05341921|Behavioral|Bhramari Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
45661773|NCT05341921|Behavioral|Sheetali Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
45816360|NCT05827666|Dietary Supplement|Almond milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 24 kcal; Fat: 1.13 g; Carbohydrates: 3.1 g; Protein: 0.3 g.
45816361|NCT05827666|Dietary Supplement|Soy milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 39 kcal; Fat: 1.70 g; Carbohydrates: 3.0 g; Protein: 2.9 g.
45816362|NCT05827666|Dietary Supplement|Rice milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 49 kcal; Fat: 1.09 g; Carbohydrates: 9.8 g; Protein: 0.1 g.
45816363|NCT05827640|Other|data recording using conventional ventilation strategies (PCV and VCV)|no intervention
45816364|NCT05827601|Diagnostic Test|respiratory specimen|participants will perform self-sampling with a nasopharyngeal swab
45816365|NCT05827601|Diagnostic Test|serum|participants will be invited to get a blood sample taken by a general practitioner or to perform a self sampling of capillary blood
45816366|NCT05827588|Device|AWAK PD|Daily 7- or 9-hour therapy (with or without a last fill) that is a form of automated peritoneal dialysis being done by subjects who are already on daily PD therapy
45816367|NCT05827575|Device|Transcutaneous Auricular Vagal Nerve Stimulation|stimulation on both ear within different area for 4 weeks；parameter：2s on，3s off,0.5ms，25hz
45816368|NCT05827562|Diagnostic Test|flow cytometry|"Levels of circulating and synovial fluid CD4+ and CD4- T cells expressing CD8αα and CD8αβ will be assessed by flow cytometry using fluorochrome-labelled monoclonal antibodies against CD3, CD4, CD8α and CD8β surface markers. Levels of the following cells will be assessed:~CD3+CD4-CD8αα+~CD3+CD4-CD8α+CD8βlow~CD3+CD4-CD8α+CD8βhigh~CD3+CD4+CD8αβhigh~CD3+CD4+CD8αα+"
45816369|NCT05827549|Drug|Blincyto|Vincristine 1.5mg/m2, L-asparaginase 6,000 IU/m2 Idarubicin 10mg/m2 will be administered for induction therapy. Ifosfamide 1.8g/m2 Etoposide 100mg/m2 will be administered for consolidation therapy, then patients will be sorted into groups depend on their potential risk and Blinatumomab IV will be administered over 28 days. Intensification course will be administered 4 times repeated. 1. etoposide 100mg/m2 Ifosfamide 3.4g/m2 with MESNA / 2.oral 6-mercaptopurine 50mg/m2, methotrexate 25mg/m2 / 3.Ara-C 1.0g/m2, Idarubicin 5mg/m2 / 4.vincristine 2mg/m2 are the courses for repetition.
45816370|NCT05827536|Dietary Supplement|PKU GOLIKE|PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
45816371|NCT05827510|Device|BTL-585F|BTL-585F device with BTL-585-4 applicator
45816372|NCT05827497|Drug|Baricitinib 2 MG|baricitinib 2 mg once daily
45955570|NCT04357288|Other|Encounter Decision Aid|The Encounter Decision Aid (EDA) is an interactive website designed for use by a participant and their clinician together. Together, the clinician and participant can go through the website together and input the participant's health information into the same stroke risk calculator also in the PDA. The EDA also provides information about the diagnosis of AF, living with this diagnosis, and possible treatments, and prompts discussion of how a participant's values affects these aspects of AF.
45955571|NCT04341311|Drug|Marizomib|- Intravenously initially given every other week over a 28 day course but will go to weekly x 3 and weekly x 4 as the dose levels increase Up to 26 courses.
45955572|NCT04341311|Drug|Panobinostat|- Panobinostat: Oral dosage is given 3 times weekly, every other week over a 28 day course
45955573|NCT04321525|Behavioral|Cognitive-behavioral therapy|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
45955574|NCT04321525|Behavioral|Personal Construct Therapy|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
45955575|NCT04321525|Behavioral|Personal Construct Therapy with virtual reality|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
45955576|NCT04304014|Dietary Supplement|L. reuteri|(10^8 CFU) once a day
45955577|NCT04304014|Dietary Supplement|B. longum and P. Pentosaceus|(10^9 CFU) once a day
45816373|NCT05827497|Drug|Methotrexate 25mg|25mg daily
45816374|NCT05827484|Biological|Autologous platelets rich plasma|30 ml of venous blood were drawn from the participant by means of venipuncture. The collected blood was mixed with 3 ml anti-coagulant acid citrate dextrose in the centrifugation sterile tube. The blood sample was then centrifuged using the centrifugation machine. 3 ml of PRP from the buffy coat layer were loaded in a 5 ml syringe. After local sterilization and draping of the site of injection and under US guidance the hematoma was aspirated from the injury site and the freshly prepared PRP was injected.
45955578|NCT04300231|Drug|epidural bupivacaine 0.05%|Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.
45955579|NCT04300231|Drug|Liposomal bupivacaine|20 ml
45955580|NCT04300231|Drug|bupivacaine 0.125%|40 mL
45454522|NCT01343810|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
45955581|NCT04300231|Drug|bupivacaine 0.5%|60 mL
45454523|NCT05717452|Dietary Supplement|Blueberry drink|22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder mixed with 250 ml water.
45454524|NCT05717452|Dietary Supplement|Placebo drink|22 g placebo powder matched for macronutrients, color, and flavor mixed with 250 ml water.
45454525|NCT00004096|Drug|carboplatin|
45454526|NCT00004096|Drug|vinorelbine ditartrate|
45955582|NCT04300231|Drug|/hydromorphone 0.05mg/ml|Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.
45955583|NCT04300231|Drug|injectable saline|40 mL
45955584|NCT04297683|Drug|Zilucoplan|"Drug: Zilucoplan~Administration: Subcutaneous injection~Dose: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight"
45955585|NCT04297683|Drug|Verdiperstat|"Drug: Verdiperstat~Administration: Oral~Dose: 600mg twice daily"
45454527|NCT01344044|Device|BCI|24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.
45454528|NCT03794089|Behavioral|Brief anxiety intervention|Modular anxiety intervention, tailored for Veterans, with emphasis on adaptive coping skills
45454529|NCT03794089|Behavioral|Usual PC-MHI care|Anxiety treatment with mental health provider in local primary care clinic
45816375|NCT05827484|Combination Product|Autologous platelets rich plasma + oral LOSARTAN administration|in addition to local PRP injection, 50 mg / day of LOSARTAN (Cozaar® 50 mg film-coated tablets) were administrated to the study group orally every morning from day 5 and till day 30 after injury.
45955586|NCT04297683|Drug|CNM-Au8|"Drug: CNM-Au8~Administration: Oral~Dose: 30 mg or 60 mg daily"
45955587|NCT04297683|Drug|Pridopidine|"Drug: Pridopidine~Administration: Oral~Dose: 45mg twice daily"
45955588|NCT04297683|Drug|SLS-005 Trehalose|"Drug: SLS-005 Trehalose~Administration: Infusion~Dose: 0.75 g/kg weekly"
45955589|NCT04297683|Drug|ABBV-CLS-7262|"Drug: ABBV-CLS-7162~Administration: Oral~Dose: Dose 1 or Dose 2"
45955590|NCT04297683|Drug|DNL343|"Drug: DNL343~Administration: Oral~Dose: Once per day"
45955591|NCT04278898|Drug|N-Acetylcysteine|N-acetylcysteine Single Dose 2700 mg taken orally
45955592|NCT04267562|Device|Minitouch System|The investigational treatment (endometrial ablation) will be performed utilizing the Minitouch System
45955593|NCT04261543|Other|High protein and early exercise|High protein is defined as protein prescription of ≥2.2 gram/kg body weight and early exercise is defined as starting cycle ergometry intervention within 24 hours of randomization
46078678|NCT00607529|Other|hand-held POC creatinine analyzer-blood test|"This study will require the collection of a finger-puncture capillary blood specimen in addition to one green stoppered heparin containing collection tube. This is taken pre-therapy. The capillary whole blood specimen will be used to perform a creatinine determination on the investigational hand-held creatinine analyzer using special test strips for the analysis."
45454530|NCT02288572|Dietary Supplement|Lactobacillus plantarum PCS 26|Taking dietary supplement on a daily basis which corresponds to 1.000.000.000 CFU of Lactobacillus plantarum PCS 26 per day for 3 months.
45454531|NCT02288572|Dietary Supplement|Placebo|Taking dietary supplement on a daily basis for 3 months.
45454532|NCT02288650|Other|early refeeding|
45454533|NCT02288650|Other|refeeding only in the recovery room (usual practice).|
45661774|NCT05372653|Drug|OPA-15406|0.3% or 1% ointment, topical, twice daily, for 52 weeks
45661775|NCT05568511|Other|App-based exercise program|Remotely-controlled, app-guided exercise program
45816376|NCT05827471|Diagnostic Test|Diagnosis of colon cancer|Clinical diagnosis results
45816377|NCT05827432|Device|Field-cycling imaging (FCI)|FCI scan
45816378|NCT05827393|Procedure|muscle transplantation|the resected extra stump of rectus muscle was transplanted to the other horizontal rectus muscle which was recessed by a standard recession technique
45955594|NCT04261543|Other|Usual Care|Usual care group has protein prescription of ≤1.2 gram/kg body weight and exercise at the discretion of attending clinicians
45955595|NCT04254107|Drug|SEA-TGT|Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle
45955596|NCT04254107|Drug|sasanlimab|Given via injection under the skin (subcutaneous) on Day 1 of each 21-day cycle
45955597|NCT04254107|Drug|brentuximab vedotin|Given by IV on Day 1 of each 21-day cycle
45661776|NCT05568511|Other|Standard of Care|These participants will follow the usual post-sepsis care after returning to home. The participants will be asked to log their daily activities in the app's health diary. The app will be activated for the baseline and follow-up physical function assessments, which will be supervised be a blinded coordinator via a video call.
45816379|NCT05827380|Behavioral|Gait adaptability training|During a period of approximately 5 weeks participants will receive 10 one hour training sessions aimed at improving gait adaptability, using the C-mill (an instrumented treadmill with augmented reality). Several aspects of gait adaptability, such as obstacle avoidance, accelerating/decelerating and precision stepping, will be offered.
45816380|NCT05827315|Diagnostic Test|Echocardiography|Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
45955598|NCT04253327|Other|questionnaire|"Patients will be contacted by their physician during regular follow-up in the out-patient clinic or contacted by phone.~The questionnaires will be filled in at the UZBrussel, Laarbeeklaan 101, 1090 Brussels or at the patients home.~Filled-in questionnaires can be hand off immediately at the physician or send by post or email.."
45955599|NCT04251026|Drug|DNL310|Intravenous repeating dose
45955600|NCT04249362|Drug|Durvalumab|All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months.
45955601|NCT04242134|Device|Drug-coating balloon|Provisional stenting technique with DCB
45955602|NCT04241835|Drug|Tazemetostat|"Tazemetostat (EPZ-6438) in tablet form at a dose of 800 mg once daily on days 1 and 15 and twice daily on days 5 to 14 of the first 28-day cycle.~Participants may continue tazemetostat treatment at 800 mg twice daily in additional 28-day cycles until progression or unacceptable toxicity."
45955603|NCT04236739|Drug|Instant MSC Product accompanying Autologous Chondron Transplantation|Application of a mixture of allogenic MSC's and autologous chondrons with a fibrin cell carrier (Tisseel®) in the cartilage defect of the knee during one surgical procedure.
45955604|NCT04235101|Drug|SYD985 + Niraparib|SYD985 powder for concentrate for solution for infusion Niraparib 100 mg per hard capsule
45955605|NCT04230967|Behavioral|Ambulation Group|Participants in the ambulation arm will be allowed ad lib activity and instructed that they should walk at least once per day out of their room with a goal of 2,000 steps per day. The Fitbit Inspire devices will be set to this goal and notifications will be given on the device for the participants meeting their goals
45454534|NCT00002224|Drug|Nelfinavir mesylate|
45454535|NCT00002224|Drug|Stavudine|
45454536|NCT00002224|Drug|Didanosine|
45454537|NCT01207921|Drug|Lenalidomide|
45454538|NCT05725486|Dietary Supplement|N-3 PUFAs Chicken Meet|Intake of n-3 PUFAs enriched chicken meet for three weeks.
45454539|NCT05725486|Dietary Supplement|Regular Chicken Meet|Intake of regular chicken meet for three weeks.
45454540|NCT01108393|Drug|Agomelatine A|"Agomelatine 25 mg film-coated tablet~Agomelatine 2x25mg film-coated tablet"
45454541|NCT01108393|Drug|Placebo|Placebo
45454542|NCT03532594|Procedure|PRODOSE Algorithm|Protamine administered according to PRODOSE algorithm
45454543|NCT03532594|Procedure|Standard Care|Protamine administered according to Standard Care
45454544|NCT01207999|Procedure|Collection of cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus DNA testing.
45454545|NCT01207999|Other|Data collection|Questionnaire completion
45454546|NCT05725408|Behavioral|Dialectical behavior therapy-informed group eating intervention protocol|A 10-week, skills-based group eating intervention based off a condensed protocol developed by various researchers (Rebecca Kamody, Thomaseo Burton, Emily Pluhar) , which was originally based off the group skills Dialectical Behavior Therapy for Adolescents protocol by Jill Rathus, Alec Miller, and Marsha Linehan.
45661777|NCT05372341|Other|descriptive|posotcovid patients will be elective surgery postoperative outcomes
45661778|NCT01660243|Drug|Nalfurafine hydrochloride(MT-9938) 2.5μg|2.5 μg (2capsules) once daily for 8 weeks
45661779|NCT01660243|Drug|Nalfurafine hydrochloride(MT-9938) 5μg|5 μg (2capsules) once daily for 8 weeks
45816381|NCT05827315|Diagnostic Test|T1 Cardiovascular Magnetic Resonance|T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
45816382|NCT05827315|Diagnostic Test|Right heart catheterisation and coronary sinus blood sampling|10 patients from the thoracic surgical group will undergo right heart catheterisation and coronary sinus blood sampling.
45955606|NCT04230967|Behavioral|Routine Care|No encouragement to ambulate will be provided to subjects. Their movement will be recorded
45955607|NCT04230148|Drug|Egaten (Triclabendazole) 250 mg tablets|Egaten 250 mg scored tablets for oral use.
45955608|NCT04227847|Drug|SEA-CD70|Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
45661780|NCT01660243|Drug|Nalfurafine hydrochloride(MT-9938) 10μg|10 μg (2capsules) once daily for 8 weeks
45816383|NCT05827289|Device|Cancer Patients Better Life Experience (CAPABLE)|The CAPABLE system serves three main goals for the patient: symptom monitoring, information needs fulfilment and interventions to improve mental- and physical wellbeing. These are available to the patient as a smartphone application that is connected to a smartwatch to monitor activity, blood pressure, sleep and heart rate. Patients are able to report symptoms experienced from the treatment and are eligible to do interventions such as mindfulness or yoga. Patients will receive the CAPABLE application and smartwatch for a minimum 3 to a maximum of 6 months after start treatment.
45816384|NCT05827263|Diagnostic Test|T-Scan occlusal recording No. I|Occlusal information was obtained using the T-Scan device before the main intervention. This process was repeated three times to confirm the findings.
45955609|NCT04227847|Drug|azacitidine|75mg/m^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle.
45955610|NCT04220814|Radiation|MRI|MRI protocol is different, a little bit longer than MRI in routine for patients. For healthy volunteer, a specific MRI for this study is done
45955611|NCT04220814|Other|Electrophysiology|Electrophysiology will be done during routine visits for patients and during inclusion visit to healthy volunteers
45816385|NCT05827263|Device|Usage of the hydrostatic appliance|The hydrostatic appliance was removed from its packaging and placed symmetrically between the upper lip and the oral vestibule of the maxilla for the most comfortable position. After 30 minutes, the hydrostatic appliance was removed, and patients were asked to keep their mouths open until the T-Scan was positioned correctly.
45955612|NCT04218422|Procedure|Battlefield Acupuncture|Acupuncture at 5 points on the ears
45955613|NCT04218422|Procedure|Sham Acupuncture|Sham acupuncture in 2 points for liver and 1 point for stomach
46078679|NCT05658848|Other|Collaborative infertility counseling|Collaborative infertility counseling for coping stratigies and marital satisfaction
45454547|NCT01113151|Dietary Supplement|Mablet (Magnesium-supplement)|3 tablets daily for 12 weeks of Mablet (360 mg magnesium hydroxide/ -oxide) Produced by: Gunnar Kjems APS
45454548|NCT01113151|Other|Placebo|3 placebo tablets daily for 12 weeks
45454549|NCT03530410|Device|Intragastric balloon placement|Patients will have endoscopic placement of intragastric balloon that will be removed endoscopically after 6 months
45661781|NCT01660243|Drug|Placebo|Placebo (2capsules) once daily for 8 weeks
45816386|NCT05827263|Diagnostic Test|T-Scan occlusal recording No. II|The occlusal registration was repeated three times using the T-Scan device in order to confirm the findings.
45816387|NCT05827250|Device|imPulse Tor|"The imPulse-Tor system passively collects audible sounds and inaudible vibrations spanning the infrasound-to-ultrasound frequency range, as well as cardiac electrical signals. The device can be safely placed directly on the chest wall to obtain readings.~imPulse System vibroacoustic recording (VAR) will be performed twice daily till discharge. An attempt will be made to have at least a 6+/-2 hr gap between the two recordings."
45816388|NCT05827146|Drug|Hepalatide|Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
45816389|NCT05827146|Drug|Hepalatide Placebo|Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
45955614|NCT04209985|Behavioral|Health coaching|Brief telephonic intervention consisting of up to five phone calls from a health coach
45955615|NCT04209348|Behavioral|Physical Activity Intervention|Participants in both arms will wear the CGM (FDA-regulated device)
45661782|NCT05604703|Diagnostic Test|Periodontal classification|300 patients will be classified according to 1999 armitage and 2018 new periodontal classification and compared.
45661783|NCT05341687|Other|No applicable|No applicable
45955616|NCT04209348|Other|Wellness Education|Participants in both arms will wear the CGM (FDA-regulated device)
45955617|NCT04205630|Drug|SYD985|SYD985 powder for concentrate for solution for infusion
45955618|NCT04201600|Device|Continuous Glucose Monitoring System (CGMS)|Continuous Glucose Monitoring System (CGMS)- minimally invasive sensors that measure glucose concentrations at 5-min intervals over several days.
45661784|NCT05567263|Procedure|Bulk-fill resin composite, (3M, ESPE)|Teeth will be restored with Bulk-fill resin composite, (3M, ESPE)
45661785|NCT05567263|Procedure|Surefil one™ Self-Adhesive Composite Hybrid|teeth will be restored with Surefil one™ Self-Adhesive Composite Hybrid
45661786|NCT05380921|Device|standard EEG|all subjects will receive both a standard EEG and a dry electrode EEG
45661787|NCT05380921|Device|dry electrode EEG|all subjects will receive both a standard EEG and a dry electrode EEG
45661788|NCT05341609|Drug|JT001|Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days
45661789|NCT05341609|Drug|Paxlovid|Day 1~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days
45955619|NCT04195633|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
45955620|NCT04195633|Drug|Cyclophosphamide|Given IV
45955621|NCT04195633|Drug|Cyclosporine|Given IV or PO
45955622|NCT04195633|Biological|Filgrastim|Given IV
45955623|NCT04195633|Drug|Fludarabine|Given IV
45955624|NCT04195633|Drug|Mycophenolate Mofetil|Given IV or PO
45955625|NCT04195633|Drug|Mycophenolate Sodium|Given PO
45955626|NCT04195633|Radiation|Total-Body Irradiation|Undergo total-body irradiation
45955627|NCT04195633|Drug|Treosulfan|Given IV
45955628|NCT04193202|Drug|Gefapixant|Administered twice daily as an oral tablet of 45 mg
45955629|NCT04193202|Drug|Placebo|Administered twice daily as a placebo oral tablet matching gefapixant
45955630|NCT04173715|Behavioral|Older Adults Group.|Physical activity and energy expenditure quantification
45955631|NCT04173715|Behavioral|Low Physical Function Status Group|Physical activity and energy expenditure quantification
45955632|NCT04173715|Behavioral|Medium Physical Function Status Group|Physical activity and energy expenditure quantification
46078680|NCT02747316|Other|Stable iron isotope 57 (57Fe) labeled iron solution|test meal labeled with 12 mg 57Fe
46078681|NCT02747316|Other|Stable iron isotope 58 (58Fe) labeled iron solution|test meal labeled with 12 mg 58Fe
45816390|NCT05827120|Device|Mechanical / pharmacomechanical thrombectomy plus local catheter directed thrombolysis|"Catheter directed thrombolysis (CDT): dedicated thrombolytic catheter with side holes is placed across the acute thrombus, and slow, continuous infusion (through the catheter, or both through the catheter and sheath) of a chemical thrombolysis agent is applied - alteplase 1mg/hour plus unfractionated heparine in anticoagulation dosage;~Mechanical thrombectomy: mechanical aspiration of fresh thrombus;~Pharmacomechanical thrombectomy (PMT): combination of mechanical disruption of the thrombus, and its aspiration, with simultaneous application of alteplase via dedicated catheter - instilation of acute/subacute thrombus with its subsequent aspiration;"
45816391|NCT05827120|Device|Local catheter directed thrombolysis alone|- Catheter directed thrombolysis (CDT): dedicated thrombolytic catheter with side holes is placed across the acute thrombus, and slow, continuous infusion (through the catheter, or both through the catheter and sheath) of a chemical thrombolysis agent is applied - alteplase 1mg/hour plus unfractionated heparine in anticoagulation dosage;
45955633|NCT04173715|Behavioral|High Physical Function Status Group|Physical activity and energy expenditure quantification
45955634|NCT04171050|Drug|Local anaesthetic|Local anesthesia injections
45955635|NCT04171050|Drug|Pudendal Nerve Block plus anesthesia|Local anesthesia injections plus a pudendal nerve block
45955636|NCT04159935|Device|iLux® system|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
45955637|NCT04155619|Behavioral|No change in meal timing|Participants will eat within an ≥11-hour daily period (no change in meal timing habits).
45955638|NCT04155619|Behavioral|No change in light exposure|Participants will not change their light exposure habits.
45955639|NCT04155619|Behavioral|Early Time-Restricted Feeding|Participants will eat within an 8-hour daily period early in the day, starting within 2 hours of waking up.
45955640|NCT04155619|Behavioral|Timed Light Therapy|Participants will use bright light therapy for 60 minutes between 6 am - 3 pm, blue light-blocking glasses for one hour before bedtime, and blackout curtains at night.
45955641|NCT04151251|Behavioral|Patient Empowerment|Group to receive a 5 minute video about typical hospital sleep disruptions and what they can do to prevent them, as well as a brochure outlining the importance of sleep
45661790|NCT05604391|Procedure|Free gingival graft placed apically|For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing it in the apical region of the gingival recession according to the randomly selected positioning technique.
45661791|NCT05604391|Procedure|Free gingival graft placed coronally|For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing the coronal region of the gingival recession according to the randomly selected positioning technique.
45816392|NCT05826496|Other|Exercise|The supervised high-intensity interval training is conducted on bicycle ergometers at 85-95% maximal workload. The high-intensity interval sequences will be separated by two steady state sequences. Blood samples are collected at baseline, 2 min and 60 min post-exercise.
45816393|NCT05826119|Drug|magnesium sulfate group|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) <90mmHg or <20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR < 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.
45955642|NCT04151251|Other|Sleep Kit|Patients receive a small pouch that includes an eye mask, ear plugs, and headphones, all to be used to aid in falling/staying asleep
45955643|NCT04128696|Drug|feladilimab|feladilimab is available as an intravenous infusion.
45955644|NCT04128696|Drug|Pembrolizumab|Pembrolizumab is available as an intravenous infusion.
45955645|NCT04128696|Drug|Placebo|Placebo is available as an intravenous infusion.
45955646|NCT04126369|Other|mindfulness intervention|The mindfulness program is conducted in a group session of up to 10 people. Each session lasts 2 hours. A total of 12 sessions will be conducted by a practitioner who is specifically trained in this type of programme.
45955647|NCT04126369|Other|psycho educative programme|The psycho-educational control intervention will follow the same format and structure as the mindfulness meditation intervention in terms of group format, session duration and frequency. This is a therapeutic education programme developed for several years in the neurology department of the university hospital of Lyon and Grenoble. The program follows the repository recommended by the french league against epilepsy.
45955648|NCT04116489|Other|Forest walk|Participants will be provided with an educational program about the forest and take a guided forest walk.
45955649|NCT04116489|Other|Wildlife rehabilitation|Participants will be provided with education on wildlife rehabilitation and assist with wildlife care such as feeding baby animals.
45454550|NCT01210417|Other|Non invasive monitoring|Three-lead electrocardiogram (ECG), PPG oxymetry, non-invasive blood pressure (NIBP) are registered
45454551|NCT03530332|Diagnostic Test|PreTRM test|Blood test to determine risk of preterm birth
45661792|NCT05565079|Biological|Regenerative tissue matrix and enamel matrix derivative|Subjects in this group will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM) and a porcine-derived enamel matrix derivative (Emdogain).
45816394|NCT05826119|Drug|Placebo|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) <90mmHg or <20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR < 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
45454552|NCT03945409|Device|OPTIVENT|OPTIVENT (SIDAM SRL, Mirandola, Italy) is a new fully automated and self-calibrating system that allows a real-time monitoring and recording of airway pressure and esophageal pressure during mechanical ventilation. The system required the insertion of an esophageal balloon catheter and an airway pressure transducer.
45816395|NCT05825898|Procedure|Surgery or Transcatheter tricuspid valve intervention|Isolated tricuspid valve surgery or Transcatheter tricuspid valve intervention
45816396|NCT05825846|Device|Virtual- reality active shooter drill|"The stress protocol used for this experiment utilized a previously studied virtual reality active shooter drill (VR-ASD). The VR-ASD scenario (~2 min) involves the participant physically walking down a ~10-foot-long virtual hallway where they will encounter wounded victims. Once at the threshold of to the attack room, they will observe one victim on the ground with a traumatic head injury and the shooter firing his handgun at the last victim, the participant will fire a shot, and the shooter will fall after being shot."
45816397|NCT05825495|Drug|Dinalbuphine sebacate|A single dose of 150 mg dinalbuphine sebacate will be intragluteally administrated at least 12 hours before surgery.
45816398|NCT05825495|Other|Routine practice|Within 3 days after surgery, paracoxib will be administrated twice a day. Ketorolac will intravenously give once breakthrough pain occurring. Enteral acetaminophen will be take regularly within 14 days after surgery.
45816399|NCT05825443|Drug|Camrelizumab|Patients received four 21-day cycles of chemotherapy (decided by the researcher) combined with camrelizumab (200 mg in day 1), followed by maintenance with camrelizumab (200 mg in day 1, q3w), until one year or the disease progressed or unacceptable toxicity.
45816400|NCT05824780|Other|Exercise training|4-week weightlifting strength training
45816401|NCT05824741|Behavioral|Infant Cardiovascular Health (CVH) Promotion|The pilot infant CVH intervention will be delivered by Nurse-Family Partnership (NFP) staff starting no later than 1 month postpartum and lasting up to 6 months postpartum. The visit schedule will be consistent with the NFP visit structure to deliver intervention content at regularly scheduled visits that are typically 60 minutes long. This pilot study will include an enhanced version of the NFP standard care plan delivered by trained nurses to promote cardiovascular health by targeting soothing, feeding, sleep, and physical activity behaviors during infancy. The intervention delivered by trained visiting nurses will include behavior change strategies (e.g., goal setting, problem solving barriers). This pilot study will also examine the feasibility and acceptability of a digital device (infant foot worn actigraphy) during this same time period.
45816402|NCT05824299|Procedure|General Anesthesia|Patients will have TURBT under general anesthesia, which is induced with midazolam, propofol, sufentanil and rocuronium. The patients will be mechanically ventilated with laryngeal mask airway (LMA). Anesthesia will be maintained with sevoflurane/desflurane, propofol and remifentanil.
45816403|NCT05824299|Procedure|Spinal Anesthesia|Patients will have TURBT under spinal anesthesia. 10~15mg of 0.5% ropivacaine will be injected in the subarachnoid cerebrospinal fluid at the levels of L2-L3 or L3-L4 in lumbar space. It will numb the nerve supply of the belly, hips, bottom as well as legs. The patient stays awake and won't feel any pain due to operation.
45816404|NCT05824169|Genetic|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
45955650|NCT04116489|Other|Wildlife sanctuary observation|Participants will be provided an educational program on wildlife care and accompany park game keepers during animal feeding and will observe iconic wildlife.
45955651|NCT04116489|Other|Bird feeding and watching|Participants will learn about bird identification and safe bird feeding. Bird feeders will be provided at the Soldier On facility for home bird feeding after study conclusion.
45955652|NCT04104243|Other|Men-Tailored DPP (Power-Up)|Evaluating whether a diabetes prevention program (DPP) tailored for men (Power-Up) will show better or similar percent weight loss and retention than a standard mixed-gender DPP
45955653|NCT04098081|Drug|galeterone|Therapeutic
45955654|NCT04098081|Drug|Gemcitabine|Therapeutic
45955655|NCT04097054|Procedure|Augmented preoperative planning|The study investigates the impact of augmented preoperative planning on OR time variance in complex and rare visceral surgical procedures.
45955656|NCT04079634|Device|Esophageal warming|Use of EnsoETM for esophageal warming to limit injury during atrial fibrillation ablation procedure
45454553|NCT01113229|Drug|Misoprostol|two misoprostol tablets taken orally (400µg)
45661793|NCT05565079|Biological|Regenerative tissue matrix|Subjects in both groups will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM).
45955657|NCT04079634|Device|Control|Standard temperature probe monitoring
45955658|NCT04068935|Procedure|fracture immobilization after reduction of displaced finger fractures|After closed reduction of a displaced finger fracture, fracture immobilization with either Buddy taping or Splint immobilization
45816405|NCT05824104|Other|Intermittent Hypoxia|The intermittent hypoxia protocol refers to four cycles of 5 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 7 days.
45955659|NCT04045600|Behavioral|Trad FCT|This intervention emulates a traditional reinforcement schedule-thinning method during FCT in which clinicians program delays to reinforcement without discriminative stimuli (e.g., the child learns that some FCRs result in reinforcement and some do not). By programming reinforcement approximately every 15 s, the rate of reinforcement will be equivalent to mult FCT. During Period 1 of this project, trad FCT served as an appropriate control condition to which mult FCT could be compared.
45661794|NCT05341453|Procedure|Individual physiotherapy (SMA-SOC)|Therapeutic procedures according to the recommended standard (SMA-SOC) will be used in the therapy. Elements of breathing gymnastics, vibration techniques, stretching, eccentric and concentric exercise procedures will be combined. Individual physiotherapy will be conducted on the basis of set goals from the kinesiological examination, it will be adapted to the individuality of the child - his cooperation, fatigue and sleep time.
45955660|NCT04045600|Behavioral|Mult FCT|This intervention involves correlating discriminative stimuli (e.g., purple and yellow index cards) with times in which reinforcement for the functional communication response (FCR) is and is not available. During Period 1 of this project, this procedure resulted in rapid reduction of destructive behavior and mitigated resurgence and renewal when the discriminative stimuli were used as programmed.
45955661|NCT04045600|Behavioral|Mult FCT + Stimulus Fading|This condition is similar to mult FCT except that the experimenters will gradually incorporate natural stimuli (e.g., rugs, tables, lamps) into sessions to approximate target settings that may occasion relapse typically without such gradual stimulus fading.
45955662|NCT04039607|Drug|Nivolumab|Participants will receive nivolumab as intravenous (IV) infusion.
45955663|NCT04039607|Drug|Ipilimumab|Participants will receive ipilimumab as IV infusion.
45955664|NCT04039607|Drug|Sorafenib|Participants will receive sorafenib as oral tablets.
45955665|NCT04039607|Drug|lenvatinib|Participants will receive lenvatinib as oral capsules.
45955666|NCT04036409|Drug|Intensive Control of Systolic Blood Pressure (SBP)|Participants in the Intensive arm have a goal of SBP <120 mm Hg. The use of angiotensin converting enzyme (ACE)-inhibitors/Angiotension receptor blockers (ARBs), Thiazide-type diuretics, calcium channel blockers (CCB), Sustained-release calcium channel blockers (CCBs) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine +amlodipine
45955667|NCT04036409|Drug|Standard control of Systolic Blood Pressure (SBP)|The same medications used in the Intensive BP arm will be used for the Standard BP arm.
45955668|NCT04033952|Behavioral|Strategy Training|This approach is different from traditional direct skill training, which emphasizes clinicians' responsibility on identifying their patients' challenges in performing activities and teaching patients task-specific problem-solving strategies. Strategy training, on the other hand, requires clinicians to take a role as a facilitator, guiding participants to learn through prompts and questions. In the training process, participants learn to develop their own problem-solving strategies and work through the problems they have, through which they can develop self-efficacy and confidence to manage participation challenges. Participants can also generalize the strategies they learn to other similar problems they encounter in daily life.
45955669|NCT04028986|Drug|Ulipristal Acetate 5 MG Oral Tablet|use of ulipristalacetate OR surgery before fertility treatment
45955670|NCT04009122|Dietary Supplement|IGEN0206|Group A
45955671|NCT04009122|Other|Placebo|Group B
45955672|NCT04000971|Other|Integrated Stroke Practice Unit|Care teams will follow patients in their home or rehabilitation/skilled nursing facility monthly for 12 visits to assess recovery, manage risk factors, and increase understanding and build positive behavior change for patients and caregivers. Primary and secondary outcomes will be assessed at 3, 6, and 12 months.
45454554|NCT03530176|Radiation|18Fluoride-Sodium Fluoride radio-isotope|The investigators will be using 18F-NaF to image premature atherosclerosis in the coronary arteries of diabetic patients.
45661795|NCT05341453|Procedure|Hippotherapy|"HT by CP is an accredited form of hippotherapy, whose methodology is based on the clinical picture of cerebral palsy, but its procedures are applicable to a wider group of children with disabilities. Therefore, investigators anticipate it´s effect for children with SMA.~Based on a special type of examination, this method precisely determines the type / breed of the horse according to the biomechanics of the movement of its back in the step, the position of the child and the neurophysiological function of the back - differentiation or sensorimotor skills. Furthermore, according to the course of therapy, the physiotherapist determines the pace of the horse's step, its length, selects special manual contacts according to the current situation and adjusts the duration of therapy to the client's fatigue.~Therapy will be performed by therapists with professional competence to perform hippotherapy by children with CP."
45816406|NCT05824052|Other|Ozone injection|Ozone injection is a process where ozone gas is injected into a substance or system for various purposes. Ozone gas (O3) is a highly reactive form of oxygen that can be generated through the use of specialized ozone generators. Ozone injection can be used in a variety of applications, including water treatment, air purification, and medical therapy.
45816407|NCT05824039|Dietary Supplement|Tea infusion|Tea infusion: The aerial parts of the medicinal plant were dried, then, they were powdered in a rotating knife grinder. The herbs were taken as tea infusion by the oral route. The powder was added to 100 ml of boiling water and the tea infusion was taken once time a day at the bed time and it was repeated for 10 days.
45955673|NCT04000971|Other|Comprehensive or Primary Stroke Center|Primary and secondary outcomes will be assessed at 3, 6, and 12 months.
45955674|NCT03985501|Other|SCD newborn screening with the MS/MS method from Zentech|The analysis of the SCD newborn screening with the MS/MS method from Zentech will be realized after achievement and biological validation of the SCD newborn screening in the usual care pathway. The results will be compared with the method used at the Lille Academic Hospital (CHU Lille) (sub-contractor for SCD newborn screening of Lyon)
45955675|NCT03972163|Behavioral|NIA Medication Management - Active Comparator|"As the attention control, we will refer staff in control offices to the National Institution on Aging (NIA)'s website on Medicines and Medication Management to review content and materials for use in Family Care Giver (FCG) support."
45454555|NCT03942679|Other|PRP|Patients in this group will receive three ultrasound guided PRP injections in the supraspinatus tendon with one week interval (Ilhanli et al., 2015). After the injection, patients will be instructed to limit the use of shoulder for at least 24 hours and to use cold therapy for pain. After the third injection, ROM, and stretching exercises will be allowed and one month after the end of injections, patients will be recommended to begin the strengthening program as tolerated. Exercise is performed with 10 repeats five sessions per week.
45661796|NCT05341453|Procedure|Therapeutic grooming|In order to influence the psychomotor development in a comprehensive way, the psychosocial activity of therapeutic grooming will also be included in the study. Its goal is to support children's communication, their interaction with the environment, the ability to establish contact with the horse and the overall emotional support of children with SMA. The purpose of this activity is to clean the horse, its possible guide, stroking and contact with the horse, work from the ground.
45661797|NCT05538013|Other|Survey evaluation|Obesity awareness, physical activity, and sedentary time questionnaires will be applied to these cases.
45661798|NCT05534269|Biological|autologous muscle precursor cells|Patients own Muscle Precursor Cells are isolated and injected into the rhabdomyosphincter
45955676|NCT03972163|Behavioral|STOPPFrail (Screening Tool of Older Persons Prescriptions)|A screening tool used by clinicians with frail older adults with life-limiting illness to review medications
45458137|NCT01234285|Drug|heparin|intravenous heparin titrated to an aPTT of 40-50 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
45955677|NCT03972163|Behavioral|"Discontinuing Medication Appropriately and Understanding the Art of Communication about Deprescribing"|Education resoruce used by clinicians to simplify and align medications with goals of care
45661799|NCT05371015|Procedure|quadratus lumborum nerve block (ropivacaine )|Echo guided quadratus lumborum nerve block with ropivacaine
45955678|NCT03972163|Behavioral|"Key Approaches to Support Informal Family Caregivers in Managing Medications"|Education resource used by clinicians to support Family Care Givers (FCGs)
45955679|NCT03972124|Drug|CBD 100 mg OD|CBD oil - purified to <1% THC in soft-gel capsules
45955680|NCT03972124|Drug|CBD 200 mg OD|CBD oil - purified to <1% THC in soft-gel capsules
45955681|NCT03972124|Drug|Placebo|Soft-gel capsules containing placebo
45955682|NCT03970070|Other|Informational Intervention|Complete Perioperative Ostomy Self-Management Telehealth program
45955683|NCT03970070|Other|Quality-of-Life Assessment|Ancillary studies
45955684|NCT03970070|Other|Questionnaire Administration|Ancillary studies
45955685|NCT03970070|Other|Survey Administration|Ancillary studies
45955686|NCT03961672|Drug|Duvelisib|Given PO
45955687|NCT03944668|Behavioral|Exercise|36 sessions of comprehensive cardiac rehabilitation over 12 weeks
45955688|NCT03915418|Procedure|Connected tools|At home, parents will record their child's sleep for 1night Then, on the date scheduled for the inclusion of the children and after the recording of the 1 night at home, the child will spend a night in a hospital environment to carry out the recording by polysomnography and tools connected simultaneously.
45955689|NCT03914612|Drug|Carboplatin|Given IV
45955690|NCT03914612|Procedure|Computed Tomography|Undergo CT scan
45955691|NCT03914612|Drug|Paclitaxel|Given IV
45955692|NCT03914612|Biological|Pembrolizumab|Given IV
45955693|NCT03914612|Other|Placebo Administration|Given IV
45955694|NCT03914612|Other|Quality-of-Life Assessment|Ancillary studies
45955695|NCT03914612|Other|Questionnaire Administration|Ancillary studies
45955696|NCT03914482|Device|MRI|The device will acquire thermoacoustic data while the ultrasound probe acquires ultrasound images, and an MR of the liver is acquired as a comparative modality
45955697|NCT03900793|Drug|Losartan|Losartan will be administered orally daily on days 1-42 (6 weeks) with dose level assignments per Table 1 of the protocol. Dosing will be performed based on weight in kilograms and rounded to the nearest 12.5 mg (half of 25 mg tablet). Dose level 1 dosing will not exceed 50 mg daily and dose levels 2 and 3 dosing will not exceed 100 mg daily. Doses should be taken at approximately the same time daily and patients should fast for > 4 hours prior to dosing
45955698|NCT03900793|Drug|Sunitinib|Sunitinib will be administered orally daily on days 1-28 (4 weeks), followed by 14-day rest period (2 weeks). Dosing will be performed based on body surface area (BSA) in mg/m2 per Table 1 of the protocol. Doses should be taken at approximately the same time daily.
45661800|NCT05371015|Procedure|quadratus lumborum nerve block (normal saline)|Echo guided quadratus lumborum nerve block with normal saline
45661801|NCT05370391|Behavioral|Comprehensive Behavioral Intervention for Tics (CBIT)|The CBIT (or CBIT-JR) intervention consists of a minimum of 6 sessions of 50-minutes each week in an individual or group setting.
46078682|NCT02816216|Behavioral|CampAir|An empirically-based dynamic e-health intervention (based on the evidence-based ASMA) to assist adolescents with uncontrolled asthma to learn how to manage their illness and improve their asthma control.
45661802|NCT05598463|Device|OASIS Pro|This device can track the joint movement and provide real-time feedback on the exercise performance and accuracy using Kinect camera sensor, and Wearable sensor (IMU). This device is connected to the website, which available for medical staff prescribe the exercise protocol and monitor individual exercise adherence.
45955699|NCT03898804|Device|BCI and FES|The intervention consists of surgical implantation of the device components, BCI and FES that will interface with computers that process and decode neural information, compute stimulation parameters, and control communication between the device components. The device will be tested during research sessions spanning a 13-month period.
45955700|NCT03897881|Drug|mRNA-4157|Individualized Neoantigen Therapy
45955701|NCT03897881|Biological|Pembrolizumab|Intravenous infusion
45955702|NCT03896880|Diagnostic Test|blood culture|"During the febrile episode, two blood samples per patient will draw from two separate sites including central venous catheter if present and directly injected to Bact/Alert® bottles and incubated in Bact/ALERT system instrument (bioMérieux Diagnostics, Lyon, France).~A-Identification of microorganisms including:~Isolation of microorganisms:~Blood culture samples with positive signals will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates.~B-Identification of the bacterial organism~Pure colonies of isolated microorganisms were identified by:~Morphology on agar,Gram stain film was made from the growth to identify morphology of the organism ,Biochemical tests~C-For fungi isolate the following will perform:~Microscopic examination of Lactophenol cotton blue (LCB) wet mounts.~Culture on Brilliance Candida differential agar"
45661803|NCT05370079|Biological|Collection of biological sample (blood and/or CSF)|"Blood sample will be collected one time for each patient:~2 *4ml of blood on dry tube 2 *4ml of blood on EDTA tube~If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml)."
45661804|NCT05340907|Device|Virtual Reality Device|A virtual reality headset is a heads-up display (HUD) that allows users to interact with simulated environments and experience a first-person view (FPV). VR headsets replace the user's natural environment with virtual reality content, such as a movie, a game or a pre-recorded 360-degree VR environment that allows the user to turn and look around, just as in the physical world. Patient undergoing bronchoscopy will be given the device before and during the procedure.
45816408|NCT05823090|Device|light box (Carex DayLight Classic Model)|The active light box is a white fluorescent 4000 Kelvin unit that emits 10,000 lux and measures 33cm x 40cm. The placebo box emits 50 lux dim red light and appears identical to the active unit. Subjects were instructed to position themselves 30-36 cm from the box with their faces fully exposed to the light. The actigraphy device is a Phillips Spectrum Plus Actigraphy watch which collects activity level and sleep information along with multiple light measurements and wearer adherence.
45955703|NCT03896880|Other|Anti fungal susceptibility testing or antibiotic susceptibility testing|isolation of microbes from positive blood culture and anti fungal susceptibility testing or antibiotic susceptibility testing according to isolated microbes by disc diffusion method and Vitek2
45661805|NCT05309161|Dietary Supplement|Crassocephalum rabens extract|dosage: a capsule (180 mg)/day; duration: 1 month
45661806|NCT05339659|Device|mHealth Intervention|Mobile health (mHealth) app to motivate and support quitting smoking.
45661807|NCT02531113|Drug|RPC1063|
45661808|NCT05308069|Device|Single vision contact lens|Subjects will wear a single vision soft contact lens only during the study visit
45661809|NCT05308069|Device|Multifocal contact lens|Subjects will wear a multifocal soft contact lens only during the study visit
45661810|NCT05509933|Drug|Budesonide|budesonide starting day 5 after transplant
45816409|NCT05822934|Drug|Carboplatin-Gemcitabine Cisplatin-Gemcitabine|Carboplatin-gemcitabine versus cisplatin-gemcitabine as neoadjuvant chemotherapy for treatment of muscle invasive urinary bladder cancer
45955704|NCT03896880|Other|phenotypic identification methods of the isolated organism by Vitek2 (BioMerieux,France)|The VITEK 2 is an automated microbial identification system that utilizing growth-based technology. With its colorimetric reagent cards, the VITEK 2 offers a state of the art technology platform for phenotypic identification methods.
45955705|NCT03896880|Other|Identification of the isolated organism by multiplex PCR|FilmArray blood culture identification (BCID) is automated multiplex PCR assay, the FilmArray blood culture identification which directly identifies common pathogens, including 7 genera/ species of Gram-positive bacteria, 10 genera/species of Gram-negative bacteria, and 5 species of Candida (as well as 3 resistance determinants) in the positive blood culture bottles. The assay requires about 2 min of hands-on sample processing time and 1 h of instrument time (which includes DNA isolation, amplification, and detection).
45955706|NCT03883542|Genetic|genomic mutations study|"Sequencing of the DNA samples extracted from the subgroups~serous BOT tissue,~serous BOT tissue with non-invasive implants and~serous BOT tissue with micropapillary grow pattern will undergo a panel testing for Type 1 genes (small panel 15-40 mutations) AND p53 AND BRCA testing~Sequencing of the DNA samples extracted from the serous BOT tissue with invasive implants will undergo a more comprehensive examination (large panel +- 1000 genes checked)"
45955707|NCT03871543|Device|AquaComfort Plus|Test Lens 1
45955708|NCT03871543|Device|Acuvue Oasys 1-Day|Test Lens 2
45816410|NCT05821972|Drug|Nebulization of dexmedetomidine and ketamine|Pre-operative nebulization of dexmedetomidine and ketamine
45661811|NCT05369533|Device|Telerehabilitation|The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. TR sessions will be a combination of games, exercises, stroke education, assessments, in addition to videoconferencing with therapists to discuss progress, issues, goals, and changes to the treatment plan.
45661812|NCT05369533|Drug|Sinemet Pill|Sinemet 25/100 will be taken 1 hour prior to TR, for the first 18 sessions.
45661813|NCT05369533|Drug|Placebo|Placebo will be taken 1 hour prior to TR, for the first 18 sessions.
45661814|NCT05368519|Device|Brijjit®|Brijjit® is a non-invasive device which serves as a force modulating tissues bridges (FMTB) to aid in wound healing. This device used in would closure and serves to modify the mechanical forces on a wound which are implicated in adverse outcomes including scar formation and complications like wound dehiscence. Brijjit® is a flexible device which attaches via adhesive to the tissue on either side of the wound, approximates the tissue and off-loads forces.
45661815|NCT05338333|Device|Lehfilcon A multifocal contact lenses|Investigational frequent replacement soft contact lens indicated for the optical correction of presbyopia
45661816|NCT05338333|Device|Lotrafilcon B multifocal contact lenses|Commercially available frequent replacement soft contact lens indicated for the optical correction of presbyopia
45816411|NCT05821972|Drug|Nebulization of dexmedetomidine|Pre-operative nebulization of dexmedetomidine
45454556|NCT03942679|Other|physiotherapy|Patients in this group will be treated with hot pack for 15 minutes, ultrasound in continuous mode (1.5 watt/cm2 for five minutes), trans-cutaneous electrical nerve stimulation in brief-intense mode for 15 minutes, range of motion (ROM), followed by stretching and strengthening exercises with 10 repeats 15 sessions (five sessions per week for three weeks). After the physical therapy, the exercise program will be continued as homework during the follow-up period.
45661817|NCT05338333|Device|CLEAR CARE®|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
45661818|NCT04255693|Behavioral|diet adherence|"This type of intervention is to be established in a-posteriori analysis by the assessment of a fact whether a subject kept to use his usual diet or it contained substantial changes."
45661819|NCT04255693|Behavioral|No diet adherence|"A-posteriori established intervention based on the examinations at the end-point"
45661820|NCT04255693|Behavioral|Change in physical activity|The changes in physical activity will be assessed a-posteriori based on the examination at the end-point versus baseline data
45661821|NCT04255693|Behavioral|No change in physical activity|The changes in physical activity will be assessed a-posteriori based on the examination at the end-point and comparison to the baseline data
45661822|NCT04255693|Behavioral|Use of antisecretory agents|"This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data. The need for the use of anti-secretory agents depends on the form of GERD and will be on the treating physician discretion. It is principal to account the use of anti-secretory agents (H2-histamine receptors blockers, proton pump inhibitors) as a major factors that may influence the outcomes."
45816412|NCT05821764|Other|Blood sample and data collection|"Solicitation of parturients during a prenatal visit between 22 and 41 weeks of gestation or during their hospitalization in a high-risk pregnancy sector and at the latest on the day of their delivery.~Blood sample :~Maternal sample within 72 hours before or after delivery during a care-based venipuncture (additional 10 mL sample) ;~The cord blood sample (10 mL) immediately after delivery.~Data collection :~A data collection sheet for the attention of the investigator (doctor or midwife) ;~Additional data relating to the history of vaccination and infection completed by the patients included during their stay in the maternity ward and before their discharge from the hospital (Delay between 0 and 6 days after inclusion)."
46078683|NCT04238234|Device|IVC Ultrasonography|Ultrasound measurements will be performed using a curved transducer set to abdominal mode (1-5 MHz; Acuson x300; Siemens Healthcare, Seoul, Korea). IVC variation will be assessed using ultrasound in the long-axis (sagittal) view. IVC diameter will be measured 1 cm distal to its junction with hepatic vein either by 2-D or M modes via a subcostal approach according to the methodology described by the American Society of Echocardiography . A two-dimensional image of the IVC as it enters the right atrium will be first obtained.
45661823|NCT04255693|Behavioral|No use of antisecretory agents|"This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data."
45816413|NCT05816525|Procedure|Partial removal of carious tissue|Nonselective carious tissue excavation will be performed in the periphery of the cavity to achieve a good marginal seal. In the pulpal wall selective, partial carious tissue excavation is performed to the soft dentin, removing tissue only the amount that is necessary for placing the restoration. The tooth is restored with high-viscosity glass-ionomer cement.
45661824|NCT04248595|Drug|Homoharringtonine|De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
46078684|NCT04238234|Device|Plethysmographic variability index (PVI) and perfusion index readings (PI)|"The PVI and PI will be recorded in the supine position by an anaesthesiologist who was not involved in the further intraoperative monitoring of the patient using Masimo SET (MightySat 9900, Masimo Corporation, Irvine, CA, USA).~PVI (%) is a measure of the dynamic change in PI that occurs during one or more complete respiratory cycles, calculated as:~PVI= [(PImax-PImin)/PImax] x100"
45661825|NCT04248595|Drug|Azacitidine|De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
45816414|NCT05816525|Procedure|Final restoration|The teeth will be restored with composite resin after 12 months follow up, if the tooth is asymptomatic, responds to sensibility tests and there are no periapical changes radiographically. Glass ionomer cement will be only partially removed to create space for the final restoration.
45458138|NCT01234285|Drug|heparin|intravenous heparin titrated to an aPTT of 50-60 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
45458139|NCT01234285|Drug|heparin|intravenous heparin titrated to an aPTT of 40-45 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
45816415|NCT05815446|Device|CT|NON CONTASR COMPUTED TOMOGRAPHY
45816416|NCT05812976|Other|Pulmonary Index of Microcirculatory Resistance|PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery.
45816417|NCT05812976|Other|Right Ventricle Index of Microcirculatory Resistance|RV-IMR measurement involves placing a coronary pressure wire in the acute marginal branch of the right coronary artery and making pressure/time measurements during maximal flow down the artery.
45661826|NCT04247425|Other|Exercise Counseling|Receive instructional guidance
45816418|NCT05811598|Device|repeated ultra low lever red light|Myopia indoor lighting therapy
45816419|NCT05807516|Other|Single-cell RNA sequencing (scRNAseq), whole-exome sequencing (WES)|Combined both retrospective and prospective observational design
45661827|NCT04247425|Other|Quality-of-Life Assessment|Ancillary studies
45661828|NCT04247425|Other|Questionnaire Administration|Ancillary studies
45816420|NCT05803616|Diagnostic Test|Liquid biopsy|ctDNA measured in the plasma and analyse by next generation sequencing (NGS) for minimal residual disease (MRD)
45816421|NCT05795075|Procedure|Computerized Modified Paramedian Approach Technique|Computerized Modified Paramedian Approach Technique ( CMPAT )
46078685|NCT04237766|Other|Experimental group|"The intervention will consist of the visualization of the movement through the Mirror Therapy application, or through the reproduction of an immersive 360º video emitted on a mobile device and visualized with virtual reality glasses.~The movements observed with both technologies will be the same. The knee extension and dorsal ankle flexion movements (quadriceps and triceps sural), together with the elbow flexion (elbow flexors) will be the movements to be performed, based on their functional need (ambulation and feeding, respectively)."
45661829|NCT04247425|Other|Resistance Training|Complete progressive resistance training
45816422|NCT05795075|Procedure|Conventional Midline Approach Technique|Conventional Midline Approach Technique
45816423|NCT05794178|Behavioral|Education|Education about health benefits of physical activity, 2018 US Physical Activity Guidelines, assigned goals tailored to baseline step counts, and worksheet to develop action and coping plans (three of each)
45816424|NCT05794178|Behavioral|Activity tracker|Fitbit activity tracker and mobile app to provide ad libitum behavioral feedback and self-regulatory support
45816425|NCT05794178|Behavioral|Text messaging (random timing and selection)|Four text messages/day at random times within a participant's availability window and drawn at random from one of three content libraries (move more [40%], sit less [40%], inspirational quotes [20%])
45955709|NCT03862963|Behavioral|Standard of diabetes care|The standard of diabetes care consisted of standard treatment protocols used by the MOH Diabetes Clinic. These included placing T2D patients on anti-hyperglycemic agents appropriate to their HbA1c levels (including sulfonylureas, metformin, and insulin) and providing oral and written information about the importance of maintaining a healthy weight, eating a healthy diet, and getting regular exercise. Participants in the control group were instructed not to make changes in their diet and activity levels during the study.
45955710|NCT03862963|Behavioral|Lifestyle Intervention|The lifestyle intervention consisted of a high-fiber, low-fat, mostly plant-based diet and 30-60 minutes per day of culturally-relevant, moderate intensity exercise. Participants initially received 12 weeks of group educational classes and some prepared meals and then followed the lifestyle intervention on their own for the remaining 12 weeks. Group classes included informative sessions on healthy eating, exercise (both aerobic and strength training), and stress management, as well as hands-on cooking classes. Classes were delivered as a combination of PowerPoint presentations, practical workshops, dine-outs, shopping tours, and cooking classes with spouses.
45955711|NCT03854019|Drug|Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)|DM/Q 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days.
45955712|NCT03854019|Drug|Placebo|Placebo once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.
45661830|NCT05337709|Other|Education intervention and medication review|Education on osteoarthritis and pain management will be provided to the patients by face-to-face communication at the first meeting, aided with a leaflet, then patients will get the follow-up calls and a video will be shown to enforce the intervention. Medication review includes the assessment of patients' knowledge on the indication, identification of any drug-related problem, and counseling on the proper use of medication.
45816426|NCT05794178|Behavioral|Text messaging (precision dosing)|Up to four text messages/day within a participant's availability window, timed and selected from one of three content libraries (move more, sit less, inspirational quotes) based on a person-specific dynamic model and contextual data
45816427|NCT05790213|Drug|Apalutamide Oral Product|Apalutamide 240 mg by mouth daily for a total of 6-months.
45816428|NCT05790213|Drug|Androgen Deprivation Therapy (ADT)|ADT therapy will consist of any generic luteinizing hormone-releasing hormone agonist which will provide either 6-months of treatment or two injections every 3-months. (e.g., one injection with a treatment period of 6 months or two injections, one at drug start and one 3-months later).
45955713|NCT03852082|Procedure|percutaneous coronary intervention|Patients with coronary heart disease co-morbid depression post percutaneous coronary intervention.
45454557|NCT02288728|Procedure|Gastric tube anastomosis|"In the gastric tube group, the lesser curvature of the gastric remnant approximately 3 cm proximal to the pylorus was removed first by a linear stapling device. An approximately 5-cm-wide tubular stomach was then constructed with preserved right gastric vessels. The length of the tube was consistent with the greater curvature of the residual stomach. The reconstructed gastric tube was lastly anastomosed with the proximal esophageal end.~(Reference: Chen XF, Zhang B, Chen ZX, Hu JK, Dai B, Wang F, Yang HX, Chen JP. Gastric tube reconstruction reduces postoperative gastroesophageal reflux in adenocarcinoma of esophagogastric junction. Dig Dis Sci. 2012;57(3):738-745.)"
45454558|NCT02288728|Procedure|Double-track anastomosis|"Double-track anastomosis group: First, cut off the jejunum about 15-20 cm away from the Treitz ligament; Second, Roux-en-Y esophagojejunostomy (E-J stomy, first anastomosis) was perform by 25mm circular stapler device; Third, from 30-40cm to the E-J stomy, perform the side-to-side gastrojejunostomy (G-J stomy, second anastomosis). Forth, from 25-30cm to the G-J stomy, perform the jejunojejunostomy (J-J stomy, third anastomosis).~(Reference: Ahn SH, Jung do H, Son SY, Lee CM, Park do J, Kim HH. Laparoscopic double-tract proximal gastrectomy for proximal early gastric cancer. Gastric Cancer. 2014;17(3):562-70.)"
45816429|NCT05790213|Procedure|Focal Therapy|Focal therapy to be completed within 8- to 12-weeks of the initiation of apalutamide but after the completion of the 8-week mpMRI to allow for it to be used in FT planning.
45816430|NCT05789472|Behavioral|Assessment|Executive functions and reaction times of all participants will be measured.
45955714|NCT03843125|Drug|Baricitinib|Administered orally.
45816431|NCT05787392|Behavioral|Chamas cha MamaToto program|Chamas is a community health volunteer (CHV)-led group programme that engages women during pregnancy and the first 1000 days of their child's life. The strategy focuses on promoting maternal, newborn, and child health (MNCH) by providing health education, peer support, and opportunities to access financial capital, all while addressing inequities that perpetuate poor outcomes.
45955715|NCT03843125|Drug|Placebo|Administered orally.
46078686|NCT02747160|Behavioral|Managing Anxiety from Cancer (MAC)|The intervention consists of six telephone-administered sessions. Session topics include psychoeducation on anxiety, behavioral strategies for managing anxiety, cognitive restructuring, communication skills training, acceptance techniques (patient only), problem-solving strategies (caregiver only), and planning for future anxiety. Session content is tailored for older adults and caregivers of older adults with cancer.
45454559|NCT01110343|Behavioral|mindfulness intervention|a 6 -week behavioral intervention lasting 1.5 hours per week with a trained parent mentor, 3 monthly booster sessions and follow-up
45458140|NCT01234285|Drug|heparin|5000 units subcutaneously three times a day, starting within 24 hours of ICU admission up to 6 days.
45816432|NCT05786066|Drug|Perampanel 6 MG|Perampanel will be administered 2.5 hours before Ketamine infusion
45816433|NCT05786066|Drug|Ketamine|Ketamine infusion (0.5 mg/kg infusion over 40 minutes) will be administered 2.5 hours post perampanel or placebo administration.
45816434|NCT05786066|Drug|Placebo|Placebo will be administered 2.5 hours before Ketamine infusion
46078687|NCT04579406|Procedure|non-cardiac surgery|All the patients are undergoing non-cardiac surgery.
45816435|NCT05784753|Behavioral|HEART Camp|Participants will meet with an in-person coach at the medical fitness center: Months 1-3 weekly for 30 minutes; Months 4-12 every other week for 15 minutes (on alternate weeks, participants will attend a 1-hour group-based exercise training and coaching).
45816436|NCT05784753|Behavioral|HEART Camp Connect|Participants will meet with a virtual coach from the medical fitness center via videoconferencing: Months 1-3 weekly for 30 minutes; Months 4-12 every other week for 15 minutes (on alternate weeks, participants will attend a virtual 1-hour group-based exercise training and coaching session via videoconferencing).
45454560|NCT01110343|Behavioral|Conventional parent Support Group|a 6 week behavioral program, consisting of 1.5 hour weekly sessions run by a trained parent mentor with a structured curriculum based on the strengths of support groups like emotional support, advocacy and training. There are 3 monthly booster sessions and follow-up.
45816437|NCT05783791|Diagnostic Test|Newborn Screening Assay|"The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device. In this study, the testing involved with this assay fulfills the following criteria:~Is noninvasive~Does not require an invasive sampling procedure that presents significant risk (the finger prick is minimal risk)~Does not by design or intention introduce energy into a subject, and~Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure, as participants will not receive results in this study."
45454561|NCT03151304|Drug|Pracinostat|45 mg capsule
45454562|NCT03151304|Drug|Azacitidine|SC or IV injection
45454563|NCT02288884|Device|Acticoat PostOp|
45955716|NCT03842670|Behavioral|Cognitive Behavior Therapy|The CBT condition will include 8 weekly, 60-minute sessions, and will be delivered according to the Epstein & McCrady (2009) cognitive-behavioral treatment manual, excluding material provided in the platform treatment. The treatment manual and accompanying client workbook provide detailed therapist instructions for each session, client exercises, worksheets, and homework assignments. The treatment focuses on cognitive and behavioral coping skills training, and emphasizes problem-solving as an overall approach to dealing with drinking. Treatment sessions may be audio-recorded for supervision and to ensure that the treatment is being delivered as intended.
45955717|NCT03842670|Behavioral|Mindfulness Based Relapse Prevention|The MBT condition will be adapted from the 8-week version of the mindfulness-based relapse prevention (MBRP) manual (Bowen et al., 2011; Witkiewitz et al., 2005). The main adaptation will be to eliminate the relapse prevention/CBT components and focus attention on mindfulness practices. The mindfulness practices in MBT are designed to increase awareness of triggers and decrease reactivity to distress or discomfort in the presence of triggers (Witkiewitz & Bowen, 2010). The relevant worksheets and homework assignments focusing on mindfulness tools will be maintained from the MBRP manual. Treatment sessions may be audio-recorded for supervision and to ensure that the treatment is being delivered as intended.
45955718|NCT03828786|Procedure|Endometrial scratching|Endometrial Biopsy by aspiration with a pipelle
45955719|NCT03815019|Drug|Megestrol Acetate|The proposed study will use megestrol 6 mg/kg/day in two doses because this dose has been effective and safe in two previous studies using megestrol to stimulate appetite in children transitioning from tube to oral feedings. The megestrol will be dosed at full dose weeks 10-11, at 66% dose week 12, at 33% dose week 14, and fully tapered at the end of week 14. Megestrol is absorbed from the small bowel, so feeding it through the tube will be acceptable.
45955720|NCT03815019|Behavioral|iKanEat Behavioral Intervention|"The 24 week iKanEat intervention is composed of 4 clinic visits and a series of 12 tele-visits. All visits (clinic and tele-visits) will focus directly on the oral-motor and behavioral skills necessary for oral eating.~Tele-visits will begin by building rapport and asking for a summary of all relevant information since the last point of contact, including parent perception of changes in weight, feeding habits, progress, stress of parent/child, and illness. The majority of the time left in the 30 minute session will be spent dealing with parent concerns, which our previous project indicates may include questions about measures, questions about implementation of the iKanEat protocol, and ensuring that children/families adhere to the oral-motor and behavioral guidelines for feeding."
45955721|NCT03800407|Other|Observational study|Outcome of EFV-based ART in children with TB/HIV coinfection compared to those with HIV only on EFV-based ART
46078688|NCT04216368|Behavioral|balance training|The training to improve balance is to work on the core muscle groups that help to maintain your posture.,and increase muscular strength.
45816438|NCT05778279|Diagnostic Test|High-resolution ultrasonography|High-resolution ultrasonography to detect fetal CNS anomalies
45816439|NCT05774236|Device|Cook´s balloon|Cervical ripening for induction of labor with a mechanical method (Cook´s balloon)
45816440|NCT05774236|Drug|Vaginal dinoprostone|Cervical ripening for induction of labor with a pharmacological method (vaginal dinoprostone)
45454564|NCT02288884|Device|OpSite PostOp|
45454565|NCT01208155|Drug|Fostamatinib|Oral tablets, 50 mg x 2, single dose
45454566|NCT01208155|Drug|Fostamatinib|Oral tablets, 100 mg Batch 1, single dose
45454567|NCT01208155|Drug|Fostamatinib|Oral tablets, 100 mg Batch 2, single dose
45454568|NCT01208155|Drug|Fostamatinib|Oral tablets, 100 mg Batch 3, single dose
45454569|NCT03530020|Other|monolithic zirconia crowns|full anatomical monolithic crowns
45454570|NCT03530020|Other|lithium silicate crowns|lithium silicate glass ceramics are highly resistance to chipping
45454571|NCT01108549|Dietary Supplement|Ribose|Ribose 5 grams PO TID was taken daily
45454572|NCT02288962|Drug|cabergoline|
45454573|NCT01210573|Device|adjustment of LVAD or pacemaker|"For patients without a device: Patients start at rest for 2 minutes and will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide.~For patients with a device: patients will be at rest and the adjustments of their device will be made by a study physician or device coordinator, done routinely in clinical practice. This will take up to 15 minutes and during this time; participants will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide."
45458141|NCT03922594|Diagnostic Test|Differential diagnosis for infectious causes of microcephaly|Zika virus, cytomegalovirus, rubella, toxoplasmosis
45458142|NCT04902937|Radiation|Adjuvant radiotherapy|Guideline-based therapy of primary non-metastatic early breast carcinoma
45816441|NCT05767970|Behavioral|Integrated Stress Toolbox for Healthcare Providers (ISTH)|The ISTH is a 12-week meditation-based well-being training. In weeks 1-8, participants engage in weekly 2-hour class sessions that are recorded and posted on a private Youtube channel for one week. There is a final two-hour session at week 12. In-class learning is augmented and extended through content in a special version of the Healthy Minds Program smartphone app that participants are asked to use on a daily basis throughout the intervention.
45816442|NCT05764473|Other|The impact of MedDiet on cardiometabolic risk factors and menopause symptoms|12-week randomised parallel cross-over study with 32 participants. Impact of diet on CMR factors and menopause symptoms will be explored with diet quality and adherence to diet determined via diet quality indices for MedDiet and Portfolio diet.
45816443|NCT05764473|Other|The impact of UCLP on cardiometabolic risk factors and menopause symptoms|12-week randomised parallel cross-over study with 32 participants. Impact of diet on CMR factors and menopause symptoms will be explored with diet quality and adherence to diet determined via diet quality indices for MedDiet and Portfolio diet.
45816444|NCT05762068|Other|Delphi procedure|The study involves generating consensus statements by experts on airway management in critically ill patients on the definition and management of a physiologically difficult airway (PDA) using a Delphi process.
45458143|NCT04902937|Drug|neoadjuvant and adjuvant chemotherapy|Guideline-based therapy of primary non-metastatic early breast carcinoma
45955722|NCT03796078|Procedure|Maxillomandibular advancement|Treatment: Mono or Bimaxillary Orthognathic Surgery. The surgery of Reposition of the jaws is carried out under general anesthesia using minimally invasive techniques, the patient is extubated After surgery, antibiotics are prescribed during admission, anti-inflammatories, antiemetics and a local cold mask is applied of closed circuit at 17ºCelsius. The patient is discharged at 24 h.
45955723|NCT03796078|Procedure|monomaxillary surgery (isolated MaxS)|Monomaxillary surgery (Isolated MaxS): The surgery of Reposition of the maxilla is carried out under general anesthesia using minimally invasive techniques, the patient is extubated After surgery, antibiotics are prescribed during admission, anti-inflammatories, antiemetics and a local cold mask is applied of closed circuit at 17ºCelsius. The patient is discharged at 24 h.
45955724|NCT03796078|Procedure|monomandibullary surgery (MandS)|Monomandibullary surgery (Isolated MandS): The surgery of Reposition of the maxilla is carried out under general anesthesia using minimally invasive techniques, the patient is extubated After surgery, antibiotics are prescribed during admission, anti-inflammatories, antiemetics and a local cold mask is applied of closed circuit at 17ºCelsius. The patient is discharged at 24 h.
45816445|NCT05759819|Device|Standard stenting|The cilostazol-coated BioMimics 3D stent on the delivery system is deployed into the target lesion.
45816446|NCT05759468|Drug|Investigational Product - MIB 626|The eligible participants will be assigned to receive either NMN or placebo using concealed block randomization in a 1:1 ratio, stratified by sex (male, female), age (60 to 75, >75 years) and trial site. The randomization list will be generated by the unblinded biostatistician using the software R (www.r-project.org), and deployed in a secure, centralized web-based application accessible to study staff following confirmation of a participant's eligibility.
45816447|NCT05759468|Drug|Placebo|Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.
45955725|NCT03770650|Procedure|Stenting|DK crush technique with SYNERGY (Boston Scientific) drug-eluting stent implantation.
45955726|NCT03767218|Combination Product|Late follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from the late follicular phase of the menstrual cycle onwards. Start of GnRH antagonist (ganirelix 0.25mg/day) when serum LH > 10 IU/L, till day of trigger.
45955727|NCT03767218|Combination Product|Early follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 2 of follicular phase onwards. Initiation of GnRH antagonist (ganirelix, 0.25mg/day) on stimulation day 6 till day of trigger.
45955728|NCT03755375|Device|TENS|transcutaneous electrostimulation to improve the pain.
45955729|NCT03755375|Behavioral|Postural exercises|breathing exercises in the lay-down position, hip anteversion and retroversion in the sitting position, and anteversion, retroversion, and lateral movement in the stand-up position
45955730|NCT03755375|Device|Biofeedback|pelvic floor muscle coordination and relaxation exercises using intravaginal probes
45955731|NCT03755375|Behavioral|Manual therapy|myofascial trigger point release maneuver using digital pressure and muscle fiber stretching in pain areas
45955732|NCT03740282|Device|Lapiplasty|Patients 14 years through 58 years with symptomatic hallux valgus who are treated with the Lapiplasty System will begin weight-bearing by 3 weeks and follow a defined post-operative protocol.
46002812|NCT04643964|Behavioral|Entrée: Interpersonal skills|In this condition, participants view a video-based intervention covering interpersonal emotion regulation skills. This intervention asks participants to respond to questions and practice communicating effectively using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
46078689|NCT04216368|Behavioral|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity, bands, weighted bars or dumbbells.
46078690|NCT05648786|Behavioral|Laddr® plus Behavioral- Group and individual counseling|"Smartphone application utilizing the Community Reinforcement Approach (CRA) to facilitate social support in substance use treatment.~Outpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services."
45458144|NCT02310334|Other|Guided Exercise Session|Participants will be provided a pace based upon their current (estimated) physiological strain index (PSI) - a measure of thermal work strain, the time, and the distance completed already.
45816448|NCT05757362|Other|Compliance Questionnaire for Therapeutic Home Exercise Program in Physiotherapy and Rehabilitation (cq-HEPT)|An online application of the developed questionnaire form
45454574|NCT01328119|Other|4-hour HD, 4-hour HDF, 8-hour HD and 8-hour HDF|Prevalent conventional HD (CHD) patients (dialysing 3 days a week during 4 hours per dialysis session) will undergo, in random order, a mid-week 4-hour HD session, a mid-week 4-hour HDF session, a mid-week 8-hour HD session, and a mid-week 8-hour HDF session with a 2-week interval between every session to assess the influence of treatment duration and of convection on the removal of uremic toxins and on the haemodynamic responses and autonomic nervous regulation. In between the study dialysis sessions these patients will receive routine CHD treatments.
45454575|NCT03942991|Drug|articaine|infiltration injection of 4%artpharmadent
45454576|NCT03942991|Drug|Mepivacaine 2% Injection|infiltration injection of 2% Mepecaine-L
45661831|NCT05367037|Device|PhysioVP|The Physiological ventricular pacing is achieved by delivering a stimulus to a cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, with a permanent lead. PhysioVP activates the heart through the native His-Purkinje conduction system, thus offering the most physiologic pacing approach to correct the PR interval and avoiding pacing-induced dyssynchrony. A specialized delivery sheath for His-Purkinje system pacing with appropriate or standard leads will be used. The atrial leads will be implanted in the right atrial appendage and will connect the leads to the standard dual-chamber PM. By continuously recording a 12-lead ECG, we determine whether cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, will be achieved.
45661832|NCT05367037|Device|DDD-VPA|In dual-chamber pacing with the addition of algorithms for ventricular pacing avoidance, also called managed ventricular pacing, the right ventricular (RV) lead is implanted in the myocardial right ventricular (septum or apex). In this pacing mode, the ventricular pacing is minimized by using algorithms for right ventricular pacing avoidance. Therefore, the RV leads will be implanted in the right ventricular myocardial sites (septum or apex) and standard bipolar active or passive fixation leads. In addition, the atrial leads will be implanted in the right atrial appendage and connect leads to the standard dual-chamber PM.
45661833|NCT05337397|Procedure|Laser ablation|Laser ablation of non-Muscle invasive bladder tumors in outpatient settings.
45816449|NCT05755698|Behavioral|Emotional Awareness and Expression Therapy|"Each EAET session will use an educational lecture, discussion, in-class experiential exercises, and homework assignments. During sessions, participants will be encouraged to identify their stressors and experience and express their avoided or suppressed emotions, using exercises such as emotional disclosure, role playing, and the empty chair technique. Participants will be given homework assignments to complete between sessions, including expressive writing, identification of stressors and avoided emotions, and healthy communication skills practice. The planned topics of the EAET sessions include the emotions-stress-pain model, expressing and experiencing emotions (anger, sadness, hurt, etc.), letting go/forgiveness of self and others, and healthy communication, including assertiveness and intimacy."
45454577|NCT03532204|Radiation|SBRT|"Patients will received 2 courses of chemotherapy before SBRT if no hepatic or extra-hepatic progression identified.~All liver metastases will be irradiated. 4 doses prescription are allowed (according to the center, and the technique uded and the dosimetric constraints): 3x15 Gy, 4 x 15 Gy, 5 x10 Gy or 5 x 8 Gy.~The remaining courses of chemotherapy 2 to 3 weeks after completion of SBRT will be administered"
45816450|NCT05755269|Procedure|Biospecimen Collection|Undergo collection of blood samples
45816451|NCT05755269|Procedure|Genotyping|Undergo genotyping
45816452|NCT05755269|Other|Survey Administration|Complete surveys
45816453|NCT05754216|Device|Nerve stimulation using nerve stimulation device and sterile wire electrode.|A nerve stimulator device will be used in this study as a research tool to investigate whether a future (currently nonexistent) medical device might be able to stimulate desired pharyngeal musculature in a therapeutic manner.
45816454|NCT05751356|Drug|TR128|TR128 will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Starting dose is 100mg, with escalation to 500mg.
45816455|NCT05748587|Diagnostic Test|Serum Iron|Serum iron levels in study groups
45816456|NCT05748587|Diagnostic Test|RBCs Alpha-synuclein|α-syn levels in RBCs
45816457|NCT05748587|Diagnostic Test|Serum Soluble lymphocyte activation gene|sLAG-3 in the serum of study groups
45816458|NCT05748587|Radiation|Brain computed tomography|Brain CT of patients after admission
45816459|NCT05748587|Diagnostic Test|Brain Iron|Iron in brain homogenate of rats
45816460|NCT05748587|Diagnostic Test|Brain Alpha-synuclein|α-syn expression in rat's brain
45816461|NCT05748587|Diagnostic Test|Brain lymphocyte activation gene|LAG-3 expression in rat's brain
45816462|NCT05748587|Drug|Deferoxamine|intramuscular deferoxamine (200 mg/kg) injection to rats
45454578|NCT03532204|Drug|Chemotherapy|At investigator's discretion
45454579|NCT03532126|Device|Dermal filler for midface deficit|During this procedure the device (a dermal filler) will be deep intradermal, subcutaneous or supraperiosteal injected according to its CE mark.
45454580|NCT03529864|Other|Exercise Therapy|
45816463|NCT05740813|Drug|ABBV-CLS-7262 Dose 1|ABBV-CLS-7262 is administered orally once per day for 24 weeks.
45816464|NCT05740813|Drug|ABBV-CLS-7262 Dose 2|ABBV-CLS-7262 is administered orally once per day for 24 weeks.
45816465|NCT05740813|Drug|Matching Placebo|Matching placebo is administered orally once per day for 24 weeks.
45816466|NCT05739019|Other|frozen embryo transfer|transfer one or two embryos in frozen embryo transfer cycles
45816467|NCT05734287|Diagnostic Test|clinical, biophysical and biochemical assessment of young females with clinical hyperandrogenism|To assess clinical, biophysical and biochemical criteria of young females with clinical hyperandrogenism as a search for PCOS
45816468|NCT05731999|Device|Previct Drugs|Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
46078691|NCT05648786|Behavioral|Behavioral- Group and individual counseling|The active control condition consists of standard outpatient treatment for substance use disorders. Outpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services.
45661834|NCT05337241|Device|Saline Enhanced Radiofrequency (SERF) Ablation|The Durablate intramural needle catheter delivers heated saline to target tissue in the left ventricle to target mid-myocardial and epicardial VT substrates
45661835|NCT05336617|Procedure|colonoscopy|A colonoscopy is an exam used to examine the colon and rectum. During a colonoscopy, a long, flexible tube is inserted into the rectum. A tiny video camera at the tip of the tube allows the doctor to view the inside of the entire colon.
45661836|NCT05335993|Biological|Oregovomab|2 mg, added to 50 mL of Sodium Chloride infused over 20 ± 5 minutes.
45661837|NCT05335993|Drug|Niraparib|300mg administered orally once daily starting at the first day of treatment (Day 1 Week 1) to the end of Week 12. Subjects whose baseline weight is <77 kg or platelet count is <150,000 μL, the daily dosing will be 200mg.
45661838|NCT05366335|Drug|Live Combined Bifidobacterium and Lactobacillus|The invesitigators give patients Live Combined Bifidobacterium and Lactobacillus solution infusion during their colonoscopy examination for a single time in the Live Combined Bifidobacterium and Lactobacillus group.
45454581|NCT01208467|Other|Laboratory Biomarker Analysis|Correlative studies
45816469|NCT05728814|Drug|Dostarlimab|"The treatment under observation is dostarlimab administered on day 1 of each treatment cycle until disease progression, unacceptable toxicity or patient/doctor's decision.~The recommended dose for dostarlimab is 4 cycles of 500 mg every 3 weeks followed by 1000 mg every 6 weeks for all subsequent cycles."
45816470|NCT05727267|Biological|HEPLISAV B; TherVacB|Administration of the described combinations via the intramuscular route
45816471|NCT05727267|Biological|TherVacB|Administration of the described combinations via the intramuscular route
45816472|NCT05727241|Diagnostic Test|Ultrasound|The intervention is ultrasound examination with three dimensional umbilical cord index, two-dimensional umbilical cord index, and doppler examination of the umbilical cord artery.
45454582|NCT00162292|Drug|BMS-582949 and Methotrexate|
45454583|NCT05725330|Other|Gamification and education with mobile game application|This study aimed to provide self-care management by playing mobile games to patients with type 2 diabetes.
45816473|NCT05721248|Other|Cessation of anti-HER2 treatment|Cessation of anti-HER2 treatment with standard treatment described as trastuzumab (Herceptin) with or without pertuzumab (Perjeta) continued as long as it is working or significant side effects occur.
45816474|NCT05710315|Drug|Relizorb|Relizorb cartridges will be used with routine enteral feedings for 5 days
45816475|NCT05710315|Other|Placebo|Placebo cartridges will be used with routine enteral feedings for 5 days
45454584|NCT01113307|Biological|Activated allogeneic white blood cells|The CUREXCELL™ dosage form consists of an activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.The cell suspension is superficially injected throughout the wound bed ( 0.1ml per 1 cm2 of wound bed).
45454585|NCT04469608|Behavioral|acupuncture|Traditional Chinese medicine clinical daycare
45661839|NCT05366335|Drug|Normal saline|The invesitigators give patients normal saline as a placebo infusion during their colonoscopy examination for a single time in the control group.
45816476|NCT05707468|Drug|ADT combined with abiraterone|The patients will receive long-term ADT combined with abiraterone.
45816477|NCT05707468|Radiation|neoadjuvant hormone and RT|The patients will receive 1 month of naADT, followed by metastasis-directed radiation and abdominal or pelvic radiotherapy. Then, radical prostatectomy will be performed at intervals of 5-15 weeks after radiotherapy, and long-term ADT will be continued.
45955733|NCT03739645|Behavioral|Skin conductance levels and slopes over time in conditioned fear as metrics.as metrics for anxiety|After fear conditioning the cue induces autonomic responses like skin conductance and cognitive ratings like expectancy of the unconditioned stimulus after cueing or conditioning. Activity across blocks in the conditioning stage shows that the skin conductance can be described by levels, and slopes which might be related to state anxiety and trait anxiety (Spielberger trait and state anxiety inventory or questionnaire). These skin conductance measures may be concrete metrics for psychological processes in healthy subjects. We will carry out a partial correlation analysis of levels, state anxiety and trait anxiety, and then a similar analysis of slopes, state anxiety and trait anxiety. These results may show that concrete skin conductance levels and slopes are related to metrics of subjective self report measures of state and trait anxiety.
45661840|NCT05366335|Drug|Basic treatment|The invesitigators give patients general treatment and drug treatment including oral Live Combined Bifidobacterium and Lactobacillus tablets as basic treatment.
45661841|NCT05507125|Behavioral|Mental health|Early life exposure to abuse and development of hidradenitis suppurativa
45661842|NCT05530915|Other|Gel capsule|Single capsule per dose
45816478|NCT05706389|Dietary Supplement|Ca-AKG|Eligible participants will be randomised to receive Ca-AKG or Placebo for 6 months.
45816479|NCT05706324|Biological|Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation|0.2mL/dose, Inhalation using a nebulizer
45955734|NCT03735979|Drug|Argatroban|Direct Thrombin Inhibitor - Argatroban is a derivative of arginine that competitively binds to the active site of thrombin thereby preventing fibrin deposition. With a half-life of 30 minutes, argatroban has an immediate anticoagulant effect after IV administration which is rapidly reversed with discontinuation of the drug.
45955735|NCT03735979|Drug|Eptifibatide|GP 2b/3a Receptor Inhibitor - The final step of platelet aggregation is mediated via the GP2b/3a receptor. Eptifibatide was specifically developed to ensure rapid inhibition of platelet aggregation (within 15 minutes), a short half-life (~2 hours) and rapid dissociation from platelets with 50% restoration of platelet function within 2-4 hours of discontinuation.
45454586|NCT01210729|Device|Solitaire FR, ev3|Placement of the stent in the occluded vessel segment, withdrawal in its unfolded state.
45955736|NCT03735979|Drug|Placebo|IV placebo solution
45454587|NCT05726266|Other|Music|Patients will listen daily to a musical playlist for 30 - 60 minutes in a row; the psychologist will set up a music playlist according to the patient's individual interests. Patients will be asked to focus on this activity, that is, without performing any other activity simultaneously.
45661843|NCT05305105|Drug|Psilocybin|Dosing at the first session will be 15mg. For the second session participants will either remain at the initial dose, or increase to 25mg.
45661844|NCT05365399|Device|smartphone-based screening tool for neonatal jaundice|In this study we aim to collect data of newborns with wider range of bilirubin levels and high melanin content, and additionally measurements of skin color reflectance with a spectrophotometer, to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors. .
45661845|NCT05365243|Device|AMMA Portalbe Scalp Cooling System|AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center and at home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
45661846|NCT05334277|Drug|Furmonertinib|Furmonertinib 80mg QD
45955737|NCT03714308|Drug|Ivt. Aflibercept (Eylea, BAY86-5321)|Treatment is applied according to routine clinical practice and independent of the study setting.
45955738|NCT03709563|Dietary Supplement|Oral Nutraceutical Supplement|Standardized Botanicals. Take 4 capsules by mouth daily with a meal
45955739|NCT03709563|Dietary Supplement|Placebo|Placebo. Take 4 capsules by mouth daily with a meal
45955740|NCT03705585|Drug|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
45955741|NCT03705585|Drug|Vaxchora|One dose. Approximately 100 mL of cool or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.
45955742|NCT03701282|Procedure|Biospecimen Collection|Undergo collection of blood
45955743|NCT03701282|Procedure|Bone Marrow Biopsy|Undergo biopsy
45454588|NCT05726266|Other|Audiobook|Patients will listen daily to an audiobook for 30 - 60 minutes in a row; the psychologist will set up a list of audiobooks according to the patient's individual interests. Patients will be asked to focus on this activity, that is, without performing any other activity simultaneously.
45454589|NCT01210885|Biological|Meningococcal Vaccine|MenABCWY combination vaccine containing four different rMenB formulations with MenACWY, intramuscular (IM) administration, vaccination at 0 and 2 months.
45661847|NCT05334277|Drug|Furmonertinib|Furmonertinib 80mg QD
45661848|NCT05334277|Drug|Furmonertinib/Pemetrexed/Carboplatin|Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks.
45661849|NCT05334277|Drug|Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab|Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) plus bevacizumab (7.5mg/kg) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) with bevacizumab (7.5mg/kg) maintenance every 3 weeks.
45955744|NCT03701282|Procedure|Computed Tomography|Undergo CT
45955745|NCT03701282|Drug|Ibrutinib|Given PO
45955746|NCT03701282|Biological|Obinutuzumab|Given IV
45955747|NCT03701282|Other|Quality-of-Life Assessment|Ancillary studies
45955748|NCT03701282|Drug|Venetoclax|Given PO
45955749|NCT03695276|Behavioral|PushCon Model|Pulmonary specialist consultation facilitated by a trained health coach, who will gather information from the patient and medical record prior to the consultation and will using health coaching skills to support implementation of recommended care.
45955750|NCT03695276|Behavioral|Usual care|The standard of care, which usually means management within primary care.
45955751|NCT03695237|Drug|Leuprolide Acetate (LA)|Administered intramuscularly as an injection
45955752|NCT03681678|Device|fCO2 Laser Therapy Group|Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
45955753|NCT03667781|Diagnostic Test|Therapeutic drug monitoring|Blood assay to evaluate for the presence of medications that the patient is prescribed. This is not being used for therapeutic purposes. It has already been validated in prior papers.
45955754|NCT03661437|Device|Actigraph|Wear Actiwatch
45955755|NCT03661437|Other|Questionnaire Administration|Ancillary studies
45955756|NCT03661437|Procedure|Systematic Light Exposure|Undergo BWL treatment
46078692|NCT02742870|Other|Correlation of MRI results with clinical characteristics of the adnexal mass|"Quantitative analysis of the magnetic resonance images realised with the Ingenia 3 Tesla Engine (Philips) and the Area 1,5 Tesla Engine (Siemens), based on the ADC cartography.The post-processing will be realized with the Syngo Onco Care application of Siemens, that allows an histogram analysis of the ADC of all sections of the adnexal mass, as opposed to a section per section approach with the Region of Interest (ROI) method.~The results will be correlated with the clinical data regarding the adnexal mass: anatomo-pathology status (malignancy and aggressiveness of the tumor) and the gynecological follow-up."
46078693|NCT05648708|Procedure|Combine Adductor Canal & Sciatic Nerve Block|The investigators will perform a combined adductor canal & sciatic nerve block on that patient group for postoperative analgesia
46078694|NCT05648708|Procedure|Combine Femoral & Sciatic Nerve Block|The investigators will perform a combined femoral & sciatic nerve block on that patient group for postoperative analgesia
46078695|NCT05648708|Drug|Bupivacaine and prilocaine hydrochloride|The investigators will perform a combined adductor canal & sciatic nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
45661850|NCT05303935|Drug|Quetiapine 50 MG|A single dose of 50mg of quetiapine taken at bedtime for one night.
45661851|NCT05303935|Drug|Placebo|A placebo sugar pill that looks like the quetiapine tablet taken at bedtime for one night.
45661852|NCT05363371|Behavioral|Minds and Mentors|Participants will be randomized into Minds and Mentors to attend weekly group therapy sessions for 12 week. The mindfulness-based relapse prevention therapy intervention will be led by a licensed counselor for eights weeks followed up by four additional sessions led by a certified recovery support specialist (peer mentor).
45661853|NCT05363371|Behavioral|Twelve Step Intervention Group|Participants will be randomized to the Twelve Step Intervention Group to attend weekly group therapy sessions for 12 week. The twelve step intervention group will be led by a licensed counselor.
46078696|NCT05648708|Drug|Bupivacaine and prilocaine hydrochloride|The investigators will perform a combined femoral & sciatic nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
45661854|NCT05363137|Other|Chatbot Assistant|The physiotherpy treatment will be supervised via chatbot
45661855|NCT05363137|Other|Standard care|The physiotherpy treatment will be standard care
45661856|NCT05332717|Dietary Supplement|Melatonin 5 mg|Participants will be taking one 5 mg tablet of Melatonin 30 minutes before bedtime nightly, for 6 weeks following their knee replacement surgeries.
45661857|NCT05332717|Dietary Supplement|Placebo (Vitamin C)|Participants will be taking one placebo tablet 30 minutes before bedtime nightly, for 6 weeks following their knee replacement surgeries.
45955757|NCT03661437|Procedure|Systematic Light Exposure|Receive DWL treatment
45661859|NCT05506813|Other|cognitive training and conventional training|cognitive training along with conventional therapy
45661860|NCT05506813|Other|motor dual task training along with conventional therapy|motor dual task training along with conventional therapy
45661861|NCT05300737|Other|intensive medical therapy|Dual antiplatelet therapy, high potency statins, HTN control, lifestyle modification
45661862|NCT05300503|Behavioral|Telehome Monitoring|Participants are enrolled into the Telehome Monitoring program
45816480|NCT05703412|Behavioral|Transition-FOCUS mHealth Intervention|tFOCUS integrates evidence-based strategies for self-management of severe mental illness (SMI) into a comprehensive mobile assessment and treatment system that is grounded in theoretical SMI models. The application promotes self-management strategies aimed at improving medication adherence to manage biologically driven psychiatric symptoms, increase social support to reduce the negative impact of social withdrawal, improve sleep hygiene to reduce levels of fatigue, and promote strategies for coping with persistent symptoms. tFOCUS application strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience
45816481|NCT05703412|Behavioral|Check-In|Check-in includes a discharge and safety plan (with medication instructions, crisis services, etc.), a timely follow-up appointment with a mental health provider, and phone check-ins by case managers immediately following post-discharge for care coordination purposes.
45816482|NCT05700903|Drug|Gonadotropin-Releasing Hormone Agonist|8 weeks of GnRH agonist
45816483|NCT05700903|Drug|Androgen receptor inhibitor|2 weeks of AR Inhibitor
45955758|NCT03648541|Drug|Spesolimab IV infusion|Solution for infusion
46078697|NCT04190472|Diagnostic Test|IOP HPV test|Immediately after the LEEP, a cervical sample was taken for the IOP-HPV test
46078698|NCT02815748|Drug|SP2086|SP2086 was taken only one time at 100mg dose in health volunteers
46078699|NCT02742948|Drug|ceftriaxone|IV ceftriaxone (2g) will be given to all participants
46078700|NCT02816294|Behavioral|Housing Prescription|
45955759|NCT03648541|Drug|Spesolimab SC solution for injection|Solution for injection
45955760|NCT03643354|Diagnostic Test|Epley maneuver/Barbeque maneuver|Subjects will be rotated using the Rotundum Device to perform the previously described maneuvers Epley/Barbeque to evaluate the presence of BPPV.
45955761|NCT03639194|Drug|ABBV-011|Intravenous
45955762|NCT03639194|Drug|Budigalimab|Intravenous
46078701|NCT00636246|Drug|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg [S,S]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/4mg [S,S]-reboxetine for 5 and one half weeks.
45816484|NCT05700903|Drug|Placebo|Placebo tablet and injection
45661863|NCT05300269|Drug|SHR-1701；Capecitabine；Oxaliplatin|"Radiation: Radiation therapy 50.4Gy in 28 fractions to the pelvis on Days 1-5 every week. Drug: Capecitabine Capecitabine 825mg/m^2 orally twice daily (bid) 5 days/week during radiotherapy.~Drug:SHR-1701 Drug: Capecitabine (XELOX) Capecitabine 1000mg/m^2 orally twice daily (bid) day1-day14, q3w. Drug: Oxaliplatin Oxaliplatin 130mg/m^2, day1, iv, q3w"
45816485|NCT05698381|Dietary Supplement|Liquid vinegar|2 tablespoons consumed twice daily with meals
45816486|NCT05698381|Dietary Supplement|Vinegar pill|2 pills consumed upon waking
45816487|NCT05694611|Diagnostic Test|Brain contrast enhanced ultrasound, brain ultrasound elastography|To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
45816488|NCT05694611|Drug|Sulfur Hexafluoride|To evaluate the differences in brain perfusion and elasticity studied by CEUS and shear-wave elastography, comparing term neonates with and without MRI verified brain pathologies and to compare the ultrasound CEUS and elastography data to MRI.
45816489|NCT05689385|Other|eHealth-based cardiac rehabilitation|"The 12-wk case manager-led eHCR program includes:~Individualized exercise prescription according to the results of cardiopulmonary exercise test.~At least one session of in-person physical therapy to familiarize participants with the process of exercise training before the initiation of telerehabilitation.~Telerehabilitation: a 30-minute moderate aerobic exercise training with remote monitoring and instruction using video conferencing. (Frequency: twice per week in the first 4 weeks, once per week in the 5th-8th week, once every 2 weeks in the 9th-12th week)~Additional self-exercise to achieve the target volume of 150-minute moderate aerobic exercise and 2 sessions of resistance training per week.~Patient education for secondary prevention delivered regularly via a communication app on the smartphone.~Weekly follow-up call from a case manager via phone call or communication app."
45816490|NCT05686954|Other|CSO LOW|Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as cottonseed oil for 28 days.
45955763|NCT03603509|Drug|Fluad Vaccine|FLUAD is an inactivated influenza vaccine indicated for active immunization against influenza. disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is. approved for use in persons 65 years of age and older.
45661864|NCT05358301|Dietary Supplement|Probiotic|Probiotic food supplement produced by SYNBIOTEC S.r.l. Each capsule of SYNBIO®slim contains the probiotic strain Lactiplantibacillus Plantarum IMC 510 at a concentration of 15 billion live cells (CFU/capsule). The assumption is of n°1 capsule/day, preferably at breakfast, for 3 months. The capsules can be opened and their content can be dispersed in a cold liquid or at intake temperature or in semi-solid food. Always store in original container or in a clean covered container, out of the reach of children. When stored in a dry, clean environment, out of direct sunlight, the product has a shelf-life of at least 24 months. Samples of probiotic supplement in closed and sealed boxes will be provided to subjects participating at the beginning of the study, in quantities sufficient for the entire duration of the study (90 capsules for 3 months).
45661865|NCT05358301|Dietary Supplement|Placebo|N°1 capsule/day of placebo food supplement (i.e., capsules without added probiotics), with the same intake modalities as probiotic.
45661866|NCT05329285|Procedure|Percutaneous Coronary Intervention (PCI)|Alternative treatment
45816491|NCT05686954|Other|CSO MID|Participants are provided a breakfast shake and a snack daily that delivers 20% of the participant's estimated energy needs as cottonseed oil for 28 days.
45955764|NCT03603509|Drug|Fluzone High-Dose|FLUZONE® HIGH-DOSE vaccine is indicated for people 65 years of age and older to help prevent influenza disease caused by influenza A and B strains contained in the vaccine.
45955765|NCT03567993|Behavioral|Comparison|Participants randomized to the comparison arm will receive twice-monthly abstinence assessments from the text messaging system, with no motivational feedback. Those in the comparison arm are neither offered nor encouraged to participate in the intervention.
45955766|NCT03567993|Behavioral|Intervention|"Participants randomized to the intervention arm will receive:~Motivational Messages~Abstinence and Motivation to Use Services Assessments~Encouragement to access the Quitline~Encouragement to use Nicotine Replacement Therapy (NRT)~Provision of NRT, if requested~Intervention subjects are encouraged to access the Quitline and use NRT. However, these are not mandatory components of the intervention and subjects can choose if they would like to engage with the Quitline or use NRT."
46078702|NCT00636246|Drug|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg [S,S]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/6mg [S,S]-reboxetine for 5 and one half weeks.
45816492|NCT05686954|Other|CSO HIGH|Participants are provided a breakfast shake and a snack daily that delivers 30% of the participant's estimated energy needs as cottonseed oil for 28 days.
45816493|NCT05686954|Other|CONTROL|Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as a mixture of oils that match the average American fat intake for 28 days.
45816494|NCT05683535|Drug|Atropine Sulfate|0.01%, 0.03%, or 0.05% atropine eye drops made from compounding pharmacies.
45816495|NCT05678244|Drug|Acetaminophen|IV acetaminophen will be added to standard of care opioid based pain regimes.
45955767|NCT03562364|Other|AlterG anti-gravity treadmill|The AlterG treadmill is an FDA approved device that allows patients to perform early partial weight bearing exercises in a tightly controlled and safe environment
45955768|NCT03536871|Dietary Supplement|multi-nutrient supplement|Compare the effects of a multi-nutrient supplement following a healthy lifestyles program in healthy young men and women, healthy older men, and sarcopenic older men.
45955769|NCT03536871|Other|Exercise|We will evaluate the effect of 12 weeks of combined endurance and resistance home-based exercise in younger and older adults.
45955770|NCT03526354|Drug|Brexpiprazole|Brexpiprazole 4mg daily for 12 weeks
46078703|NCT00636246|Drug|sertraline|Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks.
46078704|NCT00636246|Drug|sertraline|Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks
45816496|NCT05678244|Drug|Placebo|In control group placebo will be added to standard of care opioid based pain regimes.
45816497|NCT05677074|Dietary Supplement|Fish oil|The tolerance of fish oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
45816498|NCT05677074|Dietary Supplement|Cod oil|The tolerance of cod oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
45955771|NCT03526354|Other|Treatment as Usual|Current antipsychotic medication for 12 weeks
45661867|NCT05327959|Device|Clavicle open reduction and internal fixation|Clavicle open reduction and internal fixation using the A.L.P.S. Clavicle Plating System
45454590|NCT03529708|Radiation|3D CRT plus SBRT boost|Patients will receive urgent standard 3D conformal radiotherapy (3D CRT) of plus stereotactic boost to tumor causing spinal cord compression (SCC). Initial dose for 3D CRT will be either 8Gy in 1 fraction or 20Gy in 5 fractions, with SBRT boost dose15Gy in 2 fractions of 12Gy in 2 fractions (depending on 8Gy/1 or 20Gy/5 initial RT dose respectively), delivered within three weeks of first treatment.
45454591|NCT01114243|Device|Ultrasound imaging|
45454592|NCT00135382|Drug|Videx EC|
45816499|NCT05677074|Dietary Supplement|Krill oil|The tolerance of krill oil is tested using two methods: skin-prick-test and Basophil Histamine Release Assay. (We were unable to acquire enough liquid krill oil to perform oral provocation with this supplement).
45816500|NCT05676034|Drug|AMX0035|AMX0035
45454593|NCT00135382|Drug|Epivir|
45454594|NCT00135382|Drug|Sustiva|
45816501|NCT05675800|Drug|Psilocybin|Psilocybin administered with psychological support
45955772|NCT03517969|Drug|Berzosertib|Given IV
45454595|NCT01210963|Device|SENSIMED Triggerfish|Contact lens-based Sensor with recording system for continuous monitoring of IOP fluctuation
45454596|NCT03941041|Behavioral|Prenatal Yoga Course|participation in a 12-week prenatal yoga course (optimally), 1 session in duration of 90 minutes per week
45454597|NCT03529552|Procedure|Anterior Cruciate Ligament Reconstruction|Placement of an SMS bioresorbable interference screw (DEDIENNE Santé)
45454598|NCT05725174|Other|Sample Collection|Patients will have breath samples collected by blowing into a bag, and sweat samples collected by gauze. These samples will be collected at various timepoints whilst the patients are admitted on the ward.
45454599|NCT01114321|Behavioral|Protein and calorie controlled diet|Protein and calorie controlled diet Self-hypnotic relaxation
45454600|NCT00128128|Drug|Cranberry juice cocktail|Participants will consume 4 or 8 ounces of Cranberry Juice Cocktail or Placebo daily for 6 months.
45454601|NCT03531970|Drug|2% lidocaine with 1:80,000 epinephrine|Anesthetic solution
45454602|NCT03531970|Drug|Dexamethasone|Corticostroide
45454603|NCT03531970|Drug|Placebo|Placebo
45454604|NCT01211743|Other|Laparoscopic cholecystectomy|Standard 4 port laparoscopic cholecystectomy
45454605|NCT01211743|Other|Single incision laparoscopic cholecystectomy|One port placed through the umbilicus
45661868|NCT05356507|Other|Patient population|Questionnaires, standard of care
45661869|NCT05356273|Procedure|Baby massage|Starting from the baby's face first, then the abdomen and chest, back, upper extremities and finally the lower extremities were massaged with semi-circular movements, respectively.
45661870|NCT05299177|Device|InControl|Automated insulin delivery system comprising continuous glucose sensor (Dexcom G6), controller (InControl embedded in smartphone app) and insulin pump (YpsoMed Ypsopump)
45816502|NCT05675319|Drug|Allogeneic Stem Cells|Allogeneic Stem Cell Transplantation
45816503|NCT05675319|Drug|carfilzomib/lenalidomide/dexamethasone (KRD)|triple regimen for first relapse should be applied according to latest Summary of Product Characteristics (SmPC) version
45816504|NCT05675319|Drug|elotuzumab/lenalidomide/dexamethasone (ERD)|triple regimen for first relapse should be applied according to latest SmPC version
45816505|NCT05675319|Drug|daratumumab/bortezomib/dexamethasone (DVD)|triple regimen for first relapse should be applied according to latest SmPC version
45816506|NCT05675319|Drug|daratumumab/lenalidomide/dexamethasone (DRD)|triple regimen for first relapse should be applied according to latest SmPC version
45955773|NCT03517969|Drug|Carboplatin|Given IV
45955774|NCT03517969|Drug|Docetaxel|Given IV
45955775|NCT03517969|Other|Laboratory Biomarker Analysis|Correlative studies
45955776|NCT03495011|Diagnostic Test|Breast MRI|Quantitative, multiparametric breast MRI
45955777|NCT03495011|Other|Laboratory Biomarker Analysis|Only patients with pure DCIS on surgical excision will have advanced pathologic markers and Oncotype Dx DCIS Score testing.
45955778|NCT03487471|Diagnostic Test|Real-time elastography|Breast ultrasound with real-time elastography
45661871|NCT05327569|Other|Myofascial Chain Release Techniques|Myofascial release technique will be applied to the center of coordination points in the anterior superficial myofascial chain of the body. There are a total of 8 points on this myofascial chain. Pressure will be applied to each point with 6 repetitions and lasting approximately 5-6 seconds.
45661872|NCT05327101|Other|Patient Preference Survey|Patient preference survey on implantable cardiac pacemaker systems
45661873|NCT04254367|Behavioral|Learn-to-Cope|Patient education in study circles, aiming to empower patients to participate in health care and rehabilitation by increasing health literacy and sense of coherence. The study circles will meet half a day each week for eight following weeks.
45661874|NCT05326945|Other|Presence or Absence of a Blood Pressure Cuff Sheath|Monitoring of microorganism transfer from the sphygmomanometer to the patient, from the patient to the sphygmomanometer in case the sheath designed in the research is put on or not before the blood pressure measurement process
45661875|NCT05298319|Device|high flow nasal cannula|The patients were randomized into 6 groups, each group received different flow of oxygen, to observe the incidence of hypoxemia between different groups.
45661876|NCT05325853|Drug|AG-920|AG-920 Sterile Topical Ophthalmic Solution
45661877|NCT05325853|Drug|Proparacaine Ophthalmic|0.5% Proparacaine Hydrochloride
45661878|NCT05354167|Other|muscle energy technique|the subject to sit comfortably and then stabilize the subject's distal humerus with one hand, then the forearm was supinated with the therapist another hand until resistance appeared. Holding the position the subject was asked to slowly pronate the forearm that is Isometric contraction against resistance for a period of 6-10 seconds with inhale and exhale, followed by slightly increasing supination until resistance was met once again. After 5 seconds of relaxation, the procedure was repeated 5 times during a single treatment session; this technique was applied in 2 sessions for a week for 4 weeks.
45661879|NCT05354167|Other|oscillating manual energy therapy|It is also known as V-spread .The subject was asked to sit on a chair with the affected painful arm resting on the treatment table. Tender points were palpated. Then the therapist places the index and middle fingers of one hand in a V-shape around the tender point and placed the index finger of the other hand in the medial side of the elbow, diagonally across the located tender point. Gentle pressure was applied a few times using fingertips to the tissues alternatively from the medial and lateral sides to start the oscillations. On the initiation of oscillations, the application of pressure should be stopped and allow the oscillations to continue between the two points of contact on the subject's elbow.
45661880|NCT05353933|Other|Thread embedding acupuncture|Thread embedding acupuncture (TEA) that use chromic catgut thread with 3/0 size with 1 centimeter long for each acupoint (TRUSTIGUT® (C), CPT Sutures Co., Ltd, Ho Chi Minh, Vietnam). Every 2 weeks in 4 weeks (twice), 13 acupoints will be embedded including Xiawan (CV-10), Zhongwan (CV-12), Shangwan (CV-13) and Zusanli (ST-36), Neiguan (PC-6), Geshu (BL-17), Ganshu (BL-18), Pishu (BL-20) in both sides of the body.
45661881|NCT05353933|Drug|Pantoprazole 40mg|Oral pantoprazole 40 mg capsules (Pantostad 40 CAP, Stellapharm J.V. Co., Ltd, Binh Duong, Vietnam) thirty minutes to one hour before the first meal once daily for 4 weeks.
45816507|NCT05675319|Drug|ixazomib/lenalidomide/dexamethasone (IRD)|triple regimen for first relapse should be applied according to latest SmPC version
45816508|NCT05675319|Drug|pomalidomide/bortezomib/dexamethasone (PVD)|triple regimen for first relapse should be applied according to latest SmPC version
45955779|NCT03487471|Diagnostic Test|Shear wave elastography|Breast ultrasound with shear wave elastography
45955780|NCT03443791|Diagnostic Test|Women Enrolled|Diagnostic Testing will be performed. Results of individual test results will determine the degree of intervention offered.
45955781|NCT03443791|Diagnostic Test|Newborns of Female Study Participants|Newborns will be tested after birth as soon as possible for CMV positivity.
45955782|NCT03439293|Drug|Ixazomib|Ixazomib capsule.
45458145|NCT02310334|Other|Unguided Exercise Session|Participants will be instructed to complete 5 miles within 60 minutes and finish in as cool (lower body temperature) a state as possible.
45458146|NCT02314312|Drug|Everolimus + low dose cyclosporin A + prednisolone|
45458147|NCT02314312|Drug|Standard immunosupressive regimen|
45816509|NCT05675319|Drug|carfilzomib/daratumumab/dexamethasone (KDD)|triple regimen for first relapse should be applied according to latest SmPC version
45816510|NCT05675319|Drug|Autologous Stem Cells|Autologous Stem Cell Transplantation
45816511|NCT05674747|Device|Swift Microwave treatment - weekly x 4wks|"Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions)."
45955783|NCT03439293|Drug|Daratumumab|Daratumumab IV infusion.
45955784|NCT03439293|Drug|Dexamethasone|Dexamethasone tablets.
45458148|NCT01585909|Procedure|Gastroscopy|When gastroscopy is indicated for clinical reasons, duodenal biopsies to determine the activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as assessing brush border morphology are taken
45661882|NCT05325463|Procedure|conventional lung recruitment|The recruitment maneuver will be performed by pressure controlled mode maintaining a steady airway pressure of 15 cmH2O, with 5 cmH2O increments in PEEP until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 sec. The peak airway pressure will be maintained for 10 sec or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings.
45661883|NCT05325463|Procedure|ultrasound- guided lung recruitment|The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area was visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit was 40 cmH2O.
45955785|NCT03428932|Device|Closed Loop (Medtronic 670G)|A loaner Medtronic 670G insulin pump, Enlite 3 sensor and GST3C Guardian transmitter will be utilized
45816512|NCT05674747|Device|Swift Microwave treatment - Every other week x 4wks|"Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions)."
45816513|NCT05674747|Device|Swift Microwave treatment - Every other week x 24wks|"Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions)."
45816514|NCT05674487|Device|Trans-cervical balloon|Induction of labor by cervical ripening with trans-cervical balloon (Foley catheter).
45816515|NCT05674487|Drug|Misoprostol|Induction of labor by cervical ripening with Prostaglandins (Misoprostol per os)
45816516|NCT05670340|Device|Switched Prosthetic Profile|The implant will be rehabilitated with a switched emergence profile
45955786|NCT03428932|Other|Standard Care|Subjects will continue on their current treatment (insulin pump or injections), with follow up every 3 months.
45955787|NCT03417531|Dietary Supplement|Protein Supplement|Predosed protein powder; can be added to various dishes and drinks
45955788|NCT03417531|Dietary Supplement|Protein-free Supplement|Predosed protein-free powder; can be added to various dishes and drinks
45955789|NCT03417531|Procedure|Active Exercise|Program includes five strength exercises that can be easily performed at home
45661884|NCT05353855|Other|No intervention|No intervention
45661885|NCT05325307|Other|Acupressure|The experimental group will start with HT7 points and continue LI4 and EX-NH3 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
45661886|NCT05325307|Other|Placebo acupressure|In the placebo acupressure group , the points 1.5 cm away from the HT7, LI4, and EX-NH3 points will be applied for an average of 15 minutes. Less pressure will be applied.
45661887|NCT05352685|Drug|Propofol Injection|1% propofol is used for target-controlled infusion, and gradually increase the effect concentration at 0.2ug/ml. Make the subject's sedation depth reach light sedation and deep sedation respectively. EEG data were collected during wakefulness, light sedation, deep sedation, and recovery.
45661888|NCT05561647|Other|No Intervention|This is non-interventional study.
45816517|NCT05670340|Device|Matched Prosthetic Profile|The implant will be rehabilitated with a matched emergence profile
45816518|NCT05666804|Drug|Brolucizumab 6mg|Brolucizumab 6mg (intravitreal) Personalized regimen arm: 1~3 x 4-week loading injections and one 8-week injection, followed by Treat-and-extend (T&E) regimen up to Week 56
45816519|NCT05666804|Drug|Brolucizumab 6mg|Brolucizumab 6mg(intravitreal) Standard q12w/q8w regimen arm: 3 x 4-week loading injections and disease activity assessment at week 16 followed by q12w/q8w up to Week 56
45816520|NCT05661955|Drug|BGB-A445|administered intravenously
45816521|NCT05661955|Drug|Tislelizumab|administered intravenously
45816522|NCT05653336|Device|PerQseal® Closure Device System|Bioabsorbable implant delivered percutaneously to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing percutaneous catheter-based interventional procedures.
45816523|NCT05650710|Device|Nerve stimulation using nerve stimulation device and sterile wire electrode.|A nerve stimulator device will be used in this study as a research tool to investigate whether a future (currently nonexistent) medical device might be able to stimulate desired infrahyoid musculature in a therapeutic manner.
45955790|NCT03417531|Procedure|Control Exercise|Program includes five flexibility exercises that can be easily performed at home
45955791|NCT03405792|Drug|Temozolomide (TMZ)|Patients will begin treatment with adjuvant TMZ at least 4 weeks but no more than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and maximum of 12 cycles of adjuvant TMZ will be given depending on tolerability and toxicity.
45955792|NCT03405792|Device|Optune System|Patients will undergo 24-months of planned treatment with Optune therapy.
45955793|NCT03405792|Drug|Pembrolizumab|Pembrolizumab will be given intravenously every 3 weeks beginning on Day 1 of Cycle 2 of adjuvant TMZ. Treatment with pembrolizumab every 3 weeks until first disease progression or unacceptable toxicities or 2 years, whichever comes first.
45955794|NCT03400332|Drug|BMS-986253|Specified dose on specified days
45955795|NCT03400332|Biological|Nivolumab|Specified dose on specified days
45955796|NCT03400332|Biological|Ipilimumab|Specified dose on specified days
45661889|NCT05351749|Behavioral|New-prescription Alert|An enhanced drug alert notification in the Michigan Medicine electronic health record (EHR) that is tailored to the specific type of inappropriate Direct Oral Anticoagulant (DOAC) use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter a newly prescribed DOAC prescription.
45955797|NCT03400332|Other|Placebo|Specified dose on specified days
45955798|NCT03386487|Drug|PF 04457845|Study medication will be administered at 4mg by mouth daily for eight weeks.
45955799|NCT03386487|Drug|Placebo Oral Tablet|Placebo comparator will be administered by mouth daily for eight weeks.
45955800|NCT03377270|Behavioral|Respiratory Swallow Training|Training in the Optimal Respiratory Swallow Pattern and Lung Volume at Swallow Initiation
45955801|NCT03375918|Other|CONSULT-BP Educational Intervention|"The CONSULT-BP intervention includes two, 180-minute, in-persons sessions 5 weeks apart. Each session has 3 parts: 1. Pre-Clinical Practice Simulation Learning; 2. Trainee Self-Assessments of implicit bias; and 3. In-Person Clinical Practice Simulations to practice communication skills, trigger reflection, and frame group-based reflections on bias."
45661890|NCT05351749|Behavioral|New-prescription Alert with referral option|An enhanced drug alert notification in the EHR that is tailored to the specific type of inappropriate DOAC use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter new DOAC prescription. This alert will ALSO include an option for referral to the anticoagulation clinic pharmacist for assistance.
45661891|NCT05351749|Behavioral|Existing-prescription notification to prescriber|Prescriber receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
45661892|NCT05351749|Behavioral|Existing-prescription notification to pharmacist|Pharmacist receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
45816524|NCT05650580|Drug|TR115|TR115 is supplied as tablet with dosage strength of 100mg. TR115 tablet will be administered orally on a continuous twice daily (BID) schedule and a treatment cycle is defined as 28 days for the purposes of scheduling procedures and evaluations. TR115 tablets will be given until there appears evidence of progressive disease , intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Proposed daily dose (BID): 100mg, 200mg, 400mg, 800mg, 1200mg, 1600mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the Maximum Tolerated Dose (MTD) in order to better understand safety, Pharmacokinetic (PK) or Pharmacodynamic (PD).
45661893|NCT05351593|Drug|Tafasitamab|Given IV
45661894|NCT05351593|Drug|Lenalidomide|Given Orally
45661895|NCT05351281|Device|CDSS-OPTIMED|The CDSS-OPTIMED is a software program that provides the physician with a personalized alert on whether to consider stopping or starting medication for a specific patient with a life expectancy of less than 3 months.
45816525|NCT05649345|Drug|TR64|TR64 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
45816526|NCT05649332|Device|Argogen|Spray in short intervals, lightly pressing the dispenser button and pointing the spray on the area to be treated.
45816527|NCT05648812|Diagnostic Test|Brain contrast enhanced ultrasound, brain ultrasound elastography|To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
45816528|NCT05648812|Drug|Sulfur Hexafluoride|To evaluate the differences in brain perfusion studied by CEUS, comparing different patient groups and babies with no suspected brain pathology
45816529|NCT05648695|Device|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
45955802|NCT03369223|Biological|BMS-986249|Specified dose on specified days
45955803|NCT03369223|Biological|Nivolumab|Specified dose on specified days
45955804|NCT03369223|Biological|Ipilimumab|Specified dose on specified days
46078705|NCT00636246|Drug|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg [S,S]-reboxetine for 3 days orally, followed by 100mg sertraline/2mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg [S,S]-reboxetine for 5 and one half weeks.
45458484|NCT03972254|Behavioral|Modified Interaction Guidance|The main steps in the procedure are to have the family identify the primary concern they are facing, highlight the strengths that the family already has in place and expand on those strengths, convey/impart caregiving and societal norms, and offer other perspectives (McDonough, 2004). The goal of this therapy is to engage the family to take an active role in the construction of their overall treatment. The individualized treatment approach focuses and builds on existing strengths.
45816530|NCT05648695|Device|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
45955805|NCT03361345|Drug|Tranexamic Acid|Topical tranexamic acid in cream form applied to dark spots on right side of face.
45955806|NCT03361345|Drug|Vehicle|The Vehicle is going to be a cream without any active medication that will be applied as a control substance for the topical tranexamic acid cream, and will be applied to the contralateral side of the face.
45955807|NCT03348631|Procedure|Computed Tomography|Undergo CT scan
45955808|NCT03348631|Procedure|Magnetic Resonance Imaging|Undergo MRI
45955809|NCT03348631|Drug|Tazemetostat|Given PO
45955810|NCT03312686|Diagnostic Test|endoflip|Resolution of esophageal eosinophilia by a 2-month course of high dose PPI in patients will lead to improvement in esophageal distensibility, and thus should produce improvement in dysphagia symptoms.
45955811|NCT03275285|Drug|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45955812|NCT03275285|Drug|carfilzomib|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45955813|NCT03275285|Drug|dexamethasone|"Pharmaceutical form: tablets or solution for infusion~Route of administration: oral or intravenous"
45955814|NCT03256201|Behavioral|Nutritional Counseling|Patients in both arms receive a single counseling session with a licensed dietician to determine individual protein goal for body weight and current dietary intake. Goal is then met through protein supplementation (provided) if needed beyond dietary intake.
46078706|NCT00636246|Drug|Placebo|Tablets, orally once per day for 8 weeks
45454606|NCT03529474|Other|Psychology and Physiotherapy group|"Psychological program: 4 sessions,2 hours each,4 months~Psychoeducation.Influence of psychological factors on chronic pain: modulators of pain experience. Biopsychosocial model of pain.~Training techniques of psychological management of pain:Diaphragmatic Breathing and Progressive Muscle Relaxation to control vicious circle pain-tension-pain.~Kinesiophobia. Rational regulation of the activity level:Cognitive therapy (management of irrational believes about pain) and Organisation of time and reinforcement activities.~Physiotherapy program:3 sessions per week,1 hour per session,4 months:~Aerobic exercise:walking, cycling~Warm-up: active ROM exercises of inferior and superior extremities (ISE)~Progressive resistance training with elastic bands of ISE~Stretching of ISE"
45454607|NCT03529474|Other|Placebo comparator: control group|Control group Normal daily activities Usual daily activities
45454608|NCT01211119|Other|No PRF|Group B (n=6), implantation of PRF after partial menisectomy and suture; Group (n=6), partial menisectomy only
45816531|NCT05644873|Drug|magnesium sulfate group|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) <90mmHg or <20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR < 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.
45661896|NCT05351203|Procedure|caudal block|". Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound,. Short axis (transverse) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.125% bupivacaine will expand the epidural space."
45661897|NCT05351203|Procedure|Erector spinae block|● The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of L3. a curvilinear high-frequency ultrasound transducer (Siemens acuson x300 3-5 MHz ultrasound) will be placed sagittal 3 cm lateral to L3 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side.
45661898|NCT05499637|Drug|[68Ga]Ga-PentixaFor PET/CT|[68Ga]Ga-PentixaFor PET/CT
45955815|NCT03256201|Behavioral|Standard Exercise|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and AROM of upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
45955816|NCT03256201|Behavioral|Enhanced Exercise|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and resistance exercise for upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
45955817|NCT03245866|Other|Observational/ no intervention|
45955818|NCT03217110|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects with neuropsychiatric diagnoses and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
45955819|NCT03217110|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects with neuropsychiatric diagnoses and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
45955820|NCT03216187|Drug|Pregabalin|pregabalin 150 mg capsules
45955821|NCT03216187|Drug|Placebos|capsules identical to pregabalin but without active drug
45955822|NCT03195270|Drug|[18F]FDG|10 mCi of [18F]FDG via the antecubital vein in a bolus injection
45955823|NCT03195270|Device|PET/MRI|PET/MRI hybrid scanner used as diagnostic device
46078707|NCT00636246|Drug|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg [S,S]-reboxetine orally for 3 days, followed by 100mg sertraline/2mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg [S,S]-reboxetine for 5 and one half weeks
46078708|NCT00636246|Drug|[S,S]-reboxetine monotherapy|Tablets, 2 mg/day orally for 3 days, followed by 4 mg/day orally for 4 and one half weeks, followed by 6mg/day for 3 weeks
46078709|NCT02819570|Drug|I.V cefuroxime 750 mg*3/d for 2 days|
46078710|NCT02819570|Drug|I.V ampicillin 2 gram x4/d for 2 days|
45454609|NCT03529318|Procedure|Biopsies from endoscopy|"1) Patients scheduled for endoscopy (EGD or colonoscopy) for IBD will be consented to allow physicians who are performing endoscopies to take additional biopsies and blood samples for research purposes."
46078711|NCT02819570|Drug|P.O cefuroxime 500 mgx2/d for 5 days|
46078712|NCT02819570|Drug|P.O roxithromycin 150 mg*2/d for 7 days|
46078713|NCT02819570|Drug|P.O moxypen 500 mgx3/d for 5 days|
46078714|NCT02747472|Drug|GIP-A|GIP receptor antagonist
46078715|NCT02747472|Drug|GIP(1-42)|GIP receptor agonist
46078716|NCT02747472|Other|Saline|Placebo
46078717|NCT04239170|Drug|Camrelizumab(SHR-1210)|Camrelizumab(SHR-1210): A humanized monoclonal immunoglobulin
46078718|NCT02741622|Behavioral|High aerobic intensity training (HIT)|One training session, high aerobic intensity training (HIT) at 90-95 % of the maximal heart rate (HRmax)
46078719|NCT02741622|Behavioral|Long slow distance training (LSD)|One training session, long slow distance training (LSD) at 70 % of the HRmax
46078720|NCT04200638|Diagnostic Test|ProTaper Next|The canal fluid sample before and after will evaluate after root canal instrumentation
45955824|NCT03179085|Behavioral|Home-Based Kidney Care|All subjects randomized to the HBKC arm will be visited by a community health representative in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and cover materials like, (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
45955825|NCT03172754|Drug|Nivolumab|PD-1 inhibitor
45955826|NCT03172754|Drug|Axitinib|Tyrosine kinase inhibitor
45955827|NCT03137888|Radiation|Dose-Escalated Radiation Therapy|Undergo sMRI-guided radiation therapy, dose painted to maximum of 75 Gy over six weeks
45955828|NCT03137888|Procedure|Spectroscopic Magnetic Resonance Imaging|Patients will undergo sMRI scans within a 14 day window prior to starting treatment
45661899|NCT05296057|Device|Participants Receiving VR-Exposure Therapy Treatment|In the baseline interview with an exposure therapy specialist and a member of the research team, participants will be presented with approximately three sets of possible exposure scenarios, each associated with approximately three different scenes that increase in severity level. Through discussion with the exposure therapy specialist, the participant will choose the exposure scenario (out of the three options) that most closely resembles their own epilepsy- or seizure-related fears. As the treatment, the participant will be exposed to the scenes that are associated with their chosen exposure set in a hierarchical manner using an immersive head-mounted display. The participant will work through the three levels of the chosen exposure scenario for approximately two weeks, ideally on each level for four days.
45454610|NCT01110655|Other|Intravenous hypertonic Saline|Intravenous 100mL bolus of 3% saline
45661900|NCT05295979|Drug|Inflammatory skin disease formula|ISDF granules (10.85g twice daily) for 12 weeks
45454611|NCT01110655|Other|Oral hypertonic saline|Oral 100mL bolus of 3% saline
45454612|NCT05726110|Drug|Selinexor|Given PO
45661901|NCT05295979|Drug|Placebo|Placebo granules (10.85g twice daily) for 12 weeks
45661902|NCT05322343|Other|Questionnaires|"Participants will complete a series of three questionnaires at the V1 visit (at home, by a trained interviewer):~A general questionnaire, with collection of general health history and exposure data~A nutritional survey (24-hour recall), that will be repeated by telephone twice at 3-month intervals, at the V4 and V5 visits.~An evaluation of cognitive performance using a validated computerized battery (Cantab®), completed of neuropsychological tests to evaluate dementia syndromes, depressive symptoms and anxiety."
45661903|NCT05322343|Other|Fasting blood sampling.|In the morning, during the V2 visit by a nurse at the participant's home. Blood collection will include 8 blood tubes (volume approx.. 35.5 mL), plus 2 additional tubes for 500 participants accepting MRI, for a total volume of blood drawn of 41.5 mL for these participants. For the immunological substudy, a second sample will be taken at a distance (after 4 weeks) for 150 volunteer participants meeting the criteria.
45661904|NCT05322343|Other|Saliva collection and nasal or nasopharyngeal swab|On the day of the V2 visit, the nurse will collect a volume of saliva that has flowed spontaneously for 5 min in a sterile 40-mL polypropylene tube, and a nasal or nasopharyngeal swab using a specific kit.
45661905|NCT05322343|Other|Urine samples|During the V2 visit, the nurse will collect urine samples collected by the participant in the week preceding the appointment, using the equipment provided and kept in the refrigerator.
45661906|NCT05322343|Other|Hair and a tonenail (or hand nail) sampling|During the V2 visit, the nurse will collect some hair and a toenail sample from the participant, in a dedicated envelope
45661907|NCT05322343|Other|Nasal microbiota|Nasal or nasopharyngeal swab
45955829|NCT03137888|Drug|Temozolomide|Given PO
45955830|NCT03123913|Drug|Testosterone Enanthate|Testosterone enanthate in oil (140mg) delivered via intramuscular injections every 2 weeks.
45955831|NCT03123913|Drug|Somatropin|Genotropin (5.0 μg/kg/day) delivered via subcutaneous injections.
45955832|NCT03110107|Biological|Ipilimumab|Specified dose on specified days
45955833|NCT03110107|Biological|BMS-986218|Specified dose on specified days
45955834|NCT03110107|Biological|Nivolumab|Specified dose on specified days
45955835|NCT03104972|Device|tDCS|Stimulation would be applied using semi-dry 5X5 cm electrodes. The current would be 0.75mA, which based on previous computational modeling of tDCS in children and is estimated to equal that of 1-1.5 mA in adults. This decision was made after considering the parameters that would influence current distribution and density at the site of stimulation such as thinner scalp, less cerebrospinal fluid, and smaller head size of the paediatric population. A similar dosage using tDCS was well tolerated by children, and was not associated with adverse effects29. The anodal electrode will be positioned above the dlPFC (F3 based on the International 10-20 system, while the cathodal electrode would be placed over the right supraorbital.
45454613|NCT05726110|Drug|Homoharringtonine|Given per standard of care
45454614|NCT05726110|Drug|Daunorubicin|Given per standard of care
45454615|NCT05726110|Drug|Cytarabine|Given per standard of care
45454616|NCT05726110|Drug|Granulocyte Colony-Stimulating Factor|Given per standard of care
45955836|NCT03104972|Device|tRNS|Children in the active tRNS group will received 0.75mA of tRNS (100-640Hz) to their left dorsolateral prefrontal cortex (dlPFC) and the right inferior frontal gyrus (IFG) via semi-dry 5cm X 5cm electrodes, attached under designated electrode positions (F3, F8) of a tES cap that followed the International 10-20 system (InnoSphere Inc., Haifa). The left dlPFC and right IFG were chosen, based on their contribution in executive control and inhibition. tRNS will be applied for 20 minutes per session during an iPad cognitive training. Similar duration has also been used in paediatrics using tDCS29. Similar to a previous tRNS study in children, and the rational provided for tDCS we will apply 0.75mA.
45955837|NCT03104972|Device|sham|For sham-tRNS we will use the same montage as in active tRNS. For sham-tDCS we will use the same montage as in active tDCS. The only difference between active and sham tES would be that in the case of the sham tES the 30 sec of ramp up of the current from 0 to 0.75mA would not be followed by 19 min of stimulation at 0.75mA as in active tES, but would immediately be followed by 30 sec ramp down period to 0mA. Such method has been shown to provide effective blindness of the stimulation condition as both active and sham tES would lead to slight itching sensation that would disappear due scalp habitation. No further stimulation would be provided in the sham group during the daily session.
45955838|NCT03100149|Drug|RO7046015|RO7046015 will be administered at dose of 4500 milligrams (mg) for participants with body-weight greater than or equal to (>/=) 65 kilograms (kg) or 3500 mg for participants with body-weight less than (<) 65 kg.
45816532|NCT05644873|Drug|control group|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) <90mmHg or <20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR < 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
45816533|NCT05644444|Device|Lubricant A (sensate water-based personal lubricant) and Comparator A (non-sensate water-based lubricant)|"In the tolerance phase, a pea-sized lubricant will be considered a single application for oral assessment and approximately 3g of lubricant will be considered a single application for vaginal assessment.~In the treatment phase, approximately 3g of lubricant will be considered a single application."
45816534|NCT05644444|Device|Lubricant B (sensate silicone-based personal lubricant) and Comparator B (non-sensate silicone-based personal lubricant)|"In the tolerance phase, a pea-sized lubricant will be considered a single application for oral assessment and approximately 3g of lubricant will be considered a single application for vaginal assessment.~In the treatment phase, approximately 3g of lubricant will be considered a single application."
45816535|NCT05644080|Radiation|177Lu-PSMA I&T|Patients demonstrating a high tumor uptake of 68Ga-PSMA on the diagnostic PET/MRI examination in the screening part of the study are eligible for a standard of 3 cycles, with a possible extension to maximum number of 6 cycles, of 177Lu-PSMA radionuclide therapy sessions. SPECT/CT will be performed after each cycle of treatment for dosimetry calculations, while 68Ga-PSMA PET/MRI, quality-of-life schemes and clinical examinations will be used to monitor therapeutic effects during the therapy cycles and up to 1.5 year after treatment initiation. The main endpoints of the study are progression-free survival and overall survival.
45816536|NCT05643638|Biological|CYP-001 (Cymerus mesenchymoangioblast-derived mesenchymal stem cells; MCA-derived MSCs)|MCA-derived MSCs are derived from induced pluripotent stem cells (iPSCs) using the proprietary Cymerus platform technology
45816537|NCT05643638|Biological|Placebo|The placebo product is identical to CYP-001, except that it contains no active agent
45816538|NCT05643638|Drug|Corticosteroids|All enrolled subjects in this trial must receive corticosteroids at a minimum dose of oral prednisone 2 mg/kg/day (or methylprednisolone 1.6 mg/kg/day IV) as therapy for aGvHD for at least for 72 hours post enrollment.
45816539|NCT05643495|Drug|VX-864|Tablets for oral administration.
45454617|NCT05726110|Drug|Aclacinomycin|Given per standard of care
45955839|NCT03100149|Drug|RO7046015|RO7046015 will be administered at dose of 1500 mg to all participants in the indicated arm.
45816540|NCT05641532|Behavioral|Physical activity behavioral intervention in persons newly diagnosed with MS|"The newsletters will provide the knowledge, skills, resources, and strategies for promoting physical activity in persons newly diagnosed with MS. These newsletters will be released seven times during the program. The first three newsletters will be released weekly, and the last four will be released every other week.~The one-on-one video coaching chats with participants will be conducted via Zoom, which consist of discussion and elaboration of newsletters content, supportive accountability, feedback and encouragement on behavior change. The chats further provide social persuasion for promoting behavior change. The chats are semi-scripted and individualized interventions (~15 - 30 minutes/chat). The chats will occur seven times during the week when a newsletter is delivered.~The intervention includes a pedometer (NL-800 pedometer), a logbook, and a calendar for tracking daily step counts, planning of physical activity, setting goals, and monitoring progress over the program."
45816541|NCT05641376|Drug|Nebulized Dexmedetomidine|Children will receive a nebulized dexmedetomidine 2 mic/ kg diluted in 3 ml of 0.9% saline 1 h before induction of anaesthesia by standard hospital jet nebulizer via a mouthpiece with a continuous flow of 100% oxygen at 6 L /min for 10-15 min. Treatment will be stopped when the nebulizer began to sputter. At end of nebulizer administration, they will be observed for 30 min before induction of general anaesthesia. then the children will be transferred to the operation room and will receive intravenous (IV) normal saline 0.9% in 10 ml volume over 10 minutes after anesthesia induction.
45955840|NCT03100149|Drug|Placebo|RO7046015 placebo will be administered to all participants in the indicated arm.
45955841|NCT03084146|Other|12-week elimination diet|individualized 12-week elimination diet based on the 4 most reactive foods +/- a gluten-free diet if there is detection of positive anti- tissue transglutaminase (tTG) IgG and IgA and anti-deamidated gliadin peptide (DGP) IgG and IgA
45816542|NCT05641376|Drug|Intravenous Dexmedetomidine|Children will receive nebulized 3 ml of 0.9% normal saline 1 h before induction of anaesthesia by standard hospital jet nebulizer via a mouthpiece with a continuous flow of 100% oxygen at 6 L /min for 10-15 min. then the children will be transferred to the operation room and will receive intravenous (IV) dexmedetomidine 1mic/kg diluted in 10 ml of 0.9% saline over 10 minutes after anesthesia induction.
45816543|NCT05641155|Device|Focused Multipolar Stimulation (FMS) strategy|Adult cochlear implant recipients receiving different combinations of alternative modes and, sound coding parameters.
45955842|NCT03075696|Drug|Glofitamab|Glofitamab will be administered at a dose and as per the schedule specified in the respective arms.
45955843|NCT03075696|Drug|Obinutuzumab|Obinutuzumab 1000 mg single dose IV infusion on Day -7; or 2000 mg single dose administered on Day -7, or split into two 1000 mg doses administered on Days -1 and -7, and per the schedule specified in the respective arms.
45816544|NCT05634356|Behavioral|vocal-social reinforcement|experimental manipulation of social reinforcement in response to vocalizations
45816545|NCT05633953|Drug|Osilodrostat|oral administration
45816546|NCT05632757|Behavioral|Psychological assessments|The visit will take place during a multidisciplinary assessment in the ALS Center at the Timone Hospital, Neuromuscular Disease and ALS Department. The patient will be accompanied by his/her caregiver. During this multidisciplinary assessment, the patient is present at the hospital between 8am and 4pm. The various scales and self-questionnaires can be completed during this time. The time required to complete these scales and self-questionnaires is estimated to be about 90 minutes.
45816547|NCT05628766|Other|complete blood count|Thiol/disulphide levels in the blood will be checked by taking complete blood count
45816548|NCT05627206|Behavioral|Problem Management + For Moms|Psychosocial intervention conducted by a trained Wellbeing-Community health worker. Adapted from Problem Management +, thinking healthy and Strong Minds-Strong Communities intervention to target women with small children and mental health symptoms living in low-resourced settings. Combines several evidence-based strategies such us psychoeducational, motivational interviewing, cognitive restructuring and relaxation exercises. Organized in 10 weekly sessions (8 individual 2 in group) provided in-person, by phone or virtually.
45955844|NCT03075696|Drug|Tocilizumab|Tocilizumab will be administered as an IV infusion, if required, for the management of severe Cytokine Release Syndrome (CRS) occurring during or after any infusion of glofitamab, as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents.
45955845|NCT03067467|Drug|Hyperpolarized 13C-Pyruvate|Hyperpolarized 13C-pyruvate IV bolus followed by brain MRSI.
45955846|NCT03067467|Drug|Gadolinium|Brain MRI performed with and without gadolinium-based contrast.
45454618|NCT01211821|Drug|metoprolol|Tablets, Oral, 200 mg, once, 1 day
45454619|NCT01211821|Drug|BMS-914392|Tablets, Oral, 60 mg, once daily, 7 days
45955847|NCT03066258|Genetic|RGX-314|RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
45955848|NCT03054155|Device|Alexandrite Laser|Alexandrite 755nm hair removal laser
45454620|NCT03527836|Drug|Lidocaine brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with lidocaine
45454621|NCT03527836|Drug|Bupivacaine brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with bupivacaine
45454622|NCT03527836|Drug|Mixture brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with mixture solution of 20 ml bupivacaine 0.5% and 10 ml lidocaine 1%
45955849|NCT03039985|Device|Zirconia crowns (Prettau®)|Monolithic zirconia molar crowns are, after randomization, placed in patients with or without bruxism
45816549|NCT05622734|Behavioral|VOCALE LBD+|Intervention employs a web-based platform that allows participants to engage asynchronously in an eight-week online intervention involving didactic training, peer-to-peer support, and moderated problem-solving skill enactment.
45816550|NCT05615805|Other|OSDI questionnaire|Ocular Surface Disease Index
45816551|NCT05615805|Other|SPEEDII questionnaire|Standardized Patient Evaluation of Eye Dryness II questionnaire
45955850|NCT03039985|Device|lithium disilicate crowns (IPSe.max®)|lithium disilicate molar crowns are, after randomization, placed in patients with or without bruxism
45661908|NCT05322343|Other|Measurements|"In addition to the samples, anthropometric measurements (weight, height,ead, waist, hip, calf and arm circumferences, subjective evaluation of body shape trajectories over the lifecourse), blood pressure, orthostatic hypotension, walking speed, grip strength, and hearing screening of sarcopenia and Parkinson's syndromes will also be collected by the nurse on the day of the V2 visit.~Analyses may be performed on the biobank samples. These analyses will include metabolite assays (Metabolon®), and may include genotyping for research purposes (without searching for specific genes."
45661909|NCT05322343|Other|Neuroimaging|"A multi-sequence MRI will be performed at the V3 visit. None of the sequences used will require contrast injection. The MRI sequences used will be: a 3D MPRAGE T1-weighted sequence, a T2-weighted sequence (FLAIR), a diffusion EPI sequence, a magnetization transfer sequence, and a resting state functional MRI BOLD sequence. The total duration of the MRI examination will be approximately 50 minutes.~The MRI will be performed at the Bioimaging Institute on an imager dedicated to research activities (3T Prisma Siemens).During V3 visit, a measurement of skin autofluorescence of advanced glycation products will also be performed"
45955851|NCT03028831|Dietary Supplement|70g of fully digestible starch amylopectin corn starch|Fully digestible amylopectin corn starch
45955852|NCT03028831|Dietary Supplement|Resistant starch|70g high-amylose maize starch
45955853|NCT03024255|Drug|BBI-4000 gel, 5%|BBI-4000 gel, 5% applied once to each axilla daily
45955854|NCT03024255|Drug|BBI-4000 gel, 10%|BBI-4000 gel, 10% applied once to each axilla daily
45955855|NCT03024255|Drug|BBI-4000 gel, 15%|BBI-4000 gel, 15% applied once to each axilla daily
45955856|NCT03024255|Drug|Vehicle (Placebo)|Placebo, applied once to each axilla daily
46078721|NCT02819336|Device|Electroacupuncture (EA)|"The EA group will receive the verum therapies using the following procedures.~Let the patient lie down on lateral decubitus.~The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, CV6 and bilateral points of SP11 and SP6.~The verum acupunctures are inserted on each acupoint inside the installed guide-tube. (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Republic of Korea)~After de qi response is elicited, the electrical stimulation is presented for 20 minutes by middle frequency (30 Hz). (STN-111, Stratek, Republic of Korea)~The practitioner should have at least 1-year clinical experiences.~The procedure will be repeated 10 times (once a session) within 21 days."
45458485|NCT02317978|Procedure|ICSI|records of women who had ICSI will be reviewed and analysed for determining FSI
45661910|NCT05322343|Other|Medical visit|For the participants with cognitive disorders (evaluated by the neuropsychologist during the V1 visit) or Parkinson's syndrome (evaluated by the nurse during the V2 visit),a complementary visit by a neurologist may be proposed in order to specify the etiology of these disorders and to establish a possible diagnosis and etiology.
45816552|NCT05615311|Dietary Supplement|Vitamin D supplementation|Study participants assigned to the intervention group will receive 800 IU/ day of vitamin D plus 200-300 IU/day of vitamin D from parenteral and enteral sources during the first 2 weeks after birth.
45816553|NCT05615311|Other|No additional vitamin D supplementation|Study participants assigned to the control group will receive 200-300 IU/ day of vitamin D from parenteral and enteral sources during the first 2 weeks after birth.
45816554|NCT05607615|Drug|Hydroxypropyl Beta Cyclodextrin|Minimum active dose of 500 mg/kg (equivalent to 18,500 mg/m2) as an intravenous (IV) infusion once every 28 days
45816555|NCT05607615|Drug|Placebo|0.5N saline as an intravenous (IV) infusion once every 28 days
45816556|NCT05597683|Procedure|Arm I (QL block and multimodal analgesia), Arm II (multimodal analgesia without regional block)|"Arm I (QL block and multimodal analgesia): Bilateral transmuscular QL block will be done. Postoperative multimodal analgesia including administration of acetaminophen, NSAIDs,nefopam, and rescue opioids~Arm II (multimodal analgesia without regional block): No block will be done. Postoperative multimodal analgesia including administration of acetaminophen, NSAIDs, nefopam, and rescue opioids"
45955857|NCT03008278|Drug|Olaparib|Give PO
45955858|NCT03008278|Biological|Ramucirumab|Given IV
45955859|NCT03007238|Biological|Aldesleukin|Given SC
45955860|NCT03007238|Procedure|Extracorporeal Photopheresis|Undergo ECP
45955861|NCT03007238|Other|Laboratory Biomarker Analysis|Correlative studies
45955862|NCT03007238|Other|Quality-of-Life Assessment|Ancillary studies
45955863|NCT02962167|Biological|Modified Measles Virus|Administration of MV-NIS either into the tumor bed, if surgery to remove local tumor
45955864|NCT02962167|Biological|Modified Measles Virus Lumbar Puncture|Administration of MV-NIS into the cerebrospinal fluid via lumbar puncture
45955865|NCT02927262|Drug|Gilteritinib|Oral tablet
45955866|NCT02927262|Drug|Placebo|Oral tablet
45955867|NCT02922036|Device|WiSE System|The WiSE System is an implantable cardiac system to provide LV pacing stimulation in conjunction with a co-implanted system that provides right ventricular stimulation.
45955868|NCT02902198|Dietary Supplement|Placebo|Tap water 200ml
45955869|NCT02902198|Dietary Supplement|Glucose|25g Glucose in 200ml tap water
45955870|NCT02902198|Dietary Supplement|Monosodium glutamate|1g monosodium glutamate in 200ml tap water
45955871|NCT02902198|Dietary Supplement|Quinine|17mg quinine in 200ml tap water
45955872|NCT02888743|Biological|Durvalumab|Given IV
45955873|NCT02888743|Radiation|Radiation Therapy|Undergo radiation therapy
45955874|NCT02888743|Biological|Tremelimumab|Given IV
45955875|NCT02875548|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of enhancer of Zeste homolog 2 (EZH2), a histone-lysine N-methyltransferase enzyme.
45955876|NCT02858869|Biological|Pembrolizumab|Given IV
45955877|NCT02858869|Radiation|Stereotactic Radiosurgery|Undergo SRS
45955878|NCT02852031|Other|Collaborative Learning Network|
45955879|NCT02849717|Behavioral|Exercise for Cancer Patients|a standardized, daily, home-based, progressive exercise program
45955880|NCT02811523|Drug|Doxorubicin|Doxorubicin by In Vivo Lung Perfusion
45955881|NCT02800551|Radiation|dose-intensified image-guided SBRT using simultaneous integrated boost|
45955882|NCT02800551|Radiation|External 3-dimensional conformal radiotherapy (3D-CRT)|
45955883|NCT02774694|Device|"nociceptive flexion reflex (NFR) threshold (Paintracker, Dolosys GmbH, Berlin, Germany)"|"measurement of the NFR threshold using the Paintracker device"
45454623|NCT01110811|Procedure|Transoral Incisionless Fundoplication (TIF)|The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degress around the esophagus.
45454624|NCT03529240|Device|Kinesiology Taping|Kinesiology taping (KT) which was developed by Dr. Kenzo Kase, is a new application of elastic and adhesive taping. KT is applied by specialized physiotherapists and physicians. This type of taping is a very frequently used technique to accelerate recovery after musculoskeletal injuries. Also, this technique is usually used as an alternative to athletic taping to support fascias, muscles, and joints for many purpose such as positioning, inhibition, and fascilitation
45661911|NCT05349565|Other|CONVENTIONAL PHYSICAL THERAPY|"High frequency TENS for 10 mins, 3 days/week Ankle pumps for blood circulation 10 repetitions x1 set, 3 days/week. Heel slides10 repetitions x1 set, 3 days/week. Open chain knee flexion and extension 10 repetitions x1 set, 3 days/week. SLR (straight leg raise) 10 repetitions x1 set, 3 days/week. Calf stretch 10 repetitions x1 set, 3 days/week. Quad set 10 repetitions x1 set, 3 days/week.~Total 6 sessions each consisting of 30-45 minutes"
45661912|NCT05349565|Other|MUSCLE ENERGY TECHNIQUE|"Experimental group treated by applying Muscle energy technique along conventional physical therapy.~For MET patient is positioned at maximal comfort and lengthening while engaging the barrier and then patient is asked to perform isometric contraction with 6-10 sec hold and then release and lengthen the muscle 4-5 repetition x 1 set, 3days/week Total 6 sessions each consisting of 30-45 minutes"
45816557|NCT05593939|Behavioral|Exercise|Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., ~60-90% heart rate (HR) max. Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., ~60-90% heart rate (HR) max. Exercise intensity and duration will gradually increase up until week 3 to habituate the participants to the exercise. The training modality will change to reduce the risk of injuries and may be impacted by individual preferences to increase adherence. The training can be performed individually or in groups of 4-6 participants, depending on the geographical locations of the participants home address, and on the current recruitment rate.
45816558|NCT05593939|Behavioral|Time restricted feeding|Participants randomized to the time restricted feeding group will be instructed to abstain from any caloric intake during the targeted fasting window of 16 continuous hours and consume ad libitum during the eating window of 8 hours.
45816559|NCT05593939|Dietary Supplement|Nicotinamide riboside|Participants randomized to the NR group will be instructed to take the administered tablets once in the morning (1 g) and once in the evening (1 g), in both cases with a meal.
45816560|NCT05579548|Drug|Pegvaliase|Pregnant women exposed to pegvaliase within 2 weeks prior to LMP.
45816561|NCT05577845|Drug|Ramosetron|Ramosetron, 4 weeks
45955884|NCT02751138|Procedure|Surgery|Tumor resection
45955885|NCT02750319|Drug|Amiodarone|
45955886|NCT02750319|Drug|N-Acetylcysteine|
45955887|NCT02750319|Drug|Placebo|
45955888|NCT02743494|Drug|Nivolumab|Specified dose on specified days
45454625|NCT03940885|Procedure|Erector spinea plane block group|Which will receive ultrasound-guided erector spinea plane block bilaterally and the local anesthetic injected will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline
45955889|NCT02743494|Other|Placebo|Specified dose on specified days
45955890|NCT02690766|Behavioral|Standard Behavioral Weight Change Intervention|Participants enrolled in Phase 2 of the study will meet once a month for 75 minutes over the course of 4 months. Within this 75 minutes, they will complete 25 minutes of physical activity with a licensed physical activity instructor that is very experienced with working with this population, review and discuss various topics/lessons that relate to diabetes, nutrition, survivorship and physical activity with the study's interventionist and Group Leader
45955891|NCT02688699|Procedure|EndoClot|"All patients enrolled and submitted to EMR or ESD in several units of Italian endoscopy will be divided into two different groups: in a first group will be included patients at the endoscopic end of which will be applied EndoClotTM based on the lesion removed in addition to the treatment Standard (drug injection, electrocoagulation, metal clips). The second group, on the other hand, includes patients in whom EndoClotTM will not be used.~Before the end of the procedure neither the endoscopist nor the patient will know the group because the group to which the patient is assigned will be written in a sealed envelope that will be opened only at the end of the procedure before the endoscope extraction: The use of EndoClotTM will depend on the group to which the patient belongs."
45955892|NCT02669056|Other|5-HT measurement|
45955893|NCT02669056|Other|cerebral MRI|
46078722|NCT02819336|Device|Sham electroacupuncture|"Let the patient lie down on lateral decubitus.~The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, and CV6 unilaterally & SP11 and SP6 bilaterally.~The non-penetrating sham acupunctures are implemented on each acupoint inside the installed guide-tube.~The electrical stimulation is presented for 20 minutes by middle frequency (30 Hz), (STN-111, Stratek, Republic of Korea) even though the electrical stimulation is not delivered through the skin because the needles are not penetrated through the skin.~The practitioner should have at least 1-year clinical experiences.~The procedure will be repeated 10 times (once a session) within 21 days."
46078723|NCT02747082|Procedure|Retreatment of root-filled teeth with infection|Root-filled teeth with infection are being treated with either 1% NaOCl or 2% CHX as disinfection irrigation solution.
45661913|NCT05321875|Drug|Candesartan|3 years treatment with candesartan target dose: 32 mg or maximum tolerated dose after dose escalation from 16 mg
45661914|NCT05320237|Other|Immersive Virtual Reality Intervention|Eight week intervention with two sessions a week. Each session will be 30 minutes in duration and will involve participants partaking in VR and such games include targeting individual finger movement (playing piano); grasp and release and one game (catching falling stars) includes holding a controller for elbow flexion and extension (Whack-a-mole).
46078724|NCT00636324|Device|Nasal CPAP, level 7 to 9 cmH2O|Apply nasal CPAP pressure of 7-9 H2O for the first 72 hours of extubation
46078725|NCT00636324|Device|Nasal CPAP, level 4 to 6 cmH2O|Apply nasal CPAP pressure of 4 to 6 cmH2O for the first 72 hours of extubation
45661915|NCT05347069|Drug|Aspirin|Aspirin 100 mg/day
45661916|NCT05347069|Drug|No aspirin|No aspirin administered
45661917|NCT05346367|Radiation|SRT|SRT
45661918|NCT05346367|Radiation|fSRT|fSRT
45661919|NCT05496673|Diagnostic Test|Pastorex Latex Agglutination Test|Rapid diagnosis of bacterial meningitis
45661920|NCT05496673|Diagnostic Test|Biofire PCR for meningitis|Rapid diagnosis of multiple forms of meningitis
45661921|NCT05496673|Diagnostic Test|Immy CrAg Lateral Flow Assay|Rapid diagnosis of cryptococcal meningitis
45661922|NCT05516953|Drug|Baclofen Tablets|10 mg oral baclofen 1 h before anesthesia
45661923|NCT05294107|Procedure|additional biopsies|"After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up:~6 biopsies are taken on average in clinical routine~4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB).~Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing."
45661924|NCT02522767|Drug|Mesalamine|
45661925|NCT02522767|Drug|Placebo|
45661926|NCT05293717|Drug|Ruxolitinib|1.5% Ruxolitinib cream
45816562|NCT05540847|Procedure|Interfascial Injection|Interfascial Injection on Ultrasound-guided Obturator Nerve Block
45458486|NCT01364246|Biological|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
45458487|NCT02318056|Other|Aquacel® Ag Burn Glove|burn dressing
45661927|NCT05319847|Dietary Supplement|Daily Skin Supplement - Fountain of Youth|Skincare supplement
45661928|NCT02522377|Drug|Ketamine|inter venous injections
45661929|NCT02522377|Drug|Midazolam|inter venous injections
45661930|NCT05345509|Drug|Aricept Tablet|Donepezil Tablet once daily P.O
45816563|NCT05540847|Procedure|Subpectineal Injection|Subpectineal Injection on Ultrasound-guided Obturator Nerve Block
45661931|NCT05345509|Drug|IVL3003|Donepezil Long-Acting Injection, once S.C Injection
45661932|NCT05319613|Other|Virtual clinical visits with home lab kits and mailed HIV PrEP|Rural participants who enter PrEP care with University of Colorado HIV Prevention Program will receive PrEP services via telemedicine with home lab kits and mailed HIV PrEP
45661933|NCT05319067|Other|Stool sampling|Stool sample taken at home 24 hours before hospital visit
45661934|NCT05318755|Drug|GAHT for transgender men|Testosterone undecanoate
45661935|NCT05318755|Drug|GAHT for transgender women|Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)
45816564|NCT05537753|Device|Encore PFO closure device|The Encore PFO closure device comprises an implant component and a single-use delivery system.
45816565|NCT05537753|Device|FDA-approved PFO closure device|Chosen by the investigator
45816566|NCT05536752|Drug|QA102/Placebo|Capsules
45816567|NCT05536752|Drug|QA102|Capsules
45816568|NCT05536752|Drug|Placebo|Capsules
45816569|NCT05534724|Other|Partial weight-bearing (10 - 15kg)|Immediate post-operative partial weight-bearing (10 - 15kg) with a VACOPASO shoe for 6 weeks
45955894|NCT02669056|Other|Video recording|
45955895|NCT02669056|Other|EEG|
45955896|NCT02669056|Other|growth curves|
45955897|NCT02669056|Other|ASQ questionnaire|
45955898|NCT02637102|Other|Not applicable - observational study|
45955899|NCT02636582|Other|Laboratory Biomarker Analysis|Correlative studies
45955900|NCT02636582|Drug|Nelipepimut-S Plus GM-CSF Vaccine|Given ID
45955901|NCT02636582|Biological|Sargramostim|Given ID
45955902|NCT02636582|Procedure|Surgical Procedure|Undergo surgery
46078726|NCT04480190|Drug|Gemcitabine|IV Gemcitabine 1000mg/m2 to be given on Days 1, Day 8 (Before Cisplatin); 3 week cycles
46078727|NCT04480190|Drug|Cisplatin|IV Cisplatin 25mg/m2 to be given on Days 1, Day 8
46078728|NCT04480190|Drug|Fluorouracil|Infusional 5-FU 225 mg/m2/d via Continuous IV infusion, to be given Days 1-5 and 8-12 during RT
45661936|NCT04249219|Other|Viewing e-cigarette ads|All participants will see the same e-cigarette ads presented in a random order.
45661937|NCT05553457|Device|Testing of MyHand-SCI Device|Subjects will attend 1-20 sessions (approximately 90 minutes) to trial the MyHand-SCI device, including a variety of controls and components.
45955903|NCT02613650|Drug|MEK162 and mFOLFIRI|"MEK162 in combination with mFOLFIRI in a 14 day cycle~MEK162 will be given single agent 6 day lead in and then will be given in combination with mFOLFIRI~mFOLFIRI Administered Day 1 of each cycle Irinotecan 180mg/m2 iv over 90 minutes on day 1 5-fluoruracil 1200mg/m2 continuous infusion for 48 hours (2400mg/m2 in 48 hours)~Followed by MEK162 - Taken twice daily orally on Days 1-12 of each cycle~Level -1: mFOLFIRI at 80% + MEK162 30 mg twice daily 1 week on and 1 week off Level 1: mFOLFIRI + MEK162 30 mg twice daily Level 2: mFOLFIRI + MEK162 45 mg twice daily"
45955904|NCT02611258|Drug|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 3 months
45955905|NCT02532231|Other|Laboratory Biomarker Analysis|Correlative studies
45955906|NCT02532231|Biological|Nivolumab|Given IV
45661938|NCT05318599|Device|Lung auscultation|Digital lung auscultation with the Eko core digital stethoscope (Eko Devices, Inc., CA, USA).
45661939|NCT05318599|Device|Lung ultrasound|Lung ultrasonography
45816570|NCT05534724|Other|Complete weight-bearing|Complete post-operative weight-bearing with a VACOPASO shoe for 6 weeks
45816571|NCT05527912|Drug|Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy|"All subjects received two courses of the following treatment:~Rituximab ，375mg/m²， D1； Chidamiade ，20mg ，biw， d1-14； Zanubrutinib ，160mg， bid， d1-21；~three weeks for a period of treatment, all subjects complete tumor assessment after two courses of treatment, patients which achieve complete remission continue for up to 8 sessions, patients achieve partial response and stable disease combined use of the following CHOP threapy to 6 courses, Patients with progressive disease dropped out of this research.~CHOP Therapy:~Cyclophosphamide， 750mg/m² ，D1； Vincristine， 1.4mg/m² ，D1 (maximum：2mg)； Doxorubicin or pirarubicin， 50mg/m²， D1； Prednisone ，30mg ，tid， D1-5."
45816572|NCT05504083|Drug|D-0120|Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group.
45816573|NCT05504083|Drug|Benzbromarone|Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group.
45816574|NCT05502588|Behavioral|Self-Guided Forest Bathing|Participants will participate in two, 60-90 minute self-guided forest bathing sessions over the course of a year in one of four Vancouver, B.C. park trails and be given prompts to consciously use their five senses in the forest.
45816575|NCT05502588|Behavioral|Guided Forest Bathing|Participants will participate in two, 60-90 minute guided forest bathing sessions over the course of a year in one of four Vancouver, B.C. park trails. They will be invited by a certified forest therapy guide to consciously use their five senses in the forest.
45661940|NCT05318599|Other|Quality of Life's questionnaires|Impact of the diseases on subjects' health-related quality of life measured with standardized questionnaires (K-BILD, CAT)
45661941|NCT05318599|Diagnostic Test|Pulmonary functional tests|Spirometry, body-plethysmographic parameters and lung diffusion capacity for carbon monoxide will be measured.
45816576|NCT05496920|Diagnostic Test|FD-PET/CT|Standard of care PET/CT with full dose (FD) of the radiopharmaceutical
45816577|NCT05496920|Diagnostic Test|LD-PET/CT|Additional low dose PET/CT performed within protocol defined time frame LD-PET/CT with additional ultra-low dose CT-less reconstruction
45955907|NCT02529033|Device|LIDCO Rapid, Pulmonary artery catheter|Hemodynamic monitoring systems
45955908|NCT02512939|Procedure|blood test, not yet marketed, no trade name|blood test using the new TB diagnostic test
45955909|NCT02500407|Drug|BTCT4465A (Mosunetuzumab) IV|Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via IV infusion.
45955910|NCT02500407|Drug|Atezolizumab|Participants assigned to an atezolizumab combination group will receive atezolizumab 1200 mg administered as an IV infusion in combination with BTCT4465A (Mosunetuzumab).
45661942|NCT04422691|Diagnostic Test|Lung ultrasound|After verbal consent the enrolled patients' lungs are evaluated with ultrasound while in isolation. The lungs are divided into 3 fields and findings are categorized according to Soldati et al., 2020.
45661943|NCT05268757|Behavioral|Oral hygiene discontinuation|Oral hygiene discontinuation for 14 days followed by 14 days of regular oral care
45661944|NCT05514223|Other|Biomaterial collection for observational purpose|The semen will be collected to measure the free radical concentration in seminal plasma and sperm together with the diversity of microbiota. Both males with a normal semen analysis (SA) and abnormal SA according to the WHO guidelines (2010) will be included. Blood plasma will be collected to measure systemic radical concentration and all outcomes will be related to lifestyle factors and food intake acquired through hospital charts and routinely conducted questionnaires together with a food frequency Questionnaire (FFQ).
45661945|NCT05267743|Drug|Tegoprazan 50mg QD|Tegoprazan 50mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.
45816578|NCT05492786|Behavioral|Alert|Non-interruptive best practice alert in the electronic health record
45816579|NCT05492786|Behavioral|Salient alert features|Larger alert header and body font size, use of different font colors and boldface
45661946|NCT05267743|Drug|Lansoprazole 30mg QD|Lansoprazole 30mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.
45816580|NCT05492786|Behavioral|High-risk Text|Alert header indicates patient is at high risk for flu and its complications; alert body indicates the percentage of risk (e.g., in the top 3% of risk)
45955911|NCT02500407|Drug|BTCT4465A (Mosunetuzumab) SC|Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via SC injection.
45955912|NCT02497261|Procedure|Double-blind placebo-controlled peanut challenge|Children who are avoiding peanut will be gradually introduced to smoothies containing and not containing peanut, to see if they are able to tolerate eating peanut. This challenge does not change a child's ability to tolerate peanut, but will determine which children avoiding peanut are allergic to peanut and which children are not allergic and may begin eating peanut.
45955913|NCT02478853|Other|Implementation of a new regional care framework|Integrated care framework for the prevention and management of cardio-metabolic chronic diseases in primary care
45955914|NCT02367040|Drug|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered before rituximab.
45955915|NCT02367040|Drug|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Placebo will be administered before rituximab.
45955916|NCT02367040|Drug|Rituximab|Rituximab dose 375 mg/m2 body surface weekly during Cycle 1 on Days 1, 8, 15 and 22, and then on Day 1 of Cycles 3, 5, 7 and 9.The solution for IV infusions is obtained after reconstitution of a calculated concentration of 1 to 4 mg/ml rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/ml (0.9%) solution for injection or 5% D-Glucose in water.
45955917|NCT02230124|Device|MRE|
45454626|NCT03940885|Procedure|Transversus abdominis plane block|Which will receive ultrasound-guided Transversus Abdominis plane block bilaterally and the local anesthetic used will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline
45661947|NCT05291845|Biological|Candida antigen vaccine|we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
45661948|NCT05291845|Biological|Bivalent HPV vaccine|we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
45661949|NCT05291533|Other|Virtual Reality (VR) Mindfulness Program|The VR program combines immersive, 3D visuals and audio with mindfulness skills practice. The program is designed to train participants you to calm their bodied and minds and its use is designed to enhance mindfulness practice. VR is a platform that has been used for a variety of applications, including gaming, entertainment, education and training.
45661950|NCT05266963|Drug|CREON|The study will enroll 6-10 adult subjects with T1D who will receive both pancreatic enzyme replacement (CREON) or placebo each for 7 days in a random order. The effect of the intervention will be monitored by continuous glucose monitoring, diet recording, capsule counts, a mixed-meal tolerance test, and a survey to assess symptoms of PEI. This study design will allow for estimation of the effect of pancreatic enzyme replacement on the measured parameters.
45661951|NCT05266963|Drug|Placebo|Placebo
45661952|NCT05317195|Other|NP-1|NP-1; 8.4 mg nicotine; pH 8.0; moisture 30
45816581|NCT05492786|Behavioral|Risk factors|Alert body indicates the top 3 factors contributing to the high risk
45955918|NCT02218996|Other|Psychosocial treatment|Regular psychosocial treatment in clinical outpatient service.
45955919|NCT02172651|Drug|Vitamin D3|Take five 10,000 IU capsules (total 50,000 IU) once daily for 7 days, followed by one 10,000 IU capsule once daily until surgery.
46078729|NCT04480190|Radiation|Short course ChemoRT|"Radiation Therapy:~Sim: All patients will undergo 4D-CT simulation with 3 hours fasting with or without IV contrast. Compression may be used depending on the tumor motion.~Radiation Target Volume: The gross tumor volume (GTV) will be defined on all relevant imaging datasets including diagnostic CT, MRI, MRCP and/or ERCP data. An iGTV will be generated using the 4D datasets. The clinical target volume (CTV) will include the entire iGTV as well as portal lymphatic and celiac nodal space for all patients with selective treatment of the SMA and pancreaticoduodenal depending on the tumor location. A 5 mm margin will be added to the CTV to generate the planning target volume (PTV).~Radiation Dose: The dose will be 30 Gy in 10 fractions (3 Gy per fraction) for all patients using either 3D Conformal or Intensity Modulated Radiation Therapy techniques."
45816582|NCT05492045|Drug|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
45816583|NCT05492045|Drug|Other|Standard treatment of NSCLC.
45816584|NCT05491187|Drug|0.5% bupivacaine heavy|Spinal anesthesia with 0.5% bupivacaine heavy at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
45454627|NCT03940885|Procedure|Control group|this group will receive only standard general anesthesia
45454628|NCT03941431|Drug|Jueyin granules|Jueyin granules p.o. once a day for 8 weeks.
45458488|NCT02318056|Other|Mepilex® Transfer Ag|burn dressing
45816585|NCT05491187|Drug|0.5% bupivacaine heavy with fentanyl|Spinal anesthesia with 0.5% bupivacaine heavy with fentanyl at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
45661953|NCT05317195|Other|NP-2|NP-2; 8.4 mg nicotine; pH 9.0; moisture 30
45955920|NCT02172651|Drug|Placebo|Take five placebo capsules once daily for 7 days, followed by one placebo capsule once daily until surgery.
45955921|NCT02144857|Drug|etanercept|50 mg
45661954|NCT05317195|Other|NP-3|NP-3; 3.6 mg nicotine; pH 8.0; moisture 15
45661955|NCT05317195|Other|NP-4|NP-4; 3.6 mg nicotine; pH 8.0; moisture 30
45661956|NCT05317195|Other|Velo-NP|Velo-NP; 10 mg nicotine;
45661957|NCT05317195|Other|Zyn-NP|Zyn-NP; 3 mg nicotine;
45816586|NCT05482412|Device|transcutaneous (superficial) afferent electrical nerve stimulation specific for vagus nerve|Direct superficial auricular sensory branch of Cr X [Cranial Nerve Ten Vagus]
45816587|NCT05480878|Drug|Placebo|Placebo will be administered to the control group for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
45955922|NCT02144857|Drug|ustekinumab|45 mg
46078730|NCT02741778|Procedure|Minimally invasive group|In this group, all manipulations are finished by laparoscopy and thoracoscopy.
45454629|NCT03941431|Device|moving cupping therapy|Moving cupping therapy three times per week for 8 weeks.
46078731|NCT02741778|Procedure|Open group|Right lateral position, Traditional thoracotomy through the 7th intercostal incision.
45454630|NCT03941431|Device|NB-UVB therapy|NB-UVB phototherapy three times per week for 8 weeks.
45454631|NCT03941431|Drug|Jueyin placebo granules|Jueyin placebo granules p.o. once a day for 8 weeks.
45454632|NCT03941431|Device|moving cupping placebo therapy|Moving cupping placebo therapy three times per week for 8 weeks.
45454633|NCT03941431|Device|NB-UVB placebo phototherapy|NB-UVB placebo phototherapy three times per week for 8 weeks.
45454634|NCT03531424|Procedure|Angiographic guided PCI|Angiographic guided PCI is coronary revascularization based on stand-alone angiography.
45661958|NCT05317117|Diagnostic Test|NxTek™ Malaria P.f plus Rapid Diagnostic Test (RDT) and NxTek™ Malaria P.f/P.v RDT|"The NxTek (TM) Malaria Pf Plus, developed by Abbott, is a sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and pLDH on a single test line of Pf malaria in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms.~The NxTek (TM) Malaria Pf/Pv Plus, developed by Abbott, is a sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH) of Plasmodium falciparum (Pf) on one test line and of pLDH of Plasmodium vivax (Pv) malaria on a second test line in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms."
45661959|NCT05314621|Drug|olopatadine hydrochloride ophthalmic solution 0.7%)|Pataday® Once Daily Relief Extra Strength (eyedrop)
45661960|NCT05314621|Drug|Fluticasone Propionate|Flonase® Allergy Relief (nasal spray)
45661961|NCT05314621|Drug|Tears Naturale|Tears Naturale® II (eye drop)
45661962|NCT05314621|Drug|Saline nasal spray|Saline nasal spray (nasal spray)
45816588|NCT05480878|Drug|Nitazoxanide 500Mg Oral Tablet|All subjects will receive Nitazoxanide 500gm twice daily for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
45661963|NCT05266729|Drug|Polyene Phosphatidylcholine|Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.
45661964|NCT05266729|Drug|Placebo|Phosphate buffered saline placebo for injection
45661965|NCT05290597|Biological|IBI363|a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
45816589|NCT05480878|Drug|Escitalopram 10mg|All subjects will receive Escitalopram 10 mg/day for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
45955923|NCT02144857|Drug|cyclosporine|Cyclosporine 2.5-3 mg/kgr
45955924|NCT02144857|Drug|Secukinumab|300 mg
45955925|NCT02144857|Drug|Apremilast|30mg
45955926|NCT02131597|Drug|Guadecitabine|Given SC
45955927|NCT02095184|Drug|Anastrozole|1 mg daily
45955928|NCT02095184|Drug|Letrozole|2.5 mg daily
45955929|NCT02081157|Device|GalaFlex Mesh|
45955930|NCT01950234|Drug|ACTH|Acthar gel
45955931|NCT01950234|Drug|Placebo|Placebo
46078732|NCT02819258|Other|Endodontic treatment|
46078733|NCT02741856|Drug|Carboplatin|For more information please see the arm descriptions section.
45661966|NCT05314465|Other|Median nerve mobilization|Median nerve mobilization was given 20 oscillations per minute for 3 times & repeated 3 times with a pause of 1 minute between each sets for 5times/week for 4weeks.
45454635|NCT03531424|Procedure|Augmented-Reality CTA guided PCI|Augmented-Reality CTA guided PCI is coronary revascularization based on systematic use of CTA datasets displayed in augmented-reality glass plus coronary angiography.
45661967|NCT05314075|Procedure|Upper Body Forced Air Warming device|Patients will have the Bair Hugger placed over the body
45955932|NCT01886872|Drug|Bendamustine Hydrochloride|Given IV
45955933|NCT01886872|Drug|Ibrutinib|Given PO
46078734|NCT02741856|Drug|Paclitaxel|For more information please see the arm descriptions section.
45661968|NCT05314075|Procedure|Under Body Forced Air Warming device|Patients will have the Bair Hugger placed under the body
45661969|NCT05289271|Biological|Vaxelis™|Vaxelis™ 0.5 mL sterile suspension in prefilled syringe for intramuscular administration.
45661970|NCT05263609|Drug|Axitinib|If pembrolizumab infusions alone do not reduce the patient's tumor size by at least 60%,the patient will be placed in Arm B and start axitinib in addition to continuing pembrolizumab therapy (see Arm B).
45816590|NCT05464680|Other|blood sample and bronchoalveolar lavage|"These patients are put on VM as part of their care and present a suspicion of a 1st episode of PAVM for which a microbiological sample is taken and a probabilistic antibiotic therapy is started with the PIP-TAZ association (D0). A plasma PIP-TAZ assay will be performed 48 hours after the start of antibiotic therapy with PIP-TAZ. Blood urea will be measured and a mini-LBA (performed with a Combicatheter®) will be performed to measure PIP-TAZ and urea in the ELF.~On day 7 of the antibiotic therapy (last day of the planned antibiotic therapy), the same samples are taken and the same analyses are performed + bacteriology on the mini BAL. For patients for whom antibiotic therapy has been interrupted because of sterile samples, the samples taken at D7 will not be taken.~The clinical outcome of the patient will then be recorded until D60."
45955934|NCT01886872|Other|Laboratory Biomarker Analysis|Correlative studies
45454636|NCT05724862|Device|Needle-less jet anaesthesia|Infiltration anesthesia without needle depending on injection pressure
45661971|NCT05263609|Drug|Pembrolizumab|If pembrolizumab results in a reduction in tumor size that is greater than 60%, the patient will be placed in Arm A and continue pembrolizumab infusions (see Arm A).
45661972|NCT05263375|Device|Innovalve TMVR system|Innovalve TMVR system
45661973|NCT05313997|Drug|Diclofenac Sodium|"at first diclofenac sodium was prescribed to patients with chronic upper back pain.~If the patient's pain persisted, she/he was included in the physical therapy (hotpack 20 minutes, ultrason 5 minutes, Transcutaneous electrical nerve stimulation 20 minutes) program."
45661974|NCT05312983|Other|Audiological and vestibular tests|"6h of audiological and vestibular tests divide in 3 sessions :~Session A : objective audiological tests~Session B ; subjective audiological tests~Session C : balance tests."
45661975|NCT05312983|Other|Blood sampling|A 10 mL blood sample will be collected during the study.
45661976|NCT05312983|Other|neurocognitive self-questionnaire|Four self-questionnaires to fill out to measure sleep quality, memory and emotional state
45661977|NCT05260333|Device|Butterfly iQ transperineal ultrasound exam|Transperineal ultrasound
45661978|NCT05259241|Diagnostic Test|activated partial thrombin time|This study aims to find which the point-of-care test (ACT or APTT) has the best correlation with the coagulation status during transcatheter cardiac interventions (either TAVR or PCI)
45661979|NCT05511415|Drug|Oxytocin|Oxytocin solution, 20nM concentration
45661980|NCT05511415|Drug|Dexmedetomidine|Dexmedetomidine (10-9M to 10-4M)
45955935|NCT01886872|Other|Quality-of-Life Assessment|Ancillary studies
45955936|NCT01886872|Biological|Rituximab|Given IV
45955937|NCT01555905|Device|Threshold PEP or IMT device Phillips-Respironics|The subject will be instructed to take 8-15 deep, forceful breaths through the Threshold device, followed by at least 3 minutes of rest. The process will be repeated 3 more times for a total of 4 sets of 8-15 breaths. IMST will be completed three to five days per week, based upon the subject's daily baseline level of fatigue.
45955938|NCT01252953|Drug|Anacetrapib|tablet, 100mg daily
45955939|NCT01252953|Drug|Placebo anacetrapib|tablet, 1 tablet daily
46078735|NCT02741856|Drug|Cisplatin|For more information please see the arm descriptions section.
46078736|NCT02741856|Drug|Capecitabine|For more information please see the arm descriptions section.
46078737|NCT02741856|Radiation|Radiotherapy|For more information please see the arm descriptions section.
45454637|NCT05724862|Device|Conventional Injection Anesthesia|Regular Infiltration local anesthesia
45458489|NCT02318056|Drug|antibiotic|antibiotic burn dressing
45454638|NCT01111045|Drug|Bone morphogenetic protein 7|Comparison of different doses of the drug via single intraarticular knee injection
45955940|NCT01234480|Device|BD SurePath Plus Pap test|BD SurePath Plus Pap test
45955941|NCT01234480|Device|BD SurePath Pap test|BD SurePath Plus Pap test
45454639|NCT01111045|Drug|Placebo|Placebo
45955942|NCT01234480|Procedure|colposcopy with biopsy/ECC|Colposcopy with biopsy/ECC for subjects with 1)BD SurePath Pap NILM, but HPV positive, or 2) BD SurePath Plus Pap test result of ASC-US or higher 3)BD SurePath Pap ASC-US or higher
45955943|NCT01234480|Device|HPV DNA test|digene HC2 HPV DNA test
45454641|NCT03940651|Drug|Spinal Anesthesia|Patients will be randomized to type of anesthesia
45454642|NCT03940651|Drug|General Anesthetics|Patients will be randomized to type of anesthesia
45454643|NCT03527758|Device|Flo TracIQ with HPI software|Patients will be monitored intraoperatively with Flo TracIQ with HPI software in order to predict hypotensive events. Blood sample will be obtained in order to evaluate ealy organ dysfunction.
45454644|NCT01328665|Other|Expressive Writing|Writing intervention for cognitive appraisal of stressor.
45454645|NCT03152552|Drug|LIK066|LIK066 was supplied in different doses as tablets taken orally.
45661981|NCT05309551|Device|PowerBreathe Medic- Intervention group|The resistive load will be readjusted weekly to reach 50% of maximal inspiratory pressure (MIP).
45661982|NCT05309551|Device|Powerbreathe Medic- Placebo group|The inspiratory resistive load will be adjusted to the minimum value of the device (9 cm H2O) during all inspiratory muscle training sessions.
45955944|NCT01183078|Procedure|free-hand|Free-hand technique utilizes x-rays to find screw holes.
45955945|NCT01183078|Procedure|Wand technique|Wand technique is utilized to find screw holes.
45955946|NCT01038778|Biological|Aldesleukin|Given IV
45955947|NCT01038778|Procedure|Computed Tomography|Undergo FDG-PET/CT
45955948|NCT01038778|Drug|Entinostat|Given PO
45454646|NCT03152552|Drug|Placebo|Placebo was supplied as tablets and capsules taken orally.
45955949|NCT01038778|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET/CT
45955950|NCT01038778|Other|Laboratory Biomarker Analysis|Correlative studies
45955951|NCT01038778|Other|Pharmacological Study|Correlative studies
45955952|NCT01038778|Procedure|Positron Emission Tomography|Undergo FDG-PET/CT
45955953|NCT00957489|Other|Dynamax appliance|
45955954|NCT00957489|Other|Twin-block appliance|
45816591|NCT05464368|Drug|[18F]RO-948|"Johns Hopkins University has conducted the first in human study in collaboration with Roche for 18F-RO948and found that 18F-RO948isa promising radioligand for imaging tau pathology in AD, showing excellent brain uptake and displaying little off-target binding(22, 17, 34).The injected activity for18F-RO948will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose of 370MBq(10mCi)has been selected based on the radiation dose estimates for18F-RO948gathered in human subjects provided by Michael Stabin, Ph.D., and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy."
45661983|NCT05219227|Other|laser acupuncture and abdominal exercises|"laser acupuncture on certain point on the abdomen The following abdominal acupuncture points were irradiated: Cv 8 (Shenque), St 25 (Tianshu, bilateral), and Sp 15 (Daheng~, bilateral). The laser irradiations were applied directly to the skin of the points with a perpendicular beam. 478 J/cm2~Abdominal exercises:~Types of abdominal exercises:~Static abdominal exercises:~Dynamic abdominal exercises:~Hip shrugging exercise from crook lying position:~Lateral flexion of the trunk from crook lying position:~Antero-posterior flexion of the trunk from crook lying position:"
45661984|NCT01657903|Drug|Sodium Fluoride|Toothpaste containing 1450 ppm F - EU level as NaF.
45661985|NCT01657903|Drug|Potassium nitrate|All study treatments contain 5% w/w KNO3.
45454647|NCT03152552|Drug|Empagliflozin|Empagliflozin was supplied as capsules taken orally.
45454648|NCT01211977|Drug|XOMA 052|
45955955|NCT00937131|Drug|Rituximab|Concentrate for solution for infusion, Intravenous use, 375mg/m2, Maximum 8 weekly infusions
45661986|NCT05256823|Drug|Celecoxib|Patients will be treated with Celecoxib twice daily for 48 weeks.
45661987|NCT05256823|Drug|nucleos(t)ide analogue|Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
45661988|NCT05218681|Other|"Unit-based Person First Anti-stigma Awareness Rounds"|Educational rounds on stigma
45816592|NCT05464368|Drug|18F-MK6240|"18F-MK6240 is an investigational PET radiotracer discovered by Merck Research Laboratories and is being developed by Cerveau Technologies, Inc.,for imaging neurofibrillary tangles (NFTs)in the brains of people withAlzheimerdisease.18F-MK6240 has been reported to exhibit good kinetics with high binding levels to brain regions associated with deposition of neurofibrillary tangles in people with AD(35,36).The tracer has been used to monitor the progression of AD.The injected activity for18F-MK6240 will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose will be 185MBq(5mCi) has been selected based on the radiation dose estimates gathered in human subjects(37)and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy."
45955956|NCT00877851|Behavioral|Computer-based Program|The intervention group will receive an initial training session which will include a demonstration of the layout and main features of the computer-based program and some instructions on how to navigate around the different sections of the program. As a minimum level of use, participants will be asked to use the self-monitoring and goal setting aspects of the computer-based program on at least a weekly basis.
45661989|NCT05218681|Other|Individual Text-based Messaging|Weekly evidence based messages to reduce SUD stigma
45661990|NCT05255887|Other|Informing Patients With Video|24-48 hours before the surgery, the patients will be shown an informative video about the intensive care environment in a separate room through a one-on-one interview. (The content of the training to be done with the video is stated in the appendix) In the study, no attempt will be made to the control group patients other than the routine practice of the institution before the surgery. In the study, the day of discharge from the intensive care unit will be counted as the first day, and on the second day, the 'Intensive Care Experience Scale' will be applied to the patients in both the experimental and control groups by face-to-face interview method.
45661991|NCT05255653|Drug|Olaparib|300 mg twice daily for two years
45661992|NCT05255653|Radiation|Pelvic external beam radiotherapy|45.0-48.6 Gy; 1.8-2.0 Gy per fraction, 5 fractions a week
46078738|NCT04463654|Device|Zero Self-Harm app|Safety plan app for smartphones
45454649|NCT01211275|Biological|axitinib|axitinib: 5 mg BID, day 2 until day 21 of each cycle; cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
45454650|NCT01211275|Drug|chemotherapy|cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
46078739|NCT04574102|Device|Omega Refractive Capsule with FDA approved Intraocular Lens|Omega Refractive Capsule with FDA approved Intraocular Lens
45661993|NCT05255653|Drug|Chemotherapy|Preferably concurrent and adjuvant according to the PORTEC-3 schedule: two cycles of intravenous cisplatin 50mg/m² in the first and fourth week of the pelvic external beam radiotherapy followed by four cycles of intravenous carboplatin AUC 5 and paclitaxel 175 mg/m² at 21-day intervals.
45661994|NCT05255653|Drug|Durvalumab|1500 mg intravenous once every 4 weeks for in total 1 year (13 cycles) starting within the first week of radiotherapy,
45661995|NCT05255653|Drug|Medroxyprogesterone Acetate|Oral medroxyprogesterone acetate for two years
46078740|NCT04574102|Device|FDA approved Intraocular lens|FDA approved Intraocular lens
45661996|NCT05255653|Drug|Megestrol Acetate|Oral medroxyprogesterone acetate for two years
45661997|NCT05255653|Radiation|Vaginal brachytherapy|Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).
45955957|NCT00846742|Drug|Stanford V Chemotherapy|The Stanford V regimen is an abbreviated, multi-agent, dose-intensive regimen that utilizes many of the most active chemotherapy agents for Hodgkin lymphoma: Vinblastine, Doxorubicin, Vincristine, Bleomycin, Mechlorethamine, Etoposide, and Prednisone
45955958|NCT00846742|Radiation|Radiation Therapy|Patients who achieve less than a complete response after 8 weeks of chemotherapy will receive 25.5 Gy to individual nodal sites (tailored fields) starting 2-3 weeks following completion of all chemotherapy and recovery of ANC to at least 1000.
45955959|NCT00837616|Drug|17 B estradiol orally|Group A will be given estrogen by mouth daily(0.5 mg or 1mg or 2 mg of 17B Estradiol. Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
45661998|NCT05255653|Other|Observation|No adjuvant therapy
45661999|NCT05286307|Drug|IPACK block|IPACK block with 20 mL of 0.25% Bupivacaine injected into the Interspace between the Popliteal Artery and Capsule of the Knee
45816593|NCT05464368|Drug|18F-GTP1|"18F-GTP1is anInvestigational tau PET radiotracer being developed by Genentech for imaging intraneuronal neurofibrillary tangles in patients with AlzheimerDisease. 18F-GTP1 has been reported to exhibit high affinity and selectively for tau pathology, favorable dosimetry and brain kinetics. Degree of 18F-GTP1-specific binding increased withAD severity, could differentiate diagnostic cohorts, and monitor longitudinal change in tau burden.~18F-GTP1 will be provided from LMI sourced through Illinois or New Jersey certified location."
45662000|NCT05286151|Behavioral|Rhythm discrimination|Participants will complete a rhythm discrimination task once per year for 3 years.
45662001|NCT05285371|Diagnostic Test|Urinalysis (UA)|Urinalysis will be performed twice daily starting on Postoperative Day 0.
45816594|NCT05463289|Diagnostic Test|Point of Care Autonomous AI diabetic retinopathy exam|Participants will undergo point-of-care diabetic retinopathy screening using autonomous artificial intelligence software to interpret retinal images taken with a non-mydriatic fundus camera and providing an immediate result.
45662002|NCT05285371|Diagnostic Test|Complete Metabolic Panel (CMP)|A CMP will be performed on Postoperative Day 2 and Postoperative Day 4.
45816595|NCT05462730|Drug|Methylprednisolone|A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.
45955960|NCT00837616|Drug|17 B estradiol|Group B will be given estrogen via a patch applied to the skin twice a week (0.375mg or 0.05mg or 0.075mg) Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
45955961|NCT00697073|Drug|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients > 45 kg/99 lbs: idebenone 2250 mg/day
45955962|NCT00610051|Drug|Alprostadil|central venous access continuous delivery with 500mcg/48 hours in active arm
45955963|NCT00476060|Procedure|Autologous mesenchymal stem cell transplantation|Arm A: 300 million cells will be infused one time through a peripheral vein/// Arm B: Infusion of placebo one time through a peripheral vein
45955964|NCT00176254|Radiation|Radiotherapy|80 centigray (cGy) on Day 1 & 2 and 22 & 23 of chemotherapy
45955965|NCT00176254|Drug|Paclitaxel|225 mg/m2 intravenously over three hours on Days 1 and 22
45955966|NCT00176254|Drug|Carboplatin|Area under the curve (AUC) of 6 will be given intravenously over 30 minutes on days 1 and 22
45662003|NCT05285371|Diagnostic Test|Glucose Stick Test (d-Stick)|A d-Stick will be performed twice daily except on Postoperative Day 2 and Postoperative Day 4 as the CMP includes serum glucose levels.
45955967|NCT02950090|Behavioral|MobilWise|see arm description for MobilWise above
45955968|NCT02950090|Behavioral|Fitbit Only|see arm description for Fitbit above
45955969|NCT02950285|Other|Baseline alert|PCP notification at baseline that patient has atrial fibrillation, high stroke risk, and is not anticoagulated.
45955970|NCT00166608|Procedure|Blood sampling|
45955971|NCT02949895|Drug|BMS-986012|
45955972|NCT02949895|Drug|Cisplatin|
45662004|NCT05285371|Other|Medical Chart Review|A medical chart review will be performed for all subjects enrolled.
45955973|NCT02949895|Drug|Etoposide|
45955974|NCT02949622|Behavioral|Multimodal intervention program|"The intervention is structured as follows:~Review of previous session (20 min) Agenda and goals (5 min) Presentation of the topic to be worked (15 min) Training (60 min) Summary and feedback (15 min)"
45955975|NCT02949622|Other|Lifestyle counseling|The group of lifestyle counseling will have basic guidelines, according to the recommendations of public health.
45662005|NCT05284591|Biological|Daratumumab|intravenous or subcutaneous
45662006|NCT05284357|Device|Shoulder Arthroplasty Surgery with HUMELOCK I & II® Anatomic Shoulder System|"HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus. The range of cases in which it can be used is wider than a simple reconstructive anatomical prosthesis. In fact, thanks to its anchoring plate, and if cephalic perfusion criteria are met, the modular nature of HUMELOCK II® means it is possible to retain the patient's native humeral head, even in cases of severe osteopenia.~The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus, a common occurrence in severely injured shoulders. The HUMELOCK II® shoulder system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed. The HUMELOCK II® shoulder prosthesis is a hemi shoulder and a total shoulder prosthesis."
45662007|NCT05284357|Device|Shoulder Arthroplasty Surgery with HUMELOCK II® Reversible System|"HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus.~The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus). It is designed for use in complex shoulder reconstruction procedures in patients with stage 3 or 4 fragments in the proximal humerus - a common occurrence in severely injured shoulders. The HUMELOCK II® reversible system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed.~The HUMELOCK II reversible system is used when the rotator cuff is injured."
45955976|NCT02949544|Other|water immersion|warm water immersion
45955977|NCT02949661|Procedure|Superficial cervical plexus block|Patients will receive bilateral superficial cervical plexus block
45955978|NCT02949661|Procedure|Local wound infiltration|Patients will receive local wound infiltration
45454651|NCT03529084|Drug|EFG816|It will be administered orally daily.
45816596|NCT05462730|Drug|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
45816597|NCT05462236|Drug|AUM001|MNK inhibitor
45816598|NCT05462236|Drug|Pembrolizumab|PD-1 Inhibitor
45816599|NCT05462236|Drug|Irinotecan|Topoisomerase inhibitor
45816600|NCT05461222|Device|"Balt Goldballoon"|"Fetal endoscopic tracheal occlusion (FETO) is a procedure where a balloon is placed in the main airway or windpipe of the fetus, to help with the development of the lungs. This is performed using a fetoscope, a small camera that is inserted into the amniotic cavity and deploying the FETO Goldballoon into the fetal trachea."
45816601|NCT05448963|Device|da Vinci SPⓇ Single-port System|Nipple-sparing mastectomy with or without axillary lymph node dissection using da Vinci SP single-port system
45816602|NCT05434819|Procedure|Surgical Atrial Fibrillation Ablation|Surgeon will preform surgical atrial fibrillation ablation using either cryoablation or bipolar radiofrequency clamps including 2 layers of atrium or vein, a minimum of 2 burns per clamping with at least 3 lines in the ablation group. Cavo-tricuspid isthmus lines will be allowed.
45955979|NCT02949583|Drug|Punica granatum Linn.|Mouthwash (6,25% of Punica granatum Linn) 10mL per day during 14 days
45955980|NCT02949583|Drug|chlorhexidine|standard anti-bacterial mouthwash Mouthwash (0,12% chlorhexidine) 10mL per day during 14 days
45955981|NCT00516841|Drug|Volociximab|15 mg/kg weekly, IV infusions, for 8 weeks or until disease progression or unacceptable toxicity develops
45955982|NCT04694599|Device|Low flow oxygen|Low flow oxygen delivered via nasal prong or facial mask. The flow rate is adjusted according to oxygen saturation of the patient.
45955983|NCT00516880|Drug|rosiglitazone|
45955984|NCT02949739|Behavioral|Intensive lifestyle modification|The intervention is delivered as 9 face-face and 13 telephone contact sessions over 12 months. Index cases are the focus for the intervention, but lifestyle modification encourages the whole family to adopt healthy living.
45955985|NCT04694716|Other|No intervention|No intervention will be applied.
45955986|NCT04694677|Drug|women receiving tranexamic acid|women receiving tranexamic acid during myomectomy
45955987|NCT04694677|Drug|women receiving misoprostol|women receiving misoprostol in myomectomy
45955988|NCT00516958|Drug|Topical Dermacyn|Topical Dermacyn once a day for 10 Days
45454652|NCT03529084|Drug|erlotinib or gefitinib|"Investigator's choice between erlotinib or gefitinib. These will be locally sourced.~Erlotinib will be administered orally daily. Gefitinib will be administered orally daily."
45662008|NCT05284357|Device|Shoulder Arthroplasty Surgery with HUMELOCK Reversed® Shoulder System|Humelock Reversed® is a new generation of reversed prosthesis, designed for numerous shoulder pathologies: ranging from offset arthritis to a complex cephalotuberosity fracture. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post and the position of which is guided by an intuitive adaptive instrumentation. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible. Options of locking or cementing will allow the surgeon to position the prosthetic stem at the required height, according to the patient's indication and anatomy. The surgery is called total shoulder arthroplasty. It is also indicated in a failed hemi-arthroplasty or a failed total arthroplasty. It is indicated for significant rupture of rotator cuff-tear (first surgery or revision surgery)
45662009|NCT05284357|Device|Shoulder Arthroplasty Surgery with EASYTECH® Anatomic Shoulder System|"EASYTECH Anatomical Shoulder System is indicated for use in total shoulder replacement to treat a severely painful and/or disabled joint resulting from osteoarthritis or rheumatoid arthritis.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. The surgery is called total shoulder arthroplasty. EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability"
45662010|NCT05284357|Device|Shoulder Arthroplasty Surgery with EASYTECH® Reversed System (Primary intention)|"EASYTECH Reversed Shoulder System is indicated for primary total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation"
45816603|NCT05432297|Behavioral|Preventive physical exercise|Daily physical activity depending on daily condition
45955989|NCT00516958|Drug|Topical Dermacyn and Levofloxacin|Topical Dermacyn once a day and levofloxacin 750 mg PO per day; both for 10 days
45955990|NCT00516958|Drug|Topical Saline and Levofloxacin|Topical saline once a day and levofloxacin 750 mg PO daily, both for 10 days
45955991|NCT00517036|Dietary Supplement|EPA omega-3 fatty acid|1 gram per day of an EPA-enriched mixture for 8 weeks
45454653|NCT03942757|Other|bilirubin serum level determination|bilirubin serum level before and after phototherapy treatment will be measured
45816604|NCT05430906|Drug|AK104 - Chemotherapy|AK104 10mg/kg then [paclitaxel (135-175 mg/m²) or docetaxel (75 mg/m²)] and [carboplatin (AUC5 or 6) or cisplatin (75mg/m²)] of each 21-day cycle
45816605|NCT05430815|Behavioral|Enhanced Postpartum Care System|The intervention consists of a comprehensive postpartum care system that integrates American College of Obstetrician and Gynecologist's (ACOG) postpartum care guidelines together with American College of Cardiology and American Heart Association (ACC/AHA) guidelines for the prevention of cardiovascular disease in women, as well as patient preferences for care coordination and communication. The system consists of: 1) a tailored postpartum care plan that is collaboratively developed with patient and provider input and addresses both social and medical needs; 2) an electronic medical record (EMR) based tool for documenting the plan and monitoring postpartum care; and 3) a postpartum follow-up phone call at 1 week postpartum.
45816606|NCT05429242|Other|Ultrasonographic examination|Measurement of placental volume at the first trimester of pregnancy by using ultrasound.
45955992|NCT00517036|Dietary Supplement|DHA omega-3 fatty acid|1 gram per day of pure DHA for 8 weeks
45955993|NCT00517036|Dietary Supplement|Placebo comparator|1 gram per day of an inactive substance for 8 weeks
45955994|NCT00517114|Drug|Rabeprazole 20mg twice daily|
45955995|NCT00517270|Drug|Rabeprazole 20mg twice daily|
45955996|NCT00517309|Biological|V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years|
45955997|NCT00517309|Biological|Comparator: placebo (concomitant-vaccine matched) / Duration of Treatment : 4 Years|
45955998|NCT00517348|Biological|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
45955999|NCT00517387|Drug|Quetiapine XR|All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.
45956000|NCT00517426|Drug|acetazolamide|i.v. 500 mg of acetazolamide for the acute study and 500 mg of acetazolamide p.o. t.i.d. for two days
45956001|NCT00517465|Drug|Placebo|po bid
45956002|NCT00517465|Drug|RG1511|Starting multiple doses of 100mg po bid escalated in subsequent groups of patients to potential maximum multiple dose of 1200mg po bid.
46002813|NCT04643964|Behavioral|Sampler skills|In this condition, participants view a video-based intervention covering three emotion regulation skills: cognitive, behavioral, and interpersonal skills. This intervention asks participants to respond to questions and practice using skills using intervention worksheets. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
46002814|NCT00548678|Drug|intravenous diclofenac sodium (DIC075V)|intravenous diclofenac sodium
45816607|NCT05426057|Behavioral|eHealth Familias Unidas Mental Health|eHealth Familias Unidas is a program designed to target mental health and suicide ideation and behavior. It focuses on promoting mental health by strengthening family and interpersonal protective factors. The program is provided online over a total of 13 sessions: 9 video parent group sessions, each lasting 20-40 minutes in Spanish and 4 web family sessions lasting 45 minutes in either Spanish or English, depending on participant language preference. The video parent group sessions consist of: 1) culturally syntonic telenovela/soap opera series, 2) videotaped parent group discussions, 3) interactive exercises. Web family sessions will be conducted by a trained pediatric staff member.
45662011|NCT05284357|Device|Shoulder Arthroplasty Surgery with EASYTECH® Reversible System (for revision only)|"EASYTECH Reversible Shoulder System is indicated for revision total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation."
45816608|NCT05419986|Genetic|Blood collection|Molecular monitoring by measure of DNA methylation levels in blood samples collected by fingerstick blood drops, as opposed to veinous phlebotomy
45816609|NCT05417594|Drug|AZD9574|Participants will receive AZD9574 orally in both the modules.
45956003|NCT00517504|Drug|Methylphenidate|"1-week single blind placebo lead-in phase.~step-wise single blind titration of MPH at 1.25 mg bid for the first week, 2.5 mg bid for the second week , 5 mg bid for the third week, 7.5 mg bid for the fourth week and 10 mg bid for the 5th week.~Dose increased if room for improvement in child's symptoms and no clinically important side effects. Dose not increased if no room for improvement in child's symptoms or if clinically important side effects.~After single blind titration, child enters a 4-week double-blind randomized crossover study with placebo and child's best dose that produced maximal effect with minimal side effects, with each child serving as his/her own control."
45816610|NCT05417594|Drug|Temozolomide|Participants will receive temozolomide orally.
45816611|NCT05414331|Other|Discontinuing all beta-blocker|All beta-blockers will be stopped 2 months after CABG
45816612|NCT05412953|Other|Questionnaire Administration|Complete questionnaire
45956004|NCT00517582|Drug|HOE-140|Subcutaneous at time 0 and 6 hours
45956005|NCT00517582|Other|Placebo|Subcutaneous at time 0 and 6 hours
45816613|NCT05412953|Behavioral|Tonation Breathing Technique|Participate in tonation breathing techniques
45956006|NCT00517621|Drug|Paclitaxel|
46078741|NCT02741466|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. Formulation number - SR16-01.
46078742|NCT04565834|Genetic|Analysis of Single nucleotide polymorphisms in each group.|The 6 single nucleotide polymorphisms (SNPs) determined will then be genotyped according to the Thermofisher Taqman technique ona 480 LightCycler (Roche Applied Science). 10% of the genotypes will be confirmed via Sanger sequencing on a 3500xl Thermofisher sequencer according to the manufacturer's recommendations.
46078743|NCT02742636|Device|Foley catheter|The aim of this study is to evaluate if direct removal of the urine catheter after an LH (total laparoscopic hysterectomy and laparoscopic supracervical hysterectomy) is associated with similar (or better) outcomes compared to delayed catheter removal after surgery.
46078744|NCT00633854|Procedure|Ultrasound examination|Immersion Ultrasound Exam: In the immersion technique, the patient lies down on the examination table. A steridrape with a central aperture is used to form a water-tight seal around the eye. After installation of 2 drops of 0.5% proparacaine HCl, a wire lid speculum is used to hold the patient's lids open. Warm 0.9% sterile saline solution is then used to create a waterbath about 1/2 inch deep to provide acoustic coupling between the transducer and the eye. The transducer (either the 10- and 20-MHz sector scan probe or the annular array) is placed in the waterbath, but does not touch the eye.
45816614|NCT05404256|Other|Radical gastrectomy +D2 lymphadenectomy+TissuePatchTM to seal pancreatic tissue surface|Radical gastrectomy +D2 lymphadenectomy+TissuePatchTM to seal pancreatic tissue surface
45816615|NCT05404256|Other|Radical gastrectomy +D2 lymphadenectomy|Radical gastrectomy +D2 lymphadenectomy
45816616|NCT05403567|Other|Bootle Blast Home Intervention|Children will play BB at home for 8 continuous weeks. Participants will be asked to stop playing at the end of week 8 and the game will be programmatically locked to prevent further play until the post-intervention interviews and assessments are complete.
45816617|NCT05398367|Dietary Supplement|Galactagogue Supplement for Treatment of Low Milk Supply|Participants will consume a commercially available dietary supplement on the market for augmentation of breast milk production in lactating women with low milk supply
45816618|NCT05396378|Dietary Supplement|Oral glucose in liquid form|A glucose containing drink that has a fixed dose of 25 g of glucose per can.
45956007|NCT00517621|Drug|EPO|
46078745|NCT02741232|Drug|Lidocaine 1% with epinephrine 1/400000|
45956008|NCT00517738|Other|Physical training|A program of exercising under strict surveillance, with endurance and coordination maneuvers
45956009|NCT00517738|Other|Diet intervention|Energy intake tailored to basal metabolism and level of physical activity. Protein and sodium intake will be adjusted to 1.2-1.5 g/kg/d, and 1.5-2 g/d of salt, respectively. The latter will be adjusted only in those patients presenting ascites and/or edema
45956010|NCT04481165|Other|Survey|Oral interview and written questions
45956011|NCT02949856|Device|Mallinckrodt, COVIDIEN|
45956012|NCT02949856|Device|Endotracheal tube, Unomedica|
46002815|NCT00548678|Drug|ketorolac|intravenous ketorolac
46002816|NCT00548678|Drug|oral diclofenac (Cataflam)|oral diclofenac (Cataflam)
46002817|NCT00548678|Drug|aspirin|oral aspirin
46002818|NCT00548834|Drug|CDP870|
46078746|NCT02741232|Other|sham block|
46078747|NCT02816606|Procedure|Flexible reamers|These reamers allow creation of the femoral tunnel to be made in reduced knee flexion and potentially maximise tunnel length
45662012|NCT05284357|Device|Shoulder Arthroplasty Surgery with HUMERIS® Anatomic Shoulder System|The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible.
45956013|NCT02949817|Device|digital rehabilitation system with wearable multi-IMU(inertial measurement unit) sensors (Rapael kids)|1.The Rapael kids, a video-game based rehabilitation therapy system using IMU sensors as a game interface, newly-developed in Korea will be used on upper limb function of children with pediatric brain injury patients. 20 of All 40 children will receive the conventional occupational therapy and additional video-game based rehabilitation therapy, 30 minutes daily 5 times per week, for 4 weeks.
45662013|NCT05284357|Device|Shoulder Arthroplasty Surgery with HUMERIS® Reversible Shoulder System|The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals, in order to avoid the disadvantages of traditional reverse prostheses. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post, the position of which is guided by an intuitive adaptive instrumentation.A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability.The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible
45956014|NCT02949817|Other|Conventional OT group|2. Conventional OT group will recieve the conventional occupational therapy and one more conventional occupational therapy additionally. The additional occupational therapy training will be performed 30 minutes daily 5 times per week, for 4 weeks.
45956015|NCT00166647|Procedure|Blood Sampling|
46078748|NCT02816606|Procedure|70-degree arthroscope|Using this arthroscope (rather than the more traditional 30-degree) gives improved visualisation of the femoral and tibial footprints. This may translate into better positioning of the tunnel within these regions
46078749|NCT02742558|Biological|Cholvax|Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.
45454654|NCT03942757|Other|Phototherapy|Preterm infant < 35 weeks of gestation with a jaundice requiring phototherapy according to NICE guidelines can be included for the duration of the phototherapy treatment.
45458490|NCT02325544|Behavioral|Cognitive Behavioral Therapy|"12 sessions of CBT (over 4-5 months) +1 booster session. Guided by a therapy manual and patient handouts; will involve setting homework tasks. Although treatment is manualised, it allows treatment to be formulation-based i.e. tailored to the person.~Standardised medical as described in other intervention."
45816619|NCT05386238|Behavioral|Standard behavioral weight loss program|16 internet-delivered, group sessions over 6 months supported by digital handouts. The intervention will focus on changes to eating, physical activity, and self-monitoring.
45662014|NCT05284201|Device|LIFT System|The LIFT System delivers the Functional task practice and ARC Therapy to improve upper extremity function in individuals with tetraplegia.
45662015|NCT05284045|Other|Detailed information|Subjects in this arm will receive usual information + detailed information on side effects
45662016|NCT05492149|Other|Performance follow-up|Diary performance during rehabilitation will be collected and a CAT questionnaire will be completed by the patient.
45662017|NCT04243837|Drug|LYT-100|"LYT-100 is a deuterated form of pirfenidone, an orally active small molecule drug.~HV subjects will receive multiple ascending doses, starting at 100 mg BID up to 1000 mg, with food for 5-days."
45662018|NCT04243837|Other|Matching Placebo|Inactive capsule(s)
45662019|NCT04243837|Drug|LYT-100 Food Effect|"LYT-100 is a deuterated form of pirfenidone, an orally active small molecule drug.~HV subjects will receive one dose of LYT-100 or Placebo"
45662020|NCT04243837|Drug|LYT-100 BCRL|BCRL patients will receive LYT-100 BID for 6 months
45662021|NCT04243837|Drug|Placebo BCRL|BCRL patients will receive Placebo BID for 6 months
45662022|NCT04243759|Behavioral|Control App Version|"The control version is a smartphone-compatible CGNG. The cued go/no-go (CGNG) tests ability to respond fast to go targets (activation) while withholding response to no-go targets (inhibition)."
45662023|NCT04243759|Behavioral|Standard App Version|The standard version is the same as the control version with the exception that information about performance (correct or incorrect) is displayed along with RT in ms for a correct response during each inter-trial interval.
45816620|NCT05386238|Behavioral|Tailored behavioral weight loss program|16 internet-delivered, group sessions over 6 months supported by digital handouts or videos tailored to men working in blue-collar occupations. The intervention will focus on changes to eating, physical activity, and self-monitoring.
45816621|NCT05385653|Behavioral|"experimentation of the virtual reality RevBED"|"ReVBED is a VR-based exposure scenario for CBT for the induction of food craving in patients with bulimia nervosa and binge eating disorder.~The use of ReVBED requires no VR experience and only generic and commonly used virtual reality tools (a computer with VR software, a wireless virtual reality headset, two controllers and headphones), all with a CE mark, allowing its users to move in and interact with a specially designed virtual environment.~This exhibit scenario takes place in a VR environment built to represent a standard apartment consisting of four exhibit rooms (a bedroom, a teenager's bedroom, a living room and a kitchen) in which the ReVBED user moves sequentially through the scenario. In each room, specific cues of craving are displayed. These cues are not only visual, but also audio, emotional and socio-environmental. A central hall connects the other rooms and serves as a safe place for debriefing, where measures such as craving are assessed."
45956016|NCT00517777|Device|continuous positive airway pressure ventilation|nighttime
45956017|NCT00517777|Behavioral|dietary and life style recommendations|
45956018|NCT00517777|Behavioral|dietary and life style recommendations|
45662024|NCT04243759|Behavioral|Experimental, Feedback App Version|The experimental, feedback version includes the standard plus feedback on RT and inhibition errors compared to pre-drinking. The app will state that there are simple alternatives with invitation to press a box to view advice, based on research that risk information may increase risky behavior if convenient options are not given73. Feedback will be worded non-judgmentally per motivational interviewing tenets.
45662025|NCT05255263|Other|PIEB|Programmed Intermittent Epidural Bolus with Patient-Controlled Epidural Analgesia
45956019|NCT04480853|Drug|Fingolimod|Fingolimod 0.5 mg QD, oral
45956020|NCT00517816|Drug|RG1671|Administered iv at escalating doses (with a starting dose of 0.0015mg)
45956021|NCT00517855|Biological|PRTX-100 (Staphylococcal protein A)|
45662026|NCT05255263|Other|CEI|Continuous Epidural Infusion with Patient-Controlled Epidural Analgesia
45458149|NCT02316262|Procedure|Targeted Muscle Reinnervation|Targeted reinnervation (TR) is a surgical procedure originally designed to provide intuitive control of upper limb prostheses through transfers of residual nerves to otherwise redundant target muscle. Native motor innervation of the target muscle is cut, and the residual nerves-after excision of end-neuromas-are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle. The central principle underlying the nerve transfers in TR surgery is to reestablish the function of the amputated nerve and allow intuitive, seamless prosthesis control.
45662027|NCT05254717|Other|counselling|intervention groups will receive counselling on improving quality of complementary feeding by soaking complementary foods flours and basic methods of soaking complementary flours.
45816622|NCT05383716|Drug|Pembrolizumab|Two to four cycles of neoadjuvant chemotherapy in combination with pembrolizumab will be administered before surgery, followed by another one to two cycles of chemotherapy plus pembrolizumab after surgery (4 cycles neoadjuvant/adjuvant chemotherapy in total ) then use pembrolizumab monotherapy for up to 1 year.
45816623|NCT05380570|Radiation|Occupational radiation exposure|Ionizing radiation in workplaces
45816624|NCT05378945|Drug|Varenicline Tartrate Nasal Spray|Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days
45816625|NCT05378945|Drug|Placebo (vehicle)|Intranasal delivery of placebo (vehicle) twice a day (BID) for 28 days
45816626|NCT05376644|Drug|99mTc-ADAPT6|One single injection of 99mTc-ADAPT6, followed by gamma camera imaging 2 hours after injection.
45816627|NCT05376644|Drug|99mTc-DARPinG3|One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection.
45956022|NCT00151515|Drug|minoxidil|Topical 5% minoxidil foam, BID, for sixteen weeks
45956023|NCT00517894|Drug|CEOP/IMVP-Dexa chemotherapy|Cyclophosphamide 750 mg/m2 i.v. d 1, epirubicin 70 mg/m2 i.v d 1, vincristine 1.4 mg/m2 i.v. d 1+8, prednisolone 100 mg p.o. d 1-5, ifosfamide 2000 mg/m2 i.v. d 15-17, etoposide 100 mg/m2 i.v. d 15-17, dexamethasone 40 mg p.o. or i.v. d 15-19, methotrexate 800 mg/m2 i.v. d 22. Mesna was given with ifosfamide, calcium-folinate rescue after methotrexate. Filgrastim was given on days 2-7, 9-12, 18-21, 23-28
45956024|NCT00517972|Drug|Omacor (omega-3-acid ethyl esters)|
45956025|NCT04478981|Other|No intervention|This concerns a natural history study; no interventions will be used
45956026|NCT00518050|Behavioral|Focus group|"Conduct focus groups in melanoma survivors to enhance the understanding of the behavioral aspects of:~Screening, skin self-examination, sun protection, and other cancer preventive practices;~Cognitive factors (knowledge, awareness, melanoma worry, and perceived risk) related to screening and sun protection practices; and,~Impact of melanoma on quality of life, family relationships, and economic issues arising from treatment"
45816628|NCT05376319|Drug|Obinutuzumab|1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15
45956027|NCT00518050|Behavioral|Survey|History of sun exposure Medical factors Affect, cognition, and quality of life Behavioral adoption Demographics Phenotypic factors Economic/healthcare factors
45956028|NCT00166686|Drug|Clonidine|
45458150|NCT01236625|Procedure|Adhesiolysis|Blunt or sharp dissection of adhesive tissue.
45816629|NCT05376319|Drug|Rituximab|1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15
45816630|NCT05362877|Device|Earplug|Using earplugs to reduce the symptoms of temporomandibular disorder
45956029|NCT00518128|Procedure|Surgical OSA treatment|uvulopalatopharyngoplasty +/-tonsillectomy, genioglossus advancement, and hyoid suspension
45956030|NCT00518128|Procedure|Positive Airway Pressure Therapy|Continuous positive airway pressure for treatment of obstructive sleep apnea
45956031|NCT02949778|Procedure|QL-block|Bilateral quadratus lumborum block using either ropivacaine 3.75mg/ml or sodium chloride 0.9% is the intervention studied
45956032|NCT02949778|Drug|Ropivacaine|Ropivacaine 3.75mg/ml administered in QL-block as active treatment
45956033|NCT02949778|Drug|Sodium Chloride|Sodium chloride 9mg/mL administered in QL-Block as placebo
45956034|NCT04458506|Procedure|Maxillary expansion|Correction of the unilateral posterior cross bite in children
45956035|NCT00518245|Drug|enoxaparin|Enoxaparin will be given subcutanteously at a dose of 1mg/kg every 12 hours for a minimum of 48 hours (4 doses) and a maximum of 8 days until a diagnostic / therapeutic procedure is performed, or at the discretion of the investigator.
45956036|NCT00518362|Drug|TW|TW,120 mg/d
45956037|NCT00151554|Behavioral|ICU-specific information program|The intervention group receives a standardized information program with specific procedural, sensory and coping information about the ICU in addition to standard information given by surgeons and anesthetists.
45956038|NCT00518401|Biological|Mesendo|Intramuscular injection of 0.5 cc per site of the combination stem cell mixture in approximately 40 different ischemic sites of the gastrocnemius area of the calf.
45956039|NCT02957903|Drug|Ropivacaine|All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
45956040|NCT02957903|Drug|Isotonic Saline|All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
45956041|NCT00518479|Drug|Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD|
45956042|NCT00518479|Drug|Valsartan 160mg OD; Moxonidine 400mcg OD|
45956043|NCT04694755|Drug|Placebo|On the basis of dextrin and bitter agent, 5% of the drug was used to prepare.Its appearance, weight, color and smell are basically the same as traditional Chinese medicine granule.Tianjiang brand formula granules, in line with GMP standards
45956044|NCT04694755|Drug|Traditional Chinese medicine prescription|Tianjiang brand formula granules, in line with GMP standards
45956045|NCT00166725|Drug|Octreotide LAR|
45956046|NCT00518518|Drug|Staloral 300|Staloral 300
45956047|NCT00518518|Drug|placebo|placebo
45956048|NCT00518557|Procedure|Transcatheter Arterial Chemoembolization|The interventional procedure is performed as following steps: 1)transcatheter hepatic arterial angiography(including any feeding arteries to the tumor) is performed under a DSA unit; 2) super selectively catheterizaton of feeding arteries to the tumor is reached; 3)30 mg of Andostatin (Simcere Co. China) mixtured with 5 ml Lipiodol is injected into the tumor via the feeding arteries; 4) followed by 10 mg of Epifubicin mixtured with 5 ml of Lipiodol; 5) All feeding arteries to the tumor are occluded which is confirmed by re-angiography.
45956049|NCT00518596|Dietary Supplement|Probiotic supplementation (Lactobacillus plantarum)|GastroPlan capsules from a single lot will be used. The intervention consists of L. plantarum reconstituted in sterile 2.0 cc of 5% dextrose-saline, administered orally using an opaque-amber syringe.
45956050|NCT00151593|Other|Celsior®|Graft preservation solution
45956051|NCT00518635|Drug|Nutropin|Nutropin 0.1 mg/day self-administered once a day
45662028|NCT05253937|Drug|Epinephrin|The study will enroll acute myocardial infarction patients who suffered from a cardiac arrest in the cardiac catheterization laboratory during percutaneous intervention procedure. Cardiac Resuscitation was performed according to the European Resuscitation Council (ERC) Guidelines. The preferred route of epinephrine administration was through the central venous access (by internal jugular or subclavian vein). Thus, if available, it was the preferred method of medication delivery. However, in cases without central venous access, the route of epinephrine administration (peripheral intravenous or arterial intracoronary) during cardiac arrest was left to the treating physicians.
45956052|NCT00518674|Procedure|local infiltration analgesia|local wound infiltration with 30 ml ropivacaine 0.2 % (60 mg)
45956053|NCT02949505|Behavioral|Home prehabilitation program|12-week exercise therapy using daily step program (accelerometer), functional resistance exercise sessions and telephone/virtual clinic appointments
45956054|NCT00518752|Procedure|Standard Oral Care|Patients in this arm will receive standard oral care with manual brushes and routine oral hygiene products twice a day
45458151|NCT02314390|Behavioral|Group-Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2 1/2 hours.
45458152|NCT02314390|Behavioral|Individual-Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
45816631|NCT05362877|Device|occlusal splint|Using occlusal splints to reduce the symptoms of temporomandibular disorder
45816632|NCT05362877|Other|exercise|Applying exercise to reduce the symptoms of temporomandibular disorder
45816633|NCT05358587|Other|Ultrasound guided PENG block with 20 mL Local Anesthetic solution|In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %). Block will be performed 30 minutes before spinal anesthesia.
45956055|NCT00518752|Procedure|Comprehensive Oral Care|Patients will receive a comprehensive oral care protocol using mechanical brushes and oral care products formulated for patients with a dry mouth twice a day
45956056|NCT00151632|Drug|Mycophenolate mofetil|Mycophenolate mofetil is administered at a dose of 1,5 g x 2 / day for the 6 first weeks, then 1g x 2 / day until M12.
45816634|NCT05358587|Other|Ultrasound guided PENG block with 30 mL Local Anesthetic solution|In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %). Block will be performed 30 minutes before spinal anesthesia.
45956057|NCT00151632|Drug|Tacrolimus|"In arm 1: Tacrolimus is administered at half recommended dose: 0,040 mg/Kg x 2 , in order to maintain plasma levels between 6 and 10 ng/ml for the 6 first weeks, between 5 and 8 ng/ml from week 7 to M6 and between 4 and 6 ng/ml between M6 and M12.~In arm 2: Tacrolimus is administered at the recommended dose: 0,075 mg/Kg x 2 , in order to maintain plasma levels between 12 and 20 ng/ml for the 6 first weeks, between 10 and 15 ng/ml from week 7 to week 12, between 8 and 12 ng/ml between M4 and M6 and between 6 and 10 ng/ml between M6 and M12."
45662029|NCT05253703|Other|Virtual reality bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session (see arm/group description).
45662030|NCT05218603|Drug|Bortezomib|Maintenance: Administration as per routine clinical practice.
45956058|NCT00518791|Other|Multidisciplinary Care|A comprehensive individualised assessment by a dedicated multidisciplinary team (Multidisciplinary Assessment Center) and subsequent treatment by specifically trained health professionals (ParkinsonNet).
45956059|NCT00518791|Other|Usual Care|No altered organisation of care
45662031|NCT05218603|Drug|Daratumumab|Maintenance: Administration as per routine clinical practice.
45662032|NCT05217199|Other|Measurements|Demographic information of infants and parents, prenatal, postnatal and natal risk factors, Magnetic Resonance Images (MRI), Cranial Ultrasonography (c-USG), General Movements (GMs) evaluations of babies with Prechtl method from NICU will be recorded. Video recordings for General Movements (GMs) analyzes with the Prechtl method will be taken intermittently, starting in the NICU until the postterm 20th week. The infants' sensory processing (general, auditory, visual, tactile, movement, oral) will be evaluated with the adjusted Infant Sensory Profile-2 (ISP-2) family scale, which will be filled in by their mothers at the 3rd month. For motor assessments, the postterm corrected 3 month Hammersmith Infant Neurological Examination (HINE) will be used.
45956060|NCT00518830|Other|multi-component intervention|The PND-MCI included psycho-educational groups, structured pharmacotherapy if needed, and systematic monitoring of clinical progress and treatment compliance
45816635|NCT05357638|Behavioral|High Intensity Interval Training (HIIT)|8 weeks of HIIT, 2x/week for about 30 minutes/session on a cycle ergometer
45956061|NCT00518830|Other|Usual care|included all services normally available in the clinics, including antidepressant medication, brief psychotherapeutic interventions or referral for specialty treatment
45956062|NCT02949232|Drug|Prednisolone|prednisolone will be will be initiated during the first week at 40mg/day for 3 days and 30mg/day for 4 days, followed by a decrease of 5mg/day per week during the remaining 5 weeks; in the second week, patients will use 25 mg/day, in the third week 20 mg/day is used etc. In the last week the patients will only take prednisolone on day 1-3 and day 5 and 7; a tapering scheme in line with the treatment guidelines for Inflammatory Bowel Diseases (2008).
45956063|NCT02949232|Drug|Placebo Oral Tablet|Dosing following the tapering scheme of the treatment of the treatment arm
45956064|NCT00151671|Drug|Oral Impact®|Oral nutritional supplement containing L-arginin, ω3 polyunsaturated fatty acids, and nucleotides. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
45816636|NCT05357638|Behavioral|Continuous Aerobic Training (CAT)|8 weeks of CAT, 2x/week for about 50 minutes/session on a cycle ergometer
45956065|NCT00151671|Drug|Placebo|Oral solution of placebo. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
45956066|NCT04694326|Diagnostic Test|HbA1c|The participants' age, sex, education level, known diseases, unit of hospitalization and inpatient diagnosis were questioned and recorded. Height, weight and waist circumference measurements were taken. Fasting blood sugar and HbA1c measurements were made
45956067|NCT04694170|Other|additional therapy|Using conventional physiotherapy together with additional yoga exercising and regimen restriction acc to TCM.
45816637|NCT05357638|Behavioral|Movement Advice|Weekly step goal, monitored using an activity tracker, +3000 steps/day for 5 days/week, step goal is based on average step count in the 4 weeks of baseline prior to the intervention
45956068|NCT04694170|Other|conventional physiotherapy|Using conventional physiotherapy only.
45956069|NCT00518908|Drug|Sevoflurane|3.2 Vol % for postconditioning
45662033|NCT05217121|Other|Quadratus Lumborum Block|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions, the probe will be covered with a sterile sheath and a 22G, 80 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the abdominal muscles, the needle will be punctured and 5 ml of saline will be injected into the postero-lateral border of the quadratus lumborum muscle. After the block location is confirmed, 15 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (30 ml totally).
46002819|NCT00548951|Other|Snoezelen Room|Session in a Snoezelen room once per week for 12 weeks
45816638|NCT05352724|Dietary Supplement|Hydration drink|Intake of the different hydrating drinks for 4 weeks 3 times a week during sports practice
45956070|NCT00518947|Drug|Lithium|Treatment with lithium carbonate was initiated at a dose of 900-1200 mg/day. Serum lithium levels were monitored twice weekly, and the dose was adjusted to attain target levels between 0.8 and 1.0 mmol/L by the end of week one, with subsequent levels as high as 1.4 mmol/L permitted if needed.
45816639|NCT05347966|Other|Brain Health PRO|BHPro is a 45-week, multidomain web-based formal educational program which has been designed to increase dementia literacy, convey best available evidence for lifestyle changes that can mitigate dementia risk, and foster engagement toward one's own brain health.
45454655|NCT01111201|Behavioral|questionnaires|The intervention is a self-administered anonymous questionnaire that is voluntarily completed by the patient. Questions in Section One will cover general information about the patient including gender, age, race, country of birth, current zip code of residence, and level of education. Questions in Section Two will cover information regarding the cancer (breast/lymphoma) or transplant (allogeneic/ autologous). Questions in Section Three will cover travel history including the frequency of travel outside the United States and Canada in the last 5 years. Questions in Sections Four through Seven will obtain information about their last trip outside the United States and Canada.
45816640|NCT05345314|Procedure|Narrow-band imaging endoscopy|During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.
45816641|NCT05334732|Behavioral|SIS TALK Back Intervention|The participants in this arm will be seen by a trained survivor coach and receive culturally tailored intervention materials.
45816642|NCT05333835|Drug|HR17031 injection|HR17031 injection
45956071|NCT00518947|Drug|verapamil|The initial dose of verapamil was 80 mg b.i.d., and this was raised by 80 mg/day every three days to a maximum of 480 mg/day, unless intolerable side effects were produced at a lower level, in which case the dose was maintained at the highest tolerated amount.
45956072|NCT00518947|Drug|verapamil plus lithium|
45816643|NCT05333835|Drug|INS068 injection|INS068 injection
45816644|NCT05333835|Drug|SHR20004 injection|SHR20004 injection
45816645|NCT05330377|Drug|Gilteritinib 40 MG Oral Tablet|Gilteritinib is an oral FLT3 inhibitor, and is active against both FLT3-ITD and FLT3-TKD mutations. Gilteritinib will be given orally according to the assigned phase I dose cohort starting day 6 until day 19. Participants will be given the daily dose with water as at the same time each morning. Gilteritinib should be taken at least 2 hours after or 1 hour before consuming food.
45956073|NCT02949466|Drug|Triamcinolone|compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
45816646|NCT05330377|Drug|Cladribine|Cladribine is given intravenously at a dose of 5 mg/m2 I.V. over 2 hours once per day on days 1 to 5.
45956074|NCT02949466|Device|Hyaluronic acid|compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
45956075|NCT00519064|Biological|Adjuvanted influenza vaccine|
45956076|NCT00151710|Drug|Pioglitazone|
45956077|NCT00519103|Other|exercise|
45454656|NCT05607862|Other|Home Physiotherapy Group|The intervention group will receive 2 sessions per week for 8 weeks supervised and assisted by a physiotherapist at the patient's home. Muscle strengthening exercises of the lower and upper limbs, stretching, coordination and balance exercises, gait re-education with the relevant technical aids, a pattern of exercises to be performed daily by the patient and health education guidelines will be carried out.
45816647|NCT05330377|Drug|Cytarabine|Cytarabine is given intravenously at a dose of 2,000 mg/m2 I.V. over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine.
45816648|NCT05330377|Drug|Filgrastim|Filgrastim (GCSF) or biosimilar, will be given at a dose of 300 mcg S.C. once per day on days 0 to 5, started 24 hours prior to chemotherapy. If WBC is > 20 × 109/L on day 0, the filgrastim dose on day 0 will be omitted.
45816649|NCT05330377|Drug|Mitoxantrone|Mitoxantrone is given intravenously at a dose of 10 mg/m2 I.V. over 2 hours once per day on days 1 to 3.
45816650|NCT05326087|Drug|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
45816651|NCT05326087|Drug|MPA|oral MPA 10mg qd from Day 3 of ovarian stimulation till the day of ovulation trigger.
45816652|NCT05323435|Biological|Recombinant two-component COVID-19 vaccine (CHO cell)|Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter
45816653|NCT05323435|Biological|COVID-19 Vaccine (Vero Cell), Inactivated|Milky-white suspension.Stratified precipitate may form which can be dispersed by shaking
45816654|NCT05322252|Drug|Mifepristone|200mg orally
45816655|NCT05322252|Drug|Misoprostol|Per clinician
45956078|NCT00519181|Drug|Valproic Acid|Valproic acid by oral route (20mg/Kg/day) during one year.
45956079|NCT02949388|Drug|Placebo|Two capsules (both containing Placebo enclosed) taken twice a day and approximately 12 hours apart
45956080|NCT02949388|Drug|400 mg (200 mg BID)|Two capsules (both containing two 50mg tablets enclosed) taken twice a day and approximately 12 hours apart
45956081|NCT02949388|Drug|300 mg (150 mg BID)|Two capsules (one containing 50mg tablet and one containing two 50 mg tablets) taken twice a day and approximately 12 hours apart
45956082|NCT00166803|Drug|Rosiglitazone|Rosiglitazone , 4 mg daily
45956083|NCT02949310|Drug|Nefopam|
45956084|NCT02949310|Drug|Normal Saline|
45956085|NCT00519220|Other|Symptom questionnaire|Patients will answer questionnaires evaluating their symptoms of achalasia.
45956086|NCT02949349|Drug|Mycophenolate mofetil|Provided as 250mg/capsule, dose specific for each arm, orally twice a day, for 24 weeks.
45956087|NCT02949349|Drug|Azathioprine|Provided as 50mg/tablet, 1mg/kg, orally twice a day, for 24 weeks.
45956088|NCT02949349|Drug|Prednisolone|Daily dose not more than 10mg, orally, for 24 weeks.
45956089|NCT00166842|Drug|sirolimus, cyclosporine, tacrolimus|
45956090|NCT02949193|Drug|evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to sitagliptin 100mg
45956091|NCT02949193|Drug|Sitagliptin|sitagliptin 100 mg tablet qd + placebo tablet matching to evogliptin 5mg
45956092|NCT00519259|Drug|Lobeline|
45956093|NCT00519298|Drug|SAM-531|dosage form : 0.5 mg and 5 mg capsules 3 different single doses : 1 mg, 3mg and 10 mg of SAM-531
45956094|NCT00519298|Other|placebo|placebo
45816656|NCT05318820|Drug|HMPL-523|This study plans to enroll 39 healthy Chinese subjects who will be randomized (1:1:1) into one of three sequence groups (Test [T]/Reference[R]/R group, RTR group and RRT group) to receive a single dose in each cycle with a washout period of at least 7 days, where T is the test product [i.e., HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Limited.], and R is the reference product (i.e., HMPL-523 Tablets manufactured by WuXi STA).
45956095|NCT00519298|Drug|Donepezil|dosage form: 5 mg encapsulated tablets one single dose of 5 mg.
45956096|NCT00519337|Drug|Ascorbic acid|Ascorbic acid, 2 g p.o. the night before surgery followed by 500mg B.I.D. for 4 post-operative days
45956097|NCT00519337|Drug|Placebo|Placebo capsule, 4 capsules the night before surgery followed by 1 capsule B.I.D. for 4 postoperative days
45816657|NCT05311917|Other|home vision therapy|a group of vision therapy procedures in home to improve convergence insufficiency
45956098|NCT00151749|Drug|Colesevelam hydrochloride|
45816658|NCT05311917|Other|base in prism prescription|base in prism prescription according to sheards criterion
45816659|NCT05311917|Other|conventional placebo|using near glasses with aimless eye training
45956099|NCT00519415|Other|Tongue plate|A functional appliance use for maxillary protraction.It has two adams clasp and two C clasp to retained the appliance and long palatal plate in the canine area which cages the tongue and transfer the force of the tongue during physiological activity to the upper arch. It has posterior bite plate and middle screw for maxillary expansion.It should be used all the time except meal time and brushing the teeth,the acrylic appliance makes specifically for the patient.
45816660|NCT05293912|Drug|SG2501|During study treatment, subjects will receive SG2501 treatment via IV infusion once every week at doses of: 0.01, 0.03, 0.1, 0.3, 1, 2, 4 and 6mg/kg.
45816661|NCT05288751|Behavioral|Contingency Management|Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting.
45816662|NCT05288062|Procedure|Bone Marrow Biopsy|Undergo bone marrow aspirate/biopsy
45956100|NCT00519415|Other|Facemask|An extraoral appliance use for treatment of maxillary deficiency in growing patients.It takes anchorage from chin and forehead, it has removable intraoral appliance with hooks for elastics that exerted a force of 300 gr.It should be used 14 hours a day.
45454657|NCT05607862|Other|Control Group|The control group will be given health education guidelines and will continue with their usual medical-pharmacological treatment. All patients included in this study will receive physiotherapy treatment, and those in the control group will be treated once the intervention and the post-intervention assessment have been completed.
45816663|NCT05288062|Drug|Dexamethasone|Given orally
45816664|NCT05288062|Drug|Lenalidomide|Given orally
45816665|NCT05288062|Drug|Pomalidomide|Given orally
45956101|NCT00519454|Other|Peripheral lab draws|100ml blood for analysis, taken no more than 4 times in one year.
45956102|NCT00519493|Procedure|Suture|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.
45956103|NCT00519493|Device|Clozex|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.
45956104|NCT00519571|Device|ImplantLock device|dental implant
45956105|NCT00166881|Drug|Docetaxel-Irinotecan|Docetaxel-Irinotecan, weekly, days 1, 8, 15, repeated every 4 weeks
45956106|NCT00519610|Other|Chart Review|Patients' charts will be reviewed for relevant medical information.
45956107|NCT02948998|Drug|Spironolactone|The participants in this arm will be prescribed to take 20mg spironolactone orally and daily. Serum potassium concentration and creatinine and blood pressure will be monitored regularly to make the participants safe.
45956108|NCT00151788|Drug|Pactimibe sulfate|
45956109|NCT00519688|Drug|Thalidomide|100 mg, BID
45458153|NCT01234363|Device|Magnetic Resonance Elastography, and Supersonic Shear Imaging|Magnetic Resonance Elastography, and Supersonic Shear Imaging
45458154|NCT02316340|Drug|Vorinostat|400mg by mouth daily
45816666|NCT05259423|Other|Enriched Education Program|Enriched play activity education including 9 different activities each with 3 levels depending on the infant's current head and trunk control. Parents will be instructed to complete 3 activities each day for at least 5 minutes each for a total of 15 minutes per day.
45816667|NCT05259423|Other|Typical Education Program|Typical play activity education including 9 activities commonly described by popular parenting websites, mobile applications, and books. Parents will be instructed to complete 3 activities each day for at least 5 minutes each for a total of 15 minutes per day.
45816668|NCT05251272|Diagnostic Test|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
45816669|NCT05250713|Device|Transcranial stimulation|Patients will receive either direct current stimulation or alternate stimulation.
45662034|NCT05217121|Other|Modified-thoracolumbar interfascial plane block|US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 15 mL will be injected in each side (30 ml totally).
45662035|NCT05217043|Other|intracranial brain recording|Any patient benefiting from a long-term intracranial brain recording.
45662036|NCT05252377|Other|Breathing Exercise|"The patient will be asked to close their eyes~He will be asked to relax his head and neck in a semi-sitting position in bed~The patient will be asked to breathe through the nose for 3 seconds by counting~Then he will be told to hold his breath for 3 seconds~As the last step, he will be asked to breathe out again in 3 seconds."
45662037|NCT05280769|Other|oral nicotine pouch - 2 mg|"On brand oral nicotine pouch with 2 mg of protonated nicotine in original flavor"
45662038|NCT05280769|Other|oral nicotine pouch - 4 mg|"On brand oral nicotine pouch with 4 mg of protonated nicotine in original flavor"
45816670|NCT05246943|Diagnostic Test|D-dimer and lower limb venous duplex|D-dimer blood test- The D-dimer assay detects the presence of fibrin degradation products, which can indicate the breakdown of a fibrin clot Lower Limb Venous Duplex- Using an ultrasound to visually look for a clot
45816671|NCT05246904|Other|Fitting algorithm|The best fitting algorithm will be selected by the audiologist (arm 1) or software.
45816672|NCT05241600|Behavioral|Mindfulness-Based Childbirth and Parenting|MBCP is an adaptation of MBSR that incorporates both standard mindfulness practices (body scan, sitting meditation, mindful movement) and preparation for mindful birthing and parenting an infant. The class is taught by experienced midwives or social workers who have completed MBCP training requirements, which include ongoing cultivation of a personal mindfulness practice as well as education and supervision specific to the MBCP program. See Bardacke (2012) for further description of the MBCP curriculum.
45816673|NCT05241600|Behavioral|Non-Mindfulness-Based Childbirth Class|Other childbirth preparation classes available either in-person in the local community or online that do not involve formal mindfulness training will serve as the comparator condition.
45816674|NCT05239468|Drug|Bezafibrate 100 mg|One tablet of bezafibrate 100 mg IR once daily
45816675|NCT05239468|Drug|Bezafibrate 200 mg|Two tablets of bezafibrate 200 mg IR once daily for BZF 400 mg IR
45816676|NCT05239468|Drug|Obeticholic Acid 5 mg|One tablet of obeticholic acid 5 mg tablet once daily.
45816677|NCT05239468|Drug|Obeticholic Acid placebo|One tablet of obeticholic acid placebo tablet once daily
45816678|NCT05239468|Drug|Bezafibrate Placebo|One tablet of bezafibrate placebo tablet once daily
45816679|NCT05237388|Drug|Baricitinib|One pill daily
45816680|NCT05237388|Drug|Placebo|Baricitinib placebo pill
45816681|NCT05235334|Device|MySOLIUS|MySOLIUS is a portable light therapy device that is designed to deliver a small amount of targeted ultraviolet B (UVB) light to trigger the body's natural production of vitamin D.
45816682|NCT05229016|Behavioral|Reflection on health-related experiences|This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.
45816683|NCT05222620|Other|Questionnaire Administration|Ancillary studies
45816684|NCT05222620|Radiation|Stereotactic Radiosurgery|Undergo single fraction SRS
45816685|NCT05222620|Radiation|Stereotactic Radiosurgery|Undergo fractionated SRS
45816686|NCT05214612|Combination Product|Drug treatment of myasthenia gravis and treatment of crisis|Patients with myasthenia gravis who are receiving medical treatment and treatment of crisis as plasmapheresis
45816687|NCT05212454|Drug|Capecitabine|capecitabine, 0.5g per pill, given 1250mg/m2 twice a day for 2 weeks of the 3-week treatment course. The total duration of treatment is 8 courses.
45816688|NCT05210569|Device|Vivity|Vivity intraocular lens (IOL)
45816689|NCT05207189|Biological|UVT|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical vein allograft placed in replacement of a failed synthetic sling during a surgical act performed by the investigator.
45816690|NCT05206617|Other|No intervention - pure observational study|No intervention
45956110|NCT00519688|Drug|Tegafur/Uracil|125 mg/m2, based on tegafur, BID
45816691|NCT05204901|Device|Insertion and withdrawal of a magnetic-tipped wire into the lumen of the nasogastric tube for tracking of its position|In each participant, the investigator will place sensors on two sites of the sternum and track the location of the magnet as it is inserted and withdrawn from the nasogastric tube in the patients.
45956111|NCT02948803|Behavioral|smartphone based intervention with Active Coach app|
45662039|NCT05280769|Other|oral nicotine pouch - 8 mg|"On brand oral nicotine pouch with 8 mg of protonated nicotine in original flavor"
45662040|NCT05280769|Other|Smokeless tobacco|Participant's typical brand of smokeless tobacco
45956112|NCT02948920|Drug|Ephedrine|9 mg of ephedrine (3 ml)
45816692|NCT05201820|Device|Cryoanalgesia|Cryoanalgesia will be applied during surgery on 6 intercostal nerves each side
45956113|NCT02948920|Drug|NSS|3 ml of normal saline
45816693|NCT05168969|Other|Questionnaire|The families and health care providers will be invited to fill in a questionnaire related to hyperekplexia (clinical, pharmacological, and genetic data).
45956114|NCT04694482|Other|Psychometric scale administration|PTSD symptoms are assessed using a specific scale (IES-R) and compared between the two groups
45956115|NCT02948764|Device|Vacuum-Assisted Biopsy|The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, or by mammography (stereotaxy) during the second trial visit (V2) will be performed once. In analogy to the German S3 guideline on primary breast cancer management we recommend to take at least 12 biopsies with 10G needles or less in case of larger needle sizes.
45956116|NCT00519727|Drug|ISIS 325568|"4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg~Placebo: 0.9% Sodium Chloride"
45956117|NCT00151827|Drug|Olmesartan medoxomil|Olmesartan oral tablets 20 or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.
45956118|NCT00151827|Drug|Losartan|Medications are taken once daily before breakfast with water.
45956119|NCT00151827|Drug|Furosemide oral tablets|If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator
45956120|NCT00519805|Drug|dalteparin|
45454658|NCT01114399|Dietary Supplement|Diet and Vascular Health|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
45662041|NCT04900831|Diagnostic Test|Omnipolar Eletroanatomical mapping|Analyse intracardiac EGMs collected with the HD Grid catheter (Abbott, Chicago, IL) during routine Atrial Flutter ablation using the Omnipolar algorithm.
45816694|NCT05157581|Device|Extracorporeal photopheresis (ECP)|Extracorporeal photopheresis is a process that exposes a collection of white blood cells and plasma to a light sensitizing agent, methoxsalen, and returns that compartment to the body.
45816695|NCT05157581|Drug|Methoxsalen Injection|Methoxsalen is a light-sensitizing sterile compound added to the collected white blood cells and plasma during ECP.
45816696|NCT05147311|Behavioral|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 9-week period. The positive psychology program exercises include three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
45956121|NCT00519805|Procedure|quality-of-life assessment|
45956122|NCT00519844|Drug|somatropin|
45956123|NCT00519883|Other|Exercise|
45956124|NCT00519883|Other|Supportive Care|
45956125|NCT00519922|Other|Kinesthesia, Balance, and Agility (KBA) Exercise|"Participants will exercise three times per week 20 to 30 minutes per session. Agility/Active Range of Motion exercises provide warm-up, improve joint range-of-motion & agility, dynamic proprioception,functional strength & endurance.~Kinesthesia & Balance Training will challenge the subject's proprioceptive and neuromuscular control mechanisms to adapt and stabilize the knee joints during dynamic ADL activities (walking, climbing, etc); improve static and dynamic balance and sense of stability & confidence in ADL activities.~Soft pads will be used to progress some of the kinesthesia & balance challenge training. Thera-Band® balance pads at 3 levels of softness will be used. These balance pads allow both appropriate starting difficulty and progression of difficulty level (i.e., the softer the pad, the greater the difficulty). Subjects will demonstrate safe balance on a stable surface (i.e. one-footed standing on floor) prior to progressing to the first level of the soft pads."
45956126|NCT00519922|Other|Standard LE Strength Training|Standard therapeutic exercises for knee OA which are widely used. Body weight and Thera-Band® color coded elastic bands will be used as appropriate to provide resistance. Exercises will be progressed according to the individual participant's improvement. All training for the ST condition will be conducted on stable surfaces (e.g. standing on floor, sitting in chair, lying on floor). Exercises may include 4-direction straight leg lifts, heel slides, quad sets, internal & external hip rotation, heel raises, toe raises, knee extension, knee flexion, partial squats/wall slides, etc.
45956127|NCT02948881|Drug|ibandronate|
45956128|NCT00151866|Procedure|platelet transfusion|
45458155|NCT02316340|Drug|Hydroxychloroquine|600mg by mouth daily
45458156|NCT02316340|Drug|Regorafenib|160 mg by mouth daily
45662042|NCT05251519|Other|Kinesio Taping|Derotation taping with Kinesio Tex is applied to the patients through a pediatric physiotherapist.
45662043|NCT05251519|Other|Conventional Rehabilitation|Conventional rehabilitation program is applied to the patients through a pediatric physiotherapist
45662044|NCT05214001|Drug|Almotriptan 12.5 Mg Oral Tablet|Treatment for an acute, moderate to severe migraine attack
45662045|NCT05214001|Drug|Ubrogepant 50Mg Tab|Treatment for an acute, moderate to severe migraine attack
45956129|NCT04457180|Drug|Apatinib Mesylate|Apatinib will be administered daily from on D5 through D16
45662046|NCT05250505|Device|eShunt Implant|The eShunt System consists of endovascular delivery componentry and a permanent implant intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system in adults.
45454659|NCT01114399|Dietary Supplement|Diet and Vascular Health|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
45454660|NCT01114399|Dietary Supplement|Diet and Vascular Health Study|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
45454661|NCT01111279|Biological|gpASIT+TM|1 subcutaneous injection every 7 days, during 29 days.
45662047|NCT05249959|Drug|Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy (R-BAC, Rituximab - Bendamustine, Ara-C))|"Treatment schedule~INDUCTION PHASE (salvage immunochemotherapy):~• 2 courses of R-BAC (every four weeks):~Rituximab 375 mg/m2 IV day 1,~Bendamustine 70 mg/m2 IV days 2 and 3,~Ara-C 500 mg/m2 IV days 2-4~An optional pre-phase with steroid (prednisone 1 mg/kg/day, maximum of 7 days before starting induction phase) and/or single dose of Vincristine (up to 2 mg total) was allowed.~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks"
45454662|NCT01111279|Biological|gpAST+TM/adjuvant|1 subcutaneous injection every 7 days, during 29 days
45454663|NCT01111279|Biological|Placebo solution|1 subcutaneous injection every 7 days, during 29 days
46078750|NCT02742558|Biological|Shanchol|The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.
45662048|NCT05249881|Drug|Semaglutide Pen Injector|All Diabetes mellitus type2 patients fulfilling the inclusion criteria, will receive 0.25mg Semaglutide injection per week and after two weeks dosage will be escalated to 0.5 mg/week for next 10 weeks.
45662049|NCT05280379|Other|no intervention will take place|no intervention will take place
45816697|NCT05145920|Behavioral|HabitE (effective parenting habit) program (in Brazilian Portuguese)|Parents who enroll in the program will receive a series of 5 videos (~ 7 minutes each), 1 video at a time, generally every 3 days. Parents will also receive daily written texts, which include implementation tips and an assessment of a target (transition) behavior.
45816698|NCT05140837|Diagnostic Test|Psychometric hepatic encephalopathy score & Stroop test|MHE was assessed according to neuropsychological methods. Psychometric hepatic encephalopathy score include number connection test (NCT), digit-symbol test (DST), line-tracing test (LTT) and serial dotting test (SDT). Stroop test can assess psychomotor speed and cognitive flexibility by recording the interference response time between recognizing color fields and writing color names.
45816699|NCT05140837|Drug|Drug therapy|Real-world cohort study. The outcomes were examined and registered, so as to evaluate the relationship between therapeutic effects and health outcomes. Psychometric hepatic encephalopathy score and quality of life scale were measured at 3, 6, 12, 18 and 24 months of follow-up.
45956130|NCT04457180|Drug|Repaglinide|Repaglinide will be administered daily on D1 and D12
45956131|NCT04457180|Drug|Bupropion|Bupropion will be administered daily on D2 and D13
45956132|NCT00519961|Device|Elecsys®proBNP|
45956133|NCT00520000|Drug|Carboplatin|standard dose of area under the curve (AUC) AUC of 6 in all arms
45956134|NCT00520000|Drug|Abraxane|75mg/m2 - 150 mg/m2 given on days 1, 8, 15 of every 28 day cycle
46078751|NCT02816450|Behavioral|Water Intake|
45454664|NCT03527680|Dietary Supplement|Lactobacillus rhamnosus|daily one capsule containing 1.6*107 CFU of Lactobacillus Rhamnosus prepared by Tabriz Nutrition Research Center from yogurt and cheese of different farms located in the suburbs Heris, after meal for 28 days
45454665|NCT03527680|Drug|Placebo - Cap|daily one capsule of placebo
45454666|NCT03151226|Device|Capnography monitoring|capnography and pulse oximetry will be initiated in the recovery room and worn for 12-24 hours post delivery
45454667|NCT03529006|Procedure|Sequent Please inflation|PCI procedure for treatment of ISR with DEB - Sequent Please - inflation
45454668|NCT03529006|Procedure|Absorb BVS implantation|PCI procedure for treatment of ISR with Absorb BVS implantation
45662050|NCT05280223|Drug|Dexmedetomidine|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydrodissection
45662051|NCT05280223|Drug|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
46078752|NCT02816840|Radiation|PET-CT|Patients in this arm take radiotherapy positioning with PET-CT.
46078753|NCT02816840|Radiation|PET-MRI|Patients in this arm take radiotherapy positioning with PET-MRI.
45956135|NCT00520000|Drug|Abraxane|180mg/m2 - 340mg/m2, repeated every 21 days
45956136|NCT00520000|Drug|Abraxane|100mg/m2 - 175/mg/m2 given on days 1, 8 of every 21 day cycle
45956137|NCT00151905|Drug|3 % hypertonic saline|
45956138|NCT04453982|Other|Human milk donors|Human milk donors for the Rogers Hixon Ontario Human Milk Bank
45956139|NCT00520156|Device|Continuous positive airway pressure (CPAP)|Patients diagnosed with obstructive sleep apnea (OSA) will be offered standard of care treatment of CPAP (patients given oral appliances for OSA are excluded from our study). Note: our study is a survey-based and observational study following patients who are being evaluated for sleep disorders. Those patients diagnosed with OSA would be offered CPAP or possibly an oral appliance regardless of whether they are entered into our study or not.
45454669|NCT01111357|Biological|Collect of 10 ml of peripheric blood for DNA extraction|After signed written consent, all patients have a clinic exam in order to assess the presence of eligibility criteria (Patient with Rheumatoid Arthritis that fulfil the ACR criteria of diagnosis)
45816700|NCT05135598|Other|Partners for Life health behavior change program|A health behavior change intervention based on partner learning, utilizing low-tech media and a workbook.
45956140|NCT00520195|Behavioral|Physical activity|Climbing stairs instead of taking elevators at worksite during 12 weeks.
45956141|NCT02949115|Dietary Supplement|70 mL red beetroot juice|1x daily intake of 70 mL red beetroot juice
45662052|NCT05280067|Device|ZetaFuse™ Bone Graft|The ZetaFuse™ Bone Graft will be percutaneously implanted into the vertebral body defect(s) created by the lytic metastatic tumor.
45662053|NCT05279989|Other|Seated Tai Chi Qigong|Participants will receive seated Tai Chi Qigong videos.
45662054|NCT05279989|Other|Health Information Videos|Participants will receive videos of health information.
45662055|NCT05279677|Drug|Fecal microbiota transplantation plus Sintilimab and Fruquintinib|"Microbiota capsules containing 1g gut microbiota, po d1-3 before anti-tumor treatment, total for 8 cycles.~Sintilimab 200mg iv, q3w. Fruquintinib 5mg po d1-14, q3w."
45662056|NCT05278117|Procedure|outcomes of complete burst abdomen repair using posterior component separation technique with transversus abdominis muscle release reinforced by sublay mesh|outcomes of complete burst abdomen repair using posterior component separation technique with transversus abdominis muscle release reinforced by sublay mesh
45662057|NCT05277337|Biological|Alluzience|Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection
45662058|NCT05277337|Biological|powder BoNT-A (BOTOX/Vistabel)|Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection
45662059|NCT05276947|Other|position with peanut ball|The experimental group will be positioned with the peanut ball until the end of the active phase of labor.
45662060|NCT05248945|Drug|Evobrutinib|Participants will receive a single dose of film-coated evobrutinib tablet (TF2) on Day 1 and Day 19.
45956142|NCT02949115|Dietary Supplement|70 mL red beetroot juice without nitrate|1x daily intake of 70 mL red beetroot juice without nitrate
45956143|NCT02949115|Dietary Supplement|70 mL placebo drink plus potassium nitrate|1x daily intake of 70 mL placebo control drink plus 489 mg potassium nitrate (300 mg nitrate)
45956144|NCT02949115|Dietary Supplement|70 mL placebo drink|1x daily intake of 70 mL placebo control drink
46078754|NCT04291950|Procedure|Needle core biopsy|"Blood draws will be done in OR by research staff. Tissue will be obtained at the time of their definitive surgery or at the time of port placement. For women going to surgery first, four (4) 16-gauge core needle biopsies will be obtained by research staff after the tumor has been removed from the patient and the specimen is on the collection table in the OR.~For women who are getting neo-adjuvant therapy prior to surgery, the core needle biopsies will be collected at the time of port placement in the OR. The patient will be under light anesthesia for the port placement. Per standard care, we will also use local anesthetic for the needle core biopsy. Port placement requires ultrasound (US). We will take advantage of the US already available in the OR to guide the core needle biopsy. Within 30 minutes of procurement, the tissue from the biopsies will be flash frozen in liquid nitrogen by staff and taken to the lab."
46078755|NCT04544852|Behavioral|Current practice|"Intervention A depicts current practices by informing the participants that FIT kits can be obtained from from the Singapore Cancer Society (SCS) or one of their collection point free of charge. Participants will be contacted at 3 months after enrollment to determine whether they have completed the FIT test."
45454670|NCT03528928|Device|Surface electrical stimulation|Thin electrode with four conductive areas placed over the perineal area.
45816701|NCT05113030|Other|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADOLESCENT AGE GROUP WILL BE ASSESSED|Test group(1st) enrollment criteria in PCOS group will be females of adolescent age newly diagnosed with PCOS, with >16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
45816702|NCT05113030|Other|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADULT AGE GROUP WILL BE ASSESSED|Test group(2 nd) enrollment criteria in PCOS group will be females of adult age newly diagnosed with PCOS, with >16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
45956145|NCT00520273|Device|cobas s 201 TaqScreen MPX Test|Donors testing reactive for one or more of the viral markers will be advised to seek further advice/treatment from their physician.
45956146|NCT00151944|Drug|SPD476 (mesalazine)|
45956147|NCT02949037|Other|Mobile Health Care Environment (MHCE)|An integrated mobile health system modified to support type 2 diabetes self-care activities. Primary intervention includes visualization and trending of device outcomes AND tailored behavioral messages based on Patient Activation Measure scores.
45956148|NCT02948686|Other|Self-Etching Application Strategy|In Group SET, the adhesive system Ambar Universal will be used in 55 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
46002820|NCT00548951|Other|Snoezelen Room|Session in a Snoezelen room three times per week for 12 weeks
46002821|NCT00548951|Other|Control|Receive no sessions in a Snoezelen Room.
45662061|NCT05248945|Drug|Carbamazepine|Participants will receive carbamazepine tablet twice daily from Days 2 to 25.
45816703|NCT05109598|Biological|Recombinant new coronavirus vaccine (CHO cell)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person /dose Recombinant new coronavirus vaccine (CHO cells).
45816704|NCT05100485|Diagnostic Test|Esophagogasrtoduodendoscopy|Esophagogasrtoduodendoscopy was used to detech the presence of varices.
45816705|NCT05100485|Diagnostic Test|Hepatic venous pressure gradient|A method used to eveluate the portal pressure
45816706|NCT05096845|Biological|Recombinant SARS-CoV-2 fusion protein vaccine (V-01)|"Appearance: creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5mL) /vial Vaccination route: intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg Immunization schedule: two doses, one each on Day 0 and 21 (+7 days), respectively.~Storage condition: store at 2~8°C protected from light Expiry date: 24 months after production date"
45816707|NCT05096845|Other|Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.
45816708|NCT05091866|Other|Quality-of-Life Assessment|Ancillary studies
45816709|NCT05091866|Other|Questionnaire Administration|Ancillary studies
45816710|NCT05091866|Biological|Therapeutic Progesterone|Given SC
45816711|NCT05084989|Biological|Part1:Recombinant two-component COVID-19 vaccine (CHO cell)|2 doses. Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administration: Intramuscular (IM) injection
45816712|NCT05084989|Biological|Part1: Placebo|2 doses. Before reconstitution: Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: Not Applicable; Does Volume: 0.5ml/dose; Routine of administration: IM injection;
45816713|NCT05084989|Biological|Part2: Recombinant two-component COVID-19 vaccine (CHO cell)|1 dose.Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administrati
45816714|NCT05084989|Biological|Part2: COVID-19 Vaccine, mRNA|1 dose. Intramuscular injection, 30 μg/0.3 mL.
45454671|NCT05724628|Procedure|Laparoscopic appendectomy|Subjects will receive surgery (using 3 port Laparoscopic appendectomy) to remove appendix
45454672|NCT05724628|Drug|Antibiotics (IV transitioned to oral)|"Subjects will be admitted to the hospital for antibiotic treatment, initially with IV antibiotics and then transitioned to by mouth (PO) antibiotics for the rest of the course.~Drugs used would be anything from: zosyn, ciprofloxacin or ceftriaxone and flagyl, augmentin"
45454673|NCT01208701|Drug|Atorvastatin|Zarator, 80 mg pr day for 5 days
45454674|NCT01208701|Drug|Unikalk|1 tablet Unikalk pr day for 5 days
45454675|NCT03151148|Biological|TMT Lotion|TMT product and Vegetable glycerin-Cetaphil®
45454676|NCT03151148|Drug|Placebo Lotion|Cetaphil® moisturizing lotion and vegetable glycerin
45454677|NCT01113619|Drug|RP-G28 or placebo|Qualified subjects randomized to daily dosing with RP-G28 or placebo
45662062|NCT05248789|Biological|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
45662063|NCT05248711|Behavioral|Calm Daily Move|The Daily Move is a series of short, 5-min videos outlining mindful movement exercises. The Daily Move is part of the Calm app's library of content.
45662064|NCT04242667|Behavioral|e-Health (web-based) disclosure portal|Patient uses secure web-based portal to access genetic research results
45662065|NCT04242667|Behavioral|Provider mediated disclosure|Patient has disclosure of genetic research result by a provider (genetic counselor)
45816715|NCT05080881|Diagnostic Test|phonocardiographic measurement: InnoVital Systems|The instrument consists of one or more low-profile microphones in plastic housings with nitrile or silicon diaphragms. These sensors convert heart sounds into analog signals that will be acquired by the BIOPAC data acquisition system.
45816716|NCT05080881|Diagnostic Test|phonocardiographic measurement: ThinkLabs StethOne|This device senses heart sounds and may be listened to using headphones and converted to an analog signal and saved using the BIOPAC data acquisition system.
45816717|NCT05080881|Diagnostic Test|physiological measurements: BIOPAC|Non-invasive blood pressure, electrocardiogram, heart rate, respiratory rate, and leg circumference - This is a commercially available device used regularly in health care settings to monitor continual blood pressure and heart rate.
45816718|NCT05080881|Diagnostic Test|physiological measurements: Masimo Radical-7|A commercially available device for pulse oximetry and continuous non-invasive hematocrit measurement.
45816719|NCT05080881|Diagnostic Test|physiological measurements: CoVa Monitoring System 2|This device will be used for thoracic bioimpedance and other physiological measures. This is a commercially available device. It also measures ECG, heart rate, heart rate variability, estimated stroke volume, and estimated cardiac output. The study team may measure either while body bioimpedance or thoracic bioimpedance.
45816720|NCT05080881|Diagnostic Test|Thoracic impedance|Thoracic impedance is measured using the Starling device (https://usstarling.baxter.com/starling-system). Baxter uses a series of proprietary algorithms to infer stroke volume and cardiac output from thoracis impedance. Calculated values will be recorded, but the main variable that will be recorded is simply the temporal profile of thoracic impedance during the manipulations in each group (changing lower body negative pressure or therapeutic phlebotomy).
45816721|NCT05079828|Diagnostic Test|18F-PSMA-1007|PET/CT scan using 18F-PSMA-1007
45816722|NCT05079828|Diagnostic Test|68Ga-PSMA-11|PET/CT scan using 68Ga-PSMA-11
45816723|NCT05068492|Diagnostic Test|CT|enhanced CT with standard procedure
45816724|NCT05068492|Diagnostic Test|MRI|enhanced MRI with standard procedure
45956149|NCT02948686|Other|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 15 seconds, only in enamel in 55 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Ambar Universal will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
45956150|NCT02948686|Other|Self Etching with Extended time Application Strategy|In Group SETT, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 20 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
45662066|NCT05248399|Behavioral|COVID-19 Group Problem Solving|The treatment arm consists of the COVID-19 Group Problem Solving component that incorporates popular education activities aimed at: developing social cohesion among LDLs; building awareness about COVID-19 risks and protective behaviors; and developing a plan of action to reduce theirs and their peers' risk for COVID-19 transmission. The intervention will be developed to take place over a ~30-45-minute period in order to fit within the corner context of LDLs waiting for employment, and will be delivered by promoters from our team and the community partner agency, Fe & Justicia Workers Center. Following the completion of the intervention, a health promoter will be trained as a navigator assist participants who wish to get vaccinated by providing them with information about near-by vaccination sites that they can visit to get vaccinated. If needed, the promotor will assist them with making their vaccine appointment.
45816725|NCT05068492|Diagnostic Test|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
45816726|NCT05068492|Diagnostic Test|Ultrasound|Digestive ultrasound with standard procedure
45816727|NCT05052892|Diagnostic Test|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
45816728|NCT05050474|Biological|Recombinant SARS-CoV-2 Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
45956151|NCT02948686|Other|Self Etching with Extended layers number Strategy|In Group SETL, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
45956152|NCT00520390|Drug|EZN-2208|
45956153|NCT00520429|Behavioral|ACCES - Adjusting to Chronic Conditions with Education and Support|The primary objective of this research is to pilot test a brief mental heath treatment specifically tailored to meet the needs of chronically ill patients with anxiety and/or depression. Using an open-trial format, the proposed study will examine the feasibility of a brief psychosocial intervention. Primary outcomes will assess intervention effects on patient and clinician rated symptoms of anxiety and depression. If proven feasible and effective among this group of participants, the intervention (due to its brief format and focus on medically ill patient needs) will possess unique characteristics that will increase the ability of medical care settings to implement mental health treatments, and will provide valuable pilot data for the development of a larger research project to determine the efficacy of this intervention among a larger group of chronically ill patients relative to usual care.
45662067|NCT05248399|Behavioral|Control Group-standard of care|The standard of care control group will consist of the distribution of brochures containing COVID-19 prevention information.
45662068|NCT04239313|Biological|Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Population I are coxal muscle injection of low dose vaccine.
45816729|NCT05042700|Drug|Melatonin|Enema with 25 mg melatonin
45816730|NCT05042700|Drug|Placebo|Enema without melatonin
45454678|NCT01113619|Drug|RP-G28 or placebo|Daily dosing
45816731|NCT05042401|Drug|SHR-1703|SHR-1703 low dose
45816732|NCT05042401|Drug|placebo|placebo low dose
45816733|NCT05042401|Drug|SHR-1703|SHR-1703 high dose
45816734|NCT05042401|Drug|placebo|placebo high dose
45816735|NCT05039866|Biological|ST-920|No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
45816736|NCT05039450|Drug|EFX|Investigational drug, Efruxifermin
45816737|NCT05039450|Drug|Placebo|Placebo
45816738|NCT05028582|Drug|ARQ-154 Foam 0.3%|ARQ-154 Foam 0.3%
45816739|NCT05028582|Drug|ARQ-154 Vehicle|Vehicle
45816740|NCT05018208|Other|Computer-Assisted Intervention|Use smartphone app
45816741|NCT05018208|Procedure|Patient Monitoring|Wear Biofourmis wearable device(s)
45816742|NCT05018208|Other|Questionnaire Administration|Complete questionnaires
45816743|NCT05010954|Drug|LXI-15028 50mg group|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Lansoprazole 30mg matching placebo). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks
45662069|NCT04239313|Biological|Low-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Population I are coxal muscle injection of low dose adjuvant.
45662070|NCT04239313|Biological|Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo|The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I are coxal muscle injection of placebo.
45662071|NCT05212753|Device|Conventional physical therapy|Hot packs or hot water bags are superficial warming agents that will be used to heat muscle tissue, reduce muscle spasms and pain sensation. TENS is a pain reliever application.
45662072|NCT05212753|Other|Lumbar stabilization exercises|Training about the concepts of stabilization and abdominal bracing is given before starting the study. The motor control tests for local muscles transversus abdominus and multifidi are performed after the training. The abdominal bracing test is performed in the quadruped position, in prone, and in hook lying position with the patient's spine supine with hips and knees flexed and knees in contact with the surface. The second stage consists of closed-chain segmental control exercises. It is a series of weight-bearing exercises are performed on stable and unstable surfaces. The last stage of the stabilization program is an open kinetic chain exercise to promote distal stability.
45662073|NCT05212753|Other|Breathing exercises|Breathing exercises consist of the techniques of diaphragmatic and pursed-lip breathing. During diaphragmatic breathing, attention is focused on the correct abdominal breathing. The pursed-lip breathing is one step further to the diaphragmatic breathing and a technique designed to have control time and volume over-breathing. This intervention also includes Sleep Hygiene education to the subjects,
45662074|NCT05276167|Device|hyperthermic intravesical perfusion|Participants in the experimental group will be treated with hyperthermic intravesical perfusion before receiving radical cystectomy
45662075|NCT05274919|Device|Philips Achieva 7T MRI|Regular follow-up MRI on 3T scanner and optional additional scan at 7T MRI.
45662076|NCT05274919|Device|X-ray (optional)|Optional X-ray scan to assess the safety for undergoing an MR examination.
45662077|NCT05274919|Combination Product|Additional contrast injection|Contrast agent administration for the additional 7T scan (optional).
45662078|NCT05274919|Other|Question list|Questionnaire for contra-indications for an MR examination.
45662079|NCT05211973|Device|Wrist Actigraphy Device|a watch like wearable sensor
45816744|NCT05010954|Drug|Lansoprazole 30mg group|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Lansoprazole 30mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks.
45662080|NCT05211973|Device|Smart Body Weight Scale|a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
45816745|NCT05001724|Biological|KN046|KN046 is 5 milligram per kilogram, every 3 weeks.
45816746|NCT05001724|Drug|Lenvatinib|Lenvatinib is RP3D milligram per day, every day.
45816747|NCT05001724|Drug|Docetaxel|Docetaxel is 75 milligram per Square meter, every 3 weeks.
45816748|NCT05001022|Drug|ALG-020572|Single or multiple doses of ALG-020572
45816749|NCT05001022|Drug|Placebo|Single or multiple doses of Placebo
45816750|NCT04996368|Drug|Tranexamic acid injection|Randomized comparison of two doses of tranexamic acid as prophylactic before start of incision in open heart surgery use for prevention of bleeding.
45816751|NCT04994444|Drug|Nicoderm CQ 21Mg/24Hr Transdermal System|Nicoderm CQ patch started 3 weeks prior to quit date. Starting on quit date, patch/gum or patch/lozenge will be used for 8 weeks. Patch will be tapered over the 8 week period.
45816752|NCT04987892|Device|UroLift System|Prostatic lift
45816753|NCT04987892|Drug|Tamsulosin Hydrochloride|Tamsulosin HCl 0.4mg
45816754|NCT04986280|Diagnostic Test|[18F]PSMA-1007|PSMA PET/CT using the intervention.
45816755|NCT05432596|Drug|ATI-1777 2.0% w/w|ATI-1777 topical solution 2.0% w/w
45816756|NCT05432596|Drug|ATI-1777 1.0% w/w|ATI-1777 topical solution 1.0% w/w
45816757|NCT05432596|Drug|ATI-1777 0.5% w/w|ATI-1777 topical solution 0.5% w/w
45454679|NCT03527602|Procedure|Foraminal enlargement|After determining the working length, a rotary file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
45454680|NCT03528850|Other|Telemedicine evaluation|Weekly virtual visits and daily biometric readings of blood pressure, weight, oxygen saturation and pulse
45454681|NCT03940573|Device|Eclipse Insert|Rectal Control System.
45454682|NCT03527524|Other|exercise with ball|exercise with ball
45454683|NCT03527524|Other|exercise without ball|exercise without ball
45454684|NCT01211353|Behavioral|Personalized Drinking Feedback|Personalized feedback about one's drinking habits
45454685|NCT01211353|Behavioral|Education-Only|Educational information about alcohol use
45454686|NCT03528772|Drug|Minoxidil|application of minoxidil forte 5% gel three time per day on the anus for four weeks
45454687|NCT03528772|Drug|Glyceryl trinitrate|application of glyceryl trinitrate 0.2% cream three time per day on the anus for four weeks
45454688|NCT01211431|Drug|Reference|Intrathécale morphine is used for post-cesarean pain control
46002822|NCT04635501|Device|ABS 5.6.7|Patients whose access site will be closed with the ABS 5.6.7
45662081|NCT05211973|Device|Chair Scale|a wheel-chair compatible scale to measure body weight
45662082|NCT05211973|Device|Handheld Body Fat Percentage Device|a handheld device that measures body fat percentage
45662083|NCT05211973|Device|Bioelectric Impedance Analysis Scale|a research-grade full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
45662084|NCT05209867|Drug|CBD oil|"Each participant will be provided two 30mL(Milliliters) bottles (2000mg CBD per bottle) with a syringe dropper during their initial (baseline) visit with instructions to administer the solution under the tongue (0.5 cc ~1/2 dropper) twice per day (BID) 8-12 hours apart (morning and evening) at the prescribed daily dosage (63mg/day).~The investigators plan to collect samples from five patients over three time points: baseline (no CBD), and after one and two months of CBD-administration"
46078756|NCT04544852|Behavioral|Targeted intervention programme|The targeted intervention programme includes participants undergoing a structured educational program regarding colorectal cancer and the importance of screening in its prevention. The details will be explained to them using the pamphlet from MOH on Colorectal Cancer Screening. They will also be offered two FIT kits free of charge. Research team will educate participants on how to perform the FIT test. A detailed information guide on how to collect stool samples for FIT kit and how to return the completed FIT kit to the NUH Colorectal Centre will be given to them. Participants will be contacted at 3 months after enrollment to determine whether they have completed the FIT test.
45454689|NCT01211431|Drug|Experimental|A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control
45454690|NCT01117519|Drug|Infusion Therapy|Based on changes of stroke volume measured by transoesophageal doppler patients during elective hip surgery will achieve either a unbalanced infusion solution, maximum dose of 100 ml/kg BW, or a compound of balanced infusion solution including 50% crystalloid and 50% colloid, each: maximum dose of 50 ml/kg BW. The study medication will be administered only during surgery.
45662085|NCT05273983|Behavioral|Behavioural Activation|The intervention will span 6 weeks, including two intervention sessions with the primary care psychologist, and 6-weeks use of a mobile activity scheduling app (Strides). In the first intervention session, the psychologist would provide psychoeducation about depression, therapeutic rationale of behavioural activation, aid the patient in identifying their values and corresponding activities that may correspond with their values, introduce the mobile app, and help the patient schedule initial activities/goals. The second intervention session, which would be flexibly scheduled according to patient need, would focus on troubleshooting/clarification of previously discussed topics.
45662086|NCT05273827|Drug|neoadjuvant immunotherapy|Anti-PD-1 antibody was added to the conventional neoadjuvant chemotherapy.
45662087|NCT05273827|Drug|Neoadjuvant chemotherapy|Cis-platinum combined with paclitaxel or pemetrexed
45662088|NCT05273515|Other|Virtual Reality and 3D Reconstruction|Using virtual reality and 3D reconstruction to produce personalise images of what participants may look like after 15% and 25% total weight loss.
45662089|NCT05273437|Behavioral|System identification experiment for physical activity|The system identification experiment in Just Walk JITAI study has two key components that are the focus of the system identification experiment: daily adaptive step goal recommendations and within-day suggestions to either plan a bout of walking or to inspire reflection and, by extension, an increased urge to go for a walk.
45662090|NCT05245201|Other|Standard of care|Two control clinics will be selected based on a set of matching criteria, e.g., urbanity and the sex, race, and age distributions of the patient population. Control clinics will not participate in study activities.
45662091|NCT05245201|Other|Clinical decision support for PrEP|Healthcare providers at 2 intervention clinics (total of approximately 60 providers anticipated) will be prompted by an EHR-based tool to discuss PrEP with patients whose demographics and clinical history indicate increased predicted HIV risk. Providers will be offered clinical decision support tools to guide sexual health discussions and support PrEP prescribing.
45662092|NCT05481073|Device|UV sensor|Use of UV sensor to be informed about the sun exposure daily through a mobile application
45662093|NCT05209789|Behavioral|HUGS|Group therapy with the participation of two therapist positively encouraging mother-baby interactions in a non-judgmental manner
45816758|NCT05432596|Drug|Vehicle|Vehicle topical solution
45816759|NCT05019222|Drug|Sevoflurane based inhalation anesthesia|Sevoflurane group will be inducted with bolus of propofol 1% and maintained with sevofulrane as inhalation and TCI Minto model of remifentanil for general anesthesia.
45816760|NCT05019222|Drug|Remimazolam based total intravenous anesthesia|Remimazolam group will be inducted with remiamazolam at 6 mg/kg/h and maintained with remimazolam at 0.5-1.5 mg/kg/h and TCI Minto model of remifentanil for general anesthesia.
45816761|NCT04985318|Drug|Cablivi®|Intervention with Cablivi® take place outside of the study
45816762|NCT04968808|Procedure|Staged in-hospital complete revascularization|Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Staged in-hospital complete revascularization group will receive staged PCI for non-IRA in other day (during hospitalization) after PCI for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
46002823|NCT04684199|Dietary Supplement|Melatonin|Comparison between melatonin and placebo (2 weeks each) with active and placebo crossover during the study period of 34-36 days.
46002824|NCT04684199|Dietary Supplement|Placebo|
46078757|NCT04237922|Drug|Prasugrel 10mg|Prasugrel 10mg dispensing claim is used as the exposure group
46078758|NCT04237922|Drug|Clopidogrel 75mg|Clopidogrel 75 mg dispensing claim is used as the reference group
46078759|NCT04426058|Drug|CMP|Cluneal nerve Block 0.25% bupivacaine 20ml Pericapsular Nerve group block 0.25% Bupivacaine 20ml Lateral femoral cutaneous Block 0.25% bupivacaine 10ml
46078760|NCT04426058|Drug|Fascia Illica|Fascia iliaca block suprainguinal technique 0.25% bupivacaine 50ml
45662094|NCT05209789|Behavioral|Playtime|Very little intervention from the therapists
45662095|NCT05209711|Procedure|Femoral nerve block under ultrasound control with a electrostimulator peripheral nerves 7.5 ml 1% lidocaine|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (7.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
45956154|NCT04423874|Behavioral|Cold pressor task (CPT)|"The cold pressor test is among the most common and established methods for studying human reactions to pain and pain tolerance.~Participants submerge a hand in cold water (approx. 5°C) and are asked to keep their hand submerged for as long as can (until the sensation is intolerable), up to a maximum of 5 min.~The procedure is safe because the hand is removed before adverse effects can occur.~The participant will be given a break of 5 min in between trials, and will interchange hands between trials.~During this break hand may to be place in warm water (25-35°C) for up to 4 min to normalise hand temperature, which will be measured before and after each trial using a digital thermometer held firmly in the palm of the hand. Each participant will complete no more than three trials (conditions) in a randomised order."
45956155|NCT04423874|Diagnostic Test|index NOL|Measurement of the index NOL™: Four sensors, placed non-invasively on one of the four participants' fingers, will make it possible to calculate a dozen physiological parameters converts in real time into a pain index called NOL (for Nociception Level Index).
45816763|NCT04968808|Procedure|Immediate complete revascularization|Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Immediate complete revascularization group will receive simultaneous PCI for both IRA and non-IRA during index PCI. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
45816764|NCT04967118|Behavioral|Skin-to-skin contact|Diaper clad baby will be placed ventral position on bare chest of mother 30 minute prior to the heel lance
45956156|NCT04423874|Behavioral|Playback Experiments|During the experience, participants are led to listen, via headphones, to aversive non-verbal vocalizations (baby crying). The sound levels used to broadcast the non-verbal vocalisations will be scrupulously measured using approved and certified equipment during the preparation of the experiments. These sound volumes will be chosen so as not to inconvenience participants.
45956157|NCT04423874|Diagnostic Test|Video-pupillometry|This technique is based on the observation of the dilatation of the pupil during the perception of a nociceptive stimulus in test persons.
45956158|NCT00520507|Drug|Olanzapine|Olanzapine will be taken once daily at 6pm for 1 month. Dosing will be titrated up to 5mg and then changed as clinically indicated.
45956159|NCT00520507|Drug|Placebo|An inactive form of the treatment will be taken once daily at 6pm for 1 month.
45956160|NCT04694404|Drug|S-1,Oxaliplatin|Oxaliplatin 85 mg/m2 (D1, q2w) and S-1 (40mg BID for body surface area < 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area >1.5 m2; D1-10, q2w)
45956161|NCT04694365|Drug|Fluzoparib|A single oral dose of 50 mg Fluzoparib will be administered.
45816765|NCT04967118|Behavioral|Mother's heartbeats as sound and vibration|The mother's heartbeat will be recorded and the heartbeat sounds will be saved to the platform. The platform will be placed under the infant's mattress and the heartbeat will be started 30 minute prior to the heel lance.
45816766|NCT04967118|Drug|30% oral glucose|The infant will be given 30% oral glucose solution 2 minutes before the injection
45956162|NCT04406597|Device|the New Tissue Containment System|Laparoscopic Ovarian Cystectomy using the New Tissue Containment System
45956163|NCT00151983|Drug|Methylphenidate Transdermal System|To assess the efficacy of 4- and 6-hour wear times of SPD485 (MTS) compared to placebo
45956164|NCT00520585|Drug|atorvastatin|atorvastatin 20 mg once vs. atorvastatin 80 mg once vs. placebo
45816767|NCT04966702|Drug|Albendazole Pill|Using a MDA approach, fieldworkers will admister albendazole using directly observed treatment methodology to participants
45816768|NCT04966702|Drug|Ivermectin Pill|Using a MDA approach, fieldworkers will admister ivermectin using directly observed treatment methodology to participants
45816769|NCT04966702|Drug|Ivermectin Injectable Product|Veterinary ivermectin injectable will be given to livestock in the relevant cluster
45816770|NCT04966663|Drug|Nivolumab|Antineoplastic agent
45816771|NCT04966663|Drug|Pemetrexed|Antineoplastic agent
45956165|NCT04392674|Device|the new tissue containment system|using the new tissue containment system during Laparoscopic myomectomy morcellation
45816772|NCT04966663|Drug|Gemcitabine|Antineoplastic agent
45956166|NCT00520624|Device|inspiratory muscle strength training|
45816773|NCT04966663|Drug|Cisplatin|Antineoplastic agent
45956167|NCT00520624|Procedure|Surgery|
45956168|NCT00520663|Drug|14C-SB649868|SB-649868 will be provided as powder in a bottle which will be reconstituted into a solution prior to dosing via a hard gelatin capsule. Each subject will receive one unit dose of SB-649868 30 milligram reconstituted powder presented in a size 00 capsule once. The capsule will be swallowed with 160 milliliters of water.
45956169|NCT00152022|Drug|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.|
45816774|NCT04966663|Drug|Carboplatin|Antineoplastic agent
45816775|NCT04966663|Procedure|ctDNA blood test|Blood will be collected for ctDNA testing
45816776|NCT04960917|Behavioral|Evaluation of ehealth literacy workshop|Intervention components will include a three session workshop, enabling participants to raise their knowledge of the different available health resources and how to find them, their ability to determine which health resource is reliable, their ability to use the health information online to make health decisions, their knowledge of the online services offered by HMOs/Ministry of Health, and their ability to navigate HMO and preform actions such as set an appointment, find a doctor, and find contact information
45956170|NCT03459001|Other|Tube Feeding Product|a high calorie, high protein tube feed product consumed sole source per their physician's recommendation and per standard of care
45956171|NCT00520702|Procedure|Intensity Modulated Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
45956172|NCT00520702|Procedure|3-Dimensional Conformal Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
45956173|NCT00520780|Drug|Ferinject ® (Ferric carboxymaltose)|"Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase)."
45956174|NCT00520780|Drug|Normal saline (0.9%)|During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
45956175|NCT04723797|Other|Physical activity|Physical activity program consisting of running and/or cycling
45956176|NCT04380077|Procedure|vitrectomy with sulfur hexafluoride gas|vitreous substitution with 20-30% sulfur hexafluoride gas during vitrectomy
45956177|NCT04380077|Procedure|vitrectomy with balanced salt solution|vitreous substitution with balances salt solution during vitrectomy
45956178|NCT00520819|Drug|Antioxidant-rich food items|
45816777|NCT04957875|Device|emergency endoscopic therapy|When cirrhotic patients presented with AVB to the emergency department, emergency physicians consulted gastroenterologists on duty to assess the patient for suitability for endoscopy, usually after initial stabilization. Performance of endoscopy and its timing was at the discretion of the gastroenterologist on call. Therapeutic endoscopy for AVB was performed within 24 hours after consultation by an experienced attending endoscopist, using standard forward-viewing upper gastrointestinal video endoscopes at individual centers. Written informed consent for endoscopy was obtained before each procedure. The standard of care at all hospitals was to administer a vasoactive agent and antibiotics upon the patient's presentation. Packed red blood cells were transfused at the discretion of the attending gastroenterologist.
45956179|NCT00520858|Other|Resistance Exercise (RE)|
45956180|NCT00520858|Other|Aerobic Exercise (AE)|
45662096|NCT05209711|Procedure|Femoral nerve blockade under ultrasound control without a peripheral nerve stimulator 7.5 ml 1% lidocaine|"Under ultrasound visualization guidance, the needle owas positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (7.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
45956181|NCT00520858|Other|Resistance and Aerobic Exercise (RAE)|
45956182|NCT00152061|Drug|3TC and FTC|
45956183|NCT00520897|Drug|Raltegravir (MK0518)|400mg BID; 48 weeks
45956184|NCT00520897|Drug|Placebo|400mg QD
45956185|NCT00520897|Procedure|Leukopheresis|pack of cells as per protocol
45956186|NCT00520897|Procedure|Sigmoid Biopsy|gut samples as per protocol
45956187|NCT00521092|Drug|sunitinib malate|Given orally
45956188|NCT00521092|Procedure|laboratory biomarker analysis|Correlative study
45956189|NCT00521092|Procedure|pharmacological study|Correlative study
45956190|NCT04376606|Procedure|Left atrial appendage closure|Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
45956191|NCT04376606|Procedure|Radiofrequency ablation|Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
46078761|NCT02737020|Drug|Rhodiola|Rhodiola rosea 200mg pill up to four times a day
45662097|NCT05243563|Device|MonaLisa Touch|3 laser treatments at 6 week intervals for 6 months by a single trained operator
45662098|NCT05243563|Drug|Topical steroid|self-applied topical steroid therapy using clobetasol propionate 0.05%
45956192|NCT04376606|Procedure|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
45956193|NCT00521131|Drug|Levocetirizine dihydrochloride|
45956194|NCT04694092|Drug|Intensive heart rate control with landiolol|Intensive heart rate control preferably with the use of short-acting betablocker landiolol in combination with digoxin
45956195|NCT04694092|Drug|Standard approach to heart rate control|Standard heart rate control with intravenous or oral beta-blockers and/or antiarrhythmic in combination with digoxin
45956196|NCT00521170|Drug|Levocetirizine|
45956197|NCT04376489|Behavioral|Messages (participants experiencing negative affect & cigarettes are available)|Participants receive messages tailored for situations when they experiencing negative affect & cigarettes are available.
45956198|NCT04376489|Behavioral|Messages (participants not experiencing negative affect & cigarettes are available)|Participants receive messages tailored for situations when they cigarettes are available.
45956199|NCT04376489|Behavioral|Messages (participants experiencing negative affect & cigarettes are not available)|Participants receive messages tailored for situations when they experiencing negative affect.
45956200|NCT04376489|Behavioral|Messages (participants not experiencing negative affect & cigarettes are not available)|Generic messages for situations when participants are neither experiencing negative affect nor cigarettes are available.
45956201|NCT04376489|Behavioral|Moodsurf|"Smart phone app that teaches participants a mindfulness-based technique in which participant surf the mood."
45956202|NCT04376489|Behavioral|Meditate|Smart phone app that teaches participants a mindfulness-based meditation designed for smoking cessation.
45956203|NCT04376489|Behavioral|Joy|Smart phone app that teaches participants to practice breathing exercise.
45956204|NCT04376489|Behavioral|Imagine|Smart phone app that teaches participants to use their imagination to explore and manage their thoughts and feelings.
45956205|NCT04376489|Behavioral|Notice|Smart phone app that teaches participants to accept their thoughts and feelings.
45956206|NCT04424147|Combination Product|HVA Regimens as Salvage Treatment|venetoclax with a dose of 400mg per day for 14 days, combined with azacitidine (AZA) with a dose of 75mg/m2 per day for 7 days, and HHT 1mg/m2 per day for 7 days
45956207|NCT00521248|Drug|buprenorphine|sublingual buprenorphine administered every 8 hours, titrated to control of abstinence symptoms
45956208|NCT00521248|Drug|Oral morphine solution|0.4 mg/kg/day morphine every 4 hours
45956209|NCT00167115|Drug|Alcohol|
46078762|NCT02737020|Drug|Placebo|up to four times a day
46078763|NCT05629104|Other|There is no intervention since it is an observational study patients are treated according to clinical praxis|No intervention
45956210|NCT00521287|Other|Immune profiling and DC vaccine|"For observational study (immune profiling): blood sampling 3-5 mL~For DC vaccine: one dose of DC vaccine(~10 million cells)/2 week for at least 6 month or until progression."
45956211|NCT04370990|Device|O2matic|O2matic is a closed-loop-system that controls oxygenadministration according to SpO2. The aim is to maintain SpO2 within a predefined target interval, E.G. 88-92% with the lowest possible supplementation of oxygen by nasal cannula
45956212|NCT02948491|Other|Music therapy|Song that the mother sings to the child before birth, recording of the mother's voice.
45956213|NCT00521443|Procedure|Cryopreservation, thawing and blastocyst culture|Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
45956214|NCT00167154|Drug|Risperidone and placebo comparator|Up to 2 mg risperidone or matching placebo daily
45956215|NCT04320563|Procedure|Rexon-eye|This treatment involved the technology known as quantum molecular resonance (QMR) which has emerged as a new treatment for all types of dry eyes.
45956216|NCT00521482|Drug|Temozolomide|
45956217|NCT00521482|Drug|Temozolomide plus Thalidomide|
45956218|NCT00521521|Drug|docetaxel and cisplatin|
45956219|NCT00521521|Drug|docetaxel|
45662099|NCT05272969|Diagnostic Test|Beck depression inventory fast screen (Questionnaire)|Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
45956220|NCT00521560|Drug|Zevalin|"All applications of 90Y-Ibritumomab-Tiuxetan will be preceded by rituximab infusions at a dose of 250 mg/m2 at days -21 and day -14 (DL1) or day -12 (DL2) or day -10 (DL3-5), respectively.~High dose therapy will be given as BEAM"
45662100|NCT05272969|Diagnostic Test|Brief Pain Inventory (BPI) (Questionnaire)|Validated questionnaire for pain.
45662101|NCT05272969|Diagnostic Test|German Pain Inventory (Questionnaire)|German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
45956221|NCT00152100|Procedure|Stem cell transplant|
45956222|NCT00152100|Drug|Filgrastim, Alemtuzumab|
45956223|NCT00152100|Device|Miltenyi CliniMACS|
45956224|NCT04694209|Procedure|maxillary and mandibular telescopic retained overdentures supported by 4 implants|The wax of the trial denture was converted into heat-cured acrylic resin using conventional packing and flasking techniques. The prosthesis was finished, polished and screwed in the patient's mouth. Engaging (Internal hex) cylindrical, plastic patterns (Octa plastic cylinder, multi unit abutment, Red, Dentis, Daegu -Korea) were used to construct the primary copings of the telescopic prosthesis.The finished primary copings were scanned using a lab scanner (Shera Echo-scan 7. Dental Wings, Montreal-Canada). This was necessary to design and to mill the wax pattern of the secondary copings using CAD/CAM technology (Dental Wings Software, Dental Wings, Montreal -Canada). Secondary coping was designed to properly fit to the primary coping. The framework was then tried in. At that time it was ready for its intra-oral luting to the secondary copings.
45956225|NCT04694209|Procedure|maxillary and mandibular screw retained hybrid prostheses supported by 4 implants|Framework of the hybrid prosthesis is waxed using plastic copings attached to multiunit abutments. once the framework is finished , bite is recorded, teeth are set up and the waxed up prosthesis are tried in. IF accepted the wax is eliminated the wax up denture is converted inti heat cured acrylic resin
45956226|NCT00521638|Biological|TRU-015|Intravenous administration; 400 mg, 700 mg, or 1000 mg; 1x/week dosing for 4 weeks
45956227|NCT00521677|Procedure|Sage oral care|Oral care include teeth brush and oral cavity cleaning with a non alcoholic solution, TID
45956228|NCT00521677|Procedure|Traditional oral care|Cleaning of oral cavity with menthol solution, TID
45956229|NCT00521716|Device|Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
45662102|NCT05272969|Diagnostic Test|Fatigue Severity and Disability Scale (FSS) (Questionnaire)|Validated questionnaire for perceived fatigue
45662103|NCT05272969|Diagnostic Test|Rotterdam Handicap Scale (RHS) (Questionnaire)|validated questionnaire to assess a patient's functional ability and level of handicap
45662104|NCT05272969|Diagnostic Test|R-PAct (Questionnaire)|The R-PAct scale is designed specifically for Pompe disease, which consists of 18 items addressing daily life activities with three response options.
45956230|NCT00521716|Device|WaisFix100i for Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
45956231|NCT00521755|Device|Seraffix LTB|laser soldering for soft tissue wounds
45956232|NCT00521833|Procedure|phacoemulsification and intraocular lens implantation|clear cornea phacoemulsification and intraocular lens implantation using temporal or nasal incisions respectively
45816778|NCT04927988|Other|Ringer's Lactated|Using of Ringer's Lactated In Autologous Blood Cell Transfusion
45816779|NCT04927364|Device|Deep Transcranial Magnetic Stimulation (dTMS) H7 coil|The study will utilize the H7 coil to administer Deep Transcranial Magnetic Stimulation (dTMS) to the dorsal anterior cingulate cortex (dACC), a core salience network node.
45816780|NCT04922593|Drug|LY03010; paliperidone palmitate|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
45816781|NCT04922593|Drug|INVEGA SUSTENNA|INVEGA SUSTENNA (234 mg, 156 mg) is manufactured by Janssen Pharmaceuticals, Inc and is commercially available.
45956233|NCT00521872|Procedure|STARR Operation|
45956234|NCT00521911|Behavioral|Cognitive Behavioural Therapy|
45662105|NCT05272969|Diagnostic Test|Quick Motor Function Test|An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
46078764|NCT02736630|Other|body temperature|intermittant tympanic temperature measurement during surgery
45956235|NCT04273412|Behavioral|moderate-intensity lifestyle intervention|standardized 12- week program and would be delivered in 4 sessions (2 individual, 2 telephonic). This lifestyle modification program is a combination of diet therapy (optimum calorie), increased daily physical activity and behavioral modification (self-monitoring, stimulus control, motivational interviewing)
45956236|NCT00522067|Biological|Adjuvanted influenza vaccine|Vaccination with MF 59 adjuvanted trivalent seasonal influenza vaccine
46078765|NCT04239014|Drug|Olaparib|Olaparib 300 mg BD (2 × 150 mg tablets) continually in the olaparib monotherapy and ceralasertib+olaparib treatment arms.
46078766|NCT04239014|Drug|Ceralasertib|Ceralasertib 160 mg QD (2 × 80 mg tablets) from Days 1 to 7 (inclusive) of every 28-day cycle.
46078767|NCT04239014|Drug|Placebo to match olaparib|Per olaparib
45662106|NCT05272969|Diagnostic Test|Handheld Dynamometry (HHD)|To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
45662107|NCT05272969|Diagnostic Test|Six-minute walk test (6MWT)|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. If a six-minute-walk-test was performed within the last 3 months within the routine treatment, no additional test will be performed and the distance walked in meters as well as borg scale will be recorded in the study CRF, including the date of the assessment. If not performed within the last six months, a six-minute-walk test will be performed once.
45662108|NCT05272969|Diagnostic Test|Pressure pain threshold|"For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of burning, stinging, drilling or aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles."
45816782|NCT04914312|Dietary Supplement|Maqui berry/omeg-3 fatty acids|2 capsules BID per day containing a total of 600 mg of Maqui extract; 4 capsules per day supplying a total of 2000 mg EPA and 1000 mg DHA
45816783|NCT04914312|Dietary Supplement|Placebos|4 olive oil soft gelatin capsules and inert two-piece capsules containing maltodextrin
45816784|NCT04914000|Behavioral|Self-help Materials|Self-help booklet targeted by cancer type to increase smoking cessation motivation
45956237|NCT00522106|Behavioral|Behavioral graded activity|The intervention is directed at increasing the level of activities in a time-contingent way, with the goal to integrate these activities in the daily living of the patients. The intervention is performed by physical therapists in primary care, on individual basis. Treatment period of maximal 12 weeks (with maximal 18 sessions), followed by 5 pre-set boostermoments with a maximum of 7 sessions (respectively in week 18, 25, 34, 42, and 55).
45956238|NCT00522106|Other|Exercise therapy|Treatment according to the Dutch physiotherapy guideline for patients with osteoarthritis of hip and/or knee. This guideline consists of general recommendations, emphasizing provision of information and advice, exercise therapy, and encouragement of a positive coping with the complaints. The treatment consisted of a maximum of 18 sessions within a period of 12 weeks. The treatment could be discontinued within the 12 week period if, according to the physiotherapists, all treatment goals were achieved.
45956239|NCT00522184|Procedure|intra-articular injection of etanercept|
45956240|NCT00522184|Procedure|intra-articular injection of steroid|
45956241|NCT04241978|Other|Patient Decision Aid (PtDA)|Patient Decision Aid (PtDA) are tools that enables to promote and facilitate patients' involvement in medical decisions concerning their health
46078768|NCT00568321|Drug|RN624|50 mcg/kg
46078769|NCT00568321|Drug|RN624|200 mcg/kg
46078770|NCT00568321|Drug|Placebo|placebo
46078771|NCT02742480|Drug|Dabigatran|
46078772|NCT02742480|Drug|Acenocoumarol|
46078773|NCT02816060|Procedure|manual therapy|manual therapy with neural exercise will be applied on patients with neck pain
46078774|NCT00774345|Drug|Lenalidomide|Lenalidomide capsules given orally on days 1-28 of a 28 day cycle
46078775|NCT00774345|Drug|Placebo|Placebo capsules given orally on days 1 - 28 of a 28 day cycle
46078776|NCT02742402|Other|Diagnostic imaging|Abdominal ultrasound, followed by abdominal computed tomography when necessary
46078777|NCT02742402|Other|Observation|Observation for 6 to 8 hours. After observation period repeated clinical examination and repeated blood test for calculation of Adult Appendicitis Score is done.
45662109|NCT05272969|Diagnostic Test|Muscle ultrasound|Muscle ultrasound is an ideal imaging modality that allows for atraumatic, noninvasive, radiation-free point-of-care neuromuscular imaging. Muscular diseases are typically associated with an increase in the echogenicity from the muscle substance, distal attenuation of muscle echo and a corresponding loss of bone echo. A measurement on both sides deltoid, biceps and triceps brachii muscle, quadriceps femoris muscle, tibialis anterior muscle, rectus abdominis muscle and paravertebral muscles of cervical (C5-7), thoracic (Th4-6) and lumbar (L4-5) muscles. Muscle tissue alterations will be classified using the Heckmatt scale I-IV, describing muscle echogenicity. For muscle ultrasound, a linear 17MHz probe will be used. The muscle ultrasound assessment usually takes 15-20 minutes.
45956242|NCT04241978|Other|Brochure with general information about osteoarthritis|Participants of the control group will be given a brochure with general information about osteoarthritis of the hip, knee, ankle and foot instead of the PtDA
45956243|NCT00522223|Behavioral|Questionnaire|"Participants who are treated with radiation therapy: Questionnaires 5 times.~Participants who undergo a radical hysterectomy: Questionnaires 4 times."
45956244|NCT00522262|Behavioral|Aerobic exercise intervention|Women in the exercise arm underwent a year-long exercise intervention of five days per week of 45 minutes/session of moderate-vigorous intensity aerobic exercise.
45816785|NCT04902950|Drug|Tranexamic acid|"After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The Tranexamic acid soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient."
45956245|NCT00522340|Behavioral|Aerobic Exercise Program|Home walking 1 hour a day for 5 days/week for 8 weeks. Then 30 minutes a day on all or most days of the week.
45956246|NCT03458923|Drug|Diclofenac Sodium 0.1 ml containing 500µg|15 eyes will receive intravitreal 0.1 ml containing 500µg of Diclofenac Sodium monthly for three months
45956247|NCT03458923|Drug|Ranibizumab 0.5 mg Solution for Injection|15 eyes will receive intravitreal 0.5 mg of Ranibizumab monthly for three months
45662110|NCT05272969|Diagnostic Test|Vital signs|Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
45956248|NCT00522535|Procedure|Open surgical repair|Open surgical repair of abdominal aortic aneurysm
45956249|NCT00522535|Device|Stent Graft|Endovascular repair of abdominal aortic aneurysm (EVAR)
45956250|NCT04186013|Drug|Atezolizumab Injection [Tecentriq]|intravenous infusion of 1.200 mg of Atezolizumab administered intravenously every 3 weeks for a total of 6 doses
45956251|NCT04186013|Radiation|External Beam Radiation Therapy (EBRT)|60 Gy of radiotherapy in 30 fractions overs 6 weeks at 2 Gy/day
45956252|NCT00152139|Procedure|Allogeneic Stem Cell Transplantation|An infusion of HLA matched unrelated bone marrow or peripheral blood stem cells.
46078778|NCT02816372|Other|Tidal volume reduction to 4 ml/kg Predicted Body Weight (PBW)|Tidal volume reduction to 4 ml/kg predicted body weight from inclusion to weaning PEEP trial
46078779|NCT02819102|Drug|BCX7353 and probes|
46078780|NCT04342026|Other|Measure of the exposure of parent of male with /without cryptorchidism to endocrine disruptors|Measure of the exposure of parent of patient with/without cryptorchidism to endocrine disruptors (job exposure, during pregnancy)
45956253|NCT00152139|Drug|Chemotherapy and antibodies|Participants received a standard conditioning regimen consisting of total body irradiation, cyclophosphamide, thiotepa and ATG. GVHD prophylaxis consisted of cyclosporine and Methotrexate.
45956254|NCT00522574|Drug|XL019|gelatin capsules supplied in 5-mg, 25-mg, and 100-mg strengths
45956255|NCT00522613|Behavioral|Recovery Group Project|Recovery Group Workbook & Group Sessions
45956256|NCT00522652|Drug|PX-478|Oral formulation, dose escalation, taken on days 1 to 5 of a 21 day cycle until progression or development of unacceptable toxicity
45956257|NCT04725162|Radiation|18F-FDG|All subjects received 18F-FDG PET examination.
45956258|NCT00522691|Procedure|sacral nerve stimulation|sacral nerve stimulation for fecal incontinence
45956259|NCT00405431|Drug|Restasis|1 drop in study eye twice a day X 6 months
45956260|NCT00405431|Drug|Endura (artificial tears)|1 drop in study eye twice a day X 6 months
45956261|NCT00522730|Other|Parenteral nutrition|Duration : 5 days
45956262|NCT00522730|Other|Enteral nutrition|Duration : 5 days
45956263|NCT00167232|Drug|Naltrexone|
45956264|NCT00522769|Behavioral|Cognitive Behavioral Therapy|Girls enrolled in the study will either receive the 6-20 session CBT intervention at the time of enrollment or 6 months after they enroll. Assessments including questions about eating behaviors, mood, and general functioning are given on enrollment in the study, and 3- and 6-months following enrollment (also at 9- and 12-months for those in the delayed treatment condition
45956265|NCT00522808|Drug|A-831|
45662111|NCT05272969|Diagnostic Test|Borg Scale|The Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
45956266|NCT00522886|Drug|Cetuximab|"Eligible patients will be given 2 cycles(of 21 days) of carboplatin (AUC 5) day 1 and gemcitabine (1250 mg/m2) days 1,8. Patients without progressive disease will be entered in the phase I dose-escalation part of the study. Chest radiation will be given concurrently with cetuximab, cisplatin and vinorelbine, which will be escalated in 3 steps until dose-limiting toxicity occurs.~14 days after the last gemcitabine (=day 43), radiotherapy is started : First 3 weeks: 1.5 Gy BID to a dose of 45 Gy in 30 fractions, then 2 Gy QD to a mean lung dose of 19 Gy. Cetuximab: 400 mg/m2 7 days before radiotherapy (= day 36) and during the course of radiotherapy a weekly dose 250 mg/m2. Cetuximab will be delivered at the same days as chemotherapy.~Cisplatin(all steps): 50 mg/m2 days 43, 50; 40 mg/m2 day 64.~Vinorelbine:~Step 1: 10 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 2: 20 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 3: 20 mg/ m2 days 43, 50; 15 mg/m2 days 66 and 73."
45816786|NCT04902950|Drug|Saline|"After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The saline soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient."
45956267|NCT00167271|Behavioral|Cognitive Behavior Therapy|Experimental: Computerized cognitive, behavioral therapy with Body Media armband to collect data about activity, which subjects could review each evening.
45956268|NCT00522964|Behavioral|behavioral intervention|The intervention is based on Social Cognitive Theory and principles of Chinese culture and practices. The intervention program includes a one-hour small-group session for eight weeks for children and two 2-hour small-group sessions for parents.
45956269|NCT04083560|Drug|Vit B12|Vitamin B12 250mcg
45956270|NCT00511966|Other|Non-Pharmacologic Treatment|Non-Pharmacologic Treatment
45816787|NCT04889118|Biological|Pembrolizumab|IV infusion
45816788|NCT04889118|Drug|Lenvatinib|Oral capsule
45816789|NCT04889118|Drug|Placebo for lenvatinib|Oral capsule
45816790|NCT04844125|Drug|SHR-1209|SHR-1209
45956271|NCT00511966|Drug|Rabeprazole|As prescribed
45956272|NCT00152178|Drug|UFT (uracil, tegafur) and tamoxifen|UFT(uracil, tegafur:270 mg/m2/day (p.o.) for 2 years) and tamoxifen:20 mg/body/day(p.o.) for 2 years.
45956273|NCT00152178|Drug|CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen|CMF 6 cycles(q28 days X 6 cycles of cyclophosphamide:65mg/m2/day(p.o.)day 1-14, methotrexate:40mg/m2(i.v.)day 1,8 and fluorouracil:500mg/m2(i.v.)day 1,8) and tamoxifen:20mg /body/day(p.o.) for 2 years.
45956274|NCT02948140|Procedure|MRI|
45956275|NCT02948140|Procedure|Abdominal scanner|
45816791|NCT04844125|Drug|SHR-1209 Placebo|SHR-1209 Placebo
45816792|NCT04839497|Combination Product|Autologous Volar Fibroblast Injection into the Terminal Limb of Amputees|Autologous Volar Fibroblasts Treatment- harvested from patient's biopsied volar skin. Intradermal injection of Volar fibroblasts in the residual limb of transtibial amputees.
45458157|NCT04577911|Other|Basic Science Experiment|participants complete cognitive tasks while undergoing functional magnetic resonance imaging (fMRI)
45662112|NCT05272969|Diagnostic Test|Laboratory assessment: Creatine kinase|CK-Level assessment in peripheral blood (peripheral venous blood draw)
45662113|NCT05272969|Diagnostic Test|Laboratory assessment: Vitamin D Level|Vitamin D Level in peripheral blood (peripheral venous blood draw)
45662114|NCT05272969|Diagnostic Test|Laboratory assessment: calcium|calcium level in peripheral blood (peripheral venous blood draw)
45816793|NCT04838301|Drug|Allopregnanolone|Allopregnanolone 4mg IV via 30-minute infusion, once per week.
45816794|NCT04838301|Other|Placebo|Normal saline solution IV via 30-minute infusion, once per week
45956276|NCT02948179|Procedure|Preimplantation Genetic Diagnosis|Using Preimplantation genetic diagnosis, including multiple annealing and looping-based amplification cycles amplification technique, the investigators have had screened out healthy embryos by In Vitro Fertilization. Then the investigators transplanted embryos returned to the parent. Finally, participants will have healthy baby without pathogenic gene inheritance.
45956277|NCT00523081|Behavioral|Cognitive Behavioral Therapy (CBT)|Half the teens in the study will also meet with a research counselor for five to nine individual, weekly sessions that last about 50 minutes each. Whether a teen attends the weekly counseling sessions is decided by chance, like flipping a coin. If teens are assigned to these sessions, they will learn ways to deal with stress and feel better. If teens take part in the counseling sessions, the study counselor will also talk to the teen's doctor from time to time to help plan for the best possible care.
45956278|NCT00523081|Behavioral|Active control|Teens in the active control arm will keep seeing their doctor as usual. Teens and a parent are interviewed briefly over the phone to see if they are appropriate for the study. If they qualify for the study, there is an hour-long interview with teen over the telephone and a 30 minute interview with the parent. They will be interviewed six more times in the next two years.
45956279|NCT04043507|Other|Sample Collection|Blood and urine samples will be collected for research purposes along with the routinely collected blood and urine samples that are collected as part of the standard of care.
46078781|NCT02815358|Other|Segmental Stabilization Exercises|The stabilization program focuses on the reestablishment of motor control and coordination between deep and superficial trunk muscles. The exercise program is based on the following criteria progression: 1) Precise contraction of the transverse abdominal and multifidus muscles, keeping the lumbar spine in a neutral position (as the middle way between maximum flexion and extension, repeated three times); 2) Keep the neutral position for 10 repetitions of 10 seconds; 3) Perform exercises with lower limbs in different postures.
45662115|NCT05272969|Diagnostic Test|Laboratory assessment: magnesium|magnesium level in peripheral blood (peripheral venous blood draw)
45662116|NCT05272969|Diagnostic Test|Laboratory assessment: phosphate|phosphate level in peripheral blood (peripheral venous blood draw)
45956280|NCT00523120|Drug|diclofenac sodium|topical solution used in ear 5 drops 8 3/day
46078782|NCT02815358|Other|Home Exercises|Home exercises include passive stretching and active mobilization of the spine.
46078783|NCT02736708|Device|probe based confocal laser endomicroscopy|real-time, microscopic imaging of tissue at the cellular level via a small diameter probe.
46078784|NCT02815436|Other|Telephone reminder|a personal, interactive telephone reminder by a centre colleague to remind return to the centre for taking faecal tubes for screening
45662117|NCT05272969|Genetic|Genetic test: ACE polymorphism|peripheral venous blood draw for genetic analysis of ACE polymorphism
45454691|NCT03527446|Behavioral|Sprint Interval Training|The 4-week sprint interval intervention will consist of a work-rest ratio of four 30-s intervals of exercise at maximal capacity and 4-min of passive recovery at 50% of maximal capacity between intervals. There will be three sessions per week.
45662118|NCT05272969|Genetic|Genetic test: ACTN3 polymorphism|peripheral venous blood draw for genetic analysis of ACTN3 polymorphism
45662119|NCT05272969|Genetic|Blood draw for optional genetic exome sequencing|"Optionally, upon additional informed consent, exome sequencing from peripheral blood will be performed in a second step to assess whether polymorphisms or pathogenic mutations in genes that are associated with chronic pain syndromes contribute to increased pain. This analysis will be performed collectively after enrollment is complete by the Genetikum Neu-Ulm. The selection of the genes is based on the Human Phenotype Ontology (HPO) search terms myalgia, muscle pain, chronic pain, musculoskeletal pain, pain, and nociceptive pain."
45662120|NCT05272033|Device|Transcutaneous Electrical Acupoint Stimulation|Transcutaneous Electrical Acupoint Stimulation
45662121|NCT05243173|Other|Sequencing|Laboratory analysis of samples
45662122|NCT05270395|Behavioral|mPal|"mPal's patient content includes a multi-component web-based tool with the following: (1) a brief educational video that seeks to educate patients about palliative care; (2) and assessment of palliative care knowledge; (3) assessment of palliative care needs; and (4) an assessment of whether patients would like to meet with palliative care or discuss palliative care and their palliative care needs with their oncology provider.~The provider-level component includes provider education on palliative care. The system-level component includes electronic health record modifications to facilitate palliative care discussions and referrals."
45662123|NCT05208619|Procedure|Regional anaesthesia|Patients receive either a thoracic epidural analgesia or paravertebral block as an regional anaesthetic adjunct to general anaesthesia for thoracic surgery
45676817|NCT01848483|Behavioral|AIDS EPC Package plus MI|"Motivational Interviewing: In MI session #1, the nurse will set the agenda & ask the participant to discuss any adjustments to the AIDS diagnosis. In sessions #2 - 4, the participant will be asked to set the agenda related to current concerns. In sessions #3 & 4, the nurse will also introduce advance care planning.~EPC Package: Participants will be seen by palliative care providers, for approximately 30 minutes each, in the following order: 1) Chaplain: introduces the concept of EPC clinic & conducts a spiritual evaluation/intervention as needed. 2) Social worker: conducts an evaluation/intervention as needed. 3) Psychologist: conducts an evaluation/intervention as needed. 4) Palliative Care Physician: conducts symptom management, medication reconciliation & coordination of care."
45816795|NCT04831138|Procedure|MRI with ASL|"T0 (Week 0): MRI with ASL will be performed either for research alone or along with patient's standard of care imaging session including contrast-enhancement.~T1 (Day 7+-2): contrast-enhanced research MRI with ASL T2 (Day 14+-2): contrast-enhanced research MRI with ASL T3: MRI with ASL will be performed along with patient's standard of care imaging session.~T4: MRI with ASL will be performed along with patient's standard of care imaging session.~T5: MRI with ASL will be performed along with patient's standard of care imaging session."
45816796|NCT04820296|Other|Solution-Oriented Approach|First Session: Sharing thoughts about perception of childbirth, Creating positive goals, Informing about Birth, Birth Process, Basic Breathing Exercises and Deep Relaxation Exercises, Homework Second Session: Evaluating homework, Sharing thoughts about fear of childbirth, Miracle Question Technique, Evaluating with the Rating Questions Technique, Reframing the problem, Briefing on 'Body-Mind Connection at Birth, Fear-Tension-Pain Cycle, Hormones of Birth' and Breathing exercises, Homework Third session: Evaluating homework, Sharing thoughts about positive birth story, Information on symptoms indicating that the childbirth is approaching, pushing techniques, delivery positions, endorphin massage and breathing exercises (4/8 breaths, full breath when baby moves), Homework Fourth Session: Evaluating homework, Mother Baby Friendly Caesarean and Breathing exercises (3 candles a feather breath), Sharing feelings about the counseling process
45816797|NCT04819971|Drug|Tirelizumab|tislelizumab (intravenously, 200 mg on day 1 of every cycle for 4 preoperative and 12 postoperative cycles)
45816798|NCT04819971|Drug|Trastuzumab|Trastuzumab(intravenously, 8 mg/kg loading dose, then 6 mg/kg on days 1 of every cycle for 4 preoperative and 12 postoperative cycles)
46078785|NCT02815436|Other|SMS reminder|a one-way, SMS message sent from the centre to the screening participant's mobile phone
45458158|NCT01140997|Drug|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
45458159|NCT01140997|Drug|Peginterferon alfa-2a|sc, qw, for 48 weeks.
45956281|NCT00523120|Drug|dexotc|aural drops
45956282|NCT04694053|Procedure|surgical debridement|The surgical team performed an extended surgical debridement to healthy tissue of external genital, as well as perineal, perianal, and infrapubic regions.
46078786|NCT02736552|Drug|S-1 for 6 months|6 months S-1 after D2 resection
45956283|NCT04725279|Procedure|Rehabilitation Treatment: Physiotherapy, Electrotherapy or Exercises at home|The 67 patients attended the rehabilitation consultation where, after taking the anamnesis, they began to perform balance tests with a stabilometric platform and those patients with associated neck pain, with cervical motion sensors. Treatment with conventional physiotherapy, electrotherapy or exercises at home was prescribed as appropriate to each one. 3 months later, the patients were examined again in consultation, using a new anamnesis, the platform and the sensors.
45956284|NCT00523159|Drug|Endoxana, IMA901, Leukine|a single i.v. infusion of Cyclophosphamid and then patients received vaccination therapy with intradermal (i.d.) injections of GM-CSF followed by i.d. injections of IMA901
46078787|NCT02736552|Drug|S-1 for 1 year|1 year S-1 after D2 resection
46078788|NCT02819180|Biological|Butantan Influenza Trivalent, Fragmented and Inactivated vaccine|
46078789|NCT02740842|Behavioral|Interpersonal behavioral change communication|This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
46078790|NCT02740842|Behavioral|Mass media|A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
46078791|NCT02736396|Other|fMRI|Functional MRI scan to be performed
45454692|NCT03938077|Device|Storytelling 4 Empowerment|S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol & drug use, HIV & STIs, and tobacco prevention and cessation.
45454693|NCT03938233|Behavioral|A low-cost DSME program and scalable delivery model for roll-out within the Thai primary care system|The intervention will be based on behaviour-change and social support theories, delivered in monthly group meetings by lay health workers or nurses, and aided by a suite of short films to introduce key topics and stimulate discussion.
45454694|NCT05572294|Behavioral|Mindfulness meditation, breathing exercises (including incentive spirometry), and yoga therapy|Sickle cell patients admitted with a vaso-occlusive pain crisis over a consecutive 12-week period will be offered participation in the study. After providing informed consent, participants will have access to 4 videos containing guided mindfulness meditation, breathing exercises, and gentle yoga therapy. The videos are 5-12 minutes long and taught by a physical therapist who is also certified in yoga therapy. Participants may turn off the video at any time. Participants will have access to the videos for the duration of their hospitalization, and they may watch the videos as many times as they desire.
45454695|NCT01316744|Drug|ketamine hydrochloride|
45662124|NCT05207917|Procedure|Gastric bypass|In Roux-en-Y gastric bypass (RYGB), the left crus will be dissected free, any hiatal hernia left in place. The minor curvature is opened at the second vessel and the lesser sac entered. A 25 mL gastric pouch will be created by firing one horizontal and two vertical staple loads. The ligament of Treitz is then identified and a proximal loop of small intestine anastomosed to the pouch 60 cm from the ligament of Treitz with one linear stapler (full length of the stapler), creating an antecolic, antegastric alimentary limb. The opening will be closed using a single row, running absorbable suture. An entero-enteroanastomosis will be made 120 cm distal of the gastro-enteroanastomosis. The introductory opening is closed with a single row, running absorbable suture. The small intestine will be divided with one load between the gastro-entero-enteroanastomosis and the entero-enteroanastomosis in order to complete a bypass with an alimentary limb of 120 cm and a biliopancreatic limb of 60 cm.
45816799|NCT04819971|Drug|Docetaxel|docetaxel (intravenously, 50 mg/m2 on day 1 of every cycle for 3 preoperative cycles)
45454696|NCT01316744|Other|pharmacogenomic studies|
45454697|NCT01316744|Other|questionnaire administration|
45816800|NCT04819971|Drug|S1|S1 (orally, 400mg/m2 BID on day 1~14 of every cycle for 3 preoperative and 3 postoperative cycles )
45816801|NCT04819971|Drug|Oxaliplatin|Oxaliplatin(intravenously, 100 mg /m2 on day 1 of every cycle for 3 preoperative cycles ;130mg /m2 on day 1 of every cycle for 3 postoperative cycles.
45816802|NCT04802135|Other|Survey|directive questionnaire administered during an individual face-to-face interview
45816803|NCT04800874|Drug|BBP-418|BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) for which no approved therapy currently exists. It targets the molecular defect at the source by supplying excess substrate to the mutant enzyme thus boosting glycosylation of muscle α-dystroglycan. The BBP-418 drug product will be packaged in sachets and provided in a carton for in-clinic and at home use.
45816804|NCT04792489|Biological|MB-CART2019.1|Chimeric antigen receptor (CAR) T cell therapy
46078792|NCT02736396|Other|Neuropsychological tests|Cognitive assessments will be performed, including Mini Mental State Examination, Rey Auditory Verbal Learning Test, Stroop, Visual Short Term Memory Assessment.
45454698|NCT01316744|Procedure|assessment of therapy complications|
45956285|NCT00523159|Drug|IMA901 and Leukine|Intradermal injection of GM-CSF followed by intradermal injection of IMA901
45956286|NCT00152217|Drug|TS-1 (S-1)|80 mg of oral S-1 per square meter of body-surface area per day was given for 4 weeks and no chemotherapy was given for the following 2 weeks
45956287|NCT00152217|Procedure|Surgery|Stage II or III gastric cancer who underwent gastrectomy were assigned to surgery only
45956288|NCT03981185|Device|Accelerated theta burst treatment|"All participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 80% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
45956289|NCT04693897|Drug|Mirabegron 50 MG|Mirabegron 50mg once daily given to treatment in patients with overactive bladder syndrome
45956290|NCT04693897|Drug|Solifenacin Succinate 5 MG|Solifenacin 5mg once daily given to treatment in patients with overactive bladder syndrome
45956291|NCT00424242|Drug|Pemetrexed|Orally beginning at 500 mg/m2 every 3 weeks until disease progression
45956292|NCT04726553|Drug|Anifrolumab|Anifrolumab is a monoclonal antibody which inhibits the Interferon alpha beta receptor (IFNAR) which is the main transducer of signals from Type I interferons.
45956293|NCT04726553|Drug|Standard of Care|Standard of Care treatments for Systemic Lupus Erythematosus
45956294|NCT02947945|Drug|Reslizumab|All subjects will receive Reslizumab
45956295|NCT02948101|Biological|Anti-CSF1 Monoclonal Antibody PD-0360324|Given IV
45956296|NCT02948101|Drug|Cyclophosphamide|Given PO
45956297|NCT02948101|Other|Laboratory Biomarker Analysis|Correlative studies
45956298|NCT00167466|Device|Soladey-3 toothbrush|subject to brush with experimental Soladey-3 brush for 4 week
45956299|NCT00167466|Device|Placebo Soladey-3 toothbrush|subjects will brush with placebo Soladey-3 toothbrush for 4 weeks
45956300|NCT02952157|Drug|Lidocaine jelly application|
45454699|NCT01316744|Procedure|quality-of-life assessment|
45454700|NCT01316822|Drug|ARRY-382, cFMS inhibitor; oral|multiple dose, escalating
45662125|NCT05207917|Procedure|Sleeve gastrectomy|In sleeve gastrectomy (SG) a large part (80%) of the ventricle is removed. The greater curvature will be dissected free starting 4-5 cm from the pylorus up to the angle of Hiss. The left crus is then visualized and inspected for hiatal hernia. Small sliding hernias and wide hiatus are left in situ. The ventricle will then be lifted and any adhesions in the lesser sac divided. A 35 Fr bougie is placed down to the pylorus guiding the creation of a tubular sleeve with linear staplers. The first two loads are always green or purple, while blue or tan loads are used for the rest of the ventricle. The last stapler is placed 5 mm laterally to the angle of Hiss. The staple line will then be inspected and secured with clips for additional haemostasis, no oversewing or buttressing material is routinely used.
45816805|NCT04790890|Device|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a non-invasive imaging test which uses light waves to take cross-section pictures of the retina.
45816806|NCT04785573|Dietary Supplement|Mastiha oil|1 soft gel capsule of Mastiha oil every day for 3 months
45816807|NCT04782869|Device|transcranial direct current stimulation|Patients will be treated using Starstim 8 device, a device allowing to perform transcranial direct current stimulation. The position of electrodes will be personalized based on the localization of the epileptogenic zone.
45816808|NCT04782050|Device|Ultrasound liver assessment|The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
45816809|NCT04772820|Behavioral|Telephone-based coaching|A telephone-based brief behavioral activation coaching program that will involve 10 sessions over 4 months. Sessions will focus on helping people to identify meaningful activities that they can safely do to decrease loneliness, increase physical activity and improve nutrition.
45816810|NCT04749901|Other|Psycho-emotional and semiological measures|Surveys, interviews and measures
45956301|NCT02952157|Drug|Normal saline application|
45956302|NCT02951728|Drug|Rituximab|
45956303|NCT02951728|Drug|Cyclophosphamide|
45956304|NCT02951728|Drug|Doxorubicin|
45816811|NCT04733378|Procedure|Peri-operative neurological monitoring|Pre- and post-operative cerebral MRI, standardized neurological examinations at 4, 12, 24 months and neuropsychological evaluation with a Bayley III test (Bayley Scale of Infant and Toddler Development, Third Edition) at 24 months.
45956305|NCT02951728|Drug|Vincristine|
45956306|NCT02951728|Drug|Prednisone|
45956307|NCT02951728|Drug|Decitabine|
45956308|NCT04726046|Drug|Cefotetan|Cefotetan (as Disodium) 1 GM Injection before surgery
45956309|NCT00167505|Behavioral|Risk Avoidance Intervention|The risk avoidance intervention is a Title V compliant curriculum emphasizing abstinence until marriage and strong character development. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
45956310|NCT00167505|Behavioral|Risk Reduction Intervention|The risk reduction intervention is a curriculum providing skills for abstinence and condom and other contraceptive use. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
45956311|NCT00523354|Drug|Infliximab|Induction therapy with 2 infusions, each 5 mg/kg body weight within 2 wks
45956312|NCT04725968|Procedure|Urgent major general surgery|All geriatric patients (75 years and over) going under urgent major general surgery during 2018 in our centre
45956313|NCT02276794|Other|Thrust Manipulation|After positioning patients in right side-lying, a rotational TM technique will be addressed at the L4-L5 lumbar segments. The treating therapist will have up to two attempts to apply the TM.
45956314|NCT02276794|Other|Non-thrust manipulation (NTM)|A grade III rotational non-thrust manipulation will be addressed at the L4-L5 lumbar segments. Thirty oscilations will be performed.
45816812|NCT04727866|Device|transcutaneous spinal direct current stimulation (tsDCS) - coronal|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with cathode over C5-C7 transverse process on target side, anode over C5-C7 transverse process on non-target side.
45956315|NCT00512005|Device|Percutaneous mitral valve repair|Ventricular reshaping to treat functional mitral insufficiency
45956316|NCT00523393|Drug|Insulin Glargin|Titration of bedtime insulin glargin aiming at normal morning fasting glucose
45956317|NCT00523393|Drug|Human Insulin|Titration of bedtime human insulin aiming at normal morning fasting glucose
45956318|NCT04725734|Other|Pregnant women|The patients will complete a questionnaire for each quarter
45956319|NCT00523432|Drug|Topotecan|Weekly doses via IV infusion. Dose will be assigned based on time of study entry.
45956320|NCT00523432|Drug|CCI-779 (temsirolimus)|Weekly 25mg dose via IV infusion.
45956321|NCT00523471|Procedure|Blood test|
45956322|NCT00523510|Procedure|Infant feeding counseling that includes Flash-heat|Intensive infant feeding counseling which includes description and demonstration of the WHO recommended option for HIV-infected mothers to pasteurize their breastmilk. Flash-heat pasteurization will be described and demonstrated to interested mothers. More intensive counseling and support will be provided home visits.
45662126|NCT05207917|Procedure|Single anastomosis sleeve ileal (SASI) bypass|The SASI bypass will performed with a similar entry of the abdominal cavity. A 6-port set up and a liver retractor is utilized. The small bowel is measured 300cm from the ileocecal valve, in sequences of 10cm, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. The antrum is opened ventrally 5 cm proximal to the pylorus, just below the horizontal axis of canalis pylori. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 2.5 cm of the 45 mm stapler device is used for firing the anastomosis, which is completed with a 2-0 PDS running suture. The fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.
45662127|NCT05269303|Device|Live With Wearable Monitoring Device program|The participants in the intervention group will receive a home visit by a Community Healthcare Worker in the first month, and biweekly motivational messages via Whats App in the second and third months.
45956323|NCT04725890|Device|The DyaMX Device|The DyaMX device is designed to induce duodenal mucosal regeneration using pulsed electric field. The DyaMX procedure is a non-surgical, endoscopic procedure.
45956324|NCT00512044|Procedure|Local anesthesia (pudendal block)|local anesthesia as indicated
45956325|NCT00512044|Procedure|general anesthesia (spinal and general)|general according to guidelines
45816813|NCT04727866|Device|transcutaneous spinal direct current stimulation (tsDCS) - caudal|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with DCS cathode over ~T1-T4 posteriorly, anode over ~C5-T1 anteriorly
45816814|NCT04727866|Device|transcutaneous spinal direct current stimulation (tsDCS) - rostral|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with DCS cathode over ~C3-C5 posteriorly, anode over ~C5-T1 anteriorly
45816815|NCT04727866|Device|intermittent theta burst stimulation (iTBS)|3 minutes of iTBS (a form of repetitive TMS) will be delivered during a 5-minute interval of DCS
45816816|NCT04727632|Drug|[18F]Fluoroestradiol (FES) PET/CT|[18F]Fluoroestradiol (FES) PET/CT
45816817|NCT04724148|Drug|Fentanyl|To assess the accuracy of HVPG in TIPS after injecting a dose of 1~2 mg/kg fentanyl.
45956326|NCT00523588|Procedure|laser treatment (Candela Vbeam Perfecta™)|This laser has an adjustable pulse duration (0.45-40 ms), fixed wavelength 595 nm, spot size (3 mm, 5 mm, 7 mm, and 10 mm), and incident fluence range of 10-40 J/cm2. The laser is also equipped with a dynamic cooling device (DCD) (FDA cleared under K001589) that delivers cryogen (R-134a) from a small nozzle positioned 4 cm above the skin at an angle of approximately 70 degrees with respect to the skin surface. All patients will be treated with the laser device on which the varying cooling device parameters will be selected based on the clinical judgment of the treating physician. Factors used in this decision include patient age, skin type and epidermal pigmentation, size and depth of vessels, color of lesions, anatomic location, etc. In all instances, a test-dose in an inconspicuous location on the skin will be conducted prior to the first treatment.
45956327|NCT00512083|Drug|AS1411|AS1411 IV administration continuously over 7 days. Dose either 10mg/kg/day or 40 mg/kg/day.
45956328|NCT04726007|Drug|Antithrombotic Agents|Antithrombotic agents include anticoagulants, antiplatelet drugs, thrombolytic drugs.
46002825|NCT04635267|Other|Prone position in patients with ARDS|Transpulmonary thermodilution, arterial blood gas and recruitment/inflation calculation will be made every 8 hours: at baseline (just before prone position), after eight hours of prone position, after 16 hours of prone position (end of prone position), after 24 hours ( 8 hours after the end of prone position).
45454701|NCT01213381|Drug|Iniparib (SAR240550 - BSI-201)|"Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous"
45956329|NCT00521950|Genetic|TPMT genotyping; Drug: azathioprine or 6-mercaptopurine|"Assessment of the polymorphisms G238C, G460A, and A719G in a venous blood sample to identify functional genetic variants (TPMT*2, *3A, *3C) of the TPMT gene (chromosome 6) associated with reduced or negligible TPMT enzyme activity.~Patients are advised an initial treatment dose based on the enzyme activity:~Normal: AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);~Reduced: AZA 1-1.25 mg/kg/day or 6-MP 0.5-0.75 mg/kg/day;~Negligible: AZA 0-0.2 mg/kg/day or 6-MP 0-0.1 mg/kg/day;"
45956330|NCT00521950|Drug|azathioprine (AZA) or 6-mercaptopurine (6-MP)|"Patients will be advised a standard initial treatment dose:~AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);"
45956331|NCT00523666|Drug|Galantamine (Reminyl®)|8mg - 24mg
45956332|NCT00523666|Drug|Placebo/Galantamine (Reminyl®)|"Patients are treated double-blind with placebo for 6 months, followed by treatment with Galantamine (Reminyl®) for another 6 months.~Dose scheme: 8mg-24mg"
45956333|NCT00167583|Drug|Cyclosporin A|3 mg/kg bw, augmented to 5 mg if necessary and combined with prednisolone. Adapted to serum levels
45956334|NCT00167583|Drug|Interferon-alpha2a|3-6 million iU per day sc., augmented to up to 9 if necessary, later reduced (according to clinical response) to 3 x 3 million iU /week.
45662128|NCT05269147|Procedure|Sphenopalatine Ganglion Block (SPGB)|"The SPGB will be done after the patient is generally anesthetized and will be performed by the operating surgeon using a transnasal endoscopic approach through the posterior and over the middle turbinate tail in the pterygopalatine fossa.~The patient will be placed in the supine position with head extension. The prepared solution (4 ccs 2% lidocaine or 0.5% bupivacaine or normal saline and 1 cc 8 mg dexamethasone) will be given (2,5 cc) to each side of the nose.~The surgery was started 10 minutes after the application of SPBG to allow sufficient time for the block to develop."
45662129|NCT05241691|Device|Guided Growth Plate System Plus|The implant is thought as one of the surgical options to perform epiphysiodesis and hemiepiphysiodesis minimally invasive, that is without recourse to a corrective osteotomy.
45956335|NCT03943511|Other|Oral Antibiotics-Close Monitoring|To receive oral antibiotics and close monitoring, defined as twice weekly telephone calls by a member of the care team, of their chest tube and valve.
45956336|NCT03943511|Other|Standard of Care|No calls from the care team but waiting for the subject to contact the care team when the air leak has stopped.
45956337|NCT00523822|Other|Spinal Manipulative Therapy|
45956338|NCT00523861|Dietary Supplement|Moderate alcohol consumption|
45956339|NCT02951923|Dietary Supplement|Bovine Colostrum|Bovine colostrum vs. soy during rugby training
45956340|NCT02951923|Dietary Supplement|Soy|
45956341|NCT03922802|Device|Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|Subjects will receive up to 45 minutes of AIH prior to receiving transcutaneous electrical spinal cord stimulation delivered by a Transcutaneous Spinal Cord Neurostimulator while performing locomotor activities.
46078793|NCT04101981|Procedure|oocytes retrieval|The oocytes retrieval was performed after 34-36 hours from hCG administration . The collection of cumulus-oocyte complexes and FFs were performed via transvaginal ultrasound-guided aspiration with a needle of 18 gauge of diameter. The three major diameter follicles were identified by intraoperative ultrasound and FF of each follicle was collected in its own test tube.
46078794|NCT04661930|Drug|TriCor® 145mg tablets|Fenofibrate; 145 mg daily (1/day); oral administration; 10 days
46078795|NCT04661930|Other|Placebo|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
45454702|NCT01213381|Drug|Gemcitabine|"Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous"
45454703|NCT01213381|Drug|Carboplatin|"Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous"
45662130|NCT05206747|Device|Blue-blocking glasses|It will transmit 45% of visible light with the following light transmission profile.
45662131|NCT05206747|Device|Lightly-tinted glasses|It will also filter short wavelength light but at a lower threshold with near identical transmission above this threshold. It will transmit 91% of visible light with the following light transmission profile.
45662132|NCT05206435|Drug|Electronic Cigarette|Electronic Cigarettes are provided to replace tobacco cigarettes
45662133|NCT05206435|Drug|Nicotine Lozenge|Nicotine Lozenges are provided to replace tobacco cigarettes
45662134|NCT05206123|Other|Interview|Patients will be interviewed with a semi-structured qualitative interview in order to know how they lived their first sexual experiences and their sex lives during their adolescence
45662135|NCT05205811|Drug|Bupropion|Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 7 weeks.
45816818|NCT04716244|Other|interview/focus group/questionnaire|"Prior to the meetings, participants will be asked to fill in a questionnaire with demographic data including age, family status, number of pregnancies, number of children, education, and employment, history of preeclampsia or GDM, family history of CVD, and self-reported height and weight We will conduct up to 8 groups or until we reach saturation of themes. For the teleconference focus groups, the number of participants will be limited to 6 women per group, as recommended from previous research on teleconference focus groups51. The face to face focus groups will include up to -12 women. The expected duration of each group, will last 1-2 hours.~We will conduct up to 36 in-depth interviews. The expected duration of each interview will last 30 minutes to -1.5 hours.~Participants will be asked for their consent to record the meetings, audio only. The discussions will be then transcribed. An interview guide will be followed."
45956342|NCT03922802|Other|Sham Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|Subjects will perform locomotor activities with transcutaneous electrical spinal cord stimulation after receiving sham acute intermittent hypoxia
45662136|NCT05205811|Drug|Zonisamide|Zonisamide (100 mg/daily) for 7 weeks.
45662137|NCT05205811|Drug|Placebo bupropion|Placebo bupropion for 7 weeks.
45662138|NCT05205811|Drug|Placebo zonisamide|Placebo zonisamide for 7 weeks.
45956343|NCT03922802|Other|Sham Acute Intermittent Hypoxia + Sham Non Invasive Spinal Cord Stimulation + Gait Training|Subjects will perform locomotor activities with sham transcutaneous electrical spinal cord stimulation after receiving sham acute intermittent hypoxia
45956344|NCT00172809|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 135 ug/week for 24 weeks
45454704|NCT01344122|Other|KPI training only|See comparison arm description.
45956345|NCT00172809|Drug|Interferon alfa-2a|Interferon alfa-2a 3 MU tiw for 24 weeks
45956346|NCT04696120|Drug|Apixaban|Patients who are randomly assigned to apixaban group will receive apixaban 5mg or 2.5mg bid
45956347|NCT04696120|Drug|Placebo|All patients who are assigned to placebo group will receive placebo
45454705|NCT01344122|Other|KPI plus OLI|See experimental arm description.
45956348|NCT00523900|Dietary Supplement|Quaker Complete Nutrition Supplements|3-6 250ml cans of Quaker Complete Nutrition Supplements per day
46002826|NCT00548990|Behavioral|cardiovascular exercise training|
46078796|NCT04661930|Other|Usual care|All participants will otherwise receive usual medical care
46078797|NCT00916227|Drug|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
45454706|NCT03531346|Other|Daily-disposable soft contact lens|Subjects were refitted with Silicone-Hydrogel (Delefilcon A) or Hydrogel (Omafilcon A) daily-disposable soft contact lenses based on their fit, reported comfort and tear film surface quality.
45454707|NCT01114789|Other|Proteolysis|protocol designed to examine the effect of obesity on muscle proteolysis in hemodialysis and control
45454708|NCT01316978|Drug|Ibuprofen|A single 2 x 100 mg dose of an experimental Ibuprofen Fast Melt Orodispersible Tablet administered orally, with a 7-day washout between visits
46078798|NCT05480514|Device|TEST LENS|etafilcon A with cosmetic pattern
46078799|NCT05480514|Device|CONTROL LENS|Acuvue 1-Day Define Fresh Honey
46078800|NCT02814188|Other|Carbohydrate Beverage|750 ml of a 13.5% carbohydrate (sucrose) beverage
46078801|NCT02814188|Other|Placebo Beverage|750 ml of an artificially-sweetened beverage
45956349|NCT00512356|Biological|Anti-Adhesion Product|Anti-Adhesion Product (AAP) is a biological two-component product of human origin. The components of AAP are lyophilized Anti-Adhesion Protein Concentrate (AAPC), containing fibrinogen, lyophilized Thrombin Concentrate (TC) and the respective diluents for the reconstitution of the components.
45956350|NCT03890120|Drug|Cilofexor|100 mg tablet administered orally once daily
45662139|NCT05205811|Other|E-cigarette|e-cigarette for ad libitum use for two weeks prior to complete switch day and for an additional 10 weeks.
45662140|NCT05166967|Drug|Individual Antithymocyte globulin|Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 13mg/kg). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
45662141|NCT05166967|Drug|Antithymocyte globulin|A 10mg/kg total dose of antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (from day -5 to day -2). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
45816819|NCT04712214|Device|Intra-operative multispectral / hyperspectral analysis|During surgery, the operating surgeon will be using standard NHS neurosurgical equipment such as an endoscope and/or a microscope. This equipment is operated in exactly the same way as with any other procedure, but either the microscope or the endoscope in use will be connected to the system of camera and filters for multispectral/hyperspectral analysis. During each surgical intervention, tissue-specific spectral data will be collected at specific stages - mostly once the brain surface is exposed and at the end of the resection on the surgical cavity. The operation will be visually recorded in order to sync visual data with the spectral data obtained at the same moment in time. The video recording will not be patient identifiable and will be viewed only by members of the research team working on this project (see below). The use of video recording equipment will be included in the patient information sheet given to all patients prior to gaining consent
45816820|NCT04703803|Combination Product|1% lidocaine injection in trigger points|The trigger point injection procedure with 1% lidocaine will be e (the sum of all needled trigger points will have a maximum of 10 ml), in a single intervention
45956351|NCT03890120|Drug|Placebo|Tablet administered orally once daily
45956352|NCT04694014|Behavioral|EI Open ended Pre-Survey and Semi Structured Interview|Provide Interview questions via online survey with informed consent to the participants then contact a 60 minute member checking interview in person or virtually via recorded Zoom sessions for each participant
45956353|NCT04694014|Behavioral|Behavioral and Cognitive Assessment|Use Predictive index for both cognitive and behavioral assessment of the paticipants
45956354|NCT04694014|Behavioral|Geneva Emotional Competence Test (GECO)|Administer the Geneva Emotional Competence Test to each participant
45956355|NCT04693741|Procedure|secondary alveolar bone graft|"Under general anesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will be injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will be made on both sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will be dissected. Next, the bone particles will be implanted into the bone defect.~Then, The cleft site will be closed without tension by the advancement of the gingival flaps."
45956356|NCT04693741|Procedure|Harvesting of the autogenous bone graft|Under general anaesthesia ,the soft tissue in the superior iliac crest will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. The cancellous bone will harvested with an osteotome and then cut into small bone granules.
45956357|NCT04693741|Procedure|Preparation of PRP|10 ml of blood will be collected in vacuum tubes without anticoagulants which are then immediately centrifuged at a rate of 3000 rpm for 10 min. After centrifugation, the resultant product consists of three layers. The topmost layer consisting of acellular PPP (platelet poor plasma), PRF clot in the middle and RBCs at the bottom of the test tube. The attached red blood cells scraped off from it and discarded. The discarded PRF is then mixed with xenograft and placed inside the alveolar defect.
46078802|NCT04102137|Biological|Pertagen (aP BioNet)|"Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region."
45454709|NCT01316978|Drug|Ibuprofen|A single 200 mg Nurofen Meltlets Orodispersible Tablet administered orally, with a 7-day washout between visits
46002827|NCT00548990|Behavioral|flexibility/balance control|
46078803|NCT04102137|Biological|Boostagen (TDaP BioNet)|"Boostagen (TDaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TDaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region."
45454710|NCT01316978|Drug|Ibuprofen|A single 2 x 100 mg dose of Junior Strength Motrin Chewable Tablet administered orally, with a 7-day washout between visits
45662142|NCT05166343|Drug|Epinephrine Injection|Epinephrine administered via sterile epinephrine injection USP, by 0.3mg or 0.5mg epinephrine auto-injector(s)
45662143|NCT05238337|Drug|[14C]-PBI-200|[14C]-radio-labeled-PBI-200
46078804|NCT04102137|Biological|Adacel|"Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region."
45816821|NCT04697524|Behavioral|Support Group Therapy|Virtual group meetings
45454711|NCT03531268|Other|PGx Testing|Pharmacogenomic (PGx) testing will be administered to all subjects. The results of PGx testing will be evaluated for clinical utility. Subjects will be evaluated based on whether PGx testing has clinical utility or has no clinical utility.
45454712|NCT01317212|Drug|Peritumoural carboplatin administration.|Peritumoural carboplatin administration by convection-enhanced delivery (CED) through 4 implanted intracranial catheters. Infusions conducted weekly for 4 consecutive weeks.
45454713|NCT04208464|Drug|Baricitinib|4mg daily for 24 weeks from baseline
45454714|NCT04208464|Drug|Baricitinib|4mg daily for 24 weeks starting after a 12-week treatment delay from baseline
45454715|NCT01117597|Radiation|low RF exposure level|Exposure with 1.5 W/kg
45662144|NCT04126525|Drug|Pyrotinib|dual HER2 blockade in the neoadjuvant setting
45662145|NCT05205421|Biological|Oncolytic Virus Injection(RT-01)|Intravenous injection a single dose of RT-01
45662146|NCT05237947|Biological|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
45662147|NCT05237947|Other|Questionnaire Administration|Ancillary studies
45662148|NCT05237947|Biological|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
45816822|NCT04697524|Behavioral|Symptom Management Service (SMS) Consultation|Virtual individual meetings with symptom management service (SMS) over 5 minutes
45816823|NCT04697524|Other|Quality of Life (QOL) Questionnaires|Administered at each study visit
45816824|NCT04697524|Other|Interview|Virtual exit interview at end of study
45662149|NCT05237947|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
45662150|NCT05166109|Drug|Vamorolone|Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
45816825|NCT04695080|Drug|Cladribine (MAVENCLAD®)|"Cladribine (MAVENCLAD®) 3.5mg/kg, administered as weight-adjusted 10mg tablets in two treatment courses (12 months apart) lasting 8- 10 days each.~Cladribine (MAVENCLAD®) 10mg available in blister packs of 1 tablet, 4 tablets and 6 tablets."
45454716|NCT01117597|Radiation|sham exposure|intervention with sham RF exposure
45454717|NCT01117597|Radiation|high RF exposure|intervention with high RF exposure
45454718|NCT05250752|Drug|Dapagliflozin 10 MG [Farxiga]|Primary end-points are measure before (day 0), on treatment (day 1 and day 3) and after treatment (day 21)
45662151|NCT05166109|Drug|Placebo|Placebo to Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
45816826|NCT04695080|Drug|Placebo|"Placebo administered as weight adjusted tablets in two treatment courses (12 months apart) lasting 8-10 days each.~Placebo 10mg available in blister packs of 1 tablet, 4 tablets and 6 tablets."
46078805|NCT02815202|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z12-034)
45956358|NCT02951845|Drug|JNJ-54416076 (Oral Suspension)|Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.
45956359|NCT02951845|Drug|JNJ-54416076 (Formulation 1: Direct Compression Tablets)|Participants will receive JNJ-54416076 Tablet formulation 1 (5*5 mg Tablets [25 mg total]) under fasted and fed condition in Part 1.
45956360|NCT02951845|Drug|JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets)|Participants will receive JNJ-54416076 Tablet formulation 2 (5*5 mg Tablets [25 mg total]) under fasted and fed condition in Part 2.
45956361|NCT00167622|Procedure|mechanical ventilation|Non invasive mechanical ventilation at least 6 hours per day - if difficult swallowing, tracheal intubation and invasive mechanical ventilation
45956362|NCT00167622|Procedure|physiotherapy and oxygen if needed|oxygen will be delivered via facial mask whenever needed and physiotherapy
45816827|NCT04693221|Other|Choice of VNS set of parameters based on the lowest PLI|Vagal nerve stimulation according to PLI results.
45816828|NCT04693221|Other|EEG|Patient will have an EEG and 12 sets of parameters will be tested. EEG results will be analyzed which will allow to determine the set involving the lowest phase lag index.
45956363|NCT00512395|Drug|epidural analgesia (Duracain/Fentanyl/Naropin)|naropin 0.3% or duracain 0.125% + Fentanyl via epidural catheter 4-12 ml/h
45956364|NCT02276833|Other|intra-articular space injection of SVF|intra-articular injection of autologous adipose SVF derived in the same surgical procedure
45956365|NCT00512434|Procedure|Osteosynthesis|Nail or external fixator Intervention 'Osteosynthesis'
45816829|NCT04692701|Device|Pulvinar deep brain stimulation|Stimulation of the medial pulvinar
46078806|NCT05326035|Drug|WJ05129|WJ05129:Twice daily (except for single dose), 12 hours apart, fixed time is recommended
45956366|NCT00512473|Drug|Saline infusion|0.9 % NaCl
45662152|NCT05204407|Dietary Supplement|Luteolin|The luteolin target dose will be 300 mg BID taken over 12 weeks in capsule form
45662153|NCT05204407|Dietary Supplement|Placebo|The placebo target dose will be 300 mg BID taken over 12 weeks in capsule form
45662154|NCT01656733|Drug|Nicotrol Inhaler|Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
45662155|NCT01656733|Drug|Placebo Inhaler|Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
45816830|NCT04692675|Diagnostic Test|mpMRI|3T endorectal coil MR imaging of the prostate gland
45662156|NCT05236543|Drug|AZD4831|Subjects will receive single oral dose only on Day 1 and Day 11.
45662157|NCT05236543|Drug|Itraconazole|Subjects will receive Itraconazole orally on Days 8 followed by dosing from Day 9 to Day 17.
45816831|NCT04691011|Other|Muscular MRI|MRI (1.5T)
45816832|NCT04691011|Other|Electrophysiological exam|MUNIX
45816833|NCT04691011|Other|Brain MRI|MRI (7T)
45816834|NCT04691011|Other|Spinal cord MRI|7T and 3T MRI
45816835|NCT04690998|Other|Blood Samples|Genetic, proteomic, neurofilament analysis
45816836|NCT04690998|Other|MRI|Spinal and muscular MRI
45816837|NCT04686383|Drug|CAL056 mesylate|Dosage form: 20 mg CAL056 mesylate/tablet
45816838|NCT04681417|Drug|Melphalan or Melphalan + Topotecan|IAC: 2-6 cycles every 1 month (number based on the local tumor evolution), performed using radio-guided catheterization and delivery at the ostium of the ophthalmic artery, in neuroradiology operating room, and under General Anesthesia (GA). IAC will be administered at the Fondation Rothschild Hospital in collaboration with the Interventional Neuroradiology team.
45816839|NCT04681417|Drug|etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy|2 to 6 cycles of combined etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy : thermotherapy and/or cryotherapy and/or iodine-125 plaques and/or intravitreal chemotherapy injections
45816840|NCT04681417|Drug|Carboplatin administered on Day 1|Chemothermotherapy : Intravenous injection by carboplatin
45956367|NCT00512473|Drug|Human Growth Hormone|0.5 mg genotropin administered as a bolus at t = 0
45956368|NCT00512473|Drug|Pegvisomant|30 mg Somavert administered at t = - 36 hours
45956369|NCT00512512|Procedure|Transoral Endoscopic Liver Biopsy|Liver will be biopsied with transoral endoscope instead of the laparoscopic instruments during laparoscopic gastric bypass
45956370|NCT00524095|Drug|azithromycin and fluticasone|azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
45956371|NCT00524095|Drug|fluticasone and azithromycin|inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
45956372|NCT00167700|Behavioral|Dietary counselling and placebo|Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Placebo capsules.
45956373|NCT00167700|Behavioral|Dietary counselling and probiotics|Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Probiotics
45956374|NCT00167700|Dietary Supplement|Placebo capsules|Placebo capsules
45956375|NCT00167700|Dietary Supplement|Probiotics|
45956376|NCT00167700|Dietary Supplement|Prebiotics|
45956377|NCT00512551|Procedure|Tumor Biopsies|Biopsies of the cervical tumor performed first before any treatment is given, and the second about 48 hours after radiation treatment has began.
46002828|NCT00560586|Drug|Budesonide|1 puff each nostril (32 micrograms) at bedtime
46002829|NCT00560586|Drug|placebo|1 puff each nostril at bedtime
46002830|NCT00549029|Genetic|DNA|withdraw 5~10mL blood from vein only once during the whole design
46078807|NCT02814812|Procedure|CT scan|
46078808|NCT04324008|Device|Constic|Flowable resin composite
46078809|NCT04324008|Device|G-ænial Universal Flo|Flowable resin composite
46078810|NCT04324008|Device|Tetric N-Flow (self-etch)|Tetric N-Flow (Tetric N-Bond Universal, self-etch mode)
46078811|NCT04324008|Device|Tetric N-Flow (etch&rinse)|Tetric N-Flow (Tetric N-Bond Universal, etch&rinse mode)
45956378|NCT00512590|Behavioral|Relaxation and Guided Imagery|"The intervention consisted of 3 relaxation and guided imagery audiotapes used in a proscribed order for 6 weeks and used in any order for weeks 7 through 10.~Protocol: Tape 1: Basic Relaxation used for weeks 1 and 2. Tape 2: Pleasant Scene Imagery to elicit sensory involvement for enhanced sense of overall well-being; used for weeks 3 and 4. Tape 3: End-State Imagery designed to facilitate improved symptom management; used for weeks 5 and 6. Any of the tapes used as often as desired but at least once daily for weeks 7 to 10."
45662158|NCT05163769|Device|NeeuroCycle Physical and Cognitive Training System|The NeeuroCycle Physical and Cognitive Training System is a novel multimodal electroencephalogram (EEG)-based physical and cognitive training device. The system mainly comprises of a recumbent bicycle device and a customized four frontal electrode EEG-headband paired with the gamified NeeuroCycle cognitive training program delivered via an electronic application (app) on a tablet. The cognitive training program is built upon patented EEG-based attention, learning, and memory algorithms.
45956379|NCT00512629|Drug|Omegaven|Omegaven is a fish based intravenous fat emulsion
45956380|NCT00512629|Drug|Intralipid|Intralipid is a plant based intravenous fat emulsion
45956381|NCT00512668|Drug|leuprolide acetate|Given intramuscularly
45956382|NCT00512668|Drug|goserelin acetate|Given subcutaneously
45454719|NCT01114009|Procedure|Lung recruitment maneuver|Lung recruitment maneuver conducted with a PEEP 35 cmH2O and peak inspiration pressure up to 50 cmH2O maintain 2 mins, then find the closing pressure (if possible), after that, PEEP is set higher 2 cmH2O above closing pressure
45662159|NCT05163769|Device|NeeuroCycle Cognitive Training System|The NeeuroCycle Cognitive Training System is a novel electroencephalogram (EEG)-based cognitive training device. The system mainly comprises of a customized four frontal electrode EEG-headband paired with the gamified NeeuroCycle cognitive training program delivered via an electronic application (app) on a tablet. The cognitive training program is built upon patented EEG-based attention, learning, and memory algorithms.
45956383|NCT00512668|Drug|bicalutamide|Given PO
45956384|NCT00512668|Drug|nilutamide|Given PO
45956385|NCT00512668|Drug|flutamide|Given PO
45956386|NCT00512668|Drug|temsirolimus|Given IV
45956387|NCT00512668|Other|laboratory biomarker analysis|Optional correlative studies
45956388|NCT00167739|Drug|Quinine plus sulfadoxine-pyrimethamine|
45956389|NCT00512746|Other|cytology and cytometry specimen collection procedure|Samples tested and further interventions added if positive
45956390|NCT00512746|Other|Chest x ray|Patients not diagnosed with lung cancer during the course of the study, will be offered an exit chest x-ray after 5 years or sooner if they withdraw from the trial before 5 years. This could help identify a lung cancer that may not have been associated with symptoms earlier.
45454720|NCT01114009|Procedure|Lung protective strategy group|Lung protective strategy group received Lung protective strategy without recruitment maneuver
45454721|NCT05724238|Dietary Supplement|Traditional Herbal Supplements (Kuan Sin Yin)|Astragalus-based Kuan Sin Yin
45454722|NCT05724238|Dietary Supplement|Placebo|Placebo starch powder with 10% Kuan Sin Yin
45816841|NCT04681417|Device|Thermotherapy (local treatment)|Thermotherapy after carboplatin administered on Day 1
45816842|NCT04681417|Device|Cryotherapy (local treatment)|Cryotherapy (local treatment)
45454723|NCT01344278|Behavioral|Lifestyle Counseling|A lifestyle curriculum of individualized telephone counseling calls, augmented with e-mails and an interactive study Web site.
45816843|NCT04681417|Device|Iodine-125 plaques (local treatment)|Iodine-125 plaques (local treatment)
45662160|NCT05161819|Device|Repetitive transcranial magnetic stimulation|High-frequency stimulation (10Hz), 120% motor threshold, 40 trains, 1600 pulses
45956391|NCT00512746|Procedure|Autofluorescence bronchoscopy|The bronchial tree will be inspected first under white light and then under blue light. All areas that appear abnormal will initially be documented and only sampled when the bronchoscopic examination has been completed.
45662161|NCT05161819|Device|Sham stimulation|High-frequency stimulation (10Hz), 120% motor threshold, 40 trains, 1600 pulses (with sham coil)
45816844|NCT04681417|Drug|Intravitreal Melphalan chemotherapy injections (local treatment)|Intravitreal Melphalan chemotherapy injections (local treatment)
45454724|NCT04795544|Procedure|Intracuff pressure measurement|Intracuff pressure is measured by a pressure manometer.
45454725|NCT01211509|Drug|Montelukast|After diagnosis of fBOS every day an oral capsule with 10 mg montelukast of placebo
45454726|NCT02741518|Biological|Fecal Microbiota Transplantation|This is pre-screened fecal material that has been encapsulated
45454727|NCT02741518|Other|Placebo|These are capsules that have no fecal material in them.
45816845|NCT04680065|Biological|AAV2-GDNF gene therapy|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
45816846|NCT04680065|Procedure|Sham (Placebo) Surgery|Bilateral partial burr/twist holes without dural penetration
45816847|NCT04670978|Drug|albumin-bound paclitaxe combined with bevacizumab biosimilar|albumin-bound paclitaxe, 260mg/m2, every 3 weeks, 6cycles, bevacizumab biosimilar, 10mg/kg, every 3 weeks, continue until PD or unaccceptable toxicity
45956392|NCT00512746|Procedure|CT scan|All patients with abnormal sputum cytology and/or cytometry will undergo low dose spiral CT without contrast.
45956393|NCT00524251|Drug|esomeprazole|
45956394|NCT00512785|Drug|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 52 weeks
45956395|NCT00512785|Drug|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 12 weeks and 0.2 mg BID for 52 weeks
45956396|NCT00512824|Dietary Supplement|low calcium milk of 180 ml|twice daily for 24 weeks
45956397|NCT00512824|Dietary Supplement|regular milk of 180 ml|twice daily for 24 weeks
45956398|NCT00512824|Dietary Supplement|regular milk of 180 ml + probiotics|twice daily for 24 weeks
45956399|NCT00512824|Dietary Supplement|regular milk of 180 ml + probiotics|twice daily for 24 weeks
45956400|NCT00512863|Drug|Humira (adalimumab)|
45956401|NCT00524407|Drug|Epoetin alfa|
45956402|NCT03889613|Other|prospective follow-up with videocapsule|prospective follow-up with videocapsule
45956403|NCT00525889|Drug|IL-2|Administered by subcutaneous injection at a dose of 4.5x10^6 IU/day, three times weekly for 28 days starting on day 0.
45956404|NCT00525889|Drug|Rapamycin|Administered orally, initial daily dose of 2mg. At day 7, dose adjusted to achieve and maintain whole blood trough levels of 5-10 ng/ml.
45956405|NCT00524446|Dietary Supplement|Milk-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.
45956406|NCT00524446|Dietary Supplement|Soy-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.
45662162|NCT05161663|Behavioral|Peer-driven intervention|"This peer-driven intervention (PDI), modified based on respondent-driven sampling (RDS) or snowball sampling, is a chain referral approach. Index peers will be purposefully selected to reflect the diversity of African American (AA) and Hispanic/Latino (H/L) men who have sex with men (MSM) and are required to take a formal training about pre-exposure prophylaxis (PrEP) and HIV. These index peers will educate members of their social networks and encourage them to initiate PrEP. Those referred peers will schedule an appointment to complete a short survey and will be referred to our PrEP clinic if they are interested in PrEP uptake. The referred peers will serve as index peers for the following wave of recruitment. It is expected to achieve a robust sample of AA and H/L within six waves of recruitment. This PDI approach is potential to engage AA and H/L who are most at risk of HIV acquisition in PrEP uptake and could contribute to reducing the concentrated HIV epidemic."
45662163|NCT05161117|Behavioral|Virtual reality simulation app for caregiver education|"Using a virtual reality headset/goggles, caregivers will engage with an interactive app experience to identify and mediate fall risk hazards in the inpatient care environment. The app will present a hospital bedroom and bathroom laden with fall risks. As the caregiver progresses through the experience, the caregiver will ambulate (virtually) through the environment with the goal of identifying fall risks inherent within that inpatient setting. Fall risks will be targeted and identified using the app sighting function and after focusing on the fall risk for the allotted marking time, will self-resolve."
45816848|NCT04668768|Drug|Glucarpidase|Glucarpidase injection to prevent toxicities due to high dose methotrexate treatment
45956407|NCT00524446|Dietary Supplement|Maize-soy flour|Counseling + Vitamin A as for ST_DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
45956408|NCT00524524|Drug|ARQ 501|Weekly IV Infusion; 450 mg/m2
45956409|NCT03879122|Drug|Ipilimumab 5 MG/ML|Ipilimumab will be administered on day 1 of each cycle every 3 weeks. In arm 3, ipilimumab should be started at least 2 weeks but no later than 120 days after surgical castration or the first dose of LHRH analogue. Patients should receive 2 doses of ipilimumab (6 weeks). It will be followed, 3 weeks later, by 3 cycles of docetaxel and by 2 additional doses of ipilimumab and 3 more cycles of docetaxel. Four weeks later, Nivolumab will be administered on day 1 every 2 weeks until a maximum of 24 doses (48 weeks)
45956410|NCT03879122|Drug|Nivolumab 10 MG/ML|Nivolumab will be administered every 2 weeks, until clinical progression or a maximum of 24 doses. Nivolumab should be started 4 weeks after the last dose of docetaxel, providing all the adverse effects have recovered, as if a new cycle of docetaxel were to be administered
45956411|NCT03879122|Drug|Docetaxel|"Docetaxel should be given on day 1 every 21 days, for up to 6 cycles (1 cycle = 21 days). Docetaxel should be started within 7 working days from the date of randomization in the arm 1 and 2.~In arm 3, docetaxel will be given 3 weeks after the last dose of the previous treatment, providing all the side effects are grade ≤1."
45956412|NCT03879122|Drug|ADT (androgen deprivation therapy)|Androgen deprivation therapy per the standard of care
45956413|NCT00524602|Procedure|Catheter ablation using the Stereotaxis equipment|Energy delivery through ablation catheter during an interventional catheterisation of the heart.
45956414|NCT00525928|Drug|varenicline|varenicline 0.5mg daily for days 1-3, 0.5mg twice daily for days 3-7, then 1mg twice daily for length of hospitalization
45956415|NCT00167817|Drug|Aripiprazole|
45956416|NCT03868982|Device|Neurally adjusted ventilatory assist|NAVA uses the diaphragm activity to deliver mechanical ventilation
45816849|NCT04664075|Biological|Respiratory infections|With biological samples and longitudinal observations, the aim is to find and develop predictive tests to better understand how and when flu-like illness progresses to more severe disease. This may help to decide which people need to be admitted to hospital, and how their treatment needs to be increased or decreased during infection.
45816850|NCT04657835|Device|cardiac Magnetic Resonance Imaging (MRI)|Cardiac magnetic resonance imaging (MRI) will be realized before Coronary Artery Bypass Grafting for assess atrial cardiomyopathy.
45956417|NCT02946697|Behavioral|Social support intervention|The social support intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
45956418|NCT02948023|Biological|Ex-vivo cultivated limbal stem cell pool|0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.
45956419|NCT02952079|Device|Blephex|Lid margin exfoliation
45816851|NCT04657835|Biological|Blood sample|Blood sample will be realized (4 tubes of 4ml blood, 16ml in total) before Coronary Artery Bypass Grafting.
45816852|NCT04657835|Procedure|Cardiac muscle biopsy|Cardiac muscle biopsy will be realized during Coronary Artery Bypass Grafting.
45816853|NCT04657835|Device|Holter-electrocardiogram (ECG)|Holter-electrocardiogram (ECG) will be realized 1 year after Coronary Artery Bypass Graftin during 3 days to diagnose the occurrence of atrial fibrillation.
45816854|NCT04657835|Other|medical examination|medical examination will be realized 1 year after Coronary Artery Bypass Graftin. Theses datas will collected: events during the follow-up year and evaluation of the Holter-electrocardiogram result.
45816855|NCT04657302|Drug|Obinutuzumab|Participants will receive 1000 mg of intravenous (IV) obinutuzumab on Cycle 1 Day 1.
45956420|NCT02952079|Device|MiboFlo|Lid warming treatment
45956421|NCT02948218|Device|Acupuncture treatment|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
45956422|NCT00173082|Procedure|Glucose tolerance test|
45956423|NCT02947906|Other|No intervention|No intervention
45956424|NCT02947711|Drug|E2027|2 x 50 mg capsules, once daily on Day 1 and Day 12
45956425|NCT02947711|Drug|Diltiazem ER|1 x 300 mg capsule, once daily on Days 7 through 24
45956426|NCT02946736|Behavioral|FSSB/Sleep Leadership Training|Supervisors will receive a training addressing family-supportive supervisor behaviors and sleep leadership.
45956427|NCT02946736|Behavioral|Actigraphy Feedback|Supervisors and employees will receive personalized feedback on their sleep and activity measurements.
45662164|NCT05161117|Behavioral|online fall prevention education module|Participants in both intervention and control groups will complete a 20 minute online module: Management of the Patient at Risk for Falls, through the MyLearning education platform. Most caregivers would have taken this module during competencies or orientation, but at various times. It will be taken by all participants in this study to serve as a baseline understanding of identifying and caring for patients at risk for falls. Participants will be enrolled in the module by a member of the research team, and learner transcripts will available through MyLearning education to confirm completion.
45956428|NCT03845348|Other|TD03|Shampoo TD 3 days
45956429|NCT03845348|Other|TD07|Shampoo TD 7 days
45956430|NCT03845348|Drug|Ketoconazole 2% Shampoo|Ketoconazole 2% Shampoo
45956431|NCT04723563|Drug|Heparin|25,000 units of unfractionated heparin nebulized 4 times daily for the duration of hospitalization
45956432|NCT04723563|Drug|0.9%sodium chloride|5 mL of 0.9% sodium chloride nebulized 4 times daily for the duration of hospitalization
45956433|NCT00525967|Drug|Methadone plus Acetaminophen or Placebo|Methadone bid according to a established conversion morphine-to-methadone ratio plus Placebo or Acetaminophen qid
45662165|NCT05202535|Other|Aerobic exercise training|"Hospital-based aerobic exercise training for 15-30 minutes including pre and post-vitals assessment.~3x/week on alternate days for 8 weeks at 40-70% of HR Max"
45662166|NCT05202535|Other|Conventional therapy|Patient education and counseling with diet plan.Walking 3 days15min/day for 8 weeks
45816856|NCT04657302|Drug|Glofitamab|Participants will receive 2.5 mg of IV glofitamab Cycle 1 Day 8, 10 mg at Cycle 1 Day 15, and 30 mg on Day 1 of Cycles 2-12 Q3W (cycle length = 21 days).
45816857|NCT04657302|Drug|Tocilizumab|Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).
45816858|NCT04639323|Diagnostic Test|Endoscopic ruler|"Endoscopic ruler for varices in portal hypertension~Product uses: measuring the diameter of the veins under the endoscopy for the assessment of the risk of variceal haemorrhage in patients with portal hypertension~Black and white measuring rule is highly recognizable under the endoscopy~The width of each cell is 1 mm, and the measuring range is 0-10 mm~With smooth edge, safe and reliable"
45956434|NCT00524719|Procedure|Open Reduction and Internal Fixation|Fixation with volar locked plate
45956435|NCT00524719|Procedure|Non-Spanning External Fixation|Radio-radial external fixation
45956436|NCT00524719|Procedure|Closed Reduction with Percutaneous Fixation|Percutaneous intrafocal pinning (Kapandji technique)
45956437|NCT03817307|Diagnostic Test|USPIO-enhanced MRI|The USPIO contrast agent will be administered intravenously to the subjects. An MRI scan of the neck region is performed 24-36 hours later to detect lymph node metastases.
45956438|NCT02947789|Procedure|Emergency surgery|Patients undergoing emergency surgery
45956439|NCT00167856|Drug|Venalafaxine hydrochloride|Norepinephrine/Serotonin Reuptake Inhibitor (NSRI)
45454728|NCT04791176|Radiation|concurrent lenvatinib and Radiotherapy, followed lenvatinib maintenance|Radiotherapy with IMRT or VMAT with 40-60Gy/20-30f; Concurrent Lenvatinib 12mg/day (for patients≥60 kg) or 8 mg/day (for patients<60kg ) qd po. (Note: Levatinib can be given to patients in four weeks before Radiotherapy is applied, so that it can control disease during waiting for Radiotherapy). Maintenance Lenvatinib 12mg/day (for patients≥60 kg) or 8 mg/day (for patients<60kg ) qd po until disease progress or unacceptable adverse events; six months is recommended but not mandatory.
45956440|NCT04693273|Other|Decision Aid for Surgical Modality Choice|A novel decision aid that helps surgical patients choose between Wide-Awake carpal tunnel release and traditional tourniquet surgery. It involves an orientation-memory-concentration test to test if patients are cognitively capable of making decisions, then the decision aid table that has similarities and differences between the two modalities, and a few survey questions that help the investigators know what the patients prefer. Finally, patients finish the decision conflict test to see how confident these patients are about their preference.
45662167|NCT05232565|Procedure|Percutaneous Transluminal Coronary Angioplasty|Angioplasty intervention of coronary vessels or coronary bypass graft stenosis
45662168|NCT05201911|Drug|124I-AT03|IV injection of the radiolabeled compound on day 1 followed by Positron Emission Tomography/Computed Tomography (PET/CT) scanning on Days 2, 4 and 8 to. The first 3 subjects enrolled will have two additional scans on Day 1.
45956441|NCT00524758|Device|ologen (oculusgen) collagen matrix|Implant ologen collagen matrix on the top of sclera flap after loose stiched the sclera flap. The traditional trabeculectomy is performed.
45956442|NCT00524758|Drug|MMC in Trabeculectomy|MMC in Trabeculectomy
45956443|NCT00526006|Drug|esomeprazole|40 mg od for 8 wks
45956444|NCT04693117|Other|Interval Training|All individual of interventional group participated in an interval training program, which comprised of 3 days/week for twelve weeks. A booklet was given to each participant containing instructions and guideline about interval training. The interval training program was introduced as prescribed previously.17 After the workout, a cool down period of 5 minutes was given during which they perform paddling with low speed. All training program was supervised by a qualified physical therapist.
45956445|NCT03681275|Drug|Tofacitinib 5 mg|administered twice daily for two days
45956446|NCT03681275|Drug|Placebo to match Tofacitinib|administered twice daily for two days
45956447|NCT02947477|Behavioral|EmoTrak|Ecological Momentary Assessment of Emotion through Iphone App
45956448|NCT00167895|Procedure|Adding platelet concentrate to the wound|
45956449|NCT02946346|Other|vaginal sampling|
45956450|NCT03674723|Other|Dietary Intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from Mung beans and 3 levels from Mung beans with rice or wheat.
45662169|NCT05201755|Device|CPAP|Application of PEEP (positive end-expiratory pressure) through a CPAP Helmet with a set PEEP of 10 cmH2O. It is a very well tolerated and noninvasive device commonly used for ventilatory support.
45662170|NCT05159557|Device|In-Home Technology System|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).
45816859|NCT04639206|Behavioral|HOBSCOTCH|HOBSCOTCH (Home Based Self-management and Cognitive Training Changes lives) is a home-based self-management program to treat cognitive symptoms and improve quality of life while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. The HOBSCOTCH intervention consists of 8 weekly sessions conducted in-person, over the telephone, or via video-conferencing. A smart phone application will be used to collect data on seizure frequency, medication adherence, and patient engagement.
45454729|NCT03941119|Other|VR-therapy|Wearing a Virtual Reality head mounted device allows the user to become immersed in a virtual environment. We have assembled a library of 3-10 minute 360-degree films from a variety of nature settings. The VR films were intentionally chosen to be calming in distinctive ways, as supported by the literature around nature visualization and wellbeing. By varying 1) the lengths of the films (3, 5, and 10 minutes), 2) the types of natural elements (greenery, earth, sky, water), 3) distance of view (close-ups, vistas), 4) motion (flowing water, wind in trees), 5) sound, and 6) presence of different elements (humans/animals, scenery, urban sites, etc.), the content provides a wide range of attributes that can be collaboratively selected by the individual, caregiver, or health care provider for each individual. We will display these films on commercially available VR equipment and will provide audio matching the film using commercially available headphones.
45454730|NCT05072600|Drug|Pembrolizumab|pembrolizumab 200 mg Q3W
45454731|NCT04441528|Drug|Lid wipes containing terpinen-4-ol and sodium hyaluronate|Lid wipes will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.
45662171|NCT05159557|Device|Limited In-Home Technology|Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
45662172|NCT05200117|Device|Pregnolia System|The cervical stiffness is measured with the Pregnolia System three times over a two-day period.
45816860|NCT04639180|Drug|Camrelizumab|Subjects receive Camrelizumab intravenously, Dosage form: lyophilized powder
45454732|NCT04441528|Drug|Baby shampoo|Baby will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.
45816861|NCT04639180|Drug|Rivoceranib (Apatinib)|Subjects receive Rivoceranib (Apatinib) orally, Dosage form: tablet
45816862|NCT04633330|Drug|AHCC®capsules|AHCC®capsules, a standardized extract of cultured Lentinula edodes mycelia (ECLM) TID for 6 months after enrolment.
45816863|NCT04633330|Drug|Simulation of AHCC®capsules|TID for 6 months after enrolment. A compensation of AHCC®is provided to participant from control arm when HR-HPV positive at 6 months after enrolment.
45816864|NCT04611698|Device|Baha sound processor BA400|Baha sound processor BA400 is a cochlear implant designed specifically for soft tissue preservation.
45956451|NCT02946814|Drug|essential oils|
45956452|NCT02946814|Drug|essential oils without mouthwash|
45956453|NCT02946814|Drug|sterile water|
45956454|NCT00524797|Dietary Supplement|Profonycia|
45956455|NCT02946619|Behavioral|Self-Regulation Condition|
45956456|NCT02946619|Behavioral|Enhanced self-Regulation Condition|
45662173|NCT05159245|Drug|Alectinib|ALK
45454733|NCT01117675|Other|Virtual Hospital|A new home care model using a telemedicine system (Virtual Hospital) to care chronic HIV-infected patients
45454734|NCT01117675|Other|Standard of Care|Standard of Care
45454735|NCT04440826|Other|Whole Food Meal|Whole foods meal
45662174|NCT05159245|Drug|Cobimetinib|MEK1, MEK2
45662175|NCT05159245|Drug|Vismodegib|Hedgehog
45662176|NCT05159245|Drug|Trastuzumab+Pertuzumab|HER2
45662177|NCT05159245|Drug|Entrectinib|NTRK/ ROS1, ALK
45662178|NCT05159245|Drug|Atezolizumab|PD-L1
45662179|NCT05159245|Drug|Vemurafenib|BRAF V600
45662180|NCT05159245|Drug|Regorafenib|KIT/BRAF, RET
45662181|NCT05159245|Drug|Apalutamide|AR
45662182|NCT05159245|Drug|Abemaciclib|CDK4/6
45662183|NCT05159245|Drug|Selpercatinib|RET
45662184|NCT05159245|Drug|Dabrafenib|RAF
45662185|NCT05159245|Drug|Trametinib|MEK1, MEK2
45662186|NCT05159245|Drug|Dabrafenib+Trametinib|RAF, MEK1, MEK2
45662187|NCT05159245|Drug|Pralsetinib|RET
45662188|NCT04232371|Procedure|New Ablation Technique|Patient will undergo ablation using voltage mapping and triangle of Koch propagation wave collision mapping. Ablation will be performed at or slightly above the site of wave front collision.
45454736|NCT04440826|Other|Processed Food Meal|Processed food meal
45454737|NCT04440826|Other|Gluten-free and lactose-free|Gluten-free and lactose-free food meal
45454738|NCT01117753|Behavioral|OutPatient Treatment for Adolescents (OPT-A)|
45662189|NCT04232371|Procedure|Standard Ablation Technique|Ablation performed using the traditional anatomical / electrogram guided ablation approach.
45662190|NCT05230381|Drug|Continous infusion|The 20mg/kg tranexamic acid will be diluted into a 50ml syringe and infused followed by 5mg/kg/h tranexamic acid infusion.
45816865|NCT04607486|Diagnostic Test|3DfUS and IPSA of leg muscles|"3DfUS technique enhances a conventional 2D US device into a platform capable of reconstructing 3D anatomical data sets.~IPSA for quantification of hyper-resistance and its underlying components. The sensors in the IPSa include gyroscopes and accelerometers to measure joint angle and angular velocity, EMG to measure muscle activity, and a 3 degrees-of freedom force sensor to measure torque applied on the joint.~clinical functional capacity = clinical evaluation of degree of independence, mobility and gait"
45816866|NCT04605913|Combination Product|Modified GCN+TTF treatment|The regimen will consist of gemcitabine (G) administered at a dose of 800 mg/m2, cisplatin (C) 30 mg/m2, and protein-bound paclitaxel (N) 150 mg/m2 administered on cycle 1 day 1 and every 2 weeks thereafter and TTF will be administered daily (150kHz 18 hours/day) starting with Cycle 1 Day 1 (dose level 1). One cycle consists of 28 days including 2 chemotherapy treatments (same regimen studied in the PAXG trial: Reni BJC 2016 without capecitabine). After completing 6 cycles, patients will then transition to a maintenance phase of G administered at a dose of 1000 mg/m2 every 2 weeks and daily TTF (150 KHZ 18 hours/day) until progression of disease (POD) per RECIST v1.1.
45662191|NCT05230381|Drug|Single infusion|The 20mg/kg tranexamic acid will be diluted into a 50ml syringe and infused followed by same volume of 0.9% saline.
45662192|NCT05230381|Drug|Placebo|The 0.9% saline is administered with the same volume at the same speed as the other group.
45662193|NCT05227417|Behavioral|SMS|Weekly text messages that will be sent automatically by a web-based system to participants' cell-phones. Participants will be able to respond and messages will reach the system. The health providers will be in charge to respond (from the web system) to participants who reply asking for support or any other request.
45662194|NCT05157841|Drug|Bupivacaine liposome injectable suspension 266 mg|Sciatic nerve block in the popliteal fossa with EXPAREL 266 mg
45662195|NCT05157841|Drug|Bupivacaine HCl|Sciatic nerve block in the popliteal fossa with Bupivacaine HCl
45662196|NCT05157841|Drug|Bupivacaine liposome injectable suspension 133 mg|Sciatic nerve block in the popliteal fossa with EXPAREL 133 mg
45662197|NCT05198557|Drug|Inebilizumab|Participants will receive IV inebilizumab.
45662198|NCT05198557|Drug|Placebo|Participants will receive IV placebo matched to inebilizumab.
45662199|NCT05198089|Other|Internet-Based Intervention|Use MyInspiration website
45662200|NCT05155891|Device|Embosphere Microspheres|The SOC PAE procedure will be performed by attempting to embolize prostatic arteries of both sides in a single session with 300-500 um Embosphere Microspheres. The microspheres will be mixed with a contrast agent and will be delivered to the arteries supplying the prostate via a microcatheter.
45662201|NCT05155891|Procedure|HoLEP Procedure|The SOC PAE procedure will be performed with the SOC HoLEP as per standard institutional guidelines. The HoLEP procedure involves passing a telescope through the urethra and removing the central part of the prostate gland using a laser.
45662202|NCT05154487|Drug|Alpelisib Pill|Kinase inhibitor
45662203|NCT05154487|Drug|Fulvestrant injection|estrogen receptor agonist
45662204|NCT04241965|Drug|OPC-214870|Tablet(s)
45662205|NCT04241965|Other|Placebo|Tablet(s)
45956457|NCT00524836|Drug|levocetirizine dihydrochloride|
46002831|NCT00549068|Drug|Risedronate Sodium (Actonel)|
46002832|NCT04644198|Biological|Convalescent Plasma Infusion|250 mls of convalescent plasma on day 1 & 2.
46078812|NCT02814266|Other|difficult intubation|Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
45816867|NCT04597710|Genetic|utility of whole genome sequencing (WGS) to aid clinical decision making in patients referred for liver resection|All participants will attend their planned outpatient surgery appointment.The consultant will document the intended treatment plan for each participant in line with their usual care pathway.Following this, participants will be required to attend three dedicated study visits:The results of the MRI scans from Study Visit 1 will be analysed into a LiverMultiScan report.A report will be sent to the consultant who will review their original documented care plan alongside the LiverMultiScan report.The consultant may update the intended care plan as a result of the LiverMultiScan report, in line with the device CE-marking.Any changes to the care plan will be documented.The patient will then undergo their planned treatment.The tumour explant will be collected and samples will be stored, transported and processed for genetic sequencing and digital histopathology.Study Visit 2 will be performed remotely 12 months following their planned treatment,where patient reported outcomes will be collected
45816868|NCT04595435|Procedure|Lumpectomy|Removal of lump/tumor from breast utilizing an approach that saves as much breast as possible.
45662206|NCT04241419|Behavioral|High Intensity Walking|Participants will then undergo a 12 session intervention, with two sessions scheduled per week for six weeks. These will be 45 minute sessions, including 15 minutes of a warm-up and cool-down period as well as 30 minutes of walking. The intervention will include various types of over ground walking and stair work.
45816869|NCT04595435|Radiation|Intraoperative Radiation Therapy|Delivery of low energy radiation therapy directly at surgical site, immediately removal of lump and tissue prior to final surgical closure
45816870|NCT04594694|Drug|Obeticholic acid|5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily
45816871|NCT04594694|Drug|Bezafibrate 200 MG|200 mg IR tablet of Bezafibrate once daily for the remainder of the study
45816872|NCT04594694|Drug|OCA Placebo|One tablet daily for the remainder of the study
45816873|NCT04594694|Drug|Bezafibrate 200 mg Placebo|One tablet daily for the remainder of the study
45816874|NCT04594694|Drug|Bezafibrate 400 MG|400 mg SR tablet of Bezafibrate once daily for the remainder of the study
45816875|NCT04594694|Drug|Bezafibrate 400 mg Placebo|One tablet daily for the remainder of the study
45816876|NCT04594694|Drug|OCA|OCA one tablet will be administered.
45816877|NCT04594694|Drug|Bezafibrate|Bezafibrate one tablet will be administered.
45816878|NCT04589065|Device|Selective Cytopheretic Device|SCD therapy will take place for 4 hours on day 1, 3, and 5 while on hemodialysis treatment. Participants will be continue to be followed until 30 days after the last SCD treatment.
45816879|NCT04585035|Drug|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
45662207|NCT04241029|Dietary Supplement|IDOFORM®Travel|Four capsules IDOFORM®Travel orally every 24 hour (12*10^9 cfu/day) for eight weeks.
45454739|NCT01117753|Behavioral|Treatment As Usual|
45816880|NCT04585035|Drug|Other|Standard treatment of solid tumor, NSCLC or CRC
45816881|NCT04570722|Other|Ipsilateral peripheral IV insertion|Patients with successful ipsilateral intravenous access will be provided a patient education sheet describing signs and symptoms that should be reported to the study team. All participants will be contacted by the study team at twelve week intervals for 12 months after their radiology encounter for completion of symptom assessments. If a subject reports new signs or symptoms of lymphedema during follow-up, a clinic appointment for volumetric measurements and thorough evaluation will occur
45816882|NCT04546360|Procedure|Esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement.|Time frame between elastography measurement and esophagogastroduodendoscopy is within 2 weeks.
45816883|NCT04531943|Drug|Estrogen|Feminizing hormone therapy consisting of estrogen alone, as prescribed by the participant's healthcare provider.
45662208|NCT05154253|Device|Biomotum Spark: Robotic ankle assistance|A lightweight assistive wearable ankle robotic device.
45662209|NCT05154253|Device|Biomotum Spark: Robotic ankle resistance|A lightweight resistive wearable ankle robotic device.
45662210|NCT05154253|Other|Standard gait training|Standard gait training without a device.
45662211|NCT05154253|Device|Ankle foot orthosis|Standard ankle foot orthosis
45662212|NCT05154253|Other|Standard physical therapy|Physical therapy without a device.
45662213|NCT05154253|Other|Standard walking|Walking without a device
45662214|NCT05193643|Device|Sonovein Treatment|The Sonovein System provides High Intensity Focused Ultrasound (HIFU) ablation of soft tissue. The energy is delivered via an extra-corporeal treatment probe, which includes an imaging system. The high-energy ultrasound waves propagate through the skin and are focused on a portion of the target tissue, generating intense heat and causing local cell apoptosis and progressive tissue volume reduction over the following months in the tissue within the focal area. The process is then repeated in a stepwise fashion to destroy the targeted tissues.
46078813|NCT02814266|Other|easy intubation|Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
46078814|NCT04101825|Device|Auralya|Hyaluronic Acid-Dermal Filler
45956458|NCT03660449|Combination Product|Moderately hypofractionated conformal radiation combined With S-1|All patients will receive two cycles of S-1 (40mg/㎡, BID, po) on D1-14, D22-35, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.
45662215|NCT05152927|Device|Parathyroid Eye (PTeye)|Intraoperative Tool
45662216|NCT05225233|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 seconds ramp up/ramp down at the beginning of the session)
45956459|NCT04692883|Procedure|Percutaneous suturing|
45956460|NCT02946307|Device|Restore DEB（dimeter>2.00 mm）|
45816884|NCT04531943|Drug|Estrogen plus Progesterone|Feminizing hormone therapy consisting of estrogen and progesterone, as prescribed by the participant's healthcare provider.
45662217|NCT05225233|Device|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
45662218|NCT05225155|Drug|Enoxaparin|Women with thrombophilia were treated with 40 mg daily of enoxaparin (treated group), initiated on the day of embryo transfer, up to week 36 of gestation
45816885|NCT04530825|Other|Wait-List Control|-Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
45956461|NCT02946307|Device|Resolute DES|
45956462|NCT02946307|Device|Restore DEB（dimeter:2.00 mm）|
45956463|NCT00524875|Drug|Bevacizumab|One dose of bevacizumab (1.25 mg/0.05 cc) one to two weeks before pars plana vitrectomy for diabetic retinopathy
45956464|NCT00524914|Drug|apomorphine|Acute apomorphine subcutaneous 3 mg
45956465|NCT00524914|Drug|placebo|placebo subcutaneous
45956466|NCT02957864|Drug|tenofovir alafenamide|
45956467|NCT02957864|Drug|abacavir|
45956468|NCT00524953|Device|EUMATRON - EN 600 NT|frequency - once a week, starting 4 days after transplantation for four weeks (total of 4 treatments) each treatment will last ~20 minutes. In addition - standard GVHD preventive protocol will be given to patients (including cyclosporine and steroids - if necessary)
45956469|NCT00168012|Drug|Immunoglobulins Intravenous (Human)|
45816886|NCT04530825|Other|PREVENT Tool|-PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese adolescent patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
45956470|NCT02946541|Drug|evogliptin 5mg|evogliptin 5mg, QD
45956471|NCT02946541|Drug|Placebo|Placebo, QD
45662219|NCT05192239|Drug|THC 5|5 milligrams of THC in gummy form
45662220|NCT05192239|Drug|Placebo|Commercially available non-THC fruit snack
45662221|NCT05151835|Device|K2 Robotic Surgical System|The K2 Robotic Surgical System is a software-controlled, electro-mechanical system designed for surgeons to perform minimally invasive surgery in the thorax and abdomen. The K2 Robotic Surgical System consists of a Surgeon Console [SGC], a Patient Side Robot [PSR], and a Vision Cart [VCT], and is used with an endoscope, Surgical Instruments [SGI], and Accessories [ACC]. The surgeon views the three-dimensional endoscopic image on a High-Resolution Stereo Viewer (3D Viewer), which provides a view of the abdominal cavity and surgical instrumentation, along with icons and other user interface features.
45662222|NCT05190679|Other|None/Observational Studies|This is an observational study and there is no intervention.
45662223|NCT05190445|Drug|Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel|HER2/4-1BB
45816887|NCT04522973|Other|Beverage with ethanol and E-cigarette liquid with ethanol|Beverage with ethanol and E-cigarette liquid with ethanol
45956472|NCT00526201|Behavioral|12-weeks EnhanceFitness|EnhanceFitness class for 12 weeks, 3 times per week for 1 hour sessions.
45956473|NCT00526201|Behavioral|Control|Participants randomized to the wait-list control group will continue their regular activities for 12 weeks and then be offered the exercise intervention (EnhanceFitness).
45956474|NCT00525109|Other|No Intervention|No intervention
45956475|NCT03585452|Drug|Dexmedetomidine Infusion|Patients with additional dexmedetomidine infusion
45956476|NCT03585452|Drug|Propofol based general anesthesia|Patients with typical anaesthetic regimens
45956477|NCT02946502|Procedure|Handheld dynamometry (handgrip strength)|Patients will perform handgrip strength dynamometry through holding the device in their dominant hand with the maximum strength, with standardized arm and body positions, as well as incentives
45956478|NCT02947867|Drug|aganirsen|aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)
45956479|NCT02947672|Drug|Intravenous Dexamethasone|
45956480|NCT02947672|Drug|Intraperitoneal Dexamesathone|
45956481|NCT02947555|Other|Non interventional|
45956482|NCT04693546|Diagnostic Test|LifeKit Prevent Colorectal Neoplasia Test|Procedure: Colonoscopy
45956483|NCT04693546|Diagnostic Test|FIT Test|Procedure: Colonoscopy
45956484|NCT02947360|Other|Focused vascular ultrasound of the carotid arteries|Emergency physicians and a trained research sonographer will perform a focused vascular ultrasound of the carotids (FOVUS) in patients presenting to the emergency department with chest pain. The diagnostic test characteristics (sensitivity, sensitivity, negative predictive value, positive predictive value and likelihood ratios) for FOVUS carotid plaque height will be determined in relation to our primary outcome (30-day major adverse cardiac events)
45956485|NCT03539627|Drug|Azilsartan Medoxomil 40 MG Oral Tablet [Edarbi]|patients are to receive azilsartan medoxomil
45956486|NCT02947399|Radiation|Radioactive Iodine 124|After thyroid hormone withdrawal for 3-5 weeks, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
45956487|NCT02946268|Drug|Ropivacaine|Change in administration of ropivacaine. Rate, Volume and Interval of bolus altered.
45956488|NCT00168051|Drug|ReFacto|
45956489|NCT00168051|Drug|Advante|
45956490|NCT00526318|Biological|filgrastim|
45956491|NCT00526318|Drug|carboplatin|
45956492|NCT00526318|Drug|cisplatin|
45956493|NCT00526318|Drug|cyclophosphamide|
45956494|NCT00526318|Drug|dacarbazine|
45956495|NCT00526318|Drug|doxorubicin hydrochloride|
45956496|NCT00526318|Drug|etoposide phosphate|
45956497|NCT00526318|Drug|ifosfamide|
45956498|NCT00526318|Drug|isotretinoin|
45956499|NCT00526318|Drug|melphalan|
45662224|NCT05190445|Drug|Cinrebafusp alfa (PRS-343) in combination with tucatinib|HER2/4-1BB
45816888|NCT04522973|Other|Beverage with ethanol and E-cigarette liquid without ethanol|Beverage with ethanol and E-cigarette liquid without ethanol
45956500|NCT00526318|Drug|topotecan hydrochloride|
45956501|NCT00526318|Drug|vincristine sulfate|
45956502|NCT00526318|Drug|vindesine|
45956503|NCT00526318|Procedure|autologous hematopoietic stem cell transplantation|
45956504|NCT00526318|Radiation|iobenguane I 131|
45956505|NCT00526318|Radiation|radiation therapy|
45956506|NCT00526357|Drug|omega-3 fatty acid|Pharmaceutical grade fish oil administered daily in the form of 10 capsules (5 capsules b.i.d.) each containing 400mg of eicosapentaenoic acid (EPA) and 200mg docosahexanoic acid (DHA) which will equate to a daily dose of 4000 mg of EPA and 2000 mg or DHA. The matched placebo containing a 50/50 mix of soybean and corn oil will be supplied by the same manufacturer (Ocean Nutrition, Canada)
45662225|NCT05189977|Drug|Propranolol|"Propranolol (tablet, oral ): 40 mg QD Day 3 and Day 21~Intervention 1 is a single dose of prazosin administered in the presence of sertraline alone at steady state or in the presence of sertraline + brexpiprazole at steady state."
45662226|NCT05189977|Drug|Prazosin|"Prazosin (tablet, oral): 1 mg QD Day 2 and Day 20~Intervention 2 is a single dose of propranolol administered in the presence of sertraline alone at steady state or in the presence of sertraline + brexpiprazole at steady state."
45956507|NCT03479138|Diagnostic Test|Induced sputum|Characterization with flow cytometry of the phenotype of the neutrophils isolated in the sputum, microbiome
45956508|NCT04693312|Drug|Depo medrol|local injection
45956509|NCT04710381|Drug|IMUNOR|The intervention consists of the administration of IMUNOR as prevention against COVID-19 disease
45956510|NCT00525304|Behavioral|Self-management program for chronic illness|Self-management program for chronic illness will include between 10 and 16 psychoeducational and supportive group sessions.
45662227|NCT05149417|Other|SMS reminding|patients received SMS at day 2 , day 4 and day 7 after emergency departement discharge to remind them to take their treatment .
45662228|NCT05149417|Other|telemonitoring|Patients received a phone call on day 2 and day 4 to evaluate the adherence , to detect any problem that can affect the adherence to the treatment and modify the analgesic protocol treatment if needed.
45816889|NCT04522973|Other|Beverage without ethanol and E-cigarette liquid with ethanol|Beverage without ethanol and E-cigarette liquid with ethanol
45816890|NCT04522973|Other|Beverage without ethanol and E-cigarette liquid without ethanol|Beverage without ethanol and E-cigarette liquid without ethanol
45816891|NCT04520048|Procedure|Laser Doppler coupled with acetylcholine iontophoresis|Endothelium-dependent vasodilation measured by Laser-Doppler flowmetry coupled with transdermal administration of acetylcholine by iontophoresis
45816892|NCT04520048|Procedure|Aortic central pressure and the carotid-femoral pulse wave velocity|Measurement of the aortic central arterial pressure (systolic and diastolic arterial pressure) by applanation tonometry, and the index of aortic increase by applanation tonometry, the carotid-femoral pulse wave velocity using the SphygmoCor® system (PWV Medical)
45956511|NCT04692571|Device|PSICON Measurement Apparatus|Test apparatus acquires 16 sEMG channels, measure four DoFs of force/moment at the hand-wrist [hand open-close (Opn-Cls); wrist extension-flexion (Ext-Flx), radial-ulnar deviation (Rad-Uln) and pronation-supination (Pro-Sup)]. sEMG system used 16 custom encased bipolar electrodes. A commercial LTI EMG amplifier (BE328) conditioned each EMG signal before A/D conversion on a PC. A thermoplastic hand cuff secured the wrist to a six-axis load cell (AMTI, model MC3A-100) for force/moment measurement. A separate hand-grasp one-axis load cell (Omega Engineering Inc., model LCR-150) was Velcro-secured between the fingers and the thumb, to measure power grip forces. The PC acquired and stored the sEMG and load cell data, and commanded a triangular screen target. The subject controlled a second triangular cursor. Left-right movement of the cursor was controlled by wrist Ext-Flx, up-down movement by Rad-Uln deviation, cursor rotation by Pro-Sup and cursor size by hand Opn-Cls forces.
45956512|NCT03458312|Behavioral|Family and Network Consultations|"Family and Network Consultation' (FNC) seek to identify and address patients' symptoms/concerns and caregiver burden on one side and identify the resources and opportunities to ease their burdens on the other side.~Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns."
45956513|NCT00526435|Behavioral|Walk with Ease - Group|Participate in 6-week, 1 hour per week group assisted classes (with instructor).
45956514|NCT00526435|Behavioral|Walk with Ease - Self|SUbject will receive the WWE workbook and follow it without group/instructor assistance.
45956515|NCT00168090|Drug|Blood coagulation Factor VIII and vWF, human|
45956516|NCT00525382|Drug|levocetirizine dihydrochloride|
45956517|NCT04692805|Device|coils|EUS-guided injection of coils
45956518|NCT04692805|Drug|cyanoacrylate glue|EUS-guided injection of cyanoacrylate glue
45956519|NCT00526513|Drug|Insulin Glulisine|subcutaneous injection of insulin glulisine at meal, 1 to 3 injections a day based on the condition of the patient in addition to a basal SC insulin injection at bedtime
45956520|NCT03432299|Procedure|RFA for PTMC|Radiofequency ablation for papillary thyroid microcarcinoma will be performed using the system including radiofrequency generator and internally cooled electrode.
45956521|NCT00525460|Behavioral|Fertility-Sparing Survey|A questionnaire completed either in the clinic or at home
45956522|NCT00525538|Radiation|conformal radiotherapy|
45956523|NCT00168129|Procedure|Helical tomotherapy|
45956524|NCT02946151|Device|UNEEG implantable EEG electrode and data storage device|The implantable EEG electrode will be implanted subcutaneously in the relevant temporal region by a certified neurosurgeon. The EEGgraphical data recorded will be transmitted transcutaneously to the data storage device via an inductive link, providing continuous data on brain activity.
45956525|NCT02946190|Biological|Pertagen® aP + Td-pur®|see arm/group descriptions
45956526|NCT02946190|Biological|Boostrix® dTpa|see arm/group descriptions
45956527|NCT03346694|Device|Standard Island Dressing|participant randomized to control group before end of surgery to be applied on cardiovascular heart surgical sternal incision.
45956528|NCT03346694|Device|Prevena Negative Pressure wound dressing|participant randomized to dressing before end of surgery to be applied on cardiovascular heart surgical sternal incision.
45956529|NCT03346694|Device|Mepilex Border Post-Op Ag|Participant randomized to dressing before end of surgery to be applied on cardiovascular heart surgical sternal incision
46078815|NCT04314414|Other|PRC brief motivational interview intervention|The intervention will involve the following elements: establishing rapport, asking permission to discuss drugs, discussing the pros and cons associated with drug use, uncovering the gaps between current and desired quality of life and determining readiness to change. The intervention will last approximately 20 minutes and take place at the time of the clinical visit while participants are waiting to be seen by a clinician or are awaiting laboratory testing.
45816893|NCT04520048|Other|Vascular biomarker assay|Plasma biomarker levels determination using an immunoassay, including circulating sFlt-1, circulating PIGF, sFlt-1 / PIGF ratio, circulating VEGF, circulating soluble endoglin (sEng), anti-angiotensin II receptor (AT1), circulating copeptin, circulating interleukin 17 (IL-17). Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) quantification as well as the urinary endothelial microparticules measurements using flow cytometry
45454740|NCT05251792|Other|Ocular examination|All participants underwent a detailed examination, including visual acuity, slit lamp biomicroscopy, direct ophthalmoscopy, optometry noncontact tonometry,MPOD measurement and optical coherence tomography (OCT) measurement
45454741|NCT01344512|Drug|Ceftazidime|Bloods sampling on patient treated with Ceftazidime between 48 hours and 4 days after beginning of treatment.
45662229|NCT05188807|Diagnostic Test|Airway ultrasonography|we will measure hyomental distance, skin-epiglottis distance, skin-hyoid distance, epiglottis-vocalcords distance
45454742|NCT01344512|Drug|Ciprofloxacin|Bloods sampling on patient treated with Ciprofloxacin between 48 hours and 4 days after beginning of treatment.
45454743|NCT01344512|Drug|Voriconazole|Bloods sampling on patient treated with Voriconazole between 48 hours and 4 days after beginning of treatment.
45662230|NCT05148949|Biological|Standard dosage inactivated vaccine|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research & Development Co., Ltd. 0.5 ml / bottle.
45662231|NCT05148949|Biological|Double dosage inactivated vaccine|This vaccine contains 1200 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research & Development Co., Ltd. 0.5 ml / bottle.
45662232|NCT04422067|Other|Fetal cephalometry|Fetal cephalometry
45662233|NCT05219851|Radiation|Cancer patients underwent thoracic intensity-modulated radiotherapy|Cancer patients underwent thoracic intensity-modulated radiotherapy, previously received ICIs
45662234|NCT04422301|Other|Blood flow restriction|an alternative method to produce strength and muscle hypertrophy with lower intensities
45662235|NCT05188261|Drug|IW-3300|A single dose of IW-3300 administered rectally (as a low-volume [20 mL] enema) following a fast of at least 6 hours.
45662236|NCT05188261|Drug|Placebo|A single dose of placebo administered rectally (as a low-volume [20 mL] enema) following a fast of at least 6 hours.
45816894|NCT04517565|Diagnostic Test|Brain magnetic resonance imaging|Brain magnetic resonance imaging (MRI) will be done using multiple sequences to evaluate presence, type and severity of brain abnormalities in enrolled subjects.
45662237|NCT05107999|Drug|Zhizhu Kuanzhong capsules (ZZKZ)|FD patients were treated with ZZKZ and omeprazole for 4 weeks.
45662238|NCT05107999|Drug|Doxepin Hydrochloride (Doxepin)|FD patients were treated with doxepin and omeprazole for 4 weeks.
45816895|NCT04517565|Behavioral|Neuro-psychology testing|Participants will undergo age-appropriate neuro-psychology testing to assess motor, language and other neuro-cognitive functions potentially affected by Sturge-Weber syndrome.
45816896|NCT04516850|Genetic|Expression of receptors and activating proteases|Level of expression of the mRNA of the genes encoding ACE2, TMPRSS2, TMPRSS4 and AR along with reference genes (beta-actin and EPCAM) in nasopharyngeal swabs taken from patients tested for COVID-19
45816897|NCT04516850|Genetic|Polymorphism of the HSD3B1|Formalin-fixed paraffin embedded tissue blocks will be amplified using polymerase chain reaction (PCR) based experiments followed by direct sequencing (Sanger sequencing)
45956530|NCT02945995|Procedure|hip arthroscopy|Follow up after hip arthroscopy in pt with previous PAO. Follow up by questionnaires send til the cohort
45956531|NCT00168168|Drug|G-CSF/Filgrastim|
45956532|NCT02945761|Procedure|High concentration of sugar solution|
45956533|NCT02945761|Procedure|conventional surgical dressing change|
45956534|NCT02945683|Dietary Supplement|Reuterin D3|Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide
45956535|NCT02945683|Dietary Supplement|Placebo|sunflower oil, medium chain triglycerides, silicon dioxide
45956536|NCT02947321|Procedure|Genicular Nerve RFA|Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. RFA probes will be placed and connected to the RFA generator and the generator is activated. The RFA is performed.
45956537|NCT02947321|Procedure|Sham Genicular Nerve RFA|Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. The RFA probes for the control group will not be connected to the RFA generator (no neurotomy); however, the generator will still be activated to mimic the RFA group.
45662239|NCT05146921|Dietary Supplement|Multi-strain probiotic|"The intervention in this study is a multi-strain probiotic which contains four live strains of bacteria:~Lacticaseibacillus rhamnosus NCIMB 30174 Enterococcus faecium NCIMB 30176 Lactobacillus acidophilus NCIMB 30175 Lactiplantibacillus plantarum NCIMB 30173~10 billion colony-forming units (CFU) per 70 ml cup"
45956538|NCT02947009|Behavioral|Diagnostic Study|Participants will undergo laryngoscopy at baseline and with exercise challenge and will rate severity of various symptoms related to the larynx (ex. shortness of breath, voice changes, cough).
45662240|NCT05146921|Other|Placebo|placebo similar in appearance and taste to the active intervention but with no active bacteria
45956539|NCT02947204|Other|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. Vital signs will be completed every 4 hours.
45956540|NCT02947204|Other|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Vital signs will be completed every 4 hours.
45956541|NCT03225755|Drug|Growth hormone|Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
45956542|NCT00526786|Device|CryoSpray Ablation System (510(k) NO: K070893)|no drug interventions specified
46078816|NCT04314414|Other|Phone contact|The PRC will remain in at least weekly contact by phone with each participant.
46078817|NCT02815046|Drug|Botulinum toxin type A|Intravesical injections of Botulinum toxin A (Botox) into the bladder wall.
46078818|NCT02815046|Device|Polyacrylamide hydrogel|Midurethral injections of the bulking Agent Bulkamid into the submucosal tissues of the urethra.
46078819|NCT04014517|Other|Standard of Care|Standard of Care is represented by the best standard peri-operative treatment already planned for the study population: as for ERAS guidelines, it is represented by fast restoration of liquid and solid diet after surgery (approximately 24 hours after surgery) and pre-operative and post-operative dietary counselling whenever indicated by the surgeon or gastroenterologist
45816898|NCT04515004|Drug|leucoselect phytosome|A standardized grape seed procyanidin extract complexed with soy phospholipid.
46078820|NCT04014517|Dietary Supplement|Immunonutrition|Impact. Patients will be asked to consume 3 cartons/day of Nestle IMPACT for pre-operative 7 days and 1 carton/day of Nestle IMPACT for post-operative 30 days
45454744|NCT03941197|Behavioral|Ready and Healthy for Kindergarten Family Literacy program|Participants will participate in 8 parent-child health-themed literacy workshops. Participants will receive 2-3 text messages per week for 8 weeks.
45454745|NCT03527368|Behavioral|Time-restricted feeding|Participants consume food earlier in the day
45662241|NCT05186545|Drug|surufatinib + fulvestrant + chidamide|surufatinib: 250 mg/d, QD PO; Fulvestrant: 500mg, im, Q4W; Chidamide 30mg, PO, BIW; Q4W
45662242|NCT05107765|Drug|Pioglitazone|For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by end of week 1, which is within standard titration parameters as per the investigator's brochure.
45662243|NCT05107765|Drug|Placebo|Pill capsules will look same as that of active drug.
45956543|NCT00525577|Drug|Placebo|Placebo tablet, once daily
45956544|NCT00525577|Drug|AGI-1067|75 mg AGI-1067 tablet, once daily
45956545|NCT00525577|Drug|AGI-1067|150 mg AGI-1067 Tablet, once daily
45956546|NCT00407238|Device|Multi-purpose solutions (polyquaternium-1 and PHMB)|
45662244|NCT05185999|Drug|Icodextrin/Dextrose|Single 8 hour dwell of a 500mL intraperitoneal sodium-free 30% Icodextrin / 10% Dextrose solution
45816899|NCT04505774|Drug|theraputic heparin|increased dose of heparin above standard of care.
45816900|NCT04505774|Drug|prophylactic heparin|standard of care dose of heparin
45816901|NCT04505774|Drug|P2Y12|added P2Y12 inhibitor
46078821|NCT02601963|Drug|FMX-103 1.5%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
46078822|NCT02601963|Drug|FMX-103 3%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
45454746|NCT03527368|Behavioral|Usual feeding pattern|Participants consume food later in the day
45454747|NCT05064488|Drug|Evobrutinib|Participants will receive evobrutinib film-coated tablet, twice daily under fed conditions from Days 4 to 12 in Part 1 and from Days 2 to 8 in Part 2 of the study.
45662245|NCT05146141|Other|Bent-arm throw exercises|The participants will have to perform bent-arm throw exercises 5 minutes before each training session
45662246|NCT05144971|Diagnostic Test|Glucose, Creatinine|Compare diagnostic tests to reference methods
45816902|NCT04505774|Drug|Crizanlizumab Injection|crizanlizumab injection
45816903|NCT04505774|Drug|SGLT2 inhibitor|sglt2 inhibitor
45816904|NCT04504383|Drug|PN-943|Administered by the oral route BID for the duration of the study.
45816905|NCT04504383|Drug|Placebo|Administered by the oral route BID for 12 weeks.
45956547|NCT03186755|Drug|Hyaluronic acid 0.05% & Ectoine 2.0%|Treatment of 1 drop three times a day in both eyes for 8 weeks
45956548|NCT03186755|Drug|Olopatadine hydrochloride ophthalmic solution 0.1%|Treatment of 1 drop two times a day in both eyes for 8 weeks
45956549|NCT00525616|Drug|Mabthera|Two IV perfusions of 1000mg at 15 days intervals
45956550|NCT00525655|Behavioral|Web-Based Multimedia Intervention|Website designed to offer information and support for adolescents and young adults with FAP, viewed for 30-60 minutes.
45956551|NCT00525655|Behavioral|Questionnaire|Questionnaires taking 10-15 minutes to complete.
45956552|NCT00525694|Other|Glucose tolerance test|10 ounces glucose tolerance test solution
45956553|NCT00525694|Other|glucose tolerance test solution|75 grams glucose load
45956554|NCT00525694|Other|Diet Coke|10 ounces of Diet Coke
45956555|NCT00525694|Other|Coke Zero|10 ounces of Coke Zero
45956556|NCT00526903|Behavioral|Elimination Diet|Daily diet change for 8 days.
45956557|NCT00405470|Device|Advance Medial Pivot Knee Arthroplasty|medial pivot total knee arthroplasty tibial component vs standard posterior stabilized tibial component with post. Medial pivot provides a constrained medial condyle through shape of polyethylene and reduces amount of bone removal on femoral side that would otherwise be removed to accommodate PS post
45454748|NCT05064488|Drug|Digoxin|Participants will receive digoxin tablet under fed conditions, once a day on Day 1 and Day 10 in Part 1.
45662247|NCT05106985|Device|ApplTree reminder app|The reminder app will be introduced to participants to support adherence to chosen goal-related tasks. Reminder app will be introduced following a baseline phase of 10, 16 or 22 days. The duration of the baseline phase will be randomly assigned using an online random number generator.
45662248|NCT04421833|Behavioral|TOVERTAFEL|"The TOVERTAFEL is a small box that can be attached to the ceiling. Inside the box is a high-quality projector, infrared sensors, a speaker, and a processor that work together to project games onto the table. Because the colored objects respond to the movements of the hands and arms, the residents can play with the light itself.~The planned activities provide cognitive, social and physical stimulation through light projections and can all be used individually or in groups with the presence of a caregiver or facilitator. Sixteen play activities are offered."
45662249|NCT04421833|Behavioral|USUAL activities|"patients can participate in cooking workshops, cinema activities (screening of old films or documentaries on a large screen, in a cozy atmosphere), walks in the garden and the visit of a dog trained in assisted therapy by the animal."
45662250|NCT05106283|Procedure|Deep block and Combined Block|Deep serratus anterior block and combined deep and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
45662251|NCT05106127|Drug|EG-007|A Repurposed Drug
45662252|NCT05106127|Drug|Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection|Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.
45662253|NCT05106127|Drug|Lenvatinib Capsules|Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropylcellulose, and talc.
45956558|NCT00173472|Drug|Chemotherapy|
45956559|NCT00526942|Behavioral|SAAGE-designed, visual memory-based cognitive training|Training sessions take 40 minutes per day, five days per week for a total goal of 15, 40-minute sessions.
45956560|NCT02947243|Device|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the burn site, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, will be adapted for children and tailored to minimize cyber sickness.
46078823|NCT02601963|Drug|Vehicle foam (0%)|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
46078824|NCT00927979|Drug|10 mLRopivacaine 1%|Intraperitoneal nebulization of 10 mL Ropivacaine 1%
46078825|NCT00927979|Drug|Water for injection|Intraperitoneal nebulization of 10 mL water for injection
46078826|NCT00927979|Drug|10 mL Ropivacaine 1%|Intraperitoneal nebulization of 10 mL Ropivacaine 1%
46078827|NCT03285438|Drug|Reduced dose of DOAC|The patient will receive apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily during a mean follow-up period of 24 months (12 to 48 months)
46078828|NCT03285438|Drug|Full dose of DOAC|The patient will receive apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily during a mean follow-up period of 24 months (12 to 48 months)
46078829|NCT00931957|Drug|Etanercept, Methotrexate, Prednisolone|"In: Arm A, Etanercept-MTX-Prednisolone:~Etanercept 50 mg weekly (subcutaneous injection) for 12 months. Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses.~In Arm B:~Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses."
46078830|NCT00924157|Dietary Supplement|IPP|Protein hydrolysate rich in lacto-tripeptide (IPP) up to 5 to 15 mg/day
46078831|NCT00924157|Other|Placebo|Matching placebo capsules
46078832|NCT04014985|Other|An extensive biological assessment|To study the morphology of red blood cells, the markers of oxidative stress and the signaling pathway of IFGF1.
46078833|NCT02731950|Drug|Magnesium Sulfate and Bupivacaine 0.125%|Each patient will receive bupivacaine 0.125% with 5% magnesium sulphate by infusion through a catheter used for epidural analgesia, positioned presternal.
45454749|NCT05064488|Drug|Metformin|Participants will receive metformin oral solution under fed conditions, once a day on Day 1 and Day 10 in Part 1.
45454750|NCT05064488|Drug|Rosuvastatin|Participants will receive rosuvastatin tablet under fed conditions, once a day on Day 1 and Day 10 in Part 1.
45956561|NCT02947243|Drug|Morphine|As per unit's protocol
46078834|NCT00773253|Drug|Botulinum toxin A|All patients will be treated with Botox using both single-channel and multi-channel EMG mapping.
46078835|NCT00928213|Drug|Progesterone|40 units daily admission
46078836|NCT00928213|Drug|Low molecular weight Heparin|40-80 mg/day
46078837|NCT00928213|Drug|No Drug|no treatment
46078838|NCT02731872|Device|Airvo humidifier|"The Airvo humidifier has adjustable flow settings for delivery of fully saturated breathing gases at 37 °C, 100% humidity.~Flow rates are adjustable between 15 and 45 l/min. Ambient air is drawn in by a low-capacity motor. When coupled to a medical oxygen supply, the regulation of delivered oxygen concentration is ensured."
45454751|NCT05064488|Drug|Sumatriptan|Participants will receive sumatriptan tablet under fed conditions, once a day on Day 1 and Day 8 in Part 2.
45662254|NCT05184205|Device|Nasal Photodisinfection|The procedure is initiated by swabbing the Formulation Applicator, pre-saturated with photosensitizer formulation, inside the patient's nares. The operator then connects the Nasal Light Illuminator (NLI) to the Light Source and inserts the NLIs into the patient's nostrils. The Light Source is turned on, and a 4-minute illumination cycle provides two channels of diffused red light (one for each nostril) to activate the applied formulation. Illumination stops automatically upon completion of the 4-minute cycle. The process is then repeated using two new Formulation Applicators to ensure full disinfection coverage.
45662255|NCT05184205|Device|Sham Comparator: Control|Patients who are SARS-CoV-2 positive whose PCR levels are followed but no active intervention will be done. Saline will be used in their nose and the light device will be inserted but not turned on. Patient will be wearing light protecting glasses.
45816906|NCT04503460|Drug|Salmeterol Xinafoate|All participants will receive inhaled salmeterol xinafoate 50 μg twice in the morning and twice in the evening for 2 weeks; this will be followed by a 2-week washout period during which time no beta-agonists will be administered. Participants will be asked to use 'as required' ipratropium bromide during this period when needed in place of short-acting beta agonists.
45816907|NCT04503460|Drug|Salmeterol Fluticasone|Following the 2-week washout period, all participants will receive inhaled salmeterol xinafoate 50 μg combined with fluticasone propionate 250 μg twice in the morning and twice in the evening for 2 weeks. Participants will be asked to use 'as required' ipratropium bromide during this period when needed in place of short-acting beta agonists.
45956562|NCT02947282|Other|Educational Workshop|They will attend a 2 hour class on pelvic floor health
45956563|NCT04693000|Drug|Arsenic Keratosis lesion or nodular size observation after 12 weeks of therapy with solasodine ointment|An ointment containing solasodine extract of solanum melongena peel origin applied to patients with palmar arsenical keratosis; dose-twice daily for 12 weeks.Keratotic nodular size observation after 12 weeks
45956564|NCT00173511|Device|24 hr Holter monitor|
45956565|NCT03177863|Procedure|Expectancy|Clinical monitoring. See arm description
45956566|NCT02946970|Other|Quinine hydrochloride|Intragastric administration of a bitter tastant agonist (10 μmol/kg quinine-hydrochloride)
45956567|NCT02946970|Other|Control|Intragastric administration of distilled water
45956568|NCT04692727|Other|Exercise program|"Hamstring, quadriceps, gastrocnemius, iliopsoas, iliotibial band (ITB), lateral and medial retinaculum stretching exercises~Isometric exercises of vastus medialis, gluteus medius and external rotators~Isotonic exercises of vastus medialis, gluteus medius and external rotators~Closed kinetic chain exercises~Balance and coordination exercises~Core stabilization exercises"
45956569|NCT04692727|Other|McConnel patellar taping technique|Individuals are placed in a supine position with their knees extended and the quadriceps relaxed. A 5 cm wide hypoallergenic band is applied transversely over the patella without affecting the position of the patella. Then, it is started at the lateral edge of the patella with a rigid tape. The tape is terminated at the medial femoral condyle after a medial pull and / or medial tilt to the patella.
46078839|NCT00924391|Dietary Supplement|phytosterol enhanced soy based beverage|
45816908|NCT04500977|Behavioral|leadership empowerment|In the leadership program, women were taught more about the manner in which to bring about a change in one's health by adapting a healthy life style, leadership and facilitation skills and the development, implementation and evaluation process required to conduct a community program that will impact society. Women learned how to map needs and resources, define goals and objectives, develop, implement and evaluate a community based program.
45816909|NCT04489212|Other|Medical Chart Review|Review of medical chart
45662256|NCT05183737|Dietary Supplement|Microcapsules with turmeric and propolis|Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis, twice a day for 12 weeks
45662257|NCT05144347|Drug|XL114|Tablets of XL114
45816910|NCT04489212|Other|Patient Observation|Undergo observation
45816911|NCT04489212|Other|Quality-of-Life Assessment|Ancillary studies
45816912|NCT04489212|Other|Questionnaire Administration|Ancillary studies
45956570|NCT04692727|Other|Femoral rotational taping technique|This technique is applied in a standing position and hip extreme external rotation. Taping is started on the vastus medialis and is pulled diagonally from the anterior of the leg to the lateral and ends on the trochanter major.
45956571|NCT00526981|Other|Prone position|Prone position during spontaneous breathing.
45956572|NCT00527020|Drug|GSK1018921|GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.
45956573|NCT00527020|Drug|Nicotine Lozenges|Nicotine Lozenges will be supplied as 4 milligrams lozenges.
45956574|NCT00527020|Drug|Placebo|Placebo tablets will be given to the subjects.
45956575|NCT00407277|Drug|Nicotine patch|21 mg of nicotine via a dermal patch
45956576|NCT00407277|Other|placebo|placebo via a dermal patch
46002833|NCT04643730|Other|Acupressure methods|Acupressure on the KI3 and St36 points applied to the babies in the acupressure group for a total of 7 minutes before the heel prick
46078840|NCT00924391|Dietary Supplement|1% milk|
46078841|NCT02731794|Device|left ventricular assist|In left ventricular assist group, 100 IU/kg heparin was given to activated clotting time (ACT) greater than 180 seconds. A 22 French arterial cannula (Maquet, Irrlingen, Germany) was introduced into the ascending aorta, and a 26 French cannula (Eurosets, Medolla, Italy) into the left atrium and advanced into the left ventricle. The two cannulas are directly connected through a short, heparin-coated circuit to a centrifuge pump (Maquet, Getinge Group, Germany). A flow of 1.0 to 4.0 L/min/m2 is obtained and mean blood pressure was maintained 55-75 mm Hg. Note: Both LVA group and BiVA group have the operative protocols itself,includes different prime fluid and cannula pathway. The investigators think it is inapplicable to assign the different operative protocols to the Treatment Arm.
46078842|NCT02731794|Procedure|Biventricular assist|In biventricular assist group, the patients were routinely heparinized with a dose of 300 IU/kg heparin to ACT greater than 480 seconds. Cardiopulmonary bypass with a centrifuge pump (Maquet, Getinge Group, Germany) was established by 22 French aortic cannulation and 34 French two-stage venous cannula through the right atrial appendage. The extracorporeal circuit was primed with 2000 mL of lactated Ringer's solution, albumin, 25% mannitol and 5% NaHCO3. The flow was 1.0 to 4.0 L/min/m2 and mean blood pressure was maintained 55-75 mm Hg.
46078843|NCT00928291|Other|procalcitonin|plasma PCT measurement
46078844|NCT00928291|Drug|antibiotic therapy|antibiotic therapy use
45454752|NCT01115023|Other|iron cooking pot|the mother was instructed to cook the family food in the iron cooking pot for the study period (60 days) as frequently in the day as possible.
45454753|NCT03527290|Behavioral|Time Restricted Eating|The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts related to circadian rhythms, metabolism and TRE; and the evidence demonstrating benefit of TRE in animal models and humans. The goal is provide rationale for the potential benefits of a TRE approach. In addition, the RD sessions focus on developing a plan for successfully implementing a TRE approach, identifying challenges for adherence, and a plan for dealing with real or potential challenges. The counseling is focused the TRE concept, with no specific direction or counseling related to modifying the content of the participant's diet or any prescription to reduce energy intake.
46078845|NCT02736240|Biological|7-valent pneumococcal conjugate vaccine|
45454754|NCT03527290|Behavioral|Standard Cardiometabolic Health Diet|The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts and known benefits related to eating a diet for cardiometabolic health and weight management recommended by the American Heart Association and the Academy of Nutrition and Dietetics as a standard of practice for dietitians in healthcare settings. The RD sessions focus on adopting a dietary pattern aligned with this approach, identifying challenges to adopting this dietary pattern, and education and plans for dealing with real or potential challenges. The counseling gives no direction related to modifying the timing of dietary intake or any prescription to reduce energy intake.
45454755|NCT01344590|Other|Normal Saline|Standard saline procedure will be utilized.
45454756|NCT01344590|Other|Ethanol 70% pharmaceutical grade|70% pharmaceutical grade ethanol will be instilled in the line in a volume calculated to fill the lumen and the hub.
45662258|NCT05183581|Device|Feeling Hot sensor system|The Feeling Hot sensor system consists of two temperature probes placed on the penis and outer thigh of the test subject to measure skin temperature during erection.
45662259|NCT05144191|Device|Insignia uncemented Hip Stem|Device: Replacement of arthritic hip with Insignia uncemented Hip Stem
46078846|NCT02736240|Biological|13-valent pneumococcal polysaccharide conjugate vaccine|
45662260|NCT05183347|Drug|BI 1291583|BI 1291583
45662261|NCT05183347|Drug|Placebo|Placebo
45662262|NCT05183113|Other|Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and alternate between breathing 9% O2 gas mixture for up to 1 minute, or until the target SpO2 of 85 percent is reached, and normal room air (21 percent O2) until 2 minutes are complete. This cycle will be repeated 15 times, resulting in a 30-minute protocol.
45662263|NCT05182411|Other|assessment|Turkish version of Leg Activity Measure Rivearmead Mobility Index Nottingham Health Profile Functional Independence Measures
45816913|NCT04486573|Diagnostic Test|Cardiac Magnetic Resonance Imaging|A cardiac MRI is a painless imaging test that uses radiowaves, magnets, and a computer to create detailed pictures of the heart.
45816914|NCT04465240|Other|Virtual reality|Participants are immersed in a neighborhood environment in virtual reality
45816915|NCT04460326|Drug|Insulin glargine|Insulin glargine doses will be determined by calculating the total daily dose (TDD) of insulin and providing 50% of the TDD as follows: start at 0.5 units/kg/day and subtract 0.1 unit/kg/day for 70+ yrs of age, renal insufficiency, pancreatic deficiency and add 0.1 unit/kg/day if hemoglobin A1c in >10%
46078847|NCT00924547|Dietary Supplement|Docosahexanoic Acid Supplement|"The active treatment will consist of Martek's chewable DHA capsules containing 200mg in each capsule. The treatment will be provided as approximately 25mg/kg/day and 35mg/kg/day.~These dosages will be divided BID-TID and will be given for 4 weeks."
46078848|NCT00924547|Dietary Supplement|Placebo|Placebo identical to active treatment.
46078849|NCT02736162|Other|No treatment (intervention) was administered|
45662264|NCT05102851|Diagnostic Test|Troponin, Lipid profile, HBA1C, Fasting blood glucose level, Creatinine, Body Mass Index|Full history: age, sex, smoking, known diabetes, positive family history high serum creatinine, history of prior percutaneous coronary intervention (PCI) or coronary arteries bypass grafting (CABG), or acute coronary syndrome (ACS). hypertension, diet.
45662265|NCT01656967|Device|AMBU Aura-I/aScope 2|Once ventilation is achieved, the patients in group A will be intubated through the shaft of Aura-I via the the Ambu aScope.
45662266|NCT01656967|Device|LMA Fastrach Single Use|The patients in group B will be intubated by ETT via the Intubating LMA as is standard procedure.
45662267|NCT05102617|Device|PicoSure Pro Device|This device will be used for up to 4 treatments over the designated areas.
45816916|NCT04460326|Drug|NovoLog|Novolog will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor.
45956577|NCT00407277|Behavioral|smoking cessation group therapy|"a 9-week group based on the Freedom From Smoking program designed by the American Lung Association. The treatment was manualized and modified to meet the functional and cognitive capabilities of patients with psychotic disorders"
45816917|NCT04460326|Drug|Insulin Fiasp|Fiasp will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor.
45956578|NCT00527059|Drug|Levosimendan in addition to standard therapy|intravenous infusion of levosimendan (10 minutes bolus with 6 mcg/Kg according to physician judgement, followed by 0.1 mcg/Kg/min for 24 hours) in addition to standard therapy
45956579|NCT00527059|Drug|spironolactone, beta-blockers,ecc|
45956580|NCT04693078|Device|AI polyp detection system based on deep learning|A Polyp detection system based on deep learning and artificial intelligence, which can alert the operator in real-time to the presence and location of polyps during a colonoscopy.
45956581|NCT00173550|Procedure|Hysterectomy and Bilateral salpingo-oophorectomy|
45662268|NCT05102617|Device|PicoSure Device|This device will be used for up to 4 treatments over the designated areas.
45662269|NCT05102617|Drug|Topical Cosmeceuticals|Topical cosmeceuticals, such as a hydrating serum or cream, will be applied on the designated area.
45662270|NCT05180539|Behavioral|SPLASH Intervention Condition|Two-session in person group discussions focusing on behaviors in drinking contexts
45662271|NCT05180539|Behavioral|Control Condition|Two-session in person group discussions focusing on college health behaviors
45662272|NCT05100589|Dietary Supplement|PeakATP|Powder - 400mg Peak ATP, maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum
45662273|NCT05100589|Dietary Supplement|Placebo|Powder - maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum
45662274|NCT05100355|Procedure|Physiological serum injection|In case of lack of CVC blood return, Physiological serum is injected in the CVC after Chest X-Ray
45662275|NCT05100355|Procedure|Contrast agent injection|In case of lack of CVC blood return, Contrast agent is injected in the CVC after Chest X-Ray
45662276|NCT05142397|Procedure|Focused Ultrasound|Focused ultrasound generates heat effects, mechanical effects and cavitation effects that denature the diseased tissues, facilitate necrosis and allow them to be replaced by surrounding normal healthy tissues.
45816918|NCT04460326|Other|Standard carbohydrate diet|Standard carbohydrate diet as per usual hospital care (75g with each meal)
45956582|NCT03156452|Drug|Mycophenolate Mofetil|500 mg and 250mg tablets for oral administration
45956583|NCT03156452|Drug|Prednisolone|5mg tablets for oral administration
45956584|NCT00525772|Drug|ciclesonide|low dose- 50ug and 200ug
45662277|NCT05142007|Behavioral|Hypnosis|A number of steps are taken to make the treatment arms identical in all other respects. The participants are unaware that there are two treatment arms to homogenize expectations. Each session is a manualized hypnosis script which is dictated by the hypnotist, including the hypnosis test. The only degrees of freedom for the hypnotist is in intonation and speed. Identical induction and termination is used in both arms and the scripts are of comparable durations.
45956585|NCT00525772|Drug|ciclesonide|high dose- 100ug and 400ug
45956586|NCT00525811|Other|patient dialogue|Information on shared decision making, how to participate in medical decision making, information on acute low back pain, information on depression
45956587|NCT00525811|Other|patient information|Information on acute low back pain, information on depression
45956588|NCT00525850|Other|high fat diet|high saturated fat no starch diet
45956589|NCT00525850|Other|low saturated fat diet|low calorie low saturated fat low trans fat high fiber diet
45662278|NCT05142007|Behavioral|Mindfulness-based stress reduction|A number of steps are taken to make the treatment arms identical in all other respects. The participants are unaware that there are two treatment arms to homogenize expectations. Each session is a manualized hypnosis script which is dictated by the hypnotist, including the hypnosis test. The only degrees of freedom for the hypnotist is in intonation and speed. Identical induction and termination is used in both arms and the scripts are of comparable durations.
45956590|NCT02945956|Drug|Entecavir|The subjects will be taking 1 Entecavir tablet per day for 96 weeks.
45956591|NCT02945956|Drug|Entecavir + Fuzheng Huayu|The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
45956592|NCT04692610|Behavioral|Stoma prehabilitation|A stoma pouch was attached to the marked stoma site on the patient's abdominal surface after stoma education (only in group C). EST nurse filled 250 ml water into the pouch. Patients lived with these pouches until surgery. They experienced walking, sitting, sleeping, changing clothes with a pouch. They learned how to empty it. When a leak occurred, the pouch was changed by the nurse
45956593|NCT04692610|Behavioral|preoperative stoma education|A consultation period for stoma education by an EST nurse was approximately 45 minutes. Patients were shown pictures of a stoma. The stoma-care equipments and a pouch were also shown to the patients and they were informed about these equipments. They were also provided information about daily living with a stoma.
46078850|NCT03743467|Diagnostic Test|Clinical evaluation of vision and eye tests|"VFQ-25 Questionnaire~BCVA~Contrast sensitivity~Color sensitivity examination (Ishihara test 38 plates)~Complete evaluation of orthoptic features, eye movements, eyelid function, pupil function~Slit lamp examination~Shirmer test, Break up time test~Corneal pachymetry (optical pachymetry)~IOP~Quantitative and qualitative analysis of the macular area and of the optical disc by OCT: RPE, RNFL and Neuroretine Layer"
46078851|NCT02736084|Behavioral|Positive Psychology|The Positive Psychology intervention consists of 7 exercises that will be completed by the participant with the guidance of a trainer.
46078852|NCT03743545|Other|low speed drilling without irrigation|comparing between conventional implant placement drilling speed with irrigation and experimental arm (low speed without irrigation)
45662279|NCT05141695|Device|therapeutic repetitive peripheral magnetic stimulation|Patients in the treatment group will receive peripheral magnetic stimulation therapy for the upper extremity arm/forearm spastic muscles on the hemiplegic side for a total of ten sessions once a day, five sessions a week, for two weeks, each session lasting ten minutes. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
45662280|NCT05141695|Device|sham repetitive peripheral magnetic stimulation|rPMS will not be given to the sham group, the device will not be operated, the probe of the device will be positioned in the same way as the patients in the treatment group for ten minutes, and the sounds recorded during the operation of the device will be heard by the patients. Patients and evaluators will not know which group the patients are in. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
45662281|NCT05180383|Behavioral|Mobile Application to Prevent Suicide (MAPS)|Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
45662282|NCT05141071|Drug|Ivabradine 5mg Tab|Ivabradine will be administrated enterally
45662283|NCT05141071|Drug|Placebo|50 ml of saline will be administrated enterally
45662284|NCT01656889|Biological|HP-802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
45662285|NCT01656889|Biological|Vehicle|(fibrinogen solution & thrombin solution without cells)
45662286|NCT05179993|Other|Microplastics|Detection of microplastics as a yes/no value
45662287|NCT05097001|Other|DBS programming|DBS readjustment based on COMPUTER or CLINICAL program
45454757|NCT01114087|Drug|Imatinib treatment|Imatinib is a tyrosin-kinase inhibitor
45662288|NCT05096767|Other|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed
45662289|NCT05139745|Device|BTL-899|BTL-899 treatment
45662290|NCT05139433|Behavioral|Telepsychotherapy|"5 weekly psychotherapy sessions that will cover the following contents: psychoeducation on stress responses, family communication, relaxation and mindful techniques, emotion recognition, management of irritability, behavioral activation and cognitive restructuring. The sessions will be implemented via the internet by a trained psychologist. Participants will also have access to the psychoeducational videos described at intervention 2"
45816919|NCT04436198|Device|MORCHER® EYEJET® CTR Types 14, 14A, and 14C|"Intervention. Toric IOL + CTR. Whether the subject receives 14, 14A, or 14C is an either or scenario depending on the eye's axial length and is a single intervention:~Axial length > 28.0 mm: CTR model 14A Axial length 24.0-28.0 mm: CTR model 14C Axial length < 24.0 mm: CTR model 14~Lens Selection: The patients will undergo standard of care preoperative measurements and planning. The surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the IOL power, cylinder, and target axis (standard of care). Preoperative measurements will be taken using IOL-Master 700, with the addition of the Pentacam and automatic keratometry as needed (standard of care). The toric lens used will be the TECNIS IOL. It will be used on label (standard of care)."
45956594|NCT04692610|Behavioral|postoperative stoma education|A consultation period for stoma education by an EST nurse was approximately 45 minutes. Patients were shown pictures of a stoma. The stoma-care equipments and a pouch were also shown to the patients and they were informed about these equipments. They were also provided information about daily living with a stoma.
45816920|NCT04436198|Device|Toric IOL Only|"Control. Toric IOL only. Standard of care cataract surgery without placement of a capsular tension ring.~Lens Selection: The patients will undergo standard of care preoperative measurements and planning. The surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the IOL power, cylinder, and target axis (standard of care). Preoperative measurements will be taken using IOL-Master 700, with the addition of the Pentacam and automatic keratometry as needed (standard of care). The toric lens used will be the TECNIS IOL. It will be used on label (standard of care)."
45956595|NCT04692610|Behavioral|Postoperative stoma care|Usual stoma care given by enterostomal therapy nurse after a surgery with fecal diversion
45956596|NCT04692454|Other|Modern acupuncture|use the scalp and ear acupuncture methods to identify diseases and checkpoints and apply them to regulate the immune function of patients with gastroenterological cancers.
45662291|NCT05139433|Behavioral|Psychoeducational Videos|15 educational videos to be watched by the families. There will be one video about psychoeducation on stress responses, one about family communication, four about mindfulness and relaxation techniques, two about emotion recognition, one about management of irritability, one about behavioral activation, three about healthy routines, one about cognitive restructuring, and one about management of anxiety crisis.
45956597|NCT04692259|Diagnostic Test|MRI|Liver MRI before liver resection
45956598|NCT03122639|Drug|Atorvastatin 10mg|Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
45956599|NCT03122639|Drug|Placebo|Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
45662292|NCT05177419|Drug|Lysergic Acid Diethylamide|100 micrograms LSD base
45662293|NCT05177419|Drug|Lysergic Acid Diethylamide|Low dose of LSD base
45662294|NCT04229329|Combination Product|Intensive Finger Individuation Therapy|Interactive robot-mediated treatment aimed at increased individuation done repeatedly for at least1 hour per day for 2 weeks (5 training days a week).
45662295|NCT04229329|Combination Product|Intensive non-directed finger movement therapy|Interactive robot-mediated treatment not aimed specifically at increased individuation done repeatedly for at least 1 hour per day for 2 weeks (5 training days per week)
45662296|NCT05094427|Procedure|Preoperative fluoroscopically-guided dorsal ramus block placed by the operative neurosurgeon|Patients received bupivicaine injections delivered via 22-gauge spinal needle to the junction of the facet and transverse process or ala at multiple spinal levels (2.5-5 cc per injection of 0.25% or 0.5% bupivacaine).
45662297|NCT05176561|Behavioral|Auditory-Cognitive Training|Participant will complete 8 weeks of training for 2 hours per week and participate in a 1 hour meeting with clinician.
45662298|NCT05176561|Behavioral|Non-auditory Cognitive Training|Participant will complete 8 weeks of training for 2 hours per week and participate in a 1 hour meeting with clinician.
45816921|NCT04432597|Biological|PRGN-2009|On the phase I portion of the protocol PRGN-2009 will be administered on D1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. The dose level given as booster will be the same dose participants will be receiving for D1, D15 and D29. On the phase II portion of the protocol PRGN-2009 will be administered on just D1 and D15.
45816922|NCT04432597|Biological|M7824|"Subjects enrolled to Arm 1B will receive M7824 via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter."
45816923|NCT04417660|Drug|M7824|Bintrafusp alfa will be administered at a dose of 1200 mg intravenously once every two weeks until disease progression or development of intolerable adverse events.
45816924|NCT04414761|Drug|Progesterone|oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger
45816925|NCT04414761|Drug|GnRH Antagonist|GnRH antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
45816926|NCT04414748|Drug|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of COH till the day of the ovulation trigger
45816927|NCT04414748|Drug|oral Duphaston|oral Duphaston 10mg bd from Day 3 of COH till the day of ovulation trigger.
45816928|NCT04402957|Drug|LSALT peptide|LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
45816929|NCT04402957|Drug|Placebo|0.9% saline solution
45956600|NCT00527137|Drug|darbepoetin alfa|Dose 100U rHuEPO = 0.42 mcg NESP; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
45956601|NCT00527137|Drug|rHuEPO|same as previous rHuEPO dose at randomization; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
45956602|NCT02945839|Drug|Preventative Medication (PM)|Subjects in the PM group will be given acute migraine medication, preventive medication (topiramate), and the APP with the PMR component. The smartphone app and/or the electronic pill bottles will be used to monitor adherence.
45956603|NCT02945839|Behavioral|Enhanced Usual Care|General Education Class consisting of basic migraine information of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
45956604|NCT02945839|Behavioral|PMR (progressive muscle relaxation therapy)|Technique for learning to monitor and control the state of muscular tension
45956605|NCT02957786|Drug|Cytisine|Cytisine tablets
45662299|NCT05092711|Behavioral|Observation|Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .
45956606|NCT02957786|Behavioral|Behavioural support|Withdrawal-orientated cessation support
45956607|NCT02957786|Drug|Varenicline|Varenicline tablets
45956608|NCT00407394|Drug|Amoxycillin|
45956609|NCT00173628|Procedure|blood drawing|
45956610|NCT03109964|Device|Bipolar coagulation forceps (ETHICON inc.)|Hemostasis of the base of the ovarian cyst by utilization of a bipolar coagulation device.
45816930|NCT04397419|Dietary Supplement|Red Bull Energy Drink|"The intervention group receives 250 ml Red Bull Energy Drink 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~2-3 hours after surgery: 250 ml~Postoperative day 1: morning and noon (1-1-0-0) 250 ml"
45956611|NCT03109964|Device|SURGIFLO hemostatic matrix (ETHICON inc.)|Hemostasis of the base of the ovarian cyst by utilization of a an absorbable gelatin based matrix known as SURGIFLO.
45662300|NCT05092711|Drug|Observation|Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .
45662301|NCT05139043|Drug|Dexamethasone|Given IV and PO
45662302|NCT05176405|Behavioral|You-Tube Video: Elissa's EE song|Watch You-Tube video utilizing Entertainment-Education communication strategy.
45956612|NCT03083873|Biological|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
45956613|NCT03083873|Biological|LN-145-S1|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with autologous TIL (LN-145-S1) followed by IL-2 administration.
45956614|NCT00407433|Drug|Gemcitabine (Gemzar®), Oxaliplatin (Eloxatin®)|
45956615|NCT02484430|Other|Laboratory Biomarker Analysis|Correlative studies
45956616|NCT02484430|Other|Pharmacological Study|Correlative studies
45956617|NCT02484430|Drug|Sapanisertib|Given PO
45956618|NCT00516412|Drug|everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
45662303|NCT05176405|Behavioral|Active Comparator: Standard of Care|Reading materials containing information about early breast cancer screening in the form of infographics. Information is adopted from the Saudi Ministry of Health (MOH).
45662304|NCT05175781|Drug|Dexmedetomidine Hydrochloride|is a sympatholytic drug that acts as an agonist of α2-adrenergic receptors in certain parts of the brain.
45662305|NCT05175781|Drug|Ketamine Hydrochloride|Ketamine is an NMDA receptor antagoni
45816931|NCT04397419|Other|Still water|"The control group receives 250 ml still water 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~2-3 hours after surgery: 250 ml~Postoperative day 1: morning and noon (1-1-0-0) 250 ml"
45816932|NCT04395196|Dietary Supplement|Choline bitartrate|Provided in beverage form
45956619|NCT00516412|Genetic|molecular response by PCR|Bone marrow and peripheral blood samples are collected periodically and analyzed for molecular response by PCR. Molecular studies are also performed on DNA level formalin-fixed paraffin-embedded tissue
45956620|NCT00407472|Device|ATS-1 needle free device|
45662306|NCT05175781|Drug|Placebo|Normal saline
45662307|NCT04421911|Drug|Ketoprofen topical|Ketoprofen topical for 21days
45662308|NCT04421911|Drug|Diclofenac Topical|Diclofenac topical for 21days
45662309|NCT05138341|Device|Minimally invasive surgical (MIS) intracranial hemorrhage Evacuation|"Patients randomized to MIS group will be undergoing an intervention will get Minimal Invasive Surgical treatment.~The market approved Artemis Device (MIS group) will be used. The Artemis Device, Aspiration Pump, and endoscope are used to rinse (irrigate) this area and to gently suction out the rinsing fluid and any blood or clot in brain. The Device is also designed to prevent clogging during the suction of fluid and blood."
45816933|NCT04395196|Dietary Supplement|Placebo|Provided in beverage form
45956621|NCT03058835|Drug|tenofovir disoproxil and emtricitabine|Pre-exposure Prophylaxis with Truvada will be distributed to all participants eligible to receive PrEP.
45956622|NCT00516451|Drug|BMS-690514|Tablets, Oral, 100, 200, 250 or 300 mg once daily, 29 days or more
45956623|NCT00516490|Drug|triptorelin acetate|Single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
45956624|NCT00516490|Drug|Na Cl %0.9|0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer
45956625|NCT00516607|Drug|enzastaurin hydrochloride|
45956626|NCT00516607|Drug|temozolomide|
46078853|NCT00932191|Procedure|Standard phacoemulsification|Cataract nucleus removal using standard amounts of ultrasound energy
45956627|NCT00516607|Other|pharmacological study|
45956628|NCT04695145|Behavioral|Aerobic exercise in group|"Progression~The goal with every new week should be making every workout a little bit harder than the week before.~Strength sessions~Week 1-6: 12-18 reps x 2 set per exercise and muscle 30 s rest between exercises~Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises~Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability.~Conditioning sessions~Week 1-6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises~Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises~Mixed sessions~Week 1-6: 35 s work time per exercise 25 s rest between exercises x 2 rounds~Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds"
46078854|NCT00932191|Procedure|Reduced ultrasound phacoemulsification|Cataract nucleus removal using less ultrasound energy and more mechanical energy.
46078855|NCT00773175|Drug|recombinant human hyaluronidase|150 Units in 1 mL
46078856|NCT02741154|Drug|induction with aromataze inhibitor|letrozole 2.5mg once daily start in the first day of menses for 5days
46078857|NCT02741154|Drug|HMG|HMG 300 IU injection once daily start at first day of menses with follow up by trans vaginal ultrasound (TVUS ) till at least three follicles reach 14 mm in diameter
45662310|NCT05174611|Dietary Supplement|Vitamin D3|Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.
45662311|NCT05174611|Other|Placebo|Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.
45662312|NCT05090839|Behavioral|Weekly Emotional Disclosure (WED)|Online writing session with each session lasting approximately 30 minutes. Participants will be instructed to write about either a major traumatic life experience or what the participant did the previous day.
46078858|NCT02741154|Drug|GnRh a|antagonist given 0.1 ml injection once daily with continous follow up when at least three follicles reach 17mm in diameter HCG 10.000 IU injection and ovum pick up 24-36hours after injection
45956629|NCT04695145|Behavioral|Group sessions with leisure activities|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or watching movies together.
46078859|NCT02741154|Drug|HCG|10.000 IU HCG injection when at least three follicles reach 17mm in diameter
46078860|NCT04287816|Other|Zero hard-boiled egg at 0 h|No eggs will be consumed on test day along with spinach consumption
46078861|NCT04287816|Other|One hard-boiled egg at 0 h|One egg will be consumed on test day along with spinach consumption
46078862|NCT04287816|Other|Two hard-boiled eggs at 0 h|Two eggs will be consumed on test day along with spinach consumption
46078863|NCT04287816|Other|Three hard-boiled eggs at 0 h|Three eggs will be consumed on test day along with spinach consumption
46078864|NCT04287816|Other|One hard-boiled egg at 3 h|One egg will be consumed on test day three hours after spinach consumption
46078865|NCT04287816|Other|One hard-boiled egg at 0 h + One hard-boiled egg at 3 h|Two eggs will be consumed on test day: one along with spinach consumption and the other one three hours after spinach consumption
46078866|NCT02735850|Drug|L19-IL2|L19-IL2 added to SBRT
46078867|NCT02735850|Radiation|SBRT|
46078868|NCT02735850|Other|No intervention|
46078869|NCT04313790|Drug|Heparin Infusion|500 unit heparin infusion \ hour for DVT prophylaxis experimental group (n=20)
45662313|NCT05173753|Other|Novel self-adhesive hybrid composite(Surefil one)|Surefil one, is a recent introduced esthetic dental restoration for treatment of carious teeth.
45662314|NCT04226209|Other|PSSE|Physiotherapeutic Scoliosis-Specific Exercises (PSSE) group will receive exercise for 30-40 mins in a day, twice in a week, totally 8 weeks and 16 hours. Control group will be taught the basic elements of corrective exercises and want them to do the practising during 8 weeks at home.
45662315|NCT05173207|Diagnostic Test|Videofluoroscopic swallow exam with concurrent monitoring of respiratory-swallow coordination|Participants will undergo simultaneous videofluoroscopy, nasal airflow and respiratory inductance plethysmography testing.
45662316|NCT05173129|Diagnostic Test|Posture Analysis|Posture analysis and assessment of mechanical properties of posture muscles
45662317|NCT05172349|Biological|LV-Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit
45662318|NCT05133973|Device|FiberSense CGM|FiberSense system, a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
45662319|NCT05133817|Drug|Normal saline|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of normal saline by IV infusion.
45662320|NCT05133817|Drug|Norepinephrine (0.025 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
45956630|NCT00516646|Drug|ALT-711|200 mg bid
45956631|NCT00516646|Drug|Placebo|bid
46078870|NCT04313790|Other|subcutaneous heparin|5000 unit subcutaneous heparin /8 hours control group n=(20)
46078871|NCT02735928|Device|Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin|After insufflation of a 12 mmHg of capnoperitoneum at 37 °C, two balloon trocars will be placed. Parietal biopsies will be taken and ascites (< 500cc) will be removed. A nebulizer will be connected to a high-pressure injector and will be inserted into the abdomen through a trocar. A pressurized aerosol containing cisplatin at a dose of 7.5 mg/m2 body surface in 150 ml NaCl 0.9 % followed by doxorubicin at a dose of 1.5 mg/m2 body surface in a 50 ml NaCl 0.9% solution will be applied via a nebulizer immediately. Then, the system will be kept in steady-state for 30 min (i.e.: application time).
46078872|NCT02601885|Drug|ABT-555|Intravenous Infusion
46078873|NCT02601885|Other|Placebo|Intravenous Infusion
46078874|NCT04312932|Drug|LCPUFA Oil Supplement|25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
46078875|NCT04312932|Dietary Supplement|Canola Oil Placebo|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
46078876|NCT05467722|Drug|CTP-543|Single 12 mg oral dose administered on Day 1
45662321|NCT05133817|Drug|Norepinephrine (0.05 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
45956632|NCT00173667|Drug|Nifedipine 30 mg GITS|
45662322|NCT05133817|Drug|Norepinephrine (0.075 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
45816934|NCT04371900|Behavioral|Mother receives voucher valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)|M-CARES randomized vouchers for contraception valued up to 100% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred from March 4, 2019, forward.
45956633|NCT00516685|Biological|Recombinant Human rEGF-P64K/Montanide Vaccine|
45956634|NCT03016871|Drug|Carboplatin|Given IV
45956635|NCT03016871|Drug|Etoposide|Given IV
45956636|NCT03016871|Drug|Ifosfamide|Given IV
45956637|NCT03016871|Other|Laboratory Biomarker Analysis|Correlative studies
45956638|NCT03016871|Biological|Nivolumab|Given IV
45662323|NCT05133817|Drug|Norepinephrine (0.1 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
45662324|NCT05172193|Biological|SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated|SARS-CoV-2 vaccine (Vero cell) inactivated developed by Beijing Bio-Institute Biological Products Co., Ltd, can induce active immunity and prevent diseases caused by the SARS-CoV-2 virus by producing neutralizing antibody. The inactivated SARSCoV-2 Vaccine (Vero cell) is prepared by inoculating Verda Reno cells (Vero cell) with SARS-CoV-2 HB02 strain, culturing, harvesting, inactivating, clarifying, concentrating, purifying and adding aluminum hydroxide adjuvant.
45662325|NCT05171335|Drug|Lenvatinib|"Participants will receive approximately six, 28-day cycles of lenvatinib (LENVIMA®, Eisai Inc., Woodcliff Lake, NJ). Lenvatinib will be administered at 12 mg orally once daily for patients with a body weight ≥60 kg and at 8 mg orally once daily for patients with a body weight of <60 kg.~Administration of lenvatinib will occur at least 2 weeks before the first standard of care TACE procedure and study drug treatment will continue for 6 months. Lenvatinib will be held for 7 days before and 7 days after each TACE. Participants can receive up to 3 TACE procedures per protocol depending on their response and transplantation time."
45816935|NCT04371900|Behavioral|Mother receives voucher valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)|M-CARES randomized vouchers for contraception valued up to 50% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred after November 4, 2019.
45816936|NCT04371783|Procedure|Immediate FET|FET is performed in the first menstrual cycle following the stimulated IVF cycle
45816937|NCT04371783|Procedure|Delayed FET|FET is performed in the second menstrual cycle following the stimulated IVF cycle
45816938|NCT04368104|Diagnostic Test|Darwish test (office hysteroscopic bubble suction and tubal peristalsis)|Testing Darwish test (office hysteroscopic bubble suction test and proximal tubal peristalsis) in women using minipills versus other cases not using hormones..
45816939|NCT04702568|Drug|BCX9930|BCX9930 for oral administration
45816940|NCT04335799|Behavioral|Diabetes Prevention Program Intensive Lifestyle Intervention plus stress management training|12-month evidence based weight loss intervention with additional training on stress management strategies
45816941|NCT04335799|Behavioral|Diabetes Prevention Program Intensive Lifestyle Intervention plus general women's health topics|12-month evidence based weight loss intervention with an attention control of general women's health topics
45816942|NCT04307264|Procedure|Esophagogasrtoduodendoscopy, liver stiffness measurement|Time frame between liver stiffness measurement and esophagogastroduodendoscopy is less than 2 weeks.
45956639|NCT03458689|Procedure|Left hemicolectomy, laparoscopic technique|Left hemicolectomy, Laparoscopic technique
45956640|NCT00173706|Drug|L-Carnitine Injection|
45956641|NCT00527215|Drug|darbepoetin alfa|starting dose determined by calculating a subject's total dose in the month preceding enrollment. Administered QM for 25 weeks. Change made as necessary to maintain a hemoglobin concentration within the target range os 10.0 - 12.0 g.dL
45956642|NCT02998229|Device|Artisse™|Intrasaccular Device
45956643|NCT00527254|Device|Telemedicine system|Possibility of sending the SMBG values of the patients to a web page via phone mobile sms messages. The HCP had a password access to this web page to check the blood glucose values of the patients and if necessary send to them sms messages with recommendations.
45956644|NCT00527293|Procedure|adjuvant therapy|If chemotherapy is planned, it must begin no earlier than two weeks following completion of radiation. If chemotherapy is given first, a minimum of 2 weeks from the last cycle must elapse prior to the start of radiation.
45956645|NCT00527293|Radiation|3-dimensional conformal radiation therapy|3-dimensional conformal radiotherapy twice daily for 5-10 days.
45956646|NCT00527293|Radiation|brachytherapy|Patients undergo partial breast irradiation comprising either MammoSite® brachytherapy twice daily for 5-10 days
45956647|NCT00173745|Drug|botulinum toxin A injection|
46002834|NCT04643730|Other|Foot Reflexology Methods|Foot reflexology was applied to the babies in the foot reflexology group for a total of 7 minutes before the heel prick
46002835|NCT04643730|Other|Control Grup|No pre-application was made to the babies in the control group as a routine procedure.
46002836|NCT00549107|Drug|Levosimendan|
46002837|NCT00549107|Drug|Milrinone|
45662326|NCT05171335|Procedure|Transcatheter Arterial Chemoembolization|Traditional standard of care: Transcatheter Arterial Chemoembolization (TACE) treatment for hepatocellular carcinoma. Chemotherapeutic drug-coated particles are inserted via a catheter into an artery that supplies blood to a tumor where the drug works to cut off blood supply to the tumor.
45662327|NCT02522299|Drug|GSK2269557|GSK2269557 500 mcg blended with lactose per blister and will be administered using a DISKUS dry powder inhaler device. Since GSK2269557 will no longer be manufactured for use with the DISKUS device, it will be replaced with ELLIPTA Device. Subjects will receive GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
45956648|NCT04692142|Other|Flipped classroom teaching method|Participants will have 7 -day monitored remote access to a recorded lecture about orthodontic topic. At the expiry of remote access to the recorded lecture, participants from FG will be invited to attend post-lecture discussion sessions. To enhance the effectiveness of flipped classroom teaching method, the cohort of FG will be randomly, using computer generated randomisation, subdivided to two smaller groups in which each group will be consisted of half of the FG cohort. The same lecturer will moderate the discussions for each group separately.
45816943|NCT04300647|Drug|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg) will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
45662328|NCT02522299|Drug|Placebo|Lactose will be administered using a DISKUS and ELLIPTA dry powder inhaler device
45662329|NCT02522299|Device|DISKUS|It is multi-dose dry powder inhaler containing one foil strip of drug with 60 blisters
45662330|NCT02522299|Device|ELLIPTA|It is multi-dose dry powder inhaler containing one foil strip of drug with 30 blisters
45662331|NCT05088967|Drug|IBI110|R2PD d1 IV every 3 weeks
45662332|NCT05088967|Drug|sintilimab|200mg d1 IV every 3 weeks
45662333|NCT05086627|Drug|Tislelizumab|Patients were treated with Tislelizumab (days 11, 33, 55, 77)
45662334|NCT05086627|Radiation|Short-course radiotherapy|Patients were treated with short-course neoadjuvant radiotherapy
45662335|NCT05086627|Drug|Capecitabine+Oxaliplatin|Patients were treated with neoadjuvant chemoherapy with CapeOX
45662336|NCT05170945|Other|Early bowel preparation for colonoscopy|Early (<24 hours) bowel cleansing prior to colonoscopy.
45662337|NCT05083741|Device|Chitogel|post-operative dressing within standard of care
45662338|NCT05083741|Device|Nexfoam|post-operative dressing within standard of care
45662339|NCT05131321|Procedure|Primary ankle arthrodesis (fusion)|Primary arthrodesis: Subjects allocated to the fusion group will have insertion of a retrograde locked calcaneal nail. Tibiotalar joint preparation, bone grafting, subtalar preparation, and fibulectomy will not be performed unless deemed necessary by the treating surgeon.
45816944|NCT04300647|Drug|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
45816945|NCT04297189|Behavioral|Coaching and health information intervention|8 session intervention with,group meetings with coaching tools and health information on nutrition and physical activity and coping with stress.
45816946|NCT04294381|Behavioral|Decision tool|participants will be asked to use a decision tool to choose and delineate SMART health behavior goals
45816947|NCT04287283|Other|Hyperbaric Oxygen|40-60 daily hyperbaric sessions, 5 days per week. Each session consists of 90 minutes exposure to 100% oxygen at 1.5-2 ATA.
46002838|NCT04635306|Diagnostic Test|Approved GEBT test meal|FDA-approve GEBT test meal
46078877|NCT02740764|Other|Optimization of drug prescribing|The patients included in this group will have the intervention. The optimization of drug prescribing consists to a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, accepted by the specialist physicians in charge of the patient at the hospital and sent to the referring physicians of patients, who can accept or not the recommendations.
45662340|NCT05131321|Procedure|ORIF (open reduction and internal fixation)|ORIF: ORIF will be performed using modern techniques for timing and staging of fixation, soft tissue and fibula management, surgical approaches, reduction techniques, and plate choice.
45662341|NCT05130775|Other|Transesophageal echocardiograpgy|3D acquisition of the right ventricle regurgitation volume
45662342|NCT05130307|Behavioral|virtual reality game|participants interact with a computer generated world
45662343|NCT05168605|Other|Home visit|Patients receiving home Visits
45662344|NCT01365091|Drug|Saxagliptin/metformin fixed-dose combination (FDC)|Tablet, oral, 5 mg/500 mg FDC, once on Day 1 only, 1 day
45662345|NCT01365091|Drug|Saxagliptin|Tablet, oral, 5 mg, once on Day 1 only, 1 day
45662346|NCT01365091|Drug|Metformin extended-release (XR)|Tablet, oral, 500 mg, once on Day 1 only, 1 day
45662347|NCT01365091|Drug|Saxagliptin/Metformin FDC|Tablet, Oral, 5 mg/1000 mg FDC, once on Day 1 only, 1 day
45662348|NCT01365091|Drug|Metformin|Tablet, oral, 1000 mg, once on Day 1 only, 1 day
45662349|NCT05082571|Drug|vadadustat|Vadadustat tablet orally once a day for 52 weeks
45662350|NCT05054257|Drug|Autologous CAR19 T lymphocytes|First-in-human trial examining the safety and efficacy of CART19 in r/r B-ALL and B-NHL
45816948|NCT04283786|Other|Qualitative Interview|A single qualitative interview about experiences of bisphosphonate regimens, as well as wider experiences of service quality and delivery.
45816949|NCT04259710|Behavioral|Goal-setting intervention|The participant will meet weekly with the investigator, report steps and set goals for the following week.
45816950|NCT04259710|Behavioral|Goal setting with implementation intentions|In addition to the standard goal-setting intervention, the participant will fill out a form that directs them to perform implementation intentions at weeks 1, 5 and 9.
45816951|NCT04259710|Behavioral|Pedometer only|the participant will be given a pedometer and instructed how to use it.
45816952|NCT04251221|Drug|Oral Alcohol Challenge|Subjects will drink an alcohol dose designed to achieve a BAL of 0.08
45816953|NCT04234113|Drug|SO-C101|SO-C101
45816954|NCT04234113|Drug|pembrolizumab|pembrolizumab
45816955|NCT04233515|Drug|Oral anticoagulant|Clinical visit to a physician to assess stroke and bleeding risk and to possibly initiate OAC therapy or refer for left atrial appendage occlusion
45816956|NCT04228549|Device|MyPADMGT|Online tracking and feedback to help patients adopt healthy lifestyles
45956649|NCT00527371|Device|GreenLight HPS (TM)laser system [Photoselective Vaporization of the prostate (PVP)]|Photoselective vaporization of the prostate will be performed using the GreenLight HPS (TM)laser system (American Medical Systems), which is a high-power (120W) potassium titanyl phosphate (KTP) laser which was licensed by Health Canada in April 2007.
45816957|NCT04228549|Device|MyPADMGT + Nudging|Online tracking and feedback to help patients adopt healthy lifestyles plus nudging support to assist in making decisions
45956650|NCT00527371|Procedure|Transurethral resection of the prostate|Transurethral resection of the prostate will be performed with a continuous flow resectoscope and unipolar cautery using a standard technique.
45956651|NCT00168285|Behavioral|Pulmonary Rehabilitation|
45956652|NCT02516540|Behavioral|Structured exercise training plus mediterranean diet|Structured exercise training plus mediterranean diet
45956653|NCT02489422|Other|Laboratory Biomarker Analysis|Correlative studies
45816958|NCT04222998|Other|Home-based growth charts|The growth chart contains simple information of nutritious food, health, and sanitation information at the top and height chart is located at the bottom where caregivers can measure their child's linear growth. Growth charts will be installed in intervention group homes just after the baseline survey.
45956654|NCT02489422|Other|Questionnaire Administration|Ancillary studies
45956655|NCT02489422|Other|Daily Survey Administration|Ancillary studies
45956656|NCT02489422|Behavioral|Yoga Skills Training|The YST intervention consists of four 30 minute in-person sessions that instructs skills to enhance mindfulness and promote relaxation. Participants will also be encouraged to practice daily at home.
45956657|NCT02489422|Behavioral|Attention Control|The AC intervention consists of four 30 minute in-person sessions of supportive conversation. In addition, the interventionist will recommend that the patients write brief diary entries daily at home.
45816959|NCT04222998|Other|Home visits for baseline surveys|Households will be visited for baseline surveys.
45956658|NCT02489422|Other|Actigraphy Assessment|Ancillary studies
45956659|NCT02945644|Drug|Trazodone|take at bedtime for 14 days
45956660|NCT02945644|Drug|Placebo|take at bedtime for 14 days
45956661|NCT02460887|Drug|Gemcitabine|Experimental arm: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before IMRT.
45956662|NCT02460887|Drug|cisplatin|Experimental arm: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before IMRT.
45956663|NCT02460887|Drug|cisplatin|Active Comparator arm: Patients receive weekly cisplatin 40 mg/m² up to 7cycles during IMRT.
45956664|NCT02460887|Radiation|Intensity-modulated Radiotherapy|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
45956665|NCT02945488|Other|Exercise|Exercise intervention will entail 30 minutes of moderate intensity cardiovascular training 3 days/week and full body resistance training 2 days/week (supervised). Cardiovascular training will entail any weight-bearing activity that would achieve target heart rate, such as walking, jogging, stair climbing, dancing, etc. Resistance training will entail 2-3 sets of 8-12 repetitions of exercises targeting all major muscle groups with an external load applied, such as a dumbbell, barbell, medicine ball, etc.
45956666|NCT02945488|Other|Dietary plan|Mediterranean dietary plan, which contains foods, such as fish, vegetables, nuts, and oils, which are anti-inflammatory in nature.
45956667|NCT02945488|Other|Stretching|Stretching intervention will entail 30 minutes of flexibility training 3 days/week of stretches targeting all major muscle groups held for 20-30 seconds.
45956668|NCT02945605|Other|Early Vestibular Rehabilitation|"Two visits/week for a maximum of 5 weeks will be provided with the approximate duration for each visit estimated at 50-60 minutes. Consistent with a previously validated framework for exercise prescription in patients with concussion, the exercises provided by the treating therapist can be classified into five main exercise categories:~Eye-Head coordination, gaze stability and convergence exercises~Sitting balance~Standing static balance (i.e. feet-in-place)~Dynamic balance (feet moving, but not walking)~Ambulation (gait exercises)~Other exercises: Sport specific exercises, Canalith repositioning maneuvers are recorded as others"
45956669|NCT02945605|Other|Standard of Care|Standard care as directed by a physician.
45662351|NCT05082181|Behavioral|UPLIFT (Using Practice and Learning to Increase Favorable Thoughts)|UPLIFT is an 8-week program that combines cognitive behavioral therapy (CBT) and mindfulness techniques and is delivered to small groups of participants by phone. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise, and a home practice assignment. CBT-related skills include thought monitoring, identifying cognitive distortions, problem identification, goal setting, and identifying supports. Relaxation exercises are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to breath, sights and sounds and other meditations. Audio guides are provided for home practice of mindfulness exercises.
45816960|NCT04222998|Other|Home visits for end line surveys|Households will be revisited after 1 year of grace-period for baseline end line surveys.
45816961|NCT04222998|Other|Measurement of child's height-for-age and weight-for-age|The child's height-for-age and weight-for-age will be measured for participating dyads at the time of the baseline and end line surveys.
45816962|NCT04218864|Behavioral|Strength for U in Relationship Empowerment (SURE)|A brief computer-based intervention (one session plus one booster session) based on motivational interviewing.
45956670|NCT02945527|Drug|Acetazolamide|As described above
45956671|NCT02945527|Drug|Dexamethasone|As described above
45956672|NCT02945371|Behavioral|Person-centered inhibitory control training|A brief, computer-based, multisession training aimed at increasing the connection between environmental risk cues (e.g., cigarettes) and engagement of the brain network for inhibitory control.
45956673|NCT02945371|Behavioral|Active behavioral response training|A brief computer-based, multisession training aimed at training behavioral responses to personalized environmental risk cues (e.g., cigarettes) that does not engage the inhibitory control network of the brain.
45956674|NCT00168363|Drug|brimonidine|
45956675|NCT02448095|Drug|Ponatinib|Observation of tolerability and safety profiles
45956676|NCT00527410|Drug|RTA 744|Aqueous solution of RTA 744 is packaged in 5 ml vials - 1 mg/ ml. The drug is mixed in D10W and infused over 2 hours on three consecutive days.
45956677|NCT03458650|Drug|LXI-15028 50mg|In escalated single-dose study, the subjects in each dose group will receive single oral dose of 50 mg LXI-15028 tablet or 1 matching placebo tablet at fasted state,
45956678|NCT03458650|Drug|LXI-15028 100mg|100 mg LXI-15028 tablet or matching placebo 1 tablet at fasted state, In multiple-dose study, the subjects who administered 100mg single dose will continuously receive oral 100 mg LXI-15028 tablet or 1 matching placebo tablet once daily (QD) for 10 times.
45956679|NCT03458650|Drug|LXI-15028 200mg|single oral dose 2 100 mg LXI-15028 tablets or 2 matching placebo tablets at fasted state
45956680|NCT03458650|Drug|Placebo|matching placebo tablets
45956681|NCT02945059|Procedure|Selective reversible portal vein embolization|Percutaneous access to the portal vein is achieved under general anesthesia with ultrasound or fluoroscopic control. After assessment of portal venous anatomy, embolization of selected portal vein segments is performed using the powdered form of an absorbable gelatin sponge.
45956682|NCT00168402|Drug|Botulinum Toxin Type A|
45956683|NCT00529438|Drug|Bardoxolone methyl|
45956684|NCT00529477|Other|1. Wright Nebulizer|The Wright nebulizer will be used to perform the methacholine challenge.
45956685|NCT00529477|Other|Pari LC Nebulizer|The Pari LC nebulizer will be used to perform the methacholine challenge.
45662352|NCT05082181|Behavioral|BOOST (Bringing Out Our Strength Together)|BOOST is a telephone-based support program delivered in 8 weekly group sessions. Each weekly session is 1 hour long and is comprised of a check-in period, introduction of the week's topic, and group discussion. Weekly BOOST session topics include: (1) personal experience of epilepsy; (2) personal experience of mood problems (depression, anxiety, stress); (3) seizure triggers; (4) concerns related to epilepsy treatment (e.g., medication adherence, side effects); (5) changes in seizures over time; (6) the impact of behavior (e.g., sleep, substance use) on seizures; (7) social relationships and epilepsy; and (8) review of the BOOST experience.
45816963|NCT04218864|Behavioral|Attention, time, and information matched control|A brief computer based intervention (one session plus booster session) that involves viewing of popular television shows
45816964|NCT04169373|Drug|Upadacitinib|Upadacitinib tablet administered orally
45956686|NCT00529477|Other|The Pari Sinustar Nebulizer|The Pari Sinustar nebulizer will be used to perform the methacholine challenge.
45956687|NCT02444000|Drug|PCV chemotherapy alone|"PCV cycles are 6 weeks long~PCV chemotherapy is given as:~Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally"
45816965|NCT04169373|Drug|Placebo|Placebo for upadacitinib tablet administered orally
45816966|NCT04167514|Biological|Alpha-1 antitrypsin (AAT)|AAT is a lyophilized product for intravenous administration
45956688|NCT02444000|Drug|Radiotherapy+PCV chemotherapy|Radiotherapy followed by 6 cycles of PCV
46078878|NCT02731560|Drug|Rituximab|"Rituximab was administered as an intravenous infusion as per approved protocol on Day 1 and day 14. The protocol stipulated the administration of intravenous hydrocortisone 100 mg and oral pheniramine maleate 43.5 mg as pre-medication. The Rituximab itself was given as a 1 gm infusion slowly over a period of 4-6 hours.~This was done either by a specialist nurse or a trained doctor."
45816967|NCT04167514|Drug|Placebo|Albumin solution administered intravenously
45454758|NCT01344668|Other|Enhanced Diabetes Education|Provide enhanced diabetes education
45662353|NCT05082025|Drug|Copanlisib|Given by IV
45662354|NCT05082025|Drug|fulvestrant|Given by IM
45662355|NCT05128903|Drug|[18F]DPA714|"Intravenous injection~Before or within 2 weeks of starting radiation therapy~Before starting chemotherapy~1 year after the start of radiation therapy Timing cont.~1.5 to 2 years after the start of radiation therapy"
45454759|NCT01344668|Other|Standard Diabetes Education|Provide Standard Diabetes Education
45816968|NCT04165798|Diagnostic Test|Tumor Imaging|Participants will undergo tumor imaging using either a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.
45956689|NCT00529594|Drug|placebo (Control Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
45956690|NCT00529594|Drug|Etoricoxib (Treatment Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
45956691|NCT00529672|Procedure|crossectomy and short stripping|under spinal or complete anaesthesia
45956692|NCT00529672|Procedure|ultrasound guided sclerotherapy with foam|1 part 3% polidocanol mixed with 3 parts of air. Between 3cc - 12 cc per varicose vein>
45956693|NCT00529672|Procedure|endovenous laser therapy|940 nm Diode laser. About 70 J/cm will be administered. Disposables from Angiocare (registered) will be used.
45956694|NCT00173862|Drug|Gemcitabine, Ifosfamide|
45956695|NCT00529711|Drug|Hypertonic lactate|"Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours."
45956696|NCT00529711|Drug|Ringer's lactate|"Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours."
45956697|NCT00529750|Drug|IRBESARTAN|Tablets
45956698|NCT00529750|Drug|Atenolol|Tablets
45956699|NCT02387606|Drug|Placebo|Participants will receive placebo once daily.
45956700|NCT02387606|Drug|JNJ-53718678|Participants will receive JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 1. JNJ-53718678 dose in Cohort 2 will be decided based on Cohort 1 results. JNJ-53718678 as 7.5 mL (75 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 3.
45956701|NCT00529828|Procedure|Consumption of CLA enriched food|
45956702|NCT00529867|Drug|Artemether/lumefantrine tablets|"Artemether/lumefantrine tablets containing 20mg artemether and 120mg lumefantrine~Dosage: 5 - 14.9 kg: 1 tablet and 15 - 24.9 kg: 2 tablets~Administered at 0, 8, 24, 36, 48, and 60 hours on days 0, 1, and 2"
45956703|NCT00529867|Drug|Artemether/Lumefantrine suspension|"Artemether/lumefantrine suspension containing 15mg artemether and 90mg lumefantrine per 5ml suspension~Dosage: 5.0 - 7.4 kg = 7 ml, 7.5 - 9.9 kg = 10 ml, 10 - 12.4 kg = 14 ml, 12.5 - 14.9 kg = 17 ml, 15 - 17.4 kg = 20 ml, 17.5 - 19.9 kg = 24 ml, 20 - 22.4 kg = 27 ml and 22.5 - 24.9 kg = 30 ml~Administered once daily at 0, 24, and 48 hours on days 0, 1 and 2"
45956704|NCT00168441|Drug|Botulinum Toxin Type A|
45956705|NCT02944708|Drug|Conventional chemotherapy|
45956706|NCT02944708|Drug|Maintenance chemotherapy 1|
45956707|NCT02944708|Drug|Maintenance chemotherapy 2|
45956708|NCT02376686|Other|Music intervention|Patient receives Music Intervention before going to sleep. It is composed Music which the Patient hear with maysound Music player.
45956709|NCT02944630|Behavioral|Psychotherapy|Individual psychotherapy
45956710|NCT02944591|Device|COPD Co-Pilot|The COPD Co-PilotTM is a smartphone application for symptom reporting supported by a Call Center staffed with pulmonary nurses and Health Assistants who are trained to support patients with COPD. The call center staff are employees and subcontractors of the company that makes the COPD Co-PilotTM, HGE. It is located on the Campus of Temple University in Philadelphia Pennsylvania.
45662356|NCT04422145|Behavioral|Structured nurse led intervention programme|A diabetes research nurse, over a period of 12 months, provided a structured education programme to participants focussing on the avoidance of hypoglycaemia and the treatment of this if/when it occurred.
45816969|NCT04165798|Procedure|Tumor Tissue Collection|Participants without archival tumor tissue samples will undergo tumor tissue collection for newly obtained tumor tissue.
45816970|NCT04165798|Procedure|Blood Sample Collection|"Participants will have blood samples drawn for analysis of:~genetics~ribonucleic acid (RNA)~serum biomarker~plasma biomarker~circulating tumor DNA (ctDNA)"
45816971|NCT04156191|Drug|ARQ-151 cream 0.15%|ARQ-151 cream 0.15% applied to atopic dermatitis lesions once a day for 28 days
45816972|NCT04156191|Drug|ARQ-151 cream 0.05%|ARQ-151 cream 0.05% applied to atopic dermatitis lesions once a day for 28 days
45662357|NCT04422145|Other|Standard care|Participants continue on their current diabetes care plan and are looked after by their usual diabetes care provider
45662358|NCT05081869|Other|Exercise Program|An online yoga-based exercise program will be applied for 16 sessions in individuals' own environments. The exercise program will consist of stretching, mobilization, stabilization, strengthening and relaxation exercises.
45816973|NCT04155099|Biological|RBX7455|RBX7455 is a preparation of live intestinal microorganisms (active drug) purified from stool donations obtained from healthy, screened donors, mixed with preservative, lyophilized, and put into capsules. The capsules are taken orally (i.e., by mouth). After ingestion, these freeze-dried microorganisms can reconstitute and proliferate in the gut.
45816974|NCT04155099|Biological|Placebo|Capsule with cellulose filler
45662359|NCT05081869|Other|Education Program|There will be video training on the subject for both groups.
45816975|NCT04154930|Device|Restylane-L®|Intradermal injection.
45816976|NCT04154345|Other|Exercise therapy (exercising into pain)|The intervention consists of 12 weeks of progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, in which the pain allowed ranges between 4 and 7 on a verbal NPRS for 9 weeks, then pain ratings are 0-2 for the remaining 3 weeks. Every physiotherapy session includes also 15 minutes of manual therapy.
45956711|NCT00168480|Biological|Botulinum Toxin Type A|100 U, repeated treatments at > 4 month intervals up to Month 32, over a 36-month study period
45956712|NCT02944435|Drug|CB-839 Capsules|3 x 200 mg CB-839 Capsules (Reference Formulation)
45956713|NCT02944435|Drug|CB-839 Tablets|3 x 200 mg CB-839 Tablets (Test Formulation)
45956714|NCT01708538|Drug|CXL|corneal crosslinking
45956715|NCT02945449|Biological|Wharton Jelly Mesenchymal stem cells|Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
45956716|NCT00527449|Drug|Epirubicin, Carboplatin, Docetaxel|75 mg/m² Docetaxel (60 minutes i.v.) and 90 mg/m² Epirubicin (10-15 min i.v.) on day 1, 22, 42. After these 3 cycles 75 mg/m² Docetaxel (60 minutes i.v.) and Carboplatin AUC 5 (30 min i. v.) on day 63, 84, 105.
45816977|NCT04150042|Drug|Melphalan|Intravenous melphalan (to be given in conjunction with the other listed drugs).
45816978|NCT04150042|Drug|BCNU|Intravenous BCNU (to be given in conjunction with the other listed drugs).
45816979|NCT04150042|Drug|Vitamin B12B|Intravenous vitamin B12b (to be given in conjunction with the other listed drugs).
45816980|NCT04150042|Drug|Vitamin C|Intravenous vitamin C (to be given in conjunction with the other listed drugs).
45816981|NCT04150042|Drug|Ethanol|Intravenous ethanol (to be given in conjunction with the other listed drugs).
45956717|NCT02945566|Procedure|Standard TME surgery|Total mesorectal excision
45956718|NCT02945566|Drug|Long course concurrent chemoradiation|Capecitabine 825 mg/m² orally, b.i.d., on radiotherapy days. Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
45956719|NCT02945566|Radiation|Short course radiotherapy|A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
45956720|NCT00168519|Drug|nitroprusside, pentalong, imdur, AICAR, isoptin|"Sodium Nitroprusside - one 30 minute intravenous infusion~Pentalong - two tablets orally (total 160mg)~Imdur - two tablets orally (total 120mg)"
45662360|NCT05053711|Device|rTMS+rPMS_iTBS_M|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
45816982|NCT04150042|Device|Autologous Hematopoietic Stem Cells|After each cycle of chemotherapy, participants will receive an autologous hematopoietic stem cell infusion.
45816983|NCT04141644|Drug|Ipilimumab|Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks
45956721|NCT00144521|Drug|MRA(Tocilizumab)|8mg/kg/4week(i.v.)for 24 weeks
45956722|NCT00144521|Drug|MRA placebo|0mg/kg/4week(i.v.) for 24 weeks
45956723|NCT00144521|Drug|MTX|8mg/week(p.o.) for 24 weeks
45956724|NCT00144521|Drug|MTX placebo|0mg/week(p.o.) for 24 weeks
45662361|NCT05053711|Device|rTMS+rPMS_cTBS_M|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
45816984|NCT04141644|Drug|Osimertinib|Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks
45816985|NCT04137705|Other|Multiparametric MRI|A standardised MRI protocol that provides a number of quantitative metrics on liver and other organs relevant to type 2 Diabetes - pancreas, kidneys, spleen, heart, lungs and aorta
45816986|NCT04125927|Drug|Mercaptamine|Patients will be treated with 1 drop in each eye 4 times a day, at the same dose and regimen than the one indicated in adults and children from 2 years of age.
45816987|NCT04124471|Behavioral|Open-ended semi-structured interviews|Semi-structured interviews will explore such key constructs as knowledge/belief about OSAS and PAP therapy, routines and resources that promote or limit PAP use, barriers, self-efficacy, and communication and attitudes about PAP. The interviews will be performed with the parent and that they will be audio-recorded.
45956725|NCT04692376|Biological|Mesenchymal stem cells|Mesenchymal stem cells (MSCs) will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 mins) weekly. MSCs will be administrated for 8 doses.
45956726|NCT04692376|Drug|Glucocorticoids|Glucocorticoids (i.e. Methylprednisolone) will be used with an initial dose of 1mg/kg.
45956727|NCT04692376|Drug|cyclosporine|Cyclosporine (CsA) will be used with an initial dose of 2.5mg/kg/d and adjusted according to the concentration of CsA. The targeted concentration is 200-300 ng/Ml.
45956728|NCT00527527|Procedure|flexion distraction|Chiropractic treatment using the flexion distraction apparatus
45956729|NCT00527527|Other|placebo control|Placebo for comparison with flexion distraction treatment
45956730|NCT00527683|Drug|Vigabatrin|crystalline drug dissolved in orange juice, dosage escalates from 500 mg twice daily to 1.5 g twice daily over a 3 week period. This dose is maintained for 4 weeks and then tapered to zero over the next two weeks
45816988|NCT04121520|Other|Questionnaire|"Comprehensive perioperative assessment~Questionnaire administration"
45816989|NCT04114669|Behavioral|Control Condition|3 in-person study visits, approximately one hour each. These will take place at baseline, 6 months, and 12 months.
45816990|NCT04114669|Behavioral|Regret Lottery|"Delivered by the Way to Health platform, installed on a smartphone and communicates with participants via text message.Participants are eligible to receive a potential cash reward if they are adherent with their antihypertensive medication the day before, which is monitored via electronic monitoring device (EMD) from AdhereTech. Each participant is assigned a 2-digit number for the trial, and each day the Way to Health platform randomly generates a 2-digit number. Participants will receive a prize if both digits match (1 in 100 chance) and will receive a prize of lesser value if one digit matches (18 in 100 chance). If they are not adherent with their medication, but would have won if they were adherent, they receive a text message that they would have won (regret component)."
45816991|NCT04109729|Drug|Nivolumab|"Nivolumab 480mg IV every 4 weeks for up to 2 years~• Radium-223 55 kBq/kg IV q4 weeks for 6 cycles total"
45816992|NCT04093024|Drug|Nintedanib|Capsule
45956731|NCT00527683|Drug|Placebo|orange juice is administered twice daily in containers indistinguishable from the treatment arm.
45956732|NCT00527683|Behavioral|Group therapy|Participants attend group sessions once a week
45956733|NCT00173901|Drug|ceftazidime|
45956734|NCT00527761|Drug|Cisplatin|20 mg in 500 ml of normal saline by vein over 60 minutes daily for 4 days starting on day 1 of chemotherapy.
45956735|NCT00527761|Drug|Docetaxel|Starting dose 20 mg by vein over 1 hour, once a week, for three weeks (on Days 1, 8, and 15).
45956736|NCT00527761|Drug|Temodar|150 mg by mouth (PO) on Days 1 - 5.
45956737|NCT00144560|Drug|MRA(Tocilizumab)|
45956738|NCT00527800|Drug|Dihydroartemisinin-piperaquine|Once daily for 3 days, given in fixed dose tablets (40 mg dihydroartemisinin + 320 mg piperaquine) according to weight-based guidelines
45454760|NCT01212133|Drug|liraglutide|Self-administered subcutaneously (under the skin) once daily at any time, independent of meals, in the abdomen, thigh or upper arm.
45956739|NCT00527800|Drug|Artemether-lumefantrine|Dosed twice daily for 3 days, given in fixed dose tablets (20 mg artemether + 120 mg lumefantrine) according to weight-based guidelines
46078879|NCT02736006|Other|20 meters air dive|"A dive in the depth of 20 m during 40 minutes. The divers will be evaluated before and 30, 60, 180 minutes after a 20 meters air dive. Venous bubbles will be detected by precordial Doppler 30 minutes after the dive.~In association with this Doppler, Flow Mediated Dilation, blood samples analysing inflammatory and thrombotic factors and other biomarkers will be explored before and after the dive in order to know how vascular and respiratory tracts in this environment react."
46078880|NCT02740686|Other|Sample collection|Frequent exacerbators and infrequent exacerbators will have blood and sputum samples obtained around pulmonary rehabilitation. No other intervention will be administered. Healthy controls will have resting blood samples taken.
45662362|NCT05053711|Device|rTMS+sham rPMS_M|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at median nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
45816993|NCT04093024|Drug|Placebo|Capsule
46078881|NCT00566527|Biological|ProQuad® manufactured with recombinant Human Albumin (rHA)|A 2-dose regimen of ProQuad® (0.5 mL per dose) given via subcutaneous injection into the deltoid muscle at a 3-month interval. Each dose contains measles virus Enders' Edmonston strain (live attenuated), mumps virus Jeryl Lynn™ (Level B) strain (live attenuated), rubella virus Wistar RA 27 or 3 strain (live attenuated), and varicella virus Oka or Merck strain (live attenuated).
46078882|NCT05643248|Drug|NEX-20A|Subcutaneous prolonged-release injection
46078883|NCT02735772|Procedure|transobturator approach for paravaginal repair|using TOT needle to apply suturs to white line
46078884|NCT00924625|Other|Neuromuscular electrical stimulation|Strength of the quadriceps muscles will be tested at the beginning of each session. During administration of the NMES participant will sit with the knees bent at 70 degrees. The force sensing pad will be secured to the ankle joint. Two electrodes will be placed on the thigh muscle; one near the hip and the other near the knee joint. The intensity of NMES will be increased gradually according with tolerance. During each treatment 15 electrically elicited muscle contractions will be administered to each thigh. Each contraction will last 14 sec followed by 1min rest.
46078885|NCT00924625|Other|Volitional exercises|The training will include bilateral exercises using resistance equipment (Leg Extension and Leg Press machines). Each resistance exercise will have: (a) dynamic muscle action at moderate repetition velocity (1-2 s concentric, 1-2 s eccentric, 2-3 s interval); (b) 3 sets of 8 repetitions with a load corresponding to 80% of one repetition maximum(1-RM); (c) 2-min rest period between sets and exercises.
45816994|NCT04091503|Drug|Intranasal Modified Temozolomide|"Intranasally Modified Temozolomide is administered to patients at a dose of 75/150/200 mg / M2 for five days continuously. After the 5-day course, patients do not take treatment for two days, and they will be examined on an outpatient basis (blood tests, kidney and liver tests, visually mucous membranes of the mouth, nasal cavity, olfactory rapid tests, including the University of Pennsylvania test, etc.).~After 30 days after the first intranasal administration of Modified Temozolomide (IM-TMZ), all patients undergo an MRI of the brain with perfusion and ultrasound of the abdominal cavity as an outpatient, after which the results are evaluated"
45816995|NCT04085406|Device|Deep Brain Stimulation of the Subgenus Cingulate Cortex|The Abbott Infinity DBS device will be surgically implanted in the bilateral subgenual cingulate cortex to provide electrical stimulation to this region.
45956740|NCT00527800|Drug|Trimethoprim-sulfamethoxazole|Once daily dosing according to weight based guidelines
45956741|NCT04692064|Other|There is no intervention|There is no intervention
45956742|NCT00168558|Biological|Measles vaccine|"The children will be randomised to the following three arms:~Arm 1 - Very early two-dose: V (EZ) 4½ mo of age + V (EZ) 9 mo of age.~Arm 2 - 9 months one- or two-dose: V (SW) 9 mo of age + V (SW)/or nothing 18 mo of age.~Arm 3 - 9 months one- or two-dose: V (EZ) 9 mo of age + V (EZ)/or nothing 18 mo of age.~V = measles vaccination, EZ = standard titre Edmonston-Zagreb measles vaccine, SW = standard titre Schwarz measles vaccine"
45454761|NCT05231746|Biological|hSTC810|hSTC810 will be administered as an intravenous infusion (IV)
45454762|NCT04286126|Device|Active bilateral DMPFC|Participants in this arm will receive rTMS to bilateral DMPFC. The DMPFC will be targeted utilizing either Nexstim's eField neuronavigation system or Localite's neuronavigation system. Stimulation intensity will be standardized at 100% of resting motor threshold (RMT).
45956743|NCT00144599|Drug|MRA(Tocilizumab)|
45956744|NCT00144599|Drug|placebo|
45956745|NCT02945293|Other|Oxycodone|This study is interventional. Participants are given a single, one time administration of medication 10mg of oxycodone and observed
45956746|NCT02945332|Behavioral|Required supervised walking|The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.
46002839|NCT00549146|Drug|fluticasone propionate/salmeterol 250/50 DISKUS combination product|
46002840|NCT00549146|Drug|fluticasone propionate DISKUS 500mcg|
46002841|NCT04643496|Procedure|Laparoscopic or open Ileocolic resection|Laparoscopic or open Ileocolic resection
46002842|NCT00549185|Drug|SAR3419|Intravenous infusion
45662363|NCT05053711|Device|rTMS+rPMS_iTBS_U|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at ulnaris nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
45662364|NCT05053711|Device|rTMS+rPMS_cTBS_U|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at ulnar nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
45662365|NCT05053711|Device|rTMS+sham rPMS_U|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at ulnar nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
45662366|NCT05081479|Drug|N-Acetylcysteine|N-AC infusion will begin the day before CAR T cell infusion and continuously infused over 24-hours for 14 days or until time of discharge whichever is earlier. Interruptions of N-AC infusion for medical reasons are permissible. The dose for patients <45kg will be adjusted to weight based dosing.
45662367|NCT04421287|Drug|Zhenyuan capsule|0.25g/ tablets, 2 tablets / TID, for 12 weeks
45662368|NCT03824275|Drug|18F- DCFPyL PET/CT|A CT scan using a radioactive marker to better image tumors
45662369|NCT05126329|Drug|amcenestrant|tablet for oral use
45662370|NCT05053165|Drug|LB-P6|Healthy subjects will be randomized to receive LB-P6 once daily orally
45662371|NCT05053165|Drug|LB-P8|Healthy subjects will be randomized to receive LB-P8 once daily orally
45662372|NCT05053165|Drug|Placebo|Healthy subjects will be randomized to receive placebo once daily orally
45662373|NCT05079763|Other|Bacterial cellulose-monolaurin hydrogel|Hydrogel containing Komagataeibacter bylines-derived bacterial cellulose, virgin coconut oil monolaurin, cucumber fragrance and distilled water
45662374|NCT05079763|Other|Placebo cream|Cream containing distilled water, white petrolatum, steady alcohol, propylene glycol, sodium laurel sulphate, methylparaben and propylparaben
46002843|NCT04643847|Drug|Almonertinib|110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment). For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions (The number of lesions received SBRT and radiation dose are not standardized).
45662375|NCT04421521|Procedure|Acupuncture|Acupuncture with disposable needles will be implemented
45662376|NCT05050981|Drug|Hormone replacement therapy|Hormone replacement therapy: menopause hormone therapy with estrogen-only or oestrogen-progestin.
45662377|NCT05050981|Drug|Selective serotonin reuptake inhibitors|Selective serotonin reuptake inhibitors: anyone in the category, e.g.: fluoxetine, sertraline, etc.
45454763|NCT04286126|Device|Active right-sided OFC|Participants in this arm will receive rTMS to the right OFC. The right OFC will be targeted utilizing either Nexstim's eField neuronavigation system or Localite's neuronavigation system. Stimulation intensity will be standardized at 110% of resting motor threshold (RMT).
45662378|NCT05078983|Diagnostic Test|CGA-FI (COMPREHENSIVE GERIATRIC ASSESMENT - FRAILITY INDEX)|GERIATRIC ASSESMENT TEST
45662379|NCT05050903|Other|Rhinovirus infection|Inoculation with rhinovirus-16
45662380|NCT05049889|Other|Terrestrial exercise|"At visit 1 (Day 0), an exercise test will be performed (maximal incremental test), followed by a 30-minute submaximal exercise at constant load.~During this exercise, continuous data collection will be performed:~Continuous 12-lead electrocardiogram~Continuous monitoring of blood pressure and ventilation."
45662381|NCT05049889|Other|Swimming exercise|"At visit 2 (Day 7), the subjects will perform a swimming exercise in the experimental pool equipped with a turbine to create a counter-current. The water speed will be constant (4 min per 100 m, i.e. 1.5 km/h). The duration of the exercise will be 30 minutes. Each diver will breathe with the help of a snorkel.~During this exercise, continuous data collection will be performed:~Continuous 12-lead electrocardiogram~Continuous monitoring of blood pressure and ventilation."
45662382|NCT05049889|Device|Transthoracic cardiac ultrasound|The participants will have a transthoracic cardiac ultrasound to measure the dilatations of the cardiac cavities at visit 1 and 2.
45662383|NCT05049889|Device|Transthoracic pulmonary ultrasound|The participants will have a transthoracic pulmonary ultrasound to quantify the presence of signs of pulmonary vascular overload (comet tails) at visit 1 and 2.
45662384|NCT05049889|Biological|Blood collection|Several blood samples will be collected at visit 1 and 2.
45662385|NCT04421599|Other|The Necessity of Aspiration|"The patients who met the inclusion criteria and agreed to participate in the study were assigned to the Experimental Group A who were administered IM injection during which aspiration lasted for 5-10 seconds, to the Control Group who were administered IM injection during which aspiration lasted for 1-2 seconds, and to the Experimental Group B who were not administered IM injection according to the stratified block randomization list. The same Intramuscular Injection Application Protocol was applied while all the injections were administered."
45662386|NCT05074693|Other|EASE app|EASE is a mobile intervention designed to reduce ongoing mental health concerns among BLAI individuals with elevated anxiety and/or depressive symptoms by targeting anxiety sensitivity. The EASE app employs a variety of features to educate its users on how to deal with increased levels of stress, anxiety, and depression, and train users on how to better cope with the negative feelings of stress. The app contains a series of on-demand features, including a coping toolkit, stress management trainings, and a series of educational videos designed to teach participants how to better deal with stress. EASE also utilizes Ecological Momentary Assessments (EMAs) to gather information, and provide personalized messages to users in real time. Finally, EASE is outfitted with COVID-19 related elements, including a symptoms tracker (which participants can use to report symptoms of COVID-19 they may be experiencing), and a collection of COVID-19 related food, housing, and job placement resources.
45816996|NCT04083781|Drug|Concizumab|Concizumab will be administered daily subcutaneously (s.c., under the skin). When patients are randomised to concizumab prophylaxis they will receive a loading dose of 1.0 mg/kg concizumab at visit 2a (week 0: arm 2, 3 & 4) or visit 9a (week 24: arm 1) followed by an initial daily dose of 0.20 mg/kg concizumab from treatment day 2. Within an initial 5-8-week dose adjustment period on 0.20 mg/kg concizumab, the patients can be increased or decreased in dose to 0.25 mg/kg or 0.15 mg/kg concizumab. A potential dose adjustment will take place at visit 4a.1 (week 6: arm 2, 3 & 4) or 9a.3 (week 30: arm 1) and will be based on the concizumab exposure level measured at the previous visit 4a (week 4) or 9a.2 (week 28). Patients who have concizumab exposure levels of 200-4000 ng/mL will stay at 0.20 mg/kg concizumab. Patients in arm 1 will continue on-demand treatment with their usual bypassing product until visit 9a (week 24: end of main part for arm 1).
45816997|NCT04076176|Dietary Supplement|CGMP protein substitute|PKU sphere is a powdered, low phenylalanine protein substitute, containing a balanced mix of casein glycomacropeptide (CGMP) isolate, essential and non-essential amino acids, carbohydrate, vitamins, minerals, trace elements and the omega-3 long chain polyunsaturated fatty acid (LCP); docosahexaenoic acid.
45816998|NCT04076176|Dietary Supplement|L-amino acid protein substitute|Patient may choose from a list of products, specified in the protocol, that are nutritionally comparable to PKU Sphere.
45816999|NCT04067752|Other|high dialysate sodium concentration (138 mEq/L)|high dialysate sodium concentration (138 mEq/L)
45817000|NCT04067752|Other|Low dialysate sodium concentration|low dialysate sodium concentration (132 mEq/L)
45817001|NCT04067388|Other|Rapid Evaporative Ionisation Mass Spectrometry (REIMS)|Use of iKnife instrument during standard operative practice
45817002|NCT04052841|Procedure|Thermal pulsation|Participants underwent a single LipiFlow® thermal pulsation system (TearScience Inc., Morrisville, NC,USA) treatment on the first visit: after lid hygiene with wet cotton swabs(OCuSOFT, Inc., Texas, USA) and instillation of anesthetic eye drops (Alcaine, proparacaine hydrochloride 0.4 ml/2mg) in both eyes, sterile eye cups were placed on to the conjunctival sac as instructed by the manufacturer, after 12 minutes of upper and lower palpebral conjunctival surfaces heat while simultaneously graded pulsatile pressure applying, eye cups were removed slightly.
45454764|NCT01211587|Drug|safinamide|Safinamide will be provided in tablets equivalent to 50 mg in blisters. After randomization, patients receiving safinamide will take two 50 mg tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
45817003|NCT04052841|Procedure|Intense pulsed light therapy|Lid hygiene with wet cotton swabs(OCuSOFT, Inc., Texas, USA) before treatment. Intense pulsed light (IPL) with a range of wavelength (570 or 620 nm) was performed every 3 weeks，3 times in total (0, 3w, 6w). 10 pulses were transmited from one tragus through nose to the other tragus was a single pass, each treatment needed to do 2 passes. Manual lid massage was done after per IPL treatment.
46002844|NCT00549263|Drug|SB797620|
45662387|NCT05074693|Other|INSIGHT (Control) App|"A standard of care control intervention was developed using the INSIGHT platform. This app contains a library of educational videos that cover topics such as meditation and mindfulness, as well as general stress reduction techniques. Additionally, participants have access to a Report Distress feature that enables them to report moments when they are feeling high levels of stress. Finally, participants will be able to report any COVID-19 related symptoms they experience using a COVID-19 symptom tracker feature. Participants assigned to this condition will received 2 daily EMAs, during which they will be prompted to watch one of the aforementioned educational videos."
45662388|NCT05074459|Drug|Eptinezumab Mammalian Cell Line|Concentrate for solution for IV infusion
45662389|NCT05074459|Drug|Eptinezumab Yeast Cell Line|Concentrate for solution for IV infusion
45454765|NCT01211587|Drug|placebo|Identical placebo tablets will be provided in blisters. After randomization, patients receiving placebo will take two tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
45662390|NCT04221061|Drug|18F-FluorThanatrace|18F-FluorThanatrace is a novel radiopharmaceutical which measure PARP-1 expression using a Positron Emission Tomography (PET/CT) scan.
45662391|NCT05073679|Drug|Naltrexone Hydrochloride|25mg x 3 days then 50mg a day thereafter
45662392|NCT05073679|Other|Control|Methylcellulose and gelatin capsule only
45662393|NCT04224181|Radiation|Cardiac PET|A scan examining blood flow to the heart
45662394|NCT04224181|Radiation|99mTc-tilmanocept SPECT/CT|A scan to look at inflammation in the arteries
45662395|NCT04224181|Radiation|Contrast Enhanced Coronary and Aortic Computed Tomography Angiography|A scan of the heart and surrounding blood vessels
45662396|NCT05120557|Device|Ultrasound liver assessment|The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
45662397|NCT05120011|Dietary Supplement|L-carnitine|L-carnitine-L-tartrate
45662398|NCT05120011|Dietary Supplement|L-leucine|L-leucine
45662399|NCT05047003|Diagnostic Test|EyeBOX Model EBX-4 (Portable version)|The portable EyeBOX takes less than 4 minutes to complete and involves watching a video move around the perimeter of an LCD monitor positioned in front of the patient while a high-speed camera continuously records gaze positions. The Portable EyeBOX software detects subtle changes in eye movements consistent with concussion and calculates a BOX score.
45662400|NCT05046301|Procedure|Biospecimen Collection|Correlative studies
45662401|NCT05046301|Other|Contrast Agent|Given IV
45662402|NCT05046301|Procedure|Contrast-Enhanced Mammography|Undergo contrast-enhanced mammography
45662403|NCT05046301|Other|Questionnaire Administration|Ancillary studies
45662404|NCT05071807|Drug|Pecans|Participants will receive 2 oz of pecans daily to replace a typical snack and continue consuming their usual diet for 12 weeks.
45817004|NCT04052841|Procedure|Manual warm compresses|Lids hygiene of both eyes with wet cotton swabs(OCuSOFT, Inc., Texas, USA).Commercial heated eye patch was use for 10 min. Manual lid massage every 2 weeks, 5 times in total(0，2w, 4w, 4w, 8w).
45454766|NCT04269356|Drug|BMS-986256|Specified dose on specified days
45662405|NCT05071807|Other|Usual Care|Participants will receive grocery vouchers and continue consuming their usual diet for 12 weeks.
45662406|NCT05046067|Procedure|Computed Tomography|Undergo CT
45662407|NCT05046067|Procedure|Therapeutic Conventional Surgery|Undergo surgery per standard of care
45662408|NCT05043259|Biological|inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research & Development Co., Ltd. 0.5 ml / bottle.
45662409|NCT05043259|Biological|Low dose aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
45817005|NCT04048941|Procedure|One Needle Hand Acupuncture with Movement|One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
45454767|NCT04269356|Drug|Milk of magnesia|Specified dose on specified days
45454768|NCT01117831|Other|Epidemiological intervention|An analysis of 600 diabetic patients in the Island of PR to evaluate metabolic control.
45454769|NCT05538676|Diagnostic Test|BPA-PET imaging|PET imaging
45454770|NCT01117909|Other|Mobilization therapy in addition to standard therapy|Subject will receive three 60-second bouts of posterior joint mobilizations applied to the ankle joint during each treatment session. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression.
45454771|NCT01117909|Other|Sham intervention|Physical therapist will lay hands as if to perform the joint mobilization but no movement will occur.
45662410|NCT05043259|Biological|High dose aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.2 ml / dose, contains 2×10^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
45662411|NCT05071495|Device|Smartphone application|"Smartphone application named Signal, which connects patients and health providers"
45662412|NCT05069311|Drug|Multimodal analgesia|"Multimodal analgesia includes the combination of:~morphine given by PCA (patient-controlled analgesia) at 1 mg/dose~bupivacaine 0.25% and dexmedetomidine 0.5 mcg/mL (total volume of 10 mL) by epidural-catheter bolus given preoperatively~bupicavaine 0.125% and dexmedetomidine 0.5 mcg/mL at a 5 mL/hour rate per epidural-catheter given intraoperatively~bupivacaine 0.1% and dexmedetomidine 0.5 mcg/mL given by programmed intermittent epidural bolus (PIEB), set to be delivered every one-hour~etericoxib 90 mg per oral give two-hours before surgery and then continued until three days post-surgery~paracetamol 1 g (intravenously) given on the day of the surgery, continued at 10 mg/kg dose every 8 hours until three days post-surgery"
45662413|NCT05069311|Drug|Conventional intravenous analgesia|Standard analgesia includes fentanyl 2 mcg/kg (bolus) and morphine given by PCA (patient-controlled analgesia) at 1 mg/dose
45662414|NCT05039281|Biological|Atezolizumab|Given IV
45662415|NCT05039281|Drug|Cabozantinib|Given PO
46002845|NCT00549341|Drug|Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin|100U vials, doses ranged from 50U-200U, single injection.
45662416|NCT05114161|Other|Novel Care Pathway|The novel care pathway will follow a decision tree based on several criteria to stratify patients in an appropriate risk category. Patients with large radiographic lobar consolidation OR POC CRP > 60mg/L will be deemed 'appreciable risk' while patients with CRP < 20mg/L will be deemed 'low risk'. Patients with CRP between 20 - 60mg/L will be evaluated further, as follows: if they have an oxygen saturation of <95%, they will be 'appreciable risk', and if not, there are further decision points: if they are not tachypneic, they will be 'low risk'; if they are tachypneic and less than 1 year of age, they will be 'appreciable risk'; if they are tachypneic, over 1 year of age, but with either complete PCV13 immunization OR detectable wheezing as per the ED clinician, they will be classified as 'low risk'. Appreciable-risk participants will be given a prescription for antibiotics at ED discharge.
45662417|NCT05036863|Behavioral|Weekly questionnaires|Patients will complete weekly symptom monitoring PROMs. If a symptom exceeds the thresholds for clinical importance, a registered nurse will contact the patient, confirm the symptoms and coordinate the further clinical procedure in line with standard practice.
45662418|NCT05113381|Device|CerebroFlo™ EVD Catheter|The CerebroFlo™ EVD Catheter is indicated for temporary insertion into a ventricular cavity of the brain for external drainage of cerebrospinal fluid (CSF) in those patients with elevated intracranial pressure (ICP), intraventricular hemorrhage, or hydrocephalic shunt infections.
45662419|NCT05065645|Drug|Angiotensin Converting Enzyme 2|SAD: single dose; MAD: dosage 2x daily for 7 days
45662420|NCT05065645|Drug|Sodium chloride|SAD: single dose; MAD: dosage 2x daily for 7 days
45662421|NCT05034913|Other|Digital photography measurements|"The participant will be instructed to take off any thick outer layers and leave on shirt and pants. Tops will be gathered to make cloth tight to body. The participant will stand next to an 8 ½ x 11 piece of paper taped to a wall, to use as a reference for linear regression calculations."
45662422|NCT05064631|Drug|Bacterial Lysate|Bacterial lysate medicines are made from bacterial cells that are broken down and are intended to stimulate the immune system.
45662423|NCT05063383|Other|This study does not involve any interventions|This study does not involve any interventions
45662424|NCT05112289|Diagnostic Test|Brain Neuroimaging|Non-invasive magnetic resonance imaging sequences will investigate metabolic signatures unique to migraine WMH. Imaging data will be used for development of artificial intelligence (AI) algorithms to classify the cause of WMHs.
45454772|NCT04263974|Other|Smartphone Application|Exercises and recommendations, based on current scientific evidence, and delivered through the app for Smartphone called CareHand. The intervention protocol is based on strengthening and stretching recommendations for rheumatoid arthritis and osteoarthritis in hands, transferred to an application format through explanatory videos together with tools to improve the autonomy, motivation and adherence of the patient
45662425|NCT01364467|Drug|Placebo|Children aged 7-11 years old will receive placebo 200 mg three times a day (TID), while children older than 12 will receive Placebo 400 mg TID.
45662426|NCT01364467|Drug|Guaifenesin|Children aged 7-11 years old will receive guaifenesin 200 mg TID, while children older than 12 will receive guaifenesin 400 mg TID.
45662427|NCT04226365|Drug|Nortriptyline|10mg capsule Nortryptyline
45662428|NCT04226365|Drug|Placebo|10mg capsule Thick-It filler
45662429|NCT05470387|Drug|LB1148|A total of 700 mL of drug product will be administered orally as a split dose before surgery.
45662430|NCT05470387|Drug|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
45662431|NCT05062837|Drug|Hepatectomy Combined With Camrelizumab and Apatinib|Patients with CNLC IIIb hepatocellular carcinoma will receive hepatectomy. Two to four weeks later, they will receive camrelizumab and apatinib treatments.
45817006|NCT04048941|Procedure|One Needle Hand Acupuncture without Movement|One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to lay quietly on the examination table.
45817007|NCT04048941|Procedure|Control Acupuncture with Movement|Control acupuncture at acupoint LI4 is performed, which should not have a large affect on pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
45817008|NCT04044534|Drug|Intranasal insulin|Subjects in this arm will receive intranasal insulin (80 IU per day).
46078886|NCT00773097|Biological|MUC1 - Poly ICLC|The vaccine will be administered on an outpatient basis in the Digestive Disorders Clinic. The total volume of each dose of vaccine MUC1+ POLY-ICLC will be approximately 250 microliters subcutaneously (SQ) in the upper thigh. The site of injection will remain the same thigh, to enhance the potential immune response.
45458160|NCT02316418|Device|Hairstetics™ anchoring system|"Overall, up to 360 prosthetic hair implants will be set in the scalp. The procedure will be performed in accordance with the instructions in the device Instructions for Use. Training and certification of operators by the Sponsor is a prerequisite for use of the study device by the former.~Hair extensions will be attached to the fibers four weeks after the implantation."
45662432|NCT05468125|Procedure|guidance|either follow the care bundle or the best evidence practice
45662433|NCT05033899|Other|ERAS protocol|to compare between Enhanced Recovery After Surgery (ERAS) protocol and conventional care in non-insulin dependent diabetic patients undergoing lumbar spine surgery.
45662434|NCT05110417|Drug|Pyridostigmine Bromide 60 Milligrams (mg)|One tablet will be provided to patients during the second visit.
45662435|NCT02520661|Behavioral|Care Transitions Intervention|The Care Transitions Intervention uses coaches, in this case paramedics, to support patients being discharged home by transferring skills to activate patients.
45662436|NCT05033665|Behavioral|Increase water consumption|The underhydrated individuals will be instructed to increase their water intake for one week in order to meet the following two criteria: a) urinate at least 7 times per day and b) have straw-like color urine. A 2-mile run will be completed before and after the 7-day intervention.
45817009|NCT04044534|Drug|Placebo|Subjects in this arm will receive placebo.
45817010|NCT04020913|Drug|Somatropin injection|"Boys with short stature will be studied for measures of:~skeletal muscle strength, power, and endurance~muscle agility~lean body mass accrual~bone mineral density and resting energy expenditure before and after 6 months and 12 months of GH administration"
45817011|NCT04014790|Drug|RGI-2001|Subjects will receive 6 weekly doses of RGI 2001, 100 μg/kg via IV administration after completion of alloHSCT
45662437|NCT05033665|Behavioral|Maintain adequate water consumption|The subjects that are classified as euhydrated will be asked to maintain high water intake for one week to ensure proper hydration. A 2-mile run will be completed before and after the 7-day intervention.
45662438|NCT05109871|Other|KForce Link|Traction (pull-type) dynamometer
45662439|NCT05061199|Procedure|approach of anastomosis|The approach of anastomosis
45662440|NCT05031481|Drug|Venus 20 + 0,064|Venus vaginal cream 20 + 0,064, single-dose.
45662441|NCT05031481|Drug|Venus 20 + 1|Venus vaginal cream 20 + 1, single-dose.
45662442|NCT05031481|Drug|Venus 20 + 4|Venus vaginal cream 20 + 4, single-dose.
45662443|NCT05031481|Drug|Butoconazole nitrate|Butoconazole nitrate vaginal cream, 100 mg single-dose.
45662444|NCT05061121|Other|combined effect|Compare the short- and mid-term effects of Mulligan's SNAGs, Myofascial release, and their combination on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
45662445|NCT05109559|Biological|Full dose of Ad26.COV2. 5x10^10vp|A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
45662446|NCT05109559|Biological|Half dose of Ad26.COV2. 2.5x10^10vp|A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
45662447|NCT05109559|Biological|Full dose of Ad26.COV2. 5x10^10vp|A booster dose (2nd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
45662448|NCT04998643|Diagnostic Test|Muscle ultrasound to estimate lean body mass|The investigators will perform serial muscle ultrasounds in the postoperative period to estimate lean body mass.
45817012|NCT04014790|Drug|Standard of Care|Standard of care prophylaxis regimen will be administered according to institutional guidelines
45817013|NCT04009031|Device|Bootle Blast|During the baseline assessment, an occupational therapist will calibrate the video game to the child's therapy needs and functional abilities. Within a week of the first assessment, the research team will set up the video game in the participant's home where it will remain for 12 weeks. Training on how to play the game and a user manual will be provided. The researcher will work with each family to establish a play objective (minutes/day and days/week) that considers the family's schedule. Five-minute telephone check-in calls will be done weekly.
45817014|NCT04005521|Behavioral|Preventive intervention|Preventive, structured exercise protocol
45956747|NCT02945332|Behavioral|Non-required supervised walking|The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.
45662449|NCT05031247|Other|Wellbeing Program|The community navigator program was developed during a three-phase community-based participatory research project that aims to examine emotional/mental health needs and address access to mental health services among immigrants and refugees from Muslim-majority countries.
45662450|NCT04998097|Device|repetitive transcranial magnetic stimulation (rTMS)|Investigators adopted the iTBS protocol which follows the standard TBS protocols, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% motor threshold. In each session, a 2-s train of bursts will be repeated every 10 s for a total of 570 s (1800 pulses) to the left dorsolateral prefrontal cortex (DLPFC). TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks.
45662451|NCT04998097|Device|sham repetitive transcranial magnetic stimulation (rTMS)|no stimulation, Sham TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks.
45662452|NCT05059093|Diagnostic Test|Classification and segmentation deep learning models|Models that will be trained on retrospectively acquired data and run on the prospectively acquired data to extract biometric parameters and amniotic volume estimation.
45662453|NCT04218097|Other|Study questionnaire|Monitoring - data collection: Sending of an information form and the study questionnaire, the YFAS and Hospital Anxiety and Depression (HAD) scale by post within a follow-up period of 24 to 36 months. With a stamped envelope for the answer and a telephone reminder if necessary.
45662454|NCT05058859|Drug|Dapagliflozin|Dapagliflozin is to lower blood sugar levels in adults with type 2 diabetes
45662455|NCT05057767|Drug|Midazolam injection|No premedication will be given to Patients in the group undergoing a standardized anesthesia protocol which include induction with thiopental (5 mg/kg) and fentanyl (1-2 μg/kg). Atracurium will be used as a muscle relaxant. After tracheal intubation, anesthesia will be maintained with isoflurane in a concentration of 0.8%-1.2%. Ventilation will be adjusted to produce normocapnia. At the end of surgery, reversal of residual neuromuscular blockade will be accomplished using i.v. atropine 20 μg/Kg and neostigmine 40 μg/kg.
45662456|NCT04997317|Drug|177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)|177Lu-DOTA-JR11 has three main components, namely the somatostatin analogue JR11, the chemical chelator group DOTA and the beta emitter 177Lutetium (177Lu). In the Phase 0 part of the study 177Lu-DOTA-JR11 will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq).
45662457|NCT04997317|Drug|177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4|177Lu-DOTATOC is a therapeutic medicinal product and has 3 main components (a) 177Lutetium (177Lu), a beta-emitting radionuclide with a half-life of 6.64 days; (b) DOTA, a chemical chelator group; and (c) TOC (= [Tyr]3-octreotide) an agonistic somatostatin analogue which binds to sstr2 and sstr5 receptors. In the Phase 0 part of the study 177Lu-DOTATOC will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq). The remaining 2 cycles will be performed with an activity of 7.4 GBq 177Lu-DOTATOC (total number of cycles = 4).
45662458|NCT04997317|Drug|177Lu-DOTA-JR11 (Phase I/II)|In the phase I/II part of the study: 3 cycles of 177Lu-DOTA-JR11 will be administered with an activity of 4.5-7.4 GBq. Two additional 177Lu-DOTA-JR11 treatment cycles can be performed if clinically indicated
45662459|NCT04997239|Biological|Two doses of quadrivalent influenza vaccine|15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
45662460|NCT04997239|Biological|One dose of quadrivalent influenza vaccine|15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.
45662461|NCT04216693|Drug|Digoxin tablet|The NASH patients in experimental group will take digoxin tablets orally with the goal of achieving a serum digoxin concentration of 0.7-1 ng/ml for 24 weeks.
45662462|NCT04216693|Other|Placebo|The control group will receive the digoxin-like placebo treatment.
45662463|NCT05057611|Other|CRT-targeted strategy associated with a clinical hemodynamic phenotyping to personalize initial resuscitation in septic shock patients|A combination of combine a CRT-targeted strategy with a clinical hemodynamic phenotyping that may aid to personalize initial resuscitation with potential additional fluid-sparing effects.
45662464|NCT05057611|Other|Usual care (UC)|- Patients allocated to the UC group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP >65 mmHg, heart rate (HR) <120 beats per minute (BPM), arterial oxygen saturation (SaO2) >94%, Hb > 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
45662465|NCT01364389|Drug|AIN457|3 mg/kg
45662466|NCT01364389|Drug|ACZ885|3 mg/kg
45662467|NCT01364389|Drug|Prednisone|20 mg
45662468|NCT01364389|Drug|Placebo|Matching placebo to AIN457, ACZ885 and prednisone
45662469|NCT05056831|Behavioral|Behavioral Intervention|Attend face-to-face mind-body sessions
45662470|NCT05056831|Other|Best Practice|Receive usual care
45662471|NCT05056831|Other|Informational Intervention|Receive targeted text messages
45662472|NCT05056831|Other|Quality-of-Life Assessment|Ancillary studies
45817015|NCT03995966|Behavioral|Noncontingent Reinforcement (NCR)|This treatment for ASIB is based on reinforcer competition. Noncontingent Reinforcement (NCR) will consist of first conducting a competing stimulus assessment (CSA) to identify stimuli (toys, massagers, etc.) associated with reductions in ASIB and high levels of engagement. Treatment then involves NCR in which alternative sources of reinforcement are made freely available to compete with reinforcement maintaining ASIB. Providing additional sources of reinforcement is thought to decrease ASIB by producing a shift in the allocation of responding toward accessing the newly available reinforcement. Additional, more restrictive components may be added if the competing stimuli (CS) are ineffective in reducing ASIB. These additional components are applied in accordance to the least-restrictive treatment model and include response blocking, response reduction procedures, protective equipment, or mechanical restraint.
45662473|NCT05056831|Other|Questionnaire Administration|Ancillary studies
45662474|NCT04211155|Other|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
45662475|NCT04211155|Other|MRI|Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.
45662476|NCT04996381|Diagnostic Test|Scanning Chest X-rays and performing AI algorithms on images|Chest X-Rays; AI CNNs; Results
45662477|NCT05027737|Procedure|Early Ileostomy Closure|Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo standardized reversal of their diverting loop ileostomy (stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia) between post-operative days 10-14.
45662478|NCT04995835|Drug|Cefiderocol|After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
45956748|NCT02945332|Device|Fitbit Flex|
45956749|NCT04692415|Drug|Degludec|treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles
45956750|NCT04692415|Drug|Glargine U300|treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles
45662479|NCT05026723|Behavioral|MTM + ILI|Weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 20-session telephone lifestyle intervention change program
45662480|NCT05026723|Behavioral|Standard MTM|Weekly home meal delivery; an explanation of the medical tailoring of the meals; and an initial consultation with a dietitian
45662481|NCT05054881|Other|sciatic nerve blockade under ultrasound control with a peripheral nerve stimulator|"Following the ultrasound visualization of the sciatic nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated.If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
45662482|NCT05054881|Other|sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator|"Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
45662483|NCT05054413|Other|Questionnaire Administration|Complete questionnaires
45662484|NCT05025475|Device|NobleStitch EL|Closure of PFO using NobleStitch EL Closure System
45662485|NCT05025475|Device|Amplatzer|Closure of PFO with FDA approved Amplatazer PFO closure device
45662486|NCT04950283|Diagnostic Test|magnetic resonance examination, anthropometric and metabolic characterization|Participants undergo a magnetic resonance examination, anthropometric characterization and metabolic characterization via oral glucose tolerance test.
45454773|NCT04263974|Other|Conventional treatment|Conventional approach provided by the Andalusian Public Health System in Primary Care settings. This approach consists of routine visits to the general practitioner specialist, and the delivery of an exercise sheet and recommendations. This general mobility and stretching worksheet contains detailed images, as well as a description of how to perform the exercises and the dose to be taken. While most exercises are intended for the wrist and hands, this sheet also includes basic exercises for the elbow joint.
45662487|NCT05024383|Other|Chemical sensitivity|Chemical sensitivity will be evaluated with paper taste strips embedded with varying concentrations of capsaicin solutions (activates TRPV1) and allyl isothiocyanate solutions (activates TRPA1) applied to the tongues of healthy subjects and site of cancer in oral cancer patients.
45662488|NCT05024383|Other|Mechanical sensitivity|Mechanical sensitivity will be evaluated via von Frey filaments applied to the tongues of healthy subjects and and site of cancer in oral cancer patients.
45662489|NCT04949425|Drug|Adavosertib|Patients will receive Adavosertib orally.
45817016|NCT03995966|Behavioral|Combination Treatment|Combination Treatment is based on the same principles as NCR, but differs in three ways: 1) It includes three pre-treatment assessments that seek to establish competing stimuli, tasks, and self-control equipment through prompting and reinforcement; ; 2) Intensive training in each of these components is conducted to strengthen skills needed to fully access available reinforcement to compete with ASIB; and 3) Combination treatment is assessed, which includes the noncontingent delivery of competing stimuli and differential reinforcement of alternative behavior to reinforce engagement with competing tasks, and use of alternative self-control equipment. This will increase the amount and vary the sources of alternative reinforcement to more effectively reduce ASIB and self-restraint. Restrictive components may be applied as described for the NCR treatment.
45817017|NCT03978130|Other|mHealth-CR|Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
45817018|NCT03973606|Other|Heath literacy assessment in Arab women in East Jerusalem|A 4-sessions intervention to increase the participant's self-efficacy when interacting with their physician and increase their cardiovascular health knowledge.
46078887|NCT02815826|Other|Barefoot training|During 16 weeks, habitual shod runners kept their normal running training routine (wearing shoes), while they were introduced progressively to BF condition. Three training sessions were performed per week. Barefoot training started with 5% and ended with 20% of their WTV being performed without shoes. Soft surfaces (i.e. sand and grass) were adopted in the beginning of training (week 1 to 8). From week 9 to 16, participants mixed soft with harder surfaces, as treadmill and asphalt, to accomplish the training.
46078888|NCT02815826|Other|Shod training|Running training planned individually to each runner, according to their physical fitness, and performed with shoes.
46078889|NCT02731482|Other|Training Group|"Three sessions per week, each lasting 50 minutes, during eight weeks.~Aerobic training in stepping training.~Resistance training: Three sets of eight repetitions each, in both simultaneous members, using an elastic band. The trained muscles are quadriceps, hamstrings, deltoid and biceps.~Once a week, patients will receive a phone call and every two weeks, patients will get a visit of the researcher at his home."
45454774|NCT05214820|Biological|Radiopharmaceutical 68Ga-PSMA|Injection of 68Ga-PSMA followed by 3 PET/CT acquisitions
45817019|NCT03971474|Drug|Docetaxel|Given IV
45817020|NCT03971474|Drug|Gemcitabine|Given IV
45817021|NCT03971474|Drug|Gemcitabine Hydrochloride|Given IV
45817022|NCT03971474|Biological|Pembrolizumab|Given IV
45454775|NCT01118065|Drug|everolimus|
45662490|NCT05023603|Diagnostic Test|self-report questionnaire|Individual subject factors included and self-report questionnaires will be collected through an interview process.
45662491|NCT04203901|Biological|CMN-001|Autologous Dendritic Cell Therapy
45662492|NCT04203901|Biological|Nivolumab+Ipilimumab|anti-PD-1 and anti-CTLA4 antibodies
45662493|NCT04203901|Drug|Lenvatinib+Everolimus|TKI+mTOR inhibitors
45662494|NCT05023525|Drug|HSK31858, tablet|Starting dose in single ascending dose: 5 mg
45662495|NCT05023525|Drug|Placebo, tablet|Matching placebo
45662496|NCT05022589|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, 5 sessions per week, ~30 minutes per session.
45662497|NCT04991311|Drug|Glepaglutide|Glepaglutide will be delivered in a single-use autoinjector.
45662498|NCT05020951|Other|Medidata RAVE|Data collection done exclusively through Medidata Rave. Medidata Rave is a clinical data management system being used for data collection for this trial/study. Access to the trial in Rave is controlled through the CTEP-IAM system and role assignments.
45662499|NCT04411303|Behavioral|Step length biofeedback|Participants will be provided with visual feedback of their right and left step lengths on a screen in front of a treadmill.
45662500|NCT04411303|Behavioral|Propulsive force biofeedback|Participants will be provided with real-time visual feedback of anterior-posterior ground reaction forces of the paretic limb during stance phase on a screen in front of a treadmill.
45662501|NCT04411303|Behavioral|Interlimb asymmetry biofeedback|Participants will be provided with visual feedback of stride-by-stride values of their interlimb asymmetry on a screen in front of a treadmill.
45662502|NCT04411303|Behavioral|Aerobic intensity-based walking|Participants will walk at three different aerobic intensities. Aerobic intensity will be set based on target heart rate zones calculated with the Karvonen Formula. For low intensity, participants will walk at 30-40% intensity. In moderate intensity conditions, participants will walk at a 50-60% intensity level. In vigorous intensity conditions, participants will walk at an 70-80% intensity level. Aerobic intensity will be manipulated by changing walking speed.
45662503|NCT04421209|Drug|Propranolol Hcl 40mg Tab|40mg PO BID for the three days prior to surgery, 40mg PO BID the day of surgery and on post-op days 1 and 2.
45662504|NCT04421209|Drug|Placebo oral tablet|Placebo tablets administered with the same schedule of Propranolol tablets
45662505|NCT05020249|Drug|bimekizumab|Study participants will receive bimekizumab administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
46078890|NCT02731482|Other|Control Group|"The participants will receive verbal and written information about the importance of physical activity and walk in moderate intensity, at least, three times a week for 30 minutes.~Participants will not receive any supervised physical training.~Once a week, patients will receive a phone call to provide support and general advice."
45662506|NCT05020249|Other|Placebo|Study participants will receive placebo administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
45662507|NCT04947397|Diagnostic Test|Pupillometry|Pupillometry prior to extubation
45662508|NCT04989439|Other|Electrical impedance tomography and ultrasonography of the lung|Both EIT and LUS are non-invasive methods and do not pose any additional risk for the patient. The LuMon System with pediatric EIT belts (LuMon Belt, Sentec, Landquart, Switzerland) will be used. The belt will be placed on the thorax circumference of the infant and connected to the LuMonConnector (Sentec, Landquart, Switzerland). Small electrical currents (3 mA, 198 kHz) will be repetitively injected in rotation through adjacent electrode pairs, and voltage changes will be measured by all passive electrodes pairs (scan rate 48 Hz). Changes in lung electrical impedance will be continuously recorded for 5 minutes. EIT data will be analyzed off-line using Matlab (Mathworks, Natick, Massachusetts, USA). The regional tidal volume distribution, the homogeneity of tidal ventilation distribution, regional respiratory system compliance, and alveolar overdistension and collapse will be assessed. LUS will be performed by experienced users, with a 10 MHz linear transducer.
45454776|NCT03940339|Other|Suboccipital myofascial release|The MFR technique will be given in the upper cervical region with the patient in supine position. The MFR will be given for three repetitions per session, three times per week for the period of four weeks.
45662509|NCT05019937|Behavioral|Educational meeting|The investigators will hold a full-day educational meeting. The meeting will include educating 4-5 representatives of each school, and school-district representatives about the guideline and the advantages of adhering to the guideline.
45662510|NCT05019937|Behavioral|Implementation team|The school-principal forms an implementation team that is responsible for implementing the guideline within their school. The team members (n=4-5) reflect on the implementation progress, make, and refine plans according to Plan-Do-Study-Act, share lessons learned and support each other.
45662511|NCT05019937|Behavioral|Workshops|"The investigators will hold 5 workshops. Workshops will include providing in-depth knowledge and skills on the guideline recommendations. During each workshop one of the guideline recommendations will be presented and discussed.~Moreover, the concept of Plan-Do-Study-Act will be introduced and how it can be used to implement the guideline recommendation(s). During each workshop, the implementation team will share with the group their developed PLAN and barriers and facilitators that have influenced the execution of the PLAN."
45662512|NCT05019937|Behavioral|Plan-Do-Study-Act improvement cycles|The implementation team will implement the guideline in a cyclical manner by using Plan-Do-Study-Act. First a Plan is specified during the workshop by using SMART-goals, next the change is carried out between workshops (Do), the implementation team analyses whether it went well and what needs to be improved (Study), changes are made (Act) and finally the next cycle is planned.
45817023|NCT03971474|Drug|Pemetrexed|Given IV
45817024|NCT03971474|Drug|Pemetrexed Disodium|Given IV
45817025|NCT03971474|Biological|Ramucirumab|Given IV
45817026|NCT03970278|Other|No intervention|No intervention
45817027|NCT03969628|Diagnostic Test|ICCMS|Risk caries assessment will consider ICCMS criteria
45817028|NCT03965234|Drug|Cisplatin|Given via infusion
45817029|NCT03965234|Procedure|Isolated Chemotherapeutic Lung Perfusion|Undergo pulmonary suffusion
45817030|NCT03965234|Procedure|Metastasectomy|Undergo metastasectomy
45956751|NCT00527917|Device|placebo|bladder instillation
46078891|NCT00933335|Biological|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
45817031|NCT03947723|Device|Radiofrequency ablation|The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid). A corneal shield will be placed into the fornix prior to treatment. Each section will be treated with the designated power setting in the following manner. The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.
46078892|NCT04015297|Diagnostic Test|raman analysis|negative or pozitive
45454777|NCT03940339|Other|Conventional Physiotherapy|The control group will be receiving conventional physiotherapy treatment for hamstring tightness which includes static stretching, modified hold-relax stretching and contract relax technique.
45454778|NCT03528616|Drug|adenosine,Propranolol,flecainide, amiodarone, propranolol, digoxin and procainamide.|drugs used for treatment of supraventricular tachycardia
45454779|NCT02529631|Drug|orlistat 60 mg|"In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.~Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three orlistat 60 g capsules plus six placebo tablets."
45817032|NCT03921060|Drug|Denosumab|treatment with denosumab every 6 months for up to 5 years
45817033|NCT03912155|Other|Multi-scale analysis of physiological brain networks|It will be simultaneously record the surface EEG, the MEG and in patients only the intracerebral EEG (SEEG). In the case of SEEG with micro contacts, these additional signals will also be recorded in parallel and will provide greater sensitivity to high frequency activities. The physiological networks will be studied in patients thanks to stimulations (external or intracerebral) carried out within the framework of the functional cartography, and the pathological networks thanks to measures in state of rest. For external stimulation protocols, it will be constitute a reference base in MEG and EEG alone (non-invasive) on control subjects.
45817034|NCT03907891|Behavioral|Motivational social support from nurse|A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages.
45956752|NCT00527917|Device|Uracyst|20 ml sterile solution for weekly intravesical instillation
45956753|NCT02945176|Device|ARGOS-IO system|This study will enroll a minimum of 10 and a maximum of 15 patients. It is anticipated to be large enough to provide an initial estimate of common safety events and assessment of performance. Any adverse event (AE), serious adverse event (SAE), ADE (adverse device event) and SADE (serious adverse device event) will be listed. Incidence will be estimated with a 95% confidence interval (Pearson-Clopper, two-sided). The Bland-Altman method will be used to assess the limits of agreement between the IOP measurements ARGOS-IO and surgical manometry. When appropriate, two-sided 95% confidence intervals, for these limits will be calculated accounting for repeated measurements based on the method proposed by Zou (2011). Other secondary performance endpoints will be analyzed by descriptive and explorative statistical methods.
45956754|NCT02945215|Drug|IBI301|IBI301 375mg/㎡
45956755|NCT02945215|Drug|Rituximab|Rituximab 375mg/㎡
45956756|NCT00144677|Drug|sirolimus|
45454780|NCT02529631|Device|polyglucosamine|"In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.~Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three blue placebo capsules plus two placebo tablets (morning) and four polyglucosamine tablets (noon and evening)."
45454781|NCT04469062|Drug|Mirikizumab IV|Administered IV
45454782|NCT04469062|Drug|Mirikizumab SC|Administered SC
45454783|NCT04469062|Drug|Vedolizumab IV|Administered IV
45662513|NCT05019937|Behavioral|Internal facilitator|Each municipality assigns one or more internal facilitators, for example HR-strategist. The internal facilitator will meet their local implementation teams during the educational meeting and workshops. Further meeting can be scheduled based on the needs of each implementation team. The internal facilitator will create a supportive environment within which knowledge is exchanged, barriers to implementation identified, and processes or solutions to overcome those barriers developed, applied, and refined. Moreover, the internal facilitator will establish ongoing audit and feedback processes.
45817035|NCT03907891|Behavioral|Motivational social support from nurse with additional support from significant other|A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages from both a nurse and the patient's self-identified significant other.
45454784|NCT04469062|Drug|Placebo IV|Administered IV
45454785|NCT04469062|Drug|Placebo SC|Administered SC
45817036|NCT03907891|Behavioral|Attention control|A 60-minute session with a nurse focused on American Heart Association educational videos and written information.
45817037|NCT03901001|Drug|sirolimus and oseltamivir|Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
45956757|NCT00144677|Drug|tacrolimus|
45454786|NCT01212211|Other|change in drug therapy|Change in drug therapy with the help of the opinion of pharmacologists : the physician would review the drug treatment of ten residents in coordination with the opinion of pharmacologists
45454787|NCT03528538|Dietary Supplement|AlphaFen fenugreek 400 mg|A brand of fenugreek supplementation that was produced by SPECNOVA. Pure fenugreek without any additives.
45454788|NCT03528538|Dietary Supplement|AlphaFen fenugreek 500 mg|A brand of fenugreek supplementation that was produced by SPECNOVA. Pure fenugreek without any additives.
45454789|NCT03528538|Other|Placebo|rice flour in a vegetable/ cellulose capsule
45454790|NCT01114165|Other|Detection of microbial DNA in blood by SeptiFast Test|The SeptiFast Test is a multiplex polymerase chain reaction (PCR) test that can detect nucleic acids from the most common pathogens (approximately 90%) responsible for hospital-associated bacteremia and takes approx. 6 hours to perform
45454791|NCT01114165|Other|Pathogen detection by blood culture|Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling
45454792|NCT03531190|Dietary Supplement|Nutritional supplement (Protein + MIX)|Protein supplement as needed + 750 mg vitamin C, 15 g. arginine, 35 mg. zinc and two multivitamin tablets, by mouth every day for 35 days.
45454793|NCT03531190|Dietary Supplement|Nutritional supplement (Protein)|Protein supplement as needed
45454794|NCT03145766|Biological|VRVg 2|Modified formulation 1 (Low) of Purified Vero Rabies Vaccine Serum Free
45454795|NCT03145766|Biological|VRVg 1|Initial formulation of Purified Vero Rabies Vaccine Serum Free
45454796|NCT03145766|Biological|Imovax Rabies|Purified inactivated rabies vaccine prepared on human diploid cell cultures
45454797|NCT03145766|Biological|VRVg 2|Modified formulation 2 (Medium) of Purified Vero Rabies Vaccine Serum Free
45454798|NCT03145766|Biological|VRVg 2|Modified formulation 3 (High) of Purified Vero Rabies Vaccine Serum Free
45454799|NCT03145766|Biological|Human Rabies Immunoglobulins (HRIG)|Commercialized formulation of HRIG
45454800|NCT01115179|Drug|propofol|Induction with propofol (1.5 to 2mg/kg) and maintenance of anesthesia with propofol 1% (target controlled infusion with concentration levels of 3-5 ug/ml)
45662514|NCT04946305|Other|Lutathera|Prospective observational study. There is no treatment allocation. Patients administered Lutathera by prescription that have started before inclusion of the patient into the study will be enrolled.
45817038|NCT03901001|Drug|Oseltamivir|oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
45956758|NCT00531076|Biological|bevacizumab|"Intravenous bevacizumab at 7.5mg/kg and 15mg/kg concurrently with thoracic radiotherapy in sequential cohorts.~In the final dose level, bevacizumab 15mg/kg concurrent with radiation will be followed by maintenance bevacizumab 15mg/kg up to a maximum of 6 cycles"
45956759|NCT00531115|Drug|cetuximab 5mg/ml|"Weekly administration of Cetuximab (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes) Oxaliplatin. 130 mg/m2 every three weeks. on day 1 for 4 cycles Capecitabine. 1000 mg/m2 twice daily (2.000 mg/m2 total daily dose) or 750 mg/m2 if Cl Cr=30-50 ml/min (1500 mg/m2 total daily dose) for two weeks (on days 1 to 14) followed by one week of rest (on days 15 to 21).~The patients will receive 4 cycles of cetuximab plus combination chemotherapy administered every 3 weeks in order to achieve a noticeable response. Then, oxaliplatin treatment will be stopped after a maximum of 4 infusions to prevent appearance of neuropathy and then followed by capecitabine 2 weeks out of 3, and cetuximab weekly as maintenance treatment."
45956760|NCT00144716|Device|Insect Repellent plus Insecticide Treated Net|
45662515|NCT05017753|Procedure|Thoracentesis|Thoracentesis will be performed according to local practice, either at the ward or at the radiology department, in addition to standard-of-care medical treatment.
45662516|NCT05017753|Drug|Standard-of-care medical treatment|Standard-of-care medical treatment
45662517|NCT04945993|Device|Endomethasone N|Endomethasone N is a powder intended to be mixed extemporaneously with a eugenol-based liquid (i.e, Endomethasone Liquid) to obtain a permanent root canal sealer. After selection of dentists, they will screen consecutively and systematically eligible patients, will send them the Patient Information Letter and will enroll them in the clinical investigation if non opposition from the patient. Patient clinical data will be recorded in an electronic Case Report Form. Pseudonymized retro-alveolar radiographies at baseline consultation and at 5 and 10 years post-obturation consultations will be recorded in the e-CRF. These radiographies will be examined by 2 independent endodontists and the results of these examinations will be recorded in the e-CRF. Site data will be collected on a Site Questionnaire with Visual Analog Scales.
45817039|NCT03900988|Drug|N-acetyl cysteine|N-acetyl cysteine will be administered at 100 mg/kg daily as a continuous IV infusion (in 1000ml of 5% dextrose) over 24 hrs and oseltamivir 75 mg bid orally for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
45458161|NCT03502486|Other|Moderate exercise|20 minutes of cycle ergometry at 50-60% of heart rate max
45662518|NCT04945603|Other|Standard management according to international/national guidelines|Standard management according to international/national guidelines. Observational study
45662519|NCT04986943|Device|Using ABTHERA Advance without a Wittmann Patch|In this group, patients will be receiving only the ABTHERA Advance product, without the use of the Wittmann Patch
45662520|NCT04986397|Device|Cold Therapy|A Breg Polar Care Cube with WrapOn Polar Pad, Back will be filled with ice chips and water per manufacturer instructions and applied to the abdomen.
45662521|NCT04986397|Other|Standard of Care|Standard post-operative analgesia without the use of cryotherapy.
45662522|NCT04944199|Other|Physical Activity|Intervention group participants will be enrolled in a standardized step-based program to gradually increase their physical activity. Daily steps will be measured via a pedometer application on a smartphone or wearable device, with a gradual increase in the goal on a weekly basis, with a target intervention of around 4-6 weeks in total. The first week's step count will be used to calculate a baseline step count for the week. At the start of each week, the participants will be asked to increase their daily step counts by 1,000.
45817040|NCT03900988|Drug|5% Dextrose|5% dextrose 1 liter given over 24 hrs and oral oseltamivir 75 mg bid for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
45817041|NCT03872752|Behavioral|FL lay leader training and workshop implementation|Intervention components will include a training course for community lay leaders, enabling them to acquire the skills to lead food literacy workshops. This includes raising their knowledge about nutrition recommendations and food labels, raisin self efficacy, and improving nutrition related organization and preparation skills.
45817042|NCT03870360|Behavioral|HOLA Component 1|At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
45817043|NCT03870360|Behavioral|HOLA Component 2|A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
45817044|NCT03870360|Behavioral|HOLA Component 3|A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
45817045|NCT03870360|Behavioral|HOLA Component 4|One booster walking session twice a month for six months post intervention for reinforcement, then one booster walking session a month for eighteen months.
45956761|NCT00531193|Drug|BIIB014|oral administration of BIIB014, given once daily for 8 to 12 consecutive days, at various doses as specified in protocol
46002846|NCT00549341|Other|Physiologic saline|Single injection.
45817046|NCT03870360|Behavioral|Healthy lifestyles education program|Biweekly telephone check in calls for the first 16 weeks followed by monthly check in calls during the two year follow up period.
45454801|NCT01115179|Drug|Intralipid 10%|Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%) as well as the solvent of propofol 1% (Intralipid 10%; corresponding to a target-controlled infusion of propofol with concentration levels of 3-5ug/ml)
45454802|NCT01115179|Drug|Saline|Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%)
45454803|NCT03531034|Other|Combined Exercise Training|The program consisted of 30 sessions of combined aerobic and resistance exercises training during 10 consecutive weeks. Each session lasted 45 minutes and consisted of 5 minutes warm-up, 20 minutes of resistance exercise and 20 minutes of aerobic exercise. The resistance training was performed in two sets of 15 repetitions in seven exercises of weight training (Based on 1 repetition maximum test - 1RM) for large muscle groups. The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between ventilatory threshold 1 and 2 intensities. After 5 weeks of training, 1RM test was performed again to readjust the resistance load and aerobic intensity was readjusted by heart rate predicted in the incremental test.
45454804|NCT01213459|Procedure|Cervical samples|Human papillomavirus detection and typing in cervical samples.
45454805|NCT01213459|Other|Data collection|Questionnaire completion
45662523|NCT05017363|Procedure|ENGAGE|Goal-setting approach and strategies including the Perceived Efficacy and Goal Setting Tool (PEGS), which is established goal setting tools for children aged 5-9. Administration of the Canadian Occupational Performance Measure (COPM), the most widely used goal-setting tool in paediatric rehabilitation that has been used with children as young as seven years. Introducing simple strategies to assist children in identifying goals and to ensure ongoing focus on goals using principles of motivational interviewing, strategies to assess and nurture perceived competence (self-efficacy), and child-friendly feedback strategies on goal-related performance.
45817047|NCT03866239|Drug|Obinutuzumab|Obinutuzumab will be administered by intravenous (IV) infusion as either a split or single dose approximately 2 weeks before Cycle 1, Day 1 (cycle = 21 days).
45454806|NCT04468438|Diagnostic Test|serum estrogen and urinary albumin creatinine ratio|serum estrogen and urinary albumin creatinine ratio
45454807|NCT03937765|Procedure|PRP harvest and preparation|"The PRP harvest and preparation will be done in the operating room with the help of the hospital blood bank. The skin graft surgery will be completed by Dr. Jason Lowe and/or one of the Orthopaedic Surgery residents. Follow up will also be completed by Dr. Lowe or one of the residents. Data analysis will be done by Drs. Lowe and Manoharan.~Each patient that will be undergoing a skin graft surgery will be randomized into either the PRP (intervention) group or the control group. Follow up and dressing changes will be the same for both groups. Each group will be prescribed a multi-modal pain regimen to reduce narcotic usage."
45458162|NCT03502486|Other|Intense exercise|20 minutes of cycle ergometry at 70-80% of heart rate max
45817048|NCT03866239|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
45817049|NCT03866239|Drug|Cibisatamab|Cibisatamab will be administered at a fixed dose of 100 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
45458163|NCT03502486|Other|Reading|20 minutes of seated reading
45662524|NCT01364233|Device|MotifMESH|Polytetrafluoroethylene (cPTFE) macroporous mesh
45662525|NCT04985539|Device|Verily Study Watch|Participants wear the Verily Study Watch for 2 years, for longitudinal data collection.
45817050|NCT03866239|Drug|Tocilizumab|Tocilizumab will be administered by IV infusion as necessary to manage adverse events (AEs)
45817051|NCT03862924|Device|Standardized Research Electronic Cigarette|Participants will receive SREC weekly and eill be encouraged to replace their usual combustible cigarette with the SREC whenever they would normally smoke.
45817052|NCT03861156|Drug|D-0316|Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.
45817053|NCT03859973|Drug|BI 425809|Tablet
45817054|NCT03859973|Drug|Placebo|Tablet
45817055|NCT03827070|Drug|Afatinib|Used Afatinib particles of which had an average size of 22 μm and a volume concentration of small particles (<5 μm) - only 19%
45817056|NCT03827070|Drug|Talcum powder|Used Talcum powder particles of which had an average size of 24.5 μm and a volume concentration of small particles (<5 μm) - only 11%
45817057|NCT03820986|Biological|Pembrolizumab|IV infusion
45817058|NCT03820986|Drug|Lenvatinib|Oral capsule
45817059|NCT03820986|Drug|Placebo for lenvatinib|Oral capsule
46078893|NCT02814110|Drug|Granulocyte colony-stimulating factor (Filgrastim)|Drug administration
45817060|NCT03819478|Behavioral|Weight loss intervention months 0-6|All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).
45662526|NCT05014945|Procedure|(atelocollagen group)|Epidural nerve block and atelocollagen injection into the multifidus muscle were performed sequentially. The target level is determined by the clinician by combining the pre-MRI and the patient's symptoms. All procedures are performed under the guidance of fluroscopy. For epidural nerve block, use 10cc of 0.9% normal saline mixed with 3000IU of hyaluronidase to be injected. After the epidural nerve block, a solution of 1 mL of atelocollagen mixed with 1 mL of 1% lidocaine is injected into the multifidus muscle to complete the entire procedure.
45662527|NCT04984993|Device|MED3000|Gel formulation
45817061|NCT03819478|Behavioral|Exercise intervention months 0-6|All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.
45662528|NCT04984993|Drug|Tadalafil 5mg|Tablets
45662529|NCT04984837|Drug|Lacutamab|750 mg/IV
45662530|NCT04984837|Drug|Gemcitabine|1000 mg/m²
45817062|NCT03819478|Dietary Supplement|NutraBio™ CarboMax Supplement|Participants in the lower protein / higher CHO diet group (RecProt) will be provided a carbohydrate supplement (NutraBio™ CarboMax, ~50 g of carbohydrate and 220 calories) to consume daily during the 6 month weight loss intervention.
45454808|NCT05250674|Device|CEM-guided biopsy|"The evaluation population consists of adult women, presenting with clinical indication for a breast biopsy procedure after a positive abnormal CEM or MRI examination (with no clear ultrasound or mammography correlation) and considered eligible for this procedure as per standard of care.~Eligible subjects undergo the clinically indicated breast biopsy procedure using the Pristina Serena Bright ® CEM-guided biopsy. Region of interest location is determined by using stereotactic pairs of CEM images after injection of iodinated contrast media. All necessary equipment and instrumentation, medications, or other devices required to complete the subject's clinically indicated procedure shall be used and are not expected to be influenced by evaluation participation."
45454809|NCT01121653|Drug|Magnogene ® (magnesium)|evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. The study drug will be taken during 4 weeks.
45454810|NCT04468282|Drug|VGB-ST|Single oral administration of 500 mg VGB-ST
45454811|NCT01115257|Procedure|vitrectomy|The surgical technique (Group 1) included vitrectomy, with a combination of delamination and segmentation of gliotic tractional membranes using bimanual technique. Silicone oil tamponade was used in eyes with long-standing tractional retinal detachment, as deemed necessary by the surgeon, or in eyes in which a retinal break occurred during the vitrectomy.
45454812|NCT01115257|Procedure|panretinalphotocoagulation|Panretinal photocoagulation was completed according to guidelines summarized in ETDRS with extensive full subconfluent panretinal photocoagulation.
45458164|NCT02310490|Device|DermaVeil right with left side Sculptra left side|The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed
45662531|NCT04984837|Drug|Oxaliplatine|100 mg/m²
45817063|NCT03819478|Dietary Supplement|6-month NutraBio™ 100% Whey Protein Isolate Supplement|Participants in the 6-month higher protein / lower CHO diet group (6-mo HiProt) will be provided a protein supplement (NutraBio™ 100% Whey Protein Isolate, ~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention.
45817064|NCT03819478|Dietary Supplement|18-month NutraBio™ 100% Whey Protein Isolate Supplement|Participants in the 18-month higher protein / lower CHO diet (18-mo HiProt) will be provided a protein supplement (NutraBio™ 100% Whey Protein Isolate, ~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention and the 12-month follow-up.
45662532|NCT04983355|Dietary Supplement|Fish Hydrolysate|"The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the fish hydrolysate the fourth first weeks will then receive the placebo during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation."
45956762|NCT00531193|Other|[11C]SCH442416|11C]SCH442416 is a radiolabelled tracer molecule that specifically binds to adenosine A2A sites and will be used to evaluate receptor occupancy. The target activity will be 370 MBq. [11C]SCH442416 will be administered IV as a bolus injection over 30 seconds following the start of each PET scan.
45662533|NCT04983355|Dietary Supplement|Placebo|"The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the Placebo the fourth first weeks will then receive the fish hydrolysate during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation."
45662534|NCT04983121|Drug|Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)|The subjects who sign an informed consent will enter the treatment period after screening. Each eligible subject will receive pyrotinib, 320 mg once a day, with 21 days as a session, for 6 sessions in total before operation. Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) will be intravenously injected at a dose of 1.5 mg/kg, once every 3 weeks, with 21 days as a session, for 6 sessions before surgery. Breast MRI and other imaging examinations will be reviewed every 2 sessions to evaluate the curative effect, and the patient's baseline will be defined based on the imaging report at the time of enrollment. If a definite effect (complete response/partial response) is achieved, surgical treatment will be performed within 4 weeks (> 2 weeks) after completion of 6 sessions of neoadjuvant therapy.
45817065|NCT03812718|Device|Endotracheal tube (ETT)|After induction of anaesthesia patient will be intubated with polyvinyl chloride (PVC) ETT for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
45817066|NCT03812718|Device|ProSeal Laryngeal Mask Airway (PLMA)|After induction of anaesthesia ProSeal Laryngeal Mask Airway (PLMA) will be inserted for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
45817067|NCT03805789|Biological|Alpha-1 antitrypsin (AAT)|Alpha-1 antitrypsin is a lyophilized product for intravenous administration.
45956763|NCT02943616|Device|Absorb BVS|"Commercially approved Absorb GT1 BVS, herein referred to as Absorb.~Scaffold diameters: 2.5, 3.0, and 3.5 mm~Scaffold lengths: 8, 12, 18, 23 and 28 mm~Absorb is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
45956764|NCT02943421|Procedure|Transverse B-Lynch suture|
45817068|NCT03805789|Biological|Placebo|Albumin solution administered intravenously
45817069|NCT03752073|Device|Trans-cervical cervical balloon|Insertion of Foley Catheter
45817070|NCT03752073|Device|Hygroscopic cervical dilator|Insertion of Dilapan-s
45817071|NCT03748303|Drug|Allopregnanolone|Administration of weekly IM injections of Allopregnanolone.
45956765|NCT00144755|Drug|Darbepoetin alfa|prophylactic administration of darbepoetin alfa in experimental arm
45956766|NCT02943382|Other|Fingerprick autologous blood (FAB)|Pricking of cleaned finger using diabetic lancet and applying blood droplet to affected eye. Repeated with separate finger for other affected eye.
45956767|NCT00531271|Drug|ABI-008 (nab-docetaxel)|ABI-008; 60-200 mg/m²; Intravenous infusion every 3 weeks.
45956768|NCT00531310|Drug|Reduced Intensity Conditioning, Busulfan and Fludarabine|Busulfan and Fludarabine
45956769|NCT00407862|Drug|Telmisartan 80 mg|
45956770|NCT00407862|Drug|Losartan 50 mg|
45956771|NCT00527995|Drug|Sildenafil|Orally administered, Sildenafil 100mg, unique administration
45956772|NCT00144833|Drug|fosamprenavir/ritonavir (700mg/100mg BID)|
45956773|NCT00144833|Drug|fosamprenavir/ritonavir (1400mg/100mg BID)|
45956774|NCT00144833|Drug|fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID)|
45662535|NCT04982731|Other|Positive Assurance|"Positive assurance is a low-cost, non-pharmacological strategy commonly used by specialty clinics to manage anxiety in individuals with mTBI. Positive assurance is comprised of words of affirmation given to individuals with a medical condition by a healthcare provider that are centered on hope and positive recovery expectations (i.e., You will recover, This can be treated)."
45662536|NCT04420897|Procedure|Arterial blood gas samples|Blood gases taken during the operation will be analyzed retrospectively. Whether these results have an effect on graft survival will be examined by reaching their records in the postoperative period.
45662537|NCT04208971|Other|AI-enabled ECG-based Screening Tool for AF|A novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool to improve atrial fibrillation diagnosis and stroke prevention.
45662538|NCT02291289|Drug|Cetuximab|500 mg/m^2 via IV infusion on Day 1 of every 2-week cycle
45662539|NCT02291289|Drug|FOLFOX induction regimen|Administered per the Investigator's discretion in accordance with locally approved prescribing information.
45662540|NCT02291289|Drug|Fluoropyrimidine (5-FU/LV or capecitabine)|Per Investigator's discretion: 1600-2400 mg/m^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.
45662541|NCT02291289|Drug|Atezolizumab|800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg
45662542|NCT02291289|Drug|Vemurafenib|960 mg vermurafenib BID by mouth
45662543|NCT02291289|Drug|Bevacizumab|5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information
45662544|NCT02291289|Drug|Trastuzumab|Initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses by IV infusion on Day 1 of every 3-week treatment cycle
45662545|NCT02291289|Drug|Pertuzumab|Initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses by IV infusion on Day 1 of each 3-week treatment cycle
45662546|NCT02291289|Drug|Cobimetinib|60 mg orally once daily for 3 weeks followed by a 1-week treatment break
45662547|NCT02291289|Drug|5-FU/LV|1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression per the Investigator's assessment using modified Response Evaluation Criteria in Solid Tumors or death from any cause, whichever occurs first.
45662548|NCT02317575|Biological|LY900014|Administered SC
45662549|NCT02317575|Biological|Insulin Lispro|Administered SC
45662550|NCT02316717|Biological|IMM-124E|IMM-124E
45662551|NCT02316717|Other|Placebo|Matched placebo
45662552|NCT02290821|Drug|placebo|
45662553|NCT02290821|Drug|Placebos|
45662554|NCT02289963|Drug|Placebo (for Alirocumab)|Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
45662555|NCT02289963|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
45662556|NCT02289963|Drug|Lipid-Modifying Therapy (LMT)|Statins (Rosuvastatin, Simvastatin or Atorvastatin) at stable dose with or without other LMT as clinically indicated.
45662557|NCT02358369|Drug|Bimatoprost|Bimatoprost sustained release Ocular Insert
45662558|NCT02358369|Drug|Timolol 0.5%|BID drops OU, 0.5% ophthalmic solution
45662559|NCT02358369|Device|Placebo Ocular Insert|Placebo ocular insert OU.
45662560|NCT02358369|Drug|Placebo Eye Drops|Placebo eye drops BID OU.
45817072|NCT03735004|Device|Transcranial electrostimulation (TES)|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC) current, or TES with DC only will be administered through the skin electrodes positioned on the patient's head
45817073|NCT03723473|Device|Magnetic Resonance Imaging (MRI)|MRI (muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise.
45956775|NCT00528034|Procedure|Lymphoscintigraphy|Procedure where a very small amount (less than one tenth of a teaspoon) of a radioactive material is injected around the edge of the tumor in the vagina, followed immediately by the scan. The scan is done before the patient has surgery or begins radiation therapy.
45956776|NCT02944864|Drug|TQ-B3395|TQ-B3395 p.o. qd
45662561|NCT02316171|Biological|CVA21|CAVATAK is a purified preparation of CVA21
45662562|NCT02316171|Drug|Mitomycin C|Chemotherapy
45662563|NCT02315625|Drug|Sunitinib|37.5 mg once daily will continue until progression or unacceptable treatment-related toxicity
45662564|NCT02315625|Drug|Everolimus|10 mg daily will continue until progression or unacceptable treatment-related toxicity
45662565|NCT02357979|Device|Laser|CO2 - 9.3μm short-pulsed laser irradiation will occur on the occlusal enamel surface. This results in changes in crystal composition and structure, which increase the resistance of dental mineral to dissolution by acid and will work to better prevent dental caries in the occlusal surface of vital teeth when compared to fluoride therapy alone over 12 months.
45817074|NCT03710538|Dietary Supplement|Snack beverage|Consumption of a 200ml of soy beverage (100Kcal, 11g CHO, 6g proteins, 4g fat)
45817075|NCT03710538|Behavioral|Exercise|3min walk at 60% VO2max every 30 minutes,(x5)
45662566|NCT02357979|Other|Fluoride|The Fluoride varnish is painted on the occlusal surface of the tooth. Fluoride varnish makes enamel more acid resistant.
45662567|NCT04886973|Other|Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids.|Intravenous administration of 8% crystalline L-amino acids with high concentrations of branched chain amino acids.
45817076|NCT03681314|Other|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
45454813|NCT05057936|Biological|COVID vaccine|The enrolled patients will received COVID-19 vaccine according to the vaccine protocol in Thailand ie The ChAdox-1 nCOV-19 vaccine (day 1, day 84, 12 weeks duration) or Corona vac 2 doses (day 2, day 21, 3 weeks duration) of the study. All the participants underwent blood drawn for antibody and cellular immunity measurement before the final dose of vaccination, with 7 days before first vaccine dose and eight weeks after the second doses
45454814|NCT01121731|Drug|Interferon α-5|3 MIU or safe dose used three times a week (TIW) in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
45662568|NCT02357901|Drug|SUBOXONE|SUBOXONE (buprenorphine sublingual film) is used for induction therapy. Participants take sublingual film for 3 days according to the sublingual film prescribing information; they then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to randomization. Following randomization, SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
45817077|NCT03680053|Drug|Duphaston|Women will receive oral duphaston 20mg daily from Day 3 till the day of ovulation trigger.
45662569|NCT02357901|Drug|RBP-6000|Six injections administered subcutaneously every 28 days on alternate sides of participant's abdomen at either 300 mg or 100 mg dose.
45817078|NCT03680053|Drug|Cetrorelix|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
45817079|NCT03673007|Behavioral|Gift card to be used for contraceptives that is valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)|M-CARES will randomize allocation of vouchers (gift cards) for contraception valued up to 50% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred between August 18, 2018, and March 3, 2019.
45817080|NCT03673007|Behavioral|Gift card to be used for contraceptives that is valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)|M-CARES will randomize allocation of vouchers (gift cards) for contraception valued up to 100% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred after March 3, 2019.
45817081|NCT03672630|Drug|Azithromycin|Azithromycin 500 MG Oral Tablet [ZITHROMAX]
45817082|NCT03672630|Drug|Ethambutol|Ethambutol 25 mg/kg [MYAMBUTOL]
45817083|NCT03672630|Drug|Rifampin|Rifampin 600 MG [RIFADIN]
45817084|NCT03671902|Device|Fluid shift|We are using lower body negative and positive pressure to create a fluid shift in the body. This study is investigating if there are changes in phonocardiographic parameters related to changes in blood volume caused by this fluid shift
45817085|NCT03659981|Other|MRI 7T|The imaging parameters will come from the 7 Tesla Siemens MRI
45817086|NCT03657602|Drug|Kyleena Intrauterine System|Participant will be randomly allocated to this intervention
45817087|NCT03657602|Drug|Mirena Intrauterine System|Participant will be randomly allocated to this intervention
45817088|NCT03656718|Biological|nivolumab|(Subcutaneous) Specified dose on specified days
45817089|NCT03656718|Drug|rHuPH20|Specified dose on specified days Permeation enhancer
45817090|NCT03656718|Biological|nivolumab|(IV) Specified Dose on Specified Days
45817091|NCT03648359|Procedure|multiparametric MRI Diagnostics|Patients with newly diagnosed prostate cancer enrolled in active surveillance following standard protocol including PSA, DRE and TRUS biopsies and intervention with multiparametric MRI + additional biopsies if suspicious lesions are found
45817092|NCT03646175|Dietary Supplement|Choline|Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
45817093|NCT03646175|Dietary Supplement|Placebo|Participants will consume 1000 mg (2x500 mg) of placebo between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
45956777|NCT02944942|Procedure|General anesthesia|Patients undergoing general anesthesia
45956778|NCT02964000|Device|Low level 1 Watt|The Phoenix Thera-Lase System will be on 1 watt
45662570|NCT02357901|Drug|Placebo|Six injections of placebo administered subcutaneously every 28 days on alternate sides of participant's abdomen at volumes matching the experimental drug.
45662571|NCT01601847|Dietary Supplement|Cholecalciferol|Once the dietary intake of vitamin D has exceeded 200 IU/Day, the infants will receive placebo until they are 6 months of age adjusted for prematurity
45662572|NCT01601847|Drug|Cholecalciferol|Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity
45662573|NCT04886739|Drug|CGB-400|Topical gel
45454815|NCT01121731|Drug|Interferon-α5 plus Interferon-α 2b|Interferon-α5 plus Interferon-α 2b. 1.5 MIU each, or safe dose used TIW in alternate days in combined therapy. 29 days of treatment. Subcutaneous injection.
45956779|NCT02964000|Device|Phoenix Thera-Lase System 42|The Phoenix Thera-Lase System will be on 42 watts
45662574|NCT04886739|Drug|Vehicle Gel|Topical gel
45662575|NCT02515669|Drug|RO7239361|Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
45454816|NCT01121731|Drug|Interferon α-2b (INTRON® A)|3 million IU TIW in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
45662576|NCT02515669|Drug|Placebo|Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
45662577|NCT02515279|Drug|Peginterferon alfa-2a|180 micrograms subcutaneous weekly for 48 weeks.
46078894|NCT05508399|Other|DNA panel and RNA Sequencing|Including a DNA panel containing 571 cancer-associated genes, and full transcriptome sequencing.
45662578|NCT02515279|Drug|Ribavirin|1000-1600 mg day orally for 48 weeks.
45662579|NCT02515045|Drug|TriMoxiVanc|triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.
45662580|NCT02515045|Drug|Moxifloxacin HCl 0.5%|Antibiotic to be used 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.
45662581|NCT02515045|Drug|Ilevro|NSAID to be used 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.
45662582|NCT02515045|Drug|Prednisolone acetate 1%|Steroid to be started after surgery 1 drop QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued.
45662583|NCT02514577|Drug|IDP-122 Lotion|Topical lotion
45662584|NCT02514577|Drug|IDP-122 Vehicle Lotion|Topical lotion. No active ingredient.
45956780|NCT02964000|Device|Phoenix Thera-Lase System 74|The Phoenix Thera-Lase System will be on 74 watts
45956781|NCT02944903|Other|Audit|Questionnair
45662585|NCT04943887|Behavioral|eSupport Health Weekly Group Sessions for PwMS|A formal semi-structured program of psychoeducational support delivered in an online weekly small group format by health coaches (licensed therapists) who specialize in MS.
45662586|NCT05463055|Radiation|Proton Therapy System (ProBeam)|All of subjects (tumor patients, including tumors of the nervous system, head and neck, chest, abdomen, spine, pelvic cavity, limbs and other tumors) will be treated with Proton radiation therapy using the medical device Varian ProBeam Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 4 weeks, while the treatment period is 1 to 8 weeks. The period after the last treatment is divided into short-term follow-up and long-term follow-up, in which short-term follow-up will be 3 months after the end of the last treatment. Total expected participation for each subject from screening to the completion of short-term follow-up is a maximum duration of 12 weeks + 3 months ( for this trial). Long-term follow-up continues after the end of short-term follow-up until the 5th year after the end of the last radiotherapy session.
45662587|NCT02513485|Drug|Levodopa+carbidopa|Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2.
45662588|NCT02513485|Drug|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
45662589|NCT02289417|Drug|Apremilast|
45662590|NCT02289417|Drug|Placebo|
45662591|NCT02512861|Drug|Bupivacaine|"Bupivacaine will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 0.25% Bupivacaine at 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5% Bupivacaine at 0.5 ml/kg up to a maximum of 25ml of 0.5% Bupivacaine for patients > 50 kgs"
45956782|NCT00144872|Drug|Lamotrigine|Lamotrigine will be given as chewable dispersible tablets with dosing strengths of 2, 5, 25, and 100 milligrams.
45956783|NCT02945020|Drug|Dabigatran etexilate mesylate|Participants will receive dabigatran etexilate mesylate 75 mg, orally.
45956784|NCT02945020|Drug|Odalasvir (ODV)|Participants will receive ODV 25 mg, orally.
45956785|NCT02945020|Drug|Simeprevir (SMV)|Participants will receive SMV 75 mg, orally.
45956786|NCT00528073|Drug|Rifaximin-EIR|Comparison of 800 mg, 1600 mg and 2400 mg Rifaximin-EIR versus placebo in the treatment of active moderate Crohn's disease
45956787|NCT00528151|Drug|curcumin|curcumin 250 mg twice a day in the first group. placebo 1 capsule twice a day in the second group.
45956788|NCT00144911|Drug|Salmeterol|
46078895|NCT02731404|Procedure|HFJV ventilation|The investigators used the Perkins tonometer for monitoring intra-ocular pressure. Evaluation of intra-ocular pressure was done before induction of anesthesia, end of induction, during surgery and at the end of surgery.
46078896|NCT02731404|Procedure|IPPV ventilation|The investigators used the Perkins tonometer for monitoring intra-ocular pressure. Evaluation of intra-ocular pressure was done before induction of anesthesia, end of induction, during surgery and at the end of surgery.
45662592|NCT02512861|Drug|Placebo|"Saline will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5 ml/kg up to a maximum of 25ml for patients > 50 kgs"
45662593|NCT04980001|Behavioral|Families OverComing Under Stress Trauma Informed Care in Childhood Obesity among Minorities (FOCUS TIC-COM)|FOCUS TIC-COM is a program that helps doctors coach families to recognize how emotions or feelings about various life stressors may affect a child's dietary choices and physical activity. FOCUS TIC-COM is for families of children who have been identified by their doctor as overweight or obese. The goal of the program is to help children and their families understand how their mental health may impact their physical health and develop strategies to address their mental health needs.
45454817|NCT03527212|Drug|SJP-0035 0.001%|Self-administration of 1 drop (approximately 40 µL) of 0.001% SJP-0035 ophthalmic solution into each eye 4 times daily for 4 weeks
45662594|NCT04979611|Drug|68Ga-NOTA-exendin-4|A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously
45662595|NCT04979299|Other|Wheelchair|Patient will be asked to sit in a wheelchair, and a 5-minute video recording of spontaneous speech capturing the semi-structured iCGI interview is made.
45662596|NCT05012761|Drug|SR419 capsules|Ascending single and multiple doses of SR419 orally
45662597|NCT05012761|Drug|Placebo|Ascending single and multiple doses of placebo orally
45662598|NCT04979065|Dietary Supplement|Probiotics, Vitamin D|Combination of two supplement that given separately
45662599|NCT04979065|Other|Placebo|Placebo with inactive ingredient
45662600|NCT02288559|Other|Sham|Sham injection will be administered as a matching intravitreal injection of lampalizumab.
45662601|NCT02288559|Drug|Lampalizumab|10 mg dose of lampalizumab administered intravitreally
45662602|NCT02288325|Drug|Levomilnacipran ER|Levomilnacipran ER taken orally at 40, 80 or 120 mg once daily.
45662603|NCT02288325|Drug|Placebo|Dose-matched placebo taken orally once daily.
45662604|NCT02509117|Drug|PF-06751979 single ascending dose|PF-06751979 administered as a single dose (solution/suspension) in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF-06751979). The dose levels are 3 mg, 12 mg, 40 mg, 160 mg.
45662605|NCT02509117|Drug|Placebo single dose|Matched Placebo solution/suspension administered as single dose.
45956789|NCT00144911|Drug|Fluticasone Propionate/Salmeterol Combination Product|
45662606|NCT02509117|Drug|PF-06751979 multiple ascending dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days to parallel cohorts. The dose levels are 5 mg, 15 mg, 50 mg.
45662607|NCT02509117|Drug|Placebo multiple dose|Matched Placebo (solution/suspension)administered daily for 14 consecutive days.
45817094|NCT03638505|Other|PSP-QoL|"PSP-QoL is a patient-reported outcome measure for progressive supranuclear palsy (PSP). The Supranuclear Palsy Quality of Life scale (PSP-QoL) may be a helpful patient-reported scale for clinical trials and studies in PSP.~PSP-QoL consists of 28 items scored on a 3- or 5-point Likert scale, with the total score ranging from 0 to 100. Each item is scored from either 0 to 4, with the exception of four items, which are scored from 0 to 2, with higher scores indicating more-severe disability or movement abnormality. Items are in six categories: daily activities (by history); behavior; bulbar; ocular motor; limb motor; and gait/midline. The scale includes comments and/or instructions for each item and word anchors to explain the ratings."
45817095|NCT03633929|Other|KIOS OUD|Study Participants will evaluate software known as KIOS-OUD
45956790|NCT00528229|Radiation|Computer Tomography|
45662608|NCT02509117|Drug|PF-06751979 multiple dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days. The dose level is 50 mg.
45662609|NCT02509117|Drug|PF-06751979 multiple dose|Matched Placebo (suspension/solution) administered daily for 14 consecutive days to parallel cohorts.
45662610|NCT05012683|Device|Point Partial|Patient is fit with Point Partial partial finger prosthetic system
45662611|NCT01654549|Drug|H.pylori eradication|Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)
45956791|NCT00528307|Device|HIS buldle ablation|HIS bundle ablation, followed by implant of a biventricular pacemaker
45956792|NCT00168597|Drug|Vitamin A|
45956793|NCT00528346|Behavioral|cognitive training using fMRI|Participants will be scanned using fMRI while they employ the cognitive training strategies-allowing them to view their brain activity.
45662612|NCT04978051|Drug|Firazyr|Icatibant 10 MG/ML Prefilled Syringe
45662613|NCT04978051|Other|SoC|The SoC could include respiratory support measures, fluid therapy, antipyretic treatment, postural measures, low-molecular-weight-heparins, corticosteroids, such as dexamethasone, remdesivir and other therapeutic options
45662614|NCT04214353|Diagnostic Test|68Ga-PSMA-PET/CT|All participants in the study will be injected with 2.0 MBq/kg 68Ga-PSMA for PET/CT imaging, both pre- and post ADT.
45662615|NCT04214353|Diagnostic Test|18FDG-PET/CT|All participants in the study will be injected with 2.1 MBq/kg 18FDG for PET/CT imaging, both pre- and post ADT.
45662616|NCT04977817|Dietary Supplement|Similac Probiotic Tri-Blend|Probiotic dietary supplement, Similac Probiotic Tri-Blend
45662617|NCT04977739|Diagnostic Test|No intervention|No intervention
45662618|NCT04976803|Other|Determination of ATM alteration status.|ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.
45662619|NCT02508649|Drug|selepressin|
45662620|NCT02508649|Drug|placebo|
45662621|NCT04213729|Behavioral|Diet Counseling|Standard of care diet counseling provided at clinic visit 1.
45956794|NCT00528346|Behavioral|placebo|Some participants will see simulated data that does not come from their own brains.
45956795|NCT00528385|Drug|Spironolactone (Spironol) 25 mg|In the 8-weeks run-in period ACEI, cilazapril (5 mg), telmisartan (80 mg) and hydrochlorotiazyd (12.5 mg) were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 25 mg of spironolactone in two active treatment periods lasting 8 weeks each.
45662622|NCT04213729|Other|CD LFD|Daily breakfast, lunch, dinner and snacks LFD catered meals. Meals will have approximately 20% calories from fat, a goal ratio close to 1:1 omega-6/omega-3 fatty acids, and approximately 25-35 grams of fiber per day.
45662623|NCT04213729|Behavioral|Dyadic Psychological Support (DPS)|The dyadic psychosocial support (DPS) intervention will be provided for a total of 12 weeks. The 12-week DPS intervention consists of eight sessions (main sessions) and two booster sessions. The intervention will incorporate psychoeducational components that combine didactic and behavioral regulatory procedures to promote healthy diet behavior for self-determined reasons.
45662624|NCT05011825|Behavioral|Pregnant Moms' Empowerment Program|The first session introduces women to the group, seeks to build an alliance and sense of group cohesion, and provides safety planning. The second session addresses intergenerational patterns of violence and how such violence contributes to psychopathology in both the prenatal and postnatal period, focusing on violence prevention. Information regarding cognitive restructuring, behavioral activation, and coping styles is provided in session three, as well as the role of healthy relationships and social supports in promoting resilience. This session begins with discussion on health in pregnancy, labor/delivery, and coordinating care across providers. This session also provides psychoeducation related to post-delivery parenting, including infant safety, care and breastfeeding. In the final session, group leaders assist mothers with identification, sensitivity, and responsiveness to infant cues.
45662625|NCT05010421|Drug|Clobetasol 0.05% Emollient Top Cream|Topical corticosteroid treatment of affected vulvar skin areas.
45817096|NCT03632369|Diagnostic Test|Hyperpolarized xenon-129 MRI|Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level. The clinical MRI scanner Philips Achieva 3.0T will be equipped with 129Xe Quadrature Transreceive Lung Coil (Large and Small) to acquire 129Xe lung images. The resonator length of the large coils is equal to 122 cm, whereas the same size of the small coil is equal to 106 cm. The success criterion of the device performance is the obtained reasonable Xe MRI lung image.
45817097|NCT03629626|Procedure|ERAS protocol|"preoperative management Optimization of relevant medical uncontrolled situations, avoid fasting, avoid bowel preparation, avoid premedications, nutritional assessment, stop smoking, stop alcohol and appropriate counselling~intraoperative management Multimodal prevention of prophylaxis against nausea and vomiting (PONV) (according to preoperative assessment of Apfel Score) with a combination of multiple antiemetic drugs.~postoperative management Postoperative pain control is obtained with opioid sparing strategies, in order to avoid Post Operative Ileus (POI) and PONV.~It is proposed to chew gum three times daily , fluid therapy, early mobilization, early feeding within 2 hours postoperative for at least 15 minutes and eventually to promote a faster bowel function."
45817098|NCT03625687|Drug|Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks|8 weeks of direct acting antiviral treatment based on clinical indication (either Mavyret or Epclusa)
45817099|NCT03617003|Drug|WST11 mediated vascular targeted phototherapy (VTP)|All patients will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes while patients are under anesthesia during their endoscopy procedure, followed by immediate laser light application.
45956796|NCT00528463|Procedure|sciatic nerve block|Sciatic nerve block, Labatt approach, with a stimuplex needle and catheter. Once localized, a bolus of 20 mL ropivacaine 1,0% is given through the catheter and is followed by a perfusion of ropivacaine 0,2% 6-10 mL/hre for at least 24 hours pre-op and 48 hours post-op
45817100|NCT03617003|Procedure|Endoscopy|Endoscopy of the bladder
45956797|NCT02945098|Other|Kinesio Taping|Kinesio Taping application with tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
45454818|NCT03527212|Drug|Placebo|Self-administration of 1 drop (approximately 40 µL) of placebo ophthalmic solution into each eye 4 times daily for 4 weeks
45454819|NCT01215799|Drug|Bafetinib|Bafetinib 240 mg bid
45454820|NCT05207020|Device|Glycemia estimated by exhaled air analyzer|Measurement of volatile compounds in the air exhaled by the volunteer on 3 different MIBs (3 breaths in total) at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
45662626|NCT05010421|Device|Non-ablative CO2 Laser|Superficial non-ablative laser treatment of affected vulvar skin areas.
45956798|NCT02945098|Other|Placebo Kinesio Taping|Kinesio Taping application without tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
45956799|NCT00407940|Device|Lower extremity Atherectomy and Cryoplasty|
45956800|NCT02944786|Behavioral|HOPE-model|There are four sessions of person-centered health dialogues. The sessions also include pain/stress management and education about stress and pain (the HOPE model that is an adolescent-centered school health prevention program when adolescents have chronic pain).
45956801|NCT00144950|Drug|insertion of a chest drain with urokinase instillation|
45454821|NCT05207020|Behavioral|Questionnaire|The questionnaire focuses on the methods and feelings of the blood glucose self-monitoring that he is currently carrying out, a first feedback on user experience on the operation of the prototype and the collection of his expectations for a future commercial device
45956802|NCT00144950|Procedure|primary video-assisted thorascopic surgery|
45956803|NCT02944981|Drug|Gabapentin|Single oral dose
45956804|NCT02944981|Drug|Placebo|Single oral dose
45454822|NCT05207020|Biological|Veinous glycemia|Measurement of the veinous glycemia at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
45454823|NCT05207020|Biological|Capillary glycemia|7-step capillary glycemia measurement: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
45662627|NCT05010031|Radiation|Palliative radiotherapy|The first cohort of 26 evaluable patients will be treated with 4Gyx2, followed by a 6 month observation period post-RT to assess for treatment failures. If 7 or more failures are observed, cohort 1 will be closed and 4Gyx3 will be explored in the second cohort. If at most 6 failures are detected in the first cohort, dose will be further reduced to 4Gyx1 for the second cohort. Radiation therapy will be delivered according to department standards, including normal tissue constraints per hypofractionated guidelines. All techniques including conventional, 3D-CRT, or IMRT technique may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.
45662628|NCT02504827|Drug|Ceftazidime/avibactam|Ceftazidime/avibactam 2.5gm iv q8h for 3 doses
45662629|NCT02504671|Drug|GSK3196165|GSK3196165 is supplied as liquid and will be administered as SC injection.
45662630|NCT02504671|Drug|MTX|MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.
45662631|NCT02504671|Drug|Folic acid|Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.
45662632|NCT02504671|Drug|Placebo|Placebo is supplied as liquid as sterile 0.9% weight by volume (w/v) sodium chloride solution and will be administered as SC injection
45662633|NCT02314143|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules.
45662634|NCT02314143|Drug|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets.
45662635|NCT02288091|Drug|Inosine|Twenty-five eligible subjects will receive inosine for 12 weeks (administered in the form of 500 mg capsules, 1 to 6 capsules a day for a total daily dose of up to 3 gm). The dose of inosine will be titrated to target urate levels of 7-8 mg/dL based on urate level measurement that will occur at Week 2, Week 4, Week 6, and Week 9 after Baseline.
45662636|NCT04420065|Device|Preferential left ventricular pacing|Activation of an algorithm attempting to provide preferential left ventricular pacing in an anticipatory manner, thus potentially preventing iatrogenic, pacing-related, right ventricular dysfunction, and improving coupling and outcomes in dyssynchronous heart failure patients
45817101|NCT03605342|Drug|Buprenorphine|Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, which is standard practice.
45817102|NCT03605342|Behavioral|Cognitive Processing Therapy (CPT)|CPT-C is a manualized, 12-session 1:1 cognitive therapy that has been designed for patients with PTSD. In this study the sessions will be conducted weekly. CPT-C uses Socratic questioning targeting distorted cognitions such as self-blame, hindsight bias, and other guilt cognitions. CPT-C is focused on the cognitive components of the therapy without exposure.
45817103|NCT03605342|Behavioral|Individual Drug Counseling (IDC)|IDC will serve as the control group. The current standard of treatment for Veterans entering buprenorphine maintenance is to do drug counseling. Standard counseling is the primary means to achieve goals. IDC uses a semi-structured, time-limited addictions-counseling model in a 1:1 setting. The IDC manual provides an organized, concise version of what is currently practiced by most addiction counselors.
45817104|NCT03600779|Device|inhomogeneous Magnetisation Transfer (ihMT) sequence|robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 1.5T
45956805|NCT02944669|Device|ReWalk Personal Device|
45956806|NCT00168636|Drug|Vitamin A|
46078897|NCT02731326|Device|AliveCor|"The AliveCor Heart Monitor, an FDA-approved smartphone technology, snaps on to the patient's study smartphone similar to a protective case and works through a free application, AliveECG. It captures a highly sensitive (98%), specific (97%), and accurate (97%) single-lead ECG recording through two electrodes on the back of the patient's smartphone. When the application is opened, recording begins automatically when both electrodes make contact with skin. Transmissions are automatically uploaded to the study patient portal within the AliveCor cloud."
45956807|NCT00144989|Drug|Etoposide and cisplatin after chemoradiotherapy|Etoposide and cisplatin after chemoradiotherapy
45454824|NCT05207020|Biological|constitution biological collection|Sampling for storage of serum at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
45662637|NCT04420065|Device|Biventricular pacing|Standard biventricular pacing, with V-V delay programmed based on stroke volume maximization, and A-V delay delegated to the device
45662638|NCT04973527|Drug|Efficacy of LCAR-T2C CAR-T cells|CD4-directed CAR-T cells administered with lymphoid depletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
45662639|NCT05009329|Drug|JAB-21822|JAB-21822 will be administered orally
45662640|NCT05009329|Drug|JAB-21822|JAB-21822 will be administered orally
45662641|NCT04972279|Behavioral|Digital message (text + image)|"Messages can be up to 256 characters of text with an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity)."
45662642|NCT02503501|Drug|Insulin glulisine|
45662643|NCT02503501|Drug|Placebo|Bacteriostatic 0.9% Sodium Chloride
45956808|NCT00144989|Drug|Irinotecan and cisplatin after chemoradiotherapy|Irinotecan and cisplatin after chemoradiotherapy
45956809|NCT04692025|Drug|ASC41 tablet|Oral tablet
45956810|NCT00528502|Drug|Lidocaine|Lidocaine is misted into the air that you breathe during the surgery.
45956811|NCT00528502|Drug|Saline|Saline is misted into the air that you breathe during the surgery.
45662644|NCT04971889|Behavioral|Diabetes MNT|Group-based MNT sessions that provide evidence-based dietary self-care information, behavioral skills, and goal setting related to managing carbohydrate and fat intake
45662645|NCT04971889|Behavioral|Motivational Interviewing|Group-based support for dietary self-care motivation using culturally-adapted motivational interviewing exercise
45662646|NCT05007613|Drug|Cabozantinib 40 MG|Cabozantinib (Cabometyx) 40 MG PO QD
45662647|NCT05007613|Drug|Atezolizumab Injection|atezolizumab (Tecentriq) 1200mg IVF 30-60mins Q3W
45662648|NCT04971265|Behavioral|Low SES/High Supports|Participant will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a janitor in a residential building, while Kim works as a cashier in a supermarket. Where they live, all parents have 12 weeks of paid parental leave, access to free full-day center-based daycare for children aged 0 to 3, free full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten), and free parenting classes.
45662649|NCT04971265|Behavioral|Low SES/ Low Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a janitor in a residential building, while Kim works as a cashier in a supermarket. Where they live, parents have 1 week of paid parental leave, full-day center-based daycare for children aged 0 to 3 is available for around $900 per month, full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten) is available for around $1400 a month, and they can take parenting classes for $50 per hour.
45662650|NCT04971265|Behavioral|High SES/High Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a lawyer in a private company, while Kim works as a manager at a bank. Where they live, all parents have 12 weeks of paid parental leave, access to free full-day center-based daycare for children aged 0 to 3, free full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten), and free parenting classes.
45662651|NCT04971265|Behavioral|High SES/Low Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a lawyer in a private company, while Kim works as a manager at a bank. Where they live, parents have 1 week of paid parental leave, full-day center-based daycare for children aged 0 to 3 is available for around $900 per month, full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten) is available for around $1400 a month, and they can take parenting classes for $50 per hour.
45662652|NCT04970407|Biological|Botulinum toxin type A|Intramuscular Injection, concentration 300 units (U)
45662653|NCT04970407|Biological|Botulinum toxin type A|Intramuscular Injection, concentration 50 U
45956812|NCT00528619|Drug|Sunitinib, Pemetrexed, Cisplatin, Carboplatin|Dose finding study using Sunitinib daily by oral capsule in a continuous regimen or administered for 2 weeks out of every 3 weeks, with pemetrexed every 3 weeks or also with cisplatin 75 mg/m2 or carboplatin AUC=5 mg*min/mL until progression or unacceptable toxicity.
45454825|NCT05207020|Biological|Blood sample|Single blood sample before mealtimes for HbA1C molecular analysis
45454826|NCT05207020|Other|Test meal|taking a test meal before the various blood sugar measurements
45662654|NCT04970407|Biological|Botulinum toxin type A|Intramuscular Injection, concentration 50 U
45662655|NCT02502097|Drug|Gefapixant|Gefapixant 50 mg tablet, administered by mouth
45662656|NCT02502097|Other|Placebo|Matching placebo to gefapixant, tablet administered by mouth
45662657|NCT02501629|Drug|Reslizumab|Reslizumab 110 mg was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
45662658|NCT02501629|Drug|Placebo|Placebo was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
45662659|NCT02501629|Drug|Non-Oral Corticosteroid (non-OCS) Asthma Medication|Participants continue using their non-OCS background asthma medications without change during the study's treatment period.
45662660|NCT02501629|Drug|Oral Corticosteroid (OCS)|After screening and prior to study start, the participant's OCS dose was adjusted to determine the minimal effective OCS requirement.
45662661|NCT04969549|Other|Theta burst stimulation|It consists of 20 sessions of iTBS over the dlPFC.
45817105|NCT03600779|Device|inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T|robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 3T
45817106|NCT03598842|Dietary Supplement|Nutritional Supplementation Meal|Study participants will be given a nutritional supplementation for 6 months. The supplementation consists of a vegan meal plan.
45817107|NCT03598842|Dietary Supplement|Multivitamin|Study participants will be given a daily multivitamin to take for 6 months.
45817108|NCT03598842|Drug|Anti-parasitic medications|Study participants will be given anti-parasitic medications per Indian guidelines such as albendazole, ivermectin, metronidazole, or other medications to treat their parasitic infection.
45956813|NCT00168714|Drug|BG9418 (interferon beta-1a)|Exposure to Avonex during pregnancy
45956814|NCT00528658|Drug|Paracetamol|1g qid
45956815|NCT00528658|Drug|Ibuprofen|400mg tid
45956816|NCT00528658|Drug|Paracetamol Placebo|equivalent to 1g qid
45956817|NCT00528658|Drug|Ibuprofen placebo|Equivalent to 400mg tid
45956818|NCT04691674|Procedure|Endoscopy|Endoscopic removal of the pancreatic stent
45662662|NCT05007301|Device|geko device|Neuromuscular electrostimulation of the peroneal nerve, 12h per day, for up to 12 weeks.
45662663|NCT02501473|Drug|G100|GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist
45662664|NCT02501473|Drug|Pembrolizumab|PD-1 Inhibitor
45662665|NCT02501473|Drug|Rituximab|Rituximab (anti-CD20 antibody)
45662666|NCT05006521|Drug|KN-002|KN-002 dry powder inhaler
46078898|NCT02731326|Behavioral|Behavioral Altering Messaging|Behavioral altering messages relating to the participant's AF and underlying cardiac risk factors will be systematically selected from a bank of text messages developed through collaboration by the study team and an expert interdisciplinary panel from the American Heart Association. The content of the text messages will not include PHI. The final text message bank will be housed internally and maintained by the Data Manager and text messages will be pushed automatically from this database. The only identifying link to participants included in this database will be their study-provided phone number
45454827|NCT01213615|Device|Valve replacement|Aortic valve replacement of Hancock II Ultra porcine bioprosthesis
45662667|NCT02501161|Drug|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
45662668|NCT02501161|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
45662669|NCT05006443|Diagnostic Test|Cardiac Magnetic Resonance|a non-invasive assessment to determine severity of tricuspid regurgitation
45662670|NCT05004883|Behavioral|Regulation of Cues Enhanced|ROC is based on the Behavioral Susceptibility Theory and designed to incorporate psychoeducation, cue-exposure treatment, appetite awareness training, coping skills, and self-monitoring of satiety and cravings to treat high Food Responsiveness and low Satiety Responsiveness. BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments. All participants will be taught to decrease caloric intake and increase physical activity, and to use all of the behavioral skills provided in BWL. However, they will also be taught models of hunger and satiety and about food cue reactivity, and will learn skills to manage these. This arm will include an experiential component, including hunger monitoring during dinner and participating in exposure exercises.
45662671|NCT05004883|Behavioral|Behavioral Weight Loss|The BWL program includes dietary, physical activity, and behavioral change recommendations. All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories, and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
45662672|NCT05004883|Behavioral|Nutrition Education, Stress Management and Social Support|Topics included will be stress management/relaxation, social support, and nutrition education. There will be a strong mindfulness component to this group.
45662673|NCT02500537|Device|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology (Universal Handle)
45662674|NCT05003635|Device|EVEBRA device|Wear 2 weeks pre-operatively for a total duration of 200 hours. Wear 2 weeks post-operatively for 10 hours a day.
45662675|NCT05003401|Device|HabitAware Keen2|Participants will receive an awareness bracelet to be worn on the dominant wrist over a period of 4 weeks. The bracelet device will vibrate when the participant is engaging in hair pulling behaviors. As hair pulling behaviors may occur outside of awareness (i.e., automatic pulling behaviors), this vibration and detection is anticipated to increase the participants awareness of hair pulling behaviors.
45662676|NCT04966819|Other|Survivorship Care Initiative|"The survivorship initiative will consist of:~(A) Regular meetings with the rectal cancer oncology pivot nurse (IPO). These meetings present an opportunity for patients to discuss any treatment-related distress or late and long-term side-effect.~(B) Identification of a primary care physician. If the patient is not known to a Primary care physician (PCP), the IPO will add the patient to an accelerated waitlist.~(C) Development of an individualized survivorship plan. During meetings with the oncology pivot nurse, a survivorship care plan will be populated, included information on patient risk factors, treatments completed, pathology findings, and future surveillance planned. This document will be reviewed by the treating colorectal surgeon, and will be subsequently shared with the oncology team, the PCP and the patient (if the patient desires).~(D) Educational resources for patients. Patients will be offered educational materials to help address their specific needs."
45454828|NCT05723848|Device|Smartwatch (Withings Scanwatch)|All-day monitoring of patients via smartwatch
45454829|NCT03145064|Drug|Zanubrutinib|Administered at a dose of 160 mg BID orally.
45662677|NCT04966585|Drug|Posaconazole Delayed Release Oral Tablet|Three 100mg delayed-release tablets twice a day on the first day, then three 100mg delayed-release tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
45662678|NCT04966585|Drug|Matching Placebo Tablet|Three matching placebo tablets twice a day on the first day, then three tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
45662679|NCT02498821|Device|Chest X-ray|A Chest X-ray will be taken after healthcare providers have inserted the PICC to make sure it is in the correct location. The X-ray can tell your healthcare providers where the PICC is and whether is has been inserted correctly.
45817109|NCT03587844|Drug|brentuximab vedotin|MF/SS Brentuximab vedotin 0.9 mg/kg 0R 1.2 mg/kg.
45454830|NCT01115335|Procedure|Neonatal male circumcision|Circumcision performed on a male infant within the first month of life, using one of 3 devices
45454831|NCT03527134|Drug|Amantadine|patients will receive amantadine 100 mg by month 2 h before the induction of general anesthesia and then 100 mg each time, three times per day for 5 days.
45454832|NCT01213693|Drug|Salmeterol/Fluticasone combination|Salmeterol/Fluticasone 50/500 mcg 1 inhalation bid
45454833|NCT01213693|Drug|Salmeterol|Salmeterol 50 mcg 1 inhalation bid
45454834|NCT01344902|Drug|hexaminolevulinate HCl|200mg hexaminolevulinate HCl capsule 6 hours before colonoscopy
45454835|NCT04468750|Device|kinesiotape|During the rehabilitation program, all patients with GHS had kinesiotaping three times a week.
45454836|NCT01213771|Procedure|Preoperative preparation 2010|Preoperative optimisation Supportive care LEAN in patient pathways
45662680|NCT02498821|Device|Sherlock 3CG® TCS|The Sherlock 3CG® TCS is a device that is placed on the subject during the PICC insertion procedure, which helps your healthcare providers know where the PICC is as the healthcare providers are inserting it. It uses magnets and measures electrical activity of the heart to determine the location of the catheter in your body.
45662681|NCT02498821|Procedure|Peripherally Inserted Central Catheter (PICC)|A peripherally inserted central catheter (PICC) is a form of intravenous access that can be used for a prolonged period of time (e.g., for chemotherapy, antibiotics, total parenteral nutrition)
45662682|NCT04205539|Drug|Dexmedetomidine|This medication will be administered sublingually using an LMA Intranasal Mucosal Atomization Device, which allows the medication to be administered in the form of a spray. Patients will be instructed to keep the medication in their mouth for about 2 minutes, or until fully absorbed. Pulse oximetry and blood pressure will be monitored throughout the duration of treatment. After the subject is asleep, the second DTI scan will be done.
45662683|NCT02313909|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg, once daily, orally, tablet
45662684|NCT02313909|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|100 mg, once daily, orally, tablet
45662685|NCT02313909|Other|Rivaroxaban-Placebo|Matching placebo, once daily, orally, tablet
45662686|NCT02313909|Other|Aspirin-Placebo|Matching placebo, once daily, orally, tablet
45662687|NCT02287467|Biological|Intravenous hyperimmune immunoglobulin (IVIG)|Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)
45662688|NCT02287467|Biological|Placebo for IVIG|Administered IV as 500 mL of normal saline
45662689|NCT02287233|Drug|Venetoclax|Venetoclax will be taken orally once daily.
45662690|NCT02287233|Drug|Cytarabine|Low-dose cytarabine will be administered subcutaneously on Days 1 to 10 of each 28-day cycle.
45662691|NCT01646385|Drug|etanercept|use as per routine clinical practice
45662692|NCT01646385|Drug|non-biologic anti-rheumatic drugs|use as per routine clinical practice (methotrexate, azathioprine, cyclophosphamide, cyclosporine, leflunomide, other)
45662693|NCT02286843|Radiation|89Zr-trastuzumab|
45662694|NCT02286843|Device|PET/CT scan|
45662695|NCT02286843|Radiation|89Zr-pertuzumab|
45662696|NCT02282163|Drug|sulphur hexafluoride lipid-type A microspheres|Ultrasound imaging contrast agent
45662697|NCT02281773|Drug|BI 409306 100 mg QD|
45662698|NCT02281773|Drug|BI 498306 50 mg QD|
45662699|NCT02281773|Drug|Placebo|
45662700|NCT02281773|Drug|BI 498306 25 mg QD|
45662701|NCT02281773|Drug|BI 409306 10 mg QD|
46078899|NCT02815904|Other|Yakson touch|Yakson is a Korean therapeutic touch given to neonates and infants by caressing their abdomen with one hand while the other hand is placed on the back of the neonate\infant to relieve their pain or to calm them down.
45662702|NCT02285361|Drug|GIOTRIF 20mg|NSCLC with GIOTRIF 20mg
45662703|NCT02285361|Drug|GIOTRIF 40mg|NSCLC with GIOTRIF 40mg
45662704|NCT02285361|Drug|GIOTRIF 30mg|NSCLC with GIOTRIF 30mg
45662705|NCT02354235|Drug|Teneligliptin|
45662706|NCT02354235|Drug|Canagliflozin|
45662707|NCT02354235|Drug|Placebo|
45662708|NCT02280291|Drug|Ankle SSB|general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
45662709|NCT02280291|Drug|Ankle OnQ|versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
45662710|NCT02280291|Drug|DR SSB|general anesthesia/sedationwith a single shot; general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
45662711|NCT02280291|Drug|DR OnQ|versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
45662712|NCT02284893|Drug|Saxagliptin|administered orally once daily
45662713|NCT02284893|Drug|Dapagliflozin|administered orally once daily
45662714|NCT02284893|Drug|Sitagliptin|administered orally once daily
45662715|NCT02284893|Drug|Placebo matching with Saxagliptin|administered orally once daily
45662716|NCT02284893|Drug|Placebo matching with Dapagliflozin|administered orally once daily
45662717|NCT02284893|Drug|Placebo matching with Sitagliptin|administered orally once daily
45662718|NCT02284347|Device|Electromagnetic Sinus Dilation System (NuVent™)|NuVent navigation-guided balloon system may be used to locate and move tissue, bone or cartilaginous tissue obstructing the drainage pathways of the frontal, maxillary, and sphenoid sinuses that is scarred, granulated or previously surgically-altered to facilitate dilation of the sinus ostia.
45662719|NCT02279043|Behavioral|Interaction with users of IUC and non-IUC users|"Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions. Half of participants in Birth Control Connect intervention groups will be current IUC users."
45817110|NCT03587844|Drug|brentuximab vedotin|LyP Brentuximab vedotin 0.9 mg/kg2
45956819|NCT00145028|Drug|Carboplatin|
45956820|NCT00528814|Other|Active Hand Sanitizer|Active Hand Sanitizer
45956821|NCT04691752|Other|Audit|Audit from clinical records
45956822|NCT00145067|Behavioral|Disease Management Assessment|
45956823|NCT01580527|Procedure|Total parenteral nutrition|Total parenteral nutrition in postoperative of pancreaticoduodenectomy
45454837|NCT03527056|Biological|Fecal Microbiota Transplantation|This is a parallel arm study. All participants in the experimental arm will receive a single fecal transplantation via oral capsules to determine effectiveness and safety in decolonizing gastrointestinal CRE.
45454838|NCT01213849|Drug|Fluticasone furoate 50 mcg (4 inhalations)|4 inhalations of 50 mcg strength
45454839|NCT01213849|Drug|Fluticasone furoate 100 mcg (4 inhalations)|4 inhalations of 100 mcg strength
45662720|NCT02279043|Behavioral|Interaction with non-IUC users only|"Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions."
45662721|NCT02283411|Device|Abbott Sensor Based Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
45662722|NCT02351817|Device|Test A|Ostomy appliance
45662723|NCT02351817|Device|Test B|Ostomy appliance
45662724|NCT02351817|Device|Baseline|Ostomy appliance
45662725|NCT02351349|Other|multidisciplinary intervention|multidisciplinary intervention
45662726|NCT02484547|Drug|Aducanumab (BIIB037)|Low dose
45662727|NCT02484547|Drug|Aducanumab (BIIB037)|High dose
45662728|NCT02484547|Drug|Placebo|Placebo
45662729|NCT02517541|Device|SenSura Mio Convex Soft|SenSura Mio Convex Soft is a CE marked ostomy product manufactured by Coloplast
45662730|NCT04965181|Behavioral|Mindfulness-Based Addiction Treatment|Mindfulness-based Addiction Treatment (MBAT) consists of 8 weekly virtual 2-hour sessions that teach mindfulness and cognitive-behavioral strategies for smoking cessation.
45662731|NCT04965181|Drug|Nicotine Replacement Therapy|"Patch therapy (beginning quit day) for participants who smoke >10 cigarettes/day will consist of 4 weeks of 21 mg patches, 2 week of 14 mg patches, and 2 week of 7 mg patches. Patch therapy for participants who smoke less than 10 cigarettes/day will consist of 4 weeks of 14 mg patches and 4 weeks of 7 mg patches.~Lozenge therapy (beginning quit day) for participants who smoke first cigarette within 30 minutes of waking up will consist of 8 weeks of 4mg lozenges. Lozenge therapy (beginning quit day) for participants who smoke first cigarette 30 minutes of more after they wake up will consist of 8 weeks of 2mg lozenges."
45956824|NCT01580527|Procedure|Enteral nutrition|Early enteral nutrition in postoperative of pancreaticoduodenectomy
45956825|NCT05647603|Other|data collection|Information about contraception
45956826|NCT00168753|Drug|Alefacept|IM
45454840|NCT01213849|Drug|Fluticasone furoate 200 mcg (4 inhalations)|4 inhalations of 200 mcg strength
45454841|NCT01213849|Drug|Vilanterol 25 mcg (4 inhalations)|4 inhalations of 25 mcg strength
45458165|NCT02310490|Device|DermaVeil left with left side Sculptra right side|The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed
45662732|NCT04965181|Behavioral|Self-help materials|"Self-help materials for smoking cessation are based on the Treating Tobacco Use and Dependence Clinical Practice Guideline (Fiore et al., 2008) and include the Clearing the Air booklet developed by the National Cancer Institute (NCI) and a referral to the Tobacco Cessation Quitline (1-800-QUIT-NOW)."
45458166|NCT02316496|Drug|cetuximab|cetuximab 500mg/m²/ IV infusion, (q2w)
45458167|NCT02316496|Drug|Irinotecan|Irinotecan 180mg/m², in 500ml NaCl 0.9% solution, 90 min IV infusion (q2w)
45662733|NCT04965181|Behavioral|iQuit Mindfully|iQuit Mindfully involves text messages on each day between treatment sessions. The text messages provide mindfulness and cognitive-behavioral strategies and support for smoking cessation.
45662734|NCT04964557|Drug|AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
45662735|NCT04964557|Drug|Placebo|Placebo solution
45662736|NCT02496091|Device|ATLANTIS Abutment|
45662737|NCT02483611|Drug|Magnesium Sulfate|
45662738|NCT02483611|Drug|Lidocaine|
45662739|NCT02483611|Drug|Isotonic Solution|
45662740|NCT02483611|Drug|Cisatracurium|
45662741|NCT04963933|Device|Nautilus endovascular device|Patients will be treated with the Nautilus Endovascular device followed by treatment follow up for up to 6 months
45662742|NCT02483533|Drug|LIPO-202|
45956827|NCT00528892|Drug|Raltegravir|switching PI to raltegravir
45956828|NCT00528892|Drug|boosted PI|continue on boosted-PI
45956829|NCT00405626|Drug|Bellis Perenis ,Arnica montana|
45956830|NCT04691401|Device|Artificial Intelligence System (CAD EYE, Fujifilm Co.)|A dedicated CNN-based AI system (CAD EYE, Fujifilm Co, Tokyo, Japan) has been recently developed. The Computer-aided diagnosis (CAD) CAD EYE system is a real-time computer-assisted image analysis that allows automatic polyp identification without modifications to the colonoscope or to the actual endoscopic procedure. When CAD EYE identifies a polyp, both a visual (a green blinking box surrounding the identified polyp, called the detection box) and an acoustic alarm pop up and attract the endoscopist attention. Around the endoscopic image a visual assist circle is shown and lights up in the direction where the suspicious polyp is detected.
45956831|NCT00531349|Procedure|propofol general anesthesia|Regional analgesia combined with sedation or a propofol general anesthesia
45956832|NCT00531349|Drug|Sevoflurane|General anesthesia
45956833|NCT00531466|Drug|tolperisone HCl (AV650)|One tablet orally three times a day for 28 days
45956834|NCT00531466|Drug|Placebo|One tablet orally three times a day for 28 days
45956835|NCT00168792|Drug|Tenecteplase|
46078900|NCT02815904|Other|Conventional handling|Positioning of preterm infants for optimal physiological development
45662743|NCT02483533|Drug|Placebo|
45662744|NCT02482129|Drug|LME636 60 mg/mL ophthalmic solution|
45662745|NCT02482129|Drug|Dexamethasone 0.1% ophthalmic solution|
45956836|NCT00168792|Procedure|PCI|
45662746|NCT02482129|Drug|LME636 Vehicle|Inactive ingredients used for masking purposes
46078901|NCT02815904|Other|Kinesthetic stimulation|For kinesthetic stimulation, all the limbs were given six passive flexion and extension movements
45662747|NCT04962529|Procedure|Blood Draw|Blood will be drawn from each patient to check the concordance between liquid and tissue biopsy
45662748|NCT02495857|Device|Hyaluronate Injectable Viscosupplement|Test product of a 1% sodium hyaluronate for injection
45662749|NCT02495857|Device|Euflexxa IA injection|Brand product of a 1% sodium hyaluronate for injection
45662750|NCT02495857|Device|Placebo|0.9% sodium chloride, sterile
46078902|NCT02815904|Other|Kangaroo Mother Care|Providing skin to skin human touch
46078903|NCT00928525|Drug|Imatinib Mesylate|800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months
45454842|NCT01215877|Drug|Tesetaxel|"Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months~In Cycle 1, a dose of 27 mg/m2 will be administered. In subsequent cycles,~the dose will be increased to 35 mg/m2 in Cycle 2 for subjects who did not have an ANC < 1,500/mm3, a platelet count < 100,000/mm3, or a Grade 3 (or higher grade) nonhematologic adverse event considered by the Investigator to be related to protocol therapy (excluding alopecia, nausea, and vomiting) in Cycle 1. The dose is not to exceed the dose of 35 mg/m2 in any cycle subsequent to Cycle 2.~for all other subjects, the dose administered in Cycle 1 (27 mg/m2) will be administered in all subsequent cycles."
45458168|NCT02528851|Procedure|Extubation from endotracheal mechanical ventilation to CPAP|"Following randomization, the infants will be extubated to the higher CPAP group (CPAP level 2cm H2O higher than extubation EAP) or equivalent CPAP group (CPAP level equal to the extubation EAP) based on their allocation."
45458169|NCT04881097|Behavioral|no intervention|no intervention
45662751|NCT02495389|Drug|Mirabegron|Mirabegron is a medication for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved by the United States Food and Drug Administration (FDA) in July 2012.
45662752|NCT02495233|Drug|Gilteritinib|oral
45662753|NCT02495233|Drug|Erlotinib|oral
45662754|NCT02495077|Biological|Infliximab|A single dose, of 3mg/kg infusion
45662755|NCT02495077|Drug|Methylprednisolone|500mg will be Initiated just prior to or at the initiation of transplant surgery and prior to Infliximab and thymoglobulin infusion
45662756|NCT02495077|Drug|Mycophenolate Mofetil|Administered at a target dose of 2000mg daily, as tolerated, until study closure
45662757|NCT02495077|Drug|Tacrolimus|Administered at a target dose of 0.1mg/kg BID, post-op, then adjusted to target trough levels of 8-12ng/ml during 1st 3-months post-op and finally adjusted to target trough levels of 5-8ng/ml until study closure
45662758|NCT02495077|Biological|Thymoglobulin®|Administered daily for 5 days with the intention of achieving a total dose of 4.5 to 6.0 mg/kg, as tolerated
45662759|NCT02495077|Drug|Acetaminophen|"30 to 60 minutes prior to the start of the infusion~Tylenol, 600 to 1000mg by mouth or~Suppository form"
45662760|NCT02495077|Drug|Loratadine|"30 to 60 minutes prior to the start of the infusion~Claritin (Loratadine) 10mg by mouth or~Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
45662761|NCT02495077|Biological|Placebo for Infliximab|A single dose is volume matched to Infliximab (250mL) infusion
45662762|NCT02495077|Drug|Prednisone|Prednisone will be administered peri-operatively according to center practice. Prednisone should be gradually tapered to no less than 5 mg/day or 10 mg every other day by 3 months post-transplant thereafter until study closure.
45956837|NCT00405665|Drug|L-arginine|Group 1 will receive the active treatment followed by the inactive treatment. The active treatment phase will consist of L-arginine 250 mg/ml dispensed in 2.2 ml vials, from which the patient will take 2ml (500mg) and dilute with 3ml of sterile water to give 5ml of a 100mg/ml solution. Dosing in the inactive treatment phase will consist of a placebo of similar osmolarity and appearance will be formulated and dosed in a similar fashion. It will consist of 2.2ml vials of 1110mmol/L hypertonic saline. Again, the patient will take 2ml and dilute with 3ml of sterile water to give a 445mmol/L solution which has similar tonicity (10%) to the L-arginine. Both treatment phases will be administered by inhalation with a PARI eFLOW device.
46078904|NCT02740530|Device|Magstim® Rapid 2 machine|See Arms description
46078905|NCT04237610|Behavioral|behavioral assessment|Probabilistic learning task
46078906|NCT04264481|Procedure|Adductor Canal Block|Ultrasound guided perineural injection of 5cc bupivacaine, 5cc lidocaine and 10 cc Normal saline
45662763|NCT02495077|Drug|Diphenhydramine|"30 to 60 minutes prior to the start of the infusion~Claritin (Loratadine) 10mg by mouth or~Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
45817111|NCT03587844|Drug|brentuximab vedotin|MF/SS prior brentuximab vedotin-Brentuximab vedotin dose to be determined from Cohort 1
45817112|NCT03584399|Other|PICS in critically ill pediatric population|Collection of additional blood sample from those subjects meeting criteria for the study.
45817113|NCT03581214|Other|No oxygen|No facemask, room air only
45817114|NCT03581214|Other|Oxygen|10Liters/minute oxygen by facemask
45662764|NCT02278341|Drug|Roxadustat|Participants received initial dose of roxadustat orally as a tablet in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.
45662765|NCT02278341|Drug|Epoetin alfa|Participants received epoetin alfa via intravenous or subcutaneous injection, once a week, twice a week, or three times a week (TIW). Epoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of epoetin alfa was per UK SmPC of Eprex®. Participants received IV iron supplementation according to the standard of care.
45662766|NCT02278341|Drug|Darbepoetin alfa|Participants received darbepoetin alfa via intravenous or subcutaneous injection, once a week or once every other week. Darbepoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of darbepoetin alfa was per EU SmPC of Aranesp®. Participants received IV iron supplementation according to the standard of care.
45662767|NCT02278341|Drug|Iron|Oral iron treatment was recommended for supplementation to support erythropoiesis and as first-line treatment for iron deficiency, unless participant was intolerant to this treatment. For participants receiving roxadustat the recommended daily dose was 200 mg of elemental iron. Participants were advised to take roxadustat at least 1 hour before or 1 hour after oral iron. Intravenous iron supplementation for participants receiving roxadustat was allowed if all of the following criteria were met: The participant's Hb level had not responded adequately to roxadustat following two consecutive dose increases or reached the maximum dose limit, and participant's ferritin was < 100 ng/mL (< 220 pmol/L) or TSAT < 20%, or the participant was intolerant of oral iron therapy. For participants treated with epoetin alfa or darbepoetin alfa, IV iron supplementation was given according to standard of care.
45662768|NCT02282631|Behavioral|Incentive scheme|Children who actively travel to school, full or partway, enter a weekly £5 voucher draw, whereby chances of winning are proportional to the number of trips as reported by the parent.
45817115|NCT03580629|Behavioral|Liver Live Donor Champion Program|Even with adequate education of live donation, many liver transplant candidates still feel ill equipped to ask others to consider donating. Friends and family are often eager to help and may not be able to serve as donors themselves, but might be able to provide instrumental support. A Live Donor Champion (LDC) is a friend or family member who serves as an advocate for the candidate in their pursuit of live donation. The Johns Hopkins Comprehensive Transplant Center has developed the Liver Live Donor Champion program to provide education and advocacy training to waitlist candidates and their LDCs. The support provided by the LDC bridges a critical link between education and action. Using LDCs to increase live donation is a novel approach that has garnered widespread enthusiasm.
45817116|NCT03574194|Dietary Supplement|Methionine-restricted diet|The methionine-restricted diet diet (MRD) will begin 2 weeks prior to radiation therapy to deplete methionine stores in the body, continue during radiation, and extend for approximately 2 weeks after the last radiation fraction for a total of 6-10 weeks (depending on duration of radiation course).
45956838|NCT00405665|Drug|L-arginine|Group 2 will receive the inactive treatment followed by the active treatment.
45817117|NCT03523468|Procedure|uniportal sleeve lobectomy|central lung cancer sleeve resection performed by uniportal VATS
45956839|NCT03458572|Device|Seirin Pyonex press needle acupuncture|Acupuncture
45956840|NCT00531544|Drug|SU011248|SU011248 Expanded Access Protocol for Systemic Therapy
45956841|NCT00531583|Drug|Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation|Autologous PBSCT
45454843|NCT03528304|Behavioral|Contingency management|Contingency management (CM) is a behavioral intervention that uses gift cards, prizes, or access to privileges to reinforce specific healthy behaviors and lifestyle changes. CM has been used successfully for a range of addictive behaviors, including cigarette smoking and heroin, cocaine, methamphetamine, and other illicit substance use, as well as for reducing psychiatric problems and HIV risk. CM has great potential for treating smoking and overweight/obesity, as it reinforces both short- and long-term behaviors. This is important because both smoking cessation and weight loss are highly prone to short-term relapse,
45956842|NCT00531700|Other|Health messaging|Combinations of personalized health messages (tailored/targeted) and contextualized health messages (reports about localized epidemiologic risk) will be delivered to subjects
45956843|NCT00531700|Other|Health messages|community level health messages unrelated to the study originating exposures
45956844|NCT00145106|Drug|Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)|
45956845|NCT02943538|Device|Telemedicine|Monitoring and control is performed through telematics platform integrated management of chronic NOMHAD, configurated to respond the patients specific needs.
45956846|NCT02943538|Device|Telephone|A telephone control of their state and evolution will be made through the nursing staff of the unit.
45956847|NCT02943538|Other|Conventional care|Conventional care provided in the unit to patients with IBD -high moderate complexity.
46078907|NCT04264481|Procedure|Intra-Articular Steroid and Lignocaine Injection|Intra-articular injection of 40mg triamcinolone and 1-2 cc of lidocaine
46078908|NCT00932347|Drug|Camellia sinensis mouthwash|mouthrinsing, 2 times/day, for 28 days
46078909|NCT00932347|Drug|Placebo mouthwash|mouthrinsing, 2 times/day, for 28 days
45454844|NCT01216033|Drug|111-In-ABY-025|Intravenous injection of the agent
45454845|NCT03940183|Drug|Trelagliptin Succinate|the experimental group will use trelagliptin succinate 100 mg for 24weeks
46078910|NCT05382611|Diagnostic Test|ngs next generation sequencing|the samples from aneurysmatic tissue and healthy aortic tissue will be investigated using NGS
45662769|NCT02278263|Drug|Tranexamic Acid|Given intravenously or topically
45662770|NCT02278263|Drug|Normal saline (0.9% NaCl)|Administered in all 3 groups
45662771|NCT02349711|Dietary Supplement|Probiotic mixture|A 350 mg capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
45956848|NCT00145184|Dietary Supplement|Multivitamin supplement containing vitamins B, C, and E|A daily oral dose of between 1.5 to 3 times the age- appropriate Recommended Dietary Allowance (RDA) of each vitamin taken for two months starting at enrollment.
45956849|NCT00145184|Drug|Placebo|Placebo pill taken orally once per day for two months starting at enrollment.
45454846|NCT03940183|Drug|Placebo Oral Tablet|the placebo Comparator groups use placebo oral tablet for 24weeks
45454847|NCT03530956|Device|Ankle Mimicking Prosthetic Foot prototype 4+|The amputee will walk with AMPfoot 4+, a novel bionic foot, designed and built by an engineer of department MECH (VUB, B)
45454848|NCT05153980|Device|Warm-up + Blood Flow Restriction cuff (smart-cuff pro device, acting as pressurized tourniquet)|Blood Flow Restriction
45662772|NCT02349711|Dietary Supplement|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Supplement contains 348.25 mg of potato starch.
45662773|NCT04876989|Procedure|US-SGB|Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 5 ml of 1% mepivacaine is injected for the US-SGB group.
45662774|NCT04876989|Procedure|US-TPVB|Well trained pain physician performs all the ultrasound(US)-guided thoracic paravertebral block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided TPVB, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at T2 paravertebral space. 10 ml of 1% mepivacaine is injected for the US-TPVB group.
45662775|NCT02494921|Drug|Docetaxel-PNP|Given IV
45662776|NCT02494921|Drug|Ribociclib|Given Orally
45662777|NCT02494921|Drug|Prednisone|Given Orally
45662778|NCT02494921|Drug|Filgrastim|Given IV
45662779|NCT01653847|Drug|Tacrolimus with MMF|Standard dose Tacrolimus and MMF. This will follow standard of care procedures at Northwestern Memorial Hospital's Comprehensive Transplant Center. MMF trough or area under the concentration time curve (AUC) shall not be used to adjust dosing. In this group, Tacrolimus will be initiated according to our practice. The Tacrolimus dose will be adjusted from day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 10 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be reduced to 6 ng/mL to 8 ng/mL. After month 6, the target level of Tacrolimus will be reduced to 4 ng/mL to 8 ng/mL.
45662780|NCT01653847|Drug|Group 2: Tacrolimus with Everolimus.|From day 5 on, the starting dose of Everolimus (0.75 mg bid) will be increased if the trough level is < 3 ng/mL, or reduced if the trough level is > 8 ng/mL. Tacrolimus will be initiated according to our practice. In this treatment arm, the Tacrolimus dose will be adjusted from day 3 on, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be 3 ng/mL to 6 ng/mL. After month 6, the Tacrolimus dose should be adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL. MMF dose will be initiated as 1 g b.i.d. (2 g/day). Adjustments should be made for adverse events including but not limited to gastrointestinal intolerance and a decrease in white blood cell (WBC).
45662781|NCT02493751|Drug|Avelumab (MSB0010718C)|Avelumab with two dose levels: 10 mg/kg IV and 5 mg/kg IV every two weeks to find the maximum tolerated dose in combination with axitinib and continue treatment in a dose expansion.
45817118|NCT03523468|Procedure|open sleeve lobectomy|central lung cancer sleeve resection performed by open chest
45817119|NCT03504683|Behavioral|Early Time-Restricted Feeding|Eat between 8 am - 3 pm (or 7 am - 2 pm, if an early riser)
45956850|NCT02944357|Drug|Cisplatin|Given IV
45956851|NCT02944357|Drug|Gemcitabine Hydrochloride|Given IV
45956852|NCT02944357|Procedure|Radical Cystectomy|Undergo cystectomy
45956853|NCT02944357|Biological|Tumor Cell-Derived Vaccine Therapy|Given AGS-003-BLD ID
45454849|NCT05153980|Other|Warm-up|Warm-up without any special intervention (no Blood Flow Restriction)
45454850|NCT01121809|Drug|Raltegravir|Changing the dose of raltegravir from 400 mg bid to 800 mg qd
45454851|NCT01121809|Drug|Etravirine|Changing the dose of etravirine from 200 mg bid to 400 mg qd
45454852|NCT03530878|Procedure|Hip Arthroscopy|Intraarticular pathology in the form of labral tears and cartilage that are often concomitant with DDH
45817120|NCT03504683|Behavioral|Mid-day Time-Restricted Feeding|Eat between 1 pm - 8 pm (or 12 pm - 7 pm, if an early riser)
45817121|NCT03504683|Behavioral|Control Schedule|Eat between 8 am - 8 pm (or 7 am - 7 pm, if an early riser)
45817122|NCT03471364|Drug|Ketoconazole|Applied topically
45817123|NCT03471364|Other|Laboratory Biomarker Analysis|Correlative studies
45817124|NCT03471364|Other|Placebo Administration|Applied topically
45817125|NCT03471364|Other|Quality-of-Life Assessment|Ancillary studies
45817126|NCT03471364|Other|Questionnaire Administration|Ancillary studies
45817127|NCT03469284|Other|Best Practice|Given standard of care therapy
45817128|NCT03469284|Drug|Methylene Blue|Given lower dose PO
45817129|NCT03469284|Drug|Methylene Blue|Given medium dose PO
45956854|NCT02944474|Drug|Lucerastat|Capsule for oral administration containing lucerastat
45956855|NCT02944474|Drug|Placebo|Placebo capsules matching lucerastat capsules
45956856|NCT02944396|Drug|pemetrexed|intravenous; administered on Day 1 via infusion in a 21-day cycle
45956857|NCT02944396|Drug|nivolumab|intravenous; administered on Day 1 via infusion in a 21-day cycle
45662782|NCT02493751|Drug|Axitinib (AG-013736)|Axitinib with two dose levels: 5 mg and 3 mg oral BID to find the maximum tolerated dose in combination with avelumab and continue treatment in a dose expansion.
45662783|NCT02493517|Drug|Lanreotide Autogel®|Lanreotide Autogel 60mg, 90mg, and 120mg, pre-filled syringe, deep subcutaneous injection (provided as a supersaturated solution of lanreotide acetate).
45662784|NCT02493517|Drug|Lanreotide Acetate|Lanreotide PR 40mg white freeze-drying cake, 40mg/vial, deep subcutaneous injection (provided as a sterile injectable lyophilisate of lanreotide acetate).
45662785|NCT02493361|Drug|Pembrolizumab|
45662786|NCT02493361|Drug|pIL-12|
45662787|NCT04960735|Other|VOICE intervention|"The intervention consists of four stages:~S1, Value identification and description of current care processes: Needs are detected from two perspectives: feedback from patients and mapping of healthcare processes. ICHOM questionnaires are reviewed. Patient surveys and clinical forms are developed. The methodology for cost analysis is set up.~S2, Intervention implementation: Patients are recruited according to the eligibility criteria. Their care follows the current healthcare pathway and information is collected at different time points.~S3, Assessment of outcomes and continued benchmarking: Data and costs are analysed at both local level and Community level (benchmarking). Interviews and focus groups are held (optional). Root cause analysis is performed.~S4, Model construction: Based on the process mapping and on root cause analysis, the multidisciplinary team designs the new care pathway. Professionals are trained in those tasks allocated according to the new care process."
45662788|NCT04959799|Drug|Dalbavancin|Adult diabetic patients suffering from infections who received the last dose of dalbavancin according to the current standard clinical practice at least 30 (+7) days before enrolment in the study.
45662789|NCT04959331|Drug|Fosfomycin Trometamol Salt|Fosfomycin 3 g 2 sachets, taken orally, once daily for two days
45662790|NCT04959331|Drug|Nitrofurantoin|Nitrofurantoin 50 mg pills, taken orally, two pills/8 hours, for five days
45662791|NCT04959331|Drug|Pivmecillinam|Pivmecillinam 400 mg pills. taken orally, one pill/8 hours, for three days
45662792|NCT04959331|Drug|Fosfomycin Trometamol Salt|Fosfomycin 3 g one sachet, taken orally, for one day
45662793|NCT02493127|Other|Standard PCS|Subject completes the standard version of the PCS Questionnaire
45662794|NCT02493127|Other|Grip Strength|Research Assistant takes Grip Strength Measurements
45662795|NCT02493127|Other|Positively Adjusted PCS|Subject completes the positively-adjusted version of the PCS Questionnaire
45662796|NCT02478463|Drug|Cabotegravir tablet 30 mg once daily for 28 days.|GSK1265744B, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, Aquarius film-coating, white BP18237
45662797|NCT02478463|Drug|Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.|Cabotegravir will be supplied as sterile suspension for injection 200 mg/mL vial. Each vial appears as sterile white to slightly colored suspension containing 200 mg/mL of CAB for administration by intramuscular (intragluteal) injection and will be administered as 1 × 3 mL Injections (3 mL [600 mg] total) IM given once on Day 1 of injection phase
45662798|NCT02491411|Drug|Dexamethasone|Given PO
45662799|NCT02491411|Drug|Enzalutamide|Given PO
45662800|NCT02491411|Other|Laboratory Biomarker Analysis|Correlative studies
45662801|NCT02491411|Other|Quality-of-Life Assessment|Ancillary studies
45662802|NCT02517463|Drug|Ulipristal acetate|This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.
45662803|NCT04957147|Other|12 months of guideline-directed heart failure therapy|Standard guideline-directed heart failure drug +/- device therapy
45817130|NCT03469284|Drug|Methylene Blue|Given higher dose PO
45817131|NCT03465072|Other|Exercise training|8 weeks, 3 times per week, 30-40 minutes
45817132|NCT03456076|Drug|Alectnib|Participants will receive alectinib 600 mg orally BID until completion of treatment period (24 months) or recurrence of disease , unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
45817133|NCT03456076|Drug|Cisplatin|"Participants will receive Cisplatin 75 milligrams per square meter (mg/m^2) on Day 1 every 21 days IV intravenously (IV) until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
45956858|NCT02944396|Drug|paclitaxel|intravenous; administered on Day 1 via infusion in a 21-day cycle
45956859|NCT02944396|Drug|veliparib|oral capsule; varying doses administered on Days -2 to 5 in a 21-day cycle
45956860|NCT02944396|Drug|carboplatin|intravenous; administered on Day 1 via infusion in a 21-day cycle
45662804|NCT02516605|Drug|Part 1: LJN452|LJN452 capsules administered once daily for 28 days
45662805|NCT02516605|Drug|Part 1: Placebo|Matching placebo capsules administered once daily for 28 days
45662806|NCT02516605|Drug|Part 2: LJN452 Dose level 1|LJN452 capsules administered once a day for 12 weeks
45662807|NCT02516605|Drug|Part 2: Placebo|Matching placebo to LJN452 administered once a day for 12 weeks
45662808|NCT02516605|Drug|Part 2: LJN452 Dose level 2|LJN452
45662809|NCT02490475|Drug|Docetaxel|Participants will receive docetaxel on Day 1 of each 3-week cycle as 60, 75, or 100 mg/m^2 via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
45662810|NCT02490475|Drug|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 420 mg via IV infusion. For Cycle 1 ony, rhuMab will be administered on Day 2, at least 24 hours after docetaxel and following an initial 840-mg loading dose. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
45662811|NCT02477839|Drug|Lacosamide|Active Substance: Lacosamide Pharmaceutical Form: Syrup Concentration: 10 mg/mL Route of Administration: oral
45817134|NCT03456076|Drug|Vinorelbine|Participants will receive Vinorelbine 25 mg/m^2 IV on Days 1 and 8 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
45817135|NCT03456076|Drug|Gemcitabine|Participants will receive Gemcitabine 1250 mg/m^2 on Days 1 and 8 Q21D IV until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
45956861|NCT00529945|Device|PFx Closure System|
45956862|NCT00174174|Drug|Modafinil|
45956863|NCT00529984|Biological|AVX701|4 doses of AVX701 at 4e7 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
45956864|NCT00529984|Biological|AVX701|4 doses of AVX701 at 1e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
45956865|NCT00529984|Biological|AVX701|4 doses of AVX701 at 4e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
45817136|NCT03456076|Drug|Pemetrexed|"Participants will receive 500 mg/m^2 Day 1 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
45817137|NCT03456076|Drug|Carboplatin|For participants who experience unacceptable toxicity with cisplatin, carboplatin can be used.
45817138|NCT03452150|Drug|D-0316|If initial dosing of D-0316 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
45817139|NCT03447340|Behavioral|Canteen and Behavior intervention|"canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.~Behavioral : 16 core classes and 8 maintenance classes"
45956866|NCT00529984|Biological|AVX701|4 doses of AVX701 given at the maximally tolerated dose at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
45662812|NCT02477839|Other|Placebo|Active Substance: Placebo Pharmaceutical Form: Syrup Concentration: N/A Route of Administration: oral
45662813|NCT04939987|Drug|Tramadol|Opioid Control Cohort (One treatment selected)
45956867|NCT00529984|Biological|AVX701|4 Doses of AVX701 given to Stage III colon cancer subjects at the maximally tolerated dose at T=0, 3, 6, 9 weeks. There will be no option for subjects to receive additional immunizations.
45662814|NCT04939987|Drug|Gabapentin|Experimental Cohort (Multimodal Approach)
45662815|NCT04939987|Drug|Hydrocodone-Acetaminophen|Opioid Control Cohort (One treatment selected)
46078911|NCT02735538|Procedure|osteonecrosis of femoral head group|The patients with osteonecrosis of femoral head will undergo total hip replacement.
46078912|NCT02735538|Procedure|osteoarthritis group|The patients with osteoarthritis will undergo total hip replacement.
45956868|NCT00530101|Drug|Doxorubicin|"This pilot study will select patients who are at increased likelihood to develop cardiotoxicity, due to borderline cardiac function at baseline, advanced age, or the anticipation of a high cumulative dose of administered doxorubicin. Patients who will receive radiation therapy to the left chest during chemotherapy (i.e., left breast cancer) will be excluded so as to eliminate possible cardiotoxic effects from radiation. CMR studies will be performed at no charge to the patient, supported by the sponsor of this study. CMR imaging will be subject to IRB approval, informed consent, and HIPAA regulations. Contrast-enhanced CMR will be obtained at three time points:~Patients will not undergo contrast-enhanced MR unless calculated GFR is equal to or greater than 60 mL/min/1.73 m2"
45956869|NCT00145262|Procedure|Autologous Bone Marrow Mononuclear Cell Implantation|
45956870|NCT00530140|Biological|Follicular lymphoma, patient-specific, soluble protein idiotype vaccine|0.5 mg of idiotype conjugated to 0.5 mg of KLH + 125 mcg of GM-CSF 5 monthly vaccinations followed by 3 bi-monthly vaccinations, followed by one boost every three months until either relapse or death from cause unrelated to lymphoma
45956871|NCT02944552|Drug|bicyclol tablet 25mg|Patients in the low dose group administrated bicyclol tablet 25mg, one bicyclol blank analog tablet and two polyene phosphatidylcholine blank analog capsules orally, three times daily for 4-8 weeks.
45956872|NCT02944552|Drug|bicyclol tablet 50mg|Patients in the high dose group administrated bicyclol tablet 50mg and two polyene phosphatidylcholine blank analog capsules orally, three times daily for 4-8 weeks.
45956873|NCT02944552|Drug|polyene phosphatidylcholine capsule 456mg|Patients in the positive drug control group administrated polyene phosphatidylcholine capsules 456mg and two bicyclol blank analog tablets orally, three times daily for 4-8 weeks.
45454853|NCT03937687|Drug|Caffeine+TeaCrine+Dynamine|combination of caffeine, TeaCrine, and Dynamine
45662816|NCT04939987|Drug|Oxycodone-Acetaminophen|Opioid Control Cohort (One treatment selected)
45662817|NCT04939987|Drug|Ketorolac|Experimental Cohort (Multimodal Approach)
45662818|NCT04939987|Drug|Acetaminophen|Experimental Cohort (Multimodal Approach)
45454854|NCT03937687|Drug|Placebo|Placebo
45454855|NCT03937687|Drug|Caffeine|Caffeine
45662819|NCT04939987|Drug|Ketorolac tromethamine|Experimental Cohort (Multimodal Approach)
45662820|NCT04939987|Drug|Ketamine|Experimental Cohort (Multimodal Approach)
45662821|NCT04953559|Device|Active cTBS|Active continuous theta burst (cTBS) transcranial magnetic stimulation (TMS)
45662822|NCT04953559|Device|Sham cTBS|Sham continuous theta burst (cTBS) transcranial magnetic stimulation (TMS)
45662823|NCT02488915|Device|EmboTrap® Revascularization Device|
45662824|NCT02488681|Device|Micra Pacemaker Implant|
45662825|NCT02477605|Device|CONSTELLATION® 27-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 27-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 27-gauge EDGEPLUS® Valved Entry System comprised of 3 trocar/cannulas and related accessories.
45817140|NCT03447340|Other|Canteen Only|canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.
45817141|NCT03425331|Drug|Ipilimumab|Ipilimumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
45817142|NCT03425331|Drug|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
45817143|NCT03371407|Other|Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology|Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology, using an instrumentation, called the Kinarm, which assess objectively sensory, motor and cognitive functions
45662826|NCT02477605|Device|CONSTELLATION® 23-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 23-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 23-gauge EDGEPLUS® trocar/cannula set comprising of 3 trocars/cannulas and related accessories.
45662827|NCT02477605|Procedure|Vitrectomy surgery|Microincisional pars plana vitrectomy (PPV) surgery for the treatment of various vitreoretinal diseases ranging from simple to advanced cases
45662828|NCT02477527|Drug|Stribild|Change subjects from Atripla one tablet per day to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil one tablet per day.
45662829|NCT02477215|Drug|MLN9708|4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
45817144|NCT03366155|Device|Codman 3000 constant flow pump catheter|implanted Medtronic SynchroMed II Pump with codman 3000 Constant Flow Pump Catheter
45817145|NCT03366155|Drug|Panitumumab|6 mg/kg, IV
45817146|NCT03366155|Drug|FUDR-Dex|HAIP will be filled with mixture of Floxuridine and Dexamethasone. Pump will perfuse drugs to liver for 14 days. Floxuridine (0.12 mg/kg X pump volume X pump flow rate),Dexamethasone (1 mg/day X pump volume (30) X pump flow rate)
45454856|NCT03937531|Procedure|Bladder Scanner|PVR will be measured by using a bladder scanner.
45458170|NCT02316574|Behavioral|Cognitive Behavioral Coping Skills Therapy|"Cognitive Behavioral Coping Skills Therapy (CBCST) is an individual psychotherapy for alcohol dependence that helps individuals to reduce drinking by addressing the ability to regulate, or cope with alcohol cravings and other emotions that promote alcohol use."
45662830|NCT02477215|Drug|Dexamethasone|40 mg oral on Days 1, 8, 15 of each 28 day cycle.
45662831|NCT02477215|Drug|Bendamustine (multiple dose levels)|70 mg/m^2, 80 mg/m^2, or 90 mg/m^2 on days 1 and 2
45662832|NCT02477215|Drug|Bendamustine (MTD)|80 mg/m^2 on days 1 and 2
45817147|NCT03366155|Drug|Oxaliplatin|85 mg/m2, IV
45817148|NCT03366155|Drug|5FU|2000 mg/m2, IV 46-hour infusion of 5-Fluorouracil + 400 mg/m2, IV of Leucovorin
45458171|NCT01140529|Drug|Dexmedetomidine|Bolus and continuous infusion
45458172|NCT01140529|Drug|Haloperidol|Bolus doses
45662833|NCT02487199|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
45458173|NCT01140529|Drug|Saline|Bolus and continuous infusion
45662834|NCT02487199|Drug|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
45662835|NCT04951999|Other|Blood sampling|For 10 visits (out of the 12 of the protocol), ~40 ml of blood is sampled for research purposes in addition to care sampling.
45662836|NCT02475733|Drug|Ceftazidime -avibactam|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
45662837|NCT02475733|Drug|Meropenem|Randomisation (3:1) to CAZ AVI plus metronidazole or meropenem treatment
45662838|NCT02475733|Drug|Metronidazole|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
45817149|NCT03366155|Drug|Irinotecan|150 mg/m2, IV
45817150|NCT03366155|Procedure|HAIP installation|HAI pump installation
45817151|NCT03366155|Drug|cetuximab|500 mg/m2, IV
45817152|NCT03366155|Device|Medtronic SynchroMed II Pump|implanted Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter
45817153|NCT03358797|Behavioral|Attention-control|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics
45662839|NCT04925947|Drug|KN046|KN046 will be given intravenously at 5 mg/kg every 2 weeks. A cycle is defined as 2 treatments (28 days). Treatment will be given until progression, excessive toxicity, or up to two years.
45662840|NCT04942639|Device|JOE|Audiovisual support by the robot when taking maintenance treatments at home.
45817154|NCT03358797|Behavioral|Community based intervention with resilience training|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
45662841|NCT02486653|Drug|Tamsulosin|"Tamsulosin 0.4mg capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~Day 1-7: tamsulosin 0.4mg in the evening~Day 8: surgery; tamsulosin 0.4mg in the evening if the subject has not yet completed the bladder management protocol~Day 9-14: tamsulosin 0.4mg in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual <200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function."
45662842|NCT02486653|Drug|Placebo|"Placebo capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~Day 1-7: placebo in the evening~Day 8: surgery; placebo in the evening if the subject has not yet completed the bladder management protocol~Day 9-14: placebo in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual <200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function."
45662843|NCT02475655|Drug|Ruxolitinib|10 mg orally twice daily for 5 weeks
45662844|NCT02475265|Drug|estradiol 0.045 mg/levonorgestrel 0.015mg|
45662845|NCT02485717|Drug|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
45662846|NCT02485717|Other|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
45817155|NCT03358797|Behavioral|intervention-HPP|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics. In addition, there will be training in leadership skills, community interventions, community needs assessment, intervention planning and outcomes assessment.
45817156|NCT03358797|Behavioral|Pilot|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
45817157|NCT03348280|Diagnostic Test|Blood draw|Blood will be drawn to isolate monocytes after 2 weeks off of blood pressure lowering medications.
45817158|NCT03344770|Device|Active rESWT|5,000 pulses of rESWT, with 0.16mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
45817159|NCT03344770|Device|Sham rESWT|5,000 pulses of rESWT, with 0.0 mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
45817160|NCT03313115|Behavioral|Sleep/Wake Protocol|"Day RN observes if completed per pt: no caffeine after 3 pm, encourage activities to prevent napping (chart % day spent napping), Lights on blinds/door open, Reasonable effort for some noise in room, Eye glasses hearing aids applied, Chair position/mobility at least 2x30 minutes.~Night RN observe if completed per pt: Appropriate pain control, Optimize room temp, Warm bath before 2200, TV off by 2200, Prevent extra alarms after 2200, Close room curtain by 2200, Dim room lights by 2200, Family out by 2200, Door half/fully closed after 2200, # RN interruptions after 2200, Offer eye mask/ear plugs, Meds administered for sleep (dilaudid, fentanyl oxycodone, haldol, quetiapine, propofol, melatonin, or other), Dim hallway lights by 2200, Nurses station quiet"
45817161|NCT03295136|Behavioral|Health Promotion Training for Women Employees|Group intervention over a one year, acquiring health promotion tools and skills, as well as leadership and project designing and implementation skills.
45817162|NCT03283826|Biological|ATA188|ATA188 is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ progressive multiple sclerosis.
45817163|NCT03283826|Drug|Placebo|Placebo matching to ATA188
45817164|NCT03276832|Drug|Imiquimod|Applied cutaneously
45817165|NCT03276832|Other|Laboratory Biomarker Analysis|Correlative studies
45817166|NCT03276832|Biological|Pembrolizumab|Given IV
45956874|NCT00145301|Drug|Lumiracoxib|
45662847|NCT05460559|Procedure|Group A (p-PCNL) procedure|In lithotomy position, ureteric catheter will be inserted allowing injection of contrast to obtain a pyelogram. Shifting the patients in prone position will be done. Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out. Amplatz sheath will be inserted to allow nephroscope to enter the collecting system. Stone disintegration will be performed using pneumatic, ultrasonic or laser lithotripsy. Eventually after removal of all stone fragments, a nephrostomy tube will be placed.
45662848|NCT05460559|Procedure|Group B (s-ECIRS) procedure|The patients will be in Galdakao-Modified Supine Valdivia (GMSV) position . Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out till 30 Fr. Amplatz sheath will be inserted to allow a 26 Fr nephroscope to enter the collecting system. Retrograde intrarenal surgery will be applied simultaneously by a second surgeon using flexible ureteroscopy. The stones will be fragmented with holmium-yttrium-aluminum-garnet (YAG) laser and stone fragments will be evacuated by basket or removed through PCNL tract under nephroscopy.
45662849|NCT02451007|Drug|lurbinectedin (PM01183)|
45662850|NCT02473471|Device|Micro-osteoperforation|Three Micro-osteoperforation (MOPs) will be performed distal to canine by Mini screw. Before the application of the MOPs, Patient will be asked to wash their mouth twice by chorhexidine for 1 minute.
45662851|NCT02450539|Drug|Abemaciclib|Administered orally
45662852|NCT02450539|Drug|Docetaxel|Administered IV
45662853|NCT02449915|Drug|Bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
45662854|NCT02449915|Drug|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have 30mL total volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
45662855|NCT02420119|Other|non interventional|
45662856|NCT02473393|Drug|OPS-2071 tablet|
45662857|NCT02419573|Device|Endotracheal Intubation|In this traditional model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use ETI as the primary (initial) airway management intervention. If the EMS agency is assigned to this arm, basic-level EMS personnel will use bag-valve-mask ventilation only even if they would normally use an LT.
46078913|NCT00928603|Procedure|Focal Cryoablation|Cryotherapy is administered via the perineum under ultrasound guidance by third-generation 17-gauge cryoprobes using gas and thermal couples. Under transrectal ultrasound guidance cryoprobes are placed approximately 1 cm apart and within 5 mm of the capsule on the side of tumor. The extent of freezing was limited to the area or lobe of the gland with histologically proved tumor.
45662858|NCT02419573|Device|Laryngeal Tube (King)|In this test model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use LT as the primary (initial) airway management intervention. Basic-level EMS personnel will use bag-valve-mask ventilation. If trained to use LT, basic-level EMS personnel may perform LT insertion.
45817167|NCT03270163|Diagnostic Test|Transcutaneous electrical stimulation|"The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~three simple electrical stimulations,~three electrical doublets at the frequency of 100Hz~For each type of electrical stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals."
45817168|NCT03270163|Diagnostic Test|Magnetic stimulation|"The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~three simple magnetic stimulations,~three magnetic doublets at the frequency of 100Hz~For each type of magnetic stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals."
45956875|NCT00530179|Procedure|Autologous Blood Stem Transplantation|2 CYCLES OF R-CHOP + R-DICEP/R-BEAM FOLLOWED BY AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION
45956876|NCT00530179|Drug|R-CHOP|6 - 21 DAY Cycles of R-CHOP
45956877|NCT00530296|Behavioral|Cognitive Behavioral Therapy|"Group therapy, 12 sessions (90 minutes each, one session per week) manual Coping with depression course"
45458174|NCT02310724|Other|TODAY cohort|This protocol is observation only and involves no intervention, care, treatment, or management.
45458175|NCT02316652|Procedure|Scaling and root planing|Mechanical instrumentation
45458176|NCT02316652|Procedure|Scaling and root planing with solution|Mechanical instrumentation with sodium hypochlorite disinfective solution
45662859|NCT02472847|Drug|Dronabinol|Dronabinol (7.5mg) is administered only once by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants will receive dronabinol.
45662860|NCT02472847|Drug|Placebo|Placebo is administered only once by the oral route and contains only dextrose in opaque capsules. Half of the participants will receive placebo.
45956878|NCT02944318|Behavioral|The Movement Program|The program duration will be one academic year (around ten months) in 2017. The intervention strategies will focus on: (1) teachers' training and activities on health in curriculum; (2) active opportunities in the school environment (facilities and materials for PA practice) and (3) health education (posters and folders to students and parents).
45956879|NCT00168870|Drug|Gemcitabine|
45956880|NCT00168870|Drug|Treosulfan|
45662861|NCT02472145|Drug|Decitabine 20 mg/m^2|Decitabine 20 milligram per square meter (mg/[m^2]) from Day 1, 2, 3, 4 and 5 of a 28-day cycle.
45662862|NCT02472145|Drug|Talacotuzumab 9 mg/kg|Talacotuzumab 9 milligram per kilogram mg/kg on Day 8 and 22 of a 28-day cycle.
45817169|NCT03270163|Diagnostic Test|ultrasound measurement|The ultrasound measurement of the thickness of the quadriceps muscle will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening.
45817170|NCT03260647|Other|Management algorithm for Malignant Bowel Obstruction|a proposed management algorithm for MBO has been developed to provide a pathway that safeguards quality and continuity of care for patients under a multidisciplinary team. It will engage key-stakeholders and foster an inter-professional approach. It incorporates an in-patient management algorithm and a novel nursing-led ambulatory management algorithm to supplement patient's medical management
45662863|NCT02418949|Drug|Cyproheptadine|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy as well as gradually down to zero in the two weeks following treatment.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Week 4-9: (chronic dose): 8 mg taken three times daily (orally). Week 10: 8 mg taken twice daily (orally). Week 11: 4 mg taken twice daily (orally). Week 12: no drug"
45662864|NCT02418949|Drug|Placebo for Cyproheptadine|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy as well as gradually down to zero in the two weeks following treatment.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Week 4-9: (chronic dose): 8 mg taken three times daily (orally). Week 10: 8 mg taken twice daily (orally). Week 11: 4 mg taken twice daily (orally). Week 12: no drug"
45662865|NCT02418949|Other|Active Movement Practice (AMP)|Participants will alternate between active training with a custom video game and a robot active-assistive Voice and EMG-Driven Actuated (VAEDA) glove during active training occupational therapy.
45817171|NCT03214029|Diagnostic Test|Cardiac troponin testing|Fresh EDTA plasma samples will be measured with both the hs-cTnI (Abbott) and hs-cTnT (Roche) assays.
45817172|NCT03211416|Other|Laboratory Biomarker Analysis|Correlative studies
45817173|NCT03211416|Biological|Pembrolizumab|Given IV
45817174|NCT03211416|Drug|Sorafenib Tosylate|Given PO
45817175|NCT03205293|Behavioral|Intervention Program to Promote Healthy Eating and Physical Activity among Palestinian Female Schoolchildren|
45662866|NCT02418949|Other|Passive Cyclical Stretching|Participants will wear the actuated device/glove for the duration of the training sessions (2 20-min stints followed by 10 min of rest) during which time the actuated glove will cyclically stretch the joints of the digits in the hand between flexion and extension while remaining passive/relaxed.
45662867|NCT04912765|Biological|Neoantigen Dendritic Cell Vaccine|10 doses of the vaccine will be administered via intra-dermal injection concurrently with adjuvant nivolumab.
45662868|NCT04912765|Drug|Nivolumab|9 doses of 240mg IV nivolumab as a 30 minutes infusion will be administered in combination with NA DC vaccine starting from the second vaccine dose. Upon completion of 10 doses of NA DC vaccine, 480mg IV nivolumab will be administered as a 30 minutes infusion for a maximum of 9 doses.
45662869|NCT02448043|Drug|Bimatoprost 0.01%|Bimatoprost drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days
45662870|NCT02448043|Other|Placebo: saline|Placebo drops added to the proximal nail folds of the hand digits opposite the study hand two times per day for 30 days
45662871|NCT02447887|Drug|Ixazomib|The prescribed administration of ixazomib doses in this study is 1.5-4.0 mg ixazomib weekly for 3 out of 4 weeks in each cycle (1 cycle=28 days).
45662872|NCT02447887|Drug|Pegylated IFN-alpha 2b|Weekly injection
45817176|NCT03201523|Other|Socio-ecologial, community-based intervention|Intervention components will include a health newsletter, health workshops, community evening/health project registration, lay leader training, neighborhood exercise groups, community walking programs with pedometers, healthy cooking contest, and school health promotion activities.
45817177|NCT03187288|Drug|CFI-400945 Fumarate|CFI-400945 is an investigational drug that is being look at for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CFI-400945 is an oral (taken by mouth) drug that blocks Polo-like kinase 4 (PLK4) activity. PLK4 is a protein that is important in regulating cell growth and division and cell death. Many tumors are shown to make too much PLK4. When there is too much PLK4 produced, it is believed to contribute to uncontrolled cancer cell growth and division. Therefore, by blocking this protein from working, it is believed to stop tumors from growing or shrink them.
45817178|NCT03167489|Behavioral|Lifestyle Plus Emotional Regulation|Group intervention over 5 months, integrating the Mediterranean Diet into a lifestyle intervention and emotional regulation skills.
45817179|NCT03149211|Drug|UB-421|Subjects will receive 13 doses of the UB-421 by intravenous infusion at 25 mg/kg bi-weekly (Cohort 2, 26 weeks).
45817180|NCT03149211|Drug|current standard HAART treatment|Subjects will receive current standard HAART treatment as the active control group.
45817181|NCT03145077|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
45817182|NCT03145077|Other|Questionnaire Administration|Ancillary studies
45662873|NCT02471755|Device|Eelectro-acupuncture|The bilateral acupoints of EX-CA1, ST25, SP6 and RN4 were selected for the treatment program.After regular disinfection,adhesive pads were placed on surface of all these acupoints. For RN4, EX-CA1, ST25, needles (0.30*75mm) were inserted into the points vertically throughout the pads, skin, fat tissue, and abdominal muscles until the participant had feeling of pricking. For SP6, needles were inserted into the acupoint to a depth of 1 cun,accompanied by manipulation of lifting, thrusting, and twisting 3 times. Electronic stimulator was connected to EX-CA1 and ST25 with dilatational wave, 10/50HZ, 0.1 to 1.0mA. The current intensity was adjusted to abdomen shivering without pain. Treatment lasted for 30 minutes and acupuncture manipulation for RN4 and SP6 were performed every 10 minutes.
45662874|NCT02471755|Device|Sham Eelectro-acupuncture|Non-acupoints approximate to RN4, ST25, EX-CA1 and SP6 were selected bilaterally, and adhesive pads were placed on the surface of selected non-acupoints' location. Blunt needles were inserted into the pads and to touch, rather than penetrate the surface of skin. Meanwhile, like EA group, manipulations of lifting, thrusting and twisting on non-acupoint approximate to RN4 and SP6 were performed 3 times. Sham Electronic stimulator was applied to the non-acupoint approximate to EX-CA1 and ST25, providing the outward appearance of the procedure in EA group but with no current intensity actually applied. Any other interventions were rigorously maintained the same as in the EA group.
45662875|NCT02470429|Device|SYSTANE HYDRATION lubricant eye drops|Preserved with POLYQUAD (polidronium chloride) 0.001%
45662876|NCT02470429|Device|Hyabak 0.15% eye drops|Preservative-free
45662877|NCT02470429|Drug|0.9% saline eye drops|Preservative-free, one drop 4 times a day in each eye (run-in period)
45662878|NCT02447497|Drug|3M CHG/IPA Surgical Skin Preparation - Abdominal Region|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
45662879|NCT02447497|Other|Normal Saline - Abdominal Region|0.9% sodium chloride applied with foam applicator
45662880|NCT02447497|Drug|3M CHG/IPA Surgical Skin Preparation - Inguinal Region|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
45662881|NCT02447497|Other|Normal Saline - Inguinal Region|0.9% sodium chloride applied with foam applicator
45662882|NCT02417935|Drug|Duloxetine|Administered orally
45662883|NCT02417935|Drug|Pregabalin|Administered orally
45662884|NCT02417935|Drug|Placebo|Administered orally
45662885|NCT02417233|Behavioral|SMS text message|bi-weekly behavioral messages and bi-weekly check-in messages
45662886|NCT02417233|Behavioral|SMS text message + Peer Navigation|bi-weekly behavioral messages plus personalized peer navigation
45817183|NCT03141671|Drug|GnRH|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
45817184|NCT03141671|Drug|Bicalutamide|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
45817185|NCT03141671|Radiation|Salvage radiation|Radiation
45817186|NCT03141671|Drug|Abiraterone|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
45817187|NCT03141671|Drug|Prednisone|Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.
45956881|NCT02944201|Drug|Carvedilol|Carvedilol will give twice daily until prostatectomy
45662887|NCT02447029|Drug|vaginal 2% Xylocaine|patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block
45662888|NCT02447029|Drug|standard lidocaine paracervical block|1% lidocaine paracervical injection
45662889|NCT04938661|Other|Center-Based Cardiac Rehab|36 center-Based Cardiac Rehab Sessions
45662890|NCT04938661|Other|mHealth|Mobile Health Platform
45662891|NCT04938661|Other|Home-Based Cardiac Rehab|Encouraged to exercise 3 times per week at home
45662892|NCT02416453|Biological|MVA-BN-Filo|One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit [Inf. U.] on Day 29, 57, or 85.
45662893|NCT02416453|Biological|Ad26.ZEBOV|One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.
45662894|NCT02416453|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.
45662895|NCT02469961|Drug|Dexmedetomidine|Participants will receive an interscalene block and will be sedated with Dexmedetomidine and compared to sedation with propofol
45956882|NCT02944162|Biological|anti-CD33 CAR-NK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD33 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD33.
46078914|NCT05303909|Drug|Gentamicin|a single dose of IV gentamicin at a dose of 5 mg/kg infused over 30 minutes via a peripheral vein. Followed by administration of YF17D vaccine (stamaril) 0.5mls via subcutaneous injection into the deltoid region of the right or left arm.
45662896|NCT02469961|Drug|Propofol|Participants will receive an interscalene block and be sedated with Propofol and compared to sedation with Dexmedetomidine
45956883|NCT00145340|Drug|pioglitazone|30 Mg/day
45662897|NCT02469961|Other|Interscalene block|Interscalene block is used for the main anesthetic for the case
45662898|NCT04911751|Drug|KBL697|1 capsule BID of KBL697 or Placebo
45662899|NCT04911751|Drug|KBL697|5 capsules BID of KBL697 or Placebo
45662900|NCT02415595|Drug|BMS-955176|HIV Maturation Inhibitor
45662901|NCT02415595|Drug|EFV|EFV
45662902|NCT02415595|Drug|TDF/FTC|TDF/FTC
45662903|NCT02446717|Drug|ABT-493, ABT-530|ABT-493 (tablet) dosed with ABT-530 (tablet)
45662904|NCT02446717|Drug|ribavirin (RBV)|Tablet
45662905|NCT02446717|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
45662906|NCT02469415|Drug|Pacritinib|"Part 1: Pacritinib 200 mg taken by mouth twice daily.~Part 2: Pacritinib dose decreased to 200 mg in the morning and 100 mg in the evening for the first cycle of combined therapy. If no toxicity is observed in first cycle of combined therapy, Pacritinib dose may be increased to 200 mg twice a day on subsequent cycles of combined therapy."
45817188|NCT03141671|Drug|Apalutamide|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
45956884|NCT02943343|Other|No intervention|
45956885|NCT00168909|Drug|alfacalcidol|alfacalcidol 1 µg once daily, oral, for 3 years
45956886|NCT00168909|Drug|placebo|placebo once daily, oral, for 3 years
45662907|NCT02469415|Drug|5-azacitidine|Part 2 Starting Dose of 5-azacitidine: 75 mg/m2 by vein on Days 1 - 5 of Cycles 5 and beyond.
45662908|NCT02469415|Drug|Decitabine|Part 2 Starting Dose of Decitabine: 20 mg/m2 by vein on on Days 1 - 7 of Cycles 5 and beyond.
45662909|NCT02446171|Drug|Naloxegol 25 mg tablet, crushed, suspended in water, given orally|naloxegol 25 mg (1 tablet) crushed, suspended in water, given orally
45662910|NCT02446171|Drug|Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube|naloxegol 25 mg (1 tablet) crushed, suspended in water, given via nasogastric tube
45662911|NCT02446171|Drug|Naloxegol 25 mg (10 mL oral solution)|naloxegol 25 mg (10 mL oral solution)
45662912|NCT02446171|Drug|Naloxegol 25 mg tablet, given orally|naloxegol 25 mg (1 tablet) whole tablet, given orally
45662913|NCT02446015|Drug|SYSTANE® ULTRA Lubricant Eye Drops|
45817189|NCT03108820|Behavioral|TMH Intervention|Home visits and close interaction with injured patient to assure plan for care is being followed.
45817190|NCT03108820|Other|Usual Care|Review hospital discharge and rehabilitation plan, identification of primary care provider, provision of educational materials on communication skills, caregiver coping skills, and legal and financial advice.
46078915|NCT05303909|Drug|Placebo|100mls of 0.9% normal saline as placebo infused over 30 minutes via a peripheral vein. Followed by administration of YF17D vaccine (stamaril) 0.5mls via subcutaneous injection into the deltoid region of the right or left arm.
46078916|NCT04306692|Drug|Myo-inositol|2 x 1 bag per day, per os (subjects can take myo-inositol during the meal but it is not obliged).
46078917|NCT04306692|Drug|Clomiphene Citrate|"Each tablet contains 50 mg of clomiphene citrate which means 33,9 mg of clomiphene. Other constituents are sucrose, lactose monohydrate, corn starch, pregelatinized starch, yellow iron oxide (E172) and magnesium stearate (E470b).~Dosing: 1 tablet per day from cycle day 3 until 7 (extremes included), stepping up until a maximum dose of 3 tablets per day for 5 consecutive days."
46078918|NCT00928681|Biological|Single dose-group A|PF-00547659, single iv dose
45662914|NCT02415127|Drug|Interferon γ-1b|The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
46078919|NCT00928681|Biological|Single dose-group A|PF-00547659, single iv dose
45662915|NCT02415127|Drug|Placebo|The volume of placebo is planned to correspond with volume of study drug that would be given to the participant if the participant was randomized to the study drug arm.
45662916|NCT02468557|Drug|Idelalisib|Tablets administered orally twice daily
45662917|NCT02468557|Drug|Nab-paclitaxel|125 mg/m^2 administered intravenously on Days 1, 8 and 15 of each 28 day cycle
45662918|NCT02468557|Drug|mFOLFOX6|mFOLFOX6 will be administered intravenously on Days 1 and 15 of each 28 day cycle. This regimen consists of levoleucovorin 200 milligram/meter per square (mg/m^2) or racemic leucovorin 400 mg/m^2, oxaliplatin 85 mg/m^2, bolus 5-fluorouracil 400 mg/m^2, and a 46 hour infusion of 5-fluorouracil 2, 400 mg/m^2.
45662919|NCT02413489|Drug|Daratumumab|Daratumumab 16 mg/kg will be administered as intravenous infusion to participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
45662920|NCT02413333|Device|Clear Care Plus contact lens solution|3% hydrogen peroxide solution with Hydraglyde Moisture Matrix for cleaning, disinfection and overnight storage of contact lenses
45662921|NCT02413333|Device|PeroxiClear contact lens solution|3% hydrogen peroxide solution for cleaning, disinfection and overnight storage of contact lenses
45662922|NCT02413333|Device|Silicone hydrogel contact lenses|2-week/monthly replacement contact lenses per participant's habitual brand
45662923|NCT02413255|Drug|TAK-020|TAK-020 oral solution
45662924|NCT02413255|Drug|TAK-020 Placebo|TAK-020 placebo-matching oral solution
45817191|NCT03099850|Other|Data Management and Monitoring|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer Center responsible for monitoring protocol and regulatory compliance for consortium. CDMC responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study.
46078920|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
46078921|NCT00928681|Biological|Single dose-group A|PF-00547659, single iv dose
46078922|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
45662925|NCT02444533|Drug|Liposomal Bupivacaine|Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.
45662926|NCT05458219|Drug|IBI343|IBI343 will be administered intravenously (IV) on Day 1 of every 21-day cycle.
45662927|NCT01651039|Drug|Panobinostat|Each cycle is 28 days. Panobinostat will be given 20 mg: Days 1,3,5,15,17,19.
45662928|NCT01651039|Drug|Lenalidomide|Each cycle is 28 days. Lenalidomide will be given 25 mg: Days 1-21.
45662929|NCT01651039|Drug|Dexamethasone|Each cycle is 28 days. Dexamethasone will be given for patients 75 years old and younger a dose of 40 mg on Days 1, 8 and 15. Dexamethasone will be given for patients older than 75 years old, 20 mg on Days 1, 8 and 15.
45817192|NCT03062358|Biological|pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
45817193|NCT03062358|Drug|placebo|Normal saline solution administered as an IV infusion Q3W
45956887|NCT00531739|Other|Polylactic Acid Sheet|SurgiWrapTM film will be secured in two study areas: directly below the abdominal incision and on the posterior pelvic rim. The film will not be wrapped directly around an anastomosis.
45956888|NCT00145379|Drug|Tablet Metformin 500 mg|
45956889|NCT00145379|Drug|Placebo|
45458177|NCT01235065|Device|type of laryngoscope|Patients who require emergency rapid sequence intubation are randomized to intubation with either the direct laryngoscope or the video laryngoscope
45662930|NCT02349633|Drug|PF-06747775|
45458178|NCT03501784|Device|Nobio particles incorporated within Novidia Dental Bonding|Nobio particles incorporated within Novidia Dental Bonding and Flow
45956890|NCT00530374|Dietary Supplement|Oral Iron Supplement|Iron Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
45956891|NCT00530374|Dietary Supplement|Placebo|Placebo Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
45956892|NCT00168948|Drug|Sulfadoxin (12.5) Pyrimethamine (250 mg)|
45956893|NCT00530452|Drug|CG100649|Dual-acting COX-2 inhibitor & carbonic anhydrase inhibitor in gelatin capsules. Oral loading doses (2, 4, or 8 mg vs. placebo) followed by daily oral maintenance doses (0.3, 0.6, or 1.2 mg vs. placebo) for 20 days (total 21 days therapy).
45662931|NCT02349633|Drug|Palbociclib|
45662932|NCT02349633|Drug|Avelumab|
45662933|NCT05650125|Other|Biosampling|Biosampling of blood/tumour/adjacent normal tissue
45662934|NCT02275611|Drug|intranasal oxytocin spray|Administration of oxytocin in a nasal spray
45817194|NCT03062358|Other|best supportive care (BSC)|BSC will include pain management and management of other potential complications including ascites per local standards of care.
45817195|NCT03049462|Drug|Mirabegron|Women will take 100mg daily for 4 weeks. Men will take 200mg daily for 4 weeks. The medication is available in 50 mg tablets.
45817196|NCT03049462|Other|B Complex Plus Vitamin C Tablets|Males will be randomized to take placebo versus active drug (mirabegron). Those taking placebo will take 4 tablets each day to mirror to active group (taking 4 tablets of 50 mg each).
45956894|NCT00530452|Drug|Silicified microcrystalline cellulose + talc|Gelatin capsules containing cellulose/talc matched for weight and color to experimental medication. Placebo administered orally 1x/day.
45956895|NCT00530491|Procedure|Fast track lung surgery|fast track lung surgery: carbohydrate drink preoperatively, PCEA, early removal of chest tube conventional: no carbohydrate drink preoperatively, ICB+PCA, removal of chest tube depending upon chest x-ray
45956896|NCT00168987|Drug|oral nutritional supplement rich in eicosapentanoic acid|
46078923|NCT00928681|Biological|Single dose-group A|PF-00547659, single dose
45817197|NCT03043430|Drug|Ketamine 100 MG/ML|Administer ketamine via mucosal atomization device
45817198|NCT03043430|Drug|Midazolam 5 MG/ML|Administer midazolam via mucosal atomization device
46078924|NCT00928681|Biological|Single dose-group A|PF-00547659, single dose
45662935|NCT02275611|Drug|Intranasal Placebo Spray|Intranasal Placebo Spray
45662936|NCT05649891|Other|Emergency Manual|Collection of crisis checklists and fact sheets
45956897|NCT00530530|Drug|ASP8825|oral
45956898|NCT00530530|Drug|Placebo|oral
45956899|NCT00530413|Drug|Phenobarbital|Phenobarbital will be given based on weight range
45956900|NCT00530413|Other|Placebo|Placebo group
45956901|NCT00145457|Procedure|Blood sample|
46078925|NCT00928681|Biological|Single dose-group A|PF-00547659, single dose
45817199|NCT03035890|Radiation|Radiation|Radiation therapy will be administered in 3 or 5 fractions over 3-10 days, at a recommended dose of 8-15 Gy per fraction for 3 total fractions (total dose 24-45 Gy) or 6-10 Gy per fraction for 5 total fractions (total dose 30-50 Gy)
45956902|NCT00145457|Procedure|Radiography|
45956903|NCT00530569|Procedure|Blood Test|CBC and HER2 level at baseline, prior to each chemo and/or herceptin cycle, one month after chemo and/or herceptin completion, quarterly up to 12 months or a maximum of 20 blood draws.
45956904|NCT00174330|Drug|atorvastatin|
45956905|NCT00174330|Drug|amlodipine|
46078926|NCT00928681|Biological|Single dose-group A|PF-00547659, single dose
46078927|NCT00928681|Biological|Multiple dose-Group B|PF-00547659, multiple dose
46078928|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
46078929|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
46078930|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
45662937|NCT05649735|Device|Logusgyn ovules|"LOGUSGYN ovules is a CE certified Class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a vaginal ova dressing for topical use containing tindalised cultures, Guar fibre, Lactic acid and Calendula.~It is supplied in a container with 10 vaginal ova. For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13."
45662938|NCT05649735|Device|Logusgyn Lavander|"LOGUSGYN lavage is a CE certified class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a gynaecological lavage dressing containing Chlorhexidine 0.2% and tindalised ferments, lactic acid, bisabolol.~It is supplied in a container with 5 vaginal douches.~For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13."
45662939|NCT05649735|Other|Placebo|Sterile saline solution
45662940|NCT05649657|Other|Cyclic aerobic and resistance training|Two options for the participants to choose from. First, a home-based program. The participant will be requested to wear a heart rate recorder during home exercise. Second, a hospital-based program. The participants visit the rehabilitation center twice weekly to receive supervised exercise therapy. The exercise prescription comprises aerobic and resistance training. The intensity is set initially at ventilatory anaerobic threshold and gradually titrated up to respiratory compensatory point based on the breath-by-breath cardiopulmonary exercise testing. The duration is 25~35 minutes per session plus a 5-minute warm-up and 5-min cool-down. The frequency is 2~3 sessions per week and about 70 sessions in total.
45662941|NCT04892823|Procedure|Biospecimen Collection|Undergo collection of blood sample
45662942|NCT04892823|Other|Electronic Health Record Review|Review of medical records
45662943|NCT04892823|Other|Questionnaire Administration|Complete questionnaires
45662944|NCT02275065|Drug|Bictegravir|Bictegravir tablet(s) administered orally once daily
45662945|NCT02275065|Drug|Placebo|Placebo to match bictegravir administered orally once daily
45662946|NCT05649579|Drug|Dupilumab|Duplimab was administered according to the guidelines of the atopic dermatitis treatment regimen, which involved the first dose of 600 mg followed by 300 mg every two weeks. Because of comorbidities or the side effects of corticosteroid, some patients used dupilumab in the initial course of treatment, while others added dupilumab when the traditional drugs proved ineffective. The discontinuation was a joint decision between treating dermatologists and patients. Concomitant medicine was decided by clinicians, depending on the assessing of disease status and patients' choices, and reduced according to international guidelines.
45817200|NCT03035890|Drug|Immuno-Therapeutic Agent|"Immune checkpoint inhibitors that are FDA approved for use in patients with metastatic NSCLC will be acceptable for use concurrently with radiotherapy in this trial. The choice of agents will be at the treating medical oncologist's discretion, and include:~Nivolumab 240mg or 3 mg/kg once every 2 weeks (14 day cycle)~Pembrolizumab 200mg or 2 mg/kg once every 3 weeks (21 day cycle)~Atezolizumab 1200 mg once every 3 weeks (21 day cycle)~These agents should be continued per standard of care until either disease progression or unacceptable toxicity."
45817201|NCT03004261|Biological|donor derived cytomegalovirus specific T lymphocytes|donor derived cytomegalovirus specific T lymphocytes will be transfused to recipients of hematopoietic stem cell transplant when they are sero-positive for CMV-DNA.
45817202|NCT03004261|Drug|Foscarnet|Foscarnet may be used for the treatment of CMV infection before and after the CMV-CTL infusion.
45817203|NCT03004261|Drug|Ganciclovir|Ganciclovir may be used for the treatment of CMV infection before and after CMV-CTL infusion.
45817204|NCT02920996|Drug|Merestinib|Oral, predetermined dosage per protocol, once daily per 28 day treatment cycle
45817205|NCT02914067|Other|Neurocognitive testing|
45662947|NCT04875585|Drug|neoadjuvant therapy with Pembrolizumab/Lenvatinib|Neoadjuvant therapy for 6 weeks
45662948|NCT04875585|Procedure|Surgery|surgical resection of primary tumor and lymph-node-dissection.
45662949|NCT04875585|Drug|Adjuvant Treatment Phase|Adjuvant treatment with 15 cycles of Pembrolizumab
45662950|NCT02273973|Drug|Letrozole|Letrozole tablets will be administered orally at 2.5 mg QD for 16 weeks.
45817206|NCT02914067|Device|rsfcMRI|The imaging protocols will be a combined version of a standard of care (SOC) protocol with a research portion. The SOC portion of the pre-surgical scans includes a 3D T2-weighted (T2w) scans and 3D pre- and post-contrast T1-weighted (T1w) images, both at high resolution (1.0 mm3) for use in the intraoperative navigation system. This scan also includes a DTI portion for definition of fiber bundles of interest. The SOC portion of the post-surgical scans includes transverse FLAIR and post-contrast T1w images in all 3 planes. The research portion of the scan will be identical at all 3 time points and include 15 min of rsfcMRI during which the non-sedated subjects will be asked to stay still and awake while looking at a fixation cross
45817207|NCT02913482|Drug|Risdiplam|Risdiplam will be administered orally.
45458179|NCT03501784|Device|Filtek bond and flow composite|standard of care class V composite restoration performed with Filtek and 3M
45662951|NCT02273973|Other|Placebo|Placebo tablets matched to taselisib formulation will be administered orally daily on 5 days-on/2 days-off schedule for up to 16 weeks.
45662952|NCT02273973|Drug|Taselisib|Taselisib will be administered orally at 4 mg (two 2 mg tablets) daily.
45662953|NCT04860297|Biological|mRNA-1273|Sterile liquid for injection
45662954|NCT02273739|Drug|Enasidenib|Enasidenib tablets administered orally once a day in 28-day treatment cycles until disease progression or unacceptable toxicities.
45662955|NCT04859595|Other|Telephone follow-up|"Monthly follow-up by telephone from M1 to M6. The interview will unroll in 2 stages, a first stage of discussion during which the speech therapist will take news of the patient. The second, more formal phase will be the opportunity to collect the data necessary for the validation of the primary and secondary outcomes. To do this, the speech therapist will use the Functional Oral Intake Scale (FOIS) score, the DHI and an interview grid.~The interview will be conducted using an interview sheet previously written by the project team. The following elements will be discussed: the description of oral food intakes (TIMES), the perceived swallowing handicap (DHI), the instructions related to the diet and their daily application, ongoing rehabilitation follow-ups, notable events as well, then his emotional and psychological experience in relation to the disorder."
45662956|NCT05649189|Diagnostic Test|telomere length measure|length of telomere between two groups
45662957|NCT05649111|Drug|Difluprednate Eye Drops|post-operative cataract surgery medication regimen. but different dosages between the 2 groups.
45662958|NCT02273037|Device|Fetal heart rate Doppler|A wind-up, handheld fetal heart rate monitor Doppler developed by Power-free Education Technology Doppler (www.pet.org.za)
45662959|NCT02273037|Procedure|Partograph|Graphical documentation of labour progress, and maternal and fetal well-being.
45662960|NCT02465515|Biological|Albiglutide 30 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
45662961|NCT02465515|Biological|Albiglutide 50 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
45662962|NCT02465515|Biological|Albiglutide matching placebo|Once weekly subcutaneous injection. Matched to 30 mg and 50 mg albiglutide.
45662963|NCT05561361|Procedure|Super selective adrenal artery embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
45662964|NCT05561361|Drug|Spironolactone|Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
45817208|NCT02908061|Procedure|Surgery Radical Cystectomy|All surgeries will be performed in an open or laparoscopic fashion.
45662965|NCT02412631|Drug|lorcaserin|lorcaserin is an FDA-approved weight loss medication for overweight and obese patients
45662966|NCT02412631|Drug|Varenicline|Chantix is an FDA approved medication for smoking cessation
45662967|NCT02412631|Drug|Placebo|Placebo for lorcaserin
45662968|NCT02272803|Drug|Lenalidomide|
45662969|NCT02272803|Drug|Dexamethasone|
45662970|NCT02272803|Biological|Elotuzumab (BMS-901608)|
45662971|NCT05648955|Dietary Supplement|an enriched high protein and high energy oral nutrition supplement (ONS)|NA (see intervention name)
45662972|NCT02272725|Drug|Ibuprofen|Ibuprofen
45662973|NCT02272725|Drug|Placebo|Tasteless and inert visually identical (to ibuprofen) pills
45662974|NCT01650805|Drug|ponatinib|45 mg tablet, taken orally once daily
45662975|NCT01650805|Drug|imatinib (Gleevec/ Glivec)|400 mg tablet, taken orally once daily
45662976|NCT04922827|Drug|Infliximab|single intravenous administration of 5 milligrams/kilogram
45817209|NCT02908061|Procedure|Ultrapro mesh|Surgery Mesh Placement. All surgeries will be performed in an open or laparoscopic fashion.
45817210|NCT02883972|Other|Intervention letter|Behavioural-insight informed letter template
45817211|NCT02883972|Other|Control letter|Invitation letter used by local area last year (updated as required)
45817212|NCT02883972|Other|Reminder|Behavioural-insight informed SMS/email reminder message to return consent form
45662977|NCT04922827|Other|Standard of Care|Standard of Care
45662978|NCT02442349|Drug|AZD9291|Once daily tablet 80 mg
45662979|NCT02411539|Biological|VRC01|40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
45662980|NCT02411539|Biological|Placebo|Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
45662981|NCT02465437|Drug|JBT-101|JBT-101 5 mg q am, 20 mg q am, or 20 mg bid on Days 1-28. JBT-101 20 mg bid on Days 29-84.
45662982|NCT02465437|Drug|Placebo|Placebo q pm (with JBT-101 5 or 20 mg q AM) or placebo bid on Days 1-28. Placebo bid on Days 29-84.
45662983|NCT02465437|Drug|Part B Open-Label Extension|JBT-101 20mg bid on Days 1-364
45662984|NCT02442271|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
45662985|NCT02442271|Drug|ribavirin|Tablet
45817213|NCT02869633|Drug|Ibrutinib|Given by mouth
45662986|NCT02465203|Drug|Previous treatment in DEB025 study|Follow-up after DEB025 active study
45662987|NCT02463409|Drug|Theophylline|24 hour infusion of IV theophylline
45662988|NCT02528357|Drug|GSK3174998|Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to <=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W
45662989|NCT02528357|Drug|Pembrolizumab|Pembrolizumab as 100 mg/4 milliliter (mL) solution (dose: 200 mg) to be given as IV infusion for 30 min, Q3W
45817214|NCT02869633|Other|Laboratory Biomarker Analysis|Correlative studies
45662990|NCT04910503|Drug|Dexamethasone intravitreal implant|Implant every 4 months if necessary
45662991|NCT04910503|Drug|Fluocinolone Acetonide Intravitreal Implant|Implantation
45662992|NCT04910425|Drug|Fluorine F 18 DCFPyL|Given IV
45662993|NCT04910425|Drug|Gadobenate Dimeglumine|Given IV
45662994|NCT04910425|Drug|Gadobutrol|Given IV
45662995|NCT04910425|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
45662996|NCT04910425|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
45662997|NCT04910425|Procedure|Positron Emission Tomography|Undergo PET/MRI
45662998|NCT04910425|Procedure|Transrectal Ultrasonography Guided Biopsy|Undergo TRUS-guided biopsy
45662999|NCT02463331|Drug|Chloroquine diphosphate|One pill of chloroquine diphosphate per day until the end of the study
45663000|NCT02463331|Drug|prednisone|Prednisone 5-15 mg/day until the end of the study
45663001|NCT02463331|Drug|azathioprine|azathioprine 1-2mg/Kg/day until the end of the study
45663002|NCT02410837|Procedure|Electromagnetic Navigation Bronchoscopy|
45817215|NCT02856425|Drug|Nintedanib|Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details
45663003|NCT02314247|Drug|Selinexor|"20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-4 of each 4-week cycle (Protocol V.3.0).~20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-3 of each 4-week cycle (Protocol V.<3.0).~Number of Cycles: up to 12 but there is no maximal duration for treatment."
45663004|NCT02463097|Device|Insulin Pump|Closed Loop Algorithm
45817216|NCT02856425|Drug|Pembrolizumab|Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details
45817217|NCT02839642|Drug|Rivastigmine|
45817218|NCT02839642|Drug|Placebo|
45817219|NCT02811094|Other|polymerase chain reaction (PCR) technique of blood transcriptome analysis|this study (LUMIER2 study) is to test the hypothesis that a test score or prognostic transcriptomic allows to discriminate clinically quiescent or patients who will not present a push of Systemic Lupus Erythematosus
45817220|NCT02786277|Other|Alert|An alert informing the provider of the presence of acute kidney injury will be fired.
45817221|NCT02785952|Biological|Ipilimumab|Given IV
45663005|NCT05427149|Drug|25 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey)|It will be evaluated whether there is postpinal shivering in the cases.
45663006|NCT02441179|Other|Acute Intermittent Hypoxia|Patients will breath 9% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
45663007|NCT02441179|Other|Body weight-assisted treadmill training|Patient´s gait will be trained through a weight-assisted treadmill (BWSTT). All recruited patients will start BWSTT at a speed of 0.6 km/hr. The physical therapist will manually correct posture to assure an adequate gait, increasing the speed of treadmill progressively depending upon the patient progress and tolerance. This training will be done immediately after the protocol of AIH or Sham and it will last 45 minutes.
45663008|NCT02441179|Other|Sham Protocol|It consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.
45663009|NCT04257773|Behavioral|REACH Forgiveness Workbook Intervention|Participants will be asked to complete the REACH Forgiveness Workbook
45663010|NCT05406167|Device|Registry - Observational|Observation Registry for Medical Device
45663011|NCT02282969|Behavioral|Interviews|Interviews performed by study staff encompassing lung cancer screening and patient decision aids.
45663012|NCT02282969|Behavioral|Questionnaires|Questionnaires completed after viewing patient decision aid video. Questionnaires also completed regarding lung cancer screening knowledge at first visit, then again in one month.
45663013|NCT02462473|Drug|Aripiprazole|Participants will receive aripiprazole at a dose of 5 milligram (mg) or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
45663014|NCT02462473|Drug|Olanzapine|Participants will receive olanzapine at a dose of 5 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
45663015|NCT02462473|Drug|Paliperidone|Participants will receive paliperidone 3 mg or higher dose as oral formulation once daily or 39 mg or higher dose once every 4 weeks for 12 weeks as part of participant treatment.
45663016|NCT02462473|Drug|Quetiapine|Participants will receive quetiapine at a dose of 150 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
45663017|NCT02462473|Drug|Risperidone|Participants will receive risperidone 1 mg or higher dose, as oral formulation once daily or as injection of 12.5 mg or higher dose once every 2 weeks for 12 weeks as part of participant treatment.
45663018|NCT04465799|Behavioral|ENTREN|ENTREN intervention for children (cognitive-behavioral perspective + motivational interview)
45663019|NCT04465799|Behavioral|ENTREN-F|ENTREN intervention for children + family intervention.
45663020|NCT04465799|Behavioral|Control group|Behavioral modification of habits
45663021|NCT04462601|Other|Biomarker detection|Quantification of serum markers of intestinal permeability and bacterial and fungal translocation
45663022|NCT01462097|Behavioral|Aerobic exercise training|12 months of aerobic exercise
45817222|NCT02785952|Other|Laboratory Biomarker Analysis|Correlative studies
45817223|NCT02785952|Biological|Nivolumab|Given IV
45817224|NCT02785952|Other|Quality-of-Life Assessment|Ancillary studies
45817225|NCT02785952|Other|Questionnaire Administration|Ancillary studies
45817226|NCT02769117|Procedure|Ultrasound on fractured bone|A new ultrasound technique for children and adults who have sustained forearm or clavicle fractures
45817227|NCT02769117|Procedure|Ultrasound on contralateral intact bone|A new ultrasound technique for the intact bone as the control for children and adults who have sustained forearm or clavicle fractures
46078931|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
45956906|NCT00530686|Drug|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
45956907|NCT00531856|Drug|Inhaled carbon monoxide|0.7 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
45956908|NCT00531856|Drug|Inhaled carbon monoxide|2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
45663023|NCT01462097|Behavioral|Health Education|12 months of health education sessions
45663024|NCT02440789|Drug|Sirolimus|"Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.~Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks."
45663025|NCT02462083|Drug|IDP-118 Lotion|IDP-118 lotion will be applied as per the instructions provided by the investigational center staff.
45663026|NCT02538341|Biological|Herpes Zoster (HZ) Vaccine|
45663027|NCT02538341|Drug|Placebo|
45817228|NCT02763085|Device|Basic Filling Material|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Basic Filling Material). Procedures will be done using local anesthesia. The cavity is excavated and filled according to the guidelines for ordinary restorative techniques.
45817229|NCT02757573|Procedure|Hypercarbia|PaCO2 is elevated from 5 to 7.5 kPa by controlled ventilation.
45817230|NCT02748798|Drug|HP 3He|3He will be hyperpolarized using a custom-built polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of helium gas.
45956909|NCT00531856|Drug|Inhaled carbon monoxide|3.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
45817231|NCT02748798|Drug|HP 129Xe|129Xe will be hyperpolarized using a Xemed polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of xenon gas.
45817232|NCT02748798|Drug|PFP|Perfluoropropane (PFP) will be premixed and delivered to the participants with no further processing.
45663028|NCT05446181|Behavioral|Postoperative delirium|Postoperative delirium
45663029|NCT05446181|Procedure|Hip surgery|Orthopedic hip joint surgery under spinal anesthesia
45663030|NCT04257617|Drug|ZL-1201|Part 1 & 2: Escalating dose of ZL-1201, Part 3: three dose levels determined from Part 1 and Part 2.
45663031|NCT05404373|Other|Normobaric Hyperoxia (NBO)|NBO was inhaled as early as possible before revascularization, and inhaled for 1h/2h/4h according to different groups
45817233|NCT02748798|Drug|SF6|Sulfur hexafluoride (SF6) will be premixed and delivered to the participant with no further processing.
45817234|NCT02748798|Device|129Xe Small and Large Human Lung Coil|The investigational 129Xe small and large quadrature lung coils are sensitive to 129Xe resonant frequencies and therefore will be paired with the investigational drug 129Xe. The size of the coil used will depend on the participants' body size.
45956910|NCT00531856|Drug|Inhaled Carbon Monoxide|3.5 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
45956911|NCT00531856|Drug|Inhaled Carbon Monoxide|2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant.
46002847|NCT00549380|Device|Endologix, Inc. Endoluminal Technology|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
46078932|NCT00928681|Biological|Multiple dose-Group B|PF-00547659, multiple dose
45663032|NCT05404373|Other|Low flow oxygen|immediately given oxygen inhalation at a ventilation rate of 1L/ min using a oxygen storage mask and keep giving oxygen for 4 hours.
45663033|NCT02538107|Drug|Methoxy-polyethyleneglycol epoetin beta|
45663034|NCT02538029|Behavioral|Dual Task Group|Performing motor-motor or motor-cognitive tasks at the same time.
45663035|NCT02538029|Behavioral|Single Task Group|Performing motor or cognitive tasks alone.
45663036|NCT05402579|Genetic|Genomic analysis|Genetic samples will be collected using a DNA saliva collection kit (Oragene: OG-510) and will be sent for genome-wide genotyping to The Centre for Applied Genomics in The Hospital for Sick Children (SickKids)
45663037|NCT05402033|Behavioral|Survey / Interview Group|Patients with any cancer type who are informed that they may be eligible for participation in any phase therapeutic cancer clinical trial by their treating physician (typically a clinical oncologist) will be provided information about the Financial Reimbursement Program. Patients who enroll to therapeutic cancer clinical trial will be eligible for the reimbursement program and offered an opportunity to participate in this study.
45663038|NCT05445401|Behavioral|Pre-rehabilitation|Triple pre-rehabilitation interventions of exercise, nutrition and psychology
45663039|NCT05445401|Behavioral|Standard medical care|Traditional care
45956912|NCT04691479|Behavioral|Motivational Interview (MI) & Adherence Follow-Up|"MEntA: Educational & Training Program~Stratification: Identification of Personal Variables (Age, Level of study, Work status, preference of care attention, digital behaviour)~Adherence evaluation: Evaluation of Perceived Competence, Quality of Life, Mood, Activities, Social relations and Social Support~Identification of Care plan and Schedule next visits~Follow-up D30-D60-D90-D180 depending of the care plan, through the channel that belong for each care plan"
45663040|NCT05401331|Device|Treadmilll|Hemodynamic changes before and after treadmill use
45663041|NCT05401331|Other|mask|mask
45663042|NCT02272413|Drug|BI 695502|
45663043|NCT02272413|Drug|Avastin|
45817235|NCT02748798|Device|3He Human Lung Coil|The investigational 3He quadrature lung coil is sensitive to 3He resonant frequencies and therefore will be paired with the investigational drug 3He.
45817236|NCT02748798|Device|PFP and SF6 Human Lung Coil|The investigational PFP and SF6 quadrature lung coil is sensitive to inert fluorinated gas resonant frequencies and therefore will be paired with both PFP and SF6.
45817237|NCT02712086|Other|protein supplementation|Protein supplementation : Protein intake of 30 grams of protein in addition to the usual inputs (to the recommended amounts of 60 to 120 g per day), upon the resumption of oral intake until the fifth week after sleeve gastrectomy.
45817238|NCT02670447|Procedure|MRI|Magnetic Resonance Imagery will be performed on patients attempted by schizophrenia. The aim of this intervention is an early detection of the non-answering patients to the primary cares.
45817239|NCT02654236|Drug|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 4 weeks.
45817240|NCT02654236|Drug|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 4 weeks.
45817241|NCT02652195|Drug|Placebo|Placebo intranasal administration, 3 puffs per nostril, delivered prior to scanning session.
45817242|NCT02652195|Drug|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff, delivered prior to scanning session.
45817243|NCT02604563|Other|Cognitive Assessment|-Baseline and no more frequently than every 6 months until death
45817244|NCT02604563|Other|Activities of Daily Living Questionnaire|"10 items about daily functional status~Baseline and no more frequently than every 6 months until death"
45956913|NCT04691479|Behavioral|Adherence Follow-Up|The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.
45956914|NCT00174369|Drug|PD-0325901|15 mg BID
45956915|NCT00531895|Drug|duloxetine|duloxetine 60 mg/d
45956916|NCT00145535|Device|SOLX Titanium Sapphire Laser (TiSaLT)|Spot laser treatment, ~50 spots over 180°
45956917|NCT00145535|Device|Argon Laser Trabeculoplasty (ALT)|Spot laser treatment, ~50 spots over 180°
45956918|NCT02943148|Other|Davey score for striae gravidarum|
45956919|NCT02943109|Other|High Touch|"Participants receives an in person visit from an technology navigator who helps to explain the technology to the patient."
45956920|NCT02943109|Other|Low Touch|"Participants receives a visit from a patient navigator who helps to explain how to navigate the hospital system (active control)."
45956921|NCT02943109|Other|High Tech|Patient receives full-suite access to an inpatient patient portal with bi-directional communication enabled.
45663044|NCT02396381|Other|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks
45956922|NCT02943109|Other|Low Tech|Patient receives a limited access version of the inpatient patient portal with bi-directional communication disabled.
45956923|NCT02942914|Drug|LY3209590|Administered SC
45663045|NCT02396381|Other|CC|Ad libitum use of CC in an ambulatory setting for 26 weeks
45663046|NCT05426291|Other|BIOMARKER LEVELS IS IT POSSIBLE TO PREDICT ACUTE RENAL DAMAGE IN THE PREOP PERIOD?|In open heart surgery, it will be followed whether acute kidney injury will develop by looking at the biomarkers in the preoperative period.
45663047|NCT05425667|Other|virtual reality walking training|The sensory integration training of this project will combine virtual reality technology and balance interference treadmill, and manipulate vision, vestibular sense and proprioceptive systems as the main training goals. It is expected to train twice a week for 1 hour, for a total of 6 weeks of training , in order to improve the balance and walking ability of patients with lumbar stenosis and neurological claudication, and to promote the ability of subjects to transfer the effect to daily life after training.
45663048|NCT05648877|Device|Ureteroscope|Role Of Retrograde Intrarenal Surgery In Management Of Renal Stones: Single Center Experience
45663049|NCT05424809|Behavioral|Shared decision-making model|"The model is based on a person-centred care process, where an exchange of information is carried out between the health professional and the patient to make the best decision that is consistent with the person's values and preferences.~A six-stage process constitutes the model: 1) Identificacion of the decision point, 2) design of a specific patient decision aid, 3) identification of possible barriers and ways to overcome them, 4) training for professionals, 5) 3-steps implementation of shared decision-making in clinical practice, 6) evaluation"
45663050|NCT05648799|Drug|GP30341 capsules 200 mg|orall take of capsules twice a day
45663051|NCT05648799|Drug|Standard therapy|Standard medicines for treatment of a new coronavirus infection 2019 (COVID-19).
45663052|NCT05400863|Behavioral|avoid sugary and NNS drinks plus start Metformin|Subjects will receive education and counseling to avoid all sweetened drinks (drink water only). Participants will be asked to consume minimum of 3 drinks/day
45663053|NCT05400863|Behavioral|avoid sugary drinks (allowed water and drinks sweetened with NNS) plus start Metformin|Subjects will avoid drinks sweetened with sugar (can have diet drinks sweetened with NNS). Participants will be asked to consume minimum of 3 drinks/day
45663054|NCT02120807|Drug|Certolizumab|
45663055|NCT02120807|Drug|cisplatin|
45663056|NCT02120807|Drug|pemetrexed|
45663057|NCT04457531|Drug|LiuWeiLuoBi Granule|LiuWeiLuoBi Granule is a Chinese medicine made from 6 herbal medicine, including Shaji(Sea-buckthorn), Honghua (Safflower), Jinyinhua(Honeysuckle),etc.
45663058|NCT04457531|Other|Standard medical treatment|Standard medical therapy is adhered to the guidline issued by American Diabetes Association and Chinese Diabetes Society at 2017, including keeping an appropriate diet, doing some exercises, the pharmacological therapy to control the blood glucose, blood pressure and blood lipids.
45817245|NCT02604563|Other|Instrumental Activities of Daily Living, subscale of the OARS|"7 items about daily functional status~Baseline and no more frequently than every 6 months until death"
45817246|NCT02604563|Other|Karnofsky Self-reported Performance Rating Scale|"1 item about daily functional status~Baseline and no more frequently than every 6 months until death"
45663059|NCT05398601|Other|MOBILIZATION with MOVEMENT|"They would be receiving conventional treatment as follow:~TENS (Transcutaneous electrical nerve stimulation) applied asymmetrical, biphasic waveform, pulse duration at 100 ms, intensity 10 percent below the motor threshold - 10 mins Hot Pack - 10 mins ULTRASOUND - 10 mins~Additionally, the would receive MWM techniques for Knee~Medial glide~Medial+ Internal rotation glide~Lateral Glide+ Internal Rotation glide~Anterior glide~Posterior glide"
45817247|NCT02604563|Other|Number of Falls|"1 item about daily functional status~Baseline and no more frequently than every 6 months until death"
45817248|NCT02604563|Other|Physical Health Section, subscale of the OARS|"13 items about comorbidity~Baseline and no more frequently than every 6 months until death"
45817249|NCT02604563|Other|MOS Social Activity Survey|"4 items about social activity~Baseline and no more frequently than every 6 months until death"
45663060|NCT05398601|Other|Periosteal electrical dry needling|"They would be receiving conventional treatment as follow:~TENS (asymmetrical, biphasic waveform, pulse duration at 100 ms, intensity 10 percent below the motor threshold) - 10 mins HOT PACK - 10 mins ULTRASOUND - 10 mins~Additionally, the would receive periosteal electrical dry needling 4 point technique for Knee~Four sterile, single-use 30-gauge dry needles would be inserted into the following locations of the symptomatic knee(s) until they touch bone:~Medial femoral condyle~Lateral femoral condyle~Flare of the tibia~Head of the fibula Needles would be stimulated with 100 Hz for 30 minutes. The intensity of the stimulus would be adjusted so that it would be clearly felt but would not cause discomfort. The stimulus intensity would be adjusted periodically so that it is perceptible for the entire 30 minutes of PST."
45663061|NCT02532647|Drug|Remimazolam|
45663062|NCT02532647|Drug|Midazolam|
45663063|NCT02532647|Drug|Placebo|
45663064|NCT05443061|Drug|Nitroglycerin|Subcutaneous nitroglycerin injection to decrease the incidence of radial arterial occlusion after arterial catheter removal in pediatric patients.
45663065|NCT05443061|Drug|Normal saline|Subcutaneous normal saline injection to decrease the incidence of radial arterial occlusion after arterial catheter removal in pediatric patients.
45663066|NCT02537015|Drug|Bimatoprost|Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.
45663067|NCT05397119|Biological|BW-1014: 25 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 25 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
45663068|NCT05397119|Biological|BW-1014: 50 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 50 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
45663069|NCT05397119|Biological|BW-1014: 100 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 100 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
45817250|NCT02604563|Other|Unintentional Weight Loss|"2 items about nutrition~Baseline and no more frequently than every 6 months until death"
45817251|NCT02604563|Genetic|Peripheral Blood Draw|-Baseline and no more frequently than every 6 months until death
45817252|NCT02604563|Genetic|Buccal Swab|"Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)~Baseline and no more frequently than every 6 months until death"
45817253|NCT02604563|Other|Heart Health and Smoking History from BRFSS questionnaire|"7 items about heart health and smoking history~Baseline and no more frequently than every 6 months until death"
45817254|NCT02604563|Other|Gait Speed|"Research coordinator will test gait speed~Baseline and no more frequently than every 6 months until death"
45817255|NCT02604563|Other|Grip Strength|"Research coordinator will test grip strength~Baseline and no more frequently than every 6 months until death"
45817256|NCT02604563|Other|Height and Weight measurements|-Baseline and no more frequently than every 6 months until death
45956924|NCT02942914|Drug|Placebo|Administered SC
45956925|NCT02942914|Drug|Insulin Glargine|Administered SC
45956926|NCT00169026|Drug|Clozapine versus typical (conventional) and atypical antipsychotic medications|
45663070|NCT05397119|Biological|rH5 (100 µg) control - pipette - IN|100 µg recombinant H5 antigen (without adjuvant) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
45663071|NCT05397119|Biological|Saline (Placebo) - pipette - IN|Saline (negative control) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
45663072|NCT05397119|Biological|H5N1 IIV - IM|90 µg H5N1 IIV administered intramuscularly (1 mL) One booster dose administered 6 months following last immunization
45663073|NCT02271945|Drug|MEDI-551 12 mg/kg|Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13
45663074|NCT02271945|Drug|MEDI0680 2.5 mg/kg|Participants will receive IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
45663075|NCT02271945|Drug|MEDI0680 10 mg/kg|Participants will receive IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
45663076|NCT05422781|Drug|ITI-3000|ITI-3000 is a DNA vaccine (L-H LT S220A) which contains sequences for both LAMP1 and LTS220A, the truncated form of the LT antigen of MCPyV with a detoxifying serine to alanine mutation at position 220
45817257|NCT02604563|Other|Blood pressure measurement|-Baseline and no more frequently than every 6 months until death
45454857|NCT05128396|Behavioral|Cognitive Stimulation|During the initial session, a member of the research team will visit the subject's home and introduce the subject to the Cogmed training program (www.cogmed.com). Individuals will start at the same low difficulty level. As training proceeds, task difficulty will be individually adjusted based on performance by increasing/decreasing the number of items individuals have to remember, such that a participant reaches approximately 60% correct per day for each task. Each training session will start at the task difficulty level where the participant ended in the previous session. Performance and reaction time data will be continuously recorded while subjects are doing the task, and these data will be sent via the internet to the research team after each session. A member of the research team will communicate with each subject on a weekly basis (via phone call or email) to provide feedback and address any questions or concerns.
45817258|NCT02604563|Procedure|Optional bone marrow biopsy|-1 optional bone marrow biopsy
45817259|NCT02604563|Procedure|Blood draw for trauma measurements|-For Arm E only
45817260|NCT02597491|Behavioral|TLC monthly|Tobacco longitudinal care monthly
45817261|NCT02597491|Behavioral|TLC quarterly|Tobacco longitudinal care quarterly
45956927|NCT00145613|Procedure|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
45663077|NCT05648721|Other|Datos mobile health application|The mobile Health application will send women reminders to perform glucose tests and test results will be sent to the clinic personnel for evaluation. The clinic personnel will receive an alert if a woman does not send glucose charts or when there is an abnormality in the test results. In addition, women will be able to communicate with the clinic's personnel via chat, messages, phone calls, and video.
45663078|NCT05648721|Other|Regular follow-up|Regular follow-up according to the local clinic protocol
45663079|NCT05397041|Drug|BMB-101|Participants will receive one of several different oral doses of BMB-101 once or twice daily
45663080|NCT05397041|Drug|Placebo|Matched Placebo
45663081|NCT04875351|Diagnostic Test|Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test|The BCI test provides a quantitative estimate of the risk for both late (post-5 years from diagnosis) distant recurrence and of the cumulative distant recurrence risk over 10 years (0-10y) in patients treated with adjuvant endocrine therapy (LN- patients) or adjuvant chemoendocrine therapy (LN+ patients), and prediction of the likelihood of benefit from extended (>5 year) endocrine therapy.
45663082|NCT05396495|Device|NeurolyserXR|Using the NeurolyserXR to non-invasively ablate the posterior sacral branches enervating the sacroiliac joint
45817262|NCT02597491|Behavioral|MTM|Medication management therapy
45817263|NCT02597491|Behavioral|4 week assessment|4 week assessment
45817264|NCT02597491|Behavioral|8 week assessment|8 week assessment
45817265|NCT02596191|Other|Clinical evaluation|
45817266|NCT02596191|Other|electrophysiological record|
45817267|NCT02596191|Other|Muscle MRI|
45817268|NCT02596191|Other|blood samples analysis|
45817269|NCT02584270|Device|Palatal Augmentation Prosthesis (PAP)|The palatal augmentation prosthesis improves speech and swallowing function through reshaping the palatal contours in order to obtain contact of the tongue to the hard palate during function. It is intended to be fabricated after adequate healing in patients with adequate motivation for improvements in their speech and swallowing. Regular wear and associated articulation therapy are necessary for this therapy to be effective.
45817270|NCT02584270|Other|Articulation Therapy|Subjects will receive the standard of care speech and articulation therapy regardless of which arm they are matched.
45817271|NCT02567409|Drug|Berzosertib|Given IV
45817272|NCT02567409|Drug|Cisplatin|Given IV
45817273|NCT02567409|Drug|Gemcitabine Hydrochloride|Given IV
45817274|NCT02565537|Procedure|LASIK|WFG vs. WFO LASIK
45663083|NCT04859205|Behavioral|Intervention|"Participants will have access to the SUPPORT-Pro self-guided online training platform addressing many aspects of type 1 diabetes care. The SUPPORT-Pro content was developped by a team of health professionals specialized in type 1 diabetes as well as patient partners. It's content is regularly updated, evidence-based and divided into 6 categories (medication, blood glucose monitoring, diet, physical activity, hypo and hyperglycemia, health and other particularities). In each category, users can pick between 3 levels (beginner, intermediate and advanced) according to their level of confidence and knowledge.~Participants will be asked to fill out questionnaires at baseline, 3-month, and 12-month of the intervention which include the following: Eligibility assessment, identification, background, confidence, platform satisfaction."
45663084|NCT05555199|Radiation|99mTc-nanocolloid|Injection of 99mTc-nanocolloid when lung cancer is diagnosed during a navigation bronchoscopy, followed by one or two SPECT/CT-scans.
45663085|NCT05555199|Drug|ICG|If patient undergoes surgery to treat the lung cancer, ICG will be injected and retrieved fluorescent lymph nodes will undergo additional pathological assessment.
45663086|NCT01660763|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
45663087|NCT01660763|Drug|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
45663088|NCT04875273|Device|Magnetic Tape® aplicación|Magnetic tape® is applied without creating any tension on the paravertebral skin of the lumbar spine
45663089|NCT04875273|Device|Kinesiology Tape application|Kinesiology tape is applied without creating any tension on the paravertebral skin of the lumbar spine
45817275|NCT02443727|Drug|Syntocinon (synthetic oxytocin)|Dosage and details described in arm.
45817276|NCT02443727|Other|Placebo|Dosage and details described in arm.
45956928|NCT00145613|Device|Miltenyi Biotec CliniMACS|stem cell selection device
45663090|NCT04859049|Procedure|infromedial single injection|"Group 1: We used a 25G/ 1 length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 IU hyaluronic acid, 0.5ml below the inferior punctum in the lower lid medial margin."
45663091|NCT04859049|Procedure|medial canthus injection|": We used a 25G/ 1 length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 IU hyaluronic acid classical medial canthal injection"
45817277|NCT02429700|Drug|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
45817278|NCT02429700|Drug|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
45663092|NCT05420831|Procedure|Vaginal|Sacrospinous hysteropexy using the synthetic mesh
45663093|NCT05420831|Procedure|Laparoscopic|Laparoscopic Sacrohysteropexy
45817279|NCT02429700|Drug|Bleomycin|Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
45956929|NCT00145613|Drug|Systemic chemotherapy and antibodies|Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan. Rituximab was administered within 24 hours of the transplant in an effort to prevent PTLPD. In addition to T-cell depletion of the haploidentical stem cell product, Mycophenolate mofetil was provided as prophylaxis for GVHD.
45956930|NCT02943187|Behavioral|Cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
45956931|NCT02943187|Dietary Supplement|Nutrition|Participants will be given dietary recommendations and nutritional supplements to optimize cognition.
45458180|NCT02310958|Procedure|Laparoscopic surgical hernia repair|Laparoscopic surgical hernia repair in children
45663094|NCT05420675|Other|Single Leg Squat|After initial data collection (Demographic data, Inclusion criteria), surface electromyography EMG assessments will be obtained from 1 muscle ( Vastus Medialis). EMG evaluation will be done in different arm positions during the single leg squat. These records will be taken in 4 different situations: 1) Arms free, 2) Arms flexed to 90 degrees, 3) Hands on hips, 4) Arms across the chest.
45663095|NCT01937117|Procedure|Positron emission tomography (PET)|PET will be performed at baseline and on day 15
45663096|NCT01937117|Drug|Trastuzumab|8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV
45663097|NCT01937117|Drug|Pertuzumab|840 mg as a loading dose, then 420 mg every 3 weeks, IV
45817280|NCT02429700|Drug|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
45663098|NCT04256213|Drug|Nivolumab and Ipilimumab|"Nivolumab, IV D1C1 and D15C1 (before RT-CT) at 3 mg/kg Every 28 days at 480 mg during 6 months after RT-CT~Ipilimumab, 1 mg/kg, IV D1C1 (before RT-CT)"
45817281|NCT02429700|Drug|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
45663099|NCT05393765|Behavioral|Yönetebilirim|"Yönetebilirim is an interactive web-based program developed to improve the self-management skills of individuals with MS by supporting self-regulation under the leadership of nurses."
45663100|NCT02268045|Biological|RTXM83|Rituximab biosimilar (RTXM83) will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
45663101|NCT02268045|Biological|Mabthera|Mabthera will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
45663102|NCT02536781|Drug|Anthocyanin|Anti-inflammation gel
45663103|NCT02536781|Drug|Placebo|Blank gel
45663104|NCT05440253|Device|dry needling|Dry needling of the trigger point of the gluteus medius in patients diagnosed with non-specific low back pain.
45663105|NCT05440253|Procedure|ischemic compression|Ischaemic trigger point compression of the gluteus medius in patients diagnosed with non-specific low back pain.
45663106|NCT01181375|Other|Tumour Biopsies and Blood Sampling|Patients who consent to the tissue part of this study will have Biopsies taken for study purposes at the same time as their routine tumour biopsies . In addition,those who consent to the blood sampling part of the study will have their samples taken assess serum biomarkers of tumour oxygenation.
45663107|NCT05544747|Other|Action Observation Therapy|"following phases will be included in action observation therapy group:~upper limb active range of motion (AROM) exercises.~reaching movement or object manipulation.~upper limb functional tasks."
45956932|NCT00531973|Drug|liposomal doxorubicin|5-fluorouracil (500 mg/m²) + pegylated liposomal doxorubicin (50 mg/m²) + cyclophosphamide (500 mg/m²) + adjuvant radiation therapy ± endocrinological therapy (FalipoC)
45663108|NCT05544747|Other|Mirror Therapy|"following phases will be included in mirror therapy group:~AROM exercises),~reaching movement or object manipulation, and~functional task practice"
45663109|NCT05393297|Diagnostic Test|Imaging: Intra-treatment FDG-PET-CT and MRI|FDG-PET-CT and MRI scan will be used during radiotherapy to assess early treatment response and identify tumours eligible for dose-escalation.
45663110|NCT05393297|Radiation|Intra-treatment Image-Guided Adaptive Radiotherapy Dose-escalation|Tumours eligible for dose-escalation (boost), as seen on intra-treatment FDG-PET-CT and MRI scan, will receive 76.9 Gy to the residual gross primary tumour. The radiotherapy plan will be replanned to incorporate the simultaneous-integrated-boost to the GTVp which will be delivered over the last 3 weeks of treatment
45663111|NCT05544357|Other|Short set configuration resistance training|Resistance training protocol with the lowest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
45663112|NCT05544357|Other|Long set configuration resistance training|Resistance training protocol with the highest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
45663113|NCT05439863|Device|transcatheter heart valve|patients with severe aortic valve disease underwent transcatheter heart valve
45663114|NCT04858503|Other|internet-based cardiac rehabilitation enhancement intervention|Participants in the intervention group will receive a 12-week i-CARE intervention, which will be designed to cover the core elements of CAD self-care: self-care maintenance, self-care monitoring and self-care management. The intervention will comprise: 1) a single individualized face-to-face session and 2) an internet-based intervention through a mobile application. Various behaviour change techniques will be used to increase the self-efficacy of CAD patients in enacting self-care behaviours.
45817282|NCT02429687|Drug|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
45817283|NCT02429687|Drug|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
45817284|NCT02429687|Drug|Bleomycin|Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
45817285|NCT02429687|Drug|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
45663115|NCT05392283|Device|AERO vacuum cupping device|The treatment consists of 5 sessions (approx. 30 min) of vacuum massage. The vacuum pump provided by the device provides a type of vacuum massage, that can be adjusted according to applied suction and air flow. The resulting massage technique provides a type of soft tissue manipulation similar to the ancient traditional medicine technique of cupping. Nonetheless, this automated technique allows for more precise determination of the massage characteristics.
45663116|NCT05647941|Diagnostic Test|Detection of levels of circulating EV-derived lncRNA-GC1|For patients with gastric cancer receiving neo-adjuvant chemotherapy, the dynamic changes of EV-derived lncRNA-GC1 was detected to identify whether is can serve as a monitoring biomarker for treatment response.
45663117|NCT05647785|Device|Long-term follow-up of cerena™|Long term follow-up for eligible participants from the RESTORE study
45663118|NCT05647785|Device|Long-term follow-up of attune™|Long term follow-up for eligible participants from the RESTORE study
45663119|NCT02267187|Procedure|Fat Grafting|Fat Grafting is a procedure that involves moving a person's own fat from an area of the body where it is less needed to another area of the body to improve its appearance. The fat is usually taken from the thighs or abdomen with a small liposuction tube and then moved to an area that has lost volume or fullness due to aging, trauma, surgery, birth defects, or other causes.
45663120|NCT02267187|Drug|General Anesthesia|A medicine that will relax and assist the subject in keeping unconscious (in a sleep like state) during the entire procedure.
45817286|NCT02429687|Drug|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
45817287|NCT02390518|Radiation|Stereotactic Radiosurgery|"Patients with 1 to 5 brain metastases will be treated. Patients will be assigned to one of four cohorts based on the size of their brain lesions. For each patient, a single lesion will be treated at experimental dose level, other metastases (if present) will receive standard SRS doses.~Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 Cohort 1a and 1a Expansion (starting at Dose Level 3) Diameter: ≤ 10 mm Volume: ≤ 0.5236 cm3 26 Gy 28 Gy 30 Gy n/a Cohort 1b Diameter: 11-20 mm Volume: 0.5237-4.1888 cm3 26 Gy 28 Gy 30 Gy n/a *Cohort 2 Diameter: 21-30 mm Volume: 4.1889-14.1372 cm3 20 Gy 22 Gy 24 Gy n/a~**Cohort 3 Diameter: 31-40 mm Volume: 14.1373-33.5103 cm3 17 Gy 19 Gy 21 Gy 23 Gy~Dose Escalation A non-standard 5+4 design will be used for the dose escalation. For each cohort, an initial group of 5 patients will be accrued at dose level 1 and receive experimental treatment to one of their lesions."
45817288|NCT02372136|Dietary Supplement|Individualized Nutrition|"Intake of macronutrients (protein, fat, and carbohydrate) will be individualized every day by adding one or more macronutrients to human milk based on daily measurements using near-infrared analysis.~In patients receiving less milk than 140 ml x kg-1 x day-1 fortification of human milk will be adjusted to reach at least the average concentrations of protein, fat, and carbohydrate in donor's milk (Wojcik. J Am Diet Assoc. 2009 Jan;109:137-40) and 20 cal/oz as provided by the Mother's Milk Bank of North Texas.~In those receiving at least 140 ml x kg-1 x day-1 of milk at 24 cal/oz fortification will be adjusted to meet recent guidelines from the the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition (ESPGHAN) (Agostoni et al. J Pediatr Gastroenterol Nutr. 2010 Jan;50:85-91)."
45956933|NCT00531973|Drug|epirubicin|5-fluorouracil (500 mg/m²) + epirubicin (90 mg/ m²) + cyclophosphamide (500 mg/ m²) + adjuvant radiation therapy ± endocrinological therapy (FEC90)
46078933|NCT00772941|Drug|Varenicline|"Champix Tablets 0.5mg or Champix Tablets 1mg, depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows.~The usual adult dosage for oral use is 0.5 mg of varenicline once daily after eating for days 1 to 3, 0.5 mg twice daily after eating in the morning and evening for days 4 to 7, and 1 mg twice daily after eating in the morning and evening on and after day 8. The drug should be administered to patients for 12 weeks."
46078934|NCT00607295|Drug|clino-san vaginal lubricant|Clino-san 2ml vaginal application 3 times per week for 12 weeks
46078935|NCT02813798|Drug|Rivipansel|A single 840mg dose of Rivipansel over 20 minutes
45956934|NCT00174408|Drug|Genotropin|
45663121|NCT02267187|Device|Coleman Cannulas|The plastic surgeon, will use small narrow tube-like instruments called cannulas, will remove fat from various places throughout the body (commonly the abdomen and thighs). The plastic surgeon will then use the Coleman cannulas (specialized smaller cannulas with varied shapes and tip sizes specifically made to deliver smaller amounts of fat) to fill the desired area.
45663122|NCT02267187|Other|Tefla non-adherent gauze pad|The processing of the fat graft material is done using a Tefla non-adherent gauze pad in a rolling technique that separates the aqueous and oil layers from the injected component.
45663123|NCT02532179|Biological|Mouse Allergenic Extract|Subjects will receive escalating doses of glycerinated mouse allergenic extract administered subcutaneously up to a maximum study dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol., per protocol.
45663124|NCT05417789|Drug|Emactuzumab|Emactuzumab administered once every 2 weeks (q2w)
45956935|NCT00145652|Drug|Neo-Recormon and Venofer|
45956936|NCT02942992|Behavioral|Resistance exercise|resistance exercise
45956937|NCT05319769|Procedure|Atrial fibrillation ablation|Pulmonary vein isolation
45956938|NCT02942836|Device|non-intrusive respiration monitor|Equivalence of CareTaker's respiration rate detection capability to that of predicate device
45956939|NCT00174486|Drug|UK0369,003|
46078936|NCT02735694|Drug|Cycloserine|Capsule containing 250 mg of Cycloserine
45956940|NCT00174486|Drug|Cialis (Tadalafil)|
45817289|NCT02372136|Dietary Supplement|Optimized nutrition|Milk fortification will be based on current recommendations and optimized by adjustment of nutrients once a week based on blood levels of urea nitrogen (corrected for serum creatinine level) and albumin and velocity of growth (weight and length).
45817290|NCT02268552|Drug|branaplam|
45817291|NCT02207777|Procedure|Roux-en-Y gastric bypass surgery|A surgical procedure to help subjects lose approximately 16-18% (with a range of 16-25%) of their body weight.
45956941|NCT05319418|Behavioral|Daily Blood Pressure Monitoring|Patients are provided standard off-the-shelf blood pressure monitors and take their BP vitals daily. Patients report their daily BP through phone or online. BP data is viewed online by physicians who use their independent medical judgement for any changes in medical management.
46078937|NCT02735694|Drug|Placebo|Sugar capsule manufactured to mimic Cycloserine 250 mg capsule
46078938|NCT00932503|Device|Vicryl plus|triclosan-coated polyglactin 910 suture materials with antiseptic activity (Vicryl plus®, Ethicon GmbH, Norderstedt, Germany)
46078939|NCT00607607|Drug|MKC-1|capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles
45454858|NCT05128396|Behavioral|Mindfulness training|"The mindfulness meditations will be narrated by one guide and the tasks will be narrated by a different guide. We will have 7 mindfulness tasks in total, whose order of presentation will be counterbalanced across sessions: 1. mindful observing of place, 2. mindful eating, 3. mindful observing of object, 4. mindful observing of person, 5. mindful walking, 6. mindful listening, and 7. mindful writing with the non-dominant and dominant hand.~At the end of each session, participants will write brief reflections stored via the website (e.g., an estimate of the amount of time subjects experienced their thoughts as wandering) both as an integral part of the mindfulness process and as a means of increasing the likelihood that subjects fully participate in each session. Each session will be structured as follows: Login, Mindfulness Meditation Session, Mindfulness Task 1, Mindfulness Task 2, Mindfulness Task 3, Write Log Reflection, Logout."
45458181|NCT01141153|Drug|Acetylsalicylic Acid + clopidogrel + acenocoumarol|"Acetylsalicylic Acid 100 mg daily + Clopidogrel 75 mg daily + Acenocoumarol dosage with INR monitoring~Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent"
45663125|NCT05417789|Drug|Placebo|Matching placebo administered once every 2 weeks (q2w)
45663126|NCT04422977|Diagnostic Test|Sars-Cov-2 serology|Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff
45663127|NCT05389787|Device|Transcranial Magnetic Stimulation|The TMS will be administrated using the MagVenture Mag Pro R30 device equipped with a B-70 coil. The FDA-approved iTBS sequence will be applied: 10 bursts of three biphasic pulses at 50 Hz, repeated at 5 Hz, for 10 seconds for a total of 600 pulses, and will be repeated for three times. The total stimulation time is ~10 min per session (day). Patients will receive five sessions (days) of rTMS each week, and the total treatment will last for four weeks.
46078940|NCT04362722|Drug|L19IL2 +L19TNF|Single or multiple intratumoral administration of a mixture of L19IL2 and L19TNF will be performed once weekly for up to 4 weeks into all injectable lesions present at the beginning of treatment or appearing during treatment phase The dose will be constituted by 6.5 Mio IU L19IL2 (~1.08 mg) and 200 µg L19TNF.
45817292|NCT02207777|Behavioral|Low-calorie diet|Subjects will meet with a dietitian and/or behaviorist over approximately 6 months to lose approximately 16-18% (with a range of 16-25%) of their body weight.
45817293|NCT02194829|Drug|AZD1775|Given PO
45817294|NCT02194829|Drug|Gemcitabine|Given IV
45817295|NCT02194829|Drug|Nab-paclitaxel|Given IV
45956942|NCT00145691|Drug|Oxcarbazepine|
45956943|NCT05319340|Other|prescribing anticoagulant therapy|Patients who need anticoagulants were consulted by a cardiologist with subsequent recommendations
45956944|NCT05319301|Dietary Supplement|Melatonin|A single dose of melatonin (1.9 mg)
45956945|NCT00169065|Drug|Clozapine|
45956946|NCT00169065|Drug|Olanzapine|
45956947|NCT00145730|Drug|Ibuprofen|
46078941|NCT05592444|Diagnostic Test|Low iodine Spectral Detector CT Pulmonary Angiography|Low iodine Spectral Detector CT Pulmonary Angiography
46078942|NCT00924859|Other|ELISA Test|assess the overall accuracy of D-dimer values and FXIII activation peptide (FXIII-AP), using a newly developed ELISA test
45454859|NCT05128396|Behavioral|Physical Activity|Aerobic exercises will include relatively low impact activities like walking, jogging, or running in place, which will aim to put limited demands on balance. Each exercise will be explained and demonstrated in the video. All exercises can be done standing, sitting, or next to a chair that provides balance support as demonstrated in the videos. After the first session, for each subsequent session the difficulty level will start at one level below the previous session's average difficulty level (e.g. if they exercise at the most difficult level for most of the time during one session, the next session will start at the medium difficulty level). Each exercise will be explained and demonstrated in the video.
45454860|NCT05128396|Behavioral|Control Group|Individuals in the control group will participate in the same computerized Cogmed training program as described above. The main difference is that for the control group task difficulty will remain at the same low starting level, rather than increasing over time. The instructions given to subjects will be identical to the ones used in the cognitive training intervention.
45454861|NCT01121887|Behavioral|Standard treatment|"Telephone-based smoking cessation counselling based on a combination of coaching and cognitive behavioural therapy (CBT) techniques. Counsellors are also trained in giving tailored advice regarding the use of smoking cessation aids.~Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge."
45663128|NCT05389241|Other|Method A|The subjects will perform tasks on the liver phantom (identification of target lesions). They will perform the tasks with Method A (2D-CT) or Method B (2D-CT + 3D augmented reality model). the intervention type Method A means that the trainings set up is performed first with Method A an after that with Method B.
45663129|NCT05389241|Other|Method B|The subjects will perform tasks on the liver phantom (identifikation of target lesions). They will perform the tasks with Method A (2D-CT) or Method B (2D-CT + 3D augmented reality model). the intervention type Method B means that the trainings set up is performed first with Method B an after that with Method A.
45663130|NCT05388929|Drug|Methocarbamol|Methocarbamol after surgery
45663131|NCT05388929|Drug|Standard Opioid|Standard opioid after surgery or at discharge
45663132|NCT05388929|Drug|Standard opioid plus methocarbamol|Standard opioid plus methocarbamol after surgery or at discharge
45663133|NCT05438615|Other|Corneal Refractive Therapy-spherical|A comparison of two different designs of Corneal Refractive Therapy contact lenses will be done. Each will be worn for two weeks. The sponsor will mask which lens will be first or second in the trial.
45663134|NCT05438615|Other|Corneal Refractive Therapy-aspherical|A comparison of two different designs of Corneal Refractive Therapy contact lenses will be done. Each will be worn for two weeks. The sponsor will mask which lens will be first or second in the trial.
45663135|NCT04422665|Other|Resistance exercise|Single-legged resistance exercise
45817296|NCT02168400|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
45663136|NCT05388539|Procedure|Theta Burst Stimulation|3 TBS sessions per day, with an offer of 1200 pulses per session and a 30-minute interval between sessions. This protocol will be applied to patients for 15 days, totaling 45 stimulation sessions. The stimulations will be directed to the left dorsolateral prefrontal cortex (F3 obtained by the Beam method) and will be performed in a Magventure MagPro R30 device.The stimulation will be delivered at 100% of the motor threshold and will last for 6 minutes.
45817297|NCT02161380|Drug|injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),|injection of Total Volume of each intravitreal injection is 200 µL
45817298|NCT02161380|Drug|injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)|injection of Total Volume of each intravitreal injection is 200 µL
45817299|NCT02161380|Drug|injection of scAAV2-P1ND4v2 2.4 X10e10vg (High)|injection of Total Volume of each intravitreal injection is 100 µL
45817300|NCT02161380|Drug|injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)|injection of Total Volume of each intravitreal injection is 100 µL
45817301|NCT02091245|Drug|KPT-330|
45817302|NCT02087046|Device|ANS Totally Implantable Deep Brain Stimulation System|ANS Totally Implantable Deep Brain Stimulation System will be implanted in the VIM nucleus of the thalamus
45817303|NCT01891994|Drug|Eltrombopag|Oral administration of eltrombopag 150mg/day (75 mg/day for East Asian ancestry) for 6 months
45817304|NCT01751490|Other|physiotherapy|physiotherapy
45817305|NCT01751490|Procedure|shoulder stabilisation surgery|arthroscopic stabilisation surgery
45817306|NCT01740557|Biological|Aldesleukin|Given IV
45817307|NCT01740557|Biological|CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
45817308|NCT01740557|Drug|Cyclophosphamide|Given IV
45817309|NCT01740557|Drug|Fludarabine Phosphate|Given IV
45817310|NCT01740557|Other|Laboratory Biomarker Analysis|Correlative studies
45663137|NCT05388539|Procedure|Sham Stimulation|The placebo will consist of a sham stimulation activity. A noise generator, which makes the same noise as active stimulation, and a surface electrode placed over the patient's eyebrow, mimicking the tactile sensory effects of TBS. It will also occur three times a day, with a duration of 6 minutes. The interval time between procedures will be of 30 minutes. It will take place for the same 15 weekdays, totalizing 45 sham stimulations.
45454862|NCT01121887|Behavioral|Motivational Interviewing|"Telephone-based smoking cessation counselling with Motivational Interviewing added to the standard treatment protocol.~Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge."
45454863|NCT05110144|Drug|Duloxetine 30 MG|30mg orally for 4 weeks
45663138|NCT05416853|Procedure|Carotid Artery Stenting (CAS)|CAS involves insertion of a catheter or tube into an artery in the groin or the radial, and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open.
45663139|NCT05416775|Drug|SHR-8068；Adebrelimab|SHR-8068: Sterile Injection, 50mg/10mL, Intravenous Infusion Adebrelimab: injection, 600mg/12mL, intravenous infusion
45663140|NCT05416775|Drug|SHR-8068；adebrelimab and platinum-based chemotherapy|SHR-8068: Intravenous Infusion Adebrelimab: injection, intravenous infusion Pemetrexed disodium for injection: , intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip
45817311|NCT01740557|Biological|NGFR-transduced Autologous T Lymphocytes|Given IV
45817312|NCT01740557|Other|Quality-of-Life Assessment|Ancillary studies
45817313|NCT01390038|Device|Simpliciti™ Shoulder System|Total shoulder arthroplasty system
45454864|NCT05110144|Drug|Duloxetine 60 MG|60mg orally for 4 weeks
45454865|NCT05110144|Drug|Amitriptyline 25 MG|25 mg orally for 4 weeks
45454866|NCT05110144|Drug|Amitriptyline 50 MG|50 mg orally for 4 weeks
45454867|NCT05110144|Drug|Placebo 30 MG|30mg tablet with no active study ingredient for 4 weeks
45454868|NCT05110144|Drug|Placebo 60 MG|60mg tablet with no active study ingredient for 4 weeks
45454869|NCT01121965|Procedure|Pars plana vitrectomy with ILM peeling|Pars plana vitrectomy with ILM peeling
45663141|NCT05416775|Drug|Adebrelimab；platinum-based chemotherapy|Adebrelimab: intravenous infusion Pemetrexed disodium for injection: intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip
45817314|NCT01370460|Drug|Tranexamic Acid|Topical tranexamic acid (2g/100mL 0.9% saline)
45817315|NCT01370460|Drug|Placebo|100mL 0.9% sterile saline
45817316|NCT01203020|Drug|Busulfan|Busulfex 130 mg/m2 intravenous piggy back (IVPB) for 4 days (Day -6 to -3) pharmacokinetic (PK) samples for Busulfex dose adjustment drawn on Day -6
45817317|NCT01203020|Drug|Fludarabine|Fludarabine 40 mg/m2 IVPB for 4 days (Day -6 to -3)
45817318|NCT01008241|Behavioral|Paper questionnaire|Participants will complete a paper and pencil questionnaire that measures 4 domains of interest (advanced care planning; end of life care; hospice care and death and dying) as well as demographic factors (age, marital status, education etc.)
45454870|NCT04440904|Device|CT workstation (Syngo Via VB10B, Siemens, Germany)|Multiplanar reconstruction, curvature plane reconstruction, and volume rendering were used for three-dimensional reconstruction to measure the diameters and lengths of blood vessels and the distances on the body surface
45454871|NCT01212367|Biological|SCH 721015|1.0 x 10e12 viral particles on Days 1 and 4
45663142|NCT05438225|Behavioral|Automated text message reminder|Participants in the intervention group will receive monthly automated reminder text instructing them to discuss hearing issues with their PCPs, and to request a referral to audiology or otolaryngology if they have hearing loss.
45663143|NCT05388227|Other|Pole Walking|Group training sessions will be offered at the participating independent living/retirement communities. Training sessions will be held either indoors or outdoors, 2-3 times a week, for 20-60 min/session, over 12 weeks.
45663144|NCT05416229|Drug|Psilocybin|Psilocybin-assisted therapy
45663145|NCT05416229|Drug|Lactose|Placebo-assisted therapy
45663146|NCT01638533|Other|Pharmacological Study|Correlative studies
45454872|NCT01212367|Biological|SCH 721015|3.0 x 10e11 viral particles on Days 1 and 4
45663147|NCT01638533|Drug|Romidepsin|Given IV
45663148|NCT02409667|Biological|Secukinumab|Secukinumab for s.c. injection was supplied in single boxes each containing 2 pre-filled syringes (PFS) of 150 mg secukinumab in a 1 mL liquid formulation. Each 300 mg dose was administered as 2 PFS injections of 150 mg secukinumab.
45663149|NCT01641939|Drug|Taxane|Standard taxane (docetaxel 75 mg/m^2 IV every 3 weeks or paclitaxel 80 mg/m^2) IV once a week according to investigator choice.
45663150|NCT01641939|Drug|trastuzumab emtansine|trastuzumab emtansine 3.6 mg/kg IV every 3 weeks
45454873|NCT01216111|Drug|Paclitaxel Cisplatin|"Paclitaxel 80 mg/m2 D1，8，15 Cisplatin AUC=2 D1，8，15~1 cycle = 28days~PC*6"
45817319|NCT00965302|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy, also known as vertical sleeve gastrectomy, sleeve gastroplasty, or sleeve gastrectomy, will be performed over a 32 to 40 French sizing bougie.
45454874|NCT01216111|Drug|fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)|fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 intravenously on day 1 every 21 days for three cycles followed by docetaxel 100 mg/m2 intravenously
45454875|NCT05072470|Device|Roger microphone|Commercially available transmitter microphone which sends distant speech signals to a receiver that is attached/embedded into hearing aids.
45663151|NCT01641939|Drug|trastuzumab emtansine|trastuzumab emtansine 2.4 mg/kg IV once a week
45663152|NCT04934839|Diagnostic Test|Test of standing balance (Equitest System). Test of walking in tied and split conditions on a force-sensorized split-belt treadmill.|"Tests of standing balance will be performed using the EquiTest System posturographic platform. Individuals will be requested to perform three tasks within the EquiTest battery: Sensory Organization test, Motor Control test backward/forward, Adaptation Test upward/downward.~Gait analysis will be performed on a force sensorized split-belt treadmill. Participants will walk at increasing velocities from 0.2 m/s to the highest sustainable velocity in tied-belt condition. Velocity will be increased by 0.1 m/s every 20 consecutive strides.~During gait analysis in the split-belt condition, participants will walk for 30 seconds with both belts at 0.4 m/s. Then, the velocity of the belt under the prosthetic limb will be increased to 1.2 m/s. After 6 minutes, the velocity of the faster belt will be restored at 0.4 m/s for 6 more minutes. Different combinations of velocities could be tested based on the patients' characteristics, maintaining a ratio of 3:1 between the velocities of the 2 belts."
45663153|NCT01641861|Device|Papacarie®|Papacarie® is chemo-mechanical method for caries removal
45663154|NCT01641861|Procedure|Conventional method|caries removal by using rotary instrument.
45663155|NCT05515887|Drug|Shenqu Xiaoshi Oral liquid|The dosage was determined by age: 3-4 years old, 5 ml/dose; 5-14 years old 10 ml/dose. Taken half an hour after meals, three times a day.
45663156|NCT05511285|Behavioral|Digital Cognitive Behavioural Therapy for Insomnia|6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online, in addition to usual care.
46078943|NCT04237454|Device|Thermal Imaging Camera|To develop a non-ionising radiation-based method of excluding fractures in children with suspected physical abuse
45663157|NCT02409355|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 milligrams (mg) by IV infusion on Day 1 of each 21-day cycle until loss of clinical benefit.
45454876|NCT05072470|Device|Phonak Audeo hearing aid|Commercially available receiver-in-canal hearing aid
45454877|NCT01122043|Device|Endoglide|Device
45458182|NCT01141153|Drug|Acetylsalicylic Acid + clopidogrel|"Salicylic Acid, 300 mg daily + Clopidogrel 75 mg daily~Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent."
45663158|NCT02409355|Drug|Carboplatin|Carboplatin will be administered at area under the concentration-time curve (AUC) 5 IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
45663159|NCT02409355|Drug|Cisplatin|Cisplatin will be administered at 75 milligrams per square meter (mg/m^2) IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
45663160|NCT02409355|Drug|Gemcitabine|Gemcitabine will be administered at 1000 mg/m^2 (when coadministered with carboplatin) or 1250 mg/m^2 (when coadministered with cisplatin) IV infusion on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles.
45663161|NCT04874259|Procedure|Living donor liver transplantation|Living donor liver transplantation
45663162|NCT05647707|Dietary Supplement|L-Carnitine|The 36 patients will receive conventional supportive care in addition to IV L-carnitine with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose of 50 mg/kg IV every 8 h.
45663163|NCT02408887|Procedure|Total Thyroidectomy (TT)|Total removal of thyroid
45663164|NCT02408887|Procedure|Prophylactic central neck lymph node dissection (pCND)|Lymph node dissection
45663165|NCT02266875|Drug|hypertonic saline|
45663166|NCT02266875|Drug|standard saline|
45663167|NCT05495841|Device|Pre-oxygenation|Process of administrating oxygen prior to intubation
45663168|NCT04135443|Behavioral|3T Tune in! Turn on! Turn up!|A sex positive multimedia interactive mobile app delivered HIV/STI intervention developed for use by YBMSM ages 14-17. The program employs a theory based approach to address essential knowledge, perceptions of risk, peer norms, attitudes and skill with two primary goals: (1) To reduce HIV/STI the program emphasizes partner reduction, avoidance of concurrent partners, condoms and HIV/STI tests; and (2) To improve sexual health and relationships.
45663169|NCT04135443|Behavioral|General Health App|The control group will download a mobile app that addresses general health behaviors, specifically drinking more water.
45663170|NCT05647395|Behavioral|Tracheal tube cuffs differ in deflation|When removing the endotracheal tube, the gas in the cuff is drawn at a uniform and slow pace
45663171|NCT02438371|Drug|Nifedipine|
45663172|NCT02438371|Drug|Indomethacin|
45663173|NCT05647317|Other|A combination of a provider-facing desktop and mobile application with a patient-facing mobile application|A combination of a provider-facing desktop and mobile application with a patient-facing mobile application that is integrated with a remote blood pressure cuff, heart rate monitor, and scale.
45454878|NCT04440748|Device|T-Chair 2.0 Prototype|Participants in the experimental group will perform additional therapy with the T-Chair 2.0. Participants can train in two modes. Participants will either train in the active modus, whereby the participant has to move the seat in a certain direction, or in the passive modus, whereby the participant has to stay in a stable position while the seat is moving underneath the participant. The seat is able to move in mediolateral, anteroposterior, and diagonal and combined directions such as circles or eight-figures. The modus, the type of movement, the range of motion and speed of movement are chosen by the therapist according to the patients' abilities.Training will be coupled with a computer based exercise. During the session preparation time, and time for the questionnaires is needed, thus we expect the actual training time to be on average 30 minutes per training.
45458183|NCT02316730|Drug|Sanchi-Tongshu Capsule (Enteric coated pellets)|Take 0.7g (2 Capsules) of test preparation orally.
45458184|NCT02316730|Drug|Sanchi-Tongshu Capsule|Take 0.4g (2 Capsules) of reference preparation orally.
45458185|NCT01234441|Dietary Supplement|Control|A placebo non-nutritive beverage will be administered before dialysis sessions 3 times per week.
45458186|NCT01234441|Dietary Supplement|Protein|A whey protein beverage will be administered before dialysis sessions 3 times per week.
45663174|NCT04419987|Genetic|draw blood|search for new genetic variations (when the diagnostic exploration will have been non informative) by sequencing exons.
45663175|NCT05647239|Device|Shotblocker|Shotblocker is a small plastic tool that can be used in all age groups in reducing pain due to injection, is non-medicinal, non-invasive, easy to use, and inexpensive and does not require material preparation
45663176|NCT02438137|Drug|Dimethyl fumarate|Dimethyl fumarate capsules will be dispensed during routine study appointments. 120 mg tablets will be dispensed to facilitate dose titrations. Drug will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the medication with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
45663177|NCT02438137|Drug|Placebo|Placebo capsules will be dispensed during routine study appointments. Placebo will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the placebo with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
45663178|NCT04920565|Device|hemoperfusion with polymyxin B|polymyxin B is covalently immobilized on polystyrene strands, selectively removes endotoxin and at the same time there is no leaching of the ligand, immobilization is carried out by electrostatic interaction and Vanderwals force
45663179|NCT04934683|Procedure|Routine blood pressure control|Routine blood pressure control.
45663180|NCT04934683|Procedure|Tight blood pressure control|Tight blood pressure control.
45663181|NCT04934683|Drug|Etomidate|Anesthetic induction with etomidate.
45663182|NCT04934683|Drug|Propofol|Anesthetic induction with propofol.
45817320|NCT00965302|Behavioral|Intensive medical management|Intensive medical therapy for Diabetes mellitus, Type 2, will include weight management counseling, exercise, glucose control, and healthy dietary choices.
45817321|NCT00621192|Drug|meropenem|"Meropenem was administered concomitantly with compatible medications. Because an in-line filter is not appropriate due to drug binding, the 30 minute infusion was rate controlled by using appropriate infusion (syringe) pumps. Dosing and administration of other antimicrobial therapy (e.g., an aminoglycoside) was administered per local standard of care at the discretion of the infant's neonatologist. If there was a delay in the study drug shipment, sites were to use open-label meropenem to protect the safety of the participant.~20 mg/kg every 12 hours in infants <32 weeks GA and PNA < 2 weeks 20 mg/kg every 8 hours in infants <32 weeks GA and PNA ≥ 2 weeks 20 mg/kg every 8 hours in infants ≥32 weeks GA and PNA < 2 weeks 30 mg/kg every 8 hours in infants ≥32 weeks GA and PNA ≥ 2 weeks"
45817322|NCT00364286|Drug|Dasatinib (BMS-354825)|50mg Orally twice daily
45454879|NCT04440748|Other|General Rehabilitation Programme|"The general rehabilitation program that is offered to all patients of Clinic Valens fits the current standards for treatment post-stroke. This program is tailored to the patients needs and consists of a 90 minute so called focus training per day, which includes physical therapy, occupational therapy, resistance training and gait training. According to the patient needs, extra therapy will be given such as robotic therapy, speech therapy and aquatic therapy. The general rehabilitation program in both groups is comparable in content, time and intensity."
45956948|NCT02943031|Other|Individualized Precision Therapy Programs|After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
45454880|NCT01216267|Drug|Lansoprazole|lansoprazole 30 mg HS x 7 days
45454881|NCT01216267|Drug|lansoprazole|lanzoprazole 30 mg HS for 7 days
45454882|NCT03526978|Biological|Investigational sIPV|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months; Intervention: investigational sIPV
45663183|NCT02437903|Device|JUVÉDERM VOLUMA™ XC|Subjects will receive up to 4, 1mL syringes of JUVÉDERM VOLUMA™ XC for their initial injection and a maximum of 6, 1mL syringes of JUVÉDERM VOLUMA™ XC for the study. Subjects will undergo one touch-up injection approximately 2 weeks post initial treatment, and will continue to be evaluated at month 1, month 3, month 6, month 9, and month 12.
45956949|NCT05319223|Behavioral|patient blood management|three pillars of patient blood management will be applied
45956950|NCT02942875|Other|mirror therapy|"During MT, subjects will sit in front of a table on which a mirror will be placed vertically in the space ipsilateral to the paretic upper limb with its reflective surface facing the unaffected upper limb. The subjects are required to look at the mirror to observe the reflective image of the unaffected arm from shoulder to the hand, while it is performing certain designated movements. At the same time, the affected arm will be required to follow the unaffected arm to practice the same movements.~The upper limbs movements during the 30-min MT session are open and close of grasp; wrist flexion and extension; forearm supination and pronation; elbow flexion and extension; shoulder flexion and extension. A total of 120 repetitions for each action will be practiced."
45663184|NCT04933435|Other|Quality of life questionnaires|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep)
45663185|NCT02437513|Device|NewBreez|Intralaryngeal prosthesis to protect the airways
45663186|NCT04909333|Drug|Exenatide|"Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive Exenatide study medication according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of Exenatide, a 10ml 0.9% saline solution will be administered intravenously."
46078944|NCT04101435|Biological|AdimFlu-S (QIS)|This was an open study to demonstrate the use of AdimFlu-S (QIS) (2016-2017 season) vaccine in young subjects aged between 3 years old to 17 years old. All subjects were divided into two subgroups. That were subjects aged 3 to 8 years old, who received 2 doses of 0.5 mL vaccine separated by 4 weeks, and subjects aged 9 to 17 years old, who received one dose of 0.5 mL vaccine.
46078945|NCT04717375|Drug|BND-22|Monoclonal antibody administered intravenously
46078946|NCT04717375|Drug|Pembrolizumab|Monoclonal antibody administered intravenously
45663187|NCT04909333|Drug|0.9% saline solution|"Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive 0.9% saline solution according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of 0.9% saline solution, Exenatide will be administered intravenously."
45663188|NCT04909021|Biological|Investigational RSV vaccine MV-012-968 (Dosage 1)|Single dose administered intranasally on Day 1
45663189|NCT04909021|Biological|Investigational RSV vaccine MV-012-968 (Dosage 2)|Single dose administered intranasally on Day 1
45663190|NCT04909021|Biological|Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose)|Single dose administered intranasally on Day 1
45663191|NCT04909021|Biological|Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose)|Single dose administered intranasally on Day 1, followed by an identical dose administered intranasally at the Day 29 study visit
45663192|NCT04909021|Other|Placebo (single-dose)|Single dose administered intranasally on Day 1
45956951|NCT02942875|Other|control therapy|Control group subjects undergo the same bilateral upper limbs exercise protocol without mirror
45663193|NCT04909021|Other|Placebo (two-dose)|Single dose administered intranasally on Day 1, followed by an identical dose administered intranasally at the Day 29 study visit
45663194|NCT02460991|Device|DEB-TACE|
45663195|NCT02460991|Drug|Sorafenib|
45817323|NCT00278200|Biological|Inactivated EBV-infected vaccine|
45817324|NCT00255346|Drug|Dasatinib (BMS-354825)|70 mg orally twice daily
45817325|NCT00177268|Other|Blood draw, skin biopsy or urine collection|Up to 9 blood draws/year of 60 ml of whole blood. One 6 mm punch biopsy may be obtained up to 4 times per year.
45817326|NCT00114894|Other|Safe Sea ™|Safe Sea ™ applied one time at 2 mg/cm2 coverage
45956952|NCT00169143|Drug|Rituximab + ACVBP regimen plus Pegfilgrastim|
45663196|NCT03629743|Device|EEG|EEG will be collected with Brain Product's VAMP-16 channel EEG Monitor using the accompanying software. (Website with further specifications and product details: https://www.brainproducts.com/productdetails.php?id=15)
45817327|NCT00114894|Other|Placebo|Placebo Coppertone® SPF15 sunscreen(Schering-Plough) applied at 2 mg/cm2 body coverage
45956953|NCT00169143|Procedure|Autologous stem cell transplant|
45956954|NCT00145769|Drug|Short Course Adjuvent Chemotherapy|Post operative adjuvant chemotherapy: 5FU (425mg/m2) preceded by Folinic acid (20mg/m2) delivered over 5 days for 6 monthly cycles
45663197|NCT03629743|Device|ECOG|ECOG will be collected with Nihon Kohden acquisition System and accompanying software and depth electrodes.
45663198|NCT02460679|Drug|EPI-589|An immediate release film-coated table at a 250 mg dosage strength will be administered per dose and schedule specified in arm.
45956955|NCT00145769|Drug|Long Course Adjuvant Chemotherapy|Post operative adjuvant 5FU (425mg/m2) preceded by folinic acid (20mg/m2) delivered over 5 days for 4 monthly cycles
46078947|NCT04717375|Drug|Cetuximab|Monoclonal antibody administered intravenously
45663199|NCT02459899|Drug|Placebo|Placebo, once daily, before the first meal of the day
45663200|NCT02459899|Drug|Sotagliflozin|Sotagliflozin,once daily, before the first meal of the day
45663201|NCT02436889|Drug|Mirabegron|
45663202|NCT02436889|Drug|Tolterodine Tartrate|
45663203|NCT02436811|Behavioral|Written form instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
45663204|NCT02436811|Behavioral|Standardized oral instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
45663205|NCT02436811|Behavioral|Control|60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
45663206|NCT02436577|Drug|Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water|Ticagrelor 90 mg OD tablet, single dose
45663207|NCT02436577|Drug|Ticagrelor OD tablet (90 mg single dose) administered without water|Ticagrelor 90 mg OD tablet, single dose
45663208|NCT02436577|Drug|Ticagrelor IR tablet (90 mg) administered with 150 mL of water|Ticagrelor 90 mg IR tablet, single dose
45663209|NCT02265705|Drug|Baricitinib|Administered orally
45663210|NCT02265705|Drug|Placebo|Administered orally
45663211|NCT02459665|Biological|Vaginal multiple lactobacilli-containing probiotic for prevention of BV recurrence|Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
45817328|NCT02834624|Drug|Poractant alfa|Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
45817329|NCT02834624|Drug|calfactant|Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist
45817330|NCT02917603|Behavioral|Web Conferencing|Individuals will communicate with the nursing home team via web conferencing during quarterly care conference
45817331|NCT02837744|Device|Axiostat®|Axiostat Chitosan Hemostatic dressing belongs to an advanced class of wound dressing that stops bleeding within few minutes of application by providing an active mechanical barrier.
45956956|NCT00145769|Radiation|Short Course Radiotherapy|25 Gy in 5 fractions over 5 days.
45956957|NCT00145769|Radiation|Long Course Radiotherapy|50.4 Gy delivered in 1.8 Gy fractions over 5 1/2 weeks.
45956958|NCT00145769|Drug|Concurrent Chemotherapy|5FU 225mg/m2/day delivered IV over continous 7 day period for the duration of radiotherapy (5 1/2 weeks).
45663212|NCT02459665|Drug|Prophylactic use of metronidazole pills (500 mg)|Prophylactic use of metronidazole pills to prevent BV recurrence after metronidazole treatment for BV or TV
45663213|NCT02459665|Biological|Vaginal Lcr35-containing probiotic for prevention of BV recurrence|Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
45663214|NCT02459587|Behavioral|Crisis Line Facilitation (CLF)|This single session therapist-delivered intervention addresses Veterans' perceived barriers and facilitators of crisis line use during periods of suicidal crisis. The CLF session culminates with the Veteran calling the Crisis Line with the therapist in the room as a way for the Veteran to practice the logistics of making the call and to have direct experiences that may counter any negative beliefs about Crisis Line use.
45663215|NCT02459587|Behavioral|Enhanced Usual Care (EUC)|Those in the EUC condition received the same promotional items and information about the Veterans Crisis Line (VCL) as the CLF condition. Participants were encouraged to seek help via a provider or the VCL if they felt suicidal in the future. Research staff briefly explained key information about the VCL to those in the EUC condition (e.g., the links between the VCL and the VA, the 24/7/365 availability, etc.).
45663216|NCT04908397|Dietary Supplement|L-carnitine|supplement provided twice a day for 2 weeks
45663217|NCT02265237|Drug|ombitasvir/paritaprevir/ritonavir|tablets
45663218|NCT02265237|Drug|ribavirin|tablets
45663219|NCT04874025|Drug|Ibrance|Observational study of Ibrance 75 mg, 100 mg and 125 mg.
45663220|NCT05484219|Device|Functional navigation|Surgeon removes brain tumor or vascular malformation and assesses location of motor areas with functional navigation and intraoperative neuromonitoring
45663221|NCT02263365|Drug|Loperamide|Loperamide 12mg per day (4mg t.i.d) for 2 weeks post discharge
45663222|NCT04858269|Drug|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle
45663223|NCT04858269|Drug|Carboplatin|Carboplatin dosed for area under the curve (AUC) 1.5 IV on days 1, 8, 15 of each 3-week cycle
45663224|NCT04858269|Drug|Paclitaxel|Paclitaxel 45 mg/m2 on days 1, 8, 15 of 3-week cycle.
45663225|NCT05647083|Other|Massage therapy|Classical massage will be applied to the hands and feet, which is expected to take an average of 30 minutes.
45663226|NCT02261493|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
45956959|NCT00145769|Procedure|Initial Surgery|Surgery is to be performed according to the NHMRC Guidelines for the prevention, early detection and management of colorectal cancer: Elective surgery for rectal cancer
45663227|NCT02261493|Drug|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
45663228|NCT05646849|Other|Connected application|Recording and sharing sessions. Exchanges and interactions with other patients. Participation in three collective challenges.
45663229|NCT04855773|Other|PrEPmate|"PrEPmate is a multi-component mHealth intervention grounded in the information, motivation, behavioral skills (IMB) theory of behavior change and developed through user-centered design. PrEPmate promotes personalized communication between patients and providers through interactive weekly check-in messages asking participants how PrEP is going, allowing navigators to identify patients needing more help in taking PrEP, and customized daily pill-taking reminder messages. Trained PrEP navigators reach out to participants who indicate they need assistance via text or phone call and provide tailored support. Additionally, the platform supports 2-way communication between patients and PrEP navigators, including reminders for upcoming clinic visits. Participants are provided links to key information about PrEP (PrEP Basics), and video testimonials of peers taking PrEP. Messages are available in English and Spanish. PrEPmate is aimed at both patients and PrEP navigators."
45663230|NCT04855773|Device|Dot Diary|Dot Diary is a mobile phone app that integrates an electronic pill-taking and sex diary and delivers real-time feedback on PrEP protection. Using the self-management model to increase self-efficacy and patient empowerment, participants log daily PrEP pill-taking and sexual behaviors in the app, which then provides real-time feedback on the level of protection achieved from PrEP (high, medium, low), and customized instructions on doses of PrEP needed to achieve or maintain high protection. Participants can also view a weekly and monthly calendar, including visualizations of the proportion of sex acts covered by PrEP. Finally, the Dot Diary app incorporates gamification components, including an ability to earn sex-positive badges, to increase engagement. Dot Diary is aimed only at patients.
45663231|NCT02260791|Drug|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
45663232|NCT02260791|Drug|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
45663233|NCT02260635|Drug|Evacetrapib|Administered orally
45663234|NCT02260635|Drug|Placebo|Administered orally
45663235|NCT05646537|Behavioral|Neuro-Linguistic Programming Techniques|"The new behavior creation technique of NLP is based on the argument that the imagination process and reality are recorded in the same way in the brain.~Using the Participant's eye movements and imagination . He will be asked to imagine himself while caring for the stoma. participient will then be asked to re-enact the process with the correct stages of stoma care and the jurals that must be adhered to in order to successfully care for it.~Questions will be asked about where he can find the support he needs to carry out this process successfully. At the end of this whole process, he will be expected to construct what life is like with a stoma.The technique will be applied to the patient once and will be instructed to remember this successful process every time he or she feels distressed about the stoma.~At the end of 6 months, the quality of life and compliance will be evaluated by asking the scale questions again."
45663236|NCT05646459|Drug|cannabidiol|This group will locally apply cannabidiol to a posterior, localized 6-9 mm bleeding periodontal pocket.
45663237|NCT05646459|Device|floss|This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
45663238|NCT05646459|Device|proxabrush|This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
45663239|NCT04872855|Device|patient with knee arthroplasty|patient with HLS KneeTec cementless and hybrid fixation prosthesis
45663240|NCT05466201|Drug|Eltrombopag 25 MG Oral Tablet|Since thrombopoietin receptor agonists (TPO-RAs) have never been regularly used for promotion of cell engraftment post hematopoietic stem cell transplantation HSCT), we design this eltrombopag intervention to evaluate the safety and efficacy of TPO-RAs post HSCT.
45663241|NCT05466201|Drug|Supportive care|Patients receive transfusion of blood products, including platelets and red blood cells.
45663242|NCT02259231|Drug|Omaveloxolone Capsules (2.5 mg/capsule)|Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
45663243|NCT02259231|Drug|Ipilimumab (3 mg/kg)|Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg
45663244|NCT02259231|Drug|Nivolumab (240 mg)|Sterile solution containing nivolumab to be delivered intravenously at 240 mg
45663245|NCT02259231|Drug|Omaveloxolone Capsules (10 mg/capsule)|Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
45663246|NCT02259231|Drug|Omaveloxolone Capsules (50 mg/capsule)|Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
45817332|NCT02918617|Drug|Control toothpaste containing Novamin® technology|
46078948|NCT02813720|Radiation|HR-pQCT High resolution peripheral quantitative CT-scan|"HR-pQCT is a powerful device providing low dose irradiation already used in bone field.~It is a high resolution tool (voxel size=82µm) that the investigators adapted to look after the distal joint involved by onycholysis. An anteroposterior scout view is used to define the region of interest (ROI), which spanned from the top of the distal phalange to the distal part of the intermediate phalange in order to contain the distal joint of the target finger. Images are then analysed for erosions, osteophytes and volumetric bone mineral density."
46078949|NCT02694900|Other|Manually chest compressions|Chest compressions performed manually without any device
45663247|NCT02258529|Drug|Idelalisib|150 tablets administered orally twice daily
45663248|NCT02258529|Biological|Rituximab|375 mg/m^2 administered intravenously (weekly for 4 weeks and then every 8 weeks from Week 12 up to Week 100)
45817333|NCT02918617|Drug|Control toothpaste containing 1500 ppm fluoride as MFP|
45817334|NCT02918617|Drug|Test toothpaste with nano-HAP (high concentration)|
45817335|NCT02918617|Drug|Test toothpaste with nano-HAP (low concentration)|
45817336|NCT02918617|Drug|Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3|
45817337|NCT02918617|Drug|Control toothpaste without nano-HAP|
45817338|NCT02918617|Drug|Test toothpaste with nano-HAP (medium concentration)|
46078950|NCT02694900|Device|Cardiopump|Chest compressions performed with Cardiopump
45817339|NCT02918617|Drug|Test cream with nano-HAP (higher concentration)|
46078951|NCT02694900|Device|LifeLine ARM|Chest compressions performed using mechanical chest compressions system LifeLine ARM
46078952|NCT05297045|Drug|RGT001-075|Oral GLP1 Receptor Agonist
46078953|NCT05297045|Other|Placebo|Placebo comparator
46078954|NCT00772707|Device|Multi-Purpose Disinfecting Solution (OPTI-FREE RepleniSH)|OPTI-FREE RepleniSH® used according to product labeled instructions for cleaning and disinfecting study contact lenses, 30 days.
45454883|NCT03526978|Biological|Control IPV|Three intramuscular injections of the control vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the control vaccine (0.5 ml) at 18 months; Intervention:control IPV
45817340|NCT02918617|Drug|Control cream without nano-HAP|
45817341|NCT02839772|Other|Current skin care regimen plus 2% glycerine added to soaking water|
45817342|NCT02839772|Other|Current skin care regimen|
45817343|NCT02918773|Device|Smartphone otoscope|A smartphone otoscope is a pocket size smartphone attachment that uses the technology and light source of a smartphone to capture reproducible images of the ear canal and tympanic membrane. The smartphone otoscope has the capability to capture still images and video, which can be referred to post-examination as well as be incorporated into an electronic medical record. Clinicians will use the smartphone otoscope for the duration of the 6-month study period.
45663249|NCT05646225|Other|chest physiotherapy and early mobilization|"Chest Physiotherapy: Each session included a series of exercises, lasting a total of 15 minutes and including positioning self-conscious breathing control, diaphragmatic breathing control, and exercises for the chest wall and abdominal muscle walls.~Early mobilization: Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes"
45663250|NCT05646225|Other|early mobilization|Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes
45663251|NCT05449275|Other|Faradic current|The most common Electrical stimulation applied for foot drop is faradic current. Faradic current provides the strength and improvement to volitational muscles and increase the coordination and reduce spasticity.
46078955|NCT00772707|Device|Contact Lenses|Contact lenses per participant's habitual prescription removed nightly for cleaning and disinfecting.
45663252|NCT05449275|Other|Ankle foot orthosis|AFO is most commonly used technique but it also has some disadvantage mainly is the movement in limited direction and also in development of contractures and may have the problem in standing from chair
45663253|NCT02256969|Drug|Blephamide|
45663254|NCT02256969|Drug|GenTeal PM Night-Time|
45663255|NCT02256969|Procedure|Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.
45663256|NCT02256969|Procedure|Sham Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. The patient's lid margin was touched with the probes without actual probing of the meibomian gland orifices.
45663257|NCT05438121|Device|SeQuent Please Neo|DCB angioplasty will be performed in accordance with the recent recommendations. Specifically, aggressive lesion predilation (balloon-to-artery ratio: 0.8 to 1.2) using either a plain balloon or a scoring balloon will be performed.
45817344|NCT02918773|Device|Conventional otoscope|A conventional otoscope has a light and lenses to provide a view of the ear canal and tympanic membrane or eardrum. Clinicians will use the conventional otoscope for the duration of the 6-month study period.
45817345|NCT03040466|Device|reusable fiberoptic ureteroscope|We will use reusable fiberoptic ureteroscopes for the treatment of kidney and ureter stones.
45817346|NCT03040466|Device|disposable digital ureteroscope|We will use disposable digital ureteroscopes for the treatment of kidney and ureter stones.
45817347|NCT02918851|Biological|Transfusion of 7-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 5 (7-day old) red blood cells.
45956960|NCT02942953|Device|Diaphragmatic Pacer|The surgical procedure of DP implantation consists in placing four intramuscular electrodes, using a conventional abdominal laparoscopy with four ports. It consists in locating the optimum point for electrode insertion. The process involves mapping between 30 and 50 different points in each hemidiaphragm by applying an electric stimulus of 2-24 mA at 100 µsec pulse widths11. It results in both qualitative and quantitative assessment of diaphragmatic movement. Site of main electrode is identified as the location of each hemidiaphragm's change of maximum pressure and site of secondary electrode as replica of main site. Once the sites are identified intramuscular electrode placement phase is initiated. Finally the electrodes are tunneled out to the corresponding percutaneous exit site.
45817348|NCT02918851|Biological|Transfusion of 28-day stored red blood cells|Subjects will donate blood at Week 2 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 2 (28-day old) red blood cells.
45817349|NCT02918851|Biological|Transfusion of 42-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week0 (42-day old) red blood cells.
45956961|NCT02942680|Drug|acetylsalicylic acid started for 24 hours before surgery|
45956962|NCT02942680|Drug|acetylsalicylic acid stayed for 5 days before surgery|
45956963|NCT00174525|Drug|AAB-001|
45956964|NCT00529009|Drug|UDCA|
45817350|NCT03041636|Drug|Ruxolitinib|Given PO
45817351|NCT03041636|Drug|Ruxolitinib Phosphate|Given PO
45817352|NCT03042715|Behavioral|Qualitative Interviews|phase 1 of the study entail refining the psychological intervention based on caregivers' feedback
45817353|NCT02844998|Behavioral|physical activity|patients will do moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week
45817354|NCT02844998|Drug|dapoxetine 30 mg on demand|Dapoxetine, a short-acting selective serotonin reuptake inhibitors, has been utilized for the treatment of premature ejaculation in various countries
45663258|NCT05436249|Device|Neurofeedback treatment|"During the fMRI scan, the tasks consist of:~Overt finger tapping in time with a flashing cue.~Motor imagery (of finger tapping).~During overt finger tapping, feedback will consist of a slider bar that indicates tapping accuracy to target speed (1 or 4Hz). During motor imagery, neurofeedback will consist of a slider bar that indicates the success of recruiting predicted brain regions (consistent with those engaged during overt tapping)."
46078956|NCT02735460|Device|Andago V2.0|The Andago V2.0 is tested in 2 sessions, the first being a training session to define the probably optimal settings for the subsequent therapy session. In the therapy session the participant performs a specific parcours. Usually this parcours can be done within 10 minutes. However, the session is stopped as soon as the patient feels too exhausted or becomes too weary.
45663259|NCT05436249|Behavioral|At-home therapy|"Participants are assigned to groups where they will practice each day for 3 weeks at-home.~Group 1: Imagery only.~Group 2: Overt finger tapping only.~Group 3: Imagery plus overt finger tapping.~During imagery, participants will view the task while imagining that they are finger tapping in time with the flashing cue, using the imagery strategies identified during their previous neurofeedback session. During overt tapping, participants will finger tap in time with the flashing cue. A final assessment of overt tapping will be performed the day after therapy ends."
46078957|NCT00924937|Behavioral|Mediterranean Diet|Mediterranean Diet:35-38% fat (22% MUFA; 6% PUFA; <10% SAT).
45663260|NCT05646069|Device|Storz Flex-XC1 Disposable Flexible Ureteroscope|Patients will receive flexible ureteroscopy with the Storz Flex-XC1 disposable flexible ureteroscope.
45663261|NCT05646069|Device|Storz Flexible Digital Ureteroscope|Patients will receive flexible ureteroscopy with the Storz flexible Digital ureteroscope.
45663262|NCT05645991|Dietary Supplement|Coconut Sap Powder (CSP)|CSP was given once daily (1.5 g/day) for 8 weeks.
45817355|NCT03043105|Drug|Thalidomide, cyclophosphamide and prednisone|"Thalidomide: 100mg QN for 1 year; And maintained with 100mg QN for the second year;~Cyclophosphamide: 300mg/m2 on Day 1, 8, 15, 22 every month for 1 year;~Prednisone: 1mg/kg on Day 1-2, 8-9, 15-16, 22-23 every month for 1 year."
45817356|NCT02845700|Behavioral|Perceptual Retraining Treatment|"Perceptual retraining involves the systematic presentation of diluted malodors (i.e., odors perceived as threatening). For each individual, vials on either side of a pre-determined and ideographic detection threshold will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor)."
46078958|NCT00924937|Behavioral|Low Fat Diet|Low fat diet: <30% fat (12% MUFA; 6-8%PUFA; <10% SAT)
46078959|NCT05382455|Other|Delphi Questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in Ai in healthcare.~The Delphi questionnaire will be administered via Welphi.com. In the first survey, panel members will outline the AI reporting standards in systematic reviews and objectively identify critical aspects of reporting methodology and results.~In subsequent surveys, the expert panel will evaluate the modified criteria using a 1 to 5-point Likert scale with space provided for suggested edits and comments. Multiple rounds will be conducted until consensus is reached. After each round of Likert responses, the study team will calculate the agreement and distribution of responses. Likert responses will be dichotomized with positive values indicating agreement and neutral or negative values indicating disagreement.~For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed."
46078960|NCT02735304|Other|Impression intervention|The 1st intervention will compare two clinical impression techniques The Innovation treatment arm will receive the innovation treatment first and then crossover to receive the standard clinical practice treatment. The standard clinical practice treatment will receive the standard clinical practice treatment first and then crossover to receive the innovation treatment.
46078961|NCT04264559|Diagnostic Test|Infrared thermal imaging|A thermal imager is used to record thermal images.The baseline temperature of relevant acupoints or sites on the Heart and Lung meridians will be measured.
45663263|NCT05645991|Dietary Supplement|Placebo|Capsules containing aspartame (1.5 g/day) were taken orally once daily for 8 weeks.
46078962|NCT04264559|Procedure|Moxibustion|"Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively. During moxibustion, the temperature change of relevant acupoints or sites in the Heart and Lung meridians will be measured by infrared thermal imaging.~Intervention in the Heart meridian: moxibustion will be performed in acupoint HT3 of the Heart meridian for 15 minutes.~Intervention in the Lung meridian: moxibustion will be performed in acupoint LU5 of the Lung meridian for 15 minutes."
45663264|NCT05645913|Drug|Oral anticoagulant|Oral anticoagulant that was continued at least 25days, inculding warfarin and new oral anticoagulant (NOAC)
45817357|NCT02845700|Behavioral|Sham Neutral training|Control condition using systematic presentation of diluted neutral-neutral odor pairs.
45956965|NCT00529048|Other|Oral Glucose Tolerance Test|The test is preformed 3 times with 3 different amounts of glucose (25g, 75g and 125g) deluded in 300ml of water.
46078963|NCT03743389|Device|12G pigtail catheter|12G pigtail catheter would be used for post-operative chest drainage after uniportal-VATS for mediastinal nodes resection when comparing with the traditional 16F chest tube.
45663265|NCT02256891|Device|PRFM|
46078964|NCT03743389|Device|16F chest tube|16F chest tube would be used for post-operative chest drainage after uniportal-VATS for mediastinal nodes resection when comparing with 12G pigtail catheter.
46078965|NCT04101201|Dietary Supplement|µSmin® Plus|µSmin® Plus is a new Micronized Diosmin Formulation for oral administration. Diosmin is extremely well tolerated and safe to use. Diosmin is safe for most people when used short-term for up to 6 months. During the 8 weeks of the clinical investigation, the subject will administer 1 tablet of µSMIN® Plus (corresponding to 450 mg of micronized diosmin) or placebo per day.
46078966|NCT04101201|Other|Placebo|It will be supplied by the Sponsor in an amount enough for the duration of the study. The subject will administer 1 tablet per day
45663266|NCT02256891|Procedure|Double Row|
45663267|NCT02256267|Drug|LY2835219|Administered orally
45663268|NCT02256267|Drug|Rifampin|Administered orally
45663269|NCT01641471|Device|EMPI Select TENS|The unit is capable of 0-60 milliamps of output current.
45663270|NCT01641471|Device|Placebo EMPI Select TENS|The sham unit appears identical to the Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation.
45817358|NCT03043885|Device|FDBA|Graft material used to graft extraction socket
45956966|NCT00529048|Other|Isoglycemic clamp|I.v. glucose infusion initiating the glucose responds curves from the OGTT
46078967|NCT04237532|Drug|Intranasal Dexmedetomidine|The mucosal atomizing device will be used intranasally where the sedative drug will be equally divided and sprayed into each nostril while the child semi reclined position.
45458187|NCT01234441|Behavioral|Protein + Exercise|A whey protein beverage will be administered before dialysis sessions 3 times per week. Patients will also exercise by stationary bicycle during dialysis sessions 3 times per week.
45458188|NCT04463524|Device|Personal ECG digital sensor|Patients in test group will receive personal ECG sensor and in control gropu will not.
45663271|NCT05429463|Biological|Sintilimab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
45663272|NCT05429463|Drug|Carboplatin|AUC 5-6 mg/mL/min by IV infusion Q3W, given on cycle day 1.
45663273|NCT05429463|Drug|Albumin-Bound Paclitaxel|260 mg/m^2 by IV infusion Q3W, given on cycle day 1.
45663274|NCT02255565|Drug|Very Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 10mg dose
45663275|NCT02255565|Drug|Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 20mg dose
45663276|NCT02255565|Drug|Moderate Dose Quillivant XR|Oral suspension dose once a day increasing to a 40mg dose
45817359|NCT03043885|Device|PRF|Autologous blood product used to graft extraction socket
45817360|NCT03043885|Procedure|Blood Clot|Surgical treatment of extraction socket without addition of graft material
45817361|NCT00374647|Drug|mycophenolate mofetil|
45817362|NCT00374647|Drug|sirolimus|
45817363|NCT02961062|Drug|SAF312|
45817364|NCT02961062|Drug|Placebo|
45817365|NCT00374725|Behavioral|Administration of probiotic (L. rhamnosus and L. acidophilus)|
45956967|NCT00529048|Other|Gastric emptying rate|Paracetamol absorption test. Intake of 1,5g of paracetamol followed by measuring the absorption curve
45956968|NCT00145808|Device|Given® Diagnostic System|
45956969|NCT00174564|Drug|oxaliplatin|
46078968|NCT04237532|Drug|Sublingual Dexmedetomidine|The mucosal atomizing device will be used sublingually by asking the child to touch their maxillary incisor teeth with the tip of their tongue and instruct the child not to swallow the drug for 30 seconds.
46078969|NCT02731092|Dietary Supplement|Lactoferrin|Bovine Lactoferrin 100 mg/ml dissolved in sterile water
46078970|NCT05382377|Biological|KD-025|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
45817366|NCT02962934|Other|Non CRRT group|Non CRRT group:Blood samples prior to first dose of Ceftolozane-Tazobactam and at 15, 45, 1hr, 2hr 3hr 4h 5h 6h 7h 8h.
45817367|NCT02962934|Other|CRRT group|"CRRT group: Pre and Post dialysis filter blood samples taken prior to first dose of Ceftolozane-tazobactam and at 15min, 45min, 1h 2h 3h 4h 5h 6h 7h 8h.~Ultrafiltrate samples at 1 hr,2h 4h 6h 8h"
45817368|NCT02919007|Device|Silk'n HST treatment|Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual
45956970|NCT00529165|Procedure|injection-meal-interval|"The patient injects human insulin (as Actrapid from NovoNordisc) as usual in their insulin routine. The injection is subcutaneous and the dosage is dependent on the blood glucose monitoring. Patients will inject insulin previous every meal, with the following differences:~Group A: with injection-meal-interval: 50 patients educated to inject the insulin with an injection-meal-interval of 15 minutes~Group B: without injection-meal-interval: 50 patients educated to inject the insulin without injection-meal-interval~Cross-over will occur to the other group after 12 weeks. The follow up is 28 weeks."
45956971|NCT02276911|Drug|Ibuprofen|
45956972|NCT02276911|Other|normal saline|
45956973|NCT00145847|Drug|Naltrexone or Placebo|Naltrexone or Placebo 50 mg per day
45956974|NCT00169182|Drug|DOCETAXEL|75 mg/m 2 on day 1
45956975|NCT00169182|Drug|Cisplatin|75 mg/m 2 on day 1
45956976|NCT00169182|Drug|5-Fluoro-3-Pyridinecarboxylic Acid|750 mg/m 2 by 24-hour continuous infusion for 5 days
45817369|NCT02964416|Drug|Injection Tramadol|
45817370|NCT02964416|Other|placebo|0.9% Normal saline in 10 ml syringe
45956977|NCT04691908|Biological|QazCovid-in®-vaccine against COVID-19|QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
45956978|NCT04691908|Other|Placebo|Placebo (sodium chloride buffs, solvent for the preparation of dosage forms for injection 0.9%)
45956979|NCT02944825|Drug|Ciprofloxacin|first line prophylactic oral antibiotic
45956980|NCT02944825|Drug|trimethoprim/sulfamethoxazole|second line prophylactic oral antibiotic
45817371|NCT02812771|Drug|Efinaconazole|Solution
45817372|NCT02967458|Drug|Perflutren Lipid Microsphere Intravenous Suspension|The intravenous administration of Perflutren Lipid Microsphere will provide enhancement of vascular tissue when performing subharmonic prostate ultrasound imaging. This enhancement will be used to guide targeted biopsy of the prostate to vascular areas which are more likely to contain aggressive prostate cancer.
45956981|NCT02944825|Drug|No Intervention|No intervention
45956982|NCT02942758|Drug|low-dose Azacitidine|Azacitidine 75 mg/d s.c. for 7 days, repeated 28-day treatment cycle
45817373|NCT03046225|Device|Transcutaneous electrical nerve stimulation|TENS was applied in the conventional mode, through two self-adhesive electrodes of size 5x9cm positioned parallel to the lumbar spine, on the nerve roots of L3, L4 and L5, with frequency of 100 Hz and pulse duration of 100 μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was gradually increased, with his permission, during the application time.
45956983|NCT02942758|Drug|Pioglitazone|Pioglitazone 45 mg p.o. continuously from day 1
46078971|NCT02813876|Other|Enhanced recovery protocol|
46078972|NCT02731248|Other|Prospective screening study|Prospective screening study in newborns
46078973|NCT05344235|Other|SBRT|stereotactic radiotherapy of the primary prostate
45663277|NCT01640301|Biological|Aldesleukin|Given SC
45663278|NCT01640301|Drug|Cyclophosphamide|Given IV
45663279|NCT01640301|Drug|Fludarabine Phosphate|Given IV
45454884|NCT01115647|Dietary Supplement|Ready-to-Use Therapeutic Food (RUTF)|A Ready-to-Use Therapeutic Food (RUTF), locally produced in Burkina Faso. The RUSF will be nutritionally characterized by chemical analysis (macronutrients, amino acids, vitamins A, C, D, E, B12, thiamin, riboflavin, niacin, calcium, iron, zinc, copper, selenium) and will be analyzed for macronutrients and energy density. All analysis methods are either based on the Official Methods of Analysis of AOAC International or in-house validated analytical methods. The pilot production phase and Hazard Analysis of Critical Control Points (HACCP) risk inventory of the production process will be performed by a food technologist from the Department of Food safety and Food quality, Ghent University.
45663280|NCT01640301|Other|Laboratory Biomarker Analysis|Correlative studies
45663281|NCT01640301|Biological|WT1-Sensitized Allogeneic T-Lymphocytes|Given IV
45663282|NCT04863729|Behavioral|Asdzaan Be'eena Program|"The program consists of 11 weekly sessions conducted with girls ages 10-14 and their female caregivers. 5 of the 11 sessions will be taught to groups of 9-13 girls and their female caregivers, and 6 of the sessions will be taught to individual girl/female caregiver dyads. The choice to use a mix of group- and individual sessions is based on findings from the formative phase indicating certain topics should be taught in groups (e.g. Navajo history and reproductive health 101), and certain topics be taught in individual dyads (e.g. family values and the clan system).~Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers' home or another private place of their choosing, such as our local Johns Hopkins offices."
45663283|NCT01642407|Drug|Sildenafil|Body weight > 20 kg: 20 mg TID (60 mg/day) Body weight ≤ 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2
45663284|NCT02255097|Biological|pembrolizumab|
45663285|NCT05424003|Drug|Semaglutide Pen Injector|Starting dose of 0.24 mg injected weekly and increased every 4 weeks to a potential maximum dose of 2.4 mg weekly at 20 weeks followed by 52 weeks of weekly injections at the maximum tolerable dose
45663286|NCT05424003|Drug|Placebo|Placebo solution injected weekly for 72 weeks
45663287|NCT02254551|Drug|LDE225|"Lead-In: LDE225 will be administered orally at three dose levels starting at 400mg. If acceptable tolerability is demonstrated, escalations may continue up to 800 mg. LDE225 will be administered orally as a single daily dose for 21 days in combination with a fixed dose of bortezomib to be given on Days 1, 4, 8, 11 of each 21 day cycle.~Dose Expansion: LDE225 will be given as a single oral daily dose for 21 days at the MTD determined in the lead-in phase.~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity."
45663288|NCT02254551|Drug|Bortezomib|In both the lead-in and dose expansion portions of the study, bortezomib, 1.3 mg/m2, will be administered by subcutaneous injection (SQ) on Days 1, 4, 8, 11 of each 21 day cycle.
45663289|NCT05421663|Biological|CD19/CD20-directed CAR-T cells|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
45663290|NCT05651139|Device|Electrical Vibration Device|An electrical Vibration Massage device will be used to induce deep tissue vibration stimulation
45663291|NCT05642793|Drug|proactive Anti-VEGF (conbercept) use|preventive intravitreal injection of conbercept 2 weeks after vitrectomy, and repeat at 5 weeks and 8 weeks if either of the following is present: intravitreal VEGF concentration at 2 weeks postop is higher than 100 pg/ml, or clinical presentation of DME, VH or NVG.
45817374|NCT03046225|Device|Continuous passive movement device|CPM device was used for 30 minutes and realized continuous passive flexion and extension of the operated knee.
45817375|NCT03046225|Other|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, adduction and abduction of the hips and flexion and extension of the operated knees. All exercises were performed in 10 repetitions, with the patient positioned in the supine position in the bed.
45817376|NCT02813473|Radiation|Coronary Angiography|Coronary angiography is an X-ray test to diagnose diseases of the arteries that supply blood to the heart. Coronary angiography can detect weakened blood vessel walls and narrowed or blocked vessels. X-rays are taken after a special dye has been injected into the bloodstream, making the vessels and blood flow through the vessels visible on X-rays.
45956984|NCT02942758|Drug|ATRA|ATRA *45 mg/m² p.o. from day 1 to 28, 15 mg/m² from day 29 continuously; *this regimen will be chosen for the first dose to be evaluated.
45817377|NCT02813473|Radiation|Computed Tomography (CT) scan|A CT scan is an X-ray imaging technique that uses a computer to produce cross-sectional images. It can be used to examine the heart and blood vessels for problems
45817378|NCT02969876|Drug|Vortioxetine|Vortioxetine is a selective serotonin re-uptake inhibitor (SSRI), a common form of treatment for major depressive disorder.
45817379|NCT02970032|Drug|Real time heparin dose adjustment|Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
45817380|NCT02970032|Drug|Standard heparin dose|Patients will be placed on heparin infusions per their surgeon's discretion.
45817381|NCT02813551|Drug|Torsemide|
45817382|NCT02813551|Drug|Placebo|
45817383|NCT02970422|Other|Patient Survey|Participants will answer an online survey and their medical chart information will be gathered to compare responses across disease severity.
45956985|NCT02942758|Drug|standard-dose AZA|Azacitidine 75 mg/m²/d s.c. for 7 days, repeated 28-day treatment cycle
45956986|NCT00145886|Drug|rhPTH|Subjects will be treated with rhPTH for 12 months.
45956987|NCT00174603|Drug|quetiapine|
45956988|NCT02942563|Drug|FOLFOXIRI|"Irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle for 4-6 cycles,~Chemoradiation for patients who are not suitable to surgery:~Pelvic radiotherapy(45Grey/25Fraction and 5.4Grey/3Fraction boost to the tumor bed) combined with capecitabine(625mg/m², bid po, d1-5, qw), and additional four cycles of modified FOLFOX6 (mFOLFOX6) or Oxaliplatin 135mg/m²plus Capecitabine 1.0/m² bid po(XELOX) of each 3 weeks cycle for 2 cycles chemotherapy before TME.~All patients will receive 6-8 cycles of mFOLFOX6 or 4-5 cycles XELOX as adjuvant chemotherapy after TME."
45956989|NCT02942446|Device|Investigative Headgear with CPAP mask|Investigative Headgear with CPAP mask
45956990|NCT05318950|Behavioral|E-learning|8 lessons about nutrition and lifestyle
45956991|NCT05318950|Dietary Supplement|Diet|Diet A: MedDASH diet (55% carbohydrates, 25% amino acids, 20% fatty acids) Diet B: MedDASHfat diet (10% carbohydrates, 25% amino acids, 65% fatty acids)
45663292|NCT05642793|Drug|passive Anti-VEGF (conbercept) use|No intravitreal injection of conbercept is used until the patient present with postoperative DME, VH, NVG
45817384|NCT02817763|Procedure|Connective tissue graft (CTG)|Periodontal surgical technique to treat gingival recessions
45817385|NCT02817763|Procedure|CTG plus resin composite restoration|Periodontal surgical technique to treat gingival recessions Procedure/Surgery: Resin composite restoration Restorative procedure do treat tooth structure loss
45454885|NCT01115647|Dietary Supplement|CBS++|CSB is a low-cost combination of a cereal and a legume sometimes fortified with micronutrients. However, it presents shortcomings such as too many anti-nutrients, suboptimal micronutrient content, high bulk and viscosity. The World Food Program has recently proposed an enhanced CSB, named CSB++, which is prepared from heat treated maize and de-hulled soya beans, sugar, dried skim milk, refined soya bean oil, vitamins and minerals.
45956992|NCT00145925|Drug|Perindopril-indapamide|
45956993|NCT00145925|Drug|Gliclazide MR-based glucose lowering|
45956994|NCT00529321|Biological|MVA-HCV (Immunotherapy)|MVA-HCV
45663293|NCT05642013|Procedure|Early prosthesis reimplantation|Early prosthesis reimplantation, within 16 to 30 days after implants removal
45956995|NCT00169221|Drug|Iressa (Gefitinib)|postoperative chemoradiotherapy with cisplatin + gefitinib
45956996|NCT00169221|Radiation|chemoradiotherapy with cisplatin|postoperative chemoradiotherapy with cisplatin
45956997|NCT00529360|Drug|Clofarabine|Dose escalation of clofarabine on Days -9, -8, -7, -6, -5: 1 - 30 mg/m2; 2 - 40 mg/m2; 2 - 46 mg/m2; 3 - 52 mg/m2
45663294|NCT05642013|Other|Retrospective analysis of medical records|Analysis of 50 records of operated patients managed with classical two-stage implant exchange
45663295|NCT05411133|Drug|ARB202|ARB202 Atezolizumab
45817386|NCT02817763|Drug|sodium dipyrone|sodium dipyrone was recommended for all participants after the surgical procedures.
45956998|NCT00529360|Drug|Clofarabine|Use dose of clofarabine established in Part A to further define event free, disease free and overall survival.
45956999|NCT05318482|Behavioral|Motivational group|In addition to the activities of the usual rehabilitation program, the PT will perform a daily motivational session of 15 minutes in a 1 patient: 1 physiotherapist modality. On that occasion, the patient will report the number of steps performed the previous day; the physiotherapist will check and promote the increase of 10% in the number of steps for the next day. If the patient fails to achieve the goal, the PT will analyze the reasons with the patient, in order to facilitate the achievement of the goal. The PT will advise on the time and place to perform physical activity and the patients will receive a diary to record his/her progress (number of steps and heart rate, Borg Fatigue and Borg Dyspnea before and after an exercise task). The PT will record all these evaluations on an excel database.
45957000|NCT05318482|Other|Control group|Besides the activities of the usual rehabilitation program, the patients of this group will be provided by the PT only with the generic recommendations of daily exercise during the in-hospital stay
45957001|NCT00174642|Drug|Insulin Glargine|One daily injection in the evening. 100 U/ml
45957002|NCT00174642|Drug|Insulin Glulisine|Given immediately before each of the three main meals. 100 U/ml
45957003|NCT00174642|Drug|Metformin|At same dosages as the previous treatment
45957004|NCT00174642|Drug|insulin secretagogue|sulfonylurea or glinide
45817387|NCT03049501|Behavioral|Caregiving condition|The intervention will consist of multimedia features accessible via the study-provided tablet. The components include: skill-building sessions and modules; a resource guide; an annotated reading list; information and tips; expert educational seminars (video); and structured support group sessions (6 sessions). All the sessions (home-based, one-on-one, and support group sessions) will last about 60-90 minutes.
45957005|NCT05318014|Dietary Supplement|Intervention group|dietitian regular nutrition education which was following a low protein diet and supply one serving per day of 6 % low protein formula (200mL,2kcal/ml) for 24 weeks
45957006|NCT05318014|Other|Regular nutrition education|dietitian regular nutrition educataion which was following a low protein diet
45663296|NCT05650983|Behavioral|Aerobic exercise; Resistance exercise|To investigate affect/effect of dissimilar modes of exercise, Aerobic exercise versus Resistance exercise, on execution function and psychological symptoms in heroin addicts, 1 hour of characteristic exercise protocols aiming to (a) maximize the strain on the cardiovascular system with Aerobic exercise(60-70% of heart rate recovery) and (b) promote the greatest hypertrophy response with Resistance exercise(65% of 1 repetition maximum & repeated up to 15 time) were used. Both exercise programs were designed to match the male heroin addicts, with medium-intensity Strength-Trained for Resistance exercise and playing balloon volleyball for Aerobic exercise. Two exercise groups performed at 65% of their pre-determine peak oxygen uptake.
45663297|NCT05405985|Drug|Nemolizumab|Nemolizumab with Auto-Injector (AI).
45663298|NCT05405985|Drug|Nemolizumab|Nemolizumab with Dual-Chamber Syringe (DCS).
45663299|NCT05640375|Drug|Methylprednisolone|Single dose, 1 mg/kg
45663300|NCT05650671|Device|instrumented wheelchair|Measurements of pressure, temperature and humidity at the subject/cushion interface
45663301|NCT01641237|Drug|sodium fluoride|fluoride as sodium fluoride
45663302|NCT01641237|Drug|no added fluoride in a silica base|no added fluoride
45957007|NCT02942056|Drug|Cinnamon|Cinnamon tablets to treat type 2 DM
45957008|NCT02942056|Drug|placebo|placebo
45957009|NCT00146003|Drug|Efalizumab treatment|
45663303|NCT04861779|Drug|HSK29116|Oral HSK29116
45817388|NCT03049501|Behavioral|Nutrition condition|The intervention will provide resource and information tips on topics related to Nutrition for a total of 8 sessions. The first and last session will be home-based and all the other sessions will be conducted via web-conferencing using the tablet provided.
45957010|NCT00174681|Drug|Insulin Glargine|
45957011|NCT05317975|Behavioral|Add-on telerehabilitation and home-based rehabilitation|"12wk home-based rehabilitation including individualized exercise training and inspiratory muscle training with symptoms monitoring. Participants will be provided with a manual and routine telephone follow-up by a case manager.~Add-on telerehabilitation for instruction and supervision of exercise training"
45957012|NCT05317975|Behavioral|Home-based rehabilitation alone|12wk home-based rehabilitation including individualized exercise training and inspiratory muscle training with symptoms monitoring. Participants will be provided with a manual and routine telephone follow-up by a case manager.
45957013|NCT05317897|Diagnostic Test|Lung ultrasound examination|45 pediatric patients who will go elective repair of congenital acyanotic heart diseases will be included and will be examined with Lung ultrasound together with arterial blood gases preoperative and postoperative and given a score range from 0-3 according to number of B lines in each region and sensitivity of post-operative lung ultrasound score to extubation within 6 hours was examined.
45957014|NCT00146042|Drug|Docetaxel|
45957015|NCT00146042|Drug|Trastuzumab|
45663304|NCT05633121|Procedure|Rheopheresis|Technique of apheresis in double filtration, allowing the extraction of molecules of high molecular weight, and thus the improvement of the rheological conditions of microcirculation. The expected effect is the improvement of tissue oxygenation and the acceleration of the healing of skin lesions, with the consequent reduction of infectious complications.
45663305|NCT05378997|Drug|TCP-25 gel 0.86 mg/ml or placebo gel|TCP-25 gel (0.86 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
45663306|NCT05378997|Drug|TCP-25 gel 2.9 mg/ml or placebo gel|TCP-25 gel (2.9 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
45957016|NCT00146042|Procedure|Erythromycin Breath Test (ERMBT)|
45957017|NCT00169260|Behavioral|motivational counseling|behavioral motivational counselling
45957018|NCT00169260|Behavioral|placebo|
45663307|NCT05378997|Drug|TCP-25 gel 8.6 mg/ml or placebo gel|TCP-25 gel (8.6 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
45663308|NCT05623605|Drug|Moringa mouthwash|using Moringa mouthwashes in 3 different concentrations (5,10,15%) twice per day for 7 days
45663309|NCT05623605|Drug|star anise mouthwash|using star anise mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
45663310|NCT05623605|Drug|Indian costus mouth wash|using Indian costus mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
45663311|NCT05650437|Device|Ultraviolet Radiation|The therapist cut three holes, each measuring 2 by 2 cm, into a piece of cardboard that was about 4 by 20 cm in size.The first hole was exposed for 90 seconds, the second for 60 seconds, and the third for 30 seconds
45817389|NCT03050203|Other|custom pack|Preparation of the surgical field using a custom pack. The use of a custom pack provides much of the material provided for the preparation of the surgical field with a single opening of the package , reducing the risk of contamination of the material.
45458189|NCT04825015|Device|VEnaRt Cardiac Output|Every patient is monitored during liver transplantation with VEnaRt Cardiac Output versus Swan-Ganz Catheter
45458190|NCT04463758|Other|An auto-questionnaire comprising three psychometric scales|"three psychometric scales validated in French: _depression (Edinburgh Postpartum Depression Scale (EPDS)), anxiety (State-Trait Anxiety Inventory (STAI)~- and Impact of Event Scale (Revised) (IES-R)"
45663312|NCT05650437|Behavioral|Aerobic exercise|The postmenopausal women in groups (A and B) exercised on the treadmill; women should always warm up before beginning exercise and stop if they experience pain or shortness of breath. Each session lasted 30 minutes and included 5 minutes of warming up and 20 minutes of walking at 60% of their maximum heart rate (MHR). The maximum heart rate that the circulatory system can support during physical exercise is MHR=220. Three sessions a week for three months, followed by a five-minute cool-down
45663313|NCT05650437|Dietary Supplement|Vitamin D supplementation|Throughout three months, vitamin D supplements (800 IU) will be given to all postmenopausal women in both groups (A&B)
45663314|NCT05617209|Other|thrombin generation measurement|Thrombin generation will be measured in Platelets rich plasma induced either by 1 pM TF or 10 pM TF concentration in presence of different aTFPIAb concentrations (0; 0.5 µg/ml; 0.75 µg/ml; 1.0 µg/ml; 2.0 µg/ml; 4.0 µg/ml)
45663315|NCT01639833|Device|Veriset Hemostatic Patch|Topical hemostat
45817390|NCT03050203|Other|standard care|The scrub nurse prepares the surgical field opening all the sterile packs it deems necessary for the surgery
45817391|NCT02970812|Device|Electrical Muscle Stimulation|Participants were under EMS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
45817392|NCT02970812|Device|Transcutaneous Electrical Nerve Stimulation|Participants were under TENS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
45817393|NCT02846714|Behavioral|FLARE|
45957019|NCT05318911|Dietary Supplement|Novel yogurt drink|Novel ovine yogurt drink containing polar lipids
45957020|NCT05318911|Other|Placebo Drink|Placebo drink (skimmed milk)
45957021|NCT05318833|Drug|HRS7415|Drug: HRS7415
45454886|NCT01115647|Behavioral|CCC|Child-Centred dietary Counselling (CCC). Although educational/behavioral interventions can be effective to improve child growth, there is little evidence of their effectiveness for MAM. Moreover, evidence from Africa is inexistent. Currently, the main management of MAM consists of giving nutritional advice to the caretakers, but mothers of MAM children are given the same general dietary advice as mothers of well-nourished children. A more efficient, child-centred approach is therefore proposed, by adapting the counselling to the needs of the family, developing a more child-centred approach, by providing operational recommendations for MAM children and providing an adequate follow-up post-treatment.
45454887|NCT01216345|Drug|Cetuximab + Gemcitabine + Oxaliplatin|Cetuximab 500mg/m2, iv every two weeks Gemcitabine 1000mg/m2, iv every two weeks Oxaliplatin 100mg/m2, iv every two weeks
45817394|NCT02921737|Drug|TAS-102|TAS-102 (35 mg/m2/dose) orally 2 times daily beginning the morning of Day 1 of each cycle and ending the evening of Day 5 of each cycle, as well as beginning the morning of Day 8 and ending the evening of Day 12 of each cycle. No TAS-102 will be given on Days 6-7 or Days 13-28 of each cycle.
45454888|NCT04468048|Other|"Music: Nada Himalaya performed by S. G. Sachchidananda"|"Music: Nada Himalaya performed by S. G. Sachchidananda"
45817395|NCT02819011|Device|MBB AFO|Subjects will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO
45817396|NCT02819011|Other|Control|Subjects will be provided with a pair of New Balance 813 shoes
45454889|NCT03526822|Biological|Blood sample|Five blood sample in pre-, post-operative period, before radiotherapy, before adjuvant temozolomide and at relapse in newly diagnosed glioblastoma
45454890|NCT03526822|Biological|Tumor sample|One tumor sample in operative period
45454891|NCT01118533|Device|metal reusable blades MacIntosh|laryngoscope blades
45817397|NCT02846792|Biological|Nivolumab|Given IV
45454892|NCT01118533|Device|Single use plastic blades HEINE XP®|laryngoscope blades
45454893|NCT05462158|Behavioral|Impact of Nudges on CKD Testing|The investigators will examine the impact of different messages on different dimensions of testing for CKD
45663316|NCT01639833|Device|TachoSil®|Topical Hemostat
45663317|NCT05650359|Device|OrthoPulse|"The OrthoPulse device is intended to accelerate orthodontic movement of teeth and reduce the overall treatment time for the patient. The device is intended to be used in conjunction with traditional orthodontic treatment with brackets and wires or aligners.~OrthoPulse is an intra-oral (iO), Light Emitting Diode (LED) based, phototherapy device for the stimulation of metabolic activity of the alveolar bone, and the acceleration of orthodontic tooth movement during orthodontic treatment. The device uses safe, high-power LED arrays to produce photons at therapeutic wavelengths in the near infrared (nIR) portion of the light spectrum.~OrthoPulse is an established device that uses low levels of light energy to stimulate the bone surrounding the roots of teeth and facilitate tooth movement which may reduce treatment time for braces or clear aligners."
45663318|NCT05650359|Other|No intervention|No intervention
45663319|NCT05650281|Other|NO INTERVENTION|NO INTERVENTION
45663320|NCT05107011|Drug|LBL-015 for Injections|LBL-015 was given every two weeks for treatment
45663321|NCT05099991|Device|Single Foley Balloon|Foley Balloon will be placed through the cervix and inflated with 30mL of saline or water on the day prior to the procedure
45817398|NCT02846792|Drug|Plinabulin|Given IV
45817399|NCT02850068|Device|Geniculate Artery Embolization|Geniculate artery embolization (GAE) is a new procedure that is being used to reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA). Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the knee, resulting in improvement of pain, stiffness and difficulty performing daily activities from OA.
45817400|NCT02819323|Drug|PEG-ELS|polyethylene glycol based bowel preparation
45817401|NCT02819323|Drug|BLI800|BLI800 bowel preparation
45957022|NCT03458494|Other|Mediterranean Diet|Participants will receive meals traditionally consumed in Mediterranean countries
45957023|NCT03458494|Other|Low-fat diet|Participants will receive meals with a low content of total fat.
45957024|NCT00169299|Drug|Black cohosh|
45957025|NCT00169299|Drug|Multibotanical preparation|
45957026|NCT00169299|Drug|Multibotanical preparation + dietary soy counseling|
45957027|NCT00169299|Drug|Conjugated equine estrogen +/- medroxyprogesterone acetate|
45957028|NCT02942602|Drug|Atorvastatin 20 mg|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
45957029|NCT02942602|Drug|Cholestyramine 8 g|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
45454894|NCT01118611|Drug|Aurora B/C kinase inhibitor GSK1070916A|
45957030|NCT02942602|Drug|Omega-3 2g|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
46078974|NCT00928837|Dietary Supplement|Flavocoxid 500 mg|flavonoid mixture
45454895|NCT01118611|Other|laboratory biomarker analysis|
45454896|NCT01118611|Other|pharmacological study|
45454897|NCT01118611|Procedure|diffusion-weighted magnetic resonance imaging + PET CT|
45454898|NCT01118611|Radiation|fludeoxyglucose F 18 dynomic contrast|
45663322|NCT05099991|Device|Dilapan-S|Dilapan S will be placed through the cervix on the day prior to the procedure
45663323|NCT01639131|Drug|Gemcitabine|intravenous gemcitabine 800mg/m2 on days 1 and 8
45454899|NCT01118689|Drug|MLN0128|MLN0128 administered orally once daily for 28 days
45663324|NCT01639131|Drug|Docetaxel|intravenous docetaxel 70mg/m2 on day 8 of each 21 day cycle
45663325|NCT01639131|Drug|Filgrastim or Pegfilgrastim|filgrastim (granulocyte colony-stimulating factor [G-CSF]) on days 9 through 15 or pegfilgrastim 6 mg on day 9 or 10 of each cycle
45663326|NCT01641159|Drug|Buspirone|Study participants will be randomly assigned to receive either buspirone or matching placebo. Following dose escalation, the target at study day 10 is to achieve the highest tolerated dose not exceeding 60 mg. Participants who are unable to reach the 60 mg dose or who need to be reduced from 60 mg due to tolerability will be maintained on 15 mg, 30 mg, or 45 mg, whichever is the highest dose tolerated.
45663327|NCT01641159|Drug|Placebo|Study participants will be randomly assigned to receive either buspirone or matching placebo. Placebo tablets will be identical in color and size to the buspirone tablets.
45663328|NCT01641081|Drug|Formoterol Fumarate in the Pressair DPI, Low Dose|Formoterol Fumarate in the Pressair DPI 6 micrograms, twice a day for 14 days
45454900|NCT01212523|Drug|propofol and isoflurane|both drugs administered at age-related dose and titrated to effect. maximum dose of propofol 15 mg/kg/hr, maximum dose of isoflurane 1.5 MAC
45663329|NCT01641081|Drug|Formoterol Fumarate in the Pressair DPI, High Dose|Formoterol Fumarate in the Pressair DPI 12 micrograms, twice a day for 14 days
45817402|NCT03053401|Procedure|Adductor Canal Block|Under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
45817403|NCT03053401|Procedure|Femoral Nerve Block|Under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
45817404|NCT03053401|Device|Ultrasound|Use of linear ultrasound transducer probe (General Electric;GE) to guide needle placement for both Adductor Canal Block and Femoral nerve Blocks
45817405|NCT03053401|Device|Stimuplex A needle|22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany) used to perform both Adductor Canal Block and Femoral nerve Blocks.
45817406|NCT03053401|Drug|local anaesthetic injection|Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) for either Adductor Canal Block and Femoral nerve Blocks.
45817407|NCT03053401|Drug|Steroid Drug|Methylprednisolone acetate 1 mg/kg (maximum of 40 mg ) for either Adductor Canal Block and Femoral nerve Blocks.
45663330|NCT01641081|Drug|Foradil Aerolizer, Low Dose|Foradil Aerolizer 12 micrograms, twice a day for 14 days
45663331|NCT01641081|Drug|Foradil Aerolizer, High Dose|Foradil Aerolizer 24 micrograms, twice per day for 14 days
45663332|NCT01641081|Drug|Placebo|Placebo in the Pressair for 14 days
45663333|NCT01640925|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours
45663334|NCT01640925|Other|Standard bathing|The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
45663335|NCT05369481|Drug|Sildenafil 2%|Patients with male androgenic alopecia will be given topical Sildenafil 2% to apply twice daily for 6 consecutive months and then follow up.
45663336|NCT05369481|Drug|Minoxidil 5 %|Patients with male androgenic alopecia will be given topical Minoxidil 5 % to apply twice daily for 6 consecutive months and then follow up.
45817408|NCT02819557|Drug|Ataluren|White to off-white powder for oral suspension.
45817409|NCT02820181|Device|novel tracheostomy bi-ties|The investigators designed a novel tracheostomy bi-tie to ensure the safety and conveniences during exchanging and cleaning them, the primary feature of which is double belts and easy to operate.
45817410|NCT02820181|Device|traditional Tracheostomy ties|Traditionally, the tracheostomy tube is fixed using ordinary tracheostomy ties made of medical bandage or long strands.
45817411|NCT02860286|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
45817412|NCT03054103|Drug|Midazolam + Ketamine 10 MG/ML: 0.5 ML|5 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
46078975|NCT00928837|Drug|Naproxen|non-steroidal anti-inflammatory drug
45663337|NCT04853979|Other|PRONE POSITION|Any combination of prone or side position for 3 hours, 3 times a day for 3 days
45663338|NCT04853589|Device|Hyaluronic acid gel|After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 1 will receive hyaluronic acid gel.
45663339|NCT04853589|Device|Hyaluronic acid gel + carrier|After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 2 will receive hyaluronic acid gel together with a collagen carrier.
45663340|NCT04677153|Other|Test and treat plus peer mentors|Rapid start of HCV treatment at OTP within days of HCV diagnosis. Participants will receive 8 weeks of glecaprevir/pibrentasvir and will work with a peer mentor during and after treatment.
45663341|NCT04677153|Other|Usual care|Participants are referred to another location for HCV treatment.
45663342|NCT01638429|Drug|Neomycin|Neomycin: 500mg po bid for 10 days
45663343|NCT01638429|Drug|Rifaximin|Rifaximin: 550mg po tid for 10 days
45817413|NCT03054103|Drug|Midazolam + Ketamine 10 MG/ML: 1 ML|10 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
45817414|NCT03054103|Drug|Midazolam + Normal saline|Preoperative control: Normal saline placebo given preoperatively. Then protocol followed for titration of midazolam up to 2 mg IV at beginning and during case.
45454901|NCT01122121|Drug|Leuprorelin SR|Leuprorelin SR injection
45817415|NCT05440903|Behavioral|Headspace|A smartphone application that provides users with mindfulness and meditation sessions.
45817416|NCT05440903|Behavioral|TEDTalk|A smartphone application that provides users with psychoeducational audio recordings from TEDTalk.
45817417|NCT02860988|Behavioral|MCCC treatment|Participants in this condition received newly-supported reentry services to enhance fatherhood and parenting for individuals with substance use issues. These services focus on responsible parenting, economic stability and mobility, and healthy marriage and relationships.
45817418|NCT02822287|Drug|Acetylcystine|Clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle.
45817419|NCT03043274|Drug|Cangrelor|Cangrelor 30 mcg/kg bolus followed by a 4 mcg/kg/min intravenous infusion prior to PCI will be given. It will be continued for ≥ 2 hours or for the duration of the procedure, whichever is longer.
45817420|NCT03054649|Device|HARMONI® Modular Intraocular Lens System|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
45817421|NCT03054649|Procedure|Intraoperative optic exchange|Removal of one optic and replacement with another during cataract surgery for the purpose of improving refractive outcomes
45817422|NCT04333316|Procedure|large head|implantation of large head total hip
45454902|NCT01122121|Radiation|Radiotherapy|Radiotherapy 70 +/- 4 Gy
45454903|NCT01122121|Drug|Flutamide|Flutamide tablets
45663344|NCT04847973|Other|Medically-Tailored Meals (MTMs)|12 weeks of home-delivered MTMs, delivered weekly, containing food for 3 meals per day on 5 days of the week
45663345|NCT04847973|Dietary Supplement|Protein supplementation shakes|12 weeks of 1 bottle of Ensure Max Protein shake every day, in addition to partcipants' standard diet
45663346|NCT05058807|Other|Whole body vibration group|"Experimental Group will receive WBV training and balance exercises under the supervision of a physical therapist by using a vibration platform. Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps * 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps, with 30 sec rest interval~WHOLE BODY VIBRATION:~The patient stood on the platform with his/her feet barefoot shoulder width and stared at the front, delivered on a side alternating vibration platform in an intermittent way: five repetitions of 1 min vibration followed by a 1 min rest. The vibration frequency and amplitude were 20 Hz and 3.0 mm respectively.~These outcomes will be evaluated at baseline, and after 4 week and at 8th week"
45663347|NCT05058807|Other|Tai Chi group|"Control group will receive Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps * 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps ,with 30 sec rest interval Yang style Tai chi exercise which consist of 10 positions. 1. Hold the ball ward off 2: Grasping the sparrows tail left; 3.Grasping the sparrows tail Right;; 5.Repulse Monkey; 6. Part wild horse's Mane; 7.Brush knee Twist step; 8.Lift kick left; 9.Lift kick Right; 10.Cross hands with double leg stance~1st and 2nd week will last for 5reps, 3rd and 4th week will last for 10reps,5th and 6th week will last for 15reps,7th and 8th week will last for 20reps, starting with 10 minutes warming- up and ending with 10 minutes cool-down. These outcomes will be evaluated at baseline, and after 4 week and at 8th week"
45663348|NCT04853511|Device|OCT-FLIM (optical coherence tomography-fluorescence life time)|comprehensive assessment of coronary plaque with OCT-FLIM dual modal intravascular catheter imaging followed by serial 18F-FDG-PET/CT imaging
45663349|NCT04853355|Drug|Spironolactone 50 mg|Add Spironolactone 50 mg to previous regimen
45817423|NCT04333316|Procedure|dual mobility cup|implantation of dual mobility total hip
45817424|NCT02975804|Device|Tymo|All children will be calibrated using the Tymo in a static sitting position in each treatment session. The amplitude of the force and weight distribution generated by the child between the two sides of the body will be recorded. This information will be used to set up the Tymo as a training module (the intervention) by the software, in which the child will move the trunk forward, backward and sideways to participate in a computer game in sitting. The child will choose which game they want in each treatment session and they have to stay on the same game for at least 10 minutes before changing to another game.
45817425|NCT03054805|Drug|Magnesium Oxide|Magnesium oxide 250 mg per day for children with weight < 15 kg, 500 mg per day for weight <15-30 kg, and 1000 mg per day for weight > 30 kg
45817426|NCT03054805|Drug|MIYAIRI-BM|MIYAIRI-BM 1 g (1package) per day for children with weight < 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight > 30 kg
45817427|NCT00374101|Drug|omeprazole|
45817428|NCT00374101|Drug|pantoprazole|
45957031|NCT02942602|Drug|Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
46078976|NCT00928837|Other|Placebo|Placebo
46078977|NCT00928837|Other|flavocoxid 250 mg|Medical food product
45663350|NCT05377281|Procedure|Peripheral Nerve Tissue Implantation|At the time participants are receiving the standard of care deep brain stimulation (DBS) surgery, a standard incision on the lateral aspect near the ankle is made, the sural nerve is identified, an about 3 cm biopsy of the sural nerve is obtained and the incision is closed. From the biopsied section, the epinerium is removed, fascicles are cut, and (~5 pieces per side; ~ 5mm length x 1.5 mm diameter: approximately 10 cubic millimeters) implanted bilaterally into the substantia nigra.
45957032|NCT02942602|Behavioral|Lifestyle modification|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
45957033|NCT00146081|Behavioral|Weight Management|Participants (Index Participants) who identify 1 or 2 family members or friends (Co-Participants) to enroll with them are randomly assigned into either program A or B, and those who choose to enroll by themselves are randomly assigned to either program C or D. All Index Participants are invited to attend weekly group behavior change educational sessions; weekly in first 6 months, biweekly in next 6 months, and monthly in year 2. Co-Participants in program A are invited to attend all sessions with their Index Participant, but only the field workshops and personal counseling sessions if enrolled in program B.
45663351|NCT04419285|Behavioral|Locomotion task|The locomotion task takes place on a Streetlab platform. The subject must follow a line on the ground, straight or composed of turns.
45817429|NCT00374738|Behavioral|Guided Imagery for Trauma (GIFT)|Guided Imagery for Trauma (GIFT) - music and voice narration over a 12-week intervention. The control intervention included a relaxing music audio (the same music used in the guided imagery audio but without the narrative voiceover), PDA to log audio use, orientation and weekly phone consults, but did not have access to the patient advocate or to the guided imagery instructions provided on the GIFT audio.
45957034|NCT02942524|Other|Communication Intervention|Complete TEPID
45957035|NCT02942524|Other|Questionnaire Administration|Ancillary studies
45957036|NCT02942524|Other|Survey Administration|Ancillary studies
45817430|NCT00374179|Drug|CT-322|IV solution, weekly or bi-weekly
45957037|NCT02942329|Drug|apatinib|Apatinib was administered 250mg or 375mg orally daily. For gastric cancer patients, the dose would be 250mg or 375mg daily. For hepatocellular carcinoma patients, the dose would be 250mg daily.
45817431|NCT00374257|Procedure|Narrow-Band UVB Phototherapy|Performed either two or three times per week for a total of 24 treatments
45817432|NCT02979626|Procedure|Respiratory nasal swab|Nasal swabs will be obtained for testing by the study nurses. If a respiratory sample has already been collected as part of routine clinical care, this will replace the study collection, and no additional testing will be required.
45817433|NCT02822599|Drug|RiaStAP|To decrease post-operative bleeding volume.
45817434|NCT02822599|Drug|Saline|Placebo consisting of normal saline 0.9%
45957038|NCT02942329|Drug|SHR-1210|SHR-1210 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks.
45957039|NCT02958176|Behavioral|HRV Biofeedback|At-home heart rate variability biofeedback using Elite HRV app and Polar H7 chest strap
45957040|NCT02958176|Behavioral|Autogenic Training|Autogenic training recording provided on a CD
45957041|NCT00174720|Drug|Ciclesonide (XRP1526)|
45957042|NCT02942641|Procedure|Indwelling urethral catheterization (Foley)|"Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.~Patients in this group received indwelling urethral catheter as the intervention."
45957043|NCT02942641|Procedure|Clean intermittent catheterization (CIC)|"Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.~Patients in this group received CIC as the intervention."
45957044|NCT02942641|Device|Foley|
45957045|NCT05318794|Drug|Doxorubicin and Cisplatin|Pressurised intraperitoneal aerosol chemotherapy
45663352|NCT04419285|Behavioral|Posturology task SOT (Sensory Organization Test)|The task takes place on a Streetlab platform with uniform walls without decorations in order to remove any localization element.
45957046|NCT05318716|Device|Fat grafting - Revolve device|Standardized fat collection The donor areas previously agreed on by the patient and surgeon for fat harvesting will be injected with pre-standardized formulae and volume of tumescent fluid, and fat will be extracted using a standardized harvesting method between surgeons. Once the fat is collected. It will then be processed in one of two ways depending on the patient's group, using a Revolve system or via decantation. Fat will then be injected into the breast using a 10 or 20cc syringe in the standard retrograde manner to achieve the desired size and shape. A standard gauze-based dressing will be applied post-operatively, with no compression.
45957047|NCT05318716|Device|Fat grafting - Decantation|Standardized fat collection The donor areas previously agreed on by the patient and surgeon for fat harvesting will be injected with pre-standardized formulae and volume of tumescent fluid, and fat will be extracted using a standardized harvesting method between surgeons. Once the fat is collected. It will then be processed in one of two ways depending on the patient's group, using a Revolve system or via decantation. Fat will then be injected into the breast using a 10 or 20cc syringe in the standard retrograde manner to achieve the desired size and shape. A standard gauze-based dressing will be applied post-operatively, with no compression.
45957048|NCT02942212|Behavioral|Questionnaire|Participants complete a computerized questionnaire to assess demographics and smoking history.
45957049|NCT02942212|Behavioral|In-Depth Interviews|Participants take part in individual in-depth interviews discussing smoking history, attempts to quit, and suggestions for smoking cessation program. The interview should last 30-45 minutes and is audio-recorded.
45957050|NCT02942212|Other|Breath Test|Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.
45957051|NCT02942212|Drug|Nicotine Patches|Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Patch therapy for participants who smoke >10 cigarettes/day consists of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
45957052|NCT02942212|Behavioral|Advice plus Phone Counseling|Participants receive brief advice to quit smoking, as well as phone counseling for support in quitting smoking (5 sessions over the course of 6 weeks) with a counselor at the Texas Quitline.
45663353|NCT04419285|Behavioral|The quality of life questionnaire|Study the correlations between the subjects' quality of life scores and the results during behavioral tests. Identify the subjective parameters most sensitive to sensory-motor performance.
45663354|NCT01639755|Device|new texture shaped breast implants|breast implant surgery
45663355|NCT04844853|Device|electroencephalography|128-channel electroencephalography
45663356|NCT04844853|Device|Tactile stimulation|Vibrotactile sequence on the forearm
45663357|NCT04844853|Behavioral|Attention Network task (computerized)|Computer-based game challenging orienting and executive attention. The subject must chose which side an animal is going, using left and right buttons, depending on the validity of a cue and the congruency of flankers.
45663358|NCT04844853|Behavioral|Head-toes-knees-schoulders|Following motor commands such as touch your head when they are congruent or incongruent.
45817435|NCT04737421|Device|NobelActive TiUltra implant|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
45817436|NCT04737421|Device|NobelParallel CC TiUltra implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
45957053|NCT02942212|Behavioral|Advice plus Counseling Sessions|Participants receive brief advice to quit smoking, as well as 5 individual, in-person smoking cessation treatment counseling sessions.
45957054|NCT02942212|Behavioral|Self Assessment Questionnaires|Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up.
45957055|NCT00146120|Drug|Idarubicin|
45957056|NCT00146120|Drug|Cytosin-Arabinosid|
45957057|NCT00146120|Drug|Etoposide|
45957058|NCT00146120|Drug|All-trans Retinoid acid|
45957059|NCT00169338|Procedure|Deep brain stimulation|internal pallidal deep brain stimulation
45957060|NCT02942251|Other|Clinical features and medication|This group will be suggested to take optimize treatment according to Chinese treatment guidelines.
45957061|NCT02942251|Other|Psycho-social|This group will be suggested to add on psychotherapy on medical treatment.
45817437|NCT04737421|Device|NobelReplace CC TiUltra implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
45957062|NCT02942251|Other|immunology|This group will be suggested to add on Omega-3 polyunsaturated fatty acid(PUFAs) on medical treatment.
45957063|NCT02942251|Other|Laboratory abnormality|This group will be suggested to more safety antidepressants.
45957064|NCT02942251|Other|Comorbidity|This group will be suggested to treat their comorbidities as well as treat MDD.
46078978|NCT02811146|Device|Bilevel Positive Pressure Airway|Heart rehabilitation with noninvasive ventilation, for 12 weeks, 3 times a week
46078979|NCT02811146|Other|Heart rehabilitation|Heart rehabilitation, for 12 weeks, 3 times a week
45458193|NCT02314858|Behavioral|Brief Personalized Video (BPV)|The BPV group will view a portion of their own sleep study that took place during their overnight sleep study.
45663359|NCT04844853|Behavioral|Laby 5-12|Test of motor planning using labyrinths
45663360|NCT04844853|Behavioral|M-ABC 2|Test of motor functions using various subtests of gross and fine motor function.
45663361|NCT04844853|Behavioral|Stroop animals|Stroop test for preK children using animals instead of words
45817438|NCT04737421|Device|Nobel Biocare N1 TiUltra TCC implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
45817439|NCT00373789|Drug|Botulinum Toxin A, bladder detrusor muscle injection|200 U provided as a total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices.
45957065|NCT02942251|Other|Treatment as usual|Patients will accept routine treatments based on psychiatrist experience, not based on the relapse predict model.
45957066|NCT04691596|Behavioral|Non-cue-contingent weekly incentives|Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk at any time of day
45957067|NCT04691596|Behavioral|Cue-contingent weekly incentives|Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk within a +/-1 hour window of the pre-specified time of their chosen contextual walking cue
45957068|NCT04691596|Behavioral|Habit Coaching|Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit
45957069|NCT04691596|Behavioral|App use instructions|Received a basic training with the StepUp app
45957070|NCT00169377|Procedure|deep brain stimulation|Stimulator on followed by off
45957071|NCT00169377|Procedure|No stimulation|Stimulator off followed by on
46078980|NCT00772629|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
46078981|NCT00772629|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
46078982|NCT02730936|Device|Antimicrobial Hernia Repair Device|hernia repair
46078983|NCT00925093|Drug|Vancomycin|Vancomycin is administered intravenously and subsequently measured in cerebrospinal fluid sample
45663362|NCT05310981|Behavioral|iCanChange|iCC is a psychological app based intervention that will be delivered in form of up to 24 brief (10-15 minutes) interactive modules developed based on the principles of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). During the intervention, participants will be offered MI and CBT-based activities (i.e., modules and strategies) aiming at facilitating change in cannabis use. At any point during the intervention, participants can reference modules that had been completed. Due to the frequency of behavioral stage changes in this population (e.g., regression in behavioral stage of change), stage of change will be monitored regularly throughout the intervention. During the follow-up period (i.e., Week 12-24), participants will have continuous access to the smart phone application and all built-in add-ons as described above. During this period, they will have access to 3 booster session.
45663363|NCT05369091|Drug|Simvastatin 10mg|Atraumatic Extraction and administration of SIM (10 mg tablet grounded and added with normal saline, with gelatin sponge as a transporter) into the socket to observe alveolar bone healing.
45663364|NCT05017623|Drug|YH003|All subject will receive YH003 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
45663365|NCT04652037|Device|Acrysof IQ Vivity Toric Extended Vision Intraocular Lens Implantation|Implantation during bilateral cataract surgery of a new non-diffractive extended vision presbyopia and astigmatism correcting intraocular lens (Acrysof IQ Vivity Toric Extended Vision Intraocular Lens)
45663366|NCT01601535|Drug|MLN8237|Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.
45663367|NCT01601535|Drug|Irinotecan|Irinotecan will be administered intravenously during each course on study day 1 through day 5.
45663368|NCT01601535|Drug|Temozolomide|Temozolomide will be administered orally during each course on study day 1 through day 5.
45663369|NCT05422365|Drug|Intravenous immunoglobulin (IVIG), 10% solution for infusion|The study drug is administrated at a dose 0.8-1.0 g / kg once a day for 2 consecutive days, the course dose is 1.6-2.0 g / kg.
45663370|NCT04641273|Drug|BAY1817080|Tablet, intake orally.
45663371|NCT04641273|Drug|Placebo for BAY1817080|Tablet, intake orally.
45663372|NCT04641273|Drug|Placebo for Pregabalin|Capsule, intake orally.
45817440|NCT00373789|Drug|Vehicle saline as placebo|A total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices
45817441|NCT03045926|Drug|Diosmectite (Smecta®)|
45957072|NCT00146159|Drug|Mitoxantrone|dosage
45458194|NCT02314858|Behavioral|Non-Personalized Video (NPV)|The NPV group will see a stock video of someone with OSA.
45663373|NCT04641273|Drug|Pregabalin|Capsule, intake orally. Starting dose 75 mg BID first week, increase to 150 mg BID in second week.
45663374|NCT04832763|Procedure|Biospecimen Collection|Undergo collection of blood sample
45663375|NCT04832763|Other|Medical Chart Review|Review of medical charts
45663376|NCT04832763|Other|Physical Performance Testing|Undergo physical function testing
45817442|NCT02928055|Device|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (daily dose is Group-dependent). Stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
46078984|NCT00925093|Drug|Teicoplanin|Teicoplanin is administered intravenously and subsequently measured in cerebrospinal fluid sample
46078985|NCT00925093|Drug|Linezolid|Linezolid is administered intravenously and subsequently measured in cerebrospinal fluid sample
45458195|NCT02314858|Behavioral|Treatment as Usual (TAU)|The TAU group will not watch a video.
45663377|NCT04832763|Other|Quality-of-Life Assessment|Ancillary studies
45817443|NCT02983058|Radiation|PET/SPECT Scan|PET scan will be performed on a mCT scanner
45817444|NCT02983058|Device|MRI Scan|Structural MRI will be obtained to permit co-registration of PET images
45817445|NCT00373867|Behavioral|Standard physical therapy|Treatment-based classification physical therapy
45817446|NCT00373867|Behavioral|Graded exercise|Graded exercise increases an individual's tolerance to activity over time
46078986|NCT02813330|Other|Subcutaneous sterile water injection|sterile water injection in two points of low back pain
45663378|NCT04832763|Other|Questionnaire Administration|Complete questionnaire
45663379|NCT04852731|Procedure|Cardiac MRI|Injected cardiac MRI
45663380|NCT04852731|Other|Blood collection|Blood collection (including genetics at the inclusion visit)
45663381|NCT04852731|Procedure|Prolongation of the MRI examination|Prolongation of the MRI examination (4D flow sequence ; about 10 min)
45663382|NCT04843917|Diagnostic Test|Immunoglobulin G detection|Detection of immunoglobulin G against Spike Receptor Binding Domain against severe acute respiratory syndrome coronavirus 2
45663383|NCT05000853|Drug|Iron Carboxymaltose|Iron supplementation when is needed according to usual care
45817447|NCT00373867|Other|Graded exposure|Graded exposure places the individual in fearful situations and gradually increases their exposure to such situations.
46078987|NCT02813330|Other|saline injection|Saline injection in two points of low back pain
45663384|NCT04832529|Procedure|No packing of perianal abscess cavity|introducing new method to no packing of abscess cavity.
45663385|NCT04998591|Behavioral|Fasting|fasting for 7 days (caloric intake <500 kcal in liquid form)
45663386|NCT04419129|Device|Oxford UKA|knee arthroplasty
45663387|NCT04419129|Device|Vanguard TKA|knee arthroplasty
45663388|NCT04586985|Drug|FTX-6058/placebo oral capsule(s)|Subjects will receive FTX-6058 or matching placebo.
45663389|NCT04586985|Drug|FTX-6058/placebo oral capsule(s)|Subjects will receive FTX-6058 or matching placebo.
45663390|NCT04586985|Drug|FTX-6058 - Two Dosing Periods|Subjects will receive FTX-6058
45663391|NCT04586985|Drug|FTX-6058 / Midazolam Syrup|Subjects will receive FTX-6058 and midazolam syrup
45663392|NCT04586985|Drug|FTX-6058/placebo oral capsule(s)|Subjects will receive FTX-6058 or matching placebo.
45663393|NCT05273697|Procedure|Underwater Cold Snare Polypectomy|"The procedure of Underwater Cold Snare Polypectomy (UP) will be as follows:~Complete suction of air from the intestinal tract~Partial opening of the intestinal lumen by using sterile room temperature water via a water pump~Complete immersion of the lesion in water~Snaring of the lesion and a small amount of surrounding healthy tissue (1-2mm)~Excision The objective will be the en bloc resection of the lesion including healthy tissue (about 2mm). If the en bloc resection fails, a piecemeal will be performed on as few specimens as possible"
45663394|NCT05273697|Procedure|Conventional Cold Snare Polypectomy|"The procedure of Conventional Cold Snare Polypectomy (CCSP) will be as follows:~If the entry during the endoscopy has been made with water, the water will be aspirated, and the intestinal lumen will be re-stretched using air / CO2~Snaring of the lesion and a small amount of surrounding healthy tissue (1-2mm)~Excision The objective will be the en bloc resection of the lesion including healthy tissue (about 2mm). If the en bloc resection fails, a piecemeal will be performed on as few specimens as possible"
45458196|NCT01235143|Drug|Desflurane|Desflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
45458197|NCT01235143|Drug|Sevoflurane|Sevoflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
45663395|NCT05260749|Procedure|real-time fMRI neurofeedback training procedure|real-time fMRI neurofeedback training procedure running on the Turbo Brain voyager (TBV) 3.2 software (Brain Innovation, Maastricht, The Netherlands)
45663396|NCT05260749|Procedure|real-time fMRI sham-controlled neurofeedback training procedure|real-time fMRI sham neurofeedback training procedure running on the Turbo Brain voyager (TBV) 3.2 software (Brain Innovation, Maastricht, The Netherlands)
45663397|NCT04969419|Other|Exposure of skin cancer of interest|Melanoma and nonmelanoma skin cancers: squamous cell carcinoma, basal cell carcinoma and actinic keratoses.
45817448|NCT02983448|Device|transcutaneous vagus nerve stimulation|All patients will receive both active and sham transcutaneous vagus nerve stimulation, with the order being randomized
45663398|NCT04841343|Drug|Triamcinolone|Triamcinolone in sinus
45663399|NCT04852419|Drug|ZN-c5|ZN-c5
45663400|NCT05249673|Other|global postural reeducation|"GPR interventions will last 9 sessions, 1 hour each, with one-to-one supervision, once or twice a week according to the participant's needs. All participants will receive advice to follow written ergonomic suggestions and to repeat the exercises in the first physical therapy session at home twice a week for 15 minutes. Each group will get a home exercise program, which will differ according to the type of treatment received. Participants in the GPR group will execute one posture routine."
45663401|NCT05249673|Other|neck stabilization training|"Each exercise session will be comprised 10-minute warm-up exercises, 40-minute stabilization exercises, and 10-minute cool-down and stretching exercises, including neck and shoulder girdle muscles. The whole program will be carried out 3 days per week for 4 weeks.~performed. The participants will be asked to maintain the positions and contractions during the exercises and throughout the day as much as possible. The combination and progression of the exercises will be designed according to condition of the patient."
45817449|NCT03061513|Drug|Ubiquinol|Ubiquinol caplets 600mg/day
45817450|NCT03061513|Dietary Supplement|Placebo|placebo
45817451|NCT03046472|Other|Physical Therapy treatment for Postural Behavior|"Physical Therapy treatment for Postural Behavior: intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day."
45817452|NCT03062605|Drug|Iodine (Betadine)|
45817453|NCT03062605|Biological|NaOCL|
45817454|NCT03062917|Diagnostic Test|Nasal and Bronchial Sampling|Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.
45663402|NCT05245539|Drug|CVL-231|CVL-231 is a brain penetrant mAChR activator that selectively binds to the M4 mAChR subtype while sparing other muscarinic receptor subtypes (M1, M2, M3, and M5). CVL-231 is being developed for treatment of psychosis in schizophrenia.
45817455|NCT03047174|Other|Mepitel® Film|Mepitel® Film is a gentle, sterile, transparent, breathable film dressing consisting of polyurethane film coated with a special contact layer. The film dressing is supported with a paper frame for ease of application. Mepitel® Film is an ultra thin, transparent, breathable soft silicone film dressing.
45817456|NCT03047174|Other|Standard Care|"Cream: Fatty cream with 2-5% urea is applied to the irradiated skin 3-4 times daily.~Mometasone furoate cream: In addition to the fatty cream with 2-5% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily."
45663403|NCT05244057|Drug|Hepalatide|4.2mg, s.c., qd for 48 weeks
45663404|NCT05244057|Drug|Placebo of Hepalatide|s.c., qd for 48 weeks
45663405|NCT05244057|Drug|Tenofovir Alafenamide Tablets|25mg, p.o., qd for 48 weeks
45817457|NCT02829307|Drug|89Zr-GSK3128349 1 mg|89Zr-GSK3128349 is a mixture of unlabelled and zirconium-labelled GSK3128349, in the form of solution for IV administration, and is associated with about 15 MBq of radioactivity.
45817458|NCT02985710|Device|Sudoscan|The Sudoscan is a non invasive procedure and similar to standing on a scale to be weighed. Sudoscan measurements are made in compliance with the manufacturer's recommended procedures. The measurement is rapid and non-invasive, and requires no advance preparation.
45817459|NCT02985710|Procedure|Skin biopsy|For subjects that give additional consent, skin biopsy will be done in standard fashion under sterile conditions. Assessment of nerve fiber density typically involves a 3-mm punch biopsy of skin from the leg (10 cm above the external malleolus).
45817460|NCT02985710|Procedure|QSART|QSRT (quantitative sudomotor axon reflex test) testing involves having a technician wipe the subject's arms and leg with alcohol, then tissue to wipe it dry. Electrodes filled with acetylcholine are put on three areas of the leg and one on the wrist, stimulators are turned on and sweat responses are measured.
45817461|NCT03063385|Behavioral|Parental Communication intervention|In this intervention, we focus on providing parents with basic knowledge about pregnancy, HIV/AIDS, and STDs as a basis for effectively communicating with their adolescents. We work to support attitudes and develop skills to facilitate communication in general and specifically sexual communication. Based on our prior work we focus on prevention beliefs, reaction beliefs, and communication efficacy. Importantly, we include a component on HIV/AIDS stigma as we conceptualize this to impact attitudes and communication about sex. We will program the intervention in such a way so that parents will have to view the Cuídalos program sequentially and in its totality before being able to review any content.
45817462|NCT03063385|Behavioral|Health promotion control condition|"In this intervention, we provide a web-based program relying on existing Spanish language web-sites to provide participants with helpful information to prevent significant health problems affecting Puerto Rican adolescents that are related, not to sexual behavior, but to other behaviors. Similar to the experimental condition, we will develop a set of homework related to diet and exercise that we will ask parents to complete with their adolescents."
45817463|NCT03050216|Biological|ALT-803|"Preparative Regimen:~Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4~ALT-803 Stimulated Donor NK Cells:~The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be stimulated by overnight incubation with 36.1 ng/mL ALT-803 under GMP conditions and infused on day 0.~ALT-803 to Facilitate NK Cell Survival and Expansion:~ALT-803 at 10 mcg/kg subcutaneously (SC) with the 1st dose administered on day 0 (no sooner than 4 hours post NK cells), day +5 and day +10 for 3 doses total"
45817464|NCT02931565|Drug|Olinciguat|oral tablet
45817465|NCT02931565|Drug|Matching Placebo|oral tablet
45817466|NCT02986958|Other|Pre-visit patient-family agenda-setting checklist|Pre-visit patient-family agenda-setting checklist
45817467|NCT02986958|Other|Usual care|routine primary care
45817468|NCT02829463|Radiation|Magnetic resonance imaging|3.0 T Magnetic resonance imaging of knee joints. It does not harm the subjects.
45663406|NCT05244057|Drug|Pegylated Interferon alfa 2a|90ug, s.c., qw for 48 weeks
45663407|NCT05241405|Dietary Supplement|QISENG|2 capsules/day for 8 weeks.
45663408|NCT05241405|Dietary Supplement|PLACEBO|2 capsules/day for 8 weeks.
45663409|NCT04840875|Biological|chimeric antigen receptor T cell treatment|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 3 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m2( body surface area) and cyclophosphamide 250 mg/m2( body surface area) for 3 days. Then this study will be using a 3+3 dose escalation approach from dose 1 (DL-1): 5×105 (±20%) to dose 2 (dl-2): 1×106 (±20%). Below the lowest dose was reinfused at the PI's discretion.
45817469|NCT03050294|Behavioral|Phone calls|Phone calls twice daily
45817470|NCT03050294|Drug|Desoximetasone 0.25% spray|Desoximetasone 0.25% spray applied twice daily
45817471|NCT02831569|Drug|Loxoprofen sodium|
45817472|NCT02831569|Drug|Methocarbamol|
45817473|NCT03050918|Behavioral|Follow-up Phone Call|Patients will receive a first call attempt within 72 hours discharge.
45817474|NCT03065179|Drug|Nivolumab/Ipilimumab|IV immunotherapy
45817475|NCT03065179|Radiation|SBRT|SBRT will be delivered in conjunction with immunotherapy
45817476|NCT02988050|Drug|Remifentanil|Remifentanil used for conscious sedation.
45817477|NCT02988050|Drug|Dexmedetomidine|Dexmedetomidine used for conscious sedation.
45817478|NCT02988050|Drug|Propofol|Used for conscious sedation.
45817479|NCT02988050|Drug|Bupivacaine|Local anaesthetics
45817480|NCT02988050|Drug|Lidocaine|Local anaesthetic
45817481|NCT02988050|Drug|Epinephrine|With local anaesthetic for skin infiltration.
45663410|NCT05408403|Other|Regional anesthesia TFPB|Transversalis Fascia Plane Block will be performed with 25 mL of 0.25% bupivacaine,after the end of cesarean surgery before extubation.
46078988|NCT02731170|Behavioral|MIRT|MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
45663411|NCT05408403|Other|Regional anesthesia QLB|Anterior Quadratus Lumborum Block will be performed with 25 mL of 0.25% bupivacaine, after the end of cesarean surgery before extubation.
45663412|NCT05620797|Other|Immediate loading of the implants|Patients of this group will be rehabilitated by implant-retained mandibular overdenture with immediate loading of the implants as opposed to conventional maxillary complete dentures.
45663413|NCT05620797|Other|Delayed loading of the implant|Patients of this group will be rehabilitated by implant retained mandibular overdenture with delayed loading of the implants (after 3 months) opposed by conventional maxillary complete dentures
45663414|NCT04916223|Other|Therapeutic massage|"The massage therapists were scheduled on a rotating schedule with two alternates scheduled for each day to ensure adherence to assigned study arm and to avoid therapist effect as much as possible. For each enrolled subject, the therapist assessed the subject and created a treatment plan depending on his/her individual needs and preferences. For example, if a subject reported bothersome lower extremity pain, the therapist might focus the massage on that lower extremity or might avoid massaging that lower extremity, depending solely on the preference of the subject. Massage duration was determined by the assigned study arm."
46078989|NCT04101123|Other|Non-Interventional|Non-Interventional
46078990|NCT01562977|Drug|Rituximab, Gemcitabine, Oxaliplatin, Dexametasone|until progression or unacceptable toxicity develops, 8 cicles max Rituximab: 375 mg/m2, IV, day 1. Gemcitabine: 1000 mg/m2, IV, day 2. Oxaliplatin: 100 mg/m2, IV, day 2. Dexametasone: 20 mg/day, days 1-3, oral.
45663415|NCT04830735|Drug|Dasatinib Anhydrous|Given PO
45663416|NCT04830735|Drug|Placebo Administration|Given PO
45663417|NCT04489095|Diagnostic Test|Electrophysiology Study|After informed consent is obtained, patient will undergo TAVR as per usual standard of care. Using the same femoral vein access as is used standard for a portion of the TAVR procedure, an EPS will be performed during the TAVR procedure, immediately before and after valve implantation. The patient will recover on a general telemetry floor as per usual care, and the next day will undergo another EPS. This is not uncommonly done clinically for some patients after TAVR. At that point, based on the baseline EKG, intra-procedure findings, and EPS findings, the patient will either have a pacemaker implanted, a 30-day event monitor ordered, or neither of the above.
45663418|NCT04840173|Behavioral|Music|During attendance at a one hour, 6-week psychosocial classroom or virtual training, caregivers will learn to use singing and other music-based interventions, implementing them each week before the informational session.
45663419|NCT05335317|Device|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50% overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm (total handpiece length of 10 centimeter (cm), 20 treatment points along vagina), from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 100 milliseconds (ms), pause between packets of 50 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
45817482|NCT03065647|Device|Expedited Transport With Mechanical CPR|Patients with OHCA refractory to initial BLS and ACLS will be transported by EMS with ongoing mechanical CPR and ACLS to an emergency department capable of initiating ECPR.
45817483|NCT02988986|Drug|TAK-228|MTORC1/2 inhibitor
45817484|NCT02988986|Drug|Tamoxifen|Non-steroidal anti-estrogen
45817485|NCT02832115|Drug|Topical Nitroglycerine|Topical nitroglycerine is applied to wrist prior to transradial cardiac catheterization to dilate radial artery and reduce spasm in study arm patients
45817486|NCT02832115|Drug|Topical Lidocaine|Topical Lidocaine is applied to wrist prior to transradial cardiac catheterization in both study and control arms
45817487|NCT02862080|Device|cathode tsDCS|Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.
45817488|NCT02862080|Device|Ekso|Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.
45817489|NCT02862080|Device|anode tsDCS|Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.
45817490|NCT00373945|Drug|Observational Study|
46078991|NCT05638646|Other|Intervention group|Practice standard for clinical diagnosis and treatment of chronic obstructive pulmonary disease
46078992|NCT05638646|Other|control group|Maintain current treatment
46078993|NCT00607685|Drug|5 Fluorouracil with hyaluronic acid|Participants will receive a subconjunctival injection of 0.1ml of a mixure of 5 Fluorouracil (50mg/ml) with hyaluronic acid (23mg/ml) once at enrollment into the study.
46078994|NCT00607685|Drug|5 Fluorouracil|Pariticpants will receive a subconjunctival injection of 0.1ml of 5 Fluorouracil 50mg/ml once at enrollment
46078995|NCT04101279|Procedure|surgical management of stress urinary incontinence with midurethral tension free tape.|Standard protocol for the surgical treatment of stress urinary incontinence using a transobturator approach.
46078996|NCT04101279|Procedure|surgical management of stress urinary incontinence with synthetic tape with tension control mechanism.|Standard protocol for the surgical treatment of stress urinary incontinence using a transobturator approach. A absorbing gasket attached to the middle of the tape provides tension control.
46078997|NCT05450718|Drug|buprenorphine-naloxone|Low-dose initiation of buprenorphine-naloxone protocol
46078998|NCT05450718|Drug|buprenorphine-naloxone|Standard clinical guidelines for a two-day buprenorphine-naloxone initiation
46078999|NCT04265183|Other|Placing preformed metal crowns using Hall technique.|Preformed metal crowns (3M™ ESPE™ STAINLESS STEEL CROWNS) were placed after using separation elastics (Dentalastics® separators, DENTAURUM). The crowns were cemented using is a self-curing, radiopaque, fluoride-releasing, resin-modified glass ionomer luting cement (Ketac™ Cem Plus Luting Cement, 3M™ ESPE™). The technique used to place the crowns was the Hall technique (technique without tooth preparation).
46079000|NCT04237298|Device|Modified vacuum-formed retainer covering the palete|The modified vacuum-formed retainer is made where it would cover the hard palate to the second molars. The only difference in constructing this modified VFR when compared to the normal VFR would be the outline which would be trimmed by the technician.
46079001|NCT04237298|Device|Hawley retainer|Standard retention regime for patients with arch expansion. Patients will be instructed to wear the retainer 24 hours during the study period.
45663420|NCT05335317|Drug|Topical hormone estriol|Estriol suppository ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Active ingredient of 0.5 milligram in 1 suppository. Daily dose will be 1 suppository.
45663421|NCT05335317|Diagnostic Test|Сlinical blood analysis|Taking blood from a vein for Clinical blood analysis (to include the participant in the study).
45817491|NCT03054506|Device|CSP01|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
45663422|NCT05335317|Diagnostic Test|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
45817492|NCT03054506|Device|Carboxymethylcellulose (CMC)|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
45817493|NCT03054506|Device|Placebo|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
45817494|NCT03068611|Behavioral|Standard Web-based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
45817495|NCT03068611|Behavioral|Alcohol-focused Web-Based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
45817496|NCT02864732|Other|Rehabilitation exercises|
45663423|NCT05335317|Diagnostic Test|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study), immunocytochemical examination and cytology (to evaluate procedure efficiency).
45663424|NCT05335317|Diagnostic Test|Cervical oncocytology test.|Cervical smear for oncocytology test (to include the participant in the study).
45817497|NCT02864732|Device|Electrical Stimulation|
45817498|NCT02835625|Radiation|Synthetic Mammography + Digital Breast Tomosynthesis|Two-view tomosynthesis performed with GE Senoclaire 3D Breast Tomosynthesis.
45817499|NCT02835625|Radiation|Digital mammography|Two-view digital mammography performed with GE Senoclaire 3D Breast Tomosynthesis.
45817500|NCT03071887|Behavioral|Relaxation Response Resiliency Program (3RP)|The 3RP blends stress management principles, cognitive behavioral therapy, and positive psychology. The 3RP focuses on 3 major areas: (1) eliciting the relaxation response; (2) increasing stress awareness; and (3) promoting adaptive strategies. The 3RP intervention currently consists of eight, 90-minute weekly group sessions. The investigators plan to adapt the intervention to address common concerns for older, HIV-infected women, including: stress of managing a chronic long-term, life threatening illness; additional medical comorbidities; pain and fatigue; stigma and social isolation; depression and anxiety; and sexuality concerns.
46079002|NCT02731014|Other|Dry Needling|Dry Needling targeting the posterior musculature of the cervical and thoracic spine.
46079003|NCT02731014|Other|Sham Dry Needling|Sham Dry Needling performed with Park sham acupuncture needles (Acuprime, UK) will be used to perform sham dry-needling. The device consists of 2 plastic tubes that slide into one another and cause a pricking sensation when pushed against the skin.
45817501|NCT02935699|Drug|Test Drug (JDP-205)|Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of ~2 minutes
46079004|NCT02731014|Other|Manual Therapy|Manual Therapy(mobilization/ manipulation) to address joint mobility of the cervical and thoracic spine.
46079005|NCT02731014|Other|Exercise|Exercise designed to improve performance of both the deep neck flexor musculature as well as the scapular musculature. The exercise portion will also include a stretching program targeting the cervicothoracic muscles which have been placed in a shortened position as a result of poor postures.
45663425|NCT05335317|Diagnostic Test|Extended colposcopy|Extended colposcopy is performed under a microscope using a Lugol to determine external changes in the epithelium in order to determine atrophy and pathologies of the cervix and vaginal vault (dysplasia, erosion, cancer, etc.) (to include the participant in the study).
45663426|NCT05335317|Diagnostic Test|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
45663427|NCT05335317|Other|King's Health Questionnaire|The King's Health Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
45663428|NCT05335317|Diagnostic Test|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. pH (potential of hydrogen) will be investigated by test-lines paper (to evaluate procedure efficiency).
46079006|NCT00925171|Behavioral|Pulmonary Intervention|Maintenance programme of 2 hours duration, every 3 months. During the first hour patients will describe the extent to which they have been able to continue with their exercises at home on an individual basis and ways of enhancing adherence to this training will be discussed. Positive re-enforcement will be provided. Patients with suspected depression or social isolation will be referred to their GP for additional management. Patients will be advised on dyspnoea management strategies, especially controlled breathing combined with supervised activity exertion on activities relevant to their daily living. This will be followed by 1 hour of supervised strength and endurance training including walking, cycling, standing from sitting, arm exercises using dumbbells and step-ups. Patients will receive a written report on their progress by their physician and copied to their GP. This will be in addition to the standard advice given to the control group.
46079007|NCT04265027|Drug|50 mg BIA 9 1067|Hard Capsule; Oral
45663429|NCT05335317|Diagnostic Test|Ultrasound investigation|Ultrasound investigation with General Electric Voluson E8 Expert for assessing blood vessels (Doppler sonography) and vaginal wall thickness measurement (to evaluate procedure efficiency).
45663430|NCT05335317|Diagnostic Test|Perineometry|Pressure force of vaginal walls measurement with IEASE device (to evaluate procedure efficiency).
45663431|NCT05335317|Diagnostic Test|Optical coherence tomography|Optical non-invasive method of investigation vaginal mucus morphological and functional condition.
45663432|NCT05335317|Diagnostic Test|Biopsy|Biopsy of the vaginal wall to assess the condition of the vaginal wall and compare the obtained data with the data of optical coherence tomography.
45663433|NCT05335317|Diagnostic Test|Femoflor screen|Femoflor screen for the study of vaginal microbiocenosis, specifically for the detection of the pathogens, opportunistic flora and normal flora and their qualitative and quantitative evaluation (to include the participant in the study).
45663434|NCT04829721|Other|Educational Intervention with video|Women randomized to an educational video workshop group.
45663435|NCT04829643|Diagnostic Test|PET/MRI|A consecutive cohort of 247 patients with early BC and no suspicious nodes at both clinical and A-US evaluations and candidates to upfront surgery and SNB will be recruited
45663436|NCT04840017|Other|rehabilitation exercise|Rehabilitation exercise of intrinsic foot muscles
45663437|NCT04419441|Drug|Immune checkpoint inhibitor|concomitant administration of radiotherapy and immune checkpoint inhibitor
45817502|NCT02935699|Drug|Active Control (Diphenhydramine)|Diphenhydramine Injection, 50 mg/mL;a single 1.0 mL injection via intravenous (IV) push over a period of ~2 minutes
45817503|NCT04333381|Other|Educational and organizational intervention|"Patients included after a systematic educational and organizational intervention for early diagnosis and care in myocardial infarction, aimed at emergency nurses of a tertiary Hospital capable in primary PCI.~The educational intervention will consist:~Systematized educational intervention on acute myocardial infarction for emergency triage nurses will consist of theoretical and practical training through case presentations and clinical simulation.~The organizational intervention will consist:~Development and dissemination of an early diagnostic tool for acute myocardial infarction: STEMI infographics. It will be provided to all emergency nurses and emergency triage boxes~Update the STEMI hospital protocol and adapt it to the current clinical guidelines of the European Society of Cardiology (ESC)~Review organizational strategies and definition of new improvement measures~Audit the delays in STEMI~Periodic multi-disciplinary update sessions"
45817504|NCT04333381|Other|Common Practice|Common practice is based on care by emergency nurses who did not receive any systematized education of acute myocardial infarction led by interventional cardiology nurses. On the other hand, emergency management is based on Plan-Do-Study-Act methodology and in the historical sample some organizational improvement strategies did not exist or were beginning to be implemented
45817505|NCT03073759|Device|dTCS|Direct current (DC) (maximum of 2 mA) stimulation delivered through surface electrodes. One electrode will be positioned above the left or right primary motor cortex, the other electrode over the forehead.
45817506|NCT03073759|Device|Sham device|The device will administer a sham.
45817507|NCT02936479|Drug|C1-INH (Berinert)|
45817508|NCT02841241|Drug|Esmolol|Esmolol infusion
45817509|NCT00374881|Drug|Morphine|Morphine
46079008|NCT04265027|Drug|25 mg BIA9 1067|Hard Capsule; Oral
46079009|NCT04265027|Drug|50 mg Ongentys|Hard Capsule; Oral
45663438|NCT04876365|Other|Non-Interventional|This is a Non-Interventional Study.
45663439|NCT05329779|Drug|brexanolone|Brexanolone is a derivative of allopregnanolone, which is FDA-approved to treat postpartum depression.
45817510|NCT00374881|Drug|Morphine|Morphine low dose
45817511|NCT00374881|Drug|Sorbitol+Phenylephrine|Sorbitol+Phenylephrine
45817512|NCT00374881|Drug|Sorbitol+Phenylephrine+Morphine|Sorbitol+Phenylephrine+Morphine
45817513|NCT00374881|Drug|Sorbitol low concentration+Phenylephrine+Morphine|Sorbitol low concentration+Phenylephrine+Morphine
45817514|NCT00374959|Drug|ceftriaxone|
45817515|NCT00374959|Device|Endotracheal tube for aspiration of subglottic secretions.|
45817516|NCT02865434|Drug|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
46079010|NCT04265027|Drug|25 mg Ongentys|Hard Capsule; Oral
45663440|NCT05329779|Drug|placebo|The placebo is a 0.45% sodium chloride infusion.
45663441|NCT04464759|Drug|Nivolumab|Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
45663442|NCT04464759|Drug|Hydroxychloroquine|Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
45663443|NCT04464759|Drug|Ipilimumab|Combination of nivolumab, hydroxychloroquine and ipilimumab
45663444|NCT04419753|Behavioral|attention focus walking training|Use different attention focus instructions or no attention focus instruction during walking training in older adults to examine whether the attention focus instructions can ameliorate conscious motor processing and optimize rehabilitation outcome measurements.
45663445|NCT04850937|Drug|Esketamine|The experimental group will be given 0.25mg/kg esketamine slowly intravenously after anesthesia induction
45663446|NCT04850937|Drug|normal saline|The experimental group will be given 0.5ml/kg normal saline intravenously after anesthesia induction
45663447|NCT04867317|Drug|Somatropin|Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.
46079011|NCT02814578|Other|Optical coherent tomography|comparative method for BVS
45663448|NCT04867317|Other|Placebo|Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.
45663449|NCT04850781|Behavioral|Bi-weekly frozen meal home delivery|All participants randomized to this arm will receive 10 frozen meals that are mailed to their home every two weeks from a MOW vendor, TRIO foods.
45817517|NCT02865434|Procedure|SPECT Imaging (60 Minutes post-injection)|Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 60 Minutes post-injection.
45817518|NCT02865434|Procedure|SPECT Imaging (180 Minutes post-injection)|Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 180 Minutes post-injection.
45817519|NCT02865434|Procedure|Whole body planar SPECT imaging (15 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 15 minutes post-injection for dosimetry.
45817520|NCT02865434|Procedure|Whole body planar SPECT imaging (60 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 60 minutes post-injection for dosimetry.
45817521|NCT02865434|Procedure|Whole body planar SPECT imaging (180 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 180 minutes post-injection for dosimetry.
45817522|NCT02865434|Procedure|Whole body planar SPECT imaging (18-20 Hours post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 18-20 Hours post-injection for dosimetry.
45817523|NCT02865434|Procedure|Blood Collection for PK Testing (15 Mins Before Injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis within 15 minutes prior to administration of Tc 99m tilmanocept
45817524|NCT02865434|Procedure|Blood Collection for PK Testing (after injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis immediately following administration of Tc 99m tilmanocept (00:00)
45817525|NCT02865434|Procedure|Blood Collection for PK Testing (15 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 15 ± 5 minutes post injection of Tc 99m tilmanocept
45817526|NCT02865434|Procedure|Blood Collection for PK Testing (60 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 60 ± 15 minutes post injection of Tc 99m tilmanocept
45817527|NCT02865434|Procedure|Blood Collection for PK Testing (180 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 180 ± 15 minutes post injection of Tc 99m tilmanocept
45817528|NCT02865434|Procedure|Blood Collection for PK Testing (18-20 hours post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 18-20 hours post injection of Tc 99m tilmanocept
45817529|NCT02865434|Procedure|Planar Image with both Hands in Field of View|Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.
45817530|NCT00375037|Behavioral|feedback|
45817531|NCT00375037|Behavioral|Education|
45817532|NCT00375037|Other|usual care|
45817533|NCT02841397|Device|Masimo Pulse CO-Oximeter|Noninvasive pulse oximeter with various features for measurement of hemoglobin, pleth variability index, and oxygen reserve index
46079012|NCT02814578|Other|IntraVascular UltraSound|The method of goldstandard for decision stent choice
46079013|NCT00636402|Procedure|Cold Knife Tonsillectomy|Cold Knife Tonsillectomy (CKT) will be done on the other side.
46079014|NCT00636402|Procedure|Vessel Sealing System Tonsillectomy|Intervention by Vessel Sealing System Tonsillectomy (VSST) will be randomized and will be performed on one side.
46079015|NCT00607763|Drug|Micafungin (Mycamine)|IV
46079016|NCT00928915|Drug|Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)|intravenous, repeated until INR ≤ 1.2
46079017|NCT02740296|Other|No intervention|
45817534|NCT02846233|Drug|GLP1 receptor agonist|"Albiglutide or Dulaglutide will be added to a basal insulin."
45663450|NCT04850781|Behavioral|Daily home meal delivery|All participants randomized to this arm will receive meals delivered to their home multiple times per week from a MOW program employee/volunteer with a wellness check and socialization.
45663451|NCT04851717|Drug|Remimazolam|Remimazolam for intravenous sedation
45957073|NCT02276989|Drug|acetazolamide|"On evening of Day 0, subjects will arrive at the session previously stabilized on buprenorphine and pregabalin. Pregabalin titration = 6 days prior to Day 0, during which time they will receive 100mg/day x 2 days, 200mg/day x2 days, and 300mg/day x 2 days, with the subjects receiving the full dose of 400mg/day beginning Day 0.~On Day 1, pregabalin PK measures will be collected.~On the mornings (8am) of Days 1 - 5, PGB compounded with the first tracer, ACZ will be administered.~On Day 5, subjects will again undergo PK testing on PGB + ACZ tracer.~On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.~On the mornings of Days 7-8 subjects will receive their PGB dose only."
45663452|NCT04464057|Dietary Supplement|early oral feeding or early enteral nurtrion|The patients in the experimental group were fed orally within 24-48 hours after intestinal anastomosis. Start taking it at 24-48 hours after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
45663453|NCT01638819|Biological|Autologous Cord Blood Stem Cells|One infusion of 60 ml syringe of study product
45663454|NCT01638819|Biological|Placebo|Saline
45454904|NCT04542460|Procedure|PCI|"A loop recorder is implanted i all patients in both study groups to investigate:~Prevalence and severity of cardiac arrhythmias.~Effect on detected arrhythmia, in particular ventricular tachyarrhythmia, of optimal medical therapy vs. coronary revascularization by PCI.~Prevalence and severity of cardiac arrhythmias in CTO-patients with failed PCI.~Indication for prophylactic ICD implantation in CTO-patients treated conservatively or by PCI and after failed PCI.~Relation of arrhythmias to angina pectoris symptoms (CCS class), Quality of life questionnaire results and presence of myocardial reversible perfusion defects by CMRI."
45663455|NCT04445805|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBTI)|Consists of 6 prenatal 60-min sessions and 6 monthly postnatal sessions on sleep education, sleep restriction, stimulus control, cognitive therapy, and relaxation. Treatment will be delivered via telemedicine.
45663456|NCT04445805|Behavioral|Perinatal-enhanced Behavioral Therapy for Insomnia|Consists of 6 prenatal 60-min sessions and 6 monthly postnatal sessions on sleep education, sleep restriction, stimulus control, and metacognitive exercises. Treatment will be delivered via telemedicine.
45663457|NCT04445805|Behavioral|Attention Control|Will include education on sleep, circadian rhythms, and good sleep hygiene in addition to self-monitoring with sleep diaries.
45663458|NCT04849143|Other|Stingless bee honey ( Kelulut honey)|"The honey will be acquired from Brainey Sdn Bhd, a company that provides stingless bee honey certified with Good Manufacturing Practice (GMP), ISO 22000, and Halal.~As the honey used is not medical-grade honey, sterilization with 25kGy gamma-ray irradiation will be done for safety purposes to eradicate any potential life-threatening infection such as spores from Clostridium botulinum."
45663459|NCT04849143|Other|Gel dressing|Smith-Nephew's Intrasite gel
45663460|NCT01363713|Drug|DE-114 ophthalmic solution|
45663461|NCT04414917|Drug|Twin block|Dental local anesthetic administered to target the jaw 'closer' muscles, temporalis and masseter
45817535|NCT02846233|Drug|basal insulin|The participant will continue with the basal insulin.
45817536|NCT02846233|Drug|SGLT2 inhibitor|"Empagliflozin will be added to a basal insulin."
45817537|NCT02846233|Drug|Metformin|The participant will continue with metformin.
45817538|NCT02865590|Device|sinus lift with Lyophilized Equine Bone Allograft (Bio-gen , Bioteck s.p.a., Arcugnano (VI) - Italy)|
45817539|NCT02865590|Device|Sinus lift with deproteinized bovine bone allograft (Endobon Xenograft Granules, Zimmer Biomet, San Donato Milanese (MI) - Italy)|
45957074|NCT02276989|Drug|Quinine|"On the morning of Days 8-11, subjects will be administered the same dose of PGB, now compounded with the QUIN.~On Day 11, PK testing of QUIN and PGB will be repeated.~On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected.~On Day 13 patients will be discharged with take-home doses of PGB that will taper to zero over the period of one week."
46079018|NCT02814500|Drug|DP-R212|Investigational product is prescribed to all of randomized subjects
46079019|NCT02814500|Drug|Amlodipine|Investigational product is prescribed to all of randomized subjects
46079020|NCT02814500|Drug|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
45817540|NCT02867150|Device|Ward Photonics Photonica Professional|"Active Device: Ward Photonics, Photonica Professional Red light therapy system~UltraSlim Cold Light® is the name of a patented treatment regimen using the Photonica Professional device for fat removal using LED red light therapy."
45817541|NCT03075085|Behavioral|WISE (We Inspire Smart Eating)|An enhanced implementation strategy for evidence-based obesity prevention in childcare
45817542|NCT02867618|Drug|Carfilzomib|Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202
45817543|NCT02867618|Drug|TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib
45663462|NCT04414917|Device|iPill dispenser|An active pill dispenser, regulated by patient's pain score entered on an iPill App installed on their smart phone (iPhone, Android) to dispense opioid (for pain corresponding to severe pain) or prescription strength ibuprofen and acetaminophen (for moderate pain), with over the counter solutions for mild pain recommended. This pill dispenser will be given to all patients, in both Twin block and Control groups, to regulate and monitor their pain experience-driven pain medication regimen. The pill dispenser will be packaged with pain medication (1 dispenser with vicodin, 1 with prescription ibuprofen, 1 with acetaminophen) that has been coencapsulated with ingestible event markers (IEMs, Proteus Discover).
45663463|NCT04411329|Drug|Bupivacaine|local anesthetics, steriod, alpha 2 blockers
45663464|NCT04411329|Drug|Dexamethasone|dexamethazone
45663465|NCT04411329|Drug|Dexmedetomidine|dexmedetomidine
45663466|NCT04411329|Drug|Hyalouridinase|hyalouridinase
45817544|NCT02868242|Drug|LDV/SOF|Tablet(s) administered orally once daily
45663467|NCT05171673|Drug|Licart™ (diclofenac epolamine) topical system|The Licart™ (diclofenac epolamine) topical system was designed to deliver the nonsteroidal anti-inflammatory drug (NSAID) diclofenac to the site of a minor soft tissue injury through topical application. This investigational product (IP) is a 10 cm x 14 cm topical system comprised of an adhesive material containing 1.3% diclofenac epolamine that is bound to a non-woven polyester felt backing and covered with a polypropylene film release liner. The release liner is removed prior to topical application to the skin.
45957075|NCT02276989|Drug|Riboflavin|"All subjects will receive riboflavin on the following days of the study:~On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.~On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected."
46079021|NCT05575908|Procedure|Digital expert team|A digital team will be appointed based on the participant's answers in the digital screening questionnaire. Members of the team can be specialists in Physical and rehabilitation medicine, psychologist, physiotherapist, social workers, and consultants in the labor- and welfare administration. The general practitioner will also be invited to the meeting.
46079022|NCT00939341|Drug|Symbicort (Budesonide/Formoterol)|Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms
46079023|NCT02814344|Device|Electrohysterography|
46079024|NCT00925327|Other|Corneal collagen cross-linking with riboflavin/UVA light|Corneal collagen cross-linking with riboflavin/UVA light
45663468|NCT04811937|Diagnostic Test|Computer-aided polypectomy decision support by Artificial Intelligence|The AI system will capture the live video of the procedure and the AI feedbackwill be shown on a second screen installed next to the regular endoscopy screen. Screen A will show the regular endoscopy image and screen B will show the regular endoscopy image together with the areas that might harbor a polyp and the information to help the polypectomy.
45663469|NCT05147415|Other|Placebo|Inactive comparator
46079025|NCT02740062|Device|NIBS system for evaluation and non invasive current stimulation|
45663470|NCT05147415|Drug|Tesomet|Fixed-dose combination
45663471|NCT04827069|Drug|Clifutinib Besylate|receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
45817545|NCT03075553|Other|Laboratory Biomarker Analysis|Correlative studies
45817546|NCT03075553|Biological|Nivolumab|Given IV
45817547|NCT03076333|Diagnostic Test|PET/MR|Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant radiation therapy per the direction of the radiation oncologist. At the end of the second week of radiation therapy the patient will undergo a mid-treatment PET/MR. The patient will the complete their radiation therapy. Four weeks after radiation therapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery at 6-8 weeks post radiation if they are still surgical candidates.
45663472|NCT04402125|Behavioral|TargEted MAnageMent Intervention (TEAM)|"TEAM targets acquisition of self-management expertise and use of healthy behaviors that are intended to reduce stroke risk and burden. TEAM participants will continue in their regular medical care, supplemented by the TEAM intervention. Components are as follows:~A 60 minute initial session in which the nurse and the PED meet with the patient who has experienced stroke or TIA. The initial session will cover introductions, orientation, and logistic planning.~Five 60-minute group sessions with 6-10 stroke survivors (and their care partners as applicable) held approximately 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 week after enrollment. Sessions are co-lead by a nurse and a PED.~Six brief telephone sessions implemented after the conclusion of the 5 TEAM group sessions. Calls will be conducted every 2 weeks for 12 weeks. Calls will reinforce group session content, provide social support and facilitate linkage with other care providers."
45663473|NCT04800315|Drug|CC-93538|Subcutaneous once weekly
45817548|NCT02869334|Device|Active Transcranial direct current stimulation (tDCS)|Active tDCS, where an extremely weak electric current passes through the brain
45663474|NCT04800315|Other|Placebo|Subcutaneous Every other week
45817549|NCT02869334|Device|Sham Transcranial direct current stimulation (tDCS)|Sham (inactive or placebo) tDCS
45957076|NCT00174759|Drug|Clopidogrel|
45957077|NCT00146198|Drug|ALGRX 4975|
46079026|NCT04237376|Drug|Tenofovir Alafenamide 25 MG|Tenofovir Alafenamide 25 mg, per oral daily was taken by CHB pregnant mothers with viral load ≥ 2 × 10^6 IU / mL from gestational week 28 to delivery of infant to prevent MTCT.
46079027|NCT04237376|Drug|Tenofovir Disoproxil Fumarate 300 MG Oral Tablet|Tenofovir Disoproxil Fumarate 300 mg, per oral daily was taken by CHB pregnant mothers with viral load ≥ 2 × 10^6 IU / mL from gestational week 28 to delivery of infant to prevent MTCT.
46079028|NCT02811380|Device|BIP CVC|BIP CVC catheterization to minimize risk of infections for venous access during and after elective large surgery
46079029|NCT02811380|Device|Uncoated Standard CVC|Standard CVC catheterization for venous access during and after elective large surgery
46079030|NCT02730702|Device|LEBS - Low coherence enhanced backscattering|Unprepped patients will have the LEBS probe brought into contact with the rectal mucosa, upon which 10 random readings will be obtained.
45663475|NCT04786743|Other|endoscopic intervention|performing endoscopy
45663476|NCT04390581|Device|Juvéderm® VOLIFT with Lidocaine|Consists of one injection of Juvéderm® VOLIFT with Lidocaine to both hands no more than 6ml for both hands total on Day 1. Optional on Day 30.
45663477|NCT01637961|Drug|Alisertib|Given PO
45663478|NCT01637961|Other|Laboratory Biomarker Analysis|Correlative studies
45817550|NCT02869334|Behavioral|Auditory Remediation|Computer program designed to improve discrimination between sounds
45957078|NCT02941978|Behavioral|Motivational interview|Patients assigned to the intervention group receive additional medical consultation aiming to boost optimal uptake of the anticoagulation regimen prescribed. Initially (i.e., at hospital discharge), this includes a physician-patient interactive session and provision of an educational leaflet. The leaflet is designed in a culturally and linguistically conceivable template in Greek language. It uses simple terms together with both written and pictorial materials. Patients in the intervention group will also undergo short telephonic sessions at 1 week, 2 months, 6 months and 12 months following hospital discharge
45817551|NCT02869334|Behavioral|Control computer activities|Computer program (e.g. games), which are not designed to improve discrimination between sounds
45957079|NCT02941978|Behavioral|Control|Patients assigned to the control group receive usual treatment, corresponding to standard practice and management of hospitalized patients with AF. For both patient-groups, the choice of OAC agent and any other background therapy is left to the discretion of the treating physician.
45957080|NCT02941042|Drug|NNC9204-1177|A single dose administered subcutaneously ( s.c. under the skin)
45957081|NCT02941042|Drug|Placebo|A single dose administered subcutaneously ( s.c. under the skin)
45454905|NCT01115725|Drug|Gonal-f® (follitropin alfa)|Gonal-f® (follitropin alfa) will be given once daily subcutaneously at a starting dose of 150-375 international unit per day (IU/day) by self-administered injection via a pen device for first 5 days. After Day 5, Gonal-f® dose will be adjusted according to the investigator's discretion until ovarian response observed.
45817552|NCT03077893|Device|Active Provant Therapy System|Treatment with active Provant Therapy System
45817553|NCT03077893|Device|Inactive (sham) Provant Therapy System|Treatment with Inactive (sham) Provant Therapy System
45817554|NCT03054740|Drug|Gebauer Ethyl Chloride|Will be administered according to manufacturers recommendations which is to spray the aerosol can for 4-10 seconds from a distance of 3 to 9 inches. Do not spray longer than 10 seconds.
45817555|NCT03054740|Drug|Nature's Tears|Sterile water mist will be administered 1-2 sprays prior to intravenous access
45817556|NCT02997722|Drug|Ketamine|IV infusion of ketamine 0.5 mg/kg administered over 45 minutes.
45817557|NCT02997722|Drug|Normal Saline|IV infusion of 100 ml of normal saline over 45 minutes.
45817558|NCT03078127|Other|Baseline (Huff-Cough alone)|"Subjects will provide two huffs (forced expiratory maneuver with open glottis) followed by a cough every six minutes for a total of six Huff-Coughs."
45817559|NCT03078127|Device|Oscillatory Positive Expiatory Pressure Device|Subjects will use an Areobika® branded OPEP device (10 breaths through highest tolerated resistance) prior to undergoing a Huff-Cough. Subjects will use the device six times every six minutes.
45957082|NCT00146237|Drug|phenytoin|
45957083|NCT02963727|Biological|Wharton Jelly derived mesenchymal stem cell|Intra-articular Wharton Jelly derived mesenchymal stem cell injection.
45957084|NCT02277067|Drug|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
45957085|NCT02277067|Drug|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
45663479|NCT05114577|Behavioral|Recovery Sleepers program.|Attend two, 90-minute remote discussion groups (~10 other participants and 2 study team members) via Zoom. During these groups, participants will receive educational materials about how to improve sleep. They will also discuss sleep and sleep-related behaviors, including how active substance use and recovery may have changed sleep, with a small group of other participants.
45663480|NCT05114577|Behavioral|Email recommendations|Receive recommendations (via email) to help improve sleep
45663481|NCT05114265|Drug|KUR-101|Single oral dose of KUR-101
45957086|NCT02940964|Behavioral|Count on me Singapore (COMS) CPR|Using the song as a mental metronome to guide CPR.
45663482|NCT05114265|Drug|OxyNorm|Single oral dose of OxyNorm
45663483|NCT05114265|Drug|Placebo|Single oral dose of placebo
45663484|NCT04772157|Diagnostic Test|Cardiac Troponin Testing|Lithium heparin whole blood and plasma samples will be measured with Siemens POC High Sensitivity Troponin-I Test System.
45663485|NCT05399121|Behavioral|Piano Learning then Free Improvisation|"During all 29 sessions (one session per patient) all patients will be asked to perform two piano playing exercises:~Exercise 1 - Piano Learning exercise - The music therapist will guide the patient to use separate finger movement and to play a brief extract from a familiar song. The therapist guiding techniques may include (but not restricted to) demonstrating to the patient which keys to press (turn- taking), playing the same notes with them in synchronization, or harmonizing the patient's playing.~The patient will then be asked to perform exercise 2. Exercise 2: Free Improvisation exercise -The patient will be instructed to use separate finger movement while playing freely on the piano while the therapist musically. The therapist will use various MT accompaniment techniques.~Both exercises will be performed for the same amount of time (5 minutes each)."
45957087|NCT02940964|Behavioral|Standard CPR|"Standard CPR with one-and-two-and-three.... counting"
45957088|NCT05204251|Behavioral|Questionnaire|Quality of Life assessed with the SF-36 questionnaire
45957089|NCT00146276|Drug|gemcitabine|
45957090|NCT00174798|Drug|SSR240600C|once daily
45663486|NCT05399121|Behavioral|Free Improvisation then Piano Learning|"During all 29 sessions (one session per patient) all patients will be asked to perform two piano playing exercises:~Exercise 1: Free Improvisation exercise -The patient will be instructed to use separate finger movement while playing freely on the piano while the therapist musically interacts with them. The therapist will use various MT accompaniment techniques.~The patient will then be asked to perform exercise 2. Exercise 2 - Piano Learning exercise - The music therapist will guide the patient to use separate finger movement and to play a brief extract from a familiar song. The therapist guiding techniques may include (but not restricted to) demonstrating to the patient which keys to press (turn- taking), playing the same notes with them in synchronization, or harmonizing the patient's playing.~Both exercises will be performed for the same amount of time (5 minutes each)."
45663487|NCT04357353|Drug|Platelet rich plasma|PRP will be used in the experimental arm.
45663488|NCT04357353|Drug|Placebo Sham Injection|sham injection
46079031|NCT04264793|Behavioral|Behavioral Lifestyle Intervention|In addition to usual care in the health center, the intervention included 7 visits with the health center dietitian for individual nutrition counseling, invitation for group nutrition education (5 sessions), individual counseling for physical activity, invitation for a 6-weekly structured group physical activity, DVD on physical activity to perform physical activity at home.
45817560|NCT03078127|Device|Whole-Body Vibration Platform|Subjects will be seated on a PowerPlate® whole-body vibration platform for 90 seconds prior to Huff-Cough. Six intervals on the platform will be completed six minutes apart.
45817561|NCT03078127|Device|High Frequency Chest Wall Oscillatory Vest|"Subjects will use TheVest® using a standardized Minnesota Protocol divided into six, four-minute segments, each followed by a Huff-Cough."
45454906|NCT03526744|Dietary Supplement|marine protein hydrolysate 1234|"Dietary Supplement for e.g. in this order: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out."
45454907|NCT03526744|Dietary Supplement|marine protein hydrolysate 2134|"Dietary Supplement for e.g. in this order: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 1600 mg for 7 days, than 7 days wash-out."
45663489|NCT04826211|Diagnostic Test|PET/MRI|All included patients will undergo PET/MRI both prior to PST and prior to surgery. In order to analyze results the population will be divided into two groups: women with positive axillary lymph nodes after PST (Group 1) and women with negative axillary lymph nodes after PST (Group 2).
45957091|NCT00174798|Drug|Placebo|oral
45957092|NCT00174798|Drug|Tolterodine|once daily
45663490|NCT04312113|Drug|Adipose derived, autologous mesenchymal stem cells|Fat tissue will be enzymatically treated and cells will be cultured until a sufficient number are obtained for the treatment protocol.
45663491|NCT04419051|Other|Owlet Band|The Owlet Band is a wearable fabric band pregnancy tracker made up of small sensors that are able to detect natural low-level electrical signals normally produced by the mother's heart and baby's (fetal) heart.
45663492|NCT05396859|Drug|Decitabine and Cedazuridine|Given PO
45663493|NCT05396859|Drug|Entrectinib|Given PO
45663494|NCT05396859|Other|Laboratory Biomarker Analysis|Correlative studies
45663495|NCT04277715|Behavioral|Parent training|Parents will learn evidence-based techniques for increasing support and decreasing accommodation of children's chronic symptoms.
45663496|NCT04183335|Drug|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
45663497|NCT04183335|Drug|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
45817562|NCT03056144|Device|whole body vibration therapy|"The whole body vibration therapy regime is as follows:~Day Vibration 1 Rest 1 Vibration 2 Rest 2 Vibration 3 Rest 3~st 1 min;12Hz 3 min 1 min;12Hz 3 min 1 min;15Hz 3 min~nd 1 min;15Hz 3 min 1 min;15Hz 3 min 2 min;15Hz 3 min~th 2 min;15Hz 3 min 3 min;15Hz 3 min 3 min;15Hz 3 min~th 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min >5th 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min~The participants will perform mini-squats during Vibrations 1 and 3 and weight-shifting between right and left legs during Vibration 2 on the vibration platform under the supervision of a trained research assistant."
45817563|NCT02943499|Behavioral|App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
45663498|NCT04183335|Drug|Moisturizers|"Pharmaceutical form:~Route of administration: Topical"
45957093|NCT05200975|Diagnostic Test|Venapunction|Three venapunctures within a period of 72 hours, containing a maximum of 18ml of venous blood in total.
45957094|NCT00146315|Behavioral|Supervised exercise on a stationary bicycle, 3-5 days a week|Supervised exercise on a stationary bicycle, 3-5 days a week, plus a secondary prevention program for coronary heart disease
45957095|NCT00146315|Behavioral|Secondary prevention program for coronary heart disease|Secondary prevention program for coronary heart disease
45957096|NCT05187520|Device|Patient-controlled epidural analgesia (PCEA)|Epidural analgesia is a technique of neuraxial block by placement of a 20G polyether epidural catheter into the epidural lumen and fixed at the desired depth, and analgesic effect is usually achieved by administration of mixture of local anesthetics and opioids using a programmed pump.
45957097|NCT05187520|Drug|Naldebain®|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
45663499|NCT04183335|Drug|Low to medium potent topical corticosteroids|"Pharmaceutical form:~Route of administration: Topical"
45957098|NCT02940808|Dietary Supplement|Caffeine (200mg)|Oral consumption of capsule containing 200mg caffeine.
45957099|NCT02940808|Other|Placebo|Oral consumption of capsule containing a placebo substance.
45663500|NCT04183335|Drug|Topical calcineurin inhibitors|"Pharmaceutical form:~Route of administration: Topical"
45663501|NCT04254549|Drug|Rifaximin|550 mg by mouth three times daily for 14 days
45663502|NCT04254549|Drug|Placebo|By mouth three times daily for 14 days
45663503|NCT04419363|Drug|Burosumab Injection|Children affected with X-linked hypophosphatemia were switched from conventional therapy to burosumab
45957100|NCT00169416|Drug|valaciclovir HCl granules|
45957101|NCT00146354|Behavioral|Hospitalists Results Manager|
45957102|NCT04691284|Other|Blood, urine and stool sampling|Sampling of blood and urine for miR and chemokine detection. Sampling of stool for for microbiome studies.
45957103|NCT02940847|Procedure|medial brachial cutaneous nerve block and intercostobrachial nerve block with blind technique|It consists in performing a subcutaneous injection of the local anesthetic at the root of the arm, in the anterior-posterior direction.
45957104|NCT02940847|Procedure|medial brachial cutaneous nerve block and intercostobrachial nerve block with ultrasound-guided technique|Ultrasounds are used to visualize the anatomical variations, the good position of the needle and the good local anesthetic diffusion.
45957105|NCT02941003|Device|microscope|Detection of of histopathological characteristics of OCT treatment or OCT free samples from patients .
45957106|NCT02941003|Other|immunostaining|Detection of CD31/CD34, D2-40, Ki67 and p53 immunostaining of OCT treatment or OCT free samples from patients .
45957107|NCT02941003|Device|NGS|The investigators used the device to detect the gene mutations of OCT treatment or OCT free samples obtained from part of the patients.
45957108|NCT00146393|Behavioral|People with Arthritis Can Exercise program|
46079032|NCT04264793|Behavioral|Usual Care|Patients received usual care including education as part of the diabetes management from their healthcare professionals (physicians and nurses), normally every 2-3 months. Visits with the health center dietitian were arranged as per physician referral.
46079033|NCT02735226|Other|stroke network and policy intervention|Shanghai stroke service and network contributes to update the ability of stroke care of comprehensive and primary stroke center,to improve radiation ability of comprehensive stroke centers and try to form a close relationship between comprehensive stroke centers and its primary stroke centers.
46079034|NCT00607841|Drug|Ispinesib|10 mg/m2 dose as a 1-hour intravenous infusion.
46079035|NCT00607841|Drug|Ispinesib|12 mg/m2 dose as a 1-hour intravenous infusion.
46079036|NCT00607841|Drug|Ispinesib|14 mg/m2 dose as a 1-hour intravenous infusion.
46079037|NCT04015687|Drug|AG-881|Supplied as uncoated tablets.
45663504|NCT04825431|Drug|TAS-205, [14C]TAS-205|single oral administration under fasted conditions on day 1
46079038|NCT04015687|Drug|Lamotrigine|Supplied as tablets of LAMICTAL® or generic equivalent.
46079039|NCT02811068|Other|venepuncture|single venepuncture
46079040|NCT04264715|Device|405nm light|In this room, surgeries will be performed under ambient light including the wavelength 405nm
46079041|NCT02739906|Drug|BioChaperone Human Insulin (HinsBet®)|BioChaperone Human Insulin (HinsBet®) individualised single subcutaneous injection followed by test meal intake
45454908|NCT03526744|Dietary Supplement|marine protein hydrolysate 3124|"Dietary Supplement for e.g. in this order: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out."
46079042|NCT02739906|Drug|Insulin Lispro (Humalog®)|Insulin Lispro (Humalog®) individualised single subcutaneous injection followed by test meal intake
46079043|NCT02739906|Drug|Regular human insulin (Huminsulin® Normal)|Regular human insulin (Huminsulin® Normal) individualised single subcutaneous injection followed by test meal intake
46079044|NCT02810912|Other|the effect of surgical position|Investigators do not have intervention in the observation study. Investigators only use the MII-pH catheter to observe the episodes of gastric regurgitation in patients receiving supraglottic airway device under general anesthesia. Thus, investigators are going to observe the effect of surgical position change, body weight, surgical time. And investigators will have a control group, which patients undergo elective surgeries without surgical position change, no longer surgical time, and normal range of body weight.
45817564|NCT02943499|Behavioral|App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
45454909|NCT03526744|Dietary Supplement|marine protein hydrolysate 4123|"Dietary Supplement for e.g. in this order: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out."
45454910|NCT01122199|Drug|RAD001 + AMG479|Escalating doses of RAD001 + AMG479. Starting cohort will be 5 mg RAD001 once daily, continuous + AMG479 12 mg/kg on Day 1 and 15 of each 28 day cycle.
45663505|NCT04241679|Device|Auditory Nerve Test System|"The Auditory Nerve Test System provides an electrically-evoked signal from within the cochlea to facilitate intraoperative auditory nerve monitoring. The auditory nerve can be measured both at the root entry zone of the brainstem (eCNAP) and with scalp electrodes (eABR). Data on the health of the auditory nerve will be collected immediately prior to tumor dissection, during tumor dissection, and immediately after tumor dissection. The main purpose of this study is to determine feasibility of this novel intraoperative monitoring protocol.~Secondarily, if the auditory nerve is visually confirmed to be intact following tumor resection then the patients will receive a cochlear implant during the same surgery."
45817565|NCT02943499|Device|Smartphone|
45817566|NCT03000608|Drug|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
45817567|NCT03000608|Drug|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
46079045|NCT00607451|Drug|Neu-120|Capsules of 300, 900 and 2700mg; administered as a single dose with a one week washout between each administration.
46079046|NCT00925405|Procedure|Breast MRI|Magnetic resonance imaging (MRI) scans of the breasts once per year
46079047|NCT00925405|Procedure|Mammogram|Breast x-ray used to detect breast cancer and look for abnormalities in the breast.
45817568|NCT02847169|Device|filcon IV1 toric lens|toric contact lens
46079048|NCT02739672|Drug|TAH Tablet (Telmisartan/Amlodipine besylate/Hydrochlorothiazide)|Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 25 mg combination-drug would be administered orally once
45817569|NCT02847169|Device|ocufilcon D toric lens|toric contact lens
45663506|NCT04225767|Combination Product|Calcium electroporation|Patients with cutaneous or subcutaneous malignant tumours will be treated with calcium electroporation, i.e. intratumoral injection of calcium followed by electroporation by electric pulses applied directly to the tumor.
45663507|NCT04212273|Diagnostic Test|Diagnostic Sonazoid-CEUS and EOB-MRI|Undergo Sonazoid-CEUS and EOB-MRI
45676818|NCT01848483|Other|Standard of Care (SOC)|The routine standard of care provider visit occurs in the following order. The vital signs are taken and the participant sees the nurse to review medications. The provider visits are scheduled for approximately 30 minutes, except for a new patient or patient with complex medical needs. The provider conducts a history to elicit symptoms, health problems, concerns, and a physical exam, then orders labs or immunizations; and referrals to subspecialty clinics. Medications are prescribed or renewed. The patient then receives a follow-up appointment, typically every 3 months for a stable patient. If the patient starts Antiretroviral therapy (ART), an appointment to the nurse educator is required. Typically, the patient will have 1- 2 visits to the nurse educator to begin medications and follow-up for side-effects.
45817570|NCT00374582|Device|Bodystat Quadscan 4000|device determining body composition and nutritional status
45817571|NCT00374582|Device|bodystat quadscan 400|device determining body composition and nutritional status
45817572|NCT03108482|Drug|Co-crystal E-58425 (Tramadol/Celecoxib)|Co-crystal E-58425 (Tramadol/Celecoxib): Two immediate release oral over-encapsulated tablets of 100 mg, every 12 hours for 48 hours.
45817573|NCT03108482|Drug|Tramadol (Ultram®)|Tramadol: One immediate release oral over-encapsulated tablet of 50 mg, every 6 hours for 48 hours.
45817574|NCT03108482|Drug|Celecoxib (Celebrex®)|Celecoxib: One immediate release oral over-encapsulated capsule of 100 mg, every 12 hours for 48 hours.
45817575|NCT03108482|Drug|Placebo|Placebo 100 mg or 200 mg oral over-encapsulated tablets every 6 hours for 48 hours.
45817576|NCT03079375|Other|basic intervention|medication review
45817577|NCT03079375|Other|extended intervention|medication review, medication interview before discharge and follow-up
45817578|NCT02871128|Dietary Supplement|Natureheme-iron|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
45817579|NCT02871128|Dietary Supplement|Placebo|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg starch placebo of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
45817580|NCT02871128|Drug|supplement|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 1 capsule per day containing either 100 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
45817581|NCT02850601|Drug|Dexamethasone|Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate
45817582|NCT02871440|Drug|Omega 3|
45817583|NCT02871440|Drug|Optive Advanced|
45817584|NCT02871440|Drug|Optive|
45817585|NCT03079531|Drug|Secukinumab|Secukinumab 300 mg administered subcutaneously.
45817586|NCT03056456|Drug|LY900014|Administered subcutaneously (SC)
45817587|NCT03056456|Drug|Insulin Lispro (Humalog)|Administered SC
45817588|NCT03057704|Drug|Lidocaine injection flushed|The investigator administers IV lidocaine and flushes it into the subject prior to administering propofol.
45817589|NCT03057704|Drug|Lidocaine injection tourniquet|Intravenous lidocaine: tourniquet
45817590|NCT02874092|Drug|Ticagrelor|
45817591|NCT02874092|Drug|MTX therapy|
45817592|NCT02874404|Drug|Ibrutinib|Given PO
45817593|NCT02874404|Other|Laboratory Biomarker Analysis|Correlative markers
45817594|NCT02874404|Drug|PI3K-delta Inhibitor TGR-1202|Given PO
45957109|NCT02963805|Behavioral|High intensity physical activity (HIPA)|This arm consisted of a twice-weekly after-school club at the intervention school for 26 weeks during school term time, delivered by qualified coaches. Each 60 minute session engaged participants in high-intensity vigorous activity using a combination of playground-style games and circuit training activities that aimed to keep children moving and maintain a mean heart rate above 70% of age-predicted maximum heart rate (~145 beats/min) for the session duration. Intensity was verified by heart rate monitoring. Coaches delivered and monitored sessions and increased the intensity over time to allow for the children to progress. The mean heart rate for HIPA sessions was 150 beats/min, with children spending 52 min at this intensity during the session.
46079049|NCT02739672|Drug|TWYNSTA(Telmisartan+Amlodipine besylate)|TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
46079050|NCT02739672|Drug|Hydrochlorothiazide|Dichlozid 1 Tab.(Hydrochlorothiazide 25.0 mg) would be administered orally once
46079051|NCT02810678|Other|Latent Tuberculosis Infection program evaluation & diagnosis|
45817595|NCT03059810|Device|etafilcon A|Investigational Contact Lens
45817596|NCT02876900|Drug|Low Dose Asenapine maleate transdermal patch|The study will evaluate low dose Asenapine maleate transdermal patch
45663508|NCT04824183|Other|Music intervention|Three WhatsApp sessions will be delivered before the surgery. In the first session, participants will describe their experience with the diagnosis of breast cancer and acceptance. In the second session, participants will be educated on anxiety before their surgery, how anxiety is being managed in the hospital and self-care strategies for anxiety like MI, how to report preoperative anxiety. The third session will include postoperative pain education. The pain education will include information about the type of pain to expect after surgery, medications, pain reporting and MI for pain management. Telephone session; on the day of surgery and at 24 and 48 hours after surgery, a reminder will be sent to the participants by WhatsApp group chat. Face-to-face; MI delivery will involve the delivery of the MP3 to participants and monitoring of their use for 30 minutes both on the day of surgery and 24 and 48 hours after surgery.
45957110|NCT02963805|Behavioral|Fundamental movement skill (FMS)|This arm consisted of a twice-weekly after-school club at the intervention school for 26 weeks during school term time, delivered by qualified coaches. Each 60 minute session focused on improving two skills from the vertical jump, hop, sprint run, dodge, kick, catch, overarm throw, and strike. All skills were taught in equal quantities. Each session was designed to maximise participation and enjoyment, and consisted of various games, drills, self-learning activities, and offered numerous opportunities for practice. Skill components were taught to the children using simple learning cues, and skill related questions were used to develop purposeful feedback. The mean heart rate for FMS sessions was recorded at 141 beats/min, with children spending 55 min at this intensity during the session.
46079052|NCT04263155|Behavioral|The Body Project|The Body Project is a 4-hour dissonance-based program designed to address body image concerns and prevent eating disorders. The curriculum consists of written, verbal, and behavioral exercises that provide participants with the opportunity to voluntarily and publicly critique the appearance ideal.
45454911|NCT01118923|Dietary Supplement|Magnesium supplement (magnesium hydroxide/ -oxide)|3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
45454912|NCT01118923|Dietary Supplement|Placebo|3 placebo-tablets daily for 12 weeks
45454913|NCT05441956|Drug|TGRX-326|Participants are given TGRX-326 tablets orally at one of the dose levels as pre-determined.
45454914|NCT01119079|Other|Normal Saline|10ml Normal Saline instilled in the epidural space
45454915|NCT01119079|Procedure|Administration of epidural anesthesia for labor|Standard procedure
45454916|NCT04503616|Drug|Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention|Cyclophosphamide 50 mg/kg IV over 2 hours on Day +3 and +4 Abatacept 10 mg/kg IV on days +5, +14, and +28 Tacrolimus 0.02 mg/kg IV by continuous infusion, starting on day +5. May switch to oral when tolerated, adjusted to maintain a drug level between 5-12ng/mL. Treatment is discontinued on day +60 after a 4 week-taper
45454917|NCT01119157|Biological|influenza vaccine|whole virus influenza vaccine adjuvanted with aluminium phosphate, 3 x 15 μg HA / 0.5 ml, for i.m. administration subunit influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration split influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration
45454918|NCT05036668|Biological|Cryptosporidium parvum oocysts (ABO809)|ABO809 3x10^6 CE/3mL concentrate for oral suspension, single dose at Day 1
45454919|NCT01119235|Drug|PF-04531083|Dosed as a tablet in 100mg strengths. Dosage in the first cohort will be 300mg twice daily for 3 days followed by 200mg twice daily for 11 days
45454920|NCT01119235|Drug|PF-04531083|Dosed as a tablet in 100mg strengths. Dosage in this optional second cohort will be optimised based on the data arising from Cohort 1
46079053|NCT00925483|Procedure|dialysis|different dialysis schedules for each arm
46079054|NCT05169047|Other|Best Medical Treatment|For each patient who is randomized to BMT, an optimal individual treatment plan will be developed by the treating physician.
46079055|NCT05169047|Other|Subthreshold Spinal Cord Stimulation|SCS will be programmed at subthreshold stimulation.
45454921|NCT04482556|Device|Q-NRG+ Indirect Calorimetry Device|The two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first.
46079056|NCT02810834|Behavioral|Walking/Running program|"Participants will receive a behavioral intervention that consists of a school-based, walking/running/jogging program. Participants work to accumulate miles towards a goal of at least 100 miles, over the course of the school year. Program will be implemented through a champion in the school and structured/scheduled according to the schools resources (before, during, or after school). Miles are tracked at the school level, and incentives are provided for participants' completion of set milestones (25, 50, 75, and 100 miles).~The intervention will run over two school years (approximately 16 months)"
45454922|NCT04482556|Device|V(max) Encore Indirect Calorimetry Device|The two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first.
45454923|NCT01119313|Drug|LAS 41002|LAS 41002, once daily
45454924|NCT01119313|Drug|Active|Active, once daily
45663509|NCT04199793|Device|Lavare On|"For the patients randomized to Lavare On group, the Lavare™ cycle will be turned on upon device interrogation after patients return to intensive care unit from the operating room."
45663510|NCT04199793|Device|Lavare Off|"For the patients randomized to Lavare Off group, the Lavare™ cycle will be turned off upon device interrogation after patients return to intensive care unit from the operating room."
45817597|NCT02876900|Drug|High Dose Asenapine maleate transdermal patch|The study will evaluate high dose Asenapine maleate transdermal patch
45454925|NCT01119391|Behavioral|There was no intervention; this was a survey only study|There was no intervention; this was a survey only study
45663511|NCT04823871|Procedure|Speiser-catheter for uterine and tubal lavage|Procedure/Surgery: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
45817598|NCT02876900|Drug|Placebo|The study will evaluate placebo transdermal patch.
45817599|NCT03063476|Drug|C-13 labeled Lysine|Carbon-13 is a stable naturally occurring heavy isotope of carbon. Inclusion of a 13C label on lysine allows for subsequent differentiation between endogenous and exogenous lysine and 2-AAA for calculation of clearance and excretion of the lysine bolus.
46079057|NCT02810834|Behavioral|Classroom physical activity break program|"Participants will receive a behavioral intervention that consists of a classroom-based, physical activity break program. Classroom teachers, paraprofessionals, and other school staff will lead short (5-15 minute) activity breaks that include both higher intensity (ex. jumping jacks, squats) and low-intensity (ex. stretching, yoga) activities. Classrooms will be encouraged to integrate at least one short break per day. Activities are connected to national Common Core academic standards so that breaks can be integrated with academics.~The intervention will run over two school years (approximately 16 months)"
46079058|NCT00932971|Drug|PEG-IFN alfa-2a, Tenofovir|Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Tenofovir disoproxilfumarat, 245mg, once daily, orally
46079059|NCT00932971|Drug|PEG-IFN alfa-2a, placebo|Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Placebo, once daily, orally
45817600|NCT03063476|Drug|Normal saline|Because patients will have multiple blood draws during the course of the study, subjects will have an IV placed to reduce the number of needle sticks. To keep the vein open for blood collections, we will infuse Normal (0.9%) Saline (NS) at a rate of approximately 10ml/hr in order to keep the line open.
45817601|NCT02878382|Other|Conventional MAL-PDT|Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
46079060|NCT05382143|Drug|Atosiban|Pilot study
46079061|NCT02810600|Other|Gallium-68 DOTA TATE PET scan|One PET/CT scan using Gallium-68 DOTA TATE
46079062|NCT00933049|Drug|Amoxicillin|Oral amoxicillin (25mg/kg/dose)for 5 days
46079063|NCT00933049|Drug|Cotrimoxazole|Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole)
46079064|NCT00933049|Drug|Amoxicillin placebo|
46079065|NCT00933049|Drug|Cotrimoxazole placebo|
46079066|NCT02810756|Drug|New Pazopanib formulation|
46079067|NCT05381987|Device|Radial shockwave therapy|Shockwave Storz Medical device, Doulith SD1, Tower (BT)
46079068|NCT03418272|Diagnostic Test|Culture/PCR Analysis|"Microbes to be selectively cultured and PCR analysis to be conducted. Bacteria obtained in samples will be dispersed in non-selective Mueller Hinton Broth (Sigma-Aldrich), divided into two separate cultures and grown overnight at 37°C in aerobic condition and in 5% CO2 to assure survival of both aerobic and facultative anaerobic species.~Staphylococcus aureus (MSSA, MRSA)~Pseudomonas aeruginosa~Haemophilus influenza~Streptococcus pneumonia~Streptococcus Pyogenes Group B streptococci,~Klebsiella pneumonia~Moraxella catarrhalis"
45957111|NCT02963805|Behavioral|Physical activity signposting (PASS)|A researcher visited participants once per week in 6 weekly blocks to set an activity mission to complete outside school with family and friends. Twenty missions were set over 4 x 6 week blocks, each separated by a 6 week break. Each mission suggests a task as a prompt to participate in physical activity and decrease sedentariness during the week. Children received a sticker on a wall chart for returning the mission; children were rewarded with prizes if all missions were returned in each block. If all missions were returned in a block, a reward was given. 58% of children returned all twenty missions. In addition to the missions, pedometers were issued as a promotional tool for the duration of the project for self-monitoring of activity.
45663512|NCT04821453|Device|NAVA|NAVA mode of mechanical ventilation provide the trigger for a spontaneous breath from the diaphragmatic movement instead of diaphragm and allows the patient to control the dynamics of the breath generally set in CMV mode.
45957112|NCT02941081|Dietary Supplement|IHAT|1 dose/day single IMP containing IHAT powder bioequivalent to 12.5 mg Fe (i.e. 20 mg Fe taking into account IHAT's relative bioavailability to FeSO4)
45957113|NCT02941081|Dietary Supplement|Ferrous Sulphate|1 dose/day single IMP containing FeSO4 powder equivalent to 12.5 mg Fe
45957114|NCT02941081|Other|Placebo|1 dose/day containing a placebo powder (no-iron, 'sugar' compound)
45957115|NCT02940613|Behavioral|Visual feedback of symptom frequency|Participants receive visual feedback of their symptom frequency over the first 4 weeks of active treatment, based on information they provide on a symptom checklist.
45817602|NCT02878382|Other|Calcipotriol assisted MAL-PDT|Calcipotriol 50 mcg/g for 15 days prior to PDT. Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
45663513|NCT04821453|Device|CMV|CMV mode of mechanical ventilation that provides a trigger for a spontaneous breath from the airway flow sensor with dynamics of the breath set as required by the mode
45663514|NCT04820985|Other|Vaginal swab|Vaginal flora swab 3 months before stimulation, at oocyte puncture, embryo transfer and beta-human chorionic gonadotropin dosing
45663515|NCT04820985|Other|Blood test|Blood sample to measure plasma dose of progesterone
45817603|NCT02880176|Other|Financial Incentive to Increase Ambulation|Financial Incentive and possibility for financial lottery entry in addition to education on the benefits of post-surgery ambulation
45817604|NCT02880254|Device|Kurbo|health/weight loss app designed for children and adolescents to help them track intake, output and understand healthy eating habits
45817605|NCT02880254|Device|Personal Health Coach|weekly health coach via facetime or Skype to motivate and counsel subjects during the weight loss process
45817606|NCT03115580|Device|Rotational atherectomy|"Rotational atherectomy for the treatment of bifurcation lesions to remove plaque with minimal injury to adjacent normal arterial segments and potentially reduce plaque shifting, the snow plow effect."
45817607|NCT03115580|Device|Cutting Balloon Angioplasty|Cutting balloon is a special balloon catheter with three or four microsurgical blades attached longitudinally to its surface, suitable for creating discrete longitudinal incisions in the atherosclerotic target coronary segment during balloon inflation. Lesion preparation will be performed using Cutting Balloon or conventional balloon
45817608|NCT03117140|Drug|Ropivacaine 0.75%|Only ropivacaine 0.75% is administered for this arm of the interscalene block
45817609|NCT03117140|Drug|Ropivacaine 0.75% + 300 mcg Buprenorphine|Ropivacaine 0.75% + 300 mcg Buprenorphine is administered for this arm of the interscalene block
45817610|NCT03117140|Drug|Ropivacaine 0.75% + 75 mcg clonidine|Ropivacaine 0.75% + 75 mcg Clonidine is administered for this arm of the interscalene block
45663516|NCT04820829|Other|High RM, low NSS|Participants in this group will consume nine 3-oz-eq servings of RM per week and 2-oz-eq servings of NSS per week.
45817611|NCT03117140|Drug|Ropivacaine 0.75% + 8 mg dexamethasone|Ropivacaine 0.75% + 8 mg Dexamethasone is administered for this arm of the interscalene block
45817612|NCT03118466|Drug|Etoposide|A Drug that interfere with the action of topoisomerase enzymes (topoisomerase I and II). Topoisomerase enzymes control the manipulation of the structure of DNA necessary for replication.
45957116|NCT00146432|Procedure|Immunoadsorption of LPS, IL-6 and C5a|
45957117|NCT04691440|Drug|Hyperbaric oxygen|The course of hyperbaric oxygen treatment comprises a total of 6 pressure exposures, distributed 2 times daily, for 3 days.
45957118|NCT02940652|Radiation|Magnetic resonance imaging|No intervention - description of the position of the LMA obtained during routine elective MRI scanning of the brain and/or cervical spine
45957119|NCT00174876|Drug|Drug Abilify|
45957120|NCT00146471|Drug|Levetiracetam|1500-2000 mg daily add-on or Placebo Diazepam as needed
45957121|NCT00146471|Drug|Placebo|1500-2000 mg daily add-on or Placebo Diazepam as needed
45454926|NCT04467268|Behavioral|Sleep extension|The sleep extension programme was designed around four alternative assumptions: 1) that among this group of habitual short sleepers, extending time in bed (TIB) would represent a significant behavioral change to established night-time and daytime routines; 2) that for practical purposes (accommodating personal, family and work schedules) extended time in bed is best anchored against typical rise-times; 3) that sleep onset may represent a particular challenge for those advancing habitual bed-times by over 1 hour each night; and 4) that in consenting to the trial, participants were motivated to make and sustain behavioral change.
45454927|NCT01119469|Behavioral|Psychotherapy (CT or ET)|weekly 50-minute sessions for 12 weeks
45957122|NCT04691245|Device|3D US|3D US guided access to femoral artery
45957123|NCT04691245|Device|2D US|2D US guided access to femoral artery
45817613|NCT03118466|Drug|Cytarabine|Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA.
45454928|NCT03528148|Behavioral|cycling|Active cycling
45454929|NCT03528148|Behavioral|Physical therapy|Conventional physical therapy
45454930|NCT05434312|Drug|TGRX-678|Participants are given TGRX-678 tablets orally at one of the dose levels as pre-determined for the dose escalation sequence.
45663517|NCT04820829|Other|Moderate RM, Moderate NSS|Participants in this group will consume five 3-oz-eq servings of RM per week and 5-oz-eq servings of NSS per week.
45454931|NCT01119547|Other|Exercise in a group|The patient do their individual exercise program in a group.
45663518|NCT04820829|Other|Low RM, High NSS|Participants in this group will consume one 3-oz-eq serving of RM per week and 8-oz-eq servings of NSS per week.
45957124|NCT04691713|Drug|Targeting CD276 autologous chimeric antigen receptor T cells|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
45957125|NCT04690933|Other|Real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients|Signing of consent at the time of the pre-transplant consultation (1 month before grafting). Inclusion of patients during conditioning (around D-8 of transplantation). Samples related to the cohort:one blood sample from the donor (only familial donors) for genetic SNPs analysis. 5 samples: D-8, D20, D100, D200 (+/-10 days), 1 year : 1 tube of 7ml of whole blood on EDTA: Biobanking of whole blood for genetic SNPs analysis (D-8) of specific transporters for GCV, and of plasma for TTV viral load at all times. In routine care:samples taken in the event of a therapeutic escape (2 x 7 ml EDTA tubes, for resistance genotype, and ganciclovir dosage, 3 x 1 ml for Quantiferon CMV, according to CNR Herpesvirus recommendations. 1 x Paxgene tube (2.5 ml) for subsequent CMV genomic and transcriptomic studies. Cell preservation plasma and whole blood for biocollection (2 tubes EDTA de 7ml). Samples stored by the centers' virology laboratories are periodically sent to the CNR for analysis.
45957126|NCT00174993|Drug|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily for up to 48 months.
45957127|NCT00174993|Drug|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months
45957128|NCT00146510|Behavioral|HealtheLifestyle Program|
45957129|NCT00146510|Behavioral|step counters with monthly feedback on logs|
45957130|NCT04690894|Procedure|erector spinae block - caudal block|the child placed in lateral position identification of spinous process of 10th thoracic vertebral then the transducer was moved 2.5 cm laterally to visualize the transverse process and a total of 0.4mg/kg of 0.25%bupivacaine was adminstered
45454932|NCT01119547|Other|Home exercise|The patient exercise their individual program at home during 6 v.
45454933|NCT03937375|Behavioral|High PEEP|Use of high levels of PEEP combined with recruitment maneuvers and low tidal volume ventilation during general anesthesia
45454934|NCT03937375|Behavioral|Low PEEP|Use of low levels of PEEP without recruitment maneuvers and low tidal volume ventilation during general anesthesia
45663519|NCT04820673|Drug|Sarecycline|Clinicians will prescribe the sarecycline as per their own clinical judgment and standard practice.
45663520|NCT04145427|Behavioral|Control|"Initial Weight Loss consultation~1.5 hour session on how to do implement healthy diet and then have a 2-week follow-up class. Information on how to maintain a healthy combination protein, fat and vegetables daily will be provided provided.~4 lifestyle coaching sessions~Monthly visits for behavioral and dietary coaching as well as medication management."
45663521|NCT04145427|Behavioral|LCD|"Initial Weight Loss consultation~1.5 hour session on how to do implement healthy diet and then have a 2-week follow-up class. Information on how to maintain a LCD will be provided provided.~4 lifestyle coaching sessions~Monthly visits for behavioral and dietary coaching as well as medication management."
45817614|NCT03118466|Drug|Lenalidomide|It may act by inhibiting the growth of new blood vessels (angiogenesis) in tumors, enhancing the status of the immune system, or decreasing cytokine and growth factor production
45817615|NCT03118466|Drug|Mitoxantrone|It interfere with cell reproduction
45817616|NCT03068312|Drug|Ivacaftor|IVA 150 mg tablet.
45817617|NCT03068312|Drug|Placebo|Placebo matched to IVA tablet.
45817618|NCT03119168|Drug|Simethicone Solution|Patients will be assigned randomly to take Simethicone Solution plus polyethylenglycol
45817619|NCT03119168|Other|Polyethylenglycol|Patients in this arm will be randomly assigned to take polyethylenglycol as their regular bowel preparation
45957131|NCT04691830|Behavioral|Prosody treatment program|"The prosody treatment program is an evidence-based practice targeting receptive and expressive prosodic skills in addition to speech production, intelligibility, pragmatics and phonology. The program incorporates the principles of validated prosodic rehabilitation strategies such as Dynamic Temporal and Tactile Cueing (DTTC), Melodic Intonation Therapy, Lee Silverman Voice Treatment in addition to expert professional practice.~The program was applied using a systematic approach of providing cues to help accelerate the child's learning of the prosodic skills targeted in the program. The program is divided into two sections according to the age into preschool section and school age section."
45957132|NCT04691830|Behavioral|Traditional auditory and language rehabilitation|Auditory rehabilitation therapy included activities targeting auditory skills: sound detection, discrimination, identification and auditory comprehension. Language rehabilitation targeted improving semantics, syntax, pragmatics and phonology.
45957133|NCT02940379|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
45957134|NCT02940379|Drug|midazolam|"Pharmaceutical form: HCl syrup~Route of administration: oral"
45957135|NCT02940379|Drug|metoprolol|"Pharmaceutical form: tablet~Route of administration: oral"
45957136|NCT00146549|Drug|Trastuzumab|
45957137|NCT00146549|Drug|Vinorelbine|
45957138|NCT00146549|Drug|Paclitaxel|
45957139|NCT00146549|Drug|Docetaxel|
45957140|NCT02940535|Drug|Diphereline (Triptorelin embonate)|
45957141|NCT02940535|Drug|Decapeptyl (Triptorelin)|
45663522|NCT05302791|Device|Muscle Cooling|Cooling wrap will be set to 10°C
45817620|NCT02881112|Device|Provant Therapy System|Treatment with the Provant Therapy System
45817621|NCT02881658|Dietary Supplement|Plant sterols-enriched soya beverage provided by Vitasoy|the study product is a 2g plant sterols-enriched in 250ml soya beverage
45817622|NCT02881658|Dietary Supplement|Soya beverage provided by Vitasoy|the placebo product is a 250 ml soya beverage
45957142|NCT02940535|Drug|human menopausal gonadotropin|
45957143|NCT02940535|Drug|human chorionic gonadotropin|
45957144|NCT00169494|Biological|HPV-16/18 L1/AS04|
45663523|NCT05302791|Other|Resistance Exercise|Resistance Machines (Leg Press and Knee extension). 12 rep Max
45663524|NCT04709757|Device|Intermittent Dosing HF10 30/90|10kHz frequency spinal cord stimulation delivered at 30 seconds ON and 120 seconds OFF
45957145|NCT04690972|Procedure|Blood sample during surgery|During the hepato-bilio-pancreatic surgery, blood is drawn.
45957146|NCT04690972|Procedure|Taking an additional biopsy|As part of the treatment, an additional biopsy is executed and blood is drawn.
45957147|NCT04690972|Diagnostic Test|Blood sample during diagnostic test|Blood sample as part of the care
45957148|NCT05157802|Behavioral|Physical activity coaching|Physical activity coaching over 5 sessions
45458198|NCT03502252|Behavioral|Semillas de Apego|Group-based Primary Caregiver Intervention: Group-based psychosocial program for victimized mothers (or alternative primary caregivers) with children 2 to 5, that aims at promoting healthy child-parent attachments as a pathway for a proper development among children exposed to violence.
45663525|NCT04709757|Device|Intermittent Dosing HF10 30/360|10kHz frequency spinal cord stimulation delivered at 30 seconds ON and 360 seconds OFF
45663526|NCT04114539|Drug|Ecopipam|Ecopipam HCl 12.5-, 37.5-. 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings.
45663527|NCT05298579|Other|Yoga exercises|Yoga-based exercise training includes a warm-up and cool-down period for beginners
45663528|NCT03301857|Drug|Denosumab (Cohort A)|Cohort A: 120 mg administered subcutaneously (SC) every 4 weeks (Q4W).
45663529|NCT03298815|Biological|Amniotic Fluid Eye Drops (AFED)|One drop (0.25 mL) in one eye twice daily for up to 3 months
45817623|NCT05405972|Behavioral|The Connected Family Series - For Foster Families|A 4-week program involving videos and activities for both the parent and child in the home.
45817624|NCT03070730|Drug|Droxidopa|Droxidopa: 100 mg or 300 mg t.i.d
45817625|NCT03070730|Drug|Atenolol|Atenolol: 50 mg Q.D.
45817626|NCT03070730|Drug|Placebos|Placebo: t.i.d
45957149|NCT00146588|Drug|Cyclophosphamide|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
45957150|NCT00146588|Drug|Epirubicin|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
45957151|NCT00146588|Drug|Capecitabine|Given orally on days 4-17 of each 21-day treatment cycle for 12-18 weeks depending upon response.
45957152|NCT05146843|Drug|Mitoquinone|Mitoquinone pill, 20 mg/day
45957153|NCT05146843|Other|Placebo|Placebo pill, 20 mg/day
45957154|NCT00175032|Drug|Lansoprazole and naproxen and aspirin|Lansoprazole 30 mg, capsules, orally once daily; Naproxen 500 mg, capsules, orally, twice daily; and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
45957155|NCT00175032|Drug|Celecoxib and aspirin|Celecoxib 200 mg, capsules, orally once daily and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
45957156|NCT05139355|Combination Product|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
45663530|NCT03298815|Other|Saline Solution|One drop (0.25 mL) in the other eye twice daily for up to 3 months
45957157|NCT05108233|Other|Survey Administration|Complete survey
45957158|NCT00146627|Drug|Eflornithine|
45957159|NCT00146627|Drug|Nifurtimox|
45957160|NCT05106361|Behavioral|MOSAIC Plus|"Those in the experimental arm will receive the intervention is called Mother AdvocateS In the Community (MOSAIC) Plus, an intervention to reduce depressive and PTSD symptoms and prevent additional intimate partner violence among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate interpersonal psychotherapy principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."
45957161|NCT05106361|Behavioral|MOSAIC|Those in the active comparator will receive a mentor mother intervention named Mother AdvocateS In the Community (MOSAIC). This does not include the IPT component.
45957162|NCT04691050|Procedure|OrthoMTA (BioMTA)|Primary second molars without successors in which traditional root canal treatment with gutta-percha could not be performed was treated with OrthoMTA
46079069|NCT05788458|Drug|Bupivacain|"The blocks will be performed in supine position under complete aseptic condition. The site to be blocked will be painted with 5% povidone iodine followed by 70% ethyl alcohol and draped. Linear high-frequency ultrasound probe (7 -15 mhz) (General Electric; GE, LOGIQ E) will be initially placed in a transverse plane over the anterior superior iliac spine (ASIS) and then alignes to identify the following landmarks: Anterior inferior iliac spine, ilio-pubic eminence, iliopsoas muscle and tendon, the femoral artery, and Pectineus muscle. Point of injection will be musculo-fascial plane between the psoas tendon and ilio-pubic eminence."
45663531|NCT03280719|Device|Prone Radiotherapy|Prone positioning for regional nodal irradiation using the crawl breast couch.
46079070|NCT05788445|Device|nrTMS treatment|Using the nrTMS treatment coli to stimulation with high frequency
46079071|NCT05788445|Device|nrTMS sham|Using the nrTMS sham coli to stimulation with high frequency
46079072|NCT05788432|Device|Sequent Please Neo|Patients in whom treatment with (Sequent Please Neo) has been attempted
46079073|NCT05788419|Diagnostic Test|sonography|imaging method, functional test of hip joint
46079074|NCT05788393|Drug|Dexmedetomidine Injection [Precedex]|dexmedetomidine group will receive continuous intraoperative dexmedetomidine IV infusion [1ug/kg dexmedetomidine over 15 min as a loading dose and 0.5ug/kg/h for maintenance].The continuous intraoperative IV infusion of study drug will be stopped 10 min before the end the surgical procedure.
45458199|NCT03293563|Procedure|Radical nephrectomy versus partial nephrectomy (according surgeon judgement)|
45663532|NCT03280719|Radiation|Acceleration|Accelerated irradiation in 5 fractions over 12 days with simultaneously integrated boost
45663533|NCT03280719|Device|Supine Radiotherapy|Supine positioning for regional nodal irradiation using breastboard.
45817627|NCT04736498|Other|Inferior venacava Ultrasonography (IVC USG) guided fluid management|The IVC will be visualized using a paramedian long-axis view via a subcostal approach. A two-dimensional image of the IVC as it enters the right atrium will be first obtained. Variations in IVC diameter with respiration will be assessed using M-mode imaging performed 2 to 3 cm distal to the junction of right atrium and IVC. Maximum and minimum diameter will be measured from inner wall to inner wall and collapsibility index(CI) will be calculated using formula: CI = [(dIVCmax - dIVCmin)/dIVCmax] x 100% CI of ˃36% will be accepted as predicted fluid responder and ≤36% will be regarded as predicted fluid non responders. Predicted fluid responders will receive a bolus of 500 ml of Ringer's lactate over a time period of 15 min, after which the IVC diameter variation will be reassessed. Additional 250ml of Ringer's lactate bolus will be applied until a non fluid responder pattern is observed during IVC USG. Thereafter,spinal anaesthesia will be performed.
45957163|NCT00175071|Behavioral|Comparison of cooking oils|30 subjects will consume each of the two diets in randomized order for 5 weeks each. Diets will be designed to maintain body weight; will have 30% of energy as fat which 2/3 or 20% of energy will be either the conventional or reformulated fat. Blood lipids and C reactive protein (CRP) as well as indicators of how lipids are processed in the blood will be measured at the end of each dietary phase.
45957164|NCT02940418|Biological|Adipose mesenchymal cells with bone marrow mononuclear cells|Allogenic adipose-derived mesenchymal cells with autologous bone marrow mononuclear cells will be injected.
45957165|NCT00146666|Device|Intermittent compression|
45957166|NCT02940457|Device|Verum tDCS|Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 2 mA
45957167|NCT02940457|Device|Sham tDCS|Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 0 mA
46079075|NCT05788393|Drug|Lidocaine IV|lidocaine group will receive continuous intraoperative lidocaine IV infusion [1.5 mg/kg lidocaine over 15 min as a loading dose and 1.5 mg/kg/h for maintenance]. The continuous intraoperative IV infusion of study drug will be stopped 10 min before the end the surgical procedure.
46079076|NCT05788380|Other|EXERCİSE|EXERCISE FOR HEALTH AND PAIN IMPROVEMENT
46079077|NCT05788367|Procedure|The pericapsular nerve group|patients received Ultrasound guided pericapsular nerve group block using 20 ml of bupivacaine 0.5%
46079078|NCT05788367|Procedure|Interscalene brachial plexus block|patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5% before induction of general anesthesia
46079079|NCT05788354|Procedure|IUD insertion during cesarean section|placement of IUD during cesarean section after placental delivery
45663534|NCT03280719|Radiation|Hypofractionation|Moderate hypofractionation in 15 fractions over 3 weeks with simultaneously integrated boost
45663535|NCT04699929|Drug|YH001|YH001 will be administered intravenously over 60minutes every three weeks (Q3W) for up to 1 years .
45663536|NCT04797273|Behavioral|Internet-based cognitive behavior therapy|12 week Internet-based cognitive behavior therapy, delivered via an online treatment platform. The treatment includes components such as exercises in conducting recuperating activities, methods to improve sleep, exposure, and behavioral activation. The treatment content is provided through written texts, images and audiofiles in the treatment platform. The participant has access to a therapist who provides support throughout the treatment via asynchronous text messages.
45663537|NCT04797273|Behavioral|Internet-based structured treatment-as-usual|This is a 12-week treatment, delivered via an online treatment platform. The treatment components in this treatment are designed to be similar to what is typically provided in primary care to these patients and includes information about stress and how different factors such as eating habits, physical exercise, and alcohol can contribute to stress problems. The treatment content is provided through written texts, images and audiofiles in the treatment platform. The participant has access to a therapist who provides support throughout the treatment via asynchronous text messages.
45957168|NCT00169533|Drug|GW572016 oral tablets|Lapatinib either at 750, 1000, 1250 or 1500 mgs
45957169|NCT00424229|Drug|LENALIDOMIDE|
45957170|NCT00530725|Procedure|chest drainage|may be a chest tube of chest drainage procedure of any type (ie formal tube, pig-tail catheter, etc)
45957171|NCT00530725|Other|close clinical observation|close clinical observation in an operating room or intensive care unit without active intervention
45957172|NCT00175110|Behavioral|herbal therapy/botanical therapy (Hibiscus sabdariffa)|
45957173|NCT02944123|Drug|Clopidogrel 75 mg|Clopidogrel 600 mg as loading dose followed by 75 mg/day as maintenance dose.
45458200|NCT02315014|Other|whey protein|whey protein.
45663538|NCT03263559|Procedure|Haploidentical Bone Marrow Transplantation|Eligible patients with a first degree Human Leukocyte Antigen (HLA)- haploidentical donor will undergo Haploidentical bone marrow transplantation at Day 0 with non T-cell depleted bone marrow. For Graft-vs-Host Disease (GVHD) prophylaxis, patients will be given sirolimus and mycophenolate mofetil beginning on Day +5.
45663539|NCT03263559|Drug|Hydroxyurea|HU will be given daily at 30mg/kg from Day -70 through Day -10.
45663540|NCT03263559|Drug|Rabbit-ATG|Rabbit-ATG (rATG) will be given at 0.5mg/kg on Day -9, and at 2.0mg/kg on Day -8 and Day -7.
45663541|NCT03263559|Drug|Thiotepa|Thiotepa will be given at 10mg/kg on Day -7
45817628|NCT05405348|Behavioral|Intervention|The patients did not eat anything during hemodialysis.
45817629|NCT05405270|Drug|Imiquimod|Imiquimod 5% will be administered in the evening by either a vaginal applicator or administered on a vaginal tampon for three times a week during 16 weeks. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies, and at 6 months after completion of imiquimod therapy with cytology and if indicated histology.
45817630|NCT05405270|Diagnostic Test|3x vaginal swab for microbiome analysis|A vaginal swab will be taken from all patients at inclusion (before start of imiquimod), at colposcopy 20 weeks after start of imiquimod and at 6 months after completion of imiquimod treatment during follow-up appointment.
45817631|NCT05405270|Other|Expectative management|Expectative management of CIN 2 when preferred by the patient. Follow-up 6 months after baseline colposcopy with cytology and if indicated histology.
45957174|NCT02944123|Drug|Prasugrel 5 mg|Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.
45957175|NCT02944123|Drug|Ticagrelor 45 mg|Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.
45957176|NCT02944045|Drug|Methylprednisolone|"Methylprednisolone intra veinous~Day 1 to 5 : 30mg twice per day~Day 6 to 10 : 30mg per day~Day 11 to 21 : 20mg per day"
45957177|NCT02944045|Drug|Placebo|saline serum
45957178|NCT00146705|Procedure|blood samples are taken once|
45458201|NCT02315014|Other|placebo|placebo.
45957179|NCT02944084|Dietary Supplement|Rice bran extract|
45957180|NCT02944084|Dietary Supplement|Porridge in water|
45957181|NCT02944084|Dietary Supplement|Porridge in milk|
45957182|NCT02943889|Biological|Mesenchymal stem cell transplantation|Bone marrow aspiration by clinical pathologist. Isolation, propagation and differentiation of stem cells will be done in stem cell center. After confirmation of the trans-differentiation into hepatocytes at the laboratory level, it will be infused into the portal vein under ultrasound guidance.
45957183|NCT00169572|Drug|Aprepitant|
45957184|NCT00169572|Drug|Ondansetron|
45957185|NCT00169572|Drug|GW679769|
45957186|NCT00169572|Drug|Dexamethasone|
45957187|NCT02943694|Device|TaTME with CS-Compact (GelPoint pathway)|Standard TaTME with circular stapler (Short and straight, CS Compact), designed for extra-corporeal and endo-anal anastomosis procedures.
45957188|NCT00146744|Biological|Mtb72F/AS02A|
45663542|NCT03263559|Drug|Fludarabine|Fludarabine will be given at 30mg/m2 from Day -6 to Day -2
45957189|NCT02943850|Biological|Stem cell (HPC) implantation|All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.
45817632|NCT05405270|Diagnostic Test|2x vaginal swab for microbiome analysis|A vaginal swab will be taken from all patients at inclusion and at 6 months after inclusion during follow-up appointment.
45957190|NCT02943850|Device|Stereotactic surgical device|A newly developed stereotactic frame is being evaluated as a part of this trial
45957191|NCT02943967|Procedure|CXL + PRK group|Corneal cross-linking with subsequent photorefractive keratotomy after 6 months was performed in one eye
45957192|NCT02943967|Procedure|PRK group|Photorefractive keratotomy alone was performed in contra lateral eyes
45957193|NCT00530881|Drug|PHX1149|
45957194|NCT00175149|Drug|Alfacalcidiol|Alfacalcidiol are given to patientwith CKD 3-4 and secondary hyperparathyrodism. The PTH level is lowered to normal range. with increasing dose of alfacalcidiol and are followed for 6 month.
45957195|NCT00530998|Procedure|Transvaginal Appendectomy|The appendix will be removed via an incision in the vagina.
45957196|NCT00530998|Procedure|Transvaginal Cholecystectomy|The gallbladder will be removed via an incision in the vagina.
45957197|NCT00146783|Drug|Sulphadoxine-pyrimethamine|
45957198|NCT00146783|Drug|Sulphadoxine-pyrimethamine, amodiaquine|
45957199|NCT00169611|Drug|methylphenidate|
45957200|NCT02943772|Other|Local hypothermia|Cooled brick
45957201|NCT02943772|Other|Control|Control brick
45957202|NCT02943811|Device|UTERINE MANIPULATOR|Patients were operated laparoscopically with the aid or not of an intrauterine probe to manipulate the uterus
45957203|NCT00146822|Device|ENDOTAK RELIANCE G lead|
45957204|NCT02943655|Drug|combined contraceptive pills (microcept)|oral combined contraceptive once daily
45663543|NCT03263559|Drug|Cyclophosphamide|Cyclophosphamide will be given at 14.5mg/kg on Day -6 and Day -5, and at 50 mg/kg on Days +3 and +4.
45663544|NCT03263559|Radiation|Total Body Irradiation|Total Body Irradiation will be given at 200cGy on Day -1
45663545|NCT03263559|Drug|Mesna|Mesna will be given at 40mg/kg on Days +3 and +4
45817633|NCT03121820|Drug|Memantinol tablets, 20 mg|"Bioequivalence Memantine Hydrochloride (JSC GEROPHARM, Russia) 20 mg film-coated tablets fasting condition"
45817634|NCT03121820|Drug|Akatinol Memantine® tablets, 20 mg|Bioequivalence Memantine Hydrochloride (Merz Pharma GmbH & Co. KGaA, Germany) 20 mg film-coated tablets fasting condition
45817635|NCT03123614|Drug|Loteprednol Etabonate 0.5% Oph Gel|
45957205|NCT02943655|Drug|medroxyprogesterone acetate (progest)|oral 5 mg medroxyprogesterone acetate daily
45957206|NCT02943655|Drug|mefenamic acid (ponstan forte)|oral 500 mg mefenamic acid three times per day
45957207|NCT00175188|Device|Avanta (PIP joint implant with a titanium porous coating)|Implant is inserted at the time of surgery, after written consent
45957208|NCT05085067|Other|auto-crossed-linked hyaluronic acid gel|infusing auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
45957209|NCT00146861|Device|sensor programming|
46079080|NCT05788302|Behavioral|Prolonged Exposure|- Participation will occur throughout 17 weeks over 15 separate visits during which 10, 60-minute sessions of PE will take place. Session 1 of PE will focus on psychoeducation. Session 2 of PE will involve a continuation of psychoeducation and rationale for exposure as well as the collaborative construction of the in vivo exposure hierarchy. After session 2, participants will begin homework where they are instructed to confront situations on their hierarchy. Starting in session 3 of PE, participants will begin imaginal exposures to their worst trauma memory. This involves the participant recounting and visualizing the trauma memory aloud with the clinician in the room for 30-40 minutes. The session will end with 15-20 minutes of processing the imaginal exposure. Participants will continue in-session imaginal exposures until the end of treatment. Throughout the treatment, participants will listen to a recording of their imaginal exposure and engage in in vivo exposures daily.
45663546|NCT03257163|Drug|Capecitabine|Given PO
45663547|NCT03257163|Other|Laboratory Biomarker Analysis|Correlative studies
45663548|NCT03257163|Biological|Pembrolizumab|Given IV
45663549|NCT03257163|Radiation|Radiation Therapy|Undergo radiation therapy
45663550|NCT03256149|Drug|Dexamethasone|
45957210|NCT00175227|Drug|intravenous saline hydration + mannitol + furosemide|500 mls half-normal saline + 25g mannitol + 100 mg furosemide
45957211|NCT00175227|Drug|intravenous saline hydration|500 mls half-normal saline
45957212|NCT02940262|Radiation|Gallium Ga 68 Gozetotide|Given IV
45957213|NCT02940262|Other|Laboratory Biomarker Analysis|Correlative studies
45957214|NCT02940262|Procedure|Positron Emission Tomography|Undergo PET imaging
45957215|NCT00146900|Procedure|Cognitive Behavioral Therapy|12 weekly 1.5 hours weekly session of cognitive behavioral therapy (Prolonged Exposure)
45663551|NCT03256149|Drug|Placebo|Normal saline (IV placebo)
45817636|NCT03123614|Drug|Prednisolone Acetate 1% Oph Susp|
45817637|NCT03123848|Drug|Darunavir/Cobicistat|Participants will receive a FDC tablet of darunavir 800 mg and cobicistat 150 mg orally in the morning of Day 1.
45957216|NCT00146900|Procedure|Cognitive Therapy|12 weekly 1.5 hours weekly session of cognitive therapy without exposure
45957217|NCT00146900|Drug|Escitalopram|Twelve weeks of treatment with Escitalopram at Max. daily dose of 20mg
45957218|NCT00146900|Other|Placebo|Twelve weeks of treatment with placebo pills resembling the original Escitalopram 10mg tablets but containing no active substance
45957219|NCT02940145|Other|Resistance Training|The investigation was carried out over a period of 16 weeks, with 12 weeks dedicated to the RT program and 4 weeks allocated for measurements. Anthropometric, body composition, and blood samples measurements were performed at weeks 1-2, and 15-16. A supervised progressive RT was performed between weeks 3-14. The CG did not perform any type of physical exercise during this period.
46079081|NCT05788250|Procedure|Subacromial spacer implantation|A biodegradable balloon implanted arthroscopically between the acromion and humeral head with tenotomy of long head of biceps.
45663552|NCT04105257|Diagnostic Test|All patients|Comparison of the results of the CTP with MRI
45663553|NCT04097769|Drug|HX009|During study treatment, subjects will receive HX009 treatment via IV infusion once every 2 weeks at doses of 0.1, 0.3, 1, 2, 3, 5, and 7.5 mg/kg.
45817638|NCT03124550|Behavioral|Exergame Experience|Fitbit Charge HR will be used to measure physical activity and sedentary behavior during waking hours. Each participant will wear a Fitbit for a period of one week at baseline and during the entire 6-week pilot study. Data on step counts, heart rate, and moderate/vigorous activity from the Fitbits will be transmitted wirelessly to our secure research server and will be used to assess changes in physical activity and sedentary behavior over the course of the study. Participants will be instructed to wear the monitor continuously on the wrist. Data will be analyzed using previously validated accelerometer count cut-points for adults after accounting for invalid data and wear time.
45663554|NCT04090125|Behavioral|PAS Intervention|The PAS program will be initiated during the final usual care PT visits. The PAS content will be included within the last two routine PT visits (Sessions 1 and 2). Session 1 will emphasize the importance of PA in TKA recovery, work with participants to establish SMART goals regarding overall PA and provide community-based and other resources to support overall PA. Session 2 will include balance exercise content to improve joint loading symmetry and home exercises will be assigned. Then, PAS participants will receive a follow-up phone call after 4 weeks (to assist with activity progression and problem-solving) and an additional in-person visit after 8 weeks (to visually monitor exercise performance and re-assess proportional weight-bearing ability).
45663555|NCT04090125|Behavioral|Attention Control|This will include usual in-person post TKA PT followed by 2 additional contacts (Session 1 and 2) with the physical therapist. Session 1 (phone) will review recovery benchmarks, assessment of participants' daily activities and reminders about symptoms that should trigger contacting a medical professional. Session 2 (in-person) will involve physical performance tests and comparison to appropriate normative values.
45663556|NCT04089033|Procedure|Pneumatic Retinopexy|The PnR technique is performed as per the PIVOT trial under local anaesthetic. First, patients will undergo a thorough scleral-depressed peripheral retinal examination to identify all pathologic features. Second, laser retinopexy will be applied to all breaks, lattice degeneration, or both in the attached retina before gas injection. Third, breaks in the detached retina will be treated with cryotherapy before gas injection or (preferably) laser retinopexy 24 to 48 hours after gas injection, with additional laser retinopexy applied at any point per surgeon discretion. Finally, anterior chamber paracentesis will be used to express as much fluid as safely possible (generally 0.3ml), followed by intravitreal injection of 100% SF6 (ideally 0.6 ml). Patients will be positioned face down for 6 hours and then raise their head 30 degrees every hour (steam roll) and then positioned to the responsible break.
45817639|NCT02946073|Drug|buprenorphine|
45817640|NCT02946073|Other|Placebo|
45817641|NCT03071744|Drug|Lazanda|Lazanda is supplied in glass bottles, containing 8 sprays of 100 mcL containing 100 mcg/100 mcL or 400 mcg/100 mcL concentration solution.
45817642|NCT03073148|Device|Tangible Boost|Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.
45817643|NCT03073148|Other|Placebo saline|"Participants will treat their lenses with a placebo Tangible Boost kit, which contains saline in place of the Tangible Boost solution."
45817644|NCT02946229|Device|Ultrasound scan|Collection of ultrasound data sets that include routine ultrasound data (eg, extravascular lung fluid, cardiac velocity time integral and inferior vena cava) on the commercial GE Vivid S70 Ultrasound System which are used to test feasibility of next generation ultrasound algorithms being developed to process these data types.
45817645|NCT03074630|Drug|Dapagliflozin|5 weeks 10mg dapagliflozin once daily
45817646|NCT03074630|Drug|Rosuvastatin|9 weeks 10mg dapagliflozin once daily
45817647|NCT03086707|Other|Cigarette|After enrollment, and between Visit 2 and Visit 3, the subjects will abstain from smoking for a period of 8 hours. At Visit 3, after the 8-hour smoking abstinence period, the subjects will smoke 1 single cigarette.
45817648|NCT03125018|Device|LNCS ADTX Sensor|Noninvasive pulse oximeter sensor.
45957220|NCT02940067|Other|MedEx|A combination of dietary and exercise interventions over four weeks before scheduled pancreatic surgery
45957221|NCT00169650|Other|Registry and database|Subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction at Methodist Urology in Indiana will be asked to participate in a registry and database to review outcomes of the surgery.
45957222|NCT02940028|Behavioral|Expressive writing|Brief expressive writing intervention
45458202|NCT03502174|Device|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
45817649|NCT05404334|Diagnostic Test|Androgen receptor status and BRCA mutation|Androgen receptor status by IHC and germ line BRCA mutation
45663557|NCT04089033|Procedure|Pars Plana Vitrectomy|For PPV, a standard 3-port PPV (23 or 25-gauge) will be performed, including posterior hyaloid detachment, core vitrectomy and 360 peripheral vitreous shave. Subretinal fluid will be drained either through the peripheral break or through a posterior retinotomy with use of heavy liquid to assist with appropriate drainage at the discretion of the responsible surgeon. A complete air-fluid exchange will be performed. Endolaser Retinopexy or transconjunctival cryopexy will be performed to treat any retinal pathology, including lattice degeneration and breaks in the attached and detached retina. A iso-expansible concentration of SF6 or C3F8 gas will be injected at the completion of the surgery. Choice of gas will be at the discretion of the responsible surgeon. Patients will be positioned immediately face down for the first 24 hours and then according to the position of the responsible break.
45817650|NCT00374894|Drug|2,3-dimercaptosuccinic acid|
45957223|NCT02940028|Behavioral|Control writing|Brief fact-based writing exercise.
45957224|NCT02939482|Drug|Triamcinolone Acetonide and normal saline solution|80 mg/2 ml Triamcinolone Acetonide and 18 ml normal saline solution
46079082|NCT05788250|Procedure|Rotator cuff repair|Rotator cuff repair with tenotomy of long head of biceps.
46079083|NCT05788211|Other|standard of care|retrospective study: standard of care
46079084|NCT05788185|Biological|RVM-V001 30 µg|For BNT162b2 subjects
45817651|NCT03088267|Drug|amphetamine extended-release oral suspension, 2.5 mg/mL|5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO
46079085|NCT05788185|Biological|RVM-V002 30 µg|For BNT162b2 subjects
46079086|NCT05788185|Biological|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration|For BNT162b2 subjects
45817652|NCT03088267|Drug|Placebo extended-release oral suspension|6, 7 or 8 mL PO
45817653|NCT03127358|Device|AiCure|Smartphone App
45957225|NCT00405782|Behavioral|Moderate-Intensity Exercise|Exercise program designed by exercise physiologist
45957226|NCT02939521|Procedure|Surgery|
45957227|NCT00175266|Drug|alemtuzumab|
46079087|NCT05788185|Biological|RVM-V001 30 µg|For BBIBP-CorV or CoronaVac subjects
46079088|NCT05788185|Biological|RVM-V002 30 µg|For BBIBP-CorV or CoronaVac subjects
46079089|NCT05788185|Biological|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration|For BBIBP-CorV or CoronaVac subjects
46079090|NCT05788159|Drug|Lacosamide Tablets|Reference preparation (R): Lacosamide Tablets Specification: 50mg/tablet Lot No.: 7883201 Content: 50mg/tablet Expiration date: September 2026 Storage condition: not more than 30C in airtight storage Manufacturer: Aesica Pharmaceuticals GmbH
46079091|NCT05788159|Drug|Lacosamide extended release tablets|Test preparation (T): Lacosamide extended release tablets Specification: 100mg/tablet Lot number: 22121301 Content: 100mg/tablet Expiration date: December 12, 2024 Storage conditions: Store at 20℃~25℃, short-term can be at 15C~30℃ Manufacturer: Overseas Pharmaceutical,Ltd.
46079092|NCT05788146|Other|Cognitive Behavioural Therapy|A psychological intervention used to target depression
46079093|NCT05788133|Other|treatment and screening by neuropsychological tests on humanoid robot|treatment and screening by neuropsychological tests on humanoid robot
46079094|NCT05788107|Drug|HLX51|anti-OX40 tetravalent agonistic humanized monoclonal antibody
45957228|NCT00175266|Procedure|islet transplant|
45957229|NCT00175266|Drug|infliximab|
45817654|NCT03127358|Device|AiCure with gamification|Smartphone App with gaming.
45817655|NCT03088345|Drug|Vasopressin, Arginine|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
45957230|NCT02939443|Radiation|supine- and prone-position Computed Tomography|
45957231|NCT05013892|Radiation|NTS-WBRT (normal tissue sparing whole brain radiation therapy)|Radiation
45957232|NCT05013892|Radiation|HA-WBRT (hippocampal avoidance whole brain radiation therapy)|Radiation
45957233|NCT05013892|Drug|Memantine|Capsule, taken orally
45957234|NCT02939248|Drug|Crushed ticagrelor followed by morphine|Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
45957235|NCT02939248|Drug|Crushed ticagrelor, morphine,naloxone|Crushed ticagrelor (180 mg) orally followed by morphine 5 mg intravenously and naloxone 1 mg orally
45817656|NCT03088345|Drug|Placebo|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
45454935|NCT05419726|Drug|Semaglutide Injectable Product|"STUDY PROCEDURES~Patients who are to be started on semaglutide by their physician will be invited to participate in the study, and will be given a consent form. If they agree to proceed, they will be scheduled for a visit to undergo BMR and thermal imaging of BAT (Visit 1) prior to starting semaglutide. When the patient returns at week 2-4 (Visit 2) and week 18-20 (Visit 3), final BMR and thermal imaging of BAT will be done. Subjects will also perform a 24 hour food recall at each visit."
45454936|NCT02529397|Behavioral|Adaptive Working Memory Training|Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using an adaptive cognitive training program which becomes increasingly challenging as the participant masters each level. Behavioral classes will teach the principles of weight management and exercise.
45454937|NCT02529397|Behavioral|Non-adaptive cognitive training|Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using a non-adaptive cognitive training program. Behavioral classes will teach the principles of weight management and exercise.
45454938|NCT01119781|Drug|BIIB017(peginterferon beta-1a)|peginterferon beta-1a administered by a single subcutaneous (SC) injection using a pre-filled syringe on Day 1 at a dose of either 63 or 125 mcg depending on subpopulation assignment reflecting whether a healthy volunteer or level of renal impairment.
45454939|NCT05022862|Behavioral|Usual Care|Medication is dispensed to participant at each visit in 30-60 day supplies by Baltimore City Health Department (BCHD) nurses. For study participants, medication dispensation will occur in medication bottles with MEMS Caps, supplied by the study.
45454940|NCT05022862|Behavioral|Video Directly Observed Therapy alone|Usual care plus Video-DOT using the emocha platform, a HIPAA compliant commercial platform for video based DOT. The app allows a secure/encrypted video recording to be taken as the participant ingests the medication. Electronic text reminders will be sent to the participant on the smart phone when it is time to take the medication. The participant will record a video of the pill ingestion process. Study staff will verify each video to confirm the video shows the correct person and that the pill was ingested appropriately (according to standardized approach involving visualization of the pills, ingestion and observation of an empty mouth after ingestion).
45454941|NCT05022862|Behavioral|Video Directly Observed Therapy plus Financial Incentives|Usual care plus video-DOT and financial incentives contingent on adherence verified by video DOT. The amount of the financial incentive that can be earned for future verified doses decreases after a missed dose (video). The amount of the financial incentives increases incrementally back to baseline amount after verification of medication ingestion according to the prescribed schedule for several consecutive doses.
45454942|NCT01120015|Drug|diacerein|Diclofenac sodium 75mg sustained release tablet once daily was given to both groups for 3 months. Capsule diacerein 50mg in study group and matched placebo in control group were given once daily for first month and twice daily for next two months with the main meals.
45454943|NCT03526666|Other|Peripheral blood collection|Peripheral blood collection for the measurement of ascorbic acid levels and banking of plasma and buffy coat for future resrearch.
45957236|NCT00146978|Procedure|intra-arterial treatment|
45957237|NCT02939053|Device|SOZO|The SOZO device is a bioimpedance spectroscopy device that measures bioimpedance parameters.
45957238|NCT00169689|Procedure|"rTMS, repetitive transcranial magnetic stimulation"|10 Hz rTMS (10.000 stimuli) over left dorsolateral prefrontal cortex
45957239|NCT00169689|Other|rTMS|repetitive transcranial magnetic stimulation, 10 Hz, 10.000 stimuli, 2 weeks
45957240|NCT02938975|Other|Ultra 30 Insect Repellent Lotion (30% Lipo DEET)|"One application of Lipo DEET protects for up to 12 hours and has a pleasant odour and non-greasy feel on the skin. DEET is a broad spectrum insect repellent and was selected this study because it has been extensively tested for safety and toxicity for human use and its efficacy against a broad variety of arthropod vectors. DEET was first registered in 1957 and has been conclusively proven to be safe for use on adults, children, pregnant and lactating mothers.~This Liposome-based repellent is the newest advancement in insect repellent technology. The Liposome envelops the active ingredient, DEET, and slowly time-releases it as needed, thereby extending the effectiveness of the repellent and reducing dermal absorption."
45454944|NCT05405452|Device|Vibration Anesthesia Device by Blaine Labs|Device which vibrates on top of skin
45957241|NCT02938975|Other|Permethrin Factory-Treated Army Combat Uniforms|Permethrin is the U.S., Australian and United Kingdom (UK) military's standard repellent for application to fabric and is considered the most effective clothing treatment available to prevent insect bites through fabric. The Army objective is to provide 90% bite protection for at least 50 launderings; an objective easily met through factory treatment of uniforms, which demonstrates 99-100% bite protection up to 50 launderings (the expected lifetime of the uniform).
45957242|NCT02938975|Other|Placebo lotion|A liposome lotion with no DEET
45957243|NCT02938975|Other|Army combat uniform|Army combat uniform with no permethrin
45957244|NCT00169455|Biological|Live attenuated human rotavirus vaccine|
45957245|NCT02939092|Drug|Pomegranates peel extract|Pomegranate is antimicrobial
45817657|NCT02855437|Device|IVR (Phone call)|IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack if completed. We will capture patient reported outcome measures (e.g. pain, fatigue, sleep) using instruments from NIH PROMIS. Following completion of 26 week IVR period participants will crossover to RheumPro arm.
45817658|NCT02855437|Device|RheumPro (Smartphone application)|"RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled pop-up to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more pop-ups at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. Following completion of 26 week RheumPro period participants will crossover to IVR arm."
45957246|NCT02939092|Drug|Chlorhexidine|Chlorhexidine mouthwash is antiplaque agent
45957247|NCT02938936|Other|Pre-natal visit scheduling|This intervention will include a scheduled date and time for prenatal care follow-up visits. Women in the intervention group seeking care for their first ANC appointment will be offered several appointment slots on their return date by the nurse providing their first ANC visit. Women will be able select among the time options and will be provided an appointment card with their scheduled date and time. Staff will limit the number of scheduled women per hour by maintaining an appointment book. Clinic staff will be trained to differentiate between women returning for a scheduled visit from first prenatal visits, emergencies, and unscheduled return visits. First visits and emergencies will be seen during the first 2 hours after clinic opening and unscheduled women will be seen during a one-hour time slot midday. When women return on their date, they will be seen within one hour of their appointment time by clinic staff.
45957248|NCT00175305|Drug|Sandostatin LAR|
45817659|NCT02948257|Device|Cardiva Medical VASCADE VCS|At the end of peripheral endovascular interventional procedures performed via an antegrade femoral arterial approach, the femoral arterial access site is closed with the VASCADE VCS to achieve arterial hemostasis.
45454945|NCT05405452|Drug|Gebauers Ethyl Chloride 100% Topical Spray|Sterile ethyl chloride spray
45817660|NCT03127514|Drug|AMX0035|AMX0035
45817661|NCT03127514|Other|Placebo|Matching Placebo Comparator
45817662|NCT02858713|Drug|Calcipotriene + Betamethasone Dipropionate|Participants received Calcipotriene + Betamethasone Dipropionate once daily when needed for the entire study period.
45957249|NCT00147056|Device|ExAblate transcranial system|MRI-Guided Focused Ultrasound Feasibility Study for Brain
45957250|NCT02938897|Behavioral|Registered Dietitian Nutritionist (RDN) Support|RDN provided individualized medical nutrition therapy via videoconference at weeks 1, 5, and 9 and telephonic nutrition coaching support at weeks 2-4, 6-8, and 10-12.
45454946|NCT01122355|Drug|lipid modification|1) fenofibrate 160 mg po for 16 weeks, 2) niacin 500 mg po for 4 weeks, niacin 1000 mg po for 4 weeks, niacin 1500 mg po for 8 weeks
45454947|NCT01216579|Other|mannitol (an airway challenge agent)|
45454948|NCT03528070|Drug|Tranilast|Subjects will be treated with tranilast
45957251|NCT02938897|Behavioral|Diet-related educational materials|Individualized caloric recommendations (500-750 kcal reduction) were made and food-based educational materials emphasizing general healthful eating patterns and increased intakes of nutrient-rich foods were provided.
45957252|NCT02938897|Behavioral|Self-monitoring tools|Self-monitoring tools including: weekly weight log, fruit and vegetable tracker, and a SMART (specific, measurable, achievable, relevant, and time bound) goal planner were provided.
45957253|NCT02938819|Other|Goal-oriented upper-limb intervention|The Goal-oriented upper-limb intervention evaluated patients' expectations and the environmental factors influencing the performance of the specific task were identified for each of the three tasks. Patients were asked to perform the activity at home. After this, the observable target behavior corresponding to the target activity was determined. Then, an occupational and a physical therapist worked together with the patient to identify the assistance required to perform this activity such as human assistance, technical aids, assistive devices or verbal guidance.
45957254|NCT02938819|Other|Standard upper limb intervention|The standard upper limb intervention involved active upper limb range of motion, manual dexterity involving grasp and manipulation of small pieces such as marbles and stretching upper limb exercises.
45957255|NCT02938741|Drug|Anti-human Thymoglobulin|r-ATG 2.5MG/KG*4days were used in the conditioning
45454949|NCT03525340|Behavioral|Peer Navigation|Peer navigators help participants identify barriers that pose challenges to the participant's engagement in care and adherence and help develop an overall action plan for addressing these barriers by identifying specific changes that can be made/attempted to overcome an identified barrier. This may involve accompanying a participant to their social services/health appointments, or assisting a participant with disclosure of her HIV status to a family member or friend. The overall goal is to develop knowledge of social/HIV-related health services and good problem-solving skills in order to tackle multiple, potentially overlapping barriers. Over time, participants are encouraged to take increasing degrees of responsibility for identifying and implementing their own problem-solving strategies.
45663558|NCT04819893|Biological|Maternal blood sampling|5 mL sample of venous blood on arrival at the maternity ward in accordance with standard protocols
45663559|NCT04819893|Biological|Umbilical cord blood sampling|0.5mL sample from the umbilical cord after childbirth standard protocols
45663560|NCT04819893|Biological|Placenta sampling|Sampling of 3 cotyledons by cutting across the thickness of the placenta
45957256|NCT02938741|Drug|Placebo|r-ATG 2.5MG/KG*4days were not used in the conditioning
45957257|NCT00407589|Drug|BOL-303224-A|1 drop in each eye, TID for 5 days at approximately 6 h intervals, with a final, single dose on the morning of Visit 7 (Day 6).
45957258|NCT02938546|Radiation|18F-FDG|18FDG-PET scan was performed 4 weeks before the first administration of therapy or before the third cycle chemotherapy or before the 7th week of targeted therapy and after 3 days chemotherapy and targeted therapy. The lesions were analyzed by nuclear medicine physician and calculate the metabolism response. The size of percent changes was evaluated using the EORTC (European Organization for Research and Treatment of Cancer) PET criteria by oncologist who determine whether the scheme works and the scheme should continue or change. The seleted patients were double blinded to analyse the relationship between metabolism response and chemotherapy response.
45957259|NCT00175344|Procedure|Scar massage.|To objectively evaluate the effects of scar massage, those who agree to participate will be randomly assigned to one of two groups. One group will be taught to perform self-massage of the scars as soon as the scars have adequately healed. The massage should be done about 10 minutes each day for a total of 6 months. The other group will not be taught self-massage and will be asked to not massage their breast scars.
45957260|NCT00147134|Procedure|open colectomy|Procedure/Surgery: open colectomy
45957261|NCT00147134|Procedure|laparoscopic colectomy|Procedure/Surgery: laparoscopic colectomy
45957262|NCT04891393|Dietary Supplement|Coffee|"Starbucks brand Via instant coffee. (Caffeine Content: 3 mg / kg)"
45957263|NCT04891393|Dietary Supplement|Decaffeinated coffee|"Starbucks brand Via instant decaffeinated coffee. (Caffeine Content: 15 - 25 mg)"
45957264|NCT03458065|Device|ICD|Implantable Cardioverter Defibrillator
45663561|NCT04819893|Other|Data collection|Newborn, Maternal and Premature Retinopathy Screening Data Collection
45663562|NCT03253263|Drug|OHB-607|Participants will receive intravenous infusion of OHB-607 from birth up to PMA 29 weeks + 6 days.
45663563|NCT03252795|Procedure|uterus transplantation|transplantation of a uterus from a deceased donor
45663564|NCT04797117|Diagnostic Test|blood sample|"The blood samples for the study for each patient will be collected in the form of additional tubes.~either 1 tube of blood of 4 ml and 2 tubes of blood of 10 ml once a day for 1 or 2 days maximum (or 48 ml maximum) during his hospitalization~either 2 tubes of 10 ml or 20 ml maximum once during his hospitalization."
45663565|NCT03180411|Behavioral|Interview|"Cognitive Testing Phase Group: Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease. The interview may take from 45-60 minutes to complete.~Pilot Testing Phase Group: After Cognitive Testing Phase interview, participants have a second one-on-one interview. The interview will last from 45-60 minutes."
45663566|NCT03180411|Behavioral|Questionnaire|Participant completes a questionnaire about the disease, what participant understands about it, and the treatment plan recommended. Participant asked to give participant's opinion about colorectal cancer follow-up materials. The questionnaire will take 35-45 minutes.
45663567|NCT05653011|Other|Endoscopic biopsy|"When patients have colonoscopy or sigmoidoscopy for evaluation of their disease course, biopsied samples are collected.~In the IBD group, samples are obtained at endoscopically active and/or inactive lesions. In the control group, samples are obtained at endoscopically normal lesions."
45663568|NCT05652933|Diagnostic Test|Software for identifying vessel occlusion, infarct volume and penumbra|Assessment of the AI tool software
45663569|NCT03107247|Drug|Imaging Time|Participants will be asked to be imaged at an additional time point.
45663570|NCT05652777|Device|NeoSpot|Pregnant women will undergo screening of their vital signs using the NeoSpot device.
45663571|NCT05652699|Other|High Flow Nasal Oxygen|Flow 60L/minute. FiO2 according to clinical protocol. Temperature highest tolerated by patient, starting with 37 degrees Celsius.
45957265|NCT02938663|Behavioral|Questionnaires and Measurements|Participants completed anthropometric measurements and questionnaires assessing psychosocial stress, habitual dietary intake and physical activity as well as cultural identity, identity-based motivation and socioeconomic status. At home, participants recorded their habitual physical activity and food intake. Participants then returned to the laboratory to complete an assessment of identity-based motivation and received personalized information regarding their habitual physical activity and dietary patterns.
46079095|NCT05788094|Drug|Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose)|"Dihydroartemisinin-Piperaquine will be purchased as Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China). One tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine (i.e. a 1:8 ratio). A weight-based regimen containing a total dose of approximately 7 mg/kg DHA and 55 mg/kg piperaquine given in 3 divided doses once daily.~Tafenoquine KOZENIS® 150 mg film-coated tablets will be purchased from GSK (Glaxo Smith Kline Pharmaceutical industry), 450 mg (3 tablets) will be given."
46079096|NCT05788094|Drug|Chloroquine plus Tafenoquine (450 mg adult dose)|"Chloroquine will be dosed as a 25 mg/kg base given in divided doses of 10 mg/kg orally on days 0 and 1, and in 5 mg/kg dose on day 2. Tablets will be obtained from Government Pharmaceutical Organization (GPO) in Bangkok, Thailand and supplied as 250 mg tablets (155.3 mg base).~Tafenoquine KOZENIS® 150 mg film-coated tablets will be purchased from GSK (Glaxo Smith Kline Pharmaceutical industry), 450 mg (3 tablets) will be given."
45663572|NCT05652699|Other|Conventional Oxygen Therapy|Nasal Cannula, Venturi Mask or Non-rebreathing mask, according to local clinical protocols
45663573|NCT05652621|Dietary Supplement|probiotics|Resistant dextrin (water-soluble dietary fiber), Lactobacillus reuteri PLBK1, Luo Lactobacillus delbrueckii, Lactobacillus griffii PLBK3, Lactobacillus acidophilus PLBK4, Bifidobacterium lactis PLBK5）
45663574|NCT01636947|Drug|Aprepitant|Aprepitant (125 mg PO, QD) on Day 1, Aprepitant (80 mg PO, QD) on Days 2 and 3
45454950|NCT03935815|Drug|Ropivacaine injection|30 mL of 0.25% ropivacaine will be administered on both the right and left sides with a 20 gauge, 4 inch ultrasound needle using a SonoSite ultrasound machine with a linear transducer probe. The tip of the ultrasound needle will be placed posterior to the quadratus lumborum muscle (QL2) made in the plane between the quadratus lumborum muscle and thoracolumbar fascia.
45663575|NCT01636947|Drug|Aprepitant Placebo|Aprepitant Placebo (PO, QD) on Days 1, 2, and 3
45454951|NCT03935815|Procedure|Sham treatment|A sham procedure with a superficial 22 gauge needle stick will be performed without injectate.
45663576|NCT01636947|Drug|Ondansetron|Ondansetron (16 mg, IV, QD) on Day 1 and/or ondansetron (8 mg PO BID) on Days 2 and 3
45663577|NCT01636947|Drug|Dexamethasone|Dexamethasone (20 mg or 12 mg, PO) on Day 1
45957266|NCT00147329|Drug|MM-093|
45957267|NCT02938780|Other|placebo text message|The subjects in the control group will receive placebo text messages which will be timed as the intervention group that are unrelated to the study or topics of exercise and nutrition.
45663578|NCT01636947|Drug|Ondansetron Placebo|Ondansetron Placebo (PO, BID) on Days 2 and 3
45663579|NCT01636947|Drug|Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).|Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).
45663580|NCT05652387|Behavioral|Father Inclusive Prenatal Care|Pregnant and parenting couples participate in co-parenting and parenting education, and job skills and education readiness
45663581|NCT05214027|Other|Treadmill-Based Exercise (60% VO2 Max for 60 minutes)|"Each participant will undergo a single 60-minute treadmill-based exercise intervention in a randomised order.~Treadmill settings are generated based on settings which correspond to participants exercising at 60% VO2 max from their maximal exercise test on visit 2. To confirm that participants are exercising at 60% during the hour session, 1 minute samples of expired air are taken at 15 minute intervals and immediately analysed to check % VO2 max. Participants heart rate and RPE measures are also taken at 15 minute intervals throughout the exercise session and cross-checked against predicted values at 60% VO2 Max."
45663582|NCT05214027|Other|Rest (60 minutes)|Each participant will undergo a 60-minute rest period in a randomised order.
45663583|NCT01635933|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color.
45663584|NCT01635933|Device|Phemfilcon A contact lens with color|Hydrogel contact lens with color.
45663585|NCT01635855|Device|Belotero®|Hyaluronic acid dermal filler
45663586|NCT04808115|Drug|KDS-1001|"Cycles 1-6 (14 days per cycle)~1 x 109/KDS-1001 cells/infusion administered on day 1 of each cycle"
45663587|NCT05652309|Procedure|spinal block and obturator nerve block|spinal block and obturator nerve block
45663588|NCT03052725|Drug|reslizumab|Reslizumab was provided in a pre-filled syringe.
45957268|NCT02938780|Other|nutrition physical activity text message|The subjects in the intervention group will receive text messages with nutrition and physical activity-related information throughout the study period on a daily basis, varying text message arrival over a 10 am to 7 pm time frame. The American Cancer Society recommends a set of exercise and nutrition behaviors for cancer survivors based upon developed expert evidence. These behaviors have been structured to achieve healthier lifestyles, improve quality of life and reduced mortality. The intervention will provide via text messaging exemplars and social norms designed to improve compliance with this advice.
45957269|NCT04690543|Procedure|z-plasty|Z-plasty: It will be defined as a local transposition flap that will be used to improve the functional and cosmetic appearance of scars. It will be involved creating two triangular flaps of equal dimensions that will be transposed.
45663589|NCT04818801|Biological|Recombinant two-component COVID-19 vaccine (CHO cell)|The spike (S) protein is the main surface antigen of SARS-CoV-2, mediates entry of SARS CoV-2 into cells expressing the angiotensin-converting enzyme 2 (ACE2). The RBD interacts with ACE2 and can generate potent neutralizing anti-RBD antibodies.
45663590|NCT04818801|Other|Placebo|Normal saline (0.9% sodium chloride solution),
45663591|NCT02980341|Drug|Patritumab Deruxtecan|U3-1402 consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)
45663592|NCT04793919|Drug|Mylotarg|See the protocol
45663593|NCT04793919|Drug|Arsenic Trioxide|See the protocol
45663594|NCT04793919|Drug|All-trans retinoic acid|See the protocol
45663595|NCT05356767|Procedure|Pharmacomechanical thrombolysis|Pharmacomechanical thrombolysis
45663596|NCT05651763|Other|Stimulation and exercise group|Exercise protocol + application of active direct current stimulation for 30 minutes.
45663597|NCT05651763|Other|Exercise and sham stimulation group|Sham Transcranial direct current stimulation Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
45957270|NCT04690543|Procedure|square flap|Square flap: It will be defined as is another local transposition flap which will be used for release of contractures. Square will be marked on one side of the contracture, and two triangles will be marked on the other side, with the length of all the flaps equal, which will be then transposed.
45957271|NCT04839523|Device|Exufiber|A sterile nonwoven wound dressing made from highly absorbent PVA fibers.
45957272|NCT04839523|Device|Exufiber Ag+|A sterile nonwoven wound dressing made from highly absorbent PVA fibers, and coated with silver sulphate.
45957273|NCT00175383|Drug|luteinizing hormone-releasing hormone (LHRH) short acting or long acting|See Detailed Description.
45957274|NCT02938468|Drug|Dexamethasone|
45957275|NCT02938468|Procedure|Any surgical intervention aim at treating chronic subdural hematoma|
45957276|NCT02938507|Drug|Formulation 1 solabegron|
45957277|NCT02938507|Drug|Formulation 2 solabegron|
45957278|NCT02938429|Other|Physical activity measures via Actigraph GT3X+ accelerometers for 7 consecutive days|
45458203|NCT01238029|Drug|Lapatinib and Capecitabine and Vinorelbine|Dose finding Study Lapatinib: 1000-1250 oral, once daily, days 1-21 Capecitabine: 1000 mg/sqm oral, bid, days 1-14 Vinorelbine 10-22,5 mg/sqm, i.v. Day 1 + 8
45663598|NCT02837445|Device|PHC ON|Eligible patients randomized after optimization phase to PHC ON for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
45663599|NCT02837445|Device|PHC OFF|Eligible patients randomized after optimization phase to PHC OFF for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
45957279|NCT00147368|Drug|intravenous (IV) arginine|
46079097|NCT05788068|Behavioral|Mindfulness-based smoking cessation|Participants who allocate to the intervention group will receive regular mindfulness-based smoking cessation by professional team.
45663600|NCT02817633|Drug|TSR-022|TSR-022 will be administered.
45663601|NCT02817633|Drug|Nivolumab|Nivolumab will be administered.
45663602|NCT02817633|Drug|TSR-042|TSR-042 will be administered.
45663603|NCT02817633|Drug|TSR-033|TSR-033 will be administered.
45663604|NCT02817633|Drug|Docetaxel|Docetaxel will be administered.
45957280|NCT00407667|Device|transcranial galvanic stimulation|for tDCS: Siemens Universal-Neuroton 826 for arm training: Bi-Manu-Track, Reha-Stim, Berlin
45957281|NCT02938390|Procedure|Ultrasound for localizing intercostal perforating vessels|Use of an Intra-operative ultrasound during nipple sparing mastectomy to localize intercostal perforating vessels.
45663605|NCT02817633|Drug|Pemetrexed|Pemetrexed will be administered.
45957282|NCT02938312|Behavioral|Weight Loss Only|Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.
45663606|NCT02817633|Drug|Cisplatin|Cisplatin will be administered.
45817663|NCT02858713|Device|App|App named MyPso SmarTopTM Version 1.0 (LEO Pharma) was used for 28 days by participants in the intervention arm.
45957283|NCT02938312|Behavioral|Weight Loss Plus|Participants attend in-person meetings as described above. This condition also includes community-wide strategies to increase access to healthy affordable food and safe opportunities for physical activity.
45663607|NCT02817633|Drug|Carboplatin|Carboplatin will be administered.
45663608|NCT02817399|Device|Functional electrical stimulation|Electrical stimulation that cause muscle contraction while walking
45817664|NCT00375050|Drug|Riluzole|
45817665|NCT00375050|Drug|Placebo|placebo
45663609|NCT02817399|Device|Neuro-muscular electrical stimulation|Electrical stimulation that cause muscle contraction in a stationary position
45663610|NCT02817399|Procedure|Active exercises|Subjects will receive training exercise according to ACL reconstruction protocol
45663611|NCT05651607|Drug|Cannabidiol|Oral solution, taken 3 times a day (morning, noon and evening), 5 mg/kg/day from day D0 to day D4. If not effective and well tolerated, dose increase : 10 mg/kg/day from day D5 to day D9, then 20 mg/kg/day from day D10 to day D29, maximum 800 mg/day
45663612|NCT02775435|Biological|Pembrolizumab|IV infusion
45663613|NCT02775435|Drug|Paclitaxel|IV infusion
45663614|NCT02775435|Drug|Nab-paclitaxel|IV infusion
45663615|NCT02775435|Drug|Carboplatin|IV infusion Carboplatin dose should not to exceed 900 mg.
45663616|NCT02775435|Drug|Saline placebo for pembrolizumab|IV infusion
45663617|NCT05651529|Dietary Supplement|exogenous ketone salt supplement|Dietary Supplement: Fasting water and with exogenous ketone salt supplement. Participants will have to take 1 doses of supplement 30 minutes before the scan.
45817666|NCT03128372|Device|Desaturation|The delivered gas mixture will be adjusted to decrease the displayed saturation of peripheral oxygen. Each desaturation steps are of approximately 5 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
45817667|NCT02860507|Drug|sugammadex|
45817668|NCT02860507|Drug|Neostigmine|
45817669|NCT02860507|Drug|Glycopyrrolate|
45817670|NCT03082196|Drug|Test varnish|Topical application of test varnish to the teeth 4 times per year.
45817671|NCT03082196|Drug|Standard varnish|Topical application of test varnish to the teeth 4 times per year
45957284|NCT02938351|Behavioral|Collaborative care|Therapist will use iPad (Vidyo) once a week during dialysis for approximately one hour. The therapist will teach the patient cognitive-behavioral strategies to manage their mood and pain. The PI is a clinical psychologist and will provide supervision to the therapist providing the intervention. The sessions for depression will include (1) intake, (2) review of the rational for using CBT to treat depression and/or pain, (3) identifying thought patterns, (4) changing thought patterns, (5) relaxation techniques, (6) rest-activity pacing, and (7) coping strategies. Homework to practice these techniques will be provided after each session.
45957285|NCT04836910|Other|Dietary recommendations|"Fruit, vegetables, legumes (e.g. lentils and beans), nuts and whole grains (e.g. unprocessed maize, millet, oats, wheat and brown rice).~At least 400 g (i.e. five portions) of fruit and vegetables per day excluding potatoes, sweet potatoes, cassava and other starchy roots.~Less than 10% of total energy intake from free sugars Less than 30% of total energy intake from fats. Unsaturated fats (found in fish, avocado and nuts, and in sunflower, soybean, canola and olive oils) are preferable to saturated fats.~Less than 5 g of salt (equivalent to about one teaspoon) per day."
45663618|NCT05651529|Dietary Supplement|exogenous carbohydrate supplement|Dietary Supplement: Fasting water and with exogenous carbohydrate supplement. Participants will have to take 1 doses of supplement 30 minutes before the scan.
45957286|NCT04836910|Drug|Oral contraceptive pills|Hormonal treatment
45957287|NCT04836910|Drug|Metformin|Insulin resistance treatment
45957288|NCT00169728|Biological|DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa|
45957289|NCT00169728|Biological|heptavalent pneumococcal conjugate vaccine, Prevenar|
45817672|NCT03092089|Drug|Definity, (Lipid Microspheres) Intravenous Suspension|Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI
46079098|NCT05788068|Behavioral|Cognitive behavior therapy|Participants who allocate to the control group will receive CBT for smoking cessation by professional team.
46079099|NCT05788055|Diagnostic Test|Stool Analysis|Stool Analysis to detect H.Pylori Antigen in Stool
45458204|NCT02315092|Device|Fluorescence Imaging|Wounds will be imaged using violet light (405 nm) illumination to locate areas with bacterial presence to guide swabbing.
45817673|NCT03092089|Device|Myocardial Contrast Echocardiography|Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up
45817674|NCT03092089|Procedure|Repurfusion therapy with PPCI|Patients will receive reperfusion therapy with PPCI as standard of care
45817675|NCT03134144|Device|"Exoskeleton Chairless Chair"|One solution to reduce the exposure of employees to associated risks for developing work-related musculoskeletal disorders is to use exoskeletons. Using such a device in dynamic environments has the advantage over, e.g., robotics because it does not need any programming or teaching of robots. Moreover, exoskeletons are worn at the body and do not have to overcome spatial issues. In a recent review, 26 different exoskeletons have been described of which only two were designed to support the lower body during heavy work (de Looze et al. 2015). For lower intensive work tasks, like assembly tasks in the automobile industry, no study has focused on using exoskeletons to relieve employees while performing the work standing.
45957290|NCT04825717|Other|Nutrition and fluid plans prepared using calorimetry-based measurements.|Nutrition and fluid plans prepared using calorimetry-based measurements.
46079100|NCT05788042|Device|MagPro TMS device (ARTG: 204659)|rTMS will be administered using a MagPro TMS device (ARTG: 204659) which is approved for its intended use in this trial. rTMS involves the application of transient magnetic pulses which induce small currents in the underlying cortex via the principal of electromagnetic induction. rTMS will be administered using a patterned frequency stimulus called intermittent theta-burst stimulation (iTBS).This form of rTMS was chosen because a recent large multicentre trial showed 3 minutes of iTBS attained the same therapeutic effect as 30 minutes of standard rTMS, leading to FDA approval for depression. Each treatment session will comprise an extended iTBS session, i.e., 6.6 mins, delivered at 100% resting motor threshold (RMT). It will be targeted to the left DLPFC (F3 using the 10-20 International EEG system), consistent with the prior RCT of rTMS for AN.
46079101|NCT05788042|Device|tDCS mini-CT Stimulator (Soterix, USA: ARTG: 284637)|tDCS will be self-administered using the 1x1 tDCS mini-CT Stimulator (Soterix, USA: ARTG: 284637) with two saline-soaked sponge electrodes held in place on the scalp using the Soterix Ole-2 headband. The device is intended to treat different neurological and psychiatric disorders. tDCS involves the passing of weak electrical current through the brain via electrodes placed upon the scalp. The current modulates the resting membrane potential of stimulated neurons which causes changes in neuronal excitability. The anode will be placed over the left F3 (10-20 System) and the cathode over F4 (electrode sizes 5 x 5cm, 25cm2). This montage was chosen to target the left DLPFC, consistent with prior pilot studies of tDCS in AN.
46079102|NCT05788029|Procedure|laparoscopic pancreaticoduodenectomy|laparoscopic pancreaticoduodenectomy
46079103|NCT05788029|Procedure|open pancreaticoduodenectomy|open pancreaticoduodenectomy
45663619|NCT05651451|Device|Laser acupuncture|24 activated laser acupuncture treatments. Treatments was performed 3 times per week for 8 weeks.Laser acupuncture was applied withwavelength of 810 nm, power output of 150 mW in continuous wave mode and energy density laser of 4 J/cm2 with irradiation time 3 min/point
45817676|NCT02861131|Drug|Sugammadex|At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg through an intravenous line with brisk flow
45957291|NCT04823455|Procedure|fresh-frozen humeral head osteochondral allograft reconstruction for reverse Hill-Sachs lesion|Between 2001 and 2018, a total of 12 consecutive patients were surgically treated for a locked posterior glenohumeral dislocation with a humeral head defect affecting at least 30% of the head diameter. During surgery, the bone defect was substituted with a fresh-frozen humeral head osteochondral allograft.
45957292|NCT02938195|Radiation|radiotherapy|The clinical target volume of radiotherapy only includes the visible tumor and lymph nodes and the investigators wouldn't do any prophylactic radiation treatment.
45957293|NCT02938195|Procedure|Surgery|Surgery would be done 4-8 weeks after neoadjuvant chemoradiotherapy.
45957294|NCT00147524|Drug|quinapril|
45957295|NCT00147524|Procedure|Laser Doppler imaging|
45663620|NCT05651451|Dietary Supplement|energy-restricted diet|All post-menopausal women followed an energy-restricted diet for 8 weeks. Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E
45817677|NCT02861131|Drug|Neostigmine|At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be administered with Neostigmine at a dose between 0.1 to 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered.
45817678|NCT03134768|Other|This is not an interventional study|This is an observational study
45817679|NCT05247164|Procedure|EUS-guided Portal Vein sampling|"Transgastric and Transhepatic Fine Needle Aspiration of a branch of the Portal Vein under EUS guidance.~A paired peripheral sample will be acquired."
45957296|NCT00175422|Behavioral|The Period of PURPLE Crying Program|There are two treatment arms in the study. The first half of all subjects (n=500) will receive the PURPLE intervention materials (a video and a pamphlet) about infant crying. The second arm will receive comparable materials on infant safety and SIDS.
45957297|NCT04773106|Device|ARGOS-SC suprachoroidal pressure sensor|The ARGOS-SC pressure sensor was additionally used implanted during routine local intraocular pressure lowering procedures in patients in patients with glaucoma undergoing non-penetrating glaucoma surgery in the earlier ARGOS-SC01 study.
45957298|NCT00147563|Drug|Eplerenone|
46079104|NCT05788003|Diagnostic Test|self-collected and operator-collected swab followed by molecular analysis|A single midday urine sample and two cervical-vaginal swabs (both self-collected and speculum-aided collected by a female healthcare worker) will be obtained from participating women and processed using urine filtration and polymerase chain reaction (PCR) for cervico-vaginal samples.
46079105|NCT05787977|Other|Visual Feedback and Rhythmic Auditory Cue|Patients will be trained five times per week for eight weeks. After eight weeks of training the gait pattern and balance will be evaluated by the gait parameters, 6min Walk test, Pediatric Balance Scale and Berg balance scale.
46079106|NCT05787951|Diagnostic Test|Bone marrow aspirite for diagnosis|Routine investigation of acute myeloid leukemia such as bone marrow aspirite for diagnosis ,cbc
45817680|NCT05172206|Other|symptom-focused rehabilitation|Patients in this arm will be referred to a 3-week inpatient comprehensive rehabilitation program. Initially, patients will be classified into one out of three clusters namely: Cluster A (Fatigue), Cluster B (cognition), or Cluster C (physical). The content of the rehabilitation program will be individually adapted according to the patient's most relevant symptom cluster.
45817681|NCT05172206|Other|usual care|Patients in this arm do not receive any intervention beyond usual care during the study phase. However, all patients in this group will get the opportunity to also receive a rehabilitation program after the study phase.
45817682|NCT05098886|Drug|DA-5210 10/1000mg|single dose administration (one tablet once a day)
45817683|NCT05098886|Drug|DA-5210-R 10/1000mg|single dose administration (one tablet once a day)
45817684|NCT03093025|Drug|TS-121 10 mg|Orally taken once daily
45817685|NCT03093025|Drug|TS-121 50 mg|Orally taken once daily
45663621|NCT02774421|Drug|Trastuzumab after SubQ GM-CSF|
45663622|NCT02774421|Drug|Trastuzumab in combination with SubQ GM-CSF|
45817686|NCT03093025|Drug|Placebo|Orally taken once daily
45817687|NCT05098262|Drug|DA-5210 10/500mg|single dose administration (one tablet once a day)
45817688|NCT05098262|Drug|DA-5210-R 10/500mg|single dose administration (one tablet once a day)
45817689|NCT02950753|Drug|Lactated Ringer Solution|Fluid bolus of Lactated Ringer solution (30ml/kg).
45817690|NCT02950753|Drug|Normal Saline|Fluid bolus or Normal Saline (30ml/kg).
45817691|NCT03082586|Radiation|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
45817692|NCT03082586|Radiation|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
45957299|NCT03457870|Behavioral|Intermittent Energy Restriction|Dietary advice to follow a 5:2 diet.
45957300|NCT03457870|Behavioral|Chewing|Asked to chew 1 piece of gum for 10 minutes 3 times a day.
45957301|NCT03457870|Behavioral|Chewing + Intermittent Energy Restriction|Dietary advice to follow a 5:2 diet. Asked to chew 1 piece of gum for 10 minutes 3 times a day.
45957302|NCT00175461|Procedure|hip surgery|Comparison of the clinical effectiveness and cost-effectiveness of the MIS anterolateral approach (MIS Watson Jones, G3) versus anterolateral mini or posterolateral mini approaches in primary total hip arthroplasty
45957303|NCT02938273|Drug|avelumab|Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months
45663623|NCT05203419|Drug|MHS552|MHS552 will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
45957304|NCT02938273|Radiation|radiotherapy|5 times a week, 7 weeks, total dose 70 Gy
45957305|NCT02938273|Drug|cetuximab|loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7
45817693|NCT03082586|Radiation|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
45663624|NCT05203419|Drug|Placebo|Placebo will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
45957306|NCT02941939|Other|Hyperbaric chamber|
46079107|NCT05787938|Device|MRI|A procedure that uses radio waves, a powerful magnet, and a computer to make a series of detailed pictures of areas inside the body. A contrast agent, such as gadolinium, may be injected into a vein to help the tissues and organs show up more clearly in the picture. MRI may be used to help diagnose disease, plan treatment, or find out how well treatment is working. It is especially useful for imaging the brain and spinal cord, the heart and blood vessels, the bones, joints, and other soft tissues, the organs in the pelvis and abdomen, and the breast. Also called magnetic resonance imaging, NMRI, and nuclear magnetic resonance imaging.
45663625|NCT04791969|Drug|Naltrexone Hydrochloride|Intermittent Oral Naltrexone, 50 mg
45663626|NCT04791969|Drug|Placebo|Intermittent Oral Placebo
45817694|NCT03082586|Radiation|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
45817695|NCT03082586|Radiation|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;
45663627|NCT04791969|Behavioral|Ecological Momentary Intervention|"Receive ecological momentary intervention if ecological momentary assessment reports meth craving, stress, not taking study drug, or antecedents detected for high risk meth use."
45663628|NCT05651373|Drug|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
45957307|NCT02941939|Other|Ambient pressure|
45957308|NCT02941861|Other|Recurrence Rate of HCC after surgery|Recurrence Rate of HCC after surgery
45957309|NCT02941861|Other|Recurrence Rate of CCA after surgery|Recurrence Rate of CCA after surgery
45957310|NCT00147602|Drug|atorvastatin|
45663629|NCT05651373|Drug|Hydroxychloroquine|200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
45663630|NCT05651373|Drug|CertolizumabPegol injection|200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response.
45663631|NCT05198583|Other|E-Fit|The intervention lasts a total of 8 weeks and is structured in 3 modules. The first module consists of a weekly strategy training in which problems resulting from executive dysfunction are addressed. Online games form the second module. These are games implemented online to promote EF through play. The third module is also based on games: The families receive several board games to play together at home. This third module is voluntary.
45663632|NCT05605119|Drug|AUR105|Once daily
45663633|NCT02607033|Other|Exercise|Individuals will be asked to walk 3 times a week on a treadmill (initially starting at 15 minutes and progressing up to 40 minutes) and participate in a short weight training program focused on increasing strength in the legs.
45957311|NCT00169767|Other|Comparison study between KTP and HoLAP for BPH|Comparison study between KTP and HoLAp for BPH
45957312|NCT02941588|Procedure|Non-cardiac surgery|Any surgery with general anesthesia except cardiac surgery
45957313|NCT02941744|Drug|nivolumab|low fixed dose ipilimumab in combination with nivolumab
45957314|NCT02941744|Drug|ipilimumab|low fixed dose ipilimumab in combination with nivolumab
45957315|NCT02941822|Drug|Ambroxol|Details outlines in the intervention description.
45957316|NCT02941471|Device|Interferential Stimulation|Transabdominal interferential electrcial stimulation
45957317|NCT02941471|Device|TENS stimulation|Transabdominal standard electrical stimulation
45957318|NCT05317780|Drug|rAAV9-CB6-AspA|This study is an open label, expanded access trial of a simultaneous, single intravenous (IV) and intracerebroventricular (ICV) administration of rAAV9-CB6-AspA in a child with Canavan disease. The subject will also receive an immunosuppression protocol to prevent reaction to ASPA and vector capsids.
45957319|NCT02941510|Drug|Budesonide|Budesonide is FDA approved for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). It works by reducing lung inflammation to increase oxygen uptake by the body. The researchers are examining if this medication can prevent altitude sickness.
45957320|NCT02941510|Other|Placebo|Subject(s) will participate in all study activities but will receive placebo.
45957321|NCT00147680|Drug|Paclitaxel, Carboplatin|
45957322|NCT05037877|Dietary Supplement|HUM supplement|HUM supplement - 1 capsule per day
45957323|NCT05037877|Dietary Supplement|Placebo|Placebo supplement - 1 capsule per day
45957324|NCT02940184|Drug|Tablet Sitagliptin 100mg (evening before and morning of experiments)|On one of two experiment days participants will have Dipeptidyl peptidase 4 activity inhibited using a DPP-4 inhibitor (Sitagliptin).
45957325|NCT02940184|Other|Intestinal Fructose administration|On both experimental days fructose (35g dissolved in water, total volume 100mL) will be administered via an intrajejunal tube
45957326|NCT03458377|Other|Educational telephone call|Explanation of the importance of making the test. Guidelines for the usual medication of the patient. Definition of fasting, explanation of colon cleansing adjusted to the presence of predictors of poor basic preparation. Explanation of the endoscopic procedure with the elimination of erroneous concepts of the patient with respect to the procedure. Explanation of norms of action subsequent to the endoscopy. Management of scheduling, destined to improve the adherence of the patient for the test.
45957327|NCT03458143|Drug|Ketamine 150 ng/ml|conscious sedation in TCI-mode
45663634|NCT02607033|Other|Weight Loss|Individuals will be asked to meet with a registered dietitian once a week to discuss strategies to reduce daily caloric intake to gradually reduce body weight over 6 months.
45817696|NCT03082586|Radiation|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
45817697|NCT03086408|Device|THRIVE|active nasal oxygen delivery system
45957328|NCT03458143|Drug|Remifentanil|conscious sedation in TCI-mode
45663635|NCT03905889|Drug|Abemaciclib|Subjects will by given oral Abemaciclib every 12 hours for 14 days followed by 7 days off (i.e. a 21 day cycle). The initial dose will be 100 mg (Dose level 1) followed by 150 mg (Dose Level 2) depending on tolerability and toxicity assessment of the combination of medications. If at Dose Level 1 subjects cannot tolerate the combination of medications, the Abemaciclib would not be increased, and the dose will remain stable at 100 mg (Dose Level -1).
46079108|NCT05787925|Drug|Topical corticosteroid and Vitamin E|"26 patients who will administrate topical corticosteroid: triamcinolone acetonide 1% oral gel Kenacort-A Orabase * three times daily for 8 weeks applied after meals and at night with avoidance of foods and drinks for 30 minutes after the application. In addition to one capsule of 400 mg oral systemic vitamin E supplement* will be prescribed once daily at the morning"
45817698|NCT03086408|Device|Endotracheal tube or Supraglottic airway|Plastic devices for mechanical ventilation
45817699|NCT05057858|Drug|co-formulated 300 mg TDF/ 200mg FTC|Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 300 mg TDF/ 200mg FTC
45957329|NCT03458143|Procedure|Oocyte retrieval|Oocyte retrieval for In Vitro Fertilization
45957330|NCT03458143|Drug|Ketamine 200 ng/ml|conscious sedation in TCI-mode
45957331|NCT00147485|Drug|AG-024322|
45957332|NCT00175500|Device|Large Diameter Femoral Head|
45957333|NCT02939911|Device|Residual neuromuscular blockade measurement|Just prior extubation in OR and at the arrival to PACU the residual neuromuscular blockade will be measured by accelerometry
45957334|NCT02941354|Drug|turoctocog alfa|Each subject will receive a single dose of turoctocog alfa as an intravenous (i.v.) bolus injection of 50 IU/kg.
45957335|NCT04723992|Other|retrospective analysis|The investigators retrospectively analyzed the outcome and possible prognostic factors in polytrauma patients.
46079109|NCT05787925|Drug|Topical corticosteroid|"26 patients will administrate topical corticosteroid: triamcinolone acetonide 1% oral gel Kenacort-A Orabase three times daily for 8 week that will be applied after meals and at night with avoidance of foods and drinks for 30 minutes after the application"
45663636|NCT03905889|Drug|Sunitinib|Subjects will take oral Sunitinib daily for the 21-day cycle. Dosing will be at 50 mg for both Dose Levels 1 and 2. If the combination of the 2 medications is not tolerated by Subjects at Dose Levels 1 a lower dose of Sunitinib (37.5 mg) will be given (Dose Level -1).
45663637|NCT05582187|Drug|Fosmanogepix|a single dose of fosmanogepix administered by mouth under fasted conditions
45663638|NCT04804059|Drug|[14C]-APX001 Oral Solution|Total dose containing NMT 3.1 MBq (84.0 µCi) 14C
45957336|NCT02941432|Other|Black tea compress treatment|Wet compresses with black tea applied 4-5 times daily to the face for 6 days
45957337|NCT05301946|Other|Outcome Measurements|The 24-item ICF Core Set for Stroke, Standardized Mini-Mental State Examination, Stroke Impact Scale, Rivermead Mobility Index, and Home Safety Checklist were applied to the stroke patients. The assessment period took one hour.
46079110|NCT05787912|Device|Photobiomodulation|The surgical sites were irradiated with a diode laser (980 nm, 0.2W) only.
45663639|NCT04804059|Drug|[14C]-APX001 Solution for Infusion|Total dose containing NMT 3.4 MBq (93.0 µCi) 14C
45957338|NCT05291611|Behavioral|Online-based Cognitive-behavioral Therapy for OCD|26 patients with obsessive-compulsive disorder (OCD) receive treatment with cognitive-behavioral therapy. 14 sessions will take place via the internet.
45957339|NCT02941393|Device|Intrauterine pressure catheter|
45957340|NCT02941393|Device|External tocodynamometry|
45957341|NCT02941198|Device|GyneFix|The fiber is fixed to the anchoring thread by means of a stainless steel clip 1 cm from the upper part of the anchoring knot. The anchoring knot is implanted into the myometrium of the uterus thus permanently securing the implant in the uterine cavity
45663640|NCT05561829|Behavioral|Sleep Optimization|Automated digital administration of a sleep optimization module via mobile or web application, lasting approximately six weeks. Based on the participant's situation and needs, sleep restriction, sleep compression, or circadian-rhythm normalization is advised and conducted. The aim is to optimise the participant's sleep efficiency.
45957342|NCT02941198|Device|Cu T380 A|Cu T380 A will be inserted into the uterus
46079111|NCT05787912|Other|Hyaluronic acid after photobiomodulation|The surgical sites after gingivectomy were irradiated with a diode laser (980 nm, 0.2W) then covered by 2% Hyaluronic acid gel loaded in a special appliance for each patient.
45458205|NCT01144897|Radiation|PET Acetate scan|PET Acetate scans will be done to detect prostate cancer lesions.
45663641|NCT05561829|Behavioral|Stimulus Control Therapy|Automated digital administration of a stimulus control therapy module via mobile or web application, lasting approximately six weeks. The aim is to strengthen associations between sleep and the sleep environment and to eliminate conditioning of non-sleep behavior and the sleep environment.
45817700|NCT02951143|Drug|SPECTRUM cigarettes|Across six laboratory sessions, participants will consume 10 puffs of either their usual brand of cigarette (one session) or a SPECTRUM cigarette (five sessions) with a nicotine yield varying from 0.03 to 0.70 and either menthol (TPMF codes NRC 103, NRC 201, NRC 301, NRC 401, and NRC 601) or tobacco (TPMF codes NRC 102, NRC 200, NRC 300, NRC 400, and NRC 600) flavor, depending on preference. This will be followed by the collection of blood nicotine content and a cigarette purchase task.
45663642|NCT05561829|Behavioral|Relaxation Training|Automated digital administration of a relaxation training module via mobile or web application, lasting approximately six weeks. The aim is to reduce somatic tension and limit intrusive thought processes that interfere with sleep.
45817701|NCT02951143|Drug|SPECTRUM cigarettes between|Participants will be assigned one of the nicotine concentrations of a SPECTRUM cigarette. They will complete a cigarette purchase task and make real purchases for the next week. Participants will return and make purchases again, repeating 4 times.
45817702|NCT05040152|Behavioral|Dietary Counseling and Surveillance|Receive dietary recommendations
45817703|NCT05040152|Other|Exercise Intervention|Complete home exercises
45817704|NCT05040152|Other|Informational Intervention|Receive education brochures
45957343|NCT00147719|Drug|Colesevelam hydrochloride|
45957344|NCT02941159|Biological|SF2000SD|This is an intergrase inhibitor
45957345|NCT02941159|Biological|Placebo|
45957346|NCT05273671|Drug|Nalbuphine|will receive 0.1 mg/kg NAL diluted in 10 ml I.V 10 minutes before the end of surgery
45957347|NCT05273671|Drug|Dexmedetomidine|will receive dexmedetomedine 0.5 mic/kg diluted in 10 ml I.V 10 minutes before the end of surgery
46079112|NCT05787860|Drug|Ruxolitinib 1.5% Cream|topical ruxolitinib 1.5% cream twice daily for 4 weeks
46079113|NCT05787808|Dietary Supplement|Calsium, Vitamin D, Jarlsberg cheese|Oral
45817705|NCT05040152|Other|Questionnaire Administration|Ancillary studies
45817706|NCT05040152|Behavioral|Telephone-Based Intervention|Receive telephone-based weight loss intervention
45817707|NCT04707404|Procedure|Cranioplasty|The surgery implanted artificial material to repair the skull defect.
45957348|NCT05273671|Drug|normal Saline|will receive with a saline solution 10 min before the end of surgery
45957349|NCT00408018|Drug|P276-00|Potent Cyclin dependent kinase (cdk) cdk4 D1, cdk1 B and cdk9 T inhibitor
45957350|NCT00147758|Drug|Colesevelam hydrochloride|
46079114|NCT05787769|Drug|P shot arm ( Autologous Platelet Rich Plasma)|Autologous Platelet Rich Plasma + placebo tab Each injection session will consist of a total of 10 mL PRP infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum
45957351|NCT05229484|Other|an integrated multimodal lifestyle intervention (MLifeI)|The MLifeI program focused on the roles of health responsibility, review of lipid profile, complications of imbalanced lipid profile, lipid management and nutritional education.
45957352|NCT02931409|Procedure|Optimal PEEP|Optimal PEEP determined by Cstat during PEEP titration procedure.
45663643|NCT05561829|Behavioral|Cognitive Therapy|Automated digital administration of a cognitive therapy module via mobile or web application, lasting approximately six weeks. The aim is to identify, challenge, and modify dysfunctional beliefs about sleep.
45817708|NCT04707092|Drug|Antibiotic|Antibiotic in case of now allergies will be Cefazolin at induction and Amoxicillin plus Clavulanic acid for the oral treatment week
45957353|NCT02931409|Procedure|Standard PEEP|Lung protective mechanical ventilation applying a PEEP value of 6 cmH2O
45957354|NCT02931448|Device|Dosage of the blood HbCO thanks to the carboxymeter MASIMO RAD 57|
45957355|NCT02931526|Drug|Tigecycline|Patients who have the definitive diagnosis to treat with tigecycline for bacterial infection will be started on tigecycline with a loading dose 200mg IV followed by 100mg IV every 12h.
46079115|NCT05787769|Drug|PDE5i arm|Patients will be treated by tadalafil 5 mg tablet daily in addition to four Tadalafil 5 mg tablet 3 hours before intercourse on demand in addition to placebo injection. Each injection session will consist of a total of 10 mL saline solution infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum.
45957356|NCT00169845|Dietary Supplement|Alpha-Tocopherol and Beta-Carotene|Provided by Roche Vitamins Inc.
46079116|NCT05787743|Other|Facial cream with 2% palm tocotrienols extract|Apply on the face twice a day
46079117|NCT05787743|Other|Base cream|Apply on the face twice a day
46079118|NCT05787730|Device|Transobturator tape|
46079119|NCT05787704|Other|No intervention|"Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~Dual-task walking with the auditory stroop task.~Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~Navigational and dual-task walking (condition 1 and 2 together)"
45663644|NCT05561829|Behavioral|Sleep Hygiene Education|Automated digital administration of a sleep hygiene education module via mobile or web application, lasting approximately six weeks. The aim is to identify and modify environmental and lifestyle factors that may interfere with sleep.
45817709|NCT04707014|Behavioral|Hypnosis|Rapid conversational hypnosis
45957357|NCT00169845|Dietary Supplement|Placebo|Provided by Roche Vitamins Inc
45957358|NCT02931487|Behavioral|Attentional Bias Modification|Computerized
45957359|NCT02931487|Behavioral|Sham Comparator|Computerized
45957360|NCT02931370|Dietary Supplement|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
45957361|NCT00169884|Behavioral|cognitive-behavioural therapy|
45663645|NCT05475171|Drug|MGD019|Given by vein (IV)
45817710|NCT04707014|Behavioral|Attention-distracting techniques|i-pad with movies, games and music
45957362|NCT04597684|Procedure|Cementless Total Knee Arthroplasty|Total Knee Arthroplasty (TKA) with cementless knees
45957363|NCT04597684|Procedure|Cemented Total Knee Arthroplasty|Total Knee Arthroplasty (TKA) with cemented knees
45957364|NCT00147836|Drug|Human Insulin (Novolin-R, Novo Nordisk)|
45957365|NCT00147836|Device|H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland|
45957366|NCT00147836|Other|Pre-meal|
45957367|NCT00147836|Drug|Novolin-R|
45957368|NCT00147836|Drug|Human Insulin NPH (Novolin-N, Novo Nordisk)|
45957369|NCT00147836|Drug|Gliclazide (Diamicron, Servier)|
45957370|NCT00147836|Drug|Diamicron and Glucophage|
46079120|NCT05787691|Other|Individualised pain management|"TPS pain management consists in an evaluation by a pain physician, followed by specific measures for patients identified as having a particularly high risk of CPSP. The choice of these measures will be individualised according to specific risk factors and left to the discretion of the pain physician.~Potential measures: patient education, adjustment of analgesic therapy, referral to a psychiatrist or psychologist, cognitive behavioural therapy, hypnosis, use of locoregional analgesia for surgery, infusions of ketamine and/or lidocaine, introduction of gabapentins and/or antidepressants."
46079121|NCT05787678|Biological|Dupilumab|600 mg (two 300 mg injections), followed by 300 mg monthly
45957371|NCT04534738|Behavioral|Mediterranean Diet|The Mediterranean Diet is high in fruit, vegetables, legumes, nuts and seeds, whole grains, and olive oil; moderate in seafood, dairy products (e.g., cheese and yogurt but not whole milk or butter), eggs, poultry, and red wine with meals; and low consumption of sweet desserts, red meat, and highly processed foods.
45957372|NCT02931292|Procedure|Laparoscopic sleeve gastrectomy|"Special care was given to the complete mobilization of the gastric fundus, with meticulous dissection of the posterior gastric wall from the left pillar. A 36-Fr calibration bougie was used. Resection started 2 to 6 cm from pylorus, and it was conducted upward to 1.5 cm from the angle of His, to avoid the critical area. A gastric remnant of 60-80 mL volume (measured by administering methylene blue saline solution via nasogastric tube) was obtained."
45957373|NCT02931136|Drug|Huperzine A|The participants will treatment by the Huperzine A 200 ug/day in 52 weeks.
45957374|NCT02931136|Drug|Placebo|The participants will treatment by the placebo in 52 weeks.
45957375|NCT00175539|Behavioral|psychoeducational intervention|three 1.5 hour long group psychoeducational sessions
45957376|NCT02931175|Drug|ACTH gel|Starting at month 6, retreatment will be offered to study subjects who have demonstrated any level of response during the first 6 months and who meet any of these Retreatment Criteria listed below. Patients receiving retreatment will receive the dose that was assigned to them at randomization.
45957377|NCT00147875|Drug|Prednisone|
45957378|NCT00147875|Drug|Vinblastine|
45957379|NCT00147875|Drug|Doxorubicin (Adriamycin)|
45957380|NCT00147875|Drug|Gemcitabine|
45957381|NCT04690036|Drug|toripalimab injection|when EBV-DNA is positive after allo-HCT, and EBV infected T/NK cell, one dose of toripalimab 3mg/kg would be used, the same dose would be repeated 4 weeks later.
45957382|NCT02931214|Drug|GMI-1359|
45663646|NCT03846765|Drug|Phenylephrine|"Phenylephrine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Phenylephrine will be started at 0,2 μg/kg/min and adjusted according to the patient's hemodynamic status. The dose will be adjusted to MAP during a 30-minute study period."
45663647|NCT03846765|Drug|Dobutamine|"Dobutamine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Dobutamine will be started at 2 μg/kg/min; and adjusted according to the patient's hemodynamic status .The dose will be adjusted to MAP during a 30-minute study period."
45663648|NCT05163405|Drug|Bortezomib|Self-administration of subcutaneously Velcade.
45663649|NCT02482467|Other|Hormonal analysis, pelvic US|
45957383|NCT02931214|Drug|Placebo|
45957384|NCT02931019|Procedure|Intubation|
45957385|NCT00169923|Drug|rosiglitazone|
45957386|NCT02930668|Dietary Supplement|Glucosanol 350mg|
45957387|NCT02930668|Dietary Supplement|Glucosanol 500mg|
45957388|NCT02930668|Dietary Supplement|Placebo|
45957389|NCT00147914|Drug|Cefdinir (drug)|cefdinir 300mg per orally twice daily for 10 days
45957390|NCT00147914|Drug|amoxicillin/clavulanate|1000mg /62.5mg extended release per orally twice daily for 10 days
45957391|NCT02930746|Drug|BAY987516|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z46-092)
45957392|NCT02930863|Other|pulse oximetry software|This pulse oximetry software will utilize automated verbal prompts that direct the patients to breathe when their pulse oximetry reading falls at or below 93%.
45957393|NCT02930863|Behavioral|Brief post-PACU stay survey.|Complete a brief post-PACU stay survey focused around their satisfaction and experience during their time in the PACU.
45957394|NCT00147953|Drug|Rituximab|
45957395|NCT00147953|Procedure|Total nodal irradiation|
45458206|NCT01144897|Drug|Carbon-11 labeled Acetate|C-11 Acetate is a radiotracer used in PET scanning
45957396|NCT02930785|Drug|BAY987517|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code:Z46-104)"
45957397|NCT02930551|Drug|Lidocaine|
45957398|NCT02930551|Drug|Isotonic Saline|
45957399|NCT02930356|Other|NSPT|NSPT was done by ultrasonic scalers after administration of pre procedural mouth rinse in the test group (20 smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
45957400|NCT02930356|Other|Scaling and root planing|Scaling and root planing was done by ultrasonic scalers after administration of pre procedural mouth rinse in the control group (20 non smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
45957401|NCT00175617|Drug|Spironolactone|This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
45957402|NCT00175617|Drug|Minoxidil|This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
45957403|NCT02930707|Drug|Magnesium Sulfate|ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulfate 10% (200 mg), on each side of the abdominal wall.
45957404|NCT02930707|Drug|Bupivacaine|ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
45957405|NCT00148031|Drug|Pegylated Interferon and Ribavirin|Both groups with receive the same medical intervention but offered at different locations
45957406|NCT00148031|Behavioral|Psychosocial|Assessment of the likelihood of HCV treatment initiation and completion
45957407|NCT00148031|Behavioral|On-site (MMT Clinic) HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
45663650|NCT05474469|Other|Diaphragmatic breathing exercises|12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
45663651|NCT05474469|Other|Abdominal muscle strengthening exercises|12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
45957408|NCT00148031|Behavioral|Off-site HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
45957409|NCT02930473|Behavioral|NIC Psychotherapeutic Intervention(s) for Anxiety|Patients will be treated by NIC psychotherapeutic intervention(s) for anxiety (e.g. anxiety reduction) plus psychopharmaceuticals prescribed by their psychiatrist.
45663652|NCT02426307|Procedure|TAVR|TAVR: Transcatheter Aortic Valve Replacement
45454952|NCT03935659|Device|Negative Pressure Pressure Wound Therapy|Investigators will be using a Negative Pressure Wound Therapy Powered Suction Pump on primarily closed groin wounds after open common femoral artery exposure, The Negative pressure dressing will be applied in a sterile fashion in the operating room. The negative pressure dressing will be removed at day 5 postoperatively, or at discharge, whichever occurs first.
45817711|NCT02867059|Drug|(+)-SJ000557733|(+)-SJ000557733 (SJ733), in short SJ733, will be the second PfATP4 inhibitor to enter clinical development after KAE609 (Novartis) which is currently in Phase 2 stage. KAE609 (cipargamin; previously known as NITD609) is a spirotetrahydro-β-carbolines (spiroindolone). KAE609 inhibits QP15C20_SJ733_Challenge Protocol_v2.0_26July2016 Page 28 of 110 PfATP4, which results in a disruption of parasite sodium homeostasis. Compared to KAE609, SJ733 has the potential to be a very fast acting, antimalarial drug for human therapeutic application and may have a different safety profile in human participants. Finally, SJ733 blocks parasite transmission in vivo at potencies close to those where it is efficacious in blood stages, indicating its potential for transmission blockade in humans.
45663653|NCT02426307|Procedure|SAVR|SAVR: surgical Aortic Valve Replacement
45663654|NCT02325531|Other|Low support|"EHR-based tools, built by OCHIN, activated during Year 1 TOOLKIT, paper and electronic form, includes documents to help support ALL implementation, and~BASIC WEBINAR, Annual, 1-hour, topics such as:~Talking to Clinicians About ALL, Using The Monthly Feedback Report and Integrating the Toolkit into Workflows"
45663655|NCT02325531|Other|Medium support|"Same as provided to the low support arm, PLUS~STAFF TRAINING (2-day meeting in Portland, Oregon, Led by Implementation Specialists (IS), How to use the toolkit and how to train others to use it, Content guided by previous research, baseline survey results, study team and the S-N advisory group~ADAPTIVE WEBINARS, Quarterly 1-hr webinars, Content from basic webinars, tailored to topics requested by study clinics. Forum for group discussion and best practice sharing. Open any interested clinics in Arm 2 & 3."
45817712|NCT04985708|Other|data collection of clinically available procedures|when to place Impella related to PCI in patients with AMICS
45817713|NCT03088748|Device|Journey II posterior cruciate retaining total knee arthroplasty|
45817714|NCT03088748|Device|Journey II posterior bi-cruciate retaining total knee arthroplasty|
45817715|NCT02953561|Drug|Avelumab|Given IV
45817716|NCT02953561|Drug|Azacitidine|Given SC or IV
45957410|NCT02930473|Drug|Psychopharmaceuticals (any drugs prescribed by the psychiatrist)|Patients will be treated only by psychopharmaceuticals prescribed by their psychiatrist.
45957411|NCT02930434|Dietary Supplement|cholecalciferol|Administration of vitamin D3
45817717|NCT02953561|Other|Laboratory Biomarker Analysis|Correlative studies
45817718|NCT03090620|Drug|Physostigmine|Administration of physostigmine bolus followed by an infusion
45957412|NCT00175656|Procedure|Elimination of titanium elastic nail prominence at the insertion site and leaving the nails in situ|See Detailed Description.
45957413|NCT02930512|Procedure|DXA scan|
45957414|NCT02930512|Procedure|pQCT scan|
45957415|NCT00148070|Drug|Docetaxel|You will then receive your first dose of docetaxel chemotherapy. It is put through your IV over 1-2 hours. you will receive docetaxel every 3 weeks in the Cancer Center Infusion area.
45957416|NCT00148070|Procedure|Erythromycin Breath Test (ERMBT)|you will have an erythromycin breath test, which is an experimental test which is used to estimate the amount of enzyme produced by your liver which can metabolize the chemotherapy, docetaxel. For this test, you go to the GCRC where you will receive an injection of erythromycin (an antibiotic) which is labeled with a very small amount of radioactive substance. 20 minutes later you will blow air from your mouth into a blue solution until it clears. Your doctors will calculate the dose of docetaxel to be given to you based on this blood test, on your body's albumin level (a protein determined on the blood test), and on your height and weight.
45663656|NCT02325531|Other|High support|"Same as provided to the low and medium support arms, PLUS~- PRACTICE FACILITATION: Site visits with support as needed, Staff presentations, Coaching on tools (how to present to clinic staff and how to use in the clinic workflow), Tailored problem-solving support to address identified barriers, Clinical questions fielded by RN practice facilitator and site clinician champion."
46079122|NCT05787639|Drug|Evorpacept|After stereotactic radiation to primary tumor and neck on week 1 of study, Evorpacept 45 mg/kg is administered by IV infusion every three weeks starting on Week 2, Day 1 of study for a total two 21-day cycles (6 weeks)
45817719|NCT03090620|Drug|Lorazepam|Administration of lorazepam bolus followed by normal saline infusion
45817720|NCT04938752|Drug|DA-2811|single dose administration (one tablet once a day)
45817721|NCT04938752|Drug|DA-2811-R|single dose administration (one tablet once a day)
45817722|NCT02953873|Drug|Tacrolimus Extended Release Capsule|goal trough 5 - 12ng/mL
45817723|NCT02953873|Drug|Mycophenolate mofetil|≥500mg twice a day
45817724|NCT02953873|Drug|Prednisone|goal dose 5mg daily
45817725|NCT02953873|Drug|Mycophenolate Sodium|≥360mg twice a day
45817726|NCT03141242|Behavioral|ENACT group visit|Participation in two 2 hour group visits about advance care planning.
45817727|NCT03141242|Behavioral|Mailed Resources|Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
45817728|NCT03095053|Procedure|comprehensive chromosome screening|"Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 5 of in vitro embryo culture. Biopsies will be performed using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.~Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, Illumina, California, USA)."
45817729|NCT00375115|Drug|Sambucol|
45817730|NCT03098173|Procedure|Early colonoscopy|Performance of prepared colonoscopy within 24 h of arrival
45817731|NCT03098173|Procedure|Elective colonoscopy|Performance of prepared colonoscopy between 24 and 96 h after arrival
45817732|NCT03091478|Drug|Pembrolizumab|200mg every 3 weeks
46079123|NCT05787626|Other|manipulation|miofascial technique in diaphragmatic region
45454953|NCT03935659|Procedure|Standard Wound Care|Standard sterile gauze coverage of the primarily closed groin wound.
45663657|NCT02325531|Other|Comparison|No support was provided by the researchers. The EHR-based toolkit was available to all clinics in the network if they actively searched it out in the EHR.
45663658|NCT03822897|Radiation|Radiation|"35 fractions, 5/wk, 7 wks 70Gy/56Gy, or~35 fractions, 6/wk, 6 wks, 70Gy/56Gy, or~35 fractions, 5/wk, 7 wks OR 6/wk, 6 wks 70Gy/56Gy"
45663659|NCT03822897|Drug|Cisplatin|100 mg/m2 on day 1, 22, and 43 or 40 mg/m2 /wk for 7 wks
45663660|NCT04789551|Other|Blood Sample|a blood sample will be collected
45663661|NCT04788069|Dietary Supplement|Wholemeal bread|180g wholemeal bread/day + fixed portion at test day
45817733|NCT02867605|Dietary Supplement|Hyaluronan|
45817734|NCT03092024|Other|SPIN-HAND program|The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
45817735|NCT03098641|Procedure|pelvic organ prolapse repair|Surgery to repair pelvic organ prolapse through the vagina using stitches with the addition of surgical mesh.
45817736|NCT03092960|Behavioral|Minimal intensity intervention|The minimal intensity intervention control includes the Group Lifestyle Balance (GLB) videos (DVD or online), standardized messages, and access to a lifestyle coach if initiated by the participant.
45817737|NCT03092960|Behavioral|HOMBRE|HOMBRE is a Group Lifestyle Balance (GLB)-based intervention tailored for men and available in 3 delivery modalities (coach-facilitated individual approach, coach-led online virtual groups, and coach-led in-person groups). A lifestyle coach will support men in making an informed choice of modality and will provide ongoing individualized feedback. All delivery modalities provide the same evidence-based curriculum and include self-monitoring and individualized feedback from the lifestyle coach.
45817738|NCT02870101|Diagnostic Test|Nucleic acid amplification test 1 for NG and CT|A combination test using real-time PCR to detect DNA from NG and CT.
45817739|NCT02870101|Diagnostic Test|Nucleic acid amplification test 2 for NG and CT|A combination test using target amplification to detect RNA from NG and CT.
45817740|NCT02870101|Diagnostic Test|Nucleic acid amplification test 3 for NG and CT|A combination test using real-time PCR to detect DNA from NG and CT.
45817741|NCT00375596|Drug|Ketotifen/vasoconstrictor|
45817742|NCT03143894|Device|tDCS|Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.
45817743|NCT03143894|Other|Sham tDCS|Sham Transcranial direct current stimulation (tDCS)..
45817744|NCT03144518|Other|Positive Affect Intervention|See Previous Description
45817745|NCT03144518|Other|Neutral Control Intervention|See Previous Description
45817746|NCT03144518|Biological|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
45817747|NCT03148262|Device|The Comfort Flo system|The Comfort Flo system will be used for the high flow nasal cannula during procedural sedation
46079124|NCT05787574|Drug|Emapalumab|Emapalumab on Days -22 (22 days before the day of the stem cell transplant), -15, -8, and -1.
46079125|NCT05787574|Drug|Fludarabine and Dexamethasone|Fludarabine and dexamethasone for 5 days in a row on Days -22 through -18.
46079126|NCT05787574|Procedure|Stem Cell Transplant|Participants in both groups will receive their standard-of-care stem cell transplant on Day 0.
46079127|NCT05787535|Drug|Fludarabine + Cyclophosphamide|Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days
45957417|NCT02930629|Device|Train-of-Four (TOF) Watch|"For patients, on arriving in PACU after having had muscle relaxants during general anaesthesia~Two ECG electrodes will be placed 4 cm apart over the path of the ulnar nerve of the wrist after cleaning the skin with alcohol swabs.~The TOF force transducer will be placed on the volar aspect of the thumb.~The TOF Watch leads will be attached to the ECG electrodes.~A TOF stimulus will be applied: four twitches at 2Hz (every 0.5 seconds), each twitch lasting 0.2ms, and at a current of 50 mA. As far as possible, this will be done when patients are still slightly drowsy from the effects of anaesthesia.~Two TOF ratio will be elicited (two sets of four twitches 15 seconds apart), and an average of the two taken"
46079128|NCT05787535|Biological|HRYZ-T101 TCR-T Cell|On day 1, the TCR-T cells will be administered one time.
46079129|NCT05787522|Device|contouring of thoracic organs at risk|The thoracic organs at risk will be contoured by investigators independently, and by investigators assisted with software, at different time points. Judged by the golden standards established by the expert team, the contours will be evaluated. But the contoured organs in any group will not be applied in radiotherapy.
46079130|NCT05787509|Drug|Progesterone Sustained-release vaginal gel|the treatment time of vaginal progesterone
46079131|NCT05787496|Drug|NC525|Monoclonal antibody specific for LAIR-1
45817748|NCT03148262|Device|The Salter nasal cannula|A Salter nasal cannula will be used at 4L/ minute during the procedural sedation.
45817749|NCT03099655|Device|Attain Stability Quad Left Ventricular Pacing Lead|cardiac stimulation
45817750|NCT03093272|Drug|Leuprolide Acetate|a GnRH agonist
45817751|NCT03093272|Drug|Prednisone|Prednisone is a corticosteroid
45817752|NCT03093272|Drug|Docetaxel|Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly.
45817753|NCT03093272|Drug|Apalutamide|The apalutamide drug substance is an almost white to slightly brown powder. The tablet formulation of apalutamide is an immediate release oral tablet containing 60-mg of drug substance, with a non-functional green film coat
45957418|NCT02930395|Procedure|serum S100B assay|
45957419|NCT00175695|Drug|Recombinant human activated protein C or drotrecogin alpha|We are going to investigate a compound (recombinant human activated protein C (rhAPC)) that has the potential to modify disease activity in pre-eclampsia by reducing coagulation and inflammation disorders.
46079132|NCT05787483|Behavioral|MindUP group|MindUP is a Collaborative for Academic, Social, and Emotional Learning SELect (CASEL) program, meaning the program is evidence-based and meets the adequate criteria for developing students' social and emotional competence at the highest level. MindUP addresses all five components of the CASEL SEL Framework: self-awareness, social awareness, self-management, responsible decision-making, and relationship skills (CASEL, 2020). Students are taught how the workings of the brain are related to emotions, behaviors, decision making, and learning. MindUP is the first program to provide clear instruction in both SEL and mindfulness.
46079133|NCT05787483|Behavioral|active control group|business as usual; regular wellness or SEL classes
46079134|NCT05787470|Behavioral|Quantative sensory testing|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
46079135|NCT05787470|Diagnostic Test|Blood Draw|Sample of blood will be taken.
45957420|NCT02930317|Drug|Recombinant Factor VIII (50 IU/kg)|
45817754|NCT03093662|Device|Ventilation with nasal cannula|Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear) while simultaneously wearing nasal cannula (Carefusion AirLife Standard Nasal Cannula) with 15 L/min oxygen flow. Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).
45957421|NCT02930317|Drug|Recombinant Factor VIII (On-demand treatment)|
45957422|NCT00148148|Drug|caspofungin|
45957423|NCT00148148|Drug|liposomal amphotericin B|
45957424|NCT02929966|Other|palliative care program|The program includes psychological support, spiritual care and respiratory therapist support
45957425|NCT02929966|Other|standard respiratory care|the usual standard pharmacological care plus oxygen therapy
45957426|NCT04438135|Other|Repeated open application test|parallel application of two different types of lotion with and without aluminium.
45957427|NCT00169962|Drug|rhDNAse (pulmozyme)|
46079136|NCT05787457|Other|Clinical examination|
45663662|NCT04788069|Dietary Supplement|Sourdough bread|180g sourdough bread/day + fixed portion at test day
45663663|NCT04788069|Dietary Supplement|Bread with sourdough|180g bread with sourdough/day + fixed portion at test day
45663664|NCT05366985|Procedure|Socket shield technique with computer guided sectioning of the root|"A computer guide was used to section the root, leaving the coronal 2/3 of its labial part attached to the socket. An implant was then placed.~Preoperative and Postoperative (5 months later) intraoral scans were superimposed with a digital software to assess the dimensional changes of the labial alveolar ridge. Linear changes at 1,3 and 5 mm from the gingival margin and mean linear changes in a specified Area Of Interest (AOI) were measured"
45663665|NCT02311179|Device|Prosthesis, BoneMaster-Exceed cup (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
45817755|NCT03093662|Device|Ventilation without nasal cannula|Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear). Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).
45817756|NCT03100123|Drug|Aspirin 81 mg|Aspirin 81 mg po daily in tablet form.
46079137|NCT05787457|Other|Blood testing|
46079138|NCT05787457|Other|MRI|
45454954|NCT04458298|Drug|OP-101|OP-101 infusion will be administered intravenously.
45454955|NCT04458298|Drug|Placebo|Matching placebo infusion will be administered intravenously.
45817757|NCT03100123|Drug|Low-molecular-weight heparin|The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.
45957428|NCT02930239|Other|Gait rehabilitating with reduced bodyweight|Patients will perform 8 sessions of gait rehabilitation with reduced bodyweight using the anti gravity treadmill during week 2-5 post-surgery.
45957429|NCT02930239|Other|Standardized rehabilitation following an anterior cruciate ligament reconstruction at Linkoping University Hospital|Exercises for increased movement and circulation performed on a daily basis.
45957430|NCT02930161|Drug|Runihol|"Composition of Runihol®:~One tablet contains:~Active ingredients: succinic acid - 0.250 g; Riboxinum (inosine) - 0.100 g; taurine - 0.050 g; Methionine - 0.050 g Excipients - 0.184 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.~Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate."
45663666|NCT02311179|Device|Prosthesis Exceed cup without HA (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
46079139|NCT05787418|Drug|HH-120 Nasal Spray|HH-120 nasal spray 8 times per day for 7 consecutive days
46079140|NCT05787418|Drug|Placebo|Placebo 8 times per day for 7 consecutive days
46079141|NCT05787340|Other|Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach)|Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach) is a group exercise method that conforms to the biopsychosocial model via telerehabilitation.
46079142|NCT05787327|Drug|Chinese Herb|Yinqiaosan-Maxingganshitang granules
46079143|NCT05787327|Diagnostic Test|Placebo|Placebo
46079144|NCT05787275|Other|diaphragmatic positioning|Traditional medical treatment plus diaphragmatic strengthening exercises through patient self-positioning in prone on elbows then do diaphragmatic breathing 10-15 min ,twice/day, 7days/ weak
46079145|NCT05787275|Other|incentive spirometer|Traditional medical treatment plus diaphragmatic strengthening exercises through using of incentive spirometer 10-15 min ,twice/day, 7days/ weak
46079146|NCT05787275|Other|Control|Traditional medical treatment
46079147|NCT05787262|Procedure|upper endoscopy|Upper endoscopy , biopsy and histopathological examination of taken biopsies.
45957431|NCT02930161|Other|Placebo|"The composition of the drug in one tablet:~Active substance: None. The tablet core - 0.634 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.~Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate.~Tablet weight enteric coated - 0.695 g"
45957432|NCT00170001|Drug|Nexium|40 mg bid dosing
45957433|NCT00170001|Drug|Sugar Pill|40 mg BID
45957434|NCT02930200|Behavioral|Treatment as Usual|Tobacco Treatment Research Program (TTRP) or Treatment as Usual (TAU)
45957435|NCT02930200|Behavioral|QuitGuide|NCI QuitGuide Treatment App
46079148|NCT05787223|Other|Baseline Treatment|Control Group that will be provided with be given baseline treatment of static balance training (static exercise like standing on balance board, bounce on one foot, heel rises/toe rises, standing on one foot, jumping on trampoline)
46079149|NCT05787223|Other|Dynamic Training|Experimental Group that will be provided with base line treatment along with dynamic balance training (cross, side &tandem walking, step up and down, jumping &hopping on floor). Exercises Will be given the 40 minutes with 2 sessions per week over the period of 08 weeks
46079150|NCT05787210|Other|Conventiional Physiotherapy|The Control group will be administered with Conventional Physiotherapy that Includes 5 minutes of trunk control training, 5 minutes walking in the hall with And without the therapist assistance, walker or crutches, and finally 5 minutes of Breathing exercises for Relaxation
45663667|NCT02204787|Device|transcranial direct current stimulation|
45663668|NCT05393895|Drug|CSF-1|One drop bilaterally twice daily for approximately 6 weeks
45817758|NCT04700150|Other|Tai Chi 2 month|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
45817759|NCT04700150|Other|Tai Chi 4 month|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
45817760|NCT03097484|Drug|lavender and chamomile essential oils|Our patches are obtained from BioEsse Technologies™. Each patch contains a 50:50 mixture of Lavender and Chamomile essential oils in a 55 microliter standard dose patch. The patches release the aromatherapy over a 2-8 hours period and the diffusion rate of each patch is identical. The back of the patch is layered with a hypoallergenic medical grade adhesive, similar to the material found on ECG leads.
45817761|NCT02872909|Device|Ambulight (Ambicare Health)|"battery-operated low irradiance red light LED (skin cancer plaster)"
45817762|NCT04695236|Device|ZOLL Intravascular Temperature Management system, Quattro catheter|ZOLL Intravascular Temperature Management system, Quattro catheter
45817763|NCT04695236|Other|Standard Treatment|Standard Treatment for Ischemic Strokre
45817764|NCT02957305|Drug|Misoprostol 400mcg Tab|400µg of misoprostol (2 tablets)
45817765|NCT02957305|Drug|Misoprostol 200mcg Tab|200µg of misoprostol (1 tablet)
45817766|NCT04611152|Drug|KSI-301|Intravitreal Injection
45817767|NCT04611152|Drug|Aflibercept|Intravitreal Injection
45957436|NCT02930200|Behavioral|Smart-T|Smart-Treatment App
45957437|NCT00148226|Behavioral|Decision Aid|
45957438|NCT02929732|Other|Sympathetic nervous activity measurement|Polysomnography, MIBG myocardic scintigraphy, and 24h blood pressure measurement
45957439|NCT04426201|Drug|CYT107|IM administration at 10µg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
45957440|NCT04426201|Drug|Placebo|Same number, volume and frequency of IM administration of saline
45957441|NCT00148265|Drug|Triamcinolone acetate|Eyes assigned to IVTA received an intravitreal injection of 0.1 ml of Kenacort 40© [40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia] on the day of the baseline visual acuity measurement under sterile conditions in a minor procedures area as an outpatient procedure. Eyes assigned to placebo were prepared in the same way but had the barrel of the syringe without a needle pushed firmly against the eye to simulate an injection.
46079151|NCT05787210|Other|Quadriceps Strength Training|The experimental group will be administered with the same baseline treatment such as 5 minutes of trunk control training, 5 minutes walking in the hall with or without the therapist assistance, walker or crutches and 5 minutes breathing exercises for relaxation. In addition, they were given strength training protocol intervention other than the baseline treatment. This strength training protocol include progressive resistance training program in which we gave leg lift (knee flexion and extension), Hip rotations, seated marching and the quadriceps muscles would be specifically targeted.
45663669|NCT05393895|Drug|Vehicle|One drop bilaterally twice daily for approximately 6 weeks
46079152|NCT05787171|Device|WE-MBVMS using suture Vicryl (Polyglactin 910; Johnson & Johnson International, USA);|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
46079153|NCT05787171|Device|WE-MBVMS using suture PDS (polydioxanone; Johnson & Johnson International, USA)|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
46079154|NCT05787171|Device|WE-MBVMS using suture Ethibond (polyester; Johnson & Johnson International, USA）|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
45663670|NCT04801953|Drug|NiMODipine Injectable Solution|nimodipine solution is applied to cranial nerves during resection of vestibular schwannoma
45663671|NCT04801953|Other|Placebo|Sodium chloride solution is applied to cranial nerves during surgery
45663672|NCT05365737|Other|Oral rinse|Participants use mouthwasher for a given time.
45663673|NCT05365737|Other|Saliva harvest|Non-stimulated saliva harvesting
45663674|NCT05355831|Device|Active Transcranial Direct Current Stimulation|See arm/group description
45663675|NCT05355831|Device|Sham stimulation|See arm/group description
45957442|NCT00170079|Behavioral|Smoking Cessation Intervention|"A common approach to increasing long-term adherence and control of chronic medical problems such as hypertension in both general and preventive medicine is the concept of step care. The purpose of this study is to evaluate the long-term efficacy of a step care model for smoking cessation that is disseminable in primary care settings. With that introduction, we propose the following specific aims:~Aim 1: To enroll approximately 400 adult cigarette smokers recruited mainly from primary care settings;~Aim 2: To randomize these participants to: 1) State of the Art Smoking Cessation + Recycling or 2) State of the Art Smoking Cessation + Step Care; and~Aim 3: To evaluate the long-term (24 months post-randomization) relative success of the interventions. It is predicted that long-term cessation rates will be significantly higher in the step care condition."
45957443|NCT02929771|Device|Samsung GearVR|VR with head mounted display (HMD) and headphones. Treatment
45817768|NCT04611152|Other|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
45663676|NCT04787679|Procedure|Hip replacement surgery|After hip replacement surgery the sponsor obtains femoral head samples for the study
45817769|NCT02873923|Drug|undefined|Chemotherapy drug (meta-analyses of randomized trials)
45817770|NCT04590092|Device|Cooper Surgical Ring Pessary with Incontinence Knob|A pessary is a silicone ring with a knob that in inserted into the vagina to treat urinary incontinence by providing urethral support.
45817771|NCT03104647|Other|VRP-Clinic|Subjects will perform a series of neck movements guided by graphic instructions appearing in the virtual reality environment
45817772|NCT03104725|Drug|N-Acetylcysteine|Oral
45817773|NCT03104725|Procedure|Lumbar Puncture|Each participant undergoes a baseline lumbar puncture (LP 1) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4-dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP (LP 2) is completed after the PD participant has taken at least 5 doses of NAC (2 grams orally twice per day) and approximately 2 hours after the last NAC dose. For the HV participant, LP 2 occurs approximately 48 hours after LP 1 (no NAC administered).
45817774|NCT03104725|Radiation|Fluoroscopy|If needed for lumbar puncture
45817775|NCT03153956|Device|Calibrated AposTherapy®|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology.
45817776|NCT03153956|Device|Non-Calibrated Sham Apos Therapy Device|The comparator group will receive a non-calibrated sham device.
45817777|NCT02876575|Device|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
45817778|NCT03154658|Drug|Ropivacaine 0.35%|The serratus plane block is used to supplement the pain management of a patient receiving a surgical procedure of the chest wall or breast.
45817779|NCT03157232|Device|Rainbow DCI and R1-25 sensor|Noninvasive Measurement of SpHb
45817780|NCT02958787|Radiation|Radiation Therapy|Radiation Therapy Using MRI Based Treatment Planning
45817781|NCT03098420|Drug|2mg Dexamethasone|0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline
45817782|NCT03098420|Drug|4mg Dexamethasone|1 mL (4mg) of dexamethasone
45817783|NCT03098420|Drug|Ropivacaine (TAP blocks)|20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine
45663677|NCT04787367|Procedure|TAP block|"An 18-gauge needle will be introduced externally at the center of the mid axillary line between the lower costal margin and the iliac crest until the surgeon feels a pop, after which the surgeon will inject the first 2 mL of 0.25% bupivicaine to verify the correct position. Doyle's internal bulge sign (the bulge seen when the transversus abdominis muscle and peritoneum is pushed internally) will be visualized and the remainder of the 60 mL of 0.25% bupivacaine will be injected. The contralateral block will be performed according to the same technique but with only 30 ml of bupivicaine."
45663678|NCT02061891|Procedure|Invasive coronary evaluation (Deferred)|Invasive coronary angiography and revascularization (PCI/CABG)
45663679|NCT02061891|Procedure|Invasive coronary evaluation (Acute)|Invasive coronary angiography and revascularization (PCI/CABG)
45663680|NCT03797157|Dietary Supplement|H2MF|H2MF is a human milk-based breastmilk fortifier for preterm infants
45663681|NCT03797157|Dietary Supplement|Bovine milk-based fortifier|Bovine milk-based fortifier is the standard breast milk fortifier in Sweden
45817784|NCT03098420|Drug|Morphine|
45817785|NCT03098420|Drug|Bupivacaine Hydrochloride|
45817786|NCT03098420|Drug|Normal saline 1ml|1.0 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
45817787|NCT03098420|Drug|Normal saline 0.5ml|0.5 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
45817788|NCT02876887|Drug|Cocoa|
45817789|NCT02876887|Drug|Placebo|
45957444|NCT02929771|Device|iPad|iPad with headphones. Control
45957445|NCT02929615|Other|Hematopoietic stem cell transplantation|
45817790|NCT03158714|Behavioral|Couples Connecting Mindfully|
45817791|NCT03158714|Behavioral|ELEVATE|
45817792|NCT03108469|Drug|IONIS-PKKRx (ISIS 546254)|Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) of IONIS- PKKRx (ISIS 546254) weekly for weeks 1-16.
45817793|NCT03108469|Other|Placebo|Those randomized to placebo will receive subcutaneous injections 1.00 mL (200mg) weekly for weeks 1-16.
45663682|NCT03776643|Drug|ILT-101 ld-(IL2)|Subcutaneous injections of ILT-101 or Placebo starting with once-daily administration for 5 consecutive days followed by once every two weeks administration during five months
45663683|NCT02039739|Device|Orsiro™ Drug Eluting Stent group|
45663684|NCT05210049|Diagnostic Test|Esocheck/Esoguard|All enrolled patients will complete the Esocheck screening test. EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus. The collected cell material is examined with a two marker panel combining methylated CCNA1 and VIM. These methylated markers have 95% sensitivity and 91% specificity for detecting BE and EAC with an AUC=0.95 in studies performed among white men. Diagnostic yield of this test among Veterans is unknown.
45817794|NCT03159260|Device|Theraworx|Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
45957446|NCT04395703|Other|Interviews and focus groups|Unstructured and semi-structured interviews with open ended questions.
45957447|NCT02929693|Drug|gefitinib|250 mg oral once a day until progression or unacceptable toxicity develops
45957448|NCT02929693|Drug|Yiqi-yangyin-jiedu decoction|Yiqi-yangyin-jiedu decoction is a traditional chinese herbal medicine formula,and should be taken one package, twice a day, until progression or unacceptable toxicity develops.
45957449|NCT02929693|Drug|placebo|Oral granules, which the taste and smell are similar to YYJD, has no therapeutic effect, Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, one package, twice a day, until progression or unacceptable toxicity develops.
45957450|NCT00175734|Procedure|High Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
45957451|NCT00175734|Procedure|Low Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
45663685|NCT05363163|Device|Gana X|Injection in the deep dermis and subcutaneous layer of the buttocks on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
45663686|NCT03766113|Other|Neurofeedback coupling electroencephalogram and functional MRI in time actual|One visit : Neurofeedback coupling electroencephalogram and functional MRI in time actual
45957452|NCT04331275|Biological|Viral Specific T-cells (VSTs)|VSTs will be infused into solid organ transplant recipients who have evidence of viral infection.
45957453|NCT00148382|Drug|ATL-962|
45663687|NCT03766113|Other|Electroencephalogram-neurofeedback program or Neurofeedback-free mental imaging program with electroencephalogram recording|"Interventional group (Electroencephalogram-neurofeedback program) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program.~Controle Group (Neurofeedback-free mental imaging) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program of reference."
45957454|NCT00170118|Behavioral|motivational interviewing|
45957455|NCT02929654|Device|OneTouch Verio®|Colour Enhanced Blood Glucose Meter.
45957456|NCT02929654|Device|OneTouch Verio® Flex|Colour Enhanced Blood Glucose Meter.
45957457|NCT02929654|Device|Subject's Own Blood Glucose Meter|Subject's Own Blood Glucose Meter
45957458|NCT04689841|Other|Vojta Therapy|"Reflex locomotion is activated by the reflexogenic pathway. In context with reflex locomotion, the term reflex does not represent the mode of neuronal control, but rather refers to defined, automatic and always equal motor responses produced by external stimuli, applied therapeutically."
45957459|NCT04689841|Other|placebo|In the control group, a placebo intervention is administered, similar to an experimental intervention
45957460|NCT04321759|Behavioral|Cognitive Enhancement Therapy|CET's group-based exercises are delivered for 1.5 hours each week in a group of 6-8 participants led by a clinician and an assistant, for one year. During each of three modules (basic concepts, social cognition, CET applications), the groups focus on acquisition of adult social milestones in perspective-taking, social context appraisal, and other aspects of social cognition, with psychoeducational lectures, homework assignments, and in-group exercises. Weekly supervision sessions for the clinician trainers will include review of how patients respond to the different demands of computer-based training and group-based exercises and guidance about improving engagement in both.
45957461|NCT04321759|Behavioral|Social Skills Training|"The psychosocial component involves weekly skills training classes delivered over one year, with modules including Communicating Effectively, Making and Keeping Friends, Making the Most of Leisure Time, Healthy Living, Using Medications Effectively, and Making the Most of a Health Care Visit (Pratt et al., 2008). Participants attend two sessions each week (normally morning and afternoon of the same day): a 90-minute session focused on a specific skill and a 60-minute session in which the specific skill is used in role-play exercises."
45957462|NCT00148421|Drug|Darbepoetin alfa and Epoetin alfa|
45957463|NCT02929888|Drug|Lysine Acetilsalicilate|
45663688|NCT03766113|Other|Neurofeedback coupling electroencephalogram and functional MRI in time actual or a neurofeedback-free mental imaging program with electroencephalogram recording|"Interventional group (5 weeks) : 5 sessions of neurofeedback coupling electroencephalogram and functional MRI in time actual and 9 sessions of electroencephalogram-neurofeedback program~Controle Group (5 weeks) : 14 sessions of neurofeedback-free mental imaging program"
45663689|NCT04785339|Behavioral|intervention in adult Latinx immigrants|Participants will complete self-report outcome measures at pre (baseline) and post, and they will receive the intervention in-between these assessments. Thus, the time frame for data collection is 10 weeks.
45663690|NCT03757377|Device|BackBeat Moderato System|Eligible patients randomized after optimization phase to PHC ON for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
45957464|NCT02929888|Drug|Aspirin|
45957465|NCT04689763|Behavioral|Training|The programs contain sequential cognitive and exercise training, health lectures, and groups of daily living participation. We plan to assess the participants before and after the intervention programs. We expect that elders receiving training will improve on outcome measures. The results of the study will provide evidence of interventions for elderly with cognitive decline.
45957466|NCT04689412|Drug|Resveratrol|Nasal administration of resveratrol
45957467|NCT00148460|Drug|TNK-tPA|
45957468|NCT00148460|Drug|rt-PA|
45957469|NCT00170196|Drug|prednisone|
45957470|NCT02929459|Dietary Supplement|Riboflavin Dose 1|
45957471|NCT02929459|Dietary Supplement|Riboflavin Dose 2|
45957472|NCT02929459|Other|Placebo|
45957473|NCT02929576|Drug|Enzalutamide|Enzalutamide will be administered as four 40-mg capsules once daily (160 mg/day).
45957474|NCT02929576|Drug|Placebo|
45957475|NCT02929576|Drug|Paclitaxel|Paclitaxel (90 mg/m2) will be administered by constant-rate intravenous infusion of ≤ 1 hour once weekly for 16 weeks. Dose reductions or alterations to the schedule are allowed to maintain patient safety.
45957476|NCT02929420|Drug|Xiaoru Sanjie capsules|Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
45957477|NCT02929420|Drug|Xiao Yao pills|Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
45957478|NCT00175812|Drug|all-trans retinoic acid (ATRA)|All-trans retinoic acid 22.5 mg/square meter twice daily days 1-14
45957479|NCT00175812|Drug|Valproic acid|Valproic acid, highest dose without side effects from day 3 until progression
45957480|NCT00175812|Drug|Theophyllin|Theophyllin, targetted serum level 50-100 from day 3 until progression
45957481|NCT00148499|Drug|Ambroxol hydrochloride (Mucoangin?)|
45957482|NCT00148499|Drug|benzocaine|
45957483|NCT02929342|Drug|Pitolisant|
45957484|NCT02929342|Radiation|[14C]-Pitolisant|
45957485|NCT02929381|Device|Innovative colonoscopy (Olympus CF-HQ190L, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Kudo and NICE classifications.
45957486|NCT02929381|Device|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
45957487|NCT00175851|Drug|Seletracetam (ucb 44212)|
45957488|NCT00148538|Behavioral|Resistance and/or Aerobic Exercise|Resistance and/or Aerobic Exercise
45957489|NCT03457597|Drug|Midazolam hydrochloride|Midazolam hydrochloride 2.5 mg
45957490|NCT03457597|Drug|Metoprolol tartrate|Metoprolol tartrate 100 mg
45957491|NCT03457597|Drug|Pioglitazone hydrochloride|Pioglitazone hydrochloride 15 mg
45957492|NCT03457597|Drug|Tolbutamide|Tolbutamide 500 mg
45957493|NCT03457597|Drug|Omeprazole|Omeprazole 20 mg
45957494|NCT03457597|Drug|Relacorilant|Relacorilant 350mg
45957495|NCT02929147|Drug|Morphine|In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours. In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
45957496|NCT02929147|Drug|Dexketoprofen|The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours.
45957497|NCT02929147|Drug|Placebo|In the Group 3 the PCA will contain placebo.
45957498|NCT02929264|Drug|ABX-1431|Capsules, 40 mg, single dose
45957499|NCT02929264|Drug|Placebo|Capsules, single dose
45957500|NCT02929186|Behavioral|Opt-In Outreach|Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to elect to receive a home FIT kit or report prior screening.
45458207|NCT03502096|Behavioral|To-Go container|Subjects were provided a to-go container in which leftover foods would be packaged
45663691|NCT03757377|Device|BackBeat Moderato Sytsem|Eligible patients randomized after optimization phase to PHC OFF for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
45663692|NCT04418505|Device|Vielight RX Plus|The Vielight RX Plus is designed to deliver near-infrared light and red light via LEDs placed directly on the manubrium of the sternum (which covers the thymus gland) and inside one nostril, respectively.
45663693|NCT05186259|Diagnostic Test|Self-reported signs of central sensitization|Self-reported signs of central sensitization by means of the Central Sensitization Inventory (questionnaire)
45663694|NCT05186259|Diagnostic Test|Objective signs of central sensitization|Objective signs of central sensitization by means of Quantitative Sensory Testing (mechanical and heat detection and pain thresholds, endogenous pain facilitation and inhibition)
45957501|NCT02929186|Behavioral|Opt-Out Outreach|Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to choose not to receive a home FIT kit or report prior screening. A FIT kit will otherwise be sent to the subject as a default.
45957502|NCT00175890|Drug|Levetiracetam|Dosing was stratified by age. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for children one month to less than six months old and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for children 6 month to less than 4 years old, was used in this study. The total daily dose was administered b.i.d.
45957503|NCT00175890|Other|Placebo|Placebo solution, which is indistinguishable from the Levetiracetam oral solution.
45957504|NCT00148577|Device|Transcutaneous Electrical Nerve Stimulation|
45957505|NCT02929030|Device|Nano|The stent system comprises of 2 components: stent steel platform, antiproliferative drug sirolimus, and stent balloon
45957506|NCT02929303|Drug|Omegaven IV lipid emulsion|Therapy is started at a dose of 1 gm/kg/day over 12 hrs. Omegaven may be infused via a central or peripheral IV. If additional fat calories are needed they will be provided by the enteral route.
45957507|NCT02929225|Drug|Bifid Triple Viable Capsules|BIFICO is prescribed as a dose of 4 capsules twice daily in half hours after meals.
45957508|NCT02929225|Other|placebo|placebo is also prescribed as a dose of 4 capsules twice daily
45957509|NCT00148616|Drug|Memantine|Daily dosage of 20 mg Memantine add-on to Risperidone vs. Placebo add-on to Risperidone
45957510|NCT00148616|Drug|Placebos|Daily dosage of 20 mg Placebo add-on to Risperidone vs. Memantine add-on to Risperidone
45957511|NCT02928835|Device|Knee flexion Dynasplint orthosis|Standardized rehabilitation procedures started at the first day after total knee arthroplasty. Both groups received the same standardized physical therapy intervention. The experimental group used the knee flexion Dynasplint orthosis (Dynasplint Systems, Inc. Canada, Woodbridge, ON) at night, while sleeping, over six continuous hours for one month, starting seven days after the total knee arthroplasty. The control group received only the standardized physical therapy intervention.
45663695|NCT05186259|Diagnostic Test|Audiological outcome measures (audiometry, tinnitus analysis, uncomfortable loudness) in tinnitus patients with and without pain|"Audiometry Performance of pure tone audiometry according to the modified Hughson-Westlake method~Tinnitus analysis Measurement of psychoacoustic features of tinnitus, including (1) tinnitus pitch, (2) loudness, (3) masking ability, and (4) residual inhibition.~Uncomfortable Loudness measures Performance of Uncomfortable Loudness measurements to evaluate the presence of hyperacusis. ."
45663696|NCT05186259|Diagnostic Test|Cognitive functioning|"Evaluation of cognitive functioning by means of:~Auditory Stroop test~Detecting letters task~Letter-number sequencing task"
45957512|NCT00175929|Other|Placebo|Daily oral dose of two equal intakes, morning and evening, of placebo in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
46079155|NCT05787158|Other|Muscle energy techniques|Group A: 20 patients were included in this group. This studygroup was assigned with basic treatment protocol with 15 minutes of TENS and thermal therapy for 10 minutes followed by muscle energy technique (Post facilitation stretching exercises). The intervention was given three days per weekfor six weeks. Each total session lasted for 45minutes. METs were applied for the weakened muscles. (21). Group B: 20 Patients of this group were given core stability exercises by the female physical therapist in three different levels. Each level continued for a duration of two weeks in which the patients were trained for the exercises. The patients were provided sessions thrice per week with 2 sets of 10 repetitions and a hold of 10 second after TENS for 15 minutes and thermal therapy for 10 minutes
45458208|NCT03502096|Other|Control|Subjects were not provided a to-go container with the meal
45663697|NCT05186259|Diagnostic Test|Listening effort|Evaluation of listening effort by means of the modified version of the behavioral listening effort test based on a dual-task paradigm by Degeest, Keppler & Corthals (2018) .
45817795|NCT03159260|Other|Placebo|Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
45957513|NCT00175929|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
46079156|NCT05787145|Behavioral|Let's Discuss Health Group|Use of the Let's Discuss Health website to prepare four medical encounters with the radiation oncologist throughout the radiation care trajectory.
46079157|NCT05787106|Other|Cyberball task|"The game consists of ball throws between animated characters lasting about 50 throws. In the rejection condition, after 2 or 3 throws, the participant no longer receives the ball (no more passes). In the control conditions (all included), the participant receives the ball as often as the others."
46079158|NCT05787093|Device|transabdominal rectal ultrasound|transabdominal rectal ultrasound to detect megarectum and evaluate the improvements after medical therapy with macrogol
46079159|NCT05787080|Other|Massage|In the second hour of hemodialysis, vibration is applied to both calf muscles of the patients for 10 minutes three times a week for four weeks at low voltages.
45454956|NCT03935503|Procedure|TEP|By making a 2 cm incision under the umbilicus, skin subcutaneous tissues are passed through blunt dissections and the anterior fascia of the rectus muscle is exposed. An anterior rectus sheath with a scalpel is performed with a 15 mm incision. The rectus muscle is laterally lateralized and the balloon trocar or laparoscope itself is advanced from the midline to the symphysis pubis via the posterior rectus sheath. After the peritoneal cavity is dissected, a low pressure pneumoperitone 10 mm Hasson trocar or another 10 mm balloon caged trocar is advanced through the subumblic incision. 9-11 mmHg low pressure pneumoperitoneum is created to prevent the development of subcutaneous emphysema. For proper imaging, the patient should have complete muscle relaxation. The patient is given a position towards the light trandelenburg and non-hernia side.
45454957|NCT03935503|Procedure|Lichtenstein repair|"After the inguinal incision, the skin and subcutaneous camper and scarpa tissues are passed and the external oblique aponeurosis is dissected in the direction of the extension of the fibers and the medial lateral edge of the rectus is dissected to the lateral inguinal ligament, then the spermatic cord is released and suspended.The spermatic cord is separated from the inguinal canal.~In indirect hernias, the hernia sac is dissected from the spermatic cord and rejected into the abdomen by high ligation. In direct hernia, the hernia sac is pushed in and the transverse fascia is sutured with 2-3 separe stitches."
45454958|NCT01216657|Drug|Sunitinib|50 mg oral, daily, for 4 weeks, then 2 weeks without treatment, repeat at d43
45663698|NCT05186259|Diagnostic Test|Self-reported psychological factors|"Evaluation of psychological factors by means of:~Depression, Anxiety and Stress Scale (DASS-21)~Beck Depression Inventory (BDI)~Big Five Inventory (BFI)~Connor-Davidson Resilience Scale"
45663699|NCT05186259|Diagnostic Test|Self-reported lifestyle factors|"Evaluation of lifestyle factors by means of:~Baecke Questionnaire Pittsburg Sleep Quality Index Insomnia Severity Index Stress subscale of the DASS 21"
45663700|NCT05186259|Diagnostic Test|Self-reported measure of pain processing|Evaluation of self-reported pain processing by means of the Pain Catastrophizing Scale
45817796|NCT02878057|Drug|Apatinib|Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
45817797|NCT00422617|Drug|Alefacept (Amevive)|
45817798|NCT03104738|Other|25% reduction of basal insulin dose|"Subjects will be instructed to reduce their basal insulin dose to 75% instead of our institutional 50%.~Subject must check their own blood sugar before reporting to the hospital for their surgery. If the value is less than 70 or subjects are having symptoms of hypoglycemia, subjects will be instructed to immediately ingest 4-8 oz of fruit juice (without pulp) and call their doctor or the hospital."
45817799|NCT03162458|Drug|Anaferon for children (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
45817800|NCT03162458|Drug|Placebo (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
45817801|NCT03163472|Procedure|Axillary brachial plexus block with 10 mL oof local anaesthetic|patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
45817802|NCT03163472|Procedure|Axillary brachial plexus block with 30 ml of local anaesthetic|patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
45817803|NCT02880475|Drug|OXN PR tablet|Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg
45957514|NCT00175929|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 150 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
45957515|NCT02928796|Behavioral|Cognitive Stimulus|Participants to pay attention to a supplementary display monitor and respond to specified stimulus images, all while performing the simulated cardiology-based procedure.
45957516|NCT02928874|Behavioral|% COMPX (low ED vs. high ED preload)|
45957517|NCT02928874|Behavioral|EAH (low ED vs. high ED snacks)|
45957518|NCT02928913|Other|No intervention|
45957519|NCT02928679|Drug|Liraglutide 3 mg (Saxenda)|
45957520|NCT02928679|Drug|Liraglutide 3 mg placebo|
45957521|NCT02928640|Device|ClariCore System|Data collection to build the prostrate tissue classification algorithm.
45957522|NCT02928445|Drug|RVT-101 35 mg|once daily, oral, 35-mg tablets
45957523|NCT02928445|Drug|RVT-101 70 mg|once daily, oral, 35-mg tablets
45454959|NCT04400188|Drug|Fluzoparib|Given PO
45454960|NCT04400188|Drug|temozolomide|Given PO
45454961|NCT04400188|Biological|SHR-1316|Given injection
46079160|NCT05787067|Behavioral|Health Belief Model-Based Mobile Online Training|Health Belief Model-Based Mobile Online Training
45663701|NCT05186259|Diagnostic Test|Self-reported quality of life|Self-reported quality of life by means of the SF-36 questionnaire
45663702|NCT05186259|Diagnostic Test|Self-reported tinnitus severity and impact on daily life|Evaluation of self-reported tinnitus severity and impact on daily life by means of the Tinnitus Functional Index
45817804|NCT04468568|Drug|Atosiban|Atosiban intravenous. Dose: attack of 6.75 mg, and maintenance of 300 mcg / min for 3 hours, and 100 mcg / min for 21 hours.
46079161|NCT05787041|Other|high-fat diet group（AD16 20mg）|AD16 was administered with 240 mL water 30 minutes after the subjects ate a high-fat, high-calorie food.
45817805|NCT04468568|Drug|Terbutaline|Terbutaline intravenous. Dose: 2.5 mg in 500 mL saline, infusion rate of 30 mL / hr (150 mcg / h) during the surgery and for 24 hours.
45454962|NCT03935581|Device|ExAblate|Auto Focusing (AF) echo imaging
45454963|NCT03935737|Diagnostic Test|Full Dose Chest X-Ray|Full dose X ray at Day 1
45454964|NCT03935737|Diagnostic Test|Low Dose Chest X-Ray|Low dose X ray within 3 months from full dose
45663703|NCT05186259|Diagnostic Test|Self-reported hyperacusis|Evaluation of self-reported characteristics of hyperacusis by means of the Hyperacusis Questionnaire
45817806|NCT03106844|Drug|Fecal Microbiota Transplantation|Patients with at least 2 episodes of CDI and IBD will undergo a single FMT
45454965|NCT01216813|Other|informational intervention|
45663704|NCT05186259|Diagnostic Test|Self-reported tinnitus characteristics|Evaluation of self-reported tinnitus characteristics by means of the Tinnitus Sample Case History Questionnaire
45663705|NCT05186259|Diagnostic Test|Self reported neck pain related disability|Evaluation of self-reported neck pain related disability using the Neck Disability Index
45817807|NCT03168308|Drug|Sugammadex|Sugammadex 2 mg/kg
45817808|NCT03168308|Drug|Neostigmine w/ Glycopyrrolate|Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg
45817809|NCT00375128|Biological|FP9-PP (FP9 polyprotein)|
45817810|NCT00375128|Biological|MVA-PP (Modified Virus Ankara polyprotein)|
45957524|NCT02928562|Other|exercise|cyclic exercise, aerobic exercise and resistant training exercise
45454966|NCT01216813|Procedure|assessment of therapy complications|
45454967|NCT01216813|Procedure|psychosocial assessment and care|
45454968|NCT04163458|Drug|MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL|Solution for injection in pre-filled pen, subcutaneous administration
45454969|NCT04163458|Drug|MENOPUR powder and solvent for solution for injection, 75 IU|Solution for injection in vials (powder and diluent), subcutaneous administration
45454970|NCT04163458|Other|Placebo (for MENOPUR solution for injection in pre-filled pen)|Solution for injection in pre-filled pen, subcutaneous administration
45454971|NCT04163458|Other|Placebo (for MENOPUR powder and solvent for solution for injection)|Solution for injection in vials (powder and diluent); subcutaneous administration
45454972|NCT03935191|Device|Dexcom CGM System|Dexcom CGM System
45454973|NCT01122433|Device|Endotracheal intubation using the C-MAC video laryngoscope|Using the C-MAC video laryngoscope for endotracheal intubation after failed direct laryngoscopy
45454974|NCT04902040|Biological|Atezolizumab|Given IV
45454975|NCT04902040|Drug|Avelumab|Given IV
45454976|NCT04902040|Biological|Durvalumab|Given IV
45454977|NCT04902040|Biological|Nivolumab|Given IV
45454978|NCT04902040|Biological|Pembrolizumab|Given IV
45454979|NCT04902040|Drug|Plinabulin|Given IV
45454980|NCT04902040|Radiation|Radiation Therapy|Undergo radiation therapy
45454981|NCT01328899|Device|Lung Volume Reduction Coil (LVRC) (PneumRx's)|Lung Volume Reduction Coil
45454982|NCT01214005|Behavioral|smoking abstinence|3 days of biologically-confirmed smoking abstinence
45957525|NCT02928601|Drug|Ondansetron|After spinal anesthesia, half of the patients will be given intravenous 8 mg ondansetron.
45957526|NCT02928601|Drug|Saline|After spinal anesthesia, half of the patients will be given intravenous 2 mlt saline.
45957527|NCT02928484|Dietary Supplement|Probiotic mix CBP-004019/C|One capsule per day of the probiotic mix CBP-004019/C during one month.
45957528|NCT02928484|Dietary Supplement|Placebo|One capsule per day of the placebo (maltodextrin) during one month.
45957529|NCT02928523|Drug|Autologous Fecal Microbiota Transplantation|
45957530|NCT02928367|Other|rectal swab|rectal swab at baseline visit (2x) and at day 28 (2x) OR rectal swab at single timepoint (2x) (healthy volunteers)
45957531|NCT02928367|Other|nasopharyngeal swab|nasopharyngeal swab at baseline visit (1x) and at day 28 (1x) OR nasopharyngeal swab at single timepoint (2x) (healthy volunteers)
45957532|NCT02928367|Other|blood draw|blood draw at baseline visit (45ml) and at day 28 (45ml) (pneumonia patients) OR single blood draw (70ml) (healthy volunteers)
45957533|NCT02928328|Drug|GABA oral solution|Oral mouth wash containing either GABA, lidocaine or distilled water will be used to decrease burning tongue pain produced by capsaicin
45663706|NCT03746847|Drug|Gallium-68 DOTATATE|Gallium-68 DOTATATE is a radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body, which is approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.
45957534|NCT02928328|Drug|Intramuscular GABA|The effect of intramuscular injection of GABA or lorazepam will be compared with buffered isotonic saline
45957535|NCT02928328|Drug|Pain modulation|The effect of GABA alone or in combination with lorazepam on muscle pain produced by intramuscular injection of glutamate will be assessed.
45458209|NCT02315248|Radiation|Quantitative computed tomography scan for bone density analysis|A low radiation dose quantitative computed tomography (QCT) of the spine (L1 and L2) and the hips will be performed to measure bone density in the spine and hips.
45817811|NCT03168542|Device|JJVC Fitting Guides|Subjects who are habitual soft spherical or toric contact lens wearers, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guide, with either the Multifocal Contact Lens or an Investigational Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes during a 1 day visit.
45817812|NCT03109015|Drug|Sunitinib|Patients randomized to sunitinib schedule 4/2 will receive sunitinib at 50 mg daily for 4 weeks on, followed by 2 weeks off, per standard of care. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 4 weeks and 12 weeks.
45817813|NCT03109015|Drug|Sunitinib|Patients randomized to sunitinib schedule 2/1 will receive sunitinib 50 mg daily for 2 weeks on, followed by 1 week off. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 5 weeks and 12 weeks.
45817814|NCT04253756|Device|20-gauge BD Nexiva Diffusics|The BD Nexiva Diffusics catheters are suitable for use with power injectors when a direct connection is made.
45817815|NCT00375206|Biological|Trivalent DNA Vaccine (PIA0601) with or without DEI-LT (pPJV2012)|
45957536|NCT02928250|Dietary Supplement|Carnosine|Patients in intervention group received carnosine capsules orally daily
45957537|NCT02928250|Dietary Supplement|Placebo|Patients in placebo group received placebo that were similar in appearance to carnosine capsules and the administered dose was as the same schedule as carnosine.
45957538|NCT02928211|Device|Sapphire II|A Class 1 laser device used in conjunction with the ointment to measure fluorescence emissions from the anterior segment (lens) of the eye.
45957539|NCT02928211|Drug|Aftobetin-HCl|The medical imaging agent (the ointment), Aftobetin-HCl is an amyloid binding ligand formulated into an ophthalmic ointment.
45957540|NCT02928211|Radiation|Positron Emission Tomography|Amyvid 370 MBq (10 mCi) is administered as a single bolus through a short intravenous catheter in a total volume of 10 mL.
45957541|NCT00148655|Device|Decision Board|Decision board that explains the risks and benefits of treatment options
45957542|NCT00175968|Procedure|bed rest, hypocaloric nutrition|
45957543|NCT02927977|Other|control|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises and manual therapy. Participants will receive 4-6 treatments during 4 weeks.
45663707|NCT01635153|Dietary Supplement|Protein calorie supplement|Fortified porridge with 1062 kcal and 40 gm protein
45663708|NCT01635153|Dietary Supplement|Micronutrient|Dar-vite Multivitamin
45663709|NCT05132127|Drug|sutimlimab|Pharmaceutical form: solution for injection Route of administration: intravenous(iv)
45663710|NCT04446039|Drug|Escitalopram|Treatment for depression
45663711|NCT04446039|Drug|Paroxetine|Treatment for depression
45663712|NCT04446039|Drug|Fluoxetine|Treatment for depression
45817816|NCT04706780|Other|ESP block|ESP block performed using ultrasound guidance. Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
45957544|NCT02927977|Other|dry needling|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises, manual therapy and dry needling in neck muscles. Participants will receive 4-6 treatments during 4 weeks.
45957545|NCT02928016|Other|Mixed meal 1|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives. The meal provided 794 kcal and contained approximately 500 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
45817817|NCT03115177|Drug|Doxycycline|The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision for total shoulder arthroplasty.
45817818|NCT03115177|Drug|Cefazolin|
45817819|NCT04201418|Drug|Patisiran|Patisiran-lipid complex injection, for intravenous use
45957546|NCT02928016|Other|Mixed meal 2|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables.The meal provided 399 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
45957547|NCT02928016|Other|Mixed meal 3|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20g kalamata olives. The meal provided 502 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
45957548|NCT02928016|Other|Mixed meal 4|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives and 11 ml extra virgin olive oil. The meal provided 893 kcal and contained approximately 600 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
45957549|NCT02928016|Other|Mixed meal 5|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables and 11 ml extra virgin olive oil. The meal provided 497 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
45957550|NCT02928016|Other|Mixed meal 6|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20 g kalamata olives and 11 ml extra virgin olive oil. The meal provided 601 kcal and contained approximately 400 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
45957551|NCT02927899|Other|Survey Administration|Ancillary studies
45957552|NCT02927899|Dietary Supplement|Tomato-Soy Juice|Receive tomato-soy beverages with or without varying levels of arugula seed powder
45957553|NCT02927860|Other|Fitbit|A FitBit HR monitor will be placed on patients when they arrive on the nursing unit after thoracic surgery. Sleep and activity will be monitored for the duration of the patient's hospitalization and the data from the Fitbit HR device will be downloaded by the study staff to a computer.
45957554|NCT00148694|Drug|Cisplatin|Intravenously once every three weeks for a total of 12 weeks
45957555|NCT00176007|Procedure|Hypoxia|
45957556|NCT02927704|Other|Gingival crevicular fluid (GCF) sample|Single intervention has been performed for each subject. GCF samples were collected from four multi rooted teeth (premolar/molar) one of in each quadrant including two maxilla and two mandibula by single examiner in conjunction with clinical measurements in this intervention.
45957557|NCT02927782|Procedure|Early Mobilization|early postoperative mobilisation (walking and sitting). Initial postoperative mobilisation is going to be under supervision of a qualified physiotherapist. The presence of a qualified physiotherapist at first mobilisation is solely for reasons of safety. No specific exercise or regimen is planned.
45957558|NCT02927782|Procedure|Bed Rest|48 hours of strict bed rest followed by postoperative mobilisation under supervision of a qualified physiotherapist. During the bed rest period elevation of the head is tolerated to a maximum of 30°.
46079162|NCT05787041|Other|fasted group（AD16 20mg）|Subjects took AD16 on an empty stomach and fasted within 4 hours after taking the drug.
46079163|NCT05787028|Drug|AD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg|Take one AD16 tablet in the morning
46079164|NCT05787028|Drug|AD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg|Participants will take a placebo pill matching AD16 once in the morning
45663713|NCT04446039|Drug|Mirtazapine|Treatment for depression
45663714|NCT04446039|Drug|Duloxetine|Treatment for depression
45663715|NCT04446039|Drug|Sertraline|Treatment for depression
45663716|NCT04446039|Drug|Venlafaxine|Treatment for depression
45663717|NCT04446039|Drug|Tianeptine|Treatment for depression
45957559|NCT02927665|Device|Reshape Integrated Dual Balloon|
45957560|NCT03457480|Other|Computer-Assisted Intervention|Read computer messages
45957561|NCT03457480|Behavioral|Focus Group|Attend focus group
45957562|NCT03457480|Other|Informational Intervention|Receive text messages
45957563|NCT03457480|Other|Survey Administration|Complete surveys about experience
45957564|NCT00148772|Drug|Erlotinib (Tarceva)|
46079165|NCT05787015|Behavioral|Vaccine Norms Feedback|Personalized normative feedback pertaining to normative misperceptions about vaccination rates and hesitant attitudes.
46079166|NCT05787015|Behavioral|Alcohol Norms Feedback|Personalized normative feedback pertaining to normative misperceptions about alcohol use.
45663718|NCT04446039|Drug|Vortioxetine|Treatment for depression
45663719|NCT04446039|Drug|Desvenlafaxine|Treatment for depression
45663720|NCT04446039|Drug|Bupropion|Treatment for depression
45663721|NCT05087979|Device|Stable airway management (SAM) device|SAM is positioning device that will maintain patient's head, neck, and therefore their airway in the correct position during their procedure.
45817820|NCT02962609|Other|Semielevated Side-lying Position-ESL|The infants in the experimental group (n = 38) were held in the ESL position. In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infantswere held in the side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and their head and neck were held at the same level by the researcher; whereas, their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
45957565|NCT02927743|Behavioral|evidence-based online feedback|GPs received during three months weekly mails about evidence-based practice and a small questionnaire to reflect about their practice and the new knowledge
45957566|NCT02927626|Drug|Yang Yin Fu Zheng therapy|Yang Yin Fu Zheng is a Chinese herbal compound.
45957567|NCT02927626|Drug|Routine medical care|Routine medical care
45957568|NCT00176046|Drug|viscum album pini|s.c. injection of 0,001-20 mg 3 times per week
45957569|NCT00176046|Drug|viscum album pini|s.c. injection 0,001-20 mg 3 times per week
45957570|NCT02927587|Drug|The induction Cet of propofol|The induction Cet of propofol was targeted respectively at 1 and 2 ug/ml.
45957571|NCT00148850|Drug|Pioglitazone|
45957572|NCT02927353|Drug|DMB-3113|subcutaneously injected in a single dose of 40 mg.
45957573|NCT02927353|Drug|Adalimumab|subcutaneously injected in a single dose of 40 mg.
45957574|NCT02927509|Drug|TNF alpha blockers|
45957575|NCT02927314|Drug|CF102|orally q12h
45957576|NCT02927314|Drug|Placebo|orally q12h
45957577|NCT00148889|Device|Deep brain stimulation (DBS)|Bilateral pallidal stimulation with an implanted DBS device
45454983|NCT03935035|Behavioral|internet-delivered Cognitive Therapy for PTSD (iCT)|Participants will receive 10 hours of Cognitive Therapy for PTSD over 12 weeks, with a baseline assessment at the beginning and follow up interview at the end of treatment. The treatment consists of online modules (9 core modules, 11 optional modules and parent/carer modules) and a weekly phone call with a qualified and trained therapist.
45454984|NCT01216891|Behavioral|Multi-element, team-oriented treatment|Participants will receive treatment and services based on their needs coordinated by a small team that is led by a clinical coordinator. Services that are available to the participants include social skills training, medication treatment to address symptoms, education and employment advising, and substance use treatment.
45454985|NCT01115959|Drug|valproic acid|treatment of 1 month dosage of 400 mg BID
45663722|NCT03677427|Radiation|Radiation|Radiation in breast cancer
45817821|NCT02962609|Other|Semielevated Supine Position|The ESU position was applied to the infants in the control group (n=42). In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and they was laid in the supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
45454986|NCT01115959|Drug|placebo bid|
45454987|NCT03936907|Drug|OWCP Orally Disintegrating Tablet|Medical Grade Cannabis - Orally Disintegrating Tablet (MGC-ODT) containing 5 mg THC and 5 mg CBD
45817822|NCT02962687|Behavioral|Care management via videoconference|12-week nurse care management for medically complex Veterans with CI delivered via videoconference
45957578|NCT02927275|Behavioral|Experimental: Standing Modality|Cognitive performance when standing
45957579|NCT02927275|Behavioral|Experimental: Biking Modality|Cognitive performance when biking slowly
45957580|NCT02927275|Behavioral|Experimental: Walking Modality|Cognitive performance when walking at 1mph
45957581|NCT02927275|Behavioral|No Intervention: Seated Modality|Cognitive performance when sitting.
45957582|NCT00176124|Procedure|leukocyte depletion of whole blood|
45957583|NCT00176124|Other|Leukocyte filtration/Depletion|leukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours
45957584|NCT02927470|Device|Sham TMS condition|A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of sham TBS, the subject will perform the working memory task for 45 minutes.
45957585|NCT02927470|Device|OffLine TMS Condition|A total of 200 trains will be delivered successively in 40 s, totaling 600 pulses. The pulses will be delivered at 80% of motor thresholds. A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of TBS, or sham TBS, the subject will perform the working memory task for 45 minutes.
45957586|NCT02927470|Device|Online TMS condition|A single train of pulses (3 pulses at 50Hz, duration 40ms) will be delivered once during a particular time epoch on each trial, followed by a minimum of 6 seconds of no stimulation. No more than 600 pulses will be applied in a single session. Similar to the offline TMS condition, a sham TMS coil will be used to measure baseline performance on the working memory task. In each session (frontal, sham) subjects will perform the working memory task for 45 minutes.
46079167|NCT05787002|Drug|AZD0780|AZD0780 will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.
45817823|NCT02962687|Behavioral|Care management via telephone calls|12-week nurse care management for medically complex Veterans with CI delivered via telephone calls
45957587|NCT02927197|Behavioral|LearningRx cognitive training|A clinician will deliver forty 90-minute cognitive training sessions over 12-14 weeks for a total of 60 training hours. There are 23 different categories of training procedures sequenced in intensity and difficulty for a total of more than 1000 training tasks.
45663723|NCT05086419|Other|Sub-symptom threshold aerobic exercise|For the first three weeks, participants will be offered guided sub-symptom threshold aerobic exercise on a treadmill or exercise bike once a week. The remaining 2-4 sub-symptom threshold aerobic exercise workouts per. week will be on their own. Location and mode of exercise (treadmill, walking, jogging, exercise bike / bicycle, swimming, or elliptical machine) will be individually adapted to the patients experience, preferences and opportunities. The intensity of the sub-symptom threshold aerobic exercise will always be monitored using a heart rate monitor and/or ratings of perceived exertion (Borg RPE). If there still is a need for closer follow-up after the first three weeks, a physiotherapist in primary health care service will be involved under supervision from a physiotherapist (research fellow) in the project.
45957588|NCT02927002|Device|Noninvasive brain stimulation|
45957589|NCT02927119|Dietary Supplement|iodine|≥ 150 µg/day iodine supplementation (iodine containing pregnancy supplement) prior to enrollment
45957590|NCT02927041|Device|transesophageal echocardiography (hTEE)|Hemodynamic interventions include volume resuscitation, vasopressors and positive inotropes. Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
45957591|NCT00170235|Other|Prehabilitation|Exercise class pre-surgery
45957592|NCT00170235|Other|Usual care|Exercise booklet, physiotherapy if needed
45957593|NCT00148928|Biological|P501-AS15 vaccine|
45957594|NCT02926885|Device|CONVENTIONAL LIVER RETRACTOR DEVICE|LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING CONVENTIONAL RETRACTOR DEVICE
45957595|NCT02926885|Device|FLEXIBLE LIVER RETRACTOR DEVICE|LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING FLEXIBLE LIVER RETRACTOR DEVICE
45454988|NCT03936907|Drug|Sativex|Sativex® Oromucosal Spray
45454989|NCT01116115|Other|InFat™ based infant formula|High sn-2 palmitic acid oil based infant formula
45957596|NCT02926885|Procedure|LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY|LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
45957597|NCT02926963|Other|samples collection : hair and skin biopsy|
46079168|NCT05787002|Drug|Rosuvastatin|Rosuvastatin will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.
45454990|NCT01116115|Other|Standard vegetable oil based infant formula|Standard vegetable oil based infant formula
45817824|NCT03174158|Drug|Mailed nicotine replacement therapy|Daily smokers will be offered patches and lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette). Non-daily smokers will be offered a 2 week supply of 2 mg lozenges. Smokers not ready to quit will be offered one box of lozenges dosed according to time to first cigarette to use in a practice quit attempt.
45817825|NCT03174158|Behavioral|Text messaging|12 week text messaging program tailored to readiness to quit and quit date. Program includes content encouraging NRT use. Content is personalized with user's name and Massachusetts General Hospital resources.
45817826|NCT03174158|Behavioral|Brief advice|Brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training
45454991|NCT01217203|Drug|IPH2101 combined to lenalidomide|"Dose level 1 : 0.2 mg/kg IPH2101(with Lenalidomide 10 mg/day) Dose level 2 : 0.2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 3 : 1 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 4 : 2 mg/kg IPH2101(with Lenalidomide 25 mg/day)~Extension cohort: 6 patients at the Maximum Tolerated Dose (MTD)"
45817827|NCT04736641|Other|Survey study|Japanese Orthopaedic Association Hip Disease Evaluation Questionnaire (JOAHDEQ) will be applied
45817828|NCT00422630|Behavioral|The DASH diet|The DASH diet was originally conceived as the optimal diet for individuals with hypertension, based on epidemiologic and clinical trial data suggesting a beneficial effect of plant-based diets on blood pressure It is a diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with moderate amounts of nuts, legumes, fish, and poultry. Consumption of red meat, sweets, and sugary beverages is limited. As a result, the DASH diet contains more potassium, magnesium, calcium, and fiber and less total fat, saturated fat, cholesterol, simple sugars, and sodium than the average American diet
45454992|NCT01120171|Drug|Cyclophosphamide|"Cyclophosphamide (IV) 600 mg/m2 on day 1. Treatment repeats every 21 days. Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response,or unacceptable toxicity."
45454993|NCT01120171|Drug|Liposomal-encapsulated doxorubicin|"Liposomal-encapsulated doxorubicin (IV) 50 mg/m2 on day 1. Treatment repeats every 21 days.~Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response or unacceptable toxicity."
45454994|NCT01116193|Drug|Lenalidomide plus dexamethasone|Lenalidomide 25 mg p.o. once daily on days 1-21 plus Dexamethasone 40 mg p.o. once daily on days 1, 8, 15, and 22 of each 28-day cycle (4-weeks cycles) until CR achievement, progression of disease or intolerable toxicity
45957598|NCT02926807|Other|FDG-PET Scan|a 18FDG-PET to quantify vascular inflammation
45957599|NCT02926807|Other|MDCT|a MDCT to calculate the Agatston score
45957600|NCT02926807|Other|biopsy and blood collection|biopsy and blood collection to assess biomarkers
45957601|NCT00170274|Device|Activation of preventive and therapeutic algorithms for treatment of AF|Algorithms in At 500 or Enrhyhtm for prevention and termination of Atrial Fibrillation
45957602|NCT00170274|Device|AF Prevention and Therapy Algorithms On|Activation of AF-prevention and termination algorithms in AT 500 or EnRhyhtm
45957603|NCT00148967|Device|Implantable Cardioverter Defibrillator|
46079169|NCT05786989|Drug|selinexor|Given PO
46079170|NCT05786976|Other|Lotion BNO 3732|Crem body lotion twice daily
46079171|NCT05786976|Other|Body Lotion Benchmark product|Crem body lotion twice daily
46079172|NCT05786950|Drug|compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)|inhaled compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)
45454995|NCT01120327|Drug|Placebo|Placebo
45454996|NCT01120327|Drug|Amlodipine|Amlodipine
45454997|NCT01217281|Procedure|Full Mouth Non-Surgical Periodontal Therapy|Non-surgical Periodontal Therapy provided in two sessions, one for the right half and one for the left half of the dentition. Treatment sessions are provided within one week. No antibiotics or other adjunctive medications are to be used
45454998|NCT01122589|Behavioral|Motivational Interviewing/CBT|6 sessions of in jail MI/CBT counseling will be administered.
45454999|NCT01122589|Other|CONcise Tapes Reviewing Obstacles to healthy Living (CONTROL)|a series of six weekly 30-45 minutes general wellness videos
45817829|NCT00422630|Behavioral|The low glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
45455000|NCT01116271|Drug|AZD6244|50 or 75mg, capsules, PO, BID, 28 days
45455001|NCT01116271|Drug|Irinotecan|180mg/m2, IV, Day 1& 15 of each cycle
45663724|NCT04192773|Drug|IV Lidocaine|Using IV lidocaine as intervention and comparing fMRI pre- and post-lidocaine infusion
45663725|NCT05036967|Drug|HF medication|Treatment initiation patterns of patients with Heart Failure (HF) in an outpatient setting from Colombia.
45663726|NCT05171205|Device|Spinal cord stimulation|Spinal cord stimulation (SCS) is a very thin electrode implanted in the dorsal epidural space of the spinal cord to improve the patient's symptoms by stimulating the spinal nerves with pulsed electrical currents, which attenuate or enhance the flow of nerve impulses from the periphery to the central system, i.e., stimulating thick fibers to achieve therapeutic results. SCS system consists of three components: an electrode implanted in the epidural space of the patient's spinal cord, a stimulator implanted subcutaneously in the abdomen or buttocks that delivers electrical impulses, and an extension cord that connects the two.
45663727|NCT03647007|Other|FIFA 11 for health|The training consists of various football exercises, such as passing, shooting, dribbling, etc., and small-sided games. The small-sided games are performed as e.g. 3v3 with small goals (2x5 m).
45455002|NCT01217359|Drug|Interferon Alfa-2b|Patients will receive a single dose of interferon followed by serial blood draws to assess cellular responses to interferon
45663728|NCT04784247|Drug|Lenvatinib|20mg daily (two 10mg lenvatinib capsules) taken orally
45663729|NCT04784247|Drug|Pembrolizumab|(200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes. Study treatment with pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.
45817830|NCT00422630|Behavioral|Reduced calorie American Diet|The reduced-calorie diets will provide at least the Recommended Daily Allowance (RDA) for protein (0.8 g/kg/day).
45817831|NCT03115411|Device|Winged biliary stent (ViaDuct™)|Placement of winged biliary stent at ERCP for management of benign biliary stricture.
45817832|NCT03176654|Procedure|HVLAT manipulation|HVLAT will be performed 10 minutes after the first blood draw.
45817833|NCT03176654|Procedure|Sham HVLAT manipulation|Sham HVLAT will be performed 10 minutes after the first blood draw.
45957604|NCT02926846|Drug|Intravenous vancomycin & gentamicin with adjunctive lavage|"Intravenous vancomycin and gentamicin are administered, together with adjunctive lavage performed by automated peritoneal dialysis machine over 48 to 72 hours.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)"
46079173|NCT05786937|Biological|Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides|Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides
45663730|NCT02014311|Procedure|CTA+CTP guided treatment strategy|CTA+CTP guided treatment strategy
45663731|NCT02014311|Procedure|CTA guided treatment strategy|CTA guided treatment strategy
45817834|NCT03115801|Drug|Nivolumab|Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.
45817835|NCT03115801|Drug|Atezolizumab|Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
45817836|NCT03115801|Radiation|Radiation & immunotherapy|Radiation is given to one lesion, 30 Gray (Gy) in 3 fractions of 10 Gy each. over a one week interval (with a minimum of 36hrs between each fraction). On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days. Patients will receive radiation on Day 1 and immunotherapy will be given ± 24hr from Day 1.
45817837|NCT03115801|Drug|Pembrolizumab|Pembrolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
45817838|NCT00422708|Procedure|Local anesthesia|
45817839|NCT03799328|Other|multi-OIT|low dose OIT to multiple foods
45663732|NCT05034861|Device|cCTG|Self-applied home computerized CTG device used twice weekly instead of standard Doppler assessment once weekly.
45455003|NCT03939715|Biological|DermaPure®|Surgical intervention using DermaPure®
45817840|NCT03177512|Behavioral|LYNX Mobile App|Access to the LYNX mobile app which includes the Sex Pro score tool, PrEP videos, HIV/STI testing reminders and geo-location features.
46079174|NCT05786937|Biological|Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides|Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides
45663733|NCT05034861|Diagnostic Test|Doppler|Standard Doppler assessment provided once weekly in case of late FGR with positive end diastolic flow in the umbilical artery.
45455004|NCT03939715|Procedure|native tissue|Surgical intervention using native tissue
45455005|NCT03957187|Diagnostic Test|Ferritin, iron and iron binding capacity, high sensitive C-reactive protein (CRP) measurement|"Ferritin, iron and iron binding capacity will be measured for evaluation of ID using Cobas c-e and Elecsys.~The relation of inflammation to iron deficiency will be evaluated by high sensitive C-reactive protein measurement."
45455006|NCT03235492|Device|SmartAlbu|"Plan:~Consent an individual~Measure and record temperature, blood pressure, heart rate, height and weight~Obtain two samples of saliva for the SmartAlbu portable salivary sensor~Take a venous blood sample for HbA1c and~Glycated albumin~Obtain blood sample from a finger stick for point of care HbA1c device"
45455007|NCT03225664|Biological|Pembrolizumab|Given IV
45663734|NCT05032677|Procedure|Conventional Epidural Technique|Standard Lumbar Epidural Block using Touhy Epidural Needle (18G) at L2-3 inter-space and Epidural Catheter (20G) was inserted then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
45663735|NCT05032677|Procedure|Dural Puncture Epidural Technique using pencil-point 25G Whitacre needle|25G Dural Puncture Epidural Block at L2-3 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
45663736|NCT05031897|Procedure|Hematopoietic Cell Transplantation|Undergo HSCT
45817841|NCT03117517|Drug|Metformin|Metformin (1000 mg)
46079175|NCT05786937|Other|Commercial ringer´s lactate solution|Placebo
46079176|NCT05786911|Other|nutritional score|correlation between a food habit and nutritional status score of the parturient and a postpartum fatigue (FSS) and pain (ENA) score
45663737|NCT05031897|Drug|Mycophenolate Mofetil|Given IV
45663738|NCT05031897|Drug|Tacrolimus|Given IV
45663739|NCT05031897|Drug|Cyclophosphamide|Given IV
45663740|NCT05031897|Radiation|Total-Body Irradiation|Undergo TBI
45663741|NCT05031897|Procedure|Donor Lymphocyte Infusion|Undergo DLI
45663742|NCT05031897|Drug|Fludarabine|Given IV
45663743|NCT05031897|Drug|Melphalan|Given IV
45663744|NCT05002959|Device|Anatomic TESS V3|Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Anatomic configuration.
45817842|NCT03117517|Drug|Metformin, Pioglitazone|Metformin (1000 mg) Pioglitazone (30 mg)
45817843|NCT00375284|Drug|Pramipexole|
45817844|NCT02966275|Device|Glucagon-only bionic pancreas - glucagon|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
45817845|NCT02966275|Device|Glucagon-only bionic pancreas - placebo|A computer algorithm will automatically deliver placebo based on the signal from a minimally invasive continuous glucose monitor.
45817846|NCT02967367|Device|Jawbone sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
45817847|NCT02967367|Device|Withings sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
46079177|NCT05786898|Other|NEAR-TSA|"Neuropsychological and Educational Approach of Cognitive Remediation adapted to autism~32 sessions spread over 4 to 8 months (1 session per week for minors, 2 sessions per week for adults), lasting 90 to 120 minutes"
45663745|NCT05002959|Device|Reverse TESS V3|Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Reverse configuration.
45663746|NCT04801329|Drug|Vyndamax (tafamidis 61mg)|As prescribed in real world practice
45817848|NCT02967367|Device|BodyMedia Sense Wear accelerometer|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
45817849|NCT04122170|Drug|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 90 mg oral tablet; administered as 180 mg (2 × 90 mg tablet) loading dose plus 90 mg every 12 hours for 4 additional doses.
45455008|NCT03225664|Other|Pharmacokinetic Study|Correlative studies
45817850|NCT04122170|Drug|Aspirin (ASA) Oral Tablet - Pre-Treatment|Aspirin 81 mg oral tablet; administered daily between Day -7 to the morning before receiving study medication on Day 1, for a total of 8 tablets only.
45817851|NCT04122170|Drug|Bentracimab (PB2452) Infusion|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration~In subjects with potential drug interaction from concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36 g infusion."
45817852|NCT04122170|Drug|Placebo (0.9% Sodium chloride) infusion|0.9% Sodium chloride Intravenous Infusion over a 16 hour duration
45455009|NCT03225664|Drug|Trametinib|Given PO
45663747|NCT01871727|Drug|E7777 9 mcg/kg|administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive days during every cycle of 21 days
45663748|NCT04949841|Drug|Delgocitinib|Delgocitinib cream 20 mg/g
45663749|NCT05266989|Other|Transcranial Direct Current Stimulation|Non-invasive technique that modulates the excitability of the cortex by applying low-intensity current
45663750|NCT01636713|Drug|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
45663751|NCT01636713|Drug|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
45817853|NCT05405101|Procedure|ablation of aldosterone secreting adenoma|Radio frequency ablation to Conn's adenoma(s)
45817854|NCT05405101|Procedure|Unilateral adrenalectomy|Unilateral adrenalectomy for aldosterone secreting adenoma
45817855|NCT03795350|Drug|Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide|single inhalation of 99mTc radiolabelled TRIMBOW pMDI (4 puffs for a total dose of 400mcg BDP, 24mcg FF, 50 mcg GB)
45817856|NCT03118843|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
45817857|NCT03724370|Behavioral|Telehealth Monitoring System|TES will be conducted daily via Interactive Voice Response System (IVRS) during the 12 week study period.TES will be added to VHA-SRM.
45663752|NCT01636713|Drug|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
45663753|NCT04801095|Drug|WM-S1-030|WM-S1-030 orally administered once daily (QD) for 28 days of each cycle.
45663754|NCT04800471|Device|Smart insulin pens and CGM|Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices
45957605|NCT02926846|Drug|Intraperitoneal vancomycin & gentamicin|"Intraperitoneal vancomycin and gentamicin are administered, with the usual continuous ambulatory peritoneal dialysis schedule maintained.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)"
45957606|NCT02926612|Other|Next Generation Genomic Sequencing|DNA and RNA are extracted from biospecimens, amplified, sequenced, and then compared to known microbe databases, allowing for quantitative identification of non-host organisms
45817858|NCT03724370|Other|VHA-SRM|Veterans Health Administration Suicide Risk Management supportive services will be provided to participant during the 12 weeks of study participation.
45817859|NCT04736732|Other|Medical follow-up|Patients will be followed for medical evaluation and for biobanking of data and biological samples.
45957607|NCT02926495|Device|eCoin System|Median nerve neurostimulator.
45663755|NCT04800471|Other|Point of Care Glucose Group|Participants in this group will be monitored by POC glucose values.
45663756|NCT04875429|Device|Zenith Fenestrated+ Endovascular Graft in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System|Endovascular aneurysm repair
45663757|NCT04800237|Drug|VQW-765|oral capsule
45663758|NCT04800237|Drug|Placebo|oral capsule
45817860|NCT05401513|Other|Pilates Group|The individuals of the Pilates group will perform specific exercises of the method, which will involve mobility, stability and muscular resistance. The exercises will progress according to the level of difficulty (basic, intermediate and advanced), load and repetition every three or four weeks.
45817861|NCT05365022|Device|ROSA® System Robotic Assisted Knee Prosthetic Surgery|Robotic Assisted Knee Prosthetic Surgery using ROSA® (Zimmer-Biomet) System
45817862|NCT03119389|Behavioral|Donning Non-Sterile Gloves without HH|Current practice is to perform hand hygiene before donning of non-sterile gloves. In units assigned to the intervention, healthcare workers within the units will be educated that performing hand hygiene before donning non-sterile gloves is not necessary.
45817863|NCT02967991|Device|EUS-guided liver biopsy|Endoscopic ultrasound guided liver biopsy
45957608|NCT00170313|Device|Conducted AF-Response Algorithm (CAFR) On|Algorithm will be enabled.
45957609|NCT00170313|Device|Conducted AF-Response Algorithm (CAFR) Off|Algorithm will be disabled.
45957610|NCT02926300|Biological|stem cells|IV infusion
45663759|NCT01582191|Drug|Everolimus|Given PO
45663760|NCT01582191|Other|Laboratory Biomarker Analysis|Optional correlative studies
45663761|NCT01582191|Other|Pharmacological Study|Optional correlative studies
45663762|NCT01582191|Drug|Vandetanib|Given PO
45663763|NCT03591861|Procedure|Ketogenic diet|"Children under 2 years will immediately start on a full calorie classical 3:1 ketogenic diet. The 3:1 ratio indicates that the diet contains 3 g of fat for every 1 g of protein + carbohydrate, which results in about 87% of calories coming from fat.~Children 2 years or older will skip breakfast and lunch on the day of admission but start a full calorie 3:1 ketogenic diet at dinner."
45455010|NCT01212679|Drug|nerve growth factor|The experimental group patients will receive NGF 20ug/d intranasally for 2 weeks.
45663764|NCT03591861|Drug|BCNU|-Standard of care
45663765|NCT04800159|Drug|THC Cannabis|Vaporization of cannabis
45663766|NCT04800159|Drug|CBD Cannabis|Vaporization of cannabis
45663767|NCT04800159|Drug|Placebo|Vaporization of placebo
45957611|NCT02926378|Procedure|Acupuncture Treatments|Every participant will receive six acupuncture treatments across a three to four-week period. The treatments will last a total of about one hour, including a 10 minute initial assessment, needling, and 45 min of lying down with the needles. Two treatments a week will be performed by Dr. Siminovich-Blok, the PI of this study and a NYS licensed acupuncturist at NYU Langone Medical Center (NYULMC) Ambulatory Care Center. Each acupuncture treatment will consist of 1) a combination of a fixed set of points suggested by the literature, and 2) an individualized set of points based on the evaluation by the licensed acupuncturist. The first set of points will consist of 4 acupoints used consistently in the treatment of stroke through the literature.
45957612|NCT00149006|Procedure|Cell therapy|
45817864|NCT05400421|Device|System & Method for Monitoring Aortic Pulse Wave Velocity & Blood Pressure|Carotid-femoral aortic pulse wave velocity will be compared against values collected from the oximeter system. The former is assessed by placing piezoelectric pressure sensors at three locations: the right common carotid artery, the right common femoral artery (groin), and the right superficial femoral artery (thigh). The oximeter will be secured on the right index finger. Simultaneous data collection will occur for both methods, with each trail lasting 60 seconds.
45957613|NCT02926183|Drug|Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel|Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.
45957614|NCT00170352|Procedure|Hyperbaric Oxygen Treatment (HBOT)|
45957615|NCT00170352|Procedure|Enhanced Oxygen Treatment (Enhanced FiO2)|
45957616|NCT02926261|Other|Bioelectrical impedance vector analysis|Evaluation of nutritional status with Bioelectrical impedance vector analysis, hand-grip strength and computed-tomography scan
45957617|NCT02926339|Behavioral|Teens Against Tobacco Use presentation|Students receive a series of 3 anti-tobacco presentations delivered by older peers
45957618|NCT02926105|Behavioral|T&E Home-based exercise programme|"T&E exercises programme consists of home-based individually tailored balance and functional strength tests and exercises performed 3x a week over 12 months, accompanied by eight in-home visits of physiotherapists during the first six months."
45663768|NCT04832919|Behavioral|Nurse-Community-Family Partnership Intervention|Nurses conduct home visits on a monthly basis for the first five months post-baseline. During visits, nurses emphasize the importance of infection control measures and, jointly with household members, develop and follow-up on the implementation of an infection control plan tailored to the unique circumstances of the household. Nurses deliver training on infection control skills necessary for optimal implementation of the plan. Nurses offer at-home SARS-CoV-2 testing to all members of the household. Nurses conduct triage, medical case management, monitoring, and follow-up of individuals identified to have COVID-19 or any other acute health emergencies. CHWs conduct visits on a bi-weekly basis for the first five months post-baseline. CHWs deliver healthcare information and medical mistrust counseling in a culturally relevant and linguistically appropriate fashion; and provide social support, navigate household members to social welfare/vocational/economic/psychosocial services.
45957619|NCT02926105|Behavioral|Otago|Otago exercises programme consists of home-based individually tailored balance, strength and walking exercises performed 3x a week over 12 months, accompanied by eight in-home visits of physiotherapists during the first six months.
45957620|NCT02926105|Behavioral|Helsana booklet|Helsana programme consists of a booklet with recommendations and 10 exercises performed 3x a week over 12 months.
45957621|NCT00170391|Behavioral|Quarter of an Hour rule|
45957622|NCT02925832|Procedure|Deep Topical Fornix Nerve block anesthesia|DTFNB would be performed using two sponges (2x3mm) soaked with either 0.5% bupivacaine or 0.75% ropivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with proparacaine local anaesthetic drops. The sponges are to be removed after 15 minutes.
45957623|NCT02925832|Drug|Ropivacaine|0.75% ropivacaine soaked sponges
45957624|NCT02925832|Drug|Bupivacaine|0.5% bupivacaine soaked sponges
45957625|NCT02925832|Drug|Proparacaine|For anaesthetising conjunctiva
45957626|NCT02925988|Device|EEG monitoring|Neonates will receive their amplitude-integrated EEG monitoring as soon as the indication for monitoring is established, and conventional EEG electrodes will be applied in parallel.
45957627|NCT02925910|Device|Shock absorbing wheelchair|2 randomised groups will try the softwheel wheelchair compare to regular one, but in different order.
45957628|NCT00170430|Drug|Fluconazole|
45957629|NCT00170430|Drug|Metronizadole|
45957630|NCT04257526|Behavioral|Diet and lifestyle advice following a positive FIT test and diagnostic colonoscopy.|Participants will be recruited during CRC screening and will be included if they have a positive faecal immunochemical test (FIT) and are diagnosed with adenomas but are CRC negative during the colonoscopy. Participants receive evidence-based diet and lifestyle advice intervention with 'usual care'.
45957631|NCT00149084|Drug|Lansoprazole, clarithromycin, amoxicillin|
45957632|NCT00170469|Biological|AVA|
45957633|NCT00170469|Biological|rPA vaccine containing alhydrogel|
45957634|NCT02925715|Procedure|ultrasound guided central venous cannulation|ultrasound is a medical device which is frequently used for safe venous punctures as you can visualise the structures.so, device ''ultrasound'' will be used for intervention ''central line insertion'' in subclavian vein. ultrasound guided cannulation of the subclavian vein was done by supraclavicular or infraclavicular approach after randomization into either of the two groups.In the supraclavicular approach the puncture site is above the clavicle while in the infraclavicular group the puncture site is below the clavicle. Central venous cannulation is done after identifying the vein on ultrasound and using standard seldinger technique with full asepsis.
45957635|NCT00149123|Drug|hydrocortisone 200 mg/day|
45957636|NCT02925676|Device|hyposafe H02|hypoglycaemia notification device
45957637|NCT02928289|Device|VISCO360 ab interno canaloplasty surgery|360 degrees of viscodilation of Schlemm's canal
45957638|NCT02928289|Device|Selective Laser Trabeculoplasty (SLT)|360 degrees of selective laser trabeculoplasty
45957639|NCT04689607|Other|Mulligan Traction Straight Leg Raise (TSLR)|The patient was in a supine position on a low bed and the therapist faced the limb of the patient that was to be treated. The therapist grasped the lower leg of the patient just near the ankle and raises the leg off the bed to a position just above the painful range. The therapist flexes the knees. Traction was retained as far as possible with a straight leg lift if there was no pain. The pain-free traction straight leg raise range was administered for 10 second and the procedure was repeated three times.
45957640|NCT04689607|Other|Post Isometric Relaxation technique (PIR):|The knee of the affected leg was extended, and the affected hip was flexed. Then the calf of the patient was placed on the shoulder of therapist. The therapist was standing on the side of the affected leg. The flexion of the hip was performed on the affected leg until resistance was felt. The patient was asked to gently push down on the therapist's shoulder with the leg. The therapist resisted hip extension to create an isometric contraction. The duration of the contraction was 10 seconds. Then the patient was instructed to relax and the therapist gently flexed the hip until the next barrier was felt. The technique was repeated three times.
45957641|NCT04689217|Drug|intrathecal drug injection|"All patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~The patients will be divided equally into 3 groups according to the additive (fentanyl, nalbuphine or placebo), and all patients will receive the local anesthetic dose of 0.5% heavy bupivacaine according to weight and height"
45957642|NCT00170508|Biological|Fluzone®|
45957643|NCT00149162|Drug|proleukin|"One cycle of treatment : D1 : 2.5 MUI/m2 (subcutaneous); D2 to D5 : 5 MUI / m2 (subcutaneous)~1 cycle of treatment each month during 12 months"
45957644|NCT04689334|Other|Outcome|The number of surgeries
45957645|NCT02925637|Other|FaCoT|The intervention will include: functional activities, cognitive activities and strategies (pencil-pen treatment), and behavioural strategies
45957646|NCT00170547|Biological|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain.. Group 4: 382 subjects receive Fluzone 15 mcg IM on day 0
45957647|NCT00170547|Biological|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Group 1: 382 subjects receive 6 mcg ID with BD system. Group 2: 382 subjects receive 9 mcg ID with BD system, all doses on day 0.
45663769|NCT01491789|Device|The VSail-Access simulator|You will be transferred to the VSail cockpit and secured. Following the trainer's instruction, you will sail the simulator around virtual courses displayed on a computer screen, using a joystick to control the rudder angle and a mainsheet to control the set of the sail. You will do this for 1 hour.
45957648|NCT00170547|Biological|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain..Group 3: 382 subjects receive 3 mcg Fluzone ID using Mantoux technique on day 0.
45663770|NCT05264961|Behavioral|voice therapy|sessions of voice therapy
45663771|NCT01600053|Drug|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles (6 cycles = 1 course of Revlimid consolidation). Revlimid will be initiated at 5mg and can be dose escalated at the start of each cycle based on individual patient tolerability to a maximum of 25 mg. The total number of treatment cycles cannot exceed 12 cycles or two courses of six cycles each.
45817865|NCT02222922|Drug|PF-06647020 Q3W|"Part 1: PF-06647020 will be administered intravenously every 21 days in cohorts of 2-4 patients starting at a dose of 0.20mg/kg. Increases in dose will continue until MTD is determined.~Part 2: Patients with triple negative breast cancer (pre-selected for PTK7 moderately high to high expression), non small cell lung cancer (pre-selected with moderate to high PTK7 expression) and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1."
45817866|NCT02222922|Drug|fluconazole|combination drug used for drug-drug interaction sub-study
45663772|NCT04821297|Other|Health Promotion and Education|Receive messages
45663773|NCT04821297|Other|Survey Administration|Complete survey
45817867|NCT02222922|Drug|PF-06647020 Q2W|"Part 1: PF-06647020 will be administered intravenously every 14 days in cohorts of 2-4 patients starting at a dose of 2.1 mg/kg. Increases in dose will continue until MTD is determined.~Part 2: Patients with non-small cell lung cancer (pre-selected for PTK7 moderate to high expression and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1."
46079178|NCT05786885|Procedure|Microneedling will be done with application of topical vitamin C paste for depigmentation|"A Dermapen device will be used to microneedle the gingival tissue (model M8) with 24 microneedles arranged in rows, which is adjusted with 1.5 mm depth at the 6th mode speed of 700 cycles/min.~It will be used in intermittent motion on the affected area for 30-40 seconds / tooth.~Once bleeding points are observed on all areas of the pigmented gingiva, it will be irrigated using saline solution and dried using sterile gauze.~Topical vitamin C powder (1000 mg/ml) will be mixed with saline, and the resultant slurry mix will then be applied to the gingiva for 10 minutes."
46079179|NCT05786885|Procedure|Vitamin C injection|"1-1.5 ml Vitamin C will be injected into the gingiva, using an insulin syringe, once weekly, for 3 weeks.~All the injection procedures will be performed by the same operator. The treated area will be left without dressing in both groups."
46079180|NCT05786872|Device|dual-target deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat alcohol use disorder and to evaluate the efficacy and safety of DBS system.
46079181|NCT05786859|Drug|Rifaximin 200 mg|Rifaximin Treatment Group:on the basis of comprehensive treatment of liver failure, Rifaximin will be added, three times a day, 400mg each time, for a total of 4 weeks, and we will observe until 12 weeks after withdrawal.
46079182|NCT05786859|Other|Standard Treatment without Rifaximin|The standard treatment group (control group), which will receive routine comprehensive treatment for liver failure without Rifaximin.
46079183|NCT05786807|Drug|K-CAB|Tegoprazan 50 mg 1 tab twice daily Amoxicillin 500mg 2 cap twice daily Clarithromycin 500mg 1tab twice daily
46079184|NCT05786781|Device|Transarterial CT angiography|Transarterial catheter-directed CT angiography during interventional treatment of hemoptysis
46079185|NCT05786768|Drug|single infusion of Rituximab|single infusion of Rituximab 375 mg/m2
46079186|NCT05786768|Drug|single infusion of Obinutuzumab|single infusion of Obinutuzumab 300mg/1.73 m2
46079187|NCT05786742|Radiation|grade and compare reported side effects between groups|"Compare experimental ultra hypo fractionation (25 Gy in 5 daily fractions administered starting mid week and ending mid following week) to our standard fractionation (either 37,5 Gy given in 15 daily fractions, or 36 Gy in 12 daily fractions).~Toxicity analysis will be quantitatively evaluated using CTCAE (v5) at 1, 2 and 5 years post-therapy, and has needed at FU visits. Kaplan-Meier statistical analysis will be used to report toxicity evolution through time.~median IPSS scores will be reported at 3, 6, 12 months and yearly (1, 2, 3, 4 et 5) post-therapy. IPSS median time to baseline return will be calculated.~IPSS urinary scores, sexual function (SHIM) and GI toxicity (CTCAE-v5) and quality of life questionnaires ( EPIC-26) will be given at 3, 6 months and yearly thereafter (1, 2, 3, 4 et 5) post-treatment."
46079188|NCT05786729|Other|Aerobic Exercise (AER)|Aerobic exercise will be performed by utilizing aerobic exercise equipment 3 times per week.
46079189|NCT05786729|Other|Rehabilitation|Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
46079190|NCT05786638|Drug|Allergen Immunotherapy Extract|Sublingual subcutaneous allergen immunotherapy
45663774|NCT04821297|Other|Interview|Participate in an interview
45663775|NCT03573297|Drug|Cariprazine|Cariprazine capsules, oral administration, once daily
45663776|NCT03573297|Drug|Placebo|Matching placebo capsules, oral administration, once daily
45663777|NCT03569241|Radiation|whole pelvic radiotherapy|addition of prophylactic whole pelvic radiotherapy to a local metastasis-directed treatment
45817868|NCT02222922|Drug|PF-06647020 combined with Avelumab|Part 2: Patients with ovarian cancer (unselected for PTK7 expression) will be treated with PF-0664702 plus Avelumab.
45817869|NCT03503942|Behavioral|Lifestyle modification|Participants in the treatment arm will receive structured, locally tailored, group-based lifestyle interventions that consist of a core intervention phase (3 months) and a maintenance phase (33 months). The core intervention phase will consist of twice weekly group sessions on nutrition, exercise and goal-setting within the first 6 weeks followed by 6 weeks of self-directed lifestyle modification. During the maintenance phase, the participants will receive monthly short message service (SMS) on health tips as well as 6 monthly telephone calls from program coordinators.
46079191|NCT05787379|Behavioral|Concordant Care Training|Concordant Care training has four components. 1. Clinicians will complete ~3 hours of online, asynchronous training that will teach them practices including validate Veterans' experiences with Long-COVID, develop shared understanding with patients about Long-COVID, and develop patient-centered action plans. Clinicians will be provided with handouts, case examples, video demonstrations, and practice exercises to help them integrate these practices into care. 2. Tele-mentoring groups will be offered ~bi-weekly and be open to all clinician participant in the Concordant Training arm. Content will include review of specific cases, didactics on specific Concordant Care practices, role-play exercises, and review of session recordings. At least two sessions are required. 3. Clinician Pocket Card that serves as a reminder of the Concordant Care process. 4. An electronic prompt will be sent to enrolled Veterans encouraging them to speak with their clinician about their Long-COVID concerns.
45455011|NCT01212679|Drug|nomral saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks.
45957649|NCT02925520|Drug|Omegaven|"Therapy with Omegaven will be provided at a dose of 1 gm/kg/day infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Parenteral fat emulsion (Intralipid) will be administered only if necessary to administer adequate calories during Omegaven therapy. The same standards of care provided to all patients receiving parenteral nutrition solution will be followed.~Home Use of Omegaven:~The Omegaven dose for home use will be the same as that used while in the hospital: 1 gm/kg/day. As with the inpatient part of the protocol, this is a maximum dose and may be decreased at the discretion of the provider."
45455012|NCT04466644|Diagnostic Test|ELISA|Antibody test (serology) in the blood samples to determine if the subject was previously infected.
45957650|NCT00149201|Drug|5-FU continuous infusion|
45957651|NCT00149201|Drug|MTX + 5-FU sequential therapy|
46079192|NCT05787379|Behavioral|Education Packet Training|Clinicians randomized to the control arm will receive a comprehensive information packet with the latest understanding of Long-COVID. Clinicians will also be provided a packet directing them to relevant VA trainings for Long-COVID. Whole Health trainings which focus on wholistic integrated approaches to care will be highlighted. Whole Health is important for all Veterans, and it is thought to be particularly relevant for poorly understood conditions that don't easily fit in traditional medical model.
46079193|NCT05785975|Other|Certain ommunications(Nudge), community-outreach(landline call), and single FIT testing|The intervention is an integrated system made up of single FIT testing, community outreach (landline call), and specific messages (Nudge). In order to encourage people to attend the screening, a primary care physician will be used in addition to text messages that participants at the outreach get for information, education, and communication (IEC).
45957652|NCT02925559|Drug|Dapagliflozin|The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
45957653|NCT02925559|Drug|Gliclazide MR|As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
45455013|NCT04466644|Diagnostic Test|RT-PCR|For detecting the presence of SARS-CoV-2 RNA molecule in the nasopharyngeal swabs and saliva.
45455014|NCT01217593|Procedure|ultrasound|Ultrasound guidance will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
45455015|NCT01217593|Procedure|predetermined distance|The predetermined distance technique will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
45957654|NCT02925325|Behavioral|Music therapy|Music therapy (MT) treatment focuses on the use of 2 techniques of intervention: receptive MT and active MT. The work of receptive application is described as the use of prerecorded music or executed by the music therapist with effect on the patient, without the latter's active involvement in the psychotherapeutic process of musical creation. While the active application, both the music therapist and patient are involved in musical creation, for example, the use of voice, body and musical instruments (Muñoz, 2008). Contemplate their psychotherapeutic possibilities in 3 different dimensions of patient: body, emotional and social work, as explained above. Treatment with MT, as in cognitive behavioral therapy, includes breathing exercises, stress-relaxation techniques, psychoeducation, and exercises for the management of irrational thoughts and erratic behavior patterns (Dobson and Dozois, 2010).
45957655|NCT02925325|Other|Usual Treatment|It is the usual medical treatment that patients with major depressive disorder in remission but with residual symptom receives at the sponsor institution in a monthly basis.
45957656|NCT02925286|Other|Prevention program for gambling in the workplace|The intervention group will receive a gambling prevention program which includes generating and implementing policies and education on addiction and gambling. The full length of the program will be about 14 hours.
45817870|NCT03503942|Drug|Metformin|Metformin will be will be prescribed to treatment group participants at highest risk of diabetes conversion (i.e.IFG + IGT or IFG + HbA1c ≥6.0%) after at least 6 months of lifestyle interventions at a starting dose of 250 mg twice a day followed by up-titration to 500 mg twice a day after 3 months if the participants do not experience any gastrointestinal side effects.
45817871|NCT03503942|Other|Financial incentives|Participants will be given cash incentives if they meet the weight loss target, which is pre-defined as 5% of baseline weight, at the 3rd, 6th, 12th, 18th, 24th, 30th and 36th month of study period.
45957657|NCT00170586|Device|Underglove coating (skin barrier)|
45957658|NCT00149240|Biological|Botulinum toxin type A|
45817872|NCT03808922|Drug|DAS181|DAS181 4.5mg nebulized qd x 7 OR 10 days
45817873|NCT03808922|Drug|Placebo|Placebo nebulized qd x 7 OR 10 days
45817874|NCT03808922|Drug|DAS181 COVID-19|DAS181 4.5mg nebulized q12h/day x 7 OR 10 days
45817875|NCT03808922|Drug|DAS181 OL|DAS181 4.5mg nebulized qd x 7 OR 10 days ≥ 40kg DAS181 2.5mg nebulized qd x 7 OR 10 days < 40kg
45957659|NCT02925247|Behavioral|Adherence to oral anticoagulant treatment|The adherence will be evaluated by biological results
45957660|NCT02925481|Behavioral|Moderate Online yoga participation|Phase 1: Testing yoga videos for emotional regulation and self-compassion which will inform the selected videos for Phase 2 prescription Phase 2: 150 minutes of Online streaming yoga videos completed at home. Week 1/2 introductory videos that include short video clips breaking down each pose Weeks 3-12 increase in difficulty (all videos are appropriate for beginners)
45957661|NCT02925481|Behavioral|Stretching and toning|Phase 1: Developing 12 week prescription for online control videos Phase 2: Online streaming stretching and toning videos completed at home which consist of a warm-up, 1 balance, 2 core, 2-3 upper body and lower body exercises, 6 stretches, cool-down
45957662|NCT02925481|Behavioral|Low dose online yoga participation|Phase 1: Testing yoga videos for emotional regulation and self-compassion which will inform the selected videos for Phase 2 prescription Phase 2: 60 minutes of Online streaming yoga videos completed at home. Week 1/2 introductory videos that include short video clips breaking down each pose Weeks 3-12 increase in difficulty (all videos are appropriate for beginners)
45957663|NCT02925442|Procedure|t-RFA|standard thermal genicular radiofrequency ablation
45957664|NCT02925442|Procedure|C-RFA|Cooled radiofrequency ablation
45957665|NCT02925442|Procedure|Control|Simulated radiofrequency ablation for placebo controlled group
45957666|NCT02925598|Device|I-gel LMA insertion|'I-gel LMA insertion' was done following anesthesia induction.
45957667|NCT02925598|Device|AuraGain LMA insertion|'AuraGain LMA insertion' was done following anesthesia induction.
45957668|NCT02925598|Device|ETT insertion|'ETT insertion' was done following anesthesia induction.
45957669|NCT00170664|Drug|Paclitaxel|
45957670|NCT00170664|Drug|Carboplatin|
45663778|NCT03569241|Radiation|metastasis-directed treatment|stereotactic body radiotherapy
45817876|NCT03122587|Device|Transcranial Alternating Current Stimulation at 10 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 10 Hz to target alpha oscillatory activity
45957671|NCT02917954|Device|ePRO Tool Intervention|The ePRO tool includes two features: 1) My Goal Tracker and 2) Health Journal. My Goal Tracker allows patients and providers to collaboratively create goal-oriented patient care-plans, and helps patients to track outcomes related to their goals using a mobile device. The Health Journal allows patients, their caregivers and primary care providers to monitor patients' symptoms and outcomes.
45957672|NCT02917837|Other|Usual QCNL DI utilization report|See arm descriptions.
45957673|NCT02917837|Other|New DI utilization report|See arm descriptions.
45817877|NCT03122587|Device|Transcranial Alternating Current Stimulation at 40 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 40 Hz to target gamma oscillatory activity
45957674|NCT02917837|Other|Detailing|In-person detailing, usually with a small group of family physicians and a peer (physician) facilitator to discuss the topic over a 30-60 minute period.
45957675|NCT04689022|Behavioral|Mississippi Scale for Combat-Related PTSD (M-PTSD)|The treatment outcome rate was assessed by the Mississippi Scale for Combat-Related PTSD (M-PTSD). A positive outcome rate is represented with the patient post-discharge positive coping, which corresponds to 94-58 points, observed in 39 patients (17.9%). A treatment failure is regarded as the absent PTSD treatment effect after discharge, which corresponds to 148-113 points, observed in 5 patients (2.3%) and psychic disorders, which correspond to 112-95 points, observed in 174 patients (79,8%).
45817878|NCT03122587|Device|Active sham transcranial alternating current stimulation|Active sham (placebo)
45957676|NCT04689022|Diagnostic Test|visual analogue scale (VAS)|pain intensity
45957677|NCT04689022|Diagnostic Test|Douleur Neuropathique 4 questions (DN4)|neuropathic pain component
45957678|NCT00170703|Device|Cortical Electrical Stimulation|
45957679|NCT00149279|Procedure|Surgery: D2 dissection|
45957680|NCT00149279|Procedure|Surgery: D2+paraaortic dissection|
45957681|NCT02917681|Other|Two intrathecal MSC injections|
45455016|NCT01214473|Other|Synbiotics|Lactobacillus plantarum with fructo-oligosaccharide
45663779|NCT03569241|Procedure|salvage Lymph Node Dissection|metastasis-directed treatment
45663780|NCT03569241|Drug|androgen deprivation therapy|LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months
45663781|NCT04799535|Procedure|Ultrasound|Undergo breast ultrasound
45663782|NCT04799067|Other|observational study|no study drug involved, observational study.
45663783|NCT04716387|Other|Standard LLIN|Long-lasting insecticidal net containing alphacypermethrin, a pyrethroid insecticide, and manufactured by Shobikaa Impex Private Limited.
45663784|NCT04716387|Other|Piperonyl butoxide ITN|Insecticide treated net containing permethrin, a pyrethroid, and piperonyl butoxide, an insecticide synergist, manufactured by Sumitomo Chemical.
45663785|NCT04716387|Other|Pyriproxyfen ITN|Insecticide treated net containing alpha-cypermethrin, a pyrethroid, and pyriproxyfen, an insect growth regulator, manufactured by Disease Control Technologies.
45957682|NCT02917486|Other|blood sample|
45957683|NCT03315403|Diagnostic Test|LytA targeted quantitative polymerase chain reaction (qPCR)|LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)
45957684|NCT00170742|Drug|Octreotide, 30 mg i.m. LAR formulation|
45957685|NCT00149318|Other|Biochemical analyses.|Biochemical analyses.
45957686|NCT02917525|Dietary Supplement|Vitamin K2|
45957687|NCT02917525|Other|Placebo|
45957688|NCT03457441|Other|Standards vision tests|Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
45957689|NCT03457441|Device|OdySight medical application assessment|Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
45957690|NCT02917330|Other|Stretching and progressive strength training|Intervention implemented by local physiotherapist.16 weeks, three treatment sessions each week. Minimum pause between two treatment sessions is one day. Week 1 and 2: To assure the correct dosage in each exercise and a satisfactory education of the session done at home, all three sessions will be implemented with the physiotherapist the first two weeks. From week 3: Two treatment/training sessions with the physiotherapist and one shorter training session at home.
45957691|NCT00170781|Drug|Lumiracoxib|
45957692|NCT00149357|Other|Thrombophilia Testing|TP testing in Group 1 and 3 only
45455017|NCT01214473|Other|Maltodextrin|Only maltodextrin as placebo
45817879|NCT03791138|Other|online patient decision aid|An online, interactive tool that can be used to prepare for consultation with a plastic surgeon which contains evidence-based information about breast reconstruction options, the pros and cons of the options, value clarification exercises and patient narratives. It results in a summary sheet with patients' personal values and questions that can be discussed during consultation with a plastic surgeon.
45957693|NCT02917369|Other|Normal lung tissue|The investigators will extract total protein, DNA and RNA from LCLC patients.
45957694|NCT02917252|Other|3-hydroxybuturate|Drink of ketone bodies
45957695|NCT02917252|Other|Placebo|Drink of saline
45455018|NCT03198988|Device|smART Feeding Tube System|Replacing generic feeding tube with smART Feeding Tube System.
45957696|NCT02917291|Drug|FAB117-HC|(Ph 1) Intramedullary administration. Open label dose escalation, 3 patients in cohort 1 (20 million cells) and 5 patients in cohort 2 (40 million cells)
45957697|NCT02917291|Other|Control group|(Ph 2) No treatment will be administered
45957698|NCT02917291|Drug|FAB117-HC|(Ph 2) Intramedullary administration of the maximum tolerated dose (20 or 40 million cells)
45957699|NCT00170820|Drug|Everolimus|
45957700|NCT02917174|Behavioral|Mobile Asthma Management System|Patients in this group use a smartphone app in their asthma self-management.
45957701|NCT02917174|Behavioral|traditional Asthma Management System|Patients in this group use a printed asthma diary in their asthma self-management.
45957702|NCT02917018|Drug|Dexmedetomidine|Group I will receive 1 ug/kg, group II will receive 0.75 ug/kg and group III will receive 0.5 ug/kg) diluted to 50 ml NaCl 0.9% by syringe pump over 20 minutes before end of surgery.
45957703|NCT02917135|Device|Angel® Catheter|"The Angel® Catheter is a retrievable inferior vena cava (IVC) filter attached to a multi-lumen central venous access (CVC) catheter. The device is designed to be placed at the bedside in the inferior vena cava, via the femoral vein, for the prevention of pulmonary embolism (PE) and for access to the central venous system.~The Angel® Catheter is intended for short-term (less than 30 days) vascular access via the femoral vein."
45957704|NCT00149474|Behavioral|Peak Flow Monitoring|
45957705|NCT00170859|Drug|Everolimus|
45957706|NCT02917057|Drug|exenatide once weekly|Exenatide treatment in customary clinical care in the USA
45957707|NCT02917057|Drug|basal insulin|basal insulin tretament in the customary clinical care in USA
45957708|NCT02916940|Drug|Diprophos|Single subcutaneous injection of Diprophos, in the acute phase.
45957709|NCT00149513|Behavioral|Targeted Case Management|A nurse case manager will assess and follow intervention arm subjects for six months. Nurse case manager will help subjects acquire needed community health services.
45957710|NCT00149513|Behavioral|Usual care|Participants will receive usual care.
45957711|NCT02916901|Drug|CKD-519 200mg|
45957712|NCT02916901|Drug|Placebo|
45455019|NCT03193684|Drug|Empagliflozin 25 MG|subjects will receive daily dose of 25mg of empagliflozin for 3 months
45455020|NCT03193684|Drug|Control|Placebo
45957713|NCT00170898|Drug|Lumiracoxib|
45455021|NCT01116349|Procedure|Plate and screws or nailing|Patients included in the surgical group will be divided into two subgroups according to the method of fixation chosen: plate and screws or nailing. Surgeries take place under general anesthesia and a prophylaxis antibiotic is administrated. The installation and the approach will be chosen by the surgeon according to his preferences. A thoraco brachial brace is placed on the patient at the end of the intervention and it remains in place for a period of 5 to 10 days (patient comfort). A gradual mobilization of the elbow and shoulder will be initiated by the patient at home. The addition of physical therapy will be decided by the surgeon and noted down accordingly.
45455022|NCT01116349|Device|Hanging Support System (HSS) brace|Patients included in the conservative group will be taken to a plaster room where the HSS brace will be installed by a qualified technician. Advice will be provided for the care, personal hygiene and clothing. The brace will be kept for a period of 6 to 12 weeks depending on the degree of healing of fracture. The maintenance of the proximal part (Brace) may be recommended by the surgeon. The mobilization will begin with exercises at home and whether the patient does physical therapy or not is the surgeon's choice.
45455023|NCT01217671|Biological|Kamada AAT for inhalation|Alpha-1 Antitrypsin (AAT)
45455024|NCT01217671|Other|Placebo|Placebo
45458210|NCT03380143|Behavioral|Wellness Landscape Intervention|Community and organization systems intervention targeting youth population physical activity
45458211|NCT03380143|Behavioral|Standard Practice|Community development intervention
45663786|NCT04716387|Other|Chlorfenapyr ITN|Insecticide-treated nets containing two active ingredients: alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide, manufactured by BASF.
45663787|NCT01068249|Drug|Letrozole|2.5 mg daily by mouth every day, at same time as Everolimus.
45957714|NCT02916355|Drug|Anakinra|Subjects will receive Anakinra infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
45957715|NCT02916355|Drug|NaCl|subjects will receive NaCl infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
45957716|NCT00149552|Dietary Supplement|zinc|supplementation with zinc gluconate
45957717|NCT02916511|Drug|Paclitaxel|paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw*5
45957718|NCT02916511|Drug|Carboplatin|carboplatin AUC=2, ivgtt, d1, qw*5
45957719|NCT02916511|Radiation|Radiotherapy|1.8Gy/d, d1-5/week, 25Fx
45663788|NCT01068249|Drug|RAD001 (Everolimus)|10 mg by mouth daily
45663789|NCT01035099|Drug|Letrozole|"Letrozole titrated regimen may be started on day 2 of menstrual cycle:~Serum Estradiol level <150 pg/ml- No Letrozole; Serum Estradiol Level 150-250 pg/ml- 2.5mg; Serum Estradiol Level 251-350 pg/ml- 5 mg; Serum Estradiol Level >350 pg/ml - 7.5 mg;"
45663790|NCT01035099|Drug|Letrozole|Fixed dose of 5 mg per day Letrozole will be started on the second day of their menstrual cycle
45957720|NCT02916589|Dietary Supplement|Diet|
45957721|NCT02916628|Behavioral|group counseling|Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.
45957722|NCT02916628|Device|Auricular acupressure|Auricular acupressure using acupellets was performed for 6 weeks continuously
45957723|NCT02916628|Device|placebo acupressure|Placebo acupellets were prepared without metal projections, and placed on both sides in the same areas of the ear as the active condition.
45957724|NCT00163722|Other|Culture and histology|
45957725|NCT00163722|Other|Aspergillus galactomannan and PCR|
45957726|NCT02916667|Other|dietary guidelines|dietary guidelines will include chrono- nutrition diet plan
45957727|NCT00149591|Procedure|coronary balloon-angioplasty with stenting|
45957728|NCT02916394|Radiation|68Ga-NODAGA-ZIGF-1R:4：40|No Intervention
45957729|NCT02916277|Biological|endocan|to look series Endocan level for 5 days in intubated patients
45957730|NCT00170937|Drug|valsartan plus hydrochlorothiazide|
45957731|NCT02915965|Drug|DCX|docetaxel, cisplatin and capecitabine
45663791|NCT00990483|Device|3D mammograpgy system|In addition to the standard care diagnostic imaging, all participants underwent two experimental acquisitions, in two projections (Cranio-Caudal and Mediolateral Oblique) on the breast of concern: one acquisition in Mode A (narrow angle acquisition) and one acquisition in Mode B (wide angle acquisition).
45817880|NCT05364632|Behavioral|Behavioral Intervention to Increase Physical Activity|The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active. The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting until 90 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own physical activity (PA) data and the behavioural change stage, an individual action plan will be established to increase physical activity. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time.
45455025|NCT04339270|Drug|Azithropycin according to symptoms|"Patients randomized to the standardized comparator arm will benefit from the standard treatment for COPD, including with regard to the prescription of azithromycin in case of severe sputum complaints (here defined by a CASA-Q sputum symptoms score <70 to homogenize practices between centers).~CASA-Q will be evaluated every 3 months.~If the patient has a sputum symptoms score <70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score <70.~If the patient has a sputum symptoms score> 70, management is not changed."
45455026|NCT04339270|Drug|Azithromycin according to rheology or symptoms|"Treatment according to standard COPD management, except for the prescription of azithromycin, which will be prescribed in function of mucus rheology or as a function of sputum complaints (here defined by a CASA-Q sputum symptoms score <70).~The rheology of mucus will be quantified every 3 months.~If the patient has spontaneous or induced sputum, and this sputum has a critical constraint (tau-C) > 39, a prescription for 3 months of azithromycin treatment will be initiated. This prescription may be renewed every 3 months during the 12 months of follow-up planned in this study.~If the patient has a sputum symptoms score <70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score <70.~If the patient has a sputum symptoms score> 70, management is not changed."
45455027|NCT01116505|Dietary Supplement|Gluten-free diet|gluten-containing cereals removed from diet
45663792|NCT05362383|Device|transcutaneous electrical nerve stimulation (TENS):Enraf Nonius® S82 model|Will be used TENS device with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 milliampere. TENS electrodes (diameter 35-52 mm) will be placed bilaterally on mandibular elevator muscles, on the superficial masseter muscle above the gonial angle, and bilaterally on the anterior temporal muscle. The device will be applied in an identical manner to all patients in both groups and kept in position for the same time period (30 min) and for the control group the the device will be not switched on
45663793|NCT00973011|Drug|FCFD4514S|Intravitreal escalating dose
45817881|NCT05364632|Other|Aerobic Training|The same initial educational program described for the Behavioral Intervention group will be delivered to this group. Each aerobic training session will consist of 45 minutes divided into 5 minutes of warm-up, 35 minutes of aerobic exercise and 5 minutes of cool-down. During physical training, heart rate and level of respiratory distress will be monitored. The intensity of aerobic physical training will be based on the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (LA) and the respiratory compensation point (CRP). The patient may interrupt physical exercise if he presents any clinical symptoms and/or respiratory discomfort, returning as soon as his respiratory condition improves.
45957732|NCT02915965|Procedure|surgery|Ivor Lewis Esophagectomy
45663794|NCT03560349|Drug|Lidocaine HCl Gel 2%|"Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study."
45817882|NCT05364398|Procedure|ACL reconstruction|Use of hamstring tendons graft to replace the torn ACL and being passed and fixed through the femoral and tibial sides
45817883|NCT04736966|Drug|Guselkumab 30mg|30mg of Guselkumab administered by subcutaneous injection
45817884|NCT04736966|Drug|Guselkumab 70mg|70mg of Guselkumab administered by subcutaneous injection
45817885|NCT04736966|Drug|Guselkumab 100mg|100mg of Guselkumab administered by subcutaneous injection
45817886|NCT02161146|Drug|AGN-229666|One drop of AGN-229666 in the eye on Days 1 and 15.
45455028|NCT03525184|Other|Additional protein and multi-nutrient beverage|During SR+, participants will consume a multi-nutrient beverage and additional protein (~1.5 grams·kg-1 body weight·day-1 versus the lower end of MDRI of ~0.9 grams·kg-1 body weight·day-1) during and after the period of sleep restriction. The multi-nutrient beverage contains arginine, glutamine, vits C & D, zinc and omega-3 fatty acids (DHA and EPA).
45455029|NCT03525184|Other|Placebo beverage|The placebo beverage (NS and SR) will be composed of a commercially-available artificially sweetened (e.g., containing aspartame, splenda or another artificial sweetener) beverage powder base and grapefruit extract (i.e., naringen) and/or quinine (i.e., a common ingredient found in tonic water).
45455030|NCT01214707|Other|Exercise|Exercise during EMU stay
45663795|NCT03560349|Drug|placebo gel|"Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study."
45663796|NCT04812639|Other|Buccal infiltration technique|a technique for injecting local anesthetic solution in the buccal mucobuccal fold between the roots of the targeted tooth
45817887|NCT02161146|Drug|Vehicle to AGN-229666|One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.
45817888|NCT02161146|Drug|Olopatadine|One drop of olopatadine in the eye on Days 1 and 15.
45817889|NCT03447782|Drug|Naltrexone HCl (Bulk) Powder|For the NDPH Persistent group, patient will take naltrexone, 4.5 mg, po 1 time/day for three months-Naltrexone will be compounded from Naltrexone HCL powder
45957733|NCT02916238|Drug|Fluoxetine|Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.
45817890|NCT03109951|Drug|Colonoscopy preparation using polyethylene glycol|Colonoscopy preparation using standard preparation with 2L of polyethylene glycol.
45817891|NCT03408704|Other|ASP|"It consists of one educational session where doctors and staff at the center discuss current guidelines around management of patients attending for a sore throat. At the education the following is discussed:~The Swedish guidelines~Example of cases~Statistics from previous 6 month showing how well this clinic adheres to the Swedish guidelines."
45817892|NCT03123055|Drug|B-701|B-701 (vofatamab) is a human IgG1 monoclonal antibody that is highly specific for the FGFR3 receptor.
45455031|NCT04316650|Behavioral|Evaluation Scales|"PATHOS / PEACCE : hypersexuality diagnostic scale~PDQ-4+: Personality Diagnostic Questionnaire version 4~AUDIT~Life trajectory : THQ~Cognitive function (MoCA, Stroop)~ISDSS: and self report of sexual activity and desire~BARS: Brief Adhesion Rating Scale (treatment observance)~SF-36 scale : quality of life~BDI-II : Beck Depression Inventory~BSSI ; Beck suicidal Inventory~Cognitive functioning evaluation : Molest and Rape Scale~Empathy: EMPAT~Evaluation of Cognitive functioning: denial evaluation and Mc Kibben minimization~Baratt Impulsivity Scale~CSBI~Static 99 and Stable 2007"
45455032|NCT04316650|Other|osteodensitometry|Osteodensitometry
45663797|NCT04812639|Other|Inferior alveolar nerve block technique|a technique for injecting local anesthetic solution to anesthetize the inferior alveolar nerve
45817893|NCT03123055|Drug|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
45817894|NCT03340532|Other|THE INFORMATION + APPEARANCE VIDEO|THE INFORMATION + APPEARANCE VIDEO which will include the full information video, along with an additional embedded video segment emphasizing negative appearance consequences of UV exposure.
45957734|NCT02916238|Behavioral|Enhanced Usual Care|Depression symptoms monitored at 3 month intervals; results from PHQ-9 available to ART clinic physicians.
45957735|NCT00149708|Drug|growth hormone administration for 6 months|depot GH (Nutropin depot) 13.4 mg every 14 days
45957736|NCT02916082|Procedure|Cervical length measurement|Vaginal ultrasound to measure cervical length previous to use of prostaglandins.
45957737|NCT00163761|Drug|gemcitabine, vinorelbine, ifosfamide, filgastrim|Drug
45957738|NCT00163761|Drug|gemcitabine, vinorelbine, filgastrim|Drug
45957739|NCT02916043|Procedure|Cardiovascular surgery with cardiopulmonary bypass|Patients who underwent cardiovascular surgery including valve replacement or thoracic aortic surgery with cardiopulmonary bypass
45663798|NCT04812483|Drug|Eltrombopag (Revolade®)|Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) indicated in patients with ITP refractory to first-line drugs or lasting more than 6 months. Administration of Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day.
45663799|NCT04812483|Drug|standard therapy (without eltrombopag): HD-DXM|standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4
45817895|NCT03340532|Other|Information SunSmart video|The INFORMATION SunSmart video providing basic information about UV risks, including secondary skin cancer and the benefits of SP, as well as specific SP recommendations and steps to integrate SP as part of routine self-care for the healthy cancer survivor
45817896|NCT03340532|Other|Sleep hygiene video|Contain information on better sleep hygiene
45817897|NCT03124069|Device|F&P Saturn|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm.
45957740|NCT02916160|Drug|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®)|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.
45957741|NCT00149786|Behavioral|Family Based Therapy|Family therapy will be given for a total of 24 hours over the course of 12 months.
45663800|NCT04418583|Diagnostic Test|Three-dimensional imaging|Three-dimensional surface images, acquired by the Artec Leo
45663801|NCT05157399|Device|Otoband|Participants with Dizziness and Vertigo will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
45663802|NCT05157399|Device|Placebo Device|Participants with Dizziness and Vertigo will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
45663803|NCT04418973|Other|VOCs analysis in exhaled air|using an electronic nose and a mass spectrometry
45957742|NCT00149786|Behavioral|Ego-Oriented Individual Psychotherapy|Individual therapy will be given for a total of 24 hours over the course of 12 months.
45957743|NCT02916121|Dietary Supplement|folic acid 5 mg/cap|the intervention includes folic acid 5 mg/d and vitamin B12 500 ug/d
45957744|NCT02916121|Other|Placebo|placebo
45957745|NCT02916199|Device|cannulation of ampulla of Vater|Cannulation of ampulla of Vater is a procedure that a guide-wire is passed through ampulla using interventional devices
45663804|NCT00434343|Other|Global Therapeutic Massage (GTM)|
45663805|NCT00434343|Other|Myofascial physical therapy (MPT)|Connective tissue manipulation to all body wall tissues of the abdominal wall, back, buttocks and thighs that clinically were found to contain connective tissue abnormalities and/or myofascial trigger point release to painful myofascial trigger points
45663806|NCT04435431|Drug|Mesdopetam|Oral use
45663807|NCT04435431|Drug|Placebo|Oral use
45663808|NCT00098475|Drug|Dexamethasone|Given PO
45663809|NCT00098475|Other|Laboratory Biomarker Analysis|Optional correlative studies
45663810|NCT00098475|Drug|Lenalidomide|Given PO
45817898|NCT05361200|Behavioral|Dynamic high-cadence cycling|Resistance settings will be changed based on entropy of cadence every 3 sessions. Cadence will be set at 80RPM for both groups
45455033|NCT04316650|Biological|blood samples|"Lipid profile (total cholesterol, triglycerides, HDL cholesterol)~Liver function (ASAT, ALAT, total bilirubin, transferase gamma-glutamyl et alcalin phosphatases~Kydney function~Blood count~Biological Measurements and Measurement of Systematic Plasma Testosterone and TeBG Levels in Sex Offenders check for pathology of the Gonadotropin Axis~Biological Measurements of Plasma Prolactin level"
45455034|NCT04316650|Other|ECG|ECG (heart rate, search for cardiac conduction disorders or cardiac arrhythmias)
45663811|NCT00098475|Drug|Thalidomide|Given PO
45957746|NCT00170976|Drug|valsartan + amlodipine|
45455035|NCT04316650|Genetic|Blood and saliva samples|Blood and saliva samples
45455036|NCT01116583|Drug|Gabapentin|"Preoperatively (2 hours before surgery): 4 gabapentin capsules each containing 300 mg gabapentin (total gabapentin dose 1200 mg)~Postoperative day 1: gabapentin 300 mg x 2 (total gabapentin dose 600 mg)~Postoperative day 2: gabapentin 300 mg x 3 (total gabapentin dose 900 mg)~Postoperative day 3: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)~Postoperative day 4: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)~Postoperative day 5: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)"
45455037|NCT01116583|Drug|Placebo|"Preoperatively (2 hours before surgery): 4 placebo capsules~Postoperative day 1: 1 placebo capsule x 2~Postoperative day 2: 1 placebo capsule x 3~Postoperative day 3: 1 placebo capsule x 4~Postoperative day 4: 1 placebo capsule x 4~Postoperative day 5: 1 placebo capsule x 4"
45455038|NCT04315792|Drug|Endoxifen|Administration of Endoxifen for 3 weeks
45455039|NCT04315792|Drug|Placebo oral tablet|Administration of Placebo for 3 weeks
45455040|NCT01214785|Behavioral|Provision of household latrines|WaterAid and local NGO partners mobilize householders in target villages to construct and use latrines in accordance with the Government of India's Total Sanitation Campaign.
45957747|NCT03266302|Device|hemoadsorber for removal of cytokines|Use of the hemoadsorber during cardiac surgery with CPB. Hemoadsorber is integrated into the CPB circuit according to manufacturer's recommendation.
45957748|NCT00149864|Drug|Mycophenolate sodium (enteric coated)|
45455041|NCT04302376|Diagnostic Test|Cather-related thrombosis ultrasonography|Doppler and compression ultrasound to detect catheter-related thrombosis
45455042|NCT04299490|Behavioral|Sleep Fragmentation|Subjects are provided an 8-hour sleep opportunity. Two speakers are placed 12 inches from the head of the bed and four remote-activated mechanical vibrators are placed underneath the mattress. EEG microarousals (>3 s), as defined according to standard criteria, are elicited at a frequency of 30 or more events per hour.
45455043|NCT04299490|Drug|Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)|On the third day of the in-patient visit participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter pain medications, or placebo (saline).
45663812|NCT02246673|Drug|RDEA3170 15 mg|
45663813|NCT02246673|Drug|RDEA3170 10 mg|
45663814|NCT02246673|Drug|RDEA3170 2.5|
45663815|NCT02246673|Drug|RDEA3170 5 mg|
45663816|NCT02246673|Drug|Febuxostat 40 mg|
45663817|NCT02246673|Drug|Febuxostat 80 mg|
45663818|NCT03532425|Drug|B/F/TAF|B/F/TAF (Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir Alafenamide 25mg) Tablet taken orally once daily
45663819|NCT03532425|Drug|Atripla|Atripla (Efavirenz 600mg/ emtricitabine 200 mg/ tenofovir disoproxil 245 mg) Tablet taken orally once daily
45663820|NCT03532425|Drug|B/F/TAF Placebo|Tablet taken orally once daily
45663821|NCT03532425|Drug|Atripla Placebo|Tablet taken orally once daily
45957749|NCT03254212|Device|Titration of nocturnal oxygen needs to prevent desaturations|Oximetry recordings will be performed using a Pulse Oximeter. Two O2 titration sessions will be conducted at home in random order one week apart. One will consist of a stepwise night-to-night increase in O2 flow for up to 4 nights with supplemental O2, each at flow rates of 1L/min, 2L/min, 3L/min and 4L/min, respectively. During the other titration session, an automatic O2 delivery system will be used for 4 consecutive nights with O2 flow allowed to vary from 0 to 4 L/min with a 95 ± 2% SpO2 target. At the end of the titration periods, oxygen concentrators will be set at the lowest flow rate (1L/min to 4L/min) that maintained oxyhemoglobin saturation to > 90% (Tsat90%) for ≥ 98% of the estimated sleep period and reduced the oxygen desaturation index 3% (ODI3) to < 5/hour according to conventional O2 titration. If these targets are not reached, the lowest flow rate will be selected that minimizes the ODI3. These procedures will be repeated at week 5 and 11.
45663822|NCT04812093|Device|Spectroscopic otoscope measurements|Spectroscopic otoscope measurements are taken with the investigational device. Each measurement consists of placing the device in the ear canal and illuminating the ear with multiple light sources in a short period of time. If wax is present in the ear canal, it is removed by the study physician and another measurement is taken.
45957750|NCT02915848|Device|PC+S group|PC+S group: participants in the study will also receive a specific stimulation device (Activa PC+S, Medtronic) that is capable of recording the local field potentials (LFP). Approximately 10 participants are expected to take part in this study at UHN.
45957751|NCT04688593|Device|MobileLink|Patients who receive a MobileLink hip prosthesis system will be followed-up for 10 years.
45957752|NCT00149903|Drug|Mycophenolate sodium (enteric coated)|
45817899|NCT05358236|Other|Episiotomy Wound Care and Genital Hygiene Training|"Episiotomy wound healing and genital hygiene training were given face-to-face by researchers to the mothers assigned to the training group. The trainings were given to each mother individually in their rooms. The total training lasted an average of one hour. At the end of the training, the mothers were given a written and illustrated training brochure.~Training content~Primarily, external reproductive organs were shown to mothers through pictures.~Urethra, Vagina, Anus, Perineum areas were mentioned.~The definition of Episiotomy was made; and where and how it was applied was explained with visual materials. It was explained how to care for the episiotomy area to heal more rapid and healthier.~Information was given on how to change their menstrual pads.~Information was provided on what to look for when using underwear~What to watch out while taking a bath:~What to pay attention to in your stitch area"
45817900|NCT02969317|Drug|Tiotropium|Fixed dose combination
45957753|NCT04688632|Drug|Ampreloxetine <Dose A>|Ampreloxetine <Dose A> will be administered as 1 tablet of <Dose A> and 3 tablets of Ampreloxetine Placebo.
45817901|NCT02969317|Drug|Olodaterol|Fixed dose combination
45817902|NCT03314168|Other|Combined training|Resistance exercises performed with different volumes (i.e. one-single set and multiple-sets) and 20-25 minutes of aerobic exercise will be performed twice a week, during 12 weeks.
45663823|NCT03503877|Device|EmbryoScope Plus|All embryos will be cultured in the EmbryoScope Plus to obtain morphokinetic data
45817903|NCT03314168|Other|Control group|The usual care will be recommended to avoid systematic physical exercise for 3 months and will receive general clinical recommendations such as nutritional intake and lifestyle issues in their respective hospital.
45817904|NCT00375362|Drug|Nitroderm patch|
45663824|NCT03503877|Other|GLOBAL MEDIA|Embryos will be cultured in GLOBAL media
45663825|NCT03503877|Other|SAGE MEDIA|Embryos will be cultured in SAGE media
45663826|NCT04811469|Drug|CBP-174|CBP-174 oral solution, given once
45663827|NCT04811469|Drug|Placebo|Placebo oral solution, given once
45663828|NCT02246439|Drug|RHB-102|RHB-102, Bimodal Release Ondansetron Tablets
45663829|NCT02246439|Drug|Placebo Oral Tablet|Placebo
45817905|NCT03307226|Behavioral|Youth Development Accounts (YDA)|Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs) Behavioral: Youth Development Accounts (YDA)
45817906|NCT03307226|Behavioral|YDA + Multiple Family Groups (MFG)|Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development 12 Financial Management workshops on asset-building, saving and investing in Income Generating Activities (IGAs) 18 Multiple Family Groups sessions focused on strengthening family relationships and mental health
45817907|NCT03124693|Device|Rainbow DCI pulse oximeter sensor|
45817908|NCT03288194|Behavioral|Problem-Solving Treatment|
45817909|NCT03288194|Behavioral|Time Management|
45817910|NCT03124771|Device|Rainbow Resposable Adhesive Sensors|Noninvasive Measurement of SpHb
45957754|NCT04688632|Drug|Ampreloxetine <Dose B>|Ampreloxetine <Dose B> will be administered as 4 tablets of <Dose A>
45957755|NCT04688632|Drug|Ampreloxetine Placebo|Ampreloxetine Placebo will be administered as 4 tablets of placebo. The placebo tablet will match (in appearance) the ampreloxetine <Dose A> tablet.
45455044|NCT04299490|Behavioral|Sleep Continuity Disruption|An 8-hour sleep opportunity period starting from lights out is divided into eight, one-hour intervals. One of the intervals is randomly determined to be a 60 minute forced awakening, during which no sleep is permitted. Each of the remaining seven, 60-minute intervals are subdivided into tertiles (20 min. blocks). A 20-min forced awakening (FA) is randomly scheduled to occur in either the 1st, 2nd, or 3rd tertile of each hour. During FAs, staff keep subjects awake, either by voice or gentle shaking.
45663830|NCT02245737|Drug|Lanabecestat|Administered orally
45817911|NCT05357300|Device|Peripheral Nerve Stimulation|Implant of percutaneous leads for peripheral nerve stimulation of the rami dorsales of the SIJ and gluteal or abdominal implant of impulse generator
45817912|NCT05247463|Other|Increase in upper age of eligibility for breast cancer screening from 64 to 70|The upper age limit of eligibility for Breast Cancer Screening increased in England from 64 to 70 as a result of the NHS Cancer Plan, so women were offered an additional 2 rounds of screening.
45817913|NCT05247463|Other|Screening round length|The target round length (frequency) of breast cancer screening in England is every 3 years. However in practice there is variability in this due to local centre capacity. The exposures are round lengths of approximately 2 years and approximately 3 years
45817914|NCT05247463|Diagnostic Test|Screening test threshold|Radiologists and equivalent health professionals examine women's screening mammograms for potential signs of cancer, and recall some women for further diagnostic tests. Each has a different test threshold for recall, characterised by the proportion of previous cases that they have recalled.
45455045|NCT04299490|Behavioral|Undisturbed Sleep|Subjects sleep normally for an 8 hour period.
45817915|NCT05347082|Drug|Cholecalciferol|Tablets of 4000 IU
45817916|NCT05235139|Device|IOL implantation experimental (ISOPURE 1.2.3.)|Implantation of premium monofocal IOL ISOPURE 1.2.3.
45957756|NCT04688632|Drug|Moxifloxacin|Moxifloxacin will be administered orally as a single tablet.
45455046|NCT02529475|Drug|Gadoteric acid|Comparison with patients with Meniere's disease
45663831|NCT02245737|Drug|Placebo|Administered orally
45663832|NCT04781361|Drug|Intravenous isotonic fluid - NaCl 131-154 mmol/L in 5% dextrose|Isotonic group will be given fluids containing 131-154 mmol/L Sodium Chloride
45663833|NCT04781361|Drug|Intravenous Hypotonic fluid- Sodium Chloride < 130 mmol/L|"Hypotonic group will be given fluids containing lower than 130 mmol/L :~Dextrose 5% in 0.2% Sodium Chloride, or Dextrose 5% in 0.33 % Sodium Chloride,or Dextrose 5% in %0.45 Sodium Chloride, or Intravenous fluid containing Sodium Chloride < 130 mmol/L"
45663834|NCT04191447|Drug|Flamboyant 200/12|Flamboyant 200/12 capsule
45663835|NCT04191447|Drug|Budesonide / Formoterol 400/12|Budesonide / Formoterol 400/12 capsule
45957757|NCT04688632|Drug|Moxifloxacin Placebo|Moxifloxacin placebo will be administered orally as a single tablet. The placebo tablet will match (in appearance) the moxifloxacin tablet.
45957758|NCT00171015|Drug|valsartan plus hydrochlorothiazide|
45957759|NCT05786690|Other|Interventions|the temporospatial and kinematic gait characteristics
45957760|NCT05786677|Other|Physiotherapy protocol|"the physiotherapy protocol which will include: 4. Exercise in the form of: d. Breathing exercise e. Aerobic exercise (walking on treadmill with a speed of 3 miles per hour and 0% inclination) f. Bridging exercise 5. Manual techniques in the form of:~Suboccipital release~Diaphragm release~Clavi-pectoral myofascial release 6. Home Routine~c. Hot tub bath for 30 minutes d. Breathing exercise"
45957761|NCT05786677|Drug|Selective serotonin reuptake inhibitors (SSRI)|Selective serotonin reuptake inhibitors (SSRIs)
45957762|NCT05786664|Procedure|Biospecimen Collection|Undergo collection of blood samples
45957763|NCT05786664|Other|Electronic Health Record Review|Review of records
45957764|NCT05786664|Other|Quality-of-Life Assessment|Complete quality-of-life questionnaires
45957765|NCT05786664|Other|Survey Administration|Complete surveys
45957766|NCT05786651|Behavioral|Experimental: Within-Subjects Attentional Information|Visual Search Information Type (target or distractor information) Participants will have information about targets, distractors, or neither in different trials of the intervention.
45957767|NCT05786612|Device|Biatain® Silicone|Wound care dressing
45957768|NCT05786612|Device|Mepilex Border with Aquacel Extra Hydrofiber|Wound care dressing
45663836|NCT04191447|Other|Flamboyant 200/12 Placebo|Flamboyant 200/12 Placebo capsule
45663837|NCT04191447|Other|Budesonide / Formoterol 400/12 Placebo|Budesonide / Formoterol 400/12 Placebo capsule
45663838|NCT04274361|Drug|Ketamine|Ketamine infusion
45663839|NCT04274361|Drug|Placebo|Placebo infusion
45663840|NCT02244957|Device|Bi-level positive airway pressure (BPAP)|Overlap patients randomized to BPAP will be titrated as per American Academy of Sleep Medicine (AASM) guidelines and oxygen if needed based on saturations <88% while on stable bi-level settings.
45663841|NCT02244957|Drug|Nocturnal oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
45663842|NCT04251819|Drug|Placebos|Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
45663843|NCT04251819|Drug|Baclofen 5 mg|Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
45663844|NCT04251819|Drug|Baclofen 10mg|Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
45663845|NCT02243865|Device|Chordate System S200 + CT100 (active treatment)|Chordate S200 + CT100 (active treatment) gives Kinetic Oscillation Stimulation for 15 minutes to each nostril and by that giving an effect on the autonomic nervous system (ANS).
45663846|NCT02243865|Device|Chordate System S200 + CT100 (placebo treatment)|Chordate S200 + CT100 (placebo) is used in the same way as Active treatment, but no Kinetic Oscillation Stimulation is given. Catheter is not inflated and no vibration is given.
45663847|NCT04780893|Device|Modius Sleep|The device utilizes a technology called vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
45663848|NCT03443739|Other|Intermittent Fasting|Intermittent Fasting with abstinence from food and drink daily from sunrise to sunset for nineteen consecutive days in March 2018
45663849|NCT02243631|Drug|Probenecid|Treatment
45817917|NCT05235139|Device|IOL implantation active comparator (Acrysof Vivity)|Implantation of EDOF IOL Acrysof Vivity
45817918|NCT04736420|Drug|Rivaroxaban|Rivaroxaban dispensing claim is used as the exposure group
45455047|NCT04284280|Dietary Supplement|Routine vs Selective use of Human Milk Donor Fortifier|Infants will be randomized to two groups. Both groups will be fed Premature Human Milk (either Maternal own milk or Premature donor human milk). However, one group will get fortified with Donor Human Milk Fortifier once full feed is reached while the second group will get fortified using the same fortifier only when weight gain is suboptimal.
45455048|NCT01214863|Device|T3|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T3
45455049|NCT01214863|Device|T4|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T4
45455050|NCT01214863|Device|T5|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T5
45817919|NCT04736420|Drug|Warfarin|Warfarin dispensing claim is used as the reference group
45817920|NCT03124927|Device|DCI pulse oximeter sensor|
45817921|NCT03125005|Device|Rainbow Universal Pulse Oximeter Sensor|
45817922|NCT03087578|Other|electroacupncture|Patients will receive electroacupuncture treatment for 30 minutes per weekly session for 6 weeks.
45817923|NCT03087578|Drug|Mirabegron 50 MG [Myrbetriq]|Patients will receive 50 mg of mirabegron daily for 6 weeks.
45817924|NCT02807558|Drug|SY-1425 (tamibarotene)|Continuous days 1-28 of a 28-day cycle of SY-1425 at 6 mg/m2/day orally divided into twice a day dosing.
45455051|NCT04236388|Dietary Supplement|Ketone drink|Pre- and post-testing will be completed before and after participants receive 42 doses of ketone supplement drink over a 2-week period (3x/day for 14 days).
45817925|NCT02807558|Drug|azacitidine|75 mg/m2/day IV or SC days 1-7 of a 28 day cycle in combination with SY-1425.
45817926|NCT02807558|Drug|Daratumumab|16 mg/kg/day IV starting on Cycle 1 Day 1 weekly for 8 weeks, followed by dosing every two weeks for 16 weeks, followed by dosing every 4 weeks in combination with SY-1425.
45817927|NCT02971735|Other|mobile technology of e-learning (M-TEL)|UME students learn the Top 10 emergent ORL-HNS disorders using the M-TEL including the IM module or the PPS module.
45817928|NCT02907086|Other|blood collection|Patients will receive a research draw for circulating tumor material analysis with standard clinical labs
45817929|NCT05197231|Procedure|Resisted knee extension exercise|Patients in the intervention group will perform a seated knee extension exercise in three sets. Resistance will be adjusted using ankle weights, targeting 8-12 repetitions per set.
45957769|NCT05786534|Dietary Supplement|Green Seaweed|400 mg per day
45957770|NCT05786495|Other|Early Discontinuation of Antibiotics|Antibacterial treatment (i.e piperacillin/tazobactam, ceftazidime, cefepime, meropenem, vancomycin, amikacin, tobramycin, ciprofloxacin) will be stopped after 72 hours of treatment and defervescence for 24 hours, irrespective of neutrophil count
45455052|NCT04236388|Dietary Supplement|Placebo drink|Pre- and post-testing will be completed before and after participants receive 42 doses of placebo supplement drink over a 2-week period (3x/day for 14 days).
45455053|NCT03935347|Drug|Cyclophosphamide|Given IV
45455054|NCT03935347|Drug|Fludarabine|Given IV
45455055|NCT03935347|Drug|Fludarabine Phosphate|Given IV
45455056|NCT03935347|Biological|Pembrolizumab|Given IV
45455057|NCT03935347|Biological|Autologous Tumor Infiltrating Lymphocytes LN-145|Given IV
45455058|NCT03935347|Biological|Aldesleukin|Given IV
45455059|NCT04467346|Drug|Ped-TMZ|Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition for at least 8 hours before dosing
45817930|NCT05197231|Drug|IV amino acids|IV amino acids (Glavamin, Fresenius Kabi) delivered by continuous infusion at a rate of 0.1 g/kg/h. The infusion is started immediately prior to physiotherapy and continued until all blood samples required for outcome assessment are collected during a 90-minute resting period after the exercise session.
45455060|NCT04845256|Device|SOMAVAC 100 Sustained Vacuum System|Evaluate performance of sustained vacuum system compared to manual suction bulbs
45455061|NCT03939871|Drug|fluvestrant + oral vinorelbine|Eligible patients will be treated with the fluvestrant + oral vinorelbine regimen until the disease progresses or intolerable toxicity
45817931|NCT05339282|Procedure|Laparoscopic cholecystectomy|"Method of operation~Surgery was started under general anesthesia~A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~The trocar was removed, and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
45817932|NCT05324384|Drug|Sirolimus|Use of different doses of the same drug
45455062|NCT03525106|Behavioral|Booklet|Receive positive psychology manual
45455063|NCT03525106|Behavioral|Exercise Intervention|Complete positive psychology exercises
45455064|NCT03525106|Other|Quality-of-Life Assessment|Ancillary studies
45455065|NCT03525106|Other|Survey Administration|Ancillary studies
45455066|NCT03525106|Behavioral|Telephone-Based Intervention|Participate in phone sessions
45455067|NCT01122667|Drug|anacetrapib|single dose administration of anacetrapib (MK0859) 100 mg oral tablet
45663850|NCT04183413|Other|DSD|This intervention consist of three Differentiated Service Delivery Models in which stable clients can be enrolled. The fast-track model gives preferential treatment to enrolled clients. Clients arrive at clinics, usually early in the morning, and can see the nurse as well as collect their medication without queuing. This model mainly targets the working population. The facility-based treatment clubs consist of bimonthly meetings where clients meet in groups of approximately 20 members. They receive health counselling, risk factor screening and medication prescription. This model mainly targets clients living close to the facility. The community advisory groups consist of groups of up to six clients. Groups are equipped with a point of care blood pressure and blood glucose measurement devices. They take turns in collecting the medication for the entire group and meet on a monthly basis. This model targets clients in hard-to-reach areas.
45455068|NCT03116464|Behavioral|Telemental Health Family Intervention|"Approximately 12-16 session family intervention that will include the following specific strategies, the implementation of which will be tailored by clinicians to the specific interpersonal deficits identified in an assessment: (1) psychoeducation on dementia, (2) communication and problem solving skills, (3) safety building skills, (4) relationship satisfaction enhancement skills, (5) meaning making (i.e. collaboratively identifying the personal significance of events), (6) identification of core patterns from dyad relationship history, (7) techniques to shift emotional responses, (8) techniques to increase emotional attunement, and (9) techniques to increase attunement to care-recipient needs"
45455069|NCT01120561|Drug|trastuzumab-MCC-DM1|Intravenous repeating dose
45455070|NCT03940027|Procedure|EUS-guided celiac plexus neurolysis|EUS-guided celiac plexus neurolysis (EUE-CPN) is an endoscopic ultrasound-guided injection of local anesthetics and neurodegenerative agents into the abdominal ganglion area through the gastric wall, so as to achieve irreversible damage of the abdominal nerve and interrupt the pain pathway of pancreatic cancer.EUS-CPN has the advantages of less trauma, higher technical success rate and lower risk of complications compared with traditional ct-guided CPN in vitro puncture.The data showed that eus-cpn was effective in the treatment of pancreatic cancer related persistent abdominal pain up to about 70%, significantly reducing the dosage of analgesics and improving the quality of life of patients with advanced pancreatic cancer.
45455071|NCT01217125|Drug|Sirolimus|plasma levels between 4 and 8
45663851|NCT04183413|Other|CDP|Community Distribution Points are set up on a monthly basis in communities linked to the clinic. Healthcare staff sets up a temporary point of contact where clients can obtain screening for diabetes and hypertension, health counselling, referral to primary or tertiary facilities, and medication.
45663852|NCT04770519|Genetic|whole genome sequencing or whole exome sequencing|Whole genome sequencing or whole exome sequencing will be performed for all enrolled participants.
45663853|NCT03401073|Drug|Intravenous immunoglobulin|Gamunex-C [immune globulin injection (human) 10% caprylate/chromatography purified] is a sterile solution of human immune globulin protein.
45817933|NCT02975557|Drug|Brimonidine 0.15%|Brimonidine 0.15% eye drops 2 times a day for 12 weeks
45817934|NCT02975557|Drug|Brimonidine 0.075%|Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.
45817935|NCT02975557|Drug|Placebo|Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
45817936|NCT02642588|Dietary Supplement|energy gel|energy gel: gelatinous edible containing carbohydrates typically used during endurance races
45817937|NCT02976181|Device|IPG|Patient might require IPG device to be implanted under standard of care
45663854|NCT03401073|Drug|0.9% Sodium Chloride|Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
45663855|NCT03986229|Other|"Evaluate the variation in the travel speed of the center of pressure with and without compression garments."|"Each evaluation will be done according to the following protocol:~Evaluation of the pain~Berg test~One test per condition starting with open eyes~Standardized instructions:~Break about 15 minutes (wash-out) between each test.~Both conditions will be tested on the same day.~Evaluation in an environment free from visual and audible interference."
45817938|NCT04736810|Biological|AK105|IV infusion
45663856|NCT03396783|Biological|blood test|during the visit, nurse will make a blood test for biological and immunological analysis
45663857|NCT03396783|Other|electromyogram and walk test|during the visit, measuring the amount of functional motor units at the muscular level and the distance traveled during a 2 minute walk
45663858|NCT05233449|Device|NoL monitor|NoL monitor : non invasive, adhesive digital device
45663859|NCT05233449|Procedure|Stimulation|Stimulation : 100 Hertz, 5 seconds, 10-30-60 milliamps, inner forearm
45817939|NCT04736810|Drug|Cisplatin|IV infusion
45455072|NCT04221464|Biological|biological collection|Blood samples collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression
45455073|NCT04221464|Other|Tissues collections|Tumours and not tumours tissues will be collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression
45455074|NCT03936517|Drug|Prednisolone|Low dose prednisolone for the treatment of adrenal insufficiency. Usually administered once daily
45455075|NCT03936517|Drug|Hydrocortisone|Standard regimens of hydrocortisone for the treatment of adrenal insufficiency. Usually administered thrice daily.
45455076|NCT03635372|Drug|Alginate|10 cc of Alginate peroral
45663860|NCT02242305|Drug|Hyoscine Butylbromide - Tablet|
45817940|NCT04736810|Drug|Gemcitabine|IV infusion
45817941|NCT04736810|Drug|Anlotinib hydrochloride|Oral administration
45663861|NCT02242305|Drug|Hyoscine Butylbromide - Capsule|
45663862|NCT02242305|Drug|Placebo|
45663863|NCT02240121|Drug|Rifaximin EIR|Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
45663864|NCT02240121|Drug|Placebo|Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
45663865|NCT04780425|Behavioral|DESMOND|as previously described
45663866|NCT04780425|Other|usual care|usual care as per standard treatment guidelines of Ghana unstructured/adhoc diabetes education during clinic visits
45663867|NCT04780269|Device|Induction of labor with Foley catheter|A Foley catheter will be introduced transcervically in women allocated in this group, with the aid of a vaginal speculum after cervical cleaning with an aseptic solution. The balloon will be inflated with 60 mL of sterile 0.9%% sodium chloride (NaCl) after insertion past the internal os. The external end of the catheter is taped to the inner thigh without applying any traction or tension.
45817942|NCT05267990|Diagnostic Test|Multi-Detector Computed Tomography|Coronary angiography calcium score via Multi-Detector Computed Tomography
45817943|NCT03132571|Drug|Naltrexone|37.mg oral capsule taken once daily for over the course of the study (16 weeks)
45817944|NCT03132571|Drug|Bupropion|Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
45817945|NCT03132571|Other|Placebo|Oral placebo taken once daily for the course of the study (16 week)
45817946|NCT05267054|Drug|Ociperlimab|administered intravenously
45817947|NCT05267054|Drug|Tislelizumab|administered intravenously
45817948|NCT05267054|Drug|Rituximab|administered intravenously
45663868|NCT04780269|Drug|Induction of labor with PGE2|PGE2 (1mg) will be inserted into the posterior vaginal fornix. Women will be assigned one hour of bed rest while continuously monitored by cardiotocography.
45957771|NCT05786495|Other|Standard of Care|Antibacterial treatment (i.e piperacillin/tazobactam, ceftazidime, cefepime, meropenem, vancomycin, amikacin, tobramycin, ciprofloxacin) will be continued until resolution of neutropenia
45957772|NCT05786456|Procedure|Discussion|Participate in group and web-based self-study sessions
45957773|NCT05786456|Other|Informational Intervention|Receive handouts
45663869|NCT02239263|Device|Nucleus 6 Sound Processor|
45663870|NCT02238483|Drug|AZD7624 1.0 mg|Inhaled AZD7624 solution, 11 mg/mL
45663871|NCT02238483|Drug|Placebo|Inhaled placebo solution
45663872|NCT01632891|Drug|Lopinavir/ritonavir|Participants received two 200 mg/50 mg tablets of lopinavir/ritonavir orally twice daily.
45663873|NCT01632891|Drug|Emtricitabine/tenofovir disoproxil fumarate|Participants received one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily.
45663874|NCT01632891|Drug|Efavirenz|Participants received one 600 mg tablet of efavirenz orally once daily.
45663875|NCT01632891|Drug|Nevirapine|If unable to take efavirenz, participants received on 200 mg tablet of nevirapine orally once daily.
45957774|NCT05786456|Other|Media Intervention|View videos
45957775|NCT05786456|Other|Questionnaire Administration|Ancillary studies
45957776|NCT05786456|Behavioral|Telephone-Based Intervention|Participate in check-in calls
45957777|NCT05786443|Drug|Empagliflozin 10 MG|Sodium glucose cotransporter 2 inhibitor (SGLT2i) dosed once-daily over 12 weeks. Administered as oral tablet.
45663876|NCT01632891|Drug|Trimethoprim/sulfamethoxazole|Participants received one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily.
45663877|NCT02208999|Device|Neurostimulator Precision|All patients included must have been implanted with the neurostimulator Precision
45663878|NCT02208843|Drug|Afatinib|Afatinib tablet once daily until progression
45663879|NCT02208063|Drug|Telavancin|
45957778|NCT05786443|Drug|Placebo|Empagliflozin-matching placebo dosed once-daily over 12 weeks. Administered as oral tablet.
45957779|NCT05786430|Drug|Lazertinib/Pemetrexed/Carboplatin|Combination of lazertinib 240 mg (80 mg, 3 tablets) and pemed-S + carboplatin. Once a day lazertinib 240 mg pemed-S: 500mg/m2 q3w carboplatin: AUC5 q3w (only administered up to 4 cycles)
45663880|NCT02208063|Drug|Vancomycin|
45957780|NCT05786391|Other|Flat position|Flat patient position during the cystoscopy
45957781|NCT05786391|Other|Trendelenburg position|Trendelenburg position (head down) during the cystoscopy
45957782|NCT05786391|Device|Insufflation|Insufflation to 15 mm Hg
45455077|NCT03635372|Drug|Sucralfate|10 cc of Sucralfate peroral
45455078|NCT03635372|Drug|Hydrotalcite|10 cc of Hydrotalcite peroral
45663881|NCT02208063|Drug|Daptomycin|
45663882|NCT02208063|Drug|Synthetic penicillin|
45817949|NCT05027503|Other|Exercise with hippotherapy simulator|30-minute (5 min warm-up+20 min exercise+5 min cool-down) center-based exercise with the hippotherapy simulator will be done 2 days a week for 8 weeks.
45817950|NCT05027503|Other|Respiratory Physiotherapy|Respiratory physiotherapy includes breathing control (5x2), diaphragmatic breathing exercises (5x2), thoracic expansion exercises (5x2), incentive spirometer (5x2), opep device (5x2), postural drainage and percussion and cough improvement techniques (10 min). Home-based respiratory physiotherapy will be applied twice a day and every day of the week for 8 weeks.
45817951|NCT02735720|Other|TEVAR|Thoracic endovascular aortic repair, which includes the implantation of stent-graft in the thoracic aorta to repair the lesion. This may be done with a variety of stent-graft brands and types. The type and brand of stent-graft is left to the discretion of the care taking physician.
45957783|NCT05786365|Drug|Ketalar 50 MG/ML Injectable Solution|Ketamine will be administered to two different groups as 0.5 mg/kg and 1 mg/kg
45957784|NCT05786352|Procedure|ERAS protocol|The combination of interventions explained in arm descriptions.
45957785|NCT05786339|Drug|Tested Irbesartan Tablet|T
45957786|NCT05786339|Drug|Reference Irbesartan Tablet|R
45663883|NCT02208063|Drug|Cefazolin|
45663884|NCT03729609|Drug|Brentuximab vedotin (Genetical Recombination)|Brentuximab vedotin Intravenous Infusion
45663885|NCT02207907|Drug|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
45663886|NCT02207907|Drug|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
45663887|NCT02207829|Drug|Umeclidinium|Umeclidinium 62.5 mcg once daily in the morning via nDPI
45663888|NCT02207829|Drug|Umeclidinium matching placebo|Umeclidinium matching placebo once daily in the morning via nDPI
45663889|NCT02207829|Drug|Tiotropium|Tiotropium 18 mcg once daily in the morning via HANDIHALER inhaler
45663890|NCT02207829|Drug|Tiotropium matching placebo|Tiotropium matching placebo once daily in the morning via HANDIHALER inhaler
45663891|NCT02237157|Drug|Gemcitabine, local delivery|Intra-arterial targeted drug delivery
45663892|NCT02237001|Device|Suture-based meniscal repair|Suture-based meniscal repair
45663893|NCT02236611|Drug|Umeclidinium|Umeclidinium 62.5 mcg will be available as dry inhalation powder to be taken using a nDPI
45663894|NCT02236611|Drug|Glycopyrronium|Glycopyrronium bromide will be available as inhalation capsules, 44 mcg per capsule, taken using BREEZHALER inhalers
45663895|NCT02234583|Drug|DS-5565|DS-5565 15 mg tablet for oral administration
45957787|NCT05786313|Procedure|Centerpiece titanium plate|All indexes were collected from the patients with Centerpiece titanium plate for internal fixation.
45957788|NCT05786274|Diagnostic Test|Cerebral autoregulation monitoring|Perioperative characterization of cerebral autoregulation and autonomic function; characterization of adverse events after surgery
45957789|NCT05786248|Other|Impedancemetry|the impedance measurement electrodes are placed on the lower limbs and neck. After the first measurement, the patients are invited to lie down. A new series of measurements will be performed at 30 (T30), 90 minutes (T90) and in the morning.
45957790|NCT05786222|Behavioral|CSH-Delivered Overdose Prevention Support|Corporation for Supportive Housing (CSH) will deliver technical support for overdose (OD) prevention in the participating PSH buildings using a package of core implementation strategies: PSH Overdose Prevention (POP) Toolkit (an implementation manual/blueprint for overdose prevention practices); Implementation Champions (staff and tenants in each PSH building will be selected as implementation champions who support implementation and sustainment of OD prevention practices in their buildings); practice facilitation (the practice facilitator [a trained CSH employee] will work with the tenant and staff champions in small group workshops and coaching sessions, building their capacity and supporting their work toward implementation of building OD prevention practices); learning collaboratives (PSH buildings starting the intervention at the same time will attend learning collaborative meetings).
45957791|NCT05786170|Diagnostic Test|diffusion-weighted magnetic resonance imaging|diffusion-weighted magnetic resonance imaging
45957792|NCT05786105|Other|Bone Marrow samples collection|Bone Marrow samples collection - one ethylenediaminetetraacetic acid (EDTA) tube - for Optical Genome Mapping
45957793|NCT05786092|Device|Telemonitoring|Monitoring of the required parameters by means of the data provided by the devices used by patients. The data (weight, body composition, blood pressure, oxygen saturation, physical activity, heart rate and blood glucose) collected according to the predetermined schedule are then saved in a cloud accessible to researchers.
45957794|NCT05786053|Procedure|graded recession of inferior oblique muscle|. Graded recession of IO muscle depends on the amplitude of the V-pattern and degree of IOOA. Eight mm recession for amplitude 7.5 to 10 degree and mild IOOA (10 degree or +1) ,10 mm recession for amplitude 11- 15 degree and moderate IOOA (11 -15 or +2) and maximum recession for amplitude more than 15 degree and marked IOOA (more than15 degree or +3). Simultaneous correction of the horizontal deviation was performed at the same sitting.
45957795|NCT05786027|Behavioral|PDI|A 12-week in-prison peer-driven intervention to increase the uptake of primary HIV prevention strategies (readiness to initiate addiction treatment (MMT or Atlantis), initiation of MMT/Atlantis, retention in MMT/Atlantis; or the use of SSP), and reduce the use of opioids and HIV risk behaviors, in HIV-negative PWID in prison.
45957796|NCT05786014|Behavioral|High Intensity Interval Exercise|Patients in the Cycling Intervention arm will undergo two training sessions at the exercise physiology core lab to ensure participants understand the intervention exercise protocol and can safely perform it at home. The Participants will perform high intensity interval training (HIIT) 3 days per week, with each session consisting of four, 4-min intervals at 85-90% peak heart rate (PHR), separated by 3 min at 50% PHR. Each training session will begin with a 10-minute warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Subjects will then perform this exercise training at their own homes using recumbent exercise bikes provided by the investigators for that purpose. Study investigators will check in up to weekly with participants and remotely track exercise data and compliance via activity tracker.
45663896|NCT03719859|Other|Physical Therapy|"Subjects who will participate in the physical therapy intervention group will attend therapy 4-6 days after discharge from the hospital, and continue in therapy approximately once a week for three months. The physical therapy progression will follow the standard of care developed at Duke Sports Medicine Physical Therapy for rehabilitation following RSA. Some of the patients in the PT intervention cohort may have physical therapy at an institution outside of Midwest Orthopaedics at Rush. All patients, whether in the Rush system or outside, will be given a prescription with the identical instructions for physical therapy, status post (R/L) reverse total shoulder arthroplasty, 1-2 x per week x 12 weeks."
45663897|NCT03719859|Other|Home Therapy|The surgeon/Nurse Practitioner/Physician Assistant will advance rehabilitation exercises and activity guidelines at customary scheduled postoperative appointments for this surgical procedure: 2 weeks (+/- 5 days), 6 weeks (+/- 1 week), 3 months and 6 months (+/- 1 month), and 1 and 2 years (+/- 2 months).
45817952|NCT02735720|Other|Non-TEVAR medical treatment|Any clinical management by physicians caring for these patients. This includes whatever blood pressure and heart rate medication is prescribed by the treating physician, without any surgery. The type and dosage of medication is left to the discretion of the care taking physician.
45663898|NCT03705663|Behavioral|PrEP initiation|Women who are interested in or who initiate PrEP will be followed in a prospective cohort to identify and populate the PrEP cascade for cis-gender, high risk women
45663899|NCT03686397|Drug|SVT-15652|1 vial twice daily
45663900|NCT03686397|Drug|Placebo|1 vial twice daily
45957797|NCT05786014|Behavioral|Moderate Intensity Walking|Patients will undergo two familiarization training sessions in the exercise physiology core lab to ensure participants understands the walking intervention and can properly gauge intensity. Participants will be asked to walk briskly or jog so they achieve a moderate intensity (70-75% of the maximal heart rate achieved during the VO2peak test). The goal for participants in this condition will be to accumulate at least 150-minutes per week at this heart rate by brisk walking or jogging. Participants will also receive a pair of walking shoes to facilitate their engagement.
45957798|NCT05785962|Other|Vojta Therapy|The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg.
45957799|NCT05785923|Diagnostic Test|Point-of-Care Echocardiogram|Four view ultrasound of the heart performed at the bedside by trained emergency medicine physicians.
45957800|NCT05785910|Diagnostic Test|IUDS|a battery of neuropsycological test
45957801|NCT05785780|Behavioral|Targeted CRC Screening Toolkit|Strategies in the toolkit include but are not limited to: identification of patient and practice-level barriers, routine tailored patient reminders, provider reminders, & clinic staff feedback.
45455079|NCT03939793|Behavioral|IMPaCT Community Health Worker|"Once a CHW receives notification of a struggling patient, the CHW will visit the patient at their home within 1-2 days to initiate the IMPaCT intervention.~Elements of the standard IMPaCT intervention: During the first home visit, the CHW will use an in-depth semi-structured interview guide to get to know patients holistically and assess for unmet socioeconomic needs. This allows patients to express goals in line with their own needs and preferences. These individualized goals will become the basis for tailored action plans. The CHW will then provide hands-on, tailored support for the remainder of the 24-week study period to help patients achieve their goals.~Additional elements to help patients cope with failure: In this study, we will test a refined version of IMPaCT that incorporates two behavioral techniques for coping with failure: positive affect induction and attribution retraining."
45663901|NCT02233803|Drug|NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler|Micronized 400 mcg budesonide+ 12 mcg formoterol fumarate along with micronized and crystalline lactose monohydrate (excipient), per capsule dispensed by single capsule inhaler, twice daily (administered once in the morning and once in the evening approximately 12 hours later).
45663902|NCT02233803|Drug|SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhaler|Unit dose containing 320 mcg budesonide and 9 mcg formoterol fumarate (as dihidrate) along with lactose monohydrate as excipient. Administered as inhalation by TURBUHALER inhaler, twice daily (once in the morning and once in the evening approximately 12 hours later)
45663903|NCT02233803|Drug|NEUMOTEX 400 (Budesonide 400 mcg)|Budesonide 400mcg will be administered to all the subjects twice daily, during the Run-in and Washout Periods
45817953|NCT02374424|Drug|GA101_DHAP|"Aim of the study is to assess whether the addition of GA101 to DHAP is more promising than standard R-DHAP, as induction therapy before high dose chemotherapy BEAM with ASCT with respect to response.~Scheme of treatment:~GA101 1000 mg iv day 1, 8, 15 on first cycle (starting from cycle 2, GA101 1000 mg day 1)~Cisplatin 100 mg/sqm iv day 1 of every cycles in 24-hours infusion~Cytarabine 2000 mg/sqm in 3-hours infusion every 12 hours iv day 2 of every cycles~Dexamethasone 40 mg day 1-4 of every cycles~Pegfilgrastim 6 mg sc single dose 24 hours after the end of chemotherapy or G-CSF from day 4 till stem cell harvest during mobilization's course (II o III cycle GA101-DHAP)~GA101 1000 mg iv 24 hours before apheresis as purging in vivo during second courses of therapy"
45817954|NCT03134209|Device|Zipper surgical skin closure|The device acts like a scaffold to stabilize the adjacent sides of a wound in order to minimize forces that can disrupt normal healing of the skin.
45663904|NCT02233803|Drug|Salbutamol 100 mcg pMDI|Salbutamol 100mcg will be administered as pMDI on demand, as rescue medication, throughout the entire study period until Visit 5
45817955|NCT03134209|Other|Monocryl + Dermabond|conventional sutures and skin adhesive glue
45957802|NCT05785585|Dietary Supplement|Methylcobalamin|Treatment with Methylcobalamin during 12 weeks
45957803|NCT05785585|Dietary Supplement|Cyanocobalamin group|Treatment with Cyanocobalamin during 12 weeks
45957804|NCT05785585|Dietary Supplement|Control group|Treatment with microcrystalline cellulose during 12 weeks
45957805|NCT05785572|Procedure|supraescapular nerve radiofrequency|supraescapular nerve radiofrequency or interescalenic braquial plexus for pain control in shoulder arthroplasty surgery
45957806|NCT05785572|Procedure|interescalenic braquial plexus|supraescapular nerve radiofrequency or interescalenic braquial plexus for pain control in shoulder arthroplasty surgery
45663905|NCT02233647|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.
45817956|NCT03134209|Other|Polyester mesh + Dermabond|conventional sutures and skin adhesive glue
45957807|NCT05785559|Procedure|uterine biopsies|uterine biopsies performed on the areas of cesarean section scars
45957808|NCT05785546|Other|usual care|For each cohort, the patient is seen at least twice, during annual visits in multidisciplinary consultation.
45957809|NCT05785533|Other|Smartphone App|App that provides recovery guidance based on pain and functional outcomes
45957810|NCT05785533|Other|Standard of Care|Paper based discharge instruction that provide information on pain management
45957811|NCT05785520|Device|ST500 SINGLE-DOSE GEL|ST500 SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to limit the physiological degeneration of the joints and tissues, improving their functionality. The presence of a peptide mixture and sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility.
45957812|NCT05785494|Other|Narstaende.se|Web-site with supportive information, videos and chat forum targeting family caregivers of patients with life-threatening illness.
45957813|NCT05785481|Diagnostic Test|Clinical and instrumental neurological assessment|"During the neonatal period:~neurological objective exam according to the modified Sarnat score, Thompson score and Hammersmith Neonatal Neurological Examination (HINE) within 6 hours of life, 24 hours of life and before resignation; an AEEG study within 6 hours of life, for 6 hours; cerebral ultrasound within 6 hours of life, in the third and seventh day of life; a brain magnetic resonance imaging study between the seventh and 14th day of life; an EEG evaluation within 7 days.~After resignation, all patients will be included in a minimum duration follow-up program of 12 months, with assessments at 3rd, 6th and 12th month of age:~Hammersmith Neonatal Neurological Examination (HINE) and evaluation of the General Movements; evaluation of psychomotor development through Griffiths/Bayley III scales at the 12th month; EEG evaluation at the 6th and 12th month."
45455080|NCT03939793|Behavioral|Digital health monitoring with financial incentives|Participants are encouraged to use their glucometer to check their blood glucose via bidirectional texting and lottery-based financial incentives, which both serve to reinforce self-monitoring behavior.
45455081|NCT03939793|Other|Usual Care|Usual Care
45455082|NCT04391036|Device|High Eudragit® Content Vaginal Film|High (12.8%) Eudragit® Content Vaginal Film
45455083|NCT04391036|Device|Low Eudragit® Content Vaginal Film|Low (6.4%) Eudragit® Content Vaginal Film
45663906|NCT02233647|Drug|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.
45663907|NCT02233413|Device|Active LLLT helmet application|LED helmet applied with light activated
45663908|NCT02233413|Device|Non-active LLLT helmet application|LED helmet applied without light activated
45817957|NCT02596412|Other|use the module with augmented reality (Mini-Docs) on tablet during TB injection|Provision of a tablet with a module using augmented reality (Mini-Docs) during TB injections in addition to the commonly used drug technology
45817958|NCT04736654|Other|Survey study|Headache Disability Questionnaire (HDQ) will be applied.
45817959|NCT02455622|Drug|Elaprase for intravenous (IV) infusion|Patients enrolled in this study will receive once-weekly IV infusions of Elaprase at a dose of 0.5 mg/kg and will be followed for a minimum of 5 years after initiation of Elaprase treatment, or until they reach their 10th birthday, whichever is longer.Height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
45957814|NCT05785468|Drug|Caplacizumab|description and quantification of clinical response in terms of platelet count recovery in patients with aTTP treated t with caplacizumab
45957815|NCT05785442|Drug|Anakinra Prefilled Syringe|Anakinra 100 mg administration subcutaneously once daily for 10 days (at least 7 days)
45957816|NCT05785442|Drug|Placebo|0.67 ml N/S 0.9% w/v administration subcutaneously once daily for 10 days (at least 7 days)
45957817|NCT05785429|Drug|Colchicine 0.5 MG|Participant in the intervention group receive one tablet of 0.5mg colchicine per day for 12 weeks.
45957818|NCT05785429|Drug|Placebo|Participants in the intervention group receive one tablet of placebo per day for 12 weeks.
45957819|NCT05785416|Other|Proprioceptive Neuromuscular Stretching - Contract Relax stretching (PNF-CR)|PNF-CR utilized the concept of autogenic inhibition of the muscle for improving the flexibility of the muscle. It includes stretching a muscle after a brief period of activation.
45957820|NCT05785416|Other|Static Stretching (SS)|The SS technique utilized the concept of creep for improving the hamstring flexibility. The stretch was maintained for a prolonged period passively by the therapist.
45957821|NCT05785403|Other|No intervention|No intervention
45663909|NCT04778631|Device|Heat therapy|Application of warm compresses, soaked in hot tap water (between 38° and 44 °C), to the perineum, at each contraction or pushing effort from the start of perineum distension until birth.
45663910|NCT04778631|Device|Cryotherapy|Application of a perineal instant col pack to the perineum, after placental delivery or perineum suturing, for at least 20 minutes.
45663911|NCT01632579|Drug|LY3023703|Administered orally
45663912|NCT01632579|Drug|Placebo|Administered orally
45957822|NCT05785377|Drug|Bupivacaine-Neostigmine|20 mL bupivacaine 0.25% plus 1 mL Neostigmine (500 mcg)
45957823|NCT05785377|Drug|Bupivacaine|20 mL bupivacaine 0.25% plus 1 mL normal saline 0.9%
45957824|NCT05785364|Device|Mpact 3D metal MONOCER cup|adult patients requiring a total hip arthroplasty under 75 years old, will receive the Mpact 3D metal cup, as acetabular sheel device implanted
45957825|NCT05785351|Procedure|Laparoscopic Bariatric Surgery|Laparoscopic Bariatric Surgery: Gastric Sleeve and Roux-en-Y Gastric Bypass
45957826|NCT05785325|Drug|RC48-ADC plus Bevacizumab|Administer RC48-ADC intravenously in combination with bevacizumab 5mg/kg once every two weeks.
45957827|NCT05785312|Device|Online EMDR Therapy System|Online EMDR Therapy System will be delivered through online computer system that will be specifically designed for delivering EMDR therapy online
45957828|NCT05785312|Other|Face to Face Eye Movement Desensitization & Reprocessing Therapy|The Face to Face Eye Movement Desensitization & Reprocessing Therapy will be delivered in person inside clinician's room by following standard EMDR therapy protocol
45957829|NCT05785299|Diagnostic Test|Cow's milk|clinical introduction of cow's milk
45957830|NCT05785299|Diagnostic Test|Placebo|clinical introduction of placebo
45957831|NCT05785299|Diagnostic Test|Home introduction|home introduction of cow's milk
45455084|NCT01116817|Drug|Lumbar puncture (Lopinavir/ritonavir monotherapy)|Lumbar puncture at week 0
45957832|NCT05785286|Other|BPH 3-item questionnaire|BPH 3-item questionnaire. The questionnaire consists of only three items. A raw score ranging from 0 to 5 is assigned to each of the items, giving a final total score varying from 0 (no symptom) to 15 (very symptomatic).
45957833|NCT05785273|Device|Pupillometer|1st pupil evaluation between induction of general anesthesia and onset of surgery. After incision, at least 3 pupil evaluations are performed. Measurements are spaced 15 minutes apart and also taken at least 10 minutes after any variation in drugs dosage
45957834|NCT05785260|Behavioral|ACT MINDFULNESS|"Mindfulness (MCBT) practices were offered to patients with the aim of fostering the elderly's pro-active role in health prevention by making them~aware of the relationship between thoughts, emotions and symptomatology of the disorder. The exercises will also be used as a motivational work tool within a protocol of Acceptance and Commitment Therapy (ACT), a new generation cognitive behavioral approach, in which commitment components are added to mindfulness, suitable for lifestyle modification."
45455085|NCT01116817|Drug|Lumbar puncture (HAART: Lopinavir/ritonavir + 2 NRTI)|Lumbar puncture at week 0
45817960|NCT03134989|Device|Cochlear implant|Study involves measuring using Electrocochleography to measure the CM response in patients undergoing cochlear implant surgery
45455086|NCT01120795|Drug|Pegylated interferon and ribavirin|Pegylated interferon 180 ug subcutaneous per week Ribavirin 1000-1200 mg /day for genotype 1 and 800 mg /day orally for genotype non 1 Duration: 48 weeks for genotype 1 and 24 weeks for gentoype non 1
45455087|NCT01120795|Drug|Pegylated interferon and ribavirin|Pegylated interferon 180 ug/ week subcutaneously Ribavrin 1000-1200 mg /day for genotype 1 and 800 mg/day orally for genotype 2 and 3 Treatment duration 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3
45663913|NCT01632579|Drug|Celecoxib|Administered orally
45957835|NCT05785234|Drug|sufentanil-remimazolam group|Induction of general anesthesia with 6mg·kg-1·h-1 of remimazolam combined with 0.5 ng·ml-1 of sufentanil. Maintenance of general anesthesia with 1-2mg·kg-1·h-1 of remimazolam combined with 0.2 - 0.6 ng·ml-1 of sufentanil.
45957836|NCT05785234|Drug|remifentanil-remimazolam group|Induction of general anesthesia with 6mg·kg-1·h-1 of remimazolam combined with 4 ng·ml-1 of remifentanil. Maintenance of general anesthesia with 1-2mg·kg-1·h-1 of remimazolam combined with 2-6 ng·ml-1 of remifentanil.
45957837|NCT05785208|Drug|Osimertinib|Osimertinib will be administered at a dose of 80 mg daily until disease progression
45957838|NCT05785169|Behavioral|TRAncenDS|The HP+ curriculum includes total-site training and co-facilitation via participatory modules. To transform clinic culture, a multi-level approach that includes the whole facility and reaches all parties is required. The intervention aims to modify top-down mechanisms of influence. TRAnscenDS is modeled on these principles and supports the development of multiple SRD-reduction strategies (instituting comprehensive anti-racist and Diversity, Equity and Inclusion policies, monitoring and feedback systems; workforce equity), at the top two levels of the socioecological model (organizational/policy and systems/providers/staff), to in turn impact individual-level out-comes.
45663914|NCT01632345|Drug|Doravirine|Part I: Doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) depending upon randomization, taken orally every morning with or without food for at least 24 weeks. Part II: Selected dose of doravirine depending upon randomization (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet orally every morning with or without food for 96 weeks.
45663915|NCT01632345|Drug|Efavirenz|Efavirenz 600 mg tablet orally at bedtime taken without food on an empty stomach for 96 weeks
45663916|NCT01632345|Drug|TRUVADA®|Open-label TRUVADA® (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning for 96 weeks
45663917|NCT01632345|Drug|Placebo for Doravirine|Placebo tablets matching doravirine
45663918|NCT01632345|Drug|Placebo for Efavirenz|Placebo tablets matching efavirenz
45817961|NCT02002130|Drug|Placebo GABA and Placebo GAD-alum|Maltodextrin as a placebo formulation for GABA Placebo GAD-alum injection
45817962|NCT02002130|Drug|GABA and Placebo GAD-alum|Oral Active GABA with Placebo GAD-alum
45817963|NCT02002130|Drug|Active Oral GABA and Active GAD-alum injection|Active Oral GABA and Active GAD-alum injection
45817964|NCT03135379|Device|Heated ultrasound gel|"Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) set to medium setting (102 degree fahrenheit)."
45817965|NCT03135379|Device|Room temperature gel|Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) turned off.
45957839|NCT05785156|Other|quick tests|"New quick tests are~Batterie MindPlus (Brevet n° FR1908081, Suarez 2019) is a quick reaction time battery and~Minimal Cognitive Evaluation (MCE) test (Sardi et al, 2019) is a cognitive screening tests including a specific assessment of slowing"
45957840|NCT05785143|Procedure|Utilizing dry lab database to analyze the prognostic factors of multi-trauma patients and determine the optimal timing of definitive orthopedic operation|to analyze if serum lactate a predictive factor of optimal surgical timing in multi-trauma patients. In order to obtain more accurate data, we choose to utilize ili database and trauma database instead of National Health Insurance Research Database.
45957841|NCT05785117|Device|Vagal Stimulation|ear clips were placed in the ear region (auricular concha) at the stimulation site. The following stimulation settings were used: 1) density wave set to 20 Hz with a wave width of less than 1 ms; 2) intensity tuned to the patient's tolerance (4-6 mA)
45957842|NCT05785117|Other|Circuit training program|The training regimen included ten different forms of resistance and aerobic exercise that were done three times a week for four weeks. The resistance training program included push-ups, squats, crunches, lunges, and a superman exercise program that included light jumping, jogging on the spot, foot stomping, steps, and jumping jacks
45957843|NCT05785078|Behavioral|Educational session about vaccinations|An educational session about maternal and childhood vaccinations was held in the context of the Childbirth Preparation Course held monthly at the FPG. In this occasion, on-site flu vaccination was offered to pregnant women attending the course and their partners, if present.
45957844|NCT05785065|Drug|Mycophenolate Mofetil|"The participant will receive 500 mg to 1000 mg twice daily of mycophenolate mofetil administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day"
45957845|NCT05785065|Other|Placebo|"The participant will receive 500 mg to 1000 mg twice daily of placebo administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day"
45957846|NCT05785026|Other|Menthol inhalation|300 milligrams of L-menthol will be deposited on to a cellulose swab and secured inside the lower portion of a sealed facemask.
45817966|NCT01306994|Other|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination and exercise test by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest and during exercise.
45817967|NCT01306994|Procedure|Physiological Stress Test|During exercise, heart and lung function are monitored for changes caused by exercise, which increases the body's need for oxygen and puts extra demands on the heart. In this study, testing is done using a cycle ergometer and conducted according to the standardised exponential exercise protocol (STEEP).
45817968|NCT01306994|Other|Functional Enquiry Form|Evaluated before clinical examination, it is a checklist of medical problems.
45957847|NCT05785026|Other|Strawberry scent|600 microliters of 100% natural strawberry flavoring will be deposited onto on to a cellulose swab and secured inside the lower portion of a sealed facemask.
45957848|NCT05785013|Dietary Supplement|Zinc|Zinc Supplementation
45957849|NCT05785000|Other|Physical exercise programme as an add-on|Consists of an individually tailored bike exercise program guided by symptoms, pulse rate and patient specific judgement of exertion monitored also by BORG RPE and VAS and progressively increasing time and level of resistance below symptom provocation
45957850|NCT05785000|Other|Control patients receiving usual care|No exercise intervention
45957851|NCT05784987|Drug|Rituximab|375 mg/m2, d0, Cycle 1~4
45957852|NCT05784987|Drug|Mitoxantrone hydrochloride liposome|20 mg/m2, d1, Cycle 1~4
45957853|NCT05784987|Drug|Isophosphamide|1.33 g/m2, d1-3(Rescue with equal dose of mesperidine), Cycle 1~4
45957854|NCT05784987|Drug|Etoposide|65 mg/m2, d1-3, Cycle 1~4
45957855|NCT05784987|Drug|X: Orelabrutinib|MCD/BN2 subtype: BTK inhibitor-Orelabrutinib: 150 mg/d, d1-21, Cycle 2~4
45663919|NCT02232243|Drug|Hydroxychloroquine, 200mg twice dailiy|Hydroxychloroquine, 200mg twice daily (400mg/day total) was given to subjects for up to 14 days prior to surgery.
45663920|NCT02232243|Drug|Hydroxychloroquine, 400mg twice daily|Hydroxychloroquine, 400mg twice daily (800mg/day total) was given to subjects for up to 14 days prior to surgery.
45957856|NCT05784987|Drug|X: Chidamide|EZB subtype: Chidamide: 20 mg/d, d1, d4, d8, d11, Cycle 2~4
45957857|NCT05784987|Drug|X: Penpulimab|TP53 mutation - X: PD-1 monoclonal antibody - Penpulimab: 200mg/d, d0, Cycle 2~4
45957858|NCT05784987|Drug|X: Lenalidomide|Other-X: Lenalidomide: 25mg/d, d1-10, Cycle 2~4
45957859|NCT05784974|Drug|Cadonilimab|15 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
45957860|NCT05784961|Device|tDCS|"tDCS will be delivered using this electrode montage: anode on the left dosolateral prefrontal cortex (L DLPFC) using F3 EEG landmark and cathode on the left temporoparietal junction (L TPJ) on the middle point between T3 and P3 EEG landmark.~The stimulation will be delivered at an intensity of 2 milliamps, for 20 minutes, five times a day, with 20 min inter sessions (it will be carried out on 5 consecutive days from Monday to Friday). Each processing day corresponds to a visit of V2, V3, V4, V5 and V6."
45663921|NCT04776837|Behavioral|Observational Cohort|Patients will be followed by collecting clinical data, biospecimens, and quality of life assessment
45663922|NCT02205333|Biological|MEDI6469 Monotherapy|single intravenous (IV) administration of MEDI6469
45663923|NCT02205333|Biological|MEDI6469 Plus Tremelimumab|MEDI6469 in combination with Tremelimumab
45663924|NCT02205333|Biological|MEDI6469 Plus Durvalumab|MEDI6469 in combination with Durvalumab
45817969|NCT01306994|Other|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
45817970|NCT01306994|Other|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination (minus breasts, genitalia, or rectum).
45817971|NCT01306994|Other|Observational Gait Analysis|Completed during the clinical examination by researchers, it is a structured approach to evaluation of a person's walking.
45817972|NCT01306994|Other|Mental Health Interview|Completed during the clinical examination by the researchers, it is a general evaluation of mental health status.
45817973|NCT03135535|Device|Avex Footbeat|Subjects will receive diabetic shoes equipped with Boa Technology shoelace system and Footbeat compression insoles, which for simplicity will be named intervention shoes. All participants will be asked to wear the intervention shoes for duration of 4-weeks on daily basis (minimum 4 hours per day). Daily use of the intervention shoes will be assumed to improve balance, mobility, plantar sensation, lower extremity edema, and lower extremity skin perfusion.
45817974|NCT02979301|Drug|Tamoxifen|5 mg or 10 mg tamoxifen per day for 30 days.
45817975|NCT01930136|Behavioral|Calorie restriction (25%)|
45817976|NCT01930136|Behavioral|Ad libitum health diet|
45957861|NCT05784935|Device|Real time AI detection model|Bowel preparation will be conducted according to usual local practices. During colonoscopy, the colonoscope will be first advanced to the cecum in all patients as confirmed by identification of the appendicular orifice and ileocecal valve or by intubation of the ileum, as per the standard of care by experienced endoscopists. During the insertion, no action will be taken. After cecal intubation is performed, the colonoscope will be slowly withdrawn to the splenic flexure by the primary endoscopists. Real time AI detection model will be activated with the output displayed in real time on a separate monitor and will be only viewed by an independent investigator, who is an experienced endoscopists (or a person trained in polyp recognition). The primary endoscopists will be blinded to the AI real time detection result
45957862|NCT05784922|Other|Educational Lung Cancer Screening (LCS) Video|An educational video on lung cancer screening tailored to Hispanic current and former smokers.
46079194|NCT05785897|Device|Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation|"'All-comer' subjects with acute STEMI undergoing primary PCI according to current ESC guidelines will be eligible.~Eligible subjects will be pre-treated with DAPT consisting of aspirin (loading dose: 150-300 mg orally or 80-500 mg intravenously, maintenance dose: 75-100 mg daily orally) and a potent P2Y12 receptor inhibitor, either ticagrelor (loading dose: 180 mg orally, maintenance dose: 90 mg bd orally) or prasugrel (loading dose: 60 mg orally, maintenance dose: 10 mg od orally or 5 mg od orally if age >75 years or weight <60 kg) at the time of STEMI diagnosis, or at the very latest at the time of primary PCI.~Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation and final residual stenosis <30% by visual estimation or 20% by QCA."
46079195|NCT05785884|Behavioral|Low-carbohydrate diet|A 6 week randomized diet low in carbohydrates
46079196|NCT05785884|Behavioral|USDA Diet|A 6 week randomized diet aligned with USDA recommendations
46079197|NCT05785819|Drug|VLX-1005|VLX-1005, a 12-LOX enzyme inhibitor
46079198|NCT05785819|Drug|Placebo|Placebo matching VLX-1005
46079199|NCT05785650|Diagnostic Test|osteopathic palpation|comparaison of ultrasound caracteristics of areas with ad without TP
46079200|NCT05785338|Diagnostic Test|Posterior angle of the hard palate|Fetal ultrasound
46079201|NCT05784779|Drug|GH509|Orally, once daily before bedtime (qhs)
46079202|NCT05784779|Drug|Placebo|Orally, once daily before bedtime (qhs)
46079203|NCT05784688|Drug|TU2218 + Pembrolizumab|TU2218: Orally administered Pembrolizumab: Intravenously administered
45817977|NCT02979925|Device|Active Transcutaneous Magnetic Stimulation|Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
46079204|NCT05783869|Device|Echocardiography|echocardiographic study of both groups
45663925|NCT02205333|Biological|MEDI6469 plus Rituximab|MEDI6469 in combination with Rituximab
45663926|NCT04776369|Drug|Lidocaine IV|single-bolus of lidocaine IV 4 mg/kg
45663927|NCT04776369|Drug|Magnesium Sulfate Injection|single-bolus of magnesium sulfate IV 30 mg / kg
45817978|NCT02979925|Device|Sham Transcutaneous Magnetic Stimulation|Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
45817979|NCT05171114|Diagnostic Test|Measurement of joint amplitudes|Measurement of joint amplitudes by goniometry of the MCP, IPP, IPD for 2, 3, 4 and 5th radii, 1st commissure spacing and Kapandji score for the thumb
45817980|NCT04954651|Biological|Approved vaccines against Sars-Cov2|Subjects who voluntarily are vaccinated against Sars-Cov-2 with any of the approved vaccines by EU
45817981|NCT00375440|Drug|Tranexamic Acid|
45817982|NCT04867525|Other|Physician's choice according to patient's needs.|Routine care as per site standard.
45817983|NCT02983825|Device|Continuous positive airway pressure (CPAP); level changes|as per arm description
46079205|NCT05783011|Procedure|Electroacupuncture|Electroacupuncture was applied bilaterally to the LI4, ST5 and ST6 acupuncture points before and after periodontal flap surgery
46079206|NCT05783011|Procedure|periodontal flap surgery|periodontal flap surgery
46079207|NCT05781971|Dietary Supplement|high protein|Patients in high-protein group will be given a target protein amount of 2.0 g/kg/d. Standard enteral nutrition is the first choice,the remaining target value will be met by intravenous amino acid infusion.
45663928|NCT04776369|Drug|IV saline|Saline IV 50 ml
45663929|NCT02230683|Drug|IDN-6556|25 mg BID
45663930|NCT02230527|Drug|Ticagrelor|90mg twice a day by mouth
45663931|NCT02230527|Drug|Clopidogrel|75mg once a day by mouth
45817984|NCT01818986|Drug|Sipuleucel-T|
45817985|NCT01818986|Radiation|Stereotactic Ablative Body Radiation|
45817986|NCT03138577|Diagnostic Test|Ultrasound Imaging|"M-mode tracings of right diaphragm motion will be made and recorded by a skilled anesthesiologist. Patients will be examined in the supine position and scanned from a low intercostal or subcostal approach using the liver as an acoustic window. Patients will be asked to perform a voluntary sniff (VS) test, for which they will be asked to forcefully inhale through the nose in a sniffing position. The above measurement will be performed immediately preceding the brachial plexus blockade, and then at 15 minute and 30 minutes after block."
45663932|NCT03378531|Drug|AEB1102|modified human arginase I
45663933|NCT02204319|Device|Cold laser|Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device.
45663934|NCT02204007|Device|3D imaging & surrogate bone model|3D imaging & surrogate bone model to assist with acetabular shell placement. Different that standard of care preoperative imaging
45663935|NCT02203851|Drug|Risankizumab|Risankizumab administered by subcutaneous (SC) injection
45817987|NCT03138577|Drug|Supraclavicular Block|The patient will be positioned supine with the head turned to the contralateral side. The ultrasound will be placed in the supraclavicular fossa, and the skin and subcutaneous tissues will be infiltrated lateral to the probe with 2% lidocaine. The anesthesiologist can redirect the needle and perform additional injections for complete coverage of the brachial plexus. The local anesthetic will be a 2:1 mix of 1.5% mepivacaine and 0.5% bupivacaine.
45957863|NCT05784909|Device|rezum|"Technique With the patient in a lithotomy position, after cystoscopy, an RF current is applied to. Water vapour is delivered through a retractable vapor needle via emitter holes in the transurethral device. This is done in 9-second bursts to the transition zone of the prostate, where, via convection, it diffuses evenly throughout the target tissue. The depth of the needle penetrating is approximately 10 mm.~Upon contact with body-temperature tissue, the water vapour then condenses. This phase shift to a liquid state dispenses concentrated energy onto the cell membranes of the target tissue, triggering instant cell necrosis. Overlapping injection sites can be established with repeated applications in order to fully target areas of hypertrophy. Saline flush irrigation is used to both cool the urethra and to promote visualization.~At the end of the procedure Urethral catheter is fixed for 1-3 days."
45663936|NCT02228967|Behavioral|SBIRT|"SBIRT is an opportunistic approach whereby patients are screened by Health Educators for their alcohol use, and then, taking advantage of a teachable moment, are delivered a brief, motivational intervention matched to their level of risk."
45957864|NCT05784896|Diagnostic Test|v/Q scanning & CT pulmonary angiography & Echocardiography|"Echocardiography ( comparative follow up of the RVSF PASP TAPSE IVC).~CT pulmonary angiography with assessment of the following parameters :~Intravascular web. dilated bronchail arteries. Arterial retraction. dilated pulmonary arteries. RV/LV diameter more than 1. Flattening of interventricular septum. V/Q scanning Following ESC/ERS Guideline recommendations, V/Q is the preferred and recommended test for CTEPH. It has a sensitivity of >96% and normal V/Q scan can rule out CTEPH . V/Q lung scintigraphy was interpreted as positive for CTEPH if there was at least one segmental or two sub-segmental mismatched perfusion defects, as proposed by the European Association of Nuclear Medicine (EANM) guidelines for the diagnosis of acute PE."
45957865|NCT05784870|Drug|Shengxuening Tablet|Oral treatment with Shengxuening Tablets 1 week before chemotherapy, usage: 0.5gtid, for 28 consecutive days
45817988|NCT03138577|Other|Bedside Negative Inspiratory Force Meter|A bedside negative inspiratory force (NIF) meter will be used to measure negative inspiratory force prior to the block and 30 minutes after the block.
45957866|NCT05784870|Drug|Ferrous succinate|Oral treatment with ferrous succinate 1 week before chemotherapy, usage: 200mgqd, for 28 consecutive days
45957867|NCT05784857|Other|Touch Methods|"The Yakson touch method continue for 15 minutes with steady touch (5 minutes), compassionate caressing (5 minutes), and repetition of steady touch (5 minutes). In this method, the palms of the practitioner and all fingers keep in close contact so that the babies don't feel pressure.~Gentle human touch refers to steady contact of the skin without caressing or massaging. While the practitioner place one hand on the crown of the preterm infant on the eyebrow line with the fingertip touch for 15 minutes, the other hand was place on the lower abdomen covering the waist and hip of the infants."
45663937|NCT03155061|Drug|ONO-4578|ONO-4578 specified dose on specified days
45663938|NCT03155061|Drug|ONO-4538|ONO-4538 specified dose on specified days
45663939|NCT02985411|Behavioral|Immediate Gardening Intervention|Provided with supplies to plan/plant 3 vegetable gardens over the course of a year. Survivors will be paired with a master gardener from their local Cooperative Extension to help guide them and provide mentorship in vegetable gardening,
45957868|NCT05784831|Device|Reappraisal training|The EMI developed and tested here is based on theoretical and empirical findings and consists of several items and repeated training using various individual scenarios from participants' life that will be presented to participants via an app on their smartphones.
45957869|NCT05784831|Device|Ecological Momentary Assessment|The EMA tested here collects data on participants' mood and behavior.
45957870|NCT05784818|Behavioral|Up To Me Intervention + No Booster|Participants will complete two-hour sessions once a week over three weeks in which they complete modules in the Up To Me Workbook. These sessions are facilitated by a peer facilitator and a member of the USF Counseling center. Other members in the group sessions are university students who are peers who are also experiencing some form of shame around their mental health challenges.
45957871|NCT05784818|Behavioral|Up To Me Intervention + Booster|In addition to the Up To Me Intervention, participants also complete a booster/additional session where additional topics of the Up To Me workbook are covered. This additional session occurs four weeks after the completion of the third session.
45957872|NCT05784792|Other|Lugol -|Patients that undergo total thyroidectomy without Lugol solution pretreatment
45957873|NCT05784766|Diagnostic Test|30-second ECG using the Kardia Mobile|30-second ECG using the Kardia Mobile
45957874|NCT05784766|Other|routine care|medical review
45957875|NCT05784649|Other|health education|"The health education program will be conducted on the WeChat platform. The contents of health education include 1) knowledge about how to prevent anemia during pregnancy; 2) self-care education videos such as breastfeeding; 3) online courses on how to manage weight during pregnancy, and how to keep good emotions, etc.; 4) Nutrition and lifestyle guidance; 5) knowledge about recognition and prevention of risk factors or diseases: abortion, toxic substances, premature birth. The contents of health education will be totally shared 5 times from 12 weeks to 36 weeks in the pregnancy and once a month on the platform. Every participant should reply read after learning the contents. if they have any questions, they can reply for help for further connection with health professionals."
45957876|NCT05784649|Behavioral|individual counsel|The participants will receive the same health education as the control group. The pregnant women will have one routine checkup a month from 12 weeks to 36 weeks in the hospital. And they will receive counseling with a midwife and a doctor after every routine checkup. The counseling will have a total of 5 times and once a month, 45 minutes per time. The professionals will evaluate health-promoting behaviors such as nutrition and physical activity based on the procedure of the health promotion model. The model includes four continued parts: prior behaviors; personal influences; interpersonal Influences; commitment to a plan of action. Finally, the professionals will give person-centered advice to help the participants practice the content of health education, keep health-promoting behaviors, and achieve a healthy lifestyle.
45957877|NCT05784636|Device|Non-invasive BiPAP ventilation|Patients were first treated with HFNC (High-flow nasal cannula) on the basis of conventional treatment. The initial parameters were temperature: 31-37 °C, flow rate: 30-40l /min, maintaining SpO2>92%, adjusting oxygen concentration according to blood oxygen saturation, and treatment duration was 24 h. After 24 h, patients were treated with non-invasive ventilator-assisted ventilation BiPAP mode until discharge.
45957878|NCT05784636|Device|HFNC|On the basis of conventional treatment, patients were first administered a noninvasive ventilator with the following initial parameters. BiPAP mode with an initial inspiratory pressure (IPAP) of 8-15 cmH2O and an initial expiratory pressure (EPAP) of 4-8 cmH2O. These parameters were adjusted according to the patient's specific conditions. After 24 hours of treatment, patients received HFNC (High-flow nasal cannula) until discharge.
46079208|NCT05781971|Behavioral|rehabilitation|In this trial, the investigator will provide early rehabilitation treatment such as respiratory training, bicycle training, and medium frequency electrical stimulation to patients.
45817989|NCT03181724|Behavioral|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
46079209|NCT05781971|Dietary Supplement|standard protein|The investigator set a protein target of 1.2 g/Kg/d for the standard protein group, which will be supplied enterally or parenterally.
46079210|NCT05776459|Drug|AC102 gel|Drug: AC102 Single intratympanic injection
46079211|NCT05776459|Drug|Prednisolone|Active comparator: Prednisolone Tablets taken daily by mouth
46079212|NCT05776459|Other|Placebo Tablets|Placebo Tablets taken daily by mouth
45663940|NCT02985411|Other|Delayed Gardening Intervention|Subjects will be monitored for 1-year and will then receive the same vegetable gardening intervention as described under the Immediate Gardening Intervention
46079213|NCT05776459|Other|Placebo gel|Placebo Single intratympanic injection
46079214|NCT05775796|Drug|Serplulimab and Chemotherapy|Serplulimab+Paclitaxel+Cisplatin/Carboplatin Serplulimab+Pemetrexed+Cisplatin/Carboplatin
45455088|NCT01344980|Procedure|Stainless steel suture|Stainless steel suture material will be used (size 3-0) in an MGH repair technique
45663941|NCT02227875|Drug|Mylan's insulin glargine|Patients who are randomized to receive Mylan's insulin glargine during the comparative phase will receive the same dose as the dose of Lantus® received during the screening period. The recommended starting dose of Mylan's insulin glargine or Lantus®, in patients with T2DM who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted every week if essential.
45957879|NCT05784623|Other|User experience|User experience is assessed by validated scales
45957880|NCT05784610|Device|Monitorage by TOF/PTC|Installation of TOFscan® and monitoring by MAR appreciation on one of the patient's wrists and installation of TOFscan® and monitoring by ATP mode (MAR blind) on the other wrist Installation of TOFscan® and monitoring by ATP mode
45957881|NCT05784610|Device|Monitorage by ATP|Installation of TOFscan® and monitoring by ATP mode on one of the patient's wrists
45455089|NCT01344980|Procedure|Polypropylene suture|Polypropylene suture (size 3-0) will be used in a double-locking loop repair technique
45663942|NCT02227875|Drug|Lantus®|For patients who are randomized to receive Lantus® during the comparative phase the dose of Lantus® will be equal to the dose received during the screening period.
45663943|NCT02203149|Drug|Grazoprevir|One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.
45663944|NCT02203149|Drug|Elbasvir|One 50 mg tablet taken orally once daily for 12 weeks.
45663945|NCT02203149|Drug|Placebo to Grazoprevir|One tablet of placebo matched to grazoprevir, taken orally once daily for 12 weeks.
45663946|NCT02203149|Drug|Placebo to Elbasvir|One tablet of placebo matched to elbasvir, taken orally once daily for 12 weeks.
45817990|NCT05113004|Drug|Hydroxychloroquine 400mg/d|Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
45817991|NCT05113004|Drug|Leflunomide 20mg/d|Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation and consequently T cell-dependent B cell formation of autoantibodies.
45957882|NCT05784597|Drug|[68Ga]Ga-OncoFAP administration|All patients will receive a single intravenous bolus administration of 250 MBq (225 - 275 MBq)
45663947|NCT02520063|Drug|Letrozole|A dose of 2.5 mg of letrozole will be given orally once each day until one day before surgery. This drug is commercially available and is not provided by the study.
45663948|NCT02520063|Drug|Everolimus|The dose of everolimus will be escalated from 5 mg to 10 mg daily depending upon the cohort in Phase I. It is administered as an oral pill to be taken once daily up until four weeks prior to surgery.
45663949|NCT02520063|Drug|TRC105|The dose for TRC105 is either 15 or 10 mg/kg to be given intravenously every two weeks and continued until four weeks prior to surgery.
45663950|NCT02202837|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
45957883|NCT05784584|Procedure|Blood samples collection|The study population will take blood samples for virological and immunological measurements.
45957884|NCT05784558|Device|UroLift System|The UroLift System is a procedure that utilizes tiny implants to lift and hold the enlarged prostate tissue out of the way so it no longer blocks the urethra.
45957885|NCT05784558|Other|Watchful Waiting or BPH Medications|Subjects for whom the physician decides the best course of therapy to be either watchful waiting or new or continuing BPH medications.
45957886|NCT05784558|Device|Other Surgical Intervention|Physician decides the best course of therapy to be a surgical intervention other than the UroLift System.
45957887|NCT05784532|Device|STERN FIX|Sternotomy closure with STERN FIX and supplemented with wires
45957888|NCT05784519|Drug|MSCs eye drops|MSCs were used to prepare single-cell suspension, and 0.9% sodium chloride was added to balance PH value to prepare the effective, safe and stable eye drops. Giving the patient with 5×10^5 /50μl in each eye, twice a day for 2 weeks.
45957889|NCT05784506|Other|Macronutrients|Three successive food tolerance tests (glucose, protein and fat) at one-week intervals.
45957890|NCT05784506|Other|Mixed meal tolerance test (MMTT)|Mixed meal tolerance test (MMTT)
45957891|NCT05784493|Other|Study group|Washing by heated saline group
45957892|NCT05784480|Diagnostic Test|Checklist for evaluation of reversible causes|Prehospital evaluation by checklist and diagnostic testing for reversible causes of OHCA using point-of-care blood gas analysis, saliva toxicological screen and ultrasound and post-hoc toxicological analysis of blood using mass spectrometry
45957893|NCT05784467|Behavioral|Methamphetamine, PrEP, and Intersectional Stigma (eMPrISe) study|Group behavioral intervention with 12 weekly sessions lasting 2 hours focusing on coping, resistance, and resilience.
45957894|NCT05783700|Diagnostic Test|BIOIMPEDANCEMETRY|The impedance of cellular tissue can be modeled as a resistor (representing the extracellular path) in parallel with a resistor and capacitor in series (representing the intracellular path, the resistance that of intracellular fluid and the capacitor the cell membrane). This results in a change in impedance versus the frequency used in the measurement. Whole body impedance measurement is generally measured from the wrist to the ipsilateral ankle and uses either two (rarely) or four (overwhelmingly) electrodes. In the 2-elctrode (bipolar) configuration a small current on the order of 1-10 μA is passed between two electrodes, and the voltage is measured between the same whereas in the tetrapolar arrangement resistance is measured between as separate pair of proximally located electrodes. The tetrapolar arrangement is preferred since measurement is not confounded by the impedance of the skin-electrode interface
45957895|NCT05783206|Drug|MIR 19 ®|"MIR 19 ® contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.~In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs."
45957896|NCT05783206|Combination Product|Standard therapy|Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs (except MIR 19 ®)
45957897|NCT05782985|Diagnostic Test|Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)|Blood samples from the myeloproliferative neoplasms cases and the controls will be tested with Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) genes.
45957898|NCT05782894|Drug|Remimazolam besylate|0~2.0mg/kg/h
46079215|NCT05768802|Device|Myoelectric Implantable Recording Array (MIRA)|The Myoelectric Implantable Recording Array (MIRA) will use electromyography to detect the electrical activity of forearm muscles and transmit that information to an externally-powered prosthetic limb. The MIRA is implanted under the skin.
46079216|NCT05765838|Diagnostic Test|(NPS right - Nasal swab left - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
45663951|NCT02202837|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
45663952|NCT02202759|Drug|MLN0264|MLN0264 IV infusion
45663953|NCT02226549|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
45817992|NCT05113004|Drug|Mycophenolate mofetil 2000mg/d|Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
45957899|NCT05782894|Drug|Propofol|0.3~4.0mg/kg/h
45663954|NCT02226549|Drug|VDV|VDV 80 mg tablet administered orally once daily
45663955|NCT02226549|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45957900|NCT05782894|Drug|Remifentanil|1.5~12μg/kg/h
45957901|NCT05782712|Biological|adenosine dosage|Whole blood is collected using finger puncture followed by deposit a drop of blood (20 μL) using finnpipette, on a blotting paper (Whatman 903 protein saver cards™) and dried over night at room temperature to obtain dried blood spot (DBS).
46079217|NCT05765838|Diagnostic Test|(NPS left - Nasal swab right - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
46079218|NCT05765838|Diagnostic Test|(Nasal swab right - NPS left - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
46079219|NCT05765838|Diagnostic Test|(Nasal swab left - NPS right - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
46079220|NCT05765838|Diagnostic Test|(NPS right - OPS - Nasal swab left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
46079221|NCT05765838|Diagnostic Test|(NPS left - OPS - Nasal swab right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
45663956|NCT02226003|Drug|Ertugliflozin|Ertugliflozin, 5 mg or 15 mg, administered orally, once daily for 26 weeks.
45663957|NCT02226003|Drug|Sitagliptin|Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
45817993|NCT05113004|Drug|Placebo of Hydroxychloroquine 400mg/d|Placebo of Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
45817994|NCT05113004|Drug|Placebo of Leflunomide 20mg/d|Placebo of Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation
46079222|NCT05765838|Diagnostic Test|(Nasal swab right - OPS - NPS left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
45957902|NCT05782699|Device|BP monitoring during tilt testing|BP measure at various times during tilt testing
45957903|NCT05782673|Device|wearable MAIJU for motor assessment|The novel multisensor wearable MAIJU will be used to measure infants' motor performance at home. The recordings are repeated at 2 months intervals betveen 6 and 18 months of age.
45957904|NCT05782660|Other|Cash Benefit|Spending from the cards was not restricted to food but could be spent on anything and anywhere Visa was accepted. The debit cards were credited with the first payment on November 18th, 2020 and the second payment on December 18th, 2020. The program continued with monthly credits through August 2021.
45957905|NCT05782660|Other|No Cash Benefit|No monthly cash benefit.
45957906|NCT05782647|Device|HeartGuide cuffless BP monitor|Wearable (watch-type) monitor: HeartGuide 6410T (Omron Healthcare, Kyoto, Japan)
45817995|NCT05113004|Drug|Placebo of Mycophenolate mofetil 2000mg/d|Placebo of Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
45957907|NCT05781802|Other|Level of pressure support|"Patients will be evaluated in two different conditions sequentially. The first condition will be at a clinically selected level of pressure support under stable clinical conditions.~This condition will be labeled according to P0.1:~In case of P0.1<2, the clinically selected level of pressure support will be considered High Pressure support.~In case of P0.1>2, the clinically selected level of pressure support will be considered Low Pressure support.~After data collection at clinically selected level of pressure support, pressure support level will be transiently increased or decreased (i.e. from high to low/ from low to high) to the lowest/highest clinically tolerated level, aiming at the predefined P01 thresholds, and then kept for 20 minutes under stable clinical conditions. Data collection will be repeated and then the clinically selected level of pressure support restored."
45957908|NCT05781776|Other|Otago exercises and core strengthening|"Otago exercise program consisted of strengthening and balance exercises. The strengthening exercises focus on major lower limb muscles. Progression of exercises was done by increasing the duration and then intensity.~Balance exercises involved knee bends, backward walking, walking, and turning around, sideways walking, tandem stance (heel to toe), tandem walk (heal to toe walk), one leg stand, heel walking, toe walk, heel to toe walking backward, sit to stand and stair walking. Balance exercises progressed with varying levels of support depending on their balance and confidence. The individuals repeated each exercise 10 times."
45957909|NCT05781776|Other|Gaze stability exercises and core strengthening|"The exercise protocol in Gaze Stability exercises included adaptation exercises and substitution exercises. In adaptation exercises, individuals performed rapid, active head rotations while watched a visual target with the target remaining stationary. Substitution exercises, individual performed eye-head movements between targets with the goal of seeing clearly during the task. That target moved in the opposite direction of head movement.~Adaptation exercises included: Horizontal and vertical (stationary target) viewing exercises done with a near target, sitting. Horizontal and vertical (stationary target) viewing exercises done with near and far targets (6-10 feet), sitting. Horizontal and vertical (stationary target) viewing exercises were done with near and far targets, standing."
45957910|NCT05781672|Diagnostic Test|cardiac ultrasound with speckle tracking analysis|"Experimental group: cardiac ultrasound with speckle tracking analysis done during a regular cardiac visit planned after receiving cardiotoxic chemotherapy in childhood.~Control group: cardiac ultrasound with speckle tracking analysis done during a cardiac visit for minor symptoms (murmur, physical aptitude).~Advocated Tomtec software will be used to make post-processing speckle tracking analysis based on 2D ultrasound cineloop acquired during a standard echocardiography."
45957911|NCT05781568|Diagnostic Test|Biomarker dosage|The simultaneous dosage of the 3 serum biomarkers will be performed at the Clinical Pathology Laboratory, using the instrument: µTASWakoTM i30 (Micro Total Analysis System) - Fujifilm.
45957912|NCT05781516|Drug|Prednisolone|Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months.
45957913|NCT05781516|Drug|Baricitinib|Oral Baricitinib 2mg daily for 12 months.
45957914|NCT05781321|Radiation|Accelerated Hypofractionated Radiation Therapy|Undergo short course RT
45957915|NCT05781321|Procedure|Computed Tomography|Undergo CT simulation
45957916|NCT05781321|Drug|Fluorodopa F 18|Given IV
45663958|NCT02226003|Drug|Placebo to Ertugliflozin|Matching placebo to ertugliflozin administered orally, once daily for 26 weeks.
45663959|NCT02226003|Drug|Placebo to Sitagliptin|Matching placebo to sitagliptin administered orally, once daily for 26 weeks.
45957917|NCT05781321|Procedure|Magnetic Resonance Imaging|Undergo MRI
45455090|NCT01344980|Behavioral|Aggressive early active range of motion rehabilitation|Patients undergoing this form of rehabilitation will have their splints discontinued at 4 weeks and ideally will be back at work at normal duties by 6 weeks. This rehabilitation uses more movement at a faster progression than other early active range of motion protocols.
45663960|NCT02226003|Drug|Glimepiride|Open-label glimepiride rescue therapy will be initiated at 1 or 2 mg/day and may be titrated to the maximum labeled dose or maximum tolerated dose (if lower than labeled dose), as considered appropriate by the investigator, based on blood glucose measurements and in accordance with the local, approved label.
45663961|NCT02225223|Device|STAR™ Tumor Ablation System|Targeted-radiofrequency ablation (t-RFA)
45663962|NCT02225223|Device|StabiliT® Vertebral Augmentation System|Radiofrequency-targeted vertebral augmentation (RF-TVA)
45957918|NCT05781321|Procedure|Positron Emission Tomography|Undergo PET
45663963|NCT02469519|Drug|Betamethasone - ACTIVE|antenatal corticosteroid (ACS) is to be given by injection 24 hours apart for two doses.
45817996|NCT04707079|Drug|Duvelisib|Eligible subjects will be given duvelisib orally at a dose of 25 mg BID during each 28-day treatment cycle, for up to 12 cycles.
45957919|NCT05781321|Other|Quality-of-Life Assessment|Ancillary studies
45957920|NCT05781321|Other|Questionnaire Administration|Complete questionnaires
45957921|NCT05781321|Radiation|Radiation Therapy|Undergo standard course RT
45957922|NCT05781321|Drug|Temozolomide|Given PO
45957923|NCT05781282|Device|Atrial fibrillation ablation|Pulmonary vein deconnection. PV antra visualization by ICE
46079223|NCT05765838|Diagnostic Test|(Nasal swab left - OPS - NPS right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
45817997|NCT02983981|Drug|Topicort Topical Spray|open label Topicort spray
45957924|NCT05780437|Biological|AZD7442|AZD8895 and AZD1061, known collectively as AZD7442, are two fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibodies (mAb) that target two distinct epitopes on the receptor-binding domain of the spike protein of SARS-CoV- 2.
45957925|NCT05780437|Biological|Placebo|Commercially available 0.9% sodium chloride solution
45957926|NCT05780437|Biological|Remdesivir|Antiviral agent
45957927|NCT05780424|Biological|BRII-196|BRII-196 is a fully human immunoglobulin G (IgG)-1 monoclonal antibody (mAb) derived from antibody P2C-1F11 that was isolated directly from human B cells of a convalescent COVID-19 patient.
45957928|NCT05780424|Biological|BRII-198|BRII-198 is a fully human immunoglobulin G (IgG)-1 monoclonal antibody (mAb) derived from antibody P2B-1G5 that was isolated directly from human B cells of a convalescent COVID-19 patient.
45957929|NCT05780424|Biological|Placebo|Commercially available 0.9% sodium chloride solution
45957930|NCT05780424|Biological|Remdesivir|Antiviral agent
45957931|NCT05780333|Procedure|TAP block|Bilateral tap block with 20 ml of mixture 2:1:1 (0.5% bupivacaine: 0.9%NaCl: 2% lidocain) for each
45957932|NCT05780333|Procedure|ESP block|Bilateral esp block with 20 ml of mixture 2:1:1 (0.5% bupivacaine: 0.9%NaCl: 2% lidocain) for each
45957933|NCT05779839|Behavioral|Algorithm|For purpose of finding peer-to-peer support, current and/or former caregivers of persons with dementia will be matched using an algorithm. They can then choose make a connection and maintain a connection for the duration of the study.
45957934|NCT05779839|Behavioral|Random Match|For purpose of finding peer-to-peer support, current and/or former caregivers of persons with dementia will be randomly matched. They can then choose make a connection and maintain a connection for the duration of the study.
45957935|NCT05779631|Diagnostic Test|mpMRI plus a same-day cystoscopic bladder biopsy|mpMRI plus a same-day cystoscopic bladder biopsy
45957936|NCT05779631|Procedure|TURBT|Transurethral resection of the bladder tumor
45663964|NCT02469519|Other|Normal Saline - PLACEBO|normal saline of the same quantity as with the experimental drug is to be given by injection 24 hours apart for two doses
45663965|NCT01634139|Drug|Tiotropium low dose QD|2 actuations once daily in the evening
45957937|NCT05779293|Device|Non-invasive auricular vagus nerve stimulation|The only cutaneous nerve of the N. vagus, ramus auricularis, receives sensation from the posterior surface of the auricle, the posterior part of the external auditory canal and the adjacent part of the eardrum. Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular route or from the carotid. This device non-invasively stimulates the auricular branch of the vagus nerve without any action. As a result, it was found that the pain threshold increased and the mechanical pain sensitivity decreased. The application will take 30 minutes three days a week for four weeks.
45957938|NCT05779293|Other|Conventional therapy|"Conventional approaches are approaches that cover range of motion, strength, balance and ambulation training, continuing from passive to resistant exercises.~Neuromuscular electrical stimulation; It is applied to reduce pain, prevent spasticity and strengthen muscles. This newly formed type I fiber functionally shows an increase in resistance to fatigue and a decrease in maximum contraction velocity. The application will take 30 minutes three days a week for four weeks."
45957939|NCT05778266|Dietary Supplement|L-citrulline|oral supplementation of pure L-citrulline (6 g) for twelve weeks
45957940|NCT05778266|Dietary Supplement|Carboxymethyl cellulose|oral supplementation of Carboxymethyl cellulose (6 g) as a placebo, for twelve weeks
45957941|NCT05778266|Other|High Intensity Intervals Training|participants will have sessions 3 days a week for twelve weeks
45957942|NCT05774405|Drug|Climara 0.1Mg/24Hr Transdermal System|Transdermal estradiol patch is used.
45957943|NCT05774405|Other|Hydrogel patch|Adhesive Hydrogel patch
45663966|NCT01634139|Drug|Tiotropium high dose QD|2 actuations once daily in the evening
45663967|NCT01634139|Drug|Placebo|2 actuations once daily in the evening
45663968|NCT02224755|Device|HeartMate 3 LVAS|Implantation of HeartMate 3 LVAD to evaluate the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure
45663969|NCT02224755|Device|HeartMate II LVAS|Implantation of the commercially approved HeartMate II LVAD which is the standard treatment for advanced heart failure
45663970|NCT02404441|Biological|PDR001|anti-PD1 antibody
45663971|NCT02101281|Drug|rhNGF 20 µg/mL|1 drop for each eye, twice daily for 28 day
45957944|NCT05773586|Drug|APG-5918|oral tablets 10mg, 50mg.
46079224|NCT05765838|Diagnostic Test|(OPS - NPS right - Nasal swab left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
45663972|NCT02101281|Drug|rhNGF 4 µg/mL|1 drop each eye, twice daily for 28 day
45663973|NCT02224599|Biological|TAPA-pulsed DC vaccine|Subjects will given the vaccine which contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered ID. A total of three (3) cycles therapy will be administered weekly.
45663974|NCT02224599|Drug|Cyclophosphamide Pill|Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.
45957945|NCT05773586|Drug|Placebo|Matching placebo
45957946|NCT05773586|Drug|APG-5918|oral tablets 10mg, 50mg.
45957947|NCT05773586|Drug|Placebo|Matching placebo
45957948|NCT05768776|Procedure|HoLEP patients without MOSES(TM) 2.0 effect (open label)|HoLEP surgery for the treatment of Benign Prostate Hyperthrophy, without using MOSES technology
45957949|NCT05768776|Procedure|HoLEP patients with MOSES(TM) 2.0 effect (open label)|HoLEP surgery for the treatment of Benign Prostate Hyperthrophy, with the use of MOSES technology
45957950|NCT05766683|Drug|onabotulinumtoxinA at a depth of 2mm|One time administration of onabotulinumtoxinA to the corrugator supercilii muscles bilaterally. Dosing dependent on the baseline mass and volume of subject's glabellar muscles as assessed by trained cosmetic dermatologist, accounting for symmetry/asymmetry of the face and can range from 10-50 units. Will be administered at a depth of 2mm
45817998|NCT03182582|Device|Erbium:Yttrium-Aluminum-Garnet (Er:YAG) Laser Debridement|Laser debridement entailed usage of an Er:YAG laser, employing the JOULE® machine (Sciton, Inc., Palo Alto, California). Full-field ablation was performed using the 2940 nm Er:YAG Contour TRL Resurfacing® application with the following settings: fluence - 50 J/cm2, spot overlap - 50%, pattern repeat - 0.5 seconds, spot size - 3-mm (Figure 1). Debridement was carried out until all fibrinous and/or necrotic tissues were removed, and healthy, bleeding tissue was visualized.
45957951|NCT05766683|Drug|onabotulinumtoxinA at a depth of 4mm|One time administration of onabotulinumtoxinA to the corrugator supercilii muscles bilaterally. Dosing dependent on the baseline mass and volume of subject's glabellar muscles as assessed by trained cosmetic dermatologist, accounting for symmetry/asymmetry of the face and can range from 10-50 units. Will be administered at a depth of 4mm
45957952|NCT05764941|Drug|Inetetamab|8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.
45957953|NCT05764941|Drug|Pyrotinib|400mg, oral, every day.
45957954|NCT05764941|Drug|Vinorelbine|25 mg/m2, D1, D8, every 3 weeks for one cycle.
45663975|NCT02224599|Drug|Imiquimod Topical Cream|Topical Imiquimod Cream will be applied after vaccination.
45817999|NCT03182582|Procedure|Scalpel/Curette Debridement|Using a scalpel/curette, each patient's chronic wound is debrided until healthy, viable tissue is noted.
45957955|NCT05761782|Behavioral|Education|To educate catchment area residents on modifiable risk factors for cancer (e.g., screening, behavior, vaccination) and the importance of participation in cancer research. Provide participants with educational materials on cancer prevention, screening, and vaccination.
45663976|NCT04763577|Other|Assay of Bradykinin-degradating enzymes.|Aminopeptidase P activity assay; Dipeptidyl peptidase IV activity assay; Angiotensin Converting Enzyme activity assay; MME gene polymorphisme exploration.
45663977|NCT02201901|Drug|SOF/VEL|400/100 mg tablets administered orally once daily
45818000|NCT00375583|Drug|DEC/Albendazole|
45818001|NCT05081726|Diagnostic Test|Functional MRI|Series of MRI scans of the brain
45957956|NCT05756192|Other|Educational video|Intervention is a 10-minute animated video that explains cervical cancer screening and prevention.
45957957|NCT05754658|Other|Standard of Care|Drugs routinely administered for breast cancer per local standard.
45957958|NCT05754658|Other|Standard of Care|Drugs routinely administered for prostate cancer per local standard.
45957959|NCT05750017|Biological|Low Dose Recombinant Herpes Zoster Vaccine (LZ901)|0.5 mL per dose, containing a total of 50 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.
45957960|NCT05750017|Biological|High Dose Recombinant Herpes Zoster Vaccine (LZ901)|0.5 mL per dose, containing a total of 100 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.
45957961|NCT05750017|Drug|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
45818002|NCT04740229|Behavioral|Yoga|Moderate-intensity flow-based yoga movements, breathing, and relaxation for 50 minutes, 3 times per week, for 8 weeks
45818003|NCT02986711|Behavioral|Motivational Text Messages|Motivational text messages in addition to survey questions about smoking status
45818004|NCT02986711|Behavioral|Control|Only survey questions about smoking status
45818005|NCT00374569|Procedure|Gymnastic Routine|A combination of gymnastic movements are performed
45818006|NCT03141931|Dietary Supplement|Supplement|Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg
45818007|NCT03141931|Dietary Supplement|Placebo|polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)
45957962|NCT05745675|Device|Pulse oximeter|OLV-4202 pulse oximeter SW version: 01-15)
45957963|NCT05745662|Device|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
45957964|NCT05743621|Drug|TVB-2640|TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol
45957965|NCT05743621|Drug|Enzalutamide|160 mg daily PO
46079225|NCT05765838|Diagnostic Test|(OPS - NPS left - Nasal swab right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
45818008|NCT03143569|Device|aPTT guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
45663978|NCT02201901|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
46079226|NCT05765838|Diagnostic Test|(OPS - Nasal swab left - NPS right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
46079227|NCT05765838|Diagnostic Test|(OPS - Nasal swab right - NPS left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
46079228|NCT05764044|Drug|cisplatin, gemcitabine|Two additional cycles of cisplatin-based adjuvant chemotherapy 50mg/m2 D1 and gemcitabine 1000mg/m2 D1 and D8 at every 21 days.
46079229|NCT05764044|Other|Follow-up|Patients will be followed with computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.
45663979|NCT04775043|Diagnostic Test|HFRDIS questionnaire completion|HFRDIS Questionnaire (Hot Flash Related Daily Interference Scale) completion
45663980|NCT02201277|Device|Filter Placed|
45663981|NCT02224053|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
45663982|NCT02224053|Drug|AZD9291 tablet dosing|AZD9291 80mg tablet taken on Day 5 in Period 1 and Day 1 in Period 2.
45663983|NCT02224053|Drug|Omeprazole tablet dosing|Omeprzole taken from Days 1 to 5 in Period 1.
45663984|NCT02224053|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
45663985|NCT04762875|Biological|MGTA-145|MGTA-145 will be be administered as an IV infusion
45663986|NCT04762875|Biological|Plerixafor|240 µg/kg subcutaneously
45818009|NCT03143569|Device|Anti-factor Xa guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device
45818010|NCT04631497|Diagnostic Test|test|"Beck's Test~Test STAI~Test PSS~the scale of the fascination with death~COPE"
45818011|NCT02222688|Drug|cirmtuzumab|
45818012|NCT04554121|Behavioral|Brain Basics|"Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory) are paired with verbal discussions and group-based activities to strengthen metacognition and to bridge newly learned cognitive skills to everyday.~life."
45957966|NCT05738096|Other|TSEP + rhizotomy surgery|TGN patients recruited for this study will already be undergoing percutaneous rhizotomy surgery. TSEPs will be measured at baseline prior to surgery. During the rhizotomy procedure, an electrode or balloon is placed through a metal sheath to then damage the nerve. A stylet is introduced to clear tissue from the sheath in preparation for the electrode or balloon. Prior to the final insertion of the RF electrode where the gasserian ganglion will be damaged, we will place a standard stereotactic EEG electrode (SEEG). Following damaging the nerve (clinical procedure), we will record again to measure differences in the TSEPs following cell body damage. The Neuralynx system will be used to record the potentials at 40 KHz.
45957967|NCT05738096|Other|TSEPs recording only|TSEPS will also be recorded from healthy controls in a lab setting; all procedures for the healthy controls will be non-invasive.
45957968|NCT05735119|Device|Tapestry Biointegrative Implant|Collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues. Preclinical studies of the Tapestry implant showed dense collagenous fibrous connective tissue ingrowth into and around the implant.
45957969|NCT05734105|Drug|Ripretinib|50 mg tablets
45957970|NCT05734105|Drug|Sunitinib|12.5 mg tablets
45957971|NCT05732402|Drug|povetacicept|Administered by subcutaneous injection every 4 weeks
45957972|NCT05732402|Drug|povetacicept|Administered by subcutaneous injection every 4 weeks
45957973|NCT05732038|Behavioral|Healthy Minds Program (HMP)|Participants assigned to the HMP group will be asked to complete a minimum of 10 minutes per day of meditation for 12 weeks. For the first four weeks, participants will listen to prescribed meditations that will teach them the foundations of mindfulness. During weeks 5-12, participants will have full access to the HMP meditation library.
45957974|NCT05732038|Behavioral|Wellness App (WA)|"Participants in the WA group will listen to a minimum of 10 minutes per day of a caregiver specific educational podcast (including topics such as Caring for the Caregiver or Folate and Preventing Alzheimer's) delivered via a mobile app for the 12 weeks. The app contains one podcast per day for twelve weeks."
45957975|NCT05730153|Biological|advanced PRF|advanced PRF+ surgery
45957976|NCT05724316|Dietary Supplement|Vitamin D supplement|N/A (says not to repeat information here)
45957977|NCT05723705|Other|European Multicentre Training Program for Robotic Liver Surgery|LIVEROBOT is a pan-european multicentre training program for robotic liver surgery involving simulation training, a procedure video-library, on and off-site proctoring, and video-assessment.
45957978|NCT05714969|Biological|TAK-755|TAK-755 IV infusion
45957979|NCT05708846|Other|Telemonitoring|"All patients will be telemonitored in order to create a labeled and diverse dataset that will include the following data:~Physiological parameters (measured periodically), socio-demographic data, risk factors, medication tracking, symptomatology questionnaire for patients, NYHA-class, clinical interventions, health questionnaire answers, classified alarms with their respective timestamp and annotation by the MD, and measurement ranges for each personalized alarm and their changes"
45957980|NCT05701306|Drug|APG-115|Orally once every other day(QOD) for 2 weeks and suspended for 1 week, 21 days as a cycle.
45957981|NCT05701306|Drug|APG-2575|Orally once a day (QD) for 21 days, 21 days as a cycle.
45957982|NCT05700734|Drug|MK-8510|Single dose of MK-8510 administered as a tablet at a dose up to 2200 mg.
45957983|NCT05686226|Biological|E7 TCR-T cells|Participants will receive a conditioning regimen (cyclophosphamide and fludarabine), E7 TCR-T cells as a single infusion, and adjuvant high-dose aldesleukin.
45957984|NCT05685082|Behavioral|Standardized patient simulation|The standardized patient simulation participants will receive a simulation with standardized patients on how to identify social determinants of health in an individual
45957985|NCT05685082|Behavioral|Manikin-based simulation|The manikin-based simulation participants will receive a simulation with manikins on how to identify social determinants of health in an individual
45957986|NCT05679011|Diagnostic Test|6 and 10 meters walking test 6-MeWT|A 10-meter and other 6-meter flats pathways were identified. Two-meter will be provided for the acceleration zone and two-meter for deceleration for 10-MWT. One meter to acceleration and another to deceleration. The participants will perform 3-time to normal speed and 3-time faster for 10-meter and 6-meter for both.
45957987|NCT05677906|Other|Walking only (Step It Up!)|Participants will meet weekly for 60 minutes and walk together as a group. Participants will progressively build up to walking for 45 minutes at a brisk pace. Walks will start with a check-in and end with stretching as a group.
45957988|NCT05677906|Other|Combined (Step It Up! plus Civic Engagement)|Participants in the combined groups will meet weekly for 90 minutes with group members. They will participate in a group walk for 60 minutes followed by 30 minutes of civic engagement aimed at improving walkability in the community
45957989|NCT05674188|Behavioral|Augmented Reality Headset|Augmented simulation of workplace-related scenarios of pre-recorded videos using the same actors
45957990|NCT05672615|Other|Questionnaires|Participants will be given the Zung Self-Rating Anxiety Scale and Zung Self-Rating Depression Scale to complete prior to each induction intravesical treatment and prior to 3-month follow-up appointments.
45957991|NCT05672615|Other|Daily Mood Diaries|Participants will be given daily mood diaries to complete during their 6-week induction intravesical treatment, 3-week maintenance treatment course, and between 3-month follow-up appointments.
45957992|NCT05672615|Other|Urine Specimen Collection|Urine collections from patients will occur prior to each induction intravesical treatment and at 3-month follow-up cystoscopy appointments. An at home urine collection may occur 6 hours post intravesical treatment.
45957993|NCT05672615|Other|Research Blood Draw|Blood collections will occur prior to first intravesical treatment, prior to fourth intravesical treatment, and each 3-month cystoscopy as indicated by the participant's treatment course.
45957994|NCT05672615|Other|Utilize excess tissue from a standard of care procedure|Participants may indicate permission to provide excess tissue from a clinically indicated procedure for research purposes.
45957995|NCT05667506|Biological|single dose of CNCT19|"Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously.~Lymphodepletion treatment:~Drugs:Fludarabine Drugs: Cyclophosphamide"
45957996|NCT05665738|Radiation|High Dose Rate Monotherapy|High dose rate brachytherapy delivered in 13.5 Gy x 2 fractions over a single implant procedure 3 hours apart
45957997|NCT05656313|Device|Measures of speech intelligibility in a noisy situation with speech from the side and from behind (measured with CC-OLSA Test)|"The Concurrent OLSA test (CC-OLSA) is a speech recognition test with three turn-taking talkers presenting sentences of the Oldenburg sentences test at fixed signal-to-noise ratios.~CC-OLSA is the only one-talker-at-a-time speech test that is sensitive at the desired SNR and uses sentences with an intelligibility function with slopes of 10-17 %/dB."
45818013|NCT04554121|Behavioral|Brain Training|Computer-based exercises targeting impairments in cognitive domains (processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and to bridge newly learned cognitive skills to everyday life.
45957998|NCT05656313|Device|Measures of the subjective speech recognition threshold in a noisy situation with speech from the side and from behind (measured with HEISS test)|The measure of the subjective speech recognition threshold is an alternative procedure to evaluate the subjective speech intelligibility in different listening conditions. The subjective speech recognition threshold is defined as the speech presentation level of running speech needed to just follow conversation. Subjects have to adjust the presentation level of speech so that they are just able to understand the speech, using a slider on a touch screen. This adjustment is repeated 10 times. Each adjustment results in a value for the subjective speech recognition threshold in dB SNR. The outcome measure is the mean value of the 10 repetitions. The HEISS-Test will be repeated four times for the secondary objective: test for 2 test conditions (Reference, novel approach) against 2 target directions (better ear side, back).
46079230|NCT05752474|Behavioral|Exercise|Physical therapy targeting flexibility, strength, and endurance will be delivered at the participant's home, center-based, or virtually via a twice-weekly (on average) schedule to provide a total of about 6-8 sessions during the 3-4 week study period. Participants will be asked to participate in self-directed exercise for at least 30 minutes per day for 4 or more days per week.
45818014|NCT03149887|Drug|Liposomal bupivacaine|Liposomal bupivacaine solution (Exparel) for injection
45455091|NCT01344980|Behavioral|Early active range of motion rehabilitation|Patients undergoing this form of rehabilitation will have their splints discontinued at 6 weeks and ideally will be back at work at normal duties by 10-12 weeks. This rehabilitation uses less movement at a slower progression than the early AROM rehabilitation protocol specified in the experimental group
45455092|NCT05250518|Procedure|argon plasma coagulation|After hot snare polypectomy, participants will be randomized assigned to the APC group for argon plasma coagulation to prevent colorectal post-procedure bleeding.
45455093|NCT05250518|Procedure|clip closure|After hot snare polypectomy, participants will be randomized assigned to the Clip group for complete closure(spacing between adjacent clips < 1cm) to prevent colorectal post-procedure bleeding.
45458212|NCT02311036|Other|Comprehensive Rehabilitation|Comprehensive rehabilitation programs including PT, OT or ST will be done for two hour each every day and 5 days per week for 6-12 weeks. Initial assessment will be done within 3 days and the following assessment will be done 6 weeks or 12 weeks after rehabilitation intervention by physician and well-trained therapists.
45663987|NCT04774731|Other|Whole Body Vibration|Receiving WBV training three times a week before initiation of dialysis sessions for 12 weeks. Subjects stand on a platform of WBV for 3 minutes in every training session.
45663988|NCT04774107|Drug|P1101 + Ribavirin|P1101 400 µg SC
45663989|NCT02457793|Drug|Cobimetinib|Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.
45663990|NCT02457793|Drug|GDC-0994|GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.
45818015|NCT03149887|Drug|Placebo|Inert solution created to appear as liposomal bupivacaine (Exparel) for injection
45818016|NCT04759404|Other|Deep Oscillation Treatment|Deep oscillation to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
45663991|NCT01650259|Drug|OAD|OAD except Trazenta tablets
45663992|NCT01650259|Drug|Trazenta|Linagliptin
45663993|NCT04908085|Behavioral|Occupational Performance Coaching|Six sessions of OPC delivered by telephone over 10 weeks.
45957999|NCT05656313|Device|Ability to multitask in the auditory and visual domains in noisy situation with speech from the side and from behind (Multitask test)|This test uses a dual-task-paradigm assessing vigilance for auditory and visual triggers concurrently. The primary task is to listen to a novel (Harry Potter) and respond on two trigger words by pressing the appropriate button (one in each hand). The secondary task is to observe a monitor showing a sequence of random signs and respond on a target sign by pressing both buttons. The test includes at least 100 triggers (50 auditory, 50 visual) and takes 10 minutes per condition (side vs. back; novel approach vs. reference; 40 minutes in total). The multitask test will be repeated four times for the secondary objective: 2 conditions (Refrence, novel approach) against 2 target directions (better ear side, back). Following data are provided from each multitask Test measure: (1) subjective rating of the perceived ability to perform the visual and the auditory test simultaneously. (2) reaction times to auditory and visual tasks, and (3) accuracy.
45958000|NCT05656313|Device|Measure of subjective speech intelligibility and listening effort in noisy situation with speech from the side and from behind (subjective assessment; 100-point scale)|"In addition to the tests mentioned above a subjective assessment will be used to determine the subjective perception as this measure is often a good indication for clinical relevance.~For this purpose, the same speech material as used in the HEISS-test is presented by a loudspeaker in the same noisy environment as in the other three tests. The subjects rate his/her perception of the presented speech using a questionnaire on the dimensions listen effort and speech intelligibility. The subject will rate his perception on the 100 point scale with pencils with different colors to get either absolute and relative ratings.~The subjective assessment will be repeated four times for the secondary objective: 2 test conditions (Rference and novel approach) against 2 target directions (better ear side, back). Following data are provided from assessment: rating on a 100-point scale per condition and per dimension."
45958001|NCT05649852|Other|Socio-aesthetic care|Group A (Socio-aesthetic care): 3 sessions carried out by a socio-esthetician, during the first administration of chemotherapy.
45958002|NCT05649852|Other|Supportive care|Group B (control) will not benefit of socio-aesthetic care during chemotherapy but will benefit all existing support care in the center and accessible to patients: psychology consultation, sophrology, art therapy, physiotherapy, hypnosis. The patient will receive support care (maximum 2) during the intercure.
45958003|NCT05643209|Procedure|ablation|epicardial substrate homogenization (ablating abnormal fragmented prolonged low-frequency ventricular electrograms) in consecutive patients undergoing catheter ablation
46079231|NCT05752474|Behavioral|Nutrition|One-hour virtual group nutrition education classes will be held once per week by a dietitian, focusing on optimal protein intake (1.2 grams per kg of body weight) for lean body mass preservation (from food sources and oral nutritional supplements) and muscle gain. Participants will also receive oral nutritional supplements (20-30 grams of protein/day provided by our study team).
45455094|NCT01122823|Behavioral|chronic disease self-management program (online)|The online CDSMP is an internet-based program for people with 1 or more chronic conditions. It's built on self-efficacy theory, facilitated by lay leaders, and uses a curriculum emphasizing problem solving, decision making, and confidence building in weekly sessions over six weeks. It addresses generic topics and skills relevant to managing any chronic condition, including: action plans; problem solving; nutrition; exercise; fatigue; breathing; managing medications; managing stress and emotions; working with health care providers. The structure includes: 1) password-protected, interactive web-based instruction; 2) web-based bulletin board discussion groups to enable participatory learning and support; 3) and a reference book that contains the program content and supplemental information.
46079232|NCT05752474|Behavioral|Meditation|One-hour virtual group meditation sessions will be held once per week by an experienced meditation teacher. Classes will focus on breathing techniques, yoga, and mindful meditation practices. Participants will be asked to participate in self-directed meditation for at least 12 minutes daily.
45455095|NCT05250206|Other|Myopia control lens|Evaluation of the efficacy in decreasing myopia progression of the proposed ophthalmic lens prototypes.
45818017|NCT04759404|Other|Myofascial Release Treatment|Myofascial release to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
45818018|NCT02988193|Device|optima4BP Medication Management|A clinical reasoning expert system is used to determine the need for a medication treatment optimization. If a treatment optimization is needed, the expert system generates a recommendation that is sent to the treating physician.
45818019|NCT02988349|Other|Colgate® Sensitive Pro-Relief® toothpaste|Subjects will be instructed to brush their teeth twice daily for 3 min using Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks.
45818020|NCT04541329|Biological|Tildrakizumab|IL-23 inhibitor
45818021|NCT03150043|Device|Masimo Rainbow Pulse CO-oximeter|Masimo Rainbow Pulse CO-oximeter will be used to measure hemoglobin values of pregnant women during primary cesarean delivery
45818022|NCT02159352|Drug|Daclatasvir|
45818023|NCT02159352|Drug|Darunavir|
45818024|NCT02159352|Drug|Ritonavir|
45818025|NCT02159352|Drug|Lopinavir/Ritonavir|
45818026|NCT04499833|Procedure|liver transplant|liver transplant
45958004|NCT05643079|Procedure|medializing calcaneal osteotomy and/or transfer of the flexor digitorum longus tendon (FDL) with metal/Bio-Tenodesis screws|"The calcaneus osteotomy is performed dorsal proximal to plantar distal with caution of the peroneal tendons and sural nerve. After mobilization the dorsal fragment is displaced medially by~10mm. Thereafter, a guide wire is placed from plantar-lateral into the ventral portion of the calcaneus under fluoroscopic control. After stab incision and length measurement, the osteotomy is fixed with a Metal/Bio-Tenodesis screw(MBS). The lateral projection of the edge is straightened. Opening of the tendon sheath of the FDL muscle and dissection distally to Henry's node. Settling of the tendon and arming with a shuttle suture. Tendon diameter measurement. Place a guide wire at os naviculare directed from plantar to dorsal in 20°proximal guidance. Pull through the FDL tendon from plantar to dorsal and fixation with an MBS in 20°of pointed foot position and inversion with appropriate desired tension. The tendon is then sutured to the stump of the tibialis posterior tendon, retinaculum sutures."
45958005|NCT05643079|Procedure|medializing calcaneal osteotomy and/or transfer of the flexor digitorum longus tendon (FDL) with Shark Screws®|"The calcaneus osteotomy is performed dorsal proximal to plantar distal with caution of the peroneal tendons and sural nerve. After mobilization the dorsal fragment is displaced medially by approx.10mm. Thereafter, a guide wire is placed from plantar-lateral into the ventral portion of the calcaneus under fluoroscopic control. After stab incision and length measurement, the osteotomy is fixed with a Shark Screw®. The lateral projection of the edge is straightened. Opening of the tendon sheath of the FDL muscle and dissection distally to Henry's node. Settling of the tendon and arming with a shuttle suture. Tendon diameter measurement. Place a guide wire at os naviculare directed from plantar to dorsal in 20°proximal guidance. Pull through the FDL tendon from plantar to dorsal and fixation with the Shark Screw® in 20°of pointed foot position and inversion with appropriate desired tension. The tendon is then sutured to the stump of the tibialis posterior tendon, retinaculum sutures."
45958006|NCT05634577|Drug|Mitotane|Given by PO
45958007|NCT05634577|Drug|Pembrolizumab|Given by vein (IV)
45958008|NCT05633628|Behavioral|Periodic CGM group with data analysis report- Intervention group|The patients are also instructed to continue to perform SMBG by finger prick if they experience symptoms of hypo- or hyperglycemia. During visit 0 (baseline) the patients is also instructed about how they can log in to the National Diabetes Register (NDR) to access their own NDR's recorded data and use the diabetes questionnaire.
45958009|NCT05632471|Behavioral|"web-based I know digital games training for intervation grup"|"I know digital games training consisting of 10 web-based videos"
45958010|NCT05632471|Other|The control group was not trained|The control group was not trained
45958011|NCT05626491|Device|Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina
45958012|NCT05626491|Device|Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive sham treatment (no active stimulation) every other day via a headband.
45958013|NCT05624450|Drug|Tozorakimab|Single IV dose of tozorakimab or matching placebo on Day 1.
45958014|NCT05624450|Drug|Placebo|Single IV dose of tozorakimab or matching placebo on Day 1.
45958015|NCT05621564|Drug|pre-operative therapy|pre-operative therapy includes pre-operative chemotherapy, radiation, endocrine therapy, target therapy and other anti-tumor therapy
45958016|NCT05619952|Dietary Supplement|Mushroom Powder|Ground shiitake mushrooms or ground white button mushrooms
45958017|NCT05617183|Biological|CT-P47|CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via auto-injector (AI)
45958018|NCT05617183|Biological|CT-P47|CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
45958019|NCT05617027|Other|actual transcranial direct current stimulation (tDCS)|"tDCS is a non-invasive brain stimulation technique that would influence the brain's pain control mechanisms.~The anode is attached to the skull above the M1 opposite the painful side (in case of unilateral pain) or opposite the dominant hand (in case of bilateral pain). The cathode (at the supraorbital level opposite the stimulated M1) will be positioned using the 10-20 EEG system and the tDCS intensity will be 2 mA."
45958020|NCT05617027|Other|placebo transcranial direct current stimulation (tDCS)|The anode is attached to the skull above the M1 opposite the painful side (in case of unilateral pain) or opposite the dominant hand (in case of bilateral pain). The cathode (at the supraorbital level opposite the stimulated M1) will be positioned using the 10-20 EEG system and the tDCS intensity will be 2 mA for 30 secondes, and then 0 mA for the rest of the 20-minute session.
45958021|NCT05616260|Drug|Acetazolamide|Acetazolamide tablet (encapsulated)
45958022|NCT05616260|Drug|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide
45958023|NCT05616260|Device|Continuous Positive Airway Pressure|Standard CPAP device
45958024|NCT05615753|Behavioral|Acupuncture|All participants will receive a semi-standardized acupuncture protocol with additional points for patient's particular pain location,
45818027|NCT03150199|Behavioral|Positive Psychology + Motivational Interviewing|Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 8 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered step-wise within sessions (rather than intertwined).
45958025|NCT05611034|Drug|Oxaliplatin|Oxaliplatin infusion in single lung via IVLP technique
45958026|NCT05592509|Dietary Supplement|Ozonized vegetable oil with vitamines|"description: A single capsule is composed by ozonized vegetable oil (75 mg), vitamin K2 (20 mcg), vitamin B9 (130 mcg). The posology is three capsules/day.~The time of administration is two months."
45958027|NCT05586269|Behavioral|Meal Kit Delivery|Families receive 6 weeks of healthy meal kit delivery. Meal kits come with embedded nutrition education and access to online cooking demonstrations.
45958028|NCT05582213|Diagnostic Test|induction of anesthesia|This group includes (20) patients will receive induction by sevoflurane 3% using open circuit (modified Ayre's T-piece) till loss of consciousness and will be maintained on oxygen mask on the same concentration of sevoflurane and connected to capnogram
45958029|NCT05579158|Behavioral|Mobile application and wearable device|Mobile application-supported nutritional counseling includes education, monitoring, interaction, and physical activity
45958030|NCT05579158|Behavioral|Time-restricted eating|Time-restricted eating (an 8-hour period (from 10 a.m. to 6 p.m.) each day)
45818028|NCT03150199|Behavioral|MI-based Health Education Intervention|Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments. Motivational interviewing topics (e.g., pros and cons of behavior change, importance and confidence of behavior change, identification of barriers and resources to change) will be presented related to each health behavior.
45958031|NCT05579080|Device|noninvasive ventilation|The medical records whose patients used some type of non-invasive ventilatory device and devices that promote oxygen supplementation will be analyzed.
45958032|NCT05564728|Other|Conversational Agent/Chatbot App|Well Feet is developed based on adaptive learning frameworks to deliver diabetes foot care education through a conversational agent. The learning path for each participant will be customised based on their responses to pre-module quizzes.
45958033|NCT05558566|Other|Neurofeedback from the SMA|Feedback is provided regarding activity in the SMA and participant attempts to control SMA activity using the feedback as a training signal
45818029|NCT02187744|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum of 6 cycles.
45818030|NCT02187744|Drug|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
45958034|NCT05558566|Other|Neurofeedback from control region|Feedback is provided regarding activity in a control region and participant attempts to control activity in that region using the feedback as a training signal.
45958035|NCT05550922|Behavioral|Healthcare Transition-Based Education|The goal is for asthmatic adolescents to take responsibility for their own disease, be prepared for transition to adult pulmonology services, increase their self-efficacy, and gain management skills as a result of health care transition education.
45958036|NCT05550597|Drug|Fentanyl HCl|Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia
45958037|NCT05550597|Drug|Bupivacaine 0.25% Injectable Solution|Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia Ultrasound-guided Transversus Abdominal plane block using Bupivacaine 0.25% Injectable Solution
45958038|NCT05548140|Device|Novel Motorized Spiral Enteroscopy|This study involves performance of spiral enteroscopy in one arm and single balloon enteroscopy in the other arm in patients who satisfy inclusion criteria
45958039|NCT05541276|Drug|Melatonin|Melatonin for injection 1 mg/mL
45958040|NCT05541276|Drug|Isotonic sodium chloride solution|Sodium chloride 0.9 % for injection
45958041|NCT05537662|Device|Standard of care neuromodulation therapy (SCS or DRG)|Standard SCS or DRG therapy
45958042|NCT05535842|Other|GLOW|GLOW is an app for type 2 diabetes support and education that uses a conversational agent to help users develop self-management skills and learn about diabetes and healthy behaviours. This is achieved through a range of interactive strategies.
45958043|NCT05535764|Drug|Pegylated interferon alpha2a|PegINFa will be given once every 2 weeks by subcutaneous administration in the abdomen or thigh.
45958044|NCT05522855|Device|EEG Sensorband and mobile application|EEG headband to record brain signals. The Sensorband uses Bluetooth to link to the mobile application on a user's device. This raw EEG data is processed on a HIPPA compliant cloud based server and displays mental workload and brain energy data on the application. This can help the user with cognitive pacing to avoid overexertion. The control version will not display mental workload and brain energy data on the application.
45958045|NCT05502861|Behavioral|Generalist + Specialist palliative care|Clinicians are alerted in the EHR to make an active choice whether to provide generalist palliative care themselves, consult PC specialist, or to defer PC at that time.
45958046|NCT05502861|Behavioral|Pre-Intervention phase|Patients meeting eligibility criteria will be enrolled for study data collection but there will be no attempt to influence delivery of care.
45958047|NCT05496062|Device|F&P Toffee Nasal and Toffee Nasal Pillows Masks|F&P Toffee Nasal and Toffee Nasal Pillows Masks are intended to be used within the traditional PAP therapy system and are designed to facilitate equivalent PAP therapeutic efficacy as defined by standard practice.
45958048|NCT05495269|Drug|QLS-101 ophthalmic solution, 2.0 %|ophthalmic solution in a single use dropper vial
45818031|NCT02187744|Drug|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
45818032|NCT02187744|Biological|Trastuzumab-EU|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum 6 cycles.
45958049|NCT05494229|Other|Pars-plana vitrectomy|Pars-plana vitrectomy
45958050|NCT05481151|Drug|P1101 (Ropeginterferon alfa-2b-njft)|Ropeginterferon alfa-2b-njft
46079233|NCT05752474|Behavioral|Cognitive Behavioral Intervention|A 30-min telephone-based session with individual patients will take place to deliver cognitive behavioral strategies once per week by a professionally trained clinician. These strategies include education about frailty and surgery, increasing positive beliefs of the benefits of exercise and nutrition, discussing barriers, setting individualized goals for surgery and recovery, developing a detailed exercise and nutrition plan (including logistics), self-monitoring of progress using weekly exercise, diet, and meditation logs, and enhancing self-efficacy through the celebration of small wins.
46079234|NCT05752032|Genetic|ICM-203|Long term follow-up
45958051|NCT05481151|Drug|Ropeginterferon alfa-2b-njft (P1101)|Ropeginterferon alfa-2b-njft
45958052|NCT05480449|Biological|Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)|The investigational agent in this protocol is humanized CART19 cells (huCART19). Autologous T cells will be engineered to express an extracellular single chain antibody (scFv) with specificity for CD19. This will be expected to redirect specificity of the transduced T cells for cells that express CD19, a molecule that is restricted in expression on the surface of the malignant cells and on normal B cells.
45958053|NCT05474638|Device|Isometric Thumb Force (isometric mechanomyography) compared to TOF-Watch SX (acceleromyography)|Comparison of mechanomyographic measurements of thumb adduction's force induced by 100 versus 200 Hz 5 seconds tetanic ulnar nerve stimulation during neuromuscular block spontaneous recovery monitored by acceleromyography on the controlateral arm.
45958054|NCT05468112|Behavioral|SKY Meditation and Mindfulness|The intervention is a 3-day in-person meditation and mindfulness workshop using the SKY meditation approach. It utilizes a unique set of standardized breathing techniques to rapidly reduce neuro-endocrine stress responses and the autonomic imbalance due to sympathetic overdrive, thus restoring autonomic homeostasis. These are interwoven with coping and stressor appraisal strategies, and simple stretching exercises. Classes will be 3 hours long on each of three consecutive days, and participants must be willing to attend all three sessions with an additional 7 consecutive days of online sessions immediately thereafter. In addition, participants will be asked to engage in daily 10 to 25 minute home resilience practice sessions performed five days per week. They will complete a follow-up session once per week in the subsequent 8 weeks.
45958055|NCT05456100|Behavioral|Expressive Helping|Expressive helping involves a combination of emotional disclosure and peer support writing completed over four weeks.
45958056|NCT05456100|Behavioral|Expressive Writing|Expressive writing involves emotional disclosure writing over four weeks.
45818033|NCT02187744|Drug|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
45818034|NCT02187744|Drug|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
45818035|NCT03154333|Drug|diacerein 1% ointment|diacerein 1% ointment administered topically
45818036|NCT03154333|Drug|A placebo ointment|vehicle ointment administered topically
45818037|NCT04473625|Other|Stool Sample Collection|Subjects participating in the study will provide a stool sample within 30 days of enrollment.
45818038|NCT04393441|Drug|011516X (New Artificial Tear Formulation)|Topical eye drops
45818039|NCT04393441|Drug|Systane Ultra Multidose|Topical eye drops
45818040|NCT04393441|Drug|REFRESH PLUS®|Topical eye drops
45958057|NCT05456100|Behavioral|Factual Writing|Factual writing involves writing facts about cancer treatment and experiences over four weeks.
45958058|NCT05451953|Procedure|Apneic Oxygenation|Nasal cannula at a rate of 6L/min with 100% FiO2 during laryngoscopy and intubation attempt(s)
45958059|NCT05451953|Procedure|Standard of Care|No respiratory support during laryngoscopy and intubation attempt(s) (current standard of care)
45958060|NCT05442671|Behavioral|Exercise intervention|16-week home exercise intervention, enriched by mobile health technology
46079235|NCT05752032|Drug|Placebo|Long term follow-up
45958061|NCT05435443|Device|PowerBreathe and PEP Therosold tools|"Initially, the following data were collected from each subject in addition to basic epidemiological data:~M-mode diaphragmatic excursion measurements, both in inspiration and expiration via ultrasound; spirometry is also carried out, obtaining values of forced vital capacity (FVC or FVC), forced expiratory volume (FEV), portion of FVC (FEV1/FVC), peak expiratory flow (PEF), mean expiratory flow, peak inspiratory pressure (PIM) and peak expiratory pressure (PEM). A 30-day treatment plan was carried out in which one group (Tool Group) had to perform 5 minutes of exercise with each tool, alternating with one minute of rest between each minute of exercise, starting with the Therosold PEP® and then the PowerBreathe®. The resistances applied to the devices were marked according to the specific assessment of each subject, in relation to the spirometric values of PIM and PEM."
45663994|NCT02434939|Drug|Low dose ketamine|Children in this arm shall receive a slow infusion of ketamine at a sub-anesthetic dose and monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
45958062|NCT05427253|Drug|C106 solution|selective nonpeptide angiotensin II type 2 receptor (AT2R) agonist
45958063|NCT05427253|Drug|Placebo|Placebo for C106 solution
45958064|NCT05425719|Drug|MB-102|18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds
45958065|NCT05425719|Device|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants will have a transdermal sensor placed on their chest in the area between the shoulders (including the pectoralis and sternum area), and the MediBeacon Transdermal GFR Measurement System will be initiated to collect background fluorescence. After collection of background fluorescence, participants will then receive a single dose of MB-102.
45958066|NCT05423496|Diagnostic Test|KidneyCare|Using KidneyCare platform as a tool to successfully augment immunosuppressant agents through regular surveillance allowing minimization of doses and number of agents.
45958067|NCT05423496|Drug|steroid|optimization of steroids
45958068|NCT05423496|Drug|MMF|optimization of MMF
45958069|NCT05401318|Procedure|Tumor tissue sampling for organoid development|Fresh tissue from colorectal tumors will be sampled and cultivated in 3D cultures for drug testing.
45958070|NCT05366686|Behavioral|NICE Support Program|Patients in experimental group will receive a 12 week NICE Support program; patients in control group maintain their usual life activities.
45958071|NCT05358171|Other|HIgh UPF controlled diet|Following a two- week eucaloric lead-in diet, participants will be provided and consume a diet emphasizing UPF (81% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
45663995|NCT02434939|Drug|Morphine|Children in this arm shall receive intravenous infusion of morphine at analgesic dose and then monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
45818041|NCT03160027|Device|Vielight Neuro Gamma|The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.
45818042|NCT02994979|Other|Delirium-prevention|"Patients will be seen by an intervention CNA at least once daily 7 days a week. The CNA will be English/Spanish bilingual and will provide intervention components guided by structured protocols and a daily visit form. A typical visit lasts 30 minutes and begins with an introduction and orientation activity followed by provision of water, a reminiscence activity or game, a physical exercise, and a snack and second cup of water. Patients may also receive a relaxation visit at night and given a warm drink, a hand or foot massage, and quiet music. Daily visits will last for the duration of the illness and 7 days following the illness end. Illness end is defined as the last day of illness treatment (e.g., last day of antibiotics) or monitoring (e.g., last day on nursing 24-hour report). During weekly intervention staff meetings patients will be discussed with the primary medical and nursing team. The planned intervention group sample size results in a case load of 4-8 patients."
45818043|NCT02994979|Other|Sham comparator|Usual care plus sham visits by CNA
45958072|NCT05358171|Other|No UPF controlled diet|Following a two- week eucaloric lead-in diet, participants will be provided and consume a diet without UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
45958073|NCT05355935|Drug|Brensocatib|Oral tablet.
45958074|NCT05355935|Drug|Moxifloxacin|Oral tablet.
45958075|NCT05355935|Drug|Placebo|Oral tablet.
45958076|NCT05350397|Other|How Important Is Acupress Applyıng In Atrıal Fıbrılatıon Treatment?|The acupressure wristband was correctly attached to the Experimental Group and acupressure was applied. The placebo group was fitted with an inverted and loose acupressure wristband. No intervention was applied to the control group.
45958077|NCT05345847|Other|Active Surveillance|Close monitoring of liver enzymes with steroid rescue strategy (watch and wait approach)
45958078|NCT05345847|Other|Early initiation|Immediate start of high-dose steroids
45663996|NCT02434471|Device|Respiratory-triggered T1w DISCO LAVA|"The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.~Respiratory-triggered T1w DISCO LAVA precontrast~Respiratory-triggered T1w DISCO LAVA in the portal venous phase~Respiratory-triggered T1w DISCO LAVA in the equilibrium phase"
45663997|NCT02457637|Other|Standary therapy|Standary therapy for chronic liver disease with ALI and/or AD
46079236|NCT05751551|Other|Personalized, home-based motor-cognitive training|"The simultaneous motor-cognitive training in this study will be conducted in form of exergames (interactive video games) using Senso hardware (DIV-SENSO-H, Dividat GmbH, Schindellegi, Switzerland) - a stepping platform with 5 pressure sensitive plates which is connected to a screen. For the home-based training, a more mobile version of the Dividat Senso will be used: a foldable pressure-sensitive mat. In both devices, stimuli of exergames appear on the screen and the participants have to react by stepping in one of 4 directions (front, back, left, right).~The motor-cognitive training approach allows targeting different cognitive functions such as attention, executive functions, memory, and visuo-spatial functions as well as balance, and strength.~FITT-VP principles will serve as a guideline but based on the functional status of each participant (physical and cognitive), the training sessions will be personalized in terms of training content, intensity and duration."
45663998|NCT02457325|Drug|Surgery with 2%Articaine first, then Surgery with 4% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
45818044|NCT02995915|Other|Nicotine Replacement Therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or nicotine lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings
45818045|NCT02995915|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
45663999|NCT02457325|Drug|Surgery with 4%Articaine first, then Surgery with 2% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)
45664000|NCT02434081|Drug|Nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.Binding of PD-1 to its ligands, 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Nivolumab inhibits the interaction of programmed cell death Protein 1 (PD-1)with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation.
45664001|NCT02222493|Biological|PF-06438179|PF-06438179 will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
45664002|NCT02222493|Biological|Infliximab|Infliximab will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
45664003|NCT02433379|Device|EMBLEM S-ICD System|The intervention comprises programming the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) with zone cutoffs at 200 bpm and 250 bmp
45664004|NCT01439997|Drug|Desmopressin|Administration of minirin melt 60 µg: desmopressin (acetate) 60 µg oral lyophilisate.
45818046|NCT02995915|Behavioral|Cognitive Behavioral Treatment|Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.
45818047|NCT02995915|Behavioral|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence.
45818048|NCT02995915|Behavioral|Mobile Monitoring|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence.
45818049|NCT04376515|Behavioral|HOPE intervention|Online peer support community of peers trained in behavior change science
45958079|NCT05334017|Drug|Xylometazoline 0,1%|1 ml of 0,1% xylometazoline diluted with 1 ml of 0,9% isotonic saline solution given as a nasal spray
45958080|NCT05334017|Drug|Cocaine 4%|2 ml of 4% cocaine given as a nasal spray
45664005|NCT02199795|Device|Contralaterally Controlled Neuromuscular Electrical Stimulation|
45664006|NCT02199795|Device|Cyclic Neuromuscular Electrical Stimulation|
45958081|NCT05330104|Behavioral|Mobile Ecological Momentary Assessment|mEMA is a tool that allows for scheduled or triggered surveys to assess a participant's CIPN symptoms and/or fall risk
45958082|NCT05326971|Procedure|gastroscopy|Gastroscopy to evaluate the effect of long term exposure of TDF or TAF on enterocytes
45958083|NCT05319639|Drug|Oxaliplatin|Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.
45664007|NCT02403817|Behavioral|Cognitive Training|A collection of video games that rely on various aspects of visual behavior (i.e. sustained attention, vigilance, rapid discrimination, etc) for successful play.
45664008|NCT02403817|Behavioral|Eye Motor Training|Game play will be controlled by the player's eye movements (via an eye tracking device)
45958084|NCT05319639|Drug|Levo-Leucovorin|Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.
45958085|NCT05319639|Drug|5-fluorouracil|5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.
45958086|NCT05319639|Drug|Paclitaxel|Paclitaxel will be administered on day 1 of each cycle at 45mg/m2 at dose level 1; 67.5 mg/m2 at dose level 2 ; 90 mg/m2 at dose level 3; 112.5 mg/m2 at dose level 4 once every 14 days.
45958087|NCT05319639|Drug|Irinotecan|Irinotecan will be administered on day 1 of each cycle at 135 mg/m2 at dose level 1; 150 mg/m2 at dose level 2 once every 14 days.
45958088|NCT05319639|Drug|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.
45958089|NCT05316623|Device|TENS|TENS (strong and comfortable intensity) applied during exercises in a telerehabilitation setting.
45958090|NCT05307822|Other|Non-combusted cigarette variant 42001401|Menthol flavor variant of a non-combusted cigarette (42001401)
45958091|NCT05307822|Other|Non-combusted cigarette variant 42001399|Menthol flavor variant of a non-combusted cigarette (42001399)
45958092|NCT05307822|Other|Non-combusted cigarette variant 40007386|Menthol flavor variant of a non-combusted cigarette (40007386)
46079237|NCT05749952|Device|Symphonie Aqua Digital System|We will digitally capture (via computer) the shape of your limb, which will create a digital file (computer file) of what the internal shape of your socket should be. This file will then be used with a computer software program to optimize the fit of your prosthesis. This image will be used to create a check socket (temporary socket) to confirm a correct anatomical and comfortable socket. Then the check socket (temporary socket) will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
46079238|NCT05749952|Device|Symphonie Aqua System (Non-Digital)|A non-digital weight-bearing socket will be used to create the check socket (temporary socket), which will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
45664009|NCT02403817|Behavioral|Hand Motor Training|Game play will be controlled by the player's hand movements (via a joystick).
45664010|NCT04773249|Device|Lateral Epicondylitis Bandage|The lateral epicondylitis bandage was first used by Ilfeld in 1965, and it is a non-elastic band that prevents the expansion of the muscles in the proximal forearm. A lateral epicondylitis bandage will be given to the patient for 6 weeks. The bandage will be positioned 5 cm distal to the lateral epicondyle to allow for elbow flexion. After the application, patients will be asked to punch and the belt on the band will be tightened. After the patients are asked to open the fist, the suitability of the pressure applied to the forearm will be evaluated. Patients will be asked to repeat this application while wearing the band. The patients will also be asked to use the bandage throughout the day, and to remove them during bathing and sleeping.
46079239|NCT05746793|Procedure|endometrium biopsy|"The procedure is performed without any anesthesia and takes approximately 5 minutes.~A small plastic pipelle is put through the cervix into the uterine cavity. The endometrial tissue is aspirated into the pipelle."
46079240|NCT05746793|Diagnostic Test|Transabdominal ultrasound|Evaluation of fetal biometry and doppler flow study using ultrasound.
45664011|NCT04773249|Device|Wrist Extension Splint|Wrist extension splint is an upper extremity orthosis that keeps the wrist at 15-20 degrees of extension with the polyethylene bar it contains. A wrist extension splint will be given to the patient for 6 weeks. The splint will be used to keep the wrist at 15-20 degrees of extension and to wrap the distal wrist and forearm without hindering finger movements. The patients will be asked to use the splint throughout the day, and to remove them during bathing and sleeping.
45664012|NCT04189653|Other|Continuous Monitoring|Wireless continuous vital sign monitoring (HR, RR, SBP/DBP, SAT)
45818050|NCT02997085|Device|Live-Action 360° Video Virtual Reality|360° Video Virtual Reality (VVR) is made by filming with multiple HD cameras carefully arranged to capture all angles in a 360° area of a live action event. Then those angles are stitched together in post-production into a 360-degree texture sphere and the sphere is then mapped to the head tracker on the users head mounted display (HMD). Leading to the effect that when a user turns his head, the user's view of the live action video footage turns with them in real time allowing the user to look around anywhere in the 360 degrees of filmed footage of the live action event. Participants randomized to the Live-Action 360° VVR group will be outfitted with a Samsung Gear VR HMD and will view a 9-minute live-action 360° VVR video. The 9 minutes of footage will be alternating 30 second clips of central Texas locations.
45818051|NCT02997085|Device|CGI 360° Video Virtual Reality|Participants randomized to the CGI 360° VVR condition will also be outfitted with a Samsung Gear VR head mounted display. Participants will view the same content for the same duration as in the Live-Action 360° VVR condition, but the footage will be animated instead of live-action footage.
45818052|NCT03163303|Behavioral|Tobacco Status Project Intervention|90 days of Facebook messaging, weekly live sessions targeting tobacco use
45818053|NCT03163303|Behavioral|Tobacco Status Project + Alcohol Intervention|90 days of Facebook messaging, weekly live sessions targeting tobacco use and alcohol use
45818054|NCT03163303|Drug|nicotine patch|14-day supply of nicotine patch
46079241|NCT05746793|Diagnostic Test|Peripheral phlebotomy|single puncture collection of peripheral venous blood.
46079242|NCT05746793|Diagnostic Test|Urine collection|Collection of urine in a plastic cup.
45818055|NCT04349995|Device|Amplatzer PFO Occluder|Percutaneous PFO closure using Amplatzer PFO Occluder
45958093|NCT05307822|Other|Non-combusted cigarette variant 42001402|Non-Menthol flavor variant of a non-combusted cigarette (42001402)
45958094|NCT05306327|Diagnostic Test|electroencephalography (EEG)|"brain cortical activity using full scalp~cerebral blood flow velocity~during the dying process following planned withdrawal of life sustaining measures (WLSM)"
46002260|NCT04158908|Behavioral|Oncolo-GIST|"Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topic covered include:~Principles of introducing prognosis in the setting of worsened scan results~Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months… with emphasizing that the oncology team will always provide care for you)~Addressing informational needs and psychological reactions~Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith."
45818056|NCT03165175|Behavioral|prescription drug-abuse education smartphone application|As a patient-centered prevention effort, this brief intervention in a mobile phone app format focuses on helping military members reduce their risk for prescription drug misuse. It contains modules to: (1) assess risk for misuse and related behavioral health concerns; (2) provide individualized feedback on risk level; (3) store information on current medications and look up drug interaction and related information; (4) enhance communication and decision-making skills within healthcare and other interpersonal contexts by providing interactive scenarios; (5) teach about the risks of prescription drug misuse; and (6) provide available resources for help with prescription drug misuse.
45664013|NCT02403271|Drug|Ibrutinib|BTK Inhibitor
45958095|NCT05306015|Combination Product|Mindfulness meditation based on brain-computer interface|"Before surgery, The nurses will teach and explain the methods and significance of meditation training. Let the patient be familiar with the function and background of this method, and explain the use of the headband during the operation, so that the patient believes that meditation training can relieve pain.~In surgery, Wear a brain-computer interface headband for the patient to collect EEG, monitor the patient's psychological changes, and provide real-time feedback.~The patient wears a Bluetooth headset, according to the patient's preferences, different types of music are selected, and voice playback guides the patient to prepare, relax muscles and regulate breathing.~APP judges the patient's meditation state based on EEG signals, and adjusts music, voice guidance.~The nurse will give personalized guidance based on the patient's specific situation and the EEG displayed on the APP to help the patient achieve a state of meditation and relaxation."
45818057|NCT03000283|Drug|Conivaptan|"Patients will receive 20mg IV of the study drug every 12 hours equaling 40mg/day over 2 days (4 doses total), in addition to the standardized ICH management targets using the PI's version of standardized ICH management targets.Usual standard of care can include sedation and analgesia as needed, elevation of the head of the bed, mannitol and/or saline as needed to reduce ICP, and temperature control with antipyretics such as acetaminophen.~The conivaptan bolus (20mg), which is premixed with 100ml of 5% dextrose in water, is infused (peripherally) over 30 minutes, most commonly through an already placed central line."
45958096|NCT05306015|Combination Product|Routine care|Give routine treatment and care, and increase or decrease the dose or adjust according to the patient's condition in accordance with the doctor's advice. Before surgery, we will introduce the level of medical care involved in the surgery and the equipment of our hospital. Inform the patient of the surgical process and possible pain, and explain in detail the cause, location and characteristics of the pain, including the time when the pain will appear and last. Instruct patients to stabilize their emotions and maintain a calm state of mind. As far as possible to meet the patient's intraoperative care needs, give psychological care, wear a headband to collect EEG signals, but do not intervene in mindfulness meditation.
45958097|NCT05302700|Behavioral|Early Parental Sensitivity Intervention|Parental sensitivity intervention include (1)Establish an emotional connection：Using the VR tour to introduce the environment, instruments and equipment of the neonatal intensive care unit, appearance of premature infants and pipeline wires on their bodies .(2)maintain physical proximity:proactively provide mothers with the opportunity to touch the body of preterm infants.(3) parents must understand their infant's cues:Using the Premature Infant Behavioral Clues Teaching Materials to play video and we will discuss and respond to the mother's questions.(4)engage in his/her care and communicate appropriately with him/her:We will discuss the behavioral clues of the preterm infant with the mother next to the incubator, encourage the mother to ask questions and participate in care activities such as changing diapers and stamping the baby's footprints on the card, asking the mother to write down the number of days of birth, corrected age, weight and what she wants to say for her baby.
45958098|NCT05292339|Drug|Triamcinolone injection to the shoulder, elbow, wrist, or hand|Triamcinolone is a corticosteroid that decreases the inflammatory process by inhibiting the release of arachidonic acid from phospholipids.
45958099|NCT05292339|Drug|Ketorolac injection to the shoulder, elbow, wrist, or hand|Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that reduces inflammation by inhibiting Cyclo-oxygenase (COX)-2 dependent prostaglandin release via the cyclooxygenase pathway.
46079243|NCT05746793|Other|MOCK frozen embryo transfer preparative cycle.|Start with daily estradiol (progynova, oestrogel) administration at hormonal baseline (day 2 of the cycle or with confirmation using endocrine evaluation). When adequate thickness (≥6.5 mm) of the endometrium is achieved (usually after 10-14 days), progesterone is administered daily. 6 days after progesterone administration, the pipelle biopsy will be performed. When this test cycle has ended and menstruation starts, patients will be asked to collect their menstrual flow, during the first night of heavy/red flow, in a menstrual cup. The next day patients will be asked to bring their collected menstrual blood to our center and they will undergo a blood analysis needed for the start of their ART treatment.
46079244|NCT05746793|Diagnostic Test|Baseline questionnaire|questionnaire the patient has to fill in
46079245|NCT05746793|Other|collection of menstrual blood|collection of menstrual blood during the first day of heavy menstrual flow for at least 6 hours
46079246|NCT05746793|Diagnostic Test|nutritional and metabolic work-up|Including body composition analysis by BIA/whole body MRI and analysis of resting energy expenditure (REE).
46079247|NCT05746793|Diagnostic Test|cardiac work-up|Using transthoracic ultrasound.
45818058|NCT03855163|Behavioral|Inspection visits|Normative intervention aimed at enforcing compliance with legal occupational health and safety requirements
45664014|NCT02403271|Drug|Durvalumab|Anti PDL-1
45664015|NCT02219685|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
45818059|NCT03855163|Behavioral|Guidance workshops|Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
45664016|NCT02219685|Drug|Placebo|Tablet administered orally once daily
45664017|NCT02457247|Drug|Calcichew D3|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3)
45664018|NCT02457247|Drug|Adcal-D3|Adcal-D3 (Calcium 600mg/400 IU Vitamin D3)
45664019|NCT02457247|Drug|Kalcipos-D|Kalcipos-D (Calcium 500mg/800 IU Vitamin D3)
45958100|NCT05291650|Drug|Glucocorticoids|The product of the glucocorticoid is betamethasone injectable suspension and the dosage is 1 ml. To alleviate the discomfort on local tissues, the suspension injected into the infrapatellar fat pad will be pre-mixed with 0.5 ml saline and 0.5 ml lidocaine. That is, the total amount of the drug injected into the infrapatellar fat pad for the glucocorticoid group will be 2.0 ml.
45958101|NCT05291650|Drug|Saline|A total of 2.0 ml drug including 1.5 ml saline and 0.5 ml lidocaine will be injected into the infrapatellar fat pad for the placebo group.
45958102|NCT05291650|Drug|Hyaluronic acid|After completing the process of infrapatellar fat pad injection, the participants in both groups will receive 2.5 ml hyaluronic acid suspension injection through the suprapatellar bursa into the intra-articular space.
45958103|NCT05285059|Behavioral|ASRT task|"The ASRT (Alternating Serial Reaction Time) task is a computerized behavioral task measuring implicit learning. This task consists of 20 series of trials lasting 2 minutes each.~In each trial, a stimulus is displayed on the screen in one of the four possible predefined locations. The participant must press a button to indicate the position of the stimulus on the screen. Response content and response time are recorded.~At the end of every trial, the participant can take a break and resume the task whenever ready. The task lasts about 45 to 50 minutes."
45958104|NCT05283486|Drug|MYMD-1 600MG|Cohort 1: 600mg drug
45958105|NCT05283486|Drug|MYMD-1 750mg|Cohort 2: 750mg drug
45958106|NCT05283486|Drug|MYMD-1 900mg|Cohort 3: 900mg drug
45958107|NCT05283486|Drug|MYMD-1 1050mg|Cohort 4: 1050mg drug
45958108|NCT05283486|Drug|placebo 600mg|Cohort 1: 600mg placebo
45958109|NCT05283486|Drug|placebo 750mg|Cohort 2: 750mg placebo
45958110|NCT05283486|Drug|placebo 900mg|Cohort 3: 900mg placebo
45818060|NCT03855163|Behavioral|Online risk assessment tool|Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
45818061|NCT03164629|Device|cone-beam CT 3D Emboguide|cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
45818062|NCT03168295|Drug|Dapagliflozin 10mg then Placebo Oral Tablet|SGLT2 inhibitor - Dapagliflozin then Placebo
45818063|NCT03168295|Drug|Placebo Oral Tablet then Dapagliflozin 10mg|Placebo then SGLT2 inhibitor - Dapagliflozin
45818064|NCT03168841|Drug|Efinaconazole Topical|Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.
45958111|NCT05283486|Drug|placebo 1050mg|Cohort 4: 1050mg placebo
46079248|NCT05746793|Diagnostic Test|Blood pressure measurement|Blood pressure measurement
45958112|NCT05281393|Behavioral|PrEPresent|PrEP2Prevent is being done in several phases (parts) to develop and pilot test a PrEP activation, navigation and support intervention for young men who have sex with men (YMSM), trans youth and non-binary youth in Los Angeles. It targets an intervention for these young people where they need it most - on PrEP uptake. PrEP stands for pre-exposure prophylaxis.
45958113|NCT05273190|Device|Vibrotactile Stimulation|Small electric motors, similar to a vibrating cell phone or gaming joystick, deliver vibration to the throat. Participants will assess cough symptoms throughout the study period.
45958114|NCT05272046|Procedure|Per-oral Endoscopic Myotomy|Therapeutic endoscopy procedure by means of electrocautery surgical tools for treatment of various esophageal conditions such as achalasia or spastic esophageal disorders.
45818065|NCT03822949|Device|Day Light|Patients are exposed to daylight for up to 10 days prior to surgery
45818066|NCT03822949|Device|Placebo light|Patients are exposed to placebo light for up to 10 days prior to surgery
45818067|NCT03822949|Device|ICU Intense Light|ICU Patients are exposed to daylight for up to 10 days after surgery
45958115|NCT05272046|Device|Speedboat (Bipolar electrocautery knife)|Use of Creo Medical's Speedboat RS2 knife and generator in performing the POEM procedure for patients presenting with an esophageal motility disorder.
46079249|NCT05743127|Device|3D-Printed Hyrax Expander|This is a type of maxillary expander that is designed on a computer and printed in metal using 3D printers and is used to expand the upper jaw.
46079250|NCT05743127|Device|Conventional Laboratory Fabricated Hyrax Expander|This is a type of maxillary expander that is made by hand in an orthodontic laboratory and is used to expand the upper jaw.
45958116|NCT05266950|Biological|CI-135 CAR-T cells (0.5 x 10^6 CAR-T+ cells/kg，1.0 x 10^6 CAR-T+ cells/kg)|Recommended lymphodepletion regimen: cyclophosphamide (250 mg/m2/d, ×3d) and fludarabine (30 mg/m2/d, ×3d). If the patient has a hematological toxicity of grade 3 or higher, the alternative regimen is: cyclophosphamide (125mg/m2/d, ×3d) and fludarabine (15 mg/m2/d, ×3d). During lymphodepletion, physicians can give anti-myeloid drugs such as demethoxydaunorubicin or daunorubicin as appropriate.
45818068|NCT03822949|Device|ICU Placebo light|ICU Patients are exposed to placebo light for up to 10 days after surgery
45958117|NCT05266027|Drug|Nalbuphine Sebacate (Naldebain)|Nalbuphine Sebacate (Naldebain) 2mL/150mg would be intramuscularly injected during knee arthroplasty surgery.
45958118|NCT05266027|Drug|Placebo medication|Placebo medication, Nalbuphine Sebacate not contained
45958119|NCT05258669|Biological|BBV152|Each participant will receive 2 doses of the investigational product intramuscular injection of either 6 μg of BBV15 vaccine or placebo.
45958120|NCT05248867|Drug|AGN-151586|Intramuscular Injection
45958121|NCT05248867|Drug|Placebo|Intramuscular Injection
45958122|NCT05245266|Diagnostic Test|Redraw for analysis of blood samples from healthy pregnant women|If less than two fetal cells are recovered from maternal blood, a redraw is indicated
45958123|NCT05236465|Behavioral|A 3-day course|The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.
45958124|NCT05236465|Behavioral|Waiting list|Treatment as usual (TAU) in the first 10 weeks. After 10 weeks: Behavioural: A 3-day course. The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.
45958125|NCT05228886|Behavioral|SINCERE|"Each goal setting session will involve templated prompts in 211's ServicePoint to guide the creation of a patient-centered action plan specifying what, when, how much, and how often patients will engage in a behavior (e.g., I will work on filling out eligibility paperwork for 30 minutes on Wednesday evening). Again, following clear prompts, ISs negotiate the action plan with patients until patients can rate their level of confidence for achieving this behavior a 7 on a scale from 0 to 10."
45958126|NCT05228886|Behavioral|Scheduled Follow-Up|Adding to the standard Call + Resources protocol, those assigned to scheduled follow-up will receive a proactive call from 211 every 2 weeks for 3 months to explore additional service needs. These calls will be unstructured, guided by participant requests and 211 IS prompts.
45958127|NCT05228886|Other|Standard of Care|211 ISs contact referred patients, provide referral services, and follow up in an ad-hoc manner.
45958128|NCT05224869|Device|Medical Device Usage and Evaluation|Undergo hydrogel rectal spacer placement
45958129|NCT05224869|Procedure|CT simulation|CT simulation of radiation treatment planning 2-7 days after hydrogel placement
46079251|NCT05739136|Drug|Relugolix + Estradiol + Norethindrone Acetate|Relugolix combination therapy (relugolix 40 mg; estradiol 1 mg; norethindrone 0.5 mg)
45664020|NCT04929535|Drug|Hydrogen Peroxide 30 % Topical Solution|Patients will be seen by the radiation therapists involved with the study after randomization. Prior to application of hydrogen peroxide solutions, the patients' lesions will be prepared and debrided of keratinous debris and oils using sterile 70% isopropyl alcohol. Then, the appropriate hydrogen peroxide solution (30% for Arm 1 or 3% for Arm 2) will be rubbed into the lesion and a 1cm border all around the lesion until blanching of the lesion is observed. Hydrogen peroxide will be reapplied after one hour. This process will be repeated weekly for three additional applications for this study. If there is complete clinical response, further hydrogen peroxide will not be done. Patients will be accessed for definitive treatment 4 weeks later.
45958130|NCT05224869|Procedure|Stereotactic body radiation therapy|SBRT in 5 fractions over 1 week, 7 days after CT simulation
46079252|NCT05738174|Device|high-dose accelerated intermittent theta burst stimulation|1200 pulses of iTBS per session with five sessions per day applied at five days (Monday-Friday) with 120% resting motor threshold
46079253|NCT05738174|Device|sham high-dose accelerated intermittent theta burst stimulation|1200 pulses of iTBS per session with five sessions per day applied at five days (Monday-Friday) with 120% resting motor threshold with angled coil
46079254|NCT05738083|Diagnostic Test|statiscal methods|statiscal methods including conventional logistic regression and several machine learning algorithms
46079255|NCT05737030|Drug|L-ornithine L-aspartate|Amino acid combination
46079256|NCT05735275|Drug|SHR-A2102|All participants receive SHR-A2102 alone.
45958131|NCT05224869|Radiation|Brachytherapy|one month after completing SBRT
45958132|NCT05224869|Procedure|Post-implant dosimetry scan|one month after brachytherapy
45958133|NCT05219500|Drug|Ac225-PSMA I&T|Peptide capable of binding to the domain of PSMA radiolabeled with Ac225
45958134|NCT05201508|Procedure|Polyglactin mesh|Polyglactin mesh is used in keyhole manner to enforce hiatal closure
45958135|NCT05201508|Procedure|Sutures only|Traditional hiatal closure with non-absorbable sutures.
46079257|NCT05725980|Diagnostic Test|Cephalometric analysis|Cephalometric analysis will be performed evaluating upper airways landmarks.
46079258|NCT05718635|Diagnostic Test|coloured duplex|colored duplex to locate numbers sites and size of perforators.
46079259|NCT05718635|Procedure|supra facial dissection|flap raising in supra facial plane
45818069|NCT04068493|Behavioral|Enhanced Project Health|A dissonance-based obesity intervention consisting of eight weekly groups sessions (1.5 hours).
45958136|NCT05200624|Device|2RT subthreshold nanosecond laser|The 2RT™ Q-switched YAG laser (532nm) delivering 3 nanosecond pulses; 400 um spot size, is a pulsed subthreshold nanosecond (SNL) laser, which uses low energy levels to produce limited effects that selectively target melanosomes within the pigmented retinal pigment epithelial (RPE) cells.
45958137|NCT05182749|Biological|bacteriophage|A cocktail of lytic Shigella-specific bacteriophages orally administered with sodium bicarbonate solution
45958138|NCT05182749|Other|Placebo|Placebo orally administered with sodium bicarbonate solution
46079260|NCT05718128|Procedure|Endocardiomyocardial biopsy|Endocardiomyocardial biopsy
46079261|NCT05716295|Drug|MDK-703|MDK-703 will be administered as specified under Arm description.
45818070|NCT03815227|Other|Outpatient birth|Maternity out the same date or the next day of the birth and home-based follow up with a liberal midwife
45958139|NCT05172726|Drug|tapinarof cream, 1%|applied topically once daily
45958140|NCT05172089|Procedure|Observation of wound infection and time to wound closure|Observational: collecting data on length of time to wound closure
45958141|NCT05172089|Device|Pericam PSI-NR Laser Speckle imaging|non-invasive non-contact device providing two-dimensional imaging of peripheral tissue blood perfusion. Reduced blood flow may lead to insufficient tissue oxygenation and, thus, assessment of peripheral vascular function has several clinical applications.
45958142|NCT05168046|Behavioral|Mindfulness based stress reduction|program of weekly mindfulness based stress reduction intervention during 2 months and practice during 3 months
45958143|NCT05159466|Procedure|Kidney transplant|Participants will be recruited at the Tulane Abdominal Transplant Institute site where they are evaluated and followed for organ transplantation as part of standard of care. HIV-positive adult candidates on the wait list or referred for organ transplantation evaluation willing to accept an HIV positive organ will be recruited.
45958144|NCT05159427|Drug|Glucotrol XL 5Mg Extended-Release Tablet|Participants are randomized to take one tablet of this study drug by mouth.
45958145|NCT05159427|Drug|Glipizide ER 5 MG 24 HR Extended Release Oral Tablet|Participants are randomized to take one tablet of this study drug by mouth.
45958146|NCT05159427|Drug|Rifaximin 200Mg Tab|Participants will take one tablet of this study drug by mouth.
45958147|NCT05159427|Drug|13C6-Glipizide|Participants will take 1 mg of this study drug dissolved in 40 ml glucose solution by mouth.
45958148|NCT05157867|Other|Amylase trypsin inhibitors|Intraduodenal administration of amylase trypsin inhibitors (ATIs) isolated from Triticum aestivum (wheat), dissolved in physiological saline.
45958149|NCT05157867|Other|Placebo|Intraduodenal administration of placebo (physiological saline).
45958150|NCT05153759|Other|Meal service|The primary goal is to pilot the feasibility of a meal service intervention in night shift workers
45958151|NCT05144997|Drug|Lorlatinib|ALK-positive NSCL treatment
45958152|NCT05131581|Other|Changed clinical context|Changed clinical context: from midwifery clinic to youth clinic
45958153|NCT05131581|Behavioral|Extra time allotted|Extra time allotted for each visit for CST
45958154|NCT05131581|Behavioral|RLP-information|Midwife-initiated discussion of the Reproductive Life Plan
45958155|NCT05131438|Drug|sugemalimab|sugemalimab (Anti-PD-L1 antibody)
45958156|NCT05131386|Drug|Trabectedin|ET-743, Yondelis (vials of 1 mg). Route of administration: intravenous infusion
45958157|NCT05129332|Other|Vaginal Moisturizer|Natural oil-based vaginal moisturizers, like Vitamin E Oil or Coconut Oil, will be applied topically (dime-size amount) on the labia externally and vagina internally nightly, but at least 3 times per week.
46079262|NCT05716295|Drug|Checkpoint Inhibitor, Immune|Checkpoint inhibitor will be administered as specified under Arm description.
45958158|NCT05129332|Device|Vaginal Dilator|Vaginal dilator will be inserted vaginally and used daily, but at least 3 times per week.
45958159|NCT05118282|Behavioral|Combined coping skills + asthma management|This arm includes a curriculum teaching coping skills and culturally relevant asthma management skills.
45958160|NCT05118282|Behavioral|Standard Asthma Management (AM)|This arm includes a curriculum teaching standard asthma management skills.
45958161|NCT05111262|Drug|Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA|In this study, we propose a pragmatic, pilot, open-label trial where we are comparing adherence to different inhaler regimens. Patients who were previously sub-optimally adherent to maintenance ICS inhalers will either continue receiving maintenance ICS inhalers and symptom-driven SABA inhalers or symptom-driven ICS/LABA inhalers only.
45958162|NCT05098613|Drug|CD19x22 CAR T Cells|Autologous peripheral blood mononuclear cells transduced with CD19x22 CAR T lentiviral vector.
45958163|NCT05098431|Other|Quadriceps and Rectus Femoris MEP Recording|Participants will receive additional electrodes placed intramuscularly to facilitate three separate approaches of quadriceps MEP recording
45958164|NCT05091580|Behavioral|Interpersonal Counseling|Interpersonal Counseling is a brief (4-8 sessions) psychological intervention that was developed to treat depression in primary care. In IPC, counselors provide psychoeducation about the connection of depressive symptoms to social triggers and support patients in leveraging social networks to address these stressors and reduce depressive symptoms. Since depressive symptoms are often a transient reaction to life stress (e.g. TB diagnosis), many individuals are able to achieve significant alleviation of symptoms in as few as four sessions. IPC focuses on reducing interpersonal conflict and improving social cohesion in families, which may have the advantage of strengthening the ability of families to support TB patients in completing treatment to achieve cure. All individuals will be offered 4-5 sessions (weekly), with up to 3 optional booster sessions (monthly) until TB treatment is completed.
45958165|NCT05091580|Behavioral|Enhanced treatment as usual|Depression screening and referral (as needed)
45958166|NCT05091242|Drug|Clonidine|Clonidine injection 3 mcg/kg once
45958167|NCT05091242|Drug|Sodium chloride|Sodium chloride 0.9 % injection 0.2 mL/kg once
45958168|NCT05090150|Other|Home delivery of ART|Home ART refill and monitoring, adherence support
45958169|NCT05090150|Other|Smart Lockers (Pele boxes)|Decentralized ART refills and monitoring, adherence support
45958170|NCT05090150|Other|Best clinic practices + conditional lottery incentives|Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART
45958171|NCT05090150|Other|Best clinic practices|Continue with best clinic practices
46002261|NCT04157595|Other|Reproductive Genetic Carrier Screening|Carrier screening for approximately 1300 genes associated with severe autosomal recessive and X-linked recessive conditions affecting children will be performed on each member of the couple. A combined result will be issued indicating whether the couple has a 'low' or 'increased' risk of having a child with a genetic condition
46079263|NCT05715216|Drug|Nivolumab|Given by IV (vein)
46079264|NCT05715216|Drug|Etigilimab|Given by IV (vein)
46079265|NCT05712772|Other|Blue Light|Blue light exposure
46079266|NCT05712772|Other|Red Light|Red light exposure
46079267|NCT05708625|Drug|Intralesional Sodium stibogluconate|Sessions will be held once weekly for a maximum of 6 weeks
45958172|NCT05086172|Behavioral|Ultrabrief Behavioral Activation|The ultrabrief behavior activation (UBA) intervention is a condensed version of the LETS ACT intervention. The main treatment elements include: (1) explanation of treatment rationale to facilitate behavior change via increased engagement in values-related activities, (2) identification of participant-specific values via detailed assessment of life areas, values and activities, (3) values-based activity planning and scheduling, and (4) post-treatment planning. The overall goal of behavioral activation (BA) is to shift from values-incongruent behavior (including alcohol use) to behaviors that provide positive reinforcement and environmental reward with the overall goal of increasing the number of engaged-in, value-based activities. This intervention will take 90 minutes.
45958173|NCT05085535|Other|Manual Therapy|Exercises for body mobility and muscle toning, Sophrology, musculoskeletal oscillatory manual therapy
45958174|NCT05085535|Other|Exercise|Exercises for body mobility and muscle toning, Sophrology
45958175|NCT05077865|Drug|MYMD-1|150 mg capsule
45958176|NCT05077865|Drug|Placebo|Matching in appearance to MyMD-1 150mg capsule
45958177|NCT05052138|Other|Tactile massage|Tactile massage will receive two 15-min tactile massages(hand massage) per week for 4weeks
45958178|NCT05045976|Other|Web-based interactive self-management support program|The intervention group will receive a 60-90 minute introduction to the web-based interactive self-management support program. They will be instructed to do the weekly online self-assessment on symptoms, emotion, and health behaviors and how to use the web-based program to manage their health by applying self-manage skills and behavior change techniques. The contents of the interactive colorectal cancer self-management website include the following five main components: Health Support Station, Knowledge Supply Station, Sharing Stories, My Dear Friend, and Asking a Nurse.
45958179|NCT05039099|Drug|AP-101|Participants receive AP-101 by intravenous infusion (IV).
45958180|NCT05039099|Drug|Placebo|Participants receive placebo by IV.
45958181|NCT05036447|Other|Moderate-Heavy Resistance Exercise|"Leg press: 3 x 8 repetitions at 75% of 1 repetition maximum, 3 minutes rest between sets.~Knee extension: 3 x 6 repetitions at 85% of 1 repetition maximum, 3 minutes rest between sets."
45958182|NCT05032859|Drug|tapinarof cream, 1%|applied topically once daily
45958183|NCT05032859|Drug|vehicle cream|applied topically once daily
45958184|NCT05029128|Behavioral|Endurance exercise intervention|All participants engage in treadmill walking 4 days/week, 60 minutes/day, at 70-80% of HRmax for 4 weeks.
45958185|NCT05028140|Drug|PIEMONTE|Piemonte association 1 coated tablet once a day
45958186|NCT05028140|Other|PIEMONTE PLACEBO|Placebo of Piemonte association 1 coated tablet once a day
45958187|NCT05028140|Drug|EMPAGLIFLOZIN|Empagliflozin 25 mg 1 coated tablet once a day
46079268|NCT05708625|Procedure|Intralesional Cryotherapy|Intralesional Cryotherapy. Sessions will be held every two weeks
46079269|NCT05708625|Drug|Intralesional Voriconazole|Weekly intralesional Voriconazole
45818071|NCT04058587|Drug|Simmitinib|"The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days)."
45818072|NCT00375271|Procedure|perioperative hemodynamic optimization protocol|
45818073|NCT00375349|Procedure|Ultrasound to demonstrate existence of fatty liver|
45818074|NCT03865615|Drug|Oxytocin|intranasal oxytocin 40IU/mL
45958188|NCT05028140|Other|PLACEBO EMPAGLIFLOZIN|Placebo of empagliflozin 25 mg 1 coated tablet once a day
45958189|NCT05028140|Drug|PIOGLITAZONE|Pioglitazone 30 mg 1 tablet once a day
46079270|NCT05708625|Drug|Oral doxycycline|200 mg daily for 6 weeks or till complete cure
46079271|NCT05706844|Drug|Spinal anesthesia|plain or heavy Bupivacaine hydrochloride 10 mg (2 mL) injected in the spinal canal
46079272|NCT05706844|Drug|General anaesthesia|Propofol (induction: 1.0-2.0 mg/kg. infusion: 3-5 mg/kg/hour) + Remifentanil (induction: 3-5 mcg/kg, infusion: 0.5 mcg/kg/min) given intravenously
45958190|NCT05028140|Other|PLACEBO PIOGLITAZONE|Placebo of pioglitazone 30 mg 1 tablet once a day
45958191|NCT05027516|Drug|Rocephin|Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection
45958192|NCT05027516|Drug|Azithromycin|Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection + single dose of azithromycin 2g orally
45958193|NCT05025670|Behavioral|Supportive psychotherapy|Participants will receive monthly 30-45 minute supportive psychotherapy sessions. Supportive psychotherapy is an integrative and eclectic psychotherapeutic approach, based upon the individual's needs and symptoms. It draws from elements of a variety of psychotherapeutic disciplines, including cognitive-behavior, psychodynamic, and interpersonal therapies.
45958194|NCT04992013|Drug|Niraparib|Capsule taken by mouth
46002262|NCT04156347|Drug|Episcleral Topotecan|Transscleral Topotecan
46079273|NCT05706012|Other|Survey|Online survey questioning the current clinical practice on long-term antithrombotic management of AMI in SBS patients
46079274|NCT05702827|Drug|Bupivacaine-Meloxicam|All patients will receive standard of care but the study arm will also receive Bupivacaine-Meloxicam in addition.
46079275|NCT05702788|Drug|Jaktinib hydrochloride tablets|75mg of Jaktinib administered orally Twice daily(BID) with best available treatment.
46079276|NCT05702788|Drug|Jaktinib hydrochloride tablets|100mg of Jaktinib administered orally Twice daily(BID) with best available treatment.
45818075|NCT03865615|Drug|Placebo|Placebo
45958195|NCT04975789|Other|InfoViz|The pain InfoViz tool is a two-page paper tool that consists of an explanation of how to use the tool in both Hmong and English, a culturally-appropriate Faces pain severity scale, pain body diagram, and 13 pain qualities in the form of icons representing each pain quality metaphor. The interpreter explains the instructions in Hmong, then marks the body areas corresponding to the location of pain reported by the participant, and marks the pain qualities expressed by the metaphors selected by the Hmong patient. In the clinic appointment, the interpreter communicates to the physician, in English, the pain location and qualities identified by the participant, using the medical terms identified on the InfoViz tool.
45664021|NCT02402647|Behavioral|CREST|"Compensatory Cognitive Training is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET."
45958196|NCT04969263|Biological|mRNA-1273 vaccine (Pfizer/BioNTech)|30 microgram dose
45958197|NCT04969263|Biological|mRNA-1273 vaccine (Moderna)|100 microgram dose
45958198|NCT04957953|Other|Patient's consent|Primary enrolment will be carried out at the time of vaccination at the main vaccination sites, with the patient's consent. The agreement form filled in online includes the surname, first name, month and year of birth. This form serves as an agreement to participate in the study.
45958199|NCT04957953|Other|Inclusion form|"This form includes the date of the last menstrual period, vaccination data (type of vaccine, date of vaccination, 1st or 2nd injection, etc.), socio-demographic data of the pregnant woman, medical and surgical history, gynaecological and obstetrical history, a description of the current pregnancy, and the medication taken by the patient during her pregnancy....~A link to complete this form (with the unique identifier) will be sent to each woman included who has given her consent to participate."
45958200|NCT04957953|Other|Adverse reaction report form.|One month after each injection of the vaccine, information will be collected on any vaccination-related adverse reactions that may impact the pregnancy (fever, hypertension, etc.) or on the onset of a Covid-19 infection,
45818076|NCT03180385|Device|Neurally-Adusted Ventilatory Assist (NAVA)|Delivery of positive pressure is based on the electrical activity of the diaphragm (Edi) via a nasogastric (NG) catheter that is placed on the phrenic nerve, which runs along the esophagus. This results in synchronous ventilation for the patient.
45818077|NCT03180385|Device|Biphasic Positive Airway Pressure Support (BiPAP)|Conventional form of non-invasive respiratory support that does not deliver positive airway pressure in a synchronous fashion.
45958201|NCT04957953|Diagnostic Test|Follow-up report form.|In the 2 months following the expected delivery date, information will be collected on the outcome of the pregnancy (delivery, spontaneous abortion, etc.) and maternal clinical signs (pre-eclampsia, gestational hypertension, gestational diabetes, etc.). Before sending the link to this form, information will be sent to the second holder of parental authority. In the absence of opposition, data on the newborn will be collected (sex, height, weight, head circumference, Apgar, malformation, neonatal pathology, etc.)
45958202|NCT04957394|Behavioral|Family Partner|"The Family Partner intervention is based on well-known elements for preventing child abuse and neglect, such as 1) high intensity intervention with home visitations, 2) coordination of services, 3) an ecological perspective, 4) parental guidance, and 5) an emphasis on a therapeutic relationship with parents to create trust, change and agency.~Family Partners must have relevant professional background and education, such as social work, child welfare services and other health/welfare occupations. They must have a personal attitude for relation-based service delivery in a home-setting, a long work experience and in-depth knowledge of municipal welfare services.~Each practitioner will follow five families. The estimated duration of the intervention is 12 months, but might go over longer stretches of time if it is considered beneficial for the families. The minimum duration of the intervention is 3 months."
45958203|NCT04947124|Drug|QLS-101ophthalmic solution 1%|QLS-101ophthalmic solution 1.0%
45958204|NCT04947124|Drug|QLS-101ophthalmic solution 2%|QLS-101ophthalmic solution 2.0%
45958205|NCT04938908|Drug|Ophthalmic Probiotic|Bacterial lysate of Lactobacillus sakei, hydroxypropylmethylcellulose (HPMC), boric acid, sodium chloride, purified water.
45664022|NCT02402647|Behavioral|ET|The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
45664023|NCT00752583|Procedure|Peritoneal dialysis|Blood, urine and dialysate sampling
45958206|NCT04938908|Drug|Opthalmic Placebo|Placebo contains complete formulation of the active drug except for bacterial lysate of Lactobacillus sakei (i.e. HPMC, boric acid, sodium chloride, purified water)
45958207|NCT04938908|Dietary Supplement|Oral Probiotic Capsule|Live Lactobacillus sakei (5 billion cfus) in hydroxypropylmethylcellulose hard capsule, with maltodextrin excipient
45958208|NCT04938908|Dietary Supplement|Oral Placebo Capsule|Hydroxypropylmethylcellulose hard capsule, filled with maltodextrin excipient
45958209|NCT04933630|Drug|FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)|Participants exiting the TRAIT study will have received a 90-day supply of their current protocol-approved antidepressant treatment (ADT) if clinically appropriate, prior to entering the TRAIT-RS study, in addition to a continuity of care letter to be given to their medical provider to facilitate a refill of that medication as desired. (See NCT04748276 for specific formulary and prescribing guidelines).
45958210|NCT04923841|Other|High intensity light box for bright light therapy and single vision spectacle lenses|High intensity light box for bright light therapy and single vision spectacle lenses
45958211|NCT04923841|Other|High intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses|High intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses
45958212|NCT04923841|Other|High intensity light box for bright light therapy and atropine 0.01% eye drop and and single vision spectacle lenses|High intensity light box for bright light therapy and atropine 0.01% eye drop and and single vision spectacle lenses
46079277|NCT05702788|Other|Placebo|Placebo (given as two placebo tablets) administered orally BID with best available treatment.
46079278|NCT05700578|Behavioral|Safety Behavior Elimination for Traumatic Stress (SBETS)|This intervention took 30 minutes to complete. At the end of the intervention, participants were instructed to select two of their most commonly-used trauma-related safety behaviors to reduce or eliminate over the coming month.
46079279|NCT05700578|Behavioral|Modifiable Behavior Intervention (MoBI)|The intervention took 30 minutes to complete. At the end of the intervention, participants were instructed to select two of their most commonly-used unhealthy behaviors to reduce or eliminate over the coming month.
45664024|NCT00752583|Procedure|Haemodialysis|Blood, urine and dialysate sampling
45664025|NCT02198235|Drug|Dexamethasone|
45818078|NCT03859297|Behavioral|Rumination-Focused CBT|"RF-CBT targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effectively coping with rumination. RF-CBT specifically targets rumination through psychoeducation, adopting a functional analytic approach to the learned habitual behavior of rumination, and a focus on shifting process style. The adolescent is taught to notice triggers to ruminate as well as the consequences of rumination and to shift into practicing a more adaptive strategy such as an attention training exercise, behavioral activation, thinking in a concrete way, or active problem-solving. RF-CBT directly teaches adolescents to recognize rumination or when the participant gets stuck in their head and to notice the influence this has on their mood."
45958213|NCT04923841|Other|Atropine 0.01% eye drop and and single vision spectacle lenses|Atropine 0.01% eye drop and and single vision spectacle lenses
45958214|NCT04907656|Behavioral|dCBT|As per arm of the same name
45958215|NCT04906642|Device|Next Science|Solution is a clear, colorless, aqueous solution that is used to remove debris, including microorganisms, from wounds via hydrodynamic shear across the wound. This aids in the removal of foreign material such as, microorganisms, dirt, and debris.
46079280|NCT05700396|Behavioral|Breast Cancer Survivor Education Program|Weekly sessions via Zoom platform with study staff.
45455096|NCT03936595|Other|Core exercises protocol|"Participants will perform:~Squats, 4 sets of 5 repetitions at 60% 1RM~Deadlifts, 4 sets of 5 repetitions at 60% 1RM~Lunges, 4 sets of 5 repetitions at 60% 1RM~Step ups, 4 sets of 5 repetitions at 60% 1RM"
45664026|NCT02198235|Drug|Buprenorphine|
45664027|NCT04917133|Behavioral|Adapted Physical Activity program|classic 4-week rehabilitation program (standard care) + 6 APA workshops per week with collective care
45664028|NCT04917133|Other|Control|classic 4-week rehabilitation program (standard care)
45664029|NCT00408291|Procedure|Winsta PH osteosynthesis device|The Winsta PH osteosynthesis device have been developed for use in treatment of proximal humerus fractures.
45958216|NCT04906642|Other|Standard of Care|Normal Saline will be used in place of Next Science for irrigation
45958217|NCT04898127|Diagnostic Test|SARS-CoV-2 antigen rapid test|Rapid test before access to mass gathering event (concert), provided the test result is negative.
45958218|NCT04896606|Other|Standard of Care|Patients will receive standard of care for COVID-19.
45958219|NCT04896606|Biological|SARS-CoV2-CTLS|Patients may receive up to 5 CTL infusions to treat SARA-CoV-2 in combination with standard of care.
45664030|NCT04916431|Drug|mRNA-6231|Sterile frozen liquid dispersion for injection
45958220|NCT04888832|Other|Work requirement exemption months|Cross-randomized intervention will test effect of additional exemption months before work requirements in SNAP become binding and extensions of the standard SNAP recertification period.
45958221|NCT04881630|Behavioral|Automated Mobile Contingency Management (CM)|Financial incentives contingent upon smoking abstinence
45958222|NCT04881630|Other|Standard Care (SC)|Tobacco cessation telephone counseling and combination nicotine replacement therapy (nicotine patches + nicotine gum/lozenges)
45958223|NCT04880863|Drug|NAP (Naptumomab estafenatox)|Naptumomab estafenatox (NAP; ABR-217620) is a recombinant fusion protein consisting of a chimeric staphylococcal enterotoxin A/E (SEA/SEE) superantigen with several additional substitutions that is linked to a Fab moiety recognizing a tumor-associated glycoprotein, 5T4. NAP will be administered in a dose of 10 μg/kg/day by IV bolus on Days 1 - 4 of treatment cycles 1-6. Starting cycle 7, NAP at a higher dose of 15 μg/kg will be administered on Day 1.
45958224|NCT04880863|Drug|Docetaxel|Docetaxel is administered in combination with the study drug, NAP, on Day 5 of the treatment cycles 1-6. Starting cycle 7, Docetaxel will be administered in combination with the study drug, NAP, on Day 2.
45958225|NCT04880863|Drug|Obinutuzumab|Obinutuzumab is administered as pre-medication on Day -13 and -12 of the first treatment cycle.
45958226|NCT04880629|Behavioral|Baseline condition|In the baseline sleep condition, participants are instructed not to restrict their sleep on the night before completing an oral glucose tolerance test (OGTT). Participants are prescribed sleep-wake timings based on their preferred and averaged sleep durations measured over 2 weeks using a wearable sleep tracker. Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
45958227|NCT04880629|Behavioral|Sleep restriction condition|In the sleep restriction condition, participants are prescribed sleep timings to restrict their sleep by 1 to 2 hours on the night before completing an oral glucose tolerance test (OGTT). Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
45958228|NCT04875338|Drug|plate-rich plasma|1ml prp (plate-rich plasma to be prepared with the blood taken from the patient on the day of injection), , while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
45958229|NCT04875338|Drug|saline (0.9 NACI)|1 ml saline (0.9 NACI) while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
45958230|NCT04875338|Drug|betametazon|1 ml betametazon while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
45958231|NCT04869098|Dietary Supplement|whey protein|Protein drink containing 30g whey protein isolate powder (dissolved in water) consumed 1-1.5 hr prior to their main evening meal every day for 12 days, No other advice will be given.
45958232|NCT04869098|Dietary Supplement|Placebo|Energy-matched mixed-nutrient placebo drink consumed 1-1.5 hr prior to their main evening meal every day for 12 days. No other advice will be given.
45958233|NCT04861987|Drug|PCS6422 and capecitabine|PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer. Capecitabine is a commonly used oral fluoropyrimidine.
45958234|NCT04861792|Behavioral|Michigan SPARC Quality Improvement Intervention|Practice facilitation, electronic health record (EHR) support, performance monitoring and feedback combined with alcohol-related continuing medical education (CME) and maintenance of certification (MOC) and tools to support alcohol related care including a decision aid for shared decision making about alcohol use disorder (AUD).
45664031|NCT00346125|Biological|pegfilgrastim|will be given at 6 mg subcutaneously (SC) at the end of the mesna infusion
45664032|NCT00346125|Drug|doxorubicin hydrochloride|65 mg/m^2 by continuous intravenous (IV) infusion over 7 days beginning on day 1
45664033|NCT00346125|Drug|ifosfamide|9 g/m^2 by continuous intravenous (IV) infusion over 6 days beginning on day 1 with mesna 10.5 g/m^2 by continuous IV infusion over 7 days beginning on day 1
45958235|NCT04855006|Biological|Vaginal Microbiome Transplant|Vaginal Microbiome Transplant is given at least once and up to three times. The transplant is admitted with a syringe
45664034|NCT00346125|Drug|pegylated liposomal doxorubicin hydrochloride|45 mg/m2 intravenous (IV) Day 1, repeat every 28 days.
45664035|NCT00346125|Procedure|conventional surgery|The surgical procedure will be decided by the treating physician and independent of study participation
45664036|NCT00346125|Radiation|fludeoxyglucose F 18|FDG is a radioactive sugar equal to a uniform whole-body exposure of approximately 1.5 rem for each scan. Post-operative radiation therapy may be given according to institutional guidelines in patients felt to have close surgical margins.
45664037|NCT04929379|Drug|Fenofibrate|145 mg oral fenofibrate daily for 76 weeks. Dosage is decreased to 48 mg daily if iGFR is or is estimated to be below 30 ml/min/1.73 m2.
45664038|NCT04929379|Other|Placebo|Inactive tablets identical to fenofibrate
45664039|NCT04418349|Procedure|"posterior component separation modified TAR technique Transversus Abdominids Release"|"Evaluation of posterior component separation modified TAR technique Transversus Abdominids Release in the treatment of parastomal hernia"
45958236|NCT04855006|Biological|Vaginal Microbiome Transplant Placebo|Vaginal Microbiome Transplant Placebo is given at least once and up to three times. The transplant Placebo is admitted with a syringe
45958237|NCT04855006|Other|No intervention|Donors have no intervention. This group deliver the transplant to arm 'Vaginal Microbiome Transplant'.
45958238|NCT04838808|Drug|Rivaroxaban 2.5 MG [Xarelto]|Rivaroxaban 2.5mg twice daily for 90-days
45958239|NCT04838808|Drug|Placebo|Placebo tablet twice daily for 90-days
45455097|NCT03936595|Other|Structural exercises protocol|"Participants will perform:~Snatch, 4 sets of 5 repetitions at 60% 1RM~Hang clean, 4 sets of 5 repetitions at 60% 1RM~Push jerk, 4 sets of 5 repetitions at 60% 1RM~Split push jerk, 4 sets of 5 repetitions at 60% 1RM"
45958240|NCT04834726|Behavioral|Opt-In (Call-Back)|Messaging will include a prompt to agree to scheduling. If patient agrees, the access center will call these patients back to schedule, calling up to 3 times.
45958241|NCT04834726|Behavioral|Opt-in (In-Bound)|Messaging will include a prompt to agree to scheduling followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
45958242|NCT04834726|Behavioral|Standard Message|The message describes that the patient is eligible for the COVID vaccine.
45958243|NCT04834726|Behavioral|Clinician Endorsement|The message will describe an endorsement from the provider to get the vaccination.
45958244|NCT04834726|Behavioral|Scarcity|The message will highlight the limited availability and the elevated priority for the patient to receive the vaccine at Penn Medicine.
45958245|NCT04834726|Behavioral|Opt-Out Framing|This will highlight that a vaccine is reserved for the patient, implying that they need to opt-out.
45818079|NCT03859297|Behavioral|Relaxation-based Therapy|Sessions will include progressive muscle relaxation, simple breathing techniques, and guided imagery that focus on bodily and somatic relaxation. Adolescents randomized to Relaxation Therapy (RelaxT) will also receive exercises to do as homework in between sessions, parallel to the RF-CBT group.
45958246|NCT04834726|Behavioral|Phone Call|The access center will call these patients to schedule their vaccine appointment. These patients will not receive text messaging.
45958247|NCT04832750|Device|intermittent theta burst stimulation (iTBS) or sham stimulation|30 sessions of iTBS over 2 weeks (3 sessions per day, 5 days per week)
45958248|NCT04829110|Other|ETOH|Participants will consume Vodka
45958249|NCT04829110|Other|Sucrose|Participants will consume sucrose in solution with water
45958250|NCT04805658|Diagnostic Test|Clinical examinations|Clinical examinations
45958251|NCT04803877|Drug|Regorafenib 40 MG|For subjects age 18 and older, Regorafenib will be administered as 80mg oral once daily on Cycle 1, Days 1-7 and then escalated to 120 mg once daily for Cycle 1, Days 8-21 if no Grade 2 or above regorafenib adverse events occur. For subsequent cycles, the highest tolerated dose will be taken once daily on days 1-21 of each 28-day cycle.
45958252|NCT04803877|Drug|Regorafenib 20MG|For subjects younger than 18 years, Regorafenib will be administered as 60mg/m2/dose (rounded to the nearest 20mg, maximum dose of 80mg) once daily for Cycle 1, Days 8-21 if no Grade 2 or above regorafenib-related adverse events occur. For subsequent cycles, the highest tolerated dose will be taken once daily on days 1-21 of each 28-day cycle.
45958253|NCT04803877|Drug|Nivolumab|"For subjects age 18 and older, Nivolumab will be administered at 480mg IV over 30 min every 28 days.~For subjects younger than 18 years, Nivolumab 3mg/kg (maximum dose 240mg) will be administered IV over 30 minutes on day 1 and 15 of each 28-day cycle."
45818080|NCT03735823|Other|No intervention, just collect blood samples and CSF samples|No intervention
45958254|NCT04792502|Drug|Mosunetuzumab|Administered subcutaneously by injection beginning with 5 mg and increasing to 45 mg.
45455098|NCT03936595|Other|Accentuated eccentric load exercises protocol|"Participants will perform:~Deadlifts - squat jump, 4 sets of 5 repetitions at 30% body mass (BM)~Step down - squat jump, 4 sets of 5 repetitions at 30% BM~Step down - lunges, 4 sets of 5 repetitions at 30% BM~Hip thrusts, 4 sets of 5 repetitions at 30% BM"
45455099|NCT03936595|Other|Control condition|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
45455100|NCT03787615|Device|sipIT tools|Just in time drinking detection tools to promote increase fluid consumption
45958255|NCT04792502|Drug|Lenalidomide|Patients in the augmentation cohort will be dosed continuously, 10 mg orally once daily, with or without food.
45958256|NCT04781842|Other|Boxing exercise program|Participants attended an hour long class once a week for 12 weeks. Included in class was a warm up, boxing activities including weight shifting, kicking, and punching bags, strengthening activities and a cool down.
45958257|NCT04777422|Drug|Defibrotide|Defibrotide 6.25 mg/kg IV q6h up to 7 days
45455101|NCT01345214|Drug|ONO-7746|10mg, 20mg, 50mg, 100mg, 200mg and 300mg once-daily for 14 days
45455102|NCT01120873|Drug|Metamin 3D|Metamin 3D is composed by red yeast rice, bitter gourd, chlorella, soy peptide and licorice extract is a commercial product designed by Uni-President enterprises corp in Taiwan
45455103|NCT04070456|Other|Tablet-based SDH tool|A tablet-based SDH tool, which integrates responses into the EpicCare electronic health record (EHR).
45818081|NCT03185546|Other|NNC Spectrum Cigarette|Participants are provided with normal nicotine content Spectrum Cigarette for 13 weeks.
45818082|NCT03185546|Other|VLNC Spectrum Cigarette|Participants are provided with very low nicotine content Spectrum Cigarette for13 weeks
45818083|NCT03185546|Other|Moderate nicotine level e-liquid|Participants are provided with moderate nicotine level e-liquid for 13 weeks
45818084|NCT03185546|Other|Low nicotine level e-liquid|Participants are provided with very low or nicotine-free nicotine level e-liquid for 13 weeks
46002263|NCT04129086|Drug|Ketamine plus usual care|Bolus of .35 mg/kg Infusion start @ 0.15 mg/kg/hr; titrate range is 0.1 - 0.25 mg/kg/hr for 24 to 48 hours after admission and each subsequent major surgery plus multi-modal pain therapy considered as standard of care. Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
46002264|NCT04129086|Drug|Usual Care|Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
46002265|NCT04117685|Other|Observational|All groups will undergo observational data collection. No interventions will be made to patient care.
45958258|NCT04770363|Device|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is an emerging non-invasive brain stimulation technique which has been utilized in examining cortical function in healthy subjects and also showed significant outcome in neurological rehabilitation. A safe, portable, noninvasive painless, reversible, selective and focal brain stimulation technique, applied by sponge electrodes over the scalp. tDCS is capable of modulating the excitability of targeted brain zones through delivering a sustained direct current (DC), showed altering neuronal membrane potentials based on the polarity of the current. Researchers demonstrated modulating effects of anodal (increases cortical excitability) and cathodal (decreases cortical excitability) tDCS on brain tissue. The expected effects of tDCS brain stimulation exceeds the duration. Animal studies showed neuronal depolarization and increasing neuronal excitability of the anodal stimulation, and opposite results with cathodal stimulation.
45958259|NCT04766892|Drug|mavacamten|mavacamten capsules
45958260|NCT04766021|Drug|Mirabegron|Dose-response effect on thermogenesis
45958261|NCT04766021|Drug|Placebo|Placebo control condition
45958262|NCT04762251|Other|Time-restricted eating|Time restricted eating for a self-selected 9 hour window per day
45958263|NCT04762251|Other|Current Best Practice|Best practice guidelines to improve diet quality
45958264|NCT04761198|Drug|Etigilimab dosing|IV infusion of IV etigilimab every 2 weeks
45455104|NCT03110068|Diagnostic Test|contrast-enhanced ultrasound|The Aplio SSA-770A or Aplio 500 (Toshiba Medical Systems, Tokyo, Japan) equipped with a 375BT convex transducer (frequency range, 1.9 to 6.0 MHz). CHI is used with a mechanical index that ranged from 0.06 to 0.10. After activating CHI mode, a bolus injection of 2.4 ml of SonoVue (Bracco, Milan, Italy) is administered intravenously via an antecubital vein, followed immediately by a flush of 5 ml of normal saline solution. The targeted lesion should be observed continuously for 5 minutes, and the entire arterial and portal venous phases and several repetitions of the late phase are stored on the hard disk. The arterial, portal venous and late phases are defined as 0-30 s, 31-120 s and 121-360 s after the injection, respectively.
45458213|NCT01235221|Drug|BIIB041 (Fampridine-SR)|10 mg twice a day (BID) sustained-release (SR) tablets by mouth for up to 27 months (in addition to treatment in previous studies) or until the product is commercially available, whichever comes first. Doses of study treatment must be spaced at least 12 hours apart.
45958265|NCT04761198|Drug|Nivolumab|IV infusion of nivolumab every 2 weeks
46002266|NCT04108156|Drug|PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
46002267|NCT04108156|Drug|Intravitreal Ranibizumab 0.5 mg Injection|Will be administered as per the schedule described in individual arm.
46002268|NCT04103632|Diagnostic Test|EVH test|"Spirometry~Skin prick test~Peripheral blood test~FeNO measurement"
45458214|NCT03505450|Other|Population Sample|full sample of recruited participants
45458215|NCT03505450|Other|Purposive sample|purposive sample of recruited participants
45664040|NCT02253147|Device|TEOSYAL® RHA Ultra Deep|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27Gauge ½ disposable sterile needles."
45664041|NCT02217501|Drug|Clopidogrel|Clopidogrel 75 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
45818085|NCT03185546|Other|Tobacco Flavors|Participants can choose e-liquid flavors from a selection of tobacco flavors
45818086|NCT03185546|Other|Tobacco and non-tobacco e-liquid flavors|Participants can choose e-liquid flavors from a selection of flavors that includes tobacco and non-tobacco choices
45818087|NCT05365009|Diagnostic Test|Multidisciplinary aproach|regular tests
45818088|NCT05364853|Behavioral|In-Person Testing|Participants will be randomly assigned to have either in-person testing of the DAYC-2 conducted. They will then cross over into the other testing condition approximately 3 weeks after their first assessment.
45818089|NCT05364853|Behavioral|Remote Testing|Participants will be randomly assigned to have either remote testing of the DAYC-2 conducted. They will then cross over into the other testing condition approximately 3 weeks after their first assessment.
45958266|NCT04748276|Drug|FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)|Protocol-approved antidepressant treatments (ADT) will be prescribed in accordance with standard of care, whenever possible following dosing recommendations within the Study Formulary and Prescribing Guidelines (Sertraline 100 mg/day; Citalopram 20 mg/day; Escitalopram 10 mg/day; Fluoxetine 20 mg/day; Paroxetine 20 mg/day; Duloxetine 60 mg/day; Buproprion 300 mg/day; Desvenlafaxine 50 mg/day; Venlafaxine 150 mg/day). ADTs may be up or down-tapered as necessary.
45958267|NCT04732949|Drug|SNG001|SNG001 nebuliser solution, 2 syringes each containing 0.65 mL once a day
45958268|NCT04732949|Drug|Placebo|Placebo nebuliser solution, 2 syringes each containing 0.65 mL solution containing excipients of the SNG001 solution
45958269|NCT04685239|Device|dual mobility cup|The use of a Sunfit dual mobility cup
45958270|NCT04685239|Device|unipolar cup|The use of a TMT cup
45958271|NCT04684147|Biological|single dose of CNCT19|Dose: 0.5 x 10^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
45958272|NCT04659811|Drug|Pembrolizumab|200mg given intravenously (IV) on day 1 (to -1) of radiation and then every 3 weeks until progression or unacceptable toxicity
45958273|NCT04659811|Procedure|Stereotactic Radiosurgery|Given in (a) single session treatment with margin dose of 15-20 Gy to the target for a maximum target volume of 8 cc or (b) five consecutive business days treatment to total dose of 25-30 Gy to the target for a maximum target volume of 20 cc when the target volume exceeds 8 cc or the target is in proximity to critical structures
45958274|NCT04637776|Other|Hospitalization|Hospitalization for any reason
45958275|NCT04632498|Behavioral|Mindfulness Based Intervention|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
45958276|NCT04625504|Behavioral|Mindfulness Based Intervention|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
45958277|NCT04610658|Drug|Nivolumab|Participants will receive 1 mg/kg Nivolumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 treatment cycles, Nivolumab will be continued at a flat dose of 360 mg.
45958278|NCT04610658|Drug|Ipilimumab|Participants will receive 3mg/kg Ipilimumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 cycles, Ipilimumab will be discontinued.
45958279|NCT04610658|Drug|Lurbinectedin|Participants will be treated at 1 of 3 dose levels of Lurbinectedin, beginning at 1.5 mg/m^2 and increasing to 3.2 mg/m^2 or the Maximum Tolerated Dose (MTD)
45958280|NCT04595994|Drug|Selinexor|For both interventional ( Selinexor and Gencitabine) Dose-limiting toxicity (DLT) will be applied only to either of the following toxicities occurring during the first treatment cycle (days 1-21).
45958281|NCT04593264|Other|Self-guided pre-habilitation exercise program|A set of self-guided exercises developed by an athletic trainer to perform at home in order to optimize the knee for ACL repair surgery
45958282|NCT04593264|Other|Traditional pre-habilitation|Pre-habilitation exercise sessions under the direct supervision of a physical therapist.
45458216|NCT03505294|Other|Task-oriented training|"Task-oriented training consisting of 10 different motor tasks including lower extremity and upper extremity activities will be applied to the training group twice a week for 6 weeks."
45818090|NCT05364463|Procedure|Methods for cannulating the radial artery in a cardiac catheterization|The puncture will be performed in each participant according to the method has been assigned randomly: ultrasound and hyperemia, ultrasound only, hyperemia only, palpation.
45818091|NCT05058482|Device|embolism|Cerebral arteriovenous malformation embolism
45818092|NCT03657511|Behavioral|Educational Interventions to Promote Tobacco Cessation|"Women receiving a screening mammogram at KCI downtown and McLaren Macomb, will be given a self-administered questionnaire at check-in.~Women who indicate they are current smokers are eligible for the study. After the screening mammogram is complete, eligible women will be consented. Educational materials will be provided to the participant at that time. The materials provided outline evidence-based approaches to smoking cessation and include contact information for local resources including cessation support groups, Michigan Tobacco Quitline, American Cancer Society's Guide to Quitting Smoking, Quitnet, Smokfree.gov and Become An Ex. The participant will be contacted by telephone approximately 12 weeks later to determine if she is currently smoking or had quit in the last 12 weeks."
45818093|NCT04613882|Device|Soft Toric Custom Made Contact lens|Subjects will be randomized to wear soft toric custom made lenses for 30 minutes in one eye with other eye patched.
45818094|NCT04613882|Device|Soft Spherical Contact Lenses|Subjects will be randomized to wear soft spherical contact lenses for 30 minutes in one eye with other eye patched.
45818095|NCT04613882|Device|Spectacle Correction|Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.
45958283|NCT04587791|Drug|400mg Cannabidiol|Participants will receive 400mg
45958284|NCT04587791|Drug|800mg Cannabidiol|Participants will receive 800mg
45958285|NCT04587791|Drug|1200mg Cannabidiol|Participants will receive 1200mg
45958286|NCT04587791|Drug|Saline|Participants will receive saline
45958287|NCT04586478|Biological|single dose of CNCT19|Dose: 2.00 x 10^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
46002269|NCT04081298|Behavioral|Health Education|Attend nutrition and PA classes, and cooking sessions
45958288|NCT04538066|Drug|Bryostatin 1|Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
45958289|NCT04538066|Other|Placebo|Placebo administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
45958290|NCT04532918|Drug|Verinurad|The subjects will receive single oral dose of extended release capsule verinurad 7.5 mg on Day 1 of each treatment period under fasted condition.
45455105|NCT03110068|Diagnostic Test|contrast-enhanced computed tomography|The Aquilion 64-slice helical CT machine (Tokyo, Japan) is used. The imaging protocol for CT examinations is as follows: 0.5 mm × 64 mm collimation, 120 kV, 150-200 mAs for 64-slice helical CT examination. The standard triphasic scan procedure is used. An unenhanced helical sequence scan through the liver will be performed first; thereafter nonionic iodinated contrast material (Ultravist, Schering, Berlin, Germany) (1.5 mL/kg) will be administered via antecubital vein with power injection at a rate of 4 mL/s for 64-slice helical CT. The arterial phase sequence is obtained 25-32 s after contrast material administration, followed by a portal venous phase sequence 70 s after contrast agent administration.
45664042|NCT02217501|Drug|Acetylsalicylic acid (ASA)|Acetylsalicylic acid (ASA) 75-100 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
45664043|NCT01649869|Other|Placebo|Simple Syrup as 60-90% sucrose in purified water: given orally twice a day for 6 weeks
45455106|NCT03620396|Procedure|Scaling and root planing|After the serum collection is done from the patient for the assessment of trefoil factor 3, Non surgical periodontal therapy is carried out.
45455107|NCT03784963|Drug|Omega 3 fatty acids|Patients will receive 4 grams fish oil once daily
45664044|NCT01649869|Drug|Valganciclovir|Valcyte (valganciclovir hydrochloride) 50 mg of valganciclovir free base per 1 mL, oral solution: given at 16.0 mg/kg, twice a day for 6 weeks.
45818096|NCT03713203|Device|pagetex PDT|2 to 4 sessions of PDT treatment during 2.5 hours after application of Metvixia and incubation under occlusive coat.
45455108|NCT03784963|Other|Placebo|Standard of care
45455109|NCT04365998|Device|BUBOLight® Device|1 session of phototherapy with BUBOLight® device during 4 hours.
45455110|NCT04467892|Drug|methylprednisolone|received high dose (30 mg/kg) methylprednisolone slowly intravenous in 250 ml normal saline every 8 hours for only 4 days
45664045|NCT02197377|Device|Group LMA Unique™|The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
45664046|NCT02197377|Device|Group LMA Supreme™|The supraglottic airway devices were deflated fully before insertion.The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
45664047|NCT02400307|Drug|Bictegravir|75 mg tablet administered orally
45664048|NCT04927897|Diagnostic Test|Ultrasound|3D endorectal ultrasound.
45664049|NCT04927897|Diagnostic Test|Rectoscopy|Rigid rectoscopy.
45664050|NCT04927897|Other|Scan, e.g. CT (resection specimen)|For some patients, images of the resection specimen (note: NOT of the patients) during the pathological process will be acquired.
45818097|NCT02186652|Drug|Pantoprazole|
45818098|NCT03677791|Other|Virtual tour in coronary computed tomography - 360° counselling environment|Virtual tour in coronary computed tomography - 360° counselling environment for CCTA patients
45818099|NCT03677791|Other|Current practice|counselling in accordance with current practice: written patient information letter and verbal counselling at the hospital during the CT-examination
45958291|NCT04532918|Drug|Allopurinol|The subjects will receive single oral dose of tablet allopurinol 300 mg on Day 1 of each treatment period under fasted condition.
45958292|NCT04532918|Drug|Cyclosporine|The subjects will receive single oral dose of soft capsule cyclosporine 600 mg on Day 1 of treatment period 2 under fasted condition.
45958293|NCT04532918|Drug|Rifampicin|The subjects will receive single oral dose of film coated tablets rifampicin 600 mg on Day 1 of treatment period 3 under fasted condition.
45958294|NCT04527146|Other|IMAGINE-PD|The Interactive, Multimedia Approach to Genetic Counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) is a novel, interactive, web-based, audiovisual, self-guided, genetic counseling tool in the development phase. Essential genetic counseling themes, outlined by a senior certified clinical genetics counselor in accordance with national guidelines, are presented in a web-based format, utilizing videos, text, pictures, and audio. Participants can interact with IMAGINE-PD at their own pace, with the ability to move backward and forward, repeat sections, and have the ability to submit questions to the genetic counselor via e-mail.
46002270|NCT04081298|Other|Physical Activity|Participate in physical activities
45958295|NCT04527146|Other|Virtual genetic counseling|The virtual visits will be conducted by a certified genetic counselor to provide all counseling in accordance with guidelines set forth by the National Society of Genetic Counselors. The counseling visit will be conducted in real-time on an established and secure audiovisual conferencing telemedicine platform (BlueJeans) within the PennChart/EPIC electronic medical record dashboard.
45958296|NCT04527146|Other|Telephone genetic counseling|The telephone counseling will be conducted by a certified genetic counselor to provide all counseling in accordance with guidelines set forth by the National Society of Genetic Counselors.
45818100|NCT03187418|Device|MicroPulse® P3 Glaucoma Device (MP3)|"Laser settings will be programmed as follows: power-2000mW-2500mW (average 2000mW) of 810nm infrared diode laser set on micropulse delivery mode; micropulse on time-0.5ms; micropulse off time-1.1ms; and duty cycle (proportion of each cycle during which the laser is on)-31.33 %.~The laser probe will be applied in a continuous sliding or painting motion from 9:30 to 2:30 and from 3:30 to 8:30. The probe will be applied perpendicular to the limbus with the edge directly on the limbus at all times (fiberoptic tip at 3 mm posterior to the limbus).~The laser will be delivered over 360° for 160-320s. Treatment duration will be adjusted based on iris color and glaucoma severity (mild glaucoma: 160s, moderate glaucoma: 240s, advanced glaucoma: 240-320s)."
45958297|NCT04511247|Device|MagicTouch PTA Sirolimus drug coated balloon|For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion (defined as <30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
45958298|NCT04511247|Device|POBA balloon|For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty
45958299|NCT04487860|Drug|AS012|oral administration
45664051|NCT02196675|Device|Endocutter|The study utilized Echelon FlexTM Powered ENDOPATH® Stapler (Ethicon, Cincinnati, USA) along with compatible cartridges: Gray (closed staple height, 0.75mm), White (1.0mm), Blue (1.5mm), Gold (1.8mm), Green (2.0mm), and Black (2.3mm).
45818101|NCT03646981|Device|Leishmania Ab Rapid Test (CTK, Biotech)|Rapid diagnostic tests to detect antibodies anti-Leishmania
45958300|NCT04487860|Drug|Placebo|oral administration
45958301|NCT04483466|Drug|Methotrexate|Methotrexate is vibrant yellow-orange colored powder with physical properties of near insolubility in water formulated into methotrexate tablets containing an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, and yellow. The chemical name is N-[4-[[(2,4-diamino-6pteridinyl)methyl]methyl amino]benzoyl]-L-glutamic acid. Methotrexate is an anti-metabolite that is a folate antagonist that inhibits lymphocyte proliferation and functions as an immunosuppressant in arthritis.
45958302|NCT04483466|Drug|Placebo|Placebo
45818102|NCT03606889|Diagnostic Test|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
45958303|NCT04435366|Drug|Zimura|Zimura Intravitreal Injection
45958304|NCT04435366|Drug|Sham|Sham Injection
45958305|NCT04423913|Other|Administration of embolization beads|Patients will receive embolization beads, loaded with doxorubicin or not.
45455111|NCT04467892|Drug|Methyl Prednisolonate|received 1 mg/kg/day methylprednisolone divided to three doses given every 8 hours for two weeks.
45455112|NCT04467892|Device|ventilators|all patients in both groups will be ventilated with CMV for 2 weeks
45455113|NCT04269668|Device|Medtronic Minimed 670G 3.0 HCL|Hybrid closed loop system
45455114|NCT04269668|Device|Medtronic Minimed 670G 4.0 AHCL|Advanced hybrid closed loop system
45664052|NCT04772703|Diagnostic Test|COMET ASSAY|The description in the detailed description of the study
45664053|NCT02399449|Drug|Brand sodium ferric gluconate|brand product
45664054|NCT02399449|Drug|Generic sodium ferric gluconate|generic product
45664055|NCT02217345|Drug|Growth hormone|growth hormone, Genotropin (Pfizer)
45664056|NCT02217345|Drug|Placebo|placebo with identical drug pen delivery device and packaging as Genotropin (Pfizer)
45958306|NCT04414163|Drug|IMC-001|Single dose level for enrollment subject (IMC-001 20mg/kg every 2 weeks)
45818103|NCT03606889|Diagnostic Test|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
45818104|NCT03606889|Drug|Bupivacaine|0.2 ml/kg bupivicaine
45818105|NCT03283969|Other|Freeze Dried Strawberry Powder|Study participants will be randomized to receive either the freeze dried strawberry powder or the control powder first. They will be instructed to consume 39g of the powder, mixed in water, every day for 4 weeks.
45818106|NCT03283969|Other|Isocaloric powder|Isocaloric powder
45818107|NCT05363917|Drug|Natrunix with MTX placebo (+folate)|True Human IgG4 monoclonal antibody that neutralizes Interleukin-1α
46002271|NCT04081298|Other|Health Promotion and Education: Text Messages|Receive motivational text messages
45664057|NCT04906447|Behavioral|Guided Relaxation|Guided relaxation uses the mind to reduce pain, promote well-being, and improve physical function. Guided relaxation is a state of concentration and focused attention that gives people more control over their pain experience and its impact and an increased sense of well-being.
45664058|NCT04906447|Other|Acupuncture|Acupuncture is a body-based therapy that includes the insertion of thin needles at strategic points on the body that has been proven effective for reducing pain.
45818108|NCT05363917|Drug|Natrunix placebo with MTX (+folate)|Natrunix placebo with MTX (+folate)
45818109|NCT03187730|Behavioral|Integrated Smoking Cessation and Financial Counseling|Participants in the intervention group will receive up to nine counseling sessions that integrate two evidence-based counseling approaches: financial management counseling and smoking cessation counseling. Participants will also be eligible to receive a free four-week supply of NRT. Participants will be surveyed at baseline, 2- months, 6-months and 12-months to assess outcomes and treatment satisfaction.
45818110|NCT03187730|Behavioral|Waitlist Integrated Smoking Cessation and Financial Counseling|Control participants in the waitlist control group will receive usual care for the first 6 months of the study, while the Intervention Arm receives integrated counseling. The waitlist control group will receive the same counseling program as the Intervention group 6 months after enrollment (up to nine counseling sessions and four weeks of NRT). Participants will be surveyed at baseline, 2-months, 6-months and 12-months to assess outcomes and treatment satisfaction.
45818111|NCT03187730|Drug|Nicotine Replacement Therapy (NRT)|Participants in both arms will be eligible to receive a free four-week supply of NRT.
45818112|NCT05363761|Combination Product|Neurotronic Infusion Catheter|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
45818113|NCT03189134|Drug|Fluorescite|Dilute fluorescite will be applied to cardiac tissue prior to imaging
45818114|NCT03189134|Device|Cellvizio 100 Series System with Confocal Miniprobes|Microscopy system will image cardiac tissue.
45818115|NCT03261193|Drug|ITM + Sham QLB|Sham subcutaneous non-anesthetic infiltration with saline
45818116|NCT03261193|Drug|ITM + Bupivacaine QLB|QL plane block with local anesthesia
45818117|NCT05359705|Device|DJO 456|Data will be recorded while subjects wear a 456 back brace manufactured by DJO Global
45818118|NCT05359705|Device|Aspen 456|Data will be recorded while subjects wear a 456 back brace manufactured by Aspen Medical Products
45818119|NCT05359705|Device|DJO 464|Data will be recorded while subjects wear a 464 back brace manufactured by DJO Global
45818120|NCT05359705|Device|Aspen 464|Data will be recorded while subjects wear a 464 back brace manufactured by Aspen Medical Products
45818121|NCT04227145|Behavioral|SexHealth Mobile|"It will integrate two existing services in our community: a mobile medical unit (MMU) operated by Swope Health Services, and SexHealth a point-of-care contraception counseling service that our research team developed for Children's Mercy Hospital's emergency department (ED). Using a menu of adaptive services, SexHealth Mobile will bring contraceptive care to women with SUD (including a subset of women with OUD), if they wish to receive it, at targeted recovery sites Swope currently partners with."
45818122|NCT00375661|Drug|interferon-alfa-2b and ribavirin|Interferon, pnce per week plus daily ribavirin
45818123|NCT04736186|Drug|Loperamide|Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)
45818124|NCT04736186|Drug|Loperamide and golden bifid|Patients with secondary prevention will be randomly assigned to B：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+golden bifid 2 g t.i.d.
45818125|NCT04736186|Drug|Loperamide and montmorillonite powder|Patients with secondary prevention will be randomly assigned to D：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+montmorillonite powder 3 g t.i.d.
45818126|NCT02185794|Drug|Voxilaprevir|Voxilaprevir tablets administered orally once daily
45818127|NCT02185794|Drug|Placebo to match voxilaprevir|Placebo to match voxilaprevir tablets administered orally once daily
45818128|NCT02185794|Drug|SOF/VEL|400 mg/100 mg FDC tablet administered orally once daily
45818129|NCT04941170|Drug|Bupivacain|Ultrasound-guided oblique subcostal transversus abdominis plane block will be performed in the supine position under strict aseptic precautions. placing a linear high-frequency ultrasound probe obliquely near the costal margin and xiphoid process On confirming the placement of the needle in the correct target space, 1 mL of 0.25% bupivacaine will be injected to hydro-dissect the fascia layer between the RA and TA. After confirming the separation of the transversus abdominis fascia plane, the remaining 19 mL of 0.25% bupivacaine will be administered, advancing the needle infero-laterally parallel to the subcostal margin. A similar procedure will be performed on the contralateral side of the abdomen with an injection of another 20 mL of 0.25% bupivacaine.
45818130|NCT04941170|Drug|Bupivacaine|Ultrasound-guided erector spinae plane block will be performed in the sitting position. T7 spinous process will be located To perform the block. The tip of the T7 transverse process will be then identified using the ultrasound probe that is placed in a transverse orientation The ultrasound transducer will then be placed in a longitudinal orientation 2-3 cm lateral to the midline in a longitudinal orientation to identify the hyperechoic line of the transverse process with its associated acoustic shadow. After local anaesthetic infiltration, the block needle will be inserted in a craniocaudal direction until contact will be achieved with the T 7 transverse process where the tip will lay in the inter-fascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle to confirm the proper needle position. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally.
45818131|NCT05357911|Drug|AB-106, digoxin|Period 1, single dose of 0.25mg digoxin; Period 2, Coadministrate AB-106 600mg and 0.25mg digoxin
45664059|NCT01652287|Drug|BB-12 supplemented strawberry yogurt|Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
45664060|NCT01652287|Other|Strawberry flavored yogurt|Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
45818132|NCT05355883|Behavioral|Remote Ischemic Conditioning (RIC)|See descriptions under arm/group descriptions. RIC is delivered for 5 intervention visits. Visits 1 is the pre-training assessment visit, visits 2-6 are RIC plus training visits, visit 7 is a post-training assessment visit.
46002272|NCT04081298|Other|Health Promotion and Education: Web Site|Given access to nutrition website
45664061|NCT02251743|Device|Neurofeedback treatment|"Each session, the child participates in 5 training tasks. Each task lasts 5 minutes at the beginning and gradually increases to 9 minutes per task over the course of the neurofeedback as the child's attention span improves. We record four results for each of the 5 tasks:~The number of half-second periods that they met the reward parameters (i.e. theta mV below threshold; beta mV above threshold)~Average voltage of theta waves~Average voltage of beta~Average ratio of theta to beta power (TBR)"
45455115|NCT03934879|Behavioral|FitClub|Participants will rotate through each fitness module, which includes spin class, Pilates, strengthening exercises (weight training), basketball, running and rhythm, and cardio fitness. Students will meet five days per week during their first class of the day for 35 minutes and participate in two randomly assigned modules for two week periods. After 2 weeks, they participate in 2 different modules. Resting and peak heart rate (during exercise), calories burned and steps taken will be collected during each session.
45818133|NCT05355883|Behavioral|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 5 intervention visits. Visits 1 is the pre-training assessment visit, visits 2-6 are RIC plus training visits, visit 7 is a post-training assessment visit.
45818134|NCT05355883|Behavioral|Hand Arm Bimanual Intensive Therapy (HABIT)|HABIT is a child-friendly, intensive intervention directed at improving bimanual coordination and function of the affected arm. The intervention employed in this study includes various age-appropriate fine and gross motor bimanual activities that will be delivered in a play context. Children practice bimanual activities for 6 hours per day, 5 days per week, for 1 week.
45818135|NCT05355883|Behavioral|Bimanual Cup Stacking Training|Children practices bimanual cup stacking, 15 trials/day for 5 consecutive day.
45818136|NCT05355883|Behavioral|Balance training|All children undergo training on a balance board, learning to hold the board level with equal weight on each leg and using various bilateral upper extremity strategies. Participants perform the balance task for 15, 30-second trials per day at visits 2-6.
45818137|NCT04911920|Other|Questionnaire Patient Rated Tennis Elbow Evaluation|Participants are asked to complete questionnaires at three measurement time points.
45818138|NCT03374839|Drug|TIL + IL-2 + Nivolumab|"The patients will receive Nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks from day0 until week52.~Two TIL (Tumor Infiltrating Lymphocytes) injections will be performed: at week 14 and at week 18.~The TIL injections are systematically followed by subcutaneous injections of Proleukin® (IL-2) at a concentration of 6 million international unit (IU) per day for 5 days."
45818139|NCT04848272|Drug|Lanadelumab|Monoclonal antibody that targets active plasma kallikrein
45818140|NCT04848272|Other|Saline control|Saline control
45818141|NCT03347929|Drug|Naproxen 500 Mg|10 days treatment with Naproxen 500 mg twice daily
45818142|NCT03347929|Drug|Placebo|10 days treatment with Placebo1 tablet twice daily
45818143|NCT02221674|Drug|Tapentadol|
45818144|NCT05355571|Dietary Supplement|LAB4 + Saccharomyces boulardii|Probiotic containing lactic acid bacteria and Saccharomyces boulardii at a dose of 35 billion per day
45818145|NCT05355571|Dietary Supplement|Placebo|Placebo
45818146|NCT04520906|Device|microwave ablation|ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
45818147|NCT04512560|Behavioral|Surgical Training using Structured Remote Surgical Coaching in addition to Conventional Surgical Training|General surgery residents (PGY 1-5) will provide a video recording of a laparoscopic cholecystectomy that they performed as a primary surgeon. The coach will identify key moments or themes for discussion on how to improve technical skills and reduce intra-operative errors during five, 30-45 minute remote coaching sessions .
45818148|NCT04512560|Behavioral|Surgical Training using Conventional Training Program|General surgery residents (PGY 1-5) will continue their usual residency training.
45818149|NCT04736719|Drug|Apixaban|Apixaban dispensing claim is used as the exposure group
45818150|NCT04736719|Drug|Warfarin|Warfarin dispensing claim is used as the reference group
45818151|NCT04736563|Device|Joint and muscle gel Puressentiel|To evaluate the antalgic effect in patients with chronic pain related to osteoarthritis of the knee when applied to the skin of Puressentiel Joints and Muscles - Gel with 14 essential oils.
45818152|NCT04429646|Device|Percutaneous left atrial appendage closure-LAMax|Interventional device, LAMax left atrial appendage closure system
45818153|NCT04429646|Device|Percutaneous left atrial appendage closure-Watchman|Interventional device, Watchman® LAA Closure Device
45455116|NCT03934879|Other|Regular School Activities|Students will participate in regular school activities.
45664062|NCT04189575|Other|SMS Intervention|Delivery of text messages will use the Rip Road Mobile platform.
45664063|NCT02428855|Drug|Dasatinib|
45664064|NCT02428699|Other|Emulsified cod liver oil product|Participants are required to consume the dose (30 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
45818154|NCT02221284|Drug|Alogliptin|Alogliptin tablets
45664065|NCT02428699|Other|Non-emulsified cod liver oil product|Participants are required to consume the dose (5.8 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
45818155|NCT04736407|Other|Observational sampling of CSF timed around routine clinical repositioning, or not|no true intervention
45818156|NCT04736108|Drug|Abiraterone acetate|1000 mg orally daily for 24 weeks before radical prostatectomy
45818157|NCT04736108|Drug|Prednisolone|5 mg oral low dose prednisone, once daily
45818158|NCT04736108|Drug|Goserelin|10.8 mg goserelin hypodermic once per 12 weeks
45818159|NCT03196076|Drug|Perflutren Lipid microsphere|Perflutren will be administered in a bolus or continuous infusion using the dosing range and administration type within the perflutren prescribing information.Once perflutren lipid has been administered, the transducer is maintained in a constant position over the area of interest to show the target lesion in order to assess the enhancement pattern during the early, mid and late vascular phases. Images will also be taken of kidney parenchyma in a suitable longitudinal plane.If there are multiple lesions in one subject requiring a second dose, the subject will have the option to undergo a 2nd contrast-enhanced study 30-minutes after the initial contrast dose, per dosing instructions in the package insert.
45818160|NCT02971033|Drug|20mg ezetimibe|Participants assigned to this intervention will receive 20mg per day of ezetimibe for 12 weeks.
45818161|NCT02971033|Drug|Placebo|Participants assigned to this intervention will receive placebo every day for 12 weeks
45818162|NCT02971033|Drug|40mg ezetimibe|Participants assigned to this intervention will receive 40mg per day of ezetimibe for 12 weeks.
45818163|NCT05406674|Drug|Cisplatin 100 mg/m2|Cisplatin 100 mg/m2 milligram(s)/square meter
45818164|NCT05406674|Drug|Cisplatin 40 mg/l|Cisplatin 40 mg/I milligram(s)/litre
45818165|NCT05341375|Procedure|Thoracic paravertebral block|"The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block"
45818166|NCT05341375|Drug|Esketamine|Group TE received s-ketamine anesthesia induction dose of 0.3 mg/kg on the basis of TA group. Anesthesia maintenance dose of 0.2ug/kg/h was pumped to 30min before the end of the operation
45818167|NCT05341375|Behavioral|Measurement of cognitive function|Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE was assessed at one day before surgery, one day after surgery, and three months after surgery
45818168|NCT05341375|Behavioral|The assessment of cognitive function|Participants were assessed for MMSE at the same period as the group C
45818169|NCT00375817|Procedure|Myoblasts injection with MyoCath catheter|
45818170|NCT03196232|Drug|Epacadostat|Given PO
45818171|NCT03196232|Drug|Pembrolizumab|Given IV
45818172|NCT02796001|Biological|human rhinovirus|human rhinovirus
45818173|NCT02796001|Other|no intervention|4 volunteers were not re-challenged and did not participate in the second challenge
45818174|NCT04736264|Other|Visual rehabilitation module: navigation and mobility|The visual rehabilitation regime consist of education and activity include dressing, feeding, personal hygiene and grooming activities, functional mobility, room orientation and memory, reading, eye hand coordination and also optokinetic training programme. A diary will be given to assess their compliance. Reassessment based on the number of fall, stumble etc when they go through a maze (developed in Phase 1)will be done every 2weeks for 8 weeks (4 times), every 4 weeks for next 8 weeks (2 times) and the final assessment 8 weeks later. A total study intervention will be 24 weeks
45818175|NCT04736264|Other|Visual rehabilitation module: exercise|An instruction course will be conducted and a CD (with step by step exercise demonstration) will be given to the patients in group A. They will be asked to come for another session in 2 weeks. Then they will be asked to conduct the exercise for at least three times a week for 24 weeks. Exercise diary and accelerometer will also be given to patients of both groups. They will be seen in the clinic every 8 weeks.
45818176|NCT04736264|Other|Visual rehabilitation module: reading|Patient in intervention group will be asked to complete a reading task (reading the given book) a day, number of pages completed in an hour per day and time taken to complete a page in given book. They are asked to complete the books within 24 weeks with follow up every 8 weeks.
45818177|NCT05406518|Other|Psychosocial intervention|Psychosocial intervention based on the model of family therapy.
45818178|NCT04373252|Biological|FMT Lower Delivery (FMP 30)|Participants will receive two fecal microbiota transplants via antegrade enema, one week apart.
45818179|NCT03235687|Diagnostic Test|ExoDx Prostate (IntelliScore)|ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
45818180|NCT04356716|Drug|Sildenafil|Initial Sildenafil dosage will be weight dependent. Participants will start at 40 mg daily (20mg in the morning, 20 mg in the evening) or 60 mg daily (40mg in the morning and 20 mg in the evening). Sildenafil dosage may be increased to up to 80mg daily (20-40mg in the morning and 20-40mg in the evening) based on the response to lower doses. If the participant has not had improvement after initial treatment, the dose may be increased, at the discretion of the study physician.
45818181|NCT04356716|Other|Standard of Care Sildenafil|Medical record review of participants that receive Sildenafil as part of standard of care.
45818182|NCT04356716|Diagnostic Test|Ocular Coherence Tomography-Angiography (OCT-A)|Retinal photographs will be taken at each study visit.
45664066|NCT03611725|Procedure|Distal radial artery|The distal radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
45664067|NCT03611725|Procedure|Radial artery|The radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
45664068|NCT02428231|Drug|dimethyl fumarate|Participants will be dosed twice daily for 12 weeks.
45958307|NCT04396899|Biological|EHM implantation|Implantation of EHM on dysfunctional left or right ventricular myocardium in patients with HFrEF (EF <35%).
45958308|NCT04394585|Behavioral|smart phone app based human coaching program|"experimental arm~1:1 coaching using smart phone app~Patients are provided several articles about postoperative care (symptom management, diet, and exercise) in the app.~Patients are encouraged to report their diet diaries and exercise everyday by the coach.~Patients can ask to the coach using the app and the coach answer when they check them.~Comparator arm - Patient have consulting with clinical nutritionist at 1 month and 3 months postoperatively."
45958309|NCT04387084|Drug|Atezolizumab|Given IV
45958310|NCT04387084|Drug|Avelumab|Given IV
45958311|NCT04387084|Biological|Cemiplimab|Given IV
45958312|NCT04387084|Biological|Durvalumab|Given IV
45664069|NCT02427841|Drug|Fluorouracil|Given IV
45958313|NCT04387084|Biological|Nivolumab|Given IV
45958314|NCT04387084|Biological|Pembrolizumab|Given IV
45958315|NCT04387084|Other|Quality-of-Life Assessment|Ancillary studies
45818183|NCT04356716|Other|Visual Acuity (VA)|Visual acuity will be measured with Snellen Eye Chart at each study visit.
45958316|NCT04387084|Other|Short-Term Fasting|Undergo STF
45818184|NCT03200587|Drug|Avelumab|Avelumab 10 mg/kg infusion every 2 weeks (Days 1 and 15) of every 28 day cycle for up to 12 cycles
45818185|NCT03200587|Drug|Cabozantinib|Cabozantinib oral daily at 20 (starting dose 1), 40 (Dose Level 2) or 60 mg (Dose Level 3)
45818186|NCT03198884|Drug|Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG|
45818187|NCT01801189|Drug|Pregabalin|One 300 mg oral dose of Pregabalin given before surgery.
45818188|NCT01801189|Drug|Placebo (for Pregabalin)|One oral dose of placebo given before surgery.
45818189|NCT05440838|Diagnostic Test|Next-generation sequencing|Next-generation sequencing and cytokine profile will be established in all patients before the start of treatment.
45958317|NCT04378075|Drug|Vatiquinone|Vatiquinone will be administered per the treatment arm description.
45958318|NCT04378075|Other|Placebo|Vatiquinone-matching placebo will be administered per the treatment arm description
45664070|NCT02427841|Drug|Gemcitabine|Given IV
45818190|NCT04275362|Device|DJO Empowr PS Knee System|Patients will receive a DJO Empowr PS Knee System total knee replacement
45818191|NCT04275362|Device|Stryker Triathlon Total Knee System|Patients received a Stryker Triathlon Total Knee System total knee replacement
45818192|NCT04275362|Device|Biomet Vanguard Complete Knee System|Patients received a Biomet Vanguard Complete Knee System total knee replacement
45958319|NCT04351334|Drug|Alectinib|Observational treatment based on physician choice
45958320|NCT04347798|Other|Hydroxychloroquine/Chloroquine|Prospective evaluation of development of Covid-19 in inflammatory arthritis patients on biologics with anti-malarials compared to inflammatory arthritis patients on biologics without anti-malarial exposure
45455117|NCT04165018|Procedure|Fine-Needle Biopsy (FNB)|Fine-needle biopsy may be used to take samples of a pancreatic neoplasm.
45455118|NCT04258826|Drug|LY3154207|LY3154207 administered orally.
45455119|NCT04258826|Drug|Placebo|Placebo administered orally.
45664071|NCT02427841|Radiation|Image Guided Radiation Therapy|Undergo IG-IMRT
45664072|NCT02427841|Radiation|Intensity-Modulated Radiation Therapy|Undergo IG-IMRT
45664073|NCT02427841|Other|Laboratory Biomarker Analysis|Correlative studies
45664074|NCT02427841|Drug|Nab-paclitaxel|Given IV
45664075|NCT02427841|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45664076|NCT02397889|Drug|Ketamine|This arm will receive 0.5mg/kg repeated dose ketamine (6 intravenous infusions, 3 per week for 2 weeks).
45664077|NCT02397889|Drug|Midazolam|This arm will receive 0.045mg/kg repeated dose intravenous midazolam (6 intravenous infusions, 3 per week for 2 weeks).
45664078|NCT02396953|Drug|Lanreotide PRF|
45818193|NCT04275362|Device|Control|No total knee replacement
45818194|NCT05178043|Drug|Nivolumab|Nivolumab 240mg to be administered as an intravenous (IV) infusion every 2 weeks (Q2W).
45818195|NCT05178043|Drug|GT90001|GT90001 7mg/kg to be administered as an intravenous infusion every 2 weeks (Q2W) after Nivolumab infusion.
45818196|NCT05406206|Drug|Fruquintinib|Fruquintinib is a capsule in the form of 1mg and 5mg, once a day, 3 week on/1 week off.
45958321|NCT04345757|Behavioral|Structured exercise|The exercise program will be designed by a physical therapist (Ms. Patricia Ladis) who specializes in postnatal rehabilitation and will be supervised by sports medicine physicians from the Hospital For Special Surgery (HSS). The structured program will include approximately 10 minutes of core muscle group exercises. They will begin this program 2 weeks after their cesarean section. The study group will perform these exercises 5 times per week.
45958322|NCT04335669|Drug|epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab|Cytotoxic agents.
45958323|NCT04335669|Drug|epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab|Cytotoxic agents.
45958324|NCT04332939|Other|transcranial direct current stimulation|real tDCS sessions
45958325|NCT04332939|Other|Physical exercise|Aerobic exercise and physical training combined with sham tDCS
45958326|NCT04332367|Drug|Carboplatin|Carboplatin IV
45958327|NCT04332367|Drug|Paclitaxel|Paclitaxel IV
45958328|NCT04332367|Drug|Ramucirumab|Ramucirumab IV
45958329|NCT04332055|Other|ERVIN|ERVIN is state of the art for IT systems, which uses artificial intelligence (AI) and real-time patient-specific PRO data to support patients and doctors in clinical decision-making. The system is designed for surgical OA treatment of knee and hip replacement, and can be used to predict outcome scores for the actual choice OA patients face in the patient trajectory; to choose surgery or not.
45958330|NCT04310176|Drug|Bevacizumab|5 mg/m2 as 20-to-30 minute intravenous (i.v.) infusion every two weeks. Maintenance treatment (both arms): 5 mg/m2 every 2 weeks (in combination with 5-Fluorouracil) or 7.5 mg/m2 every 3 weeks (in combination with capecitabine)
45958331|NCT04310176|Drug|mFOLFOX6 regimen|Oxaliplatin 85 mg/m2 as 2-3 hours i.v. infusion on day 1 followed by levo-folinic acid 200 mg/m2 as 1- 2 hours i.v. infusion followed by i.v bolus. 5-fluorouracil 400 mg/m2, and a 46-hour i.v. infusion of 5-fluorouracil 2400 mg/m2 every two week
45958332|NCT04310176|Drug|mOXXEL regimen|Oxaliplatin 85 mg/m2 as 2-3 hours i.v. infusion on day 1 plus oral capecitabine 1000 mg/m2 twice daily on days 1 to 10, every 2 weeks
45958333|NCT04310176|Drug|Valproic acid|given orally from 500mg-1500mg daily and an intra-patient titration for a target serum level of 50-100µg/ml
45958334|NCT04310176|Drug|Capecitabine|Maintenance treatment (both arms): 1250 mg/m2 twice daily on days 1 to 14, every 3 weeks or 1250 mg/m2 twice daily on days 1 to 10, every 2 weeks
45958335|NCT04310176|Drug|5-fluorouracil|Maintenance treatment (both arms): Levo-folinic acid 200 mg/m2 as 1- 2 hours i.v. infusion followed by i.v bolus. 5-fluorouracil 400 mg/m2, and a 46-hour i.v. infusion of 5-fluorouracil 2400 mg/m2 every two weeks
45958336|NCT04298983|Drug|Abemaciclib 150 MG by mouth twice daily|Abemaciclib will start with initiation of ADT, 3 months before RT, and pause 2 weeks prior to start of RT. Abemaciclib will resume with the first ADT administration post-radiation, which is about 1 month post radiation therapy. Abemaciclib will continue for a total of 24 months.
45958337|NCT04298983|Drug|Androgen deprivation therapy (ADT)|ADT will be given every 3 months. ADT and Abemaciclib will pause 2 weeks prior to start of RT. ADT administration will resume with Abemaciclib post-radiation, which is about 1 month post radiation therapy. ADT will continue for a total of 24 months.
45958338|NCT04298983|Radiation|Radiation Therapy|RT will start 3 months after initiation of ADT and Abemaciclib. RT will be given as standard of care- 180 cGy x 28 fractions to the whole pelvis and the prostate will receive 250 cGy x 28 fractions. After RT is completed, both ADT and Abemaciclib will resume and continue for 24 months.
45958339|NCT04290403|Device|Pull Ups|Participants will be asked to wear pull-ups continence products for the duration of four weeks
46079281|NCT05699551|Behavioral|Exercise regimen|Exercise will take place Monday, Wednesday, and Friday from 12:00-1:00 pm for 4 months. Every participant will be screened for Coronavirus-19 prior to each exercise session. Aerobic exercise will consist of walking, beginning with a 10-minute duration, with gradual progression to 20 minutes. Muscle strength and endurance and range-of-motion exercise will then be performed. Muscle strength and endurance training will begin using no weight and performing one set of 6 repetitions. Progression using added resistance in the form of dumbbell weights (1-6 lbs.) and increased sets and repetitions will be applied as Subjects become increasingly fit. For static range of motion exercise, positions will be held for 10-15 seconds in the beginning and increased over time. Exercise will be kept at a moderate level of intensity. Each session will then end with relaxation training.
46079282|NCT05688839|Drug|Jaktinib hydrochloride tablets|2 doses per day, 100mg Jaktinib
46079283|NCT05688839|Drug|placebo|2 doses per day, placebo
46079284|NCT05687994|Behavioral|Audiovisual Speech Entrainment Practice|Speech Entrainment Practice is an aphasia rehabilitation treatment based on imitation of recorded speech in real time. Treatment includes repeated practice of speaking along with a recorded model, which provides contextual, temporal, auditory, and visual cues for speaking
45818197|NCT05406206|Procedure|Hepatic Arterial Infusion Chemotherapy|HAIC is a locoregional therapy for colorectal cancer liver metastasis. Oxaliplatin 85 mg/m*2 + 5-FU 2000 mg/m*2, Q4W
45818198|NCT00716755|Drug|Risperidone/Olanzapine and PET scans|Current risperidone/olanzapine users who are 50 or older will be recruited. Dopamine D2 dopamine receptors using a selective D2 dopamine receptor ligand, [11C]-raclopride, and plasma levels of risperidone and 9-OH-risperidone, or of olanzapine, and prolactin will be measured on the 1st PET visit. Subsequently, there will be gradual dose reductions of risperidone or olanzapine by 0.5 and 2.5 mg per week, respectively (as long as the total reduction does not exceed 40%). At least 5 days after the termination of the dose taper, participants will have the second PET scan. Participants will be followed up for 24 weeks after the termination of the dose reduction.
45458217|NCT03263923|Behavioral|Cognitive behavioral intervention and journaling|Cognitive behavioral skills training and 4 weeks of online journaling
45818199|NCT05406128|Other|preoperative erector spina plane block|Erector spina plane block will be applied to preoperative group patients in the preoperative period.
45818200|NCT05406128|Other|intraoperative erector spina plane block|In the intraoperative group, erector spina plane block will be applied after anesthesia induction.
45818201|NCT05141383|Other|Urine sampling|A blood sample and a urine sample after prostate massage will be carried out at baseline
45818202|NCT05406050|Drug|reference eldecalcitol soft capsule|0.75 μg, produced by Chugai Pharmaceutical Co., Ltd. Japan
45818203|NCT05406050|Drug|test eldecalcitol soft capsule|0.75 μg, produced by Wenzhou Haihe Pharmaceutical Co., Ltd. China
45818204|NCT04736095|Diagnostic Test|3D Ultrasound|Doing 3D ultrasound for diagnosis of submucous myoma
45818205|NCT04736095|Diagnostic Test|Hysteroscopy|Doing hysteroscopy for diagnosis of submucous myoma
45818206|NCT03199118|Procedure|CAF +SCTG|the use of coronally advanced flap (CAF) with sub-epithelial connective tissue graft (SCTG) from the palate to cover gingival recession
45818207|NCT03199118|Other|platelet rich fibrin|in addition to coronally advanced flap and sub-epithelial connective tissue graft, PRF is also used in the surgical procedure to cover gingival recession
45818208|NCT03202472|Device|Implanted Medical Device|Radiofrequency tag
45818209|NCT03202472|Procedure|Mammography|Undergo mammogram for image-guided placement of radiofrequency tag
45818210|NCT03202472|Other|Questionnaire Administration|Ancillary studies
45818211|NCT03202472|Procedure|Radiofrequency (RFID) -Guided Localization|Undergo radiofrequency-guided localization
45818212|NCT03202472|Procedure|Ultrasonography|Undergo ultrasound for image-guided placement of radiofrequency tag
45958340|NCT04290403|Device|Styled Briefs with tapes|Participants will be asked to wear styled briefs with tapes for the duration of four weeks
45958341|NCT04285463|Diagnostic Test|Transbronchial Lung Cryobiopsy (TBLC)|TBLC is a relatively new endoscopic technique used to obtain lung parenchyma specimens. It is a minimally invasive technique performed with a flexible or rigid bronchoscope under deep sedation or general anesthesia. Flexible cryoprobes of either 1.9 or 2.4 mm in diameter are introduced into a bronchoscope and a compressed gas, most commonly carbon dioxide or nitrous oxide, is released at high flow at the tip of the probe. As the tissue rapidly freezes, it adheres to the probe and is avulsed and extracted with a quick pullback movement followed by immediate extraction of samples.
45958342|NCT04271969|Device|SmartVest Airway Clearance System|Pulmonary airway clearance of retained mucus via high frequency chest wall oscillation (SmartVest)
46002273|NCT04081298|Other|Quality-of-Life Assessment|Ancillary studies
46079285|NCT05687994|Behavioral|Auditory Speech Entrainment Practice|Speech Entrainment Practice is an aphasia rehabilitation treatment based on imitation of recorded speech in real time. Treatment includes repeated practice of speaking along with a recorded model, which provides contextual, temporal, and auditory cues for speaking
45455120|NCT03939403|Drug|Time of administration of Corifollitropin Alfa|"The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The control grup will receive the treatment on the 5th day after the cessation of hormonal contraceptive use. The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The intervention grup will receive the treatment on the 7th day after the cessation of hormonal contraceptive use."
45455121|NCT04467658|Diagnostic Test|electroencephalography absolute delta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
45458218|NCT03263923|Behavioral|Reflective journaling|"Reflective journaling training and 4 weeks of online journaling~Training in reflective journaling and 4 weeks of online journaling"
45458219|NCT03139604|Drug|Itacitinib|Itacitinib at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.
45458220|NCT03139604|Drug|Placebo|Matching placebo tablets administered orally once daily (QD) plus corticosteroids.
45664079|NCT04905589|Dietary Supplement|BetaQuik™|MCT (Medium chain triglycerides)
45664080|NCT04905589|Dietary Supplement|WheyBasics|Whey Protein Isolate
45664081|NCT04905589|Other|Iso-voluminous water|Iso-voluminous Water as comparitor to Betaquik or WheyBasics
45818213|NCT04200404|Drug|CS1001|One course will last 28 days. CS1001 will be intravenously administered every 4 weeks (Q4W).
45818214|NCT04200404|Drug|Regorafenib|One course will last 28 days. Administration will be orally (p.o.) taken at different dose schemes.
45818215|NCT04171778|Other|whole food, plant-based diet|The study diet is whole food, plant based defined as containing no animal products or refined grains or added oils, minimal use of any sweeteners, and, for the purposes of this study, on average containing no more than 15% calories from fat.
45818216|NCT04135742|Device|Transcranial Alternating Current Stimulation|Transcranial alternate current stimulation (tACS) is a method of alternative current stimulation that can modulate neural activity by imposing local oscillatory activity.
45818217|NCT04135742|Behavioral|Cognitive Training|Cognitive training includes memory, reasoning, processing speed and role playing, etc.
45818218|NCT03202550|Drug|Oxycodone and Lorazepam (Active Comparator)|Oxycodone and Lorazepam
45818219|NCT03202550|Drug|Placebo Comparator|Placebo oral pills
46002274|NCT04081298|Other|Questionnaire Administration|Ancillary studies
46002275|NCT04062448|Drug|Ibrutinib|Ibrutinib 420 mg will be administered orally.
46002276|NCT04062448|Drug|Rituximab|Rituximab 375 mg/m^2 will be administered intravenously.
45958343|NCT04255043|Device|IVUS guidance|IVUS (Boston Scientific®) guidance + DCB (Sequent® Please) treatment
45958344|NCT04255043|Device|Angiography guidance|DCB (Sequent® Please) treatment
45958345|NCT04254419|Biological|NK cells|"Natural killer cells will be taken from the patients peripheral blood cell collection. The administration of the cells will be done via an Ommaya intra-cavitary/intra-tumoral device.~Once the infusion is ready for administration patients will be admitted to the infusion unit for monitoring. NK cells will be administered through the Ommaya in approximately 2 milliliters over approximately 2 minutes; followed by 1 milliliter preservative-free normal saline flush over approximately 1 minute."
45958346|NCT04251416|Drug|Sacituzumab Govitecan|Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
45958347|NCT04243538|Behavioral|I-HoME|I-HoME will consist of two components: (1) synchronous live video interactions between patients/CGs and a hospice nurse; and (2) educational videos.
45958348|NCT04241809|Diagnostic Test|Bioaerosol Sampling|Cyclone collection of exhaled bioaerosol
45958349|NCT04241120|Behavioral|Device and app system designed for participant to self-administer Habit Reversal Training|Participants will receive an awareness bracelet and an app that work together to implement key features of Habit Reversal Training. The participant will take part in psychoeducation, awareness training, and competing response training related to trichotillomania.
45958350|NCT04241120|Behavioral|Reminder bracelet control condition|Participants will receive a bracelet programmed to vibrate randomly several times per hour during waking hours. They will be instructed this is a reminder not to pull.
45958351|NCT04240574|Device|Debritom|hydrosurgery device that utilizes micro water jet technology that has been designed to debride acute and chronic wounds precisely and in a tissue-preserving manner.
45664082|NCT02387983|Drug|Posaconazole|Posaconazole 300 mg solid oral tablet
45958352|NCT04238689|Biological|TB31F|Monoclonal antibody
45818220|NCT03203564|Drug|Modufolin (arfolitixorin)|Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)
45818221|NCT04123886|Drug|SCB-313|SCB-313 Intrapleural injection, once daily. Single dose on Day 1 in Cycle 0 followed by 7-day safety assessment, then dose on Day 1,2,3 in Cycle 1 followed by 21-day observation .
45664083|NCT02395627|Drug|Tamoxifen|
45664084|NCT02395627|Drug|Vorinostat|
45664085|NCT02395627|Drug|Pembrolizumab|
45818222|NCT03285542|Device|DERMABOND|DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey)
45818223|NCT03285542|Device|Staples|staples for skin closure
45818224|NCT03207074|Diagnostic Test|iKnife i.e. Rapid Evaporative Ionisation Mass Spectrometry|The endometrial tissue will be analysed by this new technology and compared to gold standard (histopathology)
45818225|NCT04095806|Other|Stroke (exposure)|stroke case definition (exposure) listed in inclusion/exclusion criteria section
45958353|NCT04236609|Device|Abluminus DES+ Sirolimus Eluting Stent System (SES)|The Sirolimus-eluting stent manufactured by Envision and distributed by Concept Medical
45958354|NCT04236609|Device|XIENCE Everolimus Eluting Coronary Stent System (XIENCE family)|The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA
45958355|NCT04235504|Other|MDI|Subject continues their standard Multiple Daily Injections therapy with FGM or RT-CGM
45958356|NCT04235504|Device|AHCL|"Subject starts using the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0.~Starting time depends on which Arm the subject is assigned to: if the subject is assigned to the Treatment Arm, then the intervention starts after the RUN-IN period. If the subject is assigned to the Control Arm the intervention will start after 6 months from the date of the enrollment."
45958357|NCT04232774|Device|The Neurotronic arterial ablation catheter|a sterile, single use catheter (device) for delivering chemical agent to achieve perivascular denervation.
45664086|NCT02395471|Device|Cytosponge™ Cell Collection Device|Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.
45958358|NCT04232657|Drug|Romosozumab|39 subjects with chronic SCI will be studied with a 2:1 ratio of randomization of drug to placebo. Romosozumab (210mg SQ) will be administered once a month for 12 months. Participants will arrive at the JJPVAMC or KIR once a month to receive injections of romosozumab or placebo. A designated unblinded healthcare professional will be responsible for administering these injections.
45664087|NCT02395081|Dietary Supplement|600 IU Vitamin D3 in prenatal vitamin|Women will receive 600 IU 25(OH)D in prenatal vitamin.
45664088|NCT02395081|Dietary Supplement|2000 IU Vitamin D3 in prenatal vitamin|Women will receive 2000 IU 25(OH)D in prenatal vitamin.
45664089|NCT02395081|Dietary Supplement|4000 IU Vitamin D3 in prenatal vitamin|Women will receive 4000 IU 25(OH)D in prenatal vitamin.
45664090|NCT02394925|Device|Multifocal Test Contact lens|Used in a daily wear modality
45664091|NCT04905277|Drug|Atenolol 50 MG|50 mg Atenolol daily
45664092|NCT04905277|Drug|Placebo|one placebo daily
45958359|NCT04232657|Drug|Denosumab|Because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density. Denosumab will be administered to both groups (treatment and placebo) for an additional 12 months. Participants will be asked to arrive at the JJPVAMC once every 6 months to receive injections of denosumab by a healthcare professional.
45958360|NCT04232657|Drug|Placebo|Thirteen (13) of the thirty-nine (39) subjects enrolled in this study will be randomly selected to receive placebo (NS SQ) injections for 12 months (baseline - month 11). The placebo injections will be administered by an unblinded healthcare professional (registered nurse / physician). Participants will be blinded to their group assignment (romosozumab treatment or placebo).
45958361|NCT04232566|Procedure|Bariatric surgery|Evaluate liver fibrosis by elastography before gastric bypass surgery.
45958362|NCT04231266|Drug|ManNAc|Oral N-acetyl-D-mannosamine monohydrate (ManNAc)
45958363|NCT04231266|Other|Placebo|Placebo
45664093|NCT02427607|Drug|Perampanel|Perampanel 2 mg tablets. Doses of perampanel can be adjusted based on clinical judgment. A minimum perampanel dose of 2 mg per day is required to continue in the study. The maximum daily dose of perampanel permitted will be 12 mg per day.
45818226|NCT04088786|Drug|nanoliposomal irinotecan|The starting dose of nal-IRI will be 70 mg/m2 (cohort level 1) applied for 30 min using a closed HIPEC technique following completion of cytoreductive surgery. If there is dose limiting toxicity (DLT) in cohort level 1, then the dose will be reduced the dosage of the next cohort to 50 mg/m2 (cohort level 0). If there is no DLT, the dose of nal-IRI will be increased to 140 mg/m2, 210 mg/m2 and 280 mg/m2 . If one of the patients experiences DLT, then the cohort will expand to 6 patients and accrual to the current dose level and dose escalation will stop if 2 or more patients experience a DLT at a given dose level.
45818227|NCT03207386|Behavioral|Youth VIP|Youth VIP involves youth in partnerships with adults to adapt evidence based sexual violence prevention strategies for the local community environment. Youth VIP includes a three day intensive youth summit for prevention training and ongoing youth-adult prevention working groups.
45818228|NCT00392821|Drug|Sorafenib|Sorafenib
45958364|NCT04216277|Diagnostic Test|Procalcitonin|"In addition to usual care diagnostic and handling of acute respiratory tract infections in general practice to attending physician in the intervention arm has access to antibiotic stewardship by a procalcitonin point-of-care test. The following criteria for initiating og withholding antibiotics will be used.~Antibiotics treatment is recommended with Procalcitonin levels above 0.25 ng/ml~Antibiotic treatment is discouraged if Procalcitonin levels are below 0.25 ng/ml"
45958365|NCT04199780|Device|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS), stimulates specific areas of the brain via electric current passed through electrodes placed on the scalp. During tDCS, low amplitude direct currents penetrates the skull to enter the brain and modulates neuronal activity.
45958366|NCT04199780|Behavioral|Cognitive-Behavioral (CB) intervention|CBI generally consist of cognitive coping strategies (e.g., distraction, relabeling, reducing pain-catastrophizing) and self-management (e.g., relaxation strategies, guided imagery) designed to enhance perceived control and reduce sympathetic nervous system tone.
45958367|NCT04195737|Procedure|Ossix volumax collagen matrix|Under LA horizontal incision is made.Split-full-split thickness flap is elevated.The remaining soft tissue of the anatomic interdental papillae deepithelialized.Coronal advancement of the flap obtained and closed using sling suture.
45664094|NCT02426125|Drug|Ramucirumab|Administered IV
45664095|NCT02426125|Drug|Docetaxel|Administered IV
45664096|NCT02426125|Drug|Placebo|Administered IV
45664097|NCT02425111|Drug|Vedolizumab|Vedolizumab intravenous injection
45664098|NCT04916119|Drug|IBI323|In phase Ia study, seven dose levels of IBI323 (0.03, 0.1, 0.3, 1, 3, 10 and 20mg/kg) will be evaluated. The DLT observation period is 28 days. IBI323 is administered by iv infusion day 1 of every 14 days. After dose escalation stage completed, two dose levels (10mg/kg and 20mg/kg) will be expanded to 20 patients each. In Phase Ib study, IBI323 is administered RP2D by iv infusion day 1 of every 14 days. IBI323 and chemotherapy will be administrated in cohort C and cohort K
45664099|NCT02424565|Drug|IODEX® balm|2 ± 0.2 g of test balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
45664100|NCT02424565|Other|Placebo balm|2 ± 0.2 g of placebo balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
45664101|NCT02424253|Drug|ZPL-3893787|ZPL-3893787
45664102|NCT02424253|Drug|Placebo|Matched Placebo
45664103|NCT02393755|Drug|Capecitabine|Given PO
45664104|NCT02393755|Other|Laboratory Biomarker Analysis|Correlative studies
45818229|NCT00392821|Drug|RAD001|RAD001
45818230|NCT03208166|Device|Doctormate|Ischemic conditioning device
45818231|NCT03208166|Other|Usual Care|Standard medical care
45958368|NCT04195737|Procedure|Connective Tissue Graft|Under LA parallel incisions is made 1-2 mm first molar to canine.Graft incision 1 mm coronal to the horizontal flap incision.Through this incision designed graft thickness is obtained.The graft obtained between the two horizontal incisions has a 1 mm coronal strip that require depithelisation with a knife and closed using interrupted suture.
45958369|NCT04187833|Drug|Nivolumab|480mg intravenously every 4 weeks (28 days)
45958370|NCT04187833|Drug|Talazoparib|1mg orally daily
45958371|NCT04181970|Other|Quality assessment|There is no intervention on study subjects. A tumor review will be performed by expert centers.
45958372|NCT04173585|Drug|Bortezomib|Bortezomib is a small molecule dipeptide binding the catalytic site of the 26 S proteasome. It acts as a potent, reversible, and specific inhibitor of proteasomes and thus impairs the degradation of ubiquitinated proteins. It has demonstrated anti-neoplastic activity in myeloma and lymphoma. It is approved and widely used in multiple myeloma both for first line treatment and relapsed patients.
45958373|NCT04173585|Drug|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin is a monoclonal antibody directed against the myeloid surface antigen CD33. The antibody is linked to calicheamicin which serves as cytotoxic agent. For years, gemtuzumab ozogamicin has been tested in clinical AML trials. Though withdrawn from the US market in 2010, FDA approval was granted in September 2018, EU approval in April 2018 based on encouraging results from recent clinical trials using enhanced dosing schedules.
45958374|NCT04172987|Drug|Tirzepatide|Administered SC
45458221|NCT03139604|Drug|Prednisone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
45664105|NCT02393755|Drug|Nintedanib|Given PO
45818232|NCT04051112|Drug|SCB-313|10mg group: Intraperitoneal injection single dose on Day 0, safety observation for 7 days, then 3 continuous doses on Day7, Day8, Day9, 21 days for 1 cycle
45818233|NCT04756609|Procedure|Systematic offer of nurse-driven SARS-CoV-2 screening combined with usual practice|"I- A SARS-CoV2 self-administered questionnaire about SARS-CoV2 symptoms, possibilities of close contacts, risk exposure situations and socio-demographic characteristics will be offered to patients included who are capable of filling it out.~The patient will fill out the questionnaire and hand it in to the nurse caring for him/her.~The nurse, regardless of the answers to the questionnaire, will offer the SARS-CoV2 screening.~A nasopharyngeal swab for SARS-CoV2 will be carried out.~A patient will be considered as symptomatic if he/she presents one or more symptoms listed in the questionnaire.~For symptomatic patients, a SARS-CoV2 for multiplex PCR will be carried out. This analysis takes 75 minutes.~For asymptomatic patients, a RT-LAMP test will be carried out. This analysis takes 5 to 15 minutes."
45818234|NCT04756609|Other|Usual emergency department practice with physician-directed diagnostic testing|The physician offers a SARS-CoV2 test according to current recommendations. The tests are prescribed as a means of diagnosis for patients presenting symptoms suggestive of Covid-19 or as a means of diagnosis for patients requiring hospitalisation for another cause, before their transfer to hospital. Patients will be cared for according to usual procedures of each hospital. Patients tested positive will be asked to fill out the DEPIST-COVID questionnaire. Patients who had not completed it will be contacted by phone to answer the questions over the phone.
45818235|NCT04708171|Procedure|Awake mapping under local anesthesia|During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.
45818236|NCT04708171|Procedure|Asleep mapping under general anesthesia|During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.
45818237|NCT04708171|Procedure|Resection under general anesthesia without mapping|During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.
45958375|NCT04172987|Drug|EE/NGM|Combination oral contraceptive administered orally
45958376|NCT04171856|Device|REAplan(R)|motor skill learning with the REAplan(R) rehabilitation robot, to be perfomed with the affected arm
45958377|NCT04138381|Drug|Selinexor|oral selinexor given once weekly (Cohort A), oral selinexor given BIW (Cohort B)
45958378|NCT04138381|Drug|Imatinib|imatinib 400 mg, once daily (Cohort A)
45664106|NCT02393755|Other|Pharmacological Study|Correlative studies
45664107|NCT05454319|Device|Biofeedback|Home-based biofeedback with medical device
45664108|NCT02393209|Drug|Docetaxel|Docetaxel intravenous infusion
45664109|NCT02393209|Drug|TAK-117|TAK-117 Tablets
45664110|NCT02424097|Drug|CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste|"MI Paste & MI Varnish- in-office:~varnish application once every 3 months; at baseline, at the end of month 3, 6, and 9 (4 applications)~- at-home: brushing with regular 1,100ppm F-toothpaste, 2x per day and MI Paste Plus, home application after brushing in the evening; 3-5 minutes with in-home application tray"
45818238|NCT02187042|Other|Best supportive care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
45958379|NCT04136171|Drug|Eplontersen|Eplontersen by subcutaneous injection
45958380|NCT04136171|Drug|Placebo|Eplontersen-matching placebo by subcutaneous injection
45958381|NCT04128501|Drug|Azacitidine|Given SC
45958382|NCT04128501|Drug|Venetoclax|Given PO
45958383|NCT04127786|Biological|Purified vero rabies vaccine - serum free VRVg-2|Pharmaceutical form: Freeze-dried Route of administration: Intramuscular
45664111|NCT02424097|Drug|1,100pm F-toothpaste and 0.5%NaF rinse|"Standard of care at-home:~Crest tooth brushing 2x per day - (recommendation OTC Fluoride-rinse in the evening at home 1x per day)"
45818239|NCT02187042|Other|call center|Nurses from a call center will call the patients at regular time to help patients in the management of their cancer, with some dietetic advices, medical advices etc.
45818240|NCT03209882|Device|TILS|Continuous-wave laser of a specific wavelength (1064 nm) was administered to the participants' right forehead for 8 minutes. The laser power was 3.4 Watts.
45818241|NCT03209882|Device|sham|The sham session consisted of administering the same laser to the participants' right forehead for totally 8 minutes. However, the laser power was turned to be 0 Watts.
45818242|NCT05058391|Biological|Elaprase|Participants will receive a single dose of Elaprase 0.5 mg/kg intravenous infusion every week on Day 1.
45818243|NCT03290378|Drug|Tramadol|IV; 25 mg or 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
45818244|NCT03290378|Other|Placebo|IV; Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
45818245|NCT04659967|Behavioral|Virtual Training|Participants will receive a virtual training that is tailored to age-related hearing loss, use of non-custom personal amplification devices, and communication strategies.
45818246|NCT02076217|Drug|Copper T-380 IUD|
45818247|NCT02076217|Drug|LNG IUD|
45818248|NCT02076217|Device|Contraceptive implant Nexplanon|
45818249|NCT02076217|Drug|Depo-Provera|
45818250|NCT03290768|Device|Continuous Glucose Monitor (CGM)|Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
45818251|NCT03290768|Device|Activity Tracker|Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
45818252|NCT03290768|Behavioral|Coaching|Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
45818253|NCT05030467|Behavioral|REDUCE-BP Intervention|"Pre-visit:~Providers in the intervention arm will receive dashboards which will highlight racial/ethnic differences in rates of achieving blood pressure control within their patient panel. The dashboard will also provide individual-level information for patients with poorly controlled blood pressure.~During visit:~Providers will receive clinical decision support within relevant patients' charts that highlight the patient's under-treated blood pressure and potential impacts of social needs.~Providers will have the opportunity to provide enhanced patient education materials, which can be automatically ordered within the clinical decision support.~Post-visit:~Patient-subjects' access to the online patient portal will be streamlined by the inclusion of information about the patient portal in the patients' after-visit summary. Providers will also be able to referral patients automatically to nurse BP visits."
45818254|NCT05016037|Behavioral|Lexically based speech recast|a child's spontaneous or elicited production containing phonological errors is immediately followed with a clinician model that corrects the error(s) at the word level rather than the isolated phoneme level. As an example, a speech recast of child's production of the word bake as [be] would be the whole lexeme bake [bek] rather than production drill on [k] in isolation.
45818255|NCT04626661|Device|COMET measurement system|Photonics Healthcare B.V. has developed an innovative non-invasive bedside monitoring system to measure Cellular Oxygen METabolism (the COMET).The COMET's non-invasive cutaneous mitoPO2 measurements rely on the protoporphyrin IX-triple state lifetime technique (PpIX-TSLT). This technique measures oxygen by oxygen-dependent quenching of delayed fluorescence lifetime of 5-aminolevulinic acid-induced mitochondrial PpIX (protoporphyrin IX). PpIX is the final precursor of haem in the haem biosynthesis pathway and is synthetized in the mitochondria. Administration of exogenous 5-aminolevulinic acid enhances PpIX to detectable levels and enhances mitochondrial origin of the delayed fluorescence signal. Measurements are based on the detection of time of extinction of red light emitted by the tissue following excitation with green light. The technique has been tested and calibrated for use in isolated organs and in vivo.
45958384|NCT04127786|Biological|Purified inactivated rabies vaccine Verorab®|Pharmaceutical form:Freeze-dried Route of administration: Intramuscular
45958385|NCT04127786|Biological|Purified inactivated rabies vaccine Imovax® Rabies|Pharmaceutical form: Freeze-dried Route of administration: Intramuscular
45958386|NCT04095260|Other|Pre-season strength and conditioning program|The structured physical performance assessment will include functional movement testing, motor coordination testing, joint mobility screen, muscle strength testing, and agility performance testing. These measures will assess the effectiveness of pre-season strength and conditioning program to reduce musculoskeletal impairments and increase resistance to injury.
45958387|NCT04090957|Drug|Estetrol oral tablet|Estetrol oral tablet will be administered orally once daily.
45458222|NCT03139604|Drug|Methylprednisolone|Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose appropriate for the severity of disease as background treatment.
45664112|NCT02392507|Drug|Necitumumab|Administered IV
45664113|NCT02392507|Drug|Nab-Paclitaxel|Administered IV
45664114|NCT02392507|Drug|Carboplatin|Administered IV
45664115|NCT04904341|Drug|Cerebrolysin|neuroprotection treatment
45664116|NCT01651117|Behavioral|Peer Mentoring|Patients will receive peer mentoring.
45458223|NCT02311114|Other|In Depth interview|In Depth interview will be conducted for 30-60 min using semi-structured questionnaire to assess participants experience with telehomecare program.
45818256|NCT04976647|Drug|HLX10+chemo|HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle
45818257|NCT04976647|Drug|HLX10+HLX07+chemo|HLX07 1500mg IV q3w; HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle
45818258|NCT04976647|Drug|HLX10+HLX07|HLX07 1500mg IV q3w; HLX10 300mg IV Q3W;
45818259|NCT03291080|Drug|Liquid 13-Cis Retinoic Acid|Liquid 13-Cis Retinoic Acid
45818260|NCT03291080|Drug|Extracted capsules 13-CRA|Extracted capsules 13-CRA
45818261|NCT04553731|Behavioral|empowerment program with mHealth|empowerment program with mHealth
45818262|NCT04933123|Device|indirect restorative treatement with a glass ceramic|Inlays and onlays of glass ceramic for molars and premolars are adhesively luted.
45818263|NCT03292562|Device|Discontinue NCPAP after weaning pressures|After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
45818264|NCT03292562|Device|Discontinue NCPAP without weaning pressures|After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
45818265|NCT04874545|Drug|Propofol|Total intravenous inhalational anesthesia
45818266|NCT00368095|Behavioral|Intensive Education for Metabolic Syndrome Patients|Excercise, Intensive diatary program
45818267|NCT03216200|Device|plasma treatment|application of cold atmospheric plasma to a fungal infected toenail
45818268|NCT04735939|Radiation|radiotherapy|Determine whether there is a difference in outcomes seen when patients are assigned to take their radiotherapy at either a morning time or evening time.
45818269|NCT03888092|Drug|Z650|receive oral Z650 once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
45818270|NCT04440865|Other|Genius® System-assisted Colonoscopy|Genius® Intelligence System is used to assist Colonoscopy
45818271|NCT04440865|Other|Standard Colonoscopy|Standard Colonoscopy without Genius® Intelligence System is performed
45818272|NCT03418064|Device|Fanfilcon A toric lens|Contact lens
45664117|NCT02386189|Behavioral|Patient Care Coordination Training|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
45664118|NCT02385799|Drug|Sertraline Liquid Placebo|Liquid placebo given in parallel to active medication
45664119|NCT02385799|Drug|Sertraline|Active medication
45664120|NCT02422303|Drug|ketamine|Ketamine 0.5mg/kg will be given intravenously to group A at induction of general anesthesia.
45664121|NCT02392195|Other|Non-interventional|Observational
45664122|NCT02391961|Drug|Dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
45818273|NCT03418064|Device|Lotrafilcon B toric lens|Contact lens
45664123|NCT02391961|Drug|Placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
45664124|NCT02384941|Drug|Placebo|Placebo once daily, before first meal of the day.
45664125|NCT02384941|Drug|Sotagliflozin|Sotagliflozin once daily, before first meal of the day.
45664126|NCT02384551|Other|Dietary Carbohydrate|9 week menu of dietary carbohydrate modification
45664127|NCT02384395|Drug|Dolutegravir 50 mg|Initial therapy for AHI
45818274|NCT03181009|Drug|Omalizumab|All subjects will receive omalizumab, stored and prepared according to the investigator brochure. Subjects greater or equal to 4 yrs receive 150 mg. Subjects less than 4 yrs receive 75 mg.
45818275|NCT03181009|Drug|Food Flour Allergens|The subject's allergens will be introduced after receiving the third omalizumab dose.. Subjects will return to clinic to escalate the dose of their allergens until 300 mg (group A) vs. 1200 mg (group B) total protein daily dose is reached. There will be equivalent allergen protein portions depending on test allergen per each subject's history. Subjects will be randomized 1:1 to either group A or group B after meeting eligibility criteria. All subjects and study personnel will be blinded to group A vs B. Research staff will administer food flour to the subject orally in an age-appropriate food vehicle.
45818276|NCT04792411|Behavioral|Prehabilitation|Multimodal, tailored prehabilitation programme
45818277|NCT04430569|Drug|Alteplase|Alteplase single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.
45818278|NCT04430569|Drug|Placebo|Placebo single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.
45818279|NCT03292952|Drug|KP415 oral capsule|Daily dose
45818280|NCT03292952|Drug|Placebo oral capsule|Daily dose
45818281|NCT03296072|Drug|0.254% w/w sodium fluoride and 5% KNO3|Dentifrice containing 0.254% w/w sodium fluoride (1150 ppm fluoride) and 5% KNO3; plus 0.25% PVM/MA copolymer and 2.5% sodium lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 millilitres [mL] of tap water for 10 seconds before expectorating again.
45818282|NCT03296072|Drug|0.454% w/w stannous fluoride|Dentifrice containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
45958388|NCT04090957|Drug|Placebo oral tablet|Placebo oral tablet will be administered orally once daily.
45818283|NCT03296072|Drug|5% KNO3|Fluoride free placebo dentifrice containing 5% KNO3 (0 ppm fluoride), 0.25% PVM/MA copolymer and 2.5% lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
45818284|NCT03182725|Drug|Ivabradine|Ivabradine is prescribed for treatment of chronic heart failure through inhibition of the f-channels (If) within the sinoatrial node.
45818285|NCT03182725|Drug|Placebo|A substance that has no therapeutic effect and will act as a control.
45664128|NCT02384395|Drug|Lamivudine 300 mg|Initial therapy for AHI
45664129|NCT02384395|Drug|Abacavir 600 mg|Initial therapy for AHI
45664130|NCT02420353|Drug|Somatropin|GH dose will be calculated by nomogram estimation of body surface area, and will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin GH treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take GH, but otherwise patients will take GH every day over this 6 week period.
45664131|NCT02420353|Drug|Placebo|A placebo diluent that will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of the equivalent concentration of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take medication, but otherwise patients will take medication every day over this 6 week period.
45818286|NCT03216512|Other|Use of Noise Cancelling Headphones|During the 2 experimental sessions, participants will complete study assessments using either a noise cancelling headphone first (session 1) and then sham control second ( session 2), or vice versa, in the presence of noise distractions.
45818287|NCT03185065|Drug|Amantadine|100 mg of amantadine increased to 200 mg of amantadine, if tolerated
45818288|NCT03185065|Drug|Modafinil|100 mg of modafinil increased to 200 mg of modafinil, if tolerated
45818289|NCT03185065|Drug|Methylphenidate|5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated
45818290|NCT03185065|Drug|Placebos|1 placebo capsule increased to max of 2 capsules twice daily
45818291|NCT03419780|Biological|Blood Transfusion|Patients are randomized to receive 1 or 2 units of packed red blood cells for initial transfusion.
45818292|NCT05406271|Diagnostic Test|Intraoperative fluoroscopy|Impantation of hip prosthesis with intraoperative fluoroscopy
45818293|NCT04415671|Biological|AD-214|AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.
45818294|NCT04415671|Other|Placebo|Placebo
45958389|NCT04050982|Device|AF CARE|Patients will receive personalized messages twice weekly that will include behavior recommendations for CVRF reduction and AF education based on the initially entered psychographic profile and data entered.
45958390|NCT04050982|Behavioral|Usual Care Wait List|Participants will be given recommendations for CVRF reduction based on their initial LS7 assessment and will be provided educational materials and be wait listed for digital app 3 months later
45958391|NCT04049331|Drug|Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]|first two doses four weeks apart; following three more doses every ten weeks.
45958392|NCT04049331|Other|placebo|first two doses four weeks apart; following three more doses every ten weeks.
45958393|NCT04033055|Procedure|Inguinal hernia repair with CycloMesh™ soaked in ropivacaine hydrochloride 10mg/mL|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in ropivacaine hydrochloride 10mg/mL) is positioned once the surgery for the inguinal hernia repair has been performed."
45664132|NCT02391337|Drug|Bisoprolol|Drug intervention
45664133|NCT02391337|Drug|Digoxin|Drug intervention
45818295|NCT04398199|Drug|Hypofractionated Radiation Therapy|The prescribed dose will be 70 Gy in 25 fractions. Participants will radiation therapy once a day for 25 days, Monday through Friday (around 5 weeks).
45818296|NCT04398199|Radiation|Radiation Boost|Undergo simultaneous integrated boost (SIB) to treat both planned target volumes with daily image guidance. This approach allows daily confirmation of target localization and simultaneous delivery of lower dose per fraction to low risk areas while maintaining a high dose per fraction to the highest risk areas.
45958394|NCT04033055|Procedure|Inguinal hernia repair with CycloMesh™ soaked in saline solution NaCl 9°/°°|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in saline solution) is positioned once the surgery for the inguinal hernia repair has been performed."
45958395|NCT04015596|Drug|Naproxen Sodium|Dosed by weight (10mg/kg), twice daily, for 8 weeks
45958396|NCT04015596|Other|Placebo|Participants take placebo pills twice daily, for 8 weeks.
45958397|NCT04010461|Device|TMS|Intermittent theta burst stimulation TMS applied to the cortex to excite cerebral cortex
45958398|NCT04010461|Behavioral|n-back working memory task|Subjects perform an executive function task, in which they view the serial presentation of letters and decide whether or not a letter matches a letter presented 'n' letters back (2 letters or 1 letter)
45958399|NCT03985722|Drug|Olaratumab and Trabectedin|"Dose escalation levels:~LEVEL -1: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 0.9 mg/m2 D1 This is a security level in case level 0 causes DLT.~LEVEL 0*: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.1 mg/m2 D1. * Dose starting level is 0.~LEVEL 1: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.3 mg/m2 D1.~LEVEL 2: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.5 mg/m2 D1.~LEVEL 3**: Olaratumab 20 mg/kg C1D1 and C1D8 (induction) + Trabectedin 1.5 mg/m2 D1 and Olaratumab 15 mg/kg D1 and D8 (maintenance) + Trabectedin 1.5 mg/m2 D1~**In LEVEL 3, Olaratumab dose of 20 mg/kg will be considered only for the first 2 doses (as induction doses, cycle 1 days 1 and 8). Then, the maintenance dose will be 15 mg/m2 for the rest of cycles."
45958400|NCT03966105|Diagnostic Test|HE and Congo red staining|Biopsies will be formalin fixed, processed routinely, and sent to the Department of Pathology for evaluation by hematoxylin and eosin and Congo red staining by pathologists. Biopsy specimens with confirmed amyloid deposits via Congo red staining will be further analyzed using immunohistochemistry for subtyping.
46079286|NCT05686499|Other|Didactic Lectures and demonstrations|"Trainees will receive 4-6 hours of didactic colonscopy lecture sessions based on the American Board of Surgery Flexible Endoscopy curriculum for general surgery residents, general surgery resident curriculum (SCORE) endoscopy module, and the Joint Advisory group on GI Endoscopy program adapted to Nigeria context.~Trainees will have the opportunity to practice colonoscopy on HF or LF simulators (depending on the arm) with immediate feedback from instructors."
45664134|NCT02382991|Device|3C60-NMPK|3 months with 3C60 - 10 days wash out - 1 month with NMPK
45664135|NCT02382991|Device|NMPK-3C60|1 month with NMPK - 3 months with 3C60
45664136|NCT02390557|Other|Survey|PDQS survey reports only
45664137|NCT02390557|Other|YESHealth|Arm 3: YESHealth and PDQS survey reports to providers
45664138|NCT01649791|Drug|lenalidomide|Given orally
45664139|NCT01649791|Other|laboratory biomarker analysis|Correlative study
45664140|NCT01649791|Procedure|lymph node biopsy|Correlative study
45664141|NCT01649791|Procedure|bone marrow aspiration|Correlative study
45818297|NCT00375739|Drug|PEP005|
45818298|NCT05406037|Biological|Venous sample|at Day 0, Day 3, Day 7, Day 14, Day 28 (7 ml blood sample collecting on dry tube) D0 = Diagnostic day
45958401|NCT03954327|Drug|Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)|Emtricitabine (FTC) 200 mg/Tenofovir Disoproxil (TDF) 300 mg by mouth once per day
45958402|NCT03954327|Drug|Raltegravir|Raltegravir (RTF) 600 mg two tablets by mouth once per day
45958403|NCT03954327|Drug|Placebo Oral Capsule [CEBOCAP]|Two capsules identical to Raltegravir and one capsule identical to Truvada with no active ingredients by mouth once per day
45958404|NCT03946670|Drug|MBG453|MBG453 is being administered i.v.
45664142|NCT01649791|Other|pharmacological study|Correlative study
45664143|NCT01649791|Other|flow cytometry|Correlative study
45664144|NCT01649557|Drug|OPC-34712|oral administered once daily
45664145|NCT02390245|Other|Free Eye Screenings|This group will receive free eye screening and follow-up comprehensive ophthalmic exam if recommended.
45664146|NCT02390245|Other|Enhanced Intervention|This group will receive ophthalmic referral and a navigator for assistance in scheduling appointments; confirming appointments via phone, mail, email and/or text message; arranging transportation through Customized Community Transportation (CCT) and Philadelphia Paratransit Service; and trained medical interpreters as needed.
45818299|NCT02220894|Biological|pembrolizumab|
45818300|NCT02220894|Drug|carboplatin|
45818301|NCT02220894|Drug|paclitaxel|
45818302|NCT02220894|Drug|pemetrexed|
45818303|NCT04396249|Device|Active tVNS|One electrode tip is used as their common terminal, and the other two electrode tips are respectively connected to the skin surfaces of the auricle and the external auditory meatus. Each subject will have 10 active tVNS sessions.The active tVNS group will be stimulated with a 2 mA current for 30 minutes.
45958405|NCT03946670|Drug|Placebo|Placebo is being administered i.v.
45958406|NCT03946670|Drug|Hypomethylating agents|Decitabine is being administered i.v. Azacitidine is being administered i.v or s.c.
45958407|NCT03943446|Drug|TAK-018|TAK-018 immediate-release tablets.
45958408|NCT03943446|Drug|TAK-018 Placebo|TAK-018 placebo-matching tablets.
45664147|NCT02390245|Other|Usual Care|This group will receive ophthalmic referral.
45664148|NCT02390167|Device|ONYX NEXT BGMS|Untrained Persons WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX NEXT BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested venous blood from subjects WITH Diabetes and BG results were compared to reference method results obtained from the subjects' venous plasma.
45958409|NCT03939416|Other|Experimental|"STANDART~Physical exercise: degreed joint mobilization, self muscle elongation and postural correction.~Sophrology: mental control of insomnia and painful perception~Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease~POLD~Rhythmic transversal muscle mobilization in posterior chain musculature.~General vertebral decompression from the sacrum and pelvis~Metameric subcutaneous mobilization~Rhythmic vertebral mobilization from the spinous processes."
45958410|NCT03939416|Other|Control|"STANDART~Physical exercise: degreed joint mobilization, self muscle elongation and postural correction.~Sophrology: mental control of insomnia and painful perception~Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease"
45958411|NCT03929523|Device|End-ischemic Hypothermic Oxygenated Machine Perfusion (HOPE)|"In the experimental group, ECD liver grafts will first undergo a classical static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until transport to the transplantation center. They will then undergo a hypothermic oxygenated perfusion (HOPE) via the portal vein for a period of 1 to 4 hours (minimum 1 hour) after the back-table phase (graft preparation), in parallel with the recipient hepatectomy, using the CE-certified Liver Assist® perfusion pump/device (Organ Assist®, the Netherlands) with Machine Perfusion Solution (Belzer-MPS, CE-certified)."
45958412|NCT03929523|Device|classic static cold storage|The control group will consist of a classic static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until liver transplantation, which is the gold standard procedure in liver transplantation
45958413|NCT03927833|Device|Phototherapy lights|Phototherapy lights used continuously or timed, following an algorithm based upon TSB levels.
46079287|NCT05685628|Other|Cinnamon dressing|"Use of CINESTEAM® as a non-occlusive secondary dressing~CE marked medical device class I, secondary, absorbent, non-adhesive and composed of:~Anti-odor upper part, adsorbent containing cinnamon powder.~Weakly absorbent lower part intended to absorb excess exudates."
46079288|NCT05685628|Other|Charcoal dressing|"Use of ACTISORB® as a non-occlusive secondary dressing~CE marked medical device class IIb, without adhesive, consisting of a non-woven nylon envelope containing a layer of activated carbon. ACTISORB® can be applied as a primary or secondary dressing."
45455122|NCT04467658|Diagnostic Test|electroencephalography relative delta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
45664149|NCT02347657|Drug|VX-661 Plus Ivacaftor Combination|FDC tablet, oral use
45664150|NCT02347657|Drug|Ivacaftor|Tablet, oral use
45664151|NCT02347657|Drug|VX-661 Plus Ivacaftor Combination Placebo|FDC tablet, oral use
45664152|NCT02347657|Drug|Ivacaftor placebo|Tablet, oral use
45818304|NCT04396249|Device|Sham tVNS|Each subject will have 10 sham tVNS sessions.The sham tVNS group will be stimulated with a 2 mA current for 30 minutes. Except for the stimulation site, other parameters are the same as active group.
45958414|NCT03890432|Device|GLUCOSAFE 2|Use of GLUCOSAFE 2 software for nutrition management and insulin-therapy
45958415|NCT03890432|Device|Local protocol control group with routine care|Use of the local protocols (electronic or paper version) for nutrition management and blood glucose control.
45958416|NCT03890432|Device|Historical control group with routine care|Use of the local protocols (electronic or paper version) for nutrition management and blood glucose control.
45958417|NCT03885908|Other|in-person geriatric co-management|"The geriatrics service sees these patients for at least 2 postoperative days, if deemed clinically necessary by the geriatrician. During the inpatient hospital course, the geriatrics service will ensure the execution of preoperative recommendations and will discuss with the surgical team, who will act as a primary team, any additional recommendation in order to improve postoperative care. In-person geriatric consults to be done via telemedicine due to the current pandemic and consideration for patient safety."
46079289|NCT05680467|Other|Manual Therapy|"The protocol will last 30 minutes and will include the application of the following manual techniques:~Lumbar soft tissue and joint cranial and lateral mobilization with the patient in the supine position~Bilateral medial lumbar soft tissue mobilization~Functional massage on the quadratus lumborum muscle with the patient in a lateral position on both sides~Extension with coupled sidebending mobilization of the thoracic area with the patient in a lateral position on both sides~Soft tissue lateral mobilization of the thoracic area with the patient in a lateral position on both sides"
45664153|NCT02347189|Device|Melody Transcatheter Pulmonary Valve PB1016|
45664154|NCT02382133|Device|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
45818305|NCT03285061|Device|Deterra Drug Deactivation System|A portable bag that will neutralize and dissolve excess medication, rendering it completely unusable and safe for landfill disposal. The system meets FDA and DEA standards for at home disposal systems.
45958418|NCT03885908|Other|automated geriatric co-management|Following completion of the eRFA, the summary of impairments as well as the recommendations generated by the study team (hard-copy or email) will be provided in real-time to the surgery team for their attention.
45958419|NCT03840746|Other|Tomato, onion and lovage soup (TOL)|Soup
45958420|NCT03840746|Other|TOL soup with inulin|Soup
45958421|NCT03835767|Other|Peanut powder and Oat flour|Peanut powder with 46% protein content is manufactured by PB2. Oat flour is manufactured by GF Harvest.
45958422|NCT03835767|Other|Peanut flour and Oat flour (placebo for peanut flour)|Peanut flour (12% light roast) with 50% protein content is manufactured by Byrd Mill. Oat flour is manufactured by GF Harvest.
45958423|NCT03835767|Other|Dry Milk Powder and Corn Starch (placebo for Milk powder)|Dry milk powder with 36% protein content is manufactured by Giant Food. Corn starch is Argo brand.
45958424|NCT03835767|Other|Baked milk and Rice milk (placebo for Baked milk)|Baked milk will be in the form of a muffin provided by the NIH CC Nutrition Department. Rice milk is manufactured by Rice Dream brand.
45958425|NCT03793062|Other|No Interventions|Not applicable - No Interventions
45958426|NCT03762096|Dietary Supplement|Trans-resveratrol|1 gram, twice a day by mouth Transmax (Biotivia)
45958427|NCT03762096|Dietary Supplement|Placebo|Placebo
45958428|NCT03758638|Behavioral|Healthy Eating & Active Living Taught at Home|PAT National Center will train educators affiliated with PAT sites in HEALTH; among these, using the HEALTH training curriculum, which includes training materials, an ~8 hour training delivered through a synchronous web-based experience, and ongoing consultation. Participants at HEALTH sites receive usual care PAT+evidence-based life-style change strategies to prevent weight gain and promote weight loss embedded within and delivered as part of home visits. In addition to the usual care PAT curriculum content, goal setting related to healthy weight, and the importance of parental modeling of healthy eating and physical activity are incorporated throughout the discussion and visit. HEALTH will be delivered over 24 months via a (1) core and (2) maintenance phase. The visits begin with greater frequency, and taper. Consistent with PAT practice, the frequency and number of visits are determined by the family's needs and preferences.
45958429|NCT03758638|Behavioral|Usual Care|The Foundational (usual care) curriculum uses a strength-based, solution-focused model to provide parents with child development knowledge and parenting support, empowering parents as their child's first and most influential teacher.
45664155|NCT02346877|Behavioral|Personalized Patient Counselling|In the interventional cohort participants enrolled on the study will receive personalized patient counselling using the IMS-model based on the baseline BMQ results through a patient assistance program for patients on Enbrel (Etanercept) therapy.
45664156|NCT02346721|Drug|SOF/VEL|400/100 mg tablet administered orally once daily
45664157|NCT02389621|Drug|Lusutrombopag|Tablets for oral administration
45458224|NCT02311114|Other|Observational fieldwork|Observational fieldwork will conducted to observe everyday routine activities related to telehomecare. May last up to 1h per observation.
45664158|NCT02389621|Drug|Placebo|Tablets for oral administration
45664159|NCT02388997|Drug|omalizumab|This medication has been approved for clinical use to treat patients with moderate to severe asthma by the FDA in 2003 and for use in this study (BB-IND# 10510)
45664160|NCT02388997|Biological|Rhinovirus (strain 16)|This strain of pooled rhinovirus has been approved for use in experimental challenges (BB-IND# 15162) and for use in this study (BB-IND# 10510) by the FDA.
45664161|NCT02388763|Device|Stenfilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
45664162|NCT02388763|Device|Narafilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
45664163|NCT02388295|Drug|AZD3241|Drug: AZD3241 administered for 12 weeks orally as a tablet.
45664164|NCT02388295|Drug|Placebo|Placebo to match AZD3241 administered for 12 weeks orally as a tablet.
45958430|NCT03737955|Drug|Gemtuzumab Ozogamicin|Receive IV
45958431|NCT03737955|Other|Quality-of-Life Assessment|Ancillary studies
45958432|NCT03736720|Drug|Fluorouracil|Given IV
45958433|NCT03736720|Drug|Leucovorin|Given IV
45958434|NCT03736720|Drug|Liposomal Irinotecan|Given IV
45958435|NCT03736720|Procedure|Quality-of-Life Assessment|Correlative studies
45958436|NCT03718234|Drug|Subcutaneous hydrocortisone|Patients will be monitored and receive an interval bolus SQHC dosing regimen that more closely mimics cortisol, 17OHP and D4A circadian and ultradian rhythms than conventional oral HC dosing.
45818306|NCT04361617|Behavioral|Daily consumption of tree nuts and extra virgin olive oil|All participants will receive a 4-week supply of extra virgin olive oil and tree nuts, including unsalted English walnuts, almonds or pistachios (approximately 3-day supply of each type). Participants will be asked to include in their normal diets these products and will be provided recipes and other information that will allow them to replace other foods with the nuts and oil. We will ask participants to consume one ounce of tree nuts per day and two tablespoons of EVOO per day by incorporating these foods into their diet.
45818307|NCT02219334|Device|NoseFrida|The NoseFrida has four components, the collection container, an interchangeable filter, flexible tubing and a mouth piece. The end of the collection devise is placed on the patient's nostril, a tight seal is made via the vacuum created from suctioning of the mouth piece and secretions are easily aspirated. This device disassembles for quick disinfecting and cleaning.
45458225|NCT02311114|Other|Survey|Surveys with participants will be conducted using validated survey tools.
45818308|NCT03285373|Drug|NOAC|New Oral Anticoagulant
45818309|NCT02159040|Drug|Azacitidine|SC or IV AZA at 75mg/m2 7 days/28 day cycle
45818310|NCT02159040|Drug|Azacitidine plus Deferasirox|SC or IV AZA at 75mg/m2 7 days/28 day cycle DFX 10mg/kg/day
45818311|NCT03285529|Device|STRATIFIX|STRATIFIX symmetric PDS Plus; Stratifix knotless suture
45818312|NCT03285529|Device|VICRYL|Vicryl #1
45818313|NCT03189589|Drug|GSK2269557 500 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 500 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
45818314|NCT03189589|Drug|GSK2269557 750 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 750 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
45818315|NCT04123093|Device|Noxsano Bandage (Healthy Volunteers)|Healthy volunteers will wear the study device (Noxsano Bandage) for 3 consecutive days (up to 72 hours), followed by weekly visits for 4 weeks of observation for tolerance, side effects, and/or adverse reactions.
45818316|NCT04123093|Device|Noxsano Bandage (Wound Care)|Wound care subjects will have weekly study device (Noxsano Bandage) applications to a specific ulceration. For subjects that exhibit any reduction in wound surface area, this application will occur until the wound is healed, or for up to 3 months (whichever occurs first). For subjects that do not exhibit any reduction in wound size at 2 months, application will stop and standard treatment protocols will be pursued. At the conclusion of the treatment window (up to 3 months), subjects will be followed every 3 months for 12 consecutive months for observation of late side effects or adverse reactions (3 months of active treatment, 12 months of follow-up observation, 15 months total).
45818317|NCT02218008|Drug|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
45818318|NCT02218008|Drug|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
45818319|NCT03216902|Drug|Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution|Vehicle of DE-126 Ophthalmic Solution dosed once daily for 6weeks, followed by high dose of DE-126 dosed once daily for 6 additional weeks
45818320|NCT03216902|Drug|Topical ultra-low dose of DE-126 Ophthalmic Solution|Topical ultra-low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
45818321|NCT03216902|Drug|Topical low dose of DE-126 Ophthalmic Solution|Topical low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
45818322|NCT03216902|Drug|Topical medium dose of DE-126 Ophthalmic Solution|Topical medium dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
45664165|NCT02345161|Drug|Triple FF/UMEC/VI|The combination will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip). It will have 100 mcg of FF (blended with lactose) per blister, 62.5 mcg of UMEC (blended with lactose and magnesium stearate) per blister and 25 mcg of VI (blended with lactose) per blister.
45818323|NCT03216902|Drug|Topical high dose of DE-126 Ophthalmic Solution|Topical high dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
45818324|NCT03216902|Drug|0.005% Latanoprost Ophthalmic Solution|0.005% Latanoprost Ophthalmic Solution dosed once daily for 12 weeks
45664166|NCT02345161|Drug|Placebo to match FF/UMEC/VI|The placebo (Lactose) will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip).
45664167|NCT02345161|Drug|Budesonide/Formoterol|The combination (400 mcg Budesonide/12 mcg Formoterol) will be provided as inhalation via TURBOHALER with 60 doses.
45664168|NCT02345161|Drug|Placebo to match Budesonide/Formoterol combination|The placebo (Lactose) will be provided as inhalation via TURBOHALER with 60 doses.
45818325|NCT03190213|Drug|Pembrolizumab Injection|Pembrolizumab at a dose of 200 mg will be administered as an IV infusion over 30 minutes every 3 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 2 years. We anticipate on average patients will remain on treatment for approximately 24 weeks.
45818326|NCT03190993|Other|Sugar Sweetened Solid Treatment|Consume Sugar Sweetened Solid Treatment (product) daily.
45818327|NCT03190993|Other|Sugar Sweetened Beverage Treatment|Consume Sugar Sweetened Beverage Treatment (product) daily.
45958437|NCT03718234|Drug|Standard glucocorticoid therapy|Subjects in this arm will continue on standard oral hydrocortisone therapy
45958438|NCT03705832|Drug|Ginger Extract|2gm Capsule of Ginger extract
45958439|NCT03705832|Drug|Placebo|Matching Placebo
45958440|NCT03631017|Drug|[18F]- PARPi|injection of a microdose (< 100 ug) of [18F]- PARPi
45458226|NCT02311192|Device|Ultrasonography B-scan|The patient's eye will be anesthetized. The ultrasound probe will then be used to obtain images by keeping the probe in light contact with the eye.
45958441|NCT03631017|Diagnostic Test|PET/CT Scans|"Patients will be injected with approximately 10 mCi of [18F]PARPi and a dynamic PET scan of will be acquired for approximately 30 minutes. A second body PET/CT scan will be started approximately 60 min post injection, and a third PET/CT scan will be started at approximately 120 min post injection. The first (dynamic) and the second (body) PET/CT scan will use ultra -low dose CT scan for attenuation correction. The last PET/CT scan will be performed with the investigator's regular clinical low-dose CT settings."
45455123|NCT04467658|Diagnostic Test|electroencephalography absolute theta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
45958442|NCT03613987|Device|NAVA technology to synchronize NIPPV|Neurally adjust ventilator assist is used to synchronize the NIPPV
45958443|NCT03602677|Device|ICG fluorescence imaging|The use of indocyanine green fluorescence imaging as an addition to standard surgical procedure.
45958444|NCT03594630|Drug|Chemotherapy|Receive chemotherapy
45958445|NCT03594630|Other|Patient Observation|Receive active surveillance
45958446|NCT03594630|Other|Questionnaire Administration|Ancillary studies
45958447|NCT03594630|Procedure|Resection of Rectum|Undergo surgical resection
45958448|NCT03580668|Drug|B/F/TAF|B/F/TAF administered in accordance with the approved product monograph
45958449|NCT03579901|Device|Silicone gel-filled breast implants - Motiva Implants® Investigational breast implants|Breast augmentation
45958450|NCT03575351|Drug|Standard of Care|Standard of Care
45458227|NCT02315404|Procedure|CAP|CAP fitted to the end of the endoscope
45958451|NCT03575351|Genetic|JCAR017|JCAR017
45958452|NCT03509571|Other|Ketogenic Diet|Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with ketogenic diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet is a high-fat, low-carbohydrate diet (lipid to carbohydrate + protein ratio of 3:1) that will include ≈75% total energy as fat, ≈20% as protein, and ≈5% as carbohydrate and fiber.
45958453|NCT03509571|Other|Standard Diet|Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with SD diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet includes ≈35% total energy as fat, ≈27% as protein, and ≈44% as carbohydrate and fiber.
45458228|NCT03501628|Dietary Supplement|Placebo|Supplementation twice daily (1 serving dose per consumption) of maltodextin while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
45958454|NCT03493516|Diagnostic Test|PET scan quantifying sympathetic denervation using [18F]-LMI1195|A cardiac PET scan will be obtained to quantify the percentage of the left ventricle that is denervated and has reduced uptake of the sympathetic nerve tracer [18F]-LMI1195
46079290|NCT05680467|Other|Manual Therapy plus TECAR|The participants of this group will be given the same manual protocol as the first group in combination with the application of high frequency current. Soft tissue mobilization manipulations will be applied in combination with a capacitive conventional electrode and with a special electrode bracelet that makes the therapist's own hand as an antistatic electrode. The frequencies of the high frequency current will be 300khz, 500khz, and 1MHz, while as a reference electrode a flexible self-adhesive ground will be used placed on the abdomen
46079291|NCT05680467|Other|Control|Participants in this group will only receive general instructions about managing their back pain and counseling about avoiding activities that may worsen their symptoms.
46079292|NCT05678231|Device|Zero Degree Knee Positioner|The Zero Degree Knee (ZDK) positioning device is a knee extension pillow designed to simplify knee extension exercise following TKA surgery.
45818328|NCT03194503|Device|VL Coaching training using C-MAC video laryngoscope|"Each neonatology attending providers will receive a video laryngoscopy coaching training using a C-MAC video laryngoscope and an intubation training manikin available at each site by a site leader. During the training, site leader will act as a trainee confederate, and each neonatology attending provider will be trained to coach a trainee utilizing video images from C-MAC video laryngoscope and a cognitive aid with standardized language in a laminated card. This training part typically takes approximately 15-30 minutes including consenting process.~Each site leader will be trained by PI or PI's designee using remote simulation. In this remote simulation, each site leader will coach an actor at the Children's Hospital of Philadelphia (CHOP) using a profile video image and C-MAC video laryngoscopy image through CHOP approved video conferencing software. A standardized language will be taught to each site leader with a cognitive aid (laminated card)."
45958455|NCT03490344|Drug|Daratumumab|"Cycles 1 and 2: Daratumumab 16mg/kg weekly per cycle (28 days) as intravenous infusion (total duration: 8 weeks)~Cycles 3-6: Daratumumab 16mg/kg once every 2 weeks per cycle (28 days) as intravenous infusion (total duration: 16 weeks)"
45958456|NCT03490344|Drug|Lenalidomide|Lenalidomide maintenance therapy to be administered as standard treatment to all participants. This is administered as 5-15 mg daily 21-28/28 day cycle.
45958457|NCT03479242|Other|no interventions|no interventions are planned
45958458|NCT03460379|Drug|Escitalopram|Patients are tested for their normal prescription escitalopram medication
45958459|NCT03460366|Drug|Enalapril|Patients are tested for their normal prescription enalapril medication
45958460|NCT03460353|Drug|Dexamphetamine|Patients are tested for their normal prescription dexamphetamine medication
45958461|NCT03460327|Drug|Candesartan|Patients are tested for their normal prescription candesartan medication
45958462|NCT03460314|Drug|Buprenorphine|Patients are tested for their normal prescription buprenorphine medication
45958463|NCT03460210|Drug|Atomoxetine|Patients are tested for their normal prescription atomoxetine medication
45958464|NCT03449472|Drug|Quetiapine|Patients are tested for their normal prescription quetiapine medication
46079293|NCT05673889|Drug|ARV-471|Experimental
46079294|NCT05673889|Drug|Dabigatran etexilate|Probe substrate
46079295|NCT05673759|Device|Electroencephalogram (EEG) system|An FDA 510(k) approved EEG/ERP device designed by G-Tec ™ intended for the acquisition, display, analysis, storage, reporting and management of EEG and auditory evoked potentials (AEP) information and uses Bluetooth technology to securely transmit EEG signals to a computer. The device is patient-friendly, and no serious adverse events have occurred to-date in any research or clinical study or in clinical use.
45958465|NCT03447743|Drug|XR-NTX community location|XR-NTX will be administered at the local health care clinic
45958466|NCT03440879|Drug|Zoladex|Patients currently treated with Zoladex
45958467|NCT03433755|Drug|evolocumab|Evolocumab will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously.
46079296|NCT05673759|Behavioral|Standard Neuropsychological Testing|Prior to the EEG session, neuropsychological testing will be done to establish a baseline measurement. We administer a full standard neuropsychological battery (45 mins) for all participants which includes the following tests: MOCA (only for older participants), MMSE, CERAD, Phonemic Test and the Category Fluency test, Trails Making Test A and B, BNT, BAI, BDI, PANAS, Ishihara Color Blindness test, and the Snellen Eye Chart.
46079297|NCT05673759|Behavioral|Additional neuropsychological tests|Younger participants will receive additional testing along with the standard neuropsychological battery including Pittsburgh Sleep Quality Index (PSQI) [37] for sleep quality measures, the Test of Memory Malingering (TOMM) for effort measure, Ohio State Traumatic Brain Injury Identification Method questionnaire (OSU-TBI) [38] to gather lifetime TBI history, and the Neurobehavioral Symptom Inventory (NBSI) [39] for post-concussive symptoms. These additional tests will add an extra fifteen minutes, making the total time for neuropsychological questionnaires 1 hour in younger participants.
46079298|NCT05671705|Diagnostic Test|DEXA Scan|Fu of diagnostic tests
45455124|NCT04467658|Diagnostic Test|electroencephalography relative theta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
45458229|NCT03501628|Dietary Supplement|L-leucine + maltodextrin|Supplementation twice daily (1 serving dose per consumption) of L-leucine + maltodextin while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
45664169|NCT02345161|Drug|Albuterol/salbutamol|Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1 Albuterol/salbutamol MDI or NEBULES™ for as needed (prn) use throughout the study will be provided starting at Visit 1.
45664170|NCT02251275|Drug|Tolvaptan|Tolvaptan tablets (15 or 30 mg) self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
45664171|NCT02379637|Drug|N-acetylcysteine|
45664172|NCT02379637|Drug|Placebo|
45664173|NCT02195583|Drug|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
45664174|NCT02195583|Drug|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
45664175|NCT02195583|Drug|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
45818329|NCT03219320|Drug|NYX-2925|NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
45818330|NCT03219320|Drug|Placebo|Matching Placebo capsules.
45818331|NCT03194737|Device|UroLift System Procedure|Minimally invasive procedure in patients with acute urinary retention secondary to BPH.
45818332|NCT01632150|Biological|Elotuzumab|Powder for solution, 400-mg vials, for infusion
45818333|NCT01632150|Biological|Thalidomide|50-mg capsules administered orally
45818334|NCT01632150|Biological|Dexamethasone|2- and 4-mg tablets (and various other strengths, as needed) administered orally and in 4- and 8-mg/mL (and various other strengths, as needed) solutions for intravenous administration
45958468|NCT03433755|Drug|placebo|Placebo will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive placebo every 2 weeks or monthly subcutaneously.
45958469|NCT03430674|Behavioral|Exercise|Exercise, questionnaires and blood draws.
45958470|NCT03406507|Biological|Ravulizumab|Single intravenous (IV) loading dose on Day 1, followed by regular IV maintenance dosing beginning on Day 15, based on weight.
45958471|NCT03283150|Drug|Remifentanil|Remifentanyl will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the bispectral index (BIS) values to normalize to awake level for the MER.
45958472|NCT03283150|Drug|Propofol|Propofol will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
45958473|NCT03283150|Drug|Dexmedetomidine|Dexmedetomidine will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
45958474|NCT03277924|Drug|Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent]|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
45958475|NCT03277924|Drug|Nivolumab 100 MG/10 ML [Opdivo]|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
45958476|NCT03277924|Drug|Epirubicin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
45664176|NCT02195583|Drug|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
45664177|NCT02195583|Drug|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
45818335|NCT01632150|Biological|Cyclophosphamide|50-mg tablets administered orally
45958477|NCT03277924|Drug|Ifosfamide|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
45958478|NCT03277924|Drug|Doxorubicin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
45958479|NCT03277924|Drug|Dacarbazine|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
45958480|NCT03277924|Drug|Cisplatin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
45958481|NCT03277924|Drug|Methotrexate|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
45958482|NCT03271580|Diagnostic Test|Finger prick test for HbA1c measurement|HbA1c measurement with finger prick method
45958483|NCT03271580|Procedure|Punch Biopsy|Wound site will be anaesthetized, by punch biopsy tissue will be collected, wound site will be monitored for bleeding(if bleeding Cautery will be used to stop bleeding).
45958484|NCT03271580|Other|Vac Sponge Collection|NPWT sponge which is discarded as biological waste, will be collected for wound macrophage isolation
45958485|NCT03271580|Other|Ankle Brachial Index|Blood pressure test
45958486|NCT03249792|Drug|MK-2118 (IT)|IT injection
45958487|NCT03249792|Drug|MK-2118 (SC)|SC injection
45958488|NCT03249792|Biological|Pembrolizumab|IV infusion
45958489|NCT03218917|Drug|Brensocatib 10 mg|Administered once per day for 24 weeks
45958490|NCT03218917|Drug|Brensocatib 25 mg|Administered once per day for 24 weeks
45958491|NCT03218917|Drug|Placebo|Administered once per day for 24 weeks
45958492|NCT03207841|Other|LC/HP|Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include ~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio <1.5 and fat intake set at ~30% of the total energy intake.
45958493|NCT03204240|Other|Neuromuscular electrical stimulation|NMES-RE will involve concentric/eccentric contractions of the quadriceps from a seated position. Briefly, each session will include four sets of 10 actions evoked using 50 Hz trains of 450 µs biphasic pulses. The protocol will be implemented using surface NMES. Upon completion of the NMES-RE session, participants will be given a short break (10-15 minutes) for recovery before starting aerobic training. NMES aerobic exercise will involve twitch electrical stimulation (pulse duration/interval=200/50 µs) applied to the quadriceps muscle via surface NMES. The current amplitude will set to 175 mA. The training will start with 10 minutes of twitch stimulation at 2 Hz. After the first weeks, the duration of the session will progressively increase up to 60 minutes at 10 Hz.
45958494|NCT03177681|Other|Tongue Assessment|The coating on the top of the tongue assessed and categorized into three categories: no coating, thin coating and thick coating. The coating of the tongue may be related to the microorganisms in the intestine.
45958495|NCT03177681|Other|Stool Sample|Stool sample collected at baseline and once during Days 3-7 and once during Days 8-12.
45958496|NCT03177681|Behavioral|Questionnaires|Participants complete 4 questionnaires about symptoms in the past 24 hours, irritable bowel syndrome (IBS), most recent stool, and quality-of-life. Questionnaires completed at baseline and once during Days 3-7 and once during Days 8-12. Questionnaires should take about 30 minutes total to complete.
45958497|NCT03177681|Device|Holter Monitor|Participants wear a Holter monitor for 20-24 hours to check nervous system and heart function at baseline and once during Days 3-7 and once during Days 8-12.
45818336|NCT03421886|Device|Aerodentis system|The Aerodentis system is intended for the treatment of tooth malocclusion and is treated by applying force, over time, to teeth requiring alignment. It is an individually-fitted, plastic dental mouthpiece that is inserted and worn by the patient according to the dental practitioner's treatment plan. The Aerodentis system is comprised of a plastic mouthpiece containing an inflatable balloon that provides pressure (force) on the selected teeth designated to be moved to a final treated state. The inflatable balloon is inflated to the desired pressure using an electrical air pump unit that is programmed by the dental practitioner using Dror Orthodesign proprietary software; thus creating a course treatment specially designed for each patient.
45958498|NCT03177681|Other|Yogurt|Participants given 2 tablespoons (33 cc) of DannonÒ OikosÒ yogurt each day for 12 days.
45958499|NCT03149770|Drug|Naloxone|naloxone vs placebo
45958500|NCT03149770|Drug|Placebo|placebo vs naloxone
45958501|NCT03132675|Biological|tavokinogene telseplasmid|Intratumoral tavokinogene telseplasmid (tavo, pIL-12) delivered by electroporation every 6 weeks
45458230|NCT03501628|Dietary Supplement|Whey protein concentrate|Supplementation twice daily (1 serving dose per consumption) of whey protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
45664178|NCT02195583|Drug|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
45664179|NCT02379091|Drug|Namilumab|Namilumab subcutaneous injection
45958502|NCT03132675|Biological|Pembrolizumab|Intravenous 3 weekly treatments
45664180|NCT02379091|Drug|Placebo|Namilumab placebo-matching subcutaneous injection
45958503|NCT03132675|Device|ImmunoPulse|Device that electroporates the tavokinogene telseplasmid
45958504|NCT03127215|Drug|Olaparib|Olaparib 150 mg tablet
45958505|NCT03127215|Drug|Physician's choice|treatment according to current guidelines
45958506|NCT03127215|Drug|Trabectedin|Trabectedin 1.1mg/m² infusional solution
45958507|NCT03122925|Device|MR|MR
45958508|NCT03110744|Drug|Palbociclib|application on 21 consecutive days of a 28 days cycle
45958509|NCT03056040|Biological|Ravulizumab|All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to <60 kilograms (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to <100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
46079299|NCT05667597|Diagnostic Test|Humoral immunity|determine binding and neutralizing antibody levels against the epidemiologically predominant SARS- CoV-2 variants of concern (VOC) and the wild type SARS-CoV-2 (Wuhan strain).
46079300|NCT05661175|Procedure|one-handed technique|Traditional percutaneous nephrolithotripsy usually requires the left hand to hold the nephroscope and the right hand to control the fiber for lithotripsy.Our intervention is to control the depth and direction of the sheath with the left hand, the nephroscope in the right hand and control the fiber optic lithotripsy
45818337|NCT03421886|Device|Invisalign clear aligner system|Clear aligners are used for the treatment of tooth malocclusion. In these devices, a series of mouthpieces are used, where the force created by each mouthpiece on the treated teeth is designed to push the teeth in small, one step increments, toward the desired result.
45818338|NCT03286465|Device|Pediatric phlebotomy tubes|Use of pediatric size tubes for diagnostic blood collection.
45818339|NCT03286465|Device|Adult phlebotomy tubes|Use of adult size tubes for diagnostic blood collection.
45818340|NCT02185014|Drug|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
45818341|NCT03297944|Drug|Alprazolam 2mg (2ALP/PLC)|2mg alprazolam administered at night, placebo administered in the morning.
45818342|NCT03297944|Drug|Alprazolam 1mg (1ALP/PLC)|1mg alprazolam administered at night, placebo administered in the morning.
45818343|NCT03297944|Drug|Alprazolam 0.5mg (0.5ALP/PLC)|0.5mg alprazolam administered at night, placebo administered in the morning.
45818344|NCT03297944|Drug|Zolpidem 10mg (ZOL/PLC)|10mg alprazolam administered at night, placebo administered in the morning.
45818345|NCT03297944|Drug|Placebo (PLC/PLC)|Placebo administered at night, placebo administered in the morning.
45818346|NCT03297944|Drug|Alprazolam 1mg (PLC/ALC)|Placebo administered at night, 1mg alprazolam administered in the morning.
45818347|NCT04333004|Drug|Pembrolizumab Combined With Chemotherapy|Pembrolizumab and chemotherapy are carried out at the same time for every 3 weeks
45958510|NCT03056040|Biological|Eculizumab|All treatments were given as IV infusions. Participants received 900 mg of eculizumab q2w.
45958511|NCT03021499|Drug|Voclosporin|calcineurin inhibitor
45958512|NCT03021499|Drug|Placebo Oral Capsule|matching placebo capsule
46079301|NCT05654298|Drug|Sumatriptan|Sumatriptan 100 mg
46079302|NCT05654298|Drug|Ubrogepant|Ubrogepant 100 mg
46079303|NCT05653700|Behavioral|Arena Strive|This second-generation platform provides frontline clinicians with a comprehensive journey to access the tools, training, and technology used by other high-pressure fields to increase performance and enhance resilience.
46079304|NCT05653700|Device|WHOOP Sensor|The WHOOP sensor collects data on heart rate (HR), heart rate variability (HRV), and sleep data
46079305|NCT05653700|Behavioral|Survey|survey at baseline and end of the study
45818348|NCT03298880|Device|Supine VM VAD|Valsalva strain delivered using VAD
45818349|NCT03298880|Device|Supine VAD manometer|supine Valsalva strain delivered using manometer
45958513|NCT02988128|Device|Treatment for intracranial aneurysms|Embolization of aneurysms
46079306|NCT05651997|Procedure|MACT|"A biopsy of healthy cartilage is taken from a non-weight bearing area of the knee joint during an arthroscopic procedure.~The biopsy is processed in the GMP accredited laboratory to isolate and amplify chondrocytes.~The cells are seeded and cultured on a collagen matrix (Chondro-Gide®, Geistlich Pharma)~The membrane is implanted and sutured onto the injured site."
46079307|NCT05651997|Procedure|AMT|This treatment combines the microfracture procedure with the application of a bilayer matrix of porcine type I/III collagen (Chondro-Gide, Geistlich Pharma) and the supplementation of autologous bone.
46079308|NCT05649293|Other|measure vitamin b6 in serum|"Vitamin B6 levels can be determined by using Enzyme- linked Immuno-sorbent Assay Kit For vitamin B6 . or Chemiluminescence Immunoassays (CLIA) .~Venous blood samples will be taken from each patient. Use a serum separator tube and allow samples to clot for 10-20 minutes at room temperature and then centrifuged for 20 minutes at speed of 2000-3000 rpm (round per minute).~Remove supernatant, if precipitation appeared, Centrifuge again.~Extract as soon as possible after Samples collection, and should be tested as soon as possible after the extraction.~If not, samples must be stored in aliquot at -20°C (≤ 1 month) or -80°C (≤ 2 months) to avoid loss of bioactivity and contamination.~Hemolyzed Sample will be avoided , as hemolysis will interfere with the results ."
46079309|NCT05647564|Diagnostic Test|F-fluorodeoxyglucose positron emission tomography (FDG PET)|Imaging scan
46079310|NCT05647564|Diagnostic Test|prostate-specific membrane antigen positron emission tomography (PSMA PET)|Imaging scan
46079311|NCT05642988|Device|LifeSignals 1AX Biosensor|Biosensor worn by patients for 30-days after intra-abdominal or pelvic surgery on discharge from hospital
45958514|NCT02988128|Device|Treatment for Acute Ischemic Stroke|Revascularization of an intracranial blood vessel
45958515|NCT02973828|Procedure|Imaging|This is an observational study only, with no interventions. Volunteers will undergo MRI imaging on the MR Linac, however this will not affect, change or initiate any intervention, or change to their care path.
45958516|NCT02924038|Biological|IMA950|IMA950 vaccine
45958517|NCT02924038|Biological|poly-ICLC|poly-ICLC vaccine
45958518|NCT02924038|Biological|Varlilumab|Intravenous solution
45958519|NCT02913222|Other|Rehabilitation|Comparison of two rehabilitation approaches
45958520|NCT02798458|Device|Smartpill|The SmartPill Test is approved by the U.S. Food and Drug Administration (FDA) to measure transit time in the GI tract. This procedure uses the SmartPill capsule, a receiver, and computer software.
45958521|NCT02798458|Procedure|Endoscopic Mucosal Resection|a Sigmoidoscopy is an exam used to evaluate the lower part of the large intestine) during which an Endoscopic Mucosal Resection (removal of a small amount of tissue from the outermost layer of gut wall) will be completed.
45958522|NCT02726581|Biological|Nivolumab|Specified dose on specified days, IV (intravenous)
45958523|NCT02726581|Biological|Elotuzumab|Specified dose on specified days, IV
45958524|NCT02726581|Drug|Pomalidomide|Specified dose on specified days, PO (by mouth)
45958525|NCT02726581|Drug|Dexamethasone|Specified dose on specified days, PO
45958526|NCT02700048|Drug|intra-nasal naloxone|3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
45458231|NCT03501628|Dietary Supplement|Hydrolyzed whey protein concentrate|Supplementation twice daily (1 serving dose per consumption) of hydrolyzed whey protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
45664181|NCT02379091|Drug|Methotrexate|Methotrexate tablets
45958527|NCT02700048|Drug|Intra-nasal saline|3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
45958528|NCT02683447|Other|CRM Simulation|Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
45958529|NCT02678429|Device|Change DBS programming|Patient will change their DBS settings to move from one DBS setting to the other, allowed one hour to adjust to the new setting prior to testing
45958530|NCT02638766|Drug|regorafenib|Treatment with regorafenib 160mg once a day, 3 weeks on / 1 week off in cycles of 28 days
45664182|NCT02379091|Drug|Folic/folinic acid|Folic/folinic acid tablets
45958531|NCT02633111|Other|collected at pre-treatment tumor biopsy|to identify the tumor-specific clonotype
45958532|NCT02633111|Other|Peripheral blood tests|for MRD analysis at 3, 6, 9, 12, 15, 18, 21, and at relapse (+/- 1 month).
45958533|NCT02633111|Device|PET/CT|at 3, 6, 9, 15, 18, 21 and at relapse(+/- 1 month)
45958534|NCT02599116|Other|Bio-specimen collection|Collection of bio-specimens (fecal sample) at 3 different time points One pre-operative collection, Two post-operative collections
45958535|NCT02599116|Other|Questionnaire|Completion of lifestyle and food questionnaires (2) at each bio-specimen collection timepoint
46079312|NCT05641116|Other|physical activity program|24 face-to-face APA sessions at the sport and health center for 3 months at a rate of 2 sessions per week near his home and 9 therapeutic patient education workshops for 3 months at a rate of 3 workshops per month (telecare).
46079313|NCT05641116|Other|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice in autonomy for 3 months).
46079314|NCT05639972|Drug|Conditioning, E7 TCR-T cells, and aldesleukin|Participants will receive induction E7 TCR-T cell therapy.
46079315|NCT05634395|Device|Activity tracker|"Participants will receive a Withings Steel activity tracker (Withings, Issy-les-Moulineaux, France), which they will be asked to wear 24 hours per day throughout the whole intervention (12 months). At baseline, the Withings Health Mate mobile phone application will be downloaded onto each participant's smartphone or tablet. The clinical research assistant will instruct the participant in the use of the activity tracker. The participant will then accept and activate the sharing of the data collected with the secure server dedicated to the GrannyFit study at the Institut Curie. Participants will be asked to synchronize the activity tracker regularly (ideally daily) via Bluetooth with the Withings Health Mate application, for automatic transfer of the data to the secure GrannyFit space."
46079316|NCT05622318|Drug|Cyclophosphamide|25 mg/kg by IV on Days +3 and +4.
45958536|NCT02581098|Other|No interventions|No interventions
45958537|NCT02535832|Drug|Pioglitazone|Pioglitazone CT Scan DXA scan Needle muscle biopsy
45958538|NCT02535832|Drug|Placebo|Placebo CT Scan DXA scan Needle muscle biopsy
45958539|NCT02428712|Drug|FORE8394|
45958540|NCT02425904|Drug|Clofarabine|second-generation purine nucleoside analog
45958541|NCT02406209|Drug|NS2|NS2 ophthalmic drops (0.5%)
45958542|NCT02406209|Drug|Prednisolone acetate ophthalmic suspension (1%)|
45958543|NCT02313428|Device|Topical Oxygen Chamber for Extremities|Surrounds a limb and applies oxygen topically at a pressure slightly greater than atmospheric pressure to aid healing of chronic skin ulcers
45958544|NCT02296125|Drug|AZD9291 80 mg/40 mg + placebo|"The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
45958545|NCT02296125|Drug|Placebo Erlotinib 150/100mg|The initial dose of Placebo Erlotinib 150 mg once daily can be reduced to Placebo 100 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
45664183|NCT04886635|Other|Active surveillance|Patients will undergo two clinical response evaluations (CREs) after nCRT. During CRE-1 (5-6 weeks) patients will undergo oesophagogastroduodenoscopy (OGD) with bite-on-bite biopsies. During CRE-2 (10-12 weeks) patients will undergo positron emission tomography with computed tomography (PET-CT), endoscopy with bite-on-bite biopsies and endoscopic ultrasonography (EUS) plus fine-needle aspiration (FNA). If cancer is detected, surgery will be performed. Patients with cCR are eligible for active surveillance where regular CREs are performed to detect regrowth of cancer. Delayed oesophagectomy will be offered to patients with highly suspected or profen locoregional regrowth, without distant metastases. The safety and feasibility of active surveillance depends on several factors monitored in the SANO trial. So far, these stopping rules have not been met. In case one of the stopping rules is reached, further inclusion in the SANO-2 study will be stopped and surgical resection is offered.
45958546|NCT02296125|Drug|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
45958547|NCT02296125|Drug|Erlotinib 150/100 mg|"The initial dose of Erlotinib 150mg once daily can be reduced to 10 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
45958548|NCT02296125|Drug|Gefitinib 250 mg|"The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
45458232|NCT03501628|Dietary Supplement|Soy protein concentrate|Supplementation twice daily (1 serving dose per consumption) of soy protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
45458233|NCT01350596|Drug|Alivium®|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
45818350|NCT03298880|Other|Modified VM VAD|modified VM using VAD
45818351|NCT03298880|Other|Modified VM Manonmeter|Postural modified position VM using manometer
45818352|NCT03219866|Device|Nebulizers|Patients treated and discharged on nebulized bronchodilators
45818353|NCT03219866|Device|Dry Powder Inhaler|Patients treated and discharged on Dry Powder Inhalers
45818354|NCT03219866|Drug|Brovana|Subjects will receive a long-acting B2-agonist(LABA; Brovana, twice daily)
45818355|NCT03219866|Drug|Pulmicort|Subjects will receive a corticosteroid (ICS; Pulmicort, twice daily)
45818356|NCT03219866|Drug|Atrovent|Subjects will receive a short-acting anti-cholinergic (SAMA; Atrovent, three times a day)
45818357|NCT03219866|Drug|Advair Diskus|Subjects will receive a LABA/ICS (Advair Diskus, twice daily)
45818358|NCT03219866|Drug|Spiriva HandiHaler|Subjects will receive a long-acting anticholinergic (LAMA-Spiriva Handihaler, once daily)
46079317|NCT05622318|Drug|Tacrolimus|Target level 5-10 ng/mL (If the subject experiences nausea and vomiting that prevents the oral intake of tacrolimus anytime during treatment, tacrolimus is to be given by IV at the appropriate dose that was used to obtain the therapeutic level [IV:PO ratio = 1:4]). Administered Days +5 through +90. Taper after Day +90 and discontinue on Day +180.
46079318|NCT05622318|Drug|Mycophenolate Mofetil|15 mg/kg tablet thrice daily Days +5 through +35 every eight hours.
46079319|NCT05622318|Drug|Ruxolitinib|5 mg tablet twice daily after engraftment through Day +365. Taper after Day +365.
46079320|NCT05620303|Other|Exercise|Parents/guardians will receive three different contents weekly (i.e., infographics, video recipes, information pills, or videos) each week related to 24-h movement behaviors (i.e., PA, sedentary behavior, sleep duration) or Mediterranean Diet for 36 weeks.
45458234|NCT01350596|Drug|Ibuprofen|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Test Drug
45458235|NCT04462588|Drug|Cipro 400 MG in 200 ML Injection|medical tratment group
45664184|NCT02378935|Drug|VOX|100 mg tablet(s) administered orally once daily with food
45664185|NCT02378935|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily with food
45818359|NCT03291379|Drug|BTG-002814|BTG-002814 containing 100 mg vandetanib
45818360|NCT03300674|Drug|Hydromorphone|Hydromorphone intravenous infusion
45818361|NCT03300674|Drug|Lidocaine|Lidocaine intravenous infusion
45818362|NCT02184156|Biological|4 mL injection of Ampion|4 mL injection of Ampion
45818363|NCT02184156|Drug|4 mL injection of Placebo|
45818364|NCT03291613|Other|Pinpoint App|Tablet app with pain assessment and communication education, and pain assessment tool.
45818365|NCT03300752|Behavioral|BREATHE Intervention|PCPs randomized to BREATHE will receive the tablet which, when the screen is advanced by the PCP, will prompt the PCP through a 7-minute, 4-step brief intervention tailored to respond to the patient's specific beliefs, and shared decision-making discussion of asthma control status and treatment.
45818366|NCT03300752|Behavioral|Control Intervention|PCP will provide discussion of healthy lifestyles.
45818367|NCT04059913|Drug|Roxadustat|Roxadustat will be dosed orally per dose and schedule specified in the arm description.
45818368|NCT02158884|Device|IDEO brace|All participants will receive the IDEO brace.
45958549|NCT02296125|Drug|Placebo AZD9291 80 mg/ 40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to Placebo AZD9291 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
45958550|NCT02295722|Drug|Gemcitabine|gemcitabine 1.5 g/m2 INFUSED
45958551|NCT02295722|Drug|Melphalan|200 mg/m2
45958552|NCT02295722|Other|ASCT|Day 0 - Stem cell infusion
45958553|NCT02282059|Drug|sunitinib|subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg once a day on a continuous daily dosing regimen (CDD) or dosage modification is based on daily clinic practice
45958554|NCT02097420|Device|Mitral valve replacement SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve|Implantation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve in the mitral and aortic positions
45958555|NCT02066285|Drug|Pazopanib|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
45958556|NCT02024243|Procedure|Punch Tissue Biopsy|Subjects will have two 3 mm punch tissue biopsies of the same wound/ulcer (for OCT & infection) collected on days 0, 14, and 28. Biopsies will not be collected if the wound has closed by day 14 or 28.
45958557|NCT01964989|Biological|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)|1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to <36 months, 0.5 ml: ≥36 months to <72 months
45958558|NCT01964989|Biological|Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)|1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to <36 months, 0.5 ml: ≥36 months to <72 months
45958559|NCT01934309|Behavioral|TB reminders|The intervention to be studied involves providing clinic-based medical care providers (e.g., nurses, clinical officers, medical officers, consultants) with patient-speciﬁc clinical reminders regarding TB that are generated from a patient's electronic medical record and based on accepted clinical algorithms for TB screening and treatment.
45958560|NCT01711554|Biological|Dinutuximab|Given IV
45958561|NCT01711554|Drug|Isotretinoin|Given PO
45958562|NCT01711554|Other|Laboratory Biomarker Analysis|Correlative studies
45958563|NCT01711554|Drug|Lenalidomide|Given PO
45458236|NCT04462588|Drug|Flagyl I.V. RTU|medical tratment group
45818369|NCT03220412|Behavioral|Movies with Guns|Participants in this arm viewed movies (National Treasure, The Rocketeer) without guns. The movies, rated PG, were edited to remove guns from the scenes
45818370|NCT04028557|Other|Decision Support Systems, Clinical|Active computerized clinical decision support alert within the electronic health record that recommends initiation of an evidence-based beta blocker for heart failure and reduced ejection fraction.
45818371|NCT03195517|Other|Physical exercise|
45818372|NCT04333069|Procedure|cataract surgery|cataract surgery in form of phaco emulsification or irrigation aspiration
45818373|NCT03922087|Other|No intervention|No intervention
45818374|NCT02158806|Drug|Aspirin|150 mg aspirin in capsule form once daily for up to 24 weeks
45818375|NCT02158806|Drug|Placebo|Matching placebo capsule containing inert bulking agent
45818376|NCT03197389|Drug|Pembrolizumab|Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.
45958564|NCT01711554|Other|Pharmacological Study|Correlative studies
45958565|NCT01575860|Drug|Lenalidomide|Lenalidomide, 10mg, oral tablets, daily
45958566|NCT01558804|Other|Identifying group A strep carriers|At study entry, at 14 days, and if follow up is positive, again in 14-21 days: Standard culture for GAS and analysis of mRNA.
45958567|NCT01416831|Other|Radiation therapy and high-dose IL-2|Patients 1 - 20 will receive a single fraction of radiation. Patients 21 through the completion of the study will receive two fractions. The dose for all patients will be 20 Gy per fraction to the prescription line at the edge of the planning treatment volume (PTV) with the last dose delivered on a Friday before IL-2 administration. For patients receiving two radiation doses, the doses can be administered on the Wednesday and Friday before IL-2 starts. Patients who are assigned to IL-2 monotherapy and have progressive disease after two IL-2 cycles are then eligible to receive SBRT before cycle 3 of IL-2 commences, single fraction for patients 1-20 and two fractions for patients 21- end of study.
45958568|NCT01416831|Drug|High-dose IL-2|IL-2 will be given on a Monday at a dose of 600,000 IU per kilogram IV every 8 hours for up to 14 doses each cycle. The second cycle is planned 16 days after cycle 1 but may be delayed up to one week to allow toxicity to resolve. The maximum number of doses that can be given during two cycles will be 28 doses. Patients who respond after two cycles can receive 4 more cycles of IL-2. Patients with disease progression after 2 cycles may elect to receive radiation before a 3rd cycle of IL-2. If patients crossover, IL-2 will be given on the Monday following the last dose of radiation, at a dose of 600,000 IU per kilogram IV every 8 hours for a maximum of 14 doses each cycle. Another cycle is planned 16 days after cycle 3 but may be delayed up to one week to allow toxicity to resolve.
45958569|NCT01364051|Drug|Cediranib|Given PO
45958570|NCT01364051|Drug|Cediranib Maleate|Given PO
45958571|NCT01364051|Other|Laboratory Biomarker Analysis|Correlative studies
45958572|NCT01364051|Other|Pharmacological Study|Correlative studies
45958573|NCT01364051|Drug|Selumetinib|Given PO
45958574|NCT01364051|Drug|Selumetinib Sulfate|Given PO
45958575|NCT01303341|Other|Laboratory Biomarker Analysis|Correlative studies
45664186|NCT02378935|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45818377|NCT03198871|Drug|Acetaminophen Injectable Product|The interventional group will receive 1 gram intravenous acetaminophen at the start of wound closure to be repeated every 6 hours for 48 hours postoperatively
45818378|NCT03198871|Drug|Sodium Chloride 0.9%, Intravenous|The placebo group will be given an intravenous placebo of saline solution at wound closure and repeated every 6 hours for 48 hours postoperatively.
45818379|NCT03301298|Drug|SXC-2023|Oral capsule
45818380|NCT03301298|Drug|Placebo oral capsule|Placebo given as oral capsule.
45818381|NCT02157948|Drug|Denosumab (CP2)|Denosumab produced by a process referred to as CP2, administered subcutaneously from a prefilled syringe.
45818382|NCT02157948|Drug|Denosumab (CP4)|Denosumab produced by a process referred to as CP4, administered subcutaneously from a prefilled syringe.
45818383|NCT03302767|Other|Psychological and Social Consultation|Psychological and Social Consultation at Baseline, during the study and at the end of follow-up
45818384|NCT03220958|Drug|Metoclopramide|Metoclopramide 20mg
45818385|NCT03220958|Drug|Diphenhydramine|Diphenhydramine 25mg
45818386|NCT03220958|Drug|Normal saline|100ml normal saline
45818387|NCT03420625|Device|Foot IPC|Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA
45818388|NCT03420625|Device|Rapid calf IPC|Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
45818389|NCT03420625|Device|Slow calf IPC|Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
45818390|NCT03420625|Device|Calf NMES|Neuromuscular electrical stimulation in the calf using the DJOTM, CefarCompex Mi-Theta 500 stimulator
45818391|NCT03221192|Other|VAS questionnaire|VAS questionnaire is a PRO tool in which subjects will be asked to evaluate overall symptom severity, or the severity of individual symptoms of nasal polyps along a continuum, typically of 10 centimeter (cm) or 100 millimeter (mm) whereby 0 represents 'no symptom' and '10 or 100 represents 'as bad as you can imagine', Scores of 0-3 (or 0-30) are defined as mild disease, >3-7 (or >30-70) as moderate disease and >7-10 (or >70-100) as severe disease.
45458237|NCT04462588|Procedure|appendectomy (open or laparascopic)|appendectomy (open or laparascopic)
45818392|NCT03221192|Other|SNOT-22 questionnaire|SNOT-22 is a PRO tool to measure HRQoL associated with rhinosinusitis with or without nasal polyps. It contains 22 nose, sinus, and general HRQoL items and subjects will be required to score the experience on a 6-point scale ranging from 0 (no problem) to 5 (Problem as bad as it can be) and identify the five most important items affecting their health.
45818393|NCT03221192|Other|Data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to communicate about their experience of nasal polyps in real-time as they go about their daily lives via varying video, audio, photographic and text responses.
45818394|NCT02182830|Drug|Empagliflozin low dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
45818395|NCT02182830|Drug|placebo|starting dose 10mg; forced titration after 4 weeks 25mg dose
45818396|NCT02182830|Drug|Empagliflozin high dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
45818397|NCT03424681|Drug|Modafinil|Modafinil 300 mg by mouth daily
45664187|NCT02250651|Drug|Bimatoprost SR|Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
45818398|NCT03424681|Other|Placebo|Placebo
45958576|NCT01303341|Other|Pharmacological Study|Correlative studies
45958577|NCT01303341|Drug|Riluzole|Given PO
45664188|NCT02250651|Other|Sham: Applicator Without Needle|Sham administered on Day 1, Week 16, and Week 32.
45664189|NCT02250651|Drug|Active Comparator: Timolol 0.5%|Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
45458238|NCT03139448|Device|Oxygen via nasal cannula|Oxygen will be supplied to the patient via nasal cannula according to the routine standard of care practice at Vanderbilt University Medical Center.
45664190|NCT02250651|Drug|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
45664191|NCT02377921|Drug|aceneuramic acid extended-release (Ace-ER)|tablets for oral use
45664192|NCT02377921|Drug|Placebo|tablets for oral use
45664193|NCT02311153|Device|Mallinckrodt Endotracheal Tube (ETT)|Patient is intubated for airway protection and ventilation with the Mallinckrodt ETT.
45818399|NCT03305653|Device|Esophageal String Test (EST)|The EST is a gelatin capsule filled with a 90cm nylon string. A trailing end of the string protrudes from one end of the capsule. This end is taped to the cheek and the capsule is swallowed. As the capsule travels to the small intestine, the string inside the capsule is dislodged, leaving a string that goes from the cheek to the small intestine. The capsule dislodges from the string and the string is left in place, in the mouth, esophagus, stomach and small intestine for an hour. During this time, the string rubs against the inside of the esophagus and collects eosinophil proteins. After one hour, the string is removed through the mouth and placed in preservative to save the eosinophil proteins.
45818400|NCT03431012|Other|Agency Assignment framing|Linguistic framing used in written health messages. Each version of the messages described the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to either humans (HA: 'You can contract the virus when you touch…') or the pandemic flu virus itself (VA: 'It can infect you when you touch…')
45818401|NCT03431012|Other|Attribute framing|Linguistic framing used in written health messages. Each message described the side effects of the antivirals in terms of chances of either experiencing (negative framing: 'Uncommon side effects (10% of people will be affected)') or not experiencing side effects (positive framing: 'Uncommon side effects (90% of people will not be affected)') after using them.
45958578|NCT01303341|Drug|Sorafenib Tosylate|Given PO
45958579|NCT01267955|Other|Laboratory Biomarker Analysis|Correlative studies
45958580|NCT01267955|Other|Pharmacogenomic Study|Correlative studies
45958581|NCT01267955|Drug|Vismodegib|Given PO
45958582|NCT01064648|Drug|Cediranib Maleate|Given orally
45958583|NCT01064648|Drug|Cisplatin|Given IV
45664194|NCT02311153|Device|Laryseal Laryngeal mask airway (LMA)|Laryseal Laryngeal mask airway is used to provide airway protection and ventilation.
45458239|NCT03139448|Device|Oxygen via SuperNO2VA nasal mask|The anesthesia provider will attach the SuperNO2VA's (Revolutionary Medical, Inc) circuit port to the anesthesia machine, turn the oxygen flow rate to 10L/min, and set the APL valve to 10 cm H2O.
45664195|NCT02195427|Device|TEOSYAL® RHA Global Action|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 30G1/2 disposable sterile needles."
45664196|NCT02195427|Device|TEOSYAL® RHA Deep Lines|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27G1/2 disposable sterile needles."
45664197|NCT02214225|Biological|Quadrivalent Influenza Vaccine (QIV)|One 0.5 mL intramuscular dose into the deltoid muscle
45818402|NCT03427177|Behavioral|mychoice|The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.
45818403|NCT03302780|Device|BreEStim|BreEStim will applied for 10 to 20 minutes.
45458240|NCT02316808|Dietary Supplement|Plant stanol ester|Smoothie that contains plant stanol ester
45458241|NCT02316808|Dietary Supplement|placebo|Smoothie that contains placebo
45458242|NCT04462822|Drug|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test and Reference product in each study period
45458243|NCT04462822|Drug|ADVAIR DISKUS® 250/50|2 inhalations of Test and Reference product in each study period
45664198|NCT02214225|Biological|Trivalent Influenza Vaccine (TIV-1)|One 0.5 mL intramuscular dose into the deltoid muscle.
45664199|NCT02214225|Biological|Trivalent Influenza Vaccine (TIV-2)|One 0.5 mL intramuscular dose into the deltoid muscle.
45818404|NCT03302780|Device|tDCS active|tDCS will be applied for 20 minutes.
45818405|NCT03302780|Device|tDCS sham|
45818406|NCT04332848|Drug|ET|Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
45818407|NCT04332848|Drug|SGT|Susceptibility testing guided therapy Based on susceptibility test: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
45818408|NCT03305887|Device|"STRATAFIX™ Symmetric Knotless Tissue"|This devices will be used in deep and intermediate layers of barbed suture group.
45818409|NCT03305887|Device|VICRYL® PLUS|This devices will be used in deep and intermediate layers of conventional suture group.
45818410|NCT03305887|Device|"STRATAFIX Spiral sutures"|This devices will be used in intradermal layer of both barbed suture and conventional suture group.
45818411|NCT03305887|Device|DERMABOND™ Advance™ Skin Closure System|This devices will be used in skin layer of both barbed suture and conventional suture group.
45958584|NCT01064648|Other|Laboratory Biomarker Analysis|Correlative studies
45664200|NCT02250183|Device|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY dressing is manufactured by the company Derma Sciences, Inc. and is a moist dressing made of Active Leptospermum Honey (+15) in combination with natural gelling agents. The gelling agents act to maintain the physical integrity and viscosity of the dressing, even in the presence of body heat and fluids. As a percentage of the overall dressing, MEDIHONEY® GEL dressings contains 80% honey. The dressing has a low pH and can help to lower the overall pH of wounds. The dressing also possesses a high osmotic potential, which assists in debridement.
45818412|NCT03221738|Behavioral|App-Based Cognitive Behavioral Therapy|12-week Smartphone delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
45818413|NCT03306199|Device|Laser Atherectomy|The Turbo-Power is a laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
45818414|NCT03303404|Device|Ambulatory (24-hour) Blood Pressure|Unlike casual blood pressure measurements, 24-hour ambulatory blood pressure monitoring provides an insight into blood pressure changes in everyday life and an estimate of the overall blood pressure load exerted on the cardiovascular system over 24 hours. Blood pressure recordings over a 24-hour period of normal daily activity will be made using a noninvasive ambulatory monitor (Spacelabs, Redlands, WA). The ambulatory system will be calibrated against a mercury sphygmomanometer, and the cuff will be programmed to inflate automatically every 15 min from 6 AM to 11 PM and every 20 min between 11 PM and 6 AM. For each individual subject, the nighttime period will be defined as the time when the subject goes to bed at night until rising in the morning. Daytime will be defined as the remainder of the 24-hour period. Daytime and nighttime states will be monitored by an Actiwatch (Mini-MItter, Bend, OR), a watch-like device placed on the wrist that measures gross motor activity.
45818415|NCT03224390|Other|digital family planning screening and referral service|Clients text the service and receive a free call back to complete an automated family planning counseling session that results in a set of recommended methods that fit the client's preferences. The client is matched to family planning providers that offer these methods, and the service sends a referral code that the client can redeem at a facility. When someone receives a referral code, the service tracks them through their encounter with a provider to learn about their experience with the service, the provider, and their choice in contraception. The service also follows-up with clients who do not act on referrals to better understand their reasons and tries different behavioral nudges to promote uptake of contraception. The service does not pay costs the client may incur at a facility.
45818416|NCT03303794|Drug|Exparel|1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
45818417|NCT03303794|Drug|0.25% bupivacaine|0.25% bupivacaine in patients undergoing total knee arthroplasty
45818418|NCT03304106|Device|Commercially available cochlear implant and AI system|Use of AI technology to assist in audiologist's evaluation and programming of cochlear implant recipients
45818419|NCT03305822|Drug|LY900014|Administered SC
45818420|NCT03305822|Drug|Insulin Lispro|Administered SC
45818421|NCT04706858|Dietary Supplement|Dietary fiber supplementation|Randomization to the order of first fiber: either inulin or arabinoxylan. Third cycle will include a mix of 5 fibers: inulin, arabinoxylan, resistant starch, glucomannan, and acacia gum.
45818422|NCT04706702|Behavioral|Tele-EnhanceFitness|Livestream, instructor-led tele-exercise classes, involving balance, endurance, and strength training
45818423|NCT03435614|Drug|Opioids|Once an opioid dose reduction of 10% or greater is achieved, a daily assessment will be conducted by a physician using the DSM-5 criteria for opioid withdrawal. In addition, signs and symptoms of withdrawal will be collected daily by a blinded investigator.
45958585|NCT01064648|Drug|Pemetrexed Disodium|Given IV
45958586|NCT01064648|Other|Placebo Administration|Given orally
45958587|NCT01000753|Other|Cytology Specimen Collection Procedure|Correlative studies
45958588|NCT00959283|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
45958589|NCT00959283|Other|Pharmacological Study|Correlative studies
45958590|NCT00878163|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
45958591|NCT00878163|Drug|Erlotinib Hydrochloride|Given PO
45958592|NCT00878163|Drug|Gemcitabine Hydrochloride|Given IV
45958593|NCT00878163|Drug|Vismodegib|Given PO
45958594|NCT00635700|Drug|ziprasidone|20-160 mg/d
45958595|NCT00635700|Drug|placebo|placebo
45958596|NCT00634257|Behavioral|Questionnaires|Nine questionnaires taking about 40 minutes to complete.
45958597|NCT00582075|Drug|temozolomide|TMZ 200mg/m2 days 1-5 repeat q28 days. Patients who have received prior chemotherapy will receive 150 mg/m2 days 1-5
45958598|NCT00558961|Drug|Gleevec and Chlorambucil|The first cohort will receive Gleevec at 300 mg daily on days 1-10 and chlorambucil 8mg/m2/d from day 3-7. This will be repeated every 28 days. Cohort 2 will receive 400 mg Gleevec and Cohort 3 will receive 600 mg Gleevec. Each dose level may be expanded up to 6 patients if 1 of 3 patients experiences any dose limiting toxicities.
45958599|NCT00542451|Drug|Paclitaxel|Every week for 12 weeks
45458244|NCT01350674|Procedure|EBUS-TBNA|endobronchial ultrasound transbronchial needle aspiration
45458245|NCT04462510|Procedure|Block/Local infiltration|One group received ILI/IHG Block and the other group received local anesthetic infiltration for pain relief
45664201|NCT02250183|Device|Santyl|SANTYL® Ointment is an FDA-approved sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme SANTYL® is derived from the fermentation by Clostridium histolyticum. It possesses the unique ability to digest collagen in necrotic tissue. SANTYL® Ointment is indicated for debriding chronic dermal ulcers and severely burned areas.
45818424|NCT03437564|Drug|Vortioxetine|Vortioxetine tablet
45818425|NCT03438266|Device|JUVÉDERM VOLUMA® XC injectable gel with cannula|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with cannula.
45818426|NCT03438266|Device|JUVÉDERM VOLUMA® XC injectable gel with needle|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with a needle.
45818427|NCT03438578|Device|Efficacy Safety Score monitoring|According to data gathered from ESS and monitoring, the patients will receive needed care.
45818428|NCT03315104|Biological|FLU-IGIV|Single dose, sterile liquid formulation for IV administration.
45818429|NCT03315104|Other|Placebo for FLU-IGIV|Single dose, normal saline solution for IV administration.
45818430|NCT03228914|Drug|Oxymetazoline|Pledgets will be soaked in 0.05% oxymetazoline solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
45818431|NCT03228914|Drug|Epinephrine|Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
45818432|NCT03315572|Other|Interviewer administered version of ease of use items|The adult ease of use items will be modified to incorporate language appropriate for pediatric subjects. The interview will be administered by trained clinic-staff for subjects aged 5 to 7 years and those aged 8 to 11 years having difficulty in reading.
45818433|NCT03315572|Other|Self-administered version of ease of use items|The interview will be self-administered by subjects aged 8 to 11 years.
45818434|NCT03315572|Other|Caregiver version of ease of use items|Caregivers will be asked questions regarding their observations and experiences while their child was using ELLIPTA inhaler.
45818435|NCT03232580|Drug|rhAnnexin V-128|All patients received a single i.v injection of 99mTc-rhAnnexin V-128 at Day 0.
45818436|NCT03316976|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsule.
45818437|NCT03317288|Device|Dabir Air overlay|The Dabir Air overlay is a low profile alternating pressure overlay that is designed to place on top of mattress and operation room table.
45818438|NCT03317444|Drug|TRC101|Oral suspension
45818439|NCT03317444|Drug|Placebo|Oral suspension
45818440|NCT03442868|Device|high frequency rTMS|Participants receive 16 minutes (5Hz, 24 10-second trains with a inter-train interval of 30s) of high frequency rTMS applied to either primary motor cortex (M1), supplementary motor area (SMA) and dorsolateral prefrontal cortex (DLPFC) at different sessions. Walking performance is evaluated before and after the brain stimulation.
45818441|NCT03234374|Combination Product|INL-001 (bupivacaine HCl collagen implant)|3 x 100 mg INL-001 bupivacaine HCl collagen-matrix implants (total bupivacaine HCl dose 300 mg)
45818442|NCT03234374|Drug|Marcaine 0.25% infiltration|Marcaine 0.25% (bupivacaine HCl) 175 mg infiltration
45818443|NCT04332536|Other|Exercise with and without Codeine|This study will use our novel CPX test that incorporates instantaneous assessment of maximal isokinetic cycling power at V̇O2peak to elucidate the mechanisms that limit V̇O2peak in CHF, and compare these responses with age-matched controls.
45818444|NCT03236168|Drug|Ivermectin|A single weight based dose of ivermectin
45958600|NCT00542451|Drug|Trastuzumab|Once a week for twelve weeks Then once a week or once every three weeks for 40 weeks
45664202|NCT02249949|Drug|efatutazone|Given PO
45664203|NCT02249091|Drug|Selinexor|Patients receive Selinexor as specified in arm/group description (8 doses of 40 mg/m^2 or 6 doses of 60 mg per induction cycle).
45664204|NCT02249091|Drug|Idarubicin|Infusion, iv, 10 mg/m^2, on days 1,3,5 in cycle 1, on days 1,3 in cycle 2
45664205|NCT02249091|Drug|Cytarabine|Continuous infusion day 1 to 7, 100 mg/m^2, iv,
45818445|NCT03236168|Drug|Permethrin 5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
45818446|NCT03236168|Drug|Malathion Shampoo 0.5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
45818447|NCT03306589|Biological|Cantharidin|5 microliter (µL) of 0.2 percent Cantharidin solution (diluted in acetone) will be applied to all subjects on forearm by topical route.
45818448|NCT03306589|Biological|Lipopolysaccharide|0.5 to 4 ng/kg body weight of LPS formulated as suspension in normal saline will be administered to randomized subjects via intravenous (IV) route in dose-escalation manner.
45818449|NCT03306589|Biological|Granulocyte-Macrophage Colony-Stimulating Factor|5 to 15 µg/kg of GM-CSF will be administered to randomized subjects via subcutaneous (SC) route in the abdominal region in dose-escalation manner.
45818450|NCT03306589|Drug|Saline Solution|0.9 percent sodium chloride will be administered via IV route to all subjects at a rate of 250 mL/hour for 4 hours prior to dosing with LPS and 8 hours after dosing with LPS.
45818451|NCT03320096|Device|Microfocused ultrasound with visualization|Subjects will receive 2 treatments (day 1 and day 30), each at a 3.0mm depth and 0.30 Joule of energy. Treatment will be delivered in a 3*4 grid, 12 treatment squares, delivering 60 lines of treatment per square, i.e., 720 lines per axilla in each treatment (1440 lines total per treatment.)
45818452|NCT03309787|Behavioral|eHealth|Intervention Description: The pilot comprises of five components listed below which provide access to specialty obesity care to rural obese adults, and enhance it with technology (telehealth and remote monitoring): Team-based care; medical plan, nurses, psychologists, dietician, Health coaching, Weekly coaching sessions , Messaging and Remote Monitoring
45958601|NCT00507923|Device|Actigraph|Wear actigraph
45958602|NCT00507923|Other|Best Practice|Receive usual care
45958603|NCT00507923|Other|Quality-of-Life Assessment|Ancillary studies
45958604|NCT00507923|Other|Questionnaire Administration|Ancillary studies
45958605|NCT00507923|Other|Sleep Diary|Complete sleep diary
45958606|NCT00507923|Other|Stretching|Participate in stretching sessions
45958607|NCT00507923|Procedure|Yoga|Participate in Tibetan yoga
45958608|NCT00392353|Drug|Azacitidine|Given SC
45958609|NCT00392353|Other|Laboratory Biomarker Analysis|Correlative studies
45958610|NCT00392353|Other|Pharmacological Study|Correlative studies
45958611|NCT00392353|Drug|Vorinostat|Given PO
45958612|NCT00382070|Drug|Letrozole|Letrozole 2.5 mg taken orally once daily for 5 years
45958613|NCT00382070|Other|Placebo|Placebo tablet taken orally once daily for 5 years
45958614|NCT00368524|Behavioral|contingency management and behavioral day treatment|
45958615|NCT00326456|Drug|liposomal doxorubicin|30 mg/m2 gieven intravenously on day 1 every 3 weeks
45958616|NCT00326456|Drug|carboplatin|AUC 5 intravenously on day 1 every 3 weeks
45818453|NCT00376207|Behavioral|Physical exercise|
45958617|NCT00326456|Drug|paclitaxel|175 mg/m2 intravenously on day 1 every 3 weeks
45958618|NCT00244842|Drug|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg po BID
45958619|NCT00244842|Drug|Placebo|Placebo
45664206|NCT02248857|Other|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
45664207|NCT02248857|Other|SMS Texting Reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
45664208|NCT02213055|Drug|LICEMD|Parents/guardians of infested children will provide consent for their child's participation. Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment. Participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application.
45818454|NCT03446846|Drug|MIN-117 5.0 mg|5.0 mg MIN-117 administered as two MIN-117 2.5 mg capsules as a single dose once daily
45818455|NCT03446846|Drug|MIN-117 2.5 mg|2.5 mg MIN-117 administered as one MIN-117 2.5 mg capsule and one Placebo capsule as a single dose once daily
45818456|NCT03446846|Drug|Placebo|Placebo administered as two Placebo capsules as a single dose once daily
45818457|NCT03312517|Drug|Suvorexant 10 mg|Subject will receive suvorexant 10mg
45818458|NCT03312517|Drug|Suvorexant 20 mg|Subject will receive suvorexant 20mg
45818459|NCT03312517|Drug|Placebo oral capsule|Subject will receive placebo.
45958620|NCT04688827|Other|Exercise therapy|15 weeks of resistance training (additional to endurance training)
45958621|NCT00149942|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
45958622|NCT04688437|Radiation|standard standing-sitting posteroanterior and lateral whole spine X-ray and lumbar MRI examination|Routine examination
45958623|NCT02915887|Other|Cervical Taping|Kinesio®Tex Tape 23 was used in this study. Two strips of tape were applied. The first layer was a Y-shaped strip with 2 tails on 2 sides of the cervical vertebrae, placed over the posterior cervical extensor muscles and applied from the insertion to origin. The second strip was an I-shaped approximately 20cm long, transversally applied over the C5-C7 vertebra with a tension-on-base technique in a space correction technique.
45958624|NCT02915926|Behavioral|occupational performance coaching|
45958625|NCT02915926|Behavioral|standard OT|
45958626|NCT03171259|Other|care as usual|The investigators will be following patients with critical limb ischemia and documenting the usual care that the participants receive.
45958627|NCT03160378|Behavioral|Organizational skills training|10 sessions of parent and child training in a group format.
45958628|NCT03160378|Other|Treatment as usual|Treatment as usual in the outpatient clinic
45958629|NCT03142984|Other|Cosmetic Products|"Phase 1:~Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)~Phase 2:~Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
45958630|NCT00149981|Drug|everolimus (RAD)|Everolimus
45958631|NCT02915770|Procedure|cholangiojejunostomy|Half of participants will receive hepatectomy, cholangiojejunostomy and T-tube Drainage,while the other half will receive hepatectomy and T-tube Drainage
45958632|NCT02915770|Procedure|hepatectomy|
45958633|NCT02915770|Device|T-tube|T-tube Drainage
45958634|NCT02915731|Dietary Supplement|Vitamin A supplement|200 000 IU vitamin A (once-off dose), given to participants as part of the national vitamin A supplementation program
45958635|NCT02915653|Other|Educational materials on a new diagnostic service|Educational materials on a new diagnostic service
45958636|NCT02915809|Biological|GC3110B vaccine|0.5mL, Intramuscular
45958637|NCT02915809|Biological|GCFLU Quadrivalent Inj. vaccine|0.5mL, Intramuscular
45958638|NCT02915497|Behavioral|Abbreviated Early Prolonged Exposure Therapy|Since many trauma patients are discharged within 4 weeks, AEPET with the same length (45 minutes - 1 hour) and number of sessions as PET, is given in a shorter time period (daily for 3 days as opposed to weekly over 3 weeks).
45958639|NCT02915692|Device|ERASE Silver Coated Foley Catheter|Foley catheter from ERASE CAUTI Kit will be administered as required.
45664209|NCT02213055|Drug|Standard Head lice product|The most common treatments are pesticide-based, over-the-counter remedies of permethrin (1%), or pyrethrin-based products.After baseline scalp exam for lice count and preexisting signs of irritation, parents who agree to the comparison arm may purchase any other head lice treatment of their choice. All treatments are to be done at home by a parent or guardian. All participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application. Participants may also be examined by parents or the school nurse at any time if signs of irritation or re-infestation occur. If the child is still found to be infested during any examination, the school nurse will instruct the parent/guardian to retreat.
45818460|NCT03449342|Drug|turoctocog alfa|Patients will receive standard prophylaxis treatment and treatment of bleeding episodes, according to label. Trial product will be administered as intravenous injections (i.v.)
45818461|NCT03312595|Device|Restrata TM Wound Matrix|The RestrataTM Wound Matrix is a sterile, single use device intended for use in local management of wounds
45958640|NCT02915692|Device|Comparator Silver Coated Catheter|Foley catheter coated with silver
45958641|NCT02915536|Other|Natural exposure of high iodine|Natural exposure of high iodine intake from drinking water
45664210|NCT02310763|Biological|PF-06252616|PF-06252616 IV Infusion, 3 dose levels (5mg/kg, 20 mg/kg and 40 mg/kg) will be investigated within each subject
45664211|NCT02310763|Drug|Placebo|
45958642|NCT02915380|Biological|Evaluation of pituitary endocrine function|"The basal thyroid hormone and test to perform will be: TSH, fT4, fT3.~When available, the following hormones will be tested:~FSH, LH, estradiol (in women), testosterone (in men), sex hormone-binding globulin (SHBG), ACTH, cortisol, prolactin, Na, K; serum levels of GH and IGF-1; and serum and urine osmolality.~Adrenal function will be evaluated through ACTH-stimulation testing . Adrenal or GH insufficiency will be evaluated by insulin tolerance testing (ITT)"
45664212|NCT02342743|Device|CEFALY|
45664213|NCT04891315|Diagnostic Test|Blood test for soluble VAP-1 (sVAP-1).|~5ml blood will be taken and sVAP-1 will be measure by Enzyme linked Immunosorbent Assay
45818462|NCT03315559|Drug|[14C]-GSK2269557 IV infusion|The [14C]-GSK2269557 solution will be available in dosing strength of 10 µg, administered as single dose IV infusion over 15 minutes. It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.
45958643|NCT02915380|Behavioral|Evaluation of clinical outcome|Patients' outcome will be assessed as modified Rankin Scale (mRS) at discharge from the hospital, at 3, 6 and 12 months.
45958644|NCT02915380|Behavioral|Evaluation of neuropsychological function|Neuropsychological examination will be conducted focusing on verbal comprehension (Token Test) and visual neglect. Verbal and visual short term and working memory visuospatial construction and figural memory will be performed through Rey Osterrieth Complex figure test, and psychomotor speed attention and concentration through Trail Making Test.
45958645|NCT02915146|Radiation|combined ultraviolet phototherapy (NB-UVB + UVA1) vs. NB-UVB monotherapy|NB-UVB combined with UVA1
45818463|NCT03315559|Drug|GSK2269557 via DPI|GSK2269557 DPI will be available with dosing strength of 1000 µg, administered as oral inhalation intended to inhale twice. It will be prepared by blending GSK2269557 hemisuccinate salt (GSK2269557H) with lactose and magnesium stearate.
45958646|NCT02915419|Biological|PRP|platelet rich plasma
45958647|NCT02915419|Biological|PRF|PLATELET RICH FIBRIN
45958648|NCT00163839|Behavioral|Dietary Therapy|
45958649|NCT02915107|Device|BioFreedom|PCI with BioFreedom
45958650|NCT02915107|Device|Orsiro|PCI with BioFreedom
45958651|NCT00405860|Drug|CellCept (mycophenolate mofetil)|
45958652|NCT02914990|Drug|BPI-15086|BPI-15086 is administered once daily with a starting dose of 25 mg in a 21-day cycle. When tolerated, increasing doses of BPI-15086 will be tested in subsequent cohorts, until a maximum tolerated dose is determined.
45958653|NCT02915068|Behavioral|EHR-Physician Asthma Care Education Program|participants will receive EHR-PACE, an interactive 1.5 hour training module that teaches clinicians best practices for communicating with patients in the presence of computer systems in the exam room (specifically EHRs).
45958654|NCT02914678|Other|Fentanyl|Change in protocol from 2 to a total of 3 μg/kg fentanyl per transport
45958655|NCT00163878|Procedure|Sensory Stimulation|
45958656|NCT00163878|Device|Sesnory Modality Assessment and Rehabilitation Technique|
45958657|NCT00405977|Drug|Physiologic saline|Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group and 1 ml per kg physiological saline. The infusion will be given with during 15 minutes.
45958658|NCT00405977|Drug|Magnesium sulphate|Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group. The infusion will be given during 15 minutes.
45958659|NCT02914288|Other|High resolution magnetic resonance imaging for intracranial vessel walls|High resolution magnetic resonance imaging for intracranial vessel walls at initial (optional), 1 month, 3 month, 6 month (optional), and 12 month
45958660|NCT02914327|Drug|SNX-5422 plus ibrutinib|SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
45958661|NCT02914249|Other|Orange juice (500 mL/d)|Nutritionists prescribed a low-calorie diet that was estimated from total energy expenditure (TEE) for each individual minus 500 kcal per day (30% TEE). Both groups had the same diet plan based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ / banana and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were collected (monthly); blood samples and dietary questionnaires (every two weeks).
45958662|NCT00150020|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|
45958663|NCT02914015|Procedure|Continous QLB (quadratus lumborum block)|Inject local anesthetics in between quadratus lumborum and psoas major muscle with catheter insertion and continuous local infusion
45664214|NCT02377063|Dietary Supplement|Pressed Juice|Subjects will be taking vegetable/fruit juice supplementation for 3 days. Blood, urine and stool samples will be collected at baseline, day 4 and day 17.
45958664|NCT02914015|Device|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
45958665|NCT02914015|Drug|Ropivacaine|"0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline given immediately after the correct position of the tip of the needle has been verified.~followed with 0.2% ropivacaine infusion at a rate of 0.125ml/kg/h given through the catheter inserted in between the quadratus lumborum muscle and psoas major muscle."
45958666|NCT02914015|Drug|Morphine given as IPCA|Bolus: 1-2mg, lock time: 10min, 1h limitation: 5-10mg. without background infusion.
45958667|NCT02914093|Other|IMT|Inspiratory muscle training for 6 weeks 2x30 breaths daily as a home based program
45664215|NCT02309515|Other|Laboratory Biomarker Analysis|Correlative studies
45664216|NCT02309515|Drug|Lenalidomide|Given PO
45664217|NCT02309515|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given IM
45664218|NCT02309359|Biological|ALX-0061|
45664219|NCT02309359|Other|Placebo|
45664220|NCT02309359|Drug|Methotrexate|Stable background dose of commercially available methotrexate (not provided by the Sponsor).
45664221|NCT02247531|Drug|Lampalizumab|10 mg dose of lampalizumab administered intravitreally.
45958668|NCT00171093|Drug|valsartan + simvastatin|
45958669|NCT02914054|Drug|High dose Dexamethasone pulses|In HD-DXM arm, DXM was administered intravenously at 40 mg in 500cc normal saline (0.9% saline) during 1 hour for consecutive 4 days and then stopped. This cycle was repeated in 14 days interval to receive 3 cycles of treatment.
45664222|NCT02247531|Other|Sham Comparator|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
45664223|NCT02375971|Drug|Ranibizumab|Administered as an intravitreal injection
45664224|NCT02375971|Procedure|Laser therapy|Transpupillary diode or frequency-doubled yttrium aluminum garnet (YAG) laser ablative therapy, following anesthesia or sedation
45958670|NCT02914054|Drug|Prednisone|Patients in PDN arm received PDN orally at 1.0 mg/kg body weight daily for 4 consecutive weeks. After achieving responses the medication tapered gradually to less than 15mg daily or terminated over 4-6 weeks aimed at maintaining platelet count over 30 ×109/L.
45664225|NCT04886323|Device|Cold atmospheric plasma treatment device|Treat with cold atmospheric plasma treatment device.
45818464|NCT03315559|Drug|[14C]-GSK2269557 oral solution|The [14C]-GSK2269557 solution will be available with dosing strength of 800 µg, administered as single dose orally. It will be prepared by dissolving [14C]-GSK2269557 hemisuccinate salt (GSK2269557T) in water.
45818465|NCT03239522|Drug|[14C]-GSK1278863 solution for IV infusion|It is a clear, colorless solution free from visible particulate matter. Participants will receive 10 mL of 5 µg/mL of [14C]-GSK1278863 IV solution (total dose: 50 µg) by IV infusion over 1 hour.
45958671|NCT00150059|Drug|Pimecrolimus Cream 1%|
45958672|NCT02913976|Device|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
45958673|NCT02913976|Device|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
45458246|NCT01362218|Drug|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 8 weeks.
45664226|NCT04886323|Drug|Itraconazole Capsules|Treat with Itraconazole capsules
45664227|NCT02308735|Other|N/A - No intervention|
45664228|NCT02212197|Drug|leuprolide acetate FluidCrystal® injection depot|
45664229|NCT02212197|Drug|leuprolide acetate|
45664230|NCT02193165|Drug|triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Total toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using a Total 360 toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of mouthwash for 30 seconds.
45958674|NCT00171132|Drug|valsartan|
45958675|NCT00171132|Drug|atenolol|
45958676|NCT00171132|Drug|hydrochlorothiazide|
45664231|NCT02193165|Drug|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Crest Pro-Health toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Pro-Health toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health Multi-Protection mouthwash for 30 seconds.
45664232|NCT02193165|Drug|fluoride toothpaste + fluoride Mouthwash|Brush whole mouth with Crest Cavity Protection toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Indicator toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health For Me Breezy Mint mouthwash for 30 seconds.
45664233|NCT01617460|Drug|Aripiprazole|Flexibly dose administered orally once daily
45818466|NCT03239522|Drug|[14C]-GSK1278863 oral solution|It is a clear, colorless solution. Participants will receive 125 mL of 200 µg/mL of [14C]-GSK1278863 oral solution (total dose: 25 mg).
45818467|NCT03239522|Drug|Daprodustat 6 mg oral tablet|It is a 9.0 millimeter (mm) round, white film coated tablet.
45664234|NCT01890148|Drug|AZD5069|oral BD administration of 45 mg AZD5069
45664235|NCT01889602|Drug|Lorazepam|Lorazepam: 2mg, po, 1x
45664236|NCT01889602|Other|Placebo|Non-active placebo, po, 1x
45818468|NCT03315949|Drug|Polyethylene Glycol (PEG)|Different method for bowel cleansing using same bowel cleanser. Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy
45818469|NCT03241862|Device|Restylane® Silk|Restylane® Silk (Galderma Laboratories, L.P.) is a hyaluronic acid injectable filler, which is approved by the FDA for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids.
45958677|NCT02913898|Behavioral|IBLT|Information bias learning task-- a computer based task in which positive information is more useful when learning how best to complete it
45958678|NCT02913898|Behavioral|IBLT control|A control version of the IBLT task-- a computer based task in which both positive and negative information is useful when learning how to complete it
45958679|NCT02913937|Device|Passive ultrasonic irrigation|Endodontic irrigation followed by passive ultrasonic agitation.
45958680|NCT02913937|Device|Endodontic needle|Endodontic irrigation
45958681|NCT00150098|Behavioral|Enhanced HIV risk reduction and HIV vaccine education|
45958682|NCT02913859|Radiation|Radiotherapy to the pelvis|Radiotherapy to the pelvis and prostate
45958683|NCT02913859|Drug|Hormonal therapy (LHRH agonist and/or antiandrogens)|life-long hormonal therapy (LHRH agonist and/or antiandrogens)
45958684|NCT02913820|Other|snowfall > 5cm/day|the number of myocardial infarctions of every day analysed in this study will be correlated with the respective values of snowfall
45958685|NCT02913742|Procedure|monitoring by depth electrode|During laser interstitial thermal ablation (LITT) for mesial temporal lobe epilepsy, the study patients will receive invasive neurophysiologic intraoperative monitoring. In addition to the typical placement of LITT stereotactic laser ablation probe via occipital burr hole, the study patients will receive an 8-contact depth recording electrode placed through an adjacent burr hole. The recording electrode will be placed into the parahippocampal gyrus in parallel to the LITT device. The patient will be monitored for epileptic discharges for 10 minutes before and 10 minutes after the ablation process to record the change in discharges during the surgery. The monitoring will not be used to guide surgery. The probe will be removed with the LITT device at the end of the procedure.
45958686|NCT00150137|Drug|Methimazole|
45958687|NCT04688281|Device|Medicurtain®|Medicurtain® 5ml prefilled syringe
45958688|NCT04688281|Device|GUARDIX-SG®|GUARDIX-SG® 5ml prefilled syringe
45958689|NCT00163917|Device|Virtual reality relaxation|
45664237|NCT01889602|Drug|Topiramate 100mg|Topiramate: 100 mg, po, 1x
45664238|NCT01889602|Drug|Topiramate 150mg|Topiramate: 150 mg, po, 1x
45664239|NCT01889602|Drug|Topiramate 200mg|Topiramate: 200 mg, po, 1x
45664240|NCT01935700|Drug|Colchicine|"Adjustment the dosage of colchicine during study:~The colchicine dosage will be changed when the hepatic reserved function of the participant changes from Child A to B according as following: 2 tablets after breakfast, 1 tablet after lunch and 2 tablets after dinner; continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial. If the hepatic reserved function of the participant changes to Child C, colchicine will be stopped and participant receives regular follow-up only.If participant suffers from severe diarrhea, colchicine will be temporarily stopped. When the symptom of diarrhea subsides, colchicine will be given again but the dose will be reduced 0.5 mg/day."
45664241|NCT01618162|Drug|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
45958690|NCT02913781|Procedure|polar body removal using zona drilling by laser then suction by injecting pipette|zona drilling with laser followed by polar body removal then ICSI procedure
45958691|NCT02913781|Procedure|Classic ICSI|Classic ICSI case was done be injecting sperm inside Oocyte while polar body is already existed at 6 or 12 O'clock position.
45958692|NCT02913625|Other|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block for forearm or hand surgery
45664242|NCT01618162|Drug|placebo|Injected subcutaneously (under the skin) once daily.
45664243|NCT02193087|Drug|TDV Liquid Formulation 1|TDV Liquid Formulation 1 for subcutaneous injection
45664244|NCT02193087|Drug|TDV Liquid Formulation 2|TDV Liquid Formulation 2 for subcutaneous injection
45664245|NCT02193087|Drug|TDV IDT Lyophilized|TDV Lyophilized Formulation for subcutaneous injection
45664246|NCT02193087|Drug|Placebo|TDV liquid formulation placebo-matching solution for subcutaneous injection
45958693|NCT02913625|Other|Ultrasound guided infraclavicular block|Ultrasound guided infraclavicular block for forearm or hand surgery
45664247|NCT01617070|Drug|Kuvan|Dosed at 20 mg/kg; PO; Phase 3, Phase 4
45664248|NCT01617070|Dietary Supplement|Large Neutral Amino Acid Therapy|Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food
45664249|NCT04771767|Drug|Ketamine|Patients will receive 6 sub-anesthetic IV ketamine infusions over 8 weeks, each one lasting 40 minutes.
45664250|NCT04771767|Behavioral|Online Trauma-Focused Cognitive Behavioural Therapy|Participants will enrol in a 12-week online CBT program mirroring in-person trauma-focused CBT.
45958694|NCT02913547|Device|Silk'n HST|Treatment with Silk'n HST on the periorbital area as instructed in the user's manual
45958695|NCT00150215|Drug|PF-00184562|
45958696|NCT00150215|Drug|Olanzapine|
45958697|NCT02913703|Drug|Ghrelin|Boluses of Ghrelin will be given over a 1 minute period at 3 ug/kg. Ensure (2 cans) will also be given.
45958698|NCT02913703|Other|Saline|Boluses of saline will be given over a 1 minute period. Ensure (2 cans) will also be given.
45958699|NCT00171171|Drug|deferasirox|
45958700|NCT02913430|Drug|Fulvestrant|500mg IM Q28 days
45958701|NCT02913430|Drug|Tamoxifen|20mg PO Qdaily
45958702|NCT02913430|Drug|Palbociclib|Tamoxifen or Fulvestrant plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
45958703|NCT02913469|Drug|Morphine|The patients in group A would be administrated intravenous morphine 5mg
45958704|NCT02913469|Drug|metoclopramide|the patients in group C would be administrated intravenous metoclopramide 10mg
45958705|NCT02913469|Drug|saline|the patients in group D would be administrated intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml.
45958706|NCT00150254|Drug|CP-526,555 (varenicline)|
45958707|NCT02913352|Procedure|Latarjet procedure|Open anterior glenoid bone graft from coracoid process
45958708|NCT02913352|Procedure|Modified Eden-Hybinette|Open anterior glenoid bone graft from iliac bone crest, with capsular suture and screw fixation
45958709|NCT02913508|Drug|Vedolizumab intravenous injection|Vedolizumab intravenous injection
45958710|NCT02913508|Drug|Vedolizumab subcutaneous injection|Vedolizumab subcutaneous injection
45958711|NCT02913235|Procedure|Oral hygiene discontinuation group|Discontinuation of regular oral hygiene for 10 days
45958712|NCT02913157|Drug|Hydroxychloroquine|Orally administered Hydroxychloroquine
45958713|NCT00150293|Drug|Pregabalin|
45664251|NCT02341417|Drug|Cinacalcet|Cinacalcet was provided as 5 mg capsules for sprinkling or as 30 mg film-coated tablets for swallowing. The protocol-specified doses were: 1, 2.5, 5, 7.5, 10, 15, 30, 60, 90, 120, and 180 mg.
45664252|NCT01888900|Drug|DUAL|Asunaprevir and Daclatsvir
45664253|NCT01888900|Drug|QUAD|Asunaprevir, daclatsvir, peginterferon and ribavirin
45818470|NCT04332770|Other|levothyroxine withdrawal|All participants of this study are decided to get radioactive iodine therapy using levothyroxine withdrawal or human recombinant TSH injection prior to the study enrollment. That decision is independent with this study protocol. This study just collect continuous bio signals using wearable devices in the patients undergoing two different preparation methods for radioactive iodine therapy. That is why this study is an observational cohort study.
45818471|NCT03328208|Other|Comfort Talk® app|Test app
45818472|NCT03328208|Other|White Noise app|White Noise app built to mimic appearance of Comfort Talk® test app
45958714|NCT02913118|Drug|Andrographolid Sulfonate Injection (AS Injection)|
45958715|NCT02913118|Drug|Cephalosporin|
45958716|NCT02913118|Drug|Azithromycin, Minocycline or Doxycycline|
45958717|NCT02913118|Drug|Amoxicillin-clavulantic acid|
45958718|NCT02913118|Drug|Fluoroquinolones|
45958719|NCT02913118|Drug|Placebo|
45958720|NCT02913391|Other|recruitment group (RG)|After extubation the patient who was randomized to the Recruitment Group will use noninvasive ventilation (NIV) with alveolar recruitment maneuver with PEEP 15 cm H2O and afterwards 20 cm H2O remaining 2 minutes in each, then being maintained in NIV for 30 minutes with pressure support for a tidal volume of 6 ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
45958721|NCT02913391|Other|control group (CG)|After extubation the patient who was randomized to the Control Group will use noninvasive ventilation (NIV) for 30 minutes with pressure support for a tidal volume of 6ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
45458247|NCT01362218|Drug|Simvastatin, ramipril, acetylsalicylic acid|A once daily oral dose of simvastatin, ramipril, acetylsalicylic acid for 8 weeks
45664254|NCT02340949|Drug|Aflibercept|Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml
45664255|NCT02340949|Drug|5-Fluoruracil|Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2
45818473|NCT03210337|Drug|A-101 Topical Solution|A-101 Topical Solution
45818474|NCT03210337|Drug|A-101 Vehicle Solution|A-101 Vehicle Solution
45818475|NCT03242408|Drug|LPCN 1021|Oral testosterone undecanoate
45958722|NCT02913079|Behavioral|Sit-stand desk|
45958723|NCT02913079|Behavioral|Sitting desk|
45958724|NCT02912962|Behavioral|Self-Regulation Intervention adapted from the Alert Program ®|
45958725|NCT00150332|Drug|linezolid|
45958726|NCT02913040|Other|High Flow Nasal Cannula|Oxygen delivery through Heated Humidified High Flow Nasal Cannula
45958727|NCT02913040|Other|Low Flow Nasal Prongs|Oxygen delivery through Low Flow Nasal Prongs
45458248|NCT02315482|Procedure|pneumoperitoneum insufflation and steep trendelenburg|the sequence of pneumoperitoneum insufflation and steep trendelenburg positioning is randomized
45458249|NCT04568642|Device|Activate FiO2 controller|Closed-loop FiO2 controller will be activated in the experimental arm
45458250|NCT04568642|Device|Deactivate FiO2 controller|Closed-loop FiO2 controller will be deactivated in the experimental arm
45664256|NCT02340949|Drug|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU
45818476|NCT03242954|Other|Autonomous minor consent|Consent requirement where the participant is not required to get anyone's permission to participate in the trial.
45818477|NCT03242954|Other|Adult permission required|Consent requirement where the participant is required to obtain an adult's permission to participate in the trial.
45958728|NCT02912923|Other|Visual + Force Feedback|"Visual Feedback- Monitor displays two cursors that will represent the participant's hands, the cursors will fill with red ink as the user starts to compensate outside a normal error band. The amount of ink will increase proportionally to the magnitude of trunk compensation.~Force Feedback- Cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. The magnitude of the cue will be proportional to the magnitude of trunk compensation."
45958729|NCT02912923|Other|Visual + Force + Game Scores Feedback|"Visual Feedback- Monitor displays two cursors that will represent the participant's hands, the cursors will fill with red ink as the user starts to compensate outside a normal error band. The amount of ink will increase proportionally to the magnitude of trunk compensation.~Force Feedback- Cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. The magnitude of the cue will be proportional to the magnitude of trunk compensation.~Game Scores- Numerical score displayed next to the cursors. The participant will be rewarded with more points when less compensation is exhibited, or with less points when an increased level of compensation is measured."
45818478|NCT03242954|Other|Parental permission required|Consent requirement where the participant is required to obtain their parent's permission to participate in the trial.
45818479|NCT03459794|Drug|Ivermectin|150 mcg/kg ivermectin, by mouth.
45818480|NCT03459794|Other|Placebo|An oral placebo will be administered, once
45818481|NCT03211117|Drug|Docetaxel|Given IV
45818482|NCT03211117|Drug|Doxorubicin Hydrochloride|Given IV
45958730|NCT02912884|Drug|No cytoreductive vs cytoreductive drugs|No cytoreductive treatment vs cytoreductive drugs (hydroxycarbamide, alpha-interferon, ruxolitinib).
45958731|NCT02912728|Behavioral|CGM + Family Behavioral Intervention|use of CGM combined with a CGM focused family behavioral intervention and to assess CGM adherence
45958732|NCT02912728|Device|Standard CGM|use of CGM alone to assess CGM adherence
45958733|NCT00150371|Drug|atorvastatin|
45958734|NCT02912767|Behavioral|questionnaire|A questionnaire that has been validated by investigators at the Mayo Clinic. The questionnaire has 13 items to assess the rate of patient-reported lymphedema. The questionnaire will be mailed and then followed up with a second mailing after month 1 and a phone call after month 2. Within 3 months of sending the questionnaire a patient will be either considered as a responder vs non-responder. The date of surgery and the date of when the questionnaire is filled out will be captured.
45958735|NCT02912845|Drug|KamRAB - HRIG|wound infiltration or IM injection
45958736|NCT00407706|Procedure|blood test|
45958737|NCT02912689|Device|Neurally Adjusted Ventilator Assist|NAVA during Non-invasive ventilation
45958738|NCT02912689|Device|Pressure support ventilation|PS during Non-invasive ventilation
45958739|NCT02912806|Procedure|Total Knee Replacement|Primary total knee arthroplasty for knee osteoarthritis
45958740|NCT02912611|Procedure|Education and Protocol based management|
46079321|NCT05618834|Behavioral|Promoting Positive Care Interactions (PPCI)|"The PPCI consists of four steps: (1) stakeholder engagement in developing facility specific goals; (2) environment and policy assessments; (3) flexible staff education; and (4) ongoing mentorship, motivation, and support (in-person visits and text messages) for staff to optimize care interactions.~A research nurse facilitator (RNF), a registered nurse (RN) with prior experience in long-term care will work with an identified internal champion monthly to implement the four steps of PPCI. The PPCI intervention comprehensively focuses on intrapersonal, interpersonal, organizational, and environmental/policy factors to bring together evidence and key stakeholders to optimize daily care interactions in assisted living."
45818483|NCT03211117|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45818484|NCT03211117|Other|Laboratory Biomarker Analysis|Correlative studies
46079322|NCT05618834|Behavioral|PPCI-Staff Education Only (EO)|The EO will include a 30-45 min in-service session and monthly f/u visits for booster education. The education content and process will be the same as outlined in Step 3 of the PPCI for treatment sites.
45818485|NCT03211117|Biological|Pembrolizumab|Given IV
45818486|NCT03211117|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45818487|NCT03436147|Other|POP-Q|Pelvic Organ Prolapse Quantification
45958741|NCT02912416|Dietary Supplement|Probiotics|
45958742|NCT02912416|Dietary Supplement|Placebo|
45958743|NCT02912377|Biological|Neulasta, B12019|GCSF, Growth Colony Stimulating Factor
45958744|NCT02912494|Drug|JR-131|
46079323|NCT05618613|Drug|Elacestrant|Elacestrant 200mg, 300mg, or 400mg once daily oral dosing in cycles of 28 days.
46079324|NCT05618613|Drug|Onapristone|Onapristone 40mg or 50mg twice daily oral dosing in cycles of 28 days.
45958745|NCT02912494|Drug|Darbepoetin alfa|
45958746|NCT00150410|Drug|Inhaled insulin|
45958747|NCT02912221|Other|Incentive|Both groups will receive fitbits to track their physical activity, however one arm of the study may receive additional incentives to achieve their step count goal.
45958748|NCT02912260|Drug|MGL-3196|
45958749|NCT02912260|Drug|Placebo|
45958750|NCT00171288|Drug|fluvastatin, ezetimibe|
45958751|NCT02912533|Drug|JR-131|
45818488|NCT03245372|Procedure|Standard care|Heart rate 60-100 beats per minute, mean arterial pressure 65 mm Hg, serum lactate 2 mmol/L, oxygen saturation 95 % (90 % during one lung ventilation).
45818489|NCT03245372|Procedure|Goal directed therapy|The hemodynamic algorithm will be based on systolic volume index and fluid challenges. FloTrac sensor (this sensor connects to any existing arterial catheter and provides advanced hemodynamic parameters through pulse contour analysis) and EV1000 clinical platform (clinical platform from Edwards Lifesciences that provides advanced hemodynamic monitoring) will be used to calculate cardiac index and systolic volume index.
45818490|NCT03317431|Other|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
45818491|NCT00376285|Drug|CP-742,033|
45818492|NCT00376285|Drug|Fenofibrate|
45818493|NCT03460652|Drug|KP415 oral capsule|Once-daily oral dose
45958752|NCT02912299|Procedure|Skin biopsies|2 3mm skin biopsies will be taken
45958753|NCT02912299|Other|Blood and urine analysis|Measurement of sodium, potassium and kidneyfunction in blood and urine.
45958754|NCT02912299|Other|Blood collection for RNA-investigation|A blood sample that, in case of relevant differences between groups, could be used for RNA-profiling.
45958755|NCT02912338|Behavioral|Resistant Training|
45958756|NCT02912338|Other|Control Group|
45958757|NCT00163995|Drug|urotensin II|
45958758|NCT00150449|Drug|Pregabalin|
45958759|NCT02912182|Drug|Betamethasone|Betamethasone intravenous
45958760|NCT02912182|Drug|Placebo|Placebo intravenous NaCl intravenous administration Placebo tablets
45958761|NCT02912182|Drug|Prednisolone|Oral tablets
45958762|NCT02912026|Drug|IV F901318|Metabolic profile AUC 0 to infinity
45958763|NCT02912026|Drug|Oral F901318|Metabolic profile AUC 0 to infinity
45958764|NCT02911987|Other|high intensity training (HIT) program|The participants are randomly divided through use of sealed envelopes into four groups that all follow high intensity training (HIT) programs. Each training group follows of a 12 week program (2x/week, 2h). All training will be conducted under the guidance of expert therapists.
45958765|NCT02911987|Other|moderate intensity training (MIT) exercise therapy|MIT exercise consisting of a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'MIT' group).
45958766|NCT00164034|Device|Real time computer prompted trauma algorithms|
45958767|NCT02911870|Drug|SNAC|Oral administration
45958768|NCT02911870|Drug|Placebo|Oral administration
45958769|NCT02911870|Drug|Moxifloxacin|Oral administration
45958770|NCT02892214|Procedure|Pelvic floor physical therapy|
45818494|NCT03321097|Device|condensed RT group|"BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.~Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 4 sessions per week, for 6 weeks.~During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice."
45958771|NCT02892214|Drug|estriol cream (ovestin)|
45958772|NCT02892214|Procedure|Low-level-laser therapy|
45958773|NCT00150488|Device|Uracyst|2% weekly for 6 weeks, monthly for 4 months
45958774|NCT02872402|Behavioral|Lifestyle intervention|Women who are still breastfeeding at the first postpartum visit will be encouraged to pursue. References to local breastfeeding supporting groups will be done, if needed. The intervention will be conducted in order to reach recommendations for food servings and nutrient needs. Particular attention will be paid to increase fruits, vegetables, fish and whole grains intake, and decrease added sugars and high fat meat/dairy products. Women will be strongly encouraged to be active at least 150 min/week. They will be provided with targeted strategies for exercising, types of exercises and tips for including physical activity into the daily routine as well as fun exercises for the whole family.
45958775|NCT02872402|Behavioral|Active control lifestyle intervention|Participants in the control group will receive standard lifestyle recommendations in the form of written information at each visit.
45958776|NCT00164073|Procedure|Liver biopsy|
45958777|NCT02843230|Radiation|Avastin|
45958778|NCT02843230|Radiation|Lomustine|
45958779|NCT02843230|Radiation|Temozolomide|
45958780|NCT02843230|Device|MRI|
45958781|NCT02843230|Device|MRS|
45958782|NCT02843230|Device|DSC|
45958783|NCT02712814|Drug|Topical hormonal cream (estrogen)|Patients will be instructed to stop hormonal contraception and to apply 0.1 ml topical cream containing 0.1% of estriol to the vestibule, once daily for 3 months
45958784|NCT02712814|Procedure|Pelvic floor physical therapy|PF physical therapy once weekly for 3 months
45958785|NCT02712814|Procedure|Low Level Laser therapy|non-thermal laser irradiation (low levels of red and near infrared light) is applied directly to the vestibule
45958786|NCT00150527|Drug|Citalopram|40 mg, pill, single dose
45958787|NCT00150527|Drug|Escitalopram|20 mg, pill, single dose
45958788|NCT00150527|Drug|Dexamethasone|1 mg, pill, single dose
45958789|NCT00150527|Behavioral|Cold Pressor Test|single test
45958790|NCT02911636|Radiation|Pelvic SABR with intra-prostatic SABR|described elsewhere
45958791|NCT00171327|Drug|valsartan, fluvastatin|
45958792|NCT02911597|Drug|Naltrexone|adding naltrexone (or placebo) to a ketamine infusion to potentially block the effects of ketamine as an anti depressant.
45958793|NCT00150566|Drug|Lanthanum carbonate|
45958794|NCT02911441|Behavioral|Cognitive Behavioral Therapy|
45958795|NCT02911363|Device|Captivator cassette|The Captivator tissue cassette has an effect on the preservation of tissue histology.
45958796|NCT02911363|Other|Standard of Care|The specimen will be processed following the College of American Pathology Standards.
45958797|NCT02911480|Drug|Oxytocin|
45958798|NCT00171366|Drug|amlodipine/benazepril|
45958799|NCT00150605|Drug|Extended-release carbamazepine|
45958800|NCT02911207|Behavioral|patients choose one creative activity and one physical activity|taking part in 2 activities (a creative one and a physical one)
45958801|NCT02911168|Procedure|Proximal Intercostal Block|After identifying the correct intercostal space, the ultrasound probe will be moved medially to identify the transverse processes, then again laterally from the transverse processes to rest over the ribs so as to obtain the best view of ribs and pleura. A 10cm, 21G needle will be inserted in-plane at the caudal border of the probe. An attempt will be made to keep the needle tip and the target injection position (just under the internal intercostal membrane (IIM)) in view. Correct needle tip placement will be demonstrated by depression of the pleura/endothoracic fascia upon local anesthetic injection and by lack of retrograde spread of LA over the muscles or the ribs. The LA will be injected in 4 cc aliquots after negative aspiration of air, CSF and blood.
45958802|NCT02911168|Procedure|Paravertebral Block|After identifying the correct intercostal space, the ultrasound probe will be placed between the adjacent transverse processes in a longitudinal/parasagittal plane measuring 2.5cm from the midline. The best possible view of the transverse processes, the superior costotransverse ligament and pleura will be obtained. An attempt will be made to keep the needle tip and the target injection position (immediately beneath the costotransverse ligament) in view. Correct placement of the needle tip will be demonstrated by depression of the pleura upon injection of local anesthetic and by lack of retrograde spread of LA over the muscles or transverse processes. The LA will be injected in 4 cc aliquots after confirming negative aspiration of air, CSF and blood.
45958803|NCT02911051|Device|Actreen Hydrolite Cath|Depending of the use of the self catheterized patient could be 4 to 6 Actreen Hydrolite Cath per day
45958804|NCT00171405|Drug|aliskiren|
45958805|NCT00150644|Drug|Asoprisnil|Asoprisnil 10mg Tablet, oral Daily for 12 weeks
45958806|NCT00150644|Drug|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for 12 weeks
45958807|NCT00150644|Drug|Placebo|Placebo Tablet, oral Daily for 12 weeks
45958808|NCT02910778|Drug|Atorvastatin|Subjects will receive 80 mg atorvastatin once daily for 14 days (until study day 15). On study day 15, 80 mg atorvastatin in combination with a loading dose of 180 mg ticagrelor will be administered.
45958809|NCT02910778|Drug|Placebo|Subjects will receive placebo once daily for 14 days (until study day 15). On study day 15, placebo in combination with a loading dose of 180 mg ticagrelor will be administered.
45958810|NCT02910778|Drug|Ticagrelor|
45958811|NCT00164112|Drug|Cooperstown 5+1 alone|
45958812|NCT00164112|Drug|Azithromycin plus Cooperstown 5+1|
45958813|NCT00164112|Drug|Telithromycin plus Cooperstown 5+1|
45958814|NCT00164112|Drug|Levofloxacin plus Cooperstown 5+1|
45664257|NCT02340949|Drug|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
45664258|NCT01646203|Biological|IMC-TR1|Administered intravenously
45664259|NCT02375347|Other|Chickpea Enhanced Diet (Short term)|"Dry Roasted Chickpeas, 21.26 gram serving size bags, by mouth five times per week.~Stool Samples collected at Day 1, Day 9, and Day 14."
45664260|NCT02374957|Drug|Cilostazol|100 mg twice daily for 90 days
45664261|NCT02374255|Behavioral|GoC intervention|Training of oncologists using OncoTalk to conduct Goals of Care discussions and measure impact on patient satisfaction.
45664262|NCT02308033|Drug|Metronidazole|
45818495|NCT03321097|Device|distributed RT group|"BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.~Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 2 sessions per week, for 12 weeks.~During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice."
45818496|NCT03245762|Drug|Oxytocin|4 IU/day of oxytocin administered via nasal spray device each morning.
45818497|NCT03245762|Drug|Placebo|4 IU/day of placebo administered via nasal spray device each morning
45818498|NCT03321253|Device|Nd: YAG laser posterior capsulotomy|Nd: YAG laser posterior capsulotomy
45958815|NCT02910817|Drug|Metformin|The metformin-treated group received metformin (1000 mg per day) with the start of controlled ovarian stimulation (COH) until the day of the pregnancy check.
45958816|NCT02910817|Other|Placebo|Placebo
45458251|NCT02316964|Drug|decitabine|20 mg/m2 Given IV (intravenous) for 5 days over 60 minutes
45664263|NCT02308033|Drug|Gel vehicle|
45664264|NCT02339155|Biological|AVA|Sterile, milky-white suspension with dosage level of 0.5 mL for SC administration
45664265|NCT02339155|Biological|Raxibacumab|Sterile, liquid formulation with unit dose strength of 40 mg/ kg for IV administration
45664266|NCT02339155|Drug|Diphenhydramine|Depending upon the labelling of the specific product chosen, 25 - 50 mg will be administered orally or IV
45664267|NCT02211261|Biological|PF-06293620|subcutaneous, single dose 0.3 mg/kg
45664268|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
45664269|NCT02211261|Biological|PF-06293620|Subcutaneous, single dose 1.0 mg/kg
45818499|NCT03322657|Drug|Neostigmine|Neostigmine injection
45818500|NCT03322657|Drug|Glycopyrrolate|Glycopyrrolate injection
45818501|NCT03322657|Drug|Sugammadex|Sugammadex injection
45958817|NCT00150683|Device|vibration and passive standing versus passive standing alone|
45958818|NCT02910934|Other|Actellic CS|Indoor residual spray with Actellic CS
45958819|NCT02910505|Device|enLighten Laser|Laser for tattoo removal
45664270|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
45664271|NCT02211261|Biological|PF-06293620|Subcutaneous single dose 3 mg/kg
45664272|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
45664273|NCT02211261|Biological|PF-06293620|Subcutaneous single dose 6 mg/kg
45664274|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
45958820|NCT02910622|Other|Chimio-oncogramme|Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
45958821|NCT00171444|Behavioral|Medical education|
45958822|NCT00150722|Drug|atorvastatin (or other tolerated statin + Niaspan/placebo)|atorvastatin 80 mg for all, randomized to 1500 mg niacin/placebo and then crossed over
45664275|NCT02211261|Biological|PF-06293620|Intravenous infusion single dose 1 mg/kg
45664276|NCT02211261|Biological|Placebo|Intravenous infusion normal saline single dose
45958823|NCT02910661|Other|Focus Group|Concurrently at each site, an experienced facilitator, having no direct affiliation with the clinical team, will use standardized stakeholder-specific, semi-structured scripts (designed with patient and parent collaborators) to conduct the patient, parent, and HCP focus groups. The TAKE-IT intervention will be described, and Simplemed e-pillbox shown, to all focus groups. Questions posed to the patient and parent focus groups will focus on 2 themes: the intervention and electronic monitoring. Example stakeholder-specific scripts to guide the discussions are appended. Each focus group will last ~90 min. and be audio-recorded. An observer will take field notes.
45664277|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose 75 mg (Days 1, 29 and 57)
45664278|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
45958824|NCT02910388|Device|LLETZ with colposcopy|Loop procedure using a colposcope in order to see and remove the abnormal cervical tissue
45958825|NCT02910388|Other|LLETZ without colposcopy|Loop procedure without using a colposcope
45958826|NCT02910427|Other|Regular salt|Participants eat a regular salt diet.
45958827|NCT02910427|Other|Potassium-enriched salt|Participants eat a potassium-enriched salt diet.
45818502|NCT03247322|Other|Pharmacist-led medication therapy using mHealth application|This cohort of participants will receive clinical pharmacist-led supplemental medication therapy monitoring and management, utilizing a smartphone-enabled mHealth application, integrated with televisits and home-based monitoring of blood pressures and glucoses (when applicable).
45818503|NCT04332679|Device|Group A - control group|20 patients treated by means of a dense PTFE (d-PTFE) titanium-reinforced membrane (Cytoplast Ti-250XL; Osteogenics Biomedical) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
45958828|NCT02910427|Other|Potassium and magnesium-enriched salt|Participants eat a potassium and magnesium-enriched salt diet.
45958829|NCT04687930|Drug|genicular nerve block|nerve block of the genicular nerve at 3 points around the inflamed knee using ultrasound.
45958830|NCT04687930|Drug|intra-articular steroid injection|Triamcinilone injection into the knee joint under ultrasound guidance.
45958831|NCT00164151|Drug|HalfLytely|
45958832|NCT00164151|Drug|Visicol|
45958833|NCT00150761|Drug|Levocetirizine (drug)|
45664279|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose 150 mg (Days 1, 29 and 57)
45664280|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
45664281|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose 250 mg (Days 1, 29 and 57)
45818504|NCT04332679|Device|Group B - Test group|20 patients treated by means of Ti mesh (Trinon Titanium; Karlsruhe, Germany) and cross-linked collagen membrane (Osseoguard, Zimmer Biomet, Warsaw, IN, USA) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
45664282|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
45818505|NCT03324451|Behavioral|TTM Intervention for Insulin Initiation|The intervention contains two parts: (1) individual intervention; (2) insulin injection follow-up management. Different intervention strategies are applied to patients according to their stages of change.
45818506|NCT03324451|Behavioral|Usual care|Regular patient education on insulin injection at the control arm hospital.
45818507|NCT03324607|Drug|hyperpolarized 129Xe gas MRI|There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi. Images obtained using 129Xe MRI will be compared with standard lung function tests that are used routinely in the clinic, 6 minute walk test that assesses walking ability and several questionnaires that assess shortness of breath and life quality.
45818508|NCT03324607|Drug|Bevespi Aerosphere|There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi.
45958834|NCT00171483|Drug|Tegaserod|
45958835|NCT03777904|Diagnostic Test|Serum Ferritin level|Serum ferritin level will be collected with other clinical labs and measured in the research lab
45958836|NCT03777904|Diagnostic Test|Serum Ferritin iron content|Blood will be collected with other clinical labs and the iron content in the ferritin will be measured in the research lab
45958837|NCT03777904|Diagnostic Test|Urine Ferritin level|Urine will be collected non-invasively and analyzed for ferritin level
45958838|NCT03777904|Diagnostic Test|Urine ferritin iron content|Urine will be collected non-invasively and analyzed for iron content within the ferritin
45958839|NCT03759925|Other|Nutritional Support|Weekly nutritional components: Month 1: equivalent of 3 meals/day in the form of 14 frozen meals, and breakfast bag with items to prepare 7 breakfast meals. Month 2: equivalent of 3 meals a day in the form of 7 frozen meals, grocery bags, and breakfast bags with items to prepare 7 breakfast meals. Month 3: the equivalent of 2 meals a day in the form of 7 frozen meals and grocery bags. Month 4: Participant choice to receive either 7 frozen meals or grocery bag with equivalent food for 1 meal a day. Month 5: Grocery bag with equivalent food for 1 meal a day Nutritional counseling component: Individual counseling with Registered Dietician monthly
45958840|NCT00150839|Drug|Mirtazapine|Patients receive mirtazapine 45mg and placebo.
45958841|NCT00150839|Drug|Venlafaxine|Patients receive mirtazapine 45mg and venlafaxine 300mg.
45958842|NCT04723914|Biological|dual target CAR-T cell therapy|CD19/CD20 dual target CAR-T cell therapy
45958843|NCT00150878|Other|Conditioning therapy|Preparation before allogeneic transplantation
45958844|NCT03782740|Drug|Melatonin 10 mg|Melatonin capsule
45458252|NCT02316964|Biological|natural killer cell therapy|Undergo infusion of allogeneic NK cells on day 0
45664283|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose TBD mg (Days TBD)
45664284|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days TBD)
45818509|NCT03247790|Drug|Lasmiditan|Administered orally
45818510|NCT03249116|Other|animal-assisted intervention|Interaction with a therapy dog
45958845|NCT03782740|Drug|Placebo|Sugar pill manufactured to mimic Melatonin capsule
45958846|NCT03782740|Drug|Melatonin 20 mg|Melatonin capsule
45958847|NCT00164190|Procedure|Routine Early Percutaneous Coronary Intervention after Thrombolysis|early or delayed PCI
45958848|NCT03715504|Drug|TP-3654|oral PIM inhibitor
45664285|NCT02170077|Drug|BIA 2-093|BIA 2-093 (tablets) administered at increasing daily doses of 400 mg, 800 mg and 1200 mg once-daily or twice-daily, oral route
45664286|NCT02170077|Drug|Placebo|Placebo tablets administered orally
45958849|NCT03669367|Drug|Abatacept Injection|Abatacept subcutaneous in monotherapy 125 mg/week during the first year (12 months). Abtacept subcutaneus in monotherapy 125 mg/2weeks during the second year.
45958850|NCT03669367|Drug|hydroxycloroquina|oral hydroxycloroquina 5 mg/Kg/day for 2 years (0-48 months)
45958851|NCT03665116|Dietary Supplement|L-arginine|L-arginine capsule
45958852|NCT00150917|Behavioral|Supportive-Expressive Group Therapy|
45818511|NCT03249116|Other|active control|Interaction with a stuffed dog
45958853|NCT00164229|Behavioral|math|
45958854|NCT00164229|Behavioral|behavior regulation|
45958855|NCT00150956|Procedure|Daily home hemodialysis|
45818512|NCT03437863|Device|Mobile application|Use of a mobile application (on a borrowed device) with following features: 1) strengths reflection and identification, 2) summary of registered strengths, 3) defining goals, and 4) linking strengths to goals.
45818513|NCT03467048|Device|McGrath videolaryngoscopy|"Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords."
45818514|NCT03467048|Device|Direct laryngoscopy|"Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords."
45958856|NCT00532168|Drug|tenofovir + emtricitabine + efavirenz|tenofovir + emtricitabine + efavirenz, approved dose, oral route, QD
45958857|NCT00532168|Drug|tenofovir + emtricitabine + lopinavir-ritonavir|tenofovir + emtricitabine (QD) + lopinavir-ritonavir (BID), oral route, approved dose
45818515|NCT03249272|Drug|Regadenoson|Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
45664287|NCT02210091|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) analysis of ADVATE
45664288|NCT02210091|Biological|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) analysis of BAX 855
45664289|NCT02210091|Biological|PEGylated Recombinant Factor VIII|Prophylaxis treatment
45664290|NCT02338999|Radiation|PET/CT|The combined PET/CT scans provide images that pinpoint the anatomic location of abnormal metabolic activity within the body.
45664291|NCT02338999|Drug|Pioglitazone|Increases insulin sensitivity in muscle and adipose tissue, and inhibits hepatic gluconeogenesis.
45664292|NCT02338999|Drug|Placebo|
45818516|NCT03249272|Drug|Adenosine|Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
45958858|NCT00532168|Drug|tenofovir + emtricitabine + atazanavir-ritonavir|tenofovir + emtricitabine + atazanavir + ritonavir (100 mg), oral route, approved dose, QD
45664293|NCT02169219|Drug|Glucocorticoids|"Patients will begin prednisone therapy at a dose selected by the investigator or the treating physician with oral prednisone 60mg or 1mg/kg (if weight less than 60kg) or intravenous methylprednisolone, up to 1g/day for three days.~Prednisone will be tapered over 8 weeks as follows:~60mg for 2 weeks~40mg for 2 weeks~30mg for 1 week~20mg for 1 week~10mg for 1 week~5mg for 1 week"
45958859|NCT00532207|Drug|teriparatide|subcutaneous 20 micrograms
45958860|NCT04723836|Dietary Supplement|Riboflavin (5mg)|From 16th week gestation until end of pregnancy
45958861|NCT04723836|Dietary Supplement|5-methyltetrahydrofolate (400µg)|From 16th week gestation until end of pregnancy
45958862|NCT04723836|Dietary Supplement|Placebo|From 16th week gestation until end of pregnancy
45958863|NCT00150995|Drug|Tetrathiomolybdate|
45958864|NCT00532246|Drug|raloxifene|
45958865|NCT00532246|Drug|Placebo|
45958866|NCT00532285|Drug|Paclitaxel/Gemcitabine|Treatment will be delivered in the outpatient setting. Each three-week cycle consists of paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8).Patients will receive four cycles of therapy unless there is any evidence of no response (SD or PD) or unacceptable toxicity defined as unpredictable, irreversible, or Grade 4, or noncompliance by patient with protocol requirements.
45958867|NCT03143374|Drug|18F-AV-1451|"The experimental tracer used for this study is called 18F-AV-1451 is a specialized radioactive PET tracer used to detect the presence of tau proteins in the brain.~Participants will undergo a baseline 18F-AV-1451 brain scan. If funding is available, participants will be asked to return for one or more longitudinal visits, including a 18F-AV-1451 brain scan, every 9 to 18 months after the prior visit.~The 18F-AV-1451 PET/CT scan will require up to 3 hours of time, including preparation. The scan will take place using PET/CT scanners in the Perelman Center for Advanced Medicine or the Hospital of the University of Pennsylvania."
45958868|NCT00164268|Behavioral|Ke Ala Lokahi (Native Hawaiian cultural intervention)|
45958869|NCT00151034|Drug|Trastuzumab|
45958870|NCT00151034|Drug|Paclitaxel|
45958871|NCT00151034|Drug|Carboplatin|
45958872|NCT00151034|Drug|Gemcitabine|
45958873|NCT02817451|Biological|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
45958874|NCT02817451|Biological|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
45958875|NCT00171522|Drug|Tegaserod and Polyethylene Glycol 3350|
45958876|NCT02716012|Drug|MTL-CEBPA|Intravenous administration
45458253|NCT02316964|Biological|aldesleukin|Given SC
45458254|NCT02316964|Other|laboratory biomarker analysis|Correlative studies
45664294|NCT02169219|Drug|Rituximab|Rituximab will be administered in four weekly doses at 375mg/m2
45664295|NCT02191605|Behavioral|eSBIRT|A single 20 minute interactive computer-delivered intervention designed to promote motivation to change prenatal marijuana use, without presuming the participant to be currently using marijuana while pregnant.
45818517|NCT03249584|Device|OsteoCool™ RF Ablation|The OsteoCool™ RF Ablation system is indicated in the United States (US), Europe (EUR) and Canada (CAN) for patients with metastatic malignant lesions in a vertebral body, painful metastatic lesions involving bone (in the US, patients with metastatic lesions involving the bone must have failed or were not candidates for standard therapy) and benign bone tumors such as osteoid osteomas.
45818518|NCT02182440|Biological|recAP|One hour infusions once daily for three days
45818519|NCT02182440|Other|Placebo|1 hour IV infusion once daily for 3 days
45818520|NCT03255902|Behavioral|Parenting classes|Parenting Classes:The Incredible Years curriculum
45958877|NCT02716012|Drug|Sorafenib 200mg|Sorafenib tablets
45958878|NCT05467696|Drug|CTP-543|For each period, subjects will be dosed with CTP-543 12 mg (1 x 12 mg tablet)
45958879|NCT00151073|Drug|Zoledronic acid|
45958880|NCT00151073|Drug|Estramustine|
45958881|NCT00151073|Drug|Docetaxel|
45958882|NCT05467618|Procedure|Maxillofacial surgery|An incision on the skin over the mandible versus incision on the gingivae inside the mouth
45958883|NCT05467579|Device|Device: orthodontic - mandibular advancement clear aligner|Intervention orthodontic - mandibular advancement: mandibular retrognathia correction with a mandibular advancement using a step-wise approach with clear aligner.
45958884|NCT00171561|Drug|valsartan/hydrochlorothiazide|
45818521|NCT03468920|Drug|IV Acetaminophen|IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
45958885|NCT05467540|Device|SPINERY|Radio-Frequency device designed for palliative treatments of patient with painful metastatic bone tumors involving vertebral bodies, sacrum, iliac crest and peri-acetabulum
45818522|NCT03468920|Drug|PO Acetaminophen|Acetaminophen PO 1000mg once pre-operatively
45818523|NCT03468920|Drug|PO Placebo|PO placebo capsule compounded to match PO Acetaminophen capsule
45958886|NCT00151112|Procedure|Positioning and plexus anesthesia|positioning during plexus anesthesia
45958887|NCT05467501|Device|Theraputic ultrasound|Therapeutic ultrasound
45958888|NCT00532324|Other|CA-MRSA Decolonization|In later stages of this study, women found to be nasally and/or vaginally colonized with CA-MRSA will be randomized to receive postpartum, either: 1) attempted decolonization with intranasal mupirocin twice a day for one to two weeks with or without diluted chlorhexidine or Clorox baths two to three times a week for one to two weeks or, 2) no intervention. The primary study is observational only.
45958889|NCT00171600|Drug|VALSARTAN, VALSARTAN PLUS HCTZ, LISINOPRIL, LISINOPRIL PLUS HCTZ|
45958890|NCT05467384|Drug|Amlodipine|5mg/day in two divided doses
46079325|NCT05617963|Drug|Durvalumab|Patients showing a disease control (defined as stable disease [SD], partial response [PR], or complete response [CR] according to RECIST v1.1) at the radiological evaluation performed after the end of thoracic CRT will receive durvalumab intravenously 1500 mg every 4 weeks until disease progression, unacceptable toxicity, death or patient's decision for a maximum of 24 months.
45664296|NCT02191605|Behavioral|Tailored texting|Group text messaging software from Trumpia, Inc. will be used to create the tailored text messages that will be sent to participants assigned to this intervention. Text messages will sent after the initial study participation visit until childbirth or participant opts out of receiving them.
45664297|NCT02191137|Drug|Riociguat (Adempas, BAY63-2521)|Participants received therapy with riociguat during a 10-week titration phase. The starting dose for riociguat for all patients was 0.5 milligram (mg) three times a day (TID). The dose of riociguat was increased every 2 weeks in 0.5 mg increments to 1.0, 1.5, 2.0, and 2.5 mg until patients reached their individual optimal dose based on their systolic blood pressure and well-being. After reaching their optimal dose, patients then entered a maintenance phase and remained on this dose for an additional 14 weeks. End of treatment was reached at Visit 10 after 24 weeks of treatment with riociguat.
45664298|NCT02168439|Drug|Dexmedetomidine|
45664299|NCT02168439|Drug|Midazolam|
45664300|NCT02190591|Device|Peanut Labor Ball|Peanut Labor Ball
45818524|NCT03468920|Drug|IV Solution Placebo|This will serve as the placebo for the IV Acetaminophen intervention
45958891|NCT00151151|Behavioral|Computer-Assisted Motivational Intervention|
45958892|NCT00151151|Behavioral|Didactic Educational Counseling|
46002277|NCT04043286|Device|Definitive abutment|With two height options available, On1 Base are selected depending on the thickness of the soft tissue. It remains in position from implant placement to finalization, which leaves the soft tissue undisturbed for optimized healing, moved the restorative platform of Nobel Biocare conical connection implants from bone level to tissue level, thereby simplifying the restorative procedures
45958893|NCT05467306|Behavioral|Nurse-Navigator Enhanced PrEP Support|Pharmacies randomized to the nurse-navigator model will receive tailored support counseling, in addition to receipt of standard PrEP services. Support counseling by nurse-navigators will provide educational messaging tailored to AGYW and actionable advice targeting PrEP persistence and adherence and/or FP topics, and will address participants' questions related to the content. Counseling will include adherence encouragement (IMB domain: motivation), PrEP efficacy and safety (IMB domain: information), self-efficacy for prevention of HIV, support for potential PrEP side effects, behavioral skills (tips for remembering PrEP medications, IMB domain: behavioral skills) and strategies for remembering PrEP refill schedules. During enrollment, the nurse-navigator will explain that support counseling is voluntary and that the nurse will also be available at the pharmacy to address concerns or questions whenever they arise outside of scheduled visits.
45958894|NCT05467267|Procedure|TURBT|Patients with known bladder tumor undergoing TURBT - A biopsy from the tumor tissue will be taken. Peri operation a urine sample will be taken.
45958895|NCT05467228|Device|vibro-tactile stimulation (VTS)|To apply vibro-tactile stimulation, participants will use a wearable device. It contains two vibratory motors (Precision MicrodrivesTM, Model 307 - 100) that are low-voltage (~1V), non-invasive and will be located approximately above the lateral portions of the thyroid cartilage. For this protocol, they vibrate at frequencies between 40 - 100 Hz (i.e., 100 times per second
45958896|NCT00164307|Behavioral|Parent assisted social skills training|
45958897|NCT05467189|Drug|Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)|As part of routine treatment.
45958898|NCT00151190|Behavioral|Education for diabetes self-management|
45958899|NCT05467072|Device|Annular closure|Lumbar discectomy patients treated with Annular Closure Device BARRICAID
45958900|NCT05466760|Radiation|PET/MR|Study 1- pre-NAC PET/MR; Study 2- first follow-up PET/MR is performed after first dose of NAC; Study 3, second follow-up PET/MR is performed after third or fourth dose of the NAC. The NAC protocol is mainly antracycline-based followed by taxane-based regimen for a total of 6-8 cycles.
45958901|NCT05466721|Device|Hydrustoma C3|The participant will use the device for 14 days.
45958902|NCT05466721|Device|Control device|The participant will use the device for 14 days.
45958903|NCT00151229|Other|target blood pressure|
45958904|NCT00171639|Drug|zoledronic acid|
45958905|NCT05466604|Drug|Hyaluronidase Injection mesomedica|injection of 150 IU hyaluronidase to perioperative region, submucosally.
45958906|NCT05466604|Drug|Dexamethasone dekort|injection of 8 mg dexamethasone to perioperative region, submucosally.
45958907|NCT05466487|Device|Transcranial Alternating Current Stimulation (tACS)|Stimulation frequency and peak-to-peak intensity will be set to 10Hz and 1.5 milliampere (mA), phase offset will be set to 0 and 100 cycles will be used for ramping up. At the start of the neglect training session, the tACS will be started. When the neglect training session is finished, after maximally 40 minutes, the tACS will be switched off.
45958908|NCT05466487|Behavioral|Visual Scanning Training (VST)|The most common treatment for neglect is VST, which is an intensive compensation training (see Dutch guidelines for rehabilitation of neglect: Ten Brink, Van Kessel, & Nijboer, 2017). The aim of this training is to improve visual scanning behavior, that is, to encourage neglect patients to actively and consciously pay attention to stimuli on the contralesional side.
45958909|NCT00164346|Behavioral|neurocognitive habilitation|
45958910|NCT05466448|Drug|RZL-012|concentration of injected formulation 50 mg/mL RZL-012 of 7.5 mg/0.15 mL/injection point that results in a maximum total dose/volume of 240±30 mg/4.8±0.6 mL RZL-012
45958911|NCT05466331|Other|Mobile Tele-HCV Care|Study participants receive HCV care via telemedicine. Telemedicine appointments are performed on a mobile van.
45958912|NCT05466331|Other|Enhanced Usual Care|Study participants are referred to a clinician in their area for HCV care.
45664301|NCT02190435|Device|Stryker ADAPT computer-assisted navigation|Adaptive Positioning Technology for Gamma 3
45664302|NCT02190435|Device|Conventional technique|Conventional Technique
45664303|NCT02338843|Drug|LJPC-501|Treatment arm
45818525|NCT03470012|Device|Multi-Purpose Gentle Tape|The Multi-Purpose Gentle Tape is a general purpose medical adhesive tape for medical applications used primarily to secure dressings, lightweight tubing, and devices to skin.
45958913|NCT00151307|Device|INVOS cerebral oximeter|
45958914|NCT04723875|Drug|Paclitaxel or docetaxel + Cisplatin or carboplatin|Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
45958915|NCT05466019|Drug|Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)|FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ, Q2W Toripalimab 3mg/kg, intravenously administered on the first day of each cycle, Q2W.
45664304|NCT02338843|Drug|Placebo|PBO
45664305|NCT02190279|Drug|18F DCFBC|Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.
45818526|NCT04758624|Device|Deep Brain Stimulation|Medtronic Activa device will be implanted and administered clinically, except as part of the trial after 24 months of DBS being on it will be turned off for 3 days and will be turned back on.
45958916|NCT05465902|Biological|Recombinant COVID-19 variant Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
45958917|NCT05465902|Biological|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
45958918|NCT05465902|Biological|mRNA COVID-19 vaccine (Moderna)|1dose, Intramuscular Injection
45664306|NCT02190279|Drug|Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)|
45664307|NCT02135445|Drug|TAK-385|TAK-385 tablet
45664308|NCT02135445|Drug|Degarelix|Degarelix injection
45958919|NCT05465902|Biological|Viral Vector COVID-19 vaccine (AstraZeneca)|1dose, Intramuscular Injection
45958920|NCT00151346|Drug|Bupivacaine and Fentanyl (for CSE)|Bupivacaine 0.25% x 1 cc + Fentanyl 20 mcg, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
45664309|NCT02374099|Drug|CC-486|Each cycle will be 28 days. CC-486 will be administered orally at a dose of 300 mg daily on days 1-21 of each 28-day cycle
45664310|NCT02374099|Drug|Fulvestrant|Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
45664311|NCT02134977|Drug|Leuprorelin Acetate|Leuprorelin Acetate SR 11.25 mg Injection Kit
45818527|NCT03339206|Behavioral|Constituent message with FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
45818528|NCT03339206|Behavioral|Constituent message without FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
45818529|NCT03339206|Behavioral|Littering message (Control)|Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
45818530|NCT02181816|Drug|Azilsartan/Amlodipine|Azilsartan/Amlodipine combination tablets LD & HD
45455125|NCT04467658|Diagnostic Test|electroencephalography absolute slow alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
45818531|NCT03256136|Drug|Carboplatin|Chemotherapy
45818532|NCT03256136|Drug|Nivolumab|will allow the body's immune system to work against tumor cells
45818533|NCT03256136|Drug|pemetrexed|Chemo therapy
45818534|NCT03256136|Drug|Ipilimumab|will allow the body's immune system to work against tumor cells
45818535|NCT04735328|Behavioral|LOCI|LOCI includes training of leaders in general leadership, implementation leadership, and implementation climate.
45958921|NCT00151346|Drug|Bupivacaine and Fentanyl (for traditional epidural)|Bupivacaine 0.0625% with Fentanyl 2 mcg/mL x 15 cc, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
45958922|NCT00164385|Behavioral|Adolescent Impact|
45458255|NCT03501862|Behavioral|Mindfulness-based cognitive therapy (psychosis)|A small group intervention is based on a structured and validated protocol that will include mindfulness practice, cognitive skills
45664312|NCT02374021|Drug|Methotrexate|Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route.
45664313|NCT02374021|Drug|Sulfasalazine|1 gm bid
45664314|NCT02374021|Drug|Hydroxychloroquine|200 mg twice daily, not to exceed 6.5mg/kg
45664315|NCT02374021|Drug|Etanercept|50 mg SC weekly
45664316|NCT02374021|Drug|Adalimumab|40 mg SQ every other week
45664317|NCT02372383|Drug|Ethambutol|Anti-mycobacterial oral drug
45664318|NCT02372383|Drug|Rifampin|Anti-mycobacterial oral drug
45664319|NCT02372383|Drug|Azithromycin|Anti-mycobacterial oral drug
45664320|NCT02372383|Drug|Pancrelipase|Pancreatic enzyme replacement therapy
45818536|NCT04735328|Behavioral|CT-PTSD|CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post Traumatic Stress Symptoms (PTSD).
45818537|NCT04735328|Behavioral|EMDR|EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
45818538|NCT03260426|Dietary Supplement|Clear Liquids|Clear liquids on postoperative day zero immediately upon return to the floor and subsequent days' advancement of enteral diet to regular diet is as per discretion of the attending physician.
45818539|NCT03260426|Dietary Supplement|Regular Solid|Regular diet from postoperative day zero immediately upon return to floor and onwards
45818540|NCT03260426|Device|Abstats|Intestinal rate measured by Abstats™ in patients offered immediate solid versus clear liquids after colorectal surgery
45818541|NCT03340610|Drug|Alflibercept|Intravitreal Injection
45818542|NCT03341546|Other|A single measurement of the patient's abdominal depth|A single measurement of the patient's anterior-posterior abdominal depth
45818543|NCT03344510|Device|Kinetic Anesthesia Device|A vibrating device held to the skin in close proximity to the lidocaine injection, intended to diminish discomfort by the gate control theory of pain
45818544|NCT03344510|Other|Control|One injection will be administered without the kinetic anesthesia device.
45818545|NCT03264092|Procedure|Endoscopic ultrasound guided fine needle biopsy|Using the echoendoscope the lesion is identified and the needle is inserted in it to obtain a biopsy also under sonographic guidance
45818546|NCT03346850|Device|Nasogastric tube (NGT) feeding|A nasogastric tube goes from the nose to the stomach.
45818547|NCT03346850|Device|Nasoduodenal tube (NDT) feeding|A nasoduodenal tube goes from the nose to the duodenum.
45818548|NCT03478904|Drug|Enzalutamide Liquid|Enzalutamide liquid formulation given orally (160mg)
45818549|NCT03478904|Drug|Enzalutamide Capsule|Enzalutamide gel capsule (4X 40mg)
45958923|NCT05465863|Biological|SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)|When permitted by local guidelines, children and adolescents who were over 12 years old were notified of vaccine eligibility and encouraged to schedule an appointment
45958924|NCT05465785|Biological|Recombinant COVID-19 vaccine (Sf9 cell)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
45455126|NCT04467658|Diagnostic Test|electroencephalography relative slow alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
45664321|NCT01648699|Drug|Osmotic Release Oral System (OROS) hydromorphone|OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
45664322|NCT02134353|Drug|Inhaled mannitol|Inhaled mannitol 400 mg BD for 26 weeks
45664323|NCT02134353|Drug|Placebo Comparator: Arm B - Control|Placebo Comparator: Arm B - Control BD for 26 weeks
45664324|NCT01646125|Drug|AUY922|AUY922 was to be given by i.v. once weekly at 70 mg/m2 until disease progression, death or any other reason for discontinuation from study treatment.
45664325|NCT01646125|Drug|Docetaxel|Docetaxel was to be given i.v. once every 3 weeks at 75 mg/m2 until progression or unacceptable toxicity
45664326|NCT01646125|Drug|Pemetrexed|Pemetrexed was to be given once every 3 weeks at 500 mg/m2 until progression or unacceptable toxicity
45664327|NCT01362790|Drug|Pentostatin|Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle Regimen B: Cycle 1: 4 mg/m^2 or 2 mg/m^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m^2 on days 1 and 5 of 25 day cycle
45818550|NCT03478982|Drug|Staccato Alprazolam|single dose for inhalation
45818551|NCT03478982|Drug|Placebos|single dose for inhalation
45958925|NCT04687462|Device|1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)|TKRA operation undergoing 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)
45958926|NCT00151385|Procedure|single blood draw|
46079326|NCT05611151|Diagnostic Test|Computer Aided Detection (CADe)|Computer-aided detection (CADe) devices are used in conjunction with colonoscopy to aid in the detection of lesions in the gastrointestinal tract.
46079327|NCT05608265|Device|OSNAT 800 IO|Real-time, combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for retinal imaging
45818552|NCT03264248|Device|E-Scale|Daily bodyweight system used under legs of bed
45818553|NCT04706390|Biological|covid-19 vaccine|vaccination
45818554|NCT03270332|Drug|Albuterol|inhalation of 270μg albuterol through a spacer
45818555|NCT03270332|Drug|Placebo|inhalation of placebo through a spacer
45818556|NCT03349892|Radiation|Stereotactic Ablative Radiotherapy (SABR)|A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.
46079328|NCT05604560|Drug|Tislelizumab|Patients will receive Tislelizumab (200 mg intravenous) on Day 1 of Cycles 1-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.
46079329|NCT05604560|Drug|SX-682|Patients will receive SX-682 (200 mg twice daily by mouth) on Days 1-14 of Cycles 1-2 and Days 1-21 of Cycles 3-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.
46079330|NCT05593523|Drug|Indocyanine green (ICG)|ICG is a well, known, FDA-approved dye
46079331|NCT05593523|Device|OnLume|The OnLume Clinical Imaging System (CIS), also known as the Asimov-MSK Imaging System, used in this study is a clinical fluorescence-guided imaging system.
46079332|NCT05593354|Device|Micropulse Transscleral laser therapy|Transscleral laser cyclophotocoagulation using the IRIDEX Cyclo G6 machine
45818557|NCT03483506|Drug|BI 1467335|Film-coated tablet
45818558|NCT03483506|Drug|BI 1467335 (C-14) intravenous solution|Intravenous solution
45818559|NCT03271424|Diagnostic Test|Oraquick HIV Self Test - Choice|This is an oral swab in home HIV test.
45818560|NCT03271424|Diagnostic Test|Atomo HIV Self Test - Choice|This is a blood finger prick in home HIV test.
45818561|NCT03271424|Diagnostic Test|Oraquick HIV Self Test and Atomo HIV Self Test - Both|This is an oral swab in home HIV test and this is a blood finger prick in home HIV test.
45818562|NCT03483896|Other|Daylight Intervention|Staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.
45958927|NCT00164424|Drug|Acyclovir|
46002278|NCT04040764|Procedure|Tritanium uncemented Total Knee Replacement|This will be an internal pilot study in which patients will be blinded and randomly assigned to 1 of 2 arms with 30 patients in each arm. The first arm will receive a Triathlon knee replacement device which is cemented into place. The second arm will receive an uncemented Triathlon Tritanium TKR.
46079333|NCT05590078|Device|Virtual reality session|The 20-minute virtual reality session, in the outpatient department before surgery, immerses the patient in calm environments combined with music therapy and breathing exercises to relax and reduce anxiety.
46079334|NCT05590078|Other|State Trait Anxiety Inventory|"The State Trait Anxiety Inventory (State anxiety) is a questionnaire given to adults that shows how strong a person's feelings of anxiety are right now, just now. The score is measured on arrival in the outpatient department and just before going into the intervention room (= after the virtual reality session for the experimental group)"
46079335|NCT05590078|Other|Virtual Reality Satisfaction Score|Likert scale satisfaction questionnaire to collect the patients' satisfaction regarding virtual reality session
45958928|NCT05465746|Diagnostic Test|24-hour ambulatory blood pressure monitoring (ABPM)|Using a WatchBPO3 AFIB device (Microlife) placed around the left upper arm, BP measurements will be recorded every twenty minutes during the day and every thirty minutes at night, over a twenty-four-hour period. The device will automatically calculate the BP and the twenty-four-hour average BP, day, night, and cumulative BP load
45958929|NCT05465746|Diagnostic Test|Three-dimensional transthoracic echocardiography|Using an EPIQ CVx (Philips) echocardiograph with an ultrasound sector transducer, 3D-TTE will be performed to assess the LVM index.
45958930|NCT00532519|Drug|citalopram (cipralex)|10-20 mg/day, for 12 weeks.
45958931|NCT04687618|Device|High Flow Nasal Cannula withAutomatic control of FiO2 using OAM|The target oxygen saturation (SpO2) value will to be determined and set by the clinician according to specific patient needs. The target SpO2 in preterm infants is 90-95% with alarm limits at 89-96%. In automatic control of oxygen, the OAM automatically increases or decreases the FiO2 (oxygen delivery) setting on the Vapotherm Precision Flow based on pulse oximetry readings of the OAM. The target saturation will be set at 93% and the FiO2 will be adjusted by OAM to maintain the target saturation. The automated FiO2 setting can be overridden for a clinician pre-set period of time (30-120 sec) by simply manually adjusting the FiO2 on the Precision Flow. Automated control resumes after the clinicians pre-set period of time (30-120 sec) based on the current SpO2 and FiO2. The OAM utilizes a feedback control algorithm that receives a patient's oxygen saturation value from a build in pulse oximetry device (Masimo SET OEM - normal sensitivity, averaging time window set at 8 seconds).
45958932|NCT04687618|Device|High Flow Nasal Cannula with manual control of FiO2|In manual control of oxygen all FiO2 adjustments will be done by the clinical staff to maintain saturations between 90-95%. The alarm limits will be 89-96%.
45958933|NCT00171678|Drug|Diclofenac Topical Sodium Gel 1%|
45664328|NCT01362790|Drug|Cyclophosphamide|Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle
45458256|NCT03501862|Behavioral|Psychoeducation (psychosis)|A small group intervention will be focusing on understanding of psychosis, treatment, relapse prevention and useful information and resources.
45818563|NCT02156466|Drug|MSB0010841|MSB0010841(Anti- IL-17A/F Nanobody) will be administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
45664329|NCT01362790|Biological|SS1(dsFv)PE38 - lot 073I0809|Regimen A: Cycle 1: Cycle 1: 35mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles Regimen B: Cycle 1: 35mcg/kg days 18, 20 and 22 Cycles 2-4: (Days 6, 8 and 10), for a maximum of six treatment cycles
45664330|NCT01362790|Biological|SS1(dsFv)PE38 - lot FIL129J01|"Regimen A:~Cycle 1: Cycle 1:35mcg/kg or 25 mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles"
45818564|NCT02156466|Drug|MSB0010841|MSB0010841 will be administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
45818565|NCT02156466|Drug|MSB0010841|MSB0010841 will be administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
45958934|NCT00151463|Drug|sildenafil citrate|
45958935|NCT05465707|Biological|CM313 2 mg/kg|Once 1 week, intravenous infusion.
45958936|NCT05465707|Biological|CM313 4 mg/kg|Once 1 week, intravenous infusion.
45958937|NCT05465707|Biological|CM313 8 mg/kg|Once 1 week, intravenous infusion.
45958938|NCT05465707|Biological|CM313 16 mg/kg|Once 1 week, intravenous infusion.
46079336|NCT05590078|Other|Perioperative care satisfaction score|Likert scale satisfaction questionnaire to collect the patients' satisfaction regarding perioperative care
46079337|NCT05587036|Drug|Rifaximin|Rifaximin oral tablet, 550 mg, twice daily, two-weeks
45458257|NCT02875340|Drug|VAL401|Risperidone formulated into a liquid lipid filled capsule
45458258|NCT03237325|Drug|SGX942|1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends.
45664331|NCT02167893|Drug|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg injection kit
45664332|NCT04759989|Procedure|Actual Body Weight Dosing|30cc/kg initial bolus calculated using Actual Body Weight
45664333|NCT04759989|Procedure|Adjusted Body Weight Dosing|30cc/kg initial bolus calculated using Adjusted Body Weight
45818566|NCT02156466|Drug|MSB0010841|MSB0010841 will be administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
45818567|NCT02156466|Drug|Placebo|Placebo matched to MSB0010841 will be administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
45818568|NCT03353246|Device|InfraScanner 2000™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
45818569|NCT03274856|Drug|GLWL-01|Oral administration of 3 capsules, twice a day
45818570|NCT03274856|Drug|Placebo|Oral administration of 3 capsules, twice a day
45818571|NCT02216526|Other|Cetaphil® Restoraderm|
45818572|NCT02216526|Other|Excipial|
45958939|NCT05465707|Biological|Placebo|Once 1 week, intravenous infusion.
45958940|NCT05462431|Behavioral|Deep relaxation exercises intervention|Deep relaxation exercises intervention: breathing exercise, suitable positions for rest, and relaxation exercise instructions.
45958941|NCT00171717|Drug|Cyclosporine - cyclosporine microemulsion|
45958942|NCT05460481|Drug|Anlotinib Plus Penpulimab|Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
45958943|NCT00151502|Drug|Atorvastatin|
45958944|NCT05451433|Drug|Saccharomyces Boulardii 250 MG|Normagut capsule twice a day
45958945|NCT05451433|Drug|Placebo|Placebo capsule twice a day
46079338|NCT05587036|Dietary Supplement|Placebo|Placebo oral tablet, twice daily, two-weeks
45664334|NCT04759989|Procedure|Ideal Body Weight Dosing|30cc/kg initial bolus calculated using Ideal Body Weight
45958946|NCT00164463|Drug|Moxifloxacin|400 mg po qd 5/7 days per week
45818573|NCT03355820|Procedure|Blood sampling for antibody determination|In order to assess the persistence of immune responses seven to eight years after the last vaccine dose against HPV-16/18, a blood sample (~5 mL) will be taken from all the subjects, at Day 1.
45664335|NCT02167035|Drug|Combigan Two Times Daily (BID)|
45818574|NCT03357614|Drug|Sulopenem|Antibiotic therapy for complicated UTI
45818575|NCT03357614|Drug|Sulopenem-Etzadroxil/Probenecid|Antibiotic therapy for complicated UTI
45958947|NCT00164463|Drug|Isoniazid|isoniazid 300 mg po qd 5/7 days per week
45958948|NCT05404360|Device|BrainsWay Deep TMS HAC/H7-Coil|The BrainsWay HAC/H7-Coil Deep TMS System is composed of four main components: an electromagnetic H7/HAC-Coil, TMS stimulator, cooling system and positioning arm.
45958949|NCT05404360|Device|BrainsWay Deep TMS Sham Coil|"The experimental system has two coils in the same helmet, a sham and active coil.~The sham coil has a similar acoustic artifact as the active coil and it administers a superficial stimulation to maintain blinding. The system assigns the active or sham coil based on the patient ID during the high frequency treatment."
45958950|NCT00171756|Drug|valsartan/atenolol|
45958951|NCT00406016|Drug|ATI355|
45958952|NCT05392738|Device|I-Stent implantation|I-Stent implantation
45958953|NCT05388799|Other|Educational intervention|In addition to standard care, brochure-supported education will be given to patients who are scheduled for nose surgery.
45958954|NCT05387746|Behavioral|Caring Science, Mindful Practice and Reiki Training|Participants will complete a) 4 week internet-based course on Caring Science Mindful Practice and b) 12 hour Reiki training. The participants will also complete online post-training survey with the same questions included in pre-training survey.
45958955|NCT00164502|Behavioral|Community-based eight session group self-management program|
45458259|NCT03237325|Drug|Placebo|Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug.
45458260|NCT03498664|Device|cap for mucosectomy|endoscopic mucosal resection of colonic lesions with a plastic cap for mucosectomy
45664336|NCT02167035|Drug|Simbrinza Three Times Daily (TID)|
45664337|NCT01615198|Drug|Olmesartan|10 mg, 20 mg, 40 mg capsules
45664338|NCT01615198|Drug|Placebo|Matching placebo of LCZ696 tablet, matching placebo of Olmesartan capsule
45664339|NCT01615198|Drug|LCZ696|100 mg, 200 mg tablets
45664340|NCT02337907|Drug|Placebo|for blinding purposes
45664341|NCT02337907|Drug|Placebo|
45664342|NCT02337907|Drug|BI 409306|
45664343|NCT02337907|Drug|Donepezil|
45664344|NCT01913470|Drug|Losartan|Oral tablet to be taken once daily at 0.4mg/kg/day (max 25mg) for one week and then increased to 0.8mg/kg/day (max 50mg) for 7 additional weeks.
45818576|NCT03357614|Drug|Ertapenem|Antibiotic therapy for complicated UTI
45818577|NCT03357614|Drug|Ciprofloxacin|Antibiotic therapy for complicated UTI
45818578|NCT03357614|Drug|Amoxicillin-clavulanate|Antibiotic therapy for complicated UTI
45818579|NCT03487718|Biological|Leukocyte platelet rich fibrin plug + d-PTFE membrane|Following tooth extraction, an autologous leukocyte platelet rich fibrin plug will be placed in the socket and covered with a d-PTFE membrane
45818580|NCT03487718|Device|d-PTFE membrane|Following tooth extraction, the socket will be covered with a d-PTFE membrane
45818581|NCT03275870|Drug|Hydroxychloroquine|Treatment of patients with hidradenitis suppurativa with hydroxychloroquine 200mg BID for 6 months
45818582|NCT03276494|Device|Intraosseous|Intraosseous administration of hypertonic saline
45818583|NCT03276494|Drug|Hypertonic saline|Intraosseous administration of hypertonic saline
45958956|NCT00406055|Device|RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6|Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
45958957|NCT00532558|Drug|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily for up to 12 weeks.
45958958|NCT00532558|Drug|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks.
45958959|NCT05386849|Device|FUSION closed loop glucose control system|The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.
45958960|NCT00171795|Drug|Rivastigmine|
45958961|NCT00151541|Drug|Dapsone Topical Gel + adapalene gel 0.1%|
45958962|NCT00151541|Drug|Dapsone Topical Gel + benzoyl peroxide gel 4%|
45958963|NCT00151541|Drug|Dapsone Topical Gel + vehicle control|
45958964|NCT05385601|Other|eVOG (Mobile VideoOculoGraphy)|"Eyes movements assessed with e-VOG (mobile application developed on an iPad, that uses the face detection features of the front camera to detect and record eye movements).~Study duration is about 20 minutes, the day the subject performs his standard video-oculography examination in routine care (using Eye-Tracker®T2)"
45958965|NCT05377099|Diagnostic Test|CORVIS|Measurement of the DA ratio, IR and SSI before and after for patients under gone LASIK, femto LASIK and PRK using the CORVIS device.
46079339|NCT05579327|Drug|Tiratricol|Tiratricol tablets are flat tablets that contain 350 µg tiratricol. Treatment will be administered orally or via percutaneous endoscopic gastrostomy (PEG) tube; tablets will be suspended in water and, if needed, mixed with mashed food for oral administration or administered in water through the PEG tube as applicable.
45818584|NCT02216214|Drug|Mirabegron|oral tablet
45818585|NCT02216214|Drug|Placebo|oral tablet
45818586|NCT03277274|Drug|TAK-954|TAK-954 intravenous infusion.
45958966|NCT05364268|Device|Diagnostic Test: Diagnostic Software as Medical Device|AudibleHealth Dx is an investigational Dx SaMD consisting of an ensemble of software subroutines that interacts with a proprietary database of signal data signatures (SDS) using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. The intended use for the AudibleHealth Dx AI/ML-based Dx SaMD using FCV-SDS is for the diagnosis of acute and chronic illnesses, specifically COVID-19 illness for this study.
45958967|NCT04687384|Procedure|Robotic-assisted colectomy|Robotic-assisted colectomy performed by usage of da Vinci Xi robotic technology
45958968|NCT04687384|Procedure|Conventional laparoscopic colectomy|Conventional laparoscopic colectomy
45664345|NCT02372071|Device|BiliCare|Two measurements with the BiliCare device
45958969|NCT00164541|Behavioral|Arts Based Program|
45958970|NCT00164541|Behavioral|Curriculum|
45958971|NCT00151580|Drug|Ribavirin|18 months of oral ribavirin maintenance treatment
45958972|NCT00151580|Drug|Placebo|18 months oral placebo treatment
45958973|NCT00532597|Procedure|On-line hemodiafiltration|
45958974|NCT00532597|Procedure|Low flux hemodialysis|
45958975|NCT00532636|Procedure|Ventilation|Mask ventilation in neutral and head extension position
45958976|NCT00532636|Procedure|Ventilation|Mask ventilation in neutral and head extension position
45958977|NCT05341960|Behavioral|Food Delivery|Food box with food to feed a family of four, delivered by the Greater Cleveland Food Bank every two weeks. Based on participant preferences, includes recipes.
45958978|NCT05341960|Other|Financial Support|Provides supplemental funds to purchase healthy foods; provides choice. Includes recipes for limited budgets and assistance locating healthy food options in their specific neighborhood.
45958979|NCT00171912|Drug|imatinib mesylate|
45958980|NCT05338567|Diagnostic Test|Small intestine length measurement method|Accuracy of digital 3D reconstruction for predicting small bowel length
45958981|NCT05332015|Other|Hypotonic (distilled) water|orally given daily two liters of distilled water
45818587|NCT03279458|Device|Linshom Respiratory Monitoring Device|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted wth the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform. The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
45958982|NCT05332015|Other|Normal water|orally given daily two liters of normal water
45958983|NCT00151619|Drug|Amlodipine|
45958984|NCT00532675|Drug|LBH589|PAN 5 mg and PAN 20 mg capsules
45958985|NCT00532675|Combination Product|Lenalidomide|Lenalidomide 5mg or 25 mg
45958986|NCT00164580|Behavioral|Community-Level Intervention|
45664346|NCT02337751|Drug|TVP-1012 1mg|TVP-1012 1mg Tablets
45664347|NCT04884685|Biological|SARS-CoV-2 Inactivated Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
45664348|NCT04884685|Biological|Placebo|aluminium hydroxide solution only
45818588|NCT02214186|Other|Restrictive Fluid Therapy|The intervention in this randomized clinical trial is fluid restriction during cesarean section. The restricted group will receive 250 mL of crystalloid during surgery.
45818589|NCT03492398|Drug|HY209|6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
45958987|NCT05308030|Drug|Rivaroxaban and Aspirin|After the endovascular intervention, Anticoagulant therapy plus Antiplatelet therapy will be maintained (Aspirin 100 mg once daily and Rivaroxaban 2.5 mg twice daily) for 3 months, and then Aspirin alone indefinitely
45958988|NCT00151658|Device|Coronary Drug Eluting Stents for PCI|
45958989|NCT05300659|Other|Action for Rehabilitation for Neurological Injury (ARNI)|If randomised to upper limb training, a patient will undertake 10 therapy sessions with an instructor from the Action for Rehabilitation for Neurological Injury (ARNI) program during their hospital stay. The last two ARNI-led sessions will be filmed by a nurse/carer on either their own tablet/phone or an i-pad. Participants in the ARNI group will be encouraged to continue doing their personalized exercises while in hospital and continued at home. They will also be given a task-training board to take home
45958990|NCT00164619|Behavioral|VOICES/VOCES|45-minute intervention for small groups of African American and Hispanic heterosexual men and women. Group members are same gender and race/ethnicity. View culturally-specific condom promotion video. Facilitated group discussion to build skills in condom use and condom negotiation. Education on condom varieties to overcome participants' personal barriers to condoms use. Distribution of 3 specialty condoms of participant's choice (i.e., different sizes, textures, thicknesses, lubrication, material). [see Brief Summary above]
45958991|NCT00164619|Biological|Standard STD clinic services|Individual physical exam, STD/HIV tests, treatment as indicated
46079340|NCT05579327|Drug|Placebo|Placebo tablets will be identical in appearance to tiratricol tablets but contain no tiratricol. Treatment will be administered orally or via PEG tube; tablets will be suspended in water and, if needed, mixed with mashed food for oral administration or administered in water through the PEG tube as applicable. During the Randomized Treatment Period, participants will receive the same number of tablets as the stable dose of open-label tiratricol they were receiving before randomization.
46079341|NCT05575570|Device|EVAR|EVAR stent graft and embolization material CE marked.
45664349|NCT02166333|Dietary Supplement|200 IU/d cholecalciferol|
45664350|NCT02166333|Dietary Supplement|1000 IU/d cholecalciferol|
45664351|NCT02166333|Dietary Supplement|2000 IU/d cholecalciferol|
45664352|NCT02166333|Dietary Supplement|4000 IU/d cholecalciferol|
45664353|NCT02132949|Drug|5-Fluorouracil|Participants will receive 5-fluorouracil 500 mg/m^2 IV on Day 1 of each cycle q3w.
45664354|NCT02132949|Drug|Cyclophosphamide|Participants will receive cyclophosphamide 600 milligrams per square meter (mg/m^2) intravenous (IV) given on Day 1 of each cycle q2w.
45664355|NCT02132949|Drug|Docetaxel|Participants will receive docetaxel at a starting dose of 75 mg/m^2 IV for the first cycle and the dose may be escalated to 100 mg/m^2 for subsequent cycles q3w.
46079342|NCT05573698|Drug|DT-216|DT-216 will be administered by intravenous (IV) injection
46079343|NCT05573698|Drug|Placebo|Matching Placebo will be administered by intravenous (IV) injection
45958992|NCT05299957|Diagnostic Test|PETMRI|PET/MRI data will be acquired on the integrated PET/MRI scanner. After fast-view T1-weighted MR localizer sequence for scout imaging and Dixon VIBE sequence for attenuation correction, a whole-body PET scan will be performed to cover from the head to the proximal thigh, with an acquisition time of 4 min per bed position. Simultaneously, whole body MR image acquisition will be performed with the axial HASTE sequence and coronal STIR sequence as well as the sagittal T1-weighted Turbo spine echo and STIR sequence. Afterwards, regional PET and MRI images will be simultaneously performed. DWI will be performed using a single shot spin-echo echo-planar technique. A total of 10 b values will be used for the reconstruction of IVIM and kurtosis imaging. DCE-PWI will be acquired by using a 3D T1-weighted spoiled gradient-echo sequence. Thereafter, dedicated regional MRI will be obtained. Finally, whole body axial VIBE with fat saturation will be performed.
45958993|NCT05293600|Drug|Placebo|Placebo capsule 30 min before bedtime
45958994|NCT05293600|Drug|Acetazolamide|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with increased loop gain will be given Acetazolamide 500 mg.
46079344|NCT05570500|Behavioral|Oral health education|oral health education sessions that aims to improve both knowledge of primary school children regarding bacteria, caries, number of teeth, plaque formation and attitude of primary school children regarding tooth brushing techniques, number of times per day, dietary instructions to avoid dental caries.
45664356|NCT02132949|Drug|Doxorubicin|Participants will receive doxorubicin 60 mg/m^2 IV on Day 1 of each cycle q2w.
45664357|NCT02132949|Drug|Epirubicin|Participants will receive epirubicin 100 mg/m^2 IV on Day 1 of each cycle q3w.
45664358|NCT02132949|Drug|Paclitaxel|Participants will receive paclitaxel 80 mg/m^2 IV given weekly.
45458261|NCT03498664|Device|standard snare for polypectomy|endoscopic mucosal resection of colonic lesions with standard inject and cut mucosectomy
45818590|NCT04758546|Diagnostic Test|Screening criteria for weaning and minimal ventilatory settings for spontaneous breathing trial|Aggressive screening criteria: Walsh Conservative screening criteria: Boles High minimal ventilatory settings: pressure Support 8 + positive end-expiratory pressure 5 Low minimal ventilatory settings: pressure support 5
45818591|NCT03496220|Device|Angulus|Feedback on patient recumbency
45818592|NCT00376376|Drug|levofloxacin at 250, 500, 750, and 1000 mg doses|
45458262|NCT01362452|Genetic|T-Cell Infusion|Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.
45664359|NCT02132949|Drug|Pertuzumab|Participants will receive pertuzumab at a loading dose of 840 milligrams (mg) IV loading dose, then 420 mg IV q3w.
45664360|NCT02132949|Drug|Trastuzumab|Participants will receive trastuzumab at a loading dose of 8 milligrams per kilogram (mg/kg) IV, then 6 mg/kg IV q3w.
45818593|NCT00376454|Drug|GW493838|
45958995|NCT05293600|Drug|Trazodone|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased arousal threshold will be given Trazodone 100 mg.
45958996|NCT05293600|Drug|Atomoxetine and eszopiclone|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased muscle responsiveness will be given Atomoxetine and Eszopiclone 80 + 3 mg.
46079345|NCT05570305|Drug|Zibotentan|Zibotentan 1.5 mg once per day as a hard capsule.
46079346|NCT05570305|Drug|Dapagliflozin|Dapagliflozin 10 mg once per day as a tablet.
46079347|NCT05570305|Drug|Placebo|Matching placebo.
45664361|NCT02165397|Drug|Ibrutinib|Participants will receive 420 mg of Ibrutinib orally.
45664362|NCT02165397|Drug|Placebo|Participants will receive placebo capsules orally.
45664363|NCT02165397|Drug|Rituximab|Participants will receive rituximab 375 mg/m^2 IV.
45664364|NCT02132637|Drug|Insulin Peglispro|Administered SQ
45664365|NCT02132637|Drug|Insulin Glargine|Administered SQ
45664366|NCT02164929|Procedure|TAP block|
45664367|NCT02164929|Procedure|Epidural|
45664368|NCT02164929|Procedure|Paravertebral block|
45664369|NCT02164929|Drug|Acetaminophen 1g IV|
45664370|NCT02164929|Drug|Dexamethasone 4mg|
45664371|NCT02164929|Drug|Midazolam up to 2mg|
45818594|NCT02181504|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
45818595|NCT02181504|Drug|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
45818596|NCT02181504|Other|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
45818597|NCT03360110|Device|Phoebe test lens|Daily disposable contact lens
45818598|NCT03360110|Device|stenfilcon A lens (control)|Daily disposable contact lens
45818599|NCT02179398|Biological|Allocation to the Lab-score group|
45958997|NCT00151697|Drug|Novomix 30|
45958998|NCT00151697|Drug|Novorapid and Amaryl|
45818600|NCT02179398|Biological|Allocation to the control group|
45958999|NCT00151697|Drug|Lantus|
45959000|NCT00532714|Drug|Irinotecan plus capecitabine|"Irinotecan 80 mg/m2 intravenously for 90 minutes once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period.~Capecitabine is administered orally at a dose of 1,000 mg/m2 twice daily (total daily dose 2,000 mg/m2) as an intermittent regimen in 3-week cycles (2 weeks of treatment followed by a 1-week rest period)."
45458263|NCT01362452|Procedure|Cord Blood Infusion|Cord blood infusion on Day 0.
45959001|NCT00164658|Behavioral|Familial risk assessment and personalized prevention messages|
45959002|NCT00532753|Behavioral|Community Empowerment|
45959003|NCT05283070|Other|Questionnaires, physical tests, and heart rate variability measures|"The 2MWT will be conducted in an unobstructed hallway with patients being asked to walk at moderate intensity (brisk walk) for the duration of the activity (2 minutes). The amount of distance in metres will be recorded.~The EMLi movement consists of pushing a 2kg weighted ball from the chest level forward, and then raising the ball overhead, before returning it to the starting position (Figure 1). The number of repetitions done at moderate intensity will be recorded after 60 seconds.~HRV and questionnaires previously listed"
45959004|NCT00151736|Drug|Chlorambucil|Chlorambucil 2mg tablets
45959005|NCT00151736|Drug|R-etodolac + chlorambucil|R-etodolac 600mg tablets + chlorambucil 2mg tablets
45959006|NCT05267782|Device|Masimo's O3 Regional Oximetry|Correlation between new O3 regional oximetry monitoring, electroencephalography and somatosensory evoked potential in carotid endarterectomy and data collection during different stages of anaesthesia and correlation with new O3 regional oximetry
45959007|NCT00171990|Drug|Famciclovir|
45959008|NCT05257174|Dietary Supplement|Jing Si Herbal Tea LIQUID PACKETS|intake Jing Si Herbal Tea LIQUID PACKETS twice daily for three months
45959009|NCT05257174|Dietary Supplement|Placebo|intake Placebo twice daily for three months
45664372|NCT02164929|Drug|Propofol 1-2.5 mg/kg|
45664373|NCT02164929|Drug|Sevoflurane to keep a bispectral index of between 40-60|
45664374|NCT02164929|Drug|Local infiltration with 10 mL of plain ropivacaine 0.25%|
45818601|NCT02156076|Drug|BMS-919373|
45818602|NCT02156076|Drug|Placebo (Matching with BMS-919373)|
45818603|NCT02213094|Drug|Nicotinamide 500 mg|Nicotinamide 500 mg taken by mouth each morning
45959010|NCT05254210|Device|RF Device (Potenza™)|Test spots may be performed prior to the first treatment. Following test spots, for the treatment, the tip will be placed in contact with the skin. Parameters may be adjusted throughout the treatment and will determined by the Clinician.
45959011|NCT05242939|Other|Video game|The child will be allowed to play the game they want to play throughout the entire procedure, starting 5 minutes before the inhalation therapy. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
45959012|NCT05242939|Other|Watching cartoons|The cartoon is 5 min from the application. It will be started to be watched first and will continue until the application is finished. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
46079348|NCT05570305|Drug|Dapagliflozin and Zibotentan|Dapagliflozin 10 mg once per day as a tablet in combination with zibotentan 1.5 mg once per day as a hard capsule.
45664375|NCT02164929|Drug|Lidocaine|1.5% lidocaine
45664376|NCT02164929|Drug|Epinephrine|1:200,000 epinephrine
45664377|NCT02164929|Drug|Hydromorphone|400-800 mcg Hydromorphone will be given preoperatively
45664378|NCT04749615|Drug|Periarticular Injection (PAI)|PAI is a widely-utilized, surgeon-performed, analgesic intervention for TKA patients.
45664379|NCT04749615|Drug|Saline Control Periarticular Injection (PAI)|equal volume of saline will be used in place of analgesics used in PAI injections
45664380|NCT01888432|Drug|Everolimus + reduced tacrolimus|Everolimus was initiated at Week 4 post transplantation. The dose was adjusted to maintain the everolimus trough blood levels between 3-8 ng/mL for the duration of the study. Tacrolimus was reduced to 3-5 ng/mL.
45664381|NCT01888432|Drug|Standard tacrolimus|Tacrolimus was initiated as soon as possible after transplantation according to approved labeling recommendations. The trough level should've been 5-15 ng/mL until randomization, 8-12 ng/mL from randomization until month 4 and after month 4 until end of study reduced to 6 -10 ng/mL.
45818604|NCT02213094|Drug|Nicotinamide 1000 mg|Nicotinamide 1000 mg taken by mouth each morning
45818605|NCT02155608|Device|Active eTNS|Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open eTNS in a 12 month extension period.
45818606|NCT02155608|Device|Sham eTNS|Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly eTNS in a 12 month extension period.
45818607|NCT01629966|Drug|Placebo|Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,
45818608|NCT01629966|Drug|Vilazodone|Vilazodone, 20mg, oral administration once per day.
45818609|NCT01629966|Drug|Vilazodone|Vilazodone, 40mg, oral administration once per day.
45959013|NCT00164697|Behavioral|Parenting group|Weekly and periodic (10 weeks blocks with 6 week break) parenting group meetings (2.5-3 hr), periodic one-on-one meetings (2 hr), visits to community resources (2-3 hr per event). Legacy intervention activities are designed to enhance sensitive and responsive parenting, parent/child interaction, and promote a sense of community. Other activities include verbal and cognitive stimulation through parent and parent/child group meetings, visits to the home, and participation in community events.
45664382|NCT02188719|Biological|Anti-Thymocyte Globulin - Rabbit|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects will be given a dose range of 3.0-4.5 mg/kg total, in divided doses of 1.5 mg/kg/day. Subjects who meet eligibility criteria for Thymoglobulin® administration will be given 1.5 mg/kg intravenously (IV) on post-operative day 3, within 72 hours of transplantation. Additional doses of 1.5 mg/kg IV will be administered until CD3 count is <50/mm^3 or when the maximal dose of 4.5/mg/kg has been given.
45664383|NCT02188719|Biological|darTreg Infusion|A single dose darTreg infusion (Cohorts 2 - 4) will be received as per protocol.
45959014|NCT04725578|Behavioral|Telehealth Single Session Consultation|A remotely delivered, single, goal-directed consultation session based on Solution-Focused Brief Therapy (SFBT). SFBT is an evidence-based therapy approach that is primarily focused on the client's present problems and their immediate future. When using SFBT in a single-session the aim of the intervention becomes empowering the client to take the smallest possible steps towards their desired future.
45664384|NCT02188719|Drug|Everolimus|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects meeting eligibility criteria for Treg-supportive IS regimen will begin EVR no sooner than 30 days after liver transplantation and no later than 44 days after transplantation; with target trough levels of 6-8 μg/L.EVR target trough levels will be further reduced to 4-6 μg/L 24 - 26 weeks after transplantation.
45664385|NCT02188719|Drug|Tacrolimus|"Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Between 30 and 44 days following transplant: Subjects who are not eliminated by Exclusion Criteria C1 (Protocol Section 14.3.1) will proceed in the study and receive either TAC-based or EVR- based IS, based on eligibility Criteria C2 (Section 4.3.4 )~TAC-based IS: reduce TAC trough level to 3-8 μg/dL; continue MMF~EVR-based IS: reduce TAC trough level to 3-8 μg/dL; EVR target trough level of 6-8 μg/dL; decrease then discontinue MMF"
45664386|NCT02188719|Drug|Mycophenolate mofetil|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. 1000 mg total daily dose. MMF will be initiated within 24 hours of transplantation. MMF must be discontinued as soon as target EVR trough levels have been achieved.
45664387|NCT02188719|Drug|Prednisone|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Solumedrol 500 mg will be given IV on the day of transplantation. Additional Solumedrol will be prescribed according to site-specific standard of care. Oral prednisone should be initiated once oral medication is tolerated.
45664388|NCT02188719|Drug|Acetaminophen|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 650mg of acetaminophen will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
45664389|NCT02188719|Drug|Diphenhydramine|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 25-50mg of diphenhydramine will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
45664390|NCT02188719|Drug|Anti-Infective Prophylaxis|Intravenous ganciclovir and/or oral Valcyte will be administered for the prophylaxis of cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) for at least six months after liver transplantation.
45664391|NCT02188719|Procedure|Leukapheresis|"Leukapheresis is necessary to ensure collection of adequate numbers of autologous Tregs to support ex vivo expansion of darTregs for infusion after liver transplantation.~Participants enrolled in Cohorts 3 and 4 will undergo leukapheresis. Participants enrolled in Cohort 2 will have either whole blood collection or leukapheresis for the purpose of isolating autologous Tregs for later manufacture. If a cohort 2 subject has a hemoglobin level >/=10.5 gm/dL, he or she will undergo phlebotomy. If the patient has a hemoglobin level </=10.5 gm/dL and remains eligible for the study, the patient will undergo leukapheresis."
45664392|NCT02188719|Procedure|Blood draws|Blood draws are necessary to carefully and frequently evaluate allograft function after liver transplantation and treatment with Treg-supportive IS as well as after darTreg infusion. Peripheral blood samples will be collected and analyzed per protocol throughout subject participation in this study.
45664393|NCT02188719|Procedure|Liver biopsies|Subjects will have a liver biopsy for this study 12-14 weeks after transplantation. For subjects receiving darTregs, a second biopsy will be performed 7-10 days after darTregs infusion.
45818610|NCT03363854|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
45818611|NCT03363854|Drug|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
45818612|NCT02177838|Biological|cetuximab|Given IV
45818613|NCT02177838|Drug|cisplatin|Given IV
45818614|NCT02177838|Radiation|external beam radiation therapy|Undergo EBRT
45818615|NCT02177838|Other|laboratory biomarker analysis|Correlative studies
45818616|NCT03369158|Procedure|patient specific pedicle screw positioning guide|
45818617|NCT03369158|Procedure|Free hand technique pedicle screw positioning|
45959015|NCT00532792|Biological|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; No LT Patch Day 0 or Day 21
45818618|NCT03369158|Device|MUST pedicle screw|
45818619|NCT03372434|Device|Investigational Intraocular Lens Device #1: Model ZFR00|IOL replaces the natural lens removed during cataract surgery.
45959016|NCT00532792|Biological|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
45959017|NCT00532792|Biological|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
45959018|NCT00532792|Biological|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
45959019|NCT00532792|Biological|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
45959020|NCT00532792|Biological|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
45959021|NCT00532792|Biological|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
45959022|NCT00532792|Biological|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
45959023|NCT00532792|Biological|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
45959024|NCT00532792|Biological|Placebo|Placebo (0.5ml); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
46079349|NCT05570097|Device|intercostal nerves cryoanalgesia|Intraoperative Cryolesia of at least 5 intercostal nerves added to regional analgesia: bilateral erector spine plane block and multimodal therapy.
45664394|NCT02188719|Procedure|Liver transplantation|Inclusion in this trial is in the setting of subjects defined as having end-stage liver disease and listed for primary solitary liver transplant.
45664395|NCT01934140|Biological|Meningococcal vaccine GSK134612|1 dose administered intramuscularly in the non-dominant deltoid region.
45664396|NCT04416100|Diagnostic Test|Pulmonary function tests|Spirometry or plethysmography, measurement of diffusion capacity
45664397|NCT04416100|Diagnostic Test|Imaging|HRCT and echocardiography as scheduled within routine clinical examinations
45664398|NCT04416100|Biological|Blood sampling|Standard laboratory test as part of routine clinical examination and collection of peripheral blood for immunofibrotic phenotyping
45818620|NCT03372434|Device|Investigational Intraocular Lens Device #1: Model ZYR00|IOL replaces the natural lens removed during cataract surgery.
45818621|NCT03372434|Device|TECNIS Multifocal Intraocular Lens: Model ZLB00|IOL replaces the natural lens removed during cataract surgery.
45818622|NCT03376256|Device|Compuflo Epidural Instrument|Compuflo Epidural Instrument will be used to measure pressure levels in the thoracic epidural space while performing thoracic epidural anesthesia.
45818623|NCT03283436|Drug|Bupivacaine Hydrochloride 0.25% Injection Solution|10 mL of 0.25% bupivacaine hydrochloride (2.5 mg/mL = 25 mg)
45818624|NCT00375986|Procedure|Manual placental removal at Cesarean delivery|
45818625|NCT00375986|Procedure|Spontaneous placental removal at Cesarean delivery|
45818626|NCT03380624|Drug|Refresh Optive|Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose
45818627|NCT03380624|Drug|Refresh Optive MEGA-3|Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose and with flaxseed oil and trehalose
45818628|NCT03380780|Drug|Emicizumab|Participants will receive a single 1 milligram per kilogram of body weight (mg/kg) subcutaneous dose of emicizumab on Day 1.
45818629|NCT00376064|Drug|Octreotide acetate and cabergoline/Octrotide and Somavert|
45818630|NCT00376142|Behavioral|Psychological theory-based behaviour change interventions|
45818631|NCT03581084|Drug|N-acetylcysteine|Research participants that meet the study inclusion criteria will be admitted to a medical-surgical ward in Moffitt-Long Hospital (UCSF Medical Center) for 6 days and 5 nights and treated with an inhaled mixture of NAC and albuterol four times per day spaced at 4 to 6 hours apart.
45818632|NCT03383588|Drug|Bupivacaine|20 ml subcutaneous bupivacaine (Marcaine) 0.25%. Bupivacaine is an anesthetic which can numb an area of the body to relieve pain during surgery or medical procedures, childbirth, and dental work.
45818633|NCT03383588|Drug|Morphine|intrathecal morphine (Duramorph) 150mcg. DURAMORPH (morphine injection) is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain not responsive to non-narcotic analgesics. DURAMORPH (morphine injection) administered epidurally or intrathecally, provides pain relief for extended periods without attendant loss of motor, sensory or sympathetic function.
45818634|NCT03383588|Drug|Fentanyl|intrathecal fentanyl 10 mcg. Fentanyl (also spelled fentanil) is an opioid which is used as a pain medication and together with other medications for anesthesia.
45818635|NCT03383588|Drug|Epinephrine|Epinephrine injection is used along with emergency medical treatment to treat life-threatening allergic reactions caused by insect bites or stings, foods, medications, latex, and other causes. Epinephrine is in a class of medications called alpha- and beta-adrenergic agonists (sympathomimetic agents). It works by relaxing the muscles in the airways and tightening the blood vessels.
45818636|NCT03383588|Other|Saline solution|20 ml subcutaneous NACL 0.9% - saline solution is the placebo
45664399|NCT01933672|Drug|PF-04937319 once-daily|Tablets, 300 mg once-daily with breakfast, 14-days
45664400|NCT01933672|Drug|PF-04937319 split-dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days
45664401|NCT01933672|Drug|Sitagliptin once-daily|tablets, 100 mg once-daily with breakfast, 14-days
45818637|NCT03388268|Drug|Oral Vancomycin|Oral vancomycin 125mg 4 times per day
45818638|NCT03388268|Drug|Placebo|Sugar liquid manufactured to mimic oral vancomycin 125mg
45818639|NCT03388268|Device|Toxin enzyme immunoassay|EIA assay: Wampole/Tech Lab Tox A/B II
45818640|NCT03388268|Device|Nuceleic acid amplification test|NAAT: Xpert C. difficile, Cepheid
45818641|NCT00422786|Drug|CAP-232|Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period
45818642|NCT03581474|Device|Bronchoscopic procedure|Single-use flexible bronchoscope aScope 3 Large
45818643|NCT03390842|Drug|TRC101|Oral suspension
45818644|NCT03390842|Drug|Placebo|Oral suspension
45818645|NCT02177136|Drug|Obeticholic Acid (OCA)|
45818646|NCT02177136|Drug|Placebo|
45818647|NCT03393494|Drug|Adapalene and Benzoyl Peroxide Topical Gel|Test product
45818648|NCT03393494|Drug|Epiduo Topical Product|RLD product
45818649|NCT03393494|Drug|Placebo|Placebo gel
45818650|NCT03588806|Drug|Xtampza ER (oxycodone)|Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study.
45818651|NCT02176356|Biological|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.
45818652|NCT02176356|Drug|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.
45818653|NCT02176356|Device|JUVÉDERM® ULTRA XC|JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
45818654|NCT02176356|Device|JUVÉDERM® ULTRA PLUS XC|JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
45818655|NCT02176356|Device|JUVÉDERM® VOLUMA® XC|JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
45818656|NCT03591068|Drug|Fluticasone Propionate|OPN-375 186 μg BID, Delivered via exhalation delivery system
45664402|NCT02164539|Drug|FF|Fluticasone furoate is available as fluticasone furoate inhalation powder (100 mcg per blister), combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
45664403|NCT02164539|Drug|UMEC|Umeclidinium bromide is available as combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister)
45664404|NCT02164539|Drug|VI|Vilanterol is available as vilanterol inhalation powder (25 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
45664405|NCT02188485|Behavioral|ENGAGE|Up to 10 sessions delivered in the home.
45664406|NCT04759599|Procedure|Shock Wave Lithotripsy (SWL)|Shock Wave Lithotripsy (SWL) with focal size 2mm (F1), and 3000 shocks or Shock Wave Lithotripsy (SWL) with focal size 8mm (F3), and 3000 shocks
45664407|NCT04759443|Other|Image processing of skin|Image processing will be used to extract skin features that correlate with loss of small skin fibers.
45664408|NCT02132247|Drug|Diclofenac hydroxyethylpyrrolidine|
45664409|NCT01629381|Drug|Rivaroxaban|10 mg os once daily for 1 week
45664410|NCT01629381|Drug|placebo|10 mg os once daily for 1 week
45818657|NCT02210208|Device|Mepitel® Ag|"A soft silicone wound contact layer that allows exudates to pass vertically into a secondary absorbent dressing. The product provides fixation and protection of the tissues and has antimicrobial properties.~This silicone net dressing will be used to prevent lifting and adherence of skin grafts to the dressings, as well as to prevent pain, and promote healing."
45818658|NCT02210208|Device|Mepilex® Transfer Ag|"Mepilex® Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.~Mepilex® Transfer Ag consists of a Safetac® adhesive layer and compressed polyurethane foam containing silver sulphate and activated carbon. Safetac® is a unique adhesive technology that minimizes pain to patients and trauma to wounds and the surrounding skin. It minimizes risk for maceration by sealing the wound margins; ensuring exudate does not spread to the surrounding skin."
45818659|NCT03395990|Procedure|Active comparator: chloroprocaine|15 ml of 2% chloroprocaine was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
45818660|NCT03395990|Procedure|Sham comparator: saline|15 ml of normal saline was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
45818661|NCT00376922|Procedure|music therapy|music played for patient during bone marrow biopsy collection
45818662|NCT02209506|Drug|MLN3126|MLN3126 tablets
45818663|NCT02209506|Drug|MLN3126 Matched Placebo|MLN3126 placebo-matching tablets
45818664|NCT02153736|Behavioral|SPEEDI Intervention|Behavioral intervention provided through a collaboration between the mother of enrolled subjects and a physical therapist. Intervention starts in the Neonatal Intensive Care Unit and continues after discharge. SPEEDI includes both parent education and developmental activities.
45818665|NCT02175966|Drug|DCV/ASV/BMS-791325|
45818666|NCT02175966|Drug|Ribavirin|
45818667|NCT02175966|Drug|Sofosbuvir|
45818668|NCT02175966|Drug|Peginterferon α-2a|
45818669|NCT02153346|Other|Valuation of lost productivity questionnaire|A new, composite questionnaire that can be used to assess the impact of health conditions on lost productivity in monetary units. It measures absenteeism, presenteeism, and non work activities.
45818670|NCT02153346|Other|Work productivity and activity impairment questionnaire|A six item questionnaire used as a patient-reported quantitative assessment of the amount of absenteeism, presenteeism, and daily activity impairment attributable to a specific health problem.
45818671|NCT04750512|Procedure|ESP block|US guided ESP infiltration (saline solution vs Ropivacaine 0.2% according to randomization): bilateral injection of 30ml (60ml total) under US guidance between the deep fascia of erector spinae muscle and the the two transverse process at the level of the 10th thoracic vertebrae
45959025|NCT04687423|Drug|FCN-011|FCN-011 will be given orally in ascending doses starting at 50 mg Q12h or 100mg QD until the maximum tolerated dose or recommended dose is reached.
45818672|NCT04750512|Procedure|TAP block|"US guided TAP block (saline solution vs Ropivacaine 0.2% according to randomization):~bilateral injection of 30ml (total 60ml) under US guidance in the plane between the internal oblique and transversus abdominis muscles at the level of the midaxillary line in the Petit triangle."
45818673|NCT04750278|Drug|FP-025 100 mg|FP-025 100 mg BID
45959026|NCT00172029|Drug|Zoledronic acid|
45959027|NCT00151853|Drug|PPSB-SD|
45664411|NCT02131311|Device|disposable, single-use pessary|
45664412|NCT05269017|Drug|Vitamin D3|Devarol S amp containing 200,000 units per 2 ml giving a concentration of 5,000 units per drops for four weeks
45664413|NCT05269017|Drug|Budesonide nasal spray|64 µg per puff in a dose of 1 puff for each nostril twice daily for four weeks
45664414|NCT01628913|Drug|BEZ235|BEZ235 400 mg bid p.o. (by mouth, twice daily)
45664415|NCT01628913|Drug|Everolimus|Everolimus 10 mg qd p.o. (by mouth, daily)
45664416|NCT02164383|Drug|Nicotine patch|4-week starter kit of nicotine patch
45664417|NCT02164383|Behavioral|Cessation Counseling|5 brief counseling sessions
45664418|NCT02164383|Device|Mobile Games|
45664419|NCT02131233|Drug|Reformulated Raltegravir|Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily
45664420|NCT02131233|Drug|Raltegravir|Raltegravir 400 mg tablet orally twice daily
45959028|NCT04687189|Device|Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)|Imaging performed by woman on herself with remote healthcare professional (HCP) supervision compared to images taken when same ultrasound is administered in person by HCP. The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
45959029|NCT00406094|Drug|montelukast|10mg
45959030|NCT00406094|Drug|placebo|placebo
45664421|NCT02131233|Drug|TRUVADA™|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label)
45818674|NCT04750278|Drug|FP-025 300 mg|FP-025 300 mg BID
45818675|NCT04750278|Drug|Placebo|Placebo BID
45959031|NCT00532870|Other|laparoscopic|
45959032|NCT05178121|Behavioral|eLearning Training in Suicide Safety Planning|The training includes a web-based didactic in suicide safety planning, interactive practice in counseling microskills with a chat bot, role-playing safety planning with a standardized patient, and reviewing automated feedback on safety planning counseling skills generated from a computer coding system.
45959033|NCT00164736|Drug|Maternal zidovudine/lamivudine/lopinavir-ritonavir|Total daily dose: zidovudine 600mg, lamivudine 300mg, (taken as Combivir 1 tab twice a day with food). Lopinavir/ritonavir 400/100mg (taken as 2 tabs twice a day). Commencing after delivery and through to 28 weeks.
45959034|NCT00164736|Drug|Infant nevirapine|"Nevirapine suspension once daily dose. 0-14days: 10mg; 3-18weeks: 20mg; 19-28weeks: 30mg.~To 28 weeks while breastfeeding."
45959035|NCT00164736|Dietary Supplement|Maternal protein and calorie supplement|High energy, nutrient-dense, micronutrient fortified nutritional supplement. Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation. Vitamin A is excluded.
45959036|NCT05177146|Drug|Intravenous Ketamine (IV)|A sterile form of ketamine hydrochloride will be administered over 40-min IV infusion twice per week on non-consecutive days for four weeks. Dosing schedule is determined based on patient's weight, clinical response and tolerability. First treatment session dose will be calculated based on 0.5 mg/kg. Further dose increase will be determined by the study physician. Dose increase will not exceed 0.8 mg/kg. Patients will be closely monitored by available trained personnel with MD being present on site for the full duration of the 2-h supervision period. Specifically, IV induction will be performed under the direct supervision of anesthesiologist or delegate and psychiatrist. Vital signs will be monitored every 30 minutes during the supervision period. Side effects will be managed by the medical team administering the treatment. If required, appropriate rescue medications will be provided depending on the nature of the adverse event.
45959037|NCT05163730|Device|COVID-19/ Flu A&B Rapid Panel|Rapid Diagnostic Device
45959038|NCT05142046|Drug|Fluid balance|The intervention consists of classic and standardized anesthesia management of children undergoing cardiac surgery. All the data links to the fluid management will be extracted from the patient's chart in the intraoperative period as well as complications during the hospitalization in the postoperative period.
45959039|NCT00532909|Drug|Vandetanib|100mg or 300mg By mouth every day continuous
45959040|NCT00532909|Drug|Capecitabine|Dosage: 1000mg/m2 By mouth twice a day for 14 days or reduced dose of 800mg/m2 PO BID days1-14.
45959041|NCT00532909|Drug|Oxaliplatin|dosage: 130mg/m2. IV Day 1 of a 21 day cycle or reduced dose of 100mg/m2 IV Day 1.
45959042|NCT00532909|Drug|Bevacizumab|Dosage: 7.5mg/kg or 10mg/kg. IV Day 1 (21 day cycle)
45959043|NCT00172068|Drug|Zoledronic acid + Calcium/Vitamin D|
45959044|NCT00151931|Drug|Lanthanum carbonate|
45455127|NCT04467658|Diagnostic Test|electroencephalography absolute fast alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
45664422|NCT02131233|Drug|Placebo to Reformulated Raltegravir|Placebo to reformulated raltegravir 2 tablets orally once daily
45664423|NCT02131233|Drug|Placebo to Raltegravir|Placebo to raltegravir 1 tablet orally twice daily
45818676|NCT02174562|Behavioral|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
45959045|NCT05119816|Other|music therapy intervention|Received a customize playlists prepared by a certified music therapist to listening to during KB
45664424|NCT02131155|Drug|Placebo|Once daily
45664425|NCT02131155|Drug|Afatinib|Once daily
45664426|NCT01933594|Drug|Romidepsin|RMD administered over 4 hours via an intravenous (IV) catheter.
45664427|NCT01933594|Drug|Placebo for Romidepsin|Placebo for RMD administered over 4 hours via an IV catheter.
45664428|NCT04623190|Behavioral|Wait-List Control|-Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
45818677|NCT02174562|Behavioral|Enhanced Usual Care|Usual care enhanced with education and attention
45818678|NCT05138406|Other|Graded Motor Imagery|The graded motor imaging program will be set to 2 weeks each component. Participants will receive lateralization for the first 2 weeks, motor imagery for 2 weeks, and mirror therapy for 2 weeks. At the same time, standard rehabilitation will be applied for 6 weeks. Treatments will begin 24-48 hours after surgery. Treatments will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.
45959046|NCT05117164|Other|enteral feeding as per predefined protocol|"Infants will receive enteral feeding based on the following protocol.~Enteral nutrition Minimal enteral nutrition (MEN) will begin within 72 hours life at 10 to 20. mL/kg/day, via bolus gravity breast milk/donor human milk. MEN will not be included in the caloric goals.~Advancements in feeding will be set at 20-30 mL/kg/day, but not more than 10ml per feeding portion to reach a goal of 150ml/kg/day, but not than 120ml/kg/day cases of fluid restriction).~The goal will be to reach an overall daily caloric intake of minimum 100kcal/kg/d."
45959047|NCT05095987|Procedure|Laparoscopic Appendectomy|Laparoscopic Appendectomy for acute uncomplicated appendicitis in children
45959048|NCT00151970|Drug|Methylphenidate Transdermal System|MTS 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes
45959049|NCT00151970|Drug|Placebo|Placebo patch 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes applied daily
45959050|NCT00151970|Drug|Concerta|CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
45959051|NCT05077501|Drug|ACD856|Multiple daily oral doses of ACD856 will be administered for 7 days in an escalation scheme of dose 1, dose 2 and dose 3. The escalation schedule may be adapted based on evaluation by the internal Safety Review Committee.
45959052|NCT05077501|Drug|Placebo|Placebo oral solution
45959053|NCT05075317|Behavioral|Standard cardiac rehabilitation|Standard, multi-dimensional cardiac rehabilitation program.
45959054|NCT05075317|Behavioral|Time-Restricted Eating|Counselling to restrict their eating to between 11 am and 7 pm and to consume water-only for the remaining 16 hours per day
45959055|NCT05074771|Device|ARC intellicare|ARC is a system that allows home motor and respiratory rehabilitation. The system includes 5 inertial measurement units for limbs and neck, a tablet with a dedicated app installed, to acquire and monitor the exercises performed by the patient in his/her daily rehab activity. Sensors and tablet can be charged on the base station. ARC allows the therapist to tailor the individual rehab project, with the support of a monitoring dashboard. The artificial intelligence engine analyses data coming from sensors positioned on the limbs, providing real-time feedback to the patient on the correct number of repetitions performed for each exercise. ARC allows therapists to create new exercises and/or select exercises from the ARC library to customize treatment (including tutorials and tips) based on condition-specific validated protocols and best practice. Patients can safely perform home rehabilitation sessions by wearing sensors and following video tutorials and tips from the ARC library.
45959056|NCT00152048|Drug|Eflornithine hydrochloride|
45959057|NCT03457246|Other|D-Pigment rich texture|
45818679|NCT05138406|Other|Standard Rehabilitation|Standard rehabilitation consisting of cold therapy, stretching and strengthening exercises will be applied. Treatment will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.
45818680|NCT02136576|Device|Sensodyne|Subjects will be instructed to brush with Sensodyne twice daily (2 minutes each time in the morning and the evening) during the duration of the study.
45959058|NCT03457246|Other|Hydrance optimale riche|
45959059|NCT05062876|Drug|AD-214|1 tablet administered before the breakfast during 7 days
45959060|NCT05062876|Drug|AD-2141|1 tablet administered before the breakfast during 7 days
45959061|NCT05060068|Drug|S-ketamine (low dose)|Patients in the low-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 2 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
45458491|NCT02325544|Behavioral|Standardized Medical Care|Delivered by neurologists/ psychiatrists - both will be involved in discussing diagnosis. It will Include an information sheet about dissociative seizures and direction to self-help websites, general information provision about management of DS and support, consideration of psychiatric comorbidities / associated drug treatment and general review but no CBT techniques.
45818681|NCT02136576|Device|Crest Cavity Protection & MI Paste Plus|Subjects will be instructed to brush twice daily (2 minutes each time in the morning and the evening) using Crest Cavity Protection toothpaste. They will be instructed to apply MI Paste Plus (CPP-ACP with fluoride) twice daily to the study teeth after brushing their teeth. MI Paste Plus will be applied to the study teeth with a finger.
45959062|NCT05060068|Drug|Placebo|Patients in the placebo group will receive a bolus of 0.9% saline, followed by continuous infusion of 0.9% saline until 30 min prior to the end of the surgery.
45959063|NCT05060068|Drug|S-ketamine (high dose)|Patients in the high-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 4 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
45959064|NCT00152087|Device|Brachytherapy|
45959065|NCT04687111|Drug|Sacubitril-Valsartan|Sacubitril-Valsartan is an Angiotensin Receptor blocker and Neprilysin Inhibitor
45664429|NCT04623190|Behavioral|PREVENT tool|-PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
45664430|NCT01932970|Drug|Etelcalcetide|Etelcalcetide is provided as a sterile lyophilized powder to be reconstituted with sterile water for injection.
45664431|NCT01912768|Device|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
45959066|NCT04687111|Drug|Valsartan|Valsartan is an Angiotensin Receptor Blocker
45959067|NCT00532987|Behavioral|Questionnaire|Questionnaire form to be completed by patient
45959068|NCT00164775|Drug|Imipramine|25mg nocte for first 2 weeks then 50 mg nocte for 10 weeks
45959069|NCT00164775|Drug|Placebo|One tab nocte for first 2 weeks then 2 tabs for 10 weeks
45959070|NCT00533026|Drug|Duloxetine|
45959071|NCT00533026|Drug|Warfarin|
45959072|NCT00152126|Procedure|Stem Cell Transplantation|Autologous stem cell transplantation
45959073|NCT00152126|Drug|Busulfan, Melphalan|Transplant recipients will receive high dose Busulfan and Melphalan followed by autologous CD133+ antigen specific hematopoietic stem cell infusion. The autologous graft product will be selected using the investigational CliniMACS device.
45959074|NCT05045677|Other|digital DBT skills intervention|The digital intervention consists of 6 modules that will be delivered over 6 to 10 days. The modules cover mindfulness skills, emotion regulation skills and distress tolerance skills.
45664432|NCT01912768|Device|renu fresh multi-purpose solution|Commercially available solution indicated for cleaning, removing protein deposits, rinsing, chemical disinfection, and storage of soft contact lenses
45818682|NCT02136576|Device|Clinpro 5000|Subjects will be instructed to brush with Clinpro 5000 twice daily (2 minutes each time in the morning and the evening) during duration of the study.
45818683|NCT03600194|Device|PowerSleep Stim|The PowerSleep Stim device is a wearable and non-invasive device, consisting of a headband with 2 electrodes (one forehead and one mastoid) and speakers covered by foam over each ear. The headband is connected via a tether cable to a user interface which houses the EEG amplifier and electronics of the device. The headband is adjusted via Velcro closure. The device also includes a right mastoid electrode EEG will be recorded by the PowerSleep device. Soft audio tones (below 65dB) will be administered via the speakers system during deep sleep as determined by the functionality of the device. The version being used for this study is considered investigational as this is an earlier version which allows the study team will be able to review EEG data recorded by the PowerSleep device in real time.
45959075|NCT05045677|Other|Standard Care|Standard inpatient care includes a multi-disciplinary team approach including daily psychiatric review, medication management and in-person psychosocial interventions (social work, nursing).
45664433|NCT01912768|Device|Soft contact lenses|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days). A fresh pair will be dispensed on Day 0, Day 30, and Day 60.
45664434|NCT02305849|Drug|Peficitinib|oral tablet
45818684|NCT03600194|Device|Northwestern Stim|The Northwestern Stim Device will function similarly to the PowerSleep device, but stimulation will be provided using a standard PC (computer) setup at the bedside using standard PSG electrodes. EEG will be monitored and slow wave sleep (SWS) identified using a standard PSG channels (international 10-20 system: Fpz, F3, F4, C3, C4, P3, P4, O1, O2) referenced to left mastoid. Electro-oculogram (EOG) will be recorded using 2 electrodes placed lateral to each eye and chin electromyogram (EMG) was recorded using 3 chin electrodes. The full EEG data set will be collected using Brain Vision Recorder software (Brain Products GmBH) and stored for off-line analysis and sleep scoring. A Matlab script (R2014b, MathWorks, Natick, MA) was developed for online detection of slow-waves and to control acoustic stimulation in a phase-locked manner (targeting the up phase of the slow wave). Acoustic stimulation will be provided by headphones with an audible soft volume that do not result in arousals.
45818685|NCT03600194|Device|PowerSleep Sham|The PowerSleep Sham device is a wearable and non-invasive device, consisting of a headband with 2 electrodes (one forehead and one mastoid) and speakers covered by foam over each ear. The headband is connected via a tether cable to a user interface which houses the EEG amplifier and electronics of the device. The headband is adjusted via Velcro closure. The device also includes a right mastoid electrode EEG will be recorded by the PowerSleep device. There are no audio tones played in the Sham condition. The version being used for this study is considered investigational as this is an earlier version which allows the study team will be able to review EEG data recorded by the PowerSleep device in real time.
45818686|NCT03600194|Device|NorthWestern Sham|The Northwestern Sham device is set up will function similarly to the PowerSleep prototype. EEG will be monitored and SWS identified using a standard PSG channels (international 10-20 system: Fpz, F3, F4, C3, C4, P3, P4, O1, O2) referenced to left mastoid. Electro-oculogram (EOG) will be recorded using 2 electrodes placed lateral to each eye and chin electromyogram (EMG) was recorded using 3 chin electrodes. The full EEG data set will be collected using Brain Vision Recorder software (Brain Products GmBH) and stored for off-line analysis and sleep scoring. A Matlab script (R2014b, MathWorks, Natick, MA) was developed for online detection of slow-waves. Participant will wear headphones but no audio tones played in the Sham condition.
45818687|NCT03398330|Drug|Oxycodone Tamper Resistant|Orally taking Oxycodone Tamper Resistant 40mg in fed state
45818688|NCT03398330|Drug|OxyContin®|Orally taking OXYCONTIN® 40mg in fed state
45818689|NCT03398798|Device|".014"|".014 CuNiTi orthodontic arch wire"
45818690|NCT03398798|Device|".016"|".016 CuNiTi orthodontic arch wire"
45818691|NCT03398798|Device|Twin brackets|Ormco Insignia Metal Twin brackets
45818692|NCT03398798|Device|Self-ligating brackets|Ormco Insignia SL brackets
45664435|NCT02305849|Drug|Placebo|oral tablet
45664436|NCT02305849|Drug|Methotrexate|Oral tablet/capsule
45664437|NCT02371759|Drug|L+C maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
45959076|NCT05043883|Device|CathVision Cube® system|Intracardiac signals will be passively recorded using the investigational CathVision Cube® System in parallel with the commercial (bearing CE mark) EP recording systems LabSystem Pro, Boston Scientific EP, or EP-Tracer, Schwarzer Cardiotek. The investigational device will not be used for direct clinical care decisions or therapy. The validation of the PVI Analyzer will be performed offline and retrospectively.
45959077|NCT05039593|Other|chlorhexidine|The population of the research is the patients hospitalized in the Internal Medicine intensive care unit of Aydın Adnan Menderes University Practice and Research Hospital between 01.06.2021 and 01.06.2022, and the sample is; Patients who are older than 18 years of age, who are in the first 24 hours of mechanical ventilation, who are 18 years of age and older, and whose relatives have consented.Oral care of the patients will be done with 0.12% chlorhexidine solution, and the frequency of oral care will be in three groups. Oral care will be done twice a day for the patients in the first group, 3 times a day for the patients in the second group, and 4 times a day for the patients in the third group. Oral care of the patients will be applied according to the guide used in the training given to the nurses.
45959078|NCT00425451|Drug|PerioChip Plus (Flurbiprofen +Chlorhexidine ), Flurbiprofen Chip, PerioChip (Chlorhexidine ) and Placebo Chip|
45959079|NCT05031637|Behavioral|treatment of BP by using night-time BP|titration of BP medications to target according to night-time SBP
45959080|NCT05031637|Behavioral|treatment of BP by using daytime BP|titration of BP medications to target according to daytime SBP
45455128|NCT04467658|Diagnostic Test|electroencephalography relative fast alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
45455129|NCT04467658|Diagnostic Test|electroencephalography absolute beta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
45664438|NCT02371759|Drug|L+C mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
45664439|NCT02371759|Drug|L+E maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
45664440|NCT02371759|Drug|L+E mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
45818693|NCT03400748|Device|RF Ablation|The intervention consists of a bronchoscopic approach to ablate lung tumors with radio-frequency energy.
45818694|NCT03505190|Drug|RO7062931|RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.
45818695|NCT03505190|Drug|Placebo|Matching placebo will be administered subcutaneously (SC).
45959081|NCT00152165|Procedure|Radiostereometric Analysis beads inserted during surgery|
45959082|NCT05001451|Biological|GDX012 Suspension for IV Infusion|"Biological: GDX012 Suspension for IV Infusion (single dose) following chemotherapy for lymphodepletion.~Drug: Fludarabine; chemotherapy for lymphodepletion~Drug: Cyclophosphamide; chemotherapy for lymphodepletion"
45959083|NCT00152204|Drug|Sulfadoxine-pyrimethamine used for IPTi|Doses of IPTi with SP delivered alongside doses 2 & 3 of DTP/HB vaccination and alongside measles vaccination
45959084|NCT00152204|Drug|IPTi|Doses of IPTi with SP delivered alongside doses 2 & 3 of DTP/HB vaccination and alongside measles vaccination
45959085|NCT00533065|Drug|Donepezil|week1 - week12: 1 tablet per day (5mg) week13 - week52: 1 tablet per day (10mg)
45664441|NCT02531633|Drug|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukuma, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
45664442|NCT02531633|Drug|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
45818696|NCT04734704|Procedure|skin swabs at lesional and non-lesional sites|It will be examined in patients skin swabs sampled at lesional and non-lesional sites
45818697|NCT04734704|Procedure|skin swabs on skin|It will be examined in patients skin swabs sampled on skin
45959086|NCT04686877|Procedure|STAPLE|Stereotactic aspiration plus urokinase clot irrigation
45959087|NCT00152243|Drug|UFT (uracil, tegafur)|uracil-tegafur 360 mg per square meter per day orally 16 months
45455130|NCT04467658|Diagnostic Test|electroencephalography relative beta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
45455131|NCT04467658|Diagnostic Test|Korean ADHD rating scale|The KARS is a standardized screening tool for ADHD in Korean children and rating scale completed by the parents.
45455132|NCT04467658|Diagnostic Test|Korean Version of Diagnostic Interview Schedule for Children Version IV|The DISC-IV is a structured diagnostic tool that was developed for use in epidemiological studies in children and adolescents
45664443|NCT02531633|Drug|Prednisone|Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).
45818698|NCT03513848|Device|Retimer|The Retimer light device in this study is a commercially-available wearable light device. It permits ambulation while receiving light from LEDs positioned below the eyes. The LEDs emit green light (~500nm, 230 µW/m2, 500 lux), close to the peak sensitivity of circadian photoreceptors.
45818699|NCT03513848|Device|Retimer placebo|The Retimer device has been dimmed to reduce the light intensity to a level that will not shift circadian timing.
45818700|NCT03402932|Other|Auditory amplified|The cognitive test will be administered using a computer-based signal processing to amplify the instruction. The presentation level is customized to the individual's hearing thresholds.
45818701|NCT03402932|Other|Visual|The cognitive test will be administered visually by using timed computer slides.
45818702|NCT03402932|Other|Auditory unamplified|The cognitive test will be administered by using a generic presentation level that simulates a normal conversational level.
45455133|NCT01122979|Drug|INSULIN GLARGINE|Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
45455134|NCT01122979|Drug|NPH insulin (insulin isophane)|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
45664444|NCT02531633|Drug|Placebo to match prednisone|Placebo to match prednisone will be provided as tablets.
45664445|NCT05415605|Device|Lung Strain|The main objective of this study is to describe the physiological values of lung strain in healthy volunteers as well as its variations induced by non-invasive positive pressure ventilation and their correlation with tidal volume.
45664446|NCT05435885|Other|Pulmonary Tele-Rehabilitation|12 supervised training sessions via a specific mobile messenger during four weeks. (3 sessions/week)
45664447|NCT05435885|Other|Control (Education)|Usual care with only one educational session.
45818703|NCT00376610|Device|ASR/Re-cap|
45818704|NCT03621878|Other|Neural mobilization exercises -Tensioner technique|Exercise aiming to lengthen the neural structure using more than one joint.
45818705|NCT03621878|Other|Neural mobilization exercises -Slider technique|Exercise aiming to slide/glide the neural structure using more than one joint.
45818706|NCT03621878|Other|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device aiming to decrease patient's symptoms.
45818707|NCT00376766|Drug|levetiracetam|
45818708|NCT03403712|Drug|fosnetupitant/ palonosetron|intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination
45818709|NCT03403712|Drug|netupitant/palonosetron|oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination
45959088|NCT00152243|Procedure|Surgery alone|Gastrectomy of tumour node metastasis(TNM) stage T2N1-2 gastric cancer.
45959089|NCT00172107|Drug|ALX1-11 50 mcg|PTH(1-84) 50 mcg for subcutaneous injection into thigh or abdomen
45959090|NCT00172107|Drug|placebo|placebo powder for subcutaneous injection
45959091|NCT00172107|Drug|ALX1-11 75mcg|PTH(1-84)75 mcg for subcutaneous injection
45959092|NCT00172107|Drug|ALX1-11|PTH (1-84) 100mcg for subcutaneous injection into thigh or abdomen
45959093|NCT04945837|Other|self administered questionnaire|longitunidal descriptive study
45959094|NCT04686955|Drug|Xiao-Xian-Gui-Fu-Tang|The Xiao-Xian-Gui-Fu-Tang includes Xiao-Feng-San 2.0g, Dang-Gui-Yin-Zi 1.2g, Bai-Xian-Pi(Cortex Dictamni Radicis) 0.4g, and Di-Fu-Zi(Fructus Kochiae) 0.5g. The Xiao-Xian-Gui-Fu-Tang will be manufactured, packaged, and labeled by the KO DA Pharmaceutical Company (Taiwan), using good manufacturing practice standards.
45959095|NCT00152282|Drug|Asoprisnil/Premarin|Asoprisnil 5mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
45959096|NCT00152282|Drug|Asoprisnil/Premarin|Asoprisnil 10mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
45959097|NCT00152282|Drug|Asoprisnil/Premarin|Asoprisnil 25mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
45664448|NCT03936647|Procedure|surgical clipping, simple coiling, high-porosity stenting with/ without coiling, intra-arterial flow diversion with/ without coiling|Treatment may include the most appropriate amongst surgical clipping, simple coiling, high-porosity stenting with or without coiling, and intra-arterial flow diversion with or without coiling, which will be predetermined by the treating physician prior to randomization.
45664449|NCT03936647|Device|WEB embolization device|WEB embolization device
45664450|NCT02536313|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
45664451|NCT02536313|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
45664452|NCT05435651|Behavioral|Multitask game-based digital therapy|To practice multitask-game on the system for approximately 25 minutes/day at least 5 days a week.
45664453|NCT05435651|Behavioral|Schulte Grid digital game|To practice Schulte Grid digital game on the system for approximately 25 minutes/day at least 5 days a week.
45664454|NCT05415059|Device|Covatech Stoma bag material|Strips of Covatech Stoma bag used to asses adhesion of 3M material to be used in LEAFix device
45664455|NCT05610761|Behavioral|Core stabilization exercises with Kegel exercises|Core stabilization exercise program consists of two phases: teaching the basic movement (contraction of the Transversus abdominis and other muscles with diaphragmatic breathing) and incremental exercises added to the basic movement. The basic movement will be studied before each exercise and then the specified exercises will be added. The physiatrist will teach the exercise program to the patients. The first 6 of the 12 exercises classified according to the degree of difficulty will be performed for 5 weeks, and the next 5 weeks will be moved to the other 6 exercises. The exercises will be performed at least 3 days a week, with 10 repetitions of each movement, and the program will last for 10 weeks. Compliance with the exercise program will be questioned over the phone, and patients will be evaluated with a follow-up form before the study, at the 10th week, and at the 20th week. In addition, the Kegel exercise program specified in the other group will be applied.
45664456|NCT05610761|Behavioral|Kegel exercises|"Kegel Exercises The exercise will start as 2 sets of 10 repetitions in the morning and evening, and after getting used to it, it will be increased to 3 sets of 10 repetitions per day.~The patient, lying on his back with his knees bent, feet slightly apart from each other, will try to lift the breech, urinary tract opening and vagina on the pelvic floor by counting to 5, and should not tighten your abdominal and leg muscles, and should not hold your breath while doing this exercise.~In this way, he will count up to 5 while contracting, then he will relax by counting to 10 (after getting used to it, the holding time will be increased to 10 seconds)."
45818710|NCT03403712|Drug|dexamethasone|Oral dexamethasone (12 mg)
45818711|NCT03404648|Drug|C-11 choline PET tracer|C-11 choline PET tracer, One dose, totally 12-14 millicurie (mCi), intravenous administration while patient is lying on the table.
45818712|NCT03404648|Drug|Gadobutrol|Single dose of Gadavist® (Gadobutrol, Bayer) at no more than 0.1 mmol/kg will be administrated intravenously.
45818713|NCT03404648|Device|PET/MR scanner|C11-PET/MR and pelvic mpMRI scan for prostate cancer.
45818714|NCT03383198|Drug|Liposomal bupivacaine right injection|Right side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the left side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
45959098|NCT00152282|Drug|Placebo and Premarin|Placebo and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
45959099|NCT04927741|Other|Sweet Marjoram Essential Oil|"Subjects will receive a dilution of sweet marjoram essential oil (15 cc of grapeseed oil with 10 drops of sweet marjoram essential oil).~Oil will be applied topically by the study medical providers. Providers will wear exam gloves, dip three fingers into the oil solution and apply it topically to the subject's lower abdomen. This will be applied by going left to right for 20 seconds while applying gentle pressure - counter pressure may be applied on the uterus to help relieve cramping."
45959100|NCT04927741|Other|Grapeseed Oil|"Subjects will receive 15 cc of undiluted grapeseed oil.~Oil will be applied topically by the study medical providers. Providers will wear exam gloves, dip three fingers into the oil solution and apply it topically to the subject's lower abdomen. This will be applied by going left to right for 20 seconds while applying gentle pressure - counter pressure may be applied on the uterus to help relieve cramping."
45959101|NCT04922983|Drug|Botulinum toxin type A|A position similar to the side-plank (Vasisthasana) held for maximal time at least once daily (usual duration: 30 - 90 seconds).
45959102|NCT04922983|Behavioral|Isometric Yoga-like exercise|Extended torso and legs held diagonally by one straight arm, back against wall if necessary
45818715|NCT03383198|Drug|Liposomal bupivacaine left injection|Left side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the right side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
45959103|NCT04922983|Behavioral|Placebo|Used as placebo
45959104|NCT04916041|Device|Cataract surgery with bilateral implantation of the same type of intraocular lens|Cataract surgery with bilateral implantation of the same type of intraocular lens
45959105|NCT00152321|Behavioral|Patients (education, counseling) and Physicians (reminders,1-page guidelines).|
45959106|NCT00152321|Behavioral|Multifaceted intervention|Educational materials, counseling, opinion leader based guidelines, reminders
45959107|NCT00152321|Other|Usual Care|
45959108|NCT04914364|Other|Balance assessments|There is no formal intervention in this study. The investigators will only be completing balance assessments with no follow-up visit.
45959109|NCT00164853|Procedure|endoscopic balloon dilatation|Refer to description under arms
45959110|NCT00164853|Procedure|Standard sphincterotomy|Refer to under arms
45959111|NCT04914247|Drug|Selexipag|
45959112|NCT04687150|Other|Fecal microbiota transplantation|Fecal microbiota transplantation from a tested general donor, frozen and thawed from a fecal bank
45959113|NCT04687150|Other|Colored water|Colored water (placebo)
45664457|NCT05414825|Other|focus group interview|Group interview gathering words, views, symptoms and its repercussions, and main issues of the subjects regarding severe dysmenorrhea
45664458|NCT04423133|Behavioral|Online Family Literacy Program|Parent-child dyads will participate in 8 weekly online health-themed workshops that introduce language and literacy skills. Participants will also receive 2-3 text messages per week for the duration of the program and children's books.
45455135|NCT01122979|Drug|INSULIN GLULISINE|Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
45664459|NCT04423289|Other|Farmalarm|Monitoring after COVID-19 discharge from hospital via Farmalarm app
45664460|NCT05413733|Behavioral|Digital care pathway|"Sessions of the digital neuropsychological program:~Subjective functional ability and goals~Fatigue after ABI~Attention and concentration~Memory~Memory strategies~Working memory and executive functions~Emotional reactions~Summary and future goals"
45664461|NCT05413733|Behavioral|Care as usual|The standard care of patients with ABI including all necessary outpatient rehabilitation visits. Neuropsychological visits may include a short period of psychoeducation with a clinical neuropsychologist.
45959114|NCT00152360|Drug|Orlistat|See Detailed Description.
45959115|NCT00533104|Procedure|BM-MNC preparation|"For autologous bone marrow - mononuclear cells preparation, 500ml of bone marrow are collected under general anaesthesia; mononuclear cells are separated using a blood-cells separator (COBE SPECTRA, GAMBRO BCT) and concentrated to produce a final volume of 40ml.~Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection)."
45455136|NCT01122979|Drug|Regular insulin|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
45458492|NCT01351922|Other|No treatment given|Patients will fill out a questionaire by interview.
45458493|NCT01360424|Drug|Teriparatide|Daily administration of teriparatide 20 ug s.c. for 24 months
45664462|NCT05413499|Other|Biomarkers research|For a part of the included population, the children with a mTBI and without indication of CT scan, a non-routine blood sample will be planned
45818716|NCT03407612|Device|Continuous Passive Motion|CPM devices are used in postoperative rehabilitation and are throughout to reduce joint stiffness.
45818717|NCT03408392|Drug|Test formulation A|Test formulation: SKF101804 will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a fruit flavor and odor.
45818718|NCT03408392|Drug|Reference formulation B|Reference formulation will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a strawberry flavor and odor.
45818719|NCT04735484|Device|Gait analysis|Collecting movement data whilst participants walk
45818720|NCT03413618|Drug|Rivaroxaban|15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
45818721|NCT03413618|Drug|Diosmin|600 mg q.d. for 12 month
45818722|NCT03413618|Other|compression stockings|above knee stocking for 12 month
45818723|NCT03522350|Device|EmbryoScope|Standard of care arm
45818724|NCT03522350|Device|EmbryoScope+|Experimental arm
45959116|NCT00533104|Procedure|PB-MNC preparation|"Peripheral blood - mononuclear cells are collected through cytapheresis with the same blood-cells separator which is adjusted to obtain a 40 mL cell product. No previous mobilization with hematopoïetic growth-factor is administered.~Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection)."
45959117|NCT00164892|Drug|Oral Vioxx (Rofecoxib)|
45664463|NCT04423445|Other|Laser acupuncture combined with acupressure|Participants received laser acupuncture on the six selected acupuncture points bilaterally twice a week for 4 weeks. A seed was taped onto each of the three points of the unilateral ear (initially, the left ear), where it remained for five days. Pressing on each of the seeds for one minute three times a day was required, but the stimulation intensity was adjusted depending on the participant's individual tolerance. The de qi sensation appears to be an established intervention efficacy indicator during auricular acupressure. After five days, the seed was removed, and a new seed was taped on the other ear.
45959118|NCT00533143|Other|non invasive ventilation (NIV)|NIV is a form of mechanical ventilation delivered through a face or nasal mask and therefore not requiring endotracheal intubation. It will be delivered according to the compliance and tolerance of the patients.
45959119|NCT04686994|Drug|ASC 41|Oral tablets
45959120|NCT04686994|Drug|ASC 41 Placebo|Oral tablets
45959121|NCT02938117|Other|cycling exercises|
45959122|NCT00152399|Drug|Somatostatin UCB (drug)|
45959123|NCT02277145|Biological|clinical grade umbilical cord mesenchymal stem cells|10^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after fully lavage of the localized lesions
45959124|NCT02938078|Device|Avenova Lid Cleanser|Avenova lid cleanser is an FDA-cleared saline solution preserved with 0.01% pure hypochlorous acid.
45959125|NCT02938039|Device|Ambu LMA|Ambu Laryngeal Mask Airways
45959126|NCT02938039|Device|I-Gel LMA|I-Gel Laryngeal Mask Airways
45959127|NCT02938234|Dietary Supplement|High caloric, high protein ONS|
45959128|NCT02938000|Device|Theraband with exercise video|Theraband exercise band for resistance training
45664464|NCT05412875|Other|Best Practice|Given usual care
45664465|NCT05412875|Drug|Nicotine Replacement|Given JUUL
45664466|NCT05412875|Other|Quality-of-Life Assessment|Ancillary studies
45664467|NCT05412875|Other|Questionnaire Administration|Ancillary studies
45818725|NCT03523988|Drug|Acetaminophen|Acetaminophen gel capsule
45818726|NCT03523988|Drug|Ibuprofen|Ibuprofen gel capsule
45818727|NCT03525548|Drug|VX-445/TEZ/IVA|Participants received VX-445/TEZ/IVA orally once daily in the morning.
45959129|NCT02938000|Other|usual care with advice to exercise|advice to exercise
45959130|NCT00164931|Drug|Intravenous omeprazole infusion|
45959131|NCT00164931|Procedure|Scheduled second endoscopy|
45959132|NCT00152438|Drug|Oral Micronized Progesterone (Prometrium®)|300 mg per day in 3 - 100 mg pills, to be taken in the evening immediately before sleep.
45818728|NCT03525548|Drug|TEZ/IVA|Participants received TEZ/IVA orally once daily in the morning.
45818729|NCT03525548|Drug|IVA|Participants received IVA orally once daily in the evening.
45818730|NCT03525548|Drug|Placebo|Participants received placebo matched to VX-445/TEZ/IVA orally once daily in the morning.
45818731|NCT03525548|Drug|Placebo|Participants received placebo matched TEZ/IVA orally once daily in the morning.
45818732|NCT03528512|Drug|Ketamine|Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)
45959133|NCT00152438|Other|Placebo|3 identical placebo pills daily, no active ingredient.
45959134|NCT02937961|Biological|Early SLED|withing 6 to 12 hours
45959135|NCT02937961|Biological|Late SLED|when absolute indications will meet
45664468|NCT02187861|Drug|Venetoclax|Venetoclax will be administered as per the schedule specified under arm description.
45664469|NCT02187861|Drug|Bendamustine|Bendamustine will be administered as per the schedule specified under arm description.
45664470|NCT02187861|Drug|Rituximab|Rituximab will be administered as per the schedule specified under arm description.
45818733|NCT03528512|Drug|Midazolam and fentanyl|Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
45818734|NCT03531710|Biological|UB-311|Intramuscular injection
45818735|NCT03531710|Drug|Placebo|Intramuscular injection
45818736|NCT03533036|Device|applied VR headset|Virtual reality (VR) is a three-dimensional experience created by a headset fitted with a video display. The device, designed to be worn on the face, immerses the viewer in a virtual world and can create a visual distraction from the patient's present situation. We will use a commercially available VR device, comprised of a phone and headset. The phone is inserted into the headset to act as the visual display that can create three dimensional environments. The patient will then choose the virtual reality experience she prefers from the two relaxation programs available. The VR device will be introduced to the participant and fitted to her head prior to the procedure. The device is intended to be worn during the full length of the procedure until the conclusion of the D&C, however the participant may decide to stop wearing the device and choose to end the VR experience at any time.
45959136|NCT02937649|Procedure|Laparoscopic sleeve gastrectomy using 48-Fr bougie|After gastric mobilization, the 48-Fr bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
45959137|NCT02937649|Procedure|Laparoscopic sleeve gastrectomy using standard care bougie|After gastric mobilization, the standard care bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
45959138|NCT02937922|Other|AEROBIC|The aerobic exercise session (AE) will consist of 40 minutes on an exercise bike in heart rate (HR) corresponding to 60% of heart rate reserve (moderate intensity) acquired by the formula of Karvonen: [(HR max - HR rest) x desired intensity] + HR rest; monitored through heart monitor brand Polar and perceived exertion rating (Borg scale of 6-20). It will be added to the exercise time 5-7 minutes to proper heating.
45959139|NCT02937922|Other|RESISTANCE|The resistance exercise session (RE) will last 40 minutes and will consist in carrying out 4 sets of 12 repetitions with interval of 90 seconds between sets and exercises. The weight will be adjusted to 60 % of a maximum repetition (1-RM) (moderate intensity) in four exercise for the lower limbs: leg press, knee extension, bend knees and plantar flexion (calf). The cadence of each series will be controlled by electronic metronome and performed with 2 seconds in the concentric phase and 2 seconds in the eccentric phase. It will be added to the exercise time 5-7 minutes for the warming to be held in the leg press exercise (one set of 15 to 20 repetitions with 1/3 load set for the session).
45959140|NCT02937922|Other|COMBINED|The combined exercise session (resistance and aerobic) will last 40 minutes. The exercise resistance phase of the combined session will consist of 20 minutes, according to the resistance exercise described above. Immediately after resistance exercise, patients will perform aerobic exercise (AE) for 20 minutes. In order to keep the equivalent time among the three interventions (aerobic exercise, resistance and combined) will be performed two series (2 x 12 repetitions) in each resistance exercise.
45959141|NCT00164970|Dietary Supplement|Vitamin B12|
45959142|NCT00164970|Dietary Supplement|folate|
45959143|NCT04725461|Device|Low cost lower limb prosthetic socket|"A pre-made 3D printed cylinder used as an outer shell is selected for each subject based on their measurements. The space between the residual limb and the outer shell will be filled with an expanding polyurethane foam (Foam IT 8, Smooth On Inc.) that conforms to the residual limb and bonds with the outer shell to form a strong and lightweight socket. The foam forms a smooth surface against the protective sheath; the socket is fully formed once the foam has hardened to the 3D printed cylinder.~A prefabricated supracondylar suspension cuff made of Dacron or nylon, or a commercially available suspension sleeve may be will be applied to the prosthetic socket to aid in suspension. Commercially available components, including the International Committee of the Red Cross (ICRC) transtibial polypropylene component system will be attached to the bottom of the socket to allow the patient to ambulate in the prosthesis."
45959144|NCT02937844|Biological|Anti-PD-L1 CSR T cells|Prescribed CSR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）.
45959145|NCT02937844|Drug|Cyclophosphamide|250 mg/m^2, d1-3
45959146|NCT02937844|Drug|Fludarabine|25mg/m^2, d1-3
45959147|NCT02937883|Other|Empowerment intervention|Empowerment intervention for persons with young onset dementia
45959148|NCT02937727|Device|3T MRI compatible and LFP recordable G106R of Beijing Pins medical.|
45959149|NCT00172263|Procedure|blood sampling|
45959150|NCT00152555|Behavioral|Physical Therapy or Relaxation Therapy|
45959151|NCT02937805|Device|Moisturizing vaginal and vulvar sea buckthorn oil cream|
45959152|NCT02937805|Device|Moisturizing vaginal and vulvar cream|
45664471|NCT03958487|Behavioral|Video feedback, Feedback online|The treatment phase have 3 timepoints, 1 the patient is asked to perform an ADL alone, 2. Video feedback is administrated. This requires the participant to watch its own videotaped performance with the therapist while the therapist encourage the participant to identify errors, areas of strength, and to suggest strategies to solve errors in future sessions. 3. feedback online will be provided by the therapist on participant performance. The therapist will wait for the patient to detect and correct their error spontaneously. If the patient does not detect it, the therapist provides unspecified/specific help. This strategy is based on previous work (Schmidt, et al 2013, Ownstorth et al. 2010). The novelty of our procedure is the inclusion of distracting and conflicting/problem solving situations to be inhibited, detected and solved. Feedback will focus on these situations. The level of monitoring requirements will be adjusted to participants performance using a changing criterion design.
45959153|NCT02937610|Procedure|percutaneous endoscopic gastrostomy|PEG tube inserted with pull technique
45959154|NCT02937532|Behavioral|GHE + TOBT training|All subjects will receive 45 minutes of GHE, followed by 45 minutes of TOBT program twice a week for 8 weeks.
45959155|NCT02937532|Behavioral|CBT + TOBT training|All subjects will receive 45 minutes of CBT, followed by 45 minutes of TOBT program twice a week for 8 weeks.
45664472|NCT05435261|Procedure|BKA|"Below Knee Amputation:~Under spinal anesthesia~BKA~closure in layers (terminal closure) with suction drain."
45959156|NCT02937493|Behavioral|Lunar phases|Observation if lunar phases had an influence on occurrence of IPV
45959157|NCT02937415|Procedure|Breath carbon monoxide|Breath carbon monoxide measurement.
45959158|NCT02937415|Procedure|Pulmonary function tests.|Measurement of lung functions by blowing through a tube which measures flow and volumes of participant's lungs.
45959159|NCT02937415|Procedure|Oxidative stress and antioxidant status.|Measurement of parameters of oxidative stress and antioxidant status in blood samples.
45959160|NCT00165009|Device|Resolution clip (endo-clipping device)|Resolution clip (endo-clipping device)
45664473|NCT05435261|Procedure|Debridement with Ex_Fix (salvage)|"Debridement and External Fixation (salvage):~Under spinal anesthesia~wound debridement and wash.~external fixation."
45818737|NCT02153112|Biological|GI.1/GII.4 (15/15)|Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
45818738|NCT02153112|Biological|GI.1/GII.4 (15/50)|Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
45818739|NCT02153112|Biological|GI.1/GII.4 (50/50)|Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
45818740|NCT02153112|Biological|GI.1/GII.4 (50/150)|Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
45818741|NCT02153112|Drug|Placebo|Placebo saline solution
45818742|NCT03534986|Device|International Biophysics AffloVest|High-frequency chest wall oscillation vest
45818743|NCT03534986|Device|Hill-Rom The Vest|High-frequency chest wall oscillation vest
45959161|NCT00152594|Drug|voriconazole|
45959162|NCT02937337|Device|Laryngeal mask insertion with videostylet guided technique|
45959163|NCT02937337|Device|Laryngeal mask insertion with standard blind technique|
45959164|NCT02937220|Procedure|monolithic zirconia crown|New crown material used as final restoration for dental implants
45959165|NCT02937220|Procedure|metal ceramic crown|Conventional crown material used as final restoration for dental implants
45959166|NCT02937259|Other|Patient self-admission to inpatient treatment|Participants are given a contract whereby they are offered the possibility to admit themselves at will to the inpatient ward at the Stockholm Centre for Eating Disorders for a maximum of seven consecutive days at a time. They are also free to discharge themselves at any time. The participants may use this opportunity as often as they want to for a period of one year, or longer if the contract is renewed after one year.
45959167|NCT00407199|Drug|quetiapine|
45959168|NCT04725422|Drug|Methotrexate|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
45664474|NCT05434091|Drug|PF-07291177|PF-07291177 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
45959169|NCT04725422|Drug|Sulfasalazine|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
45959170|NCT04725422|Drug|Leflunomide|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
45959171|NCT04725422|Drug|Pamidronate|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
45664475|NCT05434091|Drug|Placebo|Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
45959172|NCT04725422|Drug|Zoledronic acid|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
45959173|NCT04725422|Drug|Etanercept|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
45959174|NCT04725422|Drug|Adalimumab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
45959175|NCT04725422|Drug|Certolizumab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
45455137|NCT05227040|Device|Nintendo Ring Fit Adventure Exergame|Participants in the RFA group were required to exercise for 30 minutes three times per week (in adventure mode) for 4 weeks. The initial exercise intensity was set according to the instructions given by the virtual coach during the first game and was gradually adjusted according to the game instructions. The research continued to track the RFA group subjects and continued to encourage the completion of 4 weeks of physical activity training.
45664476|NCT05379179|Drug|Ketamine|This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
45664477|NCT05379179|Drug|Fentanyl|This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
45664478|NCT05379023|Behavioral|Face-to-face evaluation (FF)|The intervention is the assessment modality. The control condition is face-to-face evaluation (FF).
45664479|NCT05379023|Behavioral|TeleNP evaluation|The intervention is the assessment modality. The intervention condition is TeleNP evaluation.
45664480|NCT05610605|Other|Health intervention programme: FRAGSALUD|The FRAGSALUD Program consists in two parts, a first part of health education that will be taught in a group in four sessions, and a second part of individual treatment and follow-up, individual consultations will have a bimonthly periodicity until reaching one year, at which time that the program ends and a final evaluation will be carried out to assess whether the changes are maintained 15 months after the start.
45664481|NCT05378477|Device|X92001752|The test product is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
45818744|NCT03534986|Device|Respirtech inCourage|High-frequency chest wall oscillation vest
45818745|NCT03534986|Device|Electromed SmartVest|High-frequency chest wall oscillation vest
45959176|NCT04725422|Drug|Infliximab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
45818746|NCT03536702|Other|Creative Writing Workshop|This group will participate in a writing workshop in group sessions.
45818747|NCT03536702|Other|Independent Writing - Control Group|This group will receive a book for a self writing session.
45818748|NCT03537092|Device|Vaginal Film|"2 x 2 vaginal film with no active drug"
45818749|NCT02133924|Drug|natalizumab|Natalizumab 300mg on days 0 and 14.
45818750|NCT02133924|Drug|steroids|Prednisone 2mg/kg/d (or methyl-prednisolone IV equivalent)
45959177|NCT04725422|Drug|Golimumab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
45959178|NCT02937298|Dietary Supplement|Control Meal|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream
45959179|NCT02937298|Dietary Supplement|Berry Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a berry smoothie. The berry smoothie consists of blueberries, raspberries and blackberries.
45959180|NCT02937298|Dietary Supplement|Sea Buckthorn Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a sea buckthorn berry smoothie.
45959181|NCT02937298|Dietary Supplement|Wild Garlic Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream. The wild garlic will be prepared and served as a dip alongside.
45959182|NCT02937103|Biological|Anti-CD123-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD123-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
45959183|NCT02936908|Other|Ventilatory support|Initiation of mechanical ventilatory support, invasive or non-invasive, Or modification of mechanical ventilatory support (modification of the parameters of the device, change of material, switch from non-invasive to invasive)
45959184|NCT00172302|Drug|vitamin C, intravenous injection|
45959185|NCT00152633|Drug|Losartan|
45959186|NCT00152633|Drug|Metoprolol|
45959187|NCT00152633|Drug|Losartan|Treatment with Losartan
45959188|NCT02937181|Drug|Ceftaroline|IV Ceftaroline will be given for 72 hours
45959189|NCT02937025|Device|The Left Atrial Appendage Occulder of Shanghai Push Medical Device Technology CO.td|Implanting the Occluder to close the left atrial appendage
45959190|NCT00425490|Drug|sitagliptin|
45959191|NCT02936674|Device|Light - standard|Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with standard spectral distribution
45959192|NCT02936674|Device|Light - alternate|Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with an altered spectral distribution (different color)
45455138|NCT04179110|Drug|Pembrolizumab and Ramucirumab|Patients will receive Pembrolizumab 200 mg & Ramucirumab 10 mg/kg every 3 weeks.
45455139|NCT01123057|Procedure|riboflavin-induced collagen cross-linking treatment|"The principle of the procedure is to induce collagen crosslinking of the corneal stroma by the using riboflavin/UVA-treatment.~The technique involves topical application of riboflavin/dextran solution onto eye after removal of corneal epithelium. After initial riboflavin application for 30 minutes, UVA light is shone onto the cornea for another 30 minutes with continued topical riboflavin application."
45455140|NCT01123057|Device|Riboflavin-UVA induced collagen cross-linking treatment for corneal ectasia|Use of riboflavin eyedrops during the procedure Use of UVA device (Peschke Meditrade)
45664482|NCT05378477|Device|RID Super Max Solution|RID Super Max Solution is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
45664483|NCT05378477|Drug|Nix Crème|Nix crème must be applied on dry hair for 10 minutes and then washed out with water. The product is to be applied on Day 0 and repeated again on Day 7.
45664484|NCT05378477|Device|Pouxit Végétal|Pouxit Végétal must be applied on dry hair for 30 minutes and then washed out using shampoo. According to the instructions for use, only 1 treatment must be performed.
45664485|NCT05596331|Other|eye-tracker|Eye-tracker recordings of eye movements, gaze direction and pupillary reactivity
45664486|NCT05383079|Drug|Lutetium-177 PSMA-I&T|Patients will be given 7.4 GBq of 177Lu-PSMA every 6 weeks for up to 6 Cycles
45664487|NCT05383079|Drug|Radium-223|During dose escalation, doses of Radium-223 that will be administered include 27.5 kBq/kg and 55 kBq/kg. The maximum tolerated dose of Radium-223 will be used during dose expansion. Radium-223 will be given once every 6 weeks for up to 6 doses between day 1-5 of each Cycle.
45818751|NCT03624920|Drug|THN102 Dosage A|THN102 Dosages A: placebo
45818752|NCT03624920|Drug|THN102 Dosage B|THN102 Dosage B : 200mg/2mg
45818753|NCT03624920|Drug|THN102 Dosage C|THN102 Dosage C: 200mg/18mg
45818754|NCT03537404|Drug|Narlaprevir|100 mg, film-coated tablets, taken as 200 mg per os daily
45818755|NCT03537404|Drug|Ritonavir|100 mg, film-coated tablets, taken as 100 mg per os daily
45818756|NCT03537404|Drug|Tenofovir Disoproxil Fumarate|300 mg, film-coated tablets, taken as 300 mg per os daily
45818757|NCT03537404|Drug|Raltegravir|400 mg, film-coated tablets, taken as 400 mg per os daily
45959193|NCT02936713|Other|Fermented milk product with probiotics (FMPP)|2 pots of 125g FMPP / day
45959194|NCT00172341|Drug|Staloral TM|
45959195|NCT03457753|Drug|Riluzole Oral Soluble Film|Riluzole Oral Soluble Film (ROSF) containing Riluzole 50mg .
45959196|NCT03457714|Behavioral|Guided ICBT for persons with Spinal Cord Injury|An 8-week guided internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a guide with experience delivering ICBT will provide support by email or telephone once a week. The guide will spend approximately 15 minutes per week/per client.
45959197|NCT03457714|Other|Survey|Caregiver burden and mental health will be assessed through online questionnaires.
45959198|NCT02936830|Drug|5% Sodium Fluoride Varnish|5% sodium fluoride varnish applied on the dentin by the dentist
45959199|NCT02936830|Drug|15% Nanohydroxyapetite paste|15% nanohydoxyapetite paste without potassium nitrate or fluoride applied on the dentin by the dentist
45818758|NCT03417752|Other|Exposure to firearm safety PSA|Exposed to firearm safety PSA
45959200|NCT02936830|Drug|Glycerol|Glycerol with water in a 1: 1 ratio
45959201|NCT00165048|Drug|Vioxx (Rofecoxib)|
45664488|NCT05377385|Behavioral|Questionnaire|Questionnaire about usability of the Omnipod DASH insulin administration system
45664489|NCT02163993|Drug|Galcanezumab|Administered SQ
45664490|NCT02163993|Drug|Placebo|Administered SQ
45664491|NCT05549063|Other|Mobility and Stability Exercise|Mobility and stability exercises were given to the first group, while stretching exercises were given to the other group. The number of repetitions and content of the exercises were determined before the treatment, and the same repetitions were given to both groups.
45818759|NCT03417752|Other|Exposure to health promotion PSA|Exposed to general health promotion PSA
45818760|NCT03626714|Drug|Sustained Release Injectable Tacrolimus|Long-acting formulation of tacrolimus developed using Auritec's proprietary Plexis drug delivery technology.
45959202|NCT04756414|Behavioral|Exposure based face-to-face Cognitive Behavior Group Therapy|See under detailed description
45959203|NCT00152711|Device|nCPAP|
45959204|NCT04690270|Drug|Sumatriptan 100 mg|Single dose Sumatriptan 100 mg
45959205|NCT04690153|Other|Patients with three vertical Hayman Sutures|Patients who are referred to our clinic due to postpartum hemorrhage between the ages of 18-45 and who need to undergo a surgical procedure (not responding to medical treatment) due to abnormal uterine bleeding in our clinic will be included. Patients with a previously known diagnosis of bleeding and coagulation disorders will not be included in the study. Considering that we are one of the primary referral centers in Istanbul in terms of deliveries and post-partum bleeding in our hospital, it is aimed to terminate the study with approximately 50 participants.
45959206|NCT00165087|Drug|asparaginase (E. Coli)|
45959207|NCT00165087|Drug|asparaginase (Erwina)|
45959208|NCT00165087|Drug|dexrazoxane|
45959209|NCT00165087|Drug|doxorubicin|
45959210|NCT00165087|Procedure|cranial radiation (once daily fractionation)|
45959211|NCT00165087|Procedure|cranial radiation (twice-daily fractionation)|
45959212|NCT00165087|Procedure|Intrathecal chemotherapy without radiation|
45959213|NCT02936518|Procedure|Lingual frenotomy and/or maxillary labial frenectomy|
45818761|NCT04332380|Drug|Plasma|Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
45818762|NCT03538808|Drug|Varenicline|Participants will be provided varenicline medication
45818763|NCT03538808|Other|Placebo|Participants will be provided placebo medication
45959214|NCT00152750|Drug|APO-clonidine|
45818764|NCT03540134|Device|Intracerebral Infusion of Autologous Cerebral Spinal Fluid|Unilateral infusion of 0.5 ml autologous CSF before DBS electrode insertion with MRI monitoring
45818765|NCT00377000|Drug|clindamycin 1% / benzoyl peroxide 5% gel pump|
45818766|NCT00377000|Drug|clindamycin 1% / benzoyl peroxide 5% tube|
45959215|NCT02936362|Other|Consumption of sourdough bread|Participants will be given sourdough bread to consume instead of other wheat products. 145g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
45959216|NCT02936362|Other|Consumption of white bread|Participants will be given white bread to consume instead of other wheat products. 110g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
45959217|NCT02936557|Drug|BAY987521|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code:Z09-054)"
45959218|NCT02936401|Behavioral|MBSR|Mindfulness Based Stress Reduction (MBSR) is a standardized 8 week course taught by trained instructors.
45959219|NCT02936245|Other|no specific intervention|We will not assign specific intervention in this research. We will record their baseline characteristics, received treatment, and assess the outcomes to analysis the predictors of outcome and natural history in patients with cervical spondylotic myelopathy.
45959220|NCT00152789|Procedure|Oxygen measurement - Eppendorf machine|
45959221|NCT02936128|Other|TruSkin|
45959222|NCT02936128|Other|Wound Cover|
45959223|NCT02936284|Behavioral|Music Enhancement|
45959224|NCT02936284|Behavioral|Play Date|
45959225|NCT02936167|Biological|Ringer Lactate|
45959226|NCT02936167|Biological|Plasmalyte|
45959227|NCT00152828|Drug|Celecoxib|
45959228|NCT02936089|Drug|Ara-C|Ara-C was administered at 1-2 g/m2 q12 h ×6 cycles
45959229|NCT02936089|Other|autologous HSCT|
45959230|NCT02936089|Other|allogeneic HSCT|
45818767|NCT02173704|Biological|Bexsero®|Four doses administered in the anterolateral area of the right or left thigh.
45959231|NCT02935933|Drug|bupivicaine|Paravertebral block
45959232|NCT02935933|Drug|morphine|
45959233|NCT02935933|Drug|Dexmedetomidine|
46079350|NCT05567731|Drug|ultrashort GnRHa|"the patients used the ultrashort protocols with GnRH agonist (GnRH-a, and recombinant Follicle-Stimulating Hormone for controlled ovarian hyperstimulation (COH). Form the second day of menstrual cycle, 0.1 mg/d GnRHa will be injected by subcutaneous injection for 3-4 d.~Gonadotropins will be added from the third day of menstrual cycle and the initial gonadotropin doses will be 225-300 IU/d. During the treatment, gonadotropin doses will be adjusted according to guided monitoring of follicle growth and measurement of serum estradiol (E2) levels of 10 000 units of human chorionic gonadotrophin (hCG) will be administered when 43 follicles will be 418 mm"
46079351|NCT05567731|Drug|short GnRHa|"Buserelin acetate 100 mg five times daily and FSH will be started on the 2nd day of the menstrual cycle as short application. The dose of gonadotropin hormone will be individualized according to the patient's age and previous stimulation history or response to stimulation. Cycles will be monitored by transvaginal ultrasonography and serum estradiol (E2) levels.~Follicular maturation will be completed by the administration of 10000 IU human chorionic gonadotrophin (hCG) when at least two follicles reached a diameter of >18 mm. Thirty-five to thirty-six hours after human chorionic gonadotrophin (hCG) administration, ovum retrieval will be performed by transvaginal echo-guided ovarian puncture."
45818768|NCT02173704|Biological|Routine vaccines|Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix® administered in the anterolateral area of the right or left thigh.
45818769|NCT03542474|Behavioral|High Intensity Endurance Exercise|Treadmill exercise at 80%-85% maximum heart rate for 30 minutes a day, 3 times per week, for 6 months.
45818770|NCT03543176|Other|UMEC/VI|UMEC/VI as 62.5/25 mcg, which is a once-daily single inhaler dual therapy, given to subjects, via Ellipta .
45818771|NCT03543176|Other|FLUT/SAL|FLUT/SAL as 250/50 mcg, which is a twice-daily single inhaler dual therapy, given to subjects, via Diskus.
45818772|NCT03543176|Other|CAT|Questionnaire used to asses Condition-related well-being, for COPD subjects.
45818773|NCT03543176|Other|mMRC|Questionnaire used to asses Breathlessness, due to Dyspnea, for COPD subjects.
45818774|NCT03543176|Device|Ellipta|It is a single once daily, Dry powder Inhaler (DPI), developed for delivery of therapies in COPD subjects.
45818775|NCT03543176|Device|Diskus|It is a plastic device containing twice-daily single inhaler dual therapy, developed for delivery of therapies in COPD subjects.
45818776|NCT02173548|Drug|Anakinra|
45818777|NCT02173548|Drug|Placebo|
45959234|NCT02936011|Device|CTO PCI using Absorb Bioresorbable Vascular Scaffolds|CTO PCI
45959235|NCT02935777|Dietary Supplement|Pomegranate Extract|The first computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, intervention capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
45959236|NCT02935777|Dietary Supplement|Placebo capsule|One computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, placebo capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
45959237|NCT00152867|Drug|Dexamethasone|dexamethasone 4mg PO bd for 2 days post chemotherapy
45959238|NCT02935816|Radiation|Whole body MRI|We have developed and assessed the feasibility of performing whole---body multi---parametric MRI for staging metastatic disease. We hypothesize that a whole body multi---parametric MRI will be more sensitive and specific than conventional imaging staging for detection of metastatic disease in patients with biochemical failure following local therapies. We therefore propose a comparative trial of conventional imaging verses whole---body multi---parametric MRI within this population of men
45959239|NCT02935972|Drug|Diazepam|received intravenous diazepam 5 mg slowly just before TRUS probe insertion
45959240|NCT02935972|Drug|Lidocaine 1%|received 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
45959241|NCT02935972|Drug|Diazepam and Lidocaine 1%|received intravenous diazepam 5 mg slowly just before probe insertion and 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
45959242|NCT02935855|Drug|Dabigatran|
45959243|NCT02935855|Drug|Apixaban|
45959244|NCT02935855|Drug|Rivaroxaban|
45959245|NCT02935855|Drug|Edoxaban|
45959246|NCT02935855|Drug|Warfarin|
45959247|NCT02935855|Drug|Acenocumarole|
45959248|NCT00152906|Procedure|Stereotactic radiotherapy (SRT) or highly conformal (CRT)|SRT or CRT is radiation delivered precisely conforming the high dose region to the tumor, usually in a few highdose fractions.
45959249|NCT04702555|Drug|VTS-K|An oral combination drug of VTS-Aspirin and ketamine (VTS-K)
45455141|NCT04797208|Device|Real-Time CGM|Participants will be wearing a real-time continuous glucose sensor which will enable their glucose levels to be remotely monitored. High and Low glucose alerts will also be available.
45455142|NCT04797208|Device|Capillary blood glucose testing with masked CGM|Participants will have their glucose monitored in hospital in the conventional manner using the NovaStat® glucometer or similar CE-marked glucose meter) and insulin dose adjusted by the treating clinical team as per usual hospital guidelines. A masked subcutaneous CGM will be inserted for data collection only.
45818778|NCT03543878|Device|Flicker|The Flicker intervention is delivered with the GammaSense Stimulation System by Cognito Therapeutics and involves viewing flickering lights at gamma frequency (like a strobe light but faster) to drive gamma oscillations in visual brain areas. The GammaSense Stimulation System is a device consisting of a pair of opaque glasses with a light-emitting diode (LED) illumination on the interior of the glasses. Headphones worn by the user during the stimulation session provide the auditory stimulation. When activated for the treatment session, the device will generate light and sound oscillations at 40 cycles per second (Hz) for 60 minutes. Participants will use the device daily during their active treatment period.
45455143|NCT04722536|Procedure|Cervico-isthmic cerclage|There is no intervention in this study. It's an observational retrospective study, before/after.
45664492|NCT05549063|Other|Stretching Exercise|Balance and reaching exercise, heel rise, towel picking exercise, 4-way resistance exercise, half kneeling knee to wall, single leg ankle, single leg balance with leg stretched, ice bottle rolling under the feet were performed in the first group. Achilles stretching, wall side gastrosoleus stretching, sitting plantar fascia stretching, towel gastrosoleus stretching, sitting dorsiflexion stretching with teraban were performed in the second group.
45664493|NCT04255823|Other|General practitioner and Patient receive informations related to PPI deprescribing.|"General practitioner will receive a sensibilization and an algorithm related to PPI deprescribing.~Their patients will receive any informations (patient information material on PPI deprescribing)"
45664494|NCT04255823|Other|Only General practitioner receive informations related to PPI deprescribing.|"General practitioner will receive the sensibilization and an algorithm related to PPI deprescribing.~Their patients will not receive any informations."
45818779|NCT02173158|Drug|lomitapide|
45818780|NCT04501640|Drug|mirabegron|Oral adminstration
45818781|NCT02152566|Device|Nasal High flow therapy device|Nasal high flow therapy via nasal cannula.
45818782|NCT04758390|Behavioral|IMARA (intervention group)|The IMARA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
45818783|NCT04758390|Behavioral|Health promotion control group|The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
45818784|NCT04757610|Biological|2.0 mg OPT-302|intravitreal injection
45818785|NCT04757610|Biological|0.5 mg ranibizumab|intravitreal injection
45818786|NCT04757610|Procedure|Sham|intravitreal injection
45818787|NCT03632954|Device|ACell Arm|Cytal® Wound Matrix and/or MicroMatrix®
45818788|NCT04559282|Device|New Sound Processor|The new Sound Processor is intended to be used as part of the Cochlear Baha System which uses bone conduction to transmit sounds to the cochlea. The New Sound Processor is indicated for patients with up to 55 dB sensorineural hearing loss.
45818789|NCT04734470|Diagnostic Test|Flow cytometry|The study of CD19 complex expression in lymphoproliferative disorders by flowcytometry
45818790|NCT03633344|Drug|Carbowhite|
45818791|NCT03633344|Drug|Carbowhite placebo|
45818792|NCT02171130|Drug|Nasal Glucagon|3 mg nasal glucagon powder
45818793|NCT04777214|Device|Repetitive Transcranial Magnetic Stimulation|Active TMS will be at 90% motor threshold
45818794|NCT04777214|Device|Sham TMS|Sham TMS will be administered
45818795|NCT04749810|Drug|Elizaria®|Induction cycle: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 1200 mg (4 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 1200 mg every 14 days.
45818796|NCT00377078|Drug|recombinant human lactoferrin|
45818797|NCT04495712|Drug|spironolactone|aldosterone blocker
45818798|NCT04495712|Drug|placebo|identical in appearance to spironolactone study drug
45455144|NCT03524950|Drug|Dexmedetomidine|Ninety patients will be assigned to three groups. Group A add saline in general anesthesia laparoscopic hysteromyoma surgery. Group B add dexmedetomidine 1μg/Kg10minutes as loading dose, followed by 0.7μg/Kg/h for maintenance.Group C add dexmedetomidine 0.7μg/Kg10minutes as loading dose, followed by 0.5μg/Kg/h for maintenance.
45455145|NCT03936673|Procedure|Percutaneous nephrostomy|
45455146|NCT04714190|Drug|RC48-ADC|2.5 mg/kg IV every 2 weeks
45455147|NCT04714190|Drug|Paclitaxel injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
45455148|NCT04714190|Drug|Irinotecan Hydrochloride Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
45959250|NCT02935504|Behavioral|PRogram In Support of Moms (PRISM)|"PRISM Intervention Provider and staff training Webinar Delivered in person Engage providers - Registered Nurses (RN) and Patient Care Assistants (PCA) and ensure they attend:~Toolkit Care coordination Psychiatric consultation Implementation support~Engage clinic leaders and staff~Identify leadership group and prepare for change~Assess readiness to implement PRISM~Identify steps to achieve goals~Implement PRISM components into the clinic~Support, encourage and sustain change Office prompts Screening procedures Plus all MCPAP for Moms intervention"
45818799|NCT04474496|Other|Assessing the impact of COVID-19|Surveying Marshallese adults in the U.S. to determine the impact of COVID-19
45818800|NCT03552536|Drug|MK-8583|A single oral dose of MK-8583 in capsule form
45818801|NCT03553940|Biological|Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine|Live monovalent influenza A/H3N2-based M2SR (M2 defective Single Replication vaccine), comprised of 5 out of 8 gene segments on the donor virus influenza A/Puerto Rica/8/34. HA and NA derive from an A/Brisbane/10/2007-like virus. Administered intranasally as s single dose.
45818802|NCT03553940|Other|Placebo|H3N2 M2SR vaccine placebo (normal saline). Administered intranasally as a single dose.
45818803|NCT03553940|Biological|Quadrivalent MDCK Inactivated Influenza Vaccine|A quadrivalent cell culture inactivated vaccine (ccIV4) is an inactivated subunit influenza vaccine prepared from virus propagated in Madin Darby Canine Kidney (MDCK) cells indicated for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. Administered intramuscularly as a single dose.
45818804|NCT03557372|Radiation|Mathematical Model-Adapted Radiation Fractionation Schedule|"Re-irradiation with 35 Gy delivered over 2 weeks, based upon reference dosing of 35 Gy in 10 Fractions over 2 weeks~Radiation therapy is delivered on Monday-Friday during standard clinic hours in our department. Each treatment may take 20-40 minutes.~Treatment will be once daily for the first 7 days of treatment and then three-times daily for the last three days of treatment."
45455149|NCT04714190|Drug|Apatinib Mesylate Tablets|Administered according to label, as one option for Physician's Choice (determined before randomization)
45455150|NCT03524872|Device|Original CAD/CAM prosthetic abutment|Original (Sweden&Martina) CAD/CAM abutments will be screwed to the implants at 32N/cm.
45818805|NCT04448210|Behavioral|DigiKnowIt News: Teen|Teens will interact with a multimedia educational website that will teach them about pediatric clinical trials including topics such as participant rights and safety, benefits and costs to participating in a study, and different types of procedures used in trials.
45818806|NCT03640832|Other|Developmental Serum|A 30millilitre (mL) bottle with a piston pump will be dispensed to the participants, to be used as a topical dermal (facial) application, twice daily as per normal home use.
45818807|NCT03640832|Other|Physiogel Calming Relief Anti-Redness Serum|A 30mL bottle with a piston pump will be dispensed to the participants, to be used as a topical dermal (facial) application, twice daily as per normal home use.
45818808|NCT04458818|Procedure|Prolene Mesh Vocal Cord Medialization Implant|The surgery will be performed under local anesthesia (lignocaine with adrenaline 2%) and procedural sedation with propofol 25-100mcg/kg/min (only sedative dose) will be administered, so that the patient remains vocally responsive during the procedure. Incision will be made at the lower border of thyroid cartilage under aseptic measures. Skin flaps will be raised in sub-platysmal plane, strap muscles will be separated in the midline to expose the laryngeal cartilaginous framework. A simple laryngeal window approach will be used to place the Ethicon prolene mesh 6 x 6cm Swiss roll, secured with prolene 2/0 suture trimmed to the required size. Post op voice analysis will be done on 7th day and 14th post-operative day. Monthly follow up will be advised after that.
45818809|NCT04456634|Drug|20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)|Rux administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).
45959251|NCT02935504|Behavioral|MCPAP for Moms|MCPAP for Moms Provider and staff training Delivered via web RN and PCA admin staff recommended to attend 30-60 minute presentation on perinatal depression Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns Access to one-time face-face evaluation with patient by a MCPAP for Moms psychiatrist for assessment and treatment recommendations for Ob/Gyn provider Access to Provider Toolkit which includes assessment and treatment protocols (available at www.mcpapformoms.org) Resource provision/referrals
45959252|NCT02935582|Drug|Enstilar® aerosol foam|Treatment according to local labelling
45455151|NCT03524872|Device|Compatible CAD/CAM abutment|Compatible (New Ancorvis) CAD/CAM abutments will be screwed to the implants at 32N/cm.
45664495|NCT05383001|Drug|combination regimen tremelimumab /durvalumab|"Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel, nab-paclitaxel, vinorelbine or gemcitabine~Combination treatment:~Durvalumab 1500 mg fixed dose plus tremelimumab 300 mg fixed bolus dose~Maintenance Therapy:~Durvalumab 1500 mg fixed dose Q4W up to 12 cycles within the study"
45818810|NCT04456634|Other|20 mg/120 mg artemether-lumefantrine (AL) + Placebo|Placebo administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).
45455152|NCT03524872|Procedure|Local anesthesia|Infiltration of 4% articaine with 1:100,000 adrenalin (Inibsa).
45818811|NCT04454138|Device|XEN-45 gelatin microstent|Placement either in the subconjunctival space or supratenon's area
45664496|NCT05383001|Drug|platinum-based chemotherapy (SoC)|"Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel, nab-paclitaxel, vinorelbine or gemcitabine~Combination treatment:~Continuation of second-line chemotherapy with 2-4 further cycles (Q3W) platinum-based combination therapy.~Maintenance Therapy:~Optional continued maintenance therapy with pemetrexed according to marketing authorization will be allowed for a maximum of 13 cycles."
45664497|NCT05381753|Drug|Avapritinib|Avapritinib will be administered orally at the starting of 300 mg once daily as the label recommended. Investigators can adjust the dosage, frequency, and duration as needed.
45664498|NCT05381753|Drug|Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )|Investigators will decide which TKI to use as well as the dosage, frequency, and duration.
45818812|NCT04431908|Device|olfactory device|A quantitative non-biased olfactory device intended for the rapid identification of SARS-CoV-2 infected subjects (as identified by PCR).
45818813|NCT00377624|Drug|sodium hyaluronate|
45818814|NCT03558074|Drug|ALK4290|ALK4290 400 mg tablet twice a day
45818815|NCT03558230|Behavioral|Standardized Constraint-Induced Movement Therapy|The standardized Constraint-Induced Movement Therapy aims to improve the child's weak upper extremity through intensive frequent and repetitive movements. The therapy duration is 6 hours/day for 5 consecutive days.
45818816|NCT03558230|Behavioral|Vibration|Vibration applied to the wrist.
45818817|NCT03558230|Behavioral|Placebo (for vibration)|No vibration applied to the wrist.
45818818|NCT03560102|Device|Philips Sonalleve® MR-HIFU Breast Therapy System|The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.
45818819|NCT03562988|Dietary Supplement|Vitamin C gummy|vitamin C
45818820|NCT03562988|Dietary Supplement|Vitamin C tablet|vitamin C
45818821|NCT03644108|Drug|Mucinex® ER 600 mg|Single dose of Mucinex® 600 mg ER Bi-Layer tablet
45818822|NCT04713956|Drug|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
45818823|NCT04713956|Drug|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
45818824|NCT04713956|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
45818825|NCT04713956|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
45818826|NCT04713956|Drug|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
45818827|NCT03565874|Device|Heart rate variability biofeedback|Before the start of the program and after one week of adherence to the program, two sessions will be conducted with a psychologist in order to define each participant's individual resonance frequency (i.e., breathing rhythm allowing for cardiac coherence), using the Nexus program from Mindmedia company. Then, each participant will receive training on the HRVB program using an Emwave device. The HRVB program itself will be carried individually for 20 min daily over the course of two weeks. Five daily sessions of 10 minutes will be considered as the minimum adherence to the program. Each participant will be asked to report in a diary all eventual major stressful life events.
45818828|NCT03569618|Device|Tablet-based Game|Tablet-based game aimed at improving processing speed and attention.
45818829|NCT04425746|Drug|Afamelanotide|
46079352|NCT05567731|Drug|long GnRHa|In the long protocol, daily subcutaneuous injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium < 5 mm and low estradiol (E2) < 50 and Luteinizing Hormone < 5IU/l with either HMG(Menogon; Ferring, Switzerland) or rFSH (Gonal-f; Merck Serono, Germany) in a starting dose of 150-300 IU/day according to women age, day 3 Follicle-Stimulating Hormone, Anti-Müllerian Hormone and previous gonadotropin response then adjustment of the dose according to ovarian response monitored by serum estradiol (E2) and ultrasound evaluation.
46079353|NCT05565846|Combination Product|NTX-001|One-time use surgical product of three solutions and a device
45818830|NCT04425746|Drug|Placebo|
45818831|NCT04402970|Drug|Dornase Alfa Inhalation Solution|Nebulized dornase alfa
45818832|NCT04392362|Drug|Adenosine|A vial of adenosine with 6mg
45818833|NCT04734782|Diagnostic Test|Determination of antibodies in maternal serum IgG for respiratory syncytial virus|By venipuncture, a blood sample will be taken and the levels of anti-RSV IgG antibodies will be processed in serum by commercial techniques.
45818834|NCT04714034|Diagnostic Test|"to develop and validate a scale measuring online dating addiction (ODA) in sexual minorities - the ODA Scale"|"Qualitative part: scale development and validation with testing in 3 different participant samples, i.e. preliminary testing (n=10), pilot testing (n=30-60), validation (n=300).~Quantitative part: longitudinal part conducted in the validation sample of the qualitative study part (n=300) with the aim to evaluate the association of ODA Scale scores with sexual health and mental health outcomes."
45818835|NCT04390022|Drug|Ivermectin|Single dose of STROMECTOL® tablets at 400mcg/kg
45818836|NCT04390022|Drug|Placebo|Placebo tablets will not match ivermectin but they will be administered by staff not involved in the clinical care.
45818837|NCT04370834|Biological|Tocilizumab|Given IV
45818838|NCT03570476|Drug|Olaparib|Given orally
45818839|NCT03570476|Procedure|Radical Prostatectomy|Undergo surgery
45818840|NCT03571724|Other|Non-Menthol Very Low Nicotine Cigarettes|King size non-menthol cigarettes containing 0.4mg nicotine /g tobacco
45959253|NCT02935582|Drug|Other topical|Treatment according to local practise
45959254|NCT00406172|Drug|Bevacizumab|
45664499|NCT05381675|Other|Tele-rehabillitation|"Tele-rehabilitation program will be performed by physiotherapist two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises"
45664500|NCT05381675|Other|Prescribed Exercise Program|"The prescribed exercise program will be performed two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises"
45664501|NCT02527421|Drug|DFD01 Spray|DFD-01 (betamethasone dipropionate) Spray, 0.05%
45664502|NCT02163915|Drug|TAK-137|TAK-137 tablets
45664503|NCT02163915|Drug|TAK-137 Placebo|TAK-137 placebo-matching tablets
45664504|NCT05610371|Drug|Lidocaine|The study group underwent hysteroscopy using saline to which 10ml of 2% lidocaine was added to the first 1000 ml. This dose of lidocaine was calculated to allow maximal benefits with minimal potential complications. The maximal dose of lidocaine is 5mg\kg in adults which translates to 200mg in a 40kg patient. We have set 200 mg as the maximal dose of lidocaine in our study, assuring the dosage is safe. The rest of the procedure following the first 1000ml of saline was completed using saline alone as needed.
45664505|NCT05610371|Drug|Saline|The control group underwent hysteroscopy using a saline distension medium.
45664506|NCT02163759|Drug|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6, and 8.
45664507|NCT02163759|Other|Adalimumab Placebo|Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
45664508|NCT02163759|Drug|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 [Day 1], 4, 8, and 12 [clinical remitters only]).
45664509|NCT02163759|Other|Etrolizumab Placebo|Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 [Day 1], 4, 8, and 12 [clinical remitters only]).
45664510|NCT02371369|Drug|Pexidartinib|Each capsule contains 200 mg of pexidartinib for oral administration
45664511|NCT02371369|Drug|Placebo|Placebo capsule matching pexidartinib capsule for oral administration
45664512|NCT04883827|Other|Blood collection|20-40 mL of blood to extract cell free DNA
45664513|NCT04883827|Other|Urine collection|up to 15 mL of urine to extract cell free DNA
45664514|NCT04883671|Other|Standard of Care|Participants will be randomly assigned and receive standard of care as determined by their physician and may include: palliative radiation and/or a systemic therapy (like chemotherapy, immunotherapy, or targeted therapies).
45664515|NCT04883671|Radiation|SBRT|SBRT to 1-5 sites of metastatic disease over the course of 1-8 business days to each area of cancer
45818841|NCT03571724|Other|Menthol Very Low Nicotine Cigarettes|King size menthol cigarettes containing 0.4mg nicotine /g tobacco
45818842|NCT03571724|Other|Subject's UB non-mentholated filtered cigarettes|King size non-menthol cigarettes
45818843|NCT03571724|Other|Subject's UB mentholated filtered cigarettes|King size menthol cigarettes
45959255|NCT02935660|Device|enLighten Laser|Laser tattoo removal treatment
45455153|NCT03524872|Drug|Painkillers|Patients will be prescribed ibuprofen 600 mg three times per day for five days
45664516|NCT02187783|Drug|LEE011|Study drug was provided in 200 mg and 50 mg hard gelatin capsules to be taken orally
45664517|NCT02337361|Behavioral|Electronic SBI|"Bilingual (English and Spanish) e-SBI with four key components:~1) Beverage-specific drink size assessment; 2) Individualized feedback on the woman's drink sizes and on discrepancies between her drink size and the standard size for each beverage; 3) A personalized plan for reducing consumption which includes goal setting; and 4) an analysis of high risk situations for drinking alcohol, and suggested coping strategies."
45664518|NCT02336737|Device|SiennaXP|Sub-cutaneous injection of SiennaXP magnetic marker, followed by lymph node localization using the SentiMag handheld magnetic probe
45664519|NCT02336737|Drug|Technetium Tc99m Sulfur Colloid|Injection of a single dose of radioisotope (Technetium Tc99m Sulfur Colloid)
45664520|NCT02336737|Drug|Isosulfan blue dye|Injection of a single dose of isosulfan blue dye
45664521|NCT04897711|Behavioral|Perceptual Training|Each listener is familiarized/trained with a single speaker with dysarthria. Pretest/posttest transcription data will be used to build explanatory models of intelligibility improvement.
45818844|NCT03572972|Drug|Apixaban|Treatment for NVAF patients
45818845|NCT03572972|Drug|Dabigatran|Treatment for NVAF patients
45818846|NCT03572972|Drug|Rivaroxaban|Treatment for NVAF patients
45818847|NCT03572972|Drug|warfarin|Treatment for NVAF patients
45818848|NCT03572972|Drug|Antiplatelets|Treatment for NVAF patients
45818849|NCT05314790|Other|intervening Educational Program|The implementation of an EP is based on meetings within the Department, coordinated by an outside tutor (outreach visit model). The EP content was defined beforehand by a Scientific Board, on the basis of evidence-based guidelines (EBGs) and an up-to-date literature review, but also with a specific focus on any departures from standard clinical practice recommendations (CPRs) identified at each IM department in phase 1;
45959256|NCT02935465|Behavioral|Mindfulness-Oriented Recovery Enhancement (MORE)|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
45959257|NCT02935465|Behavioral|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
46079354|NCT05565638|Behavioral|Prolonged Fasting Intervention|promote a 14-hour fast during the nighttime hours
45959258|NCT02935621|Behavioral|Mindfulness-Oriented Recovery Enhancement (MORE)|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
45959259|NCT02935621|Behavioral|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
45959260|NCT02935426|Device|n-butyl cyanoacrylate and 2-octyl cyanoacrylate|used in cyanoacrylate group
45959261|NCT02935426|Device|5-0 Polytetrafluoroethylene (PTFE) suture|used in suture group
45959262|NCT00152945|Drug|Intravenous Intralipid|intravenous infusion
45664522|NCT02130765|Device|Cardiac catheter ablation with ICD/CRT-D|Cardiac ablation catheter system
45664523|NCT02305381|Drug|semaglutide|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
45664524|NCT02305381|Drug|placebo|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
45664525|NCT02336425|Drug|QGE031|QGE031 120 mg per 1 mL liquid in vial
45664526|NCT02336425|Drug|Placebo|Placebo to QGE031 0 mg per 1 mL liquid in vial
45818850|NCT04352660|Drug|Mitomycin-C injection|MMC delivered by preoperative subconjunctival injection
45959263|NCT00152945|Drug|Intravenous leucine, glycerol|intravenous infusion
45959264|NCT02935153|Biological|Anti-CD22-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD22-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
45959265|NCT02935114|Drug|37% Carbamide Peroxide|"no Gingival dam protection (as manufacturer´s instruction)~37% Carbamide Peroxide application (2 sessions of 45 minutes)~Tooth sensitivity (Verbal and visual scale) and color evaluation"
45959266|NCT02935114|Drug|35% hydrogen Peroxide|"Gingival dam protection (as manufacturer´s instruction)~35% Hydrogen Peroxide application (2 sessions of 45 minutes)~Tooth sensitivity (Verbal and visual scale) and color evaluation"
45959267|NCT02935231|Drug|Nicotine Replacement Therapy (NRT)|1-week free NRT (gum/patch) plus a card containing instruction and potential side effects.
45455154|NCT03524872|Drug|Mouthwashes|Patients will be prescribed mouth-rinse with chlorhexidine 0.12% twice daily starting 3 days prior to surgery and for 2 weeks afterward
45455155|NCT03524872|Device|Implant placement|Dental implants (Sweden & Martina, Padua, Italy) will be placed at crestal level and according to the manufacturer's instructions.
45458494|NCT04461808|Diagnostic Test|tomosynthesis + synthetic 2D|"Women will be screened for one round with tomosynthesis + synthetic 2D, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
45664527|NCT02163447|Drug|Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
45664528|NCT02163447|Drug|3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
45664529|NCT02163447|Drug|3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy|
45664530|NCT02163447|Drug|Monthly dihydroartemisinin-piperaquine (DP) for infants|
45664531|NCT02163447|Drug|3-monthly dihydroartemisinin-piperaquine (DP) for infants|
45818851|NCT04352660|Drug|Mitomycin-C sponge|MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
45818852|NCT03650192|Device|INVSENSOR00027|Investigational, noninvasive sensor that will be placed on the subject's chest and/or back. INVSENSOR00027 measures signals regarding subject's movement and posture, heart rate, and respiratory rate.
45818853|NCT04342130|Drug|Morphine|30 mg oral tablet
45818854|NCT04338074|Drug|Tranexamic acid tablets|Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos
45818855|NCT04338074|Drug|Placebo oral tablet|2 tablets p.o. three times per day x 5 days
45959268|NCT02935231|Behavioral|Minimal Cessation Advice (MCA)|Brief smoking cessation advice using AWARD model. AWARD: (1) Ask smoking habit; (2) Warn about smoking risk; (3) Advice to quit as soon as possible; (4) Refer to smoking cessation service; and (5) Do-it-again: if relapse/fail.
45959269|NCT02935231|Other|Health warning leaflet|An A4 double-side color leaflet containing shocking pictures of diseases associated with smoking.
45959270|NCT00172380|Drug|Docetaxel Plus CDDP|docetaxel 36mg/m2 and cisplatin 75mg/m2
45959271|NCT02935348|Radiation|Whole Body MRI|Routine whole body clinical MRI will be performed according to current clinical standard of care. Axial and coronal imaging from the maxilla to proximal femurs will be performed using a combination of T1 and T2 weighted sequences, with and without gadolinium administration.
45959272|NCT00152984|Drug|Tiotropium inhalation capsules|
45959273|NCT00152984|Drug|Placebo inhalation capsules|
45959274|NCT02935387|Other|Taper|Taper
45959275|NCT02935075|Drug|Tenofovir disoproxil fumarate|Oral daily
45959276|NCT02935075|Drug|Lamivudine|Oral daily
45959277|NCT02935075|Drug|Efavirenz|Oral daily
45959278|NCT02934919|Drug|Nalmefene|30 patients with ICDs, will be treated with 18 mg per day of nalmefene during 3 months
45959279|NCT00172419|Drug|Atorvastatin|Atorvastatin, 40 mg/day for 12 weeks
45664532|NCT02370667|Other|Biomechanical Exercise (BE)|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
45664533|NCT02370667|Other|Traditional Exercise (TE)|A traditional exercise program for people with knee OA will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
45664534|NCT02370667|Other|Meditation Control (M)|A meditation program acting as a control will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
45818856|NCT03964220|Drug|Tiotropium Respimat®|Tiotropium Respimat® 1.25 mcg (on top of baseline Inhaled Corticosteroid/Long-acting beta-agonist )
45818857|NCT03964220|Drug|Inhaled Corticosteroid/Long-acting beta-agonist|baseline low dose to medium/high dose, baseline medium dose ICS/LABA to high dose ICS/LABA, additional prescription/refill of high-dose-ICS/LABA following the first prescription of baseline high dose ICS/LABA
45818858|NCT04337138|Drug|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin (Mylotarg) administered in any form or combination
45818859|NCT03657134|Diagnostic Test|CoVa-2 Monitoring System|Upon completion of EP procedure, CoVa-2 monitoring system will be applied until discharge. Data from the sensor will be sent to the Gateway and Cloud-based system and analyzed retrospectively.
45818860|NCT04332614|Behavioral|Less-is-better|Email
45818861|NCT04332614|Behavioral|Social proof|Email
45818862|NCT04332614|Behavioral|Endowment / decision staging|Email
45818863|NCT04332614|Behavioral|Standard email|Email
45818864|NCT04332757|Other|Training intervention.|The investigators have designed a phased 18-week physical development programme to train both rehabilitative and performance enhancement elements of physical preparation. The rehabilitation element of the programme will specifically target pelvic floor function and core strength and stability (known collectively as Core Reconnection training) from weeks 6 to 24 postpartum, and the training element of the programme will contain resistance and high-intensity interval training (HIIT) from weeks 12 to 24 postpartum.
45818865|NCT00422773|Drug|Cetuximab|Dose level Infusion time (h) Dose level unit 1 2 3 4 Cetuximab 2.0 mg/m² 500 500 500 500 Irinotecan, before oxaliplatin 1.0 mg/m² 95 125 165 180 Oxaliplatin, with folinic acid 2.0 mg/m² 85 85 85 85 Folinic acid, with folinic acid 2.0 mg/m² 400 400 400 400 5-FU Infusion 46.0 mg/m² 3200 3200 3200 3200
45818866|NCT04326842|Procedure|Carotid artery revascularization procedure|The patients with carotid artery stenosis will be examined before and after finishing the carotid artery revascularization procedure.
45818867|NCT04326842|Device|Optical coherence tomography angiography|Examination will be performed using optical coherence tomography angiography. This device allows quantitative analysis, since it provides numerical data about flow area and flow density maps.
45818868|NCT03329209|Drug|Vedolizumab|Vedolizumab intravenous infusion.
45818869|NCT03661346|Drug|Labetalol|"Aliquots of 20mg of Labetol~• Maximum Dose - 300mg total for case"
45818870|NCT03661346|Drug|Esmolol|"Infusion - 0.1mg/kg/min~• Maximum Dose - after 30 minutes, 0.3mg/kg/min"
45818871|NCT03329911|Drug|EU Avastin®|100 mg/4 mL
45818872|NCT03329911|Drug|BAT1706|100 mg/4 mL
45818873|NCT03329911|Drug|Paclitaxel|200 mg/m²
45959280|NCT02934880|Other|immediate APA program|10 sessions of one hour APA in 5 weeks after patient randomization. 2 sessions per week will be organized
45818874|NCT03329911|Drug|carboplatin|target area under the curve [AUC] 6 mg/mL•minute
45818875|NCT04322396|Drug|Azithromycin|Azithromycin
45959281|NCT02934880|Other|delayed APA program|10 sessions of one hour APA in 5 weeks 3 months after patient randomization. 2 sessions per week will be organized
45818876|NCT04322396|Drug|Hydroxychloroquine|Hydroxychloroquine
45818877|NCT04322396|Drug|Placebo oral tablet|Placebo Azithromycin
45818878|NCT04322396|Drug|Placebo oral tablet|Placebo Hydroxychloroquine
45818879|NCT03330457|Biological|Andexanet alfa (bolus)|fXa inhibitor antidote
45818880|NCT03330457|Drug|Betrixaban 80 mg PO QD|fXa inhibitor
45818881|NCT03330457|Biological|Andexanet alfa (infusion IV)|fXa inhibitor antidote
45818882|NCT03222037|Device|senofilcon A|Acuvue Oasys 1-Day
45818883|NCT03222037|Device|Control|Trial Frame with best spherocylindrical refraction (SCR)
45818884|NCT03961100|Drug|Entrectinib 600 mg (T1)|Test formulation 1 (T1): Multi-particulate formulation 1: entrectinib film-coated mini-tablets
45818885|NCT03961100|Drug|Entrectinib 600 mg (T2)|Test formulation 2 (T2): Multi-particulate formulation 2: entrectinib film-coated mini-tablets
45818886|NCT03961100|Drug|Entrectinib 200 mg (R)|Reference formulation (R): entrectinib hard capsules
45959282|NCT02934802|Device|Total Knee prothesis e motion PS Pro|
45959283|NCT00153023|Drug|Telmisartan|
45818887|NCT03961100|Drug|Entrectinib 200 mg (T)|Test formulation (T): entrectinib HPMC capsules
45818888|NCT03222427|Drug|LY3314814|Administered orally
45818889|NCT03222427|Drug|[13C415N3] LY3314814|Administered as an IV infusion
45818890|NCT03442699|Behavioral|Cognitive Behavioral Therapy|Up to 10 daily sessions of brief cognitive behavioral therapy for suicidal inpatients for about an hour each day.
45818891|NCT03954158|Drug|Crisaborole ointment 2%|BID regimen
45818892|NCT03954158|Drug|Vehicle|BID regimen
45818893|NCT03954158|Drug|Crisaborole ointment 2%|QD regimen
45818894|NCT03954158|Drug|Vehicle|QD regimen
45818895|NCT03222505|Device|Honda Stride Assist Device ON|Subjects performed assessments of walking and motor performance while wearing the Honda Stride Assist Device.
45818896|NCT03222505|Other|No Device Worn|Subjects performed assessments of walking and motor performance without wearing the Honda Assist Device.
45818897|NCT03224299|Drug|OCT - clear|Investigational Product #1: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear
45818898|NCT03224299|Drug|OCT- tinted|Investigational product #2: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted
45959284|NCT00153023|Drug|Valsartan|
45959285|NCT00152672|Device|nCPAP vs oral appliance|
45818899|NCT03224299|Other|ChloraPrep|Active Control: ChloraPrep® - Hi-Lite Orange® applicator
45818900|NCT03224299|Other|Saline|Negative Control: sterile 0.9% saline applied with single use applicator
45959286|NCT00165126|Procedure|Radiation therapy|Given as standard therapy
45959287|NCT02934958|Behavioral|Colon Cancer Screening Navigation|Patients with FIT Positive results that have been given the choice will be followed and navigated from referral to colonoscopy to assist in obtaining colonoscopy.
45664535|NCT02130297|Device|Laser Treatment|The subject will receive ablative fractional resurfacing with the Deep and Active FXTM platforms of the Lumenis Ultrapulse CO2 laser. The settings for treatment of scars on the face with the Deep platform will be 15% coverage, 15mJ at 150 Hz and 15% coverage, 12.5 mJ at 150 Hz for off the face. The Active platform settings will be 90 mJ with a density of 3 for the face and 70 mJ and a density of 2 for off the face. The DeepFXTM platform will be applied to the scar prior to the ActiveFX TM platform. Half of the excision scar will be treated with the appropriate settings and half will go untreated.
45664536|NCT01931956|Device|MitraClip® implant|Percutaneous mitral valve repair using MitraClip implant
45664537|NCT01887418|Drug|QuickShot™ - 50 mg Treatment B|QuickShot™ for the delivery of testosterone
45664538|NCT01887418|Drug|QuickShot™ - 100 mg Treatment A|QuickShot™ for the delivery of testosterone
45664539|NCT01887418|Drug|Delatestryl 200 mg IM Treatment C|Standard of care
45664540|NCT01886716|Behavioral|Anxiety Attention Training|Anxiety Attention Training will preferentially direct participants' attention away from reminders of anxiety.
45664541|NCT01886716|Behavioral|Alcohol Attention Training|Alcohol Attention Training will preferentially direct participants' attention away from reminders of alcohol.
45818901|NCT03333577|Device|SoundArc|non-surgical attachment method for wearing a bone conduction hearing system
45818902|NCT03334825|Other|Enhanced housing placement assistance|assistance in the rapid (fast-track) acquisition of permanent housing; and participation in a 12-month support services program designed to prevent PLWHA from relapsing into homelessness, with services focused on increasing clients' capacity to live independently and maintain housing stability
45818903|NCT03334825|Other|Standard housing placement assistance|standard connections to services and housing programs offered by HASA, HOPWA, or Ryan White
45818904|NCT03442933|Other|3 hours Road Cycling Time Trial|The road itinerary is a mixed route profile of 90 km, an elevation gain of 900 m, with mixed sections, flat, uphill and down over roads with little traffic.
45818905|NCT03442933|Other|3 hours Mountain Biking Time Trial|The mountain itinerary, is a mixed route of 55 km, an elevation gain of 600 m, with sections of wide tracks and trails, flat, uphill and down, with a medium technical difficulty.
45818906|NCT03444961|Device|CAREN system training|CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.
45818907|NCT03661814|Device|Prevena|The NPWT device is a wound dressing with a vacuum system that can be placed over abdominal wounds, placed in the immediate postoperative period over abdominal wounds after clean/contaminated colorectal surgical procedures.
45818908|NCT03335761|Device|InterStim Therapy|Device Programming
45959288|NCT02934958|Behavioral|Standard of Care|Patients will be tracked to compare how effective are usual care methods
45959289|NCT02934997|Other|Observational study|
45959290|NCT00165204|Drug|Tibolone|
45959291|NCT02934763|Drug|Propranolol|propranolol iv by target controlled infusion, to achieve specific plasmatic concentration goals
45959292|NCT02934763|Drug|Saline|Saline as placebo
45959293|NCT04689958|Drug|Standard therapy|Gabapentin, pregabalin, or amitriptyline
45959294|NCT04689958|Drug|Vitamin D 5,000IU Oral Tablet|Vitamin D 5000 IU oral tablet once daily
45959295|NCT02934841|Drug|Conbercept|
45959296|NCT02934841|Drug|sham|
45959297|NCT00153140|Drug|polyethyleneglycol3350|
45959298|NCT02934724|Procedure|Self sample from vagina|Self sample using The Rover's Evalyn Brush
45664542|NCT01886716|Behavioral|Control Training|Placebo Anxiety Training and Placebo Alcohol Training will not preferentially direct participants' attention away from reminders of anxiety or alcohol.
45959299|NCT02934724|Procedure|Self sample from the oral cavity|Self sample using COPAN FloqSwab
45818909|NCT03662282|Drug|Omegaven|Omegaven® fat emulsion will be used as a compassionate use treatment for critically ill infants with parenteral nutrition associated liver injury
45959300|NCT02934724|Other|Questionnaire|Questionnaire about vaccination status and sexual behaviour
45818910|NCT03336853|Device|HybenX|"The material was introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement up to the working length.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length.~A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria."
45959301|NCT04684420|Drug|Glucophage® XR Test|Participants will receive a single oral dose of 500 mg of test Glucophage® XR tablet under fasting or fed conditions.
45959302|NCT04684420|Drug|Glucophage® XR Reference|Participants will receive a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.
45959303|NCT00165243|Procedure|Tangential radiation|Radiation given over 6 1/2 weeks
45959304|NCT02934412|Drug|SHR-1314|Single subcutaneous injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
45959305|NCT02934412|Drug|placebo|Single subcutaneous injection of placebo at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
45959306|NCT02934607|Drug|Symbicort pMDI with spacer device|Relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with a spacer device (test)
45959307|NCT02934607|Drug|Symbicort pMDI without spacer device|Relative bioavailability of budesonide and formoterol delivered via Symbicort pMDI without a spacer device (reference)
45959308|NCT02934685|Radiation|hypofraction|70 Gy in 28 fractions over 5.6 weeks
45455156|NCT01121029|Procedure|Autologous hematopoietic stem cell transplantation|Patients will receive a stimulation with filgrastim 10mcg/Kg per day during 4 days and cyclophosphamide 1.5g/m2 per day during 2 days and mesna 300mg/m2 i.v. in 4 hours for prophylaxis (uroprotection). Lately, the stem cells will be recollected by apheresis. After that, the patients will receive a conditioning regimen with cyclophosphamide 500mg/m2 per day during 4 days and fludarabine 30mg/m2 per day during 4 days. After the last dose of cyclophosphamide, the autologous hematopoietic stem cell transplantation will be done on day 0, by peripheral vein. Then, a standard regimen of prophylaxis with oral ciprofloxacin 500mg every 12 hours, acyclovir 400mg every 8 hours, fluconazole 100mg per day and omeprazole 20mg per day for the recovery time of each patient.
45455157|NCT04143724|Drug|ACE-536|Up to 6 participants will start with luspatercept at 0.75mg/kg and the Dose Review Team (DRT) will evaluate all toxicities of each participant after Cycle 1 and determine whether or not to enroll the next cohort at the next planned dose level
45455158|NCT04143724|Drug|ACE-536|Up to 6 participants will start with luspatercept at 1.0mg/kg and the Dose review team (DRT) will evaluate all toxicities of each participant after Cycle 1 and determine whether or not to enroll the next cohort (Expansion Cohort)
45664543|NCT01912612|Drug|Duloxetine|Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then 30 mg duloxetine orally x 14 days.
45664544|NCT02370511|Device|Transcatheter Mitral Valve Replacement|Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.
45664545|NCT02303041|Drug|Buparlisib|Administered orally at starting dose of 80 mg/day
45664546|NCT02303041|Drug|Sonidegib|Administered orally at starting dose of 200 mg/day
45664547|NCT02302807|Drug|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
45959309|NCT02934685|Radiation|convention|80Gy in 40 fractions over 8 weeks
45959310|NCT00153257|Device|Ugytex|Anterior repair reinforced by a specially designed mesh: UgytexTM
45959311|NCT02934334|Other|Observational|
45959312|NCT02934490|Device|Mesh|Meshes were made by Gynemech TM PS, (Johnson & Johnson Shanghai Medical Equipment Co. SFDA registration No. 3460365, size 10 × 15cm)
45959313|NCT00165282|Behavioral|Mindfulness training|Taught mindfulness meditation by mindfulness instructor (trained health care professional/RN) and audio c/d
45959314|NCT00165282|Behavioral|Nurse education|Meets with oncology nurse to have questions answered about medical treatments and side effects
45959315|NCT02934646|Device|Robotic treatment|Passive/active elbow mobilizzation provided by NEUROExos Elbow Module Robotic device
45959316|NCT00153296|Drug|Carbamazepine|
45959317|NCT02934373|Device|A New Sound Processor|
45959318|NCT02934139|Drug|Cavosonstat|CFTR modulator that stabilizes CFTR
45959319|NCT02934139|Other|Placebo|Matched placebo
46079355|NCT05565638|Behavioral|EDUCATION CONTROL|introductory session with a health coach and educational information will be provided. Participants will also receive one email and one text message per week with tips on healthy living
46079356|NCT05563857|Combination Product|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
45818911|NCT03336853|Other|Placebo control|"The root canal was irrigated with sterile saline water with a syringe and a side-vented 30G needle activated for 20 seconds with a sterile paper point with and up and down movement up to the working length to ensure a flow of irrigant solution throughout the canal.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length. A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria."
45818912|NCT03954626|Biological|brolucuzumab 6 mg IVT|Single intravitreal injection (IVT) of brolucizumab 6 mg
45818913|NCT04332835|Drug|Plasma|Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
45818914|NCT04332835|Drug|Standard Therapy|Standard therapy defined by institutional protocol.
45959320|NCT02934100|Device|Shock Master 300|"Extracorporeal Shock Wave Therapy~In all treatments (from 1 to 10) applied number of pulses is 4500 and the frequency is based on the patients feelings (from 8 to 12 Hz). Variable is the pressure:~Treatment 1 - 2,5 Bar; Treatment 2 - 2,6 Bar; Treatment 3 - 2,7 Bar; Treatment 4 - 2,8 Bar; Treatment 5 - 3,0 Bar; Treatment 6 - 3,2 Bar; Treatment 7 - 3,4 Bar; Treatment 8 - 3,6 Bar; Treatment 9 - 3,8 Bar; Treatment 10 - 4,0 Bar.~Each patient will also receive kinesiotherapy treatment that will consist of:~eight-minute massage of posterior lower leg muscles~plantar aponeurosis stretching"
45959321|NCT02934100|Device|Skanlab 25 BODYWAVE|"Electric field diathermy therapy - Capacitive energy transfer system (CETS)~Time of each treatment (from 1 to 15) is eight minutes. Variable is the energy:~Treatment 1 - 3; Treatment 2 - 3; Treatment 3 - 4; Treatment 4 - 4; Treatment 5 - 5; Treatment 6 - 5; Treatment 7 - 6; Treatment 8 - 6; Treatment 9 - 7; Treatment 10 - 7; Treatment 11 - 7; Treatment 12 - 7; Treatment 13 - 7; Treatment 14 - 7; Treatment 15 - 7.~Each patient will also receive kinesiotherapy treatment that will consist of:~eight-minute massage of posterior lower leg muscles~plantar aponeurosis stretching"
45455159|NCT04143724|Drug|ACE-536|Up to 30 participants will start with luspatercept (at the Recommended Dose (RD) determined by the Dose Review Team (DRT)). Overall safety data from all cohorts in part A (Cohorts 1, 2 & 3) will be assessed before Part B (Cohorts 4 & 5) can be initiated
45455160|NCT04143724|Drug|ACE-536|Up to 6 participants will start with luspatercept at 1.0mg/kg and the Dose Review Team (DRT) will evaluate all toxicities of each participant after Cycle 1 and determine whether or not to enroll the next cohort at the next planned dose level
45455161|NCT04143724|Drug|ACE-536|Up to 6 participants will start with luspatercept at 1.2 mg/kg and the Dose Review Team (DRT) will evaluate all toxicities of each participant after Cycle 1.
45818915|NCT03662360|Other|essential oils|Following a specific schema, the randomization will be perfomed. Patients enrolled in Group B will receive in environmental diffusion two essential oils, to define their possible effectiveness in the control of the psychological and behavioural disorders
45959322|NCT02934100|Device|EVO US13 CosmoGamma|"Ultrasound therapy~Doses applied as following:~Each treatment (from 1 to 15) is pulsed ultrasound (1MHz, pulsed 1:4). Variable is the time and intensity:~Treatment 1 - 4 minutes, 0,4 W/cm2; Treatment 2 - 5 minutes, 0,4 W/cm2; Treatment 3 - 5 minutes, 0,5 W/cm2; Treatment 4 - 6 minutes, 0,5 W/cm2; Treatment 5 - 6 minutes, 0,6 W/cm2; Treatment 6 - 6 minutes, 0,6 W/cm2; Treatment 7 - 6 minutes, 0,6 W/cm2; Treatment 8 - 6 minutes, 0,7 W/cm2; Treatment 9 - 7 minutes, 0,7 W/cm2; Treatment 10 - 7 minutes, 0,7 W/cm2; Treatment 11 - 7 minutes, 0,8 W/cm2; Treatment 12 - 8 minutes, 0,8 W/cm2; Treatment 13 - 8 minutes, 0,8 W/cm2; Treatment 14 - 8 minutes, 0,8 W/cm2; Treatment 15 - 8 minutes, 0,8 W/cm2.~Each patient will also receive kinesiotherapy treatment that will consist of:~eight-minute massage of posterior lower leg muscles~plantar aponeurosis stretching"
45818916|NCT03225001|Device|Edwards SAPIEN XT transcatheter valve, Model 9300TFX|Edwards SAPIEN XT THV system Model 9300TFX with the associated delivery systems.
45818917|NCT03225313|Drug|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|ultra sound guided injection into the rectus sheath
45818918|NCT03225313|Drug|Normal Saline Flush, 0.9% Injectable Solution_#5|injected into rectus sheath using ultrasound & locally surrounding the hernia
45818919|NCT03225313|Drug|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|locally surrounding the hernia
45818920|NCT03949244|Drug|Latanoprost 0.005%|Latanoprost 0.005% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
45959323|NCT02934100|Device|Sham LASER CTL1106MX|"Sham laser therapy Time of each treatment (from 1 to 15) is four to five minutes. Developed is 10 points, each point takes 15 seconds. Device is unplugged and it does not emit any radiation.The patient does not know that the procedure is not really executed.~Each patient will also receive kinesiotherapy treatment that will consist of:~eight-minute massage of posterior lower leg muscles~plantar aponeurosis stretching"
45959324|NCT00172536|Behavioral|Exercise training|Subjects attended a supervised treadmill training session three times per week in an outpatient facility for three months. Training duration was 30 minutes per session, including a 5-minute warm-up and cool-down phase. Training intensity was initially set at about 60% of HR reserve and close to the anerobic threshold (AT) and the gradually increased as tolerated.
45959325|NCT00172536|Other|Control|Subjects received general education including proper diet, regular physical activity or medical care if necessary through an interview with a physical therapist.
45664548|NCT02302807|Drug|Docetaxel|Docetaxel 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
45455162|NCT01345370|Drug|Temozolomide|According to sites procedures
45664549|NCT02302807|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
45818921|NCT03949244|Drug|Latanoprost bunod 0.024%|Latanoprost bunod 0.024% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
45455163|NCT01345370|Radiation|Radiation Therapy|According to sites procedures
45664550|NCT02302807|Drug|Vinflunine|Vinflunine 320 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
45664551|NCT04890301|Behavioral|CT guided biopsy for pulmonary nodule|"The technical process of the experimental group: ① design of puncture path, positioning and fixation of patients; ② puncture point positioning; ③ installation of navigation frame and template; ④ percutaneous lung biopsy guided by PT combined with CT.~The technical process of the active comparator group: ① planning puncture path, positioning and fixation of patients; ② positioning puncture point; ③ CT guided percutaneous lung biopsy.~The operation related information, complications and postoperative pathological results were collected."
45455164|NCT04111354|Device|Pacemaker implantation|Pacemaker implantation
45455165|NCT04702802|Device|Sodium hyaluronate 3%|During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.
45455166|NCT04702802|Device|Sodium hyaluronate 3%|During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.
45818922|NCT03949244|Drug|Normal saline 0.9%|Normal saline 0.9% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
45818923|NCT03949244|Diagnostic Test|Nailfold capillaroscopy|An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.
45818924|NCT03225859|Behavioral|Self-Management Program|This therapist-assisted self-management program will increase Veterans' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in trauma-focused therapy, and encourage engagement in meaningful activities. Patients will have four contacts with their providers over the ten weeks following trauma-focused therapy completion. The intervention will help patients: 1)self-monitor symptoms, 2) continue to practice skills learned in trauma-focused therapy, 3) acquire and apply additional coping skills, 4) engage in meaningful activities, and 5) set goals
45818925|NCT05313932|Other|Sleep deprivation|Participants wake after six hours so that they are deprived of 2 hours of sleep
45818926|NCT03948386|Drug|isobaric bupivacaine|The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
45818927|NCT03948386|Drug|hyperbaric bupivacaine|TThe anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
45959326|NCT02934295|Biological|Determination of Anti-Rubella Antibody, E1|
45455167|NCT04108702|Device|Virtual reality heart|"Patients will either sit or stand while wearing a head mounted display (HMD, Oculus Rift). A 360° video, showing a neutral body from the back in a neutral room, will be projected onto the HMD.~We will record the patients' ECG throughout the entire experiment. Raw data (ECG) are acquired with Arduino and in-house software will detect, in real time, the peak of each R-wave from the recorded ECG data and trigger an additional visual stimulus (e.g. a flashing outline surrounding the virtual body) that flashes on and off SYNCHRONOUSLY with respect to the participant's heartbeat. The silhouette surrounding the virtual body flashes for a duration of 100ms and with a sinusoidal opacity."
45664552|NCT04896151|Diagnostic Test|Minnesota Multiphasic Personality Inventory -2- Restructured Form - Experimental|The MMPI-2-RF-EX is a broadband, self-report measure of personality and psychopathology was developed for research purposes in order to develop the MMPI-3 (Ben-Porath & Tellegen, 2020), which is comprised of a subset of MMPI-2-RF-EX items.
45664553|NCT02335489|Device|Implantation with the commercially available Axium neurostimulator|
45664554|NCT02527343|Drug|volanesorsen|300 mg of volanesorsen administered subcutaneous (SC) injection, once-weekly (QW).
45818928|NCT03948386|Drug|isobaric mepivacaine|The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
45959327|NCT00153335|Behavioral|patient-provider interaction|
45959328|NCT02934022|Drug|Maraviroc|150 mg tablets, two or 4 tablets once daily (dependent upon concommitant medications)
45959329|NCT02934256|Drug|Icotinib|Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Total four treatment courses.
45818929|NCT03445195|Drug|Sulbactam-ETX2514|The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.
45818930|NCT03445195|Drug|Placebo|Matching 1g IV solution.
45818931|NCT03445195|Drug|Imipenem-cilastatin|All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.
45818932|NCT03943160|Device|Diamondback 360 Extended Length Orbital Atherectomy System|All patients undergoing peripheral vascular intervention (PVI) via transradial access (TRA) and for whom TRA has been successfully achieved and peripheral lesion deemed appropriate for treatment via TRA per physician discretion.
45818933|NCT04289714|Device|Novel Electronic Monitoring Device|Four Novel electronic Monitoring Devices were trialled
45818934|NCT04277936|Drug|Levetiracetam 500 mg|Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.
45818935|NCT03666026|Behavioral|1 MyChart R/R|Up to 1 flu vaccine reminder recall notice sent via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
45818936|NCT03666026|Behavioral|2 MyChart R/R|Up to 2 flu vaccine reminder recall notices sent every 3-4 weeks via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
45818937|NCT03666026|Behavioral|3 MyChart R/R|Up to 3 flu vaccine reminder recall notices sent every 3-4 weeks via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
45818938|NCT03936608|Device|Programming individualized RV-LV pacing offset to optimize ECG|After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. The RV-LV offset that optimizes the paced QRS morphology on ECG will be programmed.
45818939|NCT03936608|Device|Nominally programming CRT device without RV-LV offset|After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. Nominal standard-of-care CRT programming with no RV-LV offset will be programmed.
45818940|NCT03670160|Drug|Phenobarbital|Phenobarbital loading dose 20 mg/kg in 2 divided doses, then 5 mg/kg/day divided every 12 hours. Phenobarbital dose will be adjusted to obtain desired trough of 25 to 30 mcg/mL. Levels will be obtained on Day 6 then weekly thereafter. Phenobarbital will be tapered over 4 weeks upon discharge from the hospital. The standardized taper is based the patient specific dose at the time of discharge.
45818941|NCT03670160|Drug|Clonidine|Clonidine 5 mcg/kg/day divided every 3 hours. Clonidine will be increased by 1.5 mcg/kg/day to achieve control of NAS symptoms based upon standardized scoring for neonatal abstinence syndrome. Clonidine will be weaned by 25% every 24 hours after successful discontinuation of oral morphine sulfate. Infants will not be discharged on clonidine.
45818942|NCT03672032|Device|Fork-tip Needle|Fork-tip Needle will be used to obtain biopsy
45818943|NCT03672032|Device|Franseen Needle|Franseen Needle will be used to obtain biopsy
45818944|NCT03446053|Biological|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
45818945|NCT03446053|Other|INT200-Placebo|Formulation buffer except active ingredient for continuous intravenous infusion over 60 minutes
45818946|NCT00375895|Drug|ciclosporin|ciclosporin administered orally twice a day, at the initial dosing of 2.5 mg/kg/d, adjusted to obtain a C2 concentration of 600 ng/ml associated with the usual ribavirin and PEGinterferon bitherapy.
45818947|NCT05314322|Procedure|Deep brain stimulation with high frequency|Deep brain stimulation implanted at the patients' Substantia Nigra
45818948|NCT05314322|Procedure|Deep brain stimulation with low frequency|Deep brain stimulation implanted at the patients' Substantia Nigra
45818949|NCT03338803|Drug|Linagliptin|drug
45818950|NCT05314244|Procedure|Pylorus resecting pancreaticoduodenectomy|The patients in pylorus resection group will underwent pylorus resecting procedure during pancreaticoduodenectomy
45959330|NCT02933983|Other|no intervention, compare URT microbiome healthy control group-chronic rhinosinusitis patients|
45664555|NCT02527343|Drug|Placebo|Volanesorsen-matching placebo administered SC injection.
45818951|NCT03452371|Behavioral|Patient Navigation|Navigators will also screen participants for barriers to smoking cessation. Patient navigation intervention calls will use motivational interviewing (MI) strategies to: (1) Assess stage of change; (2) Assess and reinforce any prior abstinence from smoking and/or any efforts made to reduce/quit smoking; (3) Explore motivation to quit smoking, drawing on recent illness, financial/family situations as appropriate; advise about the risks of smoking and benefits of quitting (4) Discuss past experience with utilizing cessation support; (5) Explore potential barriers to using smoking cessation medications; (6) Brainstorm strategies to address identified barriers; (7) Elicit commitment to accept another patient navigation counseling call, discuss timing.
45959331|NCT04651543|Other|X-Ray|X-ray obtained at one-week of the fracture
45818952|NCT03452371|Behavioral|Enhanced Traditional Care|Enhanced traditional care will include a resource card with information on quitlines, Boston Medical Center's (BMC's) Tobacco Treatment Center Program number, and websites for smoking cessation.
45818953|NCT03906968|Device|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion
45818954|NCT05314634|Behavioral|concurrent exercise|Participants conduct warm up for 5-min, aerobic exercise for 12-min, resistance exercise for 13-min, and 5-min cool down.
45818955|NCT05314634|Behavioral|aerobic exercise|Participants conduct warm up for 5-min, resistance training for 25-min, and 5-min cool down.
45818956|NCT04206800|Diagnostic Test|Ejaculatory abstinence less than 24 hours|Males will have ejaculatory abstinence less than 24 hours before providing a semen sample the day of egg retrieval
45959332|NCT00153374|Behavioral|Women's health|
45959333|NCT02934061|Device|Tizaspray® administered intranasally|0,5 mg Tizaspray® administered intranasally
45959334|NCT02934061|Drug|Sirdalud® 2 mg tablets administered|Sirdalud® 2 mg tablets administered in patients with acute low back pain
45959335|NCT02934217|Drug|Injection of Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg
45959336|NCT02934217|Drug|Placebo|One single intravenous bolus injection of Placebo
45664556|NCT05342753|Device|Restylane Kysse|Hyaluronic Acid: Injectable gel for lip augmentation and the correction of upper perioral rhytids
45959337|NCT02934217|Procedure|Echocardiography|3 years after AMI
45664557|NCT05342519|Drug|Rapamycin|While rapamycin is not approved for the treatment of vitiligo, it has been found to be efficacious in stopping disease progression in animal models. Another recent study in humans showed that doses of 0.5cc daily of 0.001% of the topical formulation are able to achieve improvement in hypopigmented lesions of the skin at both the clinical and histological level. At this dose, improvement in cell function was observed regarding maintenance of proliferative potential and prevention of senescence, with avoidance of total inhibition of cell growth as has been seen at higher potencies used for immunosuppression.
45959338|NCT00153413|Behavioral|Women's health|
45959339|NCT00165360|Drug|Temozolomide|Given once daily for 49 days followed by 28 days with no drug for a maximum of a year and a half
45664558|NCT05342519|Drug|Rapamycin|Rapamycin is an immunosuppressant that works by inhibiting the mammalian target of rapamycin (mTOR) leading to inhibition of the cell cycle and antibody production. It has also been shown to promote expansion of Treg populations. Although studies evaluating alternative dosing for vitiligo are limited, topical rapamycin has previously been used to treat angiofibromas related to Tuberous Sclerosis, vascular malformations such as port-wine stains, and inflammatory lesions such as plaque psoriasis. In a 2019 meta-analysis, 38 out of 40 reports included used topical formulations of 1% or lower potency rapamycin; the majority of publications were focused on the treatment of Tuberous Sclerosis, where the median concentration of mTOR inhibition was 0.1% dosed twice daily.
45664559|NCT05342519|Drug|Placebo|All patients will be assigned to received topical placebo cream to the lesion not being treated with the active study drug.
45664560|NCT05374109|Behavioral|SYV: Sauti ya Vijana (The Voice of Youth intervention)|Mental health is associated with ART adherence and HIV outcomes. SYV was designed to address the specific challenges of young people living (YPLWH) with HIV in Tanzania. SYV includes 10 group sessions (two sessions held jointly with caregivers) lasting approximately 90 minutes and two individual sessions delivered by trained young adult group leaders who use a manualized protocol that is designed to scale in low resource settings. The intervention is applied to the Social Action Theory (SAT), a theoretical framework used to determine factors that influence health behavior. Building off a SAT resilience framework for YPLWH, components of evidence-based treatment models to influence cognitive, self, and social regulation to improve behavioral health outcomes will be strategically used.
45818957|NCT03689504|Dietary Supplement|Standard of care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder (Chispitas) or lipid-based nutrient supplement (Nutributter)
45959340|NCT02933905|Drug|Intravitreal Ranibizumab injection|
45959341|NCT02933515|Other|yoga and occupational therapy|group OT addressed fall risk factors, such as risk factors inside and outside and how to best manage them. yoga was delivered in sitting, standing, and floor postures
45959342|NCT02933788|Drug|Cilostazol|Cilostazol sustained release capsule is new drugs developed by Otsuka Korea. This drugs have platelet aggregation inhibiting action, peripheral vasodilating action and endothelial function improving action.
45664561|NCT05582057|Behavioral|Strengths to Grow: Preteen|An online, strength based parenting program for parents of preteens (aged 9-14).
45664562|NCT05373875|Diagnostic Test|Doppler ultrasound|Doppler to listen and classify the arterial signal in the ankle and arm (Ankle brachial pressure index (ABPI))
45664563|NCT05379491|Drug|3 L PEG + linaclotide|Participants take a linaclotide capsule on the day before colonoscopy at least 30 minutes before the first meal (if this is impossible, take the capsule as early as possible on that day). Participants take 1 L polyethylene glycol electrolyte solution within 1 hour from 8 p.m the night before the examination and take another linaclotide capsule and 2 L polyethylene glycol electrolyte solution 4 hours before the colonoscopy.
45818958|NCT03689504|Behavioral|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
45818959|NCT03689504|Behavioral|Home-based family gardening|Health promoters will facilitate the building and maintenance of a family home garden using a square foot or container gardening method.
45818960|NCT03455491|Drug|XC221 100 mg|once daily during 3 days.
45818961|NCT03455491|Drug|XC221 200 mg|once daily during 3 days.
45818962|NCT03455491|Drug|Placebo|once daily during 3 days.
45959343|NCT02933788|Drug|Acetylsalicylic acid|Aspirin may prevent coronary thrombosis in patients with cardiovascular event risk factors, such as ischemic heart disease family history, hypertension, diabetes mellitus, dyslipidemia and obesity.
45959344|NCT00153452|Behavioral|perpetration of intimate partner violence|
45959345|NCT00165399|Drug|Docetaxel|Given intravenously on day 2 of four three-week cycles
45959346|NCT00165399|Drug|Estramustine|Taken orally three times a day for 5 days starting on day one of each three-week cycles (4 cycles)
45959347|NCT00165399|Drug|Casodex|Started 3 weeks after last chemotherapy treatment; taken orally once a day for 15 months
45959348|NCT00165399|Drug|Zoladex|Started one week after the start of casodex; zolades is given as an injection (in the stomach once every 3 months for a total of 5 injections.
45959349|NCT02933827|Drug|ELIXCYTE|Adipose-derived stem cells (ADSCs)
45959350|NCT02933593|Drug|Labetalol|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
45959351|NCT02933593|Drug|Hydralazine|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
45959352|NCT02933593|Drug|nifedipine|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
45959353|NCT02933632|Other|Physical Therapy-SAP|"Day 1) Patients started approach after discharged anesthesia. Patients received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;~Day 2) Patients repeated the exercises learned from day 1. Following the proposed activities patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this second day only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to the next day;~Day 3) Patients repeated the day 2. And the patient who had not started gait training in the day 2, began it on the day 3;~Day 4 and other days) Patients repeated the gait training until the discharge date."
45959354|NCT02933632|Other|Physical Therapy-ARP|"Day 1-1°approach) Patients started after discharged anesthesia. Received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;~Day 1-2°approach) Patients repeated the exercises learned from day 1-1°approach. Following patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this Day 1-2°approach only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to next approach;~Day 1-3°approach) Patients repeat the day 1-2°approach. And the patient, who had not started gait training in the day 1 - second approach, began it in this third approach;~Day 2) Patients repeated three times the day 1-3°approach;~Day 3) Patients repeated three times the day 1-3°approach."
45959355|NCT00153491|Drug|artemether-lumefantrine|
45959356|NCT00165438|Procedure|Pulmonary Function Tests|Tests include; total lung capacity, vital capacity, functional residual capacity, forced vital capacity, forced expiratory volume in 1 second, carbon monoxide diffusing capacity, pulse oximetry before and after a 6 minute walk and Pulmonary Status and Dyspnea Questionnaire
45959357|NCT00165438|Procedure|CAT Scan|Obtained at different time points during the study depending upon standard of care chemotherapy treatment
45959358|NCT02933749|Device|SctO2|The non invasive cerebral oxymetry (INVOS-Covidien) has been used to measure cerebral oxygen saturation.
45959359|NCT02933749|Device|BIS|Bispectral index
45959360|NCT02933398|Procedure|Robotic Assisted Nephrectomy|Robotic (Davinci)
45959361|NCT02933398|Procedure|Laparoscopic Assisted Nephrectomy|Regular Laparoscopic Technique.
45959362|NCT02933437|Drug|Ajmaline|Ajmaline 1milligram/kilogram max dose as bolus intravenous over 10 minutes with continuous ECG monitoring
45959363|NCT00153530|Drug|methotrexate|"chemotherapy with radiotherapy~chemotherapy without radiotherapy"
45959364|NCT00153530|Radiation|radiotherapy|whole-brain irradiation
45959365|NCT04690075|Dietary Supplement|Nutrition Management and Dietary Fiber|Routine nutrition management and dietary fiber supplements based on recommendation for 12 weeks.
45959366|NCT04690075|Dietary Supplement|Nutrition Management|Routine nutrition management for 12 weeks.
45959367|NCT02933164|Device|Continuous Glucose Monitoring System|Effectiveness and safety of a Continuous Glucose Monitoring System
45664564|NCT05379491|Drug|3 L PEG + placebo|Participants take a placebo capsule on the day before colonoscopy at least 30 minutes before the first meal (if this is impossible, take the capsule as early as possible on that day). Participants take 1 L polyethylene glycol electrolyte solution within 1 hour from 8 p.m the night before the examination and take another placebo capsule and 2 L polyethylene glycol electrolyte solution 4 hours before the colonoscopy.
45664565|NCT05308901|Drug|Pembrolizumab|200 mg IV every 3 weeks for a maximum of 2 years.
45818963|NCT03349567|Behavioral|Audit-and-feedback|We will monitor the antimicrobial-prescribing of providers in the experimental arm. Our study team will meet with providers in the experimental arm to provide guidance on optimal antimicrobial-prescribing. We will provide personalized feedback to providers in the experimental arm once every quarter.
45959368|NCT02933125|Behavioral|Group psychotherapy|"Motivational enhancement psychotherapy (MEP) for Youths:~The participating youths have to attend one session a week for 10 weeks of a group program for relapse prevention based on motivational enhancement ideas and led by two experienced psychologists from the hospital.~Parenting skill training (PST) for Caregivers:~The PST program for the youths' caregivers also consist of 10 weekly, 120-minute sessions that were led by a senior consulting psychologist."
45959369|NCT02933125|Behavioral|Standard supervision|The standard supervision by the protection officers in Taiwan's Kaohsiung Juvenile and Family Court provide the adolescents with moral education, as well as counseling in their work or studies.
45959370|NCT00165477|Drug|lenalidomide|Given orally once a day for 21 days followed by a 1 week rest period. Subject may continue to receive study drug as long as the disease does not worsen and they experience serious side effects
45458264|NCT04509284|Other|Training|The experimental group will perform a supervised progressive resistance training program, with five exercises for the upper- and lower body (box squat, bench press, trap bar deadlift, bench pull and lat pulldown), 2x/week for a 12 week period. The program will utilize a flexible progression system through three distinct training phases; 1) 2-4 sets of 10-12 repetitions, 2) 2-4 sets of 6-8 repetitions, 3) 2-4 sets of 2-4 repetitions. Number of sets are adjusted within session according to daily readiness while load is adjusted within and between sessions according to number of reps performed. A 3-5min rest period is provided throughout the program.
45664566|NCT05308901|Drug|Lenvatinib|20 mg daily for a maximum of 2 years.
45959371|NCT00165477|Radiation|Radiation|Starting 4-7 days after the start of lenalidomide and given once a day, 5 days a week for 6-7 weeks
45664567|NCT05538065|Other|Follow-up booster Alert|Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered
45664568|NCT05538065|Other|Pre-commitment|A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.
45818964|NCT03691844|Drug|AMZ001|diclofenac gel
45818965|NCT03691844|Drug|Placebo|Placebo
45818966|NCT03691844|Drug|Comparator|diclofenac gel
45959372|NCT02933086|Other|Specific exercises for lumbar stabilization|The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
45959373|NCT02933086|Other|Conventional therapy|The Group 2 (G2) will perform conventional therapy including stretching of lower limbs and trunk, with passive stretching of hamstrings; gluteus maximus; piriform; paraspinals; lumbar square; latissimus dorsi; scalene; trapezius.
45959374|NCT00153569|Biological|Tyrosinase, MAGE-3, GnTV|
45959375|NCT02932930|Procedure|QLB bloc|
45959376|NCT02932930|Drug|0.2% Ropivacaine|0,2ml/kg of 0,2% ropivacaine
45959377|NCT02932930|Drug|0.9% normal saline|0,2ml/kg of 0.9% normal saline
45959378|NCT02932813|Behavioral|THINK Program|Lessons and laboratory sessions will be 60 minutes, followed by physical activity sessions lasting 60 minutes. Laboratory activities include assessing heart rate, making healthy meals, learning portion sizes, brain challenges, and more. To improve physical activity participation, a wide selection of developmentally appropriate and multiculturally sensitive activities will be offered, such as sports, games, obstacle courses, and dance.
45959379|NCT02932969|Drug|BMS-986231|
45959380|NCT02932969|Drug|BMS-986231 Placebo|
45959381|NCT00165516|Drug|Cisplatin|Heated and given as an one-hour lavage of the chest and abdomen during surgery
45959382|NCT00165516|Drug|Sodium Thiosulfate|After the one-hour lavage, sodium thiosulfate is given intravenously
45959383|NCT00153608|Biological|WT1 126-134 peptide|
45959384|NCT04647409|Other|screening|The determination of the prevalence of NAFLD in a general population in Flanders, Belgium
45959385|NCT04644055|Diagnostic Test|EUS- share wave of the liver|Evaluation of the right and left hepatic lobe with EUS-guided share wave
45959386|NCT00172653|Procedure|functional tasks|
45959387|NCT00153647|Procedure|Cap-assisted colonoscopy|Cap-assisted colonoscopy
45959388|NCT00153647|Procedure|Cap-assisted colonoscopy|Cap-assisted colonoscopy
45959389|NCT04642378|Drug|iNCDSS based insulin regime|Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).
45959390|NCT04642378|Drug|routine insulin treatment regime|Patients of this group will receive the insulin regime recommended by professional endocrinologists.
45959391|NCT04608136|Behavioral|Diet intervention|Volunteers will be instructed on dietary recommendation throughout the research program to achieve a stable daily energy intake.
46079357|NCT05563857|Dietary Supplement|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
46079358|NCT05561543|Dietary Supplement|Peppermint oil|Peppermint oil
46079359|NCT05561543|Other|Placebo|Placebo
46079360|NCT05558579|Other|No sling use|Patients will not use standard of care sling
45959392|NCT02933047|Procedure|Total laparoscopic hysterectomy|
45959393|NCT02933047|Procedure|Total laparoscopic hysterectomy|
45959394|NCT02932852|Procedure|Lipoaspiration|The patient will have a liposuction surgery from which the autologous ADAS cell to transplant in the cornea will be obtained.
45959395|NCT02932852|Procedure|Transplantation|The ophthalmologist will carry out the transplantation of the ADAS cells with or without scaffold in the intrastromal cornea of the patient
45959396|NCT00407784|Drug|eplerenone|
45959397|NCT00153686|Procedure|capsule endoscopy|capsule endoscopy of small intestine
45959398|NCT00153686|Procedure|Mesenteric Angiogram|Mesenteric Angiogram
45959399|NCT02932774|Drug|Cetirizine|Cetirizine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
45959400|NCT02932774|Drug|Loratadine|Loratadine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
45959401|NCT02932774|Other|Placebo|Placebo syrup once daily before 10:00 AM for 2 weeks
45959402|NCT02932696|Other|Cardiac training program|"This program takes place at the Cardiovascular Rehabilitation Department at the Nîmes University Hospital and includes a combination of various physical activities: treadmill, exercise bike, rower, aerobics, gymnastics, serious games, swimming. The program begins approximately within 3 months after myocardial infarction and consists of 20 consecutive days of training. The main physical activity is aerobic interval training (AIT).~30-minute AIT sessions will occur 5x per week for 4 weeks.~1 AIT session includes a warm up for 8 minutes to reach a heart rate during exercise corresponding to 20 to 30% of maximum aerobic power determined during the initial effort test. Then interval training occurs with 4x2 min of high intensity effort (heart rate during exercise corresponding to 80% of maximum aerobic power) alternating with 2 min of active recovery at 20-30% of maximum aerobic power. Then recovery for 8 minutes."
45959403|NCT02932657|Other|Non interventional study|First individual interviews will be set up with teenagers of Nantes University Hospital . Then, focus group will be conduct with patients and professionals in Nantes and Foch University Hospital.
45959404|NCT00180063|Drug|L-NMMA(drug)|
45959405|NCT00153725|Drug|Aspirin and Pantoloc|
45959406|NCT02932423|Other|Control product E|Plain water
45959407|NCT02932423|Other|Test product A|Beverage with no sugar but sweetener
45959408|NCT02932423|Other|Test product B|Beverage with 22 g/L sugar and sweetener
45959409|NCT02932423|Other|Test product C|Beverage with 33 g/L sugar and sweetener
45959410|NCT02932423|Other|Test product D|Beverage with 47 g/L sugar and sweetener
45959411|NCT02932423|Other|Comparative product F|Beverage with 98 g/L sugar
45959412|NCT02932384|Behavioral|Intervention-Passport and Peer Mentor|In addition to the passport and incentives described below for the control condition, participants assigned to the intervention will select a peer mentor trained in motivational interviewing. The mentor will help guide the participant to complete passport items and address priorities. Participants will also be incentivized for regular meetings with his peer mentor.
45664569|NCT05538065|Other|Enhanced Alert|An enhanced alert (known as a Best Practice Advisory [BPA]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.
45818967|NCT03456427|Device|Patient-Assisted Compression (PAC)|The technologist will properly position the breast and apply minimum compression. The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. The technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. This will be done for both standard views Craniocaudal (CC) & Mediolateral Oblique (MLO).
45959413|NCT02932384|Behavioral|Control-Passport Only|"A trained staff member will use a needs assessment and the participant's own priorities to develop a 'Passport to Wellness,' a personalized set of services whose access may encourage HIV prevention or address barriers to HIV testing.~Example passport items include: getting an HIV test, attending an informational session about PEP/PrEP, meeting with a PrEP provider, attending 12-step meetings, yoga classes, a massage or Reiki session, or reviewing specific HIV prevention information online. Participants will be incentivized for each passport item they complete."
45959414|NCT02932540|Other|change of head position|patient can be allocated to the transient change of the head position, persistent lying flat position in the first 24 hours of the hospital admission and persistent sitting up in the first 24 hours of the hospital admission
45959415|NCT00153764|Drug|Cooper Complete One-A-Day Vitamin Supplement|
45959416|NCT00180102|Drug|Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone|
45818968|NCT03456427|Device|Technologist-Controlled (TC) Compression|TC compression will be conducted per standard of care practices at the site.
45959417|NCT00180102|Procedure|early allogeneic PBSCT within induction therapy|
45959418|NCT00180102|Procedure|autologous PBSCT|
45959419|NCT04690309|Drug|Treatment with human insulin preparations or treatment with insulin analogues|The doses of human insulin preparations and insulin analogues will be matched individually to achieve target values of blood glucose - fasting < 100 mg/dl (5.5 mmol/L) and postprandial < 140 mg/dl (7.8mmol/L)
45959420|NCT02931955|Other|Blood draw, stool collection.|Blood will be drawn by certified personnel according to local regulations. Stool will be collected by the patients after instructions on how to use a stool collection kit.
45959421|NCT02932189|Device|Inspiratory muscle training|For the inspiratory muscle training, an isokinetic device (K5 Power Breath, United Kingdom) will be attached to the artificial airway.
45959422|NCT02931994|Other|Knotted floss technique|The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)
45959423|NCT00153881|Drug|Capecitabine (Xeloda)|"Neoadjuvant Chemotherapy:~Docetaxel every 3 weeks for 2 cycles Carboplatin every 3 weeks for 2 cycles with prophylactic antibiotics and antiemetics as needed.~Concomitant chemotherapy and radiation:~Docetaxel weekly for 5 doses without premedication Capecitabine orally, one dose prior to each fraction of irradiation (28 cycles)."
45959424|NCT00180141|Drug|Elidel-Creme|
45959425|NCT02932033|Procedure|Tack fixation of mesh|hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) or spiral titanium tacks (active comparator) according to the result of randomization
45959426|NCT02932033|Procedure|Synthetic glue fixation|hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) according to the result of randomization
45959427|NCT02931799|Behavioral|Nurse Follow-Up|Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-discharge; to monitor patients' health status with respect to their IBD.
45959428|NCT02931799|Other|Electronic Monitoring|"Patients will be provided access to a web-based application entitled: 'Health Promise'. The application will generate surveys every 3 days, where patients will self-report their IBD symptoms, quality of life and medication adherence on three separate scales:~PRO-2 Scale for patients with Crohn's Disease~6-Point Mayo Score for patients with Ulcerative Colitis~Morisky Medication Adherence Scale (MMAS-4)~The survey responses will be monitored by an IBD advanced practice nurse, to triage patients for outpatient follow-up."
45818969|NCT04195880|Other|Interventions to Reduce Acute Care Transfers|Experimental CLCs were trained in INTERACT QI Intervention, containing tools, strategies and educational resources designed to catch and manage acute changes in conditions early that a Veteran may be experiencing, leading to a potential reduction in preventable hospital transfers from CLCs.
45818970|NCT03352609|Device|Active rTMS with MagVenture MagPro double blind rTMS system|5 sessions of rTMS delivered with MagPro (MagVenture) double blind rTMS system delivered at 110% of resting motor threshold with 3000 pulses of 10hz stimulation (5s on, 10s off) per session.
45818971|NCT03352609|Device|Sham rTMS|Double blind MagPro system delivers sham condition by mimicking rTMS sound and delivering skin stimulus via TENS pads
45818972|NCT04191668|Device|NightOwl|The NightOwl is a finger-mounted home sleep apnea testing device
45959429|NCT02931799|Other|Post-Discharge Questionnaire|Patients will complete a web-based questionnaire at 30 days post-discharge. The questionnaire will capture information related to: Demographics, Patient Satisfaction as measured by the CACHE questionnaire; IBD related quality of life as measured by the IBDQ questionnaire; Disease activity as measured by PRO-2 scale for Crohn's Disease or 6-Point Mayo Score for Ulcerative Colitis; and Patient Satisfaction with the 'Health Promise' application.
45959430|NCT02931799|Other|Post-Discharge Questionnaire|Patients will complete a web-based questionnaire at 30 days post-discharge. The questionnaire will capture information related to: Demographics, Patient Satisfaction as measured by the CACHE questionnaire; IBD related quality of life as measured by the IBDQ questionnaire; Disease activity as measured by PRO-2 scale for Crohn's Disease or 6-Point Mayo Score for Ulcerative Colitis.
45959431|NCT02931799|Other|Standard of Care|Discharge summary detailing inpatient IBD admission; in addition to outpatient follow-up with a Gastroenterologist post-discharge
45959432|NCT00153959|Behavioral|acute psychiatric day care|
45818973|NCT03354325|Behavioral|Scheduled PCP follow-up|Parents of children randomized to scheduled follow up will be instructed to follow up with their primary care physician within 4 days of discharge regardless of improvement and/or symptom resolution. Research coordinators will verify that the child has a scheduled follow up appointment prior to discharge.
45818974|NCT03354325|Behavioral|As needed PCP follow-up|At the time of hospital discharge, parents will be instructed that the child does not need to automatically follow up with his/her primary care physician. Rather, the child should follow up on an as needed basis: if the child does not improve or if new concerns arise.
45818975|NCT03892460|Device|neuromuscular electrical stimulation|bilateral quadriceps exercise with neuromuscular electrical stimulation
45959433|NCT02931760|Device|subcutaneous pacemaker|During implant of a pacemaker the device is either implanted subcutaneously or intramuscular
45959434|NCT02931760|Device|intramuscular pacemaker|During implant of a pacemaker the device is either implanted subcutaneously or intramuscular
45959435|NCT02931643|Other|High fat challenge breakfast|In this intervention, subjects are asked to consume high fat breakfast without mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
45959436|NCT02931643|Other|High fat challenge breakfast with mixed-spices|In this intervention, subjects are asked to consume high fat breakfast with mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
45959437|NCT02931877|Drug|sevoflurane|
45959438|NCT02931877|Drug|propofol|
45959439|NCT02931721|Diagnostic Test|MRI|Pelvis MRI
45959440|NCT00153998|Drug|Cetuximab|
45959441|NCT00153998|Procedure|Liver resection|
45959442|NCT00153998|Drug|Cetuximab and FOLFIRI|"Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:~Cetuximab 250 mg/m² (1.0 h i.v.) weekly~Irinotecan 180 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)"
45959443|NCT00153998|Drug|Cetuximab and FOLFOX|"Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:~Cetuximab 250 mg/m² (1.0 h i.v.) weekly~Oxaliplatin 100 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)"
45959444|NCT02931604|Device|SinuSafe Medical Device for Maxillary Sinus|Sinus lavage via the natural sinus ostium, without ostial dilation.
45959445|NCT02925208|Other|cochlear implant surgery|patients with severe to profound sensorineural hearing loss who underwent cochlear implant surgery
45959446|NCT02925130|Drug|Salbutamol|Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral.
45959447|NCT02925130|Drug|Placebo|Acute oral intake of a placebo drug
45959448|NCT00407823|Procedure|Central venous oxygen saturation continuous monitoring|
45818976|NCT03232645|Device|Ablation procedure|Cathater ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav Mifi OI ablation catheter
45818977|NCT00377936|Drug|Gemcitabine alone|Gemcitabine monotherapy 1000 mg/m2 weekly
45818978|NCT00377936|Drug|EndoTAG-1 and Gemcitabine|EndoTAG-1 11 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
45818979|NCT00377936|Drug|EndoTAG-1 and Gemcitabine|EndoTAG-1 22 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
45818980|NCT00377936|Drug|EndoTAG-1 and Gemcitabine|EndoTAG-1 44 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
45818981|NCT03457909|Device|DS-MCE|During the DS-MCE examination,the capsule is allowed to travel down into gastric cardia,from where the string is slowly pulled to allow the capsule to view the esophagus retrogradely.
45818982|NCT03696758|Procedure|Pulmonary Function Testing|Subjects will undergo spirometry, Plethysmography, and diffusion capacity.
45818983|NCT03696758|Procedure|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
45818984|NCT03696758|Procedure|Cardiac Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
45959449|NCT02924974|Drug|Morphine|mixed with bupivacaine
45959450|NCT02924974|Drug|Lidocaine|sham procedure (s.c. lidocaïne)
45959451|NCT02924896|Dietary Supplement|Palm olein|60g of palm olein will be given in a milkshake at breakfast
45959452|NCT02924896|Dietary Supplement|Interesterified palm olein|60g of interesterified palm olein will be given in a milkshake at breakfast
45959453|NCT02924896|Dietary Supplement|Soybean oil|60g of soybean oil will be given in a milkshake at breakfast
45959454|NCT00154037|Drug|Pioglitazone (drug) and/or candesartan (drug)|
45959455|NCT00180258|Device|Cardiac Resynchronization Therapy with & without defibrillator|
45959456|NCT02925169|Device|CT Scan|CT imaging
45959457|NCT02925052|Device|Gastric Tube Guide|
45959458|NCT02925052|Device|Conventional placement|
45959459|NCT02924857|Device|Chocolate Touch|The Chocolate Touch™ Paclitaxel Coated Balloon Catheter is indicated for balloon dilatation, after appropriate vessel preparation as needed, of lesions in native superficial femoral or popliteal arteries up to 18 cm in length that are appropriate for angioplasty with balloon diameters from 3.5 mm to 6.0mm.
45959460|NCT02924857|Device|Lutonix Drug Coated Balloon|The Lutonix® 035 Drug Coated Balloon Catheter is indicated for improving luminal diameter for the treatment of obstructive de novo or non-stented restenotic lesions (≤ 18 cm in length) in native femoropopliteal arteries having reference vessel diameters of 4 mm to 6 mm.
45959461|NCT00154076|Drug|Zonisamide|Initial dose is 100mg/day, increase after 2 weeks to 200mg/day. The maximum dose is 600mg/day.
45959462|NCT00154076|Drug|Topiramate|Initial dose is 25mg/day, increase every 1 week to 100mg/day. The maximum dose is 400mg/day.
45959463|NCT02924779|Other|No intervention|Retrospective observational study
45959464|NCT02924740|Behavioral|Pelvic Floor Muscle Training|Pelvic floor muscle training consist of fast (2 second) and slow contractions (5-s contraction, 10-s hold, 5-s relaxation, totally 20-s). One set of exercises includes ten fast and ten slow voluntary PFM contractions (VPFMCs). During week 1 and 2, participants will be instructed to perform two sets of exercises per day (20 fast and 20 slow contractions per day), which was progressively increased by two sets: four sets per day at week 3 and 4 (40 fast and 40 slow contractions per day); six sets per day at week 5 and 6 (60 fast and 60 slow contractions per day); eight sets per day at week 7 and 8 (80 fast and 80 slow contractions per day); ten sets per day from week 9 to week 12 (100 fast and 100 slow contractions per day).
45959465|NCT02924740|Behavioral|Vaginal Tampon Training|Vaginal tampon training will be applied for 5 days a week for 12 weeks. Exercises with tampons will be performed two days a week by physiotherapist (first author) and three days a week by patients. One set of tampon exercises consist 15 contractions. During vaginal tampon training, from week 1 to week 12, patients were instructed to perform two sets of exercises for five days a week (two days by physiotherapist, three days by themselves).
45455168|NCT04108702|Device|Virtual reality control|"Patients will either sit or stand while wearing a head mounted display (HMD, Oculus Rift). A 360° video, showing a neutral body from the back in a neutral room, will be projected onto the HMD.~We will record the patients' ECG throughout the entire experiment. Raw data (ECG) are acquired with Arduino and in-house software will detect, in real time, the peak of each R-wave from the recorded ECG data and trigger an additional visual stimulus (e.g. a flashing outline surrounding the virtual body) that flashes on and off ASYNCHRONOUSLY with respect to the participant's heartbeat. The silhouette surrounding the virtual body flashes for a duration of 100ms and with a sinusoidal opacity."
45959466|NCT00154115|Drug|levosimendan|Intravenous infusion, blus 24 mcg/kg in 30-minutes followed by 0.2 mcg/kg/min up to 24 hours
45664570|NCT05308277|Device|Leo device monitoring|After consent and enrollment, the child's respiratory impedance will be continuously recorded using the Leo device throughout the day and night during the entire hospital stay or ED visit. The device may be taken off for up to 1 hour per day (i.e., break during bath / shower time). The device will be applied to the skin overlying the mid-sternum area on the chest wall after cleaning of the skin with an alcohol swab after consent has been obtained. The device will be changed every 72 hours or earlier, by the participant's guardian, depending on signs of defect in the signal quality or battery exhaustion, based on daily check of the signal by the research team. Remote monitoring of the child's chest impedance will continue using the Leo device after discharge from hospital/ED for 7 days.
45455169|NCT04108702|Other|Standard therapy|Standard multimodal out-patient therapy program (psychological support, physiotherapy, ergotherapy).
45664571|NCT05307887|Device|Sync VR Medical PICO G2 4K Virtual Reality Technology|Virtual reality headset and software
45664572|NCT05534477|Device|Verily Clinical Study Watch|The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
45818985|NCT03696758|Drug|Metoprolol|Subjects will receive intravenous metoprolol. Dose titrated 1-5 mg every 2 minutes to achieve goal heart rate of 55-65 beats per minute, or for subjects with a resting heart rate already at goal, titrated to achieve a 10-15% reduction in heart rate.
45959467|NCT00154115|Drug|placebo|Placebo
45818986|NCT03696758|Drug|Sildenafil|Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)
45818987|NCT03461965|Behavioral|3D printed model|A printed 3D model of MMS will be created showing a model of skin, and a tumor to visually depict the surgery
45818988|NCT03461965|Behavioral|Verbal Counselling|Participants will be educated with a standardized script on skin cancer, risks for skin cancer, treatment options, and MMS
45959468|NCT00180336|Device|CRT-D|
45959469|NCT02924662|Other|There is no intervention.|
45959470|NCT02924506|Device|Mobi-C prothesis|Mobi-C Prothesis, LDR Medical (company)
45959471|NCT02924506|Device|ProDisc-C prothesis|ProDisc-C prothesis, Vivo Depuy Synthes (company)
45959472|NCT00154154|Behavioral|General Psychiatric Management|General Psychiatric Management (GPM) condition consisting of a structured algorithmic medication intervention plus psychosocial counseling.
45959473|NCT00154154|Behavioral|Dialectical Behaviour Therapy|Modification of behaviours achieved with reframing thoughts and impulses
45959474|NCT02924311|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea 40 mg/mL - recommended dose of 2 mg - intravitreal injection monthly for five consecutive months, which constitutes the loading dose. The loading dose is followed by one injection every two months. After 12 months of treatment, the interval between two injections can be prolonged or adapted according to visual and anatomical results.
45455170|NCT03787303|Drug|Triiodothyronine (T3)|Participants will have their L-thyroxine (T4) discontinued and Triiodothyronine (T3)/liothyronine sodium initiated at 3: 1 and titrated.
45664573|NCT05534477|Device|Verily Study Watch|The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
45959475|NCT02924194|Device|stimulation ON|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
45664574|NCT05534477|Device|Zio Patch|The Zio XT Patch (Zio Patch) is a single-patient use, continuously recording ECG monitor that can be worn for up to 14 days. Zio Patch is a medical device manufactured by iRhythm Technologies and has been cleared by the FDA.
45818989|NCT03702608|Combination Product|EluNIR Ridaforolimus Eluting Coronary Stent System|"The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent - 38 mm length and 2.75mm, 3.0 mm, 3.5mm, 4.0mm diameter~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - (PBMA) and CarboSil®~Ridaforolimus drug"
45959476|NCT02924194|Device|stimulation OFF|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
45959477|NCT02924467|Behavioral|1 Notice|1 Reminder notification via autodialer
45959478|NCT02924467|Behavioral|2 Notices|2 Reminder notifications via autodialer
45959479|NCT02924467|Behavioral|3 Notices|3 Reminder notifications via autodialer
45959480|NCT02924233|Drug|Sym004|"Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).~Sym004 will be administered at different dose-levels via infusion Q2W"
45959481|NCT02924233|Drug|Nivolumab|Nivolumab is a humanized immunoglobulin G4 (IgG4) anti-PD-1 monoclonal antibody. Nivolumab will be administered via 60-minute infusion Q2W
45959482|NCT00180375|Device|Prizm, Vitality, Renewal|Follow-up during 2 years
45959483|NCT02923999|Drug|P2G12 Dose Cohort 1|single dose of intravenous infusion: 0.125g of the P2G12 human monoclonal antibody
45959484|NCT02923999|Drug|P2G12 Dose Cohort 2|single dose of intravenous infusion: 0.25g of the P2G12 human monoclonal antibody
45959485|NCT02923999|Drug|P2G12 Dose Cohort 3|single dose of intravenous infusion: 0.5g of the P2G12 human monoclonal antibody
45664575|NCT05534477|Device|StepWatch 4|StepWatch 4 is an ankle-worn wearable medical device, and will be used as a reference device for measuring participants' ambulatory time, daily step count, and ambulatory status classification.
45664576|NCT05576129|Device|TGP-tACS|"38 min and 20s of 4mA peak-to-peak theta-gamma stimulation with 75 Hz-gamma coupled to the peak of 6Hz-theta waves. 3s ramp-up at the beginning of stimulation and 3s ramp-down at the end of stimulation.~Administered using a Starstim® device and 5 gel electrodes with a πcm² area."
45818990|NCT03708770|Device|everlinQ endoAVF System|
45818991|NCT03233737|Combination Product|One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
45959486|NCT02923960|Other|Standard ONS|One serving (237 ml) standard oral nutritional beverage
45959487|NCT02923960|Other|Diabetes specific ONS 1|One serving (237 ml) diabetes oral nutritional beverage
45959488|NCT02923960|Other|Diabetes specific ONS 2|One serving (296 ml) diabetes oral nutritional beverage
45959489|NCT00154193|Drug|cyclosporine|patients will receive maintenance triple immunosuppression according to local practice consisting of Sandimmun Neoral, MMF/ECMPA or azathioprin and steroids.
45959490|NCT02923843|Other|Comprehensive Geriatric Assessment|The CGA is person-centered and unique for each patient, but is based on the core elements such as socio-demographic background, social network, health and medical history, medications, functional status, cognitive status, nutritional status, somatic status and psychosocial status including depression, providing a comprehensive assessment tailored for each person.
45959491|NCT00187863|Behavioral|pain perception|pain perception
45959492|NCT04100044|Other|Exercise Counseling|Meet with physical therapist
45959493|NCT04100044|Behavioral|Exercise Intervention|Receive personalized home exercise intervention
45959494|NCT04100044|Other|Questionnaire administration|Ancillary studies
45455171|NCT03522766|Other|urine sample|The subjects are asked to give a maximum of 15 urine samples during the study
45664577|NCT05576129|Device|Sham-tACS|38 min and 20s of alternation between 10s of 4mA peak-to-peak TGP- tACS and a 6 min 30s stimulation-free interval. Each stimulation consists of 3s ramp-up, 4s TGP stimulation and 3s ramp-down. Administered using a Starstim® device and 5 gel electrodes with a πcm² area.
45959495|NCT04100044|Other|Quality-of-Life Assessment|Ancillary studies
45959496|NCT04046848|Drug|OCTA101|OCTA101 is composed of OCTA8 (human-cl rhFVIII - Nuwiq Intermediate 2 Q-Eluate) and OCTA12 (recombinant human VWF fragment dimer).
45664578|NCT01931566|Drug|Pioglitazone|Pioglitazone SR tablets
45664579|NCT01931566|Drug|Pioglitazone placebo|Pioglitazone placebo-matching tablets
45664580|NCT05511077|Other|Diet|Intervention products consist of two different oat products, one solid and one liquid. The content of oat in the products differs.
45664581|NCT04248725|Behavioral|E-TIPS|Chronic pain self-management strategies for employed individuals with physical disabilities
45818992|NCT03233737|Device|One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
45818993|NCT03233737|Device|One spray CTY-5339-P|Placebo. Metered spray bottle with ≈200 uL total spray volume. Contains no active ingredient (vehicle control).
45818994|NCT05440747|Other|TFR(Treatment-Free Remission)|Withdrawal TKIs(Tyrosine kinase inhibitors: Imatinib or Flumatinib or Nilotinb or Dasatinib)
45959497|NCT00154232|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
45959498|NCT04040608|Other|Influence of screen sizes on responses to visual analog scales of stress|"An open questionnaire will be created by the Clinical Research Direction. The questionnaire will be opened by the examinator who will fulfill the anonymized identification of participants and the type of screens. In a dedicated room at the LaPSCo, the participants will answer the same VAS on four different sizes/types of screens (24-inch screen, laptop, tablet, smartphone) and on paper. Saliva will be collected after answering questionnaires. Heart rate variability and skin conductance will be measured with the use of a wrist watch during 15 minutes, from the entrance in the room to the completion of questionnaires.~The participant will undergo the same examination within a week (15 minutes)."
45818995|NCT04144088|Drug|Wu Ling San|assigned to Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Wu Ling San for a period of 4 weeks.
45959499|NCT00180453|Device|Coronary artery drug eluting stent placement|Coronary artery drug eluting stent placement
45959500|NCT00180453|Device|Coronary artery stent placement|Coronary artery stent placement
45959501|NCT00154271|Drug|Valsartan, Valsartan HCT|
45959502|NCT04024423|Other|Epidemiologic investigation|Identification of overlaps in source(s) of care between participants with NTM isolates in a Cystic Fibrosis Care Center.
45455172|NCT03939559|Procedure|Static, dynamic and functional balance exercises|In the first group (G1), 4 exercise packages which include static, dynamic and functional balance exercises will be taught in the first part of exercise period for 4 weeks
45455173|NCT03939559|Procedure|Static, dynamic and functional balance exercises with dual task|In the second group (G2), 4 exercise packages which include static, dynamic and functional balance exercises with cognitive or motor dual task will be taught in the first part of exercise period for 4 weeks.
45458265|NCT04509284|Other|Control|The control group will be instructed to continue their everyday lifestyle with no specific instruction regarding exercise and/or diet. However, they will be encouraged not to engage in new forms of exercise or physical activity throughout the study period.
45664582|NCT05372939|Drug|AMT-101 (oral)|AMT 101 is orally administered biological therapeutic taken once daily
45664583|NCT05372939|Other|Placebo (oral)|Orally administered placebo comparator taken once daily
45664584|NCT05372939|Combination Product|Humira (adalimumab)|Humira comparator is administered subcutaneously, on Humira frequency schedule.
45664585|NCT05372705|Behavioral|Short videos|Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.
45664586|NCT04247477|Other|Ventilation strategy|Patients are ventilated in randomized order with three different ventilation strategies (A,B and C)
45664587|NCT01912456|Biological|Low-volume C1-esterase inhibitor|
45664588|NCT01912456|Biological|Higher-volume C1-esterase inhibitor|
45959503|NCT04018846|Procedure|Revascularization using a BIOPROTEC Graft|It is about a routine care study not changing the usual follow-up of patients: postoperative visits after a Doppler ultrasonography made by a vascular Doctor in 1 month, 6 months, 12 months, 18 months and 2 years.
45959504|NCT00154349|Drug|Imatinib Mesylate|
45959505|NCT02923804|Dietary Supplement|Omega-3|3x 1g capsules taken daily for 6 months
46079361|NCT05555212|Drug|QLH11811|"In Ia phase, subjects will first receive oral single dose of QLH11811, then will be observed for 7 days. If the drug is tolerated by the subjects, the subjects will continue to receive the oral repeat dose of QLH11811 for 21 consecutive days. Upon the completion of observation for DLT in the subjects (DLT observation period is the 28 days after the first dose), the subjects will continue to receive the repeat dose of QLH11811 in Cycle 2 and subsequent cycles. The dosing frequency in Cycle 2 and subsequent cycles is once daily, and each cycle has 3 weeks.~The RP2D of QLH11811 is determined on the basis of comprehensive evaluation of all safety and tolerability data and all available PK, PD and efficacy data during the dose escalation phase. In phase 1b, the cohort expansion study is carried out for all cohorts in China and the United States concurrently according to the determined RP2D."
46079362|NCT05548816|Other|Handheld Dynamometer , Special tests and Modified DASH questionarre .|A mix of tools , special tests and questionarre to help in confirming the diagnosis of subacromial impingement.
46079363|NCT05538481|Other|Semi-structured interview|A collection of individual cultural values and palliative care preferences within the focus group meetings
45664589|NCT01912456|Biological|Low-volume placebo|
45664590|NCT01912456|Biological|Higher-volume placebo|
45818996|NCT04144088|Drug|Yin-Chen Wu Ling San|assigned to Yin-Chen Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Yin-Chen Wu Ling San for a period of 4 weeks.
45818997|NCT04144088|Drug|Placebo|1/10 Wu Ling San assigned to Placebo (n =20) and were instructed to take 4.5 gm 2 times per day of Placebo for a period of 4 weeks.
45818998|NCT03359629|Device|Spectrophon Glucometry Monitor|Wearable smartwatch with integrated non-invasive glucose detection system
45818999|NCT03359629|Device|YSI 2300 Stat Plus|Reference commercial glucometer
45819000|NCT03462745|Device|AccuVein AV 300|Assess the effectiveness of the AccuVein AV300 device over the standard technique in increasing the ﬁrst-time success rate (SR) for pediatric patients who needed IV cannulation
45819001|NCT03711578|Drug|Tenalisib,|BID, Orally
45819002|NCT03463915|Drug|Bladder instillation WITH triamcinolone acetonide|Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).
45959506|NCT02923804|Dietary Supplement|Olive oil|3x 1g capsules taken daily for 6 months
45959507|NCT02923765|Other|Aerobic training by a stepper|Aerobic training by a stepper: 35 minutes/session, 5 sessions/week and 4-5 weeks in total
45819003|NCT03463915|Drug|Bladder instillation WITHOUT triamcinolone acetonide|Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).
45819004|NCT00376441|Procedure|Vaginal Surgery|patients undergoing vaginal surgery
45819005|NCT04147442|Device|Hearing aid with fine-tuned and standard programs|A digital, wireless hearing aid is programmed specifically to each subject's hearing loss and fitted with both a program that is fine-tuned for their specific music playing as well as the standard music program that uses pre-determined settings.
45819006|NCT03237871|Behavioral|Text-message survey and informational text messages|Participants will complete a text-messaged survey each week for 5 weeks assessing economic and sexual risk behaviors. Participants will also receive 3 informational text messages each week for 5 weeks on HIV prevention and economic empowerment.
45959508|NCT00187941|Drug|Mycophenolate Mofetil|Targeted MPA exposure to 30-60 mg/L/h during the first month post-transplant.
45959509|NCT02923687|Drug|Ketorolac Tromethamine|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, the experimental group will receive supplemental buccal infiltration of 30 mg/mL of Ketorolac Tromethamine.
45959510|NCT02923687|Drug|Placebo|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, control group will receive buccal infiltration of normal saline.
45959511|NCT02923492|Behavioral|SafERteens|A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
45959512|NCT00154388|Drug|Imatinib mesylate|
45959513|NCT02923414|Device|Standard escalating shocks|125 J, 150 J, 200 J
45959514|NCT02923414|Device|High energy shock protocol|360 J, 360 J, 360 J.
45959515|NCT00180492|Device|RX ACCULINK(TM) Carotid Stent System and RX ACCUNET(TM) Embolic Protection System|
45959516|NCT02923375|Biological|Mesenchymoangioblast-derived mesenchymal stem cells|The active agent in CYP-001 is allogeneic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs), which are produced using the proprietary Cymerus™ platform technology. Cymerus™ refers to the process of generating cell-based products from intermediate cells, MCAs, which in turn are derived from induced pluripotent stem cells or iPSCs. The iPSCs used in the Cymerus™ process were derived from blood donated by a fully-consented healthy adult donor, and were reprogrammed using a transgene-free, viral-free and feeder-free technique.
45959517|NCT02923453|Dietary Supplement|CNT 2000 American ginseng extract|
45664591|NCT05307653|Procedure|Penile block|Penile block was performed in supine position. The penis was retracted caudally and then fixed with a leucoplast. After identifying the symphysis pubis (SP), a 22-gauge needle was inserted vertically about 1 cm lateral to the SP, and bupivacaine 0.5% (0.1 ml/kg, maximum 2.5 ml) was injected on each side after penetrating the Scarpa's fascia.
45819007|NCT04146272|Device|Hearing Aid Mermaid Current|The current hearing aid used to treat hearing loss.
45819008|NCT04146272|Device|Hearing Aid Mermaid New|The new hearing aid used to treat hearing loss with an upgraded feedback cancellation system.
45819009|NCT04146272|Device|Power Hearing Aid Current|The current power hearing aid used to treat strong hearing loss.
45959518|NCT02923453|Dietary Supplement|Placebo|
45959519|NCT00154427|Drug|activated recombinant human factor VII|
45959520|NCT02923258|Drug|Docetaxel|20mg/m2/w for 6 weeks
45959521|NCT02923258|Drug|Cisplatinum|40mg/m2/w for 6 weeks
45959522|NCT02923258|Radiation|IMRT|a total dose of 60Gy in 30 fractions over 6 weeks
45959523|NCT02923297|Other|Blood sampling|blood sampling for determine and compare the expression patterns of GALIG gene
45664592|NCT05307653|Procedure|Erector spinea plain block|Ultrasound guided ESPB was performed in prone position by Philips © (CX50 Extreme edition). The superficial probe was placed longitudinally at the midline just above the sacrum, and both erector spinae muscles and median sacral crests were identified. Using the in-plane approach, a 22-gauge needle was inserted in a craniocaudal direction till reaching the tip of the fourth median sacral crest. After negative aspiration to avoid intravascular or intrathecal puncture, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered.
45819010|NCT04146272|Device|Power Hearing Aid New|The new power hearing aid used to treat strong hearing loss with an upgraded feedback cancellation system.
45959524|NCT02923336|Drug|non selective beta blocker|"the patient is going to receive a device called smart pill before the beginning of treatment with propranolol, after the evaluation with the smart pill device, they are goning to take propranolol (dose of propranolol 80 mg per day) for 4 weeks,finally they will receive another smart pill to evaluate the second gastrointestinal transit time"
45959525|NCT02923219|Biological|Adipose-derived stem cells|The adipose-derived stem cells therapy involve injection of patient's own adipose-derived stem cells. Local anesthetic will be applied to the face prior to the injection. For adipose-derived stem cells preparation, proper volume of fat cells will be collected from each patient just before each procedure. The stem cells will be injected into each standardized injection point in a superficial manner. The injections points are along the inferior border of cheek and mid-cheek and temple, where will be followed by 10-15 minutes of icing.
45959526|NCT00180531|Device|Renewal TR2|
45664593|NCT05307653|Procedure|Caudal block|Caudal block was performed in the left lateral position. A 22 G needle was inserted through the sacral hiatus. The loss of resistance method was used to pass through the sacrococcygeal membrane and enter the caudal epidural space. Negative aspiration was then performed. When no blood or cerebrospinal fluid was observed, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered. The patient was returned to the supine position after the procedure was completed.
45819011|NCT03473665|Drug|Indomethacin|Indomethacin Extended Release Oral Tablet 75mg every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
45959527|NCT02923141|Behavioral|Neutral Writing|
45959528|NCT02923141|Behavioral|Expressive Writing|
45959529|NCT02923141|Behavioral|Contingency Management|
45959530|NCT02922907|Dietary Supplement|arabinoxylan rice bran|a proprietary product derived from rice bran treated with extracts from three mushrooms
45959531|NCT02922907|Dietary Supplement|Placebo for arabinoxylan rice bran|inactive product
45959532|NCT02923102|Dietary Supplement|Aloysia citriodora extract|2 capsules with 200mg - daily dosage 400mg
45959533|NCT02923102|Dietary Supplement|Maltodextrin|2 capsules with 200mg - daily dosage 400mg
45959534|NCT02923024|Behavioral|Patient Ping|The patient ping will be a fax sent from Oscar Health to physician that will include information on the physician's patient's trigger event and contact information for the physician to reach out to the member.
45959535|NCT02922946|Drug|Entinostat|HDAC (histone deacetylase) inhibitor
45959536|NCT00188019|Procedure|diagnosis methods|
45959537|NCT02922595|Device|Intubation through ILMA®|"It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed"
45959538|NCT02922595|Device|Intubation through ILTS®|"It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed"
45819012|NCT03473665|Drug|Diclofenac|Diclofenac Delayed Release Oral Tablet 25mg tablets x 3 tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
45819013|NCT03473665|Drug|Meloxicam|meloxicam 7.5mg tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
45959539|NCT04706000|Genetic|Beclin 1 gene|The determination of Beclin 1, LC3-II and p62 genes, which are evaluated by immunohistochemistry, at the protein level will be done by ELISA method in MSKU Medical Faculty Medical Biology Laboratory.
45959540|NCT02922712|Drug|NISE|Nise 200mg Max per day in 2 divided doses
45959541|NCT00180570|Device|FineLine II Sterox, FineLine II Sterox, FineLine II Sterox EZ|
45959542|NCT02922790|Behavioral|standard health information|Subjects will review standard health information
45959543|NCT02922790|Behavioral|standard health information plus info. on DNA damage|Subjects will review standard health information and information on DNA damage
45959544|NCT02922790|Behavioral|Subjects will review standard health information and information on DNA damage, plus pictures of their DNA damage|Subjects will review standard health information and information on DNA damage, as well as review pictures of their cells' DNA damage
45959545|NCT02922673|Drug|Aspirin|
45819014|NCT03473665|Drug|Celecoxib|Celecoxib 200mg capsule every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
45959546|NCT02922673|Drug|Placebo|
45959547|NCT02922556|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
45959548|NCT02922556|Other|Commercially available computerized training|
45664594|NCT05340491|Drug|Toripalimab|240mg, D1, every 3 weeks per cycle, three cycles with chemotherapy and eight cycles after IMRT
45664595|NCT05340491|Drug|Chemotherapy|Gemcitabine: 1.0g/m2, D1 and D8, Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
45959549|NCT02922478|Radiation|X-ray of the spine|Every participant will undergo X-ray of the spine so that vertebral fractures can be quantified using the Genant score.
45959550|NCT02922478|Procedure|Ambulatory blood pressure monitoring (ABPM)|ABPM will be performed using the brachial, oscillometric, automated self-measurement mobil-O-Graph device (I.E.M. GmbH, Stolberg, Germany) with integrated ARCSolver®-Software (Austrian Institute of Technology Wien).
45959551|NCT02922478|Radiation|Dual X-ray absorptiometry|Individual bone mineral density and T-Score will be determined by X-ray absorptiometry.
45959552|NCT02922478|Procedure|Non-invasive procedures|Other non-invasive study procedures include structured patient interview, sampling of blood, buffy coat and spot urine (including biobanking), electrocardiogram, pulse wave velocity and analysis, transthoracic echocardiography, 4-meter gait speed test, hand grip test, questionnaires
45959553|NCT02922205|Device|Endoscopic Linear Cutter Stapler and reloads|Endoscopic Linear Cutter Stapler and reloads
45959554|NCT04705610|Other|Video-oculography / Social cognition tasks / Neuropsychological evaluations|"Recording of eye movements with a video-oculography device during oculomotor paradigms (Fixations, horizontal and vertical reflex saccades, horizontal and vertical smooth pursuit, anti-saccades)~Recording of eye gaze with a video-oculography device during emotions recognition tasks (Reading the Mind in the Eyes test (Baron-Cohen 2001); Ekman Faces task (1976))~Neurological evaluation~Neuropsychological evaluations~Social cognitions tasks~Behaviour assessment"
45664596|NCT05340491|Radiation|Intensity modulated radiotherapy|total 60-66Gy, 1.8-2.0Gy/f/day
45959555|NCT00188058|Device|Setting of positive end-expiratory pressure|
45959556|NCT02922088|Device|DuraGraft|DuraGraft is a one-time intraoperative vascular graft treatment designed to prevent graft disease and failure and reduce the clinical complications associated with graft failure.
45959557|NCT02922283|Device|IL2-PET scan|All patients in this study will undergo a IL2 PET scan at baseline and week 6 of treatment with immunotherapy.
45959558|NCT02922283|Procedure|Tumor biopsy|A procedure to acquire tissue of a predetermined melanoma metastasis will be performed in all patients that participate in phase 2 of this study.
45959559|NCT02922283|Device|CT scan|A CT scan of diagnostic quality will accompany all the PET scans and will additionally been made 12 and 16 weeks after start of immunotherapy to evaluate response to treatment.
45959560|NCT02922283|Procedure|Biopsy of non-target tissue|A biopsy of skin and colon non-target tissue involved in an immune-related side effect is optional in patients that participate in phase 2 of this study.
45959561|NCT02922049|Other|Biopsies with histopathology|All samples taken by biopsies will be correlated with the images taken by CLE.
45959562|NCT04705454|Biological|Loncastuximab Tesirine|
46079364|NCT05538481|Other|Developed survey completion|A collection of individual responses to a survey created after focus group completion and analysis
45664597|NCT05372549|Other|Oxidative stress|Oxidative stress occurs as soon as there is an imbalance between pro- / antioxidants, and molecules exhibiting antioxidant properties are at the forefront of fertility treatment and preservation. Oxidated stress will be measured by blood sample
45664598|NCT05372549|Other|cf-DNA|cfDNA, extracted from blood plasma in samples collected will uncover the potential role of cfDNA as a stress signal released in response to oxidative stress
45819015|NCT03863210|Other|"60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk"|"All participants were exposed to the intervention. The intervention consisted of a 60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk. The lecture was delivered in family medicine offices by four specialists of family medicine individually to the groups of 6-8 participants. The lecture was verbal, harmonized among four family physicians, and contained instructions for changing nutrition habits, smoking habits and instructions for increasing physical activity. At the end of the lecture, each participant received a personally tailored decision aid, which included the list of her risk factors, assessment of the 10-year risk of fatal CVD (based on the data provided by the participants before the lecture), and instructions on what she should do in terms of changing the lifestyle habits."
45819016|NCT03239665|Behavioral|Pharmacist-led Intervention (PHARM)|60 minute didactic lecture about vaccinations.
45819017|NCT03239665|Behavioral|Peer-led Intervention (PEER)|60 minute peer led small group intervention including skits and other educational material
45819018|NCT03717506|Drug|GDC 268 Lotion|GDC 268 is a topical lotion
45819019|NCT03717506|Drug|Clindamycin Phosphate Lotion 1%|Clindamycin Phosphate Lotion is an FDA-approved drug product
45819020|NCT03717506|Drug|GDC Vehicle Lotion|GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs
45819021|NCT03861338|Drug|Sublocade|The monthly Sublocade buprenorphine extended-release (BXR) injection will be administered in two doses (100 mg and 300 mg). Following a 4 day induction onto oral buprenorphine, the first 300 mg injection of Sublocade will be administered. A second 300 mg Sublocade injection will be administered 1 month later and the third and final monthly injection of 100 mg of Sublocade will be administered 2 months post the successful buprenorphine induction.
45819022|NCT03851744|Other|Sea Level|Carbohydrate consumed at 1.8 g/min during treadmill exercise at SL
45819023|NCT03851744|Other|High Altitude|Carbohydrate consumed at 1.8 g/min during treadmill exercise at HA
45819024|NCT00377780|Drug|Non pegylated liposomal doxorubicin, trastuzumab, docetaxel|max. 6 courses
45819025|NCT03242941|Procedure|Pulmonary vein ablation|After pulmonary vein isolation, during the routine waiting time of half an hour to confirm efficacy of the ablation, the septal catheter, already in place in right atrium, will be positioned on the interatrial septum. If the patient will not be in sinus rhythm, he/she will be externally cardioverted in order to determine pacing thresholds and impedances on all septal catheter electrodes. Next, atrial fibrillation will be induced by rapid atrial pacing.AF cycle length will be determined in the left atrial appendage, during 1 minute of atrial fibrillation using ablation catheter electrodes. Subsequently, a pacing scheme will be applied and capture on decapolar recording catheters, already in place for the standard ablation procedure will be assessed as well as AF termination.
45819026|NCT03719300|Drug|inodiftagene vixteplasmid|"BC-819 at 20 mg/50 mL, instilled intravesically into the bladder, with a retention time of at least 30 minutes (up to 2 hours).~Induction Phase (weekly treatments): 10 weekly treatments; Maintenance Phase: treatment every 3 weeks for up to 84 additional weeks"
45819027|NCT04735705|Device|Cerviron|Cerviron ovules ® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.
45819028|NCT00376519|Drug|cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush and mesna (MT(S)9006) on day -8 and -7 one hour after fludarabine infusion.
45819029|NCT00376519|Drug|cyclosporine|Will be administered beginning on day -3 and adjusted to maintain a level of >200. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours.
45819030|NCT00376519|Drug|fludarabine phosphate|Fludarabine 25 mg/m^2/day will be administered as a 1 hour intravenous infusion on days -9 through -7.
45664599|NCT05372549|Other|MAGENTA AI|Non-invasive technique analyzing images of oocytes that can differentiate oocytes with a higher reproductive potential reflective of their quality
45819031|NCT00376519|Drug|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3, at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).
45819032|NCT00376519|Procedure|Treg cell infusion|On day -1 prior to UCB transplantation, Treg cells will be infused IV without in-line filtration. A semi-log dose escalation of CD4+CD25+ Treg cells is scheduled with 3 patients at each step. Doses will be 0.1 x 10^6/kg, 0.3 x 10^6/kg, 1 x 10^6/kg and 3 x 10^6/kg weight (determined on the day prior to administration of the preparative therapy).
45819033|NCT00376519|Procedure|umbilical cord blood transplantation|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. The UCB will be administrated by IV infusion without in-line filtration.
45819034|NCT00376519|Radiation|total-body irradiation|Radiotherapy: 165 cGy will be administered on day -5 through -2 two fractions each day.
45819035|NCT00422864|Drug|oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
46079365|NCT05538481|Other|Systems of Belief Inventory (SBI-15R)|A 15-item questionnaire designed to measure religious and spiritual beliefs and practices and the social support derived from a community sharing those beliefs.
45664600|NCT05306093|Dietary Supplement|Nutraceutical|Food supplements are consumed during 8 weeks by healthy volunteers
45664601|NCT05306093|Dietary Supplement|Maltodextrin|Food supplements are consumed during 8 weeks by healthy volunteers
45664602|NCT04251065|Drug|Daratumumab|"Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin (D-GDP).~Induction phase:~4-6 courses (according to response after cycle 4 and to patient compliance) of D-GDP every 21 days pursuant to the following schedule: Daratumumab cycle 1: 8 mg/kg i.v. on day 2 and on day 9; cycle 2-6: 16 mg/kg i.v. on day 2 and day 9) Gemcitabine 1000 mg/sm i.v. day 1 and day 8 (gemcitabine on day 8 to be skipped in case of grade 3-4 toxicity) Cisplatin 75 mg/sm i.v. day 1 Dexamethasone 40 mg i.v. or po days 1-2-3-4-9 G-CSF from day 3 to 6, and from day 10 to 13 (to be prolonged if necessary)~Maintenance:~starting 28 days after the beginning of cycle 4 or 6 (or, in case of toxicity grade > 1, after toxicity is resolved) and up to 24 cycles from start of D-GDP according to the following schedule: Daratumumab 16 mg/kg single administration every 28 days."
45664603|NCT05338697|Diagnostic Test|Transcranial Magnetic Stimulation (TMS)|No intervention used. This study is using TMS to obtain motor evoked potential (MEP), a prognostic biomarker. The TMS procedure is being conducted during the first week of hospitalization, which required registration under an IDE. Only TMS devices that have received 510(k) clearance from the FDA are used in this study, consisting of MEGA-TMS and MagStim 200-2.
45819036|NCT00422864|Drug|fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
45819037|NCT00422864|Drug|leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
45959563|NCT02922400|Behavioral|Social Cognition Assessment and Training|The study includes an assessment and treatment phase: The assessment phase will test the efficacy and feasibility of a battery of measures evaluating social cognition and behavior. Functional magnetic resonance imaging (fMRI) will also be used to investigate functional differences in regions of the brain associated with social cognition and differences in cognitive progressing. The treatment phase will assess the efficacy and feasibility of a strategy-based social skills treatment using a virtual reality platform.
45959564|NCT00180609|Device|Automatic threshold test in Insignia Pacemakers from Guidant|
45959565|NCT02922244|Other|Control|Apply moisture cream to the treatment skin everyday after radiation therapy
45959566|NCT02922244|Other|Cucumber cream|Apply cucumber cream to the treatment skin everyday after radiation therapy
45959567|NCT02922244|Other|Centella cream|Apply centella cream to the treatment skin everyday after radiation therapy
45959568|NCT02922244|Other|Thunbergia cream|Apply thunbergia cream to the treatment skin everyday after radiation therapy
45959569|NCT02922166|Drug|SRX246|oral capsule
45959570|NCT02922166|Drug|Placebo|oral capsule
45959571|NCT04705493|Other|fluid resuscitation with crystalloid|give two-volume of fluids initial 250ml then another 250 ml
45959572|NCT02922127|Drug|Ulipristal Acetate|Daily use of Ulipristal Acetate
45819038|NCT00422864|Procedure|External beam radiotherapy|Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Weeks 8-10: as per Weeks 3-5
45819039|NCT03719378|Other|Pre Operative Oral Fluids|Patients will be self hydrating prior to their total knee replacement.
45959573|NCT02922127|Drug|Combined Oral Contraceptive Pill|Daily use of Oral Contraceptive Pill
45959574|NCT02922322|Other|Pilates Group|The Pilates group program (PG) was composed of 16 sessions, 2x per week, 60 minute session each for 8 weeks. The intervention was based on 20 out of the 34 original mat exercises proposed by the Pilates method, classified into basic, intermediate or advanced levels divided into 4 cycles of 5 exercises each. The exercises were performed during two series of 10 repetitions respecting the patients skills.
45959575|NCT02921854|Other|Blood withdrawal|For each patient, 3 blood withdrawals of 25 ml each will take place during treatment
45959576|NCT02921659|Dietary Supplement|Niagen™|nicotinamide riboside chloride, 250mg capsules
45959577|NCT02921659|Dietary Supplement|Placebo|silicified microcrystalline cellulose, vegetarian capsule
45819040|NCT03368053|Procedure|Blood sampling|Blood samples will be taken during the single study visit at Year 14 for the assessment of: HIV testing, antibody determination, cell mediated immune (CMI) responses and exploratory characterisation.
45819041|NCT03719612|Drug|DEFINITY®|All subjects will receive a single dose of DEFINITY®
45819042|NCT04706611|Procedure|Fecal Microbiota Transplantation|Procedure: Fecal Microbiota Transplantation
45819043|NCT03373591|Drug|Liposomal Bupivacaine TAP block|Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
45819044|NCT03373591|Drug|Bupivacaine TAP block|Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
45819045|NCT03720938|Other|Active Video Games|Nintendo Wii® AVGs from sports, balance, aerobics, resort and training categories.
45959578|NCT00406211|Biological|MMRV|
45959579|NCT00406211|Biological|MMR (Priorix®)|
45959580|NCT00406211|Biological|Varicella (Varilrix®)|
45959581|NCT00188097|Behavioral|Diagnosis of variceal bleeding and dits control in cirrhosis|
45959582|NCT02921932|Dietary Supplement|Ensure, Resource 2.0 and Glucerna|Preoperative nutritional supplement for undernourished patients
45959583|NCT02921932|Other|Cognitive Training, Memory Card Game|Preoperative memory card game
45959584|NCT02921932|Device|'Threshold' Inspiratory Muscle Trainer, Respironics of New Jersey Inc|Inspiratory muscle trainer protocol for strengthening respiratory muscles
45959585|NCT04689100|Drug|JMT101|Monotherapy: Accelerated titration method, IV infusion QW; Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles)
45959586|NCT04689100|Drug|JMT101|IV infusion Q2W (28-day cycles)
45959587|NCT00188136|Drug|Melphalan, ATG, Fludarabine|allo Tx during aplasia
45959588|NCT02921698|Device|FRED®|Flow Re-Direction Endoluminal Device
45959589|NCT00406250|Drug|intravitreal injection|1.25 mg in 0.05 cc of bevacizumab
45959590|NCT00406250|Drug|intravitreal injection|1.25 mg of bevacizumab intravitreally injected in a steril field
45664604|NCT01885936|Drug|Albuterol|Initially 4 mg daily for one week, 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
45959591|NCT03878056|Device|Vaginal: UpholdTM Lite Vaginal Support - Boston Scientific|Apical prolapse reconstructive surgery by Transvaginal mesh vs Robotic sacral colpopexy
45959592|NCT03863119|Drug|Vamorolone|2.0 mg/kg/day, 4.0 mg/kg/day, or 6.0 mg/kg/day at physician discretion
45664605|NCT01885936|Drug|Placebo|Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
45959593|NCT00180726|Procedure|Blood sampling, Endoscopic Bronchoscopy, Spirometry|
45819046|NCT03374683|Behavioral|RR Digital Tool|"Participants proceed through three chapters in the tool: https://outsideplay.ca.~Chapter 1: most important attributes they want for their child; their child's favourite play activities; their own childhood play activities; how their child's and their own play activities compare.~Chapter 2: imagining themselves in three video segments where they must decide whether they allow their child to climb a tree, walk home from school, and use box cutters to build a fort. They reflect on their barriers and things that helped them let go.~Chapter 3: revisiting the most important attributes they want for their child and whether there is anything they want to change, setting a realistic goal, outlining steps for attaining that goal, and setting start date."
45959594|NCT02921620|Biological|PRX-102|Intravenous
45959595|NCT02921620|Other|Placebo|Intravenous
45959596|NCT02921347|Procedure|switching between invasive and noninvasive ventilation|As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
45959597|NCT00406289|Procedure|18F-FDG-PET radiotherapy|
45959598|NCT00188175|Radiation|Intensity Modulated Radiation Therapy|Pre-op Intensity Modulated Radiation Therapy for lower limb soft tissue sarcoma.
45959599|NCT02921269|Drug|Atezolizumab|Given IV
45959600|NCT02921269|Biological|Bevacizumab|Given IV
45959601|NCT02921269|Other|Laboratory Biomarker Analysis|Correlative studies
45664606|NCT05509127|Drug|Modified universal adhesive|Application of the modified universal adhesive is done according to manufacturer's instructions using a micro-brush. It is actively rubbed for 20 seconds, gently air-dried for 5 seconds then light cured for 20 seconds.
45959602|NCT00406406|Drug|SKI-606|
45959603|NCT02921542|Device|Laser Atherectomy|The Turbo-Power is laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
45959604|NCT00180765|Procedure|Up to 100ml blood will be taken by venupuncture.|
45959605|NCT00406484|Behavioral|Standard drug counseling|Individual drug counseling
45959606|NCT00406484|Behavioral|BDRC|Behavioral Drug and HIV Risk Reduction Counseling, individual once or twice weekly sessions
45959607|NCT03835585|Device|Gun lock|A cable-style gun lock that can be applied to a wide variety of guns for safe storage. The application of this device to most firearms renders them impossible to use properly while the device is in place and locked.
45959608|NCT03835585|Other|Suicide Risk Assessment|Thorough suicide risk assessment according to guidelines established by research (Joiner et al., 1999; Chu et al., 2015). This is used to determine the severity of suicide risk and appropriate actions to be taken.
45959609|NCT03835585|Behavioral|Safety Planning|A psychological intervention for suicide risk that is based on research (Chu et al., 2015; Stanley & Brown, 2012). This involves listing the following on an index card: activities individuals can use to feel better during a crisis, contact numbers that are important to the individuals, emergency options that are always accessible, and reasons for living. Although the individualized nature of safety plans does not allow for a scripted/uniform approach, for this study they will all include 8 steps and steps 5-8 (emergency options) will be the same for each individual.
45959610|NCT03835585|Behavioral|Lethal Means Counseling|A psychological intervention for suicide risk that is based on research (Bryan et al., 2011; Chu et al., 2015; Rudd, 2006; Stanley, 2018). This involves a psychological clinician discussing, with an at-risk individual, the importance for increasing the distance/obstacles between the individual at risk for suicide and specific types of lethal means. In the present study, the lethal means targeted was firearms and the lethal means counseling approach was able to be standardized/scripted as has been done in previous research (see Stanley, 2018).
45959611|NCT02921464|Other|none - registry clinic followup only|
45959612|NCT00188214|Procedure|contrast-enhanced dynamic CT perfusion study|contrast-enhanced dynamic CT perfusion study pre treatment and post treatment
45959613|NCT02921191|Drug|filgrastim, TBO-filgrastim or pegfilgrastim|First cycle
45959614|NCT00406523|Device|JANUS Stent|
45959615|NCT02921503|Other|mobile topical corticosteroid app|app used on mobile phones that takes the input of providers and suggests topical corticosteroids with specific information on the ingredient, vehicle, and amount
45959616|NCT02920840|Device|Intermittent theta-burst stimulation|see associated arm/group description
45959617|NCT02920840|Device|Negative-peak-triggered-TMS|see associated arm/group description
45959618|NCT02920840|Device|Open-loop replay TMS|see associated arm/group description
45664607|NCT05509127|Drug|Conventional universal adhesive|Application of the conventional Single Bond Universal adhesive is done using a micro-brush followed by rubbing for 20 seconds, gentle air drying for 5 seconds then light curing for 20 seconds.
45664608|NCT05305859|Drug|venetoclax combining chidamide and azacitidine (VCA)|information already included in arm/group descriptions
45664609|NCT05338229|Device|the engineer-built system, video-game based Kinect sensor|The engineer-built system, video-game based Kinect sensor was developed by the researcher team.
45959619|NCT02920801|Drug|saxagliptin|5mg per day for 12 weeks
45959620|NCT02920801|Drug|Metformin|1500mg per day for 12 weeks
45959621|NCT00154505|Device|Lateral trunk support of wheelchair seating|
45959622|NCT00180843|Drug|salbutamol + ipratropium bromide nebules|
45959623|NCT00180843|Drug|nebulized saline|
45959624|NCT02921152|Procedure|bone marrow aspiration /trephine biopsy|
45819047|NCT03374683|Behavioral|RR In-Person Workshop|Participants engage in a facilitator guided discussion of the same tasks as the RR digital tool. Participants are taken through each task using PowerPoint slides that include the videos from the digital tool. The facilitator guide contains detailed guidance on discussion for each component and length of time to be dedicated to each slide. Participants are provided with a paper booklet to complete that mimics the online tasks.
45959625|NCT02921074|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
45959626|NCT02921074|Other|Commercially available computerized training|
45819048|NCT03374683|Behavioral|Position Statement on Active Outdoor Play|"The position statement summarizes the issues and research regarding children's access to outdoor play and provides recommendations for various stakeholders. It states that access to active play in nature and outdoors - with its risks - is essential for healthy child development and recommends increasing children's opportunities for self-directed play in all settings. The Position Statement includes recommendations for parents, educators, health professionals, administrators and various level of governments to address the barriers to children's outdoor play. It addresses common misconceptions and encourages that danger be differentiated from risk and outdoor play and fun be valued as much as safety (ParticipACTION Canada, 2015; Tremblay et al., 2015)."
45819049|NCT03480685|Device|IVUS and OCT Imaging|Use of an imaging catheter
45959627|NCT02920879|Procedure|PEEP-level, driving pressure|Different levels of PEEP and different levels of driving pressures during mask-ventilation at anesthesia induction.
45959628|NCT02920762|Other|on-interventional study - retrospective database review|
45458495|NCT04461808|Diagnostic Test|digital mammography|"Women will be screened for one round digital mammography, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
45664610|NCT05304689|Diagnostic Test|test for quantitative index of interleukins in the oral fluid|collection of oral fluid and determination of the content of cytokines by test systems in patients with postoperative wound
45959629|NCT02920567|Drug|Octreotide|After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
45959630|NCT02920567|Drug|Placebo|After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
45959631|NCT02920723|Other|Training|
45664611|NCT05336591|Other|Covid-19 pandemic|All participants worked during the Covid-19 pandemic in the preventive or curative healthcare for children with overweight and obesity. We will ask all professionals about their experiences during and after the pandemic.
45664612|NCT05335967|Behavioral|Self-management program|The self-management group will receive the self-management program for 12 weeks, including a self-management application, a self-management manual, and Professional support.
45664613|NCT05335967|Other|Information package|The patients in this group will receive an information package on a healthy diet.
45664614|NCT05335499|Drug|TAS5315 Dose 1|Treatment period: oral administration for 12 weeks, QD
45664615|NCT05335499|Drug|TAS5315 Dose 2|Treatment period: oral administration for 12 weeks, QD
45819050|NCT03378973|Drug|Dexmedetomidine|Patients will randomly assigned to received Arm 1 anesthesia or Arm 2 anesthesia during surgery.
45819051|NCT03380845|Device|Fraxel Restore|Non-ablative Laser. In the study, one side of the face will be treated with Fraxel Restore monthly for three months.
45819052|NCT03380845|Device|Fractora|Fractional Radiofrequency Microneedling Device. In the study, one side of the face will be treated with Fractora monthly for three months.
45819053|NCT04121078|Drug|TAK-906|TAK-906 capsule.
45819054|NCT04121078|Drug|Rifampin|Rifampin infusion.
45819055|NCT03248947|Drug|buprenorphine/naloxone|To relieve opioid withdrawal symptoms and craving, buprenorphine/naloxone will be prescribed by the study-physician and dispensed by the study-pharmacist on a monthly basis. The median expected dose is 16 mg daily, though adjustment by the study physician may be needed due to increased withdrawal and craving from previous study visits. Medication will be provided in the form of a sublingual film.
45959632|NCT02920723|Other|Control|
45959633|NCT00180882|Drug|rituximab|
45959634|NCT02920606|Procedure|Pulpotomy|
45959635|NCT02920606|Procedure|Endodontic treatment|
45959636|NCT02920645|Other|AVM-related ICH|
45959637|NCT02920684|Other|Passive legs mobilisation|A physiotherapist performs a passive leg movement
45959638|NCT02920684|Other|Passive cycloergometer|A motorised cycloergometer performs a passive cycling
45959639|NCT02920684|Other|Muscular electrical stimulation|A neuromuscular electrical stimulation device performs a quadriceps located stimulation
45959640|NCT02920684|Other|FES cycling|A motorised cycloergometer performs a passive cycling with quadriceps neuromuscular stimulation
45959641|NCT02920411|Other|Pediatopic Treatment Cream|Applied twice a day minimum.
45959642|NCT02920411|Other|Pediatopic Body lotion|Applied at libitum.
45959643|NCT00154622|Behavioral|work hardening program|
45959644|NCT00180921|Drug|Imatinib|
45959645|NCT02920489|Drug|Individualized epidural analgesia|Epidural analgesia will begin when asked by the parturients (during the first stage of labor) and the numeric rating scale is 5 or higher. Analgesia will be terminated at the end of the third stage of labor.
45959646|NCT02920489|Drug|Routine epidural analgesia|Epidural analgesia will begin when asked by the parturients (during the first stage of labor) and the cervix is dilated to 1 cm or more. Analgesia will be terminated at the end of the third stage of labor.
45664616|NCT05335499|Drug|TAS5315 Dose 3|Treatment period: oral administration for 12 weeks, QD
45819056|NCT03248947|Other|Pharmacist-administered buprenorphine/naloxone maintenance care|Following buprenorphine/naloxone induction/stabilization with the physician, participants with opioid use disorder will be transferred to the care of pharmacists for the maintenance phase of treatment. Maintenance visits will occur monthly with the pharmacist at the pharmacy location for six months. Buprenorphine/naloxone will be dispensed by the pharmacist at the monthly study visits following participant assessment, communication with the physician, and prescription form the physician.
45819057|NCT04114058|Drug|liposomal bupivicaine|local field infiltration
45819058|NCT04114058|Procedure|Fascia iliaca blockade|fascia iliaca compartment blockade
45819059|NCT03480919|Device|Shen Men acupuncture|20-minute acupuncture session
45819060|NCT03480919|Procedure|Epidural injection|Epidural injection for the relief of back pain
45819061|NCT03817580|Drug|Project X 26ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
45819062|NCT03817580|Drug|Project X 5.1ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
45959647|NCT02920372|Drug|EPOETIN ALFA|
45959648|NCT02920255|Other|Diagnostic|Measurement of spinal tilt
45664617|NCT05335499|Drug|TAS5315 Dose 4|Treatment period: oral administration for 12 weeks, QD
45664618|NCT05335499|Drug|TAS5315 Dose 5|Treatment period: oral administration for 12 weeks, QD
45664619|NCT05335499|Drug|Placebo|"Screening period: oral administration for 2 weeks, QD~Treatment period: oral administration for 12 weeks, QD"
45664620|NCT05531513|Behavioral|Virtual Reality (VR) Meditation|"The VR-Meditation intervention comprises an evidence-based 360-degree high-definition video VR application incorporating elements of nature, mindfulness and compassion. The VR-Meditation intervention is 4 weeks long and includes includes 4 different themes during the course of the program. Each week will focus on a distinct theme and will consist of two 20-minute VR sessions starting with a 10-minute guided meditation related to the weekly theme (one new meditation per week), followed by 10 minutes of open exploration of the virtual environment, for a total of 8 distinct sessions. The weekly themes are as follows:~Week 1 - Mindfulness of the Environment~Week 2 - Embodied Mindfulness~Week 3 - Embodied and Embedded Compassion~Week 4 - Mindfulness, Compassion, and the External Environment~In addition to baseline measures, participants in the VR Meditation condition will be asked to complete measures at mid-point (week 3), post-intervention (week 5), and follow-up (week 9)."
45664621|NCT05531513|Behavioral|Psychoeducational Pamphlet|"The Psychoeducational Pamphlet intervention is 4 weeks long. Participants receive 1 pamphlet per week for a total of 4 different pamphlets. Handouts will provide information about managing stress and enhancing well-being, without referencing nature, mindfulness or compassion (e.g., eating habits, sleep hygiene, relaxation training, art exercises). The handouts will be based on empirical findings and will be written in accessible language with visual charts and specific practices to facilitate their implementation by participants. At the end of the study (i.e., after follow-up), Psychoeducation Pamphlet participants will receive access to the VR-Meditation program.~In addition to baseline measures, participants in the Psycho-educational Pamphlet condition will be asked to complete measures at mid-point (week 3), post-intervention (week 5), and follow-up (week 9)."
45819063|NCT03817580|Drug|Prevantics Maxi Swabstick|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
45819064|NCT03862040|Drug|Cefiderocol|Administered intravenously, at a dosage determined based on renal function.
45819065|NCT03862040|Drug|Standard of Care Antibiotic|Standard of care antibiotic treatment for pneumonia
45819066|NCT03482713|Drug|Gefapixant 45 mg|Gefapixant 45 mg (film-coated tablet) to be administered orally BID
45819067|NCT03482713|Drug|Placebo|Placebo (film-coated tablet) matching gefapixant to be administered orally BID
45819068|NCT00376831|Drug|Midazolam, Fentanyl|fentanyl 0.07 mcg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
45819069|NCT00376831|Drug|KETAMINE, MIDAZOLAM|Ketamine 0.25 mg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
45819070|NCT03857750|Drug|Rocuronium|0.6 mg/kg
45819071|NCT03491917|Device|DBT plus S-View|DBT plus S-View images
45819072|NCT03491917|Device|FFDM alone|FFDM alone images
45819073|NCT03828422|Diagnostic Test|imaging|
45819074|NCT03254719|Other|Study assessments|All participants will be asked to complete study assessments at baseline visit, and weeks 3, 5, 7, and 10. Study participants will receive spinal manipulation and appropriate adjunctive therapies provided by doctors of chiropractic.
45819075|NCT04084028|Behavioral|Active Cooking Classes|6 cooking classes will be held every week for 6 consecutive weeks. The lessons are patterned after Dr. Amy Trubek's cooking pedagogy and will be tailored for those cooking for themselves for the first time. Classes begin with a brief lecture on the day's topic. Students will work in teams of 2 in the foods lab to actively practice skills and cook a meal. Students receive recipes and information sheets that cover pantry supplies, grocery lists, knife skills and cooking equipment. All students attend a 2 hour kitchen intensive demonstration as an orientation.
45819076|NCT04084028|Behavioral|Meal Kits|Students receive 6 weeks of home delivered meal kits. Meal kits include ingredients and detailed instructions for 3 meals, which each serve two people. Students may select meals from a list of 18 options that include vegan, vegetarian, and gluten free options.
45819077|NCT04084028|Behavioral|Recipes|Students are emailed a set of recipes once a week for 6 weeks. Recipes include options for breakfast, lunch, dinner, and snacks. Recipe sets include vegan, vegetarian, and gluten-free options. This intervention was cancelled by COVID-related disruptions and did not take place.
45959649|NCT00188331|Behavioral|Neuropsychological Testing|neuropsychological testing with traditional tests, CANTAB and six elements test as well as questionnaires
45819078|NCT03387319|Behavioral|Racialized Stressful Event Recall|"Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, race-related event.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses."
45819079|NCT03387319|Behavioral|Non-Racialized Stressful Event Recall|"Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, event unrelated to race.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses."
45455174|NCT02529163|Other|Late-life Schizophrenia ICP|"The ICP medication algorithms first trial begins with:~Risperidone titrated to a max dose~Failure to Risperidone will lead to a second trial with either:~Quetiapine OR Aripiprazole~If subject refuses or if this trial does not work, then offer:~Ziprasidone or Loxapine~Failure of 2 anti-psychotic trials results in:~Clozapine trial~If subject refuses a Clozapine trial then:~Olanzapine offered~titrations occur over 33-36 day period (inpatient) or 12 week period (out patient) with each 0.5 mg titration after the target dose requiring a CGI-E~If compliance is an issue then a depot preparation:~Paliperidone~Risperidone~Flupentixol~Aripiprazole~Physicians will be prompted for non-pharmacological interventions"
45664622|NCT05301491|Other|Dance Therapy Group|"Dance therapy group patients are going to be treated 3 days a week for 8 weeks. Patients who started treatment are going to be randomly divided into groups that includes four individuals, due to COVID-19 pandemic preventions.~Dance therapy is going to be applied with individualized choreographies specially prepared for the patients, taking the expert opinion of the dance therapist. Choreographies of different dance genres (step/aerobic dance, zumba, salsa, bachata, oriental etc.) are going to be used in the program. Sessions are going to be with the practitioner in a bright, clean, empty and noiseless room in front of a full-length wall mirror. The practitioner is going to participate to dance therapy throughout the sessions, allowing patients to imitate movements. Session duration is going to be 40 minutes. Patients will be given a one-minute rest period during music transitions."
45819080|NCT03852524|Drug|Methylnaltrexone|Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving methylnaltrexone (study drug) will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
45819081|NCT03852524|Other|Placebo|Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving placebo will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
45819082|NCT03388645|Biological|10^6.3 PFU of RSV A2|Each adult volunteer will receive a single intranasal inoculation of 10^6.3 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.
45959650|NCT02920294|Dietary Supplement|Probiotic 1|Fresh fermented dairy drink containing yoghurt ferments
45959651|NCT02920294|Dietary Supplement|Probiotic 2|Fresh fermented dairy drink containing probiotic strain
45959652|NCT02920294|Dietary Supplement|Placebo|Acidified dairy drink without ferments
45959653|NCT02919904|Device|ARESTM|"The ARESTM device is a commercial home sleep-testing device that can record the following parameters (for up to 7 continuous hours) when participants are asleep:~NREM and REM sleep frequency and duration~Duration and number of arousal~Blood oxygen saturation and pulse rate via a silicone-embedded optical sensor~Fluctuation in nasal airflow pressure via a nasal cannula and pressure transducer~Head movement actigraphy and flux in snoring as measures of sleep/wake patterns via two accelerometers and an acoustic microphone~Apnea/hypopnea index and respiratory disturbance index"
45959654|NCT00154661|Drug|pentoxifylline|
46079366|NCT05535309|Drug|cefoperazone sulbactam sodium|Cefoperazone sodium and Sulbactam Sodium for injection (1; 1) are white or almost white powder drugs, and the components are cefoperazone sodium and sulbactam sodium
45959655|NCT02920021|Drug|ANB020|ANB020
45959656|NCT02920021|Drug|Placebo|Placebo
45959657|NCT00180960|Drug|Oxaliplatin and irinotecan|
46079367|NCT05534490|Other|therapatic Foot massaje (sweden technic)|Everything is explained to the individuals on the day of surgery. After the surgery, when the individuals regains consciousness in the service, the Swedish massage technique is applied bilaterally for 10 minutes. In addition to the demographic data of the patient before the application and in the preoperative period; pain, mental level, delirium status, mobility, kinesiophobia, balance, and functional independence level measurement evaluations are made. Massage is continued for a total of 20 minutes, 10 minutes for each foot, once a day until the patient is discharged. The measurements are repeated on the day the individual will be discharged.
45455175|NCT02529163|Other|Treatment as Usual|"The TAU group will be offered non-pharmacological interventions such as (but not limited to):~metabolic monitoring~skin hygiene~pain management~nutritional counseling~family counselling~Financial/housing support~Group CBT (Cognitive Behavioral Therapy)~Physicians treating this group will use their own discretion as they will not be prompted like the ICP group.~Pharmacological interventions contain anti-psychotic medication selected at the discretion of the treating physician provided it fall under the current standard of care such as:~Risperidone~Aripiprazole~Quetiapine~Olanzapine~Paliperidone~Clozapine~Ziprasidone~Max dosing and the time to reach the target dose is done at the discretion of the treating physician."
45959658|NCT02919943|Procedure|Percutaneous Coronary Intervention|OCT-guided Percutaneous Coronary Intervention.
45664623|NCT05301491|Other|Exercise Group|"The patients in the control group is going to perform conventional low back exercises. The program of the patients will start with stretching and warming exercises, and will continue with strengthening exercises.~Exercises planed for control group;~Unilateral hip-knee flexion (self-assisted exercise)~Bilateral hip-knee flexion (self-assisted exercise)~Straight leg lifting with the aid of a sheet/rigid band~Posterior pelvic tilt~Bridge building exercise~Cat-camel exercise~Half shuttle in sagittal plane~Right and left rotational shuttle~Trunk hyperextension in prone position~Rotational exercise with hip-knee flexed in supine position Patients are going to do exercises with ten repetitions. As the sessions progressed, the number of repetitions will be increased."
45455176|NCT05321134|Device|Single port robotic colorectal surgical procedure|"After screening and counseling, study subjects who wish to participate will undergo the colorectal surgical procedure (determined based on routine standard clinical care) using the alternate Intuitive Da Vinci Single Port SP system rather than the currently used multiport system, (Intuitive Da Vinci Multiport Xi System).~Using standardized case report forms, the investigators will track clinical parameters and describe the safety & quality event rate for SP platform transabdominal and transanal colorectal operations."
45455177|NCT01214941|Drug|Placebo|The subjects will be given orally placebo twice a day for 5 days prior to the study.
45455178|NCT01214941|Drug|Ticlopidine|The subjects will be given orally ticlopidine 250mg twice a day for 5 days prior to the study.
45664624|NCT05301491|Other|Pyhsiotherapy Modalities|20 minutes hotpack, 3-5 minutes ultrasound and 20 minutes conventional type Transcutaneous Electrical Nerve Stimulation (TENS) are going to be applied to lumbar region of all patients in prone position.
45819083|NCT03388645|Biological|10^7 PFU of RSV A2|Each adult volunteer will receive a single intranasal inoculation of 10^7 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.
45664625|NCT05368415|Drug|Norepinephrine|mothers will received NE bolus of 3,4 or 5 mcg for management of hypotension according to group allocation
45664626|NCT05529173|Drug|Povidone-Iodine 10%|Nasal swab stick application of Povidone-Iodine 10% prior to surgery
45819084|NCT04081610|Drug|lagricel ofteno multidose|"Dosage: 1 drop 4 times a day per 7 days, both eyes~Route of administration: Ophthalmic"
45819085|NCT04081610|Drug|lagricel ofteno single dose|"Dosage: 1 drop 4 times a day per 7 days, both eyes~Route of administration: Ophthalmic"
45819086|NCT03390907|Device|Hybrid APC|Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.
45819087|NCT04713878|Other|Mesenchymal stem cells|Intravenous infusion of Mesenchymal stem cells
45819088|NCT03840278|Device|Bihormonal iLet Bionic Pancreas|Bihormonal iLet Bionic Pancreas using insulin and dasiglucagon
45819089|NCT03840278|Device|Insulin-only Bionic Pancreas|Insulin-only iLet Bionic Pancreas using just insulin
45819090|NCT03840278|Drug|Dasiglucagon|Experimental stable glucagon for use in the iLet Bionic Pancreas
45819091|NCT03496987|Device|Vacuum Bottle Drainage|Patients undergo drainage via vacuum bottles
45819092|NCT04735783|Dietary Supplement|Placebo breakfast|Participants will consume a very low-energy, placebo breakfast meal, but will be unaware of its near complete absence of energy until the end of the study.
45819093|NCT04735783|Dietary Supplement|Typical whole-food breakfast|Participants will consume a typical whole-food breakfast meal, equating to 20% of estimated energy requirements.
45819094|NCT04735783|Dietary Supplement|Water-only control|Participants will consume a volume of plain water to match the water content of the very low-energy placebo breakfast and the typical whole-food breakfast.
45819095|NCT03838874|Drug|Low-Dose Bupivacaine|10 mg (2 mL of 0.5%) administered as an isobaric spinal anesthetic
45959659|NCT00154700|Drug|Paclitaxel,Cisplatin,5-Fu,Folic Acid|
45819096|NCT03838874|Drug|Mepivacaine|70 mg (3.5 mL of 2%) administered as an isobaric spinal anesthetic
45959660|NCT02920099|Other|Nutrition Literacy Assessment Instrument (NLAI)|Assessment tool which combines elements of different nutrition literacy tools.
45959661|NCT04688983|Drug|Ponatinib|30 mg QD starting day 1, given continuously unless interruption required for toxicity
45959662|NCT04688983|Drug|Blinatumomab|A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2-week treatment-free interval.
45959663|NCT04688983|Drug|Imatinib|starting day 1, given orally at 400mg BID continuously for 8 weeks
46079368|NCT05525286|Drug|SOT102|SOT102 is an antibody-drug conjugate (ADC) targeting CLDN18.2 with the anthracycline PNU as cytotoxic moiety.
45819097|NCT04332302|Other|Power resistance training|Participants will take part in an intervention of 12 weeks duration in which they will train with musculation machines.
45819098|NCT03815240|Other|No dressing|no dressing at sacrum
45819099|NCT03815240|Other|Mepilex® Border Sacrum|adhesive sacrum dressing
45819100|NCT03815240|Other|ALLEVYN Life Sacrum|adhesive sacrum dressing
45959664|NCT00188370|Procedure|high frequency ultrasound imaging|
46079369|NCT05523635|Device|Gamma4 Nailing System|The Gamma4 Nailing System is is indicated for the treatment of stable and unstable fractures as well as for stabilization of bones and correction of bone deformities in the intracapsular, trochanteric, subtrochanteric and shaft regions of the femur (including osteoporotic and osteopenic bone).
46079370|NCT05523167|Biological|EFG PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
45819101|NCT03815240|Other|Optifoam® Gentle Sacrum|adhesive sacrum dressing
46079371|NCT05523167|Other|PBO|Subcutaneous injection of placebo coformulated with rHuPH20, a permeation enhancer
45959665|NCT02919865|Device|MR perfusion imaging|"MR perfusion imaging will be performed in addition to the routine neuronavigational sequence obtained from re-operative/therapy planning.~Following MR examination, patient may undergo a surgical biopsy or excision as determined clinically by the neurosurgeon.~All patients, including those who do not go to surgery, will undergo clinical follow-up and imaging follow-up with perfusion imaging. This will allow for assessment of lesion progression over time, yielding valuable diagnostic information in differentiating radiation necrosis from tumour recurrence, particularly in those patients who do not undergo surgery."
45664627|NCT05529173|Drug|0.9% NaCl Solution|Nasal swab stick application of 0.9% NaCl Solution prior to surgery
45664628|NCT05300867|Other|Neurorehabilitation|Neurorehabilitation with soft exsoskeleton robotic 3-week-long
45959666|NCT02920060|Drug|Intravenous levetiracetam|intravenous levetiracetam(30mg/kg bolus followed by 20mg/kg/dose IV 12 hourly).
45959667|NCT02920060|Drug|Sodium valproate|intravenous sodium valproate(20mg/kg bolus followed by 10 mg/kg/dose IV 8hrly)
46079372|NCT05510661|Device|Export Catheter|Manual thrombus aspiration with the use of export catheter during primary PCI
45664629|NCT05300867|Other|Physiotherapy|Physiotherapy 3-week-long
45664630|NCT05335109|Drug|Xenon|"Xenon is injected into the body by inhalation in the form of xenon-oxygen mixtures, in which the concentration of xenon is 30%, and oxygen is 30%.~Xenon inhalation is carried out for 30 min daily for 3 days."
45819102|NCT04071392|Procedure|Hysterosalpingogram (HSG)|An infusion pump delivered saline via balloon catheter under continuous pressure monitoring. After one minute, investigators withdraw the fluid and recorded volumes in and out. Subjects then undergo hysterosalpingogram (HSG) for evaluation of tubal patency.
45819103|NCT04045964|Drug|nicotine replacement therapy (NRT)|Participants were provided with either 2 weeks of 14-mg or 21-mg transdermal nicotine patches for every smoker in the home
45819104|NCT04045964|Behavioral|motivational advice|Received two in-hospital motivational advice sessions by a research associate (RA). The RA adapted session content from a previous tobacco-smoke exposure protocol
45819105|NCT04045964|Behavioral|Quitline referral|Quitline participants received information about tobacco-smoke exposure reduction and a referral to a tobacco Quitline.
45819106|NCT03941912|Device|Erchonia EVRL|Single treatment with the Erchonia EVRL to the neck and shoulders. The treatment applies 635 nanometers (nm) red diode light and 405 nm violet diode light simultaneously.
45819107|NCT04048460|Device|Delivery of hearing healthcare through eAudiology application|Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
45819108|NCT05314400|Diagnostic Test|Full Gadoxetate-enhanced liver MRI|Standard pulse sequences
45819109|NCT05314400|Diagnostic Test|Shortened Gadoxetate-enhanced liver MRI|Fewer pulse sequences
45819110|NCT04016324|Device|InterStim Basic Evaluation lead and foramen needle|Commercial devices within their intended use as described in approved Instructions for Use.
45819111|NCT04039412|Drug|Hybrid regimen|two-step (dual-quadruple) treatment
45959668|NCT03740815|Procedure|Serratus plane block|Ultrasound guided injection of local anesthetic between latissimus dorsi and serratus muscles at mid axillary line.
45959669|NCT03740815|Procedure|Axillary dissection|Axillary dissection is a surgical procedure that incises the axilla to identify, examine, or remove lymph nodes.
45959670|NCT03740815|Procedure|Intravenous sedation|Administration of sedatives thru an intravenous access to achieve relaxion and improve operative conditions.
45664631|NCT05335109|Drug|Oxygen 30 %|"Oxygen-air mixture is injected into the body by inhalation. The oxygen concentration is 30%.~Inhalation of oxygen-air mixture is carried out for 30 min daily for 3 days"
45664632|NCT05300399|Device|mHealth app|The local healthcare providers will be assigned to an intervention group receiving the mHealth app to be used in their daily practices or a control group.
45664633|NCT05300087|Drug|Albuterol Sulfate Inhalation Aerosol 108mcg per actuation|MDI, 2 puffs, single dose, fasting
45664634|NCT05300087|Drug|Proair HFA (albuterol sulfate) Inhalation Aerosol 90mcg per actuation|MDI, 2 puffs, single dose, fasting
45664635|NCT04137575|Behavioral|ConquerFear-Group|The intervention consist of one 1½-hour individual session in which a psychologist will conduct an oral psychological assessment, and five 2-hour group sessions. The key goals of the intervention are to: a) teach strategies for controlling worry and excessive threat monitoring; b) modify underlying unhelpful beliefs about worry; c) develop appropriate monitoring and screening behaviors; d) educate about follow-up care and empirically-supported behavioral change (e.g., weight loss, exercise, etc.) to improve overall survival; e) address existential changes brought about by a cancer diagnosis; f) promote goal-setting. Each session is accompanied by home-based practice of skills learned in session and home reading to consolidate skill acquisition. Four trained psychologists (MSc) will perform the therapy. The intervention will be delivered on Zoom, a secure online platform.
45819112|NCT04039412|Drug|Reverse hybrid regimen|one-step two-phase (quadruple-dual) treatment
45959671|NCT00154739|Drug|Gemcitabine|
45959672|NCT00154739|Drug|Cisplatin|
45959673|NCT00154739|Drug|Epirubicin|
45959674|NCT00180999|Drug|Erythropoiétine|
46079373|NCT05510661|Device|Balloon catheter|Predilatation with balloon catheter
46079374|NCT05507099|Biological|Bone Marrow Aspirate, Lipoaspirate Concentrate|Autologous Cell Therapy.
45959675|NCT02919553|Procedure|modified wet-suction technique|Normal saline will be present in this needle, and once in the lesion of interest the suction will be re-established and the needle will be moved in a to-and-fro motion to collect the sample of interest. Then the sample will be collected.
45959676|NCT02919553|Procedure|"Capillary slow pull technique"|The needle will be introduced into the lesion of interest and using the to-and-fro motion, collect the sample. The needle will then be withdrawn and the sample will then be collected.
45819113|NCT04039412|Drug|Levofloxacin quadruple regimen|non-Clarithromycin non-Bismuth quadruple therapy
45959677|NCT02919709|Biological|blood taking|
45959678|NCT02919514|Other|Physical training on hard surface.|Physical training on hard surface.
45819114|NCT04036838|Combination Product|PyloPlus UBT System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
45819115|NCT04036838|Diagnostic Test|Histology|Biopsy specimen fixed with 10% buffered formalin were cut into 4mm sections, stained with Giemsa stain, and examined by experienced pathologist
45959679|NCT02919514|Other|Physical training on sand surface.|Physical training on sand surface.
45959680|NCT02919514|Other|Physical training on soft surface.|Physical training on soft surface.
45959681|NCT00154778|Drug|Taxol, UFT,Leucovorin|
45959682|NCT00188409|Procedure|CT scan|
45959683|NCT02919631|Drug|Triheptanoin|Anaplerotic dietary oil
45819116|NCT04036838|Diagnostic Test|Rapid Urease Test|Biopsy specimen obtained and placed onto Rapid Urease Test
45959684|NCT02919631|Drug|Placebo oil|Safflower oil
45959685|NCT02919748|Other|Choral Singing|Weekly sessions at 1 hour of choral singing.
45959686|NCT02919748|Other|Health Education Program|Weekly session at 1 hour of health education talk and group activities
45959687|NCT00154817|Procedure|radiotherapy|
45959688|NCT00188448|Device|MRI|
45959689|NCT03670147|Device|PF-SCS programming|In a blinded fashion, the study physician will ask subjects to switch their PF-SCS to the LAP.
45959690|NCT03664648|Biological|HEPLISAV-B|This study is strictly observational. Administration of HEPLISAV-B, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
45959691|NCT02919319|Drug|ACT-541468 (Formulation A)|Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg
45959692|NCT02919319|Drug|ACT-541468 (Formulation B)|Soft gelatin capsules for oral administration formulated at the strength of 25 mg
45959693|NCT02919319|Drug|Placebo (Formulation A)|Hard capsules matching ACT-541468 Formulation A
46079375|NCT05506046|Behavioral|Reduced nicotine message exposure|Participants will be shown two messages about harms of reduced nicotine cigarettes. The two messages will be drawn from a pool of five messages. The messages will communicate that reduced nicotine cigarettes will still have the rest of the harmful chemicals and cause diseases as the regular cigarettes, but they would make it easier to quit.
45819117|NCT04036838|Diagnostic Test|H.pylori Culture|Biopsy specimen obtained and sent to lab for culture analysis
45959694|NCT02919319|Drug|Placebo (Formulation B)|Soft capsules matching ACT-541468 Formulation B
45959695|NCT02919319|Drug|14C-labeled ACT-541468|Tracer at a nominal dose of 250 nCi (corresponding to 2.02 µg ACT-541468) administered either orally or intravenously
45819118|NCT03831854|Drug|Lamotrigine 300 MG|300 mg of oral Lamotrigine. One of the key studies in this area was reported at the Society of Neuroscience meeting in 1997 and later published in the Archives of General Psychiatry. This study reported that, in healthy subjects 300 mg oral lamotrigine significantly decreased ketamine-induced perceptual abnormalities as assessed by the Clinician-Administered Dissociative States Scale (P<.001).31 Furthermore lamotrigine increased the immediate mood-elevating effects of ketamine (P<.05).
45959696|NCT02919319|Drug|Placebo tracer|Sterile NaCl 0.9% was used as placebo matching the tracer for oral and i.v. administration.
45959697|NCT00154856|Behavioral|Detect the variation of limb lengthening|
45959698|NCT00181038|Device|Peri-Neuronal Catheter|
45959699|NCT02919202|Procedure|Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.|Topical application to exposed dentine on one occasion.
45959700|NCT02919202|Procedure|Self-etching Dentine Bonding Agent|Topical application to exposed dentine on one occasion followed by light-curing procedure.
45959701|NCT02919358|Other|Music|
45959702|NCT02919358|Other|No music.|This is the control group.
45959703|NCT00154895|Drug|intrapleural minocycline instillation|
45959704|NCT02919397|Device|Wearable technology|Buddi wearable technology will record activity levels, participants will access activity data through smartphone application
45959705|NCT02919397|Behavioral|Diabetes Prevention Programme educational material|Educational material accessed through smartphone application
45959706|NCT02919397|Behavioral|Motivational messaging|Messages sent via smartphone application
45959707|NCT02919124|Device|Echoclip|An ultrasound transducer positioning device, the Echoclip device (Aalborg Hospital, Aalborg,Denmark), which can stabilize the involved part of the myocardium on the beating heart, keep the gel at place, and position the ultrasound transducer correctly for imaging will be used for visualising the coronary bypass anastomoses during surgery
45959708|NCT00181077|Drug|2% buffered hypertonic saline administration|
45959709|NCT02919085|Procedure|Early ambulation|Procedure to accelerate the ability of a patient to walk or move about by reducing the time to ambulation. It is characterized by a shorter period of hospitalization or recumbency than is normally practiced.
45959710|NCT02919046|Biological|GD2-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-GD2-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
45959711|NCT02918929|Drug|EDP 305|
45959712|NCT02918929|Drug|Placebo|placebo to match EDP 305
45959713|NCT00181116|Drug|Levetiracetam|
45959714|NCT02918812|Drug|Intracervical lidocaine|Intracervical lidocaine injected at four different points
45959715|NCT02918812|Drug|Intramuscular Diclofenac|Intramuscular Diclofenac 30 mins before HSG
45959716|NCT00188487|Device|magnetic resonance imaging (MRI) of the thorax|
45959717|NCT02918539|Drug|florbetapir F 18 PET scan|For those patients who do not have an existing amyloid scan, each will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 followed by a Positron Emission Tomography (PET) Scan to determine amyloid status
45959718|NCT02918422|Other|Nutritional and Dietary Manipulation|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
45959719|NCT00188526|Device|lung biopsy|
45959720|NCT02918461|Behavioral|Emerging from the Haze class|A 6-week class designed to combat chemotherapy-induced cognitive dysfunction. Patients will report symptoms at 6 months and 1 year after the end of their Haze class.
45959721|NCT02918383|Diagnostic Test|Indocyanin Green Dye (ICG)|
45959722|NCT02918578|Other|"Phone group"|"Participants in the phone group receive 12 individually tailored coaching sessions (15 - 20 min). The coaching calls are scheduled biweekly. Participants receive their tailored advice via interactive counseling."
45959723|NCT02918578|Other|"Phone and SMS group"|"The phone and SMS group receive the same coaching as the phone group. They additionally receive two tailored SMS per week over the course of six months."
45455179|NCT01214941|Drug|Ticlopidine and itraconazole|The subjects will be given orally ticlopidine 250mg twice a day and itraconazole 200mg as a single daily dose for 5 days prior to the study.
45959724|NCT02918578|Other|"single writing group"|"The control intervention consists of a minimal credible physical activity PA promotion program. Participants in the control group receive a singular written advice and an activity plan but no counseling by phone."
45959725|NCT02918188|Drug|Hydrogen|Patients will receive hydrogen-rich water orally (500mL three times one day, 0.6mM)
45664636|NCT04137575|Behavioral|Relaxation Training|The control group will receive one 1½-hour individual session and participate in five 2-hour group sessions. Patients will receive guided progressive muscle relaxation training. The intervention will be delivered on Zoom, a secure online platform.
45664637|NCT05299229|Diagnostic Test|Echocardiogrpahy and non-invasive monitoring|Study participants will have echocardiography and non-invasive monitoring by chest/back sensors and a finger cuff.
46079376|NCT05506046|Behavioral|Modified risk message exposure|Participants will be shown two messages about electronic cigarettes as an alternative to regular cigarettes. The two messages will be drawn from a pool of five messages. The messages will communicate that electronic cigarettes are less likely than regular cigarettes to cause severe diseases such as lung cancer.
46079377|NCT05506046|Behavioral|Combined message exposure (reduced nicotine + modified risk)|Participants will be shown two messages, one from the reduced nicotine message set and one modified risk message set.
45664638|NCT05333627|Behavioral|Wellbeing Course for Students (Fast Track)|The core Fast-Track lesson includes information on managing their cycle of symptoms, motivation, and an overview of strategies that can be used to manage symptoms of depression and anxiety. After the core lesson, clients can access three additional Do-It-Yourself guides that focus on thought challenging, controlled breathing/activity planning, and behavioural activation/relapse prevention. These materials are able to be accessed out of sequence on a schedule that suits their needs. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
46079378|NCT05506046|Behavioral|Control message exposure|Participants will be shown two messages about drinking bottled water. These will be selected from a pool of five message. The messages display specific water products and describe hydration as a healthy activity.
46079379|NCT05503875|Biological|adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate|Psoriasis patients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.
46079380|NCT05503108|Other|Fasting Mimicking diet program|Fasting mimicking diet by L-Nutra, a 4-day low caloric, low protein, vegetarian diet 3 days prior to and the day of neoadjuvant chemotherapy administration. The FMD will take place every 4 weeks, thus in total 5 times (2x during ddAC, 3x during Paclitaxel) during the neoadjuvant chemotherapy.
45455180|NCT01217905|Drug|AZD7687|Oral suspension
45664639|NCT05333627|Behavioral|Wellbeing Course for Students (5 weeks)|The 5-week course consists of four lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
45664640|NCT05333627|Behavioral|Wellbeing Course (8 weeks)|The 8-week course consists of five lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
45819119|NCT03831854|Drug|Placebo|300 mg of oral Placebo
45819120|NCT03831854|Drug|Ketamine|1mg/kg bolus at induction followed by 5 microgram/kg/min infusion till the end of the surgery
45959726|NCT00181194|Device|Asthma Control and Communication Instrument|
45819121|NCT03806270|Drug|Midazolam|Demizolam 15mg/ml ampules, given orally with cherry juice
45819122|NCT03806270|Drug|Hydroxyzine Dihydrochloride|Atarax 2mg/ml syrup, given orally
45819123|NCT03828734|Device|Theta TMS|TMS will be administered at the frequency of each subject's endogenous theta oscillation (4-7Hz)
45819124|NCT03828734|Device|Alpha TMS|TMS will be administered at the frequency of each subject's endogenous alpha oscillation (8-12 Hz)
45819125|NCT03828734|Device|Arrhythmic TMS|TMS will be administered arrhythmically; i.e. a sequence of pulses with randomized timing
45959727|NCT02918344|Other|Hydroset|Calcium phosphate paste is used in mandibular lengthening surgery to avoid an unaesthetic notching at the lower border and to help stabilize the segments when osteosynthesis slippage is feared for.
45959728|NCT02918344|Procedure|Standard sagittal split osteotomy|The sagittal split osteotomy (SSO) is commonly used to correct dentofacial discrepancies.
45959729|NCT02918227|Procedure|Search retrograde ejaculation|Sperm count (spz) after orgasm achieved by masturbation will be measured, corresponding to the sum of spz collected in the ejaculate (E) and the first urine after orgasm (U). These measures will be made before surgery (E1 and U1) and after surgery (E2 and U2). The values E1, E2, U1 and U2 will be achieved by multiplying the concentration of spz per unit volume by the total volume of collection.
45959730|NCT02918110|Drug|Misoprostol|Women needed to be induced will get orally administrated solution of misoprostol (Cytotec®) or vaginal slow release misoprostol (Misodel®)
45959731|NCT02918149|Other|Palpation Landmark Technique|"Clinician will follow routine palpation landmark technique procedure for LP, such as identification of anatomic landmarks by palpation (i.e., superior borders of the posterior iliac crest lies in parallel with L4 spinous process). Palpation will be followed by blind stick of the appropriate inter-spinous process space. The study member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid."
45959732|NCT02918149|Device|Ultrasound-Assisted Technique LP|"Clinician will use an ultrasound-assisted technique to perform the LP. The Phillips CX50 ultrasound machine is an FDA approved device and will be used in accordance with its approved labeling. Spinal ultrasound will be performed using a linear high-frequency transducer to locate and mark the termination of the conus medullaris, the narrowing of the spinal canal, and the midline to delineate a safe zone. The study team member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid."
45959733|NCT00181272|Drug|azithromycin|
45959734|NCT02910544|Dietary Supplement|Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
45959735|NCT02910310|Other|Uterine balloon tamponade|An intervention consisting of inserting a condom attached to a urinary catheter into the uterus and inflating it with fluid to stop postpartum bleeding
45959736|NCT02910154|Dietary Supplement|Diet|Weight loss achieved by following an evidence-based low energy diet of 800-1200 kcal/day for 12 weeks (Cambridge Weight Plan). Hereafter follow 12 weeks of 'weight maintenance' with consumption of normal heart healthy diet. Goal: total weight loss of at least 10% without significant loss of muscle mass. Monitored and supervised by a dietician
45664641|NCT05333549|Drug|Istradefylline|2 weeks on istradefylline 20mg daily, 2 weeks on istradefylline 40mg with the ability to adjust other antiparkinsonian medications, and 22 weeks on istradefylline 40mg and stable antiparkinsonian medications
45959737|NCT02910154|Behavioral|Training|Aerobic interval training and resistance exercise in group sessions twice weekly throughout the 24-week intervention. Training intensity individually adapted to the restricted calorie intake. Goal: Improved VO2 peak (at least 10%). Monitored by a physiotherapist.
45959738|NCT02910154|Drug|Medication (with statin and ACE-inhibition)|Medical treatment for hypertension and/or hypercholesterolemia if systolic blood pressure > 130 and/or low density lipoprotein (LDL) > 2.0.
45959739|NCT00181311|Procedure|hysterectomy|
45959740|NCT02910076|Drug|Hydroxychloroquine|200 MG Plaquenil three times a day
45959741|NCT02910115|Other|Cold laparotomy sponges|Cold laparotomy sponges are lap sponges that are saturated in sterile, iced normal saline
45959742|NCT02910115|Drug|Pitocin|Pitocin is administered intravenously according to the usual protocol.
46079381|NCT05502003|Other|High Intensity Interval Training|Telerehabilitation-based high-intensity exercise training will be applied to the participants for 6 weeks, 3 times a week for 35 minutes, under the control of a physiotherapist.
45664642|NCT05297825|Behavioral|Vegan diet|Healthy vegan diet.
45819126|NCT04033640|Diagnostic Test|SD Biosensor STANDARD G6PD Test|"The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care (POC) setting. The test is intended to aid in the identification of people with G6PD deficiency.~The test is currently not licensed for use in Brazil and is considered an investigational product."
45819127|NCT04033640|Diagnostic Test|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
45819128|NCT04033640|Diagnostic Test|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
45959743|NCT02910232|Device|bone void filler|Bone void filler device prepared from porous starch-hydroxyapatite composites for bone regeneration
45959744|NCT00188565|Drug|Celecoxib|
46079382|NCT05502003|Other|Moderate Exercise Training|The participants will be given telerehabilitation-based moderate exercise training under the control of a physiotherapist for 55 minutes, 3 times a week for 6 weeks.
45664643|NCT05297825|Behavioral|Omnivore diet|Healthy omnivore diet.
45664644|NCT05333237|Dietary Supplement|Intervention #1: ProvideXtra Drink|Fasted subjects will be offered 200 ml of ProvideXtra and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
45664645|NCT05333237|Dietary Supplement|Intervention #2: Fresubin Energy Drink|Fasted subjects will be offered 200 ml of Fresubin Energy Drink and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
45819129|NCT04033640|Diagnostic Test|Complete blood count (CBC)|In Manaus, hemoglobin concentration was determined by CBC using an automated hematology analyzer (Sysmex KX-21N).
45819130|NCT03497845|Biological|VN|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
45819131|NCT03497845|Biological|IN|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
45819132|NCT03497845|Biological|dk/BANG|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
45959745|NCT04688086|Diagnostic Test|Thermalytix|Thermalytix is an Artificial intelligence based automated breast screening solution that analyzes thermal distribution on the breast to generate a breast health score automatically. Thermal imaging was performed by a trained technician to capture thermal images of the participant in five views. These thermal images were uploaded to Thermalytix software on the cloud where it was automatically analyzed by AI-based Thermalytix computer-aided detection (CADe) engine. This CADe engine analyzes uploaded thermal images and outputs an interpretation report for each participant with quantitative scores corresponding to computed probability of malignancy based on the structural, vascular, areolar, thermal properties of the observed abnormality. Thermalytix also generates annotated images with markings of abnormal regions and an overall Thermalytix score suggesting likelihood of breast malignancy. The locked AI model Thermalytix algorithm version 3, dated December 2018 was used for the analysis.
45959746|NCT02909998|Other|Blood sample|Conservation at the end of the blood sample
45819133|NCT03497845|Biological|gf/WA|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
45819134|NCT03497845|Biological|bhg/QL|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
45959747|NCT02909803|Other|Lentil Variety|Participants will consume 8 varieties of lentils that are cooked by boiling
45819135|NCT03497845|Biological|AS03 adjuvant|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
45664646|NCT05333237|Dietary Supplement|Intervention #3: Generic Glucose Solution|Fasted subjects will be offered the glucose solution and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
45819136|NCT03497845|Biological|MF59 adjuvant|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
45959748|NCT02909803|Other|White Bread|Participants will consume white bread on at least two different test days
45959749|NCT00181350|Device|Relocatable fixation system|
45959750|NCT02909725|Other|Limit accumulation of sedentary time|"Participants in this group receive a Fitbit Alta activity monitor, worn on the wrist for the entire intervention. The Alta is a fitness tracker designed to help individuals track their sedentary and physical activity behaviors when paired with an external device (e.g. iPhone, computer). The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.~Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to achieve a goal of 250 steps/hour. Using the reminder to move function, if a participant has not reached the hourly goal at 50 minutes, the Alta will vibrate, cueing the participant to walk."
45959751|NCT02909725|Other|Walk|"Participants in this group receive a Fitbit Charge activity monitor. There is no reminder to move function on this band. The Charge, worn on the wrist for the entire intervention is a fitness tracker designed to help individuals track their physical activity when paired with an external device. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.~Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to meet current pregnancy physical activity recommendations; walking 30 minutes, most days of the week (150 minutes/week). Participants can use the app to view their active minutes."
46079383|NCT05496842|Behavioral|Multimodal pulmonary rehabilitation|The rehabilitation is based on the biopsychosocial ICF model of the WHO. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to the needs of the patients.
46079384|NCT05487950|Drug|Rivaroxaban group|Patients assigned in the Rivaroxaban group will receive 15 mg once day or 10 mg if dosage modification is needed due to renal insufficiency (Creatinine clairance calculated with the Cockroft formula between 30 or 49 ml/min).
46079385|NCT05477823|Radiation|External beam radiation therapy|Standard of care EBRT
46079386|NCT05477823|Radiation|Prostate brachytherapy boost|Standard of care BTX
46079387|NCT05477823|Drug|Androgen deprivation therapy|Standard of care ADT
45455181|NCT03934801|Other|Brainstorming 1|Expert recommendation statements will be collected for peer evaluation.
45664647|NCT05332925|Drug|Standard of care immune checkpoint inhbitors|This is NOT an interventional study.
45664648|NCT01912222|Drug|IXAZOMIB|
45664649|NCT05367791|Other|POSTUR|Training sessions without any stimulation
45664650|NCT05367791|Other|Localised Vibration|Training sessions with localized vibration
45664651|NCT05367791|Other|Somatosensory Electrical Stimulation|Training sessions with somatosensory electrical stimulation
45664652|NCT05366933|Drug|Vitamin B-Complex Supplement|Vitamin B-Complex Supplement containing: 5-methyltetrahydrofolate, riboflavin 5 phosphate, pyridoxal phosphate, and methylcobalamin
45664653|NCT05366855|Biological|Imsidolimab|Solution for infusion Solution for injection
45664654|NCT05366855|Other|Placebo|Solution for injection
45664655|NCT05332301|Other|High-fat test meal|Ingestion of a mixed macronutrient breakfast meal providing 846 kcal, of which 58% is fat, 29% is carbohydrate and 13% is protein.
45819137|NCT04036292|Drug|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
45819138|NCT04036292|Drug|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
45819139|NCT03501043|Drug|Dysport|Dysport 1000 to 1500 units to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors.
45819140|NCT00377390|Biological|Omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standardized asthma care for 60 weeks, beginning with the Randomization Visit, as a part of ICATA (ICAC-08, NCTNCT00377572).
45819141|NCT03261973|Device|DV8|DV8 esophageal deviation tool
45819142|NCT03820388|Drug|Propofol 2mg/kg|2 mg/kg
45819143|NCT03820388|Drug|Etomidate 0.3 mg/kg|0.3 mg/kg
45819144|NCT03820388|Drug|Propofol 1 mg/kg|1 mg/kg Propofol
45819145|NCT03820388|Drug|Etomidate 0.15 mg/kg|0.15 mg/kg Etomidate
45819146|NCT03264157|Drug|HRIG|A 20 IU/kg dose of BPL HRIG will be given on Day 0 via IM injection.
45819147|NCT03264157|Drug|HyperRAB|A 20 IU/kg dose of Comparator HRIG will be given on Day 0 via IM injection.
45959752|NCT02909725|Other|Normal daily routine; Usual Care|Participants in this group will not be provided with a Fitbit Charge activity monitor, as participants will be asked to simply continue on with their normal daily routine. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.
45959753|NCT02522260|Other|Resistance and aerobic training|Group 1) includes strength exercise of the large muscle groups (2-3 sets, 8-12 repetitions on an intensity of 80 % of 1-RM) and 3x3 min high intensity aerobic exercise (16-18 on Borg scale) on an exercise bike or treadmill twice a week for 16 weeks
45664656|NCT04250207|Drug|K-321 Solution|K-321 solution drops
45819148|NCT03264157|Biological|RabAvert|A 1.0 ml dose of active vaccine (2.5 IU/ml) will be given IM on 5 occasions: on Days 0, 3, 7, 14, and 28.
45959754|NCT02522260|Other|Aerobic training|Group 2) includes aerobic exercise on an exercise bike or treadmill, 20 min moderate intensity (13-15 on Borg scale), and 3x3 min high intensity (16-18 on Borg scale) twice a week during 16 weeks
45959755|NCT02522260|Other|Standard supportive care|Standard supportive care
45959756|NCT00155246|Drug|pentoxifylline (drug)|
45959757|NCT02909920|Other|Telerehabilitation|Initial Videoconference following telerehabilitation programs self-workout exercise with video support.
45959758|NCT02909920|Other|Traditional Physiotherapy|Traditional Physiotherapy receives assistance in a physiotherapy center with personalized therapy consisting of 1 to 1 with a physical therapist (Manual Therapy, home exercise programs and other physiotherapy techniques).
45959759|NCT00181506|Procedure|dose escalation (radiotherapy treatment schedule)|
45959760|NCT02909881|Dietary Supplement|Use of PhytoSpherix at 0 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 0 g/min during a 150 min cycling exercise
45959761|NCT02909881|Dietary Supplement|Use of PhytoSpherix at 1 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 1 g/min during a 150 min cycling exercise
45959762|NCT02909881|Dietary Supplement|Use of PhytoSpherix at 1.5 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 1.5 g/min during a 150 min cycling exercise
45959763|NCT02909881|Dietary Supplement|Use of PhytoSpherix at 2 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 2 g/min during a 150 min cycling exercise
45959764|NCT02909881|Behavioral|Cycling exercise|Male endurance athletes will complete a cycling exercise for 150 min at 50% of their respective maximum wattage
45959765|NCT02909842|Dietary Supplement|Drinking fermented milk|Drinking fermented milk containing Lactobacillus paracasei (IMULUS)
45959766|NCT02909842|Dietary Supplement|placebo|Acidified placebo milk with similar physical characteristics to the yoghurt drink
45959767|NCT02909842|Biological|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB)|Intramuscular injection of a single shot of influenza vaccine
45959768|NCT02909530|Device|EUS-FNB with EZ Shot 3Plus first|Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
45959769|NCT02909530|Device|EUS-FNB with EZ Shot 2 19G first|Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
45664657|NCT04250207|Drug|Placebo Solution|Placebo solution drops for K-321
45819149|NCT03820544|Procedure|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with SEMS placement
45819150|NCT03820544|Other|Standard of care|Undergo standard of care surgical resection
45819151|NCT03400579|Device|autoRIC® device|The autoRIC® automatically delivers four RIC cycles of five minutes of pressure at 200 mm Hg followed by five minutes of no pressure for a total 40-min treatment period
45959770|NCT00155285|Procedure|computed tomography|
45959771|NCT02909608|Other|No interventions / observations only|This is an observational study only
45959772|NCT02909569|Drug|INCB039110|All subjects will receive 400 mg PO QD for 12 weeks. If no clinical response after four weeks, dose will be increased to 600 mg PO QD. Total duration of subject participation will be six study visit over 20 weeks.
45959773|NCT02909179|Other|mCARE-II|mCARE-II is a package of interventions that provides guided client enumeration and follow-up support to community health workers, automated workflow scheduling, risk assessment, client prioritization and stratification and client-based demand generation messaging. These features are incorporated into a platform called OpenSRP, which integrates text message reminders, scheduling, and form submissions on the server side, and displays schedules and client lists on a tablet-based application for community health workers.
45959774|NCT02909413|Drug|Desﬂurane|Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Desﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, include 50％ O2 and 4～5％ Desflurane.
45664658|NCT05500703|Drug|Dexmedetomidine Injectable Solution|continuous pump of 1.5ug / kg / h Dexmedetomidine 15min before anesthesia induction, continuous infusion for 30min after anesthesia induction, and then nuclear magnetic scanning was started.
45664659|NCT05500703|Drug|Sodium Chloride 0.9% Inj|the equivalent Sodium Chloride 0.9% Inj was continuously pumped before anesthesia induction, induced by opioids for 15min, and intraoperative fMRI scanning was started after continuous infusion for 30min.
45664660|NCT04246151|Drug|Vancomycin|Vancomycin capsules
45664661|NCT04246151|Dietary Supplement|Culturelle|Culturelle capsules
45664662|NCT04246151|Drug|Vancomycin Placebo|sugar pill manufactured to mimic the vancomycin 125 mg capsule
45819152|NCT03801044|Diagnostic Test|NT-BNP, VEGF|VEGF-C levels were measured in the serum samples. R&D Systems kit (Minneapolis, MN) (Catalog Number DVEC00) was used for the assays according to the user instructions. NT-proBNP was measured on the Elecsys 2010 analyzer (Elecsys proBNP Immunoassay; Roche Diagnostics).
45819153|NCT03801044|Diagnostic Test|Echocardiography|Transthoracic echocardiography was performed by the same cardiologist blinded to all other parameters. It was done while abdomen was empty. LV end diastolic diameter (mm), interventricular septum thickness (mm), posterior wall thickness (mm), ejection fraction (%), left ventricle end diastolic volume (ml), left atrial volume (ml), left ventricle mass index (LVMI) (g/m2), left ventricle filling velocity(cm/sec), E/E' ratio, pulmonary artery systolic pressure (mm Hg) were the parameters taken by echocardiography
45959775|NCT02909413|Drug|sevoﬂurane|Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Sevoﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, 50％O2 and 1.7-2.0% Sevoflurane.
45959776|NCT00155324|Device|Extracorporeal Shock Wave Therapy (Device)|
45664663|NCT04246151|Drug|Probiotic Placebo|sugar pill manufactured to mimic 10 billion unit probiotic capsules.
45664664|NCT05331833|Radiation|The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT under PET-CT guidance and the control group with CTV-delineated IMRT using a random number table.|
45959777|NCT02909374|Other|Balance training|The balance-training program was developed based on well-established principles of exercise and on the knowledge that balance control relies on the interaction of several physiological systems, as well as interaction with environmental factors and the performed task. It includes exercise with dual- and multi task performance. It is progressive as the exercises can be performed at different levels (basic, moderate, and advanced), making it progressively challenging for each individual throughout the whole program. The training is conducted as an individually tailored group program.
45959778|NCT02909257|Drug|Same Bupivacaine Concentration|patient is exposed to the same concentration than previously successful one
45959779|NCT02909257|Drug|Lower Bupivacaine Concentration|patient is exposed to a lower concentration than previously successful one
45959780|NCT02909218|Other|Early Access to ART for All|All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines.
45959781|NCT02908945|Drug|Ketamine|Bolus dose before induction of anesthesia and infusion during maintenance of anesthesia.
45664665|NCT05331521|Drug|CETEG|At progression, patients without prior radiotherapy will undergo radiotherapy and PCV as an adjunct chemotherapy if bone marrow reserve allows in the experimental arm.
45664666|NCT05331521|Drug|PCV|In the comparator arm there is the option for second radiotherapy or even reuse of the full radiochemotherapy regimen as it had been given at diagnosis (BIC).
45664667|NCT05331521|Radiation|RT|Radiotherapy at 50.4/54 Gy in 1.8 Gy fractions for grade II and 59.4 Gy in 1.8 Gy fractions for grade III gliomas
45819154|NCT03801044|Radiation|Chest Radiography|All radiographies were taken when the patient was standing erect position during deep inhalation. They were reported by an expert radiologist blinded to clinical data. Films taken at supine position or during exhalation were excluded. Chest radiographies were classified into 3 stages to reflect degree of hypervolemia. Stage 1 was redistribution defined as increased artery-to-bronchus ratio in the upper and middle lobes. Stage 2 was interstitial edema evident by Kerley B lines and peribronchial cuffing. Stage 3 was alveolar edema phase perihilar consolidation and air bronchograms, pleural fluid, increased width of the vascular pedicle, enlarged cardiac silhouette.
45819155|NCT03801044|Diagnostic Test|Lung Ultrasound|It was performed by 28 area method which contains ultrasound examination from second to fifth intercostals spaces at parasternal region, midclavicular line, anterior and mid axillary lines. Lung ultrasound had been done by same radiologist who was an expertise in ultrasonography blinded to all other parameters. It was performed by 1,6 megaHertz convex probe when patient lying at the supine position.
45959782|NCT02908945|Device|NeuroSENSE monitor|NeuroSENSE monitors the brain using electroencephalography (EEG) and produces an index called the WAVCNS. WAVCNS is a measure of depth of hypnosis (DoH).
45959783|NCT02909296|Procedure|Endoscopic drainage|
45959784|NCT04688008|Drug|Hetrombopag|"Drug: Early phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions~Drug: Late phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions"
45664668|NCT05366231|Drug|Kesuting syrup|"Conventional treatment + Kesuting Syrup, take orally, 20 ml once, three times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later). Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully."
45959785|NCT02939833|Procedure|Scalp Nerve Blocks With Ropivacaine|
45819156|NCT03801044|Diagnostic Test|Bioelectrical Impedence Analysis|The Body Composition Monitor (BCM) (type 0BJA1394, Fresenius Medical Care AG & Co. KGaA, D-61343 Bad Homburg) was used for assessment of hydration status in patients. Peritoneal cavities were free of intraperitoneal fluid during measurement. Patients were accepted as normovolemic if their result were between -1.1lt and 1.1 lt.
45959786|NCT02939833|Procedure|Scalp Nerve Blocks With Saline|
45959787|NCT02939677|Other|Targeted exercise|"12 weeks of targeted and supervised exercise intervention vs. care as usual (home based exercises)"
45959788|NCT02939794|Drug|Ferinject|1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery
45959789|NCT02939794|Drug|Placebo|Saline (normal saline, sodium chloride)
45959790|NCT03458104|Other|Cone Beam Computed Tomography|Cone Beam CT of the larynx
45959791|NCT03458104|Diagnostic Test|Acoustic/Auerodynamic testing|Records and displays real-time sound pressure level intensity, intraoral pressure, airflow rate, and fundamental frequency
45959792|NCT03458104|Diagnostic Test|Laryngovideostroboscopy|Visualization of vocal cords in slow motion. It uses a stroboscopic lamp, which generates regular flashes of light. A flexible tube is inserted in the back of the mouth or through the nose and into the throat. Video pictures are then recorded while patients are making sound.
45959793|NCT00188604|Drug|sodium selenite|
45959794|NCT00155363|Device|conventional artificial kidney (AK) vs. high flux AK|
45959795|NCT04853173|Other|Assess pain management modalities in adult outpatient tonsillectomy surgery|use a post-operative analgesia protocol suitable for outpatient surgery. Namely a protocol of analgesia based on the taking of drugs per bone (by mouth) and not intravenous. Pain evaluation.
45959796|NCT00181545|Procedure|escalation of dose (radiotherapy treatment)|
45959797|NCT00155402|Drug|tissue fibrin glue application (Tisseel)|Apply several droplets within several seconds to several minutes
45959798|NCT04838587|Other|No intervention will be done|No intervention,Only passive surveillance of Diarrhoea cases will be done
45959799|NCT04833400|Device|ICRS|Patients undergo 30-minute aerobic training with ICRS, 3 sessions a week, for 4 weeks.
45959800|NCT04833400|Device|TAET|Patients undergo 30-minute aerobic training with TAET, 3 sessions a week, for 4 weeks.
45959801|NCT04808323|Drug|Capecitabine|825 mg/m^2 twice daily during radiation therapy. (Fluorouracil (5-FU) may be used at the discretion of the treating medical oncologists.) This chemotherapy will be given during the initial radiation dose (50 Gy over 25 frac) and continue for Cohorts A, B, and C.
45959802|NCT04808323|Device|Initial Dose of Radiation before Dose Escalation|50 Gy over 25 frac.
45959803|NCT04808323|Device|Cohort A: Dose Escalation Radiation|Cohort A will receive 14 Gy boost for a total of 64 Gy over 32 total fractions.
45959804|NCT04808323|Device|Cohort B: Dose Escalation Radiation|Cohort B will receive 18 Gy boost for a total of 68 Gy over 34 total fractions.
45819157|NCT04029584|Drug|rifampin IV|A 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline will be used to inhibit hepatic OATP1B1 transporters.
45959805|NCT04808323|Device|Cohort C: Dose Escalation Radiation|Cohort C will receive 22 Gy boost for a total of 72 Gy over 36 total fractions.
45959806|NCT04808323|Drug|FOLFOX|After the completion of radiation, subjects will receive up to eight cycles of systemic chemotherapy. (FOLFIRINOX may be used at the discretion of the treating medical oncologists.)
45959807|NCT00188643|Drug|Venlafaxine and Lamotrigine|
45455182|NCT03934801|Other|Ranking Round 1|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
45664669|NCT05366231|Drug|LianHuaQingWen Granules|"Conventional treatment + LianHuaQingWen Granules, orally, 1 bag at a time, 3 times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later).Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully."
45664670|NCT05366153|Diagnostic Test|Coronary CT|Screening/Management Plan
45664671|NCT05295875|Drug|ALT-801|Injected subcutaneously (SC)
45664672|NCT05295875|Other|Placebo|Injected subcutaneously (SC)
45819158|NCT04029584|Drug|Rifadin 300Mg Capsule|Rifadin 600mg by mouth as two 300mg rifadin capsules
45959808|NCT00155441|Behavioral|cognitive-behavioral therapy|
45959809|NCT00533299|Drug|Hydralazine and magnesium valproate|Hydralazine and valproate will start from seven days before day 1 of chemotherapy until the end of the sixth course. Hydralazine will be administered at 182mg (rapid) or 83mg (slow) according to the acetylator phenotype in a single daily dose and magnesium valproate at an oral dose of 40mg/Kg t.i.d.
45959810|NCT00533299|Drug|Placebo|Placebos will start from seven days before day 1 of chemotherapy until the end of the sixth course. Placebo tablets will be administered in an identical form that experimental drugs.
45959811|NCT04788823|Drug|Prednisone|Treatment groups will be administered different dosages of Prednisone post vasectomy reversal.
45959812|NCT04785391|Diagnostic Test|Urine collection for NEPHROCLEAR CCL14 Test|Urine will be collected and banked for future analysis with the NEPHROCLEAR CCL14 Test
45959813|NCT00181584|Drug|Zoledronic acid|Given intravenously once.
45959814|NCT00181584|Other|Placebo|Given intravenously once.
45959815|NCT04769440|Drug|mg sulphate|mgso4 infusion will start 15 minutes after intubation , 30 mg/kg LBW of 10%mgso4 in 100 ml normal saline I.V ,over 30 minutes followed by 10 mg/kg LBW for 90 minutes
45959816|NCT00155480|Procedure|computed tomography|
45819159|NCT04029584|Drug|Fluvastatin 20 MG|one oral dose of fluvastatin (Lescol ) 20mg capsule
45819160|NCT04028960|Drug|Regular insulin (Humulin-R), intranasal route|Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.
45959817|NCT04765072|Behavioral|Survivorship Patient Navigation Intervention|Patient navigator assistance for navigating the healthcare system and locating and utilizing beneficial resources
45959818|NCT04765072|Behavioral|Telehealth Survivorship Visit Intervention|Individualized survivorship care plan
45959819|NCT04762693|Device|Hyfe cough tracker|A mobile app that runs in the background of smartphones and detects putative cough sounds.
45959820|NCT00533338|Behavioral|Weight Gain Prevention Program|Intervention program including in-person instruction and counseling about exercise and diet, exercise practice sessions, and telephone counseling.
45959821|NCT00533338|Behavioral|Questionnaire|Packet of questionnaires will be completed.
45959822|NCT04716283|Other|Validated questionnaire : The Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS)|"The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. Nineteen individual items generate seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score.~The Epworth Sleepiness Scale (ESS) is a scale intended to measure daytime sleepiness .The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities."
45959823|NCT04696042|Drug|Lanreotide autogel|Lanreotide autogel 90-120 mcg, every 4 weeks
45959824|NCT04678141|Other|Dyract XP (Dentsply De Trey), Kerr Herculite Classic (Kerr Corporation),R&D Series NOVA(Kuraray Medical Inc) Clearfil TM SE Bond (Kuraray Medical),Hydrocal LC (Medicept Dental)|compomer (Dyract XP,R&D Series NOVA) , composite (Kerr Herculite Classic),Bonding (Clearfil TM SE Bond), Dycall (Hydrocal LC)
45959825|NCT00181662|Drug|Curcumin|
45959826|NCT00533416|Drug|ON 01910 Na|
45959827|NCT00155558|Drug|5-Fluorouracil, Leucovorin|
45959828|NCT00533455|Drug|Gabapentin|
45959829|NCT00533494|Behavioral|physician feedback (A)|Feedback information to physicians
46079388|NCT05477823|Diagnostic Test|Positron emission tomography (PET)/magnetic resonance imaging (MRI)|Pelvic PET scanning with tracer will take approximately 45 minutes. This will be followed by the injection of a contrast agent followed by whole body PET/MRI scanning which will take approximately 30 minutes.
45664673|NCT05365295|Other|DRM (Deese, Roediger et McDermott task)|"Eight lists of nine words are presented to the participants. Each list is heard once. Immediately afterwards, the child is asked to recall the words he or she remembers. Each child's response is then repeated one by one and the participant is asked to rate his or her confidence in the response on a five-point scale (from not at all sure to 100% sure). A 5-minute break is given in the middle of the task, after the first four lists are presented. The test takes about 20 minutes."
45664674|NCT05330585|Device|Hearing aids|Participants will listen to stimuli in the environment while wearing hearing aids which should make the stimuli more audible. Speech in noise performance is expected to improve and PFC oxygenation is expected to be reduced in this condition.
45664675|NCT05330585|Other|Unaided|Participants will listen to stimuli in the environment with their hearing loss. Speech in noise performance is expected to decline and PFC oxygenation is expected to be increased in this condition.
45664676|NCT05295407|Genetic|Genetic Assessment|The trial is to observe whether inherited risk, including rare pathogenic mutations (RPMs) in several major genes and SNPs-based genetic risk scores (GRS), is correlated with prostate cancer detection rate from diagnostic prostate biopsy.
45819161|NCT04028960|Device|SipNose intranasal device|The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.
45819162|NCT03401671|Drug|Lanadelumab|SC injection of 300mg in 2mL (150 mg/mL) solution of lanadelumab will be administered as a single dose injection in the abdomen.
45664677|NCT05295251|Other|medical ,oncological and surgical treatment of cases of acute abdomen|medical treatment and surgical intervention during covid-19 pandemic
45819163|NCT04023578|Device|RHEO KNEE XC|Microprocessor controlled knee using Magneto-Rheologic techonology.
45819164|NCT03502915|Drug|Nitrous Oxide|50% nitrous oxide/50% oxygen via Nitronox delivery device
45819165|NCT03502915|Other|Placebo|100% oxygen via Nitronox delivery device
45664678|NCT05329337|Diagnostic Test|Blood test|Sixteen mL of blood will be collected on EDTA for the purpose of this study
45664679|NCT05294159|Other|The Feasibility of Intervention Measure (FIM) and Acceptability of Intervention Measure (AIM)|The Feasibility and Acceptability of Intervention Measure (FIM and AIM) are used to evaluate the feasibilit and acceptability of our implementation strategies. The FIM and AIM is a validated implementation outcome measure where higher scores indicate greater feasibility and acceptability
45819166|NCT03506347|Drug|Vancomycin|Antibiotic
45819167|NCT04210232|Device|TECNIS® TORIC II Intraocular Lens (IOL)|Surgeons will perform standardized, small-incision, cataract surgery and implant in one or both eyes the study lenses.
45819168|NCT04019990|Other|The effect of throwers ten exercise programme on wheelchair basketball and ambulant basketball players|Throwers Ten exercise programme is a programme designed to improve the power, strength and endurance of large muscle groups required for the throwing activity. It consists of exercises involving the movement of upper limb joints in full range of joint motion or at specified specific angles, with the help of a resistance band and weights specific to individual athletes. In the literature, no study has demonstrated the effectiveness of Throwers Ten exercise programme in wheelchair basketball and ambulant basketball players.
45959830|NCT00533533|Drug|docetaxel, oxaliplatin|"Oxaliplatin will be administered in combination with docetaxel as a first-line chemotherapy in advanced gastric cancer patients. Each cycle is repeated every 3 weeks.~Docetaxel Oxaliplatin Level 1 60 mg/m2/day 1 100 mg/m2/day 1 Level 2 75 mg/m2/day 1 100 mg/m2/day 1 Level 3 75 mg/m2/day 1 130 mg/m2/day 1"
45959831|NCT00155597|Behavioral|home physical therapy|
46079389|NCT05467657|Device|repetitive Transcranial Magnetic Stimulation|It will be applyed a magnetic field over the Somatosensory cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
46079390|NCT05465629|Combination Product|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
45664680|NCT02525861|Biological|GLASSIA|Participants will receive weekly IV infusions of GLASSIA at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 mL/kg/min for 25 weeks (25 planned infusions) via an IV administration.
45664681|NCT05293613|Device|extracorporeal shock wave lithotripsy|shock wave transmited from the device through patient body towards the stone to disintegrate it
45959832|NCT04658914|Biological|Rotarix|Live-attenuated oral human rotavirus vaccine (Rotarix) manufactured by GlaxoSmithKline containing at least 10^6 CCID50(median cell culture infective doses) of G1P[8] rotavirus, RIX4414 strain produced in Vero cells. This vaccine is an oral suspension with a single dose (1.5ml) administered using an oral applicator.
45959833|NCT04658914|Biological|Trivalent P2-VP8|Trivalent P2-VP8 subunit vaccine manufactured by SK Chemicals containing 90ug of each VP8 antigen derived from P[4] (DS-1), P[6] (1076), and P[8] (Wa) rotavirus strains fused to the P2 epitope from tetanus toxoid and adsorbed to aluminium hydroxide. A single dose (0.5ml) of this vaccine is administered intramuscularly through injection.
46079391|NCT05465629|Dietary Supplement|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
46079392|NCT05464667|Radiation|Radiation Therapy (RT)|"Dose Escalation: 5 Cohorts - 30 GY in 5 fractions (baseline treatment with 0 boost dose to GTV), 35, 40, 45, 50 Gy in 5 fractions (Part 1)~Dose Expansion: Maximum Tolerated Dose determined during dose escalation (Part 2)"
45664682|NCT02524847|Drug|Methoxsalen|Sterile solution used in conjunction with photopheresis procedure.
45664683|NCT02524847|Procedure|Extracorporeal Photopheresis (ECP)|
45664684|NCT05292365|Behavioral|RE-PACT Intervention|"Create respiratory illness action plan~Weekly mHealth text messages~Monthly study assessments~Action planning and JIT coaching"
45664685|NCT05328401|Device|Verum laser acupuncture|Applied verum laser acupuncture on specific acupoints in patient with post stroke shoulder pain.
45664686|NCT05328401|Device|Sham laser acupuncture|Applied sham laser acupuncture on specific acupoints in patient with post stroke shoulder pain.
45664687|NCT05526365|Other|Reduced Idea Density|Question idea density reduced (ratio of propositions to total words used).
45664688|NCT05363267|Dietary Supplement|curcumin, high phenolic extra virgin olive oil (HP-EVOO)|"identical for all participants with the exception of the curcumin dose level~Dose 1: 1000 mg Curcumin daily dose with 1 capsule of 25 ml HP-EVOO volume at morning and night Dose 1: 2000 mg Curcumin daily dose with 2 capsules of 25 ml HP-EVOO volume at morning and night Dose 3: 4000 mg Curcumin daily dose with 4 capsules of 25 ml HP-EVOO volume at morning and night"
45819169|NCT03266419|Drug|Deep NMB using rocuronium|"Drug: rocuronium~Bolus dose: 0.7 mg/kg~Continuous infusion : 0.8-1.2 mg/kg/h for maintaining deep NMB (post tetanic count 1-2) during operation."
45819170|NCT03266419|Drug|Moderate NMB using rocuronium|"Drug: rocuronium~Bolus dose: none~Continuous infusion: 0.2-0.6 mg/kg/h for maintaining moderate NMB (train of four 1-2) during operation."
45819171|NCT03270943|Behavioral|MFY|Mindful Self-Compassion course for teens
45819172|NCT03270943|Behavioral|HLG|Healthy Lifestyles course for teens
45819173|NCT03800030|Device|Theta-gamma tACS|NeuroConn technologies, direct current-stimulator plus
45819174|NCT03800030|Device|Delta-beta tACS|NeuroConn technologies, direct current-stimulator plus
45819175|NCT03800030|Device|Sham tACS|NeuroConn technologies, direct current-stimulator plus
45819176|NCT00377468|Drug|Delta9-Tetrahydrocannabinol|
45819177|NCT03799484|Drug|Botulinum toxin type A|Botulinum toxin type A will be administered to both sides
45819178|NCT03799484|Drug|2.5% lidocaine/2.5% prilocaine|2.5% lidocaine/2.5% prilocaine will be applied to one side of the forehead
45819179|NCT03799484|Device|petrolatum ointment|petrolatum ointment will be applied to one side of the forehead
45819180|NCT04012970|Other|Manual spinal mobilisations|
45819181|NCT03508687|Drug|300mg Gemcabene|300mg Gemcabene
45819182|NCT03508687|Drug|600mg Gemcabene|600mg Gemcabene
46079393|NCT05454566|Genetic|ICM-203|Intra-articular injection
46079394|NCT05452967|Other|Distraction technique|The post operative pediatric patients will be given mobile phone in recovery for plying games and watching cartoons and with the help of this distraction technique will assess that routine rescue analgesia is needed or not
45819183|NCT03999944|Device|positive airway pressure system|Positive Airway Pressure System
45819184|NCT03273283|Behavioral|Brief Intervention|Patient's received a brief intervention on alcohol use based on motivational techniques, and a referral to treatment when indicated.
45819185|NCT00377546|Drug|Nepafenac|
45819186|NCT00377546|Drug|Ketorolac LS, Bromfenac|
45819187|NCT04290494|Drug|IV rtPA (intravenous recombinant plasminogen activator)|intravenous injection
45959834|NCT04658446|Device|Augmented Reality-Assisted Indirect Bonding|Virtual Orthodontic attachments are overlaid on top of the patient's teeth using an augmented-reality headset to guide the bracket positioning procedure.
45664689|NCT04422275|Drug|Budesonide|The drug intervention budesonide (0.5 mg /capsule) will be dissolved in 240 ml nasal saline lavage.
45959835|NCT04658446|Device|Digitally-Asssited Indirect Bonding|3D printed models with precise brackets positioned as virtually pre-planned. To aid in the transfer of the planned bracket positions to the patient's physical teeth.
45959836|NCT04628104|Radiation|cardiac magnetic resonance|"o CMR protocol:~Cine imaging to assess regional & global ventricular function according to the AHA 16-segment model.~T2-weighted imaging to detect extent & distribution of myocardial edema.~Early Gd enhancement imaging to detect extent & distribution of myocardial hyperemia.~Late Gd enhancement imaging to detect extent & distribution of myocardial necrosis.~Single-short sequences & other acceleration techniques will be used as appropriate in patients with poor ability to hold their breath.~Post-processing analysis will be done on a dedicated workstation"
45959837|NCT00533611|Drug|MK0524A, /Duration of Treatment : 4 Weeks|
45664690|NCT04422275|Behavioral|High-Concentration Essential Oil|High-concentration essential oil will include 1 ml of essential oil per jar.
45819188|NCT03403231|Behavioral|INVENT Secure Messaging Intervention|We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.
45959838|NCT00533611|Drug|Comparator : niacin /Duration of Treatment : 1 Weeks|
45959839|NCT00533650|Drug|MK0429|
45959840|NCT00533689|Procedure|Electroretinography (ERG), Visual Evoked Potentials (VEP)|
45959841|NCT04589923|Device|Lifelight® Data Collect Blood Pressure Group|The staff member will prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using Lifelight® Data Collect (from which only the RGB data will be uploaded to the cloud). These measurements and RGB data capture will be repeated two times following the initial observations. Once measurements are concluded, the study staff member will complete the post-measurement observation questions.
45959842|NCT04589923|Device|Lifelight® Data Collect Oxygen Saturation Group|The staff member will prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using Lifelight® Data Collect (from which only the RGB data will be uploaded to the cloud). These measurements and RGB data capture will be repeated two times following the initial observations. Once measurements are concluded, the study staff member will complete the post-measurement observation questions.
45959843|NCT00533728|Drug|Soluble beta-glucan (SBG)|
45959844|NCT04575844|Drug|Liraglutide|24 weeks of Liraglutide
45959845|NCT04575844|Other|Exercise training|24 weeks of Exercise training
45819189|NCT04005404|Drug|Ropivacaine (sciatic nerve block)|injection of 20 ml ropivacaine 0.375%
45819190|NCT04005404|Drug|Ropivacaine (lumbar plexus block L2-L4)|injection of 20 ml ropivacaine 0.375%
45819191|NCT04005404|Drug|Ropivacaine (lumbar plexus block Th12-L1)|injection of 20 ml ropivacaine 0.375%
45959846|NCT04575844|Drug|Liraglutide + Exercise training|24 weeks of Liraglutide + Exercise training
45959847|NCT00155675|Drug|GUSUIBU|
45959848|NCT00533806|Behavioral|Cognitive Behavior Therapy|CBT includes 12 treatment sessions over 14 weeks. The sessions deliver family-based exposure with response prevention. Participants assigned to receive CBT will learn skills to help control OCD. CBT sessions will also include education about OCD, family therapy, parent training to manage child behavior problems, and anxiety management.
46079395|NCT05452512|Other|Self monitoring|Self monitoring using smart clinical trial application
46079396|NCT05452512|Other|Smart watch assisted monitoring|Smart watch-assisted adherence monitoring
46079397|NCT05452512|Drug|Vitamin D|Vitamin D self-administration for 3 months
46079398|NCT05452499|Other|Pain neuroscience education and therapeutic exercise|Participants will receive a 9-week physiotherapy program. Consisting of 3 sessions of pain neuroscience education and 24 sessions of therapeutic exercise (16 face-to-face sessions and 8 at home).
46079399|NCT05444062|Behavioral|Educational material and treatment recommendations for patients, general practitioners and pharmacists|Educational material and treatment recommendations given to patients, their family doctors and their pharmacists.
45664691|NCT04422275|Drug|Placebo|The placebo (lactose monohydrate) drug will be dissolved in 240 ml of nasal saline lavage.
45664692|NCT04422275|Behavioral|Low-Concentration Essential Oil|Low-concentration essential oil will include 0.1 ml of essential oil per jar.
45664693|NCT02525627|Device|Trident cup, X3 inserts, 28 mm head|Orthopaedic implant
45664694|NCT02525627|Device|Trident cup, X3 inserts, 40 mm head|Orthopaedic implant
45664695|NCT02525627|Device|Symax stem|Orthopaedic implant
45664696|NCT02525627|Device|Accolade TMZF stem|Orthopaedic implant
45819192|NCT03232892|Drug|Trametinib|Trametinib 2mg, once daily, PO, 28-day cycles
45819193|NCT03787472|Device|JJV Investigational senofilcon A Multifocal Lens1|CONTROL
45819194|NCT03787472|Device|JJV Investigational senofilcon A Multifocal Lens2|TEST
45819195|NCT03778190|Procedure|Corneal Foreign Body Removal|An eye magnet will be brought close to the foreign body on the surface of the eye in an attempt to remove the foreign body.
45819196|NCT03510481|Biological|PfSPZ Vaccine|PfSPZ Vaccine is Radiation attenuated, aseptic, purified, vialed, cryopreserved, NF54 P. falciparum sporozoites produced by Sanaria, Inc.
45819197|NCT03510481|Drug|Normal Saline|Clear liquid indistinguishable from the study product will be used as a placebo rather than a comparator vaccine.
45819198|NCT03510481|Drug|artemether 20mg/lumefantrine 120mg (AL)|Licensed antimalarial in the US and Mali for use for uncomplicated malaria.
45819199|NCT03172520|Device|APS electrode|The APS electrode is an accessory intended for providing automatic periodic stimulation to nerves when used with the Medtronic Nerve Monitoring Systems.
45664697|NCT04422587|Other|RECOP unit patient|All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.
45959849|NCT00533806|Behavioral|Relaxation Therapy|Relaxation therapy includes 12 sessions delivered over 14 weeks. Participants assigned to receive relaxation therapy will discuss general family functioning, issues related to OCD, and other behavioral problems the child may be experiencing.
45819200|NCT03172520|Device|Facial Nerve Monitor|The facial nerve monitoring system records the number of stimulations of the facial nerve during the operation and this data is stored on the device until it is shut down after the surgery is complete.
45819201|NCT03109418|Drug|Ketamine|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight
45819202|NCT03109418|Procedure|Control|OSA patients receiving standard inhaled anesthesia combined with normal saline
45959850|NCT04545346|Other|Low Glutamate diet|Participants will be given extensive online dietary training and assigned to follow the low glutamate diet for one month. The low glutamate diet reduces the consumption of free glutamate, while optimizing dietary micronutrient and antioxidant intake.
45959851|NCT04538755|Drug|Placebo oral capsule|Placebo before sleep
45959852|NCT04538755|Drug|DAW2020 oral capsule|DAW2020 34 mg 4 h before sleep, single night administration
45819203|NCT03404167|Drug|AZD0914|Zoliflodacin (also known as AZD0914 and ETX0914), is a spiropyrimidinetrione antibacterial agent
45959853|NCT04535635|Other|Active Release Techniques®|The ART® procedure will consist of identifying and treating manipulatable lesions as per their protocols, while the sham group will receive a passable version of this technique. This information is under copyright and cannot be copied or outlined specifically in any form, including a research paper. The overarching procedure used by ART® will be explained however specific details referring to each protocol cannot be described. Muscles are shortened, and the therapist applies sufficient digital pressure to be in contact with the tissue in question. Directional tension is applied proximally along the muscle fiber direction, and then the structure is lengthened while the contact remains as described.
45959854|NCT04535635|Other|Sham Active Release Techniques®|"For the sham treatment, the muscle(s) in question will be taken from a lengthened to a shortened position (opposite of the protocol direction as per the ART® manual) with a broad light contact on the skin - the treating therapist will not achieve tissue depth as specified by ART® and will not attempt to take tension as is outlined in the ART® manual."
45959855|NCT00155714|Drug|type-5 phosphodiesterase Inhibitor (Sildenafil)|
45959856|NCT04511572|Procedure|embolization of the middle meningeal artery|The embolization procedure will be as follows: first femoral artery access will be obtained by using a 5 French micropuncture kit and common carotid and external carotid angiography is performed using a standard 5 French diagnostic catheter. A microcatheter is then advanced selectively under roadmap guidance into the middle meningeal artery (MMA), and MMA angiography is performed to evaluate for potential dangerous anastomoses such as the orbital branch to the ophthalmic artery. Embolization is performed using polyvinyl alcohol particles (100 microns in diameter) under blank fluoroscopic roadmap while carefully avoiding reflux. Particles are infused until lack of anterograde flow into the MMA branches is demonstrated on angiography, and the catheters are removed [31]. The procedure is performed under local anesthesia.
45959857|NCT00181740|Drug|atomoxetine (Strattera)|
45959858|NCT04686721|Diagnostic Test|Chest CT scan + baseline spirometry|Patients will perform an initial evaluation at 2 months from hospital discharge using a chest CT scan without contrast-enhancing along with a pulmonary function test using spirometry. Based on results and according to current guidelines, further follow-up or intervention will be administered.
45664698|NCT05361941|Device|EP Granules with Tobramycin|EP Granules with Tobramycin is a Ca-salt resorbable intended for orthopedic applications as a bone void filler for bone gaps or voids and in cases where risk of post-operative infection is high, such as the first stage of a two-stage revision of an infected total joint.
45664699|NCT05361941|Device|empty voids|Voids are left empty
45959859|NCT04508023|Drug|Rivaroxaban|Participants will receive rivaroxaban 10 mg tablet orally once daily.
45664700|NCT05291507|Device|Muse MRgFUS System|The intended use of the device is to thermally ablate breast tissue under magnetic resonance image guidance. The thermal ablation is performed non-invasively using extracorporeal focused ultrasound.
45664701|NCT05290025|Drug|Nicotine patch|> 20 cigarettes per day: 21 mg nicotine/ 24 hours 10-20 cigarettes per day: 14 mg nicotine/ 24 hours 5-10 cigarettes per day: 7 mg nicotine/ 24 hours
45664702|NCT05290025|Drug|Nicotine gum|Nicotine chewing gum will be available in 1 and 2 mg strengths. Patients may individually choose which strength to use. Maximum 12 chewing gums per day
45664703|NCT05290025|Drug|Nicotine lozenge|Nicotine lozenges will be available in 1 and 2 mg strengths. Patients may individually choose which strength to use. Maximum 12 lozenges per day
45664704|NCT05290025|Behavioral|Smoking cessation counselling|Once a week patients are asked about progress in cessation attempt. Sigaretts smoked the last week are recorded. Goal is set for the next week. Information on typical nicotine withdrawal symptoms and ameliorating techniques.
45664705|NCT05290025|Other|Screening for use of tobacco products|At the initiation of the trial screening questions about cigarett use for the last day and week.
45819204|NCT03771560|Drug|folinic acid|subject will take folinic acid daily for 12 weeks
45819205|NCT03404401|Drug|BLI4700|Oral bowel preparation
45819206|NCT03404401|Drug|Polyethylene glycol bowel preparation|Oral bowel preparation
45959860|NCT04508023|Other|Placebo|Participants will receive matching placebo tablet orally once daily.
45959861|NCT04508023|Other|Standard of Care (SOC)|SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
45664706|NCT05290025|Other|Screening for interest in smoking cessation|At the initiation of the trial all smoking participants are asked if the are interested in changing their smoking habits. They are given three alternatives: will make cessation attempt; will make reduction attempt; not certain.
45959862|NCT00181779|Drug|aripiprazole (Abilify)|
45959863|NCT04475809|Procedure|group C|laparoscopy will be performed with 14-16 mmHg intra-abdominal pressure. At the end of the procedure routine method for CO2 removal, passive exsufflation, will be used by applying gentle abdominal pressure to evacuate the residual gas through the port site.
45959864|NCT04475809|Procedure|Group L|laparoscopy will be performed with 8-10 mmHg intra-abdominal pressure and routine passive exsufflation will be applied for CO2 removal at the end of the procedure.
45664707|NCT02129205|Drug|PF-06650808|Dose Escalation Phase [Part 1] - PF-06650808 will be administered at doses starting at 0.2 mg/kg. Increases in dose will continue until MTD is determined.
45819207|NCT03767738|Drug|Intravitreal Aflibercept Injection (IAI)|IAI prepared and administered with a pre-filled syringe (PFS)
45959865|NCT04475809|Procedure|Group LR|the intra-abdominal pressure will be kept at 8-10 mmHg during laparoscopy. At the end of the procedure pulmonary recruitment maneuver (PRM) will be done; which consists of five manual pulmonary inflations at a maximum pressure of 40 cm H2O and the fifth will be held for 5 seconds. During this procedure, the surgeon is instructed to keep the port sleeve valve fully opened to allow the CO2 to escape the abdominal cavity.
45959866|NCT04475809|Procedure|Group LS|the intra-abdominal pressure will be kept at 8-10 mmHg during laparoscopy. At the end of the procedure, intraperitoneal normal saline (IPS) will be infused for removal of the intra-abdominal CO2; in which we fill the upper part of the abdominal cavity evenly and bilaterally with isotonic normal saline (15-20 mL/kg body weight)
45959867|NCT00533884|Other|Assessment of therapy complications|Assessment of neurocognitive function, functional status, symptom prevalence and distress, and mood alterations
45959868|NCT00533884|Other|Neurocognitive assessment|Assessment of neurocognitive domains: attention/concentration, executive function, verbal learning, verbal memory, verbal fluency
45959869|NCT00533884|Other|Quality-of-life assessment|Assessment of quality of life using Cantrill's Ladder at baseline and 3 months post-treatment
45959870|NCT00533923|Drug|Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF|intravenous
46079400|NCT05443295|Other|MoveUS Program|The MoveUS Program have 5 stages: 1 (approach stage), based on analytical movements, isometric peak contractions and learning/motor control; 2 (structural stage), based on muscular strength or resistance training through a cumulative work of short efforts, following with the analytical work of pushing or lifting/pulling; and ending in a closed kinetic chain; 3 (neural stage), that has two stage: 3A, based on a structural work that serves as a continuation of stage 2 and the work is focused on the training of increase cross-sectional muscular area; and 3B, based on a neural work focursed in an intra neuromuscular system highlighted motoneuron unit workout. Finally, stage 4 (functional stage), based on a functional readaptation to sports activity and/or work activity; or, failing that, to the activity of daily life with the highest demand.
46079401|NCT05443295|Other|Control intervention|The control intervention is based on following the conventional treatment guidelines for glenohumeral instability, where immobilization, taking non-steroidal anti-inflammatory drugs, cryotherapy, passive kinesitherapy and self-assisted, pendular exercises stand out and education.
46079402|NCT05441917|Device|Sanae method with LED|Sanae method (combination of therapies): Manual therapy, Carboxytherapy, and phototherapy.
45664708|NCT02129205|Drug|PF-06650808|Dose Expansion Phase [Part 2] - Patients will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
45664709|NCT05289479|Procedure|Pre-heating of resin composite before application|the effect of preheating of resin composite before application in class II cavities
45664710|NCT05289479|Procedure|no pre-heating of resin composite before application|The control group
45819208|NCT03989570|Procedure|transversus abdominis plane block|The TAP block will be performed laterally behind the midaxillary line between the iliac crest and the most inferior extent of the ribs. The plane between the internal oblique and transversus abdominis muscle will be located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The needle will be passed to come in plane with the ultrasound beam and placed between transversus and internal oblique posterior to the midaxillary line then, the local anesthetic will be injected
45819209|NCT03989570|Procedure|erector spinae plane block|The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes
45819210|NCT03989570|Other|control group|placebo
45819211|NCT03273673|Other|Biofeedback Intervention|Visual and Tactile Biofeedback
45819212|NCT04331990|Other|Standard Physcial Therapy|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle strengthening and stretching, and neuromuscular control exercises. Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
45959871|NCT00409227|Drug|Alpha blocker-alfuzosin|P.O. alfuzosin 10 mg once a day
45959872|NCT00409227|Drug|placebo|placebo once a day for 3 months or stone free
45959873|NCT04475380|Device|Percutaneous coronary intervention|PCI for treatment of coronary or bypass graft lesions
45959874|NCT00533962|Drug|Anterior Juxtascleral Depot of Anecortave Acetate|
45959875|NCT04473781|Procedure|Interstitial Radiation Therapy|Undergo interstitial brachytherapy
45959876|NCT00406562|Biological|Boostrix|
45959877|NCT04470037|Drug|DAAOI-P|DAAOI-P 250-1500mg
45959878|NCT04470037|Drug|Placebo|starch pill
45959879|NCT00181818|Drug|bupropion SR (sustained-release)|
45959880|NCT04462627|Diagnostic Test|Blood group determination|Determination of the blood group (ABO/LE)
46079403|NCT05441917|Device|Sanae method with Radiofrecuency|Sanae method (combination of therapies): Manual therapy, Carboxytherapy, and radiofrequency.
45959881|NCT04462627|Diagnostic Test|Antibody titration|Natural anti-A and anti-B antibody levels will be determined by a gel agglutination technique on the Biorad IH-500 automaton.
45819213|NCT04331990|Other|Intermittent Mechanical Traction|In addition to the standard treatment, patients in this group will receive intermittent knee joint decompression for 20 minutes. Patients will be lying supine with the knee semiflexed to 30° and supported by a wedge under the knee. A customized leg cuff will be placed around the lower leg and two ropes will be extending horizontally from the cuff to the vertical traction weight using a pulley system to transfer the traction force to the tibiofemoral articulation. The magnitude of the traction force will be between 10-15% of the patient's body weight. The traction force will be applied for 10 application cycles; each cycle comprised of 2 minutes traction followed by 30 seconds relief. This will sum up to 20 minutes of actual joint traction duration. The traction force application and relief time will be controlled manually by the treating therapist. Knee joint traction procedures will be applied at the end of the physical therapy session.
45959882|NCT04462627|Dietary Supplement|Probiotic|Administration of a probiotic to healthy volunteers to determine if it increases the level of circulating natural anti-A and anti-B antibodies (Probactiol Plus (Metagenics)).
45959883|NCT00406601|Drug|Sorafenib (BAY-43-9006)|800 mg/die orally on a continuous basis
45959884|NCT00409305|Drug|Betahistine|
45959885|NCT00409305|Behavioral|Dietary counseling|
45959886|NCT04442971|Behavioral|Music Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and listen to their preferred music.
45959887|NCT04442971|Behavioral|Alternative Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and listen to an audio book.
45959888|NCT04442971|Behavioral|No Auditory Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and hear silence.
45959889|NCT04442347|Biological|ARCT-810|ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) mRNA formulated in a lipid nanoparticle (LNP) under development.
45959890|NCT04442347|Other|Placebo|The placebo for this study is 0.9% sterile saline.
45959891|NCT00406679|Drug|Paracetamol (acetaminophen) solution experimental|1 gm IV
45959892|NCT00406679|Drug|paracetamol (acetaminophen) solution commercial|1 gm IV
46079404|NCT05441813|Drug|Virgin Coconut Oil|Standard of care with the addition of virgin coconut oil mouth rinse
46079405|NCT05432089|Drug|Intranasal Oxytocin|24IU (12IU*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water.
45819214|NCT04331990|Other|Continuous Mechanical Traction|Patients assigned to this group will receive the same treatment protocol as those in the Intermittent Mechanical Traction group. However, the knee traction force will be applied continuously for 20 minutes without intermittent force relief periods.
45819215|NCT02973620|Drug|Levosimendan|levosimendan infusion started at 0.1 mcg/kg/min for 6-12 hours, increased to 0.2 mcg/kg/min for 24-36 hours
46079406|NCT05430399|Drug|utidelone|Eligible patients will receive treatment with utidelone(40 mg/ m2 /day, D1-5,Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
46079407|NCT05430399|Drug|docetaxel|Eligible patients will receive treatment with docetaxel (75mg/ m2/day, D1, Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
46079408|NCT05429827|Other|normal saline|Inject 2 ml normal saline into a myofascial trigger point and evaluate the clinical effects before and after the injection.
46079409|NCT05429827|Drug|Dextrose 5% in water|Inject 2 ml 5% dextrose into a myofascial trigger point and evaluate the clinical effects before and after the injection.
45819216|NCT03512041|Behavioral|RLIC - 5 cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
45819217|NCT03512041|Behavioral|RLIC - 4 Cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
45959893|NCT00406679|Drug|placebo|equivalent volume IV 0.9% sodium chloride (equivalent volume)
45959894|NCT04441216|Other|Rhizoma Coptidis, Radix Astragali and Flos Lonicerae|granule
45959895|NCT04441216|Other|Rhizoma Coptidis, Radix Astragali and Flos Lonicerae, Ophiopogonis Radix|granule
45959896|NCT04431154|Behavioral|Provision of HIV self-screen kit with incentives and linkage promotion|This arm will receive a HIV self-screen kit and additional incentives to promote adherence and linkage to care
45959897|NCT04423159|Biological|OCV Vaccine|2 doses of OCV were administered to all enrolled participants 1st dose administered at baseline and second dose administered 28 days post 1st dose.
45959898|NCT04724954|Device|Rehabilitation Therapy on Experimental Robotic Table and standard of care|Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). They will also receive Standard of Care rehabilitation
45959899|NCT04724954|Genetic|Rehabilitation Therapy as part of Standard of Care (Control)|Control group will receive Standard of Care training only
45959900|NCT04422457|Other|68Ga-DX600 PET/CT|DX600, labeled with 68Ga will be used as a molecular imaging tracer for PET/CT scanning
45959901|NCT04420429|Procedure|Descemet membrane endothelial keratoplasty (DMEK)|All participants underwent DMEK surgery
45959902|NCT00181896|Drug|bupropion SR|Open-label prescription of Bupropion SR for 8 weeks.
45959903|NCT04686448|Drug|propofol-ketamine|patients will receive IV ketofol (0.5 mg/kg ketamine and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
45959904|NCT04686448|Drug|propofol-fentanyl|patients will receive IV fenofol (1 µg/kg fentanyl and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
45959905|NCT00181935|Drug|risperidone (Risperdal)|
45959906|NCT00181935|Drug|olanzapine (Zyprexa)|
46079410|NCT05429827|Drug|Dextrose 15% in water|Inject 2 ml 15% dextrose into a myofascial trigger point and evaluate the clinical effects before and after the injection.
45455183|NCT03934801|Other|Ranking Round 2|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
45455184|NCT03934801|Other|Ranking Round 3|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
45959907|NCT04402840|Procedure|Stellate Ganglion Block|The procedure will be done at the bedside in the ICU without interfering with ongoing treatment.
45959908|NCT04390087|Other|Exercise|Upper-body rowing performed while participants are sitting in their own wheelchair.
45959909|NCT00406757|Drug|Nelarabine injection 400mg/m2|"Cycle 1: Nelarabine 400mg/m2 will be administered once a day from Day 1 to Day 5.~Cycle 2 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to DAy 5."
45959910|NCT00406757|Drug|Nelarabine injection 650mg/m2|Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
45959911|NCT00406757|Drug|Nelarabine injection 1000mg/m2|"Cycle 1: Nelarabine 1000mg/m2 will be administered once a day on Days 1, 3 and 5.~Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5."
45959912|NCT00406757|Drug|Nelarabine injection 1500mg/m2|Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
45664711|NCT05360693|Procedure|immediate implant placement without bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done & patients will receive an immediate post-extraction implant without any grafting material in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
45664712|NCT05360693|Procedure|immediate implant placement with socket bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done and patients will receive an immediate post-extraction implant with placing bovine bone graft (Bio-oss) in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). In order to ensure standardization and reproducibility of the CBCT cross sectional images used in this study, superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
45664713|NCT04245605|Procedure|Coronary angiography|Coronary angiogram performed either in hospital or post-discharge, within 14 days after initial hospital presentation with heart failure
45664714|NCT05324969|Behavioral|MM-based MI|9 remote mindful-based MI sessions will be delivered to promote participating parents' mindful eating, mindful movements, and mindful family interactions. Parents will be encouraged to act as changing agents for their families.
45819218|NCT03512041|Behavioral|RLIC - 3 Cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
45819219|NCT03512041|Behavioral|Sham conditioning|Sham conditioning is achieved as listed in the arm/group descriptions. Sham conditioning is performed on visits 1-7, which occur on consecutive weekdays.
45959913|NCT04361929|Device|Ultrasound|The following ultrasound measurements will be assessed: DS-HB, HMDR, TT, TT-S, TW, EW, ET, DS-E, and DS-V.
45455185|NCT03934645|Other|Delirium prediction model for ICU patients, version 1|The pre-deliric model version 1 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission and has a high predictive value. The model allows for early prediction of delirium and initiation of preventive measures. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found.
45819220|NCT03512041|Behavioral|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
45819221|NCT03512041|Behavioral|Arm training|All participants undergo training on a cup stacking task, learning to assemble and disassemble cup configurations as fast as they can. Participants perform the cup stacking task 5 trials per day at visits 3-7.
45819222|NCT03512041|Behavioral|Sequence production training|All participants undergo training on a discrete sequence production task. Participants learn to associate specific color and shape symbols with sequences of key presses on a keyboard. Participants perform the sequence production task for 10-15 minutes per day at visits 3-7.
45819223|NCT03053960|Device|Computed Tomography|Undergo helical CT scan
45819224|NCT03053960|Device|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT scan
45819225|NCT03053960|Device|Cone-Beam Computed Tomography|Undergo CBCT scan
45819226|NCT03053960|Device|Magnetic Resonance Imaging|Undergo MRI scan
45819227|NCT03053960|Procedure|Therapeutic Conventional Surgery|Undergo resection of tumor
45959914|NCT04342195|Procedure|Blood draw|Participants will have approximately 45 ml of whole blood drawn (3 Tablespoons) drawn at the study visit.
45959915|NCT00409383|Drug|Genasense® (oblimersen)|Cohorts 1 and 2: Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 7 days (Week 1) and beginning again on Day 22 and continuing for 7 days (Week 4); Cohort 3: Genasense 900 mg as a 1-hour intravenous infusion on Day 1, 4, 8, and 11 (Weeks 1 and 2) and Day 22, 25, 29, and 32 (Weeks 4 and 5).
45959916|NCT00409383|Drug|Abraxane® (paclitaxel protein-bound particles for injectable suspension)|Cohorts 1 and 2: Abraxane 175 mg/m2 or 260 mg/m2 as a 30-minute intravenous infusion on Day 8 and Day 29 following end of Genasense continuous infusion; Cohort 3: Abraxane 175 mg/m2 as a 30-minute intravenous infusion on Day 4 and Day 25 following end of Genasense 1-hour infusion
45959917|NCT00409383|Drug|Temodar® (temozolomide)|Cohorts 1-3: Temodar 75 mg/m2/day orally on Days 1 through 42 (Week 1 through Week 6)
45959918|NCT04312906|Other|no intervention|No intervention
45959919|NCT00409422|Behavioral|weight management program|
45959920|NCT00534079|Drug|Dornase alfa (Pulmozyme)|1 x 2,5 ml per day, inhalation use, for 28 days
45959921|NCT00534079|Drug|isotonic saline|1 x 2,5 ml per day, inhalation use, for 28 days
45959922|NCT00533221|Drug|somatotropin|0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
45664715|NCT05324969|Other|healthy education|9 health education emails will be sent to participating parents in the control group
45664716|NCT02128269|Biological|Study Drug- ALXN1007|10 mg/kg IV q 2 weeks x 12 doses
45664717|NCT05324735|Drug|Pentoxifylline|All participants will receive pentoxifylline 400 mg (orally ingested) twice a day for 12 weeks.
45664718|NCT05324735|Drug|Placebo|All participants will receive placebo (orally ingested) twice a day for 12 weeks.
45664719|NCT05360459|Radiation|Exposure to radiotherapy|Characterization and quantification of intestinal and vaginal microbiota in patients affected by cervical or endometrial cancer who have received pelvic radiotherapy more than 24 months ago.
45664720|NCT01626885|Drug|MP-214|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg) of MP-214 for four weeks, then flexible dose (1.5-9 mg) of MP-214
45959923|NCT00533221|Drug|Placebo|0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
45959924|NCT00155870|Behavioral|questionnaires|
45959925|NCT00188799|Procedure|daily Xray volume imaging for planning radiotherapy|
45959926|NCT04893148|Drug|IGlarLixi|Changing to iGlarLixi from insulin glargine
45959927|NCT04893148|Drug|Dulaglutide|Add dulaglutide to insulin glargine
45959928|NCT04883632|Combination Product|Saypha Volume Lidocaine|correction of Nasolabial Folds using injection of Saypha Volume Lidocaine manufactured in 2 different plants at Croma Pharma
45819228|NCT03053960|Procedure|Histopathologic Examination|Correlative studies
45959929|NCT04878874|Device|Magnetic Tape|Magnetic tape® is applied without creating any tension over low back
45959930|NCT04878874|Device|Kinesiology Tape|Kinesiology Tape is applied without creating any tension over low back
45959931|NCT04872517|Device|Meridian Electroacupuncture Analysis Device (MEAD)|use MEAD to detect energy change in patient with head and neck cancer
45959932|NCT00181974|Drug|Tisseel Fibrin Sealant|
46079411|NCT05428826|Drug|Prednisone|Phase 4 Prednisone Dose : 1mg/kg/day at inclusion Route of administration : oral Duration of treatment: 9 to 21 months.
46079412|NCT05427929|Device|NVR 4mm Edi catheter|Receive NAVA ventilation using the newly designed NVR 4 mm Edi catheter
45819229|NCT05313386|Drug|BXCL501|BXCL501 is given in a film form
45819230|NCT05313386|Drug|Placebo film|Placebo is given in a film form
45819231|NCT03274999|Device|TrueTear™ Application|Intranasal and extranasal application of TrueTear™ device for approximately 3 minutes at Day 0 and Day 14.
45819232|NCT04018664|Drug|Nalbuphine HCl solution|nalbuphine solution administered at various strengths
45819233|NCT04018664|Drug|Placebo solution|Placebo
45819234|NCT03763058|Other|Music Therapy|"The music intervention is administered via a smartphone- (and computer-) based application called Music Care. The Music Care app is a receptive music intervention, allowing the patient to freely adjust the length of and choose the preferred style between different sequences of instrumental music. All musical pieces were recorded in high-quality recording studios with professional musicians. Music Care utilizes the U technique designed to gradually relax the listener. The U technique is implemented using a musical sequence of 20 minutes that was divided into 5 different musical pieces at 3 to 4 minutes each.~Participants will complete 1-2 sessions of listening to music per day, with a minimum of 15 sessions per month."
45819235|NCT03031340|Drug|Pregabalin|On the day of the surgery, 1hour + 15 minutes before the surgery starts, the subject will receive either 300mg of pregabalin or a similarly packaged placebo. On post operative day one, 150 mg of pregabalin or placebo will be given in two doses 12hrs apart.
45959933|NCT02569645|Drug|Rosuvastatin|40 mg rosuvastatin orally once per day with or without food, swallowed whole (not chewed, crushed or divided) starting 2 weeks prior to the initiation of radiation therapy and stopped at 4 weeks after the completion of radiation. Total duration of Rosuvastatin is 11 weeks if 25 fractions of radiotherapy are given, or 12 weeks if 30 fractions of radiotherapy are given.
46079413|NCT05427513|Drug|Tranexamic acid injection|will inject tranexamic acid in limb salvage surgery of sarcoma patient to check its efficacy in preventing blood loss
46079414|NCT05427513|Other|normal saline|normal saline will be injected to ensure placebo
45664721|NCT05360225|Diagnostic Test|therascreen® KRAS RGQ PCR Kit|The KRAS Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Non-small Cell Lung Cancer (NSCLC) tissue.
45664722|NCT05287763|Procedure|Palatal soft tissue graft harvesting|After local anaesthesia, a horizontal incision 2 mm apically from the gingival margin will be carried out using a #15C blade. The standardized rectangular graft with a thickness of 1.5 mm will be harvested from distal aspect of canine till first molar. The graft will be lifted and separated using tissue forceps and a blade till it is free from all sides.
45959934|NCT02500147|Drug|Metformin|Metformin ER 500 mg once a day for one week and 1000 mg once a day for the remainder of the six months
45959935|NCT02500147|Drug|Placebo|One placebo pill per day for one week and then two placebo pills per day for the remainder of the six months
45959936|NCT00182013|Drug|Risperidone|Open treatment with Risperidone
45959937|NCT00182013|Drug|Olanzapine|Open treatment with Olanzapine
46079415|NCT05418179|Dietary Supplement|Probiotic|Probiotic (Bifidobacterium animalis subsp. Lactis, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus rhamnosus) - 1 capsule/day
46079416|NCT05418179|Dietary Supplement|Placebo|Maltodextrin (1 capsule/day)
46079417|NCT05411718|Drug|Naproxen|Given by PO
46079418|NCT05411718|Drug|Aspirin|Given by PO
45664723|NCT05359055|Drug|SPH3127 tablet|100mg once daily on Day 1 and Day 8
45664724|NCT05359055|Drug|Itraconazole|200mg once daily from Day 3 to Day10.
45664725|NCT05359055|Drug|SPH3127 tablet|200mg once daily on Day 1 and Day 12.
45664726|NCT05359055|Drug|Rifampin|600mg once daily from Day 3 to Day13.
45664727|NCT02524379|Drug|Glyburide|3 day drug regimen beginning 8 hours after acute traumatic spinal cord injury.
45959938|NCT00182013|Drug|Quetiapine|Open treatment with Quetiapine
45959939|NCT02478502|Drug|cabazitaxel|cabazitaxel is given to patients with progressive testicular cancer after cisplatin-based chemotherapy
45664728|NCT05286749|Procedure|Workshop plus Clinician-Collected Cervical Swab|clinician-collection methods using speculum and cervical swabs
45819236|NCT03031340|Other|placebo|placebo
45959940|NCT00155987|Procedure|Early decompressive craniectomy|Large bifrontotemporal decompressive craniectomy
46079419|NCT05407532|Procedure|Group with oral management|The investigators provided information on oral health care plus oral exercises before meals, including salivary glands massage methods.
46079420|NCT05407532|Procedure|Group with oral care|The investigators taught and monitored patients or caregivers to do oral care after meals and before sleep.
45455186|NCT03934645|Other|Delirium prediction model for ICU patients, version 2|The pre-deliric model version 2 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found. The model allows for early prediction of delirium and initiation of preventive measures.
45455187|NCT03934645|Other|Early prediction model for delirium in ICU patients|The e-pre-deliric model enables the clinician to identify those patients likely to develop delirium following ICU admission using only nine predictors. In the e-pre-deliric model, delirium prediction score is determined by inputting the data of the patient in admission to the intensive care unit.
45664729|NCT05286749|Device|Workshop plus Participant-Collected Cervical Swab|Evalyn® Brush (Rovers® Medical Devices, Netherlands)
45664730|NCT05286749|Diagnostic Test|HPV testing on Participant-Collected Cervical Swab Samples|Roche Cobas4800 HPV Test System (Roche Molecular Systems Inc., Rotkreuz, Switzerland)
45664731|NCT02524145|Other|Static Handgrip|Subjects will perform static handgrip at 40% of maximum voluntary contraction until fatigue.
45819237|NCT03760796|Device|Corrie Health Digital Platform|The Corrie Health Digital Platform consists of the Corrie smartphone app for heart attack recovery which is paired with an Apple Watch and Bluetooth-enabled, iHealth blood pressure monitor.
45819238|NCT03405259|Device|Super Seal® Desensitizer|Single dose professional application.
45819239|NCT03405259|Device|Acclean® Fluoride Varnish|Single dose professional application.
45819240|NCT03513757|Drug|propofol|propofol 2 mg/kg at start of procedure; 2 mg/kg for movement, 150-300 mcg/kg/minute propofol infusion if movement persists
45959941|NCT04686370|Other|laser treated implant surface|Better marginal bone stability is expected for this type
45959942|NCT00182052|Drug|Rosiglitazone|Given orally twice daily. Participants may continue study treatment as long as their disease does not progress and they don't experience any serious side effects.
45819241|NCT03513757|Drug|Dexmedetomidine|single dose dexmedetomidine administered at start of sedation in the propofol-dexmedetomidine group. Dosing is based upon anticipated duration of scan from 30 - 75 minutes and will range from 0.5 mic/kg to 1.25 mcg/kg
45819242|NCT03513757|Drug|Glycopyrrolate|4 mcg/kg glycopyrrolate will be administered at the start of sedation in the propofol-dexmedetomidine group
45819243|NCT03513757|Drug|Lidocaine 1% Injectable Solution|1 mg/kg intravenous administration prior to propofol administration
45959943|NCT00182052|Other|Placebo|Given orally twice daily.
45959944|NCT02115724|Dietary Supplement|Antioxidant cocktail|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
45959945|NCT02115724|Other|Biopsy|Under sterile conditions, a small incision (¼ - ½ inch) by the study doctor will be made and the piece of fat will be taken out. Fat tissue was chosen for this study because it is a big source of small blood vessels which we are studying
45959946|NCT02115724|Other|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
45959947|NCT02115724|Drug|NMD; 0.4mg sub-lingual nitroglycerin spray|Nitroglycerin mediated dilation will be measured immediately following an administered 0.4mg dose of nitroglycerin spray, sub-lingual.
45959948|NCT02081755|Drug|Everolimus|Everolimus Dosing: 1.5 mg BID (3.0 mg/day) for 12 months
45664732|NCT02524145|Drug|Dexmedetomidine|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
45819244|NCT03513757|Drug|Nitrous Oxide|Inhalation of nitrous oxide may be used for IV placement
45819245|NCT03513757|Drug|Sevoflurane|Inhalation of sevoflurane may be used for IV placement
45819246|NCT03760640|Drug|LY900014|Administered SC
45819247|NCT03760640|Drug|Insulin Lispro|Administered SC
45819248|NCT03407053|Dietary Supplement|Ultra-processed diet|Consuming ultra-processed diet over a 2-week period
45819249|NCT03407053|Dietary Supplement|Unprocessed diet|Consuming unprocessed diet over a 2-week period
45959949|NCT02081755|Drug|Tacrolimus|Tacrolimus Dosing: 0.05 mg/kg BID for 12 months
45664733|NCT02524145|Drug|Glycopyrrolate|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
45959950|NCT02081755|Drug|Myfortic|Myfortic®: 360 mg to 1080 mg BID for 12 months
45959951|NCT02081755|Drug|CellCept|CellCept: 500 mg to 1500 mg BID for 12 months
45959952|NCT02081755|Drug|Imuran|0.5 mg/kg to 2 mg/kg QD for 12 months
45959953|NCT00156026|Procedure|loop electrosurgical excision procedure (LEEP)|1. loop electrosurgical excision procedure
45664734|NCT02524145|Drug|Isoproterenol|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
45959954|NCT00188838|Behavioral|Psychoeduction|
45959955|NCT00188838|Behavioral|Cognitive-Behavioral Therapy|
45959956|NCT01715974|Drug|GM-CSF group|30 micrograms/day of GM-CSF from the day of embryo transfer through the day of beta HCG test
45959957|NCT01715974|Drug|CONTROL|saline infusion every day from the day of embryo transfer through the day of beta HCG test
45959958|NCT00156143|Procedure|Blood sample|
45819250|NCT03756506|Device|Novel Microbicidal Liquid Polymer|The polymer is a 510K FDA cleared medical device indicated for providing a covering over minor wounds and scrapes that are clean and dry. The microbicidal liquid solution consists of organic polymers . The unique formulation eradicates any organisms (bacteria, fungi, viruses) it comes in contact with. This is a result of the solvent's activity against an infinite number of organisms After eradication is complete, the solvent then transitions into a clear, elastomeric, non-odorous film for covering disrupted tissue. The film protects the wound against entry of water, dirt, and germs. The film is elastomeric and protects in difficult regions where flexing, bending and creasing skin occurs. The clear film forms in less than a minute.6 DuraDerm® should not be used to the treat deep infected wounds. DuraDerm® can be used to protect disrupted skin surface of wounds that are clean and dry.
45664735|NCT05357417|Drug|utidelone|30mg/m2 (±10%), day 1-5 every 3-week cycle
45819251|NCT03275623|Drug|Antibiotic|Those randomized for treatment will be prescribed the most commonly used antibiotic for urinary tract infections in pregnancy. This includes: Nitrofurantoin, Cephalexin, and Amoxicillin. It is unsure which antibiotic the participant will receive but a majority of the time it will be one of the above named antibiotic. The choice will be determined by the physician, but will accommodate participants' prior medication history and adverse events.
45959959|NCT00156143|Procedure|Radiography|
45455188|NCT05301634|Procedure|infraorbital block|the patients will receive bilateral infraorbital block
45819252|NCT03275623|Other|Standard Prenatal Care|Continued surveillance of urinary cultures
45959960|NCT01288066|Procedure|Hemiarthroplasty|Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
45959961|NCT01288066|Procedure|Total arthroplasty|Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
45959962|NCT00182130|Procedure|Quality Initiative in Rectal Cancer (QIRC) strategy|
45959963|NCT00535717|Procedure|uttarbasti (per urethral administration of medicated oil )|
45959964|NCT00535756|Drug|Creon|3 capsules Creon with 25000 lipase units per main meal (3 main meals) plus 2 capsules per snack (2-3 snacks)
45455189|NCT05301634|Procedure|topical intranasal bupivacaine|the patients will receive topical intranasal application of bupivacaine
45455190|NCT04170296|Drug|EN3835|Collagenase Clostridium Histolyticum (CCH)
45664736|NCT05357417|Drug|Bevacizumab|15mg/kg, day 1
45664737|NCT01658813|Drug|5-Fluorouracil and Interferon|5-Fluorouracil Interferon-alfa-2b
45664738|NCT02187471|Drug|DS-5565|DS-5565 15 mg QD or BID; tablet for oral use
45664739|NCT02187471|Drug|Pregabalin|Pregabalin capsule for oral use; 75 mg capsule for one week, then 150 mg capsule
45664740|NCT02187471|Drug|Placebo tablet|Placebo tablet for oral use, matching DS-5565 tablet
45664741|NCT02187471|Drug|Placebo capsule|Placebo capsule for oral use, matching pregabalin capsule
45959965|NCT00535756|Drug|Placebo|Placebo
45959966|NCT00156182|Drug|Asoprisnil|10mg Tablet, oral Daily for 6 months
45959967|NCT05471479|Drug|Activated Charcoal|Activated charcoal administered as per Clinical Toxicology Recommendations Collaborative or as per current practices
45959968|NCT00188877|Procedure|intensity modulated radiation therapy|
45959969|NCT00188877|Drug|cisplatinium and fluorouracil - standard treatment|
45959970|NCT00535795|Radiation|Radiation Therapy|Radiation Therapy
45959971|NCT05471362|Device|Postpartum IUD|Postpartum IUD prevents pregnancy and short inter-pregnancy interval and allow spacing and family regulation
45959972|NCT05471284|Behavioral|Proximal|The first factor tested framing of the near, proximal threat of continued smoking.
45959973|NCT05471284|Behavioral|Distal|The first factor tested framing of the long-term, distal threat of continued smoking.
45959974|NCT05471284|Behavioral|Cost|Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
45959975|NCT05471284|Behavioral|Benefit|Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
45959976|NCT05471284|Behavioral|Loss|The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
45959977|NCT05471284|Behavioral|Gain|The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
45959978|NCT05471284|Behavioral|Control|Does not include any of the three message factors.
45959979|NCT00182169|Drug|Human recombinant growth hormone|
45959980|NCT05471167|Biological|BCG|Exposure is defined as having received the BCG vaccine during the first year of life.
45959981|NCT05471050|Drug|TAC|Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
45959982|NCT05471050|Drug|Danazol|Danazol is given at 200mg bid for 12 weeks.
45959983|NCT00156260|Procedure|Ductal lavage|
45819253|NCT04735237|Procedure|Autogenous fat injection|Done under general anesthesia. Fat is to be harvested from the abdomen using manual liposuction. Small aliquots of fat are to be injected into the philtral column (and in the vermilion and any other area of volume insufficiency if needed).
45455191|NCT01328821|Drug|CTP-499|600 mg, 1200 mg, 1800 mg and 2400 mg
45819254|NCT04735237|Procedure|Surgical revision with orbicularis oris muscle reconstruction.|Surgical repair done under general anesthesia. The original scar will be marked on the skin with methylene blue. The skin will be incised along the designed line with scar removal. The orbicularis oris muscle stump will be dissected medially and laterally and approximated by means of 4-0 inverted horizontal mattress sutures.
45455192|NCT01328821|Drug|CTP-499|400 mg immediate release capsule
45455193|NCT01212835|Procedure|Sham Comparator: no ring|Open roux-en-Y gastric bypass not banded
45455194|NCT01212835|Procedure|RYGBP-RING|Vertical Roux-en-Y banded gastric bypass
45455195|NCT04082572|Biological|Pembrolizumab|Given IV
45455196|NCT01345448|Drug|Brimonidine|0.1% Brimonidine Lotion, dosed once.
45819255|NCT03756038|Drug|Placebos|In this study, patients will receive oral placebo, an inactive solution that looks like the study drug, but contains no active ingredients
45819256|NCT03756038|Drug|Lorazepam|The purpose of this study is to determine whether a single low dose of Lorazepam/Ativan (1mg) can relieve pain and reduce negative mood in the emergency department and for 2 weeks after emergency department treatment.
45959984|NCT00535834|Procedure|diagnostic procedure|
45959985|NCT00535834|Procedure|molecular diagnostic method|
45959986|NCT00535834|Procedure|protein expression analysis|
45959987|NCT00182208|Device|Veno-device (Venowave)|
45959988|NCT05470972|Drug|Ethanol Injection|The AEST procedure was performed as follows: vaginal walls were cleansed using vaginal povidone-iodine, a 17 gauge, 30-cm length needle was inserted through the posterior vaginal fornix into the pouch of Douglas, and the cyst was aspirated till complete disappearance of the cyst on the ultrasound scanner. The collected cystic fluid was collected into a plastic tube without an anticoagulant. The needle was maintained in its place, the syringe was removed and the cyst was flushed with saline solution until obtaining a clear liquid. Then, 96% ethanol was injected as 60% of the volume of the aspirated fluid to guard against over distension or rupture of the cyst and/or ethanol diffusion into the pelvis. The collected fluid was divided into three sterile tubes for cytological and bacteriological examinations and the study investigations. Patients were allowed to be completely recovered and were discharged home.
45959989|NCT04686019|Other|Inspiratory muscle training (IMT)|"IMT and conventional neurorehabilitation - treatment as usual. The intervention group will add-on IMT sessions exercising at 30 % of MIP. MIP is measured by instructing the patient to perform five forceful inspirations against an occluded mouthpiece (Power Breath). The best score is multiplied by 0.3 to determine the resistance. IMT is performed with IMT Threshold flute with the calculated resistance. During the measurement with Power Breath the patient sits straight up and uses nose clip. The patient can receive help to hold the Power Breath if necessary.~One session of IMT with IMT threshold flute consists of 2 times 15 inspirations in normal breathing rhythm (5-10 min). Patients in the intervention group perform 2 sessions a day (morning and evening), training is performed prior to a meal, 7 days a week for 3 weeks."
45959990|NCT04686058|Drug|Propofol 10 MG/ML Injection|
45959991|NCT04686058|Drug|Midazolam injection|
45959992|NCT04686058|Drug|Pethidine Hydrochloride 50 Mg/mL Solution for Injection|
45959993|NCT04686058|Device|target controlled infusion pump|
45959994|NCT04686058|Device|patient-controlled sedation pump|
45959995|NCT00156299|Drug|choline magnesium trisalicylate|1500mg orally every 8 hours beginning at hour 0 and continuing until hour 48.
45455197|NCT01345448|Drug|Placebo Lotion|Placebo Lotion dosed once.
45455198|NCT01123135|Drug|Vaginal ERT|1gm of estrogen vaginal cream [EVC] at bed time 3 times a week
45664742|NCT02525471|Drug|RNS60|"RNS60 will be administered in two ways: by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) for 23 weeks.~In addition, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug. Study drug will be given by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) during the extension phase."
45664743|NCT05285423|Procedure|Novel technique of Vocal cord Laterlization with Prolene suture.|The procedure will be performed under General anesthesia, preferably with a tracheostomy so that the extent of vocal cord lateralization could be ascertained intraoperatively.
45819257|NCT03276637|Genetic|Whole exome sequencing|Whole exome sequencing at 125x coverage (i.e., at least 125 sequencing reads covering each position within the exome region of interest) performed at the Laboratory of Molecular Medicine's Clinical Laboratory Improvement Amendments (CLIA) certified laboratory on 75 enrolled individuals
45819258|NCT03754556|Device|Intrauterine device|Intrauterine devices, e.g. BAY86-5028 (Mirena, Skyla, Kyleena), Liletta and ParaGard
45959996|NCT00156299|Drug|Dexamethasone|10mg orally every 6 hours beginning at hour 0 and continuing until hour 48.
45959997|NCT04685863|Other|Mobilizing the knee with active neurodynamic sliding technique (active Slump slider)|60 physiotherapy students perform measurements during three tutorials. The first involves training in evaluation techniques. The second involves mobilizing the knee, out of the SLUMP position. The third tutorial includes neuronal mobilization in SLUMP.
45959998|NCT00535912|Procedure|Stem cells autograft|Treatment by Intensive Chemotherapy and autograft
45455199|NCT01123135|Drug|Placebo|Placebo
45455200|NCT04072822|Drug|Anakinra and Zinc|Anakinra is indicated for reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis. It has been previously studied in AH. Zinc is a nutritional supplement. Zinc supplementation reverses the clinical signs of zinc deficiency in participants with alcoholic liver disease.
45455201|NCT04072822|Drug|Prednisone|Prednisone is indicated for numerous conditions including inflammatory disease. Corticosteroids, such as prednisolone, are considered standard of care in alcoholic liver disease.
45819259|NCT03276871|Procedure|Telescopic Dissection|Creation of extraperitoneal space with blunt dissection using the laparoscopic probe
45819260|NCT03276871|Device|Balloon Dissection|Creation of extraperitoneal space with aid of the disposable Spacemaker balloon dissector
45959999|NCT00535951|Drug|LBH589|
45960000|NCT00156338|Procedure|fluid management|volume and sodium restriction
45960001|NCT00156338|Procedure|fluid management|volume restriction
45960002|NCT00156338|Procedure|fluid management|liberal fluid management
45960003|NCT00188955|Drug|sirolimus|
45664744|NCT05284409|Drug|Pethidine|36 patients will receive 0.5 mg/kg Pethidine IVI
45960004|NCT00536068|Drug|Acetylsalicylic acid, acetaminophen, diclofenac, naproxen, placebo|"Acetylsalicylic acid 100mg/po and acetaminophen 3x1g/po for 4 days~Acetylsalicylic acid 100mg/po and diclofenac 3x50mg/po for 4 days~Acetylsalicylic acid 100mg/po and naproxen 3x250mg/po for 4 days~Acetylsalicylic acid 100mg/po and placebo 3x1/po for 4 days"
45960005|NCT05470660|Procedure|Root coverage using coronally advanced flap combined with micro-needling|modified coronally advanced flap will be performed in sites of recession defects, then micro-needling will be performed after 1 month from the coronally advanced flap procedure to ensure the initial flap healing.
45664745|NCT05284409|Drug|Acetaminophen|36 patients will receive 15 mg/kg Acetaminophen IVI
45664746|NCT05284409|Drug|Dexamethasone|36 patients will receive 0.1 mg/kg Dexamethasone IVI
45664747|NCT05355779|Other|Not Application as this is a qualitative study|Not Application as this is a qualitative study
45960006|NCT05470660|Procedure|coronally advanced flap combined with Alloderm|modified coronally advanced flap will be performed in sites of recession defects in Association with alloderm to cover the exposed root and 3 mm of connective tissue mesial and distal to it.
45960007|NCT05470582|Biological|Flu-M, Inactivated split influenza vaccine 0.5 mL|Solution for intramuscular injection Сhildren were vaccinated with the Flu-M vaccine once/twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination; if the child is vaccinated for the first time) intramuscularly in a dose of 0.5 mL
45960008|NCT05470582|Biological|Vaxigrip, Inactivated split influenza vaccine 0.5 mL|Suspension for intramuscular and subcutaneous injection Children were vaccinated with the Vaxigrip® vaccine once/twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination; if the child is vaccinated for the first time) intramuscularly in a dose of 0.5 mL
45960009|NCT05470582|Biological|Flu-M, Inactivated split influenza vaccine 0.25 mL|Solution for intramuscular injection Children were vaccinated with the Flu-M vaccine twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination) intramuscularly in a dose of 0.25 mL
45960010|NCT05470582|Biological|Vaxigrip, Inactivated split influenza vaccine 0.25 mL|Suspension for intramuscular and subcutaneous injection Children were vaccinated with the Vaxigrip® vaccine twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination) intramuscularly in a dose of 0.25 mL
45960011|NCT00156377|Drug|Mupirocin|
45960012|NCT00182247|Procedure|venogram|
45664748|NCT01658735|Device|H-Wave|Proprietary electrotherapy device using electrical stimulation of unique wave form and energy level that is delivered through transcutaneous electrodes to nerves and soft tissue for analgesic effect.
45960013|NCT05470426|Other|COVID-19 Omicron Recurrence|COVID-19 Omicron Recurrence
45960014|NCT05470231|Dietary Supplement|Beetroot Juice|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
45960015|NCT00536185|Dietary Supplement|Fish Oil|capsules, 5.0 g/d fish oil concentrate (3.0 g/d EPA + DHA), 6 weeks
45819261|NCT03521089|Device|Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001|Transcranial direct current stimulation works by sending constant, low direct current through the electrodes. When these electrodes are placed in the region of interest, the current induces intracerebral current flow. This current flow then either increases or decreases the neuronal excitability in the specific area being stimulated based on which type of stimulation is being used. This change of neuronal excitability leads to alteration of brain function, which can be used in various therapies as well as to provide more information about the functioning of the human brain.
45960016|NCT00536185|Dietary Supplement|Placebo|capsule, 5.0 g/d corn/soybean oil (50/50 mixture), 6 weeks
45960017|NCT00156416|Behavioral|Mindfulness Meditation|8 weeks of meditation training
45960018|NCT00188994|Drug|Insulin Cardioplegia|
45960019|NCT00536224|Behavioral|Full counseling|"The health educator generated a computerized report for the patient that outlined his/her Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal. Based on the Ask-Advise-Assess-Assist-Arrange follow-up (5A's) framework for behavior change, counseling for specific risk-related behaviors (diet, physical activity, and smoking) was provided by a cardiovascular rehabilitation health educator in the emergency department and during telephone follow-up (2 sessions over 6 weeks). Patients also received a general informational handout on self-management of cardiovascular risk factors (AHA Brochure Controlling your risk factors). A full report was also be sent to the patient's primary care physician (if any) at the conclusion of counseling."
46079421|NCT05403723|Drug|Durvalumab 50 MG/1 ML Intravenous Solution|Durvalumab (1500 mg durvalumab via IV infusion) in combination with platinum doublet chemotherapy will be administered to patients once every 3 weeks for up to 4 cycles plus SBRT (platinum resistant group) or without SBRT (platinum sensitive group). Each 3-week of chemoimmunotherapy interval is considered a cycle. Patients with platinum sensitive disease will receive the combination of durvalumab and chemotherapy (total of four cycles) while those with platinum resistant SCLC will receive SBRT and continue to receive up to two additional cycles of treatment with durvalumab along with platinum/etoposide (not to exceed a total of four6 cycles of chemoimmunotherapy including 2 cycles obtained prior to SBRT). Following completion of 4-6 cycles of combination therapy, patients in both groups will continue with maintenance durvalumab (1500 mg) in q4w cycles until disease progression.
45455202|NCT04072822|Drug|Placebos|Matching placebo
45455203|NCT03939325|Radiation|ESWL|The impact of different frequencies on pattern of disintegration of renal stones
45455204|NCT04001894|Drug|Ticagrelor 90mg|Ticagrelor (90.0 mg twice daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of clopidogrel (75mg once daily).
45455205|NCT04001894|Drug|Clopidogrel 75mg|Clopidogrel (75mg once daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of ticagrelor (90.0 mg twice daily).
45455206|NCT04066114|Biological|lulizumab pegol|25 mg subcutaneously (SC) on Day 1 post transplantation then 12.5 mg SC weekly through day 77 (Week 11)
45819262|NCT03410797|Device|Inclusion of semi-occluded mask in voice therapy|Patients will be given a facemask with a semi-occlusion (SOMask) for use during in person voice therapy and for use at home therapy practice.
45819263|NCT03410953|Biological|Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).|"The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule:~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine"
45819264|NCT03521479|Drug|Squaric Acid Dibutyl Ester|Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).
45819265|NCT01495988|Drug|Vemurafenib|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.
45819266|NCT01495988|Drug|Bevacizumab|Patients assigned to the combination arm will also receive bevacizumab at 15mg/kg, intravenously, every 3 weeks.
45455207|NCT04066114|Biological|antithymocyte globulin (rabbit)|1.5 mg/kg intravenously (IV) on Day 0 (day of transplantation) and the day following (Day 1)
45455208|NCT04066114|Drug|methylprednisolone|500 mg (IV) on Day 0 (day of transplantation), 250 mg (IV) on Day 1 and 125 mg (IV) on Day 2
45455209|NCT04066114|Biological|tocilizumab|8 mg/kg (IV) on Day 2 post transplantation followed by 162 mg (SC) every 2 weeks through day 168 (Week 24)
45664749|NCT01658735|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device that delivers current at different frequency, amplitude, and wave form through cutaneous electrodes placed near body parts with pain for temporary analgesic effect. The study device is installed inside the same housing as the H-Wave Device and Sham Device, so that all appear the same. There are no identifying marks on the case that participants will recognize in order to maintain blinding.
45819267|NCT01495988|Drug|Cobimetinib|Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle.
45960020|NCT00536224|Behavioral|Minimal counseling|"Patients assigned to the minimal counseling intervention received brief counseling (<5 minutes) on the benefits of changing lifestyle and a handout with general information on self-management of cardiovascular risk factors.~Patients assigned to minimal intervention also received an AHA brochure (Controlling your risk factors) with general information on management of cardiovascular risk factors. At the end of 6-month follow-up, patients received a computerized report that outlined their Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal."
45960021|NCT05470192|Other|Qigong exercise training|"Before and after the qigong exercises, 10-minute exercises will be done to stretch the large muscle groups for warm-up-cooling purposes.~The entire Baduanjin exercise consists of 8 postures:~preparation position~Raising arms with palms up,~Shooting arrows left and right like an archer in a semi-crouching position~Keeping one arm up~Looking back with trunk rotations in a semi-crouching position~Nodding the head and lowering the body to relieve stress,~Fisting and staring~Touching feet with hands touching back and legs~Raising and lowering heels"
45960022|NCT00536302|Dietary Supplement|Collagen Hydrolysate|Collagen Hydrolysate solution 10 grams per day by mouth for 48 weeks
45960023|NCT00536302|Dietary Supplement|Placebo|Matching placebo solution per day by mouth for 48 weeks.
45455210|NCT04066114|Drug|Prednisone|"Beginning on Day 3 post transplantation, taken orally: 60 mg daily~Days 4 through 10: 30 mg daily~Days 11 through 17: 20 mg daily~Days 18 through 24: 10 mg daily~After Day 24: continued taper of dose to final maintenance dose of 5 mg, per protocol"
45960024|NCT05469880|Other|moisturizing cream and 5% benzoyl peroxide gel|"Group A: Eclaran 5% every evening and formula 609567 49 every morning, for 3 months.~Then the group is divided: Group A1/ formula 609613 37 and Group A2/ formula 609567 49 every morning, for the next 3 months"
45960025|NCT05469880|Other|anti-acne face cream and 5% benzoyl peroxide gel|"Group B: Eclaran 5% every other night and 609613 37 every morning, for 3 months.~Then the group is divided: Group B1/ 609613 37 and Group B2/ formula 609567 49 every morning, for the next 3 months"
46079422|NCT05403723|Drug|Etoposide Injection|A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
46079423|NCT05403723|Drug|Cisplatin|A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
45664750|NCT01658735|Device|Sham|The sham device is a TENS unit modified to have minimal electrical output. The device is installed in the same housing as the two active arms with equal weight, so that each device in the study appears identical.
45819268|NCT04735003|Device|Transcatheter tricuspid valve interventions|Transcatheter repair or replacement to treat tricuspid regurgitation
45455211|NCT04066114|Drug|everolimus|Initial dose of 0.75 mg taken orally twice daily on Day 14 days after transplantation. Dose will be titrated to target trough levels 3-8 ng/mL.
45455212|NCT04066114|Biological|belatacept|5 mg/kg (IV) every 4 weeks starting on Day 84 (Week 12) and continuing through Day 364 (Week 52)
45455213|NCT04066114|Drug|mycophenolate mofetil|"An option for participants who do not tolerate everolimus: to be switched to either~mycophenolate mofetil 1000 mg administered orally twice daily or~mycophenolic acid"
45664751|NCT02523599|Drug|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
45819269|NCT02934932|Drug|Brexpiprazole|Comparison of brexpiprazole 2mg to placebo Comparison of brexpiprazole 4mg to placebo
45664752|NCT02523599|Other|Placebo|Plain collagen implant (vehicle)
45664753|NCT05492357|Other|Liquid platelet-rich fibrin|Liquid platelet-rich fibrin is prepared from the patient's blood and injected into the extraction socket every two weeks (up to 3 months = Just 4 times of application)
45819270|NCT03415243|Drug|Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg|Contents of the sachet will be emptied into a glass bottle and 225 mL of hot, but not boiling water (approximately 90-95°C), will be added to the container and mixed to dissolve the contents of the sachet. The dissolved solution will be allowed to cool to approximately 40 - 50 degree Celsius (°C). After cooling, a small volume (1 to 10 microliters [mcL]) of 99mTc-DTPA (Technetium-99m-diethylene-triamine-pentaacetate will be added to the drug solution in to achieve a maximum of 108 curie(mcCi) i.e.4 megabecquerel [MBq] per individual dose at the time of dosing. The container will be capped and maintained at a temperature between 35-45°C at time of dosing and then participants will be instructed to consume the hot drink entirely within 30 seconds.
45960026|NCT00408525|Drug|donepezil|donepezil 5 mg tablets, total dose per day 10 mg for 6 week duration of study. Taken once per day.
45960027|NCT05469763|Other|Circuit training|"Mode : any rhythmical and aerobic activity using large muscle groups that can be maintained continuously.~Intensity: 60% to 90% of maximum heart rate reserve or 50% to 85% of vO2 max.~Duration: 25 to 30 minutes of continuous aerobic activity.~Frequency: three to five days per week."
45960028|NCT05469724|Other|Role of ct pulmonary angiography in diagnosis of pulmonary embolism|Role of ct pulmonary angiography in diagnosis of acute pulmonary embolism as filling defect in pulmonary artery
45960029|NCT05469529|Drug|Dexmedetomidine|5mcg dexmedetomidine to be given intrathecally along with 0.5% bupivacaine.
45960030|NCT00189033|Drug|psyllium fibre (dietary supplement)|
45960031|NCT00189033|Drug|wheat bran (dietary supplement)|
45960032|NCT00189033|Drug|rice wheat (placebo)|
45960033|NCT05469217|Other|fMRI brain imaging|Structural MRI of gray and white matter, functional MRI during performance of the N-back task
45664754|NCT05492357|Other|Advanced Platelet-rich fibrin plus|A-PRF+ is placed into the extraction socket immediately after tooth extraction
45960034|NCT05469100|Drug|Selpercatinib|Administered orally
45960035|NCT05469061|Drug|Tislelizumab|The 1st to 3rd doses were administered concurrently with FP regimen chemotherapy, 200 mg Tislelizumab each, on D1, D22 and D43 by intravenous infusion. In patients with successful conversion, one dose of 200 mg was administered 21 days after surgery in concurrent with the 4th to 6th cycles of 5-Fu, then 6 cycles of 200 mg Tislelizumab as adjuvant therapy; in patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
45960036|NCT05469061|Drug|5-FU|A FP regimen with 5-Fu 850mg/m^2 d1-4 + cis-platinum 850mg/m^2 d1-4 was used, on D1, D22 and D43 infused intravenously. 3 cycles of 5-Fu 850mg/m^2 d1-4 adjuvant chemotherapy were started at 21 days after surgery in patients with a successful conversion. In patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
45960037|NCT05469061|Drug|cis Platinum|A FP regimen with 5-Fu 850mg/m^2 d1-4 + cis-platinum 850mg/m^2 d1-4 was used, on D1, D22 and D43 infused intravenously. In patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
45960038|NCT00408642|Behavioral|Enhanced adherence support|The enhanced adherence support intervention consists of 5 one-on-one, Information-Motivation-Behavioral Skills (IMB) theory-based counseling sessions, as well as a problem-solving card which summarizes key messages and strategies. The counseling sessions are given at key points post-initiation of therapy: at baseline, 2 weeks, 2 months, 3 months, and 6 months. Three brief weekly ART planning sessions are conducted post-initiation of therapy.
45960039|NCT00408642|Behavioral|Standard adherence support|The control arm receives the standard of care adherence support which consists of three group counseling adherence sessions conducted prior to initiation of therapy.
45960040|NCT05469022|Drug|Neoadjuvant lazertinib|Lazertinib 240mg p.o once daily.
45960041|NCT05468944|Procedure|Transanal specimen extraction robotic surgery|Participants in this group underwent robotic rectal cancer resection ,the specimens were extracted through anus.
45664755|NCT05490797|Other|app based training with conventional therapy|The experimental group will receive an additional mobile application therapy including , dexterity fine motor skills, bowling game, scribble game and peglight game in addition to the conventional therapy for hand function.
45664756|NCT05490797|Other|conventional therapy|conventional hand function rehabilitation therapy including, strengthening exercises which consist of palm down wrist flexion exercise, dexterity( shifting exercise) and fine motor skills(nine peg hole exercise)
45960042|NCT05468944|Procedure|Transabdominal specimen extraction robotic surgery|Participants in this group underwent robotic assisted rectal cancer resection ,the specimens were extracted through the incision on the abdominal wall.
45960043|NCT00189072|Drug|gabapentin|
45960044|NCT05468905|Other|None of intervention|None of intervention
45664757|NCT05321381|Other|Resilience In Stressful Events (RISE) peer support team|Availability of peer support team to health care workers who experience stressful work-related events or situations
45664758|NCT04254263|Drug|pyrotinib|pyrotinib 400 mg, orally once daily for one year
45664759|NCT05321303|Other|Serious Game|"Each participant of the Serious game group played 1 scenario of MetaHospital, a screen-based simulation on the management of diabetic ketoacidosis. Immediately after the serious game was played, 5 open-ended questionnaires were sent to the students to evaluate the game usability."
45819271|NCT03415243|Drug|Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg|Caplet doses will be prepared by drilling hole of approximately(app.)1millimetre(mm)diameter and app.2-2.5mm deep into individual caplets.99mTc-DTPA(dissolved in normal saline)will be added into hole of each caplet as low volume liquid(0.5-2.0mcL)to achieve maximum of 54 mcCi(2MBq)per caplet at time of dosing(2caplets=108 mcCi[4MBq]dose per assessment visit).Applied liquid will be allowed to air dry,hole to be filled with equivalent powder blend from crushed caplet so drug content will remain constant for all caplets.Caplet will be sealed with appropriate material.Radiolabeled caplets will be packaged as unit doses(2 caplets per container)and maintained at room temperature until administration.Caplets will be swallowed with 225mL of noncarbonated room temperature water within 30 seconds.
45819272|NCT02892500|Drug|bupivacaine hydrochloride and betamethasone sodium phosphate|5ml of 0.25% bupivacaine hydrochloride and 2 ml of 3mg/ml betamethasone sodium phosphate one injection into the inferior tibiofibular ligament
45819273|NCT02892500|Drug|bupivacaine hydrochloride|5ml of bupivacaine hydrochloride into the tibiofibular ligament
45664760|NCT05321303|Other|Standard Patients|Each participant of the standardized patient's group played 1 scenario on the management of diabetic ketoacidosis and then a 30-minute analysis session with the trainer joined.
45664761|NCT04422353|Other|Video Dance classes|The dance program consists of dance lessons inspired by Forró rhythm and Samba rhythm. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
45664762|NCT04422353|Other|Unsupervised physical activities|The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
45819274|NCT02904356|Device|Repetitive transcranial magnetic stimulation|High-frequency, brainsway H-coil for repetitive transcranial magnetic stimulation will be administered to the medial prefrontal cortex for 3 weeks. The intensity of stimulation will be based on resting-motor threshold (RMT).
45819275|NCT00378872|Drug|IV Tranexamic acid 10mg/kg pt body weight|
45819276|NCT00378872|Drug|Quixil topical sealant|
45960045|NCT00156572|Procedure|Sodium supplementation|
45960046|NCT00156572|Procedure|Fluid restriction|
45960047|NCT05468866|Genetic|Genotyping of rs1980422-related single-nucleotide polymorphisms by real time PCR|detection of rs1980422-related single-nucleotide polymorphisms and percentage of (CD3,CD4,CD28) by immunophenotyping
45960048|NCT05468788|Behavioral|Intervention: Integrative Community Therapy-based Psychodrama|Participants produce theatre scenes depicting issues that they have experienced. Group leaders then use a guide to facilitate a discussion of participants' feelings, coping strategies, and sharing of local knowledge.
45960049|NCT05468788|Behavioral|Control: Improvisational Theatre|Participants play improvisational theatre games.
45960050|NCT00156611|Procedure|Balloon Angioplasty|
45960051|NCT00156611|Drug|ReoPro|
45960052|NCT00189111|Procedure|Cardiac Imaging + Treatment|
45960053|NCT00156650|Drug|Acyline|Acyline 300 mcg/kg SQ(Subcutaneously)twice monthly for 12 weeks
45960054|NCT00156650|Drug|Testosterone Gel|Testosterone (T) gel 10 g daily for 6 months
45960055|NCT00156650|Drug|Depo-Medroxyprogesterone|300 mg IM every 3 months
45960056|NCT05468437|Behavioral|Telenutrition|Nutrition education and individualized nutrition counseling will be done with a Registered Dietitian via video-conferencing with iPad FaceTime, which is aimed to decrease the risk of complications like obesity, high cholesterol, or diabetes, and explore associations between bowel and bladder function and nutrition. The telenutrition counseling consists of 6 sessions that are scheduled approximately 2 weeks apart. The first session will last approximately 1 hour, while sessions 2-6 will last approximately 30mins. During these sessions, the Registered Dietitian will share nutrition education tailored towards people with SCI. You will be involved in developing personal nutrition goals and the dietitian will help you address barriers to meeting your goals and provide individualized feedback to improve and maintain your nutrition. Telenutrition appointments will maintain privacy and will not be recorded.
45960057|NCT05468398|Device|Soothe VR|The Soothe VR system is manufactured by Applied VR. It is a HIPAA-compliant platform and has been validated by randomized control trials. It has not yet been reviewed by the FDA.
45960058|NCT00536419|Drug|Methylphenidate|Methylphenidate SODAS 0.3 mg/kg/day (day 1); 0.7 mg/kg/day (day 2); 1.0 mg/kg/day (days 3 and 4)
45960059|NCT00536419|Other|Placebo|Placebo, daily dose, 4 days, oral administration
45664763|NCT05320835|Behavioral|HIV, HCV and overdose prevention|HIV, HCV and overdose prevention
45664764|NCT05296577|Drug|anlotinib and vinorelbine|anlotinib 12mg orally ,2 weeks on/1 week off ,Q3W; vinorelbine 25-30mg/m2 intravenously ,D1/8,21 days as a cycle.Imaging will be performed after the twice anlotinib administration as 2 cycles.
45664765|NCT05296577|Drug|Vinorelbine injection|vinorelbine 25-30mg/m2 intravenously ,D1/8,21 days as a cycle.Imaging will be performed after the twice anlotinib administration as 2 cycles.
46079424|NCT05403723|Drug|Carboplatin|A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
45960060|NCT00189150|Drug|Mycophenolate mofetil|
45960061|NCT00189150|Drug|Valganciclovir|
46079425|NCT05403723|Device|Stereotactic Body Radiotherapy|Patients will receive palliative radiation to the primary tumor site up to 30 Gy for 1 week given as 5 daily fractions of 6 Gy each or 27 Gy as 3 fractions of 9 Gy administered every other day.
46079426|NCT05397158|Procedure|single administration of low dose polyethylene glycol|"Patients in single administration of low dose polyethylene glycol (PEG) group: Take 30ml lactulose and 2L PEG.~Patients in control group: Take 4L PEG."
45664766|NCT05354999|Dietary Supplement|Sodium bicarbonate and caffeine|On experimental days subjects ingest a combination of sodium bicarbonate, caffeine and placebo.
45664767|NCT05354531|Procedure|anterior subcutaneous internal fixator ( INFIX)|INFIX was invented based upon the same biomechanical principle as the traditional external fixator, but it is placed subcutaneously. It proved to be stiffer than the traditional external fixator, and at the same time eliminates the open pin tracts, which increased the infection rate and nursing care
45664768|NCT02187159|Drug|DS-5565|DS-5565 15 mg tablet for oral administration
45819277|NCT03418051|Other|Joint Mobilization|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade II anterior to posterior ankle joint mobilizations with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
45819278|NCT03418051|Other|Massage|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.
46079427|NCT05391412|Drug|Fibrinogen Concentrate Human|Patients in the intervention group will receive single administration of fibrinogen concentrate intravenously at a dose of 20-30 mg/kg (depending on body weight and clinical condition, according to SmPC). The medicinal product will be diluted in a 100 ml infusion bag and administered after induction of anaesthesia prior beginning of surgery. The infusion rate should not exceed approximately 5 ml per minute.
45819279|NCT02818946|Device|MRI|Detection of cancer by MRI for pathologic nipple discharge
45664769|NCT02187159|Drug|Pregabalin|Pregabalin 150 mg capsule for oral administration
45664770|NCT02187159|Drug|Placebo tablet|Placebo tablet (matching DS5565) for oral administration
45664771|NCT02187159|Drug|Placebo capsule|Placebo capsule (matching pregabalin) for oral administration
45664772|NCT02335411|Biological|pembrolizumab|IV infusion
45664773|NCT02335411|Drug|cisplatin|IV infusion
45819280|NCT00378404|Drug|Docetaxel|30 mg/m2 IV on days 1, 8, 15 every 28 days for 6 cycles
45819281|NCT00378404|Radiation|Radiation|50 - 80 cGy on days 1, 8, 15 every 28 days for 6 cycles
45819282|NCT01440452|Device|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
45819283|NCT01440452|Device|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
45960062|NCT00536458|Procedure|radiotherapy|mini chep+ radiotherapy
46079428|NCT05390931|Behavioral|6-session motivational interviews|A total of 6 motivational interviews will be held once a month. Motivational interviews will be conducted individually.
46079429|NCT05390931|Other|Health education structured according to the health belief model|After the participants enrolled in the study, the patients in the study group will be given a health education structured according to the health belief model at the first interview.
45455214|NCT04066114|Drug|mycophenolic acid|"An option for participants who do not tolerate everolimus: to be switched to either~mycophenolic acid 720 mg taken orally twice daily or~mycophenolate mofetil"
45664774|NCT02335411|Drug|5-FU|IV infusion
45664775|NCT02335411|Drug|capecitabine|oral tablets
45664776|NCT02186301|Drug|Rociletinib Mono-Therapy|Rociletinib will be administered twice daily
45664777|NCT02186301|Drug|Erlotinib Mono-Therapy|Erlotinib will be administered once a day
45664778|NCT02186223|Device|The Angel® Catheter|The Angel® Catheter is a temporary device that combines the functions of an inferior vena cava (IVC) filter and a 3-lumen central venous catheter (CVC). The device can be placed at the bedside into the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system. The device is intended for short-term (less than 30 days) vascular access via the femoral vein.
45664779|NCT02163057|Biological|INO-3112|1.1 mL of INO-3112 (VGX-3100 + INO-9012) delivered intramuscularly (IM) followed immediately by electroporation (EP) with CELLECTRA™-5P device for a total of 4 doses of immunotherapy.
45664780|NCT02163057|Device|CELLECTRA™-5P|CELLECTRA™-5P device was used for EP following IM delivery of INO-3112 for a total of 4 doses of immunotherapy.
45664781|NCT02185521|Other|patient assessment|Patient clinician status assessment based on Hemodynamic Instability Indicator (HII) trend. The HII indicator combines existing data such as physiologic parameters (Heart Rate, HR; Blood Pressure, BP), laboratory measurements (Albumin; Hematocrit, HCT; Bicarbonate; White Blood Cell, WBC; Blood Urea Nitrogen, BUN), and ADT information (age). HII will be displayed on charting workstation (Workstation on Wheels, WOW). Nurse's role will be to observe the value of HII while accessing WOW desktop (during regular charting), interpret HII value, and share this information to the physician when indicative of potential patient hemodynamic instability to trigger patient clinical status assessment. This intervention is associated with Experimental Study Arm: visible HII.
45664782|NCT01599585|Behavioral|Behavioral Activation|Behavioral activation(BA)will be delivered in 8 weekly sessions via webcam for the in-home arm or face to face in the in-person arm. Behavioral activation attempts to help depressed individuals reengage in their lives through focused activation strategies.
45664783|NCT02185053|Drug|CPC-201|
45819284|NCT01440452|Procedure|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
45664784|NCT02161731|Drug|Evacetrapib|Oral administration
45960063|NCT00536458|Drug|MINI CHEP|chemotherapy minichep 6 courses
45960064|NCT00536497|Drug|GW842166X|
45664785|NCT02161731|Drug|Warfarin|Oral administration
45664786|NCT02124759|Drug|Sevelamer|1.6 g sevelamer + 4.4 g maltodextrin three times a day
45664787|NCT02124759|Drug|Synbiotic|5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming units (CFU)/g) three times a day.
45960065|NCT00536536|Behavioral|Obesity management framework|Treatment in primary care will be compared to treatment in a secondary hospital setting. Treatment in both cases will be provided by a multi-disciplinary team of: obesity or practice nurse, dietitian, exercise specialist with some input from medical team.
45960066|NCT05468281|Other|Checklist implementation|. Our strategies will include a) selection of local physician champions from the ED and cardiology; b) discussion of the goals of the study with the local physician groups; c) formal introduction of the CAEP Checklist to the physicians and nurses by means of presentations at staff meetings, emails, and an online video; d) development of an action plan to address local barriers to implementation; e) creation of a free smartphone application; f) regular reminders; and g) and distribution of charts of site compliance.
45960067|NCT00156689|Drug|levetiracetam|
45960068|NCT00536614|Genetic|cetuximab|Cetuximab is an EGFR antibody inhibitor; it has been shown to increase the activity of gemcitabine (GEM) in advanced pancreatic cancer.
46079430|NCT05390931|Other|Training booklet prepared by the researchers on healthy lifestyle behavior changes|After the participants enrolled in the study and take health education, a training booklet prepared by the researchers on healthy lifestyle behavior changes will be given to the participants.
45455215|NCT03995264|Procedure|Ultrasound -guided cannulation|radial artery cannulation using the ultrasound
45455216|NCT03995264|Procedure|Palpation -guided cannulation|radial artery cannulation using the palpation
45664788|NCT02124759|Drug|Maltodextrin|This is a control group. Maltodextrin, 6 g three times a day
45664789|NCT02124759|Other|High Fat diet|The High Fat diet consists of 60% energy from fat (50% saturated), 15% of energy as carbohydrate and 25% from protein consumed while study intervention is being administered.
45664790|NCT02124759|Other|Low Fat diet|The isocaloric low fat diet will provide 55% energy from carbohydrates, 20% from fat and 25% from protein.
45664791|NCT02302339|Drug|glembatumumab vedotin|
45819285|NCT01440452|Behavioral|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
45819286|NCT03742154|Drug|Varenicline 0.5 MG|varenicline comes in bottles of 56 - 0.5 mg pills
45960069|NCT00182286|Behavioral|Assessment of continuity of care from the patient perspective|
45960070|NCT00182286|Behavioral|Relationship between continuity of care, patient outcomes, and costs|
45664792|NCT02302339|Drug|glembatumumab vedotin and varlilumab|
45819287|NCT03284359|Behavioral|Pre-Consent Nudge Bundle|The pre-consent nudge bundle survey was developed by the study team and incorporates several behavioral interventions into a bundle of 5 types of nudges: (i) injunctive norms; (ii) descriptive norms; (iii) duty of reciprocity; (iv) self-prophecy; and (v) foot-in-the-door. Injunctive norms involve the perception of what behavior is acceptable, while descriptive norms highlight what behaviors others are engaging in. The duty of reciprocity is the sense that one should repeat pro-social behavior for which they have benefited from. The foot-in-the-door nudge involves asking a participant to perform a small request which has a high consent rate followed by a larger request. The bundle consists of six questions and one statement.
45819288|NCT05313230|Other|CITRASATE SLED|Applying of CITRASATE SLED
45819289|NCT03738020|Device|HA IDF (YVOIRE classic)|Treatment with HA IDF
45819290|NCT03738020|Device|Restylane|Treatment with Restylane
45819291|NCT02734940|Drug|Lidocaine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
45819292|NCT02734940|Drug|Unrestricted Fentanyl|No changes to current practices, using unlimited narcotic medications intraoperatively.
45819293|NCT02734940|Drug|Ketamine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
45819294|NCT02734940|Drug|Precedex|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
45819295|NCT02734940|Drug|Duramorph|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
45819296|NCT00378092|Drug|Oral risperidone|Oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injection becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
45819297|NCT00378092|Drug|Risperidone Long-Acting Injection (RLAI)|RLAI 25 mg to 50 mg will be administered, intramuscularly which will be tapered and discontinued over a period of up to 6 weeks.
45819298|NCT00378092|Drug|Risperidone Long-Acting Injection (RLAI)|Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus for up to 24 months.
45819299|NCT00378170|Device|intubation of patients undergoing elective surgery|
45819300|NCT01347632|Drug|Metronidazole|All participants had BV at baseline. They all received metronidazole 500 mg po BID for 7 days
45819301|NCT02679560|Drug|Liposomal Bupivacaine|A fascia iliaca compartment block using liposomal bupivacaine will require less total opioid administration compared to a fascia iliaca block using 0.2% ropivacaine
45819302|NCT02679560|Drug|Ropivacaine HCL|Ropivacaine HCL is a member of the amino amide class of local anesthetics. Naropin injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and water for injection. It is administered parenterally.
45819303|NCT00378248|Behavioral|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group-and individual psychotherapy
45819304|NCT00378248|Behavioral|Outpatient individual psychotherapy|Eclectic individual psychotherapy in private practice
45819305|NCT03734822|Other|End tidal CO2 (EtCO2)|End tidal CO2 (EtCO2) is monitored through the endotracheal tube during general anesthesia.
45819306|NCT03734822|Device|Transcutaneous CO2 (TCO2)|Continuous and noninvasive real-time monitoring of transcutaneous CO2.
45819307|NCT03734822|Diagnostic Test|Capillary CO2 (CapCO2)|Capillary CO2 collected by finger stick and run on the i-STAT handheld blood analyzer.
45819308|NCT03734822|Diagnostic Test|Arterial blood gas (ABG)|Arterial blood gas collected from the radial artery and run on the i-STAT handheld blood analyzer.
45819309|NCT02671136|Device|Hyperbaric Oxygen therapy|
45819310|NCT02671136|Other|Conventional Wound Therapies|
45819311|NCT03728348|Diagnostic Test|mt-sDNA screening test|Stool samples will be collected by the subject for the mt-sDNA screening test.
45819312|NCT03728348|Procedure|Colonoscopy|Subjects will undergo a screening colonoscopy.
45664793|NCT02302339|Drug|glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)|
45664794|NCT02302339|Drug|glembatumumab vedotin and CDX-301|
45664795|NCT04895917|Drug|daratumumab and pomalidomide|Patient eligible to enter the study will receive 6 cycles of 28 days of subcutaneous Daratumumab (1800 mg SC) and oral pomalidomide 4 mg from day 1 to day 21. During cycle 1 and 2, Daratumumab will be administered weekly at days 1, 8, 15, and 22 then from cycle 3 to 6, Daratumumab will be administered every other week at days 1 and 15.
45819313|NCT02665988|Device|tDCS|Prior to initiating the real tDCS trial and to reduce the likelihood of irritation associated with electrical stimulation, a low dose (1/8 of an inch) topical lidocaine (4%) cream will be applied to the skin where the tDCS the sponge-coated, surface electrodes soaked in saline solution will be placed. Neurotargeting tDCS-explorer software, Version 2.3 will be used to locate the left and right DLPFC, where anodal stimulation of the left DLPFC and cathodal stimulation of the right DLPFC will be received. Real tDCS will be applied during 20-minute periods over the course of 10 sessions. After each session, vitamin-E will be applied to the skin where the electrodes had been placed to reduce likelihood of skin irritation.
45664796|NCT02161575|Drug|Ranibizumab|Intraveal injections of 0.5mg ranibizumab
45960071|NCT05468203|Drug|SGLT2 inhibitor or matched placebo|SGLT2 inhibitor or matched placebo 10mg daily
45960072|NCT05468164|Drug|Selpercatinib|Administered orally
45960073|NCT05468164|Drug|Omeprazole|Administered orally
45960074|NCT00156728|Device|Vitatron biventricular pacemaker|
45960075|NCT05468086|Device|VR Solace|Participants will use the VR audio and visual head-mounted device. The device is a standalone VR headset. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
45960076|NCT00189189|Behavioral|parent management training|
45960077|NCT05468047|Drug|Ketamine hydrochloride injection|Individuals will be administered a single dose of sub-anesthetic (0.5-0.75 mg/kg; maximum dose of 60 mg regardless of body weight) ketamine hydrochloride injection intramuscularly as part of a ketamine-assisted therapy experience.
45960078|NCT04686214|Procedure|heating|patients were aggressively warmed using multiple heating methods such as pressurized air heater and intravenous fluid heater
45960079|NCT05467969|Behavioral|Teleteaching of procedural skills through the online multiscreen display teleconference platform|Teleteaching of procedural skills include three different techniques through three different workshops. Each of the workshops was delivered by a respected expert faculty and then accompanied by skills assessment subsequently. Three different group of learners joined the workshops on knotting skills, suturing skills and laparoscopic hand-eye coordination skills respectively.
45960080|NCT05467930|Other|Survey|Survey completion by the participant to collect information about health and social experience
45960081|NCT05467930|Other|Medical History Review|Review of the participant's medical history at New York Presbyterian/Columbia University Irving Medical Center
45960082|NCT05467930|Other|Sample Collection|Collection of nasal and blood samples
45960083|NCT00182364|Drug|Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)|
45819314|NCT02665988|Device|Sham tDCS|Participants randomized to sham tDCS will undergo the same procedures as those in the real tDCS sample, including the same pre-treatment lidocaine 4% cream, localization of electrode placement, actual placement of electrodes, turning on the tDCS device in sham setting but will not receive actual stimulation during the 20 minutes of each session, as well as post-treatment vitamin E.
45819315|NCT03726164|Device|Remote Conditioning|A Blood pressure cuff will be placed on the arm and inflated to 200mm hg for 5 minutes, and then deflated for 5 minutes, a cycle repeated 3 times.
45819316|NCT03726164|Device|Sham protocol|An un-inflated blood pressure cuff will be placed on the arm for 20 minutes.
45960084|NCT00156806|Procedure|Aloe barbadensis topical application in a moisturizing cream vehicle.|
45960085|NCT00536653|Drug|Bicalutamide and Calcium/ Vitamin D supplementation|Bicalutamide 150mg once daily, Calcium and Vitamin D supplementation once daily
45960086|NCT00536653|Drug|LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation|3 monthly depot injection of LHRH agonist (Goserelin acetate 10.8mg) and Calcium/ Vitamin D supplementation daily
45960087|NCT00536653|Drug|LHRH agonists (Goserelin acetate)|3 monthly depot injection of LHRH agonists (Goserelin acetate 10.8mg)
45960088|NCT05467852|Drug|didroxyprogesterone|Didroxyprogesterone group: the first menstrual cycle after operation began on the 14th to 27th day of each menstrual cycle. Didroxyprogesterone 10mg bid was given orally. It was planned to use 6 menstrual cycles (if the patient was naturally pregnant during the medication, the drug could be stopped), and guide the patient to try pregnancy. The observation period was 12 menstrual cycles after operation. Control group: no drugs were used after operation, and the patients were guided to try pregnancy. The observation period was 12 menstrual cycles after operation. Subjects need to complete up to 6 follow-up visits, including the first month after operation, the first menstrual cycle d7-13 after operation, the fourth menstrual cycle d7-13 after operation, the seventh menstrual cycle d7-13 after operation, the 13th menstrual cycle d7-13 after operation and 1-2 months after termination of pregnancy
45960089|NCT00536692|Drug|mecamylamine|topical ocular drops
45664797|NCT02370121|Drug|Placebo|Capsules of 300 mg two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
45664798|NCT02370121|Drug|Gymnema Sylvestre|Capsules of 300 mg of calcined magnesium two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
45664799|NCT02161185|Drug|USL261|5 mg, intranasal dose for seizure cluster, may repeat as indicated by protocol
45960090|NCT05467813|Other|mirror therapy|The mirror therapy (MT) will be done with participants seated at a table. The affected upper-extremity (UE) will be placed behind the mirror and the unaffected UE in front of the mirror. Participants will be asked to do the same movements using both the unaffected and affected UE as possible. Each participant will practice two different MT protocols: unilateral mirror therapy (UMT) and bilateral mirror therapy (BMT). During UMT, the affected hand is static, while during BMT, the affected hand moves in an attempt to duplicate the unaffected hand as best as possible. The MT activities include gross motor movements, fine motor movements, and object manipulation.
45960091|NCT05467813|Other|augmented reality (AR)|The training program provides goal-directed exercises designed to be adjustable in order to match the patient's ability to minimize compensatory movements. To ensure safety, the investigators will place a handrail in front of the participant for support. The goal-directed exercise includes balance training (i.e., weight shifting, standing on one leg), activities of daily living training (i.e., reaching), and cognitive enhancement (i.e., memory training). By using the AR system, participants can observe the real performance of motions and interaction between the body and the virtual environment.
45664800|NCT02159469|Combination Product|Testosterone enanthate auto-injector|Dose Adjustment to 50 mg or 75 mg or 100 mg based upon Testosterone levels
45664801|NCT02123511|Drug|acetylcysteine|Oral rinse
45664802|NCT02123511|Other|placebo|Oral rinse
45819317|NCT03723980|Drug|Propolis|it is a natural product obtained from beehive. it has been evaluated for biocompatibility and toxicity; and it is found that it is extremely biocompatible material. In our study, propolis powder will be mixed with saline in a ratio of 1 : 1.5 (propolis powder(wt) / saline(vol)) to form paste; and inserted into the root canals. it will be inserted once and will remain in root canals for 4 days.
45664803|NCT02123511|Other|quality-of-life assessment|Ancillary studies
45960092|NCT05467813|Other|control therapy|The control intervention will include practice of upper limb activities, balance activities, activities of daily living, and cognitive enhancement tasks. The protocols of the conventional therapy will be formulated by using occupational therapy techniques, such as neurodevelopmental techniques and functional task training. The therapy will be adapted to the participants' levels of motor deficits and their prioritized goals. The protocol will include affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques to alleviate functional deficits. The therapist will work with the participant to select functionally relevant tasks, such as picking up items from a box, lifting soft drink bottles, hanging clothes, and so on.
45960093|NCT00156845|Procedure|AI-700 contrast-enhanced echocardiography|
45960094|NCT00189345|Biological|anti-EpCAM x anti-CD3 (removab)|
45960095|NCT05467774|Behavioral|Operant RF H-reflex conditioning|Operant down-conditioning of rectus femoris H-reflex
45960096|NCT05466058|Diagnostic Test|palpation - ultrasonography|Physical therapist will assess patients to detect site of pathology (A1, A2, A3, A4, A5, midpalm or wrist) then patients will be refereed to radiologist who will detect site of pathology by sonography
45960097|NCT00156884|Drug|strontium-89|
45960098|NCT00156884|Drug|cisplatin|
45960099|NCT05465590|Drug|MB1707|"MB1707 is a CXCR4 antagonist peptide-conjugated paclitaxel.~MB1707, paclitaxel (PTX) conjugated CXC chemokine receptor 4 (CXCR4) peptide antagonist, a peptide-drug conjugate (PDC), for the treatment of cancer. MB1707 is a potent CXCR4 antagonist which inhibits tumor growth and metastasis by blocking the stromal cell derived factor 1 (SDF-1, a.k.a. CXCL12)/CXCR4 signaling pathway. MB1707 contains a conjugated drug, paclitaxel. By specific binding to CXCR4 overexpressed by the tumor cells, MB1707 has a built-in targeted delivery mechanism."
45960100|NCT00182403|Drug|UFH 250 U/kg or LMWH 100 U/kg sc twice daily|
45664804|NCT02123511|Other|questionnaire administration|Ancillary studies
45664805|NCT04746573|Device|Natrox Topical Oxygen Therapy|Device delivering humidified oxygen directly to the wound bed
45819318|NCT03723980|Drug|Calcium Hydroxide|it is a synthetic antimicrobial intracanal medicament and gold standard to which other medicaments are being compared. approximately 150 mg of calcium hydroxide paste will be inserted in the root canal. it will be inserted only once and will remain in root canals for 4 days.
45819319|NCT02660528|Drug|Tocilizumab|Subcutaneous tocilizumab
45960101|NCT05464693|Diagnostic Test|ERCP biliary culture|"The sample of biliary aspirate will be assessed as follows.~Its macroscopic appearance will be analyzed: yellow, black, or purulent.~Biliary culture will be performed; if bacterial growth is observed, its identification will be carried out by means of MALDI-TOF MS mass spectrometry and antibiotic susceptibility tests will be carried out, using the automated VITEK system."
45960102|NCT05604040|Behavioral|Lifestyle Modifications|Home BP monitoring with self-monitoring of emotions, diet, physical activity, with shared medical appointment program for lifestyle changes and coping skills
45960103|NCT00156962|Drug|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
45819320|NCT02633540|Radiation|IMRT Radiation|Radiation to Larynx
45960104|NCT00156962|Drug|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
45960105|NCT00182442|Drug|Olanzapine & Quetiapine|
45960106|NCT05468983|Procedure|surgical ( implants placement)|4 implants were placed interforamen of the mandibular arch by using the surgical guide
45960107|NCT00536770|Drug|placebo + gemcitabine + erlotinib|
45664806|NCT04746339|Drug|Apixaban 2.5 MG|Apixaban 2.5mg twice daily for 30 days
45664807|NCT04746339|Drug|Placebo|placebo twice daily for 30 days
45664808|NCT02122887|Behavioral|Peace-Building Intervention Process|"The eight sessions include (1) presentation of the self to others members (2) getting familiar with the other culture (3) what is a conflict - how do conflicts come about, what are adaptive and non-adaptive modes of resolving conflict (4) getting to know the Other - preconceived notions about the other side (5) on dialogue- what is dialogue, can dialogue offer means for conflict resolution, what are the benefits of dialogue to inter-cultural and inter-racial conflicts, (6) empathy, generosity, and kindness (7) wrapping up - hopes for the future at the personal and community levels, practical suggestions (8) goodbye and summary - what have we learned ,gift giving, summary of process by group leaders."
45664809|NCT02182947|Device|Capsule endoscopy|Pediatric patients with indeterminate colitis (IC) or Crohn's disease (CD) who are scheduled to undergo routine small bowel screening or surveillance using MRE. Subjects will swallow a patency capsule (PC) to study bowel patency.Those patients, who pass an intact PC, usually within 40 hours, will ingest the wireless capsule endoscopy (WCE). The WCE will be performed within 1 week of completion of MRE.
45664810|NCT04755075|Drug|Surufatinib|Subjects to receive Surufatinib 250 mg on Day 1
45664811|NCT04755075|Drug|Surufatinib|Subjects to receive Surufatinib 250 mg on Day 1
45819321|NCT01240304|Drug|Gemcitabine|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
45960108|NCT00536770|Drug|Placebo + gemcitabine|
45960109|NCT00536770|Drug|calcitriol + gemcitabine|
45664812|NCT02370043|Drug|KQ-791|Capsules administered orally while fasting, in up to 3 periods
45960110|NCT00536770|Drug|calcitriol + gemcitabine + erlotinib|
45960111|NCT00157001|Procedure|Photopheresis Post Angioplasty|
45960112|NCT00182481|Procedure|Induced sputum cell counts|
45960113|NCT00182481|Drug|inhaled corticosteroids and other asthma drugs|
45960114|NCT05599438|Other|No intervention|No intervention
45960115|NCT04685512|Drug|tenofovir disoproxil and emtricitabine|Experimental drugs administration of 7-day short course TDF/FTC
45960116|NCT00157040|Drug|Antihemophilic factor, recombinant, manufactured protein-free|
45960117|NCT00189384|Drug|ceftriaxone, procaine penicillin and gentamicin, oral cotrimoxazole and gentamicin|
45664813|NCT02370043|Drug|KQ-791 (after meal)|Single dose of KQ-791 in capsules, after a meal, in 1 period
45664814|NCT02370043|Drug|Placebo|Capsules, administered orally, in 1 period
45664815|NCT02301403|Drug|Nicotine patch|8 weeks of nicotine patch
45664816|NCT02301403|Behavioral|in-person counseling and quitline counseling|a single brief, in-person counseling session plus a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), for counseling, including the QUITNOW app and the Website
45819322|NCT01240304|Radiation|Radiation therapy|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
45819323|NCT01240304|Procedure|pancreaticoduodenectomy|Surgery will be planned 28 days (+/- 3 days) after the last dose of chemotherapy. The liver and pancreas will be examined by palpation and inspection. In the absence of metastases, tumor mobilization and surgical resection will be performed with standard surgical technique.
45819324|NCT02614586|Drug|TAK-058|TAK-058 oral solution.
45819325|NCT02614586|Drug|Ondansetron|Ondansetron capsule.
45819326|NCT02614586|Drug|TAK-058 Placebo|TAK-058 placebo-matching, solution.
45819327|NCT02614586|Drug|Ondansetron Placebo|Ondansetron placebo-matching, capsule.
45819328|NCT01211756|Drug|Oxytocin|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
45819329|NCT01211756|Drug|Placebo|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
45819330|NCT03591458|Drug|Amitriptyline|Participants will receive a supply of Amitriptyline capsules for titration, intervention, and taper periods.
45819331|NCT03591458|Drug|Placebo|Participants will receive a supply of Placebo capsules, matching those of Amitriptyline, for the titration, intervention, and taper periods
45819332|NCT03565328|Dietary Supplement|Nicotinamide Riboside|Nicotinamide Riboside (NR) will be started at 500 mg daily (250 mg BID) be increased at two weekly intervals by 250 mg/dose (BID) (500 mg/day) to a final dose of 1000mg PO BID (2000 mg/day).
45819333|NCT03534362|Device|Nasopore|Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent applied to the post-operative outflow tract
45960118|NCT00536848|Dietary Supplement|Lactobacillus rhamnosus GR-1 + Lactobacillus reuteri RC-14|
45960119|NCT00536848|Dietary Supplement|Placebo|
45960120|NCT00536848|Drug|Metronidazole|
45960121|NCT05596318|Device|Digital CBT-I|The digital CBT-I program is called Sleepio (Big Health, Ltd). Digital CBT-I will be delivered by an animated therapist in six weekly sessions that are approximately 10-20 minutes each. Sessions can be accessed via website or app at a time that is convenient for the participant. Session content is based on standard, in-person CBT-I protocols, and includes sleep restriction, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene education. The program is interactive, automated, and tailored to participant progress. Additionally, participants will receive supplemental CBT-I content tailored for prenatal and postpartum insomnia.
45960122|NCT05596318|Device|Digital SHE|The digital SHE program was created by Big Health, Ltd and has a total of six sessions. The content for SHE includes education about sleep stages, sleep architecture, sleep cycles; education about importance of sleep for performance, mood, and health; recommendations for developing healthy sleep habits; recommendations for lifestyle factors that impact sleep; recommendations for creating a sleep-friendly bedroom.
45960123|NCT05595382|Behavioral|Emotional Appeal|Participants will be presented with a short vignette about a child undergoing cancer treatment and needing a bone marrow transplant in order to survive cancer.
45664817|NCT02301403|Drug|Preparation Nicotine Mini-Lozenges|Nicotine lozenge prior to attempting to quit smoking
45819334|NCT03534362|Device|Propel|Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement applied to the post-operative outflow tract.
45819335|NCT01206296|Drug|Intraperitoneal Gemcitabine|"Standard pancreatic resection followed by heated intraoperative intraperitoneal gemcitabine 1000 mg/m2~Adjuvant intraperitoneal gemcitabine treatments (days 1, 8 and 15 of each 4-week cycle) for 6 cycles"
45819336|NCT02593682|Drug|suvorexant|
45819337|NCT02593682|Drug|placebo|
45960124|NCT05595382|Behavioral|Rational Appeal|Participants will be presented with data regarding the importance of considering race/ethnicity when looking for a bone marrow transplant donor and the likelihood of finding a match based on the patient's racial/ethnic background.
45960125|NCT00157079|Biological|Immune Globulin Intravenous (Human), 10%|
45960126|NCT00189501|Drug|Sensipar®|
45960127|NCT05592691|Procedure|Fascial block|The end of the drug infusion will be considered the time zero (T0); subsequently blood samples (4ml) will be taken at pre-established time intervals (after 5, 15, 30, 60, 120 and 180 minutes). Blood samples will be collected in test tubes and centrifuged within 1 hour of collection; subsequently they will be stored at a low temperature and transported to the reference analysis laboratory.
45960128|NCT00157118|Drug|Protein C Concentrate (Human) Vapor Heated|
45960129|NCT00189579|Drug|Herceptin|
45960130|NCT00157235|Drug|Tiotropium bromide|
45664818|NCT02301403|Drug|Combination NRT (nicotine patch + nicotine mini-lozenges)|26 weeks of combination NRT as part of a quit smoking attempt
45960131|NCT04293328|Device|orthokeratology|Nightly wear of orthokeratology lenses to correct vision in the daytime
46079431|NCT05390931|Other|6 month follow-up|Follow-ups will be made 3 times in total, on the basis of pre-test, intermediate follow-up test (3 months), and post-test (6 months).
45664819|NCT02301403|Behavioral|Intensive In-Person Cessation Counseling|three 20-min In-person Cessation Counseling sessions
45819338|NCT02461550|Device|Irreversible Electroporation Ablation|
45819339|NCT01200602|Drug|megestrol acetate|Given orally in doses of either 10 mg/kg once a day or 5 mg/kg twice a day
45819340|NCT01200602|Other|clinical observation|No treatment is given.
45960132|NCT04293328|Device|Menicon Progent A+B|Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.
45960133|NCT04271215|Other|Chemotherapy protocol used|Chemotherapy protocol used in each participating hospital
45664820|NCT02301403|Behavioral|Extended Maintenance Counseling Calls|8 Maintenance-phase smoking cessation counseling sessions
45960134|NCT00182520|Drug|Topiramate|25 mg - 400 mg/day x 12 weeks
45960135|NCT00182520|Drug|placebo|25 - 400 mg/day x 12 weeks
45960136|NCT04269850|Biological|allogeneic fecal microbiota|Single dose of capsules with fecal transplant (capsules for adults - 400-815mg, for adolescents - 280-500mg, for children - 160-320mg) - 2 capsules/kg body weight, divided in two consecutive days Additional supportive therapy after FMT include omeprazole 40mg po, inulin 1gr x 4 times a day po, metoclopramide 40mg po.
45960137|NCT04269850|Drug|Ruxolitinib|Ruxolitinib starting dose 10 mg bid. In case of grade 4 hematological toxicity dose can be reduced by 25-75%.
45960138|NCT04269850|Drug|Methylprednisone|Methylprednisone starting dose 0.5 mg/kg bid IV or oral, with subsequent tapper by 0.1 mg/kg every 5 days.
45960139|NCT00157274|Drug|alemtuzumab|
46079432|NCT05390372|Other|human milk|For skin damage care of preterm newborns randomly assigned to the breast milk group, their own breast milk will be applied topically once every 60 minutes until complete healing. Skin damage in newborns will be evaluated by an independent nurse and specialist doctor for 60 minutes during the treatment, and the score will be given and recorded. A minimum decrease of 1 point in the skin condition assessment scale score will be considered to indicate 'improvement'. The decision that the skin integrity of the newborn is completely healed will be made by the neonatal doctor independent of the trial. Areas between 0-3 on the newborn skin condition assessment scale will be considered healed. Breastfeeding does not have any side effects in preterm newborns.
46079433|NCT05390372|Other|Routine care group|cream applied as part of hospital routine practice
45664821|NCT02301403|Behavioral|Automated Adherence Calls|11 brief, automated calls reminding them to use their medications properly
45819341|NCT01194908|Drug|Decitabine, LBH589, Tamoxifen|"Dose level -1; Decitabine (IV)(D1-5): 5mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level 0; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level +1; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 15mg/m2~Dose level +2; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +3; Decitabine (IV)(D1-5): 15mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +4; Decitabine (IV)(D1-5): 20mg/m2; LBH589 (IV)(D1,8): 20mg/m2"
45819342|NCT01184456|Dietary Supplement|GanedenBC30, GBI-30, PTA-6086|1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days.
45960140|NCT04257487|Drug|Sulodexide|2 soft capsules of Vessel® 250 LSU BID for 12 months
45960141|NCT04257487|Drug|Sulodexide and placebo|1 soft capsule of Vessel® 250 LSU and 1 soft capsule of placebo BID for 12 months
45960142|NCT04257487|Drug|Placebo|Sugar pill manufactured to mimic sulodexide 250 LSU
45960143|NCT04252066|Drug|migalastat|This is an observational study. Patients as described in Cohort 1 should have been exposed to at least 1 dose of migalastat during pregnancy and/or breastfeeding.
45960144|NCT00182559|Drug|Ciclosporin|Maintain ciclosporin in combination with/without mycophenolate mofetil and with/without steroids at target trough levels of 70-150ng/mL.
45960145|NCT00182559|Drug|Tacrolimus|Conversion from ciclosporin to tacrolimus at target trough levels of 5-8 ng/mL in combination with/without mycophenolate mofetil and with/without steroids.
45960146|NCT04247347|Behavioral|Biofeedback Training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and to continue to influence behavior."
45960147|NCT04247347|Other|Dementia Education|An educational program designed to teach family caregivers about the characteristics, types, causes, and risk factors of dementia, as well as teach about health promotion, the stages of dementia, behavior changes, communicating with a family member with dementia, and caring for oneself. The content to be presented within an audiovisual format using a tablet computer follows recommendations and guidelines developed through research and by the Alzheimer's Association and the National Institute on Aging.
45455217|NCT03936283|Behavioral|Intervention|The goal of the intervention is to help women increase their minutes of moderate-to-vigorous physical activity and to increase their knowledge of the IOM gestational weight gain guidelines. The lifestyle intervention will be delivered through telephone counseling sessions with a study dietician trained in motivational interviewing techniques, as well as through technology-based tools, automated text messages and core lifestyle intervention sessions.
45664822|NCT02301169|Behavioral|Heat pain stimuli A|
45664823|NCT02301169|Behavioral|Video A|
45664824|NCT02301169|Drug|Administration of T4P1001 capsules|This treatment is given as add on therapy to patients' regular analgesic
45664825|NCT02301169|Behavioral|Heat pain stimuli B|
45664826|NCT02301169|Behavioral|Video B|
45664827|NCT02301169|Drug|Administration of placebo capsules|This treatment is given as add on therapy to patients' regular analgesic
45819343|NCT01184456|Drug|Placebo|1 capsule per day for 90 days.
45819344|NCT01163084|Drug|Goserelin Acetate|Given SC
45664828|NCT02333383|Drug|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
45819345|NCT01163084|Other|Laboratory Biomarker Analysis|Correlative studies
45819346|NCT01163084|Drug|Leuprolide Acetate|Given IM
45819347|NCT01163084|Drug|Vismodegib|Given PO
45819348|NCT01162382|Device|Transcranial Magnetic Stimulation|Four 100-second trains and then one 65-second train, with 30-second inter-train intervals, at 1 Hz and 120% of the resting motor threshold will be applied over the right dorsolateral prefrontal cortex. Subsequently, twenty-five 30-second trains, with a 30-second inter-train interval, at 10 Hz and 120% of the resting motor threshold will be applied over the left dorsolateral prefrontal cortex.
45960148|NCT04247347|Behavioral|Resourcefulness Training|A cognitive-behavioral intervention presented within an audiovisual format using a tablet computer that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
45960149|NCT00157313|Behavioral|Integrated treatment, family involvement|
45960150|NCT00157313|Behavioral|Social skills training|
45960151|NCT04242121|Diagnostic Test|fluorescence flow cytometry|Countification of plasma cells by fluorescence flow cytometry (hematology analyzer XN-1000/20)
45960152|NCT00425568|Drug|AndroGel (Transdermal Testosterone Gel)|
45960153|NCT04232254|Behavioral|Animal-based Protein Foods|Participants will consume animal-based protein foods.
45960154|NCT04232254|Behavioral|Skewed Protein Distribution|Participants will consume 3 meals per day consisting of 10-, 30-, 60% of dietary protein for breakfast, lunch, and dinner, respectively.
45960155|NCT04232254|Behavioral|Plant-based Protein Foods|Participants will consume plant-based protein foods.
45455218|NCT01317290|Dietary Supplement|n-3 PUFA free olive oil|negative control
45960156|NCT04232254|Behavioral|Balanced Protein Distribution|Participants will consume 5 meals per day consisting of 20% of dietary protein per meal.
45960157|NCT04229797|Procedure|Mandibular distalization using extra-radicular miniscrews|Distalization of the Mandibular first molars using mandibular buccal shelf mini-screws in the presence of unerupted third molars
45819349|NCT01155518|Drug|testosterone|intramuscular every 2 weeks
45960158|NCT00534274|Other|3'-deoxy-3'-[18F]fluorothymidine|
45960159|NCT00157508|Drug|nitroaspirin|
45455219|NCT01317290|Dietary Supplement|linseed oil|
45819350|NCT01155518|Drug|clomiphene|thrice a week
45819351|NCT01155518|Drug|placebo|intramuscular saline injections every 2 weeks
45960160|NCT00189618|Drug|Aspirin|100mg p.o. OD
45960161|NCT00189618|Drug|Clopidogrel|75mg p.o. OD
45960162|NCT04177030|Behavioral|Isopesticide dietary scheme|"All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met."
45960163|NCT04177030|Behavioral|Isopesticide dietary scheme|"All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met."
45960164|NCT04175548|Other|Data extraction from medical files|Data extraction from medical files
45960165|NCT00406796|Drug|Ranibizumab|0.3mg and 0.5mg dose of Ranibizumab 0.05ml administered intravitreally
45960166|NCT00182598|Procedure|computer-based psychoeducational intervention|
45960167|NCT00182598|Procedure|community-based substance abuse counseling|
45455220|NCT04065568|Device|DISKO-tool|The training program will be based on the initial assessments of functioning and disability and the patients' performance of the test exercises. Type and number of exercises per session, level of difficulty and number of repetitions (including proportion of repetitions to the right and left side of the body) will be set. The set training program is thereafter introduced and evaluated during the first follow-up by video communication with the patients.
45455221|NCT01121341|Procedure|Vein harvesting|Endoscopic versus conventional vein harvesting
45819352|NCT01155518|Drug|placebo|oral
45819353|NCT03490916|Drug|Acetazolamide|Administration of Acetazolamide
45819354|NCT03490916|Drug|Placebo|Administration of Placebo
45819355|NCT03333746|Other|Laboratory Biomarker Analysis|Correlative studies
45960168|NCT00534391|Drug|neomycin sulfate, polymyxin B sulfate and gramicidin|to the effected eye 4 times a day
45960169|NCT00534391|Drug|Artificial tear|4 times daily
45960170|NCT00534508|Drug|Tacrolimus Ointment 0.1%|Twice daily, 14 days treatment
45960171|NCT00406835|Procedure|Whole-Brain Radiation Therapy, Stereotactic Radiosurgery|
45960172|NCT00534547|Procedure|Duodenal Exclusion|duodenal-jejunal bypass
45960173|NCT00182715|Biological|cetuximab|
45819356|NCT03333746|Drug|Lenalidomide|Given PO
45819357|NCT03333746|Biological|Nivolumab|Given IV
45819358|NCT03333746|Other|Pharmacological Study|Correlative studies
45819359|NCT01139996|Drug|Clonidine|An oral loading dose of Clonidine 0.3 mg and placement of Clonidine Transdermal system at a dose of 0.3-mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3mg after 12 hours
45819360|NCT01139996|Drug|Placebo|A placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final tablet
45819361|NCT02417870|Biological|aldesleukin|
45819362|NCT01131884|Drug|Fosamax|70mg of Bisphosphonate therapy (Fosamax) will be taken weekly for a year
45819363|NCT01131884|Drug|Placebo|Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.
45960174|NCT00182715|Drug|capecitabine|
45960175|NCT00182715|Drug|fluorouracil|
45960176|NCT00182715|Drug|leucovorin calcium|
45960177|NCT00182715|Drug|oxaliplatin|
45960178|NCT00534586|Drug|Propofol|TCI 0.5 mcg/ml 1.0 mcg/ml
45960179|NCT00534586|Drug|Remifentanil|continuous infusion 0.05 mcg/kg/min 0.15 mcg/kg/min
45960180|NCT00534586|Drug|S-Ketamine|continuous infusion 0.25 mg/kg/h 0.50 mg/kg/h
45960181|NCT00534586|Drug|Sevoflurane|via face mask 0.40 Vol% 0.80 Vol%
45960182|NCT00534625|Drug|zileuton|Single injection of zileuton 150 mg
45960183|NCT00534625|Drug|placebo|Single injection of placebo
45960184|NCT00534625|Drug|zileuton|Single injection of zileuton 300 mg
45960185|NCT00406874|Drug|omega 3 fats|1,000 mg daily
45960186|NCT00406874|Drug|folic acid|800 micrograms daily
46079434|NCT05386095|Procedure|0.25%Bupivacaine Axillary brachial plexus block|Axillary brachial plexus block will be induced with patient in supine position under GA with the linear probe ultrasound , the operating arm will be abducted by 70 , externally rotated, and the elbow will be flexed to ~90. Within the axillary crease the probe will be placed in sagittal position bounded by the pectoralis major antero-medially and the latissimus dorsi and teres major posteromedial. The median nerve lies between 9 and 12 o'clock position above the axillary artery and below the biceps muscle; (ii) the ulnar nerve located superficially between the axillary vein and artery (iii) the radial nerve lies above the conjoint tendon of the teres major and latissimus dorsi (iiii) The musculocutaneous nerve lies between biceps and coracobrachialis muscle .The block will be applied by 22 gag needles at cephalic side of the probe. A total volume of (0.5ml/kg) of 0.25% Bupivacaine plus 1 µg/kg dexmedetomidine will be used.this volume will be divided equally among the four nerves.
45455222|NCT05224154|Behavioral|Abstinent Contingent (AC) Re-Connect|Participants in this group will be able to unblock highly desired, but non-essential (e.g., social networking, shopping, games) applications contingent on meeting goals for smoking abstinence, as verified by meeting carbon monoxide goals (CO<=6ppm).
45455223|NCT05224154|Behavioral|Submission Contingent (SC) Re-Connect|Participants in this group will also be able to unblock their applications, but contingent on submitting CO samples and independent of meeting CO goals for smoking abstinence.
45455224|NCT01212913|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
45455225|NCT01212913|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
45664829|NCT02332915|Behavioral|Sound Production Treatment (SPT)|SPT is a behavioral treatment for acquired apraxia of speech. It involves verbal modeling of target words by the clinician, simultaneous productions, articulatory placement instructions, and repeated practice. Treatment is administered in the context of an hierarchy.
45455226|NCT01212913|Drug|Insulin aspart|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: twice daily
45455227|NCT05371366|Device|ASD closure with the novel occluder (ReAces)|Transcatheter closure atrial septal defect with the novel occluder (ReAces)
45455228|NCT05371366|Device|ASD closure with normal occluder|Transcatheter closure atrial septal defect with normal occluder
45819364|NCT01139294|Drug|Hylenex|1ml subcutaneous with initiation of intravenous fluids then every 24 hrs with a maximum dose of 3 injections in 72 hours
45819365|NCT05600582|Biological|CodaLytic|CodaLytic is a virotherapeutic product based on the wild-type influenza strain A/California/07/2009
45819366|NCT02402036|Drug|Regorafenib|Regorafenib orally for 21 days every 28 day cycle
45819367|NCT05600504|Other|no intervention|no intervention
45455229|NCT01345526|Device|Reconval K1 Cream|
45455230|NCT01345526|Device|Reconval Cream|
45664830|NCT02369341|Biological|Fluarix Tetra|One dose of the Fluarix™ Tetra vaccine was administered to all subjects on Day 0 (Visit 1) intramuscularly into the deltoid of the non-dominant arm.
45664831|NCT02121795|Drug|FTC/TDF|200/300 mg FDC tablets administered orally once daily
45664832|NCT02121795|Drug|F/TAF|Tablets administered orally once daily
45819368|NCT02389712|Drug|Lamotrigine|Lamotrigine dosing: 25 mg daily x 2 weeks, 50 mg daily x 2 weeks, 100 mg daily x 2 weeks, 200 mg (100 mg bid)) x 4 weeks. If patient still has at least mild depressive symptoms, the dose can be increased to 300 mg daily for 2 weeks and 400 mg for 4 weeks. Dose will be held for treatment response and can be reduced for side effects.
45960187|NCT04134208|Procedure|Computed Tomography|Undergo PET-CT scan
45960188|NCT04134208|Drug|Fluciclovine F18|Given IV
45960189|NCT04134208|Procedure|Positron Emission Tomography|Undergo PET-CT scan
45960190|NCT04110769|Diagnostic Test|next generation sequencing|the investigator will compare genetic mutation between responder and non-responder using next generation sequencing examination.
45960191|NCT04110769|Diagnostic Test|following next generation sequencing|The patient will be examined next generation sequencing before changing palliative chemotherapy for non-responders.
45960192|NCT04106830|Drug|Intravenous steroid|This study does not limit treatment methods.patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. The HD-S treatment course referred to intravenous administration of 1 g of glucocorticoid daily for 3 consecutive days and continuous dose 240 mg reduction for 60mg oral administration. Immunomodulatory therapies are necessary for the remission stage. The treatment methods include: Azathioprine (start at 50 mg per day, add 50 mg per week to 2 mg/kg.d); Mycophenolate Mofetil (The initial dose was 0.25g bid, add 0.5g per week to 0.75g bid); and Rituximab (500 mg on the 1st day, the 15th day, then 500mg per half year).
45960193|NCT00189657|Procedure|5FU/LV Mayo Clinic or LV5FU2|
45960194|NCT00189657|Procedure|LV5FU2 + irinotecan|
45960195|NCT00406913|Drug|mupirocin ointment|
45960196|NCT00406913|Other|SOC sterilization|
45960197|NCT00406952|Procedure|electronic diary|
45960198|NCT00406952|Drug|Sertraline|
45960199|NCT00406952|Drug|Placebo|
45960200|NCT00406952|Procedure|voice acoustics|
45960201|NCT04722900|Other|intrauterine exposure to elevated glucose levels|intrauterine exposure to elevated glucose levels
45960202|NCT04090879|Other|Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)|1) Altering the nicotine content of the tobacco research cigarette
45960203|NCT04090879|Other|E-Cigarettes|1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
45458496|NCT04461652|Procedure|prophylactic air-extraction catheter drainage|This is a kind of venous catheter commonly used in clinic. It may bring less pain after being inserted into the chest, with an equivalent drainage effect with traditional thick drainage tube from our experience, especially in the aspect of gas drainage effect.
45960204|NCT04076800|Procedure|Acupuncture|Acupuncture treatment will include use of somatic points (SP6; ST36; KI3; CV4; CV12; TE5; LI4; LI11; YinTang; ST28; BL23; BL22; BL20; BL13) and auricular points (most tender point on palpation with pressure feelers of 400 gr on Stomach, Endocrine, Spleen, Kidney, Hungry, Shen man and Pancreas auricular points).
45960205|NCT04071340|Device|non-contrast MSCT|non-contrast multi-slice computed tomography
45664833|NCT02121795|Drug|Allowed third antiretroviral agent|An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).
45664834|NCT02121795|Drug|FTC/TDF Placebo|Tablets administered orally once daily
45664835|NCT02121795|Drug|F/TAF Placebo|Tablets administered orally once daily
45664836|NCT02158533|Drug|High Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
45960206|NCT04071340|Device|Abdominal ultrasonography|Abdominal ultrasonography
45664837|NCT02158533|Drug|Low Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
45664838|NCT02158533|Drug|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
45664839|NCT02120781|Biological|Azficel-T (autologous fibroblasts)|"Autologous fibroblasts will be cultured from three 3-mm post auricular punch biopsies. Biopsies will be shipped from the clinical sites to the Fibrocell manufacturing site where the cells will be harvested, tested for sterility, endotoxin level, cell identity, viability and concentration. When the desired cell number is reached, cells will be transported to the investigative site as a suspension in shipping media.~Depending upon the clinical circumstances for each subject, the vocal fold(s) will be injected transorally or percutaneously in order to deposit 1.0 mL of study drug into the lamina propria layer of each vocal fold. The injection process will be visualized via a flexible fiberoptic laryngoscope inserted through the nostril."
45664840|NCT02120781|Drug|Placebo|Subjects randomized to placebo will receive injections of sterile saline into the vocal fold(s).
45819369|NCT02389712|Drug|Fluoxetine|Fluoxetine dosing: 20mg for month 1, 40mg for month 2, and if still depressed (CGI ≥ 3) 60mg for month 3 and 4. Lower doses of fluoxetine will be prescribed for those with side effects. For known Cytochrome P450 2D6 poor metabolizers, fluoxetine will not be dosed > 40mg.
45819370|NCT00378950|Behavioral|Teach to Goal (TTG)|The TTG program includes the Brief Educational Intervention (BEI) educational intervention, as well as education about diuretic self adjustment. In addition, follow-up phone calls are given to the TTG group to further reinforce the initial training and provide further training so participants will master the task.
45819371|NCT00378950|Behavioral|Brief Educational Intervention (BEI)|The BEI is a one hour educational session on CHF, symptom recognition, diet, exercise, and daily checkups.
45819372|NCT03530917|Drug|RO7020531|4 SAD Cohorts with individual dosages of 40, 100, 140 and 170 mg hard capsules and 3 MAD Cohorts with dosages of 100 and 150mg hard capsules, will be administered orally as per the dosing schedules described above.
45819373|NCT03530917|Drug|Placebo|Placebo hard capsules will be administered orally as per the dosing schedules described above.
45819374|NCT02365688|Procedure|Initial bolus pre-incision|Measured hemodynamic response to pre-incision bolus
45819375|NCT05600348|Dietary Supplement|Pork Consumption|Feeding of pork is controlled at 0, 3 or 6 oz per day for 4 weeks each in random order.
45819376|NCT02369744|Drug|Silodosin|8mg tablet, 1 tab PO daily for 2 weeks
45819377|NCT02369744|Drug|Tamsulosin|0.4 mg Tab, 1 tab PO daily for 2 weeks
45819378|NCT03577171|Drug|ABI-H0731|Participants will receive 300mg QD of ABI-H0731 tablets orally.
45819379|NCT03577171|Drug|SOC ETV|Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.
45819380|NCT03577171|Drug|Placebo Oral Tablet|Participants will receive matching QD placebo tablets orally.
45819381|NCT02367170|Procedure|Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure|Pressure changes are recorded. The phrenic nerves are stimulated with bilateral magnetic stimulators over the neck. Measurements will be performed on day 1, every 7 days after and on last day of participation. The FiO2 will be increased (at least 20%) for at least 2 min. prior to measurement to maintain oxygen saturation >92%. Prior to activating the stimulator, the artificial airway will be occluded with a pneumatic valve to create a quasi-isometric diaphragm contraction. The airway will be occluded for 3 seconds or less for each stimulation. The procedure will be repeated up to a maximum of 5 times per testing day.
45819382|NCT02367170|Drug|Midazolam|In the event a subject shows signs of distress during the Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressures, a dose of Midazolam is available. IV (in the vein) dose from 0.5 mg to 2 mg.
45960207|NCT04071340|Diagnostic Test|Urine analysis|Urine analysis
45960208|NCT04071340|Diagnostic Test|Urine culture|Urine culture
45960209|NCT04062526|Drug|[18F]NOS|[18F]NOS is an investigational radiotracer which each subject will have one [18F]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
45960210|NCT00189696|Drug|YM060|
45960211|NCT00157547|Drug|Selective serotonin reuptake inhibitors (SSRI)|Selective serotonin reuptake inhibitors (SSRI)
45960212|NCT00534664|Device|TheraBionic device|Daily outpatient treatment with theraBionic device
45664841|NCT02120625|Device|Lumbar MB RFN|Patients will be placed in a prone position and prepped. The C-arm will be adjusted to establish a true anteroposterior image of the target vertebra. The C-arm will then be rotated until the target point at the base of the SAP is clearly visualized. The Nimbus probe, with the tines (filaments) in the retracted position, will be inserted and advanced to the bony target site using a down the beam approach. The probe hub will be rotated to accomplish a full deployment of the tines with a medial or lateral angular bias, as dictated by the SAP anatomy and angle of entry of the NMEE probe. Motor stimulation at 2 Hz up to 2 volts will be administered (safety check). The lesion site will be anesthetized before the radiofrequency (RF) generator is set to achieve a temperature of 80°C for 80 seconds, following 30 second temperature ramp up. Impedance and power will be recorded.
45960213|NCT04061161|Drug|Tiotropium Bromide|Participants will be double-blind randomized for Tiotropium or Placebo treatment for 6 weeks
46079435|NCT05386095|Procedure|0.19% Bupivacaine Axillary brachial plexus block|Axillary brachial plexus block will be induced with patient in supine position under GA with linear probe ultrasound , the operating arm will be abducted by 70 , externally rotated, and the elbow will be flexed to ~90. Within the axillary crease the probe will be placed in sagittal position bounded by the pectoralis major antero-medially and the latissimus dorsi and teres major posteromedial. The median nerve lies between 9 and 12 o'clock position above the axillary artery and below the biceps muscle; (ii) the ulnar nerve located superficially between the axillary vein and artery (iii) the radial nerve lies above the conjoint tendon of the teres major and latissimus dorsi (iiii) The musculocutaneous nerve lies between biceps and coracobrachialis muscle.The block will be applied by 22 gag needles at cephalic side of the probe. A total volume of (0.5ml/kg) of 0.19% Bupivacaine plus 1 µg/kg dexmedetomidine will be used.this volume will be divided equally among the four nerves.
45960214|NCT04049149|Other|Biogenetic explanation and endocrinologist intensive managment|"JADE report and JADE APP~Biogenetic explanation~First-year intensive management by endocrinologists~Follow up by their usual care doctors for continue treatment regimen maintenance.~Yearly DM nurses follow up for blood taking and questionnaires"
45960215|NCT04049149|Other|Usual care management|"JADE report and JADE APP~Attend their usual care clinic for ongoing treatment~Yearly DM nurses follow up for blood taking and questionnaires"
46079436|NCT05375838|Biological|mRNA-1073|Sterile liquid for injection
46079437|NCT05375838|Biological|mRNA-1010|Sterile liquid for injection
46079438|NCT05375838|Biological|mRNA-1273|Sterile liquid for injection
46079439|NCT05375838|Biological|Placebo|0.9% sodium chloride (normal saline) injection
45960216|NCT00189735|Drug|FK778|
45960217|NCT00157586|Drug|Delapril, Delapril-Manidipine Fixed combination|
46079440|NCT05372666|Other|Standard white bread|Bread to be consumed within 10 minutes after 10h fasting
46079441|NCT05372666|Other|Experimental white bread|Bread to be consumed within 10 minutes after 10h fasting
46079442|NCT05372666|Other|Standard High-fiber bread|Bread to be consumed within 10 minutes after 10h fasting
45455231|NCT01218061|Other|Pre-diabetes screening|The timing of the study is :- Screening of high metabolic risk patients based on a clinical score : Finnish Diabetes Risk Score ≥ 15- if Diabetes Risk Score ≥ 15 or if history of blood glucose between 1.10 and 1.26 g/l (impaired fasting glucose): measuring fasting glycaemia + HbA1C + lipids profile + creatinemia + liver enzymes- if fasting blood glucose between 1.10 and 1.26 g/l (=V0):* OGTT (oral glucose tolerance test) to identify subjects with impaired glucose tolerance (optional)* establishment of a serum bank to identify biomarkers (serum, genomic, proteomic) - to plan for 10 years annual follow-up (V1 to V10) with blood sample (fasting glycemia + HbA1C + lipids profile + creatinemia + liver enzymes + serum bank (not after V5)) Making a total of 11 visits (V0-V10) with 6 blood samples.
45455232|NCT04100798|Procedure|Entire Papilla Preservation technique|A minimally invasive technique that allow access to the intrabony defect without affecting the interdental papilla related to it
45664842|NCT02120469|Drug|everolimus|Given PO
45664843|NCT02120469|Drug|eribulin mesylate|Given IV
45664844|NCT02120469|Other|pharmacological study|Correlative studies
45664845|NCT02120469|Other|laboratory biomarker analysis|Optional correlative studies
46079443|NCT05372666|Other|Experimental High-fiber bread|Bread to be consumed within 10 minutes after 10h fasting
45960218|NCT04008940|Device|Distal femur plates|By assessing the rate and mode of mechanical failures we aim to identify risk factors for mechanical failures among the analysed plate types. This, finally, is depending on the overall number of cases and number of failure cases.
46079444|NCT05360264|Drug|Decitabine 50 MG [Dacogen]|DACOGEN will be administered i.v. over 1 hour, at the dose of 10 mg/m2/d, daily on days 1-5 and 8-12 of each 4-wk cycle.
46079445|NCT05359094|Dietary Supplement|Placebo|Placebo (Microcrystalline α-cellulose) supplement with a Plant-Dominant Low-Protein Diet
46079446|NCT05359094|Dietary Supplement|Probiotics|Probiotics(Pediococcus acidilactici GKA4) supplement with a Plant-Dominant Low-Protein Diet
46079447|NCT05357482|Radiation|TBI|300 cGy total body irradiation (TBI, day -2)
46079448|NCT05357482|Drug|Hydroxyurea|Optimized 4-12 weeks prior to planned transplant date
46079449|NCT05357482|Biological|JSP191|JSP191, anti-CD117 monoclonal antibody at 0.6mg/kg at day -11 prior to infusion of allogeneic HSCs
45960219|NCT03966586|Behavioral|Active outreach|Participants will get bidirectional weekly SMS messaging / automated voice messaging (depending on literacy), with messages to be programmed by the participant in the enhanced counseling sessions.
45664846|NCT04758507|Biological|donor FMT|This intervention is represented by the administration, in the recipients' gut, of donor microbiota through FMT
45960220|NCT03966586|Behavioral|Appointments|Participants in the enhanced-care intervention will be given specific appointment times/dates.
45960221|NCT03966586|Behavioral|Financial support|Participants in the enhanced-care intervention will receive free clinic visits, labs, and medications. They will also receive transportation incentives on a sliding scale based on distance to clinic, to range between 200-700 INR to be given each clinic/study visit. All participants, in both the usual care and enhanced care arms, will be offered VL testing free of charge, although this will not be known to the participants prior to the visit.
45819383|NCT02367170|Procedure|Volitional Measurement of Maximal Inspiratory Pressure (MIP)|MIP is tested on all subjects on day 1, every 7 days after and on the last day of participation. To measure MIP, a subject will be suctioned, disconnected from the ventilator, and instructed to take a few spontaneous breaths. A 1-way exhalation valve connected to a NICO respiratory monitor will be placed on the ET/tracheotomy tube. The subject will be instructed to inhale and exhale as forcefully as possible for 20 seconds, followed by at least 2 minutes of rest on full mechanical ventilation support. MIP trials will be repeated 3 times, and the greatest negative pressure recorded with a NICO respiratory monitor connected to a laptop computer, which will digitize airway pressure, flow and volume signals at 100Hz. This allows for analysis of the individual pressure waves, facilitating pre-post comparisons of MIP at specific time points during inspiration.
45960222|NCT03966586|Behavioral|Microenterprise|YRG CARE is affiliated with two microenterprise programs in bag-making and food-vending which can be leveraged as part of an intervention, particularly for women. There is an established training and mentoring program for individuals who wish to join the bag-making or food-making ventures. Participants who opt for this will be linked to the bag-making and food-vending programs, with all up-front costs (e.g. vending kiosk, training, serving materials, etc.) covered.
45960223|NCT03966586|Behavioral|Enhanced counseling|Participants in the enhanced-care intervention will participant in an individual enhanced counseling program called Steps to Success, based upon a Life Steps and Problem Solving curriculum. Steps to Success will consist of five one-on-one sessions of approximately 1 to 1.5 hours each. The first session will take place at the time of the participant's second clinical visit to YRG CARE, which will be between 1-3 weeks after the participant is recruited.
45960224|NCT03966586|Behavioral|Usual clinical care and counseling|Usual clinical care and counseling
45960225|NCT00157625|Behavioral|Automatic stop order|
45960226|NCT03962335|Behavioral|Vegetarian diet|7-days dietary profile with a Vegetarian diet (VD), containing inulin and resistant starch-rich foods and including no meat and fish, but containing eggs and dairy, for 3 months
45960227|NCT03962335|Behavioral|Mediterranean diet with butyrate|7-days dietary profile with Mediterranean diet with oral supplementation with butyrate (MD+Bt), 2 g/day, for 3 months
45960228|NCT03962335|Behavioral|Mediterranean diet|7-days dietary profile with Mediterranean diet (MD), including 2 portions per week of fish and 3 portions per week of fresh and processed meat (2 of which fresh or processed red meat), for 3 months
45960229|NCT00182832|Behavioral|e-CHAMP (Enhancing Care for Hospitalized Older Adults with Cognitive Impairment)|Cognitive screening plus Computerized Decision Support System: proactive screening program for cognitive impairment combined with computerized review of the electronic medical record
45960230|NCT00182832|Behavioral|Standard Care|Standard care for hospitalized older patients with cognitive impairment
45960231|NCT03943654|Other|MotoMeds Healthline- illness assessment and treatment recommendation for non-emergent cases by telephone|The healthline uses a series of questions (based off of the WHO Integrated Management of Childhood Illness guidelines) asked to the parent of a sick child over the phone to remotely triage and assess the child's illness and then provide a treatment recommendation. MotoMeds is the accompanying motorcycle delivery service for basic medication delivery at nighttime.
45960232|NCT04724993|Other|Online Aerobic Dance Exercises|Online aerobic dance exercises will be performed with observance of physiotherapist. They will record their daily physical activity.
45960233|NCT04724993|Other|Physical Activity Counseling|Physical activity and exercise will ve explained to the participants.And they will record their daily physical activity.
46079450|NCT05357482|Drug|Filgrastim (G-CSF)|May be used to minimize the days of neutropenia, and may be administered beginning near day 10 post stem cell infusion at 5 mcg/kg (rounding to the nearest vial) at the discretion of investigator.
45664847|NCT04758507|Other|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
45960234|NCT03920800|Other|Data extraction from medical files|Data extraction from medical files
45960235|NCT03920800|Biological|Immunohistochemistry|Immunohistochemistry with Ki67 and p16 antibodies on residual samples, if this had not been foreseen in the standard of care management of the patient.
45960236|NCT00182871|Drug|testosterone|
45960237|NCT03865264|Other|Recovery Enhancement Program|Behavioral, nutritional, physical and opioid-reduction pain medication
45960238|NCT03818620|Device|Barco digital dermatoscope device images|Images of skin lesion taken with the Barco dermatoscope by site team member
45960239|NCT03818620|Device|Reference standard dermatoscope device images|Images of skin lesion taken with a standard dermatoscope device (as part of standard care)
45960240|NCT00189774|Drug|nateglinide|
45960241|NCT00157703|Drug|G207|1 x 10E9 plaque forming units, administered by stereotactic injections into the tumor (single administration)
45664848|NCT02157519|Other|Mobile Application Intervention|Participants assigned to the intervention group will receive the mobile application intervention for approximately three months after enrollment. The mobile app intervention will consist of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app will also be transmitted in real-time to the participants' oncology clinicians via a HIPAA-compliant, secure email.
45664849|NCT04754217|Device|VAVGJ|Replacement of the aortic valve and ascending aorta
45960242|NCT04686643|Drug|AGSAVI|S-amlodipine, Valsartan, Indapamide
45960243|NCT04686643|Drug|AGLS|S-amlodipine, Valsartan
45960244|NCT00534781|Device|plasma microdebrider|Coblation of the Achilles
45664850|NCT04754217|Device|CAVGJ|Replacement of the aortic valve and ascending aorta
45664851|NCT02180061|Biological|Pembrolizumab|IV infusion
45664852|NCT02179515|Biological|MVA-brachyury- TRICOM|It is an active cancer immunotherapy administered via subcutaneous injection.
45664853|NCT02120157|Drug|Cyclophosphamide|Chemotherapy administration
45819384|NCT02367170|Device|Inspiratory Muscle Strength Training (IMST)|"Occurs 5 days/wk using threshold IMST device-Respironics model 735. Prior to training, cuff pressure is assessed, FiO2 increased for 2 min. to keep O2 sats ≥92%. The ventilator circuit is disconnected, IMST device is attached to endotracheal or tracheotomy tube and subject is instructed to exhale then forcefully inhale for 10 breaths. The initial setting of device is set to -5cmH2O, subject must generate a negative inspiratory pressure more negative than -5cmH2O to open spring-loaded valve and receive inspiratory airflow. Pressure setting is made more negative/difficult to open by 2-5cm every few breaths until a setting is found where the patient has difficulty fully opening valve, resulting in valve flutter noise. Training pressure is then made more positive /easier by 2-4cm of H2O, so subject can fully open valve, and 4 sets of 6-10 breaths are completed. Training pressures advanced as rapidly as possible, provided the patient is able to open the valve withoutvalve flutternoise."
45960245|NCT00534781|Procedure|Mechanical Surgical Debridement|Surgical Debridement of the Achilles
45960246|NCT00534820|Procedure|Cytogenetic Analysis of Bone Marrow Specimen|Cytogenetic Analysis of BM Specimen
45960247|NCT00157742|Procedure|Spinal Cord Stimulation (SCS)|
45960248|NCT00157742|Procedure|Percutaneous Myocardial Laser Revascularisation (PMR)|
45960249|NCT00534859|Device|High Risk PCI|High Risk Percutaneous Coronary Intervention
46079451|NCT05357482|Drug|Sirolimus|For immune suppression (day -1)
45664854|NCT02120157|Radiation|TBI|Radiation Therapy
45664855|NCT02120157|Drug|Busulfan|Chemotherapy Administered
45664856|NCT02120157|Other|Unmanipulated Bone Marrow|Bone Marrow Transplant
45960250|NCT00534898|Drug|Bexarotene|
46079452|NCT05357482|Biological|Alemtuzumab|Alemtuzumab 1 mg/kg of alemtuzumab divided over 5 days (-7 through -3),
46079453|NCT05357482|Drug|Plerixafor|For autologous HSC collection; dose of plerixafor at 240 mcg/kg (capped at 20mg)
45960251|NCT00534898|Drug|Fenretinide|
45664857|NCT02120157|Drug|Tacrolimus|Immunosuppressive Drug Administered
45664858|NCT02120157|Drug|Mycophenolate mofetil|Immunosuppressive Drug Administered
45664859|NCT02119299|Device|SMART device|Sensor Monitored Alimentary Restriction Therapy (SMART) device
45664860|NCT04753827|Other|Drug eluting stent|Put a Drug eluting stent in the blood vessel
45664861|NCT04753827|Other|Durg coated balloon|Put a Durg coated balloon in the blood vessel
45664862|NCT02156271|Drug|ramelteon|
45664863|NCT02156271|Drug|placebo|
45664864|NCT01365455|Drug|secukinumab 150 mg|secukinumab (AIN457) 150mg or 300mg subcutaneous
45664865|NCT01365455|Drug|placebo to secukinumab 150 mg|Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous
45664866|NCT02155881|Drug|Ciclesonide|Ciclesonide nasal spray 50 mcg/actuation
45664867|NCT02155881|Drug|Ciclesonide Placebo|Ciclesonide placebo-matching nasal spray
45664868|NCT05279807|Drug|Zofenopril|Film-Coated tablets administered orally once daily according instructions provided by Principal Investigator.
45664869|NCT05279807|Drug|Amlodipine|Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
45664870|NCT05279495|Device|In a double-blinded fashion, 250 mg CANNAXR cream|Determining the Efficacy of topically applied CANNAXR cream in Decreasing UVA Premutagenic and Photoaging markers 8-oxo-dG and the common deletion. 250 mg TOPICAL CBD CANNAXR Cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks
45664871|NCT05279495|Device|Topical VEHICLE cream|Determining the Efficacy of topically applied VEHICLE cream in Decreasing UVA Premutagenic and Photoaging markers 8-oxo-dG and the common deletion. 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks
45664872|NCT05277935|Device|Use of the WeCancer app combined with the smartwatch.|To evaluate if a fitness tracker added to eHealth technology will improve quality of life compared to the use of eHealth technology alone in metastasis breast cancer patients treated with palbociclib and endocrine therapy
45960252|NCT00534898|Drug|Placebo|
45960253|NCT00189813|Drug|YM060|
45960254|NCT00157781|Device|Medtronic AT500|
45960255|NCT03770572|Genetic|AT-GTX-502|Subjects with diagnosis of CLN3 Batten disease will receive a single dose of AT-GTX-502 at low dose or high dose.
46079454|NCT05356923|Radiation|68Gallium FAPI PET/MR scan|68Gallium FAPI PET/MR scan
45819385|NCT02367170|Device|SHAM Inspiratory Muscle Strength Training (IMST)|Training will also be conducted 5 days/wk with an identical IMST device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM IMST device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout. The ventilator will be disconnected and a SHAM device will be attached to the endotracheal or tracheostomy tube. The subject will be instructed to take 6-10 breaths with a normal tidal volume through the SHAM device and will be reconnected to the ventilator for a 2-minute rest period. The process will be repeated 3 more times for a total of 4 sets of 6-10 breaths.
45664873|NCT05319431|Biological|AK104|Subjects will receive AK104 until disease progression or for a maximum of 24 months
45664874|NCT05319431|Drug|Lenvatinib|Subjects will receive lenvatinib until disease progression or for a maximum of 24 months
45664875|NCT05319431|Procedure|TACE|On demand TACE
45664876|NCT05276531|Drug|subcutaneous progesterone|clinical pregnancy rates
45664877|NCT05276531|Drug|vaginal progesterone|clinical pregnancy rates
45664878|NCT05352581|Diagnostic Test|BD Veritor At-Home|BD Veritor At-Home rapid self testing
45819386|NCT02367170|Procedure|Diaphragm thickness measurement|Ultrasound will be used to obtain measurements of the thickness of the right hemidiaphragm. Ultrasonography of the diaphragm will be performed upon enrollment, every 2-4 days during hospitalization and as long as the patient is hospitalized or up to 28 days of participation.
45819387|NCT02367170|Other|Blood and Urine samples|Peripheral blood and urine samples will be collected once upon study entry day (+/- 2 days), once every 2-4 days and once on final day of study participation (+/- 2days).
45819388|NCT01104116|Radiation|[18F]-FDG PET/CT imaging|Drug: F-18 Fluoro-2-Deoxyglucose (F-18 FDG)
45819389|NCT03579433|Device|ORA with VerifEye+|Intraoperative device that measures total corneal astigmatism in the aphakic condition and is used for the selection of IOL power. In the pseudophakic condition, ORA provides guidance for the alignment of the toric axis mark.
45819390|NCT03579433|Other|Alcon Barrett Toric Calculator|Web-based software application that utilizes an algorithm (Barrett Formula) to estimate the amount of post-operative corneal astigmatism in order to optimize IOL model selection and axis placement, with interoperative axis alignment done manually.
45819391|NCT03579433|Device|Acrysof® IQ Toric IOL|Intraocular lens implanted as a replacement for the cataractous lens during cataract surgery (Model SN6AT3, SN6AT4, Model SN6AT5, Model SN6AT6)
45819392|NCT03534427|Other|Jump rope exercise intervention|12-week jump rope exercise program
45819393|NCT02340728|Device|ERCP with SEMS plus radiofrequency ablation|
45819394|NCT02340728|Device|ERCP with SEMS alone (standard of care)|
45819395|NCT00376909|Other|educational intervention|
45819396|NCT00376909|Other|study of socioeconomic and demographic variables|
45819397|NCT01078844|Drug|memantine|memantine 5-20 mg daily
45819398|NCT01078844|Drug|Placebo|Look-alike placebo
45819399|NCT00376051|Drug|Citalopram|Titrates from 10mg/day to 40mg/day, increases 10mg per week.
46079455|NCT05355532|Genetic|different variants of SNPs that may be associated with the coronary microvascular obstruction development|Some variants of SNPs determine endothelial function, microcirculation, hemostasis, and inflammation in MI patients. They may be associated with the development of coronary microvascular obstruction during emergency PCI. A link between the different SNPs and the CMVO development will be established. SNP will be determined by real-time polymerase chain reaction with high-resolution melting curve analysis using TaqMan fluorescent probes.
45664879|NCT05352581|Diagnostic Test|BD Veritor Professional|BD Veritor Professional rapid test
45664880|NCT05318651|Device|Kwit SAS - smoking cessation app|Kwit is a mobile app for smoking cessation. Different CBT techniques are used by the app already been proved as effective : Case analysis craving tool, Achievements badges,Diary, Goal (outcome) setting, A 9-steps preparation program, psychological education, Emotional monitoring, Access to groups on social networks, different strategies ( NRT/water/meditation), Motivational cards.
45664881|NCT01658579|Drug|HOE901-U300 (new formulation of insulin glargine)|
45664882|NCT01658579|Drug|Lantus (insulin glargine)|
45664883|NCT05317481|Behavioral|BE-SMART-DR|a modification of Social Rhythm Therapy (SRT) that provides self-directed strategies to regularize sleep and other DRs to reduce short-term suicide risk that can be used lifelong to potentially also reduce long-term suicide risk
45819400|NCT01072526|Drug|Euphrasia-based homeopathic therapy|ophthalmic solution; 1 drop both eyes twice daily
45819401|NCT01072526|Drug|Cyclosporin solution|Cyclosporin solution; 1 drop both eyes twice daily
45819402|NCT03536923|Device|Leva Incontinence System For Pelvic Floor Muscle strengthening|The leva device is placed vaginally for 2.5 minutes twice daily, and pelvic floor muscle exercises are performed based on guidance from data sent from the device to their mobile phone.
45664884|NCT05317481|Behavioral|psychoeducational control comparator condition (CC)|Structured sessions, matched for BE-SMART-DR session number and therapist time, that will emphasize strategies to manage the stress of a mental disorder and stigma, and health and wellness, offering tips on well-established self-help strategies such as a healthy diet, regular moderate exercise and seeking social support when distressed.
45664885|NCT05561309|Drug|HR18034;Ropivacaine Hydrochloride Injection|"Drug: HR18034~Drug: Ropivacaine Hydrochloride Injection~Local nerve block of Ropivacaine Hydrochloride Injection to produce anesthesia for surgery and analgesia in postoperative pain management.~Other Name: Ropivacaine Hydrochloride Injection, 0.5% Injectable Solution"
45819403|NCT05312840|Drug|Cisplatin / Carboplatin，Gemcitabine，Cindilimab|1. Routine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2 / Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Cindilimab 200mg were injected intravenously on the eighth day; 2. Low dose group: every three weeks as a cycle. On the first day of each cycle, Gemcitabine 750mg / m2, Cisplatin 56mg / m2 / Carboplatin auc3 were injected intravenously 75. On the eighth day, Gemcitabine 750mg / m2 and Cindilimab 200mg were injected intravenously.
45819404|NCT00376129|Drug|Alefacept|15 mg i.m. once weekly for 12 weeks
45819405|NCT02307188|Device|Constellation Full Contact Mapping Catheter|64-electrode intracardiac mapping catheter.
45819406|NCT01035944|Device|HemCon Dressings and HemCon ChitoGauze; chitosan-based.|Perform debridement of chronic wounds using HemCon chitosan-based dressings and HemCon ChitoGauze both at bedside and in the Operating Room (OR) settings. Control for both settings will be gauze and saline dressings.
45819407|NCT01035944|Device|Gauze and saline dressings.|Control for both settings will be gauze and saline dressings.
45819408|NCT00378638|Drug|bevacizumab combined with dose dense chemotherapy|
45819409|NCT03582553|Dietary Supplement|Naringenin|An extract of Citrus Sinensis containing naringenin and its precursor naringin
45819410|NCT03582553|Other|Placebo|Cellulose
45819411|NCT01025492|Drug|Trilipix|135 mg po daily
45819412|NCT01025492|Drug|placebo|one tablet po daily
45819413|NCT04331834|Drug|Hydroxychloroquine|"Hydroxychloroquine with the following dosage:~day 0: 400 mg (2 tablets)~day 1: 400 mg (2 tablets)~day 2: 400 mg (2 tablets)~day 3: 400 mg (2 tablets)~weekly: 400 mg (2 tablets) for a period of six months"
45819414|NCT04331834|Drug|Placebos|"Placebo with the following dosage:~day 0: 400 mg (2 tablets)~day 1: 400 mg (2 tablets)~day 2: 400 mg (2 tablets)~day 3: 400 mg (2 tablets)~weekly: 400 mg (2 tablets) for a period of six months"
45819415|NCT04735159|Device|SCS implanted with Precision SpectraTM|Analyze the relationship between neuroimaging biomarkers and the different clinical scales and variables captured from each patient
45819416|NCT02202044|Device|Intravesical BCG and EMDA/MMC|Patients are assigned one course of treatment per week for 6 weeks with sequential 'Intravesical instillation of sequential Bacillus Calmette-Guérin (BCG) and Electromotive Drug Administration /Mitomycin-C
45819417|NCT03538795|Combination Product|iTBS&eCIMT|All will receive eCIMT+iTBS on an outpatient basis for 4 hours/day for 15 consecutive weekdays. eCIMT will include training of the more-affected arm following shaping principles, restraint of the less-affected arm, and the Transfer Package in combination with NDT techniques to reduce tone so that shaping of movement can be carried out. The Transfer Package is a set of behavioral techniques designed to transfer therapeutic gains from the treatment setting to everyday life. iTBS will be added to prime the areas of the brain that control movement of the more-affected arm so that the responsiveness of that tissue to motor training is enhanced. Treatment sessions will alternate between 10 minute periods of iTBS (which include time for set-up and transition) and 1-hour periods of eCIMT.
45819418|NCT01023620|Drug|Pioglitazone|Participants will take oral Pioglitazone 45 mg daily for 16 weeks.
45819419|NCT01023620|Other|Observation|Participants will be observed for 16 weeks but will not receive drug
45819420|NCT03595579|Drug|AXS-05|AXS-05 taken twice daily for 6 weeks.
45819421|NCT03595579|Drug|Bupropion|Bupropion taken twice daily for 6 weeks.
45819422|NCT02200328|Drug|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
45455233|NCT04100798|Procedure|Modified Minimally invasive Surgical Technique|a minimally invasive technique that allow access to the intrabony defect area from the buccal aspect through a horizontal incision below the papilla without elevating it.
45455234|NCT04050124|Drug|Promogran Prisma|Promogran+SOC; composite collagen, silver-oxidized regenerated cellulose matrix
45455235|NCT04050124|Other|Standard of care (SOC) dressings|standard of care dressing on donor site pain for patients undergoing split-thickness skin grafting in preparation for a larger study.
45664886|NCT05352503|Device|Watching videos with nature images accompanied by nature sounds with virtual reality glasses|The video with nature images accompanied by the sounds of nature with virtual reality glasses will be watched 3 times a day for at least 5 minutes for 2 days.
45819423|NCT02200328|Drug|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
45819424|NCT04327843|Behavioral|Customized Adherence Enhancement|Customized Adherence Enhancement (CAE): CAE targets key areas relevant to adherence in chronic psychotic disorders (CPD): 1.) inadequate understanding of mental disorder, 2.) lack of adequate medication-taking routines, 3.) poor communication with care providers and 4.) substance use which interferes with adherence and recovery. CAE delivered components are selected based upon findings from the ROMI and AMSQ. CAE will be delivered in approximately 8 sessions by a nurse interventionist, ideally at the same time that the long-acting injectable (LAI) is administered.The intervention is guided by a detailed manual and uses components and resources that are available in lower- and middle-income countries (LMICs). Social worker interventionists will be trained to deliver CAE-L.
45455236|NCT03939247|Other|Active Tecaretherapy|"The Tecaretherapy: consists of using a specific device providing high frequencies (between 300 kHz and 1 MHz) supposed to accelerate the tissues healing process"
45455237|NCT03939247|Other|Inactive Tecaretherapy|"Inactive Tecaretherapy: the device will not provide any current."
45664887|NCT05270525|Drug|Ensifentrine|Ensifentrine twice daily administered with jet nebulizer for 8 weeks
46079456|NCT05348018|Device|Playing Serious Games during a four-week test period in addition to conventional lectures|Playing SGs during a four-week test period in addition to conventional lectures in oral rehabilitation
45819425|NCT04327843|Drug|Haloperidol Decanoate|Long-acting injectable (LAI): Patients on oral haloperidol will be switched to haloperidol decanoate per manufacturer's package insert. Individuals not on antipsychotic medication at the time of screening assessment or who are on a different antipsychotic medication, will receive an oral tolerance test (OTT) consisting of up to 14 days of oral haloperidol 2-5 mg once or twice daily. If the OTT suggests good tolerability, the participant will then receive LAI (haloperidol decanoate) intramuscularly after completion of baseline assessments. Dosing of LAI will be as clinically indicated using conservative dosing to minimize drug-related adverse effects. In the CWRU studies, mean end-point dose of haloperidol decanoate was 68.0 mg, SD 21.1, Range 50-100 mg/monthly injection. It is anticipated that patients will continue on the same dose for 6 months, although dose changes will be permitted based upon clinical status. Each study participant will receive up to 8 injections during the study.
45960256|NCT03750448|Other|Telerehabilitation|The telerehabilitation intervention is based on sensor technology, developed by ICURA. The technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patients with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. The patients will receive a suitcase with five sensors (to be placed bilaterally on lower legs, thighs and one around the waist), a smartphone to record the exercises and a charging station free of charge during the 6-week intervention. At the end of the intervention the material will be returned at the first follow-up (t1). For more information please visit https://icura.dk.
45960257|NCT03750448|Other|No intervention|Patients allocated to the no intervention group will receive encouragement to stay active and be encouraged to gradually return to activities of daily living. This will be the only exercise-encouragement given to the no-intervention group.
45960258|NCT03750448|Other|Unsupervised rehabilitation|The unsupervised rehabilitation group will receive a written exercise program in order to perform daily exercises at home. The exercise program will be made using Exorlive (for more information about Exorlive please visit https://www.exorlive.com). In addition to the written program, patients will able to use a link provided to see small video-instructions on the internet of each exercise on the program. No feedback or supplementary instructions will be given after the initial face-to-face appointment.
45960259|NCT03748810|Drug|Empagliflozin|Empagliflozin 25 mg once daily add on the background OADs for 3 years
45960260|NCT03748810|Drug|Dapagliflozin|Dapagliflozin 25 mg once daily add on the background OADs for 3 years
45960261|NCT00157859|Drug|Chloroquine and sulphadoxine-pyrimethamine|
45960262|NCT03704662|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45960263|NCT03704662|Radiation|Preoperative Fractionated Radiation Therapy and Chemotherapy|Conventional concurrent chemotherapy and radiation therapy.
46079457|NCT05331365|Other|Construction and evaluation of a composite score evaluating post ankle surgery residual instability by completing questionnaires and undergoing physical tests|"Four tests and two questionnaires, each evaluating specific physical or psychological dimensions will be used to construct the composite score Ankle Go Test composite score:~Foot and Ankle Ability Measure Questionnaire (FAAM)~Ankle ligament reconstruction-return to sport after injury Questionnaire(ALR-RSI)~Single Leg Stance Test (SLST)~Side Hop Test (SHT)~Star Excursion Balance Test (SEBT)~Figure-of-8"
46079458|NCT05330312|Device|Digital cognitive behavioral therapy|Therapy for patients with pulmonary fibrosis
45455238|NCT03939247|Other|CPT|Conventional physiotherapy treatment (massage, eccentric exercises, stretching)
45960264|NCT00183027|Behavioral|Dietary composition and energy intake|
45960265|NCT00157898|Drug|MK0826; ertapenem sodium|
45960266|NCT00157898|Drug|Comparator: ceftriaxone + metronidazole|
45960267|NCT03669523|Drug|Denosumab-nivolumab combination|"Denosumab: 120 mg every 4 weeks subcutaneously~Nivolumab: 240mg intravenously on day 1 every 2 weeks"
45960268|NCT00535015|Drug|Betamarc|2 tabs BID
45960269|NCT00157976|Drug|Photrex (rostaporfin)|
45960270|NCT00535054|Drug|Tears Again|Liposome Eye Spray
45960271|NCT00535093|Device|rapid streptococcal testing|Each patient will have both RST and standard throat culture performed. Final diagnosis and treatment will be determined by throat culture
45960272|NCT00189852|Device|Chronic heart failure monitoring system|
45960273|NCT00189852|Device|Lifestyle monitoring system|
45960274|NCT03522961|Drug|Nitrofurantoin Prophylaxis/Placebo|Drug: Nitrofurantoin Drug: Placebo
45455239|NCT04044508|Dietary Supplement|Ketocal 4:1 liquid Nutricia (intervention)|Modified ketogenic diet
45455240|NCT04044508|Dietary Supplement|Fortini multifibre Nutrica (placebo)|Placebo diet
45664888|NCT05270525|Drug|Placebo|Placebo ensifentrine twice daily administered with jet nebulizer for 8 weeks
45664889|NCT05317013|Drug|CBD|CBD
45664890|NCT05317013|Other|Placebo|Placebo
45664891|NCT04949555|Other|Primary congenital glaucoma evaluation|long term evaluation of primary congenital glaucoma management
45664892|NCT04949243|Behavioral|Behavioral questionaires|Behavioral surveys and questionaires
45664893|NCT04422509|Biological|lanadelumab|single dose, or two doses administered iv
45664894|NCT04422509|Other|regular care|no lanadelumab administration, treated according to regular care
45664895|NCT05313893|Biological|Quadrivalent influenza vaccine|Subjects receive two doses of quadrivalent influenzavaccine administered 4 weeks apart by intramuscularinjection. Each 0.5-ml dosecontained 15 μg of hemagglutinin per strain.
45960275|NCT03522961|Drug|Cranberry capsules|Drug: TheraCran® One Cranberry capsules
45960276|NCT03493750|Other|Oral and dental evaluation|Mouth inspection done by a nurse, in order to count missing, coloured, injured teeth, and evaluate dental plaque, halitosis, inflammatory gums, mucosal injuries, low masticatory surface.
45960277|NCT00158093|Drug|Nebivolol|
45960278|NCT00158093|Drug|Atenolol|
46079459|NCT05329077|Device|Pulsenmore ES home ultrasound device|Pregnant participants will use Pulsenmore ES device to assess the safety and the efficacy of the device in monitoring fetal parameters
46079460|NCT05323812|Drug|TW001|daily dose of 100 mg TW001/placebo
46079461|NCT05323812|Drug|Placebo|daily dose of 100 mg TW001/placebo
45960279|NCT00158093|Drug|Moxifloxacin|
45960280|NCT00183105|Behavioral|Brief Intervention (adaptation of motivational interviewing)|
45960281|NCT00535210|Behavioral|Cardiovascular training|The cardiovascular training group will receive their usual therapy plus 3 days of 30 minutes of exercise per week. This program will last for 6 weeks while the participant is in the hospital. The cardiovascular training program will include pushing and pulling on pulleys, wheeling over mats, punching a boxing bag, and using an arm ergometer. The balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. This program will last for 6 weeks while the participant is in the hospital.
45960282|NCT00535210|Behavioral|Balance training|The balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. This program will last for 6 weeks while the participant is in the hospital. The balance training program will include sitting on mats - moving arm support from in front of the body to behind body, moving from sitting to lying and back up, and catching soft foam ball thrown directly to centre of chest and throwing it back.
45960283|NCT03429946|Drug|Spironolactone|Participants will receive spironolactone 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
45960284|NCT03429946|Drug|Placebo|Participants will receive placebo 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
45960285|NCT03429946|Other|Hypoglycemic Hyperinsulinemic Clamp|Participants undergo two 120-minute hypoglycemic (50 mg/dL) hyperinsulinemic clamps - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
45960286|NCT03429946|Other|Euglycemic Hyperinsulinemic Clamp|Participants undergo two 120-minute euglycemic (90 mg/dL) hyperinsulinemic clamps - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit.Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
45960287|NCT00189930|Biological|MVA-nef|3 imm.: 5E8_TCID50 MVA-nef, 1E8_TCID50 MVA-nef in non-dominant upper arm
45960288|NCT00189930|Biological|IMVAMUNE|3 immunizations: 1E8_TCID50 IMVAMUNE
45664896|NCT05349773|Procedure|Pneumatic tourniquet, endoscopic left radial artery harvesting|"Endoscopic radial artery harvesting technique is performed after applying a tourniquet over the distal arm proximally to the elbow. The tourniquet pressure is increased 90 mmHg over the systolic pressure and the tourniquet time will be monitored.~he changes in Heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be assessed before and after deflating the tourniquet every 5 minutes for 30 minutes."
45664897|NCT05268497|Drug|Esketamine|Esketamine will be self-administered as nasal spray.
45664898|NCT05268497|Behavioral|Cognitive Behavioral Therapy (CBT)|Clinician-directed CBT supplemented by the Mindset app will be administered.
45664899|NCT05268497|Drug|Antidepressant|Antidepressant will be administered orally.
45819426|NCT02147834|Drug|Ranolazine|"Ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
45819427|NCT02147834|Drug|Sugar pill|"sugar pill manufactured to mimic ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
45819428|NCT05598710|Procedure|Pigtail Insertion|Pigtail is inserted for any reason of ureteral obstruction except for malignant
45664900|NCT05312177|Other|Stanford Binet Intelligence Scales, Fifth Edition|The SB-5 is a comprehensive measure of cognitive and intellectual functioning for individuals from age two through 85 years of age. The SB-5 individually assess a child's functioning in five areas of cognitive functioning: Fluid Reasoning, Knowledge, Quantitative Reasoning, Visual Spatial, and Working Memory. The SB-5 is well established in the existing research literature as an assessment tool to evaluate developmental and intellectual abilities in children with ND disorders.
45960289|NCT00158132|Drug|Propranolol|Propranolol 100mg/day in 3 divided doses
45664901|NCT05312177|Other|Vineland Adaptive Behavior Scales Third Edition|The VABS-3 are a parent report, interview style measure of adaptive behavior for individuals ages birth through 90 months. The VABS-3 assesses adaptive behavior in four broad domains of Communication, Daily Living Skills, Socialization, and Motor Skills, and includes a Maladaptive Behavior Domain that assesses problem behaviors.
45819429|NCT04343287|Drug|BRM421|The active control with BRM421 solution
45960290|NCT00158132|Drug|Amantadine|Amantadine 100mg three times daily
45960291|NCT00158132|Drug|Placebo|Placebo pills
45960292|NCT04686409|Biological|COVID-19 vaccines|Participants will be vaccinated with one of the approved COVID-19 vaccines
45819430|NCT04343287|Drug|Placebo|The vehicle solution
45960293|NCT03391921|Biological|Vaccine|All patients will receive the 9-valent vaccine against HPV (Gardasil9) intramuscularly: After a first open phase evaluating tolerability of Gardasil9, women will be randomized between two different doses schedules: in the first schedule, women will receive 2 doses at time 0 and 6 months and a third dose between 18-48 months if their antibody levels are insufficient; the second schedule will be 3 doses at 0, 2 and 6 months.
45960294|NCT00189969|Biological|Elstree-BN|
45960295|NCT00158171|Drug|Nicotine Replacement Therapies|Nicotine gum 2 & 4 mg dependent on baseline smoking rate
45960296|NCT00158171|Drug|Nicotine patch|21, 14 or 7 mg patch dependent on baseline smoking rate
45960297|NCT00158171|Dietary Supplement|Folic Acid|400 mg
45819431|NCT05597774|Other|Inspiratory + expiratory muscle training group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
45819432|NCT05597774|Other|Inspiratory + expiratory muscle training sham group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
45819433|NCT05597774|Other|Exercise training program|Participants will perform a cardiovascular exercise program including warm-up, recovery between intervals and return to calm by cycloergometer.
45960298|NCT03457207|Procedure|Combined minilaparotomy- laparoscopy approach|Laparoscopic aspiration of cyst then guided its extracorporeal cystectomy then reposition and evaluation by laproscopy
45960299|NCT03370783|Drug|Ethanol|Moderate alcohol consumption
45960300|NCT00183144|Behavioral|Contingency management|
45960301|NCT00158210|Drug|Rivastigmine|
45960302|NCT03358693|Drug|Ustekinumab|Subject receives Ustekinumab open-label as per guidelines
45960303|NCT03358693|Drug|Infliximab|Subject receives Infliximab open-label as per guidelines
45960304|NCT03358693|Drug|Secukinumab|Subject receives Secukinumab open-label as per guidelines
45960305|NCT03358693|Drug|Dupilumab|Subject receives Dupilumab open-label as per guidelines
45960306|NCT03358693|Drug|Brodalumab|Subject receives Brodalumab open-label as per guidelines
45960307|NCT03358693|Drug|Ixekizumab|Subject receives Ixekizumab open-label as per guidelines
45960308|NCT03358693|Drug|Baricitinib|Subject receives Baricitinib open-label as per guidelines
45960309|NCT03358693|Drug|Abrocitinib|Subject receives Abrocitinib open-label as per guidelines
45960310|NCT03358693|Drug|Upadacitinib|Subject receives Upadacitinib open-label as per guidelines
45960311|NCT03358693|Drug|Tralokinumab|Subject receives Tralokinumab open-label as per guidelines
45664902|NCT05312177|Other|Peabody Picture Vocabulary Test, Fifth Edition|The PPVT-5 is a norm-referenced language measure that evaluates single-word receptive vocabulary. The PPVT-5 provides standard scores for individuals ages 2.6 through 90 years.
45664903|NCT05312177|Other|Expressive Vocabulary Test, Third Edition|The EVT-3 is a norm-referenced language measure that evaluates single-word expressive vocabulary. The EVT-3 provides standard scores for individuals ages 2.6 through 90 years.
45819434|NCT04369885|Device|Go Home tablet with linked GoSpiro and 3230 Pulse Oximeter|All participants will receive the intervention consisting of a home telemedicine tablet platform (GoHome) that will collect multiple spirometry tests each week (including both forced and slow spirometry measurements), pulse oximetry, and QoL Questionnaire responses. The platform will remind patients to take their medications remind patients to perform measurements, send patients helpful information, and execute a UNC clinic established COPD Action Plan.The backend of the platform is a remote server (Monitored Therapeutics CarePortal) that collects the data, send out alerts to the Principal Investigator and can track and trend the data for them.
45819435|NCT00979550|Drug|Imiquimod|commercially available topical antiviral drug
45819436|NCT00979550|Drug|non-medicated petroleum cream|Over the counter topical cream used to aid the healing process in skin lesions
45960312|NCT04723017|Other|Retrospective analysis cohort|We analyze pre-existing data base and develop machine-learning-based system that predicts the risk of hypoxemia
45960313|NCT04723017|Other|Prospective validation cohort|We validate our model to predict the risk of hypoxemia to prospective cohort
45960314|NCT00158288|Behavioral|LAAM|
45960315|NCT00535522|Drug|TAK-285 Dose Escalation Cohorts|TAK-285 50 mg tablet, orally, once or twice daily for three weeks, followed by seven days off. Dose escalation to maximum tolerated dose, with possibility of continuous dosing per cycle (daily dosing for four weeks without a break between cycles).
45960316|NCT00535522|Drug|TAK-285 Recommended Phase 2 Dosing Cohort|Expanded cohort with dose and regimen dependent upon the safety profile of the maximally tolerated dose and schedule determined in the dose escalation phase of the study.
45960317|NCT00535561|Drug|Ferrous sulfate tablets 325 mg, po, TID|
45960318|NCT00535561|Drug|Ferrous sulfate plus levothyroxine|Combination of ferrous sulfate tablet 325mg plus levothyroxine tablet 25 micrograms, po, TID
45960319|NCT00183183|Behavioral|Screening and Brief Intervention|
45664904|NCT05312177|Other|Leiter International Performance Scale, Third Edition|The Leiter-3 is a nonverbal measure of cognitive functioning and fluid reasoning skills in individuals ages 3 through 75 years. The Leiter-3 measures nonverbal IQ across four subscales, including Sequential Order (SO), Form Completion (FC), Classification and Analogies (CA), and Figure Ground (FG).
45664905|NCT05312177|Other|Social Communication Questionnaire, Current Form|The SCQ is a parent-report measure of social communication, social interactions, play, and behavior.
45664906|NCT05312177|Other|Aberrant Behavior Checklist|The ABC-2 is a parent report measure of problematic behavior at home and in the community. It measures behavior on five subscales (1) Irritability, (2) Social Withdrawal, (3) Stereotypic Behavior, (4) Hyperactivity/Noncompliance, and (5) Inappropriate Speech.
45664907|NCT05312177|Other|Repetitive Behavior Scale, Revised|The RBS-R is a parent report measure that comprehensively surveys for the presence of repetitive behaviors.
45960320|NCT00158327|Behavioral|Telephone-based collaborative care|Participants assigned to the telephone-based program will have a choice of what type of treatment they will receive. The choices will include pharmacotherapy, workbook training designed to help participants improve their coping skills, referral to a community mental health specialist, or some combination of these treatments. Participants will receive telephone calls one to two times every month for 12 months. During the calls, participants will be asked about their attitude toward and adherence to their treatment regimen. They will also be asked about recent episodes of anxiety they have experienced and what coping techniques they have used.
45960321|NCT00158327|Behavioral|Usual care|Usual care may include one or more of several different treatments such as pharmacotherapy and cognitive behavioral therapy; the treatments will be chosen by participants' physicians and will be delivered for 12 months.
45960322|NCT03249220|Device|Placement of the CBMS Probe|Patients will be treated according to standard care in place at the investigation site, when intra-ventricular drainage is needed. Patients will receive the new multifunctional device (CBMS Probe) instead of the single function device generally used. Drainage will be performed by routine standards. Temperature, intracranial pressure and cerebral blood flow will be recorded. Treatment decision will be made by the neurointensive care specialist based on standard care.
45960323|NCT00535639|Drug|Betula Verrucosa allergen extract|
45960324|NCT00190008|Drug|piracetam|
45960325|NCT00158366|Behavioral|Behavioral training|The behavioral training will teach participants ways to control their diet and increase their physical activity.
45819437|NCT04394845|Diagnostic Test|[18F]GTP1|[18F]GTP1 IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie [mCi]), with a maximum drug mass dose of 10 microgram (μg).
45960326|NCT00158366|Behavioral|Social skills training|The social skills training will teach participants how to indirectly control their weight by making social contacts and seeking social support.
45664908|NCT05348993|Drug|G03-52-01|G03-52-01 administered intramuscularly
45664909|NCT05348993|Drug|Placebo|placebo
45664910|NCT05268341|Behavioral|My Sentence Builder|computer-assisted treatment program for expressive grammar
45664911|NCT05348837|Procedure|Deep brain stimulation|Candidacy for DBS implantation will be determined by the treating team, which includes a neurologist, neurosurgeon, neuropsychologist, neuro-radiologist, and palliative care physician.
45664912|NCT05311943|Drug|olverembatinib|olverembatinib, 40mg, taken orally once every other day of a 28-day cycle
45664913|NCT05557175|Device|Repetitive transcranial magnetic stimulation|The active rTMS group will receive a 1 Hz inhibitory low-frequency rTMS protocol hotspot of the contra-lessional primary motor cortex (M1), will deliver a continuous pulse of 1 pulse per second totalling 1200 pulses of 80% active motor threshold stimulation. The duration of the stimulation will last for 20 minutes thrice a week for four weeks (12 sessions). The motor threshold will be the minimum single-pulse TMS intensity necessary to elicit a motor-evoked potential greater than 50μV in more than 5 out of 10 consecutive trials. The standard 70 mm figure-of-eight air-cooled coil handle (MagPro) will be held at right angle to the skull for effective M1 stimulation. The participants in the active rTMS groups will receive a subthreshold stimulation intensity for muscle contraction with no painful peripheral sensation
45664914|NCT05557175|Device|Sham rTMS|The sham rTMS will be applied using the same parameters as the active rTMS but the coil will be rotated 90° away from the scalp so that minimal or no flow of current will be induced
45664915|NCT05266859|Other|Calcium hydroxide|Calcium hydroxide in the power/liquid form will be used and placed on the exposed pulp
45664916|NCT05266859|Other|MTA|Mineral trioxide aggregate will be used as a powder / liquid form and placed over the exposed pulp
45664917|NCT05266859|Other|PRF|PRF will be placed directly over the exposed pulp
45664918|NCT05310851|Other|PIOMI and non-nutritive sucking|"PIOMI group; The first three minutes of the five minutes include massages aimed at strengthening the cheeks, lips, gums and tongue; the last two minutes consist of non-feeding suction application.~Infants in the Non-nutritive sucking group will receive pacifier 3 minutes before 1 hour any feeding time and, 2 minutes before 10 minutes."
45664919|NCT05266313|Behavioral|Oncosexology program|Thematic workshops throughout the year
45664920|NCT02154087|Biological|HP802-247|260 µL (130 µL, one spray, of each component) containing 0.5 x 10.6 cells per mL, alternating weekly with Vehicle
45664921|NCT05219201|Device|partial-body cryotherapy chamber session|"The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:~at -30°C for sham cryotherapy session~at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions)."
45664922|NCT05346731|Drug|Ondansetron|Ondnsetron will be administered at a dose of 0.15 mg/kg IV/PO every 8 hours on the day(s) of chemotherapy and 3 days after completion of chemotherapy
45664923|NCT05346731|Drug|Dexamethasone|Dexamethasone will be administered at a dose of 5 mg/m2 intravenously/orally once on the day(s) of chemotherapy and 3 days after completion of chemotherapy;
45819438|NCT00966992|Drug|Zoledronic acid|
45819439|NCT02099318|Other|Active SRP cases|The SRP involves preoperative rehearsal and planning. Similarly to the CT/MRI studies, the SRP will be available for surgeons during the surgery for evaluation of optional surgical approaches.
45819440|NCT02099318|Other|Control cases|Control cases will consist of video recorded cases done in the exact same way as they have been performed prior to the implementation of the SRP for neurosurgery cases. Due to the alternation of cases, both the SRP and control cases will take place in the same period.
45819441|NCT04418947|Other|Communication type|Control letter vs. intervention letter
45819442|NCT05596058|Other|dual task protocol: active exercises with concomitant cognitive training in executive functions|"The active exercise tasks will be associated with concomitant cognitive tasks specifically relying on executive function.~The goal is to engage the three core executive functions: inhibition (the ability to inhibit automated responses), working memory (the ability to hold, process, and manipulate information in mind) and shifting (the ability to change stimulus-response associations for performing an ongoing task).~Patients will be exposed to different cognitive tasks during physical activity such as walking or running on the treadmill, indoor cycling and balance exercises."
45819443|NCT05596058|Other|active exercise|Physical activity and motor task only
45819444|NCT05596058|Other|cognitive task only|cognitive exercise in executive functions
45819445|NCT00379730|Drug|Prednisolone|
45819446|NCT02074904|Drug|Topiramate|
45819447|NCT02074904|Drug|Placebo|
45819448|NCT03542305|Drug|Lorlatinib|Lorlatinib single oral dose
45819449|NCT02057276|Device|Repetitive Transcranial Magnetic Stimulation|We will use a specific rTMS paradigm called Continuous Theta Burst Stimulation (cTBS) for this study.
45819450|NCT02057276|Device|Sham Repetitive Transcranial Magnetic Stimulation|
45819451|NCT02057276|Other|Occupational Therapy|
45819452|NCT04420273|Behavioral|SSE educational intervention|Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.
45819453|NCT04420273|Behavioral|Active control:Healthy Living|Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.
45960327|NCT00158366|Behavioral|Behavioral training booster sessions|During biweekly booster treatment sessions, participants will discuss their response to different diet and exercise regimens, and researchers will discuss strategies for increasing one's success with the regimens.
45960328|NCT03139318|Radiation|GRID radiotherapy|Patients will be treated with GRID radiotherapy
45960329|NCT00183222|Drug|naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days|
45960330|NCT00158405|Procedure|Structured Treatment Interruption|
45960331|NCT00158405|Drug|Zidovudine (ZDV)|
45960332|NCT00158405|Drug|Lamivudine (3TC)|
45960333|NCT00158405|Drug|Efavirenz (EFV)|
45960334|NCT00158405|Drug|Ritonavir (NRV)|
46079462|NCT05322434|Other|The Effect Of Online Breastfeeding Counseling Given At The Post-Birth Period On Breastfeeding Behavior|The aim of the study is to investigate breastfeeding behavior and initiation of solid food by giving breastfeeding counseling to women within the framework of the Health Belief Model for 6 months from birth.
46079463|NCT05321524|Drug|OCA 0.1mg|Tablets administered orally once daily.
46079464|NCT05321524|Drug|OCA 1.5mg|Tablets administered orally once daily.
46079465|NCT05321524|Drug|OCA 5mg|Tablets administered orally once daily.
45664924|NCT05346731|Drug|Aprepitant|"Aprepitant will be administered based on body weight:~body weight 30-40 kg: days 1-3 - 80 mg orally; body weight > 40 kg: day 1 - 125 mg orally, days 2, 3 - 80 mg orally"
45664925|NCT05346731|Drug|Olanzapine|Olanzapine will be administered at a dose of 0.07 mg/kg orally on the day(s) of chemotherapy and 3 days after completion of chemotherapy (rounded up to the maximum multiple of 2.5 mg, maximum daily dose of 5 mg).
46079466|NCT05317845|Other|No treatment given|The clinical management and prescribed treatment of diabetes and eASCVD/ASCVD risk factors are independent of this study and are part of the routine clinical practice at the discretion of the treating physician.
46079467|NCT05305196|Other|Eccentric-focused exercises|"Three eccentric-focused exercises:~Shoulder external rotator eccentric contraction in shoulder abduction 90 degree~Shoulder external rotator eccentric contraction in shoulder abduction 0 degree~Shoulder abductor eccentric contraction in shoulder abduction 90 degree"
45819454|NCT05572892|Other|FAC scale|"Measurement of walking dependency according to the FAC scale :~in the first week after stroke (in neurology by physiotherapists),~then at 6 weeks, 12 weeks and 6 months (by telephone).~Trunk Control Test score (in the first week after stroke, by physiotherapists).~MRC score of hip extension and hip flexion, knee flexion/extension, ankle plantar and dorsal flexion (in the first week after stroke, by physiotherapists).~PHQ-9 depression scale (at 6 weeks by phone).~Denutrition (weight loss between neurology weight and 6-week weight, BMI +/- albumin).~Other intercurrent medical problems (at each telephone interview)."
45819455|NCT05560490|Device|FibroFix Cartilage P Knee Implantation|The FibroFix Cartilage P instrument set (Drill set) is used for the preparation of an implant site and placement of the FibroFix Cartilage P Implant to resurface an articular cartilage lesion in the anterior and central regions of the femoral condyles of the knee.
45819456|NCT05554796|Procedure|Endoscopic classic stapedotomy|Patients in this group will undergo classic stapedotomy starting with removal of stapes superstructure then perforation of footplate and finally insertion of the Teflon piston.
45819457|NCT05554796|Procedure|Endoscopic reversal stapedotomy|Patients in this group will undergo reversal stapedotomy where perforation of footplate and insertion of Teflon piston will be done at the beginning followed by removal of stapes superstructure.
45960335|NCT00158405|Drug|Indinavir (IDV)|
45960336|NCT02884765|Procedure|Non-surgical|Non-surgical treatment in both condylar fractures
45960337|NCT02884765|Procedure|Non-surgical / Surgical|Non-surgical treatment in one condylar fracture and surgical treatment of the contralateral fracture
45960338|NCT02884765|Procedure|Surgical|Surgical treatment in both condylar fractures
45960339|NCT00183261|Biological|MRKAd5 HIV-1 gag/pol/nef|1.5 x 1010 Ad vg/mL, 1.0 mL administered intramuscularly
46079468|NCT05305196|Other|Stretching exercises|"Modified sleeper stretch~Modified cross-body stretch"
46079469|NCT05305196|Other|Hot pack|Hot pack application on shoulder region
46079470|NCT05305196|Other|Massage|Massage for upper trapezius
45664926|NCT02118597|Drug|Boceprevir|Boceprevir administered according to corresponding summary of product characteristics (SmPC).
45664927|NCT02118597|Drug|Simeprevir|Simeprevir administered according to corresponding summary of product characteristics (SmPC).
45664928|NCT02118597|Drug|Pegylated Interferon (Peginterferon) Alfa-2a|Pegylated interferon (peginterferon) alfa-2a according to corresponding summary of product characteristics (SmPC).
45664929|NCT02118597|Drug|Ribavirin|Ribavirin according to corresponding summary of product characteristics (SmPC).
45819458|NCT00929474|Device|QuickOpt - SJM CRT (Group 1)|The patient's device is programmed to sequential Bi-V pacing mode with paced/sensed AV and V-V delays optimized using QuickOpt. For Group 1 patients, optimization using QuickOpt is performed at enrollment, 3, 6, 9 and 12 month visits.
45960340|NCT00183261|Biological|MRKAd5 HIV-1 gag/pol/nef placebo|1.0 mL administered intramuscularly
45960341|NCT05275738|Dietary Supplement|Nicotinamide|Study tablets for nicotinamide are produced by Blackmores Ltd.
45960342|NCT05275738|Other|Placebo|Study tablets for placebo are produced by Blackmores Ltd.
45960343|NCT00158483|Drug|Acyclovir (ACV)|
45960344|NCT05265481|Device|Tourniquet|The investigators will apply a pressure cuff tourniquet inflated to 60 mmHg
45960345|NCT05265481|Device|Manual Tapping|The investigators will apply tapping directly over the vein manually to increase the vein dimension.
45960346|NCT05265481|Device|Device tapping|The investigators will apply tapping directly over the vein with a massage device to increase the vein dimension.
45960347|NCT05256667|Combination Product|RCT-SV|Group 1- Endodontic treatment in a single visit using chemomechanical preparation and passive ultrasonic irrigation, followed by obturation and final restoration.
45960348|NCT05256667|Other|RCT-TVWD|Group 2- Endodontic treatment in two visits using chemomechanical preparation and passive ultrasonic irrigation, followed by intracanal dressing and temporary restoration for 7 days. After 7 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation and final restoration.
46079471|NCT05286060|Drug|GX-188E+GX-I7+Pembrolizumab|Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator, Ichor TDS-IM device Other Name: Ichor Tri-Grid Delivery System Drug 2: GX-I7 GX-I7 1200㎍/kg, intramuscular administration Drug 3: Pembrolizumab pembrolizumab(100mg/4mL/vial), Intravenous administration Other Name: Pembrolizumab
46079472|NCT05280496|Drug|Metformin|Metformin is used to lower blood sugar in patients with high blood sugar (diabetes).
45960349|NCT05256667|Other|RCT-TVWOD|Group 3- Endodontic treatment in two visits using chemomechanical preparation and passive ultrasonic irrigation, followed by temporary restoration for 2 days, without intracanal dressing. After 2 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation and final restoration.
45960350|NCT00183300|Behavioral|Prolonged Exposure Therapy|
45960351|NCT00158522|Drug|pegylated interferon alpha2a|
45960352|NCT05250544|Other|control group|For the adolescents in the control group; As soon as the process starts, the stopwatch will be started, and when the process is finished, it will be stopped. When the PCR Test starts, the crying state of the adolescent will be observed and recorded. After the procedure, the adolescent's fear (Childiren's Fear Scala (CFS)) and pain (Wong Baker FACES) related to the procedure will be evaluated separately by the adolescent, parent and observer and recorded in the form.
45960353|NCT05237869|Device|Blood Flow Restriction Device|Occlusion training involves the application of a cuff to the upper arm that is designed to restrict only the low-pressure blood flow in veins. It does not prevent blood flowing from the heart to the arm.
45960354|NCT05237869|Other|Standard Physical Therapy|Standard physical therapy protocol for lateral epicondylitis rehab without blood flow restriction.
45960355|NCT00190047|Drug|DP-b99|
45960356|NCT05195047|Dietary Supplement|1 week placebo(Week 1)|1 week of consecutively consuming oral placebo (1 time/day)
45960357|NCT05195047|Dietary Supplement|1 week of probiotics(Week 1)|1 week of consecutively consuming oral probiotics (1 time/day)
45960358|NCT05195047|Dietary Supplement|1 week placebo(Week 2)|1 week of consecutively consuming oral placebo (1 time/day)
45960359|NCT05195047|Dietary Supplement|1 week of probiotics(Week 2)|1 week of consecutively consuming oral probiotics (1 time/day)
45960360|NCT05195047|Dietary Supplement|1 week placebo(Week 3)|1 week of consecutively consuming oral placebo (1 time/day)
45960361|NCT05195047|Dietary Supplement|1 week of probiotics(Week 3)|1 week of consecutively consuming oral probiotics (1 time/day)
45960362|NCT00158561|Drug|sulfadoxine-pyrimethamine and chlorproguanil-dapsone|
45960363|NCT05169229|Drug|Vancomycin + Tobramycin|1 g vancomycin (powder) diluted in 6 ml tobramycin (80mg/ml) and 2 ml Saline (NaCl 0.9%). Added to the prepared allograft before the allograft is used during the revision surgery.
45960364|NCT05169229|Drug|Saline|As a placebo added to the allograft.
45960365|NCT05160415|Drug|EDG-5506|Daily oral dose
45960366|NCT00158639|Behavioral|Home BP;secure messaging;pharmaceutical care;|
45819459|NCT00929474|Device|Control - SJM CRT (Group 2)|The patient's device is programmed to either simultaneous or sequential Bi-V pacing mode as per physician's discretion. The paced/sensed AV and V-V delays could be programmed empirically or optimized using any non-intracardiac electrogram (IEGM) based method as per sites standard of care. However, the Group 2 patients can be optimized only once within the first 4 weeks post CRT replacement. Any paced/sensed AV and V-V delay optimizations performed after 4 weeks post CRT replacement in Group 2 patients will be considered a protocol deviation.
45960367|NCT00538018|Drug|Telithromycin|
45960368|NCT00183378|Behavioral|Walking Program|The therapist introduces a walking program and assists the caregiver in establishing a walking routine of 30 minutes/day for the study participant.
45960369|NCT00183378|Behavioral|Light Exposure Program|The therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
45960370|NCT00183378|Behavioral|Combined Education, Walking and Light Exposure Program|The therapist provides a combination of education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
45960371|NCT00183378|Behavioral|Routine Medical Care with Education|The therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support. Participants are free to use whatever medical services they wish during study participation.
45819460|NCT04734457|Drug|Levothyroxin|We assess the effect of early diagnosis of CH by neonatal screening and start of treatment on the final height of the patients
45819461|NCT02043860|Radiation|Total Marrow Irradiation|Subjects in this trial will receive total body irradiation (3Gy) per day for up to four days and as little as one day. Total IMT doses: 3Gy, 6Gy, 9Gy, or 12Gy.
45819462|NCT02043860|Procedure|Autologous Transplant|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning with escalating doses of total marrow irradiation prior to autologous stem cell rescue.
45819463|NCT02043860|Drug|Melphalan|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning therapy prior to transplant.
45819464|NCT02043860|Drug|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC > 1000/mm^3 over period of 3 days.
45819465|NCT03606187|Device|Stimgenics SCS Programming Approach|Stimgenics SCS Programming approach Using Intellis(TM) SCS system
45819466|NCT03606187|Device|Standard SCS Programming Approach|Standard SCS Programming approach using Intellis(TM) SCS system
45960372|NCT00538057|Drug|GW685698X & GW642444M|study drug
45960373|NCT00538096|Drug|MEDI-538|1 of 3 target doses of MEDI-538 (5,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
45960374|NCT00538096|Drug|MEDI-538|1 of 3 target doses of MEDI-538 (10,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
45960375|NCT00538096|Drug|MEDI-538|1 of 3 target doses of MEDI-538 (15,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
45960376|NCT00538135|Behavioral|Cognitive Behavioural Therapy|
45960377|NCT00538135|Other|Treatment as usual|Standard National Health Service treatment as usual for borderline personality disorder
45960378|NCT00158678|Procedure|IMRT 75 Gy|50 Gy in PTV1 and 25 Gy in 10 fractions in PTV2
45960379|NCT00158678|Procedure|Conventional radiotherapy 70 Gy|50 Gy in PTV1 and 20 Gy in PTV2
45960380|NCT00158678|Drug|concomitant cisplatin|100 mg/m2 D1, D22, D43
45960381|NCT00538174|Drug|Dapagliflozin|Tablets, Oral, once daily up, to 14 days
45960382|NCT00538174|Drug|placebo|Tablets, Oral, 0 mg, once daily, up to 14 days
45960383|NCT05139823|Procedure|geriatric follow-up home visit after discharge|An appointment for a geriatric follow-up home visit is made with the patient and the municipal home care (community) nurse 2-4 days after discharge and only on weekdays. Relatives are informed about the visit and are welcome to join with the patient's acceptance. The local home care team as well as the patient's PCP receives the same digital discharge plan and discharge summary, respectively, as in the control group. While a follow-up visit is scheduled with the home care nurse, the PCP is invited to join too if available, either in person or by a video link. Administratively, the patients are treated as geriatric outpatients, with an in-home follow up instead of a visit in the Geriatric outpatient clinic.
45960384|NCT04724486|Drug|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
45960385|NCT04724486|Drug|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
45960386|NCT04724486|Drug|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
45960387|NCT04724486|Drug|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.
45960388|NCT05120479|Procedure|Kinesiotape|"Kinesiotape (KT): KT will be placed without any extra tension (in the scientific literature it is called paper off tension). The measure determined in the measurement with a tape measure is cut. The anchor of the KT is placed on the medial epicondyle with the body segments in a neutral position (anchor length: 5 cm). Placement of the active zone of the bandage with the flexor muscles of the fingers in elongation. Origin-insertion placement. Distal anchor in neutral position. Material: Kinesiotape: Kinesiology Tape TEMTEX ® Beige (Towatek Korea Co .; South Korea)."
45960389|NCT05120479|Procedure|Sham tape|Sham tape: exactly the same procedure is followed as above, but an adhesive inelastic tape is used. Material: Omnifix elastic (Laboratorios Hartmann S.A .; Spain).
45960390|NCT00538330|Drug|Tamoxifen|Tamoxifen
45960391|NCT00538369|Other|Ramsay Scale|While receiving sedation, subjects will be monitored with the Ramsay scale
45960392|NCT00538369|Device|Bispectral index monitor|While receiving sedation, subjects will receive BIS monitoring
45960393|NCT00158717|Drug|Hepsera|
45664930|NCT01659125|Behavioral|"OCFighter"|OCFighter™ s an interactive, internet guided self-help (GSH) treatment program for obsessive-compulsive disorder (OCD). It uses the evidence based approach known as Cognitive Behavioral Therapy (CBT) and was adapted from the previously validated BT STEPS program for OCD. The program teaches the best practice CBT technique to help with OCD called exposure with ritual prevention (ERP).
45664931|NCT05555771|Behavioral|Counterpressure Maneuvers|Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating three commonly recommended maneuvers of arm tensing, squatting, and leg crossing with arm tensing. Maneuvers should be held for 1-2 minutes, or until symptoms subside.
45664932|NCT05555771|Behavioral|Usual Care|Participants will engage in behavioural interventions and avoidance measures that are commonly recommended as a part of usual care for recurrent syncope. This primarily includes recommendations such as staying hydrated, increasing salt intake, avoiding warm temperatures, avoiding standing for long periods of time, and engaging in regular physical activity. Some patients may be prescribed medication (Midodrine, Fludrocortisone), or other assistive interventions (e.g., compression stockings) at the discretion of their physician.
45819467|NCT01974284|Drug|percutaneous ethanol ablation|The volume of 99% ethanol to be injected is calculated using a standardized formula. Ethanol is instilled with a needle under ultrasound guidance after administration of local anesthesia.
45819468|NCT03543085|Device|GiMer Medical MN 1000 External Stimulator|Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (>200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
45960394|NCT00538408|Procedure|Whole body magnetic resonance angiography (dotarem)|
45960395|NCT00538408|Device|Whole body magnetic resonance angiography (vasovist)|
45960396|NCT00183417|Behavioral|Cognitive behavior therapy (CBT)|Participants will complete worksheets and group discussion on how to increase positive mood and activity.
45960397|NCT00183417|Behavioral|Supportive/expressive (S/E) therapy|Participants will be encouraged to express feelings and emotions without advice giving.
45960398|NCT00183417|Behavioral|Bibliotherapy|Participants will be given a book on how to increase their mood.
45960399|NCT00538447|Other|Database|data base for CML
45960400|NCT00538486|Drug|Telmisartan plus Metformin|Telmisartan 80mg 1/d, Metformin 250mg 2/d
45664933|NCT05218889|Drug|surufatinib + camrelizumab + nab-paclitaxel + S-1|"phase 1b: surufatinib 200 or 250 mg/d, qd po; camrelizumab: 200mg, I.V., D1, Q3W; nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; S-1: 40-60mg bid, according to BSA, D1-14, Q3W; DLTs will be evaluated at first cycle;~phase 2: surufatinib RP2D + camrelizumab + nab-paclitaxel + S-1 when evaluated SD, PR or CR after 4-6 cycles (according to RECIST 1.1), followed by maintenance treatment: surufatinib + camrelizumab + S-1"
45664934|NCT05218889|Drug|nab-paclitaxel + gemcitabine|nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W
45664935|NCT05345561|Other|Clinical data collection|Laboratory tests, Vital assessments, Maternal and fetal genotype testing, Antibodies Testing will be performed.
45819469|NCT05293340|Dietary Supplement|Avocado Vouchers|Food as Medicine to demonstrate clinically meaningful benefits for underserved communities. Avocados are fruits with fats, fiber, micronutrients, and bioactive phytochemicals.
45960401|NCT00538486|Drug|Telmisartan|Telmisartan 80mg 1/d
45960402|NCT00538486|Drug|Candesartan|Candesartan 8mg daily
45664936|NCT05262569|Other|ileus|retrospectively allocation according to a postoperative outcome-ileus
45664937|NCT01657253|Drug|PRO-148|Instill 1 drop in each eye four times a day, for 60 days
45960403|NCT00538486|Drug|Candesartan plus Metformin|Candesartan 8mg 1/d Metformin 250mg 2/d
46079473|NCT05280457|Drug|nivolumab-GX-188E-GX-I7|"Nivolumab 3 mg/kg IV administered every 2 weeks~GX-188E 2 mg IM at Weeks 1, 2, 4, 7, 10, 13, and 19~GX-I7 1200 μg/kg or the recommended dose of the introductory safety cohort is administered at weeks 2, 10, and 18"
46079474|NCT05279937|Drug|Dextrose 50% Intravenous Solution|5mL of 50% Dextrose + 5mL of 1% Lidocaine (Prolotherapy).
46079475|NCT05279937|Drug|Lidocaine 1% Injectable Solution|10mL of 1% Lidocaine (Control)
45960404|NCT00538486|Drug|Amlodipine|Amlodipine 5mg 1/d
45960405|NCT00538486|Drug|Amlodipine plus Metformin|Amlodipine 5mg 1/d, Metformin 250mg 2/d
45455241|NCT01345604|Procedure|transcruciate injection of 20cc of normal saline|Group 2 (control group) will receive a transcruciate injection of 20cc of normal saline through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
45664938|NCT01657253|Drug|Systane|Instill 1 drop in each eye four times a day, for 60 days
45664939|NCT05554367|Drug|Binimetinib|Given PO
45664940|NCT05554367|Procedure|Biopsy|Undergo biopsy
45664941|NCT05554367|Procedure|Biospecimen Collection|Undergo collection of blood samples
45664942|NCT05554367|Procedure|Bone Scan|Undergo bone scan
45664943|NCT05554367|Procedure|Computed Tomography|Undergo CT
45664944|NCT05554367|Procedure|Magnetic Resonance Imaging|Undergo MRI
45664945|NCT05554367|Drug|Palbociclib|Given PO
45664946|NCT02117427|Biological|MDGN201 TARGTEPO|Erythropoietin secreted by TARGTEPO transduced with MDGN201
45819470|NCT03606343|Behavioral|Teaching Academic Skills to Kids|Group treatment
45819471|NCT00869414|Drug|Evening only administration of insulin glargine|Evening only administration of insulin glargine, with normal saline injection administered in the morning.
45819472|NCT00869414|Drug|Morning only administration of insulin glargine|Morning only administration of insulin glargine, with normal saline injection administered at night.
45819473|NCT00869414|Drug|split dose insulin glargine|split dose of insulin glargine, half administered in the morning, half administered in evening
45819474|NCT04734769|Other|Collect retrospectively clinical data on reproductive outcomes|Collect retrospectively clinical data on reproductive outcomes
45960406|NCT00158795|Biological|Haemophilus Influenza type b vaccine|
45960407|NCT00538525|Drug|Doxorubicin, Docetaxel, Cisplatin|Doxorubicin, Docetaxel, Cisplatin
45960408|NCT00538564|Drug|tadalafil|10mg oral tablets taken 3 times a week for 2 months
45960409|NCT00538564|Drug|placebo|Placebo tablets taken orally 3 times a week for 2 months
45960410|NCT04685161|Procedure|Surgical extrusion|Invasive treatment option for fractured tooth
46079476|NCT05274399|Other|surveys and questionnaires|The data containing the questions determining the relationship between the self-care power and hopelessness of the patients who voluntarily participated in the study were collected through a questionnaire.
46079477|NCT05272488|Other|Manual therapy and vagus nerve stimulation|A neurodinamic intervention of vagus nerve through deep breaths involving diaphragm muscle and manual therapy techniques.
45960411|NCT04685161|Device|Fibre post|Easy approach for treatment
45960412|NCT00538603|Drug|pegylated liposomal Doxorubicin (CAELYX) & Carboplatin|Chemotherapy
45960413|NCT00538603|Drug|Paclitaxel & Carboplatin|Chemotherapy
45960414|NCT00158834|Drug|Salmeterol/Fluticasone propionate combination product|
45960415|NCT00158834|Drug|Fluticasone propionate|
45960416|NCT00538720|Drug|Vitamin D|Starting dose 50,000 IU by mouth 3 times weekly for three weeks (+/- one week), then 50,000 IU twice weekly for 6 weeks (+/- one week).
45960417|NCT00538720|Device|Four-dimensional computed tomography (4DCT)|Four-dimensional computed tomography (4DCT) scan of the neck.
45819475|NCT04536571|Device|Test Contact lens|Subjects will be randomized to wear test lenses for 30 minutes, and then cross-over to control lenses.
45960418|NCT00538798|Drug|[18F]SP203|
45960419|NCT05553886|Drug|To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug|To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug
45960420|NCT00536887|Drug|atorvastatin|atorvastatin 10 mg versus 40 mg during the 8 months of follow-up
45960421|NCT00158873|Drug|midazolam|
45819476|NCT04536571|Device|Control Contact lens|Subjects will be randomized to wear control lenses for 30 minutes, and then cross-over to test lenses.
45819477|NCT00843986|Drug|conivaptan|Premix bag
45819478|NCT00843986|Drug|placebo|Premix bag
45819479|NCT05514158|Drug|RC48-ADC|RC48 for injection is a novel antibody-drug conjugate, with a her-2-targeting antibody and a microtube inhibitor
45960422|NCT00158873|Drug|lorazepam|
45960423|NCT00158873|Drug|fentanyl|
45819480|NCT05514158|Drug|RC98|RC98 is a recombinant humanized IgG1 monoclonal antibody targeting programmed cell death-Ligand 1 (PD-L1)
45819481|NCT01965782|Drug|[^14C]-LY3023703|Administered orally
45819482|NCT03608839|Drug|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml|0,01 ml intravitreous dexamethasone solution 4mg/ml injection.
45819483|NCT03608839|Drug|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml|0,03 ml intravitreous dexamethasone solution 4mg/ml injection.
45819484|NCT03608839|Drug|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml|0,05 ml intravitreous dexamethasone solution 4mg/ml injection.
45960424|NCT00158873|Drug|morphine|
45819485|NCT05503160|Behavioral|Intervention|Structured (video-)call by qualified nursing staff with breast cancer patients, with the intention to overcome side effects, distress or non-adherence to endocrine therapy.
45819486|NCT03544879|Behavioral|Yoga Intervention|The 60-minute yoga sessions began with a brief breathing practice led by the instructor. The yoga instructor then led students through yoga poses at a gentle pace using chairs as props as needed. The pace of the class increased slowly over time as students became more familiar and more capable with the poses. Meditation and breathing was followed by chair poses (15-20 minutes), standing poses (10-15 minutes), floor poses (15 minutes), and lastly a supine resting pose (Savasana; 10 minutes). In the Silver Age Yoga method at that time, there were 73 available postures overall including: 35 Chair Postures, 18 Standing Postures, 20 Floor Postures, with a typical class covering 20-25 poses.
45960425|NCT00158873|Drug|remifentanil|
45960426|NCT00158873|Drug|propofol|
45960427|NCT00536926|Device|Home spirometry with data transfer via cell phone|home spirometry recording
45960428|NCT00536926|Device|Home spirometer with BT-cellphone|Data transfer of home spirometry recordings via bluetooth to clinical database.
46079478|NCT05272488|Other|Manual therapy|Manual therapy techniques. Joint manipulation techniques for temporomandibular joints and Soft tissue techniques for the muscles
46079479|NCT05266235|Device|Validation of the Withings bodyscan scale WBS08|Participants will undergo simultaneous recordings of ECGs with the comparator and the study device
46079480|NCT05263037|Device|EaseVRx|VR software with interactive content
46079481|NCT05263037|Device|Sham VR|VR with neutral non-interactive content
46079482|NCT05254353|Procedure|Analyses of proximal and distal samples|Evaluate the difference between proximal and distal CSF samples
46079483|NCT05247268|Drug|Megestrol Acetate 160 MG Oral Tablet|At a dosage of 160 mg/day
46079484|NCT05247268|Drug|Medroxyprogesterone Acetate 500 MG|At a dosage of 500 mg/day
46079485|NCT05247268|Drug|Triprorelin Acetate|Intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses
46079486|NCT05247268|Drug|Letrozole 2.5mg|At a dosage of 2.5mg/day and no more than 24 weeks
45960429|NCT00536926|Device|Home spirometer w/o BT|Standard home spirometry
45960430|NCT00190164|Procedure|Macular hole surgery with alleviated positioning|Macular hole surgery with alleviated positioning
45960431|NCT00190164|Procedure|Macular hole surgery with no alleviated positioning|Macular hole surgery with no alleviated positioning
45960432|NCT00537121|Drug|fluorouracil|Given IV
45960433|NCT00537121|Drug|irinotecan hydrochloride|Given IV
45960434|NCT00537121|Drug|leucovorin calcium|Given IV
45960435|NCT00537121|Drug|vorinostat|Taken Orally
45960436|NCT00537121|Other|pharmacological study|Correlative Study
45960437|NCT00406991|Drug|aspirin|
45960438|NCT00406991|Drug|clopidogrel|
45960439|NCT00537160|Behavioral|Behavior modification, Nutrition Education, Exercise|
46079487|NCT05239546|Drug|Dostarlimab|Participants will receive Dostarlimab 500 mg IV every 3 weeks for 9 cycles followed by 1000 mg every 6 weeks for 12 cycles until 2 years
45455242|NCT01345604|Procedure|transcruciate injection of 20 cc of 0.5% Ropivacaine|Group 1 (study group) will receive a transcruciate injection of 20 cc of 0.5% Ropivacaine through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
45455243|NCT01218217|Drug|SQ109|SQ109 150 mg tablet
45664947|NCT05214443|Procedure|POEM + F|POEM would first be performed as per usual technique. Upon completion of the myotomy, a 2cm incision would be created over the adventitial layer at the level of gastro-esophageal junction (GEJ), allowing scope entry into the peritoneal cavity. The anterior part of the gastric fundus would be located, grasped with endoscopic forceps and pulled towards the esophageal myotomy site. The intended anterior fundus would then be anchored to the edge of the muscle at the GEJ, with the use of X-TackTM system. After confirming adequate hemostasis and secure anchorage of fundus to the esophagus, the mucosal entry site for the submucosal tunnel would be closed with endoscopic clips as per usual POEM technique.
45819487|NCT03544879|Behavioral|Healthy Aging Education|The health education comparison intervention consisted of once weekly, 90-minute health information workshops conducted in group format. The 90-minute sessions generally consisted of a 60-minute lecture followed by 30 minutes of questions and discussion. The lecture titles for Weeks 1-10 were as follows: Introduction/ Exploring Communication, The Science of Successful Aging, Acupuncture 101: How it Works & What it is Good for, Quality of Life/Quality of Well Being, Fighting Cancer With Your Fork, Forgiveness via Shakespeare's: A Winter's Tale, Better Eyesight in Minutes a Day, Brain Fitness, The Importance of Organic Foods/ Organic Gardening, How Dementia Can Be Modified. Lectures were provided by a mix of credentialed experts (physicians/psychologists, etc) and other clinicians. Instructors were asked not to talk about yoga or medication in their lectures. Content was not otherwise closely monitored.
45819488|NCT05486468|Drug|Yutiq 0.18 MG Drug Implant|YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection
46079488|NCT05233189|Other|MOOC|"Registrants will be offered a personalized e-education consisting of 3 to 11 modules adapted to the treatment received in childhood by each in the form of a MOOC entitled Cancer in childhood, living well after over a total duration of about 3 to 7 weeks of training."
46079489|NCT05233189|Other|No intervention|Patients will be followed up until 18 months only
45455244|NCT01218217|Drug|Rifampicin|Rifampicin 150 mg capsules
45960440|NCT03457090|Other|Examination : a TCD and Trans-Thoracic Echocardiography|"Examination that involves the completion of a TCD and an TTE (Trans-Thoracic Echocardiography) :~To reports clinical parameters at the time of the examination : ECG data: sinus rhythm, atrial or ventricular arrhythmia, state of consciousness, heart rate, O2 saturation~To review of pharmacological parameters at the time of the examination : presence of sedation; presence, type and dose of catecholamines.~To collect biological data from the day of the examination : Partial Pressure of O2, PaCO2 (partial pressure) and hematocrit~To collect possible additional examinations : brain scan, EEG. These are non-invasive exams that do not require patient displacement. Only the samples taken by the medical team as part of the treatment will be analyzed."
45960441|NCT05432947|Drug|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with a dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
45960442|NCT05432947|Drug|18F-FDG|Intravenous injection of 18F-FDG with a dosage of 5.55 MBq (0.15 mCi)/kg.
45960443|NCT00158951|Device|CONTAK RENEWAL 2/4/4HE CRT-D|
45960444|NCT00158951|Device|EASYTRAK 2 Lead|
45960445|NCT00190203|Procedure|Decompressive hemicraniectomy and duraplasty|Decompressive hemicraniectomy and duraplasty
45960446|NCT00190203|Procedure|hemicraniectomy|hemicraniectomy
45960447|NCT00158990|Drug|triiodothyronine|
45664948|NCT02117349|Drug|Raplixa|Raplixa is a biological product approved for use in adults to help control bleeding from small blood vessels when standard surgical techniques, such as suture, ligature or cautery, are ineffective or impractical. When applied to a bleeding site, Raplixa is dissolved in the blood and a reaction starts between the fibrinogen and thrombin proteins. This results in the formation of blood clots to help stop the bleeding.
45960448|NCT00158990|Drug|sertraline|
45960449|NCT03457051|Procedure|Total Knee Arthroplasty (TKA)|In total (complete) knee arthroplasty (TKA), the orthopaedic surgeon removes the damaged areas of the knee and replaces the components with an artificial joint. The device that will be used is: Stryker TKA Triathlon system implant Cruciate retaining radius femur design. This device has been approved for use by Health Canada.
45960450|NCT03457051|Procedure|Unicompartmental Knee Arthroplasty (UKA)|Unicompartment (partial) knee arthroplasty (UKA) has been available for over 40 years and differs from TKA in that only the most affected and symptomatic compartment (most commonly medial, but occasionally lateral and patella femoral) are replaced. The device that will be used is: Stryker PKR implant cemented and fixed bearing design. This device has been approved for use by Health Canada.
45960451|NCT04685434|Other|Shriners Hospital for Children Upper Extremity Evaluation|The interventions are evaluating tools for the functional performance of the upper extremity.
45960452|NCT04685629|Diagnostic Test|25 post ICU-patients|patients who were hospitalized in an intensive care unit
45960453|NCT04685629|Other|25 post non-ICU patients|patients who were not hospitalized in an intensive care unit
45960454|NCT00537355|Biological|Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate|6 weekly subcutaneous injections (escalating doses of 3 mcg to 30 mcg)
45960455|NCT00537355|Drug|Histamine|6 weekly subcutaneous injections (escalating doses of 0.22 mcg to 1.1 mcg)
45960456|NCT00183612|Drug|Olanzapine|
45664949|NCT02117349|Device|Gelfoam|Gelfoam Sterile Sponge is a medical device (USP, Pfizer) intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product. It may be cut without fraying, used wet or dry, and is able to absorb many times its weight in blood and other fluids.
45664950|NCT02117349|Drug|Rescue treatment|Thrombin-containing hemostats included in standard care at the site
45960457|NCT05402995|Drug|Irrisept (Irrigation Solution)|Irrisept Antimicrobial Wound Lavage is intended for mechanical cleansing and removal of debris, dirt and foreign materials, including microorganisms from wounds.
45664951|NCT05213663|Other|assessment|To examine the awareness of parents of Cerebral Palsy children about the disease, physiotherapy and rehabilitation.
45960458|NCT05402995|Drug|Saline|Saline irrigation
45455245|NCT03522610|Behavioral|ADAPT|Two hour, once a week in-person parenting program for 14 weeks plus use web-enhanced supplemental ADAPT materials
45664952|NCT05259059|Other|No intervention is involved|No intervention is involved
45664953|NCT05213351|Other|Graded Motor Imagery|"Graded Motor Imagery program will be performed two times a week for six consecutive weeks and will include the following three steps: laterality training, imagined movements, and mirror therapy.~Right-left discrimination training (lateralization training)~Imagination of hand movements (motor imagery):~Mirror therapy Treatments including traditional physiotherapy approaches; joint mobilizations, stretching, scapula focused exercises etc."
45664954|NCT05213351|Other|Exercise|Treatments including traditional physiotherapy approaches; joint mobilizations, stretching, scapula focused exercises etc.
45664955|NCT05258981|Diagnostic Test|MRI|Brain MRI
45664956|NCT05167253|Biological|UB-612|UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
45960459|NCT05397106|Device|CODMAN CERTAS Plus Programmable Valve|Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
45960460|NCT05395936|Other|Myocardial Probe Temperature Screen|The myocardial probe is a needle that measures temperatures. The skin site for introducing the myocardial probe will be small enough that participants will not notice that temperatures have been collected. If participants have multiple operations, temperatures may be collected at each operation.
45960461|NCT05395936|Other|Data Collection|Study team members will collect medical history and other information to potentially understand the safety and success of breast surgery better to allow investigators to identify variables, or changes to help understand investigators roles in potential complications in breast surgery.
45960462|NCT00183651|Behavioral|Standard dialectical behavior therapy (SDBT)|Standard DBT includes: 1) individual DBT therapy (1 hour per week), 2) DBT group skills training (2.5 hours per week), 3) telephone consultation (as needed), and 4) therapist consultation team (1 hour per week).
45960463|NCT00183651|Behavioral|Individual DBT with no DBT group sessions (DBT-I)|Individual DBT (DBT-I) is 1 hour per week of individual therapy and 2.5 hours per week with the psychosocial activities group.
45960464|NCT00183651|Behavioral|Group Skills DBT with no DBT individual sessions (DBT-S)|DBT group skills training is 2.5 hours per week and includes individual case management.
45960465|NCT00537433|Other|Pictogram|"The plain language, pictogram-based medication instruction sheets (available in English and Spanish) utilize pictograms to convey information about the medication name, indication, dose, dose frequency, and length of treatment, along with information about preparation and storage. The sheets also include a medication log for parents to keep track of when they administer the medication.~Research staff reference the sheets as they demonstrate dosing with a standardized dosing instrument; teachback is performed to reinforce concepts. For medications in which a standardized dosing instrument was not included at dispensing, a standardized oral dosing syringe is provided for the caregiver to use at home. After counseling, the caregiver is given the instruction sheet to take home."
45960466|NCT05388643|Diagnostic Test|Enhanced First Trimester GDM Screening|Women who are randomly assigned to this condition will be required to have early glucose screening with a prediction model composed of additional clinical risk factors and serum biomarkers (triglycerides, PAPP-A, and lipocalin-2) with their initial prenatal laboratory assessment.
45960467|NCT05388643|Diagnostic Test|Routine Gestational Diabetes Screening|Women who will be randomized to the comparison condition of usual standard of care will undergo routine standard of care. The standard of care will consist of routine screening for diabetes in pregnancy between 24 to 28 weeks of gestation via the two-step screening method with possible early screening with either plasma fasting glucose, oral glucose tolerance test, or hemoglobin A1c at the providers discretion to represent true clinical practice.
45960468|NCT05381623|Procedure|Simplified suture-less approach|Immediately after the harvest of a free gingival graft from hard palate, at least a half carpule of local anesthetic (articaine 4% 1:100.000 epinephrine) will be infiltrated within the apical border of the harvesting site and another half mesially and distally to the harvesting site. At the end of the mucogingival procedure, the donor site will be evaluated to inquire regarding the presence of a competent coagulum over the wound area. In such a case, no additional procedure will be performed at the recipient site.
45960469|NCT05381623|Procedure|Application of hemostatic sponges and compressive sutures|Immediately after the harvest of a free gingival graft from hard palate, hemostatic collagen sponges will be applied over the harvesting site and a series of tooth suspended external mattress sutures (PGA 5/0) will be applied over the area, in order to provide a compressive effect.
45960470|NCT00537472|Drug|Low dose bupivicaine in spinal anesthetic|Bupivacaine 9 mg intrathecal single shot injection at start of surgery
45960471|NCT00537472|Drug|Standard dose bupivacaine in spinal anesthetic|Bupivacaine 13 mg intrathecal single shot injection at start of surgery
46079490|NCT05229523|Other|repeated assessments|validity and reliability of the Modified Four Square Step Test (mFSST) in children with cerebral palsy with the tests of Pediatric Berg Balance Scale (PBSS), Timed Up and Go Test (TUG), Pediatric Functional Reaching Test (PFUT)
45664957|NCT05256017|Drug|Acoziborole|Acoziborole tablets
45664958|NCT05256017|Drug|Placebo|matching placebo of acoziborole tablets
45664959|NCT01626495|Biological|CART-19|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose.
45664960|NCT02177175|Drug|Carvedilol|
45664961|NCT02177175|Other|placebo|
45819489|NCT05486468|Other|Sham Injection|Sham injection
45664962|NCT02153073|Drug|Omega-3 fatty acid ethyl esters|Omega-3 fatty acid ethyl esters granular capsules
45960472|NCT00183690|Procedure|Prolonged Exposure Therapy|Prolonged exposure therapy includes a trauma focused protocol and cognitive behavioral treatment for PTSD. Cognitive behavioral treatment includes psychoeducation, in vivo exposures, and imaginal exposures.
45960473|NCT00183690|Procedure|Active Psychotherapy|Active psychotherapy includes non-trauma focused therapy, based on time-limited psychodynamic treatment, which includes a formulation of a central issue and open-associative sessions exploring main conflicts and drives.
45960474|NCT00159107|Drug|Acamprosate|Acamprosate
45960475|NCT00159107|Behavioral|Integrative behavior therapy|Integrative behavior therapy
45960476|NCT00159107|Drug|Placebo|Placebo
45960477|NCT05370859|Other|There is no intervention for this study|There is no intervention or exposure for this study
45664963|NCT01657877|Drug|Calcium sodium phosphosilicate|CSP high percentage weight by weight
45819490|NCT00845702|Drug|Gadoterate meglumine (Dotarem)|Each subject will receive one injection of Dotarem 0.2 ml/kg
45819491|NCT00845702|Other|Time of Flight Magnetic Resonance Angiography|Each subject will undergo a TOF MRA
45819492|NCT03610399|Drug|Primaquine|Different total dose and supervision.
45819493|NCT00843830|Radiation|tumoral irradiation|On day 1 of the study treatment, patients will begin tumoral irradiation, which will be given daily for 4 days in 6Gy fractions (days 1 through 4)
45819494|NCT00843830|Biological|Dendritic cell vaccination|Three intra-tumoral injections of 1 ml cell suspensions of KLH (keyhole limpet hemocyanin)- pulsed DC (dendritic cells) will be delivered percutaneously under ultrasound into a selected hepatic metastasis in the outpatient setting.
45819495|NCT03610633|Drug|Oxytocin|The neuropeptide oxytocin (OT) increases social approach, trust, and reduces anxiety to social stress.
45960478|NCT05357365|Other|questionnaire survey|Questionnaire survey about occupational, mental, physical factors on one's health.
45458497|NCT01364324|Drug|standard first line anti-TB drugs|We will perform pharmacokinetic study in gastrectomy and non-gastrectomy group, to evaluate the effect of gastrectomy on pharmacokinetic profile of first-line anti-TB drugs in patients with TB
45664964|NCT01657877|Drug|Sodium monoflurophosphate|500 to 1500 parts per million (ppm) of fluoride
45664965|NCT01657877|Drug|Placebo|No CSP and no fluoride
45664966|NCT05211401|Drug|Active arm 200 mg|Active arm 200 mg: 1 bag containing 200 mg of rituximab (MabThera®) in 100ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
45664967|NCT05211401|Drug|Active arm 1000 mg|Active arm 1000 mg: 1 bag containing 200 mg of rituximab (MabThera®) in 100ml of NaCl 0.9%; 1 bag containing 800 mg rituximab (MabThera®) in 400 ml of NaCl 0.9%.
45819496|NCT03610633|Drug|Placebo|Saline solution.
45819497|NCT00832520|Drug|Remeron (mirtazapine)|"Mirtazapine 15 mg orally at bed time. Patients with a creatinine clearance < 50% or a bilirubin or transaminases > twice the upper limit of normal will take a 7.5 mg dose.~Drug Administration: Drug will be administered orally, every day for a period of 8 weeks~Dose modifications: None"
45819498|NCT03545893|Drug|Ibuprofen 600 mg|Ibuprofen 600mg prescription, to be taken 1 tablet as needed every 6 hours for pain.
45819499|NCT03545893|Drug|OxyCODONE 5 Mg Oral Tablet|Oxycodone 5mg Oral Tablet prescription, to be taken 1-2 tablets as needed every 6 hours for pain.
45819500|NCT03551821|Drug|ATI-50002|Topical Solution
45819501|NCT04734691|Procedure|PIPAC|PIPAC is a laparoscopic procedure for intraperitoneal administration of chemotherapy
45819502|NCT00843050|Drug|P276-00|P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
45819503|NCT04658797|Device|somofilcon A Daily Disposable Contact Lens|Daily Disposable Contact Lens
45819504|NCT04658797|Device|Single Vision Spectacle for Vision Correction|Single Vision Spectacle
45819505|NCT04658797|Other|Personal Facemask|Personal Facemask
45819506|NCT05290844|Other|cricoid pressure|cricoid force in pediatric patients
45819507|NCT01954160|Device|Symplicity Renal Denervation|Renal denervation
45960479|NCT00190242|Drug|group1|Havrix at 1440IU was administrated à weeks S0, S4 and S24
45960480|NCT00190242|Drug|group2|Havrix (1440IU) was administrated at weeks S0 and S24 according to RECOMMANDATIONS
45960481|NCT05355259|Device|GECKO Active Guidewire|The GECKO device is intended to introduce devices used for treatment, at a desired anatomical location (cervical carotid artery, for example) in the central circulatory system. The GECKO guidewire itself is not meant to perform a treatment but is used to set the primary access that will allow performance of the treatments.
45960482|NCT05340868|Drug|Semaglutide Pill|Oral semaglutide treatment
45960483|NCT00537550|Drug|Vincristine|Steroids pre-treatment
45960484|NCT00537550|Drug|Vincristin, Daunorubicine, Asparaginase, Methotrexate|Induction therapy
45960485|NCT00159146|Drug|Pindolol and venlafaxin|pindolol 20 mg and venlafaxin 150 mg
45960486|NCT00537667|Drug|anakinra|anakinra
45960487|NCT00537667|Drug|anakinra and PEG sTNF-R1|anakinra and PEG sTNF-R1
45960488|NCT00538876|Drug|decitabine|"Decitabine will be administered by intravenous injection at a dose of 20 mg/m2/day as a daily 1hr infusion (Arm A) or by continuous infusion (Arm B) for 3, 5 or 7 days. On the day following the final dose of decitabine, standard 7+3 induction chemotherapy will begin."
45960489|NCT00538954|Drug|Post operative laxation (Magnesium Oxide)|20 ml of Magnesium Oxide twice daily from the day after surgery until discharge
46079491|NCT05222841|Dietary Supplement|Spermotrend|Patients who are treated with Spermotrend (536,62g) are given 3 capsules every day for 3 months, taken orally every 8 hours.
45960490|NCT00538954|Dietary Supplement|Preoperative metabolic conditioning postoperative nutritional supplementation|Nutricia PreOP drinks 800 ml between 8-10 pm the evening before surgery Nutricia PreOP drinks 400 ml completed 2 hours before anaesthesia on the morning of surgery Nutricia Fortisip drinks 2 x 200 ml drinks from the day after surgery until day 30
45960491|NCT00538954|Other|Standard ERAS group|
45960492|NCT00538993|Behavioral|Stage based counseling|
45960493|NCT00539071|Drug|long-acting injectable risperidone|Subjects will be randomized to conventional dose Consta or high dose Consta. All of those who are randomized to the conventional Consta dose will receive it in the form of Consta at a starting dose of 50 mg q 2 weeks. Those who are randomized to high dose Consta will receive a Consta 50 mg injection plus 25 mg injection (total dose 75 mg) q 2 weeks as the starting dose.Oral risperidone will be given up to Week 4 along with the injections for both groups to provide a transition phase.At Week 6, psychopathology will be assessed with a PANSS. If no improvement from baseline is shown, the randomized dose of Consta will be increased to 100 mg q 2 weeks (given as two 50 mg injections ) for those in the high dose Consta group. The dose for those randomized to the conventional dose group will remain the same (50 mg plus placebo).
45960494|NCT00539071|Drug|long acting injectable risperidone|Study dose remains 50 mg for the length of the study.
45960495|NCT00539071|Drug|long acting injectable risperidone|Beginning dose 75 mg. Can be increased to 100 mg at Week 6.
45960496|NCT00539149|Drug|Amoxycillin|50 mg/kg/day twice daily
45960497|NCT00539149|Drug|Placebo equivalent to amoxycillin|50 mg/kg/d twice daily
45960498|NCT00539227|Procedure|NAC Sparing Mastectomy|A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC).
45960499|NCT00539227|Behavioral|Questionnaire|Questionnaires taking about 20-30 minutes to complete.
45960500|NCT00539266|Biological|bone marrow derived mononuclear cells|40 IM injections (calf muscle) of 1-8 10E9 mono nuclear cells
45960501|NCT00539266|Biological|placebo|40 IM injections (calf muscle) of placebo suspension
45960502|NCT00539344|Drug|ANG1005|IV infusion once every 21 days
45960503|NCT00539383|Drug|ANG1005|IV infusion once every 21 days
45960504|NCT00183768|Behavioral|Cognitive Behavioral Therapy|
45455246|NCT04981418|Device|customised pelvic support shorts|"These apply targeted compressive forces to the pelvic girdle through selective precisely positioned reinforced lycra panels that aim to stabilize and align body segments to improve function and reduce unwanted movements. The construction material (Nylon and Elastane) is durable and breathable, and its mechanical properties enable it to provide dynamic stability and support (rather than the rigid support provided by off-the-shelf belts) during movement/functional activities. This aims to optimise comfort and movement to increase wear compliance, which is crucial as any benefits gained rely upon this."
45960505|NCT00183768|Behavioral|Psychopharmacology|
45664968|NCT05211401|Drug|Placebo arm|Placebo arm: 1 bag of 100 ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
45819508|NCT03552289|Device|Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter|The Enforcer balloon device will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
45664969|NCT04233671|Behavioral|Mindfulness based relapse prevention and peer mentoring|"Importantly, the treatment will utilize a group format. Group process can serve as a vital agent in breaking down client denial about drug abuse problems. Groups have also been shown to be suitable for treating problems commonly associated with substance abuse, including depression, isolation, and shame.~Additionally, groups intrinsically have many rewarding benefits, including reducing isolation and enabling members to witness the recovery of others. The eight-week group therapy intervention is co-led by a licensed counselor and a peer mentor for eight weeks, then followed by group sessions led by peer mentors for an additional four weeks."
45819509|NCT03552289|Device|Conventional angioplasty balloon catheters|Commercially available angioplasty balloon devices will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
45819510|NCT03615001|Device|TDOC NXT|Assessing the Performance, Safety and Usability of our Next Generation T-DOC® NXT Catheter for Performing Urodynamic Studies
45819511|NCT01877564|Drug|Metformin|
45819512|NCT03615079|Behavioral|Cognitive behavioral therapy|An 8-week, internet-based cognitive behavioral therapy (CBT) program for depression
45819513|NCT03556579|Device|senofilcon A with new UV blocker|Test Lens
45819514|NCT03556579|Device|senofilcon A|Control Lens
45819515|NCT00835328|Drug|Exendin (9-39)|A short-term intravenous infusion of the investigational drug, Exendin (9-39), will be administered over up to 9 hours.
45819516|NCT00835328|Drug|Vehicle|A short-term intravenous infusion of normal saline (0.9% NaCl), or the vehicle, will be administered over up to 9 hours.
45455247|NCT04981418|Other|Exercise|Women will be provided with up to a maximum of 4 exercises from a pre-defined list of exercises. Suggested dosages are referred to in the protocol. The exercise programme contains a range of exercise focused around the pelvic girdle and hips (including movement control and strengthening
45458498|NCT02318212|Device|Dilapan-S|Synthetic osmotic dilators Dilapan-S or Dilasoft for cervical priming prior to induced abortion
45960506|NCT00539422|Genetic|pcr and serum markers for breast cancer|DNA extraction and genotyping of cytochrome P450-2D6*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.
45960507|NCT00183807|Drug|irinotecan, cisplatin, celecoxib|
45960508|NCT00539578|Drug|MK0777|Duration of Treatment: 4 weeks
45960509|NCT00539578|Drug|Comparator: placebo (unspecified)|Duration of Treatment: 4 weeks
45960510|NCT00539773|Drug|BCG, Interferon|Chemotherapy
45960511|NCT00409461|Drug|ATG-Sirolimus-Tacrolimus|
45960512|NCT00539812|Behavioral|Standard Care|Standard 40 hour state mandated batterer intervention program
45664970|NCT05254925|Drug|Sunscreen oil with 6% Bemotrizinol|Sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer
45960513|NCT00539812|Behavioral|Brief Alcohol Intervention combined with standard care|Brief alcohol intervention combined with standard 40 hour state mandated batterer intervention program
45960514|NCT00539890|Drug|Technosphere Insulin|
45664971|NCT05254925|Other|Sunscreen oil vehicle|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (BEMT replaced by Isopropylmyristate)
45664972|NCT05254925|Drug|Dispersion of 6% BEMT in petrolatum|Dispersion of 6% BEMT (PARSOL® Shield) in petrolatum
45960515|NCT00539968|Drug|Docetaxel plus lonafarnib|"Docetaxel: 60-75 mg/m2~Lonafarnib: 150-375 mg PO BID"
45960516|NCT00183846|Drug|irinotecan|
45960517|NCT00183846|Procedure|radiation therapy|
45960518|NCT00540085|Drug|Rocuronium|0.6 mg/kg given intravenously before intubation
45664973|NCT05254925|Other|Petrolatum vehicle|Petrolatum vehicle
45664974|NCT05254457|Biological|EN3835|Treatment or retreatment with up to two doses of EN3835
45819517|NCT00376987|Dietary Supplement|zinc oxide|Oral daily dietary supplement containing 80 mg Zinc oxide
45960519|NCT00190320|Procedure|Induction of labor vs waiting|
45960520|NCT05092399|Procedure|Bariatric Surgery|No study interventions
45960521|NCT00540202|Drug|artemether-lumefantrine|Tablets taken twice daily for 3 days according to weight based guidelines.
45455248|NCT04981418|Other|advice|standardised advice on management of pelvic girdle pain, through a discussion centred around 'Guidance for Mothers-to-be and New Mothers: Pregnancy-related Pelvic Girdle Pain' booklet (https://pogp.csp.org.uk/system/files/pogp-pgppat_3.pdf). This publicly available, specialist physiotherapy approved, standardised leaflet, provides information reflective of current best practice. The participant can use this as an ongoing resource.
45819518|NCT00832598|Radiation|[18F]FACBC PET and [18F]FLT PET imaging|[18F]FACBC PET and [18F]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc. Patients with measurable disease on MRI will undergo PET imaging at baseline (prior-to) and after approximately 1 month of treatment.
45819519|NCT04499599|Other|Dinner|Study subjects will consume a standardized ready-to-eat meal as dinner.
45960522|NCT00540202|Drug|Oral quinine|Quinine tablets given at 10mg/kg 8 hourly for 7 days
45960523|NCT00540241|Drug|Pemetrexed|in-label use
45960524|NCT00159224|Drug|Lopinavir/ritonavir simplification strategy|Simplification
45960525|NCT00540280|Radiation|Surgery alone or surgery plus preoperative Gemcitabine-Cisplatin|Surgery + Chemo + RT
45664975|NCT05253443|Behavioral|Mentalizing Imagery Therapy and caregiver skills mobile application|8-week long mobile application intervention course including caregiver skills training and Mentalizing Imagery Therapy techniques with optional weekly group meetings.
45819520|NCT04499599|Other|Fasting|Subjects in all groups will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1 and then fast overnight for approximately 15 hours.
45960526|NCT00540319|Behavioral|HIP|"The Health in Pregnancy (HIP) computer program provides tailored, interactive Video Doctor counseling about behavioral risks, educational worksheets for the patients, and a cueing sheet for providers."
45960527|NCT00540397|Drug|Fuzhenghuayu Tablet, Huangqi Decoction Granule|
45960528|NCT00183924|Drug|Estramustine|
45960529|NCT00183924|Drug|Docetaxel|
45960530|NCT00183924|Drug|Carboplatin|
45455249|NCT03934723|Behavioral|Exercise|The intervention consists of 180 minutes of moderate-vigorous aerobic exercise per week for 6 weeks.
45664976|NCT05253443|Behavioral|Caregiver skills mobile application|8-week long mobile application intervention course including caregiver skills training with optional weekly group meetings.
45664977|NCT05205941|Drug|MMV688533|Not exceeding 200mg
45664978|NCT05205473|Procedure|Sciatic nerve block under ultrasound control with a electrostimulator peripheral nerves 12.5 ml 1% lidocaine|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (12.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
45960531|NCT00159302|Procedure|Induced Sputum|
45960532|NCT00159302|Procedure|Exhaled Nitric Oxide|
45960533|NCT00159302|Procedure|Nasal Nitric Oxide|
45960534|NCT00159302|Procedure|Blood Tests|
45960535|NCT00159302|Procedure|24hr Urine Samples|
45960536|NCT00159302|Procedure|Exhaled Breath Condensate|
45960537|NCT00159302|Procedure|Spirometry|
45960538|NCT00540553|Drug|placebo|
45960539|NCT00540553|Drug|GSK971086|
45960540|NCT00540631|Biological|specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU)|"Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~to be det. A 0.1 100 TU~7 (+7) days later A 0.2 200 TU~7 (+7) days later A 0.4 400 TU~7 (+7) days later A 0.6 600 TU~7 (+7) days later B 0.1 1000 TU~7 (+7) days later B 0.2 2000 TU~7 (+7) days later B 0.4 4000 TU~7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~to be det. A 0.1 100 TU~7 (+7) days later A 0.2 200 TU~7 (+7) days later A 0.4 400 TU~7 (+7) days later A 0.6 600 TU~7 (+7) days later B 0.1 1000 TU~7 (+7) days later B 0.2 2000 TU~7 (+7) days later B 0.4 4000 TU~7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued"
45960541|NCT00540670|Drug|E5555 50 mg|E5555 50 mg (tablet) taken orally, once a day.
45960542|NCT00540670|Drug|E5555 100 mg|E5555 100 mg (tablet) taken orally, once a day.
45960543|NCT00540670|Drug|E5555 200 mg|E5555 200 mg (tablet) taken orally, once a day.
45960544|NCT00540670|Drug|Placebo|Placebo (tablet) taken orally, once a day.
45960545|NCT00183573|Behavioral|Brief Motivational Intervention|15-20 minute, motivational one-on-one counseling
45960546|NCT00183573|Behavioral|Brief Informational Intervention|15 minute informational DVD on safer sex
45664979|NCT05205473|Procedure|sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator 12.5 ml 1% lidocaine|"Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (12.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
45664980|NCT05161013|Diagnostic Test|LINFU™|A method to detect pancreatic cancer (ductal adenocarcinoma) using ultrasound technology in those who are at significantly increased risk for developing pancreatic cancer. LINFU™ involves analysis of pancreatic fluid collected.
45664981|NCT05160935|Behavioral|Education|"Each patient will be informed about the study, and written consent will be obtained from patients who agree to participate in the study, explaining the purpose and duration of the study. A Patient Identification Form will be filled, the patient's vital signs will be evaluated, and the State-Trait Anxiety Inventory will be administered to the patient.~Before the coronary angiography procedure, the patients in the experimental group will be trained by the researchers using the training booklet. Trait Anxiety Inventory will be re-administered to the patients after the procedure. Vital signs of patients will be monitored.~In the control group; In line with the information in the patient consent form before the coronary angiography procedure, verbal information will be given about the coronary angiography procedure within the scope of the routine procedure in the clinic. After the procedure, the State-Trait Anxiety Inventory will be applied again. Vital signs will be taken."
45664982|NCT05253053|Drug|TT-00420|TT-00420 tablet will be administered orally once daily per protocol defined schedule.
45664983|NCT05253053|Drug|Combination Product: Atezolizumab|Atezolizumab would be administered via infusion on Day 1 of 21-day cycle
45819521|NCT04499599|Other|Study food|Study subjects will either continue to fast for 6 hours (Fast Group), consume either a breakfast (Breakfast Group) or a Fast Bar (Fast Bar Group).
45819522|NCT05454956|Drug|TP-03|TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day in participants in the BID dosing arm and three times a day in participants in the TID dosing arm
45819523|NCT05454956|Drug|TP-03 Vehicle|Vehicle of TP-03 ophthalmic solution, administered once a day in participants in the BID dosing arm to maintain masking between arms
45819524|NCT05441384|Behavioral|Family Caregiver - Fear Of Recurrence Therapy (FC-FORT)|7 weekly sessions of 90-120 minutes each. During the 7 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework assignments.
45960547|NCT00183573|Behavioral|Intensive Informational Intervention|4-hour, information-only intensive group workshop
45960548|NCT00183573|Behavioral|Intensive Info-Motivation-Behavioral Skills Intervention|4-hour, intensive group workshop with emphasis on motivation and skills
45960549|NCT00183885|Drug|mitomycin-c, cisplatin|Intra-arterial cisplatin 60 mg/m2 and mitomycin-C 12 mg/m2 every 8 weeks
45960550|NCT00159341|Procedure|Nasal lavage|Nasal lavage was carried out at specified timepoints
45960551|NCT00159341|Procedure|Nasal filter paper|Nasal filter paper was placed at specified timepoints
45664984|NCT05253053|Drug|Combination Product: Nab-Paclitaxel|Nab-Paclitaxel would be administered via infusion on Day 1 and 8 of 21-day cycle
45819525|NCT05437562|Other|Ewing Amputation|All patients will receive Ewing Amputation to test feasibility.
45819526|NCT04512703|Device|µCor|Sensor Monitor for arrhythmia and other bio-metric markers
45819527|NCT01889420|Drug|Combination therapy|"Following determination of the maximum tolerated dosages in the phase I portion of this study, all patients enrolled in the extension portion will receive the predetermined dosage combination of pomalidomide, everolimus and dexamethasone.~Cycles will span 28 days. Dosage schedules will be:~Everolimus daily for 28 days of a 28 day cycle;~Pomalidomide daily for 21 days of a 28 day cycle~Dexamethasone once weekly (on days 1,8,15,22) of a 28 day cycle."
45819528|NCT03557125|Other|QL Block|If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.
45819529|NCT03557125|Other|Saline Skin Wheel|"The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point."
45960552|NCT00159341|Procedure|Blood sampling|Blood sampling was performed as a routine safety check
45960553|NCT05090293|Behavioral|Experimental: Lifestyle Intervention with Body Image Treatment (LIBI)|A body image protocol designed to improve outcomes in a group-delivered multidisciplinary weight loss program by addressing body acceptance within a context of positive behavior change and utilizing existing body discomfort and re-purposing it as an agent of motivation.
45960554|NCT05090293|Behavioral|Lifestyle Intervention (LI)|A multidisciplinary, group-delivered, multidisciplinary weight loss program addressing various lifestyle factors impacting weight loss.
45960555|NCT00540709|Drug|Insulin Glargine|
45960556|NCT00540748|Drug|oxytocin|5 U i.v. during surgical abortion
45960557|NCT00540787|Device|Radiofrequency ablation, antiarrhythmic drugs|Patients receive either treatment.
45960558|NCT00540787|Drug|Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs|Amiodarone will be taken at 600 mg per day for 21 days (as a loading dose) followed by 1.4g per week or 200mg per day. The daily dose may be increased to 300mg or 2.1g per week.
45960559|NCT00540787|Device|ThermoCool Radiofrequency Catheter|Patient is ablated once, repeat ablation if paroxysmal atrial fibrillation reoccurs.
45960560|NCT00159380|Drug|Aminoguanidine|500mg
45819530|NCT03616171|Behavioral|SLEEP-Extend intervention|"One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep~Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later"
45819531|NCT03616171|Other|Control|Control group will receive 1. One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
45960561|NCT00159380|Drug|Placebos|2ml
45960562|NCT00190398|Device|Carotid angioplasty and stenting with cerebral protection|Carotid angioplasty and stenting with cerebral protection
45960563|NCT00540826|Drug|Atomoxetine|in-label use
45960564|NCT00540826|Drug|stimulants (any approved ADHD medication)|in-label use
45960565|NCT00540865|Behavioral|Problem-solving therapy (PST)|The premise of PST is that psychotherapies implicitly help people to become better managers of their lives, in effect, to become better at solving problems. Unlike Case Management (CM) that seeks to increase its clients' availability and utilization of resources, PST focuses on the patients themselves and helps them develop skills in identifying, prioritizing, and solving problems, and thereby creates a sense of empowerment. Although CM and PST have different theoretical premises, they both focus on the resolution of concrete problems promoting depression.
45960566|NCT00540865|Behavioral|Case management (CM)|Different types of CM exist, but all share the theme of helping individuals cope with their illnesses through linkage to social services, advocacy, rehabilitation, and ongoing support during recovery from illnesses. CM will consist of the following components: 1) socialization to treatment; 2) needs assessment; 3) psychoeducation about depression; 4) service planning; 5) linkage to social services; 6) help with access to health care; 7) advocacy; and 8) exploration of barriers that perpetuate unmet needs.
45960567|NCT00540904|Drug|sodium bicarbonate|IV 154 mEq/L sodium bicarbonate. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
45960568|NCT00540904|Drug|NaCl|IV 154 mEq/L solution of NaCl 0.9%. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
45960569|NCT00540943|Drug|Pazopanib|Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit.
45960570|NCT00540943|Drug|Cetuximab|"Cetuximab will be supplied as a single-use 50 milliliter vial containing 100 micrograms of cetuximab as a sterile, preservative-free, injectable liquid at a concentration of 2 milligram per milliliter in phosphate.~buffered saline"
45960571|NCT00540943|Drug|Irinotecan|Irinotecan hydrochloride trihydrate is an antineoplastic agent of the topoisomerase I inhibitor class.
45960572|NCT00159458|Drug|Gemcitabine and oxaliplatin|
45960573|NCT02963259|Device|SJM Infinity™ DBS IPG or SJM Brio™ DBS IPG system|Implanted Medtronic® IPG will be explanted and replaced by a SJM Infinity™ DBS IPG or a SJM Brio™ DBS IPG system
45960574|NCT00541021|Drug|gemcitabine hydrochloride|
45960575|NCT00541021|Drug|sorafenib tosylate|
45960576|NCT00541060|Genetic|mutation|a mutation of a gene coding
45960577|NCT00541138|Drug|carboplatin|CBDCA AUC=3
45455250|NCT03522532|Procedure|Amalgam placement|Before the Amg was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
45819532|NCT00379028|Drug|Budesonide/Formoterol Turbuhaler|
45819533|NCT00379028|Drug|Salmeterol/Fluticasone Diskus|
45819534|NCT05286554|Drug|gonadotropin releasing hormone-agonist|subcutaneous injection
45819535|NCT05286554|Drug|Progesterone|vaginal suppositories (400 mg twice daily) starting on the day after oocyte retrieval and will be continued till pregnancy assessed by serum β-HCG 15 days after ICSI, and if pregnant, for 10 weeks of gestation.
45960578|NCT00541138|Drug|tamoxifen citrate|Tamoxifen 100mg bid
45960579|NCT00541138|Drug|topotecan hydrochloride|Topotecan 0.75 g/m2/d
45960580|NCT00541138|Other|pharmacological study|Start of tx, hours 24,28 and 72 during Topotecan infusion, and hours 1,2,4 and 6 after end of Topotecan infusion.
45960581|NCT00159497|Device|porous coated Trilogy®|THA
45960582|NCT00159497|Device|Trilogy Calcicoat®|THA
45960583|NCT00541177|Drug|atropine|0.25% atropine
45960584|NCT00541177|Drug|tropicamide|0.5% tropicamide
45960585|NCT02963298|Procedure|Continuous renal replacement therapy|
45960586|NCT00541216|Drug|Ephedrine|
45960587|NCT00541333|Drug|Copaxone Injection|
45960588|NCT00158912|Device|Implantable Cardioverter Defibrillator|
45960589|NCT00541372|Device|insulin injection needle size|The intervention in this study is a specific needle with a length of 5 mm and 8 mm to be used with an insulin pen.
45960590|NCT00408759|Behavioral|hypnosis|
45960591|NCT00159536|Drug|Metformin|Metformin 1000 mg x 2 per day. Orally. From inclusion (before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
45960592|NCT00159536|Drug|Placebo|Placebo, 2 tablets x 2 daily.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
45960593|NCT00541411|Drug|Vincristine, Actinomycin-D, Ifosfamide|Chemotherapy
45960594|NCT03456973|Behavioral|Nurse AMIE|Supportive care software platform
45960595|NCT00541489|Drug|Naproxcinod|750 mg, bid
45960596|NCT00541489|Drug|Naproxen|500 mg, bid
45960597|NCT00541489|Drug|Placebo|bid
45960598|NCT00190437|Drug|Amoxicillin-clavulanic|Amoxicillin-clavulanic
45960599|NCT00159575|Drug|Metformin / Placebo treatment for 4 months|M: Metformin 2000mg daily- 12-14 weeks of pretreatment + metformin 2000mg daily through conventional IVF ending on the day of pregnancy test; IE. 14 days after embryo transfer. P: Or identical placebo treatment for the same period
45960600|NCT00541567|Drug|ibipinabant|oral, tablet, once daily
45664985|NCT04945655|Other|Adolescents and parents' education and motivation at school (component 1)|"The component 1 includes first an information group session (duration: 1h30) on HPV infection and vaccination for parents. This session starts with a webconference delivered by two medical experts on HPV, using a standardized presentation. Then, a discussion is open for parents' questions and/or comments.~Second, adolescents participate during the school time to two educational group sessions on HPV infections and vaccination, using a pedagogy based on active learning. These sessions (duration: 2h each) are delivered by the school staff (e.g., nurse, teacher in life sciences) using an educational package comprising: a guide that describes activities that should be implemented during each session; one video and a fact sheet developed by health students; a serious video game that promotes HPV vaccination and accessible on an internet website. Before the sessions, the school staff is encouraged to attend an e-learning training course (duration: 1 hour)."
45819536|NCT03558061|Drug|ALK4290|ALK4290 400 mg tablet twice a day
45664986|NCT04945655|Other|General practitioners' training (component 2)|The component 2 consists of an individual e-learning training session for general practitioners (GPs) that is accessible on computer and smartphone. Lasting 3 hours, GPs are able to access to the training whenever they want and then to progress at their own pace. The training includes three main parts: up-dated information on HPV infection and vaccination; an introduction to the use of motivational interviewing techniques in the field of vaccination; and a presentation of the decision aid tool developed as part of the intervention and explanation of how to use it during consultations. GPs may ask questions to the consortium team by using a dedicated chat.
45819537|NCT01881932|Device|Acupuncture using Seirin® needles|"Participants will receive acupuncture weekly until the end of chemotherapy.~Subjects will receive acupuncture at documented acupoints. To improve blinding effect, the acupuncturist will also tap 2 guiding tubes at 2 sham points , and immediately affix a pair of needles to the surface of the same points with adhesive tape, without needle insertion."
45819538|NCT01881932|Device|Sham Acupuncture using Park Sham placebo acupuncture device|"Participants will receive sham acupuncture until the end of chemotherapy.~Acupuncturist will insert Park Sham Devices, non-penetrating sham acupuncture device consisting of a retractable needle and an adhesive tube into the sham points, and then immediately apply 2 pieces of adhesive tape next to the needles. In addition, she will tap a mock plastic needle guiding tube on the surface of each of the 8 true points in the arm and leg to produce some discernible sensation and then immediately apply a needle with a piece of adhesive tape to the dermal surface, without needle insertion."
45819539|NCT03617419|Device|GE VScan Access R2 Ultrasound System|A diagnostic ultrasound imaging system manufactured by the study Sponsor.
45819540|NCT03617419|Device|GE Corometrics 170 Series Fetal Monitor|A reference device to record a continuous fetal heart rate.
46079492|NCT05217017|Diagnostic Test|FACS|Diagnostic Test: Assessment of disability and behavior (by questionnaires)
45455251|NCT03522532|Procedure|Tetric EvoCeram placement|Before the TEC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
45960601|NCT00541606|Other|Pharmacist collaboration in diabetes care|Patients attended a minimum of 3 clinic visits (month 0, 6, 12) with one of the clinical pharmacists, where targeted physical assessment, education, and medication changes and follow up were recommended. Additional visits were arranged as clinically appropriate for drug monitoring. Referrals were facilitated to other clinicians where indicated, including ophthalmology, podiatry, CDEs, nutrition, and primary care. The pharmacists' recommendations for medication adjustment, laboratory monitoring and referrals were based upon the most recent guidelines and clinical trial evidence. Any therapy adjustment, lab testing or referrals required approval by the referring physician. A1c, lipid and BP values were collected prospectively at months 0, 6 and 12.
45960602|NCT00541606|Other|Usual care|Control patients received usual care directed by their physician, and the same data were gathered from chart review during the 12-month study period.
45960603|NCT00408798|Drug|Intracutaneous injections of Botulinum Toxin A (Botox), 0.1 cc per injection site, which equals 10 units|See Detailed Description.
45960604|NCT00541723|Drug|IncobotulinumtoxinA (Xeomin)|Intramuscular injection at day 0, at 3 and 4 injection sites per eye (4 x 3 or 3 x 4 units = 12 units per eye)
45664987|NCT04945655|Other|Access to vaccination at school (component 3)|The component 3 aims at enhancing access to HPV vaccination for adolescents by offering them the first free-of-charge injection at school, without any medical prescription. For each concerned school, we organise a vaccination day inside the school premises where health professionals (one physician and one nurse) from the local vaccination centre initiate HPV vaccination with Gardasil-9® (in accordance with the French recommendations) for all eligible adolescents.
45819541|NCT03617419|Device|GE Corometrics 170 Series Fetal Monitor|A reference device for verification of scanning the fetal heart.
45960605|NCT00541723|Drug|Placebo|Intramuscular injection at day 0, at 3 and 4 injection sites per eye.
45960606|NCT00159614|Drug|KW-3902IV|
45960607|NCT00541762|Dietary Supplement|Fat perfusion to the small intestine|"Triglycerides, long chain fatty acids, medium chain fatty acids perfused to the small intestine~Orlistat perfused to the small intestine~DEXLOX as CCK-1 receptor antagonist"
45960608|NCT00541801|Device|Doppler-echocardiography and acoustic cardiography|Patients receive a Doppler-echocardiography and an acoustic cardiography
45960609|NCT00541840|Drug|Sorafenib|"Phase I:~Level 1: Sorafenib 200 mg bid, orally Ifosfamide 2,0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Level 2: Sorafenib 400 mg bid, orally Ifosfamide 2.00 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Level 3 : Sorafenib 400mg bid, orally Ifosfamide 2.5 g/m2 , intravenously , over 4 hours , on 3 consecutive days . Mesna 500mg/m2,iv,at 0,4 and 8 hours after ifosfamide administration .~Level 4 : Sorafenib 400 mg bid, orally Ifosfamide 3.0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 600 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Phase II:~Sorafenib and Ifosfamide administered at the doses recommended in phase I until progression or unacceptable toxicity."
45960610|NCT00190476|Drug|Weekly docetaxel alone|
45960611|NCT00190476|Drug|Weekly docetaxel + cisplatin combination|
45455252|NCT03522532|Procedure|Beautifil placement|Before the BF was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
45455253|NCT03522532|Procedure|Zinc phosphate cement placement|Before the ZPhC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
45455254|NCT03522532|Procedure|Zinc polycarboxylate cement placement|Before the ZPoC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
45819542|NCT00379106|Procedure|Arm exercises.|Basic active exercise program at home.
45664988|NCT04422197|Biological|Botox|effect of botox injection in abdominal wall muscle post major abdominal surgery in terms of postoperative pain, incidence of incisional hernia.
45664989|NCT04422197|Procedure|surgery without botox injection|surgery without botox injection
45819543|NCT00379106|Procedure|Arm Exercises|Instruction in the same active exercise program along with additional exercises using exercise equipment and stretching exercises
45819544|NCT03619135|Device|Buzzy|The Buzzy is a reusable device that applies vibration to the skin surface to override the body's gate control pain pathway. It has been used effectively to reduce the discomfort of intravenous cannulation (IV placement) in pediatric patients. Also, it has been utilized to reduce the discomfort of injections in pediatric and adult patients. We are preforming this study to evaluate the effectiveness of the Buzzy in reducing the discomfort associated with intravenous cannluation (IV placement) in adults.
45819545|NCT03619135|Other|Placebo|No use of the Buzzy (standard IV access techniques)
45819546|NCT04706312|Other|stem cells|hAMSCs injection via venous in the dorsum of hand
45819547|NCT03559933|Device|PEPNS System|PEPNS System therapy will be delivered periodically up to 48 hours or less if patient is no longer being mechanically ventilated.
45819548|NCT00379262|Drug|Capecitabine|Dose:1000 mg/m2, BD, Day 1-Day 14 Interval: 21 days Cycles: 3 cycles
45819549|NCT00379262|Drug|Adjuvant chemotherapy using PF (5-Fluorouracil )|Cisplatin 80 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 96 hr every 28 days for 3 cycles
45819550|NCT00379262|Drug|Induction chemotherapy using PF (5-Fluorouracil)|Cisplatin 100 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 120 hr every 21 days for 3 cycles
45960612|NCT00159653|Drug|Xalacom|
45960613|NCT00159653|Drug|Xalatan|
45960614|NCT00159653|Drug|Timolol|
45960615|NCT00541879|Behavioral|Program ENERGY|Weekly or biweekly classroom and gym based science enrichment focused on how the body works including blood glucose regulation, healthy eating and physical activity, diabetes abd how it can be prevented
45960616|NCT00541879|Other|comparison|
45960617|NCT00541918|Drug|Diprivan (propofol, Astra Zeneca)|Total intravenous anesthesia with propofol
45960618|NCT00541918|Drug|Sevorane (sevoflurane, Abbott)|inhaled anesthesia with sevoflurane
45960619|NCT00541957|Behavioral|behavior therapy|10 sessions over 4 months
45960620|NCT00541957|Drug|Medication prescribed by PCP|Can include any antidepressant medication
45960621|NCT00190515|Drug|5FU+l-leucovorin|5FU+l-leucovorin
45960622|NCT00190515|Drug|UFT+Leucovorin|UFT+Leucovorin
45455255|NCT03522532|Procedure|Glass ionomer cement placement|Before the GIC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
45960623|NCT00541996|Drug|vabicaserin|
45960624|NCT00159692|Drug|Amlodipine|
45819551|NCT03620383|Procedure|Topical Heat|Warm heat pack applied topically in participant hand.
45960625|NCT00542074|Other|hygienic information plus 62% ethyl alcohol in emollient gel|The male partner in each couple was asked to apply Purell® to his penis at least daily, and immediately prior to and following intercourse. Couples received a brochure with information on control of STI and good hygienic practices. Brochures for intervention and control arms were similar except the intervention arm brochure provided information on how to use the study product (Purell®).
45664990|NCT05252429|Drug|Docetaxel|Docetaxel 75mg/m2; q21
45819552|NCT00793520|Drug|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
45960626|NCT00542074|Other|hygienic information|Couples received a brochure with information on control of STI and good hygienic practices.
45960627|NCT00542113|Behavioral|DvtProgram ENERGY|11 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
45960628|NCT00542113|Behavioral|DvtProgram ENERGY|6 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
45960629|NCT00542113|Behavioral|DvtProgramENERGY|Children participating in Program ENERGY but no newsletters or family challenges sent home to parents
45455256|NCT03945422|Device|AccuTite/FaceTite|Radiofrequency-assisted lipolysis (RFAL) Morpheus8: Fractional RF
45455257|NCT03895580|Other|In-store POP education|Six in-store nutrition counseling sessions with a registered dietitian nutritionist.
45664991|NCT05252429|Drug|Pembrolizumab|Pembrolizumab 200mg, q21
45664992|NCT05204303|Diagnostic Test|24-hour pH-impedance monitoring|Ambulatory transnasal reflux device to detect reflux events in the oeosphagus and pharynx.
45664993|NCT05204303|Other|Symptom questionnaires|Reflux Symptom Index (RSI) Gastroesophageal Reflux Disease Questionnaire (GERDQ) Short-form Esophageal Hypervigilance and Anxiety Scale (SF-EHAS)
45819553|NCT00793520|Drug|Placebo|Twice daily oral administration of placebo for 5 weeks.
45819554|NCT00793520|Drug|Placebo|Twice daily oral administration of placebo for 5 weeks.
45960630|NCT00542152|Drug|CYCLOSPORINE VS INFLIXIMAB|"Cyclosporine 2mg/kg/day intravenous for 7 days then Neoral 4mg/kg/day orally for 3 months.~Infliximab 5mg/kg at weeks 0, 2 and 6"
45960631|NCT00159731|Drug|Pregabalin|
45960632|NCT00408915|Drug|Continuous Subcutaneous Lisuride Infusion|
45960633|NCT00542347|Drug|Esomeprazole first|"esomeprazole 20mg po once per day for 7 days~24hr pH study on day 7~followed by washout for 7 days~generic omeprazole 20mg po once per day for 7 days~24hr pH study on day 7"
45960634|NCT00542347|Drug|Generic omeprazole first|"generic omeprazole 20mg po once per day for 7 days~24hr pH study on day 7~followed by washout for 7 days~esomeprazole 20mg po once per day for 7 days~24hr pH study on day 7"
45960635|NCT00542464|Biological|Imprime PGG TM for Injection|Doses of 1.0 mg/kg-4.0 mg/kg of Imprime PGG administered over 1-2 hr for 7 consecutive days
45960636|NCT00542581|Device|The Acrysof toric SN60T3 IOL|Intraocular Lens
45960637|NCT00190554|Drug|Surgery +(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2|
45960638|NCT00190554|Drug|(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2＋Surgery|
45960639|NCT00159770|Drug|ziprasidone versus olanzapine , risperidone or quetiapine|
45960640|NCT00159770|Behavioral|Panss , CGI-C, UKU-SERS-Pa|
45960641|NCT00159770|Procedure|Blood tests|
45960642|NCT00542698|Behavioral|Effect of Physical Activity on Type II Diabetes Mellitus|Reviewing participants and a role model's continuous glucose monitor graphs, discussing benefits of physical activity and setting physical activity goals.
45455258|NCT03895580|Other|Online POP education|Education on the use of an online grocery shopping, an online recipe tool, a grocery pickup service, a home grocery delivery service, and a phone application that promotes healthy food selection.
45664994|NCT05204303|Other|ROME IV Diagnostic Questionnaire|A symptom-based questionnaire used to diagnose disorders of gut-brain interaction (DGBI)
45664995|NCT05203367|Drug|BAR502|"Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 240 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 10, 50 and 150 mg. A maximum of 4 dose levels are pre-planned (10 mg, 50 mg, 150 mg, 300 mg)."
45664996|NCT05203367|Drug|Placebo|Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
45819555|NCT00793520|Drug|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
45819556|NCT03621085|Drug|Ketamine Hydrochloride|A total of 20 mg of Ketamine Hydrochloride will be administered intravenously
45819557|NCT03621085|Other|Placebo|Subjects will receive placebo
45819558|NCT00795236|Drug|Melatonin|One 0.5 mg tablet of melatonin will be taken by subjects who are free-running and willing to enter the intervention phase of the study. These subjects will take melatonin until entrainment status is confirmed or throughout the duration of the study.
45819559|NCT04490863|Device|Rad-67 Pulse oximeter & DCI Mini sensor|Noninvasive pulse oximeter that measures hemoglobin
45960643|NCT00542737|Behavioral|Web-Based Educational Program|Participating clinicians at each hospital will access the Web site as often as necessary for a 6-month period. The Web site will contain background and educational information on ALI/ARDS and LPV, including how to recognize ALI/ARDS and how to implement LPV in patients. Scholarly articles and other materials, including a chart to help clinicians determine appropriate ventilator settings for each patient, will be available to download. Clinicians will also be able to email questions to critical care experts.
45960644|NCT00542776|Other|blood draw|drawing blood for seroprotection and antibody titers to the 3 strains of influenza on Day 1 and Month 1 (3-8 weeks)
45960645|NCT00190593|Drug|raloxifene|
45960646|NCT00190593|Drug|placebo|
45960647|NCT00542854|Device|MP3|4 different brands of MP3 players will be tested at 3 distances from ICD/pacemaker site in children and adults with congenital heart disease.
45960648|NCT00542893|Drug|Genasense® (G3139, oblimersen sodium)|
45960649|NCT00542893|Drug|Genasense followed by DTIC; then DTIC alone|Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
45960650|NCT00542893|Drug|DTIC alone; then Genasense followed by DTIC|Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
45960651|NCT00542932|Other|Exercise|"Watched Film A (promotional film)~Film B (30 min exercise video) asked to to perform 4 times a week for 6 weeks at home"
45960652|NCT00543010|Drug|MK0767|
45960653|NCT00184041|Drug|Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine|Induction I/II, consolidation I/II/III/IV and Maintenance
45960654|NCT00543049|Drug|Sunitinib|Sunitinib, oral, 50mg once daily, 28 days then paused for 14 days, for up to one year
45960655|NCT00543049|Drug|SUNITINIB|Sunitinib, oral, 37,5 mg once daily continuously, up to one year
45664997|NCT05203289|Drug|BI 695501 - higher concentration|BI 695501 - higher concentration
45664998|NCT05203289|Drug|BI 695501 - lower concentration|BI 695501 - lower concentration
45664999|NCT05157971|Drug|Cyclophosphamide|Given IV
45819560|NCT00790478|Drug|Melatonin|Study Pill (5 mg/d) taken once daily, preferably an hour before bedtime, for 12 weeks.
45819561|NCT00790478|Other|Placebo|Study Placebo taken once daily, preferably an hour before bedtime, for 12 weeks.
45960656|NCT04685005|Dietary Supplement|"Wake Up"|The current composition of the WakeUp® beverage consists of herbal extracts of guarana, green tea, elderberry and Fruit-up
45960657|NCT04685005|Dietary Supplement|Caffeine|Caffeine
45960658|NCT00190632|Drug|Duloxetine|
45960659|NCT00543166|Drug|dehydroepiandrosterone|50 mg of dehydroepiandrosterone in the morning for 4 months in the treatment group.
45455259|NCT03522454|Dietary Supplement|Protein-rich oral nutritional supplement|Ready-to-drink beverage containing 20 g protein and 1.5 g hydroxymethylbutyrate (HMB) per serving, consumed twice daily.
45665000|NCT05157971|Drug|Cytarabine|Given SC, IV or IT
45665001|NCT05157971|Drug|Daunorubicin Hydrochloride|Given IV
45665002|NCT05157971|Drug|Mercaptopurine|Given PO
45665003|NCT05157971|Drug|Methotrexate|Given IT
45665004|NCT05157971|Drug|Pegaspargase|Given IM or IV
45665005|NCT05157971|Drug|Prednisone|Given PO
45665006|NCT05157971|Drug|Venetoclax|Given PO
45665007|NCT05157971|Drug|Vincristine Sulfate|Given IV
45665008|NCT05370755|Drug|ICP-189|Administered orally
45819562|NCT04490239|Drug|Intranasal heparin sodium (porcine)|Intranasal heparin sodium
45819563|NCT00791336|Drug|Nelfinavir|1250 mg twice daily starting for approximately 6.5 weeks.
45819564|NCT03621787|Device|Implant insertion device|Device designed to assist healthcare providers in administering subcutaneous implants safely and accurately.
45819565|NCT03562663|Device|Transcranial direct current stimulation|A constant, low current stimulation is provided non-invasively through sponge electrodes positioned over the motor cortex of the affected arm. The stimulation is provided for 20 minutes at an intensity of 2 mA.
45819566|NCT03562663|Device|Upper extremity robotics|Participants complete robotic training 3 days per week for 12 weeks, or 36 sessions. The protocol alternates between planar (shoulder/elbow) and wrist robots for the duration of the study.
45960660|NCT00543205|Drug|Genasense® (G3139, oblimersen sodium)|Genasense 7 mg/kg/day for 5 days
45960661|NCT04684966|Device|Neuromuscular Electrical Stimulation|Standart pulmonary rehabilitation with combined quadriceps and triceps surae ESNM using two identical electrotherapy devices allowing simultaneous stimulation of the quadriceps and triceps (EG group).
45960662|NCT04684966|Device|Sham Neuromuscular Electrical Stimulation|Standart pulmonary rehabilitation with combined sham NMES of the quadriceps and triceps surae performed using two identical electrotherapy devices allowing simultaneous stimulation of the quadriceps and triceps (CG group)
45960663|NCT00184080|Drug|Elsamitrusin|
45960664|NCT00159809|Drug|Viagra (Sildenafil citrate)|
45960665|NCT04684888|Procedure|Visumax Femto-flap|"Under topical anesthesia [Tetracaine eye drop 0.5%]. A-90 µm thick flap was done by using Visumax femtosecond laser. The flap hinge was set to be nasally placed. A nasal-hinge flap with 90 µm thickness, 8.8 mm flap diameter, and 90º side cut angles were created with 500 kHz Visumax FSL, 160 nJ energy [Carl Zeiss, Meditec, Germany]. The sphero- cylindrical refractive corrections with optical zone 6.5 mm and ablation zone 8.0 mm were done by excimer laser operating system [Carl Zeiss, Meditec, MEL 90, Germany]. Automatic iris registration and pupil-tracking system were activated before photoablation. The patient's eyes were examined postoperatively on a slit-lamp biomicroscope and all treatments that were given for home use have been explained in terms of frequency of instillation, possible side effects, and benefits before discharging them on the same day.~Follow up visits were scheduled clearly on printed patients' discharging cards."
45960666|NCT04684888|Procedure|Sub Bowman's keratomileusis (SBK)-flap|"Under topical anesthesia [Tetracaine eye drop 0.5%] .A-90µm flaps done using Maria one use plus SBK mechanical microkeratome with a nasal located hinge. The sphero- cylindrical refractive corrections with optical zone 6.5 mm and ablation zone 8.0 mm were done by excimer laser operating system [Carl Zeiss, Meditec, MEL 90, Germany]. Automatic iris registration and pupil-tracking system were activated before photoablation. The patient's eyes were examined postoperatively on a slit-lamp biomicroscope and all treatments that were given for home use have been explained in terms of the frequency of instillation, possible side effects, and benefits before discharging them on the same day.~Follow up visits were scheduled clearly on printed patients' discharging cards~."
45960667|NCT00543244|Drug|Pegylated interferon alfa and ribavirin|"Pegylated interferon alfa-2a 180 ug/week or pegylated interferon alfa-2b 1.5 ug/kg/week Ribavrin 800-1200 mg/day (genotype 1: < 75 kg 1000 mg/day, >=75 kg 1200 mg/day; genotype 2: 800 mg/day)~HCV genotype: baseline (Day 0) HCV RNA (real time PCR test): baseline (Day 0), Day 1 (4,8,12 hours after pegylated interferon + ribavirin), Day 2 (24,36 hours), Day 3(48 hours), Day 4 (72 hours), Day 5 (96 hours), Week 2,4,6,8,12,16,20,24, and 28,32,36,40,44,48,72 (for genotype 1 with 48 weeks of treatment), and 48 (for genotype 1 or 2 with 24 weeks of treatment)"
45960668|NCT00190710|Drug|Gemcitabine|
45665009|NCT05250089|Other|Simulation|Each simulation will focus on a trauma case deemed to be complex, that is to say one involving difficult decision-making. Each simulation session lasts approximately thirty minutes. It includes a time to complete the questionnaires necessary for carrying out the study, before and / or after the simulated practice depending on the type of questionnaire, a brief briefing on the simulation scenario, and the time for the simulated practice.
45665010|NCT02175771|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either 100 mcg or 200 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 400 mcg. Study drug was administered in the morning and in the evening."
45960669|NCT00190710|Drug|Carboplatin|
45960670|NCT00159848|Behavioral|Treatment Optimization Program (educational material)|
45960671|NCT03456661|Drug|Levobupivacaine|Infiltration with 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml), US guided, using pectoralis block technique.
45960672|NCT03456661|Drug|Levobupivacaine + Dexmedetomidine|Infiltration with chirocaine 0.25% 29,5ml + 0,5ml dexmedetomidine (50µg) (total volume 30ml), US guided, using pectoralis block technique.
45960673|NCT05079295|Procedure|CSDH evacuation|Burr hole for chronic subdural hematomas
45960674|NCT00184119|Procedure|Psychiatric Intensive Care Unit|
45960675|NCT00184119|Procedure|Care in whole acute unit|psychiatric acute care as usual
45819567|NCT00771602|Drug|Rituximab|375 mg/m^2 by standard IV (intravenous) infusion on days 1, 8, 15, and 22 of weeks 1-4.
45455260|NCT03522454|Behavioral|Home-based supervised exercise program|WEBB (Weight-bearing Exercise for Better Balance) program combining walking and weight-bearing exercises to build strength and balance, administered by a trained therapist at the participant's home.
45455261|NCT01215019|Drug|Mannitol|20% Mannitol, 1-5 doses as needed to control ICP
45819568|NCT00771602|Drug|Alemtuzumab|Dose escalation of 3, 10 and 30 mg subcutaneously (SQ) during week 1, followed by dose of 30 mg subcutaneously three times weekly (e.g. Monday-Wednesday - Friday) starting on week 2 for a total of 12 weeks (2-13).
45819569|NCT04332146|Behavioral|Mindfulness-based program (MBI-p-R)|The MBI-p-R was developed in line with the model of Mindfulness-based Stress Reducation (MBSR) proposed by Kabat-Zinn. It will be conducted for 1.5 hours for each session, once a week for 8 weeks. There are four key operational components to be included in each session: engagement and introduction, mindfulness practices, daily life application, and consolidation of learning.
45819570|NCT04332146|Behavioral|Booklet-based psychoeducation|The participants in the control group will be provided a booklet at baseline, including general information in handling every day stress by a new mother, as well as a record for their weekly activities. The contents covered a range of topics including work-stress, balanced diet, physical exercise, sleeping quality, bonding with baby and the treatment for depression. The participants will be contacted by phone call and/or whatsapp weekly for a short talk based on the record and content on the booklet. They will also be asked to record their daily life weekly for discussion.
45960676|NCT03456544|Drug|Vancomycin|Patients who have vancomycin associated acute kidney injury will be in the Van-AKI group, and those who don't have vancomycin associated acute kidney injury will be in the none VAN-AKI group.
45960677|NCT00159887|Drug|Sildenafil citrate|
45960678|NCT00543361|Drug|MK0767|Duration of Treatment: 52 Weeks
45960679|NCT00543361|Drug|Comparator: placebo (unspecified)|Duration of Treatment: 52 Weeks
45960680|NCT00543361|Drug|Comparator: metformin|Duration of Treatment: 52 Weeks
45960681|NCT00184158|Procedure|decompression|Conservative, simple decompression and nerve transfer
45960682|NCT00543478|Drug|Saccharomyces boulardii|250mg, twice a day in sachets, for 8 weeks
45960683|NCT00543478|Drug|Methyl cellulose powder (low viscosity)|twice a day sachets for 10 weeks
45455262|NCT01215019|Drug|NaCl|3% sodium chloride injection, 1-5 doses, as needed to control ICP
45455263|NCT03795428|Drug|Pemziviptadil (PB1046) Injection|Once-weekly subcutaneous injection
45455264|NCT01116973|Other|PICC|Peripheral inserted catheter placement to take the reading
45960684|NCT05075005|Other|Treatment Cohort|Subjects will walk on a specified University of Florida Natural Area Teaching Laboratory's (NATL) nature trail for approximately 30 minutes, three times per week for 8 weeks while wearing the minimalist shoes provided by the study team. Time, distance, and GPS walking route will be recorded utilizing the MapMyRun smartphone application, which is free to download and easy to use. The study team will assist each subject with downloading the application onto their smartphone and provide a brief training on app use at their pre-trial visit. Subjects will be asked to save each training session within the app to report to the study team upon completion of the 8-week training protocol. Subjects will be instructed to walk at a comfortable pace and to stop if they begin experiencing increased pain or discomfort.
45960685|NCT05075005|Other|Control Cohort|Subjects will walk on hardscapes (e.g. sidewalk, asphalt, track, etc) for approximately 30 minutes, three times per week for 8 weeks while wearing the minimalist shoes provided by the study team. Similarly to the treatment group, subjects will be asked to utilize the MapMyRun smartphone application to record their training sessions. Subjects will be instructed to walk at a comfortable pace and to stop if they begin experiencing increased pain or discomfort.
45665011|NCT02175771|Drug|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either Fp/Sx MDPI 100/12.5 mcg or Fp/Sx MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg Fp/Sx. Study drug was administered in the morning and in the evening."
45819571|NCT00769652|Behavioral|Medical nutrition therapy|Medical nutrition therapy (MNT) refers to intervention with a registered dietitian or nutrition professional. MNT is a cyclical process which includes nutrition assessment, intervention, follow-up, and reassessment. Patients will receive a total of three (3) visits with the dietitian over a six-week period with follow-up during weeks 2-3 and weeks 6-9 based on their treatment schedule.
45960686|NCT05072158|Other|None, this is an observational study|This is a qualitative study, we will be asking for patient experiences with PFDs and the impact on their sexual function.
45960687|NCT00543517|Drug|MK0767|
45960688|NCT00159926|Procedure|Cell saver|Cell saver intraoperatively for coronary artery bypass grafting using cardiopulmonary bypass
45960689|NCT00159926|Procedure|No cell saver|Conventional suction for coronary artery bypass grafting using cardiopulmonary bypass
45960690|NCT00190788|Drug|Drotrecogin Alfa (Activated)|
45960691|NCT00190788|Drug|placebo|
45960692|NCT00543556|Drug|MK0767|
45960693|NCT00543595|Drug|MK0916|
45960694|NCT00543634|Drug|Premarin/MPA|0.625 mg/2.5 mg X4
45458266|NCT02320786|Behavioral|CoPILOT|Participants in both groups will receive twelve hours of training in a standard powered wheelchair however the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
45665012|NCT02175771|Drug|FLOVENT HFA|"FLOVENT HFA is a hydrofluoroalkane (HFA) inhaler containing fluticasone propionate.~During the treatment period, participants were randomized to either 110 mcg or 220 mcg of FLOVENT two puffs, twice a day for a total daily dose of 440 mcg or 880 mcg. Study drug was administered in the morning and in the evening."
45960695|NCT00543634|Drug|Premarin/MPA|0.625 mg/5 mg X 2
45819572|NCT00769652|Behavioral|Standard Care|"Standard nutritional care includes the National Cancer Institute's booklet Eating Hints for cancer patients: before, during & after treatment."
45819573|NCT05277818|Procedure|Surgery lumbar disc herniation|Surgery for a degenerative or traumatic mono-segmental lumbar disc herniation
45819574|NCT05246384|Drug|RP7214|RP7214 will be administered daily twice a day orally; Azacitidine will be administered from Days 1 to 7 of each 28-day cycle
45819575|NCT05238740|Other|ViviGen®|It will investigate the radiological and clinical outcome of stand-alone ALIF procedure L5/S1 using two arms/ treatments, namely either ViviGen® Bone Matrix (intervention group) or rhBMP-2 (control group). ViviGen®/ rhBMP-2 ratio will be 1:1.
45960696|NCT00543634|Drug|Provera 10 mg|2.5 mg of MPA, 4 tablets dissoved in water
45960697|NCT00160004|Behavioral|Intensive Controlled Exercise|
45960698|NCT00543673|Other|Milk based formula A|feed as per HCP directions
45960699|NCT00543673|Other|#2 Standard formula|Feed as per HCP directions
45960700|NCT00543673|Other|#3 Human Milk|Feed as per HCP directions
45960701|NCT00543673|Other|Milk based formula C|Feed as per HCP direction
45960702|NCT00184197|Drug|Botulinum toxin|
45960703|NCT00184197|Drug|Placebos|
45960704|NCT00543751|Drug|MK0767|
45960705|NCT00543790|Drug|PRA-027|PRA-027 capsules; cohort-specific doses or 40, 120, 240 or 500 mg; 1 dose daily for 28 days
45960706|NCT00543829|Drug|doxorubicin, docetaxel, tamoxifen|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion) with tamoxifen (30 mg tablet p.o. for 5 years post surgery)
45960707|NCT00543829|Drug|doxorubicin, docetaxel|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion)
45960708|NCT00543868|Drug|MK0782|
45960709|NCT00190827|Drug|duloxetine|
45960710|NCT00190827|Drug|placebo|
45960711|NCT00543946|Drug|GAP-134|24-Hour IV infusion, SAD
45960712|NCT00160043|Drug|SH T00268C|1250 mg experimental drug od
45960713|NCT00160043|Drug|PTK787/ ZK 222584|1250 mg experimental drug bid (500mg + 750mg)
45960714|NCT00544063|Drug|irinotecan hydrochloride|
45960715|NCT00544063|Drug|oxaliplatin|
45960716|NCT00184236|Behavioral|Multitreatment approach|12 months regimen consisting of group meetings every 2 weeks involving a physician, psychologist, physiotherapist and clinical nutritional physiologist. 21 h treatment during the first 3 months: 3 activity sessions (3 h) and 3 group conversations (4 h). Attendance inclusion criterium was set to minimum of 80%
45819576|NCT05238740|Other|rhBMP-2|It will investigate the radiological and clinical outcome of stand-alone ALIF procedure L5/S1 using two arms/ treatments, namely either ViviGen® Bone Matrix (intervention group) or rhBMP-2 (control group). ViviGen®/ rhBMP-2 ratio will be 1:1.
45819577|NCT03626623|Device|Cytal Wound Matrix 1-Layer|Cytal® Wound Matrix 1-Layer is composed of a porcine (pig) derived extracellular matrix known as urinary bladder matrix. It is intended for the management of a variety of wounds.The individual device is intended for one time use.
45665013|NCT02175771|Drug|ADVAIR DISKUS|"ADVAIR DISKUS contains a dry powder formulation of fluticasone propionate (Fp) and salmeterol xinafoate (Sx) in a lactose excipient.~During the treatment period, participants were randomized to Fp 250 mcg/Sx 50 mcg or Fp 500 mcg/Sx 50 mcg one inhalation, twice a day for a total daily dose of 500/100 mcg or 1000/100 mcg. Study drug was administered in the morning and in the evening."
45665014|NCT02175771|Drug|albuterol/salbutamol HFA|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
45960717|NCT00184236|Behavioral|Aerobic interval training|Walking/running 'uphill' on a treadmill twice a week for 3 months. 10 min warming-up at 70% of Hfmax before performing 4x4 intervals at 90-95% of Hfmax. 3 min active recovery at 70% of Hfmax between each interval. 5 min cool-down period, giving a total of 40 min.
45960718|NCT04684927|Device|MID-C System -Minimal invasive deformity correction system for the treatment of AIS|"A 5 years follow-up will be performed for all patients who underwent AIS repair surgery using the MID-C System. The follow-up in order to assess safety and efficacy measurments. Eligible Patients will be followed and assessed at the following time points: Immediate Post-op up to 6 weeks, 6 months, 12 months, and then annually out to 5 years post-implantation.~During the study, the following rating scales and assessments will be conducted to assess the probable benefit and safety of the treatment: Physical exam,X-rays,Cobb angle measurements,Adverse Events (AEs) and Scoliosis research society (SRS-22) questionnaire: The questionnaire is commonly used to assess health related quality of life in children with AIS."
45960719|NCT00160082|Drug|Xepol|
45960720|NCT00544180|Drug|Risedronate|
45960721|NCT00544219|Biological|rituximab|375 mg/m2 i.v. per cycle
45960722|NCT00544219|Drug|cyclophosphamide|750 mg/m2 i.v. per cycle
45960723|NCT00544219|Drug|doxorubicin hydrochloride|50 mg/m2 i.v. per cycle
45665015|NCT01657799|Drug|Veliparib|Veliparib capsules for oral administration
45819578|NCT03626623|Other|Standard of Care (SOC)|Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds. SOC associated procedures and policies may vary across clinical settings.
45819579|NCT05149742|Behavioral|Cognitive and audiometry evaluation|"For both Patients and controls:~Cognitive functions evaluation~Tonal and vocal audiometry~Self questionnaires"
45960724|NCT00544219|Drug|prednisone|100 mg/day p.o. per cycle
45960725|NCT00544219|Drug|vincristine sulfate|1.4 mg/m2 (max. 2.0 mg) i.v. per cycle
45960726|NCT00544219|Procedure|positron emission tomography|PET Scan during treatment
45960727|NCT00190866|Drug|Duloxetine|
45665016|NCT01657799|Drug|Placebo|Placebo to veliparib capsules for oral administration
45665017|NCT01657799|Radiation|Whole brain radiation therapy|30.0 grays (Gy) of WBRT given in 10 daily fractions of 3.0 Gy each, excluding weekends and holidays
45819580|NCT01804166|Drug|Infliximab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive infliximab as instructed by their personal physicians.
45819581|NCT01804166|Drug|Golimumab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive golimumab as instructed by their personal physicians.
45819582|NCT04459585|Drug|Dabigatran Etexilate Mesylate|Single oral 150 mg capsule dose
45960728|NCT00190866|Drug|placebo|
45960729|NCT00544258|Drug|PEP005|
45960730|NCT00160121|Drug|Lanthanum carbonate|
45960731|NCT00544336|Other|questionnaire administration|no intervention
45960732|NCT00544336|Other|survey administration|no intervention
45960733|NCT00544336|Procedure|quality-of-life assessment|no intervention
45960734|NCT00544375|Device|Optical measurement|Optical measurement neonatal tissues
45960735|NCT00160160|Drug|eprosartan/HCTZ|
45960736|NCT00544453|Drug|[123I] MNI-308|Injection of [123I] MNI-308 and SPECT scanning
45665018|NCT05249777|Drug|TD0069 hard capsule|TD0069 hard capsule (800 ± 7.5% mg/capsule) contains 600 mg fine powder of mixed herbal medicines and 200 mg excipients.
45819583|NCT04459585|Drug|Quizartinib|Single oral 60 mg dose of quizartinib administered as two 30 mg tablets (26.5 mg free base per tablet)
45960737|NCT00544492|Device|catheter for AV fistula cannulation|catheters for buttonhole technique (blunt, bevel point), catheters for rope ladder technique (sharp, bevel point or sharp, cylindrical point)
45960738|NCT00544570|Biological|filgrastim|
45960739|NCT00544570|Drug|carmustine|
45960740|NCT00544570|Drug|cyclophosphamide|
45960741|NCT00544570|Drug|etoposide|
45960742|NCT00544570|Drug|melphalan|
45960743|NCT00544570|Procedure|autologous hematopoietic stem cell transplantation|
45960744|NCT00544570|Procedure|peripheral blood stem cell transplantation|
45960745|NCT00544570|Radiation|radiation therapy|
45960746|NCT00544570|Radiation|total-body irradiation|
45960747|NCT00190905|Drug|duloxetine HCl|
45960748|NCT00544609|Drug|Sorafenib|Level 1: 200 mg/day Level 2: 400mg/day Level 3: 800mg/day
45960749|NCT00544609|Procedure|Radiotherapy|3th-8th week: sorafenib daily with radiotherapy day 1, 2, 3, 4 and 5, 9th week: sorafenib daily with radiotherapy day 1 and 2
45960750|NCT00544687|Drug|CRx-191|topical (mometasone furoate + nortriptyline HCl)
45960751|NCT00544687|Drug|mometasone furoate|topical mometasone furoate
45960752|NCT00544687|Drug|nortriptyline HCl|topical nortriptyline HCl
45960753|NCT00544687|Drug|Karison® Creme|topical Karison® Creme (clobetasol-17-propinate 0.05%)
45960754|NCT00544687|Drug|Vehicle|topical (placebo)
45960755|NCT00544726|Behavioral|Physical training|
45960756|NCT00544726|Behavioral|No training|
45960757|NCT00160238|Drug|Betahistine 24 mg bid (Betaserc)|
45960758|NCT00544765|Drug|TAC|Docetaxel 75 mg/m² as a 1 hour i.v. infusion on day 1 every 3 weeks in combination with Doxorubicin 50 mg/m² as an i.v. bolus and Cyclophosphamide 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks
45960759|NCT00544765|Drug|NX|Vinorelbine 25 mg/m² as a < 10 min i.v. infusion on days 1 and 8 repeated every 3 weeks and Capecitabine 2000 mg/m² orally in 2 daily doses on days 1-14 repeated every 3 weeks
45960760|NCT00544804|Drug|lapatinib ditosylate|
45960761|NCT00544804|Genetic|gene expression analysis|
45960762|NCT00544804|Other|diagnostic laboratory biomarker analysis|
45960763|NCT00544921|Drug|GLY-230|
45960764|NCT00544921|Other|Placebo|No drug administered
45960765|NCT00160277|Drug|Moxonidine|
45458267|NCT04462666|Drug|Huzhang granule|Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
45819584|NCT05080556|Drug|Carboplatin|Treatment in both arms will be administered intravenously (IV) every 21 days (q21D) and for a maximum of 6 cycles in Arm 1 and 12 cycles in Arm 2.
45819585|NCT00746018|Device|LigaSure vessel sealing system|The investigators intend to enroll a total of 60 patients planned to undergo a total hysterectomy and bilateral salpingo-oophorectomy. There will be two techniques compared in this protocol. The first 30 patients will have the right tube removed with one application of the LigaSure. The LigaSure will be placed and the most proximal portion of the right fallopian tube adjacent to the uterine cornua and will be used to coagulate and cut the tube. The next 30 patients will have the tube ligated in the same fashion as group A however an additional step will be added once the fallopian tube has been removed. The LigaSure will be used to cauterize the remaining medial tissue on the cornua region of the uterus.
45819586|NCT04451707|Other|non-cholera Vibrio infection|Epidemiology of patients diagnosed with non-cholera Vibrio infection
45819587|NCT01797380|Drug|Placebo|Placebo daily for duration of double-blind portion of trial
45819588|NCT01797380|Drug|Escitalopram|Escitalopram 10 mg po daily for duration of double-blind portion of trial
45819589|NCT03571555|Behavioral|Sentebale Psychosocial Programme|Residential interventions (camps) for the young people, and community based support (clubs) for the young people and the caregivers.
45819590|NCT00737594|Drug|Placebo|Matching placebo capsules for oral administration
45960766|NCT02963181|Drug|Yohimbine|Oral Yohimbine will be used to identify the integrity of post-ganglionic sympathetic nerves in patients with NOH
45960767|NCT02963181|Drug|Melatonin|"Monitor the effects of melatonin on supine hypertension in NOH patients with intact and denervated post-ganglionic nerves.~Identify the mechanistic pathway of melatonin in blood pressure regulation"
45458268|NCT04462666|Drug|Etoricoxib|take one capsule per day in the morning, at approximately 30 minutes after the meal.
45458269|NCT04462666|Drug|Huzhang granule Placebo|Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
45819591|NCT00737594|Drug|Cobiprostone|Cobiprostone capsules for oral administration
45819592|NCT00732680|Drug|Botulinum Toxin Type A|10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
45819593|NCT04441255|Drug|TAK-788|TAK-788 Capsule.
45819594|NCT00726830|Drug|methadone hydrochloride|Given orally
45819595|NCT00726830|Drug|morphine sulfate|Given orally
45819596|NCT00726830|Drug|oxycodone hydrochloride|Given orally
45819597|NCT03628885|Behavioral|Top Concern Tailored Intervention|General Vaccine Information video plus a brief (< 50 sec) animated video address the parent's top ranked question or concern from the provided list of possible concerns.
45819598|NCT03628885|Behavioral|All Concerns Tailored Intervention|General Vaccine Information video plus one or more brief (< 50 sec) animated videos that address all of the parent's indicated question or concern from the provided list of possible concerns.
45960768|NCT00544999|Drug|cytarabine|
45960769|NCT00544999|Drug|daunorubicin hydrochloride|
45960770|NCT00544999|Drug|everolimus|
45960771|NCT00544999|Other|laboratory biomarker analysis|
45960772|NCT00544999|Other|pharmacological study|
45960773|NCT00545116|Other|Hesperidin|250 mg of hesperidin twice a day taken oraly in a biscuit or in milk for 6 months
45960774|NCT04684771|Dietary Supplement|MYOSTIM®|Food supplement n° NCT 2485/8 (Red fruits flavor bar) and NCT 2485/7 (Black chocolate flavor bar) delivered by the Federal Public Service, Health, Food chain safety and environment.
45960775|NCT04684771|Dietary Supplement|PLACEBO|Bars with no active ingredient and the same flavor (chocolate and red fruits).
45960776|NCT00160316|Drug|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone|p.o. daily
45960777|NCT00545194|Drug|Prostaglandin E2|
45960778|NCT00190944|Drug|Teriparatide|
45960779|NCT00190944|Drug|placebo|
45960780|NCT03456505|Behavioral|Mindfulness Meditation Training|A researcher will guide participants through 5 mindfulness meditations, each lasting 11 minutes in length.
45960781|NCT03456505|Behavioral|Active Listening|A researcher will read participants 5 selections from The Natural History of Selborne, each lasting 11 minutes in length.
45960782|NCT03456466|Drug|TQB2303|375mg/m2 ，iv
45960783|NCT03456466|Drug|Rituximab|375mg/m2 ，iv
45960784|NCT03456388|Drug|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
45960785|NCT03456388|Drug|placebo enteric-coated tablets|There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
45960786|NCT03456349|Drug|HTL0018318|HTL0018318
45960787|NCT03456349|Drug|Placebo|Placebo
45960788|NCT00160355|Procedure|Hematopoietic stem cell transplantation|To determine the safety in regards to engraftment and toxicity within 100 days of infusing a haploidentical T- and B-cell depleted hematopoietic stem cell graft into patients with Wiskott-Aldrich syndrome who have received a reduced intensity conditioning regimen.
45960789|NCT00160355|Device|Miltenyi CliniMACS selection system|This system depletes the hematopoietic stem cell graft of T and B lymphocytes.
45960790|NCT00160355|Drug|Fludarabine, Melphalan, Thiotepa|Participants will receive a reduced intensity conditioning regimen consisting of Fludarabine, Melphalan, Thiotepa, and OKT3 prior to receipt of the haploidentical stem cell graft. Rituximab will be given in an effort to prevent PTLPD. In addition to T-cell depletion of the donor product, cyclosporine will be given for GVHD prophylaxis.
45960791|NCT03456310|Diagnostic Test|transperineal ultrasound|"trans-perineal US: B mode capable 2D ultrasound system with cine loop function, a 3.5-6.0 MHz curved array transducer. A mid-sagittal and axial views is obtained by placing a transducer on the perineum (Parting of the labia can improve image quality).~Dynamic MRI:~Magnetic resonance (MR) imaging of the pelvic floor is a two-step process that includes:~analysis of anatomic damage on axial fast spin-echo (FSE) T2-weighted images. then sagittal and coronal (FSE) T2-weighted are obtained.~functional evaluation using sagittal dynamic single-shot T2-weighted sequences during straining and defecation."
45819599|NCT00691652|Biological|rituximab|Administered weekly times 4 weeks and then monthly during the study for up to 8 cycles and will be given on day 1 of clofarabine. A peripheral or central intravenous (IV) line will be established. The initial dose rate at the time of the first infusion should be 50/mg/hr for the first hour. If no toxicity is seen, the dose rate may be gradually escalated (50 mg/hr increments at 30 minute intervals) to a maximum of 300 mg/hr. If the first dose of rituximab is well tolerated, the starting flow rate for the administration of subsequent doses will be 100 mg/hr then gradually increased (100 mg/hr increments at 30 minute intervals) not to exceed 400 mg/hr.
46079493|NCT05213039|Other|assessments|All of the children with cerebral palsy will be assessed by two different physiotherapist observers. The timed 360° turn test, Expanded and revised Gross Motor Function Classification System (GMFCS-E&R) for functional motor levels of the subjects, lower extremity muscle tone will be measured with the Modified Ashworth Scale (MASH) at the beginning of the one-time study and recorded. Pediatric Berg Balance Scale, Timed Up and Go Test, Pediatric Functional Reaching test and Modified Four Square Stepping Test, 3m walking back test (3MGYT) will be performed.Evaluations will be made by two separate physiotherapists with at least 5 years of experience in this field. The time it took for individuals to complete activities during the tests with a stopwatch will be recorded.
45458270|NCT04462666|Drug|Etoricoxib Placebo|take one capsule per day in the morning, at approximately 30 minutes after the meal.
45458499|NCT03494140|Device|Viscontour® Serum Med|Viscontour® Serum Med is a CE-certified preservative-free isotonic solution containing 5.0 mg sodium hyaluronate.
45665019|NCT05249777|Drug|TD0069 Placebo|TD0069 placebo (800 ± 7.5% mg/capsule) contains excipients
45819600|NCT00691652|Drug|clofarabine|Phase 1 dosing: Initially, 3 patients will be enrolled into a dose level during the dose escalation portion. Level 1: 2mg fixed dose times 14 days for up to 8 cycles. Level 2: 4mg fixed dose times 14 days for up to 8 cycles. Level 3: 6mg fixed dose times 14 days for up to 8 cycles. Phase II dosing: The phase II dose of oral clofarabine will be determined from the phase 1.
45665020|NCT02116803|Drug|dovitinib|Dovitinib was available in two formulations: capsules of 100 mg strength, and tablets of 100 mg strength and taken orally.
45819601|NCT00691652|Genetic|DNA methylation analysis|We will use an HPLC assay developed by Yu et al31 to determine the DNA methylation (DMI) index in peripheral blood and bone marrow of patients entering this trial and after treatment with clofarabine and rituxan
45819602|NCT00691652|Genetic|gene expression analysis|Total RNA will be processed for determination of gene expression by microarray
45960792|NCT00545311|Drug|NVA237|
45960793|NCT00545311|Drug|NVA237|
45960794|NCT00545311|Drug|NVA237|
45960795|NCT00545311|Drug|NVA237|
45960796|NCT00545311|Drug|Placebo|
45960797|NCT00545350|Other|Fall prevention exercise program|"Weekly physical exercise sessions in small groups, led by a qualified and specially trained instructor, and supplemented by simple exercises to do at home.~The exercise program will focus on progressive balance retraining but will also include strength/resistance, coordination and flexibility training exercises."
45960798|NCT00160394|Drug|Duac® Gel / Differin® Gel|
45960799|NCT04684693|Device|Laser|Laser puncture and exercise
46079494|NCT05211804|Drug|Ophthalmic Drugs|Patients will receive the same treatment as if not a part of the project
45665021|NCT02116803|Drug|fulvestrant|Fulvestrant is generally available as solution for injection in pre-filled syringes containing 250 mg of fulvestrant in 5 mL solution.
45665022|NCT05201027|Device|trifocal intraocular lens|cataract extraction and implantation of a posterior chamber trifocal intraocular lens
45665023|NCT05156411|Other|eccentric arm-cranking training|Over the twenty training sessions, able-bodied participants will exercise on the KREHA device. An arm-crank has to be decelerated, which will be rotated by a prematurely defined revolution rate and training duration. During this intervention a certain power has to be applied. During the whole time of training a continous progression in power and training duration is applied
45665024|NCT05248919|Drug|undefined|Sofosbuvir (400mg/day) and Velpatasvir(100mg/day)
45960800|NCT04684693|Procedure|Control|Exercise
45960801|NCT00191022|Drug|LY686017|
45960802|NCT00191022|Drug|paroxetine|
45960803|NCT00191022|Drug|placebo|
45960804|NCT00545389|Drug|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
45960805|NCT00545428|Procedure|Rhinoplasty|Mastoid bone autograft for dorsal nasal augmentation
45960806|NCT00545467|Drug|Aripiprazole|Aripiprazole will be given as a fixed does, 15 mg/day, orally throughout 8 weeks in the 2 arms.
45960807|NCT00160433|Drug|Asoprisnil|0.5 mg Tablet, oral Daily for 12 weeks
45960808|NCT00160433|Drug|Asoprisnil|1.5 mg Tablet, oral Daily for 12 weeks
45960809|NCT00160433|Drug|Asoprisnil|5.0 mg Tablet, oral Daily for 12 weeks
45960810|NCT00160433|Drug|Placebo|Tablet, oral Daily for 12 weeks
45960811|NCT00184392|Procedure|debridement or saline irrigation|debridement of crusts, blood and secretions from the nose 1 week and 2 weeks after surgery
45960812|NCT00545545|Biological|Safety and efficacy of escalating doses|Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle) and irinotecan on Day 1 of each week for 4 weeks with a 2-week rest. Number of Cycles: until progression or unacceptable toxicity develops.
45819603|NCT00691652|Genetic|microarray analysis|we will scan the microarray slides with an Axon scanner, and quantify data using the GeneSight software. Local background is subtracted and data points with no signal, high background, or spot asymmetry are eliminated. We will adjust genes with low expression and low signal intensity to a minimal raw value of 5: This avoids unwarranted mathematical distortions due to division by decimals << 1. After calculating the ratio of the Cy5 /Cy3 fluorescence signal intensity for each gene, we normalize the data relative to the mean intensity from all genes.
45960813|NCT00545545|Biological|Safety and efficacy of escalating doses.|Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle). Number of Cycles: until progression or unacceptable toxicity develops.
45819604|NCT00691652|Genetic|polymerase chain reaction|
45960814|NCT00545701|Biological|A/H5N1 inactivated, split-virion influenza virus|0.5 mL, Intramuscular
45960815|NCT00545857|Drug|pioglitazone|Pioglitazone daily; dose varies with size
45960816|NCT00545857|Drug|Placebo control|Comparison of pioglitazone vs. placebo on the outcome of type 1 diabetes mellitus
46079495|NCT05210504|Drug|L-Lysine|5g L-lysine in 50ml water, administered orally
46079496|NCT05210504|Drug|Normal Saline|Normal (0.9%) Saline
45458271|NCT05170477|Procedure|apical patency|In Gp A, apical patency will be maintained till obturation using electronic apex locator confirmed radiographically. Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration.
45960817|NCT00160472|Procedure|removal of ovarian vessels|
45960818|NCT00545896|Procedure|Extracorporeal shockwave therapy|Extracorporeal application of shockwaves on the surface of chronic wounds.
45960819|NCT00184431|Behavioral|Physical therapy technique and exercises|The experimental group receives task specific physical therapy three times a week for the first four weeks after discharge from hospital and one session pr week for the next eight weeks in addition to ordinary physical therapy The active comparator group receives only ordinary physical therapy during this period.
45960820|NCT00545935|Drug|Methylenblue-Amodiaquine (MB-AQ)|For 3 days twice daily 10 mg/kg MB accompanied by once daily 10 mg/kg AQ
45960821|NCT00545935|Drug|Methylenblue-Artesunate (MB-AS)|3 days once daily 4 mg/kg AS accompanied by twice daily 10 mg/kg MB given over 7 days
45960822|NCT00545935|Drug|Artesunate-Amodiaquine (AS-AQ)|For 3 days once daily 10 mg/kg AQ accompanied by 4mg/kg AS.
46079497|NCT05205954|Behavioral|Hepatology Home Hospital|The Hepatology Home Hospital intervention entails the following: patient-reported symptoms and vital signs with appropriate triggers for phone calls and home visits, and regular communication with hepatology clinicians regarding care delivered at home to ensure continuity of care.
45960823|NCT05057260|Other|No drug invervention|No clinical trial
45960824|NCT00160511|Drug|Levetiracetam|
45960825|NCT00191061|Drug|duloxetine hydrochloride|
45960826|NCT05047237|Behavioral|Pharmacist-Led Optimization Intervention|Educational information mailed to participants and up to three pharmacist visits.
46079498|NCT05197140|Other|food: cooked 85% lean ground beef|see arm description
45960827|NCT00160550|Drug|Levetiracetam|
45960828|NCT00160589|Drug|Levocetirizine|
45960829|NCT00546130|Drug|Irinotecan hydrochloride|"Irinotecan hydrochloride 60 mg/m2, IV (in the vein) on days 1, 8, 15 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
45960830|NCT00546130|Drug|Cisplatin|Cisplatin 60 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
45960831|NCT00546130|Drug|Krestin|Krestin 3,000 mg, PO everyday until progression or unacceptable toxicity develops.
45960832|NCT00191178|Drug|insulin lispro protamine suspension:insulin lispro rDNA origin low mix|
45960833|NCT00191178|Drug|insulin glargine|
45960834|NCT00546169|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|haemorrhages in cholecystectomy
45960835|NCT04684342|Diagnostic Test|Routine Laboratory investigations|"Complete blood picture~Liver function test and prothrombine time & concentration.~Blood urea and creatinine~Blood glucose, serum Na and K~CRP and ESR~Clinical specimens will be collected from patients according to the suspected site of infection (e.g. blood, urine, ascitic fluid, sputum or endo- tracheal aspirates) VITEK 2Compact inflammatory markers"
45960836|NCT00160628|Drug|Levetiracetam|
45960837|NCT00546286|Drug|dorzolamide hydrochloride (+) timolol maleate|"Combination treatment of dorzolamide HCl (2%)/ timolol maleate (0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients who achieve target IOP at 6 weeks, dorzolamide/timolol is continued for another 6 weeks."
46079499|NCT05197140|Other|food: Impossible Burger (R)|see arm description
46079500|NCT05162729|Behavioral|Game-like online working memory training|Participants in the WM group will be receiving two types of WM training tasks (two mini-games) in each session. Half of the training time will be spent on playing a game that requires visual-spatial WM, and the other half of the training time will be spent on playing a game that demands verbal WM. In both the games, the participant is asked to remember the pictures or audios (numbers) presented, and then recall them and select them on the screen.
45960838|NCT00546286|Drug|Comparator: dorzolamide HCl/timolol maleate + prostaglandin|"Combination treatment of dorzolamide HCl (2%)/timolol maleate(0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients not achieving target IOP at 6 weeks, a prostaglandin is added for another 6 weeks."
45960839|NCT00184509|Behavioral|integrated psychosocial treatment (behavior)|
45960840|NCT00546325|Drug|Rimonabant|White opaque film-coated, for oral administration containing 20 mg of active rimonabant. Once daily before breakfast
45960841|NCT00546325|Drug|Placebo|Matching placebo tablets. Once daily before breakfast
45960842|NCT00546403|Drug|Modafinil|Adjunctive treatment with titrated dose of modafinil
45960843|NCT00546403|Drug|Placebo|Adjunctive treatment with placebo
45665025|NCT02115321|Drug|Grazoprevir|GZR was supplied as two 25 mg tablets in the Part A CP-B arm, or as either one GZR 100 mg tablet or one fixed-dose combination (FDC) tablet containing GZR 100 mg + EBR 50 mg in a single tablet (MK-5172A) in the Part A NC arm. GZR was taken q.d. by mouth.
45960844|NCT00546442|Drug|Metformine|850-2550 mg/daily for 48 weeks
45960845|NCT00546442|Other|Placebo of metformine|850-2550 mg/daily for 48 weeks
45960846|NCT00191256|Drug|Gemcitabine|
45960847|NCT00191256|Drug|Carboplatin|
45960848|NCT00191256|Drug|Paclitaxel|
45960849|NCT00546520|Drug|Ciclesonide|
45960850|NCT00546559|Drug|statins (simvastatin, pravastatin)|
45960851|NCT00160745|Drug|Rosuvastatin|
45960852|NCT00546676|Drug|Telithromycin|
45960853|NCT00546832|Drug|TDS-943 (topical diclofenac sodium 4% spray)|
45665026|NCT02115321|Drug|Elbasvir|EBR was supplied as 50 mg tablets and was taken q.d. by mouth.
45665027|NCT02115321|Drug|MK-5172A|MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.
45665028|NCT05200325|Other|Educational materials for TissueCypher|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
45960854|NCT00546832|Drug|celecoxib|
45960855|NCT00546832|Other|placebo|
45960856|NCT02963532|Other|We are observing criteria present at extubation|We will not be performing any intervention. We will only be observing what clinical data is present at the time of extubation and how predictive are different pieces of clinical data.
45960857|NCT00160784|Procedure|Arthroscopy|Randomized placement into 2 groups; arthroscopic manipulation or home therapy
45960858|NCT00160784|Procedure|Arthroscopic manipulation|Manipulation of shoulder performed during arthroscopy
45960859|NCT00160784|Other|Home therapy|Shoulder exercise program performed at home that may increase shoulder function
45665029|NCT05248841|Drug|HEC-Glargine|Subjects will receive 0.5 IU/kg of HEC-Glargine subcutaneously as a single morning dose on Day 1.
45960860|NCT00546949|Procedure|Minimal invasive decompression|foraminotomy, laminotomy, microscopic decompression
45960861|NCT00546949|Procedure|Interspinous Process Decompression (IPD)|Interspinous device
45960862|NCT00546988|Biological|allogeneic stem cell transplant|
45960863|NCT00184587|Drug|candesartan cilexetil|
45960864|NCT00184587|Drug|placebo|
45960865|NCT00160823|Procedure|Self-administered leaflet|
45960866|NCT05015764|Other|Fluid Management|Removal of excess extracellular fluid using diuretics
45960867|NCT05015764|Device|Reprieve Cardiovascular System|System with Fluid Management Module
45960868|NCT05012956|Procedure|Laparoscopic sacrocolpopexy|During laparoscopic sacrocolpopexy, the anatomical position of the vaginal vault and cervix (if present) is restored by suturing a surgical mesh to the vaginal cuff or cervix and variable portions of the anterior and posterior vagina, while connecting the other end of the mesh to the anterior longitudinal ligament over the sacrum.
45960869|NCT05012956|Procedure|gynecologic laparoscopic surgery|Gynecologic laparoscopic surgery at UZ Leuven, other than sacrocolpopexy
45960870|NCT00547027|Behavioral|print-based physical activity intervention|individually-based, print-based physical activity intervention
45960871|NCT00547027|Behavioral|usual care|print-based materials of nutritional information
45960872|NCT00547144|Drug|Gemcitabine|1000 mg/m2 intravenoulsy once a week according to protocol schedule
45960873|NCT00547144|Procedure|Dendritic Cell Immunotherapy|The cells will be administered by intratumoral injection on 2 different days(at least 21 days apart)
45960874|NCT00547183|Drug|tadalafil|2.5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
45960875|NCT00547183|Drug|tadalafil|5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
45960876|NCT00547183|Drug|placebo|Placebo tablet taken by mouth once a day, no more than 1 dose per day, for 12 weeks
45960877|NCT00547261|Drug|SSR97225|every 3 weeks
45960878|NCT00184626|Drug|biphasic insulin aspart|
45960879|NCT00184626|Drug|insulin glargine|
45960880|NCT00184626|Drug|metformin|
45960881|NCT04684186|Procedure|Endovascular fiducial marker insertion|Fiducial markers will be inserted using an endovascular route
45960882|NCT04684186|Procedure|Bronchoscopic fiducial marker insertion|Fiducial markers will be inserted using an endoscopic route
45960883|NCT00547417|Drug|tadalafil|20 mg tadalafil tablet taken by mouth, as needed, no more than once a day, for 12 weeks.
45960884|NCT00160862|Drug|SLV317|
45960885|NCT00191295|Drug|Atomoxetine|
45960886|NCT00191295|Drug|Placebo|
45960887|NCT00547495|Drug|tadalafil|5 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
45960888|NCT00547495|Drug|placebo|placebo tablet taken by mouth, as needed, no more than 1 dose per day, for 12 weeks
45665030|NCT05248841|Drug|US-Lantus|Subjects will receive 0.5 IU/kg of Lantus subcutaneously as a single morning dose on Day 1.
45665031|NCT05248139|Drug|Intraoperative delivery of medication, Kenalog (Triamcinolone)|Subconjunctival triamcinolone acetonide 4 mg (0.4 mL of 10 mg/mL solution), single-dose injected 6-8 mm inferior to the inferior limbus with a bent 27-gauge needle at completion of cataract surgery.
45665032|NCT05248139|Drug|Topical post-operative eyedrops, Prednisolone acetate|Standard of care Presnisolone acetate 1% ophthalmic drop taper: 4 times per day for first week, then tapering one drop per week for 3 additional weeks. Discontinued after 4 weeks.
45665033|NCT04230239|Drug|CPX-351|"CPX-351 has IV administration Vyxeos contains 2.2 mg/mL and 5 mg/mL powder for concentrate for solution for infusion of Daunorubicin and cytarabine.~Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine. After reconstitution, the solution contains 2.2 mg/mL daunorubicin and 5 mg/mL cytarabine"
45665034|NCT05199389|Device|Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)|MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.
45665035|NCT05247125|Combination Product|Blue light exposure + Melatonin treatment|3 mg Melatonin pill will be given 1 hour before going to bed. Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.
45665036|NCT05247125|Drug|Melatonin treatment|3 mg Melatonin pill will be given 1 hour before going to bed.
45665037|NCT05247125|Device|Blue light exposure|Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.
45819605|NCT00691652|Other|high performance liquid chromatography|Fifteen µg of DNA will be sonicated for 60 seconds on ice into 200 bp-1000 bp fragments. Samples are then denatured at 1000C for 5 minutes and cooled on ice to prevent re-annealing. Sixty units of nuclease S1 (Invitrogen) and 112.5 mu of snake venom phosphodiesterase I (Sigma) in 12 µl of S1 dilution buffer is then added to the samples and incubated at 370C for 18 hours. Samples are reheated to 1000C for 5 minutes, snap cooled again on ice, and another sixty units of nuclease S1 and 112.5 mu of snake venom phosphodiesterase I are added and incubated at 370C for another 4 to 6 hours. The pH of each sample was raised to 8.5 with 0.5 M Tris, pH 10. Two and a half units of alkaline phosphatase (Sigma) are added and incubated for 2 additional hours at 370C. One hundred µl of 0.05M potassium phosphate, pH 7 is added to final samples before 50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
45819606|NCT00691652|Other|laboratory biomarker analysis|50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
45819607|NCT00691574|Dietary Supplement|Melatonin|up to 3 mg, daily, for up to 1 year
45819608|NCT00691574|Device|Enviro-light artificial light box|Subjects will sit in front of an artificial, fluorescent light box (10,000 lux) while completing 25-hours of hourly plasma samples. The light lux level will be well below that identified as safe by the FDA.
45960889|NCT00547495|Drug|tadalafil|10 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
45960890|NCT00547495|Drug|tadalafil|20 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
45960891|NCT02277223|Dietary Supplement|Curcumin|"Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is >35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin."
45665038|NCT05247125|Combination Product|Placebo|Placebo light exposure will be performed by using lamp turned off; and placebo pill will be given in the evening
45665039|NCT05154851|Biological|HB-adMSCs|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
45819609|NCT03631927|Other|Observation|Observation
45819610|NCT00685880|Drug|Prolotherapy (10% dextrose solution)|Dextrose diluted with sterile water.
45960892|NCT02277223|Drug|Placebo|"Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is >35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin."
45819611|NCT00685880|Drug|Betamethasone|CELESTONE® SOLUSPAN® * (betamethasone injectable suspension) Injectable Suspension is a sterile aqueous suspension containing 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. Subjects will receive a 0.25 to 0.5 mL Celestone Soluspan injection.
45819612|NCT00681044|Biological|filgrastim|16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
45819613|NCT00681044|Drug|melphalan|70-100 mg/m2/day will be administered intravenously on Days -3 and -2
45819614|NCT00681044|Procedure|Stem Cell Infusion|infusion of previously collected stem cells on Day 0
45819615|NCT03632083|Device|Hy-Care Contact Lens Solution|Hy-Care Contact Lens Solution
45819616|NCT03632083|Device|Lite Contact Lens Solution|Lite Contact Lens Solution
45665040|NCT05245955|Device|Assessments of the hand sensory function with the ReHapticKnob|During the assessment sessions with the ReHapticKnob, subjects sit comfortably on a chair in front of a screen and place the fingers of the hand on the handles of the device. The different assessments consist of moving the hand or forearm of the subjects to two different positions and asking the subject to discriminate between them (discrimination thresholds for the amplitude of grasping and forearm pronosupination positions), of passively moving the hand or forearm of the subject at low velocities and asking the subject to say when he/she detects the movement (detection thresholds for passive movements), or of rendering two objects with different stiffness and asking the subject to discriminate between them (discrimination thresholds for the stiffness of objects pinched with the hand).
45665041|NCT05154383|Biological|Experimental arm : High-Dose Quadrivalent Influenza Vaccine (Efluelda)|Patient will received one dose of High Dose Quadrivalent Influenza Vaccine according to marketing authorization.
45665042|NCT05154383|Biological|Active Comparator: Standard-Dose Quadrivalent Influenza Vaccine|Patient will received one dose of Standard Dose Quadrivalent Influenza Vaccine according to marketing authorization.
45665043|NCT05196815|Other|Ultrasound|Participants will have a routine ultrasound of the heart (echocardiogram) before the procedure. During this test we will take a few extra measurements, this will not add any significant time to the scan
45819617|NCT03632083|Device|fanfilcon A soft contact lens|fanfilcon A soft contact lens
45819618|NCT03632083|Device|comfilcon A soft contact lens|comfilcon A soft contact lens
45819619|NCT05035394|Procedure|Cataract surgery|Cataract Surgery in a standardized fashion
45819620|NCT05035394|Procedure|KDB|Goniotomy with KDB glide will be performed at the end of Cataract Surgery
45819621|NCT05035394|Procedure|Istent|Two iStent inject W will be injected into Schlemms Canal at the end of Cataract Surgery
45819622|NCT05010980|Other|CMR|clinical indication
45819623|NCT05010980|Other|scintigraphy|clinical indication
45819624|NCT03633487|Drug|Mucinex®|Mucinex® 1200 mg ER Bi-Layer tablet
45819625|NCT04933916|Drug|EMB-001|Combination product metyrapone and oxazepam
45819626|NCT04929002|Other|No intervention|No intervention
45819627|NCT03574441|Device|Tegaderm dressing + catheter support pad|Tegaderm TM is a transparent tape. This intervention adds a support pad that comes in the epidural kit to help secure the catheter
45819628|NCT03574441|Device|Tegaderm dressing + Steri-strip dressing|Tegaderm TM is a transparent tape. This intervention adds Steri Strips TM of tape to help secure the catheter
45819629|NCT03574441|Device|Tegaderm dressing only|Tegaderm TM is a transparent tape. This intervention uses only Tegaderm to secure the catheter
45819630|NCT00423020|Drug|Erythropoietin|
45819631|NCT00671606|Procedure|Intraoperative Lymphatic Mapping|Intraoperative hysteroscopic injection of patent blue dye and radiocolloid for detection of sentinel lymph nodes.
45458272|NCT05170477|Procedure|Non-apical surgery|in Gp B apical patency will not be maintained. Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration
45665044|NCT05196815|Procedure|Catheters|During the TAVI procedure 3 catheters (tubes) will be inserted into the blood vessels at the top of the participants legs as per normal standard care (there will be no extra skin punctures as part of the study).
45819632|NCT01756586|Drug|Dexamethasone|
45819633|NCT01756586|Drug|Bupivacaine|Control
45819634|NCT03636061|Drug|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
45819635|NCT03636061|Drug|Placebo (vehicle) nasal spray|Placebo
45819636|NCT04404907|Other|no intervention|This is a secondary analysis of registry data.
45819637|NCT00661466|Drug|Bupivacaine Collagen Sponge|
45819638|NCT00661466|Drug|Placebo|placebo
45819639|NCT04403113|Other|Structured neck and trunk stabilization exercises|Intensive structured neck and trunk stabilization exercises based on Neurodevelopmental therapy method-Bobath concept principles. These exercises were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.
45819640|NCT04403113|Other|Feeding and oral motor intervention strategies|Feeding and oral motor intervention strategies program were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.
45458273|NCT01359020|Drug|ibuprofen, dipyrone, acetaminophen|The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration
45458274|NCT03498586|Drug|Half-normal saline|Use of half-normal saline as an irrigant for open-irrigated ablation catheters
45819641|NCT04403113|Other|Caregiver training related to feeding|In caregiver training related to feeding; a) positioning and feeding technique during feeding, b) ensuring safety for aspiration, c) using suitable containers and ingredients, d) adjusting (adapting) food consistency properly, e) preparing small amounts of high-calorie, balanced diet and f) reducing food spillage while feeding and how to ensure efficacy for shortening the feeding time, g) providing appropriate postural and physical support for self-feeding. All of these activities were continued for 6 weeks with a home program.
45819642|NCT00639626|Drug|insulin detemir [rDNA origin] injection|Starting dose of 0.1-0.3 units/kg/day in a once daily subcutaneous injection.
45819643|NCT01718444|Drug|Progestin|
45819644|NCT01718444|Drug|Clomiphene Citrate|
45819645|NCT00641108|Drug|ADAM SPECT plus Cognitive Therapy|
45819646|NCT00641108|Drug|ADAM SPECT plus No Therapy|
45819647|NCT00638222|Other|Carvedilol and Placebo|All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
45819648|NCT00634322|Drug|glucarpidase|IV dose based on weight, two doses given for 5 minutes, 24 hours apart
45819649|NCT00634322|Drug|leucovorin|IV or po given every 6 hours
45819650|NCT00379886|Drug|Propofol Thiopental|
45819651|NCT01705106|Drug|capecitabine|Given PO
45819652|NCT01705106|Drug|celecoxib|Given PO
45819653|NCT01705106|Other|pharmacological study|Correlative studies
45665045|NCT05196815|Procedure|Soft study wire|Participants will have a soft study wire inserted to measure the pressure in the left ventricle. This step is in addition to standard care.
45665046|NCT05196815|Radiation|X-ray|Participants will have chests x-ray when the soft study wire is inserted.
45665047|NCT05196815|Drug|Dobutamine|Participants will be given a low dose infusion of dobutamine, to make the heart pump quicker and more vigorously.. This will last for approximately 5 minutes
45665048|NCT05245877|Drug|enoxaparin/tinzaparin/dalteparin|Patients randomized to the preoperative thromboprophylaxis will have their thromboprophylaxis initiated approximately 2-14 hours prior to the planned pancreatic surgery skin incision (depending on the center's current practice and logistics). Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function according to the local standard of care. A center may reduce the dose 25-50% if the dose is given very close to the skin incision (i.e. at the morning of the operation instead of the evening before the operation).
45665049|NCT05245331|Device|Peristeen® Transanal irrigation system with the conic catheter|"The High-TAI (400-1000ml) will be self-performed using the Peristeen® Transanal irrigation system with the conic catheter every 48 hours during the first two week of treatment. Then patients could change frequency and volume of TAI depending on their needs and/or preference.~The Low-TAI will be self-performed using a standard 250ml water enema every 48 hours during the first two week of treatment. Then patients could change frequency of TAI depending on their needs and/or preference."
45819654|NCT01705106|Other|laboratory biomarker analysis|Correlative studies
45819655|NCT01705106|Other|pharmacogenomic studies|Correlative studies
45819656|NCT00626444|Drug|Intravenous vitamin C|Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks.
45819657|NCT00624650|Drug|Diuresis (furosemide) part I|"Goal: Overall I/O net negative 50ml/hour~Initiation:~Continuous IV furosemide at 3mg/hour or last known protocol specified dose~Titrate up or down by 3mg/hour increments every hour as needed to establish diuresis goal~Do not exceed 30mg/hour~Furosemide Bolus:~If unable to establish adequate diuresis at maximum dose may attempt furosemide bolusing as follows~By intravenous bolus give 30, then 60, then 80, and 120 mg - one bolus dose every hour until urine output results in 1 ml/kg PBW/hr net negative fluid balance per hour~Bolusing trials may be done at will but total furosemide dose may not exceed 800mg/24hour period"
45819658|NCT00624650|Other|Fluid Bolus (crystalloid or albumin)|15 ml/kg PBW crystalloid (round to nearest 250 ml) or 25 grams albumin as rapidly as possible. Used for patients with a measured CVP<8 or measured PaOP <12mmHg in addition to concurrent urine output of <0.5 ml/kg/hr
45819659|NCT00624650|Other|Fluid Bolus (crystalloid or albumin)|"10 ml/kg PBW crystalloid (round to nearest 70ml) or 25 grams albumin as rapidly as possible.~Perform thermodilution immediately before and after and 60 minutes after each bolus. If EVLW increases > 2ml/kg PBW within 60 minutes after a bolus do not give any further boluses until next regularly scheduled measurement. This therapy is available for patients with a map < 60 or who are on vasopressors that also have a measured GEDI less than goal"
45819660|NCT00624650|Drug|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|"(may use any alone or in combination)~Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~Vasopressin - 0.04 international units/hour~Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg."
45960893|NCT02277262|Device|Biological swine dermis not cross-linked prosthesis positioning in incisional hernia prevention|The mesh placement will be preceded by the plane preparation. The subcutaneous tissue will be dissociated from the anterior rectum-muscles fascia. The retro-muscular rectum muscles plane will be dissected preparing a 5-6 cm pouch necessary to the prosthesis positioning. The mesh will be fixed with at least 8 long-lasting absorbable transfix stitched. The prosthesis will be placed with at least a 5 cm overlap. If the peritoneal plane can be sutured a Jackson-Pratt 10 suction drain will be placed under the prosthesis. A Jackson-Pratt 10 suction drain will always be placed over the prosthesis. Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. Another Jackson-Pratt 10 suction drain will be placed over the anterior fascia if the subcutaneous tissue is thick. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
45960894|NCT02277262|Procedure|Direct suture of the anterior abdominal wall fascia|Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
45960895|NCT00547573|Drug|tadalafil|10 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
45960896|NCT00547573|Drug|tadalafil|20 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
45819661|NCT00624650|Drug|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|"(may use alone or in combination)~Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~Vasopressin - 0.04 international units/hour~Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg.~In the experimental arm vasopressors are a treatment option in patients with a Mean Arterial Pressure of < 60"
45819662|NCT00624650|Drug|Dobutamine|"Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol.~Used in patients with a measured cardiac index < 2.5"
45819663|NCT00624650|Drug|Dobutamine|"Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol."
45819664|NCT00624650|Other|Concentrate all drips and nutrition|"Concentrate all drips and nutrition in order to minimize fluid volume as much as possible. Intravenous fluid to be run at keep vein open rate.~EVLW arm: Patients with a MAP > 60 and off vasopressors for >12 hours, as well as patients with a measured cardiac index >2.5 that also have a measured GEDI > goal."
45819665|NCT00624650|Drug|Diuresis (furosemide) part II|"Withhold furosemide if:~Significant hypokalemia (K+ <= 2.5 meq/L), or hypernatremia (Na+ >= 155 meq/L) occurs within last 12 hours may then be restarted if the prevailing condition no longer exists~Dialysis dependence~Oliguria (less than 0.5ml/kg/hour) with either creatinine > 3, or clinical suspicion of rapidly evolving ARF~More than 800mg has been given in less then 24 hours~Creatinine increases > 1.5 mg/dl in any 24 hour period"
45819666|NCT00624650|Procedure|Dialysis|"Need for CVVHD or intermittent hemodialysis to be determined by treating clinicians.~CVC arm: If fluid management to be accomplished with dialysis then fluid balance goals to be determined per clinicians.~EVLW arm: Fluid balance as per algorithm~When using intermittent HD it is recommended that no more than 2 liters net negative fluid is removed per dialysis session. Total fluid removal per run to be estimated by the clinicians to attain CVP or GEDI goals per algorithm."
45819667|NCT03965533|Drug|GSK2831781|GSK2831781 will be available as Dose-1 and Dose-2 as IV infusion or SC injection. Subjects will receive GSK2831781 Dose-1 IV diluted in 0.9% saline or GSK2831781 SC as multiples of Dose-2 SC.
45819668|NCT03965533|Drug|Placebo|Placebo will be 0.9% saline solution which will be administered in subjects as IV infusion or SC injection.
45819669|NCT01693484|Drug|ICG (Indocyanine Green)|Diagnostic drug used for visualisation of blood perfusion in various tissues.Administered intravenously, 2X: 1X prior to anesthesia, and 1X after tourniquet on operative extremity has been released for at least 15 minutes. When excited by laser light source, it subsequently emits at a near infrared frequency.
45819670|NCT03637699|Behavioral|Positive Psychology|5-week positive psychology intervention
45819671|NCT01690910|Device|Rifton Gait Trainer|
45819672|NCT01690910|Device|Front Wheeled Walker|
45819673|NCT00377065|Drug|raltegravir|raltegravir 400 mg P.O. bid tablet twice daily for 12 weeks
45819674|NCT00377143|Drug|Warfarin Dosing|
45819675|NCT00613886|Device|Programmable Shunt Insertion (Codman, Medtronic)|Medical Device - Shunt insertion surgery of adjustable valve and laparoscopic assistance for placement of peritoneal catheter. Patient will be brought to operating room suite where general anesthesia is induced. Patient will be placed with a small roll on shoulder, supine, on the operating room table. Patient's head will be turned with the parietal area uppermost in the field. Patient will be prepared and draped in the usual sterile fashion. Site prep includes parietooccipital area, side of neck, chest, and entire abdomen. Ventricular catheter placed and then attached to shunt valve. Catheter is then fitted over grooved blue burr hole guide. Excess catheter pulled down to pull valve into pocket on the skull. Sterile dressings applied.
45819676|NCT00613886|Behavioral|Assessments in physical therapy, occupational therapy, and speech therapy|Follow-up testing to be administered by trained Physician Assistant in the outpatient setting on an approximately monthly basis: 10m walk, timed up-and-go, Mini-Mental Status Exam, 9-hole Grooved Pegboard, Motor Visual Perception Test (MVPT), Modified Rankin Score (MRS)
45960897|NCT00547573|Drug|placebo|placebo tablet taken by mouth as needed for 12 weeks not more than once a day
45665050|NCT05245331|Device|Standard reusable enema|"The High-TAI (400-1000ml) will be self-performed using the Peristeen® Transanal irrigation system with the conic catheter every 48 hours during the first two week of treatment. Then patients could change frequency and volume of TAI depending on their needs and/or preference.~The Low-TAI will be self-performed using a standard 250ml water enema every 48 hours during the first two week of treatment. Then patients could change frequency of TAI depending on their needs and/or preference."
45665051|NCT05194475|Other|Thermogenic Ready-to-drink Beverage|Thermogenic ready-to-drink beverage, which will be ingested by the participant.
45960898|NCT00160901|Drug|two complex naturopathic add-on therapies, leaflet 5-a-day|
45960899|NCT00191373|Drug|Gemcitabine|
45960900|NCT00191373|Drug|Trastuzumab|
45960901|NCT00547612|Other|high performance liquid chromatography|
45960902|NCT00547612|Other|pharmacological study|
45665052|NCT05194475|Other|Placebo Ready-to-drink Beverage|Placebo ready-to-drink beverage, which will be ingested by the participant.
45665053|NCT05245175|Other|Sodium chloride particles|Patients are exposed to sodium chloride particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
45960903|NCT00547612|Radiation|[18F]-labeled substance P antagonist receptor quantifier|
45960904|NCT00547690|Other|Acupuncture and Strengthening|Acupuncture and strengthening
45960905|NCT00547690|Other|Strengthening Alone|Strengthening training program
45960906|NCT00547768|Drug|Fexofenadine HCI|
45960907|NCT00547807|Other|Non-nutritive sucking|Non-nutritive sucking is applied by using a gloved finger
45960908|NCT00547807|Other|Swaddling|Swaddling is an age-old practice of wrapping infants snugly in swaddling cloths, blankets or similar cloth so that movement of the limbs is tightly restricted
45960909|NCT00184665|Drug|insulin detemir|
45960910|NCT00184665|Drug|insulin NPH|
45960911|NCT00184665|Drug|insulin aspart|
45960912|NCT00547846|Drug|PDC-748|
45960913|NCT04983238|Drug|BYON5667 & SYD985|Ocular administration: BYON5667, Intravenous administration: SYD985
45665054|NCT05245175|Other|Lactose particles|Patients are exposed to lactose particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
45665055|NCT05245175|Other|Clean air|Patients are exposed to clean air for 4 hours in the Fraunhofer Allergen Challenge Chamber.
45665056|NCT05245175|Other|Sodium chloride particles with house dust mite|Patients are exposed to sodium chloride particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
45665057|NCT05245175|Other|Lactose particles with house dust mite|Patients are exposed to lactose particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
45819677|NCT03947983|Behavioral|Sensor-controlled digital game (SCDG)|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid rehospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal HF health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback (e.g., reduce fluid intake or call doctor for weight gain) to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
45819678|NCT03947983|Behavioral|Sensor Only|Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). This group will also be provided with standardized evidence-based HF educational material.However, the data from the Withings sensors will not be routed to the SCDG.
45819679|NCT00610532|Drug|phenytoin|intravenous phenytoin (15 mg/kg) single dose
45819680|NCT00610532|Drug|phenytoin and probenecid|intravenous phenytoin (15 mg/kg) single dose and oral probenecid 2000 mg single dose
45819681|NCT01669148|Device|Tomosynthesis|The mean glandular radiation dose for each image will be approximately 145 millirads (mrad) for a standard size breast (4.2 cm compressed breast thickness).
45819682|NCT01669148|Device|Conventional|conventional (2D) imaging (standard mammography)
45819683|NCT03638323|Other|Speech therapy|During a 1-hour speech-language consultation, a lack of word evaluation will be conducted and patient will answer a Hearing Difficulty Questionnaire
45819684|NCT04708808|Behavioral|music therapy|cases will randomly assigned to receive music therapy group with routine care, plus music given via headphone, or assign to control group with no music given.
45819685|NCT03642457|Drug|Bupivacaine|20 cc 0.5%
45819686|NCT03642457|Drug|Bupivacaine liposome|133mg liposomal bupivacaine
45819687|NCT00379418|Drug|Abciximab|
45819688|NCT00379496|Procedure|Antidepressants|
45819689|NCT00379496|Procedure|acupuncture|
45819690|NCT00378716|Drug|5-fluorouracil|
45819691|NCT00378716|Drug|leucovorin calcium|
45819692|NCT00378716|Drug|tegafur|
45819693|NCT00378716|Drug|uracil|
45819694|NCT03644095|Drug|Mucinex® SE|Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet
45665058|NCT05152277|Drug|HRS9531|Administered SC once
45665059|NCT05152277|Other|placebo|Administered SC once
45665060|NCT05152277|Drug|HRS9531|Administered SC for multiple dose
45819695|NCT03644095|Drug|Vicks Cough Syrup for Chesty Coughs|Vicks Cough Syrup for Chesty Coughs 15 mL (200 mg guaifenesin q4h) immediate release (IR) syrup
45819696|NCT01633814|Drug|Transdermal estradiol|transdermal estradiol, delivery rate 100 µg day-1
45665061|NCT05152277|Other|placebo|Administered SC for multiple dose
45665062|NCT05243381|Biological|20 ml blood test|20 ml blood test
45819697|NCT01633814|Drug|Placebo|placebo patch.
45458275|NCT03498586|Drug|Normal saline|Use of normal saline as an irrigant for open-irrigated ablation catheters
45458276|NCT02317120|Genetic|NGS BRCA 1 and BRCA 2 full sequencing|
45458500|NCT01352000|Behavioral|Smoking Cessation|Approximately 3400 quitline clients will be randomized to one of three conditions at the point of their 2-week follow-up call.
45458501|NCT01364402|Drug|Epoetin beta|50,000U intravenously
45458502|NCT01364402|Drug|Saline 0.9%|normal saline intravenously
45665063|NCT05150171|Other|e-self-management intervention|The app is developed based on a combination of behavioural change techniques informed by Social cognitive theory and the EULAR recommendations on management of hand osteoarthritis. The 12-week intervention consists of 25 short informational videos addressing the themes prioritized by the patient research partners. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The informational videos and exercise program are delivered in a progressive order across the 12 weeks. Encouragement and motivational messages are provided each week to enhance continued adherence to the intervention.
45665064|NCT05149937|Other|interprofessional, person-centered care concept|interprofessional, person-centered care concept
45819698|NCT04332133|Procedure|laser interference,INTRAVITREAL INJECTION|sub threshold micro pulse laser for DME for group 1 and intravitreal injection of Ranibizumab for group 2
45819699|NCT04713943|Dietary Supplement|>Your< Iron Syrup|Once daily dose of >Your< Iron Syrup in the amount of 1 mg/kg body weight of elemental iron for 12 weeks
45819700|NCT04713943|Other|Placebo|Once daily dose of placebo syrup for 12 weeks
45819701|NCT04585490|Drug|Durvalumab|Cohort 1 (1500 mg IV every 21 days, for 1 year), •Cohort 2 (10mg/kg every 2 weeks for 1 year)
45819702|NCT04585490|Drug|Carboplatin|Target area under the curve (AUC) not to exceed 750mg on Day 1 of every 21-day cycle
45819703|NCT04585490|Drug|Pemetrexed|500mg/m2 on Day 1 of every 21-day cycle
45960914|NCT04983238|Drug|Placebo & SYD985|Ocular administration: Placebo, Intravenous administration: SYD985
45665065|NCT05149781|Procedure|Standardized diagnosis and treatment|Patients with endocrine hypertension undergo surgery or medication depending on the cause after completion of standard diagnostic procedures. Patients with primary hypertension receive medication.
45665066|NCT05149157|Other|Symptomatic malaria|This observational study will be recruiting patients who have symptomatic malaria (confirmed by presence of asexual stage parasitaemia of any Plasmodium species on blood film)
45960915|NCT00184743|Drug|somatropin|
45960916|NCT04982419|Device|Remote ischemic preconditioning|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
45960917|NCT04982419|Device|Sham remote ischemic conditioning|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 60 mmHg for 5 minutes and deflation for 5 minutes (Control)
45665067|NCT05148845|Biological|Booster vaccine|"To evaluate the effectiveness and safety of the single dose Ad26.COV2.S (Jansen) COVID-19 vaccine plus a homologous boost with Ad26.COV2.S (Janssen) COVID-19 vaccine among Sisonke participants as compared to unboosted Sisonke participants~In addition we will continue to evaluate VE of the Sisonke Boost compared to:~i) Vaccinated populations pre boosts ii) Unvaccinated populations in South Africa."
45665068|NCT05192837|Behavioral|Intensive preoperative smoking cessation counselling|"The study intervention consists of an interview by a Tabacco Treatment Specialist (TSS) 4 weeks before surgery with individual counselling and offered nicotine substitution. The intervention meeting is based on the Chronic Care Model (CCM) to improve quality of ambulatory care.~In brief, the intervention includes:~Informative content about advantages of smoking cessation~Scheduling service for a motivational interview by a TSS in office to implement a treatment plan~For participants willing to quit smoking a preoperative quit day will be scheduled after the first intervention meeting 2-3 weeks before surgery~Patients will be encouraged by a TSS to use nicotine replacement. Bupropion or Vareniclin will be provided on an individual basis~TSS will schedule repeated follow-up meetings to support smoking abstinence or nicotine reduction before and after surgery for all patients"
45665069|NCT05192525|Device|mChemotherapy|"The intervention is composed of one core intervention mChemotherapy, one pre-chemotherapy consultation, and two app follow-up visits. mChemotherapy will be specifically utilized to facilitate symptom self-management for intervention group covering chemotherapy for six weeks. The mChemotherapy includes six components: (i) self-monitoring, (ii) alerts, (iii) reminder, (iv) consultation, (v) my prescription, (vi) knowledge base. Intervention group participants will be given an individual username and password to log in to the mChemotherapy platform. The intervention nurses will deliver the intervention and contact patients through this platform."
45665070|NCT05475197|Device|Kinesio taping|We planned to perform two different taping applications to evaluate the acute effect of kinesio taping application on the carpal tunnels of individuals with carpal tunnel syndrome.
45819704|NCT04585490|Drug|Paclitaxel|175mg/m2 on Day 1 of every 21-day cycle
45819705|NCT04585490|Drug|Cisplatin|Cisplatin (75mg/m2 per institution guidelines) may be substituted for Carboplatin
45819706|NCT04585490|Device|AVENIO ctDNA Surveillance Kit|Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)
45819707|NCT04713865|Procedure|endovascular treatment|The bare metal stent covers the deep femoral artery lower than 50%
45819708|NCT04713865|Procedure|endovascular treatment|The bare metal stent covers the deep femoral artery in 50-90%
45819709|NCT04713865|Procedure|endovascular treatment|The bare metal stent totally covers the deep femoral artery
45819710|NCT04571216|Drug|NFL-101 dose 1|Subcutaneous injections
45819711|NCT04571216|Drug|NFL-101 dose 2|Subcutaneous injections
45819712|NCT04571216|Drug|Placebo|Subcutaneous injections
45819713|NCT04714099|Drug|Topical Cyclosporine A|In our study we used 0.05% CsA prepared in castor oil by transferring (20ml ) of sterile castor oil in a sterile glass vial under laminar flow, removing a volume (400ul)of oil with micropipette (sterile tips), and replacing this volume with an equal volume of alcoholic CsA solution [200mg cyclosporine in 8 ml ethanol (96%)] under laminar flow.
45819714|NCT04714099|Drug|Placebo|Placebo
45819715|NCT04566770|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular other name:Ad5-nCoV
45819716|NCT04566770|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo|Intramuscular other name:Ad5-nCoV
45819717|NCT04350307|Device|22-gauge needle|22-gauge Quincke needle used for epidural injection
45819718|NCT04350307|Device|25-gauge needle|25-gauge Quincke needle used for epidural injection
45960918|NCT04974385|Drug|Liposomal bupivacaine|Validate the analgesic efficacy of admixed LB + bupivacaine compared with plain bupivacaine when injected for ISNB for total shoulder arthroplasty.
45960919|NCT04974385|Drug|Bupivacaine|Active comparator as standard of care.
45960920|NCT00547885|Drug|Dihydrocodeine|"Group 1: 2* 60 mg dihydrocodeine long acting + up to four placebo short action~Group 2: 3* 60 mg dihydrocodeine long acting + up to six placebo short action~Group 3: 4* 60 mg dihydrocodeine long acting + up to eight placebo short action~Group 4: 2 placebo for long acting + up to 4*30 mg dihydrocodeine short acting~Group 5: 3 placebo for long acting + up to 6*30 mg dihydrocodeine short acting~Group 6: 3 placebo for long acting + up to 8*30 mg dihydrocodeine short acting"
45960921|NCT00161018|Drug|Quetiapine, Risperidone, Fluphenazine|
45960922|NCT00191412|Drug|Pemetrexed|
45960923|NCT00547924|Behavioral|Transoesophageal echocardiography|Transoesophageal echocardiography in liver transplantation: left ventricular function during reperfusion
45960924|NCT00547963|Behavioral|brief counseling|baseline assessment + two 40 minute sessions of brief counseling
45960925|NCT00548002|Drug|trovafloxacin and levofloxacin|Trovafloxacin: <60 kg 200 mg iv/orally once daily and >60 kg 300 mg iv/orally once daily Levofloxacin: < 60 kg 500 mg iv/orally once daily and >60 kg 500 mg iv/orally bid
45960926|NCT00191490|Drug|Gemcitabine|
45960927|NCT00191490|Drug|docetaxel|
45960928|NCT00191490|Drug|cisplatin|
45960929|NCT00548080|Drug|MK0991, caspofungin acetate / Duration of Treatment:|
45960930|NCT00548275|Behavioral|Enhanced Sexual Risk Management|management of sexual risk
45960931|NCT00548275|Behavioral|Standard Sexual Risk Management|management of sexual risk
45960932|NCT00161096|Drug|pantoprazole 20 mg (drug)|
45458503|NCT02325700|Procedure|Aortic repair|Aortic bypass
45960933|NCT00184782|Procedure|FDG-PET|
45960934|NCT04973683|Drug|AL101|Given IV
45960935|NCT04973683|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
45960936|NCT00548314|Other|dermal matrix|1mm thickness matrix composed of collagen-elastin hydrolosate
45960937|NCT00548314|Procedure|Split skin graft|
45960938|NCT00548314|Device|VAC therapy (KCI)|VAC therapy for 3-5 days 125mmHg
45960939|NCT00548353|Drug|MK3207|M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets).
45960940|NCT00548353|Drug|Comparator: Placebo (unspecified)|M3207 (20 mg) Pbo; patients will be administered a single dose of 100 mg of MK3207 Pbo (i.e., 5 x20-mg tablets).
45960941|NCT00184821|Procedure|Ischemic preconditioning|
45960942|NCT00184821|Procedure|Forearm ischemic exercise|
45960943|NCT00184821|Procedure|Annexin A5 scintigraphy|
45458504|NCT03552380|Drug|Entinostat|RP2D will be determined with a 6 patient safety lead-in. Entinostat will continue until disease progression or prohibitive toxicity. Cycles 1-4 are 21 day cycles. Cycles 5 and subsequent are 14 day cycles.
45819719|NCT04536584|Other|Personalized Coaching (Arm A)|Patients will receive personalized physical activity coaching with an online digital platform to take online educational workshops and interact with other peers of the cohort with a online private forum. They will also have a connected watch that will measure several physical activity metrics.
45819720|NCT04536584|Other|Standard supportive approach (Arm B)|Patients will receive the standard recommendations during their visits with the oncologist. The exercise recommendations include strength training and aerobic activities.
45819721|NCT04348357|Other|Telemedicine|A video-call application hosted by Texas Tech University Health Science Center El Paso and easily accessible from mobile phones or video-enabled PCs will be used (webex teams)
45819722|NCT04348357|Other|Office visit|Patient comes to the office to receive routine postoperative care
45960944|NCT00184821|Drug|Diazoxide|
45960945|NCT00184821|Drug|glibenclamide|
45960946|NCT00184821|Drug|adenosine|
45960947|NCT00548509|Drug|Menatetrenone (Vitamin K2)|
45960948|NCT02277301|Behavioral|Mellow Babies|Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
45960949|NCT00548626|Procedure|Single needle|Patients will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
45960950|NCT00548626|Procedure|Multiple needle|Patients will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
45960951|NCT00191529|Drug|somatropin|
45960952|NCT04953637|Other|Physiotherapy|Participants in the physiotherapy group will receive gait and balance focused physiotherapy at One Step Ahead Mobility physiotherapy clinic for 1-hour per day, 3 times/week for 8 weeks.
45960953|NCT00548665|Device|Carotid ultrasound for plaque screening|Carotid ultrasound for plaque screening
45819723|NCT04516538|Behavioral|Mini Mental State Examination|test for evaluating a person's cognitive functions and memory capacity
45960954|NCT00548665|Behavioral|Brief advice for smoking cessation|We will use the 5A's heuristic (Ask about smoking, Advise on cessation, Assess willingness to change, and for those willing to make quit attempt: Assist with attempt to quit, and Arrange for follow-up) and the gold standard for brief smoking cessation advice. At each visit, smokers will receive smoking cessation counseling and nicotine replacement therapy, similar to the experimental group.
45960955|NCT00184860|Procedure|PET-scan, MRI-scan|
45960956|NCT00548704|Drug|Dexrazoxane|
45960957|NCT00548743|Behavioral|Screening and follow up|Two stage screening with EPDS and PHQ-9, treatment for depression at physician's discretion and follow up phone calls and visits
45960958|NCT00548743|Behavioral|Usual care|usual care for identification and management of postpartum depression
45819724|NCT04516538|Diagnostic Test|6 Minutes Walk Test|a standardized test of an individual's functional ability that involves walking the greatest distance a person can walk in six minutes. This walking may be limited by shortness of breath or fatigability.
45819725|NCT04516538|Diagnostic Test|Timed up and go|A simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time it takes for a person to get up from a chair, walk three metres, turn around, walk to the chair and sit down.
45960959|NCT00184899|Drug|Intravenous infusion of Intralipid/heparin|
45960960|NCT00184899|Drug|Intravenous infusion of Glycerol/heparin|
45960961|NCT00548782|Other|Paleolithic diet|diet
45960962|NCT00548782|Other|ADA ( American Diabetes Association) recommended diet|diet
45960963|NCT00548821|Drug|Cisplatin|
45960964|NCT00161291|Drug|Letrozole in combination with Bevacizumab|Patients will be administered Letrozole at 2.5 mg PO a day and Avastin at 15 mg/kg IV every 3 weeks for 24 weeks. Patients will then undergo surgical treatment and receive adjuvant therapy according to the treating physician.
45960965|NCT00548899|Drug|Nexavar (Sorafenib)|Tablet, Sorafenib follows a patient specific escalation scheme starting with 200 mg daily up to a maximum dose of 800 mg daily during EC chemotherapy on day 2-19. The achieved dose will be continued during paclitaxel chemotherapy during week 1-11 all day
45960966|NCT00191568|Drug|Gemcitabine|
45665071|NCT02367781|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|"Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab was administered to participants who were randomized to Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin) and to participants in Arm B (Nab-Paclitaxel + Carboplatin) who cross over at progression."
45819726|NCT04516538|Diagnostic Test|Isokinetic Body weight-based quadriceps intermittent fatigue test (BW-QIF Test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isokinetic BW-QIF test blocks consist in 100 contractions at 120° deg.s-1 and 60° of range of motion (0.5-s contraction /0.5-s rest)."
45819727|NCT04516538|Diagnostic Test|Cycloergometer body weight-based quadriceps intermittent fatigue test (BW-QIF Test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The BW-QIF test blocks on the cycloergometer consist in 100 s of cycling at 60 Revolution Per Minute (RPM)."
45819728|NCT04516538|Diagnostic Test|Isometric BW-QIF Test (Body weight-based quadriceps intermittent fatigue test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isometric BW-QIF test blocks consist in 10 contractions (5-s contraction / 5-s rest)."
45819729|NCT04342663|Drug|Fluvoxamine|Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.
45819730|NCT04342663|Drug|Placebo|Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 3 capsules per day as tolerated.
45819731|NCT00589550|Biological|PEG-interferon alfa-2b|administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
45819732|NCT00589550|Drug|Sorafenib|
45819733|NCT00589550|Genetic|gene expression analysis|
45819734|NCT00589550|Genetic|polymerase chain reaction|
45819735|NCT00589550|Genetic|reverse transcriptase-polymerase chain reaction|
45819736|NCT00589550|Other|flow cytometry|
45819737|NCT00589550|Other|immunoenzyme technique|
45819738|NCT00589550|Other|laboratory biomarker analysis|
45819739|NCT01636466|Drug|Everolimus|Everolimus will initially be dosed at 0.75 mg tablet taken orally twice a day. The dose will be adjusted to maintain serum trough concentrations of 5-8 ng/ml.
45819740|NCT00583466|Drug|Autologous blood injection|Autologous blood will be drawn from the patient and then reinjected under the lesion to create a safety cushion
45819741|NCT00583466|Drug|Normal saline|Normal saline will be injected under the lesion to create submucosal cushion
45819742|NCT00583466|Drug|HPMC|Hydroxypropyl methylcellulose (HPMC) will be injected under the lesion to create submucosal cushion
45819743|NCT00568802|Drug|Hydroxyurea|
45819744|NCT00568802|Drug|Placebo to match hydroxyurea|
45819745|NCT00576524|Device|ITD|ITD will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
45819746|NCT00576524|Device|Sham|Sham will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
45819747|NCT04499924|Drug|tucatinib|300 mg given twice daily orally
45665072|NCT02367781|Drug|Carboplatin|Carboplatin was administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
45665073|NCT02367781|Drug|Nab-Paclitaxel|Nab-paclitaxel was administered as IV infusion at a dose of 100 milligrams per square meter (mg/m^2) on Days 1, 8, and 15 of each 21-day cycle.
45819748|NCT04499924|Drug|trastuzumab|6 mg/kg loading dose will be administered intravenously (IV; into the vein) on Cycle 1 Day 1, followed by 4 mg/kg IV on Cycle 1 Day 15 and then Days 1 and 15 of each cycle thereafter
45819749|NCT04499924|Drug|ramucirumab|8 mg/kg will be administered IV on Days 1 and 15 of each cycle
45665074|NCT02367781|Drug|Pemetrexed|Switch maintenance to pemetrexed can be administered within 6 weeks of Day 1 of the last induction cycle.
45819750|NCT04499924|Drug|paclitaxel|60 or 80 mg/m^2 IV on Days 1, 8, and 15 of each cycle
45819751|NCT04499924|Other|tucatinib placebo|Given twice daily orally
45819752|NCT04499924|Other|trastuzumab placebo|IV on Days 1 and 15 of each cycle
45819753|NCT03949621|Drug|Vedolizumab SC|Vedolizumab SC liquid.
45960967|NCT00191568|Drug|Oxaliplatin|
45960968|NCT00191568|Procedure|Radiotherapy|
45960969|NCT00548938|Drug|Gliadel wafer|Implanted at surgery
45960970|NCT00548938|Drug|Temozolomide|During External Beam Radiation
45960971|NCT00548938|Radiation|External Beam Radiation Therapy|60 Gy
45960972|NCT00161330|Drug|oral amoxicilline/clavulanic acid|
45960973|NCT00161330|Drug|iv ceftriaxone|
45960974|NCT04939480|Drug|Atezolizumab|Atezolizumab 1200 mg intravenous solution
45960975|NCT00548977|Other|Drawing blood to study genetic polymorphism|
45960976|NCT00184938|Drug|morphine|
45960977|NCT00184938|Drug|naloxone|
45960978|NCT00184938|Drug|Technetium-TC99m-labeled Annexin A5|
45960979|NCT00184938|Procedure|forearm ischemic exercise|
45960980|NCT00184938|Procedure|ten minute forearm ischemia|
45960981|NCT00549016|Device|PTPE Encapsulation of Nitinol Stents|Both common femoral arteries (CFAs) are surgically exposed to allow bilateral access of diagnostic and therapeutic devices. The endoluminal stent graft is then deployed in accordance with the Instructions for Use.
45960982|NCT00549133|Drug|Irbesartan|
45960983|NCT00549211|Drug|GSK557296|
45960984|NCT00191607|Drug|Gemcitabine|
45960985|NCT00191607|Drug|liposomal doxorubicin|
45960986|NCT00549289|Drug|cyclosporine A|
45960987|NCT00549367|Behavioral|Nutrition Counselling|Clients will receive ongoing nutrition assessment and dietary counselling. The intervention arm will receive all baseline assessments and individual nutritional assessment, counselling and nutrition management plans using standards of practice
45960988|NCT00161408|Behavioral|cognitive behavioural therapy|
45960989|NCT00161408|Behavioral|psychoeducation|
45960990|NCT00549406|Procedure|computerized visual training|two one-hour training sessions per week, for five consecutive weeks
45960991|NCT00549406|Procedure|computerized word puzzles|two one-hour sessions per week, for five consecutive weeks
45960992|NCT00549406|Procedure|video-game based visual training|two one-hour training sessions per week, for five consecutive weeks
45960993|NCT00184977|Drug|N-acetylcysteine|
45960994|NCT00184977|Drug|fluticasone propionate|
45960995|NCT03456232|Other|High-flux hemodialysis|High-flux hemodialysis using diffusion, ultrafiltration and convection principle to remove harmful substances in the blood and excessive water.
45960996|NCT03456232|Other|Hemodiafiltration|Hemodiafiltration is a combination of hemodialysis and hemofiltration with two modes of treatment advantages, both by diffusion and convection principle to remove harmful substances in the blood.
45960997|NCT03456154|Drug|Botox Injectable Product|60u will be used at 3 sites of masseter muscle, on each side of the face
45960998|NCT03456154|Device|Occlusal splint|In this group patients will receive an occlusal splint which will be worn everyday for 6 months at night.
45960999|NCT00161447|Drug|Acyline|Acyline 300 mcg/kg SQ every 2 weeks for 12 weeks
45961000|NCT00161447|Drug|Testosterone Gel|Testosterone Gel (10 g daily
45961001|NCT00161447|Drug|Depo-Medroxyprogesterone|DMPA (injected into muscle) Day 0 & month 3
45961002|NCT00191685|Drug|duloxetine|
45961003|NCT00549523|Drug|Placebo|Capsules containing 0 mg bid (placebo)
45961004|NCT00549523|Drug|Low Dose|Capsules containing 400 mg bid of L. frutescens.
45961005|NCT00549523|Drug|Mid Dose|Capsules containing 800 mg bid of L. frutescens.
45961006|NCT00549523|Drug|High Dose|Capsules containing 1200 mg bid of L. frutescens.
45961007|NCT00161486|Drug|Testosterone gel|Testosterone gel 100 mg daily for 4 weeks
45961008|NCT00161486|Drug|Acyline|Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks
45961009|NCT00161486|Drug|Placebo acyline|Placebo acyline injections every two weeks (2 doses)
45961010|NCT00161486|Drug|Placebo Testosterone gel|placebo testosterone gel daily for 4 weeks
45961011|NCT00549796|Other|Percutaneous coronary intervention (PCI)|Patients undergo routine, clinically indicated PCI
45961012|NCT02963571|Procedure|posterior percutaneous pedicle screw internal fixation|The patients underwent minimally invasive posterior percutaneous pedicle screw fixation in acute thoracolumbar vertebral fractures with simple anterior spinal column injury.
45961013|NCT00549835|Procedure|Real Acupuncture|
45961014|NCT00549835|Procedure|Sham Acupuncture|"Sham needles are developed to exclude sham effect and to prove real acupuncture efficacy. We will use specifically retractable Park Sham Device (AcuPrime, Exeter, UK) for control group. Because this sham device gives the impression of insertion with telescopic needle body and some pricking sensation with a bunt needle tip. It is a valid control for many acupuncture trials as it doesn't penetrate skin and doesn't create active stimulation as much as real needles or acupressure. To avoid unnecessary stimulation of penetrating skin in this population, we plan to use non-penetrating sham device rather than penetrating non-acupuncture point with real needles as control intervention.~All other procedures will be same as Real Acupuncture group except using non-penetrating sham needles on non-acupuncture points. After final session, we will ask all subjects in both groups which form of treatment each subject believe to have during study and will analyze blinding credibility."
45961015|NCT00549874|Drug|Rosiglitazone|oral 8 mg/once daily for 6 months
45961016|NCT00549874|Drug|Glyburide|20 mg/ once daily for 6 months
45961017|NCT00161525|Procedure|Pneumatic displacement|Pneumatic displacement of the subretinal hemorrhages is attempted with an intravitreous injection of 0.4 ml of pure C2F6 or 2 injections of 0.2 ml on subsequent days. The gas is withdrawn from a laboratory cylinder through a millipore filter and injected into the eye through a 30 gauge needle inserted 4.0 mm posterior to the limbus in the superior temporal quadrant. The tip of the needle is monitored in the vitreous by indirect ophthalmology prior to injecting the gas.Post injections the central retinal artery is examined whether is patent.The intraocular gas expands 3.3 times over the next 3 days to create a 40% bubble.The patient is asked to assume a gaze position 40° below the horizontal for 20 minutes every hour while awake and to sleep on 2 pillows with his head turned to the right.
45961018|NCT00185016|Behavioral|a training to improve recognition of partner abuse.|
45961019|NCT00549913|Biological|NeoFuse|immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse) combined with MasterGraft Resorbable Ceramic Granules in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
45961020|NCT00549913|Procedure|posterolateral spinal fusion with instrumentation|autograft in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
45961021|NCT00549952|Other|no intervention study|
45961022|NCT00191763|Drug|Gemcitabine|
45961023|NCT00191763|Drug|cisplatin|
45961024|NCT00161564|Drug|Rituximab|
46079501|NCT05162729|Behavioral|Game-like online social emotional training|"Participants in the SE group will be also receiving two types of SE training tasks in each session, to match with the ones in the WM training. There are two mini-games for training.~To match with the spatial-visual WM training, participants in the SE group will be asked to first look at a picture that depicts a daily social scenario (i.e., a child who fell down and hurt himself), and then to choose an emotion that the child in the picture may feel from four options of facial emotions displayed on the screen. The other mini-game, with the aim to match with the auditory WM training, will first tell a short story of a social scenario (i.e. David accidentally fell down and got hurt), and then will ask the child to choose the emotion that the character in the story may feel from the four options displayed on the screen. Each mini game lasts for about 7 minutes in each training session."
45665075|NCT02152761|Drug|bimagrumab|Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.
45665076|NCT02152761|Other|placebo|Matching placebo was administered as intravenous infusion starting on Day 1 until week 20.
45665077|NCT05191277|Drug|Treatment 'discontinuation of antidepressant medication'|Pharmacological intervention: Participants will discontinue their antidepressant medication.
45819754|NCT04474730|Device|BMT Physical Activity app|This app sends reminders to patients, collect activity data from Apple Watch, and allow patients to submit symptoms.
45665078|NCT05191277|Drug|Treatment 'continuation of antidepressant medication'|Pharmacological intervention: Participants will remain on their antidepressant medication.
45665079|NCT05191277|Behavioral|Expectation 'high'|Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the open trial arms, participants will receive full information about their treatment (i.e., high expectation). expectation).
45665080|NCT05191277|Behavioral|Expectation 'moderate'|Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the hidden trial arms, participants will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation).
45961025|NCT00550030|Radiation|UVB-311nm radiation|UVB-311nm radiation randomized to one body half given 3 times a week for 6 weeks; the other body half remains UV-non-irradiated.
45961026|NCT00550030|Other|No treatment|no UV exposure
45961027|NCT00185055|Drug|Olmesartan medoxomil|
45961028|NCT00185055|Drug|Irbesartan|
45961029|NCT00185055|Drug|Valsartan|
46079502|NCT05161832|Behavioral|Nocebo|Nocebo ultrasound with diagnosis of a fake shoulder cuff injury.
46079503|NCT05161832|Behavioral|Placebo|Placebo ultrasound with no diagnosis of injury.
45458505|NCT03552380|Drug|Nivolumab|Nivolumab will continue until disease progression or prohibitive toxicity. Cycles 1-4 are 21 day cycles. Cycles 5 and subsequent are 14 day cycles.
45665081|NCT04242173|Drug|Cemiplimab-Rwlc|Cemiplimab-rwlc will be administered as a flat dose of 350 mg IV over approximately 30 minutes every 21 days (+/- 3 days)
45665082|NCT05242289|Device|CytoSorb|Medical device used hemoperfusion and cytokine adsorption in conjunction with lung transplantation.
45665083|NCT05189015|Drug|Olmesartan|- Olmesartan group: Olmesartan, 20 (40) mg once a day, oral administration
45961030|NCT00161603|Behavioral|Semi-structured, open-ended interviews|
45961031|NCT00550108|Other|Ethanol lavage|Ethanol lavage of pancreatic cysts.
45961032|NCT00550186|Other|placebo|
45961033|NCT00550186|Drug|Ringers Lactate|
45819755|NCT04474730|Other|Watch Only|A locked Apple Watch will be used to collect physical activity data from the Watch Only patients.
45819756|NCT05313919|Diagnostic Test|Comprehensive functional diagnostics of coronary circulation|"Comprehensive functional diagnostics of coronary circulation in patients with INOCA (ischemia and no obstructive coronary arteries) including:~echocardiography with assessment of diastolic function~flow-mediated dilation of brachial artery~coronary angiography~functional coronary assessment (RFR, FFR, IMR, CFR, dp/dt, Tau)~provocative test with acetylcholine (registration of symptoms, ECG and angiographic spasm)~laboratory tests (full blood count, serum creatinine level, eGFR, lipidogram, serum CRP/hsCRP level, serum NT-proBNP level)~serum level of inflammatory cytokines and chemokines"
45961034|NCT00550186|Drug|HaemoHES 6%|
45961035|NCT00550225|Drug|GSK961081|GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.
45665084|NCT02152605|Drug|UMEC/VI|Dry white powder delivered via DPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg
45665085|NCT02152605|Drug|Placebo|Dry white powder delivered via DPI (2 strips with 30 blisters each, both containing lactose with magnesium stearate), administered as one inhalation of placebo
45665086|NCT05188703|Behavioral|Patient Navigation|Participants will be assigned to a patient navigator and will have quarterly appointments. Patient navigators will assist with access and coordination of medical care.
45665087|NCT05239091|Drug|Dextrose solution|A total of 3 doses of dextrose prolotherapy will be administered with an interval of 2 weeks.
45819757|NCT04429880|Drug|Oxytocin|Oxytocin given by intravenous route
45819758|NCT03645811|Behavioral|Music Therapy|Music therapy was applied in the application room. Via a portable computer, students listened to the mahur maqam for 20 minutes under the supervision of the investigators using an MP3 player.
45819759|NCT03645811|Behavioral|EFT|EFT includes taps, nine gamut sequences, and eye movements on the meridian system, focusing on the individual's inhibiting thoughts, disturbing emotions, or memories. EFT regulates the flow of energy in the meridian system of the individual, causing relaxation in the mind, body, and emotions.
45819760|NCT05600738|Device|RNS/DBS activation|This will be performed to study the EEG responses to DBS/RNS stimulation electrical pulses. The stimulation frequencies will be sequentially increased and each stimulation will last for 2 minutes.There will be a 1-2 minute wash out period after each trial.
45819761|NCT04327700|Device|TheraBionic|Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three courses of 60-minute treatments per day, administered in the morning, at noon and in the evening at the patient's home, with the exception of the first 60-minute treatment, which will be delivered at the research site. Each 4 week treatment period will be considered a cycle of treatment.
45819762|NCT04327700|Drug|Regorafenib|Patients will receive 160 mg regorafenib (four 40 mg tablets) orally once daily for the first 3 weeks of each 4-week cycle per approved prescribing information.
45819763|NCT04311632|Biological|TCD601|Investigational Product
45665088|NCT05239091|Drug|Lidocain|A total of 3 doses of lidocaine will be administered with an interval of 2 weeks.
45819764|NCT04311632|Drug|Tacrolimus (TAC)|Standard of Care Concomitant Immunosuppression
45819765|NCT04311632|Drug|Corticosteroids (CS)|Standard of Care Concomitant Immunosuppression
45819766|NCT04311632|Drug|Mycophenolate Mofetil (MMF)|Standard of Care Concomitant Immunosuppression
45819767|NCT04311632|Drug|ATG|Standard of Care induction therapy in solid organ transplantation
45819768|NCT04706078|Diagnostic Test|The biotype of gingival|The biotype of gingival was also determined by periodontal probe.
45819769|NCT01692158|Drug|Heparin, Low-Molecular-Weight|single subcutaneuous administration of 40 mg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
45819770|NCT01570634|Drug|Calcium Aluminosilicate Anti-Diarrheal (CASAD)|CASAD 3 500mg capsules po tid for 14 days with 4 weeks of follow up
45819771|NCT03928327|Drug|TAK-788|TAK-788 Capsules
45819772|NCT03928327|Drug|Itraconazole|Itraconazole Oral solution
45819773|NCT03928327|Drug|Rifampin|Rifampin Capsules
45819774|NCT01055756|Drug|Loratadine + Pseudoephedrine sulfate|Loratadine (5 mg) + Pseudoephedrine sulfate (120 mg)
45961036|NCT00550225|Drug|GSK961081 matching placebo|GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.
45458506|NCT03552380|Drug|Ipilimumab|Ipilimumab will be administered in combination with entinostat and nivolumab for Cycles 1-4 only.
45458507|NCT02318290|Drug|Opiates|Mechanically ventilated patients receiving opiates for more than 96 hours will be evaluated for withdrawal symptoms upon weaning of the opiates
45665089|NCT02152371|Drug|Dulaglutide|Administered SQ
45665090|NCT02152371|Drug|Placebo|Administered SQ
45665091|NCT02152371|Drug|Insulin Glargine|Administered SQ
45665092|NCT02152371|Drug|Metformin|Administered orally
45665093|NCT02332291|Drug|Escitalopram|Escitalopram 10-20mg daily
45819775|NCT03648853|Device|Tetanic Stimulus|5 second 100 Hz 70 mA tetanic stimulus will be applied to three different locations in a random order
45819776|NCT00652574|Drug|Dasatinib|70 mg by mouth twice daily x 28 days, for up to 2 years after surgery.
45819777|NCT04240184|Other|Physical workload|Cohort study - The specific study aims are to investigate 1) exposure-response associations between quantity of occupational lifting and short-term (day-to-day) changes in LBP, 2) the influence of accumulated workdays and rest days during a working week on LBP, 3) long-term association between occupational lifting exposure and LBP when assessed over 1 year, and 4) the role of psychological and social factors on the above associations.
45819778|NCT03649867|Other|Semi-structured interviews|Each participant will attend a 30-45 minute semi-structured interview conducted by the CI
45819779|NCT01550510|Drug|Ascorbic Acid|3x a week for 9 weeks
45819780|NCT01550510|Drug|Irinotecan|350mg/m2 once a week every 3 weeks
45819781|NCT04333225|Drug|Hydroxychloroquine|Weekly treatment in individuals at high risk
45819782|NCT00566462|Drug|perampanel|2 mg/d for 14 days followed by 4 mg/d for 14 days
45819783|NCT00566462|Drug|placebo|Matching placebo for for 14 days followed by 4 mg/d for 14 days
45819784|NCT00556400|Drug|Lo-Ovral Oral Contraceptive Pills|
45819785|NCT00556400|Drug|Placebo - sugar pill|
45819786|NCT03918811|Procedure|Positive Pressure Extubation Technique|Positive-pressure extubation is performed by only one operator. Ventilator parameters are set to pressure support ventilation mode, with an inspiratory pressure of 15 cm H2O and PEEP of 10 cm H2O. Then, the cuff is deflated, and the ETT is removed without endotracheal suction. Once the ETT is removed, a suction catheter is introduced through the mouth to suction secretions drawn to the oropharynx by the air flow from the ventilator passing between the ETT and the larynx.
45819787|NCT03918811|Procedure|Traditional Extubation Technique|Traditional extubation is performed by 2 operators. Without reconnection to the ventilator, the closed suction system catheter is introduced by one of the operators into the ETT and suctioning is initiated. The cuff is immediately deflated by the other operator, and the ETT is removed with continuous endotracheal suction during the whole procedure by the first operator.
45961037|NCT00161642|Drug|CMD-193|
45961038|NCT00185094|Drug|Olmesartan medoxomil|
45961039|NCT00185094|Drug|Losartan potassium|
45961040|NCT00185094|Drug|Atenolol|
45961041|NCT00550264|Other|Automatic notification of readmissions|The experimental group physicians will receive automatic e-mail notification when a patient is readmitted, including contact information for the readmitting team.
45961042|NCT00550303|Drug|bazedoxifene/conjugated estrogens combination|
45961043|NCT00550342|Drug|rituximab|375 mg/m2 intravenously for 4 doses
45961044|NCT00550381|Drug|HKI-357|Single-dose capsule
45961045|NCT00161681|Drug|Levonorgestrel/Ethinyl Estradiol|
45961046|NCT02963454|Device|Microdialysis Probe (Muscle microdialysis)|"Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply."
45961047|NCT02963454|Drug|Dobutamine|Dobutamine (5 μg/kg/min) will be used as indicated
45665094|NCT02332291|Drug|Bupropion XL|Bupropion XL 150-450mg daily
45961048|NCT02963454|Drug|Levosimendan|Levosimendan (0.2 μg/kg/min) will be used as indicated
45961049|NCT00550498|Biological|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 3-5 million cells, in a maximum volume of 0.3 ml. Cells will be injected in vitreal at 3.5 millimeter of limbus with a 26 gauge insulin needle.
45961050|NCT04900675|Other|Bright light intervention|Exposure with 5,000 lux at eye level for one hour and a Correlated Color Temperature of 5,300 Kelvin every morning for three weeks.
45961051|NCT04900675|Other|Reddish placebo light|Exposure with 50 lux at eye level for one hour and a Correlated Color Temperature of 2,200 Kelvin every morning for three weeks.
45458508|NCT01317680|Device|Omnispec model ED1000|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
45665095|NCT01656395|Drug|MK-1029|MK-1029 10 mg, 30 mg or 150 mg oral tablets taken QD at bedtime, based on randomization.
45961052|NCT00191802|Drug|teriparatide|
45961053|NCT00550576|Drug|Digibind (Fab)|Intravenous Digibind (Digoxin Antibodies-Fab) is delivered only once in 30-45 minutes to patients after receiving the informed concent.
45961054|NCT00550693|Device|Chlorhexidine-impregnated foam dressing|Patients during the intervention period had this foam dressing applied around their central venous catheter. This was replaced once a week as recommended by the package insert unless the dressing was soiled, bloody, or fell off.
45961055|NCT00550810|Drug|Sunitinib (SU011248)|SU011248 (study medication) will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2 week rest period to form a complete cycle of 6 weeks. Study medication will be orally self administered once daily without regard to meals beginning on Day 1 of the study. Cycles will be repeated in the absence of unacceptable toxicity or disease progression
45961056|NCT00191841|Drug|gemcitabine|
45665096|NCT01656395|Drug|Montelukast 10 mg|Parts I-II: Participants will receive Montelukast 10 mg tablets QD
45665097|NCT01656395|Drug|Placebo|Parts I-II: Participants will receive Placebo tablets QD
45665098|NCT02114931|Biological|ABP 501|Solution for subcutaneous injection in a syringe containing 40 mg/0.8 mL ABP 501
45665099|NCT05185739|Drug|Pembrolizumab|Pre-operative Pembrolizumab (200mg IV every 3 weeks) for 2 cycles
45665100|NCT05185739|Drug|Lenvatinib|Pre-operative Lenvatinib (8 or 12mg PO once daily according to bodyweight <60gk≥) for 6 weeks
45819788|NCT00521924|Biological|infliximab|infliximab 3 mg/kg and basic treatment
45665101|NCT05185739|Drug|Pembrolizumab and Lenvatinib|Pre-operative combination of pembrolizumab and lenvatinib at the standard doses and duration as per cohort 1 and 2
45665102|NCT05184881|Other|Retrolaminar block|2- Cervical retrolaminar block: will be performed on prone-positioned patients. Under fluoroscopic visualization, after identification of the lamina at the desired level, a 25-gauge, 3.5-inch spinal needle was introduced and when the needle tip will be confirmed at the posterior aspect of the cervical lamina corresponding to cervical facet arthropathy level. 5 mL of a mixture of 3 mL 1% lidocaine and 2 mL dexamethasome (8mg/2ml) will be injected.
45819789|NCT00521924|Drug|DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.|Methotrexate (15 - 25 mg/week); chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89
45819790|NCT03927781|Drug|Pregabalin 300mg|One 300mg capsule will be administered PO 1 hour before surgery
45819791|NCT01553240|Device|TMS and functional MRI (Magstim)|single and paired pulse low frequency TMS. 3T structural MRI scans, amplitude modulated continuous arterial spin labeling( CASL) perfusion imaging sequence optimized for 3T is employed for perfusion MR scans using GE FAIR sequence for parallel imaging.
45819792|NCT03907579|Behavioral|Inflatable colon educational module|Participants attend a brief educational presentation in an inflatable colon, learning about colorectal cancer prevention and screening.
45819793|NCT00379964|Drug|caspofungin acetate|Cancidas 50 mg dose followed by 70 mg load on day 1 was administered in Indian adults with persistent fever and neutropenia for a maximum duration of empirical treatment from 28 days ((for patients without documented infection) to 90 days (for patients with documented baseline or emergent fungal infection). Patients were treated until the resolution of neutropenia (ANC>500/mm3), and for up to 72 hours later.
45961057|NCT00191841|Drug|Cisplatin|
45961058|NCT00550849|Drug|RTA 402|5 mg oral capsules
45665103|NCT05184881|Other|Medial Branch Block|1- Cervical medial branch block: will be performed on prone-positioned patients using a posterior approach. Under fluoroscopic visualization, after identification of the waists of the articular pillars at the desired levels, each medial branch block was administered with a 25-gauge, 3.5-inch spinal needle. When the place of the needle tip will be confirmed at the mid-point of the waists of articular pillars, 1 ml of the mixture of 0.5 mL 1% lidocaine and 0.5 mL dexamethasome (8mg/2ml) will be injected at each level.
45665104|NCT05144711|Procedure|Selective caries excavation|Selective caries excavation leaving stained but leathery dentine towards the pulp
45665105|NCT05144711|Procedure|Non selective caries excavation|Complete excavation of caries regardless of the risk of pulp exposure
45665106|NCT05238935|Other|prescribed physiotherapy course|provide full assessment and treatment program as postoperative rehabilitation management
45665107|NCT05184725|Device|SaMD CARINAE|SaMD CARINAE delivers the following digital therapeutic intervention to the patients: 1) Personalised patient-centred health education program to improve patient's disease and recovery self-management skills. 2) AI-based behaviour change program to promote healthier lifestyle habits. 3) Personalised mental well-being coaching program to improve patient's ability to cope with emotional disturbances such as stress and anxiety. 4) A collaborative digital support platform to enable information exchange between patients, caregivers, and healthcare professionals.
45819794|NCT01545518|Drug|IVIG|IVIG 2 mg/kg in two divided doses with placebo crossover
45819795|NCT04320823|Device|Updated Plasma Collection Feature|Plasma collection using a novel, patented system that supports a more individualized collection approach.
45819796|NCT04320823|Device|Current Plasma Collection Approach|Plasma collection using the current collection approach.
45819797|NCT01539590|Drug|BB3|Daily intravenous administration of 2 mg/kg BB3 for four (4) days
45819798|NCT01539590|Drug|Normal saline|Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
45819799|NCT00380042|Device|Cortical Stimulation|Cortical stimulation of prefrontal cortex
45819800|NCT00380042|Device|Sham|Sham stimulation
45819801|NCT04313647|Biological|1X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (2.0*10^8 nano vesicles/3 ml)
45819802|NCT04313647|Biological|2X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (4.0*10^8 nano vesicles/3 ml)
45819803|NCT04313647|Biological|4X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (8.0*10^8 nano vesicles/3 ml)
45455265|NCT01215331|Drug|Insulin|Insulins most commonly used during pregnancy by our group are rapid acting insulins and long acting human insulins (long acting analogs are not authorized in pregnancy). An ultra-fast acting insulin will be started before a meal (1, 2 or 3 meals) at 4-6 IU (according to the weight) if the glycemic value 2 hours after this meal is ≥ 6.7 mmol/L in 50% of cases. It will be increased by 2 units every 2 days until obtaining the aimed objectives. Long acting insulin will be started at 4-6 units at bedtime if the glycemic value before breakfast is ≥ 5.3 mmol/L in 50% of cases, and it will be increased by 2 units every 2 days until reaching the objective. A combination of both insulins could be necessary (maximum of 4 injections per day).
45458509|NCT01317680|Device|Sham control|We use the same probe that induces the same sensation on the penis and the same noise yet no energy
45819804|NCT04313647|Biological|6X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (12.0*10^8 nano vesicles/3 ml)
45819805|NCT04313647|Biological|8X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (16.0*10^8 nano vesicles/3 ml)
45961059|NCT00550849|Drug|RTA 402|25 mg oral capsules
45458510|NCT03494062|Behavioral|Exercise|Home-based exercise training
45819806|NCT00537446|Device|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of high-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 12 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
45819807|NCT00537446|Device|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of low-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 6 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
45819808|NCT01526408|Drug|Famciclovir|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months on drug).
45819809|NCT01526408|Drug|Placebo|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).
45819810|NCT03660787|Drug|Seroguard|Seroguard 0.41 g/L solution
45819811|NCT03660787|Drug|Placebo|Saline
45819812|NCT04713644|Drug|Standardized Propofol Administration|Intravenous bolus propofol administration of 0.5 mg/Kg dose, plus 0.5 mg/Kg extra if necessary
45819813|NCT00000734|Drug|Sulfamethoxazole-Trimethoprim|
45819814|NCT00000734|Drug|Zidovudine|
45819815|NCT03926065|Other|Plain Vegetables Served in 100% Portion Size|Lunch includes (a) vegetables without added flavoring (b) the baseline portion size of vegetables
45819816|NCT03926065|Other|Plain Vegetables Served in 200% Portion Size|Lunch includes (a) vegetables without added flavoring (b) 200% of the baseline portion size of vegetables
45961060|NCT00550849|Drug|RTA 402|50 mg oral capsules
45961061|NCT00550888|Procedure|suture techniques|
45961062|NCT00550927|Biological|bevacizumab|
45961063|NCT00550927|Drug|enzastaurin hydrochloride|
45961064|NCT00550927|Other|diagnostic laboratory biomarker analysis|
45961065|NCT00550927|Other|pharmacological study|
45961066|NCT00550966|Behavioral|Psychoeducative program in fibromyalgic patients|Multi-component program including information about the illness, counselling about physical exercise and training in autogenic relaxation. The intervention consists on nine 2 hour sessions delivered during a two month period. The pharmacological treatment prescribed by the physician is maintained in both groups.
45961067|NCT00161720|Drug|Protein C Concentrate (Human) Vapor Heated|Protein C Concentrate (Human) Vapor Heated
45961068|NCT00185133|Drug|Olmesartan medoxomil|
45819817|NCT03926065|Other|Enhanced Vegetables Served in 100% Portion Size|Lunch includes (a) vegetables with added flavoring (b) the baseline portion size of vegetables
45819818|NCT03926065|Other|Enhanced Vegetables Served in 200% Portion Size|Lunch includes (a) vegetables with added flavoring (b) 200% of the baseline portion size of vegetables
45961069|NCT00185133|Drug|Amlodipine|
45458511|NCT03467360|Drug|acetazolamide in combination with platinum and etoposide-based radiochemotherapy|Radiation therapy will be combined with platinum and etoposide-based chemotherapy combined with 3-6 tablets per day of acetazolamide during the entire course of therapy (dosage appropriate to the inclusion phase).
45665108|NCT05238623|Diagnostic Test|additional EIT Measurement|Patients who receive standard CT and pulmonary function testing also receive electroimpedance tomography measurement. The lunghealthy Patients in the control group only receive a EIT.
45665109|NCT05237687|Drug|Sirolimus|Patients will be randomly assigned to sirolimus or standard of care
45819819|NCT03888404|Other|Pregnancy preferences (Aim 1)|The primary exposure of interest for Aim 1 will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
45819820|NCT03888404|Other|Sociocultural environment (Aim 2)|For Aim 2 will assess the roles of contextual and individual variables on pregnancy decision-making and care-seeking outcomes (including state political environment, stigma, social emotional and instrumental support, feelings about the pregnancy, SES).
45665110|NCT05184413|Other|Multimodal treatment|A multimodal telerehabilitation intervention will be conducted through Whatsapp video calls. The combined treatment includes: 1) One 30-minute session of education in neurosciences of pain, using audiovisual material with examples and metaphors to improve the patient's understanding. In addition, two sessions of reinforcement of key contents will be held every 15 days; 2) Therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
45819821|NCT03888404|Other|Pregnancy preferences (Aim 3a)|The primary exposure of interest for Aim 3a will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
45819822|NCT03888404|Other|Pregnancy (Aim 3b)|The exposure of interest for Aim 3b will be experiencing pregnancy. DAP level will be examined as an effect modifier.
45819823|NCT03663283|Drug|Liposomal Bupivacaine|Interscalene Nerve Blocks
45961070|NCT00551005|Drug|celecoxib|
45819824|NCT03663283|Drug|Bupivacaine Hydrochloride|Interscalene Nerve Blocks
45961071|NCT00551005|Drug|etoposide|
45961072|NCT00551005|Other|immunoenzyme technique|
45961073|NCT00551005|Other|laboratory biomarker analysis|
45961074|NCT00551044|Drug|Bicalutamide|Bicalutamide 150mg once daily, oral administration, for 12 months
45819825|NCT00380198|Drug|Apadenoson|
45819826|NCT00000764|Drug|Isotretinoin|
45819827|NCT00000764|Drug|Interferon alfa-2a|
45961075|NCT00551083|Other|Computerized Decision Support System for Depression (CDSS-D)|The CDSS for depression was based on an up-to-date model of the Texas Medication Algorithm Project that employs the principles of Measurement Based Care (MBC), while at the same time having a user interface for providers that is easy-to-use. MBC is the systematic use of measuring clinical outcomes at routine visits to guide treatment management. These outcomes may include symptoms, side effects, and medication adherence. Recent efforts from the large, multi-site effectiveness study, Sequenced Treatment Alternatives to Relieve Depression (STAR*D), show that a treatment plan guided by MBC is integral in implementing algorithm based care.
45458512|NCT03500536|Behavioral|IntelliCare|A suite of mobile apps that use principles of computerized therapy to decrease symptoms of depression.
45819828|NCT03909763|Drug|Berberine plus danazol|Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks
45819829|NCT00484718|Drug|celecoxib|oral, 100 mg bid
45819830|NCT00484718|Drug|Oxycodone|oral, 20 mg bid
45819831|NCT00484718|Drug|placebo|oral bid
45819832|NCT03665155|Drug|89Zr-daratumumab|2 mCi of 89Zr-daratumumab will be administered on day 0.
45819833|NCT03665155|Device|PET/CT scans|PET/CT images will be obtained on post-administration days 1, 2-4, 5-6, and/or 7-8 following administration of 89Zr-DFO-daratumumab to determine the optimal time point for imaging.
45819834|NCT03665155|Other|Blood draws|Blood and serum samples will be weighed and counted in a scintillation well counter calibrated for 89Zr. Immediately before or after each PET/CT imaging session,
45819835|NCT00477230|Device|Endoscopic Ablation System|Single ablation procedure with Endoscopic Ablation System
45819836|NCT00477230|Drug|Standard Anti-arrhythmic Drug (AAD) Therapy|Medication as prescribed by physician.
45961076|NCT00551083|Other|Usual Care (UC)|"Usual Care was up to the discretion of the study physician and the patient treated. These physicians were provided with up-to-date treatment protocols for depression, but were not instructed to strictly adhere to a treatment algorithm. Therefore, they treated depressed patients as they usually would."
45961077|NCT00161759|Drug|Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin|
45961078|NCT00551122|Biological|filgrastim|
45961079|NCT00551122|Biological|lenograstim|
45961080|NCT00551122|Biological|pegfilgrastim|
45961081|NCT00551122|Drug|cisplatin|
45961082|NCT00551122|Drug|gemcitabine hydrochloride|
45961083|NCT00551122|Drug|ifosfamide|
45961084|NCT00551122|Drug|paclitaxel|
45961085|NCT00551239|Biological|rituximab|Given IV
45961086|NCT00551239|Drug|fludarabine phosphate|Given IV
45961087|NCT00551239|Drug|pixantrone dimaleate|Given IV
45961088|NCT00191880|Drug|atomoxetine|
45665111|NCT05184413|Other|Unimodal treatment|An unimodal telerehabilitation intervention will be performed through Whatsapp video calls. The treatment will include only a therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
45665112|NCT05183789|Diagnostic Test|Evaluation of serum levels of IL-6 and IL-8|Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits).
45665113|NCT01657019|Drug|Lisdexamfetamine dimesylate|50 or 70 mg administered orally, once a day for 52 weeks
45665114|NCT05237453|Radiation|Photons|MR-guided adaptive radiotherapy
45665115|NCT05182229|Other|Home-based (a hybrid model) CDT|Participants will be provided therapist-administered, in person complete decongestive therapy (CDT) two times per week for two weeks (4 sessions), followed by real-time, virtual CDT consultations two times per week for three weeks (7 sessions) and one in person follow-up visit.
45665116|NCT05182229|Other|Clinic-based CDT|Participants will be provided therapist administered, in-person CDT two times per week for six weeks (12 sessions).
45819837|NCT03901105|Drug|flortaucipir F18|No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) at baseline will be read by independent, blinded readers. IV injection, 240 megabecquerel (MBq) (6.5 mCi), single dose in AZES
45819838|NCT03901105|Procedure|Brain PET Scan|positron emission tomography (PET) scan of the brain
45819839|NCT00448682|Drug|Docetaxel|
45819840|NCT00448682|Drug|Floxuridine|
45819841|NCT00448682|Drug|Leucovorin|
45819842|NCT00448682|Drug|Oxaliplatin|
45819843|NCT04713488|Biological|Sputnik Light|solution for intramuscular injection Composition for 1 dose (0.5 ml)
45819844|NCT03675451|Drug|89ZR-DF-IAB2M|injection of 10 milligrams of radioactive 89Zr-Df-IAB2M followed by PET/CT scan
45665117|NCT02329327|Biological|Andexanet|There were 2 possible dosing regimens: Low dose = 400 milligram (mg) bolus plus 4 mg/minute continuous infusion for 120 minutes; High dose = 800 mg bolus plus 8 mg/minute continuous infusion for 120 minutes.
45665118|NCT05235269|Drug|I124-AT01 only|Intravenous injection of I124-AT01 on Day 1 and again at Week 6 followed by a full body Positron Emission Tomography/Computed Tomography (PET/CT) scan.
45819845|NCT03675451|Drug|68Ga-PSMA-HBED-CC|Optional but recommended 68Ga-PSMA-HBED-CC (5±2mCi) injection and PET/CT scan (1 to 3 hours after the injection) will also be performed prior to radical prostatectomy depending on subject's availability and compliance.
45819846|NCT03870152|Procedure|Electrocautery Ablation (EC)|For the purposes of the trial, one round of EC treatment consists of two individual EC treatments with a post-EC bronchoscopy in between to check for a response to the 1st EC treatment. Within each round, the second EC treatment will only be administered if the post-treatment bronchoscopy confirms presence of persistent high grade disease. Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline.
45819847|NCT00380120|Drug|sodium warfarin|dosage: as much as it is required to prolong the international normalized ratio, checked every 2-3 weeks, between 2.0 and 3.0
45819848|NCT00380120|Drug|Sodium warfarin|As much drug as it is necessary to prolong the international normalized ratio between 2.0 and 3.0
45819849|NCT03675685|Biological|CCH (collagenase clostridium histolyticum)|A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.
45819850|NCT00000770|Drug|Nevirapine|
45819851|NCT00000770|Drug|Zidovudine|
45819852|NCT00000770|Drug|Didanosine|
45665119|NCT05182151|Drug|Istradefylline 40 mg|adenosine A2A receptor antagonist
45665120|NCT05181917|Behavioral|STUDIA app|STUDIA application has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. . This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.
45665121|NCT02328937|Device|etafilcon A|spherical hydrophilic soft contact lens worn in a daily wear modality
45665122|NCT02328937|Device|lotrafilcon B|
45665123|NCT02328937|Device|comfilcon A|
45665124|NCT05181605|Drug|Folfirinox and Stereotactic Body Radiotherapy|Neoadjuvant treatment is composed of folfirinox plus stereotactic body radiotherapy
45665125|NCT02328547|Drug|Fecal microbiota transplantation capsules|Fecal microbiota transplantation capsules contain extensively screened donor stool and are prepared by OpenBiome, Medford, MA.
45819853|NCT03677089|Behavioral|12 ECHO Autism telehealth clinics|Twice-monthly 2-hour ECHO Autism Clinics will be provided during a 6-month period. Each Clinic will include a didactic presentation, 2 to 3 Primary Care Provider-generated case presentations, expert feedback, and group discussion. Although the ECHO Clinic will include discussion of specific cases, no identifiable personal health information will be shared, individual patients will not be identified, and no direct patient care will be provided.
45665126|NCT02328547|Drug|Placebo capsules|Placebo capsules prepared by OpenBiome, Medford, MA
45819854|NCT03677245|Other|Strider Balance Bike|Learning to ride a Strider balance bike
45819855|NCT00383630|Biological|Intramyocardial injection of bone marrow mononuclear cells|6mL of bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
45819856|NCT00383630|Biological|Intramyocardial injection of CD34+ selected bone marrow mononuclear cells|6mL of CD34+ selected bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
45819857|NCT00383630|Device|LVAD alone|LVAD implantation without any intramyocardial injection of bone marrow cells.
46079504|NCT05156099|Device|Ultrasound Scanning|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.
45665127|NCT04889443|Procedure|Surgical cartilage repair procedure requiring harvest procedure or Autologous Stromal Cell Implantation|Any surgical cartilage repair procedure of the knee that requires a harvest biopsy of knee cartilage, which will leave a controlled small cartilage injury
45665128|NCT04883281|Radiation|Intensity modulated radiation therapy (IMRT) with or without chemotherapy|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
45665129|NCT04883281|Drug|cisplatin, cetuximab, or carboplatin-paclitaxel|chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
45665130|NCT05142293|Other|Ambulatory procedure|In the same-day hospitalization group, some patients will be hospitalized on an ambulatory process
45819858|NCT04285411|Device|Accuracy of the VitalDetect™ pulse oximetry system|The purpose of this study was to validate the SpO2 accuracy of the VitalDetect™ pulse oximetry system during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. It was expected that the Accuracy Root Mean Square (ARMS) performance of the oximetry system would meet the required specification of ARMS of 3.0% or less.
45819859|NCT00368654|Drug|Methotrexate|Initial dose 5 mg, then 15 mg per week
45961089|NCT00551278|Device|GeneSearch™ Breast Lymph Node (BLN) Assay|"For in vitro diagnostic use only.~The GeneSearch™ Breast Lymph Node (BLN) Assay is a qualitative, in vitro diagnostic test for the rapid detection of greater than 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes.~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Veridex lymph node cutting scheme, is required."
45819860|NCT00368654|Drug|Raptiva|Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg
45819861|NCT03888469|Device|Verofilcon A contact lenses|Investigational daily disposable soft contact lenses
45819862|NCT03888469|Device|Etafilcon A contact lenses|Commercially available daily disposable soft contact lenses
45819863|NCT00000776|Drug|Flucytosine|
45819864|NCT00000776|Drug|Fluconazole|
45961090|NCT04724525|Other|soft contact lens Toric|soft contact lens toric with different axis and power that use in human's eye
45961091|NCT00551317|Drug|Darapladib (SB480848)|
45665131|NCT02300311|Drug|nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area approximately 20 x 20 cm2 up to 3 times in a 24 hour period
45665132|NCT02300311|Drug|placebo matching nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
45665133|NCT05141903|Dietary Supplement|Dietary supplement, probiotic, antibiotic conditioning -all groups|Dietary supplement, probiotic, antibiotic conditioning -all groups
45665134|NCT05140499|Drug|Liposomal bupivacaine|Popliteal nerve block
45665135|NCT05140499|Drug|Bupivacaine Hydrochloride 0.5 % Injectable Solution|Continuous nerve catheter
45819865|NCT00000776|Drug|Amphotericin B|
45819866|NCT00000776|Drug|Dexamethasone|
45819867|NCT04283773|Combination Product|p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267)|Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).
45819868|NCT04283773|Combination Product|Ki67 antibody (DAKO) for malignant cases only|Treatment of slides that cut from paraffin embedded blocks related to malignant case group by immunohistochemical method by Ki67 antibody.
45819869|NCT00329732|Drug|0.5% bupivicaine and 2% lidocaine|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion. If the subject has a bilateral headache or the headache is known to switch sides then the block will be performed bilaterally. If the headache is strictly unilateral, the block will be performed only on the side of the headache
45819870|NCT00329732|Drug|Saline placebo|matching volume of saline (placebo)
45961092|NCT00551356|Drug|Insulin lispro mix 25|Insulin lispro mix 25 given SC twice-daily in conjunction with oral antidiabetic medications.
45961093|NCT00551356|Drug|Glargine|Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.
45961094|NCT00551395|Procedure|selective laser trabeculoplasty - early completion|180 degrees of laser on day 1 and other 180 degrees on day 2.
45961095|NCT00551395|Procedure|Selective laser trabeculoplasty - late completion|180 degrees of laser on day 1 and other 180 degrees at 1 month follow up point.
45961096|NCT02963337|Drug|remifentanil|Remifentanil PCA will be used to deliver intravenous drug boluses from 20 to 40 micrograms per 2 min lockout interval.
45819871|NCT03438500|Device|Cardiac Extracorporeal Shockwave Therapy (Modulith SLC)|40 - 60 spots per visit (200 shots/spot) at Energy Level 3
45665136|NCT05233631|Procedure|Therapeutic Endoscopic ultrasound|A minimally invasive procedure to assess digestive (gastrointestinal) and lung diseases. Procedure allows detailed imaging of the regional anatomy by approximating the frequency transducer to the region of interest.
45961097|NCT02963337|Drug|combined spinal-epidural analgesia|Patient controlled epidural analgesia will be used to deliver epidural boluses of 6-10 ml of 0,1% bupivacaine with 2 micrograms of fentanyl per ml per 15 min lockout interval.
45961098|NCT00551434|Dietary Supplement|Creatine|Creatine 21 g daily
45961099|NCT00551434|Dietary Supplement|L-arginine and creatine|L-arginine
45961100|NCT00551434|Dietary Supplement|l-arginine|l-arginine 9 g daily
45961101|NCT00551434|Dietary Supplement|placebo, double|placebo
45961102|NCT00161798|Biological|Tick-borne encephalitis vaccine|
45458277|NCT02317120|Genetic|Multiplex ligation-dependent probe amplification (MPLA) BRCA1 BRCA2|Firstly many pairs of probes, containing: a universal primer sequence, a specific hybridisation target sequence and a stuffer DNA region to vary the size of the resulting product, are hybridised adjacent to each other on the target DNA strand .The two adjacent probe sequences are ligated to form a continuous section of DNA.The ligated probes are then amplified using PCR. The amplified fragments are analysed by capillary electrophoresis to detect the different fragment lengths. These data can be analysed to show the relative copy number of each fragment that is present in the sample.
45665137|NCT05231915|Genetic|HOXB13 c.853delT mutation|Identify the Allelic frequency of the HOXB13 c.853delT mutation in patients with a cancer prostate in Martinique
45665138|NCT04229381|Procedure|Physical Therapy|Undergo physical therapy
45819872|NCT04281901|Drug|Platelet- and extracellular vesicle-rich plasma|ear wick soaked in platelet- and extracellular vesicle-rich plasma
45819873|NCT04281901|Drug|Standard conservative treatment|standard conservative measures, including antimicrobials, antiseptics and aural toilette for treating a chronically inflamed radical cavity.
45819874|NCT00000782|Biological|gp160 Vaccine (Immuno-AG)|
45819875|NCT00000782|Biological|gp160 Vaccine (MicroGeneSys)|
45819876|NCT04280653|Device|NDE L68 StableFit® Punctal Plug|Tear lake evaluation of the planned study eye, prior to insertion of the Punctal Plug and then tear lake evaluation at days 7 and 28 after punctal plug insertion.
45819877|NCT00000800|Drug|Methadone hydrochloride|
45819878|NCT00000800|Drug|Zidovudine|
45819879|NCT00000806|Drug|Telinavir|
45819880|NCT03679975|Drug|Riluzole Oral Soluble film (ROSF) 50 mg|Enrolled subjects underwent an instrumental evaluation of swallowing safety before and after administration of a single dose of the ROSF formulation containing 50 mg of riluzole.
45819881|NCT03198416|Device|High-resolution pharyngeal manometry catheter|The system is a widely-used tool in gastrointestinal medicine for high resolution mapping of pressures within tubular organs.The device will be deployed trans-nasally into the pharyngeal and esophageal lumen in exactly the same fashion as is done for motility studies.
45961103|NCT00551473|Drug|Lavoltidine|
45961104|NCT03455803|Device|CPAP|Continuous positive airway pressure
45961105|NCT00191919|Drug|Duloxetine Hydrochloride|
45961106|NCT00191919|Drug|Placebo|
45961107|NCT00161837|Biological|Vero Cell-derived Influenza Vaccine|
45961108|NCT00161837|Biological|Egg-derived Influenza Vaccine|
45458278|NCT01359098|Drug|Ciprodex Otic Suspension|4 gtt b.i.d. for 7 days.
45665139|NCT04229381|Other|Quality-of-Life Assessment|Ancillary studies
45665140|NCT04229381|Other|Questionnaire Administration|Ancillary studies
45665141|NCT04229381|Procedure|Relaxation Therapy|Undergo progressive muscle relaxation
45665142|NCT05178485|Drug|Bupivacain|FDA approved drug
45819882|NCT03887299|Combination Product|ReliaTect™ Post-Op Dressing (contains chlorohexidine gluconate or CHG)|Dressing will be applied in the operating room at the end of case and be in place until postoperative day 7
45819883|NCT03887299|Other|Standard Wound Care|Wound care will be administered as standard protocol in our institution
45819884|NCT00244010|Device|Allogeneic stem cell transplant|Participants will receive a reduced intensity conditioning regimen consisting of fludarabine, thiotepa, melphalan, and OKT3 followed by an infusion of haploidentical stem cells. Rituximab will be administered within 24 hours of the infusion in an effort to prevent posttransplant lymphoproliferative disorder LPD. In addition to T-cell depletion of the donor product, participant will receive mycophenolate mofetil for prophylaxis of GVHD.
45819885|NCT03684265|Drug|Meloxicam Capsule (Test)|single dose
45819886|NCT03684265|Drug|Meloxicam Tablet (Reference)|single dose
45819887|NCT00218036|Drug|Modafinil 200mg|10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1/2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
45819888|NCT00218036|Drug|Modafinil 400mg|10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
45819889|NCT00218036|Drug|Citalopram 20mg|10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
45665143|NCT05178485|Other|Normal Saline|FDA approved
45665144|NCT05230433|Dietary Supplement|High-fat Challenge|The shake will be composed of a mixture of BOOST Glucose Control(R) (Nestlé Products) supplemented with palm oil. Each participant will consume a volume of liquid equivalent to 25% of their estimated daily caloric needs, calculated by the USDA Dietary Reference Intakes using a moderate activity factor.
45665145|NCT05229185|Device|DeXtreme training (error-enhancement)|15-20 min DeXtreme - 15 min conventional therapy - 15-20 min DeXtreme
45665146|NCT05175365|Behavioral|Dance|Each session consists of a 60-minute dance class taught by a professional dancer. Dance classes begin with a seated warm-up with various coordination, rhythm, range of motion, memorization and coordination exercises. The level of difficulty of the exercises increases as the sessions progress. Balance is also an important part of training as well as the feeling of being part of a group, of interacting with each other. The hour ends with stretching in a sitting position.
45665147|NCT04228289|Drug|Oxytocin|40 IU intranasal spray
45819890|NCT00218036|Drug|Citalopram 40mg|10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.
45819891|NCT00218036|Drug|Placebo|Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg
45819892|NCT03848221|Drug|Systane Complete|Systane Complete is an artificial tear.
45819893|NCT03848221|Drug|Sensitive Eyes Rewetting Drops|Sensitive Eyes Rewetting Drops is a rewetting drop.
45819894|NCT05314699|Behavioral|resistance-aerobic exercise, RA|Participants conduct 5-min warm up, 13-min resistance exercise, 12-min aerobic exercise, and 5-min cool down.
45819895|NCT05314699|Behavioral|aerobic-resistance exercise, AR|Participants conduct warm up for 5-min, aerobic exercise for 12-min, resistance exercise for 13-min, and 5-min cold down.
45819896|NCT00205868|Device|Precision Spinal Cord Stimulation System|Stimulation on throughout study
45819897|NCT04271761|Other|Non-interventional, post-market, pilot study of Carina Cochlear System|Several objective acoustic measurements will be performed that do not require active participation from the subject.
45819898|NCT00233090|Drug|Modafinil|single dose of 200 mg. a day of modafinil for four weeks
45819899|NCT00233090|Drug|Placebo|daily dose of placebo for four weeks.
45819900|NCT04266925|Behavioral|3 referees present|We compared player behavior with one versus three referees present on youth soccer fields during match play. The time between these two matches ranged from a few hours to several weeks.
45819901|NCT04266925|Other|1 referee present|We compared player behavior with one versus three referees present on youth soccer fields during match play. The time between these two matches ranged from a few hours to several weeks.
45819902|NCT05182502|Device|Tixel|Subjects will receive 3 monthly treatments with the Tixel device to treat the signs of photodamage
45961109|NCT03455725|Device|CardiAMP Cell Therapy System|The CardiAMP Cell Therapy system consists of the CardiAMP Potency Assay, the Helix/Morph intramyocardial delivery catheter system, and the CardiAMP Cell Separator. The system allows the investigator to identify patients with a high chance to respond to im autologous stem cell therapy (using the CardiAMP Cell Potency Assay), to isolate the stem cells from a bone marrow harvest at the point of care (using the CardiAMP CS system), and to percutaneously inject the autologous cells into the myocardium using the Helix/Morph delivery catheters.
45665148|NCT04228289|Other|Placebo|matching intranasal spray
45819903|NCT04247581|Device|1-lead ECG|"1 lead ECG - All participants will record three single-lead ECGs at rest and three single-lead ECGs after exercise.~Intervention Other: Exercise - All participants will undergo three trials of exercise.~Other interventions: 12-lead ECG - All participants will simultaneously record 12-lead ECGs during rest and exercise sessions."
45819904|NCT02921906|Other|High protein meal|Breakfast with high protein / low carbohydrate content
45819905|NCT02921906|Other|High carbohydrate meal|Breakfast with high carbohydrate / low protein content
45819906|NCT02921906|Drug|Paracetamol|Standard dose of paracetamol administered with each meal to allow measurement of rate of gastric emptying.
45819907|NCT02921906|Other|Fasting state - sulphonylurea only|People with diabetes take sulphonylurea medication in the absence of any food stimulus
45819908|NCT04243369|Device|Non-diagnostic software solution|Collaboration Live is a non-diagnostic software solution intended for use with Philips (Philips Ultrasound, 22100 Bothell Everett Highway, Bothell, Washington 98021) EPIQ and Affiniti Series Ultrasound Systems (software version 5.0.2) that allows users to communicate (by text, voice, screen share, webcam video and remote takeover) from an ultrasound system or workstation to a remote destination.
45819909|NCT00000812|Drug|Thalidomide|
45819910|NCT03849937|Behavioral|Changing Talk Online (CHATO)|Three, one-hour online training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication strategies.
45819911|NCT02741180|Other|3D Imaging|"roadmapping of electrophysiology (EP) procedures"
45819912|NCT02741180|Other|Late Gadolinium Enhancement (LGE)|useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.
45819913|NCT00000818|Drug|Zidovudine|
45819914|NCT00377689|Behavioral|high intensity functional exercise|high intensity functional exercise
45819915|NCT00177866|Drug|Celebrex|"Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week washout period then placebo PO BID for the remaining 8 weeks - or - placebo PO BID for the first 8 weeks, followed by a 1 week washout period then Celebrex 200 mg PO BID for the remaining 8 weeks."
45819916|NCT00177866|Drug|placebo|placebo PO BID for either the first eight weeks or the last eight weeks of the study.
45819917|NCT03693937|Radiation|SRT-100|The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.
45961110|NCT03455725|Other|Sham Treatment|Patients will receive sham bone marrow procedure and a ventriculogram. A scripted sham percutaneous procedure will be performed
45961111|NCT00551512|Drug|CBP501 and Cisplatin|CBP501 is given IV on Day 1 of each cycle (every 21 days). Dose escalation of CBP501 and cisplatin will be starting doses of 3.6 mg/m² CBP501 and 50 mg/m² cisplatin (Dose Level 1). Step 1, if during the first 2 cycles, at least 2 out of 3 to 6 patients experience Dose Limiting Toxicity (DLT) at 50 mg/m² cisplatin, then the cisplatin dose will be de-escalated to 30 mg/m². If no more than 1 out of 6 patients experiences DLT, cisplatin dose will be escalated to 75 mg/m². Step 2, dose escalation will be performed using the cisplatin MTD, with escalating CBP501 doses. CBP501 dose escalation will take place until the MTD has been defined or 74 mg/m² is reached.
45961112|NCT00551551|Other|Pelvic floor muscle training with physiotherapist|8 sessions of 20-30 minutes each between 24 and 36 weeks of gestation with a physiotherapist or midwife
45961113|NCT00551551|Other|Written information about kegel exercises|Information about pelvic floor disorders prevention with personal pelvic floor exercises
45961114|NCT00161876|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
45961115|NCT00424320|Drug|Sodium bicarbonate|
45961116|NCT00551590|Drug|Placebo tablet|placebo PO (placebo control for sitagliptin) for three days
45961117|NCT00551590|Drug|Sitagliptin tablet|Sitagliptin 100 mg PO for three days.
45961118|NCT00551590|Drug|Saline infusion|Saline IV (placebo control for exendin(9-39)) on two consecutive study days
45961119|NCT00551590|Drug|Exendin(9-39) infusion|Exendin(9-39) IV on two consecutive study days.
45961120|NCT00551629|Biological|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
45961121|NCT00551629|Biological|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
45961122|NCT00551629|Biological|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
45961123|NCT00551629|Biological|PR51 (6, 15)|vaccine formulation containing 6 mcg of PRP-OMPC and 15 mcg of HBsAg
45961124|NCT00161915|Drug|Fibrin Sealant|
45458279|NCT01359098|Drug|Ciprodexa Otic Foam|0.3% Ciprofloxacin, 0.1% Dexamethasone Otic Foam, 1 actuation, q.d. for 7 days
45458280|NCT02320864|Procedure|Total knee replacement surgery|The surgeon removes damaged cartilage and bone from the surface of the knee joint and replaces them with a man-made surface of metal and plastic.
45665149|NCT05228951|Drug|Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor dalpiciclib, trastuzumab and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
45665150|NCT05227937|Drug|Amikacin|patient will be treated with amikacin 15 mg/kg IV or IM, based on actual body weight; for patients >120% of IBW, we will use AdjBW (IBW + 0.4(ABW-IBW)) rounded to nearest 50 mg. Patients who already have an IV will receive the medication IV, otherwise the dose will be given IM.
45819918|NCT03696589|Behavioral|Physical Activity Coaching|Based in the self-determination theory, participants will be coached on beneficial exercises, how to utilize supports and overcome barriers to PA engagement. Emphasis of exercise coaching will be on increasing aerobic exercise engagement and will include us of Fitbit devices to facilitate uptake and monitor aerobic exercise. Intervention will be delivered by a physical or occupational therapist, who will work with the participant to develop a plan, set goals and targets, and track changes. Additional resources that will support exercise engagement will be provided. Participants will have the choice to receive their face-to-face session either in person or remotely via secure video-based service.
45819919|NCT00089414|Drug|Ethinyl Estradiol/Drospirenone|Drug administered dependent upon arm.
45819920|NCT00089414|Drug|Placebo|
45819921|NCT00089414|Drug|CDB 2914|
45458281|NCT01319240|Drug|insulin degludec|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
45819922|NCT00000824|Drug|Lymphocytes, Activated|
45819923|NCT00075608|Biological|filgrastim|16mcg/kg IV daily beginning three days prior to stem cell collection through last day of stem cell collection
45819924|NCT00075608|Drug|melphalan|140-200 mcg/kg IV over two days
45819925|NCT00075608|Procedure|autologous stem cell transplantation|infusion of previously collected stem cells on Day 0
45819926|NCT00075608|Procedure|stem cell infusion|infusion of previously collected stem cells on Day 0
45961125|NCT00185172|Other|placebo|Placebo oral tablets for 2 weeks
45961126|NCT00185172|Drug|olmesartan medoxomil|olmesartan medoxomil oral tablets for 8 weeks
45961127|NCT00185172|Drug|olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets|olmesartan medoxomil oral tablets,or olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets
45961128|NCT04863118|Other|Strength training in shallow water and dry land|"Dry land: The intervention will last for 60 minutes, consisting of exercises to strengthen the global extensor musculature, that is, involving the upper limbs, trunk and lower limbs. Weights and equipment for strength training will be used. The sessions will start with 10 minutes of warm-up, the central part of exercises to strengthen the extensor muscles and the last part will consist of oriented stretches. In the central part, a typical strength training will be performed (2-6 series; 85% of RM), using submaximal subjective effort and with repetition control.~Shallow water: The intervention performed on dry land will be adapted and produced in an aquatic environment. Aquatic implements will be used for strength training."
46079505|NCT05156099|Device|Ultrasound Scanning - 2 months later|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.
46079506|NCT05155787|Device|Neurofeedback|Neurofeedback training as a method is going to let the brain producing the alpha signal (8-13 Hz).
45665151|NCT05174039|Drug|Miglustat 100Mg Oral Capsule|Subjects will initiate miglustat at Week 1 and dosing will be escalated until 600mg/d. If a subject has not reached the maximum dose (600 mg/d) by Week 8, the Week 8 dose will be subject's MTD.
45665152|NCT04422119|Procedure|Multi-Foam dressing|Application of a multi-layer foam dressing with Safetac in surgical wound
45665153|NCT04422119|Procedure|Usual care|Care of surgical wound with povidone-iodine and a gauze dressing with plaster.
45665154|NCT05138705|Biological|Quadrivalent Influenza Virus Split Vaccine|0.5ml Quadrivalent influenza vaccine The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/ H3N2, B/Victoria and B/Yamagata strains
45665155|NCT05138549|Drug|Astaxanthin|12 mg oral astaxanthin supplement
45665156|NCT05138549|Other|Placebo|Oral placebo identical to astaxanthin supplement
45819927|NCT03704467|Drug|M6620|Participants received 90 milligrams per square meter (mg/m^2) of M6620, intravenously (IV) on Day 2 of every 3 weeks (Q3W) cycle for a maximum of 6 cycles in combination treatment with carboplatin and avelumab on Day 1. The M6620 dose may be de-escalated to 60 mg/m^2, or 40 mg/m^2.
45819928|NCT03704467|Drug|Avelumab|Participants received IV infusion of avelumab 1600 mg on Day 1 of each Q3W cycle for maximum of 6 cycles in combination treatment with carboplatin and M6620. Thereafter, avelumab 800 mg intravenously on Day 1 of every two weeks as a maintenance mono-therapy until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
45819929|NCT03704467|Drug|Carboplatin|Participants received carboplatin area under the concentration-time curve 5 on Day 1 of each Q3W cycle for a maximum of 6 cycles in combination treatment with avelumab and M6620.
45819930|NCT03705481|Device|Remote treatment of PCI.|To evaluate the safety and performance of CorPath GRX POP System, in the ReMOTE (location outside hospital) delivery and manipulation of coronary guidewires and stent/balloon catheters, and manipulation of guide catheters during PCI procedures.
45819931|NCT00000836|Drug|Sevirumab|
45819932|NCT02210078|Biological|Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes|Given IV
45819933|NCT05177900|Device|Study Tool Computer|Nonconventional pulses delivered with custom-ware designed by Boston Scientific
45819934|NCT00000842|Drug|Nerve Growth Factor, Recombinant Human|
45819935|NCT02145260|Drug|Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate)|A lower dialysate sodium will bes used in the active comparator arm (138 mmol/L)
46079507|NCT05155787|Device|Shame neurofeedback|shame neurofeedback
45455266|NCT01215331|Drug|Metformin, glyburide and insulin|"Metformin (tablets of 500 mg) will be started at 250 mg/day x 1 day, and increased thereafter by 250 mg per day every 3 days until obtaining an adequate glycemic control. If metformin does not prove its effect at a dose of 750 mg, or if the side effects (mainly gastric) command to slow down or not to increase the posology, glyburide will be added.~Glyburide (tablets of 5 mg) will be started at a dose of 2.5 mg and will be increased by 2.5 mg every 3 days until obtaining an adequate glycemic control. The maximal dose in the study will bw 10 mg. It corresponds to the half of the maximal dose recommended in Canada.~Treatment failure is defined as glycemia above the Canadian Diabetes Association therapeutic objectives in spite of maximal doses or whether the doses can not be increased because of side effects. Insulin will be added to oral hypoglycemic agents."
45665157|NCT02300233|Drug|Volanesorsen|300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks.
46079508|NCT05153889|Other|Hospitalized in Intensive care unit|Patient hospitalized in Intensive care unit with ECG monitoring
46079509|NCT05153889|Other|Hospitalized in General cardiology ward|Patient hospitalized in General cardiology ward without ECG monitoring. patients randomized in this group will not be hospitalized in intensive care unit unless an event require intensive care unit monitoring.
45455267|NCT03772184|Procedure|Cervical inversion|inverting the cervical lip after delivery
45665158|NCT02300233|Drug|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
45665159|NCT04241549|Drug|Cusatuzumab|Cusatuzumab at a dose 20 milligram per kilogram (mg/kg) once every 2 weeks will be administered intravenously.
45665160|NCT04241549|Drug|Azacitidine|Azacitidine at a dose 75 milligram per square meters (mg/m^2) will be administered subcutaneously or intravenously.
45665161|NCT05137379|Behavioral|A joint functional score based on the affected joint|A joint function score according to the affected joint in patients with Ehlers-Danlos syndrome treated by surgery,: Shoulder (SSV; QuickDash), Knee (Lysholm tenger), Ankle (EFAS), Elbow and wrist (QuickDash) )
45665162|NCT02175225|Drug|Deferoxamine Mesylate|
45665163|NCT02175225|Drug|Placebo (for Deferoxamine Mesylate)|
45455268|NCT03526276|Other|CPP-ACP paste|Children will brush their teeth with CPP-ACP paste twice daily.
45455269|NCT03526276|Other|Fluoride toothpaste|Children will brush their teeth with fluoridated toothpaste twice daily
45455270|NCT03526276|Other|Both (Fluoride and CPP-ACP)|Children will brush their teeth with fluoridated toothpaste and apply CPP-ACP immediately after toothbrushing, twice daily.
45819936|NCT02145260|Drug|Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)|A higher dialysate sodium will be used in the experimental arm (142 mmol/L)
45819937|NCT00000848|Drug|Indinavir sulfate|
45819938|NCT00000848|Drug|Saquinavir|
45819939|NCT01795586|Drug|Eribulin|"Eribulin will be administered on days 1 and 8 slow IV push over 2 to 5 minutes. Premedications will be given per institutional guidelines.~Level 1: 0.9 mg/m^2; Level 2: 1.1 mg/m^2; Level 3: 1.4 mg/m^2"
45819940|NCT01795586|Drug|Carboplatin|Carboplatin will be administered intravenously on day 1 and day 8 of each cycle, immediately following eribulin infusion at a dose of area-under-the-curve (AUC) 2 over 30 minutes in 250 ML of 0.9 % normal saline. Carboplatin dose will be calculated using the Calvert formula using AUC of 2 as follows: Carboplatin dose (mg) = 2 X (GFR + 25).
45819941|NCT03707041|Drug|P218 (1000 mg) Oral Capsules|1000 mg P218 (4 x 250 mg capsules)
45819942|NCT03707041|Drug|Placebo Oral Capsules|Placebo capsules matched to the P218 capsules with regard to appearance and taste
46079510|NCT05151133|Biological|Low dose UCMSCs|Receive one course of treatment with a single injection : 0.5×10^6 cells/kg, with a total volume of 100 ml UCMSCs;
46079511|NCT05151133|Biological|Moderate dose UCMSCs|Receive one course of treatment with a single injection : 1.0×10^6 cells/kg, with a total volume of 100 ml UCMSCs;
46079512|NCT05151133|Biological|High dose UCMSCs|Receive one course of treatment with a single injection : 2.0×10^6 cells/kg, with a total volume of 100 ml UCMSCs;
45961129|NCT04863118|Other|High-intensity training in shallow and deep water|"Shallow water: The intervention will last 60 minutes. The exercises consist of: immersion, balance, strength, agility and displacement in the water. As they will start with 10 minutes of warm-up and the last part will consist of stretches oriented along the edge of the pool and on the depth reduction platform. In the main part of the intervention, different styles of exercises will be performed, with or without the use of implements. Displacements will have varying speeds in the same session, defined by Borg's Scale of subjective sensation of effort.~Deep water: The intervention carried out in shallow water will be adapted with the use of floating belts and reproduced in deep water."
45961130|NCT04836286|Behavioral|Emotive Intelligent Spaces (EIS)|The EIS leverages innovations across multiple disciplines, including sensory environment, computer science, psychology, and real-time human-computer interface. The colors of the LED lights on the EIS wooden panels are controlled by an artificial intelligence computer algorithm that will translate children's physiological responses (Galvanic skin response, body temperature, and blood volume pulse), captured by a digital wristband, into their emotional state and the associated preferred colored lighting. The algorithm was created in a co-investigator's published study11, using fuzzy logic and machine learning techniques (i.e., Decision Tree; accuracy 86%).To successfully carry out this project, our team blends expertise in educational psychology, early intervention, computer science, architecture, and interior design.
45961131|NCT04827355|Device|External Upper Esophageal Sphincter (UES) Compression Device|External Upper Esophageal Sphincter (UES) Compression Device fit to manufacturer guidelines.
45961132|NCT04827355|Device|Sham Device|External Upper Esophageal Sphincter (UES) Compression Device fit to pressure known not to provide treatment.
45961133|NCT04798885|Behavioral|GAIN 2.0|1) three structured group sessions of two hours duration performed jointly by a neuropsychologist, an occupational therapist and a physiotherapist. Relatives are also invited. 2) Up to five weekly semi-structured individual sessions of 30 min. duration with an allocated therapist
45961134|NCT00191997|Drug|Olanzapine|
45961135|NCT00551668|Procedure|proximal patellar surgery|Initial proximal patellar surgery
45961136|NCT00551668|Procedure|Nonoperative|Nonoperative without surgery
45961137|NCT00551824|Drug|Mitomycin C|Esophageal dilation session with topical mitomycin applied over esophageal mucosa after dilation.
45961138|NCT00161954|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
45961139|NCT00185250|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2 MIU per application in week 1 and 4 MIU per application in weeks 2 to 24 given subcutaneously every other day
45961140|NCT00185250|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2 MIU per application in week 1, 4 MIU per application in weeks 2 to 3 and 8 MIU per application in weeks 4 to 24 given subcutaneously every other day
45665164|NCT05171153|Other|Densitometry with Trabecular Bone Score|"Conventional bone densitometry at the level of the proximal femur and lumbar spine (L1-L4) (anteroposterior and lateral) measured with a General Electric Prodigy Advance Full enCORE version 11.x equipment. With the data from the lateral densitometry, and using the VFA Dual Vertebral Assessment H8650DA/DM software, a quantitative morphometric analysis of the thoracolumbar vertebrae (T4-L4) will be carried out. Additionally, microarchitectural parameters of the lumbar spine will be evaluated with TBS (iNsight v3.0) and bone quality in the proximal femur with the DEXA-3D 3D-SHAPER v2.10.1 software. Vertebral fracture will be excluded from the DXA and TBS analysis of the spine."
45961141|NCT00185250|Drug|Placebo|0.25 ml in week 1 and 0.50 ml in weeks 2 to 24 given subcutaneously every other day
45961142|NCT00185250|Drug|Placebo|0.25 ml in week 1, 0.50 ml in weeks 2 to 3 and 1.00 ml in weeks 4 to 24 given subcutaneously every other day
45961143|NCT04798066|Biological|HB-adMSCs|Autologous adipose derived mesenchymal stem cells
45665165|NCT05171153|Other|Quantitative Ultrasound of Calcaneus|Quantitative bone ultrasound of calcaneus evaluated with a SONOST 3000, (OsteoSys Co, Korea).
45665166|NCT05171153|Other|Laboratory test|Analysis of general biochemical parameters and serum phospho-calcium metabolism, including: total calcium, albumin, phosphorus, 25-OH-vitamin D, intact PTH (iPTH), creatinine, estimated glomerular filtration rate, carboxy-terminal telopeptide of type I collagen ß-CTx (Crosslaps) and N-terminal propeptide of type I procollagen (P1NP).
45665167|NCT05170841|Drug|Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 MG|Administered as one single tablet to be taken every 8 hours
45665168|NCT05170841|Drug|Tramadol Hydrochloride 100 MG|Administered as two capsules with 50 mg each to be taken every 8 hours
45819943|NCT03707041|Drug|P218 (100 mg) Oral Capsules|100 mg P218 (2 x 50 mg capsules)
45819944|NCT03707041|Biological|PfSPZ Challenge|3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
45819945|NCT03879044|Device|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
45819946|NCT02212574|Drug|Lomustine|Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1.
45819947|NCT02212574|Drug|Vincristine|Chemotherapy Cycle A Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15.
45819948|NCT02212574|Drug|Cisplatin|Chemotherapy Cycle A Cisplatin is given directly into a vein over 8 hours on Day 1.
45819949|NCT02212574|Drug|Cyclophosphamide|Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2.
45819950|NCT02212574|Drug|Mesna|Chemotherapy Cycle B MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours.
45819951|NCT02212574|Drug|Vincristine|Chemotherapy Cycle B Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.
45961144|NCT00551863|Behavioral|IVPT|Violence prevention intervention based on Motivational Interviewing and CBT
45961145|NCT00551902|Procedure|Trabeculectomy with anterior chamber infusion system|Trabeculectomy with anterior chamber infusion system
45961146|NCT00551902|Procedure|Trabeculectomy without anterior chamber infusion system|Standard trabeculectomy surgery
45961147|NCT00161993|Drug|Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution|
45961148|NCT00161993|Drug|Gammagard S/D (Solvent/Detergent)|
45961149|NCT00551941|Procedure|BMP-7 in adjunct to fresh frozen allograft|non-union of diaphysary tibial fractures treated with BMP-7 in adjunct to fresh frozen allograft
45961150|NCT00551941|Procedure|allograft together with DBM|non-union of diaphysary tibial fractures treated with allograft together with DBM
45961151|NCT00185289|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
45961152|NCT00551980|Behavioral|Cognitive, Relaxation, Exercise Therapy|The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
45961153|NCT00552136|Procedure|Ankle Arthroplasty|
45961154|NCT00552136|Procedure|Ankle Arthrodesis|
45455271|NCT04972916|Other|Patient navigation-based tobacco harm reduction intervention|At the first intervention interview, the patient navigators will educate participants about the benefits of quitting, introduce smoking cessation resources, motivate participants to link with treatment, help participants attend smoking cessation treatments, and assess barriers that prevented them from being able to consider smoking cessation. The cessation treatment resources will be discussed include PennState Health Smoking Cessation Clinic, Pennsylvania Quitline, or visiting their primary care provider (PCP) to discuss cessation, prescription medications, and/or nicotine replacement therapy. A follow-up call will be made 1 month later to further assist and motivate to use tobacco treatment services, and assess interim tobacco treatment engagement outcome.
45819952|NCT03708367|Device|LipiFlow Thermal Pulsation System|Treatment at preoperative visit for study group
45455272|NCT01218295|Device|Spirotiger®|training session :10 minutes twice a day X 4 weeks
45961155|NCT00162071|Drug|apadenoson|
45961156|NCT00552214|Device|Blood test|Screening of HIV-1 RNA, HCV RNA and HBV DNA in Human Blood Donor Plasma Specimens
45819953|NCT03708367|Device|LipiFlow Thermal Pulsation System|Treatment at 3 month visit as the cross-over group
45819954|NCT00000854|Drug|Nandrolone decanoate|
46079513|NCT05136560|Drug|Dexamethasone|Intervention drugs would be administered for 1 or 2 days.
45665169|NCT05170841|Drug|Placebo|Administered as one tablet if matching Dexketoprofen Trometamol 25 mg and Tramadol Hydrochloride 75 MG or two capsules if matching Tramadol Hydrochloride 100 MG
45665170|NCT05169671|Drug|ATH-1020|ATH-1020 in oral capsule form
45819955|NCT03862027|Device|Esophageal Balloon catheter|"Pressures [Esophageal Pressure (Pes), Airway Pressure (Paw), and Transpulmonary Pressure (Ptp)] are measured directly through the ventilator. The waveforms of Paw, Pes, and Ptp will be visualized on the ventilator. Ptp is obtained from Paw - Pes. All patients will have baseline measurements recorded of ICP, CPP, and MAP.~PEEP will be increased on the ventilator to achieve a Ptp between 0 and +2 cm H2O (Optimal PEEP).~Measurements of Intracranial pressure (ICP), cerebral perfusion pressure (CPP), and mean arterial pressure (MAP) will be repeated 5 minutes after the change in PEEP."
45665171|NCT05169671|Drug|Placebo|Placebo in oral capsule form
45819956|NCT03856255|Device|Micro-Tech Endoscopic Gauge|Use of Micro-Tech Endoscopic Gauge to measure any polyp detected during a screening or surveillance colonoscopy.
45819957|NCT04298918|Drug|Placebo|Participants will receive oral placebo in combination with trastuzumab emtansine.
45819958|NCT04298918|Drug|Venetoclax|Participants will receive oral venetoclax.
45961157|NCT00185328|Drug|Estradiol/DRSP (Angeliq, BAY86-4891)|1 tablet of 2 mg drospirenone and 1 mg estradiol, orally administered once daily, over three 28-day treatment cycles
45961158|NCT04766164|Behavioral|Survey|Data will be obtained via self-report from participants via a one-time Qualtrics survey.
45961159|NCT00552253|Drug|Levothyroxin treatment|Levothyroxin 100 micogram will be administered once daily 1 hour before meal of just after meal for 3 months, and the dose will be titrate to keep serum TSH level between 0.1~0.3 mU/L. It will be discontinued for 3 months. Then
46079514|NCT05134116|Other|Treatment as usual + cerebral oximetry monitoring the first 72 hours of life|SafeBoosC - Safeguarding the Brain of Our Smallest Children - an Investigator-initiated Randomised, Blinded, Multinational, Phase II Feasibility Clinical Trial on Near-infrared Spectroscopy Monitoring Combined With Defined Treatment Guidelines Versus Standard Monitoring and Treatment as Usual in Premature Infants
46079515|NCT05127460|Other|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative. The system will send a message to corresponding physicians if positive finding.
46079516|NCT05125016|Drug|REGN4336|Administered once weekly (QW) or every 3 weeks (Q3W) by subcutaneous (SC) injection.
45665172|NCT05109221|Device|ultrasound|using of ultrasound in prediction of difficult intubation in obese surgical patients
45819959|NCT04298918|Drug|Trastuzumab emtansine|Participants will receive intravenous (IV) trastuzumab emtansine.
45819960|NCT03712189|Device|LifeFlow|The LifeFlow® is a hand-operated rapid infuser designed to administer fluids to patients by a single user, for clinical situations in which a large volume or rapid infusion of fluid or colloid is required. The device delivers fluid in 10mL increments with each complete handle compression, which refills during release, automating a push-pull mechanism. The syringe then automatically refills with handle release.
45819961|NCT00001676|Drug|SQ Fludarabine|
45819962|NCT03714919|Drug|Dextromethorphan|Preoperative oral dextromethorphan 1 mg/kg
45819963|NCT03714919|Drug|Acetaminophen|Preoperative oral acetaminophen 15 mg/kg
45819964|NCT03714919|Drug|Dexmedetomidine|Intraoperative intravenous dexmedetomidine 0.5 μg/kg
45819965|NCT03714919|Drug|Ketamine|Intraoperative intravenous ketamine 0.5 mg/kg
45961160|NCT00162110|Drug|cetuximab|mg, IV, 225 mg/m2, weekly, 4-52 weeks depending on response.
45961161|NCT00552331|Device|Plates to treat fractures of the distal femur|use of dynamic condylar screws or locking condylar plates in the treatment of distal femur fractures
46079517|NCT05125016|Drug|Cemiplimab|Administered concomitantly every 3 weeks (Q3W) by IV infusion
46079518|NCT05125016|Other|18F-DCFPyL|Prostate-specific membrane antigen (PSMA) Positron emission tomography (PET)/Computer tomography (CT) imaging agent to be used at select sites
46079519|NCT05118789|Drug|NVL-520|Oral tablet of NVL-520
46079520|NCT05108779|Drug|QLF32004|In the phase, five dose groups were proposed.The frequency of administration was once a week, and the treatment cycle was 3 weeks.
45961162|NCT00552331|Device|LISS|treatment of distal femur fractures with less invasive stabilization systems
45961163|NCT00552370|Drug|Lantus®|
45961164|NCT00552487|Drug|synacthen|1 µg synacthen in the vein
45961165|NCT00162149|Drug|Nevirapine|Tablets, Oral, 200 mg, Twice daily, 3 days.
45961166|NCT00162149|Drug|Nevirapine + Atazanavir/Ritonavir|Tablets + Capsules/Capsules, Oral, 200 mg + 300/100 mg, twice daily + once daily, 10 days.
45961167|NCT00162149|Drug|Nevirapine + Atazanavir/Ritonavir|Tablets + Capsules/Capsules, Oral, 200 mg + 400/100 mg, twice daily + once daily, 10 days.
45961168|NCT00162149|Drug|Atazanavir + Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
45961169|NCT00552526|Dietary Supplement|Ketogenic diet|Ketogenic diet is a very strict high fat diet
45961170|NCT00552526|Drug|Antiepileptic drug (AED)|An AED,not used by the patient before, which we consider to be the most appropriate will be given orally or by gastrostomy. Serum concentration, the body weight, side effects and effects on the epilepsy will be considered when deciding the dose of the AED. Traditions for amount of medicine/kg body weight or optimal serum concentration at our center will be followed. This tradition will be the same as in other major European epilepsy centers but might propose lower, but not higher amounts than recommended by the drug company. Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate, zonisamide, vigabatrin, tiagabil, lamotrigine, pregabalin, rufinamide, clobazam, clonazepam, tiagabine, gabapentin, phenytoin, phenobarbital, ethosuximide, acetazolamide, nitrazepam and other new antiepileptic drugs that might be released during the study period.
46079521|NCT05107752|Behavioral|Cognitive Processing Therapy (CPT)|Cognitive processing therapy (CPT) is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of PTSD that have developed after experiencing a variety of traumatic events including child abuse, combat, rape and natural disasters. CPT is generally delivered over 12 sessions and helps patients learn how to challenge and modify unhelpful beliefs related to the trauma. In so doing, the patient creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life. This treatment is strongly recommended for the treatment of PTSD.
46079522|NCT05107752|Drug|Stellate Ganglion Block|SGB is a procedure that has demonstrated efficacy for the reduction of PTSD symptoms. SGB is performed using real-time ultrasonography with an in-plane technique, and consists of 7-10 mL of ropivacaine 0.5%, which is injected around and into the site of the ganglion at the level of the C4 and C6 anterior tubercle (Mulvaney, Curtis et al., 2020). Ropivacaine is a long-acting amide local anesthetic agent and a pure S-enantiomer with a high pKa and relatively low solubility. Patients are not sedated during the procedure. Successful sympathetic blockade is confirmed by the presence of Horner's syndrome, which is characterized by constriction of the pupil (miosis) and drooping of the upper eyelid (ptosis). If Horner's syndrome is not observed within 20 minutes of the first injection, the right-sided SGB is repeated one hour later using the same technique. If Horner's syndrome is not confirmed after the second injection, no additional injections are provided.
45455273|NCT03972202|Diagnostic Test|MRI|Brain MRI will be performed (no contrast) to correlate brain anatomy/function with behavioral testing.
45455274|NCT03972202|Device|TMS|Repetitive TMS will be applied to transiently disrupt cerebellar speech pathways.
45665173|NCT05107583|Behavioral|Low-Carbohydrate Pre-Exercise Meal|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a low-carbohydrate lunch meal (<10% carbohydrate; 35% estimated energy requirements) 2.5 hours prior.
45665174|NCT05107583|Behavioral|High-Carbohydrate Pre-Exercise Meal|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a high-carbohydrate lunch meal (~2.2 g/kg carbohydrate; 35% estimated energy requirements) 2.5 hours prior.
45665175|NCT05107583|Behavioral|Fasted Exercise|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having skipped lunch, and having consumed nothing other than plain water since breakfast (08:00; 25% estimated energy requirements). Exercise will therefore commence after an 8 hour period of fasting.
45819966|NCT00000866|Biological|MN rgp120/HIV-1|
45819967|NCT00000866|Biological|TBC-3B Vaccine|
45819968|NCT03863522|Procedure|Fine needle aspiration|Fine needle aspiration is a type of biopsy procedure to diagnose suspicious lesions. After giving numbing medicine, a thin needle is inserted into the breast to obtain a sample. This procedure is followed by the standard of care and will last about 10 minutes. The sample will be analyzed by a diagnostic cartridge and by the cytopathologist.
45819969|NCT03863522|Device|Cancer Detection cartridge|The Cancer Detection cartridge has the ability to measure methylated gene changes in breast cells. The device will not be in contact with the patients. The FNA samples will be smeared on a slide which will be placed into the cartridge for analysis.
45961171|NCT00552565|Drug|Rezular 15mg|Oral Tablets
45961172|NCT00552565|Drug|Placebo|placebo
45961173|NCT00552565|Drug|Rezular|Rezular 37.5mg 3xday up to 12 weeks
45961174|NCT00552565|Drug|Rezular|Rezular 75mg 3xday up to 12 weeks
45961175|NCT00552604|Drug|standardized cannabis extract|Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
45961176|NCT00552604|Drug|Placebo|Matching placebo capsules, twice daily
45961177|NCT00552643|Device|Suspension of polystyrene beads (POLYHEAL 1)|Topical application of Polyheal 1 (15 mL/200cm2 of wound area, TID, 28 days, one cycle
45819970|NCT04223635|Drug|Pexidartinib|Single, 200-mg capsule will be administered orally on Day 1 with 240 mL of water, following an overnight fast of at least 10 hours.
45819971|NCT00000872|Drug|Abacavir sulfate|
45961178|NCT00552643|Device|Saline (0.9% NaCl)|Saline topical application 15 mL/200cm2 of wound area, TID, 28 days, one cycle
45961179|NCT00162188|Drug|Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
45961180|NCT00192153|Biological|CAIV-T or TIV|
45961181|NCT04755088|Drug|Surufatinib|Subjects to receive Surufatinib 300mg on Day 1
45961182|NCT04755088|Drug|Surufatinib|Subjects to receive Surufatinib 300mg on Day 1
45961183|NCT04751890|Behavioral|Structured home-based exercise|Low-intensity interval walking program prescribed at hospital and performed at daily at home
45961184|NCT04751890|Behavioral|Walking advice|Walking advice according to the guidelines for peripheral artery disease patients
45961185|NCT00162227|Drug|Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
45819972|NCT00000872|Drug|Nelfinavir mesylate|
45665176|NCT05106491|Device|Synchronized Cardiac Support with the icor kit|Patients with cardiogenic shock, requiring a venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization will be treated with Synchronized Cardiac Support (SCS).
45819973|NCT00000872|Drug|Nevirapine|
45961186|NCT04709926|Other|Survey|Paramedics will complete a 5 minute survey that is asking for their opinions on why they did or did not take part in the PRESTO training package and also why they think paramedics might not engage with research training in general.
45455275|NCT03972202|Behavioral|Speech-motor behavioral testing|Language/speaking tasks will be performed during which participants are asked to speak in response to audio/video cues; participants' responses will be recorded. For patients with cerebellar ataxia, additional diagnostic surveys may be completed.
45961187|NCT04709926|Other|Interview (optional)|Paramedics will also be given the option to participate in a 1hr interview to explore the questions asked in the survey in more detail.
45961188|NCT00425529|Device|Module AOX (attached to Sondalis ISO)|
45961189|NCT04705012|Other|Submucosal supportive therapy|Increased frequency of submucosal cleaning using a rotating chitosan brush
45665177|NCT05135273|Biological|Pfs230D1-EPA/Matrix-M Vaccine|Each single-use vial of Pfs230D1M-EPA contains 160 µg/mL of conjugated Pfs230D1M and 124 µg/mL or 143 µg/mL of conjugated EPA in 4 mM phosphate-buffered saline (PBS), in a volume of 0.5 mL. Each vial of Matrix-M1 contains saponin content of 0.375 mg/mL in PBS, at a pH of 7.2, in a final volume of 0.75 mL. Components will be combined in volumes defined in the protocol at point of use.
45819974|NCT00000872|Drug|Lamivudine|
45961190|NCT04701580|Diagnostic Test|11C-UCB-J PET-CT|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
45961191|NCT04701580|Diagnostic Test|18F-FDG PET-MR|Positron Emission Tomography (PET) of glucose metabolism using the radioligand 18F-FDG, and brain MRI performed simultaneously.
45961192|NCT04711031|Other|FLUS|The participating GPs use ultrasonography on a weekly basis and will use the ultrasonography device already available to them; however, the ultrasound machine system and type of transducer will be reported. The GPs will use a 14-zone FLUS scanning protocol that has previously been validated in a general practice setting. Each of the scanning zones on the patient's left side can be denoted from 1L to 7L and from 1R to 7R on the right side. Each scanning zone should be assessed using FLUS. The transducer is placed in the middle of a scanning zone making a cross sectional image of an intercostal space and the underlying pleura blades. The patients will be examined in an upright position. The GPs will be trained in the 14-zone scanning protocol during a FLUS training program prior to recruitment of patients. FLUS pathological findings are predefined, and the variables will be dichotomized into present or not present for each scanning zone.
45961193|NCT00552682|Drug|Duloxetine 60 mg, QD|Duloxetine 60 mg, 1 table/day, 1 year
45961194|NCT04678414|Behavioral|Healthcare Activity|Attend focus group
45665178|NCT05135273|Biological|Verorab Rabies Vaccine|Verorab Rabies Vaccine is a purified inactivated rabies vaccine (Wistar rabies PM/WI 38 1503-3M strain) prepared on Vero cells. It is supplied as a powder and solvent for suspension for injection in a prefilled syringe. Before reconstitution, the powder is a white and homogeneous pellet. The solvent is a limpid solution.
45961195|NCT04678414|Other|Survey Administration|Complete survey
45961196|NCT04678297|Behavioral|Physical activity + emotion regulation intervention|The intervention meet twice weekly for 12 weeks, 1.25 hrs./session. This intervention will be led by certified instructors trained in working with back pain patients. The instructor leads participants through a series of physical activity exercises at a slow-moderate pace. Participants will be asked to practice every day for 20 minutes to maximize the benefit of the intervention. Participants also receive a home practice manual containing some basic, safe postures that can be performed on days they are not attending the formal in-person sessions.
46079523|NCT05094791|Device|Telescoping Lag Screw|Intertrochanteric fracture fixation using Arthrex Hip Nail with Telescoping Lag Screw
45455276|NCT01345916|Drug|CHF 1535 100/6 NEXT DPI® 2 months|CHF 1535 100/6 NEXT DPI® 2 months
45455277|NCT01345916|Drug|CHF 1535 100/6 pMDI 2 months|CHF 1535 100/6 pMDI 2 months
45455278|NCT01345916|Drug|BDP DPI 2 months|BDP DPI 2 months
45665179|NCT05133713|Device|Catheter directed therapy|Thrombectomy
45819975|NCT00000872|Drug|Stavudine|
45819976|NCT00000872|Drug|Zidovudine|
46079524|NCT05094791|Device|Standard lag Screw|Intertrochanteric fracture fixation using Zimmer Natural Nail Cephalomedullary Nail using standard lag screw
46079525|NCT05094791|Device|Standard lag screw with addition of worm screw|Intertrochanteric fracture fixation using Smith and Nephew TRIGEN INTERTAN with addition of worm screw
45819977|NCT04232137|Behavioral|Postpartum coffee ceremony|The promise of a postpartum coffee ceremony
45819978|NCT00000878|Drug|Lamivudine|
45819979|NCT00000878|Drug|Stavudine|
45819980|NCT00000878|Drug|Zidovudine|
45819981|NCT04204057|Drug|Tenalisib|Tenalisib 800 mg BID, Orally
45819982|NCT00000104|Procedure|ERP measures of attention and memory|
45819983|NCT00001736|Drug|Cysteamine|
45819984|NCT03848455|Diagnostic Test|genetic diagnosis|The venous blood of the two groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and non-PD patients.
45961197|NCT04678297|Behavioral|Physical activity control intervention|The interventions meet twice weekly for 12 weeks, 1.25 hrs./session. This intervention is designed to require a similar amount of physical exertion. Classes involve conventional exercises appropriate for patients with CLBP, including a comprehensive set of exercises that stretch all the major muscle groups, with an emphasis on the trunk and legs. The intervention will include all 12 stretching exercises used in the exercise intervention of previous studies that have successfully used it in comparison to yoga, plus 3 additional stretches (hip internal rotators, hip adductors and hip flexion).Participants will be asked to practice every day for 20 minutes home as well. Printed handouts will be provided to facilitate home practice. In addition, a video demonstrating all the exercises will be provided to assist participants in practicing safely. Classes will be led by a licensed physical therapist who has previous experience leading exercise classes.
45665180|NCT05133713|Drug|Systemic anticoagulation|Conservative therapy
45961198|NCT00185367|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-2: 3.0 mg EV; Day 3-7: 2.0 mg EV + 2.0 mg DNG; Day 8-24: 2.0 mg EV + 3.0 mg DNG; Day 25-26: 1.0 mg EV; Day 27-28: placebo;In addition SH D 593 B (Miranova) matching placebo
45961199|NCT00185367|Drug|SH D 593 B (Miranova)|7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-21: 0.02 mg EE + 0.10 mg LNG; Day 22-28: placebo; In addition EV/DNG (Qlaira, BAY86-5027, SH T00658K) matching placebo
45961200|NCT04663633|Other|Core stability training|Functional Rhythmic Core Stability exercises performed by the experimental group. 30 minutes insert included in the Gymnasts regular training.
45665181|NCT05133089|Device|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
45961201|NCT04652089|Drug|Simvastatin 20mg|Simvastatin 20mg once a day for 7 days
45961202|NCT04652089|Drug|Placebo|Placebo once a day for 7 days
45961203|NCT00192192|Biological|CAIV-T|
45961204|NCT00552721|Other|Physical therapy with strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) with an emphasis on strength training.
46079526|NCT05084586|Drug|Intravesical Solution|After the Transurethral Resection of Bladder Tumor(TURBT) surgery, 50 mg Epirubicin solution in 150 ml saline was continuously instiled into the bladder for 2 hours. A drainage catheter was closed in order to fill the bladder with epirubicin solution.
45455279|NCT01123291|Procedure|follow-up coronary angiography|follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
45455280|NCT01123291|Procedure|Clinical follow-up|no routine follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
45665182|NCT05224427|Behavioral|Near-Peer Coaching|Targeted coaching by near-peer medical students
45665183|NCT05129423|Drug|MTPS9579A|MTPS9579A will be administered.
45665184|NCT05129423|Drug|Placebo|Placebo matched with MTPS9579A will be administered.
45665185|NCT05129189|Drug|ASC22 group|The trial group received ASC22 1mg/kg hypodermic injection Q4W and Chidamide 10mg PO BIW.
45819985|NCT00000884|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|Dosage will vary based on route of administration
45665186|NCT02299375|Drug|Losmapimod tablets|Losmapimod tablets will be provided as 15 mg strength in a formulation containing lactose. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period.
45819986|NCT00000884|Biological|ALVAC-HIV MN120TMG (vCP205)|Dosage will vary based on route of administration
45819987|NCT00000884|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|Dosage will vary based on route of administration
45819988|NCT00001748|Procedure|Peripheral blood progenitor cell transplant|
45819989|NCT00000110|Procedure|magnetic resonance spectroscopy|
45961205|NCT00552721|Other|Physical therapy without strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) without strength training.
45961206|NCT00407108|Procedure|Vitrectomy|
45961207|NCT04637581|Behavioral|Wraparound|Wraparound is a 12-month family-driven intensive care coordination model.
45961208|NCT00409032|Drug|Strontium malonate|
45961209|NCT04684303|Procedure|Lumbar medial branch radiofrequency ablation neurotomy|Procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
45961210|NCT04684303|Procedure|Lumbar medial branch cryo ablation neurotomy|Procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
46079527|NCT05084586|Drug|Intravesical Solution|After the Transurethral Resection of Bladder Tumor(TURBT) surgery, 50 mg Epirubicin solution in 50 ml saline was instiled into the bladder for 2 hours. A drainage catheter was closed in order to fill the bladder with epirubicin solution.
46079528|NCT05080595|Other|Transportation assistance (Lyft rides)|Lyft rides will be provided to patients for any transplant-related medical visits
46079529|NCT05077085|Drug|Bezlotoxumab|single intravenous infusion of bezlotoxumab 10 mg/kg
46079530|NCT05077085|Procedure|Fecal Microbiota Transplantation (FMT)|single infusion of 198 cc fecal suspension (derived from 60g donor feces) via duodenal tube or coloscopy
46079531|NCT05077085|Drug|Vancomycin oral|14 days vancomycin oral 125mg QID (250mg QID when 125mg not available)
45819990|NCT00000110|Drug|dietary fat|
45819991|NCT00000896|Drug|Indinavir sulfate|
45819992|NCT00000896|Drug|Lamivudine/Zidovudine|
45819993|NCT00000896|Biological|Hepatitis A Vaccine (Inactivated)|
45819994|NCT00000896|Drug|Interleukin-12|
45819995|NCT00000896|Drug|Nevirapine|
45819996|NCT00000896|Drug|Stavudine|
45819997|NCT00000896|Drug|Sargramostim|
45819998|NCT00001790|Drug|FK463|
45819999|NCT00000902|Drug|Ritonavir|
45820000|NCT00000902|Drug|Nelfinavir mesylate|
45820001|NCT00000902|Drug|Nevirapine|
45820002|NCT00000902|Drug|Lamivudine|
45820003|NCT00000902|Drug|Stavudine|
45820004|NCT00000902|Drug|Zidovudine|
45961211|NCT04609306|Other|H2O2 application to incision|A lap sponge soaked in 3% H2O2 will be applied to the incision and allowed to sit for 3 minutes.
45665187|NCT02299375|Drug|Placebo tablets|Placebo tablets will be provided in a formulation containing lactose and visually matching the losmapimod tablets. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period
45961212|NCT00407147|Device|Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor|"antibiotic treatment based on clinical decision making with traditional thought processes used in both groups. In addition the physician will be given access to Procalcitonin values with recommended thresholds for likelihood of infection."
45961213|NCT00192231|Biological|CAIV-T|
45665188|NCT02299375|Drug|Salbutamol MDI|Salbutamol MDI will be provided as a rescue medication.
45961214|NCT04710680|Other|no intervention|no intervention
45961215|NCT04684498|Drug|Oseltamivir phosphate capsules|Treatment group vs. Control group
45961216|NCT00552799|Drug|Penicillin VK|Biconcave tablet 250mg oral, b.d.
45961217|NCT00552799|Other|placebo|biconcave tablet matching active comparator as much as possible in size and shape
45961218|NCT00409071|Drug|Cocculine®|12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
45820005|NCT00000902|Drug|Zalcitabine|
45820006|NCT00000902|Drug|Didanosine|
45820007|NCT04331600|Drug|Chloroquine phosphate|Oral chloroquine phosphate for 14 days
45820008|NCT04331600|Other|Telemedicine|Telemedical supervision for 42 days
45820009|NCT03844321|Behavioral|Mindfulness-Based Cognitive Therapy|8 sessions of online mindfulness-based cognitive therapy
45665189|NCT04421651|Behavioral|Dance Movement Therapy group|DMT-intervention was facilitated by a dance movement therapist and included 20 x 75 mins sessions within 10 weeks.
45665190|NCT05102747|Radiation|Hypofractionated SRT (stereotactic radiotherapy)|3*10Gy over 1 week
45961219|NCT00409071|Drug|placebo|12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
45961220|NCT04524325|Other|Trans men|We are studying the effects of testosterone taken by trans men on mechanisms of blood pressure control and comparing those results to cisgender women that have normal (ie lower) testosterone levels.
45961221|NCT00162305|Drug|BMS-512148|Capsules, Oral, 100 mg, Once daily, 14 days.
45961222|NCT00162305|Drug|BMS-512148|Capsules, Oral, 25 mg, Once daily, 14 days.
45961223|NCT00162305|Drug|BMS-512148|Capsules, Oral, 5 mg, Once daily, 14 days.
45961224|NCT00162305|Drug|Placebo|Capsules, Oral, 0 mg, Once daily, 14 days.
45961225|NCT04513015|Dietary Supplement|Antioxidant diet|"The antioxidant diet will include the principal antioxidant molecules/nutrients previously shown to be beneficial in IBD: Flavonoids, particularly resveratrol and curcumin; Olive oil; Glutathione, Vitamins A, C, E; Carotenoids; Selenium and Omega 3 Fatty Acids (PUFAs). The daily amount of these substances will be calculated following the published evidence, whether these amounts will not be achievable by a standard diet, a supplementary formulation will be proposed."
45961226|NCT04513015|Dietary Supplement|Normal dietetic scheme|Isocaloric, normolipidic diet for age and sex
45961227|NCT00162344|Drug|Technetium Tc99m Sestamibi|
45665191|NCT05102747|Radiation|Historical single-dose SRS (stereotactic radiosurgery)|20 to 25Gy/1 fraction
45665192|NCT05223959|Behavioral|Culturally adapted Psychoeducation|This is a culturally adapted psychoeducation program consisting of 12 sessions. Each CaPE session lasts for approximately 60 minutes, beginning with a 20-30-minute presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for recurrence).
45665193|NCT02151903|Drug|DI-Leu16-IL2|DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
45820010|NCT03844321|Behavioral|Brief Mindfulness|3 sessions of online mindfulness therapy
45820011|NCT00000128|Device|Bifocal Spectacle Lenses|
45820012|NCT04331678|Behavioral|Comparator App|"Participants will download and agree to use the study app at least once per week during the 3-month intervention period.~The app allows participants to invite a network of friends and family to provide emotional and logistical support during their treatment."
45820013|NCT00000188|Drug|Selegiline|
45820014|NCT00000914|Drug|Indinavir sulfate|
45820015|NCT00000914|Drug|Ritonavir|
45961228|NCT04419805|Device|Single Palatal TAD|A single mini-screw inserted in the mid-palate
45961229|NCT04419805|Device|Two buccal TADs|Two buccal TADs inserted in the upper jaw
45961230|NCT04395625|Procedure|Direct bonding of Orthodontic brackets|Patients in group 1 had their upper right and lower left quadrants bonded with indirect bonding, and their upper left and lower right quadrants with direct bonding
46079532|NCT05069428|Drug|Ramelteon 8mg|administered crushed, orally at 20:30
46079533|NCT05059626|Drug|simvastatin 10mg|Simvastation acts as a systemic LOX inhibitor.
45961231|NCT04395625|Procedure|Indirect bonding of Orthodontic brackets|Patients in group 2 had their upper left and lower right quadrants bonded with indirect bonding, and their upper right and lower left quadrants with direct bonding.
45665194|NCT05221307|Other|exercises|Group 1 will be given MPEs for 45 minutes, 3 days a week for 8 weeks. In the second group, traditional Neurodevelopmental Treatment (NGT-Bobath) approach will be applied for 45 minutes a day, 3 days a week for 8 weeks. Treatments will be carried out by the same physiotherapist. Evaluations will be made twice, before and after the treatment.
45665195|NCT05102201|Device|Paro (social robot) intervention|Participants in the Paro group will receive a group (6-8 people as a group), facilitated, and 30-minute weekly session Paro intervention for 6 weeks
45961232|NCT00409149|Behavioral|CALM Approache|
45961233|NCT00409149|Behavioral|DASH approach|standard dietary DASH approach in hypertensive patients
46079534|NCT05059626|Drug|Bazedoxifene 20/Estrogens,Con 0.45Mg Tb|Duavee is a selective estrogen receptor modulator.
45665196|NCT02151591|Drug|Varenicline|"12-weeks of treatment. Dose will be titrated as follows:~Days 1-3: 1 0.5mg tablet once per day Days 4-7: 1 0.5mg tablet twice per day Day 8 - Week 11: 1 1mg tablet twice per day"
45665197|NCT05101421|Dietary Supplement|Rice ceramide supplementation|At the dosage of 40mg daily for 3 months
45665198|NCT02174523|Drug|40mg lurasidone|
45665199|NCT02174523|Drug|placebo|
45665200|NCT05099783|Diagnostic Test|late gadolinium enhanced magnetic resonance imaging|Candidate inpatients or outpatients will be identified if pharmacological or electrical cardioversion has be performed and MRI were performed after cardioversion at least twice.
45665201|NCT05128877|Other|relaxation techniques|Mitchell's physiological relaxation technique is based on reciprocal inhibition and involves diaphragmatic breathing and a series of ordered isotonic contractions.
45820016|NCT00000914|Drug|Nelfinavir mesylate|
45820017|NCT00000914|Drug|Efavirenz|
45820018|NCT00000920|Drug|Ritonavir|
45820019|NCT00000920|Drug|Saquinavir|
45820020|NCT00000920|Drug|Lamivudine|
45961234|NCT04382326|Biological|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
45961235|NCT04382326|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
45961236|NCT00162383|Drug|Debrisoquine|
45961237|NCT00162383|Drug|Mephenytoin|
45961238|NCT00162383|Drug|Dapsone|
45961239|NCT00162383|Drug|Caffeine|
45961240|NCT04683874|Device|3D printed tray|3D printed tray
45458282|NCT01319240|Drug|insulin degludec/liraglutide|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
46079535|NCT05059626|Drug|Placebo|Placebo for statin and SERM pretreatments.
46079536|NCT05040711|Behavioral|Mindfulness Coach|"This study will use Mindfulness Coach, an iOS- and Android-based app designed to deliver a mindfulness training course centered on Veteran's Affairs (VA) protocols. Developed by the VA's National Center for PTSD, the app provides an engaging introduction to MT, regardless of specific psychiatric illness or patient population. The app provides a training plan with 14 sequential levels, a practice now area with evidence-based mindfulness audio exercises, assessments using the Five-Factor Mindfulness Questionnaire Short Form (FFMQ-SF)90, and education about mindfulness. To progress to the next level, the user must interact with every element. The training plan levels include psychoeducation and exercises (guided meditations and seated practices), which increase in duration as users progress. Levels 1,7 and 14 also include an assessment with the FFMQ-SF. The practice now area has guided meditations to practice new skills."
45665202|NCT04881799|Drug|Phentermine/Topiramate (Qsymia)|Maximum dose of 15 mg/92 mg orally once daily in the morning. The dose will be titrated to this level (described earlier).
45665203|NCT04881799|Drug|Placebo|Daily injection
45665204|NCT02297815|Drug|Broad-spectrum antibiotics|Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil, cefadroxil, cephalexin
45665205|NCT02297815|Drug|Narrow-spectrum antibiotics|Amoxicillin, Penicillin
45665206|NCT02114385|Biological|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
45665207|NCT02114385|Biological|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
45820021|NCT00000920|Drug|Zidovudine|
45820022|NCT00000938|Drug|ceftriaxone|
45820023|NCT00000938|Drug|doxycycline|
45820024|NCT00001862|Drug|Enbrel|
45820025|NCT00000194|Drug|Cycloserine|
45820026|NCT00000200|Drug|Methadone|normal maintenance dose
45820027|NCT05440682|Procedure|CP group|Pre- post-cranioplasty and 6 months follow-up MRI assessment. Each MRI session lasts about 60 minutes and will measure Diffusion Tensor Imaging, Tractography and resting state fMRI.
45820028|NCT00000206|Drug|Buprenorphine|
45820029|NCT00000944|Drug|Indinavir sulfate|
45820030|NCT00000944|Drug|Lamivudine|
45820031|NCT00000944|Drug|Zidovudine|
45820032|NCT00000950|Drug|Ethambutol hydrochloride|
45820033|NCT00000950|Drug|Isoniazid|
45820034|NCT00000950|Drug|Pyrazinamide|
45820035|NCT00000950|Drug|Pyridoxine hydrochloride|
45820036|NCT00000950|Drug|Rifampin|
45820037|NCT00000218|Drug|Carbamazepine|
45820038|NCT00000224|Drug|Buprenorphine|
45820039|NCT00001886|Procedure|Real time 3-dimensional stress echocardiography|
45961241|NCT00192270|Biological|CAIV-T|Each dose of the vaccine was formulated to contain approximately 1 x 10^7 TCID50 of each of three (two subtype A and one subtype B) reassortant 6:2 influenza strains, as described above, for a total of ~3 x 10^7 TCID50 per dose.
45961242|NCT00162422|Drug|albuterol|
45961243|NCT04355143|Drug|Colchicine Tablets|COLCRYS (colchicine, USP) tablets for oral administration, containing 0.6 mg of the active ingredient colchicine USP, administered po every 12 hours x 30 days.
45961244|NCT04355143|Other|Current care per UCLA treating physicians|Current care
45961245|NCT04343365|Other|Evolutionary Tumor Board (ETB)|The ETB consists of evolutionary biologists, mathematicians, research scientists, statisticians,data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators.The ETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The ETB will collect data through a chart review regarding adherence and results of ETB recommendation
45961246|NCT00185445|Drug|Fludarabine Phosphate (Fludara)|All patients will receive fludarabine phosphate orally for 3 consecutive days per cycle and mitoxantrone on day 1. Each patient will receive up to six treatment cycles. Treatment cycles will be given at 4 weeks intervals.
45961247|NCT00552838|Behavioral|Academic Detailing by the Antimicrobial Utilization Team (AUT)|Physicians caring for patients who were prescribed one of three antimicrobials were randomly assigned to academic detailing by the AUT. The AUT would review the antimicrobial prescription and provide consultation to the ordering physician if the prescription is appropriate and provide feedback on a better alternative if inappropriate.
45961248|NCT04309981|Biological|Adult differentiated autologous T-cells with anti-BCMA specificity|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-BCMA specificity will be transfused.
45961249|NCT04305340|Device|Myant SKIIN Device|"Supine position: Participant lays on a bed on their back for 5 minutes~Sitting position: Participant sits on a chair for 5 minutes~Standing position: Participant stands for 5 minutes.~Exercise measurement: treadmill exercise test - the protocol entails increases of 0.5 mph every minute with zero change in the incline. Starting point would 1.5 mph. The test will be interrupted if the target heart rate of 190 beats per minute is reached or if symptoms and/or arrhythmias and ST depression would be observed. Patient will be monitor during recovery for 5 minutes.~Cool-down: Participants cool-down for 5 minutes"
45961250|NCT00192309|Biological|CAIV-T|Liquid CAIV-T vaccine for this study consisted of three cold-adapted, attenuated, reassortant strains representing the hemagglutinin (HA) and neuraminidase (NA) antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) and B/Yamanashi/166/98 influenza virus strains. The reassortant vaccine strains were grown in specific pathogen-free (SPF) eggs and the allantoic fluid, which contained virus, was harvested, concentrated and purified. Each dose of CAIV-T used in this study was formulated to contain approximately 107 FFU of each of the 6:2 influenza reassortant vaccine strains.
45961251|NCT00192309|Biological|TIV|TIV in this study consisted of Flushield™, manufactured by Wyeth Vaccines, Marietta, PA, USA. Each 0.5 mL dose contained no less than 15 ug of the hemagglutinin antigens from each of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Yamanashi/166/98 strains, making TIV in this study antigenically matched to the influenza strains contained in CAIV-T.
45961252|NCT00192309|Biological|Placebo|Placebo in this study consisted of physiological saline. The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
45961253|NCT04297111|Dietary Supplement|Probiotic|GanedenBC30 (Bacillus coagulans GBI-30, 6086) capsule made of 1 billion colony forming units (cfu). Description: pure cell mass of an L-(+) lactic acid-producing, gram-positive, spore-forming shaped bacterium that is aerobic to microaerophilic. Maltodextrin used as filler.
45961254|NCT04297111|Other|Placebo|Maltodextrin capsule, no active ingredient
45961255|NCT00552877|Device|Percutaneous coronary intervention (Xience V stent)|Cypher Select plus coronary stent Xience V coronary stent
45961256|NCT04233034|Device|HCL|Hybrid Closed Loop therapy
45665208|NCT05220605|Drug|BromAc|Bromelain and acetylcysteine are combined in various concentrations (either 100ug, 150ug or 200ug of bromelain, with 20mg of acetylcysteine). This is then delivered by a nebuliser to up to 12 healthy volunteers. The primary aim is determining safety.
45665209|NCT05098457|Device|GP0112|Injectable gel
45665210|NCT05098457|Device|Restylane Lyft Lidocaine|Injectable gel
45820040|NCT04332991|Drug|Hydroxychloroquine|"Hydroxychloroquine is available in 200 mg oral tablets of hydroxychloroquine sulfate.~For this COVID-19 trial, we will use an oral or enteral dose of hydroxychloroquine 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course."
45820041|NCT04332991|Drug|Placebo|Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
45820042|NCT00000956|Biological|gp160 Vaccine (MicroGeneSys)|
45820043|NCT00000230|Drug|Buprenorphine|
45665211|NCT02114151|Drug|Simeprevir|100 participants will receive 1 capsule of 150 mg orally once daily for 12 weeks.
45665212|NCT02114151|Drug|Sofosbuvir|100 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks.
45665213|NCT05098379|Behavioral|Tele-Rehabilitation Home Exercise Program|"Participants will engage in 150 minutes of exercise per week (30 min/day for 5 days/week) for 8 weeks and will have weekly virtual Exercise Coaching sessions with a trained project team member. Customized home exercise programs will be reviewed weekly during the coaching sessions and will be modified as needed to ensure participants can complete their exercises safely and effectively. Exercise coaches will send weekly messages to 'check-in' with participants in order to motivate and remind participants to adhere to their tailored home exercise programs.~During weekly exercise coaching sessions, exercises will be reviewed for form, safety, and progression. Exercises will be revised as needed to ensure that they are in line with participants' goals, needs, and preferences."
45820044|NCT00000236|Drug|Buprenorphine/naloxone|
45820045|NCT00000974|Drug|Pentamidine isethionate|
45820046|NCT00000242|Drug|Carbamazepine|
45820047|NCT03719677|Behavioral|Habit development intervention|Lifestyle behavior change intervention targeting physical activity and dietary habit development as well as improving physical and social functioning
45820048|NCT00000980|Drug|Spiramycin|
45961257|NCT04233034|Drug|verapamil 120mg tablet|verapamil tablet
45961258|NCT04233034|Device|non-HCL|Usual diabetes care
45961259|NCT04233034|Drug|placebo|placebo pill manufactured to mimic verapamil 120mg tablet
45961260|NCT00552916|Device|Compex Motion Stimulator|'True' Functional Electrical Stimulation Assisted Walking
46079537|NCT05040711|Behavioral|Active Comparator|A a widely available health and wellness app that provides users with daily content on general health, WebMD, will serve as the attention control. Similar health-based apps have been used as controls in other mHealth psychotherapy intervention trials.100,101 The control group will be instructed to access the app 4x/week (same as intervention group) and will receive an orientation and 2 booster sessions as well. I considered other control group options including treatment as usual, but attention control was selected due to the variability of treatment as usual.
45665214|NCT05220293|Drug|Betamethasone Dipropionate Nasal Cream 0.0644%|Betamethasone Dipropionate Nasal Cream 0.0644%, up to 5g per sinus.
45458283|NCT01319240|Drug|liraglutide|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
45665215|NCT05220293|Device|Pre-filled syringe and applicator device|Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
45665216|NCT05220137|Behavioral|Modified A-B-C: Working with Events, Thoughts, and Feelings|The Modified A-B-C session teaches the Veteran how to draw connections between events, thoughts, and feelings and incorporates preliminary cognitive restructuring to help challenge stuck points. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
45665217|NCT05220137|Behavioral|Challenging Questions|The Challenging Questions session teaches the Veteran to question and confront maladaptive self-statements and stuck points. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
45665218|NCT05220137|Behavioral|Patterns of Problematic Thinking|The Patterns of Problematic Thinking session teaches the Veteran to identify counterproductive thinking patterns. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
45820049|NCT03831451|Behavioral|Stroke preparedness intervention|Face-to-face interaction with research staff lasting between 5-10 minutes
45820050|NCT03831451|Behavioral|Healthy lifestyle stroke risk reduction intervention|Face-to-face interaction with research staff lasting between 5-10 minutes
45820051|NCT00000992|Drug|Itraconazole|
45820052|NCT03721549|Biological|Norwalk GI.1 Virus|Norwalk virus causes viral gastroenteritis, which is also known as acute nonbacterial gastroenteritis, food poisoning, food infection, or stomach flu.
45820053|NCT00000254|Drug|40% Nitrous oxide|Used as pain assay positive control
45820054|NCT00000254|Other|Sham comparator|0% isoflurane in oxygen
45820055|NCT00000254|Drug|0.2% isoflurane|
45820056|NCT00000254|Drug|0.4% isoflurane|
45820057|NCT00000254|Drug|0.6% isoflurane|
45961261|NCT00552916|Device|Compex Motion Stimulator|'False' FES
45961262|NCT00185484|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|Oral administration of YAZ (0.02mg ethinyl estradiol-ß-cyclodextrin clathrate and 3mg drospirenone, 24 day hormone tablets followed by 4 days of placebo tablets for 13 cycles
45820058|NCT03834025|Behavioral|Phase 1 Condition 1|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation.
45820059|NCT03834025|Behavioral|Phase 1 Condition 2|Providers assigned to this condition will be sent recruitment materials that include an additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2).
45820060|NCT03834025|Behavioral|Phase 1 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3).
45961263|NCT04218721|Other|InvolveMe|An eHealth application that allows participants to report symptoms and needs prior to out-patient visits at the hospital. The application creates a summary that allows patients to prioritize what is important to talk with their health care providers about. Health care providers can use the summary to prepare the consultation.
45961264|NCT04218019|Device|TTFields|The NovoTTF-200 A device used in this trial delivers very low intensity, alternating electric fields to the tumor site through the scalp. These fields are known as Tumor Treating Fields or TTFields.
45820061|NCT03834025|Behavioral|Phase 1 Condition 4|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4).
45820062|NCT03834025|Behavioral|Phase 2 Condition 1|Providers who enroll in the study and are assigned to this condition will be in this group. Other than the opportunity to participate in a learning collaborative, participants receive no compensation.
45961265|NCT04710290|Dietary Supplement|Beta-Glucan|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
45961266|NCT04710290|Dietary Supplement|Glutamine|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
46079538|NCT05040386|Behavioral|EPIC|Participants randomized to the intervention arm receive usual COPD care + EPIC. EPIC is informed by the ENABLE model or early palliative care. ENABLE (Educate, Nurture, Advise, Before Life Ends) is a theory-based, rigorously tested, and multicomponent early palliative care model that improved quality of life and emotional symptoms in patients with advanced cancer. The PI adapted ENABLE to meet the specific needs of patients with COPD and their care partners through EPIC. EPIC includes a series of weekly telephone-based, nurse coach-led sessions for patients (six) and their care partners (four) aided by a manualized curriculum. Participants also complete activities geared to solving problems and making difficult decisions, attend a Supportive Care clinic visit, and complete advance directives.
46079539|NCT05040386|Other|Usual COPD Care|Participants randomized to this arm receive standard of care for COPD. This includes routine clinic visits with their clinician, medications, inhalers, vaccinations, tobacco cessation counseling, illness education, cardiopulmonary rehabilitation, specialist referrals, and other COPD therapies deemed appropriate by their clinician.
46079540|NCT05038124|Radiation|Preoperative Stereotactic Body Radiotherapy (SBRT)|Target lesions will be treated with preoperative SBRT consisting of biologically effective dose (BED10) of 50.4 - 81.6 Gy delivered in either three fractions or a single fraction.
46079541|NCT05035407|Drug|IL-2 (Aldesleukin)|dose of 720,000 IU/kg (based on total body weight) as an intravenous bolus over a 15 minute period beginning within 24 hours of cell infusion and continuing for up to four days (maximum 12 doses).
45820063|NCT03834025|Behavioral|Phase 2 Condition 2|Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 30% of the NC Medicaid rate for a patient visit.
45820064|NCT03834025|Behavioral|Phase 2 Condition 3|Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 100 percent of the NC Medicaid rate for a patient visit for their time participating in the learning collaborative.
45455281|NCT05158634|Other|Evaluations|"Within the scope of the study, the participants will be evaluated for 30 minutes in a single session. The participants' trunk stabilization and endurance, balance, functional mobility, upper extremity endurance, functional health and quality of life will be questioned by questionnaires, scales and tests. Evaluation will begin with a literature-supported demographic data form prepared for the participants.~Assessments to be made are listed below. Trunk Control Measurement Scale (TCMS) Pediatric Balance Scale (PBS) Time Up and Go test (TUG) Trunk Flexor Test (TFT) The Pediatric Outcomes Data Collection Instrument (PODCI)"
45820065|NCT00000260|Drug|Nitrous oxide|
45820066|NCT00000266|Drug|Flupenthixol|
45820067|NCT03748771|Device|ApneaLink Air|"The ApneaLink Air device is indicated for use by Health Care Professionals (HCP), where it may aid in the diagnosis of sleep disordered breathing for adult patients.~ApneaLink Air records the following data: patient respiratory nasal airflow, snoring, blood oxygen saturation, pulse and respiratory effort during sleep. The device uses these recordings to produce a report for the HCP that may aid in the diagnosis of sleep disordered breathing or for further clinical investigation. The device is intended for home and hospital use under the direction of a HCP."
45961267|NCT04710290|Dietary Supplement|Immunoglobuin|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
46079542|NCT05035407|Drug|Cyclophosphamide|30 mg/kg IV infusion over 1 hour (+ 10 min) Once daily x 2 doses (Days -6 and -5)
46079543|NCT05035407|Biological|KK-LC-1 TCR|1 x 108 transduced KK-LC-1 TCR T cells
45961268|NCT04710290|Dietary Supplement|Corn starch|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
45961269|NCT00185523|Procedure|Allogeneic hematopoietic cell transplantation|
45961270|NCT04187053|Procedure|Conventional mechanical therapy|Both experimental and sham arms will receive the Conventional mechanical therapy
45961271|NCT04187053|Drug|Saline|Sham group will receive saline as a sham for methylene blue
45820068|NCT00001016|Drug|Trimetrexate glucuronate|
45961272|NCT04187053|Drug|Methylene Blue|Experimental arm will receive methylene blue
45961273|NCT04187053|Device|Light emitting laser|Experimental arm will receive Light emitting laser
45961274|NCT04187053|Device|Non-light emitting laser|Sham group will receive Non-light emitting laser
45961275|NCT00162461|Drug|Phenytoin single dose (300 mg)|
45961276|NCT04167124|Behavioral|multi-sensor lifestyle intervention|
45961277|NCT00192348|Biological|CAIV-T|
45665219|NCT05220137|Behavioral|Challenging Beliefs|The Challenging Beliefs session teaches the Veteran to generate alternative thoughts based on the outcome of cognitive restructuring. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
45665220|NCT05220137|Behavioral|Veteran's choice of Module (Safety/Trust/Power and Control/Esteem/Intimacy)|The therapist will present the Module options to the Veteran and the Veteran will select one Module to work on. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
45820069|NCT00001016|Drug|Leucovorin calcium|
45820070|NCT05228912|Drug|COVID-19 Vaccines|Each group will receive a complete scheme of the vaccine according to local government assignation
45820071|NCT03836989|Device|Electrical stimulation device (tens unit)|An electrical stimulation device with adjustable voltage. Useful for both Sensory and Subsensory
45820072|NCT04942106|Other|Arm 1 - Side-lying position followed by Supine position|Infants will be observed for two bottle feedings in a single day when they are receiving at least 30% and no more than 50% of feedings orally. In this arm, infants will be bottle-fed in the side-lying position first followed by the supine position. In the side-lying feeding position, the infant will be placed on the caregiver's lap with one ear and hip facing the ceiling at a 45 to 60 degree angle. In the supine feeding position, the infant will be placed facing the caregiver in a reclining position at a 45 to 60 degree angle. In both feeding positions, the infant's head, neck, and upper body will be supported by the caregiver to maintain a neutral straight alignment with the chin tilted down slightly without the neck being extended or in excessive flexion. The infant will also be loosely swaddled with a single blanket so their legs, shoulders, and elbows are supported in a flexed position but with the lower arms free to move.
45820073|NCT04942106|Other|Arm 2 - Supine position followed by Side-lying position|Infants will be observed for two bottle feedings in a single day when they are receiving at least 30% and no more than 50% of feedings orally. In this arm, infants will be bottle-fed in the supine position first followed by the side-lying position. In the side-lying feeding position, the infant will be placed on the caregiver's lap with one ear and hip facing the ceiling at a 45 to 60 degree angle. In the supine feeding position, the infant will be placed facing the caregiver in a reclining position at a 45 to 60 degree angle. In both feeding positions, the infant's head, neck, and upper body will be supported by the caregiver to maintain a neutral straight alignment with the chin tilted down slightly without the neck being extended or in excessive flexion. The infant will also be loosely swaddled with a single blanket so their legs, shoulders, and elbows are supported in a flexed position but with the lower arms free to move.
45820074|NCT03811951|Drug|Novolin R|Novolin R is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerol 16 mg/mL, metacresol 3 mg/mL, zinc chloride approximately 7 mcg/mL and water for injection. The pH (potential Hydrogen) is adjusted to 7.4. Hydrochloric acid 2N (concentration) or sodium hydroxide 2N may be added to adjust pH. Novolin R vials are latex-free. The drug substance is being purchased from McKesson.
45820075|NCT04816526|Biological|Descartes 08|Car T-cells
45820076|NCT05220956|Behavioral|Intermittent fasting|One arm will undergo a TRF diet (Time-Restricted Feeding) for 12 weeks while both arms undergo a training according to the 10 rules of healthy nutrition of the DGE.
45820077|NCT05220956|Behavioral|DGE diet|The control arm is not a subject to any time restrictions concerning eating while both arms undergo a training according to the 10 rules of healthy nutrition of the DGE.
45820078|NCT04332289|Other|Heavy water experiment|3 times daily heavy water (deuterated-water) and mixed meal administration for one week
45820079|NCT00001022|Drug|Zidovudine|
45820080|NCT00001022|Drug|Zalcitabine|
45820081|NCT00001022|Drug|Didanosine|
45820082|NCT03816709|Device|Therapeutic Ultrasound|A therapeutic ultrasound treatment was applied to the left medial gastrocnemius muscle with the following parameters: 3 MHz, 1.0 W/cm2 for 15 minutes.
45820083|NCT05218148|Drug|sintilimab|Sintilimab 200mg was administered as a 30-60 min intravenous (IV) infusion every 3 weeks.3 cycles before surgery and 5 cycles after surgery.
45820084|NCT05218148|Drug|Trastuzumab|Trastuzumab was 8mg/kg for the first time, and 6mg/kg for the follow-up. 3 cycles before surgery and 5 cycles after surgery.
45820085|NCT05218148|Drug|S-1 plus oxaliplatin|"Oxaliplatin 130 mg/m2 was administered IV every 3 weeks. S-1 was given orally twice daily for the first 2 weeks of each 3-week cycle. The S-1 dose was 40 mg for body surface area (BSA) < 1.25 m2, 50 mg for BSA 1.25 to <1.5 m2 and 60 mg for BSA ≥1.5 m2.~Body surface area &lt;1.25m2: Tegio 40mg bid day 1 ~ 14; Body surface area 1.25 ~ &lt;1.5m2: Tegio 50mg bid day 1 ~ 14; Body surface area ≥1.5m2: Tegio 60mg bid day 1 ~ 14; 3 cycles before surgery and 3 cycles after surgery."
45820086|NCT00001934|Drug|Zenapax|
45820087|NCT04183231|Drug|Anti-caries varnish|topical tooth varnish
45820088|NCT00000278|Drug|Disulfiram|
45820089|NCT00001028|Drug|Pentamidine isethionate|
46079544|NCT05035407|Drug|Fludarabine|25 mg/m2 IV infusion over 30 minutes (+ 10 min) To be administered following completion of cyclophosphamide. Once daily x 5 doses (Days -6, -5, -4, -3, -2)
45820090|NCT00001028|Drug|Dapsone|
45820091|NCT03890419|Device|Green light|Green light exposure
45820092|NCT03890419|Device|Clear light|Full spectrum light exposure
45820093|NCT03890419|Device|Blue Light|Blue light exposure
45820094|NCT00000284|Drug|Cotinine fumarate|
45961278|NCT00162500|Biological|Peptide Vaccine (MUC-1)|
45820095|NCT00001940|Drug|Voriconazole|
45961279|NCT04159324|Other|optimized cross-sectoral, structured and coordinated treatment pathway that integrates a patient-centred outcome evaluation|the optimized treatment pathway includes coordinated transitions between rehabilitation phases and institutes using individual case management and portal solutions
45961280|NCT04118491|Device|hyperbaric oxygen and sham hyperbaric oxygen|see arm descriptions
45961281|NCT00185562|Drug|Adalimumab|
45961282|NCT00162539|Other|echography|Correlation of neonatal thyroid volume with maternal iodine deficiency
45961283|NCT04683835|Device|Neurosteer Aurora system|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity, which is accessible via any web interface
45961284|NCT04684030|Device|Continuous glucose monitoring system(CGMS)|Patients will randomized 1:1 to either continuous glucose monitoring system(CGMS) or conventional self-monitoring of blood glucose (SMBG) group. After the randomization, patients in CGMS group will given education on how to use the device and check the result using the smart phone. The data collected from the sensors were computed to generate the respective ambulatory glucose profiles so as to determine the total numbers of scans conducted during the study period.
45961285|NCT04684030|Device|Self-monitoring of blood glucose (conventional fingerpricking method)|Patients will randomized 1:1 to either continuous glucose monitoring system(CGMS) or conventional self-monitoring of blood glucose (SMBG) group. After the randomization, patients in SMBG group will check their blood glucose by finger pricking method and record the data in a notebook to share the data in their outpatient clinic visit.
45961286|NCT04114864|Behavioral|Psycho-educational sessions|"Participants of clusters allocated to the ME-WE intervention group will complete a programme based on seven weekly sessions of approximately 2 hours each, plus a follow-up meeting after 3 months from the end of the programme. All sessions maintain a similar structure (objectives, ice-breaker, central activity/ies, and final activity). At the end of some sessions, participants will be asked to do some exercises at home, between one meeting and the next one, in order to keep what has been done during the previous session fresh in their minds.~Contents of sessions will be as follows: (1) Getting to know each other; (2) The Advisor: dealing with annoying thoughts; (3) The Noticer: being in connection with our feelings; (4) The Discoverer: growing and thriving; (5) Values: connecting to meaning and vitality; (6) Developing a flexible self-view and self-compassion; (7) Building strong social networks."
45961287|NCT00192387|Biological|CAIV-T, Liquid|
45820096|NCT03907033|Drug|Liposomal bupivacaine|Liposomal bupivacaine is a novel formulation of local bupivacaine and allows prolonged release of the medication, thereby providing longer lasting effects. It is approved by the FDA and has been shown to provide excellent pain control after surgery.
45961288|NCT04104607|Drug|CC-1, PSMAxCD3|Infusion of CC-1 over 24 hours for 7 days with possible intra-patient dose-escalation
45961289|NCT04095364|Drug|Carboplatin|Given IV
45961290|NCT04095364|Drug|Letrozole|Given PO
45820097|NCT03907033|Drug|Bupivacaine Hydrochloride|We currently administer local plain bupivacaine during vaginal hysterectomy to decrease pain in the postoperative period. Bupivacaine is an anesthetic that works by blocking nerve conduction and producing a numbing effect.
45961291|NCT04095364|Drug|Paclitaxel|Given IV
45961292|NCT00185601|Behavioral|Internet Diabetes Self-Management Program|
45961293|NCT00162617|Drug|Red blood cell transfusion|
45961294|NCT00192426|Biological|CAIV-T|
45820098|NCT00001946|Procedure|Magnetic resonance angiography|
45961295|NCT00162656|Drug|half cyclophosphamide|
45961296|NCT00162656|Drug|without COPADM3|
45961297|NCT00162656|Drug|mini CYVE, without 3 maintenance courses|
45961298|NCT00162656|Drug|LMB B|
45961299|NCT00162656|Drug|LMB C|
45961300|NCT00424307|Device|HiResolution Bionic Ear System|
45961301|NCT00185757|Drug|Cytokine Induced Killer Cells|CIK cell dose escalation will be performed in cohorts of three patients per group. The initial dose utilized will be 1x107 expanded cells/kg. Previously, unmanipulated donor lymphocytes administered at this dose did not result in significant GVHD 7. The expansion of the CIK cell population is expected to diminish the T cell subsets responsible for GVHD further reducing the risk of GVHD to recipients. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD in the recipients
45961302|NCT00162695|Drug|Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide|
45961303|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp.1: 3 mg/kg IV (single dose)
45961304|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp. 2: 15 mg/kg IV (single dose)
45665221|NCT04752189|Behavioral|Enhanced Replicating Effective Programs (Enhanced REP)|Deploy Enhanced REP to optimize the delivery of a drug use prevention intervention in community schools and test its feasibility, acceptability, and appropriateness; Enhanced REP includes tailoring the curriculum, training, and providing ongoing provider consultation, or facilitation, to support implementation.
45665222|NCT04752189|Behavioral|Standard implementation|Standard implementation of the Michigan Model for Health is akin to Standard REP and includes the curriculum materials, standard training and as-needed technical assistance.
45820099|NCT00001034|Drug|Ganciclovir|
45820100|NCT00001046|Biological|MF59|
45820101|NCT00001046|Biological|rgp120/HIV-1 SF-2|
45820102|NCT03818815|Combination Product|OP0201|OP0201 20mg per day in two divided doses for 10 days
45961305|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp. 3: 30 mg/kg IV (single dose)
45961306|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp. 4: 3 mg/kg IM (single dose)
45961307|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp.5: 3 mg/kg IM (two doses)
45961308|NCT00162734|Drug|Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks|
45961309|NCT00185796|Procedure|Total Lymphoid Irradiation (TLI)|TLI is administered ten times in 120cGy fractions on day -11 through day -7 and day -4 through day -1
45665223|NCT02297503|Drug|Azzalure|Glabellar lines
45665224|NCT02297503|Device|Restylane/Emervel filler|Facial tissue augmentation
45961310|NCT00185796|Procedure|Anti-Thymocyte Globulin as Conditioning (ATG)|Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg. Thymoglobulin doses will be based on the adjusted ideal body weight if the patient is greater than or equal to 15 kg over ideal body weight.
45961311|NCT00162812|Drug|Epirubicin|100 mg/m² every three weeks (4 cycles) or every two weeks (6 cycles)
45961312|NCT00162851|Drug|alemtuzumab|
45665225|NCT02297503|Device|Restylane Skinbooster|Facial skin rejuvenation
45961313|NCT04083937|Radiation|Hypofractionated radiotherapy with photons|hypofractionated radiotherapy with photons (total dose 57.0 Gray in 19 fractions)
45665226|NCT05053997|Behavioral|NAVIGATE|Patients' symptoms are systematically monitored by use of bi-weekly patient reported outcomes and nurse navigators will initiate appropriate actions in terms of medical treatment or guidance of self-management strategies. Nurse navigators will motivate and support patients in health behavior changes and in selfmanaging their treatment and symptoms, and, if relevant, refer to existing rehabilitation services at the hospital or at the local rehabilitation center. Physiotherapists will supervise a training program aimed at improving patients' physical function and thus potentially surgery and overall treatment adherence and outcomes.
45961314|NCT04083937|Radiation|Hypofractionated radiotherapy with protons|hypofractionated radiotherapy with protons (total dose 57.0 Gray relative biological effectiveness (RBE) in 19 fractions)
45961315|NCT04083937|Radiation|Normofractionated radiotherapy with photons|normofractionated radiotherapy with photons (total dose 70.0 Gray in 35 fractions)
45961316|NCT00162890|Behavioral|Therapeutic exercise|
45961317|NCT04025749|Behavioral|Computerized Executive Functions training|Home-based executive function training with adaptive difficulty, through NeuronUp (https://www.neuronup.com) over 12 weeks (30 min/day, 5 days per week, 30h in total).
45820103|NCT03818815|Combination Product|Placebo|Placebo 0mg per day in two divided doses for 10 days
45820104|NCT03818815|Drug|Amoxicillin-clavulanate|Oral Amoxicillin-clavulanate in two divided doses for 10 days
45820105|NCT00001958|Drug|Hydroxyurea|
45820106|NCT00001964|Drug|Cyclosporine A|Cyclosporine A
45961318|NCT04025749|Other|Care as usual|Care as usual
45665227|NCT04421885|Drug|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference|600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr.
45665228|NCT04421885|Drug|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr.
45961319|NCT00162929|Biological|AdHer-2/neu transduced dendritic cells|Group 1 1 ×10'7 expanded cells (2.5 ×106 DCs per injection site) Group 2 5 ×10'7 expanded cells (1.25 ×107 DCs per injection site) Group 3 1 ×10'8 expanded cells (2.5 ×107 DCs per injection site)
45961320|NCT04015414|Drug|Varenicline|191 patients will receive varenicline for 12 weeks and regular phone calls with brief counseling Tabex: 188 patients will receive cytisine for 25 days and regular phone calls with brief counseling
45665229|NCT04881643|Behavioral|Trauma-focused cognitive behavioural therapy via a digital support|A blended treatment approach to PTSD, blending internet-based CBT with face-to-face sessions with a therapist
45665230|NCT02113449|Drug|Carbon Dioxide|Nasal administration of carbon dioxide (CO2) through the delivery device for 10 seconds
45665231|NCT02366923|Device|stenfilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
45665232|NCT02366923|Device|delefilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
45665233|NCT02326597|Other|Decision Aid Tool|The tool is a web based decision aid that provides information about the risks and benefits associated with sickle cell disease therapies. Participants will be provided a unique access ID and password to access the information.
45820107|NCT00001964|Drug|ATG|ATG
45820108|NCT00001964|Drug|MMF|MMF
45820109|NCT03801265|Procedure|Lumbar plexus block|Patient will be positioned in lateral decubitus position with side to be blocked facing upwards. Midline will be identified by palpating the spinous process. Intercristal line will be drawn connecting iliac crests. The point of needle insertion will be 4 cm lateral to the intersection of both lines. The transverse process will first contact with a finder needle. Subsequently an 18 gauge 10 cm insulated needle will be used and advanced until it contacted the transverse process. Needle will then be redirected cephalad or caudad and advanced 2 cm, until the quadriceps femoris twitch is obtained. Local anesthetic will then be injected after confirming a motor response between 0.3-0.5 milli amperes.
45961321|NCT04015414|Drug|Cytisine|185 patients will receive cytisine for 25 days and regular phone calls with brief counseling
45961322|NCT00185835|Drug|ZD-1839|
45961323|NCT00185835|Drug|Cisplatin|
45961324|NCT03985267|Behavioral|Mindfulness based Swinging Effect Intervention|Participants will receive psycho-education about mindfulness and how it operates. That will also assist patients to warm up for the actual intervention. Then the actual swinging effect intervention will commence respectively.
45961325|NCT03979495|Other|mFOCUS|To evaluate the effectiveness of the system, team and individual components of mFOCUS vs. standard care by conducting a 4-arm cluster randomized controlled trial (RCT) of individuals who are due for follow-up of an abnormal screen.
45961326|NCT00162968|Drug|escitalopram|
45961327|NCT00192543|Behavioral|diet of fish and fruit|fish and fruit in specified quantities
45961328|NCT00192543|Behavioral|fruit and fish|no drugs
45961329|NCT00192543|Behavioral|diet only|Fish and fruit
45961330|NCT00192543|Behavioral|regular diet|no change in regular diet
45961331|NCT03970603|Other|Early Weight-Bearing|Being directed to bear weight on the affected ankle two weeks from suture button fixation for syndesmotic disruption
45961332|NCT03970603|Other|Delayed/Late Weight-Bearing|Being directed to bear weight on the affected ankle six weeks from suture button fixation for syndesmotic disruption
45961333|NCT03970330|Drug|Naltrexone|4.5mg daily dose, taken orally
45961334|NCT03970330|Drug|Norethindrone Acetate|5 - 15mg daily dose, taken orally
45961335|NCT03970330|Drug|Placebo|daily placebo pill, taken orally
45961336|NCT00163007|Procedure|Nutritional support|
45961337|NCT00185874|Biological|Intratumoral Dendritic Cell Immunotherapy|
45961338|NCT00185874|Biological|autologous dendritic cells|
45961339|NCT03911596|Device|Smart Autofocusing Eyeglasses|The smart eyeglasses system is meant to be a next generation alternative technology which replaces the generic eyeglasses used for correction of refractory defects in human vision. These smart eyeglasses do not fix any internal eye problems. They just externally compensate for the loss of eye focusing functions caused by presbyopia. This system is a medical assistive device which is meant to improve the quality of life of presbyopic patients.
45961340|NCT04724408|Device|VieScope|see above
45961341|NCT04724408|Device|Conventional|see above
45961342|NCT00192582|Behavioral|Motivational Interview with care plan and education|
45961343|NCT03859063|Behavioral|Intervention|Participants randomized to the intervention arm will be followed with monthly meetings by a stroke coordinator for 18 months. The stroke coordinator will assess the patients risk factors within the domains of physical function, cognitive function, social function, medication and lifestyle factors and make a treatment plan targeting the individual needs for further follow-up.
45961344|NCT03859063|Behavioral|Control|Community based follow-up as usual
45961345|NCT03788044|Other|Education|Education + Medication adherence monitoring + Feedback when low adherence
45961346|NCT04724174|Procedure|pancreaticogastrostomy|Pancreaticogastrostomy technique was performed according to the precise description of Addeo et al.
45961347|NCT04724174|Procedure|pancreaticojejunostomy|Pancreaticojejunostomy technique was performed using the 5/0 polypropylene interrupted monofilament suture in a one-layered duct-to-mucosa end-to-side anastomosis (Cattell-Warren anastomosis).
45961348|NCT03757585|Drug|Open-label Treatment with Omega-3 Fatty Acids + Inositol|Open-label Treatment with Omega-3 Fatty Acids + Inositol
45961349|NCT03757585|Drug|Open-label Treatment with N-acetylcysteine|Open-label Treatment with acetylcysteine
45961350|NCT00163046|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime for 28 days
45961351|NCT00163046|Drug|Placebo|Matched placebo 30 minutes prior to bedtime for 28 days
45961352|NCT00185952|Drug|Nifedipine|Nifedipine 10 mg tablets, two tablets orally every 6 hours. Placebo tablets, two tablets orally every 6 hours.
45961353|NCT03541447|Drug|Tolvaptan|Starting morning and afternoon doses of 45 and 15 mg, respectively, to be up titrated every two days to 60 and 30 mg and then to 90 and 30 mg, according to tolerability.
45665234|NCT02326597|Other|Standard Practice|Standard of care teaching and discussion regarding treatment options given by patient's healthcare provider.
45665235|NCT02366767|Device|Automatic closed-loop insulin delivery|Sensor transmit glucose data every 5 minutes to the control algorithm which adjusts insulin delivery every 5 minutes.
45665236|NCT02366767|Device|Control|Threshold suspend
45665237|NCT02150343|Drug|HDM-SPIRE|1 dose every 4 weeks
45820110|NCT03801265|Procedure|Quadratus lumborum type 3 block|Patient will be placed in a lateral position with the side to be blocked facing up. A low frequency transducer will be used to identify three layers of abdominal musculature, probe will be then moved posteriorly till the transverse abdominus aponeurosis is visualized, the QL muscle is then identified by tracing the aponeurosis posteriorly. The transducer is then moved more posteriorly to visualize the shadow of transverse process and the origin of QL muscle. Psoas muscle is then identified lying anterior to the QL muscle. A 22 gauge 8 cm is inserted in plane posterior to the probe and advanced intramuscularly through the QL to interfacial plane between QL and psoas major and local anesthetic is deposited.
45820111|NCT03801265|Drug|Ropivacaine injection|0.5% ropivacaine 20 ml (100 mg) will be injected for both groups.
45820112|NCT00000290|Drug|Cocaine|
45961354|NCT03541447|Drug|Octreotide LAR|A single dose of two 20 mg i.m. injections.
45961355|NCT03541447|Other|Placebo|A single dose of two 20 mg i.m. injections.
45961356|NCT00163085|Drug|NR2B NMDA Antagonist CP-101,606 (traxoprodil)|
45961357|NCT00192621|Drug|Combivir (zidovudine [AZT] / lamivudine [3TC])|
45961358|NCT00192621|Drug|Kaletra (lopinavir [LPVr])|
45961359|NCT03516604|Drug|PF-04995274|PF-04995274 tablets
45961360|NCT03516604|Drug|Citalopram|Citalopram capsule
45665238|NCT02150343|Drug|Placebo|1 dose every 4 weeks
45665239|NCT02149875|Drug|Dl-3-n-butylphthalide|Intravenous infusion of 100 ml dl-3-n-butylphthalide and sodium chloride injection for 10 days, twice daily.
45665240|NCT02149875|Drug|Cerebrolysin|Intravenous infusion of 30 ml Cerebrolysin per day in 100 ml normal saline for 10 days.
45665241|NCT02149875|Drug|Placebo|100 ml saline intravenous infusion once daily for 10 days.
45665242|NCT05096507|Procedure|Hip fracture Surgery (Primary)|Surgery for primary hip fracture requiring general or neuro-axial anaesthesia
45665243|NCT05096351|Other|Blood test|Collection of blood samples at 1 and 6 months for HLA typing for donor and recipient antibodies
45665244|NCT05095961|Drug|Prednisone|5 day course of oral prednisone pre-operatively. 30mg per day.
45665245|NCT05125367|Procedure|coronary stent implantation|coronary stent implantation using everolimus-eluting balloon expandable stents
45665246|NCT05125367|Procedure|bypass grafting|coronary artery bypass graft
45665247|NCT05124899|Drug|CAP UnScented|Sunscreen lip balm.
45820113|NCT00000296|Drug|Cotinine fumarate|
45820114|NCT00000212|Drug|Desipramine|
45820115|NCT00000302|Drug|Buprenorphine|
45820116|NCT00001052|Biological|Aluminum hydroxide|
45820117|NCT00001052|Biological|QS-21|
45820118|NCT00001052|Biological|rgp120/HIV-1MN|
45820119|NCT00001058|Drug|Indinavir sulfate|
45820120|NCT00001058|Drug|Ritonavir|
45820121|NCT00001058|Drug|Ethambutol hydrochloride|
45820122|NCT00001058|Drug|Clarithromycin|
45820123|NCT00001058|Drug|Rifabutin|
45961361|NCT03516604|Drug|Placebo Oral Tablet|Placebo tablet, identical to PF-04995274 tablet
45961362|NCT03516604|Drug|Placebo oral capsule|Placebo capsule, identical to citalopram capsule
45961363|NCT00163124|Procedure|spinal manipulation & patient education/nutrition|
45961364|NCT00185991|Drug|gentamicin|"Daily gentamicin (5 mg/kg intravenously, then placebo doses IV after 8 and 16 hours).~Eight hour gentamicin (2 mg/kg intravenously, then 1.5 mg/kg IV after 8 and 16 hours)."
45961365|NCT00163163|Procedure|Echographic measurements|
45961366|NCT00163163|Procedure|Blood samples|
45961367|NCT00186030|Behavioral|HIV Skills-based Prevention|
45961368|NCT03434158|Drug|Olaparib|300 mg twice a day
45961369|NCT00552994|Device|Cypher Select plus|Drug eluting stent
45961370|NCT00552994|Device|Xience V stent|Drug eluting stent
45665248|NCT05124899|Drug|CAP Herbal Mint Flavour|Sunscreen lip balm.
45665249|NCT05124899|Drug|CAP Mountain Berry Flavour|Sunscreen lip balm.
45665250|NCT05124899|Drug|SPF Standard Sunscreen|SPF Standard (7 percent [%] Padimate-O and 3% Oxybenzone)
45820124|NCT00000308|Drug|Dextroamphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
45820125|NCT00000308|Drug|D-amphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
45820126|NCT00000308|Drug|placebo|placebo
45820127|NCT03968965|Device|3D MvIGS Spine Navigation|The 7D Surgical MvIGS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw implantation in patients undergoing posterior fixation in single or multiple levels. The surgical light containing the machine vision cameras is the sole luminaire during image guided surgery.
45820128|NCT03968965|Other|2D Fluoroscopy|Pedicle screws will be placed using 2D fluoroscopy as the intraoperative imaging modality.
45961371|NCT00186108|Drug|Oral Triamcinalone|
45961372|NCT00163202|Procedure|Blood samples|
46079545|NCT05033626|Procedure|Simultaneous thyroidectomy and hyoid suspension|Under endotracheal anesthesia, a horizontal skin incision up to 50 mm long is made at the level of the upper thyroid cartilage, the skin and subcutaneous fat are dissected. The sternohyoid and sternothyroid muscles are retracted. An audit of the thyroid gland is performed. Step by step, using the ultrasonic dissector, the sections of the gland necessary for resection are separated, ligated and transected. Using microsurgical techniques, neurolysis of the recurrent laryngeal nerves is performed. The quality control of the return of the laryngeal nerves is ensured to the required extent using the neuromonitoring apparatus.
46079546|NCT05033626|Procedure|Thyroidectomy|The hyoid bone is mobilized in the anterocaudal direction and is fixed to the thyroid cartilage with four permanent non-absorbable sutures. If sufficient mobilization does not occur during the operation, the tendon of the stylohyoid muscle is dissected. Surgical drainage is installed 24 hours after surgery.
46079547|NCT05021601|Procedure|Bi-atrial ablation|This intervention includes mitral valve surgery concomitant with left atrial ablation and right atrial ablation.
45961373|NCT00163202|Drug|Atorvastatin|
45961374|NCT03412045|Device|hyperbaric oxygen therapy|hyperbaric oxygen therapy applied to patients in vaso-occlusive crisis
45665251|NCT05124665|Behavioral|Social Support|"The intervention to be evaluated in this study is a multidimensional, socio-behavioral Norming intervention. The various components of this intervention are designed to harness household dynamics and prosocial inclinations to encourage individuals to accept the HIV testing invitation. Each component is briefly described in the arm description."
45820129|NCT00001064|Drug|Allogenic Dendritic Cells|
45820130|NCT00001994|Drug|Atovaquone|
45820131|NCT00000314|Drug|M-CPP|
45961375|NCT03318952|Drug|lidocaine|A buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed of 2% lidocaine with 1:100,000 epinephrine will be administered.
46079548|NCT05021601|Procedure|Left atrial ablation|This intervention includes mitral valve surgery concomitant with left atrial ablation alone.
46079549|NCT05018312|Behavioral|Modified Collaborative Assessment (MCA)|The Modified Collaborative Assessment (MCA) will be assessment of the patients that Is more thoroughly-done, and which will be inspired by the school of Therapeutic Assessment and Collaborative Assessment. It will include the EASE, SCID-interview, PSE, ADOS and SCIP-interviews.
45455282|NCT03934489|Behavioral|PERSIST|12-week group, adapted from Dialectical Behavior Therapy, that focuses on emotion regulation skills training and practice.
45820132|NCT00000320|Drug|Buprenorphine formulation: liquid vs. tablet|random assignment to liquid buprenorphine or tablet buprenorphine
45820133|NCT00000326|Drug|Heroin Dependence|
45820134|NCT03978403|Drug|"M207 3.8 mg Sled (two 1.9 mg patches made on a Sled coater, foil pouches)"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a Sled coater and packaged in foil pouches"
45820135|NCT03978403|Drug|"M207 3.8 mg MACAP (two 1.9 mg patches made on a MACAP coater, foil cups)"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a MACAP coater and packaged in foil cups"
45820136|NCT03978403|Drug|"M207 3.8 mg MiniMac (two 1.9 mg patches made on a MiniMac coater, foil cups"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a miniMac coater and packaged in foil pouches"
45820137|NCT03978403|Drug|Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose|Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose
45820138|NCT00002000|Drug|Valacyclovir hydrochloride|
45820139|NCT00002000|Drug|Acyclovir|
45820140|NCT03979807|Drug|Olodaterol/Tiotropium Bromide|(Stiolto®) delivered via Respimat inhaler
45820141|NCT03979807|Drug|Umeclidinium/ Vilanterol|(Anoro®) delivered via Ellipta Inhaler
45820142|NCT00001082|Drug|Levocarnitine|500 mg tablet taken orally daily
45820143|NCT00001082|Drug|Adefovir dipivoxil|120 mg tablet taken orally daily
45820144|NCT00001082|Drug|Adefovir dipivoxil placebo|Oral placebo tablet taken daily
45820145|NCT00002006|Drug|Zidovudine|
45820146|NCT00002006|Drug|Sargramostim|
45820147|NCT04169113|Other|Group 1 - Opiate Tablets post Hip Arthroscopy|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
45961376|NCT03318952|Drug|articaine|A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered
45961377|NCT03455647|Behavioral|ASF promotion plus Girinka|Behavior change communication promoting the consumption of milk produced in the household and other optimal maternal and child nutrition practices. The intervention will be implemented by government of Rwanda Community Health Workers.
45961378|NCT00192660|Drug|Lamivudine|
45961379|NCT00192660|Drug|Stavudine|
45961380|NCT00192660|Drug|Didanosine|
45961381|NCT00192660|Drug|Zidovudine|
45961382|NCT00192660|Drug|Tenofovir|
45961383|NCT00192660|Drug|Abacavir|
45961384|NCT00192660|Drug|Efavirenz (EFV)|
45961385|NCT00192660|Drug|Nevirapine|
45961386|NCT00192660|Drug|Indinavir|
45961387|NCT00192660|Drug|Saquinavir|
45961388|NCT00192660|Drug|Amprenavir|
45961389|NCT00192660|Drug|Ritonavir|
45961390|NCT00192660|Drug|Nelfinavir|
45961391|NCT00192660|Drug|Tipranavir|
45820148|NCT04169113|Other|Group 2 - Opiate Tablets post Hip Arthroscopy|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
45961392|NCT00192660|Drug|enfuvirtide (T20)|
45961393|NCT04684069|Device|Long-axis syringe free in-plane|Long-axis syringe-free in-plane catheter placement
45961394|NCT04684069|Device|Short-axis out-of-plane|Short-axis out-of-plane catheter placement
45961395|NCT00163241|Drug|celecoxib|
46079550|NCT05018312|Behavioral|Assessment as Usual (AAU)|Assessment as usual is the standard assessment the patients will receive in the clinic. It includes one or more interviews with a mental health professional in the clinic.
45665252|NCT05052905|Device|LibraVR|"LibraVR is a standalone VR-based rehabilitation software for use in physiotherapy. It is designed to work with standard off-the-shelf hardware that is tested and approved for use in conjunction with the software.~LibraVR system consists of the software (LibraVR Clinic) running on a PC (database of patients, creation of protocols, uploading protocols to mobile), and the LibraVR Mobile APP that runs on commercial mobile smartphones embedded in a lightweight cardboard or plastic VR viewer that the child wears as they would eyeglasses. The software displays a range of immersive VR exercises."
45820149|NCT00002012|Drug|Interferon alfa-n3|
45820150|NCT00380276|Drug|MPC-7869|800 mg BID Oral dosing
45820151|NCT04149925|Device|AEON Endostapler|Surgery with AEON Endostapler
45961396|NCT00553033|Procedure|Laparoscopic liver surgery|Ultrasonic dissector, harmonic scalpel
45961397|NCT03144583|Biological|Adult differentiated autologous T-cells|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.
45961398|NCT03114397|Device|transcranial direct current stimulation - active|transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes.
45961399|NCT03114397|Device|transcranial direct current stimulation - sham|transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes. The sham intervention consists of 30 seconds of stimulation at the beginning and the end of the 20minutes of intervention.
45961400|NCT03016819|Drug|AL3818|Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
45961401|NCT03016819|Drug|Dacarbazine|Dacarbazine 1000 mg/m2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle
45961402|NCT03016819|Drug|AL3818 or placebo|AL3818 or placebo 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
45961403|NCT00186225|Procedure|ablative allogeneic hematopoietic cell transplantation|
45961404|NCT00163280|Drug|ATL-104|Daily does of ATL-104 (50,100 or 150mg) or placebo for 3 days prior to the start of chemotherapy and peripheral blood stem cell transplantation. Following stem cell transplantation patients received 3 further daily doses of ATL-104 (50, 100 or 150mg) or placebo.
45961405|NCT02916316|Drug|R-CHOP with doxorubicin|Chemoimmunotherapy every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.
45961406|NCT00186264|Drug|venlafaxine XR|
45961407|NCT00186264|Drug|hydrocortisone|
45961408|NCT02890693|Behavioral|interdisciplinary lifestyle and psychosocial intervention|The multidimensional interdisciplinary lifestyle and psychosocial intervention will be offered on top of usual care. It will consist of individual sessions (face-to-face or telephone contact) with different members of the interdisciplinary team (dietician, physiotherapist, clinical psychologist or coach) and two group sessions. It will take place during pregnancy and during the first year postpartum.
45961409|NCT00163319|Drug|Ciclesonide|
45961410|NCT02812420|Biological|Durvalumab|Given IV
45961411|NCT02812420|Procedure|Therapeutic Conventional Surgery|Undergo cystectomy with pelvic lymph node dissection
46079551|NCT05006716|Drug|BGB-16673|BGB-16673 doses are to be administered as a once daily regimen
45820152|NCT04149925|Device|Echelon Flex Powered Stapler|Surgery with Echelon Flex Powered Stapler
45820153|NCT00380354|Drug|GSK256066|
45820154|NCT03799783|Drug|dexmedetomidine|To administer dexmedetomidine IV 2 μg/kg in 10 minutes (loading dose) followed by continuous infusion at a rate of 1 μg/kg/h until procedure was complete
45820155|NCT00001088|Biological|APL 400-047|
45820156|NCT00001088|Drug|Bupivacaine hydrochloride|
45820157|NCT04713566|Other|oral rinces|natural and commercial oral rinses were compared for efficacy
45820158|NCT00001094|Drug|Lamivudine/Zidovudine|
45820159|NCT00001094|Drug|Nelfinavir mesylate|
45820160|NCT00001094|Drug|Saquinavir|
45961412|NCT02812420|Biological|Tremelimumab|Given IV
45961413|NCT02789800|Behavioral|DIMAC02|Integrated Approach For Chronic Diseases (DIMAC02) is an integrated approach for chronic disease prevention and management services that aims to improve and coordinate different regional initiatives in 11 Family Medicine Groups(FMG) related to : Self-management, Case management, Patient-centred care for persons with multimorbidity, Motivational approach, Interprofessional collaboration. DIMAC 02 specific objectives are: 1) To make available, in FMG's, an interdisciplinary educational intervention for prevention and management of chronic diseases for patients with low and high risk for complication. 2) To Increase the flow of communications between FMG and hospital facilities to improve continuity of care.
45961414|NCT02556931|Drug|Fludarabine|Days -6 through -2: 30 mg/m^2 IV daily
45961415|NCT02556931|Drug|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
45961416|NCT02556931|Radiation|Total body irradiation|Day -1: 200 cGy in a single fraction
45961417|NCT02556931|Drug|Tacrolimus|Start on Day 5 through either Day 60 or Day 90 depending on cohort assignment. May be continued through Day 180 depending on GVHD status.
45961418|NCT02556931|Drug|Mycophenolate mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
45961419|NCT00163358|Drug|Ciclesonide|
45961420|NCT00186303|Procedure|high dose chemotherapy then autologous hematopoietic cell transplant|
45961421|NCT00186303|Procedure|ablative allogeneic hematopoietic cell transplant|
45961422|NCT02316184|Behavioral|Motivational Interviewing|Motivational Interviewing is a client-centered method of exploring individual's interest in making behavioral changes. In this study, the targeted behavior is alcohol use.
45961423|NCT02316184|Behavioral|Brief Advice|
45961424|NCT04683952|Device|Exercise training with Humified High Flow Nasal Cannula|The experimental group will be trained using HHFNC with the most adequate continuous flow, in a range between 25 and 30 L / min.
45961425|NCT04683952|Other|Exercise training - Control Group|The control group will perform exercise training in spontaneous breathing.
45820161|NCT00001094|Drug|Delavirdine mesylate|
45820162|NCT00001100|Drug|ganciclovir|
45665253|NCT05122013|Behavioral|A comprehensive remote multidisciplinary intervention for weight regain after sleeve gastrectomy|A remote 3-months multidisciplinary intervention for weight regain after sleeve gastrectomy including bi-monthly remote consultations with a registered dietitian, physical activity consultant and sleep consultant, combined with weekly text messages meant to enhance happiness and subjective wellbeing.
45820163|NCT00000332|Drug|Nimodipine|
45820164|NCT00000338|Drug|Lisuride|
45820165|NCT04085341|Drug|GB-102|Intravitreal injection of GB-102
45820166|NCT00002018|Drug|Interferon alfa-n3|
45455283|NCT03934489|Behavioral|Facilitated Peer Support|12-week group, adapted from community-based peer support groups, that focuses on participant-generated topics and facilitated discussion.
45455284|NCT04466254|Drug|CPGJ602|Q2W/QW iv
45455285|NCT04466254|Drug|cetuximab|QW iv
45455286|NCT01345994|Procedure|electro-acupuncture|acupuncture stimulation with electricity
45665254|NCT05122013|Behavioral|Control group|Standard nutritional care: One frontal meeting with the study's registered dietitian at the clinic, including nutritional and behavioral assessment and recommendations, followed by guidance to to continue follow up in order to support healthy lifestyle.
46079552|NCT05005026|Other|VR Game 1|"Individuals playing VR game 1 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
45665255|NCT05093621|Drug|Furosemide|Standard of care diuretic
45665256|NCT05093621|Drug|Torsemide|Standard of care diuretic
45665257|NCT02112045|Drug|Granix|
45665258|NCT02112045|Drug|High dose melphalan (HDR)|
45820167|NCT00002024|Drug|Ganciclovir|
45820168|NCT00001106|Drug|Zidovudine|
45820169|NCT00000344|Drug|Buprenorphine/naloxone|
45820170|NCT04103515|Device|Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty|Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty
45820171|NCT04103515|Device|Zimmer-Biomet Posterior Stabilizing total knee arthroplasty|Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
45820172|NCT05075018|Other|Observational|Individuals' musculoskeletal problems will be evaluated with the Cornell Musculoskeletal Disorder Questionnaire, quality of life, physical activity, Nottingham Health Profile physical activity International Physical Activity Questionnaire, endurance stabilizer device, functional exercise capacity 1 minute sit and stand test, shortness of breath using the Modified Borg Scale. Measurements will be made only once.
45820173|NCT00002030|Drug|Pentamidine isethionate|
45820174|NCT00377377|Drug|EP1572 (ghrelin agonist) oral and duodenal application|
45820175|NCT00001112|Drug|Zidovudine|
45820176|NCT00001112|Drug|Interferon gamma-1b|
45820177|NCT00377767|Behavioral|To change structure and roles of primary care teams to optimize prevention of obesity|
45820178|NCT00002036|Drug|Anti-HIV Immune Serum Globulin (Human)|
45820179|NCT00000350|Procedure|radioactive substance|
45820180|NCT03782701|Drug|Brimonidine tartrate ophthalmic solution 0.025%|One time dosing of brimonidine tartrate ophthalmic solution 0.025% (1 drop applied to ocular surface)
45820181|NCT03782701|Other|Sterile balanced saline solution|One time dosing of sterile balanced saline solution (1 drop applied to ocular surface)
45961426|NCT00186342|Procedure|ablative allogeneic hematopoietic cell transplantation|
45961427|NCT02171104|Biological|Stem Cell Transplantation|Infusion given on Day 0
45961428|NCT02171104|Drug|IMD Preparative Regimen|"Anti-thymocyte Globulin (ATG)~Fludarabine~Busulfan"
45961429|NCT02171104|Drug|Osteopetrosis Only Preparative Regimen|"Anti-thymocyte Globulin (ATG)~Fludarabine~Busulfan~Thiotepa"
45961430|NCT02171104|Drug|Osteopetrosis Haploidentical Only Preparative Regimen|"Rituximab~Alemtuzumab~Busulfan~Fludarabine"
45961431|NCT02171104|Drug|cALD SR-A (Standard-Risk, Regimen A)|N-acetylcysteine start day +1 through day +28
45961432|NCT02171104|Drug|cALD SR-B (Standard-Risk, Regimen B)|N-acetylcysteine start day +1through day +56
45961433|NCT02171104|Drug|cALD HR-D (High-Risk, Regimen C)|N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100
45961434|NCT02171104|Drug|cALD HR-D (High-Risk, Regimen D)|N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100
45961435|NCT00163397|Drug|Ciclesonide|
45961436|NCT00186381|Procedure|high dose chemotherapy then autologous hematopoietic cell transplant|
45961437|NCT00163436|Drug|Ciclesonide|
45961438|NCT00186420|Drug|Taxotere|
45961439|NCT02086630|Behavioral|Heart to Heart|
45961440|NCT01818661|Drug|AV-1451|This is used to assess Tau burden in the brain.
45961441|NCT01628029|Other|Counseling|Undergo CBT
45961442|NCT01628029|Drug|Methylphenidate Hydrochloride|Given PO
45961443|NCT01628029|Procedure|Phototherapy|Undergo light therapy
45665259|NCT02112045|Procedure|Autologous Stem Cell Transplant (ASCT)|
45961444|NCT01628029|Other|Placebo Administration|Given PO
45961445|NCT01628029|Other|Quality-of-Life Assessment|Ancillary studies
45961446|NCT01628029|Procedure|Sham Intervention|Undergo sham light therapy
45961447|NCT01628029|Drug|Therapeutic Melatonin|Given PO
45961448|NCT00186459|Behavioral|Hypocaloric diet of varying macronutrient composition|
45961449|NCT00163475|Drug|Roflumilast|
45961450|NCT01626313|Behavioral|FOCUS Individualized Family Resiliency Training|Eight session psycho educational training for families to enhance communication and reduce stressors related to return to post-military life.
45665260|NCT01629693|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
45820182|NCT05314387|Device|SMR TT Hybrid Glenoid without Cementless Finned Short Stem|The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.
45820183|NCT05314387|Device|SMR TT Hybrid Glenoid with Cementless Finned Short Stem|"The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.~The fins are intended to enhance press-fit fixation. The same proximal morse taper is used for coupling to the same humeral bodies in the SMR Shoulder System. The SMR finned short stem is intended for cementless fixation."
45820184|NCT00000356|Drug|LAAM|
45961451|NCT00186576|Procedure|nonmyeloablative allogeneic hematopoietic cell transplant|
45961452|NCT00163514|Drug|Ciclesonide|
45961453|NCT00717652|Drug|arbutin, tretinoin, triamcinolone|arbutin, tretinoin, triamcinolone
45961454|NCT00717652|Drug|Triluma|Hydroquinone, Fluoncinolone, Tretinoin
45961455|NCT00461539|Other|Treatment as usual|Those participants receiving standard care will be referred to special programs as needed to reduce their involvement in risky health behaviors.
45961456|NCT00461539|Behavioral|Behavioral health intervention|Participants assigned to the health education intervention will attend 10 weekly education sessions that will be led by trained health educators. Parents or guardians may be asked to attend sessions depending on their interest in the intervention and the age of the youth participant. Topics covered will include teenage smoking, alcohol and drug abuse, risky sexual behaviors, and obesity. Cognitive-behavioral strategies, role playing, and media clips will be used to stimulate discussion and involvement in the intervention.
45961457|NCT00186654|Procedure|Acupuncture|
45961458|NCT00186654|Procedure|Perinatal massage|
45961459|NCT00066040|Drug|Cervitec chlorhexidine varnish|
45961460|NCT00066040|Drug|Duraphat fluoride varnish|
45961461|NCT00066040|Drug|xylitol gum from Fennobon, Finland|
45961462|NCT05454826|Other|Exercise|1st group (n=15) relaxation exercises, 2nd group (n=15) relaxation exercises+cold compression. The exercise program will be applied for 6 weeks, 3 days a week * 45 minutes. Relaxation exercises will be applied to the patients 3 days a week using web-based methods (Zoom).
45961463|NCT05454826|Other|Cold Application|1st group (n=15) relaxation exercises, 2nd group (n=15) relaxation exercises+cold compression. The exercise program will be applied for 6 weeks, 3 days a week * 45 minutes. Relaxation exercises will be applied to the patients 3 days a week using web-based methods (Zoom).
45961464|NCT00163553|Drug|Pethidine|
45961465|NCT00163553|Drug|Placebo|
45961466|NCT05420818|Procedure|Transversalis Fascia Inversion|This study will be carried out at SBU Istanbul Training and Research Hospital, General Surgery Clinic. Patients diagnosed with M2 and M3 direct primary inguinal hernia according to EHS classification and who will undergo TEP repair surgery will be randomized into 2 groups. After direct hernia reduction in the patients in the first group, the transversalis fascia at the hernia site will be pulled inward and fixed to the Cooper ligament with 2 or 3 absorbable tackers. Standard surgery will then be continued. The patients in the second group will undergo standard surgery without any seroma prevention procedure. Demographic data of patients in both groups, postoperative pain (VAS values) at postoperative 1st, 7th day and 3rd month, clinical/radiological seroma rate, postoperative pain, QOL, recurrence and other complications will be recorded. When the desired number of patients and follow-up period are reached, the data in the 2 groups will be compared.
45961467|NCT05415475|Biological|CEA CAR-T cells|Administration method: intravenous infusion or intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
45665261|NCT01629693|Device|Comfilcon A contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
45665262|NCT05136339|Behavioral|Community-based mentoring and education sessions|Community-based mentoring and education sessions, group activities, and application of a community toolkit for healthy weight loss delivered by trained Health Promoters from Hispanic and Somali communities to their social networks.
45665263|NCT02147691|Drug|Azelaic acid 15%|Applied to the face each AM and PM
45961468|NCT00192699|Device|Bimetric femoral stem|Cemented Bi-Metric femoral stem
45961469|NCT05402449|Other|Placebo|Same Additives to Probiotic group but replace probiotics with Corn starch and Maltodextrin.
45961470|NCT05402449|Dietary Supplement|Probiotics|Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-263 (heat-killed) and GMNL-89 (alive) and Lactobacillus rhamnosus GMNL-74 ( alive).
45961471|NCT00163592|Drug|Tissucol®|
45961472|NCT00163592|Procedure|Control: Conventional treatment, i.e. compression with swabs|
45961473|NCT05399680|Device|S.M.A.R.T. RADIANZ™ Vascular Stent System|The S.M.A.R.T. RADIANZ™ Vascular Stent System is designed to deliver the S.M.A.R.T.™ self-expanding stent (S.M.A.R.T.™ stent) to the iliac arteries, superficial femoral arteries and/or proximal popliteal arteries using a 6F (2.0 mm) sheathed delivery system introduced through the radial artery.
45961474|NCT05399680|Device|BRITE TIP RADIANZ™ Guiding Sheath|BRITE TIP RADIANZ™ is a catheter guiding sheath that facilitates percutaneous entry of an intravascular device into the peripheral vasculature through the radial artery.
45961475|NCT05399680|Device|SABERX RADIANZ™ PTA Balloon Catheter|SABERX RADIANZ™ is a catheter with a distal inflatable balloon.
45961476|NCT04683601|Other|Thoracoscopic esophagectomy in left decubitus|Making surgical field at thoracoscopic esophagectomy in left decubitus
45961477|NCT04683445|Drug|Eribulin|Eribulin，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle
45961478|NCT04683445|Drug|Trastuzumab|Trastuzumab，8mg/kg for the first dose，6mg/kg for the following dose，Intravenous infusion，3-week cycle
45961479|NCT04683445|Drug|pertuzumab|Pertuzumab，，840mg for the first dose，420mg for the following dose，Intravenous infusion，3-week cycle
45961480|NCT04683445|Drug|Pyrotinib|Pyrotinib，400mg，oral，every day
45961481|NCT04683445|Drug|Pembrolizumab|Pembrolizumab，200mg，Intravenous infusion，3-week cycle
45961482|NCT04683445|Drug|Camerlizumab|Camerlizumab，200mg，Intravenous infusion，3-week cycle
46079553|NCT05005026|Other|VR Game 2|"Individuals playing VR game 2 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
45455287|NCT04466176|Drug|Test Product|2 inhalations of Test and Reference product in each study period
45665264|NCT02147691|Drug|Brimonidine 0.33%|Applied to the face each AM 30 minutes after the application of Azelaic acid 15%
45665265|NCT02111811|Other|Veterans Work and Health Initiative|CBT based intervention focused on work productivity
45665266|NCT01655693|Drug|Doxorubicin 20 mg/m2|
45665267|NCT01655693|Drug|Doxorubicin 30 mg/m2|
45665268|NCT01655693|Drug|Best Standard of Care|
45665269|NCT05090657|Combination Product|methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation|After topical application photosensitive solution bilateral nasal light diffusers will be inserted into each nostril and two 2-minute non-thermal light applications of 670 nm light will be used to activate the photosensitizer to achieve an oxidative burst to destroy pathogens.
45665270|NCT05120765|Behavioral|The CONNECT Program|The CONNECT Program is a 6-week, group-based, telephone-based, mental health intervention for socially isolated older adults. This group-therapy intervention is based on principles of Acceptance and Commitment Therapy (ACT). The group sessions take place once a week and they last 90 minutes each.
45665271|NCT05120375|Drug|BAT6021|Ⅳ infusions
45665272|NCT05089409|Drug|ATB1651, 2 mg/mL|The participants will apply daily doses of ATB1651, 2 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
45820185|NCT04143373|Procedure|warm saline irrigation|The objective of this research was to compare the effect of irrigation during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° C and 37 ± 1 ° C for control and experimental sides, respectively.
45820186|NCT00000374|Drug|Olanzapine|The dosage for Olanzapine will be 2.5 mg to 20mg per day. The dose of the Olanzapine will be based on the participant's clinical improvement and side effects.
45820187|NCT00000374|Drug|Risperidone|The dosage for Risperidone will be 1 mg to 6mg per day. The dose of the Risperidone will be based on the participant's clinical improvement and side effects.
45820188|NCT00002042|Drug|Epoetin alfa|
45961483|NCT00192777|Drug|Xeloda|
45665273|NCT05089409|Drug|ATB1651, 5 mg/mL|The participants will apply daily doses of ATB1651, 5 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
45665274|NCT05089409|Drug|ATB1651, 10 mg/mL|The participants will apply daily doses of ATB1651, 10 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
45665275|NCT05089409|Drug|ATB1651, 20 mg/mL|The participants will apply daily doses of ATB1651, 20 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
45665276|NCT05089409|Drug|ATB1651, 30 mg/mL|The participants will apply daily doses of ATB1651, 30 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
45665277|NCT05089409|Other|Placebo|The participants will apply placebo to all 10 toenails including at least 1 affected great toenail for 28 days
45961484|NCT00192777|Procedure|External Beam Radiotherapy|
45961485|NCT00553072|Drug|Magnesium sulphate|250 mg/kg/dose in 1 ml normal saline
45961486|NCT00553072|Drug|Normal saline|1 ml/kg/dose
45961487|NCT05385016|Behavioral|Cooking Skills|This session will consist of a hands-on cooking demonstration in a demo kitchen. Skills addressed in this portion of the session will include proper kitchen utensil and appliance use, measuring dry and wet ingredients, following/reading a recipe, preparing ingredients, cooking a meal, etc. The participant will follow a visual recipe that provides a breakdown of each skill needed to complete each step of the recipe. Additionally, during the cooking session investigators will address nutrition topics related to food/kitchen safety, basic nutrition education (i.e., portion sizes, food groups, reading food labels, meal planning etc.) in a discussion format.
46079554|NCT04998136|Drug|Semaglutide 2.4 mg|Administered subcutaneously (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 44 weeks. Doses gradually increased to 2.4 mg
45665278|NCT05089019|Drug|Selpercatinib|Administered orally
45961488|NCT05385016|Behavioral|Physical Activity|This session will consist of a group functional fitness class. Each session will include a warm-up (~5 min) moderate-to-vigorous intensity aerobic and resistance exercise (~20 min) and cool-down/stretching (~5 min). Exercises may be accompanied by music and will include walking/jogging, dancing, imitating animal movements, vertical/horizontal jumps, squats, hurdles, walking on balance beam etc. Thera-Band, kettle bells, free weights, and medicine balls will be used during strength exercises for major muscle groups. These sessions will be led by certified personal trainers with experience in adaptive physical activity.
45961489|NCT05381194|Drug|BPaL regimen|"The regimen consists of only oral medication using bedaquiline, linezolid, and pretomanid for 26 weeks.~Bedaquiline (400 mg/day for the 2 weeks, 200mg/TIW afterward). Pretomanid 200mg/day. Linezolid 600mg/day for the 9 weeks, 300mg/day afterward."
45961490|NCT05808842|Other|CeraVe|"CeraVe gentle facial cleanser (CeraVe; New York, NY) to be used morning and evening~CeraVe lotion (CeraVe; New York, NY) to be used morning and evening, reapply as needed for dry skin~A mineral CeraVe sunscreen (CeraVe; New York, NY) to be applied in the morning and reapplied every 2 hours if going outside"
45961491|NCT05808842|Other|CeraVe and Calecim|"CeraVe gentle facial cleanser (CeraVe; New York, NY) to be used morning and evening~Calecim® Professional Serum (CellResearch Corporation; Singapore) to be used morning and evening~Calecim® Restorative Hydration Cream (CellResearch Corporation; Singapore) to be used morning and evening, reapply as needed for dry skin~A mineral CeraVe sunscreen (CeraVe; New York, NY) to be applied in the morning and reapplied every 2 hours if going outside"
45961492|NCT05808829|Other|Progressive Muscle Relaxation Exercise|University students did progressive muscle relaxation exercises at least 4 times a week for 6 weeks. Once a week, exercise was done with the researcher by online interview via Zoom.
45455288|NCT04466176|Drug|Reference Product|2 inhalations of Test and Reference product in each study period
45820189|NCT03789175|Dietary Supplement|Nicotinamide Riboside (NR)|Niacin is a form of vitamin B3 and has been used to treat hypercholesterolemia for many years. There is growing evidence that nicotinamide adenine dinucleotide (NAD+ can maintain mitochondria through various mechanisms and that it is possible to improve mitochondrial function by dietary supplementation with the vitamin B3 analogue nicotinamide riboside (NR), an intermediate in the NAD+ salvage pathway. We have observed that culturing the fibroblasts of a LFS patient with mitochondrial deficiency in medium containing NR rescues the defect in mitochondrial respiration.
45665279|NCT04226339|Procedure|total knee arthroplasty with a kinetic alignment|"During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~it will be set to reproduce the preoperative constitutional deformity in varus or valgus as it was measured before surgery"
45665280|NCT04226339|Procedure|total knee arthroplasty with a mechanical alignment|"During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~It will be set to 180° as defined for a mechanical femorotibial alignment"
45665281|NCT05050643|Other|EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy
45665282|NCT05050643|Other|EBQI-LC|A Learning Collaborative is a systematic approach to process improvement based on the Institute for Healthcare Improvement Breakthrough Series Collaborative model. During the Collaborative, organizations will test and implement system changes and measure their impact. They will share their experiences to accelerate learning and broader implementation of best practices.
45820190|NCT00381056|Behavioral|Labor and Delivery Team Coordination Course|
45820191|NCT00002048|Drug|Zidovudine|
45820192|NCT04130425|Device|Hely & Weber MTC Fracture Brace|Prefabricated muenster orthosis
45820193|NCT04130425|Device|Thermoplastic orthosis|Muenster orthosis fabricated out of thermoplastics and secured with Velcro
45820194|NCT04130425|Device|Delta cast orthosis|Muenster orthosis fabricated out of Delta Cast and secured with Velcro
45961493|NCT05808816|Drug|Lactobacillus Crispatus M247|Oral supplementation of Lactobacillus Crispatus M247 in patients with cervical low grade lesions HPV related
45961494|NCT05808790|Procedure|Minimally invasive pulmonary metastasectomy|Surgical margin is equal to tumor size, if possible The goal is a parenchymal-sparing resection
45961495|NCT05808790|Radiation|Stereotactic ablative radiotherapy|Depending on tumor location, 54 Gy in 3 fractions, 55 Gy in 5 fractions, 60 Gy in 8 fractions.
45961496|NCT05808777|Other|Phone interview|A interview follow-up with a physician by phone was performed at 12 months after the onset of ICH.
45961497|NCT05808738|Behavioral|therapeutic play|therapeutic game will be played to prepare children for hydrotherapy treatment
45961498|NCT05808712|Other|validation|Translation and validation design
45961499|NCT05808686|Other|Ischemic Conditioning|We will use a randomized block design to randomize individuals into either Ischemic Conditioning-Low or Ischemic Conditioning-High group using an online randomizer. A handheld sphygmomanometer and blood pressure cuff will be given to study participants. For the Ischemic Conditioning-High group participants, while sitting, the cuff will be placed around the non-dominant upper arm and inflated to 225 mmHg for 5 min, then released for a 5-min recovery period. A 5-min inflation period is most used. Five cycles of inflation/recovery will be performed. For the Ischemic Conditioning-Low group participants, the cuff will be inflated to 10 mmHg instead. All participants will perform the intervention daily for 2 weeks. Participants will complete daily log sheets documenting the time and pressure of each cuff inflation.
45820195|NCT00001136|Biological|ALVAC-HIV MN120TMG (vCP205)|
45820196|NCT00002054|Drug|Pentamidine isethionate|
45820197|NCT00000386|Behavioral|Exposure and Response Prevention|
45961500|NCT05808647|Behavioral|5-day controlled metabolic dietary intake|Over 5-days, all food will be provided from the metabolic kitchen and participants will be instructed to eat all of the food provided each day and only the food provided each day.
46079555|NCT04998136|Drug|Placebo (semaglutide 2.4 mg)|Administered s.c. as well as reduced-calorie diet and increased physical activity for 44 weeks
45820198|NCT00000386|Behavioral|Family Treatment Program|
45820199|NCT00000386|Behavioral|Relaxation Training|
45665283|NCT05048849|Biological|MVC-COV1901(S protein with adjuvant)|Approximately 500 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
45665284|NCT01655381|Drug|Tocilizumab|Tocilizumab 8 mg/kg administered intravenously.
45820200|NCT00000386|Behavioral|Behavior therapy|
45820201|NCT00000386|Behavioral|Family Counseling|
45820202|NCT00000398|Behavioral|Coping skills training|
45820203|NCT00000398|Behavioral|Physical exercise training|
45820204|NCT00000398|Behavioral|Coping skills training plus physical exercise training|
45820205|NCT00002060|Drug|Inosine pranobex|
45820206|NCT00002066|Drug|Thymopentin|
45820207|NCT00002072|Drug|Epoetin alfa|
45820208|NCT00002078|Drug|Interferon alfa-n3|
45820209|NCT00000404|Behavioral|Patient education in self-care of knee OA|
45820210|NCT00000434|Behavioral|Fit and Strong!|Fit and Strong! is a multi-component exercise and health education program that includes flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
45820211|NCT00000440|Drug|naltrexone (Revia)|
45820212|NCT00000440|Drug|sertraline (Zoloft)|
45820213|NCT00002084|Drug|Valacyclovir hydrochloride|
45820214|NCT00002084|Drug|Acyclovir|
45820215|NCT00000446|Drug|sertraline (Zoloft)|
45961501|NCT05808634|Drug|BA3182|Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM
45961502|NCT05808608|Drug|AK104|Anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)
45961503|NCT05808608|Drug|Axitinib|An oral, small molecule, TKI selective for VEGFRs; 5mg bid orally
45665285|NCT05085275|Drug|Ferric Citrate 1 GM Oral Tablet [AURYXIA]|All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
45665286|NCT05085275|Drug|Placebo|All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
45961504|NCT05808595|Dietary Supplement|AlphaWave® L-Theanine|One capsule of AlphaWave® L-Theanine will be taken twice daily for 28 days.
45665287|NCT05117333|Other|Reminder (information letter)|Reminders
45665288|NCT05116865|Biological|HH-120 Dose 1|Dose level 1 of HH-120
45665289|NCT05116865|Biological|HH-120 Dose 2|Dose level 2 of HH-120
45820216|NCT04131517|Drug|Padsevonil|Study Medication: Padsevonil Dosage formulation: Oral tablets; 400 mg BID (Part 1) and 200 mg BID (Part 2)
45820217|NCT04131517|Drug|Microgynon 30®|Study Medication: Microgynon 30® Dosage formulation: Oral tablets Dose: Ethinyl estradiol 30 µg + levonorgestrel 150 µg
45820218|NCT00001256|Drug|prednisone and methotrexate|
45820219|NCT00000452|Drug|naltrexone (Revia)|
45820220|NCT00000452|Behavioral|Compliance Enhancement Tech.|
45820221|NCT00000452|Behavioral|Cognitive Behavior Therapy|
45820222|NCT00377533|Device|wheelchair rear anti-tip device|assistive device
45820223|NCT00000458|Drug|sertraline (Zoloft)|
45820224|NCT00000458|Behavioral|cognitive behavior therapy|
45820225|NCT00000470|Procedure|cardiac surgical procedures|
45820226|NCT00000470|Procedure|cardiopulmonary bypass|
45820227|NCT03782233|Drug|A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).|50 patients undergoing laparoscopic gastrectomy surgery will be allocated to group D. A continuous intravenous infusion of 0.5-0.6 mg/kg/h rocuronium to keep the target neuromuscular blockade (PTC = 1-2).
45820228|NCT03782233|Drug|A continuous intravenous infusion of 0.2-0.3 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (TOF = 1-2).|33 patients undergoing laparoscopic gastrectomy surgery will be allocated to group M. A continuous intravenous infusion of 0.2-0.3 mg/kg/h rocuronium to keep the target neuromuscular blockade (TOF = 1-2).
45820229|NCT00002090|Drug|Azithromycin|
45820230|NCT00002096|Drug|Zidovudine|
45820231|NCT00002096|Drug|Didanosine|
45820232|NCT00002096|Drug|Ganciclovir|
45820233|NCT04285489|Device|Hakim Shunt Programmable System|patient accept Hakim Shunt Programmable System due to HCP
45820234|NCT00002102|Drug|Trimetrexate glucuronate|
45820235|NCT00002102|Drug|Leucovorin calcium|
45820236|NCT00380666|Procedure|PET/CT scan|
45820237|NCT00002108|Drug|Lamivudine|
45820238|NCT00002108|Drug|Zidovudine|
45961505|NCT05808595|Other|Placebo|One capsule of Placebo will be taken twice daily for 28 days.
45665290|NCT05116865|Biological|HH-120 Dose 3|Dose level 3 of HH-120
45820239|NCT04317313|Other|FDG PET radiomic feature evaluation|"A total of 1245 radiomic features will be calculated and extracted from baseline FDG PET scans. These features include shape features, first order features, textural features and wavelet features.~In the second part, based on the results of least absolute shrinkage and selection operator Cox regression algorithm, the most significant radiomic features will be selected to construct the radiomic signature."
45665291|NCT05116865|Drug|Placebo|Placebo to match
45665292|NCT05048537|Radiation|18F-FACBC PET/CT|10mCi 18F-FACBC IV injection, then whole body PET/CT after 4 mins
45820240|NCT00381134|Drug|losartan 100 mg orally once daily|
45820241|NCT00381134|Drug|spironolactone 25 mg orally once daily|
45820242|NCT00381134|Drug|placebo once orally once daily|
45820243|NCT04714021|Other|CO2|to insufflate CO2 into the stomach instead of air during the PEG
45820244|NCT04714021|Other|air|to insufflate air into the stomach instead of CO2 during the PEG
45820245|NCT00002114|Drug|Procysteine|
45820246|NCT00378001|Drug|FSH-IBSA|
45820247|NCT00378001|Drug|GONAL-F|
45820248|NCT00000506|Drug|fenfluramine|
45820249|NCT00000506|Drug|phentermine|
45820250|NCT00000512|Drug|lovastatin|Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
45820251|NCT00000512|Drug|colestipol|Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation.
45820252|NCT00000512|Drug|niacin|Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
45820253|NCT00000512|Other|Placebo for colestipol|Placebo for colestipol.
45820254|NCT00000512|Other|Placebo for lovastatin|Placebo for lovastatin
45820255|NCT00000536|Behavioral|sodium, dietary|
45820256|NCT00380822|Drug|miglitol|
45665293|NCT05116085|Drug|Tislelizumab|Administered intravenously
45665294|NCT05115695|Other|traditional physiotherapy approach|Traditional upper extremity strengthening and tonus regulation (weight shifting, weight bearing, active reaching in sitting exercises) exercises consisting of Neurodevelopmental Therapy (NDT-Bobath) approaches will be applied to the second group for 45 minutes, 3 days a week for 6 weeks.
45820257|NCT03777865|Biological|13vPnC|All subjects receive a single dose (0.5mL) of 13vPnC
45820258|NCT00000542|Drug|Inhibitors, ACE|
45820259|NCT00000542|Drug|amlodipine|
45458284|NCT03498430|Drug|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib will be administered intravenously on 60mg once in a 3 weeks-on/1 week-off dose regimen (on Days 1, 8 and 15)
45820260|NCT00000542|Drug|lisinopril|
45820261|NCT00000542|Drug|doxazosin|
45820262|NCT00000542|Drug|chlorthalidone|
45820263|NCT00000542|Drug|pravastatin|
45820264|NCT00000542|Behavioral|diet, fat-restricted|
45820265|NCT04109443|Behavioral|Young Men & Media Program|The online sexual health media literacy website includes content about (1) male anatomy; (2) HIV/STI prevention; (3) overall sexual health; and (4) sexually explicit online media (SEOM) literacy.
45820266|NCT04109443|Behavioral|Available websites on safe sex and preventing STIs|Available websites (such as by the CDC) that provide information about sexual health and preventing sexually transmitted infections (STIs) including HIV.
45820267|NCT00000548|Procedure|mechanical ventilation|
45820268|NCT04107493|Device|Portable Oxygen Cylinder|A POC is a medical device that is indicated for patients who require supplemental oxygen, including COPD patients
45820269|NCT04107493|Device|Mobi|ResMed's variant of POC
45820270|NCT00002120|Drug|Trimetrexate glucuronate|
45820271|NCT00002120|Drug|Trimethoprim|
45820272|NCT00002120|Drug|Sulfamethoxazole|
45820273|NCT00002120|Drug|Dapsone|
45820274|NCT00002120|Drug|Leucovorin calcium|
45820275|NCT00002126|Drug|Filgrastim|
45820276|NCT03231397|Drug|Assess AAA rupture risk by PET-CTA scans|Assess AAA rupture risk by PET-CTA scans
45820277|NCT03231397|Drug|18F-fludeoxyglucose (FDG)|Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
45820278|NCT03231397|Diagnostic Test|11C-PBR28|Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
45820279|NCT03189433|Drug|Ryanodex (dantrolene sodium) for injectable suspension|Ryanodex (dantrolene sodium) for injectable suspension, 250 mg/vial to be reconstituted in 5 mL of sterile water for injection to yield a 50 mg/mL suspension that will be administered as a rapid IV push of 2.5 mg/mL.
45820280|NCT00002132|Drug|Itraconazole|
45820281|NCT00002132|Drug|Fluconazole|
45820282|NCT00002138|Drug|Tecogalan sodium|
45820283|NCT03776539|Drug|ELX-02|ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug. All groups will get the same treatment.
45820284|NCT00002144|Drug|Foscarnet sodium|
45820285|NCT00000578|Drug|theophylline|
45820286|NCT00000578|Drug|beclomethasone|
45820287|NCT03774745|Drug|Mifepristone 200 MG|All subjects receive mifepristone tablet on treatment day 1.
45820288|NCT03774745|Drug|micronized Progesterone|Subjects randomized to progesterone receive treatment starting day 2.
45820289|NCT03774745|Drug|Placebo oral capsule|Subjects randomized to placebo receive treatment starting day 2.
45820290|NCT00000584|Drug|immunoglobulins|
45820291|NCT00000590|Drug|immunoglobulins|
45820292|NCT03769207|Device|Ambulatory ECG|Eligible participants are asked to wear the ambulatory ECG monitor
45820293|NCT00000614|Drug|warfarin|
45820294|NCT02973464|Drug|Valganciclovir|Oral at a dose of 450mg or 900mg per day begin within 10 days till to Day 100 posttransplant
45820295|NCT02973464|Drug|Ganciclovir|intravenous GCV 5mg/kg/d after renal transplantation for the first 14 days, and then oral GCV 1g 3 times daily till to Day 100 posttransplant.
45820296|NCT00000626|Drug|Vinblastine sulfate|
45820297|NCT00000626|Drug|Dacarbazine|
45820298|NCT00000626|Drug|Filgrastim|
45820299|NCT00000626|Drug|Bleomycin sulfate|
45820300|NCT00000626|Drug|Doxorubicin hydrochloride|
45820301|NCT03766165|Behavioral|Intervention|Participants will receive job announcements plus educational sessions, mentoring, behavioral economic text messages, and a start-up grant.
45820302|NCT03766165|Behavioral|Control|Participants will receive job announcements only.
45820303|NCT00002150|Drug|Celgosivir hydrochloride|
45820304|NCT00001382|Biological|PROSTVAC|
45820305|NCT03109873|Radiation|External Beam Radiation Therapy|Undergo External Beam Radiation Therapy
45820306|NCT03109873|Drug|Metformin Hydrochloride|Given orally
45820307|NCT03109873|Other|Placebo|Given orally
45820308|NCT04713254|Drug|Lu AG06466|10, 20, 30 mg/day oral capsules on Day 5-18
45820309|NCT04713254|Other|Midazolam|4 mg syrup, oral single dose on Day 1 and Day 15
45820310|NCT04713254|Other|Metoprolol|100 mg tablets, oral single dose on Day 1 and Day 15
45820311|NCT04713254|Other|Bupropion|100 mg tablets, oral single dose on Day 3 and Day 17
45820312|NCT00002156|Drug|Fomivirsen sodium|
45961506|NCT05808569|Behavioral|Test|A specific self-test composed by 16 questions , will be administered to BC patients undergoing adjuvant RT.
45961507|NCT05808556|Device|Sticker pads containing lavender and ylang ylang oil|The sticker pad group attached an sticker pad (0.3% lavender oil and 0.7% ylang ylang oil) to their shirt, close to the right side of the neck, for 14 days,
45961508|NCT05808556|Device|Placebo|The placebo group attached a sticker pad without lavender and ylang ylang oil to their shirt, close to the right side of the neck, for 14 days.
45455289|NCT03939013|Diagnostic Test|Xpert HCV VL|Use of Cepheid GeneXpert HCV VL test as diagnostic tool to test for HCV RNA for diagnosis of hepatitis C infection, to test for sustained virological response at 12 weeks post treatment completion
45455290|NCT04656652|Drug|DS-1062a|DS-1062a will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle
45820313|NCT00002156|Drug|Ganciclovir|
45820314|NCT04092907|Drug|HBM9036 0.25% Ophthalmic Solution|Ophthalmic Solution
45820315|NCT04092907|Drug|placebo|Ophthalmic Solution
45820316|NCT00002162|Drug|Saquinavir|
45820317|NCT00002162|Drug|Lamivudine|
45820318|NCT00002162|Drug|Stavudine|
45820319|NCT00002162|Drug|Zidovudine|
45820320|NCT00002162|Drug|Zalcitabine|
45820321|NCT00002162|Drug|Didanosine|
45820322|NCT00000638|Drug|Isoniazid|
45820323|NCT00000638|Drug|Pyrazinamide|
45820324|NCT00000638|Drug|Pyridoxine hydrochloride|
45820325|NCT00000638|Drug|Rifampin|
45820326|NCT04086433|Device|gastric tissue resection|human stomach specimens will be resected with the surgical staplers for pressure testing and staple malformation assessment
45820327|NCT00000650|Drug|Ditiocarb sodium|
45820328|NCT00000656|Drug|Zidovudine|
45820329|NCT00000656|Drug|Didanosine|
45820330|NCT00001430|Procedure|PBSC|
45820331|NCT00001430|Drug|IL-2|
45820332|NCT00001430|Drug|EPOCH II|
45820333|NCT00000662|Drug|Zidovudine|
45820334|NCT00002168|Drug|Indinavir sulfate|
45820335|NCT00002168|Drug|Lamivudine|
45820336|NCT00002168|Drug|Stavudine|
45820337|NCT00002168|Drug|Zidovudine|
45820338|NCT00002168|Drug|Didanosine|
45820339|NCT00001442|Drug|paclitaxel concurrent with radiation therapy|
45820340|NCT00002174|Drug|Thalidomide|
45820341|NCT04710212|Other|No intervention.|Observational study with no intervention.
45820342|NCT00000668|Drug|Ganciclovir|
45820343|NCT00000680|Drug|Zidovudine|
45820344|NCT00000680|Drug|Aldesleukin|
45820345|NCT00000692|Drug|Butyldeoxynojirimycin|
45820346|NCT00001460|Behavioral|inpatient evaluation and management|
45820347|NCT00000698|Drug|Ganciclovir|
45820348|NCT03764449|Drug|Oral Balovaptan|"In Period 1, balovaptan was administered as a single oral dose.~In Period 2, balovaptan was administered as an oral dose once daily on Day 1 to Day 14."
45820349|NCT03764449|Drug|IV Balovaptan|"In Period 1, IV infusion of balovaptan was administered after the balovaptan oral dose.~In Period 2, IV infusion of balovaptan was administered after the final oral dose of balovaptan."
45820350|NCT00002180|Drug|Tenofovir|
45820351|NCT00002186|Drug|Crofelemer|
45820352|NCT00002186|Drug|Acyclovir|
45820353|NCT00001502|Drug|RMP-7 and carboplatin|
45665295|NCT05115695|Other|muscle strengthening exercise/Proprioceptive Neuromuscular Facilitation (PNF)|Muscle strengthening with scapular and upper extremity patterns of PNF exercise approach will be applied to the first group for 6 weeks, 3 days a week, 30 minutes a day.
45665296|NCT01656161|Drug|Triptorelin embonate 22.5 mg|
45961509|NCT05808543|Other|Both EARS training package (BEARS)|The BEARS training package comprises of three games addressing different hearing functions: speech-in-noise perception, music listening and sound-source localisation. Each game is based on an audio-visual task performed through a virtual-reality interface. Players are guided through on-screen visual prompts to support the gameplay with feedback given on their performance and progress through levels of increasing difficulty. The BEARS training package design allows for the training to be self-administered, played anywhere and at any time. There is no upper limit to the frequency of use of the BEARS training package, it is advised to play the games for a minimum of 1 hour a week over a minimum of 2x 30-minute sessions, all three games will need to be played.
45820354|NCT04084015|Device|Axillary Impella®|All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy
45665297|NCT05082077|Device|LIVERguard|The LIVERguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of livers during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the liver. The intended organ storage time for the LIVERguard is up to 16 hours.
45820355|NCT00002192|Drug|Rifapentine|
45820356|NCT00002192|Drug|Ethambutol hydrochloride|
45820357|NCT00002192|Drug|Clarithromycin|
45820358|NCT00002192|Drug|Azithromycin|
45820359|NCT00002198|Drug|Abacavir sulfate|
45665298|NCT05048381|Diagnostic Test|Next Generation Sequencing|Next Generation Sequencing of sweat and whole blood samples for non-coding miRNAs to define biomarkers that enable to differentiate between patients with active tuberculosis, a differential diagnostic disease and healthy individuals.
45665299|NCT05081141|Diagnostic Test|Diagnostic test for HHV8 exposure|Venipuncture for blood sampling
45665300|NCT05081063|Diagnostic Test|Routine labs|Routine labs will be performed with CBC, BMP, Fox screen, ROTEM viscoelastic test, PT/INR, PTT and venous lactate for standard of care for all patients.
45665301|NCT05114993|Device|wearing a disposable surgical mask|Physiologic vital signs will be monitored every minute for 5 minutes without a mask, followed by every minute for 15 minutes with a surgical mask.
45820360|NCT00000704|Drug|Zalcitabine|
45820361|NCT03061279|Device|Fixation by Acutrak headless screw|The fixation provided by the Acutrak headless compression screws provide sufficient fixation to achieve union and a favorable clinical outcome in both horizontal and vertical medial malleolus fractures when compared to bicortical and unicortical screw fixation, tension band wiring, and mini-fragment or buttress plating
45820362|NCT03061279|Device|Fixation by headed screws, plates, and or wires|DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes Locking contrast dynamic compression (LC-DCP) Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire are the alternative methods of treatment of medial malleolus fracture.
45820363|NCT00000728|Drug|Zidovudine|
45820364|NCT00000728|Drug|Aldesleukin|
45820365|NCT00001520|Drug|neostigmine|
45961510|NCT05808543|Other|Usual Care|This is an annual review appointment with the patient and their clinician. This could be face-to-face, virtual video consultation, questionnaire, or be cochlear remote care checks. As a minimum this review will check the following: Microphone covers changed, Reported or recorded device use, all external and internal equipment working (known through no reported or recorded degradation in hearing ability). During the appointment, the clinician would establish if there were any concerns regarding the cochlear implant functioning and the patient's rehabilitation programme. They will then make any repairs or adjustments to the device and manage additional support and contact as required. Between the annual review appointments patients can attend the implant centre for repair appointments or have spare equipment posted. There is no limit to the level of contact between the patient and the implant centre.
45961511|NCT05808530|Behavioral|Cognitive Stimulation Therapy|"CST involves the use of standard tasks that focus on cognitive functions, designed to meet varying levels of difficulty in accordance with the individual's ability and rehabilitation. A detailed guide for CST is available for a range of health and care professionals, including care workers, occupational therapists, psychologists, and nurses (https://www.ucl.ac.uk/international-cognitive-stimulation-therapy/) publications/cst-manuals). The CST application consists of 14 sessions of 45-50 minutes, 2 days a week.~Intervention Group Week 1=Getting acquainted and applying pre-tests Week 2=Physical games and Sounds Week 3=Childhood and Food Week 4=Current events and Faces / Scenes Week 5=Word association and Creativity Week 6=Categorizing Objects and Orientation Week 7= Money usage and Games Week 8=Word Games and Team Competition Week 9=Closing and post-test application"
45961512|NCT05808517|Behavioral|Tai Chi|Tai Chi (TC) is a traditional Chinese exercise, also known as a mind-body exercise. It is suitable as an alternative or supplementary form of routine physical exercise for older adults. TC focuses on gentle and rhythmical movements while maintaining a meditative state. Low to moderate activities have benefits to improve sleep disturbances in older adults. In addition, growing evidence widely supports meditation as a potential intervention to improve sleep disturbances through reducing repetitive negative thoughts such as worry and rumination.
45961513|NCT05808517|Other|repetitive transcranial magnetic stimulation|The brain stimulation technique repetitive transcranial magnetic stimulation (rTMS) provides the opportunity to non-invasively modulate cortical excitability. In general, low-frequency rTMS (≤ 1 Hz) is thought to inhibit cortical excitability.
45961514|NCT05808504|Other|Neuropsychological assessment|interview with a neuropsychologist and carrying out tests measuring overall cognitive abilities, depression, apathy and anxiety (respectively using the MOCA, MADRS, LARS, STAI scales)
45961515|NCT05808504|Other|Neurological assessment|Only for patients with Parkinson disease. Evaluation consisting in a disease severity assessment using the Hoehn and Yahr and Schwab and England scales, as a well as a measure of levodopa equivalent daily dose.
45961516|NCT05808504|Other|Cognitive task|"The task consists in pressing a left or right button as fast and as accurately as possible according to the direction of an arrow displayed at the center of a screen. On 25 % of the trials, a stop signal will occur right after the stimulus, indicating the participant to stop his impending button press. The delay between the presentation of the arrow stimulus and the stop signal will be adjusted to ensure a final 50% accuracy (decreased following an accurate response and increased after an error), which is necessary to comply with the assumptions for a robust calculation of the stop signal reaction time (SSRT)."
45961517|NCT05808504|Procedure|EEG|A high-resolution (256 channels) electroencephalographic recording will be done at rest and during the Stop task, before and after each real or sham stimulation.
46079556|NCT04985838|Behavioral|HEADS: UP (Helping Ease Anxiety and Depression)|A group-based Mindfulness Based Stress Reduction (MBSR) course adapted for people affected by stroke and delivered online using a video communication platform. An introductory session in the first week is followed by 8 weekly sessions (2.5 hours, incorporating 30-minute comfort breaks). A 6-hour silent retreat is offered in week 7. An optional follow-up session is offered six-eight weeks after completion of the 9-week course. Course materials include a manual (provided after the introductory session), weekly pre/post-session emails with instructions and information about joining the sessions and engaging in personal practice, including links to audio files to complement class-based sessions.
46079557|NCT04983771|Device|Annotate ultrasound scans|Each expert will be asked to hand-labelled anatomical structures on relevant ultrasound images
46079558|NCT04983342|Device|Apollo Armband|The Apollo armband is approximately the size of an Apple Watch and can be worn on the ankle, wrist, or arm with two adjustable fabric straps. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy, combatting fatigue and pain. In addition to the wearable, Apollo is a software system that curates music for the body, rather than for the ears.
46079559|NCT04975958|Drug|AN2025|oral administration
45665302|NCT05047679|Behavioral|Perioperative Pain Neuroscience Education|Perioperative pain neuroscience education addresses modifiable preoperative risk factors, and in particular cognitive and emotional risk factors, such as fear of movement and pain catastrophizing (i.e., excessively negative orientation toward pain). This education is a cognitive-based therapeutic intervention which reconceptualizes pain, informs patients about what to expect from the evolution of their pain, de-emphasizes the patho-anatomical content and focuses on factors contributing to the development of pain. It explains this all within a biopsychosocial framework, which means that it aims to optimize patients' beliefs. Furthermore, it intends to reassure the patient about the decision to have surgery, to potentially decrease perioperative distress.
45820366|NCT03763747|Device|Scoreflex NC Scoring PTCA catheter|To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
45820367|NCT00002204|Biological|HIV p24/MF59 Vaccine|
45820368|NCT00001526|Drug|Daclizumab (Zenapax)|
45820369|NCT00002294|Drug|Fluconazole|
45820370|NCT03758365|Drug|MC2-01 Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
45820371|NCT03758365|Drug|Clobetasol Propionate 0.05% Lotion|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
45820372|NCT03758365|Drug|Betamethasone Dipropionate 0.05% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
45820373|NCT03758365|Drug|Triamcinolone Acetonide 0.1% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
45961518|NCT05808504|Procedure|tACS (real or sham)|Real or sham tACS will be applied with the same equipment (StarStim, Neuroelectrics). The stimulation will consist in applying a current (max 2 mA) at frontal sites (F8 and Cz according to standard EEG position, and defined based on dosimetry analyses on averaged head models) for 12-15 minutes during the task. A 10 s ramp (fade-in/fade-out) will be used to avoid current perception of the stimulation and optimize blinding. Sham stimulation will be done using the same protocol, but with no stimulation in between onset and offset.
45665303|NCT05047679|Behavioral|Perioperative Biomedical Education|Perioperative biomedical education will discuss the anatomy, physiology and biomechanics of the lumbar spine with the patient. Additionally, the content of this education includes the expected course of postoperative back and leg pain, as well as ergonomic advice on patient-specific daily activities. This education will be given within a biomedical framework, which means that it aims to explain the patients' complaints and recovery while focusing on anatomy and biomechanics, as opposed to patients' beliefs and cognitions.
45665304|NCT05080283|Device|CP1110 Sound Processor System|Sound Processor
45665305|NCT05080283|Device|Nucleus 7 Sound Processor (model: CP1000) system|Sound Processor
45665306|NCT05046431|Drug|BAT2506|50mg/0.5mL
45961519|NCT05808491|Radiation|online resilience intervention|online resilience intervention were presented in four 60-minute sections, once a week for four weeks embracing four sections
45961520|NCT05808478|Behavioral|AAC + Eye Tracking|The AAC treatment will be supported by the use of an innovative high-tech tool, such as Eye Tracking. The duration of treatment will be 6 months, with sessions of 45 minutes twice a week.
45665307|NCT05046431|Drug|EU Simponi|50mg/0.5mL
45961521|NCT05808478|Behavioral|AAC|Treatment involves the use of conventional AAC, with low-tech tools, such as PECS or sign language. The duration of treatment will be six months, twice a week, with sessions of 45 minutes.
45961522|NCT05808387|Dietary Supplement|Resveratrol|Trans-resveratrol, 1000 mg daily for 90 days
45961523|NCT05808387|Dietary Supplement|Placebo|Starch, 1000 mg daily for 90 days
45665308|NCT05078957|Other|Stool sampling|Stool samples will be collected from participants at baseline and annually during 5 years
45665309|NCT05078957|Other|Frailty phenotype|According to Fried frailty phenotype based on the assessment of 5 criteria: shrinking (unintentional weight loss), weakness (grip strength), poor endurance (exhaustion), slowness (walking speed) and physical activity. Frail phenotype is defined as the presence of at least 3 criteria of the above mentioned and Pre-frail phenotype as the presence of 1 or 2 criteria.
45665310|NCT05078957|Other|Blood plasma collection|Blood plasma collection to measure persistent inflammation and immune activation
45665311|NCT05078879|Drug|Empagliflozin|This is an open-label pilot study to evaluate the efficacy, safety, and tolerability of empagliflozin as a treatment for severe congenital neutropenia (SCN) in patients with glucose-6-phosphatase 3 (G6PC3) deficiency. Participants will be on a 12-month daily regimen of empagliflozin at a starting dose of 10 mg (phase A), which may be increased after 2 months to 25 mg (phase B). Evaluate the safety and efficacy of the biomarker response (the change in absolute neutrophil count [ANC] after one year of empagliflozin treatment relative to baseline ANC prior to drug treatment) in patients with G6PC3 deficiency.
45665312|NCT05078723|Dietary Supplement|Limonene|The investigators will ask the participants to swish 5 times and swallow 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract). The participant will be monitored for a total of 2 hours. Breath samples will be acquired at a total of 11 time points throughout the study. Measurements include 2 baseline measurements followed by the orange peel extract consumption.
45665313|NCT05077787|Other|Massage therapy|Massage therapy includes stroking, kneading, rolling, tapping, vibration and effleurage over the face, chest ,abdomen and back. Massage therapy will be given for 5 minutes and will be repeated twice.
45665314|NCT05077787|Other|Kinaesthetic stimulation|Kinaesthetic stimulation includes passive flexion and extension movements of shoulder joint, elbow joint, hip joint, knee joint and both lower limbs together. It will be given for 5 minutes in each intervention
45665315|NCT05046275|Other|Data analysis|No intervention, data analysis only
45665316|NCT04422041|Other|Time to discharge less than 24 hours|Allow the joint medical discharge of the newborn together with its mother in less than 24 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
45665317|NCT04422041|Other|Discharge time between 24 and 48 hours|Allow the joint medical discharge of the newborn together with its mother between 24-48 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
45665318|NCT05045027|Procedure|Biospecimen Collection|Undergo collection of tissue samples
45665319|NCT05045027|Procedure|Diagnostic Imaging|Undergo multinuclear metabolic imaging
45665320|NCT05045027|Procedure|Magnetic Resonance Imaging|Undergo MRI
45961524|NCT05808348|Other|Scales and questionnaires|"We will ask participants about their age, gender, height, weight, education level, medical history, number of falls in the last 1 year, status and length of COVID-19-related hospitalizations, and whether they have gotten the COVID-19 vaccine. The participants will be interviewed in person as part of the evaluation process.~The Modified Baecke Physical Activity Questionnaire, the Fall Efficacy Scale-International, and the Numerical Pain Rating Scale will be used to assess the participants' levels of pain, fear of falling, and physical activity, respectively."
45665321|NCT05043857|Radiation|Stereotactic Body Radiotherapy (SBRT)|"Postoperative Stereotactic Body Radiation Therapy (SBRT) after tumor resection targeting 2 volumes~CTV1 (clips+isotropic 5mm expansion, edited on anatomic barriers): receiving 40 Gy in 5 fractions of 8 Gy~CTV2 (CTV1+ anisotropic 10-15 mm expansion including corresponding vessels, retroperitoneum posterior to the SMV/SMA or celiac axis, edited on anatomic barriers): receiving 30 Gy in 5 fractions of 6 Gy."
45665322|NCT04421807|Other|Scapulatoracic stabilization exercises|Scapulatoracic stabilization exercises consisted of 3 phases; the warming phase which consists of mobility and stretching; exercise phase consisting of static, dynamic and functional phase; the cooling phase consisting of mobility and stretching. Scapulatoracic stabilization exercises additionally applied to CDT were performed 3 days a week for 8 weeks. These exercises were specially planned for the patients and applied gradually
46079560|NCT04975958|Drug|AN0025|oral administration
46079561|NCT04975958|Drug|Atezolizumab 1200 mg in 20 ML Injection|infusion
46079562|NCT04973930|Behavioral|Interpersonal Psychotherapy|Time-limited, affect-focused, empirically supported psychotherapy
45665323|NCT04421807|Other|Complex decongestive therapy (CDT)|In the treatment phase of CDT, manual lymph drainage, skin care, compression bandage, draining exercise were applied 5 days a week for 3 weeks. Compression socks, self-drainage, skin care and unloading exercises were applied for 5 weeks in the protection phase of CDT. Thus, patients were followed up with the CDT program for 8 weeks.
45961525|NCT05808322|Drug|Ropeginterferon alfa-2b|A maximum of 3 doses of ropeginterferon alfa-2b will be given biweekly during the whole study period. A single dose of 250 μg ropeginterferon alfa-2b will be subcutaneous administrated at Day 1 visit. SARS-CoV-2 antigen test will be conducted at D15 and D29 visits. For patients who still have positive result in SARS-CoV-2 antigen test at Day 15 visit, the second dose of ropeginterferon alfa-2b at 350 μg will be subsequently administered at Day 15 visit. For patients who still have positive result in SARS-CoV-2 antigen test at Day 29 visit, the third dose of ropeginterferon alfa-2b at 500 μg will be administered at Day 29 visit.
45961526|NCT05808322|Procedure|SOC|SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.
45665324|NCT04421261|Device|Air-Q Self Pressurized Airway Device with Blocker|used in low risk adult females undergoing elective surgeries
45961527|NCT05808296|Other|Lavander oil Aromatherapy|Lavander oil Aromatherapy
45961528|NCT05808296|Other|Saline Solution|Saline solution application
45961529|NCT05808270|Behavioral|Nutrition care process|"According to the randomization and simple blinding, there will be 2 study groups in which group 1 will be operated on Nutrition care process and group 2 with Conventional nutritional intervention.~The Nutrition Care Process is a standardized model intended to guide RDNs in providing high quality nutrition care. The NCP consists of four distinct, interrelated steps: Nutrition Assessment, Diagnosis, Intervention, and Monitoring/Evaluation (AND, 2023).~In the case of Conventional nutritional intervention, we will base ourselves on the application of a habitual nutritional clinical history, where information will be obtained on the reasons for consultation and the specific needs of the patient to carry out an intervention based on their priorities."
45961530|NCT05808257|Device|Thulium Fibre Laser|The TFL is a relatively new laser in the field of urology. First introduced on the market in 2017, it offers theoretically superior stone dusting qualities and smaller fiber sizes to allow for better irrigation.
45665325|NCT04421261|Device|I-Gel|used in low risk adult female patients undergoing elective surgeries
45961531|NCT05808257|Device|Holmium:Yttrium-Aluminum-Garnet|The Ho:YAG is currently the most commonly used laser in the field of urology and for the better part of the last 3 decades has been considered the gold standard for laser lithotripsy.
45820374|NCT03758365|Drug|Hydrocortisone Butyrate 0.1% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
45820375|NCT03758365|Drug|Desonide 0.05% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
45820376|NCT03758365|Drug|Vehicle|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
45961532|NCT05808244|Behavioral|tgCBFI|Six weekly sessions CBT-based family intervention programme
45961533|NCT05808244|Behavioral|Usual psychiatric care|Integrated community psychiatric care with medical follow-up
46079563|NCT04973930|Drug|Venlafaxine HCl ER|FDA-approved antidepressant medications
46079564|NCT04972942|Drug|Daratumumab|"Total body irradiation (TBI)-based myeloablative allogeneic hematopoietic stem cell transplantation (HCT) using best available donor.~Daratumumab (DARA) treatment post-HCT Phase 1: 3 dose levels to determine safety (15 patients)~Dose expansion:~Induction: DARA IV weekly x 8 doses (Weeks 1-8)~Consolidation: DARA every 2 weeks x 8 doses (Weeks 9-24)~Maintenance: DARA every 4 weeks (Stop at Day +270)"
46079565|NCT04960579|Biological|P-BCMA-ALLO1 CAR-T cells|Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy
46079566|NCT04960579|Drug|Rimiducid|Safety switch activator
45455291|NCT04656652|Drug|Docetaxel|Docetaxel will be administered as an IV infusion on Day 1 of each 3-week cycle.
45458285|NCT03370952|Procedure|laproscopy|laparoscopic ovarian cystectomy
45665326|NCT02111577|Biological|DCVAC/PCa|DCVAC/PCa concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). DCVAC/PCa was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of DCVAC/PCa was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.
45665327|NCT02111577|Biological|Placebo|Placebo concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). Placebo was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of placebo was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.
45665328|NCT05074433|Drug|casirivimab+imdevimab|Co-administered sequentially subcutaneous (SC)
45665329|NCT05074433|Drug|Placebo|Administered SC
45665330|NCT05111795|Device|Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres|SIRT work-up procedure and SIRT procedure
45665331|NCT04757883|Other|Study of the synthesis of antibodies directed against SARS|Between 5 mL and 45 mL of additional blood will be collected to study the synthesis of antibodies against CoV-2 SARS and to investigate whether specialised immune cells also show an effective response against the virus.
45820377|NCT00002300|Drug|Megestrol acetate|
45820378|NCT00001538|Biological|APL 400-003|
45820379|NCT03757039|Device|Multifocal soft contact lenses|Commercially available contact lenses
45820380|NCT03757039|Other|Progressive addition lens spectacles|Per subject's habitual prescription
45820381|NCT00002306|Drug|Fluconazole|
45820382|NCT00002210|Drug|Delavirdine mesylate|
45820383|NCT00381212|Biological|AGS-004|Four intradermal injections of AGS-004-001 immunotherapeutic, 4 weeks apart.
45820384|NCT00002216|Drug|Lamivudine/Zidovudine|
45820385|NCT00002216|Drug|Abacavir sulfate|
45820386|NCT00002216|Drug|Amprenavir|
45820387|NCT00002216|Drug|Nelfinavir mesylate|
45820388|NCT00002222|Drug|Valganciclovir|
45820389|NCT00002312|Drug|Delavirdine mesylate|
45820390|NCT00002312|Drug|Zidovudine|
45455292|NCT01215409|Drug|Vardenafil (Levitra, BAY38-9456)|5 mg or 10 mg or 20 mg of Vardenafil, orally when necessary for 2 months
45665332|NCT05216445|Behavioral|Mindfulness Training|The Mindfulness Training will be an 8-week course, with group-based online weekly sessions. The mindfulness training, translated and adapted in Urdu, includes 8 guided audio meditations and one introductory audio recording which gives the participants an overview and introduction of the forthcoming 8-week training (e.g what mindfulness is, some common terms used repeatedly). It also includes 8 chapters, corresponding to each week and a workbook to record home practice. The training will start with an online group session after which the participants will be emailed the 1st week's reading material (chapter 1), audio recordings (for that week), home practice (for that week). At the start of every week, the participants will be emailed the required material for that week. Online sessions will be conducted weekly. The participants will also be sent poems and/or quotations relating to the week's theme and based on the session proceedings.
45455293|NCT03936205|Drug|Dexmedetomidine|Patients allocated to this group receive a combination of Morphine and Dexmedetomidine
45665333|NCT04751877|Drug|Isatuximab|Isatuximab by IV route, per 28 days cycle - Cycle1: 10 mg/kg on days 1, 8, 15, and 22. Cycles 2 to 12: 10 mg/kg on days 1 and 15. From cycle 13: 10 mg/kg on day 1.
45820391|NCT04072237|Biological|MarzAA (marzeptacog alfa [activated])|Single intravenous dose and ascending doses of subcutaneous injection of MarzAA (Coagulation Faction VIIa Variant)
45820392|NCT00002318|Drug|Doxorubicin hydrochloride (liposomal)|
45820393|NCT00002318|Drug|Bleomycin sulfate|
45820394|NCT00002318|Drug|Vincristine sulfate|
45820395|NCT00002318|Drug|Doxorubicin hydrochloride|
45820396|NCT00381290|Behavioral|Diet|The prescribed diet will include traditional healthy food and up to two meal replacement supplements. Initially, the diet will be set to result in an overall loss of 800 to 1000 calories per day.
45820397|NCT00381290|Behavioral|Exercise|The program will consist of 60-minute exercise sessions per week for the duration of the study. The exercise sessions will incorporate aerobic exercise and resistance training. Participants will also be encouraged to exercise at home.
45820398|NCT03743311|Procedure|Hemorrhoidectomy, Thrombectomy , Operation on Longo method|Surgical procedures for treatment of Hemorhoid
45820399|NCT03743311|Drug|Detralex|Conservative treatment of Hemorhoid
45820400|NCT03743311|Other|Combined therapy|Surgical + conservative treatment of Hemorhoid
45820401|NCT00380900|Drug|AGG-523|
45820402|NCT00002228|Drug|Enfuvirtide|
45820403|NCT04714177|Drug|Edaravone Dexborneol|Edaravone Dexborneol 37.5 mg, containing Edaravone 30 mg and Dexborneol 7.5 mg, Edaravone Dexborneol 37.5 mg BID, 14 days, addition to standard of care of Intracerebral Hemorrhage
45820404|NCT04714177|Drug|Placebo|Edaravone Dexborneol matching injection, addition to standard of care of Intracerebral Hemorrhage
45820405|NCT00001628|Drug|Angiotensin II type 1 receptor antagonists|
45820406|NCT00002234|Drug|Efavirenz|
45820407|NCT00002234|Drug|Adefovir dipivoxil|
45961534|NCT05808231|Drug|Standard of Care + Quinine Sulfate|Standard of Care + Quinine Sulfate
45961535|NCT05808231|Drug|Standard of Care|Standard of Care for COVID-19 mild and moderate symptom
45455294|NCT04686266|Behavioral|Health Information + Health Coaching|Virtual Health Coaching for You: The focus of these sessions is helping caregivers take care of themselves. These are virtual health coaching sessions by trained Health Coaches over 6 months with content based on the theoretical framework from our prior research
45455295|NCT03939091|Diagnostic Test|Ultrasonography|Renal Ultrasonography
45665334|NCT04751877|Drug|Lenalidomide|Lenalidomide by oral route, per 28 days cycle - 25 mg daily on days 1-21.
45665335|NCT04751877|Drug|Bortezomib|Bortezomib sub-cutaneous, per 28 days cycle - Cycles 1 to 12: 1.3 mg/m2 on days 1, 8, 15. Cycles 13-18: 1.3 mg/m2 on days 1, 15.
45665336|NCT04751877|Drug|Dexamethasone|Dexamethasone by oral route, per 28 days cycle - 20 mg daily on days 1, 8, 15 and 22.
45820408|NCT00002234|Drug|Lamivudine|
45820409|NCT00002234|Drug|Didanosine|
45820410|NCT04070287|Combination Product|SMART Pack|The SMART pack is a re-branded and repackaged box for HIV self-testing kits. The intervention aims to promote distribution of HIVST kits through in institutions, vocational centers, and social media platforms. The intervention would also include a referral systems, where participants provided with the HIV self-testing kits are provided with information with youth-friendly health facilities for uptake of testing for sexually transmitted infections. The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the SMART pack and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Yaba local government area in Lagos state.
45820411|NCT04070287|Combination Product|Luv Box|"The Luv box is packaged in two colors: blue and pink. The LUVBox would be made available in supermarkets, on-line stores, mini-marts, pharmacies, neighborhood stores and markets, for easy accessibility in hard to reach areas. The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the Luv Box and the location where the pack can be obtained for individuals who are interested.For this pilot study, the intervention will be implemented in Yaba in Lagos state."
45820412|NCT04070287|Combination Product|Bili Vibes|The HIV self-testing kits will be available for interested individuals at the community youth events. These events and information the HIV self-testing kits will be on flyers that would be promoted at community centers and schools. For this pilot study, the intervention will be implemented in Ngenevu/Bunker communities in Enugu state.
45961536|NCT05808205|Device|• ALIAXIN EV: Essential Volume • ALIAXIN FL: Lips • ALIAXIN SR: Shape & Restore • ALIAXIN GP: Global Performance • ALIAXIN LV: Lips Volume|"According the investigator judgment and IP' Instruction For Use (IFU), each subject can be treated in one or more of following face area:~Temporal / frontal area~Orbital / Malar area~Perioral area~Lips."
45961537|NCT05808192|Drug|Immunosuppressive|compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.
45455296|NCT03655028|Behavioral|rhythmically auditory stimulation enhanced music|Patients in the intervention group will listen to music enhanced by rhythmic auditory stimulation while engaging in a 12-week home-based exercise program
45455297|NCT03655028|Behavioral|control|Patients in the control group will not listen to music while engaging in a 12-week home-based exercise program
45961538|NCT05808166|Biological|Hecolin® (Recombinant Hepatitis E Vaccine (Escherichia coli)).|Hecolin® will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 1), and 0, 1 and 6 months for the non-pregnant participant (arm 3).
45961539|NCT05808166|Other|Isotonic Sodium Chloride injection|Placebo will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 2)
45961540|NCT05808153|Radiation|radiotracer injection|MRI with radiotracer injection
45961541|NCT05808114|Behavioral|Friends program|A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions
45961542|NCT05808114|Behavioral|TAU|Individually tailored and delivered specialized child psychiatric care
45961543|NCT05808101|Other|Neuro-QoL T-score determination|Neuro-Qol depression scale, using a T-score of 55 as a threshold
45961544|NCT05808088|Other|Hypnotherapeutic sound-files|The participants have access to hypnotherapeutic sound files which they can use as the please.
45961545|NCT05808075|Other|NovaProTM Fill Universal Dental Composite|NovaProTM Fill Universal ,Nanova product
45665337|NCT02170779|Behavioral|Spasticity: Take Control|4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures
45961546|NCT05808049|Other|MXP22 (Probiotic and antioxidant capsule)|Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days
45455298|NCT03936049|Drug|Liraglutide|Liraglutide dispensing claim is used as the exposure group
45961547|NCT05808049|Other|Placebo (Microcrystalline Cellulose)|Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days
46079567|NCT04937803|Device|Drug-coated balloon|Drug-coated balloon is a fast-exchange balloon dilatation catheter, used to treat coronary artery stenosis lesions and improve myocardial blood flow.
46079568|NCT04937803|Device|Zotarolimus-Eluting Coronary Stent|Zotarolimus-Eluting Coronary Stent is treated for coronary artery stenosis lesions .
45455299|NCT03936049|Drug|DPP-4 inhibitor|DPP-4 inhibitor dispensing claim is used as the reference group
45455300|NCT04674020|Drug|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
45455301|NCT01215487|Procedure|Stem Cell and Mutational Assay|Laboratory blood testing
45455302|NCT03522376|Other|Loaded inspiratory muscle test|Loaded inspiratory muscle tests will be set at 30% and 50% of maximal inspiratory pressure. The orders of the two loaded test conditions will be conducted in random order with at least 24 hours separation. This is an observational study. Subjects will perform only 15 breaths with each loaded test condition to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training.
45665338|NCT02170779|Other|Usual care|2 visits: baseline followed by usual care of brochure for stretching then outcome measures
45665339|NCT04751799|Device|Virtual reality headset before colposcopy|Patients wear a virtual headset presenting 360° 3D views of relaxing environments
45665340|NCT04751799|Device|Virtual reality headset during colposcopy|Patients wear a virtual headset presenting 360° 3D views of distracting environments
45665341|NCT02147067|Drug|Ranolazine|Ranolazine 1,000 mg twice daily
45820413|NCT04070287|Combination Product|BeterDoc|"The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the BeterDoc Safety Kits and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Ibadan, Dugbe and Agbowo in Oyo state."
45961548|NCT05808036|Other|Dietary intervention: DOMINO app|Life style intervention and diet low in FODMAPs.
45961549|NCT05808036|Other|Dietary intervention: low FODMAP diet|Strict low FODMAP diet.
45961550|NCT05808023|Other|FODMAP powder reintroduction|The FODMAP powders will be reintroduced in three different doses, each for three consecutive days.
45961551|NCT05808010|Biological|Mononuclear cells|2 times gastric submucosal injection of mononuclear cells (10^8) at 1 month interval
45961552|NCT05808010|Drug|Weifuchun+Hydrotalcite/L-Glutamine and Sodium Gualenate Granules|Orally delivered tablets for 7 months. Take it according to the instructions.
45961553|NCT05807997|Other|Refusal of ICU admission.|patients aged 18--99 who were presented to the general intensive care unit from January 2018 to the end of December 2023 and were not admitted.
45961554|NCT05807984|Radiation|Carbon ion radiation therapy DT: 74Gy/20 fractions|patients with unresectable local recurrent rectal cancer will be treated with carbon ion radiation therapy as re-irradiation
45961555|NCT05807958|Device|Skin Prick Automated Test|A skin prick automated test will be performed in each participant.
45665342|NCT02147067|Drug|Placebo|Placebo
45665343|NCT02170389|Other|Laboratory Biomarker Analysis|Correlative studies
45820414|NCT04070287|Combination Product|IUNGO|The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the HIV self-testing kits and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Akure South, Orita-Obele, Ipinsa, Ilara Mokin and Ijare in Ondo state.
45961556|NCT05807945|Drug|Ropivacaine 7.5% Injectable Solution|The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 7.5%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
46079569|NCT04930744|Drug|Isoniazid|Isoniazid, dose prescribed by participant's physician, will be taken by mouth daily. Isoniazid, is in a combination pill pack with the other standard ATT medications.
46079570|NCT04930744|Drug|Rifampicin|Rifampicin, dose prescribed by participant's physician, will be taken by mouth daily. Rifampicin is in a combination pill pack with the other standard ATT medications.
46079571|NCT04930744|Drug|Ethambutol|Ethambutol, dose prescribed by participant's physician, will be taken by mouth daily. Ethambutol is in a combination pill pack with the other standard ATT medications.
45665344|NCT02170389|Procedure|Nephrectomy|Undergo partial or radical nephrectomy
45665345|NCT02170389|Biological|Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003|Given ID
45665346|NCT02146599|Other|Administration of patient self-assessment|
45961557|NCT05807945|Drug|Ropivacaine 2% Injectable Solution|The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 2%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
45961558|NCT05807932|Drug|Venetoclax|Study treatment consists of the conditioning therapy including 6 or 8 days of Venetoclax treatment.
45961559|NCT05807932|Drug|Amsacrine|Amsacrine is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation
45961560|NCT05807932|Drug|Ara-C|Ara-C is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation
45961561|NCT05807932|Drug|Tacrolimus|Tacrolimus is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.
45961562|NCT05807932|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.
45961563|NCT05807893|Drug|Serplulimab combined with bevacizumab and first-line chemotherapy|Serplulimab combined with bevacizumab and first-line chemotherapy
45961564|NCT05807880|Drug|The combination treatment of anlotinib, penpulimab and capecitabine.|Patients will receive the combination treatment of anlotinib, penpulimab and capecitabine every three weeks until PD or intolerance to drug toxicity. For each cycle, patients receive anlotinib 10mg, po, qd from day 1 to day 14, penpulimab 200mg, iv in day 1, and capecitabine 650mg/m2, po, bid.
45961565|NCT05807828|Procedure|VR simulation on basic THA skills|The medical students' VR group will perform three VR simulation sessions on basic THA skills on the cup and stem implantation before actual implantation.
45961566|NCT05807815|Procedure|Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation|"FiO2 will be titrated by reducing 10% if Ori>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation <95 or PaO2<60 mmHg"
45961567|NCT05807776|Drug|Tislelizumab|Tislelizumab 200mg, iv, d1, Q3W
45961568|NCT05807776|Drug|Tislelizumab, Lenvatinib|"Tislelizumab combined with lenvatinib:~Tislelizumab 200mg, iv, d1, Q3W Lenvatinib 8mg，po，qd."
45961569|NCT05807763|Procedure|Laparoscopic paraesophageal hernia repair without fundoplication|"Patients undergoing laparoscopic paraesophageal hernia repair will be evaluated for risk of esophageal reflux using intra-operative impedance planimetry and endoscopic gastroesophageal valve grade. Patients deemed low risk for esophageal reflux will then be randomized to partial fundoplication or no fundoplication."
45961570|NCT05807737|Device|Ultrasound scanning with artificial intelligence|Three residents who are eligible to perform ultrasound-guided regional anesthesia will scan volunteers in random order with artificial intelligence software (Nerveblox) fed by an FDA-cleared ultrasound device.
45961571|NCT05807711|Drug|L-Methyl Folate and methylcobalamine|Dietary supplement labeled to contain methylfolate 800 micrograms and methylcobalamine 1000 micrograms
45961572|NCT05807685|Behavioral|laughter therapy|Description: Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researchers who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
45961573|NCT05807659|Drug|fractionated busulfan-based conditioning regimen|"Drug: Chidamide 30 mg oral twice weekly for 2 weeks Drug: Fludarabine 35 mg/m2 intravenously daily for 5 days in the 2nd week Drug: Cytarabine~1 g/m2 intravenously for 5 days in the 2nd week Drug: Busulfan 3.2 mg/kg intravenously daily for 2 days in the 1st week, 1.6 mg/kg intravenously daily for 4 days in the 2nd week Procedure/Surgery: allogeneic hematopoietic stem cell transplantation"
45665347|NCT02146131|Device|Standard FB with fluoroscopy|Technique used, to go through the patient's airway, locate and obtain samples from pulmonary lesions
45665348|NCT02146131|Device|R-EBUS with ultrathin bronchoscope|Technique used to go through the patient's airway and using radial ultrasound, locate and obtain samples from pulmonary lesions
45665349|NCT02107131|Drug|Intravitreal ranibizumab 0.3mg|
45961574|NCT05807633|Device|Novosyn®|Novosyn® for uterus closure in patients undergoing cesarian section
45961575|NCT05807620|Other|Skincare Regimen|Gentle Cleansing Lotion (Revision Skincare®) to be applied twice daily Facial Moisturizer (Goodier Cosmetics) to be applied twice daily Neutrogena Ultra Sheer Dry Touch SPF 30 (Johnson & Johnson) to be applied morning and afternoon reapplication as per FDA recommendation.
45961576|NCT05807607|Procedure|Implantation of PNS electrodes during surgery, mapping to select sites with the best effect and daily modulation.|PNS electrodes are implanted in the area of peripheral nerves of the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate peripheral nerves at different sites in the stump. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
45961577|NCT05807607|Procedure|SCS electrode implantation at surgery, mapping to select sites with the best effect and pain modulation|SСS electrodes are implanted in the area of targeted peripheral nerves in the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate the spinal cord at different sites. Stimulation starts at a specific site at a frequency of 1 Hz and increases by 0.1 Hz until the patient no longer feels phantom pain. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
45961578|NCT05807607|Procedure|Change according to the scale of the PainDetect questionnaire|This procedure uses the method of electroencephalography (EEG). EEG signals are recorded during the entire experiment. First, the patient is recorded at rest with stimulator on (PNS/SCS) with eyes open and then closed, in the stimulator off state (eyes open, then closed) in order to return the patient to the preoperative state. The stimulation is then turned back on to the original level of pain suppression. The moments of pain suppression are fixed by marking.
45961579|NCT05807594|Behavioral|HMZ 2.0 Intervention|The intervention may be adapted such that a woman receives more support with each adaptation (only women who need added support to regulate GWG will receive adaptation). The model-based predictive control system in the HMZ 2.0 digital platform will continually and automatically evaluate GWG, identify when a woman may exceed GWG guidelines, and recommend an adaptation. The registered dietitian will review the data and behavior strategies that are suggested (guided PA workouts, EI cooking demonstrations, customized grocery planning, portion size control, food scales, and meal replacements). Practical, easy-to-adopt examples will be provided (walking in 5-10 min increments throughout the day to increase PA kcal, reduce sitting by 5 min/hour; replace 8 oz of whole milk with skim milk to reduce EI kcal) to facilitate behavior change while adhering to safety standards. Each woman's unique preferences and past successes with strategies are also considered when personalizing the dosage.
45665350|NCT02106975|Drug|Ascorbic Acid|Intervention
45665351|NCT02106975|Drug|Placebo: 5% Dextrose in water|Placebo
46079572|NCT04930744|Drug|Pyrazinamide|Pyrazinamide, dose prescribed by participant's physician, will be taken by mouth daily. Pyrazinamide is in a combination pill pack with the other standard ATT medications.
45665352|NCT02145429|Behavioral|Problem Solving therapy and Brief Behavioral Treatment of Insomnia|"Problem Solving therapy teaches problem solving skills that participants can use in their everyday life. A problem is identified, various solutions identified and explored with the underlying focus to learn behavioral and self management strategies.Social casework and management of chronic disease is also included as per the participant's need.~Brief Behavioral Treatment of Insomnia focuses on improving sleep by promoting sleep hygiene such as time spent in bed and decreasing night time stimuli. The therapy has been suitably modified to suit the needs of the participants to be recruited in the Low and Middle income countries keeping in mind the low level of literacy and the local social and health care services."
45665353|NCT05133765|Device|Insulin pump|Alterations in insulin pump therapy or carbohydrate consumption
45665354|NCT04740333|Other|No intervention- observational study|No intervention- observational study
45665355|NCT02144337|Behavioral|Steps To Active Kids (STAK) programme|Intervention described in Arm/Group Description.
45665356|NCT04739709|Drug|APP13007, 0.05%|APP13007 eye drop, 0.05%
45665357|NCT04739709|Drug|Matching Vehicle Placebo for APP13007, 0.05%|Matching vehicle placebo eye drop
45665358|NCT04417881|Other|MEESSI score|MEESSI score in predicting mortality and readmission of patients managed for acute heart failure (AHF) in Emergency Department.
45665359|NCT02520011|Drug|Alvocidib|
45665360|NCT02520011|Drug|Cytarabine|
45665361|NCT02520011|Drug|Mitoxantrone|
45665362|NCT05110625|Behavioral|preDIABE-TEXT|Participants will receive text messages (three per week) in their mobile phones during six months.
45665363|NCT05110625|Other|Online Education|Primary healthcare workers will receive an online educacion about prediabetes. This intervention will aim at: 1) raising awareness about the importance of T2DM prevention; 2) increasing knowledge about effective strategies for diabetes prevention; 3) improving knowledge about brief counselling techniques; and, 4) enhancing communication skills.
45820415|NCT00002324|Drug|Nevirapine|
45820416|NCT00002324|Drug|Zidovudine|
45820417|NCT00002330|Drug|Ganciclovir|
45455303|NCT03607370|Procedure|Surgery after 12 weeks of delay after chemoradiotherapy.|Surgery consists oncologic resection of the rectal cancer with total excision of the mesorectum after 12 weeks of delay after the end of chemoradiotherapy.
45820418|NCT03740659|Drug|Levofloxacin + Dexamethasone|Levofloxacin + Dexamethasone ophthalmic solution + dexamethasone 21-phosphate administered twice: 90(±15) min. and 60(±15) min. before limbal paracentesis.
45820419|NCT03740659|Drug|Levofloxacin|Levofloxacin ophthalmic solution (Oftaquix®) administered twice: 90 (±15) min. and 60 (±15) min. before limbal paracentesis).
45820420|NCT03740659|Drug|Dexamethasone|Dexamethasone ophthalmic solution (Tamesad®) administered twice: 90 (±15) min. and 60 (±15) min. before Limbal paracentesis.
45820421|NCT00002336|Drug|Clarithromycin|
45820422|NCT00001646|Drug|Voriconazole|
45961580|NCT05807594|Behavioral|Attention Control Intervention|Consistent with guidelines for comparator groups, all women will receive prenatal care offered by recruitment sites with routine provider visits, counseling about prenatal behaviors (e.g., no smoking), and clinical oversight of health. Women randomized to the attention control group will complete the same measurement procedures as the intervention group.
45961581|NCT05807581|Other|physical activity|treadmill running 3 times weekly
45961582|NCT05807581|Other|iTBS|repetitive TMS stimulation 5 days weekly for two weeks
45961583|NCT05807542|Drug|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.
45961584|NCT05807542|Drug|Paclitaxel-albumin|Paclitaxel-albumin will be administered on day 1 of each cycle at 260mg/m2 once every 21 days.
45961585|NCT05807542|Drug|Carboplatin|carboplatin will be administered on day 1 of each cycle at AUC=5 once every 21 days.
45961586|NCT05807503|Drug|Cerebrolysin|Cerebrolysin administration in short period of time after TBI
45961587|NCT05807438|Other|Self myofascial Release|Myofascial release participants on their own will roll the foam roller in each area for two minutes.
45961588|NCT05807438|Other|myofascial release|Myofascial release will be applied to the participants by the physiotherapist.
45961589|NCT05807425|Procedure|Polidocanol foam sclerotherapy|The preparation of the foam is done according to the Tessari's technique using 2 disposable 20ml syringe, a three-way tap and a 10cm reusable extender adapted to intravenous needle. The sclerosant is applied according to the Blanchard's technique through a disposable transparent anoscope with the patient in jack-knife (knee-chest) position. In each session treatment can be performed on more than one hemorrhoidal cushion. The maximum dose per treatment session is 20ml (mixture of 4ml of polidocanol 3% with 16ml of air).
45961590|NCT05807373|Procedure|voice recordings|A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice)
45665364|NCT04224233|Other|Home-based physical activity programme|iLiFE is a 12-week individualised programme, adapted to the participants' needs and preferences. This programme will be conducted in participants' home and include everyday tasks to train endurance, balance, flexibility and strength. The intervention incudes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt activities to everyday tasks, increase frequency and/or intensity, monitor progress, clarify doubts, motivate higher daily energy expenditure and manage expectations. Phone-calls aim to clarify doubts and to monitor patients' motivation/evolution, following a motivational interview. At the start of the program, the physiotherapist will be present at all sessions, but these face-to-face visits will decrease over time. Patients will also receive a personalised manual (iLiFE manual) with activities to do in their everyday tasks.
45665365|NCT04224233|Other|Usual care|Participants will receive a leaflet with exercises and PA recommendations.
45961591|NCT05807347|Drug|Venetoclax|VA regimen Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7. CAG regimen Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7 Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7 Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC >20×109/L
45961592|NCT05807334|Other|DASH eating plan with eggs|Participants will receive guidance to follow a DASH dietary pattern tailored to their caloric requirements and their personal and cultural food preferences, along with sample meal plans and other supplemental educational materials to help them adopt and maintain the dietary pattern during this study. During this 8-week phase, they will also be instructed to eat 2 whole eggs per day to supplement the DASH eating pattern.
45455304|NCT01213069|Other|Questionnaires|The subjects are asked to fill out a questionnaire on the personal and professional situations, organ donation legislation, what happens in everyday practice, their own experience with donating their own organs, and what position they take.
45961593|NCT05807334|Other|DASH eating plan without eggs|Participants will receive guidance to follow a DASH dietary pattern tailored to their caloric requirements and their personal and cultural food preferences, along with sample meal plans and other supplemental educational materials to help them adopt and maintain the dietary pattern during this study. During this 8-week phase, they will also be instructed to exclude eggs from their diet on a daily basis.
46079573|NCT04930744|Drug|Metformin hydrochoride|Metformin hydrochloride 500 mg tablet once daily starting one week after the initiation of TB treatment, then increasing to study twice daily through study week-12 (11 weeks total metformin treatment).
46079574|NCT04921163|Dietary Supplement|sodium aluminium phospate (SALP)|1 pancake daily for 4 days
45455305|NCT03524716|Behavioral|Fitbit and Text Messages|Physical activity tracker wristband and daily text messages delivered to the participants' phones.
45455306|NCT01346228|Behavioral|Panic Control Treatment (PCT)|2 Day treatment for Panic Disorder
45455307|NCT01123525|Drug|Adenosine|1.2 mM adenosine instead of supranormal potassium in the cardioplegic solution
45665366|NCT04222829|Procedure|Megadose Shinbaro Pharmacopuncture|"Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.~Shinbaro is a refined herbal formulation used to treat inflamed lesions and bone diseases."
45665367|NCT05037539|Drug|Fentanyl Citrate 50Mcg/Ml Inj_#1|Injectable Fentanyl in Sublingual Route 50 mcg
45665368|NCT05037539|Drug|Morphine|Oral Morphine Syrup 2.5 ml ( 5 mg)
45665369|NCT02519231|Drug|Naproxen|Naproxen 440mg 1x pid
45820423|NCT00001646|Drug|Amphotericin B|
45820424|NCT00001658|Drug|Amoxicillin|
45820425|NCT00378469|Behavioral|45 minute exercise on ergocycle|
45820426|NCT00002252|Drug|Octreotide|
45820427|NCT03738163|Device|Epaderm Cream|The treatment with the investigational device will be according to the prescription by the investigator together with the instruction stated on the investigational device.
45820428|NCT00002342|Drug|Tecogalan sodium|
45820429|NCT02757547|Device|Transcranial magnetic stimulation - Placebo Arm|Each seizure patient (subject) will receive 5 days in a row the placebo (sham) magnetic stimulation using the placebo (sham) coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total. The placebo coil produces the same noise and movement as an active coil, but doesn't deliver any magnetic stimulation.
45961594|NCT05807308|Behavioral|Technology-based cognitive and artistic therapeutic activities|Therapeutic and artistic activities within the program (drawing, mandala, etc.). The program will be implemented in 6 sessions in two weeks. At the beginning and end of the program, children's anxiety and spiritual well-being levels will be evaluated.
45961595|NCT05807295|Other|Relaxation Program|The relaxation program will include progressive muscle relaxation exercises and videos for relaxation. Videos will be sent to caregivers' social media accounts. Initial applications will be implemented with caregivers. The relaxation program is planned to last 6 weeks. The program is planned to last 8 weeks in total, with pre-test and post-test applications.
45961596|NCT05807282|Other|Interventions to Decrease Heat Stress among Latinx Farmworkers in Idaho|The interventions will be developed in collaboration with our study partners and will include increasing access to shade at the workplace, providing hydration packs to participants, and providing education regarding the signs and symptoms of occupational heat stress.
45961597|NCT05807256|Other|collection and analysis of treatments and procedures already performed by normal clinical practice|The patients' anthropometric variables; laboratory test results; PMA techniques (types of fertilization/drugs used for stimulation) and the outcome of the eventual pregnancy (ongoing treatment during the pregnancy itself, development of maternal/fetal complications, such as hypertension, preeclmpsia, thrombotic events, renal failure, disease flare, neonatal outcome) and data on the type of ovarian stimulation drug treatment.
45961598|NCT05807243|Other|Dietary intervention for healthy weight loss|Balanced and varied dietary plan adjusted to each participant's needs, with an approximate reduction of 500 Kcal from their total metabolic expenditure. The diet will be followed by the subjects during the 4 weeks of the study.
46079575|NCT04921163|Dietary Supplement|Aluminium-free pancake|1 pancake daily for 4 days, without aluminium
46079576|NCT04918199|Device|Computer based assessment (iBox)|Individual allograft survival probabilities of death censored allograft survival seven years after the time of risk evaluation, computed using the iBox (NCT03474003), a qualified prognostication system designed to predict long term allograft survival up to seven years after evaluation.
45665370|NCT02519231|Drug|Placebo|Placebo tablet 440mg 1x pid
45961599|NCT05807230|Behavioral|Three-level network rehabilitation services within the medical alliance|Data of all levels of medical and health institutions in Huzhou region are shared, and advanced rehabilitation technologies are passed down from senior hospitals to grassroots medical institutions. Grassroots medical institutions to patients home for 3 months of rehabilitation training.
45961600|NCT05807191|Other|Kangaroo care based on kangaroo care guide|Under the supervision of the researcher, a kangaroo care practice was applied to premature babies by their mothers based on the kangaroo care guide. This practice took 65 minutes. In addition, before the application, the kangaroo application information was explained to the mothers through a brochure.
45961601|NCT05807165|Radiation|Hypofractionated Stereotactic Radiotherapy (HF-SRT)|The administered dose-fractionation schemes range between 30 and 35 Gy delivered within two weeks with a dose per fractionation ranging from 6 to 7 Gy.
45961602|NCT05807165|Radiation|Hippocampus-Sparing Whole-Brain Radiotherapy (HS-WBRT) plus memantine|"The prescribed dose is 30 Gy delivered in 12 fractions for therapeutic or adjuvant WBRT.~The prescription of memantine for finally twice-daily dosing will be prescribed as follows:~During the first 3 weeks concurrent with the delivery of hippocampus-sparing WBRT, 5-mg morning dose will be initially prescribed [Week 1 -3]~5-mg twice a day in the following week [Week 4]~A morning dose of 10 mg and an evening dose of 5 mg in the following week [Week 5]~10-mg twice a day for the subsequent weeks up to Week 24 [Week 6 - 24]"
45961603|NCT05807152|Device|RenalGuard device|Patients will be given an intravenous loading dose of 40 mg of furosemide and continuous infusion of furosemide based on baseline eGFR. An additional bolus of 40 mg of furosemide will be administered and the infusion rate increased according to the same protocol of the control group (Figure 1). The venous peripheral cannula will be connected with the extracorporeal circuit of the RenalGuard System (PLC Medical Systems Inc., MA) for fluid infusion. The RenalGuard System is capable of delivering sterile replacement solution to a patient in an amount matched, or higher or lower, to the volume of urine produced by the patient. Thus, in the RenalGuard group, estimated daily targeted negative fluid balance will be utilized to define, for each patient, hourly negative fluid balance to be set in the RenalGuard system display.
45961604|NCT05807113|Other|Atopi intensive care BNO 3731|Crem twice daily
45665371|NCT02106351|Biological|Botulinum toxin type A|Subjects randomised to receive Dysport 2 U/kg, 8 U/kg or 16 U/kg administered intramuscularly in the study limb.
45961605|NCT05807113|Other|Benchmark product|Crem twice daily
45961606|NCT05807100|Diagnostic Test|Baseline Standardized Mini Mental Test|Cognitive status assessment was done with Standardized Mini Mental Test.
45665372|NCT04998539|Other|Wheelchair forward direction|Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the forward direction. Participants will push the wheelchair when moving forward.
45665373|NCT04998539|Other|Wheelchair backward direction|Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the backward direction. Participants will pull the wheelchair when moving backwards.
45665374|NCT04998539|Other|Upright technique|Participants will move the wheelchair across the 5 m soft surface using the upright technique. The upright technique involves the wheelchair being moved with all 4 wheels on the ground.
45665375|NCT04998539|Other|Wheelie technique|Participants will move the wheelchair across the 5 m soft surface using the wheelie technique. The wheelie technique involves the wheelchair being tipped backward and balanced on the rear wheels. Participant wheelchair occupants will always be upright when being moved using the wheelie technique.
45665376|NCT04998539|Other|Wheelchair occupant upright body position|The participant occupying the wheelchair (wheelchair occupant) will be seated with a body position that is upright (back is leaning against the wheelchair back rest and arms on wheelchair arm rests) while the wheelchair is being moved.
45665377|NCT05036603|Other|chest physiotherapy|diffferent chest physiotherapy methods
45665378|NCT05071235|Device|LG1 (LLLT group 1)|Application of LLLT (low-level laser therapy) AsGa 904 nm 10 J/cm².
45961607|NCT05807100|Diagnostic Test|6th month Standardized Mini Mental Test|Cognitive status assessment was done with Standardized Mini Mental Test.
45665379|NCT05071235|Device|LG2 (LLLT group 2)|Application of LLLT (low-level laser therapy) AsGa 904 nm 8 J/cm².
45665380|NCT05071235|Device|LG3 (LLLT group 3)|Application of LLLT (low-level laser therapy) AsGa 904 nm 4 J/cm².
45820430|NCT02757547|Device|Transcranial magnetic stimulation - Active Arm|Each seizure patient (subject) will receive 5 days in a row of active magnetic stimulation using the active TMS coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total.
45820431|NCT00378157|Behavioral|Joint attention intervention|Eight weeks with two daily sessions (20 minutes) with joint attention intervention in the pre-school.
45820432|NCT00002348|Drug|Mitoguazone|
45961608|NCT05807087|Procedure|Conventional osteotomy|The nasal skeleton was accessed using a closed approach or an open approach is done via a transcolumellar and infracartilaginous incision. Osteotomy was made using osteotomes.
45961609|NCT05807087|Procedure|Piezosurgery osteotomy|full exposure of the nasal bony pyramid is needed.
45961610|NCT05807035|Biological|Radvax|Vaccine extracted from patient's own tumour tissue formulated with polysaccharide adjuvant
45961611|NCT05806502|Diagnostic Test|Nω-hydroxy-nor-arginine|Arginase inhibitor
45961612|NCT05806281|Behavioral|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
45961613|NCT05806216|Device|EarliPoint Diagnosis|Diagnosis by the EarliPoint System: Evaluation for Autism Spectrum Disorder
45961614|NCT05806216|Behavioral|Clinically Certain Expert Clinician Diagnosis|Diagnosis by an expert clinician using gold standard developmental assessment tools.
45961615|NCT05799677|Other|Reflexology|Additive reflexology treatment
45455308|NCT03522220|Behavioral|3D navigation video game intervention|Participants intensively train with a video game (Super Mario DS)
45665381|NCT05071235|Device|CG (control group)|Application of placebo LLLT (low-level laser therapy), that is, with the device turned off.
45665382|NCT05071235|Procedure|Dressing|Application of Helianthus annuus oil dressing.
45665383|NCT02143947|Device|Maximal Arch Subtalar Stabilization|Custom made semi-rigid thermoplastic heel cup extending to the base of the metatarsals with a full foot length 3.0mm thick EVA and ultra-suede top cover
45665384|NCT02143947|Device|Full Contact Orthosis|"The Full Contact orthosis is constructed from a 5/32 blue polypropylene with posting material comprised of white polypropylene."
45665385|NCT02075073|Biological|SB3|
45665386|NCT02075073|Biological|EU sourced Herceptin®|
45665387|NCT02075073|Biological|US sourced Herceptin®|
45820433|NCT02721277|Drug|SMOFlipid|SMOFlipid contains a mixture of 4 different lipid sources: soybean oil which provides essential fatty acids, olive oil which is high in monounsaturated fatty acids that are less susceptible to lipid peroxidation than polyunsaturated fatty acids, medium-chain triglycerides which show a faster metabolic clearance than long-chain triglycerides, and fish oil which provides the supply of omega-3 fatty acids.
45820434|NCT00002258|Drug|Interleukin-3|
46079577|NCT04918199|Other|Physician assessement|Based on anonymized electronic health records, physicians have to determine a percentage of death censored allograft survival seven years after the time of risk evaluation,
46079578|NCT04917471|Dietary Supplement|Beet root juice|70 ml bid
46079579|NCT04917471|Dietary Supplement|Placebo juice|70 ml bid
46079580|NCT04908930|Behavioral|On-field activity group - Aim 3|Athletes of two new teams at the middle school level to pilot the practice structure intervention and continuously monitor on-field activity with head impact sensors to evaluate the feasibility, acceptability, and sustainability of the practice structure
46079581|NCT04903873|Drug|EU101|EU101 will be administered via intravenous infusion.
45820435|NCT00002264|Drug|Cryptosporidium Immune Whey Protein Concentrate (Bovine)|
45961616|NCT05798481|Drug|Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.|Exactly 2.5 mg or 5 mg sodium nitrite and 50 mg N-acetylcysteine are weighed and mixed together just before use. The mixture is placed under the participant's tongue. The powder slowly dissolves in saliva and generate S-nitrosoacetylcysteine. Investigators will ask the subjects not to swallow the drug at least for 30 min. Administration of nitrite and N-acetylcysteine individually at these concentrations is not expected to change any blood NO chemistry or the systemic blood pressure. Hence, investigators will not investigate the effects of nitrite and N-acetylcysteine individually in this study. Placebo control is not needed for this study because the baseline parameters will serve as control. Investigators will assess the drug effect based on the difference between pre-treatment and post-treatment values.
45820436|NCT05752526|Drug|Diclofenac 1%|vaginal hydrogel containing 1% Diclofenac
45820437|NCT05752526|Drug|Diclofenac 3%|vaginal hydrogel containing 3% Diclofenac
45961617|NCT05797675|Procedure|prf + osseodensification|prf+ osseodensification in close sinus lift
45961618|NCT05792098|Procedure|percutaneous dilatational tracheostomy (PDTS)|Tracheostomy made by percutaneous dilatational technique
45961619|NCT05792098|Diagnostic Test|Ultrasound examination|Ultrasound verification of guidewire position
45961620|NCT05792098|Diagnostic Test|Bronchoscopy|Bronchoscopic control of guidewire position
45961621|NCT05787847|Behavioral|Incentives for Abstinence|Participants in the incentives for abstinence condition will have the opportunity to earn financial incentives for abstaining from stimulant use.
45665388|NCT02074059|Drug|Lucinactant for Inhalation|Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
45665389|NCT02074059|Device|nCPAP alone|nCPAP therapy
45665390|NCT01364597|Drug|Brivaracetam (BRV)|The max BRV dose will be 5.0 mg/kg/day, not to exceed a dose of 200 mg/day for subjects with body weight >40kg. Subjects may receive oral solution or oral tablets. The LTFU subjects will start dosing in N01266 on the individualized BRV dose they were receiving at the completion of the core study. Subjects must be able to tolerate the min BRV dose specified in the core study to be eligible for entry into the Evaluation Period of N01266. Dose can be adjusted as considered necessary by the Investigator and required by the subject's medical condition. All subjects who prematurely discontinue the study should complete an EDV and have their BRV dose down titrated by a maximum of half the dose every week for a maximum of 4 weeks until a dose of 1 mg/kg/day (50 mg/day for subjects with body weights >50kg) is reached.
45665391|NCT02143713|Drug|Elagolix|Elagolix tablets administered orally
45665392|NCT04738149|Drug|Bimatoprost|Participants will be receiving 2 drops per 4cm2 twice a week for 12 weeks
45820438|NCT05752526|Drug|Placebo|vaginal hydrogel, no active ingredient
45820439|NCT00378235|Drug|IL13-PE38QQR|
45820440|NCT00002270|Drug|Interferon alfa-2b|
45820441|NCT00002270|Drug|Zidovudine|
45820442|NCT00002354|Drug|Indinavir sulfate|
45961622|NCT05787847|Behavioral|Health Education|The Health Education condition is based on a previous intervention used as a control in a number of other studies. Sessions consist of an educational program addressing a variety of health, wellness, and lifestyle topics adapted from a previously implemented wellness manual.
45961623|NCT05787548|Behavioral|Contact information|Information on how to contact Geisinger if the patient needs care
45820443|NCT00002354|Drug|Stavudine|
45961624|NCT05787548|Behavioral|Urgent care map|A map of the patient's nearest Geisinger urgent care location, with information about urgent care
45961625|NCT05787548|Behavioral|Self-triage chart|A chart demonstrating what to do in response to several common conditions where the patient might be compelled to visit the ED
45961626|NCT05787314|Behavioral|Low Glycemic Index Diet|"Participants who came to the hospital for control and were interested in the study contacted the study researchers and eligibility was determined through face-to-face interviews. Potential participants were invited to a screening visit to verify eligibility.~The LGID program was initiated as an outpatient treatment in patients who applied to a dietitian. 3) Medium and high GI carbohydrates (GI > 55) were excluded from the diet and only low GI (GI < 50) foodstuffs were allowed. 4) A list of low glycemic index foods were given to the patients. In addition, a list of foods to avoid (medium and high glycemic index) is provided."
45665393|NCT04738149|Device|Excimer laser|Participants will be receiving excimer laser 2x a week for 12 weeks
45665394|NCT04738149|Device|Microneedling with a dermaroller|Participants will have 4cm2 area pre-treated with dermaroller 2x per week for 12 weeks
45665395|NCT02519855|Biological|ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (concomitant) or at Week 4 (nonconcomitant)
45820444|NCT05752448|Behavioral|POSTCare Survivorship transition process|Survivorship coaching intervention
45820445|NCT00002360|Drug|Didanosine|
45820446|NCT03733483|Behavioral|Sleep Deprivation|Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.
45820447|NCT00002276|Drug|Ibuprofen|
45820448|NCT00002276|Drug|Zidovudine|
45820449|NCT05752370|Device|High flow oxygen|Use of HFO
45820450|NCT05752370|Other|Usual care|Room air or normal flow oxygen
45820451|NCT00378547|Drug|paracetamol + placebo + placebo|Comparing the analgesic effect of combinations of paracetamol + placebo + placebo
45820452|NCT00378547|Drug|paracetamol + pregabalin + placebo|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + placebo
45820453|NCT00378547|Drug|paracetamol + pregabalin + dexamethasone|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
45820454|NCT00002282|Drug|Clotrimazole|
45820455|NCT00002282|Drug|Fluconazole|
45665396|NCT02519855|Biological|Placebo to ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (nonconcomitant) or at Week 4 (concomitant)
45961627|NCT05781698|Drug|Mesalamine|mesalamine is the cornerstone used for the treatment of mild to moderate ulcerative colitis
45961628|NCT05781698|Drug|Fenofibrate|Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment for hypercholesterolemia and hypertriglyceridemia
45961629|NCT05736653|Device|Task-specific PCMS|120 pairs of TMS and PNS volleys will be administered during electromyography-triggered functional electrical stimulation (FES)-assisted task-specific training (task-specific PCMS). In the task-specific PCMS, participants will first grasp a spherical ball when prompted by an auditory 'Ready' cue, and upon seeing a visual 'Go' cue will voluntarily extend the wrist and fingers to release the ball. After the 'Go cue', our customized stimulation delivery algorithm triggers the TMS and PNS only when the extensor digitorum communis (EDC) muscle activity exceeds a pre-determined threshold. The algorithm will then trigger FES to EDC after detecting EDC activity (~2 ms after PNS) for the next 2 seconds, allowing the pairing of PCMS (TMS and PNS) with the voluntary movement of EDC without the confounding effects of FES.
45961630|NCT05736653|Device|Task-specific sham-PCMS|120 pairs of sham-PCMS stimuli will be administered during task-specific practice. The TMS coil will be placed ~10 cm behind the participant's head, and PNS electrodes will be placed in the same position as for task-specific PCMS, but no stimulation will be delivered. Like the task-specific PCMS condition, participants will perform the same grasp and release a ball task in an identical manner. FES will be delivered after detecting voluntary EDC activity, similar to the task-specific PCMS condition.
46079582|NCT04898608|Other|Intradialytic Exercise|"Participants will do concurrent exercise (a combination of aerobic exercise and resistance training) for 30-60 minutes during the second hour of their routine hemodialysis sessions.~To determine the intensity of the prescribed exercise, maximum heart rate is used for aerobic workout and 1RM for resistance protocols.~Exercises will be performed at a moderate exercise intensity (12-14 on the Borg RPE Scale).~All protocols are tailor-made based on each individual's needs and physical abilities."
46079583|NCT04895995|Behavioral|Daylight dCBT Application|Participants will complete up to four modules of digital intervention delivered in a self-paced format.
45820456|NCT02658877|Drug|Omalizumab|Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient's pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.
46079584|NCT04889183|Drug|Semaglutide|Patients will be treated for 24 weeks with semaglutide 3.0 mlg/ml s.c. once weekly. The starting dose of semaglutide will be 0.24 mg per week subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg.
46079585|NCT04889183|Drug|Placebo|Patients will receive a matching placebo sc. once weekly during the treatment period of 24 weeks.
45455309|NCT03522220|Behavioral|video game intervention without 3D navigation|Participants train with a video game (Super Mario Bros)
45455310|NCT03522220|Behavioral|No 3D navigation|Participants read on a kindle device (control group)
45665397|NCT02519855|Biological|Influenza Vaccine|A single open-label administration of 0.5 mL intramuscular injection on Day 1
45665398|NCT02142387|Other|BLS CPR program with dispatcher assisted CPR simulation|the training program more focuses on cooperation with a dispatcher, from recognition to perform DA-CPR and hands-on practice.
45820457|NCT02658877|Drug|Placebo|Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.
45820458|NCT00002288|Drug|Zidovudine|
45820459|NCT00002366|Drug|Ritonavir|
45820460|NCT00378313|Drug|gemcitabine, epirubicin, paclitaxel|
45820461|NCT00002372|Drug|Indinavir sulfate|
45820462|NCT00002372|Drug|Amprenavir|
45820463|NCT00002372|Drug|Nelfinavir mesylate|
45820464|NCT00002372|Drug|Saquinavir|
45665399|NCT05070455|Biological|Asceniv™|Each subject will receive an intravenous infusion of Asceniv™ on Study Day 1 (required to be within 28 days of screening) and every 21 or 28 days thereafter according to their current interval of IGIV treatment. Subjects will receive Asceniv™ at the same dose or higher dose if medically appropriate (300-800 mg/kg), every 21 or 28 days for five months (seven or six doses respectively).
45820465|NCT05752292|Behavioral|Standard Health Information|Standard health information about postpartum screening and lifestyle programs for diabetes prevention
45820466|NCT05752292|Behavioral|Values Affirmation (VA)|Interactive prompts to reflect on core personal values
45820467|NCT05752292|Behavioral|Tailored Risk Information (TRI)|Interactive prompts to provide tailored information on risk factors for type 2 diabetes
45820468|NCT05752292|Behavioral|Motivational Interviewing-based (MI)|Interactive prompts based on principles of motivational interviewing
45820469|NCT05752292|Behavioral|Action planning (AP)|Interactive prompts to problem solve challenges
45820470|NCT00002378|Drug|Ritonavir|
46079586|NCT04884763|Drug|Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments|Erenumab-aooe (EREN) 140 mg s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
45455311|NCT03368144|Device|ClearLumen II Peripheral Thrombectomy System|Patients will be treated with the ClearLumen Peripheral Stent Graft System
45455312|NCT01215565|Drug|Sutent|Sunitinib 50mg/day (per os) for 6 cycles duration of one cycle = 6 weeks (4 weeks of treatment over 6 weeks)
45820471|NCT00002378|Drug|Nelfinavir mesylate|
45820472|NCT00002378|Drug|Saquinavir|
45820473|NCT00002378|Drug|Delavirdine mesylate|
45820474|NCT00002378|Drug|Lamivudine|
45820475|NCT00002378|Drug|Stavudine|
45820476|NCT00002378|Drug|Zidovudine|
45820477|NCT02589145|Drug|Lenalidomide|"Dose Escalation Phase Starting dose of Lenalidomide: 50 mg by mouth on Days -9 to -2.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Phase I."
45820478|NCT02589145|Drug|Vorinostat|1000 mg by mouth on Days -9 to -2.
45665400|NCT05034575|Other|Eye Tracking Technology Sensor|Eye tracking will be performed using Tobii Pro eye tracking technology sensor (Tobii Pro Fusion, Stockholm, Sweden), providing binocular eye tracking up to 250 Hz. The sensor, positioned on the inferior aspect of the computer monitor, reflects infrared (IR) light beams off of each cornea and are subsequently captured.
45961631|NCT05736653|Device|PCMS-rest|120 pairs of TMS and PNS volleys will be administered with the EDC muscle at rest every 10 s (~20 min, 0.1 Hz). TMS will be used to elicit motor-evoked potentials (MEPs). Antidromic activation of spinal motor neurons will be elicited by supramaximal peripheral nerve stimulation (PNS) applied to the radial nerve near the elbow. Volleys will be timed to arrive in the spinal cord based on central and peripheral conduction times calculated for each subject so that the pre-synaptic terminal is depolarized via TMS ~1-2 ms before spinal motor neurons are depolarized via PNS at a pulse duration of 200us. We will also perform stimulation of the cervical roots (C-root) by placing the coil behind the neck and stimulating the C-root (C6 and C7 vertebrae), which innervate the finger extensor muscles. Conduction times will be calculated from latencies of the primary motor area (M1) MEP, C-root, and M-wave.
45961632|NCT05726357|Procedure|vital pulp therapy|removal of the coronal pulp followed by placing a biocompatible material to preserve the vitality of the radicular pulp
45961633|NCT05721989|Drug|Ziltivekimab B|Participants will receive a single s.c. injection of 15 mg ziltivekimab B (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
45961634|NCT05721989|Drug|Ziltivekimab D|Participants will receive a single s.c. injection of 15 mg ziltivekimab D (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
45961635|NCT05721989|Drug|Ziltivekimab C|Participants will receive a single s.c. injection of 15 mg ziltivekimab C (30 mg/mL) by single-use pre-filled syringe assembled into a shield-activated pen-injector on Day 1.
45961636|NCT05720650|Other|No intervention|No intervention
45961637|NCT05718245|Device|HEPA filter|HEPA filters with the capacity to reduce PM2.5 levels
45961638|NCT05718245|Device|Sham filter|sham filters without the capacity to reduce PM2.5 levels
45961639|NCT05718193|Diagnostic Test|DeFrame|The DeFrame system is applicated during colonoscopy. The DeFrame system superimposes a rectangular box on the polyp lesion area in the colonoscopy field of view, notifying the endoscopists of the presence of the lesion.
46079587|NCT04884763|Drug|Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments|Placebo (EREN-P) s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
45455313|NCT05128058|Drug|Ritlecitinib 50 mg|50 mg single dose
45455314|NCT05128058|Drug|Ritlecitinib 200 mg|200 mg single dose
45455315|NCT03526198|Device|Force plate|Device: force plate An equipment model with the approach of providing the evaluated person with the movement that is closest to the biomechanical and functional reality of the ankle and foot joint and which could equalize the possible changes of the center of mass would contribute to the clinical evaluation and would provide a more efficient therapeutic reasoning rehabilitation.
45455316|NCT01121497|Drug|Physostigmine|Intravenous bolus of physostigmine 1 mg, 3-5 minutes before completion of the colonoscopy procedure
45665401|NCT05069987|Other|Virtual Reality Immersion|An immersive virtual reality experience will be generated by a head mounted device which shows the user pre-recorded videos (SynVR Relax & Distract, SyncVR Medical BV, Utrecht, The Netherlands). These videos are recorded in 360 degree views and matched with the users' viewing direction by the head mounted device matches. The user will not be able to see its in vivo surroundings (i.e. the Cathlab) and will be focused on the digital content. The VR immersion will be put into place throughout the entire TAVR procedure starting before femoral access obtainment and ending after access closure.
45665402|NCT05069207|Other|POWER breathe K5|Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
45961640|NCT05718193|Diagnostic Test|Classified DeFrame|The Classified DeFrame system is applicated during colonoscopy. The Classified DeFrame system superimposes a rectangular box on the polyp lesion area in the colonoscopy field of view, the color of the rectangle box will turn blue when the polyp is considered as an adenoma, notifying the endoscopists of the presence of the lesion.
45961641|NCT05718193|Diagnostic Test|conventional colonoscopy|conventional colonoscopy
45961642|NCT05709509|Drug|Colchicine|Colchicine: A major alkaloid from Colchicum autumnale L. and found also in other Colchicum species. commonly used as anti-inflammatory drugs.
46079588|NCT04877093|Drug|Clonidine Pill|The study will use a flexible-dose adjustment schedule to identify the minimum dose needed to alleviate symptoms while also ensuring acceptable adverse effects. In other words, all subjects will start at the minimum dose (0.1 mg/night). Near the end of every week, each subject will be assessed for symptom alleviation and adverse events by asking the patient two questions from the CAPS-5 (questions B2 and E6. At baseline, each patient will have scored a ≥3 on each of these questions. If one or both scores remain at ≥3 and if any reported adverse events are marked acceptable by both the clinician and subject, then the dosage for the following week will be increased one level according to the titration chart. However, if both scores for these questions are ≤2 and any current adverse events are acceptable, then the dosage will remain the same. Finally, if any adverse events are deemed unacceptable, the clonidine dosage will be reduced to the lowest acceptable daily dosage.
46079589|NCT04877093|Other|Placebo|Blinded placebo capsules will be provided to participants.
46079590|NCT04866017|Drug|Tislelizumab|administered by intravenous infusion
46079591|NCT04866017|Drug|Durvalumab|administered by intravenous infusion
46079592|NCT04866017|Drug|Ociperlimab|administered by intravenous infusion
46079593|NCT04865679|Device|Axoguard Nerve Cap®|Entubulation of the nerve stump into the Axoguard Nerve Cap® following surgical excision of symptomatic neuroma
46079594|NCT04852861|Diagnostic Test|immunogenicity after first and second dose|Humoral and cellulair immunity after first and second dose of the different vaccines administrated.
46079595|NCT04850911|Drug|Ketamine Hydrochloride|Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who have failed to respond to conventional monoaminergic agents.
46079596|NCT04850911|Other|No intervention (placebo)|Placebo injection (0.9% sodium chloride)
46079597|NCT04850716|Other|non-intervention|non-intervention
46079598|NCT04836533|Other|Experimental: Computerized Cognitive Training|Participants will complete 4 weeks of executive functioning / processing speed training through the BrainHQ platform on their personal computers.
45961643|NCT05709509|Procedure|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention: a family of minimally invasive procedures used to open clogged coronary arteries (those that deliver blood to the heart)
45961644|NCT05709509|Other|Optimal medical treatment including statin, aspirin, P2Y12 inhibitor, and nitrate.|The subjects just received optimal medical treatment including statin, aspirin, P2Y12 inhibitor, and nitrate.
45961645|NCT05706909|Device|Genex with ABMC|Core decompression, injection of autologous bone marrow concentrate and the use of genex® Bone graft Substitute as an adjunct associated with the decompression procedure
45961646|NCT05705193|Other|NeuroFlex (computerized gamified tasks)|"The computerized cognitive remediation intervention (NeuroFlex) consists of a series of gamified tasks (e.g., BrainHQ, Neurogrow, Ultimate Word Master) administered via computer tablet. The intervention provides both bottom up training to improve basic processing of sensory stimuli and top down training to improve executive functions. Participants will be asked to complete approximately 7.5 hours a week of computer treatment over an approximately 6-week period, for a total of approximately 45 hours of treatment. The treatment will be completed remotely by the participant within their own home or other private location that is most convenient for the participant."
45455317|NCT05002010|Device|Echo|Measure the Left ventricle (LV): IVS (interventricular septum), LVEDD(left ventricle end diastolic dimension ),LVESD((left ventricle end systolic dimension ), PWD(posterior wall dimension), LV systolic dysfunction and LV diastolic dysfunction.
45455318|NCT03526120|Other|Pistachio|Dailly 44 g unsalted pistachios snack for 12 weeks
45455319|NCT01213147|Drug|clomiphene citrate|100 mg per day oral for 7 days
45665403|NCT05068817|Other|Pilates mat exercises|"Pilates mat exercises: Each Pilates session will last for one hour and commence with a 10 minute warm up and finish with a 10 min cool down. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centring which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the cranio-cervical junction).~Pilates exercise program will consist of warm up exercises, main treatment program (10 level) and cooling down exercises."
45665404|NCT05068817|Other|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit, 20 min/day, 3 days/week for 12 weeks.
45665405|NCT05068817|Other|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program 3 days/week for 12 weeks
45665406|NCT04421183|Diagnostic Test|draw blood|draw blood from the all of patients
45665407|NCT04212143|Other|there is no intervention|There is no intervention in this study. It is observational only.
45665408|NCT04219319|Drug|Efficacy of LCAR-T2C CAR-T cells|CD4-directed CAR-T cells administered with lymphodepletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
45665409|NCT04996121|Drug|XZP-5955 tablets|"Phase I dose escalation:~For each dose cohort, XZP-5955 tablet will be administered orally, single dose for day 1 and then from day 4, administered for continuous cycles of 21 consecutive days for each cycle~Phase I dose expansion:~XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle. Some patients for PK sample collection, the drug will be administered single dose for day 1, then from day 4, administered for continuous cycles of 21 consecutive days for each cycle~Phase II:~XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle"
45665410|NCT02518919|Other|Child life intervention|The participants will receive IV ketamine for sedation. In addition in this arm, 'Child Life Intervention', comfort measures provided by a trained child life therapist during painful procedures.
45820479|NCT02589145|Drug|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein on Day -8 and 2775 mg by vein on Day -3.
45820480|NCT02589145|Drug|Busulfan|"Busulfan test dose administered by vein either as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1."
45820481|NCT02589145|Drug|Melphalan|60 mg/m2 by vein on days -3 and -2.
45820482|NCT02589145|Drug|Rituximab|Patients with CD20+ tumors receive Rituximab 375 mg/m2 by vein on day -9 in the AM as an inpatient.
45820483|NCT02589145|Drug|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
45961647|NCT05702749|Procedure|Microsurgical resection of VS|Microsurgical resection of VSs can be accomplished by three approaches including middle cranial fossa, retrosigmoid, and translabyrinthine. The surgical approach utilized is typically selected on the basis of tumor location and size, and patient age and hearing status.
45820484|NCT02589145|Drug|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
45820485|NCT02589145|Drug|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
45820486|NCT02589145|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1
45820487|NCT02589145|Drug|Enoxaparin|40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3.
45820488|NCT02589145|Procedure|Stem Cell Transplant|Stem cell transplant performed on Day 0.
45820489|NCT02589145|Drug|Palifermin|Palifermin per departmental standard of care with 3 doses to be administered prior to starting chemotherapy and 3 doses starting on day 0.
45961648|NCT05702749|Radiation|Stereotactic radiosurgery|Radiation therapy will be delivered using single fraction stereotactic radiosurgery with Gamma knife technology, or linear accelerator following institutional standard of care.
46079599|NCT04836533|Drug|Experimental: Open-label antidepressant treatment|Participants will be assigned to open-label or placebo-controlled antidepressant treatment for 8 weeks.
45455320|NCT01213147|Drug|buserelin|50 µg Subcutaneous twice a day from cycle day 2 of menstrual cycle
45820490|NCT00002384|Drug|Cidofovir|
45820491|NCT02568007|Drug|Cyproheptadine|
45820492|NCT00002390|Drug|Abacavir sulfate|
45820493|NCT00002396|Drug|Tenofovir disoproxil fumarate|
45820494|NCT02549755|Drug|11C-Acetate|"The 11C-Acetate radiopharmaceutical will be administered intravenously at a dose of 20-40 mCi (0.74-1.5 GBq).~There will be a total of three 11C-acetate radiopharmaceutical administrations for each patient"
45820495|NCT00002402|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
45665411|NCT02518919|Other|Music listening|The participants will receive IV ketamine for sedation. In addition in this arm, 'Music Listening' to music chosen by the patient using headphones
45665412|NCT04995887|Device|Jada® System|The Jada® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.
45665413|NCT04995731|Behavioral|Information about clinical risk factors for endometrial cancer and endometrial hyperplasia (EH)|Bleeding type, age, race, parity, early menarche or late menopause, body mass index, body composition, hypertension, type II diabetes, anovulation, polycystic ovary syndrome and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.
45820496|NCT00002402|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
45820497|NCT00002402|Biological|Aluminum hydroxide|
45820498|NCT00002408|Drug|Crofelemer|
45820499|NCT00002414|Drug|CPI-1189|
45820500|NCT00002420|Drug|Emivirine|
45820501|NCT00002420|Drug|Hydroxyurea|
45820502|NCT00002420|Drug|Delavirdine mesylate|
45820503|NCT00002420|Drug|Stavudine|
45820504|NCT00002420|Drug|Didanosine|
45820505|NCT00381368|Drug|Ibandronic acid|
45820506|NCT04024501|Drug|Verinurad ER8 capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad ER8 capsule with 240 mL water, following an overnight fast of at least 10 hours.
45820507|NCT04024501|Drug|Verinurad A-capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad A-capsule with 240 mL water, following an overnight fast of at least 10 hours.
45820508|NCT04024501|Drug|Verinurad A-capsule formulation (fed)|Each participant will receive single dose treatment of 12 mg verinurad A-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
45820509|NCT04024501|Drug|Verinurad B-capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad B-capsule with 240 mL water, following an overnight fast of at least 10 hours.
45820510|NCT04024501|Drug|Verinurad B-capsule formulation (fed)|Each participant will receive single dose treatment of 12 mg verinurad B-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
45820511|NCT05719844|Diagnostic Test|Neuropsychological tests|"List of neuropsychological tests:~Matrix reasoning~D2-R~Coding~Symbol search~Digit span~Alertness (computerized TAP battery)~Divided Attention (computerized TAP battery)~Go / No go (computerized TAP battery)~Incompatibility (computerized TAP battery)~Working memory (computerized TAP battery)~16-item Free and Cued Recall or Stories subtest of the Children Memory Scale (CMS) for children only (< 17 years old)~complex figure of the memory efficiency battery 144 or Word pairs of the Children Memory Scale for children only (< 17 years old)"
45820512|NCT05717348|Drug|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
45820513|NCT05709626|Drug|No aspirin (Prasugurel monotherapy)|12-month prasugrel monotherapy
45820514|NCT05709626|Drug|12-month DAPT|12-month dual antiplatelet therapy with prasugrel and aspirin
45820515|NCT05707364|Behavioral|Pre-visit Lab Workflow|"Based on buy-in from the providers/staff one or both of the practices below will be introduced into the clinic workflow to order pre-visit labs.~All procedures are within the standard of care, only the order of operations is being changed. After sharing lab results with patient from the most recent routine physical, physician records labs for the next calendar year in EMR.~Prior to appointment, Medical Assistant (MA) will review notes and orders to setup pre-visit labs.~Patient contacted to complete labs prior to the scheduled routine physical.~Resulted labs are triaged based on urgency.~After Visit Summary used to communicate about labs and surveys."
45820516|NCT03538015|Drug|Carvedilol 3.125 mg|Participants will receive a 3.125 mg oral dose of carvedilol twice daily during the 4-week treatment period
45961649|NCT05702749|Other|PREHAB|A PREHAB visit will be done once weekly for 3 weeks to determine exercise regimen prior to surgery or radiotherapy. Therapy includes balance exercises (twice daily), gaze stabilization exercises (12-20 minutes daily), and habituation exercises (as applicable).
45961650|NCT05694351|Behavioral|Healthy meals and physical activity in families with type 2 diabetes|Families will participate in telehealth family education on diabetes management and prevention through lifestyle modifications in their everyday occupations regarding current recommendations for physical activity, grocery shopping, meal preparation, and family meal routines. Each family will be assisted in setting tailored goals for the family as a whole and individually regarding physical activity and dieting habits. The goals will be incorporated into family daily routines, to secure manageability and sustainability of the new lifestyle habits. Local facilities and communy networks will be engaged in this process to empower and motivate the participants. Working with the goals will be monitored and facilitated throughout the intervention period of 3 months. Before discharge, each family will co-produce a maintenance plan for physical activity and healthy dieting.
45961651|NCT05693844|Biological|CD40 ligand expressing MSLN-CAR T cells|Dose escalation: Dose1 (1×10^6 cells/kg) . Dose 2 (3×10^6 cells/kg) .Dose 3 (6×10^6 cells/kg) Dose expansion: RP2D
45820517|NCT03538015|Drug|Carvedilol 2.5 mg|Participants will receive a 2.5 mg oral dose of carvedilol twice daily during the 4-week treatment period
45820518|NCT03538015|Drug|Placebo capsule|Participants will receive a matching oral dose of placebo capsule twice daily during the 4-week treatment period
45820519|NCT05752214|Other|WEB Register|Observational, non-profit, multicentre longitudinal study on the assessment of quality of life and its association with demographic variables and visual function of visually impaired patients attending the visual rehabilitation service.
45820520|NCT00381446|Device|Marketed contact lens care products|
45820521|NCT03342157|Drug|senna/docusate|Stimulant laxative
45820522|NCT04331210|Drug|Diclofenac Sodium|Group 1 will take oral diclofenac sodium and group 2 will take Rectal diclofenac sodium as an analgesic
45820523|NCT00381524|Behavioral|Increase condom use|Voluntary increase in condom use
45820524|NCT04016077|Drug|PF-06651600 30 mg|PF-06651600 in 10 mg oral tablets will be administered on days 1 to 10.
45820525|NCT00002426|Drug|Adefovir dipivoxil|
45961652|NCT05693844|Drug|Albumin-bound paclitaxel|Administered intravenously at dose of 100-200mg/m2 on day -5
45961653|NCT05693844|Drug|Cyclophosphamide|Administered intravenously at dose of 15-30mg/kg on day -3 and day -2
45961654|NCT05693844|Drug|Fludarabine|Administered intravenously at dose of 30mg/m2 on day -3 and day -2
45961655|NCT05690698|Drug|Quatiapine|Atypical antipsychotic
45961656|NCT05690698|Drug|Haloperidol|Antipsychotic
45961657|NCT05682963|Other|Square Step Exercises Program|Intervention description: patient will be treated for eight weeks, two days a week, one session a day, and total 16 session. Each session will be 45 minute.
45961658|NCT05682963|Other|Home Exercise Program|Frenkel's coordination exercises will be applied as a home program for 8 weeks, 2 days a week, with each exercise session 15-30 minutes excluding rest periods.
45961659|NCT05674513|Drug|Ulipristal acetate|Evaluating the pharmacodynamic and pharmacokinetic outcomes after 1 dose of Ulipristal acetate 30mg in individuals with and without active CYP3A5 alleles
45961660|NCT05669976|Behavioral|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention integrates a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to mental health and social support resources (e.g., SGM-specific support groups within the community).
45961661|NCT05669976|Behavioral|Safety Planning Intervention|The Safety Planning Intervention (SPI) is a single-session, empirically supported, suicide prevention intervention. The patient navigator will deliver the SPI.
45961662|NCT05665296|Other|cervicothoracic mobilization|Each participant in study group will receive cervicothoracic mobilization (central PA and transverse Grade III or grade IV) with comprehensive corrective exercise. The duration will eight weeks three sessions per week.
45961663|NCT05665296|Other|CCE|"Each participant will receive comprehensive corrective exercise include three phases: Initial phase -Improvement phase and Maintenance phase.~The initial phase exercises progress in frequency and intensity during this phase, as long as participants are able to demonstrate good quality movement. The initial phase duration is 2 weeks and the exercises will be performed for seven sets of 10-s hold .~Improvement phase exercises are progressed by considering individual characteristics of each participant and by observing the overload principle and the progression in the number of repetitions of each set during the 4 weeks of the improvement phase. The exercises will be performed from five sets of ten repetitions to six sets of 15 repetitions .~Maintenance phase exercises:The exercises are the same as in the improvement phase without any progression in intensity and frequency. The maintenance phase duration is 2 weeks"
45961664|NCT05665036|Combination Product|SIG-005 (hIDUA Producing Spheres)|Laparoscopic administration of SIG-005 spheres, an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce hIDUA
45961665|NCT05659160|Procedure|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
45961666|NCT05657964|Device|Gokhale sensor|Participants enrolled in the Gokhale Arm will be provided the Gokhale PostureTracker, a wearable posture monitoring sensor developed for interactive posture coaching, and a loaner smartphone with pre-installed App. Participants will be provided instruction to apply the sensor on their lumbar area and receive real-time visual feedback on their posture kinematic during the class. Participants can also perform normal daily activities while wearing the device. Data collected by the sensor will be sent to a HIPAA compliance server and shared with Stanford researchers.
45961667|NCT05657119|Behavioral|MI FSN - Lethal Means Reduction|"Motivational Interviewing lethal means reduction, firearm storage supplies, Tailored text messages~Participate in a 15-20-minute motivational interviewing (MI) session conducted by trained University of Michigan research staff focused on encouraging suicide lethal means~Be offered to take home gun safety and lethal means reduction materials, including trigger locks, cable locks, ammo boxes, medication boxes and mental health resources~Receive 4 weeks of tailored text message reminders and encouragement"
46079600|NCT04836533|Other|Active Comparator: Solitaire Training|Participants will complete 4 weeks of Solitaire training through the BrainHQ platform on their personal computers.
46079601|NCT04836533|Other|Placebo Comparator: Placebo-controlled antidepressant treatment|Participants will be told they have a 50/50 chance of receiving a placebo or antidepressant.
46079602|NCT04836377|Other|Safety and efficacy assessments|Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention
45665414|NCT04995731|Procedure|transvaginal ultrasound examination|All patients will undergo a standard transvaginal ultrasound examination followed by power Doppler endometrial vascularity assessment. After ultrasound examination, all patients will undergo endometrial sampling either through hysteroscopy or dilatation and curettage operation (D, C) or will have histopathological evaluation of biopsy specimens obtained by hysterectomy. Histopathological evaluation will serve as a gold standard for the ﬁnal diagnosis.
45665415|NCT05066321|Behavioral|Mindfulness Oriented Recovery Enhancement Sessions|The MORE intervention will involve 8 weekly sessions (approximately 1 hour each), during which participants will be taught how to use mindfulness skills to regulate addiction severity, pain, and stress.
45665416|NCT04995497|Drug|Intravenous Administration of Lidocaine Post Cardiac Surgery|Lidocaine will be administered via intravenously. Initial dose will be at 2 mg/kg ideal body weight followed by dosing at 2 mg/kg/hr for 48 hours
45665417|NCT04995497|Drug|Administration of Lidocaine Post Cardiac Surgery via ESP Catheter|Lidocaine will be administered via ESP catheter. Initial dose will be at 2 mg/kg ideal body weight split between two catheters followed by dosing at 2 mg/kg/hr for 48 hours
45665418|NCT05063279|Other|Progressive resistance training|Progressive resistance training, performed with a target number of repetitions of 10 per set. Sets are performed to exhaustion, and external load will be adjusted to meet the target number of repetitions.
45961668|NCT05657119|Behavioral|Scripted FSN - Lethal Means Reduction|"Scripted lethal means reduction, firearm storage supplies, tailored text messages~Participate in a 10-15-minute scripted session focused on gun safety and lethal means reduction~Be offered to home gun safety and lethal means reduction materials, including trigger locks, cable locks, ammo boxes, medication boxes and mental health resources~Receive 4 weeks of tailored text message reminders and encouragement"
45961669|NCT05657119|Behavioral|General Firearm Safety Intervention - General Firearm Safety|"General information on gun safety, firearm storage supplies, tailored text messages~Participate in a 10-minute scripted conversation about safe gun storage practice~Be offered to take home safe gun storage materials, including trigger locks, cable locks, and ammo boxes~Receive 4 weeks of tailored text message reminders and encouragement"
45961670|NCT05657119|Behavioral|General Firearm Comparison - General Firearm Safety|"firearm storage supplies~* Be offered to take home safe gun storage materials, including trigger locks, cable locks, and ammo boxes"
45961671|NCT05650190|Device|Novel spectacle lens design|Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia
45665419|NCT05063201|Drug|Cariprazine 1.5 MG|Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
45820526|NCT04021771|Other|Educational Curriculum Intervention|The intervention includes: 1) Online web-based education module created with the Rise 360 platform that has ten lessons, providing the learner with an introduction, background, and a map of how to navigate a discharge conversation for patients with diagnostic uncertainty. Core content are presented with multiple interactive components such as flip-cards, multiple-choice, drag-and-drop, sketch videos, and narrated clips. 2) Mobile application game designed to facilitate practice of the content learned in the online curriculum 3) Deliberate practice sessions allow trainees to practice communication techniques presented within the online module and to receive feedback on their performance. These sessions will be conducted with standardized patients via a video platform, during a scheduled appointment.
45820527|NCT00002432|Drug|Foscarnet sodium|
45961672|NCT05650190|Device|Spectacle lenses|Single vision, impact resistant spectacle lenses
45961673|NCT05646173|Device|vagus stimülation device|Vagustim is a wearable medical technology device that focuses on non-invasive bilateral auricular vagus nerve stimulation (VNS). VNS is a clinically approved, safe and effective neuromodulation method.
45961674|NCT05646173|Device|Electrophysical agents|Electrophysical agents (EPAs) are those modalities that administer thermal, mechanical, electrical or light energy to the patient to provide physiological effects and therapeutic benefits.
46079603|NCT04831411|Procedure|Total Knee Arthroplasty|The extremities of patients admitted to the operating room to be applied TKA will be determined using a safe surgical Fast-Track recovery protocol. Patients will be operated by the same surgical team using the same technique. Spinal anaesthesia or general anaesthesia will be applied to the patients according to the evaluations of the anesthesiologists.
45820528|NCT05701436|Drug|Oxaliplatin|130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
45820529|NCT05701436|Drug|Doxorubicin|20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
45820530|NCT05701436|Drug|Lobaplatin|50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
45820531|NCT05701436|Drug|Cisplatin|50 mg per square body surface area was used for monthly transhepatic arterial infusions.
46079604|NCT04831411|Other|Whole Body Vibration|Whole Body Vibration
46079605|NCT04831411|Other|Progressive Resistance Training|Progressive Resistance Training
46079606|NCT04828694|Drug|BICX104|Erodable implantable pellet containing 1 g naltrexone and 11 mg magnesium stearate.
46079607|NCT04828694|Drug|Vivitrol|Intramuscular injection containing 380 mg of naltrexone.
46079608|NCT04827056|Drug|Placebo|Placebo will be administered orally, as individual films in the SL space.
46079609|NCT04827056|Drug|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg|BXCL 501 40µg will be administered orally, as individual films in the SL space.
46079610|NCT04827056|Drug|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg|BXCL 501 80µg will be administered orally, as individual films in the SL space.
46079611|NCT04827056|Procedure|Ethanol Infusion|Study team will be using a modified alcohol-IV clamp procedure developed and standardized by Subramanian and colleagues (Subramanian, Heil et al. 2002). The infusion will be performed using a 6% ethanol solution in 0.9% saline. The computer assisted administration program automatically calculates and corrects the infusion rate based on real-time BrAC data entry by staff, based on the pharmacokinetic profile of each subject (targeting a breath alcohol concentration (BrAC) of 100 mg%).
46079612|NCT04827056|Behavioral|PTSD Reactivity Condition|Participants will be exposed to two conditions in random order: PTSD cues and neutral cues. The cues will consist of a 5 minute presentation of the stimulus (trauma or neutral) followed by immediate evaluation of craving and anxiety. There will be a relaxation procedure between each condition. The imagery scripts are developed based on the scene construction questionnaire developed by Lang et al (Lang, Kozak et al. 1980, Lang, Levin et al. 1983) using a standardized format designed by Sinha (Sinha 2001).
46079613|NCT04827056|Behavioral|Alcohol Cue Reactivity|Participants will be exposed to two conditions: a neutral cue (water) followed by an alcohol cue. Individuals will be instructed that they may smell and handle the beverage, but they cannot consume the beverage. Following the presentation, the research assistant takes the beverage and leaves the room, while the subject completes the anxiety and alcohol craving assessments.
46079614|NCT04807127|Drug|Immune checkpoint blockade|ICI, administered as standard-of-care treatment
45665420|NCT05063201|Drug|Placebo|Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
45665421|NCT04217057|Drug|64Cu-DOTA-ECL1i|Will be produced by the Cyclotron Facility at Washington University School of Medicine
45961675|NCT05646173|Other|home exercise program|The home exercise program will be explained to the patients by the physiotherapist and will also be given to the patient in the form of a brochure. Patients will be instructed to do the exercises regularly, three times a day for ten repetitions each day. The content of the exercises is updated weekly.
45961676|NCT05644340|Procedure|Speed 8 (Fast balancing gas flow)|General anesthesia will be induced via intravenous agents, and anesthesia maintenance will be provided via inhalation for all the patients. The maintenance will be provided with sevoflurane using automated gas flow with the selected speed of 8. The anesthesia machine indicates amount of sevoflurane inhaled, inspired and exhaled oxygen, carbon dioxyde, air and sevoflurane concentrations. Accordingly these data and actual flow rate will be recorded every 15 minutes.
45961677|NCT05644340|Procedure|Speed 4 (Medium speed balancing gas flow)|General anesthesia will be induced via intravenous agents, and anesthesia maintenance will be provided via inhalation for all the patients. The maintenance will be provided with sevoflurane using automated gas flow with the selected speed of 4 (Medium speed). The anesthesia machine indicates amount of sevoflurane inhaled, inspired and exhaled oxygen, carbon dioxyde, air and sevoflurane concentrations. Accordingly these data and actual flow rate will be recorded every 15 minutes.
45961678|NCT05642429|Biological|AV-1959D|Three doses of AV-1959D administered as a sterile suspension via intradermal injection
45961679|NCT05642429|Biological|Placebo|Three doses of Placebo administered as a sterile suspension via intradermal injection
45961680|NCT05631977|Other|Point of care ultrasound cardiac examination|The study intervention consists of a POCUS cardiac examination by site approved personal using an FDA cleared US scanner. Usual care of study participants will not be impacted.
45961681|NCT05630872|Drug|Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC|Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC, from study week 6 until 2 weeks after completion of TB treatment: Morning dose DTG 50 mg QD plus TDF/3TC from study-supplied ARV regimen. Evening dose: DTG 50 mg orally QD from study-supplied source.
45961682|NCT05630872|Drug|DTG 50 mg orally QD plus TDF/3TC|DTG 50 mg orally QD plus TDF/3TC from two weeks after completion of TB treatment to end of study (week 48).
45961683|NCT05630872|Drug|2HPZM|Daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen
45961684|NCT05630872|Drug|2HPM|Daily rifapentine-moxifloxacin plus isoniazid regimen
45961685|NCT05630014|Behavioral|Aliviado DSD Caregiving Mastery Program|Family caregiver intervention consisting of mHealth-app based educational videos and articles; caregiver-administered assessment tools and care plans; and motivational push notification reminders and encouragements.
45665422|NCT05026853|Behavioral|PRO Integration into Clinical Practice|HCPs will document their discussion and recommendations/referrals in MiChart (Epic EMR)
45665423|NCT04993859|Diagnostic Test|Non-invasive Urodynamic Test (niUDS)|A noninvasive urodynamics is a simple test used to evaluate urinary flow.
45820532|NCT05701436|Drug|Oxaliplatin, Leucovorin, fluorouracil|Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.
45820533|NCT05701436|Drug|Lobaplatin, Raltitrexed|Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
45820534|NCT05691686|Other|Finely milled whole wheat-legume bread|The intervention examines the effect of finely milled wheat-legume bread in subjects with normal body weight.
45820535|NCT05691686|Other|Less processed whole wheat-legume bread|The intervention examines the effect of less processed whole wheat-legume bread in subjects with normal body weight.
45820536|NCT05691686|Other|Less processed whole wheat bread|The intervention examines the effect of less processed whole wheat bread in subjects with normal body weight.
45820537|NCT05691686|Other|White wheat bread|The intervention examines the reference food product in subjects with normal body weight.
45820538|NCT02487277|Drug|PEGPH20|
45961686|NCT05627947|Drug|Mitomycin c|Comparing the effect of Mitomycin C versus Cyclosporine after primary pterygium surgery
45961687|NCT05626049|Other|Primary Spine Provider Model|Patients with LBP seeking care at intervention clinics will be offered an appointment with a DC or PT at the initial point of contact.
45961688|NCT05626049|Other|Usual Care|Patients in this arm will receive usual care (no change to medical care).Usual care is defined as any care designated by a primary care physician (PCP).
45820539|NCT02487277|Drug|Gemcitabine|
45820540|NCT02487277|Drug|Nab-paclitaxel|
45820541|NCT00002438|Drug|Itraconazole|
45820542|NCT00002444|Drug|Nitazoxanide|
45820543|NCT02436265|Drug|Dexamethasone|IV dexamethasone
45820544|NCT02436265|Drug|Ropivacaine|Ropivacaine only
45820545|NCT05684510|Device|clear aligners|clear aligners will be applied to the upper and lower arch, then a class II elastics 1\4 and 6,5 oz will be use from the precision-cut Hook on the maxillary aligner to the button of mandibular first molar
45961689|NCT05617794|Device|Diffusion Optics Technology (DOT) Pattern Spectacle Lens|DOT Pattern Spectacle Lens
45961690|NCT05617794|Device|Control Spectacle Lens|Control Spectacles
45961691|NCT05617118|Drug|Baclofen 10mg|Baclofen is a medication, a central myorelaxant, a GABAb stimulator.
45961692|NCT05617118|Drug|Botulinum toxin type A|Botulinum toxin, often shortened to BoNT, is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species.
45665424|NCT04993859|Diagnostic Test|Urinary proteomic screen|Urine proteomics is a powerful platform to identify urinary excreted proteins and peptides in different stages of disease or therapy and to determine their quantity, functions, and interaction.
45665425|NCT04993859|Other|Dysfunctional Voiding Symptom Score Survey (DVSS)|The Dysfunctional Voiding Symptom Score provides accurate and objective grading of voiding behaviors of children.
45665426|NCT05060627|Drug|Belantamab mafodotin|"In phase 1:~Dose level -1: Belantamab-Mafodotin 1.9 mg/kg day 1, Q8W~Dose level 1,2,3: Belantamab-Mafodotin 2.5 mg/kg day 1, Q8W In phase 2: maximum tolerated dose (MTD) of the combination"
45820546|NCT05684510|Device|traditional treatment Fixed appliances with class II elastics.|Agroup of patients in which participants will be undergo to the fixed multibracket treatment (with slot size 0.022 × 0.028 and MBT prescription , after completing leveling and alignment , Elastics will be applied from the hooks of canines brackets to the hooks of lower first molar when the 0.019× 0.025-inch stainless steel archwires placed.
45820547|NCT04016623|Device|1-day toric test contact lens|somofilcon A 1-day toric test contact lens
45820548|NCT04016623|Device|1-day toric control contact lens|somofilcon A 1-day toric control contact lens
45820549|NCT05751746|Drug|Magnesium sulfate|Magnesium sulfate will be administered following a protocol that obstetricians already use in our hospital.
45820550|NCT02973230|Other|Dosage of VEGF serum concentration|Blood samples were collected by peripheral venous puncture before treatment; a total 15 mL of blood was withdrawn (2 mL for β-hCG, 3mL for progesterone, 10 mL for VEGF determinations). Blood samples for VEGF were collected in siliconized tubes and were allowed to coagulate at room temperature for 2-6 hours.
45820551|NCT03316105|Device|Elira Investigational TENS device|TENS unit placed on skin will deliver electric stimulation to abdominal area.
45820552|NCT00002450|Drug|Tenofovir disoproxil fumarate|
45820553|NCT03277183|Drug|Low dose erythropoietin|Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
45820554|NCT03277183|Drug|High dose erythropoietin|Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
45820555|NCT00002456|Drug|cyclosporine|
45820556|NCT00002456|Drug|methotrexate|
45665427|NCT05060627|Drug|Carfilzomib|"In phase 1:~Dose level -1, 1: Carfilzomib 20/45 mg/m2 days 1, 8, and 15, Q4W.~Dose level 2: Carfilzomib 20/56 mg/m2 on days 1, 8, and 15, Q4W~Dose level 3: Carfilzomib 20/70 mg/m2 on days 1, 8, and 15, Q4W.~In phase 2: maximum tolerated dose (MTD) of the combination"
45665428|NCT05060627|Drug|Dexamethasone|Description: Dexamethasone 40 mg weekly (days 1, 8, 15 and 22) or 20 mg in patients > 75 years old., Q4W
45820557|NCT00002456|Procedure|allogeneic bone marrow transplantation|
45820558|NCT01525927|Drug|chemotherapy|Chemotherapy for three cycles prior to radiotherapy
45820559|NCT01525927|Radiation|radiotherapy|Standard radiotherapy for non-responders vs reduced dose radiotherapy for responders.
45820560|NCT01525927|Radiation|Reduced dose radiotherapy|Patients who achieve a response to chemotherapy then go on to receive reduced dose radiotherapy.
45820561|NCT00002474|Drug|carboplatin|
45820562|NCT00002474|Drug|cyclophosphamide|
45665429|NCT05025605|Drug|BXCL501 80 Micrograms|Sublingual film containing 80 Micrograms BXCL501
45820563|NCT00002474|Drug|mitoxantrone hydrochloride|
45820564|NCT00002474|Procedure|autologous bone marrow transplantation|
45820565|NCT00002474|Procedure|bone marrow ablation with stem cell support|
46079615|NCT04807127|Drug|Targeted therapy|TKI, administered as standard-of-care treatment
45665430|NCT05025605|Drug|Placebo Film|Matching Sublingual Placebo film
45665431|NCT05025605|Drug|BXCL501 120 Micrograms|Sublingual film containing 120 Micrograms BXCL501
45665432|NCT05025605|Drug|BXCL501 60 Micrograms|Sublingual film containing 60 Micrograms BXCL501 Europe Only
45665433|NCT04421105|Drug|Lysergic acid diethylamide (LSD) 5µg|
45665434|NCT04421105|Drug|Lysergic acid diethylamide (LSD) 10µg|
45665435|NCT04421105|Drug|Lysergic acid diethylamide (LSD)20 µg|
45820566|NCT00002480|Radiation|radiation therapy|
45820567|NCT04013737|Device|EPIC IMPOC|Clinical Decision Support System for antibiotic prescribing.
45820568|NCT05670470|Drug|CTP0303|Subjects who are randomized into group CTP0303 will receive bowel preparation from evening to next morning.
45820569|NCT05670470|Drug|Orafang Tab|Subjects who are randomized into group Orafang Tab will receive bowel preparation from evening to next morning.
45820570|NCT05751590|Device|comined use of gliddescope and fiberoptic broncscopy|endotrachotreal intubation will be done by combined use of Glidescope and Fiberoptic broncscopy
45820571|NCT05751590|Device|fiberoptic bronscopy|endotrachotreal intubation will be done by Fiberoptic broncscopy
45820572|NCT04011631|Procedure|Internal defibrillation during cardiac surgery, using the iD-system|When ventricular fibrillation of ventricular tachycardia occurs during surgery, the iD-Paddle will be applied directly to the heart. A maximum of 4 shocks are delivered to the heart to restore normal sinus rhythm. If 4 shocks are not successful standard operating procedure will be enable conform hospital protocol.
45820573|NCT00002492|Drug|cisplatin|
45820574|NCT00002492|Drug|doxorubicin hydrochloride|
45820575|NCT00002492|Drug|isolated limb perfusion|
45820576|NCT00002492|Procedure|conventional surgery|
45820577|NCT00002492|Radiation|brachytherapy|
45820578|NCT00002492|Radiation|radiation therapy|
45820579|NCT05751512|Drug|MRG003|Administered intravenously
45820580|NCT05751512|Drug|Cetuximab injection|Administered intravenously
45820581|NCT05751512|Drug|Methotrexate Injection|Administered intravenously
45820582|NCT02373865|Drug|Sitagliptin|Sitagliptin will be given in a daily dosage of 100 mg
45820583|NCT02373865|Drug|Glimepiride|Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
45820584|NCT02373865|Drug|Sitagliptin-Placebo|Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg
45820585|NCT02373865|Drug|Glimepiride-Placebo|Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
45820586|NCT00002498|Drug|CMF regimen|
45820587|NCT00002498|Drug|cyclophosphamide|
45961693|NCT05614167|Other|correlation|A total of 97 children with CP between the ages of six and 12 years participated in the study. Muscle strength was measured with a handheld dynamometer. Motor function in children with CP was classified with the Gross Motor Function Classification System (GMFCS), graded with the Gross Motor Function Measure (GMFM)
46079616|NCT04807127|Radiation|Radiotherapy|RT, administered as standard-of-care treatment
46079617|NCT04807114|Drug|Immune checkpoint inhibitor|Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 > 50%)
45665436|NCT04421105|Drug|Placebo|
45665437|NCT02518685|Device|TransPyloric Shuttle|
45665438|NCT02518685|Device|Sham procedure|
45665439|NCT02518685|Behavioral|Lifestyle Counseling|The goal of lifestyle modification counseling is to promote adherence to a reduced calorie diet, increased physical activity and to recommend behavioral modification strategies.
45665440|NCT05025059|Procedure|Discussion|Participate in coaching sessions
45665441|NCT05025059|Other|Exercise Intervention|Perform walking exercise
45665442|NCT05025059|Other|Exercise Intervention|Perform strength exercises
45665443|NCT05025059|Other|Informational Intervention|Receive WWE workbook and Growing Stronger Strength Training Program instruction manual
45665444|NCT05025059|Other|Informational Intervention|Maintain exercise log
45961694|NCT05611281|Drug|GS3-007 oral liquid or Placebo GS3-007 oral liquid oral medication|The dosage was calculated according to body weight and dose group once a day according to the assigned group.
45961695|NCT05609422|Other|Physical therapy program|"Stretching exercises~Strength Training Kneeling exercises~Standing exercises~Gait Training"
46079618|NCT04807114|Drug|Chemotherapy + Immune checkpoint inhibitor|Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 < 50%)
46079619|NCT04806984|Other|Participant outreach|Participants in the experimental arms will receive a call center phone call or MyChart message to remind them to schedule their appointments.
46079620|NCT04790396|Device|Carotid ultrasound under pulsed-wave doppler mode|Carotid ultrasound under pulsed-wave doppler mode to check whether carotid pulse is present
45665445|NCT05025059|Other|Medical Device Usage and Evaluation|Wear fitness tracker
45665446|NCT05025059|Other|Quality-of-Life Assessment|Complete questionnaires
45665447|NCT05025059|Other|Questionnaire Administration|Complete questionnaires
45665448|NCT05024747|Drug|NicoDerm CQ patch (GSK Dungarvan)|A single patch of a NicoDerm CQ (GSK Dungarvan) 21 mg per system of 22 centimeter square (cm^2) surface area will be placed topically.
45665449|NCT05024747|Drug|NicoDerm CQ (Alza)|A single patch of a NicoDerm CQ (Alza) 21 mg/system of 22 cm^2 surface area will be placed topically.
45665450|NCT05058833|Diagnostic Test|Echocardiography|Echocardiographic grades of diastolic function was defined according to 2016 ASE/EACVI recommendations for the evaluation of LV diastolic function. Cardiac diastolic dysfunction was defined as elevated E/e'≥15.
45665451|NCT05058833|Diagnostic Test|Coronary flow reserve and index of microcirculatory dysfunction|Coronary microcirculatory dysfunction was defined as having both depressed CFR (≤2.0) and elevated IMR (≥23U).
45820588|NCT00002498|Drug|fluorouracil|
45820589|NCT00002498|Drug|methotrexate|
45820590|NCT00002498|Drug|mitoxantrone hydrochloride|
45820591|NCT00002504|Biological|aldesleukin|
45820592|NCT00002504|Biological|recombinant interferon alfa|
45820593|NCT02360059|Drug|Metformin|Metformin dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.
45820594|NCT02360059|Other|Placebo|Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.
46079621|NCT04789850|Drug|Itacitinib|200 mg oral for 360 days
45458513|NCT03452072|Drug|0.25% Timolol gel with paraffin gauze dressings|Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply 0.25% topical timolol gel (1 drop = 0.1ml for each cm2 of wound area), and re-cover wound with clean dressing
45665452|NCT02520089|Procedure|bone autograft of iliac crest|The investigators will take bone autograft of iliac crest of the patient and then apply into the site of pseudoarthrosis, this graft have osteogenic, osteoinductive and osteoconductive properties
45820595|NCT02360059|Behavioral|Questionnaires|Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.
45665453|NCT02520089|Procedure|Platelet Rich Plasma plus bone autograft|Sample of 40 mL of peripheric blood and processed to obtain 5 mL of platelet rich plasma, and collocated into pseudoarthrosis
45665454|NCT05056883|Drug|K-237 0.3-0.4mg/kg (once daily)|Ivermectin 3mg tablet
45665455|NCT05056883|Drug|Placebo 0.3-0.4mg/kg (once daily)|Placebo 3mg tablet
45665456|NCT05055323|Drug|Pyrvinium Pamoate|Given PO
45665457|NCT04991753|Other|Placebo|Placebo infusion will be administered intravenously.
45665458|NCT04991753|Drug|Nipocalimab|Nipocalimab infusions will be administered intravenously.
45665459|NCT04991597|Other|Cold Compress Pack|Palmar aspect of forearm will have a cold compress pack placed on it.
45665460|NCT04991597|Other|Room Temperature Compress Pack|Palmar aspect of forearm will have a room temperature compress pack placed on it.
45665461|NCT04991597|Drug|Lidocaine Epinephrine|Lidocaine with epinephrine will be buffered 3:1 with sodium bicarbonate
45665462|NCT04991597|Drug|Lidocaine Epinephrine|Lidocaine with epinephrine will be buffered 9:1 with sodium bicarbonate
45820596|NCT02360059|Other|Sensory and Fine-Motor Tests|Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit.
45665463|NCT04216667|Procedure|Catheter ablation|Catheter ablation
45820597|NCT05667974|Biological|PIKA-adjuvanted inactivated rabies vaccine|PIKA rabies vaccine
45820598|NCT05667974|Biological|Rabipur|Active Comparator
45820599|NCT04006795|Other|Serum|Participants will be topically applied adhesive patch containing developmental serum
45820600|NCT04006795|Other|Lotion|Participants will be topically applied adhesive patch containing developmental lotion
45820601|NCT04006795|Other|Cream|Participants will be topically applied adhesive patch containing developmental cream
46079622|NCT04789850|Drug|Placebo|200 mg oral for 360 days
46079623|NCT04787107|Device|Mechanical Chair Massage|Healthcare staff will be placed into either massage or break intervention
45665464|NCT02105961|Drug|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
45665465|NCT02105961|Drug|Placebo|Sterile 0.9percent sodium chloride solution
45665466|NCT04950101|Other|anal sampling|anal sampling will be performed both in men without HIV and men having HIV in order to see if they have HPV or not
45665467|NCT04949867|Drug|Glucagon|Glucagon is filled in the pump and given automatically in case of hypoglycemia or pending hypoglycemia.
45665468|NCT04949867|Device|Closed-loop System|Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
45820602|NCT04006795|Other|Normal Saline|Participants will be topically applied adhesive patch containing normal saline
45820603|NCT05665790|Radiation|radiotherapy|radiotherapy
45820604|NCT05665790|Procedure|palliative surgery|palliative surgery
45820605|NCT00002510|Biological|filgrastim|
45820606|NCT00002510|Drug|cyclophosphamide|
45820607|NCT00002510|Drug|etoposide|
45820608|NCT00002510|Drug|mesna|
45820609|NCT00002510|Procedure|peripheral blood stem cell transplantation|
45820610|NCT00002510|Radiation|radiation therapy|
45820611|NCT01500109|Drug|Oral acetaminophen|Oral acetaminophen administered as a cherry flavored elixir will be dosed preoperatively 15 mg/kg and redosed every 6 hours for 24 hours. Placebo oral acetaminophen will be administered to the other two arms of the study according to the same timetable. Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
45961696|NCT05609422|Other|scooter board activities|"Scooter board bear walk.~Scooter board crab walk.~Sitting on scooter board, use it to move forward and backward, move the pool rings from one end to another.~Cross sitting on scooter board, pulls along the rope using his/her hands~Sit with knees pulled into the chest (like a bug pose) and move around with arms only.~Prone over scooter board, pulling rope to move forward. Pull self along an anchored rope to retrieve items~Scooter rolls outs. Place knees on floor and hands holding the edge of the front scooter board. Push board out a few inches then pull back, the further you roll, the harder it gets.~Kneeling, Push self forward and backward with the use of a therapy ball (lots of Motor Planning).~Supine flexion on scooter board, Clip clothespins to a rope hanging above."
45961697|NCT05609344|Behavioral|SBIRT|Low risk individuals will receive an educational pamphlet about alcohol use and the impact on health. Moderate Risk individuals will receive a brief alcohol intervention. High risk individuals will receive the brief alcohol intervention and be referred to specialty treatment.
45961698|NCT05606341|Drug|CpG1018|"0.1 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
45961699|NCT05606341|Drug|CpG1018|"0.25 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
45961700|NCT05606341|Drug|CpG1018|"0.5 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
45961701|NCT05606341|Drug|Placebo|Sterile saline injection supplied by the NYU Investigational Pharmacy.
45961702|NCT05602493|Drug|Soludronate®|In the first visit, the randomized process will take place. Tooth extraction procedure will be performed.
45961703|NCT05602493|Drug|sterile saline|sterile saline
45961704|NCT05597241|Drug|apimostinel|N-methyl-D-aspartate (NMDA) receptor modulator
45961705|NCT05597241|Drug|Placebo|Placebo
45961706|NCT05596513|Other|motor learning and occupational therapy|"Constraint-induced movement therapy (CIMT)~Hand-arm bimanual intensive training (HABIT)"
45961707|NCT05596513|Other|Motor Learning Approaches From Working on a Vertical Surface|"Ball on wall, kneel to stand~Kneel walk cross over~Vertical playground puzzles and games~Color on big boxes~Fridge magnets~Erasing a whiteboard or chalkboard~Tactile feedback from textured walls"
45961708|NCT05591105|Behavioral|Lidocaine 2% Injectable Solution and ketamine|At the end of surgery, they will continue receiving analgesia according the schedule and, addicionally, lidocaine (1 mg/kg/h) and Ketamine (0,15 mg/kg/h) for 90 minute as part of postoperative analgesia.
45961709|NCT05591105|Drug|Placebo|At the end of surgery, they will continue receiving analgesia according the schedule.
45961710|NCT05588687|Behavioral|Virtual reality|Children will watch Ice Age in virtual reality during blood draw and the researcher will monitor their pain, anxiety and fear.
45961711|NCT05588687|Device|Tablet|Children will watch Ice Age with a tablet during blood draw and the researcher will monitor their pain, anxiety and fear.
45961712|NCT05570734|Behavioral|LUNA Care Coordination|Participants in this group will have 6 or more 30-minute care coordination sessions with the LUNA Care Coordinator. The LUNA Care Coordinator will assist with appointments and referrals, medications, and assist with accessing the health education videos. They will work closely with the participant's primary care provider and the LUNA Behavioral Health Provider.
45961713|NCT05570734|Behavioral|LUNA Behavioral Health|Participants in this group will have 6 or more 30-minute behavioral health sessions with the LUNA Behavioral Health Provider. The LUNA Behavioral Health Provider will screen and address life stressors, social support, and health care use. The purpose of these sessions is to check on participant's progress with their care plan. The behavioral health sessions will involve discussion of issues that may interfere with optimal diabetes self-management. The LUNA Behavioral Health Provider will help participants overcome any potential barriers to managing their diabetes by setting goals and helping to address life stress or other issues that may be interfering with their diabetes self-management.
45961714|NCT05570734|Behavioral|Health Education Videos|Participants in this group will have access to eight 20 to 30-minute health education video sessions with corresponding print material and activities to reinforce what they learn. The health education videos focus on medication adherence, self-monitoring, stress and coping, nutrition, physical activity and culturally driven beliefs and values.
45961715|NCT05570734|Behavioral|Virtual Integrated Visits|Participants in this group will have two virtual integrated visits with the LUNA care team. Through video conferencing, they will meet at the same time with the LUNA Care Coordinator, the LUNA Behavioral Health Provider, and their primary care provider to ensure an integrated care plan.
45961716|NCT05562622|Device|Novel spectacle lens design|Use of lenses may reduce the rate of progression of juvenile myopia
45961717|NCT05562622|Device|Spectacle lenses|Use of lenses may reduce the rate of progression of juvenile myopia
45665469|NCT05018897|Behavioral|To Share or Not to Share|Strategic disclosure intervention to help participants evaluate the pros and cons of disclosing suicidality and provide guidance on best way to disclose to get needs met. Six one-hour virtual sessions conducted weekly.
45665470|NCT05018897|Behavioral|Peer Support|Peer-led support group for mood disorders. Six one-hour virtual sessions conducted weekly.
45665471|NCT04989491|Drug|Rituximab|One single dose of rituximab intravenously (IV)
45665472|NCT04989491|Other|control group|No treatment
45961718|NCT05559801|Drug|Bone marrow-derived mesenchymal stromal cells (MSCs)|Mesenchymal stromal cells (MSCs) are cells of non-hematopoietic stromal origin that reside in bone marrow and a variety of tissues. MSCs will be prepared in a GMP Cell Production facility and administered to children age 3-10 years (at time of enrollment) with Osteogenesis Imperfecta Type III.
45961719|NCT05553418|Device|In-clinic wear first|Participant will remain in clinic and wear devices adhered on abdomen or arm approximately 27hrs prior to injection
45961720|NCT05553418|Device|Home wear first|Device will be applied to the abdomen or arm to deliver placebo subcutaneously. After device application, participant will go home and return to clinic before delivery.
45961721|NCT05550662|Drug|129Xenon|There is no study medication evaluated. As part of the MRI, participants will inhale hyperpolarized 129Xe gas at a dose of up to 1/6th of total lung capacity (TLC) (lung volume), mixed with nitrogen to a total volume of 1.5 L. The polarized 129Xe will be inhaled in a single breath-hold. This is intended to fill the lungs gas, allowing for lung MRI.
45961722|NCT05546658|Drug|Psilocybin|Psilocybin administration under supportive conditions
45961723|NCT05542277|Device|ClearPlasma|ClearPlasma ClearPlasma™ is an extra-corporeal plasma filtration device, designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma™ is a non-pyrogenic, sterile, single-use medical device
45961724|NCT05541705|Behavioral|Treadmill Oscillation Walking|Each participant with stroke will partake in 18 training sessions. Training sessions will be for one hour three times a week for 6 weeks. During training, participants will walk at their self-selected walking speed on the treadmill that moves side-to-side for 1 cm in a sinusoidal pattern. The sinusoidal oscillation frequency will match each participant's natural stride frequency calculated from baseline evaluation. Subjects will be instructed to respond naturally and maintain continuous walking. Participants will wear a safety harness with no body weight support. For each training session, six 6-minute bouts of treadmill oscillation trials will be performed (Hsiao et al. 2016) and rest period will be provided between bouts. Because lower extremity muscle activity increases with increasing oscillation frequency, the treadmill oscillation frequency will be increased by 5% each week to continue to drive progressive adaptive changes (25% over 6 weeks) (Pohl et al. 2002).
45961725|NCT05538169|Device|low-level laser diode (Pioon Laser)|"Settings: the spot tip area of this tool is 0.088 cm2, semi-conductor diode, with a wavelength of 980 nm (near infrared), 200 mW output power, 1.97W/cm2 of power density, 3 J energy per point and application time 15 seconds per point].~PBM will apply punctually, in continuous emissions.~Extra-oral points: six points on each parotid gland, three points on each submandibular gland.~Intra-oral points: two points on each sublingual gland.~A total of 22 points will be applied in each session."
45961726|NCT05523479|Behavioral|Traditional online education|A 30-60 minute, online, interactive, educational video that is customized to each provider type and offered with provider-specific continuing education credits
45961727|NCT05523479|Behavioral|Interprofessional education|Interprofessional education (IPE) consists of both classroom-based IPE and just-in-time IPE. In classroom-based IPE, a trained physician educator with content expertise who works in the ICU leads a 60-to-90-minute, in-person, IPE workshop consisting of a 30-minute didactic session and a 30-to-60-minute small group session, during which participants work together to apply the content to authentic cases. The workshops, which are designed according to modern principles of adult learning and IPE, present the rationale and evidence supporting the preventive, post-extubation therapies. They are specifically designed to foster authenticity, reinforce role identity, and relate the content to life experience. In just-in-time IPE, trained local champions meet with the interprofessional ICU team each morning to identify eligible patients and, as needed, briefly review the evidence supporting proper use of the assigned preventive, post-extubation strategy.
45961728|NCT05523479|Behavioral|Clinical protocol|"An adequately explicit protocol provides specific rules for use of the preventive, post-extubation therapy based on patient data. A ready-to-customize version of the protocol with instructions to work with key local stakeholders to revise the protocol, accounting for local needs and resources, is provided. After local customization, a local champion then disseminates the protocol based on local practices."
45961729|NCT05523479|Other|Risk-stratified preventive post-extubation noninvasive ventilation (NIV) or high-flow nasal cannula oxygen (HFNC)|Preventive post-extubation NIV for high-risk patients and preventive post-extubation HFNC for low-risk patients
45961730|NCT05523479|Other|Preventive post-extubation high-flow nasal cannula oxygen (HFNC)|Preventive post-extubation HFNC for all eligible patients (without risk stratification)
45961731|NCT05510882|Other|different treatment modalities for OSA|Group I: patients will be treated with CPAP. Group II: patients will be treated with digitally fabricated MAD. Group II: patients will be treated with physical therapy.
45961732|NCT05508698|Behavioral|Precommitment Nudge|Ask participants to commit to a decision about getting a flu shot
45961733|NCT05508698|Behavioral|Salience|Additional text and icon in the flu shot alert makes the pre-visit questionnaire response salient to the clinician, which could facilitate action or further discussion with the patient
45961734|NCT05494580|Drug|Pamiparib|Oral
45961735|NCT05494580|Drug|Surufatinib|Oral
45665473|NCT05018117|Drug|Nicotine gum|The effects of over-the-counter nicotine gum will be compared to a placebo gum
46079624|NCT04786730|Drug|Centanafadine|Doses of centanafadine will be taken once daily in the morning on Days 1 through 14. The fixed dose strengths will be administered according to body weight. Up to 12 subjects will be enrolled in the 9 to 12 years age cohorts (Cohorts 1 and 6), up to 8 subjects will be enrolled in each of the 6 to 8 years age cohorts (Cohorts 2 and 3), and up to 5 subjects will be enrolled in each of the 4 to 5 years age cohorts (Cohorts 4 and 5).
46079625|NCT04785586|Behavioral|Healthy Weight Coaching|Lifestyle intervention based on Healthy Weight Coaching (HWC) is a 52 week long web-based weight loss program consisting of weekly modules, exercises, peer support, and one-on-one coaching. It encompasses themes such as diet, physical activity, coping with stress, sleep, and general health.
45665474|NCT05018117|Other|Placebo gum|The effects of over-the-counter nicotine gum will be compared to a placebo gum
46079626|NCT04785586|Behavioral|Individual meetings|Individual sessions via video, offered to the participant at three (3) different time points during the 12 month intervention.
46079627|NCT04785586|Behavioral|Group meetings|Group sessions via video, offered to the participant at three (3) different time points during the 12 month intervention.
46079628|NCT04774185|Device|New hearing aid loudspeaker|The new hearing aid loudspeaker will be fitted to the participants individual ear anatomy and hearing loss.
45458514|NCT03452072|Other|Vaseline dressing|Vaseline will be applied to wound bed immediately after surgery before dressing is applied. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply Vaseline, and re-cover wound with clean dressing
45665475|NCT05017727|Device|Closed-loop automated oxygen control with Oxygenie Auto-O2 software (SLE6000)|The 'Oxygenie' is a closed loop automated oxygen control system that has been incorporated into a software module for the SLE6000 infant ventilators. This software control system allows targeting SpO2 values by controlling FiO2.
45665476|NCT04203329|Device|Femoral Venous Vascular Closure|Femoral venous vascular closure following catheter-based cardiac ablation a-fib cases utilizing 6-12 French inner diameter procedural sheaths at time of closure.
45665477|NCT05016869|Drug|fruquintinib plus capecitabine|"Ⅰb: capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W; fruquintinib 3mg/4mg/5mg, d1-14, PO QD, Q3W.~ⅠⅠ: fruquintinib RP2D, d1-14, PO QD, Q3W, capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W"
45961736|NCT05491252|Behavioral|PAtient CEntered Self-Management Intervention (PACE-SMI)|"Week 1: General disease knowledge. Week 2: Role of self-care behaviors towards effective management of type 2 diabetes, motivational video and real story of a diabetic patient to serve as a role-model. Lastly, provision of diabetes self-care guidebook.~Week 3: Home visit to observe facilitators and barriers on initiating and maintaining behavioral change with social support as a key strategy.~Week 4: ECB session on Diet. Week 5: ECB session on Physical Activity. Week 6: ECB session on Foot Care. Week 7: ECB session on Medication Adherence. Week 8: Booster session comprising reflection, performance feedback and review of behavioral goals fostering continued performance accomplishment and addressing difficulties of maintaining behaviour change over time."
45961737|NCT05486663|Other|Tactile/kinesthetic Group|Tactile/kinesthetic stimulation is performed in three stages. In the first stage; for tactile stimulation; The baby is placed in the prone (prone) position in the incubator. Light massage was applied in the head, shoulder, back, legs and arms of the infants. Each massage is applied 12 times for 1 minute. Massage was performed for 5 seconds. In the second stage Kinesthetic stimulation, including elbow flexion-extension movement, palm massages, flexion-extension of the knees and legs and plantar massages, was applied while the neonate was in supine position. Each kinesthetic stimulation was performed for 5 seconds. Each movement was repeated six times, with a total duration of 5 minutes. Tactile stimulation was repeated once after kinesthetic stimulation. The total duration of TKS was 15 minutes which was performed three times daily preferably between breastfeeding or bottle feeding for 14 consecutive days.
45961738|NCT05480618|Behavioral|Slow Breathing|"On two separate visits (on Day 1 and between Day 7 and 9 of their self-practice) the subject will be coached on yoga breathing techniques.~The breathing techniques will be varied in:~frequency (between 0.25 and 0.1 Hz)~Inspiratory:Expiratory (I:E) ratio or 'Duty Cycle'~with and without ujjayi (yogic throat restriction)~with and without inspiratory/expiratory breath holding~At the end of the first coaching visit the subject will be given a diary to record their own practice of the breathing techniques they were coached on."
45961739|NCT05468931|Device|Prostate stimulator|Prostate stimulation device for sexual dysfunction
45961740|NCT05467449|Device|DxFLEX 10C|A device combining flow cytometry and reagents for immunophenotyping analysis
45961741|NCT05465291|Procedure|Exercise group|This group will receive passive/active range of motion (ROM) exercises. ROM exercises will include major muscle groups (i.e. biceps, triceps, and lower limbs) and will be applied from second day till seventh day of admission .
45961742|NCT05465291|Procedure|Neuromuscular Electrical Muscle Stimulation group|"Patients in NEMS group will receive neuromuscular electrical stimulation from second day till seventh day of admission.~Neuromuscular electrical stimulation will be implemented simultaneously on the rectus femoris, vastus lateralis, and vastus medialis muscles of both lower limbs, with two stimulators, in two 30-min sessions per day starting from the second day till seventh day of admission ."
45961743|NCT05465291|Procedure|Neuromuscular Electrical Muscle Stimulation and Exercise group|Patients in this group will be subjected to Neuromuscular Electrical Muscle Stimulation and Exercise.
45961744|NCT05464654|Drug|3 g Polynucleotide vaginal suppositories|3 g polynucleotide vaginal suppositories were administered nightly for 6 days.
45961745|NCT05464654|Drug|Conjugated estrogens cream 1g Tube|Conjugated estrogen cream 1g was applied intravaginally on Monday, Wednesday and Friday for three months.
45961746|NCT05460468|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.
45961747|NCT05459480|Other|the jigsaw technique in web-based distance education|The online training for the intervention group continued for a total of 6 weeks according to the jigsaw technique.
45961748|NCT05456750|Device|Intravascular laser irradiation of blood|Low intensity intravenous laser irradiation of blood phototherapy is a method of a 632.8 nm red light penetrate into a vein through fiber and the brightness is 100 fold of the sun. The light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes.
45458515|NCT02325778|Procedure|CTI ablation Timing|The timing of when the CTI ablation is performed. There are no other relevant interventions used in the procedure.
45665478|NCT02141997|Biological|adalimumab|adalimumab administered as subcutaneous injection every other week (EOW)
45665479|NCT02141997|Biological|ABT-122|ABT-122 administered as subcutaneous injection every other week (EOW)
45665480|NCT04411433|Drug|Favipiravir (3200 mg + 1200 mg)|"Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
45665481|NCT04411433|Drug|Favipiravir (3600 mg + 1600 mg)|"Drug: Favipiravir (3600 mg + 1600 mg) Dosage and method of administration: in a regimen of 2x1800 mg (oral) loading dose on day-1 followed by 1600 mg maintenance dose (2x800 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
45961749|NCT05451563|Device|Double-S|Wearable device for intercourse
45961750|NCT05443503|Other|Mobile health applications (mHealth apps) based intervention|Patients can choose among or choose to be assigned to 2 tracks for management for their low back pain. The tracks include one focused on relaxation and symptom management, and another track on increasing activity. Each include educational material adapted from various sources from North America Spine Society (NASS), Center for Disease Control (CDC), National Institue of Health (NIH). Patients will stay in track for 28 days. After this, they may choose to remain in track and continue to perform maintenance activities or to engage in a different track.
46079629|NCT04774185|Device|Standard hearing aid loudspeaker|The standard hearing aid loudspeaker will be fitted to the participants individual ear anatomy and hearing loss.
45458516|NCT03493984|Other|Ginger exosomes|Naturally occurring plant exosomes from ginger
46079630|NCT04771208|Behavioral|"I kua na'u Let Me Carry Out Your Last Wishes"|A combination of Native Hawaiian advance care planning video decision support tool and personalized video declarations shared with providers and family members.
46079631|NCT04770259|Other|Timely pre-surgical conditioning|Timely pre-surgical conditioning seeks to prepare frail, pre-frail and / or dependent older patients for the surgery process. For which a work plan has been designed according to your needs and health conditions.
46079632|NCT04770220|Drug|Experimental: ALZ-801|ALZ-801 tablet 265 mg BID
45961751|NCT05434650|Device|electrophysiology study and ablation with an Abbott Ablation Catheter|During the cardiac ablation procedure, an ablation catheter (a thin, flexible tube that can be threaded through the blood vessels to the heart) will deliver radiofrequency energy (a type of heat) to one or more areas in the upper left chamber of the heart that is causing the irregular heartbeat. The tip of the catheter will transmit energy to one or more small spots of heart tissue. This energy creates a small scar on the heart. This scar will block the electrical pathway that is causing the rapid heartbeat
45961752|NCT05433181|Drug|ACE2 Chewing Gum|The IP is formulated as an oral plant powder, which is packaged into a chewing gum. No specific excipient, buffer, salt or pH is required. CTB-ACE2, with efficient binding to both GM1 and ACE2 receptors, effectively blocks binding of the spike protein and viral entry into human cells. Oral epithelial cells are enriched with both receptors. In addition, ACE2 directly binds to the spike protein and inactivates SARS-CoV-2 virus. Therefore, CTB-ACE2 chewing gum is being evaluated for impact on entry and transmission of SARS-CoV-2.
45961753|NCT05433181|Other|Placebo Chewing Gum|Chewing gum containing wild-type lyophilized plant cells manufactured to match the IP.
45961754|NCT05416372|Behavioral|Religious Engagement in Health Intervention|Religious Engagement in Health Intervention for blood pressure (BP) includes three evidence-based components: (1) educational sessions for Christian and Muslim leaders on religious teachings and medical aspects of BP, (2) equipping religious leaders to provide BP teaching in their communities using knowledge learned from educational sessions and through longitudinal mentorship meetings, and (3) community BP screening organized by religious leaders in partnership with local health care workers, and referrals for clinical care as needed.
45665482|NCT04411433|Drug|Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|"Hydroxychloroquine Dosage and method of administration: in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
45961755|NCT05410600|Other|Arm ergometer smart trainer cycling program|Arm ergometer exercise training using the smart trainer.
45961756|NCT05409235|Drug|OTT166|Participants will receive OTT166 ophthalmic solution
45455321|NCT03143816|Drug|Technosphere insulin|This multi-center study will enroll 60 patients with T1D, A1c values between 6.5 to 10%. The patients will be randomized in 1:1 fashion to either TI or NL. Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals. Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B). There will be a total of 7 study visits (screening visit, randomization visit, 2 clinic, and 3 phone visits). There will be a 4-week treatment comparison between TI and NL and 1-week of post-study follow up. (Phone visit; Figure-1). Standard lab tests (A1c, complete metabolic panel {CMP}, complete blood count {CBC}) will be performed at the screening visit.
45665483|NCT04411433|Drug|Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|"Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).~Favipiravir Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
45961757|NCT05409235|Drug|Vehicle control|Participants will receive vehicle control
45961758|NCT05384834|Behavioral|#HerHeart tool|An integrated application consisting of a lifestyle-based CVD risk assessment and companion behavioral intervention. It will be administered at baseline and 3 months follow-up.
45961759|NCT05358860|Device|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
45961760|NCT05358392|Other|emotional freedom technique (EFT)|EFT is an energy psychotherapy derivative application, consisting of cognitive and somatic components, used to heal personal negative emotions and related emotional and physical disorders. Stress hormones are secreted in response to the stress response in the person, and then the amygdala and other cerebral parts that respond to stress are activated. There are basic steps to be followed in EFT application; By giving a message to the emotional body (subconscious) with suggestion sentences, clicks are made on the twelve energy meridian endpoints (acupressure points).
45961761|NCT05357573|Drug|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
45961762|NCT05356793|Drug|SCH-1|Novel anti-infective eyedrop
45961763|NCT05356793|Drug|Placebo|SCH-1 vehicle minus active components eyedrop
46079633|NCT04770220|Drug|Placebo Comparator: Placebo|Placebo tablet BID
46079634|NCT04768972|Drug|ION363|ION363 will be administered by IT bolus injection.
46079635|NCT04768972|Drug|Placebo|Placebo will be administered by IT bolus injection.
46079636|NCT04761055|Other|Clinical Breast exam (CBE)|The standard CBE will be performed by a nurse practitioner (NP) who will record any positive CBE finding.
46079637|NCT04761055|Device|iBreastExam device|The iBE is an FDA 510(k) cleared portable device which utilizes an array of dynamic capacitive pressure sensors to perform electronic palpation for breast abnormalities. The iBE exam will be administered by a mammogram technologist, blinded to CBE results.
45961764|NCT05352516|Biological|HLX14|"Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 (once every 6 months (Q6M)).~Treatment period 1: D1-D364, subjects will receive subcutaneous injection of HLX14 60mg on D1 and D183.~Treatment period 2: D365-D546, on D365, subjects will be continue with a third dose of HLX14."
45961765|NCT05352516|Biological|Prolia®|"Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 or Prolia® (once every 6 months (Q6M)).~Treatment period 1: D1-D364, subjects will receive subcutaneous injection of Prolia® 60mg on D1 and D183.~Treatment period 2: D365-D546, on D365, subjects in the Prolia® arm will be re-randomized 1:1 to either continue with a third dose of Prolia® or transition to HLX14 and receive a single dose of HLX14."
45961766|NCT05352139|Procedure|Resection (removal) of the degenerative tissue using the Hydrocision TenJet system|During the procedure, the TenJet device will remove degenerative tendinopathic tissue using pressurized saline without causing harm to the healthy tendon fibers.
45961767|NCT05352139|Device|Hydrocision Tenjet System|The TenJet system will be used during surgery to remove the damaged tissue from the joint
45961768|NCT05332873|Device|Rivet Shunt|The Rivet Shunt device will be implanted via a percutaneous, transcatheter approach
45961769|NCT05332678|Drug|SLS-005 - Once Weekly|Please see Arm description.
45961770|NCT05332678|Drug|SLS-005 - Twice Weekly|Please see Arm description.
45961771|NCT05323968|Diagnostic Test|Abdominal Ultrasonography|The result of the Abdominal Ultrasonography will be compared with that of the Abdominal Computerized Tomography
45961772|NCT05323968|Diagnostic Test|Abdominal Computerized Tomography|The result of the Abdominal Computerized Tomography will be compared with that of the Abdominal Ultrasonography
45961773|NCT05322174|Behavioral|Baby Sleep|See arm description
45961774|NCT05322174|Behavioral|Baby Care|See arm description
45961775|NCT05298553|Device|Group A|Participants will be asked to perform a simultaneous 30-seconds 12-lead ECG and single-lead ECG for each wearable device: Skylab CART-I ring followed by Apple Watch.
45961776|NCT05298553|Device|Group B|they will be asked to perform a simultaneous 30-seconds 12-lead ECG and single-lead ECG for each wearable device: Apple Watch followed by the Skylab CART-I ring.
45961777|NCT05297838|Other|Stationary Bike|Stationary Bike while hand is submerged in ice bath
45961778|NCT05297838|Other|Virtual Reality (VR) Headset|VR headset containing gameplay
45961779|NCT05297838|Other|Ice Bath|Pain was elicited via a cold pressor test, which is an established method of producing controlled and repeatable painful stimuli in an experimental setting
45961780|NCT05287958|Diagnostic Test|EIT|EIT comprises a chest belt that is connected to a computer via a universal serial bus (USB) or an Ethernet cable. The chest belt captures EIT data, which is transmitted via the USB or Ethernet cable to the computer. Tomography-like impedance images of the lungs are computed and displayed on the computer. The impedance images will be used to evaluate lung recruitment and other pulmonary function parameters that are currently measured using standard-of-care PFT devices.
45961781|NCT05282459|Drug|Enasidenib mesylat dose escalation|Subjects will participate dose escalation with a starting dose of 100 mg. Enasidenib will be self administered orally and daily.
45961782|NCT05280704|Procedure|Volar digital block with lidocaine|Volar digital block with lidocaine
45665484|NCT04411433|Drug|Hydroxychloroquine|"Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (200 mg oral 2 times daily) on day-2 to day-5 (5 days in total).~Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (200 mg oral 2 times daily) throughout 5 days (5 days in total)."
45961783|NCT05280704|Procedure|Volar digital block with saline|Volar digital block with saline
45961784|NCT05280704|Procedure|Dorsal digital block with lidocaine|Dorsal digital block with lidocaine
45961785|NCT05280704|Procedure|Dorsal digital block with saline|Dorsal digital block with saline
45961786|NCT05267873|Drug|Duloxetine, Vortioxetine|
45961787|NCT05259956|Behavioral|Schroth based scoliosis specific exercise|The intervention is set to be delivered in a one-hour Schroth-based exercise session, with the frequency of twice a week for five weeks. The exercise consists of active auto-correction in 3D, stabilizing the corrected posture, and training in ADL.
46079638|NCT04761055|Diagnostic Test|mammogram|All patients will have routine standard mammographic views performed. Patients with positive iBE and/or CBE findings will have additional mammographic and/or ultrasound imaging to determine if a correlating breast lesion is present using the same standard of care algorithm as is used currently for positive CBE findings.
46079639|NCT04759664|Drug|LUT014 Gel (Dose 1)|Topical gel
45458517|NCT03493984|Other|Aloe exosomes|Naturally occurring plant exosomes from aloe
45961788|NCT05259956|Behavioral|"3 plus 1 multidimensional exercise therapy"|The intervention is set to be delivered in a 90-minute exercise session, with a frequency of twice a week for five weeks. The exercise consists of a one-hour Schroth-based exercise session and an additional 30-minute manipulative therapy of pelvic asymmetry.
45961789|NCT05226624|Behavioral|Rooming-in care|Implementation of Rooming-in model of care
45961790|NCT05226624|Behavioral|Baseline standard of care|Baseline standard of care
45961791|NCT05224037|Diagnostic Test|iLivTouch|Eligible subjects will undergo liver stiffness and controlled attenuation parameters examination with two devices on the same day
46079640|NCT04759664|Drug|LUT014 Gel (Dose 2)|Topical gel
46079641|NCT04759664|Drug|Placebo|LUT014 matching placebo topical gel
46079642|NCT04746924|Drug|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous injection.
46079643|NCT04746924|Drug|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous injection.
46079644|NCT04746924|Drug|Pembrolizumab|Pembrolizumab is a monoclonal antibody formulated for intravenous injection.
46079645|NCT04746924|Drug|Placebo|Placebo infusions will consist of a sterile, normal saline solution.
45961792|NCT05222295|Other|Supervised Pulmonary Telerehabilitation|For pulmonary rehabilitation to be applied in the simultaneous telerehabilitation method, digital blood pressure measurement device, digital finger pulse oximeter device will be given to severe COPD patients for safe exercise and they will be informed about confidence intervals and how to use saturation and heart rate monitors. The relevant program and points to be considered will be delivered to the patients in the form of an online PDF brochure.
45961793|NCT05222295|Other|Cognitive Telerehabilitation|These patients will be asked to do a standardized pulmonary telerehabilitation program three times a week for 8 weeks by watching videos consisting of commands and exercise videos transmitted to them, some of them by actively doing, imagining.
45820612|NCT01500109|Drug|Ofirmev®|Intravenous acetaminophen is initiated after intravenous access is obtained intraoperatively and before surgical incision. Dosing is age based as follows: 5 months-2 years 12.5 mg/kg, 2-5 years 15 mg/kg. Redosing will be every 6 hours for 24 hours. The two other arms will receive a placebo in the form of normal saline given intravenously. Intraoperative opioids will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
45961794|NCT05221281|Behavioral|Multimodal intervention consisting of four core components|"Core Component 1: Individualized Assessment: Each participant will undergo individualized assessment of their biopsychosocial risk profile (PIBD INTERMED), self-efficacy (IBD-SES-A), function (IBD-DI), transition readiness (TRAQ) and IBD knowledge (IBD-KID2), and depression, anxiety and activation.~Core Component 2: Transition Navigator: Participants will be assigned a transition navigators, who will have knowledge of IBD, an understanding of the care pathway involved in transitioning IBD patients, and the skills and ability to provide psychosocial support.~Core Component 3: Participant Skills-building: Skills-building materials delivered virtually. Navigators will also be trained as motivational coaches and will lead separate personalized virtual sessions targeting individual skills that have been identified as deficient during the assessment phase.~Core Component 4: eLearning Curriculum: Organized online eLearning modules with reinforcement of knowledge by the navigators."
45961795|NCT05221281|Behavioral|Standard of care|"The control group will be provided a standardized version of routine care for transition. In addition to recruiting centers' standard of care, all participating centers will implement the following transition interventions:~A written letter explaining the goals of transition to the patient and family.~Completion of age-appropriate checklists to ensure adolescents are meeting milestones of transition (developed by the TRACC Network).51~Annual online live educational webinars on transition and adolescent issues (hosted by the CIDsCaNN Education Committee).~Completion of the Pediatric INTERMED,52 with appropriate biopsychosocial intervention.~Completion of a transfer-of-care summary letter sent to the receiving adult gastroenterologist using a standardized letter template.53~The Control Group may also receive any interventions currently in place in their participating care center, but will not receive the formal 4-component intervention described below."
45961796|NCT05205265|Device|Rivet Shunt|The Rivet Shunt device will be implanted via a percutaneous, transcatheter approach
45961797|NCT05183607|Other|Virtual Nutrition Education|4 interventional sessions will be provided using a virtual communication platform and delivered remotely to each participant by a registered dietitian. The virtual counseling sessions will be led by a registered dietitian and delivered to each participant remotely
45961798|NCT05133141|Device|Echelon Contour|There is no intervention, beyond necessary clinical care, in this study. Echelon Contour is used for transection and resection in colorectal surgical procedures per its instructions for use (IFU).
45961799|NCT05129293|Behavioral|Prospective Memory Intervention|Cognitive remediation focusing on prospective memory
45961800|NCT05129293|Behavioral|Educational|Psychoeducation
45961801|NCT05121376|Genetic|Dose 1 of BMN 331|BMN 331 AAV Gene Therapy
45961802|NCT05121376|Genetic|Dose 2 of BMN 331|BMN 331 AAV Gene Therapy
45961803|NCT05121376|Genetic|Dose 3 of BMN 331|BMN 331 AAV Gene Therapy
45961804|NCT05121376|Genetic|Dose 4 of BMN 331|BMN 331 AAV Gene Therapy
46079646|NCT04738968|Device|Cochlear implant|A cochlear implant is standard care for profoundly deaf persons. It enables hearing through electrical stimulation of the auditory nerve.
46079647|NCT04728282|Procedure|RTSA with subscapularis repair|Lateralized reverse total shoulder arthroplasty with repair of subscapularis
46079648|NCT04728282|Procedure|RTSA without subscapularis repair|Lateralized reverse total shoulder arthroplasty without repair of subscapularis
45455322|NCT01123681|Device|Choice of endotracheal tube|Types of endotracheal tube, normal cuff without sub-glottic aspiration, normal cuff with sub-glottic aspiration, Special cuff with sub-glottic aspiration
45665485|NCT04411433|Drug|Hydroxychloroquine combined with Azithromycin|"Drug: Hydroxychloroquine combined with Azithromycin Hydroxychloroquine Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Hydroxychloroquine Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (2x200 mg oral, 2 times daily) throughout 5 days (5 days in total).~Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total)."
45961805|NCT05121376|Genetic|Dose 5 of BMN 331|BMN 331 AAV Gene Therapy
45961806|NCT05117840|Device|Low-dose CT scan|Standard of care screening for individuals at high-risk of lung cancer
46079649|NCT04695067|Behavioral|Central fatigue group|a fatigue protocol that pitchers need to pitch 80 trials in a simulated game
46079650|NCT04689360|Drug|elamipretide|Elamipretide is an aromatic-cationic tetrapeptide that readily penetrates cell membranes and transiently localizes to the inner mitochondrial membrane.
46079651|NCT04674813|Drug|CC-95266|Specified dose on specified days
46079652|NCT04674813|Drug|Fludarabine|Specified dose on specified days
45455323|NCT04646564|Drug|standard of care|patients receive appropriate therapy at the discretion of the treating oncologist, i.e. systemic therapy according to molecular subtypes, including chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.
45458518|NCT03493984|Other|Placebo|Exosome placebo tablet
46079653|NCT04674813|Drug|Cyclophosphamide|Specified dose on specified days
46079654|NCT04674813|Drug|Bendamustine|Specified dose on specified days
45961807|NCT05113901|Drug|Methylprednisolone|21 x 4mg tablets at 6 weeks, qualifying for MUA if ROM <90° at 8 weeks
45961808|NCT05113901|Drug|Placebo|21 sugar tablets at 6 weeks with standard management, qualifying for MUA if ROM <90° at 8 weeks
45961809|NCT05109065|Diagnostic Test|SCID (Standardized Clinical Interview for DSM-V)|The Structured Clinical Interview for DSM-5 (SCID-5) is a semistructured interview guide for a clinician or trained mental health professional to diagnose major mental illnesses.
45961810|NCT05109065|Diagnostic Test|PSS (Perceived Stress Score)|The Perceived Stress Scale (PSS) is the most widely used psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. Demographic information will also be collected.
45961811|NCT05109065|Diagnostic Test|Urine Toxicology Screen|Participants will be asked to provide a urine sample. Evidence of active substance abuse (marijuana, opioids, other non-prescription drugs) by the urine toxicology screen will disqualify participants from the study.
45961812|NCT05109065|Diagnostic Test|Vitals|Height and weight will be measured in order to calculate BMI.
45665486|NCT04987463|Drug|Vigabatrin|Vigabatrin in capsules administered orally, initially (between V1 and V2) once daily in the evening,and starting from V2 administered two times daily.
45961813|NCT05109065|Diagnostic Test|Blood Work|A venipuncture will be performed for the purpose of collecting blood tissue for study.
45961814|NCT05109065|Diagnostic Test|PQ-B|The Prodromal Questionnaire - Brief Version (PQ-B) is a self-report measure designed to identify people who may be experiencing psychotic symptoms when they do not have a schizophrenia diagnosis.
45665487|NCT04987463|Drug|Rapamycin|Rapamycin in liquid administered orally, in the morning, every other day or daily depending on the patient's body weight. The starting dose of rapamycin will be calculated according to the body weight of the patient measured at V1.
45665488|NCT04987463|Drug|Placebo|Placebo in liquid administered orally, once daily, in the morning. The starting dose of placebo in liquid will be calculated according to the body weight of the patient measured at V1.
45820613|NCT01500109|Drug|Opioid only|Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
45961815|NCT05109065|Diagnostic Test|COVID Screening|Questionnaire to assess risk of transmission of COVID-19.
45961816|NCT05109065|Diagnostic Test|Positive and Negative Syndrome Scale (PANSS)|Instrument that is completed by clinical interviewer to measure symptom severity in individuals with psychotic disorders.
46079655|NCT04662281|Drug|LX9211|11-week assessment period
45665489|NCT04987463|Drug|Placebo|Placebo in granules administered orally, initially once daily in the evening,and after reaching the targeted dose administered two times daily.
45820614|NCT00002516|Biological|dactinomycin|
45820615|NCT00002516|Drug|cyclophosphamide|
45820616|NCT00002516|Drug|doxorubicin hydrochloride|
45820617|NCT00002516|Drug|etoposide|
45820618|NCT00002516|Drug|ifosfamide|
45820619|NCT00002516|Drug|mesna|
45961817|NCT05105451|Other|Collecting clinical data, EGG，arterial blood gas data and venous blood sample|Collecting clinical data(before induction of anesthesia and first day after surgery), EGG（first day after surgery），arterial blood gas data(before induction of anesthesia and first day after surgery) and venous blood sample （before induction of anesthesia and first day, third day and 7th day after surgery）
45961818|NCT05089864|Other|Stent Placement Timing - Early|Stent placement 5-7 weeks after STAR procedure
45961819|NCT05089864|Other|Stent Placement Timing - Late|Stent placement 12-14 weeks after STAR procedure
45961820|NCT05081011|Device|Voice Assistant Device|Voice AI-enabled smart speaker device delivers daily insulin titration instructions.
45961821|NCT05075603|Drug|Efineptakin alfa|NT-I7 is administered via a single intramuscular injection after CAR-T infusion on Day 21.
45961822|NCT05075603|Drug|Tisagenlecleucel|Administered as standard of care as described in the package insert on Day 0.
45961823|NCT05075603|Drug|Axicabtagene ciloleucel|Administered as standard of care as described in the package insert on Day 0.
45961824|NCT05075603|Drug|Lisocabtagene Maraleucel|Administered as standard of care as described in the package insert on Day 0.
46079656|NCT04662281|Drug|Placebo|11-week assessment period
45820620|NCT00002516|Drug|vincristine sulfate|
45820621|NCT00002516|Procedure|conventional surgery|
45820622|NCT00002516|Radiation|low-LET cobalt-60 gamma ray therapy|
45820623|NCT00002516|Radiation|low-LET photon therapy|
45820624|NCT00377845|Procedure|Regular Tampax used in 3 hours|
45820625|NCT00002522|Drug|cisplatin|
45820626|NCT00002522|Drug|cyclophosphamide|
45820627|NCT00002522|Drug|etoposide|
45820628|NCT00002522|Procedure|autologous bone marrow transplantation|
45820629|NCT00002522|Procedure|bone marrow ablation with stem cell support|
45820630|NCT00002522|Procedure|peripheral blood stem cell transplantation|
45820631|NCT00002522|Procedure|syngeneic bone marrow transplantation|
45820632|NCT00002522|Radiation|radiation therapy|
45961825|NCT05065216|Drug|Recombinant human tissue kallikrein|Treatment is completed by Day 21 and the duration of each individual's participation in the study will be 90 days from the time of consent to completion of all study activities.
45961826|NCT05039892|Drug|3D185|All eligible subjects will receive the RP2D regimen to be established based on the results of the ongoing phase I study from Cycle 1 Day 1 (C1D1) until disease progression, intolerable toxicity, withdrawal of consent, whichever occurs first.
45961827|NCT05038150|Drug|SGN1|SGN1, will be administered as an IV infusion, via an IV catheter over 2 hours, which unit dose strength is 0.9-2.0×109 cfu /vial.
46079657|NCT04661254|Other|Lymphapheresis|- From the blood product of lymphapheresis: Autologous naïve regulatory CD45RA+CD4+CD25+FoxP3+ T lymphocytes (Tregs) selected and amplified ex vivo; obtained by selection and sorting of CD4+CD25 +CD127lowCD45RA+ cells, derived from lymphapheresis and amplified ex vivo for 10 +/- 1 days, under cGMP condition in the presence of IL2 and Rapamycin
45961828|NCT05035615|Diagnostic Test|IUO Acute Leukemia Panel|This Investigational Panel , comprised of 6 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of immature hematopoietic cell populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, B-cell acute lymphoblastic leukemia or acute myeloid leukemia.
45961829|NCT05035589|Drug|Tocilizumab|Tocilizumab administered at a dose of 8mg/kg up to a maximum of 800mg
45961830|NCT05032339|Diagnostic Test|IUO Plasma Cell Disorders Panel|This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of plasma cell populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, plasma cell disorders.
45961831|NCT05032313|Diagnostic Test|IUO CLPD Limited Panel|This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having Chronic Lymphoproliferative Disease .
45961832|NCT05031286|Other|Cutaneous thermal stimuli|Application of thermal stimuli of different intensities to the skin
45961833|NCT05024214|Drug|Lenvatinib + Envafolimab|"Lenvatinib will be administered with water orally once a day (with or without food) continuously in 28-day treatment cycle.~Envafolimab, 400 mg per dose, subcutaneous injection, dosed on D1 and then D15 of Treatment Cycle 1, and D1 of Treatment Cycle 2 and every subsequent cycles, with every 28 days as one treatment cycle."
45961834|NCT05024214|Drug|Sunitinib|Sunitinib will be administered with water orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) in 42-day treatment cycle.
45961835|NCT05018091|Drug|Dexamethasone 4mg|4mg intravenous dexamethasone, administered shortly after induction of anesthesia
45961836|NCT05018091|Drug|Dexamethasone 8 Mg/mL Injectable Suspension|8mg intravenous dexamethasone, administered shortly after induction of anesthesia
45665490|NCT01628367|Procedure|Minimally Traumatic Tooth Extraction|"The surgeon will perform a minimally traumatic tooth extraction in the following fashion. Intrasulcular incisions will be performed with at 15-C scalpel around the tooth to be extracted.~A periotome will then be introduced into the periodontal ligament space in order to sever the subcrestal attachment and expand the periodontal ligament space. Elevators will be used to initiate luxation of teeth. After significant mobility has been achieved through elevation, forceps will be used only to deliver the tooth. Finally, the socket will be curetted to remove all granulomatous tissue and irrigated with sterile isotonic saline solution."
45665491|NCT01628367|Device|Immediate Implant Placement|A threaded titanium alloy implant with an internal hex connection and a Resorbable Blast Texturing (RBT) surface (Tapered Internal® Implant System, Biohorizons, Inc., Birmingham, AL, USA) will be placed using a surgical guide. Implant diameter of 3.8mm with lengths of either 12 or 15mm will be used. Implants will be placed approximately 3-4mm below the free gingival margin or 2-3mm below the cemento-enamel junction of adjacent teeth.
45665492|NCT01628367|Biological|Bone Graft Placement|Circumferential defects or dehiscences around the immediately placed implant will be grafted. enCore™ Combination Allograft (Osteogenics Biomedical, Lubbock, Texas, USA) will be used as the bone graft material.
45820633|NCT02350777|Procedure|Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion|For related donors, beginning 5-6 days before the day of HPC(A) or HPC (M) TCD boost infusion, the normal donor will receive GCSF per institutional guidelines. On the fifth and sixth days of this course of G-CSF, the donor will undergo daily leukapheresis designed to provide a minimum of 5x10^6 CD34+ cells/kg of the transplant recipient's weight. For unrelated donors, the G-CSF will be administered and the leukapheresis obtained according to the National Marrow Donor Program protocol IND, and institutional guidelines. Mononuclear cell fractions (i.e., CD34+ cells) collected on the fourth and fifth days will be pooled.
45820634|NCT02350777|Device|CliniMACS Cell Selection System|
45820635|NCT05751200|Other||
45820636|NCT01482325|Device|Blood pressure monitoring with GE Healthcare DASH2500 Patient Monitor|10-20 Non-Invasive Blood Pressure readings on investigational software in the DASH2500 Patient Monitor
45820637|NCT00002528|Drug|tamoxifen citrate|20 mg daily beginning within 6 weeks of surgery for 5 years or until relapse, whichever occurs first.
45820638|NCT00002528|Procedure|conventional surgery|Either total mastectomy or, optionally if the tumor was smaller than 5 cm, a breast conserving procedure (lumpectomy or quadrantectomy).
45820639|NCT00002528|Radiation|radiation therapy|No radiotherapy is to be given after mastectomy. Radiotherapy is optional after breast conserving surgery according to prospectively determined guidelines within each institution. It should be given to the breast only and not to the draining node areas.
45820640|NCT00002528|Procedure|Axillary clearance|Axillary node dissection.
46079658|NCT04649099|Device|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
45961837|NCT05018091|Drug|Dexamethasone 16mg|16mg intravenous dexamethasone, administered shortly after induction of anesthesia
45961838|NCT05013736|Device|Magnetic Resonance Imaging|3 Tesla Discovery MR750 MRI scanner (GE Healthcare, Waukesha, WI) will be used to perform structural imaging, diffusion MRI, relaxometry and microstructural imaging. The exact scan length and parameters of each scan type (T1, T2, DWI) will be set for this study to optimize the quality of data and decrease the length of scanning session for each type of scan. All of the imaging methods have been previously implemented at UW-Madison. Each sequence will take approximately 5-10 minutes.
45961839|NCT05013736|Behavioral|Behavioral Assessments|The behavioral assessments (GMA: General Movements Assessment; HINE: Hammersmith Infant Neurological Examination; Bayley-IV, Bayley Scales of Infant and Toddler Development 4th ed) are infant and age-specific and will be administered by trained pediatric occupational and physical therapists.
45961840|NCT05013736|Device|Non invasive Transcranial Magnetic Stimulation|TMS will be used to assess cortical excitability and circuitry (not as a neuromodulation intervention). Single-pulse TMS (Magstim 200², Magstim, UK) with a scalp surface coil will be used to assess how the brain is developing and how connected the tract is, between the brain and a target muscle on the arm. 10-20 TMS stimulation pulses will be delivered at a range of stimulation intensities (50-100%) increasing by 5% maximal stimulator output (MSO) at each stage. In sum, around 150 stimulation pulses per hemisphere are expected for TMS assessment for each infant.
45961841|NCT05012917|Other|Patient/Proxy-SSPedi|"SSPedi and Mini-SSPedi: SSPedi is a symptom assessment scale for children 8-18 years of age that includes 15 symptoms considered most important by children receiving cancer treatment or HSCT, their parents and healthcare professionals. Each symptom is rated on a 5-point Likert scale consisting of 0=not at all bothered, 1=a little, 2=medium, 3=a lot and 4=extremely bothered. The recall period is yesterday or today.~Mini-SSPedi was developed for children 4-7 years of age and is comprised of the same 15 symptoms. Mini-SSPedi has a recall period of today with a 3-point Likert scale consisting of 0=not at all bothered, 2=medium and 4=extremely bothered'. So, the anchors and mid-point are identical to SSPedi. A faces-type scale accompanies the response options and the symptom descriptions are simplified.~Proxy-SSPedi: Proxy-SSPedi is identical to SSPedi except that the leading question refers to your child rather than you. It is designed for children 2-18 years of age."
45665493|NCT01628367|Biological|Membrane placement|A non absorbable d-PTFE membrane (Cytoplast® TXT-200, Osteogenics Biomedical, Lubbock, Texas, USA) will be trimmed to an appropriate size and shape to completely cover the implant site, and extend about 3-5mm beyond on the facial aspect. The membrane will be tucked under the sub-periosteal flap. Care will be taken to ensure that the membrane is resting on bone all around the socket margins. The membrane will be kept a minimum of 1.5mm from the adjacent tooth roots in the interdental area.
45665494|NCT01628367|Biological|Collagen plug placement|A bio-absorbable collagen wound dressing (CollaPlug®, Zimmer Dental, Carlsbad, CA, USA) will be trimmed to the appropriate size, so as to cover the socket
45665495|NCT01628367|Drug|Medications|Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days. Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain. Patients will also receive a prescription for Vicodin as needed for pain, every 4 to 6 hours
45665496|NCT01627899|Device|One Touch VerioIQ Blood Glucose Monitor|BGM with pattern alert technology and with associated pattern guide
45665497|NCT05012735|Drug|Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5)|Participants will wash their face with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) for up to 14 days.
45665498|NCT05012735|Device|Prototype Ultrathin Hydrocolloid Bandage|Participants will cover their closed and popped pimples in the evening with one or two bandages from Days 0 through 6.
45820641|NCT02341495|Drug|Deferasirox|Deferasirox (20mg/kg/day)on days 1-7 of protocol every 4 wks for 8 cycles PO
45820642|NCT02341495|Drug|Cholecalciferol|Cholecalciferol(4,000 units/day) on days 1-7 of protocol every 4 wks for 8 cycles PO
45820643|NCT02341495|Drug|Azacitidine|Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol 28 days for 32 wks
45820644|NCT00002534|Biological|anti-thymocyte globulin|
45820645|NCT00002534|Drug|cyclophosphamide|
45820646|NCT00002534|Drug|cytarabine|
45820647|NCT00002534|Drug|methylprednisolone|
45820648|NCT00002534|Drug|thiotepa|
45820649|NCT00002534|Procedure|allogeneic bone marrow transplantation|
45820650|NCT00002534|Procedure|in vitro-treated bone marrow transplantation|
45820651|NCT00002534|Radiation|low-LET electron therapy|
45820652|NCT00002534|Radiation|low-LET photon therapy|
45820653|NCT05751122|Other|Dynamic flex cast with neurodevelopmental treatment|"Neurodevelopmental therapy in combination with dynamic flex cast to treat experimental group.~Three times a week, 1 hour session per day.~Dynamic flex casting is casting which manipulate bone alignment and maintains range of motion or sustained stretch. Casting will be changed weekly for 3 months.~Neuro developmental approach is individualized treatment which is attuned to each child's specific problems, aims and goals.~Key elements in NDT are: facilitation (using sensory inputs to improve motor performance), management of compensatory motor behavior, and an overall management strategy (a 24-hour interdisciplinary management approach) NDT involves task specific postures and movements."
45820654|NCT05751122|Other|Rigid Ankle foot Orthosis with neurodevelopmental treatment|"Rigid ankle foot orthosis will be applied to ankle joint at the start of intervention.~Neurodevelopmental treatment will be applied to both groups with protocol; Three times a week, 1 hour session per day.~Assessment on 1st day,6th week and 12th week"
45820655|NCT02320825|Radiation|single-fraction SRS|
45820656|NCT02320825|Radiation|high-dose hypofractionated SRS|
45820657|NCT02320825|Behavioral|Quality of Life Measures|
45820658|NCT00002546|Drug|cisplatin|
45820659|NCT00002546|Drug|ifosfamide|
45820660|NCT00002546|Procedure|adjuvant therapy|
45820661|NCT00002546|Radiation|radiation therapy|
45820662|NCT01477177|Device|Polar Wand carbon dioxide cryotherapy|Patients with Barrett's esophagus dysplasia will be treated with the Polar Wand device at 0 month, 2 and 4 months,6 months (with four quadrant surveillance biopsies), 8 and 10 months (treatment as necessary), and, at 12 months for final surveillance with biopsies throughout entire initial Barrett's segment length.
45961842|NCT05012917|Other|Co-SSPedi|"Co-SSPedi: Co-SSPedi is based upon either SSPedi (age 8-18) or mini-SSPedi (age 4-7).~Co-SSPedi is meant to be completed by both child and parent together. The format and wording is identical to self-report SSPedi and mini-SSPedi (depending on child age) to maximize the ability of the child to participate in symptom reporting.~The approach uses written instruction that asks the dyad who will hold the device and enter the agreed-upon scores. The instruction then asks one member to read the leading question, each symptom and response options out loud. The child answers how bothered they are by that symptom out loud. The parent then states if they agree or they can offer a different answer. If the answer is different, the instruction asks the dyad to discuss until they agree upon an answer. The agreed-upon answer is then entered into co-SSPedi. This process is repeated for the remaining 14 symptoms."
45961843|NCT05009875|Other|Medical Food SBD111|Two capsules administered twice daily with morning and evening meals for 52 weeks
45961844|NCT05009875|Other|Placebo|Two capsules administered twice daily with morning and evening meals for 52 weeks
45961845|NCT05007288|Other|Restorative Eye Treatment (RET) cream|RET cream will be applied topically to either the left of right eyelid once daily for 4 consecutive weeks.
45961846|NCT05007288|Other|INhance with Trihex Technology|INhance will be applied topically to both eyelids once daily for 10 consecutive days after the SOC blepharoplasty surgery.
45961847|NCT05000411|Drug|Compound Danshen Dropping Pills (CDDP)|The patients in this group are treated with 20 tablets of Compound Danshen Dropping Pills (CDDP) before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI.
45665499|NCT04947449|Device|fractional CO2 laser|Standard of care laser treatment of burn-related injuries will be performed. This protocol assesses the effects of those treatments on skin blood flow and sweating responses.
45665500|NCT04946903|Drug|RLD2007|Take it once per period.
45665501|NCT04946903|Drug|RLD2008|Take it once per period.
45665502|NCT04946903|Drug|HCP1902|Take it once per period.
45665503|NCT04985825|Drug|Imgatuzumab|Imgatuzumab administered as an intravenous infusion on Day 1 and Day 8 of the first 21-day cycle, and on Day 1 of each subsequent 14-day cycle.
45961848|NCT05000411|Drug|Placebo|The patients in this group take 20 tablets of placebo before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI .
45820663|NCT05655884|Other|Music Listening Application|"15 minutes before going to the surgery, the child's favorite and chosen music piece will be loaded onto the mp3 player and played by the researcher via the creatone music pillow for 15 minutes. After the child returns to the service from the recovery room (the room where the patient is observed in the operating room for a certain period of time until he recovers from the surgery and his general condition is stable), and after he regains consciousness, music will be played by the music group again for 15 minutes."
45665504|NCT05012657|Device|Point Partial|The Point Partial partial finger prosthetic system consists of 1-4 ratcheting mechanical partial digits and mounting brackets
45665505|NCT02519777|Drug|Placebo for maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
45665506|NCT02519777|Drug|Placebo for dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
45961849|NCT04999644|Drug|Full Nicotine Cigarettes|A full nicotine tobacco cigarette that will be smoked by participants
45961850|NCT04999644|Drug|Reduced Nicotine Cigarettes|A reduced nicotine tobacco cigarette that will be smoked by participants
45961851|NCT04999644|Behavioral|Average Nicotine Expectancy|"Participant instructed the cigarette is the same level of nicotine as your usual brand."
45961852|NCT04999644|Behavioral|Very Low Nicotine Expectancy|"Participant instructed the cigarette is a very low level of nicotine compared to your usual brand."
46079659|NCT04642404|Drug|Epidiolex 100 mg/mL Oral Solution|Cannabidiol (CBD): is the primary non-psychoactive and non-addictive compound in cannabis, has already shown potential in treating pain such as arthritis, neuropathic, cancer and chronic pain
46079660|NCT04642404|Drug|Placebo|Placebo drug will be a solution with the same taste, texture and color as the drug.
46079661|NCT04642352|Drug|superior laryngeal nerve block|A unilateral injection of 2 cc of a 1:1 mixture of 0.25% bupivacaine and Kenalog-40 via a 27 gauge needle to the thyrohyoid space (front of neck, just above larynx/voice box) via a 27 gauge needle to the thyrohyoid space (front of neck, just above larynx/voice box) on the side which exhibited most discomfort/tenderness/cough on palpation. If neither side was uncomfortable, the right side will be used.
45455324|NCT04646564|Radiation|radiotherapy + standard of care|"Patients receive radiotherapy to all known metastases. SBRT technique is preferred, especially for metastases in bone, lung and liver. Conventional RT can be used when SBRT is not appropriate, such as metastasis in mediastinal or contralateral supraclavicular nodal regions. Total doses of 30Gy to 50Gy in 5 fractions for SBRT are recommended depending on the tolerance of adjacent normal tissue. Total dose of 60Gy in 25 fractions is recommended for conventional RT.~Patients can receive systemic therapy concurrently with RT at the discretion of treating radiation oncologist. After completion of SBRT to all sites of known metastatic disease, patients will continue standard of care therapy per the treating oncologist."
45455325|NCT01117129|Drug|rituximab [MabThera/Rituxan]|1000 mg by i.v. infusion on day 1 and 15
45455326|NCT01117129|Drug|placebo|i.v. infusion on day 1 and 15
45455327|NCT01117129|Drug|methotrexate|10-25 mg weekly
45665507|NCT02519777|Drug|Dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
45665508|NCT02519777|Drug|Maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
45665509|NCT04985513|Procedure|Ventilation during cardiopulmonary bypass|Ventilation was performed using an inhaled oxygen fraction of 20% and a tidal volume of 5ml/kg at the time of cardiopulmonary bypass.
45820664|NCT05655884|Other|Foot Reflexology Practice:|Children in this group; Before going to the surgery, foot reflexology will be applied by the researcher, only to the left foot, for 10 minutes. After the child returns to the service from the recovery room (the room where the patient is observed in the operating room for a certain period of time until he recovers from the surgery and his general condition is stable), and after he regains consciousness, foot reflexology will be applied again, only on the left foot, for 10 minutes.
45820665|NCT00378625|Drug|Artesunate|
45961853|NCT04995601|Device|RF Health MAC|The RF Health MAC is a novel device that is applied to the lower legs of patients that provides intermittent active compressions to the calf muscles which results in increased blood flow in the veins, moving blood towards the direction of the heart and reducing the risk of clot formation.
45961854|NCT04994769|Device|Epitomee Capsule|Epitomee Capsule combined with lifestyle counseling.
45961855|NCT04986475|Other|Music Therapy|Music therapy was performed by listening to the ney sound during the non-stress test procedure.
45961856|NCT04962503|Drug|Afamelanotide|Six adult patients with clots located in the higher segments of the brain and who are ineligible for alternative treatments will be enrolled in the study and evaluated for six weeks. The study will assess patients' brain injury with computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as using recognised methods of clinical evaluation to measure changes in patients' neurological and cognitive function following treatment.
46079662|NCT04637282|Drug|PLX-200|15 mg/mL oral solution of experimental drug
45665510|NCT04213859|Behavioral|VRET - Virtual Reality Exposure Therapy|VRET will include 4 weekly 1-hour sessions over the course of 4 weeks. The treatment protocol is based on the Virtual Reality (VR) treatment manual guidelines (Rothbaum & Hodges, 1997,1999) and includes psychoeducation, anxiety management training, cognitive restructuring and exposure. The first therapy session focuses on creating an individually-tailored conceptualization and treatment plan. Following this process, participant and therapist conduct a short introductory VR flight exposure simulation to familiarize the participant with the VRET apparatus. The VRET apparatus is an advanced, large-scale VR system that allows maximal immersion within the virtual environment. The second, third and fourth sessions include psychoeducation, relaxation training, cognitive restructuring and individually-tailored VR exposures (the therapist can manipulate the turbulence level and other flight-related variables to fit participants' fears and current progress).
45455328|NCT01117129|Drug|rituximab [Mabthera/Rituxan]|1000 mg by i.v. infusion on day 1 and 15, 2nd and further cycles in patients with (group A) or without (group B) clinical response in cycle 1
45455329|NCT03133988|Biological|Margetuximab|anti-HER2 monoclonal antibody
45455330|NCT01123759|Other|Feeding low mercury fish|Subjects fed 6 oz of either tilapia (low omega-3 fish) or salmon (high omega-3 fish) for 3 months. Both fish are low in mercury
45455331|NCT01218373|Device|HOMESWEETHOME Services|Monitoring and alarm handling services. eInclusion services. Domotic services. Daily scheduler. Navigation services. Cognitive training services. Non-technology based services.
45455332|NCT01218373|Device|No HOMESWEETHOME services installed|Normal care and healthcare without HOMESWEETHOME services.
45455333|NCT03934411|Drug|Tramadol|The subjects will orally ingest 100 mg tramadol retard actavis
45455334|NCT03934411|Other|Placebo|The subjects will orally ingest 100 mg calcium powder
45665511|NCT05008913|Drug|[14C]Adavosertib|Patients will receive a single administration of [14C]Adavosertib as an oral solution on Day 1.
45961857|NCT04960566|Other|Cognitive Behavioral Therapy|The CBT intervention is based on the theoretical framework that under stress (reflux symptoms) a person makes a rapid cognitive appraisal of the potential threat (automatic thoughts), leading to both emotional and physical responses in the body, thereby reacting behaviorally (avoidance, increased HCU) in an attempt to mitigate unpleasantness. CBT is a collaborative, present-focused treatment that utilizes a skills-based approach with home practice exercises. CBT targets automatic thoughts and appraisals of threat via education, self-monitoring of stressors and symptoms, and strategies to reframe problematic thinking patterns to more adaptive ones. Resonance frequency breathing (RFB) is achieved when a person breathes at a pace, typically 4 to 6 breaths per minute, that engages the body's baroreflex to modulate arousal. Prior research demonstrates 4 to 6 weeks of RFB training is sufficient to significantly increase baseline HRV with enduring effects for up to 6 months.
45961858|NCT04960566|Other|Sham-SOC Lifestyle Coaching|Sham-SOC Lifestyle Coaching
45961859|NCT04935424|Device|ApolloVue® S100 Image System (Apollo Medical Optics)|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group. The ApolloVue S100 image system is a high resolution OCT imaging system that provide real-time visualization of human skin tissue microstructure. The system provides cellular level, two-dimensional, cross-sectional (B-scan) and en face (E-scan) that can assist clinical diagnosis.The system is also equipped with imaging guiding system that could assist in position scanning skin area.
46079663|NCT04637282|Drug|Placebo|Taste and color-matched drug-free solution
46079664|NCT04611321|Drug|IBI318|IBI318 will be given fixed dose via intravenous (IV) infusion on Day 1 of each 14-day cycle until disease progression or loss of clinical benefit.
46079665|NCT04600570|Other|ultrasound|ultrasound measurement for optic nerve outer diameter
46079666|NCT04598477|Biological|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer
46079667|NCT04598477|Drug|prednisone|Oral prednisone tablets
46079668|NCT04594408|Drug|Epinephrine|1 mL of 1:1000 mixed into irrigation bag.
46079669|NCT04594408|Drug|Tranexamic acid|1 g IV x 1 dose to be administered intraoperatively.
45455335|NCT01346384|Device|laryngeal tube (VBM Medizintechnik)|laryngeal tube number 4
45455336|NCT04631120|Other|Integrated Dementia Practice Unit Design|"Dementia Central: monthly review of participant progress~Dementia Mobile: monthly nurse/lay health educator visits for assessments, education and coaching~Dementia Link: communication between Dementia Central and Dementia Mobile using the eTransX mHealth platform and HealthStream educational interface for care providers and the patient/caregiver dyad."
45961860|NCT04924244|Other|Music Therapy|We will play music of the subject's choice of genre during the procedure.
45961861|NCT04924244|Other|No Music|No music will be played during the subject's interventional procedure
45961862|NCT04919811|Drug|Taletrectinib|600mg QD
45961863|NCT04918329|Other|Observational study|Non interventional study
45961864|NCT04916080|Drug|N-acetyl cysteine|mucolytic and anti-oxidant. Dose 10mg/Kg/ 12 hours orally
45961865|NCT04896476|Device|EchoMark|The EchoMark is to be secured a minimum of 3 cm away from the anastomosis.
45961866|NCT04862975|Drug|Dolutegravir|Dolutegravir will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
45961867|NCT04862975|Drug|Efavirenz|Efavirenz will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
46079670|NCT04594408|Drug|Epinephrine and Tranexamic Acid|1 mL of 1:1000 epinephrine mixed into irrigation bag, and 1 g tranexamic acid x 1 dose to be administered intraoperatively.
45665512|NCT04982705|Drug|[Part 1.1] IDG-16177|[Part 1.1] Subjects will receive a single oral dose of IMP. Dose strenght for each cohort (Cohort 1-5) is planned as 0.5, 1, 2, 5, 10mg, respectively.
45665513|NCT04982705|Drug|[Part 1.1] Placebo of IDG-16177|[Part 1.1] subjects will receive a single oral dose of IMP.
45665514|NCT04982705|Drug|[Part 2] Sitagliptin|Administration of Sitagliptin 100mg once daily for 4 weeks.
45665515|NCT04982705|Drug|[Part1.2] IDG-16177|[Part 1.2] Administration once daily for 14 days; Dose strenght for each cohort (Cohort 6-8) is planned as ≤ 2, ≤ 4, ≤ 8mg, respectively.
45665516|NCT04982705|Drug|[Part 2] IDG-16177|[Part 2] Administration once daily for 4 weeks.
45665517|NCT04982705|Drug|[Part 1.2] Placebo of IDG-16177|[Part 1.2] Administration once daily for 14 days.
45665518|NCT04982705|Drug|[Part 2] Placebo of IDG-16177|[Part 2] Administration once daily for 4 weeks.
45455337|NCT04631120|Other|Standard of Care|Standard clinical practices of the physician and institution including an initial assessment, Zarit Burden Interview (ZBI) for caregiver, followed by provision of standard patient- and caregiver-centered educational material. Two phone sessions with a study nurse post-enrollment in months 1 and 6 to discuss the educational material and perform a needs assessment.
45961868|NCT04862975|Drug|Emtricitabine|Emtricitabine will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
45961869|NCT04862975|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
45961870|NCT04858477|Other|Visual estimation of polyp size|For each colonoscopy, a fellow will first visually estimate the polyp size
45961871|NCT04858477|Other|Napoleon measurement of polyp size|For each colonoscopy, a fellow will first visually estimate the polyp size and then measure the polyp with Napoleon. The Micro-Tech Endoscopic Polyp Measurement Device named Napoleon is a small catheter with a 15mm ruler calibrated at 1mm intervals with 5mm demarcations. It is classified as a Class 1, 510(k) exempt device by the FDA.
45961872|NCT04855305|Drug|Hyperpolarized 129Xe|Hyperpolarized 129Xe will be administered in multiple doses in volumes that are tailored to the participant's total lung capacity (TLC) followed by a breath hold of up to 15 seconds.
46079671|NCT04573439|Dietary Supplement|Dietary Supplement: Dietary supplement: Protein intake|"Oral consumption of hourly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates and fats from a protein-free formula mixture.~The last 4 meals will contain labelled 13C phenylalanine."
46079672|NCT04562935|Other|admission to pediatric intensive care with mechanical ventilation|admission to pediatric intensive care with mechanical ventilation
46079673|NCT04557215|Drug|Rifaximin|Rifaximin is indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
45455338|NCT01218451|Biological|Meningococcal group C polysaccharide conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
45665519|NCT04202783|Other|Exosomes|Focused ultrasound delivery of intravenously-infused exosomes
45665520|NCT04944095|Other|Change in SARS-CoV-2 Antibody Levels|Changes in plasma antibody levels over 12 months will be determine post-vaccination with one of the authorized SARS-CoV-2 vaccines.
45665521|NCT02515331|Drug|LHW090|Capsule - oral dose
45665522|NCT02515331|Drug|Placebo|Capsule - oral dose
45665523|NCT02515097|Drug|IDP-122 Lotion|Medicated topical lotion
46079674|NCT04557215|Drug|N-acetylcysteine|N-acetylcysteine (NAC) is a clinically approved mucolytic agent.
45665524|NCT02515097|Drug|IDP-122 Vehicle Lotion|Vehicle topical lotion with no active ingredient
45820666|NCT00378859|Behavioral|Skim milk|
45820667|NCT00378859|Behavioral|Lean meat|
45820668|NCT05648864|Device|Viamigo|Mobile application with the aim to enhance the independent outdoor mobility of the user while a coach (informal caregiver) can monitor the route from a distance.
45820669|NCT04005391|Other|Offer of Participant's Choice of Contraception Method|Women will be offered a range of contraceptive options (condoms, contraceptive pills, medroxyprogesterone acetate injection, levonorgestrel implant) to choose from; they can decline to start a contraceptive method
45820670|NCT00002552|Biological|filgrastim|
45820671|NCT00002552|Biological|sargramostim|
45820672|NCT00002552|Drug|carmustine|
45820673|NCT00002552|Drug|cyclophosphamide|
45820674|NCT00002552|Drug|cytarabine|
45961873|NCT04854369|Drug|68 Ga-PSMA-11 prepared using a PSMA-11 Sterile Cold Kit|The PSMA-11 Sterile Cold Kit is supplied as a kit for preparation of radiolabeled Gallium-68 PSMA-11 Injection, with 3 configurations (A, B or D) to accommodate the specificities of the 68Ge/68Ga generator that is used.
45961874|NCT04842032|Drug|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
45961875|NCT04842019|Drug|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
45961876|NCT04838782|Procedure|Repeat Surgical Management of Recurrent GBM|Routine of surgical operative management. Details of treatment will be left to local centers, and recorded in the case report form (CRF).
45961877|NCT04833140|Drug|Estradiol patch|The patch will provide 100mcg of estradiol daily.
45961878|NCT04833140|Drug|Placebo|Placebo patch will contain no estradiol.
45961879|NCT04828070|Other|Observation|all participants followed for clinical data for one year, vital status check at 5 years
45961880|NCT04826562|Drug|Dolutegravir/Lamivudine|single tablet antiretroviral
45961881|NCT04798820|Other|Dietary education|Dietary education provided to gastrectomy patients by dietitian.
45961882|NCT04796961|Other|Implementation Intervention|The implementation intervention involves training, coaching, expert consultation, organizational strategy meetings.
45455339|NCT01218451|Biological|Pneumococcal 13-valent conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
45665525|NCT02141295|Drug|5-FU|5-FU will be administered according to dose and schedule described in respective arm.
45961883|NCT04778618|Drug|Antithymocyte Globulin|Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 10mg/kg). Antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (days -5 and -2). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate
45455340|NCT01218451|Biological|Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
45665526|NCT02141295|Drug|Bevacizumab|Bevacizumab will be administered according to dose and schedule described in respective arm.
46079675|NCT04557215|Drug|Placebo|An inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied.
46079676|NCT04554147|Behavioral|FAITH! App-enhanced Hypertension Intervention|"FAITH! HTN App: The program promotes HTN self-management through a 10-week education module series on HTN. Participants will follow each module weekly and use a wireless home BP monitor for self-tracking which syncs to the app. The app includes module quizzes, a BP tracking dashboard and a moderated sharing board to foster discussion on HTN management.~Patient-Provider-CHW ICM. The patient-provider-CHW triad works together for personalized, collaborative goal setting. The patient will complete app modules, self-monitor BP, and engage with a sharing board integrating HTN topics. At weekly virtual visits (telephone or video), the CHW will record patient BPs, assist with addressing social determinants of health (SDOH) identified by the patient (eg, local community resources), and review HTN modules. The CHW will upload clinical/SDOH data to the patient electronic medical record (EMR) for FQHC care providers to review. This cycle will be completed weekly over the 10-week intervention."
45665527|NCT02141295|Drug|Folinic acid|Folinic acid will be administered according to dose and schedule described in respective arm.
45458519|NCT03433040|Drug|17-Hydroxyprogesterone Capronate|17-Hydroxyprogesterone Capronate 250mg versus 500mg
45665528|NCT02141295|Drug|Oxaliplatin|Oxaliplatin will be administered according to dose and schedule described in respective arm.
45665529|NCT02141295|Drug|Vanucizumab|Vanucizumab will be administered according to dose and schedule described in respective arm.
45961884|NCT04775979|Drug|diphenylcyclopropenone (DPCP)|Depigmenting agent
45961885|NCT04774744|Other|Educational Intervention|Receive digital health coaching program
45961886|NCT04774744|Other|Questionnaire Administration|Ancillary studies
45961887|NCT04774744|Other|Supportive Care|Receive standard of care support services
45665530|NCT02514551|Drug|Ramucirumab|Administered IV
45665531|NCT02514551|Drug|Paclitaxel|Administered IV
45665532|NCT02141217|Drug|Amoxicillin/clavulanate|Amoxicillin/clavulanate 1 g bd for at least 5 days or maximum 7 days depending upon the treatment response.
45665533|NCT02141217|Drug|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon the treatment response.
45665534|NCT02138253|Drug|IDN-6556|
45665535|NCT02138253|Drug|Placebo|Placebo control
45665536|NCT02514473|Drug|VX-809|
45665537|NCT02514473|Drug|Placebo|
45665538|NCT02514473|Drug|VX-770|
45665539|NCT02513771|Drug|Sitagliptin|100 mg one tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up
45665540|NCT02513771|Drug|Placebo for sitagliptin|One tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up.
45665541|NCT05006885|Drug|ALT-801|Injected subcutaneously (SC)
45820675|NCT00002552|Drug|etoposide|
45820676|NCT00002552|Drug|leucovorin calcium|
45820677|NCT00002552|Drug|methotrexate|
45820678|NCT00002552|Drug|perfosfamide|
45820679|NCT00002552|Drug|therapeutic hydrocortisone|
45820680|NCT00002552|Procedure|allogeneic bone marrow transplantation|
45820681|NCT00002552|Procedure|autologous bone marrow transplantation|
45820682|NCT00002552|Procedure|in vitro-treated bone marrow transplantation|
45820683|NCT00002552|Procedure|peripheral blood stem cell transplantation|
45820684|NCT00002552|Procedure|syngeneic bone marrow transplantation|
45820685|NCT00002552|Radiation|radiation therapy|
45961888|NCT04773457|Other|Surgical Site Infection|infection at the site of the surgery (spine or abdomen)
45665542|NCT05006885|Other|Placebo|Injected subcutaneously (SC)
45961889|NCT04767841|Drug|Metformin|Metformin 1000mg tablet plus celecoxib 200 mg capsule
45961890|NCT04767841|Drug|Placebo|Placebo tablet plus celecoxib 200 mg capsule
45961891|NCT04761861|Drug|Vildagliptin 50 MG|Vildagliptin 50 MG tablet once daily
45961892|NCT04761861|Drug|Placebo|Placebo one tablet daily
45455341|NCT04967144|Diagnostic Test|Nerve conduction study|"Participants with carpal tunnel syndrome will consist of individuals whose diagnosis has been confirmed by an electrophysiological study.~Participants in the control group will consist of those who have been confirmed not to have carpal tunnel syndrome by nerve conduction study."
45665543|NCT02104947|Drug|idarucizumab|idarucizumab
45961893|NCT04741919|Procedure|Yag Laser peripheral Iridotomy|Laser peripheral iridotomy will be performed using neo-dynium:yttrium:aluminium-garnet laser after pretreatment with 2% pilocarpine and brimonidine 0.15%. Superior LPIs will be placed between the 11- and 1-o'clock positions such that they were covered completely by the upper eyelid; nasal/temporal LPIs will be placed between the 2- and 4-o'clock positions or the 8- and 10-o'clock positions such that they were completely clear of the lid margin. Preference will be given to iris crypts, avoiding iris vessels when possible. Laser peripheral iridotomies will be performed in both eyes during the same visit and will be confirmed to be patent after the procedure. Intraoperative data collected will include initial per-shot laser energy in milli joules, number of laser shots, and total laser energy in millijoules. All the patients will be treated with flurometholone 0.1% eye drops QID for 5 days after surgery.
45961894|NCT04735627|Device|Levodopameter|The device is a microneedle sensor that can detect levodopa levels in the interstitial fluid.
45961895|NCT04716699|Procedure|Biospecimen Collection|Undergo collection of blood and tumor samples
45961896|NCT04716699|Drug|Lidocaine|Given IV
45961897|NCT04716699|Procedure|Resection|Undergo surgical resection per standard of care
45961898|NCT04702191|Behavioral|Triple P|Triple P - level 4 group is a group-based parenting intervention for families with children who exhibit behavioural or emotional difficulties. Group sessions typically focus on topics such as positive parenting, helping children develop, managing misbehaviour, and planning ahead. Practitioners then provide individual feedback on progress using positive parenting strategies and goal setting. Trained practitioners will deliver the program according to the manualized protocol (Turner, Markie-Dadds, & Sanders, 2010). This will include eight weekly sessions with maximum of 12 parents. The first four sessions will be as group sessions. These four group sessions will be followed by three one-to-one practical and personalised telephone consultations. Finally, there will be one group session, which will complete the programme and parents' contact with the Triple P practitioners. The main aim of this session is to review progress and plan for the future.
45665544|NCT02513459|Drug|Risankizumab 600 mg IV|Re-induction treatment; 3 infusions every 4 weeks, after which eligibility was assessed if clinical response was re-gained
45665545|NCT02513459|Drug|Risankizumab 180 mg SC|Maintenance treatment every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
45665546|NCT02104557|Other|Non intervention|Non intervention
45665547|NCT02104557|Other|Non intervention|Non intervention
45961899|NCT04702191|Behavioral|Circle of Security Parenting|Circle of Security - Parenting (COS-P) will be delivered according to the protocol outlined by Cooper, Hoffman and Powell (Cooper et al., 2009). COS-P is a manualized eight-session parent-education group program which has the same broad aims and core components of the COS-Intensive model from which it was developed (i.e., to increase caregiver sensitivity and responsiveness to child cues, empathy for the child by supporting parental reflective functioning, recognition and understanding of child attachment cues, and awareness of the impact of the caregiver's own attachment history on caregiving patterns). The program is led by one or two facilitators and includes 10-12 caregivers. The program uses clinical DVD clips of problematic parent-child interaction and healthy alternatives to illustrate attachment patterns and parenting styles, and to promote group discussion.
45961900|NCT04700111|Device|DOT Pattern|DOT Pattern Spectacle Lens
45961901|NCT04700111|Device|Control Spectacles|Control lens
45961902|NCT04691817|Drug|Atezolizumab|1200mg infusion
45961903|NCT04691817|Drug|Tocilizumab|Tocilizumab 6mg/kg or 4mg/kg infusion
45665548|NCT04209023|Device|Transcranial Magnetic Stimulation|Individual pulses (100% motor threshold intensity, continuous temperature of 24 degrees C) will be delivered upon the presentation of the stimulus or the verbal command for the language tasks. Two research coordinators will perform the intervention, with one coordinator presenting the stimulus/giving commands, and the other positioning the TMS coil and delivering the individual pulse or pulse trains. The stimulus presentation will last for a duration of 1 second, in conjunction with the time-course of the pulse's disruption. One or both research coordinators must track the successful or unsuccessful inhibition of task completion for each trial. The number of trials may vary depending on task and region-of-interest; however the intervention is not to exceed a total of 20 minutes.
45665549|NCT04982081|Biological|hiPSC-CM therapy|20 patients with congestive heart failure who met the inclusion and exclusion criteria will be recruited. After being fully informed and signed the informed consent, the patients will be randomly divided into two dosage groups: 100 million cells (10 patients) and 400 million cells (10 patients). Human iPSC-derived cardiomyocytes will be injected into the myocardium through a transcatheter endocardial injection system.
45665550|NCT04725513|Device|Shockwave Therapy|Participants will receive shockwave therapy once a week for three weeks
45961904|NCT04685980|Procedure|spinal anaesthesia with local anaesthetic and intrathecal morphine|Patients undergoing cesarean delivery and received spinal anaesthesia with local anaesthetic and intrathecal morphine
45961905|NCT04673552|Procedure|laparotomy|Any open procedure such as laparotomy or lumbotomy for acute necrotizing pancreatitis will be evaluated, with assessment of results, complications and deaths
45961906|NCT04657692|Procedure|Anesthesia; general or regional|General anesthesia: general anesthesia with endotracheal tube Regional anesthesia: spinal anesthesia, epidural anesthesia, combined spinal epidural anesthesia
45961907|NCT04652570|Drug|VB119|Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study.
45961908|NCT04629703|Drug|Fostamatinib|Fostamatinib (150 mg twice daily) for 14 days and Standard of Care
45961909|NCT04629703|Drug|Placebo|Placebo (twice daily) for 14 days and Standard of Care
45961910|NCT04627974|Device|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
45961911|NCT04626934|Other|specific cognitive intervention|The intervention will include all together 12 sessions, each being 45 minutes, for a total of 3 weeks. The intervention will include: 4 treatments in the area of memory and attention, 4 treatments in the area of problem solving, 4 treatments in the area of planning and analysing.
45961912|NCT04626934|Other|conventional occupational therapy treatment|The intervention will include all together 12 sessions of conventional occupational therapy treatments, each being 45 minutes, for a total of 3 weeks.
45961913|NCT04614103|Biological|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145), followed by IL-2.
45961914|NCT04614103|Biological|LN-145|A tumor sample is obtained by image-guided core biopsy from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145) followed by IL-2.
45665551|NCT04725513|Device|Photobiomodulation Therapy|Participants will receive photobiomodulation therapy twice a week for three weeks
45665552|NCT04725513|Other|Physical Therapy|Participants will enroll in physical therapy and complete an at-home exercise protocol
45665553|NCT04725201|Drug|Intravenous unfractionated heparin|See experimental arm description for intervention description.
45961915|NCT04607590|Other|Best Practice|Receive usual care
45961916|NCT04607590|Procedure|Quality-of-Life Assessment|Ancillary studies
45961917|NCT04607590|Other|Questionnaire Administration|Ancillary studies
45961918|NCT04607590|Procedure|Yoga|Participate in yoga sessions
45961919|NCT04603209|Radiation|Intraoperative Radiation Therapy (IORT)|IORT involving 50kV Xrays to a dose of 20 Gy during breast-conserving surgery
45961920|NCT04598854|Device|Intravascular laser irradiation of blood|Low intensity intravascular laser irradiation of blood phototherapy is a method of a 632.8 nm red light penetrate into a vein through fiber and the brightness is 100 fold of the sun. The light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes.
45961921|NCT04598854|Device|Intravascular laser irradiation of blood (Sham)|zero intensity of the laser energy
45961922|NCT04577690|Drug|Bupivacaine 0.25% with epinephrine 1:200000 by PECS block and wound infiltration|The anesthesiologist will administer bupivacaine 0.25% with epinephrine 1:200000 by PECS block after induction of anesthesia before surgical incision. The EP cardiologist will also administer bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
45961923|NCT04577690|Drug|Bupivacaine 0.25% with epinephrine 1:200000 by wound infiltration only|The EP cardiologist will administer Bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
45455342|NCT04967144|Diagnostic Test|Montreal Cognitive Assessment Test|Montreal Cognitive Assessment Test evaluates eight separate cognitive functions. Thirty is the highest score. The scores equal to or above 26 are considered normal cognitive function.
45665554|NCT04725201|Drug|Sham|See sham comparator arm description for intervention description.
45665555|NCT05006105|Device|seven-day ECG Holter|Participants receive a seven-day ECG Holter after hospital discharge.
45665556|NCT05006105|Device|24-hour blood pressure monitor|Participants receive a 24-hour blood pressure monitor, approximately four weeks after hospital discharge.
45665557|NCT05006105|Other|Questionnaire: vision of mHealth|Participants receive a questionnaire concerning their vision of mHealth, approximately four weeks after hospital discharge.
45665558|NCT05006105|Other|Questionnaire: user experience & feeling of safety|Participants receive a questionnaire concerning their user experience and feeling of safety of using mHealth, after using mHealth for six months.
45665559|NCT05006105|Device|Insertable loop recorder|Participants receive an insertable loop recorder, approximately six weeks after hospital discharge.
45665560|NCT02069379|Drug|Metformin|Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.
45961924|NCT04575896|Drug|Glecaprevir/pibrentasvir|Glecaprevir/pibrentasvir 300mg/120mg once daily by mouth for 2 weeks post-transplant.
45665561|NCT02069379|Drug|Placebo|Placebo capsules prepared identically to Metformin capsules
45961925|NCT04565509|Behavioral|General Communication Message|A messaging strategy will be developed from focus groups that generally describes COVID-19 and the importance of testing.
45961926|NCT04565509|Behavioral|Focused/Targeted Message|A messaging strategy that is developed from focus groups that is targeted to address specific concerns of the different communities. Messages may target groups being tested (staff versus students) or sociodemographic or race/ethnicity differences between schools depending on the focus groups input.
45961927|NCT04565509|Behavioral|Best Message Alone|The best message will be either the general or focused/targeted message described above.
45961928|NCT04565509|Behavioral|Best Message + Augmented Message or Implementation Strategy|The augmented messaging and implementation strategies will be informed by the barriers and facilitators identified based on the CFIR domains and results of focus groups and surveys in Aim 2.
45820686|NCT00378781|Drug|Heparin|Heparin flush solution into CVC once daily.
45665562|NCT02511431|Drug|Lonafarnib|prenylation inhibitor to be administered daily at doses of 50 mg, 75 mg or 100 mg.
45665563|NCT02511431|Drug|Ritonavir|FDA approved drug for use of boosting other drugs. Will be used to boost Lonafarnib as they both use the same cytochrome P450 system. Will be administered at 100 mg daily.
45665564|NCT02511431|Other|Placebo|Placebo
45665565|NCT05005247|Biological|GBS-NN/NN2|GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
45820687|NCT00378781|Drug|Minocycline-EDTA|M-EDTA flush solution into CVC once daily.
45820688|NCT05750966|Drug|very short-course of standard of care antibiotics (24 hours)|The duration of antibiotics is 24 hours after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
45820689|NCT05750966|Drug|standard course of standard of care antibiotics (4 to 7 days)|The duration of antibiotics is 4 to 7 days after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
45820690|NCT00002564|Other|educational intervention|
45820691|NCT00002564|Procedure|therapeutic dietary intervention|
45820692|NCT00377923|Drug|Progesterone|
45820693|NCT05750888|Behavioral|integrated exercise therapy with 3D printing exerciser for training intrinsic foot muscles|The therapeutic exercise program with a custom-made 3-D printing foot core exerciser, consisting of warm-up exercise, active range of motion in the foot and ankle joints, foot core system strengthening program using the 3D printing device, and stretching exercises for foot and ankle.
45820694|NCT05750888|Behavioral|regular exercises for the elderly|The regular exercise provided for the elderly in the dwelling community, including walking, simple aerobic exercises, stretching exercises
45820695|NCT03990415|Behavioral|Exercise|Exercise is a behavioral intervention, the primary aim of this investigation is to elucidate if strength training is a more effective exercise intervention than walking for the improvement of balance in older adults.
45820696|NCT00002570|Drug|fluorouracil|425 mg/m2 IV by bolus injection daily for 5 consecutive days q 28 days
45820697|NCT00002570|Drug|leucovorin calcium|20 mg/m2 IV - number of cycles is determined by patient and physician
45820698|NCT05750810|Other|Severe exacerbation frequency|A severe exacerbation will be primarily defined as a hospitalization (with or without ICU) or an emergency department visit as a result of worsening of COPD symptoms.
45820699|NCT04002973|Device|INVSENSOR00037|Noninvasive regional oximeter.
45820700|NCT00002576|Drug|cyclophosphamide|
45820701|NCT00002576|Drug|doxorubicin hydrochloride|
45820702|NCT00002576|Drug|mitoxantrone hydrochloride|
45820703|NCT00002576|Drug|prednisolone|
45665566|NCT02137785|Drug|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
45665567|NCT02137785|Drug|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
45820704|NCT00002576|Drug|vincristine sulfate|
45820705|NCT03977935|Device|the second-generation MCCG|Patients in the experimental group swallowed the second-generation MCCG (Ankon Navicam-2).
45820706|NCT05750732|Behavioral|Weight loss diet|Participants in the study group will be given training on the weight loss diet, which is a routine part of their treatment.
45820707|NCT03985657|Device|CPAP|Continuous positive airway pressure (CPAP). Room air at pressures between 6-8 centimeters of water (cmH2O) delivered via heated humidified tubing and a nasal mask.
45820708|NCT00002582|Drug|CMF regimen|
45820709|NCT00002582|Drug|cyclophosphamide|
45820710|NCT00002582|Drug|doxorubicin hydrochloride|
45820711|NCT00002582|Drug|fluorouracil|
45820712|NCT00002582|Drug|goserelin acetate|
45820713|NCT00002582|Drug|leuprolide acetate|
45820714|NCT00002582|Drug|methotrexate|
45820715|NCT00002582|Drug|tamoxifen citrate|
45820716|NCT00002582|Procedure|oophorectomy|
45820717|NCT00002582|Radiation|radiation therapy|
45820718|NCT02249377|Other|Platelets-Rich-Plasma|Platelet-Rich Plasma
45820719|NCT02249377|Drug|Corticosteroid|Corticosteroid
45820720|NCT05750654|Device|Small Phlebotomy Tube Group|"In the small tubes group, the recommended blood volumes are 0.5 mL for hematology and single chemistry tests, and 1 mL when multiple chemistry tests are needed. A, a non-formulary medication order will be placed in the electronic medical record to alert nurses to collect blood in small tubes. Participants will continue to use small tubes anytime they are in the ICU or IMU."
45820721|NCT05750654|Device|Standard Phlebotomy Tube Group|In the standard tubes group, the recommended blood volumes are 4.0 mL for hematology and 3.0 for chemistry tests.
45820722|NCT00002588|Drug|etoposide|
45820723|NCT00002588|Drug|topotecan hydrochloride|
45820724|NCT02239627|Drug|Epidural steroid|
45820725|NCT02239627|Drug|Clonidine|
45820726|NCT05750576|Device|Chlorhexidine-impregnated dressings|Sterile adhesive transparent dressings impregnated with Chlorhexidine Gluconate gel applied to ECMO cannulae for up to 7 consecutive days for each dressing, in the absence of exudation or bleeding at the point of insertion and until explantation of the ECMO, sometimes requiring dressing changes.
45820727|NCT05750576|Device|Non impregnated dressings|Single transparent adhesive dressings not impregnated with Chlorhexidine Gluconate applied to ECMO cannulae for up to 7 consecutive days for each dressing, in the absence of exudation or bleeding at the point of insertion and until explantation of the ECMO, sometimes requiring dressing changes.
45820728|NCT00002594|Biological|Sargramostim|Given IV
45820729|NCT00002594|Drug|cyclophosphamide|Given IV
45820730|NCT00002594|Drug|melphalan|Given IV
45961929|NCT04549181|Behavioral|Phase II: Problem-Solving for Rural HF Dyads|Participants in the Intervention Group will be trained to use a 4-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems collaboratively over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Dyadic problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this dyadic intervention is to move HF dyads toward a positive problem orientation and use of rational problem-solving strategies that support greater patient and family caregiver-contributed HF self-care.
45961930|NCT04547816|Procedure|Biofeedback therapy|Biofeedback therapy is a procedure when the patient is taught to make proper squeezing by adequate increase of intra-abdominal and rectal pressures and relaxation of the muscles of the pelvic floor. This procedure is widely described and is to be performed with the use of devices registered for this purpose Urostim and WPM Solar, MMS, the Netherlands
45665568|NCT02137785|Device|Blue Light Photodynamic Therapy Illuminator (BLU-U)|10 J/cm2 blue light delivered at 10mW/cm2
45665569|NCT05003453|Drug|1.5% Palmitoylethanolamide (PEA) sold as Levagen+|A topical cream containing 1.5% PEA applied to the affected site 2-times daily, liberally to coat and cover affected area.
45665570|NCT05003453|Drug|Placebo Comparator|A comparator placebo topical moisturiser cream (an unscented moisturising base cream) applied to the affected site 2 times daily, liberally to coat and cover affected area.
45665571|NCT01655069|Drug|Solifenacin succinate suspension|Oral suspension
45961931|NCT04547816|Procedure|Tibial neuromodulation|TNM is a standard procedure that is previously described as an effective method to treat functional insufficiency of the anal sphincter. It acts on the lumbosacral nerve plexus with an electric current through the posterior tibial nerve of one of the patient's limbs. For the study purpose a registered device for electric therapy (BioBravo, MTR Plus Vertriebs GmbH, Germany) is to be used.
45961932|NCT04547816|Behavioral|Pelvic floor muscles training|"PFMT is a complex of 5 exercises aimed to make functional training of pelvic floor muscles. This complex does not require additional equipment. It may be performed at home. The patients will be trained to perform this complex of exercises by a healthcare provider.~The complex of physical therapy consists of a single basic exercise for training coordinated muscle tension of abdominal wall and relaxation of the pelvic floor muscles, and 4 exercises to increase the contractility of pelvic floor muscles without additional involvement of the muscles of the abdominal wall. This allows to coordinate and consciously control the contraction and relaxation of the pelvic diaphragm. Initial course of training is 10 working days. Than patients continue the intervention for 6 months at home with online monitoring of the correctness and regularity of training."
45961933|NCT04547816|Behavioral|Diet modification|Diet modification play an important role in the regulation of colonic transit and defecation. Dietary factors may act through faecal bulk by additional stimulation of mechanoreceptors of the rectum. At the same time, adequate intake of vitamins (for example, B12) may improve electric conductivity of nerves and thus impact the tone of pelvic floor muscles. Among other factors known to affect functional state of pelvic floor muscles and colonic transit are dietary fibers, adequate intake of water, regular meal intake. For the study purposes, it is planned to provide standard recommendation based on the national recommended daily allowances according to patients' sex, age and physical activity level.
45961934|NCT04531176|Other|Weight Management Program (WMP)|Weight Management Program (WMP)
45961935|NCT04531176|Other|Traditional care|Traditional care
45455343|NCT04467580|Diagnostic Test|abdominal [18F]FDG PET/CT|Patients will have within a maximum period of 15 days before the surgery (resection of intestinal stenosis), records by MRI and by digital PET/CT with low injected activity of [18F]FDG, focused on the abdomen, the MRI will be performed maximum 30 days before the intervention (if available and performed according to the procedure for the study, it will not be repeated for the study).
45665572|NCT02068599|Drug|TV-45070|TV-45070 ointment administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
45665573|NCT02068599|Drug|Placebo|Placebo ointment matching active intervention administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
45665574|NCT04708509|Device|Extubation Advisor|Participants undergoing a Spontaneous Breathing Trial (SBT) to assess readiness for extubation will be connected to a portable monitor displaying ECG, capnography, and other waveforms. This monitor will also be connected to a laptop containing the Extubation Advisor (EA) software. During the SBT, relevant patient information will be entered into the EA application and the EA application will record waveform data. When the SBT is complete, the EA application will analyze the waveform and patient data to generate a score summarizing the risk of extubation failure. A report will be generated and provided to the respiratory therapist and attending physician to help determine whether to proceed with extubation or not. Patients will be followed for 72 hours after extubation, when the clinical outcome case report form will be completed.
45820731|NCT00002594|Procedure|autologous bone marrow transplantation|
45820732|NCT00002594|Procedure|bone marrow ablation with stem cell support|
45820733|NCT00002594|Procedure|peripheral blood stem cell transplantation|
45820734|NCT02234011|Drug|Ketamine|
45820735|NCT02234011|Drug|Placebo|
45820736|NCT02198833|Biological|Urine Culture|Obtain urine culture every third day
45820737|NCT02198833|Device|Foley Catheter Tip Culture|Catheter Tip Roll Plate Culture
45820738|NCT02198833|Device|Scanning Electron Microscopy|Houston Site Only
45820739|NCT02198833|Procedure|Device Specific Adverse Event Assessment|Assessment will be made of catheter patency and/or trauma related to catheter placement
45820740|NCT02198833|Procedure|Foley Catheter Insertion|Insert Foley catheter for 15 day duration
45961936|NCT04531176|Drug|Phentermine / Topiramate Extended Release Oral Capsule|Medication for chronic weight management (Rx)
45961937|NCT04531176|Drug|naltrexone/bupropion extended-release|Medication for chronic weight management (Rx)
45961938|NCT04531176|Drug|liraglutide 3.0 mg|Medication for chronic weight management (Rx)
45820741|NCT00002600|Biological|filgrastim|
45961939|NCT04531176|Drug|Orlistat|Medication for chronic weight management (Rx)
45665575|NCT01654601|Drug|DWCZP|Multiple dose
45665576|NCT01654601|Drug|Clozaril|multiple-dose
45455344|NCT04956224|Biological|VLA2001|"whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide (Wuhan strain)~2 vaccinations 28 days apart~Booster Vaccination on Visit B1"
45455345|NCT01123837|Other|Intravenous fluid|"The treatment group will receive a 250cc bolus over 2 hrs of D5LR prior to the end of surgery and continued in the PACU. Blood glucose will be checked 3 different times using an Accu-chek monitor along with the type and number of rescue medications given at 30, 60, and 120 minutes after anesthesia and the post-op morning.~The control group will receive a 250cc bolus over 2 hours of LR. Blood glucose will be monitored 3 times along with the type and how much of rescue medications are given at 30, 60 and 120 minutes post-op and the morning after surgery."
45665577|NCT01654523|Device|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania
45665578|NCT04979429|Behavioral|Perioperative Pain Self-management (PePS)|4 sessions of telephone CBT-based pain self-management.
45665579|NCT02068443|Drug|Alogliptin|Alogliptin tablets
45665580|NCT02068443|Drug|Metformin hydrochloride|Metformin hydrochloride tablets
45665581|NCT02068443|Drug|Metformin hydrochloride Placebo|Metformin hydrochloride placebo-matching tablets
45665582|NCT05001113|Procedure|the subxiphoid approach thoracoscopic thymectomy|A 2-cm straight incision was made in the middle of the xiphoid process, the incision was used as a thoracoscope hole, and the xiphoid process could be removed if necessary. The surgeon used the oval forceps to release the left and right soft tissue gaps behind the sternum, from the anterior mediastinum tunnel. Two 0.5 cm extrapleural thoracic ports under the bilateral costal arches were created, and this incision was used as an operation hole. The thread puncture cone with a diameter of 0.5 cm was placed under the guidance of the finger.
45820742|NCT00002600|Drug|carboplatin|
45961940|NCT04472767|Drug|Nivolumab|Given IV
45961941|NCT04472767|Drug|Ipilimumab|Given IV
45961942|NCT04472767|Drug|Cabozantinib|Given PO
45961943|NCT04472767|Procedure|Transarterial Chemoembolization|TACE treatment will be administered using either the DEB-TACE or cTACE modality in a series of up to 3 individual procedures within the 9-12 weeks following Day 21 (= cycle 1 day 21) of a patient's first infusion of nivolumab/ipilimumab. The first TACE treatment should start no more than 7 working days after being cycle 1 day 21.
45961944|NCT04456946|Device|Low Level Laser Therapy|Low Level Laser Therapy
45961945|NCT04456946|Device|Occlusal Splint Treatment|Occlusal Splint Treatment
45961946|NCT04409860|Radiation|CCRT|Radiation concurrent platinum-containing chemotherapy (cisplatin or carboplatin)
45961947|NCT04409860|Drug|Paclitaxel, Cisplatin|The regimen of adjuvant chemotherapy following CCRT is Paclitaxel(150mg/m2 D1), Cisplatin(60mg/m2 D1) , q3w, three cycles.
45665583|NCT05001113|Procedure|the lateral intercostal approach thoracoscopic thymectomy|"Right-side approach: Use the left supine position. The observing port was created at the right axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces.~Left-side approach: Use the right supine position. The observing port was created at the left axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces."
45665584|NCT04978649|Drug|Allisartan Isoproxil|Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.
45820743|NCT00002600|Drug|cyclophosphamide|
45820744|NCT00002600|Procedure|autologous bone marrow transplantation|
45820745|NCT00002600|Procedure|peripheral blood stem cell transplantation|
45820746|NCT02177773|Procedure|Computed Tomography (CT)|Undergo Gallium Ga 68-DOTA-TOC PET/CT
45820747|NCT02177773|Drug|Gallium Ga 68-Edotreotide|Given Intravenously (IV) before imaging
45820748|NCT02177773|Procedure|Magnetic Resonance Imaging (MRI)|Undergo gallium Ga 68-DOTA-TOC PET/MRI
45820749|NCT02177773|Procedure|Positron Emission Tomography (PET)|Undergo gallium Ga 68-DOTA-TOC PET in combination with CT or MRI
45961948|NCT04368195|Procedure|Erector spinae block|Erector Spinae Plane Block (ESPB) - first recently described for the treatment of thoracic neuropathic pain, is a peri-paravertebral regional anesthesia technique that has since been reported as an effective technique for prevention of postoperative pain in various surgeries (10-12). In ESPB, local anesthetic is reported to be administered in to the interfascial plane between the transverse process of the vertebra and the erector spinae muscles, spreading to multiple paravertebral spaces.
45961949|NCT04361487|Device|NOVOSTITCH PRO Meniscal Repair System|Standard of care surgery with in which the meniscus is repaired using NOVOSTITCH PRO
45961950|NCT04360746|Other|Pharmaceutical intervention|Pharmaceutical intervention will include a complete medication review by a clinical pharmacist with the following process: medication reconciliation, medication indication and dosage check, medication effectiveness and appropriateness assessment, drug-drug or drug-disease interactions check, medication duplications check, length and cost of treatment evaluation. The pharmacist will use the following tools: Medication appropriateness index (MAI), ACB (Anticholinergic cognitive burden) score and the using the assessment of underutilization (AOU) index.
45961951|NCT04360746|Other|Rehabilitation|A multidisciplinary team provided medical, nursing, physical, occupational, and social work interventions. Rehabilitation care include: (a) individual physical therapy (PT), 2 to 3 times a week; (b) 30 to 40 min of PT in an adapted fitness room, aerobic training on a treadmill with and without partial weight support and stationary bicycles, 2 to 3 times a week ; (c) 30 to 40 min of virtual reality training by performing challenging functional tasks, 2 times a week and (d) 30 to 45 min of individual occupational therapy (OT), cognitive evaluation and stimulation, safety education, and learning to use assistive devices, 3 times a week.
45820750|NCT00382226|Drug|Azopt|
45820751|NCT05750498|Other|No interventions|There are no interventions
45665585|NCT04978649|Drug|Amlodipine|Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
45820752|NCT02144155|Drug|Oxytocin: 24IU - 168 IU|Oxytocin: 24IU - 168 IU
45820753|NCT02144155|Drug|Placebo|placebo drug
45820754|NCT00002618|Biological|filgrastim|
45820755|NCT00002618|Drug|cytarabine|
45961952|NCT04315506|Behavioral|SGR|The SGR program will reduce smokeless tobacco use by 1/4 until you reach zero. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.
45961953|NCT04315506|Behavioral|Control|Participants will be sent the Enough Snuff cessation manual. One weeks after it is sent, participants will then receive text messages from the study team twice a week for five weeks.
45665586|NCT04978415|Procedure|peribulbar block versus subtenon's block|"Sixty patients undergoing vitreoretinal surgery were randomized to receive either peribulbar or sub-Tenon's capsule injection of 8 ml of a 20:80 mixture of 2% lidocaine and 0.75% bupivacaine with 60 IU hyalouronic acid.~two groups 30 patient each (group p and group s) after connecting the patient to the monitor, we give him sedation 50 mg propofol, apply a nasal cannula group P: receives 2 injection peribulbar block group S: receives single injection subtenon Patients rate their pain sensation in both groups using an 11-point (0-10) numerical visual analogue scale immediately after surgery."
45665587|NCT02508935|Drug|XARTEMIS XR|XARTEMIS XR [7.5 mg oxycodone hydrochloride and 325 mg acetaminophen (APAP)] Extended-Release Tablets
45665588|NCT02508701|Behavioral|Message X Onsite/Offsite Vaccination|Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination
45820756|NCT00002618|Drug|doxorubicin hydrochloride|
45820757|NCT00002618|Drug|leucovorin calcium|
45820758|NCT00002618|Drug|mercaptopurine|
45820759|NCT00002618|Drug|methotrexate|
45820760|NCT00002618|Drug|prednisone|
45820761|NCT00002618|Drug|vincristine sulfate|
45820762|NCT00002618|Radiation|low-LET cobalt-60 gamma ray therapy|
45820763|NCT00002618|Radiation|low-LET electron therapy|
45820764|NCT00002618|Radiation|low-LET photon therapy|
45820765|NCT02145169|Drug|Inhaled Nitrous Oxide|Patients undergoing procedural sedation with Ketamine will receive inhaled Nitrous Oxide
45820766|NCT05750342|Dietary Supplement|Experimental Product Caqui|Supplement extracted from persimmon
45961954|NCT04312867|Behavioral|Project STRONG|Project STRONG is a 6-module web-based, dyadic intervention for middle school boys and their parents to complete. Its goal is primary prevention of adolescent dating violence by targeting parent-child communication and emotion regulation ability.
45455346|NCT01123837|Other|D5LR or lactated ringers|"The purpose of the study is to see if giving dextrose fluid in the veins (IV) decreases the risk of postoperative nausea and vomiting (PONV) in female urologic, gynecologic and breast outpatient surgery patients and at what blood sugar level.~The reason for this study is that IV dextrose may decrease the incidence of PONV and the use of medications to treat PONV, while leading to sooner discharge after surgery. This can decrease overall healthcare cost and improving patient satisfaction."
45961955|NCT04312867|Behavioral|Health Promotion|Health promotion is a 6 module web-based, health information program designed to provide health content similar to that provided in a middle school health class. This program is designed to mirror Project STRONG for time and delivery method.
45820767|NCT05750342|Dietary Supplement|Control product placebo|Product with identical characteristics to the experimental product.
45665589|NCT05000333|Other|Self-questionnaire|The study will be proposed to caregivers who work at Centre Hospitalier Intercommunal de Villeneuve-Saint-Georges, who agree to answer the questionnaire anonymously
45665590|NCT02507375|Drug|Erlotinib|Erlotinib will be administered as oral tablets.
45665591|NCT02507375|Drug|Pertuzumab|Pertuzumab will be administered as intravenous (IV) infusion.
45665592|NCT05000177|Other|30-minute computer typing task|The subject sits in front of a computer screen and perform computer typing tasks for 30 minutes. The same computer table and chair were used for all subjects. The height of the table and screen, and the distance of the keyboard from the subject were adjusted according to their familiar and comfortable position.
45665593|NCT05000177|Other|30-minute rest|Rest for 30 minutes
45665594|NCT02507219|Drug|Ibuprofen|On the day of sessions 2-4, subjects will receive either placebo, 200 mg of ibuprofen or 600 mg of ibuprofen after signing the consent form for this study in a randomized, double-blind, counter balanced order. Each study session will occur 1-2 weeks following the previous session. Ibuprofen will be capsuled, and identical placebo capsules will be produced.
45820768|NCT02110069|Drug|Vincristine|Vincristine dose dependent upon weight. Weekly for 2 months (Induction); Weekly 2 months; every 2 weeks for next 5 months; every 3 weeks for 5 months (Maintenance)
45961956|NCT04311099|Drug|Active drug|Injection of Ropivacaine
45961957|NCT04311099|Drug|Placebo|Injection of Saline solution
45961958|NCT04311099|Procedure|Injection of Ropivacaine - Ultrasound-guided transverse abdominal plane block|Lateral ultrasound-guided transverse abdominal plane block 40 ml ropivacaine 2 mg / ml
45665595|NCT02483975|Drug|FF|FF will be provided as a dry powder inhaler with 30 doses per device, each containing 50 mcg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
45665596|NCT02483975|Drug|Placebo|Placebo will be provided as dry powder inhaler with 30 doses per device, each containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
45665597|NCT02483975|Drug|Montelukast|Montelukast will be provided as 4 mg and 5 mg chewable tablets.
45665598|NCT02483975|Drug|Albuterol/Salbutamol|Albuterol/Salbutamol will be provided as inhalation aerosol.
45665599|NCT02047227|Drug|Pergoveris®|Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 International Unit (IU) recombinant human follicular stimulating hormone (rhFSH)/ 150 IU recombinant human luteinizing hormone (rhLH) after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 millimeter (mm); 250 microgram (mcg) of r-hCG (Ovidrel) was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject's response per site standard clinical practice.
45820769|NCT02110069|Drug|Sirolimus|Continuous dosing to maintain trough level of 10-15ng/ml.
45820770|NCT00002624|Procedure|adjuvant therapy|
45820771|NCT00002624|Procedure|diagnostic thoracoscopy|
45961959|NCT04311099|Procedure|Injection of Ropivacaine - Laparoscopic assisted transverse abdominal plane block|Laparoscopic assisted subcostal transverse abdominal plane block 40 ml ropivacaine 2 mg / ml
45961960|NCT04311099|Procedure|Injection of placebo - Ultrasound-guided transverse abdominal plane block|Lateral ultrasound-guided transverse abdominal plane block with saline solution
45961961|NCT04311099|Procedure|Injection of placebo - Laparoscopic assisted transverse abdominal plane block|Laparoscopic assisted subcostal transverse abdominal plane block with saline solution
45820772|NCT00002624|Procedure|therapeutic thoracoscopy|
45961962|NCT04307212|Other|50% heart rate reserve (HRR) low intensity exercise|Trained and untrained participants will exercise at a constant load intensity of 50% HRR (low intensity)
45455347|NCT03524638|Other|Visbiome|Colorectal surgery plus administration of Visbiome on post-operative day 2.
45820773|NCT00002624|Procedure|video-assisted surgery|
45820774|NCT00002624|Radiation|radiation therapy|
45820775|NCT00002630|Biological|filgrastim|
45820776|NCT00002630|Drug|cyclophosphamide|
45820777|NCT00002630|Drug|melphalan|
45820778|NCT00002630|Procedure|peripheral blood stem cell transplantation|
45820779|NCT00002630|Radiation|low-LET cobalt-60 gamma ray therapy|
45820780|NCT00002630|Radiation|low-LET photon therapy|
45961963|NCT04307212|Other|75% HRR moderate intensity exercise|Trained and untrained participants will exercise at a constant load intensity of 75% HRR (moderate intensity)
45665600|NCT02047227|Drug|GONAL-f®|GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject's response per site standard clinical practice.
45665601|NCT02047227|Drug|Recombinant human chorionic gonadotrophin (r-hCG)|On r-hCG day, 250 mcg of r-hCG was administered once subcutaneously
45961964|NCT04307212|Other|Control no exercise|Trained and untrained participants will have a no exercise control day
45961965|NCT04303559|Drug|Eloctate Injectable Product|This is a factor VIII-Fc fusion protein.
45961966|NCT04303559|Drug|Emicizumab Injection [Hemlibra]|This is a bispecific monoclonal antibody FVIII mimic.
45961967|NCT04303390|Drug|Cefuroxime|second generation cephalosporin
45665602|NCT02483585|Drug|Erenumab|Administered once a month by subcutaneous injection
45665603|NCT02483585|Drug|Placebo|Administered once a month by subcutaneous injection
45961968|NCT04303390|Drug|Cefazolin|First generation cephalosporin
45961969|NCT04303390|Other|24 hours|Duration of antibiotic therapy
45961970|NCT04303390|Other|48 hours|Duration of antibiotic therapy
45961971|NCT04282967|Behavioral|Exercise|For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.
45961972|NCT04234139|Procedure|liver transplant|solid organ transplant
45961973|NCT04230785|Genetic|Sequencing of circRNA/lncRNA/miRNA|Next generation sequencing and quantitative real-time polymerase chain reaction of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA)
45961974|NCT04221204|Drug|Highly selective FGFR1-3 inhibitor|All subjects in each cohort will receive a single oral dose of 3D185, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive daily doses (Once daily [QD], 28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first. The dose limiting toxicity (DLT) evaluation period includes the single-dose PK study period and the first treatment cycle (within 35 days after the first dose). The enrolled subjects will be sequentially assigned to the planned dose cohorts according to the protocol and receive 3D185 treatment to observe the occurrence of DLT.
45961975|NCT04185298|Behavioral|mSIM intervention plus activity monitoring|Participants will receive the full mSIM intervention and be monitored (via Fitbit)
45961976|NCT04185298|Behavioral|Activity monitoring|Participants will have activity monitored (via Fitbit)
45665604|NCT02046993|Behavioral|Smart phone telemonitoring HBP + enhanced usual care|Smart phone telemonitoring home Blood pressure (HBP) Patients input their HBP readings to their smart phone which is sent to the data center regulary
45665605|NCT02046993|Behavioral|Enhanced usual care|Encouraged to do HBP measurement and record BP readings in paper diary
45665606|NCT02101983|Drug|Cytosine Arabinoside|
45665607|NCT04974593|Other|low fat diet|A trained dietitian will provide instruction of the LFD according to standard practice.
45961977|NCT04175691|Genetic|Sequencing of circRNA/miRNA/lncRNA|Next generation sequencing of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA)
45961978|NCT04165746|Other|Foster Care|"Upon entry into the Child Protection System, if the child is assigned to one of the districts participating in the RCT, the court will notify the study team. Children that have been randomly assigned to Foster Care will be placed in a foster home within 48 hours of referral to the Family Court/Child Protection System.~Children and Foster Parents will receive biweekly visits from Social Workers. Children and Foster parents will also participate in the caregiving intervention described below. Children will remain in the placement until such time as the social workers, psychologists and Family Court Judge determine that one of the following outcomes is appropriate: reunification with biological family or adoption."
46079677|NCT04524091|Other|Positive end expiratory pressure|Initially, the patients will be ventilated using pressure support ventilation with an inspiratory pressure adjusted to achieve 6 - 8 ml/kg of PBW with a minimal esophageal pressure swing of 5 cmH2O and a PEEP of 5 cmH2O. After 5 minutes, we will measure five IPSexp and five IPSinsp in random order and considering a resting period between each occlusion in order to avoid learning effect and disconfort. The IR will be calculated using the average of the measured IPSexp and the average of the IPSinsp. Besides, we will register the average of esophageal pressure and transpulmonary pressure swings continuously. The same procedure will be carried out with 10 and 15 cmH2O of PEEP. Inspiratory pressure will be kept constant throughout the protocol.
45665608|NCT04706793|Drug|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks
45665609|NCT04706793|Drug|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks
45820781|NCT02047747|Drug|Dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
45820782|NCT05750186|Other|Abdominal Massage|Abdominal massage is a noninvasive application that stimulates bowel movements by applying patting, kneading and vibration movements over the abdominal wall to the area where the intestines are located. It increases peristalsis, creates a mechanical and reflex effect on the intestines, reducing the individual's feeling of pain and discomfort.
45820783|NCT00002642|Drug|cisplatin|50 mg/m2, IV Days 1 and 8, two 28 day cycles prior to surgery and two 28 day cycles after surgery
45820784|NCT00002642|Drug|etoposide|50 mg/m2, IV Days 1-5, two 28 day cycles prior to surgery and two 28 day cycles after surgery
45961979|NCT04165746|Behavioral|Caregiving Intervention|During AVI an intervenor meets with a caregiver (foster parent or caregiver at the institution) and child in the home environment. During each session, the intervenor videotapes the caregiver and child doing play-based activities. During that meeting, the intervenor reviews the videos with the caregiver and provides positive, constructive feedback to the caregiver. AVI is aimed at increasing sensitivity in parents/caregivers in order to encourage positive interactions. The guiding principles are to create a positive environment and to convey that the caregiver is the expert on their own child. The AVI methodology was selected to be used as a method of caregiving intervention with the study participants due to its demonstrated results in its use with children in contexts of social vulnerability, as well as families included in the child protection system. This will be the first time that AVI is being used in foster and institutional care in Brazil.
45961980|NCT04093167|Drug|Pembrolizumab|200mg IV 2 mg/kg IV 400 mg IV 4 mg/kg IV
45665610|NCT04974281|Combination Product|PD-1 and Lenvatinib Plus TACE|PD-1 Antibody and Lenvatinib Plus Transarterial chemoembolization(TACE )： Patients were recommended to receive TACE once every 6 weeks. Patients were recommended to begin oral administration of Lenvatinib 3 days after the first TACE treatment, and meanwhile to start intravenous drip of PD-1 antibody 3 days after the first TACE treatment, once every 3 weeks.
45820785|NCT00002642|Procedure|conventional surgery|surgery some time between weeks 9 and 12
45961981|NCT04092946|Device|Digital intervention|"Individuals included will be offered a program based on three pillars: education, cognitive-behavioural therapy (CBT) and therapeutic exercise.~The therapeutic exercise component will be delivered in the form of exercise sessions to be performed independently by the individual at home using SWORD Phoenix. These programs will have a duration of between 8 and 12 weeks, according to the condition, following pre-defined protocols. These protocols can be adapted to the needs, performance and progress of each individual by their assigned physical therapist. Individuals will be asked to perform at least 3 exercise sessions per week, in different days, but will not be excluded in case of lower adherence.~In addition to the exercises, the individuals will also have access to educational articles written by the clinical team, as well as to a CBT program delivered through a combination of written articles and pre-recorded audio sessions."
45961982|NCT04091165|Other|My Plate Calorie Tracker|"My Plate Calorie Tracker is a user-friendly weight management, calorie record application, available for smart phone devices. Users have the option to input items manually (i.e., calories, carbohydrates, fats, and proteins), select from a list of popular food items, or scan barcodes on the food packaging. In addition to food entries, users can also enter daily water intake and physical activities. Once an account is created, data entered into the mobile application can be sync'd to the My Plate Calorie Tracker website."
45961983|NCT04088149|Drug|GXNPC1|Autologous ADSCs
46079678|NCT04514549|Device|Emerald|The Emerald is a wireless sensor that can track the motion, breathing, and sleep of subjects without touching or requiring any interaction with the subjects, allowing them to go about their normal lives. The physical device is roughly a 30 x 35 x 5 cm box that contains directional antennas and a motherboard to process these signals. In typical operation, the device is mounted onto a wall within a clinic or home setting using peel-away (reversible) mount strips.
46079679|NCT04498117|Biological|Oregovomab|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
45665611|NCT02482805|Behavioral|Cognitive Behavioral Therapy|Exposure therapy for social anxiety disorder
45665612|NCT02503865|Drug|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin|Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day
45665613|NCT02503865|Dietary Supplement|"Analimentary detoxication"|Vegetable and salt diet
45665614|NCT01623531|Drug|Fibrinogen|Intravenous concentrated fibrinogen will be infused according to a hemostatic algorithm based on ROTEM (FIBTEM)
45665615|NCT02503787|Device|Spinal Cord Stimulation (SCS)|SCS programming options
45665616|NCT04943471|Other|Big Five Questionnaire, Patient health questionnaire-9 and generalised anxiety disorder -7 questionnaire|Questionnaire
45665617|NCT02482571|Device|Mild Hypoxia|During normoxia, the computer-controlled gas blender provides a gas mixture that generates pressures of expired O2 and CO2 similar to the resting values measured for each subject (32-35mmHg and 100-110 mmHg, respectively). During mild hypoxia, we will target the same expired CO2 of normoxia and a 60 mmHg reduction of expired O2 from the resting value (to a minimum limit of 50 mmHg), which is expected to reduce arterial oxygen saturation to 82-85%. In mild hypoxia, the fraction of inspired oxygen is reduced from ~21% (room air) to ~12% (equivalent to an altitude of 4000 meters). During both conditions of normoxia and mild hypoxia, the brain activity of subjects is monitored with functional magnetic resonance spectroscopy (fMRS) while they are presented with visual stimuli.
45665618|NCT02481947|Drug|BLI400 Laxative|21 gm BLI400 powder
45665619|NCT02481947|Drug|Lubiprostone|24 mcg capsule bid
45665620|NCT02503085|Drug|Nurofen for Children®|
45820786|NCT00002642|Radiation|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, weekly for 5 weeks
46079680|NCT04498117|Drug|Paclitaxel|175 mg/m^2, every 3 weeks
45820787|NCT03983941|Drug|Ropivacaine injection|Total dose not to exceed 3 mg/kg of ropivacaine.
45820788|NCT01434511|Biological|OBI-1|intravenous infusion, up to every 2-3 hours for the first 24 hours of treatment
45820789|NCT02973074|Dietary Supplement|OLEOvital|2sachets with 30mg iron per day for a 4 weeks period
45961984|NCT04086849|Diagnostic Test|Radiomic, pathomic, and clinical markers|This is a non-interventional study.
45961985|NCT04075110|Drug|Montelukast 10mg|Montelukast is an orally dosed drug (available as a chewable tablet) which is FDA-approved for the treatment of chronic asthma and prophylaxis and the prevention of exercise-induced bronchoconstriction. It is also approved for the relief of symptoms of both seasonal and perennial allergic rhinitis.
45961986|NCT04075110|Drug|Placebo|Placebo tablet once daily
45961987|NCT04067479|Dietary Supplement|Amino Acids|Oral bolus of essential amino acids
45961988|NCT04063384|Other|alcohol beverage|Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.
45961989|NCT04063384|Other|Placebo beverage|placebo beverage conditions.
45961990|NCT04055909|Drug|nangibotide low dose|nangibotide 0.3 mg/kg/h
45961991|NCT04055909|Drug|nangibotide high dose|nangibotide 1.0 mg/kg/h
45961992|NCT04055909|Drug|placebo|matching placebo
45455348|NCT03524638|Procedure|Colorectal Surgery|Colorectal surgery alone
45455349|NCT01346930|Drug|Macitentan|10 mg, tablet, once daily
45665621|NCT02503085|Drug|Algifor Dolo Junior®|
45458286|NCT03370952|Procedure|combined laproscopic and minilaparotomy ovarian cystectomy|"Under general anaesthesia, the patient is placed in the modified dorsal lithotomy position a 10-mm umbilical trocar is inserted. A panoramic view of the pelvis was obtained together with full assessment of the ovarian mass(es).~Aspiration of the cyst:Delivery of affected ovary outside the abdominal cavity:~Ovarian cystectomy:~Re-introduction of the ovary to inside the abdominal cavity:"
45665622|NCT02481869|Biological|Arthrocentesis/PRP|PRP (n=20): single intra-articular injection of 5 ml of a leukocyte-reduced platelet rich plasma (ACP, Arthrex, Naples, FL) at the time of closed reduction and initial stabilization using ankle-spanning external fixation
45820790|NCT05750108|Device|Parasym device (active, current (mA) < discomfort threshold)|Active transcutaneous Vagal Nerve Stimulation (tVNS) (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to the ear at 20 hertz (Hz), 250 microseconds (ms) at a current just below discomfort threshold for 30 minutes twice a day, starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
45820791|NCT05750108|Device|Parasym device (sham, current (mA) = 0)|Parasym device will be attached to the ear twice a day, turned on but current set to 0 milliamp (mA), starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
45961993|NCT04054050|Other|Light therapy|Bright light (10,000 lux) therapy will be administered via a light box.
45961994|NCT04013711|Diagnostic Test|Thermography|Thermograms will be acquired of both treated and non-treated cancer site for comparison.
45961995|NCT03997708|Other|Med-LFD|All participants of this group at phase 1 (elimination phase), will initially follow the Med- LFD (2-6 weeks). At phase 2 (reintroduction phase), patients will gradually reintroduce foods rich in FODMAPs (6-8 weeks) and test their tolerance. At phase 3 (maintenance phase), following the reintroduction of foods rich in FODMAPs, patients will follow an individualized diet based on their personal tolerance (a combination of high and low FODMAPs).
45961996|NCT03997708|Other|Nutritional Guidelines of the British National Institute for Health and Care Excellence (NICE) Managing IBS|All participants of this group will be informed to follow a diet based on the nutritional guidelines of the British National Institute for Health and Care Excellence (NICE) for Managing IBS for 4 weeks.
45961997|NCT03991234|Behavioral|Reading Intervention|Reading intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction to build skill on letter-sound associations, decoding, sight words, & contextualized reading.
45961998|NCT03991234|Behavioral|Math Intervention|Math intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction on number knowledge & counting strategies to build arithmetic skill.
45961999|NCT03991234|Behavioral|Coordinated Intervention|Coordinated intervention provides 15 weeks (30-minute sessions per week) of explicit instruction addressing the similar skills as in the reading intervention arm & similar objectives as the math intervention arm.
45820792|NCT02020837|Procedure|Lymphaticovenous Micro-Anastomosis|
45820793|NCT05750030|Combination Product|FMT combined with Atezolizumab plus Bevacizumab|Single FMT from patients with HCC who responded to PD-(L)1-based immunotherapy to patients with HCC who failed to achieve complete or partial response (according to mRECIST) to atezolizumab/bevacizumab. After single FMT, patients will continue to receive atezolizumab/bevacizumab every 21-days according to protocol.
45962000|NCT03989986|Behavioral|iPeer2Peer Mentorship|Mentors and participants can have up to ten Skype calls over the course of 15 weeks.
45962001|NCT03978689|Drug|CUE-101|CUE-101 is a novel biologic to treat HPV - driven recurrent / metastatic head and neck cancer given as monotherapy in parts A&B and in combination in Parts C&D according to the schedule described in the protocol.
46079681|NCT04498117|Drug|Carboplatin|AUC 6 IV Day 1 x 6 cycles (every 21 days)
45820794|NCT02006407|Radiation|Cranial Radiotherapy|Standard cranial radiotherapy administered dependent upon patient and brain tumor type.
45820795|NCT02006407|Device|MRI with Diffusion Tensor Imaging (DTI)|Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI)
45962002|NCT03978689|Drug|Keytruda|Keytruda is first-line therapy in HPV16 and HLA A*0201-positive recurrent and/or metastatic HNSCC patients given in combination with CUE-101 in Parts C&D according to the schedule described in the protocol.
45665623|NCT02481869|Drug|Arthrocentesis/Saline|Control (n=20): single intra-articular injection of 5 ml of sterile 0.9% saline at the time of closed reduction and initial stabilization using ankle-spanning external fixation
45665624|NCT02502149|Biological|rFVIIIFc|As per arm description
45962003|NCT03965481|Radiation|Dynamic Enhanced CT|Undergo standard CECT
45962004|NCT03965481|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI scan
45962005|NCT03965481|Procedure|Positron Emission Tomography|Undergo PET/MRI scan
45962006|NCT03915899|Behavioral|WIN (Welcome Incoming Neighbor)|WINs will conduct active community surveillance to rapidly identify and welcome in-migrants, provide them with information about the availability of CHP, utilize a motivational interviewing approach to encourage CHP adoption, refer in-migrants to free services, and follow-up in-migrants to assess and further encourage engagement in CHP.
45962007|NCT03910387|Drug|Gemcitabine|Given gemcitabine/nab-paclitaxel combination therapy
45962008|NCT03910387|Drug|Nab-paclitaxel|Given gemcitabine/nab-paclitaxel combination therapy
45962009|NCT03910387|Drug|Telotristat Ethyl|Given PO
45962010|NCT03875768|Behavioral|Tracking plus coaching|Participants will track their nutrition intake every day for six months using a study app and receive tailored feedback via text message based on their nutritional intake and adherence to the DASH dietary pattern. If necessary, they will receive responsive coaching from a Nourish registered dietitian in order to increase adherence to the DASH dietary pattern and their engagement with the intervention.
45962011|NCT03861793|Biological|ALKS 4230|SC injection administered in the back of the arm or the abdomen
45962012|NCT03861793|Biological|Pembrolizumab|Administered as an intravenous (IV) infusion over 30 minutes
45820796|NCT02006407|Behavioral|Neuro-cognitive Testing (CogState)|CogState is a computerized software testing system that offers various cognitive assessments based traditional expansive neurocognitive tests.
45962013|NCT03856775|Device|Quantitative EEG and Seizure detector|Paediatric intensive care unit nurses, residents or fellows will perform hourly review of a bedside graphical display of the previous hour's epoch of quantitative EEG for seizure patterns. One page of quantitative EEG data represents one hour of recording. The graphical display will include a seizure-detection marker, seizure probability indicator, bilateral rhythmicity spectrogram and bilateral amplitude integrated EEG.
45820797|NCT04331054|Drug|2: Usual practice + SYMBICORT RAPIHALER|2 puffs bid during 30 days by inhalation
45820798|NCT04331054|Other|1: Usual practice|Usual practice
45962014|NCT03818880|Device|Novel spectacle lens design|Spectacle lens to control progression of myopia
45962015|NCT03816553|Drug|SHR-1210|SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg (3mg/kg for underweight patients).
45962016|NCT03816553|Drug|Apatinib|Apatinib will be administered 250mg orally, once daily until progression.
45962017|NCT03784820|Behavioral|UNITE|UNITE includes three stages: early treatment (psychoeducation and understanding the couple's experience of BED within the relationship); mid-treatment (effective communication, interpersonal problem-solving, and emotion regulation skills), and late treatment (relapse prevention). Additional relevant topics may be covered including body image, weight stigma, weight and health concerns, and intimacy and sexuality issues.
46079682|NCT04498117|Biological|Placebo|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
45962018|NCT03784820|Behavioral|CBT-E|CBT-E includes four stages: an introductory stage (psychoeducation, normalization of eating patterns, and symptom self-monitoring); a second, brief stage (review progress and formulate plans for the subsequent treatment phase); a third stage (elimination of dieting, reducing shape checking and avoidance behaviors, educating about mood tolerance, and targeting overevaluation of shape and weight); and the fourth stage (maintaining progress and minimizing relapse risk).
45962019|NCT03769675|Device|High Frequency Spinal Cord Stimulator|The SCS implant will follow standard clinical practice for these FDA approved indications. Two percutaneous leads will be placed in the posterior spinal epidural space under radiographic guidance and attached to either an external stimulator (trial phase) or a subcutaneously implanted impulse generator (IPG). Intraoperative impedance testing will be performed to ensure electrical integrity. Patients with HF10 SCS will receive 30 µs pulses delivered at 10,000 Hz with amplitude adjusted to optimal analgesic response. Programming will occur postoperatively and as needed based on patient feedback in standard clinic visits. .
45962020|NCT03760523|Drug|Minnelide|Patients will take Minnelide orally once daily on Days 1-21 of 28 day Cycle. Dose Escalation Schedule: Dose Level -1: .5 mg, Dose Level 1: .75 mg, Dose Level 2: 1 mg, Dose Level 3: 1.25 mg.
45962021|NCT03729245|Biological|bempegaldesleukin|Specified dose on specified days
45962022|NCT03729245|Drug|sunitinib|Specified dose on specified days
45962023|NCT03729245|Biological|nivolumab|Specified dose on specified days
45962024|NCT03729245|Drug|cabozantinib|Specified dose on specified days
46079683|NCT04498117|Drug|Carboplatin|AUC 5-6 IV Day 1 x 6 cycles (every 21 days)
45820799|NCT00002654|Drug|chemotherapy|
46079684|NCT04496414|Device|Bactiseal Catheter|Bactiseal Catheter manufactured by Codman & Shurtleff, Inc. in the United States is a silicon catheter impregnated in rifampicin and clindamycin.
45820800|NCT00002654|Drug|cisplatin|
45820801|NCT00002654|Radiation|low-LET cobalt-60 gamma ray therapy|
45820802|NCT00002654|Radiation|low-LET electron therapy|
45820803|NCT00002654|Radiation|low-LET photon therapy|
45820804|NCT02973308|Other|Observer|Observer A and observer B
45820805|NCT01426555|Other|FES-Rowing|FES- Rowing Exercise
45820806|NCT01426555|Drug|Zoledronic acid|5 mg IV single dose
45962025|NCT03727737|Device|Repetitive Transcranial magnetic Stimulation|RTMS will be delivered via magventure machine, on an approved FDA IDE protocol to DLPFC region to improve memory in older adults (veterans and non-veterans) with mild and moderate TBI.
45962026|NCT03712397|Drug|nanoliposomal irinotecan|combination therapy of nal-IRI , leucovorin and 5-FU in sequence at day 1, every 14 days counted as one cycle
45665625|NCT04207619|Other|hyperinsulinemic-hypoglycemic clamp|An intravenous catheter will be placed in an antecubital vein for infusion of insulin and glucose. A second catheter will be placed retrograde in a dorsal vein of the contra-lateral hand for blood withdrawal. The hand will be placed in a heating box or pad at 70°C for arterialization of venous blood. A primed infusion of regular insulin (120 mU/min/m2) will be initiated and continued for approximately 2 hours. Beginning 20 minutes prior to the start of the insulin infusion, arterialized venous blood glucose will be measured at 5 minute intervals via a Hemocue or YSI analyzer. Following initiation of insulin infusion, blood glucose will be allowed to fall to 50 mg/dL and then maintained at this level using a variable infusion of exogenous dextrose (20% solution). Our goal is to achieve steady-state (blood glucose stabilized at 50 +/- 5 mg/dL) within the first 45 minutes following the start of insulin infusion.
45962027|NCT03660423|Other|Integrative Dance|Integrative dance may be defined as dance that encourages the participation of all individuals, regardless of ability, supporting and celebrating these differences as a community. In the intervention, adults with developmental disabilities will be dancing in a contemporary dance class alongside college students.
45962028|NCT03623074|Device|Novel spectacle lens design|Use of lenses may reduce the rate of progression of juvenile myopia
45820807|NCT01434745|Drug|Simvastatin|Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day
45962029|NCT03623074|Device|Spectacle lenses|Use of lenses may reduce the rate of progression of juvenile myopia
45962030|NCT03557918|Drug|Tremelimumab|"Tremelimumab 750 mg IV on Day 1 of each 28 day cycle; up to 7 cycles.~Subjects that complete all initial 7 cycles but later progress during follow up may receive an additional 7 cycles of tremelimumab providing they meet eligibility criteria."
45962031|NCT03557463|Dietary Supplement|Dairy protein|A controlled, randomized, double blind pilot study was conducted using two different protein sources as nutritional supplementation to enhance vaccine response.
45962032|NCT03554356|Device|CryoBalloon Focal Ablation System|CryoBalloon Focal Ablation System
45962033|NCT03544099|Drug|Pembrolizumab|Pembrolizumab 200mg Intravenous Solution
45665626|NCT04207619|Other|13C-MRS procedure/Acetate infusion|Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples
46079685|NCT04481295|Other|High-flow nasal cannula|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
46079686|NCT04481295|Other|Low SpO2|Low SpO2
45665627|NCT02480621|Drug|Liposomal Bupivacaine with Bupivacaine|Pain medications injected locally during surgery around affected ankle.
46079687|NCT04468230|Drug|Nicotine Transdermal Patch|Nicotine Treatment Condition
46079688|NCT04459650|Procedure|Platelet Rich Plasma system|Participants will receive PRP obtained with PRP harvesting kits on one side of the scalp and no injections on the other side of the scalp (split-scalp technique). The entire half of the intended scalp will receive inter-follicular injections of PRP under aseptic conditions at the amount of 0.05-0.1 ml/cm2 in a retrograde fashion from deep to superficial, at every centimeter throughout the treated site. For study purposes, Study Day 0 is defined as the first day of injection. Subsequently the patient will continue therapy every 4 weeks for a total of 3 injections (12 weeks).
45962034|NCT03528408|Drug|Nivolumab|Nivolumab 240 mg IV over 30 minutes given Day 1, 15 and 29 of each Cycle
45458287|NCT02315794|Device|SPI®ART|implant prothetic restoration using a yttrium oxide stabilized zirconia abutment
45665628|NCT02046603|Drug|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 52 weeks.
45665629|NCT02046603|Drug|DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study. The study protocol does not specify any particular therapy.
45665630|NCT02046603|Drug|Oral Corticosteroids|Stable oral corticosteroids doses (≤10 mg/day prednisone or equivalent) are allowed. The study protocol does not specify any additional detail on types of oral corticosteroids.
45665631|NCT02046603|Drug|Methotrexate|Methotrexate per investigator's discretion.
45665632|NCT01885078|Drug|Baricitinib|Administered orally
45820808|NCT01434745|Dietary Supplement|Lactose|Lactose will be administered in a capsule formula.
45820809|NCT05591924|Procedure|Phelebotomy|Collection of 10mL of heparin anticoagulated blood, 10mL of EDTA anticoagulated blood, and 3mL of blood in a PAX gene tube
45962035|NCT03528408|Drug|Ipilimumab|Ipilimumab 1 mg/kg IV over 60 minutes given Day 1 of each Cycle
45962036|NCT03527199|Diagnostic Test|Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC)|Standard of care-Pelvic CT or MRI and MDP bone scan + or - 18F-NaF PET/CT
45962037|NCT03527108|Drug|Nivolumab|The treatment will be given on a 28-day cycle, with doses of nivolumab and ramucirumab given on days 1 and 15. The dose of nivolumab will be fixed at 240 mg. Nivolumab should be administered first, followed by premedication, and then ramucirumab. Ramucirumab should be administered approximately 30 minutes after premedication
45962038|NCT03527108|Drug|Ramucirumab|The treatment will be given on a 28-day cycle, with doses of nivolumab and ramucirumab given on days 1 and 15. The dose of ramucirumab will depend upon the patient weight as noted below. Nivolumab should be administered first, followed by premedication, and then ramucirumab. Ramucirumab should be administered approximately 30 minutes after premedication
45962039|NCT03514602|Behavioral|Multicomponent behavioral intervention|Pregnant patients in the intervention group will receive multicomponent interventions consisting of education, feedback, contingent financial incentives, and peer support. At initial intervention visit, they will choose a quit date within the next 14 days and sign a no-smoking pledge and a no-smoking contract. The contract lists the intervention components, the patient's and the counselor's responsibilities, importance of keeping scheduled visits, and rules on contingent incentives. After the quit date, pregnant women will meet with counselors daily for 5 consecutive days (Monday to Friday) for abstinence monitoring in weeks 1-2. The frequency of abstinence monitoring will decrease to twice a week (Monday and Thursday) in weeks 3-8, weekly in weeks 9-12, and biweekly in weeks 13 until delivery.
45820810|NCT05591924|Procedure|Broncheoalveolar Lavage|Bronchioalveolar lavage fluid (BALF) samples will be obtained from participants who are mechanically ventilated, and a bronchoscopy is indicated as part of routine clinical care. The BALF will be collected by a qualified ICU physician using standard clinical practice. Briefly, patients will receive appropriate sedation and analgesia, a flexible video-bronchoscope will be inserted into the patient's airway, and bronchial segments will be identified. The bronchoscope will be wedged in the most appropriate lung segment and 40-100mL of sterile normal saline (NS) as clinically indicated, will be injected into the bronchoscope port with using a 50mL syringe. Next, the instilled NS (i.e.: lavage fluid) will be collected in a sterile container using gentle suction. The BALF will then be partitioned and sent to clinical laboratories, and the remaining BALF (10-20mL) will be used in the ESTABLISH research study.
45665633|NCT01885078|Drug|Placebo|Administered orally
45962040|NCT03514602|Behavioral|Education only control|"The control group will receive one 60-minute counseling mainly based on a pregnancy-tailored self-help booklet entitled Need Help Putting Out That Cigarette? distributed by the American College of Obstetricians and Gynecologists."
45458288|NCT02315794|Device|SPI®EASY|implant prosthetic restoration using a commercially pure titanium grade 4 abutment
45665634|NCT02046369|Drug|Lurasidone|Lurasidone flexibly dosed 20-80 mg once daily
45962041|NCT03501381|Drug|Entinostat|Entinostat should be taken 1-2 hours prior to the HD IL-2 infusion. Dose reductions for entinostat should be followed. Entinostat will continue after high dose IL-2 every 2 weeks
46079689|NCT04454671|Other|Ultrasound-guided percutaneous neuromodulation (NMPE)|It is a technique based on electrical stimulation of a peripheral nerve through an ultrasound-guided needle or a muscle at a motor site. The stimulation is performed with low or medium frequency currents in which a sensory and / or motor response is sought by stimulating the peripheral nerve
46079690|NCT04454671|Other|Ultrasound-guided dry needling|Dry needling technique under ultrasound imaging in order to ensure accurate placement of the needle for optimum results.
46079691|NCT04453033|Device|Celeste Specialized Phototherapy Device|Ocular phototherapy light panel
46079692|NCT04445740|Behavioral|i♥rhythm project|behavioral mobile health intervention, targeting parents of 5-8 year olds, designed to promote consistent behavioral rhythms in children through consistent bedtimes, light exposure, meal timing, and physical activity.
45665635|NCT02046369|Drug|Placebo|Placebo Comparator once daily
45665636|NCT04725123|Diagnostic Test|Microbiome analysis|Stool microbiome analysis of 16S rRNA sequencing to an anticipated number of 8,000,000 reads
45665637|NCT02101359|Drug|T2380|200 microlitres of T2380 will be administrated intracamerally
45665638|NCT02101359|Drug|Mydriatics|3 drops of tropicamide and phenylephrine were instilled 30 minutes before surgery. The second and the third instillation of both phenylephrine and tropicamide will be realised respectively within 20 and 10 minutes before surgery.
45665639|NCT02101359|Drug|Tetracaine|Two drops of tetracaine were instilled in the eye to be operated 5 minutes and 1 minute before surgery
45665640|NCT02100969|Drug|HIZENTRA ®|Patients must fulfill inclusion criteria and remain stable at week 0, which means QMG does not increase by 3 points, will enter receive Hizentra for 12 weeks.
45665641|NCT01885000|Drug|Brimonidine tartrate was applied cutaneously once daily for 8 days.|
45962042|NCT03501381|Drug|Interleukin-2|In the event of clinical benefit after a course of HD IL-2 (stable disease or tumor shrinkage) patients will receive a second treatment course of HD IL-2 therapy. Patients with evidence of tumor shrinkage after the 2nd HD IL-2 treatment course may receive a 3rd treatment course of HD IL-2.
45962043|NCT03495674|Behavioral|Exercise Intervention|Complete cycling classes
45962044|NCT03495674|Other|Informational Intervention|Receive information about exercise guidelines
45962045|NCT03495674|Device|Monitoring Device|Wear Fitbit
46079693|NCT04445545|Device|High intensity laser therapy (HILT)|Laser application with powers greater than 500 milliwatts (mW) in the myofascial trigger point and muscle belly of the upper trapezius. Laser therapy will be applied to the upper trapezius muscle with a total energy delivery of 1,060J divided into 3 phases will be achieved (phase 1, 500J; phase 2, 60J; phase 3, 500J). It will work with an average power of 3W and an energy density of 50J/cm2. For the application of laser therapy, the 12W BTL-6000 equipment that emits infrared wavelengths of 1064nm will be used.
46079694|NCT04445545|Device|Therapeutic Ultrasound (US)|Application of ultrasound therapy in the myofascial trigger point of the upper trapezius muscle. The ultrasound application will be performed with the person in a seated position. The ultrasound parameters will consist of a frequency of 1MHz, the intensity of 1.5 W/cm2, a Duty cycle of 100%, an ERA of 5cm2, and a treatment time of 6 minutes.
46079695|NCT04445545|Procedure|Stretching exercise|t the end of the assigned treatment will be added a treatment protocol of upper trapezius stretching exercises for the evaluated limb with shortening. The stretches will consist of 4 series of 30 seconds with an interval of 30 seconds between series
45665642|NCT01885000|Drug|Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days.|
45665643|NCT04735341|Device|Ion Endoluminal System|Ion Endoluminal Procedure for pulmonary nodule
45665644|NCT04171960|Other|Blood Draw Within 12 Hours of Injury|- Specimens collected for i-STAT testing and, if applicable, for optional collection of DNA for possible future genetic testing.
45665645|NCT04171960|Other|3T MRI|- 3T Magnetic Resonance Imaging (MRI) at 2 weeks and 6 months following injury.
45665646|NCT04171960|Other|In-Person Outcome Assessment at Baseline|-3 Outcome Assessments administered at Baseline.
45820811|NCT05591924|Procedure|Tracheal Aspirate|Tracheal Aspirate (TA) will be obtained from participants who have an endotracheal tube or a tracheostomy in situ at the time of ICU admission through out the ICU admission on the study days, as long as distal airway access is available.
45820812|NCT05591924|Procedure|Rectal Swab|A Rectal will be obtained at the time of ICU admission and on all study days during the ICU admission
45820813|NCT01401049|Drug|Fospropofol|To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
45820814|NCT01401049|Drug|Propofol/Lidocaine|We plan to assess the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion).
45820815|NCT00381758|Drug|Methylphenidate Extended Release Capsules|
45820816|NCT01402531|Drug|Submucosal Bevacizumab|200 mg Bevacizumab, injected submucosally- 100 mg per nostril
45820817|NCT00381836|Drug|Darbepoetin Alfa|
45820818|NCT01971853|Drug|oral placebo|Ibuprofen placebo and Acetaminophen placebo will be added to a Demerol-Vistaril regimen
45820819|NCT01971853|Drug|Oral Analgesics|Ibuprofen at 5.0 mg/kg and Acetaminophen at 15.0 mg/kg will be added to a Demerol-Vistaril regimen
45820820|NCT00002678|Drug|dexamethasone|40 mg daily for four days given orally and repeated every 28 days should commence on day 29 of the twelfth cycle of induction therapy.
45820821|NCT00002678|Drug|melphalan|9 mg/m2 daily for 4 days given orally on an empty stomach every 4 weeks
45820822|NCT00002678|Drug|prednisone|100 mg daily for 4 days given orally on a full stomach with each cycle of melphalan
45820823|NCT01397695|Drug|Bevacizumab|The bevacizumab will then be sprayed by the treating physician in the clinic, under direct observation. Spray will be achieved by administering the bevacizumab through a mucosal atomization device. 0.1cc will be sprayed into both nares. Patients will then sit for 5 minutes, the application will be repeated for a total of 40 applications, thereby administering 50mgs into each nostril, a total of 100mgs into each patient. The 5 minute spacing has been arbitrarily chosen as sufficient time for 0.1cc of solution to be absorbed by the nasal mucosa. That will complete the treatment.
45820824|NCT00002684|Drug|cisplatin|
45820825|NCT00002684|Drug|ifosfamide|
45820826|NCT00002684|Drug|paclitaxel|
45820827|NCT01982383|Device|Micropulse Laser Treatment|
45820828|NCT01982383|Other|No treatment|
45820829|NCT05600647|Device|Electromagnetic Field therapy with an exercise program|"The magnetic field is generated through a mattress that is connected to the device. The maximum program, program 4, for 20 minutes with an intensity of 35 microtesla (level 10) and 50-60 Hz. the patient was lying on the mattress in a supine position.~the exercise program included postural correction strengthening exercises, stretching, proprioception and balance training"
45820830|NCT05600647|Other|exercise program|the exercise program included postural correction, strengthening exercises, stretching, proprioception and balance training
45820831|NCT01356667|Behavioral|DARTNA|3-hour protocol provided 2x/week over 12 weeks
45820832|NCT01356667|Behavioral|Treatment-As-Usual|Participants will receive typical substance abuse behavior treatment interventions typically provided to patients including individual counseling, group therapy, and standard culturally-based interventions.
45962046|NCT03495674|Other|Questionnaire Administration|Complete questionnaire
45962047|NCT03478566|Device|Transcutaneous CO2 monitoring|The aim is to assess the accuracy of ambulatory, at home, transcutaneous CO2 monitoring in pediatric Neuromuscular Disease (NMD).
45962048|NCT03478488|Drug|KN035 plus Gemcitabine & oxaliplatin|KN035 a programmed death ligand immune check inhibitor Per Investigator decision
45962049|NCT03478488|Drug|Gemcitabine & oxaliplatin|The standard of care for the patients with unresectable/metastatic biliary tract cancer
45962050|NCT03475264|Diagnostic Test|Lung MRI|Participants will be undergoing hyperpolarized xenon and proton lung MRI
46079696|NCT04432857|Drug|AN0025|oral administration
46079697|NCT04432857|Drug|Pembrolizumab|Infusion
45665647|NCT04171960|Other|In-Person Outcome Assessment at Follow-Up|- Full set of Outcome Assessment at 2 weeks, 6 weeks, and 6 months following injury.
46079698|NCT04432636|Other|Data collection of environmental factors|- Data collection of environmental factors (including maternal nutrition and social level, mode of delivery, birth weight, mode of infant feeding, antibiotic treatments) at the recruitment
45665648|NCT04171960|Other|Phone Outcome Assessment|- 6 Outcome Assessments administered at 3 months following injury by Phone.
45665649|NCT04171960|Other|Blood Draw After 12 Hours of Injury|- Specimens collected at 12-24 hours, 2 weeks, and 6 month following injury then processed for storage for future use.
45665650|NCT01884688|Drug|ENK Cell Infusion|Day 0(1 dose) ENK Cell Infusion Day 0 to + 12 (13 doses) Aldesleukin (IL2), 3x10 IU
45962051|NCT03465618|Drug|89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging|A low dose spiral CT is performed first per the standard procedure. These images will be used for both attenuation correction and registration of the serial image set. The initial PET brain scan will be acquired up to about 24 hours post injection. Based upon the discretion of the physician, non-surgical patients have the possibility of a second scan and third up to about 48 hours post injection. The times per bed position may be adjusted after the first patient is imaged, and his/her scans evaluated. Additional low dose CT scans will be performed at the image session for attenuation correction and image registration. PET study may be done on a PET-MR scanner for ease.
45665651|NCT01883362|Drug|Midostaurin|Midostaurin was supplied in 25mg soft gelatin capsule taken orally twice a day for 28 days of each cycle. Patients will be treated for 12 cycles.
45665652|NCT01883362|Other|Standard of Care|Standard of Care was not defined per protocol. The investigator prescribed based on the commonly used medications given in the post SCT setting.
45820833|NCT02972918|Drug|Levosimendan|24h preoperative infusion of levosimendan (0,1 mcg/Kg/min)
46079699|NCT04432636|Other|Collection of maternal feces|- Collection of maternal feces: the first sample after delivery and once a week during the period of hospitalization of their infant (i.e. 5 to 8 samples per mother)
45820834|NCT05600491|Drug|Temozolomide|Two weeks after surgery, temozolomide was administered orally at 200 mg·m-2 ·d -1 for 5 days. From day 29, patients were treated with a standard therapy regimen (Stupp).
45820835|NCT05749484|Other|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
45820836|NCT05600413|Dietary Supplement|L-Citrulline|4 weeks of L-Citrulline supplementation (6 grams/day)
45820837|NCT05600413|Dietary Supplement|Placebo|4 weeks of Placebo (crystalline cellulose)
45820838|NCT01934647|Drug|MK-8892|Single oral capsule with 1 mg, 4 mg, or 8 mg of MK-8892
45820839|NCT05440526|Procedure|Herbst Group|"Herbst Group:~Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured.~The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint."
45962052|NCT03465618|Other|Blood and Urine samples|Venous blood and urine samples will be obtained at approximately 0.5 hours post injection at the end of each scan
45962053|NCT03451786|Device|IOL|Intraocular lens
45665653|NCT04613440|Other|Family Letter (Standard of Care)|The family letter is given to probands in the standard of care arm and provides information on the familial mutation and serves to encourage first degree relatives to complete genetic testing.
45665654|NCT04613440|Other|Educational Video|The educational video is provided by the clinical genetic testing laboratory and explains the importance and implications of genetic testing. This educational video is shared with first degree relatives in the intervention arm
45820840|NCT05440526|Device|TFBC Group|"TFBC Group:~The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months."
45962054|NCT03451331|Drug|Nivolumab|Nivolumab 360mg (and/or) Maintenance Single Agent Nivolumab 480mg (starting ~ 2-4 weeks after completing combination chemotherapy plus nivolumab)
45962055|NCT03451331|Drug|Gemcitabine|1000 mg/m^2
45962056|NCT03451331|Drug|Carboplatin|AUC 4.5 (based on the Calvert formula)
45962057|NCT03451331|Drug|Oxaliplatin|130 mg/m^2
45665655|NCT04613440|Other|Mailed Saliva Kit for Genetic Testing|The FDR's email will be sent to the genetic testing lab, Invitae, which will allow them to log on to the online portal, create a unique account, and order a genetic testing saliva kit free of charge. The FDR will receive the kit and instructions in the mail. The FDR will collect the saliva sample and send the sample back to the genetic testing laboratory.
45665656|NCT04613440|Other|Telephone Counseling|The FDR's will be contacted and receive post genetic testing phone counseling
45665657|NCT02100813|Drug|LEO 43204|
45665658|NCT02100813|Drug|Placebo|
45665659|NCT04724967|Drug|CeraVe Hydrating Cleanser|topical cleanser applied twice a day for 28 days
45962058|NCT03431129|Diagnostic Test|Hyperpolarized gas and proton lung MRI|Lung MRI for participants undergoing radiation therapy (RT)
45962059|NCT03412877|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
45962060|NCT03412877|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
45962061|NCT03412877|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in Cohort 3 may receive 72,000 IU/kg IV.
45665660|NCT04724967|Drug|CeraVe Moisturizing Cream|topical cream applied twice a day for 28 days
45665661|NCT01930162|Drug|HSC835|HSC835 is a stem cell therapy product providing a source of Hematopoietic stem cell (HSC).
45820841|NCT01354951|Other|Prostate Biopsy, Focal Brachytherapy , Assessment of QOL|A re-staging transrectal or transperineal ultrasound-guided prostate biopsy as currently performed at participating institutions. Focal brachytherapy will be performed at 8 weeks following the transrectal or transperineal biopsy or sooner if the patient has recovered from the repeat biopsy and the treating physician determines it is safe to proceed with treatment. The regions will be targeted with the prescription dose and receive 144 Gy of Iodine-125 (I-125). The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then approximately 3 ± 1 months, 6 ± 1 months, 12 ± 2 months, 18 ± 2 months, and 24 ± 2 months after treatment.
45820842|NCT05572736|Device|Conduction system pacing|Pacing from the His-Purkinje system (His-bundle pacing, left bundle branch area pacing, or deep septal pacing).
45820843|NCT05572736|Device|Biventricular pacing|Pacing from the coronary sinus and right ventricular leads.
45820844|NCT00379561|Drug|PSA-Activated PSA-PAH1|
45820845|NCT00002696|Drug|CAF regimen|
45820846|NCT00002696|Drug|CMF regimen|
45820847|NCT00002696|Drug|cyclophosphamide|
45820848|NCT00002696|Drug|doxorubicin hydrochloride|
45962062|NCT03412877|Biological|Individual Patient TCR-Transduced PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
45962063|NCT03412877|Drug|Pembrolizumab (KEYTRUDA )|Arm 2: Pembrolizumab 2 mg/kg IV over approximately 30 minutes on Days -2, 21, 42, and 63.
45962064|NCT03407469|Behavioral|Questionnaires|Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE). It should take less than 10 minutes to complete the questionnaires each time.
45962065|NCT03406299|Drug|Tegafur|Tegafur(S-1) 35 mg/m2/b.i.d., day 1 - 7 (maximum dose: 120 mg/day)
45962066|NCT03406299|Drug|Leucovorin|Leucovorin 30 mg/b.i.d., day 1-7
45962067|NCT03406299|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 in 250 mL of 5% Glucose, given as 2-hour intra- venous infusion, day 1
45962068|NCT03406299|Drug|Gemcitabine|"Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate (, 10 mg/m2/min) infusion, day 1; After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin. in SLOG arm.~Gemcitabine 1000 mg/m2 in 100 mL of normal saline, IV drip for 30 mins on D1 and D8 ，in GC arm"
45820849|NCT00002696|Drug|fluorouracil|
45820850|NCT00002696|Drug|methotrexate|
45820851|NCT00002696|Procedure|adjuvant therapy|
45962069|NCT03406299|Drug|Cisplatin|Cisplatin 25 mg/m2 in 250ml of normal saline, IV drip for 2 hours on D1 and D8
45962070|NCT03404960|Drug|Niraparib + Nivolumab|Niraparib 200mg PO daily on days 1-28 of each 28-day cycle. Nivolumab 480mg IV day 1 of each cycle.
45962071|NCT03404960|Drug|Niraparib + Ipilimumab|Niraparib 200mg PO daily on days 1-21 of each 21-day cycle. Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only.
45665662|NCT04630912|Other|Acceptance and Commitment Therapy|There is no specific protocol for ACT with dementia, therefore a published ACT protocol, 'Better Living with Illness' (Brassington et al., 2016), will be used flexibly to guide the intervention.
45665663|NCT02045979|Drug|BI 695501|BI 695501 single s.c. injection
45665664|NCT02045979|Drug|adalimumab-EU source|adalimumab-EU source single s.c. injection
45665665|NCT02045979|Drug|adalimumab-US source|adalimumab-US source single s.c. injection.
45665666|NCT01929226|Biological|ETI-204|Monoclonal Antibody
45820852|NCT00002696|Procedure|conventional surgery|
45665667|NCT01929226|Other|Placebo|Placebo for ETI-204
45820853|NCT00002696|Procedure|neoadjuvant therapy|
45820854|NCT00002696|Radiation|radiation therapy|
45820855|NCT01350583|Drug|Sodium Bicarbonate (NaHCO3)|Treatment consisted of 0.15 g/kg/day Sodium Bicarbonate (NaHCO3) increasing to 0.3 g/kg/day after 1 week if well tolerated. Further dose increment to 0.6 g/kg/day was to be done after 2 weeks of starting sodium bicarbonate if prior dose levels were well tolerated.
45962072|NCT03396445|Drug|Boserolimab|IV infusion
45962073|NCT03396445|Biological|Pembrolizumab|IV infusion
45962074|NCT03396445|Drug|Pemetrexed|IV infusion
45962075|NCT03396445|Drug|Carboplatin|IV infusion
45962076|NCT03396445|Drug|Nab-paclitaxel|IV infusion
45962077|NCT03385655|Drug|Adavosertib|250mg, may dose escalate to 300mg if no drug-related GI tox in cycle 1
45962078|NCT03385655|Drug|Savolitinib|600mg once daily, orally.
45962079|NCT03385655|Drug|Darolutamide|600mg twice daily, orally.
45962080|NCT03385655|Drug|CFI-400945|Dose level assigned at enrollment, starting at 32mg/day on Days 1-7 and 15-21 or 15-28 depending on toxicity experienced.
45962081|NCT03385655|Drug|Ipatasertib|400mg daily 3 weeks on, 1 week off
45962082|NCT03385655|Drug|Durvalumab and Tremelimumab|Durvalumab 1500mg day 1 every 4 weeks; Tremelimumab 225mg day 1 cycle 1
45665668|NCT04703751|Device|Transcoronary delivery of a pharmacological agent (nitroglycerin) and cell based agent (Cardiocell) using the CIRCULATE Catheter|Investigated device - the CIRCULATE Catheter will be introduced, using a standard radial or femoral access and a typical guiding catheter and typical coronary wire, first into the right coronary artery. After that the one dose of NTG (200µg) will be administered followed by a typical angiographic recording to visualize the vasodilatatory effect of the medication. Then CardioCell in doses of 10mln cells each (6.7mL) will be administered transcoronary to each of the coronary arteries (right coronary artery (RCA), LAD, left circumflex (Cx)). Angiography will be performed routinely before and after each product administration.
45665669|NCT05122702|Drug|modified Shenling Baizhu San|modified Shenling Baizhu San granules, twice daily for 12 weeks.
45962083|NCT03385655|Drug|Carboplatin|AUC 5 IV 60min Day 1 q 21 days
45820856|NCT00002702|Biological|aldesleukin|
45962084|NCT03355469|Drug|Low Intensity Exercise + Metformin|Low Intensity exercise (LoEx) measured by a percentage of maximal heart rate in combination with metformin.
45962085|NCT03355469|Drug|High Intensity Exercise + Metformin|High Intensity exercise (HiEx) measured by a percentage of maximal heart rate in combination with metformin.
45962086|NCT03355469|Drug|Low Intensity Exercise + Placebo|Low Intensity exercise (LoEx) measured by a percentage of maximal heart rate in combination with placebo.
45962087|NCT03355469|Drug|High Intensity Exercise + Placebo|High Intensity exercise (HiEx) measured by a percentage of maximal heart rate in combination with placebo.
45820857|NCT00002702|Procedure|adjuvant therapy|
45820858|NCT00002702|Procedure|conventional surgery|
45820859|NCT00002702|Procedure|neoadjuvant therapy|
45962088|NCT03330028|Drug|Dexamethasone|10 mg by vein approximately 60 minutes before Paclitaxel.
45665670|NCT05122702|Other|Placebo|Placebo granules, twice daily for 12 weeks.
45665671|NCT04734405|Drug|Prof-001|Prof-001 cream
45820860|NCT00002702|Radiation|radiation therapy|
45820861|NCT01890577|Drug|Aranesp|Observational study; minimum single dose of Aranesp required for eligibility; no protocol-specified regimen; study must not influence normal clinical practice.
45665672|NCT04734405|Drug|Fluconazole 150 mg|Fluconazole capsule
45665673|NCT04734405|Drug|Placebo cream|ointment base to mimic Prof-001
45665674|NCT04734405|Drug|Placebo capsule|encapsulated lactose powder to mimic 150 mg fluconazole capsule
45962089|NCT03330028|Drug|Diphenhydramine|50 mg by vein approximately 60 minutes before Paclitaxel.
45962090|NCT03330028|Drug|Famotidine|20 mg by vein approximately 60 minutes before Paclitaxel.
45962091|NCT03330028|Drug|Mitomycin C|Mitomycin C 30 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
45962092|NCT03330028|Drug|Cisplatin|Cisplatin 200 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
45962093|NCT03330028|Drug|Paclitaxel|"Starting dose of Paclitaxel is 20 mg/m2 in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.~Dose-escalation scheme of Paclitaxel is in increments of 5 mg/m2."
45665675|NCT02045433|Radiation|SABR Boost Therapy|"Initial Pelvic (+/- Para-aortic) fractionated external beam Radiation with 45 Gy to combined PTV with a boost to 55Gy for PET positive/CT enlarged nodes;~Image Guided Hypofractionated Radiation Treatment boost to Cervix High risk CTV/PTV 28GY/4 fx.~Patients will receive 4 fractions of 7 Gy each via stereotactic body radiation as boost therapy to a volume that encompasses the cervical tumor. A minimum of 40 hours should separate each treatment."
45665676|NCT01911442|Drug|Lurasidone 20 mg daily|Lurasidone 20 mg once daily
45665677|NCT01911442|Drug|Lurasidone|Lurasidone 60 mg once daily
45665678|NCT01911442|Drug|Placebo|Placebo
45820862|NCT05749406|Other|Focus group|Small virtual focus group discussion about experiences/attitudes towards post-operative anal dilatation.
45820863|NCT05749406|Other|Semi-structured interview|Individual virtual interview to ascertain participant's experiences of performing anal dilatation post-operatively for their child with an anorectal malformation.
45820864|NCT00002708|Procedure|surgical procedure|
45820865|NCT00002708|Radiation|radiation therapy|
45962094|NCT03324373|Drug|Lenvatinib|Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.
46079700|NCT04432636|Other|Collection of infant feces|- Collection of infant feces: the first sample after birth and once a week during the period of hospitalization of the baby (i.e. 5 to 8 samples per mother) and a sample collected at the corrected age of 1 year and 2 years (i.e. 8 to 10 samples per infant)
45962095|NCT03324373|Drug|Everolimus|Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular protein, FKBP-12, resulting in an inhibitory complex formation (mTORC1) and thus inhibition of mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic elongation factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.
45962096|NCT03324373|Procedure|Partial or Radical Cytoreductive Nephrectomy|"Surgical removal of a kidney.~After completion of 8 weeks of therapy and restaging, investigators will require 2 weeks wash out period. The patients will be evaluated by urology oncology team and appropriate surgery will be planned. This includes partial nephrectomy and radical nephrectomy."
45962097|NCT03313011|Diagnostic Test|Testing protocol for the study|All patients will see a Neurologist for a neuro exam and consult, see a Speech Pathologist for assessment of speech and language skills, see the Study Coordinator for neuropsych testing (brief tests of thinking, memory, visual spatial skills, etc), undergo an MRI of the brain and a DaTscan of the brain.
45962098|NCT03311711|Behavioral|SPIRIT-in person|The SPIRIT-in person intervention adapted for dementia will include one session and will be conducted in a private room at the clinic. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.
45962099|NCT03311711|Behavioral|SPIRIT-remote|The SPIRIT-remote intervention adapted for dementia will include one session and will be conducted through teleconference. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.
45962100|NCT03311711|Behavioral|Usual care|Participants will receive the usual care that is provided through the clinic they receive care through. This may include completing advanced directives, referral to a support group, or referral to a social worker for further discussion about end of life issues.
45962101|NCT03311555|Drug|Apalutamide|240mg tablet daily for 36 weeks
45962102|NCT03311555|Drug|Androgen deprivation|ADT will consist of treatment with a GnRH agonist or antagonist per physician and institutional preference. Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix (Firmagon 120 mg or 240 mg SC) will be administered monthly, every 3 months, or every 6 months, depending on institutional standards, for 36 weeks total.
45962103|NCT03311555|Radiation|Salvage radiation therapy|On week 9 (+/- 28 days), subjects will begin salvage radiation therapy to the prostate bed. The total dose to the prostate bed must be 66-74 Gy in 1.8-2 Gy daily fractions over a total of 6-8 weeks
46079701|NCT04432636|Other|food questionnaire|- A food questionnaire completed by the mother the week after delivery,
45665679|NCT01928758|Drug|Reduced Nicotine Content Cigarettes|Research cigarettes will have gradually reduced nicotine content
45665680|NCT01928758|Drug|Usual Nicotine Content Cigarettes|Usual Nicotine Content Cigarettes
45665681|NCT01910116|Drug|Shinbaro|GCSB-5 (Shinbaro) is a mixture of six purified oriental herb extracts in a fixed ratio, namely, Saposhnikovia divaricata Schischk, Glycine max Merrill, Cibotium barometz J. Smith, Eucommia ulmoides Oliver, Achyranthes japonica Nakai, and Acanthopanax sessiliflorus Seem
45665682|NCT01910116|Drug|Placebo|The study medication and placebo were identical in appearance.
45820866|NCT00002708|Radiation|stereotactic radiosurgery|
45820867|NCT01315873|Drug|Bendamustine|"On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m^2 after bortezomib . Patients will be dose reduced to 75 mg/m^2, and then to 60 mg/m^2 bendamustine on days 1 and 4 if ANC is not >1 x 10^9/L and platelets are not >50 x 10^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
45820868|NCT01315873|Drug|Bortezomib|"On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m^2 followed by bendamustine given at 90 mg/m^2. Patients will be dose reduced to 75 mg/m^2, and then to 60 mg/m^2 bendamustine on days 1 and 4 if ANC is not >1 x 10^9/L and platelets are not >50 x 10^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
45820869|NCT01895959|Drug|Euflexxa|Euflexxa will be injected weekly for 3 consecutive weeks on the knee joint.
45665683|NCT01614886|Drug|Active Comparator|1-step titration group begin treatment with a rivastigmine patch 9 mg/day for 4 weeks, followed by a dose increase to 18 mg/day.
45665684|NCT01614886|Drug|ENA713|-3-step titration group will begin treatment with a rivastigmine patch 4.5 mg/day for 4 weeks, followed by a further dose increase of 4.5 mg/day at 4-week intervals up to the maintenance dose of 18 mg/day.
45962104|NCT03311555|Drug|Docetaxel|About 4 weeks (+/- 2 weeks, pending recovery of adverse events from radiation to Grade 2 or less) after completing radiation, patients will start docetaxel 75mg/m2 intravenously, every 3 weeks for 6 cycles.
45962105|NCT03297060|Other|SSL Implementation Strategy|Science to Service Laboratory (SSL) is an approach developed by the SAMHSA-funded Addiction Technology Transfer Centers (ATTCs) that consists of didactic training + performance feedback + leadership coaching to improve SBIRT adherence within the pediatric trauma center
45665685|NCT04622254|Drug|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
45665686|NCT04622254|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
45665687|NCT01880554|Device|Contrast-enhanced intraoperative ultrasound|"Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:~Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages"
45665688|NCT04171726|Drug|Edoxaban|A non-vitamin K antagonist (VKA) oral anticoagulant that selectively inhibits factor Xa.
45665689|NCT02100657|Drug|Plitidepsin|
45962106|NCT03278366|Behavioral|Dancing|Participants in the intervention group will participate in daily dance activities with their teacher by following along with a video created by the dance researchers at Skidmore College. Teachers will be specifically asked to utilize the movement phrases just prior to administering any formal assessment activity within their classroom (tempo may be chosen at teacher's discretion). Furthermore, teachers may choose to utilize the dance phrases as 'brain breaks' at any point throughout their school day.
45962107|NCT03271866|Drug|metformin|metformin 1500mg per day
45962108|NCT03270891|Diagnostic Test|PGx test|A laboratory developed genetic test that differentiates common and uncommon alleles in genes that have been previously identified as being involved in either the metabolism or response of drugs used in the treatment of depression and/or anxiety. The results are provided as a report that contains information related to the allele status of the patient's genes, translates this into a phenotype, and relates this phenotype to recommendation classes for drugs.
46079702|NCT04432636|Other|a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age|a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 1 year
45455350|NCT01219153|Drug|Extended high dose letrozole regimen /GnRH antagonist protocol|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
45962109|NCT03268421|Behavioral|Fibromyalgia Integrative Training for Teens|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
45962110|NCT03268421|Behavioral|Cognitive Behavioral Therapy|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
46079703|NCT04432636|Other|a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age|a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 2 years
46079704|NCT04432636|Other|Sample of milk|A sample of 15 mL of milk drunk by the preterm at the 7th postnatal day (if not possible between the 7th and the 10th postnatal days).
46079705|NCT04432636|Other|The 'Ages and Stages Questionnaire' ASQ|- The 'Ages and Stages Questionnaire' ASQ survey completed by the parents and given to the pediatrician at the corrected age of 2 years medical check-up
45665690|NCT02100657|Drug|Bortezomib|
45665691|NCT02100657|Drug|Dexamethasone|
45665692|NCT02067663|Device|Paragard|The IUD will be placed as part of standard clinical care.
45665693|NCT02067663|Drug|Mirena|The IUD will be placed as part of standard clinical care.
45820870|NCT01895959|Device|Magnetic Resonance Imaging (MRI)|MRI of the knee will be acquired during baseline (a week prior to the treatment), follow up visit 1 (1 week after treatment) and follow up visit 2 (3 months after treatment).
45820871|NCT01303003|Drug|Dexamethasone|40 cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
45665694|NCT01909804|Drug|SOF|400 mg tablet administered orally once daily
45665695|NCT01909804|Drug|VEL|Tablet administered orally once daily
45665696|NCT01909804|Drug|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45820872|NCT01303003|Procedure|TAP block|Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
45820873|NCT01256281|Procedure|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
45820874|NCT00002714|Biological|bleomycin sulfate|
45820875|NCT00002714|Drug|Stanford V regimen|
45820876|NCT00002714|Drug|doxorubicin hydrochloride|
45665697|NCT01880086|Drug|Clomiphene citrate|
45665698|NCT01880086|Drug|Placebo|Placebo pill that will have appearance identical to the treatment pill but will not contain active medication.
45665699|NCT01879852|Behavioral|Quadriceps intensive strengthening|Quadriceps intensive strengthening includes high-intensity neuromuscular electrical stimulation to the quadriceps muscle for 10 minutes and overload to the the eccentric phase of quadriceps strengthening exercises.
45820877|NCT00002714|Drug|etoposide|
45962111|NCT03268421|Behavioral|Graded Aerobic Exercise|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
45665700|NCT01879852|Behavioral|Standard rehabilitation|Standard rehabilitation will include interventions for typical knee impairments (effusion, knee motion deficits, lower extremity muscle weakness, and gait deviations) as well as advanced rehabilitation interventions as indicated (jump and agility exercises)
45665701|NCT04611568|Other|Educational Intervention|Receive educational and training material
45665702|NCT04611568|Other|Educational Intervention|Receive educational lecture
45820878|NCT00002714|Drug|mechlorethamine hydrochloride|
45820879|NCT00002714|Drug|prednisone|
45665703|NCT04611568|Behavioral|Health Education|Receive melanoma curriculum
45665704|NCT04611568|Behavioral|Media Campaign|View digital media strategies
45962112|NCT03259503|Drug|Busulfan|Given IV
45962113|NCT03259503|Drug|Gemcitabine|Given IV
45962114|NCT03259503|Drug|Melphalan|Given IV
45962115|NCT03259503|Drug|Olaparib|Given PO
45962116|NCT03259503|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
45962117|NCT03259503|Other|Pharmacokinetic Study|Correlative studies
45962118|NCT03259503|Biological|Rituximab|Given IV
45962119|NCT03259503|Drug|Vorinostat|Given PO
45962120|NCT03259035|Drug|Folfox Protocol|6 cycles of q2weekly FOLFOX, or
45962121|NCT03259035|Drug|Capox|4 cycles of q3weekly CAPOX
45665705|NCT04611568|Other|Survey Administration|Complete survey
45820880|NCT00002714|Drug|vinblastine sulfate|
45820881|NCT00002714|Drug|vincristine sulfate|
45820882|NCT00002714|Radiation|radiation therapy|
45962122|NCT03217565|Drug|IV Tedizolid Phosphate|A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.
45962123|NCT03217565|Drug|Oral Suspension Tedizolid Phosphate|A single dose of tedizolid phosphate administered as an oral suspension.
45962124|NCT03214562|Drug|Cytarabine|Given IV
45962125|NCT03214562|Biological|Filgrastim|Given SC
45962126|NCT03214562|Drug|Fludarabine|Given IV
45962127|NCT03214562|Drug|Idarubicin|Given IV
45962128|NCT03214562|Biological|Pegfilgrastim|Given SC
45665706|NCT01879618|Drug|Fragmin|variable dosing regimen
45665707|NCT01926886|Drug|Trastuzumab|Trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w; Trastuzumab 600 mg q3w SC injection will be administered as per the schedule specified in the arm.
45820883|NCT05313061|Drug|MTX|MTX continuation
45820884|NCT00002720|Drug|tamoxifen citrate|
45820885|NCT00002720|Procedure|conventional surgery|
45820886|NCT01821859|Drug|Abraxane|Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion.
45820887|NCT01821859|Drug|Bevacizumab|Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.
45962129|NCT03214562|Drug|Venetoclax|Given PO
45458289|NCT03331640|Drug|OFF|"OFF:~5-FU 2000 mg/m2 as 24 hour infusion + Na folinic acid 200 mg/m2 on D1, 8, 15, 22 Oxaliplatin 85 mg/m2 on D8, 22 3 weeks rest after D22; Cycle q42d"
45458290|NCT03331640|Drug|FOLFIRI Protocol|Irinotecan 180 mg /m2 5-FU 400 mg/m2 (bolus) + 2400 mg/m2 as 46 hour infusion Na folinic acid 200 mg/m2 Cycle q2w
45665708|NCT01909336|Drug|0.3% Saline in 3.3% dextrose|Hypotonic Solutions: 0.3% Saline in 3.3% dextrose
45665709|NCT01909336|Drug|0.45% Saline in 5% dextrose|Hypotonic Solutions: 0.45% Saline in 5% dextrose
45665710|NCT01909336|Drug|0.9% Saline in 5% dextrose|Isotonic Solutions 0.9% Saline in 5% dextrose
45665711|NCT01926028|Biological|NDV-3A|0.5mL injection IM
45820888|NCT05749328|Dietary Supplement|Carbohydrate|To ensure the safety of the trial, preoperative gastric ultrasound measurements will be performed on all patients to assess their gastric volume. See above for other details
45820889|NCT05600023|Drug|Nitrofurantoin|Nitrofurantoin has been found to successfully eradicate gram-negative bacteria such as Enterococcus faecalis that one of the most important bacteria in endodontic lesions
45820890|NCT05600023|Drug|Double Antibiotic|DAP is a combination of two antibiotics which are ciprofloxacin and metronidazole
45962130|NCT03196180|Drug|Imiquimod|Given intravaginally
45962131|NCT03196180|Drug|Topical Fluorouracil|Given intravaginally
45962132|NCT03190382|Other|Decision Support Tool|Patients enrolled in the study will receive the decision tool prior to the first PAD clinic visit and the medical decision making conversation with the provider.
45962133|NCT03162627|Drug|Selumetinib|"Dose Escalation Phase Starting Dose: 50 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
45962134|NCT03162627|Drug|Olaparib|"Dose Escalation Phase Starting Dose: 150 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
45962135|NCT03099434|Behavioral|Facebook App|This web-based mobile application allows candidates to write a simple and effective story to share with their previously built network on Facebook to help share their story and identify a potential live donor.
45962136|NCT03099434|Behavioral|Live Donor Champion + Facebook App|"A Live Donor Champion (LDC) is a friend, family member, or community member who serves as an advocate for the candidate in their pursuit of live donation. The investigators have developed a six-month program that provides education and advocacy training to waitlist candidates and their LDCs."
45962137|NCT03037632|Behavioral|Family Heart Talk Booklet|
45962138|NCT03019328|Other|Peanut in diet|
46079706|NCT04423627|Drug|Clonidine|Clonidine 0.2 mg/day oral tablet
46079707|NCT04423627|Drug|Hydrochlorothiazide|Hydrochlorothiazide 37.5 mg/day oral tablet
46079708|NCT04423627|Drug|Placebo|Placebo
46079709|NCT04398654|Device|CardioMEMSTM HF sensor - pulmonary artery pressure measurement|CardioMEMSTM HF sensor implantation to meassure pulmonary artery pressure. Evaluation of the pressure curves by telemetric transmission and coordination of necessary adjustments of the therapy.
45665712|NCT01926028|Biological|NDV-3|0.5mL injection IM
45665713|NCT01926028|Biological|Placebo|aluminum hydroxide and buffered saline
45665714|NCT01925950|Drug|orBec|
45665715|NCT01925950|Drug|Placebo|
45962139|NCT03015805|Behavioral|Contingency Management|"Contingency Management (CM) utilizes behavior modification & cognitive behavioral strategies to target adolescent alcohol or other drug (AOD) use. Protocol components are as follows: (a) The provider introduces CM to the family and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the caregiver; (d) Concurrently, a point and level system contract is filled in by the family, which provides rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks."
45962140|NCT03015805|Behavioral|Probation as Usual|Standard services that a young person would receive while under probation supervision in the state of Oregon.
45962141|NCT02992743|Drug|letetresgene autoleucel (GSK3377794)|Letetresgene autoleucel (GSK3377794) as an IV infusion.
45962142|NCT02992743|Drug|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
45962143|NCT02992743|Drug|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
45962144|NCT02927912|Radiation|Electron Beam Therapy|Undergo IOERT boost
45962145|NCT02927912|Procedure|Lumpectomy|Undergo lumpectomy
45962146|NCT02927912|Other|Quality-of-Life Assessment|Ancillary studies
45962147|NCT02927912|Other|Questionnaire Administration|Ancillary studies
45962148|NCT02927912|Radiation|Radiation Therapy|Undergo whole breast radiation therapy
46079710|NCT04395001|Drug|duloxetine|All participants will receive duloxetine 30 mg once daily for one week and 60 mg once daily for 24 weeks.
45820891|NCT05599867|Behavioral|quality of life|to assess quality among patients with patients with IBD
45820892|NCT05271643|Behavioral|Cognitive Behavioral Therapy (CBT)|CF-CBT-A is an 10-session program for adolescents with cystic fibrosis introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained mental health clinician on their CF team who will guide them through learning and practicing coping skills. Parents/guardians involvement will be encouraged. A parent/guardian will attend the baseline and final session, have the opportunity for a mid-program check-in, and receive a workbook of psychoeducational material that parallels the adolescent workbook, featuring tips for supporting their teens, and weekly e-mail communication.
45962149|NCT02927912|Procedure|Reconstructive Surgery|Undergo oncoplastic reconstruction
45962150|NCT02893397|Device|Activity Monitor|Wear a fitbit
45962151|NCT02893397|Behavioral|Exercise Intervention|Undergo supervised exercise sessions
45962152|NCT02853344|Biological|Pembrolizumab|IV infusion
45962153|NCT02821013|Drug|Intermittent PD-1 inhibitor therapy|
45962154|NCT02821013|Drug|Continuous PD-1 inhibitor therapy|
46079711|NCT04395001|Behavioral|Web-based Cognitive Behavioral Therapy (CBT)|The web-based CBT program is an automated program (i.e., users learn skills with interactive, personalized training without any therapist contact) that includes 8, 35- to 45-minute training sessions, each of which provides an educational rationale and training in cognitive or behavioral pain coping skill drawn from face-to-face CBT.
45962155|NCT02793492|Device|Misago® RX Self-expanding Peripheral Stent|the Misago® RX Self-expanding Stent is a bare metal, nitinol stent
45962156|NCT02776735|Drug|Sarilumab|Pharmaceutical form:Solution Route of administration: Subcutaneous
45665716|NCT04415320|Drug|X-396(Ensartinib)|All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.
45665717|NCT01878292|Drug|Placebo|Dose matched placebo tablets, once per day, oral administration.
45665718|NCT01878292|Drug|Vilazodone|Vilazodone tablets, 15 mg per day, oral administration
45665719|NCT01878292|Drug|Vilazodone|Vilazodone tablets, 30 mg once per day, oral administration
45665720|NCT01908634|Dietary Supplement|Milk-based Strawberry Beverage without meal|
45665721|NCT01908634|Dietary Supplement|Water-Based Strawberry Beverage without meal|
45665722|NCT01908634|Dietary Supplement|Milk-based strawberry Beverage with meal|
45665723|NCT01908634|Dietary Supplement|Water-Based strawberry Beverage with meal|
45665724|NCT01878214|Behavioral|Targeted messaging|6 targeted mailed messages and 6 booster text messages
45665725|NCT01878214|Behavioral|Standard messaging|1 informational letter
45665726|NCT01907854|Drug|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily + metformin tablets (at least 1000 mg/day)
45665727|NCT01907854|Drug|sitagliptin|100 mg/day sitagliptin tablets once-daily + metformin (at least 1000 mg/day)
45665728|NCT01907854|Drug|placebo|Sitagliptin placebo tablets once-daily
45665729|NCT01907854|Drug|placebo|Sitagliptin placebo tablets once-daily
45962157|NCT02740634|Drug|F-18 AV 1451|Tau binding agent
45962158|NCT02740634|Drug|C-11 PiB|Amyloid binding agent
45962159|NCT02739620|Device|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation will be performed 5 times/week for one hour each day for 2 months.
45962160|NCT02738229|Drug|Valacyclovir|
45962161|NCT02738229|Drug|placebo|
46079712|NCT04395001|Other|Nurse-delivered Motivational Interviewing|Subjects randomized to the duloxetine and web-based Cognitive Behavioral Therapy (CBT) with nurse support will receive 6 phone calls from MI trained nurse at week 3, 6, 10, 14, 18 and 22. Telephone sessions may run for 20 minutes on the average.
46079713|NCT04391764|Drug|Naltrexone|Naltrexone at a dose of 50 mg per day
46079714|NCT04391764|Drug|Placebo oral tablet|Placebo tablets will be identical in size, colour, shape, and taste and will be given in the similar manner.
45820893|NCT05566184|Device|Modified pacifier|In the experimental group, a modified pacifier will be given to the child during the procedure, and the data will be collected. In the application of vascular access to children, a) before the procedure (20 minutes before), b) just before the procedure (20. minutes), c) during the procedure (between 20.-40. minutes), and d) 20 minutes after the procedure (40. minutes). Physiological variables that will be evaluated four times, once for each application, will be observed on the monitor, the FLACC Pain Assessment Scale will be recorded by the researcher and salivary cortisol level will be measured.
45962162|NCT02722486|Device|Vestibular Rehabilitation/Balance Belt|With this device, a subject stands on a force platform on the ground, which measures his/her center of pressure. Additionally, there is laptop displaying the video-based exercise programs and a camera that senses the subject's linear sway, roll, and pitch. Information about the subject's position is transmitted via Bluetooth technology to a non-invasive vibrotactile belt which fits comfortably around the subject's waist, over his/her clothing. Using the Sensory Kinetics software, the subject will play a series of games projected on the laptop screen, which prompt him/her to sway in various directions while keeping both feet planted on the force platform.
45962163|NCT02722486|Other|Standard Vestibular Rehabilitation|This is the standard three-month vestibular rehabilitation therapy that patients are routinely referred to at Boston Children's Hospital.
45962164|NCT02675426|Drug|Placebo|Tablet; Oral
45962165|NCT02675426|Drug|Upadacitinib|Tablet; Oral
45962166|NCT02656433|Device|Transcranial Random Noise Stimulation|A special Helmet supply weak electrical currents in the head
45455351|NCT01219153|Drug|Short low dose letrozole regimen /GnRH antagonist protocol|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland)2.5 mg /daily is administered for 5 consecutive days starting on cycle day 3.~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 3 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
45820894|NCT01194427|Drug|Vorinostat and Tamoxifen|vorinostat 400 mg PO once daily and tamoxifen 20mg PO once daily for 14 days
45962167|NCT02656433|Other|Physiotherapy|Standard of care physiotherapy aimed to the motor impairment the subject presents
45455352|NCT04466020|Other|Qualitative research interviews to be conducted|None. Qualitative research interviews to be conducted
45458291|NCT01144975|Drug|XOMA 052|Sterile solution, dose level varies by dose group and study drug administration day, SC injections administered by study personnel at time points specified in the protocol (the subject will receive a total of 8 injections)
45962168|NCT02647294|Dietary Supplement|Maxicor|Patients with NAFLD will be randomly allocated to receive or n-3 PUFA (3,6 g/day, oral treatment) or placebo (1:1).
45962169|NCT02647294|Other|Placebo|Patients with NAFLD will be randomly allocated to receive or placebo or n-3 PUFA for 12 months (1:1).
45962170|NCT02631837|Procedure|vNOTES hysterectomy|Surgical removal of the uterus by Natural Orifice Transluminal Endoscopic Surgery using a colpotomy
45458292|NCT01144975|Drug|Placebo|Sterile solution, SC injections administered by study personnel (the subject will receive a total of 8 injections)
45665730|NCT02480153|Biological|PF-06410293|PF-06410293 will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
45665731|NCT02480153|Biological|Adalimumab|Adalimumab will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
45820895|NCT05749250|Device|Acoustic cavitation of ultrasound enhancing agents|Cavitation therapy
45820896|NCT05599555|Biological|mRNA BNT162b2 vaccine|mRNA vaccine Comirnaty (BNT162b2 mRNA, BioNTech/Fosun-Pharma, Mainz, Germany/Shanghai, China)
45820897|NCT05599555|Biological|CoronaVac vaccine|Inactivated CoronaVac vaccine (Sinovac Life Sciences, Beijing, China)
45962171|NCT02631837|Procedure|LSC hysterectomy|Surgical removal of the uterus by transabdominal laparoscopy
45962172|NCT02579473|Drug|SER-214|SER-214 is a poly(2-ethyl-oxazoline) (POZ) polymer conjugate of the potent dopamine agonist rotigotine that is designed to provide continuous drug delivery following a single weekly injection
45962173|NCT02526511|Procedure|Arterial Spin Labeling Magnetic Resonance Imaging|Undergo arterial spin labeled perfusion magnetic resonance imaging
45962174|NCT02526511|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic contrast-enhanced perfusion magnetic resonance imaging
45962175|NCT02526511|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging
45665732|NCT04972253|Drug|Infigratinib|Oral, dosage per protocol
45665733|NCT02500979|Drug|Pramlintide acetate|Pramlintide acetate administered by a separate pump
45665734|NCT02500979|Drug|Placebo|Placebo administered by separate pump
45962176|NCT02526511|Procedure|Perfusion Magnetic Resonance Imaging|Undergo perfusion magnetic resonance imaging
45820898|NCT00002738|Drug|leucovorin calcium|
45458293|NCT04463056|Biological|Elizaria®|Induction cycle: 600 mg (2 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 900 mg every 14 days.
45458520|NCT03493906|Other|Patient Ambassador Support|Patient Ambassador Support, with former patient treated for acute leukaemia being ambassadors for newly diagnosed patients for a period of 12 weeks.
45665735|NCT02500979|Drug|Lispro insulin U-100|Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)
45665736|NCT02500979|Drug|Regular insulin U-100|Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump
45665737|NCT02500901|Drug|Enzalutamide|Following completion of 28-day lead-in cycle, enzalutamide 160 mg PO daily will continue to be administered in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
45665738|NCT02500901|Drug|Niraparib|Niraparib will be administered daily in three dose-escalation cohorts of 6 subjects per dose levels of 100mg PO, 200mg PO or 300mg PO in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
45665739|NCT02479139|Biological|Vehicle|Vehicle for ANT-1207 liniment formulation without active ingredient.
45665740|NCT02479139|Biological|ANT-1207|Botulinum toxin Type A topical liniment (ANT-1207).
45665741|NCT02478359|Behavioral|Physical Activity Coaching (Walk On!)|The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
45665742|NCT01877668|Drug|Tofacitinib 5 mg BID|Tofacitinib orally (po) 1 tablet of 5 mg and placebo po 1 tablet BID x 12 months Placebo injections subcu every 2 weeks x 12 months
45665743|NCT01877668|Drug|Tofacitinib 10 mg BID|Tofacitinib po 2 tablets of 5 mg BID x 12 months Placebo injections subcu every 2 weeks x 12 months
45665744|NCT01877668|Drug|Adalimumab|Placebo po 2 tablets BIDx 12 months Adalimumab 40 mg subcu injections every 2 weeks x 12 months
45665745|NCT01877668|Drug|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 1 tablet of 5 mg and placebo po 1 tablet BID x 9 months Placebo injections every 2 weeks x 12 months
45665746|NCT01877668|Drug|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 2 tablets (5 mg) BID x 9 months Placebo injections every 2 weeks x 12 months
45665747|NCT01877278|Device|Wearable pulsed electromagnetic fields|
45665748|NCT04629352|Device|Verum Transcranial Direct Current Stimulation (tDCS)|In verum transcranial direct current stimulation (tDCS), patient will receive twice-daily for 5-days, 10-sessions course of tDCS [anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2]. For Verum-tDCS condition, 2-mA of constant current will be delivered for 20-minutes, additional ramp-up and ramp-down of 20 seconds each.
45962177|NCT02504866|Other|Exercise|Exercise training of different intensity
45962178|NCT02503475|Other|Real-Time fMRI|"Real-Time fMRI: AR, CR, Sham, and Free Strategy groups will be compared to determine the following:~(1) whether a cognitive strategy improves rtfMRI neurofeedback to modulate brain activity and pain; (2) which strategy is most effective at individual and group levels at modulating brain activity and pain; and (3) whether the investigators can predict individual ability to modulate brain activity or pain using a particular strategy and applying mixed effects modeling of treatment efficacy using baseline measurements."
45962179|NCT02503475|Behavioral|CBT or MBSR|CBT/MBSR: The study will investigate whether CBT versus MBSR differentially enhance behavioral and neural indices of the ability to implement cognitive regulation (CR) and attention regulation (AR) during evoked pain in the lower back in participants with chronic low back pain. An additional wait list control (WL) group will be used to determine the effects of time on pain symptom severity and well-being.
45820899|NCT00002738|Drug|trimetrexate glucuronate|
45820900|NCT04706455|Device|sodium hyaluronate 0.1%|Instillation of one drop sodium hyaluronate 0.1%
45820901|NCT04706455|Device|sodium hyaluronate 0.3%|Instillation of one drop sodium hyaluronate 0.3%
45820902|NCT00002744|Drug|asparaginase|
45820903|NCT00002744|Drug|cyclophosphamide|
45962180|NCT02503475|Device|Acupuncture|Acupuncture: The investigators will compare the efficacy and mechanisms of verum and sham electroacupuncture.
45962181|NCT02481349|Other|Best Practice|Undergo standard of care
45962182|NCT02481349|Other|Informational Intervention|Receive DVD for home practice
45962183|NCT02481349|Other|Quality-of-Life Assessment|Ancillary studies
45962184|NCT02481349|Other|Questionnaire Administration|Ancillary studies
45962185|NCT02481349|Other|Yoga|Complete couple-based Hatha yoga program
45820904|NCT00002744|Drug|cytarabine|
45820905|NCT00002744|Drug|daunorubicin hydrochloride|
45820906|NCT00002744|Drug|dexamethasone|
45820907|NCT00002744|Drug|doxorubicin hydrochloride|
45820908|NCT00002744|Drug|mercaptopurine|
45820909|NCT00002744|Drug|methotrexate|
45820910|NCT00002744|Drug|pegaspargase|
45820911|NCT00002744|Drug|prednisone|
45820912|NCT00002744|Drug|therapeutic hydrocortisone|
45962186|NCT02427620|Drug|Cyclophosphamide|Given IV
45962187|NCT02427620|Drug|Cytarabine|Given IV
45962188|NCT02427620|Drug|Dexamethasone|Given PO or IV
45962189|NCT02427620|Drug|Doxorubicin|Given IV
45665749|NCT04629352|Device|Sham Transcranial Direct Current Stimulation (tDCS)|In sham transcranial direct current stimulation (tDCS), each SCZ patient will receive twice-daily for 5-days, 10-sessions course of tDCS [anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2]. However, no current will be delivered beyond initial ramp-up time though the tDCS device display will indicate that 2mA current is being applied.
45665750|NCT01906372|Drug|Adrenocorticotropic Hormone Gel|H.P. Acthar Gel 80 units will be self-administered subcutaneously twice weekly by the subject for a period of 6 months.
45665751|NCT01925170|Device|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
45665752|NCT01925170|Device|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
45665753|NCT01925170|Drug|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
45820913|NCT00002744|Drug|thioguanine|
45665754|NCT01925014|Diagnostic Test|Diagnostic CT with low-dose radiation|Effective dose is aimed at approximately 2 millisievert (mSv) in an average patient.
45820914|NCT00002744|Drug|vincristine sulfate|
45962190|NCT02427620|Drug|Doxorubicin Hydrochloride|Given IV
45665755|NCT01925014|Diagnostic Test|Diagnostic CT with standard-dose radiation|Effective dose is aimed at approximately 8 millisievert (or less) in an average patient.
45665756|NCT01876810|Drug|Gemfibrozil|600 mg of gemfibrozil (one capsule) twice daily for two weeks.
45665757|NCT01876810|Drug|Placebo|One lactose pill twice a day for two weeks.
45665758|NCT01876732|Drug|Vitamin B12|Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first hemodialysis (HD) session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a Kidney Disease Quality of Life- 36 (KDQOL-36) prior to therapy and again post treatment.
45665759|NCT01905592|Drug|niraparib|300 mg (3x100 mg capsules) once daily until progression or unacceptable toxicity develops
45820915|NCT00002744|Radiation|low-LET cobalt-60 gamma ray therapy|
45458521|NCT03316430|Other|Podocyturia quantification|Podocyturia quantification at first planned prenatal care visit before 16 weeks of gestation
45820916|NCT00002744|Radiation|low-LET photon therapy|
45665760|NCT01905592|Drug|Physician's choice|Choice of 4 standard of care metastatic breast cancer chemotherapies, until progression or unacceptable toxicity develops
45820917|NCT01788475|Drug|Dexamethasone|Ozurdex (dexamethasone) 0.7mg steroid implant
45820918|NCT01183897|Biological|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic|"This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles.Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles The patients have primary refractory BM disease. Protocol treatment is through 24 months.~Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started no later than after cycle 4 (i.e., after response is scored), but sooner if CR is achieved after cycles 1, 2, or 3, or if early HAMA develops."
45820919|NCT00381914|Drug|Vitamin D|400 IU vitamin D / day
45820920|NCT00381914|Drug|Vitamin D|800 IU vitamin D / day
45820921|NCT00381914|Drug|Vitamin D|1200 IU vitamin D / day
45962191|NCT02427620|Drug|Ibrutinib|Given PO
45962192|NCT02427620|Other|Laboratory Biomarker Analysis|Correlative studies
45962193|NCT02427620|Drug|Methotrexate|Given IV
45962194|NCT02427620|Biological|Rituximab|Given IV
45962195|NCT02427620|Drug|Vincristine|Given IV
45962196|NCT02427620|Drug|Vincristine Sulfate|Given IV
45962197|NCT02415621|Drug|Abiraterone Acetate|1000 mg by mouth (PO) every day (QD)
45962198|NCT02403505|Biological|Recombinant COVID-19 Spike Protein plus TICE® BCG Mix for percutaneous use|"By the percutaneous route with the multiple puncture device~Recombinant COVID-19 Spike Protein 0.01 MG, 1.0 mL plus TICE® BCG Organism 50 MG Mix"
45962199|NCT02401035|Drug|IV pantoprazole|Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight
45665761|NCT01876420|Device|The CoreValve™ Evolut R TAV™ system|CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 & 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
45820922|NCT05749094|Diagnostic Test|Optic nerve ultrasound|The patients are examined in a supine relaxed position. The probe is gently placed on the closed eyelid with a standard ultrasound gel and adjusted to a suitable angle to display the optic nerve entry into the eyeball. Measurements are done 3mm distal to the posterior aspect of the ocular globe. Ultrasosonographic 14L5 probe is used with a safe thermal index, mechanical index and intensity limit. All patients will also undergo a bedside fundoscopic examination. Official ophthalmology consultation will be requested in patients with visual symptoms or abnormal fundoscopy.
45820923|NCT00423007|Drug|Bromfenac|
45820924|NCT00423007|Drug|Placebo|
45820925|NCT04713787|Drug|Albendazole|Albendazole, 5-(prophylthio)-2-benzimidazole carbamate, is a broad-spectrum benzimidazole antihelminthic drug. It is provided as a white to off-white, circular, film-coated tablet with a slightly raised pentagonal projection on either side. This trial will use the 400 mg tablet formulation.
45820926|NCT04713787|Drug|Oxfendazole|The active pharmaceutical ingredient is methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, which is a broad-spectrum benzimidazole antihelminthic. Oxfendazole is the sulphoxide metabolite of fenbendazole.
45820927|NCT00002750|Drug|melphalan|
45820928|NCT00002756|Biological|filgrastim|
45820929|NCT00002756|Drug|asparaginase|
45820930|NCT00002756|Drug|cyclophosphamide|
45820931|NCT00002756|Drug|cytarabine|
45820932|NCT00002756|Drug|daunorubicin hydrochloride|
45820933|NCT00002756|Drug|etoposide|
45820934|NCT00002756|Drug|leucovorin calcium|
45820935|NCT00002756|Drug|mercaptopurine|
45820936|NCT00002756|Drug|methotrexate|
45820937|NCT00002756|Drug|prednisone|
45962200|NCT02365766|Drug|Pembrolizumab|In this dose-finding cohort, pembrolizumab (MK-3475) will be administered (cisplatin-eligible patients only) at starting dose 200mg IV every 21 days for 4 cycles to determine RP2D. Once MTD is established in phase Ib, pembrolizumab will be administered on phase II cohorts I and II at RP2D every 21 days for 5 cycles.
45962201|NCT02365766|Drug|Gemcitabine|For cisplatin-eligible patients on phase Ib and phase II cohort 1, gemcitabine 1000mg/m2 IV, D1 and D8 every 21 days for 4 cycles. For cisplatin-ineligible patients on phase II cohort II, gemcitabine 1000mg/m2 will be administered D1, D8 and D15 every 28 days for 3 cycles.
45962202|NCT02365766|Drug|Cisplatin|For cisplatin-eligible patients, cisplatin 70mg/m2 IV will be administered D1 every 21 days for 4 cycles.
45665762|NCT04608682|Drug|Sugammadex|The muscle relaxant infusion will be discontinued and a bolus of sugammadex (2mg/kg) will be given while performing TceMEPs.
45665763|NCT04608682|Drug|Saline|The muscle relaxant infusion will be discontinued and 2ml saline will be infused, TceMEPs monitoring will be performed 5 minutes later.
45665764|NCT04619602|Drug|GSNO|Intervention will be 30 minutes of inhaled GSNO agent in enrollment blocks of three subjects/dose (0.5 mL/kg of 0.25 mM, 0.5 mM, or 1 mM) to infants.
45665765|NCT01875874|Biological|ELAD|Continuous treatment with the ELAD System for a minimum of 3 days to a maximum of 10 days. The subject's ultrafiltrated blood is circulated through 4 cartridges, each containing approximately 110 grams of C3A cells (approximately 440 grams total).
45665766|NCT04619446|Device|Removable Twin Block|Twin block appliance (RFA) was introduced by William Clark in 1988. Many modifications for this appliance have been introduced lately. It has been named twin block for the characteristic of two unattached maxillary and mandibular plates with acrylic bite blocks, which makes 70o angle when come in contact with each other. Delta clasps are added for better retention of the appliance. This appliance plays a vital role in the treatment of mandibular retrognathia
45820938|NCT00002756|Drug|therapeutic hydrocortisone|
45820939|NCT00002756|Drug|vincristine sulfate|
45820940|NCT05599477|Device|Endoscopic sutured gastroplasty with endomina|"The endomina is is used to perform endoscopic sutured gastroplasty. Two guidewires are introduced via an upper GI endoscopy down to the duodenum. The endomina system is introduced and the endoscope is inserted and fixed to the system. Next a needle preloaded with suture is introduced into the platform. The stomach wall is grasped with a forceps and pulled back. The needle is pushed through the wall, and a first tag is released. The needle is retracted, the first plicature is released and a second plicature is made with the same needle at the opposite wall. Then the pretied knot is grasped and tightened until both plicatures are firmly apposed. The same procedure is repeated along the great curvature from the incisura to the upper body.~The procedure will include the placement of 6-9 sutures. The first suture is done at the level of the incisura, at the lower part of the greater curvature. The following stitches are placed along the body of the stomach"
45820941|NCT01183429|Drug|3F8 and 13-cis-retinoic acid|3F8 is dosed at 80 mg/m2/day (cycles 1-2) or 20 mg/m2/day (cycles 3 and beyond) and infused iv over 30-90 minutes. 13-cis-retinoic acid is dosed at 160 mg/m2/day, divided into two doses, x14 days. If a dose is missed, it can be made up at the end of the cycle. It is not taken on same days as 3F8. *High-dose 3F8 will be administered only for patients enrolled on protocol from A(0) to A(7). Starting with A(8), patients receive standard dose (20mg/m2/day) during cycles 1 and 2.
45820942|NCT01157533|Drug|Vancomycin|Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
45962203|NCT02365766|Procedure|Consolidative Surgery|Following completion of treatment, subjects will then have surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
45962204|NCT02324387|Procedure|Molecular Breast Imaging (MBI)|Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled neoadjuvant chemotherapy (NAC) treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
45820943|NCT01760941|Radiation|Radiation Therapy|Undergo standard of care radiation therapy
45962205|NCT02324387|Drug|Tc99m sestamibi|8 mCi of 99mTc sestamibi by vein before each molecular breast imaging (MBI).
45962206|NCT02313623|Procedure|Prostate Fusion Biopsy|For subjects with scheduled fusion biopsies, we propose a research plan to acquire additional biopsy cores for research purposes without impacting clinical protocol. After acquiring clinically-necessary biopsies, we propose taking an additional research biopsy to establish a matched-pair of clinical and research samples.
45962207|NCT02153944|Drug|Propranolol|Propranolol 40 mg was given orally during study visit
45820944|NCT01760941|Other|Quality-of-Life Assessment|The patient quality of life as measured by the ESAS-r; Edmonton Symptom Assessment System revised.
45962208|NCT02153944|Drug|Methylphenidate|Methylphenidate 20mg was given orally during study visit
45962209|NCT02153944|Drug|Placebo|Placebo was given orally during study visit
46079715|NCT04384263|Behavioral|Tai Chi|Participants in the Tai Chi group will practice a Yang style, 8-form Tai Chi routine. Specifically, the routine will incorporate slow, deep breathing and mental relaxation by utilizing Tai Chi movements which: 1) are slow and smooth; 2) without break or pause; and 3) have minimal muscular force and exertion. In addition, investigators will emphasize the breathing techniques of Tai Chi exercise. Investigators will adopt methods of progression to enable the participants learn and safely adapt to the Tai Chi routine and improve skills of practicing, specifically: 1) Tai Chi forms will be taught one at a time; 2) participants will receive instructional videos with step-by-step instructions of how to perform the new Tai Chi form that has been taught in the live online Tai Chi exercise session. Participants will be encouraged to practice Tai Chi offline between live online Tai Chi exercise sessions; however, no time requirement will be proposed.
46079716|NCT04379817|Diagnostic Test|Gallium-68 labelled DOTA-conjugated SSTR targeting peptide PET/CT|Assess somatostatin receptor expression
45962210|NCT02091960|Drug|Enzalutamide|Capsules for oral administration
45962211|NCT02091960|Drug|Trastuzumab|Intravenous infusion (IV) or subcutaneous injection if it is standard of care within a country
45962212|NCT02060721|Drug|Macitentan|Macitentan 10mg, oral tablet, once daily
45962213|NCT02060630|Procedure|Open surgical revascularization|
45665767|NCT04619446|Device|Fixed Functional , AdvanSync Appliance|AdvanSync2 (Ormco Co., Glendora, Calif) is a FFA being introduced recently as an advancement of Herbst appliance. It is a molar-to-molar appliance, connected by a telescopic rod, which allow for simultaneous treatment with braces. It is much smaller in size than the conventional Herbst appliance and reduces treatment duration up to six to nine months. It is much more acceptable by the patients as they complain less about sores and discomfort, and is esthetically pleasant since it's not visible in the mouth. Short arms of this appliance help to decrease irritation and discomfort of the patient, and helps to advance the mandible in a constant forward direction to encourage growth, and reduce malocclusion.
45962214|NCT02060630|Device|Endovascular revascularization|A variety of FDA approved devices will be used within this treatment arm. The trial will submit a proof-of-concept IDE application to the FDA to cover all devices.
45962215|NCT01946854|Behavioral|Questionnaire|"Completion of 3 questionnaires at baseline and at final visit about quality of life, and 1 questionnaire about symptoms, diagnosis, treatment, prognosis, and patient's relationship with caregivers. These will take about 35-50 minutes to complete.~Completion of 3 quality of life questionnaires every 3 months for 1 year."
45820945|NCT01760941|Other|Survey Administration|The surveys consists of Radiation Therapy Worthfullness survey; BPI: brief pain inventory; NUS: narcotics usage survey.
45820946|NCT05556668|Device|Percutaneous placement of biodegradable biliary stents|Benign biliary strictures treated with polydioxanone (PPDX) stents (Ella-DV biliary stent, ELLACS, Hradec Králové, Czech Republic). The stents are implanted using a percutaneous transhepatic cholangiography. Before stent implantation, balloon bilioplasty is be performed.
45820947|NCT05749016|Drug|inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen|Inetetamab (Cipterbin) is a newly marketed anti-HER2 monoclonal antibody with amino acid modified Fc region and enhanced antibody-dependent cellular cytotoxicity (ADCC) effect. There was no robust evidence evaluating the combination of inetetamab with pertuzumab and neoadjuvant chemotherapy (paclitaxel + carboplatin) in the neoadjuvant setting. This study aimed to evaluate the efficacy and safety of inetetamab + pertuzumab+paclitaxel + carboplatin (TCbIP) as a neoadjuvant chemotherapy regimen in the treatment of patients with locally advanced HER2-positive breast cancer.
45820948|NCT01756573|Drug|Dexamthsone|
45820949|NCT01756573|Drug|Bupivacaine|
45820950|NCT00382304|Drug|tolevamer potassium-sodium (GT267-004)|
45820951|NCT01126801|Drug|Estradiol|Oral estradiol 1.0 mg/day for four weeks.
45962216|NCT01782027|Drug|3H-cholesterol bound to albumin|up to 100 uCi of [3H]-cholesterol (containing approximately 0.2 mg of cholesterol) mixed with a solution containing human serum albumin will be administered as an intravenous bolus injection
45962217|NCT01565187|Behavioral|Questionnaires|Transplant Effects Questionnaire, Response Evaluation Measure, Patient Health Questionnaire, Generalized Anxiety Scale, Alcohol Use Disorders Test, Body Image Questionnaire, Quality of Life Uniscale, Scales of Psychosocial Well-Being, Sense of Coherence Scale.
45962218|NCT01527149|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous HDC-ASCT
45665768|NCT02500121|Other|Placebo|Normal saline
45820952|NCT01126801|Other|Placebo control|Placebo control matched to estradiol tablets. Daily dosing for one month.
45962219|NCT01527149|Drug|Cyclophosphamide|Given IV
45962220|NCT01527149|Drug|Cytarabine|Given IV
45665769|NCT02500121|Drug|Pembrolizumab|Pembrolizumab, 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or for up to 24 months
45665770|NCT01875250|Biological|PROSTVAC-F (Fowlpox)/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.
45665771|NCT01875250|Biological|PROSTVAC-V (Vaccinia)/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.
45820953|NCT05445830|Procedure|High-Intensity-Interval-Exercise|Subjects will perform high-intensity-interval exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, blood pressure, ventilatory response, oxygen uptake, and blood lactate. In addition, blood samples will be collected before, immediately after, and 2 hours after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
45962221|NCT01527149|Drug|Dexamethasone|Given IV or PO
45962222|NCT01527149|Drug|Doxorubicin Hydrochloride|Given IV
45962223|NCT01527149|Other|Laboratory Biomarker Analysis|Correlative studies
45962224|NCT01527149|Drug|Methotrexate|Given IV
45962225|NCT01527149|Biological|Ofatumumab|Given IV
45962226|NCT01527149|Drug|Vincristine Sulfate|Given IV
45962227|NCT01504789|Behavioral|Baseline Fitness Test|Complete fitness tests to measure strength, flexibility, balance, and aerobic capacity. All of the baseline fitness tests will be repeated at the end of the program (at about the 16th week) during a follow-up visit.
45962228|NCT01504789|Behavioral|Questionnaires|At the baseline visit, complete questionnaires about demographic information taking about 35 minutes to complete. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. It should take about 10 minutes to complete these questionnaires. Patients also be asked to fill out a questionnaire every week that asks about level of physical activity. The questionnaire should take about 5 minutes to complete.
45962229|NCT01504789|Behavioral|Individualized Exercise Program|The exercise programs will be individualized based on results from baseline fitness assessments and individual medical history using ACSM guidelines. For resistance and flexibility exercises each patient will receive an exercise prescription and instructional session prior to beginning the program. Invitation extended to attend monthly Group Exercise sessions with a family member. Resistance tubes, pedometer, exercise book, and video issued for use at home.
45962230|NCT01504789|Behavioral|Written Materials|Either culturally adapted AI materials or non-culturally intervention materials will be mailed to patients every 2 weeks. The 7 themed sessions are: Getting Started;Goal Setting;Effective Energy Balance;Getting Confident;Uncovering Barriers;Lapsing, Relapsing, Collapsing;and Continuing to be Active.
45962231|NCT01370278|Other|Normal Saline|Normal saline administered in stent/airway tubes under direct visualization via the bronchoscope.
45962232|NCT01370278|Other|Sodium Bicarbonate|4.2% bicarbonate solution mixed with equal volume of sterile water administered into stent/airway tubes under direct visualization via the bronchoscope.
45962233|NCT01359956|Drug|Dacarbazine|900 mg / m2 every 3 weeks
45962234|NCT01359956|Drug|Fotemustine|100 mg / m2 every 3 weeks
45962235|NCT01359956|Drug|Interferon Alfa-2b|5 M units every 3 weeks
45665772|NCT01875250|Drug|Enzalutamide (Xtandi)|An androgen receptor inhibitor.
45820954|NCT05445830|Procedure|Moderate-Intensity-Continuous-Exercise|Subjects will perform moderate intensity continuous exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, blood pressure, ventilatory response, oxygen uptake, and blood lactate. In addition, blood samples will be collected before, immediately after, and 2 hours after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
45962236|NCT01306045|Drug|AZD6244|Cycle = 21 days AZD6244 Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours
45962237|NCT01306045|Drug|MK-2206|Cycle = 28 days MK-2206 200 mg by mouth (PO) every (Q) Week
45962238|NCT01306045|Drug|Lapatinib|Cycle = 21 days Lapatinib 1500 mg by mouth (PO) every day (QD)
45962239|NCT01306045|Drug|Erlotinib|Cycle = 21 days Erlotinib 150 mg by mouth (PO) every morning (QAM)
45962240|NCT01306045|Drug|Sunitinib|Cycle = 42 days Sunitinib 50 mg by mouth (PO) on days 1-28
45962241|NCT01306045|Procedure|Molecular Profiling|Molecular profiling of tumor tissue. Not Otherwise Specified (NOS) arm. Participants who do not meet the eligibility criteria for enrollment or who meet eligibility criteria for a particular arm but can't be enrolled
45962242|NCT01278303|Device|Treatment of Aortic Wall Injury|A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.
45962243|NCT01198067|Drug|Pomalidomide|Given PO
45962244|NCT01196936|Drug|Tamoxifen Citrate|5 mg PO Daily
45962245|NCT01196936|Drug|Placebo|1 tablet daily
45962246|NCT01196936|Procedure|Digital mammography|Correlative studies
45962247|NCT01196936|Other|immunohistochemistry staining method|Correlative Studies
45962248|NCT01196936|Other|pharmacological study|Correlative Studies
45665773|NCT01904032|Drug|Vitamin D3|50,000 international units (IUs) weekly Vitamin D3
45962249|NCT01196936|Other|laboratory biomarker analysis|Correlative Studies
45962250|NCT01196936|Genetic|protein expression analysis|correlative studies
45962251|NCT01196936|Other|pharmacogenomic studies|correlative studies
45962252|NCT01196936|Other|questionnaire administration|Ancillary studies
45962253|NCT01196936|Procedure|Fine needle aspiration|
45962254|NCT01196936|Other|Quality of Life Assessment|Ancillary Studies
45962255|NCT01192568|Drug|Oxybutynin|10% Oxybutynin Chloride Topical Gel, 0.5 g, 0.75 g, and 1 g/day, administered transdermally.
45962256|NCT01075971|Drug|Buprenorphine hydrochloride marketed sublingual tablet (Subutex)|8 mg or 16 mg daily, sublingual route on Days 1 and 2
45665774|NCT01904032|Drug|Vitamin D3 comparator|5,000 international units (IUs) of a weekly Vitamin D3 comparator
45665775|NCT01903876|Behavioral|Bystander & Sexual Violence Prevention|This 3-hour web-based program consists of six 30-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama, which allows for the modeling of positive behaviors and illustrate both positive and negative outcome expectations for intervening and for perpetrating abuse against women. Behaviors modeled include communicating with female sex partners, obtaining informed consent to have sex, and intervening to prevent abuse from taking place.
45665776|NCT01903876|Behavioral|General Health Promotion|This general health promotion web-based program is 3-hours and provides a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise.
45665777|NCT01921348|Device|acupressure pellets|The treatment group will have acupressure pellets placed in pre-determined acupressure point on the ear that relates to rhinitis.
45665778|NCT01921348|Device|acupressure pellets|The sham group will have acupressure pellets placed in a pre-determined non-specific acupressure point on the ear that is not related to rhinitis.
45665779|NCT01921270|Drug|Low Dose - AbobotulinumtoxinA|"Participants will receive low dose AbobotulinumtoxinA injections. Location of injections will be determined by the clinician to treat the individual's dystonic symptom.~Muscles that may be included for in injection for OMD with Jaw Closing:~Medial Pterygoid 50 units, Masseter 25 units~Muscles that may be included in injection for OMD with Jaw Opening:~Lateral Pterygoid 50 units, Anterior digastrics 10 units~Muscle that will be included in injection for OMD with Tongue Protrusion:~Genioglossus 7.5 units"
45665780|NCT02325739|Drug|FGF401|FGF401 is a FGFR4 inhibitor.
45665781|NCT02325739|Biological|PDR001|PDR001 is a humanized anti-PD1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2
45665782|NCT05121922|Behavioral|Metacognitive Therapy|Psychological treatment provided by the patient's regular general practitioner
45665783|NCT01903720|Drug|dexamethasone implant|OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
45820955|NCT05445830|Procedure|Strength training|Subjects will perform a series of a whole-body resistance exercises, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, blood pressure, ventilatory response, oxygen uptake, and blood lactate. In addition, blood samples will be collected before, immediately after, and 2 hours after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
45665784|NCT02366689|Drug|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (triclosan/fluoride) using Total 360 toothbrush for 1 minute, 2 times/day for 6 months (study duration).
45665785|NCT02366689|Drug|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 months (study duration).
45820956|NCT05445830|Procedure|Baseline assessment|Subjects will perform a series of baseline assessment including neurophysiological function, circulatory and vascular function, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status, muscle biopsies, cytokine profiling, and T-cell metabolism.
45820957|NCT05445830|Procedure|1 year follow-up|Subjects will perform the same series of baseline assessment in 1-year time, including neurophysiological function, circulatory and vascular function, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status, muscle biopsies, cytokine profiling, and T-cell metabolism.
45962257|NCT01075971|Drug|Buprenorphine hydrochloride fast dissolving tablet (FDT)|8 mg or 16 mg daily, sublingual route on Days 3, 4, and 5
45962258|NCT00775749|Drug|transdermal nicotine patch|The 7 mg transdermal nicotine patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
45962259|NCT00775749|Drug|placebo patch|The placebo patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
45962260|NCT00576979|Drug|cyclophosphamide|Given IV
45962261|NCT00576979|Drug|etoposide|Given IV
45962262|NCT00576979|Procedure|allogeneic bone marrow transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
45820958|NCT00002762|Behavioral|patient interviewing to obtain menstrual history|
45820959|NCT00002762|Procedure|blood sampling|
45665786|NCT02366689|Drug|fluoride only toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 months (study duration). Immediately after each brushing, rinse whole mouth with 20 ml of Crest fluoride Mouthwash for 30 seconds.
45665787|NCT02366689|Drug|Cetylpyridinium chloride mouthwash|Immediately after each brushing with Crest Pro-Health toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health Mouthwash for 30 seconds.
45820960|NCT01727167|Drug|200ppm CO for one hour|This is the study intervention. The treatment group will breath 200 ppm of CO for one hour over the three days immediately prior to surgery.
45962263|NCT00576979|Procedure|allogeneic hematopoietic stem cell transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
45962264|NCT00576979|Procedure|peripheral blood stem cell transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
45962265|NCT00576979|Radiation|intensity-modulated radiation therapy|Undergo IMRT
45962266|NCT00576979|Radiation|tomotherapy|Undergo IMRT using helical tomotherapy
45962267|NCT00338065|Behavioral|Postural change|Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes
45962268|NCT00338065|Behavioral|Water drinking|Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking.
45962269|NCT00324922|Drug|trimethoprim-sulfamethoxazole|trimethoprim/sulfamethoxazole 320/1600 mg po bid
45962270|NCT00324922|Drug|vancomycin|1g iv bid
45962271|NCT00192816|Behavioral|reaction to pain|
45665788|NCT02366689|Drug|Fluoride only mouthwash|Immediately after each brushing with Crest Cavity Protection toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health For Me mouthwash for 30 seconds.
45962272|NCT05380414|Biological|Tumor samples (archival FFPE) and blood samples|Molecular screening
45962273|NCT05380102|Device|Telemetry monitoring|All participants will be on standard telemetry monitoring for Heart Rate, Respiration Rate and movements using the gold standard (Electrocardiography and Capnography respectively).
45962274|NCT05380102|Device|Continuous monitoring through Earlysense|EarlySense (USFDA approved ballistocardiography device) will be placed under the patients mattress to measure Heart Rate, Respiratory Rate and movements
45962275|NCT05380102|Device|Continuous monitoring through Dozee VS|Dozee VS will be placed under the patients mattress to measure Heart Rate, Respiratory Rate and movements
45962276|NCT00163709|Procedure|BNP test|
45962277|NCT05377879|Device|OPT-IVF dosage|Dosage predicted for each patient by the decision support tool OPTIVF
45962278|NCT05356975|Behavioral|Superset|"A strength circuit training will be performed in a supersets fashion. Three strength circuit training in three blocks.~One leg squat, side plank, and push up.~Deadlift, lumbar extension stretch, and row.~Glute bridge, crunches, and front raise."
45665789|NCT01903252|Drug|TP05|3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)
45665790|NCT01903252|Drug|Asacol 400 mg|3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)
45665791|NCT01920958|Other|TachoSil®|TachoSil® is a collagen sponge that is coated with the active substances human fibrinogen and human thrombin and that supports hemostasis and tissue sealing in surgery.
45962279|NCT05356975|Behavioral|Concurrent|Six resistance exercises in a traditional fashion: three exercises for the lower body (one leg squat, deadlift, and glute bridge). Three exercises for the upper body (push up, row, and front raise). And three aerobic exercises (floor tap squat, jumping jacks, and skaters).
45962280|NCT00192855|Drug|Entacapone|Entacapone 600mg BID
45665792|NCT04415398|Device|Automated flying Drone carrying an Automated external defibrillator (AED)|Totally n=3 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over 4 months during daytime Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.
45665793|NCT05103280|Other|Assistive tennis shoes|Assistive shoes include carbon-fiber and spring loaded shoes.
45665794|NCT01613716|Drug|Ozurdex|Ozurdex .7 mg injected into the treated eye
45665795|NCT05112952|Drug|Lazertinib|Lazertinib tablet will be administered orally.
45665796|NCT01872910|Drug|Placebo|Administered orally
45665797|NCT01872910|Drug|LY3023703|Administered orally
45962281|NCT05351476|Behavioral|Resistance Exercise|300 Kcal worth of weight lifting, 3 times/week for 12 weeks
45962282|NCT05351476|Behavioral|Endurance Exercise|300 Kcal worth of treadmill walking, 3 times/week for 12 weeks
45962283|NCT00407186|Drug|cisplatin+capecitabine|cisplatin 20 mg/m2 (i.v., q 1 w, 5 weeks), capecitabine 575 mg/m2 (b.i.d., oral, on radiotherapy days.
45962284|NCT00407186|Radiation|radiotherapy|45 Gy in 25 fracions (5 days/week)
45962285|NCT00407186|Drug|epirubicin+cisplatin+capecitabine|3 courses q 3 w: epirubicin 50 mg/m2 (i.v., day 1), cisplatin 60 mg/m2 (i.v., day 1), capecitabine 1000 mg/m2 (b.i.d., oral, day 1-14)
45962286|NCT05345743|Procedure|Surgery|All types of surgery requiring general anesthesia
45962287|NCT00553111|Other|educational video|educational video
45820961|NCT01727167|Other|Control|This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
45820962|NCT05748938|Biological|RD14-01|ROR1 Targeted CAR-T cells
45820963|NCT01702909|Drug|Interleukin-2|Interleukin-2
45820964|NCT00002768|Biological|filgrastim|10 microgram/kg body wt subcutaneously daily beginning on d 14 and con't until peripheral blood collection is completed
45820965|NCT00002768|Drug|busulfan|1 mg/kg PO q 6 hrs for 16 doses on days -7 thru -4.
45820966|NCT00002768|Drug|cytarabine|2000 mg/ sq meter IV over 2 hours q 12 hrs x 8 doses on days 1-4
45962288|NCT05335720|Drug|rhEGF|EASYEF® spray 50 mcg, sprayed twice a day for 14 days.
45962289|NCT00163748|Drug|gemcitabine, vinorelbine|
45962290|NCT05324137|Drug|CM326|CM326 injection
45962291|NCT05324137|Other|Placebo|Placebo
45962292|NCT00192933|Procedure|NovoSeven treatment according to guideline|
45962293|NCT05302492|Device|CPAP|CPAP: continue positive airway pressure ventilator is the standard treatment of OSA.
45665798|NCT01872910|Drug|Celecoxib|Administered orally
45665799|NCT03457402|Behavioral|Shaping Delay Tolerance|Participants will be introduced to an adaptive tablet-based application that asks the child to choose between two options: 1) a shorter duration of game play that begins immediately, or 2) a longer duration of game play that begins after a delay. Depending on the child's choices, the application alters the pre-reward delay with the intent of training the child to tolerate longer delays for larger rewards (i.e., more game play). Children may participate in up to 25 approximately 30-minute training sessions over 3-6 weeks.
45665800|NCT01920568|Biological|Denosumab 70 mg/mL|Denosumab will be given as a SC injection of 120 mg by administering a 1.7 mL volume in a single injection
45665801|NCT01920568|Drug|Zoledronic acid 4 mg|Zoledronic acid 4 mg (or equivalent clearance-adjusted dose in subjects with baseline creatinine clearance <=60 ml/min) will be diluted in either 0.9% sodium chloride or 5% dextrose injection and administered IV.
45665802|NCT01920568|Drug|Placebo IV|The placebo will consist of 1.7 mL 0.9% w/v sodium chloride
45665803|NCT01920568|Drug|Placebo SC|The placebo will consist of either 0.9% w/v sodium chloride or 5% dextrose injection
45665804|NCT01920568|Dietary Supplement|Calcium supplement|Subjects are strongly recommended to take daily supplements of at least 500 mg calcium from the day of consent and until completion of the Week 73 follow-up visit.
45665805|NCT01920568|Dietary Supplement|Vitamin D supplement|Subjects are strongly recommended to take daily supplements of at least 400 IU of vitamin D from the day of consent and until completion of the Week 73 follow-up visit.
45665806|NCT01920178|Device|PinPointe Foot Laser|Active Laser Treatment Group will receive active Pinpointe Foot Laser beam. Control Placebo Sham Laser Group will receive only the localizing (aiming) non-active beam of the Pinpointe Foot Laser
45665807|NCT01901848|Behavioral|Cognitive Processing Therapy (CPT)|CPT is based on a social cognitive theory of PTSD that includes primary emotional responses to traumatic events such as fear, anger, and sadness, as well as secondary emotions resulting from a patient's faulty interpretations of the traumatic event. CPT addresses PTSD by facilitating affective expression so that affective components of the trauma memory can be altered. In addition, faulty beliefs about the trauma are challenged and modified using Socratic questioning.
45665808|NCT01901848|Drug|Bupropion|Bupropion is an anti-depressant medication that is commonly used in smoking cessation treatment.
45665809|NCT01901848|Drug|nicotine replacement therapy (NRT)|NRT in the form of nicotine patches and an NRT rescue method (e.g., nicotine gum, lozenge, inhaler) will be prescribed for participants for use on/after quit date.
45665810|NCT01901848|Behavioral|Integrated Care for Smoking Cessation (ICSC)|ICSC is a manualized treatment for smoking cessation involving six sessions of counseling.
45665811|NCT01901848|Behavioral|smokefreeVET|SmokefreeVET is a program that was developed by the National Institutes of Health and Department of Veterans Affairs. The program includes a text messaging protocol for reaching out to Veterans who wish to stop smoking.
45665812|NCT04415632|Other|low glycemic index diet|• Three-day cycle menu of LGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
45665813|NCT04415632|Other|High glycemic index diet|Three-day cycle menu of HGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
45665814|NCT01901614|Procedure|LALAK|"A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
45820967|NCT00002768|Drug|etoposide|40 mg/kg (total dose) IV cont infusion over 96 hrs on days 1-4 of consolidation therapy and 60 mg/kg IV over 4 hrs on day -3 of transplant
45820968|NCT00002768|Drug|methotrexate|For patients with documented CNS disease at first relapse, 12 mg intrathecal for a total of 6 doses given before and/or after transplantation
45665815|NCT01901614|Procedure|IEK|"A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
45665816|NCT01901614|Drug|Retrobulbar Block or General Anesthesia|
45820969|NCT00002768|Procedure|peripheral blood stem cell transplantation|Infusion on Day 0
45820970|NCT00002774|Drug|Tirapazamine|"Tirapazamine is a benzotriazine with selective cytotoxicity for hypoxic cells. Under hypoxic conditions, it undergoes a 1-electron reduction to form a cytotoxic free radical that poisons topoisomerase II and causes DNA breaks, chromosomal aberrations, and cell death.~Tirapazamine was administered on Days 1 and 22 prior to the administration of neoadjuvant cisplatin and on Days 43, 45, 47, 71, 73, and 75 within 1 or 2 hours prior to each simultaneous cisplatin dose.~Tirapazamine dose was as follows:~Level 1 - 300 mg/m2 during the induction phase and 160 mg/m2 during the simultaneous phase (n = 4)~Level 2 - 330 mg/m2 during the induction phase and 260 mg/m2 during the simultaneous phase (n = 4)~Level 3 - 300 mg/m2 during the induction phase and 220 mg/m2 during the simultaneous phase (n = 25)"
45820971|NCT00002774|Drug|Cisplatin|The simultaneous chemoradiotherapy (CRT) regimen included cisplatin 20 mg/m2 administered 3 times per week.
45962294|NCT05302492|Device|Light box|Light box: is the treatment choice for circadian rhythm disorders. now apply to sleep disturbance without OSA or PLMS.
45962295|NCT05298241|Other|Hand-grip Strength Game|Interactive Handgrip Strength Game for ICU patients receiving the game and to assess the impact on psychological.
46079717|NCT04378439|Behavioral|Peer Navigation|"First, as health advisors, community health leaders will raise awareness of HIV, STIs, and HCV and local prevention and care services and help social network members access services. Thus, the community health leader will describe to the process for HCV testing, and how providers are required to maintain confidentiality. As opinion leaders, community health leaders will reframe health-compromising and bolster health-promoting norms and expectations about testing and use of other prevention and care services.~Each community health leader will also conduct formal in-person group activities with their social network members. Our partnership decided that each community health leader will also hold at least 4 formal group sessions during the 12 months of intervention"
45665817|NCT01901614|Device|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections.
45665818|NCT01901614|Drug|Topical Anesthesia|
45665819|NCT01901614|Device|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
45665820|NCT01901302|Drug|CB-5945|
45665821|NCT01901302|Drug|Placebo|
45962296|NCT00163787|Behavioral|outcome measures and self report|
45962297|NCT00192972|Procedure|Catheter ablation (pulmonary vein isolation)|
45820972|NCT00002774|Drug|5-fluorouracil|"100 mg/m2 per day on Days 1 and 22, and continuous infusion (CI) 5-FU at a dose of 1000 mg/m2 per day for 120 hours per cycle starting on Days 1 and 22.~The simultaneous chemoradiotherapy (CRT) regimen included continuous infusion (CI) 5-FU 600 mg/m2 per day for 96 hours per cycle in Weeks 1 and 5 of RT."
45962298|NCT05295199|Other|Progressive relaxation exercise|Progressive relaxation exercise is a type of exercise that involves voluntary stretching and relaxation of major muscle groups in the human body, from the hands to the feet.
45962299|NCT05283343|Device|SP-1P|A subject undergoes corneal thickness measurement with pachymeter.
45962300|NCT05277961|Radiation|Ultraviolet radiation|UV6 tubes
45962301|NCT00193011|Drug|Docetaxel|Docetaxel
45962302|NCT00193011|Drug|Cyclophosphamide|Cyclophosphamide
45962303|NCT00193011|Drug|Methotrexate|Methotrexate
45962304|NCT00193011|Drug|5-Fluorouracil|5-Fluorouracil
45665822|NCT04606420|Behavioral|Lifestyle medicine|"Diet: A low fat (10-15%) whole foods vegan diet, high in complex carbs and low in refined carbs (fruits, vegetables, whole grains, legumes, soy, seeds & nuts). Calories unrestricted. Multivitamin, fish oil, curcumin, vitamin C, B12, CoQ10, lion's mane, probiotic, and magnesium. 21 meals/week and supplements provided to participants and caregivers at no cost to them.~Exercise: Aerobic (e.g., walking) and strength training 30 minutes/day based on a personalized prescription from an exercise physiologist or certified personal trainer and registered nurse.~Stress Management: Meditation, gentle yoga-based poses, progressive relaxation, breathing exercises, and meditation (with optional glasses) 1 hour per day, supervised by a certified stress management specialist.~Group Support: Participants and their spouses/caregivers participate in a support group one hour/session, 3 days/week, supervised by a licensed mental health professional in a supportive, safe environment."
45962305|NCT05276791|Other|EMR|Endoscopic mucosal resection, according to standard care
45962306|NCT05276791|Other|ESD|Endoscopic submucosal dissection, according to standard care
45962307|NCT05272228|Dietary Supplement|Dietary supplement - standard product|Single dose intervention with Standard product Coenzyme Q10 (ubiquinone) 2 capsules - 100 mg total coenzyme Q10
46079718|NCT04378439|Behavioral|mHealth|"In addition to in-person individual and group activities, community health leaders will use mHealth platforms preferred by each social network member (i.e., Facebook , Instagram, testing, and/or GPS-based mobile apps) to communicate with them during the intervention. They will use social media to plan activities and to support use of needed prevention and care services. For example, when planning a group activity (described above), the community health leader will use social media to remind social network members about the activity and help them problem solve barriers to attending. A community health leader and social network member may also communicate in-real-time via social media about the process of participating in a syringe services program or accessing PrEP."
46079719|NCT04347629|Behavioral|Advance Care Planning Video Decision Aid|The video decision aid explores ACP options for medical care for end-stage renal disease (ESRD) and reviews hemodialysis, peritoneal dialysis, as well as medical management without dialysis; it also reviews cardiopulmonary resuscitation (CPR). Patients will also audio- or video-record their preferences using a tablet.
45820973|NCT00002774|Radiation|Radiotherapy (RT)|"During the CRT regimen, RT was given within 3 hrs of the tirapazamine infusion. The dose for the parallel opposed fields was 2 Gy/fraction/day given 5 dys/week up to a total dose of 66-70 Gy at the target lesion. The dose to the supraclavicular region was 50 Gy at a depth of 3 cm, delivered in 25 fractions. Supervoltage photons (≥4 megavolts) were used to treat both locations.~After 50 Gy were delivered to the primary site and regional lymph nodes, all sites were reassessed for clinical response by physical exam, direct fiber optic evaluation, and radiographic imaging (CT or MRI).~Subjects with a CR at both the primary site and the neck completed RT treatment to a total dose ≥66 Gy to the primary site and the involved lymph node(s). Subjects with a CR at the primary site but a partial response (PR) at the neck completed RT treatment to the primary site followed by neck dissection. Subjects with a PR at the primary site stopped radiation at 50 Gy and underwent salvage surgery."
45665823|NCT04415242|Other|positioning|different positioning prior surgery
45665824|NCT01919398|Drug|LY2940680|Administered orally
45665825|NCT04626154|Diagnostic Test|Objectively monitoring thoracoabdominal asynchrony|Objectively monitoring thoracoabdominal asynchrony
45820974|NCT05599165|Other|Different signal processing for consonant recognition|Consonant recognition will be measured in noise with three different signal processing conditions: control (no signal processing), important frequency regions enhanced by signal processing, and combined conditions of important frequency regions enhanced and confused frequency regions removed by signal processing.
45820975|NCT00002780|Biological|aldesleukin|
45962308|NCT05272228|Dietary Supplement|Dietary supplement - Investigational product IP1|Single dose intervention with Investigational product IP1; Q10 MICROENCAPSULATED 2 capsules - 100 mg total coenzyme Q10
45962309|NCT05272228|Dietary Supplement|Dietary supplement - Investigational product IP2|Single dose intervention with Investigational product IP2; Final formulated product BQSM® 2 capsules - 100 mg total coenzyme Q10
45962310|NCT00193089|Drug|Docetaxel|Docetaxel
45962311|NCT00193089|Drug|Vinorelbine|Vinorelbine
45962312|NCT00193089|Drug|Trastuzumab|Trastuzumab
45962313|NCT04724057|Device|AutocathFFR|The MedHub Autocath FFR device is a software only medical device. The FFR is computed from several standard DICOM format 2D angiography images retrieved from the C-arm imaging system, which display the structure of the vessels. The MedHub AutocathFFR device software analyzes these images and automatically (without the need for user selection or markings) and computes and displays the FFR on the viewed blood vessel.
45962314|NCT05260216|Combination Product|Comprehensive prevention and treatment|Children with low risk of caries will receive routine prevention including fluoride foam application twice a year and oral hygiene guidance. Children with middle or high risk of caries will receive fluoride varnish application twice a year and caries restorative treatment in addition to routine prevention. The risk-graded intervention is one kind of comprehensive prevention and treatment.
46079720|NCT04339062|Drug|Cemiplimab|Cemiplimab: via IV, flat predetermined dosage every 21 days.
46079721|NCT04339062|Drug|Everolimus|Everolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while eceiving Cemiplimab
45962315|NCT05260216|Combination Product|Routine prevention|Routine prevention includes fluoride foam application twice a year and oral hygiene guidance.
46079722|NCT04339062|Drug|Sirolimus|Sirolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab
46079723|NCT04339062|Drug|Prednisone|40 mg orally the day prior to the start of cemiplimab dosing (Cycle 1, Day 1) and then daily at tapered dosing while receiving Cemiplimab
46079724|NCT04321343|Drug|PXL065|PXL065 oral tablet
46079725|NCT04321343|Drug|Placebo oral tablet|Placebo oral tablet
45665826|NCT02500043|Drug|TAS-102|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
45665827|NCT02500043|Drug|Placebo|35 mg/m2/dose of placebo orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
45665828|NCT02499575|Drug|0.5% ropivacaine|Adductor block: 10 mL of 0.5% ropivacaine; popliteal block: 30 mL of 0.5% ropivacaine
46079726|NCT04318080|Drug|Tislelizumab|200 mg intravenously (IV) every 3 weeks (Q3W)
45665829|NCT02499575|Drug|Exparel|106 mg (8 mL, equivalent to 120 mg bupivacaine HCl)
45665830|NCT02065791|Drug|Canagliflozin|One 100 mg over-encapsulated tablet orally once daily
45962316|NCT05256082|Diagnostic Test|six-minutes-walking test|Patients conducting a six-minutes-walking test
45962317|NCT00193167|Drug|Topotecan|
45962318|NCT00163904|Behavioral|High mono-unsaturated fat/low carbohydrate diet|
45665831|NCT02065791|Drug|Placebo|One matching placebo capsule orally (by mouth) once daily
45962319|NCT00163904|Behavioral|High carbohydrate/low fat diet|
45962320|NCT05208307|Biological|Belantamab Mafodotin|Given IV
45962321|NCT05208307|Drug|Dexamethasone|Given PO
45962322|NCT05208307|Drug|Pomalidomide|Given PO
45820976|NCT00002780|Biological|cytokine therapy|
45665832|NCT04940663|Behavioral|EMA|Participants will complete surveys about their feelings and social habits through a smartphone app (EMA)
45665833|NCT01654289|Other|Mindfulness Meditation|"Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and regular at-home daily practice. Didactic sessions center on awareness of physical, emotional, cognitive, and interpersonal responses to stress. A half day meditation retreat on a weekend day at the end of week 6 will allow participants to practice their skills."
45665834|NCT01654289|Other|Exercise|Exercise training will primarily focus on walking or jogging, activities that are convenient, easy to teach and do not require special equipment. Individualized programs will be developed for those who have access to specific equipment, are unable to do walking/jogging, or prefer different types of exercise. Each weekly exercise session will include 1½ hours of didactic and 1 hour of group exercise. A half day exercise retreat designed to match the meditation retreat will occur the weekend of week 6. The retreat will include didactics, group discussion and activities, and individualized exercise practice.
45665835|NCT02499029|Drug|N-acetylcysteine|NAC pills were administered each week. NAC is a N acetyl pro-drug of the naturally-occurring amino acid cystine. NAC is a white, crystalline powder with the molecular formula C5H9NO3S and with a molecular weight of 163.2.
45665836|NCT02499029|Drug|Placebo|Identical looking placebo pills were administered each week.
45820977|NCT00002780|Biological|sargramostim|
45962323|NCT00193245|Drug|Topotecan|
45665837|NCT04970225|Other|1 blood sample|4 tubes of 7 ml per sample (a single sample)
45820978|NCT00002780|Drug|carboplatin|
45962324|NCT00193245|Drug|Docetaxel|
45962325|NCT00163943|Behavioral|Dietary weight loss +/- aerobic exercise|
45962326|NCT05169697|Drug|A:YH002+YH001|YH002 on CnD1,YH001 on CnD8,Q3W
45962327|NCT05169697|Drug|B:YH002+YH001|YH002 and YH001 on same day,Q3W
46079727|NCT04305158|Drug|Nitrous Oxide|Patient receiving nitrous oxide are evaluated for success of the procedure
46079728|NCT04303195|Drug|NG101|Capsules
46079729|NCT04303195|Drug|Placebo|Capsules
46079730|NCT04300192|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
46079731|NCT04292470|Drug|Amitriptyline|Amitriptyline tablet
45665838|NCT04970225|Other|2 blood samples|4 tubes of 7 ml per sample / 2 samples : before / after antibiotic treatment
45665839|NCT04939883|Drug|Carvedilol|Carvedilol will be dispensed in a staggered and progressive manner, initially from 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily or development of contraindications
45665840|NCT04939883|Drug|Placebo|Patients will receive placebo in a presumed staggered and progressive manner similar to the intervention group. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy.
45820979|NCT00002780|Drug|cyclophosphamide|
45820980|NCT00002780|Drug|thiotepa|
45820981|NCT00002780|Procedure|peripheral blood stem cell transplantation|
45820982|NCT01692691|Drug|Dacarbazine|Dacarbazine IV - Day 1
45820983|NCT01692691|Drug|Carmustine|Carmustine IV- Day 2
45820984|NCT01692691|Drug|Neulasta|Neulasta SC - Day 3
45962328|NCT05169697|Drug|YH002+YH001|A traditional 3+3 dose escalation algorithm
45962329|NCT00193284|Drug|Gefitinib|
45962330|NCT00193284|Drug|Docetaxel|
45962331|NCT00193284|Drug|Carboplatin|
46079732|NCT04276532|Procedure|sentinel lymph node sampling (SLN)|"Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus sentinel lymph node sampling (SLN).~The principles of surgery procedures and post-operative adjuvant therapies will follow the latest NCCN guidelines；~Surgery carried out by laparotomy, laparoscope, or robotic surgery are accepted；~Colored dyes including indocyanine green (ICG) (preferred), methylene blue, carbon nanotube for sentinel lymph node are accepted."
46079733|NCT04276532|Procedure|pelvic lymphonodectomy (PLN)|Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus pelvic lymphonodectomy (PLN) with para-aortic sampling
45962332|NCT00193284|Drug|Fluorouracil|
45962333|NCT05167045|Behavioral|Brain Health PRO|The BHSP is an educational program designed to teach about dementia. It aims to provide best available evidence for lifestyle changes that can help lower dementia risk, and to provide specific recommendations for positive lifestyle changes (e.g., physical exercises to try at home, healthy recipes). The program was developed as a collaborative effort by Canadian investigators who have expertise in the different areas of dementia prevention, along with input from older-adult citizen advisors.
45962334|NCT00163982|Drug|Norfloxacin|
45962335|NCT05149690|Other|Experimental: monopolar dielectric diathermy and supervised therapeutic exercise|The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar musculature by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. Once the application of (MDR) is finished, an exercise program supervised by a physiotherapist will be carried out. The exercise program will consist mainly of three types: stability and lumbo-pelvic motor control, strengthening and stretching of the lumbar muscles (Annex XIV), with a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday, a total of 8 treatment sessions.
45962336|NCT05149690|Other|Active Comparator: Supervised therapeutic exercise|The Control Group formed by 30 subjects will be administered a training program consisting of three types of exercises, taking into account: stability and lumbopelvic motor control, strengthening and stretching of the lumbar muscles, exactly the same as the Experimental Group. With a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday with a total of 8 treatment sessions.
45665841|NCT02477111|Device|Endovascular abdominal aortic aneurysm repair|Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
45665842|NCT04969367|Other|Medical Device Usage and Evaluation|Wear activity monitor (Fitbit)
45665843|NCT04969367|Procedure|Biospecimen Collection|Undergo collection of blood samples
45665844|NCT04969367|Other|Questionnaire Administration|Complete questionnaires
45820985|NCT05539040|Procedure|Right Atrial ganglionated plexus ablation|"A 3D electroanatomic map of the right atrium will be made. During sinus rhythm, the ablation catheter will be positioned at a spot to test with HFS. The right atrium will be paced at a fixed rate, for up to four beats to ensure that there is no ventricular capture then a short burst of HFS will be synchronized to each paced stimulus for up to 15 trains. This will be performed using a custom-built GP stimulator that has been validated for reproducibility against Grass Stimulator (AstroMed).~All Sites will be marked on the 3D map and the positive sites will be ablated at the end of the mapping. If the patient converts to AF, then DC cardioversion will be performed. If mapping in sinus rhythm is not feasible, HFS will be performed continuously for several seconds to identify atrioventricular dissociating GPs (AVD-GPs).~Every ablated GP site will be re-tested with HFS at the end of the procedure until they are all rendered non-functional."
45962337|NCT00193323|Drug|Docetaxel|
45962338|NCT00193323|Drug|Gemcitabine|
45665845|NCT04969367|Other|Quality-of-Life Assessment|Complete questionnaires
45962339|NCT00164021|Procedure|Physiotherapy, exercise, percutaneous gastrostomy feeds|
45962340|NCT00164021|Drug|Anti-reflux pharmacotherapy|
45962341|NCT05129371|Other|Breathing exercise|Following the protocol prepared, the breathing exercise group is given breathing exercises for about 20 minutes, 3 times a week for 8 weeks, under the supervision of the trainer, in the hospital face-to-face, and after discharge through video calls over the WhatsApp application. Reminders (by text message or voice call) are used for the remaining 4 days of the week, allowing the patient to do it on their own.
45820986|NCT05539040|Diagnostic Test|Holter Monitor|"48 hour Holter monitors will be performed post procedure to monitor for recurrence of AF.~These will be performed at 3, 6, 9, 12 months"
45820987|NCT05539040|Procedure|Pulmonary vein isolation|"Transseptal puncture for access into the left atrium will be guided by TOE and fluoroscopy.~ACT will be maintained at 300s with heparin. A 3D electroanatomic map of the left atrium will be created and all PVs will be identified. Touch-up radiofrequency ablation will be performed at electrical gaps around the reconnected PVs until complete PVI is achieved."
45820988|NCT05539040|Procedure|Right cavo-tricuspid and left roof linear ablation|CONTROL ARM (Redo-PVI) only: If all Pulmonary veins are isolated at the start of the procedure, the operator will be allowed to perform a right cavo-tricuspid and left roof linear ablation.
45820989|NCT05539040|Diagnostic Test|Personal ECG recordings|All patients will be provided with an AliveCor KardiaMobile-6L ECG recorder. The device will continue to be used within its CE-marked and NICE-approved purpose. Patients will be asked to take a daily recording from this, once the blanking period is over, in addition to taking a recording if symptomatic. Patients will submit this to the connected care team at Hammersmith Hospital via a secure NHS.net email address, who will assess the recordings both for the study and clinical purposes.
45962342|NCT05129371|Other|Placebo Breathing Group|The placebo group is asked to breathe normally through the nose with eyes closed, sitting in the same position as the intervention group for 10-15 minutes, 3 times a week for 8 weeks, under the supervision of the trainer, in the hospital face-to-face, and after discharge through video calls over the WhatsApp application.
45962343|NCT00193362|Drug|Paclitaxel|
45665846|NCT04968353|Device|Incisally-beveled attachment|Incisally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
45665847|NCT04968353|Device|Gingivally-beveled attachment|Gingivally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
45665848|NCT04968353|Device|Optimized attachment|Optimized attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
45962344|NCT00193362|Drug|Carboplatin|
45962345|NCT00193362|Drug|Gemcitabine|
45962346|NCT00193362|Drug|Vinorelbine|
45962347|NCT04683757|Other|Establishment of a Survival Prediction Model|a nomogram to predict the survival of patients with ER positive / HER-2 negative advanced breast cancer
45962348|NCT04683523|Other|Exercise|Resistance training using dumbbells and therabands
45962349|NCT05115292|Biological|BJ-005|dosed with intravenous infusion
45962350|NCT00193401|Drug|Topotecan|
45962351|NCT00553189|Drug|ABT-888|
45962352|NCT00553189|Drug|Topotecan|
45962353|NCT00164099|Drug|Synbiotic 2000|See protocol - 4 bacteria, 4 fiber mixture
45665849|NCT04968353|Device|Horizontal attachment|Horizontal attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
45665850|NCT04968119|Other|Exercise Intervention|Participate in telehealth exercise sessions
45665851|NCT04968119|Other|Quality-of-Life Assessment|Ancillary studies
45665852|NCT04968119|Other|Questionnaire Administration|Ancillary studies
45665853|NCT02065713|Drug|Golimumab|Prefilled syringe with golimumab 50mg (Simponi®) administrated subcutaneously, once monthly, for 24 weeks.
45665854|NCT02065713|Drug|Methotrexate|MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity
45665855|NCT02065713|Drug|Placebo|The prefilled syringe with placebo will be administrated subcutaneously, once monthly, for 24 weeks.
45962354|NCT05093452|Behavioral|Motivational Interviewing|Mothers randomized in the intervention group will receive an educational session based on the motivational interviewing (MI) approach with a midwife. The midwife will have first received a standardized 3 days training session on the content and techniques of MI. The MI intervention will be carried out in simple and understandable language in order to allow discussion and questions from parents rather than provide prescriptive and direct information. The intervention will last approximatively 15 to 20 minutes.
45962355|NCT05093452|Other|Information flyer|Mothers randomized in the control group will receive a locally information flyer on childhood vaccines without any oral explanation by the midwife.
45962356|NCT05088421|Drug|BWC0977|"SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days."
45962357|NCT05088421|Drug|Placebo|SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
45962358|NCT00193440|Drug|Rituximab|
45962359|NCT00193440|Drug|CHOP|
45820990|NCT05539040|Other|Quality of life questionnaire|A Quality of life questionnaire will be performed at baseline, 6 and 12 months to assess the effect of the procedures on patients quality of life.
45820991|NCT01127503|Drug|Metyrosine|Metyrosine (250 mg capsules) were to be used at all dose levels (administered as multiples of that dosing unit). The starting dose was 250 mg/day of metyrosine. Dose escalation was to be carried out weekly for 8 weeks (up to a maximum of 8 capsules/day [2000 mg/day if metyrosine]) with dosage increments of 1 capsule/day per week. Weekly dose escalation was to stop based upon the investigator's assessment of safety, but not efficacy (i.e., dose escalation was to be forced to the maximum of 8 capsules/day assuming acceptable safety and tolerability).
45820992|NCT01127503|Drug|Placebo|Placebo capsules were identically matched to Metyrosine.
45962360|NCT00193440|Drug|CVP|
45962361|NCT00193440|Drug|Ibritumomab Tiuxetan|
45962362|NCT05077969|Drug|Famotidine|80 mg tablet, QID for 14 days
45962363|NCT05077969|Drug|Celecoxib|400 mg (initial dose), then 200 mg capsule, BID for 5 days
45962364|NCT05077969|Drug|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
45962365|NCT00164138|Procedure|Pelvic floor training group|pelvic floor training, electrotherapy, bladder retraining.
45962366|NCT05063734|Drug|THR-687 dose level 1|3 intravitreal injections of THR-687 dose level 1, 1 month apart
45962367|NCT05063734|Drug|THR-687 dose level 2|3 intravitreal injections of THR-687 dose level 2, 1 month apart
45962368|NCT05063734|Drug|THR-687 selected dose level|3 intravitreal injections of THR-687 selected dose level, 1 month apart, possibly followed by a 4th intravitreal injection with the same dose level of THR-687 at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
45665856|NCT04701489|Device|Splenic ultrasound|GE LOGIQ E10 device with C1-6 ultrasound probe
45962369|NCT05063734|Drug|Aflibercept|3 intravitreal injections of aflibercept, 1 month apart, possibly followed by a 4th intravitreal injection with aflibercept at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
45962370|NCT05062564|Device|LipiFlow Thermal pulsation system|Single treatment with LipiFlow thermal pulsation system on the eyelids within two months before surgery
45962371|NCT05062564|Procedure|Eyelid warm compresses plus massages|Eyelid warm compresses plus massages twice a day for the preoperative month
45962372|NCT00193518|Drug|Arsenic Trioxide|
45665857|NCT02497781|Drug|Ceftazidime -avibactam|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
45665858|NCT02497781|Drug|Cefepime|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
45665859|NCT02497469|Drug|Vedolizumab|Vedolizumab infusion
45665860|NCT02497469|Drug|Adalimumab placebo|Adalimumab placebo-matching injection
45665861|NCT02497469|Drug|Adalimumab|Adalimumab injection
45962373|NCT00164177|Drug|HalfLytely|
45962374|NCT04722510|Device|repeated transcranial magnetic stimulation|Transcranial magnetic stimulation is a non-invasive brain modulation technique that has proven to be a useful study and treatment tool in neuropsychiatric disorders. This technique allows to increase (with high frequency protocol, > 1 Hz) or decrease (with low frecuency protocols, 1 hz or less) neuronal excitability in a focused cortical area.
45962375|NCT00164216|Drug|mefloquine plus artesunate|
45665862|NCT02497469|Drug|Vedolizumab placebo|Vedolizumab placebo-matching infusion
45665863|NCT02497391|Drug|Evacetrapib|administered orally
45665864|NCT04939727|Other|OUD-CDS + Suicide Risk Model associated CDS|Access to OUD-CDS + Suicide Risk CDS
45665865|NCT02476175|Drug|Mirabegron|Patients will keep the antimuscarinic providing some efficacy and that is tolerated and Mirabegron will be added (dual therapy).
45665866|NCT02065557|Biological|Adalimumab|Subcutaneous (SC) injection
46079734|NCT04274764|Behavioral|Personalized eHealth Education & Motivational Interviewing|This intervention uses a web-based application to generate personalized education materials for patients based on their eye health screening results and barriers to follow up care. A glaucoma counselor trained in brief, glaucoma-specific motivational interviewing (MI) uses the individualized content generated from this web- based application to form the basis of her conversation with the patient to coach the patient to engage in follow-up care.
46079735|NCT04273048|Other|Diet Intervention - Group 1|They will be provided with a Mediterranean diet plan.
46079736|NCT04273048|Other|Exercise Intervention - Group 1|They will be provided with an exercise plan to follow.
45665867|NCT02065557|Biological|Placebo|Subcutaneous (SC) injection
45665868|NCT02065245|Biological|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion
45665869|NCT02065245|Biological|Placebo|Placebo administered by peripheral intravenous infusion.
45665870|NCT02065245|Biological|Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion.
45665871|NCT02043015|Behavioral|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
45665872|NCT02043015|Behavioral|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
45665873|NCT02043015|Behavioral|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
45665874|NCT02043015|Drug|Pre-exposure prophylaxis with FTC/TDF|For men who meet eligibility criteria, PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit. Men who accept PrEP will be required to have clinic visits, in addition to the regularly scheduled study visits, one month after starting PrEP and at least every 3 months afterward to monitor blood creatinine, AST/ALT and phosphorus levels.
45820993|NCT05748782|Other|Baska Mask|The Baska mask (Logikal Health Products PTY Ltd., Morisset, NSW, Australia) is a supraglottic airway device introduced in 2012 with many innovations that might be expected to overcome these derangements.
45820994|NCT05748782|Device|Endotracheal tube|BASKA Mask
45820995|NCT01122511|Drug|700 ug dexamethasone|Intravitreal injection of 700 ug dexamethasone into study eye
45820996|NCT01122511|Biological|ranibizumab|Intravitreal injection of ranibizumab into study eye
45820997|NCT01122511|Other|sham|Sham needle-less injection administered in the study eye
45820998|NCT05535218|Drug|Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]|"Neoadjuvant treatment: 10 mg/kg sacituzumab-govitecan IV, on days 1, 8, of each 21 day cycle; Pembrolizumab will be administered in combination with sacituzumab-govitecan on day 1, every 21 days, at the standard dose of 200 mg intravenously. A total of 4 cycles is planned before surgery.~After surgery patients will receive additional 13 cycles of pembrolizumab at the standard dose, every 3 weeks, accounting for a total of 17 cycles of perioperative pembrolizumab (neoadjuvant + adjuvant)."
45820999|NCT05531708|Biological|Anti-mesothelin CAR-T cells|D0: Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
45821000|NCT05531708|Drug|Fludarabine|D-7 to D-3: Fludarabine (25 mg/m^2/day) will be administered intravenously for 5 days.
45821001|NCT05531708|Drug|Cyclophosphamide|D-7 and D-6: Cyclophosphamide (60 mg/kg/day) will be administered intravenously for 2 days.
45821002|NCT01663285|Drug|Neoadjuvant Cisplatin and Gemcitabine|Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
45821003|NCT00002786|Biological|aldesleukin|
45821004|NCT00002786|Biological|therapeutic tumor infiltrating lymphocytes|
45821005|NCT00378937|Drug|acetaminophen|
45821006|NCT00378937|Drug|codeine phosphate|
45821007|NCT00378937|Drug|dextropropoxyphene hydrochloride|
45821008|NCT00378937|Drug|morphine sulfate|
45821009|NCT00378937|Drug|oxycodone hydrochloride|
45821010|NCT00378937|Procedure|management of therapy complications|
45821011|NCT00378937|Procedure|quality-of-life assessment|
45821012|NCT00002792|Drug|busulfan|
45821013|NCT00002792|Drug|cyclophosphamide|
45821014|NCT00002792|Drug|cyclosporine|
45821015|NCT00002792|Drug|methotrexate|
45821016|NCT00002792|Drug|tacrolimus|
45962376|NCT05043961|Procedure|Palisade sacroiliac joint radiofrequency ablation using 3-tined needles|"Palisade-RF is performed using a conventional temperature-controlled RF generator generating monopolar and bipolar lesions at 85°C for 150 sec, with a 60 sec ramp time. Four, 18 Gauge 3-tined, 90 mm cannulas with an active tip of 10 mm (RF Trident; Diros Technology) will be used along with a four-output radiofrequency generator configured for quadripolar and bipolar output.~The RF energy is delivered, making one quadripolar or two bipolar lesions at a time. This procedure is repeated at the remaining target sites by leapfroging the needles, until the entire length is lesioned.~Lesioning the L5 dorsal ramus:~o The RF needle is inserted at the inflexion between the ala of the sacrum and the S1 superior articular process. The RF energy is delivered, creating a monopolar lesion."
45821017|NCT00002792|Procedure|allogeneic bone marrow transplantation|
45821018|NCT00002792|Procedure|peripheral blood stem cell transplantation|
45821019|NCT01673425|Drug|Live Attenuated Influenza Vaccine|All participants will be given FluMist.
45821020|NCT05599087|Biological|Acellular system|Regenerative Endodontic Procedure Tissue engineering procedure
45962377|NCT00193557|Drug|Bortezomib|
45962378|NCT05039671|Behavioral|Measurement-based care (MBC)|Clinicians will receive a 3-hour interactive MBC training followed by six months of post-training consultation. Training and consultation will include how to collect, score, and use student- and parent-reported progress measures with students and families to inform collaborative progress monitoring and treatment decisions.
45962379|NCT00164255|Drug|sulfadoxine/pyrimethamine|
45962380|NCT00164255|Drug|sulfadoxine/pyrimethamine plus artesunate|
45665875|NCT02043015|Other|Staff and provider MSM and LGBT sensitization training|The training for clinicians will focus on specific sexual health issues for MSM, including taking sexual histories in a non-judgmental way, physical examination techniques including anal examinations, and collection of rectal swabs for STI testing. Trainings will include topics about stigma, sexual identity and coming out, anal sex, STIs, and mental health. Training on LGBT sensitization will be provided for medical providers and staff in target clinics.
45962381|NCT05023642|Other|resistance training|"Interventions will include a three-phase strengthening training protocol.~Adaptation phase: three sessions, emphasis on learning the technique, body self-awareness, and movement coordination;~Basic phase: 12 sessions, to increase muscle strength; and~Specific phase: 21 sessions, to intensify the process of strength gain and muscular hypertrophy.~Participants will perform the following exercises during the strength-training protocol intervention: pec deck/seated lever fly, adductor, pulldown, abductor strengthening, alternating dumbbell curl, leg press at a 45-angle, triceps pulley, lateral raise, knee flexion and extension, ankle joint flexion and extension in the leg press, and crunches. If the participant has difficulty performing a specific exercise, an equivalent activity will replace it. From the eighth week onwards, participants will perform additional exercises focused on strengthening the gastrocnemius and soleus."
45962382|NCT00409500|Drug|AQW051|
45962383|NCT05003362|Behavioral|ACT|mindfulness intervention for patients with pain/migraine
45962384|NCT00164294|Behavioral|Brief intervention|
45962385|NCT00409656|Drug|Basiliximab|
45665876|NCT02043015|Behavioral|HIV Testing and Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
45821021|NCT05748704|Other|Short-term modified fasting|STMF regimen consists of a low-calorie diet aimed at providing 800-1,000 kcal/day, lasting five days and with the following composition: 10% carbohydrates, 15% proteins, 75% lipids. During the days of STMF, patients will be required to write down the foods consumed in a food diary in order to calculate calorie and nutrients intake. The STMF regimen will be administered tentatively on a monthly basis (depending on the therapeutic regimen the patient undergoes) and in any case no more frequently than once every three weeks.
45821022|NCT05598385|Procedure|Open cannulation|A small incision is made to access the FA and FA. Afterwards, the incision site is traditionally closed with sutures.
45962386|NCT00164333|Behavioral|TAP: Treatment Advocacy Program|
45962387|NCT04683328|Biological|SCTA01|Recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
46079737|NCT04250675|Device|Intermittent pneumatic leg compressions|Patients will be asked to use the ArtAssist® device to compress the foot and ankle (120 mmHg) of both legs for 2 hours daily for 3 months.
46079738|NCT04250675|Device|Sham|Patients will be asked to use the ArtAssist® device to compress the foot and ankle (30 mmHg) of both legs for 2 hours daily for 3 months.
46079739|NCT04230473|Biological|single dose of CNCT19|"Dose A: 0.25 x 10^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose B: 1.00 x 10^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose C: 2.00 x 10^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide"
45962388|NCT04683328|Biological|SCTA01 Placebo|The excipients of SCTA01
46079740|NCT04221932|Device|CRRT KPI Reports|This will involve the regular report of CRRT KPI reports across the CRRT programs across the province. It will also include standardization of CRRT practices across Alberta. Reports will include those for the program (i.e., structure), device (i.e., process) and patient outcomes (i.e., outcomes).
46079741|NCT04217590|Drug|Sodium Zirconium Cyclosilicate|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.
46079742|NCT04217590|Drug|Placebo|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
46079743|NCT04216823|Device|perfusion index|perfusion index in the prediction of peripheral block success was previously reported for infraclavicular brachial plexus block, axillary brachial plexus block, interscalene brachial plexus block, and supraclavicular brachial plexus in adult patients
46079744|NCT04214730|Combination Product|NK combined with Chemotherapy|Patients will receive 4 cycles of NK treatments combined with Chemotherapy within 8 months
46079745|NCT04214730|Drug|Chemotherapy|Patients will only receive Chemotherapy.
46079746|NCT04214717|Combination Product|DC-CIK combined with Chemotherapy|Patients will receive 4 cycles of DC-CIK treatments combined with Chemotherapy within 8 months.
46079747|NCT04214717|Drug|Chemotherapy|Patients will only receive Chemotherapy.
46079748|NCT04212728|Biological|Auotologous AMSCs plus autologous PRP|150 mL subcutaneous abdominal adipose tissue will be harvested via liposuction . AMSCs will be isolated and cultured from adipose tissue. Before injection, 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.Cultured AMSCs will be collected and suspended by 3ml autologous PRP.
45962389|NCT04683016|Other|Questionnaires|"Patients will be asked two sets of questions:~questionnaire about their perception of periodontal disease (Brief Illness Perception Questionnaire; 9 questions, answers will be registered on a scale of 0 to 10);~Oral Health Impact Profile 14 (OHIP-14) questionnaire.~All these two sets of questions will be asked before and after non surgical periodontal therapy"
45962390|NCT04981405|Biological|COVID-19 Vaccines|"Gam-COVID-Vac EpiVacCorona COVIVAC"
45962391|NCT00409695|Drug|Low Dose Thymoglobulin (ATG)|2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
45962392|NCT00409695|Drug|High Dose Thymoglobulin (ATG)|1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
45665877|NCT02043015|Behavioral|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for STIs will be treated at the clinic site.
45665878|NCT02064231|Device|Coloplast Test A|Coloplast Test A is a new ostomy appliance developed by Coloplast A/S
45665879|NCT02064231|Device|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance developed by Coloplast A/S
45665880|NCT02064231|Device|Own product|Own product is tested to get baseline results. Own product can be any 2-piece product that is commercially available. The manufactures can be Coloplast, Hollister, Convatec, Dansac, B. Braun and others.
45665881|NCT02064231|Device|Coloplast Test C|Coloplast Test C is a new ostomy appliance developed by Coloplast A/S
45665882|NCT02064231|Device|Coloplast Test D|Coloplast Test D is a new ostomy appliance developed by Coloplast A/S
45665883|NCT02063217|Drug|Sodium Oxybate|Sodium oxybate h.s.
45962393|NCT00164372|Behavioral|Peer Education Intervention|
46079749|NCT04212728|Biological|Auotologous PRP|30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.
45665884|NCT02063217|Behavioral|Sleep deprivation|36hr sleep deprivation
45665885|NCT02497001|Drug|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])
45665886|NCT02497001|Drug|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)
45665887|NCT02497001|Drug|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)
45665888|NCT02497001|Drug|Symbicort® Turbuhaler® (TBH) Inhalation Powder|
45665889|NCT04182555|Device|Bilirubin estimates from Smartphone Application|Bilirubin estimates through color analysis of digital images obtained through smartphone application.
45665890|NCT04182555|Diagnostic Test|Bilirubin concentration measured in standard blood samples|Bilirubin measured in total serum bilirubin.
45665891|NCT04182555|Device|Bilirubin estimates from standard transcutaneous device|Bilirubin estimates performed by transcutaneous device ( Dräger JM-105)
45665892|NCT04182555|Other|Visual assessment of jaundice|Degree of jaundice will be assessed by Kramer scale
45665893|NCT04733079|Other|Cleanweb electronic messaging ePro|Patient and their medecin will communicate regulary via Cleanweb electronic messaging ePro to adapt the posology of THU untill the target urecemia is reached
45665894|NCT04733079|Other|Usual follow-up|Adaptation and follow-up of ULT according to referring physician's habits
45665895|NCT02366143|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until loss of clinical benefit.
45665896|NCT02366143|Drug|Bevacizumab|Bevacizumab was administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, or death.
45665897|NCT02366143|Drug|Carboplatin|Carboplatin was administered at area under the concentration-time curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
45665898|NCT02366143|Drug|Paclitaxel|Paclitaxel was administered as IV infusion at a dose of 200 milligrams per square meter (mg/m^2) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
45665899|NCT02098395|Drug|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
45665900|NCT02098395|Drug|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
45665901|NCT02098395|Drug|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
45962394|NCT04977232|Drug|Escitalopram|Selective serotonin reuptake inhibitors (SSRI) were most commonly used first line pharmacotherapy for depression.
45962395|NCT04977232|Behavioral|Game intervention|Participants will be instructed to play the commercial video game for about 30-60 minutes at least three times per week.
45962396|NCT04974814|Drug|Rosuvastatin 40mg|patients in active arms will be preloaded with a single 40 mg rosuvastatin in ER before PCI
45962397|NCT04974814|Drug|Atorvastatin 80mg|patients in active arms will be preloaded with a single 80 mg atorvastatin in ER before PCI
45962398|NCT04974814|Drug|Control Test|patients in control arm will not preloaded with statin in ER before PCI
45962399|NCT00409734|Behavioral|Children with pyloric stenosis|Both cohorts' feeding habits will be observed and recorded for the purposes of comparison
45962400|NCT00409734|Behavioral|Children without pyloric stenosis|Both cohorts' feeding habits will be observed and recorded for the purposes of comparison
46079750|NCT04208334|Dietary Supplement|Curcumin|We give an Intervention arm to consume Curcumin 4000mg/day for 60 consecutive days.
46079751|NCT04208334|Other|Placebo|We give a control arm to consume placebo for 60 consecutive days.
45962401|NCT00164411|Biological|Tetanus-diphtheria toxoids (Td)|
45962402|NCT00164411|Biological|7-valent pneumococcal conjugate vaccine|
45962403|NCT00164411|Biological|23-valent polysaccharide vaccine|
45962404|NCT04921345|Drug|Nemolizumab|Participants will receive subcutaneous (SC) injection of 10, 20 or 30 milligrams (mg) nemolizumab, every 4 weeks (Q4W) for 52 weeks with a loading dose of 20, 40 or 60 mg at Day 1 based on the body weight.
45962405|NCT04921345|Drug|Nemolizumab|Participants will receive SC injection of 5, 10 or 15 mg nemolizumab, Q4W for 52 weeks with a loading dose of 10, 20 or 30 mg at Day 1 based on the body weight.
46079752|NCT04205019|Biological|Neuro-Cells|Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
46079753|NCT04193397|Behavioral|Exercise training|Resistance training program performed during 6 months, 3 sessions per week
45962406|NCT04910815|Device|Atmo Gas Capsule|The Atmo gas capsule is an ingestible electronic device. This capsule consists of gas and temperature sensors, electronic circuits, radio transmitter and silver oxide batteries. It can measure the concentrations and types of intestinal gases in individuals and give an indication of gut transit time. This data is used for research purposes to gain an understanding of the microbiota's localised functionality. The data from the sensors is transmitted out of the body over the radio frequency to a handheld receiver. The capsule passes out of the human body at the end of the measurement and is disposable.
45962407|NCT04910815|Diagnostic Test|Glucose Breath Test|Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen gas as a by-product. The hydrogen produced through fermentation is measured in the patients exhaled breath
45665902|NCT02098395|Drug|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
45665903|NCT02098395|Drug|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
45665904|NCT02098395|Drug|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
45665905|NCT02041923|Behavioral|H-HOPE|Infant remediation using a developmentally appropriate multisensory intervention addresses the specific behavioral organization needs of premature infants. Maternal redefinition and re-education by a nurse-community advocate team uses participatory guidance to address the needs of mothers of premature infants.
45665906|NCT02041923|Other|Attention Control|Mothers received equal amount of attention from the team. Attention consisted of additional teaching regarding premature infant care.
45665907|NCT02365519|Biological|LME636 ophthalmic solution|
45665908|NCT02365519|Biological|LME636 Vehicle|Inactive ingredients used as a placebo comparator
45665909|NCT04700163|Biological|C144-LS and C-135-LS|A combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein
45821023|NCT05598385|Procedure|Percutaneous cannulation|Cannulation is performed through a suture-mediated closure system.
45821024|NCT05598307|Drug|magnesium bolus followed by normal saline infusion|a bolus dose of magnesium will be followed by normal saline infusion
45821025|NCT05598307|Drug|magnesium bolus followed by magnesium infusion|a bolus dose of magnesium will be followed by a magnesium infusion
45821026|NCT05598307|Drug|normal saline bolus followed by normal saline infusion|a bolus of normal saline will be followed by normal saline infusion
45458294|NCT04463056|Biological|Soliris®|Induction cycle: 600 mg (2 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 900 mg every 14 days.
45665910|NCT02061813|Drug|Abametapir Lotion 0.74% w/w|applied 0.2 mL topically under occlusive condition
45962408|NCT04910815|Diagnostic Test|Fructoolifosaccharides (FOS) Breath Test|FOS is a long chain carbohydrate that can only be broken down by bacteria with hydrogen gas as a by-product. The hydrogen produced through fermentation is measured in the patients exhaled breath
46079754|NCT04169568|Procedure|Manuel cuff blood pressure|Blood pressure will be obtained using a sphygmomanometer. Only Registered Nurses will apply BP cuff after careful inspection of the upper extremity for bruising, swelling or tenderness.
46079755|NCT04158141|Drug|Carboplatin|Given IV
46079756|NCT04158141|Drug|Cisplatin|Given IV
45665911|NCT02061813|Drug|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.
45665912|NCT02061813|Drug|Saline 0.9%|A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control
45821027|NCT05747612|Other|Counseling and Coaching|"Counseling is the art of helping yourself, that is, a helping relationship based on a series of interventions and stimuli for creativity, aimed at pursuing and maintaining an ever better relational, social and existential quality of life. Coaching is a fundamentally action-oriented method, aimed at concrete changes, the improvement of performance and the achievement of objectives."
45962409|NCT04910815|Procedure|Jejunal Aspiration and culture|Endoscopic procedure to determine microbial load of the Small bowel. This is the gold standard to determine the Active SIBO cases
45821028|NCT01090141|Drug|Micafungin|100 mg IV infusion over 1 hour
45821029|NCT01090141|Drug|Micafungin|300 mg IV infusion over 1 hour
45962410|NCT04910815|Drug|Rifaximin|Rifaximin (550g) 1 capsule twice a day for 14 days.
45962411|NCT04910815|Drug|Placebo|randomised administration of either placebo or Rifaximin (550g) 1 capsule twice a day for 14 days. The placebo will be encapsulated maize starch and pregelatinised maize starch
45962412|NCT00193635|Drug|mycophenolate mofetil|oral drug administration
45962413|NCT04903249|Behavioral|Core Exercise Promotion Intervention|"Participants are instructed to increase weekly time spent exercising to >90 minutes over 12 weeks. Exercise will be defined as activities that use large muscle groups, increase heart rate and breathing rate, and are performed intentionally for the purpose of exercise (as opposed to physical activities of daily living, e.g., housework). Participants complete a videoconferencing visit with the study team and are given task and safety related information pertaining to exercise for survivors of cancer. Participants engage in exercise-related goal-setting and action planning and are provided activity trackers to monitor their activity levels over the 12-week study period."
45821030|NCT05597293|Device|Glucose monitoring using FreeStyle Libre 2|Glucose monitoring in patients with type 2 diabetes using FreeStyle Libre 2
45962414|NCT04723979|Drug|Eptacog alfa|Recombinant coagulation factor VII activated
45962415|NCT04723979|Other|Standard of care|Patients have been treated according to local routine clinical practice at the discretion of the treating physician.
45962416|NCT04902703|Drug|Sargramostim|Sargramostim is a granulocyte macrophage colony stimulating factor that will be administered at a dose of 250 mcg/m2 per day subcutaneously, 5 days/week, for 24 weeks
45665913|NCT02061813|Drug|Placebo|
45962417|NCT04902703|Drug|Saline - placebo comparator|Saline will be administered subcutaneously, 5 days/week, for 24 weeks
45962418|NCT00193674|Drug|Dydrogesterone|20 mg/day, oral
45962419|NCT00193674|Drug|Placebo|Placebo
45962420|NCT04899778|Drug|Oral Contraceptive Pill, norethindrn a-e estradiol-iron|tablet
45962421|NCT00164450|Drug|Rifapentine + isoniazid once weekly for 3 months|
45962422|NCT00193713|Drug|bifeprunox|
45962423|NCT00164489|Behavioral|Weight control and physical activity promotion|
45962424|NCT04861246|Device|Laser|The device will be used to do Laser treatment. To compare the therapeutic effect to laser treatment before and post treatment for 14 and 60 days.
45962425|NCT04861246|Device|ApolloVue® S100 Image System|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain OCT images before and after laser treatment of skin.
45962426|NCT04861246|Device|VISIA®|The device is skin analysis system and will be used to obtain before and after images of laser treatment.
45962427|NCT03455413|Device|Swisstom BB2 EIT device|Swisstom BB2 EIT device and NeoSensor Belts will be used to assess lung aeration, ventilation distribution and strech during invasive ventilation in perioperative care.
45962428|NCT00164528|Behavioral|Positive Behavior Support|
46079757|NCT04158141|Procedure|Decortication|Undergo decortication
45665914|NCT02096835|Device|Transcutaneous electrical acupoint stimulation|A surface electrode will be applied to the P6 acupoint on the dominant upper extremity, located approximately 3cm proximal to the distal wrist crease between the tendons of the flexor carpi radialis and the palmaris longus, and a negative surface electrode placed on the opposing dorsum aspect of the forearm.
45665915|NCT02096835|Device|Sham transcutaneous electrical acupoint stimulation|The same TEAS protocol will be applied unless silicone covers will be attached to both electrodes. The device will also be turned on during the procedure.
45665916|NCT02096835|Drug|Tropisetron|will be given at the start of skin closure
45665917|NCT02096835|Drug|Dexamethasone|will be given after induction
45665918|NCT02324569|Drug|SYR-472|SYR-472 tablets
45665919|NCT02324569|Drug|Placebo|Placebo tablets
45665920|NCT02294773|Procedure|Intrauterine Insemination|Intrauterine insemination is either performed on the day the home ovulation predictor kit first turns positive or the day after the first positive.
45665921|NCT02294773|Drug|Clomiphene|Patient is to take clomiphene citrate during cycle days 3-7.
45821031|NCT05597293|Device|Glucose monitoring using FreeStyle Libre pro iQ|Glucose monitoring in patients with type 2 diabetes using FreeStyle Libre pro iQ
45821032|NCT05597059|Diagnostic Test|Machine Learning Prediction|Machine Learning Prediction
45821033|NCT05517980|Drug|KP104|Participants will receive loading and/or weekly maintenance intravenous (IV) or subcutaneous (SC) doses of KP104.
45821034|NCT01048723|Drug|RAD001|Patients were instructed to take RAD001 in the morning, at the same time each day.
45821035|NCT05513612|Biological|Autologous CAR-T cells|CAR-T cells will be infused intravenously.
45821036|NCT05513612|Drug|Fludarabine|Administered according to package insert
46079758|NCT04158141|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
46079759|NCT04158141|Drug|Pemetrexed|Given IV
46079760|NCT04158141|Drug|Pemetrexed Disodium|Given IV
46079761|NCT04158141|Radiation|Pencil Beam Scanning|Undergo PBS
45665922|NCT02294773|Drug|Letrozole|Patient is to take letrozole during cycle days 3-7.
45821037|NCT05513612|Drug|Cyclophosphamide|Administered according to package insert
45962429|NCT04855981|Other|whole body vibration|All participants in the WBV group will perform the WBV training on a vibrating device (Confidence Vibration Plate Power Plus, China), which produces a lateral peak-to-peak oscillation. They will stand on the WBV platform with a 150° knee angle during the exposure minute. They started the training with three sets of 1 min separated by a 1-min resting period and vibration amplitude of 1 mm. They will add one set every session until they performed 10 sets of WBV. The frequency started at 20 Hz, which will be increased gradually by 2 Hz every 2 weeks +magnesium (Mg) (250 g) and vitamin B6 supplementation
45962430|NCT04855981|Other|aerobic exercise|the subjects will receive aerobic exercises+ magnesium (Mg) (250 g) and vitamin B6 supplementation
45962431|NCT04855981|Other|supplementation|the subjects will receive magnesium (Mg) (250 g) and vitamin B6 supplementation
45962432|NCT04841356|Procedure|Immediate Compression Garment|"Immediately following surgery, in the operating room, the compression garment will be donned on the surgical limb. The garment is set to the following pressures to facilitate gradient compression: 40mm Hg (lower leg), 30mm Hg (knee), 20 mm Hg (thigh) utilizing a standardized garment tensioning tool. Subjects will wear the garment during all waking hours (target wear time of 12 hours daily) for the first 3 weeks after surgery. Additionally, subjects will be instructed to perform a therapeutic exercise program designed to manage swelling by targeting major lower extremity musculature (gastrocnemius, soleus, quadriceps, hamstrings, and gluteal musculature) and promoting venous and lymphatic return. These exercises will be performed five times daily during the first three weeks after surgery.~Subjects will receive standard of care rehabilitation following surgery as directed and coordinated by the surgeon and participant. This rehabilitation is not part of this research study."
45962433|NCT00193752|Other|PET IMAGING|PET imaging in cervical cancers to predict, prognosticate outcome in cervical cancers
45962434|NCT04835545|Other|extreme hypercapnia induced by ventilation insufficiency|extreme hypercapnia
45962435|NCT00164567|Behavioral|Onsite IPV specialist|
45962436|NCT00164567|Behavioral|Empowerment focused intervention|
45962437|NCT04834453|Diagnostic Test|transcranial ultrasound|- Transcranial Doppler sonography will be performed with the patients in the supine position., using low frequency probe of 2 MHz will be placed on temporal bone- will be performed daily
45962438|NCT00193791|Other|CT + RT|Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
45821038|NCT05596045|Drug|ASC10|Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days
45962439|NCT04832425|Drug|PRAX-114|40 mg once daily
45962440|NCT04832425|Drug|Placebo|Placebo once daily
45962441|NCT04724135|Other|Survey|The first part will assess the sociodemographic variables and reproductive characteristics, and the second part contain the Menopause-Specific Quality of Life (MENQOL) questionnaire The 29 questions of the MENQOL are divided into four domains: vasomotor (items 1-3), psychosocial (items 4-10), physical (items 11-26), and sexual (items 27-29).
45962442|NCT00193830|Procedure|HIgh Dose Rate Vs Low DOse Rate Brachytherapy|
45962443|NCT00164606|Behavioral|Positive Parenting Program (Triple-P)|
45962444|NCT04825639|Other|No intervention|no intervention
45962445|NCT00193869|Drug|Dexamethasone|
46079762|NCT04158141|Procedure|Pleurectomy|Undergo pleurectomy
45821039|NCT05596045|Drug|Placebo|Participants will be randomized to receive placebo
45821040|NCT05594407|Drug|dexmedetomidine-ketamine-lidocaine|In the DKL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution
46079763|NCT04158141|Other|Quality-of-Life Assessment|Ancillary studies
46079764|NCT04158141|Other|Questionnaire Administration|Ancillary studies
46079765|NCT04109131|Other|Samples collection: Plasma|"At baseline~Part A:~TNBC/ HER2+ BC: once a year~NSCLC/SCLC: every 4 months~Melanoma: every 6 months~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis~Part C:~o Every 3 months (+/- 1 month)"
46079766|NCT04109131|Other|Samples collection: CSF|Part B: Mandatory CSF sampling at CNS diagnosis when clinically possible unless medically contra-indicated - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis Part C: Additional CSF sampling in case CSF sampling is performed for routine clinical practice
45458295|NCT01359332|Procedure|Moderate hypothermia|procedure of moderate hypothermia therapy, between 32 ° and 34 ° C for 24 hours
45665923|NCT02365285|Drug|Galantamine|16 mg po prior to the infusion of intralipid
45665924|NCT02365285|Drug|Placebo Oral Capsule|Placebo oral capsule prior to the infusion of intralipid/heparin
45665925|NCT02365285|Drug|Intralipid|Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
45665926|NCT02365285|Drug|Heparin|heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine
45665927|NCT02041299|Drug|Deferiprone|
45821041|NCT05594407|Drug|Remifentanil|In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
45821042|NCT05747456|Device|IPN-21-SENSE|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face."
45962446|NCT04818658|Other|Assessment of the stainless steel crown using the Hall Technique and Compomer Restoration on primary molars|Intra-oral clinical examination is performed and restorations are evaluated by the practitioner. Periapical radiography is taken according to national guidelines.
45962447|NCT04683484|Biological|Nanocovax|Recombinant Protein spike (s) SARS-CoV-2 and adjuvant (0,5 mg Al PO4)
45665928|NCT02041299|Drug|Deferoxamine|
45665929|NCT01645735|Drug|Ceftaroline fosamil|Ceftaroline fosamil 600 mg IV over 60 minutes q8h; treatment duration 5 to 14 days
45962448|NCT04683484|Biological|Placebo|0,5 mg Al PO4
45665930|NCT01645735|Drug|Ceftriaxone plus vancomycin|Ceftriaxone 2g IV over 30 minutes q24h plus vancomycin 15 mg/kg IV q12h initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
45962449|NCT00164645|Behavioral|Problem Solving intervention|
45962450|NCT04683367|Procedure|laparoscopic surgery|laparoscopic repair of hernia
45962451|NCT00176163|Behavioral|Operant behavioral treatment; Drug: THC|
45962452|NCT04683211|Other|Evaluation of iodine supplementation|survey of iodine supplementation
45962453|NCT04683289|Procedure|trabeculotomy|performing partial unroofing of the SC and viscoelastic injection into the 2 ostia of the canal. This was followed by connecting the scalemm canal to the anterior chamber
45962454|NCT04683172|Device|Active Transcranial Direct Current Stimulation|"tDCS consists of delivering a low-intensity (1 to 2 milliamperes) direct electrical current by means of a pair of electrodes (anode and cathode) applied to the scalp. Electrodes generally have a diameter (round electrode) or a diagonal (rectangular electrodes) ranging from 2 to 3.5 cm.~To stimulate a given cortical zone, the anode is placed over of the selected zone, generally identified by means of an EEG headset (10/20 System Positioning). For the treatment of pain, the anode is placed over the primary motor cortex (M1) on the contralateral side to the pain or on the left side in patients with diffuse pain. The cathode is placed over a supposedly neutral cortical zone, usually the contralateral supraorbital cortex with respect to the anode. In this study, the stimulation intensity will be 1.5 mA using round sponge electrodes 3.5 cm in diameter."
45962455|NCT04683172|Device|Sham Transcranial Direct Current Stimulation|"The tDCS device has a Sham mode that allows for true placebo stimulation. A simulated session is thus designed as a real stimulation session without its effects. Sensations similar to tDCS are created by generating currents only at the start of the session.~Same modalities as for the Active tDCS procedure will therefore be put in place: a pair of electrodes (anode and cathode) are applied to the scalp.To stimulate a given cortical zone, the anode is placed over of the selected zone, generally identified by means of an EEG headset (10/20 System Positioning). For the treatment of pain, the anode is placed over the primary motor cortex (M1) on the contralateral side to the pain or on the left side in patients with diffuse pain. The cathode is placed over a supposedly neutral cortical zone, usually the contralateral supraorbital cortex with respect to the anode."
45962456|NCT00164684|Behavioral|Father Friendly Initiative|
45665931|NCT02365207|Drug|BCG strain of Mycobacterium bovis|Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
45962457|NCT04683133|Diagnostic Test|Optical coherence tomography assessment|Optical coherence tomography assessment of coronary arteries with intermediate to severe stenosis
45962458|NCT00193908|Drug|Cavilon (TM) Durable Barrier Cream|Cavilon (TM) Durable Barrier Cream will be applied to either the medial or the lateral side of the treated breast. Side will depend on randomisation.
45962459|NCT00193908|Drug|Sorbolene|Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation
45665932|NCT01645111|Drug|Clevidipine|
45665933|NCT02364037|Behavioral|CHOICE Project Structured Contraceptive Counseling|Women in both phases of the study will receive the structured contraceptive counseling developed by the Contraceptive CHOICE Project.
45665934|NCT02364037|Behavioral|Contraceptive Education Session|Prior to Phase 2, health care providers at the recruitment sites will undergo a contraceptive education session with a focus on evidence-based provision of contraception including LARC (IUDs and implant) and same-day insertion.
45665935|NCT02364037|Device|Cost Support for IUDs and implants|Women in Phase 2 of the study who desire an IUD or implant can receive one through the study at no cost if they do not have insurance coverage. If women have insurance that covers the device, her insurance will be billed for the cost of the device.
45665936|NCT01919164|Drug|Sprifermin|Participants received Sprifermin as intra-articular injection.
45821043|NCT05747456|Device|IPN-21-SENSE|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face."
45962460|NCT00193908|Radiation|Radiotherapy|Minimum prescribed dose to the chest wall is 45Gy in 25 fractions. Planning and Treatment is per the study protocol
45665937|NCT01919164|Drug|Placebo|Participants received Placebo matched to sprifermin as intra-articular injection.
45665938|NCT01901224|Drug|Metformin 1000 mg|
45665939|NCT01901224|Drug|Placebo|
45665940|NCT05109676|Other|Questionnaire|A questionnaire will be offered to patients and identify the schedules of administration of progesterone, the day and time of blood samples taken as part of the care, the potential adverse events associated with this administration.
45821044|NCT00379717|Drug|Cisplatinum|
45821045|NCT00379717|Drug|Docetaxel|
45962461|NCT00164723|Procedure|Capsule endoscopy|Capsule endoscopy and colonoscopy
45962462|NCT04810117|Diagnostic Test|Serodiagnosis of IgG and IgM|IgG and IgM antibodies will be detected in COVID-19 patients
45962463|NCT02277340|Procedure|EAPA|Under sedation and local anesthesia, a pit of pilonidal disease is widened, hair and debris removed and cavity first ablated by endoscopy assisted diathermy the filled with crystallized phenol. The remaining pits were also fulgurated.
46079767|NCT04109131|Other|Samples collection: Non-CNS Metastatic Tumour Tissue|Part B: Highly recommended non-CNS metastatic tumour tissue collection (1FFPE and 1 FT) at CNS metastases diagnosis (Part B) (NB: Bone lesions are excluded) - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis
45665941|NCT01901146|Drug|ABP 980|ABP 980 was administered at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
45665942|NCT01901146|Drug|Trastuzumab|Trastuzumab was administered at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
45665943|NCT01901146|Drug|Paclitaxel|Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care).
45821046|NCT00379717|Device|Tomotherapy|
45821047|NCT05746754|Radiation|CSI|30 Gy in 10 fractions to CNS
45821048|NCT04706377|Dietary Supplement|B12 fix 1000mcg|oral dispersible tablet with vitamin B12 1000mcg
45821049|NCT04706377|Other|Placebo|Placebo tablet
45821050|NCT05509166|Behavioral|LGBTQ-affirmative Cognitive Behavioral Therapy|10-session LGBTQ-affirmative psychotherapy using CBT techniques
45821051|NCT05509166|Behavioral|LGBTQ-affirmative Treatment-As-Usual|10-session LGBTQ-affirmative psychotherapy
45962464|NCT04789252|Biological|Bioinformatics analysis of single cell transcriptomics data|"Sample collection: Myeloid cell purification + Single cell sequencing~Primary analysis: QC sequencing data + Reads alignment + UMI quantification~Bioinformatics analysis: Quality Control (Number of genes, UMI content,%mitochondrial genes, % riboprotein genes,Filtering low quality cells) + Normalization and scaling (Normalization, Remove unwanted sources of variation, HVG detection) + PCA Clustering Markers (PCA and PC selection, Clustering, t-SNE, Differential expression for markers identification)~Validation: FACS analysis + immunohistochemistry"
45962465|NCT04748809|Other|Diet 1|Dietary intervention
45962466|NCT04748809|Other|Diet 2|Dietary intervention
45962467|NCT00176241|Drug|gemcitabine|2000-3000mg/m2 IV on days 1 & 15
45962468|NCT00176241|Drug|paclitaxel|150 mg/m2 IV on days 1 & 15
45962469|NCT00176241|Radiation|radiation|50-80 cGy on days 1,2,15,16
45962470|NCT04742959|Drug|TT-00420|TT-00420 tablet will be administered orally once daily per protocol defined schedule.
45962471|NCT04742959|Combination Product|Nab-Paclitaxel|Nab-Paclitaxel would be administered via infusion on Day 1,8, and 15 of 28-day cycle
45962472|NCT04732897|Procedure|dynamic dressing|Dynamic dressing is made by bandages of the foot with gauze pad, stretchable adhesive tape and elastic compression band
45962473|NCT04727203|Behavioral|AHAA|Multi-component healthy lifestyle program
45962474|NCT00164801|Drug|Baclofen, Diltiazem|
45962475|NCT00176280|Drug|Leukine|
45962476|NCT00176280|Drug|Dexamethasone|
45962477|NCT04719793|Biological|Umbilical Cord-derived Wharton's Jelly|Intraarticular injection
45821052|NCT04706299|Other|Resistance Exercise|Participants will perform for each leg, 3 sets comprised of 15 repetitions set to 180 degrees per second of an isokinetic, concentric knee extension and flexion. Resulting in a 20 second long working set (10 seconds extension, 10 seconds flexion), per set. Each set will be followed by a 90 second period of recovery. After completing 3 sets on initial leg, testing will be set up for second leg.
45821053|NCT04450004|Biological|Intramuscular Vaccine|Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.
45821054|NCT01583647|Drug|MK-0524A|1 tablet of MK-0524A (1g ER niacin/20mg laropripant) orally
45962478|NCT04723940|Drug|Bactrim|Bactrim will be given for 6 weeks to treat joint infection
45455353|NCT03635450|Biological|Infusion of hCT-MSC|Infants who meet enrollment criteria for moderate to severe hypoxic ischemic encephalopathy will receive 1 infusion of hCT-MSC within the first 48 postnatal hours. hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked. hCT-MSCs are manufactured from umbilical cord tissue donated to the Carolinas Cord Blood Bank, an FDA-licensed, FACT-accredited, public cord blood bank at Duke University Medical Center, after written informed consent from the baby's mother. Cord tissue is harvested from the placentas of male babies delivered by elective C-section after a normal, full- term pregnancy.
45455354|NCT01117285|Other|3-day post-graduate course|"A 3-day course in using the COTiD program in clinical practice. The 3 days are not provided uninterrupted but there are at least two weeks between each day to provide time to practice with the guideline (for discussion on the 2nd day).~The course consists of theory on the content of the guideline and its effectiveness, Practice parts of the guideline by rol playing, and discussing each others skills through watching video material."
45458522|NCT02318446|Drug|Folic Acid|Test group(n= 24) Existing Anti-epileptic Drugs + Oral Folic acid 1mg tablet daily for 1month
45458523|NCT02318446|Drug|Saccharine|Placebo group(n=12) Existing Anti-epileptic Drugs + Oral saccharine 10 mg tablet daily for 1month
45821055|NCT01583647|Drug|MK-0524A|2 tablets of MK-0524A (1g ER niacin/20mg laropripant) orally
45962479|NCT04723940|Drug|Cefadroxil|Cefadroxil will be given for 6 weeks to treat joint infection
45458524|NCT02325934|Drug|Stribild|Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil
45821056|NCT05745428|Other|molecular and cellular analyses|sample blood
45962480|NCT04723940|Drug|Doxycycline Hcl|Doxycycline HCl will given for 6 weeks to treat joint infection
45962481|NCT04723940|Drug|Clindamycin|Clindamycin will given for 6 weeks to treat joint infection
45962482|NCT04684849|Other|APP Diary|Subjects keep a multi- item electronic digital App survey of symptoms for 2 weeks
45962483|NCT04684849|Other|Paper Diary|Subjects keep a multi-item paper survey of symptoms for 2 weeks
45962484|NCT04680793|Other|Rehabilitation|The program takes place over a total period of 9 weeks: for 4 weeks they will be cared for two days a week, then after a week's break, for 4 weeks they will be cared for three days a week for a total of approximately 80 hours of care. The program is multidisciplinary and includes: balneotherapy, ergometry, occupational therapy, gymnastics, physiotherapy, walking, sophrology, yoga as well as different workshops for the therapeutic education of the patient led by several professionals (dieticians, physiotherapists, doctors, psychologists).
45962485|NCT04678570|Other|White Noise|"The infants will be listened to a song Called  Bebeginiz Aglamasin from Orhan Osman's colic album which was prepared with the help of Dr. Harvery Karp's ''The Happiest Baby'' album through a portable speaker located at 50 cm away from the infant at 55-decibel frequency.~Listening to this song will start 5 minutes before the insertion of the Orogastric Tube, will continue during the procedure and another 5 more minutes after the procedure is completed. The rest of the noise in the environment will be controlled."
46079768|NCT04109131|Other|Brain MRI|"Part A:~Brain MRI at inclusion is allowed within 45 days before enrolment~Brain MRI pre-CNS diagnosis (Part A) : HER2 BC/TNBC: once a year; NSCLC/SCLC: every 4 months; Melanoma: every 6 months (+/- 1 month)~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis~Part C:~o Brain MRI post-CNS diagnosis (Part C): every 3 months (+/- 1 month window)"
46079769|NCT04109131|Other|Samples collection: Serum|"At baseline~Part A:~TNBC/ HER2+ BC: once a year~NSCLC/SCLC: every 4 months~Melanoma: every 6 months~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis for cohorts 1-5."
45962486|NCT04678570|Other|Swaddling Method|The preterm infants will be placed in the supine position on a 90 cm2 soft cloth. The upper edge of the cloth will be aligned with the infant's shoulder, with the arms placed close to the body, with the horizontal ends of the cloth folded in the opposite direction to cover the top of the body. The arms will be put into flexion and the body will be covered with a cloth. In order not to limit the movements of all limbs of the preterm infant, attention will be paid to leave a finger space between the infant and the cloth cover and to leave a suitable space for the feet to be comfortable before folding the lower part of the cloth cover forward. In the swaddling method, the baby's head can move freely. The swaddling method will be applied approximately 5-10 minutes before the procedure and will be removed from the infant 5 minutes after the procedure. Because swaddling will increase the body temperature of the infant, the standard temperature of the incubator will be lowered.
45962487|NCT04644133|Other|Paper diary|Subjects will be asked to complete a 2 week paper stool diary.
45962488|NCT04644133|Other|Electronic APP diary|Subjects will be asked to complete a 2 week paper stool diary.
45962489|NCT00193986|Device|Arbitrary Waveform Defibrillator|
45665944|NCT01901146|Procedure|Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection|
45962490|NCT00164840|Drug|Esomeprazole|
45821057|NCT04403516|Drug|Dexamethasone Intracanalicular Insert, 0.4mg|To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo pterygium surgery.
45962491|NCT04641247|Drug|Niraparib|Niraparib tablets or capsules will be given once a day via the oral route.
45962492|NCT04635007|Drug|Tranexamic acid|100 women: will receive preoperative 1 gram of TXA (kapron®, Amoun, Egypt) 10 minutes before skin incision, by slow intravenous injection over 10 minutes (Tranexamic acid injection will be prepared by diluting 1gm (10ml) TXA in 100 ml. of normal saline. TXA will be administrated as an intravenous infusion or slowly injection) and preoperative placebo (4 tablets similar to misoprostol in size and shape as peroxide) will be administrated rectally.
45962493|NCT04635007|Drug|Misoprostol 200mcg Tab|100 women: will receive preoperative 800 micrograms of misoprostol (4 tablets) rectally after spinal anesthesia and urinary catheterization (as per WHO dose recommendation) (Conde-Agudelo et al., 2013) and preoperative placebo (10 minutes before skin incision, 10 ml of distilled water ampoules by slow intravenous injection over 10 minutes).
45821058|NCT04403516|Drug|Prednisolone Acetate 1%|To reduce post-surgical pain and inflammation in patients who undergo pterygium surgery.
45962494|NCT04590898|Device|Peri-device leakage closure after left atrial appendage occlusion|Peri-device leakage closure after left atrial appendage occlusion
45962495|NCT00176319|Behavioral|Aerobic endurance exercise training (ergometer)|
45962496|NCT04565470|Other|online questionnaire|Web-based questionnaire about use of self-management strategies
45962497|NCT00164879|Procedure|Endoscopic stenting followed by elective laparoscopic resection|
45962498|NCT04546945|Diagnostic Test|CD56|detection of CD56 by flow cytometry
45962499|NCT00194064|Drug|Olanzapine|
45962500|NCT04503343|Other|non-drug intervention|mindfulness training, relaxation training, or electrical cerebellar stimulation
45962501|NCT00164918|Device|nasogastric tube|
45962502|NCT04467970|Procedure|Unicompartmental Knee Replacement|Unicompartmental Knee Replacement involves replacement of the medial compartment of the knee in patients with anteromedial osteoarthritis.
45962503|NCT04467970|Procedure|High Tibial Osteotomy|High Tibial Osteotomy involves medial wedge opening high tibial osteotomy in cases of anteromedial osteoarthritis.
45962504|NCT00176358|Device|PTCA and Stent Implantation|
45962505|NCT00176358|Behavioral|Exercise Training|
45962506|NCT04427917|Drug|PF-06835919|PF-06835919 300 mg repeated doses
45458525|NCT02325934|Drug|Stribild, crushed|Crushed Stribild tablet
45458526|NCT01360658|Drug|Intravenous immunoglobulins|Single administration of 2 g/kg intravenous immunoglobulins over 2 days
45665945|NCT01644643|Drug|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
45962507|NCT04427917|Drug|Placebo|Placebo repeated doses
45962508|NCT00164957|Device|continuous pump feeding|
45962509|NCT00164957|Other|intermittent bolus feeding|
45665946|NCT01644643|Drug|Best Available Therapy|Patients randomized to receive Best Available Therapy will receive the best available standard of care (SOC) anti-infective therapy for their infection administered in accord with approved local label recommendation
45665947|NCT01644643|Drug|Metronidazole|Anti-infective, 500 mg (cIAI only) Patients randomized to receive CAZ-AVI for cIAI will also receive metronidazole (500 mg) administered by IV infusion in a volume of 100 mL at a constant rate over 60 minutes immediately following the CAZ-AVI infusion
45962510|NCT00194103|Behavioral|Telephone Monitoring and Feedback|In addition to attending IOP, participants receive phone contact from our counselors but only to receive a monitoring assessment. There is no feedback or counseling from study staff in this condition.
45962511|NCT00194103|Behavioral|Telephone Monitoring and Counseling|In addition to attending IOP, participants have phone contact with study counselors, which includes monitoring, feedback, and counseling.
45962512|NCT00164996|Procedure|Local pharyngeal anaesthesia|
45665948|NCT01864564|Other|Early Screen|Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.
45821059|NCT01555489|Drug|Ascorbic Acid|3x per week
45821060|NCT05243654|Drug|Metformin|Metformin 1000mg XR OD + standard-of-care MDT
45821061|NCT05243654|Drug|Placebo|Placebo + standard-of-care MDT
45821062|NCT01035073|Drug|Duloxetine|30-60 mg daily for 8 weeks
45821063|NCT05236868|Drug|Seltorexant|Seltorexant will be administered orally as a tablet and as an intravenous infusion of 14C-seltorexant.
45821064|NCT01561495|Radiation|Proton Therapy|
45821065|NCT04330976|Behavioral|Nutrition and physical activity intervention|Messages sent on nutrition and physical activity in pregnancy
45962513|NCT00164996|Device|Ultrathin endoscope|
45962514|NCT04418557|Diagnostic Test|RT-PCR and antibody testing|Testing of amniotic fluid, cord blood, amnion and chorion, umbilical cord, vaginal mucous, maternal and neonatal sera, neonatal throat swab, and breast milk.
45962515|NCT04682782|Drug|Esketamine|Esketamine is infused through the whole period of surgery. Participants randomized to the esketamine arm will receive 1 mg/ml solution infused at 0.1 mg/kg/hour (0.1 ml/kg/h) .
45962516|NCT04682782|Drug|Saline|Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.1 ml/kg/hour throughout the surgery.
45962517|NCT00176397|Procedure|Percutaneous coronary intervention (left main)|
45962518|NCT04682665|Drug|Icosapent Ethyl Oral Capsule|Soft gelatin capsules containing 1g pure EPA-EE. Administered as 4g per day to be taken as 2 capsules in the morning and 2 capsules in the evening.
45962519|NCT04682665|Other|Placebo|Soft gelatin capsules containing light mineral oil. 4 capsules to be taken per day (2 in the morning and 2 in the evening).
45962520|NCT00165035|Device|CoStar Paclitaxel Drug Eluting Coronary Stent System|Drug eluting stent
45962521|NCT00165035|Device|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent|Drug eluting stent
45962522|NCT03455374|Device|Treatment with CSI atherectomy device|Following peripheral angiography, patients with significant SFA or below the knee artery disease (≥ 50%) or total occlusions (100%) will have a baseline OCT imaging of the target vessel and the lesion be treated with proper size CSI burr. Repeat OCT imaging will be performed after CSI. Drug eluting balloon angioplasty may be performed in discretion of the operator. If DEB is used, a final OCT imaging will be performed to assess lesion expansion and possible dissections. Balloon sizing will be based on 1:1 vessel ratio with the length covering from minimally diseased distal segment to minimally diseased proximal segment. We will try to avoid use of stents.
45962523|NCT04409353|Device|PICO G2 4k|Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
45665949|NCT01864174|Drug|Metformin XR|
45665950|NCT01864174|Drug|Metformin IR|
45962524|NCT04330339|Behavioral|Fasting|Fasting
45962525|NCT04326673|Other|Testosterone Measurements in healthy volunteers after fasting|salivary testosterone measurements taken in morning and evening and a single blood test for testosterone taken
45962526|NCT04326673|Other|Testosterone Measurements after glucose loading|salivary tstosterone and blood testosterone measurements
45962527|NCT00194181|Drug|TPA Infusion|
45962528|NCT00165074|Drug|Infasurf (drug)|Infasurf 3 cc/kg instilled via endotracheal tube q 12-24 hours x 2 doses
45962529|NCT04322695|Behavioral|Rehabilitation Education Care Program|The RECP contained the following domains: (1) assessment and detection of disability; (2) home exercise; (3) activities to improve mobility; (4) dietary management; (5) patient education; and (6) vocational counseling.
45665951|NCT01864174|Drug|Placebo matching with Metformin XR|
45665952|NCT01864174|Drug|Placebo matching with Metformin IR|
45665953|NCT04420351|Drug|Urokinase thrombolysis|The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.
45665954|NCT04420351|Drug|Aspirin;Clopidogrel|The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018.
45665955|NCT01864018|Drug|Cyclophosphamide|Given PO
45665956|NCT01864018|Drug|Dexamethasone|Given PO
45665957|NCT01864018|Drug|Ixazomib Citrate|Given PO
45665958|NCT01864018|Other|Laboratory Biomarker Analysis|Correlative studies
45962530|NCT04307953|Drug|AZD0530 Difumarate|AZD0530 for the duration of the trial
45962531|NCT04307953|Drug|Matching placebo|Matching placebo during 6 month RCT, AZD0530 thereafter
45962532|NCT04306861|Diagnostic Test|MRI|Baseline contrast-enhanced MRI and 2 follow-up contrast-enhanced MRIs (mid-treatment and treatment completion)
45962533|NCT00165152|Procedure|Genetic Counseling|Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
45962534|NCT00165152|Procedure|Informed Consent Counseling|Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
45962535|NCT04297267|Drug|Gemcitabine|Gemcitabine 1250mg/m2,d1,d8,every 3 weeks
45962536|NCT04297267|Drug|Cisplatin|Cisplatin 75mg/m2,d1，every 3 weeks
45962537|NCT00176475|Biological|rituximab|Patients will receive a single day infusion of standard dose rituximab (375 mg/m2) on days -1, 6, 13, 20 approximately every 4 months (in conjunction with alternating doses of the lymphocyte infusion).
45962538|NCT00176475|Biological|therapeutic allogeneic lymphocytes|The product will then be assigned to the specific patient and the released product will be transported to and administered to the patient at CINJ, after premedication of the patient with acetaminophen 650 mg PO and diphenhydramine- HCl 25 mg PO. Blood product administration will be every 8 weeks and undertaken according to CINJ standard procedures
45962539|NCT04283968|Biological|Fecal Microbial Transplantation|Fecal Microbial Transplantation in adults with Atopic Dermatitis
45665959|NCT01864018|Other|Pharmacological Study|Correlative studies
45665960|NCT01864018|Other|Quality-of-Life Assessment|Ancillary studies
45665961|NCT01864018|Other|Questionnaire Administration|Ancillary studies
45665962|NCT04604314|Device|CEREC Tessera|Full ceramic endocrown restorations will be made from the high strength ceramic, CEREC Tessera
45665963|NCT01900444|Biological|IMOJEV|0.5 mL, Subcutaneous
45962540|NCT04283968|Biological|placebo fecal transplantation|placebo fecal transplantation
45962541|NCT00165191|Drug|Doxorubicin|
45962542|NCT00165191|Drug|Cisplatin|
45962543|NCT00165191|Drug|5-fluorouracil|
45665964|NCT02294227|Biological|Secukinumab|Secukinumab 150 mg (1 mL liquid formulation) in pre-filled syringes were supplied by Novartis. Each secukinumab 300 mg dose was given as two sc injections of secukinumab 150 mg.
45665965|NCT02294227|Other|Placebo|Placebo to secukinumab was also available in 1.0 mL liquid formulation in prefilled syringe to match the active drug.
45665966|NCT02496767|Drug|Tirasemtiv|
45665967|NCT02496767|Drug|Placebo tablets|
45665968|NCT02496533|Procedure|Hand Massage|The hand massage procedure comprises 4 minutes of manipulation of the subject's hands (2 minutes per hand) by a skilled massage therapist or appropriately trained staff.
45665969|NCT02496221|Drug|Albiglutide 50 mg|Albiglutide 50 mg pen is a single-use fixed dose, fully disposable pen injector system for SC delivery in the abdomen containing 67 mg lyophilized albiglutide and 0.65 mL diluents designed to deliver a dose of 50 mg in a volume of 0.5 mL after reconstitution
45962544|NCT04267003|Device|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
45962545|NCT04231357|Drug|platelet rich plasma|platelet rich plasma prepared from peripheral blood using single spin centrifugation
45962546|NCT04224571|Drug|Bortezomib Injection|Bortezomib: patients with BM relapsed, add for 4 doses on D1,4,7, 11 in induction; dosage 1.3 mg/m2/dose as per parenteral;
45962547|NCT04224571|Drug|rituximab injection|Add rituximab in patients with CD20 positive ALL, rituximab: 6 doses of on D8,11of induction, D1,15 of consolidation1 and 2 with dosage 375 mg/m2 as parenteral (Terminated in Oct 2020)
45962548|NCT00176514|Drug|Administration of the antineoplastic|
45665970|NCT02496221|Drug|Placebo|Placebo is a single-use fixed dose, fully disposable pen injector system for SC delivery of 0.5 mL injector volume in the abdomen
45665971|NCT02496221|Drug|CCK (Kinevac)|CCK (Kinevac) will be infused intravenously. Kinevac is supplied in vials containing 5 microgram (mcg)/vial. Infusion prepared aseptically by adding 5 mL of Sterile Water for Injection United States Pharmacopeia (USP) to the vial to create a solution of 1 mcg/mL. Infuse 0.003 mcg/kg dose in 100 mL of Sodium Chloride Injection USP, 0.9%
45821066|NCT04330976|Behavioral|Control|Messages sent on general health during pregnancy
45821067|NCT04331743|Drug|Liposome-entrapped Mitoxantrone Hydrochloride Injection|Intravenous infusion
45821068|NCT05296759|Drug|botulinum toxin A|botulinum toxin A injection
45821069|NCT05296759|Drug|Gabapentin|Gabapentin oral intake
45665972|NCT02475629|Biological|ibalizumab|2000mg intravenous ibalizumab (loading dose), followed 14 days later by 800mg intravenous ibalizumab every 2 weeks
45821070|NCT05296759|Drug|Duloxetine|Duloxetine oral drug intake
45821071|NCT05546047|Drug|Acthar Gel 80 UNT/ML Injectable Solution|Follow up and observation for 12 months off Acthar gel or Acthar gel and Tacrolimus
45821072|NCT05743556|Device|HILT laserotherapy|application of high intensive laser therapy on cervical muscles
45821073|NCT05743556|Device|TRT therapy|application of radiofrekvention therapy on cervical muscles
45821074|NCT05234762|Drug|ES-481|Dose escalation during two Treatment Periods
45821075|NCT05234762|Other|Placebo|Placebo dosed at same dosing as ES-481
45821076|NCT01532635|Radiation|Total Body Irradiation (TBI)|TBI twice daily for 4 days and occurs 6 to 9 days prior to the transplant. Total radiation dose is 12 Gy.
45821077|NCT01532635|Biological|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
45962549|NCT00165230|Drug|Thalidomide|
45962550|NCT00165230|Drug|Temodar|
45962551|NCT04210492|Radiation|45 Gray (Gy) regimen|Deescalated 3-fraction stereotactic body radiotherapy regimen to 45 Gy in 3 fractions.
45962552|NCT04175041|Device|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
45962553|NCT04166500|Procedure|Hysteroscopy|outpatient hysteroscopy after the first menstrual cycle in the follicular phase (9-12 days).
45821078|NCT01532635|Drug|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
45821079|NCT01532635|Drug|Tacrolimus|Tacrolimus is started the day before the transplant and stops a few months after transplant.
45821080|NCT01532635|Drug|Mycophenolate Mofetil (MMF)|MMF is started the day before transplant and stops a few weeks after transplant.
45821081|NCT01532635|Biological|Hematopoietic Stem Cell Transplant (HSCT)|"CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed using donor cells from two related donors.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem cells."
45962554|NCT00176553|Drug|Dextromethorphan|Patients will receive an inert carrier with or without dextromethorphan. The study drug will be administered at 1.5 mg/kg/dose on a BID schedule. The first dose to be given prior to each scheduled intravenous and/or intrathecal administration of methotrexate and continued for a total of seven days.
45962555|NCT00165269|Procedure|Mantle irradiation|Limited to above the diaphragm
45962556|NCT00165308|Drug|Tamoxifen|Given orally, daily for one year.
45962557|NCT00194376|Procedure|Continuous positive airway pressure ventilation|CPAP ventilation is a therapeutic modality which uses positive pressure of air through a sealed nasal mask to treat a condition known as sleep apnea
45962558|NCT00165347|Drug|PTK787/ZK222584|
45665973|NCT02475629|Drug|Optimized Background Regimen (OBR)|All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.
45962559|NCT00176670|Drug|midazolam or GameBoy or parental presence|
45665974|NCT02475395|Device|TRAK device|Use of TRAK to attain sperm concentration measurement
45821082|NCT01085773|Behavioral|Exercise on Prescription|The physical training consisted of both aerobic and strength training and took place in supervised groups.
45821083|NCT01085773|Behavioral|Nordic Walking|Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
45962560|NCT00165386|Procedure|Magnetic Resonance Imaging|
45962561|NCT00165386|Procedure|Bone Marrow Biopsy|
45962562|NCT00176748|Drug|AG 6013736|5 mg po bid
45962563|NCT00165464|Drug|Taxotere|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
45962564|NCT00165464|Drug|Cisplatin|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
45665975|NCT01653743|Drug|MSJ-0011|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 250 microgram (mcg) MSJ-0011 (choriogonadotropin alfa [recombinant human Chorionic Gonadotropin, r-hCG]) subcutaneously (SC) within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of greater than or equal to (>=) 18 millimeter (mm); not more than 3 follicles each with a mean diameter of >=16 mm and serum Estradiol (E2) level within an acceptable range for the number of follicle present, and not more than 2,000 picogram per milliliter (pg/mL).
45665976|NCT01653743|Drug|urinary hCG (u-hCG)|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 5,000 IU u-hCG intramuscularly dose within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of >=18 mm; not more than 3 follicles each with a mean diameter of >=16 mm and serum E2 level within an acceptable range for the number of follicle present, and not more than 2,000 pg/mL.
45665977|NCT01653743|Drug|Follitropin alpha|Low-dose step-up protocol involves starting dose of follitropin alfa as 75 International Units (IU) subcutaneously per day ,increments by 37.5 IU every 7 days (Day 8, 15, 28) will be done if no ovarian response will be observed for maximum of 28 days.
45821084|NCT05742074|Other|Faecal microbiota transplantation|25-30 capsules of faecal material
45821085|NCT05742074|Other|Placebo|25-30 placebo capsules
45962565|NCT00165464|Drug|Irinotecan|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
45962566|NCT04118140|Other|Somatic Acupressure|7-week self-acupressure plus usual care (an education booklet)
45962567|NCT04118140|Other|Sham acupressure|Same dose as the true acupressure group but on the sham acupoints plus usual care (an education booklet)
45962568|NCT04118140|Other|Usual care|Usual care only (an education booklet)
45962569|NCT00194415|Behavioral|Safer-sex counseling|Subjects will receive safer-sex counseling during pregnancy
45962570|NCT00194415|Procedure|Type specific serologic HSV testing|Subjects will be testing for HSV by Western Blot
45962571|NCT04090723|Behavioral|CBI-CC with peer navigation|Computer delivered brief alcohol intervention enhanced with information of HIV infection, HIV risk, and comorbid mental health disorders
45962572|NCT04082650|Drug|vitamin D|4000IU per day
45962573|NCT04082650|Other|Placebo|The same doses with vitamin D
45962574|NCT00165542|Other|A PROTEIN level|
45962575|NCT00194454|Behavioral|Modified cognitive behavioral therapy plus problem-solving|9 sessions with a psychosocial nurse practitioner in which participants learn to use behavioral strategies and specific problem-solving approaches to reduce or prevent behavioral and mood disturbances characteristic of stroke.
45962576|NCT00194454|Other|usual care|Usual care with primary provider plus a booklet about mood and behavioral changes following stroke
45962577|NCT04047589|Behavioral|Survey regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.|Survey created at Indiana University to gain information regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.
45962578|NCT04047589|Behavioral|Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations|Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations, and potential resources the cancer center might provide to help make effective exercise recommendations in the future
45962579|NCT04036942|Procedure|Ablation of the gastroesophageal junction with hybrid argon plasma|In the management group with argon plasma hybrid after marking 270 degrees of the esophagogastric junction, submucosal elevation and argon plasma burn of the marked and elevated area is performed.
45962580|NCT04036942|Procedure|mucosectomy with band of the gastroesophageal junction|In the management group with mucosectomy after marking 270 degrees of the esophagogastric junction, a submucosal elevation of the marked area is performed to subsequently perform ligation and resection with a hot snare below the ligation area.
45962581|NCT00165581|Device|High Dose Intracavitary Brachytherapy|
45458527|NCT02318680|Other|Review of follow home visits after discharge from Nykøbing Falster Hospital|The intervention is follow home visits which is randomized and is an intervention that is assigned by the investigator.
45665978|NCT02293993|Drug|SGI-110|
45821086|NCT05295511|Other|Recreational Team Handball programme|All training sessions consisted of a standardized 15-min warm-up (running, coordination, strength, flexibility and balance exercises), followed by 3x15-min periods of recreational team handball matches interspersed by 2-min breaks, performed in an indoor team handball court. The matches were played as small and formal game formats (4v4, 5v5, 6v6 or 7v7).
45821087|NCT00986947|Drug|IVIg and rituximab|"A maximum of four doses (each single dose being 2gm/kg) of IVIg will be administered over a four-month period, with one dose administered each month. Each single dose of 2gm/kg will be administered in two half-doses (1gm/kg each) to be given one day apart, with one day of hemodialysis on the intervening day between the two half-doses.~If a compatible kidney transplant organ offer is received, upon admission to the hospital and immediately prior to the transplant operation, patients will receive a single infusion of Rituximab (375 mg/m2 BSA)."
45821088|NCT00559897|Other|3'-deoxy-3'-[18F]FLT|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
45821089|NCT00559897|Procedure|Single photon emission computed tomography|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
45821090|NCT05488340|Drug|LBP-EC01 0.1 x IV dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.6mL of LBP-EC01 (approximately 1x10^11 PFU) diluted in 0.4mL of Lactated Ringer's solution given on Days 1 through Day 3.
45821091|NCT05488340|Drug|LBP-EC01 0.01x IV Dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.06 mL of LBP-EC01 (approximately 1x10^10 PFU) diluted in 0.94 mL of Lactated Ringer's solution given on Days 1 through Day 3.
45821092|NCT05488340|Drug|LBP-EC01 IV Infusion Dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous infusion dose of 6mL of LBP-EC01 (approximately 1x10^12 PFU) diluted in 94 mL of Lactated Ringer's solution given over 2 hours on Days 1 through Day 3.
45821093|NCT05488340|Drug|Placebo|Dose regimen selected from Part 1 of placebo (Tris buffer).
45821094|NCT05488340|Drug|LBP-EC01|Dose regimen selected from Part 1 of LBP-EC01 (1x10^10 - 1x10^13 PFU) per dose.
45821095|NCT05488340|Drug|TMP/SMX|TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.
45821096|NCT05482802|Behavioral|An active training tool on weight bias and knowledge about obesity|The intervention will take place at the university simulation center and include three components. First, a short lecture on obesity and weight bias. Second, four scenarios that simulate meetings between health professionals and people with obesity which will be presented by professional role-players in sequence. Each scenario will include a different therapeutic situation and include varying degrees of weight bias, stigma, and discrimination to stimulate students to think and react. Third, an active open discourse with a person with obesity will be held.
45821097|NCT05482802|Behavioral|A short-written document on obesity|A short-written document on obesity which will be based on current literature.
45821098|NCT05213000|Behavioral|Exercise|90 minute exercise session
45821099|NCT00979147|Procedure|TKA surgery with modular polished tibial baseplate/XLK design|TKA surgery with modular polished tibial baseplate/XLK design
45821100|NCT00979147|Procedure|TKA surgery with the nonmodular APT/GVF design|TKA surgery with the nonmodular APT/GVF design
45821101|NCT00979147|Device|P.F.C.® Sigma Knee System|P.F.C.® Sigma Knee System with modular XLK poly
45821102|NCT00979147|Device|P.F.C.® Sigma Knee System|P.F.C. ® Sigma Knee System with an all-poly GVF tibia
45821103|NCT00539617|Drug|Erlotinib|Tarceva single agent therapy: 150 mg/day PO
45962582|NCT03997201|Procedure|Ripple Mapping guided ischaemic VT ablation|"Endocardial mapping of the ventricle performed with Ripple Mapping (CARTO3v6, Biosense Webster Inc). Ablation (SmarTouch Thermocool Catheter, Biosense Webster Inc) delivered to areas of abnormal late electrical activity within ventricular scar tissue."
45962583|NCT00176787|Drug|Capecitabine|
45962584|NCT00176787|Procedure|Radiation|
45665979|NCT04206215|Device|transcranial Direct Current Stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. In the sham group, the tDCS device will not be active for the full 20 minutes.
45665980|NCT04206215|Device|Transcranial Ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
45665981|NCT02322775|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
45665982|NCT02322775|Biological|Placebo|Placebo administered subcutaneously every 4 weeks
45821104|NCT00539617|Drug|5-fluorouracil|5-FU bolus: 400 mg/m2 IV once every 2 weeks for 16 weeks 5-FU infusion: 2400 mg/m2 IV over 46-48 hours, once every 2 weeks for 16 weeks
45821105|NCT00539617|Drug|Leucovorin|400 mg/m2 IV once every 2 weeks for 16 weeks
45821106|NCT00539617|Drug|Oxaliplatin|85 mg/m2 IV once every 2 weeks for 16 weeks
45821107|NCT05182580|Diagnostic Test|Results utilized from autonomous AI diagnostic system for diabetic retinopathy and/or diabetic macular edema|If patients receive a negative result they do not see the retina specialist
45821108|NCT05467514|Drug|Liraglutide|Application of liraglutide 1.8 mg subcutaneous daily for 6 months to evaluate subclinical atherosclerosis, by means of carotid doppler US, lipid profile in patients with type 1 diabetes mellitus
45962585|NCT00176787|Procedure|Surgery|
45962586|NCT00165620|Drug|Iomeprole|
45962587|NCT00176943|Drug|Aldara Cream 5%|
45962588|NCT03978208|Drug|ATB-346 low dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
45962589|NCT03978208|Other|Placebo|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
45962590|NCT03978208|Drug|ATB-346 mid-dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
45962591|NCT03978208|Drug|ATB-346 standard dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
45665983|NCT04888273|Behavioral|Transition Intervention|Each adolescent-parent pair will be invited to complete 5 components of the intervention (peer support session, parent education session, transition meeting with healthcare providers, family doctor contact, and reading a transition navigation guide) over a 3-month period. These intervention components were designed with the intention of making the transition process transparent for the duo, preparing the adolescent to take responsibility of their own health as it relates to their disorder, and helping the parent step back from the process to help the adolescent integrate to adult care better.
45665984|NCT02322229|Drug|Ocriplasmin 0.125 mg in a 0.1 mL volume|
45458528|NCT05143294|Behavioral|Conectar Jugando Classroom Program|Modern Board Games Intervention in Elementary Classrooms
45665985|NCT02363959|Drug|Hyperbaric Oxygen Therapy|2 hours of breathing >99% medical grade oxygen inside an air-pressurized chamber at 2 ATA once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.
45665986|NCT02363959|Procedure|Endobronchial Biopsy of Airway Epithelium|During standard post-transplantation bronchoscopies, participants in this study will undergo an endobronchial biopsy of the airway epithelium for each donor lung.
45821109|NCT00976339|Drug|Cholecalciferol|"Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each."
45962592|NCT03936829|Drug|Cyclophosphamide|Admitted to the hospital every 4 weeks. Cyclophosphamide was intravenously instilled (500mg mg/m2 of BSA) after contraindications are excluded. ECG monitoring will be taken during the medication. A total of 6 treatments will be performed.
45962593|NCT00165659|Drug|DONEPEZIL HYDROCHLORIDE|
45962594|NCT00176982|Drug|Hydroxychloroquine|
45962595|NCT03887377|Drug|Botulinum Toxins|We will be comparing botulinum toxin following breast reduction surgery to placebo injection. We will then compare photos of each breast reduction scar at set intervals following surgery.
45962596|NCT03887377|Other|Normal saline|Normal saline will serve as the placebo control on the contralateral breast
45962597|NCT00165737|Drug|Donepezil Hydrochloride|
45962598|NCT00194493|Behavioral|ESRA-C|Graphical summary of patient symptoms and quality of life
45962599|NCT03819595|Other|Supervised exercise|a free 12-week, small-group (~10 people) exercise program supervised by specially trained instructors, combining two weekly 1h sessions of moderate to high intensity aerobic and strength exercise. Participants are encouraged to undertake an additional group-based walking exercise guided by target heart rates.
45962600|NCT03819595|Other|Personalized Program PVS|"a standardized promotion prescription of physical activity, balanced diet and smoking cessation, using the computer tool Promote Healthy Living integrated into the electronic medical record."
45962601|NCT04682899|Drug|procalcitonin-guided antibiotic therapy|In procalcitonin group, clinican make a decision of antibiotic precription based on the results of procalcitonin.
45962602|NCT04682899|Drug|guideline-guided antibiotic therapy|In guideline group, clinican make a decision of antibiotic precription based on the recommendations of GOLD guideline.
45962603|NCT03789916|Drug|Ticagrelor|90 mg bis in die
45962604|NCT03789916|Drug|acetylsalicylic acid|100 mg die
45962605|NCT03774238|Other|FMD analysis|Blood sample and vascular exploration.
45962606|NCT00165815|Drug|ARICEPT|
45962607|NCT00177021|Drug|Aldara Cream 5%|
45962608|NCT03768310|Biological|CD19.CAR-multiVST for Group A|Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the transplant (between days 30 and 90). A time period of 6 weeks will constitute the time for clinical safety monitoring.
45962609|NCT03768310|Biological|CD19.CAR-multiVST for Group B|Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the bone marrow transplant. A time period of 6 weeks will constitute the time for clinical safety monitoring. If patients with relapse after transplant or those with evidence of disease before bone marrow transplant have at least a partial response to the treatment or have stable disease, they will be eligible to receive up to 6 additional doses of T cells separated by a minimum of four weeks. Patients are eligible to receive additional doses only after they have completed the initial 6-week clinical safety monitoring period.
46079770|NCT04084470|Dietary Supplement|Different types of bread|Two studies comprising a double-blind randomized cross-over study. All subjects start with a run-in period of 3 days, thereafter they will receive three different types of bread in a randomized order for 1 day each, with a wash-out period of at least 7 days in between. Before test days 2 and 3, there is also a run-in period of three days.
45458529|NCT01317758|Drug|AS03 Adjuvant|Adjuvant/diluent manufactured by GlaxoSmithKline (GSK)
45665987|NCT02362789|Biological|Secukinumab|150 mg secukinumab in 1 ml solution for subcutaneous injection (pre-filled syringe)
45821110|NCT05456828|Biological|ASKG712|ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
45821111|NCT04579640|Dietary Supplement|Vitamin D|Capsules containing 800 IU (20 micrograms) or 3,200 IU (80 micrograms) cholecalciferol
45962610|NCT03729154|Behavioral|First Step|First Step is a comprehensive early intervention that is delivered by a behavioral coach who works in collaboration with the classroom teacher and parents. First Step addresses moderate to severe behavior problems of young children and includes both classroom and home components. The program takes about three months from start to finish and requires approximately 60 hours of the coach's time for implementation over this three month period.
45962611|NCT03697603|Drug|Brexpiprazole|Tablets, Oral, once daily, 14 weeks
45665988|NCT02362789|Biological|Placebo|Matching placebo in 1 ml solution for subcutaneous injection (pre-filled syringe)
45665989|NCT01646827|Drug|Aripiprazole IM Depot|One injection of 400 mg aripiprazole IM depot
45665990|NCT02293837|Drug|Tocilizumab (TCZ)|Subjects assigned to this group will receive tocilizumab intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight <30kg) every 4 weeks for 24 weeks.
45665991|NCT02293837|Drug|Placebo|Subjects assigned to this group will receive placebo intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight <30kg) every 4 weeks for 24 weeks.
45821112|NCT00517075|Device|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
45962612|NCT03697603|Drug|Placebo|Tablets, Oral, once daily, 14 weeks
45962613|NCT00165854|Drug|E7070|
45962614|NCT00177060|Drug|hydromorphone|
45821113|NCT00517075|Device|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
45962615|NCT03686644|Procedure|Wearing of night splint ankle foot orthoses (phase A)|"Children wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results."
45962616|NCT03686644|Procedure|No wearing of night splint ankle foot orthoses (phase B)|"Children no wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results."
45665992|NCT02293837|Other|Standard of Care|Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines [Standard of Care, SOC])
45665993|NCT04894825|Drug|M108|Monotherapy: Accelerated titration method, IV infusion Q3W; Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles)
45665994|NCT04894825|Drug|M108|IV infusion Q3W. (21-day cycles)
45665995|NCT02361307|Procedure|Seamless ADL training|The experimental group receive the seamless ADL training which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training
45665996|NCT02361307|Procedure|Conventional ADL training|The control group receive the conventional ADL training programme
45665997|NCT04880317|Diagnostic Test|Cardiac Magnetic Resonance|All enrolled patients will undergo a contrast-enhanced CMR examination for the assessment of extracellular volume
45665998|NCT04880317|Diagnostic Test|Additional CT acquisition|All enrolled patients will undergo an additional CT scan at 5 minutes post-contrast injection to evaluate myocardial relative enhancement
45665999|NCT04880317|Diagnostic Test|Blood tests|Patients will undergo blood tests to review hematocrit, Sars-CoV-2 antibody status and cardiac fibrosis biomarkers
45962617|NCT03682900|Other|Click City Tobacco Prevention Program|Fifth and sixth grade classroom tobacco prevention computer activities designed to postpone or prevent youth smoking, through changing theoretically-based risk factors predictive of subsequent use.
45962618|NCT03564613|Drug|DTG|Subjects with DTG exposure during any trimester will be included
45666000|NCT02320903|Device|VillageWhere App|
45666001|NCT02320123|Behavioral|Educational DVD|African American patients and their primary non-professional caregivers will watch a DVD created to introduce end-of-life care planning to African Americans receiving palliative care.
45666002|NCT02360995|Drug|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (sold in the US), using a Total 360 toothbrush, 2 times/day for 6 weeks (study duration).
45666003|NCT02360995|Drug|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
45962619|NCT00194571|Behavioral|Educational counseling intervention|This intervention involves 5 face to face educational counseling sessions with a specially trained patient educator; sessions are fully manualized and complemented by handouts given to the diagnosed parent.
45962620|NCT00165893|Device|Accu-Spina Device/IDD therapy|
45962621|NCT00165893|Procedure|Physical Therapy|
45962622|NCT03512314|Drug|Tadekinig alfa|Open label, 26 weeks on Tadekinig alfa treatment.
45962623|NCT03421639|Drug|GnRH analog (3,75mg Leuprolide)|3,75 Leuprolide monthly for 3 months
45962624|NCT03421639|Drug|Aromatase inhibitor plus GnRH analog (3,75mg Leuprolide)|1mg/day of Anastrazole plus Leuprolide 3.75mg/monthly for 3 months
45962625|NCT00177099|Drug|FK506, GP11046, GP11511|
45962626|NCT03413800|Drug|Lenalidomide-Dexamethasone-DLI|Lenalidomide (Len) and Dexamethasone (Dex) for 6 months followed by three donor lymphocyte infusions (DLIs)
45962627|NCT00165971|Procedure|BIS monitoring|
45962628|NCT03335839|Drug|tissue plasminogen activator|Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.
45962629|NCT03335839|Other|Saline|Placebo
45962630|NCT03303742|Other|deep chamfer|finish line marginal design of a full coverage crown preparation
45962631|NCT03303742|Other|feather edge|finish line marginal design of a full coverage crown preparation
45666004|NCT02360995|Drug|fluoride toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
45666005|NCT02360995|Drug|Fluoride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest fluoride Mouthrinse for 30 seconds each time.
45666006|NCT02360995|Drug|cetylpyridinium chloride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest Pro-Health Mouthrinse for 30 seconds each time.
45666007|NCT04197037|Procedure|Evaluation of sialorrhea through questionnaires that measure daytime and nighttime sialorrhea and the impact on quality of life.|Sialorrhea will be evaluated by the Nocturnal hypersalivation rating scale (NHRS) and Drooling Severity and Frequency Scale (DSFS)
45821114|NCT00517075|Device|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
45821115|NCT00517075|Device|repetitive transcranial magnetic stimulation|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
45821116|NCT04579172|Procedure|Cervico- isthmic compression suture|Circular isthmic-cervical sutures will be applied . To avoid ureter and bladder injury, the bladder will be reflected downward. A silastic drain will be inserted into internal and through the external os , so as to drain the uterine cavity and to keep the cervical canal open. Firstly, at the left side of the uterus, a Vicryl number two (No..2) stitch will be inserted very close to the cervix from the anterior to the posterior side of the broad ligament.
45962632|NCT03301792|Behavioral|Group prenatal care|Enrolled subjects will be randomly assigned in a 2:1 ratio to group or traditional care.
45962633|NCT03207256|Drug|TGR-1202|Oral Daily TGR-1202
45962634|NCT03207256|Drug|TGR-1202 + Ublituximab|Oral Daily TGR-1202 + Ublituximab IV Administration
45962635|NCT00166010|Drug|Nesiritide|Standard dose of nesiritide which is a loading dose of 1 mcg/kg IV over 30 minutes followed by a nesiritide infusion at 0.01mcg/kg/min. All patients will be continually evaluated. At any time the attending physician may add or adjust treatment if deemed clinically indicated.
45962636|NCT03183388|Behavioral|BE-SMART|Participants will take part in 12 therapy sessions, at a rate of about 1 session every one to two weeks. Sessions are anticipated to last about 1 hour each. Sessions may be focused on teaching skills to regulate emotions or regularize sleep and activity. These therapy sessions may be videotaped and audiotaped (only with the expressed written consent of the participant, and when appropriate, the participant's parent or guardian). Participants will be asked to complete worksheets and practice the skills learned from these sessions and will be asked questions about feelings. There will be an interview, assessments and scanning performed prior to treatment and at the midpoint and end to assess progress. The intervening 9 sessions may be by video telecommunication. Participants may be given devices to track actigraphy and ecological momentary assessments.
45962637|NCT03104491|Drug|Inotuzumab Ozogamicin|"Inotuzumab ozogamicin, IV, 28 day cycles~ALL Phase 1 dosages:~Dose Level -2 (0.1 mg/m^2)~Dose Level -1 (0.2 mg/m^2)~Dose Level 0 (0.3 mg/m^2)~Dose Level 1 (0.4 mg/m^2)~Dose Level 2 (0.5 mg/m^2)~Dose Level 3 (0.6 mg/m^2)~NHL Phase 1 dosages:~Dose Level -1 (0.2 mg/m^2)~Dose Level 0 (0.3 mg/m^2)~Dose Level 1 (0.4 mg/m^2)~Dose Level 2 (0.5 mg/m^2)~Dose Level 3 (0.6 mg/m^2)~Dose Level 4 (0.7 mg/m^2)~Dose Level 5 (0.8 mg/m^2)"
46079771|NCT04080284|Drug|Niraparib|Study treatment will be administered orally Q day continuously. Up to three capsules of 100mg strength will be taken at each dose administration. Initiation dose will be defined per current FDA guidelines for Niraparib treatment in ovarian cancer. Dose interruption (no longer than 28 days) will be allowed. Dose reduction will be allowed based on treatment side effects. Dose reductions to 2 capsules daily (200mg) and subsequently to 1 capsule daily (100mg) will be allowed. No further dose reductions will be allowed. The timing of efficacy or safety evaluations should not be affected by dose interruptions or reductions.
46079772|NCT04074967|Drug|Phase Ib ARRY-614 + nivolumab|ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule.
46079773|NCT04074967|Drug|Phase Ib ARRY-614 + nivolumab+ipilimumab|ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule.
45962638|NCT04685824|Device|Biofeedback Training|Audiovisual stimulation
45666008|NCT02360605|Behavioral|automated telephone reminder|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT. ATR will remind the patient of the importance of completing and returning the FIT results and encourage screening completion. There will also be an option where the patient can request another FIT kit be mailed to them, one to hear information on common problems with FIT completion or how to call the clinic if they have questions. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up ATR calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
45821117|NCT04579172|Procedure|Anterior wall uterine resection:|After fetal delivery, two corners of the uterine incision and the superior and inferior lips will be clamped immediately by four Mayo clamps. Blunt dissection downward to the bladder-uterus peritoneal reflection will perform, to the partial anterior wall of the uterine myometrium where the placenta was deeply adherent (a myometrium defect, with only the serous layer of the uterus) will be respected, together with the placenta. It is important to ensure that sufficient myometrium above the peritoneal reflection will be available for an optimum closure. Then, as much remaining placenta as possible will be removed piecemeal from the edge of the uterine incision. Clamps and multiple hemostatic sutures will be applied rapidly
45821118|NCT05163938|Device|REThink Therapeutic Game|"Game based Cognitive-Behavioral Therapy: REThink therapeutic game is an online therapeutic game developed by David and collaborators (2018).~The seven levels of the game were developed based on the REBT model and each level trains an ability:~Level 1: identify the emotional reactions, and differentiating between basic emotions, complex emotions, and functional and dysfunctional emotions; Level 2: identify cognitive processes.~Level 3: identify the relation between cognitive processes, emotions, and behavioral reactions; Level 4: change irrational cognitions into rational cognitions; Level 5: build problem-solving skills; Level 6: build relaxation skills; Level 7: consolidate of the previous skills and building happiness skills. A new level will be unlocked once every three days. In order for a level to be unlocked, the previous one must have been completed.~Duration of the intervention: 21 days (a total of seven levels unlocked every three days)"
45821119|NCT05163938|Device|Treatment as Usual|Treatment As Usual: In the treatment as usual group the child/adolescent benefits from a free trial version of the REThink game which means a shorter version of each level of the game.
45821120|NCT00523939|Drug|cytarabine liposome injection|50 mg intrathecal every 14 days for 8 doses, then every 28 days for six doses
45821121|NCT00382538|Drug|Addition of mifepristone 200 mg 24 hours before induction|
45821122|NCT00954187|Drug|Gabapentin|Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days
45821123|NCT00954187|Drug|pregabalin|50 mg PO TID
45821124|NCT04802018|Device|Clinical decision support system based on non-invasive multimodal monitoring|Non-invasive multimodal vital signs monitoring with the wearabl to monitor for a period of 10 days after the date of positive diagnosis to COVID-19. The device will be linked to the Home App, which will allow the sending of temperature, HR and RR data to the server every 15 minutes a day and the notification of symptoms by the patient three times a day.
45821125|NCT04796012|Drug|Atezolizumab|Feasibility and RMS Cohorts: Administered at 15 mg/kg (max 1,200 mg) IV on Day 1 of each 21-day cycle
45821126|NCT04796012|Drug|Vincristine|Feasibility and RMS Cohorts: Administered at 1.5 mg/m^2 (max 2 mg) IV on Day 1 of each 21-day cycle
45821127|NCT04796012|Drug|Irinotecan|Feasibility and RMS Cohorts: Administered at 50 mg/m2 IV on Days 1-5 of each 21-day cycle
45821128|NCT04796012|Drug|Temozolomide|Feasibility and RMS Cohorts: Administered at 100 mg/m^2 (max 200 mg) IV or PO 1 hour before irinotecan injection on Days 1-5 if each 21-day cycle
45821129|NCT00947791|Drug|ketamine|a single IV infusion of ketamine, IV 0.5 mg/kg
45821130|NCT00947791|Drug|midazolam|a single IV infusion of midazolam, 0.045 mg/kg
45821131|NCT05139992|Biological|COVID-19 Vaccine|Vaccination against SARS-CoV-2
45821132|NCT00504985|Behavioral|Surveys|2 surveys, taking about 10-15 minutes each, during Emergency Center visit
45821133|NCT05136326|Radiation|External-beam radiation|External-beam radiation 50.4 GY (45 Gy in 25 fractions + Boost 5.4 Gy in 3 fractions over 5 weeks)
45821134|NCT05136326|Drug|Capecitabine|825 mg/sqm/bid per os (p.o.) 5 days/week for 5 weeks;
45821135|NCT05136326|Drug|Temozolomide|75 mg/sqm p.o. 5 days/week for 5 weeks
45821136|NCT05387941|Drug|Dexamethasone Ophthalmic|one drop daily in each eye with retinopathy of prematurity of a predefined stage.
45821137|NCT00382772|Biological|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
45821138|NCT00379015|Biological|trastuzumab|
45821139|NCT00379015|Drug|cyclophosphamide|
45821140|NCT00379015|Drug|docetaxel|
45821141|NCT00379015|Drug|epirubicin hydrochloride|
45821142|NCT00379015|Procedure|conventional surgery|
45821143|NCT00379015|Procedure|neoadjuvant therapy|
45821144|NCT05447000|Behavioral|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring anxiety levels with mindfulness program
45821145|NCT05447000|Behavioral|Deep Relaxation Exercises intervention|Deep Relaxation Exercises intervention: Monitoring anxiety levels with deep Relaxation Exercises intervention
45821146|NCT05447000|Other|No Intervention|No Intervention
45821147|NCT00930787|Device|Strattice Reconstructive Tissue Matrix (Hernia Repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
45821148|NCT00930787|Device|Proceed Surgical Mesh (Hernia repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
45821149|NCT00382382|Other|diffusion tensor imaging (DTI)|Both groups will have a diffusion tensor imaging (DTI) perform.
45821150|NCT05381857|Other|Human Biological Samples|Blood, urine, nasal swab, fecal samples
45962639|NCT04685824|Device|Immersive Virtual-Reality|Audiovisual stimulation
45962640|NCT00166049|Behavioral|Family Partnership Intervention (FPI)|HF patient and family receive structured patient and family education sessions plus intervention to improve family communication one month after enrollment.Patient and family member received one individual dyadic education/counseling session after baseline data collection, and two group sessions (2-3 months after baseline) focused on developing family approaches to HF self management.Telephone counseling for the dyad and reinforcing mailed newsletters at 5-6 months after baseline.
45962641|NCT00166049|Behavioral|Patient and Family Education|HF Patient and one family member receive structured education sessions one month after enrollment.Two sessions, one indivdual with patient-family member dyad after baseline, and one in a group setting between 2-3 months after baseline. The group session was 2 hours in duration. Telephone counseling for the dyad ast 5-6 months, mailed newsletters at Mailed newsletters at 5-6 months.
45962642|NCT00166049|Behavioral|Usual care with educational material|Usual care with provision of printed educational material, provided once at baseline
45962643|NCT04685395|Drug|Ribamipide gargle \benzdymine HCL gargel|ribamipide gargle 6 time daily 5ml dosage
45962644|NCT04685122|Procedure|Phacoemulsification and intraocular lens implantation for cataract|Phacoemulsification and intraocular lens implantation for cataract
45962645|NCT00537784|Biological|Autologous platelets|Local injection 10mL, about 2.5 x 10E10 platelets.
45962646|NCT00537784|Biological|no injection|
45962647|NCT04685278|Biological|Blood samples|Blood samples were collected in dry tubes on days 1, 3, 5, 8 and 10 of hospitalization
45962648|NCT00166088|Dietary Supplement|Mediterranean Diet|The Mediterranean diet group will receive all meals as a prototypical Mediterranean diet for 4 consecutive weeks prepared by the GCRC metabolic kitchen with dietary instruction. During the second month of the study they will be asked to follow a Mediterranean diet using their own home-cooked meals
45962649|NCT00166088|Dietary Supplement|Mediterranean Dietary Supplement|The subjects randomized to the typical diet + targeted Mediterranean dietary supplement group will not receive dietary counseling. They will be given a one-month supply of specific supplements by the GCRC nutritionists and advised to consume these daily, in addition to their usual diet.
45962650|NCT05336812|Drug|Acalabrutinib|Given PO
45962651|NCT05336812|Biological|Obinutuzumab|Given IV
45962652|NCT05336812|Drug|Venetoclax|Given PO
45962653|NCT00537862|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
45962654|NCT00537901|Radiation|First-Line Bevacizumab and Chemotherapy|Chemotherapy
45962655|NCT00537901|Drug|Bevacizumab|Chemotherapy
46079774|NCT04074967|Drug|Phase II ARRY-614 + nivolumab|"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule."
45962656|NCT00166127|Drug|Levosimendan|
45962657|NCT00194649|Drug|Miglustat (Zavesca)|100 mg Miglustat BID (twice daily) for six weeks
45962658|NCT05425147|Other|Perioperative autonomic function assessment|Patients will have BRS and HRV measurements taken for approximately 20 minutes, one day before surgery and on the day of surgery. We use LiDCO rapid to conduct non-invasive pulse and beat-to-beat blood pressure monitoring.
45962659|NCT05425069|Drug|Comparison MoCA test and EEG connectivity pre, intra and postoperative between groups P vs D-P|We compare de impact in EEG, anesthetic condition, and recovery EEG and cognitive clinical characteristic with MoCA test between both groups (propofol vs propofol dexmedetomidine)
45962660|NCT03455257|Behavioral|Cash Transfer|The heads of households will receive a cash transfer for up to 7 family members in the home every quarter. Head of households will be expected to attend meetings every 4 months at their local community health centers led by Community Health Workers (CHW). Meetings will have 2 components: 1) children under 5 will be measured to identify children at risk of malnutrition and 2) group education sessions. There will also be monthly growth monitoring and education sessions led by CHW for a subgroup of head of households with children identified as risk of malnutrition with rapid referrals to regional tertiary clinics for any children with health problems that cannot be addressed by CHW.
45962661|NCT00166244|Drug|Mycophenolate Mofetil|"1 g for adult patients and 300 mg/m2 for paediatric patients. Fixed dose arm: 1 g twice a day (bid) for adults and 600mg/m2 bid for paediatric patients.~Concentration controlled arm: initial dose will be 1 g bid for adults and 600mg/m2 bid for paediatric patients. Abbreviated AUCs (taken at timepoints: 0, 30min and 120min in fasted patients) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine mycophenolic acid levels in plasma."
46079775|NCT04074967|Drug|Phase II ARRY-614 + nivolumab+ipilimumab (melanoma)|"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule."
46079776|NCT04074967|Drug|Phase II ARRY-614 + nivolumab+ipilimumab (RCC)|"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule."
46079777|NCT04073797|Drug|Inclisiran|Inclisiran 284 mg, one injection
46079778|NCT04073797|Diagnostic Test|68Ga-DOTATATE PET-MRI|68Ga-DOTATATE PET-MRI at baseline and 12 weeks
46079779|NCT04073797|Drug|Colchicine|Colchicine 500 mcg tablet once daily
45962662|NCT05424913|Other|research-specific blood sample|blood sample of 50 ml maximum levels of serum Insulin Regulated Amino Peptidase, lipidome markers and inflammation markers
45962663|NCT00194688|Drug|H. pylori treatment|
45962664|NCT05424718|Behavioral|MyPEEPS Mobile|Mobile technology to deliver HIV prevention information specifically developed for at-risk young men that have sex with men (YMSM).
46079780|NCT04070261|Other|iOS application usability test|user tasks, questionnaires, semi-structured interviews
45962665|NCT05311969|Other|cognitive evaluations and non cognitive evaluations|"Cognitive evaluations with executive functions evaluations :~Mini Mental State Examination~Stroop Victoria Test~Hayling test~Frontal Assessment Battery test mental flexibility:~Trial Making Test (TMT) A and B~Connection test~Alphaflex test~Verbal and visuospatial working memory~Wechsler Adult Intelligence Scale (WAIS) span~Visuo-spatial span~Visuo-spatial span simplified version~Month Of the Year Backwards (MOTYB) Planning~Tinker Toy test~Clock Test~Non-cognitive evaluations:~The Katz Autonomy Scale Neuropsychiatric Inventory version Care team Geriatric Depression Scale 15-item version Apathy inventory"
45962666|NCT05311930|Drug|2.5mg/d Hetrombopag|After the subjects signed the informed consent and passed the screening, they entered the treatment period and received a starting dose of 2.5 mg/d of Hytrombopag. During the treatment process, the clinician adjusted the drug dose according to the patient's own conditions. The maximum drug dose was 7.5 mg qd, 28 d Evaluate efficacy and safety after completion;
45666009|NCT02360605|Behavioral|prevention coordinator|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT by a prevention coordinator (PC). PC will call to encourage completion and ascertain any barriers to completion. The PCs will use Health Literacy and motivational interviewing techniques described in the training section to enhance understanding and confidence and reduce ambivalence to completing and returning the FIT. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up PC calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
45821151|NCT05438030|Diagnostic Test|Cardiac MRI scan|Undertaken at the radiology department at Hammersmith Hospital. The scan will be performed by the MRI radiographers, under the supervision of a consultant radiologist or cardiologist.
45821152|NCT05438030|Diagnostic Test|Echocardiogram scan|Undertaken at the Peart Rose research unit, by a British Society of Echocardiography accredited sonographer.
45821153|NCT05352061|Behavioral|CBT for Syndemics and Adherence Factors|Each hour-long session is conducted via zoom or in person with a study clinician. Sessions focus on HIV medication adherence, coping with life stressors, and managing other challenging situations (e.g., possible traumatic experiences, drug and alcohol use and sexual behavior) that may affect mental or HIV-related health.
45962667|NCT00177138|Drug|Tacrolimus|Starting POD #1 0.06 mg/kg/day in 2 divided doses;
46079781|NCT04060017|Drug|Levoleucovorin Calcium|Liquid leucovorin calcium dosed by weight
46079782|NCT04060017|Other|Placebo|Placebo
46079783|NCT04058561|Device|MAGEC® Spinal Bracing And Distraction System|The magnetically controlled growth rod (MCGR) system is a remotely distractible, magnetically controlled growing rod. The remote capabilities allow for less invasive and less time-consuming outpatient distraction visits, which solves many of the problems facing current growing rod technologies. The MCGR system allows for more frequent lengthenings, and the implanted growing rods can be lengthened more often, which allows MCGR to better approximate normal spine growth compared to Traditional Growing Rods.
46079784|NCT04053673|Drug|RBN-2397|an oral PARP7 Inhibitor
46079785|NCT04052334|Drug|TIL|Participants will receive an infusion of Tumor-infiltrating lymphocytes (TIL) after tumor resection and TIL product is generated.
46079786|NCT04052334|Drug|Interleukin-2|Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously (IV) bolus (about 15 minutes) every 8 to 16 hours for up to 15 doses, beginning approximately 8 to 16 hours after T-cell infusion.
46079787|NCT04052334|Drug|Fludarabine|Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 30 minutes for 5 days, prior to T-Cell infusion
46079788|NCT04052334|Drug|Cyclophosphamide|Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL normal saline (NS) over approximately 2 hours, 7 days prior to T-Cell infusion
46079789|NCT04046549|Drug|Belatacept|Belatacept Dose 1 will be administered intravenously on post-op Day 1, repeated on post-op Day 3 or 4, and at the end of Weeks 2, 4, 8 and 12; then Dose 2 every four weeks from Week 16 to Week 48.
45962668|NCT00177138|Drug|Alemtuzumab|30 mg IV intra-op and POD #12; then 30 mg IV >monthly for 1 year (only if ALC>200 mm, up to a total of 10 doses in year)
45962669|NCT04687891|Diagnostic Test|transabdominal ultrasound and transvaginal ultrasound|Within a week before scheduled delivery,antepartum transabdominal and transvaginal ultrasound will be performed with moderately full bladder.
45962670|NCT00166283|Behavioral|memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
45962671|NCT00166283|Behavioral|placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
45962672|NCT02427997|Behavioral|Treadmill training with Virtual Reality|"VR is defined in general as a high-end-computer interface that involves real time simulation and interactions through multiple sensorial channels. The VR system to be used requires subjects to negotiate virtual obstacles while walking on a treadmill, in a safe environment. This dual task activity has large cognitive components such as information processing, planning, and attention while allowing for training in a more stimulating and enriching environment that includes both cognitive and motor components."
46079790|NCT04046549|Drug|VIB4920|VIB4920 Dose 1 will be administered intravenously on post-op Days 1, and 14, and at the end of Weeks 4, 6, 8 and 10; then will continue every four weeks from Week 12 to Week 48.
45458530|NCT01317758|Other|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided by sanofi pasteur
46079791|NCT04042935|Drug|Alpha Lipoic Acid|Stage II-IVB HNSCC patients receiving concurrent systemic therapy and radiation in the definitive, adjuvant, or palliative setting will receive ALA according to their prescribed dose level. ALA will be taken orally or per feeding tube. It will start 1 week prior to the start of CRT, continue on through CRT, and then continue for 2 weeks after the completion of CRT. Patients will be given dosing diaries to document date and time of each drug administration as well as any missed doses. They will also have weekly visits to report AEs and concurrent medications, have a history and physical exam, report VAS pain scores and OMAS scores, and fill FACT-HN surveys.
45962673|NCT02427997|Behavioral|Treadmill training|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
45962674|NCT02266615|Genetic|Biobanking of biomaterial for future genetic research.|
45962675|NCT00177177|Drug|L-carnosine (dietary supplement)|an antioxidant and AGE inhibitor, 500 mg/day, titration each week to reach 2000 mg/day in 4 weeks L-Carnosine is a dietary supplement
45962676|NCT05311774|Drug|Duloxetine 30 mg|tablet
45962677|NCT05311774|Drug|Tramadol|tablet
45962678|NCT05311774|Drug|Placebo|tablet
45962679|NCT00166322|Procedure|IBZM-SPECT (bolus and constant infusion paradigm)|single IBZM-SPECT assessment at study inclusion
45962680|NCT05307133|Other|Sleeve Gastreextomy|The aim of the present study is to elucidate whether serum levels of oxytocin and sleeve gastrectomy induced weight loss are correlated in pre-menopausal morbidly obese women.
45962681|NCT05302102|Other|Unilateral plyometric training|The paretic-limb-only plyometric training group received a plyometric exercise program performed unilaterally through the paretic leg only for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
45962682|NCT05302102|Other|Bilateral plyometric training|The double-limb plyometric training group received a plyometric exercise program performed bilaterally through the paretic and non-paretic legs for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
45962683|NCT05302102|Other|Standard physical therapy|The control group received the standard physical rehabilitation program conducted for 45 minutes, thrice a week for 12 consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
46079792|NCT04028947|Procedure|Prophylactic Infrapatellar Saphenous Neurectomy in Primary Total Knee Arthroplasty|Prophylactic infrapatellar saphenous nerve neurectomy will be performed at the same time as the TKA.
46079793|NCT04027309|Drug|Gilteritinib|Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
45821154|NCT05119088|Other|Return to Sport testbattery|At baseline, approximately 3 weeks before surgery and 6 months after surgery: patients conduct a testbattery consisting of 2 PROMs: the NPI-No and BPII2.0-No together with three physical tests: isokinetic strength tests, hop tests and Y-balance test. For the cross-cultural validation of NPI and BPII2.0 patients also conduct KOOS, IKDC 2000 and Tampa Scale.
45821155|NCT00911053|Drug|Melatonin|Melatonin will be administered under FDA IND #26,318, doses between 0.025 mg and 20 mg.
45962684|NCT00194727|Drug|Vinorelbine|20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
45962685|NCT00194727|Drug|Capecitabine|825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
45962686|NCT00166400|Drug|metoprolol succinate|Treatment with potent beta-blockade titrated to the maximally tolerated dose.
45962687|NCT02042287|Device|Vaginal lactic acid and glycogen gel|Medical device (registration number: 10-355-717, first licensed 12.08.2010)
46079794|NCT04027309|Drug|Midostaurin|Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
46079795|NCT04003584|Procedure|Coronary bypass surgery|Reviewed postoperative coronary bypass patients and compared postoperative pain levels
45821156|NCT00911053|Behavioral|Regular Sleep Schedule|Subjects will maintain a regular sleep schedule of their choosing.
45821157|NCT00911053|Behavioral|Light|Subjects will be exposed to light.
45962688|NCT02042287|Drug|Metronidazole|Oral antibiotic
45962689|NCT05296213|Drug|Silver diamine fluoride- potassium iodide|SDF-KI (riva star, SDI.Ltd )was applied ( as a professional application) by micro brush over the early enamel lesions on the buccal surface of molar teeth
45962690|NCT05296213|Drug|Casein phosphopeptide amorphous calcium phosphate|CPP-ACP (tooth mousse, GC, Matraville Sydney, Australia) was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
45962691|NCT05296213|Drug|experimental tricalcium silicate|prepared tricalcium silicate paste was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
45962692|NCT05295004|Behavioral|Mindfulness Meditation Training|Patient will watch a 10 minute video on how to use mindfulness meditation to help with sleep after a total joint replacement procedure.
45821158|NCT04760678|Other|Observational study|No intervention (observational study in human participants)
45821159|NCT04755530|Dietary Supplement|Regular whole milk|400 g/day of regular whole milk
45821160|NCT04755530|Dietary Supplement|Yogurt with live bacteria|400 g/day of yogurt with live bacteria
45821161|NCT04755530|Dietary Supplement|Yogurt with inactivated bacteria|400 g/day of yogurt with inactivated bacteria
45821162|NCT04755530|Dietary Supplement|Acidified whole milk|400 g/day of yogurt with acidified whole milk
45821163|NCT04713176|Drug|DWJ1248 with Remdesivir|PO, 1 tablet of DWJ1248 TID(up to 14 days) IV, Remdesivir(up to 5 or 10 days)
45821164|NCT04713176|Drug|Placebo with Remdesivir|PO, 1 tablet of placebo TID(up to 14 days) IV, Remdesivir(up to 5 or 10 days)
46079796|NCT03988933|Drug|Rifampin double dose|Double dose of rifampin for 2 months.
45666010|NCT02360605|Behavioral|Health literacy appropriate education and demonstration|The Research Assistant (RA) will employ health literacy communication principles in providing a CRC recommendation and brief screening information using the CRC pamphlet and a FIT kit with simplified instructions and accompanying self-addressed, stamped envelope. A scripted message and illustrations will model what the patient needs to do to complete the FIT. The RA will appropriately demonstrate, using the kit, and will suggest patients show the pamphlet and FIT kit to their provider that day and talk to them about screening. Annual screening will be further emphasized at enrollment by giving patients an empowering message about the benefits of completing a FIT annually and telling them they will be mailed a reminder letter and FIT kit and receive outreach phone calls in 12 and 24 months for the next two years as well as a post survey and satisfaction interview over the phone at 6 months.
45821165|NCT04754984|Behavioral|Pelvic floor workshop|Physiotherapist-led workshop on managing pelvic floor symptoms
46079797|NCT03988933|Drug|Rifampin triple dose|Triple dose of rifampin for 2 months.
45821166|NCT04330508|Other|Depression and Cognitive Tests|Health Related Quality of Life, neurocognitive tests, PHES
46079798|NCT03988933|Drug|Rifampin standard dose|Standard dose of rifampin for 4 months.
46079799|NCT03988400|Behavioral|Sensory Augmentation|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration delivered over the hip abductor musculature will scale with the mechanical state of the pelvis at the start of each step. For example, if the step begins with the pelvis far mediolaterally from the stance foot, the swing leg hip abductors will receive strong vibration. If instead the step begins with the pelvis close mediolaterally to the stance foot, the stance hip abductors will receive strong vibration.
46079800|NCT03988400|Behavioral|Random Vibration|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration applied to the hip abductors will vary randomly (following a normal distribution) on a step-by-step basis.
45821167|NCT05424926|Other|collection of clinical parameters and blood sample|"A baseline visit, with collection of clinical parameters and blood sample to measure anti-infliximab antibodies and infliximab trough levels.~Follow-up visits at 3 months (in outpatient clinic for clinical evaluation), 6 months and 12 months (in day hospitalization for clinical evaluation and blood sample collection for ADA detection and infliximab trough level measurement)."
45821168|NCT05423912|Behavioral|Couple in Control Intervention|To assess the acceptability, feasibility, and preliminary efficacy in 4 cohorts of 6 MCI dyads each (N-48 individuals) to take part in a trial of the CiC program. Participants engaging in the pilot testing aim of the project will meet in 90-120-minute virtual intervention group meetings over the course of 8-9 consecutive weeks (depending on the program finalization to occur through Objective 1 activities). They will be asked to take part in structured quantitative interviews pre-intervention and then 4 and 8 weeks post-intervention. A purposive convenience subsample of intervention participants will be interviewed virtually over Zoom videoconference for one 30-60 minute discussion on their experiences in and perceptions of the intervention. Interview durations will be based on the participant's verbosity of response, and participants can end the interview at any point or choose to schedule a follow up call to continue the interview later should they become fatigued.
45821169|NCT05097170|Procedure|NIRS during ventricular tachycardia ablation|"NIRS: Near-infrared spectroscopy is a measurement technique that non-invasively and continuously monitors the balance between cerebral oxygen consumption and delivery.~BIS: BIS is an electroencephalogram-derived parameter developed to monitor the hypnotic effects of anesthesia."
45821170|NCT05095532|Biological|Bone marrow-derived mesenchymal stem cells|MSC transplantation
45821171|NCT05095532|Other|Placebo|Standard of Care
45821172|NCT04330352|Behavioral|"Mindfulness-based STOP touching your face practice"|1. Remind yourself to STOP. Whatever you are doing in this moment (e.g. touching your month, pinching your nose, rubbing your eyes, resting your chin on your hands), pause for a minute. 2. Take a deep breath. This reconnects you with your body. Pay attention to your breathing and just allow yourself to continue to breathe normally and naturally. 3. Observe what is happening for you in this moment-including thoughts, feelings, and emotions (e.g. feel distracted, anxious or nervous?). What do you notice in your body (e.g. feel itchy or tingling on any part of your face)? You can be aware of anything: posture, sensations, tension in your body, or, once again, your breath. You might notice the sound around you. You might even notice your thoughts or emotions. 4. Proceed with whatever you were doing before you came to a STOP or something that you want to do in the moment (e.g. proceed with touching your face, or stop face-touching and take an alternative behavior).
45821173|NCT04713410|Drug|Prednisolone|Regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day.
45962693|NCT00408057|Other|no intervention|no intervenion
45962694|NCT05284240|Device|Auryon Laser System|"The Auryon BTK Study is a prospective, single arm multicenter study evaluating the safety and procedural effectiveness of the Auryon laser in treating infrapopliteal disease in patients with critical limb ischemia and claudication.~The primary exposure of interest for this study is the use of the AURYON system for atherectomy."
45962695|NCT00166478|Drug|Exisulind Therapy|
45962696|NCT05282875|Drug|management of immunosuppressive therapy|"3 groups :~Discontinuation of immunosuppressive agents~Reduction of immunosuppressive agents~Maintenance of immunosuppressive agents"
45962697|NCT00194766|Drug|Temozolomide|Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
45962698|NCT00166556|Drug|Campath-1H and Tacrolimus|
46079801|NCT03983694|Other|Erythrocyte transfusion|The cerebro-vascular effects of a clinically prescribed erytrocyte (red blood cell) transfusion is examined. Before the transfusion, BabyLux sensor is placed on the neonatal fronto-parietal region and held in place by a self-adhesive bandage. A baseline prior to transfusion is established through a series of five repeated measurements of 1 minute taken during a stable period just before the transfusion is started. Once transfusion has ended, another series of five repeated measurements of 1 minute taken during a stable period are performed to determine the responses. Cerebral oxygenation as determined by a commercial spatially resolved NIRS device with neonatal sensor will be continuously recorded during transfusion.
45962699|NCT05276206|Drug|NSAID , NALUFIN , local anesthetic andTAP Block|"The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present.~In all groups non steroidal anti-inflammatory drugs will be given as a rescue analgesic and the total dose will be calculated and compared"
45962700|NCT05276089|Behavioral|Video message|"The five-minute video will be sent to the patient's mobile phone, outlining reasons to reduce opioid use and highlighting the support available. It invites patients to consider 3 responses:~I would like to reduce my opioid medication with support.~I understand this video but I want to continue my current dose.~I would like to speak to someone to understand more. Option 1) will enable the GP practice to initiate existing opioid reduction support, Option 2) will continue care and support as usual, and Option 3) will enable the team to offer more information."
45962701|NCT00408096|Procedure|Copeland or Global CAP resurfacing prosthesis|Both Copeland and Global Cap are uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact surfaces.
45962702|NCT00166595|Drug|Risperidone|
45962703|NCT05259631|Drug|Sevoflurane|Patients are to be sedated by sevoflurane inhalation. For this purpose, any certificated devices are suitable - AnaConDa or Mirus evenly. Starting dose of sevoflurane is to be 2 ml/h and may be modified at the discretion of the attending intensivist to achieve and maintain the target level of sedation
45962704|NCT05259631|Drug|Propofol|Patients of this group will receive an intravenous infusion of propofol with starting dose of 1 mg/kg/h. The precise dose to maintain the desired level of sedation is left at the discretion of the attending intensivist and may be revised at any time. The upper dose limit for propofol is 4 mg/kg/h. In case of tolerance to propofol infusion, midazolam or antipsychotics (haloperidol) can be added to achieve the desired level of sedation
45962705|NCT05220163|Diagnostic Test|CAD|It is an artificial intelligence (AI) system for detection of TB on CXR images. The system input is a frontal CXR, and the outputs are 1) a heatmap indicating suspicious regions on the image; and 2) a score (0-100) which implies the likelihood that the x-ray image shows TB.
45962706|NCT05220163|Diagnostic Test|Xpert|A novel diagnostic for active case finding (GeneXpert MTB/RIF) for TB on sputum collected and performed at POC in a mobile van.
45962707|NCT05205304|Drug|D'Oxyva|The transdermal CO2 was administered via non-invasive vaporization technique accommodated by deoxyhemoglobin vasodilator (D'Oxyva)
45962708|NCT00194805|Behavioral|Telehealth for Diabetes Self Management|
45962709|NCT00194805|Other|Telehealth for Diabetes Self Management|Web based education format delivered for a six month period
45962710|NCT00166634|Procedure|Ambulatory Blood Pressure Monitoring (ABPM)|
45962711|NCT05181904|Other|Gastric ultrasound|Assessment of gastric content with gastric ultrasound monitoring: gastric ultrasounds will be performed in eligible children, when enteral feeding is stopped for planned extubation, and repeated 6 hours after, at extubation and every hour between feeding interruption and extubation. The stomach will be classified as empty or full according to PERLAS criteria. In total, 8 gastric ultrasounds will be performed over a period of 12 hours.
45962712|NCT00408135|Drug|telithromycin (HMR3647)|
45962713|NCT00166673|Device|FreeStyle Navigator Continuous Glucose Monitoring System|
45962714|NCT05160376|Other|Self-help CBT with email reminder and text message|"An online transdiagnostic self-help intervention that is delivered through an online mental health platform.~Email reminder and text message will be sent to remind participant to complete the module"
45962715|NCT05160376|Other|Feedback calls on participants' progress|Feedback calls (approximately 15 minutes) on participants' progress from a clinical psychology trainee or an undergraduate trained psychology student under the supervision of a clinical psychology professor
45666011|NCT02360293|Behavioral|Stay Strong w/coaching|Pts randomly placed in the Stay Strong w/coaching group receive an app-mediated physical activity intervention. Pts are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly and will receive tailored push notifications. Each week the pt will receive a new automatically calculated personalized physical activity goal. Stay Strong coaches will call pts up to 3 times in the first 6-8 weeks of the study to help pts meet physical activity goals including problem solving support. Pts will also be reminded to follow-up with their healthcare provider as needed for the remainder of the 12-month program.
45666012|NCT02360293|Behavioral|Stay Strong|Pts randomly placed in the Stay Strong arm are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly. Pts will have access to a standard app-mediated intervention that is linked to the wearable device.
45666013|NCT04880083|Dietary Supplement|Commercially Available Starter Infant Formula|Study formula is provided in powder form and will be administered orally, ad libitum, via an infant feeding bottle and the volume of formula offered to the infant will be guided by the recommended feeding table for the age group or by physician recommendation. The amount consumed by the infant will vary by each infant's weight and appetite.
45962716|NCT05153161|Device|Memesto|Edgewater plans to develop the next generation Memesto, a wearable device able to sense increasing agitation in ADRD sufferers and automatically deliver agitation-reducing personalized voice messages and music most effective at calming the individual based on past interventions. This innovative product will be the first wearable ADRD device to track agitation via body-worn sensors and automatically deploy agitation-reducing voice and music therapy without any caregiver interaction. The new system will use analytics to track the effectiveness of the various media and update the calming 'play list' over time.
45962717|NCT05140330|Behavioral|ALAPAGE workshop|7 weekly group sessions over 2 months (1 introduction session, 2 physical activity sessions and 4 nutrition sessions) and 1 evaluation session at 3 months
45666014|NCT02359903|Drug|Infliximab (BCD-055)|infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha
45962718|NCT05140330|Behavioral|control workshop|3 evaluation group sessions over 2 months and 1 session at 3 months. After those 4 sessions, the participants will benefit from an ALAPAGE workshop
45455355|NCT01117285|Other|Combined implementation strategy|"The combined implementation strategy provides strategies for occupational therapists (OTs), physicians, and managers.~OTs receive:~3-day post-graduate course~2 extra training days: Lectures and skills practice focused on using the COTiD program and promoting the use of the program within their organization and network.~Coaching on the job: Barriers to using the COTiD program in practice are discussed using motivational interviewing.~Discussion platform~Web-based registration system: Provides guidance in using the COTiD program for every individual client.~Regional meetings: successes and difficulties in using the COTiD are discussed.~Managers and physicians receive:~Information on the COTiD program through a website and newsletters.~Motivational reminders."
45666015|NCT02359903|Drug|Infliximab (Remicade)|
45666016|NCT02291419|Drug|ticagrelor|ticagrelor 90 mg bid
45666017|NCT02291419|Drug|aspirin|aspirin 81 mg daily
45666018|NCT02319031|Drug|Daclatasvir|
45821174|NCT04713332|Dietary Supplement|Vitamin E|Members of the vitamin E family are hydrophobic fat-soluble compounds found in a variety of food sources such as vegetable oils, fruits, and vegetables consumed through diet. Vitamin E exists in 8 isoforms, a, b, g, d-tocopherol, and a, b, g, d-tocotrienol. The recommended daily allowance for adults is 15 mg per day for alpha-tocopherol, an amount which is easily met by dietary sources, and 30 mg per day for synthetic all-rac-alpha-tocopherol. The upper limit for intake is 1,000 mg per day. Very often, the dosage of vitamin E is given in international units (IU) as capsules, with a typical dose being 400 IU per day, which is above the recommended daily allowance. The health benefits of consuming vitamin E through diet or supplementation are believed to be for its antioxidant properties as a peroxyl radical scavenger. Vitamin E protects cells from cell damage caused by free radicals that damage cell membranes through lipid oxidation leading to DNA damage and cancer development.
45821175|NCT04713332|Dietary Supplement|Hydrogen rich water|Molecular hydrogen is a new medical gas that can be dissolved in water and administered through drinking, inhalation, baths, intravenous drip. A growing body of evidence indicates that hydrogen, as a novel antioxidant, scavenges hydroxyl radical and peroxynitrite. In contrast to other antioxidants, gaseous molecular hydrogen efficiently penetrates cytoplasmic membranes and targets intracellular organelles, largely owing to its small size and neutral electricity. Thus, hydrogen has been suggested as a suitable candidate for the therapeutic strategies for various diseases, including certain types of cancer. Hydrogen has emerged as a promising cancer remedy as a preventative agent or in combined therapy with anticancer drugs. Hydrogen water consumption might mitigate the side effects of anticancer drugs by decreasing oxidative stress and ameliorating metamorphosis due to decreased apoptosis.
45821176|NCT04713332|Dietary Supplement|placebo|Placebo containing gelatin is made by cooking down the protein collagen found in the skin, hooves, connective tissues, and bones of animals. The cooking process breaks down the bonds between proteins to make smaller, more bioavailable building blocks that your body can easily absorb. Like collagen, gelatin is packed with beneficial amino acids, especially the anti-aging superstar's glycine and proline, which are lacking in the standard Western diet. These amino acids make gelatin especially powerful for healing skin, gut, and joint damage. Because collagen and gelatin come from the same source, they have identical amino acid profiles
45821177|NCT05089682|Device|DBS Stimulation during sleep|Open and closed-loop electrical modulation triggered and based on ongoing sleep staging by researcher as well as automated closed-loop algorithm for stimulation.
45821178|NCT05087186|Behavioral|Guided imagery and FLASH technique|"Five virtual group sessions delivered by psychological therapists;~Sessions 1 and 2: Guided imagery~Sessions 3 and 4: FLASH technique~Session 5: Refresher on guided imagery and FLASH technique"
45821179|NCT00476827|Drug|Bevacizumab|Bevacizumab(Avastin) 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle. until progression or unacceptable toxicity develops
45962719|NCT00194844|Behavioral|Nurse Caring|Nurse Caring: Couples receive three one hour counseling session with a nurse interventionist at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
45666019|NCT02319031|Drug|Sofosbuvir|
45666020|NCT02319031|Drug|Ribavirin|
45666021|NCT02318797|Behavioral|Patient Self-Directed Care|Patient self-management toolkits, web portal with information on health conditions, personal health care use data, health tracking tools and wellness programs
45666022|NCT02318797|Behavioral|Provider-Supported Integrated Care|Registered nurse on staff at community mental health centers with access to patient-level physical health information to: 1) work with patients on coordinating their care, 2) enhance communication between providers and payer, and 3) provide patient wellness support and education
45455356|NCT03526042|Drug|Losartan|Competitive blockade of AT1R-antibodies effect by binding to the angiotensin 1 receptor
45666023|NCT02359435|Drug|Reverse hybrid therapy|pantoprazole 40 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. for the first 7 days, followed by pantoprazole 40 mg b.d. and amoxicillin 1 g b.d. for another 5 days
45666024|NCT02359435|Drug|Standard triple therapy|pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., and amoxicillin 1 g b.d. for 12 days
45666025|NCT02318719|Drug|Placebo|Placebo
45666026|NCT02318719|Drug|DS-5565|
45666027|NCT04887337|Procedure|Arthroscopic stabilization|Early arthroscopic stabilization with Bankart repair
45666028|NCT04887337|Other|Rehabilitation including a period of immobilization followed by physical therapy|Rehabilitation including a period of immobilization followed by physical therapy
45666029|NCT01870726|Drug|INC280|"Phase Ib: INC280 was given at the starting dose of 200mg capsules twice daily with escalation to higher strengths.~Phase II: INC280 was given at the dose of 400mg (tablets) twice daily."
45666030|NCT01870726|Drug|Buparlisib|Buparlisib was given at the starting dose of 50mg once daily with escalation to higher strengths.
45666031|NCT04599868|Drug|Magnesium sulfate|"Patients will be assessed hourly for pulse and blood pressure, contraction frequency, vaginal bleeding. With strict monitoring for symptoms of magnesium sulfate toxicity.~All patients will receive dexamethasone to enhance fetal lung maturity. Rhesus factor status will be determined for all patients, . Hb level will be measured and anemic patients will receive correction by blood transfusion Cervical length will be measured after 24 h& 48 h from administration of magnesium sulfate in both groups Maternal serum magnesium will be measured at admission and after 4 hours ,12 hours and 24 hours after administration of magnesium sulfate Patients of both groups will be assessed for their neonatal outcomes include deaths and gestational age at delivery, fetal birth weight. Apgar score at five minutes, neonatal intensive care unit admission and duration of admission and neonatal calcium level at time of delivery will be also assessed."
45666032|NCT04414774|Device|GG-Suicide-Ideation|GG-Suicide-Ideation (GGSI) is a mobile application, consisting of 55 stages. The content of each stage is a list of statements representing core themes, that were found in research and clinical practice to be related to suicide ideation. These are, for example, hopelessness, helplessness, thwarted belongingness, perceived burdensomeness, low self-esteem, tolerance of mental pain, and more. On each stage, several statements are presented on screen, one at a time. The statements express adaptive or maladaptive thinking in the specific core theme of that stage. In case the statement is positive and adaptive, the user needs to drag the statement downwards, towards him. In case the statement is negative and maladaptive, the user needs to drag the statement upwards, away from him. The user advances in stages - three stages per day.
45666033|NCT01900054|Drug|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
45666034|NCT01612156|Drug|2% lidocaine gel|2% lidocaine gel will be used to coat the urethral catheters and cotton tipped swab before use during the examination.
45666035|NCT01612156|Drug|Water based lubricant|Water based lubricant will be applied to all urethral catheters and cotton tipped swabs before use in the pelvic floor examination.
45666036|NCT01899742|Drug|Umeclidinium/Vilanterol 62.5/25 mcg|Inhalation Powder
45666037|NCT01899742|Drug|Tiotropium 18 mcg|Inhalation Powder
45666038|NCT04602988|Device|EEG|EEG monitoring of brain rhythms
45666039|NCT01615822|Drug|OZ439 100mg|OZ439 100mg oral suspension, single dose
45821180|NCT00476827|Drug|Docetaxel|Docetaxel 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
45821181|NCT00476827|Drug|CPT-11|CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
45821182|NCT00476827|Drug|Paclitaxel|Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
45821183|NCT00476827|Drug|Vinorelbine Tartrate|Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
45821184|NCT00476827|Drug|Gemcitabine|Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.until progression or unacceptable toxicity develops
45821185|NCT05084300|Other|Pain Neuroscience Education|A total of 10 PNE sessions (Neuroscience pain education) will be carried out, two each week in addition medical treatment similar to control group (Usual care). The NPE sessions will be conducted by an experienced NPE certified physical therapist in 35 minute face-to-face group sessions. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
45821186|NCT05084300|Other|Usual care|The control group (Usual care) is treated with usual treatment, managment or medication for fibromyalgia, anxiolytics, antidepressants, analgesics. Depending on the medical needs and criteria of patients´s primary care physician.
45821187|NCT05411588|Drug|PF-07275315|Active drug
45821188|NCT05411588|Drug|Placebo|Placebo
45821189|NCT04330898|Device|Biotronik peacemakers, implantable cardioverter-defibrillators and cardiac resynchronizers|Any of these Biotronik cardiac stimulation devices with the Home Monitoring function activated for the remote control of patients
45821190|NCT00901303|Drug|ABVD chemotherapy|Adriamycin 25 mg/m2 bleomycin 10 units/m2 vinblastine 6 mg/m2 dacarbazine 375 mg/m on Days 1 and 15 of each 28 day cycle
45962720|NCT00194844|Behavioral|Self Caring|Self Caring: Couples receive a mailed videotape and workbook at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
45455357|NCT03526042|Drug|Enalapril|Renin-angiotensin-aldosterone system (RAAS) blockade without any effect on AT1R-antibodies effect or concentration (control group)
45666040|NCT01615822|Drug|OZ439 400mg|OZ439 400mg oral suspension, single dose
45666041|NCT01615822|Drug|MQ 250 mg, single dose|Mefloquine 250 mg tablet, single dose
45666042|NCT01615822|Drug|MQ 750mg, single dose|Mefloquine 750mg oral tablet, single dose
45666043|NCT01615822|Drug|Placebo|
45666044|NCT01898884|Drug|VP 20629|
45666045|NCT01898884|Drug|Placebo|
45666046|NCT01613326|Drug|NVA237|NVA237 50 μg inhalation capsules once a day, delivered via SDDPI
45666047|NCT01613326|Drug|Tiotropium|Tiotropium 18 μg once a day delivered via HandiHaler® device
45666048|NCT01613326|Drug|Placebo to tiotropium|Placebo to tiotropium 18 μg o.d. once a day delivered via HandiHaler® device.
45666049|NCT01613326|Drug|Placebo to NVA237|Placebo to NVA237 50 μg once a day delivered via SDDPI
46079802|NCT03978468|Other|Interagency Collaboration (ICollab)|The intervention has the following components: 1) ICollab Component 1: The Nurse Clinician will review clinic and emergency room (ER) visit notes for clinicians' recommendations and communicate these to the home health nurse (HHN). 2) ICollab Component 2a: The intervention team will meet weekly by phone with HHNs (6 times/ child). The Nurse Clinician will document meeting notes for each child in the ER, communicate this information with the HHN, and share it with the primary care provider (PCP) by routing the note through the ER or faxing the note. 3) ICollab Component 2b: The Nurse Clinician will be available as a resource for the HHN during regular work hours for clinical problem-solving. 4) ICollab Component 2c: the intervention team physician will offer her contact information for clinical problem-solving about the child to the PCP. The Nurse Clinician will communicate with the PCP about the plan developed in the meetings, and changes to plan of care.
45666050|NCT01613326|Drug|salbutamol/albuterol|salbutamol/albuterol given as a rescue medication via inhaler when needed
45666051|NCT01613248|Drug|MK-1602|Single 1, 10, 25, 50 or 100 mg dose of MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve the various MK-1602 dose levels to be studied. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
45666052|NCT01613248|Drug|Placebo-matching MK-1602|Single administration of placebo-matching MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve placebo study medication. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
45666053|NCT01613248|Drug|Rescue medication|"If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs]), anti-emetics, triptans or other medication not explicitly excluded."
45666054|NCT01898806|Drug|Intralesional Triamcinolone 2.5 mg/ml|Intralesional Triamcinolone at a strength of 2.5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
45666055|NCT01898806|Drug|Intralesional Triamcinolone 5 mg/ml|Intralesional Triamcinolone at a strength of 5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
45821191|NCT05083676|Behavioral|Acceset Intervention|". The intervention comprises of: i) Digital peer support training for youth befrienders to equip them with the knowledge and application of the four active ingredients-Mattering, selfhood, compassion, and mindfulness-to provide effective peer support as they respond to youth seekers' emotional experiences.~ii) Acceset Intervention with features or digital markers of psychological well-being, peer emotional disclosure process and community engagement."
45821192|NCT00459121|Drug|carboplatin|Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1
45821193|NCT00459121|Drug|paclitaxel|Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1.
45821194|NCT00459121|Drug|Zactima|Zactima- 100 mg orally daily, starting on day 1 of cycle 1.
45821195|NCT00459121|Procedure|neoadjuvant therapy|Neoadjuvant surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment.
45821196|NCT04696796|Procedure|Mediolateral Episiotomy with BasIQ-4 Surgical Knife|Mediolateral episiotomy will be performed with BasIQ-4 Surgical Knife which cuts from distal to the center with inner knife.
45821197|NCT04696796|Procedure|Mediolateral Episiotomy with Episiotomy Scissors|Mediolateral episiotomy will be made from the central to the distal with episiotomy scissors
45821198|NCT00432445|Radiation|Proton Beam Radiation Therapy|Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks.
45821199|NCT00432445|Procedure|Ophthalmic EUA|Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
45821200|NCT05061680|Device|endoscopic short duration papillary large balloon dilation|During the large balloon papillary dilation investigators follow the cholangiogram and stop the dilatation as soon as the disappearance of the waist of the papilla is noticed.
45821201|NCT05348863|Behavioral|SPARK|The SPARK digital platform provides support to the patient (shown as an app) as well as provides the possibility for the health care provider to review and give feedback on blood glucose levels through the care giver interface of the platform.
45821202|NCT05347303|Other|Finding-oriented orthopedic manual therapy treatment combined with foam roller|Blind randomized controlled clinical trial, where a total of 87 people, men and women, of legal age, university athletes of collective disciplines will be evaluated. The experimental group will receive foam roller therapy and manual therapy guided by findings (n = 44) for 8 weeks.
45821203|NCT05347303|Other|Foam roller treatment|Subjects will perform slides on the instrument using their body weight on the following muscles: quadriceps, hamstrings, gastrocnemius, and tensor fascia lata, for 60 seconds with 3 repetitions for each. Each repetition will have a rest period of 30 seconds, this will be done on both lower limbs.
45821204|NCT05343403|Other|Family Integrated Care|The intervention will consist of FICare, including parental participation in medical rounds (FCR). Parents and healthcare professionals will be educated and supported by the four pillars of FICare: parent education, education of healthcare professionals, psychosocial support and a supportive environment of the neonatal ward.
45821205|NCT04691024|Other|Exercise|Spinal stabilization exercises
45821206|NCT00904423|Drug|Vitamin D|up to 2400 mg; oral tablet
45821207|NCT04689698|Diagnostic Test|Thomayer test|Testing of the ankle in sagittal line and Thomayer test before and after flossing of sole.
45821208|NCT00904189|Radiation|Standard of care given for treatment of cancer|Subjects receiving a known dose of radiation during Total Body Irradiation.
45666056|NCT01898806|Drug|Intralesional Triamcinolone 10 mg/ml|Intralesional Triamcinolone at a strength of 10 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
45821209|NCT04683848|Biological|MT-3921|Solution for infusion; Intravenous (IV)
45962721|NCT00194844|Behavioral|Combined Caring|Combined Caring: Couples receive one counseling session from a nurse interventionist at approximately one week after enrollment. Upon completion of the session the nurse will hand the couple a self-caring videotape and workbook. Couples will be mailed an additional videotape and workbook at approximately 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
45821210|NCT04683848|Biological|Placebo|Solution for infusion; Intravenous (IV)
45821211|NCT05328895|Other|Transcutaneous Auricular Vagus Nerve Stimulation with Betahistine|"Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on the left ear was selected and stimulated with electronic acupuncture apparatus (Hwato, SDZ-IIB), with continuous wave, 25 Hz in frequency, 4 to 8 mA in intensity depending on patient's tolerance. The first 3 treatments were conducted in hospital, during which, the patients were trained to use the apparatus under the instruction of research staff. Afterwards, the rest treatments were exerted at home, twice a day, after every breakfast and dinner respectively, 30 min each time. The treatment was given from Monday to Friday a week, totally for 12 weeks.~Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day."
45821212|NCT00399841|Device|Precision for Spinal Cord Stimulation|During Trial Implant Period, stimulation from single lead initially turned on at the T7 or T8 level, then crossover. At time of permanent implant, subject chooses which level they want the stimulator turned on.
45666057|NCT01898806|Drug|Intralesional Saline|Intralesional Saline (Placebo). Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months.
45821213|NCT00387673|Behavioral|Somatosensory Stimulation and Massed Practice Training|a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session); SS group b) somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); SS+ABT group and c) sham somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); ABT group then carry out training in the 3 subject groups simultaneously, each group consisting of 2 subjects at a time, with 2 sets of subjects/year over a 2-year period, yielding a target sample of 36 subjects.
45821214|NCT04669808|Drug|STP705|Dry powder for intra-and peri-lesional injection.
45821215|NCT00879619|Drug|sunitinib malate|Given PO
45821216|NCT00879619|Drug|docetaxel|Given IV
45821217|NCT00879619|Drug|prednisone|Given PO
45821218|NCT05040698|Drug|Fostamatinib|Open label Fostamatinib
45962722|NCT00407225|Drug|Difluprednate Ophthalmic Emulsion|
45962723|NCT05133622|Other|Physical Activity Level|IPAQ-SF assesses the physical activity levels of the individuals. The short form of the questionnaire consists of seven questions and provides information about the time spent sitting, walking, moderately vigorous, and vigorous activities. In scoring, below 600 MET-min/week indicates individuals who are not physically active, 600-3000 MET-min/week values indicate low physical activity levels, and 3000 MET-min/week and above values indicate individuals with high physical activity levels. In our study, sedentary individuals who receive 600-3000 MET-min/week from the questionnaire will be included
46079803|NCT03978468|Other|Usual Care|The primary medical team identifies the need for home health nursing services for Children with Medical Complexity(CMC), and the hospital care coordinators help caregivers choose a home health agency. Hospital-based physicians write home health orders that are communicated to the home health agency. The clinic manager of the home health agency uses these orders to develop the home health plan of care, Centers for Medicare & Medicaid Services(Form CMS-485) and communicates the plan to the agencies' HHNs. PCPs oversee the home health plan of care.
46079804|NCT03972371|Device|The ProVee Urethral Expander System|The ProVee Urethral Expander System is supplied as a single use, sterile device and consists of a nitinol expander implant and custom implant delivery system. The delivery system is designed to allow the implant to be deployed under direct vision.
46079805|NCT03963232|Drug|Galcanezumab|Administered SC
46079806|NCT03963232|Drug|Placebo|Administered SC
46079807|NCT03958565|Biological|Tyrosine Kinase Inhibitor|Targeted therapy given as standard of care.
46079808|NCT03958565|Drug|Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]|Given Q4 weeks as standard of care
45666058|NCT02291029|Drug|CFZ533 active - Cohort 1|multiple doses of CFZ533 s.c. injection
45666059|NCT02291029|Drug|CFZ533 placebo- Cohort 1|multiple doses of placebo s.c. injection
45666060|NCT02291029|Drug|CFZ533 active - Cohort 2|multiple doses of CFZ533 intravenous infusion
46079809|NCT03958565|Drug|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Given Q12 weeks for bone disease as standard of care
45666061|NCT02291029|Drug|CFZ533 placebo - Cohort 2|multiple doses of placebo intravenous infusion
45666062|NCT02291029|Drug|CFZ533 active -Cohort 3|multiple doses of CFZ533 s.c. injection
45666063|NCT02291029|Drug|CFZ533 active - Cohort 3|Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection
45821219|NCT00382616|Drug|Phosphatidylserine-Omega3|
45821220|NCT00878605|Drug|Cyclo-Z|Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose
45962724|NCT05133622|Other|Evaluation of knee extension and elbow flexion muscle strength|"To measure the knee extension strength, the individual brings the knee from 90 degrees flexion to full extension in sitting. To standardize the test, the lower extremities will be fixed of the chair with a belt, allowing full extension of the knee. Three measurements will be performed from the distal tibia with a dynamometer, and the score will be recorded in Newtons.~Elbow flexion will also be measured in a sitting position in a chair. To standardize the given resistance, the upper extremity of the individual will be fixed to the arm support of the chair, allowing elbow flexion with a belt. During the measurement, the individual will try to flex the forearm in supination. Meanwhile, three measurements will be taken from the distal forearm with a dynamometer. The average score will be recorded in Newtons."
45962725|NCT05133622|Other|Evaluation of functional strength of trunk muscles|"Sit-ups test: The sit-ups test is a measure the endurance of the abdominal and hip-flexor muscles. The physiotherapist will fix the feet and ask the individuals to do trunk flexion in the knee flexion position. The number of movements performed for 30 seconds will be recorded.~Push-ups test: The test will be in the prone position, with the hands at shoulder level and the elbows flexed, positioned near to the body. Individuals will raise the head, shoulders, and trunk from the ground with their elbows in full extension. The test is performed with the knees in full extension for men and modified knees in flexion for women. The number of movements performed for 30 seconds will be recorded."
45962726|NCT05133622|Other|Muscle Endurance|"Lateral bridge test: Lateral bridge test involves static, isometric contractions of the lateral muscles on each side of the trunk that stabilizes the spine.~Modified Biering-Sorensen test: The test measuring how many seconds the individual can keep the unsupported upper body horizontal, while placed prone with the buttocks and legs fixed to the couch by three wide canvas straps and the arms folded across the chest.~Trunk flexors endurance test: Trunk flexion test involving a static, isometric contraction of the anterior muscles, stabilizing the spine until the individual exhibits fatigue. The researcher stops the test when the individual cannot hold the assumed position.~Prone bridge test: The prone bridge test measures the muscular endurance of the abdominal muscles."
46079810|NCT03958552|Other|Palliative Care Consultation|Trained provider will discuss illness trajectories, establish and communicate patient-directed goals that guide health care decisions, identify and treat illness-related symptoms, and identify psycho-spiritual needs and approaches to mitigate suffering.
45666064|NCT02290873|Drug|Remimazolam|For induction and maintenance of sedation
45666065|NCT02290873|Drug|Midazolam|For induction of maintenance and sedation
45666066|NCT02290873|Drug|Placebo|Inactive control arm
45666067|NCT02290405|Behavioral|Multiple Sleep Latency Test (MSLT)|The daytime protocol will include a 4-trial Multiple Sleep Latency Test (MSLT) along with 4-trials of a computer -administered battery of reaction time tasks. The assessment protocol will start two to three hours after participants' respective morning rising times and will begin with a battery of the neuro-cognitive testing followed by an MSLT nap. Per standard MSLT procedures, the daytime testing will be scheduled so the four performance testing and sleepiness assessment trials occur two hours apart. All daytime testing will be conducted under the supervision of trained laboratory technologists.
45666068|NCT02359045|Drug|D1400147|Treatment A
45666069|NCT02359045|Drug|D14000136|Treatment B
45666070|NCT02359045|Drug|D14000137|Treatment C
45666071|NCT02359045|Drug|Epanova®|Treatment D
45666072|NCT02358343|Behavioral|Engagement Interview|An Engagement Interview will comprise a one-on-one session with the patient, during which the health-care provider will use reflective statements and non-judgmental listening techniques, will explore barriers to treatment, and will help patient articulate ambivalence about engaging in treatment. This session will be enhanced with a 40-minute DVD that the subject will watch with the therapist in the dialysis facility. The subject will be encouraged to take the DVD home with them and watch it with their family members as well.
45666073|NCT02358343|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a short-term psychotherapy that will focus on how the individual is thinking, behaving, and communicating today rather than on their childhood experience. The therapist will assist the patient in identifying specific distortions (cognitive assessment) and biases in thinking and will provide guidance on how to change this thinking. During the course of intervention, study subjects will undergo assessment of severity of depressive symptoms using Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR) every two weeks for the first six weeks (weeks 0, 2, 4, and 6) and every three weeks for the next six weeks (weeks 9 and 12).
45821221|NCT00878605|Drug|Placebo|Placebo control
45821222|NCT04529174|Dietary Supplement|CardioLux™HDL|"Enrollment will occur according to the inclusion/ exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).~Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.~Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.~Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)"
45666074|NCT02358343|Drug|Antidepressant Drug Therapy|The site investigators will prescribe sertraline drug at a starting dose of 25 mg oral tablets. Dose titration will be implemented using standardized assessments of depressive symptoms and drug side effects; and the research team and the patient make joint decisions to maintain, increase, or decrease the dose. This will help establish the highest effective but tolerable dose tailored for each patient. The QIDS-SR scale will be used to assess the clinical response for dose titration. The FIBSER scale will be used to assess side effects and the degree to which they interfere with day-to-day functions. The participant-specific dose at week 6, up to a maximum of 200 mg/d, will be continued for the remaining 6 weeks.
45666075|NCT02356783|Device|Pedometer|Wireless pedometer
45666076|NCT02289469|Other|PictureRx medication history platform|Tablet PC-based tool to take more complete and accurate medication history
45666077|NCT02318095|Drug|Gemcitabine/nab-Paclitaxel|Prospective, single arm study ; eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel. All chemotherapy administered to study subjects is standard of care. The chemotherapy combination, gemcitabine/nab-paclitaxel, is considered to be a standard-of-care, non-investigational chemotherapy combination; chemotherapy dosing and treatment schedule will be managed by the treating medical oncologist. Restaging will be completed post chemotherapy.
45821223|NCT04529174|Dietary Supplement|Placebo|"Enrollment will occur according to inclusion /exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).~Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.~Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.~Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)"
45821224|NCT00353275|Drug|Strict Glycemic control|Blood glucose target range is 80-110 mg/dL.
45821225|NCT00353275|Drug|Conventional Glycemic Control|Blood glucose target range is 110-140 mg/dL.
45821226|NCT00822679|Drug|Eszopiclone|Subject receives Eszopiclone for 3 consecutive nights. 3 mg orally at bedtime for patients age 64 and under, and 2 mg QHS for patients age 65 and older.
45821227|NCT00822679|Other|Placebo|Subjects are given placebo for 3 consecutive nights
45821228|NCT04652180|Procedure|Esophagectomy|In this monocentre randomized controlled trial, we compare robot-assisted thoracic approach with conventional open transthoracic Ivor Lewis esophagectomy.
45821229|NCT05034614|Diagnostic Test|Papette brush collection|Cervical cell brush that gathers collects cervical cells during Pap smear collection
45821230|NCT05034614|Diagnostic Test|Spatula/cytology brush collection|Combination of extended-tip spatula with endocervical brush that collects cervical cells during Pap smear collection
45821231|NCT00323635|Drug|tolterodine|tablet, 4 mg, daily, 1 month
45821232|NCT00314353|Drug|Bevacizumab|"7.5 mg/kg IV Day 1 every 21 days for eight cycles*~*For patients with stable or responding disease after 8 cycles, continue bevacizumab at the same dose levels until disease progression."
45821233|NCT00314353|Drug|Oxaliplatin|130 mg/m2 IV Day 1 every 21 days for eight cycles
45821234|NCT00314353|Drug|Capecitabine|"850 mg/m2 po BID Days 1-14 every 21 days for eight cycles*#~*For patients with stable or responding disease after 8 cycles, continue capecitabine at the same dose levels until disease progression.~#For patients with baseline calculated creatinine clearance of 30-50 mL/min, the starting dose will be reduced to 650 mg/m2 BID"
45821235|NCT00314353|Drug|Irinotecan|200 mg/m2 IV Day 1 every 21 days for eight cycles
45821236|NCT04642976|Device|Ganglionated Plexi mapping and ablation using Natus Cortical Stimulator and standard ablation catheters|Ganglionated plexi will be mapped using high frequency stimulation with standard ablation catheters attached to a Natus Cortical Stimulator for high frequency stimulation. Vagal innervation to the heart will be assessed with non-invasive Parasym tragal stimulation.
45821237|NCT00279409|Drug|aripiprazole|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
45821238|NCT00279409|Drug|Sugar pill|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
46079811|NCT03954392|Behavioral|Cognitive behavior therapy with social cognitive training (CBT+SCT)|The cognitive behavioral therapy is based on Beck's cognitive therapy model for the treatment of depression. We will conduct individual therapy based on the Coping with Stress manual used in other depression treatment studies with adolescents. In addition, the investigators will teach the teen explicitly about theory of mind and social perspective taking during each session and we will use examples from their own life to help them learn the skills.
46079812|NCT03954392|Behavioral|CBT-only|The cognitive behavioral therapy is based on Beck's cognitive therapy model for the treatment of depression. The investigators will conduct individual therapy based on the Coping with Stress manual used in other depression treatment studies with adolescents.
45821239|NCT00253981|Device|Monochromatic Near-Infrared Light Energy (MIRE)|Subjects randomized to the intervention group (Monochromatic Near-Infrared Light Energy), received treatment three times a week for a total of four weeks.
45821240|NCT05235919|Device|repetitive transcranial magnetic stimulation (rTMS)|30 minutes rTMS session 5 days/week for 3 weeks.
45821241|NCT05235919|Other|Sham stimulation|30 minutes sham stimulation 5 days/week for 3 weeks.
45821242|NCT00804349|Device|Autotitrating Positive Airway Pressure|Patients will be treated with Autotitrating Positive Airway Pressure therapy
45821243|NCT00178477|Procedure|MRI with breath-holding|Breath holding for diminished tumor motion.
45821244|NCT05007392|Drug|Dotinurad|Dotinurad oral tablets.
45821245|NCT05007392|Drug|Febuxostat|Febuxostat oral tablets.
45821246|NCT05007392|Other|Dotinurad Matched Placebo|Dotinurad matched placebo oral tablets.
45821247|NCT05007392|Other|Febuxostat Matched Placebo|Febuxostat matched placebo oral tablets.
45962727|NCT05133622|Other|Flexibility|"Back scratch test The back-scratch test evaluates upper extremity flexibility. The individual will externally rotate one arm over her/his shoulder to reach the lowest point on the back with the palm facing the back. The other extremity reaches the highest point on the back with the palm facing forward by internal rotation of the other arm. The distance between the middle fingers of both hands will be measured with a tape measure.~Sit and reach test Sit and reach test evaluates lower extremity flexibility. In the test, a sit and reach board is used. The 0 reference point is taken as the 25 cm inner part where the feet are placed on the sit and reach the board. The part closer to the individual from the reference point shows negative values, and the part towards the far side shows positive values. Individuals will reach as far as with their fingertips by placing their feet on a sit-and-reach board."
45666078|NCT02318095|Radiation|Radiation therapy|5 fractions of hypofractionated IGRT or IMRT at 5Gy per fraction will be delivered before surgery. Restaging will be completed post radiation therapy.
45962728|NCT05133622|Other|Balance|"Single leg stance test Individuals bend one knee and place the sole on the other thigh and maintain their balance in this position. The test will be performed separately for the right and left extremities with eyes open and closed. The single-leg stance balance time was recorded as seconds (Linda,2013).~Functional reach test The functional reach test evaluates dynamic balance and limit of stability. This test measures the distance between the length of an outstretched arm in a maximal forward reach from standing while maintaining a fixed base of support. The scoring record is centimeter. Higher scores indicate a good level of balance (Lin,2012)."
46079813|NCT03947385|Drug|IDE196|IDE196 dosed orally, twice daily for each 28-day cycle
45666079|NCT02318095|Other|Sugical resection|Surgical resection of the pancreas post radiation therapy
45821248|NCT00379093|Behavioral|Brief advice|"The intervention will have the following components:~A) At the time of the recruitment visit, all intervention group patients will receive:~A personalized risk report;~An educational booklet titled Healthy Drinking as You Age;~A drinking diary;~Brief advice to reduce their drinking by their physicians;~B) After the recruitment visit, all intervention group patients will receive up to 3 telephone calls from a health educator. After each call, intervention group patients may choose to receive a letter updating their health risks.~Also, at the conclusion of their interaction with the health educator, they may choose to have a letter summarizing the calls sent to their physician."
45821249|NCT00379171|Behavioral|Cow's milk with fish oil|
46079814|NCT03947385|Drug|Binimetinib|Binimetinib dosed orally, twice daily for each 28-day cycle
45821250|NCT00379171|Behavioral|Cow's milk without fish oil|
46079815|NCT03947385|Drug|Crizotinib|Crizotinib dosed orally, twice daily for each 28-day cycle
45821251|NCT00379171|Behavioral|Formula with fish oil|
46079816|NCT03935724|Biological|Neuro-Cells|Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
45455358|NCT01316432|Drug|Cenderitide|Cenderitide is a novel rationally designed chimeric natriuretic peptide to be administered in this trial as either a subcutaneous injection or infusion.
45666080|NCT02318095|Drug|Adjuvant chemotheapy|Adjuvant chemotherapy may be given after surgery at the clinical discretion of the medical oncologist
45666081|NCT02317705|Drug|OTL38|
45666082|NCT02317705|Device|Near infrared camera imaging system|Near infrared camera imaging system
45666083|NCT02317705|Procedure|Laparotomy|primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
45666084|NCT02474069|Drug|Secukinumab|
45666085|NCT02317627|Drug|KD025|
45666086|NCT02517905|Drug|Bupivacaine liposome|Local administration
45666087|NCT02517905|Drug|Placebo|Local administration
45666088|NCT02473913|Drug|Milk Thistle|
45666089|NCT02473913|Drug|Placebo|
45666090|NCT02316847|Drug|diazepam nasal spray|
45666091|NCT02473523|Other|PedsQL Cancer Module|The PedsQL cancer module acute version is a 27 item assessment that includes eight scales including pain (2 items), nausea (5 items), anxiety related to procedures (3 items), anxiety related to treatment (3 items), worry (3items), cognitive problems (5 items), perceived physical appearance and communication (3 items). This assessment will take approximately 15-30 minutes to complete.
45821252|NCT00379171|Behavioral|Formula without fish oil|
45821253|NCT02973373|Device|MRI with High-frequency non-invasive ventilation|MRI performed under high-frequency non-invasive ventilation
45821254|NCT02973373|Other|MRI without High-frequency non-invasive ventilation|MRI performed without High-frequency non-invasive ventilation
45821255|NCT04998422|Drug|HG381|HG381 is available as white to off-white cake or powder for solution for injection at a unit dose strength of 5 mg per vial. HG381 will be administered as IV injection.
45821256|NCT00379249|Drug|Rosuvastatin|
45821257|NCT04621916|Drug|FVIII|This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.
45821258|NCT04621916|Drug|Emicizumab|This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.
45821259|NCT00801931|Drug|Alemtuzumab|Each dose of alemtuzumab is to be diluted in 5% dextrose in water (D5W) or normal saling (NS) (maximum concentration: 0.3 mg/mL) for intravenous (IV) infusion over two hours.
45821260|NCT00801931|Radiation|Total Body Irradiation|
45821261|NCT00801931|Drug|Melphalan|Melphalan 45mg/m2 (1.5 mg/kg IV for children <1 year of age or <10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
45666092|NCT02473523|Other|PedsQL Multidimensional Fatigue Scale|The Multidimensional Fatigue Scale is an 18 item questionnaire encompassing 3 subscales including general fatigue (6 items), sleep and rest fatigue (6 items) and cognitive fatigue (6 items). This assessment will take approximately 10-20 minutes to complete.
45666093|NCT02473523|Device|Biodex System 3 Dynamometer|"The Biodex System 3 Dynamometer will be used to measure isometric quadriceps muscle contractions. Participants will be stabilized in the chair with abdominal and shoulder straps. The isometric tests for knee extension will be done on both dominant and non-dominant leg. The tests consist of 3 maximal muscle contractions each lasting five seconds separated by 40 second rest intervals. This assessment will take approximately 10 minutes to complete."
45666094|NCT02473523|Device|Jamar Hydraulic Hand Dynamometer|"A calibrated Jamar hydraulic hand dynamometer will be used to measure grip strength. The participant will be seated in a chair with elbow flexion to 90 degrees against torso and the forearm in neutral. The participant will grasp the device and the handle will be adjusted so that digits are able to comfortably grasp the device. The maximum score after 2 trials will be recorded as grip strength for both right and left hand. This assessment will take no more than 5 minutes to complete."
45962729|NCT05133622|Other|Fatigue|"Individuals will score perceived fatigue during walking and running activities with the Modified Borg Scale. According to the scale, 0 indicates no fatigue, and a score of 10 indicates unbearable fatigue (Borg,1987)."
45962730|NCT05124067|Drug|Dexamethasone|patients will receive dexamethasone (0.15 mg/kg IV; maximum 5 mg)
45962731|NCT05124067|Drug|Ondansetron|patients will receive ondansetron (0.05 mg/kg IV; maximum 4 mg)
45962732|NCT05124067|Drug|Dexmedetomidine|Patients will receive dexmedetomidine (0.3 μg/kg)
45962733|NCT05124067|Drug|normal Saline|patients will receive normal saline.
45962734|NCT00194883|Drug|Recombinant Human Growth Hormone|
45962735|NCT05109286|Behavioral|CrossFit|CrossFit training
45962736|NCT02277184|Drug|Ficlatuzumab|"Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2C - 8C)"
45962737|NCT02277184|Drug|Cisplatin|"Each vial contains 10 mg of DDP, 19 mg of sodium chloride, 100 mg of mannitol, and hydrochloric acid for pH adjustment. One vial is reconstituted with 10 ml of sterile water. The pH range will be 3.5 to 4.5.~Cisplatin will be given as a bolus, infused over 1-2 hours along with appropriate hydration and anti-emetics.~Reconstituted solution of cisplatin is stable for 20 hours when stored at 27°C and should be protected from light if not used within 6 hours. The vials and injection should not be refrigerated. Cisplatin has been shown to react with aluminum needles, producing a black precipitate within 30 minutes."
46079817|NCT03935269|Device|Cereset Research Wearable|CRW is a stress-relaxation device where participants listen to sounds that help to balance brain rhythms. Participants will be asked to come to an office for 5 days over 1-2 weeks, on your their schedule. Sessions will take approximately one (1) hour to complete.
45666095|NCT02473523|Other|Sit and Reach Test|Hamstring flexibility will be assessed by the Sit and Reach Test. The sit and reach is a test to measure hip, hamstring and lower back flexibility. To measure flexibility participants will perform the YMCA sit and reach test. Participants will sit down without shoes or socks with the soles of their feet against the vertical platform of the sit-and-reach box located at the 26 cm (a little over 10 inches) mark. Participants keep their legs straight and their hands overlapped, while reaching for a less than maximum distance twice as a warm-up. This test will take no more than 5 minutes to complete.
45821262|NCT00801931|Drug|Busulfan|(Busulfex) will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration >0.5 mg/mL), through a central venous access device over 2 hours.
45821263|NCT00801931|Drug|Phenytoin|Fosphenytoin can be administered in D5W or 0.9% sodium chloride to a final concentration ranging from 1.5 to 25 mg PE/ml at a rate of 1-3 mg phenytoin sodium equivalents (PE)/kg/min up to 50-150 mg PE/minute.
45821264|NCT00801931|Drug|Fludarabine|Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
45821265|NCT00801931|Drug|Cyclophosphamide|Cyclophosphamide should be infused over one hour. The drug can be diluted in D5W, NS, or other solutions (100-250 mL) to a maximum concentration of 20 mg/mL.
45821266|NCT00801931|Drug|Horse Antithymocyte Globulin|Horse Antithymocyte Globulin (ATG [horse]) will be diluted in 0.9% sodium chloride or 0.45% sodium chloride for IV infusion (through an inline filter with pore size of 0.2 micrometer) to a concentration of 1-4 mg/ml and infused through a central venous catheter over 8 hours in Regimen E.
45821267|NCT00801931|Drug|Rabbit Antithymocyte Globulin|Rabbit Anti-Thymocyte Globulin (rabbit ATG) will be diluted in 0.9% sodium chloride or D5W for IV infusion (through an in-line filter with pore size of 0.22 micrometer) to a concentration of 0.5 mg/ml and infused through a central venous catheter over 8 hours for all doses on Days -4, -3, -2, and -1 in Regimens A, B, D and F.
46079818|NCT03935269|Procedure|Stress management therapy|Undergo Cereset research office intervention
46079819|NCT03935269|Other|Questionnaire administration|Ancillary studies
46079820|NCT03935269|Other|Quality of Life Assessment|Ancillary studies
46079821|NCT03927391|Drug|Enzalutamide|enzalutamide treatment
45666096|NCT02473523|Other|Test of Motor Proficiency|The Bruininks-Oseretsky Test of Motor Proficiency is a 9 item standardized assessment that includes standing with feet on a line with eyes open and closed, standing on a line with one foot with eyes open and closed, standing on a balance beam on one leg with eyes open and closed and standing heel to toe on a balance beam. These tests will be administered no more than two times with a maximum score of 10 seconds. Two additional subtests include walking forward on a line and walking heel to toe on a line for a maximum of 6 steps for both tasks. Total time to complete this test is approximately 10-20 minutes.
45666097|NCT02473523|Other|Verbal Numeric Pain Scale|The verbal numeric pain scale will be administered before and after each yoga session. The principal investigator (PI) will ask the participant about his/her pain on a scale of 0-10 and the PI will record the number. This will take less than 10 seconds.
45962738|NCT02277184|Radiation|Intensity Modulated Radiotherapy (IMRT)|"Immobilization should be performed to ensure daily reproducibility of setup.Treatment planning CT scans will be required to define tumor, clinical and planning target volumes.The treatment planning CT scan should be performed with IV contrast. All tissues to be irradiated must be included in the CT scan.~Targets are defined as primary (requiring a higher dose) and secondary (targets at lower risk requiring a lower dose). The primary target is the PTV3 of the primary tumor and lymph nodes containing clinical or radiographic evidence of metastases. The secondary target is the PTVs consist of an area at intermediate risk (PTV2) and that containing the lowest risk of lymph node involvement (PTV2).~The treatment plan will be based on an analysis of the volumetric dose, including dose volume histogram (DVH) analyses of the PTV and critical normal structures. Inverse planning will be utilized to deliver optimal dose to the PTVs while excluding noninvolved normal tissue."
45962739|NCT00166790|Drug|chemotherapy agents|
45962740|NCT00166790|Procedure|suction curettage|
45962741|NCT00194922|Dietary Supplement|E. Coli Strain M17 Probiotic|30 ml PO BID for 12 weeks
45962742|NCT05093101|Other|case series review of clinical data|Extraction of pre-surgical and chemotherapy blood test laboratory data and clinical and instrumental data related to patient history from digitized medical records and analysis
45962743|NCT00166829|Drug|sirolimus, tacrolimus, mycophenolate mofetil|
45962744|NCT05056363|Other|Home Based Traditional Scoliosis Exercises|Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.
45962745|NCT05056363|Other|Core Stability Training|Patients in this group will receive traditional scoliosis exercises. In addition, the training group will receive core stabilization exercises for multifidus, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, iliopsoas, gluteus maximus, and pelvic floor muscles.
45962746|NCT00177333|Drug|Doxycycline|
45962747|NCT05046535|Behavioral|Sleep quality and physical activity|"Self-reported assessments will be used to measure the following: overall sleep quality, insomnia symptoms, Obstructive sleep apnea.~Physical activity will be measured objectively using the 6MWT, 9HPT, and cardiorespiratory fitness using the VO2 submaximal test on the recumbent stepper."
45962748|NCT05046535|Genetic|Nicotine dependence|DNA sequencing for 20-25 subjects out of the whole sample will be performed. Sanger sequencing to all subjects will also be performed to identify related genes
45962749|NCT05046535|Diagnostic Test|Nicotine and cotinine serum levels|Cotinine serum level which is a major metabolite of nicotine and the preferred biomarker for measuring tobacco use will be measured together with nicotine levels using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
45455359|NCT01316432|Other|Placebo|Placebo will be administered as a 24-hour SQ infusion
45666098|NCT02473523|Other|:Yoga Therapy|Those who consent will participate in 60-minute yoga sessions 2-3 times per week for 4-6 weeks. Only specified yoga poses will be implemented during the classes. Additional detail is included in the Description sections of this registration. The principal investigator is a Certified Yoga Therapist (CYT) and is a registered yoga teacher with 500 hours of training (RYT 500).
45666099|NCT02316769|Procedure|King Vision video laryngoscope|Patient intubated with the King Vision Video Laryngoscope
45821268|NCT00801931|Drug|Thiotepa|Thiotepa should be diluted in NS (1-5 mg/ml) and infused over 2 hrs on Days -8, -4. IV fluids should be at maintenance rate (1500 ml/m2).
45821269|NCT00382850|Procedure|Nissen fundoplication|
45821270|NCT05348642|Dietary Supplement|pasteurized A. muciniphila|pasteurized A. muciniphila - oral daily dose
45821271|NCT05348642|Dietary Supplement|placebo|Placebo = identical to verum regarding the form, size, taste, color and intake
45821272|NCT00780481|Drug|Bradykinin|Intrabrachial - 0, 10, 20, 40 ng/100cc/min over 5 minutes at each dose.
45962750|NCT05046535|Behavioral|Smoking|Surveys that measure nicotine dependence and smoking behavior
45962751|NCT05019742|Drug|SPH3127|SPH3127 - selective renin inhibitor
45962752|NCT05019742|Drug|Placebo|Placebo
45455360|NCT01124539|Drug|AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)|IV AR-67 administered once daily for 5 days on an every 21-day cycle
45962753|NCT00166868|Drug|Lactobacillus casei rhamnosus (Lcr35)|
45962754|NCT00166868|Drug|Neomycin|
45962755|NCT00194961|Drug|Recombinant Human Growth Hormone|
45962756|NCT04943458|Other|Monitoring of cerebral autoregulation|Patients will be monitored for cerebral autoregulation using a Vittamed 505 monitor to identify the dynamics of the autoregulation index VRx (t). Intracranial pressure (ICP) will also be measured by non-invasive ultrasound using a robotic TCD device, Dolphin4D (Israel), which simultaneously records MCA blood flow in both hemispheres of the brain. APAs will be assessed using mathematical models.
45962757|NCT04910152|Drug|BRD4 Inhibitor PLX51107|Given PO
45962758|NCT00166907|Behavioral|Balance and Exercise|
45455361|NCT03141788|Device|Clear Aligner|Clear Aligner used to straighten teeth to desired outcome
45458296|NCT02315950|Other|Botulinum toxin and cineMRI-UDS|The investigators will be testing the capability of cineMRI combined with simultaneous urodynamics in the context of OAB in this proposal and expect to reveal a new understanding of diseased lower urinary tract physiology. Participants will receive an injection of intravesical botulinum toxin after filling out validated questionnaires and receiving a pre-treatment cineMRI-UDS.
45458297|NCT03113383|Device|Thoracoabdominal Aortic Aneurysm Repair|Thoracoabdominal aortic aneurysm repair
45458298|NCT03319316|Drug|Durvalumab|Combination of durvalumab + tremelimumab treatment
45666100|NCT02316769|Procedure|McGrath MAC video laryngoscope|Intubation with the McGrath MAC video laryngoscope
45666101|NCT02473445|Drug|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release capsules
45666102|NCT04966169|Device|GentleWave System|The GentleWave hydrodynamic cavitation system is a 510k FDA-approved multisonic energy system that is used in complex root canal procedures.
45666103|NCT02473367|Drug|Raltegravir 1200 mg|Two tablets of 600 mg raltegravir administered orally, once daily, over 5 days of Pre-treatment, and once at the start of Periods 1-4.
45962759|NCT00177372|Drug|mifepristone/misoprostol|mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
45962760|NCT04892914|Device|Embr thermal device|Participants use the Embr thermal device for 4 weeks
45962761|NCT04834765|Other|Mindfulness-based art therapy|The researchers developed a novel MBAT intervention consisting of 10 easily reproducible, clay-based MBAT directives, administered through an online platform delivery strategy. By developing an MBAT intervention that uses an online delivery strategy, the researchers realized it may have the potential of decreasing demands placed on counseling centers.
45666104|NCT02473367|Drug|TUMS|Three tablets of TUMS Ultra Strength (US) 1000, taken orally, concomitantly with raltegravir in Period 2, and 12 hours after raltegravir in Period 4
45666105|NCT02473367|Drug|Leader Antacid|20 mL Leader Antacid Maximum Strength (MS) taken orally 12 hours after raltegravir, in Period 3
45666106|NCT04965701|Drug|Osimertinib 80 MG|Osimertinib is administered according to clinical practice at the recommended dose of 80 mg, orally, once a day.
45666107|NCT02316613|Drug|Rituximab|
45666108|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
45666109|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
45821273|NCT05345990|Drug|Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)|"Hepatect® is a solution to be administered Intravenously. Zutectra® is a solution to be administered subcutaneously.~Treatment for 12 weeks with hepatitis B immunoglobulins with following administration scheme:~D0: 10.000 IU Hepatect® i.v. D1-6: 500 IU Zutectra® s.c. D7: 10.000 IU Hepatect® i.v. D9- D84: 500 IU Zutectra® s.c. every 2nd day"
46079822|NCT03913169|Other|Educational Implementation of Interprofessional Curriculum|The intervention utilized in this project will involve a 2-year curriculum. The year one/pre-clinical curriculum will be presented to pre-clinical doctor of osteopathic medical students (DO) and physician assistant students (PA) students. The year two/clinical curriculum will be presented to third year DO students and second year PA students once clinic sites are identified.
45962762|NCT04834765|Other|Art-only|The AO modules consist of an open-ended art-making exercise, with minimal direction. The AO intervention is designed as an 'art for art's sake' intervention with the focus on the art-making and less on outcome or product. Participants are asked to pull their ball of clay out and spend ten minutes creating a form from the clay to visually express their experience in the present moment.
45666110|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
45666111|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
45666112|NCT02355691|Device|PREVENA|The device is a sealed negative pressure wound therapy tool. The device will be placed on the skin during surgery and left in place until their followup at 7 days.
45821274|NCT04278326|Procedure|Vaginal Biopsy|"Vaginal biopsies~Additional cervical and vaginal biopsies~Non invasive cervico-vaginal swab like a smear"
45821275|NCT00019747|Drug|thalidomide|oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
45962763|NCT04834765|Other|Mindfulness-only|The MO modules consist of only the mindfulness practices from the ABM intervention. The participants to follow along with a five-minute light yoga sequence, where asanas (yoga postures) are cued with breath. Yoga, for the purposes of the study, is explicitly defined to participants as the unity of breath with body movement. Poses were chosen based on their accessibility to a variety of body types and abilities, and chosen because they are documented to aid in grounding, increased haptic awareness, lowered levels of stress and anxiety, and restoration.
45666113|NCT02473289|Drug|Sirukumab 50 mg|Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
45666114|NCT02473289|Drug|Placebo|Participants will receive matching placebo on Day 1, 28 and 56.
46079823|NCT03910452|Drug|Busulfan|3 days of IV Busulfan. An alkylating chemotherapeutic agent determined to have broad myelosuppressive effects. On this study is being used as part of conditioning regimen for myelosuppressive properties as per package insert and standard of care.
45666115|NCT02354599|Drug|MT203 80 mg or matching Placebo|MT203 80 mg or matching placebo injection
45666116|NCT02354599|Drug|MT203 150mg or matching Placebo|MT203 150mg or matching placebo injection
45666117|NCT02354599|Drug|MT203 300 mg or matching placebo|MT203 300 mg or matching placebo injection
45821276|NCT00019747|Procedure|adjuvant therapy|Initial dose: 100 mg by mouth (po) every bedtime ( Q hs) for four weeks, then progress to 200 mg po Q hs for four weeks, then progress to maintenance dose: 300 mg po Q hs.
45821277|NCT00019747|Other|Placebo|oral placebo once daily
45821278|NCT02970799|Device|Intranasal Neurostimulator|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
45821279|NCT05048719|Drug|LY3502970|Administered orally
45821280|NCT05048719|Drug|Dulaglutide|Administered subcutaneously
45962764|NCT00166946|Procedure|foreskin from healthy adults for organotypic culture|
45962765|NCT04819399|Drug|Catumaxomab|"Procedure: 6 weekly intravesical administration at each dose level; 3 sequential cohorts consisting of 3 patients (part I)~cohort 50 µg~cohort 70 µg~cohort 100 µg~Part II will be treated at recommended dose"
45962766|NCT04800172|Drug|Roflumilast|administration of roflumilast 500 mcg tablet once daily for 3 months.
45962767|NCT04800172|Drug|placebo|administration of placebo tablet once daily for 3 months.
45962768|NCT04769596|Device|NEUROMARK™ System|The NEUROMARK™ System is designed to deliver energy to the nasal cavity intended to interrupt nasal nerves aimed to reduce symptoms related to Chronic Rhinitis.
45962769|NCT04769596|Device|Sham Device|A Sham device will be used in the nasal cavity
45962770|NCT04769518|Procedure|Advanced Recovery Room Care (ARRC)|High acuity care
45962771|NCT00177411|Drug|Parathyroid Hormone-related Protein|Parathyroid Hormone-related Protein in doses started at a 4 microgram single bolus intravenous dose. Dose will be increase to a maximum of 400 micrograms or until a dose limiting toxicity occurs at a lower dose.
45962772|NCT01792531|Behavioral|Parent training group|The More & Less group will focus on how to use positive parenting practices (e.g., reinforcement/encouragement, limit setting, monitoring, problem-solving, positive involvement, and emotion regulation) instead of ineffective practices (e.g., coercive behavior, negative reciprocity, escalation, and negative reinforcement). Using a parent-group approach to intervention administration, each of the twelve More & Less sessions (1.5h/wk) consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments. The information and procedures will be tailored to focus on changes in the home environment, mostly related to child food habits and physical activity.
45962773|NCT01792531|Behavioral|Standard treatment with focus on lifestyle|The treatment will be provided by local pediatricians in outpatient pediatric departments and will be based on lifestyle modifications, as recommended in the action plan for Stockholm County.
45666118|NCT02316223|Behavioral|Supporting Asthma Management Behaviors in Aging Adults (SAMBA)|The SAMBA program will be led by an asthma care coach (ACC) and the home program by a community health worker (CHW). All interventions, including usual care, will include EMR-based asthma self-management and decision support tools for clinicians in all practice sites. The ACC and CHW will provide education, goal setting, and general self-management support with assigned patients and coordinate with PCPs through in-person and phone contacts over 12 months. Outcomes will be measured through interviews, EMR chart abstractions, and from the Statewide Planning and Research Cooperative System (SPARCS) dataset to identify all ED visits and hospitalizations to any New York State facility.
45821281|NCT05048719|Drug|Placebo|Administered orally
45821282|NCT05048719|Drug|Placebo|Administered subcutaneously
45821283|NCT00759577|Drug|Solifenacin|5mg and 10 mg, oral once daily
45962774|NCT01792531|Behavioral|Parent training group with booster sessions|Parent training group with additional booster sessions at 8-week intervals for the following year.
45821284|NCT05338112|Diagnostic Test|Tzanck smear|The Tzanck smear is gently taken with a sterile scalpel from the ground of erosion or bullous lesions of pemphigus vulgaris. The sample taken is examined by staining the slide.
45821285|NCT00748579|Drug|CK-1827452|I.V. infusion for 0.5 hour at 54mg/hr followed by 1 hour at 21mg/hr
45821286|NCT00748579|Drug|CK-1827452|I.V. infusion for ≤ 1 hour at 72mg/hr followed by 1 hour at 36mg/hr
45821287|NCT05329922|Behavioral|ALICE: Audiological rehabilitation|Persons who are randomised into this arm of the study will be asked to train their listening and communication skills using the ALICE app.
45821288|NCT04599764|Other|HD-tDCS|Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak direct currents.The respective excitability alterations-enhancement by anodal and reduction by cathodal tDCS-can last for over an hour after the end of stimulation.
45821289|NCT04599764|Other|computer-based cognitive training|Computer-based cognitive training (CCT) is a potentially important tool for individuals at risk of dementia. Cognitive training in healthy older adults and those at risk of dementia has been linked to benefits in cognitive functioning.
45821290|NCT04524962|Biological|Descartes 30|Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.
45821291|NCT00746239|Drug|Placebo and Escitalopram|Placebo and Escitalopram (5 to 40 mg)
45821292|NCT00746239|Drug|Ramelteon and Escitalopram|Ramelteon 8 mg and Escitalopram (5-40 mg)
45821293|NCT04977674|Drug|Naltrexone|Pre-treatment with naltrexone 45 min before the ketamine infusion.
45821294|NCT04977674|Drug|Placebo|Pre-treatment with placebo 45 min before the ketamine infusion.
45821295|NCT04977674|Drug|Ketamine|Participants receive intravenous ketamine infusion (0.5 mg/kg over 40 min) at both study visits.
45821296|NCT04972136|Device|Active Bilateral Theta Burst Stimulation|A total of 30 active BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
45821297|NCT04972136|Device|Sham Bilateral Theta Burst Stimulation|A total of 30 sham BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
45821298|NCT04965038|Drug|Alteplase|Intravenous thrombolysis with alteplase within 4.5 hours of symptom onset
45962775|NCT01655836|Radiation|Brachytherapy|Undergo high dose rate brachytherapy
45962776|NCT01655836|Radiation|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
45962777|NCT01655836|Procedure|Quality-of-life assessment|Ancillary studies
45962778|NCT01655836|Other|Questionnaire administration|Ancillary studies
45962779|NCT03457324|Drug|JCM-16021|This prescription with seven ingredients.
45962780|NCT03457324|Drug|Placebo|Placebo
45962781|NCT00177489|Behavioral|multicomponent psychosocial intervention|The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.
45962782|NCT00177489|Other|Control arm|"Caregivers in the control group received 2 brief check-in telephone calls during the 6-month intervention."
45962783|NCT04716985|Dietary Supplement|MOLECULAR HYDROGEN|Magnesium Tablet
45962784|NCT04716985|Dietary Supplement|PLACEBO MAGNESIUM|Magnesium carbonate tablet
45962785|NCT04711174|Behavioral|LMA removal|the timing when conducting LMA removal
45962786|NCT00195078|Drug|ZD1839 (IRESSA)|
45666119|NCT02286895|Biological|pentavalent rotavirus vaccine (PRV)|Each two-ml dose contains 5 live human-bovine reassortant rotaviruses with a minimum of 2.0 - 2.8 x 106 infectious units (IU) per reassortant, depending on the serotype, and not greater than 116 x 106 IU per aggregate dose. Each vaccine dose contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq contains no preservatives. RotaTeq is a pale yellow clear liquid that may have a pink tint. This vaccine was administered orally.
45821299|NCT04963790|Behavioral|Tailored COVID-19 vaccine messages|Survey responses from participants will be aggregated to create hesitant patient segments. Then, specific content messages will be created following the health belief model, in a way that is meaningful to the recipients in the different segments, to persuade them to receive the COVID-19 vaccine.
45821300|NCT04963790|Other|Other health messages|Other health messages unrelated to COVID-19 will be sent to participants in the control arm
45821301|NCT04960124|Drug|JNJ-42847922|Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.
45821302|NCT00402883|Drug|Bevacizumab|15mg/kg week 1, 4, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, and 49.
45821303|NCT00402883|Drug|Pemetrexed|500mg/m2 week 1, 4, 16, 19 and 22.
45821304|NCT00402883|Procedure|Radiotherapy|1.8 Gy single daily fractions(Monday-Friday), to total dose 61.2 Gy (7 weeks)
45821305|NCT00402883|Other|Folic Acid|350 to 1,000 ug or equivalent supplementation administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinues study therapy.
45821306|NCT00402883|Other|vitamin B12|1,000ug administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinues therapy.
45821307|NCT00402883|Drug|carboplatin|AUC=5 administered intravenously weeks 1 and 4.
45821308|NCT05311826|Procedure|STANDARD PHYSIOTHERAPY TREATMENT|"The standard postoperative rehabilitation process starts from the first postoperative day. Two sessions are provided daily, with the exception of Sunday and Saturday afternoon. A single physiotherapy session, lasting 30 minutes, can include bed exercises for upper and lower limbs and recovery of autonomy (sitting position, standing and ambulation). In this phase, the sessions are characterized by educational and counseling activities.~The patient will be encouraged to carry out the activities independently."
45821309|NCT05311826|Procedure|EXPERIMENTAL diaphragmatic breathing exercise|The subjects in the intervention group (EXP) will receive, in addition to standard physiotherapy treatment, diaphragmatic breathing exercise. Four exercises in different position (supine and side lying) will be provided for each physiotherapy session by a senior physiotherapist. Patients will be instructed to perform the same exercises independently to achieve relaxation and relief of pain symptoms.
45821310|NCT04940312|Behavioral|App-based physical activity coaching|Individualized app-based coaching via a smartphone
45821311|NCT04939844|Drug|Isatuximab, bortezomib, lenalidomide, dexamethason|All participants will receive the same treatment as described under arm.
45821312|NCT04936568|Other|Palliative Care Referral System - PCRS|Implementation of a system to help oncologists to identify criteria for referring patients to specialized outpatient palliative care (Palliative Care Referral System - PCRS)
45821313|NCT05295212|Drug|Atezolizumab|Pemetrexed (500mg/m2)/Paclitaxel (260mg/m2) Carboplatin (AUC=4-5) Atezolizumab(1200mg) ivgtt, every 21 days Range from 4 cycles
45962787|NCT00195078|Drug|Cisplatin|
45821314|NCT05294120|Device|Reflectance ConfocaL Microscopy And Optical Coherence Tomography Guided|"Patients will undergo RCM/OCT with an imaging specialist in the Dermatology Service.~This is not expected to take longer than 30 minutes. Prior to imaging, a digital photograph will be taken of the biopsy proven BCC."
45821315|NCT05294120|Radiation|Radiation Therapy|After the completion of skin imaging, patients will undergo simulation and tumor radiotherapy. An equivalent total dose in 2 Gy fractions (EQD2) of 45-46 Gy will be delivered for treatment.
45821316|NCT05287178|Behavioral|DBT Skills + Parent Training|The DBT Skills +PT group intervention integrates DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC). Each session includes a mindfulness practice, homework review to discuss use of skills previously learned, didactics to learn a new set of DBT and PT skills, and assignment of homework. The DBT Skills portions cover the four modules of traditional DBT Skills: Mindfulness, Emotion Regulation, Distress Tolerance (including skills specifically focused on managing difficulties with addiction), and Interpersonal Effectiveness. PT skills include both PMT and EC components such as: praise, use of parental attention to reward positive behavior, reward systems, effective commands and consequences, psychoeducation on children's emotional development, teaching children to label emotions, validating children's emotions, and handling children's negative emotions, and fostering positive emotions.
45821317|NCT04328948|Radiation|Chemoradiotherapy|Chemoradiotherapy
45821318|NCT04538144|Other|Simulated heat wave|Individuals will be exposed to thermoneutral climate conditions and two simulated heat wave conditions.
45821319|NCT05286320|Drug|Lenvatinib/Pembrolizumab plus SBRT combinations|Five-fraction SBRT (week 4-week 5) to PVTT and connected HCC tumor in 2 weeks Lenvatinib 12/8 mg/day for 96 weeks (no lenvatinib from 7 day before SBRT to 7 days after SBRT) Pembrolizumab 200 mg q 3 week x 32 cycles
45821320|NCT00728845|Biological|bevacizumab|Only patients eligible for bevacizumab will receive bevacizumab. Dose is at 15 mg/kg on day 1 of each cycle.
45821321|NCT00728845|Drug|carboplatin|Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel
45821322|NCT00728845|Drug|hydroxychloroquine|200 mg orally BID (total daily dose of 400 mg)
45821323|NCT00728845|Drug|paclitaxel|Dose of 200 mg/m2 IV on day 1 of each cycle
45821324|NCT04306016|Other|Sensory stimulation|Sensory stimulation can be formed in different aspects, and the most important ones are visual stimulation and auditory stimulation. Visual stimulation interventions involved providing a calendar, clock or familiar objects such as photographs of family caregivers; while auditory stimulation included calling the name of patients, helping to orientate the time and location, introducing hospital information, the ICU surrounding and treatment, and communicating with patients, who could not talk due to artificial airway, through a blackboard and use of gestures.
45821325|NCT00379873|Device|ProAdjuster|
45821326|NCT00726037|Drug|Ontak|One dose of Ontak 9 mcg/Kg IV over 30 minutes times 3 doses. 1 dose every other day
45962788|NCT00195078|Procedure|Radiation Therapy|
45962789|NCT04693819|Diagnostic Test|Somatic modulation|"Type of modulations: 3 jaw and 6 cervical spine modulations, 1 control movement (i.e. without any expected somatic modulation effect) Jaw modulations: laterotrusion to the left, laterotrusion to the right and protrusion Cervical spine modulations: isometric flexion, extension and left and right lateroflexion of the head against resistance of the investigator's hand, compression and traction of the cervical spine in sitting position.~Control movement: the investigator's hand rests against the patient's forehead without any force application"
45455362|NCT03525964|Procedure|Individualized treatment of Acute Achilles tendon rupture.|The most proximal border of the calcaneus and the most distal point of the musculotendinous junction of the Achilles tendon and the medial gastrocnemius muscle is identified and marked on the skin. These two points on the un-injured leg defines the original length of the total Achilles tendon and consist of the free tendon and the fascia [1]. The difference in length between the injure and the un-injured leg determines elongation for the ruptured Achilles tendon. The relative elongation of the ruptured tendon together with overlap of the tendon ends on the cross-sectional area determines the treatment for the patients receiving individualized treatment: 1) patients with 0-6% elongation of the tendon and a minimum of 25% tendon are treated non-operatively 2) patients with 7% elongation or more or less than 25% tendon overlap are treated operatively. The cut-off at 7% elongation is determined for 75% sensitivity and 65% specificity of elongation.
45962790|NCT00167141|Drug|injection of hormonal male contraceptive|testosterone injections 4 times
45962791|NCT04660045|Drug|Acalabrutinib|Acalabrutinib, oral, 100 mg BID, continuous
45666120|NCT02286895|Biological|measles vaccine (MV)|A lyophilized vaccine in a pack containing one vial plus one ampoule of sterile water for injection. After reconstitution, each 0.5 ml/dose of MV contains active substances not less than 1000 units of 50% cell culture infectious doses (CCID50) of MV. Measles Vaccine Live Attenuated virus is propagated on Human Diploid Cells. This MV is currently part of the local EPI program in Mali. This vaccine was administered subcutaneously to the right deltoid.
45962792|NCT00177528|Drug|venlafaxine-XR|
45962793|NCT04612387|Behavioral|Mind-body therapy|Online yoga, meditation and nutrition tips.
45455363|NCT03525964|Procedure|Non-operative treatment|Circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
45666121|NCT02286895|Biological|yellow fever vaccine (YFV)|A freeze-dried live attenuated yellow fever virus of the 17D strain for injection. After reconstitution, one dose (0.5 ml) contains active substances not less than 1000 units of 50% lethal doses (LD50) of yellow fever virus. This YFV is currently part of the local EPI program in Mali. This vaccine was administered intramuscularly to the left deltoid.
45666122|NCT02286895|Biological|meningitis conjugate vaccine (PsA-TT-5μg)|A meningococcal A vaccine, with meningococcal A polysaccharide (PsA) conjugated to the carrier protein, tetanus toxoid (TT). After reconstitution, one dose (0.5 ml) contains 5μg meningococcal A polysaccharide and 5-16 μg tetanus toxoid as a carrier protein. PsA-TT-5μg was considered experimental at the initiation of this study, but received approval from the WHO for infants on 30 December 2014. For all participants enrolled January 1st, 2015 or later, PsA-TT-5μg was not included in Group A or Group B, due to its December 2014 expiration date. This vaccine was administered intramuscularly to the right thigh.
45666123|NCT02472977|Drug|Ulocuplumab|
45821327|NCT04890860|Other|cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass|cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass
45821328|NCT04928053|Genetic|ocytocine dosage and genetic analyse|All patients are assessed using 4 paradigms: Reading the Mind in the Eyes Test (RMET), Interpersonal Reactivity Index (IRI), Empathy Quotient (QE), and a modified Delay Discounting task. They have a blood prelevment
45821329|NCT05278676|Drug|Dotinurad|Dotinurad oral tablet.
45458299|NCT03319316|Drug|Tremelimumab|Combination of durvalumab + tremelimumab treatment
45666124|NCT02472977|Drug|Nivolumab|
45821330|NCT00703885|Drug|0.25 mg alprazolam|"0.25 mg alprazolam PO (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
45821331|NCT00703885|Drug|1.0 mg alprazolam|"1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
46079824|NCT03910452|Drug|Alemtuzumab|5 days of IV Alemtuzumab. A humanized monoclonal antibody directed against CD52 (which is abundantly expressed on all human lymphocytes), and causes T cell activation in vitro as well as complement-mediated lysis and antibody-dependent cellular toxicity. For this study, being used as part of the conditioning regimen per package insert and standard of practice.
46079825|NCT03910452|Drug|Cyclophosphamide|2 days of IV Cyclophosphamide. This is an antineoplastic, and for this study is bine used for its immunosuppressive mechanism of action per package insert and standard of care
46079826|NCT03910452|Drug|Sirolimus|Post Peripheral blood stem cell infusion. It is used for its immunosuppressive mechanism of action.
45962794|NCT03457285|Other|Physiotherapy|"Participants, with a confirmed diagnosis of AS, will be invited to participate. Once participants have provided informed consent, they will be required to complete the outcome measures provided. Participants will be set up to use the online exercise application and educated on its use.~Participants will then have access to videos of suitable exercises or exercise classes to follow and education material on their condition to read. Participants will be able to complete AS specific outcome measures and record their progress. Participants will also have a monthly video call with the senior rheumatology physiotherapist to discuss their exercise programme, symptoms and management. The participants will also record their compliance with their exercise programmes.~After the 6 month pilot period, participants will be required to complete the same outcome measures completed at the start of the study."
45962795|NCT00167258|Behavioral|Voucher Reinforcement|
45962796|NCT00167258|Behavioral|Extra Counseling Services|
45962797|NCT00167258|Behavioral|Voucher Reinforcement + Extra Counseling Services|
45962798|NCT00195117|Behavioral|Intervention Group|Subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
45962799|NCT04566250|Combination Product|Non-Opioid Prescription and Infographic|"The study intervention will involve 3 components:~A standardized non-opioid prescription: A prescription for Naproxen 500mg PO BID PRN x 60 tabs, Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs and Pantoprazole 40mg PO daily x 30 tabs (to be taken only while utilizing Naproxen).~A limited opioid rescue prescription: A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.~Patient education infographic: The infographic will contain information on how to take the prescribed medications, along with instructions that the morphine rescue prescription should only be used in cases where the non-opioid pain medications are not providing satisfactory pain control."
45962800|NCT04548583|Drug|Remestemcel-L|adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis
46079827|NCT03910452|Radiation|Total Body Irradiation|2 fractionated doses on -2 day. It is used for its immunosuppressive mechanism of action. It is SOP for conditioning for transplant.
45666125|NCT02060487|Drug|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 5 mg tablet TID until study treatment discontinued or end of study
45821332|NCT00703885|Drug|placebo|"Placebo (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
46079828|NCT03910452|Biological|Allogeneic peripheral blood stem cell|IV infused donor peripheral blood stem cell. Stem cells are cells that give rise to the blood cells - red blood cells that carry oxygen, white blood cells that help the body to fight infections, and platelets that help make the blood clot. Collected and infused per the standard of operating procedures established by the Department of Transfusion Medicine.
46079829|NCT03886831|Drug|PRT543|PRT543 will be administered orally
45455364|NCT03525964|Procedure|Operative treatment|Open surgery with suture of the ruptured achilles tendon prior to circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
45821333|NCT00703339|Drug|Treprostinil sodium for inhalation|"Administration of inhaled treprostinil sodium 0.6 mg/ml in 3mL ampoules Duration of Treatment: single dose~Dose:~Cohort 1: dosed at 3 breaths (18 mcg)~Cohort 2: dosed at 6 breaths (36 mcg)~Cohort 3: dosed at 9 breaths (54 mcg)~Cohort 4: dosed at 12 breaths (72 mcg)~The decision to advance to the next cohort will be made after review of all safety information including vital signs, physical examination, clinical laboratory tests, ECGs, and adverse events."
45455365|NCT03869554|Diagnostic Test|Detection of Fabry disease|Systematic detection of Fabry disease
45455366|NCT01347164|Behavioral|RISE life coaching intervention|6 2-hour sessions
46079830|NCT03871608|Other|Examination of functional etiologies on DTM Disorders|Evaluating functional etiologies accessible to rehabilitation, consists of 4 categories (Orofacial dyspraxia, parafunctions, posture, Chewing) and includes 11 items in total
46079831|NCT03871608|Other|Assessment of symptoms on DTM Disorders|Examining the symptoms of the patient, consists of 5 categories (Muscle examination, Areas of cellulalgic infiltrates, Mandibular kinetics, Joint sounds, Thrust)and includes 21 items
45666126|NCT02060487|Drug|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 20 mg tablet TID until study treatment discontinued or end of study
45666127|NCT02060487|Drug|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 80 mg tablet TID until study treatment discontinued or end of study
45666128|NCT02059395|Other|Mastery based learning|Participants are allowed to follow the course content at their own speed
45666129|NCT02059395|Other|Time based learning|Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course according to the official course layout
45666130|NCT04973085|Device|Cold or body temperature circulated water|"Water will be circulated through an adhesive wrap, applied to the front of the participant's neck, for 2 hours in either the cold (experimental) or body temperature (active comparator) study arm.~Subject's will be randomized to one study arm, then cross over to the other study arm after completion of their first intervention."
45821334|NCT04330586|Drug|Ciclesonide Metered Dose Inhaler [Alvesco]|Ciclesonide 320ug oral inhalation q12h for 14 days
46079832|NCT03860961|Other|Questionnaire Administration|Ancillary studies
46079833|NCT03860961|Other|Survivorship Care Plan (SCP)|Given survivorship care plan
46079834|NCT03860961|Other|Treatment Plan|Given treatment plan
46079835|NCT03858985|Device|Cervical Transcutaneous Vagus Nerve Stimulation (Active Comparator)|Both sham and active nVNS treatment produce low-voltage electrical signal that induce reliable sensation on subject skin on upper anterior cervical area (overlying carotid artery).
46079836|NCT03858985|Device|Cervical Transcutaneous Vagus Nerve Stimulation (Sham Comparator)|Both sham and active nVNS treatment produce low-voltage electrical signal that induce reliable sensation on subject skin on upper anterior cervical area (overlying carotid artery).
45821335|NCT00382694|Drug|Fludarabine|
45455367|NCT01347164|Behavioral|HIV Counseling|Standard one-hour HIV counseling session
45666131|NCT02059239|Drug|Bendamustine|Days - 24 and Day - 23 followed by a short break of 10 - 14 days.
45666132|NCT02059239|Drug|Carmustine|300 mg/m2 on Day -6
45821336|NCT04516772|Device|Visian TICL|The Visian TICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
45962801|NCT04548583|Drug|Remestemcel-L|adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis
45962802|NCT04548583|Other|Placebo|Normal saline
45962803|NCT00167297|Drug|Atomoxetine|
45962804|NCT04687579|Other|Screening|Screening: All health professionals at the hospitals will participate in the screening of umbilical hernia. The screening will be done in the outpatient clinic, the Emergency Department and at the hospital wards.
45666133|NCT02059239|Drug|Etoposide|100 mg/m2 on days -5 to -2
45666134|NCT02059239|Drug|Melphalan|140mg/m2 on Day -1
45666135|NCT02059239|Drug|Cytarabine|200 mg/m2 on days -5 to -2
45666136|NCT02059239|Drug|Alemtuzumab|20 mg/m2 days -6 to -2 for UNRELATED donors, and 20 mg/m2 days -4 to -2 for RELATED donors
45821337|NCT00673309|Procedure|Stable Isotope Infusion study|Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
45821338|NCT00673309|Drug|Insulin High Dose|Insulin IV administered continuously throughout hospitalization until wounds are 95% healed.
45666137|NCT02059239|Biological|Autologous Stem Cell Transplantation|
45666138|NCT02059239|Biological|Allogeneic Stem Cell Transplantation|
45666139|NCT02059239|Drug|Rituximab|Only to be administered in subjects with B-cell malignancies. Dose is 375 mg/m2 on Days 1 and 8 post-transplant
45666140|NCT04722783|Behavioral|Parent-Child-Interaction Therapy adapted for children with autism spectrum disorder (PCIT-A)|PCIT is a behavioral family therapy approach emphasizing the integration of traditional child play therapy techniques within a behavioral framework of parent-child therapy and was developed by Eyberg (1988). It is based on attachment theory, social learning theory, and parenting styles theory. Recently, the intervention was adapted to children with ASD by our team (McNeil, Quetsch, & Anderson, 2019). PCIT-A will last about 8 months, 1 day per week, 60min per day (see Study Protocol, Fig. 2).
45821339|NCT00673309|Drug|oxandrolone|Oxandrolone given daily throughout hospitalization until 95% wound healing.
45821340|NCT00673309|Drug|Propranolol|Propranolol to be given daily throughout hospitalization until 95% wound healing.
45962805|NCT04687579|Procedure|Preoperative optimization|Ascites will be drained using percutaneous drainage or PleurX. Diuretics be used to control ascites preoperative. Haemoglobin < 5 mmol/L indicates the need for red blood cell concentrates using two dosage SAG-M (350-400 mL of red blood cell concentrates in each dose) will be done. Thrombocytopenia < 150 10^9/L will be treated with a TPO-analog using avatrombopag 40-60 mg dispensed as an intravenous fluid. Culture verified infection will be treated with specific antibiotics depending on the blood culture. International Normalized Ratio > 1.7 will be treated with either phytomenadion, Octaplex or fresh frozen plasma depending on the INR.
45962806|NCT04687579|Procedure|Umbilical hernia repair|A curved incision placed superiorly or inferiorly around the umbilicus. The umbilicus proper is retained in the skin flap. The blunt dissection is made to the hernia sac. The neck of the herniated sac is then dissected from adjacent tissues by a combination of blunt and sharp dissection. The edges of the fascial defect are measured and the fascial defect is closed with a non-absorbable running suture 2-0. A fitted lightweight polypropylene mesh is placed in an onlay fashion and fixed with 4-8 single non-absorbable sutures in the corners and at the midline, with a mesh overlap of at least 4 cm. The umbilicus is re-inserted with a single knot absorbable suture 3-0. Hemostasis is ensured. Skin closure is performed with Nylon suture 3-0. 20 ml bupivacaine 0.5% is injected to the fascia for early pain control.
45962807|NCT00177567|Drug|lithium carbonate|
45962808|NCT00177567|Drug|Depakote-ER|
45962809|NCT00177567|Drug|risperidone|
45962810|NCT00177567|Drug|olanzapine|
45962811|NCT00177567|Drug|paroxetine|
45962812|NCT00177567|Drug|bupropion|
45962813|NCT00177567|Drug|lamotrigine|
45962814|NCT00177567|Drug|venlafaxine|
45455368|NCT03873038|Drug|MK-2060|"Part 1: Single doses (8 mg, 20 mg, or 40 mg) of MK-2060 will be administered via IV infusion on Day 1.~Part 2: Three doses of 25 mg of MK- 2060 administered via IV infusion on Days 1, 3 and 5; Followed by single doses of 25 mg of MK-2060 administered via IV infusion on Days 8, 15, and 22."
45455369|NCT03873038|Drug|Placebo|Part 1: Single dose of placebo will be administered via IV infusion on Day 1. Part 2: Three doses of placebo administered via IV infusion on Days 1, 3 and 5; Followed by single doses of placebo administered via IV infusion on Days 8, 15, and 22.
45455370|NCT01347242|Genetic|Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene|transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
45821341|NCT00673309|Drug|Growth Hormone|Recombinant Human Growth hormone to be administered daily until 95% wound healing.
45821342|NCT00673309|Drug|Insulin Low Dose|Insulin administered IV until 95% wound healing
45962815|NCT00177567|Drug|tranylcypromine|
45962816|NCT00177567|Drug|mirtazapine|
45962817|NCT04519684|Drug|Mesenchymal stem cells|Allogeneic bone marrow derived mesenchymal stem cells
45962818|NCT04519684|Other|Placebo|Normal Saline
45962819|NCT04506190|Procedure|Revisional bariatric surgery|Subjects who undergo revisional bariatric surgery
45962820|NCT04466059|Diagnostic Test|Automated AI-Guided Diagnosis of Hematological Malignancies|In BELUGA, we want to investigate whether the automated analysis of blood (from peripheral blood and bone marrow aspirates) smears and flow-cytometry-based analyses can provide a benefit for diagnostic quality and, ultimately, patient care.
45666141|NCT04722783|Behavioral|Early Start Denver Model (ESDM) intervention|ESDM intervention provides intensive teaching by trained therapists and parents during natural play and relationship-focused daily routines. It is evidence-based and uses principles of developmental psychology and applied behavior analysis. It was designed for toddlers and preschoolers with autism spectrum disorder by Rogers and Dawson (2010). The first intensive part of ESDM intervention (20h per week) will last 40 weeks of intervention within a period of 12 months. It includes 2 days per week for 6h a day clinic therapy, and 5 days per week for 1h homework tasks, and 2 days per week for 1.5h an early special needs education at home. After the first 12 months, children receive the second lower intensity part of ESDM (7 hours per week). It includes 1 days every two weeks 1h day clinic therapy, and 5 days per week for 1h homework tasks, and 1 days per week for 1.5h an early special needs education at home (see Study Protocol, Fig. 2).
45666142|NCT04722783|Behavioral|1-hour ESDM|The active control group for PCIT-A stays in the ESDM day clinic therapy for the 12 hours per week while the PCIT-A group will receive 11 hours of ESDM day clinic therapy and 1 hour PCIT-A per week (see Study Protocol, Fig. 2).
45666143|NCT04722783|Behavioral|Early special needs education (ESNE)|The wait-list control group will receive early special needs education. It consists of a 90-minute visit at participants' homes once a week by an employee educated in early special needs education. As soon as space in ESDM is available children will receive the ESDM intervention (stepped-wedge design, see Study Protocol, Fig. 2).
45821343|NCT00673309|Drug|IGF-1/IGFBP-3|Insulin Like Growth Factor-1/Insulin like Growth Factor Binding Protein 3 administered until 95% wound healing
45821344|NCT00673309|Drug|Itraconazole|Itraconazole administered until 95% wound healing
45821345|NCT00673309|Drug|Growth Hormone and Propranolol|Growth Hormone and Propranolol given until 95% wound healing
45962821|NCT04441840|Dietary Supplement|Active Probiotic Culture|Both conditions matched in appearance and serving size
45455371|NCT03781375|Drug|Etanercept|Administered by subcutaneous injection twice a week
45455372|NCT03781375|Drug|Placebo to Etanerceot|Administered by subcutaneous injection twice a week
45455373|NCT03781375|Drug|Methotrexate|Administered orally or subcutaneously once a week at the same dose as prior to study entry
45455374|NCT01123915|Biological|Opal-HIV-Gag(c) Low Dose|
45455375|NCT01123915|Biological|Opal-HIV-Gag(c) Medium dose|
45455376|NCT01123915|Biological|Opal-HIV-Gag(c) High dose|
45455377|NCT01123915|Other|Dimethyl Sulfoxide|
45458531|NCT01317758|Biological|Sanofi H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, administered at 3.75, 7.5, or 15mcg, with either AS03 adjuvant or PBS.
45821346|NCT00673309|Drug|Oxandrolone and Propranolol|Oxandrolone and Propranolol
45821347|NCT00673309|Drug|Placebo or Control|Administration of Placebo or Control until 95% wound healing
45821348|NCT04508036|Diagnostic Test|Withdrawal of blood samples for D-Dimer|Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for D-dimer levels.
45821349|NCT04508036|Diagnostic Test|Withdrawal of blood samples for Fibrinogen|Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for Fibrinogen levels.
45821350|NCT04508036|Diagnostic Test|Echocardiographic Examination|At postnatal 3rd, 7th and 14th days, Ductus Arteriosus will be echocardiographically examined to obtain calculations and confirm status of ductal patency or closure.
45821351|NCT04495556|Diagnostic Test|MRI|The study will include MRI at baseline (first study visit) and month 24 (final study visit). MRI at month 24 (end of study) will be used to determine McDonald Criteria and final review of CVS.
45821352|NCT04828057|Drug|Tafluprost, timolol maleate|Patients prescribe PG mono who occurs OSD or I IOP lower insufficient. patients switch to combination therapy.
45821353|NCT04795765|Procedure|SpineJack system|For use in the reduction of painful osteoporotic vertebral compression fractures.
45821354|NCT04795765|Procedure|Balloon kyphoplasty|Treatment of osteoporotic vertebral compression fractures.
45962822|NCT04441840|Dietary Supplement|Inactive Probiotic Culture|Both conditions matched in appearance and serving size
45962823|NCT00195156|Drug|ATRA-IV|
45962824|NCT00195156|Drug|Depakote|
45962825|NCT04381078|Other|ACE - AudioVisual Guide|Audiovisual guide to Alveolar Bone Graft Procedure, Pre-surgical orthodontics and post-operative care
45962826|NCT04369417|Behavioral|Relaxation Response Resiliency Program for Siblings of Children with ASD|Virtually delivered psycho-educational resiliency training program for teenage siblings of children with ASD.
45962827|NCT00167375|Drug|eszopiclone 3 mg qHS|
45962828|NCT00167375|Behavioral|General cognitive/behavioral interventions for insomnia|
45962829|NCT00195000|Drug|Mylotarg|6 mg/m2 on day 1
45962830|NCT00195000|Drug|Cytarabine|100 mg/m2 given as continuous infusion daily for 7 days.
45962831|NCT00195195|Drug|Sirolimus|Transplantation patients treated with sirolimus who consent to participate in the study (register)
45962832|NCT00583804|Device|IST-12|Implanted stimulator and sensor device, with twelve implanted stimulating electrodes and two myoelectric signal recording electrodes.
45666144|NCT02059161|Drug|MK-1293|MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
45666145|NCT02059161|Drug|Lantus™|Lantus™ dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
45962833|NCT04299880|Drug|Napabucasin|Oral
45962834|NCT04299880|Drug|Nab-paclitaxel|Intravenous
45962835|NCT04299880|Drug|Gemcitabine|Intravenous
45962836|NCT04299880|Drug|Nivolumab|Intravenous
45962837|NCT04299880|Drug|Paclitaxel|Intravenous
45962838|NCT04299880|Drug|Irinotecan|Intravenous
45962839|NCT04299880|Drug|Leucovorin|Intravenous
45962840|NCT04299880|Drug|5Fluorouracil|Intravenous
45666146|NCT02059161|Drug|Prandial Insulin|Participants will continue their prandial insulin during the study.
45666147|NCT04417647|Device|VZ powder (purified clinoptilolite)|VZ powder will be applied topically to the open surface of the verum treatment-assigned wound to cover the entire wound area. Following each VZ application, wounds will be protected by wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing).
45666148|NCT04417647|Procedure|Standard of care (SoC)|wound cleansing (0.9% saline solution) and wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing) will be applied to the SoC-assigned wound.
45666149|NCT01897714|Drug|Melflufen|
45666150|NCT01897714|Drug|Dexamethasone|
45666151|NCT05131737|Procedure|High altitude exposure|Exposure to 2500m of altitude
45666152|NCT05131737|Procedure|Low altitude exposure|Exposure to 490 m
45666153|NCT01861522|Drug|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
45962841|NCT04299880|Drug|Bevacizumab|Intravenous
45962842|NCT04282330|Diagnostic Test|3D CEST imaging|Chemical Exchange Saturation Transfer (CEST) is an emerging MRI technique that can acquire multiple endogenous contrasts to probe cerebral metabolism.
45962843|NCT00167453|Procedure|Exercise, Education|
45962844|NCT00195234|Biological|HIV CTL MEP 1000 micrograms, 19 months per subject|
45962845|NCT04248010|Device|neuroConn DC-Stimulator MR|standard tDCS, active & sham
45962846|NCT04248010|Device|Soterix MxN HD-tES|HD-tDCS, active & sham
45962847|NCT04188067|Device|ACTIVE rTMS|All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
45962848|NCT04188067|Device|SHAM rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
45666154|NCT01861522|Drug|Placebo|Two Placebo tablets will be taken orally twice a day
45666155|NCT01860976|Drug|Abatacept|
45962849|NCT04122898|Other|Pelvic Floor Muscle Training|The intervention will consist of a home-based PFM training program with weekly follow-up by phone by a physiotherapist. Before commencing PFM training, the gymnasts in the intervention group will have an individual session with a physiotherapist including thorough teaching on how to perform a correct PFM contraction (inward lift of the pelvic floor assessed with suprapubic 2D ultrasound) and instructions on how to perform the training program. The athletes will be offered at least one individual follow-up session with the same physiotherapist during the intervention period. The program will consist of 3 sets of 8-12 maximum contractions per day. An electronic app (Athlete monitoring) will be used to assess adherence to the program. The athletes will be asked to register their training sessions in a personal account. A reminder to adhere to the program will be sent by phone. The training period will be 3 months and the exercises will take approximately 10 minutes per day to perform.
45962850|NCT00177606|Behavioral|withdrawal of life sustaining treatments|
45962851|NCT00167492|Drug|Myfortic|720 mg by mouth every 12 hours
45962852|NCT04087096|Drug|Denosumab|Denosumab will be administered at postoperative months 1, 7, and 13
45962853|NCT04087096|Drug|Placebo|Placebo will be administered at postoperative months 1, 7, and 13
45962854|NCT04087096|Drug|Zoledronic Acid|Zoledronic Acid 5mg will be administered intravenously at postoperative month 19
45962855|NCT04687657|Drug|umbilical cord blood|During the consolidation chemotherapy stage, the umbilical cord blood transfusion is given twice (interval of 1 month) to support treatment. On the first day after umbilical cord blood transfusion, the proportion of NK cells in peripheral blood is detected. If it is less than 20%, the NK cells sre activated by subcutaneous injection of recombinant human interleukin-2 (rhIL-2) on the second day after infusion.
45458532|NCT02318758|Drug|UT-15C|sustained release oral treprostinil
45666156|NCT01860976|Drug|Placebo|
45666157|NCT01860040|Drug|Cisplatin|Alkylating antineoplastic agent (Chemotherapy)
45666158|NCT01860040|Drug|Pemetrexed|Antimetabolite antineoplastic agent (Chemotherapy)
45666159|NCT01860040|Drug|Gemcitabine|Antimetabolite antineoplastic agent (Chemotherapy)
45962856|NCT04064593|Diagnostic Test|Polygraphy|"The polygraphy consists of recording during sleep, respiratory flow by mean of a nasal cannula, respiratory movement by mean of a thoracic belt with inductance plethysmography, blood oxygenation and heartbeats by a fingertip transcutaneous oxymetry.~Starting and ending of the recording will be programmed based on patient interview regarding usual sleep hours.~Polygraphy data are anonymized before being sent to the Cloud and therefore to the core lab.~Polygraphic data will be scored in centralized manner.~Results of the polygraphy will be sent to the cardiology department with advice for treatment and follow-up.~If necessary, the core-lab will provide tele-counseling regarding SDB management."
45962857|NCT00177645|Procedure|sodium bicarbonate|inhalation of sodium bicarbonate or sodium chloride
45962858|NCT00167531|Behavioral|treadmill walking with partial weight support|
45666160|NCT04618744|Drug|ORMD-0801 (Insulin) capsule 8 mg BD|8 mg ORMD-0801, 1 capsule, twice a day, once in the morning and once in the evening.
45666161|NCT04618744|Other|Placebo|Matching Placebo
45821355|NCT04795765|Procedure|Vertebroplasty|Treatment of osteoporotic vertebral compression fractures.
45821356|NCT04857866|Drug|XmAb27564|Single ascending dose of XmAb27564
45962859|NCT00167531|Behavioral|assisted overground walking|30 minutes per day of overground walking with the assistance of one therapist
45962860|NCT04030234|Drug|Intensive BP treatment group|"Participants in the Intensive BP treatment group have a goal of SBP <120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate.~One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors; Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics"
45962861|NCT04030234|Drug|Standard BP treatment group|Participants in the Standard BP treatment group have a goal of SBP <140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
45962862|NCT00532012|Drug|RhuDex®|
45962863|NCT00177684|Drug|Amphotericin B|
45821357|NCT04857866|Drug|Placebo|Single dose of placebo
45455378|NCT01123993|Device|Music CD|During 4-week interventional period of each group, a researcher gives a CD to care giver and advises him/her to open the music for patient for at least 60 minutes daily, after dinner to bedtime. Meanwhile, the care giver notes the exact duration that patient actually listens to it in the calendar provided and returns the CD and document to the researcher at the end of interventional period.
45455379|NCT03938779|Behavioral|Pelvic Floor Muscle Training (PFMT)|PFMT is a protocol of exercises for prevention and treatment for Stress Urinary Incontinence in elite females athletes, volleyball team
45455380|NCT03938779|Diagnostic Test|Pad test|Pad test is a standardised test for quantifying urine loss. Pad test is not invasive and provide an easy, inexpensive and objective assessment of urine loss.
45455381|NCT03938623|Other|Training|Teaching general practitioners to use the patient-centered approach when suggesting colorectal cancer screening
45666162|NCT01896934|Drug|Sertraline|50-200mg daily
45821358|NCT00000127|Procedure|Optic Nerve Sheath Decompression Surgery|
45821359|NCT04495400|Procedure|Thoracolumbar Fracture Fixation|The is surgery is preformed on patients who have had a blunt trauma fractures between the T10 and the L2. The surgical management for more severe/unstable fractures usually involves posterior instrumentation with percutaneous or open pedicle screw fixation. While the traditional open pedicle screw fixation technique has demonstrated good radiologic and clinical outcomes, a minimally invasive percutaneous approach has been increasingly used in recent years.
45821360|NCT02973451|Drug|Laparoscopic Guided Bupivacaine|Bupivacaine Laparoscopic GuidedTransversus Abdominis Plane Block
45455382|NCT03779503|Device|midafilcon A|midafilcon A 1 day daily disposable contact lens
45455383|NCT03779503|Device|somofilcon A|somofilcon A 1 day daily disposable contact lens
45666163|NCT02039505|Drug|Vedolizumab|Vedolizumab intravenous infusion
45666164|NCT02039505|Drug|Vedolizumab placebo|Vedolizumab placebo
45666165|NCT02095197|Drug|Triamcinolone 80mg|C7-T1 Cervical interlaminar epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.
45666166|NCT02039427|Drug|Ketorolac|ketorolac 30 mg mixed with normal saline 1 ml : total volume of 2 ml
45666167|NCT02039427|Other|Dexamethasone|dexamethasone acetate10 mg : total volume of 2 ml
45821361|NCT02973451|Drug|local Bupivacaine|Bupivacaine Trocar Site Infiltration
45821362|NCT00000193|Drug|Gamma hydroxybutyric|
45458533|NCT02318758|Other|ethanol|Absolut 100 vodka
45458534|NCT05187806|Behavioral|motivational interview|After the pretest, the experimental group was intervened with a motivational interview (MI) method that consisted of four sessions.The pretest and posttest Diabetes Self-Management Scale total scores and HbA1c values of the patients in the experimental and control groups were compared.
45458535|NCT02441686|Drug|Bortezomib|
45666168|NCT02039427|Drug|Placebo|Normal saline 2 ml
45666169|NCT02094885|Biological|Bioseal Fibrin Sealant|
45666170|NCT02094885|Other|Manual Compression|
45666171|NCT01896856|Drug|SGI-110 Dose Escalation|"Dose level 1 (DL1): 45 mg/m^2 administered as a subcutaneous injection~Dose level 1G (DL1G): 45 mg/m^2 administered as a subcutaneous injection + growth factor support~Dose level -1 (DL-1): 30 mg/m^2 administered as a subcutaneous injection~Dose level -1G (DL-1G): 30 mg/m^2 administered as a subcutaneous injection + growth factor support"
45666172|NCT01896856|Drug|Regorafenib|160 mg taken orally
45821363|NCT00000199|Drug|Piracetam|
45821364|NCT00668785|Drug|ranibizumab|Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
45821365|NCT04844840|Drug|STP705|STP705 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA, respectively
45821366|NCT04844840|Other|Placebo|Saline
45821367|NCT00655057|Drug|S-citalopram|Participants will take 10 to 30 mg of s-citalopram daily for 12 weeks.
45821368|NCT00655057|Behavioral|Cognitive behavioral therapy (CBT)|Participants will attend twice weekly CBT sessions for 2 weeks and then once weekly sessions for 10 weeks. Sessions will focus on modifying thoughts and behaviors that may contribute to depression.
45962864|NCT00167570|Device|Prosthetic socket fabricated using selective laser sintering|
45962865|NCT03983590|Other|Visual Analogic Scale|VAS are collected in the first 24 hours after inclusion, 15 minutes, during and 15 minutes after the bed bath. Each time of collection are noted.
45455384|NCT01124071|Behavioral|Provision of 2 Korean meals per day 6 days per week|At each participant's baseline visit, participant's will have an individualised lifestyle session addressing dietary and exercise goals and techniques to achieve weight loss. Participants in the Korean diet group will pick up lunch and evening meals Monday-Friday. Raw ingredients and cooking instructions will also be provided on friday for saturday meal preparation. Ongoing lifestyle sessions will be performed weekly for participants.
45666173|NCT01896856|Drug|TAS-102|35 mg/m^2 taken orally
45666174|NCT01896856|Drug|SGI-110|45 mg/m^2 administered as a subcutaneous injection
45666175|NCT01896856|Drug|Irinotecan|125 mg/m^2 administered IV
45666176|NCT02038959|Other|Virtual Visits|Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).
45666177|NCT04599556|Biological|anti-CD7 CAR-T|Lymphodepleting chemotherapy followed by anti-CD7 CAR-T infusion
45666178|NCT01896700|Drug|Methylphenidate|Escalating dose of methylphenidate, 20mg, 40mg, 60mg/day, for 2 weeks each
45666179|NCT01896700|Drug|Placebo|Escalating matched dose of placebo
45666180|NCT02352493|Drug|ALN-CC5|Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection
45666181|NCT02352493|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
45821369|NCT00655057|Procedure|TRODAT-1 single photon emission computed tomographic (SPECT) imaging|Participants' striatal dopamine transporter (DAT) levels will be measured using [99mTc]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.
45821370|NCT00000211|Drug|Buprenorphine|
45666182|NCT02286193|Behavioral|Patient clinical encounters with Community Resource Specialist (CRS)|CRS will work with patients to create goals, develop action plans and link to community resources to support goals
45666183|NCT01896232|Drug|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg, titrated up to 15 mg based on serum PTH and corrected calcium levels.
45666184|NCT01896232|Drug|Cinacalcet|Cinacalcet was administered orally once a day. The starting dose was 30 mg daily, titrated up to 180 mg daily based on serum PTH and corrected calcium levels.
45666185|NCT01896232|Drug|Oral Placebo|Administered orally once a day.
45666186|NCT01896232|Drug|Intravenous Placebo|Administered intravenously (IV) three times per week.
45666187|NCT02460224|Drug|LAG525|LAG525 was administered via intravenous (i.v.) infusion
45458536|NCT02441686|Drug|Lenalidomide|
45666188|NCT02460224|Drug|PDR001|PDR001 was administered via i.v. infusion
45666189|NCT02094573|Drug|Brigatinib|Brigatinib tablets
45666190|NCT01859494|Device|NINJA 3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.
45666191|NCT04181307|Behavioral|BE-EHR module|The BE-EHR module includes six components: 1) a tailored advisory for patients over 75 with diabetes, 2) medication refill protocol with information on Choosing Wisely guidelines, 3) pre-population of the medication preference list with metformin, 4) lab result protocol with information on Choosing Wisely guidelines, 5) peer comparisons regarding performance meeting guidelines, and 6) media campaign with information about Choosing Wisely guidelines. The set of nudges is referred to collectively as the BE-EHR module.
45666192|NCT01858636|Device|Angio-Seal VIP 6 French (6F) and 8 French (8F) devices|These devices are used for the vascular closure procedure
45666193|NCT02058849|Drug|Beetroot|10g Beetroot powder mixed with 4-8 oz.
45666194|NCT02058849|Other|Placebo|Placebo
45458537|NCT02441686|Drug|Dexamethasone|
45458538|NCT03500146|Drug|Anticholinergic|Patients prescribed medication for OAB
45666195|NCT01858558|Biological|aMIL|On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.
45666196|NCT01858558|Drug|No aMIL|On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.
45666197|NCT02058537|Drug|Bethanechol|Due to the fact that this study has only 1 arm and all study subjects will receive the study drug in the same manner and dose, there are no other details to cover.
45666198|NCT01612000|Biological|PanBlok|Intramuscular injection
45821371|NCT04765657|Drug|inclisiran sodium|Subcutaneously injected on Day 1, 90 and 270 (Core Part). Subcutaneously injected on Day 360 and every 6 months thereafter until EOS visit (Extension Part)
45821372|NCT04765657|Drug|Placebo|Subcutaneously injected on Day 1, 90, and 270.
45821373|NCT04358432|Drug|AK102|Administered by subcutaneous injection
45821374|NCT04358432|Drug|Placebos|Administered by subcutaneous injection
45821375|NCT04358432|Drug|Statins and/or Ezetimibe|Lipid-lowering therapies
45962866|NCT03962023|Other|Echocardiography and MRI|Analysis of echocardiography and MRI parameters
45962867|NCT00532090|Drug|RG4733|Administered orally daily at ascending doses to successive cohorts of patients
45962868|NCT00532090|Drug|RG4733|Administered orally at ascending doses to successive cohorts of patients, on a 3 days on/ 4 days off schedule
45962869|NCT00532090|Drug|RG4733|Administered orally at ascending doses to successive cohorts of patients, on days 1-7 of each 21 day cycle
45962870|NCT00195312|Biological|HIV-1 gag DNA (formulated with bupivacaine)|
45962871|NCT00195312|Biological|IL-15 DNA (formulated with bupivacaine)|
45962872|NCT00195312|Biological|IL-12 DNA (formulated with bupivacaine)|
45962873|NCT00195312|Biological|Sodium chloride injection USP (0.9%)|
45962874|NCT00167609|Drug|dehydroepiandrosterone 100 and 400 mg|
45962875|NCT03920176|Diagnostic Test|Computed tomography coronary angiography|CTCA >64 detector row scanner
45666199|NCT01612000|Biological|rHA adjuvant|Intramuscular injection
45962876|NCT03920176|Other|ASSIGN Score|ASSIGN Cardiovascular Risk Score
45962877|NCT03888079|Drug|Local anesthetic|1% or 2% lidocaine with 1:100,000 epinephrine, augmented by intravenous sedation and analgesia
45962878|NCT03888079|Drug|general anesthetic|Endotracheal intubation, intravenous narcotic agents, and inhaled agents
45962879|NCT00167648|Drug|Leuprolide or goserelin|Leuprolide 7.5 mg (4-week depot) or goserelin 3.6 mg (4-week depot)
45962880|NCT00167648|Drug|Transdermal estradiol|Estradiol patches, six at 0.1 mg each, changed every 3-4 days
45962881|NCT03852706|Other|LORETA|Twenty sessions of neurofeedback training using LORETA in combination with z-scores.
45962882|NCT03852706|Other|Treatment as usual|Treatment-as-usual
45962883|NCT02907034|Procedure|Virtual reality experimentation sequency (VR)|
45821376|NCT00635167|Drug|Contrast Enhanced-Transrectal Ultrasound|Drug Once a subject is identified TRUS schedule will be set up revolving around the EBRT treatment schedule. A schedule of 6 contrast enhanced TRUS examinations per subject is planned as follows: week 0 (prior to EBRT, baseline [Visit 2]); week 5 (middle of treatment [Visit 3]); week 10 (end of treatment [Visit 4]); week 18 (2 months after end of EBRT [Visit 5]); week 26 (4 months after end of EBRT [Visit 6]); and week 36 (6 months after end of EBRT [Visit 7]).
45821377|NCT04353830|Drug|IBI939|Several dose levels will be evaluated for IBI939 administered as a single agent and in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI939 may receive combination treatment with Sintilimab or IBI939+ Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.
45821378|NCT04353830|Drug|IBI939+ Sintilimab|"IBI939: Several dose levels will be evaluated for IBI939 in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit."
45962884|NCT02907034|Procedure|Classical narrative approach (CN)|
45962885|NCT00177762|Behavioral|behavior weight loss|
45962886|NCT02906722|Drug|Intravenous colimycin|administration once, twice or 3 times per day according to renal function
45962887|NCT02906722|Drug|Intravenous placebo|administration once, twice or 3 times per day according to renal function
45962888|NCT02906722|Drug|Nebulized colimycin|Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
45962889|NCT02906722|Drug|Nebulized placebo|Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
45962890|NCT00167687|Drug|prazosin|"Pharmacological treatment: In order to prevent the possible side effect of first-dose hypotension, all participants will receive only 1mg of study medication or placebo nightly for the first two days of study participation. Titration will proceed according to the following schedule:~Prazosin Dosing: 9 AM 3 PM 9 PM Days 1-2 1 mg (one capsule) Days 3-4 1 mg 1 mg 1 mg Days 5-7 2 mg 2 mg 2 mg Day 8-10 2 mg 2 mg 6 mg Day 11-14 4 mg 4 mg 6 mg Day 15-42 4 mg 4 mg 8 mg"
45666200|NCT01895608|Behavioral|Balance rehabilitation + dual-tasking|Balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands with the addition of cognitive tasks, (e.g., counting backwards or reciting lists) to be added when the participant
45666201|NCT01895608|Behavioral|Standard balance rehabilitation|Standard balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands.
45666202|NCT01895608|Behavioral|Cognitive training (speed of processing)|Speed of processing cognitive training involves systematically increasing the complexity of visual tasks. Task demands are increased by reducing stimulus duration, adding visual or auditory distractors, increasing number of concurrent tasks or increasing the visual field.
45962891|NCT02906878|Procedure|Platelets transfusion|Prophylactic platelet transfusion in thrombocytopenic patients for the placement of a central venous catheter
45962892|NCT02906956|Behavioral|Preferred music playlist|Client will be instructed in a home program based on repetitive task practice principles and will complete this program with and without the use of a preferred music playlist during practice.
45962893|NCT02906995|Drug|Sublingual tablet 4 mg versus Nicorette Lozenge 4mg|"One dose of study drug (sublingual tablet or Nicorette Lozenge) will be administered to each subject in the morning on Day 1.~The second administration of drug will occur at least 48 hours after the initial administration. Subjects will receive the other dosage form and be instructed according to whether they are receiving the sublingual tablet or the lozenge."
45962894|NCT00195390|Biological|Prevenar|Prevenar 0.5ml/ Vial and PFS
45962895|NCT02906800|Drug|Digoxin|The digoxin dose will be adjusted to achieve a plasma concentration of 0.6-1.2 ng/ml according to current recommendations in heart failure patients (doses adapted to renal function, comorbidities, concomitant medications, age, and plasma concentration). The risk related to digoxin treatment will be minimized in our study since the duration of exposure to digoxin will be limited to 9 days every 3 weeks for 3 cycles (total duration of treatment 27 days).
45962896|NCT02906683|Drug|TAS-303|Oral administration for 8 weeks, once daily.
45962897|NCT02906683|Drug|Placebo|Oral administration for 8 weeks, once daily.
45962898|NCT02906605|Drug|JNJ-809|JNJ-809 (1*10^9) colony forming units (CFU) given as an infusion.
45962899|NCT02906605|Drug|Apalutamide|Apalutamide 240 mg orally daily.
45962900|NCT00195468|Drug|CYCLOSPORINE|
45962901|NCT02906527|Drug|Non-exposed group|Non-exposed group / Patients receiving VKA
45962902|NCT02906527|Drug|Exposed group|Exposed group / Patients receiving DOAC
45962903|NCT00167765|Drug|Abciximab|
45962904|NCT02906410|Other|Item-Level Calorie information|Information identifying the calorie content of individual items will be provided, as would be done on a restaurant menu board.
45962905|NCT02906410|Other|Meal-Level Calorie information|"Information from the calorie content of individual items that have been selected by the participant will be dynamically aggregated and presented as a Total Calories label on the menu screen."
45962906|NCT02906449|Behavioral|Meditation Technique|Alertness training or relaxation training
45962907|NCT02906371|Drug|Tocilizumab|Patients with ≥ 40% blasts in the bone marrow at pre-infusion will be enrolled in the early tocilizumab cohort and will follow early CRS treatment algorithm.
45962908|NCT02906371|Drug|Tocilizumab|Patients with ˂ 40% blasts in the bone marrow at pre-infusion (~ Day -5 to -1) will follow the standard CRS Rx algorithm
45962909|NCT02906371|Biological|CART 19|CART-19 cells transduced with a lentiviral vector to express either anti-CD19ζ scFv TCRζ:41BB, administered by i.v. injection using an intra-patient dose escalation approach: 10% on day 0, 30% on day 1 with a total dose goal of ~1.5 x107 - 5 x109 (~3x105 - 1x108/kg) T cells.
45962910|NCT00167804|Behavioral|Virtual Reality Exposure|VRE uses computer generated environments to conduct exposure therapy.
45962911|NCT02906293|Other|Abdominal acoustic measurement|"On Day 1 participants will record their intestinal rate at baseline fasting, pre-small meal, and upon completion of the meal. On Day 2 participants will record their intestinal rate at baseline fasting, pre-large meal, and upon completion of meal."
45962912|NCT02906254|Other|ECIL-4 guidelines group|Antibiotics were stopped when patients had been afebrile for more than 48 hours
45962913|NCT02906254|Other|Short-course antibiotic therapy|Antibiotics were stopped on day 5 in febrile or afebrile patients
45455385|NCT01124071|Behavioral|Western Diet|At each participant's baseline visit, participant's will have an individualised lifestyle session addressing dietary and exercise goals and techniques to achieve weight loss. Participants in the Western diet group will be provided with a Western recipe cookbook and food vouchers (weekly) to purchase the necessary ingredients for the Western meal preparation. Ongoing lifestyle sessions will be performed weekly for participants.
45455386|NCT01117363|Other|dietary intervention (rye porridge or wheat bread)|A breakfast consisting of either active (rye porridge) or control (wheat bread) is given during 2 3-wk intervention periods in a randomized cross-over design. The two dietary intervention periods are separated by a 3-4 wks wash out.
45455387|NCT01218529|Drug|Lapatinib|Co-administration of lapatinib 1250mg once daily during the WBRT period (2 weeks)and then monotherapy with lapatinib 1500mg once daily for 4 weeks.
45455388|NCT03938467|Drug|Antiseptic Cleanser|Contains 0.05% Chlorhexidine gluconate in sterile water for irrigation. The mechanical action of the Irrisept system removes bacteria and debris without harming underlying tissues. Irrisept has demonstrated broad spectrum bactericidal activity against antibiotic-resistant strains. Its contents are wrapped in two sequential sterilization wraps which repel water blood, and saline, making it effective against both air and water borne bacteria.
45666203|NCT01895608|Behavioral|Cognitive training (general cognition)|General cognitive training involves systematic training of 14 key cognitive abilities, including visual scanning, response time, eye-hand coordination, spatial perception, and working memory. Initial starting point is determined by the software using baseline evaluation.
45666204|NCT02409680|Drug|Low dose aspirin|Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA compared to an identical appearing placebo. Compliance and outcomes will be assessed biweekly.
45666205|NCT02409680|Drug|Placebo|Placebo
45821379|NCT04353830|Drug|IBI939+ Sintilimab|"IBI939: IBI939 in combination with Sintilimab will be given with RP2D. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit."
45962914|NCT02906098|Behavioral|Patient centered oral health education|Procedure: The theory-based educational intervention follows a specific structure. The initial phase contain 3 treatment sessions (45-60 min each) during a period of 12 weeks (baseline, 2-3 weeks and 10-12 weeks). Follow up are performed at 6- and 18-months.
45962915|NCT02906098|Behavioral|Standard educational intervention|Procedure: The initial phase contain educational intervention in accordance with conventional routines (oral health information and oral hygiene instruction at one or several occasions). Follow up are performed at 6- and 18-months.
45455389|NCT03933943|Drug|LY3361237|Administered SC
45666206|NCT04618354|Other|No interventions|This clinical study is a retrospective study, and no interventions have been implemented for patients.
45455390|NCT03933943|Drug|Placebo|Administered SC
45455391|NCT01218607|Drug|Bosentan|Treatment will be initiated at a dose of 62.5 mg twice daily for 4 weeks and then increased to the maintenance dose of 125 mg twice daily for 12 weeks.
45455392|NCT01218607|Drug|Placebo|Placebo will be taken twice daily for 16 weeks
45455393|NCT01219231|Behavioral|Exercise|6 months of aerobic exercise
45962916|NCT00195546|Drug|DVS-233|
45962917|NCT00167843|Drug|sulfadoxine-pyrimethamine|
45962918|NCT02906059|Drug|AZD1775|
45962919|NCT02906059|Drug|Irinotecan|
45962920|NCT02906176|Drug|Vfend (voriconazole) intravenous infusion|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h
45962921|NCT02906176|Drug|Vfend (voriconazole) tablet|Vfend (voriconazole) 200 mg tablet once
45962922|NCT02905942|Drug|PEG-rhG-CSF|PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 100μg/kg(bw).For patients more than 45kg, 6mg was suggested.
45666207|NCT01895452|Drug|ALKS 9072, Low Dose|Intramuscular injection, given monthly
45666208|NCT01895452|Drug|ALKS 9072, High Dose|Intramuscular injection, given monthly
45666209|NCT02094417|Drug|AMG531|Subcutaneous, weekly injection
45821380|NCT04458272|Drug|DS-1001b|250 mg, twice daily, continuous oral administration
45821381|NCT00000217|Drug|Carbamazepine|
45821382|NCT00000223|Drug|Buprenorphine|
45821383|NCT00630487|Drug|Placebo|Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase. To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels. Central lab will randomize placebo patients to dose change or maintenance of dose. This will ensure continued blinding of the study to patients and personnel.
45962923|NCT02905942|Drug|rhG-CSF|rhG-CSF was given day +1 after transplantation with a dose of 5μg/kg once per day
45962924|NCT02905864|Drug|Liraglutide 3 mg (Saxenda)|
45962925|NCT02905864|Drug|Liraglutide 3 mg placebo|
45962926|NCT00177840|Procedure|acupuncture|
45666210|NCT01894984|Drug|Risperidone|This is an observational study. Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor [SSRI]) will be maintained and will cease at Week 3.
45666211|NCT01894984|Drug|Oral atypical anti-psychotic|This is an observational study. Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
45666212|NCT04694313|Device|OPM|Simultaneous MEG SQUID + SEEG acquisition followed by a simultaneous MEG OPM + SEEG acquisition.
45821384|NCT00630487|Drug|Somatropin|Fixed doses for patients: MALE: < 45y 0,4 mg, > 45y 0,2mg FEMALE: < 45y 0,5mg, >45y 0,3mg. for the first 4 weeks half of the dose will be given. After that dose will be increased to the targeted maintenance dose according to IGF-I Levels +/- 2 SD of age adjusted reference range. In case of side effects dosage will remain on half-dose (during the first 4 weeks) or reduced to half dose (after the first 4 weeks). At week 52 patients have the opportunity to switch to open label study restarting with half the given fixed dose which will be adjusted to full dose after 4 weeks.
45821385|NCT00000229|Drug|Buprenorphine|
45821386|NCT00000235|Drug|Buprenorphine|
46079837|NCT03856593|Behavioral|Standard letter|The standard letter will be signed by the Chief Medical Examiner-Coroner and County Health Officer of Los Angeles County to notify prescribers of the death in their practice. The letter includes the decedent's name, date of birth and date of death, and outlines the annual number and types of prescription drug deaths seen by the medical examiner, discusses the value of and way to access the State's prescription drug monitoring program and includes five Centers for Disease Control and Prevention (CDC) guideline-recommended safe prescribing strategies: 1) Avoid co-prescribing of opioids with benzodiazepines, 2) prescribe minimal dose necessary for acute pain, 3) consider slow tapers with pauses to below 50 morphine milligram equivalents (MME) per day, 4) avoid prescriptions lasting greater than 3-months for pain, and 5) prescribe naloxone in conjunction with opioids for patients taking > 50 MME per day. The letter also states that CURES review is required by law as of October 2, 2018.
45962927|NCT00167882|Drug|5-aminosalicylate (Pentasa, Ferring)|
45962928|NCT02905708|Device|Air-Activated heating packs|The subject disrobe and will dress in a jacket, pants, gloves and socks (ensemble) which will be removed from a vacuum pack. He will be assisted by the nurse in pre-operative area. The ensemble will remain in place until the subject is fully recovered from anesthesia.
45455394|NCT01219309|Dietary Supplement|Omega 3/6 fatty acids|3 capsules bid orally
45455395|NCT01219309|Dietary Supplement|Placebo (olive oil)|3 capsules bid orally
45455396|NCT01218685|Biological|Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS|1 full dose of 15 micrograms, IM, for volunteers 9 years of age or older; children 6 months to 2 years of age, half of the dose,IM, with 21 days interval; children 3 years old up to 8 years old, 1 full dose, IM, twice, with 21 days interval.
45821387|NCT03659240|Other|Cranberry beverage|During the intervention period, research participants will consume a cranberry beverage daily.
45455397|NCT01222039|Other|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|"Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Low dose: 1 x10e6 / Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin."
45962929|NCT02905708|Device|Forced Air Warming Device|forced air-warming inflatable device applied according to standard hospital protocol.
45458539|NCT03500146|Procedure|PTNS|Patients prescribed PTNS for OAB
45666213|NCT02375672|Drug|Pembrolizumab|Pembrolizumab (MK-3475) 200mg IV over 30 minutes every 3 weeks
45666214|NCT02375672|Drug|mFOLFOX6|"mFOLFOX6 Treatment D1 and D15 (Cycle = 28 days)~Oxaliplatin 85 mg/m^2 IV with~Leucovorin 400 mg/m^2 IV followed by~5FU 400 mg/m^2 bolus and then 2400 mg/m^2 via continuous infusion"
45666215|NCT01894516|Drug|GLPG0634|GLPG0634 capsules.
45666216|NCT01894516|Drug|Placebo|Placebo capsules.
45666217|NCT02491463|Biological|GSK3389245A_LD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
45821388|NCT03659240|Other|Placebo beverage|During the intervention period, research participants will consume a placebo beverage daily.
45821389|NCT00379327|Procedure|Acupuncture|Acupuncture administered in last three weeks of pregnancy
45962930|NCT02905747|Behavioral|Medical Exercise Therapy|physiotherapy intervention with Medical exercise therapy (MET) during 3 months
45962931|NCT04681885|Device|Tapered bristles A|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week .
45962932|NCT04681885|Device|Tapered bristles B|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.
45962933|NCT04681885|Device|End rounded bristles|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.
45962934|NCT00177879|Behavioral|website comparison|
45962935|NCT00167921|Drug|Premarin® Vaginal Cream|
45962936|NCT00167921|Drug|Premarin® oral tablets|
45962937|NCT04681924|Other|Diet intervention|Low carb diet group are compared to low fat diet group and followed up for 6 months
45962938|NCT04681690|Other|No intervention, observation only.|Observation only
45962939|NCT02905630|Other|Exercise training|high intensity aerobic interval training
45962940|NCT00167960|Drug|Piperacillin/tazobactam and other β-lactam/β-lactamase|
45962941|NCT02905786|Device|Cobas h232 (Roche Diagnostics)|NT-proBNP point-of-care test
45962942|NCT02905786|Other|Clinical audit and feedback|Clinical audit and feedback to detect previously unrecognized HF patients and inform GPs about their current quality of HF care
45962943|NCT02905786|Other|Assistance by a specialized HF nurse|Assistance by a specialized HF nurse in general practice for education of patients, advice in diagnosis and treatment, transition of care
45962944|NCT02905513|Behavioral|Contraceptive app instant messages|
45666218|NCT02491463|Biological|GSK3389245A_HD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
45962945|NCT02905513|Other|Mobile phone app|
45962946|NCT02905552|Other|No intervention|
45962947|NCT00167999|Drug|piperacillin-tazobactam|
45962948|NCT00177996|Drug|sertraline hydrochloride|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of sertraline. The doses and titration schedules used in this study are consistent with recommended FDA guidelines.
45962949|NCT02905474|Other|Usual Care|Usual standard CKD care involves an outpatient clinic visit every 3 to 4 months (at minimum every 6 months) for a clinical assessment by their renal clinical care team.
45962950|NCT02905474|Device|Integrated mobile medication app|Use of mobile app to maintain, manage medication list on a smartphone device that allows for bidirectional transfer of medication information
45962951|NCT02905474|Device|Commercially available mobile medication app|Use of mobile app to manually record and maintain medication records with no integration to databases.
45962952|NCT02905279|Behavioral|Biofeedback Relaxation Training|Participants will receive one-session biofeedback relaxation training (24 minutes) for anxiety reduction. Prior to biofeedback, participants will receive education about spiders and the development and maintenance of spider phobia.
45962953|NCT02905279|Behavioral|Exposure Therapy|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. Prior to exposure therapy, participants will receive education about spiders and the development and the development and maintenance of spider phobia.
45962954|NCT02905279|Behavioral|Exposure with Threat-Relevant Opposite Actions|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure, participants will engage in actions opposite to the tendencies associated with threat avoidance. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
45821390|NCT00379327|Device|Non-puncturing Acupuncture Needle|Streitsberg non-Acupuncture Needle
45821391|NCT00000241|Drug|Flupenthixol|
45666219|NCT02491463|Biological|Bexsero|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
45962955|NCT02905279|Behavioral|Exposure with Threat-Irrelevant Opposite Actions|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure therapy, participants will engage in actions opposite of the action tendencies associated with the fear, but unrelated to the specific threats associated with spider phobia. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
45962956|NCT00168077|Drug|Prothrombin Complex Concentrate|
45962957|NCT00195585|Drug|Isovorin|
45962958|NCT00195585|Drug|UFT|
45962959|NCT02905396|Device|Spinal cord stimulation|implantation of spinal cord stimulator
45962960|NCT02905123|Behavioral|Check Your Drinking|
45962961|NCT02905045|Drug|Ketoprofen|
45962962|NCT02905045|Drug|placebo|
45962963|NCT04723329|Behavioral|Web-based exercise training based on the transtheoretic model|Motivating interviews will be provided to the patients to receive training on the website by contacting them one-on-one. In the following 1st and 3rd months, patients will be contacted individually again to confirm whether they follow the website, and they will be asked to fill in the scales on the website by providing consultancy on the issues they need. In the 6th month, the final test data will be obtained from the website using the same data collection forms.
45962964|NCT00168116|Procedure|radiation treatment and surgery|
45962965|NCT00168116|Procedure|radiation alone|
45962966|NCT02905162|Other|Transitional HIV care for prison releasees|Transitional HIV care program for releasees
45455398|NCT01222039|Other|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|"Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. High dose: 3 x10e6/Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin."
45455399|NCT01328977|Behavioral|education|teaching
45666220|NCT02491463|Drug|Placebo|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
45666221|NCT02038881|Biological|IMVAMUNE®|0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml
45666222|NCT01857622|Drug|DU-176b 15mg|oral DU-176b 15mg once daily
45666223|NCT01857622|Drug|DU-176b 30mg|oral DU-176b 30mg once daily
45666224|NCT01857622|Drug|DU-176b 60mg|oral DU-176b 60mg once daily
45666225|NCT01857310|Dietary Supplement|5 mg folic acid and 30 mg elemental zinc|
45821392|NCT00000253|Drug|10% N2O|
45821393|NCT00000253|Drug|20% N2O|
45821394|NCT00000253|Drug|30% N2O|
45821395|NCT00000253|Drug|40% N2O|
45821396|NCT00000259|Drug|15 % Nitrous oxide|
45821397|NCT00000259|Drug|0.3 % Sevoflurane|
45821398|NCT00000259|Drug|30% Nitrous oxide|
45821399|NCT00000259|Drug|0.6% Sevoflurane|
45821400|NCT00000259|Other|Placebo|
45821401|NCT04330664|Drug|MRTX849|KRAS G12C Inhibitor
45821402|NCT04330664|Drug|TNO155|SHP2 Inhibitor
45821403|NCT04331665|Drug|Ruxolitinib|Ruxolitinib is an inhibitor of JAK1 and JAK2 (proteins important in cell signalling) approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.
45821404|NCT00379405|Drug|Saquinavir/Ritonavir : 2 capsules (500 mg) / 12 hours|Saquinavir/Ritonavir: 2 capsules (500 mg) / 12 hours
45821405|NCT04321538|Device|Gocheck Kids|GoCheck Kids is a photoscreening device. It takes a special picture of the eyes that allows for detection of refractive error and eye misalignment.
45962967|NCT02904772|Drug|alipogene tiparvovec|A dose of 1x10(*12) gc/kg alipogene tiparvovec (Glybera) of body weight administered as a single set of intramuscular injections at multiple sites in multiple muscles of both upper legs and if necessary, the lower legs.
45962968|NCT02904772|Drug|Prednisolone|IV bolus methylprednisolone 1mg/kg half hour prior to administration
45962969|NCT02904772|Drug|Cyclosporins|Immuno + group will receive cyclosporine (3 mg/kg/day) from three days prior to until 12 weeks following IMP administration
45962970|NCT02904772|Drug|Mycophenolate mofetil|Immuno + group will receive Mycophenolate mofetil (2x 1 g/day) from three days prior to until 12 weeks following IMP administration
45962971|NCT00195741|Drug|divalproex sodium|
45962972|NCT00168155|Drug|perioperative chemotherapy|
45962973|NCT02904889|Behavioral|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
45962974|NCT02904889|Other|Usual care|Homecare professionals will get no training and their clients will receive usual homecare.
45666226|NCT01857310|Drug|Placebo Comparator: Placebo|
45666227|NCT02472353|Drug|Metformin|Metformin will begin to be administered prior to treatment with doxorubicin. Metformin will continue to be given throughout doxorubicin cycles until the completion of doxorubicin therapy.
45666228|NCT02472353|Drug|Doxorubicin|Standard of care treatment with doxorubicin
45666229|NCT02491073|Other|blood draw|Investigate the possibility of assay artifacts impacting the measurement of thyroid hormones, in particular FT4 and FT3, in ESL treated subjects compared to non-ESL-treated subjects.
45666230|NCT02314117|Drug|Ramucirumab|Administered IV
45458300|NCT01350752|Behavioral|RDTs & Provider Training on Malaria Diagnosis and Treatment|In Cameroon and Nigeria, malaria RDTs will be made available in health facilities and health care providers will receive training and job aids on malaria diagnosis and treatment. The training course covers the following topics: clinical and parasitological diagnosis of malaria, how to use a rapid diagnostic test, algorithm based on malaria test result, recommended treatment for confirmed malaria cases (including dosage and regimen for artemisinin-based combination therapies), advice for treatment of test-negative patients
45666231|NCT02314117|Drug|Capecitabine|Administered orally
45666232|NCT02314117|Drug|Cisplatin|Administered IV
45666233|NCT02314117|Drug|Placebo|Administered IV
45666234|NCT02314117|Drug|Fluorouracil|Administered IV
45666235|NCT01893346|Drug|CAZ-AVI|Single IV dose of Ceftazidime and Avibactam. Dosage regimen will vary depending on cohort.
45666236|NCT02490371|Device|Low frequency rTMS|1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse at 90% resting motor threshold for 10 sessions.Patients in the rTMS-ex group will receive the experimental rTMS A Magstim Rapid Stimulator (Magstim Company, Whitland, UK) equipped with an air-cooled figure-of-eight coil (each loop 70 mm in diameter) and neuro-navigation system will be used to deliver the intervention.
45666237|NCT02490371|Behavioral|structured physiotherapy upper limb training|Structural Physiotherapy upper limb training for 30-minutes
45666238|NCT01856686|Drug|BP22042013|This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
45962975|NCT02904850|Biological|group of patients|Plasma dosage of erlotinib and OSI-420 is made from the blood usually taken Further information are collected in the medical record of the patient during the CT scan reassessment after collection.
45962976|NCT02904967|Biological|Extra Blood Draw|
45962977|NCT02904733|Other|mHealth platform|Use of a mHealth platform to inform and empower patient of hies/her own health
45962978|NCT00178035|Drug|paroxetine|
45962979|NCT00178035|Behavioral|One night of Total Sleep Deprivation|
45962980|NCT02904616|Device|mobile spectrofluorimeter|
45962981|NCT02904538|Drug|Dexamethasone|
45962982|NCT02904538|Drug|isotonic saline|
45962983|NCT02904655|Other|healthy diet|Participants were provided meals and snacks for one month that represented a healthy diet that is high in unsaturated fats, approximating a Mediterranean diet
45962984|NCT02963103|Drug|Tacrolimus|Oral
45962985|NCT00407264|Drug|Fluticasone propionate|
45962986|NCT02904499|Drug|Dabigatran|
45962987|NCT02904343|Device|domestic hemodialysis machine|WEGO, DBB-27C
45962988|NCT02904343|Device|imported hemodialysis machine|Fresenius, 4008s
45962989|NCT00195780|Drug|Divalproex Sodium (Depakote ER)|
45962990|NCT00407342|Drug|Alefacept (drug)|alefaceptgiven iv
45962991|NCT00407342|Procedure|Narrowband UVB phototherapy|
45962992|NCT00553423|Drug|Lactulose|Lactulose 30 ml q6h for 48 hrs
45962993|NCT00553423|Drug|Placebo|Placebo 30 ml q6hrly for 48 hrs
45962994|NCT02904148|Procedure|Shoulder mobilisation|early shoulder mobilisation
45962995|NCT02904304|Drug|Desloratadine+Phenylephrine+Ibuprofen|01 tablet, orally, every 12 hours.
45962996|NCT02904304|Drug|Placebo|01 tablet, orally, every 12 hours.
45962997|NCT00407459|Drug|Bevacizumab, Pemetrexed, Carboplatin|"Bevacizumab: 15 mg/kg intravenous infusion over 30 to 90 minutes, following chemotherapy, on Day 1 every 3 weeks~Pemetrexed: 500 mg/m2 intravenous infusion over 10 minutes on Day 1 every 3 weeks~Carboplatin: AUC 5 intravenous infusion over 1 hour on Day 1 every 3 weeks"
45962998|NCT00178074|Behavioral|total sleep deprivation|
46079838|NCT03856593|Behavioral|Comparator letter|"The comparator letter includes all the details in the standard letter plus additional text involving an if/when/then statement along with an injunction to providers to share safety information with patients so that they identify as a safe prescriber. Specifically, the additional text reads as follows: When your next patient presents with pain, keep the above 5 recommendations close at hand to assist with their safe care. Also, be comfortable voicing your concern about prescribing safety with them so that they are also aware of the dangers scheduled drugs may carry. If/when/then is a form of pre-suasion that provides simple rules that tie goals to specific actions and has been used successfully to encourage behavior in many areas including medication adherence and drug abuse rehabilitation."
45666239|NCT01856686|Dietary Supplement|Low carbohydrate diet|the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
45455400|NCT03933709|Dietary Supplement|Nutritional Support System (NSS)|Envelope 1 4.9g of Spirulina, 100mg ascorbic acid, 5mg folic acid and 10mg of glutamine. Was to be added to shake 1 during the first 10 days. Envelope 2 1g PUFAs n-3 and was to be added to shake 2 which was given throughout the intervention. Envelope 3 4.9g of Spirulina Maximum, 100mg ascorbic acid, 5mg folic acid, 5.2g vegetable protein, 125mg nicotinic acid, 50mg zinc, 100 mcg selenium and 800 UI cholecalciferol. Was to be added to shake 1 from day 11 until the end of week 6, after which it was suspended for 10 days and substituted for envelope 5 and then to be retaken until the end of the intervention. Envelope 4. 1g arginine and was to be added to shake 3 from day 8 until the end of the intervention. Envelope 5 contained the same ingredients as envelope 3 with an additional 10mg glutamine and was to be added to shake 1 from the start of week 7 for 10 days, after which envelope 3 was restarted. Probiotic at a dosage of 200 mg every 12 hours for 3 days at the beginning and week 6
45666240|NCT02058147|Drug|Insulin glargine/lixisenatide Fixed Ratio Combination|Insulin glargine/Lixisenatide FRC was self-administered by subcutaneous (SC) injection in the morning within one hour before breakfast using one of the 2 prefilled disposable SoloStar® pen-injectors: Pen A containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 50 mcg/mL lixisenatide in a ratio of 2 U:1 mcg, used for administration of doses from 10 U to 40 U (10 U/5mcg to 40 U/20mcg). Pen B containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 33 mcg/mL lixisenatide in a ratio of 3 U:1 mcg, used to administer doses from 41 U to 60 U (41 U/13 mcg to 60 U/20 mcg). The starting dose was 10 U/5 mcg. Dose was then adjusted individually to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
45962999|NCT00178074|Procedure|PET imaging|
45963000|NCT02904031|Drug|5-fluorouracil|
45963001|NCT02904031|Drug|oxaliplatin|
45963002|NCT02904031|Drug|l-leucovorin|
45963003|NCT02904031|Drug|panitumumab|
45963004|NCT02904109|Drug|Triflusal|Once daily oral administration of 600 mg triflusal Disgren® for 8 days.
45963005|NCT02904109|Drug|Placebo|Once daily oral administration of placebo mannitol for 8 days.
45963006|NCT02904070|Device|Vaginal swabbing|
45963007|NCT00178113|Drug|- Lyc-O-Mato (dietary supplement, 30 mg lycopene/day)|
45963008|NCT00178113|Drug|- Certagen (multivitamins with minerals)|
45963009|NCT00407498|Drug|P276-00|Starting dose of 9 mg/m2/day from day 1to 5 and day 8 to 12 in 21 day cycle.Protocol wa amended to dose the subjects for day 1 to5 in 21 day cycle after 34.4 mg/m2/day cohort.Maximum dose administered was 259 mg/m2/day
45963010|NCT04681456|Behavioral|There is no medical intervention for the purposes of this Registry.|There is no medical intervention for the purposes of this Registry.
45963011|NCT04681495|Behavioral|STAC|STAC is a brief, stand-alone bullying bystander intervention for middle school students, to reduce bullying and mental health risks for bystanders. The primary outcome will be showing usability for the technology-based program (STAC-T) prototype.
45963012|NCT04681378|Procedure|double layer step up-step down technique|the incision is closed using Vicryl 1-0 stitch starting from one corner. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously by alternating continuous stitches through the upper (step up) and the lower (step down) uterine flaps. The original string is returned to the starting point and tied with knot as in Turan technique. Following the double layered step up-step down closure, additional single sutures were added for hemostasis if required
45666241|NCT02058147|Drug|Insulin glargine (HOE901)|Insulin glargine (100 U/mL) was self-administered by SC injection at approximately the same time every day. Dose was adjusted individually to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
45963013|NCT04681573|Diagnostic Test|blood tests|"Single arm : all NAFLD patients evaluating the FIB4-FS and the eLIFT-FMVCTE with two patient groups considered at inclusion:~Low-risk group (neither metabolic syndrome nor AST ≥35 UI/l): Liver biopsy won't be mandatory in this group because of the very low risk of advanced fibrosis (4%). These patients will be considered as having no-mild F0-2 liver fibrosis and the study visit will be scheduled for clinical data recording, blood sampling, and LSM with Fibroscan. Liver biopsy could still be performed in the low-risk group if the investigator deems it is required for the clinical management of the patient.~At-risk group (presence of a metabolic syndrome and/or AST ≥35 UI/l): Because of the increased prevalence of significant liver lesions in this group, the patients will have a liver biopsy with clinical data recording, blood sampling, and Fibroscan the same day."
45963014|NCT04681612|Diagnostic Test|MSNA|"Assessed via Muscle Microneurography during the first 14 days of the acute phase.~Indices: busts/min, busts/100bpm"
45963015|NCT04681612|Diagnostic Test|Heart Rate Variability|Assessed via 24hr ECG monitoring during the first 14 days of the acute phase. Indices: Time-domain, Frequency-domain, Non-linear
45963016|NCT04681612|Diagnostic Test|Blood Pressure Variability|Assessed via Ambulatory BPM during the first 14 days of the acute phase. Indices: SD, wSD, ARV, CV
45963017|NCT04681612|Diagnostic Test|CMR|Cardiac Magnetic Resonance during the first 14 days of the acute phase. Assessment of oedema, Late Gadolinium Enhancement ischaemic pattern. Assessment of cardiac function parameters
45963018|NCT04681612|Diagnostic Test|History, Lab, clinical and hemodynamic parameters|1. Description of event, 2. Risk factors, 3. Medical history, 4. ECG parameters, 5. ECHO parameters, 6. Hemodynamic parameters of acute phase and hospitalization, 7. Coronary angiogram paraemeters, 7. Complete lab parameter assessment, 8. Thrombofilia assessment, 9. SF-12 QoL and Anxiety and Depression Scale (HADS) questionnaires
45963019|NCT02904187|Other|Positron Emission Tomography (PET)|
45963020|NCT02904187|Other|Electroencephalogram (EEG)|
45455401|NCT03933709|Other|deworming|nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days.
45666242|NCT02058147|Drug|Lixisenatide (AVE0010)|Lixisenatide was self-administered by SC injection within 0 to 60 minutes before breakfast or evening meal. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
45666243|NCT02058147|Drug|Metformin|Pharmaceutical form: Tablet; Route of administration: Oral administration.
45666244|NCT02489981|Drug|Spiriva|60 puffs
45666245|NCT04205045|Diagnostic Test|Lactose Breath Test|Lactose Breath Test is performed during the recruitment step. Fasting subjects are asked to ingest 20 g of lactose in a 10% water solution. Breath samples are collected at baseline and every 30 min after lactose ingestion, for an overall test duration of 4 h. A cut-off value of 20 ppm over the baseline will be used to identify lactose malabsorbers.
45666246|NCT04205045|Other|Gut permeability test|A 3-sugar probes test is conducted by administering 5 g lactulose, 2 g mannitol and 2 g sucralose in water solution to fasting subjects. Urine are collected at baseline (before sugar ingestion) and for time periods 0-5 h and 5-24 h.
45666247|NCT04205045|Other|Milk Test|Milk test will be performed by administering to fasting subjects a portion of 250 ml of semi-skimmed milk treated with ultra-high temperature (UHT). Glycaemia measurements, blood withdrawals and questionnaires completion will be performed at baseline and repeated after 30 minutes, 1, 2, 4 and 6 hours after milk ingestion. Urine collection will be performed at baseline and for 6 time intervals after milk ingestion (0-2, 2-4, 4-6, 6-8, 8-12, 12-24 hours).
45666248|NCT04415554|Diagnostic Test|echocardiography|echocardiography exam of the infant
45666249|NCT02471183|Drug|Selexipag|Tablets for oral administration containing 200 micrograms (mcg) of selexipag to be administered twice a day. The individual dose is to be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).
45666250|NCT04964063|Other|Potassium Nitrate + Sodium Fluoride|Potassium Nitrate 5% weight/weight (w/w) and Sodium Fluoride 0.15% weight/volume (w/v) fluoride ion.
45821406|NCT04321538|Device|Welch Allyn Spot Vision Screener|The Welch Allyn Spot Vision Screener is a photoscreening device. It takes a special picture of the eyes that allows for the detection of refractive error and eye misalignment.
45821407|NCT04321538|Diagnostic Test|Physical Exam|Retinoscopy and an oculomotor testing will constitute the physical examination.
45821408|NCT00379483|Drug|Deferasirox|
45821409|NCT04509427|Behavioral|Instructional handouts|Handouts will include written instructions for each aspect of the multifaceted exercise/posture training program
45821410|NCT04509427|Behavioral|Physical therapist instruction and monitoring via teleconferencing|The intervention physical therapist (PT) meets with them via Zoom for 60 minutes to help them start the program in the first week. This PT will meet with them again in week 2 to complete initial instructions. The PT will meet with them week 3 and then every other week for 15-minutes to help individuals safely progress the program.
45963021|NCT02903875|Other|Patient therapeutic education (PTE) programme|
45963022|NCT00168272|Device|Transcranial Magnetic Stimulation|
45963023|NCT00195858|Behavioral|aerobic and resistance exercise|aerobic and resistance exercise
45963024|NCT02903563|Other|observational|
45821411|NCT04509427|Behavioral|Web-based instructional videos|Instructional videos that will lead participants through every part of the intervention - like a commercial exercise video.
45963025|NCT02903524|Drug|Doxorubicin Hydrochloride Liposome injection and cyclophosphamide|
45963026|NCT02903524|Drug|pirarubicin and cyclophosphamide|
45666251|NCT04204967|Drug|Fentanyl Transdermal System|in the experimental arm transdermal fentanyl will be administered with a starting dose of 50 mcg/hr simultaneously with the preexistent remifentanil continue infusion. Remifentanil infusion rate will be increased or decreased based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit. After randomization, the transdermal fentanyl dose can be modified every 24 hours according to the study protocol to achieve the desired effect in terms of PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected
45963027|NCT00168350|Drug|memantine|
45963028|NCT02903602|Behavioral|Sharing Histories training method for CHW|Female Community Health Worker training participants were led through a guided process of recalling and sharing their autobiographical memories of their personal experiences in the first 1000 days of each of their children (pregnancy, childbirth, postpartum, newborn, breastfeeding, complementary feeding, infant diarrhea and hygiene, pneumonia). On the basis of memories, cultural beliefs and practices are identified and training content is built.
45963029|NCT02903602|Behavioral|Standard training method for CHW|Female Community Health Workers were trained with standard participatory teaching method with three phases: identify knowledge, provide new knowledge, evaluate learning.
45963030|NCT02903485|Other|nurses perform presurgical assessement and surveillance during surgery|
45963031|NCT02903485|Other|the anesthetic team performs presurgical assessement and surveillance during surgery|
45666252|NCT04204967|Drug|Remifentanil|"In the active comparator arm remifentanil infusion is administered alone, the infusion rate will be increased or decreased according to the study protocol based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit.~In the experimental arm remifentanil is use together with transdermal fentanyl"
45666253|NCT01855828|Drug|Pertuzumab|First dose is 840mg, maintenance dose is 420mg. Pertuzumab will be administered once every 3 weeks for 24 weeks (8 doses total)
45666254|NCT01855828|Drug|Trastuzumab|"For weeks 1-12, first dose is 4 mg/kg, maintenance dose is 2 mg/kg administered every week (12 doses total).~For weeks 13-24, dose is 6mg/kg administered every 3 weeks (4 doses total)."
45666255|NCT01855828|Drug|Paclitaxel|Administered at 80mg/m2 every week from week 1 to 12 (12 doses total).
45666256|NCT01855828|Drug|5-fluorouracil|Administered at 500 mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
45963032|NCT02903641|Behavioral|Personalized information|"During a prior study in June-July 2016, we collected anthropometric measures on the index children, including the children's height. Based on these data, for households assigned to the information treatment, enumerators provided personalized information to the children's primary caregiver about the index child's current height, during a baseline household visit. The enumerators carried a display card that visually showed where the child's height fell compared to healthy children of the same age and gender like those in East Africa. The enumerators emphasized to the caregivers that short stature is due to poor chronic malnutrition and is not just attributable to genetics or a recent illness. During this visit, the enumerators additionally pointed out that chronic malnutrition is not immediately life-threatening."
45666257|NCT01855828|Drug|Epirubicin|Administered at 75mg/m2 every 3 weeks during weeks 13-24 (4 doses total).
45821412|NCT04509427|Behavioral|Posture training|Participants will learn how to hold a neutral spine posture during sitting, forward leaning in sitting, sit-to-stand-to-sit, standing, forward leaning in standing, supine-to-sit-to-supine, supine-to-prone-to-supine, and lifting. Principles learned with these functional movement patterns will then be put to practice in common tasks like sweeping, washing dishes, dusting, and gardening. This will be taught over two sessions in the first two weeks of the program. To reinforce holding neutral spine with all activities, participants will perform a 5-minute posture warm-up routine prior to exercising.
45821413|NCT04509427|Behavioral|Marching in place|Participants will perform marching in place five times a week. Participants will be instructed to slowly progress to a goal of performing 30 minutes of marching in place per session. They will be instructed to lift their knees to a height that is between their waist and knee when marching. They will be instructed to march between a rating of 10 -14 on the 20-point Borg scale for rate of perceived exertion
46079839|NCT03845101|Behavioral|CBT with virtual reality exposure therapy|The patients receiving the in virtuo exposure will be immersed using an Oculus Go head-mounted display, enabling viewing of 360° spherically camera recorded VR environments. The VR scenarios will thus be high-resolution 360° stereoscopic films, that are played around the viewer. For ease of use, the individual videos will be administered from an app that has been designed to be as intuitive to operate as possible. The patient will only have to put on the headset, adjust the focus and choose the desired environment by looking at it in the app. 360° video was chosen because it gives the most photorealistic visuals, while also being the cheapest to produce. The downside is that it does not allow direct user-interaction (e.g. the viewer cannot affect the environment in any way). To circumvent this, there are multiple junctions throughout the films where the actors will talk directly and unsolicited to the viewer while also allowing time for the viewer to respond.
46079840|NCT03845101|Behavioral|CBT in vivo|The therapeutic intervention is manual-based cognitive-behavioral CBT group therapy adapted from the approach of Turk, Heimberg & Magee and Graske & Barlow with worksheets from Arendt & Rosenberg and inspiration from Bouchard et al. The treatment will consist of 14 weekly two-hour group sessions following the manual to ensure equal and uniform treatment for every patient throughout the study. Concurrent psychopharmacological treatment is allowed in both intervention arms.
46079841|NCT03837483|Genetic|OTL-103|Autologous hematopoietic stem cells collected from mobilized peripheral blood transduced ex vivo with a lentiviral vector encoding the WAS cDNA
45455402|NCT03933709|Other|recommended diet|WHO Diet
45455403|NCT03931993|Biological|Placebo comparator|
45455404|NCT03931993|Biological|Grass MATA MPL|
45666258|NCT01855828|Drug|Cyclophosphamide|Administered at 500mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
45666259|NCT04417335|Biological|BCG vaccine|Bacille Calmette-Guérin is a live attenuated strain of Mycobacterium bovis developed in 1921 to prevent tuberculosis and other mycobacterial related infections.
45666260|NCT04417335|Biological|Placebo|0.9% NaCl
45821414|NCT00607477|Drug|Minoxidil|2.5 mg taken twice daily for 1 week, followed by 5 mg taken twice daily for the next week, followed by 10 mg twice daily for the next week
45963033|NCT02903641|Behavioral|Labeled cash transfer|Households received a cash transfer labeled for child food consumption and were told the money is designed to cover additional spending for food for the index child (and any other younger children in the household) over the next six weeks. Though it was given as a single, lump sum payment, the transfer was evenly split and handed to the household in six sealed envelopes, to help the households better allocate the money. To further encourage them not to spend the money all at once, each envelope was labeled with a number, the index child's name, and the dates for the week the money in the envelope should be spent. Enumerators clearly stated that this is a one-time money transfer.
45963034|NCT02903758|Other|cross sectional|
45963035|NCT02903719|Drug|Ropivacaine|All included patients with a right sided shoulder pain score on a numeric rating scale (NRS) equal to or above 6 and without postoperative exclusion criteria will have two (1st and 2nd intervention) ultrasound guided phrenic nerve blocks performed.
45963036|NCT00178269|Drug|docetaxel|
45963037|NCT00178269|Procedure|Radiation Therapy|
46079842|NCT03829631|Device|Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618|The brace is an FDA Class I, one-size adjustable design to fit waists ranging from 24-70 inches. Participants will be instructed to wear the brace for six weeks during the daytime
45821415|NCT00607477|Drug|Hydralazine|25 mg taken twice daily for 1 week, followed by 50 mg taken twice daily for the next week, followed by 100 mg twice daily for the next week
45821416|NCT03603314|Drug|SENS-401|29 mg dose group: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
45821417|NCT03603314|Other|Placebo Oral Tablet|placebo, oral route, by mouth, twice a day, during 4 weeks
46079843|NCT03823144|Device|Human Intravital Microscopy|Intravital microscopy (IVM) allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.
46079844|NCT03807167|Other|Mattis Dementia Rating Scale|This scale was developed to assess the cognitive status of patients with neurodegenerative diseases. There are 37 items that are presented in a fixed order and grouped into five sub-scales: attention, initiation, construction, conceptualization and memory. Patients and healthy subjects with a score below 125 are not included because of major cognitive impairment.
46079845|NCT03807167|Other|Unified Parkinson 's Disease Rating Scale-III|This scale is used to rate the severity of extra-pyramidal symptoms (akinesia, rigidity and tremors). These symptoms may be the cause of reduction of motor activity apart from any reduction in motivation, they onstitute a confounding factor that it should be controlled.
46079846|NCT03807167|Other|Mini Neuropsychiatric Investigation|This is a structured interview that allows rapid screening in about 20 minutes of troubles Psychiatric. It is based on short questions to which the patient must answer yes or no and on a decision tree. Patients must validate clinical diagnoses of depression.
46079847|NCT03807167|Other|Montgomery and Asberg depression Rating Scale|This scale is composed of 10 items from 0 to 6 from a semi-structured interview, to obtain a total depression score of 0 to 60 (0 no depression, 60 maximum intensity of depression).
45821418|NCT03603314|Drug|SENS-401|43.5 mg dose groupe: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
45821419|NCT04423861|Drug|Nitazoxanide|Patients will receive nitazoxanide 600 mg BID for 7 days.
45821420|NCT04423861|Drug|Placebo|Patients will receive matching placebo BID for 7 days.
45821421|NCT04418869|Other|Exercise bouts|Each subject performed three bouts with 45 minutes of exercise (continuous exercise, intermittent exercise and resistance exercise) in a randomized order. In addition a control session were performed where the subjects sat on a chair for 45 minutes.
45821422|NCT04330196|Diagnostic Test|Oral glucose tolerance test|Participant ingests 75g of glucose
45963038|NCT02903251|Drug|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30.
45963039|NCT02903251|Other|intranasal spray without oxytocin|6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30.
45963040|NCT00168467|Drug|Ramipril|
46079848|NCT03807167|Other|Clinical Global Impression|heterosexual assessment that rates the severity of symptoms suicidal and changes in suicidal symptoms. Any subject with a score greater than 4 is not included.
45455405|NCT03933787|Drug|Saxagliptin 5mg|Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
45666261|NCT02489279|Behavioral|Sustained Attention Control (SAC) Method|Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
45666262|NCT02489279|Behavioral|Scrabble|Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
45666263|NCT04417491|Device|Dry Needling|Real dry needling will be conducted according to the fast-in and fast-out principle. The intervention will be applied until a total of four local twitch responses will be elicited
45666264|NCT04417491|Device|Sham Needling|Sham dry needling with be conducted with a sham needle device. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient
45821423|NCT04330196|Diagnostic Test|Ingestion of placebo|Participant ingests 700mg of aspartame
45963041|NCT02903290|Other|Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait|
45963042|NCT02903290|Other|walking track GAITRite,manual dynamometer, and treadmill|
45963043|NCT02903329|Other|Detoxification|Two ways of composing the detoxification protocol
45963044|NCT04723589|Biological|Thawed plasma|"Plasma not labeled convalescent plasma is presumed to be free of COVID antibodies, but is not tested for antibodies. To ensure that we are using antibody-free plasma, we will test each unit of plasma with a quick COVID test before it is utilized in this study."
45963045|NCT02903056|Other|Rett Syndrome|Diagnosis of Rett Syndrome
45963046|NCT00195936|Drug|Cinacalcet|Single oral dose of Cinacalcet for children with Hypophosphatemic Rickets
45963047|NCT02903095|Drug|TD-1439|
45963048|NCT02903095|Drug|Placebo|
45963049|NCT00168506|Drug|SSRI|
45963050|NCT00168506|Drug|CBT|
45963051|NCT00168506|Drug|CBT/SSRI|
45963052|NCT02902783|Other|Data Collection|Data collection relevant to this study will be obtained by observation and review of hospital charts. Limited data will be obtained through relevant organ donation organizations (ODOs).
45666265|NCT02489045|Drug|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
45821424|NCT00000271|Drug|Desipramine|Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
45821425|NCT00000271|Drug|Placebo|Participants were treated with matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
45821426|NCT00000277|Drug|Mazindol|
45821427|NCT04444544|Other|High Risk Abdominal Surgery|Pancreatectomy, Esophagectomy, Gastrectomy and Hepatectomy
45455406|NCT03933787|Drug|Placebo oral capsule|Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
45666266|NCT02488109|Other|Higher Calorie Refeeding|
45821428|NCT00599131|Drug|Cisplatin|1. Day 1: 100 mg/m2, administered as an i.v. infusion will run over one hour. 2. Day #23: Subjects with a < 50% response (NR) to induction chemotherapy will undergo salvage laryngectomy followed by RT. Cisplatin will be added to radiation for patients whose surgical pathology reveals high-risk features (i.e. extracapsular spread, > 2 positive lymph nodes, perineural invasion, or positive margins). Cisplatin will either be dosed a 100 mg/m2 every 21 days or 40 mg/m2 weekly at the discretion of the prescribing physician.
45821429|NCT00599131|Drug|Cetuximab|1. Cetuximab will be administered at 400 mg/m2 on Day 20 (2 hour administration). 2. Cetuximab will be administered in combination with radiation therapy to those subjects who had a Partial or Complete response after the first cycle of the chemotherapy regimen is administered. The dosage for these administrations is 250 mg/m2 over sixty minutes and it will be administered for six weeks.
45821430|NCT00599131|Drug|5-Fluorouracil|5-FU will be administered 750 mg/m2 in 0.9% normal saline as a 24-hour continuous infusion, days #1-4.
45821431|NCT00599131|Drug|Docetaxel|75 mg/m2 by I.V. over one hour on Day # 1 only
45821432|NCT04302350|Procedure|nitrous oxide|During one-lung ventilation with an open chest, the nonventilated lung collapses initially due to elastic recoil, which quickly brings the lung down to its closing capacity. Remaining gas in the lung is then removed by absorption into the pulmonary capillary blood. The rapid diffusion properties of N2O（Blood gas distribution coefficient is 0.47）would be expected to speed lung collapse and so facilitate surgery. The previous study suggested that increasing the concentration of N2O in mixtures of N2O/O2 will lead to a faster rate of collapse. When using nitrous oxide in oxygen during lung ventilation, ongoing oxygen uptake by blood shunting will serve to increase the partial pressure of nitrous oxide in parts of the lung that are still expanded. This will soon result in a partial pressure gradient for nitrous oxide uptake also, with a consequent faster rate of lung collapse than would occur in a patient being ventilated with 100% oxygen.
45963053|NCT02902939|Device|minimal extracorporeal circulation (MEC)|We should use the modification of extracorporeal circulation to reduce the systemic inflammatory response due to excessive haemodilution, allogenic blood transfusion.
45455407|NCT03933787|Other|ergometric test in healthy volunteers|The volunteers will undergo an ergometric test in each session
45455408|NCT01124851|Drug|ABT-652|See arm description for details
45666267|NCT02488109|Other|Lower Calorie Refeeding|
45666268|NCT02351167|Drug|Combination NRT (Nicotine patch, Nicotine lozenge)|
45821433|NCT00584935|Drug|Rituximab|The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15).
45821434|NCT04297358|Drug|Hyperbaric oxygen|40 consecutive (5/7) sessions of hyperbaric oxygen
45963054|NCT02902939|Procedure|The cytokines modulations|We should use the modification of cytokines by CytoSorb devices and cytokines removal by PMMA membranes during extracorporeal circulation in patients with risk factors of complications (long duration of extracorporeal circulation, re-do procedures and other)
45963055|NCT02902861|Drug|Methotrexate|methotrexate 50 mg/ml in syringes for sub-cutaneous injection; Once weekly (every 7 days) s.c. administration of 17.5 mg MTX; If PASI50 is not reached after 8 weeks, the dosing will be increased to 22.5 mg
45963056|NCT02902861|Drug|Placebo ( for Methotrexate)|NaCl-Solution manufactured to mimic Methotrexate
45963057|NCT00168545|Biological|Measles vaccine|
45455409|NCT01124851|Drug|Placebo|See arm description for details
45455410|NCT01124929|Drug|RNTCP Category I treatment for 6 months|2H3R3Z3 E3 + 4H3R3
45666269|NCT02351167|Drug|Varenicline|
45666270|NCT02351167|Drug|Placebo|
45666271|NCT02351167|Behavioral|Intensive smoking counseling|
45455411|NCT01124929|Drug|RNTCP Category I treatment for 9months|2H3R3Z3 E3 + 7H3R3
45455412|NCT01219465|Biological|umbilical cord mesenchymal stem cells|Transfusion of the umbilical cord mesenchymal stem cells (2 x 107 cells) intravenously.
45666272|NCT02350309|Drug|Lemborexant 5 mg|Lemborexant 5 mg tablet.
45666273|NCT02350309|Drug|Lemborexant 10 mg|Lemborexant 10 mg tablet.
45666274|NCT02350309|Drug|Lemborexant-matched placebo.|Lemborexant-matched placebo tablet.
45666275|NCT02350309|Drug|Flurazepam 30 mg|Flurazepam 30 mg capsule.
45666276|NCT02038647|Drug|Alisertib|Alisertib tablets
45666277|NCT02038647|Drug|Placebo|Placebo matching tablets
45455413|NCT03934333|Drug|BDA MDI 160/180 mcg|Budesonide/albuterol sulfate pressurized inhalation suspension, single dose given as 2 inhalations of 80/90 mcg.
45455414|NCT03934333|Drug|Pulmicort Flexhaler 180 mcg|Pulmicort Flexhaler aerosol, power, single-dose given as 2 inhalations of 90 mcg.
45963058|NCT02902705|Other|Biopsy of abdominal subcutaneous white adipose tissue (2-3 g)|The biopsies of abdominal subcutaneous white adipose tissue (2-3 g) will be performed during elective surgery (i.e. peritoneal dialysis catheter) for CDK patients or during elective urologic surgery (e.g. radical prostatectomy) for Non-CDK patients. 50-100 mg will fixed in osmium tetroxide for cellularity measurement and 1g of fresh adipose tissue were used from adipocyte isolation. The remnant part of the biopsies will be snap frozen in liquid nitrogen and stored at -80°C until use (gene expression).
45963059|NCT02902978|Drug|E6130|
45963060|NCT02902978|Drug|Placebo|E6130 matched placebo
45963061|NCT02903017|Drug|Tranexamic acid 5%|Via nasogastric tube, 100 mL
45963062|NCT02903017|Drug|Placebo|Via nasogastric tube, 100 mL
45963063|NCT02902744|Drug|ILUVIEN®|Patients will receive Iluvien as the standard of care treatment for diabetic macular edema.
45963064|NCT00168584|Drug|Vitamin A|
45963065|NCT02902666|Drug|Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet|
45963066|NCT02902666|Drug|Paracetamol 500 mg/codeine phosphate hemihydrate 30 mg tablet|
45963067|NCT02902822|Procedure|Screening|"The screening visit consists in a general dermatological examination of the subject, with special focus on the onset of the following skin diseases during the follow-up period:~bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);~fungal skin infections (tinea corporis, cruris, pedis);~pigmented tumors (melanoma);~non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma)."
45821435|NCT04295486|Drug|Aspirin|Non-enteric coated 81 mg Aspirin tablet.
45821436|NCT00000289|Drug|Ondansetron|
45821437|NCT00000295|Drug|Micronized Progesterone|
45963068|NCT02902822|Device|Tele-dermatology|"The system consists in a simple web-based/smartphone application through which subjects can send pictures of recently onset non-widespread skin lesions with special focus on the following diseases:~bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);~fungal skin infections (tinea corporis, cruris, pedis);~pigmented tumors (melanoma);~non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma).~A dermatology will judge online pictures based on a standard scale. Each subject who will use the system will be also seen by routine clinical visit to confirm the online diagnosis. Subjects who will not send any picture will be seen for a dermatological examination at the end of each year."
45821438|NCT04384939|Device|magnetic-end Double-J ureteral stent|"Inserting the ureteral stent with magnet (same process as classic ureteral stent)~Removing the ureteral stent with magnet without general anaesthesia. Usually, the classic ureteral stent removed during a general anaesthesia."
45821439|NCT04348591|Behavioral|Cognitive Restructuring|All participants will learn how to change their thinking in order to be less upset when confronted with stressors
45963069|NCT02902354|Other|Nifedipine for tocolysis|observational
45963070|NCT02902393|Biological|Thromboelastography|
45963071|NCT00168623|Drug|Vitamin A|
46079849|NCT03807167|Other|Apathy diagnostic criteria|The clinical criteria make it possible to make a diagnosis of apathy with a functional repercussion. It is based on a lack of motivation felt by the patient, causing a functional or social impact that is not the consequence of a disturbance of consciousness or a disability engine. The cognitive, emotional and behavioral dimensions are affected.
45963072|NCT02902510|Other|Therapeutic yoga for people with Parkinson's Disease|Held for 8 weeks, individuals participated in therapeutic yoga 60 minutes 2x/week.
45963073|NCT02902315|Other|Cryotherapy|The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
45963074|NCT02902315|Other|Vitamins C and E|The session of resistance exercises with intervention will be based on the supplementation with vitamin C (1000 mg) and vitamin E (800 IU) by oral intake (100mL of water) 40 minutes before basal blood collection.
46079850|NCT03807167|Other|walking speed test|The patient is timed to walk 10m. A speed <1m / sec is a criterion exclusion because it shows severe sarcopenia and constitutes a bias.
45666278|NCT02038647|Drug|Paclitaxel|Paclitaxel intravenous injection
45666279|NCT02058069|Device|Robotic Arm Assisted Total Knee Arthroplasty|The total knee implant system used for this study was the Kinetis implant system (MAKO Surgical Corp.).
45666280|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
45821440|NCT04348591|Device|neurostimulation|all participants will receive inhibitory, excitatory, and sham transcranial magnetic stimulation over different neural targets during the experimental session. The purpose of the neurostimulation is not treatment, but causal interference/enhancing of brain circuitry to identify candidate neural regions for future interventions
45821441|NCT00000733|Drug|Ribavirin|
45455415|NCT01124227|Drug|icodextrin|2000 ml icodextrin intraperitoneally one or two times a day. Dose will be adapted clinically as in standard peritoneal dialysis.
45455416|NCT03931915|Drug|TAK-385|TAK-385 40 mg tablets + Leuprorelin acetate placebo injection
45455417|NCT03931915|Drug|Leuprorelin acetate|TAK-385 placebo tablets + Leuprorelin acetate 1.88 mg / 3.75 mg injection
45666281|NCT02057835|Drug|BI 691751 high dose|BI 691751 high dose
45666282|NCT02057835|Drug|BI 691751 middle dose|BI 691751 middle dose
45666283|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
45666284|NCT02057835|Drug|BI 691751 low dose 1|BI 691751 low dose 1
45666285|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
45666286|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
45666287|NCT02057835|Drug|BI 691751 low dose 2|BI 691751 low dose 2
45666288|NCT02057757|Drug|Nitazoxanide|"Participants 1 to 3 years old: 5 mL oral suspension (100 mg NTZ) every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL oral suspension (200 mg NTZ) every 12 hours for 5 days.~Participants 12 years and older: two 300-mg NTZ tablets orally twice daily for 5 days."
45666289|NCT02057757|Drug|Placebo|"Participants 1 to 3 years old: 5 mL placebo oral suspension every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL placebo oral suspension every 12 hours for 5 days.~Participants 12 years and older: two placebo tablets orally twice daily for 5 days."
45821442|NCT03531320|Drug|D07001-softgel capsules|Active Ingredient:Gemcitabine hydrochloride
45821443|NCT04246723|Drug|Narlaprevir|100 mg oval shaped, concave, yellow film-coated tablets taken as 200 mg per os once daily. 28 tabs/36 tabs/ 56 tabs in bottle.
45821444|NCT04246723|Drug|Ritonavir|100 mg tablets taken as 100 mg per os once daily. 30 tablets in bottle
45821445|NCT04246723|Drug|Sofosbuvir|"400 mg yellow, capsule-shaped film-coated tablets debossed with GSI on one side and 7977 on the other side, taken as 400 mg per os once daily. 28 tablets in bottle."
45821446|NCT00000301|Drug|Amantadine|
45821447|NCT00000307|Drug|Naltrexone|
45821448|NCT00000313|Drug|Fenfluramine|
45821449|NCT00000757|Biological|gp160 Vaccine (MicroGeneSys)|
45821450|NCT00000319|Drug|Buprenorphine|
45821451|NCT00000325|Behavioral|Gonadorelin|
45821452|NCT04415996|Other|HVLA L3/4|"The participant will be lateral decubitus and the investigator will locate the third lumbar vertebra. Then with one hand the investigator will contact the interspinous space underlying L3 and with the other hand he will take the top leg into flexion until the investigator feels tension in L3/L4 joint. Then he puls the tables´s arm until felling tension in the region to be manipulated. Afterwards the investigator will globally rotate the participant in the horizontal plane and will approach to the L3/L4 joint. With one arm the investigator will contact the deltopectoral groove and with the other one will contact the external iliac fossa. Finally, the investigator will compress and rotate the pelvis and will apply an impulse in a rapid rotation, without losing the parameters with a body drop allowed by the flexion of the knees and the contraction of the large pectorals."
45821453|NCT04415996|Other|Sham|The participant will be in lateral decubitus and the top leg and knee will be flexed until the foot reaches the popliteal region of the other leg. There won't be applied any tension in no structure. This intervention will be applied during 90 seconds each side.
45821454|NCT04181203|Drug|Apalutamide|"240 mg PO daily should start the same day as the first LHRHa administration for 6 months.~months."
45821455|NCT04181203|Radiation|Salvage radiotherapy (SRT)|"The SRT treatment will be administered to a total dose of 66 Gy (in 33 fractions of 2 Gy) directed at the prostate bed with an additional 56.1 Gy (in 33 fractions of 1.7 Gy) directed at the pelvis region. The pelvis will be irradiated in all patients.~An additional simultaneously integrated boost of 69.3 Gy (in 33 fractions of 2.1 Gy) can be delivered to a local relapse based on Positron Emission Tomography - Computed Tomography (PET/CT) and Magnetic Resonance Imaging (MRI) images."
45821456|NCT04181203|Drug|Luteinising Hormone Releasing Hormone agonist (LHRHa)|Doses of LHRHa may vary due to availability of different brand names and pharmaceutical forms. It will be left to the discretion of the investigator.
45821457|NCT03521102|Drug|Acetaminophen 1000mg IV|1000mg of IV acetaminophen in 100ml of normal saline, administered as an intravenous drip over 10 minutes + 2ml of normal saline, administered as a slow intravenous push
45821458|NCT03521102|Drug|Hydromorphone 0.5 mg IV|100ml of normal saline, administered as an intravenous drip over 10 minutes, + 0.5mg of IV hydromorphone in 2ml of normal saline, administered as a slow intravenous push
45666290|NCT02037477|Drug|Vonoprazan|Vonoprazan tablets
45821459|NCT00000763|Drug|TNP-470|
45821460|NCT00380263|Drug|PACAP38|10 pmol/kg/min given one time
45821461|NCT00000769|Drug|Interleukin-4|
45821462|NCT00380341|Procedure|Instrument-applied spinal manipulative therapy|
45821463|NCT05440591|Drug|Dapagliflozin|Dapagliflozin 10mg tablets
45821464|NCT05440591|Drug|MetFORMIN 500 Mg Oral Tablet|Metformin 500 mg tablets twice daily
45821465|NCT05440591|Drug|Dapagliflozin / metFORMIN Pill|Combination pill
45821466|NCT04099303|Biological|Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed|0.5 mL, Intramuscular Other Name: DTcP
45821467|NCT04099303|Biological|Diphtheria and Tetanus Combined Vaccine, Adsorbed|2mL, Intramuscular Other Name: DT
45963075|NCT02902315|Other|Vitamins C and E associated with cryotherapy|The session of resistance exercises with intervention will be based on the supplementation with vitamin C (1000 mg) and vitamin E (800 IU) by oral intake (100mL of water) 40 minutes before basal blood collection. The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
45963076|NCT02902315|Other|Placebo|The volunteers from placebo exercise session will receive two pills (containing wheat flour) and the remaining procedures were conserved.
45666291|NCT02037477|Drug|Esomeprazole|Esomeprazole capsules
45666292|NCT02037477|Drug|Rabeprazole sodium|Rabeprazole sodium tablets
45821468|NCT04099303|Biological|Diphtheria-tetanus-acellular pertussis vaccine|0.5 mL, Intramuscular Other Name: DTaP
45821469|NCT04099303|Biological|Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine|0.5 mL, Intramuscular Other Name: PENTAXIM
45821470|NCT00000775|Biological|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
45821471|NCT00379951|Drug|ertapenem sodium|ertapenem sodium as a single dose of 1gm I.V. was infused over a 30 min interval for a minimum of 3 days to a maximum of 14 days.
45821472|NCT00000331|Drug|Test Drug|
45821473|NCT00000331|Drug|Placebo Drug|
45963077|NCT00178347|Radiation|Exposure to irradiation|Treatment for Cancer using Radiation -dose will be the standard of Care for the type of Cancer being treated
45963078|NCT02902588|Other|ICG-PULSION|Intravenous administration of indocyanine green
45963079|NCT02902588|Device|LiMON, Pulsion Medical Systems|Application of near infrared light
45963080|NCT02902588|Other|Gadolinium (Gadovist, Bayer, Germany)|Injection of gadolinium
45963081|NCT00168662|Biological|Measles and inactivated polio vaccine|
45963082|NCT02902627|Device|Non Invasive Monitoring Device (ANI)|Pain measure by ANI monitor and with visual analogical scale
45963083|NCT02902432|Drug|Endostar|The patients will be randomized to CRT arm and CRT+Endostar arm. All patients will receive one cycles of induction chemotherapy, intensity modulated radiation therapy (IMRT) with weekly cisplatin and 3 cycles of chemotherapy after IMRT.
45963084|NCT02902471|Other|Forced oscillations measure|
45963085|NCT00168701|Drug|BG00012|
45963086|NCT02902276|Other|additional blood sample|Two blood samples will be taken at ICU admission
45963087|NCT02902042|Drug|Encorafenib|Dose determined in phase I. Start dose: 450 mg qd
45963088|NCT02902042|Drug|Binimetinib|Dose determined in phase I. Start dose: 45 mg bid
45963089|NCT02902042|Drug|Pembrolizumab|Dose determined in phase I. Start dose: 200 mg q3w
45963090|NCT02902042|Drug|Pembrolizumab alone|200 mg q3w
45963091|NCT00178425|Procedure|Serial blood sampling as described in protocol|
45963092|NCT00178425|Procedure|Estimation of Creatinine Clearance at regular intervals|
45455418|NCT01125007|Device|Two kind toothbrushes|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
45963093|NCT02902159|Other|BWW Online Peer Support|Free access to BWW online peer support and other services offered by them (except live therapy), for 6 months.
45963094|NCT02902159|Other|NHS Moodzone Online Information|Directed to access to online information from NHS Moodzone
45963095|NCT00168740|Drug|rituximab|
45963096|NCT02901847|Other|PAD tailored care|PAD tailored care
45963097|NCT00196053|Device|Archimedes Constant Flow Implantable Pump|
46079851|NCT03807167|Other|accelerometer presentation|accelerometer presentation and pose
46079852|NCT03807167|Other|data acquisition from the accelerometer|withdrawal of the accelerometer and data acquisition from the accelerometer
45666293|NCT02057523|Drug|Acthar|Those interested will be started on Acthar 80 units twice weekly for 6 months. Those with minor adverse effects such as weight gain, worsening hypertension, or glucose intolerance will have their doses reduced to 40 unit twice weekly. Those with major adverse effects such as allergy or infection will discontinue the medication. If the primary endpoint of 50% reduction in proteinuria or total proteinuria less than 150mg/day is not reached, therapy may be continued for a total of 12 months.
45666294|NCT02037165|Drug|Placebo to BI 1026706|Placebo tablet
45666295|NCT02037165|Drug|Pregabalin|Pregabalin hard capsule
45666296|NCT02037165|Drug|BI 1026706|BI 1026706 oral solution
45666297|NCT02037165|Drug|Celecoxib|Celecoxib hard capsule
45963098|NCT02901925|Drug|ABY-029|Using a sample size of 6-12 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.
46079853|NCT03807167|Other|Apathy Evaluation Scale,|clinician version and near-helping version. It's a hetero rating scale from an interview semi structured by a trained clinician. It assesses cognitive, emotional and behavioral apathy than three items of various apathy. The total score ranges from 18 (total absence of apathy) to 72.
46079854|NCT03807167|Other|fatigue Visual Analog Scale|To date, there is no valid fatigue scale in the depression of the elderly subject, a fortiori in French. The fatigue scale in adult depression includes has been validated with an EVA (Visual Analogue Scale) (38). We therefore propose to use this type of evaluation to control this aspect.
45666298|NCT02470403|Drug|LIK066|LIK066 25 mg tablets
45666299|NCT02470403|Drug|Placebo|Matching placebo tablets
45666300|NCT01855750|Drug|Ibrutinib|560 mg capsules administered by mouth once daily (21-day cycles)
45963099|NCT02901964|Other|Hip Abductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip abductors.
45963100|NCT02901964|Other|Hip Aductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip aductors.
45963101|NCT02901886|Behavioral|Intensive smoking cessation intervention|The intervention includes 1) Individual motivational counseling (5 meetings within 6 weeks) in combination with 2) nicotine replacement therapy.
45963102|NCT00168779|Drug|telmisartan 80 mg / hydrochlorothiazide 25 mg|
45963103|NCT00168779|Drug|valsartan 160 mg / hydrochlorothiazide 25 mg|
45963104|NCT00168779|Drug|placebo|
45963105|NCT04681300|Other|Skin biopsy|a skin sample will be taken using a 4 mm punch biopsy in lesional skin
45963106|NCT04681300|Other|Plastic surgery remnants|healthy skin from plastic surgery interventions
45963107|NCT04681222|Procedure|LFCN|LFCN block was performed in combination with PENG block
45963108|NCT04681222|Procedure|Wound infiltration|Wound infiltration was performed in combination with PENG block
45963109|NCT03455335|Drug|20 million hMSCs|
46079855|NCT03807167|Other|executive function|"Modified Card Sorting Test MCST(Modified Card Sorting Test) (Wisconsin Test): This test assesses conceptualization, attention and mental flexibility using a deck of cards.~Trail Making Test (TMT): This test is used to assess mental flexibility.~Fluences verbal: This test tests the capacities of setting up search strategies in memory semantics and oral language.~Stroop Paradigm: This test is used to evaluate the resistance to interference, ie the patient's ability to inhibit some over-learned and automated responses."
45963110|NCT03455335|Drug|40 million hMSCs|
45963111|NCT03455335|Drug|80 million hMSCs|
45963112|NCT00196092|Device|Roll-in|Proctored entry.
45963113|NCT00196092|Device|Surgical|Surgery
46079856|NCT03807167|Other|MRI|An MRI lasting 30 minutes is programmed
46079857|NCT03807167|Other|Apathy Motivation Index|"This is a self-questionnaire of 18 items, each side on a 5-level Likert scale (0: not everything at 4: very often). It differentiates between behavioral apathy and social apathy.~Emotional."
45963114|NCT00196092|Device|Standard Risk|Standard Endovascular repair
45666301|NCT01855750|Drug|Placebo|4 matched capsules administered by mouth once daily (21-day cycles)
45666302|NCT01855750|Drug|Rituximab|375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
45666303|NCT01855750|Drug|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
45666304|NCT01855750|Drug|Doxorubicin|50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
45666305|NCT01855750|Drug|Vincristine|1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
45666306|NCT01855750|Drug|Prednisone (or equivalent)|100 mg capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
45666307|NCT04963439|Drug|Macitentan|Macitentan dispersible tablets will be administered orally as per assigned treatment sequence.
45821474|NCT03492476|Device|Circaid|"Three observation periods were defined with the following products:~D1 to D5: intensive hospital treatment performed by the night and day wearing of the circaid® compression system~Day of Discharge (DD) from the hospital to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime compression system circaid®~DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime circaid® compression system"
45963115|NCT00196092|Device|High Risk|High Risk Endovascular repair.
45963116|NCT00196092|Device|Compassionate Use|Endovascular repair for compassionate use patients.
45963117|NCT00196092|Device|Treatment for females|Endovascular repair in female patients
45963118|NCT00196092|Device|Standard Risk Continued Access|Continued Access Endovascular repair for standard risk patients.
45963119|NCT00196092|Device|High Risk Continued Access|Continued Access Endovascular Repair for High Risk Patients.
45963120|NCT02901613|Device|Negative-pressure wound therapy|
45821475|NCT03492476|Device|Short-stretching Bandage (Reference treatment)|"Three observation periods were defined with the following products:~D1 to D5: intensive hospital treatment performed by the night and day wearing of short stretching tapes.~DD (Day of discharge from the hospital) to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with a possible treatment at night, as recommended by HAS.~DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with possible treatment at night"
45963121|NCT02901652|Device|noninvasive respiratory support devices|
45963122|NCT00168857|Drug|telmisartan|
45666308|NCT04939103|Device|TRUS-FNA|Transrectal Ultrasound Guided Fine Needle Aspiration for rectal tumor
45666309|NCT01855126|Other|Blue light|After a two week baseline collection period, half of the subjects will initially be given light masks that deliver blue light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that blue light exposure will delay the timing of the CBTmin.
45821476|NCT00000337|Drug|Selegiline|
45963123|NCT00168857|Drug|losartan|
45963124|NCT02901691|Other|musical rhythmic stimulation|
45963125|NCT00178581|Drug|Glutamine|
45963126|NCT02901730|Procedure|532nm laser group|LPI with 532nm laser.
45963127|NCT02901730|Procedure|561nm laser group|LPI with 561nm laser.
45963128|NCT02901535|Other|Spirometry|Spirometry in baseline
45963129|NCT02901535|Other|telemonitoring|telemonitoring (phone call nurse - 45 and 90 days)
45963130|NCT02901535|Other|teleconsultation|teleconsultation (general practioner received phone call to respiratory care)
45963131|NCT02901535|Other|Spirometry - 20 weeks|Spirometry (20 weeks)
45963132|NCT02901769|Other|fMRI|two fMRI paradigms, emotional prosody recognition and decision making
45963133|NCT00196131|Drug|morphine|only patients with a head injury currently receiving Morphine continuously or prm can and have an ICP drain can be enrolled into study
45963134|NCT00168896|Drug|Carboplatin plus Irinotecan vs Carboplatin plus Etoposide|
45963135|NCT02901457|Other|"The Healthy Body Image intervention"|Interactive workshops (3 x 90 minutes) include training techniques to increase media literacy, enhance self-esteem, positive body image, awareness of perfectionism, and include discussions related to truths and myths related to life style factors. Homework is an extension of each workshop that is simple and not time-consuming tasks to increase reflection and awareness of how all the mentioned factors are a part of their lives.
45963136|NCT02901418|Biological|200 IU HBIG|additional 200 IU HBIG within 24 hours was used for the experimental group of newborns
45963137|NCT02901379|Drug|Atorvastatin 80mg|Subject will be given atorvastatin 80mg for two weeks
45963138|NCT02901379|Drug|Atorvastatin 10mg|Subjects will be give atorvastatin 10mg as part of standard therapy in hospital
45963139|NCT00196170|Procedure|RF ablation of the cavo-tricuspid isthmus|8mm tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
45963140|NCT00196170|Procedure|cryo ablation of the cavo-tricuspid isthmus|Cryo 10mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
45963141|NCT00196170|Procedure|irrigated tip radiofrequency ablation of the cavo-tricuspid isthmus|irrigated tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
45963142|NCT00196170|Procedure|cryo 6.5mm tip ablation of the cavotricuspid isthmus|cryo 6.5mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
45963143|NCT00168935|Drug|Fresubin protein energy Drink (CAVE! nutritional intervention)|
45963144|NCT02901340|Dietary Supplement|one to two liters of water daily|
45963145|NCT02901106|Drug|Dimethyl fumarate|"Patient follow-up at 6, 12, 18, 36, and 60 months after the start of Dimethyl fumarate~Systematization of cerebral MRI examination at 18 month and 5 years from the beginning of treatment by Dimethyl fumarate"
45963146|NCT04723628|Behavioral|Intervention group (telephone counseling)|Then, each patient was given 45-60 minutes of individual instruction. The patient training content was prepared based on the Knowledge, Motivation and Behavioral Skills Model (IMB). A total of 12 weeks of follow-up was performed with a weekly short reminder message and a two-weekly phone call. The research data were collected again at the end of 12 weeks.
45821477|NCT00000781|Drug|Nevirapine|
45821478|NCT00000781|Drug|Zidovudine|
45963147|NCT02901223|Procedure|Standard quadrantectomy|standard conservative surgery with no use of any plastic techniques
45963148|NCT02901223|Procedure|oncoplastic breast surgery|Integration of plastic techniques with oncological procedures
45963149|NCT00196209|Procedure|catheter ablation|catheter ablation to treat persistent atrial fibrillation
45963150|NCT00196209|Procedure|external electric cardioversion|external cardioversion and drug prophylaxis to treat persistent atrial fibrillation
45455419|NCT01222429|Other|vegan diet|Intervention group participants will follow a low-fat vegan diet and will receive instruction on this diet through the course of the study
45455420|NCT01222429|Other|diet following ADA guidelines|participants will be given instruction on the ADA guidelines for diabetes, and will follow an individualized plan based on these guidelines
45455421|NCT03932071|Drug|Zoledronic Acid|
45455422|NCT03931759|Diagnostic Test|laparoscopic surgery|patients with diabetes mellitus in laparoscopic surgery
45455423|NCT01218841|Dietary Supplement|Fish oil lipid emulsion|0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
45963151|NCT02901145|Drug|Nivolumab,low dose cyclophosphamide|treatment with IV Nivolumab 3mg/kg every 2 weeks . after a month-addition of low dose cyclophosphamide at a starting dose of 50 mg/kg/day x7 days every 14 days with dose adaptation based on level of Tregulatory cells on follow up immunophenotype.
45963152|NCT02901301|Drug|Pembrolizumab|200mg, IV, q3weeks, Day 1
45455424|NCT01218841|Dietary Supplement|MCT/LCT|0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
45666310|NCT01855126|Other|Red light|After a two week baseline collection period, half of the subjects will initially be given light masks that deliver red light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that red light exposure will have no effect on the timing of the CBTmin.
45666311|NCT04717479|Other|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
45666312|NCT01622673|Drug|Raltegravir|"Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours~Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
45821479|NCT00000781|Drug|Zalcitabine|
45821480|NCT00000781|Drug|Didanosine|
45821481|NCT03486704|Behavioral|Face to Face VRRS and telerehabilitation|"Face to Face cognitive training using VRRS plus telerehabilitation. Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Cognitive training will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.~The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
45821482|NCT03486704|Behavioral|Usual rehabilitation program|The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.
45963153|NCT02901301|Drug|Trastuzumab|6mg/kg (8mg loading dose), IV, q3weeks, Day 1
45963154|NCT02901301|Drug|Capecitabine|1000mg/m2, PO, BID, Day 1-14
45963155|NCT02901301|Drug|Cisplatin|80mg/m2 (level 1), IV, q3weeks, Day 1
45963156|NCT02901028|Other|Laboratory testing|Subjects will visit the Human Performance Laboratory on two separate occasions to perform the testing procedures. testing consists of VO2, strength, biomechanics, dynavision, etc.
45963157|NCT02901028|Other|Blood and Urine Draws|subjects will have a blood draw and provide a urine sample
45963158|NCT02900989|Behavioral|Suicide screening|"Patients of the emergency unit usually do not pass this kind of questionnaire in the absence of warning signs. Then it could result in adverse effects on behavior and ideation.~The study had to be declared as an interventional study according to French law."
45963159|NCT02900950|Procedure|Multicolour inking specimens|
45666313|NCT01622673|Drug|TUMS® Ultra Strength|"3 tablets TUMS® Ultra Strength (US) 1000 mg~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
45963160|NCT02900950|Procedure|Monocolour inking specimens|
45963161|NCT00169013|Drug|Gabapentin|
45963162|NCT02900911|Other|Early rehabilitation|"Early swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting 2 weeks before radiotherapy~Expiratory/Inspiratory training: the training load is the maximum inspiratory/expiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), three times a day.~All sessions will be conducted under the supervision of an expert physiotherapist/swallowing therapist. The total duration of the training program is 6 months."
45963163|NCT02900911|Other|Late rehabilitation|Late swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting after completing radiotherapy
45963164|NCT02900716|Drug|DTRMWXHS-12|DTRMWXHS-12
45666314|NCT01622673|Drug|MINTOX® Maximum Strength|"20 mL MINTOX® Maximum Strength (MS)~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
45963165|NCT02900716|Drug|DTRM-505|DTRMWXHS-12 and everolimus
45963166|NCT02900716|Drug|DTRM-555|DTRMWXHS-12 and everolimus and pomalidomide
45666315|NCT01855048|Biological|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
45666316|NCT01855048|Other|INT200-Placebo|Formulation buffer for continuous intravenous infusion over 60 minutes
45666317|NCT02469857|Drug|AB103 0.5 mg/kg|
45666318|NCT02469857|Other|NaCl 0.9%|
45963167|NCT00169052|Behavioral|Health Care Management and Supported Rehabilitation|
45963168|NCT02900599|Other|Observationnal (no intervention)|
45963169|NCT02900677|Behavioral|Physical and nutrition program|6 education programs with physical enhancement and nutrition related information for 12 weeks
45963170|NCT02900794|Device|Gold Laser|Under endoscopic visualization, the Gold Laser will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary.
45963171|NCT02900794|Procedure|Microdebridement|Under endoscopic visualization, the microdebrider will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates.
46079858|NCT03800940|Procedure|Fistulography and trans-drain occlusion|"Fistulography: an 18G needle is inserted into the tube and diluted contrast medium is slowly injected into the tube.~Trans-drain occlusion: a 0.035-inch guidewire is inserted via the puncture needle. The drain tube is removed, cut at 4 cm proximal to the skin fixation site, and preserved for reinsertion. After inserting a 40cm 5Fr KMP catheter over the guidewire, the guidewire is removed. Afte rinsing the KMP catheter with 3ml 5% glucose water, withdraw the catheter and simultaneously inject glue (33%, 1:2, 0.5ml of NBCA + 1ml Lipiodol) into the catheter until the proximal 5cm of the catheter remains inside the tract. The guidewire is re-inserted through the catheter, and then the original drain tube is re-inserted over the guidewire. The guidewire is removed and the drain is fixed."
46079859|NCT03800940|Procedure|Fistulography|Fistulography: an 18G needle is inserted into the tube and diluted contrast medium is slowly injected into the tube.
46079860|NCT03785925|Biological|Bempegaldesleukin|Specified dose on specified days
46079861|NCT03785925|Biological|Nivolumab|Specified dose on specified days
46079862|NCT03781154|Behavioral|Group Exercise|Patients will exercise in a virtual group for 60 minutes, twice a week. Five social-cognitive theory-based discussion sessions with the group, and group exercise instructor will be held throughout the course of the intervention, lasting 30 to 60 minutes. The goal of these sessions is to enhance long-term physical activity behavior change.
46079863|NCT03768700|Other|Data gathering|Questionnaires and collection of medical data on patients during hospitalization, at D28, at 90 and at 1 year
46079864|NCT03764514|Device|Spinal Cord Stimulator|Permanent Implantation
46079865|NCT03763357|Device|Heat Therapy (HT)|Water at 42-43 degrees C will be circulated through the water circulating trousers to obtain calf skin temperature 39 degrees C followed by PET/CT imaging of generator-based 62Cu-ETS.
46079866|NCT03757845|Other|Mediterranean Diet|subjects will be asked to eat from a sub-menu items compliant with Mediterranean Diet
46079867|NCT03752398|Biological|XmAb®23104|Monoclonal bispecific antibody
46079868|NCT03752398|Biological|Yervoy® (ipilimumab)|Monoclonal antibody
46079869|NCT03750318|Device|Vital sign monitoring|Each patient will be set up for monitoring on admission. Duration of opioid therapy for post-operative in-patients may range from 1-3 days. Once opioid therapy is no longer required, Aingeal monitoring will be ended and each patient would be encouraged to have at least 1 day Aingeal monitoring to be recorded during the study. De-identified log files will be extracted from the Surveillance Station and reprocessed to produce counts of the number of alarms raised during monitoring. A sample of the data will be reviewed to determine whether cardiac and respiratory alarms are defined as True or False, with an overall Alarm Rate per patient per day and False Positive Alarm Rate per patient per day derived. Vital sign trend graphs for each patient will be produced.
46079870|NCT03734692|Drug|Rintatolimod|200 mg by IP administration over 1-2 hours
46079871|NCT03734692|Drug|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion
46079872|NCT03734692|Drug|Cisplatin|50mg/m^2 solution
45666319|NCT04960865|Other|Kinesio Taping under tension.|Kinesio tape will be applied to participants under tension.
46079873|NCT03717298|Dietary Supplement|Ocoxin-Viusid®|"An oral solution of Ocoxin-Viusid® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT.~The treatment with Ocoxin-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously from the inclusion of the patient in the study, up to one year."
46079874|NCT03700476|Drug|Sintilimab|Sintilimab 200mg will be given every 3 weeks for 12 cycles, started on day 1 of induction chemotherapy.
45821483|NCT03486704|Behavioral|FTF VRRS plus unstructured CS|"Face to Face cognitive training using VRRS plus at-home unstructured cognitive stimulation.~Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week."
45963172|NCT00169091|Drug|Clozapine|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 12.5 mg on Day 1 to up to 300 mg on Day 12.
45666320|NCT04960865|Other|Kinesio Tape without tension|Kinesio tape will be applied to participants without any tension.
45666321|NCT04960865|Other|Rigid Taping|Rigid Taping will be applied.
45666322|NCT02036853|Drug|Triheptanoin|"Schedule A: Subjects previously treated with triheptanoin will continue to dose at approximately 35% of total daily calories (~1-4g/kg/day, depending on age).~Schedule B: Subjects who are naïve to triheptanoin will begin a 2-week fixed titration schedule up until they have reached 35% of total daily calories (~1-4 g/kg/day depending on age). If a subject has not reached the target of 35% of total daily calories, by the end of the 2-week fixed titration period, dose titration should continue until achieved or until the maximally tolerated dose has been established."
45963173|NCT00169091|Drug|Haloperidol|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 2 mg on Day 1 to up to 12 mg on Day 12.
45666323|NCT02469623|Device|Dipole Density Mapping with AcQMap followed by ablation|
45666324|NCT02469077|Behavioral|6 week aerobic exercise intervention|"Participants randomly assigned to the 6 week aerobic exercise intervention will complete an 18 session aerobic exercise manipulation supervised by an American College of Sports Medicine-certified personal trainer (3 exercise sessions per week for 6 weeks).~Each exercise session will consist of a 5 minute warm-up, 30 minutes of aerobic exercise, followed by a 5 minute cool-down period. Aerobic exercise will consist of treadmill walking/running, stepping, elliptical, or cycling exercise as preferred by the participant. Duration of exercise will be standardized at 30 minutes with a target exercise intensity between 70-85% Heart Rate Reserve (RPE = 15, hard). Because of the focus on de-conditioned individuals with Chronic Low Back Pain, the duration and intensity of exercise will be progressively increased up to target during the first two weeks to avoid symptom exacerbation and minimize study drop-out."
45963174|NCT02900755|Drug|Perampanel|The subjects will be administered oral perampanel for six months. Dose will be titrated according to the tolerance and be maintained at least 1 month before second EEG evaluation.
45458301|NCT01350752|Behavioral|Extended provider training (Cameroon only)|2-day training course which supplements basic provider training on malaria diagnosis and treatment, which focuses on understanding change in malaria treatment guidelines, professionalism, and communication skills
45666325|NCT02469077|Drug|Placebo|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
45666326|NCT02469077|Drug|Morphine|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
45666327|NCT02469077|Drug|naloxone|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
45666328|NCT02486627|Drug|plazomicin|
45963175|NCT02900638|Behavioral|Mentoring|Youth in the intervention group will participate in one-on-one mentoring sessions (between mentors and mentees) once per week after school. Mentoring sessions will focus on the development of a social bond between mentor and mentee.
45963176|NCT02900209|Other|Influenza Vaccination|
45963177|NCT00169130|Drug|doxorubicin|
45963178|NCT00169130|Drug|cyclophosphamide|
45963179|NCT00169130|Procedure|Autologous stem cell transplantation|
45963180|NCT02900404|Other|XAPPORT|A mobile device app based on different guidelines provides adequate guidance to physicians attending patients undergoing elective surgery, who have to interrupt treatment with rivaroxaban for surgery, in deciding how to approach the pre- and postoperative management of anticoagulation.
45963181|NCT02900404|Other|"Expert Panel (gold standard)"|A national panel of experts comprising anesthetists and surgeons from various disciplines advised in developing an algorithm supporting physicians how to approach the perioperative management of anticoagulation in patients receiving rivaroxaban and requiring elective surgery.
45963182|NCT02900248|Other|Provider determined|Provider will treat patient as he/she feels best
45963183|NCT00178620|Drug|Retavase 10 U IV Bolus|Retavase IV Bolus, 10 U, one dose at time of myocardial infarction
46079875|NCT03700476|Drug|Gemcitabine|Gemcitabine 1g/m2, d1 & 8 of every cycle, every 3 weeks for 3 cycles before radiation.
46079876|NCT03700476|Drug|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
45963184|NCT00178620|Procedure|Angioplasty/Heart Catheterization|"Candidates will receive all the approved standard therapy for heart attacks patients and will go directly for emergent heart catheterization.~Following local anesthesia, a small flexible tube (catheter) will be inserted in an artery of your leg and advanced to the arteries of your heart. By injecting x-ray contrast through the catheter, any blockage in the artery can be seen. If your heart attack artery is still blocked by blood clot or cholesterol deposits, it will be opened up by angioplasty (balloon surgery procedure to open the blocked artery) and stenting (placement of a slotted metal tube in the artery to prevent it from closing on itself)."
45963185|NCT00178620|Device|Drug eluting stent placed in heart attack related artery|Stents will be placed (if needed) during the end of the angioplasty/heart catheterization.
45963186|NCT02900365|Procedure|early cataract surgery & IOL implantation|first week cataract extraction and IOL implantation.
45963187|NCT02900365|Procedure|late cataract surgery & IOL implantation|first month cataract extraction and IOL implantation.
45963188|NCT00169169|Drug|ACVBP|
45963189|NCT00169169|Drug|ACE|
45666329|NCT02486627|Drug|meropenem|
45963190|NCT00169169|Drug|rituximab|
45963191|NCT00169169|Procedure|Autologous stem cell transplant|
45963192|NCT02900014|Procedure|sampling mesenchymal stem cells|nasal mesenchymental stem cells are collected in patients with cleft undergoing general anesthesia, during the initial surgical management of cleft
45963193|NCT02900131|Drug|Jaungo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in trial group 2 will apply Jaungo to the lesion twice a day for three weeks.
45963194|NCT02900131|Drug|Placebo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in control group will apply placebo to the lesion twice a day for three weeks.
45666330|NCT02486627|Drug|levofloxacin (oral)|
45666331|NCT01644565|Biological|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5|
45666332|NCT01644565|Biological|Recombinant fimbrial adhesin dscCfaE|
45666333|NCT01644565|Biological|Modified E. coli heat labile enterotoxin LTR192G|
45963195|NCT04681261|Other|this study is not an intervention study|this study is not an intervention study
45963196|NCT00169208|Drug|rituximab|375 mg/m² IV, D1 each cycle during 4 cycles
45963197|NCT00169208|Drug|fludarabine|40 mg/m²/day IV , D1 each cycle during 4 cycles
45666334|NCT02485925|Device|THERMOCOOL® SMARTTOUCH™|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH™ contact force sensing catheters (study device)
45666335|NCT04936217|Other|Data collection|For each patient, the following data will be collected and analyzed: age at operation, sex, Body Mass Index (BMI), ASA score, ASIA score, type of bladder dysfunction assessed by urodynamic evaluation, urinary abnormalities assessed by morphological examination (ultrasound and / or computed tomography) and cystoscopy, creatinine clearance, operative indications, initial mictional mode, surgical assembly, immediate and later complications.
45666336|NCT04936217|Other|Interview using a validated questionnaire|A telephone survey will be conducted by means of a questionnaire in order to evaluate the patient's quality of life.
45666337|NCT02282293|Drug|Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)|
45666338|NCT02282293|Drug|Monthly placebo + daily trimethoprim/sulfamethoxazole (TS)|
45666339|NCT01854658|Drug|GFF MDI (PT003)|GFF MDI administered as two puffs BID
45666340|NCT01854658|Drug|GP MDI (PT001)|GP MDI administered as two puffs BID
45666341|NCT01854658|Drug|FF MDI (PT005)|FF MDI administered as two puffs BID
45963198|NCT00169208|Drug|mitoxantrone|10 mg/m² IV, D2-3-4 each cycle during 4 cycles
46079877|NCT03700476|Radiation|intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
46079878|NCT03676998|Device|Measurement of diaphragm function|A bilateral magnetic stimulation induces a non voluntary diaphragm contraction and a drop in airway pressure that is measured.
45666342|NCT01854658|Drug|Placebo|
45666343|NCT01892020|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
45963199|NCT02899975|Other|Validation|Validation of fitness and information software for elderly and caregivers. The participants use a Fitness Software for 2-3 months in their own homes. They should use it 3 times a week The aim of this Intervention is to find out if the regularly use of the Software maintains or improves your physical capabilities. The caregivers also use the games and get a lot of Information about supporting the elderly Person in their everyday life
45963200|NCT02899936|Drug|3 drug dose - IDA|Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
45963201|NCT02899936|Drug|2 drug dose - DA|Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA)
45963202|NCT00178698|Other|thermochemotherapy|cisplatin 60 mg/m2 i.v. over 4 hours on day 1 gemcitabine 600 mg/m2 i.v. over 60 minutes on day 3 interferon-alpha 1 million international units s.c. daily for protocol duration
45963203|NCT00178698|Drug|Cisplatin, Gemcitabine, Interferon-a|cisplatin 60 mg/m2 i.v. over 4 hours gemcitabine 600 mg/m2 i.v. over 1 hour interferon-alpha 100,000 i.u. s.c.daily fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration
45963204|NCT00178698|Other|thermochemotherapy|After hydration and anti-emetics, cisplatin 60 mg/m2 i.v. is given over 4 hours on day 1. Also on day 1, begin daily low-dose interferon-alpha 1 million international units s.c. On day 3, 36 hours after cisplatin infusion, induce fever-range whole-body thermal therapy to 40 oC (104 oF) for a duration of 6 hrs. When the target temperature of 40 oC is reached, gemcitabine 600 mg/m2 is administered i.v. over 60 minutes, and the temperature is maintained at plateau for a total of 6 hours. The cycle is repeated at 21 to 28 day intervals.
45963205|NCT02899897|Device|echocardiography in IV fluid therapy|
45963206|NCT00169247|Drug|cetuximab|
45963207|NCT00169247|Drug|Cisplatin|
45963208|NCT00169247|Procedure|Radiotherapy 70 Gy, 35 fractions|
45963209|NCT02899819|Other|meconium|The meconium will be sampled in the first 2 days of life
46079879|NCT03669627|Biological|aTIV Primer|MF59-adjuvanted trivalent influenza virus primer: 2 doses (0.25mL) one month apart
46079880|NCT03669627|Biological|QIV Primer|Unadjuvanted quadrivalent influenza vaccine primer: 2 doses (0.5mL) one month apart
45666344|NCT01892020|Drug|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
46079881|NCT03669627|Biological|aTIV Booster|MF59-adjuvanted influenza virus vaccine booster: 1 dose (0.25mL), year 2
46079882|NCT03669627|Biological|QIV Booster|Unadjuvanted quadrivalent influenza vaccine booster: 1 dose (0.5mL), year 2
46079883|NCT03661970|Other|Cognate Speech Synthesizer sound percepts|The cognate speech synthesizer will generate an acoustic output, as well as a visual display of the acoustic signals. The outputs on the monitor and the synthesizer will be recorded.
46079884|NCT03644667|Biological|tocilizumab|6 doses: 8mg/kg (maximum of 800 mg) given once every four weeks by intravenous infusion over a 20-week period, with a minimum of 21 days between each infusion.
46079885|NCT03644667|Biological|Placebo|The placebo is 0.9% sterile normal saline. 6 doses: 8mg/kg (maximum of 800 mg) given once every four weeks by intravenous infusion over a 20-week period, with a minimum of 21 days between each infusion.
45666345|NCT02485691|Drug|cabazitaxel XRP6258|Pharmaceutical form: solution Route of administration: intravenous
45666346|NCT02485691|Drug|enzalutamide|Pharmaceutical form: capsule Route of administration: oral
45666347|NCT02485691|Drug|abiraterone acetate|Pharmaceutical form: tablet Route of administration: oral
45666348|NCT02485691|Drug|prednisone|Pharmaceutical form: tablet Route of administration: oral
45821484|NCT03486704|Behavioral|Face to Face VRRS plus active tDCS and telerehabilitation|"Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics.~The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
45821485|NCT03486704|Behavioral|Face to Face VRRS plus placebo tDCS and telerehabilitation|"Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with placebo tDCS applied to the dorsolateral prefrontal cortex of the left hemisphere over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics.~The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
45821486|NCT04712708|Device|Rebound Therapy|Rebound therapy is the therapeutic use of full sized trampoline or mini sized trampoline. It provides opportunities for exercise recreation and therapy; and it is distinct from gymnastic trampolining. It is used for facilitating movements, improving balance, enhancing coordination and promoting motor performances in children with different disorders includes learning disabilities, communication disorders and motor dysfunction (Rebound Therapy South Africa, 2020; The Chartered society of Physiotherapists, 2016).
46079886|NCT03644667|Drug|Standard of Care Triple IS|"Standard of care triple maintenance IS includes:~A calcineurin inhibitor-tacrolimus (Prograf ®) per site standards by sublingual, oral or intravenous route to attain target trough levels.~Exception: Should a participant be unable to tolerate tacrolimus, the site physician investigator may choose cyclosporine treatment.~An anti-proliferative treatment-mycophenolate mofetil or Myfortic® (enteric-coated mycophenolate sodium) will be administered, per protocol.~Exception: Should a participant be unable to tolerate mycophenolate mofetil, the site physician investigator may choose an alternative treatment.~Steroids-methylprednisolone/prednisone dosing will be given according to the local center standard of practice early post transplantation. After 6 months, prednisone may be withdrawn at the discretion of the site physician investigator, per protocol."
46079887|NCT03638141|Drug|Durvalumab|Durvalumab IV
46079888|NCT03638141|Drug|Tremelimumab (Cohort A dose)|Tremelimumab IV
46079889|NCT03638141|Drug|Tremelimumab (Cohort B dose)|Tremelimumab IV
46079890|NCT03573453|Other|enteral nutrition|administration of enteral nutrition
46079891|NCT03531463|Procedure|Operative treatment with Reversed Total Shoulder Prosthesis|"The standardized approach is the delto-pectoral to minimize any damage of the deltoid muscle. A cemented monoblock humeral stem will be implanted. Braided polyester suture-cerclages engaging the insertion of the subscapular and infraspinatus tendons enforced by a bonegraft or a horseshoe-graft from the humeral head will be used"
46079892|NCT03530384|Other|Cognitive training|Computerized cognitive training targeting inhibitory control of motor response used during 45 minutes sessions twice a week for 6 weeks
46079893|NCT03530384|Other|Control training|Fictitious computerized training used during 45 minutes sessions twice a week for 6 weeks
46079894|NCT03481933|Device|Transcranial stimulation|"10 days of stimulation (20min, 1.59mA) in double-blind sham-controlled. 3 arms (N=20 in each arm):~left-excitatory tDCS (N=20)~right-inhibitory tDCS (N=20)~sham tDCS (N=20)~4 language/semantic evaluations: base-line; 3 days; 2 weeks; 4 months post-tDCS~2 MRI/PET acquisitions: pre-stimulation (base-line); 2 weeks post-tDCS"
46079895|NCT03466463|Genetic|GNT0003|Intravenous infusion, single dose
46079896|NCT03442816|Device|MHRC Camera|Evaluate the technical capabilities of the device to obtain quality images in reflectance and fluorescence imaging modes in a diverse population.
46079897|NCT03427411|Drug|M7824|Flat dose of 1,200 mg of M7824 intravenous (IV) once every 2 weeks
46079898|NCT03420807|Device|MHRC|Evaluate the feasibility of detection of beta-amyloid plaques by using their spectral signature in autofluorescence or reflectance.
45666349|NCT02517515|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
45666350|NCT02517515|Drug|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
45666351|NCT02466659|Device|CIAO therapy Amblyz glasses|3-hour CIAO Therapy Amblyz glasses
45821487|NCT04712708|Other|Physical Therapy Program|"The Mat Exercises:~Stretching exercises to all spastic muscle groups (Kalkman et al., 2018). Gentle exercises was applied for 40-60 seconds and repeated from 3-5 times/ movement as supported by (Fragala et al., 2003).~Strengthening Exercises:~Dynamic Rising Positioning~The Gym Exercises:"
45963210|NCT02899702|Drug|PRIVIGEN (CSL Behring)|"Single administration of intravenous immunoglobulin solution Privigen® (CSL Behring AG, Bern, Switzerland) at a dose of 2g / kg. IGIV 2g/kg within 12 hours following PICU admission (or outbreak of first shock signs).~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
45963211|NCT02899702|Drug|Albumin|"4%(LFB) ALBUMIN Single administration of human Albumin 4% diluted albumin (VIALEBEX® LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg (4gG, 100 ML, Sodium chloride 0.61 G / 100ML Water for injections QSP 100 ML Sodium caprylate 0.3 G / 100ML) We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
45963212|NCT02899780|Device|Ultraviolet light emitting optical fiber|A ultraviolet light emitting optical fiber will be threaded through the existing catheter and withdrawn.
45821488|NCT04276064|Device|Auditory closed-loop stimulation: slow oscillation boosting|Auditory-closed loop stimulation: slow oscillation boosting
46079899|NCT03416868|Behavioral|Ambulatory voice biofeedback|Patients will be provided cues regarding their vocal behavior in daily life. Depending on the result of Study 1 in this IRB protocol/NIH grant, The cues will either be: 100% feedback = a vibrotactile cue on a smartwatch every time the patient voices incorrectly... 25% feedback = a vibrotactile cue on a smartwatch every 4th time the patient voices incorrectly... Summary feedback = the patient's overall compliance (percentage of voiced time within desired limits) will be presented via a smartwatch every 2 minutes of voicing.
45963213|NCT00169286|Procedure|Telephone care management|
45963214|NCT00169286|Procedure|peer-led chronic disease self-management workshop|
45963215|NCT00169286|Procedure|professionally-led cognitive behavioral psychotherapy group|
45963216|NCT02899741|Drug|Omega-3|1000mg every day for 90 days
45963217|NCT02899624|Biological|Extra blood draw samples|
45963218|NCT02899624|Biological|additional tissue samples|
45963219|NCT00178737|Behavioral|Electronic reminder message|
45963220|NCT00169325|Procedure|Magnetic resonance imaging|
46079900|NCT03402269|Other|Clavicle fracture injury- observation|The study is an observational study with assessments at 1 month, 3 months, 6 months and 1 year following injury. Assessments include range of motion, strength, patient reported outcomes and radiographic healing
46079901|NCT03386396|Dietary Supplement|High protein/low carbohydrate|A high protein/low carbohydrate shake will be given to the child.
46079902|NCT03386396|Dietary Supplement|High carbohydrate/low protein|A high carbohydrate/low protein shake will be given to the child
46079903|NCT03371719|Drug|Apalutamide|Given PO
45458302|NCT01350752|Behavioral|School based malaria education (Nigeria only)|Schools will be invited to undertake activities to raise awareness about malaria RDTs and treatment among children and community members. The intervention includes training teachers on peer health education, malaria awareness activities and providing support to hold a malaria educational event
45458303|NCT04462978|Other|Non IgE-mediated food allergy|
45963221|NCT02899585|Other|Questionnaires|
45963222|NCT02899585|Other|Score|
46079904|NCT03371719|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
46079905|NCT03371719|Other|Placebo|Given PO
45963223|NCT02899507|Drug|Amoxicillin-Clavulanic acid|Patients without evidence of tracheobronchial aspiration were randomized to immediate prophylactic Amoxicillin-Clavulanic acid 1,2 gr/8h
45963224|NCT00178776|Behavioral|Transtheoretical Model Group Therapy|
45963225|NCT00178776|Behavioral|Education & Advice|
45963226|NCT02899234|Other|E-cigarette|A third generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings.
45963227|NCT00169364|Device|positron emission tomography|
45963228|NCT02899390|Behavioral|Lifestyle Intervention|"Before implementation of the National Diabetes Prevention Program, adaptations will be made in order to be culturally acceptable in the community taking in consideration the type of food they eat and their activities in the population.~The lifestyle intervention will be implemented by group and individual sessions and is aimed at achieving a 7% loss weight from baseline and 150 minutes per week of physical activity. Sessions will be held weekly in a period of 6 months. Individual sessions consist in nutritional counseling according to energy needs and food preferences of each participant."
45963229|NCT00178854|Drug|Risperidone|
45963230|NCT02899351|Device|Respiratory Volume Monitor|
46079906|NCT03367702|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
46079907|NCT03367702|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
46079908|NCT03335657|Other|CBPT|The CBPT program focuses on a patient-oriented cognitive-behavioral self-management approach to improve physical function and reduce pain, through reductions in pain catastrophizing and fear of movement and increases in self-efficacy.
46079909|NCT03335657|Other|Education Treatment|Participants receiving the education control arm are receiving a placebo intervention to control for the attention of the interventionist. They will receive standardized educational material addressing recovery from orthopaedic trauma.
45821489|NCT04276064|Device|Auditory closed-loop stimulation: slow oscillation disruption|Auditory closed-loop stimulation: slow oscillation disruption
45821490|NCT04276064|Device|Sham stimulation|Sham stimulation
45821491|NCT00000343|Behavioral|counseling|
45821492|NCT04388384|Drug|Neratinib|Neratinib standard dose 240 mg once daily for 1 year
45963231|NCT00169403|Procedure|Deep brain stimulation|
45821493|NCT00000787|Behavioral|Pre- and post-test counseling|
45821494|NCT00000349|Drug|Flupenthixol|
45963232|NCT02899468|Device|BrightBrainer Virtual Reality (BBVR) Rehabilitation System|During the active treatment stage (3 sessions per week x 6 weeks), each BBVR therapy session will consist of a series of custom games targeting one or several cognitive domains of executive function, attention, short-term memory, working memory and language comprehension. In addition, the BBVR device incorporates uni- and bi-manual activities by having the subject manipulate hand-held devices, which are programmed to measure in real time the subject's 3D hand movement and index flexion/extension. Therefore, in addition to completing the cognitive tasks, subjects must manipulate virtual hands through a hand-held interface to also enhance visual-motor perception, hand-eye coordination, and upper limb function. In addition, wrist weights can be added to increase upper limb strength training.
45963233|NCT02899117|Other|Yoga|There are 4 yoga sessions completed with a certified instructor during cancer treatment
45963234|NCT00196365|Drug|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily
45963235|NCT00196365|Drug|levonorgestrel/EE 0.15/0.03 mg tablets and placebo|1 tablet daily
45963236|NCT02898844|Behavioral|Mixed Diet Condition|One roommate dieted and the other ate normally.
45963237|NCT02898844|Behavioral|Both Diet Condition|Both roommates dieted.
45963238|NCT00407576|Drug|[11C]MeS-IMPY|
45963239|NCT02898922|Biological|hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae|20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China
45821495|NCT00000805|Drug|Ganciclovir|
45821496|NCT04270682|Drug|Blinded CDCA 250 mg TID|Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
45963240|NCT02898961|Drug|30 mg/kg amikacin or 8 mg/kg gentamicin|"In order to improve the achievement of target peak concentrations, either 30 mg/kg amikacin or 8 mg/kg gentamicin was prescribed in ICU patients with severe sepsis.~In combination with broad-spectrum antibiotics, according to the suspected pathogens and local clinical practice, 30 mg/kg amikacin or 8 mg/kg gentamicin was given (30 min intravenous infusion; the dosage ampoule was systematically emptied with a 5 ml flush). The peak serum concentration sampling occurred 30 minutes after the end of the infusion."
45963241|NCT02898805|Other|Placebo|
45963242|NCT02898805|Other|Prescribed Diet|
45963243|NCT02898805|Dietary Supplement|LopiGLIK®|
45963244|NCT02898805|Dietary Supplement|Armolipid Plus|
45963245|NCT00196404|Drug|DR-3001a|4mg daily vaginally
46079910|NCT03333954|Device|PRIMA|"The PRIMA Bionic Vision System is a device for treatment of patients who have lost their sight through outer retinal degenerative conditions of the eye such as atrophic dry age related macular degeneration.~The PRIMA System is designed to provide partial restoration of the patient's visual function through electrical stimulation of the retinal neurons by a sub-retinally implanted stimulator that replace part of the degenerate photoreceptors"
46079911|NCT03330106|Drug|Pevonedistat|Pevonedistat intravenous infusion.
46079912|NCT03330106|Drug|Docetaxel|Docetaxel intravenous infusion.
46079913|NCT03330106|Drug|Carboplatin|Carboplatin intravenous infusion.
45458304|NCT01238107|Drug|MT-102|BETA BLOCKER
45821497|NCT04270682|Drug|Placebo|Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
45963246|NCT00196404|Drug|DR-3001b|6 mg vaginally daily
45963247|NCT00196404|Other|Placebo|Administered vaginally to match experimental arms
46079914|NCT03330106|Drug|Paclitaxel|Paclitaxel intravenous infusion.
46079915|NCT03286530|Drug|Ruxolitinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive Ruxolitinib.~After the screening procedures confirm participation in the research study. The participant will be given a drug diary. The participant will be asked to document information in the drug diary about the study treatment."
46079916|NCT03239145|Drug|Pembrolizumab|Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells
46079917|NCT03239145|Drug|Trebananib|AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen
46079918|NCT03213951|Other|Experimental beta probe|3mCi (or similar) dose of 68Ga-PSMA-11 will be given prior to resection of cancer. Experimental beta probe designed to detect 68Ga-PSMA-11 will be used on prostate tissue after it has been surgically removed.
45821498|NCT04270682|Drug|Open-Label CDCA 250 mg TID|Adult cohort patients will receive open-label 250 mg CDCA TID during the run-in and washout periods of the study or as rescue medication during the double-blind periods, if needed, based on clinical symptoms.
45821499|NCT04270682|Drug|Rescue Medication CDCA 250 mg TID|CDCA 250 mg TID will be provided as rescue medication during the double-blind periods, if needed, based on laboratory results.
45821500|NCT04270682|Drug|CDCA Weight-Based Dose TID|Patients in the pediatric cohort will complete a weight-based dose titration to a tolerated dose and will maintain that tolerated dose for the remainder of the study. Pediatric cohort dosing of CDCA will not exceed an equivalent dose of 750 mg/day.
45821501|NCT00000355|Drug|Buprenorphine|
45821502|NCT04022785|Drug|Azacitidine|Given IV or SC
45821503|NCT04022785|Drug|BRD4 Inhibitor PLX51107|Given PO
45821504|NCT00383006|Behavioral|Skills for affect regulation (behavior)|
45963248|NCT02898883|Behavioral|Building Resilience after Childhood Emergencies (BRACE)|See arm/group description for details regarding this intervention
45963249|NCT02899039|Biological|extra blood draw samples|
45963250|NCT02898688|Behavioral|Control Site|Control sites will continue with their standard practice regarding discussing vaccines with their patients.
45963251|NCT02898688|Behavioral|Intervention Site|Intervention Sites will each assign a Vaccine Champion and will have Assessment, Feedback, Incentives, and eXchange (AFIX) visits. AFIX is a quality improvement program to raise immunization coverage levels, reduce missed opportunities to vaccinate, and improve standards of practices at the provider level. A Continuing Medical Education (CME) module will be given to all providers, covering the recommended maternal vaccinations and how to talk to patients about vaccines. Intervention sites will have access to written materials covering all recommended maternal and infant vaccinations, the diseases they prevent, potential adverse reactions and common patient questions with talking points and references for each topic.
45963252|NCT02898688|Behavioral|Patient-level Control Group|"Participants randomized the control arm will complete a computer-based questionnaire, on an iPad with a preloaded app. The questionnaire asks about vaccine knowledge, attitudes, and beliefs and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questionnaire includes questions requiring a yes or no response, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), questions to capture the vaccines participants plan to get for themselves and their children, and open-ended questions."
45963253|NCT02898688|Behavioral|Patient-level Intervention Group|"Participants randomized to the intervention arm will complete a computer-based questionnaire on an iPad with a preloaded app, prior to watching informational videos covering topics on maternal and childhood vaccines. The questionnaire asks about vaccine knowledge, attitudes, beliefs, and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questions require yes or no responses, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), and open-ended responses. After watching at least one informational video, the participant completes a questionnaire asking about the perceived usefulness of the app, degree of agreement with the vaccine information presented in the video, and ways to make the app more useful to participants."
45821505|NCT00000361|Drug|Corticosteroids|
45821506|NCT00000361|Drug|Methotrexate|
45963254|NCT02898766|Other|Enteral Nutrition Formula|
45963255|NCT02898571|Dietary Supplement|Placebo|Placebo comparitor
45963256|NCT02898571|Dietary Supplement|Vitamin C|Active treatment
45821507|NCT00000811|Drug|Azithromycin|
45963257|NCT02898571|Dietary Supplement|epicatechin|Active treatment
45963258|NCT02898649|Device|Irreversible electroporation|IRE is operated to tumor under laparotomy or CT-guided percutaneous approach. Unipolar (19G) or bipolar (16G) electrode probe is inserted to around tumor. After insertion of probe, short duration (70-90㎲) of electric current (25~45A) is generated by IRE device (NanoKnife IRE device, AngioDynamics, Queens bury, New York). It is possible to obtain a three-dimensional ablation zone using multiple electrode. IRE can cause apoptosis of tumor cells, without adjacent tissue damage.
45963259|NCT00553618|Drug|Proleukin and Dacarbazine|"IL-2 (Proleukin), injected just under the skin, at a dose of 12 million units on days 1-4 for each of the six months of therapy.~Dacarbazine, administered as an IV infusion through a freely flowing IV, at a dose of 750 mg, repeated every four weeks."
45963260|NCT02898337|Device|AliveCor handheld mobile ECG|"Specific Aim 1: independent risk factors for methadone-associated QTc interval prolongation will be determined through retrospective analysis of electronic medical records of methadone-treated patients in a narcotic treatment center. Patients will be asked to come to the Narcotic Treatment Center for one 12-lead ECG~Specific Aim 2: QTc intervals from ECGs generated by the AliveCor® heart monitor will be compared prospectively to simultaneous twelve lead ECGs for validation purposes in the methadone-treated patients in a narcotic treatment center."
45821508|NCT00000811|Drug|Atovaquone|
45821509|NCT00000811|Drug|Sulfamethoxazole-Trimethoprim|
45963261|NCT02898376|Other|skin-oriented spa care|"standardized procedure : 72 care sessions over 18 days of treatment~+/- Additional care according to the specificity of each spa"
45963262|NCT02898376|Drug|Pentoxifylline|400 mg bid during at least 6 months
45821510|NCT00000367|Drug|Treatment of depression|
45821511|NCT00000367|Behavioral|Suicide prevention intervention|
45963263|NCT02898376|Drug|Tocopherol acetate|500 mg bid during at least 6 months
45821512|NCT00000367|Drug|Suicide prevention treatment|
46079919|NCT03213951|Diagnostic Test|PSMA-PET|PSMA-PET imaging done prior to surgery and compared to whole mount imaging.
45821513|NCT04246970|Other|Prehabilitation|Supervised training program of 8-weeks and a frequency of 2 days/week. It includes interval aerobic exercise (5 cycles of 2 minutes at 70 percentage of Watts or heart rate of cardiopulmonary exercise testing (CEPT) and 3 minutes of active rest at 40 percentage; peripheral muscle training and balance exercises in a circuit of 10 phases, 10 to 15 repetitions, from 1 to 3 sets (the participants will work at moderate intensity, no more than 5-6/10 on the modified Borg scale); Inspiratory Muscle Training (IMT) through a threshold loading device [2 sessions / day, 3 sets of 15 repetitions, at 60-70 percentage of the maximum inspiratory pressure (cmH2O)]; ventilatory reeducation by an incentive inspirator based on the vital capacity evaluated in the initial spirometry. Both the aerobic modality and the resistance training, will increase the intensity of work (HR, Watts, Kg or cmH2O) between 2-5 percentage every 2 weeks complying with the principle of training overload.
45963264|NCT00196443|Device|urea contained compressing stockings|
45963265|NCT00196443|Device|compressing stockings|
45963266|NCT00169481|Biological|Pneumococcal (vaccine)|
45458305|NCT02316028|Drug|Decitabine|"administration of decitabine by hepatic arterial infusion~Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.~Proposed dose levels:~10 mg/m2 per course~15 mg/m2 per course~20 mg/m2 per course"
45458306|NCT01359488|Drug|VRS-317|VRS-317 Single Dose
45963267|NCT02898532|Behavioral|Educational programmes|Children with ADHD or ADHD-like symptoms practicing target shooting sport in Danish Shooting Associations, during schooltime, for 6 months.
45963268|NCT02898415|Procedure|Liver transplantation|
46079920|NCT03200626|Procedure|Autologous hematopoietic cell transplant|Autologous hematopoietic cell transplant
46079921|NCT03192696|Device|Atherectomy Catheter|Treatment of restenotic lesions within stents previously placed within the artery.
46079922|NCT03164564|Drug|Oral CAB|CAB 30 mg tablet
46079923|NCT03164564|Drug|Oral TDF/FTC|TDF/FTC 300 mg/200 mg fixed dose combination tablet
45821514|NCT04246970|Other|Prehabilitation and posttransplant training program|Prehabilitation will be followed by a posttransplant training program. In this, the patient will perform supervised exercise (IIa interval aerobic exercise and resistance training) 2 days / week, and a physical exercise program at home until completing a total of 5 sessions / week in the aerobic modality. In the unsupervised phase (IIb), the patient will continue with the learned physical exercise program, but without supervision, 5 sessions / week (including a minimum of 2 non-consecutive sessions to perform resistance training).
45821515|NCT00000373|Drug|olanzapine + fluoxetine|
45821516|NCT00000373|Drug|placebo + fluoxetine|
45821517|NCT00000823|Drug|Zidovudine|
45821518|NCT00000823|Drug|Didanosine|
45963269|NCT02898298|Behavioral|Positive Emotion Regulation Training|Participants will receive a 3-session psycho-educative training on emotion regulation.
45963270|NCT00408174|Drug|Balsalazide disodium|
45963271|NCT00169520|Drug|docetaxel|
46079924|NCT03164564|Drug|Placebo for oral CAB|Placebo tablets
46079925|NCT03164564|Drug|Placebo for oral TDF/FTC|Placebo tablets
46079926|NCT03164564|Drug|CAB LA|600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
46079927|NCT03164564|Drug|Placebo for CAB LA|Administered as one 3 mL intramuscular injection in the gluteal muscle
46079928|NCT03153410|Drug|Cyclophosphamide|"200 mg/m2 is to be administered as a 30 minute IV infusion one day prior to GVAX for a total of 8 doses.~Other Names:~Cytoxan CY"
45666352|NCT04957979|Other|Nursing/Medical Model of Care Coordination|"No social worker on the clinic's care coordination team.~Services provided:~Coordinated medical care for patients~Patient education~Assistance in developing care plan~Support for patient self-management~Referrals for continuing care~Referral to community resources~Referral to mental health services if needed or requested~Referral to interventional counseling for behavioral health issues"
45666353|NCT04957979|Other|Medical/Social Model of Care Coordination|"Social worker is part of the clinic's care coordination team.~Need not be licensed as a social worker~Must have time dedicated to care coordination for a specific clinic or clinics~Must interact with individual patients to provide them with services~Must interact with individual clinicians about their individual patients in care coordination~Services provided:~Coordinated medical care for patients~Patient education~Assistance in developing care plan~Support for patient self-management~Assistance with referrals for continuing care~Assessment and plan to address social and resource needs including housing, transportation or financial needs; Assist patient in locating and obtaining needed community resources~Assistance with identifying and addressing psychological/emotional issues and referrals as needed~Interventional counseling for behavioral health issues or referrals to interventional counseling, depending on licensure"
45455425|NCT01124383|Procedure|General anesthesia|For women in the general anesthesia group, general anesthesia is induced using midazolam 1-3 mg, sufentanil 0.15-0.25 mcg/kg and propofol 1-3 mg/kg. Rocuronium 0.6 mg/kg is allowed. Anesthesia is maintained with sevoflurane titrated to maintain a blood pressure within 20% of preoperative normal and, if needed, ephedrine can be used for this purpose. Patients are ventilated in a normocapnic range with a positive end-expiratory pressure of 3 to 5 mmHg.
45458307|NCT01359488|Drug|VRS-317|VRS-317 Single Dose
45666354|NCT01891864|Drug|GP2015 Etanercept|Sandoz has developed GP2015 Etanercept (Sandoz's code for the drug product containing the active ingredient etanercept) to be biosimilar to Enbrel.
45666355|NCT01891864|Drug|Enbrel|Enbrel is used as reference product to GP2015.
45666356|NCT02485301|Biological|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administrated intramuscular
45666357|NCT02485301|Drug|Placebo|A single dose administrated intramuscular
45821519|NCT04235660|Radiation|Yttrium-90 Radiation Segmentectomy|This therapy arm involves two separate steps, a planning/mapping arteriogram and a therapy delivery. The planning arteriogram will be performed to confirm arterial anatomy is acceptable for RS (≤2 segment delivery) and that lung shunting is not too high to preclude treatment with RS. Once confirmed, patients will return for RS (within 45 days of mapping). Dose will be calculated based off the desired treatment volume using pre-treatment cross-sectional imaging. The desired segmental dose will be calculated to be ≥ 200Gy. RS will be performed by one of three separate interventional radiologists with experience in radioembolization. Actual administered activity and location of dose administration will be recorded.
45963272|NCT00169520|Drug|SB-715992|
45458308|NCT01359488|Drug|VRS-317|VRS-317 Single Dose
46079929|NCT03153410|Drug|GVAX|"5E8 cells is to be administered one day after CY, pembrolizumab, and IMC-CS4/ LY3022855 for a total of eight doses.~Other Names:~Pancreatic cancer vaccine Panc 10.05 pcDNA1/GM-Neo, Panc 6.03 pcDNA1/GM-Neo"
46079930|NCT03153410|Drug|Pembrolizumab|"200 mg will be administered as a 30 minute IV infusion one day prior to the GVAX pancreas vaccine for a total of 18 doses.~Other Names:~MK-3475 KEYTRUDA"
45666358|NCT02484911|Drug|Olanzapine|5mg,twice a day orally on day 1 to day 4
45666359|NCT02484911|Drug|Aprepitant|125 mg capsule per oral, 1 hour before chemotherapy on day 1, 80 mg capsule daily in the morning during days 2 to 3.
45666360|NCT02484911|Drug|Palonosetron|0.25mg IV 30-60min before chemotherapy on day 1
45666361|NCT02484911|Drug|Dexamethasone|6mg IV on day 1 ，3.75mg IV on day 2 to 4
45666362|NCT04306367|Drug|Pembrolizumab|200 mg given intravenously.
45666363|NCT04306367|Drug|Olaparib|300 mg given orally.
45963273|NCT02898064|Device|thoracolumbosacral orthosis or cervicothoracolumbar orthosis|"An off the shelf spinal brace which will be applied to the patients trunk. They will have straps and harnesses which the patient can fasten and remove if needed. The brace will need to be worn by the intervention group all the time for 3 months except when lying in bed. In the presence of lower thoracic (T8 downwards), thoraco-lumbar and lumbar (L1- L3) fractures, a thoracolumbosacral orthosis will be applied. For upper thoracic fractures (T1-T7) a cervico-thoracic or cervico-thoraco-lumbar orthosis will be used."
45963274|NCT02898064|Other|Standard care|Standard surgery, radiotherapy, chemotherapy, drug therapy as applicable and decided by the participants consultant as part of standard care
45963275|NCT02897947|Procedure|Surgery for lumbar spinal stenosis in Norway|
45963276|NCT02897947|Procedure|Surgery for lumbar spinal stenosis in Sweden|Surgery for neurogenic claudication due to lumbar spinal stenosis in Sweden
45458309|NCT01359488|Drug|VRS-317|VRS-317 Single dose
45458310|NCT01359488|Drug|VRS-317|VRS-317 Single dose
45963277|NCT02897947|Procedure|Surgery for lumbar spinal stenosis in Denmark|Surgery for neurogenic claudication due to lumbar spinal stenosis in Denmark
45963278|NCT02897986|Drug|administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination|
45963279|NCT00169559|Drug|GW590735|1µg to 20µg daily doses of GW590735
45963280|NCT00169559|Drug|fenofibrate|Marketed Drug
45963281|NCT00408213|Drug|mycophenolate mofetil [CellCept]|1g po bid
45963282|NCT00408213|Drug|Placebo|po bid
45666364|NCT04925609|Drug|Brigatinib|Brigatinib is a second generation novel, orally administered, tyrosine kinase inhibitor (TKI) that potently inhibits activated variants of ALK and to a lesser extent ROS1.
45666365|NCT02466425|Drug|SHP465|12.5mg and 25mg capsules (one capsule daily)
45963283|NCT02898142|Other|Postprandial test|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting. This post prandial test is the same in the two study groups.
45963284|NCT02898025|Device|Active Interferential Current|Involves the application of medium frequency alternating currents
45963285|NCT02898025|Device|Active Laser|Involves the application of low level laser over the knee
46079931|NCT03153410|Drug|IMC-CS4|75 mg for dose level 1 and 100 mg at dose level 2 will be administered (Day 1, Day 8 and Day 15) as a 30 minute(s) IV infusion one day prior to GVAX pancreas vaccine for a total 18 doses.
45666366|NCT02466425|Drug|Placebo|Matching placebo capsule that appear identical in size, weight, shape, color
45666367|NCT04925453|Combination Product|active tDCS and cognitive training intervention|Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first 13 minutes (shut off: Minute 13) of the session and the last 13 minutes of the session (turn on: Minute 33). The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.
45666368|NCT04925453|Combination Product|sham tDCS and cognitive training intervention|Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first and last 13 minutes of the session. For sham stimulation, the electrodes will be placed at the same positions as for active stimulation, but current will be ramped down immediately after the initial 30s ramp up period. The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.
45666369|NCT04616014|Drug|ORMD-0801 QD|8 mg, QD
46079932|NCT03113422|Drug|Induction Venetoclax|"1 cycle = 28 days.~Cycle 1-6: Obinutuzumab IV. Cycle 1, Day 1 obinutuzumab 100 mg and Cycle 1, Day 2 obinutuzumab 900 mg for total dose of 1000 mg. On Cycle 1, Day 8 and Day 15 obinutuzumab 1000 mg. Starting with Cycle 2, obinutuzumab 1000 mg on Day 1 only of each cycle.~Cycle 1-6: Bendamustine 90 mg/m² IV on Days 1 and 2 of each cycle over 15 minutes after obinutuzumab.~Cycle 2-6: Venetoclax 800 mg by mouth daily on Days 1-10 administered before obinutuzumab and/or bendamustine."
45963286|NCT02898025|Device|Placebo Interferential Current|It is a sham interferential therapy
45963287|NCT02898025|Device|Placebo Laser|It is a sham laser therapy
45666370|NCT04616014|Drug|ORMD-0801 BD|8 mg, BD
45963288|NCT02897752|Device|gait training with WA|Thirty seven units (1 unit=20 minutes) of gait training with WA by a physical therapist for the WA group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
45963289|NCT02897752|Other|usual gait training|Thirty seven units of usual gait training by a physical therapist for the UT group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
45963290|NCT00196482|Drug|changing of fortifier|
45963291|NCT00169598|Procedure|positron emission tomography|
45666371|NCT02451917|Drug|Glargine insulin|The initial insulin dose for those randomized to IGlar was 80% of the total daily NPH dose that was being discontinued. All of them had pre-prandial Regular insulin switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. After 24 weeks, basal insulins were switched; in other words, individuals on IGlar in the first period switched to INPH, and the doses of pre-meal insulin were sustained
45666372|NCT02451917|Drug|NPH insulin|The same total daily NPH insulin dose was maintained for those randomized to INPH. All of them had pre-prandial Regular insulin (Humulin R™, Lilly, Brazil) switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. . After 24 weeks, basal insulins were switched; in other words, individuals on NPH in the first period switched to glargine insulin, and the doses of pre-meal insulin were sustained.
45666373|NCT02349451|Biological|adalimumab|
45963292|NCT02897713|Other|intensive enteral nutrition|After recruitment, patients should be assessed for EN initiation during first 24 hours after ICU admission. 80% of energy target should be reached within 72 hours.
45963293|NCT02897713|Other|routine enteral nutrition|Attendings decide when and how EN should be administered according to guidelines from academic organizations, such as ESPEN or ASPEN.
45963294|NCT02897635|Behavioral|Individualized Integrative Medicine Intervention|
45963295|NCT02897674|Dietary Supplement|Palm olein|two thirds of the 30% fat calories will come from palm olein
45963296|NCT02897674|Dietary Supplement|Interesterified palm olein|two thirds of the 30% fat calories will come from interesterified palm olein
45666374|NCT02349451|Biological|ABT-122|
45666375|NCT04956731|Other|Pharmacist Provision of Medication Abortion|Pharmacists providing start to finish medication abortions
45666376|NCT04956263|Drug|YG1699|"YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~The proposed dosage form is a yellow, film-coated tablet for oral administration. The proposed tablet strengths for the current clinical research are 5 mg and 25 mg. The tablets are packaged in high-density polyethylene (HDPE) bottles with HDPE caps and desiccant inserters. Each HDPE bottle contains 30 tablets of drug product.~The study drug YG1699 is manufactured by Youngene Therapeutics Inc., Ltd., China."
45666377|NCT04956263|Drug|Dapagliflozin|Farxiga® is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Faxiga® is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate. In addition, the film coating contains the following inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and yellow iron oxide.
45666378|NCT02409368|Drug|Nivolumab|
45963297|NCT02897674|Dietary Supplement|soybean oil|two thirds of the 30% fat calories will come from soybean oil
45963298|NCT00408252|Other|biopsies|No intervention, only biopsy for translational project
45963299|NCT00408252|Drug|SU011248|no intervention
45963300|NCT02897869|Drug|POL7080|7 doses of POL7080 alone over 2.5 days
45963301|NCT02897869|Drug|Amikacin|3 doses of Amikacin alone over 2.5 days
45963302|NCT02897869|Drug|POL7080 + Amikacin|7 doses of POL7080 and 3 doses of Amikacin over 2.5 days
45666379|NCT04898348|Drug|KBL697|3 capsules twice a day dosing of KBL697
45666380|NCT04898348|Drug|Placebo|3 capsules twice a day dosing of Placebo
45666381|NCT01853878|Biological|Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A|Intramuscular administration
45666382|NCT01853878|Biological|Placebo|Intramuscular administration
45666383|NCT04891484|Drug|Ondansetron group|patients will be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia
45666384|NCT04891484|Drug|Saline group|patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia
45666385|NCT02342678|Behavioral|Yoga Therapy|
45666386|NCT02342678|Behavioral|Physical Conditioning|
45963303|NCT00169637|Drug|rhGH|
45963304|NCT02897830|Drug|Ixazomib|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21)."
45963305|NCT02897830|Drug|Lenalidomide|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21).~Maintenance therapy will start within 28 days after the last dose of Lenalidomide in last cycle of Late Consolidation: Lenalidomide 10 mg/d taken on Days 1 through 21 for thirteen 28-day cycles"
45963306|NCT02897830|Drug|Dexamethasone|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week)."
45963307|NCT02897518|Device|Imago V-Balde|the endotracheal intubation will be performed with videolaryngoscopes (imago V-Blade) according to the user manual
45963308|NCT02897518|Device|Glidescope|the endotracheal intubation will be performed with videolaryngoscopes (Glidescope) according to the user manual
45963309|NCT00196521|Device|Tension-free vaginal tape obturator system|
45963310|NCT02897557|Device|Insulet Artificial Pancreas (AP) System|
45666387|NCT02408120|Drug|Insulin glargine|"Half of total daily dose (TDD) will be given as insulin glargine and will be given once daily, at the same time of the day.~Daily insulin dose will be adjusted as follow:~If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change~If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day~If the fasting and pre-dinner BG is >180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day~If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day~If a patient develops hypoglycemia (BG <70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%."
45963311|NCT00169676|Other|observation|registry and database for surgery outcomes
45666388|NCT02408120|Drug|Insulin aspart|"Half of total daily dose will be given as insulin aspart and in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, the dose of aspart will be held.~Daily insulin dose will be adjusted as follow:~If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change~If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day~If the fasting and pre-dinner BG is >180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day~If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day~If a patient develops hypoglycemia (BG <70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%."
45963312|NCT02897596|Drug|Grazoprevir 100 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Grazoprevir (100 mg) during 8 weeks.
45963313|NCT02897596|Drug|Elbasvir 50 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Elbasvir (50mg) during 8 weeks.
45963314|NCT02897596|Drug|Grazoprevir 100 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Grazoprevir (100 mg) during 12 weeks.
45963315|NCT02897596|Drug|Elbasvir 50 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Elbasvir (50mg) during 12 weeks.
45963316|NCT02897791|Behavioral|written evaluations|answering questions about pictures and stories
45963317|NCT02897440|Procedure|Full Repairng of soft tissue surrounding the hip|Full repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
45963318|NCT02897440|Procedure|Partial Repairng of soft tissue surrounding the hip|Partial repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
45963319|NCT04681027|Drug|Oxymorphone hydrochloride (HCl)|Opioid
45963320|NCT00408330|Drug|Azelaic Acid 15% Gel|15% gel, topically applied daily for six weeks
45963321|NCT00408330|Drug|Inactive 15% gel base|placebo, topically applied daily for six weeks
45963322|NCT00169715|Procedure|Percutaneous Caliceal Diverticuli|Standard of care to remove a stone from a caliceal diverticulum is to do a percutaneous procedure for stone removal and then fulgerate the diverticulum to prevent stone recurrence. We plan to aspirate urine from this diverticulum and compare it to urine collected from the renal pelvis of the same kidney.
45963323|NCT02897245|Other|No intervention|
45963324|NCT02897167|Genetic|Retrospective study of frozen samples|Frozen samples of serum and peripheral blood mononuclear cell (PBMC) stored in the Biobank Valdecilla will be selected.
45963325|NCT02897167|Genetic|Prospective study of fresh samples|Samples of serum and cells will be drawn.
45963326|NCT02897128|Other|Observational Only - Transcutaneous Oxygen Measurement|The transcutaneous oxygen at your surgical site will be measured at three time points prior to your surgery.
45963327|NCT00408369|Drug|DB289|
45963328|NCT00407615|Device|Flex Pad/Static Magnet|
46079933|NCT03113422|Drug|Maintenance Venetoclax|Patients whose disease is the same or improved will receive venetoclax 800 mg by mouth daily for 24 cycles (1 cycle=1 month) and obinutuzumab 1000 mg IV every 2 months for 12 cycles. Patients with no evidence of disease will receive obinutuzumab 1000 mg IV every 2 months for 12 cycles.
46079934|NCT03103841|Procedure|Sleep studies [Polysomnography]|Undertaking of sleep measurements by polysomnography and use of validated sleep questionnaires
45458540|NCT03493672|Diagnostic Test|Objective measurement of physical activity and fitness|Physical activity and fitness will be assessed objectively with a smartphone
45963329|NCT02897206|Drug|Imipenem|A wide-spectre antibiotic from the carbapenem group
45963330|NCT02897206|Drug|Placebo|An imipenem-matching placebo
45963331|NCT02897323|Other|description|
45963332|NCT02897401|Biological|pregnancy test|Collection of 5 mL of urinary sample.The pregnancy test is done in each investigator center.
45963333|NCT02897401|Biological|urinary cotinine assesment|Collection of 10 mL of urinary sample for cotinine analysis. The analysis is maid during the study and is centralised at the hospital Paul Brousse.
45963334|NCT02897401|Biological|Urinary NNN assesement|Collection of 20 mL of urinary sample for NNN analysis. The analysis is maid at the end of the study and is centralised in a laboratory located at Strasbourg.
45963335|NCT02897401|Behavioral|Questionnaire (Fagerstrom test)|This questionnaire will permit to assess the smoking habits of the participants.
45963336|NCT02897401|Procedure|Measurement of carbon monoxide levels expired|This test will permit to determinate if the participant are axposed to passive smoking or not.
45963337|NCT00196560|Device|Immobilization in External Rotation|
45963338|NCT00169754|Other|mapping kidney anatomy|videotape of surgical procedure to document location of attached stones and condition of calyces and papilla.
45821520|NCT04235660|Radiation|Stereotactic Body Radiation Therapy|SBRT will be delivered with linear accelerator-based photon beams with either fixed angle non- coplanar fields or dynamic arcs. An internal target volume (ITV) will be generated to account for tumor movement during breathing cycle. Finally, a planning target volume (PTV) will be an expansion of 3- 5mm from the ITV. For Child Pugh A patients, prescription dose will either be 5000cGy in 5 fractions delivered every other day or 4800cGy in 3 fractions delivered twice weekly. For Child Pugh B patients, prescription dose of 4000cGy in 5 fractions delivered every other day. Inverse planning will be used. 95% of the PTV or more will receive at least 100% of the prescription dose. Normal tissue dose constraints for each dose level will be respected with acceptable deviations permitted as outlined in appendix VII. Patients will be seen at least once per week by a clinician to grade toxicities, with on- treatment labs (CBC, CMP, INR) each week.
45821521|NCT00000379|Drug|Fluoxetine|
45821522|NCT00000379|Behavioral|EMDR|
45821523|NCT03367364|Behavioral|Patient education bundle (PEB),|A charge nurse will intervene in real-time via an EHR-triggered alert when there is documentation that a dose of VTE prophylaxis medication is not given for any reason. The charge nurse will speak to the bedside nurse and one of them will provide the patient with the education bundle including one-on-one personalized discussion, supplemented by a 2-page paper handout and patient education video.
45821524|NCT03367364|Behavioral|Nurse feedback and coaching (NFC)|Nurse leadership (i.e. managers, directors) will provide data to all nurses on their personal clinical effectiveness with the proportion of doses of VTE prophylaxis administered. The data will have comparisons to their nurse peers on the same floor. Coaching for nurses will include one-on-one conversations with bedside nurses with lower performance than their peers.
45821525|NCT00000385|Drug|Lithium|Lithium 600 mg to 2700 mg per day
45821526|NCT00000385|Drug|Placebo|Matching placebo
45821527|NCT04365920|Combination Product|Recovery Management Checkups (RMC)|"The RMC model was designed to improve treatment linkage, engagement, and long-term treatment retention. The conceptual framework was based on the public health theory of chronic disease management, which utilizes ongoing assessment and monitoring through regular face-to-face checkups and early (re)intervention to facilitate detection of relapse, reduce the time to treatment re-entry, and consequently, improve long-term outcomes. The original RMC model includes: 1) a fixed schedule of face-to-face quarterly checkups to assess need for SUD treatment, 2) personalized feedback based on an assessment and motivational interviewing to increase treatment motivation, 3) problem solving around barriers to treatment access and retention, and 4) assistance with scheduling and linkage to treatment. Individuals were deemed to be in need of treatment if they reported weekly, or more frequent, substance use since the last checkup, any past-month SUD symptoms, or self-perceived need for treatment."
45821528|NCT04365920|Combination Product|RMC-Adaptive|"Participants in the RMC-Adaptive group will receive face-to-face monthly checkups during the first 2 months post-release with additional face-to-face checkups dependent upon the participant's progress. Based on the data presented in the prior section, as long as participants need treatment, they will receive monthly checkups.~In addition, for every checkup that a participant does NOT need treatment, the number of months before the next checkup will be increased by 1 month (e.g., after 2 checkups without need, they will receive the next checkup 2 months later, after 3 it will be 3 months, after 4 it will be 4 months, and so on). Based on these decision rules, individuals who have NO treatment need over 24 months will still receive 5 checkups."
45821529|NCT00000391|Drug|Peptide T|
45821530|NCT00002894|Drug|carboplatin|
45821531|NCT00002894|Drug|cisplatin|
45821532|NCT00002894|Drug|paclitaxel|
45821533|NCT00000829|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|Administered as an injection at 24 months of age
45821534|NCT00000829|Biological|Pneumococcal Conjugate Vaccine, Heptavalent|Administered as an injection at 0, 2, 4, and 15 months of age
45821535|NCT00000829|Biological|Placebo|Administered at 0, 2, 4, and 15 months of age
45821536|NCT03282344|Drug|NKTR-214|0.006mg/kg IV on day 1 and every 3 weeks thereafter will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks.
45821537|NCT03282344|Drug|Nivolumab|360mg (flat dose) IV infusion administered over 30 (±5) minutes every 3 weeks.
45821538|NCT03896425|Device|Transcranial direct current stimulation (tDCS)|Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
45963339|NCT02897089|Device|Adhesive agent|Agents used to bond the restorative materials to teeth structure.
46079935|NCT03070886|Drug|Bicalutamide|Given orally
45821539|NCT03889093|Other|Yttrium-90|This is to evaluate the immunologic effects of yttrium 90.
45821540|NCT00000403|Drug|Doxycycline|
45821541|NCT00000841|Drug|Indinavir sulfate|
45821542|NCT00000841|Drug|Lamivudine|
45821543|NCT00000841|Drug|Stavudine|
45821544|NCT00000841|Drug|Zidovudine|
45821545|NCT04226456|Drug|N-acetyl cysteine|Injection of a 10% solution of N-acetylcysteine through transtympanic injection in both ears
45821546|NCT00002900|Procedure|management of therapy complications|
45821547|NCT00000415|Procedure|Physical activity|
45821548|NCT00000415|Drug|Calcium supplement|
45821549|NCT00000847|Biological|ALVAC-HIV MN120TMG (vCP205)|
45821550|NCT00000847|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
45821551|NCT00000847|Biological|rgp120/HIV-1 SF-2|
45821552|NCT04195568|Device|Surpass Evolve Flow Diverter System|The Surpass Evolve Flow Diverter System is indicated for the endovascular treatment of adults (age 18 or above) with unruptured saccular wide-neck or fusiform intracranial aneurysms ≤12 mm.
45963340|NCT02897284|Behavioral|Mindfulness 8 weeks|8 sessions of mindfulness
45963341|NCT02897284|Behavioral|Mindfulness 2 weeks|2 sessions of mindfulness
45963342|NCT00169793|Other|evaluation of kidney stone risk after bariatric surgery|24 hour urine collections done pre and post surgery
45963343|NCT00169793|Other|Evaluate risk of kidney stones after bariatric surgery|24 hour urine collections are done before and after surgery
45666389|NCT02408120|Drug|Supplemental insulin aspart|"Insulin aspart will be administered following the supplemental insulin scale protocol.~For the arm receiving supplemental insulin aspart at BG levels greater than 140 mg/dL, then supplemental insulin scale is as follows:~BG >141-180 mg/dL; 2-4 units of insulin aspart~BG between 181-220 mg/dL; 3-6 units of insulin aspart~BG between 221-260 mg/dL; 4-8 units of insulin aspart~BG between 261-300 mg/dL; 5-10 units of insulin aspart~BG between 301-350 mg/dL; 6-12 units of insulin aspart~BG between 351-400 mg/dL; 7-14 units of insulin aspart~BG > 400 mg/dL; 8-16 units of insulin aspart~For the arm receiving supplemental insulin aspart at BG levels greater than 260 mg/dL, then supplemental insulin scale is as follows:~BG between 261-300 mg/dL; 5-10 units of insulin aspart~BG between 301-350 mg/dL; 6-12 units of insulin aspart~BG between 351-400 mg/dL; 7-14 units of insulin aspart~BG > 400 mg/dL; 8-16 units of insulin aspart"
45963344|NCT04680754|Other|head-neck stretching exercises|Neck stretching exercises which include basic movements of the neck are simple and effective exercises. Stretching exercises provide neuromuscular coordination and flexibility in patients by reducing pain and muscle weakness (Nakamura, Kodama, and Mukaino 2014). For this reason, neck stretching exercises should be performed in early postoperative period and a nurse should teach the patient the head-neck stretching exercises and ensure the patient's comfort after thyroidectomy.
45666390|NCT02342288|Procedure|Head raised 10 degrees|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. Head was raised to 10 degrees. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
45666391|NCT02342288|Procedure|Head in neutral position|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
45666392|NCT01853644|Drug|Tivozanib|1.5 mg Given PO (orally)days 1-21 or every 28 day cycle
45666393|NCT01853254|Drug|Peginterferon alfa-2a|Both combination and monotherapy for both genotype 2/3 and genotype non-2/3: 180 μg subcutaneously once weekly.
45821553|NCT00000439|Drug|sodium valproate|subjects were randomized to sodium valproate vs placebo. Serum sodium valproate was monitored. This intervention was added on treatment as usual which was defined as being on lithium carbonate and also attending individual dual recovery counseling.
45821554|NCT03746431|Drug|[111In]-FPI-1547 Injection|[111In]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide. Patients will receive [111In]-FPI-1547 Injection of 185 MBq (5 mCi) for imaging.
45963345|NCT02896894|Other|Big White Wall (BWW)|"The BWW is an internet-based intervention that incorporates several elements of mental health care that have been shown to be effective, in a virtual environment that provides anonymity (see www.bigwhitewall.com). The on-line portal gives users access to self-assessment tools to track symptoms for a wide range of conditions over time, educational materials, a social network that allows communication between people who may have similar problems, and access to on-line courses. The service is monitored at all times by Wall Guides to ensure that users are responded to and that the content posted is appropriate and safe."
45963346|NCT02896816|Other|Surface EMG, MRI and PET Scan|It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed. In addition, individuals with Parkinson's disease will undergo brain scans at Massachusetts General Hospital to examine whether there are any relationships between muscle activity and brain function.
45963347|NCT02896816|Other|Surface EMG|It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed.
45963348|NCT02897011|Drug|Methotrexate|
45963349|NCT00169832|Drug|Rosiglitazone or placebo|Rosiglitazone 4 to 8 mg/day or placebo, for 12 months
45963350|NCT00196599|Drug|emtricitabine, FTC (drug)|
45963351|NCT00196599|Drug|didanosine, ddI (drug)|
45963352|NCT00196599|Drug|efavirenz (drug)|
45963353|NCT02896972|Procedure|Vitrectomy|Vitrectomy with inverted ILM technique or ILM peeling
45963354|NCT02896543|Other|measurement|Blood is obtained into ethylene diamine tetraacetic acid（EDTA） tubes from all subjects via antecubital vein puncture to measure the number of dendritic cells(DCs) and the concentration of sP-selectin. The number of dendritic cells(DCs) and the concentration of sP-selectin are measured in all patients with STEMI at 0 and 5-7 days after admission. The number of dendritic cells(DCs) and the only once in control group after admission.
45963355|NCT02896660|Device|ActiGraph Link|Subjects will be asked to wear the actigraph continuously for a 90-day period, and visit a clinician on day 30, 60, and 90 of the study for data collection.
46079936|NCT03070886|Drug|Docetaxel|Given IV
45458541|NCT03090932|Other|Blood draw|Research subjects will have two tubes of blood drawn, approximately 20mL.
45458542|NCT03493594|Other|Nutrition education program|online platform support, workshop, seminar and cooking demo etc
45963356|NCT00178971|Drug|adjunctive treatment with buspirone|buspirone 15-30 mg qd
45963357|NCT00178971|Drug|placebo|placebo
45963358|NCT02896621|Drug|Chlorthalidone plus amiloride|A capsule with chlorthalidone plus amiloride was taken once daily in the morning for eight weeks.
45963359|NCT02896621|Drug|Amlodipine|A capsule of amlodipine was taken once daily in the morning for eight weeks.
46079937|NCT03070886|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
46079938|NCT03070886|Drug|Flutamide|
46079939|NCT03070886|Drug|Goserelin Acetate|
45963360|NCT02896504|Drug|Exposure: Adjuvant chemotherapy treatment|
45666394|NCT01853254|Drug|Ribavirin|For genotype 2/3, 800 mg orally daily, in 2 split doses for 24 weeks. For genotype non-2/3, 1000 mg orally daily for participants weighing < 75 kg or 1200 mg orally daily for participants weighing ≥ 75 kg, in 2 split doses, for 48 weeks.
45821555|NCT03746431|Drug|[225Ac]-FPI-1434 Injection multi-dose|[225Ac]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive multiple doses of [225Ac]-FPI-1434 Injection. Dose is per cohort assignment.
45963361|NCT02896504|Drug|Exposure: Adjuvant hormonal therapy treatment|
45963362|NCT02896582|Drug|Obinutuzumab|1000 mg D1, D8, D15 in GA-DHAP 1000 mg D-8 in GA-BEAM 1000 mg every 2 months for 3 years then every month if MRD+
45963363|NCT02896582|Drug|Dexamethasone|40 mg D1 to D4 in GA-DHAP
45963364|NCT02896582|Drug|Aracytine|2g/m² D1 & D2 in GA-DHAP 400 mg/m² D-6 to -3 in GA-BEAM
45963365|NCT02896582|Drug|Cisplatinum|100 mg/m² D1 in GA-DHAP
45963366|NCT02896582|Drug|Etoposide|400 mg/m² D-6 to D-3 in GA-BEAM
45963367|NCT02896582|Drug|Melphalan|140 mg/m² D-2 in GA-BEAM
45963368|NCT02896582|Drug|Carmustine|300 mg/m² D-7 in GA-BEAM
45963369|NCT00196638|Drug|Antiretroviral combination (drugs)|
45963370|NCT00196638|Drug|Pegylated Interferon alpha (drug)|
45666395|NCT02373098|Drug|Fingolimod 0.5 mg|66 relapsing remitting MS (RRMS) patients were recruited. Patients who met all inclusion and none of the exclusion criteria were treated by Fingolimod 0.5 mg.
45821556|NCT03746431|Biological|FPI-1175 Infusion|FPI-1175 is an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody without a radioisotope. Patients will receive FPI-1175 Infusion at a dose per cohort assignment.
45821557|NCT03746431|Drug|[225Ac]-FPI-1434 Injection single-dose|[225Ac]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive a single dose of [225]-FPI-1434 Injection. Dose is per cohort assignment.
45963371|NCT00407693|Drug|[C-11]PRB28|
46079940|NCT03070886|Other|Laboratory Biomarker Analysis|Correlative studies
46079941|NCT03070886|Drug|Leuprolide Acetate|
45666396|NCT01853176|Drug|Liposomal Injection Bupivacaine (Exparel)|
45666397|NCT01853176|Drug|Standard bupivicaine|
45666398|NCT02372396|Behavioral|Compassion Meditation (CM)|Compassion meditation is a meditative practice focused on the wish that others and the self may be free of suffering. Because this particular form of meditation has been shown to elicit positive emotion and feelings of connection with other people, it is uniquely well suited to addressing PTSD, which is characterized by strong negative affect, deficits in positive emotion and social connectedness.
45821558|NCT00002912|Drug|etoposide|
45821559|NCT00002912|Drug|mitoxantrone hydrochloride|
45821560|NCT00002912|Drug|valspodar|
45821561|NCT00000853|Biological|rgp120/HIV-1MN|
45821562|NCT03731845|Genetic|Blood sample for genetic test|Patients will be genotyped for single nucleotide polymorphism previously found to be associated with age at natural menopause
45821563|NCT03731845|Biological|Blood sample for hormonal measurement|at each visit : 2x7ml. At the end of the study hormonal measurements (AMH, P4, LH, FSH, E25)
45821564|NCT03731845|Other|Ovarian ultrasound scan|Ovarian ultrasound scan at follow up visits (Y1,Y1.5, Y2.5 Y3.5 Y4.5 Y5.5)
45821565|NCT04183790|Drug|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration
45821566|NCT04183790|Drug|IVA|Mono tablet for oral administration.
45963372|NCT02896426|Behavioral|Collaborative Problem Solving|CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.
45963373|NCT02896426|Behavioral|Positive Solutions For Families|Positive Solutions for Families groups provide information for families on how to promote children's social and emotional skills, understand their problem behavior, and use positive approaches to help children learn appropriate behavior.
45963374|NCT02896153|Other|Questionnaire|
45963375|NCT02896270|Drug|Valproic Acid|The concomitant immunosuppressive regimen is to be reduced at the discretion of the investigators. It is suggested to lower immunosuppressive therapy only in valproic acid target trough levels have been attained.
45963376|NCT00196677|Drug|Vitamins, minerals and medical herbs|
45963377|NCT02896465|Other|Oral rehydration solution|
45963378|NCT02896465|Other|Zinc|
45963379|NCT02896465|Other|Human milk oligosaccharides|
45963380|NCT02896465|Other|Breastfeeding|
45963381|NCT02896309|Dietary Supplement|Sodium bicarbonate|
45963382|NCT02896309|Dietary Supplement|Sodium chloride|
45963383|NCT02896231|Drug|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
45963384|NCT02895958|Drug|Zepatier|Zepatier (elbasvir and grazoprevir +/- Ribavirin) will be administered in a community setting to HCV infected G1/4 treatment naïve patients on stable opiate substitution therapy with Cirrhotic and Non-cirrhotic liver disease
45963385|NCT02896192|Drug|Setmelanotide|RM-493 once daily subcutaneous injection
45963386|NCT02896192|Drug|Placebo|During the double blind placebo withdrawal period, patients will receive RM-493 or placebo at variable times over an 8 week period in order for patients to serve as their own control.
45963387|NCT00169949|Drug|aripiprazole|
45963388|NCT02896036|Procedure|Veress needle entry with concomitant CO2|The Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle.
46079942|NCT03070886|Drug|Nilutamide|
46079943|NCT03066271|Other|Exercise +|Usual care
46079944|NCT03066271|Other|Control +|Usual care
46079945|NCT03043378|Behavioral|Questionnaires|Participants complete three questionnaires at consultation visit.
45666399|NCT02372396|Behavioral|Relaxation|Relaxation Training is selected as the control condition because it is a good match for nonspecific aspects of the meditative practice (e.g., attention, support, contact with a mental health provider) and it is structurally similar to meditation (e.g., restful, in session and at home exercises).
45963389|NCT02896036|Procedure|Veress needle entry with subsequent CO2|A skin incision will be made with the scalpel. The Veress needle will be inserted until intraperitoneal location obtained. This will be followed by starting CO2 gas insufflation until the standard 15 mmHg.
45666400|NCT01835548|Drug|NT0102|NT0102 (methylphenidate polistirex [MPP] extended release [XR] ODT) was given once daily at a dose equivalent to 20-60 mg methylphenidate hydrochloride.
45821567|NCT00000445|Drug|naltrexone (Revia)|
45821568|NCT00002924|Other|mutation analysis|
45821569|NCT00000451|Drug|sertraline|16 week outpatient study
45963390|NCT02895997|Other|Travel Telehealth Delivery|Clinical Operations Room (COR) staff will travel to Sydney Australia to deliver telehealth to patients in Georgia United States. Upon arrival, participants will have eight nights and seven days free of clinical responsibilities. Thereafter, each participant will work four consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. The following week, participants will work three consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. Upon return to the USA, participants will have a week free of clinical responsibilities.
45963391|NCT02895919|Other|Culture|culture of ascitic fluid in standard culture media of blood culture bottles at bedside and fluid collected for culture in laboratory (study arm).
45963392|NCT02895880|Behavioral|usual care|In order to characterize the content of and variation in usual care, the first 25 patients enrolled in the study will complete a post-visit questionnaire that asks what their doctor told them (if anything) about their risk of cardiovascular disease, risk reduction and statins specifically, and how this information was presented
45963393|NCT02895880|Behavioral|statin communication tool|The Statin Choice decision aid uses icon arrays to communicate the expected benefits of statins. This modified risk communication tool will maintain the components of the validated original. The adapted paper-based risk communication tool will describe modified risk profiles applicable to the survivors at increased risk for cardiac disease due to chest irradiation.
45963394|NCT00196755|Drug|Sevelamer Hydrochloride (Renagel®)|Sevelamer hydrochloride three times per day with each meal
45963395|NCT00196755|Drug|Calcium acetate (PhosLo® )|Calcium acetate three times per day with each meal
45963396|NCT00169988|Drug|risperidone|
45963397|NCT00169988|Drug|sertraline-primary|
45963398|NCT02895607|Procedure|Ambulatory care among eligible patients|"The management of Anterior Cruciate Ligament (ACL) Reconstruction reconstruction in outpatient will be proposed in consultation with the surgeon.~After an explanation of the course of treatment a fact sheet on the protocol will be provided to the patient and his doctor to the patient to decide its support in CA (ambulatory surgery) or HC (conventional hospitalization)."
45963399|NCT02895529|Drug|Itraconazole|Participants will receive 200 milligram (mg) of itraconazole intravenously (IV) twice daily on Day 1 and Day 2, followed by 200 mg once daily through Day 14. From Day 15 to Day 28, participants will receive 200 mg (20 milliliters [mL]) of itraconazole oral solution orally twice daily. Participants, who are not suitable for oral administration of itraconazole based on the investigator's judgment, will receive 200 mg of itaconazole IV once daily from Day 15 to Day 28.
45666401|NCT01835548|Drug|Placebo|Matching ODT placebo was given once daily.
45666402|NCT02340962|Drug|TG-2349|TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.
45666403|NCT02340962|Drug|Ribavirin|RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration. Each tablet contains 200 mg of ribavirin and the following inactive ingredients: pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, cornstarch, and magnesium stearate. The coating of the tablet contains Chromatone-P® or Opadry® Pink (made by using hydroxypropyl methyl cellulose, talc, titanium dioxide, synthetic yellow iron oxide, and synthetic red iron oxide), ethyl cellulose (ECD-30), and triacetin.
45821570|NCT00000451|Drug|naltrexone|16 week outpatient study
45821571|NCT00000865|Drug|Abacavir sulfate|
45821572|NCT00000865|Drug|Lamivudine|
45821573|NCT00000865|Drug|Stavudine|
45821574|NCT00000865|Drug|Zidovudine|
45821575|NCT00000865|Drug|Didanosine|
45821576|NCT00000469|Drug|aspirin|
45963400|NCT02895529|Drug|Caspofungin|Participants will receive 70 mg of caspofungin IV once daily on Day 1 followed by 50 mg IV infusion once daily thereafter through Day 28.
45821577|NCT00000469|Drug|lovastatin|
45821578|NCT00000889|Drug|Aldesleukin|
45821579|NCT00000505|Drug|tissue plasminogen activator|
45821580|NCT00000505|Procedure|angioplasty, transluminal, percutaneous coronary|
45821581|NCT04169672|Drug|Surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
45821582|NCT04169672|Drug|Toripalimab|Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
45821583|NCT00380419|Behavioral|Interpersonal Psychotherapy (IPT)|IPT sessions will address adjustment to pregnancy, concerns about interpersonal relationships, and parenting concerns. Sessions will be weekly, but may be determined by clinical desires of patient and therapist.
45821584|NCT00000511|Dietary Supplement|mineral supplements|
45821585|NCT00000511|Dietary Supplement|Trial 1: fatty acids, omega-3; Trial 2: Mineral supplements|
45666404|NCT02340962|Drug|Interferon Alfa-2a|"IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.~Each prefilled syringe of 180 μg/0.5 mL IFN (expressed as the amount of interferon alfa-2a) also contains acetic acid (0.0231 mg), benzyl alcohol (5 mg), polysorbate 80 (0.025 mg), sodium acetate trihydrate (1.3085 mg), and sodium chloride (4 mg) at pH 6 ± 0.5."
45821586|NCT00000511|Behavioral|dietary supplements|
45821587|NCT03541291|Device|SMART-SYNC LM03|Doppler ultrasound cardiac gating device for fetal MRI application
45821588|NCT03344731|Behavioral|Cognitive evaluation|Cognitive task
45963401|NCT02895802|Behavioral|Verbal instructions with picture diagram|verbal instructions and picture diagram
45963402|NCT02895802|Behavioral|Verbal instructions with video of ADSC|Verbal instructions and watching video depicting ADSC
45963403|NCT02895802|Behavioral|verbal instructions w. video of w/o DS|verbal instructions and watching video depicting person without DS washing her hands
45963404|NCT02895802|Behavioral|verbal instructions w. video w/DS|verbal instructions and watching video depicting person with DS washing his hands
45963405|NCT00170027|Device|Magnetocardiograph|
45963406|NCT00179088|Behavioral|Patient may be able to put weight on the operated leg|
45963407|NCT02895646|Other|Collection of blood sample|
45963408|NCT00169910|Drug|AUC monitored withdrawal of MMF or CNI|AUC monitored withdrawal of MMF or CNI from a immunosuppressive drug regimen with steroids, CNI and MMF in stable renal transplant recipients
45963409|NCT02895763|Other|Form administrations|
45963410|NCT02895490|Other|educational intervention|Receive a DVD containing educational information and communication skills
45963411|NCT02895490|Other|communication skills training|Receive a DVD containing educational information and communication skills
45963412|NCT02895490|Other|educational intervention|Receive information about the LINC group
45666405|NCT01852942|Drug|Losartan|Participants will start with 50 mg of losartan by mouth daily. The dose will be increased to 100 mg by mouth daily after 14 days. The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.
45963413|NCT02895490|Other|questionnaire administration|Ancillary studies
45963414|NCT02895490|Other|quality-of-life assessment|Ancillary studies
45963415|NCT02895412|Biological|Donor-derived WT1-CTL and P-CTL|"Donor-derived WT1-CTL and P-CTL.~P-CTL will be given prophylactically a minimum of 28 days after transplantation followed by administration of monthly infusions of WT1-CTL for up to four doses."
45963416|NCT00196794|Drug|Tolevamer potassium-sodium (GT267-004)|
45963417|NCT02895685|Other|Dyad training|Participants will be paired in teams at the introduction. Participants will be instructed to train and supervise each other in pairs and will receive information on how to give constructive feedback. Participants will practice in pairs during on-site classes and encouraged to train in pairs during the self-regulated training at home. At the on-site classes, participants will be instructed to practice with their partner, during the expert-guided self-training and receive all feedback in pairs. Participants will train at the same table with space for two people. Outside the classroom, participants will decide themselves when and how often they will meet to practise. Participants are instructed to actively observe his or her partner while practising and are encouraged to discuss their performance and any difficulties they encounter. Testing will be done individually. With the training log, the investigators will measure whether the participants train in pairs at home as instructed.
45963418|NCT02895724|Drug|Medical Oxygen|Hyperbaric oxygen therapy
45963419|NCT00553774|Dietary Supplement|Cocoa Flavanols|Cocoa Flavanols (BD for 21 - 28 days)
45963420|NCT00553774|Other|Placebo|Placebo (BD 21 - 28 Days)
46079946|NCT03042689|Drug|Regorafenib|Regorafenib will be administered on a 28 day cycle Treatment will be administered on outpatient basis at a pre-determine dosage.
45963421|NCT00170144|Drug|Branchamin 4%|
45666406|NCT01852942|Drug|Placebo|one tablet by mouth daily
45666407|NCT01852162|Drug|Dabigatran|Dabigatran 150mg
45666408|NCT01852162|Drug|Placebo|Matching placebo tablets
45666409|NCT04590040|Other|Placebo|0% nano-HAP toothpaste
45666410|NCT04590040|Device|15% nano-HAP toothpaste|Toothpaste with identical base formulation as the placebo containing 15% nano-HAP
46079947|NCT03040895|Other|Group-based ICDP-intervention|Group-based ICDP-intervention for caregivers through a sequence of eight meetings
46079948|NCT03040895|Other|Treatment as usual|Treatment as usual through the data collection period (6 months)
45666411|NCT04590040|Device|5% KNO3 toothpaste|Toothpaste with identical base formulation as the placebo containing 5% KNO3
45821589|NCT03344731|Device|Non-invasive brain stimulation|Transcranial Magnetic Stimulation (TMS)
45821590|NCT00000901|Drug|Indinavir sulfate|
45821591|NCT00000901|Drug|Lamivudine|
45821592|NCT00000901|Drug|Stavudine|
45821593|NCT00000523|Behavioral|exercise|
45821594|NCT00000541|Behavioral|dietary supplements|
45821595|NCT00000541|Drug|vitamin C|
45821596|NCT00000541|Drug|vitamin E|
45821597|NCT00000541|Drug|beta-carotene|
45821598|NCT00000541|Drug|folic acid/Vitamin B6/Vitamin B12|
45963422|NCT00553852|Drug|Recombinant GH Saizen (Merck-Serono)|Treatment will start at the initial dose 0.15-0.30 mg/day; dose adjustment will be performed according to IGF-I levels. The duration of medical treatment is 6 months.
45963423|NCT03455296|Other|fluid therapy; crystalloid|maintenance fluid e.g. Ringer or Ringer acetate plus replacement fluid with crystalloids e.g. Ringer,or Ringer acetate or saline 0.9%, 500ml / 30 min. guided by ScVO2 with target value ≥ 70% versus lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study in group A & group B respectively. Maintenance fluid without replacement will be initiated if ScVO2 or lactate value normalized.
45963424|NCT02895061|Drug|Alfacalcidol|Alfacalcidol 1 microgram/capsule
45963425|NCT00170183|Drug|Nesiritide|
45963426|NCT02895139|Device|Additive Manufactured Orthotic Device|The 3D foot scan data will be used to generate a 3D model of the foot orthotic which will then be adapted to be suitable for solid printing. The final model will be saved in .stl format for use in the printing software. The additive manufactured orthotic insoles and all features or additions will be produced in a single build from additive materials matched for hardness to medium density EVA. Post production the orthotic will be cleaned to remove support material and a top cover will be attached to the final additive manufactured orthotic insole.
45963427|NCT02895139|Device|Moulded orthotic|The foam impression box and prescription will be sent to an external company for production of the handmade moulded orthotics. Handmade moulded orthotics will be produced by heating and wrapping medium density Ethylene-vinyl acetate (EVA) around plaster casts of the impression boxes. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the moulded orthotic insole. A top cover will be attached to the final moulded orthotic insole.
45666412|NCT04596124|Device|fitostimoline plus|randomized controlled multicentric study
45821599|NCT00000913|Drug|Ritonavir|
45821600|NCT00000913|Drug|Nelfinavir mesylate|
45821601|NCT00000913|Drug|Saquinavir|
45963428|NCT02895139|Device|Milled orthotic|The 3D foot scan data will be used to generate a 3D model of the foot orthotic. This will then be saved in .pan format for use in a CNC milling software. Orthotics and all features will be milled in a single mill from a block of medium density EVA. Post milling the orthotics will be cleaned. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the milled orthotic insole. A top cover will be attached to the final milled orthotic insole.
45963429|NCT04680559|Behavioral|MCBI|The topics covered in the sessions are: Week 1: Introduction to mindfulness and attention to breathing. Week 2. Open awareness of bodily sensations. Week 3: Work with thoughts, introductory theory and practice in attention to sounds. Week 4: Working with thoughts, advanced theory and practice in mental landscape. Week 5: Introductory theory and practice in labeling emotions. Session 6: Advanced theory in working with emotions and practice in difficult emotions. Week 7: Introductory theory on self-compassion and compassion. Practice in self-compassion. Week 8: Practice in compassion and active compassion (acts of kindness and shared humanity).
45963430|NCT04680559|Behavioral|Active Comparator|Free observation of the psychotherapist's own feelings, thoughts, distractions, biases and behavior in general for 8 weeks. Observations of these variables are recorded during psychotherapy sessions with patients participating in the research.
46079949|NCT02996578|Dietary Supplement|polyphenol rich chocolate bar|High polyphenol content chocolate bar. Each participant will consume 581.4mg of polyphenols
46079950|NCT02996578|Dietary Supplement|polyphenol rich cocoa powder|High polyphenol content cocoa powder. Each participant will consume 6g containing 554mg of polyphenols
46079951|NCT02996578|Dietary Supplement|low polyphenol content chocolate bar|Low polyphenol content matched chocolate bar. Each participant will consume 198.5mg of polyphenols
45821602|NCT03111290|Device|Direct Cortical Stimulation|A train of periodic electrical pulses is delivered between two local electrodes implanted in the brain
45821603|NCT03111290|Device|Direct Cortical Stimulation Sham|Sham trials where no electric pulse is delivered
45821604|NCT00000547|Drug|enalapril|
45821605|NCT00002930|Procedure|positron emission tomography|
45821606|NCT00002930|Radiation|fludeoxyglucose F 18|
45821607|NCT00000565|Procedure|intermittent positive-pressure breathing|
45666413|NCT01835470|Drug|Abatacept|
45666414|NCT02451137|Drug|Insulin glargine, 300 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45666415|NCT02451137|Drug|Insulin glargine, 100 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45666416|NCT02451137|Drug|Insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45666417|NCT02451137|Drug|Background Therapy|Anti-diabetic drugs at investigator discretion and consistent with local labeling guidelines for use with insulin.
45666418|NCT02372006|Drug|afatinib|
45821608|NCT03061526|Other|optical coherence tomography|measurement of reflectivity in different retinal layers based on optical coherence tomography findings
45821609|NCT00000577|Drug|Albuterol|
45821610|NCT00000577|Drug|Colchicine|
45821611|NCT00000577|Drug|Adrenal Cortex Hormones|
45821612|NCT00000577|Drug|Adrenergic-Beta Agonists|
45821613|NCT03321799|Device|Negative Pressure Wound Therapy (NPWT)|A computer randomization system will be used on the day of surgery to allocate patients to either the conventional or NPWT dressing. Due to the nature of this study, blinding of patients and surgeons to their allocated cohort will not be possible.
45821614|NCT03321799|Device|Sterile Antimicrobial Dressings|Control group, current hospital standard.
45821615|NCT03278119|Diagnostic Test|PET Scan and nocturnal polysomnography|Amyloid PET scans will be used to assess amyloid burden in the brain, and nocturnal polysomnography will be used to assess sleep and cardiopulmonary variables
45821616|NCT03015896|Other|Laboratory Biomarker Analysis|Correlative studies
45821617|NCT03015896|Drug|Lenalidomide|Given PO
45821618|NCT03015896|Biological|Nivolumab|Given IV
45821619|NCT00000925|Drug|Optimune oral nutritional supplement|
45821620|NCT00000583|Biological|hepatitis B vaccines|
45821621|NCT02994836|Biological|Anti-TNF: Infliximab (Infusion)|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
45821622|NCT02994836|Drug|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Infusion-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
45821623|NCT02994836|Biological|Anti-TNF:Adalimumab (Subcutaneus)|Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
45821624|NCT02994836|Drug|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Injection-subcutaneous use)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
45821625|NCT00000937|Drug|Antibiotics|
45666419|NCT02406248|Drug|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
45963431|NCT00179166|Drug|TPN nutritional supplement|intravenous administration of nutritional supplement for 4 hours at a dosage of 30 kcal/kg/day, in the form of lipids, carbohydrates and protein; the non-protein calories are comprised of lipids (30%) and carbohydrates (70%)
45821626|NCT00000613|Behavioral|dietary supplements|
45963432|NCT02895334|Behavioral|MyHeartBaby Program|Participating Caregivers will receive an electronic tablet loaded with a telemedicine intervention program (MyHeartBaby) to support caregivers remotely in the daily care and adjustment to having an infant with chronic medical needs with video-based telemedicine support services. There are a total of six sessions occurring at weeks 3, 6, 9, 12, and 15 of the study.
45963433|NCT00170222|Drug|doxycycline|
45963434|NCT02894983|Other|Flexion-ulnar cast|The group will be treated with closed reduction and flexion-ulnar deviation position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
45963435|NCT02894983|Other|Functional cast|The group will be treated with closed reduction and functional position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
45821627|NCT00000613|Drug|genistein|
45963436|NCT02895022|Drug|Lidocaine 2% adrénalinée|
45963437|NCT02895022|Device|Epidural catheter|
45963438|NCT02895022|Procedure|Caesarean section|
45821628|NCT00000613|Behavioral|diet, soy proteins|
45821629|NCT02924402|Biological|XmAb13676|Biological
45963439|NCT02895256|Drug|Any treatment for cluster headache|
45455426|NCT01124383|Procedure|Local anesthesia with sedation|For women in the local anesthesia group a paracervical block is performed by the gynecologist using a total of 20 mL of 1% lidocaine intracervically at 2, 4, 7 and 10 o'clock positions and in the area of uterosacral ligaments. Once the block completed, the surgeon waits at least five minutes before performing cervical dilatation to allow for sufficient analgesia. Intravenous sedation consists of midazolam, sufentanil and propofol administered by the anesthesiologist in sufficient doses to maintain a spontaneous ventilation with a Ramsay score < 4.
45455427|NCT01222663|Device|standard therapy|Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate
45455428|NCT01222663|Device|hemoperfusion|Extracorporeal hemoperfusion with Toraymyxin PMX-20R and conventional medical therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate.
45666420|NCT02450903|Drug|LDK378|Oral LDK378 750mg once daily
45666421|NCT02371616|Device|Calcium sodium phosphosilicate|5% w/w calcium sodium phosphosilicate
45666422|NCT02371616|Other|Sodium fluoride|1426 ppm fluoride as sodium fluoride
45666423|NCT02371616|Other|Sodium monofluorophosphate|1426 ppm fluoride as sodium monofluorophosphate
45963440|NCT00409851|Drug|valsartan+amlodipine|
46079952|NCT02996578|Dietary Supplement|low polyphenol content cocoa powder|Low polyphenol content cocoa powder. Each participant will consume 6g containing 191.2mg of polyphenols
46079953|NCT02992821|Procedure|Bed-side pocket size ultrasound imaging|
46079954|NCT02992821|Procedure|High frame rate tracking doppler|
46079955|NCT02987257|Drug|Harmonized supportive care|Harmonized supportive care with placebo cyclosporine days 0-14 and etanercept placebo days 0 and 3
46079956|NCT02987257|Drug|Cyclosporine 5 mg/kg bid days 0-14|Harmonized supportive care with placebo etanercept days 0 and 3
45821630|NCT00000619|Procedure|catheterization, Swan-Ganz|
45821631|NCT02909348|Drug|Pembrolizumab|3mg/kg, intravenous and on day1 of each 21 day cycle until progression or unacceptable toxicity develops.
45821632|NCT02973529|Device|Absorb|Randomization to implantation of Absorb BVS in bifurcation lesion
45821633|NCT02973529|Device|Desolve|Randomization to implantation of Desolve BRS in bifurcation lesion
45821634|NCT04329416|Other|Predicted depth of insertion|A left-sided double-lumen tube was introduced beyond the vocal cords when the train-of-four stimulation of the ulnar nerve revealed 1 or 2 twitches, the stylet was removed, the double-lumen tube was rotated 90° counterclockwise and then advanced blindly to the predicted depth of insertion.
45821635|NCT04329416|Other|Optimized depth of insertion|The optimal position of the double-lumen tube, defined as the inflated endobronchial cuff is placed in the left main bronchus just below the carina without herniation, which was confirmed using a flexible bronchoscope in both supine and lateral decubitus positions.
45821636|NCT04329416|Other|Adjustment of depth of insertion|If the endobronchial cuff was placed too deeply or too proximal, subsequently, the double-lumen tube was withdrawn or advanced, respectively, using the flexible bronchoscope until the optimum position of the double-lumen tube was achieved.
45821637|NCT02859727|Drug|CDZ173|140 mg/day
46079957|NCT02987257|Drug|Etanercept 50 mg sc day 0 and day 3|Harmonized supportive care with placebo cyclosporine days 0-14
45666424|NCT02370914|Device|Nautilus NeuroWaveTM System|Recording of subjects with Nautilus NeuroWave diagnostic device
45666425|NCT02370914|Behavioral|SCAT|A Neurocognitive evaluation of the patients to assess for concussion.
45666426|NCT02370602|Drug|TAK-063|TAK-063 tablets
45666427|NCT02370602|Drug|[^11C]T-773|[^11C]T-773 IV solution
45666428|NCT02370368|Device|XBOX Kinect Just Dance 2014|The XBOX Kinect Just dance 2014 is videogame based interactive dance programme designed to encourage activity while gaming.
45666429|NCT02370368|Other|Agility Ladder Drills|Types of ladder drill exercises including single leg hop right and left leg, bunny hop, slalom jumps, bunny twist, lateral runs right and left, high knees with forward progression, backward run, bunny hop backward, single leg lateral hops, lateral bunny hops and snake carrioca moguls.
45963441|NCT05424445|Drug|Misoprostol|Women presenting at the study site with an indication for IOL will receive written and oral information about the study. They will have the opportunity to ask questions. If the woman agrees to participate and is deemed eligible, she will sign informed consent. The Swedish national guidelines regarding the method of IOL will be followed. Women will have an abdominal palpation to exclude malpresentation, a CTG, and a digital cervical exam to establish bishop score (BS) prior to inclusion (as per clinical practice). Randomization will be performed by the attending physician, midwife or study coordinator. Randomization will be by opening numbered opaque sealed envelopes in sequential order containing the randomization code. There are no restrictions for use of other medications. All concomitant medication will be recorded in the CRF.
45963442|NCT00170261|Device|Use of an Implantable Loop Recorder|
45963443|NCT05424289|Device|videolaryngoscope|Videolaryngoscope is a high-resolution micro camera mounted on the tip of a curved blade connected to small portable digital monitor improves the view of the vocal cords
45963444|NCT00409890|Drug|Hyoscine Butyl Bromide|
45963445|NCT05424094|Behavioral|multi-professional group programme 'kinderleicht'|12-16 children/adolescents who participate in the multi-professional group programme 'kinderleicht' receive coaching in the areas of behaviour, exercise, nutrition and medicine from qualified professionals on fridays during 11 months.
45963446|NCT00170300|Device|Implantable Cardiac Resynchronisation (pacing) device|
45963447|NCT05423977|Drug|ZV0203|Participants will be allocated to one of the following dose groups: 0.3, 0.6, 1.2, 1.8, 2.7 and 3.6 mg/kg, and receive a treatment of ZV0203-ADC followed by 21 days of dose limited toxicity (DLT) observation period.
45963448|NCT05423938|Dietary Supplement|Diabetic|It is a hypercaloric and hyperproteic dietary supplement formulated to contribute to control the glycemia with: a specific mix of carbohydrate with a low GI, fiber, EVOO and EPA&DHA
45963449|NCT05423938|Dietary Supplement|Control|It is a hypercaloric and hyperproteic dietary supplement formulated without the ingredients to contribute in the glycemia control
45963450|NCT00179205|Drug|Nepro nutritional supplement|oral nutritional supplement (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 480 calories: 71 calories from protein, 206 calories from carbohydrates and 206 calories from fat.
45963451|NCT00179205|Drug|placebo|oral placebo (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 60 calories: 0 calories from protein, 60 calories from carbohydrates, and 0 calories from fat.
45963452|NCT05423899|Behavioral|Grace Robot|The Grace robot was designed by Awakening Health/Hanson Robotics for healthcare settings and to interact with the elderly and those isolated by the COVID-19 pandemic. Grace is a robot with a human-like appearance, which can move, actively listen, engage in conversation and react appropriately to human emotions. Intervention activities will mostly consist of active listening and general discussions about topics of interest (e.g. hobbies, music). The participant will also have the option of other types of interactions with the robot, including robot-led meditation, robot-led light exercise, listening to music and singing. Because loneliness is a subjective experience and does not have a standardized solution, this is a personalized intervention approach. We anticipate that each older adult participant will have different needs and wishes when interacting with the robot, which will allow for a more natural interaction with the robot.
45963453|NCT05423899|Behavioral|Treatment as Usual|The treatment as usual active control group will not receive the robot intervention. The investIgators have deliberately chosen the participating long-term care (LTC) homes due to their high frequency of social interactions for their clients as part of their routine care (e.g. one-on-one and group activities, family interaction, exercise groups) compared to most LTC homes settings, making TAU an active control.
45963454|NCT05423821|Other|Anesthesia efficacy in patients undergoing MRI|atropine will be administered when bradycardia develops, oxygen will be given if hypoxia develops
45666430|NCT04897256|Behavioral|TURN-IT exercise program|Based on the exercise motor learning principles, participants spend 10-15 minutes at each Exercise Station that focuses on particular constraints of turning ability. The stations will focus on important underlying aspects of turning, such as weight-shifting and increasing axial rotation during functional turning tasks. Each station will be progressed across levels to make more challenging (such as adding a dual task). Initially participants will be supported in an overhead body-weight support system (ZeroG) to allow them to practice challenging exercises without the risk of falling.
45821638|NCT04329338|Other|Lactobacillus pentosus KCA1|Lactobacillus pentosus KCA1 suspended in dairy and taken orally for 14 days
45821639|NCT00000949|Drug|Aldesleukin|
45821640|NCT00002936|Drug|altretamine|
45821641|NCT00002936|Drug|etoposide|
45963455|NCT05423704|Other|Proton radiotherapy|Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
45963456|NCT05423626|Device|technologies of robotic mechanotherapy with FES|"Technologies of robotic mechanotherapy with FES (ExoAtlet I):~Simulator is designed for rehabilitation in case of motor deficiency of the lower extremities and recovery of walking caused by stroke and other diseases and injuries of the central nervous system.~The main components of the simulator are:~exoskeletal robotic device for moving the patient and forming a walking pattern~a device for functional electrical stimulation (FES) of peripheral nerves controlling the muscles of the rehabilitated limb."
46079958|NCT02913274|Device|Paclitaxel (Taxol) eluting angioplasty balloon|Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Then dilatation by a DEB of the same size for 2 minutes.
45821642|NCT00000649|Drug|Nevirapine|
45821643|NCT00000649|Drug|Zidovudine|
45821644|NCT00002942|Procedure|autologous bone marrow transplantation|
45821645|NCT00002942|Procedure|peripheral blood stem cell transplantation|
45821646|NCT00000955|Drug|Tuberculin Purified Protein Derivative|Administered intradermally at 5 TU per 0.1 mL
45963457|NCT05423626|Device|biofeedback virtual reality technologies|"Brief information biofeedback virtual reality technologies:~ReviVR Multisensory Passive Rehabilitation Simulator is intended for rehabilitation in case of motor deficiency of the lower extremities and recovery of walking caused by stroke and other diseases and injuries of the central nervous system.~The main components of the simulator are:~hardware and software complex, including a monitor and a personal computer;~virtual reality helmet;~sandals with air chambers."
45666431|NCT02340806|Device|CADD-Solis pump (Smiths Medical)|The maintenance epidural solution for both groups will be bupivacaine 0.625 mg/mL with fentanyl 1.95 mcg/mL. The intermittent bolus volume will be 10 mL administered every 60 minutes. The first bolus will be given 30 minutes after intrathecal injection. In addition to the programmed boluses, patients will be able to administer patient-controlled epidural analgesia (PCEA) boluses of 5 mL every 10 minutes to a maximum of 15 mL (three PCEA boluses in a one hour period).
45963458|NCT00170378|Drug|Enoxaparin|
45963459|NCT00179244|Drug|Rispridone (drug) and Bupropion ER (drug)|
45963460|NCT05423197|Drug|89Zr-panitumumab IV|Subjects will be given a bolus of 1.0 mCi (range 0.8 - 1.2 mCi) of 89Zr-panitumumab before undergoing further standard of care diagnostic evaluation of the lesions
45963461|NCT05423197|Drug|Panitumumab|Panitumumab 30mg will be given orally
45666432|NCT01835158|Drug|Cabozantinib S-malate|Given PO
45666433|NCT01835158|Other|Laboratory Biomarker Analysis|Correlative studies
45963462|NCT05423002|Other|Flickering light stimuli|The intervention will be exposed to flickering lights (≤200 lux). More specifically, the participants will be asked to be exposed to a specified flickering light (1Hz, 30 seconds On, and 30 seconds OFF) for 2 hours starting at their habitual bedtime (HBT).
45963463|NCT05423002|Other|Constant light stimuli|The intervention will be exposed to constant background lights (≤200 lux). The participants will be asked to be exposed to a specified constant light for 2 hours starting at their habitual bedtime (HBT).
45821647|NCT02789384|Other|Procedure/Surgery|"Procedure/Surgery: Newly obtained biopsy if applicable and Blood samples collection.~For each patient:~Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~Blood samples will be obtained for genetic profiling and assessment of markers.~The classification as CINSARC will be performed for each patient. Patients should be treated by neoadjuvant anthracycline-based chemotherapy. Chemotherapy regimen must contain at least doxorubicin (dose range: 60 -75 mg/m²) and ifosfamide (dose range: 2.5-3g/m²) to be delivered on a 21-days cycle basis up to 6 cycles prior surgery. After neoadjuvant chemotherapy completion, patients will be treated by surgery followed or not by radiotherapy.~All patients should be managed according to the usual medical practices."
45821648|NCT00000961|Drug|Anti-HIV Immune Serum Globulin (Human)|
45963464|NCT05423002|Other|Dim light|This light condition is the baseline (≤10 lux).
45963465|NCT00170417|Behavioral|Cognitive Behaviour Therapy|
45963466|NCT00196872|Drug|Epirubicine|Epirbubicne is given
45963467|NCT00196872|Drug|Cyclophosphamide|Cyclophosphamide is given
45963468|NCT00196872|Drug|Taxol|Taxol is given
45821649|NCT00000961|Drug|Zidovudine|
45821650|NCT04048304|Drug|duration of standard antibiotic therapy|antibiotic therapy for spine infections. 3 vs 6 weeks if no implant left in place. 6 vs 12 weeks if implant left in place. The antibiotic agents used are officially indicated for orthopedic infections, including spine infections and available in Switzerland since decades. Standard dosing will be applied and only modified according to the patient's co-morbidities, intolerances and weight.
45963469|NCT00196872|Drug|Xeloda|Xeloda is given
45963470|NCT00196872|Drug|Ibandronat|Ibandronat is given
46079959|NCT02913274|Device|high-pressure angioplasty balloon|Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Then dilatation either by a shame balloon or by a DEB balloon of the same size for 2 minutes.
45666434|NCT01835158|Drug|Sunitinib Malate|Given PO
45666435|NCT02337764|Drug|TVP-1012 1mg|TVP-1012 1mg Tablets
45666436|NCT04420442|Procedure|Scar Transformation Group|Surgical excision of the NSSI scars followed by IntegraTM transplantation and wound closure with a negative pressure wound system. After 21 days the silicone layer of the IntegraTM will be removed and split thickness skin will be transplanted. After suture removal a compression therapy by individually tailored garments will be started for 12 months.
45666437|NCT01834222|Biological|Non-intervention|Non-intervention
45821651|NCT00000655|Drug|Atovaquone|
45821652|NCT00000655|Drug|Sulfamethoxazole-Trimethoprim|
45821653|NCT00002948|Biological|filgrastim|
45821654|NCT00002948|Drug|topotecan hydrochloride|
45963471|NCT04680325|Dietary Supplement|Juice daily consumption|Single-service bottles of juice were provided for 15 days of daily consumption in each arm
45963472|NCT00170456|Biological|rPA vaccine containing alhydrogel|
45963473|NCT05422846|Other|standard treatment|The control group will be provided with the necessary approaches for diabetic foot ulcer care and diaphragmatic breathing exercises.
45963474|NCT05422846|Other|aerobic exercise|The aerobic exercise group will be provided with the necessary approaches for diabetic foot ulcer care and in addition to diaphragmatic breathing exercises, they will be provided with aerobic exercise twice a week with a physiotherapist.
45963475|NCT05422846|Other|exercise protocol|The protocol exercise group will be provided with the necessary approaches for diabetic foot ulcer care and exercises suitable for the physical condition of the wound and the patient, in addition to diaphragmatic breathing exercises. This group will also work with a physiotherapist twice a week.
45666438|NCT04594642|Drug|TNB-486|TNB-486 is a bispecific antibody targeting CD19 on tumor cells and CD3 on T-cells.
45821655|NCT00002948|Procedure|bone marrow ablation with stem cell support|
45963476|NCT00179283|Drug|sertraline|
45963477|NCT00179283|Drug|venlafaxine XR|
45963478|NCT05422807|Behavioral|BFST for Teens with Type 2 Diabetes|12 (90 minute sessions) over 6 months of Behavioral Family Systems Therapy (BFST), delivered by a Licensed clinical social worker. BFST consists of 4 components: problem-solving, communication skills training, cognitive restructuring, and functional and structural family therapy.
45963479|NCT04679974|Behavioral|Melodic-based Communication Therapy|"General procedures involved in (M.B.C.T.) are as follows: 25 common first words are selected as the targets (e.g., apple, ball, car, dog, cat, eat, go, etc.). Pictures and objects will be used as stimulus items. The top 3-5 incentives as identified by parent survey will be given according to the therapies specific reinforcement schedule. All treatment and evaluation sessions will be videotaped for future/further analysis and verification purposes. For the purposes of the study design, the same 25 words will be used for all participants.~Participants will first listen to the target word set to a melodic tone and rhythm on a compact disc (CD). Clinicians will present the stimulus item (e.g., apple) prior to beginning the steps. Therapy will then progress from clapping and singing the melody to answering sung questions and finally to answering spoken questions with the target word"
45963480|NCT05420506|Device|NROT1|Dental anchored intestinal placement of obesity treatment device with endoscopic intervention
45963481|NCT05420389|Other|breast massage|Mothers who were included in the breast massage group who met the research criteria were informed about the use of milking pumps in the routine application of the hospital and the condition anxiety scale was filled out on the first day. These mothers were shown breast massage during the use of milking pumps, they were provided with their own application and a brochure was given explaining the application.As long as the breast milk follow-up form to record the amounts of milk they milked was in the hospital, the researcher explained how to fill it out when discharged and was asked to fill out the last-day conditional anxiety scale (SATI-I). Milk amounts are measured in ml.
45963482|NCT05420389|Other|hot compress|Mothers who were included in the hot application group were informed about the use of milking pumps in the routine application of the hospital and the condition anxiety scale (STAI-I) was filled out on the first day. These mothers were shown the hot application they would make during the use of milking pumps, they were provided with the application and a brochure was given explaining the application.The hot chest compress to be used in this group will be used in the Lansinoh brand Thera°Pearl® Hot Breast Therapy pad, which is sold in medical medicines in pharmacies approved by the Ministry of Health.The breast milk follow-up form, in which they will record the amounts of milk they milk, was explained by the researcher in the hospital and how to fill it out when they were discharged, and they were asked to fill out a last-day anxiety scale.
45963483|NCT05420389|Other|breast massage-hot compress|Mothers who were included in the breast massage and hot application group were informed about the use of milking pumps in the routine application of the hospital, the data collection form and the condition anxiety scale were filled out on the first day. These mothers were shown breast massage and hot application during the use of milking pumps, they were provided with their own application and a brochure was given explaining the application.As long as the breast milk follow-up form to record the amounts of milk they milked was in the hospital, the researcher explained how to fill it out when discharged and was asked to fill out the last-day conditional anxiety scale (SATI-I). Milk amounts are measured in ml.
45963484|NCT05420350|Drug|Lamotrigine and Bupropion|Lamotrigine-oral pill taken once or twice a day with varying dosage per study timeline Bupropion-oral pill 100mg taken twice a day
45963485|NCT05420350|Drug|Placebo|Oral pill matched with lamotrigine to be taken once or twice a day per study timeline Oral pill matched with bupropion to be taken twice a day
45963486|NCT00170534|Behavioral|Behavior|
45821656|NCT00002948|Procedure|peripheral blood stem cell transplantation|
45963487|NCT03097939|Drug|Ipilimumab|1 mg/kg of IV Ipilimumab is admistered over 90 minutes every 6 weeks
45963488|NCT03097939|Drug|Nivolumab|3 mg/kg of IV Nivolumab is administered over 30 minutes every 2 weeks
45963489|NCT03014635|Biological|Botulinum Toxins, Type A|Intramuscular injection
45963490|NCT03014635|Biological|Placebos|Intramuscular injection
45963491|NCT00170573|Drug|Caelyx|Caelyx 40 mg/ m2biweekly
45963492|NCT00196911|Procedure|Implantation of stimulation electrodes in the STN|
45963493|NCT02885272|Procedure|Computed Tomography|Undergo PET/CT scans
45963494|NCT02885272|Radiation|Fludeoxyglucose F-18|Given IV
45666439|NCT01833832|Drug|Cisplatin|Patients who are successfully debulked will then undergo hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin.
45821657|NCT04009148|Other|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
45821658|NCT02594293|Drug|PegIFN alfa-2a|180 μg/ 0.5 ml ,hypodermic injection once a week
45821659|NCT00000967|Drug|Interferon alfa-2a|
45821660|NCT00000967|Drug|Zidovudine|
45963495|NCT02885272|Procedure|Magnetic Resonance Imaging|Undergo standard of care MRI
45963496|NCT02885272|Procedure|Positron Emission Tomography|Undergo PET/CT scans
45821661|NCT00000661|Drug|Oxazepam|
45963497|NCT02793583|Biological|Ublituximab|
45963498|NCT02793583|Drug|Umbralisib|
45963499|NCT02793583|Biological|Bendamustine|
45666440|NCT01833832|Procedure|Cytoreductive surgery|Patients will undergo cytoreductive surgery to achieve a Completeness of Cytoreduction Score (CC) of 0 or 1.
45666441|NCT01833832|Drug|sodium thiosulfate|sodium thiosulfate will be given to limit the toxicity of cisplatin
45666442|NCT01833520|Drug|Ra-223 Dichloride|"Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I."
45666443|NCT01850602|Drug|PA21|
45821662|NCT00000661|Drug|Zidovudine|
45821663|NCT02749058|Procedure|Capsulectomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulectomy during total hip arthroplasty.
45821664|NCT02749058|Procedure|Capsulotomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulotomy during total hip arthroplasty. Surgeon will repair the joint capsule.
45821665|NCT00000979|Drug|Zidovudine|
45821666|NCT00000979|Drug|Didanosine|
45821667|NCT00002960|Biological|recombinant adenovirus-p53 SCH-58500|
45821668|NCT02699606|Drug|Erdafitinib|Participants will receive 8 mg of erdafitinib, once daily with option to up-titrate to 9 mg.
45821669|NCT00000667|Biological|gp160 Vaccine (MicroGeneSys)|
45821670|NCT00000991|Drug|Pentamidine isethionate|
45821671|NCT00000991|Drug|Sulfamethoxazole-Trimethoprim|
45821672|NCT00000991|Drug|Dapsone|
45821673|NCT00000991|Drug|Zidovudine|
45963500|NCT00170612|Biological|Pneumovax 23|23-valent PPS, 25 micrograms/serotype
45963501|NCT00170612|Biological|Prevnar|7-valent PCV, 2 micrograms/serotype, except serotype 6B which is 4 micrograms/serotype
45963502|NCT00196950|Biological|Meningococcal (vaccine)|
45963503|NCT02773966|Radiation|Kypho-IORT|During kyphoplasty/vertebroplasty a intraoperative radiotherapy of the affected vertebrae is done with a miniature X-ray generator (INTRABEAM®, Carl Zeiss, Surgical, Oberkochen, Germany). The prescription dose will be 8 Gy in a distance of 13 mm from the isocenter of the radiation source. IORT will take about five minutes. After radiation the applicator will be removed and the operation will be finished as usual.
45963504|NCT02773966|Radiation|EBRT|The external beam radiotherapy will be usually carried out as an outpatient procedure. All patients will receive a planning CT before the first irradiation. EBRT will be performed with 30 Gy, added in 3 Gy per fraction or 8 Gy single dose (only for international study centers, not permitted in Germany) on a conventional linear accelerator (LINAC).
45963505|NCT00170690|Drug|Treosulfan|Treosulfan 600 mg/m² p.o. on daý 1-28, 57-84, etc
45963506|NCT00170690|Drug|Treosulfan|Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
45963507|NCT02675569|Procedure|Catheter|A method of vascular access for hemodialysis that all participants will have in place prior to randomization.
45821674|NCT00000673|Drug|Ganciclovir|
45821675|NCT00000685|Drug|Zidovudine|
45821676|NCT00002972|Drug|paclitaxel|
45666444|NCT01850602|Drug|Sevelamer hydrochloride|
45821677|NCT00000691|Drug|Foscarnet sodium|
45666445|NCT01832818|Device|NuNec Cervical Disc|Patients will be enrolled and implanted with the NuNec device at a single level C3 to C7.
45666446|NCT02405780|Drug|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may continue to receive FKB327 40 mg every other week by subcutaneous injection for up to 76 weeks.
45963508|NCT02675569|Procedure|Fistula|A type of vascular access strategy for hemodialysis which involves connecting the artery and the veins in the participant's arm.
45963509|NCT00196989|Drug|Pioglitazone|
45963510|NCT00196989|Drug|GW677954|
45963511|NCT02673775|Other|Clean Air|Subjects will have the clean air exposure first, followed by the ozone exposure
45963512|NCT02673775|Other|Ozone|Subjects will have the ozone exposure first, followed by the clean air exposure
45963513|NCT00170729|Drug|Prednisolone acetate|
45963514|NCT00170768|Drug|Darifenacin|Darifenacin modified release 7,5 mg tablets once daily titrated to 15 mg once daily
45963515|NCT00170768|Drug|Oxybutynin|Oxybutynin extended release 10 mg tablet once daily titrated to 15 mg, then to 20 mg once daily
45666447|NCT02405780|Drug|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may then receive FKB327 40 mg every other week by subcutaneous injection from week 30 to week 76.
45963516|NCT00170768|Drug|Placebo|Placebo once daily tablet (sham titration)
45963517|NCT00197067|Biological|RTS,S/AS02D and RTS,S/AS02A|
45963518|NCT02655562|Drug|Montelukast|"Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO<25ppb were given placebo (p.o., 10mg, qd).~Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO<25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients."
45963519|NCT00170885|Drug|Everolimus|
46079960|NCT02913274|Device|low-pressure balloon|Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Thenn dilatation by a shame balloon i.e conventional low pression balloon of the same size for 2 minutes.
46079961|NCT02896335|Drug|Palbociclib|125 mg by mouth daily
45963520|NCT02607748|Other|18F-NaF PET and coronary CTA imaging|
46079962|NCT02888691|Other|Low carbohydrate diet|
45455429|NCT03928873|Device|Low energy ESWT|1500 impulses and 0.006mJ/mm2, 3bar, once per week for 4 weeks
45963521|NCT02502253|Drug|grape seed polyphenolic extract, resveratrol|Bioactive Dietary Polyphenol Preparation (BDPP) is a combination of two nutraceutical preparations (grape seed polyphenolic extract [GSE], and resveratrol) that contain abundant concentrations of polyphenols.
45963522|NCT00179439|Procedure|nasal potential difference testing|
45963523|NCT05412667|Dietary Supplement|TWK10|"4 days without training: drink 2 hours before bedtime.~3 days of training: drink within 30 minutes after training (uniformly brewed in the laboratory).~To analyze the amino acid concentration in blood, drink it immediately before blood collection."
45455430|NCT03928873|Device|High energy ESWT|1500 impulses and 0.01mJ/mm2, 5.8bar, once per week for 4 weeks
45455431|NCT03928873|Device|Sham ESWT|sham treatment using ESWT Probe with only vibration without transferring energy once per week for 4 weeks
45666448|NCT02369510|Drug|Low-dose epinephrine|0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications
45666449|NCT02369510|Drug|High-dose epinephrine|0.2ml of 1:1000 epinephrine will be added to the standard spinal medications
45821678|NCT00002984|Drug|cisplatin|Cisplatin will be given at a dose of 100 mg/m2 at a concentration of 1 mg/ml over one hour on Day 1 and 29 for a total of 2 courses
45821679|NCT00002984|Drug|fluorouracil|5-FU will be given at 500 mg/m2 in 1 liter D5 1/2 by continuous infusion every 12 hours for a total of 8 doses (Total 1.0 g/m2/day X 4 days) on Days 1-4 and 29-32 for a total of 2 courses
45821680|NCT00002984|Drug|paclitaxel|30 mg/m2 - 45 mg/m2 given weekly. The dose each subject receives will depend on when they enter the study
45821681|NCT00002984|Procedure|surgical procedure|Surgical resection should take place approximately 4 weeks following completion of the chemotherapy.
45821682|NCT00002984|Radiation|radiation therapy|The dose of radiation to the tumor and nodal area will be 4500 cGy given as 180 cGy fractions daily, Monday through Friday, for 5 weeks
45821683|NCT02341807|Biological|AAV2-hCHM|Comparison of different dosages of AAV2-hCHM
45963524|NCT05412667|Other|Placebo|"4 days without training: drink 2 hours before bedtime.~3 days of training: drink within 30 minutes after training (uniformly brewed in the laboratory).~To analyze the amino acid concentration in blood, drink it immediately before blood collection."
45963525|NCT00170924|Drug|Valsartan|
45963526|NCT01356940|Drug|dalfampridine ER|dalfampridine ER 10mg bid for 4 weeks
45963527|NCT01356940|Drug|placebo|identical placebo tablet administered bid for four weeks
45963528|NCT00197223|Biological|Influenza vaccine|
45666450|NCT02369510|Drug|No epinephrine|0.2ml of preservative-free saline will be added to the standard spinal medications
45666451|NCT01650194|Drug|enzalutamide|Participants received 160 mg of enzalutamide orally once daily (4 capsules, 40 mg each).
45666452|NCT01650194|Drug|abiraterone acetate|Participants received 1000 mg of abiraterone acetate orally once daily (4 tablets, 250 mg each).
45666453|NCT01650194|Drug|prednisone|Participants received 5 mg of prednisone orally twice daily (2 tablets, 5 mg each).
45666454|NCT02367716|Device|CRT|The study will include the Quartet™ family of left heart leads or any newer St. Jude Medical quadripolar CRT systems, including CRT-P systems, that China Food and Drug Administration (CFDA) might approve in the future
45666455|NCT02366936|Device|Tortle Midliner|The Tortle Midliner is a breathable, knit beanie with two support rolls to help position the infant's head in midline while supine. It can also be worn sidelying or prone. The design includes Velcro adjustments and tabs for nasal cannula and feeding tubes. It is compatible with some ventilation devices, nasal CPAP, X-ray, and bilirubin shades. The beanie is designed to prevent dolichocephaly and provide passive stretch to cervical rotators if head preference has developed. It comes in three sizes and can fit preemies weighing 500 to 2500 g.
45666456|NCT05369936|Other|Aromatherapy|Lavender will be inhaled through three phases
45666457|NCT05369936|Other|Placebo|Vapors of the distal water will be inhaled through three phases
45821684|NCT02323867|Device|Alpha Beta T cell depletion|
45666458|NCT01648166|Other|Environmental sampling|Soil, water, blood, urine, hair and radon testing in homes in Appalachia
45666459|NCT02336282|Device|transcranial Direct Current Stimulation (tDCS)|transcranial Direct Current Stimulation (tDCS) involves modulation of cerebral cortex excitability by the application of weak direct current to the scalp. tDCS is a technique that applies safe, low level direct current through large pads on the scalp to stimulate the underlying brain region, with current level < 0.10 C/cm2. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
45666460|NCT02336282|Device|Sham|The sham intervention will be used in both arms with one arm receiving the sham intervention on day 1 and the other receiving the sham intervention on day 2. The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramp up and no intervention is provided. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
45666461|NCT02336282|Other|Cognitive Assessment|"Three tests will be used to evaluate cognitive function: Dimensional Change Card Sort Test, Flanker Inhibitory Control and Attention Test, and List Sorting Working Memory Test. These measures have a computerized format and are nationally standardized.~The Gray Oral Reading Test measures reading comprehension. Participants are asked to read a set of passages and recall specific details from the stories.~The Woodcock Johnson Understanding Directions measures listening comprehension. Participants listen to a series of complex instructions, then follow the directions by pointing to various objects in a colored picture."
45666462|NCT02336282|Other|Brain Games Stimulation|Cognitive exercises using the Lumosity Brain Games program will be used simultaneously with the tDCS intervention. Participants will be asked to engage in training for 20 minutes a day, two days per week over 5 weeks. This program involves cognitive exercises designed to enhance executive function and processing speed.
45666463|NCT02404220|Drug|Entospletinib|
45666464|NCT02404220|Drug|Vincristine|
45666465|NCT02404220|Drug|Dexamethasone|
45666466|NCT02404220|Drug|CNS Prophylaxis|
45821685|NCT00002990|Biological|BCG vaccine|
45821686|NCT00000997|Drug|Zalcitabine|
45821687|NCT00000697|Drug|Foscarnet sodium|
45963529|NCT00170963|Drug|valsartan/amlodipine|
45963530|NCT05405959|Device|Kinesio tape|The Kinesio Tex Gold FP (Kinesio Tex Tape, Kinesio Holding Corporation, Albuquerque, NM, USA) was used. It was waterproof, porous and adhesive, had a width of 5 cm and a thickness of 0.5 mm. The same brand of tape was used in both groups.
45963531|NCT05405959|Device|Sham Kinesio Tape|The Kinesio Tex Gold FP (Kinesio Tex Tape, Kinesio Holding Corporation, Albuquerque, NM, USA) was used. It was waterproof, porous and adhesive, had a width of 5 cm and a thickness of 0.5 mm. The same brand of tape was used in both groups.
45963532|NCT02492776|Drug|Omeprazole|20 mg oral capsules administered once daily for 8 days
45963533|NCT02492776|Drug|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 5 days
45963534|NCT02492776|Drug|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
45963535|NCT02447614|Procedure|Adenotonsillectomy|Adenotonsillectomy
45821688|NCT00001009|Drug|Dextran sulfate|
45821689|NCT00000703|Drug|Bleomycin sulfate|
46079963|NCT02888691|Other|High carbohydrate diet|
46079964|NCT02844647|Other|Hyperpolarized Pyruvate (13C)|MRI contrast agent
46079965|NCT02821754|Drug|Durvalumab|Flat dose of 1500 mg every 4 weeks.
46079966|NCT02821754|Drug|Tremelimumab|Flat dose of 75 mg every 4 weeks for up to 4 doses.
45821690|NCT00000703|Drug|Vincristine sulfate|
45821691|NCT00000703|Drug|Doxorubicin hydrochloride|
45821692|NCT00000703|Drug|Cyclophosphamide|
45821693|NCT00000703|Drug|Allopurinol|
45821694|NCT00000703|Drug|Methotrexate|
45821695|NCT00000703|Drug|Cytarabine|
45821696|NCT00000703|Drug|Leucovorin calcium|
45963536|NCT02447614|Other|Conservative treatment|Mometasone Furoate Aqueous Nasal Spray or uticasone propionate (1/once qd) and（or）Leukotriene antagonists(4 or 5mg/once qn) or H1 receptor antagonists
45963537|NCT02447614|Other|no treatment|just regular follow-up
45963538|NCT02285725|Procedure|Microdrilling Surgery|All patients will undergo an arthroscopic surgical procedure in which small holes are drilled throughout the areas of damaged cartilage (standard of care)
45963539|NCT02285725|Biological|Injections of BMAC + PRP + HA|All patients will receive up to 12 post-operative intra-articular knee injections of BMAC (derived from iliac crest), PRP (derived from peripheral blood) and HA (Supartz)
45963540|NCT00171002|Drug|valsartan/amlodipine|
45963541|NCT05400031|Biological|propolis|"After obtaining written consent, oral identification of all participants will be performed prior to randomization. Oral diagnosis of children receiving chemotherapy will be repeated on day 0, day 5, and day 10, and the difference between the Oral Mucositis Rating Scale mean scores of the children in the groups will be examined.~Oral Mucositis Assessment: Oral Mucositis Rating Scale will be used. The oral mucosa of children will be evaluated using the World Health Organization Oral Mucositis Classification."
45455432|NCT01225783|Other|Self measurement of limb volume +water displacement|Comparison will be made between self measurement is two types of tape measure compared with water displacement
45455433|NCT03928951|Other|General practitioner reassessment of urinary infection antibiotherapy prescribed by emergency departments|Antibiotherapy will be prescribed by emergency physicians and general practitioners will be contacted 4 to 5 days later to know if antibiotherapy was modified
45666467|NCT02335658|Drug|DSP-5423P|40-80mg/day
45666468|NCT02366468|Drug|ranibizumab 0.5 mg|intravitreal injection
45666469|NCT02366312|Drug|vismodegib|vismodegib is a synthetic, small molecule inhibitor of the sonic Hh pathway, which is involved in tumorigenesis, thus providing a strong rationale for its use in the treatment of a variety of cancers.
45666470|NCT05370560|Other|Plasma transthyretin concentration|Plasma transthyretin concentrations were measured by BS 200 Autoanalyser (Mindray, Shenzhen, China) using immunoturbidimetric method.
45963542|NCT05400031|Biological|Placebo|Placebo
45666471|NCT02335346|Drug|Duloxetine|Administered orally
45666472|NCT02403674|Drug|Doravirine, Tenofovir, Lamivudine|One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth.
45666473|NCT02403674|Drug|ATRIPLA™|One ATRIPLA™ tablet taken q.d. by mouth
45821697|NCT00000703|Drug|Zidovudine|
45821698|NCT00000703|Drug|Dexamethasone|
45821699|NCT00001015|Drug|Ribavirin|
45821700|NCT00000709|Drug|Zidovudine|
45455434|NCT01125085|Radiation|131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)|"Patients will be treated with WBRT administering a total dosage of 30 Gy in fractions of 3 Gy~Dosimetric evaluation with 131I-L19SIP or 124I-L19SIP will be performed to assess eligibility for RIT.~Patients eligible for RIT will receive a therapeutic dose of 131I-L19SIP.~Total treatment duration is up to 4 weeks"
45455435|NCT01125241|Drug|wuling capsule|orally, three tablets each time,three times a day
45455436|NCT01125241|Drug|placebo of wuling capsule|orally, three tablets each time and three times a day
45821701|NCT00001027|Drug|Pentamidine isethionate|
45821702|NCT00000721|Drug|CD4 Antigens|
45821703|NCT00000727|Drug|Pentamidine isethionate|
45821704|NCT00000727|Drug|Pyrimethamine|
45963543|NCT02963883|Other|SVO2 group / control group|
45455437|NCT01125319|Other|blood sample|
45821705|NCT00000727|Drug|Sulfamethoxazole/Trimethoprim|
45821706|NCT00000727|Drug|Sulfadoxine/Pyrimethamine|
45821707|NCT00000727|Drug|Zidovudine|
45821708|NCT00001039|Drug|Ethambutol hydrochloride|
45821709|NCT00001039|Drug|Clarithromycin|
45821710|NCT00001057|Drug|Zidovudine|
45821711|NCT00001057|Drug|Didanosine|
45963544|NCT05399563|Other||
45963545|NCT00171041|Drug|valsartan|
45963546|NCT05393674|Drug|Fedratinib Oral Capsule [Inrebic]|400 mg once daily p.o. from cycle 1-n, dose adjustment will be made according to the protocol
45963547|NCT05393674|Drug|Nivolumab|240 mg every 2 weeks i.v. from cycle 2-n
45963548|NCT05392699|Biological|human single chain IL-12 mRNA-single dose|human single chain IL-12 mRNA administered as specified in the treatment arm with injection once only
45963549|NCT05392699|Biological|human single chain IL-12 mRNA-multiple dose|human single chain IL-12 mRNA administered as specified in the treatment arm with injection once per week for 3 weeks
45963550|NCT05392426|Device|Left Ventricular Global Longitudinal Strain|Left Ventricular Global Longitudinal Strain is collected from Speckle tracking imaging (STI) technique of echocardiography. This index is tested before and after the surgery.
45963551|NCT05392426|Device|EF CO SV EDV ESV|Ejection fraction、cardiac output、stroke volume、end diastolic volume、end systolic volume. These indexes are collected before and after the surgery, using traditional echocardiography.
45963552|NCT00179556|Drug|Isoflavone supplement|
45963553|NCT00171080|Drug|valsartan|
45963554|NCT00171080|Drug|irbesartan|
45963555|NCT05391568|Other|Real Dry Needling|"Needle will be placed at trapezius muscle. Fast-in, Fast-out technique will be used at the active trigger point of upper trapezius muscle."
45963556|NCT05391568|Other|Sham Dry Needling|"Sham needle will be placed at trapezius muscle. Simulated Fast-in, Fast-out technique will be used at the active trigger point of upper trapezius muscle."
45963557|NCT02229877|Drug|Omeprazole|40 mg oral capsules administered twice daily for 8.5 days
45963558|NCT02229877|Drug|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days
45963559|NCT02229877|Drug|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
45963560|NCT02229877|Drug|Gefapixant|Gefapixant oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days
45963561|NCT00171119|Drug|valsartan|
46079967|NCT02821754|Procedure|Trans-arterial Catheter Chemoembolization (TACE)|TACE will be performed on Day 36 (+/-96hrs).
45455438|NCT03931837|Device|Tourniquet: Systolic blood pressure + 75 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
45458543|NCT05187728|Other|No Intervention|No more intervention will be given.
45963562|NCT02122666|Procedure|muscle biopsy|A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).
45666474|NCT02403674|Drug|Placebo|Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.
45821712|NCT00001705|Drug|GP100 peptide|
45821713|NCT00001705|Drug|IL-2|
45821714|NCT00002293|Drug|Nystatin|
45458544|NCT05126056|Other|Plant stanol ester|Product with active ingredient vs product without active ingredient
45666475|NCT04908020|Other|Follow-up patients|The intervention consists in the assessment of some psychological aspects (post traumatic stress symptoms and coping) of cancer patients in follow-up care, through specific tests. Each patient fills out the test battery during the psychological consult. At the same time, it is involved a parent to collect personal and clinical data through an ad hoc questionnaire.
45821715|NCT00002299|Drug|Interferon beta-1b|
45963563|NCT02963961|Behavioral|Preoperative Cognitive Training Battery|Patients will engage in a daily preoperative cognitive training battery (BrainHQ, Posit Science) that aims to improve attention, memory, and visuospatial processing.
45666476|NCT02403206|Device|Femtosecond laser|Laser console and a patient interface used to cut tissue during cataract removal of the crystalline lens
45666477|NCT02403206|Procedure|Continuous Curvilinear Capsulorhexis (CCC)|Standard-of care manual procedure (using either needles or forceps) for creating capsulorhexis, ie., opening in capsular bag during anterior segment ophthalmic surgery
45821716|NCT00002299|Drug|Ganciclovir|
45821717|NCT00380497|Drug|PEG-Lyte®|
45963564|NCT02102113|Drug|Placebo|placebo
45963565|NCT02102113|Drug|Very Low Dose THC|Subjects will receive 0.010mg/kg.
45963566|NCT02102113|Drug|Low Dose THC|Subjects will receive 0.018 mg/kg over 20 minutes.
45963567|NCT02088775|Procedure|PET scan|Undergo PET-CT scan
46079968|NCT02821754|Procedure|Radiofrequency Ablation (RFA)|RFA will be performed on Day 36 (+/-96hrs).
46079969|NCT02821754|Procedure|Cryoablation|Cryoablation will be performed on Day 36 (+/-96hrs).
46079970|NCT02815618|Device|BabyLux Neuro-monitor|Measurement of cerebral blood flow index (CBFi) and tissue oxygen saturation (StO2).
46079971|NCT02781883|Drug|BP1001 in combination with Ventoclax plus decitabine|BP1001 in combination with Ventoclax plus decitabine
46079972|NCT02781883|Drug|BP1001 plus decitabine|BP1001 plus decitabine in ventoclax intolerant or resistant subjects
46079973|NCT02772003|Biological|Electroporation-Mediated Plasmid DNA Vaccine Therapy|Undergo electroporation
45821718|NCT00380497|Drug|Pico-Salax®|
45821719|NCT00001063|Drug|Stavudine|
45821720|NCT00001063|Drug|Zidovudine|
45821721|NCT00001063|Drug|Didanosine|
45821722|NCT00002305|Drug|Flucytosine|
45821723|NCT00002305|Drug|Fluconazole|
45821724|NCT00002305|Drug|Amphotericin B|
45821725|NCT00001753|Procedure|Magnetic resonance imaging|
45821726|NCT00001765|Device|Nexell Isolex with T-cell Depletion|
45821727|NCT00001765|Device|Baxter isolex 300i|
45821728|NCT00001081|Drug|Nitazoxanide|
45821729|NCT00002311|Drug|Wobenzym|
45821730|NCT00002317|Drug|Trimetrexate glucuronate|
45963568|NCT02088775|Procedure|CT Scan|Undergo PET-CT scan
45963569|NCT02088775|Procedure|hepatic artery embolization|Undergo standard radioembolization
45963570|NCT00553228|Biological|Tdap|0.5 mL IM once at visit #2
45963571|NCT00553228|Biological|Td|0.5 mL IM once at visit #2
45963572|NCT02963688|Genetic|Ion AmpliSeq BRCA 1/2 Panel (Life Technologies, Carlsbad, CA, USA) ,Ion PGM platform|BRCA1,2 Germline /Somatic mutation test
45963573|NCT05379790|Drug|Irinotecan|3 weekly IP irinotecan (max 6 cycles), dose via dose-escalation design as specified per arm.
45666478|NCT02333630|Other|AsthmaCare mobile health application|Personalized, interactive mobile health application designed to send daily medication reminders and assist with self management
45963574|NCT05379790|Drug|CAPOX|Capecitabine 1000 mg/m2 twice daily day 1-14 (per os), and Oxaliplatin 130 mg/m2 on day 1 IV infusion.
45963575|NCT00171236|Drug|Fluvastatin|
45963576|NCT01744171|Biological|Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine|Given ID
45455439|NCT03931837|Device|Tourniquet: Systolic blood pressure + 100 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
45963577|NCT01744171|Other|Laboratory Biomarker Analysis|Correlative studies
45963578|NCT05357521|Other|stress test|TSST- psychosocial stress test
45963579|NCT00171275|Drug|Fluvastatin|
45821731|NCT00002317|Drug|Leucovorin calcium|
45821732|NCT00001123|Drug|Ribavirin|
45821733|NCT00002323|Drug|Nevirapine|
45821734|NCT00002323|Drug|Zidovudine|
45821735|NCT00002329|Drug|Celgosivir hydrochloride|
45963580|NCT05350267|Behavioral|HALO|"Health and Lifestyle Behaviors in Offspring, or HALO is designed for mothers who recently had bariatric surgery who have a school-aged child. HALO focuses on providing each mother with education and parenting strategies to improve her child's healthy lifestyle behaviors, such as her child's eating and physical activity, while she is engaged in her own lifestyle behavior change after bariatric surgery."
45963581|NCT05350267|Behavioral|Enhanced Standard of Care|The comparator group will receive monthly mailings of publicly available and age-appropriate handouts on healthy eating, physical activity, screen time, and healthy sleep habits
45963582|NCT05349448|Drug|Hylase plus Triamcinolone plus sterile isotonic saline|transforaminal fluroscopic epidural injection
45963583|NCT05349448|Drug|Hylase plus Dexmedetomidine plus Triamcinolone|transforaminal fluroscopic epidural injection
45821736|NCT00001873|Device|Isolex 300i plus MoAbs|
45821737|NCT00380965|Drug|Cesamet™ (nabilone)|
45963584|NCT00197262|Drug|GW685698X Aqueous Nasal Spray|
45963585|NCT00171353|Drug|valsartan|
45963586|NCT05347810|Other|Application of repetitive forces mimicking exoskeleton use|The investigational treatment consists of applying a predefined set of continuous and repetitive forces to the participant's thigh. It is applied using a custom device that has been designed specifically for this study. The forces to be applied are based on forces measured during exoskeleton use and will not exceed pain pressure thresholds reported in literature. The participants will hold an enabling switch at all times which they can activate to release the force exerted to their thigh. Alternatively, the experimenter can activate an emergency switch if the situation seems unsafe.
45963587|NCT01656343|Drug|Calcineurin inhibitors (CNI)|No Intervention
45963588|NCT01656343|Drug|Belatacept|No Intervention
45963589|NCT01550185|Drug|eltrombopag olamine|Given PO
45963590|NCT01550185|Procedure|standard follow-up care|Receive standard care
45458545|NCT05126056|Other|Placebo|Placebo
45458546|NCT01352234|Drug|Acetylsalicylic Acid 160 mg|Capsule containing Acetylsalicylic Acid 160mg pill with lactose
45963591|NCT01539811|Procedure|Surgical incision and drainage of diabetic foot infection|Incision and drainage of diabetic foot infection with or without amputation of toes or the forefoot, depending on the condition of the foot
45963592|NCT01539811|Drug|Short course antibiotics|Short course (<2 weeks) of antibiotics will be prescribed
45458547|NCT01352234|Drug|Acetylsalicylic Acid 80 mg|Capsule containing Acetylsalicylic Acid 80mg pill with lactose
45666479|NCT02333630|Other|Asthma education|A website with links to written asthma education and videos
45666480|NCT02401412|Device|Test Ostomy Barrier|
45666481|NCT02401412|Device|Control Ostomy Barrier|
45666482|NCT02365298|Device|etafilcon A|etafilcon A soft contact lens
45666483|NCT02365298|Device|nelfilcon A|nelfilcon A
46079974|NCT02772003|Biological|HCV DNA Vaccine INO-8000|Given IM
46079975|NCT02772003|Other|Laboratory Biomarker Analysis|Correlative studies
46079976|NCT02772003|Other|Quality-of-Life Assessment|Ancillary studies
46079977|NCT02772003|Biological|Rocakinogene Sifuplasmid|Given IM
45666484|NCT02365064|Device|AirCurve 10 ASV|Device is able to provide both ASV therapy and CPAP therapy modes.
45821738|NCT00001129|Device|Electronic Medication Reminder System|
45821739|NCT00001129|Behavioral|Medication Manager|
45821740|NCT00001135|Drug|Nevirapine|
45821741|NCT00003002|Biological|HER-2/neu peptide vaccine|
45821742|NCT00003002|Biological|sargramostim|
45821743|NCT00001891|Procedure|Myocardial contrast echocardiography|
45821744|NCT00001891|Procedure|Dobutamine echocardiography|
45821745|NCT00383864|Drug|Pegylated interferon and ribavirin|
45821746|NCT00001903|Drug|RSV Polyclonal Immunoglobulin|
45821747|NCT00002335|Drug|Emtricitabine|
45963593|NCT01539811|Drug|Long course antibiotics|Long course (>2 weeks) of antibiotics will be prescribed
45963594|NCT01527136|Drug|entolimod|Given IM or SC
45963595|NCT01527136|Other|pharmacological study|Correlative studies
45963596|NCT01527136|Other|laboratory biomarker analysis|Correlative studies
45963597|NCT00171392|Drug|Enteric-coated mycophenolate sodium|
45963598|NCT05331586|Behavioral|Remote Exercise|The pregnant women will perform a home-based structured exercise programme. The exercise will be remotely monitored since the first gestational trimester until delivery
45963599|NCT00179595|Behavioral|relaxation response- meditation|
45963600|NCT05331430|Other|Dry needling on cervical trigger point|One experimental group will receive dry needling treatment on the upper trapezius fibres using the Hong technique and the other experimental group will receive passive muscle stretching treatment on the upper trapezius fibres.
45963601|NCT00171431|Drug|Tegaserod|
45963602|NCT00197301|Biological|Vaccination|
45963603|NCT01330030|Drug|Selegiline|6mg/24 hrs for 8 weeks
45963604|NCT01330030|Other|matching placebo|placebo/24hrs for 8 weeks
45963605|NCT00171470|Drug|Tegaserod|
45963606|NCT00179634|Behavioral|Visualization relaxation|
45963607|NCT00179634|Behavioral|Visual Milieu Enhancement (Fine art photograph)|
45963608|NCT01280032|Radiation|intraoperative radiotherapy|intraoperative radiotherapy (8 Gy) during kyphoplasty for spinal metatsases
45963609|NCT00171509|Drug|Cyclosporine microemulsion|
45963610|NCT00941356|Dietary Supplement|Bio-K+ CL1285|2 capsules per day before breakfast
45963611|NCT00941356|Dietary Supplement|Placebo|2 capsules per day before breakfast
45666485|NCT02401256|Drug|Efavirenz|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
45821748|NCT02336672|Device|Cryothermal ablation|Procedures are performed with patients sedated by anaesthesiologists. Device setting and application time are set and recorded on a computer, that analyzes the changes of the tissue's properties. The setting of the maximal application time is based on the results of our previously described ex-vivo and in-vivo studies and is adjusted to the tumour's size, thus ensuring a reduction of procedure-related complications. Application of Power Doppler makes the procedure safer. The HybridTherm probe is guided under real-time EUS into the tumour, and the success of its placement is an index of the treatment's feasibility. The system analyzes the effects on the tissue and EUS records the changes of the tissue, the growing edema around the treated area, and the tissue devitalization.
45821749|NCT00002341|Drug|Itraconazole|
45821750|NCT04331431|Procedure|Spinal cord tumor resection|Excision of intradural tumors
45963612|NCT05309512|Biological|KN052|0.01mg/kg, 0.1mg/kg, 0.3mg/kg, 1mg/kg, 2mg/kg, 4mg/kg, 6mg/kg, 9mg/kg, RP2D once every two or three weeks intravenously
45963613|NCT00179712|Drug|CC-5013|
45963614|NCT00179712|Drug|topotecan|
45963615|NCT00832702|Procedure|Cardiac MRI|CMRI provides unique clinical utilities including excellent soft tissue characterization and contrast, three-dimensionality, quantitation of blood flow, and overall superior temporal and spatial resolution to image vascular and myocardial abnormalities.
45963616|NCT00611572|Drug|iomazenil|Given as IV infusion
45963617|NCT00611572|Drug|iomazenil|saline IV infusion
45963618|NCT00197340|Drug|Epidural ropivacaine|
46079978|NCT02751710|Other|Whole-body FDG PET-CT alone|FDG PET-CT imaging
46079979|NCT02742246|Behavioral|Individual clinician-provided CBT|Individual clinician-provided CBT
46079980|NCT02742246|Behavioral|CBT4CBT|CBT computer program assisted therapy
46079981|NCT02708108|Behavioral|Dietary Intervention|Beginning at time of diagnosis, the dietary component of the intervention uses a personalized menu to implement high protein, moderate fat, and low glycemic index/high fiber diet to achieve a minimum net -10% daily caloric deficit during the induction phase of chemotherapy.
46079982|NCT02708108|Behavioral|Activity and Exercise Intervention|"Beginning at the time of diagnosis, the exercise and activity component uses an activity menu to implement a target level of 200 minutes per week of moderate exercise activity (as estimated by metabolic equivalents) during the induction phase of chemotherapy."
45821751|NCT00001909|Drug|Soluble recombinantly produced IL-4R|
45821752|NCT00001189|Procedure|radiotherapy|
45821753|NCT00002347|Drug|Saquinavir|
46079983|NCT02684162|Biological|Donor Lymphocytes|Given IV
46079984|NCT02684162|Drug|Guadecitabine|Given SC
45821754|NCT00002347|Drug|Nevirapine|
45963619|NCT00171587|Drug|PTK787/ZK 222584 (vatalanib)|
45963620|NCT05276401|Drug|5% Bisphosphocin Topical Gel|Topical Gel
45963621|NCT05276401|Drug|Placebo Topical Gel|Topical Gel
45963622|NCT05276401|Drug|10% Bisphosphocin Topical Gel|Topical Gel
45963623|NCT05265052|Drug|3D1002 (50 mg)(Phase IIa)|1 tablet of 3D1002 per oral dose
45963624|NCT05265052|Drug|3D1002 (100 mg)(Phase IIa)|2 tablets of 3D1002 per oral dose
45963625|NCT05265052|Drug|3D1002 (150 mg)(Phase IIa)|3 tablets of 3D1002 per oral dose
45963626|NCT05265052|Drug|3D1002 monotherapy (Phase IIb)|3D1002 is administered at recommended dose with mimic OxyContin tablets.
45963627|NCT05265052|Drug|OxyContin monotherapy (Phase IIb)|OxyContin is administered at an initial dose of 10 mg per dose with mimic 3D1002 tablets.
45963628|NCT05265052|Drug|3D1002 + OxyContin (Phase IIb)|3D1002 is administered at recommended dose, and OxyContin is administered at an initial dose of 10 mg per dose.
46079985|NCT02684162|Other|Laboratory Biomarker Analysis|Correlative studies
46079986|NCT02676960|Other|MRI without sedation|
45821755|NCT00002347|Drug|Zidovudine|
45821756|NCT00002347|Drug|Zalcitabine|
45821757|NCT00001237|Drug|granulocyte-macrophage colony stimulating factor (GM-CSF)|
45821758|NCT00002353|Biological|P3C541b Lipopeptide|
45821759|NCT00002359|Biological|HIV-1 Immunogen|
45963629|NCT05261893|Other|Elongation Longitudinaux Avec Decoaption Osteo Articulaire|It creates tension in the spine and stretch the fascia and is a myofascial stretch technique and manual physical therapy tool
45963630|NCT05261893|Other|Post Facilitation Stretching|Post Facilitation Stretching effectively decreases hamstring muscle tightness while also increasing popliteal angle range. Post-facilitation exercise can help to relieve knee pain. It effectively raises ROM or aligns collagen fibers due to the muscle contraction performed immediately before stretching.
45963631|NCT00171626|Drug|Diclofenac Topical Sodium Gel 1%|
45963632|NCT05261854|Device|Pressure biofeedback|Deep cervical flexor training by using preesure biofeedback will be given 5 days a week for 6 week Conventional exercise for deep cervical muscle training will be given 5 days a week for 6 weeks
45963633|NCT05261854|Other|Conventional exercises for deep cervical muscle training|Conventional exercise for deep cervical muscle training will be given 4 days a week for 6 weeks
45963634|NCT04723290|Diagnostic Test|Serological tests for SARS Cov-2|Each participant will have a blood test on a dry tube of maximum 8 ml of whole blood
45963635|NCT05261815|Other|Ultrasound Therapy|Ultrasound Therapy improves the pain management in patients with herniation. It eases down the severity of symptoms as well.
45963636|NCT05261815|Other|High Intensity Laser Therapy|Treatment of low disc herniation should be non-surgical, pharmacological and by physical therapy modalities. Laser radiation with high intensity used as a modality called high intensity laser therapy. It is used to relieve the pain by three process; Photo-chemical, Photo-thermal, Photo-mechanical. High Intensity Laser Therapy uses high intensity laser irradiation and low light absorption.
45963637|NCT05259358|Other|exercise|exercises that increase muscular endurance
45963638|NCT00171665|Drug|Diclofenac topical sodium gel 1%|
45963639|NCT00179751|Drug|CC-5013|
45963640|NCT00179751|Drug|gemcitabine|
45963641|NCT05255419|Device|OnCall mobile health peer support app|"Mobile health platform that provides anonymous access to peer support services that has been co-design by and for Canadian public safety personnel. OnCall is for frontline public safety providers; features include links to mental health self-assessment tools, a wellness toolbox, tips to cope articles and peer wisdom videos, and options to reach out to a peer support provider of their choice via telephone or text. The OnCallSupport app is for the peer support providers which includes a list of resources and an opportunity to create post-action reports following the peer support encounter. Connections are made to peer support via a telephone service that disguises the contact information of both parties. The app platform includes options to complete feedback surveys related to the app and to the peer support encounter."
45963642|NCT05252806|Diagnostic Test|MRI examination of the prostate|Participants will undergo one MRI examination of approximately 45 minutes including an intramuscular injection with an antispasmodic agent to minimize bowel movement
46079987|NCT02648009|Drug|Hyperpolarized (13) Pyruvate Injection|MRI with Hyperpolarized Pyruvate (13) Injection
45963643|NCT05223478|Drug|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
45963644|NCT05223478|Drug|Phentolamine Ophthalmic Solution Vehicle|Phentolamine Ophthalmic Solution Vehicle
45963645|NCT04710459|Procedure|cryotherapy|Group 1 included 30 patients, they were subjected to chemoradiotherapy plus endobronchial cryotherapy. Group 2 included include 30 patients, they were subjected to chemoradiotherapy.
45963646|NCT00171743|Drug|Cyclosporine microemulsion|
45963647|NCT05209360|Device|Medial or Lateral Wedge|A foam wedge that is placed inside the shoe under the CDO, that runs along the length of the foot. The tall side of the wedge will be placed on the medial (Medial Wedge) or lateral (Lateral Wedge) aspect of the shoe to preferentially load the medial or lateral side of the foot.
45963648|NCT05209360|Device|Carbon Fiber Custom Dynamic Orthosis|A device that consists of a proximal cuff that wraps around the leg just below the knee, a posterior strut that runs the length of the leg, and a semi-rigid footplate that goes under the length of the foot.
45963649|NCT02432326|Drug|BBI608|The BBI608 starting dose is 240 mg twice daily (480 mg total daily). Dose will be decreased to 160 mg twice daily (320 mg total daily) at modification level 2 and 80 mg twice daily (160 mg total daily) at modification level 3. For BBI608 once daily dosing, doses at starting level and modification level 1 are 240 mg once daily, and 480 mg once daily at escalated levels. Dose will be decreased to 160 mg once daily at modification level 2 and 80 mg once daily at modification level 3.
46079988|NCT02648009|Drug|Gadolinium|MRI with Gadolinium
46079989|NCT02619682|Drug|Ixazomib Citrate|Given PO
46079990|NCT02619682|Other|Laboratory Biomarker Analysis|Correlative studies
46079991|NCT02619682|Drug|Lenalidomide|Given PO
46079992|NCT02617589|Drug|Nivolumab|
46079993|NCT02617589|Drug|Temozolomide|
46079994|NCT02617589|Radiation|Radiotherapy|
46079995|NCT02587403|Device|Fortiva™ Porcine Dermis|Fortiva Porcine Dermis implantation during repair of complex ventral hernia
46079996|NCT02587403|Device|Strattice™ Reconstructive Tissue Matrix|Strattice tissue matrix implanted during repair of complex ventral hernia
46079997|NCT02540707|Drug|solifenacin|solifenacin 5 mg per day for 12 weeks
46079998|NCT02540707|Drug|mirabegron|mirabegron 25 mg per day for 12 weeks
46079999|NCT02531932|Drug|Carboplatin|Carboplatin will be administered if ANC > 1.0 and platelets are >75k
46080000|NCT02531932|Drug|Everolimus|The study drug Everolimus will be self-administered (by the patients themselves).
46080001|NCT02506959|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
46080002|NCT02506959|Drug|Busulfan|Given IV
46080003|NCT02506959|Drug|Gemcitabine Hydrochloride|Given IV
46080004|NCT02506959|Other|Laboratory Biomarker Analysis|Correlative studies
46080005|NCT02506959|Drug|Melphalan|Given IV
46080006|NCT02506959|Drug|Panobinostat|Given PO
45963650|NCT02432326|Drug|BBI503|The BBI503 starting dose is 200 mg once daily. Dose at modification level 1 to 3 will be 100 mg once daily.
45963651|NCT00179790|Procedure|Extracorporeal Photopheresis|Patient will undergo ECP treatment pre and post stem cell transplant infusion
46080007|NCT02506959|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
46080008|NCT02506959|Other|Pharmacological Study|Correlative studies
46080009|NCT02504346|Drug|AZD9291|
45963652|NCT05200936|Drug|MM-120|MM-120 is a psychedelic drug that can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages MM-120 manifests primarily visual, as well as auditory, hallucinations.
45963653|NCT05200936|Other|Placebo|A treatment which is designed to have no therapeutic value.
45963654|NCT00171782|Drug|VALSARTAN+HYDROCHLOROTHIAZIDE|
45963655|NCT02417701|Other|Laboratory Biomarker Analysis|Correlative studies
45963656|NCT02417701|Other|Pharmacological Study|Correlative studies
45963657|NCT02417701|Drug|Sapanisertib|Given PO
45963658|NCT00197379|Drug|roxithromycin|
46080010|NCT02471807|Device|Edwards FORMA Tricuspid Transcatheter Repair System|
46080011|NCT02446626|Procedure|Skin biopsy|Optional 2-3mm skin punch biopsies will be performed.
46080012|NCT02446626|Procedure|Blood draw|Peripheral blood draws will be performed.
45963659|NCT04723745|Behavioral|V-TRACTS Assessment/Feedback|The proposed V-TRACTS assessment strategically targets emotional, cognitive and behavioral functions that we have determined are highly predictive of long-term outcome in Veterans. The assessment targets domains of head injury, psychological trauma, depression, suicidality, anxiety, chronic pain and sleep, substance use and activity level. This assessment will, in most cases, be completed online using the Qualtrics platform and online using telehealth or other approved platform for the clinical interview. Once the assessment is complete, the clinical team will convene a consensus meeting to review the case and determine a course of recommended additional assessment and/or rehabilitation action. After a consensus is reached, a V-TRACTS psychologist/supervised fellow will provide comprehensive feedback encompassing the entire assessment battery and offer rehabilitation options that would be targeted to the individual veteran's needs via VA telehealth or other approved online service.
45821760|NCT04925713|Biological|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~Immunomodulatory Agent~Route of Administration:~Intralesional (i.e. injection of cutaneous, subcutaneous or lymph nodal lesions)~Mechanism of Action:~Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses."
45963660|NCT04723745|Behavioral|OPTIONAL Brief Assessment of Thinking|A neuropsychological/cognitive assessment will be conducted to gather information about functioning in the areas of memory, attention, and thinking. This assessment is designed to be done online in a single session, and it will take approximately 45-90 minutes to complete. The test battery is designed to focus on the specific cognitive abilities thought to be impacted by blast, mTBI, PTSD, etc. This battery is not intended to be an exhaustive assessment of all neuropsychological functions.
45963661|NCT04723745|Behavioral|OPTIONAL STEP-Home-Brief|STEP-Home-Brief is a condensed version of the 12-week experimental program STEP-Home that will target four core skills (problem solving, emotional regulation, attention training, and health and wellness). It will be individualized to Veterans' problems: vocation/career, community reintegration, psychoeducation to destigmatize barriers to mental health, substance misuse, anger management, and family and intimate partner relationships. STEP-Home-Brief will include 1-3 sessions using the same treatment modules as the 12-week program in a condensed, targeted format.
45963662|NCT04723745|Behavioral|OPTIONAL At-home Exercise Program|This is a 5-week, full-body exercise program that can be done in the convenience of the Veteran's home, using only bodyweight as resistance and with household items as equipment. Given the online delivery of this program, they will receive access to instructional videos and materials that demonstrate how to perform each exercise safely and correctly. Participants will be contacted by study staff weekly over the phone to maintain interest and monitor adherence during the study.
45963663|NCT04723745|Behavioral|OPTIONAL Referral to 12-week STEP-Home|Referral to the experimental 12-week STEP-Home workshop research study (VABHS IRB #3210).
45963664|NCT04723745|Behavioral|OPTIONAL Clinical Referral|Clinical referrals to VABHS clinical services based on assessment and patient-directed primary problem/complaint.
45963665|NCT00197418|Drug|rabeprazole, amoxicillin, clarithromycin, metronidazole|
45963666|NCT05101369|Drug|INCB086550|INCB086550 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radio labeled INCB086550.
45963667|NCT00171821|Drug|Deferasirox|
45963668|NCT00179829|Procedure|WT 1 Testing|
45963669|NCT05098054|Drug|Soticlestat|Soticlestat tablets.
45963670|NCT05070442|Behavioral|Norm-based messaging and peer comparison features|"Participants are shown a version of NUSMart which includes Nutri-Score labels that are enabled and displayed besides all the products in the store. Additionally, they are shown a video that gives them background information about Nutri-Score labels and describes the following features enabled in this intervention:~Norm-based messaging will be displayed in the form of a happy or sad emoticon based on whether the participant's current basket average Nutri-Score (weighted by number of servings) is above or below other shoppers (Nutri-Score=3.98).~Peer comparison will be implemented as a vertical ruler display of the participant's current basket average Nutri-Score (weighted by number of servings) as well as that of their peers.~Nutri-Score=3.98 was chosen as it is 10% better than the mean Nutri-Score of baskets purchased by participants in the Nutri-Score labelled intervention arm of a prior study."
45458548|NCT03500068|Diagnostic Test|biopsies & blood analyses|They will take blood and a biopsy from the metastase in the patient
45666486|NCT02401256|Drug|Bupropion|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
45666487|NCT02401256|Drug|Rosuvastatin|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
45821761|NCT00001933|Drug|Nefiracetam|
45821762|NCT00001249|Drug|Yttrium-90 radiolabeled anti-Tac antibody|
45821763|NCT00380575|Drug|YM087|
45821764|NCT00001951|Drug|TMTDS|
45821765|NCT00001963|Procedure|hemoglobin-transported nitric oxide|
45821766|NCT00002365|Drug|LXR015-1|
45963671|NCT05070442|Behavioral|Financial Incentives leveraging on loss aversion|"Participants are informed that they have received an additional $5 towards their participant reimbursement. However, this amount will be forfeited if they check-out with a basket average Nutri-Score (weighted by the number of servings) that falls below the average Nutri-Score of other shoppers i.e. 3.98. An indicator on the screen that informs the participants of this potential forfeiting will be included."
45963672|NCT00179868|Behavioral|C-Reactive Protein levels|"Each patient enrolled in the study will have a serum quantitative c-reactive protein (crp) level drawn on the day of transplant, day 7 of transplant, and twice weekly after that until recovery of neutrophil count (approximately 20-25 days). Patients will be followed for 100 days post-transplant for the development of the following complications:~Sepsis- defined as fever, positive blood culture, need for fluid resuscitation and/or pressor support.~Acute GVHD > grade II defined according to the Seattle criteria~VOD- defined according to the modified Seattle criteria"
45666488|NCT02401256|Drug|Montelukast|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
45666489|NCT02349295|Drug|Placebo|Administered SC
45821767|NCT00380731|Behavioral|Individual Cognitive Behavioral Therapy|CBT includes 16 weekly 60-minute individual CBT sessions for social anxiety disorder.
45963673|NCT05054023|Drug|Soulagel®|topic gel
45963674|NCT05054023|Drug|Arthrosyl®|topic gel
45963675|NCT00171860|Drug|imatinib mesylate|
45963676|NCT00553930|Drug|Pegylated interferon alfa-2a and Ribavirin|All patients will be treated with the combination of pegIFN-α 2a (135 μg per week)plus oral Ribavirin at a dose of 800 mg per day. The treatment will be continued up to 20 weeks after reaching an undetectable plasma RNA-HCV. Treatment will be discontinued for patients who did not achieve a reduction of al least 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 and will be considered as viral failures.
45963677|NCT00553930|Drug|Pegylated interferon alfa 2a and Ribavirin|Pegylated interferon alfa 2a (135 ug/week)and Ribavirin (800 mg/day). Duration: 20 weeks after reaching an undetectable plasma RNA_HCV. Treatment will be discontinued for patients who did not achieve a decrease of >= 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 of treatment or earlier and will be considered as viral failures.
45963678|NCT00179907|Procedure|Photon Radiosurgery System (Intrabeam)|In this study we had intended to perform a similar dose escalation study with doses ranging from 10-19 Gy, 10-16 Gy and 10 - 14 Gy for tumors < 20 mm, 21-25 mm and 26-40 mm respectively
45963679|NCT05038345|Procedure|Pull through surgery|The principal purpose of pull through surgery for Hirschsprung disease is to remove aganglionic bowel and reconstruct the intestinal tract by connecting the normally innervated bowel just above the anus so that normal sphincter function is preserved.
45963680|NCT00171899|Drug|imatinib mesylate|
45821768|NCT00002377|Drug|Valganciclovir|
45963681|NCT05031325|Device|Endoscopic submucosal dissection with Purastat|Purastat (peptidic gel) application
45821769|NCT00002377|Drug|Ganciclovir|
45963682|NCT05004259|Drug|Daratumumab / Hyaluronidase Injection|Subcutaneous injection of daratumumab and hyaluronidase
46080013|NCT02446626|Device|Xenodiagnosis|Larval ticks will be obtained from Dr. Sam Telford from a laboratory maintained tick colony at Tufts Veterinary School. These ticks are hatchedfrom eggs laid by ticks that have fed only on specific pathogen free laboratory animals that were purchased from established vendors. Between 25-30 larval ticks that have been aged and are known to be ready to attach will be placed on the study participant.
46080014|NCT02375841|Behavioral|psychometric tests, questionnaires and neurocognitive assessments|
45821770|NCT00380809|Procedure|Rotational Atherectomy + PES|
45821771|NCT00380809|Procedure|Standard Treatment (PES without Rotational Atherectomy)|
45458549|NCT01364792|Drug|Valaciclovir|4 times 2 grams valaciclovir per day, administrated orally, for seven days.
45666490|NCT02349295|Drug|Ixekizumab 80 mg Q4W|Administered SC
45666491|NCT02349295|Drug|Ixekizumab 80 mg Q2W|Administered SC
45821772|NCT00001339|Drug|doxorubicin, vincristine, and etoposide with mitotane|
45821773|NCT00001993|Drug|Butyldeoxynojirimycin|
45821774|NCT00001993|Drug|Zidovudine|
45821775|NCT00001999|Drug|Globulin, Immune|
45821776|NCT00001999|Drug|Ganciclovir|
45821777|NCT00002383|Drug|Saquinavir|
45963683|NCT00197457|Procedure|serum pepsinogen|
45963684|NCT00197457|Procedure|urea breath test|
45963685|NCT00171938|Drug|imatinib mesylate|
45963686|NCT05003050|Other|Meditation|Holistic natural therapy
45821778|NCT00002389|Drug|Abacavir sulfate|
45821779|NCT00002389|Drug|Lamivudine|
45821780|NCT00002389|Drug|Zidovudine|
45821781|NCT00001357|Drug|Interleukin-2|
45821782|NCT00001381|Drug|suramin|
45821783|NCT00002005|Drug|CD4 Antigens|
45821784|NCT00002011|Drug|Methoxsalen|
45821785|NCT00002017|Drug|Interleukin-2, Polyethylene Glycolated|
45821786|NCT00002023|Drug|Zidovudine|
45821787|NCT00002029|Drug|Fat Emulsion 2%|
45821788|NCT00002029|Drug|Fat Emulsion 20%|
45821789|NCT00002035|Drug|Zidovudine|
45821790|NCT00002035|Drug|Didanosine|
45821791|NCT00002041|Drug|Amphotericin B|
45821792|NCT04716907|Genetic|Single-Nucleotide Polymorphisms (SNP) within the TCRA/D region|DNA extraction from blood samples, PCR and Sequencing
45963687|NCT05003050|Other|Pranic Healing|Energy therapy
45963688|NCT04981132|Behavioral|Pain Neuroscience education + Progressive therapeutic exercise training|The education group will have a comprehensive patient education which includes; description, transmission, representation of pain, central sensitization, neuroplasticity, its relation to body systems, psychosocial and emotional factors affecting pain, pain behavior, and lifestyle changes to cope with pain, etc. Plus, the group will have supervised progressive therapeutic exercises via the telerehabilitation method.
45963689|NCT04981132|Behavioral|Progressive therapeutic exercise training|The exercise group will have supervised progressive therapeutic exercises via the telerehabilitation method.
45963690|NCT02351947|Other|upper limb rehabilitation for chronic stroke|subjects in this group will receive upper limb motor learning rehabilitation and undergo fMRI/EEG testing as well as testing of motor function (AMAT and FM).
45458550|NCT02318836|Drug|Lofexidine Hydrochloride (HCl) tablets|Lofexidine HCl tablets (two 200 µg tablets) will be administered orally with 240 mL room temperature tap water as a single 400 µg dose in the morning on Day 1 after a 10 hour overnight fast.
45821793|NCT04716907|Biological|Blood sample|Dosage of sj/βTREC ratio, lymphocytes, cytokines and chemokines.
45821794|NCT04716907|Diagnostic Test|CT Scan|Thymus and lung imaging
45821795|NCT04716907|Biological|Bronchial fibroscopy|Bronchoalveolar lavage in mechanically ventilated patients for dosage of recent thymic emigrants in lungs
45821796|NCT00002047|Drug|Zidovudine|
45821797|NCT00002053|Drug|Pentamidine isethionate|
45821798|NCT00002059|Drug|Inosine pranobex|
45963691|NCT00179946|Procedure|HLA typing|
45963692|NCT02281513|Other|Smartphone Application|Is a self-monitoring tool to document fruit and vegetable consumption, sleep quantity and quality, and physical activity
45963693|NCT02281513|Other|Fitbit Activity Monitor|Is connected to this smartphone application so that participants who wear this monitor have data that automatically populates the smartphone application for physical activity.
45963694|NCT02281513|Other|Coaching Sessions|Using motivational interviewing (a counseling style used in helping persons change their behavior) at baseline after completion of all baseline assessments and at follow up after completion of all follow up assessments. Coaching session includes discussion of facilitators and barriers to increasing physical activity, fruit and vegetable consumption and sleep, as well as setting goals to work towards at next meeting. The coach will monitor the information that the participant enters into the smartphone application and will provide feedback on a weekly basis to the participant.
45963695|NCT00171977|Drug|Imatinib Mesylate|
45963696|NCT04679662|Device|Transcatheter mitral valve repair (PLAR Implant and Delivery System)|The PLAR Implant is placed mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
45963697|NCT04679545|Drug|CBD|A water-soluble sublingual tablet containing 20 mg of CBD.
45963698|NCT04679545|Drug|Placebo|An inactive compound.
45963699|NCT04679701|Device|Amparo Confidence Socket|"The Amparo Confidence Socket technology takes a different approach by starting with a prefabricated socket (https://www.amparo.world/confidence-socket-en). The socket is made from a moldable thermoplastic and has the attachment point pre-assembled. This prefabricated socket is essentially an off-the-shelf product that can be heated, then molded directly to the patient's residual limb. This removes many of the intermediate steps in traditional socket fabrication. The product's molding temperature is between 60-70 ˚C but the insulation of a silicone liner between the plastic and limb ensures safe temperatures for the patient. This process is currently used in several workshops in Europe and with approximately 50 patients currently using the product. In general, it has been shown to be safe and effective in creating below-knee prosthesis."
46080015|NCT02364557|Radiation|Stereotactic Body Radiotherapy|"Patients receive 1, 3, or 5 fractions of radiation, beginning within 6 weeks of study entry.~For metastases in the peripheral lung, patients receive a single fraction of 30 Gy or 3 fractions for a total of 45 Gy.~For a single liver metastases, patients receive a single fraction of 30 Gy.~For metastases in the abdominal-pelvic or liver (>1), patients receive 3 fractions for a total of 45 Gy.~For metastases in the central lung or mediastinal/ cervical lymph nodes, patients receive 5 fractions for a total of 50 Gy.~For spinal metastases, patients receive 1 fraction of 20 Gy.~For non-spinal osseous metastases, patients receive 3 fractions for a total of 30 Gy.~For thoracic/cervical spine metastases, patients receive 5 fractions for a total of 35 Gy."
45458551|NCT01364948|Other|Coconut oil application|Four ml coconut oil application twice daily for first week
45666492|NCT04877587|Drug|Ascorbate|"A patient-individualized pharmacokinetically-guided dose escalation design will be used for Ascorbate. The goal of the within-patient dose escalation is to achieve a target plasma ascorbate level between 20mM and 30mM. The administered dose levels under consideration are listed below.~Dose Level Ascorbate~2 60 g/m2 IV Days (1,2,8,9,15,16)~1 50 g/m2 IV Days (1,2,8,9,15,16) 0 (Starting dose) 40 g/m2 IV Days (1,2,8,9,15,16)~1 30 g/m2 IV Days (1,2,8,9,15,16)"
45821799|NCT00002065|Drug|Disulfiram|
45666493|NCT04877587|Drug|Gemcitabine|Gemcitabine 900 mg/m2 given at a fixed dose rate of 10 mg/m2/min on D1, D8 and D15 to be given over 90 min every 28 days
45821800|NCT00002071|Drug|Epoetin alfa|
45821801|NCT00002395|Drug|Topotecan|
45666494|NCT02281357|Biological|Tralokinumab|Tralokinumab dose
45666495|NCT02281357|Other|Placebo|Placebo dose
45666496|NCT02284243|Drug|Intranasal Dexmedetomidine|
45821802|NCT00002401|Drug|Indinavir sulfate|
45821803|NCT00002401|Drug|Delavirdine mesylate|
45963700|NCT02240407|Genetic|Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase|The dose selected for this study is a fixed dose of 4.6 x 10^13 vg per TA muscle (range of 7.64 x 10^11 vg/gm to 4.6 x 10^11 vg/gm based on TA weight).
45666497|NCT02284243|Drug|Intranasal Placebo|
45821804|NCT00002401|Drug|Lamivudine|
45821805|NCT00002401|Drug|Zidovudine|
45821806|NCT00002407|Drug|Indinavir sulfate|
45821807|NCT00002407|Drug|Nevirapine|
45821808|NCT00002407|Drug|Lamivudine|
45821809|NCT00002407|Drug|Stavudine|
45821810|NCT00002407|Drug|Didanosine|
45821811|NCT00002413|Drug|Emivirine|
45821812|NCT00002419|Drug|Abacavir sulfate|
45963701|NCT02240407|Drug|Rapamycin|Patients will receive Rapamycin (dose 0.6-2 mg/m^2/day, adjusted to maintain a trough serum sirolimus level of 2-4 ng/mL.) every day starting from 7 days before first injection of AAV9 until four months after second injection.
45963702|NCT02240407|Other|saline|Same volume as rAAV9-DES-hGAA injection will be used.
45963703|NCT02240407|Drug|Rituxan|Patients will receive Rituxan (dose: 750 mg/m^2 twice) 21 and 7 day prior first AAV9 injection, with a Rituxan dose 375 mg/m^2 on the day of the injection. Rituxan will be repeated 7 days prior to the 2nd injection of the vector. The maintenance dose of Rituxan will be 375 mg/m^2.
45963704|NCT02240407|Drug|Diphenhydramine|25-50mg will be provided before each Rituximab dose.
45963705|NCT02240407|Drug|Acetaminophen|We will provide 650 mg of tylenol before each dose of Rituximab.
45963706|NCT02240407|Drug|Lidocaine|Lidocaine will be used based on standard of care: Percutaneous infiltration, concentration 0.5-1%, 1-10 mL, 5-300mg total dose.
45963707|NCT02240407|Drug|LMX 4 Topical Cream|Topical anesthesia cream will be used prior to gene therapy/saline injection.
45821813|NCT00002419|Drug|Amprenavir|
45821814|NCT00002419|Drug|Efavirenz|
45821815|NCT00002419|Drug|Adefovir dipivoxil|
45821816|NCT00381355|Procedure|Written Action Plan for Acute Asthma|
45458552|NCT01364948|Other|No oil application|Oil application was not done
45666498|NCT02284009|Biological|Albiglutide weekly injection|Albiglutide will be provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a subcutaneous (SC) injection in the abdomen, thigh or upper arm region. The pen will deliver either 30 mg of albiglutide, 50 mg of albiglutide in a 0.5-mL injection volume. It may be administered at any time of day without regard to meals. It will be administered once a week on the same day each week
45666499|NCT02284009|Biological|Placebo weekly injection|Placebo provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a SC injection in the abdomen, thigh or upper arm region. It may be administered at any time of day, once a week on the same day each week, without regard to meals.
45821817|NCT00381433|Drug|AVI-4065 Injection|
45821818|NCT00381511|Drug|low molecular weight heparin|
45963708|NCT00172016|Drug|Zoledronic acid|
46080016|NCT02364557|Procedure|Surgery|All surgical resections will be approached with intent of an R0 resection (rendering the patient with no evidence of measureable disease and pathologic negative margin) and must occur within 6 weeks of study entry. Approach to surgery will be based upon the treating surgeon. An open, laparoscopic, or thorascopic approach is acceptable.
45821819|NCT00002425|Drug|Saquinavir|
45821820|NCT00002431|Drug|Chlorhexidine gluconate|
46080017|NCT02345265|Drug|Cediranib Maleate|Given PO
46080018|NCT02345265|Drug|Olaparib|Given PO
46080019|NCT02345265|Other|Questionnaire Administration|Ancillary studies
46080020|NCT02340169|Drug|Topicort® (desoximetasone) Topical Spray, 0.25%|Topicort® (desoximetasone) Topical Spray, 0.25% applied to affected areas twice a day for 28 days
46080021|NCT02338986|Drug|Plasma|Plasma
46080022|NCT02337829|Drug|Acalabrutinib (Arm A)|"A1a) acalabrutinib, dose A daily: biopsy (T) schedule W;~A1b) acalabrutinib, dose A daily: biopsy (T) schedule V.~A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y;~A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z"
45821821|NCT00002077|Drug|Fluconazole|
45821822|NCT00002083|Drug|Peptide T|
45821823|NCT00002089|Drug|Azithromycin|
45821824|NCT00002095|Drug|Ganciclovir|
45821825|NCT00002101|Drug|Ethambutol hydrochloride|
45821826|NCT00002101|Drug|Clarithromycin|
45821827|NCT00002101|Drug|Rifabutin|
45821828|NCT02335424|Biological|pembrolizumab|IV infusion
45821829|NCT00002107|Drug|Aldesleukin|
45963709|NCT04958122|Drug|Cefixime 400mg|Oral cefixime 400 mg, one capsule, twice a day for 10 days
45963710|NCT04958122|Drug|benzathine penicillin|Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
45963711|NCT02232646|Drug|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
45963712|NCT04950673|Device|Cognivue|Computerized Cognitive Assessment Device
45963713|NCT00197613|Drug|(A) zidovudine, lamivudine and nevirapine|
45963714|NCT00197613|Drug|(B) zidovudine, lamivudine and efavirenz|
45963715|NCT00197613|Drug|(C) zidovudine, didanosine, and nevirapine|
45963716|NCT00197613|Drug|(D) zidovudine, didanosine, and efavirenz|
45963717|NCT00197613|Drug|(E) stavudine, lamivudine, and nevirapine|
45458553|NCT03493438|Other|exercise|A hot pack and conventional transcutaneous electrical stimulation (TENS) will be applied with a Chattanoga Intelect® stimulator for 20 minutes at a frequency of 100 Hz and a transition time of 60 μs. The duration of application was 3 days per week and six weeks for each of the four groups. These practices were also applied to individuals in all four groups.
45666500|NCT02284009|Biological|Insulin|Commercially available basal/bolus insulin regimen, self administered by the subject, in accordance to the prescription of the physician and as per the package insert
45821830|NCT00002113|Drug|Flucytosine|
45821831|NCT00002113|Drug|Fluconazole|
45963718|NCT00197613|Drug|(F) stavudine, lamivudine and efavirenz|
45963719|NCT00197613|Procedure|Adherence Strategy Standard of Care (SOC)|
45963720|NCT00197613|Procedure|Adherence Strategy Community-Based DOT|
45963721|NCT00180024|Drug|irbesartan (drug)|
45963722|NCT00172055|Drug|Zoledronic acid|
45963723|NCT04941313|Drug|3D229|3D229 is an investigational drug.
45963724|NCT04941313|Other|Placebo|Matching placebo
45963725|NCT04934449|Device|Occlusal splint|Using occlusal splints during sleep for 2 months
45963726|NCT04682275|Other|Psychological measurements|A questionnaire test (Beck depression Inventory) for depression was performed.
45963727|NCT00172094|Drug|NPS 1776 (800 mg)|NPS 1776 (800 mg) powder
46080023|NCT02337829|Drug|Acalabrutinib (Arm B)|"B1c) acalabrutinib, dose A daily: biopsy (U) schedule W;~• B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y."
46080024|NCT02333357|Behavioral|Multimedia 12-Step Toolkit|The Multimedia 12-Step Toolkit includes counselor written guides, posters, client worksheets, engagement activities, and videos designed to be shown during group treatment sessions to explain and encourage 12-step participation.
46080025|NCT02333357|Behavioral|Treatment as Usual|Treatment as Usual is defined as five standard 12-step facilitation group sessions as counselors would normally conduct with their clients.
46080026|NCT02317874|Drug|Carboplatin|Given IV
46080027|NCT02317874|Drug|Paclitaxel|Given IV
46080028|NCT02317874|Drug|Talazoparib|Given PO
46080029|NCT02257528|Other|Laboratory Biomarker Analysis|Correlative studies
46080030|NCT02257528|Biological|Nivolumab|Given IV
46080031|NCT02240745|Other|Stress-echocardiography|Stress-echocardiography (incl dobutamin and atropin)
46080032|NCT03481907|Device|Nuvagen Collagen Powder|Daily application of Nuvagen collagen powder for 2 to 4 weeks following wounding
46080033|NCT02210403|Device|transcranial direct current stimulation (tDCS)|
46080034|NCT02179086|Radiation|3-dimensional conformal radiation therapy|Undergo standard-dose 3D-CRT
46080035|NCT02179086|Radiation|intensity-modulated radiation therapy|Undergo standard-dose IMRT
46080036|NCT02179086|Radiation|photon beam radiation therapy|Undergo dose-escalated and -intensified photon IMRT
45666501|NCT02280499|Device|standard PROMOS prosthesis|
45666502|NCT02400476|Drug|Neratinib|
45666503|NCT02400476|Drug|Loperamide|
45666504|NCT02400476|Drug|Colestipol|2 g twice daily with or without food for one 28 day cycle
45666505|NCT02400476|Drug|Budesonide|9 mg extended release tablets once daily with or without food for 28 days
45666506|NCT02363738|Drug|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.
45821832|NCT00002119|Drug|WF10|
45821833|NCT00383318|Procedure|Gene mutation sample|
45821834|NCT00002437|Drug|Cidofovir|
45821835|NCT00002437|Drug|Probenecid|
45821836|NCT04329650|Drug|Siltuximab|A single-dose of 11mg/Kg of siltuximab will be administered by intravenous infusion.
45821837|NCT04329650|Drug|Methylprednisolone|"A dose of 250mg/24 hours of methylprednisolone during 3 days followed by 30mg/24 hours during 3 days will be administered by intravenous infusion.~If the patient is taken lopinavir/ritonavir, the dose will be 125 mg/ 24 hours during 3 days followed by 15mg/24 hours during 3 days."
45821838|NCT00002443|Drug|Indinavir sulfate|
45821839|NCT00002443|Drug|Zidovudine|
45821840|NCT00001561|Drug|Myeloma Immunoglobulin Idiotype Vaccine-KLH|
45821841|NCT00001561|Drug|GM-CSF|
45821842|NCT00002449|Drug|Aldesleukin|
45821843|NCT00003014|Drug|carboplatin|
45821844|NCT00003014|Radiation|radiation therapy|
45821845|NCT00002125|Drug|Foscarnet sodium|
45821846|NCT00001579|Drug|5-Fluorouracil|
45821847|NCT00001579|Drug|Ethynyluracil|
45821848|NCT00001579|Drug|Leucovorin|
45963728|NCT00172094|Drug|PLACEBO|Placebo in non-carbonated fruit flavored drink (150 ml)
45963729|NCT00172094|Drug|NPS 1776 (400 mg)|NPS1776 in powdered form to be mixed with a non-carbonated fruit flavored drink
45963730|NCT00197691|Procedure|blood draws, etc.|
45963731|NCT03455179|Other|Slow-speed traditional resistance training|The training session will consist in a general warm-up, 6 resistance exercises, including 2 upper limb exercises (elbow curl and chest press), 2 lower limb exercises (lunge and standing hip abduction), and 2 exercises combining both upper and lower limbs at the same time (squat plus upright rowing and squat plus shoulder press) and finally the cooldown routine.The participants will perform in each training session 6 submaximal repetitions equivalent to 85% of the one-repetition maximum (1RM) and 3-4 sets per exercise (high intensity training sessions).
45963732|NCT03455179|Other|High-speed resistance training|The participants will perform the same exercises than the TRADICIONAL group with12 submaximal repetitions equivalent to 40-50% 1RM (low-intensity) and 3-4 sets per exercise.
45963733|NCT03455179|Other|Multicomponent training|Participants will perform, in this order, balance exercises followed by resistance/coordination, aerobic/coordination and flexibility exercises in each session. The balance training will consist in static, dynamic and proactive balance exercises. In the resistance training block, the participants will perform 3-4 sets of 15 submaximal repetitions Participants will perform 2 resistance exercises (squat plus upright rowing and lunge) at traditional slow-speed (2s of concentric contraction and 2s of eccentric contraction).The intensity of the aerobic block will progress from 65 to 85% of the maximum heart rate over the training weeks.
45821849|NCT00003020|Biological|LMB-7 immunotoxin|
45963734|NCT04682002|Other|Osteopathic manipulative treatment|"OMT will be used to treat pregnancy women after having performed a manual osteopathic assessment. The first osteopathic evaluation is carried out during the 12th week, with the possibility to undertake a personalized treatment built on the needs of the single patient; the chosen techniques are based on the collected data by the operator. A black-box type of treatment is undertaken."
45963735|NCT04682002|Other|Usual care|Administration of routine care based on international guidelines
45963736|NCT04682002|Other|Mindfulness|Mindfulness group weekly meetings. Mindfulness practices consist of cognitive and behavioral treatments for depression and anxiety, including mindfulness-based stress reduction and mindfulness-based cognitive therapy.
45963737|NCT04682002|Other|Yoga|Weekly yoga group meetings. Yoga is a mind-body practice that encompasses a system of postures, deep breathing, and meditation. In this context, yoga practice is adapted to pregnancy with the aim of benefit women who suffer from anxiety, depression, stress, low back pain, and sleep disturbances.
45963738|NCT04682002|Other|Clinical nutrition|Nutritional advice to all women participating in the study at 12 weeks of pregnancy, with the possibility of starting an individualized path.
45963739|NCT04682002|Other|Coaching|There will be five personalized coaching sessions during the pregnancy.
45963740|NCT04904809|Device|Perclose ProGlide Suture-Mediated Closure System and/or Perclose ProStyle Suture-Medicated Closure and Repair System|The Perclose ProGlide SMC and Perclose ProStyle SMCR in this study will be used for multiple access site closures in a single vein in the ablation procedure.
45963741|NCT01909102|Behavioral|ACT-based intervention|
45963742|NCT01909102|Behavioral|usual care|
45963743|NCT04895254|Device|Diagnostic colonoscopy|The feasibility of the motorized spiral enteroscope to achieve cecum intubation in difficult colons.
45963744|NCT04895254|Procedure|Therapeutic colonoscopy|The feasibility of the motorized spiral enteroscope for performing interventions such as polypectomy
46080037|NCT02179086|Radiation|intensity-modulated radiation therapy|Undergo dose-escalated and -intensified photon IMRT
45458554|NCT03762265|Drug|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
45458555|NCT03762265|Drug|Placebo|Pharmaceutical form: Tablet Route of administration: Oral
45821850|NCT00002131|Drug|Vesnarinone|
45963745|NCT01781455|Drug|BBI503|
45963746|NCT01765777|Procedure|Osteopathic Manipulative Medicine|
45963747|NCT01765777|Procedure|Phototherapy|
45458556|NCT01352312|Drug|Bendamustine|Bendamustine at the dose of 50 mg/m2 (or 70 or 90 or 40 mg/m2 depending on the dose level) daily on day 1 and 2.
45821851|NCT00001615|Drug|Corticosteroid|
46080038|NCT02179086|Radiation|proton beam radiation therapy|Undergo dose-escalated and -intensified proton beam radiation therapy
46080039|NCT02179086|Drug|temozolomide|Given PO
46080040|NCT02179086|Other|laboratory biomarker analysis|Correlative studies
46080041|NCT02160015|Drug|Ibrutinib|Given PO
45821852|NCT00002137|Drug|Tecogalan sodium|
45821853|NCT00002455|Biological|Corynebacterium granulosum P40|
45821854|NCT00002455|Procedure|adjuvant therapy|
45821855|NCT00380887|Drug|Premarin|
45821856|NCT00002461|Biological|filgrastim|
45821857|NCT00002461|Biological|sargramostim|
45821858|NCT00002461|Drug|carmustine|
45821859|NCT00002461|Drug|cisplatin|
45821860|NCT00002461|Drug|cyclophosphamide|
45821861|NCT00002461|Drug|etoposide|
45821862|NCT00002461|Procedure|autologous bone marrow transplantation|
45821863|NCT00002461|Procedure|in vitro-treated bone marrow transplantation|
45963748|NCT04891666|Dietary Supplement|Lactobacillus plantarum DSM 33464|1 sachet SmartGuard® per day for 24 weeks
45963749|NCT02909062|Device|Electronic Activity Monitoring (EAM)|All registered patients will receive a wearable EAM device that will measure their physical activity. Patients will wear this device around their wrist for the designated period of assessment. The EAM device has the potential to measure active minutes, number of steps, distance walked and number of floors climbed. For the purpose of this study the EAM data captured will focus on daily step count.
45963750|NCT02909062|Behavioral|Daily Questionnaire|Participants will be asked to complete this self-administered, paper-based questionnaire each day that they are expected to wear the EAM device. The questionnaire was designed specifically for the purpose of this study. It consists of 5 items that ask about the patient's perceived level of physical activity and fatigue in each 24 hour period that they have worn the EAM device. The daily questionnaires will be optional; however each participant will be encouraged to complete them.
46080042|NCT02160015|Other|Laboratory Biomarker Analysis|Correlative studies
46080043|NCT02160015|Drug|Lenalidomide|Given PO
46080044|NCT02160015|Biological|Rituximab|Given IV
45666507|NCT02363738|Other|Saline|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.
45666508|NCT04894526|Other|Alternating Energy Intake|To alternate between caloric overconsumption (130% of usual total energy needs) and caloric underconsumption (70% of usual total energy needs) on a daily basis for 6 days/week followed by one ad libitum day for 4 weeks.
45666509|NCT04894526|Other|Regular Energy Intake|To consume the usual energy intake (100% of total energy needs) on a daily basis for 6 days/week, also followed by one ad libitum day for 4 weeks.
45666510|NCT02331680|Drug|OPC-41061|
45666511|NCT02331680|Drug|OPC-41061|
45821864|NCT00002461|Procedure|peripheral blood stem cell transplantation|
45666512|NCT02331680|Drug|Placebo|
45821865|NCT00002461|Radiation|radiation therapy|
45458557|NCT01352312|Drug|Pentostatin|Pentostatin 4 mg/m2 on day 1 of each cycle. For patients with estimated or measured glomerular filtration rate (GFR) 30 to 60 ml/min/m2 pentostatin will be administered at the reduced dose of 2 mg/m2 on day 1 of each cycle.
45458558|NCT01352312|Drug|Ofatumumab|Ofatumumab 300 mg on day 2 of first cycle. Subsequently, from cycle 2 to 6, ofatumumab 1000 mg on day 2 will be administered.
45963751|NCT00172133|Drug|ALX1-11 (drug)|100 mcg PTH(1-84) injected subcutaneously daily in either the thrigh and abdomen.
45963752|NCT00202293|Drug|Olanzapine|
45963753|NCT00202293|Drug|Lithium|
46080045|NCT02152033|Behavioral|Home-based Continuing Care|All sessions will occur over the phone or Cisco WebEx meetings. Parents will participate in 5 individual sessions and 1 joint session with their child (45-50 min. each). Young Adults (YAs) will participate in 1-3 individual meetings (30- 45 min. each) and 1 joint session (45-50 min.). In addition, YAs will be contacted weekly for the first 8 weeks of HCC, then every other week for the remaining 24 weeks (20 calls total). He or she will be asked questions addressing risk and protective factors for relapse. Finally, parents will be trained to collect and test their child's urine sample and deliver incentives to the YA contingent upon biologically-verified abstinence and verified engagement in continuing service plan activities. Urine samples will be collected regularly over a 32 week period.
45666513|NCT02331446|Behavioral|Physical exercise intervention|
45666514|NCT02349061|Drug|Ustekinumab IV|Weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0.
45666515|NCT02349061|Drug|Placebo Infusion|Placebo intravenously at Week 0.
45666516|NCT02349061|Drug|Placebo SC|Placebo subcutaneously at Weeks 8 and 16.
45666517|NCT02349061|Drug|Ustekinumab SC|Ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40 and up to Week 104 in study extension (for eligible participants)
45666518|NCT02349061|Other|Concomitant Medication|Concomitant treatment (mycophenolate, azathioprine/6-mercaptopurine, methotrexate, hydroxychloroquine and/or chloroquine, oral corticosteroids, NSAIDs, antihypertensive medications, and topical medications) through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48.
45666519|NCT02331368|Procedure|Autologous Stem Cell Transplant|
45666520|NCT02331368|Drug|Melphalan|140-200 mg/m^2
45666521|NCT02331368|Drug|Lenalidomide|5-15 mg/day starting 45-90 days post-transplant
45666522|NCT02331368|Drug|MK-3475|200 mg/day every 3 weeks starting day +14 post-transplant for a total of 9 doses.
45666523|NCT02362724|Device|Sapphire|silicone hydrogel contact lens
45666524|NCT02362724|Device|Pearl|silicone hydrogel contact lens
45666525|NCT02362646|Biological|MPC Intramyocardial Injection|Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation
45666526|NCT02362646|Drug|Control Solution|
45666527|NCT04907162|Diagnostic Test|Beck depression inventory fast screen|Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
45666528|NCT04907162|Diagnostic Test|German Pain Inventory|German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
45666529|NCT04907162|Diagnostic Test|Brief Pain Inventory|Validated questionnaire for pain.
45963754|NCT00202293|Drug|Chlorpromazine|
45963755|NCT04870606|Drug|Proxalutamide (GT0918)|Proxalutamide (GT0918)+Standard of care determined by PI and local regulatory
45963756|NCT04870606|Drug|Placebo|Placebo+Standard of care determined by PI and local regulatory
45963757|NCT02908867|Other|Therapeutic Strategies|Using questionnaires (Erectile Function of International Index and American Impairment Scale) and search in public markets using semi structured form
45963758|NCT00197730|Drug|Multivitamins - vitamins B complex, C and E|Age-appropriate dosages of vitamin C, vitamin E, thiamine, riboflavin, niacin, vitamin B6, folate, and vitamin B12 administered orally to children aged 6 weeks to 6 months, and two capsules per day for children aged older than 6 months for at least 12 months
45821866|NCT00003026|Drug|bicalutamide|
45821867|NCT00003026|Drug|flutamide|
45821868|NCT00003026|Drug|triptorelin|
45821869|NCT00003026|Radiation|radiation therapy|
45821870|NCT00002143|Drug|Acitretin|
45821871|NCT00002149|Drug|Clavulanate potassium|
45821872|NCT00002149|Drug|Pseudoephedrine hydrochloride|
45821873|NCT00002149|Drug|Amoxicillin trihydrate|
45821874|NCT03868046|Drug|Treatment with immune checkpoint inhibitors.|Treatment with approved immune checkpoint inhibitors, namely ipilimumab, nivolumab, pembrolizumab, atezolizumab and avelumab, alone or in combination, administered per standard protocol.
45821875|NCT03868046|Diagnostic Test|Blood tests.|Patients will undergo ordinary blood tests obtained at specific moments predefined per protocol and extraordinary blood tests at the time of the detection of an eventual irAE.
45821876|NCT02973295|Drug|Silymarin|Capsules contains 100 mg of silymarin
45963759|NCT00197730|Drug|Placebo|Placebo capsules administered orally once day orally to children aged 6 weeks to 6 months, and twice per day for children aged older than 6 months
46080046|NCT02152033|Behavioral|Services as Usual|Young Adults (YAs) will be told to follow the continuing service plan recommended by the residential treatment program. Parents will be told to support this and be sent information on continuing care developed by the Treatment Research Institute and the Partnership @ Drugfree.org (http://continuingcare.drugfree.org). We will provide no supplemental services during the study. We will train parents; however, on how to collect urine samples for research purposes only. They will not be trained on how to test the urine sample, only how to collect it and mail the sample to our staff for testing. We will offer separate 4 hour-workshops to parents and YAs after they have completed participation as an added study participation incentive for this group.
45666530|NCT04907162|Diagnostic Test|Fatigue Severity and Disability Scale (FSS)|Validated questionnaire for perceived fatigue
45666531|NCT04907162|Diagnostic Test|Quick Motor Function Test|An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
45821877|NCT02973295|Other|Placebo Oral Capsule|Capsule will be identical in shape, size and color, packed in the same way like verum
45455440|NCT03931837|Device|Tourniquet: Systolic blood pressure + 150 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
45666532|NCT04907162|Diagnostic Test|Handheld Dynamometry (HHD)|To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
45821878|NCT04329884|Procedure|Cooled RFA treatment with COOLIEF* device|Patients who are randomized to receive CRFA will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
45821879|NCT04329884|Drug|intra-articular corticosteroid injection|Patients who are randomized to receive intra-articular corticosteroid injections will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
45963760|NCT02909023|Biological|blood samples are performed to measure active T cellular immune response during a routine visit|"During the visit 1 (V1), after signing the informed consent, 40 mL blood sampling are carried out and analyzed with the test ELISPOT to check if the patient shows a T immune response against HBV.~The visit 2 will be performed 4-8 weeks (depending on the availability of the patient) following V1 visit, in case the patient shows an immune response against HBV positive T following the sample taken at V1. 150 ml blood sampling are carried out at this visit."
45963761|NCT02908828|Dietary Supplement|Calanus oil|
45963762|NCT02908828|Dietary Supplement|placebo dietary oil|
46080047|NCT02148237|Behavioral|Contingency Management|Participants in this condition will receive usual WIC care in addition to Contingency Management (CM). BF will be determined by direct observation.
46080048|NCT01931631|Behavioral|Low-fat, low-Glycemic Index, vegan diet|Low-fat, low-Glycemic Index, vegan diet
45455441|NCT01225939|Drug|AZD8329|tablet
45821880|NCT00003032|Biological|filgrastim|
45821881|NCT00003032|Drug|cisplatin|
45821882|NCT00003032|Drug|cyclophosphamide|
45821883|NCT00003032|Drug|mitoxantrone hydrochloride|
45821884|NCT00003032|Drug|tamoxifen citrate|
45963763|NCT00172172|Drug|PTH/Calcium|PTH(1-84) subcutaneous injection and calcium 700 mg oral
45963764|NCT00172172|Drug|PTH/placebo|PTH (1-84) injected subcutaneously and placebo provided orally
45963765|NCT00172172|Drug|placebo|Placebo injected subcutaneously and 700 mg calcium orally
45963766|NCT02908711|Drug|0.5% ropivacaine|Adductor canal block (ACB) performed as part of their analgesic regimen for primary total knee arthroplasty achieved with 20 cc of 0.5% ropivacaine under constant ultrasound visualization.
45963767|NCT00202332|Procedure|Coronary artery bypass|
45455442|NCT01225939|Drug|AZD8329|Solution
45455443|NCT03928483|Behavioral|Modified WW Food program|Participants will receive a structured, holistic, behavioral weight management program that encourages development of healthy habits to help individuals eat healthier, move more, and shift to a more helpful mindset.
45455444|NCT01226017|Other|Measuring oxytocin level in blood|Blood sampling and instruments measuring anxiety and stress
45666533|NCT04907162|Diagnostic Test|Six-minute walk test (6MWT)|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
45821885|NCT00002155|Drug|Indinavir sulfate|
45821886|NCT00002155|Drug|Lamivudine|
45821887|NCT00002155|Drug|Zidovudine|
45821888|NCT00003038|Drug|doxorubicin hydrochloride|
45821889|NCT00003038|Drug|suramin|
45821890|NCT00001633|Procedure|Coronary magnetic resonance angiography imaging|
45821891|NCT00002473|Procedure|conventional surgery|
45821892|NCT05752591|Diagnostic Test|Diagnostic testing|Blood diagnostic testing for hypothalamic-pituitary-gonadal axis and hypothalamic-pituitary-thyroid axis. In case of gonadal or thyroid dysfunction, genetic testing for known implicated genes
45821893|NCT00003044|Drug|cisplatin-e therapeutic implant|
45821894|NCT00002485|Procedure|psychosocial assessment and care|
45821895|NCT02047994|Drug|Triple therapy|"Participants who are positive with Helicobacter pylori in Group1 will receive triple therapy.~Esomeprazole 40 mg bid for 10 days~Clarithromycin 500 mg bid for 10 days~Amoxicillin 1000 mg bid for 10 days"
45821896|NCT00002161|Drug|Adefovir dipivoxil|
45821897|NCT03836378|Procedure|BioXclude™|The addition of BioXclude™ dehydrated human amnion-chorion membrane into deep pockets with scaling and root planing.
45666534|NCT04907162|Diagnostic Test|Pressure pain threshold|"For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of burning, stinging, drilling or aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles."
45666535|NCT04907162|Diagnostic Test|Myotonometer Assessment|Muscle stiffness, muscle tone, relaxation periods and viscoelasticity will be assessed by a myotonometer of selected muscles (non-invasive measurement). The method of measurement consists of recording damped natural oscillation of soft biological tissue in the form of an acceleration signal and the subsequent simultaneous computation of the parameters of State of Tension, Biomechanical and Viscoelastic properties. Measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles.
45666536|NCT04907162|Diagnostic Test|Vital signs|Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
45666537|NCT04907162|Diagnostic Test|Borg Scale|the Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
45821898|NCT03833804|Other|Processing of clinical notes in the EHR data collected during routine care|Clinical notes collected in the first day of hospital admission during usual care as input to natural language processing and machine learning algorithm.
45821899|NCT04713397|Diagnostic Test|Leg Length Discrepancy Scoliometer Test|"A scoliometer used as an indirect and quantitative method to evaluate LLD for the first time in this study, and described it as Leg Length Discrepancy Scoliometer Test. Scoliometer were used on Adams' forward bending position and the level of the pelvis accepted as equal when the scoliometer degree pointed zero on the sacral basis (angle of trunk rotation on sacrum). When considering pelvis level is high on the longer side and is low on the shorter side, if the angle of the scoliometer on the sacrum is negative (slope to the left), the left extremity was considered as shorter. In order to determine its correlation with an indirect method, scoliometer degree on the sacral basis was recorded then wooden blocks were added to the unequal leg side on the sacral basis until the pelvic equality was achieved on the scoliometer. Afterward, a correlation between the first measurement of ATRsacrum and the height of the wooden block which provides ATRsacrum to reach zero was investigated."
45821900|NCT00002167|Drug|Tin ethyl etiopurpurin|
45821901|NCT03805412|Device|DEXCOM G6 RT-CGM|CGM is a way to measure glucose levels in real-time. A tiny electrode called a glucose sensor is inserted under the skin to measure glucose levels in tissue fluid. A small plastic piece of tube remains inserted in the skin. It is connected to a transmitter that sits on top of the skin. It is approved for use on the abdomen for 10 days. It either records the sugars downloaded in the clinic (blinded part of the study) or it sends the information via wireless radio frequency to a monitoring/ display device or to a cellular phone so participants can see data. DEXCOM G6 is FDA approved for use in patients with diabetes and will be used in accordance with instructions as approved for diabetes.
45821902|NCT05752513|Procedure|Late bladder dissection|The bladder dissection is reserved as the last step of the cesarean hysterectomy with excellent dissection of the ureteric course till the ureteric tunnel to reduce the incidence of inadvertent ureteric clamping during uterine vessel ligating and transection
45821903|NCT05752513|Procedure|early bladder dissection|The bladder dissection is early as in classic cesarean hysterectomy
45821904|NCT00002173|Biological|HIV-1 Immunogen|
45821905|NCT03805022|Drug|Doxorubicin|A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 3 cycles.
45821906|NCT03805022|Drug|Ifosfamide or dacarbazine|A treatment cycle consists of 3 weeks. Treatment may continue up to 3 cycles. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 3 cycles.
45821907|NCT03805022|Drug|Doxorubicin|A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 6 cycles.
45821908|NCT03805022|Drug|Ifosfamide or dacarbazine|A treatment cycle consists of 3 weeks. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 6 cycles.
45821909|NCT03805022|Drug|At the discretion of the investigator|Drug at the discretion of the investigator.
45821910|NCT05752435|Procedure|COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS|comparison of therapeutic efficacy between intralesional bleomycin and cryotherapy in plantar warts
45821911|NCT00003050|Drug|cyclophosphamide|
45821912|NCT00003050|Drug|doxorubicin hydrochloride|
46080049|NCT01931631|Behavioral|ADA diet|Diet in accordance with the American Diabetes Association
45821913|NCT00003050|Drug|paclitaxel|
45821914|NCT00003050|Drug|tamoxifen citrate|
45821915|NCT00003050|Procedure|surgical procedure|
45821916|NCT00003050|Radiation|radiation therapy|
45821917|NCT03798860|Diagnostic Test|blood samples|For performing the Luminex solid phase assay (SPA) test, 7.5 ml of patient whole blood are collected from a peripheral vein.
45821918|NCT00002179|Drug|Indinavir sulfate|
45821919|NCT00002179|Drug|Lamivudine|
45821920|NCT00002179|Drug|Zidovudine|
45821921|NCT00003056|Drug|cyclosporine|
46080050|NCT01919749|Other|treated recommended|Treatment will be recommended after reviewing the profiling analysis
46080051|NCT01899326|Drug|Desipramine Hydrochloride|Given PO
45455445|NCT01219543|Drug|AZD1480 Daily|Oral Dose, Capsule, Daily Dosing
45666538|NCT04906616|Behavioral|Mlambe|A combined economic and relationship-strengthening intervention at the couple level to redirect funds spent on alcohol into financial investments (e.g., education, income-generating business) and to improve couple relationships and adherence to ART.
45666539|NCT02280421|Drug|ASP2151 400mg + 100mg ciclosporin|
45666540|NCT02280421|Drug|ASP2151 1200mg + 100mg ciclosporin|
45666541|NCT04906382|Procedure|Biopsy|Undergo biopsy
45666542|NCT04906382|Drug|Carboplatin|Given IV
45821922|NCT00003056|Drug|cyclosporine and methotrexate|
45821923|NCT00002185|Drug|Nelfinavir mesylate|
45455446|NCT01219543|Drug|AZD1480 BID|Oral Dose, Capsule, BID Dosing
45455447|NCT01125397|Behavioral|LEARN group|Participants will complete a 12-week behavioral weight management intervention (the LEARN program) prior to bariatric surgery, which is the current standard clinical practice at Mayo Clinic Rochester. This involves weekly group meetings, weigh-ins, and goal setting.
45455448|NCT01219621|Procedure|Symphony Dual Chamber Rate Responsive Device|Echocardiography ANP/BNP measurements
45821924|NCT01923506|Radiation|stereotactic body radiation therapy|Undergo SBRT
45821925|NCT01923506|Procedure|quality-of-life assessment|Ancillary studies
45821926|NCT01923506|Other|laboratory biomarker analysis|Correlative studies
45455449|NCT01125475|Device|RebiSmart|Treatment with Rebif New Formulation using RebiSmart.
45821927|NCT05752279|Drug|Plasma-Lyte 148|Plasma-Lyte® 148 intravenous fluid for resuscitation in patients with keto-acidosis
45821928|NCT05752279|Drug|0.9% sodium chloride|0.9% sodium chloride intravenous fluid for resuscitation in patients with keto-acidosis
45821929|NCT00003062|Drug|temozolomide|
45821930|NCT00002191|Drug|Albendazole|
46080052|NCT01899326|Biological|Filgrastim|Given PO
46080053|NCT01899326|Other|Laboratory Biomarker Analysis|Correlative studies
46080054|NCT01897168|Device|No intervention|
45455450|NCT01222819|Drug|filgrastim|5 mcg/kg (rounded to 300 mcg or 480 mcg)
45455451|NCT01222897|Drug|Valacyclovir hydrochloride|
45455452|NCT01226173|Device|Bio-Rad Platelia Dengue NS1 Ag test|The purpose of the study is to screen blood donors for the presence of dengue NS1 antigen at the ARC in Puerto Rico region using the Bio-Rad Platelia Dengue NS1 Ag test.
45455453|NCT03150056|Drug|GSK525762|GSK525762 will be administered.
45455454|NCT03150056|Drug|Abiraterone|Abiraterone will be administered.
45455455|NCT03150056|Drug|Enzalutamide|Enzalutamide will be administered.
45455456|NCT03150056|Drug|Prednisone|Prednisone will be administered as a concomitant medication in combination with abiraterone
45455457|NCT01329367|Behavioral|Control group|"Subjects will receive Nutritional education together with weight management counselling for overweight and obesity.~-10 weekly personal interviews with a registered nutritionist for body weight control."
45455458|NCT01329367|Behavioral|Protein group|"Participants will receive Nutritional education and personalised structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of legumes and fish (protein rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
45458559|NCT03493360|Other|Visual feedback|Participants will be asked to perform 10 repetitions of low back flexion, extension and lateral side-flexions while looking at their back in a mirror for visual feedback.
45666543|NCT04906382|Drug|Paclitaxel|Given IV
45666544|NCT04906382|Biological|Tislelizumab|Given IV
45666545|NCT04892719|Diagnostic Test|Fluoroscopic chest imaging with 4Dx technology software analysis|4DxV utilizes a novel software algorithm to analyze data from cinefluoroscopy images to calculate regional ventilation and pulmonary function changes. Cinefluorography uses a fluorescent screen with X-rays to make real-time moving images the lung described below. This is the same x-ray fluoroscopy that is used in clinical imaging and the fluoroscopic imaging time is approximately 1 minute leading to an effective radiation dose of 2 mSv (200 mRem). This is significantly lower that the radiation exposure from a standard chest CT. Fluoroscopy images are acquired at each of five views for approximately enough time to capture at least one complete, continuous breath. The subject is required to remain in the same position for each of the five fluoroscopy imaging sequences. These images will be analyzed by the novel 4Dx technology to provide the 4Dx lung function analysis report.
45821931|NCT00383396|Drug|Topical Cyclosporine|
45821932|NCT00002197|Drug|Abacavir sulfate|
45821933|NCT00003068|Drug|amifostine trihydrate|
45821934|NCT00003068|Drug|cyclophosphamide|
45821935|NCT00003068|Drug|mitoxantrone hydrochloride|
45821936|NCT00003068|Drug|thiotepa|
45821937|NCT00003068|Procedure|peripheral blood stem cell transplantation|
45821938|NCT00002503|Radiation|strontium chloride Sr 89|
45821939|NCT01719458|Drug|(S,S)-[11C]MRB|PET radioligand
45821940|NCT00003080|Drug|endocrine-modulating drug therapy|
45821941|NCT00003080|Drug|melphalan|
45821942|NCT00003080|Drug|mitoxantrone hydrochloride|
45821943|NCT00003080|Drug|tamoxifen citrate|
45821944|NCT00003080|Drug|thiotepa|
45821945|NCT00003080|Procedure|peripheral blood stem cell transplantation|
45821946|NCT00002203|Drug|Lamivudine/Zidovudine|
45821947|NCT00002203|Drug|Lamivudine|
45821948|NCT00002203|Drug|Zidovudine|
45821949|NCT01568918|Drug|Tamsulosin hydrochloride|Participants will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
46080055|NCT01856192|Drug|Cyclophosphamide|Given IV
46080056|NCT01856192|Drug|Doxorubicin Hydrochloride|Given IV
46080057|NCT01856192|Other|Laboratory Biomarker Analysis|Correlative studies
46080058|NCT01856192|Drug|Lenalidomide|Given PO
46080059|NCT01856192|Drug|Prednisone|Given PO
45821950|NCT01568918|Other|Placebo|The placebo capsule matching the active study drug will be given daily from 5 days prior to the operation until hospital discharge.
45963768|NCT04804774|Behavioral|WW program modified for people with Type 2 diabetes|This 6-month intervention includes the use of WW's mobile app, weekly virtual workshops, and private online community. The program involves: self-monitoring of weight, dietary intake, and physical activity; dietary changes; increasing physical activity; shift in mindset; and behavioral strategies to manage goals. Participants will set goals and weigh-in with a coach via virtual workshop weekly and be encouraged to use the app and private online community daily. The virtual workshop features a behavior change technique and enables the participant to practice it to support their goals. Participants are given a personalized food plan based on expert healthy eating guidelines, an activity plan to promote regular physical activity and techniques to help shift mindset for lasting change. The coach will help with goal setting, overcoming setbacks, and follow-up on progress toward goals weekly. Participants will be encouraged to participate in a private Facebook group for motivational support.
45963769|NCT04799938|Behavioral|Exercise|180 minutes of moderate-intensity exercise per week
45963770|NCT00172211|Drug|Physioneal|
45666546|NCT02362412|Drug|FK949E|A tablet containing 50 mg or 150 mg of quetiapine taken orally.
45666547|NCT02280187|Procedure|Spine Fusion|All patients have been treated with a spinal fusion procedure with InductOs (rhBMP-2/ACS) following standard practice in each center.
45666548|NCT02347813|Drug|Pioglitazone|15 mg of pioglitazone orally for 2 weeks, and if well tolerated, 30 mg pioglitazone orally for 5 1/2 months.
45963771|NCT04798846|Procedure|dorsal plating|Spanning Plate inserted dorsally below tendons Spanning External Fixator by rods inserted in distal radius and metacarpals
45963772|NCT00202371|Procedure|Red Blood Cell transfusion|
46080060|NCT01856192|Biological|Rituximab|Given IV
45666549|NCT02329730|Biological|1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
45666550|NCT02329730|Biological|5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
45963773|NCT04681846|Procedure|Staged approach using antibiotic-cement impregnated PMMA spacer|It will be prepared in the following manner. the cement will be mixed with vancomycin in a ratio of 2 gm to each 40 gm of the spacer. The spacer should be shaped into a cylinder before its solidification. The spacer should be as big as possible to fill the whole defect, without compromising the soft tissue and skin closure. Also, cement should wrap the two ends of bone extremities on 2 or 3 centimeters.
46080061|NCT01856192|Drug|Vincristine Sulfate|Given IV
45666551|NCT02329730|Biological|10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
45666552|NCT02329730|Biological|20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
45821951|NCT02973139|Other|Medical Thoracoscopy|Medical thoracoscopy will be performed as per standard protocols.
45821952|NCT02973139|Other|Fibrinolytic Group|Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 doses
45821953|NCT00003086|Biological|filgrastim|
45821954|NCT00003086|Drug|CAF regimen|
45821955|NCT00003086|Drug|carboplatin|
45821956|NCT00003086|Drug|cisplatin|
46080062|NCT01849146|Drug|Adavosertib|Given PO
46080063|NCT01849146|Radiation|Radiation Therapy|Undergo radiation therapy
46080064|NCT01849146|Drug|Temozolomide|Given PO
46080065|NCT01831999|Behavioral|RecoveryTrack - Extended Care (RT-E)|Counselors in this condition will be trained on the RecoveryTrack-Extended Care (RT-E) web-based monitoring system so that they are able to navigate the computer application, and implement the clinical content and procedures of the intervention. Counselors will conduct monitoring and feedback sessions using RT-E for clients newly admitted to IOP over a course of eight months. If the client is not attending treatment, counselors will attempt contact over the phone and via other methods. When contacted, the counselor will conduct the RT-E assessment and, as the situation warrants, provide support to reengage the client in treatment or support recovery in other ways mentioned. HIV risk will be assessed as well, with encouragement of testing and referral to HIV specialists as needed.
46080066|NCT01813864|Behavioral|CASPAR/Treatment Planning|All counselors in the study will receive additional training in treatment planning and the CASPAR Resource Guide software to easily identify and link patients to services not available at substance abuse treatment centers such as General Educational Development (GED) training, dental clinics, job training, etc.
46080067|NCT01800760|Dietary Supplement|Probiotics|Probiotics once a day for three weeks.
46080068|NCT01751672|Behavioral|SBIRT|Screening, Brief Intervention, and Referral to Treatment. Standard, single session SBIRT.
46080069|NCT01751672|Behavioral|SBIRT+|Expanded Screening, Brief Intervention, and Referral to Treatment. One Standard SBIRT session, plus 2-6 additional Brief Intervention sessions as needed.
45821957|NCT00003086|Drug|cyclophosphamide|
46080070|NCT01591239|Behavioral|Home-Based Intervention|Parents will be trained through a 3 1/2-hour series on providing a 3-session drug and alcohol intervention program to their adolescent. The parent-led intervention will require parents to meet with their adolescent and work together to help strengthen family cohesiveness, enhance communication, and promote healthy life choices.
46080071|NCT01591239|Behavioral|Educational Group|Printed fact sheets will be delivered to parents in a single two-hour session. These fact sheets will provide general drug-related information from the public domain (e.g., substance use trends and well-known dangers of substance involvement), and focus on communication approaches and talking points when discussing substance use with their adolescent (e.g., why adolescents use; how the media may influence attitudes about substances).
46080072|NCT01572480|Drug|Carfilzomib|Carfilzomib intravenous (IV) 20-36 mg/m^2 per dose on days 1, 2, 8, 9, 15, and 16 of each cycle based on arm; until disease progression or unacceptable toxicity.
46080073|NCT01572480|Drug|Revlimid|Revlimid by mouth (PO) 25 mg/day, days 1-21 every 28 days of each cycle based on arm; until disease progression or unacceptable toxicity.
46080074|NCT01572480|Drug|Dexamethasone|Dexamethasone by mouth (PO) 20 mg per dose on days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle based on arm; until disease progression or unacceptable toxicity.
45666553|NCT02329730|Biological|1μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 1μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
45666554|NCT02329730|Biological|5μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 5μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
45666555|NCT02329730|Biological|10μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 10μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
45821958|NCT00003086|Drug|doxorubicin hydrochloride|
45821959|NCT00003086|Drug|fluorouracil|
45821960|NCT00003086|Drug|ifosfamide|
45821961|NCT00003086|Drug|melphalan|
45821962|NCT00003086|Drug|paclitaxel|
45821963|NCT00003086|Drug|thiotepa|
45821964|NCT00003086|Procedure|peripheral blood stem cell transplantation|
45821965|NCT00003086|Radiation|samarium Sm 153 lexidronam pentasodium|
45821966|NCT05752045|Device|Eye Fundus Double Capture for Eye Diseases Screening with OphtAI Medical Device|Double ophthalmological imaging capture of eye fundus with different fundus camera to screen patient for various eye diseases.
45821967|NCT01334450|Device|TMS , H2-coil|Trans cranial magnetic stimulation with H2-coil
45963774|NCT02908594|Device|Medical Exercise Peddler 3000, Medi-Bike, Taiwan|"A horizontal electromagnetic cycle ergometer (Medical Exercise Peddler 3000, Medi-Bike, Taiwan) was used for the exercise program. The cycling equipment includes the resistance of 6 Levels, from Level 1 the lightest to Level 6 the heaviest. Other indicators examined are RPM (rotary per minute), DICT (The distance for this exercise), TIME (The time of exercise). This is the simplest way to use this Motion Exercise Machine. Press the ST / SP (Start/ Stop) button to start an exercise program for 30 minutes."
45821968|NCT00002209|Drug|CPI-1189|
45963775|NCT04791280|Procedure|Faeces collection|"faeces collection at inclusion~follow-up visit 6 months after inclusion"
45963776|NCT04723901|Biological|Dual target CAR-T cell therapy|CD19/CD22 dual target CAR-T cell therapy
45963777|NCT00197769|Biological|9 valent pneumococcal con jugate vaccine|
45963778|NCT04791241|Other|check-list including lung ultrasound|"The investigator will follow the checklist which includes the collection of anamnestic data and clinical signs, the performance of a pulmonary embolism clinical probability score and a cardiopulmonary ultrasound with count -standardized rendering. After completing this checklist, the investigator will note their diagnosis (list of proposals on the data collection sheet), the treatments started (closed list of therapeutic classes). If he orders other tests, he will write them down and then note the diagnosis made and the treatments prescribed after obtaining the results of these tests.~The therapeutic management of patients compared to the usual care in the respective departments may be modified depending on the results of the cardiopulmonary ultrasound . The emergency physician may initiate therapy before the results of additional examinations that he would have usually performed without cardiopulmonary ultrasound."
45963779|NCT04768855|Drug|LY3540378|Administered IV or SC.
45963780|NCT04768855|Drug|Placebo|Administered IV or SC.
45666556|NCT02329730|Biological|20μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 20μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
45666557|NCT02328326|Other|CO-IMPACT|Primary care-integrated activation and social support intervention that provides tools and training in patient activation and effective support techniques for patients and their family supporter
45963781|NCT04768855|Drug|LY3540378|Administered SC.
45963782|NCT02908633|Procedure|canaloplasty and phacoemulsification|
45821969|NCT00003092|Drug|paclitaxel|
45821970|NCT00381199|Drug|Amitriptyline Hydrochloride|
46080075|NCT01523444|Behavioral|computer-assisted Screening & Brief Advice|"The computer-facilitated screening and brief advice (cSBA) intervention is a self-administered, computer-facilitated screening that asks about lifetime and past-12-month use of substances followed by scientific information about how substance use affects health and true-life stories illustrating the health risks of substance use. The cSBA program prints out a Report Form with the screening results, risk level, and talking points designed to prompt a 2 to 3-minute provider/teen conversation about the health effects of substance use, which recommends abstinence."
45821971|NCT00381199|Drug|Nabilone|
45821972|NCT00002509|Biological|filgrastim|
45821973|NCT00002509|Drug|carboplatin|
45821974|NCT00002509|Drug|cyclophosphamide|
45821975|NCT00002509|Drug|etoposide|
45963783|NCT02908438|Drug|Gonadotrophin releasing hormone agonist(GnRHa)|GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
45821976|NCT00002509|Drug|mesna|
45963784|NCT00202410|Biological|Bacille of Calmette-Guerin|A single intracutaneous dose of 0.1 mL freeze-dried BCG (1 mg/mL; Berna Institute, Basel).
45821977|NCT00002509|Procedure|autologous bone marrow transplantation|
45821978|NCT00002509|Procedure|peripheral blood stem cell transplantation|
45821979|NCT00002515|Biological|filgrastim|
45821980|NCT00002515|Drug|carboplatin|
45963785|NCT00202410|Other|placebo|subcutaneous administration of physiologic solution
45458560|NCT03493360|Other|No visual feedback|Participants will be asked to perform 10 repetitions of low back flexion, extension and lateral side-flexions while looking at a mirror that is covered and no visual feedback is provided.
45821981|NCT00002515|Drug|thiotepa|
45821982|NCT00002515|Drug|topotecan hydrochloride|
45821983|NCT00002515|Procedure|autologous bone marrow transplantation|
45821984|NCT00002515|Procedure|bone marrow ablation with stem cell support|
45821985|NCT00002515|Procedure|in vitro-treated bone marrow transplantation|
45963786|NCT04760899|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
45963787|NCT04756999|Behavioral|massage therapy|Reflexology is massage therapy used to maintain and improve health, as well as relieve some symptoms.
45963788|NCT02908555|Other|No intervention|This is a descriptive study with no intervention
45963789|NCT02908321|Behavioral|CBT|The group based manualised CBT intervention consists of The Cool Kids Anxiety Program: Autism Spectrum Disorder Adaptation (Cool Kids ASD).
45963790|NCT04743895|Device|Stainless Steel Wire Cerclage|Wire cerclage used to close sternum after cardiothoracic surgery.
45963791|NCT04742296|Device|low level laser therapy|We will use laser light that has continuous wave mode, power of 100 mW, energy density of 7,5 joule/cm2, treatment time as 300 seconds.
45963792|NCT04731844|Drug|Curcumin plus Piperine|Curcumin with piperine is a well-tolerated over-the-counter supplement.
45821986|NCT00003098|Other|fat reduction with increased fiber|Patients are randomized to dietary fat reduction with increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
45666558|NCT02328326|Other|PACT|participants will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
45963793|NCT00197808|Biological|menjugate|men C conjugate vaccine
45666559|NCT01649804|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 104 weeks
45963794|NCT00197808|Biological|Men C conjugate vaccine|men C conjugate vaccine
45963795|NCT00197808|Biological|Men C conjugate|men C conjugate vaccine
45963796|NCT00197808|Biological|Men C Conjugate|men C conjugate vaccine
45666560|NCT02397278|Drug|Platelet rich plasma (PRP)|Patient will receive 3 intra articular injections with autologous PRP in the affected knee and then follow conventional therapy.
45963797|NCT00197808|Biological|Men C conjugate|men C conjugate vaccine
45963798|NCT00197808|Biological|Men C conjugate|men C conjugate vaccine
45963799|NCT00172328|Biological|Hepatitis B vaccine|
45963800|NCT04710394|Behavioral|Smell Training|Participants will be provided with 4 labeled jars, each containing an odor pre-impregnated cotton pad. Participants will sniff each scent for 10 seconds, twice daily, once in the morning and once in evening. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
45963801|NCT04675255|Procedure|Frequently sampled glucose tolerance testing|Frequently sampled glucose tolerance testing
45963802|NCT04675255|Procedure|abdominal subcutaneous adipose tissue biopsy|abdominal subcutaneous adipose tissue biopsy
45666561|NCT02360228|Device|tACS (alpha)|
45821987|NCT00003098|Other|fat reduction without increased fiber|Patients are randomized to dietary fat reduction without increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
45963803|NCT04675255|Procedure|MRI scan to assess intrahepatic triglyceride content|MRI scan to assess intrahepatic triglyceride content
45963804|NCT00172367|Drug|Lycopene|
45963805|NCT04673539|Diagnostic Test|Spanish version of the Brief-BESTest in stroke patients|Adaptation and validation of the Spanish version of the Brief-BESTest in stroke Patients
45963806|NCT00202488|Drug|H. pylori treatment|
45963807|NCT04668664|Device|EchoTip® Insight™ Portosystemic Pressure Gradient Measurement System (EchoTip® Insight™)|Measuring the portal pressure gradient in patients with cirrhosis who are referred for an esophagogastroduodenoscopy (EGD) and/or endoscopic ultrasound (EUS).
45963808|NCT04632316|Drug|Cyclophosphamide-Fludarabine (Cy/Flu)|Lymphodepleting conditioning regimen
45666562|NCT02360228|Device|tDCS|
45963809|NCT04632316|Drug|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
45963810|NCT04630327|Other|Beck Depression Inventory-21 (diagnostic survey)|Kazakh or Russian versions of the Beck Depression Inventory-21will be filled by female cancer patients
45963811|NCT04630327|Other|Beck Anxiety Inventory|Kazakh or Russian versions of the Beck Anxiety Inventory will be filled by female cancer patients
45963812|NCT04630327|Other|Interview using The International Classification of Diseases in tenth edition (ICD-10) criteria|Interview using The International Classification of Diseases in tenth edition (ICD-10) criteria as a gold standard of diagnosing depression or anxiety
45963813|NCT00197886|Drug|Changing dose of norepinephrine and blood pressure|
45963814|NCT04626427|Device|WavelinQ™ EndoAVF System|AVF endovascular creations using the WavelinQ™ EndoAVF System
45963815|NCT00172445|Procedure|blood sampling, neck lymph node biopsy|
45963816|NCT04612114|Diagnostic Test|Belun Ring|Simultaneous recording of Belun Ring data (pulse oximeter, pulse rate and actigraphy) and standard of care PSG will be performed for one night.
45963817|NCT00202527|Device|Nasal continuos positive airway pressure|
45963818|NCT00172484|Procedure|education program|A well-designed questionnaire concerning about awareness of stroke symptoms, knowledge, and management was done in adults of stroke victims' family members and general population.
45963819|NCT00172484|Procedure|nursing program|To establish a systemic stroke prevention, education protocol
45963820|NCT00172484|Procedure|rehabilitation program|From a sample of 648 stroke patients who were referred to rehabilitation between November 2002 and October 2002, 345 charts were successfully reviewed. Besides, 126 subjects were randomly selected and successfully contacted for telephone follow-up; and data from 87 subjects of telephone survey were included for statistical analysis. Comparison of functional status between early rehabilitation and ordinary scheduled rehabilitation for acute stroke patients was done from admission to 3 months after stroke onset. The efficacy of early application of electric stimulation for the upper paralyzed extremity was performed.
45963821|NCT02908360|Genetic|double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse|
45963822|NCT02908399|Device|FLIR ONE|
45963823|NCT02908243|Other|collection of baseline data|collection of baseline data including ages, types, severity, inhibitors and comorbidities
45963824|NCT00197925|Biological|Onco-peptide loaded autologous dendritic cells|
45666563|NCT02359994|Device|PerClot Polysaccharide Hemostatic System|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot. The prescribed hemostatic agent will be applied according to its Instructions for Use.
45821988|NCT00381277|Drug|Gatorade|
45821989|NCT00381277|Drug|Performance|
45666564|NCT02359994|Device|Arista AH|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of the control device. The prescribed hemostatic agent will be applied according to its Instructions for Use.
45666565|NCT04905446|Other|Deuterated nicotinamide (D4-NAM) IV infusion|Nicotinamide adenine dinucleotide (NAD) is a vitally important substance that is found in all cells of the body. D4-NAM (in normal saline) will be infused via an indwelling catheter.The IV infusion will continue for 8 hrs.
45666566|NCT04905446|Procedure|Skeletal muscle biopsy|Participants will have a muscle biopsy performed on the muscle in the thigh. We will collect a small sample of blood before the biopsy. This procedure is used to sample muscle cells from the right or left leg Vastus Lateralis (thigh) muscle.
45666567|NCT04905446|Procedure|Skin tissue biopsy|This procedure is used to sample skin tissue from the upper thigh via a punch biopsy.
45821990|NCT04712630|Procedure|Non-incised papila surgical approach without grafting biomaterial|Periodontal reconstructive surgery
45821991|NCT04712630|Procedure|Non-incised papila surgical approach with grafting biomaterial|Periodontal reconstructive surgery
45821992|NCT00002521|Drug|cisplatin|
45821993|NCT00002521|Drug|cyclophosphamide|
45821994|NCT00002521|Drug|etoposide|
45821995|NCT00002521|Procedure|autologous bone marrow transplantation|
45821996|NCT00002521|Procedure|bone marrow ablation with stem cell support|
45821997|NCT00002521|Procedure|peripheral blood stem cell transplantation|
45821998|NCT00002521|Procedure|syngeneic bone marrow transplantation|
45821999|NCT00002521|Radiation|radiation therapy|
45822000|NCT00581906|Radiation|DCE-MRI, DW-MRI and MRS|Pts undergo DCE-MRI, DW-MRI or 1^H-MRS studies on either the 1.5T scanner or the 3T MRI scanners. Patients will be grouped based on their treatment: group one will include pts who undergo surgery (we will no longer accrue pts in this group) & group two will include pts who undergo chemoradiation therapy.Pts who undergo surgery will have pretreatment DCE-MRI, DW-MRI &/or 1H-MRS studies on the GE 1.5T or 3T MRI scanner. Pts who participate in chemo-radiation therapy protocols will have pretreatment DCE-MRI, DW-MRI &/or 1H-MRS studies on the 3T Philips MRI scanner in the radiation oncology suite & will undergo additional recommended weekly DW-MRI including IVIM studies at the same MRI scanner during the course of treatment. Pts will undergo two recommended DCE-MRI studies (unless contraindicated) when possible. 1st intra-treatment DCE-MRI is recommended between the 1st & 2nd weeks of treatment & the 2nd intra-treatment DCE-MRI is recommended between the 3rd & 4th weeks of treatment.
45963825|NCT02908165|Drug|conventional TACE in combination with sorafenib, administered on a continuous schedule|Patients assigned to Group A will begin sorafenib on a continuous schedule starting at 400mg BID from Cycle 1 Day 1, one week prior to cTACE treatment on Cycle 1 Day 8. After week 6, cTACE will be provided on demand (as needed, up to 4 treatments total in the first 4 cycles) at week 2 in subsequent cycles, and sorafenib will continue to be administered. Patients will be allowed to undergo dose adjustments of sorafenib as long as it remains above the ¼ dose (400mg QOD).
45822001|NCT00003104|Radiation|radiation therapy|
45822002|NCT05751889|Behavioral|Serious Game|Serious Game embedded with healthcare information regarding HCV and safe sexual practice.
45822003|NCT05751889|Behavioral|Traditional Health Education|Reading materials regarding HCV and safe sexual practice.
45822004|NCT00003110|Biological|bleomycin sulfate|Patients receive bleomycin by continuous infusion for 72 hours every 3 weeks. Induction therapy consists of 3 cycles. Patients who achieve complete remission receive 2 more cycles. Patients with partial remission or stable disease may continue therapy until disease progression or unacceptable toxicity occurs.
45822005|NCT00002215|Drug|Emivirine|
45822006|NCT00002215|Drug|Nelfinavir mesylate|
45963826|NCT02908165|Drug|conventional TACE in combination with sorafenib, administered on a sequential schedule|Patients assigned to Group B will undergo cTACE up to 4 treatments within the first 4 cycles as needed prior to starting sorafenib. After it is determined that no further TACE treatment is necessary (via imaging and clinical assessment on follow-up), administration of sorafenib will begin on Day 1 of the following cycle. Dosing will begin at 400mg BID and maintained continuously provided no unmanageable toxicities develop, with follow-up assessments performed on week 6 of every 1-2 cycles as needed. Patients in Group B will also be allowed to undergo dose adjustments of sorafenib as long as it remains above the ¼ dose (400mg QOD).
45963827|NCT04556500|Other|investigating the psychometric properties of Turkish Affordance in the Home Environment for Motor Development-Toddler (AHEMD-T)|AHEMD-T will apply to parents who have 18-42 months child/children
45963828|NCT00202566|Drug|Ivabradine|
45455459|NCT01329367|Behavioral|Antioxidant group|"Participants will receive Nutritional education and personalized structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of fruits and vegetables (antioxidant rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
45455460|NCT01222975|Drug|Risperidone|orally disintegrating tablets
45455461|NCT01129063|Drug|Clopidogrel|"Pharmaceutical form : tablet~Route of administration: oral"
45666568|NCT02326298|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 200 mg/mL~Route of Administration: Subcutaneous use"
45666569|NCT02326298|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 0.9 % saline~Route of Administration: Subcutaneous use"
45963829|NCT04534270|Drug|Dapagliflozin|Dapagliflozin will be given 5mg per day (weight≤30kg) or 10mg per day (weight>30kg), for 12 weeks
45963830|NCT02908282|Device|REMOGEN OMEGA|Lubricant eye drops: preservative-free, hypotonic microemulsion of polyunsaturated fatty acids and hydrating polymers provided in single-dose containers of 0.25 ml.
45963831|NCT02908282|Device|Povidone|Artificial tears: preservative-free eye drops containing 2% povidone.
45666570|NCT02396420|Device|Embosphere Microspheres|
45666571|NCT02279719|Drug|BBI608|BBI608 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
45666572|NCT02279719|Drug|BBI503|BBI503 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
45666573|NCT02279719|Drug|Sorafenib|Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.
45666574|NCT02279407|Drug|placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
45666575|NCT02279407|Drug|Omega-3 carboxylic acids|4 g administered as 4 x 1 g capsules
45666576|NCT02279407|Drug|Dapagliflozin|10 mg administered as 10 mg tablet
45455462|NCT03928561|Device|Active intense Pure Air XL air cleaner|Cat allergen is nebulized in the EEC. When the concentration is stable, air cleaners are switched on. The number of air cleaners placed in the EEC is defined according to the volume of the EEC and the air renewal. Patients are exposed to cat allergen in the presence of active air cleaners in the EEC
45666577|NCT02279407|Drug|Placebo|Placebo matching to dapagliflozin 10 mg
45666578|NCT02326220|Drug|Placebo|
45666579|NCT02326220|Drug|Alirocumab|
45822007|NCT00003116|Biological|filgrastim|Filgrastim (G-CSF) is administered subcutaneously twice a day beginning 3 hours after completion of cell infusion and continuing until blood counts recover.
45822008|NCT00003116|Drug|busulfan|high-dose oral busulfan every 6 hours on days -8 to -5
45822009|NCT00003116|Drug|cyclophosphamide|cyclophosphamide IV twice a day on days -4 and -3
45822010|NCT00003116|Drug|cyclosporine|cyclosporine IV over 6 hours on day -1 and then 10 hours on day 0 for 2 doses (allogeneic only)
45822011|NCT00003116|Procedure|bone marrow ablation with stem cell support|
45822012|NCT00003116|Procedure|peripheral blood stem cell transplantation|Allogeneic peripheral blood progenitor cells IV are administered on day 0.
45822013|NCT00002221|Drug|Peripheral blood stem cells|
45822014|NCT00002227|Drug|Efavirenz|
45822015|NCT00002227|Drug|Lamivudine|
45963832|NCT04492540|Other|aerobic exercise and MIND diet program|the aerobic exercise in form of treadmill training intensity of exercise moderate intensity, target heart rate (THR) will be60-70% of heart maximum (HR MAX), time of session 60 min initial 10 min warm up exercise on treadmill in low intensity and target phase 40 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercise 3 times per week for 12 weeks
45963833|NCT04492540|Other|MIND diet program|control group will receive diet program for 12 weeks
45963834|NCT00172601|Procedure|mobilization|
45963835|NCT00197964|Behavioral|Enhance asthma knowledge, self-efficacy, social support|
45963836|NCT02908126|Drug|Oxytocin|Oxytocin drug
45963837|NCT02907931|Other|Point of Care Ultrasound|
45963838|NCT00202605|Drug|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate|
45963839|NCT04455334|Other|Error-augmented treadmill training|walk on split-belt treadmill
45963840|NCT04455334|Other|active control group|walk on tie-belt treadmill
45963841|NCT04455334|Other|Error-augmented concept combined physical therapy group|Error-augmented concept combined physical therapy
45963842|NCT04455334|Other|conventional physical therapy group|conventional physical therapy
45963843|NCT04455334|Other|NO INTERVENTION|NO INTERVENTION
45963844|NCT02907853|Behavioral|Contingency Management|as described above
45963845|NCT02907658|Behavioral|PROTECT intervention group|The indicated preventive intervention PROTECT consists of a cognitive-behavioral 4-session brief-protocol (90 minutes). It targets empirically identified risk factors of Internet Use Disorder (IUD), i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
45963846|NCT02907775|Device|ShefStim|Electrode arrays will be worn over the affected arm with stimulation applied over the extensor aspect of the upper arm
45822016|NCT00002227|Drug|Stavudine|
45963847|NCT02907775|Device|Electrodes|electrodes placed over the radial nerve in radial grove
45963848|NCT00198003|Behavioral|Educational program to address patients' expectations|
45963849|NCT02907580|Behavioral|Local educational information|Participants in this arm receive educational information regarding influenza vaccination based on local educational information.
45963850|NCT02907580|Behavioral|National educational information|Participants in this arm receive educational information regarding influenza vaccination based on national educational information.
45963851|NCT02907502|Dietary Supplement|Young-child formula with low protein content|Young-child formula with low protein content
45963852|NCT02907502|Dietary Supplement|Young-child formula with protein content similar to that of cow's milk|Young-child formula with protein content similar to that of cow's milk
45963853|NCT04682080|Behavioral|Needle-free injection|"This study was performed among children aged 4-10 years who required dental treatment and were treated at the Department of Pedodontics, Faculty of Dentistry, Gaziosmanpasa University. A total of 120 patients were evaluated in accordance with the exclusion criteria and 94 children (39 girls and 55 boys) were included in this study. Children who needed dental treatment were randomly divided into two groups. All dental injections were administered by the same operator (MB), a pediatric dentist with two years of experience in using the Comfort-In system.~In both groups, the children were asked to rate their pain intensity by choosing the closest statement on the colorful Wong-Baker Pain Scale at four time points: immediately after injection (Pain 1), during treatment (Pain 2), at the end of the treatment (Pain 3) and postoperative first day.Anxiety levels were recorded using the Modified Children's Dental Anxiety Scale face version"
45963854|NCT00407732|Behavioral|psychosocial intervention|motivational enhancing case management intervention
45963855|NCT04682119|Drug|LY3526318|Administered orally.
45822017|NCT03689972|Drug|Natalizumab|Natalizumab 300 mg SC injection or IV infusion.
45822018|NCT00002233|Drug|Indinavir sulfate|
45963856|NCT04682119|Drug|Placebo|Administered orally.
45963857|NCT02907385|Device|LifeSeal™ Kit|LifeSeal™ Kit is applied as an additional protective layer over a stapled anastomosis
46080076|NCT01523444|Behavioral|computer-assisted Screening & Brief Advice Plus|The cSBA+ intervention contains cSBA intervention elements plus the delivery of a brief, two-session motivational enhancement therapy (MET) intervention to be delivered a Behavioral Health Counselor (BHC) at the clinic immediately after meeting with the primary care provider. In the first session of this intervention, youth should be encouraged to think about: (1) The role alcohol and drugs play in his/her life; (2) His/her personal goals for changing alcohol and drug use; (3) Strategies for reaching and maintaining goals. The goal at the end of the session is positive movement in the direction of abstinence or change. The aim of the second session is reinforcement of goals set forth in the prior meeting with the BHC.
46080077|NCT01515137|Drug|Erlotinib|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
46080078|NCT01515137|Drug|Erlotinib plus sulindac|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
45822019|NCT00002233|Drug|Abacavir sulfate|
45822020|NCT00002233|Drug|Amprenavir|
45822021|NCT00002233|Drug|Lamivudine|
45822022|NCT00002527|Drug|aspirin|
45822023|NCT00002527|Other|placebo|
45822024|NCT03688178|Biological|Human CMV pp65-LAMP mRNA-pulsed autologous DCs|2x10^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
45822025|NCT03688178|Drug|Temozolomide|Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 4 (+ 2) weeks for up to 12 cycles (patients with unmethylated MGMT gene promoter will receive only cycle 1)
45822026|NCT03688178|Biological|Varlilumab|Varlilumab is an agonist anti-CD27 monoclonal antibody
45963858|NCT00198120|Drug|D-cycloserine|D-Cycloserine 0.6mg/kg/day in week 1 D-Cycloserine 1.1mg/kg/day in week 2 D-Cycloserine 1.7mg/kg/day in week 3-8 Flexible dosing based on response. Capsule Strength: 10mg, 20mg
45963859|NCT00198120|Drug|Placebo|Placebo: same dosing schedule and capsule strength
45963860|NCT02907541|Other|QI4U learning|Learners will have access to 8 QI methods modules on QI4U
45963861|NCT02907541|Other|Facilitated learning|Learners will have access to quarterly learning events and bespoke training on QI methods through facilitated peer-to-peer learning workshops
45963862|NCT02907541|Other|QI4U and Facilitated learning|Learners will have access to the 8 QI modules on QI4U and attend quarterly learning events and bespoke training on QI methods through peer-to-peer learning workshops
45963863|NCT02907424|Dietary Supplement|2 months of treatment|standard 2 months of treatment
45963864|NCT02964065|Biological|Live-Attenuated influenza Vaccine(LAIV)|
45666580|NCT02279173|Drug|Romiplostim|Romiplostim subcutaneous weekly injection
45666581|NCT02282917|Drug|AR-42|AR-42 will be administered in a total of ten oral doses, +/- 1 dose, at 40 mg/dose, will be self-administered by study participants at approximately 8:00pm (+/- 1 hour) for 3 weeks pre-operatively, with the last dose being administered the night before surgery. The treating surgeon will perform the clinically indicated surgical procedure 3 weeks post-initial dose of medication as well as the specimen collection.
45666582|NCT02358668|Drug|BTI320|BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.
45822027|NCT03688178|Biological|Td|A single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally
45822028|NCT03688178|Biological|Unpulsed DCs|Patients in Group I will receive 1 x 10^6 autologous unpulsed DCs in saline administered to a single side of the groin intradermally 1 day before the fourth vaccine.
45822029|NCT00002533|Drug|fluconazole|
45963865|NCT02964065|Biological|Placebo|
45822030|NCT00002533|Radiation|radiation therapy|
45822031|NCT00003122|Procedure|surgical procedure|
45963866|NCT02907346|Behavioral|Reinforcement for wearing CGM|The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
45963867|NCT00198159|Drug|ZD1839 Iressa|
45963868|NCT02907112|Behavioral|Meat reduction|Advice, Motivational material and food products provided to participants
45963869|NCT02907190|Other|Bean Type|1/2 cup of freshly boiled beans will be eaten by participants on separate study visits
45666583|NCT02358668|Drug|BTI320 matching placebo|Placebo
45666584|NCT02282605|Drug|XF-73 nasal gel|
45666585|NCT02282605|Drug|Placebo nasal gel|
45666586|NCT02282605|Other|Chlorhexidine gluconate 2% topical cloths|
45666587|NCT02282527|Biological|Liquid Alpha₁-PI|Liquid Alpha₁-PI, 60 mg/kg, 8 weekly intravenous infusions
45666588|NCT02282527|Biological|Prolastin-C|Prolastin-C, 60 mg/kg, 8 weekly intravenous infusions
45822032|NCT02973217|Device|Immunostimulating Interstitial Laser Thermotherapy|
45822033|NCT00002539|Biological|filgrastim|
45822034|NCT00002539|Drug|cisplatin|
45822035|NCT00002539|Drug|doxorubicin hydrochloride|
45822036|NCT00002539|Procedure|conventional surgery|
45822037|NCT00381589|Drug|ipratropium bromide 0.03% spray|
45822038|NCT00002239|Drug|Enfuvirtide|
45822039|NCT00002239|Drug|Ritonavir|
45822040|NCT00002239|Drug|Abacavir sulfate|
45822041|NCT00002239|Drug|Amprenavir|
45822042|NCT00002239|Drug|Efavirenz|
45963870|NCT02907190|Other|Starchy Foods|1/2 cup serving of one of 4 starchy foods will be eaten by participants on different study visit
45963871|NCT02964026|Device|pulmonary artery catheter|PAC must be placed between the day of admission and the day following a qualifying cardiac surgery
45963872|NCT02907307|Device|LactiSal vaginal gel 1%|to be administered daily intravaginally for 6 days
45963873|NCT02907307|Device|LactiSal vaginal tablet 50mg|to be administered daily intravaginally for 6 days
45963874|NCT02907307|Drug|Clotrimazole vaginal tablet 100mg|to be administered daily intravaginally for 6 days
45963875|NCT00553345|Drug|selenium|
45963876|NCT00553345|Drug|vitamin E|
45822043|NCT00383474|Drug|Bortezomib|Given IV
45822044|NCT00383474|Other|Laboratory Biomarker Analysis|Correlative studies
45822045|NCT00383474|Drug|Tipifarnib|Given orally
45822046|NCT00002245|Drug|Abacavir sulfate|
45822047|NCT00002245|Drug|Amprenavir|
45963877|NCT00553345|Procedure|chemoprevention|
45963878|NCT02907229|Device|NCVC-CS1|Intervention Description
45963879|NCT02907151|Other|Survey|Complete a survey prior to the consultation and a questionnaire after
45963880|NCT00407771|Drug|Tirofiban|
45963881|NCT00198198|Drug|Aripiprazole|
45963882|NCT02206087|Drug|PER977|Reversal of heparin-induced anticoagulation
45963883|NCT02206087|Drug|Placebo|Reversal of heparin-induced anticoagulation
45963884|NCT02206087|Drug|Heparin Sodium|
45963885|NCT02193139|Drug|WL8713, 6 mg|
46080079|NCT01515137|Drug|Placebo|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
46080080|NCT01482637|Other|CAS|All clients will be asked to complete the CAS instrument.
45963886|NCT02193139|Drug|WL8713, 12 mg|
45963887|NCT02193139|Drug|WL8713, 18 mg|
45963888|NCT02193139|Drug|WL8713, 24 mg|
45963889|NCT02193139|Drug|Placebo|
45963890|NCT00198237|Drug|docetaxel & capecitabine|
45963891|NCT02191774|Procedure|Medical abortion at home|Medical abortion using Mifepristone at the clinic followed by Cytotec at home
46080081|NCT01481428|Behavioral|Computer-facilitated HIV intervention|Individuals assigned to the experimental condition will complete the self-directed CARE HIV intervention during each of their first three sessions. The 20 minute intervention sessions involve several components including a brief risk assessment, review of identified risks, structured skill building videos, and the development of a risk prevention action plan. Because of the adaptive nature of the CARE program, the content of each session will be tailored to address the current risks of the participant. While the main focus of the intervention is on risk, individuals who report being HIV infected will receive a referral to treatment if they are not currently receiving medical care and their session will address, among other things, adherence to HIV care.
46080082|NCT01481428|Behavioral|Attention Control|Life skills training DVDs that match the duration of the anticipated experimental condition. The DVDs address topics such as positive listening skills, anger management, and stress reduction.
46080083|NCT01465555|Behavioral|Cognitive Behavioral Intervention|Counselors in this condition will work with the modified RecoveryTrack tested in the pilot study which has been altered to provide automated Clinical Alerts at either the intake, Month 1, or Month 2 CRM interview for High Risk patients. In addition, High Risk patients will be flagged in the counselor's caseload for discussion with clinical supervisors. Counselors in this condition will receive the Clinical Alert + Cognitive Behavioral Intervention (CBI) training, as well as monthly feedback from the Principal Investigator on their delivery of the CBI Months 1-3, with a booster session at Month 6.
46080084|NCT01439113|Procedure|Ultrasound guided IV placement|The nurse will use the emergency department's ultrasound machine to locate peripheral veins and then cannulate the vessel under ultrasound guidance.
46080085|NCT01407770|Genetic|DNA analysis|Genetic
45666589|NCT05650099|Device|One or two dental implants (Biomet3I dental implant system) were placed 10 years ago|All patients were 10 years ago referred to the Department of Oral and Maxillofacial Surgery (University of Groningen, University Medical Hospital) because of missing posterior teeth and were treated with dental implant placement and implant-supported restorations. Patients will have a regular routine control visit (as part of regular follow-up of these patients)
45963892|NCT04723550|Device|Hospital telemedicine management system|Patients upload data of blood glucose, diet and exercise. Then doctors guide patients' diet, exercise and medication adjustment through the telemedicine system.
45666590|NCT02278939|Behavioral|Filipinos Fit and Trim Weight Loss Program|This 3-month pilot RCT with wait-list control Fit and Trim lifestyle intervention is designed to reduce weight by increasing physical activity, and health eating to improve fasting glucose and hemoglobin A1c. This intervention will use a mobile phone health app diary to self-monitor weight, physical activity, and diet to improve health outcomes to reduce type 2 diabetes risks in Filipino Americans. Program goals are to lose 5% body weight, increase and maintain steps to 12,000 steps/day (20% increase in step-counts each week), reduce total daily fat intake (25% of total calories from fat), and sugar-sweetened beverages over 3 months.
45666591|NCT02278471|Drug|Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)|
45666592|NCT05565235|Drug|patients will receive intraoperative serratus block with bupivacaine|no additives
45666593|NCT05565235|Drug|serratus block with bupivacaine /magnesium|magnesium added
45666594|NCT05565235|Drug|serratus block with bupivacaine with nalbuphine|nalbuphine added
45822048|NCT00002245|Drug|Lamivudine|
45822049|NCT00003128|Biological|filgrastim|
45822050|NCT00003128|Drug|ifosfamide|
45822051|NCT00003128|Drug|paclitaxel|
45822052|NCT04331197|Drug|Clomiphene Citrate 50mg|Clomid 50 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
45822053|NCT04331197|Drug|Letrozole 2.5mg|Femara 2.5 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
45822054|NCT03687086|Other|Program A|Cognitive behavioral therapy type A plus medications prepared in packaging type A.
45822055|NCT03687086|Other|Program B|Cognitive behavioral therapy type B plus medications in packaging type B.
45963893|NCT04723550|Other|Usual care|Outpatient/telephone follow-up：continued care, as usual, from their primary care provider through out duration of action 6 months intervention period
45963894|NCT02161627|Device|Saluda Medical External Trial System|
45963895|NCT02161627|Device|Saluda Medical External Trial System|
45963896|NCT00198354|Drug|gemcitabine + cisplatine|gemcitabine 1250 mg/m², D1+D8 cisplatine 80 mg/m², D1 (D1=D22)
45963897|NCT00198354|Drug|Paclitaxel + Carboplatine|paclitaxel 200 mg/m², D1 carboplatin AUC 6, D1 (D1=D22)
45963898|NCT02160262|Drug|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed, once daily
45822056|NCT05751733|Drug|Apatinib Mesylate|Apatinib Mesylate (Etan) is a new type of small molecule anti-angiogenic agent, which is a small molecule TKI against VEGFR2 independently developed in China and has the effect of anti-C-Kit and PDGFR.
45822057|NCT05751733|Drug|Sunitinib, Imatinib dosage, Dasatinib, Reveratinib|Second-line TKI drugs
45822058|NCT00002798|Drug|asparaginase|
45822059|NCT00002798|Drug|daunorubicin hydrochloride|
45666595|NCT04420039|Device|Endoscopic biliary transmural drainage|"Endosonography-guided biliodigestive anastomosis using a dedicated biliary lumen-apposing stent in order to proveide a biliary drainage in cases of palliative malignant biliary obstruction.~Two different strategies will be compared: single lumen-apposing stent vs lumen-apposing stent plus dousble-pigtail plastic stent."
45666596|NCT02278003|Other|memory test|
45666597|NCT02278003|Drug|Propofol|
45822060|NCT00002798|Drug|fludarabine phosphate|
45822061|NCT00002798|Drug|therapeutic hydrocortisone|
45822062|NCT00002798|Procedure|allogeneic bone marrow transplantation|
45822063|NCT00002798|Radiation|3-dimensional conformal radiation therapy|
45963899|NCT02158585|Drug|Lamotrigine|Lamotrigine will be taken orally on a daily basis for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses for patients are 25mg twice a day, 50mg twice a day, and 100 mg twice a day during titration; 150mg twice a day for the 12-week study period; 150mg once a day for Week 1 of the taper; and 75mg once a day for Week 2 of the taper. Each increase in dose will be maintained for two weeks before deciding to further increase or decrease based on tolerability. Patients who discontinue at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.
45963900|NCT02158585|Drug|Placebo|The placebo will match the lamotrigine dosage, frequency and duration.
45963901|NCT00202917|Drug|Fludarabine|
45963902|NCT00202917|Drug|Thiotepa|
45963903|NCT00202917|Drug|Melphalan|
45963904|NCT00202917|Drug|OKT-3|
45963905|NCT00202917|Procedure|CD3/CD19 depletion on CliniMACS|
45963906|NCT02145364|Device|Ultherapy® treatment|Microfocused ultrasound treatment
45963907|NCT02135536|Biological|NGM282|NGM282
45963908|NCT00202956|Drug|Bugusan|
46080086|NCT01407770|Genetic|gene expression analysis|Genetic
45666598|NCT02277769|Drug|Dupilumab|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
45666599|NCT02277769|Drug|Placebo (for Dupilumab)|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
45963909|NCT02109406|Drug|AZD2115 Dose 1|AZD 2115, Dose 1 administered as two inhalations BID
46080087|NCT01407770|Other|enzyme-linked immunosorbent assay|Genetic
45666600|NCT05649787|Behavioral|Supervised aerobic training|Supervised moderate to high-intensity interval aerobic training
45666601|NCT05649787|Behavioral|Supervised aerobic plus low to moderate-intensity strength training|Supervised moderate to high-intensity interval aerobic training plus low to moderate-intensity strength training
45666602|NCT05649787|Behavioral|Supervised aerobic plus moderate to high-intensity strength training|Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training
45666603|NCT01641991|Biological|BioThrax®|BioThrax® is a sterile, milky white suspension made from cell free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis, will be administered as a 0.50mL IM injection 6 month boost for all groups
45666604|NCT01641991|Biological|BioThrax®|BioThrax® will be administered as: Arm A: 0.50mL SC injection on Days 0 and 14; Arm B: 0.50mL SC injection on Days 0 and 28; Arm C: 0.50mL SC injection on Days 0, 14 and 28; Arm D: 0.25 mL SC injection on Days 0, 14 and 28.
45822064|NCT00002798|Biological|filgrastim|Given SC
45822065|NCT00002798|Drug|cytarabine|Given IV or IT
45963910|NCT02109406|Drug|AZD 2115, Dose 2|AZD 2115, Dose 2 administered as two inhalations BID
45963911|NCT02109406|Drug|Placebo MDI|Placebo MDI administered as two inhalations BID
45963912|NCT02109016|Drug|Lucitanib|"Lucitanib given orally to all patients, once daily (q.d.), on a continuous schedule over 28-day cycles, in fasting conditions (at least 2 hours prior to and 2 hours after any meal), until progressive disease or unacceptable toxicity.~Starting dose is 10 mg/day and can be reduced in 2.5 mg decrements to 5 mg/day based on individual tolerability."
45963913|NCT00202995|Drug|Glatiramer Acetate|20 mg s.c. daily
45963914|NCT00202995|Drug|Betaseron|250 mg every other day
46080088|NCT01407770|Other|flow cytometry|Genetic
45963915|NCT00202995|Drug|Rebif|44 ug 3 times a week
45963916|NCT04678219|Other|Dietary Intervention|Subjects will be placed on 1 of 2 diets for a treatment period of 8 weeks with the support of dietitians; it will then be evaluated whether they can continue this diet on their own for 4 weeks.
45963917|NCT04677868|Drug|Methotrexate|Methylprednisolone 1 mg/kg/day MTX (10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II;
45963918|NCT00198393|Drug|Gefitinib|250 mg/day, until progression
46080089|NCT01407770|Other|laboratory biomarker analysis|Genetic
46080090|NCT01407770|Other|questionnaire administration|Genetic
45822066|NCT00002798|Drug|idarubicin|Given IV
45822067|NCT00002798|Drug|dexamethasone|Given PO
45822068|NCT00002798|Drug|thioguanine|Given PO
45822069|NCT00002798|Drug|etoposide|Given IV
45822070|NCT00002798|Drug|methotrexate|Given IT
45822071|NCT00002798|Drug|cyclophosphamide|Given IV
45822072|NCT00002798|Biological|aldesleukin|
45822073|NCT00002798|Drug|busulfan|
45822074|NCT00002251|Drug|Ganciclovir|
45822075|NCT00002257|Drug|Ganciclovir|
45822076|NCT00003134|Drug|irinotecan hydrochloride|
45822077|NCT00002545|Drug|carmustine|
45822078|NCT00002545|Radiation|low-LET photon therapy|
45822079|NCT00002804|Biological|filgrastim|
45822080|NCT00002804|Drug|doxorubicin hydrochloride|
45822081|NCT00002804|Drug|ifosfamide|
45822082|NCT00002804|Drug|mesna|
45822083|NCT00002804|Drug|vincristine sulfate|
45822084|NCT00002804|Procedure|conventional surgery|
45822085|NCT00002804|Radiation|brachytherapy|
45822086|NCT00002804|Radiation|low-LET cobalt-60 gamma ray therapy|
45963919|NCT00198393|Drug|gemcitabine|1250 mg/m² D1 and D8 (D1=D28, until progression)
46080091|NCT01407770|Procedure|adjuvant therapy|Genetic
46080092|NCT01407770|Procedure|assessment of therapy complications|Genetic
46080093|NCT01407770|Procedure|quality-of-life assessment|Genetic
45666605|NCT05555407|Diagnostic Test|Scintigraphic gastric emptying scan|Nuclear medicine scan that provides an assessment of gastric motility
45666606|NCT05555407|Device|Wireless patch system (WPS)|Wireless wearable patches applied to the abdomen after 3 small areas of the abdomen that connect to a recording device for a total of 6 days and subjects will track mealtimes, bowel movements, and sleep using an iPhone app.
45666607|NCT05649709|Drug|L-VA dual therapy|1000mg amoxicillin capsules twice times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
45666608|NCT05649709|Drug|H-VA dual therapy|1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
45666609|NCT05649631|Dietary Supplement|Sodium|50 IHA patients were randomized into two groups with low sodium (50mmol/d) and normal sodium (100mmol/d) without potassium supplement. A 14 days dietary intervention was performed respectively to compare the changes in blood pressure (BP) and serum potassium in two groups.
45822087|NCT00002804|Radiation|low-LET electron therapy|
45963920|NCT00198393|Drug|Docetaxel|75 mg/m² D1 (D1=D22, until progression)
45963921|NCT02104336|Drug|EPI-743|EPI-743 is the quinone oxidation product of alpha-tocotrienol
45666610|NCT02277691|Drug|TAK-536TCH tablet|TAK-536TCH tablets
45822088|NCT00002804|Radiation|low-LET photon therapy|
45822089|NCT00002810|Biological|filgrastim|
45822090|NCT00002810|Drug|melphalan|
45822091|NCT00002810|Procedure|bone marrow ablation with stem cell support|
45963922|NCT02103322|Drug|Imatinib Mesylate Tablets, 400 mg|Brown, oval, scored, film coated, beveled edge tablet. Debossed with AN on scored side and 795 on the other side.
45963923|NCT02103322|Drug|Imatinib Mesylate Tablets, 400 mg|"Very dark yellow to brownish orange, film-coated tablets, ovaloid, biconvex with bevelled edges, debossed with 400 on one side with score on the other side, and SL on each side of the score."
45963924|NCT02100436|Biological|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|A unadjuvanted subvirion monovalent inactivated split influenza virus vaccine (H3N2v MIV) produced in eggs. Subjects are enrolled in 3 cohorts stratified by age. 6-35 month old subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart, or 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart. 3-8 year old subjects and 9-17 year old subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
45963925|NCT00554827|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
45963926|NCT00554827|Dietary Supplement|Folic Acid|"1 mg orally~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered daily throughout the study and for at least 30 days after last dose of pralatrexate."
45963927|NCT00554827|Drug|Pralatrexate|Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or
45963928|NCT00203034|Drug|rasagiline mesylate|0.5 mg rasagiline mesylate oral once daily
45963929|NCT00203034|Drug|1.0 mg rasagiline mesylate|1.0 mg rasagiline mesylate oral once daily
45963930|NCT00203034|Other|Placebo|oral placebo once daily
45963931|NCT04677673|Drug|Chemotherapy|Modified SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 100mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 60mg/M2 oral (twice daily) Repeated every 22nd day
46080094|NCT01407770|Radiation|3-dimensional conformal radiation therapy|Genetic
45822092|NCT00002810|Procedure|peripheral blood stem cell transplantation|
45822093|NCT00003140|Drug|letrozole|Given orally
45822094|NCT00003140|Other|placebo|Given orally
45963932|NCT04677673|Procedure|Curative gastrectomy|Radical gastrectomy with D2 lymph node dissection
45963933|NCT00203073|Drug|glatiramer acetate 20 mg|glatiramer acetate 20 mg
45963934|NCT00203073|Drug|glatiramer acetate 20 mg, with mitoxantrone|glatiramer acetate 20 mg, with mitoxantrone
45963935|NCT04677634|Dietary Supplement|ISOThrive Prebiotic Nectar|The test material is ISOThrive. It is an approximately 90% pure maltosyl-isomalto-oligosacchride (MIMO) prebiotic syrup produced by bacterial fermentation/bio-conversion of sucrose and maltose. It is taken 1g daily.
46080095|NCT01407770|Radiation|breast irradiation|Genetic
45666611|NCT02277691|Drug|TAK-536CCB tablet|TAK-536CCB tablets
45666612|NCT02277691|Drug|HCTZ 12.5 mg tablet|HCTZ tablets
45666613|NCT02395172|Drug|Avelumab|Participants received 10 milligrams per kilogram (mg/kg) of avelumab as a 1-hour intravenous infusion once every 2 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
45666614|NCT02395172|Drug|Docetaxel|Participants received 75 mg per square meter (m^2) (per label) of docetaxel by intravenous infusion once every 3 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
45666615|NCT04876027|Drug|GLP-1 RAs|GLP-1 receptor agonist is a glucagon-like peptide 1 analog, which is related to improving blood sugar control, weight loss and appetite suppression, and reducing cardiovascular risk.
45822095|NCT00003392|Biological|filgrastim|10 mcg/kg/d, day 2 through last day of leukapheresis
45822096|NCT00003392|Drug|carboplatin|18 AUC IV, approximately days 21, 42
45822097|NCT00003392|Drug|cyclophosphamide|4 gm/m2 IV, day 1
45822098|NCT00003392|Drug|melphalan|140 mg/m2 IV , approximately day 63
45822099|NCT00003392|Drug|paclitaxel|170 mg/m2 IV day 1
45822100|NCT00003392|Procedure|bone marrow ablation with stem cell support|
45822101|NCT00003392|Procedure|peripheral blood stem cell transplantation|
45822102|NCT00002551|Drug|fluorouracil|See arm assignments.
46080096|NCT01407770|Radiation|external beam radiation therapy|Genetic
45666616|NCT04876027|Other|calorie restricted diet|Calorie restricted diet can improve insulin sensitivity, liver fat in patients with visceral obesity, and metabolism and hormone levels in obese women with PCOS.
45963936|NCT00554866|Other|blood sample and buccal swab sample|"one blood sample (500 mL) will be obtained from each VLBW infant between 6 and12 hours after birth from an umbilical-artery or peripheral artery catheter.~Additional DNA collection buccal cell samples were obtained with a sterile OmniSwab."
45666617|NCT04859101|Other|Gum|2 minutes of gum chewing prior to procedure
45822103|NCT00002551|Drug|leucovorin calcium|See arm assignments.
45963937|NCT02078674|Biological|Monovalent Avian Influenza VLP (H7N9)|
45963938|NCT02078674|Biological|Matrix-M1™ adjuvant|
45963939|NCT02078674|Biological|Placebo|
46080097|NCT01407770|Radiation|hypofractionated radiation therapy|Genetic
46080098|NCT01407770|Radiation|intensity-modulated radiation therapy|Genetic
45666618|NCT04859101|Other|Control|2 swallows prior to procedure
45666619|NCT05543551|Other|Diaphragmatic breathing with Resistance Training|"Wall press-up:~Stand arm's length from the wall. Place your hands flat against the wall at chest level, with your fingers pointing upwards. With your back straight, slowly bend your arms, keeping your elbows by your side.~Dumbbell biceps curls:~Hold a pair of light weights and stand with your feet hip-width. Keeping your arms by your side, slowly bend them until the weight in your hand reaches your shoulder. Slowly lower again.~Back squats:~Place barbell with weights onto the squat rack. Bring your body under the bar. Rest barbell over your traps and shoulders. Make sure hands are even on each side of the bar. Keep your feet in the same position as they would be for an air squat. Brace your midline and keep your chest up.~Leg press:~Position feet about shoulder width apart. Try to push through your heels, keeping the knees lined up over the toes. Extend the legs until nearly straight, avoiding locking the knees."
45822104|NCT00002551|Drug|levamisole hydrochloride|See arm assignments.
45822105|NCT00002551|Radiation|radiation therapy|See arm assignments.
45822106|NCT00003146|Drug|busulfan|
45822107|NCT00003146|Drug|melphalan|
45822108|NCT00003146|Drug|thiotepa|
45822109|NCT00003146|Procedure|bone marrow transplantation|
45822110|NCT00003146|Procedure|peripheral blood stem cell transplantation|
45822111|NCT00003398|Biological|anti-thymocyte globulin|
45822112|NCT00003398|Biological|filgrastim|
45822113|NCT00003398|Drug|cyclophosphamide|
45822114|NCT00003398|Drug|thiotepa|
45822115|NCT00003398|Procedure|allogeneic bone marrow transplantation|
45822116|NCT00003398|Procedure|bone marrow ablation with stem cell support|
45822117|NCT00003398|Radiation|radiation therapy|
45822118|NCT00002263|Drug|Zidovudine|
45822119|NCT00002263|Drug|Sargramostim|
45822120|NCT00002816|Drug|cytarabine|Given IV
45822121|NCT00002816|Drug|dexamethasone|Given IV
45963940|NCT00198432|Drug|Paclitaxel, vinorelbine, cisplatin|
45963941|NCT02075281|Biological|HM11260C|Glucagon-like peptide-1 analogue
45963942|NCT02075281|Biological|Placebo|
45963943|NCT02074579|Drug|TU-100|15g daily, orally as 5g three times daily for 4 consecutive weeks
46080099|NCT01407770|Radiation|whole breast irradiation|Genetic
45822122|NCT00002816|Drug|etoposide|Given IV
45822123|NCT00002816|Drug|idarubicin|Given IV
45822124|NCT00002816|Drug|ifosfamide|Given IV
45822125|NCT00002816|Drug|leucovorin calcium|
45963944|NCT02074579|Drug|Placebo|Matching placebo given 5g three times daily orally for 4 consecutive weeks
45963945|NCT02072863|Drug|Oprozomib|Study subjects will receive oprozomib administered orally.
45963946|NCT02072863|Drug|Melphalan|Study subjects will receive melphalan 9 mg/m2.
45963947|NCT02072863|Drug|Prednisone|Study subjects will receive prednisone 60 mg/m2.
45963948|NCT02072161|Drug|ETC-1002|ETC-1002 capsules, taken once daily oral
45963949|NCT02072161|Drug|Placebo|Placebo capsules, taken once daily oral
45963950|NCT02072161|Drug|Statin Therapy|Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.
45963951|NCT00198471|Drug|Vitrase|
45963952|NCT02067793|Drug|NRX-1074 1 mg|Single intravenous administration of 1 mg into arm on Day 0
45963953|NCT02067793|Drug|Placebo|Single intravenous injection into the arm on Day 0
45963954|NCT02067793|Drug|NRX-1074 5 mg|Single intravenous injection of 5 mg into the arm on Day 0
45963955|NCT02067793|Drug|NRX-1074 10 mg|Single intravenous injection of 10 mg into the arm on Day 0
45963956|NCT02066545|Drug|CLS001 Topical Gel|
45963957|NCT02066545|Drug|CLS001 Topical Gel Vehicle|
45666620|NCT05543551|Other|diaphragmatic breathing with out resistance training|"Diaphragmatic Breathing:~Lie on your back on a flat surface (or in bed) with your knees bent. You can use a pillow under your head and your knees for support if that's more comfortable.~Place one hand on your upper chest and the other on your belly, just below your rib cage.~Breathe in slowly through your nose, letting the air in deeply, towards your lower belly. The hand on your chest should remain still, while the one on your belly should rise.~Tighten your abdominal muscles and let them fall inward as you exhale through pursed lips. The hand on your belly should move down to its original position. You can also practice this sitting in a chair, with your knees bent and your shoulders, head, and neck relaxed"
45666621|NCT02275819|Other|Exercise|Exercise (walking 3 times a week for 60 minutes) or Inspiratory Muscle Therapy (breathing against an inspiratory resistive load 3 times a week for up to 60 minutes)
45666622|NCT02358044|Drug|Sofosbuvir|400 mg tablets, taken orally (PO) every day (QD) for 12 weeks.
45666623|NCT02358044|Biological|PegIntron|PegIntron administered subcutaneously every week (QW) at 1.5 mcg/kg for 12 weeks.
45666624|NCT02358044|Drug|Ribavirin|Capsule and/or tablet administered PO twice daily (BID) based on weight (1000 - 1200 mg) for 12 weeks.
45666625|NCT02358044|Drug|Grazoprevir/Elbasvir (100 mg/50 mg) FDC|Grazoprevir/Elbasvir (100 mg/50 mg) FDC, taken PO QD for 12 weeks.
45666626|NCT02275117|Biological|ALD403|
45666627|NCT02275117|Biological|Placebo|
45666628|NCT04869553|Other|Management pain with distraction methods ABC|"Every patient will receive :~The usual pain management of their ward (Treatment A),~The usual pain management of their ward with a hypnosis session (Treatment B)~The usual pain management of their ward with a virtual reality session (Treatment C)"
45666629|NCT04869553|Other|Management pain with distraction methods BCA|"Every patient will receive :~The usual pain management of their ward with a hypnosis session (Treatment B)~The usual pain management of their ward with a virtual reality session (Treatment C)~The usual pain management of their ward (Treatment A)"
45822126|NCT00002816|Drug|mesna|Given IV
45822127|NCT00002816|Drug|pegaspargase|Given IV
45822128|NCT00002816|Drug|therapeutic hydrocortisone|
45822129|NCT00002816|Drug|thioguanine|
45822130|NCT00002816|Drug|vincristine sulfate|Given IV
45822131|NCT00002816|Radiation|low-LET cobalt-60 gamma ray therapy|
45822132|NCT00002816|Radiation|low-LET electron therapy|
45822133|NCT00002816|Radiation|low-LET photon therapy|
45822134|NCT00002816|Drug|Methotrexate|Given IV
45822135|NCT05751499|Diagnostic Test|• Blood Markers CRP, TNFα, IL-6, IL-8, IL-1, and IL-1β AND FIBRINOGEN|"Low Back Outcome Scale~Center for Epidemiological Studies-Depression Scale (CES-D)~International Physical Activity Questionnaire~Roland-Morris Disability Questionnaire~Force Platform~Pain Self-Efficacy Questionnaire (PSEQ)~Numeric Rating Scale~Job Content Questionnaire~Pits Burgh Sleep Quality Index (PSQI)~Orebo Musculoskeletal Pain Screening Questionnaire~Gait & Balance App~Keele STarT Back Screening Tool (SBST)~Fear-Avoidance Beliefs Questionnaire (FABQ)~Pain Catastrophizing Scale"
45822136|NCT00002269|Drug|Ampligen|
45822137|NCT00002269|Drug|Zidovudine|
46080100|NCT01393509|Drug|PU-H71|PU-H71 will be administered as an intravenous infusion over 1 hour two times a week on a 2 week on and 1 week off (Q21 day) schedule with a starting dose of 10 mg/m2. A Cycle on study will be defined as 21 days. The same schedule of administration will be used for all patients in this Phase I trial, and a MCRM (modified continual reassessment method)design will be employed. The MPN expansion may explore different dosing schedules.
45822138|NCT00002275|Drug|Fat Emulsion 2%|
45822139|NCT00002275|Drug|Fat Emulsion 20%|
45822140|NCT00003152|Biological|filgrastim|
45822141|NCT00003152|Biological|recombinant interferon alfa|
45822142|NCT00003152|Drug|cyclophosphamide|
45666630|NCT04869553|Other|Management pain with distraction methods CAB|"Every patient will receive :~The usual pain management of their ward with a virtual reality session (Treatment C)~The usual pain management of their ward (Treatment A)~The usual pain management of their ward with a hypnosis session (Treatment B)"
46080101|NCT01375829|Drug|Ixabepilone|Given IV
46080102|NCT01375829|Other|Pharmacological Study|Correlative studies
46080103|NCT01375829|Drug|Temsirolimus|Given IV
46080104|NCT01366716|Behavioral|Cash CM|Participants in the cash CM condition will be assigned to the identical 12-week escalating schedule of reinforcement, except that the contingencies will be provided in cash rather than vouchers, and no negotiation process will be involved (although counselors may recommend how clients might best spend their money).
45822143|NCT00003152|Drug|prednisone|
45822144|NCT00003152|Drug|vincristine sulfate|
45822145|NCT00003152|Procedure|autologous bone marrow transplantation|
45822146|NCT00003152|Procedure|bone marrow ablation with stem cell support|
45822147|NCT00003152|Procedure|peripheral blood stem cell transplantation|
45822148|NCT00003152|Radiation|radiation therapy|
45822149|NCT05751421|Drug|Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution|zynrelef will be administered during surgery
45822150|NCT05751421|Drug|Bupivacaine HCl 0.5% Injectable Solution|adductor canal block will be performed using bupivacaine before surgery
45822151|NCT05751421|Procedure|primary total knee replacement|primary total knee replacement
45822152|NCT00002822|Drug|carboplatin|
45822153|NCT00002822|Drug|cisplatin|
45822154|NCT00002822|Drug|cyclophosphamide|
45822155|NCT00002822|Drug|doxorubicin hydrochloride|
45822156|NCT00002822|Drug|etoposide|
45822157|NCT00002822|Drug|ifosfamide|
45822158|NCT00002822|Drug|mesna|
45666631|NCT05649319|Procedure|ERAS protocol|The ERAS protocol involves a pre-admission patient education using audiovisual videos, the reduction of perioperative fasting time with administration of preoperative carbohydrate loading and early resumption of oral feeding after surgery, multimodal postoperative nausea and vomiting prevention, early removal of the nasogastric tube and urinary catheter, and multimodal analgesia to minimize opioid consumption after surgery.
45666632|NCT05536219|Diagnostic Test|Serum anti-IFN-I antibodies|Anti-IFN-I autoantibodies presence will be assessed through serological methods (ThermoFisher Kit)
46080105|NCT01366716|Behavioral|Voucher CM|Participants in the voucher condition will earn voucher incentives according to the schedule developed by Higgins (1993, 1994). It involves a 12-week escalating schedule of reinforcement to initiate cocaine abstinence.
45822159|NCT00002822|Drug|vincristine sulfate|
45963958|NCT04723121|Diagnostic Test|Urine ELISA for immunological markers (IL-2 and IL-10)|IL-2 and IL-10 levels were measured in the supernatants. Natural human-produced IL-2 and IL-10 concen¬trations were determined in the urine of all patients and controls by solid phase ELISA Quantikine IL-2 Immunoassay and IL-10 Immunoassay, respectively
46080106|NCT01344382|Behavioral|Community Reinforcement and Family Training|The philosophy of Community Reinforcement and Family Training (CRAFT) is that drug abuse is caused by multiple biological and environmental factors, many of which are beyond the parents' control. However, because parents have an important relationship with their child, they may able to influence his or her behavior. CRAFT for parents (CRAFT-P) will teach the parent new ways to interact with their child. Sessions will be designed to build the parents' motivation to comply with the training, conduct a functional analysis of their child's drug use pattern, train methods of behavior management and communication skills, enrich the parent's life and to suggest and motivate treatment entry.
46080107|NCT01344382|Behavioral|Al-Anon Facilitation|Al-Anon Facilitation (ANF) parallels the Twelve Step Facilitation intervention developed by Nowinski et al. (1992) for Project MATCH. The content focuses on introducing parents to Alanon or Naranon's purpose and philosophy, educating about 12-step concepts, the fellowship community, denial and enabling, acceptance, caring detachment, and surrendering to a higher power. The trainer's role is to help the parent to gain insight into the ways they interact with their child and to educate and encourage the parent to become actively involved in a 12-step community and to take advantage of its many offerings.
46080108|NCT01126190|Biological|Neugranin|Neugranin will be administered per dose and schedule specified in the arm description.
45666633|NCT05649241|Drug|Nicotine patch|Nicotine replacement therapy patch
45666634|NCT05649241|Drug|Nicotine gum|Nicotine replacement therapy gum
45666635|NCT05649241|Behavioral|Medication Therapy Management|Medication therapy management delivered by pharmacist - 1 in-person coaching session, and 5 follow-up telephonic coaching sessions.
45666636|NCT05507827|Drug|Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)|CD19/C22CAR T cells will be administered at a dose of CAR+ cells/kg body weight via IV administration
46080109|NCT01126190|Biological|Pegfilgrastim|Pegfilgrastim will be administered per dose and schedule specified in the arm description.
45666637|NCT05507827|Drug|Treg CD34+HSPC (Orca-T)|Purified donor-derived regulatory T-cell (Treg) plus CD34 + hematopoietic progenitor cells
46080110|NCT01126190|Drug|Chemotherapy|The chemotherapy regimen for this trial consists of doxorubicin 60 mg/m^2 and docetaxel 75 mg/m^2 in combination
46080111|NCT00995384|Procedure|CT Scan|Cardiac CT with special attention to valves in Endocarditis patients.
46080112|NCT00921609|Diagnostic Test|Oral glucose tolerance test|An oral glucose tolerance test is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
46080113|NCT00842517|Behavioral|Contingency Management|
46080114|NCT00842036|Behavioral|Community Reinforcement and Family Training|Community Reinforcement and Family Training (CRAFT) is an intervention designed for the concerned significant other (CSO) of a drug or alcohol using loved one. The CRAFT intervention consists of approximately 12 sessions lasting 45-60 minutes. The goal of the CRAFT intervention is to train the CSO in new ways to interact with the person of concern (PC). There are four components that the CSO is trained on which include awareness training, community reinforcement training, treatment entry training, and CSO mood enhancement.
45666638|NCT05649007|Device|hip arthroplasty with prosthesis|Use of femoral stem and acetabular cup for hip arthroplasty
45666639|NCT02274493|Device|da Vinci® Robotic Surgical System|Da Vinci Robotic Surgical system to be used in procedures that harvest the latissimus dorsi muscle for reconstructive procedures
45666640|NCT02274493|Procedure|LD muscle flap harvest procedure|Latissimus dorsi muscle flap harvest procedure using da Vinci® Robotic Surgical System for use in reconstructive surgery.
45666641|NCT02274493|Procedure|Reconstructive surgery|Reconstructive surgery is considered to be standard of care.
45822160|NCT00002822|Radiation|radiation therapy|
45822161|NCT00002281|Drug|Filgrastim|
45822162|NCT00002281|Drug|Epoetin alfa|
45963959|NCT04723121|Diagnostic Test|Reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) analysis|blood samples using QIAamp® RNA Blood Mini kit (QIAGEN, USA). 1 μg of total RNA was reverse transcribed with random primers, using High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). RT-qPCR analysis was carried out with SYBER Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). Primers for TNF-α, CTLA4, T-bet+, GATA3+, FoxP3+ and GABDH as PCR control
45822163|NCT00002281|Drug|Zidovudine|
45822164|NCT00002287|Drug|Zidovudine|
45822165|NCT00002828|Drug|fluorouracil|
45822166|NCT00002828|Drug|raltitrexed|
45822167|NCT00003410|Drug|motexafin gadolinium|
45822168|NCT00003410|Procedure|magnetic resonance imaging|
45822169|NCT00003410|Procedure|surgical procedure|
45822170|NCT00384020|Drug|Paroxetine (Seroxat)|
45822171|NCT00384020|Drug|Escitalopram (Lexapro)|
45822172|NCT05725213|Drug|Metvix® 160 mg/g Creme|Patients are treated with Metvix creme and exposed to artificial daylight
45822173|NCT00384098|Drug|CTA018 cream|
45963960|NCT00203112|Drug|glatiramer acetate with minocycline|Subcutaneous injection glatiramer acetate 20mg, with oral minocycline 100mg
45963961|NCT00203112|Drug|Glatiramer acetate with placebo|Subcutaneous injection glatiramer acetate 20mg, with oral placebo
45963962|NCT00554905|Procedure|Radiofrequency ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, California, USA) and a needle electrode with a 15-gauge insulated cannula with 10 hook-shape expandable electrode tines with a diameter of 3.5cm at expansion (LeVeen; RadioTherapeutics, Mountain View, California, USA).
45963963|NCT00554905|Procedure|TACE|TACE first, then RFA within 2 weeks
45963964|NCT04677478|Other|Impact of respiratory isolation on quality of life|Semi-structured interviews
45963965|NCT00173108|Behavioral|clinic-based intervention program and home-based intervention program|The intervention includes education of child development skills, health and feeding consultation, intervention of mother-infant interaction, and parent support. Clinic-based intervention program is delivered in clinic while home-based intervention program is delivered at home.
45963966|NCT02062060|Drug|Abametapir Lotion 0.74% w/w|
45963967|NCT02062060|Drug|Vehicle Lotion|
45963968|NCT00198510|Drug|Vitrase|7.5 IU of Vitrase
45963969|NCT00198510|Drug|Vitrase|55 IU of Vitrase
45963970|NCT00198510|Drug|Vitrase|75 IU of Vitrase
45963971|NCT02057380|Drug|linsitinib|oral
45666642|NCT02274493|Behavioral|Questionnaires|Questionnaire about pain, as well as participant's shoulder, arm, and hand range of motion completed at baseline, and at follow up visits 3-6.
45963972|NCT02057380|Drug|erlotinib|oral
45963973|NCT02057380|Drug|paclitaxel|Intravenous (IV) infusion
45963974|NCT02057380|Drug|Bortezomib|Subcutaneous or IV
45666643|NCT02273167|Drug|NER1006, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
45666644|NCT02273167|Drug|NER1006,1-Day Morning Split-Dosing|"The subject will self-administer the first dose of the investigational product on the morning of the colonoscopy and take mandatory additional clear fluid.~After a 1-2 hour break the subject will self-administer the second dose plus additional clear mandatory fluid."
45963975|NCT02057380|Drug|Dexamethasone|IV, Oral
45963976|NCT02057341|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
45963977|NCT00554944|Procedure|Esophageal probe|Near-infrared spectroscopy (NIRS) sensor, polarographic-type tissue oxygen sensor (Licox®, esophageal probe
45963978|NCT02052778|Drug|Futibatinib|oral once daily dosing, 21-day cycle
45963979|NCT00203151|Drug|edratide|0.5 mg, 1.0 mg, 2.5 mg injection once weekly
45963980|NCT02050828|Drug|AKB-9778|
45963981|NCT02050828|Drug|ranibizumab|
45963982|NCT02050828|Drug|Placebo|
45963983|NCT02050828|Drug|Sham|
45963984|NCT02048059|Drug|ANG1005|
45963985|NCT00198549|Drug|Vitrase (ovine hyaluronidase) Lyophilized|
45963986|NCT02046694|Drug|Allopurinol|At week 1, patients will begin allopurinol daily (100 mg for weight >30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks).
45963987|NCT02044081|Drug|C16G2 Rinse|Active rinses are 1.6 mg/mL C16G2.
45963988|NCT02044081|Drug|Placebo|Placebo is the vehicle without C16G2
45963989|NCT02044081|Drug|C16G2 Gel|Active C16G2 Gel is 3.2 mg/mL
45455463|NCT03928561|Device|Placebo Intense Pure Air XL air cleaner|Cat allergen is nebulized in the EEC. When the concentration is stable, placebo air cleaners are switched on. The placebo effect is obtained thanks to the removal of air cleaners filters prior to the exposure. The number of placebo air cleaners placed in the EEC is defined according to the volume of the EEC and the air renewal. Patients are exposed to cat allergen in the presence of placebo air cleaners in the EEC.
45822174|NCT00002557|Drug|CHOP regimen|
45822175|NCT00002557|Drug|doxorubicin hydrochloride|
45822176|NCT00002557|Drug|etoposide|
45822177|NCT00002557|Drug|leucovorin calcium|
45822178|NCT00002557|Drug|methotrexate|
45822179|NCT00003158|Drug|carboplatin|
45822180|NCT00003158|Drug|etoposide|
45822181|NCT00003158|Drug|paclitaxel|
45822182|NCT00003158|Radiation|radiation therapy|
45822183|NCT00002563|Procedure|psychosocial assessment and care|Evaluate psychosocial function at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
45822184|NCT00002563|Procedure|quality-of-life assessment|Evaluate quality of life at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
45822185|NCT00003416|Biological|filgrastim|
45822186|NCT00003416|Biological|recombinant interferon alfa|
45963990|NCT00203190|Drug|Topiramate|
45963991|NCT02041195|Drug|RM-493|
45963992|NCT02041195|Drug|Placebo|
45963993|NCT02019589|Drug|Progesterone|
45963994|NCT02019589|Drug|Placebo|
45963995|NCT02018926|Drug|Mocetinostat|Mocetinostat (a histone deacetylase [HDAC] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5, for 10 doses in each 28 day cycle
45963996|NCT02018926|Drug|Azacitidine|Azacitidine (a hypomethylating agent [HMA]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle
45963997|NCT02017912|Biological|Autologous MSC-NTF cells|Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
45963998|NCT02017912|Biological|Placebo|Excipient administration by combined intramuscular and intrathecal administration
45963999|NCT00203346|Procedure|Greater Occipital Nerve Block|
45964000|NCT02013310|Drug|HT-0712|
45964001|NCT02013310|Drug|Placebo|
45964002|NCT01993264|Other|Fetal Echocardiogram|Subjects will then have sequential, abbreviated fetal echocardiograms performed by designated, highly trained, and experienced sonographers every 4 weeks, from 20-36 weeks.
45666645|NCT02273167|Drug|MOVIPREP, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take recommended additional clear fluid. Subject will take the second dose together with recommended additional clear fluids on the morning of the colonoscopy.
45666646|NCT01850524|Drug|Ixazomib|IXAZOMIB capsules.
45666647|NCT01850524|Drug|Placebo|IXAZOMIB matching-placebo capsules.
45666648|NCT01850524|Drug|Dexamethasone|Dexamethasone tablets.
45666649|NCT01850524|Drug|Lenalidomide|Lenalidomide capsules.
45666650|NCT02272777|Drug|Imatinib|Imatinib 400mg QD，300mg QD or 600mg QD
45666651|NCT02272777|Drug|Nilotinib|Nilotinib 300mg BID or 400mg QD
45964003|NCT01989325|Drug|Carfilzomib, proteasome inhibitor; intravenous|multiple dose, single schedule
45964004|NCT01989325|Drug|Filanesib, KSP(Eg5) inhibitor; intravenous|multiple dose, single schedule
45964005|NCT01989325|Drug|Dexamethasone, steroid; oral or intravenous|as indicated, per the carfilzomib prescribing information
45964006|NCT01989325|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|standard of care
45964007|NCT00409929|Drug|AEB071|
45964008|NCT01978366|Drug|HT-100|May be administered in either fed or fasted state
45964009|NCT03455023|Other|pharmaceutical care|Patients receive pharmaceutical care including individualized evaluation and intervention of adherence, efficacy and safety in cancer pain treatment.
45822187|NCT00003416|Drug|dexamethasone|
45964010|NCT02962986|Drug|Norepinephrine|Norepinephrine diluted in 5% dextrose solution to a concentration of 6mcg/mL
45822188|NCT00003416|Drug|melphalan|
45822189|NCT00003416|Procedure|peripheral blood stem cell transplantation|
45964011|NCT02962986|Drug|Phenylephrine|Phenylephrine diluted in 0.9% normal saline solution to a concentration of 100mcg/mL
46080115|NCT00842036|Behavioral|Treatment Entry Training|Treatment Entry Training (TEnT) is a component of the Community Reinforcement and Family Training intervention and it is currently under investigation to determine if it is sufficient to produce the primary and most consistent outcome of CRAFT- treatment entry of the drug user. The intervention will consist of a minimum of 4 sessions and a maximum of 6 sessions that are each 45-60 minutes long. TEnT will include awareness training, safety training, and the Treatment Entry Training component of CRAFT.
45455464|NCT01317368|Drug|Naropine|"20 mL of 0,75% Naropin is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL of saline 0,9% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
45666652|NCT05648929|Other|Patient Satisfaction Questionnaire|During regular clinical examinations patient will go through a short questionnaire at week 4, 16 and 24 to check patient satisfaction with expanders
45666653|NCT05648929|Diagnostic Test|Pregnancy test|Pre-op; to sufficiently check pregnancy as exclusion criteria
45666654|NCT05648929|Procedure|Blood draw|pre- expander implantation, alongside anaesthesia pre- expander explantation and exchange with definite implant alongside anaesthesia - no additional vein irritation needed
45666655|NCT05648929|Procedure|Expander based breast reconstruction|implantation of 2 different expanders intraindividually
45666656|NCT05648929|Procedure|Ultrasound of breast|Measurement of capsular thickness pre- expander removal
45666657|NCT05648929|Other|S(AE )monitoring|(S)AE evaluation will be performed from Visit 1 (Day 0 = Expander implantation) to Visit 15 (Day 168-196 = Reoperation) according to visit plan.
45666658|NCT02357810|Drug|Pazopanib Hydrochloride|Given PO
45666659|NCT02357810|Drug|Oral Topotecan Hydrochloride|Given PO
45666660|NCT02357810|Other|Laboratory Biomarker Analysis|Correlative studies
45822190|NCT05751109|Procedure|ipack+adduktor kanal|nerve block
45822191|NCT00002569|Drug|lomustine|
45822192|NCT00002569|Drug|procarbazine hydrochloride|
45822193|NCT00002569|Drug|vincristine sulfate|
45822194|NCT00002569|Radiation|radiation therapy|
45822195|NCT00002840|Drug|lomustine|
45822196|NCT00002840|Drug|procarbazine hydrochloride|
45822197|NCT00002840|Drug|vincristine sulfate|
45822198|NCT00002840|Radiation|radiation therapy|
45822199|NCT00002846|Biological|aldesleukin|
45822200|NCT00002846|Procedure|conventional surgery|
45822201|NCT05720767|Drug|HMPL-523|HMPL-523 is a selective small-molecule SYK inhibitor.
45822202|NCT05720767|Drug|Itraconazole|Itraconazole is an FDA approved synthetic triazole antifungal agent
45822203|NCT05720767|Drug|Rifampin|Rifampin is an FDA approved semisynthetic antiobiotic derivative indicated in the treatment of both tuberculosis and meningococcal carrier state
45822204|NCT00003170|Dietary Supplement|glutamine|
45822205|NCT00003170|Other|placebo|
45822206|NCT05751031|Drug|Raltegravir|Raltegravir exposure in pregnant women living with HIV in routine clinical care. No study intervention administrated.
45964012|NCT04676893|Drug|D418 Tab.|1T
45964013|NCT04676893|Drug|CKD-388 Tab.|1T
45964014|NCT04677361|Combination Product|MILs™ in Combination with Pembrolizumab|Efficacy and Safety of MILs™ in Combination with Pembrolizumab in Patients with NSCLC and SCLC
45964015|NCT01972867|Device|NanoKnife Procedure|Subjects will be placed in the dorsal lithotomy position, under sterile technique. The NanoKnife procedure will be carried out under general anesthesia. A Foley catheter will be placed to aid in draining the bladder during treatment.
45964016|NCT04677127|Behavioral|Health Belief Model and Health Literacy Level based Education and Counseling|Patients given education and counseling constructed with health belief model (perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cue to action, self-efficacy). The constructed education given through groups dichotomised by health literacy levels (low/high). Groups of 11-13, had weekly educations for 6 weeks, 6 weeks of counselling and 12 week of follow-up.
45964017|NCT00409968|Procedure|Tumor Biopsy|A sample of tumor tissue will be collected by either a CT-guided core biopsy, bronchoscopy, or other type of biopsy (such as subcutaneous, cutaneous, or lymph node).
45964018|NCT04677088|Biological|TCR-T cells|Patients will receive 1 x 10^4 cells/kg to 5 x 10^6 cells/kg bodyweight of TCR redirected T cells by IV infusion.
45666661|NCT04858243|Other|Home-Based ART|Community-based male-specific counseling followed by home-based ART initiation (or at any location that is convenient for participants) and home-based ART continuation for a 3-month period, followed by linkage to a local health facility for further ART continuation.
45666662|NCT04858243|Other|Facility-Based ART|Community-based male-specific counseling followed by linkage to a local health facility for ART initiation and continuation.
45666663|NCT02357576|Drug|Intralipid 20% I.V. Fat Emulsion|
45964019|NCT04676971|Drug|hzVSF-v13|Dosage form: 100mg / 200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1, 3, 7, D14(if necessary)
45964020|NCT04676971|Drug|Placebo (Normal saline solution)|Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7, D14(if necessary)
45964021|NCT01968733|Drug|Solithromycin|
45964022|NCT01968733|Drug|Moxifloxacin|
45964023|NCT00410553|Drug|Eribulin Mesylate|Given IV
45964024|NCT00410553|Drug|Gemcitabine Hydrochloride|Given IV
45964025|NCT00410007|Behavioral|High Sodium Diet|250-350 mmol
45964026|NCT00410007|Behavioral|Low Sodium Diet|25-35 mmol
45964027|NCT00410007|Behavioral|Hypertonic saline infusion|7 ml/ kg of 3% saline were given over 30 minutes.
45964028|NCT01968187|Drug|FE 992097|
45964029|NCT01968187|Drug|Placebo|
46080116|NCT00842036|Behavioral|12- step Al/Nar- Anon Facilitation|The underlying philosophy of the 12- step approach for concerned significant others (CSO) is that the CSO is powerless to control the drinker/drug user and must detach, focusing instead on accepting the situation and on strengthening his or her mental health. Eight content areas are discussed with the CSO over the course of the intervention. There will be a minimum of 8 sessions and a maximum of 12 sessions that are each 45-60 minutes long.
45666664|NCT01850446|Drug|Ergoferon|Safety and Efficacy
45822207|NCT00002852|Drug|paclitaxel|Given IV
45822208|NCT00002852|Drug|carboplatin|Given IV
45964030|NCT01966549|Drug|CNTO 6785|CNTO 6785 (6 mg/kg) will be administered by intravenous (into a vein) infusion on Weeks 0, 2, 4, 8 and 12. Participants who weigh more than 100 kg will receive a dose of 600 mg of CNTO 6785.
45964031|NCT01966549|Drug|Placebo|Sterile, 5 percent dextrose will be used as the placebo in this study. Placebo will be administered by intravenous infusion on Weeks 0, 2, 4, 8 and 12.
45964032|NCT01965613|Biological|Xilonix|IV
45964033|NCT00410592|Drug|Esomeprazole 40mg|
45964034|NCT00410592|Drug|Pantoprazole 40mg|
45964035|NCT00410592|Drug|Lansoprazole 30mg|
45964036|NCT01965106|Drug|QPI-1007 Injection|1.5 mg QPI-1007 Injection
46080117|NCT00735423|Device|No intervention|IDE used for outcome measurement not intervention
45666665|NCT01850446|Drug|Oseltamivir|Safety and Efficacy
45666666|NCT02465567|Drug|BGF MDI 320/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
45666667|NCT02465567|Drug|GFF MDI 14.4/9.6 μg|Glycopyrronium, and Formoterol Fumarate
45666668|NCT02465567|Drug|BGF MDI 160/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
45666669|NCT02465567|Drug|BFF MDI 320/9.6 μg|Budensonide, and Formoterol Fumarate
45822209|NCT00002852|Procedure|therapeutic conventional surgery|Undergo surgery
45822210|NCT05750719|Genetic|BRCA1/2 genetic testing|All patients will undergo genetic testing for BRCA 1 and BRCA 2 germline mutations, employing next generation sequencing (NGS) techniques.
45822211|NCT00003422|Drug|fluorouracil|
45822212|NCT00003422|Drug|leucovorin calcium|
45822213|NCT00003422|Procedure|adjuvant therapy|
45822214|NCT00003422|Procedure|conventional surgery|
45822215|NCT00003422|Procedure|neoadjuvant therapy|
45822216|NCT00003422|Radiation|radiation therapy|
45822217|NCT00003176|Drug|carmustine|
45964037|NCT01965106|Drug|(including placebo)|Sham injection procedure
45964038|NCT00173537|Procedure|for BMPR II study|
45964039|NCT00173537|Genetic|BMPRII|
45964040|NCT00410085|Drug|L-NMMA (N-mono.methyl-L-arginine)|
45964041|NCT01951690|Drug|defactinib (VS-6063)|
45964042|NCT01941043|Drug|CERC-301|
45964043|NCT01941043|Other|Placebo|
45964044|NCT00410631|Biological|filgrastim|
45964045|NCT00410631|Drug|carboplatin|
45964046|NCT00410631|Drug|cisplatin|
45964047|NCT00410631|Drug|cyclophosphamide|
45964048|NCT00410631|Drug|dacarbazine|
45964049|NCT00410631|Drug|doxorubicin hydrochloride|
45964050|NCT00410631|Drug|etoposide phosphate|
45964051|NCT00410631|Drug|ifosfamide|
45964052|NCT00410631|Drug|isotretinoin|
45964053|NCT00410631|Drug|melphalan|
45964054|NCT00410631|Drug|topotecan hydrochloride|
45964055|NCT00410631|Drug|vincristine sulfate|
45964056|NCT00410631|Drug|vindesine|
45964057|NCT00410631|Procedure|autologous hematopoietic stem cell transplantation|
45964058|NCT00410631|Procedure|conventional surgery|
45964059|NCT00410631|Procedure|peripheral blood stem cell transplantation|
45964060|NCT00410631|Radiation|iobenguane I 131|
45964061|NCT00410631|Radiation|radiation therapy|
45964062|NCT01938742|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent influenza A/H7N9 virus vaccine for intramuscular use is a sterile, clear and slightly opalescent suspension. sanofi A/H7N9 antigen. Group 1 receives 3.75mcg A/H7N9 IM on days 1 and 21, Group 2 receives 7.5 mcg IM on days 1 and 21, Group 3, 4, 5, & 6 receives 15 mcg IM on days 1 and 21, and Group 7 receives 45 mcg IM on days 1 and 21.
45964063|NCT01938742|Drug|MF59|MF59 adjuvant is an oil-in-water emulsion composed of a small amount of squalene administered with different dosages. Group 1, 2 & 3 receives 0.7 ml of MF59 Intramuscularly (IM) on days 0 and 21. Group 4 receives MF59 on day 0, Group 5 receives MF59 on Day 21.
45964064|NCT00173615|Procedure|Extracorporeal membrane oxygenation|
45964065|NCT01930357|Biological|Purified Vero Rabies Vaccine Serum Free (VRVg)|0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
45964066|NCT01930357|Biological|Imovax® Rabies: Human Diploid Cell Vaccine (HDCV),|0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
45964067|NCT01913158|Drug|Anucort-HC, 25 Mg Rectal Suppository|Hydrocortisone acetate suppositories
45964068|NCT01913158|Drug|Placebo suppository|Hydrogenated palm kernel oil suppositories
45666670|NCT01644175|Drug|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
45666671|NCT01644175|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
45822218|NCT00003176|Drug|temozolomide|
45666672|NCT01644175|Drug|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
45666673|NCT02357420|Drug|Relamorelin|Double blind relamorelin was given subcutaneously BID for 12 weeks.
45666674|NCT02357420|Drug|Placebo|Placebo given subcutaneously for 12 weeks.
45666675|NCT05648461|Radiation|Five fraction of post operative radiotherapy|Target volume will include tumor bed & ipsilateral level I-III levels.
45666676|NCT04856761|Drug|S-1|S-1 was administered at a dose of 80-120 mg/day on 14 days of a tri-weekly cycle for 8 cycles.
45666677|NCT04856761|Drug|Capecitabine|Capecitabine was administered at a dose of 1250 mg/m² bid on 14 days of a tri-weekly cycle for 8 cycles.
45964069|NCT01908595|Drug|M518101|
45964070|NCT00173654|Procedure|blood drawing|
45666678|NCT01832038|Drug|Lacosamide|"Strength: Lacosamide (LCM) 50 mg, LCM 100 mg~Formulation: Tablet~Frequency: twice daily during the study period (until the date of approval)~At the completion of EP0008 [NCT01710657], all subjects who choose to enroll in EP0009 will be taking a dose of Lacosamide 200 mg/day. At the beginning of EP0009, the investigator may maintain the LCM dose or increase or decrease the dose. During the Treatment Period, the investigator will be allowed to increase or decrease the dose of LCM to optimize tolerability and seizure reduction. The LCM dose may be decreased to 100 mg/day or increased, no faster than 100 mg/day per week, up to 400 mg/day."
45666679|NCT05648383|Behavioral|mHealth intervention|Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care
45666680|NCT05648383|Behavioral|Standard care|Participants will receive standard care, including lifestyle recommendations.
45964071|NCT01903954|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
45964072|NCT01903954|Drug|placebo|Orally b.i.d.
46080118|NCT00590850|Procedure|ORIF with Plate and Screws|ORIF with plate and screws
45666681|NCT04856059|Diagnostic Test|Cardiac MRI, ECG/Holter and Blood Biomarkers|Cardiac MRI including T1/T2 mapping, ECG and blood biomarker evaluation will be performed at baseline and follow-up
45666682|NCT05369689|Other|No interventions|As this is a prognosis evaluation study, there are no interventions.
45666683|NCT01849588|Drug|Sorafenib|
45822219|NCT05708365|Other|Standard-Lung Protective Ventilation|"ICU ventilator protocol adhering to the following lung protective ventilation strategy:~Plateau Pressure ≤ 30 cm of water~PEEP and FiO2 set according to ARDSnet table~Driving Pressure ≤ 15 cm of water~Respiratory rate between 8 and 30 breaths per minute"
45822220|NCT05708365|Other|Ultra-Lung Protective Ventilation|"ICU ventilator protocol adhering to the following lung protective ventilation strategy:~Plateau Pressure ≤ 30 cm of water~PEEP and FiO2 set according to ARDSnet table~Driving Pressure ≤ 15 cm of water~Respiratory rate between 8 and 30 breaths per minute"
45822221|NCT00003428|Drug|arzoxifene hydrochloride|
45822222|NCT00002858|Drug|cisplatin|
45964073|NCT01903954|Drug|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
45964074|NCT01903954|Drug|setrobuvir|Loading dose of 800 mg orally b.i.d on Day 1, followed by 200 mg orally b.i.d., 28 or 48 weeks
45964075|NCT01893190|Drug|Nimodipine|Based upon Investigator Judgement
45964076|NCT01893190|Drug|Nimodipine Microparticles|Based upon Investigator Judgement
45964077|NCT00198588|Drug|argatroban|beginning dose: 0.7microgram/kg/H
45964078|NCT00173693|Behavioral|exercise for strength, balance, health education|
45964079|NCT01887886|Drug|erlotinib|150 mg orally daily
45964080|NCT01887886|Drug|onartuzumab|15 mg/kg IV every 3 weeks
45964081|NCT01887886|Drug|placebo|IV every 3 weeks
45964082|NCT01885156|Drug|Naftin 1% Cream|Topically applied once a day
45964083|NCT01885156|Drug|Placebo Cream|Topically applied once a day
45964084|NCT01882699|Device|Cereve Sleep System|cerebral hypothermia
45964085|NCT01877395|Biological|Purified Vero Rabies Vaccine (VRVg)|0.5 mL, Intramuscular
45964086|NCT01877395|Biological|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
45964087|NCT01874938|Biological|LY2875358|Administered IV
45964088|NCT01874626|Drug|Placebo|Placebo cream
45964089|NCT01874626|Drug|SST-0225 Topical Ibuprofen Cream|SST-0225 Topical Ibuprofen Cream
46080119|NCT00590850|Procedure|Pin Fixation|Clavicle fixation with clavicle pin
45666684|NCT05648305|Procedure|Root Canal Treatment/ Re-treatment|The provision of Root Canal Treatment for teeth with Endodontic infection or to prevent Endodontic infection.
45666685|NCT02357342|Drug|Sirolimus|intravitreal injection
45666686|NCT02357342|Drug|Standard of Care intravitreal injections of anti-VEGF|intravitreal injections of anti-VEGF
45964090|NCT00410709|Drug|NatrOVA Creme Rinse (1%)|
45964091|NCT01873534|Drug|FMX-8|FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.
45666687|NCT02271529|Device|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
45964092|NCT01871428|Drug|aleglitazar|150 mcg orally daily
45964093|NCT01871428|Drug|placebo|matching aleglitazar placebo orally daily
45964094|NCT01870609|Drug|defactinib (VS-6063)|
45964095|NCT01870609|Drug|Placebo|Sugar pill manufactured to mimic defactinib tablet
45964096|NCT00410748|Drug|OROS hydromorphone HCI CR|
45964097|NCT01867762|Drug|JNJ 49095397|JNJ 49095397 400 microgram will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
45964098|NCT01867762|Drug|Placebo|Placebo will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
45964099|NCT00198627|Drug|Co-Trimoxazole; TMP-SMZ|
45964100|NCT01862224|Drug|JNJ-38518168|JNJ-38518168 30 mg once daily, Week 0 to Week 52.
45666688|NCT02325518|Drug|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension|
45666689|NCT02325518|Drug|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution|
45666690|NCT02325518|Drug|Subject's habitual PGA monotherapy|
45666691|NCT02270983|Drug|Linaclotide 145 micrograms|
45666692|NCT02270983|Drug|Linaclotide 290 micrograms|
45666693|NCT02270983|Drug|Placebo|Matching placebo
45666694|NCT02449889|Drug|highly purified human chorionic gonadotropin|
45666695|NCT02449889|Drug|recombinant human chorionic gonadotropin|
45964101|NCT01862224|Drug|Placebo|Matching placebo once daily (Week 0 to Week 12).
45964102|NCT01862224|Drug|Methotrexate|All participants will continue receiving methotrexate up to Week 12. After Week 12, the dose of methotrexate may be adjusted as per Investigator's discretion.
45964103|NCT01861249|Drug|SAR339658|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous"
45666696|NCT01831804|Drug|GSK1278863|White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.
45666697|NCT01831804|Drug|Placebo|White to off-white smooth ointment for topical application as single or repeat doses.
45666698|NCT02270671|Behavioral|ABMT|Attention Bias Modification Training
45964104|NCT01859962|Drug|PPI-668|
45964105|NCT01859962|Drug|BI 207127 Dose 1|
45964106|NCT01859962|Drug|BI 207127 Dose 2|
45964107|NCT01859962|Drug|Faldaprevir|
45964108|NCT01859962|Drug|Ribavirin|
45964109|NCT01859962|Drug|BI 207127 Placebo|
45964110|NCT00198666|Drug|Zinc|Elemental Zinc
45964111|NCT01853995|Device|Fixed Lingual Mandibular Growth Modificator (FLMGM)|New Class II Corrector
45964112|NCT00173888|Drug|Docetaxel, Cisplatin|docetaxel 36mg/m2 IF 30 mins on day 1,8,15 cisplatin 75mg/m2 IF 2 hrs on day 15
45964113|NCT00173888|Drug|Gemcitabine, Cisplatin|gemcitabine 1000mg/m2 IF 30mins on D 1,8,15, cisplatin 75mg/m2 IF 2 hrs on day 15
45964114|NCT01853722|Drug|DCN01|Three serial applications per periocular region.
45964115|NCT01853722|Drug|Unisol|Three serial applications per periocular region.
45964116|NCT00554983|Biological|recombinant birch pollen allergen|subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
45964117|NCT00554983|Biological|placebo|subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
45964118|NCT00555022|Drug|GSK1160724|GSK1160724 will be available with dosing strengths of 10, 50 and 125 micrograms/blister for inhalation using the DISKUS inhaler.
45964119|NCT00555022|Drug|Tiotropium bromide|Tiotropium bromide capsules will be supplied with a dose of 18 micrograms administered via a HandiHaler device.
45964120|NCT00555022|Drug|Placebo|Subjects will receive placebo.
45964121|NCT00203385|Drug|Divalproex|Depakote up to 2000mg/d
45964122|NCT00555100|Drug|lenalidomide|10mg-25mg PO/day,day1-day21 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.
45666699|NCT02270671|Other|Placebo|Placebo Training
45964123|NCT00555100|Drug|dexamethasone|40mg PO/day, day1-4,9-12,17-20 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.
45964124|NCT00555139|Drug|GSK561679 tablet|GSK561679 tablets are white film-coated tablets, containing 200 (milligrams) mg of the free base, GSK561679A.
45666700|NCT04415164|Drug|Xueshuantong lyophilized powder|Xueshuantong lyophilized powder (500mg), diluted with 250 ml of 0.9% sodium chloride injection, IV (in the vein), once a day, continue for 10 days.
45964125|NCT00555139|Drug|GW876008 tablet|GW876008 tablets are white to off-white round film-coated tablets, containing 100 mg of GW876008X (free base).
45822223|NCT00002858|Drug|cyclophosphamide|
45822224|NCT00002858|Drug|doxorubicin hydrochloride|
45822225|NCT00002858|Drug|etoposide|
45822226|NCT00002858|Radiation|radiation therapy|
45822227|NCT00002575|Procedure|conventional surgery|
45822228|NCT00002575|Procedure|laparoscopic surgery|
45964126|NCT00555139|Drug|alprazolam|Alprazolam capsules 0.25 mg are hard gelatine capsules containing 1 tablet of commercial alprazolam (Xanax 0.25).
45964127|NCT00555139|Drug|Placebo|GW876008 placebo tablets will visually match the active GW876008 tablets. GSK561679 placebo tablets will visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that will visually match the active but containing only a filler.
45964128|NCT00198705|Behavioral|Improved management of severe neonatal infections|
45964129|NCT01842451|Drug|VX-135|
45964130|NCT01842451|Drug|Daclatasvir|
45964131|NCT01825954|Device|RINCE|The intervention uses the NeuroPoint device to deliver repeat applications of RINCE therapy stimulation. The sham uses the NeuroPoint device, but the RINCE therapy stimulation is not turned on.
45666701|NCT04415164|Drug|Placebo|Xueshuantong lyophilized powder Placebo. The usage of placebo is the same as that in the experimental group.
45666702|NCT04415164|Other|Guidelines-based standard care|Guidelines-based standard care for acute ischemic stroke
45666703|NCT04875481|Other|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
45666704|NCT04875481|Other|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
45666705|NCT02324270|Drug|Diclofenac epolamine|Diclofenac epolamine in a topical patch formulation; applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
45666706|NCT02324270|Other|Placebo|Topical patch not containing diclofenac epolamine applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
45666707|NCT02270515|Other|Patient-Centered Medical Home for Kidney Disease (PCMH-KD)|A PCMH-KD enhances the usual dialysis care team by adding a primary care doctor, pharmacist, nurse coordinator and community health worker to the care team.
45822229|NCT00002864|Drug|octreotide acetate|Octreotide LAR (SMS 201-995 pa LAR) 90 mg depot injection monthly for 2 years (plus Tamoxifen 20 mg PO daily for 5 years)
45822230|NCT00002864|Drug|tamoxifen citrate|20 mg PO for 5 years
45822231|NCT00002870|Biological|filgrastim|
45822232|NCT00002870|Drug|cyclophosphamide|
45822233|NCT00002870|Drug|epirubicin hydrochloride|
45822234|NCT00002870|Drug|fluorouracil|
45822235|NCT00002870|Drug|thiotepa|
45822236|NCT00002870|Procedure|peripheral blood stem cell transplantation|
45822237|NCT00002581|Drug|cyclophosphamide|
45822238|NCT00002581|Drug|fluorouracil|
45822239|NCT00002581|Drug|methotrexate|
45822240|NCT00002581|Drug|tamoxifen citrate|
45822241|NCT00002581|Procedure|conventional surgery|
45822242|NCT00002581|Radiation|radiation therapy|
45964132|NCT04676620|Procedure|CK surgery|CK and LASIK are both effective methods for the correction of hypeopia. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity, and corneal biomechanics compared with traditional refractive surgeries.
45964133|NCT00203463|Drug|topiramate|
45964134|NCT04676581|Other|Leech Therapy|Patient who received leeches (for more than 2 days) at the Amiens University Hospital over a period of 9 years (2010-2018)
45964135|NCT00407849|Drug|triamcinolone acetonide|Intravitreal injection
45964136|NCT04676503|Dietary Supplement|BIOVAGINIL|Biovaginil is a notified food supplement formulated as 480 mg capsules. Each capsule contains Lactobacillus crispatus NTCVAG04 3 billion and Vitamin A 120 μg.
45964137|NCT04676269|Biological|Amnion only|Patients endometrium will be transplanted with amnion only (without seeded cells)
45964138|NCT04676269|Biological|Amnion - endometrium cells|Patients endometrium will be transplanted with amnion seeded with endometrium cells isolated from the patients themselves
45964139|NCT04676269|Biological|Amnion - amnion epithelial cells|Patients endometrium will be transplanted with amnion seeded with amnion epithelial stem cells isolated from other patients' caesarean sectio amnion membrane (tested HLA-DR negative to prevent rejection)
45666708|NCT02448875|Device|CyPass Micro-Stent|Small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure. Designed to be permanently implanted in the eye.
45666709|NCT02448875|Device|Viscoelastic|Healon 5 ophthalmic viscoelastic used to increase the size of the aqueous drainage area created by the CyPass Micro-Stent
45666710|NCT05648149|Behavioral|hierarchical multi-dimensional cognitive training scheme based on computer|The scheme was constructed five main categories of cognitive function: (1) attention, memory, numeracy, thinking response and perception; (2) There are 10 training items, which are drawing, quick matching, flash memory, number memory, face memory, color tracking, number span, word naming, symbol number form, quick arithmetic; (3) Each training item is divided into basic and advanced training. Only if the basic training reaches more than 80%, can the advanced training be entered; (4) In order to facilitate patient training, all items were embedded in the wechat mini program, and corresponding cognitive training was carried out in the mini program; (5)Small program background can monitor training results.
45666711|NCT05648071|Drug|Sintilimab|The specific treatment regimen is as follows :Non-squamous NSCLC: Sintilimab (200 mg) plus Bevacizumab (7.5mg/kg) is started on the first day of each treatment cycle and administered every three weeks. Nedaplatin (80-100 mg/m2) (d2) +pemetrexed 500 mg/m2 (d2) Q3W is administered in this regimen for 4 cycles followed by sintilimab plus Bevacizumab until disease progression or intolerable toxicity.
45666712|NCT01831726|Drug|Dovitinib (TKI258)|Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
45666713|NCT04868617|Device|ATTRACT-I|The aim of this investigation is to evaluate the performance and safety of an ostomy baseplate with a novel skin protection technology and its ability to reduce peristomal skin complications compared to SenSura® Mio. The subject will be randomized to either test product or comparator at enrollment. The subject will wear the test product for approximately 35 days and then cross-over to the comparator (or vice-versa) for approximately 35 days. At each baseplate change, the subject will answer questions about their skin, and take pictures of their stoma and used baseplate. They will also answer quality of life questionnaires at each study visit.
45964140|NCT04676269|Biological|Amnion-EnSC-AESC|Patients endometrium will be transplanted with amnion seeded with endometrium cells-amnion epithelial stem cells co-culture
45964141|NCT01819909|Procedure|Postoperative Jackins Exercise Protocol|Jackin's exercises were initially designed for patients with difficulty performing forward elevation. The patient initially is positioned supine to perform shoulder flexion. When the patient can actively elevate in the supine position, one to two pounds of weight is placed in the patients hand and the patient is asked to repeat the maneuver of supine active elevation. When the patient can do this with little difficulty, the head of the bed is elevated approximately 20 degrees from the supine position and the sequence is repeated. Once the patient is able to perform flexion in this elevated head position, the inclination of the patient is increased in 20 degree increments until the patient is able to perform upright sitting shoulder flexion.
45964142|NCT01819909|Procedure|Postoperative Pulleys Exercise Protocol|Pulleys have been used in postoperative shoulder rehabilitation to improve passive as well as active range of motion and develop strength.
45964143|NCT00198744|Behavioral|Medifast FIT! for Kids|
45964144|NCT00198744|Behavioral|standard recommendations for dietary intake in children|
45964145|NCT00198744|Behavioral|both diet plans with and without a parent dieting|
45822243|NCT00003182|Drug|cisplatin|
45822244|NCT00003182|Drug|gemcitabine hydrochloride|
45822245|NCT00002587|Drug|paclitaxel|
45822246|NCT00002587|Drug|topotecan hydrochloride|
45822247|NCT00003434|Biological|carcinoembryonic antigen peptide 1|
45822248|NCT00003434|Biological|hepatitis B antigen peptide|
45822249|NCT05750641|Other|removing milk and dairy products from diets without medical treatment|A specialist dietician prepared a diet list based on providing adequate balanced nutrition and is handed over to the diet group without any medical treatment
45964146|NCT00407927|Drug|Epinastine Nasal Spray|
45822250|NCT05750641|Other|According to current standard algorithms and guidelines, appropriate treatment for FD types.|According to current standard algorithms and guidelines, appropriate treatment for FD types was arranged for the patient group who preferred to receive a free diet
45822251|NCT00002876|Drug|cisplatin|
45822252|NCT00002876|Drug|etoposide|
45964147|NCT01818154|Other|LED phototherapy|
45964148|NCT01818154|Other|narrowband UVB phototherapy|
45822253|NCT00002593|Drug|fluorouracil|Given IV as described in Arm Description
45822254|NCT00002593|Drug|leucovorin calcium|Given IV as described in Arm description.
45822255|NCT00002593|Drug|levamisole hydrochloride|Given as described in arm description
45822256|NCT00003194|Biological|filgrastim|
45964149|NCT01818076|Drug|Botulinum Toxin Type A|Botulinum toxin type A, Dose A applied to the lateral canthal area
45964150|NCT01809964|Biological|ANT-1401|
45964151|NCT01809964|Biological|Vehicle|
45666714|NCT05464069|Device|Nerivio|Nerivio is a Remote Electrical Neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
45666715|NCT04954001|Drug|FCN-159|FCN-159 is administered orally in once daily schedule for 28 days a cycle.
45964152|NCT00203541|Device|TELFA™ A.M.D. Island dressing|
45964153|NCT01807546|Drug|rigosertib|Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
45964154|NCT01803412|Drug|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 200 mg/mL strength. Each subject will receive drisapersen 3 mg/kg administered IV once a week, continuously throughout their duration of participation
45666716|NCT01831258|Device|SensAwake On|
45666717|NCT01831258|Device|SensAwake Off|
45666718|NCT03689699|Drug|Nivolumab|A dose of 480mg every 4 weeks as a 30 minute IV infusion for 6 doses has been selected for this study. 6 total doses.
45666719|NCT03689699|Drug|Degarelix|Standard treatment at a dose of 240mg subcutaneously (SQ) as a loading dose followed by 80mg SQ every 4 weeks for 4 doses.
45964155|NCT01803412|Drug|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation
45964156|NCT01803412|Drug|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation
45964157|NCT02963220|Behavioral|CBT-AR|20-30 sessions of cognitive behavioral therapy for avoidant/restrictive food intake disorder (CBT-AR), held once per week in an outpatient setting
45666720|NCT03689699|Drug|BMS-986253|BMS-986253 (also referred to as anti-IL8 mAb or HuMax IL8) is a fully human-sequence IgG1κ monoclonal antibody (mAb) directed against human interleukin-8 (IL-8). Subjects will be treated with an intravenous (IV) flat dose of 2400mg every 2 weeks.
45666721|NCT01849276|Drug|metformin hydrochloride|Given orally
45822257|NCT00003194|Drug|carboplatin|
45822258|NCT00003194|Drug|cyclophosphamide|
45822259|NCT00003194|Drug|etoposide|
45666722|NCT01849276|Drug|cytarabine|Given IV
45822260|NCT00003194|Drug|thiotepa|
45666723|NCT01849276|Other|laboratory biomarker analysis|Correlative studies
45666724|NCT02465489|Drug|Deferiprone extended release|Deferiprone 1000 mg extended release tablet formulation
45666725|NCT02465489|Drug|Deferiprone immediate release|Ferriprox (deferiprone) 500 mg immediate release tablet formulation
45964158|NCT01802866|Drug|ACU-4429|Take orally once daily for 24 months
45964159|NCT01802866|Drug|Placebo|Take orally once daily for 24 months
45964160|NCT03454984|Drug|Guadecitabine|30/m2/day SubCutaneous for 5 days (Cycle = 28 days). total of 10 cycles
45666726|NCT01829464|Drug|Placebo|TAK-875 placebo-matching tablets
45666727|NCT01829464|Drug|TAK-875|TAK-875 tablets
45666728|NCT01829464|Drug|TAK-875|TAK-875 tablets
45666729|NCT04953923|Drug|Cedazuridine|Tablet for oral administration
45666730|NCT04953923|Drug|Placebo|Capsule for oral administration
45964161|NCT01785433|Drug|Tiotropium HFA BAI 4.5 mcg|
45964162|NCT01785433|Drug|Tiotropium HFA BAI 9.0 mcg|
45964163|NCT01785433|Drug|SPIRIVA® HandiHaler® 18 mcg/day|
45964164|NCT01785433|Drug|Spiriva® Respimat® 5 mcg/day|
45666731|NCT04953923|Drug|Moxifloxacin|Tablet for oral administration
45666732|NCT01847092|Drug|AZD1722|
45666733|NCT01847092|Drug|Placebo|Placebo for AZD1722
45666734|NCT01601821|Drug|CsA+Rapamune+CS|Part 1: Rapamune will be given as a loading dose of 6 mg once followed by maintenance dose of 2 mg to achieve a target trough level of 8-15 ng/ml. Part 2: Rapamune dose will be adjusted to achieve a target trough level of 10-15ng/ml through 6 months
45666735|NCT01601821|Drug|CsA+MMF+CS|"The control arm is the standard local practice (official protocol) in Iran:~Cyclosporine + MMF + Corticosteroid. The time period is from pre-study screening / baseline evaluation up to 12 months for patients who are maintained on CsA + MMF + CS."
45666736|NCT02323646|Drug|Placebo|Matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
45822261|NCT00003194|Drug|topotecan hydrochloride|
45822262|NCT00003194|Procedure|peripheral blood stem cell transplantation|
45822263|NCT00002882|Biological|Aldesleukin (IL-2)|Infusion for a total of 96 hours on days 1-4
45822264|NCT00002882|Biological|Recombinant Interferon Alfa (IFN-A)|"IFN-A Therapy Groups:~Schedule A: IV IFN-A induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.~Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks~Adjuvant Biochemotherapy Group: IFN-A is given subcutaneously on days 1-5"
45822265|NCT00002882|Drug|Cisplatin|IV Days 1-4
45822266|NCT00002882|Drug|Dacarbazine|IVPB on day 1
45822267|NCT00002882|Drug|Vinblastine|IVPB on days 1-4
45964165|NCT00203580|Drug|Tinzaparin sodium|
45964166|NCT01781104|Drug|RM-131|Double blind RM-131 (100 ug) will be delivered subcutaneously once daily for 14 days.
45964167|NCT01781104|Drug|Placebo|Placebo delivered subcutaneously once daily for 14 days.
45964168|NCT01777594|Drug|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
45964169|NCT01777555|Drug|CVT-301|
45964170|NCT01777555|Drug|Placebo|
45964171|NCT01777165|Drug|ABT-719|1 arm of ABT-719 higher dose, 1 arm of ABT-719 intermediate dose, and 1 arm ABT-719 lower dose
45964172|NCT01777165|Drug|Placebo|Placebo infusion
45964173|NCT00203619|Device|Wireless capsule endoscopy|wire less capsule endoscopy
45964174|NCT00203619|Other|standard care|standard diagnostic evaluation as decided by treating physician
45964175|NCT01773928|Biological|Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)|
45822268|NCT00002882|Procedure|Adjuvant Therapy|Patients receiving adjuvant radiotherapy will start adjuvant systemic therapy within 8 weeks from lymphadenectomy and a week after completion of and recovery from radiotherapy.
45964176|NCT01773928|Biological|VCIV manufactured with the current manufacturing process (VCIV current)|
45666737|NCT02323646|Drug|Telapristone Acetate|Telapristone acetate, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
45666738|NCT01846624|Drug|Decitabine|Given IV
45666739|NCT01846624|Drug|Midostaurin|Given PO
45666740|NCT05647915|Drug|Berberine plus lifestyle intervention|"berberine hydrochloride 500mg twice a day for 6 months plus lifestyle intervention.~Lifestyle intervention is based on Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update) and China Blue Paper on Obesity Prevention and Control, including health education on diet, physical activity and weight loss, etc."
45666741|NCT05647915|Behavioral|Placebo plus lifestyle intervention|"Placebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention.~Lifestyle intervention is based on Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update) and China Blue Paper on Obesity Prevention and Control, including health education on diet, physical activity and weight loss, etc."
45666742|NCT01829230|Device|1 Day Acuvue Moist|Lenses will be worn in a daily wear modality
45666743|NCT02269657|Device|EOS® imaging system|The EOS® imaging system is a low dose, 3-dimensional imaging system that provides weight bearing images which provide visual information with respect to the interaction between the joints and the rest of the musculoskeletal system, particularly the spine, hips and legs. The imaging system is used for clinical purposes with additional images captured as part of this study to collect data from subjects in two different arm positions during imaging.
45666744|NCT04588714|Behavioral|Resilience-based, Energy Management to Enhance Wellbeing (RENEW)|The program includes unlimited website access and 10 scheduled phone calls with an assigned peer mentor.
45964177|NCT01773928|Biological|Fluzone®, licensed trivalent influenza vaccine (TIV)|
45964178|NCT00174161|Behavioral|self-care, health behavior|
45964179|NCT01768975|Drug|OLT1177 Gel|4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1
45822269|NCT05750563|Dietary Supplement|diosmin and micronized flavonoids|the symptomatic treatment of haemorrhoids
45822270|NCT05750563|Other|Placebo|Use as comparator
45822271|NCT00002888|Drug|cisplatin|
45822272|NCT00002888|Drug|fluorouracil|
45822273|NCT00002888|Drug|paclitaxel|
45822274|NCT00002599|Biological|filgrastim|
45822275|NCT00002599|Biological|recombinant interferon alfa|
45822276|NCT00002599|Biological|sargramostim|
45822277|NCT00002599|Drug|carmustine|
45964180|NCT01768975|Other|Placebo gel|Identical dose and dosing regimen as the Investigational Drug (OLT1177 Gel)
45964181|NCT01756924|Drug|CEM-102|
45964182|NCT01756924|Drug|IV or Oral standard of care antibiotics|
45964183|NCT01756924|Drug|Rifampin|
45964184|NCT00198861|Other|Injection and Non-Injection Drug Users|(1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors.
45964185|NCT01756339|Drug|Solithromycin|
45964186|NCT01756339|Drug|Moxifloxacin|
45964187|NCT01756339|Other|Placebo to match solithromycin|
45964188|NCT00174200|Drug|Risperidone 2 mg|
45964189|NCT00203658|Drug|Tinzaparin sodium|
45964190|NCT01754935|Drug|VX-509|50 mg oral tablet
45964191|NCT01754935|Drug|VX-509 matching placebo|0 mg oral tablet
45964192|NCT00174239|Drug|cabergoline|
45964193|NCT00174239|Drug|controlled-release levodopa / carbidopa|
45964194|NCT01751152|Drug|NNC0114-0006|A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
45964195|NCT01751152|Drug|placebo|A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
45964196|NCT00203697|Drug|minocycline|
45964197|NCT00174278|Drug|Somatropin|
45964198|NCT01750957|Drug|Placebo|orally daily, 12 weeks
45964199|NCT01750957|Drug|RO4917523|Dose A orally daily, 12 weeks
45964200|NCT01750957|Drug|RO4917523|Dose B orally daily, 12 weeks
45964201|NCT01746082|Biological|Influenza A/H3N2 variant Vaccine|Investigational influenza virus H3N2v vaccine, a monovalent type A inactivated vaccine (H3N2v MIV) for intramuscular use, is a sterile clear and slightly opalescent suspension prepared from influenza virus propagated in embryonated chicken eggs. The H3N2v MIV contains no preservative. Subjects will be stratified by age (approximately 100 (up to 120) subjects 18-64 years old and approximately 100 (up to 120) subjects >/=65 years old) to receive two doses of H3N2v MIV, delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart
45964202|NCT00198900|Behavioral|survey of information|
45964203|NCT01745497|Drug|Ferrous sulfate|3mg/kg liquid
45666745|NCT04588402|Biological|The study being observational in nature, there is no intervention. The investigators will only collect cervical samples from married women within a specified age range at different intervals.|"Women will be approached one time only, when they will attend the gynecology out-patients department for various reasons. After signing the informed consent, the participants will fill in a risk factor questionnaire to study the socio-demographic information, sexual history and HPV vaccination history and the determinent of HPV infection. The questionnaire will be administered by a trained social worker or nurse.~A gynecologist will collect cervical cells from the participant's cervix during a gynecological examination. The cervical specimen will be examined for presence of specific HPV genotypes and Chlamydia infection."
45822278|NCT00002599|Drug|cyclophosphamide|
45964204|NCT01745497|Drug|Placebo|Equivalent volume of liquid with similar color and taste.
45964205|NCT00174317|Drug|Celecoxib|
45666746|NCT02269423|Biological|V920|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^6, 2x10^7, or 1x10^8 pfu.
45666747|NCT02269423|Other|Placebo|Normal saline placebo.
45666748|NCT05647837|Diagnostic Test|lumper puncture|lumper puncture
45822279|NCT00002599|Drug|doxorubicin hydrochloride|
45822280|NCT00002599|Drug|melphalan|
45964206|NCT00174317|Drug|Diclofenac|
45964207|NCT01743625|Drug|COV155|COV155 tablets
45964208|NCT01743625|Drug|placebo|
45964209|NCT01737892|Drug|Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation|Epinephrine Inhalation Aerosol HFA, Single dose 125 mcg, 1 inhalation
45964210|NCT01737892|Drug|Arm C-Epinephrine Inhalation Aerosol CFC|Epinephrine Inhalation Aerosol - CFC, Single dose 220 mcg, 1 inhalation
45964211|NCT00203736|Drug|Sulfadoxine-pyrimethamine|
45964212|NCT00203736|Drug|Artesunate plus sulfadoxine-pyrimethamine|
45964213|NCT01731730|Drug|Placebo Injection|3mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
45964214|NCT01731730|Drug|AYX1 Injection 110 mg|3mL solution for intrathecal injection with 110 mg of AYX1
45964215|NCT01731730|Drug|AYX1 Injection 330 mg|3mL solution for intrathecal injection with 330 mg of AYX1
45964216|NCT01719016|Procedure|Cardiac PET, Coronary catheterization|"Patients would under go a Cardiac rest and stress PET scan and include the following drug administration:~N-13 Ammonia radionuclide - Two doses, 10 mCi for rest, 20 mCi for stress~Lexiscan - stress agent for PET scan~Patients would also undergo Coronary catheterization including the following drug administration and device usage:~Combowire to obtain pressure and flow readings on Combomap machine (Volcano Therapeutics, CA).~Adenosine - stress agent during catheterization, 140 ug/Kg/min"
45964217|NCT01718938|Drug|velusetrag dose 1|
45964218|NCT01718938|Drug|velusetrag dose 2|
45964219|NCT01718938|Drug|velusetrag dose 3|
45964220|NCT01718938|Drug|placebo|
45964221|NCT00174356|Drug|CI 1033|
45964222|NCT00174356|Drug|PACLITAXEL|
45964223|NCT00174356|Drug|CARBOPLATIN|
45822281|NCT00002599|Drug|methylprednisolone|
45822282|NCT00002599|Drug|prednisone|
45822283|NCT00002599|Drug|vincristine sulfate|
45822284|NCT00002599|Radiation|low-LET cobalt-60 gamma ray therapy|
45822285|NCT00002599|Radiation|low-LET photon therapy|
45822286|NCT05693701|Behavioral|Implementation Strategy Bundle|Bundle includes multimodal communications to notify donors about high cholesterol and its treatment, website with resources, and an optional care navigator. Resources for their primary care provider will also be disseminated.
45822287|NCT05693701|Other|Usual care notification|Carter BloodCare will notify participants of their high cholesterol, potential for genetic causes, and recommendation to see their care provider by sending its routine, standard notification letter. These participants will also be eligible to receive the intervention bundle at the end of the study.
45822288|NCT00003440|Drug|paclitaxel|Given IV over 1 hour or 3 hours
45822289|NCT00003440|Biological|trastuzumab|Given IV
45964224|NCT00198939|Behavioral|Integrated Family and Cognitive-Behavioral Drug Prevention Intervention|The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
45964225|NCT00198939|Other|Psychoeducation|Drug education curriculum was delivered to participants assigned to this condition.
45964226|NCT01718158|Biological|Peginterferon Lambda-1a|
45964227|NCT01718158|Biological|Peginterferon Alfa-2a|
45964228|NCT01718158|Drug|Ribavirin|
45964229|NCT01718158|Drug|Daclatasvir|
45964230|NCT01718158|Drug|Telaprevir|
45964231|NCT00174395|Drug|eletriptan|
45964232|NCT00203775|Drug|risperidone|
45964233|NCT00555256|Drug|sunitinib and rapamycin (Drug will be held)|Any toxicity causing a total of 14 days delay of therapy will be considered dose limiting.
45964234|NCT01703923|Drug|FP01|
45964235|NCT01703923|Drug|placebo|
45964236|NCT01703533|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
45666749|NCT05434117|Behavioral|High-intensity interval Nordic walking|Participants will complete supervised exercise sessions twice weekly for 10 weeks. Exercise specialists will educate participants in proper use of walking poles and basic Nordic walking techniques and supervise the exercise training sessions. HIIT-NoW will be 45 min in duration using Nordic poles and consists of (i) a 10-min warm-up at 30-59% heart rate reserve (HRR, light-to-moderate intensity); (ii) 4 × 4 min of high-intensity work periods at 60-89% HRR (vigorous intensity) interspersed with 3 min of low-intensity work periods at 30-59% HRR (light-to-moderate intensity); and, (iii) a 10-min cooldown at 30-39% HRR (light intensity). To allow participants to acclimatize to the HIIT-NoW protocol, the training intensity will target 60-69% HRR for the first week, 70-79% HRR in the second week, and 80-89% HRR from the third week onward. If participants do not tolerate 89% HRR well, they will exercise as close to 89% HRR as possible.
45666750|NCT05434117|Behavioral|Standard cardiovascular rehabilitation|Individuals assigned to standard CR will attend onsite exercise-based CR comprised of one onsite exercise session per week for 8-10 weeks. The onsite CR offers exercise sessions tailored to the fitness of patients and strengthening exercise.
45964237|NCT01703533|Drug|Placebo|Strawberry flavored solution and Water for Injection
45964238|NCT00174434|Drug|SU011248|SU011248 provided as capsules. The starting dose is 25 mg orally, daily in a continuous regimen beginning on day 2. Dose rest for 1 week is allowed. Dose escalation to 37.5 mg po OD is allowed within the constraints of acceptable toxicity parameters. Dosing will continue for 1 year or until disease progression or unacceptable toxicity, whichever comes first.
45822290|NCT00003440|Procedure|quality-of-life assessment|Ancillary studies
45964239|NCT00174434|Drug|Paclitaxel|Paclitaxel is provided as an intravenous infusion for 1 hour weekly for 3 weeks followed by a 1-week rest. The starting dose is 90 mg/m2. The weekly dose may be decreased to 65 mg/m2 in subsequent cycles based on tolerability. Dosing will continue for 1 year or until maximum benefit, disease progression or unacceptable toxicity, whichever comes first.
45964240|NCT01702441|Drug|Subcutaneous AKB-9778|
45964241|NCT01691755|Drug|Placebo|oral doses once a day for 26 weeks
45964242|NCT01691755|Drug|aleglitazar|150 mcg orally once a day for 26 weeks
45964243|NCT00203814|Drug|Sulfadoxine-pyrimethamine|
45822291|NCT00003440|Other|laboratory biomarker analysis|Correlative studies
45964244|NCT00203814|Drug|Artesunate plus sulfadoxine-pyrimethamine|
45666751|NCT01827670|Drug|Stannous fluoride|Test dentifrice containing 0.454% SnF
45666752|NCT01827670|Drug|Sodium monofluorophosphate|Control dentifrice containing 0.76% w/w Sodium Monofluorophosphate [1000 parts per million (ppm) fluoride]
45666753|NCT02267317|Drug|Eritoran|Pharmacologic inhibitor of TLR4 receptors.
45822292|NCT05690581|Drug|CM369|Specified dose on specified days.
45964245|NCT00174473|Drug|Voriconazole|
45964246|NCT01674361|Drug|Bitopertin|Bitopertin once daily orally.
45964247|NCT01674361|Drug|Placebo|Placebo matched to bitopertin once daily orally.
45964248|NCT01674361|Drug|SSRI|Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.
45666754|NCT02267317|Drug|D5W|5% Dextrose Water = Vehicle
45822293|NCT00003200|Drug|Taxotere|
45666755|NCT01844830|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Intranasally administered regional anesthetic
45822294|NCT00003200|Radiation|Radiation therapy|
45822295|NCT05750485|Other|Pupilometric evaluation|Pupilometric evaluation under procedural sedation with propofol
45822296|NCT05750407|Behavioral|Lifestyle change|Three modules target healthy eating, activity, and weight control behaviors
45822297|NCT00003446|Drug|fluorouracil|
45964249|NCT01667341|Biological|GEN-003 with Matrix M-2|IM administration of GEN-003 Vaccine with 50ug Matrix M-2 Adjuvant.
45964250|NCT01667341|Biological|GEN-003|IM administration of GEN-003 Vaccine, antigens alone (without adjuvant).
45964251|NCT01667341|Biological|Placebo|IM administration of 0.5 mL dose of Dulbecco's phosphate buffered saline.
45964252|NCT00174512|Drug|GTN|
45964253|NCT00174512|Drug|Moxifloxacin|
45964254|NCT00199017|Drug|Dexamethasone/Prednisolone|
45666756|NCT01844830|Drug|Placebo|Inactive ingredients supplied in identical nasal sprayer
45666757|NCT05426473|Other|QuickDASH form|Patients have to complete these two forms, Quick DASH and SF-36, before surgery then 6 weeks after
45822298|NCT00003446|Drug|leucovorin calcium|
45822299|NCT00003446|Drug|trimetrexate glucuronate|
45822300|NCT05683873|Procedure|Electrocardiogram|Inclusion visit, V1, V2 and V3
45822301|NCT05683873|Procedure|transthoracic echocardiography|V1, V2 and V3
45822302|NCT05683873|Biological|standard biology|Inclusion visit
45964255|NCT00199017|Drug|Cyclophosphamide|
45964256|NCT00199017|Drug|Vincristine|
45964257|NCT00199017|Drug|Daunorubicin|
45964258|NCT00199017|Drug|Asparaginase|
45964259|NCT00199017|Drug|G-CSF|
45964260|NCT00199017|Drug|Mercaptopurine|
45964261|NCT00199017|Drug|Cytarabine|
45964262|NCT00199017|Drug|Methotrexate|
45964263|NCT00199017|Drug|VP16|
45964264|NCT00199017|Drug|Vindesine|
45964265|NCT00199017|Drug|Adriamycin|
45964266|NCT00199017|Drug|Thioguanine|
45964267|NCT00199017|Drug|HDARAC|
45964268|NCT00199017|Procedure|CNS irradiation|
45964269|NCT00199017|Procedure|Mediastinal irradiation|
45964270|NCT00199017|Drug|Cladribine|
45964271|NCT01665391|Drug|fresolimumab|1 mg/kg total body weight administered intravenous (IV)
45964272|NCT01665391|Drug|fresolimumab|4 mg/kg total body weight administered intravenous (IV)
45964273|NCT01665391|Drug|Placebo|Placebo administered to match active treatment group
45964274|NCT01665352|Drug|TTP054|Administered orally once daily for 12 weeks.
45964275|NCT01665352|Drug|Placebo|Administered orally once daily for 12 weeks.
45964276|NCT01660633|Drug|High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)|200 mg melphalan/m2 will be divided into two separate, consecutive doses of 100 mg/m2 administered on day -3 and day -2 prior to ASCT. The High-Dose Melphaln HCL for Injection (Propylene Glycol-Free) will be reconstituted to 5 mg/mL (also containing 270 mg/mL of Captisol®). The Melphalan HCL for Injection (Propylene Glycol Free) will be further diluted with normal saline to a concentration of no greater than 0.45 mg/mL and infused over 30 minutes ( + or - 3 minutes)via a central venous catheter.
45964277|NCT01660633|Other|Autologous Transplantation|Patients who are myeloablative conditioning in multiple myeloma undergoing autologous transplantation( patients own blood-forming stem cells are collected to replace diseased bone marrow or bone marrow damaged by cancer treatment)
45964278|NCT00174551|Drug|prazosin|
45964279|NCT00203853|Device|pillbox, wristwatch|
45964280|NCT04676659|Drug|TNK-tPA|Experimental arms for low, middle, and high dosing; and active control arm for the standard protocol
45964281|NCT01655680|Drug|ABT-126|ABT-126 Middle Dose
45964282|NCT01655680|Drug|ABT-126|ABT-126 Low Dose
45964283|NCT01655680|Drug|ABT-126|ABT-126 High Dose
45964284|NCT01655680|Drug|Placebo|Placebo
45964285|NCT00174590|Drug|risperidone|
45964286|NCT01653379|Drug|DP001|DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
45822303|NCT05683873|Biological|determination of serum GDF-15, osteoprotegerin and ST-2|Inclusion visit, V1, V2 and V3
45822304|NCT05683873|Biological|Ultrasensitive Troponin-Ic|Inclusion visit, V1, V2 and V3
45822305|NCT05683873|Other|Collection of clinical and radiological data|Inclusion visit, V1 and V3: clinical data only V2: clinical and radiological data
45822306|NCT05683873|Other|72-hour continuous Holter-ECG recording|V1
45822307|NCT00003938|Drug|liposomal amphotericin B|
45822308|NCT05750251|Procedure|levator muscle resection surgery|conventional ptosis surgery
45822309|NCT05750251|Procedure|Müller's muscle-conjuctival resection surgery|conventional ptosis surgery
45822310|NCT05750251|Procedure|full-thickness anterior blepharotomy surgery|conventional eyelid retraction surgery
45822311|NCT00003212|Drug|doxorubicin hydrochloride|
45822312|NCT00003212|Drug|ifosfamide|
45822313|NCT00002611|Biological|dactinomycin|
45822314|NCT00002611|Biological|filgrastim|
45822315|NCT00002611|Drug|cyclophosphamide|
45964287|NCT01652482|Drug|5-fluorouracil|Standard 5-fluorouracil (5-FU) chemotherapy (400 milligram per square meter [mg/m^2] administered as intravenous bolus and then 5-FU 2400 mg/m^2 administered as continuous intravenous infusion over 46 +/- 2 hours) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
45964288|NCT01652482|Drug|Cetuximab|Cetuximab 400 mg/m^2 intravenous infusion as a loading dose on Day 1 Cycle 1, followed by 250 mg/m^2 intravenous infusion weekly until documented disease progression or unacceptable toxicity.
45964289|NCT01652482|Drug|Irinotecan|Standard Irinotecan chemotherapy (180 milligram per square meter [mg/m^2] administered as intravenous infusion over 60 +/- 30 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
45964290|NCT01652482|Drug|Leucovorin|Standard Leucovorin chemotherapy (400 mg/m^2 [racemic form] or 200 mg/m^2 [L-isomer form] administered by intravenous infusion over 120 +/- 10 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
45964291|NCT01652482|Drug|MEHD7945A|MEHD7945A 1100 milligram (mg) intravenous infusion every 2 weeks until documented disease progression or unacceptable toxicity.
45964292|NCT00174629|Drug|Docetaxel/DDP|
45964293|NCT00174629|Drug|docetaxel/gemcitabine|
45964294|NCT02962947|Drug|Propranolol|80 mgR propranolol once daily
45964295|NCT02962947|Drug|Placebo|placebo once daily
45964296|NCT00555334|Procedure|RFA|radiofrequency ablation
45964297|NCT00555334|Drug|lamivudine or entecavir|lamivudine (100mg qd) or entecavir (0.5mg qd) after RFA
45964298|NCT01640080|Drug|Esketamine|Type= exact number, number= 0.20, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.20 mg/kg administered on Day 1 and Day 4.
45964299|NCT01640080|Drug|Esketamine|Type= exact number, number= 0.40, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.40 mg/kg administered on Day 1 and Day 4.
45964300|NCT01640080|Drug|Placebo|Form= intravenous infusion, route= intravenous use. One single placebo intravenous infusion administered on Day 1 and Day 4.
45964301|NCT00174668|Drug|Insulin Glulisine|insulin glulisine 3 x daily (TID) subcutaneously 15 min before the start of a meal
45964302|NCT00174668|Drug|Insulin Therapy|NPH (70%) plus regular insulin or insulin aspart (30%)
45964303|NCT00174668|Drug|Insulin Glargine|1 x daily (OD) subcutaneously at any time (but every day at the same time) according to BG
45964304|NCT01636843|Drug|NNC0109-0012|Administered subcutaneously (s.c., under the skin), once weekly.
45964305|NCT01636843|Drug|placebo|Administered subcutaneously (s.c., under the skin), once weekly.
45964306|NCT00174707|Drug|epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by ciclophosphamide/Methotrexate/fluorouracile (±TAM)
45822316|NCT00002611|Drug|doxorubicin hydrochloride|Source and Pharmacology: An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Binds to DNA and inhibits nucleic acid synthesis, with its major lethal effect occurring during the S phase of the cell cycle. Has some topoisomerase II inhibitory activity. Since it is primarily excreted by the liver, any liver impairment may enhance toxicity. 40% to 50% is excreted in the bile; <5% in the urine. The drug has a very short initial t½ of <20 minutes and a terminal t½ of 17 hours. Animal studies indicate cytotoxic levels persist in tissue for as long as 24 hours.
45822317|NCT00002611|Drug|etoposide|
45964307|NCT00174707|Drug|epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)
45666758|NCT04874467|Procedure|Supportive periodontal therapy|"A complete professional prophylaxis session will be performed, which includes ultrasound debridement, scaling with curettes and dental polishing with a rubber cup. On the other hand, in implants affected by mucositis, supra and sub-gingival debridement will be performed using a combination of ultrasound with a titanium tip and titanium curettes.~All patients will receive personalized hygiene instructions. Patients will be instructed to brush their implants twice daily using the modified Bass technique with a medium-hard manual toothbrush and low-abrasive toothpaste. In addition, they will be taught to use specific interproximal brushes. If access with an interdental brush is not possible, flossing will be indicated. Oral hygiene instructions will be reviewed at each visit."
45964308|NCT00174707|Drug|epidoxorubicine, docetaxel, cyclophosphamide|Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
45964309|NCT01635907|Drug|Dovitinib|
45964310|NCT01633372|Drug|itacitinib|
45964311|NCT01235923|Drug|three times weekly Epo|Epo 400 units/kg administered subcutaneously three times per week for a total of 4 weeks
45964312|NCT01235923|Drug|weekly Epo|Epo 1,200 units/kg administered subcutaneously once a week for a total of 4 weeks
45964313|NCT00204009|Behavioral|Disease Surveillance, Family Studies, Questionnaire Followup|
45964314|NCT01144741|Other|PTSD Checklist-Civilian (PCL-C)|Completed by patients before the interview; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
45964315|NCT01144741|Other|Modified Flanagan Quality of Life Scale|Completed by patients before the interview; it is a 16-item survey designed for use in persons with chronic illness.
45964316|NCT01144741|Other|Center for Epidemiologic Studies Depression Scale (CES-D)|Completed by patients before the interview; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
45964317|NCT01144741|Other|Functional Enquiry (or Review of Systems) Form|Completed during the interview; it is a checklist of medical problems.
45822318|NCT00002611|Drug|vincristine sulfate|
45822319|NCT00002611|Procedure|conventional surgery|
45822320|NCT00002611|Radiation|radiation therapy|
45666759|NCT04594096|Behavioral|Telehealth visits|Receiving telehealth visits with a medical provider (MD or NP) 2-3 days after last chemotherapy administration in the cycle
45666760|NCT04594096|Behavioral|Standard of Care|Receiving care as usual from the UC Davis Comprehensive Cancer Center
45666761|NCT01827592|Drug|Elobixibat 10 mg|Elobixibat 10 mg/day
45822321|NCT00003944|Biological|filgrastim|
45455465|NCT01317368|Drug|Naropine|"20 mL Saline 0,9% is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Ropivacaine 0,75% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
45666762|NCT01827592|Drug|Elobixibat 5 mg|Elobixibat 5 mg/day
45822322|NCT00003944|Drug|carboplatin|
45822323|NCT00003944|Drug|cyclophosphamide|
45822324|NCT00003944|Drug|paclitaxel|
45822325|NCT00003944|Drug|topotecan hydrochloride|
45964318|NCT01144741|Other|Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire|The STOP Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
45666763|NCT01827592|Drug|Placebo|Placebo
45666764|NCT02323334|Drug|LY3202626|administered orally
45666765|NCT02323334|Drug|Placebo (Part A, B, C)|administered orally
45666766|NCT02323334|Drug|Itraconazole|administered orally
45822326|NCT00003944|Procedure|peripheral blood stem cell transplantation|
45822327|NCT00003950|Drug|cyclosporine|
45964319|NCT01144741|Other|FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI)|Completed after data analysis from the existing surveys, it will be a specific quality of life interview, taking into consideration individual's total health outcome.
45964320|NCT01144741|Other|Medical Records Review|Review of medical records will be used, along with STOP-FSS Survey to assess patient histories and outcomes.
45964321|NCT00174746|Drug|AVE2635A|
45964322|NCT01080196|Behavioral|RENEW|"RENEW will occur on a recumbent ergometer that appears like a normal stepper ergometer. While resisting the foot pedal movement the participant experiences eccentric muscle contractions about the knee and hip while performing negative work. The progression of the 3 x/week (every other day), 12 week RENEW program will be determined as a function of the rating of perceived exertion (RPE) using a target workload on the monitor. RENEW will be increased very slowly over the first 3 weeks and, subsequently, to maintain an 11-13 perceived exertion. During the formal RENEW training regimen the participants become fully acclimated to the device (week 3-4) the total RENEW load will increase weekly with no increase in their RPE."
45666767|NCT02448719|Drug|TAK-792 30 mg|TAK-792 30 mg was administered in the morning after a fast.
45666768|NCT02448719|Drug|TAK-792 30 mg placebo|TAK-792 30 mg placebo was administered in the morning after a fast.
45666769|NCT02448719|Drug|TAK-792 100 mg|TAK-792 100 mg was administered in the morning after a fast.
45822328|NCT00003950|Drug|CPT-11|
45666770|NCT02448719|Drug|TAK-792 100 mg placebo|TAK-792 100 mg placebo was administered in the morning after a fast.
45964323|NCT00199134|Drug|Letrozole|Size of the tumor is followed
45964324|NCT00174824|Drug|Insulin glargine|
45666771|NCT02448719|Drug|TAK-792 250 mg|TAK-792 250 mg was administered in the morning after a fast.
45666772|NCT02448719|Drug|TAK-792 250 mg placebo|TAK-792 250 mg placebo was administered in the morning after a fast.
45666773|NCT02448719|Drug|TAK-792 500 mg|TAK-792 500 mg was administered in the morning after a fast or after breakfast.
45666774|NCT02448719|Drug|TAK-792 500 mg placebo|TAK-792 500 mg placebo was administered in the morning after a fast or after breakfast.
45666775|NCT02448719|Drug|TAK-792 750 mg|TAK-792 750 mg was administered in the morning after a fast.
45666776|NCT02448719|Drug|TAK-792 750 mg placebo|TAK-792 750 mg placebo was administered in the morning after a fast.
45666777|NCT02448719|Drug|TAK-792 1250 mg|TAK-792 1250 mg was administered in the morning after a fast.
45666778|NCT02448719|Drug|TAK-792 1250 mg placebo|TAK-792 1250 mg placebo was administered in the morning after a fast.
45964325|NCT00199173|Device|SIR Spheres intra-arterial hepatic|
45964326|NCT00174863|Drug|SR31747A|
45964327|NCT00712582|Drug|Etoposide, carboplatin, ifosfamide|Patients in consolidation A will receive three drugs in a regimen called ICE. You will have 3 cycles. Each new cycle begins 2 to 3 weeks after the last one.
45666779|NCT02322866|Drug|Sarecycline|1.5 mg/kg/day taken orally at the same time each day.
45666780|NCT02322866|Drug|Placebo|Placebo-matching sarecycline tablets, taken orally at the same time each day.
45964328|NCT00712582|Drug|Rituximab, Ifosfamide, Etoposide, Carboplatin|It consists of four drugs in a regimen called augmented RICE (augRICE). It is given every 3 weeks for 2 cycles.
45822329|NCT00003452|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Bladder Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45822330|NCT00003464|Drug|temozolomide|
45822331|NCT00003464|Radiation|radiation therapy|
45822332|NCT00003230|Drug|paclitaxel|
45822333|NCT00003956|Drug|fluorouracil|
45822334|NCT00003956|Drug|leucovorin calcium|
45822335|NCT00003956|Drug|lonafarnib|
45822336|NCT00002623|Drug|carboplatin|
45822337|NCT00002623|Drug|cisplatin|
45822338|NCT00002623|Procedure|conventional surgery|
45822339|NCT00002623|Radiation|radiation therapy|
45822340|NCT00003962|Biological|aldesleukin|
45822341|NCT00003968|Drug|bryostatin 1|
45822342|NCT00003974|Biological|lung tumor associated antigen|
45822343|NCT00003974|Drug|DetoxPC|
45822344|NCT00003974|Drug|chemotherapy|
45822345|NCT00003974|Drug|cyclophosphamide|
45964329|NCT00712582|Drug|Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine|"It consists of four drugs in a regimen called augRICE. It is given every 3 weeks for 2 cycles. After the rituximab on day 3, you will then be admitted to the hospital for 2 to 3 nights.~Part 2: Stem Cell Collection, Part 3: High dose chemoradiotherapy and stem cell transplant. Your doctor may want you to get radiation therapy. If so, it will start 2 weeks before the highdose chemotherapy. This regimen is called CBV-N chemotherapy. It is given by vein in the hospital."
45964330|NCT00174902|Drug|inderal (drug), acetylsalicylic acid (drug)|
45964331|NCT00693238|Radiation|Low Risk Proton Radiation|
45964332|NCT00693238|Radiation|Intermediate Risk Proton Radiation|
45964333|NCT00204087|Behavioral|Cognitive behavioral therapy (CBT)|
45964334|NCT00204087|Behavioral|Supportive Counselling (SC)|
45964335|NCT00174980|Drug|perfluorocarbon emulsion (Oxycyte) infusion|one time dose of 3mL/kg over 15 minutes
45964336|NCT00568282|Procedure|phlebotomy|Standard of care
45964337|NCT00373711|Drug|Iodine-124|2 mCi, oral
45666781|NCT04198376|Procedure|Group A The Laterally Closed Tunnel Technique with SCTG|Following the administration of local anaesthesia 2% lignocaine hydrochloride.In the LCT technique a bevelled intrasulcular incisions will be made around the necks of the affected teeth with Orban Knife.The tunnelling will be accomplished with tunneling instrument (TKN2).A mucoperiosteal tunnel will be prepared using a specially designed tunneling instrument.The muscle and collagen fibres will be released using surgical blades and gracey curettes.Subepithelial CTG will be harvested from palate using single incision technique.The graft will be removed and will be placed on saline soaked gauze and kept wet until its transfer to the recipient bed.An immediate closure of the donor site is performed using modified mattress sutures.The graft will be adapted to the CEJ by means of sling suture.Finally the margins of the pouch will be pulled together over the graft and sutured with interrupted sutures.The surgical sites will be protected with a non eugenol periodontal dressing.
45822346|NCT00002635|Biological|filgrastim|
45666782|NCT04198376|Procedure|Group B Modified Coronally Advanced Tunnel Technique with SCTG.|In MCAT technique all the buccal tissues will be undermined and connected only the papillary region will be left attached.A full thickness preparation of the papillary region will be created this will be done with a small elevator.A second surgical site to obtain the subepithelial CTG using single incision technique.A support suture will be performed to guide the CTG into the recipient site.The graft will be gently pushed into the pouch with a packing instrument and by pulling the support suture.The entire gingivopapillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva.The anchorage in the lingual gingiva will be placed far apically.The suture must capture the buccal flap and graft to avail optimal stabilization.The surgical sites will be protected with a non eugenol periodontal dressing.
45822347|NCT00002635|Drug|aminocamptothecin|
45822348|NCT00003494|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Recurrent or Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45822349|NCT00003500|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Refractory or Recurrent Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45964338|NCT00373711|Drug|Iodine-123|2 mCi, oral
45964339|NCT00373711|Drug|F-18 FDG|10-15 mCi, iv
45964340|NCT02894047|Biological|blood|measurement of CaSR expression levels on synovial fluid monocytes
45964341|NCT02894359|Device|cone beam imagery of cervical spine|
45964342|NCT00199212|Drug|Combination of trastuzumab and PS-341|Trastuzumab and velcade are used according standard procedure
45964343|NCT00175058|Device|AO Therapy (aqueous oxygen)|90-min adjunctive reperfusion of hyperoxemic blood into target coronary artery, immediately following revascularization by means of PCI with stenting
45964344|NCT00555373|Drug|Sirolimus|"Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours)."
45964345|NCT00555412|Drug|A - 10 mg loxapine q 4 h x 3 (30 mg total)|loxapine aerosol inhalation high dose regimen (30 mg total)
45964346|NCT00555412|Drug|B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)|loxapine aerosol inhalation middle dose regimen (20 mg total)
45964347|NCT00555412|Drug|C - 5 mg loxapine q 4 h x 3 (15 mg total)|loxapine aerosol inhalation low dose regimen (15 mg total)
45964348|NCT00555412|Drug|D - inhaled placebo q 4 h x 3|placebo aerosol inhalation (0 mg total)
45964349|NCT00555451|Drug|HE3286|"Dose escalating cohort driven study. 6 planned cohorts.~HE3286 5 mg or placebo QD for 28 days;~HE3286 10 mg (5 mg BID) or placebo BID for 28 days~HE3286 20 mg (10 mg BID) or placebo BID for 28 days~HE3286 40 mg (20 mg BID) or placebo BID for 28 days~HE3286 4 mg (2 mg BID), 20 mg (10 mg BID) or placebo BID for 28 days~HE3286 10mg (5 mg BID) for 28 days (open-label cohort in patients with T2DM)"
45964350|NCT00199251|Drug|RUPATADINE|
45964351|NCT00555490|Dietary Supplement|Soy protein|35 % of protein from soy protein for 4-years
45964352|NCT00175097|Other|Diet: soybeans and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybeans and products made thereof.
45964353|NCT00175097|Other|Diet: soybean flour and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean flour and products made thereof.
45964354|NCT00175097|Other|Diet: soybean milk|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean milk.
45964355|NCT00175097|Other|Diet: Animal protein based diet|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate animal protein.
45964356|NCT02894242|Device|F&P Deimos Nasal Pillows Mask|Investigative Nasal Pillows Mask to be used for OSA therapy
45666783|NCT05405491|Other|PCR based strategy|Early adjustment of antimicrobial therapy according to the results of a multiplex PCR-based testing, used in addition to standard microbiological culture of the tracheal aspirate, in immunocompromised patients with suspected VAP or HAP requiring MV
45964357|NCT02894281|Device|pupillary light reflex|measure with infra-red cameras
45666784|NCT05405491|Other|Standard care|Broad-spectrum antimicrobial therapy adjustment after results of standard microbiological culture of the tracheal aspirate in immunocompromised patients with suspected VAP or HAP requiring MV
45822350|NCT00003512|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45964358|NCT02894164|Other|No intervention|
45964359|NCT00204126|Device|Treadmill with partial body weight support|
45964360|NCT00204126|Device|Surface Functional Electrical Stimulation|
45964361|NCT02894086|Other|database.|database
45964362|NCT00175175|Behavioral|"Allied health professional-run osteoporosis service (case-management)"|
45964363|NCT02894125|Other|SPA Therapy|
45964364|NCT02894320|Behavioral|Behavioral observation|
45964365|NCT00199290|Drug|Trafermin (genetical recombination)|
45964366|NCT04676542|Other|Exercise|One hour of a beginning martial art class ,and a one hour walk at 4.0 mph pace.
45666785|NCT02463071|Drug|AZD0585|1g soft capsule
45666786|NCT02463071|Drug|AZD0585 placebo|1g soft capsule
45666787|NCT02266381|Procedure|US-guided renal access|Patients undergo MPCNL using only US-guided renal access.
45666788|NCT02266381|Procedure|Fluoroscopy-guided renal access|Patients undergo MPCNL using only fluoroscopy-guided renal access.
45666789|NCT02266381|Procedure|US combined with fluoroscopy-guided renal access|Patients undergo MPCNL using US combined with fluoroscopy-guided renal access
45666790|NCT01827046|Drug|rt-PA|Up to 9 doses of 1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
45666791|NCT02356562|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|tablet, ombitasvir coformulated with paritaprevir and ritonavir; tablet, dasabuvir
45666792|NCT02356562|Drug|Sofosbuvir|tablet
45666793|NCT02356562|Drug|Ribavirin|tablet
45666794|NCT02448563|Behavioral|Nutrition and physical activity education|Eight weekly in-person groups
45666795|NCT02266225|Other|Lifestyle-integrated Functional Exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
45666796|NCT02354690|Drug|Vemurafenib|Vemurafenib is used to treat patients with BRAF mutated metastatic melanoma. Patients will start treatment in a dose of 960 BID 7 days before tumor harvest and ends at the day of admission (day -8).
45666797|NCT02354690|Drug|Lymphodepleting chemotherapy|First patients undergo lymphodepleting chemotherapy regimen consisting of cyclophosphamide 60 mg/kg for 2 days and fludarabine 25 mg/m2 for 5 days (constitutes day -7 to -1 of admission).
45666798|NCT02354690|Drug|TIL infusion|"7 days after start of vemurafenib treatment, patients undergo surgery to removal of a tumor in order to isolate, activate and expand tumor infiltrating lymphocytes (TIL) to high numbers. In vitro preparation usually takes 4-6 weeks using the young TIL method.~On day 0 patients receive an infusion of TIL (1x10e9-2x10e11 cells)."
45666799|NCT02354690|Drug|Interleukin-2|After infusion of TILs, patients will receive interleukin-2 infusions according to the decrescendo regimen (18 MIU/m2 for 6 hours, 18 MIU/m2 for 12 hours, 18 MIU/m2 for 24 hours followed by 4,5 MIU/m2 for another 3 x 24 hours)
45666800|NCT02354222|Drug|Canagliflozin|
45822351|NCT05749861|Drug|CKD-348(5)|QD, PO
45822352|NCT05749861|Drug|CKD-828, D097, D337|QD, PO
45822353|NCT00003242|Drug|bryostatin 1|
45822354|NCT00003242|Drug|cisplatin|
45822355|NCT00003242|Drug|paclitaxel|
45822356|NCT00003980|Drug|BIBX 1382|
45964367|NCT04676776|Drug|Levonorgestrel|All participants receive 1.5 mg levonorgestrel on day 1
45964368|NCT04676776|Drug|Mifepristone|All participants receive 200 mg mifepristone on day 3
45964369|NCT00175214|Behavioral|Multifaceted intervention (patient education, physician guidelines, reminders)|
45964370|NCT04676464|Diagnostic Test|Ultra- sound|Ultrasound assessment of quadricep muscle layer thickness QMLT within 72hrs of initial CT scan
45964371|NCT04676230|Procedure|Experimental group|Caries management based on the ICCMSTM: Patient intervention according to the caries risk likelihood: high, moderate or low. Surfaces intervention according to the surface diagnosis decision matrix (ICCMSTM): Mi: Initial caries management, Mm: Moderate caries management, and Me: Extensive caries management.
45964372|NCT04676230|Procedure|Control group|Systematic patient caries risk intervention (all managed as high risk patients). Surfaces intervention with conventional caries management of cavitated/dentin caries lesions (restorative treatment).
45964373|NCT00204165|Procedure|MRI of the small bowel|
45964374|NCT04676074|Device|Electronic Upper limb( body) ergometer|Electronic pedal for the upper limb using for training the upper body. Intensity, speed and resistance can be adjusted.
45964375|NCT00175253|Drug|alemtuzumab|
45964376|NCT00175253|Procedure|islet transplant|
45964377|NCT00199329|Drug|ondansetron adding in PCA|
45964378|NCT04675918|Procedure|Cardiac arrest|Definition of characteristics of cardiac arrest and resuscitation as well as post-resuscitational care and follow up.
45964379|NCT04675645|Other|HU-Go app|A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
45964380|NCT00175292|Drug|Probiotic - VSL#3|
45964381|NCT04675684|Behavioral|Recovery-group|The complex intervention are instructions in ruminations-therapy and mindfulness, advice in healthy diets, physical - and social activities and sleep hygiene, and support in smoking cessation, alcohol counseling and medication adherence.
45666801|NCT02354222|Drug|Teneligliptin|
45964382|NCT00555529|Procedure|radial artery applanation tonometry (RAAP)|non-invasive tonometry
45964383|NCT00555607|Drug|prednisolone|Prednisolone oral tablets (10 mg active ingredient per tablet) once a day at a dose of 0.5mg/kg bodyweight, during 14 days.
45964384|NCT02963792|Other|Preventing Professionals burnout|
45964385|NCT00555685|Drug|NaCl 7,5% (Hypertonic Saline Solution)|Patients in the intervention arm will receive 100ml of NaCl 7,5, twice daily during 3 days
45964386|NCT00555685|Drug|NaCl 0,9%|Patients in the placebo arm will receive 100ml of NaCl 0,9% twice daily during 3 days
45822357|NCT05664061|Drug|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals|twice daily inhalation throughout the treatment period
45964387|NCT00555724|Drug|BIIB022|IV infusion once every three weeks until disease progression or unacceptable toxicity
45964388|NCT00199368|Drug|Istradefylline ( KW-6002)|
45964389|NCT00555763|Device|Tonometry|Tonometry : measurement of intraocular pressure with an applanation tonometer
45666802|NCT02354222|Drug|Placebo|
45666803|NCT04904276|Drug|Fostamatinib|Fostamatinib disodium
45666804|NCT02353442|Other|Posterior shoulder mobilizations|A second investigator performed 5min of posterior capsule shoulder mobilization for the experimental group, 3times/week during 4 weeks.
45822358|NCT05664061|Drug|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|twice daily inhalation throughout the treatment period
45822359|NCT05664061|Drug|Placebo|twice daily inhalation throughout the treatment period
45964390|NCT00555802|Other|exercise|exercise
45964391|NCT04675528|Drug|DHP107(Oral paclitaxel)|DHP107 200 mg/m2 orally twice daily on Days 1, 8, and 15 in every 28 days (On food effect study day, DHP107 200 mg/m2 orally once daily on Days 1, 8 of Cycle 1 with fasted or fed condition according to the assigned sequence)
45964392|NCT04675177|Drug|Polidocanol foam sclerotherapy|"i. Patients underwent preparation, two hours before the intervention, with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed.~ii. Preparation of the polidocanol (Aethoxysklerol 3%) foam according to Tessari technique immediately before application, so that the microbubbles of the foam did not disintegrate; iii. The procedure was performed in the medical office. Application according to the Blanchard technique through a disposable transparent anoscope, in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle; iv. Patients were treated in a maximum of 3 sessions, at 3 weeks intervals; v. Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air; i. In each session, the sclerosant was injected in one or more hemorroidary cushion;"
45964393|NCT04675177|Procedure|Doppler-guided hemorrhoidal artery ligation|"i. Patients underwent preparation with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed.~ii. The procedure was performed in the operating room of an outpatient surgery unit, under regional anestesia.~iii. A proctoscope with a Doppler transducer in its tip was introduced inside the anal canal to search for the superior rectal artery.~iv. Each branch was ligated with suture above the dentate line. The device was rotated slowly in clockwise direction to locate further arteries at that level.~v. Rectoanal repair consisted in a continuous running suture was applied longitudinally just over every prolapsed hemorrhoid."
45964394|NCT00175370|Drug|Vancomycin|Randomized double-blind equivalence trial to test the hypothesis that 2 days is equivalent to 7 days of vancomycin treatment for intravascular device associated bacteremia due to coagulase negative staphylococcus. The definitions for the surveillance of intravascular device associated bacteremia from the Laboratory Centre for Disease Control-Health Canada will be used. Surveillance blood cultures on days 4 and 9 following removal of intravascular device. Relatedness of strains will be determined by pulsed-field gel electrophoresis (PFGE).
45964395|NCT00204243|Drug|Naltrexone|surgically implanted naltrexone releasing during 5 to 6 months
45964396|NCT00204243|Drug|Methadone|Methadone maintenance treatment, flexible high dose (80 to 120 mg / Day)
45964397|NCT04675138|Other|No intervention will be provided to the subject|No intervention will be provided to the subject
45666805|NCT02353442|Other|External rotators strengthening|Individuals performed 3x10 repetitions of external rotators strengthening in sidelying position 3times/week during 4 weeks.
45666806|NCT02353442|Other|Placebo ultrasound|A second investigator performed 5min of placebo ultrassound for the control group, 3times/week during 4 weeks.
45666807|NCT02353442|Other|Scapular squeezing|Individuals performed 3x10 repetitions scapular squeezing exercise 3times/week during 4 weeks.
45822360|NCT00003248|Biological|rituximab|
45822361|NCT00003248|Drug|fludarabine phosphate|
45822362|NCT05663905|Drug|Ambroxol Hydrochloride|IV ambroxol hydrochloride 30mg TDS as adjunct therapy to standard therapy for severe pneumonia in ICU for 14 days. Each dose of 30mg of ambroxol will be diluted in 50ml of NS/D5% to be given intravenously over an hour.
45822363|NCT05663905|Other|Standard Therapy|Standard therapy for severe pneumonia as per recommended in the ICU Management Protocols by Malaysian Society of Intensive Care (MSIC). This includes antibiotics stewardship and supportive therapy.
45822364|NCT00002641|Biological|filgrastim|
45822365|NCT00002641|Drug|doxorubicin hydrochloride|
45822366|NCT00002641|Drug|ifosfamide|
45822367|NCT00002641|Drug|isolated perfusion|
45822368|NCT00002641|Procedure|adjuvant therapy|
45822369|NCT00002641|Procedure|conventional surgery|
45964398|NCT04675372|Drug|Dexmedetomidine|Dexmedetomidine group (Group D) was given 1.5ug/kg/h Dexmedetomidine continuous infusion
45964399|NCT04675372|Drug|Midazolam|Midazolam group (Group M) was continuously pumped with 0.05mg/kg/h midazolam
45964400|NCT00175409|Procedure|Blood collection|For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
45964401|NCT00175409|Procedure|Blood collection|For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
45964402|NCT04449991|Procedure|Repeat kidney biopsy|Intensification of immunosuppression if NIH AI > 3
45666808|NCT02353442|Other|Upper trapezius stretching|Individuals performed 3x30s of upper trapezius stretching, 3times/week during 4 weeks.
45964403|NCT00204282|Behavioral|Educational presentation, group discussion, questionnaires|
45964404|NCT04424602|Drug|cyclo phosphamide|500mg vial
45964405|NCT04424602|Drug|mycophenolate|500mg film-coated tablets.
45964406|NCT00175448|Procedure|physiotherapy|See Detailed Description.
45964407|NCT00199407|Drug|Istradefylline (KW-6002)|
45964408|NCT04389892|Diagnostic Test|Contrast enhanced harmonic endoscopic ultrasound|"During the echoendoscopy the image was fixed on the region of interest (pancreatic cyst) and the extended pure harmonic detection mode was selected. 2,4ml contrast enhancement (Sonovue-Bracco Italy) was injected in the right antecubital vein of the participants followed by a flush of 5ml 0.9% saline solution to ensure that the entire quantity of the agent goes in to the blood flow.~After the administration the pancreatic cyst was observed for at least 120 seconds.We followed the enhancing behavior of the cyst wall, the septa and the solid components. Arterial enhancement (contrast uptake) was considered the first 25-30 seconds after injection and the venous phase (wah-out) 30-45 seconds after injection.~EUS-FNA was performed in all patients without contraindications"
45964409|NCT00175487|Procedure|Hip replacement|This study evaluates femoral head resurfacing versus a large femoral head (Durom®) total hip system. This is a prospective randomized trial.
45666809|NCT02353442|Other|Posterior Capsule Stretching|Individuals performed 3x30s of posterior capsule stretching, 3times/week during 4 weeks.
45666810|NCT02351960|Drug|Dexlansoprazole|Dexlansoprazole capsules
45666811|NCT02351180|Drug|Inhaled beclomethasone|Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection
45666812|NCT02351180|Drug|Placebo|Placebo will serve as a control treatment
45822370|NCT00002641|Radiation|radiation therapy|
45822371|NCT00003992|Biological|trastuzumab|
45822372|NCT00003992|Drug|cyclophosphamide|
45964410|NCT00199446|Drug|Istradefylline (KW-6002)|
45964411|NCT04314973|Device|Active Pelvis Orthosis|Walking with the robotic device providing the assistive protocol.
45964412|NCT04314973|Other|Walking exercises|Walking exercises without wearing the robotic device.
45964413|NCT04306393|Drug|Nitric Oxide Gas|"80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.~Weaning criteria: maintenance of a PaO2/FiO2 ratio >/= 300 for at least 24 hours consecutively."
45964414|NCT04304092|Other|Exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
45666813|NCT02350478|Drug|Linagliptin|The subject will receive Linagliptin 5mg orally once daily for 12 weeks.
45666814|NCT02350478|Drug|Placebo|The subject will receive placebo orally once daily for 12 weeks.
45964415|NCT00175526|Behavioral|preeclampsia|This research project, 'a severity score for pre-eclampsia,' will develop such a clinical tool that is specific to the condition. To develop and validate the tool w
45964416|NCT00204321|Drug|sirolimus (drug), mmf (drug)|
45964417|NCT00175565|Drug|inhaled fluticasone 500 mcg b.i.d.|
45964418|NCT04257799|Other|Structured Light Imaging (SLI) System|Investigation of SLI and Tomographic Imaging to see if they will identify cancer cells at the edge of tissue specimens removed during the operation.
45822373|NCT00003992|Drug|doxorubicin hydrochloride|
45822374|NCT00003992|Drug|paclitaxel|
45822375|NCT00003992|Drug|tamoxifen citrate|
45822376|NCT00002647|Drug|verteporfin|
45822377|NCT00002647|Procedure|conventional surgery|
45822378|NCT00003524|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stomach Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45822379|NCT00003530|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Primary Liver Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45822380|NCT00002653|Drug|carmustine|
45822381|NCT00002653|Drug|cyclophosphamide|
45822382|NCT00002653|Drug|doxorubicin hydrochloride|
45964419|NCT04251208|Other|Observational Study|No intervention will be administered.
46080120|NCT00582296|Behavioral|questionnaires, telephone interview, optional blood drawn|Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family & personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
45964420|NCT04251013|Device|Biliary brushing with the RX Cytology brush, Boston Scientific|"Biliary brushing during ERCP:~Performing a dozen back and forth movements in the stenosis~Bile aspiration if possible, by the catheter of the brush for cytological analysis~The contents of the brush will be spread over 3 blades (numbered) then sectioned and placed in cytolit with the contents of the tubing of the brush flushed with a few cc of cytolit. Each brush in a numbered pot. Blades 1,2 and 3 +/- bile 1 joined to pot n ° 1; blades 4,5 and 6 +/- bile 2 joined to pot 2~In the event of technical failure (impossibility of accessing the stenosis with the first or second brush, impossibility of removing the brush), the patient will be considered to have failed for this brush (absence of pathological material brought back)"
45964421|NCT04251013|Device|Biliary brushing with the Infinity® brush, US Endoscopy|"Biliary brushing during ERCP:~Performing a dozen back and forth movements in the stenosis~Bile aspiration if possible, by the catheter of the brush for cytological analysis~The contents of the brush will be spread over 3 blades (numbered) then sectioned and placed in cytolit with the contents of the tubing of the brush flushed with a few cc of cytolit. Each brush in a numbered pot. Blades 1,2 and 3 +/- bile 1 joined to pot n ° 1; blades 4,5 and 6 +/- bile 2 joined to pot 2~In the event of technical failure (impossibility of accessing the stenosis with the first or second brush, impossibility of removing the brush), the patient will be considered to have failed for this brush (absence of pathological material brought back)"
45964422|NCT00204399|Behavioral|Telephone counseling support|
45964423|NCT00175604|Drug|Botox|The babies that require a neck collar for CMT will be randomly placed into two groups. One group will receive standard treatment which includes physiotherapy and occupational therapy. The other group will receive standard treatment plus an injection of Botox.
45964424|NCT04242043|Diagnostic Test|intel@med-feasibility|"Initial evaluation by the Nurse using the AI tool which enters into MEDVIR the patient's symptoms or functional complaints and comorbidities and is complemented by a telemedicine solution for data transmission to the remote tele-expert physician located in a regulatory center or health center. The remote doctor (a geriatrician from Prevention Care for Elderly Unit (UPSAV) platform of the Clinical Gerontology Division of the Limoges University Hospital) analyses the data collected by the Nurse and establishes a symptom severity criterion and a diagnosis with the help of the AI technology.~Both the geriatrician and the NHs nurse are not aware of the proposals made by AI.~The geriatrician can nevertheless initiate a visit to the resident's place of residence in order to verify the information necessary to establish the diagnosis and thus improve the relevance of the algorithm. For the resident, this study doesn't interfere with the usual care."
46080121|NCT00582296|Behavioral|questionnaires, telephone interview and optional blood drawn|Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family & personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
46080122|NCT00472654|Behavioral|Weight Loss|Diet for weight loss for 6 weeks; all weight loss participants will attend 6 weekly counseling sessions (about 50 minutes per session)
45666815|NCT02349542|Drug|Liposomal bupivacaine|One (1) 20 mL vial of 266 mg liposomal bupivacaine (3% (~8mg free bupivacaine)) will be injected into each surgical (knee) site following simultaneous bilateral total knee arthroplasty. In addition, 30 mL of 0.25% bupivacaine (75 mg free bupivacaine) will be injected into each surgical (knee) site for a total of 83 mg free bupivacaine injected into each surgical (knee) site.
45666816|NCT02321930|Drug|tofacitinib 5mg po bid|
46080123|NCT00472654|Dietary Supplement|Vitamin D 2500 IU|Daily Vitamin D 2500 IU supplement for 6 weeks
45666817|NCT01647542|Drug|TAK-875|TAK-875 tablets
45666818|NCT01647542|Drug|TAK-875 Placebo|TAK-875 placebo-matching tablets
45666819|NCT02321462|Drug|Eziclen|Eziclen solution administered orally as split-dose the day before and on the day of colonoscopy.
45822383|NCT00002653|Drug|melphalan|
45822384|NCT00002653|Drug|prednisone|
45822385|NCT00002653|Radiation|radiation therapy|
45822386|NCT00003254|Drug|ethynyluracil|10mg/m2/dose, PO, Days 1-28, q 5wk
46080124|NCT00472654|Behavioral|Weight Maintenance|Diet for weight maintenance for 6 weeks
46080125|NCT00413998|Procedure|CABG + Mitral valve annuloplasty|Patients will receive a mitral annuloplasty ring in addition to coronary artery bypass grafting.
46080126|NCT00413998|Procedure|CABG|Patients will undergo coronary artery bypass grafting alone.
45822387|NCT00003254|Drug|fluorouracil|1.0mg/m2/dose, PO, Days 1-28 BID, q 5wk
45822388|NCT05749549|Drug|BR1733|Subjects will receive oral administration of BR1733.
45666820|NCT02321462|Drug|Fortrans®|Fortrans® solution administered orally as split-dose the day before and on the day of colonoscopy.
45666821|NCT02391584|Device|XprESS|Balloon dilation of the Eustachian tube
45666822|NCT02391584|Other|Control|Continued medical management
45666823|NCT02266147|Drug|SD-101|
45666824|NCT02266147|Radiation|Radiation therapy|
45666825|NCT04873843|Behavioral|Functional digital game training group|Functional digital game training group is divided in 16 participants. In one session, participants in the functional digital game training group completed 40 minutes of intervention using various functional digital game such as working memory, memory, and attention. (Total 10 session)
45822389|NCT00002659|Drug|cisplatin-e therapeutic implant|
45822390|NCT00003998|Drug|carboplatin|
45822391|NCT00003998|Drug|docetaxel|
45822392|NCT00003998|Drug|paclitaxel|
45822393|NCT00003998|Procedure|surgical procedure|
45822394|NCT00004004|Drug|procarbazine hydrochloride|
45822395|NCT05749471|Diagnostic Test|ASEX (Arizona Sexual Experience) administration|ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30. Generally, a subject with a total ASEX score of > 19, any one item with a score of > 5, or any three items with a score of > 4 would have sexual dysfunction.
45822396|NCT00003260|Drug|FOLFIRI regimen|
45822397|NCT00003260|Drug|FOLFOX regimen|
45822398|NCT00003260|Drug|fluorouracil|
45822399|NCT00003260|Drug|irinotecan hydrochloride|
45822400|NCT00003260|Drug|leucovorin calcium|
45666826|NCT04873843|Behavioral|Individual cognitive training|Functional digital game training group is divided in 16 participants. In one session, participants in the individual cognitive training group completed 40 minutes of intervention using various cognitive training such as working memory, memory, and attention. (Total 10 session)
45666827|NCT04865965|Procedure|Acute Bout of Exercise|Exercising for 60 minutes at 55-60% of VO₂ peak
45822401|NCT00003260|Drug|oxaliplatin|
45822402|NCT00002665|Drug|asparaginase|10,000 units/d IV or IM 15 - 24
45822403|NCT00002665|Drug|cyclophosphamide|con: 650 mg/m2 IV 1, 15, 29 maint: 650 mg/m2 IV 1
45822404|NCT00002665|Drug|cytarabine|cons: 75 mg/m2/d IV Push 2 - 5, 9 - 12, 6 - 19, 23 - 26
45964425|NCT04230187|Drug|mFOLFOXIRI plus Bevacizumab|Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 8 cycles and followed by bevacizumab and fluoropyrimidine based maintence treatment
45822405|NCT00002665|Drug|daunorubicin hydrochloride|ind: 60 mg/m2 IV 22 and 23
45964426|NCT04230187|Drug|mFOLFOX6 Plus Bevacizumab|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 8 cycles and followed by bevacizumab and fluoropyrimidine based maintence treatment
45964427|NCT00199485|Drug|Angelica Sinensis|Angelica Sinensis / placebo
45964428|NCT00175643|Drug|imiquimod|
45964429|NCT04222309|Procedure|Laparoscopically harvested omental free flap|Laparoscopically harvested omental free flap into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.
45964430|NCT00554008|Procedure|laparoscopic appendectomy|appendix removal via scope
45964431|NCT00554008|Procedure|open appendectomy|open operation for removal of appendix
45964432|NCT00204438|Drug|0.15mg desogestrel /0.03mg ethinyl estradiol|
45964433|NCT00554047|Other|Multidisciplinary Memory Clinic|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by Multidisciplinary Memory Clinics (MMCs)
45964434|NCT00554047|Other|General Practitioners|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by general practitioners
45964435|NCT00175682|Drug|Prazosin HCL|See Detailed Description
45964436|NCT00554086|Drug|Escalating dose of Casodex from 50mg daily to 150 mg daily|Casodex dosage increase from 50mg to 150mg daily until baseline serum PSA is reduced by 50%
46080127|NCT00323960|Drug|3 MPDN pulse + PDN|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.
45822406|NCT00002665|Drug|dexamethasone|main: 10 mg/m2/day PO 1 - 28
46080128|NCT00323960|Drug|3 MPDN pulse + PDN + CSA|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses
46080129|NCT00323960|Drug|3 MPDN pulse + PDN + MTX|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.
45822407|NCT00002665|Drug|doxorubicin hydrochloride|main: 25 mg/m2 IV 1, 8, 15, and 22
45822408|NCT00002665|Drug|etoposide|60 mg/kg based on ideal body weight day -3
45964437|NCT04173364|Drug|Ropivacaine 0.5% Injectable Solution|Injectable solution of ropivacaine 0.5%
45964438|NCT04173364|Drug|Ropivacaine 0.1% Injectable Solution|Dilution of ropivacaine to the concentration of 0.1%
45964439|NCT04171453|Drug|Lyrica CR (Pregabalin)|Lyrica CR 82.5mg, 165mg, or 330mg OD
45964440|NCT00199524|Device|Navigator Ureteral Access Sheath|ureteral access sheath
45964441|NCT04171297|Procedure|Ultrasound evaluation of DE|To evaluate diagnostic accuracy of ultrasound for the presence of deep endometriosis.
45666828|NCT05647135|Other|Medical food|enteral formulas with different protein composition
45666829|NCT05402917|Procedure|Erector Spinae Plane Block|Interfascial plane (area) blocks are blocks in which the local anesthetic agent is injected into the potential area between the two fasciae. The ESPB we used in our study is a member of interfascial plane blocks. The erector is applied between the spinal muscle and the transverse process, spreading the drug from the injection site to both cranial and caudal. Unlike other defined interfascial plane blocks, ESPB can show paraspinal block characteristics since the injection site is above the transverse process.
45666830|NCT05395039|Other|VCHIPS|Participants in this group will have the opportunity to receive virtual visits with the patient during the hospital stay, led by a study nurse.
45822409|NCT00002665|Drug|leucovorin calcium|5 mg q 6 hours for 4 doses, PO 1, 3, 8, 11 after each methotrexate if WBC < 3,000 /μl
45822410|NCT00002665|Drug|mercaptopurine|con: 60 mg/m2 PO 1 - 28
45822411|NCT00002665|Drug|methotrexate|10 mg/m2 IT or IV, d 2, 9, 16, and 23; Maximum 15 mg/admin
45822412|NCT00002665|Drug|prednisone|"ind: 60 mg/m2/d PO 1 - 21*, 22 - 28 Patients will receive full dose through day 8 and then tapered to zero between Day 29 and 42.~ind2: 60 mg/m2/d PO through day 42"
45822413|NCT00002665|Drug|thioguanine|main: 60 mg/m2/day PO 1 - 14
45822414|NCT00002665|Drug|vincristine sulfate|ind: 1.4 mg/m2 2 mg max, IV 1, 8, 15, and 22 ind2: 1.4 mg/m2 2 mg max IV 29 and 36 main: 1.5 mg/m2 2 mg max, IV 1, 8, 15, and 22
45822415|NCT00002665|Procedure|allogeneic bone marrow transplantation|day 0
45822416|NCT00002665|Radiation|radiation therapy|day -7 through day -4 total dose of radiation is 1,320 cGy.
45822417|NCT00003536|Drug|antineoplaston A10|
45822418|NCT00003536|Drug|methotrexate|
45822419|NCT00003536|Procedure|alternative product therapy|
45822420|NCT00003536|Procedure|biological therapy|
45822421|NCT00003536|Procedure|biologically based therapies|
45822422|NCT00003536|Procedure|cancer prevention intervention|
45822423|NCT00003536|Procedure|chemotherapy|
45964442|NCT04138732|Behavioral|Improve health behaviors of medical personel|This arm will receive the intervention treatment aimed to help improve their health behaviors, as determined by employee-based steering committee. Interventions will target nutrition, physical activity and stress reduction
45964443|NCT04111315|Drug|Metamizole Sodium|Novalgin® Oblong tablets 0,5 g 2-2-2
45964444|NCT04111315|Drug|Ibuprofen 600 mg|Ibufen-L® tablets 500 mg 2-2-2
45822424|NCT00003536|Procedure|complementary and alternative therapy|
45822425|NCT00003536|Procedure|differentiation therapy|
45964445|NCT04111315|Behavioral|Patient education|Leaflet and phone call
45964446|NCT00204516|Biological|mRNA coding for melanoma associated antigens|mRNA vaccine s.c. applied weekly
45964447|NCT00204516|Drug|GM-CSF|Given s.c. as adjuvant drug one day after vaccine
45964448|NCT00175721|Procedure|The Combined Cardiac Kidney Diabetes Care Clinic|See Detailed Description.
45822426|NCT00003542|Biological|pegylated interferon alfa|
45964449|NCT04105582|Biological|Neo-antigen pulsed Dendritic cell|Patients that have already finished their conventional treatment (chemotherapy and/or surgery) will be vaccinated with dendritic cells pulsed with synthetic peptide
45964450|NCT04093180|Procedure|Intensive Neurophysiological Rehabilitation System|Intensive Neurophysiological Rehabilitation System (INRS) is a multicomponent approach that consists of different treatment modalities.
45964451|NCT04093180|Procedure|Activity and care as usual|Control group continues usual activity and care while staying in the waiting list.
45964452|NCT04679584|Other|Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings|Oberservatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care
45964453|NCT00199563|Drug|Viagra|Sildenafil 100mg daily for 12 weeks
45964454|NCT04679350|Drug|hzVSF-v13|Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)
45964455|NCT04679350|Drug|Placebo (Normal saline solution)|Dosage form: 0.9% NaCl solution Frequency: Dose at Day 1, 3, 7
45964456|NCT00175760|Procedure|Diagnosis of Celiac Disease|During GI endoscopy a minimum of 4 small intestinal biopsies will be taken from all subjects and controls.
46080130|NCT00323037|Drug|carvedilol controlled release|Carvedilol controlled release (10, 20, 40 or 80 mg) and placebo taken in the morning. Two placebos taken in the evening. A total of 4 pills will be taken PO daily.
46080131|NCT00323037|Drug|carvedilol immediate release|Carvedilol immediate release (3.125, 6.25, 12.5 or 25 mg) and placebo, taken PO, twice-daily.
45822427|NCT00381667|Drug|GW642444M|M salt
45822428|NCT00381667|Drug|GW642444H|H salt
45822429|NCT00381667|Other|placebo|placebo
45822430|NCT00003548|Drug|aminocamptothecin colloidal dispersion|
45822431|NCT00381823|Behavioral|Cognitive Behavioral Therapy|
45822432|NCT00004010|Biological|bleomycin sulfate|
45822433|NCT00004010|Biological|filgrastim|
45822434|NCT00004010|Drug|ABVD regimen|
45822435|NCT00004010|Drug|cyclophosphamide|
45822436|NCT00004010|Drug|dacarbazine|
45822437|NCT00004010|Drug|doxorubicin hydrochloride|
45964457|NCT04679506|Drug|Cladribine|CLAE regimen (cladribine + cytarabine + etoposide) for reinduction of R/R T-ALL/LBL
45964458|NCT02962830|Drug|Sufentanil|intra-amniotic injection of 10 micrograms of Sufentanil
45964459|NCT04065100|Diagnostic Test|Sebum test|Measuring sebum in newborn
45964460|NCT00199602|Drug|warfarine - low molecular heparin|
45964461|NCT00554125|Drug|sirolimus|given at an initial dose of 3 mg/m2, and adjusted over time to achieve steady-state whole-blood trough levels of approximately 5-8 ng/mL
45964462|NCT00175838|Drug|Hydroxyurea|Hydroxyurea (or hydroxycarbamide) is an antineoplastic drug commonly used to treat haematological malignancies.
45964463|NCT00175838|Drug|Aspirin|Aspirin is an anti-aggregating agent, and has been shown to reduce/alleviate minor ischaemic symptoms.
45964464|NCT03986671|Device|Transmembrane EMG Oropharynx Probe|Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmembrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).
45964465|NCT03981640|Other|Acute exercise|Participants will lie in a semi-supine position with their feet attached to the pedals of a custom-arranged cycle ergometer. Participants' 40% heart rate reserve will be calculated, giving the target value to achieve during exercise based on appropriate resistance applied on the cycle ergometer, corresponding to a moderate exercise intensity. After a 5-minute resting baseline, participants will perform dynamic cycling exercise at steady state for up to 20 minutes. They will then stop exercising, and there will be a 5-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived exertion will be taken from participants during the last 30 seconds of steady-state cycling exercise.
46080132|NCT00128297|Drug|Pamidronate|
45822438|NCT00004010|Drug|etoposide|
45822439|NCT00004010|Drug|prednisone|
45822440|NCT00004010|Drug|procarbazine hydrochloride|
45822441|NCT00004010|Drug|vinblastine sulfate|
45822442|NCT00004010|Drug|vincristine sulfate|
45822443|NCT00004010|Radiation|radiation therapy|
45822444|NCT05646979|Behavioral|EFT group|EFT protocol will be applied to the women in the experimental group who will have a cesarean section at 32-38 weeks of gestation.
45822445|NCT00004016|Biological|recombinant interferon gamma|
45822446|NCT05749315|Other|Play Based Therapy|Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
45822447|NCT05749315|Other|Functional Communication Training|Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
45964466|NCT03981640|Other|Cold pressor test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will have their hand immersed in ice water for 2 minutes. This cold pressor test represents the non-exercise, physical sympathetic stressor. Participants' hand will then be removed from the ice water, followed by a 3-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. Ratings of hand pain and cold perception will be taken from participants during the last 30 seconds of the cold pressor test.
45964467|NCT03981640|Other|Mental stress test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will perform a mental arithmetic task for 5 minutes. This mental stress test represents the non-exercise, psychological sympathetic stressor. Participants will be instructed to subtract a given number from a randomly selected three-digit number and verbally state their answer and continue to do so for the duration of the test. Participants will be instructed to state their answers as quickly and accurately as possible. Participants will then stop the arithmetic task, and a 3-minute recovery period will follow. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived stress will be taken from participants during the last 30 seconds of the mental stress test.
45964468|NCT00204555|Drug|Imiquimod|
45964469|NCT00408044|Procedure|cardiac surgery with sternotomy|
45964470|NCT03964441|Biological|Invasive fetal sampling, blood sampling of mother and father|to perform an exome sequencing analysis in trio
45822448|NCT00004022|Biological|aldesleukin|
45964471|NCT03964441|Biological|blood sampling from the mother to recover the circulating cell free fetal DNA|to perform a sequencing analysis of the genome of circulating free fetal DNA
45964472|NCT03964441|Other|Parent interviews (optional organizational study)|Interview with a sociologist or psychologist to explore perceptions of ES and the impact of the results, expectations regarding certain types of results not currently available, the emotional situation, and position regarding the continuation of the pregnancy At 4 different times: at inclusion, at the time of the CGA-array results, at the time of the ES results and at a distance from the ES results
45964473|NCT03964441|Other|parent questionnaire (optional organizational study)|To evaluate the experience, perceptions, the impact of the analyses on the decision, satisfaction and concerns regarding the ES and its results, opinions on certain types of results not currently available, as well as anxiety and possible psychological distress At 4 different points in time: at inclusion, at the delivery of the CGA-array results, at the delivery of the ES results and at a distance from the delivery of the ES results
45964474|NCT03964441|Other|professional interviews (optional organizational study)|interview to understand how the decision is formed
45964475|NCT03964441|Other|Focus group for professionals (optional organizational study)|interview to specify whether variants of unknown significance) VUS will potentially be returned to the clinicians, or even to the patient via the clinician.
45964476|NCT03952078|Drug|CPI-818|Interleukin-2 inducible T-cell Kinase Inhibitor
45964477|NCT00199641|Device|enteral nutrition|
45964478|NCT00175955|Drug|Levetiracetam|
45964479|NCT03948139|Device|Functional Brace|The study will generate five standardized sized braces based on measurements from prior scans that will be stocked at each institution and modified by the local orthotist to fit the needs of each patient. This will facilitate expedited care while obtaining the same clinical and radiographic results as the fully customized braces. This idea has the potential to be extrapolated to the wider clinical community, creating a true shift in pediatric orthopaedic clinical practice throughout the country.
45964480|NCT03948139|Device|Hip Spica Cast|Traditional spica casts, the current standard of care for diaphyseal femoral shaft fractures with minimal shortening in children age 0-5 years old. Although spica cast immobilization is standard of care for femur fractures in young children, caring for a child in a spica cast presents a significant socioeconomic burden on families and the healthcare system. Basic hygiene and transportation for a child in a spica cast requires burdensome adjustments for caretakers, as well as the added expenses of specialized car seats or transportation services. Improper spica cast care can lead to skin complications, additional visits for cast adjustments, or even revision casting in the operating room.
45964481|NCT03847909|Drug|DCR-PHXC|Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
45964482|NCT03847909|Drug|Sterile Normal Saline (0.9% NaCl)|Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo
45964483|NCT00199680|Procedure|PET|
45822449|NCT00004022|Biological|autologous tumor cell vaccine|
45822450|NCT00004022|Biological|muromonab-CD3|
45822451|NCT00004022|Biological|therapeutic autologous lymphocytes|
45822452|NCT00004022|Procedure|surgical procedure|
45822453|NCT00381901|Biological|trastuzumab|
45822454|NCT00381901|Genetic|polymorphism analysis|
45822455|NCT00381901|Procedure|adjuvant therapy|
45822456|NCT00003278|Drug|dexamethasone|
45822457|NCT00003278|Radiation|radiation therapy|
45666831|NCT02264977|Device|GORE® TAG® Thoracic Branch Endoprosthesis|
45666832|NCT02264821|Drug|ropivacaine infiltration|wound infiltration
45666833|NCT02264821|Drug|intrathecal morphine|100 µg added to the spinal anaesthesia
45666834|NCT02264821|Drug|placebo|placebo in spinal anaesthesia and in wound infiltration
45666835|NCT05386147|Device|Flourish HEC Vaginal Care System (contains a class II medical device plus other unregulated components)|see arm description
45666836|NCT05385055|Other|THS use|Subjects (current THS users) will continue using THS in real-life setting
45666837|NCT05385055|Other|Cigarette smoking|Subjects (current cigarette smokers) will continue smoking cigarettes in real-life setting
45822458|NCT00004028|Drug|carmustine|
45822459|NCT00004028|Procedure|conventional surgery|
45822460|NCT00003554|Biological|rituximab|
45822461|NCT00003554|Drug|melphalan|
45822462|NCT00003554|Drug|prednisone|
45822463|NCT04642027|Radiation|Conventional sEBRT|A total dose of70 Gy in 35 daily fractions of 2 Gy during 7 weeks
45822464|NCT04642027|Radiation|Hypofractionated sEBRT|A total dose of 60 Gy in 20 daily fractions of 3 Gy during 4 weeks
45822465|NCT00003284|Biological|filgrastim|
46080133|NCT02813564|Behavioral|Cognitive Assessment & Video-game INtervention Solutions (CAVINS)|"This is a computerized video-game like intervention. The participants will exercise/strengthen the cognitive (mental) deficits that may be responsible for symptom profiles such as socialization impairments, academic disabilities, and repetitive behaviour for several weeks. This program will stimulate communication between brain regions that make up an information processing neural network in order to promote proper network development."
45964484|NCT03758287|Drug|CT053PTSA|
45964485|NCT03758287|Drug|Gefitinib|
45964486|NCT03726346|Device|Toffee Full Face Mask|Participants will be placed on this arm for a total of 14+- 4 days from visit 2. Participants will be using the Toffee mask during this treatment arm.
45455466|NCT01317368|Other|Placebo|"20 mL 0,9% Saline is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Saline 0,9% will be given as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
45964487|NCT00204594|Drug|rM28|
45822466|NCT00003284|Drug|carboplatin|
45964488|NCT00204594|Drug|autologous PBMCs|
45964489|NCT04679779|Other|designed occupational therapy program|Exercises facilitating hand skill patterns will include basic reach, grasp, carry and release and the more complex skills of in-hand manipulation and bilateral hand use.
45964490|NCT04679779|Other|Wii virtual reality games|"Bowling~Frisbee~Basketball~Boxing"
45964491|NCT04679077|Other|Cytocam-IDF imaging device|Observation of the microcirculation
45964492|NCT03722953|Other|Control|"Ultrasound~Blood Pressure~Heart Rate~Oxygen Saturation"
46080134|NCT00939185|Drug|Azithromycin|Zithromax was dispensed according to the Summary of Product Characteristics (SPC) as either a tablet or suspension. Zithromax was administered as a total dose of 30 mg/kg which was given as single daily doses of 10 mg/kg for 3 days, or as a 5 day dose starting with 10 mg/kg on Day 1, then 5 mg/kg on Days 2-5.
46080135|NCT02808026|Drug|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast
45964493|NCT03722953|Other|Aerobic Exercise|"Ultrasound~Blood Pressure~Heart Rate~Oxygen Saturation"
45964494|NCT03697096|Other|Routine Care|Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
45964495|NCT03697096|Other|INSPIRE CPOE Smart Prompt|"Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having a UTI due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards."
45964496|NCT00204633|Drug|Darbepoetin alfa|
45964497|NCT00176111|Procedure|peripheral nerve stimulation (procedure)|
45964498|NCT03635515|Device|Gentlewave|The Gentlewave system from Sonendo is a FDA cleared root canal irrigation device that uses broad spectrum acoustic energy, internally degassed distilled water, 3% NaOCl, and 8% EDTA to allow for a more thorough cleaning within the tooth. The fluids work to remove necrotic tissue, debris, biofilm, and bacteria while leaving dentin intact and preserving tooth structure. The Gentlewave irrigation replaces the NaOCl ultrasonic activation and EDTA steps of the standard endodontic protocol. Use of the Gentlewave system is contraindicated in teeth with immature apices, teeth with insufficient coronal structure, and teeth with root apices extending into the maxillary sinus.
45455467|NCT01329445|Other|DeNovo NT, Natural Tissue Graft|DeNovo NT Natural Tissue Graft of 1 or 2 lesions up to 5 cm squared in area.
45455468|NCT02887040|Radiation|Radiation|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive radiation.
45455469|NCT02887040|Drug|Atengenal|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
45455470|NCT02887040|Drug|Astugenal|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
45455471|NCT01219699|Drug|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
45822467|NCT00003284|Drug|etoposide|
45822468|NCT00003284|Drug|ifosfamide|
45822469|NCT00003284|Drug|paclitaxel|
45822470|NCT00003284|Procedure|peripheral blood stem cell transplantation|
45822471|NCT00003284|Radiation|radiation therapy|
45822472|NCT05749237|Other|respiratory exercises|respiratory exercises
45822473|NCT05749237|Other|relaxation exercises|relaxation exercises
45822474|NCT00384410|Drug|Nabilone|
45822475|NCT00384488|Behavioral|Interactive Voice Response System (IVR)|
45822476|NCT00004040|Biological|recombinant interferon alfa|
45822477|NCT00004040|Biological|rituximab|
45964499|NCT03635515|Procedure|Standard Endodontic Protocol|The tooth will be sufficiently anesthetized with local anesthetic. The tooth will be rubber dam isolated. The pulp chamber will be accessed removing all caries, defective restorations, and defective crowns. EAL and radiographs will be used to determine the working length of each canal, all canals will be cleaned and shaped using rotary files to at least a size 25.04 canal size to within 0.5 to 1 mm of the apical terminus. Between each file 5.25% NaOCl will be used to disinfect and clear the canals of debris. A final passive ultrasonic activation of NaOCl will be done for 30 seconds per canal. Each canal will then soak in 17% EDTA for 1 minute, rinsed in 5.25% NaOCl, and finally undergo a final rinse of 95% ethanol. Canals will be obturated with root canal sealer and gutta-percha.
45964500|NCT00204672|Drug|Achipex|
45964501|NCT03525613|Drug|APL-2|Complement (C3) Inhibitor
45964502|NCT03525613|Drug|APL-2|Complement (C3) Inhibitor
45964503|NCT03525613|Other|Sham Procedure|Subjects will receive a Sham procedure every month
45964504|NCT03525613|Other|Sham Procedure|Subjects will receive a Sham procedure every other month
45964505|NCT00199719|Drug|Ribavirine|
45964506|NCT00176189|Device|All ceramic FPDs|
45964507|NCT03523117|Drug|Ferric carboxymaltose|Intravenous iron
45964508|NCT03523117|Drug|Ferrous Sulfate|oral iron therapy
45455472|NCT01219699|Drug|Fulvestrant|"In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene.~Fulvestrant is an estrogen receptor antagonist, administered by monthly intramuscular injection"
45666838|NCT05385055|Other|Smoking abstinence|Subjects (former cigarette smokers) will continue smoking abstinence (confirmed by cotinine test, with a threshold of < 100 ng/mL)
45964509|NCT00204711|Other|SNAP II EEG System|A portable EEG monitor (SNAP II EEG System, Everest -St. Louis) is unique in that it monitors both low frequency EEG signals (1-40 Hz), which are typically used, and high frequency EEG signals (80-420 Hz), which are not usually used, and calculates a derived EEG parameter (the SNAP Index). The SNAP Index ranges from 100 (completely awake) to 0 (no brain activity) and has been shown in a few studies to correlate with increasing sedation and loss of consciousness in human volunteers and patients receiving general anesthesia during surgery.
45964510|NCT03514186|Behavioral|Speech and Language Therapy|"Includes:~one hour of individual therapy using a multimodality treatment called Verb Network Strengthening Treatment (VNeST) that simultaneously targets semantics (word retrieval) and syntax (sentence construction);~one hour of constraint induced language therapy (CILT) where participants are paired and practice requesting and providing specific information using only spoken language;~one hour in the computer lab working on programs called Oral Reading for Language in Aphasia (ORLA) and AphasiaScripts; and~one hour in a conversation group that emphasizes multimodality communication"
45964511|NCT03430882|Drug|Carboplatin|Given IV
45964512|NCT03430882|Drug|Paclitaxel|Given IV
45964513|NCT03430882|Drug|Sapanisertib|Given PO
45455473|NCT03933319|Drug|pegylated liposomal doxorubicin|Eligible patients will be treated with the PLD+trastuzumab regimen until the disease progresses or intolerable toxicity
45455474|NCT04587440|Other|Pelvic inclination measurement|Ultra-sound based measurements of the pelvic inclination lying, standing and seating position. EOX X-ray in seating position.
45455475|NCT01223053|Drug|Ketoprofen 10% cream|100 mg (10%) in 1 gram of topical cream applied three times per day for 7 days. Safety follow up on day 14.
45666839|NCT04854889|Drug|Decitabine|Demethylating agents
45666840|NCT02261467|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
45666841|NCT02261467|Drug|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
45666842|NCT05646823|Dietary Supplement|Probiotic blend|Bifidobacterium longum CCT 1934; Bifidobacterium lactis CCT 7858; Lactobacillus rhamnosus CCT 7863; Streptococcus thermophilus ATCC 19258) Final concentration: 1 x 10e10 CFU/ day
45666843|NCT05646823|Dietary Supplement|Placebo|vehicle only - Maltodextrin gluten free
45964514|NCT03374254|Biological|Pembrolizumab|200 mg Pembrolizumab solution for IV infusion Q3W
45964515|NCT03374254|Drug|Binimetinib|tablet orally BID at 30 or 45 mg depending upon DLT profile
45964516|NCT03374254|Drug|Oxaliplatin|85 mg/m^2 as IV infusion. Administered Q2W as part of mFOLFOX7 cocktail. Dose may be de-escalated to 70 mg/m^2 if the standard dose of mFOLFOX7 is deemed too toxic per mTPI, based upon occurrence of DLTs.
45964517|NCT03374254|Drug|Leucovorin|400 mg/m^2 as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation.
45964518|NCT03374254|Drug|5-Fluorouracil [5-FU]|2400 mg/m^2 over 46-48 hours as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation. Dose may be de-escalated to 2000 mg/m^2 if the standard dose of mFOLFOX7 or FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
45964519|NCT03374254|Drug|Irinotecan|180 mg/m^2 as IV infusion. Administered Q2W as part of FOLFIRI cocktail. Dose may be de-escalated to 150 mg/m^2 if the standard dose of FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
45964520|NCT00199758|Drug|cisplatin|
45964521|NCT00199758|Drug|Gemcitabine|
45964522|NCT00199758|Drug|Taxol|
45964523|NCT03291886|Drug|Entinostat|Given PO
45964524|NCT03291886|Drug|Entinostat(Placebo)|Given PO
45964525|NCT03291886|Drug|Exemestane|Given PO
45964526|NCT04679116|Procedure|Laparoscopic bilateral inguinal hernia repair|Laparoscopic bilateral inguinal hernia repair
45964527|NCT04679116|Procedure|Open bilateral inguinal hernia repair|Open bilateral inguinal hernia repair
45964528|NCT00204750|Procedure|Bougie Dilation|Bougie dilation will be performed as standard
45666844|NCT04864405|Other|Morning administration of endocrine therapy|Endocrine therapy administered within one hour of patient wake up time
45666845|NCT04864405|Other|Evening administration of endocrine therapy|Endocrine therapy administered within one hour of the patient bed time
45822478|NCT00384254|Behavioral|5 A|Dental providers are trained to provide Ask, Advise, Assess, Assist and Arrange to all tobacco using patients. Written materials are provided, including information on local cessation resources, pharmacotherapy and tobacco quitlines.
46080136|NCT00925639|Drug|Isoflavone|150 mg of concentrated extract of soy containing 60 mg of isoflavone comprising 40 mg of genistein, 14,55 mg of daidizein, 3,02 mg of daidzine, 1,14 mg of glicitine, 0,91 mg genistine and 0,38 mg of glicetein.
45822479|NCT00384254|Behavioral|3 A|Providers are trained to provide Ask, Advise and Arrange intervention to all tobacco using patients. Written materials, prescription for NRT and a Fax-to-Quit referral are provided.
45822480|NCT05630911|Other|Standing tasks with different task difficulty|The three different standing positions will include wide-base standing on foam (WBF) with low-level of task difficulty, narrow-base standing on foam (NBF) with moderate-level of task difficulty, and tandem standing on foam (TAF) with high-level of task difficulty.
45964529|NCT00204750|Procedure|Needle-knife incision|Needle-knife incision will be performed
45964530|NCT03252808|Biological|TBI-1401(HF10)|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered by intratumoral injection at 2-week intervals. Patients may continue to receive the injections for up to 1 year if eligible for injection.
45964531|NCT03252808|Drug|Gemcitabine|1000 mg/m^2 Gemcitabine administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
45964532|NCT03252808|Drug|Nab-paclitaxel|125 mg/m^2 Nab-paclitaxel administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
45964533|NCT03252808|Drug|TS-1|TS-1 (40-60 mg per body surface area) administered by oral at twice daily for 4 weeks followed by 2 weeks of rest.
45964534|NCT00176345|Behavioral|Exercise Training|
45964535|NCT03191461|Diagnostic Test|Adenosine stress test MRI|Participants will receive a contrasted adenosine stress CMR examination on a 1.5T Siemens Avanto scanner (Siemens Medical Solutions, Malvern, PA) dedicated to cardiovascular imaging. Adenosine stress was selected due to attenuated endothelium dependent and -independent vasodilation after doxorubicin receipt in humans to allow the investigators to understand the potential effect of perivascular fibrosis on perfusion reserve. Standardized CMR protocols will be performed to measure LV volumes (to assess wall motion abnormalities and identify any potential myocardial dysfunction), Native T1, ECV, and myocardial perfusion reserve in the short-axis plane
45964536|NCT00199953|Drug|Rabeprazole 20 mg twice a day for 90-day period treatment|
45822481|NCT00004046|Drug|exatecan mesylate|
45822482|NCT00003560|Drug|carboplatin|
45822483|NCT00003560|Drug|docetaxel|
45964537|NCT03184090|Drug|Palbociclib|palbociclib in combination with endocrine therapy (investigator's choice)
45964538|NCT03184090|Drug|Endocrine therapy (non IMP)|Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be different from previous treatment line.
45964539|NCT03160846|Drug|Inotrope|Home intravenous infusion of Dobutamine, Dopamine, or Milrinone
45964540|NCT00176384|Behavioral|Aerobic endurance exercise training (ergometer)|
45964541|NCT00204789|Drug|Difluoromethylornithine|
45964542|NCT00176540|Drug|dextromethorphan hydrobromide|
45964543|NCT02968381|Behavioral|Imagery Intervention|Telephone coaching sessions, use of guided imagery and website.
45666846|NCT05646667|Other|interscalene with Erector spinae plane block group|patients will receive interscalene brachial plexus block using 10 ml of bupivacaine 0.5% and US guided Erector spinae plane block at T2 using 10 ml of bupivacaine 0.5%.
45666847|NCT05646667|Other|Interscalene group|patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5%.
45964544|NCT02968381|Behavioral|Control Condition|Telephone coaching using standard cognitive behavioral methods
45964545|NCT00199992|Procedure|application of autologous platelet gel|
45964546|NCT02901496|Behavioral|Endurance Exercise Training|Three months of supervised training. Interval training, 3 sessions weekly of 45 min. During intervals the intensity will be minimum 70 % of VO2 max
45822484|NCT00002671|Drug|aminocamptothecin|
45822485|NCT00003290|Biological|gonadotrophin releasing hormone|
46080137|NCT00925639|Drug|Placebo|Starch pill
46080138|NCT02808104|Drug|mazindol|
46080139|NCT05165771|Drug|GS-5718|Tablets administered orally
46080140|NCT05165771|Drug|GS-5718|Tablets administered orally
45822486|NCT00003290|Radiation|radiation therapy|
45822487|NCT00002677|Drug|chemotherapy|
45822488|NCT00002677|Drug|tributyrin|
45822489|NCT05749003|Other|sensorimotor training exercise|Patients will be trained through three stages: static, dynamic and functional. Each exercise will be repeated 3-5 times during a session and with enough periods of rest between each set of exercises. The exercise graduated from easy to more difficult and the patient was not progressed to a more difficult stage until performing the easier one.
45822490|NCT05749003|Other|conventional physical therapy program of exercise.|stretching exercise for 30 minutes, then strengthening exercise and usual burn care for the lower extremity. Exercises will be applied for 3 times a week for 8 consecutive weeks.
45822491|NCT00003566|Procedure|videothoracoscopy|
45964547|NCT02901496|Behavioral|Resistance Exercise Training|Three months of supervised resistance training. Subjects will perform 3 weekly sessions of 45 min. The intensity will be kept at minimum 60% of 1RM.
45964548|NCT02901496|Behavioral|No Exercise|Control to exercise
45964549|NCT02901496|Drug|Tocilizumab|Tocilizumab infusion will be administered monthly (8 mg/kg body weight i.v., maximun 800 mg). Each subject will receive 3 infusions during the study period.
45666848|NCT05646589|Behavioral|Person-centred care transition support|A set of activities targeting how healthcare professionals can improve quality with care transition and support health literacy for self-management of secondary stroke prevention for persons who are to be discharged from hospitals after stroke or TIA
45964550|NCT02901496|Drug|Placebo|Saline infusion will be administered monthly (same volume as Tocilizumab). Each subject will receive 3 infusions during the study period.
45964551|NCT00176579|Procedure|dual x-ray absorptiometry|Dual x-ray absortiometry by densitometer will be performed to measure bone mineral density
45964552|NCT02830360|Drug|Antiarrythmic Drug Therapy|Patients will be prescribed antiarrhythmic drugs (either amiodarone or sotalol based on specific clinical presentation, including medical history, functional class, ejection fraction, and renal function.)
45964553|NCT02830360|Procedure|Catheter ablation|Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
45964554|NCT02827435|Drug|Rocuronium bromide|Pharmacokinetic-pharmacodynamic modeling blood sampling and Rocuronium bromide concentration measure muscle relaxation evaluation
45964555|NCT00176618|Drug|sulindac|Sulindac 150 mg po BID
45964556|NCT00176618|Drug|curcumin|Curcumin 250 mg po BID
45964557|NCT02675959|Drug|Defibrotide|defibrotide will be given prophylactically prior to AlloSCT to determine if it decreases the incidence of SOS in this high risk population, and determine that it is safe and feasible to give along with myeloimmunoablative therapy and allogeneic transplant.
45964558|NCT02657005|Drug|TK216|Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein
45666849|NCT05646589|Behavioral|Regular care transition|Regular care transitions, initiated by an electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
45822492|NCT05748925|Drug|dapagliflozin|The patients will be randomized into two groups Study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food.
45964559|NCT00410787|Drug|OROS hydromorphone HCI (slow release)|
45964560|NCT00554164|Drug|(R-)CHOP protocol|Patients with a persistently positive interim-PET scan assigned to arm B1 will receive another six cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone).
45964561|NCT00554164|Drug|B-ALL protocol|Patients with a persistently positive interim-PET scan assigned to arm B2 will receive six blocks of the B-ALL protocol (rituximab, methotrexate, ifosfamide, etoposide, cytarabine, vincristine, cyclophosphamide, doxorubicine, vindesine, dexamethasone).
45964562|NCT00554164|Drug|(R-)CHOP protocol|Patients with a negative interim-PET scan assigned to arm A1 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone). Arm A1 was closed when the number of patients required for the randomisation between arms A1 and A2 was reached.
45964563|NCT00554164|Drug|(R-)CHOP protocol|Patients with a negative interim-PET scan assigned to arm A2 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone) plus two additional doses rituximab. Since the number of patients required for the randomisation between arms A1 and A2 has been reached, all patients with a negative interim-PET scan are treated according to arm A2.
45964564|NCT00176657|Drug|HEMOBAG Assessment|
46080141|NCT05165771|Drug|Placebo to match GS-5718|Tablets administered orally
45822493|NCT05748925|Drug|placebo|Control group: will be maintained on their medication
46080142|NCT05165771|Drug|Tofacitinib 5 mg|Tablets administered orally
45666850|NCT05348083|Procedure|ESPB|Echo-guided bilateral ESPB performed at T9 level at the end of surgery with a mixture of ropivacaine 0.375% and epinephrine 5 mcg/mL 20 mL each side.
45822494|NCT00003572|Biological|peripheral blood lymphocyte therapy|
45822495|NCT00003572|Drug|mycophenolate mofetil|
46080143|NCT05165771|Drug|Placebo to match Tofacitinib|Tablets administered orally
45822496|NCT00003572|Drug|tacrolimus|
45822497|NCT00003572|Procedure|allogeneic bone marrow transplantation|
45822498|NCT00003572|Radiation|radiation therapy|
46080144|NCT00929461|Drug|Lipovenoes® 10% and Omegaven®,|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
45455476|NCT01223053|Drug|Placebo|Matching placebo cream containing identical constituents as the active comparator except for ketoprofen
45822499|NCT00004052|Biological|QS21|
45822500|NCT00004052|Biological|bcr-abl peptide vaccine|
45822501|NCT05625217|Diagnostic Test|Total Body PET/CT Imagin|Total-body PET imaging at different timepoints
45822502|NCT00004058|Drug|tetradecanoylphorbol acetate|
45822503|NCT00002689|Drug|dexamethasone|
45822504|NCT00002689|Drug|fluorouracil|
45822505|NCT00002689|Radiation|brachytherapy|
45822506|NCT00002689|Radiation|phosphorus P32|
45822507|NCT00002689|Radiation|radiation therapy|
45822508|NCT00003296|Biological|filgrastim|
45822509|NCT00003296|Drug|pegylated liposomal doxorubicin hydrochloride|
45822510|NCT00004064|Biological|oregovomab|
45822511|NCT00003302|Procedure|biopsy|
45822512|NCT00003302|Diagnostic Test|magnetic resonance imaging|
45822513|NCT00003302|Diagnostic Test|mammography|
45822514|NCT00382057|Drug|Testosterone|
45964565|NCT02572141|Drug|Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens|mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 6 cycles followed by colectomy (3 to 5 weeks after) followed by mFOLFOX6 (6 cycles); CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by CAPOX (4 cycles).
45666851|NCT01643473|Behavioral|Adherence Intervention|Patients randomized to the TAI group will complete a tailoring survey at the baseline visit to identify the most salient adherence barriers to the individual, which will be used to create an individualized adherence profile. Following completion of the tailoring survey, patients will collaborate with the RA to identify the most suitable mix of intervention strategies for improving medication adherence (i.e., reminder aids, motivational interviewing, case management) that are matched to the barriers outlined on patients' individualized adherence profiles.
45964566|NCT02572141|Drug|Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens|Colectomy (maximum 4 weeks after randomization) followed by mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 12 cycles; Colectomy (maximum 4 weeks after randomization) followed by CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 8 cycles
45964567|NCT00410865|Genetic|INGN 201|Mouth rinse given one time on the first day and two times on Days 2-5 of each course of INGN 201. The injection and rinse (first day of each cycle), or the two rinses (Days 2-5 of each cycle), will be separated by at least two hours.
45964568|NCT02470039|Drug|insulin 338 (GIPET I)|Oral administered once daily in combination with metformin with or without DPP-4 inhibitor
45964569|NCT02470039|Drug|insulin glargine|Injected s.c./subcutaneously (under the skin) once daily in combination with metformin with or without DPP-4 inhibitor
45964570|NCT02470039|Drug|placebo|Administered once daily
45964571|NCT00176696|Device|Use of FACE monitor and BIS monitor|Face monitor records facial muscle activity
45964572|NCT02459236|Drug|CERC-301|CERC-301, a highly selective, orally bioavailable, NMDA receptor subunit 2B (NR2B), also referred to as Glutamate NMDA receptor subunit epsilon-2 (GluN2B) antagonist
45964573|NCT02459236|Drug|Placebo|
46080145|NCT04225832|Behavioral|CBT Coping Intervention|A cognitive behavior therapy group intervention for HIV-negative Latinx sexual minority men aimed at increasing HIV testing and prevention strategies.
45666852|NCT01643473|Other|Attention Control|Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
45666853|NCT05646277|Other|e-Consultation|first orthodontic consultation in remote
45822515|NCT00382057|Drug|Anastrozole|
45964574|NCT00200031|Device|Interstim therapy|
45964575|NCT00554203|Drug|Sulfasalazine|sulfasalazine 2 grams daily for 6 weeks
45822516|NCT00382057|Drug|Goserelin|
45964576|NCT00554242|Dietary Supplement|Grape seed extract and ascorbic acid|Grape seed extract 450 mg and ascorbic acid 1500 mg daily
45964577|NCT00176735|Drug|Capecitabine|
45964578|NCT00554281|Device|Use of glucose sensor (Paradigm Guardian)|Use glucose sensor to prevent episodes of severe hypoglycemia
45964579|NCT00554320|Procedure|tDCS|During each session, the anode electrode will be placed on the motor cortex (contralateral to the most [or predominant] painful side [or the side where the symptoms begin or the left as a default]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
45964580|NCT00554320|Procedure|tDCS|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
46080146|NCT02730624|Drug|Piperacillin-tazobactam|4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h and blood sample were obtained by direct venepuncture at 0, 0-0.5, 0.5-2, 2-4 and 4-6 hour after drug administration
46080147|NCT02807870|Drug|Methylphenidate|Methylphenidate treatment with a initial dosage of 0,3 mg/kg per day (weekly dosage adjustments).
45822517|NCT00003578|Drug|CHOP regimen|
45964581|NCT00410943|Drug|OROS Hydromorphone HCI SR (slow release)|
45964582|NCT03455101|Other|There is no intervention.|There is no intervention.
45964583|NCT00176774|Drug|Irinotecan|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
45964584|NCT00176774|Drug|5-Fluorouracil|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
45964585|NCT00176774|Drug|Leucovorin|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
46080148|NCT02807870|Behavioral|Parental training|Weekly parental training conducted by behavioral psychologists.
45666854|NCT05646277|Other|Consultation|first orthodontic consultation in face-to-face
45822518|NCT00003578|Drug|carmustine|
45822519|NCT00003578|Drug|cyclophosphamide|
45822520|NCT00003578|Drug|cytarabine|
45822521|NCT00003578|Drug|doxorubicin hydrochloride|
45822522|NCT00003578|Drug|etoposide|
45822523|NCT00003578|Drug|melphalan|
45822524|NCT00003578|Drug|prednisone|
45822525|NCT00003578|Drug|vincristine sulfate|
45822526|NCT00003578|Procedure|autologous bone marrow transplantation|
45822527|NCT00003578|Procedure|peripheral blood stem cell transplantation|
45822528|NCT05617651|Drug|IY-NT-T|Ilaprazole 20mg
45822529|NCT05617651|Drug|IY-NT-R|Ilaprazole 10mg
45964586|NCT00176774|Drug|Tetrathiomolybdate|one 40 mg oral (by mouth) dose of TM three times a day with meals and one 60 mg oral dose (without food) at bedtime beginning at bedtime on day 1 of your first 6-week cycle of treatment. The between meal dose must be taken at least one hour before or one hour after a meal.
45964587|NCT02434744|Drug|KD026|Dosed in combination
45964588|NCT02434744|Drug|Placebo|Dosed in combination
45964589|NCT02434744|Drug|Metformin|Drug prescribed by each subject's prescribing physician
45964590|NCT02429167|Device|Cranial nerve non-invasive neuromodulation via PoNS device|The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
45964591|NCT02429167|Device|Sham PoNS device|The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. The sham control device is physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, minimizing any neuromodulatory effect. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
45964592|NCT02421679|Drug|TNX-102 SL|TNX-102 Sublingual tablets
45964593|NCT00200070|Device|Spinal Cord Stimulation|
45964594|NCT02389777|Biological|ST266 immediate|ST266 will be applied immediately to the UV light burn wound topically by spray twice per day
45964595|NCT02389777|Biological|ST266 delayed|ST266 will be applied to the UV light burn topically by spray twice per day beginning 6-12 hours after the burn
45964596|NCT02387788|Drug|AKB-9778|Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
45964597|NCT02383810|Drug|Elsiglutide|
46080149|NCT02807870|Other|Psychoeducational groups for parents|Weekly psychoeducational groups conducted by educators.
46080150|NCT02807870|Drug|Placebo pill|Placebo pill during 8 weeks.
46080151|NCT00925795|Other|consumption 1. EVOO; 2. ROO|EVOO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by ROO in doses of 50 mL/daily for 20 days
46080152|NCT00925795|Other|consumption 1. ROO; 2. EVOO|ROO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by EVOO in doses of 50 mL/daily for 20 days
46080153|NCT02739438|Other|Electronic cigarette use|Subjects who use electronic cigarettes daily and have not used conventional cigarettes in the previous 3 months.
45666855|NCT05344651|Device|Surgery/implantation|The glaucoma drainage device consists of a plate and a tube. During surgery the plate is positioned underneath the conjunctiva and two extraocular muscles in the upper temporal quadrant of the eye. The tube is positioned in the anterior chamber.
45822530|NCT05615857|Device|Use of Endocuff during colonoscopy|We will be adding the Endocuff device to the proximal end of the colonoscope, adding an additional tool to facilitate the visualization of the difficult-to-see mucosal areas as well as the rectum. There will be no need for retroflexion to evaluate the colon
45822531|NCT05748691|Diagnostic Test|Clinical implementation of hs-cTnT|To investigate the clinical impact on the transition from a hs-cTnI assay to a hs-cTnT assay in consecutive patients presenting to the Emergency Department or Acute Medical Unit with suspected acute coronary syndrome.
45666856|NCT05341843|Drug|sertraline|sertraline at the intended dose of 50 mg twice daily for 8 weeks.
45666857|NCT05341843|Drug|placebo|a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 8 weeks)
45666858|NCT05646199|Drug|Metformin|Participants will receive metformin
45666859|NCT05646199|Drug|Semaglutide Injectable Product|Participants in this group will receive injectable Semaglutide
45822532|NCT00003584|Drug|estramustine phosphate sodium|
45822533|NCT00003584|Drug|prednisone|
45822534|NCT00003584|Drug|vinorelbine tartrate|
45822535|NCT00002701|Drug|busulfan|
45964598|NCT02383810|Drug|Placebo|
45964599|NCT00410982|Drug|Busulfan|Day -10 = 32 mg/m^2 Intravenous Test Dose; Days -8 thru -5 = 105 mg/m^2 Intravenous
45964600|NCT00410982|Drug|Gemcitabine|Day -8 = 75 mg/m^2 Intravenous bolus; Day -3 = 75 mg/m^2 Intravenous bolus.
45964601|NCT00410982|Drug|Melphalan|Day -3 and Day -2 = 60 mg/m^2 Intravenous.
45964602|NCT00410982|Other|Hematopoietic Cell Transplantation|Infusion of stem cells on Day 0.
45964603|NCT00410982|Drug|Rituximab for Patients with B-Cell Malignancies|375 mg/m^2 Intravenous on Days 1 and 8.
45964604|NCT00410982|Drug|Palifermin|60 microgram/kg by vein on Days -13 to -11 and Days 0, +1, +2
45964605|NCT02372578|Drug|ASP3662|oral
45964606|NCT02372578|Drug|pregabalin|oral
45964607|NCT02372578|Drug|ASP3662 placebo|oral
45964608|NCT02372578|Drug|pregabalin placebo|oral
45964609|NCT02367313|Drug|Vapendavir|Vapendavir 264 mg twice daily
45964610|NCT02367313|Drug|Vapendavir|Vapendavir 528 mg twice daily
45964611|NCT02367313|Drug|Placebo|Placebo twice daily
45964612|NCT00410319|Behavioral|Fear-reducing Information|
45964613|NCT00410319|Behavioral|Symptom-based exercise|
45964614|NCT02363491|Drug|OPN-305|For the dose confirming part of the study, patients will receive a starting dose of 5 mg/kg OPN-305.
45964615|NCT00554359|Drug|I5NP (a small interfering RNA)|Single IV injection of experimental drug
45964616|NCT00554359|Drug|placebo|Single IV injection of saline
45964617|NCT00411021|Procedure|Pipelle (Endometrial Sampling)|
45964618|NCT00554398|Drug|MK-0518 400mg twice a day|Raltegravir, MK-0518
45822536|NCT00002701|Drug|cyclophosphamide|
45822537|NCT00002701|Drug|cytarabine|
45822538|NCT00002701|Drug|etoposide|
45666860|NCT05646121|Device|Suprasorb® A + Ag wound dressing and rope|Suprasorb® A + Ag Antimicrobial Calcium Alginate Wound Dressings / Packing Rope are soft, conformable wound coverings with a high mannuronic acid content (mass per unit area ≥100 g/m2). The silver impregnated calcium alginate fibres react with wound exudate or blood to form a gel which creates a moist wound environment. The silver contained in the wound dressing has broad antimicrobial activity, including against MRSA and VRE. Antimicrobial action (>3 log steps) associated with the ionic silver from the silver alginate fibres (1.5%) is observed in vitro after just 24 h and this remains stable for up to seven days
45822539|NCT00002701|Drug|idarubicin|
45822540|NCT00002701|Drug|mercaptopurine|
45822541|NCT00002701|Drug|methotrexate|
45822542|NCT00002701|Drug|mitoxantrone hydrochloride|
45822543|NCT00002701|Drug|thioguanine|
45964619|NCT00554437|Behavioral|UW Falls Prevention Program|The intervention model is of a community-based multifactorial intervention that links participants to existing medical care and service networks. The intervention used an algorithm based on the University of Wisconsin Falls Prevention Clinic, designed to identify predisposing factors for falls; induce risk reduction changes in medical conditions, medications, behavior, physical status, and home environment through recommendations to participants and their physicians; and make sure these changes are long-lasting through follow-up and linkages to other care networks.
45964620|NCT00554476|Drug|Triamcinolone Acetonide- Indomethacin-Cryotherapy-Casting|
45964621|NCT00204867|Other|CTC surveillance|In vivo CTC surveillance of 6-9 mm polyp
45964622|NCT02349022|Radiation|[89Zr]Df-IAB2M|
45964623|NCT02343445|Drug|P-1037|P-1037 is a novel ENaC inhibitor
45964624|NCT02343445|Drug|Hypertonic Saline|4.2% saline solution
45964625|NCT02343445|Drug|Saline|0.17% saline solution
45964626|NCT02338648|Drug|SUN-131 1.5% TDS|Active transdermal patch
45964627|NCT02338648|Drug|Placebo TDS|Placebo transdermal patch for blinding
45964628|NCT02336698|Drug|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
45964629|NCT02336698|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
45964630|NCT02336698|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
45964631|NCT00204906|Dietary Supplement|vitamin D supplementation|
45666861|NCT02258659|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
45666862|NCT02258659|Drug|carboplatin|Given IV
45666863|NCT02258659|Radiation|radiation therapy|Undergo radiation therapy
45964632|NCT02335918|Drug|Combination of varlilumab and nivolumab|"Phase I: Varlilumab dosing will be dependent on the cohort assigned in combination with 3 mg/kg of nivolumab every two weeks.~Phase II: Patients with CRC, RCC or GBM enrolled in Phase ll will receive 3.0 mg/kg of varlilumab in combination with 240 mg of nivolumab every 2 weeks. Patients with SCCHN or ovarian cancer will receive varlilumab at a dose of either 3 mg/kg every 2 weeks, 3 mg/kg every 12 weeks, or 0.3 mg/kg every 4 weeks, in combination with 240 mg of nivolumab every 2 weeks.~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
45964633|NCT00200109|Device|Occipital Nerve Stimulation|Each group had a different plan
45964634|NCT04679155|Behavioral|Eating Time Restriction|early vs late time of day restriction
45666864|NCT02258659|Drug|paclitaxel|Given IV
45666865|NCT02258659|Drug|fluorouracil|Given IV
45666866|NCT02258659|Drug|hydroxyurea|Given PO
45666867|NCT02258659|Drug|cisplatin|Given IV
45666868|NCT02258659|Other|laboratory biomarker analysis|Correlative studies
45666869|NCT02258659|Procedure|quality-of-life assessment|Ancillary studies
45666870|NCT02320058|Drug|Ipilimumab|
45666871|NCT02320058|Drug|Nivolumab|
45822544|NCT00002701|Drug|tretinoin|
45822545|NCT00002701|Procedure|allogeneic bone marrow transplantation|
45822546|NCT00002701|Procedure|autologous bone marrow transplantation|
45822547|NCT00002701|Radiation|radiation therapy|
45822548|NCT00004070|Biological|IL-12|
45822549|NCT00003320|Procedure|surgical procedure|
45822550|NCT00003320|Radiation|radiation therapy|
45822551|NCT00003320|Radiation|stereotactic radiosurgery|
45822552|NCT05748613|Behavioral|Computerized Anxiety Sensitivity Treatment|Brief computerized treatment for anxiety sensitivity
45822553|NCT05748613|Behavioral|Health Education Control|Brief computerized presentation on healthy behaviors
45822554|NCT00004076|Drug|mureletecan|
45822555|NCT00004082|Drug|carboplatin|
45822556|NCT00004082|Drug|docetaxel|
45822557|NCT00004082|Drug|gemcitabine hydrochloride|
45822558|NCT00002707|Drug|Cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
45822559|NCT00002707|Drug|Docetaxel|100 mg/m2 IV every 21 days for 4 cycles
45822560|NCT00002707|Drug|Doxorubicin|60 mg/m2 IV every 21 days fo 4 cycles
45822561|NCT00002707|Drug|Tamoxifen|20 mg p.o. once daily for 5 years starting on day 1 of ther first AC cycle
45822562|NCT00003596|Drug|cisplatin|
45822563|NCT00003596|Drug|fluorouracil|
45964635|NCT04678609|Other|Exercise|CKC: exercise with joints fixed on the ground OKC: exercise with joints not fixed on the ground
45964636|NCT00176813|Drug|Gemcitabine|
45964637|NCT00176813|Drug|Cisplatin|
45964638|NCT00176813|Drug|Celecoxib|
45964639|NCT04678375|Diagnostic Test|Retinal diseases diagnosed by artificial intelligence algorithm|An artificial intelligence algorithm was applied to diagnose referral diabetes retinopathy, referral age-related macular degeneration, referral possible glaucoma, pathological myopia, retinal vein occlusion, macular hole, macular epiretinal membrane, hypertensive retinopathy, myelinated fibers, retinitis pigmentosa and other retinal lesions from fundus photography.
45964640|NCT04678531|Drug|Swabs containing tea tree oil and chamomile oil|Swabs will be used in 26 patients for 8 weeks and will be discontinued in the following 4 weeks.
45964641|NCT04678531|Drug|Baby shampoo|Baby shampoo will be used in 23 patients for 8 weeks and will be discontinued in the following 4 weeks.
45964642|NCT04678063|Other|Exposure to Placebo|Patients are exposed to placebo in the EEC
46080154|NCT02739438|Other|Cigarette use|Subjects who smoke at least ¼ pack cigarettes per day for the past 1 year, with no history of electronic cigarette use in the last 30 days.
46080155|NCT02739438|Other|Control group|Subjects with no history of prior conventional cigarette (< 100 cigarettes lifetime) or electronic cigarette use.
46080156|NCT03372720|Procedure|Laser Therapy|Undergo fractional CO2 laser therapy
45964643|NCT04678063|Other|Exposure to dose A and dose B of cat allergen|Patients are exposed to dose A and B for successive exposures in the EEC
45964644|NCT04678063|Other|Exposure to a single dose of cat allergen|Patients are exposed to a single dose of cat allergen in the EEC according to the dose selected to achieve the main objective (dose A or B)
45964645|NCT02332759|Device|Materna Medical|
45964646|NCT02330653|Biological|Fecal Microbiota Transplant (FMT)|The study intervention consists of frozen, bottled or encapsulated fecal microbiota preparations that have been screened and prepared to a uniform and rigorous standard by OpenBiome. FMT is performed by patients receiving a retention enema and swallowing capsules, introducing stool from a healthy donor into their intestinal tract.
45964647|NCT02330653|Biological|Placebo|Placebo administration will consist of both a placebo retention enema and placebo capsules.
45964648|NCT02320708|Drug|Acetaminophen (ACE) (1000 mg)|2 Test ACE 500 mg tablets taken orally one time
45964649|NCT02320708|Drug|Commercial ACE (1000 mg)|2 ACE 500 mg caplets taken orally one time
45964650|NCT02320708|Drug|Commercial Ibuprofen (IBU) (400 mg)|2 IBU 200 mg soft-gels taken orally one time
46080157|NCT03372720|Other|Questionnaire Administration|Ancillary studies
46080158|NCT03372720|Procedure|Sham Intervention|Undergo sham laser therapy
46080159|NCT02807792|Device|Perianal access device|Perianal access device
45666872|NCT02319668|Drug|0.2% w/v Chlorhexidine digluconate|Participants will brush their teeth with the reference product (toothpaste) and thoroughly rinse their mouth with water and wait 5 timed minutes before using 10 ml of the 0.2% w/v Chlorhexidine digluconate mouthwash, except when using at site, where no brushing will take place prior to using the mouthrinse.
45666873|NCT02319668|Drug|Sodium fluoride toothpaste (Aquafresh Mild & Minty)|Participants will apply a strip of toothpaste to cover the head of the toothbrush and will brush in their usual manner for two timed minutes twice daily. They will then rinse their mouth thoroughly with water after brushing
45666874|NCT02092467|Drug|tofacitinib|Oral tablet, 5 mg BID
45822564|NCT00003596|Drug|mitomycin C|
45964651|NCT02320708|Drug|Placebo|2 placebo caplets for acetaminophen taken orally one time
45964652|NCT02320708|Drug|Placebo|2 placebo soft-gels for ibuprofen taken orally one time
45964653|NCT02320708|Drug|Placebo|2 placebo tablets for Test acetaminophen taken orally one time
46080160|NCT00925873|Drug|Active comparator (no fludarabine)|"Ara-C (100 mg/m2/d by continuous IV infusion 7 days), idarubicin (8 mg/m2/d (IV) for 5 days), GM-CSF a dose of 5 mg/kg/d on day 1. (Novartis Laboratory, Rueil-Malmaison, France).~The consolidation course: intermediate-dose Ara-C (1g/m2 g 3-hour infusion twice a day 1 through 3) and idarubicin (10 mg/m2 on days 4 through 5). In the allocated arm~Maintenance therapy for one year with 6-thioguanine (100 mg/m2/d orally on days 1 through 4 every week, Ara-C (60 mg/m2 SC on day 5 weekly) interrupted every 3 months with a reinduction course including CCNU (40 mg orally on day 1), mitoguazone (350 mg/m2 on day 1) and Ara-C (40 mg/m2 sc twice daily day 1 to 5)"
45964654|NCT02310802|Drug|OBE001 dose 1|OBE001 dispersible tablets for single oral administration
45964655|NCT02310802|Drug|OBE001 dose 2|OBE001 dispersible tablets for single oral administration
46080161|NCT00925873|Drug|Experimental (fludarabine)|"The same regimen with addition of fludarabine in every treatment sequence~Induction course: Fludarabine (20 mg/m2/d, IV for 30 minutes) was started in the assigned group on day 2 and continued until the end of cytarabine treatment on day 7.~Consolidation course: In the allocated arm, fludarabine (20 mg/m2/d, IV) was administered on days 2 through 3, 4 hours prior to cytarabine infusion.~Reinduction courses: Ara-C associated in the allocated group with fludarabine (20 mg/m2/d, IV) on days 1 through 2."
45822565|NCT00003596|Radiation|radiation therapy|
45822566|NCT05608993|Other|High Intensity Intervention|The High Intensity intervention will include clinician education, individualized clinician audit and feedback with peer comparison, and electronic health record (EHR) changes of prescription fields.
45822567|NCT05608993|Other|Low Intensity Intervention|The Low Intensity intervention will include clinician education and EHR changes only.
45822568|NCT05747365|Diagnostic Test|Blood and urine diagnostic evaluation|Blood and urine samples will be obtained from both case and control groups in order to evaluate EDCs concentrations
45822569|NCT00002719|Biological|filgrastim|
45822570|NCT00002719|Drug|amsacrine|
45822571|NCT00002719|Drug|carmustine|
45822572|NCT00002719|Drug|cytarabine|
45964656|NCT02310802|Drug|OBE001 dose 3|OBE001 dispersible tablets for single oral administration
45964657|NCT02310802|Drug|Placebo|Placebo dispersible tablets for single oral administration
45964658|NCT02310412|Biological|INTERCEPT treated platelets|
45964659|NCT02309671|Drug|FE 999049|
45964660|NCT02309671|Drug|follitropin beta|
45964661|NCT02296645|Drug|ZuraPrep|Apply topically.
45964662|NCT02296645|Drug|ChloraPrep|Apply topically.
45964663|NCT02295865|Drug|JNJ-38518168 60 mg|Two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, orally, once daily.
45964664|NCT02295865|Drug|JNJ-38518168 30 mg|One tablet of JNJ-38518168, 30 mg, orally, once daily.
45964665|NCT02295865|Drug|JNJ-38518168 3 mg|One tablet of JNJ-38518168, 3 mg, orally, once daily.
45964666|NCT02295865|Drug|Placebo|Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.
45964667|NCT02288845|Drug|ITI-007|
45964668|NCT02283229|Behavioral|Newborns with preventive caring advices|Advices to prevent head molding
45964669|NCT02283229|Other|Newborns with normal caring advices|Normal handling
45964670|NCT02282761|Drug|ITI-007|
45964671|NCT02282761|Drug|Placebo|
45822573|NCT00002719|Drug|etoposide|
45964672|NCT02282215|Biological|CLT-008|Single intravenous infusion
45964673|NCT02282215|Biological|G-CSF|Daily subcutaneous injections
45964674|NCT00176969|Drug|Capsaicin|
45964675|NCT02266342|Device|GORE® TAG® Thoracic Endoprostheses|Endovascular therapy to treat thoracic disease
45964676|NCT04678687|Procedure|Liver, lung, heart and kidney biopsy|Liver, lung, heart and kidney biopsies will be performed on each case in the COVID-19 group.
46080162|NCT05590598|Combination Product|Azelastine + Mometazone, nasal spray|140 mcg + 50 mcg/dose (Sandoz d.d., Slovenia), one actuation in each nostril twice daily, morning and evening (recommended interval between administrations is approximately 12 hours), for 14 consecutive days.
46080163|NCT05590598|Combination Product|Momat Rhino Advance|140 µg + 50 µg/dose - one actuation into each nostril twice daily - morning and evening (interval between administrations is 12 hrs), corresponding to 560 µg/day of azelastine and 200 µg/day of mometasone for 14 consecutive days
46080164|NCT02735148|Other|Body Weight Supported Treadmill Training|"There were three intervention arms in this study,~Body Weight Supported Treadmill Training,~Conventional Training and~Combined Training."
46080165|NCT00925951|Device|Wet Cupping|Wet cupping (Seongho trade & company, Korea) will be practiced at two selected points (among the 6 acupoints, left or right BL23, BL24, BL25)
46080166|NCT00925951|Drug|Acetaminophen|Acetaminophen 500 mg tablets will be offered to both of the wet cupping group and waiting group for relieving severe pain.
46080167|NCT04237142|Diagnostic Test|Vaginal secretions collection|Vaginal secretions are collected under speculum with a swab (10 seconds of impregnation of the swab). The swab is immersed in a tube containing an extraction buffer for 10 seconds. The tube is mixed and sent to the laboratory for subsequent analysis of biomarkers (IGFBP1 T/N, PIBF, PP14) and storage.
46080168|NCT04237142|Diagnostic Test|Blood sample|2 tubes of blood sample were collected and sent to the laboratory for serum storage and biomarkeurs assay (PIBF and MIF)
46080169|NCT00933127|Genetic|DNA analysis|
45455477|NCT04561700|Diagnostic Test|Reporting of sucking patterns captured by Instrumented Bottle|In the intervention group, data on nutritive sucking and feeding cues captured by the Instrumented Bottle will be made available to speech therapists to document the feeding session and provide written recommendations in their weekly report.
45964677|NCT00204945|Drug|nesiritide|a bolus, then infusion of nesiritide for 10-15 minutes
45964678|NCT00177008|Drug|Aripiprazole|
45964679|NCT04677985|Combination Product|Menthol based topical analgesic|Topical analgesic or placebo was applied to upper and lower body muscles and tendons and pain pressure threshold was measured with a handheld algometer.
45964680|NCT00554632|Drug|Ethinyl estradiol and norgestimate|Oral contraceptive
45964681|NCT00554632|Drug|Ethinyl estradiol and norelgestromin|Transdermal hormonal contraceptive changed weekly
45964682|NCT02963870|Other|Security Plan|This study compared two groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with the Security Plan plus the usual treatment and a group receiving standard treatment only.
45964683|NCT00204984|Drug|oral hydralazine and intravenous nesiritide|vasodilators
45964684|NCT02254993|Drug|C16G2|antimicrobial peptide
45964685|NCT02253745|Drug|V81444|V81444 capsules for oral administration, 100 mg twice daily for 13 days and once on Day 14
45964686|NCT02253745|Drug|Placebo|Capsules to match V81444 twice daily for 13 days and once on Day 14
45964687|NCT02236195|Drug|Mocetinostat|
45964688|NCT00200148|Procedure|Normovolemic Hemodilution (ANH)|For those patients randomized to ANH, the pre-calculated volume of blood will be withdrawn to a target hemoglobin of 8.0 - 8.5 g/dl (maximum of 3 L) using the formula VL=EBV x (HO-HF)/Hav, as above. The removed blood will be stored in a standard citrate-phosphate-dextrose buffer solution in blood storage bags in the operating room. During removal of blood, colloid and crystalloid solutions will be administered via peripheral intravenous lines in order to maintain euvolemia. For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.For patients randomized to ANH, autologous blood will be re-infused in the reverse order from which it was removed, and allogeneic blood will given only after all autologous blood has been given.
45964689|NCT00200148|Procedure|Standard of care|An 8.5 French central venous catheter and an arterial line will be placed in all patients. If the patient has a central line already in place, this may be used in place of the 8.5 French internal jugular catheter. Continuous monitoring of heart rate, blood pressure, ECG (II, V5), CVP, end tidal CO2, oxygen saturation, temperature and urine output will be performed for all patients.For all hepatic resections, standard low CVP anesthetic management will be employed.For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.All patients will receive standard postoperative management. Routine laboratory studies, including comprehensive panel, CBC and coagulation profile, will be obtained daily in the post-operative period.
45964690|NCT02236156|Drug|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
46080170|NCT00933127|Genetic|polymerase chain reaction|
46080171|NCT00933127|Genetic|polymorphism analysis|
46080172|NCT00933127|Other|laboratory biomarker analysis|
45666875|NCT02092467|Drug|tofacitinib|Oral tablet, 10 mg BID
45822574|NCT00002719|Drug|idarubicin|
45822575|NCT00002719|Drug|mitoxantrone hydrochloride|
45822576|NCT00002719|Procedure|peripheral blood stem cell transplantation|
45822577|NCT00003326|Drug|paclitaxel|
45822578|NCT00002725|Drug|bryostatin 1|
45822579|NCT00002725|Drug|chemotherapy|
45822580|NCT00003602|Drug|cytarabine|
45822581|NCT00003602|Drug|etoposide|
45822582|NCT00003602|Drug|idarubicin|
45822583|NCT00003602|Drug|mitoxantrone hydrochloride|
45822584|NCT04609423|Dietary Supplement|Cod liver oil|5 ml of cod liver oil as a source of 10 ug of vitamin D and 1.2 g of long-chained n-3 polyunsaturated fatty acids (DHA 0,6g and EPA 0,4g) per day for 6 months x 1 time/day together with the first meal of the day. 5ml of Cod liver oil also contains 250ug vitamin A and 10 mg vitamin E.
45964691|NCT02236156|Drug|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
45964692|NCT02236156|Drug|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
45964693|NCT00177086|Other|Alfuzosin Hydrochloride|One tablet every day for 4 weeks
45964694|NCT02235259|Drug|XG-104|Comparison of XG-104 (3 concentrations) versus placebo eye drops efficacy
45964695|NCT02235259|Drug|Placebo|
45964696|NCT00205023|Procedure|Sonohysterography|SHG during surgery for endometrial cancer.
45964697|NCT03455062|Other|Questionnaire about fertility|"Recruitment of participants through the list of cardiac, renal, hepatic, pancreatic or pulmonary transplant patients collected from the the Organ Transplant Unit.~A letter from the the Organ Transplant Unit will initially be sent to patients informing them of the study and if they do not wish to participate they can report their opposition by email.~A fertility questionnaire will be send and that will have to be returned by the patient in order to be included in the study.~The questionnaires, anonymous, will be numbered according to their order of return."
45964698|NCT00177125|Device|ErectAid|
45964699|NCT02207257|Drug|PER977|Reversal of edoxaban-induced anticoagulation
45666876|NCT02092467|Biological|adalimumab|Pre-filled syringe, 40 mg subcutaneous injection, every other week
45666877|NCT02092467|Biological|etanercept|Pre-filled syringe, 50 mg subcutaneous injection, every week
45666878|NCT02462759|Drug|Nusinersen|Administered by intrathecal injection.
45666879|NCT02462759|Procedure|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
45666880|NCT04951583|Combination Product|FMT + ICI|"This study will include 3 cohorts of patients: (1) Patients with advanced or unresectable NSCLC, (2) patients with advanced or unresectable melanoma, and (3) patients with unresectable or advanced uveal melanoma. Patients with NSCLC, melanoma, uveal melanoma and will be analyzed in three separate subgroups given their differing clinical outcomes.~Each group will be treated with ICI as per their respective first line options, in combination with investigational FMT capsules."
45666881|NCT04951115|Drug|Carboplatin|AUC = 5-6 mg/mL per min on Day 1 of each 21-day cycle, for 4 cycles
45822585|NCT04609423|Dietary Supplement|Corn oil (placebo)|5 ml of corn oil per day for 6 months x 1 time/day together with the first meal of the day
45666882|NCT04951115|Drug|Cisplatin|75-80 mg/m2 on Day 1 of each 21-day cycle, for 4 cycles
45822586|NCT00003332|Drug|cisplatin|
45822587|NCT00003332|Drug|gemcitabine hydrochloride|
45964700|NCT02207257|Drug|Placebo|Reversal of edoxaban-induced anticoagulation
45964701|NCT02207257|Drug|Edoxaban|
45964702|NCT00554710|Drug|infliximab+azathioprine|infliximab 5 mg/kg at week 0,2 and 6 + azathioprine 2-2.5 mg/kg
45964703|NCT00554710|Drug|methylprednisolone or budesonide|methylprednisolone 32 mg followed by taper or budesonide 9 mg/day followed by taper
45964704|NCT00205062|Procedure|PET-CT|
45964705|NCT04659265|Other|Suspected diagnosis of a pre-treating physician|Participants receive the information that the pre-treating physician thought the patient is suffering from a medical emergency (no diagnosis), an acute myocardial infarction (correct diagnosis) or a pulmonary embolism (wrong diagnosis)
45964706|NCT00177203|Behavioral|Brief Behavioral Treatment of Insomnia or Information|"The behavioral treatment involves education about sleep and its disorders; habits that help and hurt sleep; and recommendations about sleep hours and time in bed. It involves two meetings with a nurse who is part of the research team.~In the information condition, participants are given similar information in printed brochures that are published by the American Academy of Sleep Medicine. They are instructed to read the information."
45964707|NCT00200187|Procedure|low venous pressure general anesthesia|
45964708|NCT00200187|Procedure|combined spinal-epidural anesthesia|
45964709|NCT04659109|Drug|glenzocimab|IV administration as a sterile product
45964710|NCT04659109|Drug|Placebo|IV administration
45964711|NCT00177242|Drug|Gefitinib|
45964712|NCT04659070|Drug|Experimental : Ezetimibe / Rosuvastatin + Telmisartan|Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks
45964713|NCT04659070|Drug|Active comparator1 : Ezetimibe / Rosuvastatin|Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks
45964714|NCT04659070|Drug|Active comparator2 : Telmisartan|Telmisartan 80mg PO, Once daily for 8 weeks
45964715|NCT04659148|Procedure|Total proctocolectomy|Total proctocolectomy: surgical removal of the colon, rectum, and anus
45964716|NCT04658875|Dietary Supplement|Spirulina maxima supplementation|Supplementation with Spirulina maxima (4.5 g/d) in capsules during 12 weeks.
45964717|NCT04658875|Other|Wash-out|2 weeks washout period to each study subject to avoid any possible carryover effect.
45964718|NCT04658875|Other|Placebo supplementation|Supplementation with placebo (4.5 g/d) in capsules during 12 weeks.
45964719|NCT04658875|Other|Isoenergetic diet|All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 26 weeks
46080173|NCT02735070|Drug|Resfenol|Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
45666883|NCT04951115|Drug|Etoposide|80-100 mg/m2 on Day 1, Day 2, and Day 3 of each 21-day cycle, for 4 cycles
45822588|NCT00003332|Procedure|surgical procedure|
45822589|NCT00003332|Radiation|radiation therapy|
45822590|NCT00004094|Drug|carboplatin|
45822591|NCT00004094|Drug|fluorouracil|
45822592|NCT00004094|Drug|hydroxyurea|
45822593|NCT00004094|Drug|paclitaxel|
45822594|NCT00004094|Procedure|conventional surgery|
45822595|NCT00004094|Radiation|radiation therapy|
45822596|NCT05745571|Other|Blood sample|The study foresees a phase of patient recruitment, in which, in the hours immediately following the blood sampling, the isolation of the PBMCs, their incubation and cytofluorimetric analysis will be carried out and the conservation of the material to be analyzed subsequently by molecular biology and immunochemistry.
45964720|NCT04658875|Other|Systematic physical exercise program|Participants in the systematic physical exercise program groups will exercise for five days a week. The physical activity program will consist of Monday to Friday chair exercises performed during 24 weeks. The approximate exercise duration will be 40 to 50 min. Each exercise session has an initial or warm-up phase (~ 10 min), a main physical conditioning phase (~ 25 min), and a cool-down or relaxation phase (~ 10 min). The physical activities to select have a metabolic equivalent tasks (METs) considered as moderate, between 3.0 and 6.0 METs. Trained personnel will assist older adults to perform the activities, including articular flexibility using elastic bands, postural and proprioception exercises with materials such as rubber balls, wood sticks, and small sandbags. These activities will be selected according to the deterioration and joint stiffness that the participants could present.
45964721|NCT00177281|Drug|S CKD602|
45964722|NCT04658524|Diagnostic Test|Thyroid function|laboratorial thyroid tests
45964723|NCT00200226|Drug|misoprostol|misoprostol 400mcg 12 hrs prior to procedure
45964724|NCT00200226|Drug|vitamin B6|Vitamin B6 50 mg orally 12 hrs prior to procedure
45964725|NCT00408083|Drug|MultiHance|0.5 mmol/kg as a single dose administration
45964726|NCT00408083|Drug|Magnevist|0.5 mmol/kg as a single dose administration
45964727|NCT04658485|Device|Active tDCS|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of the primary motor cortex (M1) with the cathode located over the right primary somatosensory cortex (S1).
45964728|NCT04658485|Device|Sham tDCS|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide a sham stimulation with the anode place over the primary motor cortex (M1) and cathode located over the right primary somatosensory cortex (S1). The sham stimulation consists of 30 seconds of stimulation ramping up to a maximum of 2 mA, then 19 minutes of the device providing no stimulation and then ramping down from 2 mA intensity to 0 in the last 30 seconds. This configuration is designed to mimic the sensory experience of active tDCS.
46080174|NCT02735070|Drug|Coristina d|Patients included in the study will take the drugs 4 times a day, orally. Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
46080175|NCT00933205|Drug|Tipranavir|
46080176|NCT02813486|Biological|Biological: GC3111 vaccine|0.5mL, Intramuscular
45822597|NCT05592769|Device|HealthBeacon Injection Care Management System (ICMS)|"All participants will receive access to the HealthBeacon ICMS to remotely monitor adherence to therapy in the home setting. The system includes the following items/services:~The HealthBeacon Smart Sharps Bin~The HealthBeacon Companion App~HealthBeacon Care Team Support (including smart dose reminders and intervention calls)~Waste Management Services~Participants will also be issued the following interventions to enable collection of the secondary endpoints:~-Participant Feedback Questionnaire (issued electronically upon study completion, to gather feedback on the HealthBeacon ICMS)"
45666884|NCT04951115|Drug|Durvalumab|1500 mg on Day 1 of each 21-day cycle, for 4 cycles. Following this, 1500 mg once every 4 weeks until disease progression
45822598|NCT00004100|Drug|cisplatin|
45822599|NCT00004100|Drug|gemcitabine hydrochloride|
46080177|NCT02813486|Biological|Biological: Boostrix® vaccine|0.5mL, Intramuscular
46080178|NCT02734836|Device|Balloon Angioplasty|
45666885|NCT04951115|Radiation|Stereotactic Body Radiotherapy|6 Gy of radiotherapy targeting multiple sites of intrathoracic disease on Days 1-5 of cycle 1.
45666886|NCT04420871|Drug|150 mg of Xeloda®|Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period. 150 mg of Xeloda® produced by Genentech USA, Inc., a subsidiary of the company, was used as the reference intervention in this study.The subjects randomly received single oral administration of 150 mg of Xeloda®.
45822600|NCT00004100|Drug|vinorelbine tartrate|
45822601|NCT00002737|Biological|recombinant interferon alfa|
45822602|NCT00002737|Drug|chemotherapy|
45822603|NCT00002737|Drug|isotretinoin|
45822604|NCT00003338|Procedure|immunoscintigraphy|
45822605|NCT00003338|Radiation|technetium Tc 99m epratuzumab|
45964729|NCT04658719|Device|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed.
45964730|NCT04658719|Device|Standard Care|Uncoated Foley Catheter
45964731|NCT00200265|Behavioral|diet|diet
46080179|NCT02734836|Other|Optical Coherence Tomography|
46080180|NCT02810522|Device|OneTouch Select® Plus Glucose Test Strips|
45964732|NCT00408122|Procedure|PET/CT scan and EUS|
45964733|NCT04658563|Other|High Density Exercise Training Program - Yoga|A total of 8 weeks will be applied in our study, each session of the high-density yoga program will be started with 10 minute pranayama (breath) exercises as it is in classical yoga as a preliminary preparation for the participation of individuals; the program will be completed by applying 10-20 minutes warming-stretching movements, 40 minutes surya namaskar (SN) sets, 20-30 minutes dynamic yoga asanas and 10 minutes savasana. Participants will be encouraged to study the perceived difficulty levels between 14 and 17 using the Borg scale during the sessions
45964734|NCT04658329|Drug|Antiretroviral|Study the response to antiretroviral treatment (clinical, immuno-virological) and contribute to the identification of the antiretroviral strategies and combinations most suited to the particularities of the infection.
45822606|NCT05744947|Other|Data collection|"Specific Readapt -DISCO complementary questionnaire rehabilitation"
45964735|NCT04658602|Procedure|Preformed stainless steal crown cemented by glass ionomer lutting cement (Ketac cem,3M Espe)|Covering the affected molar with preformed metal crown cemented by glass ionomer lutting cement
45964736|NCT00200304|Behavioral|Internet weight loss with SlimFast and human counseling|
45964737|NCT00200304|Behavioral|Internet weight loss with SlimFast and computer counseling|
45964738|NCT00200304|Behavioral|Internet weight loss program with SlimFast|
45964739|NCT00408161|Behavioral|Contingency Management|prize contingency management (CM) -- 6-month treatment plus standard case management treatment and follow-ups at 9, 12, and 18 months after intake
45964740|NCT00408161|Behavioral|standard case management treatment|6-month treatment standard case management treatment, and follow-ups scheduled at 9, 12, and 18 months after intake.
45964741|NCT00557518|Drug|Alagebrium|200 mg bid
46080181|NCT02734914|Device|SF-URS with automatic control of RPP|A new F-URS monitoring and control of RPP using intelligent pressure control device
46080182|NCT02734914|Device|conventional F-URS|Ureteroscopy will be conducted using the ureteral access sheath from Cook Medical to treat renal calculi.
45666887|NCT04420871|Drug|150 mg of capecitabine|Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period.The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.The subjects randomly received single oral administration of 150 mg of capecitabine.
45666888|NCT02349386|Drug|BHR-200 (0.36% transdermal 17β-estradiol gel)|An absorptive hydroalcoholic gel preparation containing 17β-estradiol.
45666889|NCT02349386|Drug|Placebo|An absorptive hydroalcoholic gel preparation gel of the same ingredients as BHR-200, but without 17β-estradiol.
45822607|NCT00003620|Drug|alvocidib|Given IV
45964742|NCT00557518|Drug|Placebo|bid
45822608|NCT00003620|Other|laboratory biomarker analysis|Correlative studies
45822609|NCT00003344|Drug|irinotecan hydrochloride|
45964743|NCT00557557|Drug|Drug: 5-FU|Dose escalation (200 to 900 mg/m²) scheme, one hour isolated hepatic perfusion prior to standard treatment.
45964744|NCT00557557|Drug|Drug: Oxaliplatin|40 mg/m², one hour isolated hepatic perfusion prior to standard treatment.
45964745|NCT04657978|Procedure|Substrate guided left atrial ablation|Ablation therapy targeting areas of low voltage, which may include encirclement, homogenization or targeting of abnormal electrograms and anchored to a non-conducting structure if the region is in close proximity or likely to create an isthmus for arrhythmias.
45964746|NCT04658134|Dietary Supplement|Glycine|Oral glycine tablets (100 mg/kg/day) in divided doses
45964747|NCT04658212|Procedure|3D LCBDE|three-dimensional (3D) video system for LCBDE (laparoscopic cholecystectomy and laparoscopic common bile duct exploration )
45964748|NCT04658212|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
45964749|NCT00177359|Behavioral|gait intervention|
45822610|NCT00003344|Radiation|radiation therapy|
45822611|NCT00003626|Drug|dolastatin 10|
45822612|NCT00003632|Biological|filgrastim|
45822613|NCT00003632|Drug|carmustine|
45964750|NCT04658017|Device|GARNET device|Use of new filter in conjunction with standard of care dialysis.
45964751|NCT00200382|Drug|PS-341 (Velcade-drug)|
46080183|NCT02807480|Behavioral|Exposure-based therapy|Exposure-based therapy
46080184|NCT02807480|Behavioral|Behavioral Activation therapy|Behavioral Activation therapy
46080185|NCT02807480|Behavioral|Computer-based behavioral assessment|Computer-based tasks during which participants respond to images on the screen, including abstract images, emotional faces, and pleasant and unpleasant images.
46080186|NCT02807480|Behavioral|Surveys and Interviews|Surveys and interviews in which participants will be asked to answer questions related to their mental and physical health history and current symptoms.
46080187|NCT02807480|Device|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) will be used to obtain information concerning the structure of the brain, as well as to assess changes associated with blood flow in the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).
46080188|NCT02807480|Device|Electroencephalography (EEG)|Electroencephalography (EEG) will be used to assess changes in the electrical activity of the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).
45822614|NCT00003632|Drug|cytarabine|
45822615|NCT00003632|Drug|etoposide|
45822616|NCT00003632|Drug|melphalan|
45822617|NCT00003632|Drug|methotrexate|
45822618|NCT00003632|Procedure|peripheral blood stem cell transplantation|
45822619|NCT05744557|Other|num Vapocoolant|Spray will be administered for 4 to 6 seconds from a distance of 3 to 6 inches to desired sites of skin
45964752|NCT04657744|Drug|Sphingomod|1 capsule contains 0.5 mg Fingolimod
45964753|NCT04657744|Drug|Gilenya|1 capsule contains 0.5 mg Fingolimod
45964754|NCT00177398|Drug|Glargine insulin vs regular insulin|
45964755|NCT04657627|Behavioral|PACE plus calorie labelling information|The intervention group will be exposed to PACE plus calorie labelling information via Instagram and Twitter social media posts every day for 13 weeks.
45964756|NCT04657627|Behavioral|Calorie-only labelling information|The comparator group will be exposed to calorie-only labelling information via Instagram and Twitter social media posts every day for 13 weeks.
45964757|NCT04657471|Other|revised HOME-CoV score|"Educational lectures, posters, and pocket cards showing and explaining the revised HOME-CoV score are communicated to participating Emergency Departments.~For included patients, the physician-in-charge calculates the revised HOME-CoV. Patients with a score <2 qualified for home treatment. They qualified otherwise for hospitalization. For patients with a score > 4, hospitalization in a unit allowing monitoring of vital parameters is recommended. However, the physician-in-charge can overrule the qualification for home treatment or for hospitalization in case of major medical or social reasons. A justification explaining the cause of overruling is required."
45964758|NCT00177437|Behavioral|home testing kit|
45822620|NCT00004112|Biological|rituximab|
45964759|NCT04657354|Procedure|Assessment|Early surgical assessment
45964760|NCT04657510|Other|COVID-19|Patients affected versus not affected by COVID-19, with the same starting condition (proximal femur fracture)
45964761|NCT04657237|Procedure|Thoracic Paravertebral block|TPVB will be given using high frequency linear U/S transducer, place the U/S ultrasound probe was placed parallel to the vertebral spine at T4, and, T6 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of pleura, transverse process and paravertebral space, the needle was inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 0.25% bupivacaine (20 ml) delivery slowly divided equally at T4and T6; the pleura will be seen to be pushed downward
45822621|NCT00004112|Drug|CHOP regimen|
45964762|NCT00177476|Behavioral|behavioral weight loss|
45822622|NCT00004112|Drug|cyclophosphamide|
45964763|NCT00205296|Behavioral|exercise|this will test the effect of exercise on insulin sensitivity, fitness and body composition
45964764|NCT04657042|Diagnostic Test|Magnetic Resonance Imaging|Four-dimensional MRI of torso
45964765|NCT04656886|Drug|Intravenous Infusion|
45822623|NCT00004112|Drug|doxorubicin hydrochloride|
45822624|NCT00004112|Drug|prednisone|
45964766|NCT04656808|Behavioral|Guilt Focused Intervention|Psychotherapy, group intervention
45964767|NCT04656808|Behavioral|Cognitive behavioral therapy|Psychotherapy, group intervention
45964768|NCT00177515|Behavioral|"video doctor, computer module"|computerized counseling about emergency contraception and peri-conception folate
45964769|NCT04656457|Device|Treadmill|Treadmill is not used to harness power, but as exercise machines for running or walking in one place. Rather than the user powering the mill, the machine provides a moving platform with a wide conveyor belt driven by an electric motor or a flywheel. The belt moves to the rear, requiring the user to walk or run at a speed matching that of the belt. The rate at which the belt moves is the rate of walking or running. Thus, the speed of running may be controlled and measured
45666890|NCT04935047|Other|Multilingual Support|Multilingual Support is a classroom intervention, which is designed to be delivered in classes of adult learning of a new language. The intervention involves the use of a language assistant, who is at minimum independent user (B1) in the language to be learned (in this case Norwegian), according to the language proficiency scale of the Common European Framework of Reference (CEFR) for languages, learning, teaching, assessment (Little, 2006). The language assistant will be in the classroom for seven hours a week, collaborating with the teacher in providing language training. In classrooms where participants have different primary languages, the language assistant(s) must cover all languages represented in the classroom.
45666891|NCT04934891|Drug|ION547|ION547 will be administered by SC injection.
45666892|NCT04934891|Drug|Placebo|ION547-matching placebo will be administered by SC injection.
45666893|NCT04892888|Biological|COVID-19 Vaccine|COVID-19 Vaccine Intramuscular Injection
45666894|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
45666895|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
45666896|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
45666897|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
45666898|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
45666899|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
45666900|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
45666901|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
45822625|NCT00004112|Drug|vincristine sulfate|
45822626|NCT05743465|Other|No Intervention|As this is an observational study, no intervention will be administered in this study.
45822627|NCT00003350|Drug|paclitaxel|Given IV
45822628|NCT00003350|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
45822629|NCT00003350|Other|laboratory biomarker analysis|Correlative studies
45822630|NCT00003350|Procedure|quality-of-life assessment|Ancillary studies
45822631|NCT05584267|Radiation|radiotherapy|Different cohorts received different doses of radiotherapy
45822632|NCT05584267|Drug|Chemotherapy + immunotherapy|Chemotherapy + immunotherapy
45964770|NCT04656457|Other|resisted exercises|Resistance exercises will be involved in this technique are for upper and lower limb (Exercise program including shoulder flexion, abduction and horizontal adduction, elbow extension and flexion, calf raise, leg extension and squatting)
45964771|NCT00200421|Drug|Nebivolol and Atenolol|
45964772|NCT04656613|Biological|Gam-COVID-Vac|the Gam-COVID-Vac is combined 2 -component vector vaccine against the SARS-СoV-2-induced coronavirus infection
45964773|NCT04656613|Other|placebo|Placebo Comparator
45964774|NCT04656769|Procedure|Peridural analgesia|We attempted to evaluate the effectiveness of peridural analgesia through cancer survival and recurrence outcomes.
45964775|NCT04656574|Behavioral|Simulation-based training|The simulation training included the activities that midwives should do during the birth and management of vaginal delivery with episiotomy. The students received theoretical training, and to reinforce it, they were asked to mold a fetal head from a potato, make a cardboard cervix showing dilatation measurements during vaginal delivery, and make a fetal position identification model taking the occiput as a reference point.
45964776|NCT00177554|Drug|Chemotherapy and Radioimmunotherapy|CHOP-R x 3 cycles followed by zevalin and extended rituximab
45822633|NCT00003356|Biological|aldesleukin|
45666902|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
45666903|NCT02036775|Drug|Lasolvan prolonged-released capsules|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
45822634|NCT00003356|Biological|rituximab|
45822635|NCT00004136|Procedure|Radiofrequency Ablation|Tumors heated to target temperature by electrodes for maximum of 20 minutes
45822636|NCT00003638|Biological|Detox-B adjuvant|
45822637|NCT00003638|Biological|THERATOPE STn-KLH vaccine|
45822638|NCT00003638|Biological|keyhole limpet hemocyanin|
45822639|NCT00003638|Drug|cyclophosphamide|
45822640|NCT00004142|Drug|Floxuridine|Part of hepatic arterial chemotherapy on days 1-7. Treatment repeats every 5 weeks for 6 courses.
45822641|NCT00004142|Drug|Fluorouracil (5-FU)|Part of hepatic arterial chemotherapy over 1 hour on days 15, 22, and 29. Treatment repeats every 5 weeks for 6 courses.
45964777|NCT00205335|Device|Ascencia Breeze Glucose meter|All study participants received glucose meter and test strips.
45964778|NCT00205335|Device|Breeze Glucose Monitor (Bayer)|Each participant received a Breeze monitor and glucose test strips.
45964779|NCT04656340|Other|non-medication, non-interventional therapies|non-medication, non-interventional therapies
45964780|NCT04655989|Device|DBB-EXA ES Hemodialysis System|The DBB-EXA ES Hemodialysis Delivery System is intended to support an optional online priming, rinseback and emergency bolus features. The appropriate priming of the hollow fiber dialyzer and blood tubing lines removes debris and air prior to device use, as well as ensuring proper rinseback.
45964781|NCT04656106|Drug|Ryzodeg®|All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in South Korea. Hence independently of this study, the treating physician has determined the starting dose of Ryzodeg® as well as any dose adjustments thereafter.
45964782|NCT04656262|Drug|Cyclophosphamide|Cyclophosphamide is formulated as coated tablets of 50mg for oral administration
45666904|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
45666905|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
45666906|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
45666907|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
45666908|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
45666909|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
45666910|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
45666911|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
45666912|NCT02034591|Drug|Apixaban|
45822642|NCT00004142|Procedure|Conventional surgery|Open laparotomy to identify target tumor in liver using intraoperative ultrasound.
45822643|NCT00004142|Procedure|Radiofrequency ablation|Radiofrequency tissue ablation over 20 minutes to each tumor.
45822644|NCT00002749|Drug|carboplatin|
45822645|NCT00003362|Biological|QS21|
45822646|NCT00003362|Biological|gp100 antigen|
45822647|NCT00003362|Biological|incomplete Freund's adjuvant|
45822648|NCT00003362|Biological|sargramostim|
45822649|NCT00003362|Biological|tyrosinase peptide|
45822650|NCT05741593|Other|Analysis of the verbatim from the transcription of the recorded interviews.|recorded semi-structured interviews between the patients and the pharmacist
45822651|NCT00004148|Biological|recombinant vaccinia-B7.1 vaccine|
45822652|NCT00003650|Drug|asparaginase|
45822653|NCT00003650|Drug|cyclophosphamide|
45822654|NCT00003650|Drug|cytarabine|
45822655|NCT00003650|Drug|daunorubicin hydrochloride|
45822656|NCT00003650|Drug|dexamethasone|
45822657|NCT00003650|Drug|etoposide|
45822658|NCT00003650|Drug|mercaptopurine|
45822659|NCT00003650|Drug|methotrexate|
45822660|NCT00003650|Drug|methylprednisolone|
45822661|NCT00003650|Drug|mitoxantrone hydrochloride|
45964783|NCT04656262|Drug|Doxorubicin|Doxorubicin is formulated as 60 mg/mq for infusional use (i.v use)
45964784|NCT00200460|Drug|Nebivolol|
45964785|NCT04655950|Other|protocols and practices for the immobilization of vertebral osteomyelitis in different French hospitals and bone and joint infections Centers|"Evaluation of the frequency of neurological complications in a large prospective cohort, and to identify clinical and imaging risk factors for neurological complications.~We search for association between type and duration of spine immobilization and neurological status at the end of follow-up"
45964786|NCT04655872|Drug|[14C]TPN171H|A single 10 mg oral dose of [14C]TPN171H containing approximately 100 microcurie of [14C]-TPN171H.
45964787|NCT00177632|Behavioral|behavioral weight loss|
45964788|NCT04655833|Other|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
45964789|NCT00200499|Drug|Nebivolol|
45964790|NCT04655677|Biological|CD19/CD20-directed CAR-T cells|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
45964791|NCT04655560|Other|no intervention|qualitative study
45964792|NCT00557596|Drug|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly, only on weeks when gemcitabine is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1
45666913|NCT02034591|Dietary Supplement|Boost Plus|
45666914|NCT02391116|Drug|Copanlisib (Aliqopa, BAY80-6946)|Participants assigned to receive copanlisib intravenous (IV) infusion at a dose of 60 mg as single agent on Days 1, 8, and 15 of 28-day treatment cycle. Copanlisib treatment was to be continued until disease progression (PD), unacceptable toxicity, or until another criterion was met for withdrawal from the study treatment
45822662|NCT00003650|Drug|prednisone|
45964793|NCT02962635|Device|bioelectrical impedance measurement and biomarker measurement|Measuring volume status with bioelectrical impedance measurement and comparing with biomarker level
45964794|NCT04655794|Drug|3HP|all patients taking 3HP under directly observed preventive therapy (DOPT) program
45666915|NCT02091921|Drug|Ticagrelor|All patients will be switched from clopidogrel to ticagrelor 90 mg twice daily for two weeks and the VerifyNow and VASP platelet reactivity assays repeated, samples will be collected before and 6±1 hours after the last ticagrelor dose.
45666916|NCT04716933|Biological|Pembrolizumab|IV infusion Q3W
45666917|NCT04716933|Drug|Carboplatin|IV infusion Q3W
45822663|NCT00003650|Drug|vincristine sulfate|
45666918|NCT04716933|Drug|Cisplatin|IV infusion Q3W
45666919|NCT04716933|Drug|Pemetrexed|IV infusion Q3W
45666920|NCT04716933|Drug|Lenvatinib|Oral capsule once daily
45666921|NCT04716933|Drug|Placebo matching lenvatinib|Oral capsule once daily
45666922|NCT02447081|Device|Subjects implanted with Amulet Device|Percutaneous Left Atrial Appendage occlusion with successful implant of occlusion device.
45666923|NCT02391038|Drug|MLN0264|MLN0264 IV.
45666924|NCT02260921|Device|iovera°|
45666925|NCT02260921|Device|Sham Comparator|
45666926|NCT02462603|Drug|PTC-589|PTC-589 is a redox active molecule and will be provided in a 250 mg tablet formulation.
45822664|NCT00003650|Radiation|radiation therapy|
45822665|NCT00002755|Biological|filgrastim|
45964795|NCT04655443|Other|Standard Care|Standard cardiovascular care
45964796|NCT04655209|Behavioral|apply a-tDCS on the ipsilesional M1 followed by MT (M1-Seq)|The participants in the M1-Seq group will first receive a-tDCS over ipsi-lesional M1 without any active arm practice for 20 minutes. For the next 20 minutes, the participants will start the MT, while the electrodes will be remained on the scalp with the stimulator off (sham tDCS condition). Then the electrodes will be removed, and the participants will receive additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice.
45964797|NCT04655209|Behavioral|apply a-tDCS on the ipsilesional PMC followed by MT (PMC-Seq)|The procedures for the PMC-Seq group will be the same as the M1-Seq, except that a-tDCS will be applied on ipsilesional PMC but not M1.
45964798|NCT04655209|Behavioral|MT only with sham tDCS (MT)|For the MT group, the procedure will be the same as the other groups except that sham tDCS will be used for the first 40 minutes.
45964799|NCT04655131|Dietary Supplement|Whey protein isolate|Commercially available, FDA approved whey protein isolate for dietary supplementation
45964800|NCT04654975|Procedure|Esophagectomy for esophageal cancer|Surgical removal of (a part of) the esophagus and surgical reconstruction with another organ (mostly stomach, but may be colon or small bowel as well)
45964801|NCT04655014|Other|High Intensity Circuit Training|The High Intensity Circuit Training comprises of 7 full body exercises as per recommendation of ACSM Where the participants shall be given total of 18 sessions of their respective protocol, comprising of 20 minutes, 3 times/ week for duration of six weeks
45964802|NCT00200538|Drug|memantine|
45964803|NCT04655599|Drug|Olorinab|Olorinab tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
45822666|NCT00002755|Drug|CMF regimen|
45822667|NCT00002755|Drug|cyclophosphamide|
45822668|NCT00002755|Drug|doxorubicin hydrochloride|
45822669|NCT00002755|Drug|fluorouracil|
45822670|NCT00002755|Drug|methotrexate|
45822671|NCT00002755|Drug|tamoxifen citrate|
45822672|NCT00002755|Drug|thiotepa|
45822673|NCT00002755|Procedure|autologous bone marrow transplantation|
45822674|NCT00002755|Procedure|peripheral blood stem cell transplantation|
45822675|NCT00002755|Radiation|low-LET cobalt-60 gamma ray therapy|
45822676|NCT00002755|Radiation|low-LET electron therapy|
45666927|NCT02034513|Drug|insulin degludec|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
45666928|NCT02034513|Drug|insulin glargine|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
45666929|NCT02034513|Drug|insulin aspart|Administered 2-4 times daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
45666930|NCT05370248|Other|Tidal volume 6 ml/kg|Tidal volume is defined as the amount of air that moves in or out of the lungs with each respiratory cycle, given by the mechanical ventilator.
45666931|NCT05370248|Other|Tidal volume 10 ml/kg|Tidal volume is defined as the amount of air that moves in or out of the lungs with each respiratory cycle, given by the mechanical ventilator.
45666932|NCT02348840|Device|mHealth|A cell phone that can capture data measurements from devices on blood pressure, oxygen level, the heart rate of pregnant women, and the heart rate of the baby.
45666933|NCT02462057|Other|Email message regarding the HealthyFood benefit|
45666934|NCT02461745|Drug|ombitasvir, paritaprevir/r, dasabuvir + ribavirin|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) + RBV (ribavirin tablets) for 12 weeks
45666935|NCT02461745|Drug|ombitasvir, paritaprevir/r, dasabuvir|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets)
45822677|NCT00002755|Radiation|low-LET photon therapy|
45822678|NCT04207424|Procedure|Emblization of the gastro-epiploic arcade|Endovascular embolization of the gastro-epiploic arcade using 300-500 micrometres calibrated polyvinyl-alcohol microparticles
45822679|NCT00002761|Biological|filgrastim|
45822680|NCT00002761|Biological|recombinant interferon gamma|
45822681|NCT00002761|Drug|busulfan|
45822682|NCT00002761|Drug|cyclophosphamide|
45822683|NCT00002761|Drug|cyclosporine|
45822684|NCT00002761|Drug|cytarabine|
45822685|NCT00002761|Drug|idarubicin|
45822686|NCT00002761|Procedure|peripheral blood stem cell transplantation|
45822687|NCT04191122|Other|COPESS|The intervention includes brief psychotherapy to be delivered within primary care settings
45822688|NCT00382135|Drug|tadalafil|20mg tadalafil tablet taken by mouth once a day for 40 weeks
45666936|NCT02034435|Other|Low Salt diet plus Placebo tablet|
45666937|NCT02034435|Other|Low Sodium diet plus Salt tablet|
45666938|NCT02034435|Drug|Epleronone|50mg daily
45666939|NCT02034435|Drug|Amlodipine|5mg daily
45666940|NCT04691427|Device|Virtual Eye Rotation Vision Exercises (VERVE)|A video game designed with elements of vision therapy will be delivered to participants utilizing consumer-available virtual reality headsets (VIVE Pro Eye).
45666941|NCT04714281|Device|Dialyser|Three consecutive treatment periods of four weeks, one last study week where the patient is re-assigned to the same type of dialyzer used before beginning the study and one follow-up week per patient. Each treatment period includes 12 hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX CorAL 600 Fresenius Medical Care, comparator FX CorDiax 600 Fresenius Medical Care and comparator xevonta Hi 15 (B. Braun).
45666942|NCT02033889|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg orally (1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
45822689|NCT00382135|Drug|placebo|Placebo tablet taken by mouth once a day for 40 weeks
45822690|NCT00003662|Biological|anti-thymocyte globulin|
45822691|NCT00003662|Drug|busulfan|
45822692|NCT00003662|Drug|cyclophosphamide|
45822693|NCT00003662|Drug|cyclosporine|
45822694|NCT00003662|Drug|melphalan|
45822695|NCT00003662|Drug|methylprednisolone|
45822696|NCT00003662|Procedure|umbilical cord blood transplantation|
45822697|NCT00003662|Radiation|radiation therapy|
45822698|NCT00004154|Drug|Fenretinide|200 mg/day (two 100 mg capsules) for 25 days of 28 day cycle.
45822699|NCT00004154|Other|Placebo|Two placebo capsules for 25 days of 28 day cycle.
45822700|NCT00002767|Biological|Detox-B adjuvant|
45822701|NCT00002767|Biological|recombinant interferon alfa|
45822702|NCT04133324|Diagnostic Test|C-reactive protein|C-reactive protein at postoperative days four and two.
45822703|NCT00002773|Biological|allogeneic tumor cell vaccine|
45822704|NCT00002773|Biological|recombinant interferon alfa|
45822705|NCT00002773|Biological|sargramostim|
45822706|NCT00002773|Drug|cyclophosphamide|
45822707|NCT00004160|Drug|cisplatin|
45822708|NCT00004160|Drug|gemcitabine hydrochloride|
45822709|NCT00004160|Drug|paclitaxel|
45822710|NCT00004160|Radiation|radiation therapy|
45822711|NCT05562115|Other|Tear collection|Collection of tears by Schirmer strip (2 to 4 mm).
45822712|NCT00003368|Drug|irinotecan hydrochloride|
45822713|NCT05562037|Other|Stepped Care|Patients meeting a non-response criterion will be stepped up to the next step
45822714|NCT05509543|Drug|IY-NT-T|Ilaprazole 20mg
45822715|NCT05509543|Drug|IY-NT-R|Ilaprazole 10mg
45822716|NCT00003674|Drug|dalteparin|
45822717|NCT00003674|Drug|standard therapy|
45822718|NCT05561101|Other|Caregivers burden|Assessment of caregiver burden after admision at Emergency Department of their elderly relative
45822719|NCT00003380|Drug|etoposide|
45822720|NCT00003380|Drug|pegylated liposomal doxorubicin hydrochloride|
45822721|NCT00002779|Drug|fludarabine phosphate|
45822722|NCT00002779|Drug|octreotide acetate|
45822723|NCT00003680|Drug|CMF regimen|
45822724|NCT00003680|Drug|cyclophosphamide|
45822725|NCT00003680|Drug|fluorouracil|
45822726|NCT00003680|Drug|methotrexate|
45822727|NCT00003680|Drug|tamoxifen citrate|
45822728|NCT00003680|Drug|thiotepa|
45964804|NCT04655599|Drug|Placebo|Olorinab matching placebo tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
45964805|NCT00177710|Drug|Amphotericin B|
45822729|NCT00003680|Procedure|peripheral blood stem cell transplantation|
45666943|NCT02033889|Drug|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally (1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
45964806|NCT04654936|Behavioral|MIND diet|12 week MIND diet study: Participants access a website that is theory driven using the Behaviour Change Wheel to help motivate and promote MIND diet adherence. Participants are to consume MIND diet foods daily and meet MIND diet weekly recommendations
46080189|NCT02739516|Drug|Human chorionic gonadotropin|In letrozole stimulated cycle; Human chorionic gonadotropin ( hCG) 10000 IU was given intramuscular when the mean ovarian follicle diameter was ≥18 mm.
46080190|NCT02739516|Drug|FSH co-trigger|In letrozole stimulated cycle; FSH (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once intramuscular when the mean ovarian follicle diameter was ≥18 mm.
45666944|NCT02033889|Drug|Placebo to Ertugliflozin|Placebo to ertuglioflozin (1 placebo ertugliflozin 5 mg tablet and/or 1 placebo ertugliflozin 10 mg tablet), orally once daily from Day 1 to Week 104.
45666945|NCT02033889|Other|Glimepiride|Open-label Glimepiride will be used for glycemic rescue therapy (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) in the 26-week initial period. Blinded Glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period.
45666946|NCT02033889|Drug|Placebo to Glimepiride|Placebo to glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of placebo to glimepiride is at the discretion of the investigator.
45666947|NCT02033889|Biological|Basal Insulin|Basal insulin will be administered in the initial 26-week period for participants with glucose values exceeding protocol-specified values and for participants requiring rescue therapy in the 78-week extension period. Dosing and titration of basal insulin is at the discretion of the Investigator.
45666948|NCT02033889|Drug|Metformin|Metformin >=1500 mg/day, orally, once a day
45822730|NCT00003680|Radiation|radiation therapy|
45822731|NCT00002785|Biological|filgrastim|
45822732|NCT00002785|Drug|asparaginase|
45822733|NCT00002785|Drug|cyclophosphamide|
45822734|NCT00002785|Drug|cyclosporine|
45822735|NCT00002785|Drug|cytarabine|
45822736|NCT00002785|Drug|daunorubicin hydrochloride|
45822737|NCT00002785|Drug|dexamethasone|
45822738|NCT00002785|Drug|etoposide|
45822739|NCT00002785|Drug|leucovorin calcium|
45822740|NCT00002785|Drug|mercaptopurine|
45822741|NCT00002785|Drug|mesna|
45822742|NCT00002785|Drug|methotrexate|
45822743|NCT00002785|Drug|methylprednisolone|
46080191|NCT02739516|Drug|Letrozole|Letrozole oral tablets (Femara 2.5 mg tablet; Novartis Pharma Services, Switzerland) 2.5 mg tab twice daily for 5 days from cycle day 3.
45822744|NCT00002785|Drug|pegaspargase|
45822745|NCT00002785|Drug|prednisone|
45822746|NCT00002785|Drug|therapeutic hydrocortisone|
45822747|NCT00002785|Drug|vincristine sulfate|
45822748|NCT00002785|Procedure|allogeneic bone marrow transplantation|
45822749|NCT00002785|Radiation|low-LET cobalt-60 gamma ray therapy|
45822750|NCT00002785|Radiation|low-LET photon therapy|
45822751|NCT00004178|Biological|therapeutic autologous lymphocytes|
45822752|NCT00004184|Biological|monoclonal antibody 4B5 anti-idiotype vaccine|
45964807|NCT04654936|Behavioral|MIND diet with no support|Participants are to consume MIND diet food recommendations over a 12 week period with no support except for a self-monitoring resource and MIND diet guidelines
45964808|NCT00557635|Procedure|Chirurgical procedure|Chirurgical procedure to treat pseudo-arthrosis, with of osseous matrix implantation and autologous bone marrow injection.
45964809|NCT04654858|Procedure|Direct composite restorations|bulk-fill composite (Filtek BulkFlow, 3M Espe) will be used aftar infiltration or block anaesthesia for affected molar,following by carious tissue removal. Marginal bevelling of enamel will be performed. A universal adhesive (Scotchbond Universal, 3M Espe) will be placed after selective enamel etching A bulk-fill composite will be used and covered using a nanohybrid composite, (Filtek XT, 3M Espe).
45964810|NCT04654624|Drug|SDF|Steps of SDF 38% application were carried out following the manufacturer's instructions. Eligible primary carious teeth were first dried and isolated using cotton rolls and gauze. Adjacent soft tissues were isolated using petrolleum gelly in order to prevent any irritation or staining from SDF that was directly placed into the carious lesion using a microbrush, allowed to absorb for 2 minutes, then dried with air. Parents were instructed that children should not eat for one hour after treatment. The second application was done after 6 months.
46080192|NCT04428853|Behavioral|iyengar yoga|different yoga postures including warm up, cool down and meditation that incorporate 75 minutes of training
46080193|NCT02807324|Other|Venapunction|The only invasive procedure is a venapunction where 75 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare).
46080194|NCT00933283|Drug|Telaprevir|Telaprevir 750 mg will be administered orally, every 8 hours from Day 1 to Day 7, along with methadone, once daily.
45822753|NCT00004184|Biological|sargramostim|
45822754|NCT00004184|Drug|alum adjuvant|
45822755|NCT00003386|Biological|BCG vaccine|
45822756|NCT00003386|Biological|autologous tumor cell vaccine|
45964811|NCT04654624|Drug|ART|Steps of ART caries removal were carried out following the Frencken et al. criteria where the cavity opening was widened using the tip of a dental hatchet. The carious dentin was then removed using a spoon excavator starting at the enamel-dentin junction, unsupported enamel was removed using the hatchet, and finally the cavity was cleaned using a wet cotton pellet and dried. After complete removal of infected dentin, the cavity walls and floor were conditioned for 10 seconds, washed and dried with cotton pellets, then restored with chemically cured glass ionomer cement that was applied under finger pressure, then coated with petroleum jelly.
45964812|NCT00177749|Drug|Posaconazole|
46080195|NCT00933283|Drug|Methadone|Methadone 30 to 130 mg will be administered as a stable oral therapy from Day -14 to Day -1, in combination with telaprevir from Day 1 to Day 7, and then alone as a continued intake dose for an additional 30 to 32 days.
46080196|NCT00634478|Radiation|Pre-lemniscal Radiation Deep Brain Stimulation|
45666949|NCT02447003|Biological|Pembrolizumab|IV infusion of 200 mg.
46080197|NCT02807246|Biological|Maflor®, Mamsel Pharmaceuticals, Turkey|"Dietary Supplement: Probiotics probiotics at a dose of 1x109 CFU/day. (Maflor®, Lactobacillus rhamnosus GG 109 CFU, Mamsel Pharmaceuticals, Turkey)~Other Name: Maflor®"
46080198|NCT02807246|Other|drops of saline|Dietary Supplement: Breast milk +drops of saline
46080199|NCT02730156|Other|Altitude exposure|Altitude exposure
46080200|NCT02739126|Procedure|Radial EBUS biopsy|Radial EBUS is an endobronchial USS which is used to obtain biopsies from a peripheral lung mass.
46080201|NCT02739126|Device|Types of Radial Ultrasound probes|The Radial USS probe comes in two sizes. A thick USS probe that is 1.7mm and the thin USS is 1.4mm in diameter.
45666950|NCT01844284|Device|XIENCE PRIME®/XIENCE Xpedition™|Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
45666951|NCT01844284|Device|Absorb™ BVS|Subjects receiving Absorb™ BVS
46080202|NCT02813018|Procedure|0.2 ml/kg of 0.2% ropivacaine|In the preemptive group, 5 minutes before skin incision, the epidural catheter is dosed with 0.2 ml/kg of 0.2% ropivacaine, followed by continuous infusion of 5 minutes before skin incision at 0.2 ml/kg/h.
45822757|NCT00003386|Drug|carboplatin|
45822758|NCT00003386|Drug|cisplatin|
45822759|NCT00003386|Drug|cyclophosphamide|
45822760|NCT00003386|Drug|paclitaxel|
45822761|NCT00003386|Other|dinitrophenyl|
45666952|NCT02054715|Behavioral|print educational intervention|print educational intervention
45666953|NCT02054715|Behavioral|multimedia psychoeducational intervention|multimedia psychoeducational intervention
45666954|NCT02446769|Device|AVAPS-AE Non-invasive ventilation therapy|Participants will use the device greater than or equal to 4hrs per night for the 60 days after discharge.
45822762|NCT00003386|Procedure|surgical procedure|
45822763|NCT00384566|Drug|Carvedilol|anit hypertensive medication
45666955|NCT02420093|Device|"Pelvis Support Assembly"|"Use of a portable and adjustable Pelvis Support Assembly in the seat of the subject's work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting. This device is not officially named at this time but is as represented in US Patent number is US 8,857,906 B2."
45666956|NCT02419937|Drug|Tocilizumab|162 mg subcutaneously once (vs. 0.9% normal saline placebo injection once in placebo arm)
45666957|NCT02419937|Drug|Placebo|Saline injection
45666958|NCT04594018|Drug|Finlândia Association + finasteride placebo|Finlândia association hair lotion + finasteride placebo
45666959|NCT04594018|Drug|Minoxidil + finasteride|Minoxidil hair lotion + Finasteride 1 mg
45822764|NCT00384566|Drug|Metoprolol|Anti hypertensive medication
45822765|NCT00004832|Drug|3,4-diaminopyridine|
45822766|NCT00384644|Device|NiRS measurment of tissue oxygenation|NiRS measurment of tissue oxygenation
46080203|NCT02813018|Procedure|0.2mg/kg of Normal Saline|In the saline group, 5 minutes before skin incision, the epidural catheter is dosed with 0.2 ml/kg of normal saline, followed by continuous infusion of 5 minutes before skin incision at 0.2 ml/kg/h.
45822767|NCT00002791|Biological|filgrastim|
45822768|NCT00002791|Drug|dacarbazine|
45822769|NCT00002791|Drug|doxorubicin hydrochloride|
45822770|NCT00002791|Drug|ifosfamide|
45822771|NCT00002791|Drug|mesna|
45964813|NCT00200577|Drug|TIL + IL2|Patients are treated with 2 injections Of TIL (1st injection M1 and the second M2)The received concomitant IL2 at M1 and M2 on days Jo (injection TIL) to J5 and J8 to J12
46080204|NCT02730078|Behavioral|VEMOFIT|The VEMOFIT intervention involves four biweekly two hours sessions over a period of about six weeks, and a booster at three months follow-up. It consists of a mixture of 1) exploring illness perceptions and personal meanings of diabetes, 2) cognition-focused education on diabetes and practical skills in self-management and 3) emotion-focused training on recognising emotions in the self and others. Each group will consist of 10 to 12 participants of equal representation by the patients and their significant others.
45666960|NCT02054481|Drug|BI 655066|Medium dose
45666961|NCT02054481|Drug|BI 655066|High dose
45666962|NCT02054481|Drug|Ustekinumab|
45666963|NCT02054481|Drug|BI 655066|Low dose
45822772|NCT00002791|Procedure|conventional surgery|
45822773|NCT00002791|Radiation|brachytherapy|
45822774|NCT00002791|Radiation|intraoperative radiation therapy|
45822775|NCT00002791|Radiation|radioisotope therapy|
45822776|NCT00384722|Device|EASYTRAK 3 Downsize Lead|EASYTRAK 3 Downsize Lead
45822777|NCT00004190|Drug|gemcitabine hydrochloride|
45822778|NCT00004190|Drug|oxaliplatin|
45822779|NCT00004196|Biological|recombinant interferon alfa|
45964814|NCT04654585|Other|The STOP intervention|The stop intervention is a heath professional (medical doctor) led intervention assisting smokers with low socioeconomic position in their smoking cessation attempt. It consists of routine care and adapted advice supplemented with a free delivery of any or several type(s) of nicotine replacement therapy (NRT) (patches, inhalers, gum, tablets, etc.) and/or an e-cigarette + e-liquid. The delivery of those smoking aids is based on the smokers' preference and choice.
45964815|NCT04654585|Other|Standard Care|"Participants randomised to the standard care group will be given standard care in assisting their smoking cessation attempt, but without free delivery of NRT or e-cigarettes.~Standard care includes motivational interviewing, advice to quit and prescription for NRTs. The number and online address of the French smoking cessation support helpline could also be provided. Health professionals will also be in position to prescribe NRT or other treatments (for example: Varenicline or Bupropion) which can help with smoking cessation, according to routine practice. The health professional could also give advice on e-cigarette use if he or she finds it suitable."
45964816|NCT00205491|Drug|Venlafaxine|
45822780|NCT00004196|Procedure|lymphangiography|
45822781|NCT00004196|Drug|Observation|
45822782|NCT00385034|Device|Interactive computer based health-risk survey before doctor's visit|
45964817|NCT04654819|Device|Dental anesthesia simulator usage|Training on dental anesthesia simulator
45964818|NCT04654780|Behavioral|Taxes|"a High in food tax will be applied to study changes in purchasing and consumption behavior of participants in this group. The tax will correspond to a 20% increase over the market price, that is, a tax that reaches the levels recommended by the WHO."
45666964|NCT01610752|Behavioral|SmartMoms|This intervention will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
45666965|NCT02054325|Drug|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
45666966|NCT02054325|Drug|Glucose|An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
45666967|NCT02446691|Biological|MenACWY|Four Intramuscular doses of MenACWY vaccine at 2, 4, 6 and 12 months of age followed by two blood samples at 13 and 24 months of age.
45822783|NCT00004838|Drug|succimer|
45666968|NCT02091375|Drug|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) dissolved in the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
45666969|NCT02091375|Drug|Placebo control|Placebo oral solution contained the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
45822784|NCT00381979|Other|Supportive Expressive Therapy|
45822785|NCT00004844|Procedure|tissue implantation|
45822786|NCT05500807|Drug|Emicizumab|Subcutaneous injection of emicizumab for prophylaxis
45822787|NCT00004202|Drug|carboplatin|
45822788|NCT00004202|Drug|chemotherapy|
45964819|NCT04654780|Behavioral|Subsidies|A subsidy will be applied to fruits and vegetables that means a reduction of 20% in their price, to study the changes in purchasing behavior and of the participants of said group.
45964820|NCT04654780|Behavioral|Control|Average or current food prices will apply. Based on the average of the values reported by three supermarkets
45964821|NCT04654390|Drug|DWP16001 Amg|Tablets, Orally, Once daily
45964822|NCT00205530|Behavioral|Brain Injury Family Intervention (BIFI)|The Brain Injury Family Intervention (BIFI) was developed over the last decade based upon considerable clinical experience and research review. The BIFI is a structured approach to helping families address their most common and salient issues, concerns, and challenges. The BIFI is implemented in five 90-minute sessions.
45964823|NCT04654741|Drug|Medroxyprogesterone Acetate|1 pill per day
45964824|NCT04654741|Drug|Ganirelix Acetate|1 injection per day
45964825|NCT04654234|Device|Total body PET/CT (uExplorer)|A total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER) with a 192-cm scan range was applied for cancer diagnosis, organ function assessment and treatment outcome prediction. The total-body PET scanner can acquire scans with lower administered activity or short acquisition time, total-body dynamic acquisition at a longer delayed time point, and high detectability of exiguous changes of the whole body, and tumor as well.
45964826|NCT04654195|Genetic|polymorphism analysis|DNA will be purified from whole blood samples by commercial DNA isolation kits. Genotyping and genetic polymorphism detection for some metabolic enzymes genes will be performed by real time PCR.
45964827|NCT04654195|Drug|Doxorubicin-Cyclophosphamide regimen|Treatment with a combination of Doxorubicin and Cyclophosphamide, This regimen comprises 60 mg/m² Doxorubicin and 600 mg/m² Cyclophosphamide administered intravenously on day 1 of each 21-day cycle, and repeated for a total of four cycles.
45964828|NCT00200616|Procedure|Antimicrobial prophylaxis|
45964829|NCT04654156|Diagnostic Test|Contrast Boost post processing technique|Contrast Enhancement Boost is a post-processing technique that uses an iodine density map generated by subtracting a pre- and post-contrast CT acquisition to artificially enhance pulmonary artery enhancement.
45964830|NCT04654078|Drug|IN-C004 with water|One time dose of IN-C004 taken with water
45964831|NCT04654078|Drug|IN-C004 without water|One time dose of IN-C004 taken without water
45822789|NCT00004202|Drug|efaproxiral|
45822790|NCT00004202|Drug|paclitaxel|
45822791|NCT00004202|Radiation|radiation therapy|
45822792|NCT00003686|Drug|pilocarpine hydrochloride|Pilocarpine 5 mg po qid x 4 weeks
45822793|NCT00003686|Drug|Placebo|Placebo 5 mg po qid x 4 weeks
45964832|NCT04654078|Drug|K-CAB tab. with water|One time dose of K-CAB tab. taken with water
45964833|NCT00177983|Behavioral|(relapse rate)|
45964834|NCT04654000|Procedure|Rheopheresis procedure|rheopheresis is performed using an automated monitor (Plasauto, company HemaT) in a double-filtration cascade. Plasma purify from of high molecular weight proteins
45822794|NCT05495035|Drug|Olverembatinib, APG-2575, Dexamethasone|"Period 1: Subjects will orally take olverembatinib 40mg adult equivalent dose alone QOD from Day 1 to Day 14 (D1 - D14) =. The investigator may start the combination therapy in advance based on medical conditions of the subjects, but not earlier than Day 5/the third dose (D5).~Period 2: 1) Subjects will orally take olverembatinib 40mg adult equivalent dose QOD from Day 15 to Day 42 (D15 - D42)).~2) Subjects will orally take APG-2575 at a ramp up 200mg/400mg/600mg adult equivalent dos QD from D13 to D42 at a dose . In addition, a 3-day dose escalation from D13 to D15 will be needed, and the designated reference dose will be reached on D15.~3) Subjects will orally take dexamethasone 6 mg/m2/day, QD from D15 to D42 at 6 mg/m2/day."
45964835|NCT04654000|Procedure|Sham-apheresis|Sham-apheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient.
45964836|NCT00205569|Behavioral|First Steps Educational Curriculum|10 sessions with the research participant to review an educational curriculum regarding brain injury rehabilitation and community reintegration
45964837|NCT03454789|Drug|brachial plexus block for LB Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
45964838|NCT03454789|Drug|brachial plexus block for BS Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
45964839|NCT03454789|Drug|brachial plexus block for LS Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
45964840|NCT03454789|Drug|brachial plexus block for BL Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
45964841|NCT04653727|Other|Cross-sectional survey|No intervention.
45964842|NCT00178022|Behavioral|Case management and problem solving therapy|
45964843|NCT04653532|Behavioral|Exercise Programme and Counselling|A 6 month exercise and physical activity programme supported by an exercise specialist
45964844|NCT04653532|Device|Polar Ignite and App|A fitness watch that links to a mobile phone application (App) which enables the exercise specialist to provide greater support and feedback throughout the programme
45964845|NCT00200655|Drug|Pravastatin|
45666970|NCT05129865|Drug|LYT-300|A prodrug of allopregnanolone, a small molecule drug
45666971|NCT05129865|Other|Placebo|Placebo for LYT-300
45666972|NCT04690335|Biological|MV-012-968|MV-012-968 is a recombinant, live attenuated RSV vaccine.
45666973|NCT04690335|Other|Placebo|Saline solution
45666974|NCT02032875|Drug|Daclatasvir|
45666975|NCT02032875|Drug|Sofosbuvir|
45666976|NCT02032875|Drug|Ribavirin|
45666977|NCT04713033|Diagnostic Test|surface electromyogram (sEMG)|A device that measures electrical signals from your skin will be connected to those stickers and will make a graph that is characteristic to your vocal function.
45822795|NCT00004856|Biological|trastuzumab|Given IV
45822796|NCT04438525|Diagnostic Test|sting challenge|At the Moment, sting challenges are the only reliable method to identify patients who are not protected by insect venom immunotherapy.
45822797|NCT04438525|Other|blood donation|To perform BAT Inhibition Tests, blood samples of patients with confirmed vespid venom allergy, who have not undergone venom immunotherapy, are necessary.
45822798|NCT00003692|Procedure|therapeutic thoracoscopy|
45822799|NCT00003692|Procedure|video-assisted surgery|
45822800|NCT05492773|Device|Micro-osteoperforations Technique|Micro-Osteoperforations Technique (MOPs) Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement.
45822801|NCT05492773|Device|Active comparater|Active Comparator: Traditional treatment The patients in this group will be receive treatment with the traditional clear aligners technique without any surgical procedure.
45822802|NCT04438057|Biological|CCP|Randomized open label study to receive 2:1 CCP to standard of care
45822803|NCT00003698|Drug|fosbretabulin disodium|
45964846|NCT00200655|Drug|Placebo|
45964847|NCT04653649|Biological|HSP-CAR30|Anti-CD30 CAR T-cells
45964848|NCT00178061|Behavioral|Interpersonal Social Rhythm Therapy (IPSRT)|
45964849|NCT04653493|Biological|CD19 CAR engineered autologous T-cells|"Given IV~Following preconditioning with lymphodepleting chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) T cells as a single or split dose (day 0, 1 and 2, CAR cells will be intravenously infused at the 10%, 30% and 60% ratio respectively). Dosing of CD19 CAR-T cells will follow a dose-escalation schema, with dose changes based on dose-limiting toxicities."
45964850|NCT04653493|Drug|Cyclophosphamide|Given IV
45964851|NCT04653493|Drug|Fludarabine|Given IV
45964852|NCT04653493|Drug|Mesna|Given IV
45964853|NCT00200694|Drug|ramipril 5 mg + valsartan 80 mg/day,|
45964854|NCT00200694|Drug|ramipril 10 mg + valsartan 160 mg/day,|
45666978|NCT04713033|Diagnostic Test|flexible laryngoscopy|"A device that examines the throat and nasal passages. The flexible laryngoscope or scope consists of an eyepiece and a fiber-optic light enclosed in a thin, flexible tube. The scope looks like a strand of black spaghetti with a tiny light on the end of it. The scope is inserted through the nose, and can be moved around to help the doctor see all areas of the nasal passages and throat."
45822804|NCT04600375|Behavioral|Verbal consultation|Verbal consultation only without written information before receiving written action plan
45964855|NCT00200694|Drug|ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide.|
45666979|NCT02032407|Drug|Dapsone Gel|Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
45964856|NCT00557713|Drug|bevacizumab|"-Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)~-Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))~-Surgery (6-8 weeks after last bevacizumab dose)~-Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)"
45964857|NCT00557752|Device|Non-invasive ventilation|Applied continuously for the first 24 hours, then every 24 hours, trial of discontinuation. Interface specific for the associated injuries.
45964858|NCT00178100|Behavioral|Interpersonal Psychotherapy|
45964859|NCT00178100|Drug|paroxetine|
45964860|NCT04653415|Drug|Gabapentin 300mg|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
45964861|NCT04653415|Drug|Methylprednisolone 125 mg|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
45666980|NCT04689867|Behavioral|Cognitive Behavioral Suicide Prevention for psychosis CBSPp)|Cognitive and behavioral approach to suicide prevention among individuals with psychosis
45822805|NCT04600375|Behavioral|Written Action Plan|Written handout of treatment plan and disease management strategies
45822806|NCT00004208|Drug|ATG + CSA|Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)
45822807|NCT00004208|Behavioral|Supportive care|Patients randomized to this arm will be treated as outpatients.
45822808|NCT00004862|Biological|filgrastim|
45822809|NCT00004862|Biological|oblimersen sodium|
45822810|NCT00004862|Drug|cytarabine|
45822811|NCT00004862|Drug|fludarabine phosphate|
45822812|NCT05533333|Behavioral|Falls prevention exercises|A dual-task activity involves the simultaneous performance of two activities involving physical and cognitive tasks.
45822813|NCT00004220|Drug|gemcitabine hydrochloride|
45822814|NCT00004220|Drug|oxaliplatin|
45964862|NCT04653415|Drug|Tablet|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
45964863|NCT04653415|Drug|Normal Saline 10 mL Injection|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
45964864|NCT00205608|Device|Positron Emission Tomography|camera is new
45964865|NCT04653259|Other|LYFE MD app|"LyfeMD app is a digital health platform for patients living with both Crohn's disease (CD) and Ulcerative colitis (UC). LyfeMD is meant to help people live and thrive while managing their inflammatory disease with holistic, easy-to-implement, evidence based lifestyle therapies. LyfeMD is one app with multiple features - ranging from customized diet using anti-inflammatory principles identified from recent research, exercise plans to mindfulness and stress reduction programs. It helps patients make therapeutic diet choices to treat inflammation and provides stress reduction strategies when they feel unwell. The LyfeMD app also supports patients to maintain remission even when they're feeling well with trusted resources designed to keep them symptom free.~In addition to delivering personalized and interactive support, the app uses behaviour science to help patients change their habits, improve their health and reduce the burden IBD places on their lives."
45964866|NCT00557791|Drug|Bevasiranib|Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks
45964867|NCT00557791|Drug|ranibizumab|Lucentis® (0.5 mg) administered intravitreally every 4 weeks.
45964868|NCT00178139|Behavioral|Music Therapy|Music Therapy
45964869|NCT04653298|Other|Evaluation of quality of life, comorbidities and return to work status|Quality of life will be evaluated thanks to several methods: Short Form 36, EQ 5D 5L and return to work status Questionnaires will be evaluated through postal and phone call at least 12 months after ECMO.
45964870|NCT04653376|Procedure|Tonsillectomy surgery|The tonsillectomy procedure was performed under general anesthesia using the classical dissection method. Extracted tonsil tissue samples were sent to the medical genetics department in tubes to investigate the ER stress and apoptosis.
45964871|NCT00178217|Behavioral|Music Therapy|The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.
45666981|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 6
45822815|NCT05492071|Device|Local Vibration Application Following Flow Mediated Dilation|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure). Vibration is applied with a commercially available vibration plate to forearm at 20 hz and 3 mm of vertical amplitude for 5 minutes, 30 minutes after termination of FMD.
45822816|NCT05492071|Other|Flow mediated dilation|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure).
45964872|NCT04653025|Device|Implant placement|After tooth extraction implants were placed either immediate or delayed approach
45964873|NCT04653103|Procedure|Liver biopsy|Biopsy of the liver to assess for Non-alcoholic steatohepatitis
45964874|NCT04652947|Diagnostic Test|MRI diagnostic|no intervention, patient only have MRI
45964875|NCT00205647|Drug|Oral N-acetycystein (NAC)|
45964876|NCT04652635|Procedure|Nail plate removal, nail bed repair|Injection of local anesthetic, removal of nail plate, inspection of nail bed, repair of nail bed with suture and/or adhesive
45964877|NCT04652752|Device|CONNETTIVINA HI TECH patch|It is a medical device for topical application in the form of a patch with adhesive transparent polyurethane edge and a central pad impregnated with a solution of hyaluronic acid sodium salt, able to create a hydrating environment, such as to favor the natural healing process of tissue repair in case of bruises, abrasions, small cuts, superficial wounds, burns
45964878|NCT04652284|Drug|Rifabutin|150 mg
45964879|NCT04652284|Drug|Amoxicillin|1000 mg
45964880|NCT04652284|Drug|Esomeprazole|40 mg
45964881|NCT04652284|Drug|Clarithromycin|500 mg
45964882|NCT04652284|Drug|Tinidazole|500 mg
45964883|NCT04652323|Drug|Biocompatibility of calcium silicate cements|The presence of inflammation, edema, necrosis, dystrophic calcification, and thickness of fibrous capsule formation was recorded by histological examination 7, 30, and 60 days after the implantation procedure of materials.
45964884|NCT04652011|Procedure|Minimally Invasive Gynecologic Surgery|Minimally Invasive Surgery for gynecologic disease (laparoscopy, robotic surgery, vaginal surgery)
45964885|NCT04652011|Procedure|osteopathic manipulative treatment|Osteopathic manipulative treatment
45964886|NCT04652011|Drug|Pain killer|Common pain killer (paracetamol, Ibuprofen, ketoprofen)
45964887|NCT00178295|Radiation|Radiation Therapy|standard of care for the cancer being treated
45666982|NCT01843972|Drug|BI 691751|oral solution
45666983|NCT01843972|Drug|Placebo|placebo solution
45666984|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 2
45666985|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 5
45666986|NCT01843972|Drug|BI 691751|1 tablet
45666987|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 3
45964888|NCT00205686|Drug|DHEA|
45666988|NCT01843972|Drug|BI 691751|oral solution BI 69175, dose 4
45666989|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 7
45666990|NCT01843972|Drug|BI 691751|oral solution BI 69175, dose 1
45666991|NCT01826422|Dietary Supplement|EPA and DHA|Each capsule contains 225mg of DHA, 45mg of EPA, other omega 3 fatty acids 20mg.
45822817|NCT00003704|Drug|capecitabine|
45822818|NCT00003704|Radiation|radiation therapy|
45822819|NCT00004868|Drug|semaxanib|
45964889|NCT00205686|Behavioral|exercise|
45964890|NCT04651933|Genetic|Homologous recombination deficiency model|A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH)
45964891|NCT04652128|Drug|Zoledronic acid|Subject will receive a single infusion of zoledronic acid 5mg/100mL intravenously.
45964892|NCT04652128|Drug|Placebo|Subject will receive a single infusion of physiological saline 100mL intravenously.
45964893|NCT04651894|Device|reactive hyperaemia index measurement|"reactive hyperaemia index with EndoPAT®~Pulse wave velocity measurement with Sphygmocor®"
45964894|NCT00205725|Drug|Ziprasidone, Olanzapine|
45964895|NCT04651738|Diagnostic Test|DNA methylation testing|Methylation testing of host DNA, namely, BHLHE22, CELF4, HAND2, and ZNF177
45964896|NCT04651426|Device|The FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1|"The FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1 which mechanism of action is through the ability of biominerals to reflect the far infrared radiation (FIR). Normally the human body temperature would dissipate regular far infrared radiations but, thanks to the FIT Therapy (Far Infrared Technology), these waves are reflected and allowed to reach deeper areas in the human body (wavelength spectrum is 4-21 µm with a denser concentration around 11 µm).~Every FIT device act as a mirror and they are able to induce an antalgic effect simply thanks to this biophysical process, therefore without releasing any active ingredient or creating a thermic shock.~The plasters are made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on. This particular mix in powder form is characterized by particles sizes above 100 nm."
45964897|NCT00178373|Drug|Modafinil|
45964898|NCT00178373|Drug|sugar pill|
45964899|NCT00200928|Biological|BCG|
45964900|NCT04651777|Drug|FF/UMEC/VI|The investigational drug is a single Ellipta inhaler containing 200 ug fluticasone furoate, 62.5 ug umedlidinium and 25 ug vilanterol. The drug is delivered in an Ellipta inhaler in a single dose once daily.
45964901|NCT04651231|Procedure|releasable sutures in punch trabeculectomy|punch trabeculectomy,scleral flap suturing
45964902|NCT04650958|Procedure|Deep brain stimulation|Deep brain stimulation (DBS) has been in use to treat patients with movement disorders since 1989, with many thousands of publications showing its effectiveness. DBS for dystonia received the US FDA mark in 2003 and China FDA mark in 2016. In this study, the DBS system devices are manufactured and donated by SceneRay (Suzhou, China). The Stimulator System is implanted by a qualified neurosurgeon and consists of three implantable components: the leads, the extension wires and the neurostimulator. The DBS programming will start within 1 week after the surgery completed.
45964903|NCT00178412|Behavioral|Care Project for Hospitalized Elders & Family Caregivers|"Phase 1 in-hospital contact: Family caregivers complete baseline data, listen to a tape about helping the elderly relative cope with hospitalization, and work on a mutual agreement/identification of goals for participation in family member's hospital care (i.e., selection of two complications to focus on based on patient's illness condition)~Phase 2 pre-hospital discharge: Family caregivers listen to a second tape about coping with the hospital experience, participating in their family member's in-hospital care, and preparing for hospital discharge/transition to home"
45964904|NCT00178412|Behavioral|Comparison Group|"Phase 1 in-hospital contact: Family caregivers complete baseline data and listen to an informational tape about hospital policies.~Phase 2 pre-hospital discharge: Family caregivers listen to a second informational tape about the hospital and medical center."
45964905|NCT04651309|Other|Transperineal Ultrasound|The ultrasound examination will be conducted using the technique described by Hassan et al (2013). Briefly, transperineal ultrasound images are obtained by placing a covered transducer between the labia below the symphysis pubis. Small lateral movements of the probe are then made to align the ultrasound beam in a midsagittal orientation to include the whole cervical length after which the probe is rotated 90 degrees in order to measure the cervical dilatation. The probe is rotated up and down until the echogenic circle of the cervix is seen. Please note that this technique is widely used within the delivery room and that the ultrasound machine that will be used is frequently used within the delivery room.
45964906|NCT00205764|Drug|Melphalan|
45964907|NCT00557908|Drug|VWF/FVIII products|"Participants in the prospective phase of the study undergo an escalation of treatment from receipt of one to three levels of VWD product. All subjects enrolled will begin treatment on the level one and remain on this regimen for the duration of follow-up, or until they meet the criteria for escalation to level two or three (if indeed they do meet the criteria.)~Dosing for joint bleeding, epistaxis, and GI bleeding indications: 50 U RCo/kg once per week, 50 U RCo/kg twice per week, or 50 U RCo/kg three times per week.~Dosing for menorrhagia: 50 U RCo/kg on day 1 of menses for 2 cycles, 50 U RCo/kg on days 1 and 2 of menses for 2 cycles, or 50 U RCo/kg on days 1, 2, and 3 of menses"
45964908|NCT00557986|Procedure|Primary surgery|Primary breast surgery before systemic therapy
45964909|NCT00558142|Drug|Acetylcysteine|Participants will receive packs of either 8 placebo capsules or 8 acetylcysteine (600mg) capsules. They will be asked to take 2 tablets at 08.00 and 22.00 on the day before the study and the day of the study. On the day of the study participants will receive an IV infusion of either normal saline or acetylcysteine (200mg/kg)
45964910|NCT00558142|Drug|Visipaque 320|100mls IV dose as single dose
45964911|NCT00558142|Drug|Visipaque 320|The dose of Visipaque will be administered by the consultant cardiologist performing the coronary angiography
45666992|NCT01826422|Dietary Supplement|Placebo Comparator|Placebo capsules will contain gelatin and sunflower oil. Fatty acid composition is as follows: lauric (C12:0), 0.19%; myristic (C14:0), 0.29%; palmitic (C16:0), 7.59%; palmitoleic (C16:1), 0.25%; stearic (C18:0), 3.49%; oleic (C18:1), 31.08%; linolenic (C18:3), 1.13%; linoleic (C18:2), 55.64%; DHA 0.02%; arachidic (C20:0), 0.30% and arachidonic (C20:4), 0.01%.
45822820|NCT00003710|Drug|irinotecan hydrochloride|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
45666993|NCT01843660|Drug|Tramadol HCl-Paracetamol|Participants will receive 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325mg) for up to a total duration of 6 hours. Additional dose may be given based upon the clinical requirement.
45666994|NCT02090283|Drug|SD-101 dermal cream (6%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
45822821|NCT00003710|Drug|mitomycin C|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
45822822|NCT05232097|Behavioral|Behavioral therapy|Diaphragmatic breathing exercises
45666995|NCT02032173|Drug|Ranibizumab 0.5mg|Intravitreal injection with standard dose of 0.5 mg/0.05mL Pro re nata (PRN)
45666996|NCT04712409|Procedure|Single anastomosis duodeno-ileal bypass|Sleeve gastrectomy followed by division of the duodenum bypassing the jejunum with end-to-side duodeno-ileal diversion
45666997|NCT04712409|Procedure|Biliopancreatic diversion with duodenal switch|Sleeve gastrectomy, followed by division of the duodenum bypassing the jejunum with end-to-side duedeno-ileal diversion and Roux-en-y entero-enteric anastomosis, leaving 100 cm common channel.
45964912|NCT00205842|Drug|alvimopan|
45964913|NCT04650997|Behavioral|Eccentric exercise|Knee eccentric exercise with sham or focused extrocorporeal shockwave therapy for 12 weeks
45964914|NCT04650724|Drug|T cell infusion agent targeting BCMA chimeric antigen receptor|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
45964915|NCT04650802|Device|Gait training|Participants receive five weeks individual robotic gait training in LOPES II, targeting paretic propulsion (60 minutes, two time a week). The robotic gait training is complemented with daily home exercises (15 minutes/day) focusing on increasing strength and practice of learned strategies in daily life.
45964916|NCT00205920|Biological|BLVR Hydrogel|10 mL BLVR Hydrogel
45964917|NCT04651036|Drug|QL0605|a pegfilgrastim biosimilar to US Neulasta.
45666998|NCT04712409|Procedure|SADI-S as a revisional procedure|In patients previously submitted to sleeve gastrectomy a single anastomosis duodeno-ileal bypass will be performed as 2nd time surgery
45666999|NCT04712409|Procedure|BPD-DS as a revisional procedure|In patients previously submitted to sleeve gastrectomy a biliopancreatic diversion with duodenal switch will be performed as 2nd time surgery
45667000|NCT04689477|Device|Vascular occlusion test|The ischemic challenge will consist in a standardized Vascular Occlusion Test (VOT), as previously described in the literature. Briefly, a blood pressure cuff will be placed proximal to the forearm, and rapidly inflated at 40 mmHg above systolic pressure, and kept inflated during three minutes. Then the cuff will be rapidly deflated. The resulting deoxygenation (DeO2) and reoxygenation (ReO2) slopes will be reported as change in O2 saturation over time.
45667001|NCT02031471|Drug|tocilizumab|Fixed dose of 162 mg subcutaneously weekly
45667002|NCT02461589|Drug|semaglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.
45822823|NCT05232097|Behavioral|Physiotherapy|Body awareness aiming at the patient becoming aware of the tensed thoracic and abdominal muscles and to reduce the tension by relaxation exercises taught by the psychophysical physiotherapist
45822824|NCT00004226|Radiation|radiation therapy|
45822825|NCT05485675|Behavioral|Stand & Move at Work|Web-based platform only.
45822826|NCT05485675|Behavioral|Stand & Move at Work+|Web-based platform and support from an expert facilitator
45822827|NCT00004232|Biological|filgrastim|
45822828|NCT00004232|Drug|cyclosporine|
45667003|NCT02461589|Drug|liraglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.
45822829|NCT00004232|Drug|methylprednisolone|
45822830|NCT00004232|Drug|prednisone|
45822831|NCT00004232|Procedure|allogeneic bone marrow transplantation|
45822832|NCT00004232|Procedure|peripheral blood stem cell transplantation|
45822833|NCT00004238|Drug|pralatrexate|
45822834|NCT00004874|Radiation|tositumomab and iodine I 131 tositumomab|Dosimetric Dose:Unlabeled anti-B1 (450mg) will be given as peripheral or central IV infusion over one hour or longer depending upon rate-dependent side effects. A trace-labeled dose of 131I-anti-B will be infused over 20 minutes, if rate-dependent side effects permit. An amount of unlabeled Anti-B1 Antibody is added to the 5 mCi of Iodine-131 Anti-B1 Antibody sufficient to result in a final amount of 35 mg of Anti-B1 antibody. On study Day 7 (may be delayed up to study Day 14), patients will receive the therapeutic dose, which consists of an infusion of 450mg of Anti-B1 Antibody followed by an infusion of Iodine-131 Anti-B1 Antibody.
45964918|NCT04651036|Drug|US Neulasta|US Neulasta
45964919|NCT00178451|Drug|Abciximab|
45964920|NCT04650529|Device|stent, ballooning|DES, BMS, BRS, DEB, and POBA can be used for PCI
45964921|NCT04650685|Device|The novel Salvadora persica toothbrush|The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
45964922|NCT04650685|Device|The Salvadora persica (miswak) chewing stick|The Salvadora persica chewing stick will be used twice daily without the application of toothpaste. The Salvadora persica chewing sticks need to be prepared prior to use. A five-finger grip technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
45964923|NCT04650685|Device|Standard toothbrush and toothpaste (control)|The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
45964924|NCT04650334|Behavioral|Collaborative Care|Health services intervention to implement a team based model of care for perinatal depression.
45964925|NCT00205959|Device|Locking proximal humerus plate|
45964926|NCT00205959|Device|Proximal Humerus Internal Locking System|
45964927|NCT00205959|Device|Proximal Humerus Nail|
45964928|NCT00178490|Drug|High blood pressure treatment|Participants who are identified as having high blood pressure will be given by a pediatric nephrologist a 12-month treatment plan for their high blood pressure. The treatment plan will include a combination of diet, weight loss, increased exercise, and if needed, blood pressure medication. Participants receiving medication treatment will be treated with a calcium channel blocker and/or ACE inhibitor.
45964929|NCT04650412|Other|Bundle of comorbidities care|Pulmonary function tests, blood gas analysis, transthoracic echocardiography, sleep study after stabilization of patient's index clinical condition, thus 1 month after hospital discharge
45964930|NCT04650373|Procedure|Bariateric surgery|Adult patients underwent RYGB surgical treatment during the period from 2014 to 2019
45964931|NCT04650763|Biological|PRP injection|PRP was prepared using patient's blood and mixed with saline or mixture of calcium chloride and thrombin to form a liquid solution; in order to inject at the surgical site after placement of implant.
45964932|NCT04650763|Device|Automated blood cell separator to extract PRP|Blood was withdrawn from antecubital vein and mixed with anticoagulant. Blood sample was then centrifuged to obtain platelet rich plasma which was injected at surgical site after implant placement.
45964933|NCT00205998|Device|Locking Compression Plate 2,4mm|
45822835|NCT05230927|Other|Multidisciplinary Rehabilitation|All patients admitted to an inpatient rehabilitation program will undergo medical history collection, physical, clinical, and functional examination, exercise testing, educational sessions, exercise training (cycle ergometer/treadmill, arm ergometer, breathing, and strength exercises where indicated, calisthenics exercises), psychological counseling, and metabolic evaluation with a personalized diet when needed.
45822836|NCT00004244|Biological|recombinant interferon alfa|
45964934|NCT00205998|Device|Locking Compression Plate 3,5mm|
45667004|NCT02461589|Drug|placebo|Administered subcutaneously ( s.c., under the skin) once daily.
45964935|NCT00178529|Behavioral|Psychoeducation, Counseling and Skill Training|
45667005|NCT04420793|Other|Questionnaire|3 voice recording tasks and 1 text entry task will be performed.
45667006|NCT04934189|Behavioral|Empowerment Self Defense Training|We have contracted with Prepare, Inc., the New York City chapter of IMPACT International to deliver the tailored ESD violence prevention intervention. IMPACT is an international ESD violence prevention organization with chapters across the United States. Prepare, Inc. will provide facilitators who have completed IMPACT's nationally standardized ESD violence prevention program requirements that include receipt of over 100 hours of training. IMPACT training is open to trans and cisgender women. The extensive training of IMPACT facilitators promotes intervention efficacy, while the risk of potential bias conferred by their experience with a pre-existing curriculum is mitigated by our community-engaged approach (i.e.,TW community members, service providers, and scientists [PI and Co-I] collectively shape the content of the final tailored ESD intervention, and TW co-facilitators will be present in every training session).
45667007|NCT02089737|Drug|Panitumumab|Panitumumab for intravenous infusion
45964936|NCT04649749|Diagnostic Test|MRI|MRI scan
45667008|NCT04688853|Biological|TEG002|TEG002 cells are autologous T cells transduced with a specific γδTCR
45822837|NCT00004244|Biological|recombinant interleukin-12|
45822838|NCT00004880|Biological|dendritic cell vaccine therapy|
45822839|NCT00004880|Procedure|conventional surgery|
45964937|NCT04650139|Procedure|PCI - percutaneous coronary intervention|percutaneous coronary intervention
45964938|NCT04649827|Other|Clinical Observation|This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, medications, and other risk factors such as the severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and main outcomes during hospitalization.
45455478|NCT04561700|Diagnostic Test|Control|In the control group, the information captured by the Instrumented Bottle will not be made available to speech therapists and therefore, will not be used to document a feeding session or provide weekly recommendations.
45667009|NCT02460575|Biological|Lactobacillus reuteri 17938|probiotic
45667010|NCT02460575|Biological|Placebo|Composition Sunflower oil, medium chain triglyceride oil and silicon dioxide. Total viable count of L. reuteri is zero CFU/ 5 drops.
45964939|NCT00206037|Device|COLLOSS E|
45964940|NCT00206037|Device|TomoFix Plate|
45964941|NCT04650022|Device|Mechanical thrombectomy|Stent retriever for treatment of cerebral arterial occlusions
45964942|NCT00178568|Behavioral|Stress Management and Healthy Sleep Practices|Eight weekly sessions of 1 hour each reviewing stress management techniques and tips for improving sleep.
45964943|NCT04649944|Diagnostic Test|Serological test and phone interview|"Families are interviewed by telephone to gather information about the family cluster (i.e. age and number of cohabitants, their symptoms and swab results, if performed), the subject who tested positive (i.e.sex, age, course of the disease, symptoms suggestive of COVID-19) and children aged between 4 and 16 y.o. (i.e. sex, age, drug therapy and/or chronic diseases, symptoms suggestive of COVID-19).~Children, young adults and the cohabitant who previously tested positive to the swab undergo a serological test for the detection of IgG and IgM antibodies for Sars-Cov-2."
45964944|NCT04650061|Behavioral|Motivational Interview (MI) & Adherence Follow-Up|With MI, the key goal is to empower the patient to commit to follow CPAP therapy, while providing empathic support, in a positive atmosphere, and without prejudice. The nurse does not directly advocate for behavior change (i.e. use CPAP as prescribed), but asks key questions to help the patient explore their feelings about the change, weighs the pros and cons of such change, and allows the patient to realize the discrepancy between the current risk (that is, not using CPAP as directed) and the benefits with good adherence.
45964945|NCT04650061|Device|Adherence Follow-Up|The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.
45964946|NCT00206115|Drug|Seroquel Sustained Release (SR)|
45964947|NCT00206115|Drug|Seroquel Immediate Release (IR)|
45667011|NCT04923191|Other|Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care|percutaneous coronary intervention
45964948|NCT00206115|Drug|Placebo|
45667012|NCT02089347|Biological|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly.
45667013|NCT02089347|Biological|Diphtheria and Tetanus toxoids adsorbed|0.1 mL, Subcutaneously
45822840|NCT05218993|Diagnostic Test|A new dual-task measurement method with images|Football players will perform Illinois t test with and without cognitive demand with images. These images will represent scenarios from football with some of the players in the scene are from his team and others from opposing team. The player will be asked to look at the image and say the number on the player in following scenarios; The player to whom he can pass the ball, The player who is most likely to intervene the ball, The player who can score the goal. In order to reduce the other possibilities, opposing team players will be positioned in a specific way to block all team-mates but one.
45667014|NCT02419469|Drug|Cytarabine|"Participants initially receive intrathecal treatment using Cytarabine 100 mg on Day 1. Induction chemotherapy must begin within 3 days of the intrathecal Cytarabine dose.~Consolidation Therapy 1: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and 8 - 11.~Consolidation Therapy 3B: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and Days 8 - 11."
45667015|NCT02419469|Drug|Daunorubicin|Induction Therapy: Daunorubicin 25 mg/m2 by vein weekly for 4 doses.
45667016|NCT02419469|Drug|Vincristine|"Induction Therapy: Vincristine 1.5 mg/m2 by vein weekly for 4 doses.~Consolidation Therapy 1: Vincristine 1.5 mg/m2 by vein Week 3 and Week 4.~Consolidation Therapy 2: Vincristine 1.5 mg/m2 by vein every 10 days for 5 doses.~Consolidation Therapy 3A: Vincristine 1.5 mg/m2 by vein weekly for 3 doses.~Consolidation Therapy 3B: Vincristine 1.5 mg/m2 by vein Weeks 3 and 4.~Maintenance Therapy (24 months): Vincristine 1.5 mg/m2 by vein every 28 days."
45822841|NCT05218993|Diagnostic Test|A new dual-task measurement method with cards|Football players will perform Illinois t test with and without cognitive demand with cards and balls. On the path of Illinois t test, there will be 3 football balls, 3-meters apart from each other, and there will be cards behind each, which can only be seen when the player about to hit the ball. This cards will vary in color (blue or red), which mean right or left. If the player sees red card, he will shoot the ball to the left side goal and if the player sees blue card, he will shoot the ball to the right side.
45822842|NCT00004250|Biological|dactinomycin|
45822843|NCT00004250|Drug|isolated limb perfusion|
45822844|NCT00004250|Drug|melphalan|
45822845|NCT00003728|Drug|asparaginase|
45822846|NCT00003728|Drug|cyclophosphamide|
45822847|NCT00003728|Drug|cytarabine|
45822848|NCT00003728|Drug|daunorubicin hydrochloride|
45822849|NCT00003728|Drug|dexamethasone|
45822850|NCT00003728|Drug|doxorubicin hydrochloride|
45822851|NCT00003728|Drug|etoposide|
45822852|NCT00003728|Drug|leucovorin calcium|
45822853|NCT00003728|Drug|mercaptopurine|
45822854|NCT00003728|Drug|methotrexate|
45822855|NCT00003728|Drug|methylprednisolone|
45822856|NCT00003728|Drug|mitoxantrone hydrochloride|
45822857|NCT00003728|Drug|prednisolone|
45822858|NCT00003728|Drug|therapeutic hydrocortisone|
45822859|NCT00003728|Drug|thioguanine|
45964949|NCT04649554|Device|Exablate treatment|Ablation
45964950|NCT04649437|Diagnostic Test|Quantitative sensory testing|Quantitative sensory testing recordings will be collected by pressure algometry Assessment of temporal summation of pressure pain and conditioning pain modulation will be used to investigate the involvement of pain sensitization.
45822860|NCT00003728|Drug|vincristine sulfate|
45822861|NCT00003728|Drug|vindesine|
45822862|NCT00003728|Procedure|allogeneic bone marrow transplantation|
45822863|NCT00003728|Procedure|peripheral blood stem cell transplantation|
45964951|NCT04649281|Device|Accelerometry|Recording of sleep and physical activity by accelerometry during one week.
45964952|NCT04638556|Diagnostic Test|lncRNA detection|The lncRNAs in the plasma of three groups of patients will be tested.
45964953|NCT00206154|Drug|Budesonide/formoterol pMDI|
45964954|NCT00206154|Drug|Budesonide pMDI|
45964955|NCT00206154|Drug|Formoterol Turbuhaler|
45964956|NCT04638868|Device|Microsieve device|Both portal venous and peripheral blood will be processed through a label-free size-based silicon microsieve microfiltration device, which will isolate both epithelial-type and mesenchymal-type pancreatic cancer circulating tumor cells. Downstream mutational analyses will be performed to confirm identity of the cells.
45964957|NCT04638868|Device|Cell surface marker-based platform|Both portal venous and peripheral blood will be processed through a cell surface marker-based platform, which contains antibodies for epithelial cell markers on pancreatic cancer circulating tumor cells. Downstream mutational analyses will be performed to confirm identity of the cells.
45964958|NCT00178724|Other|No Treatment Given|Intervention is not given.
45964959|NCT04639063|Other|Microscopic examination using H&E stained slides|Reexamination of the stained slides of the patients from the hospital archive and adding a CD10 stain when required
45964960|NCT00559702|Drug|natalizumab|natalizumab
45964961|NCT00559702|Other|standard of care|standard of care as determined by the Investigator and Treating Neurologist
45964962|NCT00559741|Biological|cetuximab|
45964963|NCT00559741|Drug|fluorouracil|
45964964|NCT00559741|Drug|irinotecan hydrochloride|
45667017|NCT02419469|Drug|Prednisone|Induction Therapy: Prednisone 60 mg/m2/day by mouth for 28 days.
45822864|NCT04833829|Behavioral|CHIMES Intervention|"There are six components to the intervention:~Posters and other print materials to prompt providers and patients to discuss MH care engagement.~Brief verbal scripts to help HIV providers facilitate patient MH engagement and discuss barriers to MH utilization.~Expanded MH screening procedures, including at initial intake.~Case management, emphasizing MH care engagement.~Interactive trainings for all HIV providers on MH needs, screening/treatment, and barriers to MH service utilization specific to YB-GBMSM.~Regular case review meetings."
45964965|NCT00559741|Drug|leucovorin calcium|
45964966|NCT00559741|Other|pharmacological study|
45964967|NCT00559780|Behavioral|Resistance training|12 weeks of resistance training (3/week)
45964968|NCT00559780|Behavioral|Neuromuscular electrical stimulation of the quadriceps muscle|12 weeks of neuromuscular electrical stimulation of the quadriceps muscle (1h/day)
45964969|NCT00559780|Behavioral|Standard rehabilitation|12 weeks of standard physiotherapy exercises (1h/day)
45964970|NCT00178763|Device|Heckel Infrared Radiant Heat Device|thermotherapy, maintain a core temperature of 40 degrees centigrade for 6 hours duration
45964971|NCT00178763|Other|cisplatin, gemcitabine, interferon-alpha|cisplatin 60 mg/m2 administered over 3 hours intravenously 36 hours before heat. gemcitabine 600 mg/m2 administered intravenously over 1 hour during 40 degree heat. interferon-alpha 1 million international units subcutaneously daily during protocol.
45964972|NCT00178763|Other|thermochemotherapy|fever-range whole-body thermal therapy to 40 degrees centigrade combined with cisplatin 60 mg/m2 + gemcitabine 600 mg/m2 + daily interferon alpha 1 million units.
45964973|NCT00559858|Dietary Supplement|pyridoxine hydrochloride|
45455479|NCT01223131|Drug|Insulin glargine (HOE901)|"Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous"
45822865|NCT04833829|Behavioral|Standard of Care|The standard of care practices of referring patients to mental health services of the clinic during Months 1 - 12 of the study.
45822866|NCT00004886|Drug|docetaxel|
45822867|NCT00004886|Drug|dofequidar fumarate|
45822868|NCT00382759|Procedure|stem cell transplant|
45822869|NCT00003734|Drug|flutamide|
45667018|NCT02419469|Drug|PEG asparaginase|"Induction Therapy: PEG asparaginase 2000 IU/m2 by vein on Day 4 of induction.~Consolidation Therapy 1: PEG-asparaginase 2000 IU/m2 by vein Week 3 and Week 7.~Consolidation Therapy 2: PEG-asparaginase 2000 IU/m2 by vein Weeks 1 and 4.~Consolidation Therapy 3A: PEG-asparaginase 2000 IU/m2 by vein in Week 1.~Consolidation Therapy 3B: PEG-asparaginase 2000 IU/m2 by vein Week 3."
45667019|NCT02419469|Drug|Ofatumumab|"Induction Therapy: Ofatumumab 300 mg by injection or vein on Day 2 and Ofatumumab 2000 mg by injection or vein on Day 15.~Consolidation Therapy 1: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.~Consolidation Therapy 2: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.~Consolidation Therapy 3A: Ofatumumab 2000 mg by injection or vein Week 1 and Week 3."
45822870|NCT00003734|Drug|triptorelin|
45822871|NCT00003734|Radiation|radiation therapy|
45964974|NCT00559858|Other|placebo|
45964975|NCT00559858|Procedure|quality-of-life assessment|
45964976|NCT00559975|Biological|Subunit influenza vaccine|0.5 mL single dose vaccine
45964977|NCT00559975|Biological|Adjuvanted influenza vaccine|0.5 mL single dose vaccine
45964978|NCT00559975|Biological|Adjuvanted influenza vaccine combined with CpG7909|0.5 ml influenza vaccine combined with 10 mcg of CpG7909
45964979|NCT00559975|Biological|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 30 mcg of CpG7909
45964980|NCT00559975|Biological|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 100 mcg of CpG7909
45964981|NCT00206193|Drug|mifepristone|
45964982|NCT00206193|Drug|misoprostol|
45964983|NCT00206193|Drug|sulprostone|
45964984|NCT04638439|Drug|P1101 + Nivolumab + Entecavir|"P1101 (Ropeginterferon alfa-2b) 450 µg subcutaneously (SC) Q2W for 6 doses (12 weeks) *, followed by 0.3 mg/kg Nivolumab for 6 doses (12 weeks) **, with a follow up of 24 weeks. All patients will also receive Entecavir 0.5 mg QD from Day 1 to Follow-up 24.~*: HBsAg will be checked at treatment week 12 (or 16, if applicable).~**: Only patients with > 0.5 log10 decline in HBsAg at treatment week 12 or 16 will be sequentially treated with Anti-PD1."
45964985|NCT00178802|Other|thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)|"5-fluorouracil 400 mg/m2 i.v. over 24 hours for 5 days~Doxil (liposomal doxorubicin) 40 mg/m2 over 1 hour~Fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration daily~Low-dose interferon-alpha 100,000 i.u. s.c. daily for the duration of the protocol"
45964986|NCT00560014|Dietary Supplement|Arginine and canola oil|Canola oil 1 tablespoon BID Arginine 9.0grams BID
45964987|NCT00560014|Dietary Supplement|Coromega and Arginine|Arginine 9.0 grams BID Coromega dose based on weight
45964988|NCT04638010|Behavioral|Cancer control navigation (CNN)|Cancer Control Navigators (CNNs) housed at 2-1-1 call centers aid callers. CNNs receive electronic summary profiles of participants assigned to navigation. Navigators call the participant, build a collaborative relationship with them, identify their needs, work with them to identify barriers to services and coordinate solutions, and provide logistic (e.g., making appointments) and emotional support. Navigation services are provided by telephone only.
45964989|NCT04638010|Behavioral|General referral (usual care)|Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.
45964990|NCT00201045|Other|Physician/Pharmacist Collaborative Teams|The patient's physician collaborates with a clinical pharmacist to improve management of hypertension
45964991|NCT04638166|Other|Mineral water|Drinking mineral water for 12 weeks
45964992|NCT04638166|Other|Plain water|Drinking plain water for 12 weeks
45964993|NCT04637737|Device|anterioposterior Weight Shifting Training with Visual Biofeedback|"The training group received an additional anterioposterior weight shifting training with visual Biofeedback 5 times per week for 4weeks. AP training is made to instantly know your training status during training by measuring and processing the foot pressure in real time using the F-Scan (Tekscan) hardware system and Software Development Kit (SDK).~Before training, all patients are instructed to place both feet at shoulder width, place the inverted foot approximately 30 cm in front of the unaffected side foot, move the body forward with the chest straight in an upright position, and be instructed to put the weight on the affected side.~On the screen shown, measure the maximum weight distribution during the first 10 times and set the value added by 5% as the target value.~It is designed to induce the maximum weight shift through the archery game."
46080205|NCT02730078|Behavioral|Attention-meetings (AG)|Patients in the health clinics randomised to the AG, will receive the usual T2D care by the clinic doctors and education by the clinic paramedics based on the recommendations in the Malaysian clinical guidelines. At T1, T2 and T4, patients (not including their significant others) in AG will be gathered in groups of 10-12 people for the primary and secondary outcomes evaluation. This session will include general discussion on feeling about and coping with T2D, social support at home and satisfaction with treatment and care received at the respective clinics.
46080206|NCT02810210|Other|fundus examination|"In cohort 3, a fundus examination will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups."
46080207|NCT02810210|Other|Head ultrasound|"In cohort 3, a head ultrasound will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups."
46080208|NCT02730000|Procedure|ART with Equia|Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
45667020|NCT02419469|Drug|Rituximab|"Induction Therapy: If Ofatumumab not available, Rituximab 375 mg/m2 by vein on Day 1 and on Day 15.~Consolidation Therapy 1: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.~Consolidation Therapy 2: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3A: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 3."
45667021|NCT02419469|Drug|Methotrexate|"Induction Therapy: Intrathecal methotrexate 12 mg on Day 8 and Day 29.~Consolidation Therapy 1: Intrathecal methotrexate 12 mg Weekly, Weeks 1 - 4.~Consolidation Therapy 2: Methotrexate by vein every 10 days starting at 100 mg/m2 and increasing by 50 mg/m2 as tolerated. and Intrathecal methotrexate 12 mg Week 1.~Consolidation Therapy 3A: Intrathecal methotrexate 12 mg in Week 1.~Consolidation Therapy 3B: Intrathecal methotrexate 12 mg Week 1 and 2.~Maintenance Therapy (24 months): Methotrexate 20 mg/m2 by mouth weekly, hold on days of intrathecal methotrexate.~Maintenance Therapy (24 months): Intrathecal methotrexate 12 mg every 3 months for 4 doses."
45667022|NCT02419469|Drug|Cyclophosphamide|"Consolidation Therapy 1: Cyclophosphamide 1 gram/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3B: Cyclophosphamide 1 gram/m2 by vein Week 1."
45667023|NCT02419469|Drug|Mercaptopurine|"Consolidation Therapy 1: Mercaptopurine 60 mg/m2/day by mouth Days 1 - 14.~Maintenance Therapy (24 months): Mercaptopurine 75 mg/m2 by mouth nightly."
45667024|NCT02419469|Drug|Doxorubicin|Consolidation Therapy 3A: Doxorubicin 25 mg/m2 by vein weekly for 3 doses.
45667025|NCT02419469|Drug|Dexamethasone acetate|"Consolidation Therapy 3A: Dexamethasone 10 mg/m2 by mouth on Days 1 - 7 and Days 15 - 21.~Maintenance Therapy (24 months): Dexamethasone 6 mg/m2/day by mouth Days 1 - 5 every 28 days."
45822872|NCT04812847|Diagnostic Test|Identification of MDR characteristics|Identification of MDR in culture media, followed by amplification of related genes from the bacterial isolates
45822873|NCT00003740|Biological|trastuzumab|
45822874|NCT05477875|Drug|oral cannabinoid|dronabinol
45822875|NCT05477875|Combination Product|oral codeine/acetaminophen|10 tablets of acetaminophen-codeine combination (300-30mg) without refills.
45964994|NCT04637737|Behavioral|Conventional therapy|The control group received the usual gait training.
45964995|NCT04637854|Procedure|Operating microscope|Third molar extraction using microscope
45964996|NCT04637854|Procedure|Surgical loupes|Third molar extraction using loupes with co-axial illumination
45964997|NCT04637854|Procedure|Naked eyes|Third molar extraction using naked eyes
45964998|NCT04637659|Procedure|Root Canal Treatment|Chemo-mechanical preparation will be performed using reciprocating instruments . Irrigation will be carried out with 5.25% NaOCl during instrumentation and a final flush of 17% EDTA followed by 5.25% NaOCl. After drying with paper points, canal obturation will be achieved through continuous condensation wave technique. Obturation with gutta-percha will be performed using Reciproc blue R25 master cones and root canal sealer using the BeeFill 2 in 1 device (VDW, GmbH) with a small heat carrier (#40 tip size and .03 taper) following the manufacturer's instructions. After the down-packing phase, the back-filling will be performed with the same device and manual compaction using endodontic pluggers.
45964999|NCT00201084|Behavioral|Uncertainty reduction|At physician discretion, 24 hour ambulatory BP monitoring and/or electronic bottle cap monitoring and/or lifestyle counseling
45965000|NCT04637503|Biological|GD2, PSMA and CD276 CAR-T cells|infusion, for 1x10^6~1x10^7 cells/kg via IV
45667026|NCT02419469|Drug|Thioguanine|Consolidation Therapy 3B: Thioguanine 60 mg/m2/day by mouth for 14 days.
45667027|NCT04687761|Drug|Azacitidine|AZA 75 mg/m2/daily SC days 1 to 7 or on a 5-on/2-off [weekend]/2-on schedule in 28-day cycle
45822876|NCT00004256|Biological|sargramostim|
45822877|NCT00004256|Procedure|quality-of-life assessment|
45822878|NCT00004256|Radiation|radiation therapy|
45822879|NCT00382525|Device|Cardiac Rhythm Management device|
45822880|NCT00004262|Procedure|conventional surgery|
45822881|NCT00004262|Radiation|3-dimensional conformal radiation therapy|
45822882|NCT00004262|Radiation|stereotactic radiosurgery|
45822883|NCT00004262|Drug|motexafin gadolinium|Given IV
45822884|NCT00004262|Procedure|magnetic resonance imaging|Undergo MRI with both the clinical 1.5 Tesla and research 8 Tesla magnets
45822885|NCT00004262|Procedure|spectroscopy|Undergo plasma-atomic emission spectroscopy (DCP-AES)
45822886|NCT05471791|Device|Back2Play App|This App uses the Apple watch to monitor activity level and heart rate and combines this with self reported symptoms and stage of recovery to send notifications, suggestions and provide resources to help participants adhere to the guidelines.
45965001|NCT00408239|Drug|YM150|Oral
45965002|NCT00408239|Drug|enoxaparin|Sub cutaneous
45965003|NCT04637308|Drug|Succinylated gelatin|"Succinylated gelatin (SG, Gelofusine; B. Braun, Crissier, Switzerland) is a clear, inexpensive, safe, colloidal plasma volume-expanding solution, weight-average molecular weight (MWw) 30 kDa."
45965004|NCT04637542|Other|Mobile Learning|"The necessary interviews and correspondences were carried out in order to conduct the research. Permission was obtained from Health Sciences University Istanbul Training and Research Hospital Clinical Research Ethics Committee. The purpose of the study was explained to the students as per the sample criteria and their consents were obtained. All of the students participating in the study attended four hours of theoretical lessons in the classroom related to anatomy of the genital system. Following the theoretical training, students were divided into experiment (mobile application) and control (genital organ model) groups. Both groups where then given the Structured Student Presentation Form, Status and trait anxiety inventory and Knowledge Examination (pre-test) on paper.~The didactic content prepared for the institution's standard curriculum (control group) or mobile learning is similar for both training methods."
45965005|NCT00201162|Dietary Supplement|Soy|Dietary supplement of isolated soy protein containing isoflavones
45965006|NCT00201162|Dietary Supplement|Placebo|dietary supplement casein placebo
45965007|NCT04637464|Other|Early termination of empirical antibiotics|Termination of empirical antibiotics for febrile neutropenia based on clinical parameters, regardless of neutrophile count.
45965008|NCT00408278|Drug|ATRA|45 mg/m2 day until CR Consolidation: 3 cycles (45 mg/m2 days 1-15) Maintenance:15 days every 3 months
45965009|NCT00408278|Drug|Idarubicina|Induction: 12 mg/m2 days 2, 4, 6 and 8 Consolidation: 5 mg/m2 days 1-4 in cycle 1 and 12 mg/m2 day 1 in cycle 3.
45965010|NCT00408278|Drug|Mitoxantrone|Consolidation: Mitoxantrone 10 mg/m2 days 1-3 in cycle 2
45965011|NCT00408278|Drug|ARA-C|In high risk patients, consolidation with ara-C in cycles 1 and 3.
45965012|NCT00560053|Drug|Alternating chemotherapy|"4 cycles of alternating chemotherapy VBMCP/VBAD (every 5 weeks). VBMCP: Vcr 2 mg ev day 1, BCNU 0.5 mg/kg ev day 1, Cyclophosphamide 10 mg/kg day 1, Melphalan 0.25 mg/kg v.o. days 1-4, Prednisone 1 mg/kg v.o. days 1-4, 0.5 mg/kg days 5-8 and 0.25 mg/kg days 9-12.~VBAD: Vcr 1 mg e.v. day 1, BCNU 30 mg/m 2 e.v. day 1, Adriamycine 40 mg/m 2 day 1, Dexamethasone 40 mg/m 2 days 1-4, 9-12 and 17-20."
45965013|NCT00560053|Procedure|Autologous Transplantation|"Autologous Transplantation :~BUMEL:Busulfan, total dose 12 mg/kg (days -6 a -3; prophylaxis with difenilhidantoine) Melphalan 140 mg/m 2 , ev day -2 TASPE: To investigator criteria"
45965014|NCT00560053|Drug|Maintenance|"At 3 months of transplantation or with >1.500 neutrophiles/ > 75.000 platelets mm 3 .~Prednisone: 50 mg alternating days during 2 years Interferon alfa 2-b: 3 M UI s.c. Three times a week until relapse."
45455480|NCT01223131|Drug|NPH insulin|"Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous"
45822887|NCT00004892|Drug|O6-benzylguanine|
45822888|NCT00004892|Drug|polifeprosan 20 with carmustine implant|
45822889|NCT00004892|Procedure|conventional surgery|
45822890|NCT04805203|Other|blood sample analyses|maximum 4 blood samples analyses per patient. At diagnosis of covid 19, in intensif care (if applicable), at covid19 recovery and 6 months after recovery
45965015|NCT00560053|Procedure|Second transplantation|In cases that no reach CR with BUMEL is programmed second transplantation, after 4-8 months .
45822891|NCT00004268|Drug|midodrine|
45822892|NCT00004274|Drug|Estrogen|
45822893|NCT00004904|Biological|anti-thymocyte globulin|
45822894|NCT00004904|Biological|filgrastim|
45822895|NCT00004904|Drug|cladribine|
45965016|NCT00560053|Procedure|ALOGENIC MINI TRASPLANTATION|ALOGENIC MINI TRASPLANTATION Fludarabine 30 mg / m 2 / day, days -7, -6, -5, -4, -3 Melphalan 70 mg / m 2 / day, day -2 Prophylaxis EICH: CsA + MTX or CsA + MOFETIL
45965017|NCT00560092|Drug|intrathecal magnesium sulfate|intrathecal magnesium sulfate
45965018|NCT00560170|Drug|Simvastatin (Zocor)|40mg of Simvastatin (n=20) orally per-day for 28 days
45965019|NCT00560170|Drug|10mg/10mg of Ezetimibe/Simvastatin (Vytorin)|10mg/10mg of Ezetimibe/Simvastatin (n=20) orally per-day for 28 days
45965020|NCT04637152|Drug|Sacubitril-Valsartan|Use of sacubitril/valsartan after suspension of ACE inhibitors or ARBs.
45965021|NCT02963909|Biological|IXIARO|An inactivated vaccine indicated for active immunization for the prevention of disease caused by Japanese encephalitis virus (JEV).
45965022|NCT02963909|Other|Placebo|0.9% Sodium Chloride 5 mcg
45965023|NCT02963909|Biological|YF Vax 17D Strain|A stabilised Yellow Fever Vaccine (Live) that is an injectable suspension of the attenuated 17D strain of yellow fever virus. The vaccine is injected by the subcutaneous route.
45965024|NCT02963909|Biological|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
45822896|NCT00004904|Drug|cyclophosphamide|
45822897|NCT00004904|Drug|etoposide|
45822898|NCT00004904|Drug|methylprednisolone|
45965025|NCT04637191|Device|MentalPlus®|A digital game named MentalPlus will be used to evaluate the possibility of this game becoming a neuropsychological test.
45965026|NCT04637347|Device|Catheterization approach|In plane infraclavicular subclavian vein VS in plane supraclavicular subclavian vein catetherization
45965027|NCT04637269|Biological|anti-BCMA CAR-T|5×10^7 /KG 15×10^7 /KG 45×10^7/KG Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days prior to cell infusion.
45965028|NCT00408356|Drug|Zinc|
45667028|NCT04687761|Drug|Venetoclax|Venetoclax (ramp-up) 400 mg/daily oral days 1 to 28
45667029|NCT04687761|Drug|Quizartinib|Quizartinib 40 mg/daily oral, days, 8 to 28
45822899|NCT00004904|Drug|tacrolimus|
45822900|NCT00004904|Procedure|allogeneic bone marrow transplantation|
45822901|NCT00004904|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45822902|NCT04804969|Device|MyoVista wavECG Test|The MyoVista wavECG is a standard 12-Lead high-performance, multi-channel resting interpretive electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information.
45965029|NCT04636918|Drug|Cyclosporine Ophthalmic|Prospective interventional study (single arm)
45965030|NCT00560209|Drug|ONO-1101|placebo for 1 minute IV
45965031|NCT00560209|Drug|ONO-1101|0.06 mg/kg for 1 minute IV
45965032|NCT00560209|Drug|ONO-1101|0.125 mg/kg for 1 minute IV
45965033|NCT04636957|Drug|Ciprofloxacin-Fluocinolone Acetonide, 0.3%-0.025% Otic Solution|0.25mL/vial, each vial contains 0.75mg of ciprofloxacin and 0.0625mg of fluocinolone acetonide.
45965034|NCT04636957|Drug|Ciprofloxacin 0.3% solution|0.4mL/vial, each vial contains 1.2mg ciprofloxacin
45965035|NCT00178958|Device|Holter Monitor|
45965036|NCT04636996|Other|artificial intelligence assisted follow-up|We will use a new portable artificial intelligence assisted device to monitor the patients' postoperative heart rate and sleep quality, guiding the following follow-up process
45965037|NCT04636567|Drug|Nerindocianine for injection|Procedure: routine minimally invasive abdominopelvic surgery.
45965038|NCT04636606|Procedure|Home Exercise|Educational training program about oral dysphagia in patients with temporomandibular disorders.
45965039|NCT04636606|Procedure|Manual Therapy Combined with Home Exercise|Manual therapy program combined with educational training program about oral dysphagia in patients with temporomandibular disorders.
45965040|NCT04636606|Procedure|Orofacial Myofunctional Therapy combined with Manual Therapy and Home Exercise|Orofacial Myofunctional Therapy program with combination of Manual therapy and educational training program about oral dysphagia in patients with temporomandibular disorders.
45667030|NCT04687761|Drug|Cytarabine|Low-dose subcutaneous cytarabine (LDAC) 20 mg/m2/daily SC, days 1 to 10
45667031|NCT04687761|Drug|Venetoclax|Venetoclax (ramp-up) 600 mg/daily oral, days 1 to 28
45667032|NCT04687761|Drug|Quizartinib|Quizartinib 40 mg/daily oral, days 8 to 28
45667033|NCT02419313|Drug|incobotulinumtoxinA|Subjects randomized to the active drug intervention arm will receive incobotulinumtoxinA (Xeomin). A series of rating scales and examinations will take place prior to treatment and for 24 weeks after treatment. At 12 weeks the subjects will cross over to the placebo (saline) arm.
45667034|NCT02419313|Drug|Saline|same volume as injected for incobotulinum toxin A into forearm muscles under EMG guidance.
45667035|NCT04730583|Drug|Kybella|Injection into the cutaneous Neurofibromas lesion
45822903|NCT00004286|Drug|immune globulin|
45822904|NCT00003746|Drug|2-chlorodeoxyadenosine (CDA) daily|Daily administration
45822905|NCT00003746|Drug|2-chlorodeoxyadenosine weekly|Weekly administration
45822906|NCT00003752|Drug|bexarotene|
45822907|NCT02973152|Procedure|Thyroplasty|This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.
45965041|NCT04636645|Other|Normal treadmill|Participants will exercise for 25 minutes under low-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at 0-degree incline. For each session, 20% support will be given to participants.
45965042|NCT04636645|Other|Anti-gravity treadmill with lower limb positive pressure|Participants will be exercised for 25 minutes under normal-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at 0-degree incline. Participants will be blinded to the study groups.
45965043|NCT04636645|Other|Anti-gravity treadmill with without lower limb positive pressure|Participants will be exercised for 25 minutes three times a week for 8 consecutive weeks on the normal treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
45965044|NCT04636489|Dietary Supplement|Highland barley β-glucan dietary supplement|100 mL oral liquid mainly containing highland barley β-glucan once daily for 8 weeks
45965045|NCT04636489|Other|Placebo controls|Placebo with a similar appearance and taste to highland barley β-glucan supplement
45965046|NCT04636684|Diagnostic Test|Proteomic analysis|Proteomic analysis based on mass spectrometry on the sample of valve tissues.
45965047|NCT00560287|Device|Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers|A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
45965048|NCT00560287|Device|Non invasive ventilation|A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
45965049|NCT00560326|Drug|Tacrolimus Ointment 0.03%|Once or twice daily topical application
45965050|NCT00201279|Drug|13-cis Retino Acid|
45965051|NCT00560365|Other|laboratory biomarker analysis|
45965052|NCT00560365|Procedure|computed tomography|
45965053|NCT00560365|Procedure|magnetic resonance imaging|
45965054|NCT00560365|Procedure|quality-of-life assessment|
45965055|NCT00560443|Drug|ketorolac|0,5 mg/kg per os one time
45965056|NCT00560443|Drug|tramadol|2,5 mg/ kg per os in one dose
45965057|NCT00560521|Behavioral|CPAP|Frequency of three times a week, using a positive end expiratory pressure (PEEP) of 10 mmH2O for 30 minutes for four weeks.
45965058|NCT00179114|Drug|Botulinum Toxin Type A|
45965059|NCT00179114|Drug|Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)|
45965060|NCT04636450|Procedure|Rotatory technique pulpectomy|Primary mandibular molars treated with a rotatory technique pulpectomy and a K3 system or a Kedo-S system.
45965061|NCT04636450|Procedure|Manual pulpectomy|Primary mandibular molars treated with a manual pulpectomy and a K-file system or a Kedo-SH system.
45965062|NCT04636372|Device|Intense pulsed light therapy|Patients with xerophthalmia were treated with intense pulsed light of meibomian gland.
45965063|NCT04636372|Other|Hot compress massage|Patients with xerophthalmia were treated with hot compress massage of meibomian gland.
45965064|NCT04636411|Dietary Supplement|Oral Magnesium Supplementation|250 mg of elemental magnesium daily for three months
45822908|NCT02973152|Procedure|Reinnervation|For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
45822909|NCT04092842|Device|Silicone prosthesis|Silicone prosthesis
45822910|NCT04092842|Procedure|Usual practice|Usual surgery
45822911|NCT04066868|Other|Patient-reported outcomes assessment|Patient-reported outcomes are electronically assessed using EORTC QOL measures
45822912|NCT04066868|Other|CTCAE rating|CTCAE Ratings are conducted by clinicians
45965065|NCT04636411|Other|Standard Care for diabetic patients|Health education, oral antihyperglycemic medications according to American Diabetes Association (ADA) guidelines
45965066|NCT00201318|Drug|Cyclophosphamide Doxorubicin Vincristine Lamivudine|
45965067|NCT00179153|Dietary Supplement|Nepro nutritional supplement|oral nutritional supplement (Nepro); every other day, 3 days per week, for 6 months
45965068|NCT04636099|Device|CT angiography（CTA）|The CTA group was peformed upper abdomen enhenced and CT Angiography before surgery
45822913|NCT04066868|Other|PRO data is displayed|PRO data is displayed right next to the CTCAE rating
45822914|NCT00003758|Drug|cytarabine|
45965069|NCT04636294|Diagnostic Test|SARS-CoV-2 PCR|SARS-CoV-2 PCR of nasopharyngeal lysate.
45965070|NCT00201357|Drug|Thalidomide (THADO)|patients who receive thalidomide (100 mg BID).
45965071|NCT04636021|Diagnostic Test|COVID-19 testing|Pre and post procedure COVID-19 testing for patients undergoing outpatient cardiac procedures.
45965072|NCT00179192|Procedure|angioplasty|angioplasty performed at the time of the angiogram; approach and technique to be determined by the interventional radiologist
45965073|NCT00179192|Procedure|surgery|surgical revision of patient's PTFE in a timely fashion not to exceed 72-96 hours after the angiogram; method of revision to be determined by the surgeon performing the procedure
45965074|NCT04635982|Other|Kinesiotape of the physical performance|It has done a countermovement vertical jump, a twenty meter sprint and a kinesio tape application technique
45965075|NCT04635865|Device|3D-printed patient-specific plate|"We adopt an in-house approach for designing by surgeons. All patient-specific devices are designed in 3-matic 13.0 (Materialise). Both cutting and transferring guides are then additively manufactured by Fused Deposition Manufacturing (FDM) using ULTEM 1010, or by Stereolithography using MED610 resin (Stratasys Ltd, Eden Prairie, MN, USA). Both ULTEM 1010 and MED610 are FDA cleared biocompatible materials applicable to high-temperature autoclaving.~Patient-specific surgical plates are designed by delineating a plate path on bone surface, then followed by the placement of screw holes. Surgical plates are generated by the built-in command in 3-matic. After that, surgical plates are fabricated by SLM using grade 2 titanium powder."
45822915|NCT00003758|Drug|idarubicin|
45822916|NCT00003758|Procedure|allogeneic bone marrow transplantation|
45822917|NCT00003758|Procedure|autologous bone marrow transplantation|
45822918|NCT00003758|Procedure|peripheral blood stem cell transplantation|
45822919|NCT00004310|Drug|Clomipramine|
45822920|NCT00004922|Drug|irinotecan hydrochloride|
45965076|NCT04635865|Device|Conventional commercial reconstruction plate|Bone segments will be stabilized using commercial titanium surgical plates (DePuy Synthes, United States), which are bent manually before fastening the screws.[
45965077|NCT00201396|Radiation|CCRT|Radiation with weekly Cisplatin
45965078|NCT00201396|Drug|Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin|Induction C/T + CCRT
45965079|NCT04635709|Device|biofeedback training and interferential therapy|compare the effect of applying both types of devices on the pelvic floor muscles
45965080|NCT04635592|Diagnostic Test|SARS-CoV2 nasal swab|SARS-CoV2 nasal swab and venous blood for SARS-CoV2 antibodies
45965081|NCT04635475|Behavioral|RISE Bundle|Toolkit to build capacity where students receive education and provide symptom based and tailored accommodations after concussion
45965082|NCT04635514|Procedure|Lateral colporrhaphy|
45965083|NCT04635358|Behavioral|Hypnosis|Setting up hypnosis sessions
45965084|NCT04635358|Behavioral|Psychological support|Setting up psychological support
45965085|NCT04635358|Behavioral|Nutrional support|Setting up nutritional support
45965086|NCT00201435|Drug|Paclitaxel weekly in combination with capecitabine|
45965087|NCT00201435|Drug|Docetaxel every 3 week in combination with capecitabine|
45965088|NCT00560599|Drug|mupirocin and chlorhexidine|"Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.~Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine."
45965089|NCT00560599|Behavioral|household cleaning and disinfection|Environmental cleaning with topical ethanol and laundering of clothes and linen.
45965090|NCT00560599|Drug|mupirocin, chlorhexidine, & household cleaning/disinfection|"Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.~Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine.~Environmental cleaning with topical ethanol and laundering of clothes and linen."
45965091|NCT04635202|Behavioral|exercise training on elliptical device|This group (n=30) will receive aerobic training on an elliptical trainer for 16 weeks (3 sessions per week). The session will start with 5 minutes warming up at 50 % of maximal heart rate (MHR), 20-minute continuous ET at 70% of MHR, 12 minutes (4×3) intervals at 90% of MHR with a 3-minute active recovery at 70% of MHR between intervals, and finally 5-minute cool-down period at 50% of MHR
45667036|NCT04730583|Device|980nm laser|Pulse laser at a wavelength of 980nm to the cutaneous Neurofibromas lesion
45965092|NCT04635202|Behavioral|group B (control group)|this group will receive general advises on maintaining physical activities for 16 weeks without any additional supervised training
45965093|NCT04635046|Procedure|Transfer or extirpation of the peroneus longs tendon|Tendon transfer or extirpation of peroneus longus or brevis tendon, ligamental reconstruction +/- calcaneal osteotomy
45965094|NCT04635124|Behavioral|Dog visit|An visitor visits the participant with a dog
45965095|NCT04635124|Behavioral|Encourage to engage in activity|In each visit the visitor invites the participant to engage in an activitty
45965096|NCT04635553|Drug|Praziquantel 600 milligram|A single treatment with a dose of 40 milligram/kilogram (mg/kg)
45965097|NCT04634812|Drug|KBP-5074|a single oral dose of [14C]-KBP-5074
46080209|NCT02730000|Procedure|ART with Riva Self Cure|Occlusal-proximal ART restorations in primary molars using Riva Self Cure will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
46080210|NCT02810288|Behavioral|Voluntarily response all items in the questionnaire.|"The study type is a cross-sectional study, by means of electronic self-administered survey as online questionnaire sent by e-mail.~The questionnaire for the survey was developed with reference to previously published guidelines on the design of questionnaire surveys. The content validity of the questionnaire was verified by review of clinicians not participating into the project and by a statistician."
45667037|NCT04730583|Device|755nm Alexandrite Laser|Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion
45822921|NCT00004316|Drug|capsaicin|
45822922|NCT04712786|Other|pars plana vitrectomy|23 gauge pars plana vitrectomy was performed for retinal detachment, vitreous hemorrhage or epiretinal membrane
45822923|NCT00004928|Dietary Supplement|calcitriol|
45822924|NCT00004928|Drug|zoledronic acid|
45667038|NCT04730583|Device|Radiofrequency|Using an insulated micro-needle, the radio-frequency will be delivered to the cutaneous Neurofibromas lesion
45667039|NCT04730193|Drug|Caffeine|Caffeine, also known as Trimethylxanthine, will be purchased through the University of Oklahoma Health Sciences Pharmacy and formulated into capsule pills containing 100mg of active ingredient
45667040|NCT04730193|Drug|Placebo|Placebo pill will be formulated with a non active ingredient such as rice flour powder
45667041|NCT02419001|Drug|Period 1 - Treatment Sequence AB|Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
45667042|NCT02419001|Drug|Period 1 - Treatment Sequence AC|Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
45667043|NCT02419001|Drug|Period 2 - Treatment Sequence AB|Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg
45822925|NCT00004328|Drug|enalapril|
45822926|NCT00004328|Drug|polystyrene sulfonate|
45822927|NCT02972684|Device|Thrombo-elastometry POC testing|Use of thrombo-elastometry point of care test and algorithm guided predetermined intervention during peri operative haemorrhage
45822928|NCT00004934|Drug|carboplatin|
45822929|NCT00004934|Drug|epirubicin hydrochloride|
45822930|NCT00004934|Drug|paclitaxel|
45822931|NCT00004934|Procedure|conventional surgery|
46080211|NCT02729688|Device|customized pressure guide bandage|"Investigators developed the customized pressure guide elastic bandage (CPG-EB). The experienced nurse applied the elastic bandages to each patient with sub bandage pressure monitoring. The target pressure was 35-45 mmHg. Measurements of the pressure applied by bandages was performed at point B1 corresponding to the height where the Achilles' tendon turns into the gastrocnemius muscle with Picopress (MicroLAB Elettronica, Ponte S. Nicolo, Italy). If the target pressure 35-45 mmHg was achieved, the circular ink stamp was applied into the entire bandages. The markers in CPG-EB had elliptical shape when they were not stretched. They turned into circular shape when they were stretched.~For the OEB, Bandaging was applied by spiral methods. Three EB were applied with 50 % stretching and 50% overlapping from foot to just below knee level."
46080212|NCT02729688|Device|Ordinary elastic bandage|Bandaging was applied by spiral methods. Three ordinary elastic bandages were applied with 50 % stretching and 50% overlapping from foot to just below knee level.
45455481|NCT04543526|Device|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creating anastomoses during standard and robot-assisted laparoscopic RYGB, manufactured by Ezisurg Medical.
45455482|NCT03933241|Behavioral|nasal irrigation|nasal irrigation after Transnasal transsphenoidal surgery for pituitary tumor
45822932|NCT00003776|Biological|filgrastim|
46080213|NCT02813174|Behavioral|Compassionate Mind Training from Compassion-Focused Therapy|
45965098|NCT00201513|Behavioral|Isolated Transversus abdominis (TrA) exercise|Eight weeks Isolated Transversus abdominis (TrA) exercise(low load) program; Isolated TrA control through biofeedback
45455483|NCT02763956|Device|GelStix™ Nucleus Augmentation Device|Intradiscal Gelstix insertion
45455484|NCT02763956|Other|Placebo|Intradiscal saline injection
45822933|NCT00003776|Drug|cisplatin|
45822934|NCT00003776|Drug|doxorubicin hydrochloride|
45822935|NCT00003776|Drug|ifosfamide|
45822936|NCT00003776|Drug|leucovorin calcium|
45455485|NCT01125553|Drug|insulin degludec/insulin aspart|Each subject will be allocated to two single injections of trial product on two separate dosing visits with each of the two insulin degludec/insulin aspart formulations. The trial products will be administered as a subcutaneous injection (under the skin).
45822937|NCT00003776|Drug|methotrexate|
45455486|NCT01347320|Other|Preoperative MRI|Preoperative staging
45822938|NCT00003776|Drug|trimetrexate glucuronate|
45455487|NCT01125631|Biological|PF-04360365 8.5 mg/kg|8.5 mg/kg every 8 weeks (4 doses total)
45455488|NCT01125631|Drug|Placebo|Placebo every 8 weeks (4 doses total)
45455489|NCT01347398|Procedure|PSG|Sleep study made by PSG (polysomnography)
45455490|NCT01347398|Procedure|MicroMESAM system|Sleep study made by MicroMESAM system
45667044|NCT02419001|Drug|Period 2 - Treatment Sequence AC|Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg
45822939|NCT00003776|Procedure|surgical procedure|
45822940|NCT00004940|Drug|cysteine hydrochloride|
45822941|NCT00003788|Drug|carmustine|
45822942|NCT00003788|Drug|lomustine|
45822943|NCT00003788|Drug|porfimer sodium|
45822944|NCT00003788|Drug|procarbazine hydrochloride|
45822945|NCT00003788|Procedure|neoadjuvant therapy|
45822946|NCT00003788|Procedure|surgical procedure|
45822947|NCT00003788|Radiation|radiation therapy|
45667045|NCT02031237|Radiation|Single Fraction Stereotactic Radiosurgery (SRS)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
45667046|NCT02031237|Radiation|Fractionated Whole Brain Radiation Therapy (WBRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
45667047|NCT02031237|Radiation|Fractionated Stereotactic Radiation Therapy (FSRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
45667048|NCT02031237|Device|Magnetic Resonance Imaging (MRI) Assessments|MRI scans will include a routine clinical MRI series.
45667049|NCT02088957|Drug|Brivaracetam intravenous solution|"Active Substance: Brivaracetam~Pharmaceutical Form: Solution for infusion~Concentration: 10 mg/mL~Route of Administration: Intravenous bolus use"
45822948|NCT00385112|Procedure|Echocardiogram|2D echocardiogram with Doppler flow
45822949|NCT00004340|Drug|calcitriol|
45822950|NCT00004340|Drug|growth hormone|
45822951|NCT00004982|Drug|Combination Iron Chelation Therapy|
45822952|NCT00004346|Drug|chenodeoxycholic acid|
45822953|NCT00004346|Drug|lovastatin|
45822954|NCT00003794|Procedure|psychosocial assessment and care|
45822955|NCT00003794|Procedure|quality-of-life assessment|
45822956|NCT00384800|Drug|Thalidomide(THADO), Tegafur/Uracil(UFUR)|
45822957|NCT00384878|Drug|Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin|
45965099|NCT00201513|Behavioral|sling exercise|Eight weeks sling(high load) exercise program; Isolated TrA control through biofeedback
45965100|NCT00201513|Behavioral|group exercise|Eight weeks non-specific group exercise program; Isolated TrA control through biofeedback
45965101|NCT00560638|Drug|loteprednol etabonate ophthalmic suspension, 0.5%|TID
45965102|NCT00560638|Drug|loteprednol etabonate ophthalmic suspension, 0.5%|QID
45965103|NCT00560638|Drug|vehicle of loteprednol etabonate|TID or BID according to the randomization
45822958|NCT02972762|Drug|Diprivan|anesthesia will be maintained with remifentanil and Diprivan.we use Diprivan close-loop to control the anesthesia depth,and the anesthesia depth will be detected with BIS machine.the usage of remifentanil、ropivacaine、sufentanil and cisatracurium in both arms is no difference.
45965104|NCT04634656|Drug|Lidocaine|Patients will receive lidocaine in a loading dose of 1 mg/ kg diluted in 10 ml of normal saline that will be infused over 5 minutes after induction of anesthesia then followed by a continuous infusion at 1.5 mg/ kg/ h diluted in normal saline to a volume of 50 ml until the end of surgery
45965105|NCT04634656|Drug|Normal saline|Patients will receive normal saline after induction of anesthesia with the same volume and rate changes as lidocaine group until the end of surgery
45822959|NCT00004988|Drug|VNP20009|
45965106|NCT00201552|Drug|Statin|
45965107|NCT04634500|Drug|Dapagliflozin|Dapagliflozin Tablet
45822960|NCT00004358|Drug|calcitonin|
45822961|NCT00004364|Drug|desmopressin|
45822962|NCT00005000|Drug|Nelfinavir mesylate|
45965108|NCT04634422|Procedure|Plasma exchange and convalescent plasma|In addition to standard care, participants will receive 2 plasma exchange procedures max. 30 hours apart using the membrane or centrifuge method. PLEX will be initiated within 30 hours of randomization. The exchange volume of 60 mg of plasma per kg body weight will be substituted with albumin 5% and Ringer/saline 50% at the beginning followed by 50% FFP towards the end of the procedure. At the end of the 2nd procedure, participants will receive additional 2 units of CCP (equalling 600 ml CCP) with an administration rate of 100 to 250 ml/hr. Anticoagulation may be provided by citrate or by heparin but it is suggested that in patients with active bleeding regional citrate anticoagulation be utilized. PLEX may be performed via a central venous catheter if patient is deemed unsuitable for peripheral venous access, the latter is recommended. Possible SAE related to PLEX+CCP will be recorded as air embolism, anaphylaxis, TRALI and reported as an outcome.
45822963|NCT00005000|Drug|Efavirenz|
45822964|NCT00005000|Drug|Lamivudine|
45965109|NCT00201591|Behavioral|Exercise training for 10 weeks|
45965110|NCT04633954|Drug|Brimonidine Tartrate 0.15% Oph Soln|One drop of Brimonidine Tartrate 0.15% Oph Soln prior to FLACS
45965111|NCT04634032|Genetic|mRNA expression and SNP analysis|mRNA expression and SNP analysis from samples
45965112|NCT04634032|Diagnostic Test|Blood sampling|Peripheral blood sampling for SNP analysis
45965113|NCT00560872|Device|remote magnetic catheter navigation|use of the Stereotaxis system
45822965|NCT00005000|Drug|Keyhole-Limpet Hemocyanin|
46080214|NCT04253964|Drug|Pembrolizumab|ALL PARTICIPANTS: Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle for 4 cycles. Participants with predictive biomarker PD-L1 greater than or equal to 50% will not receive any other drugs besides pembrolizumab.
45822966|NCT00005000|Drug|Stavudine|
45965114|NCT00560872|Procedure|cavotricuspid isthmus ablation|conventional (manual) approach
45965115|NCT00201630|Drug|Uroxatrol (drug)|
45965116|NCT04634188|Diagnostic Test|Procalcitonin|Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically
46080215|NCT04253964|Drug|Carboplatin|FOR PARTICIPANTS IN EITHER ARM with non-squamous OR squamous subtype, predictive biomarker PD-L1 less than 50%: Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.
45822967|NCT00005000|Drug|Zidovudine|
45822968|NCT00005000|Drug|Didanosine|
45822969|NCT00004376|Drug|guanfacine|
45822970|NCT00005006|Drug|Parathyroid Hormone|Alendronate 70mg/week; Teriparatide 20mcg/ day
45965117|NCT00179231|Drug|olanzapine vs. clozapine|
46080216|NCT04253964|Drug|Paclitaxel|FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
46080217|NCT04253964|Drug|Nab paclitaxel|FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles.
46080218|NCT04253964|Other|Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13)|The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.
45822971|NCT00005006|Drug|Alendronate|Alendronate 70mg/week
45822972|NCT00005006|Drug|Teriparatide|Teriparatide 20mcg/day
45822973|NCT00004382|Drug|tin mesoporphyrin|
45822974|NCT00004382|Procedure|Phototherapy|
45822975|NCT00005012|Drug|Peginterferon alfa-2b|
45822976|NCT00004400|Drug|testosterone|
45822977|NCT00003812|Biological|filgrastim|
45822978|NCT00003812|Drug|carboplatin|
45822979|NCT00003812|Drug|etoposide|
45822980|NCT00003812|Drug|paclitaxel|
45822981|NCT00003812|Drug|topotecan hydrochloride|
45822982|NCT00003812|Radiation|radiation therapy|
45822983|NCT00005018|Drug|Hydroxyurea|
45822984|NCT00005018|Drug|Abacavir sulfate|
45822985|NCT00005018|Drug|Efavirenz|
45822986|NCT00005018|Drug|Didanosine|
45822987|NCT00003824|Drug|cephalexin|500 mg oral bid for 3 days starting the night before resection
45822988|NCT00003824|Procedure|surgical procedure|
45822989|NCT00003824|Drug|Ciprofloxacin|500 mg oral bid for 3 days starting the night before resection
45965118|NCT04634305|Procedure|Total elbow arthroplasty|Total elbow arthroplasty by a single operator
45965119|NCT04633876|Behavioral|Individual coaching|Individual coaching on lifestyle change, sleep, nutrition, physical activity and stress management.
45965120|NCT04633876|Behavioral|Group coaching|Group coaching on lifestyle change, sleep, nutrition, physical activity and stress management.
45965121|NCT04633876|Other|Control group|Group receives no lifestyle coaching but did get baseline results from assessments which might motivate for lifestyle change.
45965122|NCT04633720|Other|Changes in positive end-expiratory pressure and tidal volume|"When the patient is in the supine position 10 minutes after induction of anesthesia, the following 4 mechanical ventilator settings are applied to the patients in order.~Positive end-expiratory pressure 8 cmH2O, tidal volume 8 ml/kg Positive end-expiratory pressure 10 cmH2O, tidal volume 5 ml/kg Positive end-expiratory pressure 10 cmH2O, tidal volume 8 ml/kg Positive end-expiratory pressure 12 cmH2O, tidal volume 5 ml/kg"
45965123|NCT00201669|Drug|Clofarabine|Clofarabine 30 mg/m2/day will be administered as a 2-hour intravenous infusion (IVI) on days 1-5.
46080219|NCT04253964|Other|QLQ-C30 Global Health/Quality of Life Questionnaire|30 item questionnaire - Functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, and nausea and vomiting), global health status and quality of life scale, also several single-item symptom measures
46080220|NCT04253964|Other|COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes|Dyspnea scale scores in patients with respiratory disease (particularly COPD) to establish baseline functional dyspnea burden (taken pre-study at Week 0 and Post Treatment at week 13)
46080221|NCT04253964|Drug|Pemetrexed|FOR PARTICIPANTS IN EITHER ARM with nonsquamous subtype, predictive biomarker PD-L1 less than 50%: Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
46080222|NCT02810366|Other|Physician versus Computer Coded Verbal Autopsy|Comparing the performance of computer coded verbal autopsies (CCVA) to physician coded verbal autopsies (PCVA) at the population level.
45667050|NCT02088957|Drug|Brivaracetam oral tablets|"Active Substance: Brivaracetam~Pharmaceutical Form: Film-coated tablet~Concentration: 10 mg and 25 mg tablets; Daily Dose: 200 mg/day (100 mg bid)~Route of Administration: Oral use"
46080223|NCT02810132|Drug|Metformin|See above
45667051|NCT02088957|Drug|Phenytoin intravenous solution|"Active Substance: Phenytoin~Pharmaceutical Form: Solution for infusion~Concentration: 50 mg/mL~Route of Administration: Intravenous use"
45667052|NCT02088957|Drug|Phenytoin oral tablets|"Active Substance: Phenytoin~Pharmaceutical Form: Tablet~Concentration: Weight based~Route of Administration: Oral use"
46080224|NCT02810132|Drug|Placebo|See above
45667053|NCT02418845|Drug|SYM-1219|
45667054|NCT02418845|Drug|Placebo|
45822990|NCT04791319|Drug|Placebo|Placebo will be administered subcutaneously.
45455491|NCT01329133|Procedure|Deep Brain Stimulation (DBS)|In a first time: Implantation of DBS electrodes, stereotactically, in each hemisphere into the targeted brain structure under local anesthesia. In a second time (next week): installation of the deep brain neurostimulator and connection to the electrodes implanted under general anesthesia. And one month later: beginning of the stimulation.
45667055|NCT02088177|Drug|Long-acting injectable naltrexone|Vivitrol is a long-acting opioid antagonist which blocks opioid agonists from binding at opioid receptors. It be administered as described above.
45667056|NCT02030535|Drug|olodaterol|free combination with tiotropium
45667057|NCT02030535|Drug|tiotropium|free combination with olodaterol
45667058|NCT02030535|Drug|Placebo|
45667059|NCT02030535|Drug|tiotropium|fixed dose combination with olodaterol
45667060|NCT02030535|Drug|olodaterol|fixed dose combination with tiotropium
45667061|NCT04710537|Other|AlloDerm|Enrolled patients will have one of their breasts reconstructed with AlloDerm at the time of their breast reconstruction surgery.
45822991|NCT04791319|Drug|Bermekimab|Bermekimab will be administered subcutaneously.
45822992|NCT04791319|Drug|Dupilumab|Dupilumab will be administered subcutaneously.
45822993|NCT00004406|Drug|human parathyroid hormone|
45822994|NCT04786171|Diagnostic Test|4D X-ray Velocimetry|X-ray velocimetry uses fluoroscopy to quantify local ventilation in the lung.
45822995|NCT00005024|Drug|carboplatin|
45822996|NCT00005024|Drug|cyclophosphamide|
45822997|NCT00005024|Drug|doxorubicin hydrochloride|
45667062|NCT04710537|Other|DermACELL|Enrolled patients will have one of their breasts reconstructed with DermACELL at the time of their breast reconstruction surgery.
45667063|NCT02029989|Device|Glucose and lipids|"Point-of-care (POCT) screening for diabetes and dyslipidemia.~Glucose and Lipids"
45667064|NCT02029989|Device|Glycosylated Hemoglobin A1c|"Point-of-care (POCT) screening for diabetes~Glycosylated Hemoglobin A1c"
45667065|NCT02029989|Device|Blood Pressure and Heart Rate|"Point-of-care (POCT) screening for hypertension~Blood Pressure and Heart Rate"
45667066|NCT02029989|Device|Body mass index|Height and weight measurement used to calculate BMI = Mass(kg)/(height (m))squared
45667067|NCT02029989|Device|Waist and Hip circumference|"Measurement for Central Obesity~Waist and Hip circumference"
45667068|NCT02029989|Behavioral|Comprehensive Medication Management|Defined at http://www.pcpcc.org/guide/patient-health-through-medication-management
45822998|NCT00005024|Drug|granisetron hydrochloride|
45822999|NCT00005030|Drug|SCH 66336|
45965124|NCT04633798|Procedure|IPL/Lipiflow|To treat patients with MGD using intense pulsed light combined with lipiflow
45965125|NCT04633798|Procedure|IPL/MGX|To treat patients with MGD using intense pulsed light combined with meibomian gland massage
45965126|NCT04633486|Diagnostic Test|zoom-endoscopy|Endoscopic monitoring of intestinal transplant recipients is done with zoom-endoscopes for exact diagnostic of intestinal mucosa.
45965127|NCT04633525|Procedure|Optimum Cup Orientation|Participants will have X-rays taken before surgery to determine the target optimal zone for orientation of the cup implant, using EBRA software. The surgeon may or may not implant in this target zone, depending on what they believe is in the patient's best interest. X-rays will be taken at 12 months after surgery to determine if they target cup orientation was achieved.
45823000|NCT00005030|Procedure|conventional surgery|Exploratory laparotomy and/or resection of hepatic metastases. Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization. Other patients undergo surgery on days 8-15.
45823001|NCT00004424|Drug|fentanyl|
45823002|NCT00004424|Drug|Midazolam|
45455492|NCT03928249|Dietary Supplement|Eriocitrin|"A crossover, double-blind, randomized, placebo-controlled clinical study with a duration of 26 weeks will be performed. All individuals and the principal investigator will remain blind to treatment until all analyzes are completed.~Participants will be invited to attend 12-hour fasting to measure glucose levels, glycated hemoglobin and to perform the glucose tolerance test, in addition to an individual interview (Appendix B) to confirm eligibility according to the inclusion and exclusion criteria . The collection of blood and the glycemic curves will be performed at the beginning of the first, 12th, 14th and 26th week in the Laboratory of Clinical Analyzes ( Araraquara)~At the beginning of the first, 12th, 14th and 26th week the following anthropometric parameters will be evaluated: body weight (kg), muscle mass (kg), fat mass (kg), body fat (%) (InBody 720, Biospace, Tokyo, Japan ) and waist-hip ratio."
45965128|NCT00201708|Drug|Docetaxel|Arm A:75 mg/m2 every 2 weeks)for 4 cycles. Arm B:75 mg/m2 every 2 weeks for 4 cycles.
45965129|NCT00201708|Drug|Doxorubicin|60 mg/m2 intravenously as push over 2-5 minutes, every 14 days for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide) , Arm B (Docetaxel after doxorubicin/cyclophosphamide)
45965130|NCT00201708|Drug|Cyclophosphamide (AC)|600 mg/m2 over 30 to 60 minutes every 14 days (2 weeks) for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide), Arm B (Docetaxel after doxorubicin/cyclophosphamide)
45965131|NCT04633291|Device|CP279|catheterisations.
45965132|NCT04632901|Diagnostic Test|VA assessment|"The VA of all participants will be evaluated by counting the smallest line that can be read within a time duration greater than or equal to the average reading time of the larger lines minus 2.58 times the SD of the reading time of these lines.~In clinical practice, the VA is the common parameter of VA adding a tolerant time limit to clearly determine the end of the test."
45965133|NCT04632901|Diagnostic Test|CVA assessment|"The CVA of all participants will be evaluated by counting the smallest line that can be read within a time duration greater than or equal to the average reading time of the larger lines minus 1.96 times the SD of the reading time of these lines.~In clinical practice, the CVA is the minimum VA that can be read in maximal speed."
45965134|NCT04633018|Device|AsthmaMD mobile application|asthma management app with Spanish-language user interface
45965135|NCT04633018|Other|Usual care|Asthma management without the app
45965136|NCT00410358|Drug|Gimatecan|
45823003|NCT00004424|Drug|propofol|
45965137|NCT04632979|Procedure|Backwards running on a Treadmil with a negative slope|Running backward on a treadmill with a negative slope
45965138|NCT04632862|Drug|DWP16001|DWP16001 A mg
45965139|NCT04633174|Device|Sous Vide Device (SVD)|A basin will be filled to the marked line with water from jugs at room temperature, for each frozen extremity. The sous vide device (SVD) will be attached to the distal edge of the basin. The SVD will be turned on and set to maintain the bath at a constant 38 degrees celsius for 30 minutes duration. The thermometers will be powered on continuously and the researcher will record temperatures simultaneously from each thermometer every 2 minutes. At the end of the 30 minute treatment, the SVD will be powered off and the extremity assessed by the researcher for warmth and pliability. If the extremity still feels cold or frozen, an additional 30 minutes in the water bath will commence, with subsequent reassessment. Rewarming will be considered complete when the affected tissue becomes red or purple, soft, and pliable.
45965140|NCT04633135|Device|Philips stove|Philips Smokeless stove HD4012LS
45965141|NCT04633135|Device|Gyapa stove|Wood stove made in Ghana
45823004|NCT05196373|Drug|STP705|STP705 Powder for Injection composed of siRNA-TGF-B1 and siRNA-COX-2 packged in a proprietary polymer nanoparticle formulation for delivery.
45823005|NCT00004430|Drug|Dihematoporphyrin derivative|
45823006|NCT00004430|Drug|prednisolone|
45823007|NCT00004430|Procedure|Laser surgery|
45823008|NCT00003842|Biological|interleukin-4 PE38KDEL cytotoxin|
45965142|NCT00410397|Procedure|Osteopathic Manipulative Medicine|Pelvic balancing, myofascial release of the anterior pelvis.
45965143|NCT00410397|Procedure|Sham Manipulation|Neutral positional, gentle palpation
45965144|NCT04632745|Other|Wrist Rehabilitation|participants will undergo immobilization for the first 6 weeks of treatment
45965145|NCT04632823|Combination Product|Comprehensive Non-pharmacological Treatment Program|dietary supplement, specific type of exercise, self-management education
45965146|NCT04632277|Other|Water|Participants will receive a tab water
45965147|NCT04632277|Dietary Supplement|Water with low Mg|Participants will receive Low Mg bottle water (50mg/l)
45965148|NCT04632277|Dietary Supplement|Water with high Mg|Participants will receive High Mg bottle water (100mg/l)
45823009|NCT00003842|Drug|isolated perfusion|
45823010|NCT00003842|Procedure|surgical procedure|
45823011|NCT05195437|Other|QoLiSSY and PedsQL 4.0 questionnaires|"Patients have been reaching adult size complete the two questionnaires of the study :~Quality of Life of Short Stature Youth questionnaire (QoLiSSY), assessing health-related quality of life in short stature youth.~Pediatric Quality of Life Inventory (PedsQL) 4.0 : general health-related quality of life.~The patients have previously completed the PedsQL 4.0 and QoLiSSY questionnaires when starting their growth hormone therapy and after one year of growth hormone therapy."
45823012|NCT00005036|Drug|irinotecan hydrochloride|Given IV
45823013|NCT00005036|Drug|oxaliplatin|Given IV
45823014|NCT00005036|Drug|leucovorin calcium|Given IV
45667069|NCT02048241|Behavioral|Parent Management Training|This is a psychological treatment that focuses on decreasing tantrums and outbursts by reducing the ability of the tantrum to coerce parents into giving in to the demand that precipitated the tantrum.
45965149|NCT04632628|Behavioral|Web-based Cognitive Behavior Therapy for Insomnia (CBT-I)|Participants will complete 4 web-based CBT- I sessions. Lesson 1: Sleep Hygiene and Stimulus Control Lesson 2: Sleep Restriction and Relaxation Strategies Lesson 3: Identifying and Restructuring Dysfunction Thoughts Lesson 4: Practical Recommendations, Review, and Maintenance of Change
45965150|NCT00179504|Behavioral|Relaxation Response|Relaxation training
45965151|NCT04632355|Other|Interview|This interview will be conducted to collecting all outcomes about musculoskeletal pain in COVID-19 survivors
45455493|NCT03635294|Other|Blood sample|combining genomics, transcriptomics, metabolomics and morphological analyses performed on induced pluripotent stem cell (iPSC)-derived neural cells
45455494|NCT02640664|Drug|Ranibizumab|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
45667070|NCT02048241|Other|Placebo|Weekly dispensation of pills matching Intuniv but without the active medication
45667071|NCT02048241|Drug|Intuniv|Weekly administration of medication in doses as per protocol
45667072|NCT02087943|Drug|Apremilast|Orally twice a day (BID)
45667073|NCT02087943|Drug|Apremilast|Orally twice a day (BID)
45965152|NCT04632472|Device|Active fixation bipolar lead versus passive fixation quadripolar leads in Cardiac Resynchronization Therapy|Cardiac resynchronization therapy trial comparing types of leads.
45965153|NCT00410436|Behavioral|Resistance Exercise|Subjects demonstrating adequate compliance during the run-in period will then be randomized in equal numbers to Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM), or waiting-list control (C).
45667074|NCT02087943|Drug|Placebo|Orally twice a day (BID)
45667075|NCT02087943|Drug|Placebo|Orally twice a day (BID)
45667076|NCT04710303|Biological|hAd5-S-Fusion+N-ETSD vaccine|The hAd5-S-Fusion+N-ETSD vaccine is a hAd5 [E1-, E2b-, E3-] vector-based targeting vaccine encoding the SARS-CoV-2 S and N proteins. The hAd5-S-Fusion+N-ETSD vaccine is designed to induce both humoral and cellular responses even in individuals with pre-existing adenoviral immunity.
45667077|NCT02029521|Dietary Supplement|Oral reduced l-glutathione|The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg. The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
45667078|NCT02029521|Dietary Supplement|Placebo|calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
45823015|NCT00005036|Drug|fluorouracil|Given IV
45823016|NCT00005036|Procedure|quality-of-life assessment|Ancillary studies
45823017|NCT05454007|Behavioral|Step length asymmetry training|Participants will engage in four, five-minute periods of step symmetry training during session 2. This training uses established sensorimotor adaptation-based methods (e.g. split-belt treadmill walking, walking with unilateral leg weighting) to elicit motor aftereffects of more equal step lengths. Two minute sitting rest breaks will be given between training blocks or at the participant's request. A video recording will be taken of the first and final two minutes of training.
45823018|NCT00003854|Other|immunohistochemistry staining method|
45823019|NCT00003854|Procedure|lymphangiography|
45823020|NCT00003854|Procedure|sentinel lymph node biopsy|
45823021|NCT00003854|Procedure|therapeutic conventional surgery|
45823022|NCT00003854|Radiation|whole breast irradiation|
45965154|NCT04632394|Diagnostic Test|Generation of computational model from cardiac MRI.|Routine cardiac MRI scan results will be sent to Johns Hopkins University where a computer-generated model of the heart will be made, which will demonstrate predicted areas critical to VT generation and maintenance. This data will be sent back to St George's, and integrated with the standard VT ablation mapping software to allow comparison of its accuracy with standard mapping techniques.
45965155|NCT04632394|Procedure|VT ablation|Routine VT ablation as described elsewhere in the literature. However, a brief period of extra time (~30 minutes) will be spent analysing the areas of the heart which the MRI scan predicted as being important for generation of VT. We will study the effect of ablation of these areas (if indicated) on distant parts of the heart.
45965156|NCT00179543|Behavioral|Relaxation response|
45667079|NCT04685811|Drug|68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron|68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron; single dose each, approximately 100-300 mBq.
45965157|NCT04632550|Procedure|Circumferential pulmonary vein isolation(CPVI) group|"PVI(pulmonary vein isolation) will be performed using a radiofrequency catheter~Esophageal temperature will be monitored to prevent esophageal injury.~Evaluation of procedure time, radiofrequency ablation time~Evaluation of the complication after the procedure.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
45965158|NCT04632550|Procedure|Posterior box isolation(POBI) group|"PVI will be performed using a radiofrequency catheter~Additional POBI(Posterior box isolation) is performed according to the traditional method and experience of the practitioner.~Esophageal temperature will be monitored to prevent esophageal injury.~The bidirectional block of each lesion set is the target of the procedures. But, we remain the incomplete block if three times of linear ablation failed to achieve the bidirectional block for the safety purpose.~Evaluation of procedure time, radiofrequency ablation time~Evaluation of the complication after the procedure.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
45965159|NCT04632550|Procedure|POBI+Anterior linear ablation(AL) group|"PVI, POBI will be performed using a radiofrequency catheter~Additional AL(anterior linear) ablation is performed according to the traditional method and experience of the practitioner.~Esophageal temperature will be monitored to prevent esophageal injury.~The bidirectional block of each lesion set is the target of the procedures. But, we remain the incomplete block if three times of linear ablation failed to achieve the bidirectional block for the safety purpose.~Evaluation of procedure time, radiofrequency ablation time~Evaluation of the complication after the procedure.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
45965160|NCT04632082|Behavioral|Telepsychoeducation with personalized videos|1 session with a psychologist plus 1 video a week for 4 weeks chosen based on symptom presentation
45965161|NCT04632082|Behavioral|Telepsychoeducation without personalized videos|1 session with a psychologist focused on reassurance and aspects of the outbreak
45965162|NCT04632160|Device|IASD System II|The implant is placed across the interatrial septum using a percutaneous transcatheter approach.
45458311|NCT02320942|Other|Exercise Intervention|The semi-supervised intervention is a progressive program with a goal of three aerobic and two resistance exercise sessions per week. Aerobic exercise will consist of 20-40 minutes of bicycling using a stationary bike located on CP6 (supervised or un-supervised) or brisk walking at home. Resistance exercise will include exercise for the upper and lower extremities with stretch bands. Patients will complete at least one supervised aerobic and resistance session per week with the exercise trainer and complete a daily log of their exercise, including adherence, adverse events and symptoms.
45667080|NCT04709211|Procedure|Facia Iliaca block|patients will receive Ultrasound-guided Facia Iliaca block using 50 ml 0f Bupivacaine 0.25%
45823023|NCT05450107|Procedure|Open Reduction Internal Fixation|Surgical intervention by lag screw or plate fixation
45823024|NCT05450107|Procedure|Cast immobilisation|Cast immobilsation for a total of 6 weeks with gradual increase in weight bearing after 2 weeks
45823025|NCT05449639|Device|Relief implantation|The device will be implanted by endoscopic procedure by a standard resectoscope.
45823026|NCT00004436|Drug|leuprolide|
45823027|NCT00004436|Drug|prednisone|
45823028|NCT00005042|Drug|semaxanib|
45965163|NCT00179582|Drug|VSL#3|
45823029|NCT04573231|Drug|18F-DCFPyL|PSMA is highly expressed on prostate cancer and is associated with metastasis and resistance to anti-androgen therapies. Researchers have evaluated the expression of PSMA in the tumor and tumor-associated neovasculature in primary tumors and distant metastases in patients with breast cancer.
45823030|NCT00004442|Drug|chenodeoxycholic acid|
45823031|NCT00004442|Drug|cholic acid|
45823032|NCT00004442|Drug|ursodiol|
45823033|NCT05444569|Drug|LY3537021|Administered SC.
45823034|NCT05444569|Drug|Liraglutide|Administered SC.
45965164|NCT04632121|Drug|Nicorandil 20 MG|Nicorandil is a nicotinamide ester that dilates peripheral and coronary resistance vessels via action on ATP-sensitive potassium channels and possesses a nitrate moiety that promotes systemic venous and coronary vasodilation. As a result of these dual actions, nicorandil reduces preload and afterload and results in an increase in coronary blood flow. In addition to these effects, nicorandil may have cardioprotective actions mediated through the activation of potassium channel
45965165|NCT04631887|Behavioral|Doing What Matters in Times of Stress: An Illustrated Guide|"The Doing What Matters in Times of Stress: An Illustrated Guide is a booklet that is developed by World Health Organization. It is a stress management booklet formed to provide people skills for coping with stress and adversity. The booklet has accompanying audio exercises."
45965166|NCT00186732|Procedure|Subcuticular Suture|
45965167|NCT00186732|Procedure|Surgical Staples|
45965168|NCT00560911|Behavioral|educational program for the self-management of OAC|"Patients in the self-management group participated in 4 consecutive weekly instruction sessions of 90 to 120 minutes each, in groups of 3 to 6 patients.~After participation in the structured programme, the patients were encouraged to control their INR values by self-monitoring once a week and to adjust their anticoagulant dosage accordingly."
45965169|NCT00560911|Behavioral|1 hour education - afterwards physician leaded OAC control|"Patients in the routine control group participated a single 90-minute session~During the whole study period, they were advised with regard to changes in the anticoagulant dosage by their usual attending physicians, either in general practice or at a hospital-based specialised anticoagulation clinic."
45455495|NCT03222830|Procedure|personal embryo transfer|"According to the histological dating and transcriptomic profile of endometrium of natural cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on 7 days after ovulation. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy. outcome of the FET cycle ."
45455496|NCT01226251|Device|In vitro chair side test|Colour evaluation of a strip
45965170|NCT04632043|Other|Endotracheal intubation|Endotracheal intubation
45965171|NCT00179699|Drug|CC-5013|
45965172|NCT00179699|Drug|pemetrexed|
45965173|NCT04631614|Other|Warm up|Warm up through a walk or exercise bike for 5 minutes with moderate intensity according to modified Borg scale (CR-10)
45965174|NCT04631614|Other|Passive calf muscle stretching|With the participant lying in the supine position, the physiotherapist will passively perform the ankle dorsiflexion movement to stretch the participant's calf to the limit tolerated by the participant. This procedure will be performed in two repetitions with 30 seconds of held in the stretching position and 30 seconds of rest between repetitions.
45965175|NCT04631614|Other|Ankle joint mobilization - weight-bearing mobilization with movement (WB-MWM) technique|To perform the WB-MWM technique, the participant will be instructed to take a weight-bearing position with the tibia in a vertical position. The physiotherapist will be stay in front participant's ankle and will use the hands to stabilize the participant's foot as close as possible to the anterior region of the talus. A rigid belt will be placed on the participant's tibia and around physiotherapist´s hip. Then, the physiotherapist will project his hip backwards to produce a nonpainful anterior tibia glide. The participant will be asked to perform a forward lunge as far as possible without raising heel off the table and without reproducing knee symptoms. After achieving the maximum forward lunge, the participant will be instructed to hold this position for 5 seconds and then return to the starting position. This procedure will be performed in two sets of 10 repetitions with two minutes of rest between sets.
45965176|NCT04631614|Other|Clam exercise|The participant will side lying with trunk straight and both hips and knees at 45º and 90º of flexion, respectively. An elastic band will be used as external resistance, that will be positioned above the participant's knee. The individual will be instructed to perform the abduction and lateral rotation of the hip (keeping the heels in contact) against the resistance of the elastic band and then return to starting position. This exercise will be performed in three sets of 12 repetitions with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort <60%.
45455497|NCT01317446|Drug|amine fluoride/stannous fluoride|10 ml qd, oral, topical, 6 months duration
45455498|NCT03928171|Other|Intra-abdominal pressure during laparoscopy|Insufflation pressure of the abdomen during laparoscopy
45455499|NCT01226329|Behavioral|Right Question Project - Mental Health (RQP-MH)|"The RQP-MH trainings each take approximately 45 minutes to complete and are delivered approximately three weeks apart. The manualized intervention uses a Question Formulation Technique (QFT) and a Framework for Active Decision-Making (FADM). The QFT consists of asking patients to generate and revise questions to obtain more informative answers from their providers. The FADM teaches participants to identify questions that will help them consider their role in a decision, the process of decision-making, and the reasons behind a decision. All intervention sessions will be taught by a bachelors-level Care Manager."
45458312|NCT01141465|Drug|Fluticasone / formoterol metered dose inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
45823035|NCT05444569|Drug|Placebo|Administered SC.
45823036|NCT00004448|Drug|omega-3 fatty acids|
45823037|NCT00004448|Drug|prednisone|
45823038|NCT00003860|Biological|filgrastim|
45823039|NCT00003860|Drug|carboplatin|
45823040|NCT00003860|Drug|etoposide|
45823041|NCT00003860|Drug|ifosfamide|
45823042|NCT00003860|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45823043|NCT00005048|Drug|estramustine phosphate sodium|
45823044|NCT00005048|Drug|paclitaxel|
45823045|NCT00004454|Genetic|lymphocyte gene therapy|
45823046|NCT04756765|Drug|Talazoparib Tosylate|Talazoparib1 mg/day is to be administered orally on a continuous dosing schedule.
45823047|NCT00004466|Drug|Atorvastatin|
45965177|NCT04631614|Other|Hip abduction exercise in side lying|The participant will side lying with trunk straight, both hips in a neutral position and both knee in extension. An elastic band will be used as external resistance, that will be positioned above the participant's knee. The individual will be instructed to perform the hip abduction against the resistance of the elastic band and then return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort <60%.
45965178|NCT04631614|Other|Knee extension exercise in a sitting position|The participant will be seated at the treatment table with the trunk straight and both knees in 90º of flexion. The external resistance will be positioned above the participant's ankle. The individual will be instructed to perform the knee extension at a protective angle (90º-45º of flexion), progressing to full extension (90º-0º of flexion) as long as the full knee extension does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort <60%.
45965179|NCT04631614|Other|Squat exercise|The participant will be stand with the trunk straight, knees in extension and feet hip-width apart. Dumbbells will be used as external resistance.The individual will be instructed to perform the squat movement at a protective angle (0º-45º of knee flexion), progressing to a deep squat (90º of knee flexion) as long as the movement does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort <60%.
45965180|NCT04631614|Other|Forward lunge exercise|The participant will be stand with one lower limb in a long stride forwards of the other limb, trunk straight and both knee in extension. Dumbbells will be used as external resistance. From this position, the participant will be instructed to bend both knees to lower your body at a protective angle (0º-45º of knee flexion), progressing to a greater knee flexion (90º) as long as the movement does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort <60%.
45965181|NCT00201747|Drug|CPT-11|CPT-11 will be administered intravenously on days 2 and 9 (24 hours after MMC, when the MMC is required) Two weeks of rest (beginning days 15 and 22) (drug free) will complete the cycle, with therapy planned to be resumed on day 29.
45965182|NCT00201747|Drug|Mitomycin C|MMC will be administered intravenously on day 1 (Arm A) and days 1 and 8 (Arm B)
45965183|NCT04632004|Other|Invitation to participate|Patients, visitors, and staff members of the University Medical Center Goettingen are invited to participate within our survey study. Study participation has no effect on any medical treatment.
45965184|NCT04631458|Other|standard of care.|Observational trial.
45965185|NCT00179738|Drug|CC5013|
45965186|NCT04631653|Device|VeriSee®|Screening of diabetic retinopathy using a validated deep learning-based software,VeriSee®
45965187|NCT00186771|Device|Paired Pulse|True treatment with rTMS over the temporoparietal cortex.
45965188|NCT00186771|Device|Paired Pulse|Sham treatment with rTMS over the temporoparietal cortex.
45965189|NCT04631341|Dietary Supplement|Melatonin|Melatonin 5mg every night, for one year
45667081|NCT04709211|Procedure|Anterior Quadratus Lumbroum block|patients will receive Ultrasound-guided Anterior Quadratus Lumbroum block using 50 ml 0f Bupivacaine 0.25%
45823048|NCT00004466|Drug|Placebo|
45823049|NCT05432011|Procedure|PENG Block|At the end of surgery, in Post Anesthesia Recovery Room (PACU), PENG block with 20 mL of 0.5 % Ropivacaine will be executed as described by Giron-Arango et al. using a low frequency curvilinear probe. A 22G 80 mm needle (Stimuplex Ultra 360, B.Braun) will be used.
45823050|NCT05432011|Procedure|Lateral Femoral Cutaneous Nerve Block|At the end of surgery, in Post Anesthesia Recovery Room (PACU), ultrasound guided Lateral Femoral Cutaneous Nerve Block will be performed with 10 mL of 0.5 % Ropivacaine using a high frequency linear probe. A 22G 50 mm needle (Stimuplex Ultra 360, B.Braun) will be used.
45823051|NCT05432011|Procedure|Wound Infiltration|At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.5 % Ropivacaine.
45458313|NCT01141465|Drug|Fluticasone / salmeterol dry powder inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
45667082|NCT04709211|Drug|bupivacaine|bupivacaine
45667083|NCT02443883|Drug|Ramucirumab|Administered IV
45667084|NCT02460263|Device|Tablo Hemodialysis System|
45667085|NCT02443805|Biological|300 IR|300 IR tablet of HDM Allergen Extracts
45667086|NCT02443805|Biological|Placebo|Placebo tablet
45667087|NCT01652885|Drug|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%
45965190|NCT04723238|Drug|Duloxetine 60mg Test Drug Enteric Coated Granules|Investigational Medicinal Product
45823052|NCT00005054|Drug|temozolomide|
45667088|NCT02459951|Other|clenched fist|Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.
45667089|NCT04931927|Behavioral|Making Connections Intervention-Telehealth (MCI-T)|Single session telehealth engagement intervention plus telehealth treatment as usual (TAU) [MCI-T +TAU]
45965191|NCT04723238|Drug|Duloxetine 60mg Reference Product Enteric Coated Granules|Cymbalta (Eli Lilly)
45965192|NCT04631575|Drug|SHR6390|SHR6390, PO,single-dose
45965193|NCT04631068|Procedure|Cataract surgery|Small incision cataract surgery with implantation of an intraocular lens
45965194|NCT00201786|Drug|Pentostatin|Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS. To prevent nephrotoxicity, patients will also receive 500 ml normal saline as pre- and post drug hydration (total 1000 ml).
45965195|NCT04631146|Drug|Camrelizumab|PD-1 inhibitors
45965196|NCT04723433|Other|Oxygen gas -Conservative|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) between 90% and 94%.
45965197|NCT04723433|Other|Oxygen gas -Liberal|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) higher than 96%.
45965198|NCT04630678|Other|Virtual Reality Therapy|Virtual reality games were applied to participants for 30 minutes.
45965199|NCT04630678|Other|Conventional Physiotherapy|Joint and muscle mobilization, strengthening, and stretching exercises by neurodevelopmental treatment principles were applied to participants for 30 minutes.
45965200|NCT04630678|Other|Activity Training|Unilateral, bilateral, and bimanual activity training that supported manual skills for 30 minutes.
45455500|NCT01226329|Behavioral|Pamphlet|"Participants in this group receive a handout called Managing Your Mental Health (available in Spanish and English) that provides tips on how to manage mental health through the proper maintenance of physical health and stress."
45455501|NCT03207620|Diagnostic Test|using serum periostin and eotaxin-2 level|"collect serum sample from each group and detection of serum periostin and eotaxin-2 are using Eliza kits.~each group is divided into two groups (patients who are already using ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity."
45823053|NCT00385346|Behavioral|Expressive writing|Patients in the intervention group write on three day for 20 minutes about highly emotional topics In the control group patients write on three days for 20 minutes about topics with relatively low emotional involvement such as diet, time management and sport.
45965201|NCT04630522|Drug|Drug: JMT103- 120 mg SC Q4W|JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 4-week cycle.
45965202|NCT04630522|Drug|Drug: JMT103- 120 mg SC Q8W|JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 8-week cycle.
45965203|NCT04630522|Drug|Drug: JMT103- 180 mg SC Q8W|JMT103 is administered subcutaneously at a dose of 180 mg on day 1 of each 8-week cycle.
45965204|NCT04630522|Dietary Supplement|Dietary Supplement: Calcium Dietary Supplement: Vitamin D|Calcium is given orally at a dose of 500 mg at least, once daily. Vitamin D is given orally at a dose of 400 IU at least, once daily.
45965205|NCT00179816|Drug|High-Dose Chemotherapy with Tandem PBSC Rescue.|Patients on this study will undergo a tandem Peripheral Blood Stem Cell Rescue following high-dose chemotherapy. The first Peripheral Blood Stem Cell Rescue will consist of Etoposide, Carboplatin, Cyclophosphamide, and Mesna. Once the patient recovers, the patient will be evaluated again and will then undergo a second stem cell transplant consisting of the chemotherapy drugs; Melphalan, Cyclophosphamide, and Mesna.
45667090|NCT04931927|Behavioral|Treatment as usual (TAU)|Telehealth treatment as usual without the single session telehealth engagement intervention
45965206|NCT04630444|Drug|Riluzole|30 PTSD patients with riluzole 100 mg daily (50 mg bid).
45965207|NCT04630405|Device|Wright jet nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
45965208|NCT04630405|Device|Aerogen Solo|Aerogen Ltd., Galway, Ireland
45965209|NCT00186810|Drug|Busulfan, Cyclophosphamide, Horse ATG|Transplant recipients received a myeloablative conditioning regimen of cyclophosphamide, Anti-Thymocyte Globulin (horse), and Busulfan. Cyclosporine and methotrexate were administered for GVHD prophylaxis.
45667091|NCT04922957|Drug|ALLOCETRA-OTS|The product contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension containing early apoptotic cells.
45667092|NCT04922957|Other|Placebo|Ringer's lactate solution
45823054|NCT00004478|Drug|droxidopa|
45823055|NCT00003878|Drug|polifeprosan 20 with carmustine implant|
45823056|NCT00003878|Procedure|conventional surgery|
45823057|NCT04734145|Diagnostic Test|Breathprinting test|Consented, enrolled participants will undergo a breathprinting test (e-nose) during the presurgical visit and at the same facility as their presurgical or prebiopsy visit, before any attempt is made to obtain cytohistological diagnosis of the pulmonary nodule.
45823058|NCT00005060|Drug|Taxotere-Cisplatin-5FU|Preoperatively
45823059|NCT00005060|Drug|Immediate surgery|Immediate surgery followed by Taxotere-Cisplatin-5FU
45823060|NCT04723927|Other|Older adults|The data for motor function and gait pattern analysis was obtained.
45823061|NCT00003884|Drug|zoledronic acid|
45823062|NCT00003884|Procedure|quality-of-life assessment|
45823063|NCT05443334|Drug|Semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
45965210|NCT00186810|Procedure|Allogeneic stem cell transplant|Allogeneic stem cell transplant Matched sibling donor transplant Cord blood transplant
45965211|NCT04630600|Other|No intervention|Normal waiting room without an aquarium
45965212|NCT04630600|Other|Partially-equipped aquarium in the waiting area|Waiting room with a partially-equipped Aquarium
45965213|NCT04630600|Other|Fully-equipped aquarium in the waiting area|Waiting room with a fully-equipped Aquarium
45667093|NCT02087241|Drug|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
45667094|NCT02087241|Drug|AZD1775 Matching Placebo|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
45965214|NCT04630288|Drug|Clopidogrel|Describe the safety of Ticagrelor vs Clopidogrel use, in patients with ACS in terms of major bleeding between 30 days and one year after the index ACS event. An ITT approach and IPCW method to adjust for change of initial treatment will be used for the analysis.
45965215|NCT04630288|Drug|Ticagrelor|Describe the safety of Ticagrelor vs Clopidogrel use, in patients with ACS in terms of major bleeding between 30 days and one year after the index ACS event. An ITT approach and IPCW method to adjust for change of initial treatment will be used for the analysis.
45965216|NCT00179855|Procedure|Extracorporeal Photopheresis|"ECP will be performed using the UVAR® XTS™ photopheresis system (Therakos). Whole blood is drawn and separated by centrifuge to collect the buffy coat (lymphocyte solution). Methoxsalen (8-MOP) is added to the blood, and the final solution of cells is passed as a film, 1mm thick, through a disposable plastic device, exposed to a UVA light source (2J/cm2/cell) and then returned to the patient.~ECP will be performed weekly on 2 consecutive days for 4 weeks. After 4 weeks the interval will be prolonged to every 2 weeks and ECP will be stopped after maximal response has been maintained for 2 weeks. The actual study finishes at d56 but ECP may be continued beyond that (off-study) at the discretion of the physician."
45965217|NCT00561028|Other|blood sample analysis - mycoplasma and chlamydia antibodies|Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).
45965218|NCT00201942|Procedure|PET scan|
45965219|NCT00561067|Drug|Erythropoietin|EPO 500 IU/kg diluted in 50 ml saline and infused in 30 minutes; treatment is started within eight hours after the spinal injury; the same drug dosage will be infused at 24 and 48 hours
45965220|NCT00561067|Drug|Methylprednisolone|MP 30 mg/kg intravenous (iv) in the first hour, followed by 5.4 mg/kg/h for 23 hours if treatment is started within three hours after the spinal injury,or for 48 hours if treatment is started between three and eight hours (protocol NASCIS III, National Acute Spinal Cord Injury Study)
45965221|NCT00561106|Drug|prednisone- valacyclovir|prednisone, a dose of 1 mg/kg body weight was given daily for 7 days. The treatment was tapered over the next 14 days. Those taking valacyclovir received 1000 mg in two daily doses for 7 days.
45965222|NCT00561106|Drug|prednisone-placebo|prednisone, a dose of 1 mg/kg body weight was given daily for 7 days
45965223|NCT00179894|Behavioral|Physician training|Physicians are trained in guidelines for medication management.
45965224|NCT04630639|Device|Sparkle|The Sparkle device is a single-use device intended to aid the diagnosis of sleep-disordered breathing; however, this study is intended only to validate the respiratory effort signal and does not assess diagnostic performance.
45965225|NCT00561184|Biological|H5N1 influenza vaccine|One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 7.5 micrograms of H5N1 influenza antigen
45965226|NCT00561184|Biological|H5N1 influenza vaccine|One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 15.0 micrograms of H5N1 influenza antigen
45823064|NCT00003890|Drug|MG 98|
45667095|NCT02087241|Drug|pemetrexed|This drug is a part of a general group of chemotherapy drugs called anti-metabolites. It prevents cells from using folate to make DNA and RNA. Because cancer cells need these substances to make new cells, this drug helps to stop the growth of cancer cells.
45965227|NCT00186849|Drug|Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin|See Detailed Description section for details of treatment interventions.
45965228|NCT00186849|Procedure|Peripheral Blood Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
45965229|NCT00179933|Behavioral|Newborn Individualized Assessment Program|
45965230|NCT04629898|Behavioral|multi-task in the real world and virtual reality video sport games|This was a 2-staged intervention study. The 1st stage intervention uses multitasks in the real world including stepping exercise, ball-kicking activity and bean-bag tossing activity. The 2nd stage intervention used video sport games conveyed by Xbox Kinect. Tennis and golf games were selected.
45965231|NCT04629859|Procedure|mandibular setback and maxillary advancement|12 patients will undergo mandibular setback and maxillary advancement
45458314|NCT01141465|Drug|Budesonide / formoterol dry powder inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
45667096|NCT02087241|Drug|carboplatin|This drug is a platinum chemotherapy drug that acts like an alkylating agent. It stops the growth of cancer cells, causing the cells to die.
45667097|NCT02087085|Drug|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye using Brimo DDS® applicator on Day 1, and every 3 months through Month 21.
45667098|NCT02087085|Other|Sham|Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.
45823065|NCT04718779|Other|Digital Engagement Application (GD App)|This is a chart review (prospective) data analysis study to describe the effect of the treatment change on the clinical parameters and patient reported outcomes (PROs) with the use of a digital engagement application (GD app) (to evaluate participants clinical engagement, shared decision making, emotional wellbeing, activities of daily living, goal attainment and Gaucher Disease specific measures).
45823066|NCT04718779|Other|No Intervention|This is a chart review (retrospective) data analysis study to describe the effect of the treatment change on the clinical parameters.
45965232|NCT04629859|Procedure|mandibular setback|12 patients will undergo mandibular setback
45823067|NCT00385190|Drug|HCV-796|
45667099|NCT04685577|Drug|Nefopam|Nefopam HCl inhibits the proliferation and viability of human mesenchymal fibroblasts with elevated β-catenin expression without affecting normal fibroblasts. Nefopam HCl primarily targets cells in which β-catenin is above normal physiologic levels. This threshold effect makes Nefopam HCl a good prospective therapeutic agent by limiting its effect to abnormal mesenchymal cells.Nefopam HCl has been found safe and effective for the reduction of dermal scarring following standardized human dermal wounds of critical depth that produces HTS in normal human volunteers Phase 1 study. In the current study, it is proposed that the concentration of the cream will be 3% and the timing of application will be delayed until after re-epithelialization at about 21 days to maximize the antiproliferative effects of NEFOPAM during the fibrotic/proliferative phase of healing.
45667100|NCT04685577|Other|Placebo (Vehicle)|Participants will receive vehicle with out the investigational product
45667101|NCT02443337|Drug|LY3023414|Administered orally
45667102|NCT02443337|Drug|Necitumumab|Administered IV
45965233|NCT00201981|Drug|Rebamipide|"OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks~OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks"
45965234|NCT00179972|Device|Adhesive and non-adhesive oximetry sensors|A sample of 32 premature infants will be recruited to participate in this study in which an adhesive sensor and a nonadhesive sensor are compared. Both sensors will be simultaneously tested in each subject, for a period of 14 days, with one sensor on the right foot and the other sensor on the left foot. Data will be collected on sensor longevity, skin integrity at the sensor site, reason for sensor replacement and ease of use rating by the clinician. Data will be summarized using descriptive statistics.
45965235|NCT04629742|Other|Seawater Pizza|A seawater pizza administered to 12 healthy subjects
45823068|NCT04717297|Behavioral|Medication Management Remote Intervention|First, the study pharmacist reviews the older adult's medication for potentially inappropriate medications. The pharmacist collaborates with the prescribing physician(s) to deprescribe as indicated. The pharmacist educates the older adult and OT on any changes that were made. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT provides training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered remotely.
45823069|NCT04717297|Behavioral|Waitlist Control|A trained research assistant will complete two attention control visits in the homes of participants. Visit will consist of semi-structured interview exploring the participant's life history.
45823070|NCT04717297|Behavioral|Medication Management In-Person Intervention|Participants in the waitlist control will be offered the medication management intervention to be completed in person. If they consent, the study pharmacist will review their medication for potentially inappropriate medications. The pharmacist will collaborate with the prescribing physician(s) to deprescribe any inappropriate medication as indicated. The pharmacist will educate the older adult and OT on any changes. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants will receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT will provide training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered in person.
45823071|NCT00005066|Drug|O6-benzylguanine|
45965236|NCT04629742|Other|Standard pizza|A standard pizza administered to 12 healthy subjects
45965237|NCT00561223|Drug|iloprost Inhalation|inhale 2.5 mg, repeat times one
45965238|NCT00561223|Drug|iloprost|inhaled 2.5 mg, repeat times one
45965239|NCT04629391|Device|Total shoulder arthroplasty|A prosthesis (either anatomic or reverse) will be implanted in shoulders patients that suffer from primary glenohumeral arthritis.
45823072|NCT00005066|Drug|carmustine|
45823073|NCT04711915|Drug|0.1 mg/kg Dimethyltryptamine (DMT)|0.1 mg/kg DMT
45823074|NCT04711915|Drug|0.3 mg/kg Dimethyltryptamine (DMT)|0.3 mg/kg DMT
45965240|NCT04629235|Other|wonder around|wonder around after 8 hours of bedrest
45458315|NCT01141465|Drug|Fluticasone / salmeterol dry powder inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
45965241|NCT04629235|Behavioral|bedrest|24 hours of bedrest
45965242|NCT00180011|Drug|Omalizumab|injectable medication
45965243|NCT00186966|Drug|Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome)|See Detailed Description section for details of treatment interventions.
45965244|NCT00186966|Drug|Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan|See Detailed Description section for details of treatment interventions.
45965245|NCT00186966|Procedure|Hematopoietic stem cell transplant|See Detailed Description section for details of treatment interventions.
45965246|NCT00186966|Radiation|Total body irradiation|See Detailed Description section for details of treatment interventions.
45965247|NCT04629001|Diagnostic Test|Covid-19 PCR , IGM|test for Covid-19
45965248|NCT04629040|Other|Lateral wedge insole|Lateral wedge insole for knee osteoarthritis patient
45965249|NCT04629040|Other|Ordinary insole|Ordinary insole
45965250|NCT00180050|Drug|Budesonide|
45965251|NCT00575302|Drug|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 300 U
45965252|NCT00575302|Drug|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 450 U
45667103|NCT04685343|Behavioral|Quantitative Sensory Testing|Quantitative sensory testing (QST) consisting of 4 pain induction and sensory sensitivity tasks (i.e., pressure applied to the thumbnail, arms, shoulders, and lower abdomen, a cold water task, and one video-watching task).
45667104|NCT04685343|Other|fMRI|Functional magnetic resonance imaging (fMRI) session consisting of structural and functional brain scans.
45965253|NCT00575341|Drug|Dehydroepiandrosterone|25 mg DHEA, oral, once daily
45965254|NCT00575341|Drug|placebo|placebo, oral, once daily
45965255|NCT04579471|Diagnostic Test|SARS-CoV-2 IgG|Collection of clinical variables, assessment of IgG antibodies for SARS-CoV-2, plasma collection for translational immunology studies
45965256|NCT00180089|Drug|Budesonide|
45965257|NCT00575419|Drug|N-acetylcysteine|"Dose Level 1: 150 mg/kg/day~Dose Level 2: 300 mg/kg/day~Dose Level 3: 600 mg/kg/day~Dose Level 4: 900 mg/kg/day~Dose Level 5: 1200 mg/kg/day"
45667105|NCT04684251|Procedure|Coil embolisation of hemorrhoidal arteries.|Coil embolisation of hemorrhoidal arteries as previously described.
45823075|NCT00004490|Drug|sodium dichloroacetate|
45965258|NCT04579588|Biological|Flu shot|All participants will receive a single shot of the flu vaccine
45455502|NCT03207620|Diagnostic Test|airway corticosteroid sensitivity|each group is divided into two groups (patients who are already using inhaled corticosteroid ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity.
45455503|NCT01223209|Drug|LTX-315|0.25-2.0 mg/ML, maximum 5 injections during 36 days.
45455504|NCT02691338|Other|EEG|EEG analysis
45455505|NCT02691338|Other|Routine follow up tests|Routine tests for patients after CVA. This include: neurologic evaluation, Brain CT, Angiography
45965259|NCT00575497|Procedure|More frequent hemodialysis|Six Day per week short daily hemodialysis
45823076|NCT05156983|Drug|TAK-330|Participants will receive TAK-330, 25 IU/kg single intravenous infusion on Day 1 and an additional dose of 25 IU/kg TAK-330 can be administered if required.
45965260|NCT00575497|Procedure|More frequent hemodialysis|Six nights per week nocturnal hemodialysis
45823077|NCT05156983|Drug|SOC 4F-PCC|Participants will receive 4F-PCC as SOC on Day 1. The dose and infusion speed of the SOC 4F-PCC will be based on local institutional protocols. An additional dose of SOC 4F-PCC not exceeding total dose of 50 IU/kg or 5,000 IU, whichever is smaller can be given during the surgery if required.
45823078|NCT00005072|Biological|Leuvectin|1000 ug of Leuvectin injected intratumorally
45823079|NCT00004496|Drug|alpha-melanocyte stimulating hormone|
45823080|NCT05138653|Drug|Drug: CVL-354|Oral solution/suspension
45965261|NCT00575497|Procedure|More frequent hemodialysis|Every other day short daily hemodialysis
45823081|NCT05138653|Drug|Drug: Placebo|Oral solution/suspension
45823082|NCT05133895|Drug|Tocilizumab monotherapy|intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months
45823083|NCT00382603|Device|OptiFree Multi-Purpose Disinfecting Solution|
45823084|NCT00003902|Drug|capecitabine|
45823085|NCT00003902|Drug|vinorelbine tartrate|
45667106|NCT02443103|Drug|Guanabenz acetate|
45667107|NCT02022657|Drug|Truvada|Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP
45667108|NCT02418455|Drug|UX003|solution for intravenous infusion
45667109|NCT02417753|Drug|AZD9150|AZD9150 IV infusion over 3 hours Cycle 1: days 1, 3, 5, 8, 15 and 22 of a 28 day cycle. Cycle 2 and beyond Days 1, 8, 15 and 22 of a 28 day cycle
45667110|NCT02417441|Device|Eeva|Embryos of subjects randomized in this group were assessed using Eeva System and morphological grading to identify optimal embryos for transfer.
45667111|NCT02021643|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
45667112|NCT02021643|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
45667113|NCT02021643|Drug|PEG|Pegylated interferon alfa-2a (Peg-IFNα-2a) 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week
45667114|NCT02415959|Drug|Creon IR|
45667115|NCT02415959|Drug|Creon® (DR/GR)|
45823086|NCT00003908|Drug|carboplatin|
45823087|NCT00003908|Drug|docetaxel|
45823088|NCT04558879|Behavioral|CT|12 weeks of exercise Cardiovascular Training
45823089|NCT04558879|Behavioral|RT|12 weeks of exercise Resistance Training
45823090|NCT00382837|Drug|Epratuzumab|
45823091|NCT00003914|Drug|dolastatin 10|
45965262|NCT00575497|Procedure|More frequent hemodialysis|Every other night hemodialysis
45823092|NCT00005078|Drug|carboplatin|
45965263|NCT00575497|Procedure|More frequent hemodialysis|5 days per week short daily hemodialysis
45965264|NCT00575497|Procedure|More frequent hemodialysis|5 nights per week hemodialysis
45965265|NCT00575497|Procedure|Conventional Hemodialysis|3 days per week short daily hemodialysis
45965266|NCT00180128|Drug|all-trans retinoid acid|
45965267|NCT00180128|Drug|idarubicin|
45965268|NCT00180128|Drug|mitoxantrone|
45965269|NCT00180128|Drug|daunorubicin|
45965270|NCT00180128|Drug|cytarabine|
45965271|NCT00575536|Procedure|Rhizotomy for children with spasticity|Optical Stimulation versus electrical stimulation in children who need Rhizotomy Surgery for spasticity
45965272|NCT00575575|Behavioral|cognitive behavior therapy|cognitive behavior therapy once a week
45965273|NCT00575614|Drug|prucalopride|1 mg o.d.
45965274|NCT00575614|Drug|placebo|o.d.
45965275|NCT00575731|Behavioral|Weight management strategies|
45965276|NCT00180167|Drug|randomization between two established Chemotherapies|
45965277|NCT04579627|Behavioral|Questionnaire|A single survey questionnaire to staff to report their demographics and facial hair styles between January and April 2020
45965278|NCT04579354|Other|virtual reality tour|Patients will be guided via VR on their way through the hospital to the operating theater
45965279|NCT04579705|Other|Using a brush|Surgical hand scrubbing will be performed in 1 minute and 2 minutes using a disposable nail brush.
45965280|NCT00575809|Other|Mucositis and nutritional assessments|Mucositis and nutritional assessments before and during the hematopoietic stem cell transplantation
45965281|NCT00180206|Device|Birmingham Hip Resurfacing|
45965282|NCT00575848|Dietary Supplement|Glycine|Subjects will consume glycine twice daily, once with breakfast and once with dinner. The medication is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
45965283|NCT00575848|Dietary Supplement|Placebo|Subjects will consume placebo twice daily, once with breakfast and once with dinner. The placebo is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
45965284|NCT00575926|Drug|LingZhi capsule|LingZhi or Placebo 300 mg x 4 or 300 mg x 6 capsules daily according to age group
45455506|NCT04108312|Diagnostic Test|Anatomical MRI Scan|T1-weighted (T1w) magnetization prepared rapid gradient echo (MPRAGE) sequence (TR=8.776 milliseconds, TE=3.656 milliseconds, flip angle=8°, matrix=320x320, 0.8mm3 resolution) and T2-weighted (T2w) CUBE sequence (TR=61.803 milliseconds, TE=3200 milliseconds, flip angle=8°, matrix=320x320, 0.8mm3 resolution)
45455507|NCT02529241|Drug|Group 1:LCB01-0371|"Period:LCB01-0371 Tablet 400 mg~Period: LCB01-0371 Tablet 400 mg"
45455508|NCT02529241|Drug|Group 2:LCB01-0371|"Period:LCB01-0371 Tablet 800 mg~Period: LCB01-0371 Tablet 1200 mg"
45823093|NCT00005078|Drug|paclitaxel|
45823094|NCT00005078|Drug|tirapazamine|
45823095|NCT04698031|Drug|Clopidogrel treatment|After randomization, patients will receive clopidogrel 75 mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking medication with Arm 2 to ensure the double-blind nature of the intervention. Clopidogrel is FDA approved for secondary prevention of stroke. Follow-up will be for 24 months with repeat brain MRI obtained at 24 months to assess for interval presence of silent brain infarctions.
45823096|NCT04698031|Drug|Aspirin treatment|After randomization, patients will receive Aspirin 325 mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking medication with Arm 2 to ensure the double-blind nature of the intervention. Aspirin is FDA approved for secondary prevention of stroke. Follow-up will be for 24 months with repeat brain MRI obtained at 24 months to assess for interval presence of silent brain infarctions.
45823097|NCT00003920|Biological|filgrastim|
45823098|NCT00003920|Drug|cyclosporine|
45823099|NCT00003920|Procedure|peripheral blood stem cell transplantation|
45455509|NCT02456012|Drug|oral esomeprazole 20 mg twice daily|for 36 weeks
45823100|NCT00003920|Radiation|indium In 111 monoclonal antibody m170|
45823101|NCT00003920|Radiation|yttrium Y 90 monoclonal antibody m170|
45823102|NCT00005084|Procedure|conventional surgery|
45823103|NCT00005084|Procedure|magnetic resonance spectroscopic imaging|
45965285|NCT00576004|Procedure|Pelvic organ prolapse repair and Burch colposuspension|Abdominal pelvic organ prolapse repair and retropubic Burch colposuspension
45965286|NCT00576043|Procedure|Simulator Training|3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator with the GI-Mentor Virtual simulator device
45965287|NCT00576160|Behavioral|PST therapy|Problem-Solving Therapy (PST) is a behavioral approach that teaches patients how to systematically solve their own behavioral difficulties. During telephone treatment sessions, the patient will discuss the problems and difficulties they face and that give rise to medication non-adherence.
45965288|NCT00576238|Drug|betamethasone valerate|Topical application according to a fixed schedule for three weeks
45965289|NCT00576238|Drug|betamethasone valerate|Topical application according to a fixed schedule for three weeks
45965290|NCT00576238|Drug|urea|Topical application twice daily for up to 6 months
45965291|NCT00576277|Drug|AV411|
45965292|NCT00576355|Behavioral|Interpersonal and Social Rhythm Therapy for Adolescents (IPSRT-A)|IPSRT-A involves 20 weeks of individual therapy, incorporating informed psychological, behavioral, and practical strategies adapted to the developmental needs of adolescents.
45965293|NCT00576355|Behavioral|Treatment As Usual (TAU)|TAU includes the offering of educational information about bipolar disorder and referral to a mental health provider.
45965294|NCT00576394|Drug|IV Insulin drip|IV insulin drip at 100units insulin in 100ml saline designed to keep blood glucose between 120-180mg/dl
45965295|NCT00576394|Drug|Insulin|IV insulin drip to keep serum glucose between 80-120mg/dl.
45965296|NCT00576433|Drug|Methotrexate|As prescribed
45823104|NCT00005084|Radiation|radiation therapy|
45823105|NCT00003926|Drug|amifostine trihydrate|"Patients receive amifostine intravenous (IV) over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1.~Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined."
45965297|NCT00576433|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
45965298|NCT00576511|Drug|prucalopride|4 mg o.d.
45965299|NCT00576511|Drug|placebo|Placebo o.d.
45965300|NCT00576550|Drug|Urea|Urea cream applied twice daily up to six months
45965301|NCT00576550|Drug|betamethasone valerate|Application once daily for two weeks
45965302|NCT00576550|Drug|betamethasone valerate|Application twice daily for two weeks
45965303|NCT00576589|Drug|CE-326,597|CE-326,597 administered orally, once daily for 14-days at 1 to 2 doses (25 mg QD, 100 mg QD) with the morning meal.
45455510|NCT02456012|Drug|oral esomeprazole 20 mg once daily|for 36 weeks
45455511|NCT01226407|Drug|CG200745|Multiple administration (IV) over the cycles untile MTD/LTD
45823106|NCT00003926|Drug|busulfan|Patients receive oral busulfan every 6 hours on days -8 to -6.
45823107|NCT00003926|Drug|filgrastim|All patients receive filgrastim (G-CSF) IV for 1 week.
45455512|NCT01317524|Dietary Supplement|Homogenized milk|900 mL homogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread
45455513|NCT01317524|Dietary Supplement|Unhomogenized milk|900 mL unhomogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread
45455514|NCT01317524|Dietary Supplement|Skimmed Milk|900 mL skimmed milk 44 g of salted butter 2 slices of bread 2 pieces of crisp bread
45455515|NCT03932929|Device|Scotchbond Universal Adhesive (3M ESPE)|Adhesive system
45458316|NCT01141465|Drug|Fluticasone / salmeterol metred dose inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
45823108|NCT00003926|Drug|melphalan|melphalan intravenous (IV) over 30 minutes on days -5 and -4
45823109|NCT00003926|Drug|thiotepa|thiotepa intravenous (IV) over 2 hours on days -3 and -2.
45823110|NCT00003926|Procedure|peripheral blood stem cell transplantation (PBSC)|PBSC are reinfused on day 0
45965304|NCT00576589|Drug|Placebo|CE-326,597 matching placebo administered orally, once daily for 14-days with the morning meal.
45965305|NCT00576706|Drug|Rebamipide|Rebamipide 100㎎, 12 weeks
45965306|NCT00576706|Drug|Misoprostol|Misoprostol 200㎍ 12 weeks
45965307|NCT00576745|Procedure|Vicryl Suture|A 4-0 vicryl suture will be used to close the subcuticular layer
45965308|NCT00576745|Device|3M TM S Surgical Skin Closure System|These steri-strips will be applied to close the skin in this cohort of patients
45965309|NCT00180284|Device|SITELINE 2 Polyurethane (pacing lead)|SITELINE 2 Polyurethane (pacing lead)
45965310|NCT00576784|Drug|pioglitazone and glimepiride|switch from any insulin treatment to 30 mg pioglitazone and 3 mg glimepiride.
45965311|NCT00576862|Drug|INSULIN GLARGINE|The subjects will continue the treatment with HOE 901 in the same way as they have done in the previous study. Based on the investigator's assessment and the approved SPC in Belgium/Luxembourg, the dosage can be adjusted individually. HOE 901 is to be injected once daily. HOE 901 must not be mixed with any other insulin, including regular human insulin or fast-acting insulin analogues.
45965312|NCT04578808|Other|Unruptured intracranial aneurysms|UIA of bifurcation between 3 and 7 mm for whom a clinical and imaging follow-up without occlusion treatment was scheduled by local multidisciplinary staff will be included. Extensive clinical, biological and imaging data will be recorded during a 3 years follow-up (visits at 1 and 3 years after inclusion).
45965313|NCT04723199|Device|Electrocautetery LAMS|Electrocautetery LAMS
45965314|NCT00576940|Drug|Reconvan|isocaloric, immunomodulating entral diet
45965315|NCT00576940|Drug|Peptisorb|isocaloric, isopeptic standard diet
45965316|NCT00202020|Drug|Cilostazol 200mg/day Oral|
45458317|NCT01141465|Drug|BUD/FOR dry powder inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
45823111|NCT05122819|Procedure|Mandibular Molar Extraction Under Local Anesthesia|"Local Anaesthetic to be used: 2% Lidocaine in 1.8 ml cartridge (regularly used for dental anaesthesia regardless of the technique).~Pain on injection and local anaesthesia success will be checked by using numeric pain rating scale (NPRS)."
45823112|NCT00005090|Biological|bleomycin sulfate|10 U/m^2 given on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
45823113|NCT00005090|Drug|carmustine|150/m^2 on days -6 to -4 (4-6 days before transplant).
45965317|NCT00202020|Drug|Aspirin 100mg/day Oral|
45965318|NCT00577018|Drug|Prucalopride|4 mg o.d.
45965319|NCT00577018|Drug|Prucalopride|1 mg o.d. for 2 days, 2 mg o.d. for 2 days and 4 mg o.d. thereafter
45965320|NCT00577018|Other|Placebo|o.d.
45965321|NCT04578847|Drug|Imatinib|Initial dose - 400 mg daily. If on imatinib, the dose should be decreased to 300 mg daily on the first stage, to 200 mg daily - on the second stage.
45965322|NCT04578847|Drug|Nilotinib|Initial dose - 300 or 400 mg twice daily. If on nilotinib to 400mg daily on the first stage, to 200 mg daily - on the second stage.
45965323|NCT04578847|Drug|Dasatinib|Initial dose 100 or 140 mg daily. If on dasatinib then to 50 mg daily on the first stage, to 25 mg daily - on the second stage.
45965324|NCT04578847|Drug|Bosutinib|Initial dose 500 mg daily. If on bosutinib, the dose should be reduced to 300 mg daily on the first stage, to 200 mg daily on the second stage.
45965325|NCT00180362|Device|procedure|
45965326|NCT00577057|Procedure|Conventional Radiotherapy|
45965327|NCT00577057|Procedure|Accelerated Radiotherapy|
45965328|NCT00577057|Drug|Cisplatin|
45965329|NCT00577057|Drug|5-fluorouracil|
45965330|NCT00577057|Drug|Capecitabine|
45965331|NCT00187005|Drug|Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
45667116|NCT02021565|Behavioral|Immediate Intervention Group|Assistive Technology (AT) Specialists, experts on assistive technology devices and how to performing transfer tasks, train Veteran and caregiver dyads to safely, skillfully, and (when appropriate) independently perform three activities of daily living (ADLs): transferring in and out of bed, toileting, and bathing. During the baseline assessments, AT Specialists also recommend assistive technology equipment (grab bars, bed rails, raised toilet seats, etc.), environmental modifications, adaptive methods, and energy conservation techniques. On the first day of the intervention, AT Specialists provide and install recommended equipment and train the dyad to complete the three ADLs using the recommended the modified methods.
45965332|NCT00187005|Drug|L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine|See Detailed Description section for details of treatment interventions.
45965333|NCT00180401|Behavioral|CRT-P and CRT-D devices|
45965334|NCT00577330|Dietary Supplement|Myalgesin™ (celery seed extract, Boswellia serrata extract, Phellodendron extract)|Twice daily
45965335|NCT04579003|Other|Mobilization|"Moist hot pack for 10 mins/1 set/ 6 consecutive days, Ultrasound for 5 mins/1 set/ 6 consecutive days, TENS on shoulder region for 10 mins/1 set/ 6 consecutive days, Shoulder mobilization posterolateral glide for 30 secs with 30 secs rest for 5 mins.~A total of 6 consecutive sessions were given each consisting of 30 mins."
45667117|NCT02021565|Other|Delayed Intervention Control Group|Receives the in-home training intervention six weeks after completing the initial baseline assessment. This allows for a control comparison group while still providing the intervention to all participants.
45667118|NCT05370677|Genetic|ARMS|amplification refractory mutation system
45667119|NCT02021331|Device|immediate implant placement without provisionalization|
45667120|NCT02021331|Device|immediate implant placement with immediate provisionalization|
45667121|NCT04682535|Other|Social relationships|Exposure to social interactions with spouse, friends, and family. Perceived loneliness, emotional strain, and emotional support.
45823114|NCT00005090|Drug|cyclophosphamide|100 mg/kg on day -2 (2 days before transplant).
45823115|NCT00005090|Drug|dacarbazine|375 mg/m^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
45823116|NCT00005090|Drug|doxorubicin hydrochloride|25 mg/m^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
45823117|NCT00005090|Drug|etoposide|60 mg/kg on day -4 (4 days before transplant).
45823118|NCT00005090|Drug|vinblastine|6 mg/m^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
45823119|NCT00005090|Procedure|peripheral blood stem cell transplantation|2 x 10^6 CD34+ blood mononuclear cells/kg of actual body weight
45965336|NCT04579003|Other|Mobilization with movement|"Moist hot pack for 10 mins/1 set/ 6 consecutive days, Ultrasound for 5 mins/1 set/ 6 consecutive days, TENS on shoulder region for 10 mins/1 set/ 6 consecutive days, Shoulder mobilization with movement (MWM) 10 repetitions with 30 secs rest for 5 mins.~A total of 6 consecutive sessions were given each consisting of 30 mins."
45965337|NCT00202059|Drug|Zoledronic acid|
45965338|NCT00202059|Behavioral|Physical activity intervention|
45965339|NCT04578418|Dietary Supplement|Hydrolyzed collagen|Hydrolyzed collagen supplementation twice daily
45667122|NCT04681833|Drug|Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo|Low Repeat Dose
45965340|NCT04578418|Other|Heavy slow resistance training|Heavy slow resistance training 3 times weekly
45965341|NCT04578418|Dietary Supplement|Placebo|Placebo supplementation twice daily
45458318|NCT03498352|Procedure|Thoracic surgery|Lung resection surgery
45667123|NCT04681833|Drug|Recombinant Respiratory Syncytial Virus Vaccine (BARS13)|High Repeat Dose/High Repeat Multiple Dose
45667124|NCT04681833|Drug|Placebo|Liquid diluent/Lyophilised Powder
45667125|NCT02085135|Drug|ALKS 5461|Sublingual tablet taken once daily
45667126|NCT02441309|Drug|Mifamurtide|
45667127|NCT02441309|Drug|Ifosfamide|
45965342|NCT00180440|Device|ICD|all models of Guidant/Bsc ICD's
45965343|NCT00577369|Other|Desflurane Levels|The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
45965344|NCT00577447|Dietary Supplement|docosahexaenoic acid (DHA)|Capsule containing 200mg of DHA
45965345|NCT00577447|Dietary Supplement|Placebo|Placebo capsule containing corn and soybean oil
45965346|NCT00180518|Device|Over-the-wire & Rapid Exchange ACCULINK (tm) Carotid Stent & ACCUNET (tm) embolic protection system|"Two rapid exchange devices will be evaluated: the RX ACCUNET Embolic Protection System (RX ACCUNET) and the RX ACCULINK Carotid Stent System (RX ACCULINK).~The RX ACCUNET Embolic Protection System is intended to facilitate the placement of diagnostic and therapeutic devices during interventional procedures and to capture embolic material that may be present during carotid artery interventional procedures.~The RX ACCULINK™ Carotid Stent System is intended for the treatment of carotid artery stenosis in the internal carotid artery (ICA), with or without involvement of the contiguous common carotid artery (CCA), in asymptomatic patients and symptomatic patients."
45965347|NCT00187044|Biological|PolyEnv1 vaccine|administered subcutaneously as 10*7 pfu in 0.8 mL
45823120|NCT05122663|Behavioral|Vestibular Rehabilitation|Vestibular Rehabilitation refers to the specific interventions that physical therapists provide to patients with dizziness and vertigo symptoms. These interventions can involve repositioning maneuvers, habituation exercises, gaze stabilization, and/or balance training exercises, depending on the specific etiology of dizziness and vertigo per an established clinical protocol utilizing a patient's history and exam findings. Physical therapists instruct patients in how to perform these exercises at home and provide instructions and referral for patients to follow-up with an outpatient physical therapist for further care.
45965348|NCT00577603|Procedure|mesh reinforcement of stoma|Patients randomized to receive mesh will undergo stoma formation and will have a 8 cm x 12 cm piece of AlloDerm graft placed as a tissue reinforcement around the stoma and extending under the midline incision. The mesh will be trimmed to provide a minimum of 3cm of overlap around the stoma in all directions. The mesh will be secured with transabdominal number one Prolene (Ethicon, Inc) sutures every 4cm around the mesh. Additional fixation will be provided with Protack spiral tacks (US Surgical, Inc) every 1cm around the mesh. The midline fascia will be closed with running number one Prolene sutures. Skin will be closed in standard fashion.
45965349|NCT00577603|Other|no intervention|
45965350|NCT00577681|Drug|Antiretroviral Therapy (ART)|Either episodic ART or continuous ART. All groups will have plasma specimens taken to compare changes in lipoprotein particle sizes and numbers and changes in inflammatory and coagulation markers.
45965351|NCT02963675|Other||external unexposed reference group
46080225|NCT02734992|Behavioral|ACT+ MTAU|Participants will be randomly assigned to one of the two groups: ACT-based intervention, plus their usual health care or Medical Treatment as Usual only (MTAU). The MTAU group will follow their usual medical treatment (prescribed headache medication). Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hour. The control group will receive the ACT intervention following the completion of the 3-months follow-up assessment of the treatment group. Participants in both groups will complete primary and secondary outcome scales, as well as ACT process effects scales at pre, post and 3-months follow-up. The treatment group only will be also assessed at 6 and 12-months follow-up. The ACT protocol and the patients' workbook were developed for the needs of the Algea project (Vasiliou & Karekla, 2015). Techniques will focus on key ACT processes aiming at promoting psychological flexibility for the head pain experience.
46080226|NCT02734992|Behavioral|Waitlist Control +MTAU|Participants in the Waitlist control+ MTAU will not receive any active intervention. Upon completion of the 3 months follow-up assessment of the ACT+MTAU group, participants allocated in the Waitlist control+MTAU will receive the ACT intervention.
46080227|NCT02807168|Other|NT-proBNP (Cardiac Biomarkers)|
46080228|NCT02806934|Procedure|biological and ultrasound test|biological and ultrasound test 20 days after implantation in order to see the implantation rate
46080229|NCT02734680|Radiation|Concurrent chemoradiotherapy(CCRT)|Radiation and take gemcitabine(GEM)
46080230|NCT02734680|Radiation|Stereotactic Radiotherapy(SBRT)|Stereotactic Radiotherapy(SBRT) (total dose: 45 Gy; single dose: 3 Gy; Frequency:15)
46080231|NCT02734680|Drug|S-1|Taking S-1 orally after radiation
46080232|NCT02807012|Other|Nursing educational intervention|"The nursing educational intervention by home visits will consist in three home visits by nurses until 14, 21 and 30 days after discharge to the intervention group. The nurses will give verbal information to family caregiver related to the care of elderly with stroke based on protocol with orientation related: information about stroke; emotional support; how to access health services; nutrition; airway; hygiene; positioning and transferring; prevent falls; dress/undress; medications; physiological eliminations; skin care. Furthermore, nurses will give some printed materials that contain orientations related to the care.~The control group could have ou not the usual care guidelines provide by health services that have access."
46080233|NCT02734524|Biological|NK cells|Natural killer cell infusion is an intervention between two arms. Dosage of infused cell >1×10^9，q28d*4
46080234|NCT02734524|Drug|Taxol|135-175mg/m2,q28d*4
45823121|NCT05122663|Other|Usual Care|Usual Care refers to any combination of diagnostic testing, medications, and patient education or counseling provided by a patient's treating ED physician.
45823122|NCT00004580|Drug|Lopinavir/Ritonavir|
46080235|NCT02734524|Drug|Carboplatin|AUC=5,q28d*4
46080236|NCT03977155|Drug|BOS-589|oral tablets
46080237|NCT03977155|Drug|Placebo|oral tablets
45823123|NCT00004580|Drug|Nevirapine|
45823124|NCT00005096|Drug|docetaxel|
45965352|NCT00577759|Other|Active Intervention|Quality improvement activities, including monthly teleconferences and chart audit with feedback, to help practices refer to community resources
45965353|NCT00577759|Other|Passive Intervention|Provision of tools to help with referrals to community resources
45965354|NCT00577759|Other|No intervention|No intervention
45965355|NCT00577798|Drug|doxorubicin hydrochloride|Standard therapy for patients undergoing chemotherapy for their non-Hogdkin's lyphoma and Hogdkin's lymphoma
45667128|NCT02027025|Drug|SPARC1103 low dose|once daily
45965356|NCT00577798|Procedure|contrast-enhanced magnetic resonance imaging|Cardiac magnetic resonance imaging (cMRI) offers the unique advantage of being able to analyze both function and structure (myocardial changes in the form of both a functional decrease in ejection fraction and structural changes within the myocardium defined as delayed contrast uptake).
45667129|NCT02027025|Drug|SPARC1103 high dose|once daily
45667130|NCT02027025|Drug|SPARC Placebo|
45667131|NCT01652729|Drug|Exenatide once weekly suspension|
45667132|NCT01652729|Drug|Sitagliptin|
45667133|NCT01652729|Drug|Placebo|Placebo oral capsule once daily
45823125|NCT00004604|Biological|CEA RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed dendritic cells
45823126|NCT05421013|Drug|STP705|STP705 targets TGFB-1 and COX-2 mRNA respectively.
45823127|NCT00004640|Drug|Chlorhexidine rinse|chlorhexidine solution on tooth loss in low income
45823128|NCT05104099|Drug|Metvixia Topical Cream|"Metvixia is applied with a spatula, in a thick layer, to clinically visible lesions and all over the vulva. After applying the cream, the area will be covered with a bandage which should remain in place for 3 hours. After 3 hours of application, the bandage and the cream will be carefully removed. The application area will be cleaned and then immediately exposed to a continuous spectrum of light at a wavelength of 405 nm by a xenon lamp.~The most fluorescent areas will be identified. Then in white light, the practitioner will perform at least two biopsies under non-topical local anesthesia in the area of application of Metvixia®: one in the fluorescent area and one in the non-fluorescent area.~If there is no fluorescent labeling, two samples will be taken from two different non-fluorescent areas. In the event that all the zone is fluorescent , two samples will be taken from two different fluorescent zones."
45823129|NCT00004646|Drug|prednisone|
45823130|NCT04330651|Procedure|ECLS|Emergency application of Extracorporeal Life Support in post-surgical patients
45965357|NCT00187083|Drug|Topotecan, dexamethasone, vincristine|See Detailed Description section for details of treatment interventions.
45823131|NCT00005108|Drug|Estradiol|
45965358|NCT00187083|Drug|E. coli Asparaginase, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
45965359|NCT00187083|Drug|erwinia asparaginase|See Detailed Description section for details of treatment interventions.
45667134|NCT02083965|Biological|rFVIIIFc|Administered as specified in the treatment arm.
45965360|NCT00187083|Drug|fludarabine, methotrexate, mercaptopurine|See Detailed Description section for details of treatment interventions.
45965361|NCT00187083|Drug|idarubicin, etoposide, cytarbine, teniposide|See Detailed Description section for details of treatment interventions.
45965362|NCT00187083|Procedure|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
46080238|NCT02807090|Other|Lumbar Stabilization Exercise|There will be 16 sessions, twice a week, with 40-60 minutes each session. In this arm the participants will learn basic notions about anatomy and biomechanics and the lumbar stabilization technique. They will be evaluated by a pressure biofeedback in the first day that will be used in the training. The lumbar stabilization technique consists of three stages: cognitive, associated and automatic. The biofeedback is used in the first stage and it helps patients to do the best contraction of stabilization muscles in different levels of pressure. Then, in stage two the patients do the contraction without the use of biofeedback and in the last phase different exercises are associated with the contraction of stabilization muscles.
46080239|NCT02807090|Other|Circular dance|There will be 16 sessions, twice a week, with 60 minutes each session. In this arm the participants will do the exercises in a group of 20 subjects. In every meeting there will be the follow stages: reception, reflection, warming/stretching, explanation about circular dance, choreography orientation, practice and finishing.
45667135|NCT04681287|Drug|inetetamab and PD-1 inhibitor combined with chemotherapy.|"Chemotherapy selected by doctors: albumin bound paclitaxel, vinorelbine, gemcitabine, capecitabine, and aribrin were administered according to clinical routine;~The first dose was 8 mg / kg, followed by 6 mg / kg, once every 3 weeks~PD-1 inhibitor 200mg D1 every 3 weeks as a cycle Treatment to disease progression or toxicity intolerance, or death from any cause.~The efficacy was evaluated every 2 cycles and adverse events were recorded. After 4-6 cycles of treatment, if the patient is intolerable to chemotherapy for any reason, the chemotherapy can be stopped and the combination of inistumab and PD-1 can be continued."
45667136|NCT04683627|Drug|Diclofenac sodium active topical patch|A topical patch with diclofenac sodium will be evaluated against the placebo patch for the treatment of OA pain of the knee
45667137|NCT04683627|Drug|Placebo patch|A placebo patch without diclofenac sodium will be used for the placebo arm.
45667138|NCT02438813|Drug|Deoxycholic acid|Deoxycholic acid (ATX-101) injection as the treatment of SMF as per standard of care in clinical practice.
45667139|NCT02438813|Procedure|Surgical Procedures|Surgical procedures for treatment of SMF as per standard of care in clinical practice.
45667140|NCT02438813|Procedure|Laser Liposuction|Laser Liposuction for the treatment of SMF as per standard of care in clinical practice..
45667141|NCT02438813|Device|Energy Devices|Energy Devices for the treatment of SMF as per standard of care in clinical practice.
45823132|NCT00005108|Drug|Progesterone|
45667142|NCT02438813|Other|Other Treatments|Other treatments for SMF as per standard of care in clinical practice.
45667143|NCT02437409|Device|pREset thrombectomy retriever|Interventional recanalization of acute cerebral vessel occlusions with the pREset thrombectomy system alone or in combination with intravenous or intraarterial thrombolytics (rt-PA).
45667144|NCT02459093|Device|poliglecaprone 25 suture|cesarean delivery incision closure with poliglecaprone 25 suture
45823133|NCT04648579|Device|Hillrom|Hillrom Connecta solution will record vital signs in an automated way, without the need for human intervention, and activate TRR activation when at least one criteria is met. The frequency of monitoring vital signs will be defined based on the MEWS score.
46080240|NCT04237272|Other|Pod System E-cig|Participants assigned to this intervention will try to pod system e-cigarette in the lab and receive a pod system e-cigarette to use for a three week sampling period.
46080241|NCT04237272|Other|Customizable Tank E-cig|Participants assigned to this intervention will try to customizable tank system e-cigarette in the lab and receive a customizable tank system e-cigarette to use for a three week
46080242|NCT04237272|Other|Control|Participants will not receive any e-cigarette
46080243|NCT00930059|Drug|PF-04447943|tablets, 25 mg every 12 hours for 12 wks
45667145|NCT02459093|Device|polyglactin 910 suture|cesarean delivery incision closure with polyglactin 910 suture
45667146|NCT02458469|Drug|Buspirone|The initial dose of Buspirone is 15 mg daily (7.5 mg bid.). To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day until a maximum dose 30mg/day is reached.
45667147|NCT02458469|Drug|Trazodone|100 mg dose before bed-time
45823134|NCT04648579|Other|Control|Hospital usual care regarding vital signs collection and TRR activation.
45823135|NCT00004652|Drug|pimozide|
45823136|NCT00004658|Drug|ribose|
45823137|NCT00004658|Drug|thymidine|
45965363|NCT00577837|Drug|risedronate|tablet, 5 mg risedronate daily for 6 months
45965364|NCT00577837|Drug|risedronate|tablet, 100 mg risedronate monthly for 6 months
45965365|NCT00577837|Drug|risedronate|tablet, 150 mg risedronate monthly for 6 months
45965366|NCT00577837|Drug|experimental|tablet, 200 mg risedronate monthly for 6 months
45965367|NCT00180557|Device|Flextend II, Fineline 2, Fineline Atrial J, Selute Picotip|
45965368|NCT00577876|Procedure|Trimix Injection with Doppler Ultrasound|"In case a large APA was identified, it will be dissected following the usual technique. Upon completion of the dissection, patients will have intracavernosal injection of 10 units (0.1 ml) of a Trimix administered (PGE1 10 mcg/ml, papaverine hydrochloride 30 mg/mL and phentolamine mesylate 1mg/mL.~Once the patient achieves a pharmacologic erection, the initial Doppler Ultrasound is completed, the accessory pudendal artery will be temporarily clamped to stop blood flow. After the artery is clamped, the Doppler Ultrasound will be repeated. We estimate an extension of the surgery no longer than 5 or 10 minutes in comparison to the usual operating time. Once the Doppler Ultrasound is completed, the clamp will be removed and the surgery continued in its usual fashion."
45965369|NCT00577915|Other|Radiology/MRI scan|MRI spectroscopy
46080244|NCT00930059|Drug|Placebo|matching placebo tablets, every 12 hours for 12 wks
45667148|NCT02458469|Drug|Placebo|One placebo pill before bed-time
45823138|NCT00004658|Drug|uridine|
45823139|NCT04293055|Behavioral|Maintenance program|1-year weight loss maintenance program, consisting of monthly newsletters
45965370|NCT00577954|Procedure|Multimodal MRI|Multimodal MRI
45965371|NCT00202098|Procedure|Variable ventilation|"Patients will be mechanically ventilated with Variable Ventilation (3 step with increased level of variability) and traditional CMV, for a total of 4 step. Each step lasts in 60 minutes. During this period the investigators will record the gas exchange parameters and the mechanics of the respiratory system."
45965372|NCT00578032|Behavioral|Quality of Life Questionaires & Interview: EORTC QLQ C-30, EORTC QLQ H&N-35, Health Behaviors, Subjective Significance Questionnaire, Qualitative Assessment|All patients will complete the predefined questionnaires at the following four time points along the course of their care: preoperative clinic visit, and 3 months (±1 month), 6 months (±1), and 9 months (1 and +3) post-operatively. Completion of the questionnaires should take approximately 30 minutes
45965373|NCT00180596|Device|Contak heart failure devices|
45965374|NCT00578110|Device|Glaucoma Diagnosis, Name: Neucodia|Sensitivity and Specificity
45455516|NCT03524560|Other|Comprehensive geriatric assesment|Comprehensive Geriatric Assesment (CGA) consisting of detailed history and examination, drug consumption information, Body Mass Index (BMI), Waist Circumference (WC), Timed Up & Go test (TUG), Clock Drawing Test (CD), Activities of Daily Living and Instrumental Activities of Daily Living scales (ADL & IADL), Mini Mental State Examination (MMSE), Tinetti Gait and Tinetti Balance scores (TG &TB), 30 items Geriatric Depression Scale (GDS) was performed for each subject
45455517|NCT02468596|Other|QTRAC assessment|Computerized analysis of the muscular response of musculus abductor pollicis brevis, to series of electrical stimulations of the median nerve
45455518|NCT02468596|Other|Clinical assessment of peripheral nerve function|Clinometric assessment using RT-MRC, Martin vigirometer, RT-mISS, T25W, 9 hole peg test, and ataxia scale
45455519|NCT00812006|Drug|rizatriptan benzoate|rizatriptan 10 mg Orally Disintegrating Tablet (ODT) orally for a moderate or severe migraine attack
45455520|NCT00812006|Drug|Comparator: placebo|Placebo to rizatriptan 10 mg ODT orally for a moderate or severe migraine attack
45965375|NCT00578149|Drug|Bevacizumab|
45965376|NCT00578149|Drug|Carboplatin|
45965377|NCT00578149|Drug|Paclitaxel|
45965378|NCT00187122|Drug|Vincristine|See Detailed Description section for description of treatment plan.
45965379|NCT00187122|Procedure|Radiation Therapy|See Detailed Description section for description of treatment plan.
45965380|NCT00187122|Drug|Daunomycin|See Detailed Description section for description of treatment plan.
45965381|NCT00187122|Drug|L-Asparaginase|See Detailed Description section for description of treatment plan.
45965382|NCT00187122|Drug|Cytarabine|See Detailed Description section for description of treatment plan.
45965383|NCT00187122|Drug|Methotrexate|See Detailed Description section for description of treatment plan.
45965384|NCT00187122|Drug|Mercaptopurine|See Detailed Description section for description of treatment plan.
45965385|NCT00187122|Drug|Etoposide|See Detailed Description section for description of treatment plan.
45965386|NCT00187122|Drug|Cyclophosphamide|See Detailed Description section for description of treatment plan.
45965387|NCT00187122|Drug|Prednisone|See Detailed Description section for description of treatment plan.
45965388|NCT00187122|Drug|Dexamethasone|See Detailed Description section for description of treatment plan.
45965389|NCT00180635|Drug|Aminoguanidine|500mg
45965390|NCT00180635|Drug|Placebos|2ml
45455521|NCT03133234|Drug|osimertinib|Oral dose of 80mg once daily
45965391|NCT00578266|Drug|Cyclophosphamide,Campath IH and TBI|"DAY 5 TREATMENT~6 5 CYTOXAN 50 mg/kg WITH MESNA~5 CYTOXAN 50 mg/kg WITH MESNA;~4 CYTOXAN 50 mg/kgWITH MESNA; CAMPATH 3-10 mg~3 CYTOXAN 50 mg/kg WITH MESNA; CAMPATH;~2 TBI; CAMPATH; TACROLIMUS~1 TBI (second fraction); CAMPATH (am) 0 STEM CELL INFUSION (pm)"
45455522|NCT01125787|Drug|ofatumumab + bendamustine|Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
45455523|NCT02457442|Drug|Propofol and Remifentanil|High propofol and low remifentanil, changing remifentanil (up-and-down method)
45455524|NCT02457442|Drug|Propofol and Remifentanil|Low propofol and high remifentanil, changing propofol (up-and-down method)
45455525|NCT02457442|Drug|Sevoflurane and Remifentanil|High sevoflurane and low remifentanil, changing remifentanil (up-and-down method)
45455526|NCT02457442|Drug|Sevoflurane and Remifentanil|Low sevoflurane and high remifentanil, changing sevoflurane up-and-down method)
45455527|NCT02457442|Drug|SPR 1|"Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~SPR 1: Changing Propofol for skin incision."
45965392|NCT00578422|Other|Ivus (Intravascular Ultrasound) of Amputation Specimens|Human lower extremity arterial segments will be obtained at autopsy and from amputation specimens. All imaging studies and vessel fixation will be undertaken immediately upon vessel procurement; in most cases this will occur within 2 hours of dissection and within 24 hours of death. The ex vivo portion of the study will make use of 150 excised vessels obtained over a 48-month period from randomly selected autopsy cases. From these vessels we expect to collect data from a minimum of 560 plaques
45965393|NCT00578422|Procedure|IVUS (Intravascular Ultrasound)|Standard diagnostic arteriographic images will be obtained. Appropriate oblique views will be acquired at the common femoral bifurcation. Next, IVUS will be performed obtaining ultrasound data from a 10 cm lower extremity artery.
45965394|NCT04578496|Drug|Afamelanotide|
45965395|NCT00202137|Behavioral|Home blood pressure monitoring|Monitor blood pressure using home blood pressure monitor
45965396|NCT00202137|Behavioral|Physician monitoring of blood pressure|Blood pressure measured as standard care from physician (no home monitor given for blood pressure monitoring)
45965397|NCT00578500|Procedure|ovarian transplantation|Patients will undergo laparoscopic oophorectomy, aspiration of oocytes and maturation followed by cryopreservation. In case of ovarian failure and approval by treating physicians, restoration of fertility will be attempted by thawing of oocytes or by transplantation of ovarian cortex to induce ovulation and obtain oocytes for fertilization and embryo transfer.
45965398|NCT00578578|Dietary Supplement|eicosapentaenoic acid (EPA),|three capsules daily (1350 mg daily) of EPA for 8 weeks or three capsules daily placebo for 8 weeks
45965399|NCT00578656|Dietary Supplement|Baked Milk|Extensively heated milk
45965400|NCT00578851|Device|C2a - Taper™ Acetabular System|The C2a-Taper™ Acetabular System is a ceramic on ceramic hip articulating system. The bearing surfaces consist of ceramic femoral heads and acetabular liners.
45965401|NCT00578890|Procedure|Medical/surgical treatment versus medical treatment|A 12 week course antibiotics versus a limited resection of infected bone associated with a 4 week course antibiotics.
45965402|NCT00579007|Behavioral|telephone interviews|Telephone interviews take place before the first counseling appointment (baseline), and 1 week, 6 months and 12 months post-notification of the individual's genetic test results. In the event that a participant chooses not to undergo genetic testing, follow-up interviews will take place 1 month, 6 months and 12 months after the initial counseling visit.
45965403|NCT00579046|Drug|Darbepoetin alfa|"Dosage form: injection (to store between 2 and 8 °C). Dosage: various dosages are available (10, 15, 20, 30, 40, 50, 60, 80, 100, 150 or 300 µg/ml).~Frequency: every week for 2 months: 8 injections"
45965404|NCT00579085|Drug|Ketamine|IV Ketamine .35mg/kg times ten days.
45965405|NCT00579085|Other|IV NSS|Placebo inactive ingredients
46080245|NCT05533944|Other|Simulation training in Boškoski-Costamagna ERCP Trainer|Coached simulation training in Boškoski-Costamagna ERCP Trainer, by participating in three intensive courses during the first three months of training, with a monthly basis
46080246|NCT04173962|Drug|Ketamine|administered 1 week prior to a laboratory-induced stress
45667149|NCT04931771|Device|vFFR guided revascularization|3D-angio-based vessel FFR (CAAS, Pie Medical Imaging, Maastricht, The Netherlands) uses 3-Dimensional Quantitative Coronary Angiography (3D-QCA) for functional assessment of coronary stenosis. vFFR is calculated using two angiographic views with at least 30 degrees difference in rotation/angulation to generate the 3D reconstruction of the coronary artery.
45667150|NCT04931771|Device|FFR guided revascularization|Fractional flow reserve (FFR) is a technique used in coronary catheterization to measure pressure differences across a coronary artery stenosis (narrowing, usually due to atherosclerosis) to determine the likelihood that the stenosis impedes oxygen delivery to the heart muscle (myocardial ischemia)
45667151|NCT01843348|Drug|Everolimus|
45823140|NCT04293055|Behavioral|Phone coaching|Some individuals will receive 4 consecutive weeks of phone coaching. The first coaching call will be approximately 30 minutes in duration and follow-up calls will be 10-15 minutes in duration. Coaches will help support participants in their weight loss maintenance efforts. Once coaching calls are completed, the participant will not have any other contact with their coach.
45823141|NCT00005120|Drug|Calanolide A|
45823142|NCT04624321|Behavioral|Health and lifestyle tool|Health and lifestyle tool used online
45823143|NCT04624321|Other|Usual care|Usual care at ordinary healthcare provider
45965406|NCT00579085|Other|Normal Saline|"INFUSION PLAN:~All patients will be infused intravenously with 100 ml of normal saline for four hours (25 ml/hr) daily for 10 days.Both patient arms will receive 2mg of Versed x two doses IV. They will also receive Clonidine (0.1 mg, po)"
45965407|NCT00579202|Device|Gambro HD-C4 Small Dialyzer|Involves the use of FDA 510(k) cleared hemodialyzers and will have no impact on the patient's routine dialysis therapy.
45965408|NCT00579241|Procedure|Ultrasound on Temporal Bone|All Patients undergoing dobutamine stress echocardiography have an intravenous line placed and a continuous infusion of a commercially available contrast agent administered. Prior to contrast infusion, baseline transcranial ultrasound images at 0.4 mechanical index using low mechanical index pulses and color Doppler will be performed and recorded. After this the contrast infusion will begin, and resting cardiac images will occur.
45965409|NCT04578262|Procedure|Epley Manoeuvre|This manoeuvre is constituted by five steps. In the first step, while the patient is in supine posture the head will be positioned 45 degrees turned towards the unaffected ear and the head slightly overhang on the edge of the couch. In this second step maintaining the previous position of the head, physiotherapist will turn head 45 degrees turned towards the affected ear. Next, in the third step, the whole body will turn until is located 135 degrees from the baseline supine position. In the fourth step, while the head keeps turned to the affected ear the subject will be incorporated until he is sitting. In the fifth step, while the subject is seated with the head in neutral position the chin will be bended 20 degrees. Each procedure will be held among 30 seconds or two minutes, while the dizziness or the nystagmus vanish. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain).
46080247|NCT04173962|Drug|Midazolam|administered 1 week prior to a laboratory-induced stress
46080248|NCT02734446|Drug|Reuterin D3 drops|5 drops/day for 3 months
46080249|NCT02734446|Other|Placebo|5 drops/day for 3 months
46080250|NCT00772005|Drug|armodafinil|150 mg/day armodafinil
45667152|NCT01843348|Drug|Tacrolimus|Capsules: 0.5 mg, 1 mg or 5 mg. Dosing schedule: transplant to month 2: 4-8ng/ml, month 3 to month 12 3-5 ng/ml according to standard blood levels
45823144|NCT00004664|Drug|megestrol|
45823145|NCT00004664|Behavioral|Exercise|
45823146|NCT00004670|Procedure|pallidotomy|
45823147|NCT05396755|Procedure|Endoscopic retrograde cholangiography (ERC)|invasive evaluation of the biliary tract with ERC and endoscopic interventions every 8 weeks until 6 months (24 weeks)
45823148|NCT00004682|Drug|immune globulin|
45823149|NCT00004688|Drug|carmustine|
45823150|NCT00004688|Drug|mercaptopurine|
45823151|NCT00004688|Drug|streptozocin|
45823152|NCT00004694|Drug|heparin|
45823153|NCT04608409|Drug|Lapatinib and Paclitaxel|Participants will receive twice-daily Lapatinib, beginning two days prior to Paclitaxel treatment.
45823154|NCT05091853|Device|Adhesix mesh|2 meshes are used; the self-gripping Progrip mesh and the self-adhesive Adhesix mesh
45823155|NCT04607551|Procedure|Prone positionning|4 to 5 persons required for the procedure, one of them being dedicated to the management of the head of the patient, the endotracheal tube, the jugular ECMO cannula and the ventilator lines and another dedicated to the femoral ECMO cannula. The person at the head of the bed will coordinate the steps. The other persons will stand at each side of the bed. The direction of the rotation will be decided giving priority to the side of the central venous lines. The length of vascular and ventilator lines will be checked for appropriateness, the endotracheal tube and gastric tube will be secured, and the patient's knees, forehead, chest, and iliac crests will be protected using adhesive pads. The patient will be then moved along the horizontal plane to the opposite side of the bed selected for the direction of rotation. Patients will be proned at least four times during the first days on ECMO. Each prone session will stand for at least 16 hours
45965410|NCT04578262|Procedure|Sham Manoeuvre|The sham manoeuvre consist is going to star with the participant in a neutral seated position. Sum to it, head is rotated 45 degrees towards the unaffected vestibule. After that, the participant will be guided by the physiotherapist to a lateral decubitus position towards the affected side on which his nose will be pointing above. To conclude, the seated position will be reached again without head rotation. Each position of the sham manoeuvre will be maintained along one minute. During all the process the videonystagmography glasses will be dressed by participants and they will be indicated not to close eyes in the intervention. After the execution of the manoeuvre, also this group will be evaluated 48 hours after. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain).
46080251|NCT00772005|Drug|placebo|placebo
46080252|NCT00772005|Drug|armodafinil|200 mg/day armodafinil
46080253|NCT00772005|Drug|armodafinil|250 mg/day armodafinil
46080254|NCT05006131|Other|Screening for pancreatic cancer|Screening for pancreatic cancer using EUS or MRI
45823156|NCT04607551|Procedure|Supine position|Patients assigned to supine will remain in a semi-recumbent position.
45823157|NCT00004700|Drug|insulin-like growth factor I|
45823158|NCT00004730|Drug|magnesium sulfate|
45823159|NCT00004736|Drug|Nelfinavir mesylate|
45823160|NCT00004736|Drug|Ethambutol hydrochloride|
45823161|NCT00004736|Drug|Isoniazid|
45823162|NCT00004736|Drug|Pyrazinamide|
46080255|NCT02806856|Device|tDCS neuroConn|Cathodal on M1
46080256|NCT02806856|Device|Sham stimulation|Sham
46080257|NCT03333408|Drug|Postoperative Oral Antibiotics (Clindamycin or Augmentin)|Patients will receive postoperative oral antibiotics (Clindamycin or Augmentin) for 10-14 days upon discharge.
45455528|NCT02457442|Drug|SPR2|"Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~Changing Sevoflurane for skin incision."
45667153|NCT01843348|Drug|Cyclosporin A|Capsules: 10 mg, 25 mg, 50 mg or 100 mg. Transplantation to month 2: 75 - 125 ng/ml, month 3 to month 12: 50 - 100 ng/ml
45667154|NCT01843348|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|Tablets: 180 mg or 360 mg. Dosing: duration of study 360 mg bid and no less than 360 mg daily dose
45823163|NCT00004736|Drug|Lamivudine|
45823164|NCT00004736|Drug|Rifabutin|
45823165|NCT00004736|Drug|Stavudine|
45823166|NCT00004736|Drug|Zidovudine|
45823167|NCT04592731|Drug|Gel containing Acetylated Natural Nucleotides|The study drug is a gel containing acetylated natural nucleotides.
45823168|NCT04592731|Drug|Vehicle Gel|The vehicle gel contains no acetylated natural nucleotides but with the same base as study drug.
45823169|NCT00004748|Drug|colchicine|
45823170|NCT00004748|Drug|methotrexate|
45823171|NCT00004748|Drug|ursodiol|
46080258|NCT02813096|Drug|folfox4 chemotherapy regimen|"Folfox regimen:Oxaliplatin 85 mg/m2 in 250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1;leucovorin 200 mg/m2 in 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 400 mg/m2 5-FU in 20mL 0.9% NaCl solution, IV(administered as follow leucovorin); then 600 mg/m2 5-FU in 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops."
45667155|NCT01843348|Drug|Mycophenolate mofetil (MMF)|Capsules: 250 or 500 mg. Dosing: duration of study 500 mg bid and no less than 500 mg total daily dose
45823172|NCT04585477|Device|AVENIO ctDNA Surveillance Kit|Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)
45455529|NCT01220011|Procedure|Fetoscopic laser surgery|Fetoscopic laser surgery
45455530|NCT04541498|Other|Impact of air pollution and climate changes|To assess the short- and long- term impact of air pollution and climate changes
45667156|NCT01843348|Drug|Corticosteroids|A minimum dose of 5 mg prednisolon or equivalent
45667157|NCT01843348|Drug|Simulect|Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.
45667158|NCT01843192|Device|Endocutter|
45667159|NCT01825876|Drug|Evacetrapib|Oral administration
45667160|NCT01825876|Drug|Warfarin|Oral administration
45667161|NCT01842958|Device|Straumann Bone Level Implants, 4.1 mm implant diameter|Straumann Bone Level Implants, 4.1 mm implant diameter
45823173|NCT04585477|Drug|Durvalumab|1500mg intravenous dose or 20mg/kg if weight is 30kg or less, manufactured by AstraZeneca
45823174|NCT00004754|Drug|epoprostenol|
45823175|NCT04570657|Biological|MEDI3506|Participants will receive multiple doses of MEDI3506 at dose level 1 or dose level 2
45823176|NCT04570657|Drug|Placebo|Participants will receive multiple doses of placebo
45823177|NCT00005576|Biological|monoclonal antibody Ch14.18|Given IV
45823178|NCT00005576|Drug|isotretinoin|Given orally
45823179|NCT00005576|Biological|aldesleukin|Given IV
45823180|NCT00005576|Biological|sargramostim|Given IV
45823181|NCT00386204|Device|Q-switched Ruby Laser|
45823182|NCT00004760|Behavioral|Exercise|
45823183|NCT04713163|Drug|covid19 vaccine|Vaccine
45823184|NCT00004772|Drug|Immune globulin|
45823185|NCT04712929|Other|Fluconazole|( Tab Fluconazole 100 mg as a mouthwash ( tablet dissolved in 10 ml of drinking water and used as a rinse for 2 minute and swallowed) once a day for 14 days WHO criteria 5As and 5Rs for tobacco cessation
45965411|NCT04577950|Procedure|Lymphatic drainage of endometrial cancer|Nanocoll® is injected a day before surgery in the cervix at four points. A lymphoscintigraphy is performed 2 or 3 hours afterward. At the beginning of the surgery, the operative field already in place and before the beginning of laparoscopic, 2ml (10mg) of ICG, distributed in four points around the tumor, is injected under the endometrium intra-myometrial under endoscopic control. As ICG spreads slower than blue dye, ICG is always injected first. Then, Bleu Patenté® is injected at two sites in the uterine isthmus, opposite of the uterine arteries. The risk of false negative results, because a tracer migrated too quickly, is reduced when the injection takes place when patients are already anesthetized.
46080259|NCT02813096|Other|Placebo|"Placebo regimen:250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1; 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 20mL 0.9% NaCl solution, IV; then 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops."
46080260|NCT03816007|Behavioral|Yoga and Mantram Repetition|An existing yoga intervention designed for persons with chronic pain will be augmented with training in mantram repetition. The intervention meets 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
46080261|NCT03816007|Behavioral|Veteran Calm|A relaxation intervention used previously as a comparator intervention will be delivered by a health educator 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
45667162|NCT01842958|Device|Straumann Bone Level Implants, 3.3 mm implant diameter|Straumann Bone Level Implants, 3.3 mm implant diameter
45667163|NCT02413229|Drug|DSXS1411|DSXS (Taro Pharmaceuticals Inc.)
45667164|NCT02413229|Drug|Placebo|Placebo (vehicle) (Taro Pharmaceuticals Inc.)
45667165|NCT01825798|Drug|Metformin|Metformin will be dispensed in a liquid suspension of 100 mg/mL. For children 6-9 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if metformin is well-tolerated, the dose will be increased to 850 mg twice daily.
45823186|NCT05082961|Other|Collection of blood samples|Samples to evaluate the circulating CD8+ T cell count.
45965412|NCT04578067|Behavioral|Lifestyle intervention|on physical activity and healthier eating
45965413|NCT00187161|Drug|Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin|The additional information is contained in the Detailed Description section.
46080262|NCT02734368|Drug|Hyperpolarized Helium-3|
46080263|NCT04262999|Other|effect of sodium valproate on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate drug therapy.
46080264|NCT04262999|Other|effect of levetiracetam on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on levetiracetam drug therapy.
46080265|NCT04262999|Other|effect of sodium valproate+levetiracetam on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate+levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate+ levetiracetam drug therapy.
46080266|NCT04262999|Other|control group|Control group individuals will be systemically healthy.
46080267|NCT05582174|Drug|Vonoprazan|Vonoprazan 40 mg bid orally for 72 hours, and from day 4-30 VPZ 20 mg daily
45667166|NCT01825798|Drug|Placebo|The placebo hydrochloride oral solution will be prepared to match the appearance, smell and taste of the metformin as closely as possible. For children from 6-9 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if placebo is well-tolerated, the dose will be increased to 850 mg twice daily.
45667167|NCT05370599|Drug|Anti-hypertensive agent: amlodipine|Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
45667168|NCT05370599|Drug|Anti-hypertensive agent: Chlorthalidone|Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
45667169|NCT05370599|Drug|Anti-hypertensive agent: Losartan|Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
45667170|NCT05370599|Device|Home BP monitoring with cuffed device|Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
45667171|NCT05370599|Device|Home BP monitoring with cuffed device + BP patch|Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
45823187|NCT00004784|Drug|methotrexate|
45823188|NCT00004784|Drug|ursodiol|
45823189|NCT00004796|Drug|lactulose|
45823190|NCT00004802|Drug|dichlorphenamide|
45823191|NCT00004808|Drug|fluconazole|
45823192|NCT00004814|Drug|copolymer 1|
45823193|NCT00004826|Drug|clozapine|
45823194|NCT04555603|Drug|Inlyta|axitinib
45823195|NCT04555603|Drug|Bavencio|avelumab
45823196|NCT04555603|Drug|Keytruda|Pembrolizumab
45823197|NCT00423254|Biological|PSMA/PRAME|Low dose
46080268|NCT05582174|Drug|esomeprazole|A high dose PPI infusion (esomeprazole 80mg iv bolus followed by 8mg per hour for 72 hours), and frorm day 4-30 oral esomeprazole daily
45965414|NCT04578184|Diagnostic Test|Corneal epithelial thickness measurements|Corneal epithelial thickness measurements using two optical coherence tomography devices in healthy and keratoconus corneas.
45965415|NCT00579475|Drug|Mifegyne|tablets, 50 mg every other day
45965416|NCT00579475|Drug|placebo|
45965417|NCT00579592|Drug|Campath-1H, rituximab, myfortic|Campath-1H 30mg IV x 2 doses, rituximab 375mg/m2 IV x 1 dose, myfortic 720mg bid, cyclosporine po bid (target trough 200ng/ml) x 10-20 days
45965418|NCT00579631|Behavioral|Questionnaire or Interview|Complete a self-report survey once over the telephone or by mail. The questions are about your health beliefs and behaviors, your current health, and your mood. It should not take longer than 45 minutes to complete. About 15 of these people will participate in an additional, short audiotaped interview about sun protection.
45965419|NCT00180791|Drug|Etoposide, carboplatin, melphalan, cisplatin, thiotepa|
45965420|NCT01054248|Drug|dihydroartemisinin-piperaquine|Standard 3 days regimen DHA-piperaquine: (DHA/PPQ 40 mg/320 mg) 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
45965421|NCT01054248|Drug|Artesunate-mefloquine|Standard three day regimen of artesunate-mefloquine (12/24 mg/kg) given as artesunate 4mg/kg/day and mefloquine 8mg/kg/day on Days 0, 1 and 2.
45965422|NCT01054248|Drug|arthemeter-lumefantrin|Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet).
45965423|NCT00579865|Behavioral|questionnaires|complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure.
45965424|NCT00579865|Behavioral|questionnaires|complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure. Patients who have undergone bypass or resection will complete an additional set of questionnaires at 9 and 14 weeks.
45965425|NCT00579904|Dietary Supplement|walnuts|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to walnuts. They will eat walnuts once daily for six weeks.
45965426|NCT00579904|Dietary Supplement|almonds|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to almonds. They will eat almonds once daily for six weeks.
46080269|NCT00926107|Drug|Temsirolimus|Temsirolimus 25mg weekly until clinical progression
45455531|NCT03524482|Behavioral|SmokeFreeText|"SmokefreeTXT is a 6-8 week fully automated text-based cessation intervention. The program is free to U.S. subscribers who have a mobile phone, and is available on smokefree.gov or by texting QUIT to short code 47848. Participants are encouraged to set a quit date within the next 14 days, followed by count-down messages leading to the quit date. Starting on the quit date, participants receive 6 weeks of intervention text messages, and assessment questions (mood, cravings, smoking status). The message library contains 166 messages and 41 behavior change techniques,40 which are delivered at the greatest frequency during the first 2 weeks and taper over time. When in need of assistance, participants can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system. Participants can opt-out by texting STOP at any time. With informed consent, we will be able to access the SmokefreeTXT data for these participants."
45455532|NCT03524482|Behavioral|Path2Quit|Path2Quit will deliver 20-60 second video clips by multimedia messaging service. The message library will include 75-170 messages. Written text messages will be limited to brief phrases to indicate the topic of the video. Messages will be pushed to participants in the morning, in the afternoon, and 2 hours before the reported usual bedtime. The cultural adaptations will be infused throughout the video segments. Topics include deep structure: race and smoking in general, African American smoking statistics; norms for smoking; concerns about nicotine replacement/medication; family/collectivism; unique stressors; racism/discrimination, depression; co-morbid addiction; neighborhood/environmental influences; menthol cigarettes; race-specific weight issues and concerns; and working as a community against the tobacco industry.
45455533|NCT01220089|Behavioral|Standard maintenance|Participants will receive written materials in months 7-18
45455534|NCT01220089|Behavioral|Intensified maintenance|Participants will continue with in-person counseling visits in months 7-18
45455535|NCT03145532|Other|tDCS plus robotic training|Children will first receive 20 min of tDCS (real or sham, see Arms), then will receive 1 hr of upper limb robotic therapy in which the child will use their impaired arm and hand to move a joystick controlling a cursor to a set of targets on a video screen in front of the child.
46080270|NCT02733978|Device|the ozone generator device (Human Pro medic, German)|noninvasive oxygen-ozone treatments with 52 ug/mL ozone (total volume: 20-50 mL) in a special bag for 30 min per day for 20 days using the ozone generator device (Human Pro Medic, German)
45455536|NCT04628650|Device|Digital Pain-Management Tool|Self management digital tool for chronic pain
45455537|NCT01129219|Other|Strength training|Strength training for 24 weeks
45455538|NCT03132038|Drug|Nivolumab|3 mg/kg, every two weeks, during a maximum of one year
45455539|NCT01129375|Drug|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
45455540|NCT01129375|Drug|placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
45965427|NCT00180830|Drug|Glivec|
45965428|NCT00180830|Drug|Gleevec|
45965429|NCT00580021|Other|Genotyping|Samples for DNA extraction will be shaved from archival paraffin-embedded tissue blocks (using normal lymph node preferentially)and placed in appropriate receptacles labeled only with the subject unique study number. This material will be transported to the genotyping laboratory, where it will be stored until the clinical record abstraction is complete. Briefly, DNA will be extracted from the archive paraffin-embedded material using standard protocols and the samples will be analyzed for the presence of the Ashkenazi BRCA founder mutations using either PCR-based or gel-electrophoresis-based approaches.
45965430|NCT00202176|Drug|Ipratropium Bromide|Nebulized Ipratropium Bromide (4 mL) or saline solution (0.9% NaCl) (4mL) will be administered to subjects once only.
45965431|NCT00580060|Biological|GM-CSF DNA, NSC 683472 gp100: 209-217(210M), NSC 699048 Tyrosinase: 368-376(370D)|In the Dose Ranging part of the study, cohorts of 3 patients will be treated at increasing dose levels of GM-CSF DNA delivered subcutaneously (100, 400, or 800 mg), followed by administration of both peptides subcutaneously to the same site on day 5 or day 6. Patients will be treated monthly for three immunizations.
45965432|NCT00180869|Procedure|transfusion of allogeneic red blood cell concentrate|
45965433|NCT00180869|Procedure|transfusion of leuko-reduced red blood cell concentrate|
45965434|NCT00580099|Other|assisted exercise|4 weeks of passive range of motion exercise
45455541|NCT01129375|Drug|omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration:oral"
45455542|NCT03635138|Other|Metal nanoparticles ( O Zn and Cu)|Np of OZn nanoparticles mixed with dental adhesive
45823198|NCT00423254|Biological|PSMA/PRAME|high dose
45965435|NCT00580099|Other|cuddle|cuddle infant for 20 minutes
45965436|NCT00580177|Procedure|Lichtenstein mesh|The different techniques are compared and evaluated according to primary and secondary objectives.
45965437|NCT00580177|Procedure|PerFix Plug®|The different techniques are compared and evaluated according to primary and secondary objectives.
45965438|NCT00580177|Procedure|Prolene® Hernia System|The different techniques are compared and evaluated according to primary and secondary objectives.
45965439|NCT00187239|Device|Autointrinsic Conduction Search Algorithm|Autointrinsic conduction search is programmed on in those patients randomized to AICS ON.
45965440|NCT00180908|Drug|Etoposide, Ifosfamide, Methotrexate|
45965441|NCT00180908|Drug|Doxorubicin, Methotrexate|
45965442|NCT04578145|Diagnostic Test|HIV self-testing among female sex workers|"Barriers faced by FSWs in terms of undergoing HIV blood test seemingly overcome through the implementation of alternative strategy of testing, by using OFT self-testing (Ora-Quick).~Ora-Quick test used in this study measures antibody in oral fluid of participants. The oral fluid is collected used a test swab from participant's gum by wiping upper and lower gums once. The specimen mixed with buffered developer solution in test tube. Test result will appear in a short time, by 20 to 40 minutes and leading to interpret."
45965443|NCT00202215|Behavioral|Chrysalis Day Program|
45965444|NCT00580450|Drug|Thymosin alpha 1|1.6 mg sc once a day for 16 weeks
45965445|NCT00180947|Drug|Vinorelbine, cyclofosfamide|
45965446|NCT00580528|Behavioral|Tailored Internet Newsletters|Tailored newsletters delivered via the Internet with content for improving eating and activity to reduce blood pressure
45965447|NCT00580528|Behavioral|Tailored print newsletters delivered via mail|Tailored Newsletters with content to improve eating and activity to reduce blood pressure
45965448|NCT00202254|Behavioral|Physiotherapy|
45965449|NCT00202254|Behavioral|Occupational therapy|
45965450|NCT00202254|Behavioral|Speech pathology|
45965451|NCT04577872|Other|Pelvic floor muscle training|The treatment for the sitting group comprised 8 sessions, with a 1-hour combined pelvic floor muscle training (cPFM-T) session each week in a group and 15 minutes of individual home training, six times a week for a total of 8 weeks of treatment. All training sessions comprised warming-up, gradual muscle strengthening and relaxation exercises. In the study, before and after the training programme, we used a self-administered questionnaire.We measured changes in pelvic floor muscle activity with a vaginal surface electromyographic instrument. We performed the transversus abdominis measurements at the same time as the vaginal measurements and pelvic floor muscle tasks.
45965452|NCT00580684|Biological|pneumococcus conjugate vaccine 7 valent to reduce carriage|plain polisacaride vaccine 23 valent to reduce carriage
45965453|NCT00180986|Procedure|Platelet concentrates|
45455543|NCT03635138|Other|Dental Adhesive pure|Dental Adhesive with commercial preparation
45455544|NCT03928405|Other|Exercises with Nintendo Wii virtual reality device|In the first session, each Nintendo Wii components were introduced to each individual. The selected games and how they were played were taught to each individual by the physiotherapist and practically taught. The games were played with the help of physiotherapists in the first session so that individuals could transfer the correct weight on the Nintendo Wii balance board and to use the game console's control. The patient was supported with verbal and physical feedback when the patient played incorrectly during the games in the next sessions. Games that require serious balance and coordination were considered as a difficult activity for the patient and were not used in this study. The difficulty of the games was set to the simplest level for each patient. As the patients were successful the games' difficulty level was upgraded. The difficulty of the games has been increased according to the classification determined by the Nintendo Wii device.
45823199|NCT04552327|Device|Solcera|Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
45823200|NCT04552327|Device|Placebo|Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
45823201|NCT04552327|Drug|Solaraze|Twice daily application for a duration of 60 days
45823202|NCT00005588|Radiation|radiation therapy|
45823203|NCT04552015|Diagnostic Test|TST vs PPD microneedle test|TST vs First patch: 800 um in length, PPD1 formulation; Second patch: 1,500 um in length, PPD1 formulation; Third patch: 800 um in length, PPD2 formulation; and Fourth patch: 1,500 um in length, PPD2 formulation
45823204|NCT00004778|Drug|betamethasone|
45823205|NCT00004778|Drug|dexamethasone|
45823206|NCT00004778|Drug|thyrotropin-releasing hormone|
45823207|NCT00005594|Drug|ISIS 2503|Beginning dosage of ISIS 2503 is 6 mg/kg/day given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. This will be repeated for the first two weeks of every three-week treatment cycle.
45965454|NCT00580762|Procedure|Roux-en-y gastric bypass (RYGB)|
46080271|NCT02809898|Procedure|surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result
45965455|NCT00209040|Behavioral|Acoustic Startle Testing|See protocol description for methodological details
45965456|NCT00580918|Other|functional magnetic resonance imaging fMRI|functional magnetic resonance imaging fMRI
45965457|NCT00581035|Biological|Prevenar and Meningitec|1 dose of Prevenar at 2,3.5,6 and 12 months and 1 dose of Meningitec at 2,6 and 12 months
45965458|NCT00581035|Biological|Prevenar|1 dose at 2,3.5,6 and 12 months
45965459|NCT00581035|Biological|Meningitec|1 dose at 2,6 and 12 months
45965460|NCT04577521|Device|BioVisc Ortho Single|BioVisc Ortho Single consisted of a prefilled syringe containing 90 mg/3 mL of IA-HA and is an injectable-grade HA from a biofermentation origin. Biovisc ortho single prefilled syringes are intended for single-use only, and the entire content of the syringe was injected into the target joint.
45823208|NCT05364541|Device|MyoVista wavECG|A standard 12-Lead, multi-channel resting interpretive trans-thoracic electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information for the detection of Left Ventricular Diastolic Dysfunction.
45823209|NCT00005600|Procedure|management of therapy complications|
45823210|NCT00005612|Biological|filgrastim|
45823211|NCT00005612|Drug|carboplatin|
45823212|NCT00005612|Drug|cyclophosphamide|
45823213|NCT00005612|Drug|etoposide|
45823214|NCT00005612|Drug|paclitaxel|
45823215|NCT00005612|Drug|topotecan hydrochloride|
45823216|NCT00005612|Procedure|peripheral blood stem cell transplantation|
45823217|NCT00005618|Drug|arsenic trioxide|
45823218|NCT04534153|Drug|Fexofenadine Hydrochloride without sodium lauryl sulfate|without sodium lauryl sulfate
45823219|NCT04534153|Drug|Fexofenadine Hydrochloride with sodium lauryl sulfate|with sodium lauryl sulfate
45823220|NCT00005624|Drug|CI-994|CI-994 as outlined in treatment arm.
45823221|NCT00382915|Device|CReSSmicro handheld topography device|The CReSS micro device represents the state-of-the-art technology for measurements of ambulatory puff topography taken in the smoker's natural environment. Although all topography measurements are limited, at least to some degree, by the artificial act of smoking while using a device, or smoking through a mouthpiece, this small, lightweight and portable device is easy to use outside of the laboratory setting to capture more naturalistic smoking behavior and allows for less intrusion from the research team and research environment.
45965461|NCT00187317|Behavioral|Balance training (exercise)|Perturbation-based balance training. 30-minute sessions three times per week for six weeks.
46080272|NCT00939107|Procedure|spinal manipulation|Spinal manipulation to the lumbopelvic spine in combination with information about examination findings and advice about back care
45455545|NCT04625062|Behavioral|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, participants view a dynamic display of the speech signal in the form of a real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants were cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency.
45455546|NCT04625062|Behavioral|Motor-based treatment|Motor-based articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract were used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.
45667172|NCT05370599|Device|Home BP monitoring with cuffed device + BP watch|Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
45667173|NCT04911491|Device|IMST|Inspiratory muscle strength training (IMST) is a form of physical training that utilizes the diaphragm and accessory respiratory muscles to repeatedly inhale against resistance using a handheld device.
45667174|NCT04911491|Device|Sham Training|Repeated inhalations against a low resistance will be performed using a handheld device.
45667175|NCT01824472|Device|CPAP|Treatment for sleep apnea
45667176|NCT01824472|Behavioral|CBT|Treatment for insomnia
45667177|NCT01824472|Device|sham CPAP|Placebo for sleep apnea
45667178|NCT01824472|Behavioral|CC|Placebo (sham) for insomnia
45667179|NCT02412761|Drug|Lisinopril|Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.
45667180|NCT02412761|Drug|Amlodipine|Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose
45667181|NCT02412761|Drug|Hydrochlorothiazide|Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose
45667182|NCT01842334|Behavioral|Cognitive Behavioral Therapy|CBT administered to to both DCS and placebo group.
45823222|NCT00385502|Drug|EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)|nail lacquer applied daily for 48 weeks
45823223|NCT00005630|Biological|ras peptide cancer vaccine|
45823224|NCT00005630|Biological|sargramostim|
45823225|NCT00005636|Drug|cisplatin|
45823226|NCT00005636|Drug|pemetrexed disodium|
45823227|NCT00005642|Drug|semaxanib|This is a dose-deescalation study. Patients receive SU5416 IV over 1 hour twice weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 6-12 patients receive deescalating doses of SU5416 until the maximum target-inhibiting dose (MTID) is determined.
45823228|NCT04524949|Drug|IMCY-0098 450 μg|Small synthetic peptide for SC admin. Solvent: alum hydroxide
45823229|NCT04524949|Drug|IMCY-0098 1350 μg|Small synthetic peptide for SC admin. Solvent: alum hydroxide
45823230|NCT04524949|Drug|Placebo|Solvent: alum hydroxide
46080273|NCT00939107|Procedure|McKenzie exercises|McKenzie exercises according to the principles of Mechanical Diagnosis and Therapy
45823231|NCT00005648|Drug|Gemcitabine with R115777|R115777 200 mg, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
45823232|NCT00005648|Drug|Gemcitabine with Placebo|Placebo, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
45823233|NCT00005654|Drug|clomiphene citrate|
45823234|NCT00005654|Drug|metformin|
45823235|NCT00005666|Procedure|PET scan use in radiotherapy planning|
45823236|NCT00382447|Device|standard nebulizer|Standard small volume nebulizer for aerosolized medication delivery
45823237|NCT00382447|Device|breath actuated nebulizer|Nebulizer that dispenses medication only during the inspiratory phase
45823238|NCT04504747|Other|molecular analysis of blood and tumor|RNAseq, DNAseq, CTCs
45823239|NCT00005684|Drug|warfarin|
45823240|NCT00005684|Drug|heparin|
45823241|NCT00386282|Drug|mifepristone-misoprostol treatment|200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone.
45965462|NCT00187317|Other|Flexibility and relaxation exercise|30-minute sessions, three times per week for six weeks.
45455547|NCT01352624|Behavioral|$AFE|$teps for Achieving Financial Empowerment ($AFE) is an individualized, psycho-educational intervention that aims to teach veterans with psychiatric disabilities how to save money, create a viable budget, avoid money scams and financial exploitation, and access vocational and mental health resources.
45455548|NCT03931447|Biological|JNJ-72537634|Participants in Cohort 1 and 3 will receive Dose 1 and participants in Cohort 2 and 4 will receive Dose 2 of JNJ-72537634 as oral capsule.
45667183|NCT01842334|Drug|Nicotine Replacement Therapy|NRT administered to both DCS and placebo group.
45667184|NCT02457611|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
45823242|NCT05040685|Procedure|Axillary mapping reverse|At the time of performing the ALND associate the ARM, injecting between 2-5mL of indocyanine green subcutaneously in the ipsilateral upper extremity at the medial inter-muscular and massaged for 5 min. First, identify the ARM nodes by indocyanine green, then perform conventional axillary lymphadenectomy trying to preserve the ARM nodes. And, in a second time, extract ARM nodes for their individualized anatomopathological study.
45823243|NCT05324683|Other|No intervention planned|No intervention planned; study is observational
45823244|NCT05323903|Other|Telesimulation|Telesimulation is an application that is a teaching process by which telecommunication and healthcare simulation resources are used to provide education, training and assessment to learners at an off-site location. In this study, simulation was recorded and this was shared with the students through means of telecommunication.
45823245|NCT05323903|Other|Kahoot Game|Kahoot is a game-based learning platform, used as educational technology in schools and other educational institutions.
45823246|NCT05313451|Other|Soluble fiber|15g/day during 2 months
45823247|NCT05313451|Other|Placebo|Maltodextrin 15g/day during 2 months
45823248|NCT04456699|Drug|Olaparib|300 mg BID, oral until progressive disease or end of study
45823249|NCT04456699|Drug|5-FU|2400 mg/m^2 over 46 to 48 hours Q2W IV infusion until disease progression or end of study; bolus 5FU (400mg/m2) can be added prior to infusional 5FU, per local standards and at the investigator's discretion
45823250|NCT04456699|Drug|Bevacizumab|5 mg/kg or 7.5 mg/kg Q2W or Q3W IV infusion until progressive disease or end of study
45823251|NCT04456699|Drug|Capecitabine|1000mg/m^2 oral capsule BID for 14 days, then 7 days off, Q3W) until progressive disease or end of study
45823252|NCT04456699|Drug|Leucovorin/ levoleucovorin|400 mg/m^2 (leucovorin) or 200 mg/m^2 (levoleucovorin) may be added to Bevacizumab + 5FU per investigator's discretion Q2W IV infusion until progressive disease or end of study
45823253|NCT00385658|Drug|Fluvastatin extended release, fenofibrate|
45823254|NCT00385658|Drug|Fixed combination simvastatin/ezetimibe|
45455549|NCT03931447|Biological|Placebo|Participants will receive matching placebo as oral capsule in all cohorts.
45455550|NCT01352702|Drug|Dabigatran|Patients assigned to this group will receive Dabigatran
45455551|NCT01352702|Drug|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
45455552|NCT03525730|Drug|Valproic Acid|Valproic acid (enteric) 30mg/kg, divided over 2 doses per day, orally on day 1-14.
45455553|NCT03525730|Drug|Pyrimethamine|Pyrimethamine 200mg once daily (QD) orally on day 1 and 100mg on day 2-14.
45455554|NCT01223443|Device|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
45667185|NCT04593628|Behavioral|Connect for Caregivers|The STAR Center developed Connect for Caregivers to help improve connectedness among older caregivers of individuals with Alzheimer's Disease and Related Dementias (ADRD). Connect for Caregivers includes three components: (1) psychoeducational materials on the importance of connectedness for health and well-being; (2) a card sort-based 'discussion prioritization tool' that systematizes and routinizes the process of identifying and prioritizing barriers to connectedness; (3) personalized resources to address the identified barriers/targets. We will tailor Connect for Caregivers for Hispanic/Latino and Spanish-speaking caregivers guided by the Selective and Directed Treatment Adaptation Framework. The intervention is given once during the study.
45667186|NCT04593550|Procedure|Biospecimen Collection|Undergo collection of blood samples
45667187|NCT04593550|Behavioral|BrainCheck Cognitive Assessment|Undergo cognitive function assessment BrainCheck
45823255|NCT04452955|Biological|PRL3-zumab|Starting dose of 6 mg/kg will be administered as IV infusion over 60 minutes every 2 weeks (±2 days)
45823256|NCT05305573|Biological|COVID-19 Vaccine HIPRA 40 ug/dose|Subjects will receive one injection of COVID-19 Vaccine HIPRA (PHH-1V)
45823257|NCT05305573|Biological|Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection|Subjects will receive one injection of Comirnaty Vaccine
45823258|NCT00005762|Drug|Indinavir sulfate|
45823259|NCT00005762|Drug|Ritonavir|
45823260|NCT00005762|Drug|Amprenavir|
45823261|NCT00005762|Drug|Nelfinavir mesylate|
45823262|NCT00005762|Drug|Efavirenz|
45823263|NCT00005762|Drug|Saquinavir|
45823264|NCT04447807|Behavioral|Metacognitive Training|MCT is a structured, interactive approach that addresses cognitive biases, social cognition, and self-esteem. This study will conducted this intervention using group format, on a weekly basis, with duration of 9 weeks total.
45823265|NCT04447807|Other|Treatment as Usual|Patients will continue to receive medical attention in the Bipolar Disorder Program -PROMAN- part of the University of São Paulo Medical School.
45823266|NCT00005768|Drug|Estrogen|
45823267|NCT00005774|Drug|Early surfactant|Early surfactant followed by extubation within 30 minutes and application of continuous positive airway pressure (CPAP)
45823268|NCT00005774|Drug|Standard practice|Surfactant according to current center practice, only after initiation of mechanical ventilation.
45823269|NCT00005786|Drug|arsenic trioxide|Given IV
45823270|NCT00005786|Other|laboratory biomarker analysis|Correlative studies
45823271|NCT00005792|Drug|etoposide phosphate|Etoposide phosphate 1363 mg/m^2/day IV over 4 hours (total dose 2726 mg/m^2, or 2400 mg/m^2 etoposide equivalents), beginning 24 hours after the completion of the last infusion of topotecan Days -4, -3
45823272|NCT00005792|Drug|melphalan|Melphalan 50 mg/m^2/day IV over 30 minutes (total dose 150 mg/m^2), followed immediately by topotecan. Days -7, -6, -5
45965463|NCT04577560|Genetic|First polar body biopsy in MII oocytes|Since PBs are by-products of the meiotic division of the oocyte and are not required for fertilization and subsequent embryo development, they can be removed to assess exclusively maternal chromosomal information without harming the embryo integrity. As previously described, PB biopsy does not impact the morphokinetic parameters of the embryo development and can be safely applied without the risk of impairing the reproductive potential of the embryo.
45667188|NCT04593550|Procedure|Cognitive Assessment|Undergo 3D-Confusion assessment
45667189|NCT04593550|Procedure|Electroencephalography|Undergo EEG
45965464|NCT04577560|Genetic|PGT-A blastocyst|preimplantation genetic screening for aneuploidies
45965465|NCT00581074|Behavioral|diet (grapefruit or grapefruit juice)|weight loss diet
45667190|NCT04918121|Drug|Yutiq 0.18 MG Drug Implant|a sustained-release steroid insert (Yutiq)
45823273|NCT00005792|Drug|topotecan|Topotecan 3.3 mg/m^2/day (starting total dose = 10 mg/m^2 for level 2) IV over 30 minutes. No topotecan will be administered on the first dose level Days -7, -6, -5
46080274|NCT00933361|Drug|ghrelin|As starting dose the investigators choose a dose level which was shown in our last study to be safe in human beings, i.e. 8μg/kg intravenously. With an assumed bioavailability of 25% of subcutaneously administered ghrelin the corresponding dose for dose level 1 is therefore 32 μg/kg. In the first 4 dose levels for each subsequent dose level the dose is increased by 50% compared to the previous one, from the 5th dose level onwards the increase is 25%: Dose level 1 = 32 μg/kg Dose level 2 = 48 μg/kg Dose level 3 = 72 μg/kg Dose level 4 = 108 μg/kg Dose level 5 = 135 μg/kg Dose level 6 = 169 μg/kg Dose level 7 = 211 μg/kg The investigators define the maximum tolerable dose as 20mg ghrelin (equivalent to 5ml) for reasons of the high drug volume to be administered subcutaneously.
45667191|NCT04931381|Other|Chemotherapy guided by organoid drug sensitivity test|Chemotherapy guided by organoid will be given to advanced pancreatic cancer patients.
45667192|NCT02457065|Behavioral|"Melanoma Survivor plaque"|The investigators give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors.
45667193|NCT02083653|Drug|Sym004 (12 mg/kg)|Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
45667194|NCT02083653|Drug|Sym004 (9/6 mg/kg)|Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
45667195|NCT02083653|Other|Best Supportive Care (BSC)|BSC is the best palliative care as per Investigator's discretion, excluding antineoplastic agents. BSC may include, but is not limited to, antibiotics, analgesics, antiemetics, blood transfusions, and nutritional support.
45667196|NCT02083653|Drug|Fluorouracil (5-FU)|5-FU will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
45667197|NCT02083653|Drug|Capecitabine|Capecitabine will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
45667198|NCT02436239|Drug|Vilazodone|Vilazodone tablets, once daily, oral administration
45667199|NCT02026011|Drug|Naltrexone|Naltrexone is an opioid receptor antagonist with highest affinity for mu opioid receptors
45667200|NCT02026011|Drug|Placebo|Sugar pill, matched to the active study medication in capsule size and color
45823274|NCT00005792|Procedure|Autologous Stem Cell Rescue|reinfusion of stem cells, Day 0
45823275|NCT00005798|Drug|Carboplatin|Carboplatin will be given at a dose of 267 mg/m2 in D5 W IV over one hour daily on days -6, -5, and -4. (Total dose 800 mg/m2)
45823276|NCT00005798|Drug|Cyclophosphamide|Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 6000 mg/m2)
45823277|NCT00005798|Drug|Thiotepa|Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 500 mg/m2 )
45965466|NCT00581191|Drug|SLV-351|SLV-351 capsules taken once
45965467|NCT00187356|Procedure|Radial Artery and Saphenous Vein Grafts Randomized to either right coronary or left circumflex coronary artery territories|Each patient will receive both study grafts (Radial artery and Study Saphenous vein graft). The within-patient randomization scheme will dictate whether the radial goes to the right or circumflex territory. The saphenous vein graft will go to the opposing territory.
45965468|NCT00581269|Behavioral|low-impact aerobic exercise|subjects will undergo supervised physical activity for a maximum of 30-60 minutes, every other day, 3 days per week for 3 months; to offer variety in the exercise prescription, subjects will alternately use a treadmill, an elliptical trainer, a Nu-Step cross-trainer and a recumbent stationary bicycle
45965469|NCT00581269|Dietary Supplement|low-calorie (low-fat) diet|subjects will undergo a 20% reduction in total daily calories from their usual daily energy consumption every day for 3 months
45965470|NCT00581425|Biological|Imiquimod and Interferon alpha|Imiquimod first two weeks and last two weeks. Interferon middle five weeks.
45965471|NCT04577248|Device|edge-to-edge valve repair|edge-to-edge valve repair
45965472|NCT04577092|Other|Warm-up exercise|In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips.
46080275|NCT02729766|Other|Induced hypotonic hyponatremia - SIAD model|
46080276|NCT02729766|Drug|Empagliflozin 25mg Tbl|
46080277|NCT02729766|Drug|Placebo P-Tablet|
45823278|NCT00005810|Biological|filgrastim|
45823279|NCT00005810|Drug|carboplatin|
45823280|NCT00005810|Drug|docetaxel|
45965473|NCT04577092|Other|Motor-Cognitive exercise|After warm up period; participants had been asked to count back from the two-digit number while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.
45965474|NCT04577092|Other|Motor-Motor exercise|participants had been asked to hold with both hand half-filled glasses with 90 degree of flexion elbow and near the trunk while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.
45965475|NCT04577092|Other|Cool-down exercise|In 10-minute cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed.
45965476|NCT00187395|Procedure|Randomized to either a 'less tight' group or a 'tight' group|
45965477|NCT04577170|Diagnostic Test|Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography|Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography will be performed in consecutive FD patients. All TCD and TCCD studies will be performed by stroke neurologists experienced in vascular sonography.
45667201|NCT02436005|Device|Phenacite|Subjects will be randomized to wear the Phenacite contact lenses binocularly.
45667202|NCT02436005|Device|comfilcon A|Subjects will be randomized to wear the comfilcon A contact lenses binocularly.
45965478|NCT04577053|Device|Scientific Consciousness Interface Operations (SCIO) Class II FDA approved medical device|Manufactured by QX World Ltd. in Budapest, Hungary
45667203|NCT02456909|Device|Patient-Controlled Analgesia pump with Cues|The end of the lockout period will be cued via the PCA pump
45965479|NCT00581464|Behavioral|Standard Behavioral Therapy|Standard therapy to help participants with smoking cessation.
45667204|NCT02456909|Device|Patient-Controlled Analgesia pump without Cues|The PCA pump will be programmed such that no cues will be provided to the end of the lockout period.
45667205|NCT02456909|Drug|Morphine|Morphine will be administered for post-operative pain in both the Cues and Non-Cues groups
45667206|NCT04199273|Procedure|Magnetic stimulation|Cervical bilateral phrenic nerve stimulation with the MagStim 200 tool.
45823281|NCT00005810|Drug|estramustine phosphate sodium|
45823282|NCT00005816|Biological|therapeutic autologous dendritic cells|
45823283|NCT00005816|Procedure|conventional surgery|
45823284|NCT05303623|Other|Conventional Physiotherapy|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day.
45823285|NCT05303623|Other|Conventional Physiotherapy+ inspiratory muscle training|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. In this group addition to conventional physiotherapy inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
45823286|NCT05303623|Other|inspiratory muscle training|In this group inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
45823287|NCT00385892|Device|Abdominal binder|
45823288|NCT00385970|Drug|Tegafur-uracil (UFT)|From within 9 weeks after surgery, 300 mg/m2, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
45965480|NCT00581464|Behavioral|Mindfulness Based Addiction Therapy|A novel mind body therapy that extends basic behavioral therapy principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
45965481|NCT04577131|Behavioral|Weekly check-in|Weekly check-in phone calls from a pharmacist to review blood pressures and the number of times tested in that week
45965482|NCT00209079|Drug|Gleevec, Taxotere|Gleevec taken 4 times daily, 100 mg per tablet. Taxotere intravenously once a week for two weeks.
45965483|NCT04576975|Drug|Ketamine|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
45965484|NCT04576975|Drug|Dexmedetomidine|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
46080278|NCT02812940|Drug|Everolimus|GvHD prophylaxis
45667207|NCT04199273|Procedure|Electric stimulation|Cervical bilateral phrenic nerve stimulation after ultrasonography nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager)
45667208|NCT02025621|Drug|Levosimendan|
45667209|NCT02025621|Drug|Placebo|matching placebo
45823289|NCT00385970|Drug|Calcium folinate (LV)|From within 9 weeks after surgery, 75 mg, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
45823290|NCT00385970|Drug|Krestin (PSK)|From within 9 weeks after surgery to 12 months after surgery, 3 g/day, PO every day
45823291|NCT05006677|Drug|non-vitamin K antagonist oral anticoagulants (NOACs)|Collecting information of patients with VT who received NOACs
45823292|NCT05006677|Drug|vitamin K antagonists (VKAs)|Collecting information of patients with VT who received VKAs
45965485|NCT04576975|Drug|Normal Saline 0.9%|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
45965486|NCT03453073|Behavioral|chocolate consumption level|level of consumption of 1 oz. of chocolate, as assessed at baseline
45965487|NCT03453073|Other|physician diagnosis of first occurrence of serious chronic disease|
45965488|NCT00187434|Device|Infant Flow System|
45965489|NCT00187434|Device|Bubble CPAP|
45965490|NCT00581620|Biological|pneumococcus conjugate vaccine|Infants from 1 to 6 months: 3 doses at 2; 4; 6 m and booster from 12 to 15 months.
45965491|NCT00209118|Drug|paroxetine|
45965492|NCT00581815|Device|Proton-decoupled 31P MRS at 1.5T|The study will use a dual 1H-31P surface coil pair obtained from IGG Medical Advances, Milwaukee, WI. The coil pair consists of a fixed, 12 cm square 31P resonator co-mounted with a flexible two-loop proton coil. The P.I. and colleagues have used this device for approximately 10 years with no apparent ill effects
45965493|NCT00581815|Device|1H Spectroscopy at 1.5T and 3T|The study will use surface coils manufactured by commercial vendors. The pulse sequence programs to be used will be monitored automatically by the scanner to insure that SAR limits are not exceeded.
45965494|NCT00582088|Biological|VEE C-84|Subjects will receive a 0.5 mL subcutaneous injection in the upper outer aspect of arm; maximum of four boosters in 1 year if titer <1:20.
45965495|NCT00582244|Behavioral|CBT and relaxation|Group A: CBT and relaxation.
45823293|NCT05006677|Drug|antiplatelet agents|Collecting information of patients with VT who received antiplatelet agents
45823294|NCT05006677|Other|non-antithrombotic therapy|Collecting information of patients with VT without any antithrombotic therapy
45823295|NCT00386048|Behavioral|Brief Cognitive-Behavioral Pain Management Training|Participants complete a manualized, single session of training which includes: (A) education about the causes of sickle cell pain, (B) education about how the nervous system processes pain signals, and (C) explanations of how one can use cognitive and behavioral treatment (CBT) strategies to decrease the extent of pain experienced (all based on how the nervous system processes pain). Four specific CBT skills are taught and practiced by the participant (Progressive muscle relaxation, Controlled Deep Breathing, Imagery, and Distraction). The protocol explicitly emphasizes the use of CBT as a complimentary pain management tool to use in addition to the standard of care methods.
45823296|NCT00386126|Drug|Iron Sucrose IV 200mg, once a week, for 5 weeks|
45823297|NCT00386126|Drug|Ferrous sulfate 200mg PO TID, for 8 weeks|
45965496|NCT00582244|Behavioral|Physical activity|Group B: Physical exercise program.
45965497|NCT00582244|Behavioral|CBT and physical activity|Group AB: Combined CBT and exercise program. Women assigned to Group AB will undergo the CBT and exercise elements of the program concurrently. To as great an extent as possible, the on-site CBT and in-clinic exercise training sessions will be scheduled on the same day.
45965498|NCT00582244|Other|Control group|Waiting list control group
45965499|NCT00181025|Drug|Tasonermine (TNFa)|
45965500|NCT00181025|Drug|Melphalan|
45965501|NCT00582283|Drug|I124-NM404|I-124-NM404
45965502|NCT00209313|Drug|Acyclovir|Acyclovir 800 mg twice daily or placebo
45965503|NCT00582439|Device|Reamer-Irrigator-Aspirator (RIA)|Patients must already be scheduled for bone grafting of a fracture or nonunion with harvest of autologous graft material from their femur using the RIA system. The reaming procedure will be conducted using the trochanteric entry portal through the tip of the greater trochanter.
45965504|NCT04576624|Behavioral|Lifestyle Intervention|A combined approach of a lifestyle structuring intervention to improve the general health and quality of life of persons with cognitive impairments. The investigators propose to combine a multi-modal cognitive intervention and lifestyle redesign approach to improve the cognitive health of older persons with cognitive impairments.
45965505|NCT04576624|Behavioral|social activity|24 social gathering events
45965506|NCT00582634|Drug|docetaxel and cisplatin|Docetaxel (75mg/m2) followed by cisplatin (75mg/m2) on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for4 cycles.
45965507|NCT04723407|Other|questionnaires|Questionnaire completion
45965508|NCT00181064|Behavioral|Modified Atkins diet|15 grams of carbohydrates per day - high fat diet
45965509|NCT00582673|Drug|AFQ056|
45965510|NCT00582673|Drug|Placebo|
45965511|NCT04576780|Other|Integrated Large Complex Polyp Referral Pathway|"The referring doctor will use a standardized template to send the referral along with its associated video or high-resolution photographs.~Referrals will be reviewed in a consensus fashion by at least 2 expert physicians at St. Michael's Hospital (SMH) on a bi-weekly basis. Polyps will be scored using a standardized evaluation form that documents relevant polyp features to assist the determination of whether a lesion is amenable to curative endoscopic resection.~Cases will be triaged as being: (1) a standard polyp suitable for local removal in the community; (2) a complex polyp requiring expert removal at SMH with priority assigned based on the suspected risk of invasive disease; (3) a polyp that is not amenable to endoscopic resection or that is suspicious for cancer will that be recommended for surgical resection."
45965512|NCT04576858|Diagnostic Test|Circulating tumor DNA|Measurement of circulating tumor DNA from plasma over a period of 2 years.
45965513|NCT00209352|Drug|Acyclovir|
45965514|NCT00181142|Drug|Zenapax|
45965515|NCT00582829|Other|Generic Print Intervention|"Generic Print Intervention: The generic print intervention will consist of the pamphlet, Colorectal Cancer Screening Saves Lives published by the Center for Disease Control that will be mailed to the participant."
45965516|NCT00582829|Other|Tailored Print Intervention|Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.
45965517|NCT00582829|Other|Tailored print plus tailored phone intervention|Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
45965518|NCT00582868|Device|Licox Brain Oxygen Monitor|use of data from brain oxygen monitor for analysis
45823298|NCT04421443|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-group format. For ethical reasons, if any of the patients feel uncomfortable during the study with the online-group format, will may leave the group and receive individual attention. The study plans follow-ups every three months until two years after post-treatment, all of them will be conducted online.
45823299|NCT05296603|Drug|IBI-322 Plus Lenvatinib|"IBI322 is based on the 3+3 model, with a dose ascent starting from 10mg"
45455555|NCT01352780|Behavioral|Motivational interviewing|"Motivational interviewing technique will be used to improve patient adherence to multiple health behaviour changes and support patients with psoriasis to self- manage effectively. The intervention will discuss on four main topics: diet, physical activity, stress management and psoriasis treatment.~Motivational interviewing is a patient centered directive counselling technique that focuses on assisting patients to identify their problems and involves exploring ambivalence in an empathic manner. A key goal in motivational interviewing is to increase the importance of change from the client's perspective. This is accomplished by using specific types of open ended questions, selective reflections and reflective listening."
45667210|NCT04729023|Procedure|Pars plana vitrectomy combined with cataract surgery.|In the combined surgery group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will receive pars plana vitrectomy combined with phacoemulsification and intraocular lens (IOL) implantation at the same time.
45667211|NCT04729023|Procedure|Pars plana vitrectomy with subsequent cataract surgery.|In the control group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will first receive pars plana vitrectomy and a subsequent phacoemulsification with IOL implantation will be performed at least 6 month after the PPV.
45667212|NCT05128149|Other|no intervention|no intervention
45667213|NCT02020941|Drug|carfilzomib|Given IV
45667214|NCT02020941|Drug|dexamethasone|Given IV or PO
45667215|NCT02020941|Other|laboratory biomarker analysis|Correlative studies
45823300|NCT04405297|Device|Adipose-derived regenerative cells|Adipose-derived regenerative cells will be obtained from a small-volume lipoaspirate procedure. The lipoaspirate will then be enzymatically digested to produce a stromal vascular fraction (SVF) that will be injected into the targeted joint.
45823301|NCT04399993|Other|Intervention Protocol in Diaphragm|"The protocol consists of three techniques. The two first techniques will be applied for 10 respiratory cycles.~Muscle Stretching Technique:~the researcher will perform a cephalic traction on the inferior costal border with the ulnar border during the inspiratory phase.~Phrenic-center inhibition technique:~the researcher, with a hand on the sternum to caudal and other hand on the umbilical region to cranial, will approach his hands on the horizontal plane, when the volunteer exales.~Functional diaphragm technique:~the researcher will perform a vertical pressure on the diaphragm for 5 minutes and will search for the facilitated parameters and maintain them until the release of all the periarticular elements."
45823302|NCT04399993|Other|Sham technique|In the sham group a manual contact without any therapeutic intention will be performed, in a distant region of the diaphragm (for example on the trapezius muscle). This contact will be maintained during the same amount of time as for the treatment group.
45823303|NCT05293093|Other|Wheelchair Skills Training Program|a standardized training method for users of manual and powered wheelchairs and it combines evidence on motor-skills learning with evidence on how to perform specific wheelchair skills. A recent systematic review and meta-analysis provided evidence that WSTP is a safe and effective intervention that has a clinically meaningful effect on powered wheelchair skill capacity, in particular for new wheelchair users. The WSTP has shown to be effective in several wheelchair-dependent populations and promising to be used in people with complex movement disorders. Yet, adaptation to the specific needs and capabilities of individuals with complex movement disorders is necessary as it has not been assessed in this population. During the 4-week training phase, the participants will receive 3 training sessions per week of 45 minutes, including exercises as described in the Wheelchair Skill Training Program Version 5.1.2
45823304|NCT04568330|Other|best support care|Best support care
45823305|NCT04568330|Other|moisture cream|BSC plus moisture cream
45823306|NCT04568330|Other|10% urea-based cream|BSC plus 10% urea-based cream.
45823307|NCT04569890|Drug|Certolizumab Pegol 200 MG/ML [Cimzia]|CZP 200mg twice a week subcutaneous.
45823308|NCT04569890|Drug|Hydroxychloroquine|400mg HCQ orally daily
45823309|NCT04569890|Drug|Prednisone|10mg GC orally daily
45667216|NCT02024529|Biological|4 mL injection of Ampion|4 mL injection of Ampion
45667217|NCT02024529|Drug|4 mL Injection of Placebo|4 mL Injection of Placebo
45667218|NCT02020863|Device|Closed Loop|Fluid management in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of fluid the patient receives using feedback from standard operating room monitors.
45667219|NCT01824394|Device|nMARQ Navigation Catheters|
45965519|NCT00582868|Other|CSF|analysis of CSF for cleaved tau protein
45965520|NCT00582868|Other|Whole blood|Analysis of whole blood for cleaved-tau protein
45965521|NCT00582985|Drug|TRC105 chimeric anti-CD105 antibody|TRC105 is a human/murine chimeric IgG1 antibody administered i.v. every two weeks (on days 1 and 15) or weekly (on days 1, 8, 15 and 22) of each 28 day cycle; until progression or unacceptable toxicity develops.
45667220|NCT01824394|Device|NaviStar ThermoCool Catheters|
45823310|NCT04569500|Other|PETAL program|patients and their close relations will benefit from the therapeutic education program PETAL in order to accompany them throughout their experience of laryngectomy and to reduce its impact on social and professional aspects of life.
45965522|NCT00187551|Other|Interruption of enfuvirtide|treatment interruption
45965523|NCT00187551|Other|enfuvirtide interrupton|enfuvitide will be interrupted in patients harboring resistant virus
45823311|NCT04485637|Other|Communication with basic table|Communication showing only the normal range of blood pressure readings, which is often used but may make it hard to interpret numbers outside of the normal range
45965524|NCT00181181|Drug|atorvastatin|Atorvastatin 80 mg daily for 3 months
46080279|NCT00929617|Behavioral|Experimental 1: exercise with 2 counseling types|Patients will participate in 12 individual exercise sessions with an exercise specialist which will include stretching exercises and aerobic treadmill walking; plus attend 6 discussion group sessions with a trained facilitator; plus 3 face-to-face, individual counseling sessions with an exercise specialist
45455556|NCT03525652|Biological|Therapeutic vaccine|The therapeutic vaccine will be custom prepared ex vivo using the peripheral mononuclear cells from the patient and the vaccine which presented as maturated dendritic cells will be infused back to the patients in 3 times.
45667221|NCT01823536|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|Subjects received at day 1 a single dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
45667222|NCT01841554|Device|Cardioband|
45823312|NCT04485637|Other|Communication with enhanced table|Communication with enhanced table, with reference information showing how combinations of diastolic and systolic blood pressure reflect normal, elevated and hypertension ranges (adapted from the American Heart Association)
45823313|NCT04485637|Other|Communication with enhanced graph|Communication with enhanced graph, showing reference information about how to interpret blood pressure readings (adapted from Blood Pressure UK) with diastolic blood pressure on the x-axis and systolic blood pressure on the y-axis
45823314|NCT04569812|Procedure|Cardiopulmonary Resuscitation|flowchart-assisted standard resuscitation or chest compressions-only resuscitation for 5min
45823315|NCT00423163|Drug|micafungin|
45823316|NCT00423163|Drug|voriconazole|
45823317|NCT04569656|Drug|hydrolyzed guar gum|treatment with Stick pack 30 ml containing PHGG 5 gr e Hyaluronic Acid 200 mg for 6 weeks
45823318|NCT04569578|Other|Policy|"The intervention will include:~i. Formalized physical activity policies implemented in preschools including the following:~A minimum of 3 hours of total daily outdoor time scheduled both in the morning and in the afternoon~At least 10 minutes teacher-led active play per day~A minimum of 1 weekly outdoor excursion~Meet the children outdoors when they arrive at preschool and/or picked up by their parents~Only use screen tablets and computers for educational teaching purposes~Communicating to, and encouraging, the parents to actively transport their children to and from preschools~ii. A study website with an activity bank also serving as a platform for inter-professional education that preschool teachers can share and communicate about engaging activities and experience~iii. Weekly follow-up and feedback by web-based questionnaires"
45965525|NCT00181181|Other|placebo|placebo daily
45965526|NCT04576468|Procedure|Open flap debridement|Surgical intevention
45965527|NCT04576468|Procedure|perforated membrane|surgical intervention
45965528|NCT04576468|Procedure|leucocyte - platelet rich fibrin|surgical intervention
45965529|NCT04576351|Other|Observation|The study is a multi-center Norwegian prospective observational clinical study of the occurence of neurological, neuropsychological and psychiatric manifestations and sequelae in patients with COVID-19 at 6- and 12-months follow-up.
45965530|NCT00187590|Behavioral|Case manager phone call after an ER visit|
45965531|NCT00181220|Drug|valproic acid|
45965532|NCT00583063|Drug|sunitinib|25 mg daily (oral dosing)
45823319|NCT04379635|Drug|Tislelizumab|administered via Intravenous (IV) injection
45823320|NCT04379635|Drug|Cisplatin injection|administered via IV infusion
45965533|NCT00583063|Drug|rapamycin|4 mg daily (oral dosing)
45965534|NCT04576312|Drug|UNI911 inhalation 1% and intranasal spray 1%|Niclosamide is a broad spectrum, host tageting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide 1% solution is administered as inhalation by nebulization and intranasal by a nasal spray.
45965535|NCT04576312|Drug|Placebo|The placebo formulation contains the vehicle. The solution is administered in the same way as the active drug. Placebo was only administered for cohorts 1-5.
45965536|NCT04576234|Dietary Supplement|entral feeding|Intermittent enteral feeding group recieved intermittent feeding as the feed was given over a 24 hour period with intervals of rest (e.g. three hours feeding two hours rest)
45965537|NCT00209391|Drug|Gadodiamide Injection|
46080280|NCT00929617|Other|Usual Care - written materials|Patients will receive written materials about exercise for cancer survivors
46080281|NCT02729610|Device|double-lumen endotracheal tube (DLT group)|In this arm, after anesthesia induction, a double lumen endotracheal tube will be intubated for one-lung ventilation
46080282|NCT02729610|Device|endobronchial blocker (BB group)|In this arm, after anesthesia induction, an endobronchial blocker will be intubated for one-lung ventilation
46080283|NCT00604097|Behavioral|Attachment-Based Family Therapy|12-16 week family-based therapy
46080284|NCT00604097|Behavioral|Enhanced Usual Care|Rapid referral to community outpatient care with weekly monitoring of symptoms by study team
46080285|NCT02810054|Procedure|Minimally Invasive Surgical Techniques (MIST)|Using minimally invasive surgical techniques.
46080286|NCT02810054|Procedure|Enamel Matrix Derivative (EMD)|Use of enamel matrix derivative for the treatment of intrabony periodontal defects.
46080287|NCT00933439|Drug|Duloxetine|Approximately 30 participants with major depressive disorder and concentration and/or cognition difficulties, recruited from the community and physician referrals, will be treated with duloxetine for 12 weeks. Their cognitive performance will be assessed pre- and post-treatment with a cognitive testing battery.
46080288|NCT03182946|Diagnostic Test|Platelet mapping Thromboelastography|These diagnostic tests will be acquired in patients with brain injury, to determine prediction of clinical, functional and psychological outcome.
45823321|NCT04379635|Drug|Paclitaxel injection|administered via IV infusion
46080289|NCT00608075|Drug|lithium|600 mg - 1800 mg per day
46080290|NCT00608075|Drug|Lithium|600 - 1800 mg
46080291|NCT02809742|Drug|Ropivacaine|Epidural : automatic intermittent boluses associated with patient controlled bolus using ropivacaine
46080292|NCT00929851|Drug|CHF1535|Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose
46080293|NCT00929851|Drug|Formoterol fumarate|Formoterol fumarate 12 µg per metered dose
46080294|NCT02729376|Drug|galeterone|
46080295|NCT04236362|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
45823322|NCT04379635|Drug|Pemetrexed Disodium|administered via IV infusion
45455557|NCT03525652|Biological|PD-1 Knockout T Cells|PD-1 knockout T cells will be custom prepared ex vivo using the white blood cells from the patient and the maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
45823323|NCT04379635|Drug|Placebos|Placebo to match tislelizumab IV infusion
45667223|NCT01823224|Drug|"2 capsules Oral Tylenol 2000 mg and IV salt water"|"The participants randomized to receive the '2 capsules Oral Acetaminophen 500 mg and IV salt water repeated 4 hours after that dose to equal 2000mg. A pre-op pain score was obtained and pain scores every 15 min x 1 hour then per recovery routine and they did a 24 hour home diary to record pain scores for 24 hours post surgery. Their opioid morphine equivalent was recorded intraoperatively, recovery and at home. This was compared to the other group receiving IV acetaminophen.and the pain scores and morphine equivalents were collected the same as in the comparative group. Each group received a placebo version oral or iv accordingly."
45823324|NCT04379635|Drug|Carboplatin|administered via IV infusion
46080296|NCT04236362|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
46080297|NCT05628792|Diagnostic Test|CT|Ultra High Resolution CT scan
46080298|NCT00933517|Drug|vectibix|9mg/kg at D1 of each 21-days cycle
46080299|NCT00933517|Drug|fluorouracile|500 mg/m2 at D1 of each 21-days cycle
46080300|NCT00933517|Drug|Epirubicine|100 mg/m2 at D1 of each 21-days cycle
46080301|NCT00933517|Drug|cyclophosphamide|500 mg/m2 at D1 of each 21 dyas cycle
46080302|NCT00933517|Drug|docetaxel|100 mg/m2 at D1 of each 21 days cycle
46080303|NCT04249505|Device|"2WIN Photoscreener"|"non-cycloplegia refraction by Adaptica 2WIN"
46080304|NCT04249505|Device|"Plusoptix A12"|"non-cycloplegic refraction by Plusoptix A12 photoscreener"
46080305|NCT04249505|Device|"Retinomax"|"non-cycloplegic refraction by Retinomax K+ auto refractor"
45823325|NCT04569188|Biological|Convalescent plasma|COVID-19 elderly patients treated with convalescent plasma
45823326|NCT04568876|Dietary Supplement|Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension|Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes
45823327|NCT04568876|Combination Product|Standard Therapy|Standard therapy established for individual patients
45823328|NCT04375657|Combination Product|TRIIM Treatment|Personalized combination of somatropin, metformin, and DHEA
45823329|NCT04375657|Combination Product|Active Control|Metformin and DHEA
45823330|NCT02210468|Device|APIC-CF, 4 cc|
45823331|NCT02210468|Device|APIC-CF, 2 cc|
45823332|NCT02210468|Other|Placebo Comparator: Saline|Placebo Comparator: Saline
45965538|NCT00181298|Drug|Memantine|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4.
45965539|NCT00181298|Drug|Placebo|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4
45823333|NCT04265287|Other|Data collection|Demographic, clinical, microbiological, critical care support and management data will be collected.
45667224|NCT01823224|Drug|"IV tylenol 1000mg and 2 oral capsule sugar pills"|"IV acetaminophen 1000mg and 2 oral capsule sugar pills were given to participants that were randomized to receive the IV acetaminophen. The same collection of pain scores and morphine equivalents was completed the same as the other group."
45823334|NCT02210546|Other|Magnetic Resonance Imaging (MRI)|
46080306|NCT02806700|Behavioral|Twitter Diabetes Intervention|This group will be asked to use twitter for heart health ( e.g. tweeting, following, receiving tweets)
45667225|NCT01840228|Drug|Micronized progesterone suppository|
45667226|NCT01839916|Biological|therapeutic allogeneic lymphocytes|Given IV
45965540|NCT04576273|Diagnostic Test|Pathology examination|Gross and microscopic evaluation
45965541|NCT00583180|Drug|Capsaicin|instillation of sterile water or 1000 micrograms of capsaicin into the wound at the end of open groin hernia surgery in previous study.no new intervention will be performed in the current study.
45667227|NCT01839916|Other|laboratory biomarker analysis|Correlative studies
45965542|NCT00583258|Drug|Alfuzosin (Xatral)|10 mg PO once a day
45667228|NCT01823146|Drug|Oxytocin spray|single dose of 24 IU oxytocin, self-administered intranasally (IN)
45667229|NCT01823146|Drug|Placebo spray|single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
45667230|NCT02083185|Drug|Relugolix|Relugolix tablets
45823335|NCT02210546|Other|Mammography (Mx) + ultrasonography (US)|
45823336|NCT02210624|Biological|HYNR-CS inj.|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
45965543|NCT00583258|Drug|Placebo Alfuzosin|10 mg PO once a day
45965544|NCT04576039|Diagnostic Test|saline infusion sonography|Instillation of 10cc of saline infusion in the uterine cavity while performing an ultrasonic evaluation of the uterine cavity and endometrium.
45667231|NCT02083185|Drug|Leuprorelin|Leuprorelin subcutaneous injection
45667232|NCT04417023|Other|B3 for NMD: Bench to Bedside and Back|Transformative discoveries leading to improved care in Neuromuscular Disease
45667233|NCT04179669|Drug|IBI306|Administered by subcutaneous injection
45667234|NCT04179669|Drug|placebo|Administered by subcutaneous injection
45667235|NCT02019927|Device|Transcorneal Electrical Stimulation|The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.
45667236|NCT02019927|Device|Sham|Sham
45667237|NCT04185441|Drug|Tanzânia association|Tanzânia association capsule
45667238|NCT04185441|Drug|Omnic Ocas|Tamsulosin 0,4 mg
45667239|NCT04185441|Other|Omnic Ocas placebo|Tamsulosin placebo
45667240|NCT04185441|Other|Tanzânia association placebo|EMS association placebo
45823337|NCT04569110|Other|Not applicable. Observational study. Retrospective analysis of samples.|Not applicable. Observational study. Retrospective analysis of samples.
45965545|NCT00187629|Behavioral|dietary phosphorus|varying amts dietary phosphorus
45965546|NCT00583336|Device|ShuntCheck|Thermal dilution test for CSF flow
45965547|NCT00181532|Drug|Celecoxib|
45965548|NCT04576390|Drug|Ondansetron 4 mg|Antiemetic drug
45965549|NCT04576390|Drug|Palonosetron 75 mcg|Antiemetic drug
45965550|NCT00583570|Behavioral|dietary education|dietary education
45965551|NCT00583648|Other|Urinanlysis|sending a Urine sample to the laboratory for processing
45965552|NCT00181571|Drug|methylphenidate HCl (Concerta)|up to a maximum dose of 1.3 mg Concerta/kg/day, and not more than 144 mg/day for any subject regardless of weight.
45965553|NCT00181571|Drug|Placebo|up to a maximum dose of 1.3 mg Placebo /kg/day, and not more than 144 mg/day for any subject regardless of weight.
45965554|NCT00187707|Drug|Gabapentin|Subjects will take a single dose of 400 mg of gabapentin
45965555|NCT00583687|Device|Vigileo TM / Flotrac TM (Minimally invasive cardiac output system consisting of arterial line sensor and cardiac output monitor)|Attachment of the arterial line sensor and pulse contour cardiac output monitor to the arterial line of the patient.
45965556|NCT00583687|Other|Passive leg raising|Passive leg raising for prediction of fluid responsiveness with arterial pulse contour analysis.
46080307|NCT02739282|Other|Systematic therapeutic drug monitoring|Blood samples with antiepileptic drug level measurement
46080308|NCT00926341|Drug|Pioglitazone|Tab. Pioglitazone-30 mg/day, oral, 24 weeks
46080309|NCT00926341|Drug|Telmisartan|Tab. Telmisartan- 40 mg/day, oral, 24 weeks
46080310|NCT05279105|Behavioral|Program support|The intervention to be evaluated in this study is program design and selection considerations by humanitarian organisations. It will comprise of factors that motivate organisations to chose certain delivery models in providing health care in conflict-affected settings
45965557|NCT00583687|Other|Volume challenge / Change of vasoactive drugs or inotropics|Either a volume challenge (using colloids or crystalloids) or a change in the dosage of of vasoactive drugs or inotropics, or a combination of them, as proposed by the treating physician.
45965558|NCT00583687|Device|Inspectra TM/O-To-See TM (Tissue oxymetry with near infrared spectroscopy and laser-Doppler)|Tissue oxymetry continuously measured with near infrared spectrometry and laser Doppler during the whole study period.
45965559|NCT00583726|Behavioral|motivational interviewing|telephone counseling
45965560|NCT00583726|Behavioral|written materials only|dietary guidance materials and pedometers
45965561|NCT00583765|Drug|Regional citrate anticoagulation|Continuous venovenous hemodiafiltration with regional anticoagulation using dilute trisodium citrate. This requires the use of a continuous renal replacement therapy (CRRT) machine in venovenous hemodiafiltration mode. Anticoagulation and buffer are provided by the use of a dilute solution of trisodium citrate in the replacement fluid which is infused in a predilution mode. Standard bicarbonate containing dialysate is used.
45823338|NCT04567472|Behavioral|Helping Ease Anxiety and Depression following Stroke|HEADS: UP online is a group-based mindfulness course with an accompanying text-based manual. HEADS: UP comprises 9 x 2.5 hour mindfulness sessions, which incorporate a 30-minute break. A 6-hour silent retreat is offered in week 7. A follow-up session will be offered 6 - 8 weeks after the end of the course. Course materials include accessible information packs delivered weekly, electronically, and CD/audio resources to complement the sessions. The accompanying text-based manual will be delivered 'up front' (hard copy and electronic). A summary email and reminder of personal practice will be sent to participants after each session, including links to audio resources complementing class-based sessions. Signposting to other resources and media, including sites with downloadable voice files e.g. Mindfulness Scotland will be included.
45823339|NCT04330573|Other|No intervention. Observational study|Observational study
45823340|NCT04567316|Drug|[14C]-radiolabelled BI 1358894|Part 1
45965562|NCT00187746|Drug|Adefovir dipivoxil|Subjects will be given a single oral dose of 10 mg of adefovir dipivoxil
45965563|NCT00181649|Drug|Recombinant human prolactin|
45965564|NCT04575805|Behavioral|Internet-delivered Combined Cognitive Bias Modification (iCBM-C)|The iCBM-C is online CBM intervention which is the combination of iCBM-I and iCBM-A interventions for obsessive-compulsive symptoms delivered in eight sessions, twice per week for 4 weeks. The presentation order of the two intervention components will be counterbalanced to allow exploration of any order effects. Thereby, half of the participants in iCBM-C group will complete the iCBM-A task followed by iCBM-I, while the other half will complete the iCBM-I task followed by iCBM-A during each session.
45965565|NCT04575805|Behavioral|Internet-delivered Cognitive Bias Modification-Interpretation (iCBM-I)|The iCBM-I is online CBM intervention for obsessive-compulsive symptoms comprised of delivery of OCD related scenarios taking place over eight sessions, twice per week for 4 weeks.
46080311|NCT02806778|Other|BIS Monitor-guided sedation|The patients enrolled in the study will undergo BIS Monitor-guided sedation. Standard BIS Monitor will be used for the procedure to monitor the depth of sedation.
45667241|NCT04416945|Other|Household Reactive Case Detection|Within 7 days of the index case notification, all members of the index case's household and everyone in the neighboring five households will then be invited to participate in the study. After consenting, a finger stick blood sample will be collected for each consenting individual for testing with the HS-RDT for P. falciparum, a standard combination RDT, and four blood spots on filter paper.
45823341|NCT04567316|Drug|BI 1358894|Part 2
45667242|NCT04416945|Other|RACD of cases' co-workers/co-travelers|"Index cases will be screened by the VMW at their households at the time of case investigation to determine if they have traveled or worked in a forest or forest-fringe area within the past 30 days. If eligible, the case will trigger two reactive recruitment strategies to screen and treat others who recently traveled or worked with the case in a forest or forest-fringe location:~Peer-referral RACD (PR-RACD): In this strategy, the case will identify specific co-travelers or co-workers resident in their village who had spent the night with the case at a forest or forest-fringe area and spent the night there in the past 30 days.~Venue-based RACD (VB-RACD): In this strategy, co-workers will be recruited directly from (accessible) forest or forest-fringe work sites where the index case worked and spent at least one night in the past 30 days."
45823342|NCT04338061|Drug|Evobrutinib|Evobrutinib twice daily (BID) in double-blind (DB) treatment period.
45823343|NCT04338061|Drug|Placebo (match to Teriflunomide)|Placebo match to Teriflunomide once daily in double-blind treatment period.
45823344|NCT04338061|Drug|Teriflunomide|Teriflunomide once daily in double-blind treatment period.
45823345|NCT04338061|Drug|Placebo (match to Evobrutinib)|Placebo match to Evobrutinib BID in double-blind treatment period.
45823346|NCT04569422|Drug|Benoxyl|reduce pain
45823347|NCT04568720|Diagnostic Test|blood sample|Isolated the blood sample and detected the CTC
45965566|NCT04575805|Behavioral|Internet-delivered Cognitive Bias Modification-Attention (iCBM-A)|The iCBM-A is online CBM intervention for obsessive-compulsive symptoms comprised of delivery of the modified dot-probe task taking place over eight sessions, twice per week for 4 weeks.
46080312|NCT02806778|Other|Jugular bulb catheter|Jugular bulb catheter will be implanted in the patients enrolled in the study.
46080313|NCT02729532|Device|Xpert|The Xpert MTB/RIF assay is a nucleic acid amplification (NAA) test that uses a disposable cartridge with the GeneXpert Instrument System
46080314|NCT00926419|Biological|Varicella Vaccine|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)
46080315|NCT00926419|Biological|Hepatitis A Vaccine|Hepatitis A virus vaccine, inactivated, Single dose
46080316|NCT04259879|Other|Fasting|Food intake restriction
46080317|NCT02806466|Procedure|Fiberoptic bronchoscopy|
46080318|NCT00929929|Dietary Supplement|L-leucine.|10 g of leucine per day, during 12 weeks.
45455558|NCT03772327|Device|"Adheretech smart bottle"|"A smart pill bottle that measures the exact number of pills in the bottle in real-time, sends this HIPAA-compliant data to a central server, and based on the results, can remind participants to take their medication through a phone call or text message."
45823348|NCT02210702|Drug|Ethinyl Estradiol 35mcg/Norethindrone 1mg|
45823349|NCT02210702|Drug|Ethinyl Estradiol 20mcg/Norethindrone 1mg|
45455559|NCT03772327|Behavioral|Routine adherence counseling|Participants will be provided with routine adherence counseling
45823350|NCT04568096|Combination Product|Aerosolized All-Trans Retinoic acid plus oral Tamoxifen|After randomization and standard treatment The infected patients will receive Aerosolized All-Trans Retinoic Acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled All-Trans Retinoic Acid therapy plus tamoxifen 20mg orally once daily. for 14 days
45823351|NCT04568096|Other|Standard treatment|Standard treatment is according to the protocol of treatment of 2019-nCoV infection
45823352|NCT04568018|Drug|Surfactant|Inhalation of surfactant emulsion at 150 mg
45823353|NCT04334317|Drug|TAK-071|TAK-071 tablet.
45823354|NCT04334317|Drug|Placebo|TAK-071 placebo-matching tablet.
45823355|NCT02210390|Behavioral|Psycho education|Psycho-education Sessions will be offered weekly basis
45823356|NCT02278094|Device|Tongue Muscle Trainer (TMT)|Subject will be instructed to compress the Iowa Oral Performance Instrument (IOPI) IOPI's bulb using tongue in three directions (anterior and both lateral sides). Then, hold 30-35 seconds each time. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
45823357|NCT02278094|Device|Threshold Inspiratory Muscle Trainer (TIMT)|Resistance of the TIMT devices will be set from 30% of the maximum inspiratory pressure. Nose clip follow by normal breathing. Seal the mouth to the device's mouth piece then inhale through the device. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
46080319|NCT00929929|Dietary Supplement|Maltodextrin.|10 g of maltodextrin per day, during 12 weeks.
45455560|NCT01352858|Drug|TolDC|Tolerogenic dendritic cells (TolDC), derived ex vivo from autologous monocytes, administered arthroscopically into an inflamed knee following saline irrigation.
46080320|NCT00929929|Behavioral|Exercise program.|Progressive resistance exercise program 4 days a week, during 12 weeks.
46080321|NCT00608231|Drug|Dexmedetomidine Hydrochloride Infusion|Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery
46080322|NCT00608231|Drug|Normal Saline|Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
45455561|NCT01352858|Drug|Arthroscopy & saline irrigation alone|
45455562|NCT02290054|Procedure|Control|Implementation of adhesive pads on the ears is performed while the patient is sleeping but before thoracic incision.
45455563|NCT02290054|Procedure|Treated|Auriculotherapy uses semi-permanent needles and implementation of adhesive pads to mask the needles.
45455564|NCT02290054|Procedure|Intra-venous anesthesia|
45455565|NCT01347944|Drug|lenalidomide|Patients who were prescribed Revlimid from 31October 2008 to present.
45823358|NCT02278094|Procedure|Walking Exercise|Subjects will be encouraged to perform walking exercise in the field 10000 steps/ 60 minutes daily then continue three to five times a week during first months. Followed by 12500 steps and 15000steps per day during the second and third months.
45823359|NCT02278094|Device|Continuous Positive Airway Pressure (CPAP)|CPAP regular therapy per day (use ≥ 4 h/day) then continue three to five times a week for a total of 3 months.
45823360|NCT04985071|Procedure|Pancreaticoduodenectomy|Patient with periampullary cancer will be underwent pancreaticoduodenectomy in 2 types of pancreatic-jejunal anastomosis reconstructions. We describe the postoperative complications (pancreatic fistula and bleeding) and analysis the risk factors relate to those complications
45823361|NCT02278172|Dietary Supplement|Vitamin D|3000IU (75 μg) vitamin D in a commercially available oral spray solution
45823362|NCT02278172|Dietary Supplement|Placebo|Placebo oral spray solution manufactured to mimic the vitamin D oral spray
45823363|NCT04983667|Dietary Supplement|Zn-AA|Oral supplementation of either 30 mg daily or Zinc-AA complex or placebo, from the study recruitment during first trimester of pregnancy, all through pregnancy and up to the sixth month after giving birth.
45823364|NCT04971031|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days.
45823365|NCT04971031|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered 7 times over two consecutive days.
45823366|NCT04566614|Other|ctDNA blood sampling|Screening/baseline blood sample to be analysed for ctDNA
45823367|NCT04970641|Behavioral|Three Good Things (3GT) Positive Psychology journaling activity|Evening journaling activity each day to reflect on three good things that the subject has noticed about their day's events.
45823368|NCT04566224|Device|Macintosh size 2 blade|intubate with Macintosh size 2 blade
45823369|NCT04566224|Device|Macintosh size 3 blade|intubate with Macintosh size 3 blade
45455566|NCT01223521|Device|Immediate intrauterine contraception|A Cu-IUD or LNG-IUS is inserted after abortion.
45667243|NCT04416945|Other|Case Management and Follow-up|"All individuals who test positive by either HS-RDT or Standard RDT will be told of their results and treated on site per national guidelines:~Individuals with P. falciparum infection will be treated with an age-appropriate course of artemether-lumefantrine (AL) and a single low dose of primaquine (SLD-PQ). Weight-based dosing is described in Tables 2 and 3 below.~At all study sites in Lao Peoples Democratic Republic, patients with a P. vivax infection identified by RDT (both febrile and asymptomatic) will be given a unique coded and signed informational letter directing them to the nearest district hospital (or other testing facility) for G6PD deficiency testing and possible radical cure administration depending on results. At the health facility, G6PD normal individuals will be treated with AL and a 14-day course of PQ, whereas G6PD deficient individuals will receive AL alone as per the national guidelines and referred to a hospital for further primaquine management decisions."
45667244|NCT04185363|Drug|Maralixibat|All subjects will receive Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) twice daily for up to 104 weeks
45667245|NCT04682925|Other|skin care arm of where evidence-based practices in the implementation guide|"The nasal mucosa and nasal skin under the nasogastric tube will be cleaned and dried twice a day with a pH-compatible cleanser.~A water-based moisturizing cream will be applied to the nasal skin under the nasogastric tube twice a day, after care with a pH-compatible cleanser.~Spray skin barrier will be applied twice a day after applying water-based moisturizing cream to the nasal skin under the nasogastric tube.~The nasal mucosa and nasal skin under the nasogastric tube will be evaluated twice daily for signs of pressure-related injury. All these care interventions applied to the skin care arm will be applied together with the doctor and nurse responsible for the treatment and care of the patient."
45965567|NCT04575571|Other|No intervention, this is an observational study that uses validated questionnaires and qualitative interviews..|No intervention, this is an observational study that uses validated questionnaires and qualitative interviews.
45823370|NCT04566458|Other|No intervention|retrospective chart review study
45965568|NCT00583843|Procedure|Ultrasound|Ultrasound weekly during initial fields of radiation, and daily during the boost phase.
45455567|NCT03931525|Device|Fractitional Radiofrecuency with Drug Delivery|Electromagnetic energy within the spectrum of radio frequencies applied to the skin whose purpose is to generate thermal effects and which will be complemented with a skin drug
45455568|NCT03931525|Device|Fractitional Radiofrecuency|Electromagnetic energy within the spectrum of radio frequencies applied to the skin whose purpose is to generate thermal effects
45965569|NCT00209430|Drug|Iodixanol 320 mgI/mL|
45823371|NCT04958707|Other|Information including knowledge and skills related to dementia patient care|The intervention will be administered to the participants via a smartphone app (Zalo app). Weekly, the investigator will post one of the eight topics identified in Phase 1 in the chat room. After posting the topic, one investigator will call the participants to ensure they read and understand the contents.
45823372|NCT04958707|Other|Usual care|Caregivers will be introduce to the website www.alzheimer.org to search for eligible information
45823373|NCT02210858|Other|Laboratory Biomarker Analysis|Correlative studies
45823374|NCT02210858|Drug|Tipifarnib|Given PO
46080323|NCT02729142|Procedure|Tibial cortical density evaluation|Bone evaluation in transplant patients will be performed by HR-pQCT at baseline (either within 6 months before surgery or within 15 days following surgery) and 6 months post-intervention in order to assess its evolution.
46080324|NCT02812784|Device|Nephrocheck TM|
45823375|NCT04564586|Behavioral|DPPFit|Participants issued Fitbit Device and set up Fitbit App. They are then enrolled in the automated text messaging platform. Day 1 of the intervention begins the Monday after consent. All consented participants receive the full intervention.
45823376|NCT04566146|Other|scapular muscle training, serratus anterior strength, scapular stabilization exercises|patients will be scheduled to attend physical therapy three sessions per week for one month. Three sets of 10 repetitions for each exercise were prescribed per session, with a 1-minute rest between sets.
45823377|NCT04563104|Diagnostic Test|Lung Ultrasound|We will evaluate the role of lung ultrasound on the duration of antibiotics, we hypothesize that ultrasound imaging may have a role, will be correlated with, procalcitonin (PCT). The created database will help in establishing conclusion and recommendations that will help to improve the antibiotics duration and decrease the resistance.
45823378|NCT04565912|Drug|Sage extract mouthwash|Patients will be exposed to sage extract mouthwash and will be instructed to use 10 ml of sage extract mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month.
45965570|NCT00181688|Drug|Iressa (ZD1839)|
45823379|NCT04565912|Drug|Chlorohexidine based mouthwash|Patients will be exposed to Chlorohexidine based mouthwash , and will be instructed to use 10 ml of 0.12% chlorohexidine based mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month
45823380|NCT04281199|Procedure|Hematopoietic Cell Transplantation|Undergo HCT
45823381|NCT04281199|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
46080325|NCT04015531|Radiation|Conventional radiotherapy|50 Gy / 25 fractions / 5-6 weeks / Sequential boost of 10 Gy in 5 fractions, in case of conservative surgery.
45823382|NCT04281199|Radiation|Tomotherapy|Undergo IMRT with tomotherapy
45965571|NCT00181688|Drug|Arimidex (Anastrozole)|
45965572|NCT04575454|Other|Multimodal evaluation of brain function : PET-MRI, electrophysiology, eye-tracking|"After 2 days of sedation withdrawal, each data should be collected within 3 days for organisation purposes :~After installation and movement management with standardized routine care protocol: 18Fluoro-Desoxy-Glucose's infusion for PET~Starting PET continuous acquisition~Morphological MRI sequences~MRI in Resting state N°1~MRI DTI acquisition~IRM in 2D-Arterial Spin Labelling~IRM in Resting state 2~End of PET continuous acquisition The day before or the day after PET-MR: standard 20 min EEG, somaesthetic evoked potentials, auditory evoked potentials, mismatch negativity, P300 oddball paradigm, local-global paradigm, P300 after music stimulation, EEG resting state for 10 min, CRS-R repeated before each examination (and at least 5 times for chronic patients), eye-tracking study of the environmental exploration."
46080326|NCT04015531|Radiation|Hypofractionated radiotherapy|40 Gy / 15 fractions / 3 weeks / Concomitant boost with total dose of 48 Gy in 15 fractions, in case of conservative surgery.
46080327|NCT02729220|Other|Bronchoscopy|Sampling of airways
45823383|NCT04281199|Radiation|Total-Body Irradiation|Undergo TBI
45965573|NCT00583882|Other|Routine change of central venous catheters|Changeing CVCs on a regular basis to decrease infection rate.
45965574|NCT03453034|Drug|TQ-B3233|QD or BID in different stage of this research
45965575|NCT00209469|Drug|alendronate sodium|
45965576|NCT00181727|Drug|divalproex sodium extended release|
45965577|NCT03452995|Procedure|PHYSIOTHERAPY|Lymphodreinage and kinesiotaping are current methods of treatment of edema, pain and indirectly recovery of the knee ROM in TKA. Edema, pain and knee ROM are strictly corelated and, by reducing edema, we reduce the pressure by relieving pain, and allowing an improvement in movement.
45965578|NCT03452956|Other|None-Observation Only|No intervention-this is an observational study
45965579|NCT00187785|Behavioral|Spanish speaker level|
45965580|NCT00583999|Other|no interventions, only regular blood-draw|No interventions, only regular blood-draw (liver biopsy obtained per routine during the surgery)
45965581|NCT00584038|Behavioral|educational instruction and phone follow-up|Educational instruction and phone follow-up.
45965582|NCT00584038|Behavioral|educational instruction in clinic|Educational instruction in clinic.
45965583|NCT00584155|Drug|Normal Saline and 0.3% ofloxacin|The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear and are only to be used in the designated ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
45965584|NCT00584155|Drug|Lactated Ringer's with 0.03% Ofloxacin|The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
45965585|NCT00411372|Drug|fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg|
45965586|NCT00181922|Drug|ziprasidone (Geodon)|
45965587|NCT00584311|Other|MRI and Ultrasound|MRI and US of the joint
45965588|NCT00584350|Other|Hydratation according LVEDP + NaHCO3|"Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.~At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours."
45965589|NCT00584350|Other|normal saline|hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).
45965590|NCT00584350|Other|Sodium bicarbonate|hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
45965591|NCT00411489|Procedure|endolumenal surgery|
45965592|NCT00182039|Drug|Metoprolol controlled release (CR)|Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
46080328|NCT00933595|Other|Smoking Cessation|"A Motivational Interview session (~40-50 minutes) will be delivered by a trained nurse coordinator.~Treatment with varenicline (1 mg daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12)or nicotine replacement therapy (21 mg of a skin patch + nicotine gum 4 mg ad lib added for breakthrough craving up to 20 pieces/day."
46080329|NCT04236674|Device|Buzzy thermomechanical device|Buzzy thermomechanical device placed near intervention site.
46080330|NCT04236674|Behavioral|Music Selection|Patient specified procedural music
46080331|NCT02733744|Biological|Fecal Microbiota Transplantation (FMT)|FMT will be given through the ingestion of 30 capsules (15 capsules daily x 2 consecutive days)
46080332|NCT00930085|Other|SELDI-TOF MS for plasmatic proteic profile|An extra blood sample is required to determine the plasmatic proteic profile used to identify one or several signatures which are correlated to the clinical evolution (mortality at D30).
45455569|NCT02290132|Drug|Rabbit Anti-human Thymocyte Globulin (ATG)|The conditioning regimen in this study consisted of Rabbit antithymocyte globulin (ATG 2.5 mg/kg×4 days) , total-body irradiation (10 Gy in five fractions), cyclophosphamide (60 mg/kg×2 days) and etoposide or teniposide (30-40mg/kg) .
45823384|NCT04281199|Radiation|Volume Modulated Arc Therapy|Undergo IMRT with VMAT
45823385|NCT04565678|Drug|Mitapivat tablets|Oral tablets
45823386|NCT04565678|Drug|Mitapivat coated granules|Oral coated granules
45823387|NCT04279483|Behavioral|7-11|Assigned to make a small (~$3.00) purchase from any 7-11 store(s) using a study-provided debit card during each retail environment visit
45823388|NCT04279483|Behavioral|CVS|Assigned to make a small (~$3.00) purchase from any CVS store(s) using a study-provided debit card during each retail environment visit.
45823389|NCT02210936|Other|Educational Intervention|"The design is primarily a pre-post, non-equivalent comparison group test of program effectiveness. If final sample size permits, we will examine program effects for each practice environment separately. For measures that require interview data there will be no comparison group data.~We will construct matched comparison groups of physicians for each environment for which only secondary data analysis will be conducted. The matched comparison group will be constructed using prescription data from the DoD's pharmacy data transaction system (MACH and DORN VAMC) and from SCRIPTS (community-based physicians and VA prescribers)."
45823390|NCT04564352|Dietary Supplement|Adansonia digitata|Juice of AD fruit
45823391|NCT04564430|Drug|Catapresan|The intervention is either a single intravenous bolus of 3mcg/kg Catapresan (150mcg/1ml) or an equal amount of saline at the time of tourniquet inflation.
45823392|NCT04564430|Other|Saline|controlgroup receiving saline
45823393|NCT04564118|Drug|Retrospective analysis of assigned treatment|analysis of treatment assigned by physicians within routine clinical practice
46080333|NCT05015153|Other|Pulmonary rehabilitation (PR)|20 sessions of PR in respiratory rehabilitation centre will be performed over a period of 3 months
45823394|NCT04274101|Other|Clinical Manifestations|Clinical manifestations in patients treated with Nifurtimox and Benznidazole
45965593|NCT00182039|Drug|Placebo|Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
45965594|NCT00584389|Drug|rimonabant|20mg/d (oral) once daily for 12 weeks
45965595|NCT00584389|Behavioral|Dietary intervention|Dietary intervention to match weight loss in group 1. The energy prescription will be based on the estimate of the energy deficit estimated from the weight loss in group one. For example a weight loss of 5kg over 12 weeks equates to an approximate energy deficit of 30,000 kcal or a daily energy reduction of approximately 357 kcal. If this is achieved in group 1 the daily energy target for subjects in group 2 will be daily energy expenditure minus 357 kcal.For the subjects randomised to the dietary intervention group there will be a delay until group 1 subjects have completed the study.
45965596|NCT00584428|Procedure|High-Dose Chemo with Autologous BMT|Carboplatin/VP-16/Cytoxan for women 18-59 and Carboplatin/Thiotepa/Cytoxan for women 60-70
45965597|NCT00216372|Drug|Lanreotide (microparticle formulation)|A single 30 mg intra-muscular injection on day 0. The duration of the blinded phase is 10 days. Patients may enter the open phase where they receive 30 mg intra-muscular injections, every 10 days until investigator/or patient decide to stop treatment.
46080334|NCT02733666|Procedure|Absorbable screw group|Open reduction was performed and one absorbable screw was used for fixation in the experimental group
46080335|NCT00933673|Drug|L-asp, DXM, IFO, VP-16, DDP|L-asp 6000 u/m2; DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 60 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
46080336|NCT02812550|Procedure|colonoscopy procedure|endoscopy performed with a standard forward view colonoscopy or with full-spectrum endoscopy
45667246|NCT04682925|Device|hydrocolloid (Convatec Granuflex-extra thin) dressing|The nasal skin of the patients and the surrounding skin will be cleaned with a pH-compatible cleaner, dried and a new hydrocolloid cover will be applied once a day. All these care interventions applied to the hydrocolloid dressing arm will be applied together with the physician and nurse responsible for the treatment and care of the patient.
45667247|NCT04682925|Other|control|In routine care, the skin under the nasogastric tube is evaluated once a day for redness and wound formation by the nurse responsible for the patient's care and is cleaned and dried with appropriate cleaners.
45823395|NCT04274101|Diagnostic Test|Serologic response|Serologic response in patients treated with Nifurtimox and Benznidazole
45823396|NCT04274101|Diagnostic Test|Direct method|Direct method tests in patients treated with Nifurtimox and Benznidazole
45823397|NCT04274101|Behavioral|Adverse events|Adverse events in patients treated with Nifurtimox and Benznidazole
45823398|NCT04564040|Drug|Acalabrutinib Treatment A|Participants will receive 100 mg AT suspension in water via NG tube.
45823399|NCT04564040|Drug|Acalabrutinib Treatment B|Participants will receive 100 mg acalabrutinib capsule suspension via NG tube.
45823400|NCT04564040|Drug|Acalabrutinib Treatment C|Participants will receive 100 mg AT suspension in water via NG administration plus 20 mg rabeprazole.
45965598|NCT00216372|Other|Placebo|A single intra-muscular injection on day 0.
45965599|NCT00584584|Drug|QAX576|
45965600|NCT00584584|Drug|Placebo|
45965601|NCT00584662|Drug|Oxymetazoline Hydrochloride|Oxymetazoline Hydrochloride TWO SPRAYS BID
45965602|NCT04575532|Device|Use of the pinpointIQ solution (physIQ, Inc.)|Patients are monitored for 28 days post COVID19 diagnosis or COVID19 post-hospitalization discharge using the pinpointIQ solution.
46080337|NCT02739204|Drug|Celecoxib|200 mg of Celecoxib daily for 6-month treatment after surgery within 1 - 6 months
45667248|NCT02412371|Drug|Paclitaxel|Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)
45667249|NCT02412371|Drug|Placebo for Veliparib|Capsule for oral administration
45667250|NCT02412371|Drug|Carboplatin|Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)
45667251|NCT02412371|Drug|Veliparib|Capsule for oral administration
45823401|NCT04564040|Drug|Acalabrutinib Treatment D|Participants will receive 100 mg AT orally.
45823402|NCT00005804|Drug|cyclophosphamide|
45823403|NCT00005804|Procedure|allogeneic bone marrow transplantation|
45823404|NCT00005804|Radiation|radiation therapy|
46080338|NCT00927485|Drug|Calcumin (Curcumin)|Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).
46080339|NCT00927485|Other|Risk Factor Questionnaire|Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.
45823405|NCT04563962|Behavioral|Contingency Management-ART|Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated adherence to tenofovir-based ART or PrEP.
45823406|NCT04563962|Behavioral|Contingency Management-Methamphetamine|Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.
45823407|NCT04563650|Biological|blood sample|Sample collection of 4 to 10 tubes of whole blood will be done according to centre Saint-Victor's protocol.
45823408|NCT02211092|Behavioral|Physical activity intervention|A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.
45823409|NCT02211092|Other|Usual care|Access to usual community resources but no active lifestyle coaching.
45823410|NCT04565444|Dietary Supplement|Ketone|"Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~Isocaloric carbohydrate control: dextrose + vanilla flavouring"
45667252|NCT02412371|Radiation|Radiotherapy|Radiation treatment with total dose of 60 - 63 Gy administered on Days 1 to 5 of each week for 7 weeks
45667253|NCT02411747|Behavioral|Testing|
45667254|NCT02411747|Behavioral|Directed self-regulated simulation training|
45823411|NCT04565444|Dietary Supplement|Ketone + Protein|"Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~10g Whey Protein~L-[ring-2H5]-phenylalanine tracer (enriched to 4%)"
46080340|NCT00927485|Other|Blood samples|Three tubes of blood at visits 0, 4 and 12 months.
45667255|NCT01822756|Drug|ruxolitinib|
45667256|NCT01822756|Drug|gemcitabine|Other names: Gemzar®
45823412|NCT04565444|Dietary Supplement|Protein|"Isocaloric carbohydrate control: dextrose + stevia~10g Whey Protein~L-[ring-2H5]-phenylalanine tracer (enriched to 4%)"
45823413|NCT04563728|Behavioral|Surveillance camera(s)|the mock camera intervention is for testing whether the impression of surveillance would have the effect to reduce the recidivism of elder abuse in home settings; 2) whether less costly options (mock cameras) are as effective as surveillance camera(s) in reducing the recidivism of elder abuse; 3) feasibility and acceptability of surveillance camera(s)
46080341|NCT00927485|Other|Biopsies (Sigmoidoscopy)|Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.
46080342|NCT00927485|Other|Biopsies (Upper endoscopy)|Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.
46080343|NCT00926653|Drug|Escitalopram|10 to 20 mg daily as part of another study in which participants are enrolled
45667257|NCT01822756|Drug|nab-paclitaxel|Other names: Abraxane®
45667258|NCT01822756|Drug|filgrastim|Prophylactic GCSF support was filgrastim and was given in Cycle 1 on Days 2 to 5, 9 to 12, and 16 to 19, unless chemotherapy was held for toxicity, then prophylactic GCSF support was also held.
45667259|NCT01822678|Drug|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
45667260|NCT01822678|Drug|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
45667261|NCT01822678|Drug|Placebo|Placebo
45667262|NCT01822366|Behavioral|Trauma-focused Cognitive Behavioral Therapy|
45965603|NCT04575298|Dietary Supplement|Acceptability, tolerance study for an infant formula with human milk oligosaccharides|Prospective study
45965604|NCT00209508|Drug|GPI 1485|
45965605|NCT00182195|Procedure|Control Ventilation Strategy|
45965606|NCT00584779|Drug|Gabapentin|CLcr:14-5 mL/min
45965607|NCT00584779|Drug|Gabapentin|CLcr: 29-15 mL/min
45965608|NCT00584779|Drug|Gabapentin|Hemodialysis
46080344|NCT04237064|Diagnostic Test|Photoacoustic imaging|Photoacoustic imaging
45965609|NCT00584779|Drug|Gabapentin|CLcr: 29-30 mL/min
45965610|NCT00584818|Drug|PB127 for Injectable Suspension|"Stages 1 & 2 0.009 - 0.204 mg/kg continuous IV during rest and stress conditions. Infusion rate of 50 - 125 mL/hr will be adjusted for image quality and diagnostic quality. Infusion limited to 60 minutes or less.~Stage 3 - will utilize infusion rate and dose established in Stages 1 & 2. 0.062 mg/kg continuous IV infusion at 150 mL/hr during rest and 100 mL/hr during stress conditions."
45965611|NCT00216411|Biological|Botulinum toxin type A|
45965612|NCT00216411|Drug|Placebo|
45965613|NCT00584896|Drug|PB127 for Injectable Suspension|0.062 mg/kg continuous IV infusion (100-250 mL/hr) during echocardiography, not to exceed 60 minutes infusion, single dose.
45823414|NCT02211248|Other|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
45823415|NCT02211248|Other|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
45823416|NCT04565132|Device|High Definition transcranial Direct Current Stimulation|1x1 tDCS low-intensity stimulator and 4x1 multichannel stimulation adaptor (Soterix Medical Inc, New York, NY)
45823417|NCT04259125|Diagnostic Test|Blood draw|Evaluation of plasma inflammatory markers including cytokines and micro-RNA.
45965614|NCT00182234|Behavioral|Community Interlink Program|The study intervention is a referral to a specialized oncology nursing program. The standardized care provided by this program includes comprehensive assessment and care planning specific to breast and colorectal cancers during the initial phases of treatment, with a minimum of two home visits. Through consultation with the patient, nurses either provide direct (non-medical) care to address needs identified and/or coordinate linkage to services in the community.
45965615|NCT00585091|Drug|phenylephrine|All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.
45965616|NCT00585208|Drug|Ramelteon|Ramelteon 8mg daily
45965617|NCT00585208|Drug|Placebo|matching placebo for ramelteon 8mg daily
46080345|NCT02733822|Drug|Naloxone|
45823418|NCT04259125|Other|Survey|Regarding epilepsy and development.
46080346|NCT02805998|Behavioral|Web-based CBT-I|
46080347|NCT02805998|Other|Treatment as Usual|
45823419|NCT04564664|Drug|Oxygen|High-flow nasal cannula oxygen therapy vs. standard oxygen therapy
45823420|NCT02211482|Drug|dolutegravir, lamivudine|single arm
45823421|NCT04562636|Other|Environmental message|Participants will be randomized to view a set of four messages about the environmental harms of meat production from the Meatless Monday campaign.
45823422|NCT04562636|Other|Health message|Participants will be randomized to view a set of four messages about the health harms of meat consumption from the Meatless Monday campaign.
46080348|NCT00930241|Drug|Advagraf®|Advagraf® (one daily dose of Tacrolimus)
45823423|NCT04562636|Other|Neutral Message|Participants will be randomized to view a set of four messages about checking their credit score.
45823424|NCT04562168|Diagnostic Test|Autoderm® dermatology search engine (ML model) testing|GP using a smartphone camera will take an image of the skin problem and will use the Autoderm ML interface to upload the anonymized image. The obtained predicted diagnosis will be recorded in case report form.
45823425|NCT04929847|Other|Self-prepared emollient|The emollient is hypo-allergenic, free of perfume and has very high hydrating capacities together with antioxidants.
45965618|NCT00216450|Drug|rabeprazole sodium|
45965619|NCT00182273|Procedure|Canalith repositioning maneuver (CRM)|
45965620|NCT00585442|Drug|calcitriol|1.0 mcg daily
45965621|NCT00585442|Drug|Placebo|Placebo
45965622|NCT00585481|Procedure|Samples collection for viral diagnosis|"At Enrollment and Termination Visits all subjects will have phlebotomy performed for RSV antibody levels (3 mL of blood).~Subjects diagnosed with an LRTI during the study will have a nasopharyngeal lavage (NPL) for viral diagnosis. Phlebotomy for antibody levels will be performed if the current episode represents the first LRTI since study enrollment."
45965623|NCT00585481|Procedure|Lung Function Analysis|Subjects enrolled in one study site (located in Porto Alegre city) will perform Lung Function Analysis. First measurement will be performed up to Visit 6 and repeated at Termination Visit. Measurements collected in the first analysis will include respiratory compliance and resistance by passive deflation pressure - volume curve, lung volumes by gas dilution method (washout with SF6), lung clearance index with SF6, and maximal flows (rapid thoracic compression from raised volumes).
45965624|NCT00585520|Drug|Progesterone|200mg BID for 5 days
45965625|NCT00585520|Drug|Placebo|Placebo
45965626|NCT00216489|Drug|rabeprazole sodium|
45667263|NCT01838590|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
45667264|NCT01838590|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45823426|NCT04561934|Drug|Silver diamine fluoride|Application of 38% SDF (Riva Star, SDI, Bayswater, Australia), and Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE).
45823427|NCT04561934|Other|resin modified glassionomer cement|resin modified glassionomer cement
45823428|NCT04562402|Procedure|Phacoemulsification|cataract surgery via phacoemulsification
45823429|NCT04562402|Procedure|Endoscopic cyclophotocoagulation|Endoscopic ablation of the ciliary body
45823430|NCT04231747|Biological|CC-97540|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC 97540.~During CC 97540 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC 97540 product, subjects will receive treatment with CC 97540 therapy.~Each cycle will include lymphodepleting chemotherapy followed by one dose of CC 97540 administered by intravenous (IV) injection."
45823431|NCT04561778|Device|HOT-CRT|Subjects enrolled in the study will receive a permanent cardiac implantable electronic device (CIED) (CRT-pacemaker or CRT-defibrillator) as clinically indicated. Subjects randomized to HOT-CRT will have His bundle pacing lead placed initially to achieve CRT. If complete resynchronization is achieved (BBB normalization) but capture thresholds are high (1.5-2V), the lead may be placed in the distal conduction system (left bundle branch area). If only partial QRS narrowing is achieved, a coronary sinus lead may be placed and left ventricular timing may be optimized to achieve maximal resynchronization.
45823432|NCT04561778|Device|Biventricular Pacing|Subjects enrolled in the study will receive a permanent CIED (CRT-pacemaker or CRT-defibrillator) as clinically indicated. Subjects randomized to Biventricular pacing will undergo left ventricular lead placement in the coronary sinus venous branches.
45823433|NCT04330495|Drug|Hidroxicloroquina|Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.
45823434|NCT04330495|Drug|Control group|Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months
45823435|NCT04563260|Drug|Normal saline injection|Normal saline 2 mL, intravenous injection
45823436|NCT04563260|Drug|Palonosetron Injection [Aloxi]|Palonosetron 1.5 mL (0.075 mg) + Normal saline 0.5 mL, intravenous injection
45823437|NCT02211170|Drug|BIBR 796 BS, low dose|
45823438|NCT02211170|Drug|BIBR 796 BS, high dose|
45965627|NCT00408395|Biological|Influenza vaccine|Seasonal Influenza Vaccine
45965628|NCT00585598|Other|replacing supralaryngeal airway with ET tube|changing tube in trauma bay
45667265|NCT01611454|Device|XPF thyroid collar|Interventionalist wear the experimental (XPF) thyroid collar during fluoroscopy guided interventions.
45667266|NCT01611454|Device|Standard 0.5mm lead equivalent thyroid collar|Interventionalist wear a standard 0.5mm lead equivalent thyroid collar during the same type of comparator fluoroscopy guided interventions. Comparator arm uses same type of lead thyroid collar but the XPF under investigation.
45667267|NCT01611298|Biological|Tetanus|"Stem cell transplant donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest.~Stem cell transplant recipients will receive one dose of tetanus toxoid 0.5mL intramuscularly (or subcutaneously if platelet count less than 50,000/uL) into deltoid or medial lateral thigh 7-10 days prior to stem cell transplant (FIRST dose).~Stem cell transplant recipients will receive a subsequent dose of tetanus toxoid 0.5mL given intramuscularly into deltoid or medial lateral thigh (or given subcutaneously if platelet count is less than 50,000/uL) approximately 3 months following allo stem cell transplant. Patients must meet re-evaluation criteria to receive injection."
45667268|NCT01822132|Drug|Extended release naltrexone|
45667269|NCT01822132|Drug|Placebo|
45667270|NCT04593004|Device|Teledermatology|Patients will be assessed and followed-up by trained physicians through a store-and-forward system (teledermatology online service - Evita® app), which allows patients to upload pictures of skin areas affected by acne as well as their symptoms or questions related to their disease.
45667271|NCT04593004|Other|Face-to-face consultation|Patients will be assessed and followed-up by trained physicians through regular face-to-face outpatient consultations.
45823439|NCT02211170|Drug|Placebo|
45823440|NCT02211170|Drug|Lipopolysaccharide|Lipopolysaccharide (LPS) for endotoxin challenge
45823441|NCT04180189|Other|Weighted fiber blanket|Using weighted blanket for four weeks
45823442|NCT02211560|Other|Phosphatidylserine|
45823443|NCT02211560|Other|Placebo|
45823444|NCT04173793|Drug|AK102|Administered by subcutaneous injection
45965629|NCT00585754|Drug|Guanfacine|1.5mg BID
45965630|NCT00585754|Drug|Placebo|placebo
45965631|NCT00209547|Drug|fospropofol disodium|
45965632|NCT00585793|Drug|NRTI/NNRTI/ Kaletra|Fixed dose and cild formulation Kaletra
45965633|NCT00585871|Drug|clonidine|0.1 mg tid
45965634|NCT00585871|Drug|metoprolol|25 mg tid
45965635|NCT00408512|Drug|thiazides|Up to 25 mg per day
45965636|NCT00408512|Procedure|Non thiazidic treatment|Amximum tolerated dosage as indicated from the label
45455570|NCT01353014|Other|Dietary advice with genetic information|This group will receive dietary advice for caffeine, vitamin C, sugar and sodium based on genes that affect the metabolism of or sensitivity to caffeine, vitamin C, sugar and sodium.
45455571|NCT01353014|Other|General dietary recommendations|This group will receive general dietary recommendations from recognized health organizations for caffeine, vitamin C, sugar and sodium, with no genetic information.
45667272|NCT01821898|Drug|Oral Budesonide|This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day
45823445|NCT04173793|Drug|Placebo|Administered by subcutaneous injection
45823446|NCT04173793|Drug|Statins and/or Ezetimibe|Lipid-lowering therapies
45823447|NCT04561466|Drug|Béfizal|600 mf befizal a day for one year
45823448|NCT04173637|Biological|AK101|an anti-IL-12/23p40 monoclonal antibody
45823449|NCT04173637|Biological|Placebo|matching placebo
45823450|NCT04561856|Drug|Dexamethasone|Intravenous 4mg
45823451|NCT04561856|Drug|Dexamethasone|Perineural 4mg
45823452|NCT04561856|Drug|Placebo|Normal Saline 2ml
45823453|NCT02211716|Device|BeGraft Peripheral Stent Graft System|
45823454|NCT04912687|Diagnostic Test|EGFR gene mutation analysis on liquid biopsy|Blood samples will be collected at inclusion for plasma DNA collection and analysis.
45823455|NCT00382681|Device|FID 107027 Multi-Purpose Disinfecting Solution|Investigational, multi-purpose disinfecting solution intended for use in cleaning, rinsing, conditioning, disinfecting, and storing soft contact lenses.
45823456|NCT00382681|Device|ReNu MultiPlus Multi-Purpose Solution No Rub Formula|Commercially marketed product indicated for cleaning, rinsing, disinfecting, and storing soft contact lenses.
45823457|NCT04173403|Drug|450mg AK102|AK102 Q4W
45823458|NCT04173403|Drug|300mg AK102|AK102 Q4W
45823459|NCT04173403|Drug|150mg AK102|AK102 Q2W
45823460|NCT04173403|Drug|Statins and/or Ezetimibe|Lipid-lowering therapies
45823461|NCT03562273|Radiation|Quality Of Life Sizing Nomogram|"If the participant meets the eligibility criteria of the study, and participant chooses to take part, they will receive the tumor bed boost in 8 Gy in 1 fraction just prior to starting whole breast radiation after joining the study. Treatment to the whole breast will begin within 7-8 days from the TB boost (GammaPodTM) treatment.~The radiation therapy will take approximately 6 weeks to complete. Follow-up visits specifically for this study will continue for one year, although the physician will continue to follow as part of routine care."
45823462|NCT03541369|Drug|AMG 427|AMG 427 will be administered as an intravenous (IV) infusion in adult subjects with relapsed/refractory AML.
45455572|NCT03927937|Procedure|AUTOTRANSPLANTATION TOOTH|Tooth with imposible prognosis is replace with a healthy tooth from the same patient.
45667273|NCT01821898|Other|Elimination diet|This group will receive an elimination diet
45823463|NCT03539887|Drug|Intranasal ketamine|Intranasal ketamine will be prepared as 100mg/ml ketamine in 0.9% saline. An mucosal atomization device will be used to provide 5 intranasal applications of solution (volume 100 μl), separated by 3 minutes, over a total of 15 minutes. Each of five ketamine applications will provide 10 mg of study drug, for a total of 50mg. The dose to be used (0.5-1mg/Kg) is 6 to 18 times lower than the sedation dose (6-9mg/Kg).
45823464|NCT03539887|Drug|Placebo|Saline alone. An mucosal atomization device will be used to provide 5 intranasal applications of saline (volume 100 μl), separated by 3 minutes, over a total of 15 minutes.
45823465|NCT04123717|Drug|Intravenous Ibuprofen|The treatment phase consists of assignment to a study arm, either IV Ibuprofen, IV Paracetamol, IV paracetamol-Ibuprofen, or PO ibuprofen, and administration of the appropriate medication. The IV medications will be administered over a 15-minute period. The safety of infusion of IVIbuprofen in just 10 minutes has been established, and to infuse over 15 minutes to ensure that IV Paracetamol and IV Ibuprofen have equal infusion times. For IV paracetamol-Ibuprofen, the IV paracetamol-Ibuprofen will be administered as a sequential infusion of IV Ibuprofen over 15 minutes, followed by a flush of the IV line, followed immediately by IV paracetamol infusion over 15 minutes. Oral ibuprofen will be administered as a syrup or tablet based on patient weight and parental preference.
45823466|NCT03472495|Drug|Diltiazem Oral Product|Diltiazem Immediate Release 60 MG PO Q6H (30 MG PO Q6H if patient is <60 kg)
45823467|NCT03472495|Drug|Diltiazem Injectable Product|Diltiazem Continuous Infusion Titrated
45823468|NCT04103749|Device|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care ERCP or other duodenoscope-based procedure performed with the Exalt single use duodenoscope study device.
45823469|NCT04094701|Other|Control Group Regimen|Norco (hydrocodone-acetaminophen) 5mg-325mg, 30 total pills. This is the standard of care prescribing procedure for pain management after hip arthroscopy.
45823470|NCT04094701|Other|Opioid reduced regimen|Tylenol extra strength (1000 mg, three times daily for 10 days following surgery), Gabapentin (300 mg at night for 10 days following surgery) and Norco (hydrocodone-acetaminophen) 5mg-325mg, 5 total pills
45823471|NCT04092829|Procedure|FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE|The intervention group will be prepared with hormone replacement therapy with estrogens according to usual clinical practice. Frozen embryos will be transferred after ten doses of exogenous progesterone.
45823472|NCT03459469|Drug|Tegavivint|This is an Investigational drug
45823473|NCT03428659|Other|Data acquisition of functional abilities in sub-acute stroke|MRI data, motor evoked potentials, gait function and behavior data acquisition
45455573|NCT02204098|Biological|Mammaglobin-A DNA Vaccine|
45455574|NCT02204098|Procedure|Optional biopsy|
45455575|NCT03109262|Procedure|Computed Tomography (CT)|As part of PET/CT and SPECT/CT scans.
45455576|NCT03109262|Procedure|Positron Emission Tomography (PET)|As part of PET/CT scan
45823474|NCT04067089|Procedure|TAVR - Transcatheter aortic valve replacement|TAVR - Transcatheter aortic valve replacement with Acurate Neo bioprosthesis (Boston Scientific) using minimalist approach
45823475|NCT04067089|Procedure|Surgical aortic valve replacement|Surgical aortic valve replacement
45823476|NCT03351361|Drug|Nivolumab + Ipilimumab|Nivolumab dosed intravenously over 30 minutes at 240 mg every 2 weeks combined with Ipilimumab dosed intravenously over 30 minutes at 1 mg/kg every 6 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol.
46080349|NCT00930241|Drug|Prograf®|Prograf® (two daily doses of Tacrolimus)
45667274|NCT04592614|Behavioral|Choose to Move - Next Steps|Choose to Move - Next Steps consists of a series of group meetings delivered virtually for 2 years. Group meetings (1-hr each) of 6-11 older adults will be facilitated by a trained Activity Coach and delivered remotely via the Zoom or GoToMeeting platform (password protected; access through phone or internet). Each group meeting will provide information on a health-related topic of interest and will include time for goal setting, discussion and sharing among participants. Older adults will have the option to sign up for a bi-weekly CTM electronic newsletter containing health information and ideas and resources for older adults to be physically active and socially connected at home (and elsewhere as local restrictions permit). Activity Coaches will also facilitate social connections between participants to encourage contact (by phone or online) outside of group sessions (for interested participants only).
45823477|NCT03351361|Drug|Chemotherapy|Doublet of chemotherapy according to standard of care carboplatin (AUC 5) with a dose that will be capped to 700 mg and pemetrexed (500 mg/m²) over 4 to 6 hours every three weeks (restricted to non-squamous histology) or carboplatin (AUC 6) with a dose that will be capped to 700 mg and paclitaxel (90 mg/m²) D1 D8 D15 over 4 to 6 hours every 4 weeks, with a maximum of 4 cycles of carboplatin based doublet, and the possibility to use maintenance with pemetrexed.
45455577|NCT03109262|Device|90-Yttrium (Y-90) Glass Microspheres|Radiolabel for PET/CT scan
45455578|NCT03109262|Diagnostic Test|Technetium 99mTc albumin aggregated (99mTc-MAA)|Radiolabel for 99mTc-MAA SPECT/CT Scan
45823478|NCT04057807|Drug|LPS|LPS (0.4 ng/kg)
45823479|NCT04056715|Device|Zio XT|ambulatory cardiac monitoring device
45965637|NCT00585949|Procedure|Percutaneous Coronary Angioplasty|This is a procedure by which the blood vessels of the heart are imaged with an insertion of a catheter in the groin and blocked arteries are opened.
45455579|NCT03109262|Procedure|Single-photon emission computerized tomography (SPECT) scan|As part of SPECT/CT scan
45455580|NCT01220245|Procedure|Heparin-bonded ePTFE endoluminal fem-pop bypass|Heparin-bonded ePTFE endoluminal femoropopliteal bypass versus surgical femoropopliteal bypass
45455581|NCT01220245|Procedure|Surgical femoro-popliteal bypass.|Surgical femoro-popliteal bypass.
45455582|NCT02290210|Drug|URC102 0.25mg|
45667275|NCT02411591|Drug|Necitumumab|Administered IV.
45667276|NCT02411591|Drug|Abemaciclib|Administered orally.
45667277|NCT04929899|Behavioral|Bright Ideas - CIN Training|Bright IDEAS is a validated problem-solving skill training intervention.
45965638|NCT00585949|Procedure|Angiography|Angiography is an imaging technique to see coronary blood vessels.
45965639|NCT00585988|Device|Hip Resurfacing System|This arm will utilize a hip resurfacing system.
45455583|NCT02290210|Drug|URC102 0.5mg|
45455584|NCT02290210|Drug|URC102 1.0mg|
45455585|NCT02290210|Drug|URC102 2.0mg|
45455586|NCT02290210|Drug|placebo|
45455587|NCT03931135|Drug|IV Cyclizine versus IV Dexamethasone for prevention of nausea and vomiting after intrathecal morphine in patients undergoing cesarean section|"The first group (Dexamethasone) will receive 8 mg IV dexamethasone within 1-2 minutes after the umbilical cord is clamped.~The second group (Cyclizine) will receive 50 mg cyclizine within 1-2 minutes after the umbilical cord is clamped"
45455588|NCT01125865|Device|SEMS insertion|Self-expandable metallic stent will be inserted for malignant hilar obstruction.
45455589|NCT01125865|Device|DLS insertion|DoubleLayer plastic stent will be inserted for malignant hilar obstruction.
45455590|NCT01353092|Device|Re5 Pulsating ElectroMagnetic Fields|"Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):~30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon"
45455591|NCT01353092|Device|Re5 Pulsating ElectroMagnetic Fields (PEMF)|"Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):~30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)"
45455592|NCT01872598|Drug|Masitinib|
45455593|NCT01872598|Drug|Placebo|
45667278|NCT02454959|Device|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
45823480|NCT03268135|Diagnostic Test|measurement of RNAs|
45965640|NCT00585988|Device|M2a-Magnum™ Large Metal Articulation|This arm will utilize the M2a-Magnum™ implant system.
45965641|NCT04722393|Other|Exercise|Exercise training
45965642|NCT03452761|Dietary Supplement|Ketone Salts|Subjects will take 2 servings of ketone salts daily for 6 weeks
45965643|NCT04722861|Other|GVFQ-40|GVFQ-40 is a 40-item questionnaire developed to evaluate the visual ability of glaucoma patients in detail. It consists of 40 items and measures the impact of glaucoma on restriction of participation in daily activities in five domains of functioning. Each item is rated on a five-level scale from ''no difficulty'' to ''can't do because of vision''. Another possible response is that the activity is not performed for nonvisual reasons.
45965644|NCT03452722|Drug|intraventricual recombinant tissue plasminogen activator application|
45965645|NCT03452683|Behavioral|Movn Mobile App|Movn is a mobile application that is downloaded to a cell phone where participants can enter their weight and symptoms every day.
45667279|NCT02454959|Device|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
45823481|NCT04863781|Behavioral|Mobile cognitive-behavioral stress management intervention|Each weekly module will consist of a cognitive component and a relaxation component. The cognitive component during the first 3 weeks will educate users about the Transactional Model of Stress, that discrimination is a type of stressor, and the impact of stress on health. Building on this information, users will then learn how to match coping responses to the changeability of stressors during weeks 4 and 5. The cognitive component will conclude by focusing on the four most common coping strategies used by African American women in response to stress. Modules 2 through 4 will teach progressive muscle relaxation through a series of tension and relaxation cycles. Modules 5 through 8 will train users in diaphragmatic breathing. Finally, users will be trained in three types of mindfulness mediations.
45823482|NCT04863781|Behavioral|Control|The introductory course defines stress, describes the different sources of stress, and the influence of personality on stress. The coping module includes training in cognitive coping skills, guided imagery, progressive relaxation, autogenic training, and the importance of physical activity to manage stress. All lessons include course assessments. During the intervention period, controls will receive weekly text messages encouraging completion of material.
45667280|NCT01821118|Biological|Ponezumab|Infusion of Ponezumab (Day 1=10mg/kg; Day 30 and Day 60 dose = 7.5mg/kg) or placebo (saline); administered via infusion for a total infusion time of 20 minutes.
45667281|NCT01821118|Other|placebo|placebo (saline)- given via infusion total infusion time of 20 minutes
45823483|NCT03234907|Drug|Vedolizumab IV|Vedolizumab IV infusion
45823484|NCT03234907|Drug|Placebo|Vedolizumab placebo-matching
45823485|NCT04000243|Diagnostic Test|Endoscopic diagnosis of Hp|Detection of a regular arrangement of collecting venules (RAC) pattern in the lesser gastric curvature
45823486|NCT03980977|Other|skin biopsy|"skin biopsy will be taken under local anesthesia using a patch of lidocaine and prilocaine. In practice, during the skin biopsy, the skin must be cleaned with chlorhexidine or alcohol, to the exclusion of any other antiseptic. The biopsy will preferably be done with a dermatome (or punch, 12 G)."
45823487|NCT03980977|Other|tumor biopsy|an additional tumor sample will be taken during programmed diagnostic procedure.
45823488|NCT03980977|Other|blood sample|blood sample will be taken for biological collection
45823489|NCT03228667|Drug|N-803 + Pembrolizumab|Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
45823490|NCT03228667|Drug|N-803 + Nivolumab|Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
45823491|NCT03228667|Drug|N-803 + Atezolizumab|Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
45823492|NCT03228667|Drug|N-803 + Avelumab|Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
45823493|NCT03228667|Drug|N-803 + Durvalumab|Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
45823494|NCT03228667|Drug|N-803 + Pembrolizumab + PD-L1 t-haNK|Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
45823495|NCT03228667|Drug|N-803 + Nivolumab + PD-L1 t-haNK|Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
45823496|NCT03228667|Drug|N-803 + Atezolizumab + PD-L1 t-haNK|Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
45965646|NCT00408551|Drug|floxuridine|Given IV
45965647|NCT00408551|Drug|fluorouracil|Given IV
45965648|NCT00408551|Drug|irinotecan hydrochloride|Given IV
45965649|NCT00408551|Drug|leucovorin calcium|Given IV
45965650|NCT00408551|Drug|oxaliplatin|Given IV
45965651|NCT00586183|Procedure|PET scan|The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
45965652|NCT04575415|Drug|Bevacizumab|Bevacizumab 15mg/kg or clinical routine dose by intravenous drip infusion on day 1 of a 21-day cycle
45965653|NCT04575415|Drug|Erlotinib|Erlotinib 150mg, orally once a day
45965654|NCT04575415|Drug|Gefitinib|Gefitinib 250mg, orally once a day
45965655|NCT04575415|Drug|Icotinib|Icotinib 125mg three times a day
45965656|NCT04575415|Drug|Afatinib|Afatinib 40 mg or clinical routine dose once daily
45965657|NCT04575415|Drug|Dacomitinib|Dacomitinib 45mg or clinical routine dose once daily
45965658|NCT04575415|Drug|Osimertinib|Osimertinib 80 mg once daily
45667282|NCT01650779|Biological|Agalsidase beta|Commercially available agalsidase beta 1.0 mg/kg administered as an intravenous infusion q2w up to Month 6.
45667283|NCT02411201|Drug|DOTAREM|Single intravenous injection of 0.1 mmol/kg body weight
45965659|NCT00586222|Dietary Supplement|Omega-3 Fatty Acid|600 mg of eicosapentaenoic acid, 340 g of docosahexanoic acid, and 96 mg gama-linoleic acid for 12 weeks.
45965660|NCT00586222|Other|Placebo|placebo pill of the same size, color, and shape as the dietary supplement.
45965661|NCT00408668|Biological|PEV3A|
45965662|NCT00408668|Biological|FP9 ME-TRAP|
45965663|NCT00408668|Biological|MVA ME-TRAP|
45667284|NCT01838044|Drug|pregabalin and celecoxib|"During the first study period subjects in Arm A will be administered a daily fixed dose of celecoxib 200 mg once daily and pregabalin 150 mg (75 mg BID) for one week (during Week 0) followed by pregabalin 300 mg (150 mg BID) daily for the remaining 4 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
45823497|NCT03228667|Drug|N-803 + Avelumab + PD-L1 t-haNK|Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
45667285|NCT01838044|Drug|Placebo and celecoxib|"Subjects in Arm B will be administered a daily fixed dose celecoxib 200 mg and placebo of pregabalin for 5 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
45667286|NCT02410811|Other|Cardiac magnetic resonance imaging (CMR)|CMR is obtained on all participants in all arms/groups
45823498|NCT03228667|Drug|N-803 + Durvalumab + PD-L1 t-haNK|Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
45823499|NCT03976843|Drug|18F-DCFPyL|18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
45823500|NCT03958747|Diagnostic Test|Ultrasound - Serial and Tibial Nerve|Participants will undergo a serial and tibial nerve ultrasound
45823501|NCT03958747|Procedure|Skin Biopsy|Two skin biopsies will be obtained as 4.0 mm punch biopsies at distal end of leg in sural nerve territory (10 cm above lateral malleolus) and from the thigh
45823502|NCT03958747|Other|Abbreviated Neurologic Exam|Exam to include strength assessment of the tibialis anterior and gastrocnemius and deep tendon reflex exam of the Achilles on the limb to be examined by nerve conduction velocity and ultrasound.
45823503|NCT03958747|Other|Blood draw|12 ml blood sample will be taken
45823504|NCT03958747|Diagnostic Test|Nerve Conduction Study|Sural and tibial nerve assessments
45823505|NCT03958747|Other|QLQ-CIPN20 Questionnaire Administration|Self-reported neuropathy scoring questionnaire completed same day as blood draw.
45823506|NCT04844983|Drug|STP705|The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.
45823507|NCT04844983|Other|Placebo Saline|Normal Saline
45823508|NCT03155425|Drug|SHR-1210|A humanized monoclonal immunoglobulin
45823509|NCT04330027|Biological|Growth factors|A new patented product named lyophilized Growth Factors that is an advanced and refined form of conventional platelet-rich plasma
45823510|NCT04330027|Other|Saline|0.9% Sodium Chloride
45823511|NCT00002893|Drug|fluorouracil|
45823512|NCT00002893|Drug|leucovorin calcium|
45823513|NCT00002893|Drug|raltitrexed|
45823514|NCT03101917|Device|The Microtable® Stereotactic System|x
45667287|NCT02435381|Drug|Carisbamate|600mg Orally on days 2-4
45667288|NCT02435381|Drug|Placebo|Placebo treatment only
45667289|NCT01837966|Other|Lavender oil|2 drops for aromatherapy
45667290|NCT01837966|Other|Placebo|2 drops unscented mineral oil for aromatherapy
45667291|NCT02435147|Drug|denosumab|Patients will receive denosumab 60 mg subcutaneously every six months as part of their standard osteoporosis treatment.
45823515|NCT03053245|Behavioral|Mobile Critical Care Program|The m-CCRP revolves around the central figure of a care coordinator who will organize and align recovery resources. The care coordinator is a registered nurse whose scope of practice includes health coaching, case managing, community organizing, and nursing care provider. The m-CCRP support team will consist of a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), an ICU collaborative care nurse (Dr. Lasiter), and a psychologist (Dr. Unverzagt). This team will meet weekly with the care coordinator. Drs. Khan and Boustani will be accessible to the coordinator through phone or pager at all times.
45823516|NCT03053245|Behavioral|Attention Control|Patients in this group will receive regular wellness calls from the research team.
45823517|NCT00002899|Procedure|adjuvant therapy|
45823518|NCT00002899|Radiation|radiation therapy|
45823519|NCT00002899|Radiation|stereotactic radiosurgery|
45823520|NCT03905941|Drug|Metformin|Metformin 2000 mg/day will be used in this study. Metformin is a antihyperglycemic agent that is used as a first line medical therapy to treat type 2 diabetes mellitus. It is also used to prevent progression of impaired glucose tolerance. It decrease hepatic glucose production and increase insulin sensitivity.
45667292|NCT02435069|Drug|Dose Response - NS and USP Glycerin - First Intervention|This trial used a repeated measures, single subjects alternating treatments A-B-C-B'-C'-B1' withdrawal design in which all subjects were tested under all conditions and each subject acted as his or her own control. The subjects were randomly assigned to either normal saline or USP glycerin to control for order effects. Baseline data A served as the control and was obtained pre-operatively. The B-C arm evaluated dose-response relationship and was used to identify the minimum dosing volume and frequency of ACE administration of NS and USP Glycerin necessary to promote fecal continence. When the optimal dose as identified, the child continued on that dose for 2 weeks to insure treatment stability and effectiveness.
45667293|NCT02435069|Drug|Effectiveness - NS and USP Glycerin - Second Intervention|To prevent statistical bias from subject loss due to treatment failure, each child was randomized to a second treatment sequence once they have achieved continence with minimal side effects on optimal dosing The second phase B'-C'-B1' of the study compared the two regimens at optimal dose and administration frequency. This phase was used to confirm the effectiveness of NS and USP Glycerin at optimal dosing on continence and assess side effects.
45667294|NCT04917809|Drug|Erdafitinib|Participants will receive erdafitinib at a dose of 6 mg orally once daily for the first 14 days (±3 days). Serum phosphate levels will be assessed on day 14 (±3 days) and the dose of erdafitinib may be lowered based on the serum phosphate level. Treatment with erdafitinib at a dose of 6 mg orally once daily, or at a lower dose level for another 14 days (±3 days) until the day of their standard-of-care TURBT/biopsy. Standard-of-care TURBT/biopsy will be performed after approximately 28 days (±5 days) from the start of treatment with erdafitinib, and biologic and pathologic tumor response will be assessed. All participants will then be followed up for recurrence or progression in accordance with the standard of care.
45667295|NCT04917731|Drug|Botulinum toxin type A|Botox injected at digital artery
45667296|NCT04927559|Other|Survey Administration|Complete survey
45823521|NCT03905941|Drug|Oral combined hormonal contraceptives|"Oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg will be used in this study. OCs are normally used to prevent pregnancy by suppressing ovulation and to prevent endometrial hyperplasia by inducing regular withdrawal bleeding. OCs help control both clinical and biochemical hyperandrogenism in PCOS and are considered first line medical therapy until the age of menopause."
45823522|NCT00383227|Biological|Hepatitis B adjuvanted vaccine|
45965664|NCT00586300|Other|Physical training program|The physical training will be completed in two phases. In Phase 1, which will last 9 months, participants will complete the program under the supervision of an experienced trainer. Sessions will occur three times each week in a designated study facility. The program will include the following components: stretching and balance, flexibility and range of motion, muscle strengthening, and aerobics. The program will also emphasize the importance of individualizing exercise regimens according to each person's specific needs (function and fitness). In Phase 2, the primary objective will be to promote long-term exercise (for up to 24 months from the time of study entry) that incorporates the four modalities of exercise instruction introduced in Phase 1, but on an independent basis.
45965665|NCT00586300|Behavioral|Self-management training program|The self-management training program is designed to target primarily coping skills and self-efficacy. This will be accomplished by using a variety of educational and behavioral methods. The program will be delivered in two phases. The initial 9-month phase will consist of 12 weekly 60-minute classroom sessions, followed by 24 weeks of a structured telephone intervention program. Phase 2 will continue to incorporate the telephone intervention program, at less frequent intervals, for up to 24 months from the time of study entry.
45965666|NCT00586300|Other|Physical training and self-management training programs|"This multidimensional intervention will combine both the physical training and self-management training programs described for Groups 1 and 2."
45965667|NCT00586378|Device|Ovatio DR and Ovatio VR|implantable cardioverter defibrillator
45455594|NCT01872598|Drug|Standard of care|Masitinib and placebo will be administered as add-on therapy in patients who are receiving a stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.
45455595|NCT01226641|Device|Telemedicine|CPAP treatment with telemedicine system
45667297|NCT02454101|Procedure|cord milking|milking of the cord 5 times toward the neonate
45455596|NCT01226641|Device|Standard care|Standard care, including CPAP
45667298|NCT02454101|Procedure|delayed cord clamping|delay clamping of the cord for 120 seconds
45965668|NCT00209625|Drug|irinotecan|
45965669|NCT00209625|Drug|leucovorin|
45965670|NCT00209625|Drug|fluorouracil|
45455597|NCT01353170|Other|Dialysate calcium concentration|Calcium dialysate concentrations: 1.25, 1.35 and 1.5 mmol/l
45667299|NCT02409719|Other|Schedule|Illustrative daily planner to point the day that the exercise was performed
45667300|NCT02409719|Other|Verbal Information and Booklet|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given. Also, an illustrative daily schedule to mark on the exact day in which the exercise was performed
45455598|NCT03620318|Drug|Crenolanib besylate|
45823523|NCT02775331|Other|Shift planning with self-rostering and shift ergonomics|Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
45667301|NCT01820572|Drug|Belatacept|
45667302|NCT01820572|Drug|Tacrolimus|
45667303|NCT01820572|Drug|Cyclosporine|
45965671|NCT00586417|Other|punch biopsy|skin biopsies
45965672|NCT00408707|Procedure|local infiltration analgesia|
45965673|NCT00586534|Behavioral|I/GDC + VR/CER|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
45455599|NCT01220323|Device|direct current stimulation|Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
45667304|NCT01820260|Drug|Ingenol mebutate gel|
45667305|NCT01820260|Drug|placebo|
45965674|NCT00586534|Behavioral|I/GDC|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
45965675|NCT00586807|Other|Stable amino acid isotopes|Stable amino acid isotopes given per IV, dose based on weight and given over the length of the study visit.
45667306|NCT01819480|Procedure|Transoral robotic surgery|Transoral robotic surgery using the daVinci robot to remove primary tumor
45667307|NCT01610596|Drug|Halobetasol Propionate Lotion 0.05%|Apply twice daily for 1-2 weeks, not to exceed 50 grams per week
45667308|NCT01610596|Drug|Placebo|
45667309|NCT01818700|Drug|Buprenorphine|8weeks treatment with Norspan®(Buprenorphine)
45667310|NCT01817764|Drug|Umeclidinium/vilanterol|Dry white powder delivered via NDPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning
45667311|NCT01817764|Drug|Fluticasone propionate/salmeterol|Dry white powder delivered via ACCUHALER/DISKUS (1 strip with 60 blisters, containing 250 mcg fluticasone propionate and 50 mcg salmeterol per blister), administered as one inhalation of FSC 250/50 mcg each morning and evening
45667312|NCT01817764|Drug|Placebo|Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)
45667313|NCT04726618|Drug|Hyperpolarized 129-xenon gas and Perfluoropropane gas|"Hyperpolarized 129-xenon gas will be used as a contrast agent for MRI. Xenon will be inhaled by the participant at a maximum dose volume of 1/6 of the participant's total lung capacity.~Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane)."
45667314|NCT01803880|Device|Mechanical Debridement|mechanical shaver that removes areas of damaged tissue
45667315|NCT01803880|Device|RF-Based Debridement|Electrical energy that removes areas of damaged tissue (Coblation®)
45667316|NCT01803646|Drug|AM-101|AM-101 gel for intratympanic injection
45667317|NCT01803646|Drug|Placebo|Placebo gel for intratympanic injection
45823524|NCT02775331|Other|Shift planning with shift ergonomics|Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
45667318|NCT01817530|Other|Elagolix placebo|oral coated tablet
45667319|NCT01817530|Drug|Elagolix|oral coated tablet
45667320|NCT01817530|Drug|0.5 mg estradiol / 0.1 mg norethindrone acetate|oral hard capsule
45667321|NCT01817530|Drug|1 mg estradiol / 0.5 mg norethindrone acetate|oral hard capsule
45823525|NCT03841981|Diagnostic Test|Anthropometric and physical examination|"Weight and height.~Waist-to-hip ratio.~Body composition: Bioelectrical impedance and [Dual energy X-ray absorptiometry (DEXA)]."
45965676|NCT00216528|Drug|risperidone|
45965677|NCT00586885|Drug|L-alanine|6g of L-alanine (powder)once per day for the first month, twice per day for the second month, then three times per day from the third month for 10 months.
45965678|NCT00587002|Procedure|IVUS|Intravascular ultrasound with virtual histology
45965679|NCT00182312|Drug|Caffeine citrate injection|"Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy."
45667322|NCT01817530|Drug|E2/NETA placebo|oral hard capsule
45667323|NCT01816984|Drug|PI3K inhibitor BKM120|Given PO
45667324|NCT01816984|Biological|cetuximab|Given IV
45667325|NCT01816906|Device|Footwear :PU|"One group of patients will receive Footwear with PU insoles"
45667326|NCT01816906|Device|Footwear: MCP|One group of patients will receive footwear with MCP insoles
45823526|NCT03841981|Diagnostic Test|Indirect calorimetry, accelerometer and seven-day dietary recall|Energy availability assessment.
45823527|NCT03841981|Diagnostic Test|Biochemical, hormonal and metabolic phenotyping|"Lipid profile.~Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.~Sex steroid profile.~Hypothalamic-pituitary-adrenal axis study.~Ferrokinetic study.~Subclinical chronic inflammatory markers."
45667327|NCT01816594|Drug|BKM120|Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 was administered orally 100 mg/day.
45965680|NCT00209664|Drug|irinotecan|
45965681|NCT00209664|Drug|S-1|
45965682|NCT04575493|Dietary Supplement|Crano-cure|Research literatures have revealed that Tribulus terrestris (Gokhro), Vaccinium macrocarpon (karonda), Cuminum cyminum (Zeera sufaid), Rheum emodi (Revand chini) and Piper cubeba (Kabab chini) are important therapeutic plants. Many pharmacological researches have been done on these plants. For instance, antioxidant, antiseptic, anti-microbial, anti-bacterial, anticancer etc. In the above claims and facts, the study is conducted to formulate and evaluate the polyherbal capsule and to find out the most effective combination having anti-bacterial activity.
45965683|NCT04575493|Drug|Ciprofloxacin 500 mg|Being a standard drug as antibiotic and will be used in Control group.
45965684|NCT00587119|Drug|Budesonide|Oral Budesonide, 3 mg three times daily, will be given for 1 year.
45667328|NCT01816594|Drug|Trastuzumab|Trastuzumab is a humanized monoclonal antibody directed against the extracellular juxtamembrane domain of the HER2 receptor. Administered 4mg/kg i.v. load followed by 2mg/kg i.v. weekly.
45667329|NCT01816594|Drug|Paclitaxel|Paclitaxel is a cytotoxic agent with proven antitumor activity in a variety of solid tumors. The antitumor activity of paclitaxel is based on tubulin-binding and stabilization of non-functional microtubule bundles, thereby blocking normal mitotic spindle development and subsequent cell division. Administered weekly 80mg/m2 i.v.
45667330|NCT01816594|Drug|BKM120 Placebo|Neoadjuvant BKM120 placebo Administered orally 100 mg/day.
45667331|NCT01802320|Drug|Akt Inhibitor MK2206|Given PO
45965685|NCT00216567|Drug|topamax|
45667332|NCT01802320|Other|Laboratory Biomarker Analysis|Correlative studies
45965686|NCT00182351|Procedure|D-dimer|
45965687|NCT00182351|Procedure|Serial Compression Ultrasound|
45965688|NCT00587353|Other|Behavioral and pharmacologic tobacco use intervention|A novel approach to providing an intervention for tobacco users who are receiving radiation therapy is to provide an individual tobacco use intervention that utilizes concepts of motivational interviewing strategies to facilitate self-exploration of the reasons for continued smoking and a treatment plan that is comprehensive and builds self-efficacy, provides one-on-one counseling, and includes tobacco treatment pharmacotherapies. The pharmacotherapies will be tailored to the patients needs. One could utilize varenicline, bupropion, and/or nicotine replacement therapies.
45965689|NCT00587392|Device|NDO Full-thickness Plicator|The NDO Full-thickness Plicator intervention was performed as part of the original open-label Plicator study as previously reported. This intervention did not take place as part of this long-term follow-up data collection study.
45965690|NCT00587470|Drug|Candesartan|Maximum vasodilation.
45965691|NCT00587470|Drug|atacand|maximum vasodilation
45965692|NCT00587470|Drug|Placebo|Placebo
45965693|NCT00209703|Drug|Oxaliplatin|
45965694|NCT00209703|Drug|l-Leucovorin|
45667333|NCT01802320|Other|Pharmacological Study|Correlative studies
45965695|NCT00209703|Drug|5-Fluorouracil|
45965696|NCT04575103|Drug|Antipsychotic|Antipsychotic treatment >0.5 DDD
45667334|NCT02453711|Drug|semaglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
45667335|NCT02453711|Drug|liraglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
45667336|NCT02453711|Drug|placebo|Once-daily subcutaneous (s.c., under the skin) administration.
45667337|NCT04917107|Behavioral|Qigong|"The Five Element Qigong Healing Movements practice includes five gentle horizontal and vertical arm and leg movements performed with guided breathing."
45667338|NCT02453555|Drug|Linagliptin|
45667339|NCT02453555|Drug|Empagliflozin placebo + linagliptin placebo low dose|Matching placebo empagliflozin + linagliptin
45667340|NCT02453555|Drug|Empagliflozin + linagliptin low dose|tablet
45667341|NCT02453555|Drug|Linagliptin placebo|Matching placebo linagliptin
45667342|NCT02453555|Drug|Empagliflozin + linagliptin high dose|tablet
45667343|NCT02453555|Drug|Empa + lina highdose placebo|
45667344|NCT02453321|Procedure|Continuous Femoral Nerve Block|A 27g plastic catheter placed below the inguinal crease to perform a conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
45667345|NCT02453321|Procedure|Nerve Block, Continuous Adductor Canal|A 27g plastic catheter placed on the anterior medial thigh midway between the groin and knee to provide a local anesthetic conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
45823528|NCT03841981|Diagnostic Test|Sonographic studies|"Polycystic ovarian morphology.~Carotid intima-media thickness.~Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness."
45823529|NCT03841981|Diagnostic Test|24-hour Ambulatory blood pressure monitoring|A&D TM2430EX oscillometric devices (A&D Company Limited, Tokyo, Japan).
45823530|NCT03841981|Procedure|Percutaneous biopsy|Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.
45823531|NCT03841981|Diagnostic Test|Cardiovascular autonomic function studies|Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.
45823532|NCT03841981|Diagnostic Test|Oral smear and feces specimen|Microbiome studies.
45823533|NCT03818581|Drug|Suvorexant|10-mg or 20-mg Suvorexant capsules
45823534|NCT03818581|Other|Placebo|Matching placebo capsules
45823535|NCT03793855|Behavioral|Nutritional Strategy|Counseling based on dietary goals and mindfulness techniques.
45823536|NCT03793855|Behavioral|Dietary Prescription|Dietary prescription according to guidelines.
45823537|NCT00002905|Drug|cyclophosphamide|
45823538|NCT00002905|Drug|didanosine|
45823539|NCT00002905|Drug|doxorubicin hydrochloride|
45823540|NCT00002905|Drug|etoposide|
45823541|NCT00002905|Drug|mitoxantrone hydrochloride|
45823542|NCT00002905|Drug|prednimustine|
45965697|NCT00182390|Procedure|Red blood cell transfusion|
45667346|NCT02453321|Procedure|Continuous Sciatic Nerve Block|A transgluteal approach to the sciatic nerve is use to place a 27g catheter. It will only be dose postoperatively after verifying sciatic nerve function still intact. The infusion will be 0.003% bupivacaine at 2ml/hr. This is not the intervention of interest, but our institution's predominant practice is to include the sciatic nerve block as part of the analgesic regimen for total knee arthroplasty.
45667347|NCT02453321|Drug|Bupivacaine|The concentration of the continuous infusion of bupivacaine though the peripheral nerve catheters will be 0.0625% for the femoral and adductor canal blocks and the concentration for the sciatic continuous catheter will be 0.03%.
45667348|NCT04927091|Other|Integration of HIV and PWID services|Co-location of clinical services for HIV and PWID patients
45965698|NCT00587548|Other|Localizing the ureters during surgery|One-time injection 4.5mCi of 99mTechnetium labeled diethylene-triamine-penta acetate (DTPA) prior to the time of ureteral localization. The Neoprobe 2000 gamma probe will be utilized for ureter location.
45823543|NCT00002905|Drug|zidovudine|
45965699|NCT00587626|Device|Inactive InterX 5000|Patients will receive will receive InterX placebo treatment 3 times a week for 4 weeks.
45823544|NCT00002911|Drug|marimastat|
45965700|NCT00587626|Device|InterX 5000 Treatment|Patients will receive will receive InterX treatment 3 times a week for 4 weeks.
45965701|NCT00216606|Drug|topiramate|
45965702|NCT00587665|Drug|ketamine|Single IV dose of 0.1 mg/kg of ketamine
45965703|NCT00587665|Drug|Placebo|Saline given of equal volume to drug
45965704|NCT00182429|Drug|Metronidazole and Rifampin|
45965705|NCT00587704|Procedure|PVB using nerve stimulation|5ml of 1% ropivacaine injected incrementally
45965706|NCT00587704|Procedure|PVB using anatomic landmarks|5ml of 1% ropivacaine injected incrementally
45965707|NCT00587821|Other|Blood draw|Peptide profiles from blood samples of all subjects will be determined by mass spectrometric analysis.
45965708|NCT00216645|Drug|doxorubicin hydrochloride|
45965709|NCT00587899|Procedure|Pulmonary Vein Isolation|The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation using a device that delivers radiofrequency energy to the heart muscle in order to create scar tissue to block electrical impulses that can trigger episodes of AF.
45965710|NCT00182468|Other|Screening for intimate partner violence|Women are screened for intimate partner violence prior to seeing a health care provider.
45965711|NCT00588016|Drug|Itraconazole|Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
45965712|NCT00216684|Drug|fentanyl|
45965713|NCT00588133|Drug|tranexamic acid|"Loading dose: 6.6 mg/kg Prime dose: 50 mg for 2.5 Liter circuit (assuming 1 L/kg Vd in prime fluids), 40 mg for 2 Liter circuit Rate of infusion: 6 mg/kg/hr~Renal Insufficiency (normal loading dose and prime dose):~Serum Creatinine = 1.6-3.3: reduce infusion to 4.5 mg/kg/hr Serum Creatinine = 3.3-6.6: reduce infusion to 3.0 mg/kg/hr Serum Creatinine = >6.6: reduce infusion to 1.5 mg/kg/hr"
45965714|NCT00588133|Drug|tranexamic acid|10 mg/kg tranexamic acid given over 20 minutes followed by an infusion of 1 mg/kg/hr
45965715|NCT00588172|Drug|Metformin|1000mg bid for 1 week
45965716|NCT00182507|Drug|Olanzapine|
45965717|NCT04574752|Diagnostic Test|next generation sequencing|diagnostic performance of molecular and culture techniques in S. aureus screening using paired nasal and groin swabs, to determine, if any, discrepancy between the diagnostic techniques on S. aureus detection in orthopaedic patients
45965718|NCT00209742|Drug|UFT|P.O. everyday
45965719|NCT00209742|Drug|USEL/Leucovorin|P.O. everyday
45965720|NCT00209742|Drug|Krestin|P.O. everyday
45965721|NCT00182546|Procedure|Two diagnostic management strategies|
45965722|NCT03452605|Dietary Supplement|cocoa flavanol supplementation|cocoa flavanols (containing 196 mg epicatechin)
45965723|NCT00216723|Drug|Aripiprazole|"The recommended starting and target dose for Abilify is 10 or 15mg/day administered on a once-a-day schedule without regard to meals.~(Administer 10 to 30 mg/day according to the patient's condition)"
45823545|NCT00002917|Drug|paclitaxel|
45823546|NCT00383695|Biological|cetuximab|
45823547|NCT00383695|Drug|capecitabine|
45823548|NCT00383695|Drug|oxaliplatin|
45823549|NCT00383695|Procedure|adjuvant therapy|
45823550|NCT00383695|Procedure|conventional surgery|
45667349|NCT01610284|Drug|Fulvestrant|Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
45667350|NCT01610284|Drug|BKM120|BKM120 100 mg once daily
45667351|NCT01610284|Drug|BKM120 matching placebo|BKM120 matching placebo, once daily
45823551|NCT00383695|Procedure|neoadjuvant therapy|
45823552|NCT00383695|Radiation|radiation therapy|
45823553|NCT00383773|Procedure|Retinal endo vascular surgery|
45823554|NCT00383851|Drug|ATN-224|
45823555|NCT00383851|Drug|Temozolomide|
45823556|NCT02658565|Procedure|Lymphadenectomy|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
45823557|NCT00002923|Drug|KRN5500|
45823558|NCT03779581|Other|Self Correction exercises|Active self-correction exercises to restore movements in different planes as close to physiologically normal as possible.
45965724|NCT03452566|Drug|Ingenol mebutate gel|3+3 phase 1 design as described above. After the maximum tolerated dose is defined, the phase 2 segment of the study will take place. Simon's Phase 2 study design tool was used, reinforced by Jung's admissible study designs for phase 2 clinical trials. Considering the margin of error of 0.05 and study power of 80%, and estimating the probability of placebo partial response of 15% and partial response to ingenol mebutate in 45%, the optimized number of patients to be recruited is 19. Six patients will be seen in the first stage of this segment of the study, and if only one patient or none has a partial response, the study will be promptly discontinued. Otherwise, the second and final stage of segment of the study will include an additional thirteen patients who will be treated.
45965725|NCT03452488|Drug|BIO101|"Oral capsules containing the BIO101 active principle is 20-hydroxyecdysone (20E) at 97%.~Component : 251 mg per capsule including 175 mg of active principle 20E containing also the following compendial excipients: colloidal silica, microcrystalline cellulose and magnesium stearate."
45965726|NCT03452488|Drug|Placebo oral capsule|Oral capsules containing Microcrystalline cellulose, Colloidal anhydrous silica
45965727|NCT00182585|Procedure|computer-based HIV, STD & Hepatitis Education|
45965728|NCT00182585|Procedure|educator-delivered HIV, STD and Hepatitis education|
45667352|NCT02452463|Biological|Durvalumab|Given IV
45965729|NCT03452449|Procedure|planned lumbar spine surgery|planned lumbar spine surgery including decompression, discectomy, foraminotomy, laminectomy
45667353|NCT02452463|Drug|Nintedanib|Given PO
45823559|NCT03779581|Device|orthotic devices|the orthotic devices designed to correct the scoliosis curve
45965730|NCT00209781|Drug|Sulfadoxine-Pyrimethamine (Fansidar)|
45667354|NCT02452463|Other|Placebo|Given PO
45667355|NCT02452463|Procedure|Quality-of-Life Assessment|Ancillary studies
45823560|NCT03766321|Biological|Fecal microbiota transplantation|Fecal microbiota transplantation will be performed during two endoscopic procedures (baseline and at 6 months) by allogenic infusion of collected feces in the duodenum-jejunum.
45965731|NCT00209781|Device|ITNs|
46080350|NCT04260269|Drug|Fluoropyrimidine|"This is the assessment of a specific evaluation of cardiac safety for patients with solid tumors who have experienced cardiotoxicity grade 1-4 during treatment with a fluoropyrimidine based treatment and are re-challenged with a different fluoropyrimidine.~This multicentre, retrospective database is built to assess the impact on the cardiac and global safety of two different fluoropyrimidine based treatment regimens, of which the first has caused cardiotoxicity grade 1-4.~Cardiac data will be collected by medical record review from initiation of first fluoropyrimidine-based treatment and switch to second fluoropyrimidine-based treatment until death or last follow-up. Basic demographics, cancer and treatment information from the whole course of cancer until death or last follow-up."
45667356|NCT02432105|Drug|EXE844 Sterile Otic Suspension, 0.3%|
45823561|NCT03766321|Biological|Placebo|patients will undergo endoscopic procedure with biopsy during sedation but without any kind of intervention
45823562|NCT02636569|Drug|topical diclofenac daily|"Topical diclofenac will be applied daily for 30 days. Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from one actinic keratosis, one sun exposed area and one not sun exposed area. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have three biopsies taken; one AK, one sun exposed, and one non sun exposed."
45823563|NCT02636569|Drug|placebo|"placebo Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from, one actinic keratosis, one area that is typically exposed to the sun as well as a site that is typically protected from sun light. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have two biopsies taken. One of these biopsies will be from the skin on your arm that was treated with medication for the prior 30 days, and the other biopsy will be from a site that typically is not exposed to the sun."
45823564|NCT02461927|Drug|Ketamine + Naltrexone|Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 2 injections).
45965732|NCT00588328|Device|PET/CT scan|PET/CT scans
45667357|NCT02432105|Procedure|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
45667358|NCT02431793|Behavioral|EMC2 Strategy|Patients of providers randomized to the EMC2 arm will received study related educational tools at the time of their discharge including: (a) health-literacy appropriate MedSheet for hydrocodone-acetaminophen and (b) prescription written with Universal Medication Schedule Take-Wait-Stop language. Additionally, providers related to the patient will be prompted to counseling the patient including: (c) (c-1) ED providers prompted via EHR, (c-2) PCP prompted to counsel on follow-up visit via automated message and (c-3) pharmacists prompted to counsel via request printed on prescription.
45667359|NCT02431793|Behavioral|SMS Text Reminders|In addition to the components of the EMC2 strategy arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
45965733|NCT00588367|Device|Mayo Interactive Breath Hold Monitor|Biofeedback device
45965734|NCT00209820|Behavioral|Supervised Nordic Walking|
45667360|NCT04916327|Dietary Supplement|Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
45667361|NCT04916327|Dietary Supplement|Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
45667362|NCT03628391|Drug|Haloperidol|haloperidol for ICU delirium, titrated on validated screening tool-based diagnosis
45965735|NCT00209820|Behavioral|Unsupervised Nordic Walking|
45965736|NCT00209820|Behavioral|Advice to stay active|
45965737|NCT00182663|Drug|clarithromycin|Given PO
46080351|NCT02738970|Drug|Trastuzumab|Participants will receive a single dose of trastuzumab 600 mg SC separately, co-mixed or co-formulated with pertuzumab.
45823565|NCT02461927|Drug|Ketamine + Placebo|Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
45823566|NCT02461927|Drug|Placebo (psychoactive placebo midazolam) + Placebo|Subjects in this arm will receive (1) intravenous psychoactive placebo midazolam (0.045 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
46080352|NCT02738970|Drug|Pertuzumab|Participants will receive pertuzumab as a single agent injection, co-mixed or formulated as FDC with trastuzumab depending upon cohort. The dose will range from 400 to 1200 mg.
45667363|NCT03628391|Drug|Placebo|placebo for ICU delirium, titrated on validated screening tool-based diagnosis
45823567|NCT03736447|Biological|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
45823568|NCT03736447|Biological|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
45823569|NCT03723655|Drug|mavacamten|mavacamten capsules
45823570|NCT00002935|Drug|porfimer sodium|
45823571|NCT00002941|Drug|carmustine|
45823572|NCT00002941|Drug|cyclophosphamide|
45823573|NCT00002941|Drug|etoposide|
45823574|NCT00002941|Drug|mesna|
45823575|NCT00002941|Procedure|peripheral blood stem cell transplantation|
45823576|NCT04329793|Device|Assisted gait training with Walkbot System|The experimental group will receive at least 3 treatment sessions per week consisting of 40 minutes in robot-assisted gait training with Walkbot System in addition to their usual Physical therapy sessions. In total, the number of Walkbot sessions will be 20, in uninterrupted weeks.
45823577|NCT04329793|Other|Physical Therapy|The control group will receive their usual Physical therapy sessions during 6 weeks.
45823578|NCT00383305|Device|Cool-Cap|
45823579|NCT04329637|Other|Integrative healt care|Meditation and use of a care cordinator
45823580|NCT00002953|Drug|cyclophosphamide|
45823581|NCT00002953|Drug|epirubicin hydrochloride|
45823582|NCT00002953|Drug|paclitaxel|
45823583|NCT03705637|Drug|Exparel|"Donor sites will receive up to 50mg of 0.25marcaine with epinephrine injected uniformly into the wound.~The donor site will also receive one bottle (266mg) of Exparel, diluted to be administered uniformly into the entire donor site, spaced out ever 3-4cm. The dilution will be as follows:~o 20ml Exparel + 10ml injectable 0.9% NS (30ml) for every 100cm2 of donor site.~Injection of local anesthesia will be performed after the donor site has been harvested and is hemostatic. The goal is to provide the maximum time possible for the local anesthetic to work while under anesthesia, so it can benefit the patient and not be administered at the end of the case just prior to extubation."
45823584|NCT03693781|Drug|Colchicine 1 MG Oral Tablet|Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (>70 kg or <71 kg) for 30 weeks of duration.
45823585|NCT03693781|Drug|Colchicine 1 MG Oral Tablet|Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (>70 kg or <71 kg) for 30 weeks of duration.
45823586|NCT03693781|Drug|Placebo Oral Tablet|Corresponding tablets for 30 weeks
45823587|NCT02283853|Drug|dimethyl fumarate|administered orally
45823588|NCT02283853|Drug|Interferon β-1a|administered by intramuscular injection
45667364|NCT01801930|Drug|OCV-103 and OCV-104|0.3 mg of each
45667365|NCT01801930|Drug|OCV-103 and OCV-104|1 mg of each
45667366|NCT01801930|Drug|OCV-103 and OCV-104|3 mg of each
45667367|NCT01801930|Drug|OCV-103 and OCV-104|6 mg of each
45667368|NCT01610206|Drug|Gemcitabine|Patients will receive gemcitabine 1000 mg/m2 administered weekly on days 1 and 8 (30 minutes IV infusion) of each cycle for up to 6 cycles. Each cycle is 21 days.
45823589|NCT03670849|Device|LapAR|LapAR system will map (transform) the live LUS image in the reference frame of the laparoscopic camera, and fuse it with the live laparoscopic video in real time. For thermal ablations that involve a needle, we also track the needle and overlay its path on the AR view.
46080353|NCT02806076|Procedure|No-touch RFA arm|No-touch RFA arm indicates RFA procedure without direct tumor puncture. In this study, RFA is done by using dual cooled electrode.
46080354|NCT02806076|Procedure|Conventional tumor puncture RFA arm|"Conventional tumor puncture RFA arm indicates RFA procedure using conventional tumor puncture technique. In this study, RFA is done by using dual cooled electrode."
45965738|NCT00182663|Drug|thalidomide|Given PO
45965739|NCT00182663|Drug|dexamethasone|Given PO
45965740|NCT00588679|Other|Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging|All MR examinations will be performed on a 3.0 Tesla whole body GE MR scanner located at the main campus (1275 York Avenue) or the Breast and Imaging Center (BAIC)(located on Second Ave. between 65th and 66th Streets). The MR examination will include MR imaging and spectroscopic imaging employing a combined torso phased array and endorectal coil receiver. The examination will require one hour to one hour and ten minutes.
45667369|NCT01610206|Drug|pazopanib|Patients will receive pazopanib 800mg PO daily on days 1-21 of treatment cycles
45965741|NCT00216762|Drug|Rituximab|Rituxan ® 1000 mg IV x 2 infusions, 2 weeks apart
45455600|NCT01220323|Device|direct current stimulation|Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
45965742|NCT00588757|Device|Optease IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
45965743|NCT00588757|Device|Gunter-Tulip IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
45965744|NCT00182702|Drug|ixabepilone|Given IV
45667370|NCT04586296|Other|Telemedicine|IVR will consist of a 3 minute call at a decreasing interval from the time of surgery. Questions will assess pain control, signs of infection, prosthesis failure.
45667371|NCT04414462|Other|exergaming training|"HEADING: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~TIGHTROPE TENSION: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~SNOWBOARD SLALOM: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~TABLE TILT: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)"
45667372|NCT04414462|Other|training - Group II|"Wobble board for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~Habituation exercises for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~Double leg stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~Single leg stance with eyes open and eyes open on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~Tandem walk stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks."
45823590|NCT02401789|Device|Implants (OsseospeedTM,EV Astra Tech System, DentsplyTM, Mölndal)|
45823591|NCT03668041|Drug|Trazodone|Trazodone is approved by the Food and Drug Administration (FDA) for treating major depression in adults but not for PTSD. Although trazodone has not been approved by the FDA to treat insomnia or PTSD, some doctors have tried it for these purposes. The doses in this study will be lower than the doses used to treat depression.
45823592|NCT03668041|Drug|Eszopiclone|Eszopiclone is approved by the FDA for treating insomnia, but it's unknown if eszopiclone can help treat insomnia when it's related to PTSD. Some doctors have tried it for this purpose. The doses in this study will be the same as the doses used to treat insomnia. A small study found it to be helpful for treating patients with PTSD.
45965745|NCT00182702|Other|laboratory biomarker analysis|Correlative studies
45965746|NCT00588835|Drug|aprepitant|125mg on Day 1; 80mg on Day 2-3 during CE cycle. Dexamethasone is added as well.
45667373|NCT01816048|Drug|TAK-700|TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles
45667374|NCT01816048|Radiation|Fluorine F 18 Sodium Fluoride|Undergo NaF F18 PET/CT scan
45667375|NCT01816048|Procedure|Positron Emission Tomography|Undergo 18F NaF PET/CT scan
45823593|NCT03668041|Drug|Gabapentin|Gabapentin is an FDA approved medication for the treatment of seizures, a type of nerve pain and some forms of chronic pain. Some doctors have prescribed it for insomnia. While the total daily doses in this study are less than the usual total daily dose, the highest dose of gabapentin used in this study will be higher than the typical dose taken at a single time. Doses even higher than this have been taken and observed to be acceptable for treating patients with PTSD.
45965747|NCT00588835|Drug|Dexamethasone and Ondansetron during CE-treatment|Standard anti-emetic regimen during CE treatment
45965748|NCT00209859|Drug|Methotrexate|
45965749|NCT00209859|Drug|Intraarticular betamethasone|
45965750|NCT00209859|Drug|Cyclosporine/placebo-cyclosporine|
45965751|NCT00588913|Biological|aldesleukin|
45965752|NCT00588913|Biological|therapeutic autologous lymphocytes|
46080355|NCT00926731|Drug|AZD1152|Variable dose via a 7-day continuous infusion
46080356|NCT00926731|Drug|LDAC (low dose cytosine arabinoside)|20 mg subcutaneous injection given twice daily
45667376|NCT01816048|Procedure|Computed Tomography|Undergo 18F NaF PET/CT scan
45965753|NCT00588913|Drug|zoledronic acid|
45965754|NCT00182741|Dietary Supplement|calcitriol|
45965755|NCT00182741|Drug|mitoxantrone hydrochloride|
45965756|NCT00182741|Drug|prednisone|
45965757|NCT00589030|Radiation|brachytherapy|The target dose of TheraSphere® is 80-150Gy
45965758|NCT00589030|Radiation|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150Gy
45965759|NCT00589147|Device|The Zimmer NexGen Legacy Knee System, modular cemented tibia|modular cemented tibia
45965760|NCT00589147|Device|The Zimmer NexGen Legacy Knee System, non-modular cemented tibia.|non-modular cemented tibia.
45965761|NCT00589147|Device|The Zimmer NexGen Legacy Knee System, non-modular uncemented tibia|non-modular uncemented tibia
45965762|NCT00589186|Biological|Ad5F35-LMP1/LMP2-transduced autologous dendritic cells|
45965763|NCT00589186|Drug|celecoxib|
45965764|NCT00589186|Other|flow cytometry|
45965765|NCT00589186|Other|immunoenzyme technique|
45965766|NCT00589186|Other|laboratory biomarker analysis|
45965767|NCT00182780|Dietary Supplement|American ginseng|
45965768|NCT00182780|Other|Placebo|
45667377|NCT01612858|Drug|Metformin|Metformin at a dose of one 500mg tablet twice a day with meals for one week, after which the dose will increase to 500 mg three times a day with meals for the remaining 11 weeks of the study.
45965769|NCT00589225|Genetic|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic testing.
46080357|NCT02805686|Device|spectral domain optical coherence tomography|
45455601|NCT01223677|Behavioral|Rumination Focused CBT|see arms
45823594|NCT03668041|Other|Placebo|The active study medications listed above will be compared with a placebo, which is a pill that looks like a study medication but has no medication in it.
45823595|NCT04329247|Other|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
45667378|NCT01612858|Drug|Pioglitazone|Pioglitazone at a dose of one 30 mg tablet once per day for the 12 weeks of the study.
45667379|NCT04581850|Behavioral|Sleep recording|Sleep is recorded at home during 7 nights in a row using a connected headband. The participant also has to fill in a sleep agenda every day.
45667380|NCT04581850|Behavioral|Cognitive tasks|Working memory and inhibition capacity is assessed during computer-based tasks (2-back and Go/No-Go tasks) at enrollment and 1 month after enrollment.
45667381|NCT04581850|Other|Questionnaires|"The participant has to fill in several questionnaires at enrollment and 1 month after enrollment in order to assess:~PTSD severity~chronotype~Sleep quality~Daytime sleepiness~Mood state~Depression~Mental disorders and their consequences"
45667382|NCT04585984|Dietary Supplement|Experimental - Probiotic|Patients in the experimental group will take one compound (pill) a day for 21 days, containing a 50% combination of two probiotics: Lactobacillus rhamnosus and Bifidobacterium longum, at a dose of 10^9 cfu/day. The carrier of lyophilized probiotics is maltodextrin and the mixture is encapsulated in hypromellose capsules.
45667383|NCT04585984|Dietary Supplement|Placebo|Patients in the control group will take one unit of placebo a day for 21 days.
45667384|NCT01612780|Device|XprESS Multi-Sinus Dilation Tool|Sinus balloon dilation
45823596|NCT00002965|Biological|Recombinant Interferon Alfa (INF alpha)|Subcutaneous injection Monday through Friday for 8 weeks.
45823597|NCT02263417|Device|Deep Brain Stimulation (DBS) of Gpi|
45823598|NCT02263417|Device|Deep Brain Stimulation (DBS) of STN|
45823599|NCT02116699|Other|oropharyngeal mother's milk|Application of 0.2 mL of own mother's milk onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
45823600|NCT02116699|Other|oropharyngeal sterile water|Application of 0.2 mL of sterile water onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
45823601|NCT00002971|Drug|O6-benzylguanine|
45823602|NCT00002977|Biological|filgrastim|
45965770|NCT00589264|Dietary Supplement|zinc|10 mg elemental zinc + 10 mg elemental iron + 0.5 mg copper syrup taken daily for 1 year, from 6 to 18 months of age
45455602|NCT01125943|Drug|Acetylcholine|Intra-arterial infusion
45455603|NCT01125943|Drug|Nitroprusside|Intra arterial infusion
45823603|NCT00002977|Drug|melphalan|
45823604|NCT00002977|Drug|thiotepa|
45965771|NCT00589264|Dietary Supplement|iron + copper|10 mg elemental iron + 0.5 mg copper in syrup given daily for one year from 6 months to 18 months of age
45965772|NCT00589381|Drug|fenretinide lipid matrix|
46080358|NCT02805686|Device|multifocal electroretinogram|
46080359|NCT04259957|Device|Immersive Virtual Reality|Immersive virtual reality games and mindfulness in Oculus Quest Virtual Reality headset
46080360|NCT02729454|Other|Mental practice and physical therapy|
46080361|NCT02729454|Other|physical therapy|
46080362|NCT00926809|Drug|Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin|Lansoprazole, Amoxicillin 1000 mg, Clarithromycin 500 mg
46080363|NCT00926809|Drug|Lansoprazole (proton pump inhibitor), placebo|Lansoprazole, Amoxicillin placebo, Clarythromycin placebo
46080364|NCT02805920|Drug|Bupivacaine|comparison of different volumes-dosages of 0.25% Bupivacaine
45455604|NCT01125943|Drug|Bevacizumab|Intra arterial infusion
45667385|NCT01612702|Drug|Dexamethasone|Dexamethasone 10 mg intravenous administration
45667386|NCT02431559|Drug|Durvalumab|Durvalumab is administered as an IV infusion over 60 ± 5 minutes.
45667387|NCT02431559|Drug|Pegylated Liposomal Doxorubicin|PLD was administered as an IV infusion in accordance with local prescribing information.
45823605|NCT00002977|Procedure|peripheral blood stem cell transplantation|
45823606|NCT00003391|Biological|monoclonal antibody muJ591|
45823607|NCT00003397|Biological|filgrastim|
45823608|NCT00003397|Biological|rituximab|
45823609|NCT00003397|Biological|sargramostim|
45823610|NCT00003397|Drug|carmustine|
45823611|NCT00003397|Drug|cisplatin|
45823612|NCT00003397|Drug|cyclophosphamide|
45823613|NCT00003397|Drug|dexamethasone|
45823614|NCT00003397|Drug|etoposide|
45823615|NCT00003397|Drug|gemcitabine hydrochloride|
45823616|NCT00003397|Drug|melphalan|
45823617|NCT00003397|Drug|paclitaxel|
45823618|NCT00003397|Procedure|bone marrow ablation with stem cell support|
45823619|NCT00003397|Procedure|peripheral blood stem cell transplantation|
45823620|NCT00384319|Device|ThermoSuit(R) System|The ThermoSuit device is used to cool patients using direct contact of the skin with cold water.
45823621|NCT00003403|Drug|GPX-100|
45823622|NCT00383383|Biological|Hepatitis B adjuvanted vaccine|
45823623|NCT00383383|Biological|Engerix-B|
45823624|NCT00003409|Drug|motexafin gadolinium|
45823625|NCT00003409|Radiation|radiation therapy|
45823626|NCT00003415|Drug|amifostine trihydrate|
45823627|NCT00003415|Drug|topotecan hydrochloride|
45823628|NCT00002989|Drug|busulfan|
45823629|NCT00002989|Drug|cyclophosphamide|
45823630|NCT00002989|Drug|idarubicin|
45965773|NCT00209898|Procedure|Fast initiation procedure|
45965774|NCT00182819|Drug|temozolomide|Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles
45823631|NCT00002989|Drug|melphalan|
45823632|NCT00002989|Radiation|radiation therapy|
45823633|NCT00002995|Biological|dactinomycin|
45823634|NCT00002995|Biological|filgrastim|
45823635|NCT00002995|Biological|sargramostim|
45823636|NCT00002995|Drug|cyclophosphamide|
45823637|NCT00002995|Drug|vincristine sulfate|
45823638|NCT00002995|Radiation|radiation therapy|
45823639|NCT00003001|Drug|fluorouracil|
45823640|NCT00003001|Drug|gemcitabine hydrochloride|
45823641|NCT00003001|Drug|leucovorin calcium|
45823642|NCT00003421|Biological|bleomycin sulfate|
45823643|NCT00003421|Drug|ABVD regimen|
45823644|NCT00003421|Drug|chlorambucil|
45823645|NCT00003421|Drug|dacarbazine|
45823646|NCT00003421|Drug|doxorubicin hydrochloride|
45823647|NCT00003421|Drug|etoposide|
45823648|NCT00003421|Drug|prednisolone|
45823649|NCT00003421|Drug|procarbazine hydrochloride|
45823650|NCT00003421|Drug|vinblastine sulfate|
45823651|NCT00003421|Drug|vincristine sulfate|
45823652|NCT00003421|Radiation|radiation therapy|
45823653|NCT01588015|Biological|tetanus-CMV fusion peptide vaccine|Given SC
45823654|NCT01588015|Other|laboratory biomarker analysis|Correlative studies
45823655|NCT00003427|Drug|irinotecan hydrochloride|
45823656|NCT00003427|Drug|oxaliplatin|
45823657|NCT00002947|Radiation|indium In 111 pentetreotide|
45823658|NCT00003433|Biological|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|
45823659|NCT00003439|Biological|recombinant interleukin-12|
45965775|NCT00182819|Radiation|radiation therapy|50.4 Gy, standard fractionation (28 x 1.8 Gy), conformal techniques
46080365|NCT04262765|Drug|Ramipril, Amlodipine and Atorvastatin|compare the pharmacokinetic of ramipril (and ramiprilat), atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate from reference products given as a multiple dose
45823660|NCT00003007|Biological|recombinant interferon alfa|
45823661|NCT00003007|Biological|sargramostim|
45823662|NCT00003007|Drug|cyclophosphamide|
45823663|NCT00003007|Drug|dexamethasone|
45823664|NCT00003007|Drug|melphalan|
45823665|NCT00003007|Procedure|peripheral blood stem cell transplantation|
45823666|NCT01478035|Drug|Phenytoin|Phenytoin 18 mg /Kg/day iv as loading dose. 24 hours later phenytoin 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
45823667|NCT01478035|Drug|placebo|Placebo 18 mg /Kg/day iv as loading dose. 24 hours later placebo 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
45823668|NCT00003013|Drug|CMF regimen|
45823669|NCT00003013|Drug|cyclophosphamide|
45823670|NCT00003013|Drug|doxorubicin hydrochloride|
45823671|NCT00003013|Drug|fluorouracil|
45823672|NCT00003013|Drug|methotrexate|
45823673|NCT00003013|Drug|paclitaxel|
45823674|NCT00003013|Drug|tamoxifen citrate|
45823675|NCT00003013|Procedure|conventional surgery|
45823676|NCT00003013|Radiation|radiation therapy|
45823677|NCT00003445|Drug|docetaxel|
45823678|NCT00003451|Biological|recombinant interferon alfa|
45823679|NCT00003451|Biological|recombinant interleukin-12|
45823680|NCT00003463|Drug|carmustine|
45823681|NCT00003463|Drug|irinotecan hydrochloride|
45823682|NCT00003463|Drug|polifeprosan 20 with carmustine implant|
45823683|NCT00003463|Procedure|surgical procedure|
45823684|NCT01338649|Device|Bright Light Treatment (Sun Ray Sunbox SB-558)|Bright Light Treatment (Sun Ray Sunbox SB-558) using light intensity of 10,000 lux, administered during two 1 hour periods during the day.
45823685|NCT01338649|Device|Dim red light (Sun Ray Sunbox SB-558)|Dim red light box administered during two 1 hour periods during the day using
45823686|NCT00003019|Drug|methotrexate|
45823687|NCT00003019|Drug|vinblastine sulfate|
45823688|NCT01247233|Radiation|Whole Breast Irradiation + Boost or Hypofractionated irradiation|Whole Breast Irradiation 50 Gy + Boost 16 Gy or Whole breast, either 40 Gy in 15 fractions in 3 weeks or 42.5 Gy in 16 fractions in 3 weeks
45823689|NCT01247233|Radiation|Accelerated partial breast irradiation|Tumor bed 40 Gy in 10 fractions, 2 fractions of 4 Gy per day in 5 to 7 days.
45823690|NCT01120249|Drug|everolimus|Given orally
45823691|NCT01120249|Other|placebo|Given orally
45823692|NCT00003493|Drug|dexamethasone|
45823693|NCT00003493|Drug|pegylated liposomal doxorubicin hydrochloride|
45823694|NCT00003493|Drug|vincristine sulfate|
45823695|NCT00788125|Drug|carboplatin|
45823696|NCT00788125|Drug|dasatinib|
45823697|NCT00788125|Drug|etoposide phosphate|
45823698|NCT00788125|Drug|ifosfamide|
45823699|NCT00788125|Genetic|microarray analysis|
45823700|NCT00788125|Genetic|western blotting|
45823701|NCT00788125|Other|immunohistochemistry staining method|
45823702|NCT00788125|Other|laboratory biomarker analysis|
45823703|NCT00788125|Procedure|therapeutic conventional surgery|
45823704|NCT00788125|Radiation|radiation therapy|
45823705|NCT00003505|Drug|antineoplaston A10|
45823706|NCT00003505|Drug|antineoplaston AS2-1|
45823707|NCT00003505|Procedure|alternative product therapy|
45823708|NCT00003505|Procedure|biological therapy|
45823709|NCT00003505|Procedure|biologically based therapies|
45823710|NCT00003505|Procedure|cancer prevention intervention|
45823711|NCT00003505|Procedure|complementary and alternative therapy|
45823712|NCT00003505|Procedure|differentiation therapy|
45823713|NCT00003025|Biological|vitespen|
45823714|NCT00003031|Drug|amphotericin B deoxycholate|
45823715|NCT00003031|Drug|voriconazole|
45823716|NCT00003517|Drug|antineoplaston A10|
45823717|NCT00003517|Drug|antineoplaston AS2-1|
45823718|NCT00003517|Drug|bicalutamide|
45823719|NCT00003517|Drug|flutamide|
45823720|NCT00003517|Drug|leuprolide acetate|
45667388|NCT02431559|Drug|Motolimod|Motolimod was administered as an SC injection. Within 30 minutes prior to each dose of motolimod, subjects were administered 650-1000 mg acetaminophen by mouth to help mitigate potential adverse events (AEs) commonly associated with the administration of motolimod (e.g., fever, myalgia). On days with concurrent motolimod and durvalumab dosing, motolimod administration occurred 30-60 minutes after the end of the durvalumab infusion. After completion of Phase 1, a protocol amendment was implemented to remove motolimod dosing from the study.
45823721|NCT00003517|Procedure|alternative product therapy|
45823722|NCT00003517|Procedure|antiandrogen therapy|
45823723|NCT00003517|Procedure|biological therapy|
45823724|NCT00003517|Procedure|biologically based therapies|
45823725|NCT00003517|Procedure|cancer prevention intervention|
45823726|NCT00003517|Procedure|complementary and alternative therapy|
45823727|NCT00003517|Procedure|differentiation therapy|
45823728|NCT00003517|Procedure|endocrine therapy|
45823729|NCT00003517|Procedure|hormone therapy|
45823730|NCT00003523|Drug|aminocamptothecin colloidal dispersion|
45823731|NCT00383461|Behavioral|smoking cessation intervention|
45667389|NCT04910399|Dietary Supplement|Blue fish hydrolysate|"The experimental product is a dietary supplement composed of a hydrolysate of fatty blue fish containing low molecular weight peptides and n-3 polyunsaturated fatty acids.~One of the two study groups (28 volunteers) will take 4 capsules of the active product (blue fish hydrolysate), for 90 days.~Each day the capsules will be taken as followed : 2 capsules in the morning and 2 capsules in the evening."
45823732|NCT00383461|Other|counseling intervention|
45823733|NCT00003037|Drug|cisplatin|
45823734|NCT00003037|Drug|docetaxel|
45965776|NCT00589498|Dietary Supplement|1000 extra calories|Each subject received 1000 kcal/d in addition to weight maintenance requirements. The diet composition throughout the study was 40% carbohydrate, 40% fat, and 20% protein.
45965777|NCT00589537|Other|questionnaire administration|
45965778|NCT00589537|Procedure|computed tomography|
46080366|NCT03112434|Drug|Botulinum toxin type A|Botox injection in upper extremity for spasticity in pediatric CP patients
45823735|NCT00003037|Drug|gemcitabine hydrochloride|
45823736|NCT00002803|Drug|cyclophosphamide|
45823737|NCT00002803|Drug|doxorubicin hydrochloride|
45823738|NCT00002803|Drug|vincristine sulfate|
45823739|NCT00002803|Procedure|conventional surgery|
45823740|NCT00383929|Drug|Candesartan cilexetil|32mg oral
45823741|NCT00383929|Drug|Hydrochlorothiazide|12.5 mg oral
45823742|NCT00383929|Drug|Hydrochlorothiazide|25 mg oral
45823743|NCT00003541|Biological|filgrastim|
45823744|NCT00003541|Drug|CHOP regimen|
45823745|NCT00003541|Drug|carboplatin|
45823746|NCT00003541|Drug|cyclophosphamide|
45823747|NCT00003541|Drug|doxorubicin hydrochloride|
45823748|NCT00003541|Drug|etoposide|
45823749|NCT00003541|Drug|ifosfamide|
45823750|NCT00003541|Drug|prednisone|
45823751|NCT00003541|Drug|vincristine sulfate|
45823752|NCT00003541|Procedure|peripheral blood stem cell transplantation|
45823753|NCT00003541|Radiation|radiation therapy|
45823754|NCT00002809|Biological|anti-thymocyte globulin|
45823755|NCT00002809|Biological|filgrastim|
45823756|NCT00002809|Biological|sargramostim|
45823757|NCT00002809|Biological|therapeutic immune globulin|
45823758|NCT00002809|Drug|cyclophosphamide|
45823759|NCT00002809|Drug|methotrexate|
45823760|NCT00002809|Drug|tacrolimus|
45823761|NCT00002809|Procedure|allogeneic bone marrow transplantation|
45823762|NCT00002809|Radiation|radiation therapy|
45823763|NCT00003553|Other|HLA Matched Peripheral BLood Stem Cells|Cell Product
45823764|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Vaccine Lot 1
45823765|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Vaccine Lot 2
45823766|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Vaccine Lot 3
45823767|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Control Vaccine
45823768|NCT00002827|Biological|bleomycin sulfate|Given IV
45823769|NCT00002827|Biological|filgrastim|Given IV
45823770|NCT00002827|Drug|dexrazoxane hydrochloride|Given IV
45823771|NCT00002827|Drug|doxorubicin hydrochloride|Given IV
45823772|NCT00002827|Drug|etoposide|Given IV
45823773|NCT00002827|Drug|vincristine sulfate|Given IV
45823774|NCT00002827|Radiation|low-LET cobalt-60 gamma ray therapy|
45823775|NCT00002827|Radiation|low-LET electron therapy|
45823776|NCT00002827|Radiation|low-LET photon therapy|
45823777|NCT00384475|Drug|Ciclesonide Nasal Spray|
45823778|NCT00003565|Drug|docetaxel|
45823779|NCT00003049|Drug|fluorouracil|
45823780|NCT00003049|Drug|leucovorin calcium|
45823781|NCT00003049|Procedure|conventional surgery|
45823782|NCT00003049|Radiation|radiation therapy|
45823783|NCT00003055|Drug|cisplatin|
45823784|NCT00003055|Drug|irinotecan hydrochloride|
45823785|NCT00002833|Biological|Filgrastim|Donors receive Filgrastim SC (Subcutaneously) every 12 hours for 2 days prior to stem cell collection.
45823786|NCT00002833|Drug|Cladribine|Continuous infusion for 5 days, beginning 4 hours before Ara-C first dose.
45823787|NCT00002833|Drug|Cyclosporine|For GVHD prophylaxis, cyclosporine via continuous IV infusion. Oral cyclosporine administered once tolerating oral feeding and continued for 6 months postinfusion. Then dose tapered 10% weekly until discontinued.
45823788|NCT00002833|Drug|Cytarabine (Ara-C)|Group 1A: Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3; Group 1B: Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours.
45965779|NCT00589537|Procedure|magnetic resonance imaging|
45965780|NCT00589537|Procedure|quality-of-life assessment|
45965781|NCT00216840|Drug|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
45965782|NCT00589615|Behavioral|multidisciplinary osteoporosis prevention educational program|The program includes individualized counseling aimed at improving diet, muscle strength, balance, and informing individuals about home hazards and the use of medicine.
45455605|NCT03927859|Other|a mail letter, a phone call and a phone call plus mailed letter|"All patients will be administered an intervention that will contain one or more of 3 possible interventions (a mail letter, a phone call and a mail plus phone call). Some patients will also be assigned into a condition where none of the interventions will be present.~Patients at Black Creek CHC will only be offered a phone or a phone plus incentive intervention or a no intervention."
45823789|NCT00002833|Drug|Fludarabine Phosphate|IV over 30 minutes daily on days -6, -5, -4 and -3.
45823790|NCT00002833|Drug|Idarubicin|IV Days -6, -5 and -4.
45455606|NCT01129453|Biological|CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine|CVD 1902 consists of ΔguaBA, ΔclpX Salmonella enterica serovar Paratyphi A vaccine strain diluted in sterile phosphate buffered saline to achieve the desired inoculum. Form: liquid. Dose: 10^6, 10^7, 10^8, or 10^9 CFU per mL. Route: oral.
45667390|NCT04910399|Dietary Supplement|Placebo|"The placebo product containing mainly maltodextrin is presented in the same form as the active product, so that people handling the product cannot distinguish between them. The placebo is flavoured in order to have a fishy smell just like the active product.~One of the two study groups (28 volunteers) will take 4 capsules of placebo per day, for 90 days.Each day the capsules will be taken as followed : 2 capsules in the morning and 2 capsules in the evening."
45823791|NCT00002833|Drug|Methylprednisolone|Begins 5 days after infusion and is gradually tapered.
45823792|NCT00002833|Procedure|Peripheral Blood Stem Cell Transplantation|Cell infusion Day 0.
45823793|NCT00003061|Drug|cytarabine|
45823794|NCT00003061|Drug|methotrexate|
45823795|NCT00003061|Radiation|radiation therapy|
45823796|NCT00003571|Genetic|mutation analysis|
45823797|NCT00003571|Genetic|tumor replication error analysis|
45823798|NCT00003577|Drug|CMF regimen|
45823799|NCT00003577|Drug|cyclophosphamide|
46080367|NCT00933751|Device|Central vein catheterization|Blood samplings from IVC catheter
46080368|NCT04185584|Other|Not Applicable (Observational Study)|Not Applicable (Observational Study)
45667391|NCT04926545|Drug|Xiao Chai Hu Tang (XCHT)|"XCHT 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, except the 1st cycle of chemotherapy for irinotecan used cohort patients.~Additional XCHT, 9g qd will be orally administrated for 4 days during the Round 0 study for irinotecan naive cohort patients."
45667392|NCT04926545|Other|Raloxifene|Raloxifene 60mg po, used as probe for pharmacokinetic testing. For irinotecan naive cohort patients, raloxifene 60mg will be orally administrated on Day 1 and Day 5 (4th day of XCHT administration) during round 0 study, Day 3 (the day before chemotherapy) during round 2 and round 3 study. For irinotecan used cohort patients, raloxifene 60mg will be orally administrated on Day 1 (irinotecan using day) during round 1 study, Day 4 (irinotecan using day) during round 2 study, and Day 3 (the day before chemotherapy) during round 3 study.
45823800|NCT00003577|Drug|epirubicin hydrochloride|
45823801|NCT00003577|Drug|fluorouracil|
45823802|NCT00003577|Drug|methotrexate|
45823803|NCT00003577|Procedure|adjuvant therapy|
45823804|NCT00003577|Radiation|radiation therapy|
45823805|NCT00002839|Drug|cisplatin|
45823806|NCT00002839|Drug|fluorouracil|
45823807|NCT00002839|Procedure|conventional surgery|
45823808|NCT00002839|Procedure|neoadjuvant therapy|
45823809|NCT00002839|Radiation|radiation therapy|
45823810|NCT00003583|Drug|amifostine trihydrate|
45823811|NCT00003583|Drug|cisplatin|
45823812|NCT00003583|Drug|etoposide|
45823813|NCT00003583|Radiation|radiation therapy|
45823814|NCT00002845|Biological|aldesleukin|
45823815|NCT00003067|Biological|aldesleukin|
45823816|NCT00003067|Biological|lymphokine-activated killer cells|
45823817|NCT00003589|Drug|cisplatin|
45823818|NCT00003589|Drug|gemcitabine hydrochloride|
45823819|NCT00003589|Drug|paclitaxel|
45823820|NCT00002851|Procedure|adjuvant therapy|
45823821|NCT00002851|Radiation|low-LET electron therapy|
45823822|NCT00002851|Radiation|low-LET photon therapy|
45823823|NCT00003595|Biological|filgrastim|
45823824|NCT00003595|Biological|rituximab|
45823825|NCT00003595|Drug|CHOP regimen|
45823826|NCT00003595|Drug|cyclophosphamide|
45823827|NCT00003595|Drug|doxorubicin hydrochloride|
45823828|NCT00003595|Drug|prednisone|
45823829|NCT00003595|Drug|vincristine sulfate|
45823830|NCT00003073|Drug|liposomal cytarabine|
45823831|NCT00002863|Drug|chemotherapy|
45823832|NCT00002863|Procedure|conventional surgery|
45823833|NCT00002863|Procedure|cryosurgery|
45823834|NCT00003079|Drug|bryostatin 1|
45823835|NCT00003079|Drug|cytarabine|
45823836|NCT00002869|Biological|recombinant interferon alfa|
45823837|NCT00002869|Drug|cytarabine|
45823838|NCT00002869|Drug|hydroxyurea|
45823839|NCT00002875|Biological|filgrastim|
45823840|NCT00002875|Drug|cisplatin|
45823841|NCT00002875|Drug|cyclophosphamide|
45823842|NCT00002875|Drug|lomustine|
45823843|NCT00002875|Drug|mesna|
45823844|NCT00002875|Drug|vincristine sulfate|
45823845|NCT00002875|Radiation|low-LET electron therapy|
45823846|NCT00002875|Radiation|low-LET photon therapy|
45823847|NCT00003607|Radiation|radiation therapy|
45823848|NCT00003613|Drug|O6-benzylguanine|Given IV
45823849|NCT00003613|Drug|carmustine|Given topically
45823850|NCT00003613|Other|laboratory biomarker analysis|Correlative studies
45823851|NCT00003085|Procedure|laparoscopy|
45823852|NCT00003085|Procedure|ultrasound imaging|
45823853|NCT00002881|Drug|flutamide|
45823854|NCT00002881|Drug|goserelin acetate|
45823855|NCT00002881|Drug|leuprolide acetate|
45823856|NCT00002881|Drug|suramin|
45823857|NCT00002881|Drug|therapeutic hydrocortisone|
45823858|NCT00002881|Procedure|orchiectomy|
45823859|NCT00003091|Biological|aldesleukin|
45823860|NCT00003091|Biological|recombinant interferon alfa|
45823861|NCT00003619|Biological|filgrastim|
45823862|NCT00003619|Dietary Supplement|vitamin E|
45823863|NCT00003619|Drug|busulfan|
45823864|NCT00003619|Drug|cytarabine|
46080369|NCT02738814|Drug|propofol|When severe emergence agitation(PAED > 13) is occurred, Pharmacologic treatment of emergence agitation relies on the administration of IV propofol 0.8 or 1 mg/kg.
46080370|NCT05148455|Other|standard-of-care clinical skin examination|inspection of melanocytic nevi by dermatologist
45823865|NCT00003619|Drug|etoposide|
45823866|NCT00003619|Drug|fludarabine phosphate|
46080371|NCT05148455|Diagnostic Test|skin assessment with the 2D FotoFinder ATBM master system|The FotoFinder® ATBM master device provides the combination of total body mapping with deep learning-driven body scan algorithm which identifies all pigmented skin lesions of the body surface by pattern recognition software and supplies a risk assessment score (0.0-1.0; 0 indicating no suspicion for melanoma, 1 indicating a high suspicion for melanoma).The integrated software analyzer scores regarding malignancy probability of the moles (FotoFinder® score: 0.0-1.0) will be collected.
46080372|NCT05148455|Other|data collection by participant questionnaire|At baseline, the participants will complete a questionnaire concerning their previous exposure to sun, their current sun-related protective behaviours, their history of skin check frequency and skin cancer at baseline. Additionally, in each consultation newly-created study-specific questions concerning the participants' examination experience, the sun-related protective behaviours and worries about skin cancer throughout the study will be investigated.
45667393|NCT04926545|Drug|FOLFIRI regimen|Patients will receive 3 cycles of FOLFIRI regimen for chemotherapy. Irinotecan intravenous (IV) infusion (180 mg/m2) through a drip into the bloodstream over 90 minutes. Folinic acid (400 mg/m2) IV infusion through a drip into the bloodstream over 2 hours. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) into the bloodstream over 5 minutes, followed by 5-FU (2400 mg/m2) continuous IV infusion through a drip or pump into the bloodstream for 46-48 hours.
46080373|NCT00933829|Procedure|Absorbable Suture Arm|use of irradiated polyglactin 910
46080374|NCT00933829|Device|Non-absorbable suture (Prolene)|suture
45823867|NCT00003619|Drug|isotretinoin|
45823868|NCT00003619|Drug|topotecan hydrochloride|
45823869|NCT00003619|Procedure|bone marrow ablation with stem cell support|
45823870|NCT00003619|Procedure|peripheral blood stem cell transplantation|
45823871|NCT00002887|Drug|cisplatin|
45823872|NCT00002887|Drug|etoposide|
45823873|NCT00002887|Drug|hydroxyurea|
45823874|NCT00002887|Drug|vinblastine sulfate|
45823875|NCT00002887|Drug|vindesine|
45823876|NCT00002887|Drug|vinorelbine tartrate|
45823877|NCT00002887|Procedure|drug resistance inhibition treatment|
45823878|NCT00003937|Drug|cisplatin|
45823879|NCT00003937|Drug|dexrazoxane hydrochloride|
45823880|NCT00003937|Drug|doxorubicin hydrochloride|
45823881|NCT00003937|Drug|etoposide|
45823882|NCT00003937|Drug|ifosfamide|
45823883|NCT00003937|Drug|methotrexate|
45823884|NCT00003937|Procedure|conventional surgery|
45823885|NCT00003625|Drug|cyclosporine|
45823886|NCT00003625|Drug|etoposide|
45667394|NCT02388269|Device|gammaCore®-G|The gammaCore®-G device is a reusable, hand-held, portable device consisting of two 3.0 VDC batteries (not replaceable or user serviceable), signal generating and amplifying electronics, and two buttons for operator control of the signal amplitude. The device provides visible (light display) and audible feedback on device and stimulation status
45823887|NCT00003625|Drug|vincristine sulfate|
45667395|NCT01652573|Drug|nasal salmon calcitonin|400 IU daily in two sprays (one to each nares)
45823888|NCT00003625|Radiation|radiation therapy|
45823889|NCT00003637|Drug|cisplatin|
45823890|NCT00003637|Drug|fluorouracil|
45823891|NCT00003637|Radiation|radiation therapy|
45823892|NCT00003097|Other|preventative dietary intervention|
45823893|NCT00003943|Biological|filgrastim|5 ug/kg
45823894|NCT00003943|Drug|carboplatin|AUC 5
45823895|NCT00003943|Drug|cyclophosphamide|3 gm/m2
45823896|NCT00003943|Drug|paclitaxel|250 mg/m2
45823897|NCT00003943|Drug|topotecan hydrochloride|10 mg/m2
45823898|NCT00003943|Procedure|peripheral blood stem cell transplantation|harvest via apheresis
45823899|NCT00003955|Biological|dactinomycin|
45823900|NCT00003955|Biological|filgrastim|
45823901|NCT00003955|Biological|pegfilgrastim|
45823902|NCT00003955|Biological|sargramostim|
45823903|NCT00003955|Drug|cyclophosphamide|
45965783|NCT00589732|Drug|Valsartan|Valsartan 160mg per day
45667396|NCT01652573|Drug|Saline Nasal Spray Placebo|
45667397|NCT02388191|Drug|Naproxen sodium|550 mg, oral, on day 1. Number of Cycles: 1
45667398|NCT02388191|Other|Placebo tablet|
45667399|NCT01815736|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
45823904|NCT00003955|Drug|irinotecan hydrochloride|
45823905|NCT00003955|Drug|vincristine sulfate|
45823906|NCT00003955|Radiation|radiation therapy|
45823907|NCT00003103|Biological|oblimersen sodium|
45823908|NCT00003103|Drug|docetaxel|
45823909|NCT00003109|Drug|irinotecan hydrochloride|
45823910|NCT00003109|Drug|raltitrexed|
45823911|NCT00003643|Biological|bleomycin sulfate|
45823912|NCT00003643|Biological|filgrastim|
45965784|NCT00182897|Behavioral|Skills Building for Caregiver Health and Care-recipient|
46080375|NCT00933829|Procedure|suture|non-absorable sutures and absorable sutures
45667400|NCT01815736|Drug|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
45667401|NCT01815736|Drug|EFV/FTC/TDF|600/200/300 mg FDC tablet administered orally once daily
45667402|NCT01815736|Drug|RTV|100 mg tablet administered orally once daily
45667403|NCT01815736|Drug|ATV|300 mg capsule administered orally once daily
45823913|NCT00003643|Drug|cisplatin|
45823914|NCT00003643|Drug|etoposide|
45823915|NCT00003643|Drug|paclitaxel|
45823916|NCT00003961|Biological|sargramostim|
45823917|NCT00003661|Biological|anti-thymocyte globulin|
45823918|NCT00003661|Drug|busulfan|
45823919|NCT00003661|Drug|cyclosporine|
45823920|NCT00003661|Drug|melphalan|
45823921|NCT00003661|Drug|methylprednisolone|
45823922|NCT00003661|Procedure|umbilical cord blood transplantation|
45823923|NCT00003661|Radiation|radiation therapy|
45823924|NCT00003967|Drug|etoposide|
45823925|NCT00003967|Drug|topotecan hydrochloride|
45823926|NCT00003115|Drug|hydromorphone hydrochloride|
45823927|NCT00003667|Drug|cyclophosphamide|
45823928|NCT00003667|Drug|dexrazoxane hydrochloride|
45823929|NCT00003667|Drug|disaccharide tripeptide glycerol dipalmitoyl|
45823930|NCT00003667|Drug|doxorubicin hydrochloride|
45823931|NCT00003667|Drug|vincristine sulfate|
45823932|NCT00003667|Procedure|surgical procedure|
45823933|NCT00003667|Radiation|radiation therapy|
45823934|NCT00003979|Drug|CHS 828|
45823935|NCT00003673|Drug|chemotherapy|
45823936|NCT00003673|Drug|gemtuzumab ozogamicin|
45823937|NCT00003679|Drug|cyclophosphamide|
45823938|NCT00003679|Drug|docetaxel|
45823939|NCT00003679|Drug|doxorubicin hydrochloride|
45823940|NCT00003679|Drug|tamoxifen citrate|
45823941|NCT00003679|Procedure|conventional surgery|
45823942|NCT00003679|Radiation|radiation therapy|
45823943|NCT00003985|Drug|KRN7000|
45823944|NCT00384553|Drug|Rituximab|
45823945|NCT00384553|Drug|DHAP|
45823946|NCT00384553|Drug|TEC|
45823947|NCT00384553|Drug|autologous stem cell transplantation|
45823948|NCT00003991|Biological|aldesleukin|
45823949|NCT00003991|Drug|histamine dihydrochloride|
45823950|NCT00003997|Drug|irofulven|
45823951|NCT00384631|Other|subconjunctival normal saline|0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals
45823952|NCT00384631|Drug|Avastin|intravitreal injection of avastin 2.5mg repeated twice at monthly intervals
45823953|NCT00003127|Drug|amifostine trihydrate|740 mg/m2 IV, Day 1, q 28 days X 6 cycles
45823954|NCT00003127|Drug|carboplatin|target AUC=6, IV Day 1, q 28 days X 6 cycles
45823955|NCT00003127|Drug|paclitaxel|175 mg/m2, IV, Day 1 q 28 days X 6 cycles
45823956|NCT00004003|Drug|cisplatin|
45823957|NCT00004003|Drug|fluorouracil|
45823958|NCT00004003|Drug|gemcitabine hydrochloride|
45823959|NCT00004009|Drug|tipifarnib|
45965785|NCT00589771|Drug|Saccharomyces boulardii|"Saccharomyces boulardii one capsule 250mg TDS for 6 weeks~Ispaghula husk 1 Tsf daily after dinner for six weeks"
45965786|NCT00589771|Drug|Placebo|"Cap Placebo TDS for six weeks~Ispaghula husk 1 Tsf daily after dinner for six weeks"
45965787|NCT00216879|Drug|Calcipotriol plus betamethasone dipropionate gel (LEO 80185)|
45965788|NCT00589927|Drug|cilostazol|cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
45965789|NCT00589927|Drug|placebo|placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
45823960|NCT00003133|Biological|filgrastim|
45667404|NCT01815736|Drug|FTC/TDF|200/300 mg tablet administered orally once daily
45823961|NCT00003133|Drug|cisplatin|
45823962|NCT00003133|Drug|doxorubicin hydrochloride|
45823963|NCT00003133|Drug|gemcitabine hydrochloride|
45823964|NCT00003133|Drug|paclitaxel|
45823965|NCT00003685|Procedure|fatigue assessment and management|
45823966|NCT00003685|Procedure|nausea and vomiting therapy|
45823967|NCT00003685|Procedure|pain therapy|
45823968|NCT00003685|Procedure|quality-of-life assessment|
45823969|NCT00003685|Radiation|radiation therapy|
45823970|NCT00004015|Drug|sodium borocaptate|
45823971|NCT00004015|Procedure|adjuvant therapy|
45823972|NCT00003691|Biological|filgrastim|
45823973|NCT00003691|Drug|cisplatin|
45823974|NCT00003691|Drug|doxorubicin hydrochloride|
45823975|NCT00003691|Drug|paclitaxel|
45965790|NCT00182936|Behavioral|Delirium Abatement Program|
45965791|NCT00589966|Behavioral|Coping Skills Training|Coping Skills Training teaches skills for managing physical, emotional, and social challenges of symptoms commonly experienced by men who have undergone treatment for early stage prostate cancer. Coping skills include activity pacing, managing negative mood, communication enhancement, and applied relaxation.
46080376|NCT02805608|Drug|Injection of 68Ga-NOTA-AE105|One injection intravenously of 68Ga-NOTA-AE105
45667405|NCT01815736|Drug|COBI|150 mg tablet administered orally once daily
45667406|NCT01651949|Biological|9vHPV Vaccine|9vHPV, V503 (9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen
45667407|NCT02387957|Drug|Fovista®|
46080377|NCT02805608|Drug|Injection of 18F-FDG|One injection intravenously of 18F-FDG
45667408|NCT02387957|Drug|bevacizumab|
45667409|NCT02387957|Drug|ranibizumab|
45667410|NCT02387957|Drug|aflibercept|
45667411|NCT01800916|Device|Coloplast Adhesive baseplate A|Coloplast Adhesive baseplate A is a newly developed 1-piece ostomy appliance.
45667412|NCT01800916|Device|Coloplast Adhesive baseplate B|Coloplast Adhesive baseplate B is a newly developed 1-piece ostomy appliance
45667413|NCT01800916|Device|Coloplast Adhesive baseplate C|Coloplast Adhesive baseplate C is a newly developed 1-piece ostomy appliance
45667414|NCT01800916|Device|SenSura 1-Piece|SenSura 1-piece is the commercial CE-marked Coloplast 1-piece SenSura .
45667415|NCT01815580|Drug|Atripla or Stribild|Antiretroviral therapy
45667416|NCT04585906|Behavioral|Common Elements Treatment Approach|The intervention integrates psychoeducation and addresses safety (when identified as a problem area). It also includes relaxation techniques, problem solving, and cognitive coping.
45667417|NCT01651403|Drug|Tenofovir DF|"Participants weighing ≥ 17 kg will receive TDF one tablet administered orally once daily (150, 200, 250 or 300 mg tablets based on body weight).~Participants weighing < 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF oral powder in a dose of 8 mg/kg once daily up to a maximum dose of 300 mg."
45667418|NCT01651403|Drug|TDF Placebo|"Participants weighing ≥ 17 kg will receive TDF placebo tablet administered orally once daily.~Participants weighing < 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF placebo oral powder once daily."
45823976|NCT00003139|Drug|pilocarpine hydrochloride|5mg pilocarpine hydrochloride tablets
45823977|NCT00003139|Other|Placebo|
45823978|NCT00003697|Drug|vadimezan|
45823979|NCT00004033|Drug|liposomal NDDP|
45823980|NCT00004033|Procedure|therapeutic thoracoscopy|
45823981|NCT00003703|Drug|SarCNU|
45823982|NCT02972983|Drug|Daptomycin|Adjuvant therapy for up to five days
45823983|NCT02972983|Other|Placebo|Placebo
45823984|NCT00003709|Drug|carbendazim|Patients receive oral carbendazim weekly for 3 weeks followed by 1 week of rest. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxic effects. Cohorts of 3-6 patients receive escalating doses of carbendazim. If dose limiting toxicity (DLT) is seen in 1 of 3 patients treated at a given dose level, 3 additional patients will be entered at the same dose level. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience DLT. Patients are followed for up to 30 days posttreatment.
45823985|NCT00003145|Drug|Fludarabine Phosphate|Given IV
45823986|NCT00003145|Radiation|Total-Body Irradiation|Undergo TBI
45823987|NCT00003145|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
45823988|NCT00003145|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
45823989|NCT00003145|Drug|Cyclosporine|Given PO or IV
45823990|NCT00003145|Drug|Mycophenolate Mofetil|Given PO or IV
45823991|NCT00003145|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
45823992|NCT00003145|Other|Laboratory Biomarker Analysis|Correlative studies
45823993|NCT00004039|Biological|recombinant interferon alfa|
45823994|NCT00004039|Biological|rituximab|
45823995|NCT00004039|Drug|cyclophosphamide|
45823996|NCT00004039|Drug|doxorubicin hydrochloride|
45823997|NCT00004039|Drug|prednisone|
45823998|NCT00004039|Drug|vincristine sulfate|
45823999|NCT00003151|Dietary Supplement|bismuth subcitrate|
45824000|NCT00003151|Drug|amoxicillin|
45824001|NCT00003151|Drug|clarithromycin|
45824002|NCT00003151|Drug|metronidazole hydrochloride|
45824003|NCT00003151|Drug|omeprazole|
45824004|NCT00003151|Drug|tetracycline hydrochloride|
45824005|NCT00004045|Drug|exatecan mesylate|
45824006|NCT00003715|Biological|BCG vaccine|
45667419|NCT01799590|Drug|Topiramate|Topiramate tablets will be administered orally in the dose range of 50 to100 milligram per day (mg/day). Dose will be increased or decreased as per Investigator's discretion. Maximum daily dose limit will be 200 mg.
45824007|NCT00003715|Biological|autologous tumor cell vaccine|
45824008|NCT00003715|Biological|recombinant interferon alfa|
45824009|NCT00003715|Drug|chemotherapy|
45965792|NCT00589966|Behavioral|Prostate Cancer Education|Prostate Cancer Education provides information on the following topics: common treatment side-effects, medical options for symptom management, nutrition to support recovery, and guidelines for communicating with your healthcare team.
45667420|NCT04902131|Drug|A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL|Single dose cross-over bioequivalence trial
45824010|NCT00003715|Drug|cyclophosphamide|
45824011|NCT00004051|Drug|irinotecan hydrochloride|
45667421|NCT04902131|Drug|A MENOPUR powder including solvent for solution for injection, 75 IU|Single dose cross-over bioequivalence trial
45667422|NCT01815424|Drug|placebo|placebo BID for 16 weeks and then re-randomized into active groups
45824012|NCT00003721|Drug|incyclinide|This is a dose escalation study. Patients receive oral COL-3 once daily. Treatment continues in the absence of disease progression and unacceptable toxic effects. Cohorts of 3-6 patients each receive escalating doses of COL-3. Dose escalation to the next level occurs after 3 patients have completed 28 days of treatment without dose limiting toxicity (DLT). Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more of 6 patients experience DLT.
45824013|NCT00003727|Biological|filgrastim|
45824014|NCT00003727|Biological|recombinant interferon alfa|
45824015|NCT00003727|Biological|sargramostim|
45824016|NCT00003727|Biological|therapeutic autologous lymphocytes|
45824017|NCT00003727|Drug|carmustine|
45824018|NCT00003727|Drug|cyclophosphamide|
45824019|NCT00003727|Drug|etoposide|
45667423|NCT01815424|Drug|CP-690,550|CP-690,550 5mg BID for 52 weeks
45667424|NCT01815424|Drug|CP-690,550|CP-690,550 10mg BID for 52 weeks
45824020|NCT00003727|Drug|gemcitabine hydrochloride|
45824021|NCT00003727|Drug|melphalan|
45824022|NCT00003727|Procedure|bone marrow ablation with stem cell support|
45455607|NCT01129453|Other|Placebo|30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
45667425|NCT02431247|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF) 10 mg will be administered once daily.
45667426|NCT02431247|Drug|DRV/COBI FDC|A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.
45667427|NCT02431247|Drug|FTC/TDF FDC|A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.
45667428|NCT02431247|Drug|D/C/F/TAF FDC - Matching Placebo|Matching placebo of D/C/F/TAF FDC will be administered once daily.
45824023|NCT00003727|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45824024|NCT00003157|Drug|cisplatin|
45824025|NCT00003157|Drug|gemcitabine hydrochloride|
45824026|NCT00003157|Radiation|radiation therapy|
45824027|NCT00384007|Procedure|Hydrodiscectomy with Spinejet|
45824028|NCT00004057|Drug|L-778,123|
45824029|NCT00004057|Drug|paclitaxel|
45824030|NCT00004063|Biological|recombinant interferon alfa|
45824031|NCT00004063|Drug|cisplatin|
45824032|NCT00004063|Drug|gemcitabine hydrochloride|
45824033|NCT00004063|Procedure|hyperthermia treatment|
45824034|NCT00003733|Drug|carboplatin|
45824035|NCT00003733|Drug|paclitaxel|
45824036|NCT00003733|Drug|topotecan hydrochloride|
45824037|NCT00003739|Biological|filgrastim|
45824038|NCT00004075|Drug|tanespimycin|
45824039|NCT00003745|Drug|topotecan hydrochloride|
45824040|NCT00003163|Biological|filgrastim|
45824041|NCT00003163|Biological|sargramostim|
45824042|NCT00003163|Drug|cyclophosphamide|
45824043|NCT00003163|Drug|melphalan|
45824044|NCT00003163|Procedure|autologous bone marrow transplantation|
45824045|NCT00003163|Procedure|peripheral blood stem cell transplantation|
45824046|NCT00003163|Radiation|radiation therapy|
45824047|NCT00004081|Drug|docetaxel|
45824048|NCT00003751|Drug|penicillamine|
45824049|NCT00003751|Radiation|radiation therapy|
45965793|NCT00590083|Biological|CTL administration|"Adenovirus specific T cells will be given by intravenous injection from day 30 post transplant.~One infusion of Adenovirus-specific CTL given to patients at risk for Adenoviral disease after matched or mismatched unrelated or matched or mismatched related donor stem cell transplant. Four dose levels will be explored. The lowest level will be 1x dose of 5x10e6cells/m2 and the highest will be 1x dose of 1.35x10e8/m2."
45965794|NCT00209937|Drug|Gaboxadol|
45824050|NCT04097119|Dietary Supplement|Dietary supplementation|Subjects receive a specific dietary supplementation designed to support HDL function daily for 12 weeks
45824051|NCT00004087|Biological|filgrastim|as prescribed by physician
45824052|NCT00004087|Procedure|autologous bone marrow transplantation|1-2 weeks before treatment
45667429|NCT02431247|Drug|FTC/TDF FDC Matching Placebo|Matching placebo of FTC/TDF FDC will be administered once daily.
45667430|NCT02431247|Drug|DRV/COBI FDC Matching Placebo|Matching placebo of DRV/COBI FDC will be administered once daily.
45667431|NCT01814878|Drug|Tramadol HCl/Acetaminophen ER|2 tablets of ER (tramadol HCl [75 mg]/acetaminophen [650 mg]) will be administered at 0, 12, 24 and 36 hours
45824053|NCT00004087|Procedure|peripheral blood stem cell transplantation|1-2 weeks before treatment
45667432|NCT01814878|Drug|Tramadol HCl/Acetaminophen IR|2 tablets of IR (tramadol HCl [37.5 mg]/acetaminophen [325 mg]) at 0, 6, 12, 18, 24, 30, 36 and 42 hours
45667433|NCT02407457|Device|AFX EVAR AAA Graft System|Endvovascular Abdominal Aneurysm Repair (EVAR) using commerically available, FDA approved endovascular graft systems implanted via femoral access.
45824054|NCT00004087|Radiation|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
45824055|NCT00004087|Radiation|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
45824056|NCT00003757|Biological|rituximab|
45824057|NCT00003175|Drug|fluorouracil|
45824058|NCT00004099|Drug|cisplatin|
45824059|NCT00004099|Drug|fluorouracil|
45667434|NCT02407457|Device|FDA Approved EVAR AAA Graft Systems|
45667435|NCT01814800|Biological|RI-002|Immune Globulin Intravenous (IGIV)
45667436|NCT01814332|Drug|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
45667437|NCT01814332|Drug|Placebo|Placebo compound treatment for comparison with IP
45824060|NCT00004099|Drug|leucovorin calcium|
45824061|NCT00004099|Procedure|neoadjuvant therapy|
45824062|NCT00003763|Procedure|radionuclide imaging|
45824063|NCT00003763|Radiation|indium In 111 folic acid|
45824064|NCT04712695|Other|Exercise Based Interventions|Proprioception Training Interventions
45824065|NCT00003181|Biological|aldesleukin|
45824066|NCT00003181|Biological|sargramostim|
45824067|NCT00003181|Drug|vinblastine sulfate|
45824068|NCT00004105|Drug|estramustine phosphate sodium|
45824069|NCT00004105|Drug|paclitaxel|
45824070|NCT00004105|Drug|vinorelbine ditartrate|
45824071|NCT00003187|Biological|filgrastim|
45824072|NCT00003187|Drug|cyclophosphamide|
45667438|NCT02407223|Drug|Group 1: Placebo|Participants will receive placebo SC at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 mg SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with < 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88.
45667439|NCT02407223|Drug|Group 2: Ustekinumab 45 mg|Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
45965795|NCT00182975|Drug|DHEA replacement|
45965796|NCT00590278|Drug|Tomudex|
45965797|NCT00590278|Procedure|Radiotherapy|
45824073|NCT00003187|Drug|cyclosporine|
45824074|NCT00003187|Drug|cytarabine|
45824075|NCT00003187|Drug|methotrexate|
45455608|NCT01223755|Drug|Sirolimus|Patients will be given SRL for one year starting at the oral daily dose of 3 mg, with periodical whole blood level measurements. The daily dose will be adjusted to keep SRL concentration within 5-10 ng/ml. Drug levels will be assessed at day 7 after starting treatment and every two weeks for the first month. Subsequently SRL concentrations will be monitored at monthly intervals (or at least 5 days after drug dose adjustments) until the end of the treatment period.
45455609|NCT01223755|Drug|conventional therapy|Conventional treatment relates usually to the administration of antihypertensive drugs for patients with high blood pressure. Thus, for the present study, no major change in antihypertensive treatment should be introduced throughout the whole study period unless deemed clinically necessary (the reasons of the changes should be, however, clearly explained in the CRF). Only small changes in the doses of the ongoing treatments are recommended in order to maintain the same level of blood pressure control (target systolic/diastolic blood pressure <130/80 mmHg). This approach is aimed to minimize the confounding effect of any change in concomitant treatments on some efficacy variables (such as urinary protein excretion rate).
45824076|NCT00003187|Drug|methylprednisolone|
45824077|NCT00003187|Procedure|allogeneic bone marrow transplantation|
45824078|NCT00003187|Procedure|in vitro-treated bone marrow transplantation|
45824079|NCT00003187|Radiation|radiation therapy|
45824080|NCT00003769|Drug|perillyl alcohol|
45824081|NCT00003769|Procedure|surgical procedure|
45824082|NCT00003775|Drug|leflunomide|
45824083|NCT00004123|Drug|Doxorubicin hydrochloride (DOX)|Doxorubicin IV bolus followed immediately by IV over 4 days every week for 5 weeks concurrently with external beam radiotherapy 5 days a week for 4 weeks.
45824084|NCT00004123|Procedure|Conventional surgery|Surgical resection of primary tumor and all adjacent gross disease approximately 6 weeks after chemoradiotherapy
45824085|NCT00004123|Radiation|Intraoperative radiation therapy (IORT)|Intraoperative radiotherapy (IORT) to tumor bed if all gross disease has been resected and if area of maximal tumor adherence to retroperitoneum can be encompassed within a single IORT field (maximum 15 cm).
45965798|NCT00590278|Procedure|Haematology|
45965799|NCT00590278|Procedure|Biochemistry|
45965800|NCT00216918|Drug|Atomoxetine Hydrochloride|
45965801|NCT00590356|Device|StarClose®|Closure device for femoral artery suture site occlusion
45965802|NCT00590356|Device|AngioSeal®|Closure device for femoral artery suture site occlusion
45965803|NCT04574791|Drug|TiZANidine 2 MG Oral Capsule|Tizanidine 2 mg q8h (standing; # 42 tablets) + Multimodal pain regimen
45965804|NCT00183014|Behavioral|The Lifetime Fitness Program|A series of 4 weekly 1-hour group discussion sessions that utilize attribution retraining techniques from the field of motivational psychology in combination with behavioral strategies based in social cognitive theory; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
45455610|NCT02290288|Procedure|vaginal surgery|
45455611|NCT02290288|Procedure|laparoscopic surgery|
45824086|NCT00004123|Radiation|Radiation Therapy (RT)|5 days a week for 4 weeks
45824087|NCT00003781|Drug|docetaxel|
45824088|NCT00003781|Procedure|pain therapy|
45824089|NCT00003781|Procedure|quality-of-life assessment|
45824090|NCT00003787|Behavioral|educational/counseling intervention|
45824091|NCT00003787|Behavioral|therapeutic dietary intervention|
45824092|NCT00003193|Drug|amifostine trihydrate|
45824093|NCT00003193|Drug|paclitaxel|
45824094|NCT00003193|Procedure|conventional surgery|
45824095|NCT00003193|Radiation|radiation therapy|
45824096|NCT00004129|Radiation|brachytherapy|
45824097|NCT00004129|Radiation|phosphorus P32|
45824098|NCT00003793|Genetic|clonality analysis|
45824099|NCT00003793|Genetic|microsatellite instability analysis|
45824100|NCT00003793|Genetic|mutation analysis|
45824101|NCT00384787|Biological|VRC-HIVDNA009-00-VP|HIV DNA vaccine containing the HIV genes gag, pol, nef, and env A,B, and C. The HIV DNA vaccine will be given in three doses intramuscularly at study entry and Months 1 and 2
45824102|NCT00384787|Biological|VRC-HIVADV014-00-VP|Adenoviral vector HIV booster vaccine containing the HIV genes gag, pol, and env. The adenoviral vector HIV booster vaccine will be administered intramuscularly (Group 1), intradermally (Group 2), or subcutaneously (Group 3) at Month 6
45965805|NCT00183014|Behavioral|Exercise class|1-hour exercise class aimed at increasing strength, flexibility and endurance; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
45965806|NCT04574674|Behavioral|Flexibility exercise programme|Static passive flexibility exercises.
45965807|NCT04574674|Behavioral|Resistance exercise programme|Body weight and resistance bands exercises.
45965808|NCT00210015|Drug|INS37217 Nasal Spray|
45965809|NCT04574557|Diagnostic Test|micro RNA|"miRNA was isolated from serum using a miRNeasy Mini Kit (Qiagen, Cat; 217004)cDNA was isolated from obtained miRNA samples using a miScript Reverse Transcription Kit (Qiagen, Cat; 218060) Quantitative Real-Time PCR (qPCR) will be done using (miScript SYBR Green PCR Kit Qiagen Cat. No: 218073)The qPCR assays were performed in duplicate The relative expressions of Three miRNAs were selected for RT-PCR validation Two were selected from over-expressed miRNAs (miR-34a, miR-146b), one from under-expressed miRNAs (miR-122) were analyzed using the standard 2-ΔΔCT method. These miRNAs were selected due to their pathophysiological relation with NASH.~Predicted gene targets of all differentially expressed miRNAs will be identified. Genes with functions that are potentially relevant to the pathogenesis of NASH and gene targets that are commonly studied e.g. lipogenesis (e.g. FAS), inflammation (c-JUN kinase) will be included in the study"
45965810|NCT00590473|Device|Interstim|Unilateral vs. Bilateral Placement of Interstim IPG
45965811|NCT00590512|Dietary Supplement|High sodium|
45965812|NCT00590512|Dietary Supplement|Low sodium|
45965813|NCT00216957|Procedure|Coronary bypass surgery without cardiopulmonary bypass|
45965814|NCT00183053|Device|BedEx Patient Occupancy Monitoring System|
45965815|NCT00590551|Other|sling or no sling|Groups will be assigned as follows: 1-supine and with sling, 2-30o HOB elevation without leg elevation and with sling, 3-30o HOB elevation with 10o leg elevation and with sling, 4-supine and without sling, 5-30o HOB elevation without leg elevation and without sling, and 6-30o HOB elevation with 10o leg elevation and without sling
45965816|NCT00183131|Behavioral|Brief Personalized Feedback|
45455612|NCT01126021|Behavioral|Financial incentives|Participants are eligible for incentives if they participate in at least 30 games per day.
45455613|NCT01126021|Behavioral|No incentives|Participants will be given training and access to the software to participate in mental exercises but will not be given financial incentives for participation.
45965817|NCT00590629|Drug|Niaspan|1500 mg Niaspan for 16 weeks
45965818|NCT00590668|Diagnostic Test|Transesophageal Echocardiography|Measurement of peak diastolic flow velocity
45965819|NCT00590785|Drug|Doxorubicin|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
45965820|NCT00590785|Drug|Cyclophosphamide|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
45965821|NCT00590785|Drug|G-CSF|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
45965822|NCT00590785|Drug|tamoxifen|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
45965823|NCT00590785|Drug|ciprofloxacin|High-dose sequential doxorubicin x 4 given with G-CSF on Days 3 - 12+ and followed by high-dose cyclophosphamide x 3 (A+C) given with G-CSF and ciprofloxacin on Days 3-12, followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamxifen 20 mg daily for 5 years.
45965824|NCT00210054|Drug|denufosol tetrasodium (INS37217)|
45824103|NCT00004135|Biological|filgrastim|
45824104|NCT00004135|Biological|therapeutic allogeneic lymphocytes|
45824105|NCT00004135|Drug|cyclophosphamide|
45824106|NCT00004135|Drug|fludarabine phosphate|
45824107|NCT00004135|Procedure|peripheral blood stem cell transplantation|
45824108|NCT00384943|Behavioral|Moderate-intensity Exercise|
45965825|NCT00183209|Behavioral|Family First|Family First = 14 sessions lasting 1.5 hours each based on Social Action Theory and Motivational Interviewing (7 sessions on reducing alcohol and drug use and 7 sessions on reducing parenting challenges). Brief Video Intervention was a single session designed to increase motivation to reduce/eliminate problem drinking or drug use.
45965826|NCT00217035|Dietary Supplement|TPN or TPN enriched with glutamine|Each patient undergoes two nutritional support periods either with or without Glutamine supplementation.
45965827|NCT00210093|Drug|denufosol tetrasodium (INS37217)|
45965828|NCT00183326|Behavioral|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is a psychotherapeutic intervention designed to help children, youth, and their parents overcome the negative effects of traumatic life events. It was developed by integrating cognitive and behavioral interventions with traditional child abuse therapies that focus on enhancement of interpersonal trust and empowerment. It targets PTSD symptoms, which often co-occur with depression and behavioral problems. TF-CBT also targets other issues experienced by those suffering a trauma including poor self-esteem, mood instability, and difficulty trusting others.
45455614|NCT02290600|Device|Continuous Glucose Monitor|CGM sensor calibration individualization
45824109|NCT00004141|Drug|Cisplatin|
45824110|NCT00004141|Drug|dacarbazine|
45824111|NCT00004141|Drug|Granulocyte-macrophage colony-stimulating factor|
45824112|NCT02972905|Drug|GSK2269557 ELLIPTA DPI|GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.
45824113|NCT02972905|Drug|Placebo ELLIPTA DPI|Placebo ELLIPTA DPI contains lactose
45824114|NCT00004147|Drug|incyclinide|
45824115|NCT00003799|Drug|fluorouracil|Given IV
45824116|NCT00003799|Drug|oxaliplatin|Given IV
45965829|NCT00183326|Behavioral|Child-centered supportive therapy (CCT)|CCT demonstrates an empathic approach to healing. An environment consisting of empathy, unconditional positive regard and acceptance are key elements in this mode of therapy.
45965830|NCT00477295|Drug|Zonisamide|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
45965831|NCT00477295|Drug|Carbamazepine|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
45965832|NCT00217074|Other|acupuncture|
45965833|NCT00183365|Behavioral|Parent Skills Training|Parent skills training will include 10 weeks of psychoeducational and skills training group sessions for parents.
45965834|NCT00183365|Behavioral|Protecting Families Program (PFP)|Participants will receive 10 weeks of PFP, which will include a community meal at the beginning of each session, a parent skills training group, and a concurrent cognitive behavioral therapy (CBT) group for the focal child.
45965835|NCT04571788|Procedure|Foldable Capsular Buckle|Intraoperatively, the location and size of the fissure hole is located under the microscope to determine the location and extent of the conjunctival incision. Once local infiltration anesthesia is complete, a 2 ml needle is inserted into the outer surface of the sclera >10 mm behind the corneoscleral rim, and a cotton swab is used to apply light pressure on the side of the wound to help drain the fluid. Under the microscope, the emptied and folded FCB was inserted vertically into the external scleral channel and the drainage valve was sutured with 5.0 non-absorbable sutures 8-10 mm behind the angular scleral rim. The balloon was then filled with 1 ml of alkaline Ringer's solution using a 1 ml syringe through the drainage valve. Subconjunctival injection of tobramycin and dexamethasone was followed by gentle pressure and bandaging of the eye.
45667440|NCT02407223|Drug|Group 3: Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
45965836|NCT04571788|Procedure|Silicone scleral padding|Intraoperatively, the location and size of the fissure is located under the microscope to determine the location and extent of the incision of the bulbar conjunctiva. When the fissure hole is located microscopically, a retrobulbar block anesthesia is performed and fluid is released according to the degree of retinal detachment. Silicone was then implanted on the scleral surface as an external cushion and intraocular pressure was applied, and the opening was finally sutured, with laser closure performed within a week after surgery. After the surgery, subconjunctival injection of tobramycin and dexamethasone was routinely performed, and the operated eye was bandaged, with observation of the fundus and closure of the aperture.
45965837|NCT00476593|Drug|Diclofenac|"Preservative- free Diclofenac Na 0.1% eye drops (Voltaren Ophta SDU;Novartis Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design."
45965838|NCT00476593|Drug|Dexamethasone|"Dexamethasone sodium phosphate 0.1% eye drops (Spersadex OmniVision, Novartis Pharma), one drop six times daily for three days in one eye.~Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design."
45965839|NCT00210132|Drug|Ropivacaine|
45824117|NCT00003799|Radiation|radiation therapy|Undergo radiotherapy
45824118|NCT00003799|Drug|leucovorin calcium|Given IV
45824119|NCT00003799|Procedure|therapeutic conventional surgery|Undergo surgery
45667441|NCT01797562|Diagnostic Test|Panels 1.3, 2.2 and 3.2 experimental allergens|Three allergen panels will be applied to the upper backs of study subjects and will be worn for 48 hours. Allergen test sites will be evaluated at 3, 4, 7(±1) and 21(±2) days post application.
45667442|NCT04602754|Drug|BERLIM 25/20 ASSOCIATION|Berlim 25/20 association coated tablet.
45667443|NCT04602754|Other|EMPAGLIFLOZIN PLACEBO|Empagliflozin placebo coated tablet.
45824120|NCT00003205|Drug|bryostatin 1|
45824121|NCT00004153|Genetic|reverse transcriptase-polymerase chain reaction|
45824122|NCT00004153|Procedure|sentinel lymph node biopsy|
45824123|NCT00003211|Biological|filgrastim|
45824124|NCT00003211|Drug|amifostine trihydrate|
45824125|NCT00003211|Drug|cisplatin|
45824126|NCT00003211|Drug|cyclophosphamide|
45824127|NCT00003211|Drug|vincristine sulfate|
45965840|NCT00183404|Drug|Olanzapine|Olanzapine tablets, dosed once or twice per day, dosage 2.5 to 20 mg per day
45965841|NCT00217113|Behavioral|Geriatric home visit and Action Plan|
45965842|NCT00183521|Behavioral|Raise-CO2 breathing regulation training|Reverse hyperventilation (defined by low arterial CO2) is often characteristic of individuals with panic disorder. Participants will be randomly assigned to one of three groups: raise-CO2 breathing, lower-CO2 breathing, or a control group. Participants in the raise-CO2 group will be taught techniques to recover from hyperventilation faster.
45965843|NCT00183521|Behavioral|Lower-CO2 breathing regulation training|According to the false suffocation alarm theory, anxiety is experienced when an overly sensitive hypothalamic mechanism is triggered by rising pCO2. Participants in the lower-CO2 group will be taught techniques to reach hyperventilation levels, then switch to breathing techniques that reduce hyperventilation symptoms.
45965844|NCT00183521|Behavioral|Control|Participants in the control group will not be taught any breathing techniques but will be included in all assessments.
45965845|NCT00210171|Procedure|Toxicity : Time to progression, 1 and 2 years survival|
45965846|NCT00476476|Drug|Erlotinib|Orally every day for about 4-6 weeks
45965847|NCT00183560|Behavioral|Mindfulness based cognitive therapy (MBCT)|Following antidepressant discontinuation, participants receive MBCT, an 8-week group program that integrates aspects of cognitive therapy and mindfulness meditation.
45965848|NCT00183560|Drug|Antidepressants|Participants continue on dosage of the antidepressant that was used to achieve clinical remission.
45965849|NCT00183560|Drug|Placebo plus clinical management|Following discontinuation of active antidepressant, participants are placed onto the placebo and clinical management regimen.
45965850|NCT00217152|Drug|CellCept|
45965851|NCT00183599|Behavioral|5 Minutes of Simple Advice|
45965852|NCT00183599|Behavioral|Motivational Enhancement Therapy (MET)|
45965853|NCT00183599|Behavioral|Cognitive Behavioral Therapy (CBT)|
45965854|NCT00210210|Drug|Ketamine|
45667444|NCT04602754|Other|ROSUVASTATIN CALCIUM PLACEBO|Rosuvastatin calcium placebo coated tablet.
45965855|NCT00476086|Drug|Gemcitabine|
45965856|NCT00476086|Drug|Oxaliplatin|
45965857|NCT00476086|Radiation|Radiation|
45667445|NCT04602754|Drug|EMPAGLIFLOZIN|Empagliflozin 25 mg coated tablet.
45667446|NCT04602754|Drug|ROSUVASTATIN CALCIUM|Rosuvastatin 20 mg coated tablet.
45965858|NCT00183638|Behavioral|Internet-based tailored prevention messages|Participants will receive five 30-second flash clips promoting condom norms, positive attitudes, self-efficacy, and risk awareness. Participants in the Youthnet program will be asked their gender and ethnicity so they may be assigned to a role model of the same gender and ethnicity via a computer program. This role model will appear online 5 times during the survey to deliver interactive messages that will be tailored to HIV/STD risk reduction and will specifically address attitudes about condom usage.
45965859|NCT00183638|Behavioral|Non-tailored messages|The control program will deliver five general, non-tailored messages containing information on reproductive health not specific to condoms or STDs.
45965860|NCT00476047|Combination Product|Tositumomab and Iodine I 131 Tositumomab|Give IV
45965861|NCT00217191|Drug|Ibuprofen|
45965862|NCT00183716|Behavioral|Trauma Recovery and Empowerment Model (TREM)|TREM is a 29-session group intervention for women who have experienced psychological trauma (e.g., childhood physical or sexual abuse), focusing on skill development, understanding the effects of trauma, and empowerment.
45965863|NCT00183716|Behavioral|Usual care|Participants will receive usual care for women who have experienced psychological trauma.
45965864|NCT00476008|Drug|Memantine|One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months
45965865|NCT00476008|Drug|Placebo|One tablet placebo morning and evening (BID) for 12 months
46080378|NCT02805608|Device|Positron Emission Tomography and CT|Following of injection of 68Ga-NOTA-AE105 the patients will be PET/CT scanned starting 20 minutes post injection
46080379|NCT02805608|Device|Positron Emission Tomography and MRI|Following injection of 18F-FDG the patients will be PET/MRI scanned starting 60 minutes post injection
45667447|NCT04602754|Other|BERLIM 25/20 ASSOCIATION PLACEBO|Berlim 25/20 association placebo coated tablet.
45667448|NCT01813474|Drug|olaparib|tablet oral
45667449|NCT01868542|Drug|insulin detemir|Insulin detemir was administered once daily to the subjects. The dose was titrated based on the previous breakfast SMPG values.
45667450|NCT01797094|Biological|botulinum toxin Type A (44U)|44 units botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
45667451|NCT01797094|Biological|botulinum toxin Type A (32U)|32 units botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
45667452|NCT02383589|Drug|Mycophenolate Mofetil Placebo|MMF matching placebo will be administered orally Q12H.
45667453|NCT02383589|Drug|Mycophenolate Mofetil|MMF will be administered at a starting dose of 500 milligrams (mg) Q12H and the dose will be titrated to achieve a goal of 1 gram (gm) Q12H.
45667454|NCT02383589|Drug|Rituximab|Rituximab will be administered at a dose of 1000 mg via IV infusion.
45667455|NCT02383589|Drug|Rituximab Placebo|Rituximab matching placebo will be administered via IV infusion.
45667456|NCT01810432|Drug|Evacetrapib|Administered orally
45824128|NCT00003211|Procedure|peripheral blood stem cell transplantation|
45667457|NCT01810432|Other|High-fat Meal|Administered orally, at breakfast.
45824129|NCT00003211|Radiation|radiation therapy|
45824130|NCT00003805|Drug|piperacillin sodium|
45824131|NCT00003805|Drug|piperacillin-tazobactam|
45824132|NCT00003805|Drug|tazobactam sodium|
45824133|NCT00003805|Drug|vancomycin|
45824134|NCT00004159|Drug|gemcitabine hydrochloride|
45824135|NCT00004159|Drug|paclitaxel|
45824136|NCT00003811|Biological|bleomycin sulfate|
45824137|NCT00003811|Drug|amifostine trihydrate|
45824138|NCT00003811|Drug|cisplatin|
45824139|NCT00003811|Drug|etoposide|
45824140|NCT00003811|Procedure|conventional surgery|
45824141|NCT00004177|Biological|filgrastim|as prescribed by physician
45824142|NCT00004177|Procedure|peripheral blood stem cell transplantation|1-2 weeks from treatment
45667458|NCT01796860|Other|AFO|The purpose of this study is to investigate the impact of a specifically designed ankle foot orthosis (AFO, hinged, with tamarack joint and adjustable check strap) on the spatial and temporal gait parameters, electromyography (EMG), and walking endurance, in select individuals living with MS. Over the 13 week period, the subject will participate in 5 gait training sessions which will be at weeks 1, 2, 3, 7, and 10.
45667459|NCT01796548|Drug|Oxybutinin Extended-Release|Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally
45667460|NCT02406677|Other|Study voucher card|Study voucher card to offset any patient copayments or medication costs for the filling of any prescriptions of clopidogrel or ticagrelor
45667461|NCT02404805|Drug|dolutegravir|dolutegravir tablets 50mg, once daily x 7 days.
45965866|NCT04722705|Device|fractional Er:YAG laser|"At baseline, three lesions were randomized. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment.~The same dermatologist performed 2,940 nm Er:YAG fractional laser. (long pulse mode, 1500mJ, 2Hz, 2 pass) The face was cooled after treatment with gauze soaked in ice water. The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
45965867|NCT04722705|Device|Intense pulse light|"At baseline, three lesions were randomized. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment.~The same dermatologist performed IPL. (irridation energy: 12.5J/cm2, pulse duration: 10ms, 1pass) The face was cooled after treatment with gauze soaked in ice water. The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
45965868|NCT00412035|Drug|Botulinum toxin A injection|10 units per kilo to maximum of 400 units
45667462|NCT02404805|Drug|simeprevir|simeprevir tablets 150mg, once daily x 7 days.
45965869|NCT00412035|Drug|saline injection|10 units per kilo to maximum of 400 units
45667463|NCT02430311|Drug|Olaparib|Tablet-150mg, Oral
45667464|NCT02430311|Drug|Paclitaxel|Injection
45965870|NCT00183833|Drug|capecitabine, imatinib mesylate|Capecitabine and imatinib mesylate will both be taken by mouth twice a day
45965871|NCT00210288|Biological|SC599|
45965872|NCT00183911|Drug|floxuridine, 5-Fluorouracil, leucovorin|
45965873|NCT00183911|Procedure|External Beam Radiotherapy|
45965874|NCT00183911|Procedure|Surgery|
45965875|NCT00412152|Drug|Oxycodone nalaxone prolonged release tablets (OXN)|
45667465|NCT02430311|Drug|Olaparib|Tablet-100mg, Oral
45667466|NCT02383433|Drug|Regorafenib|Given PO
45667467|NCT02383433|Drug|Gemcitabine Hydrochloride|Given IV
45667468|NCT02404649|Device|Two implant designs in a Sinus Bone Augmentation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus bone augmentation procedure.
45667469|NCT02404649|Device|Two implant designs in a Sinus Floor Elevation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus elevation only procedure.
45667470|NCT02383355|Drug|Raltegravir|Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy
45667471|NCT02383355|Drug|Continuation of own regimen|Continuation of own antiretroviral medication during the 10 weeks follow-up
45667472|NCT02381795|Drug|Nasal Carbon Dioxide|
45667473|NCT02404493|Device|EpiCeram Skin Barrier Emulsion|EpiCeram Skin Barrier Emulsion
45965876|NCT02963402|Drug|Tocilizumab|
45667474|NCT02404493|Drug|1% Colloidal Oatmeal Balm|Experimental Product 1% Colloidal Oatmeal Balm
45667475|NCT02380859|Behavioral|Prism adaptation|Prism adaptation is one type of sensorimotor adaptation. Prism adaptation described any adaptation to a prismatic shift in vision (i.e. any magnitude or direction of shift). In this study we are using adaptation to upward-shifting prisms, which induces a downward sensorimotor after-effect.
45667476|NCT02380703|Behavioral|Aggression Prevention Training (APT)|
45667477|NCT02380703|Other|Enhanced Usual Primary Care (EU-PC)|
45667478|NCT02379923|Device|Crossing of Coronary Artery CTO|"Standard angiographic procedures will be followed for this study. The primary objective of this trial is to evaluate confirmation of placement of any guidewire beyond the chronic total occlusion (CTO) in the true vessel lumen in patients in which at least one Asahi series of guidewires and/or Corsair microcatheter were used.~Procedure success will be defined as angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital MACE.~Other Name: ASAHI Corsair Microcatheter, ASAHI PTCA Guide Wires"
45667479|NCT04916171|Other|incidence|It is aimed to determine the incidence of endometriosis and/or adenomyosis in patients diagnosed with polycystic ovary syndrome, or to determine the incidence of polycystic ovary syndrome in patients diagnosed with endometriosis and/or adenomyosis.
45667480|NCT02379221|Drug|Injectable|20% benzocaine gel, 2% lidocaine, 1:100k epinephrine nerve block injection
45965877|NCT02963402|Drug|Adalimumab|
45965878|NCT00210327|Drug|Bortezomib (drug)|
45965879|NCT00425516|Drug|Taxotere|
45965880|NCT00425516|Drug|5-Fluorouracil|
45965881|NCT00425516|Drug|Epirubicin|
45965882|NCT00425516|Drug|Cyclophosphamide|
45965883|NCT00412191|Drug|Lamotrigine|In treatment regimen A lamotrigine XR tablets will be available 100 and 200mg tablets, for regimen B and C of lamotrigine tablets 300 mg will be available.
45965884|NCT00183950|Drug|Noscapine|
45965885|NCT00408746|Behavioral|palatal development|Impressions of preterm and term palates.
45965886|NCT00210366|Drug|Idarubicin|
45965887|NCT00408785|Drug|Botulinum Toxin Type A|botulinum toxin type A 100 units, human serum albumin 0.5 mg, sodium chloride 0.9 mg
45965888|NCT00408785|Drug|sodium chloride|sodium chloride 0.9 mg
45965889|NCT00475735|Drug|MK0249|MK-0249, 10 mg per day was taken orally daily. If patients were unable to tolerate 10 mg per day, they were allowed to titrate down to 5 mg per day.
46080380|NCT02729064|Drug|Humulin R|Study subjects will receive intranasal insulin (Humulin R) via a metered nasal dispenser.
46080381|NCT02729064|Drug|Normal Saline|Study subjects will receive intranasal placebo (normal saline) via a metered nasal dispenser.
45965890|NCT00475735|Drug|Concerta (methylphenidate)|Titration of Concerta began with two 18-mg capsules (36 mg) for 3 consecutive days, followed by three 18-mg capsules (54 mg) for another 3 consecutive days, ending with four 18-mg capsules (72 mg) for the remainder of the treatment period. If patients were unable to tolerate 72 mg per day, they were allowed to titrate down to 54 mg per day. Concerta was taken orally once daily.
45965891|NCT00475735|Drug|Placebo|For 4 of the 6 treatment sequences, patients had one 4-week treatment period with placebo of MK-0249 (tablets) and placebo of Concerta (capsules). For patients assigned to active treatments of MK-0249 or Concerta, in order to preserve the blind, placebo of the non-active component was provided, ie, if MK was assigned (tablets), then placebo of Concerta (capsules) was also provided. Each patient was to dose with tablets and capsules, either active or placebo. Placebo was taken orally once daily.
45965892|NCT00475657|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
45965893|NCT00475657|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
45965894|NCT00210405|Dietary Supplement|"Sprinkles containing mulitple micronutrients"|
45965895|NCT00210405|Behavioral|Education/communication on use of micronutrient sprinkles|
45965896|NCT00210405|Dietary Supplement|Fortified food aid (corn-soy blend)|This intervention was part of the overall food assisted maternal and child health and nutrition program, and included fortified food aid commodities. Corn soy blend was targeted to the child, while the family also received wheat, lentils and oil.
45965897|NCT00408941|Drug|Propofol|
45965898|NCT00408941|Drug|Prilocaine|
45965899|NCT00217230|Biological|CAIV-T|
45667481|NCT02379221|Drug|Topical|4% Topicaine gel
45667482|NCT02404103|Drug|Flunisolide HFA|
45667483|NCT02404025|Drug|Eltrombopag|Eltrombopag was provided as white round film-coated tablets containing 12.5 mg or 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag).
45667484|NCT02404025|Drug|Rabbit ATG|Rabbit ATG, as an intravenous drip infusion, diluted by 500 mL of saline or 5% glucose injection was administered at a dose of 2.5 to 3.75 mg per kg per day as a slow intravenous infusion over 6 hours.
45965900|NCT02963480|Procedure|Cardiac Surgery|
45965901|NCT00217269|Device|Coronary Artery Stenting|Endeavor Drug eluting stent
45965902|NCT00217269|Device|Coronary Artery Stenting|Taxus Drug Eluting Stent
45965903|NCT00475423|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
45965904|NCT02963519|Device|VistaCare®|
45965905|NCT02963519|Device|Dressings|
45667485|NCT02404025|Drug|CsA|CsA as capsules, oral solution, or fine granule, was administered at a dose of 3 mg per kg twice a day.
45824143|NCT00004177|Radiation|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
45824144|NCT00004177|Radiation|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
45824145|NCT00003817|Drug|dolasetron mesylate|
45824146|NCT00003817|Drug|granisetron hydrochloride|
45824147|NCT00003817|Drug|ondansetron|
45824148|NCT00003817|Drug|tropisetron|
45824149|NCT00003817|Procedure|quality-of-life assessment|
45824150|NCT00003829|Drug|cyclophosphamide|
45824151|NCT00003829|Drug|fludarabine phosphate|
45965906|NCT00210444|Biological|Botulinum toxin type A|
45965907|NCT00475306|Drug|metoclopramide 10 mg|an anti-emetic medication
45965908|NCT00475306|Drug|Diphenhydramine 25 mg|used for prophylaxis against akathisia
45824152|NCT04329403|Drug|Adapalene 0.1% Gel|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
45965909|NCT00475306|Drug|Placebo|placebo
45965910|NCT00475306|Drug|Metoclopramide 20 mg|Metoclopramide 20 mg
45965911|NCT00475228|Drug|Levonorgestrel IUD|intrauterine insertion for arm 1 immediately after D&E procedure and for arm 2 at 3-6 weeks post-procedurem
45965912|NCT00183989|Drug|Fludarabine, Mitoxantrone and Rituximab|
45667486|NCT02377817|Device|PrenaBelt|"The PrenaBelt is a belt-like, positional therapy (PT) device designed specifically for pregnant women. While the PrenaBelt does not prevent the user from lying on her back or right side during sleep, it is expected to significantly decrease the amount of time she spends in these two positions via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PrenaBelt is worn at the level of the waist. By virtue of its design and position on the user's body, the PrenaBelt affects subtle pressure points on the back and right side of the user when she lies on her back or right side, respectively, activating her body's natural mechanism to spontaneously reposition itself to relieve discomfort, thereby reducing the amount of time she remains on her back or right side."
45965913|NCT04722237|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an evidence-based psychological therapy that has been used to improve physical and mental health among adults with health conditions, including cancer (Graham, Gouick, Krahe, & Gillanders, 2016). It fosters engagement with, rather than avoidance of, painful experiences, to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing problems.
45965914|NCT00184067|Biological|Montanide ISA 51|
45965915|NCT00217308|Drug|Lactobacilli GR-1 and RC-14|Probiotic Lactobacilli will be compared to placebo
45965916|NCT00184106|Drug|Seroxat, Cognitive therapy, Seroxat+ cognitive therapy|Seroxat was administered over 24 weeks 20-50 mg/d, and Cognitive therapy was provided over 12 weeks. The patients were assessed at pre, post and 1 yrs follow up
45965917|NCT00210483|Drug|almotriptan malate|
45965918|NCT00184145|Other|EMDR (Eye Movement Desensitization and Reprocessing)|Psychotherapy which is approved for PTSD.
45965919|NCT00184145|Other|Exposure therapy|All participants in the study received exposure therapy som second treatment. Exposure therapy is the therapy of choice for animal phobia.
45965920|NCT00210561|Drug|tramadol hydrochloride , acetaminophen|
45965921|NCT00217347|Device|Esophageal Capsule Endoscopy|
45965922|NCT00184223|Behavioral|Motivational Interviewing|2 sessions of 45 minutes each with manual guided motivational interviewing delivered individually by a trained therapist.
45965923|NCT00184223|Other|Treatment as usual|Treatment as usual is individualized according to the clinical condition of the patients during the stay and in accordance with general national and international medical standards. It includes detoxification, pharmacotherapy, and general psychotherapy. Also, treatment is given for any coexisting non-substance-related disorder, including psychiatric disorders.
45965924|NCT00210600|Drug|PROCRIT (Epoetin alfa)|
45965925|NCT00184262|Behavioral|ERP cognitive therapy|15 exposure and response prevention (ERP) sessions in 3 months with a cognitive therapy rationale
45965926|NCT00184262|Behavioral|ERP behavioral therapy|15 exposure and response prevention (ERP) sessions in 3 months with a behavioral therapy rationale
45667487|NCT02377817|Device|Sham PrenaBelt|The Sham PrenaBelt and PrenaBelt are the same device except the plastic balls are removed from the Sham PrenaBelt so it cannot provide pressure points.
45824153|NCT04329403|Drug|Differin 0.1% Topical Gel|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
45824154|NCT04329403|Other|Placebo|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
45824155|NCT00003217|Biological|filgrastim|
45965927|NCT00217386|Biological|anti-thymocyte globulin|
45824156|NCT00003217|Drug|cyclophosphamide|
45824157|NCT00003217|Drug|cytarabine|
45824158|NCT00003217|Drug|dexamethasone|
45824159|NCT00003217|Drug|doxorubicin hydrochloride|
45824160|NCT00003217|Drug|methotrexate|
45824161|NCT00003217|Drug|vincristine sulfate|
45965928|NCT00217386|Biological|etanercept|
45965929|NCT00184301|Behavioral|inpatient treatment|inpatient treatment during 1 year
45965930|NCT00184301|Behavioral|outpatient treatment|intensive outpatient treatment consisting of two-weekly group sessions during 1 year
45965931|NCT00184340|Device|eTherapy|secured e-mail system between patient and therapist
45965932|NCT00217503|Biological|bevacizumab|
45965933|NCT00217503|Biological|filgrastim|
45965934|NCT00217503|Biological|pegfilgrastim|
45965935|NCT00217503|Drug|bortezomib|
45965936|NCT00217503|Drug|cyclophosphamide|
45965937|NCT00217503|Drug|doxorubicin hydrochloride|
45965938|NCT00217503|Drug|etoposide|
45965939|NCT00217503|Drug|ganciclovir|
45965940|NCT00217503|Drug|valganciclovir|
45965941|NCT00217503|Drug|zidovudine|
45965942|NCT00184379|Behavioral|Psychoeducation|Structured disorder-related educational program for relatives
45965943|NCT00210678|Behavioral|No intervention|No treatment is given to the patients as this is an observational study.
45965944|NCT00217542|Biological|recombinant interferon alfa-2b|Given SC
45965945|NCT00217542|Drug|amifostine/azacitidine|Given SC
45965946|NCT00184457|Behavioral|Strength training intervention|
45965947|NCT00210717|Drug|paliperidone palmitate|
45965948|NCT00184496|Drug|Methadone|To methods for switching morphine to methadon. Stop-and go versus overlap
45965949|NCT00210756|Drug|epoetin alfa|
45965950|NCT00217659|Drug|anastrozole|
45965951|NCT00217659|Drug|goserelin acetate|
45965952|NCT00184574|Drug|biphasic insulin aspart|
45965953|NCT00184574|Drug|metformin|
45965954|NCT00210795|Drug|epoetin alfa|
45667488|NCT02403635|Drug|Midazolam|
45667489|NCT02403635|Drug|ASP2151|
45667490|NCT04907903|Other|internet-based intervention|Intervention consists in 8 weekly online cognitive-behavioral modules (for a total duration of 2 months).
45824162|NCT00004183|Drug|capecitabine|
45965955|NCT00408980|Behavioral|Fat and calorie controlled diet|
45965956|NCT00217698|Drug|cisplatin|
45965957|NCT00217698|Drug|gefitinib|
45965958|NCT00217698|Drug|gemcitabine hydrochloride|
45965959|NCT00184613|Device|pump|
45667491|NCT02402933|Drug|Nasal Glucagon|3 mg nasal glucagon powder
45667492|NCT05370365|Procedure|Below elbow cast|Patients will be stay with a below elbow cast for 4 or 6 weeks
45667493|NCT01796470|Drug|Entospletinib|Entospletinib tablets administered orally twice daily
45667494|NCT01796470|Drug|Idelalisib|Idelalisib tablets administered orally twice daily
45667495|NCT05102890|Other|ESOGER|For patients in the intervention group, ESOGER will be administered by phone by a member of the clinic team prior to their virtual or in-persons consultation with their primary care provider. ESOGER is already available on an online platform for data entry. Based on feedback our team obtained from interviews with current users of ESOGER, administration of the tool is expected to take between 5 and 10 minutes. A report summarizing the health and social status of the patient along with flagged potential vulnerabilities will be generated automatically by the online ESOGER platform. This report will then be uploaded to the patient's electronic chart by a member of the clinic and made available for the primary care provider at the time of the consultation.
45824163|NCT00003223|Drug|fenretinide|200 mg/day PO, days 1-25 q 28 days x 6 cycles.
45824164|NCT00004189|Biological|filgrastim|
45965960|NCT00184613|Drug|insulin glargine|
45965961|NCT00184613|Drug|insulin aspart|
45667496|NCT01868074|Device|Insole|Custom-molded arch-supporting insole
45667497|NCT04414852|Drug|Apatinib Mesylate|All the subjects will be administrated with 250mg apatinib on day 1
45667498|NCT04415008|Drug|HAD induction with intermediate dose cytarabine|daunorubicin,cytarabine,homoharringtonine
45667499|NCT04171024|Device|Sham electrical stimulation|A non invasive sham diaphragm electrical stimulation using transcutaneous thoracic probes
45667500|NCT04171024|Device|Transcutaneous diaphragm electrical stimulation|A non invasive diaphragm electrical stimulation using transcutaneous thoracic probes
45824165|NCT00004189|Drug|becatecarin|
45965962|NCT00217776|Behavioral|Open Airways Educational Intervention|
45965963|NCT00217776|Behavioral|Peer Asthma Action Educational Intervention|
45824166|NCT00004189|Drug|cisplatin|
45824167|NCT00003229|Biological|aldesleukin|
45824168|NCT00003229|Biological|gp100 antigen|
45824169|NCT00003229|Biological|tyrosinase peptide|
45824170|NCT00003835|Drug|leucovorin calcium|Given IV
45824171|NCT00003835|Drug|fluorouracil|Given IV
45824172|NCT00003835|Drug|irinotecan hydrochloride|Given IV
45824173|NCT00003835|Other|laboratory biomarker analysis|Correlative studies
45824174|NCT00003847|Drug|biricodar dicitrate|
45824175|NCT00003847|Drug|doxorubicin hydrochloride|
45824176|NCT00003847|Drug|vincristine sulfate|
45824177|NCT00004195|Drug|eniluracil|Will be given to either subject pre-operative and metastatic disease
45824178|NCT00004195|Procedure|conventional colon surgery|Only if the subject is amenable to surgical resections
45824179|NCT00003853|Drug|4'-iodo-4'-deoxydoxorubicin|
45824180|NCT00385021|Drug|5-Fluorouracil, leucovorin, oxaliplatin, avastin|
45965964|NCT00210834|Drug|epoetin alfa|
45965965|NCT00184652|Drug|somatropin|
45965966|NCT00217815|Drug|Mycograb, Docetaxel|
45965967|NCT00184691|Drug|somatropin|
45965968|NCT04722471|Drug|Vaginally administered progesterone|The artificial endometrial preparation for an embryo transfer with the use of 400 mg vaginal tablet (one tablet twice a day) or 200 mg (two tablets twice a day)
45965969|NCT00184730|Drug|somatropin|
45965970|NCT00210873|Drug|topiramate|
45965971|NCT00184769|Drug|somatropin|
45965972|NCT00217854|Procedure|Bronchoscopic|Bronchoscopic procedure
45965973|NCT00210912|Drug|topiramate|
45965974|NCT00184847|Drug|acetylcholine|
45965975|NCT00184847|Procedure|twenty minutes of forearm ischemia|
45965976|NCT00184847|Procedure|three 5-minute periods of forearm ischemia|
45965977|NCT00184847|Drug|adenosine|
45965978|NCT00184847|Drug|caffeine|
45965979|NCT00217893|Behavioral|Counseling|One-on-one behavioral counseling with pre-teen child; 8 to 10 weekly or bi-weekly sessions; focus on identifying sources of exposure to ETS and means to avoid exposure; goal-setting, role-playing, monitoring progress, feedback includes reported info and urine cotinine level.
45965980|NCT00217893|Behavioral|Urine Cotinine Feedback|Urine collected from child at each weekly/bi-weekly counseling session; cotinine level discussed at subsequent session.
45965981|NCT00217893|Behavioral|Contingent Incentives|Child earns small prizes for on-task behavior in sessions, plus earns tokens redeemable for other prizes based on reduction in ETS exposure (reported and cotinine level).
45965982|NCT00217893|Behavioral|Usual education program|Participants will receive the usual education about ETS.
45965983|NCT00184886|Drug|Methotrexate 15 mg/week for 12 weeks|
45965984|NCT00210951|Other|No Intervention|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
45965985|NCT00184925|Procedure|Tracheostomy|trachesotomy with subglottic drainage
45965986|NCT00184925|Device|cannula with subglottic drainage|
45965987|NCT00217932|Drug|Divalproex Sodium (Depakote)|
45965988|NCT00184964|Procedure|CT-scan, PET-scan|
45965989|NCT00210990|Drug|doripenem|
45824181|NCT00004201|Drug|carboplatin|
45965990|NCT00185003|Drug|endotoxin|
45965991|NCT00185003|Drug|Potassium channel blockers: TEA, Quinin, Tolbutamide|
45965992|NCT00185003|Drug|L-NMMA|
45965993|NCT00185042|Drug|Pactimibe, CS-505|
45965994|NCT00185081|Drug|Indium labeled IMP-205xm734|
45824182|NCT00004201|Drug|cisplatin|
45824183|NCT00004201|Drug|gemcitabine hydrochloride|
45824184|NCT00003241|Drug|phenylacetate|
45667501|NCT04601506|Behavioral|Choice Architecture Nudge|"Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record system when they initiate an opioid order for a patient who has not had an opioid prescription within the past six months. The alert provides guidance language about opioid prescribing and prompts the PCP to open the SmartSet to order non-opioid treatment alternatives. When the SmartSet is opened, PCPs can choose to click on a variety of treatment order options, including both non-opioid pharmacological options and non-pharmacological options.~PCPs will also be sent alerts when they initiate an opioid order for a patient will a current opioid prescription. The alerts prompt PCPs to consider tapering the patient's opioid. The alert also displays the MME of the patient's current opioid prescription and automatically calculates what a 10% reduction in MME relative to the current prescription would be. The alert contains options to either cancel the refill order, or to continue with the order."
45824185|NCT00003859|Drug|carboplatin|
45824186|NCT00003859|Drug|cyclophosphamide|
45824187|NCT00003859|Drug|etoposide|
45824188|NCT00003859|Drug|vincristine sulfate|
45824189|NCT00003859|Procedure|surgical procedure|
45824190|NCT00003859|Radiation|radiation therapy|
45824191|NCT00003865|Drug|toremifene|
45824192|NCT00004207|Drug|liposomal daunorubicin citrate|
45824193|NCT00004213|Drug|triapine|
45824194|NCT00004219|Drug|granisetron hydrochloride|
45824195|NCT00004219|Drug|lerisetron|
45824196|NCT00004219|Radiation|radiation therapy|
45824197|NCT00003877|Biological|filgrastim|
45965995|NCT00185120|Drug|Olmesartan medoxomil|
45965996|NCT00185120|Drug|Hydroclorothiazide|
45965997|NCT00185120|Drug|Benazepril|
45965998|NCT00185120|Drug|Amlodipine|
45965999|NCT00218049|Drug|GBR 12909|50mg GBR 12909 over 12 days
45966000|NCT00218049|Drug|GBR 12909|GBR 12909 75 mg over 12 day period
45966001|NCT00218049|Drug|GBR 12909|GBR 12909 100 mg over 12 day period
45966002|NCT00211068|Drug|No intervention|This study is an observational study. No medication will be provided or administered to the participants. Participants will receive standard-of-care treatment from their individual physicians.
45966003|NCT00185159|Drug|Olmesartan medoxomil|tablets
45966004|NCT00185159|Drug|Placebo Tablets|Tablets
45966005|NCT02963636|Other|Pharmacist clinical intervention|Pharmacists will make a clinical intervention with patients. They will review patient drug therapy already prescribed in their usual care. This includes a medication reconciliation, an assessment of drug related problems, an assessment of the regimen complexity and adherence to treatment. A care plan will be elaborated. Moreover, immediate and future interventions with the patient or other health professionals will be implemented and monitored. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.
45966006|NCT00218127|Drug|Levoacetyl Methadol|WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day
45966007|NCT00218127|Drug|Levoacetyl Methadol|MaxEffect+CBT evaluation to 48 mg Adjust to effect (+/-)
45966008|NCT00218127|Drug|Levoacetyl Methadol|LAAM Fixed Dose evaluation up to 48 mg 48 mg
45966009|NCT00185198|Drug|Testogel (Testosterone, BAYV001915)|50mg (5g gel sachet), 75mg (5g+2.5g sachet) or 100mg (2x5g sachet) per day applied to the skin of the shoulders, arms or abdomen for 18 months
45966010|NCT00185198|Drug|Placebo|5g gel sachet, 5g+2.5g sachet or 2x5g sachets per day applied to the skin of the shoulders, arms or abdomen for 6 months followed by 12 months treatment with testosterone 1% gel as described for arm 1
45966011|NCT00211107|Drug|Dapoxetine|
45966012|NCT04722198|Dietary Supplement|PS128|daily ingestion 2 capsules of Lactobacillus plantarum PS128 (>10 billion CFU/capsule)
45966013|NCT00185237|Drug|Menostar (estradiol transdermal delivery system)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
45966014|NCT00185237|Drug|Placebo|Placebo patch
45966015|NCT00411567|Drug|inhaled corticosteroid therapy|
45966016|NCT00185276|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: lower dose corresponding approx. 0.1 mmol/kg body weight
45966017|NCT00185276|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: higher dose corresponding approx. 0.2 - 0.3 mmol/kg body weight
45966018|NCT00218166|Drug|GABA Agonists|GABA drugs administered acutely by mouth
45966019|NCT00185315|Drug|Ventavis (Iloprost, BAYQ6256)|Inhaled iloprost
45966020|NCT00185354|Drug|BAY86-5016, SH P00331F|Drug amount per patch: 0.9 mg EE2 + 1.9 mg gestodene (GSD)
45966021|NCT00185354|Drug|SH P00331N|Drug amount per patch: 0.6 mg EE2 + 6 mg NGM
45966022|NCT00185393|Biological|Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)|treatment with 90 Yttrium-labeled anti CD 20 antibody
45966023|NCT00185393|Other|no treatment|no treatment
45667502|NCT04601506|Behavioral|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration & nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
45667503|NCT01810042|Drug|ranibizumab|0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.
45667504|NCT02424539|Drug|FFNS|FF as a aqueous suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose administered via a metered side-actuated nasal spray device.
45667505|NCT02424539|Other|Placebo|Placebo as a aqueous suspension to match the other study treatments minus the active component(s) for intranasal inhalation administered via a metered side-actuated nasal spray device.
45667506|NCT01809262|Drug|single dose of 5 mcg|solution for inhalation
45667507|NCT01809262|Drug|single dose of placebo|solution for inhalation
45667508|NCT01809262|Drug|single dose of 40 mcg|solution for inhalation
45667509|NCT01809262|Drug|single dose of 20 mcg|solution for inhalation
45667510|NCT01809262|Drug|single dose of 2 mcg|solution for inhalation
45824198|NCT00003877|Drug|carboplatin|
45824199|NCT00003877|Drug|cyclophosphamide|
45667511|NCT01809262|Drug|single dose of 10 mcg|solution for inhalation
45667512|NCT04915703|Procedure|Flushing of PTBD catheter|flushing of internal external PTBD catheter 3 times a day
45667513|NCT01808248|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
45667514|NCT01808248|Drug|PEG|Peginterferon alfa 2a (PEG) 180 μg administered once weekly by subcutaneous injection
45824200|NCT00003877|Drug|paclitaxel|
45824201|NCT00003877|Drug|thiotepa|
45824202|NCT00003877|Procedure|in vitro-treated bone marrow transplantation|
45824203|NCT00003877|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45966024|NCT00409019|Drug|Telbivudine|Study cancelled: Withdrawn before enrollment of any participants
45966025|NCT00409019|Drug|Adefovir|
45966026|NCT00409019|Drug|Tenofovir|
45966027|NCT00211146|Drug|epoetin alfa|
45966028|NCT00409058|Behavioral|Teen Online Problem Solving|We will test the following hypotheses: 1) Children with TBI receiving TOPS will have fewer behavior problems, greater social competence, and better functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 2) Caregivers of children receiving TOPS will report less depression and psychological distress, less parent-child conflict, and better family functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 3) Social resources will moderate treatment efficacy, such that children with limited social and economic resources will show greater improvements in the more comprehensive TOPS intervention. We hypothesize better teen problem solving and communication skills, fewer teen emotional/behavioral problems, less parental burden and distress, and less parent-teen conflict at follow-up among the TOPS group compared to the IRC group.
45966029|NCT00211224|Drug|Riluzole|
45966030|NCT00409097|Drug|Rosiglitazone|
45966031|NCT00218205|Drug|Epirubicin|
45966032|NCT00218205|Drug|Estramustine Phosphate|
45966033|NCT00218205|Drug|Celecoxib|
45667515|NCT01808248|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
45824204|NCT00003883|Drug|fluconazole|
45824205|NCT00003883|Drug|itraconazole|
45824206|NCT04225819|Dietary Supplement|Vitamin D3|Softgel capsules containing 5,000 IU cholecalciferol (Vitamin D3), sunflower oil, beef gelatin, glycerin, water
45824207|NCT04225819|Other|Placebo|Sfotgel capsules containing sunflower oil, beef gelatin, glycerin, water
45824208|NCT00003253|Drug|paclitaxel|
45824209|NCT00003253|Other|antitumor drug screening assay|
45824210|NCT00004225|Biological|Ad5CMV-p53 gene|
45824211|NCT00004225|Radiation|radiation therapy|
45824212|NCT00004237|Drug|cyclophosphamide|
45824213|NCT00004237|Drug|doxorubicin hydrochloride|
45966034|NCT00409136|Behavioral|Human Alert|An alert from study staff informing a physician that his/her patient is at high risk for DVT and/or PE, but is not receiving any prophylaxis.
45966035|NCT00211263|Behavioral|Enhanced Clinical Intervention|
45966036|NCT00211263|Drug|mood stabilizer|
45966037|NCT00185510|Drug|Methylprednisolone Aceponate (Advantan, BAY86-4862)|In maintenance phase, Methylprednisolone Aceponate cream is applied topically twice a week.
45966038|NCT00185510|Drug|Placebo|2 days a week Vehicle (Advabase)
45966039|NCT00218244|Other|Lower Nicotine Smokeless Tobacco Product|Skoal for 50% reduction;Skoal bandits for 75% reduction.
45667516|NCT04914845|Drug|KPT-9274|KPT-9274 is a first-in-class orally bioavailable, non-competitive, small molecule, dual modulator of p21 protein (Cdc42/Rac)-activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase /PBEF/visfatin (NAMPT). NAMPT is the rate-limiting enzyme in the metabolic scavenging pathway that utilizes nicotinamide to replenish nicotinamide adenine dinucleotide (NAD), an essential metabolic cofactor and second messenger. Recent investigations have shown that in in vitro and in vivo models, NAMPT is uniquely essential for relapsed or refractory AML stem cells. Targeting relapsed AML stem cells, through targeting of NAMPT, may allow for a promising therapeutic opportunity for patients with relapsed or refractory AML.
45966040|NCT00218244|Other|Behavioral Counseling|Behavioral counseling alone for reduction in tobacco use.
45966041|NCT00185549|Behavioral|CF. DOC|
45966042|NCT00211302|Drug|aripiprazole|10-15 mg/day; if needed, dosage may be increased to 30 mg/day after week 2; maintenance 15 mg/day; periodically reassessed
45966043|NCT00185666|Procedure|Stereotactic radiosurgery|
45966044|NCT00218283|Drug|Nicotine Lozenge|Oral Nicotine replacement product
45966045|NCT00218283|Behavioral|Behavioral Counseling|Use of behavioral counseling to reduce tobacco use.
45966046|NCT00185705|Drug|Telmisartan|
45966047|NCT00211341|Dietary Supplement|Vitamin A|Weekly single oral dose 7000 micrograms
45966048|NCT00185783|Drug|Hydrocortisone Administration (Standard of Care Therapy)|
45966049|NCT00185861|Drug|Arsenic Trioxide|
45966050|NCT00185861|Procedure|Stereotactic radiosurgery|
45966051|NCT00211380|Drug|aripiprazole|10-15 mg daily; if needed dosage may be increased to 30 mg daily after 2 weeks; maintenance 15 mg/day, periodically reassessed.
45966052|NCT00185939|Drug|Augmentin|
45966053|NCT00218322|Drug|Atomoxetine hydrochloride|Atomoxetine up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
45824214|NCT00004237|Drug|epirubicin hydrochloride|
45824215|NCT00004237|Drug|mitoxantrone hydrochloride|
45824216|NCT00004237|Drug|vinorelbine tartrate|
45824217|NCT00004237|Procedure|conventional surgery|
45824218|NCT00004237|Radiation|radiation therapy|
45824219|NCT00003259|Drug|vinorelbine tartrate|
45824220|NCT00003913|Biological|anti-thymocyte globulin|
45824221|NCT00003913|Biological|filgrastim|
45824222|NCT00003913|Drug|busulfan|
45824223|NCT00003913|Drug|cyclophosphamide|
45824224|NCT00003913|Drug|methylprednisolone|
45824225|NCT00003913|Procedure|umbilical cord blood transplantation|
45824226|NCT00003913|Radiation|radiation therapy|
45824227|NCT00004243|Drug|docetaxel|
45824228|NCT00004243|Drug|oxaliplatin|
45824229|NCT00004249|Biological|QS21|
45966054|NCT00218322|Drug|Placebo|Placebo up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
45966055|NCT00185978|Behavioral|diet, physical activity, reduced sedentary behavior|
45966056|NCT00218361|Drug|Hydromorphone|
45966057|NCT00186134|Behavioral|physical activity|
45966058|NCT00218478|Behavioral|Cue Desensitization|During the study session, both groups will be shown a nature video and will be asked to handle and smell various items; these will act as the neutral, non marijuana-related cues. Next, the participants will watch a video of individuals smoking marijuana and will be asked to handle and smell marijuana-related items; these will act as the marijuana-related cues.
45966059|NCT00186173|Behavioral|After school sports program|After school team sports intervention designed specifically for overweight and obese children
45966060|NCT00186173|Behavioral|After school health education|After school health and nutrition education program
45966061|NCT00218517|Drug|Selegiline hydrochloride|Daily oral selegiline, 5 mg po qd x 7 days, then 5 mg po bid for 7 weeks
45966062|NCT00218517|Drug|Placebo|Matching placebo capsules using blue 00 capsules
45966063|NCT00218556|Behavioral|Cognitive behavioral treatment for depression|Cognitive behavioral intervention to prevent depressive symptoms during treatment for hepatitis C
45966064|NCT00186212|Behavioral|workbook/journal on coping with breast cancer|
45966065|NCT00186212|Behavioral|standard educational materials on breast cancer|
45966066|NCT00211419|Drug|Anecortave Acetate 15 mg|
45966067|NCT00211419|Drug|Triamcinolone Acetate 4 mg|
45966068|NCT00211419|Procedure|Photodynamic Therapy with Verteporfin|
45966069|NCT00211419|Procedure|Thermal Laser|
45824230|NCT00004249|Biological|keyhole limpet hemocyanin|
45824231|NCT00004249|Drug|polysialic acid|
45824232|NCT00003925|Drug|gemcitabine hydrochloride|
45824233|NCT00003925|Drug|leucovorin calcium|
45824234|NCT00003925|Drug|tegafur-uracil|
45824235|NCT00004255|Biological|anti-thymocyte globulin|
45824236|NCT00004255|Biological|filgrastim|
45824237|NCT00004255|Drug|cyclophosphamide|
45824238|NCT00004255|Drug|fludarabine phosphate|
45824239|NCT00004255|Drug|methylprednisolone|
45824240|NCT00004255|Drug|tacrolimus|
45824241|NCT00004255|Procedure|allogeneic bone marrow transplantation|
45824242|NCT00004255|Procedure|in vitro-treated bone marrow transplantation|
45824243|NCT00004255|Radiation|radiation therapy|
45824244|NCT00003931|Genetic|reverse transcriptase-polymerase chain reaction|
45824245|NCT00004261|Drug|EF5|
45966070|NCT00186251|Procedure|high dose chemo then auto hematopoietic cell transplant|
45966071|NCT00211458|Drug|Anecortave Acetate Sterile Suspension (15 mg)|
45966072|NCT00186290|Procedure|ablative allogeneic hematopoietic cell transplantation|
45966073|NCT00211497|Drug|MBI 226 Acne Solutions|
45966074|NCT00186329|Drug|Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo|
45966075|NCT00218595|Behavioral|DBT|Dialectical behavior therapy plus opiate replacement medication.
45966076|NCT00218595|Behavioral|I/GDC|Individual and group drug counseling plus opiate replacement medication.
45966077|NCT00186407|Procedure|high dose chemo then auto hematopoietic cell transplant|
45824246|NCT00004261|Other|flow cytometry|
45966078|NCT02962713|Procedure|ART with Equia|Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
45966079|NCT02962713|Procedure|ART with Giomer Beautifil-Bulk Restorative|Occlusal-proximal ART restorations in primary molars using Giomer will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Giomer Beautifil-Bulk Restorative and occlusion will be checked.
45966080|NCT00186524|Behavioral|Breast Cancer Support Group|
45966081|NCT00218673|Behavioral|Peer mentor intervention|groups sessions, 8
46080382|NCT00609401|Drug|Nexavar (Sorafenib)|400 mg bid
46080383|NCT00609401|Drug|IL-2|IL-2 3 MU per 5 day/week for 2 weeks every 4
45824247|NCT00004261|Other|fluorescent antibody technique|
45667517|NCT02424383|Device|PTA (Lutonix® 035 DCB Catheter)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The Lutonix® DCB through the blood vessel to the narrowed area to be treated."
45667518|NCT01867294|Drug|Doxycycline|Given PO
45824248|NCT00004261|Other|immunohistochemistry staining method|
45824249|NCT00004261|Procedure|biopsy|
45966082|NCT00186563|Procedure|Micro-plasmapheresis|
45966083|NCT00211575|Behavioral|Disease Management Assessment|
45966084|NCT00186602|Behavioral|Peer counseling|
45966085|NCT00218712|Behavioral|Cognitive behavioral intervention|Cognitive behavioral intervention will include personalized cognitive counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
45966086|NCT00218712|Behavioral|Standard counseling|Participants will receive standard counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
46080384|NCT00933907|Drug|LACTIC ACID(ND)|Treatment duration: 6 weeks
46080385|NCT02805842|Drug|Tacrolimus BID|Administration of Tacrolimus BID
46080386|NCT02805842|Drug|Advagraf QD|administration of Advagraf QD
46080387|NCT05272553|Other|Narrative Exposure Therapy|NET (Schauer et al., 2011) is an evidence-based, short-term, manualised treatment for trauma-spectrum disorders; it aims to reduce symptoms of traumatic stress in individuals who continue to suffer from past experiences of traumatic stressors; NET combines principles of CBT, Testimony Therapy, and Exposure Therapy.
46080388|NCT03102996|Drug|Nephrotrans|Sodium hydrogen carbonate, ATC-Code: A02AH
46080389|NCT03102996|Other|Placebo|Identical capsules without active substance.
46080390|NCT00926965|Drug|amisulpride|amisulpride tablet 100-1200mg/day for 24 months
46080391|NCT00926965|Drug|Olanzapine|Olanzapine tablet 2.5 to 30 mg/day for 24 months
45667519|NCT01867294|Procedure|Management of Therapy Complications|Moisturizer given topically
45667520|NCT01867294|Other|Placebo|Given topically
45667521|NCT01867294|Other|Questionnaire Administration|Ancillary studies
45667522|NCT01867294|Drug|Spironolactone|Given topically
45824250|NCT00004831|Drug|cysteine hydrochloride|
45824251|NCT00004285|Device|Standard dose, low flux hemodialysis|
45824252|NCT00004285|Device|Standard dose, high flux hemodialysis|
45824253|NCT00004285|Device|High dose, low flux hemodialysis|
45824254|NCT00004285|Device|High dose, high flux hemodialysis|
45824255|NCT00004843|Procedure|parathyroidectomy|Standard parathyroidectomy with a bilateral approach
45824256|NCT00004843|Other|Observation|Usual care
45824257|NCT00004297|Drug|diazepam|
45824258|NCT00004297|Drug|lorazepam|
45824259|NCT00004855|Drug|Lopinavir/Ritonavir|
45824260|NCT00004855|Drug|Abacavir sulfate|
45824261|NCT00004855|Drug|Nevirapine|
45824262|NCT00004855|Drug|Lamivudine|
45824263|NCT00004855|Drug|Stavudine|
45824264|NCT00003289|Drug|7-hydroxystaurosporine|
45824265|NCT00004861|Drug|gemcitabine hydrochloride|
45824266|NCT00004861|Drug|tacedinaline|
45824267|NCT00004315|Drug|ursodiol|
45824268|NCT04074343|Drug|TAS-102|Given PO
45824269|NCT04074343|Drug|Irinotecan|Given IV
45824270|NCT00003301|Drug|irinotecan hydrochloride|
45824271|NCT00003307|Drug|amifostine trihydrate|
45824272|NCT00003307|Radiation|radiation therapy|
45824273|NCT00004327|Drug|octreotide|
45824274|NCT00003313|Biological|filgrastim|
45824275|NCT00003313|Drug|amifostine trihydrate|
45824276|NCT00003313|Drug|carboplatin|
45824277|NCT00003313|Drug|paclitaxel|
45824278|NCT00003313|Radiation|radiation therapy|
45824279|NCT00004867|Procedure|conventional surgery|
45824280|NCT00004867|Procedure|positron emission tomography|
45824281|NCT00004867|Procedure|radionuclide imaging|
45824282|NCT00004867|Radiation|fludeoxyglucose F 18|
45824283|NCT00004867|Drug|chemotherapy|
45824284|NCT00004867|Radiation|Radiotherapy|
46080392|NCT00926965|Drug|Conventional antipsychotics|the subjects were randomized to the conventional antipsychotic group to maintain their original conventional antipsychotics
45667523|NCT01867294|Drug|Sunscreen|Given topically
45824285|NCT00004873|Drug|cisplatin|
45824286|NCT00004873|Drug|docetaxel|
45824287|NCT00004873|Drug|epirubicin hydrochloride|
45824288|NCT00004873|Drug|fluorouracil|
45824289|NCT00004333|Drug|NTBC|
45824290|NCT00004879|Biological|panitumumab|
45824291|NCT00003325|Procedure|Sentinel lymph node mapping|Sentinel lymph node mapping
45824292|NCT00004339|Drug|tetrathiomolybdate|
45824293|NCT00004339|Drug|trientine|
45824294|NCT00385099|Drug|GW876008|
45824295|NCT00003331|Drug|fluorouracil|
45824296|NCT00003331|Drug|leucovorin calcium|
45824297|NCT00003331|Drug|topotecan hydrochloride|
45824298|NCT00004885|Drug|FOLFIRI regimen|
45824299|NCT00004885|Drug|fluorouracil|
45824300|NCT00004885|Drug|irinotecan hydrochloride|
45824301|NCT00004885|Drug|leucovorin calcium|
45824302|NCT00004891|Drug|chemotherapy|
45824303|NCT00004891|Procedure|computed tomography|
45824304|NCT00004891|Procedure|conventional surgery|
45824305|NCT00004891|Procedure|neoadjuvant therapy|
45824306|NCT00004891|Procedure|positron emission tomography|
45824307|NCT00004891|Procedure|radionuclide imaging|
45824308|NCT00004891|Radiation|fludeoxyglucose F 18|
45824309|NCT00004891|Radiation|radiation therapy|
45824310|NCT00003337|Procedure|immunoscintigraphy|
45824311|NCT00003337|Radiation|technetium Tc 99m epratuzumab|
45667524|NCT01867294|Drug|Therapeutic Hydrocortisone|Given topically
45667525|NCT02424149|Drug|Phenazopyridine|
45667526|NCT02423291|Drug|Brentuximab Vedotin|Brentuximab vedotin, 1.8 mg/kg, administered via outpatient IV infusion on Day 1 of each 21-day cycle.
45667527|NCT02401529|Drug|IV dexamethasone|0.15 mg/kg
45667528|NCT02401529|Drug|Oral prednisolone|0.25mg/kg/day for 7 days then tapering for next 7 days
45667529|NCT02401529|Drug|Paracetamol|acetaminophen 15 mg/kg/dose every 6 hours
45667530|NCT02401529|Drug|IV saline|IV saline
45667531|NCT01867216|Drug|Placebo|Administered orally as capsules
45667532|NCT01867216|Drug|LY2922470|Administered orally as capsules
45667533|NCT01866826|Drug|Rifaximin|subject will receive three capsules of rifaximin (183.3 mg each) by mouth twice daily (total 1100 mg Daily)
45824312|NCT00003343|Drug|endocrine-modulating drug therapy|
45824313|NCT00003343|Drug|mitoxantrone hydrochloride|
45824314|NCT00003343|Drug|prednisone|
45824315|NCT00003343|Drug|prinomastat|
45824316|NCT00004903|Biological|filgrastim|
45824317|NCT00004903|Biological|recombinant interferon alfa|
45824318|NCT00004903|Drug|cisplatin|
45824319|NCT00004903|Drug|cyclophosphamide|
45824320|NCT00004903|Drug|cytarabine|
45824321|NCT00004903|Drug|etoposide|
45824322|NCT00004903|Drug|melphalan|
45824323|NCT00004903|Procedure|peripheral blood stem cell transplantation|
45824324|NCT00004357|Drug|Methylprednisolone|IV
45824325|NCT00004357|Drug|Prednisolone|Oral
45824326|NCT00004363|Drug|chlorpropamide|
45824327|NCT00004363|Drug|desmopressin|
45824328|NCT04069117|Drug|letrozole 2.5mg (Femara; Novartis Pharma Services, Basel, Switzerland)|letrozole /antagonist protocol
45824329|NCT00004921|Biological|filgrastim|
45824330|NCT00004921|Drug|carboplatin|
45824331|NCT00004921|Drug|cyclophosphamide|
45824332|NCT00004921|Drug|melphalan|
45824333|NCT00004921|Drug|paclitaxel|
45824334|NCT00004921|Procedure|adjuvant therapy|
45824335|NCT00004921|Procedure|bone marrow ablation with stem cell support|
45824336|NCT00004921|Procedure|peripheral blood stem cell transplantation|
45824337|NCT00004375|Procedure|ultraviolet A-1 light treatment|
45824338|NCT00004927|Drug|ixabepilone|
45824339|NCT00004933|Drug|hydroxyurea|0.5 to 5 grams PO per day
45824340|NCT00004933|Drug|Homoharringtonine|2.5 mg/ sq m/ day CIVI for 14 days
45824341|NCT00004939|Drug|,4-diaminopyridine|
45824342|NCT00004981|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
45824343|NCT00004981|Drug|Lamivudine/Zidovudine|
45824344|NCT00004981|Drug|Abacavir sulfate|
45824345|NCT00004987|Drug|Dextrin 2-sulfate|
45824346|NCT00004993|Drug|Parathyroid hormone (hPTH 1-34)|
45824347|NCT00004999|Drug|Lamivudine/Zidovudine|
45824348|NCT00004999|Drug|Capravirine|
45824349|NCT00004999|Drug|Nelfinavir mesylate|
45824350|NCT00003361|Drug|decitabine|
45824351|NCT00003367|Dietary Supplement|green tea|
45824352|NCT00003367|Dietary Supplement|soy protein isolate|
45824353|NCT00003367|Dietary Supplement|vitamin E|
45824354|NCT00003379|Drug|cisplatin|
45824355|NCT00003379|Drug|paclitaxel|
45824356|NCT00003379|Radiation|brachytherapy|
45824357|NCT00003379|Radiation|radiation therapy|
45824358|NCT00003385|Drug|carboplatin|
45824359|NCT00003385|Drug|paclitaxel|
45824360|NCT00003385|Drug|pegylated liposomal doxorubicin hydrochloride|
45824361|NCT00004381|Drug|tin mesoporphyrin|
45824362|NCT00005005|Drug|PTH|
45824363|NCT00005005|Drug|Alendronate|
45824364|NCT00004387|Procedure|fetal nigral transplantation|
45824365|NCT00004393|Drug|risperidone|
45824366|NCT00004399|Drug|magnesium sulfate|
45824367|NCT00004399|Drug|nimodipine|
45824368|NCT00004423|Drug|-aminosalicylic acid|
45824369|NCT00005017|Drug|Ritonavir|
45824370|NCT00005017|Drug|Abacavir sulfate|
45824371|NCT00005017|Drug|Amprenavir|
45824372|NCT00005017|Drug|Efavirenz|
45824373|NCT00005017|Drug|Lamivudine|
45824374|NCT00005017|Drug|Stavudine|
45824375|NCT00005023|Biological|HER-2/neu peptide vaccine|
45824376|NCT00005023|Biological|sargramostim|
45667534|NCT01866826|Other|Placebo|subject will receive three capsules of placebo by mouth twice daily.
45966087|NCT00186641|Procedure|high dose chemo and auto hematopoietic cell transplant|
45966088|NCT00218751|Behavioral|Home Visiting|
45966089|NCT00186680|Procedure|high dose chemo then auto hematopoietic cell transplant|
45966090|NCT00211614|Drug|Lansoprazole|
45455615|NCT03524248|Radiation|Image guided radiation therapy|Real-time 4D video imaging guidance with combination use of cone-beam computerized tomography (CBCT) useful for daily setup and target motion tracking in advanced image-guided radiotherapy (IGRT).
45667535|NCT04579276|Procedure|Thoracic paravertebral block|Intrathoracic method undergone through video assisted surgery (VATS
45667536|NCT04579276|Procedure|thoracic epidural analgesia|locoregional analgesia under ultrasound control
45455616|NCT03930901|Other|Health education learning package|Health education learning package (HELP) was introduced to children in the selected schools. The package involved different items and activities during the study period, e.g. comic booklet on the intestinal parasitic infections, stand banners, posters, lectures, songs, drawing competition, puppet show, lectures, with a toolkit that involved soap, slipper (plastic clogs shoes), & nail clipper).
45455617|NCT02290678|Behavioral|Adventure-based Programming|
45667537|NCT04584970|Device|Applied VR|The Applied VR device is a lightweight mobile virtual reality headset with embedded software, creating an immersive experience. The Applied VR is specifically designed for medical use.
45667538|NCT04584970|Device|Apple iPad|The Apple iPad is a tablet device controlled by touch screen with a variety of games and applications.
45667539|NCT01791244|Drug|Rebif®|
45667540|NCT01865812|Drug|Obeticholic Acid|All participants were treated with OCA (oral administration, 10 mg, once daily [QD]) for 8 weeks and continued their prestudy dose of ursodeoxycholic acid (UDCA). After completion of the 8-week Primary Treatment Phase of the study and the 4-week follow-up period, during which time participants did not take OCA, all eligible participants were offered the opportunity to enter an open-label, long-term safety extension phase, during which they could receive 10 mg OCA QD for up to 2 years.
45667541|NCT04600258|Dietary Supplement|Dark Chocolate|The patients will receive 40g per day of dark chocolate for 2 months
45667542|NCT01808092|Drug|ceftazidim-avibactam (CAZ-AVI, experimental product)|2000mg ceftazidime plus 500mg avibactam
45667543|NCT01808092|Drug|meropenem (active comparator)|1000mg of Meropenem
45667544|NCT04584814|Device|No intervention|Basal analysis
45966091|NCT00218790|Procedure|Cool Dialysate|Decreased temperature of the dialysis bath
45966092|NCT00186758|Device|Transcranial Magnetic Stimulation (TMS)|"Phase l clients receive either True or Sham TMS treatments on left or right side of head for 10 days.~Phase ll clients will receive either Sham or True TMS treatments on the other side of the head - the same type as in phase l -"
45966093|NCT00186797|Procedure|Allogeneic stem cell transplant|
45966094|NCT00186797|Drug|Fludarabine, Cyclophosphamide|
45966095|NCT00211653|Drug|N-Acetylcysteine|
45966096|NCT00186836|Biological|Engerix-B and Twinrix|
45966097|NCT00218868|Procedure|Skin scrape|scrape cytology using two different cytological staining techniques, and additional touch imprint cytology compared with histopathology of superficial basal cell carcinoma and actinic keratosis
45966098|NCT00186914|Biological|Marrow stromal cell infusion|"This is a pilot study of infusions of ex vivo expanded, gene marked donor bone marrow stromal cells following allogeneic bone marrow transplantation. The study is a within patient dose escalation safety evaluation. It is believed that this patient population may benefit from these donor stromal cell infusions.~As the stromal cells will be obtained from the original stem cell donor, no conditioning is required.~Patients will receive two infusions of mesenchymal cells (MSC) approximately 14 to 21 days apart unless there is unacceptable toxicity after the first infusion. The first dose of cells to be given will be 1x10^6 MSC/kg and the second dose of cells will be 5x10^6 MSC/kg. The patients will be followed for approximately 28 days following the second infusion for any toxicity. Only after all six patients have safely completed both infusions will we consider 5 x 10^6 MSC/kg a safe dose of allogeneic mesenchymal stem cells for infusion."
45966099|NCT00211731|Behavioral|Chronic Disease Self Management Course|
45966100|NCT00186953|Drug|Optison|"Intervention description:~Based on recommendation by the FDA, we began with a dose of 0.125ml/m^2 and escalated at 0.15 ml/m^2 increments, to 0.275 ml/m^2 and 0.425ml/m^2 and 0.500ml/m^2. We will now continue to escalate the dose of Optison at 0.300ml/m^2 increments to a maximum single dose of 4ml or a total cumulative dose of 8.7 ml as recommended by the manufacturer."
45966101|NCT00218907|Procedure|Educational video|
45966102|NCT00187031|Drug|Topotecan, Filgrastim (G-CSF), Pegfilgrastim|See detailed description section for additional details.
45966103|NCT00187070|Drug|Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine|See Detailed Description section for details of treatment interventions.
45966104|NCT00187070|Procedure|Stem cell transplant,|See Detailed Description section for details of treatment interventions.
45667545|NCT04584814|Device|scare ventilator at 20|To set scare ventilator by 20 cycles per minute
45667546|NCT04584814|Device|scare ventilator at 40|To set scare ventilator by 40 cycles per minute
45966105|NCT00187070|Radiation|Radiation Therapy|See Detailed Description section for details of treatment interventions.
45667547|NCT01774084|Dietary Supplement|Experimental: PreOp, NutriciaNordica AB|
45966106|NCT00211770|Behavioral|Behavioral Assessment|functional behavioral assessments are conducted at two separate visits for each subject.
45966107|NCT00187109|Drug|Recombinant Human Thrombopoietin|
45966108|NCT00412308|Procedure|Tidal volume used in mechanical ventilation|
45966109|NCT00187148|Biological|EnvDNA|administered as 100 mcg of DNA in 1.5mL PBS every 28 days for 3 injections
45966110|NCT00211848|Drug|Polyenylphosphatidylcholine (PPC)|
45667548|NCT01774084|Dietary Supplement|Placebo Comparator: Water|
45966111|NCT00211848|Drug|Pegylated Interferon|
45966112|NCT00211848|Drug|Ribavirin|
45667549|NCT01807234|Drug|Ketorolac|Single dose of Ketorolac (Sprix) nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
45966113|NCT00187187|Device|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
45667550|NCT01807234|Drug|Sumatriptan|Sumatriptan (Imitrex) 20 mg one single dose of nasal spray for an acute migraine attack.
45667551|NCT01807234|Drug|Placebo|Placebo one spray in each nostril and placebo one nasal spray.
45824377|NCT00005029|Drug|topotecan hydrochloride|
45824378|NCT00005035|Drug|oxaliplatin|
45824379|NCT00004429|Drug|growth hormone|
45824380|NCT00005041|Drug|tipifarnib|
45824381|NCT00004441|Drug|tauroursodeoxycholic acid|
45667552|NCT04571242|Device|DTM Programming|DTM-SCS programming
45966114|NCT00187187|Device|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
45966115|NCT00412347|Drug|Insulin Drip Therapy|
45966116|NCT00187265|Device|Cardiac Resynchronization Therapy|
45966117|NCT00187304|Device|Aortic valve replacement|
45966118|NCT00211926|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single dose of vaccine containing 100 mcg of each serotype conjugate
45966119|NCT00211926|Biological|placebo|single dose of placebo
45966120|NCT00187343|Device|Breast IMRT|
45966121|NCT00218946|Drug|Sucrose|30 % sucrose
45966122|NCT00218946|Device|Pacifier|
45667553|NCT04571242|Device|Conventional SCS programming|Conventional SCS programming
45966123|NCT00218946|Other|sterile water|
45966124|NCT00187382|Drug|Multiple vs. single courses of antenatalcorticosteroids|
45966125|NCT00218985|Behavioral|Exercise training|Intensity controlled exercise training before the scheduled bypass surgery
45966126|NCT00187421|Procedure|Indocyanine green intraoperative angiogram and transit-time flowmetry|"ICG graft angiography following each distal anastomosis, and imaging of proximal anastomoses after all grafts completed.~transit time flowmetry performed on all grafts after all grafts completed."
45667554|NCT01790932|Drug|BKM120|
45667555|NCT02377427|Drug|Mepolizumab|Mepolizumab is supplied as 100 mg lyophilised cake in sterile vials for subcutaneous administration in upper arm or thigh. The vial will be reconstituted with sterile water for injection prior to individual use.
45667556|NCT02421887|Drug|Antioxidant Supplement|An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine
45667557|NCT02421887|Other|Placebo|Placebo
45667558|NCT01609582|Drug|TAK-875|TAK-875 tablets
45824382|NCT00004441|Drug|ursodiol|
45824383|NCT00005053|Drug|glufosfamide|
45824384|NCT00004465|Drug|SYNSORB Pk|
45824385|NCT00004465|Drug|Placebo|
45824386|NCT00005569|Drug|SLPI (Secretory Leukocyte Protease Inhibitor)|
45824387|NCT00005575|Drug|Imipramine|
45824388|NCT00005575|Behavioral|Cognitive-behavior therapy|
45824389|NCT00385333|Procedure|Feasibility Study - Imaging System|
45824390|NCT00004471|Genetic|pGT-1 gene lipid complex|
45824391|NCT00005059|Drug|carboplatin|
45824392|NCT00005059|Drug|paclitaxel|
45824393|NCT00005065|Drug|paclitaxel|Given IV
45824394|NCT00005065|Drug|carboplatin|Given IV
45824395|NCT00005065|Drug|motexafin gadolinium|Given IV
45824396|NCT00005065|Procedure|conventional surgery|Undergo complete surgical resection
45824397|NCT00005065|Radiation|radiation therapy|Undergo radiation therapy
45966127|NCT00211965|Biological|S. aureus Types 5 and 8 Capsular Polysaccharide Conjugate|single IM dose of 200 mcg total conjugate
45966128|NCT00211965|Biological|placebo|single dose IM
45966129|NCT00219024|Drug|aliskiren|
45966130|NCT00187460|Behavioral|Publicly released hospital cardiac report cards|Participating hospital corporations were randomized to either early feedback or delayed feedback (21 months later) in the form of publicly released hospital report cards of performance on a set of cardiac process-of-care quality indicators.
45966131|NCT00187499|Drug|Inhaled fluticasone 500 ug BID for 8 weeks|
45966132|NCT00212004|Drug|pioglitazone|
45966133|NCT00212004|Other|control|
45966134|NCT00187538|Behavioral|Dietary|dietary
45966135|NCT00219063|Drug|aliskiren|
45966136|NCT00187577|Drug|Latanoprost (Xalatan)|
45966137|NCT00187577|Drug|Bimatoprost (Lumigan)|Bimatoprost solution will be applied to affected eyelid(s) with cotton-tipped applicator daily.
45966138|NCT00187577|Drug|Topical application of latanoprost solution to eyelid|Subject will apply latanoprost to affected eyelid with cotton-tipped applicator daily.
45824398|NCT00386191|Drug|clopidogrel (SR25990C)|oral administration
45667559|NCT01609582|Drug|TAK-875 Placebo|TAK-875 placebo-matching tablets
45667560|NCT01789606|Drug|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
45667561|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/8 mg, orally once daily
45667562|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/16 mg, orally once daily
45824399|NCT00386269|Drug|Codeine Phosphate Analgesia|
45824400|NCT00005071|Procedure|biopsy|
45824401|NCT00005071|Procedure|bronchoscopy|
45824402|NCT00005071|Procedure|computed tomography|
45824403|NCT00005071|Procedure|quality-of-life assessment|
45824404|NCT00423241|Device|SEMPERFLO Pain Management System|continuous infusion of 0.5% bupivacaine at 2mL per hour
45824405|NCT00423241|Device|ON-Q PainBuster Post-Op Pain Relief System|continuous infusion of 0.5% bupivacaine at 2mL per hour
45824406|NCT00385177|Drug|SN2310 Injectable Emulsion|Escalating doses given IV every three weeks
45824407|NCT00005581|Drug|cyclophosphamide|
45824408|NCT00005581|Drug|epirubicin hydrochloride|
45824409|NCT00005581|Drug|fluorouracil|
45824410|NCT00005581|Drug|paclitaxel|
45824411|NCT00005077|Drug|oxaliplatin|
45824412|NCT00004489|Drug|alendronate sodium|
45824413|NCT00004489|Drug|calcium carbonate|
45824414|NCT00004489|Drug|cholecalciferol|
45966139|NCT00212043|Drug|carboplatin and gemcitabine|
45966140|NCT00219102|Drug|aliskiren|
45966141|NCT00212082|Drug|doxorubicin, docetaxel|
45966142|NCT00187733|Other|Fasting blood and urine collection|Not applicable no drugs dispensed
45966143|NCT00219180|Drug|aliskiren|
45667563|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/16 mg, orally once daily
45667564|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/32 mg, orally once daily
45667565|NCT01773226|Device|"Autologous Protein Solution APS(TM)"|A therapy prepared at the point-of-care from a small sample of the patient's own blood containing high concentrations of anti-inflammatory and anabolic proteins
45667566|NCT01773070|Drug|ABT-450/ritonavir|ABT-450 coformulated with ritonavir. Drug is not administered -- this study is follow-up for participants previously receiving the drug.
45824415|NCT00005083|Procedure|conventional surgery|
45824416|NCT00005083|Procedure|magnetic resonance imaging|
45824417|NCT00005083|Procedure|magnetic resonance spectroscopic imaging|
45824418|NCT00005587|Radiation|radiation therapy|
45824419|NCT00005593|Drug|carboplatin|Patients receive carboplatin IV continuously over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
45824420|NCT00005593|Drug|fludarabine phosphate|Patients receive fludarabine IV over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
45824421|NCT00005593|Drug|topotecan hydrochloride|This is a dose escalation study of topotecan. Patients receive topotecan IV continuously on days 6-8. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
45824422|NCT00004495|Drug|cyanocobalamin|
45824423|NCT00004495|Drug|folic acid|
45824424|NCT00004495|Drug|pyridoxine|
45824425|NCT00005089|Biological|rituximab|375 mg/m^2 on days 1,8 of cycle 1, then on days 1-3 of cycles 2-3.
45824426|NCT00005089|Drug|cyclophosphamide|750 mg/m^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
45824427|NCT00005089|Drug|doxorubicin hydrochloride|50 mg/m^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
45824428|NCT00005089|Drug|prednisone|100 mg on days 10-14 of cycle 1, then on days 3-7 of cycles 2-3.
45824429|NCT00005089|Drug|vincristine sulfate|1.4 mg/m^2 on day 10 of cycle 1, then on day 3 of cycles 2-3.
45824430|NCT00005089|Radiation|radiation therapy|4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
45824431|NCT00004549|Procedure|Magnetic resonance imaging|
45824432|NCT00005599|Drug|bryostatin 1|
45824433|NCT00005599|Drug|paclitaxel|
45824434|NCT00004561|Behavioral|exercise|
45824435|NCT00005611|Drug|BMS-188797|
45824436|NCT00004567|Drug|Mycophenolate Mofetil|
45824437|NCT00005113|Drug|Cyclosporine|Oral tablet taken daily. Dosage is dependent on weight and is titrated to target trough level.
45966144|NCT00187772|Behavioral|Child-Parent Psychotherapy (CPP)|
45966145|NCT00187811|Procedure|Delta amino leavulinic acid photodynamic therapy|
45966146|NCT00212160|Procedure|omentectomy|RYGB with omentectomy
45966147|NCT00187850|Procedure|PP|Partial pulpotomy
45966148|NCT00187850|Procedure|DPC|Direct pulp capping
45966149|NCT00219219|Drug|Zoledronic acid|
45966150|NCT00187928|Drug|Topiramate|
45824438|NCT00005113|Drug|Sirolimus|Dosage in liquid or tablet form is dependent on body surface area and is titrated to target trough level.
45966151|NCT00212199|Drug|orlistat|
45966152|NCT00212199|Behavioral|Brief cognitive behavioral counseling|
45667567|NCT01773070|Drug|ABT-333|Drug is not administered -- this study is follow-up for participants previously receiving the drug.
45667568|NCT01773070|Drug|ABT-267|Drug is not administered -- this study is follow-up for participants previously receiving the drug.
45824439|NCT00005113|Drug|Tacrolimus|dosage is in oral form titrated to target trough level
45966153|NCT00187967|Device|pumps used for cardiopulmonary bypass|
45667569|NCT01772368|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~Fp at 100 mcg was an active comparator (single dose). Further, participants were instructed to administer two inhalations of Fp MDPI 50 mcg twice daily (100 mcg total dose) during the Run-in (to replace the participant's current inhaled corticosteroid) and Washout Periods between treatments."
45966154|NCT00219258|Drug|Zoledronic acid|
45667570|NCT01772368|Drug|FS MDPI|FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. The fluticasone propionate component was a fixed dose of 100 mcg. The salmeterol xinofoate dosage varied: 6.25, 12.5, 25 or 50 mcg.
45966155|NCT00188006|Device|heparin-coated cardiopulmonary bypass|
45966156|NCT00212238|Behavioral|internet behavioral weight loss program|
45966157|NCT00188045|Drug|Propranolol - Spironolactone|
45966158|NCT00212277|Drug|Norethindrone,Ethinyl Estradiol|
45966159|NCT00188084|Procedure|DNA Index|
46080393|NCT05579054|Diagnostic Test|Foot Posture Index (FPI-6)|FPI-6 is a valid and reliable assessment tool for pediatrics in which 6 items are scored separately for the right and left feet while the patient was in an upright position in a relaxed posture with their body-weight evenly distributed on the both feet. Each item is scored as -2, -1, 0, 1, 2 and the assessment categorized as follows: 0 to +5 normal; +6 to +9 pronated; 10+ higly pronated; -1 to -4 supianted; and -5 to -12 higly supinated.
46080394|NCT04260113|Drug|Apatinib Mesylate|Apatinib orally 500mg once daily half an hour after meal
45667571|NCT01772368|Drug|Advair Diskus|ADVAIR DISKUS (100/50 mcg fluticasone propionate/salmeterol xinafoate) consists of a dry powder formulation of fluticasone propionate and salmeterol xinafoate in a lactose excipient. The dry powder is contained within individual blisters on a double foil strip within the device. Activation of the device opens a single blister of medication which is then dispersed into the air-stream by patient inhalation.
45667572|NCT01772368|Drug|Albuterol|Albuterol (Pro-Air) hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
45824440|NCT00005617|Biological|dendritic cell-MART-1 peptide vaccine|Number DC: dependent on the group route of immunization: dependent on the group subjects will receive 3 biweekly vaccinations. In case of grade III-IV toxicity in 1/3 subjects at any dose group or route, up to 6 subjects will be included in that group.
45824441|NCT00005617|Procedure|leukapheresis|Patients require a single leukapheresis to obtain 2x10^9 PBL, which are cryopreserved in RPMI 1640, 20% autologous serum, 10% DMSO. Aliquots are thawed at days -7, 7 and 21 for the first, second, and third immunizations respectively. Blood is drawn at the time of leukapheresis and on the day of the first vaccination for autologous serum, which is sufficient for the cell cultures of all patient groups.
45824442|NCT00004573|Drug|ganciclovir|
45824443|NCT00005623|Drug|cyproterone acetate|
45824444|NCT00005623|Procedure|quality-of-life assessment|
45966160|NCT00188084|Procedure|S-Phase%|
45966161|NCT00188084|Procedure|CD45 expression|
45966162|NCT00188084|Procedure|P16 metabolic way|
45966163|NCT00212316|Drug|sodium phenylbutyrate|
45966164|NCT00219336|Behavioral|Self-guided Motivational Intervention|Using a randomized two-group design, a self-guided motivational intervention based on Project CHOICES will be compared to an informational only intervention, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS.
45966165|NCT00219336|Behavioral|Informational Only|Using a randomized two-group design, an informational intervention using a brochure from the CDC will be compared to a self-guided motivational intervention based on Project CHOICES, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS
45966166|NCT00188162|Device|CT|
45966167|NCT00219375|Drug|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
45966168|NCT00219375|Drug|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
45966169|NCT00188240|Drug|Pegasys; Copegus.|
45966170|NCT00188279|Procedure|Minimum Dose Computed Tomography (MnDCT) scan|Minimum Dose Computed Tomography (MnDCT) scan at regular follow up intervals for up to 5 years post-operatively.
45966171|NCT00219414|Device|Adacolumn Apheresis System|
45966172|NCT00188318|Procedure|hyperfractionated accelerated radiotherapy|
45966173|NCT00219453|Device|Jet Injector with Protector Cap (HSI-500)|
45966174|NCT00188357|Behavioral|Education|
45966175|NCT00188396|Drug|Citalopram|
45966176|NCT00212433|Drug|Tagitol V, Lo So, Readi-Cat 2|
45966177|NCT00188435|Procedure|Minimum Dose CT|
45966178|NCT00219531|Behavioral|perception of rectal balloon distention|functional Magnetic Resonance Imaging (fMRI) study with measurement of brain MRI response to rectal balloon distention.
45455618|NCT01220479|Behavioral|Exercise training program|"Exercise Diabetic and Healthy groups perform a similar training program including two exercise sessions per week, of 90 minutes each, during 9 months (excluding holidays) under supervision by physical education teachers and pediatricians. Sessions comprise various weight-bearing activities: rope skipping, jumping, ball games and gymnastics.~Control groups are relatively inactive."
45667573|NCT01788046|Drug|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at weeks 5, 9, 13, and 17 (4-week intervals) by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
45667574|NCT01788046|Drug|Placebo|Administered intravenously (IV) three times per week.
45966179|NCT00188474|Behavioral|LCADLS, FACIT-PAL, FACIT-TS questionnaires|LCADLS, FACIT-PAL, FACIT-TS questionnaires
45966180|NCT00219570|Drug|clindamycin|
45966181|NCT00219570|Drug|nadifloxacin|
45966182|NCT00188513|Procedure|conformal intensity modulated radiotherapy (IMRT)|
45966183|NCT00212472|Drug|Factor VIII concentrates|To be determined at the discretion of the investigator.
45966184|NCT00212472|Other|Low-dose treatment|50 FVIII u/kg three times a week.
45966185|NCT00212472|Other|High-dose treatment|200 FVIII u/kg per day.
45966186|NCT00188552|Drug|pentoxifylline|
45966187|NCT00188552|Drug|α-Tocopherol|
45966188|NCT00411606|Procedure|Thermography|Subjects will have a picture of their face taken with a thermal camera
45966189|NCT00411723|Drug|RTL1000 (recombinant T cell receptor ligand)|Dosage form: IV infusion. Dosage: Single dose @ 2, 6, 20, 60, 100 or 200mg. Duration: 1 - 2 hours.
45966190|NCT00411723|Drug|RTL1000 Placebo|Dosage form: IV infusion. Dosage: Same volume as Experimental. Frequency: Single dose. Duration: 1 - 2 hours.
45966191|NCT00188630|Drug|N-acetylcysteine|
45455619|NCT01126177|Drug|Interferon beta 1a|SNG001, IFN-β1a solution for inhalation
45667575|NCT01806298|Drug|Saizen® solution for injection (referred as Saizen®)|Saizen® solution for injection will be administered subcutaneously daily for 39 weeks according to locally approved product labeling for the currently marketed formulation of Saizen®.
45667576|NCT01772134|Drug|Umeclidinium bromide 62.5mcg|Inhalation Powder, LAMA 62.5mcg
45824445|NCT00005119|Procedure|Measures of calcium and bone turnover|
45824446|NCT02972749|Behavioral|Intervention|Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy.
45824447|NCT00005629|Biological|AFP gene hepatocellular carcinoma vaccine|"Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.~Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug"
45824448|NCT00004579|Biological|gp160 MN/LAI-2|
45824449|NCT00004579|Biological|ALVAC-HIV MN120TMG (vCP205)|
45824450|NCT00004585|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
45667577|NCT01772134|Drug|Umeclidinium bromide 125mcg|Inhalation Powder, LAMA 125mcg
45667578|NCT01772134|Drug|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation Powder, ICS/LABA
45667579|NCT01772134|Drug|Placebo|Inhalation Powder, Placebo
45824451|NCT00004585|Drug|Lamivudine/Zidovudine|
45824452|NCT00004585|Drug|Abacavir sulfate|
45824453|NCT00004585|Drug|Efavirenz|
45824454|NCT00005635|Biological|trastuzumab|
45824455|NCT00005635|Drug|paclitaxel|
45824456|NCT00005137|Other|exercise program|subjects were measured before and after a 20-week long on-site exercise training program
45824457|NCT00004639|Procedure|Furlow double z-plasty palatoplasty palate repair|
45824458|NCT00004639|Procedure|Von Langenbeck palatoplasty palate repair|
45824459|NCT00005641|Biological|anti-thymocyte globulin|
45824460|NCT00005641|Drug|busulfan|
45824461|NCT00005641|Drug|cyclophosphamide|
45824462|NCT00005641|Drug|cyclosporine|
45824463|NCT00005641|Drug|leucovorin calcium|
45966192|NCT00188630|Other|5% dextrose solution|
45966193|NCT00219609|Drug|UK-390,957|
45966194|NCT00188669|Drug|pentoxifylline|
45966195|NCT00188669|Drug|alpha-Tocopherol|
45966196|NCT00188747|Procedure|Thromboelastograph, Point of Care|
45966197|NCT00219648|Drug|PEP03|
45966198|NCT00409214|Drug|LS11 (talaporfin sodium)|
45966199|NCT00409214|Device|Light source (interstitial light emitting diodes)|
45966200|NCT00409214|Procedure|Intraoperative placement of device in glioma|
45966201|NCT00219687|Other|dispatcher-assisted CPR with compressions & ventilations|Delivery of telephone CPR instructions to lay callers with chest compressions and ventilations when the patient is identified to be in cardiac arrest
45966202|NCT00219687|Other|dispatcher-assisted CPR instructions with compressions only|Delivery of telephone CPR instructions to lay callers with hands-only chest compressions when the patient is identified to be in cardiac arrest
45966203|NCT02963051|Drug|Copper|1 mg, 3 mg, 5 mg or 7 mg intravenously on cycle 1 day 1, 8 and 15
45966204|NCT02963051|Drug|Disulfiram|"80 mg three times a day~Source of disulfiram: Cantex Pharmaceuticals"
45966205|NCT02963051|Drug|Copper gluconate|"1.5 mg three times a day~Source of copper gluconate: Cantex Pharmaceuticals"
45966206|NCT00219726|Drug|Imatinib mesylate|
45966207|NCT00409253|Drug|URAPIDIL (EUPRESSYL*)|Urapidil (Eupressyl*) :IV (PSE) 1 microg/kg/min° until reduction PAM 15 %. Reduction ¼ of the posology to obtain PAM between 105 and 125 mmHg with adjustment 0.25 microg/kg/min/15 min. Maximal dose = 30mg/h.
45966208|NCT00409253|Drug|NICARDIPINE|Nicardipine : IV 6.25 mg bolus until PAD >105 mm/Hg. Perfusion (PSE) 4 mg/h to obtain PAM between 105 and 125 mm/Hg with adjustment 2mg/h/5 min without overshoot 20 mg/h Maximal treatment duration : 7 days
45966209|NCT00219765|Drug|Imatinib mesylate 600 mg|
45966210|NCT00219765|Drug|Cytarabine|
46080395|NCT02738736|Behavioral|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions
46080396|NCT00930319|Other|Firmagon given by prescription according to SPC|Non-interventional,observational Firmagon given by prescription according to SPC
46080397|NCT00608387|Behavioral|Chronic disease management Web-based software|Participants will have access to remotely based medical providers through the use of the Web-based software.
46080398|NCT02728986|Device|Profore|Profore multilayer compression bandage + standard regimen for wound care according to investigator's choice
45667580|NCT01994889|Drug|Tafamidis|Tafamidis 20 mg in soft gel capsules administered once a day for 30 months
45667581|NCT01994889|Drug|Tafamidis|Tafamidis 80 mg in soft gel capsules administered once a day for 30 months
45667582|NCT01994889|Drug|Placebo|Placebo in soft gel capsules administered once a day for 30 months
45824464|NCT00005641|Drug|methotrexate|
45824465|NCT00005641|Drug|methylprednisolone|
45824466|NCT00005641|Procedure|allogeneic bone marrow transplantation|
45824467|NCT00005641|Procedure|in vitro-treated bone marrow transplantation|
45824468|NCT00005641|Radiation|radiation therapy|
45824469|NCT00004645|Procedure|Plasma exchange|
45824470|NCT00005647|Drug|paclitaxel|Patients receive paclitaxel IV over one hour on day 1. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
45966211|NCT00219765|Drug|Daunorubicine|
45966212|NCT00409370|Device|SOMA safe enclosure|
45966213|NCT00212550|Procedure|Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB.|Sputum induction
45966214|NCT00188786|Procedure|daily Cone Beam CT for imaging guidance for radiotherapy|
46080399|NCT02728986|Device|Coban2|Coban2 compression system + standard regimen for wound care according to investigator's choice
46080400|NCT02809274|Other|questionnaires|• Influence of iron parameters on Patient-reported symptoms as assessed by Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) for assessment of the severity of symptoms, Quality of life evaluation by The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and fatigue assessment by PROMIS Fatigue Scale: Short Form
46080401|NCT05249855|Behavioral|Psychological measurement|Psychological assessment
45667583|NCT02082483|Other|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
45667584|NCT02017899|Biological|S. sonnei 1790GAHB|
45667585|NCT02017899|Biological|Placebo|
45667586|NCT01993329|Drug|Gefapixant 50 mg|Gefapixant 50 mg tablet administered orally
45667587|NCT01993329|Drug|Gefapixant 300 mg|Gefapixant 300 mg tablet administered orally
45667588|NCT01993329|Drug|Placebo to mimic 50 mg tablets|Sugar pill manufactured to mimic gefapixant 50 mg tablets
45667589|NCT01993329|Drug|Placebo to mimic 300 mg tablets|Sugar pill manufactured to mimic gefapixant 300 mg tablets
45824471|NCT00005647|Drug|semaxanib|Patients receive SU5416 IV over one hour on days 1 and 4. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
45824472|NCT00005665|Drug|interferon alpha|
45824473|NCT00004669|Drug|hydrocortisone|
45824474|NCT00385411|Drug|valproate microgranules|20 to 30 mg/kg/day
45824475|NCT00004699|Drug|insulin-like growth factor I|
45824476|NCT00385489|Drug|LXR-623|
45824477|NCT00004705|Drug|amiloride|
45824478|NCT00004705|Drug|uridine|
45824479|NCT00004729|Behavioral|Ketogenic diet|
45824480|NCT00004735|Biological|Tetanus toxoid|
45824481|NCT00004735|Biological|Hepatitis A Vaccine (Inactivated)|
45824482|NCT00004747|Drug|mucoid exopolysaccharide P. aeruginosa immune globulin IV|
45824483|NCT00004759|Drug|methylprednisolone|
45824484|NCT00004759|Drug|tirilazad|
45824485|NCT00005713|Behavioral|Continuing, preventative care|Training for intervention clinic staff was based on National Asthma Education and Prevention Program guidelines for the diagnosis and management of asthma, and included screening to identify new cases and health education to improve family management.
45824486|NCT02972827|Device|NICOM/FloTrac|Use of noninvasive cardiac output and minimally invasive cardiac output monitors
45966215|NCT00212589|Drug|Capecitabine|
45966216|NCT00212589|Drug|Fluorouracil + folinic acid|
45966217|NCT00188825|Other|placebo|
45966218|NCT00188825|Drug|basiliximab|
45966219|NCT00212628|Drug|Minodronic acid hydrate|
45966220|NCT00219804|Drug|tetrabenazine or placebo|
45966221|NCT00188864|Drug|dexamethasone|
45966222|NCT00212667|Drug|ONO-5920|
45966223|NCT00188903|Procedure|Diastolic measurements during TEE|Transesophageal echocardiography with diastolic measurements
45966224|NCT00219843|Drug|PV-10 (rose bengal disodium, 10%)|
45824487|NCT02972827|Other|Crystalloid Fluid Challenge|500-1000ml Normal Saline or Plasmalyte intravenous fluid bolus will be given at baseline, and following a positive passive leg raise response as defined by a 10% or greater increase in any of: stroke volume index, cardiac index, or pulse pressure, as measured by the NICOM or FloTrac Monitors.
45667590|NCT04417101|Drug|Chinese Herb|The participants will be instructed to take their JBT and take it as a dose of 3 g (per bag) each time, trice daily for 4 weeks.
45966225|NCT00188942|Drug|Fluoxetine+Olanzapine|
45966226|NCT00188942|Drug|Olanzapine|
45966227|NCT00188942|Procedure|Functional Magnetic Resonance Imaging|
45966228|NCT00212706|Drug|ONO-8025 (KRP-197)|
45966229|NCT00219882|Drug|standardized turmeric root extract|1.5 gm of standardized tumeric root extract three times per day for seven consecutive days, followed by 3 gm of standardized tumeric root extract three times per day for seven consecutive days
45966230|NCT00189020|Biological|PCV7|PCV7 at age 2 and 4 months
45966231|NCT00189020|Biological|PCV7|PCV7 at age 2, 4 and 11 months
45966232|NCT00212745|Behavioral|Andrews/Reiter behavioral treatment for epilepsy|The behavioral intervention in this study uses lifestyle counseling to avoid triggers for seizures and strategies to stop beginning seizures. Participants are taught to practice meditative relaxation exercises.
45966233|NCT00219921|Drug|Intrathecal morphine at surgery, 0.1mg and placebo|
45966234|NCT00219921|Drug|Patient Controlled Analgesia with iv morphine and placebo|
45966235|NCT00219921|Drug|intrathecal morphine AND patient controlled analgesia with iv morphine|
45966236|NCT00212823|Drug|almotriptan malate|
45966237|NCT00189059|Drug|amitriptyline|
45667591|NCT02016183|Drug|Candesartan cilexetil / hydrochlorothiazide|Candesartan cilexetil / hydrochlorothiazide combination tablets
45824488|NCT00004771|Drug|leuprolide|
45966238|NCT00189176|Drug|Tetrathiomolybdate|
46080402|NCT02694510|Other|Light-protection of TPN solutions|TPN bags and infusion sets in the Light-protected group will be covered by aluminum foils to protect the inside TPN solution from exposure to ambient or photo-therapy lights in the NICU. Protection will be made throughout the study period until the infant reaches full feeding and TPN is discontinued.
45966239|NCT00219960|Drug|North American Ginseng (Panax Quinquefolius)|
45966240|NCT00189215|Device|cardiac stabilizer instead of cardiopulmonary bypass|
45667592|NCT02377349|Biological|Boostrix™|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
45667593|NCT02377349|Drug|Saline placebo|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
45667594|NCT02421419|Drug|Dexamethasone Sodium Phosphate|adreno-cortical steroid anti-inflammatory drug
45667595|NCT02421419|Drug|Xylocaine|a local anesthetic agent
45667596|NCT02421419|Drug|Sodium Chloride|Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment
45667597|NCT02420717|Drug|Cyclophosphamide|Given IV
45667598|NCT02420717|Drug|Cytarabine|Given IV
45667599|NCT02420717|Drug|Dasatinib|Given PO
45966241|NCT00212862|Other|Patients with chemotherapy induced anemia|Physicians are instructed to continue to treat all patients according to their own best clinical judgment, but to submit information on the parameters and outcomes of this treatment to the database. Patients will have to fill the questionaire at the time of enrollment and baseline.
45966242|NCT00189332|Drug|852A|
45966243|NCT00189371|Drug|paclitaxel, carboplatin, epoetin alpha|
45966244|NCT00212901|Drug|High dose ACE-I vs ARB|
45966245|NCT00189410|Drug|Pegylated Liposomal Doxorubicin and Carboplatin|
45966246|NCT00220038|Behavioral|smell tests|subjects are instructed to sniff two vials, one containing the solvent, the other a dilution of the odorant. They are asked to scan the vial with the stronger odor.
45966247|NCT00212940|Behavioral|Supportive Therapy for Adherence to ART (behavior)|
45667600|NCT02420717|Drug|Dexamethasone|Given PO or IV
45667601|NCT02420717|Drug|Doxorubicin|Given IV
45667602|NCT02420717|Other|Laboratory Biomarker Analysis|Correlative studies
45824489|NCT00004771|Drug|testosterone|
45824490|NCT00004789|Drug|heme arginate|
45966248|NCT00189527|Procedure|respiratory settings|
45966249|NCT00220077|Procedure|Endoscopy|
45966250|NCT00189566|Drug|Paclitaxel|
45966251|NCT00189566|Drug|Topotecan|
45966252|NCT00189566|Drug|Carboplatin|
45667603|NCT02420717|Drug|Leucovorin|Given IV or PO
45667604|NCT02420717|Drug|Mercaptopurine|Given PO
45667605|NCT02420717|Drug|Methotrexate|Given IV and PO
45667606|NCT02420717|Drug|Prednisone|Given PO
45667607|NCT02420717|Biological|Rituximab|Given IV
45667608|NCT02420717|Drug|Ruxolitinib Phosphate|Given PO
45667609|NCT02420717|Drug|Vincristine|Given IV
45824491|NCT00004789|Drug|tin mesoporphyrin|
45824492|NCT00004795|Drug|dehydroepiandrosterone|
45824493|NCT00005743|Behavioral|exercise|
45824494|NCT00005743|Behavioral|weight loss|
45824495|NCT00004801|Drug|monoclonal factor IX replacement therapy|
45824496|NCT00004807|Drug|dextromethorphan|
45824497|NCT00004807|Drug|topiramate|
45824498|NCT00004807|Drug|Donepezil|
45824499|NCT00004825|Drug|recombinant human insulin-like growth factor I|
45824500|NCT00385567|Drug|PEHRG214|
45824501|NCT00385645|Drug|Combivir+Kaletra|
45824502|NCT00385645|Drug|Combivir+Reyataz|
45824503|NCT00385879|Behavioral|Case management|
45824504|NCT00005305|Other|No interventions - observational study|
45824505|NCT00385957|Drug|AZT+3TC+IDV+RTV|
45966253|NCT00212979|Other|non intervention study|
45966254|NCT00189605|Device|Perc-DLR/Perc-DLG|Device technique will be used per IFU
45966255|NCT00189605|Drug|Fluoroscopy guided transforaminal epidural steroid injection (TFESI)|Injection of steroid solution into the lumbar level
45966256|NCT00220116|Drug|Capecitabine, Oxaliplatin|
45966257|NCT02963129|Drug|Mupirocin|Mupirocin ointment in the nose for 5 days
45966258|NCT02963129|Other|Placebo|Placebo ointment in the nose for 5 days
45966259|NCT00220155|Drug|Gemcitabine|
45966260|NCT00189644|Procedure|6 FEC 100|
45966261|NCT00189644|Procedure|4 FEC 100 followed by 4 Taxol|
45966262|NCT00213018|Drug|Carraguard (PC-515)|
45966263|NCT00189683|Procedure|Monitoring|
45966264|NCT00189683|Procedure|Xeloda|
45966265|NCT00213057|Drug|Carraguard (PC-515)|
45966266|NCT00189722|Drug|Tacrolimus|
45966267|NCT00220194|Drug|leuprolide acetate|
45667610|NCT02016105|Drug|GP2017 Adalimumab|
45824506|NCT00385957|Drug|AZT+3TC+EFV|
45824507|NCT00386035|Drug|Delayed ART|Participants follow a drug conservation (DC) regimen in which ART is stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count is at least 350 cells/mm3, and then are followed by episodic ART based on CD4 cell count.
45667611|NCT02016105|Drug|Humira ® Adalimumab|
45667612|NCT02400905|Device|BioMimics 3D Vascular Stent System|Femoropopliteal stenting
45667613|NCT02400749|Drug|Apremilast|"Apremilast tablets will be provided to sites in blister cards.~Patients will be provided a titration blister pack containing apremilast 10 mg, 20 mg and 30 mg at the Day 0 and week 16 visits (refer to section 6.1). Following the 6 day titration period (for Day 0 and week 16) blister packs will contain apremilast 30 mg bid or placebo bid."
45824508|NCT00386035|Drug|Continuous ART|Group 2 participants follow a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count.
45966268|NCT00189761|Drug|Tacrolimus|
45966269|NCT00213096|Drug|Nestorone/ethinyl estradiol contraceptive vaginal ring; levonorgestrel/ethinyl estradiol oral contraceptive|
45966270|NCT00189800|Drug|Solifenacin succinate|
45966271|NCT00220233|Drug|olmesartan medoxomil|
45667614|NCT02400749|Drug|Placebo|Placebo tablets will be provided to sites in blister cards.
45667615|NCT02420327|Drug|Placebo patch & placebo capsule|On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.
45667616|NCT02420327|Drug|Placebo patch & galantamine capsule|On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).
45667617|NCT02420327|Drug|Nicotine patch & placebo capsule|On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.
45667618|NCT02420327|Drug|Nicotine patch and galantamine capsule|On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).
45667619|NCT04898465|Other|Social Paediatric Intervention|Family will meet the hospital's social-paediatrician and social worker. Together they will evaluate the need for social support, risk for neglect and refer families for local social services if needed. The visit will contain primary and secondary prophylaxis of child abuse and neglect.
45667620|NCT04420559|Other|Intramuscular Injection|Intramuscular Benzathine Penicillin Injection Procedure
45824509|NCT00386113|Biological|Fluarix and adjuvanted influenza vaccine|
45966272|NCT00220233|Drug|amlodipine|
45966273|NCT00220233|Drug|hydrochlorothiazide|
45966274|NCT00220272|Drug|SR57667B|
46080403|NCT02812472|Other|Treadmill training with functional electrical stimulation|
46080404|NCT02812472|Other|Treadmill training without functional electrical stimulation|
45667621|NCT02374853|Drug|Vancomycin|Topical prophylactic antibiotic
45667622|NCT02374853|Other|No Vancomycin|Placebo: Sterile water. No Vancomycin.
45667623|NCT02015793|Biological|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
45667624|NCT02015793|Biological|Placebo for adalimumab|Placebo for adalimumab pre-filled syringe, administered by subcutaneous injection to maintain double-blind.
45824510|NCT00005107|Drug|N-monomethyl-L-arginine|
45824511|NCT00005773|Drug|Inhaled Nitric Oxide|Study gas was initiated at a concentration of 5 ppm, and the dose was increased to 20 ppm when the infant had <=20 mm Hg increase in PaO2 (less than full response).
45966275|NCT00189839|Drug|tacrolimus|Immunosuppression
45966276|NCT00213174|Behavioral|school playgrounds|
45966277|NCT00189878|Drug|Methotrexate (drug)|Methotrexate 10 to 15 mg weekly for 8 weeks
45966278|NCT00189878|Drug|placebo capsules|4-6 placebo capsules - identical to capsules containing methotrexate
45966279|NCT00220311|Drug|Fludarabine Phosphate (Fludara)|6 cycles (1 cycle: 5 treatment days every 28 days)
45966280|NCT00189917|Biological|IMVAMUNE (MVA-BN)|1x10E08 TCID50, subcutaneous vaccination
45966281|NCT00213213|Drug|Sucrose|
45966282|NCT00189956|Biological|IMVAMUNE (MVA-BN)|Two vaccinations of 0.5 ml MVA-BN vaccine, separated by a 4 week interval.
45966283|NCT00213252|Drug|Montelukast plus prednisolone|Single dose of oral prednisolone with a subsequent daily five-day course of oral Montelukast
45966284|NCT00213252|Drug|Prednisolone|Six daily doses of oral prednisolone
45966285|NCT00189995|Drug|clozapine|
45966286|NCT00189995|Drug|haloperidol|
45966287|NCT00213291|Drug|darbepoetin alfa|Darbepoetin alfa will be administered by SC/IV injection every 14-28 days. Patients starting on the 14 day dose regimen will receive two times their baseline weekly dose; patients on the 28 day schedule will receive four times their average weekly dose. The exception to a Q14 or Q28 dosing schedule will be for patients requiring 10 mcg every 10 days. These patients will go to 20 mcg Q21 days before extending to the Q28 day schedule. Naive patients will start on a dose of 0.9 mcg/kg every 14 days. Study subjects who are successfully treated for 12 weeks on the 14 day schedule may be enrolled in the 28 day schedule study.
45966288|NCT00190034|Drug|N-Acetylcysteine 600mg/tab|
45966289|NCT00412503|Drug|Topotecan, Temozolomide|
45966290|NCT00213330|Procedure|rectal distension|
45966291|NCT00190112|Procedure|ventral cardiac denervation|
45966292|NCT00412581|Drug|Lenalidomide|25 mg by mouth daily for 2 weeks, followed by 1 week of rest.
46080405|NCT05628714|Other|Patient decision aid for patients with superficial basal cell carcinoma|An online WebApp
46080406|NCT04116788|Device|Artefact IRM assessment|IRM
46080407|NCT02728908|Device|Medfield Strokefinder MD100|Measurement with Medfield Strokefinder MD100
45966293|NCT00412581|Drug|Dacarbazine|600 mg/m^2 intravenously on Day 1 of every study cycle.
45667625|NCT02347631|Device|Soft Contact Lens - Daily Disposable Alcon Dailies Total 1 and ACUVUE TruEye|"Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the trial. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this experimental arm, Alcon Dailies Total 1 lenses will be worn first."
45966294|NCT00412620|Drug|ABT-925|
45966295|NCT00412620|Drug|Placebo|
45966296|NCT00190151|Drug|ciprofloxacin|
45966297|NCT00190190|Procedure|With Peeling of Limiting the Intern of the Retina|With Peeling of Limiting the Intern of the Retina
45455620|NCT01126177|Drug|Placebo|Placebo (excipients of the SNG001 solution only)
45966298|NCT00190190|Procedure|Internal limiting membrane peeling|Traditional Procedure Without Peeling of Limiting
45966299|NCT00412659|Procedure|Surgery for pilonidal disease, midline excision|A midline excision is made for the treatment of pilonidal sinus disease.
45966300|NCT00412659|Procedure|Surgery for pilonidal disease, Karydakis operation|A Karydakis operation is done for the treatment of pilonidal sinus disease.
46080408|NCT00927251|Device|Pacing Lead (Model 4296 LV Lead)|Implant and follow-up of study device
46080409|NCT02738658|Device|Bioresorbable vascular scaffold|
46080410|NCT02738658|Device|Everolimus-eluting stent|
46080411|NCT04259567|Device|Cytokine absorption|Use of CytoSorb absorber
45824512|NCT00005773|Drug|Standard iNO therapy|Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI >=25).
45824513|NCT00005779|Drug|Interleukin-12|
46080412|NCT02733510|Drug|methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
46080413|NCT02809508|Dietary Supplement|Oily fish|A selection of oily fish, including salmon, herring and mackerel, provided for dinner and lunch
45824514|NCT00005779|Biological|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
45824515|NCT00005785|Drug|GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV|
45824516|NCT00005791|Drug|cisplatin|
45824517|NCT00005791|Drug|fluorouracil|
45824518|NCT00005791|Drug|irinotecan hydrochloride|
45824519|NCT00005797|Drug|busulfan|administered on Day -7 through Day -4. The total dose is 12.8 mg/kg
45824520|NCT00005797|Drug|Cyclophosphamide|administered at a dose of 60 mg/kg on each of two successive days (Days -3 and -2)
45824521|NCT00005797|Drug|VP-16|administered as a single infusion on Day -3. The dose is 60 mg/kg and is calculated on actual body weight unless the patient's weight is >/= 150% of IBW, in which case adjusted body weight will be used.
45824522|NCT00005797|Radiation|Fractionated Total Body Irradiation (FTBI)|FTBI is performed on day -7 through day -4. The total dose of radiation is 1,320 cGy.
45824523|NCT00386347|Drug|GSK364735 oral solution and oral tablets|
45824524|NCT00005809|Procedure|computed tomography|
45824525|NCT00005809|Procedure|diagnostic colonoscopy|
45824526|NCT00005815|Drug|temozolomide|
45966301|NCT00190229|Drug|Cyclophosphamide|Cyclophosphamide
45966302|NCT00213408|Procedure|Radiofrequency catheter ablation of typical atrial flutter|
45966303|NCT00190268|Drug|3,4-diaminopyridine|3,4-diaminopyridine
45966304|NCT00220350|Drug|leuprolide acetate|
45966305|NCT00190307|Drug|aspirin 75 mg/day|aspirin 75 mg/day
45966306|NCT00220389|Drug|SPM 907|
45966307|NCT02963168|Drug|Oradoxel|oral docetaxel will be supplied in capsules and oral HM30181A-UK tablets
45966308|NCT00409448|Behavioral|Counselor-assisted problem solving (CAPS)|In CAPS, a trained counselor will guide families through a 6-month structured online problem-solving and skill-building program via one-on-one videoconference sessions.
45966309|NCT00409448|Behavioral|Internet-resource comparison (IRC)|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources, but not the CAPS website content.
45966310|NCT00190346|Device|Humidification devices: HH vs HME|
45966311|NCT00190385|Procedure|Ultrasonographic screening|Ultrasonographic screening
45966312|NCT00190424|Drug|CpG-ODN|
45966313|NCT00122798|Procedure|Stroke treatment|
45966314|NCT00190463|Drug|Amphotericin B|
45966315|NCT00213486|Drug|irinotecan|
45966316|NCT00190502|Drug|Polyclonal anti-T-cell antibodies|
45966317|NCT00220428|Biological|T-Cell Vaccination|
45966318|NCT00190541|Procedure|Mesorectal excision with lateral lymph node dissection|Mesorectal excision with lateral lymph node dissection
45966319|NCT00190541|Procedure|Mesorectal excision without lateral lymph node excision|Mesorectal excision without lateral lymph node excision
46080414|NCT02809508|Dietary Supplement|Poultry|A selection of poultry, mainly chicken, provided for dinner and lunch
46080415|NCT05543876|Procedure|suturing procedure|Children presenting to the emergency department for suturing
46080416|NCT00927043|Other|Epidemiological study according to clinical practice|Epidemiological study according to clinical practice.
45966320|NCT00213525|Other|Questionnary for environmental factors research|Questionnary for environmental factors research
45966321|NCT00122837|Drug|Duloxetine|
45966322|NCT00122837|Drug|venlafaxine|
45966323|NCT00122837|Drug|placebo|
45966324|NCT00220467|Behavioral|Aerobic exercise|
45966325|NCT00190580|Drug|valsartan|valsartan, dosage from 20mg to 180mg, once or twice a day plus conventional antihypertensive drugs
45966326|NCT00190580|Drug|Conventional antihypertensive drugs|Conventional antihypertensive drugs including calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors and/or beta-blockers
45966327|NCT00220506|Drug|Provigil|
45966328|NCT00190619|Drug|Duloxetine|
45966329|NCT00190619|Drug|Placebo|
45966330|NCT00213564|Drug|response to infliximab associated with methotrexate|
45966331|NCT00122876|Procedure|Photodynamic therapy|
45667626|NCT02347631|Device|Soft Contact Lens - Acuvue TruEye and Alcon DAILIES TOTAL 1.|"Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the study. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this active comparator arm, Acuvue TruEye lenses will be worn first."
45966332|NCT00122876|Drug|Talaporfin Sodium|
45966333|NCT00220545|Procedure|Laparoscopic ovarian diathermy|
45966334|NCT00190658|Drug|Somatropin (rDNA origin) for injection|
45966335|NCT00190697|Drug|arzoxifene|
45966336|NCT00122915|Device|Cortical lead, 8 electrodes (Model 2976) with Synergy neurostimulator|
45966337|NCT00190736|Drug|Atomoxetine Hydrochloride|
45966338|NCT00190736|Drug|placebo|
45966339|NCT00220584|Drug|donepezil|donepezil 5 mg daily for 3 weeks (days 1-21); 10 mg daily for 3 weeks (days 22-42)
45966340|NCT00122993|Behavioral|Healthful eating and food choices behavior change programs and changes in worksite food availability and prices|Food choices and eating behavior programs and environmental changes will be implemented for 18 months in intervention garages.
45966341|NCT00122993|Behavioral|Physical Activity|Physical activity programs are offered at the intervention garages for an 18 month period.
45966342|NCT00122993|Behavioral|Environment|Changes in the food and physical activity environment are made for an 18 month period in intervention garages. These include improving the healthfulness of the foods available in vending machines, and improving the fitness rooms at the garages.
46080417|NCT02805764|Device|Homeoblock|A removable, functional dental appliance to be worn nightly for 1 year Pending 510(k) clearance for the use of reducing snoring and mild to moderate obstructive sleep apnea in adults. A class II medical device.
46080418|NCT00927095|Drug|Continuous OC (EE/DROS)|Continuous EE(20ug)+DROS(3mg) daily for 3 months
45667627|NCT02015637|Drug|Delafloxacin|single dose
45824527|NCT00005815|Drug|thalidomide|
45824528|NCT02132754|Biological|MK-4166|
45824529|NCT02132754|Biological|Pembrolizumab|
45824530|NCT02151786|Drug|Lansoprazole|Lansoprazole intravenous 30 mg
45824531|NCT02132130|Drug|CGF166|CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion
45824532|NCT02131662|Drug|BAY1002670|Subjects received 4 milligram (mg) Vilaprisan (VPR) tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
45824533|NCT02131662|Drug|BAY1002670|Subjects received 2 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
46080419|NCT00927095|Drug|Intermittent OC (EE/DROS)|Intermittent EE(20ug)+DROS(3mg) daily for 21 days each month
46080420|NCT00927095|Drug|placebo|daily placebo
45667628|NCT02015637|Drug|Ceftriaxone|single dose
45966343|NCT00213681|Device|Boussignac CPAP - bilevel ventilation support|
45966344|NCT00190814|Drug|duloxetine|
45966345|NCT00190814|Drug|placebo|
45966346|NCT00220623|Drug|antidepressant medications, flexible drug choice|
45966347|NCT00220623|Behavioral|CBT, Psychodynamic or Supportive Psychotherapy|
45966348|NCT00220662|Behavioral|Readiness and Motivation Therapy|
45966349|NCT00220818|Drug|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
45966350|NCT00220818|Drug|Lansoprazole|Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.
45966351|NCT00213759|Drug|filgrastim|The G-CSF (filigrastin) will be administered by intravenous way with the amount of 10 µg/kg/day during 3 days . The infusion will last from 20 to 40 minutes according to weight of the child and the product will be diluted in dextrose 5%.
45966352|NCT00213759|Drug|dextrose 5%|The placebo (dextrose 5% ) will be injected by intravenous way with the amount of 0.66 ml/kg during 3 days consecutive. The infusion will last from 20 to 40 minutes.
45966353|NCT00190853|Drug|Duloxetine|
45966354|NCT00213798|Procedure|Biopsy samples|
45966355|NCT00190892|Drug|olanzapine|
45966356|NCT00190892|Drug|carbamazepine|
45966357|NCT00220857|Drug|Rabeprazole|
46080421|NCT00933985|Drug|dexrazoxane hydrochloride|Given IV
46080422|NCT00933985|Drug|doxorubicin hydrochloride|Given IV
46080423|NCT00933985|Drug|obatoclax mesylate|Given IV
45966358|NCT00213837|Device|Mandibular prosthesis made of a new highly biointegratable material|Replacement of mandibular bone after partial or total mandible resection,avoiding then bone grafting. The porous titanium prosthesis is implanted under general anaesthesia in laryngeal surgeries. Bone resection and prosthesis placement is performed during the same surgical intervention. The prosthesis is attached onto the healthy bone with surgical screws. Simultaneous grafting of vascularised tissues may be done if the prosthesis surrounding area has been strongly irradiated.
46080424|NCT00933985|Drug|liposomal vincristine sulfate|Given IV
46080425|NCT00933985|Other|pharmacological study|Correlative studies
45667629|NCT02347085|Drug|GFF MDI (PT003)|
46080426|NCT00933985|Other|laboratory biomarker analysis|Correlative studies
45667630|NCT02347085|Drug|Placebo MDI|
46080427|NCT05377476|Other|Motor Imagery training|Individuals included in this group will receive 20 minutes of motor imagery training in addition to 40 minutes of standard rehabilitation.
46080428|NCT05377476|Other|Action Observation training|Individuals included in this group will receive 20 minutes of action observation training in addition to 40 minutes of standard rehabilitation.
46080429|NCT05377476|Other|standard rehabilitation|40 minutes of standard rehabilitation.
45667631|NCT02374463|Behavioral|MMBI|Multimodality Balance Intervention (MMBI): Our MMBI will be held 3-times a week for an hour and will consist of a group dynamic balance class (30 minutes), a supervised obstacle course (10 minutes), and lower extremity and core strengthening (20 minutes). The group exercise classes will focus on dynamic weight shifts with an emphasis on the lateral and diagonal directions. Over the 6 months of class, the exercises will gradually increase in difficulty to challenge balance. A skilled instructor will lead each class and 1-2 assistants will be present to assist with fall risk prevention. The supervised obstacle course will focus on obstacle negotiation, gait over challenging surfaces, and moving in lateral, diagonal, and backward directions. Finally, strength training of the lower extremities and core will focus on strengthening major muscles of the lower extremity and core utilizing commonly available gym equipment, ankle weights and body weight.
45667632|NCT02374463|Behavioral|Tai Chi|Tai Chi Intervention: The supervised Tai Chi class will be held 3-times a week for one hour. All Tai Chi classes will be taught in a group setting by an experienced instructor. The emphasis during the class will be on standing movements, body alignment, weight shift and changes of direction. Movements will be adapted as the class progresses to increase the difficulty of weight shift and change in direction over time so that participants balance is continually challenged throughout the 6 months. Chairs or hand rails will be available for the participants to use as needed for balance recovery.
45667633|NCT02015481|Drug|Cabaletta|
45667634|NCT02374307|Other|Exercise and education|Exercise according to the falls prevention programme. Information on motivation, the effectiveness of falls prevention and the importance of adherence.
45667635|NCT04898075|Behavioral|Remote Contingency Management (CM) for nicotine abstinence|Participants will be paid increasing amounts of payment for each negative saliva cotinine test.
45667636|NCT04898075|Other|Control|Participants will be paid for providing saliva nicotine test, regardless of whether the test is positive or negative.
45667637|NCT02397473|Drug|Galcanezumab|Administered SC
45667638|NCT02397473|Drug|Placebo|Administered SC
45824534|NCT02131662|Drug|BAY1002670|Subjects received 1 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
46080430|NCT02805296|Other|Light irradiance|Comparison of double vs. single phototherapy
46080431|NCT02738268|Device|Low-level laser therapy|Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment in combination with the standard skin care.
45667639|NCT04891757|Drug|FHD-286|FHD-286 as a single, orally administered agent.
45824535|NCT02131662|Drug|BAY1002670|Subjects received 0.5 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
46080432|NCT02738268|Device|sham laser|
46080433|NCT05009303|Device|OneStep Smartphone App and C-Mill Treadmill|OneStep technology is a smartphone application that utilizes smartphone sensors to provide ongoing gait diagnostics. Each participant will have two sessions, during which, they will walk on a C-Mill smart treadmill for up to 15 minutes (with a minimum of 2 minutes), while carrying 2 smartphones and being recorded via two video cameras. The second walking session, conducted under similar conditions, will be used for test-retest reliability.
45667640|NCT02344745|Other|Lavandula angustifolia essential oil (Aura Cacia)|The participants will be instructed to take a deep breath while holding the towel with two drops of essential oil 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
45667641|NCT02344745|Other|Distilled water|The participants will be instructed to take a deep breath while holding the towel with two drops of distilled water 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
45667642|NCT02370641|Dietary Supplement|PomX|1000 mg POMx daily for 4 weeks
45667643|NCT01621191|Drug|Duloxetine|Administered Orally
45667644|NCT02343263|Drug|Bupivacaine|1 milliliter (mL) of 0.75% Bupivacaine Hydrochloride will be infused into 4mL of fibrin sealant (diluting the Bupivacaine HCl to 0.15%). The bupivacaine-infused fibrin sealant will then be applied to the tonsillectomy (or adenotonsillectomy) wound bed.
45667645|NCT02343263|Biological|Fibrin Sealant|Fibrin sealant will be applied to the wound bed topically as per product instructions.
45667646|NCT02081859|Device|Embryoscope|The embryoscope is a microscope that allows for continuous time-lapse monitoring.
45824536|NCT02131662|Drug|Placebo|Subjects received matching placebo tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
45966359|NCT00190931|Drug|Atomoxetine Hydrochloride|
45966360|NCT00190931|Drug|placebo|
45966361|NCT00220896|Drug|Donepezil|
45966362|NCT00123032|Behavioral|Diet|Increase the availability of fruits and vegetables, serve recommended portion sizes and reduce availability of excessive energy-dense foods at school cafeterias to improve the diet of participants at school breakfast, lunch and snacks.
45966363|NCT00123032|Procedure|Exercise|Increase active recess time, implement classroom action breaks and increase school PE class time to increase physical activity among participants.
45966364|NCT00190970|Drug|Ruboxistaurin|
45667647|NCT02081859|Other|Conventional Criteria|
45667648|NCT04420715|Other|Training on coronary angiography using 3D coronary artery simulator|Participants will have a test of coronary arteriography before and after training, compare the scores to analysis if the simulator training is effective.
45667649|NCT04897451|Other|Questionnaire|EQ5D-5L questionnaire self-reported 3 months after delivery
45966365|NCT00220935|Device|Orthotrac Pneumatic Vest|
46080434|NCT02812628|Procedure|LAPR|Patients undergoing conventional LAPR, the common surgical procedure to treat low rectal cancer ≤5m from anal verge.
46080435|NCT02812628|Procedure|LAPR-TILT|Patients undergoing LAPR-TILT, a modified APR procedure that is supposed to be safer and less invasive as compared to the LAPR.
46080436|NCT00934063|Drug|somatropin|For s.c. (under the skin) injection. Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46080437|NCT00934063|Other|No treatment given|Control group not receiving treatment
46080438|NCT02738424|Other|Calculate the ADC scores|The MRI will be performed on the two groups of patients in the usual care. The intervention will be based on the ADC scores calculation. The scores will be obtained with three types of post-processing softwares : Siemens, PACS Carestream, Osirix.
46080439|NCT02812394|Drug|CVT-301 (Dose Level 1)|All subjects will receive a single dose of low-dose CVT-301 with a 1-day washout between the doses.
46080440|NCT02812394|Drug|CVT-301 (Dose Level 2)|All subjects will receive a single dose of high-dose CVT-301 with a 1-day washout between the doses.
46080441|NCT02812394|Drug|Sinemet®|All subjects will receive carbidopa/levodopa tablets administered every 8 hours.
46080442|NCT00930475|Drug|RAD001 (Everolimus) in combination with carboplatin|phase I: dose levels: 2,5 mg, 5 mg, 7,5 mg and 10mg daily in combination with carboplatin AUC2 weekly until progress
45667650|NCT02342639|Drug|Rifaximin|550mg pills
45667651|NCT02342639|Drug|Placebo|Placebo pill
45667652|NCT01625091|Drug|Naltrexone|The study involves taking the drug naltrexone for up to 4 months. This will be given in a single pill each day for 4 months.
45824537|NCT04188366|Behavioral|FAMES|Participants will receive three distinct and revolving components - early, continuous, and motivational contact - that incorporate motivational techniques and the Diagnostic and Statistical Manual of Mental Disorders 5TH Edition (DSM-5) Cultural Formulation Interview (CFI).
45824538|NCT04188366|Behavioral|Treatment-as-Usual|Participants will receive usual services and family-based treatment offered
45824539|NCT05150106|Other|Clinical assessments of laryngeal function|Participants will undergo acoustic, aerodynamic, respiratory kinematic, nasoendoscopic, and laryngeal EMG recordings, as well as real-time MRI of the upper airway for comprehensive characterization of shared and distinct features of laryngeal dystonia and voice tremor.
45824540|NCT02106156|Drug|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a administered according to corresponding summary of product characteristics (SmPC).
45824541|NCT02106156|Drug|Ribavirin|Ribavirin administered according to corresponding summary of product characteristics (SmPC).
45824542|NCT05137002|Drug|CIN-107|CIN-107 tablets by mouth once daily
45824543|NCT05137002|Drug|Placebo|Placebo tablets by mouth once daily
45966366|NCT00191009|Drug|atomoxetine hydrochloride|
45966367|NCT00191009|Drug|placebo|
45966368|NCT00220974|Behavioral|Internet-based tailored advice on cardiovascular risk|
45966369|NCT00213915|Drug|12 g of L-arginine glutamate during 6 weeks twice a day|
46080443|NCT00930475|Drug|RAD001 (Everolimus) in combination with carboplatin|phase 2: 10mg RAD001 in combination with carboplatin
46080444|NCT05623592|Drug|Methotrexate|17,5/15/10 mg Methotrexate subcutaneously
46080445|NCT05623592|Drug|Sodium chloride|Sodium chloride subcutaneously
46080446|NCT02728518|Drug|Nebulized Amikacin|400mg twice daily nebulized amikacin
46080447|NCT02728518|Drug|Intravenous Amikacin|20mg/kg once daily intravenous amikacin
45667653|NCT01625091|Drug|Placebo|Placebo is an inert pill that looks the same as naltrexone. The placebo will be taken once each day for up to 4 months.
45667654|NCT02396849|Device|Continuous Positive Airway Pressure (CPAP)|Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
45667655|NCT02396849|Device|Continuous Positive Airway Pressure (CPAP) Sham|Subjects assigned to this group will be asked to use the CPAP Sham machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
45667656|NCT02370251|Drug|Omegaven|Once the direct bilirubin is 2 mg/dL or more x 2 weeks, Intralipid will be switched to Omegaven at 1 g/kg/day. The bilirubin level will be monitored to determine when resolution of cholestasis (DB <2 mg/dL) occurs.
45667657|NCT02396537|Drug|Lidocaine|Administered intranasally prior to Midazolam administration.
45667658|NCT02396537|Drug|Midazolam|Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.
45667659|NCT02396537|Drug|0.9% Saline|Administered intranasally prior to Midazolam administration.
45966370|NCT00191048|Drug|Atomoxetine|
45966371|NCT00221013|Procedure|"augmented CRRT regimen"|We randomly assigned critically ill patients with acute kidney injury to receive CRRT in the form of post-dilution continuous veno-venous hemodiafiltration (CVVHDF) at 25 ml/kg/hr (lower intensity) or 40 ml/kg/hr (higher intensity) of effluent flow.
45966372|NCT00123149|Drug|Epoetin alfa|
45966373|NCT00411840|Procedure|intraarterial and intramuscular injection of BMCs|
45667660|NCT04891367|Other|Cognitive behavioral therapy|The G-CBT manual for adolescents has been developed in the OCD-clinic in Aarhus and pilot tested in Aarhus. The G-CBT manual is based on the NordLOTS I-CBT manual in overall content and structure, with a few additional elements added with inspiration from previous individual and group CBT literature as well as the author's ideas. The main therapeutic ingredient is exposure and response prevention. The manual is made up of three individual family sessions, 13 weekly adolescent group sessions, three parent group sessions and two adolescent group booster sessions.The manual contains detailed guiding of therapists for each session and a comprehensive collection of working sheets for the adolescents to be used during sessions.
45966374|NCT00191087|Drug|Duloxetine|
45966375|NCT00213954|Procedure|ultrasound-guidance with echography|Locoregional anesthesia with or without ultrasound guidance practice
45966376|NCT00191126|Drug|gemcitabine|1250 mg/m2, IV, day 1 and 8, q 21 days x 3 cycles
45966377|NCT00191126|Drug|Cisplatin|75 mg/m2, IV, q 21 days x 3 cycles
45966378|NCT00191126|Procedure|surgery|surgery
45667661|NCT02342171|Other|Convalescent Plasma|Patients will be treated with plasma from recovered EVD patients.
45966379|NCT00221052|Drug|Diclofenac|
45667662|NCT01624467|Biological|Necitumumab|800 mg necitumumab, administered once per week IV
45667663|NCT01624233|Drug|80 mg ixekizumab|Administered SC
45667664|NCT01993017|Other|Cognitive Behavioral Therapy (CBT)|"The main intervention is the impact of screening on quality of life and health care costs. CBT is provided only if depressive symptoms are detected and participant prefers this type of treatment.~CBT will be centrally telephone-administered by a trained CBT treatment specialist. The treatment specialist will work with local team members throughout a participant's involvement in the study, and will closely follow each participant until he or she has reached a requisite level of improvement ."
45824544|NCT01598610|Device|CONTOUR® PLUS Investigational BG Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the CONTOUR® PLUS Investigational BG Monitoring System. Study staff test subject venous blood. All Blood Glucose (BG) results are compared to a reference laboratory glucose method.
45966380|NCT00123188|Procedure|Ultrasound and Biopsy|Transvaginal ultrasound and Endometrial Biopsy
45966381|NCT00213993|Drug|antiperspirant|antiperspirant topically once daily to one foot
45966382|NCT00191204|Drug|Duloxetine|
45966383|NCT00221091|Procedure|ventriculo-peritoneal shunt|
46080448|NCT00927121|Device|Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset|"The CR-stimulation was originally developed by Prof. Dr. Dr. Peter Tass for deep brain stimulation (DBS). The CR-stimulation through high frequency short pulses causes a neuronal reorganization in the stimulated brain area establishing a normal neuronal activity.~Based on intensive modeling studies, experimental proof of concept (POC) animal studies and a clinical POC, we proved that the pathologic activity can be recuperated to a desynchronized/healthy state with the acoustic CR-stimulation.~The acoustic CR-stimulation signal will be generated by the ANM CR-Stimulator and transmitted to the ears through a speaker system"
46080449|NCT00634400|Drug|Candesartan|
46080450|NCT00634400|Drug|Placebo|
45824545|NCT04738812|Drug|Intensified TB treatment (initial phase)|"8 weeks of RHEZ with high dose of rifampicin (R) and isoniazid (H). Fixed dose combination (FDC) of RHZE with the addition of FDC of RH and single caps of R.~6 weeks of prednisone with tapering doses. 3 days of albendazole 400 mg."
45824546|NCT04738812|Drug|WHO standard TB treatment (initial phase)|8 weeks of RHEZ with FDC.
45966384|NCT00123227|Drug|Rosiglitazone|
45966385|NCT00221130|Procedure|surgical operation of cell transplantation|
45966386|NCT00191243|Drug|Gemcitabine|"A: second line therapy - 1000 mg/m2, IV, day 1 and day 8 q 21 days until disease progression~B: 1000 mg/m2, IV, day 1 and day 8 q 21 days, until treatment failure"
45966387|NCT00191243|Drug|docetaxel|"A: 80 mg/m2, IV, q 21 days until treatment failure followed by second line single agent gemcitabine~B: 80 mg/m2, IV, q 21 days until treatment failure"
45966388|NCT00214032|Drug|Pycnogenol|pycnogenol 300 mg daily
45966389|NCT00214032|Drug|Placebo|placebo 3 capsules daily
45966390|NCT00123266|Drug|Microplasmin|2 mg/kg, IA over 75 mins
45966391|NCT00221169|Procedure|Surgical resection|pet ct prior to surgery
45824547|NCT04737954|Diagnostic Test|Venepuncture|Venous blood draw
45824548|NCT04737954|Diagnostic Test|Fingerstick|Capillary blood draw
45824549|NCT01625988|Drug|LY2951742|
45824550|NCT01625988|Drug|Placebo|
45966392|NCT00191321|Drug|Teriparatide|
45966393|NCT00214071|Biological|Influenza vaccine|
45966394|NCT00191360|Drug|Somatropin|
45966395|NCT00221208|Behavioral|Resistance Training|
45966396|NCT00123305|Drug|Microplasmin|1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.
45966397|NCT00123305|Drug|Microplasmin|1mg/kg bolus of placebo solution followed by 1,2 or 3mg/kg infusion of placebo solution
45966398|NCT00214110|Drug|Tamoxifen|
45966399|NCT00191399|Drug|Olanzapine|
45966400|NCT00191399|Drug|Fluoxetine|
45966401|NCT00221247|Procedure|Acupuncture|acupuncture
45966402|NCT00123344|Device|AT501 pacemaker|
45966403|NCT00191438|Drug|gemcitabine|
45966404|NCT00191438|Drug|capecitabine|
45966405|NCT00191438|Drug|docetaxel|
45966406|NCT00221286|Drug|pegylated interferon alfa-2a|
45966407|NCT00221286|Drug|tenofovir DF / emtricitabine combination therapy|
45966408|NCT00221286|Drug|pegIFN / TDF / FTC combination therapy|
45966409|NCT00123383|Drug|Modafinil|
45966410|NCT00214266|Drug|Campath 1H®, Rituximab, mycophenolate mofetil|Induction therapy with Campath 30mg IV x 2 doses, Rituximab 375mg/m2 x 1, corticosteroids, and mycophenolate 1000mg bid
45966411|NCT04722965|Procedure|Fistulotomy with marsupialization|A probe is placed in the fistula tract and it's laid open over that probe. The tract is curretted. Wound edges are sutured to the bottom of the fistula using interrupted sutures of vicryl 3-0 completing the marsupialization.
45966412|NCT04722965|Procedure|Fistulotomy with open wound|A probe is placed in the fistula tract and it's laid open over that probe. The tract is curretted. The wound is left open.
45667665|NCT01993017|Drug|Antidepressant Medication|"The main intervention is the impact of screening on quality of life and health care costs. Antidepressant Medication is provided only if depressive symptoms are detected and patient prefers this type of treatment.~Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week, with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated."
45966413|NCT00221325|Drug|Intraventricular Rituximab Plus MTX|"Intraventricular injection of rituximab into an Ommaya reservoir on day 1 of each week. Intraventricular rituximab plus methotrexate (MTX) on day 4 of each week.~First three patients at dose A : 25 mg rituximab on day 1, and MTX (12 mg) plus rituximab (10 mg) on day 4 each week.~If there are no dose limiting toxicities at Dose A in all of the first 3 patients or in 5 of the first 6 patients, the next 3 patients will receive dose level B: 25 mg rituximab on day 1, and combination MTX (12 mg) plus rituximab (25 mg) on day 4 of each week.~Oral leucovorin rescue 24 hours after each MTX administration. Maximum injections will be 16 over 9-weeks. Subjects who experience a partial response at week 10 will be given the option for extended dosing."
45966414|NCT00123461|Drug|Hectorol (doxercalciferol capsules), 0.5mcg|
45966415|NCT00191516|Drug|Atomoxetine|
45966416|NCT00191555|Drug|olanzapine|
45455621|NCT03680092|Drug|Cyclophosphamide|Day 3 and day 4 following transplant. Dosing will be based on patients' actual weight up to 120% of ideal body weight, above which it will be based on adjusted ideal body weight (ideal weight plus 50% of the difference between ideal and actual weight).
45824551|NCT02131272|Drug|Insulin detemir|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OAD's i.e. metformin treatment should continue unchanged during the treatment period.
45824552|NCT02131272|Drug|Insulin NPH|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OADs i.e. metformin treatment should continue unchanged during the treatment period.
45966417|NCT00191555|Drug|haloperidol|
45966418|NCT00123500|Behavioral|Diet|Diet
45966419|NCT00123500|Behavioral|Physical Activity|Physical Activity
45966420|NCT00123500|Behavioral|Environment|Environment
45966421|NCT00123500|Other|Control Group|Control Group
45824553|NCT02131272|Behavioral|Diet/exercise|Intervention will be performed through family based changes in eating and activity behaviours.
45966422|NCT00221364|Drug|Mass treatment with oral azithromycin to an entire village|
45966423|NCT00123539|Drug|Estrogen Replacement Therapy|
45966424|NCT00123539|Procedure|Surgery|
45455622|NCT03680092|Drug|abatacept|Abatacept at a dose of 10mg/kg will be administered on days +5, +14 and +28, +56, +84, +112, +140, +168
45455623|NCT03680092|Drug|Methotrexate|standard of care Methotrexate 5 mg/m2 on Days 1, 3, 6 and 11
45455624|NCT03680092|Drug|Tacrolimus|Tacrolimus per institutional guidelines
45667666|NCT01993017|Other|Standard Care|Participants will receive standard care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.
45667667|NCT01993017|Other|Depressive symptom screener|8-item Patient Health Questionnaire, PHQ-8
45667668|NCT01993017|Other|No intervention|
45824554|NCT02130882|Drug|benralizumab|An afucosylated humanized antibody to IL-5 receptor alpha
45824555|NCT02130882|Other|Placebo|A sterile solution containing 20 millimolar histidine/histidine-hydrochloride (HCl) 0.25 M trehalose dihydrate, and 0.006% (w/v) polysorbate 20, pH 6.0, in saline
45966425|NCT00214305|Behavioral|Range of Motion Therapy Program|The program involves exercises and maneuvers that include voluntary maximal movements of the tongue, pitch range exercises, head lifting (Shaker exercise), resistance to laryngeal excursion (Mendelsohn Maneuver), breath holding after swallow and cough, thermal-tactile stimulation (ice), suck-swallow, optimal posturing, and dietary changes.
45667669|NCT01992549|Biological|Human-cl rhFVIII|
45966426|NCT00214305|Behavioral|Postural Sensory Therapy Program|The program involves all of the above, except that range of motion exercises (voluntary maximal movements of the tongue, pitch range exercises, head lifting, resistance to laryngeal excursion, breath holding after swallow and cough) are not performed.
45966427|NCT00191594|Drug|Duloxetine Hydrochloride|
45966428|NCT00221442|Drug|Zonegran|zonegran (zonisamide)
45966429|NCT00221442|Drug|sugar pill|fake pill
45966430|NCT00123578|Drug|Lorazepam|Lorazepam
45966431|NCT00123578|Drug|Pentobarbital|Pentobarbital
45966432|NCT00214344|Behavioral|family preparation for withdrawing life support|
45966433|NCT00221481|Drug|divalproex or olanzapine|
45966434|NCT02962752|Dietary Supplement|Blackadder Juice|
45966435|NCT02962752|Other|Placebo|
45966436|NCT00191633|Drug|Atomoxetine|
45966437|NCT00221520|Drug|midazolam with 2 different levels of sedation scores|
45966438|NCT00191672|Drug|Gemcitabine|
45966439|NCT00191672|Drug|Paclitaxel|
45966440|NCT00191672|Drug|Docetaxel|
45966441|NCT00214578|Drug|Seroquel (quetiapine)|
45966442|NCT00123617|Procedure|Phase III group-based cardiac rehabilitation|Phase III group-based cardiac rehabilitation
45966443|NCT00221559|Procedure|Blood sampling for determination of serum Zn|
45966444|NCT00191711|Drug|Gemcitabine|
45824556|NCT02130570|Other|Multi-Model Intensive Discharge Intervention|"Inpatient medication safety interventions~Inpatient discharge advocate~Structured visiting nurse (VNA) appointments~Post-discharge phone call by primary care personnel within 2 business days of discharge~Structured post-discharge clinic appointment with PCP and other PCMH personnel within 2 weeks of discharge~Improved communication between inpatient and primary care teams~High-risk patients will receive additional interventions as needed:~Home pharmacist visit~Enrollment in the Partners integrated Care Management Program (iCMP)~Enrollment in telemedicine programs for patients with CHF~Palliative care consultation regarding goals of care~Novel health information technology to facilitate communication and transfer of clinical information"
45824557|NCT02149836|Drug|ezogabine|"Treatment Week 1: 100mg of Ezogabine by mouth three times per day (total daily dose = 300mg) Treatment Week 2: dose will be increased to 150 mg Ezogabine by mouth three times per day (total daily dose = 450mg).~Treatment Week 3: dose will be increased to 200mg of Ezogabine by mouth three times per day (total daily dose = 600mg).~Treatment Week 4: dose will be increased to 250mg of Ezogabine by mouth three times per day (total daily dose = 750mg).~Treatment Week 5: dose will be increased to 300mg of Ezogabine by mouth three times per (total daily dose = 900mg).~Participants will continue to take 900mg of Ezogabine per day and return weekly to the clinic for the remainder of the study.~Following this primary outcome visit, participants will be instructed to taper the study medication over the following 3 weeks based on FDA recommended guidelines as follows:~250 mg po TID daily x 1 week, then 200 mg po daily x 1 week, then 100 mg po daily x 1 week, then discontinue"
45966445|NCT00221637|Drug|Sodium Valproate|
45966446|NCT00123656|Drug|esomeprazole|esomeprazole dosed qam for 8 weeks
45966447|NCT00123656|Drug|fluticasone|fluticasone dosed 220 mcg 2 puffs swallowed BID for 8 weeks
45966448|NCT00214617|Drug|Rosuvastatin at 5 mg/day and 40 mg/day|
45966449|NCT00221676|Biological|Alfarix|
45966450|NCT00123773|Procedure|Positron Emission Tomography|
45966451|NCT00214656|Drug|Recombinant Activated Factor VII|
46080451|NCT04262375|Biological|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
45667670|NCT01992159|Drug|Romosozumab|Administered by subcutaneous injection
45966452|NCT00191750|Drug|Pemetrexed|
45966453|NCT00221715|Device|femoropopliteal artery bypass|Bypass by autologous saphenous vein
45966454|NCT00221715|Device|femoropopliteal artery bypass|bypass by dacron or PTFE Prosthesis
45966455|NCT00214695|Drug|Experimental Peritoneal Dialysis Solution|
45966456|NCT00221754|Drug|Pravastatin (drug)|
45667671|NCT01992159|Drug|Placebo|Administered by subcutaneous injection
45667672|NCT01988493|Drug|Tepotinib 300 mg|Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
45667673|NCT01988493|Drug|Tepotinib 500 mg|Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
45667674|NCT01988493|Drug|Tepotinib 1000 mg|Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal
45966457|NCT02963207|Other|Modified Sano's classification|Set of characteristics described by Singh et al. 2013 to evaluate colorectal lesions.
45966458|NCT02963207|Other|NICE classification|Set of characteristics described by Hewett et al. 2012 to evaluate colorectal lesions.
45966459|NCT00191828|Drug|olanzapine|
45966460|NCT00214734|Drug|rAHF-PFM|
45966461|NCT00191867|Drug|Teriparatide|
45966462|NCT00221793|Procedure|Deep brain stimulation|Brain Stimulation of the Subthalamic Nucleus
45966463|NCT00123851|Drug|Tarceva (OSI-774)|
45966464|NCT00123851|Drug|Capecitabine|
45966465|NCT00123851|Drug|Oxaliplatin|
45966466|NCT02962440|Drug|somapacitan|All subjects will receive one subcutaneous (s.c., under the skin) dose of somapacitan containing [3H]-somapacitan
45966467|NCT00123890|Drug|GW873140|
45966468|NCT00409487|Device|Continuous positive airway pressure (CPAP)|8 weeks of CPAP
46080452|NCT04262375|Biological|Oleclumab|Oleclumab is a human immunoglobulin G1 lambda monoclonal antibody (mAb) with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab selectively binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. This, in turn, leads to increased antitumor immunity.
46080453|NCT02728674|Other|Person in the case is a male.|Person in the case is a male.
45667675|NCT01988493|Drug|Tepotinib|Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
45667676|NCT01988493|Drug|Sorafenib|Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
45667677|NCT02081079|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
45667678|NCT02081001|Drug|Novo Nordisk GlucaGen®|single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
45824558|NCT02130024|Drug|Ranibizumab 0.5 mg|Administered as an intravitreal injection
45966469|NCT00409487|Drug|Valsartant treatment|8 weeks of Valsartant treatment (160 mg / day)
45966470|NCT00412698|Drug|rimonabant|"Administration of one tablet containing 20 mg of active rimonabantonce daily in the morning.~White film-coated tablets, for oral administration containing 20 mg of active rimonabant"
46080454|NCT02728674|Other|Person in the case is a female.|Person in the case is a female.
45667679|NCT02081001|Drug|G-Pump™ (glucagon infusion)|single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
45667680|NCT04726449|Other|Screening for acute confusional state|The intervention will consist of two psychometric test to screen for acute confusional state with the usual physical examination by the emergency physician. The neurological examination abnormalities will be noted
45667681|NCT02080221|Drug|FOLFOXA|
45824559|NCT02130024|Drug|Aflibercept 2.0 mg|Administered as an intravitreal injection
45824560|NCT02105688|Drug|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
45966471|NCT00412698|Drug|Placebo|Administration of one rimonabant placebo tablet once daily in the morning. Undistinguishable placebo tablets.
45966472|NCT00123929|Drug|docetaxel|100 mg/m2 every 3 weeks times 4
45966473|NCT00123929|Drug|doxorubicin|75 mg/m2 every 3 weeks times 4
45966474|NCT00214812|Drug|HEC placebo gel|
46080455|NCT02728674|Other|Symptom in the case is breathlessness.|Symptom in the case is breathlessness.
45966475|NCT00124007|Biological|VRC-HIVADV014-00-VP|
45667682|NCT02079909|Drug|T-817MA-H|224 mg or 448 mg T-817 MA once daily
46080456|NCT02728674|Other|Symptom in the case is pain.|Symptom in the case is pain.
46080457|NCT00936637|Other|Extensively hydrolyzed infant formula|
46080458|NCT00930631|Drug|[3H] BMS747158|Single bolus intravenous injection of [3H] BMS747158
46080459|NCT00636558|Drug|CVA21|IV infusion, dose escalation of one or two infusions of escalating strength
45667683|NCT02079909|Drug|T-817MA-L|224 mg T-817 MA once daily
45667684|NCT02079909|Drug|Placebo|Placebo
45824561|NCT02105688|Drug|Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet|Placebo Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
45824562|NCT05151120|Biological|blood sample|In practice the only intervention of the study is 49 mL extra blood along with the blood draw that is already planned for diagnosis/follow-up
45824563|NCT02105454|Drug|Grazoprevir (GZR)|100 mg oral tablet (total daily dose)
45824564|NCT02105454|Drug|Elbasvir (EBR)|10 mg oral capsule (total daily dose = 5 capsules)
45824565|NCT02105454|Drug|Ribavirin (RBV)|200 mg oral capsule (total daily dose = 4-7 capsules)
45966476|NCT00124007|Biological|VRC-HIVDNA016-00-VP|
45966477|NCT00214929|Behavioral|treatment at home|
45966478|NCT00475033|Biological|13-valent Pneumococcal Conjugate Vaccine|13-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
45966479|NCT00475033|Biological|7-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
45966480|NCT00192062|Drug|gemcitabine|
45966481|NCT00192062|Drug|vinorelbine|
45966482|NCT00412776|Drug|Proxinium|700 µg Proxinium, once weekly until complete resolution of all target tumours or radiographic tumour progression
45966483|NCT00192101|Drug|gemcitabine|
45966484|NCT00192101|Drug|cisplatin|
45966485|NCT00215007|Drug|Levofloxacin|
45667685|NCT04178031|Device|IUD insertion|"Insert a warm, moistened speculum. Cleanse the cervix with an antiseptic solution. Apply gentle traction with the tenaculum to straighten the canal. Remove the sound by its handle and gently insert to measure the depth of the uterus. Do not apply great force if there is resistance. Apply further traction to the tenaculum and attempt to re-insert the sound at a different angle. Once the sound is inserted and removed, note the depth of the uterine cavity. The woman can expect to feel cramping as the sound is inserted and withdrawn.~Load the IUD and insert it into the uterine cavity according to the manufacturer instructions. As the IUD is inserted through the cervix into the uterus, the patient may have pain and cramping similar to strong menstrual cramps.~Gently remove the tenaculum. Trim the strings of the IUD to 3-4 cm in length Remove the speculum and assess the woman."
45667686|NCT02014467|Drug|Denosumab|Injection
45966486|NCT00474994|Drug|sunitinib malate|
45966487|NCT00192140|Biological|FluMist|A single intranasal dose of FluMist will be administered to approx. 300 subjects.
45966488|NCT00474955|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms or 135 micrograms sc weekly for 48 weeks
45966489|NCT00412815|Behavioral|Exercise training|
45966490|NCT00124046|Procedure|Surgery|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
45966491|NCT00124046|Procedure|Medical Treatment|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
45966492|NCT00215046|Drug|Vinblastine|drug - dosage and frequency is based on size of patient and response to treatment.
45966493|NCT00215046|Drug|Methotrexate|drug - dosage is based on size of patient and frequency and duration is based on response to treatment.
46080460|NCT00609479|Procedure|Osteosynthesis|"Micronail osteosynthesis. A cast for the first 14 days, thereafter starting physiotherapy. Control at weeks 1,2,5,12.~Hoffmann-II-non-bridging osteosynthesis. Removal of device after 5 weeks. physiotherapy starts at 14 days. Control at weeks 1,2,5,12."
45667687|NCT02014467|Drug|Placebo|Injection
45667688|NCT02014467|Dietary Supplement|Elemental Calcium|Oral, at least 600 mg
45667689|NCT02014467|Dietary Supplement|Vitamin D|Oral, at least 400 IU
45824566|NCT01625910|Behavioral|Behavioral counseling|Counseling of parents to improve their child's diet and physical activity
45824567|NCT02104752|Drug|Curcumin|360 mg/day (divided into twice daily oral doses)
45824568|NCT02104752|Drug|Placebo|"Inactive, matched placebo (Sugar Pill)"
45824569|NCT02102724|Dietary Supplement|Fish oil that contains omega-3 fatty acids|Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids
45824570|NCT02102724|Dietary Supplement|Placebo|Gelcaps that contain 1 gram of oleic sunflower oil
45824571|NCT02102490|Drug|Abemaciclib|Administered orally
45966494|NCT00192179|Biological|Cold-adapted influenza vaccine trivalent (CAIV-T)|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 ml into each nostril). Each dose of CAIV-T used in this study contained approximately 10^7+/-0.5 fluorescent focus units (FFU) (equivalent to 10^7+/-0.5 TCID50) of each of the following three influenza virus strains: Influenza Cold Adapted Virus Type H1N1, strain A/New Caledonia/20/99; Influenza Cold Adapted Virus Type H3N2, strain A/ Panama/2007/99; Influenza Cold Adapted Virus Type B, strain B/Hong Kong/ 330/01.
45966495|NCT00192179|Biological|Placebo|The placebo consisted of physiologic normal saline.
45966496|NCT00124085|Behavioral|Disease Management|
45824572|NCT02101554|Drug|Ages 7-11|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
45824573|NCT02101554|Drug|ages 12-17|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
45824574|NCT02128932|Drug|semaglutide|Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly subjects will receive 0.5 mg semaglutide weekly for 26 weeks.
45966497|NCT00124085|Behavioral|Disease Management + Educational Home Visits|
45966498|NCT00474487|Biological|Meningococcal ACWY Polysaccharide Vaccine|One dose of the licensed meningococcal ACWY polysaccharide vaccine was administered by subcutaneous injection.
45966499|NCT00474487|Biological|MenACWY CRM (19 to 55 years)|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection to subjects 19 years to 55 years of age.
45966500|NCT00474487|Biological|Meningococcal ACWY Conjugate Vaccine|One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered by intramuscular injection.
45966501|NCT00474487|Biological|Novartis MenACWY Vaccine (56 to 65 Years)|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection administered to subjects 56 years to 65 years of age.
45966502|NCT00124124|Drug|KLH; Peptides; Dendritic Cells|Upon entry into the study, patients randomized to the dendritic cell arm will undergo a complete baseline evaluation and leukapheresis 0.5 to 3 x 106 DCs per peptide antigen (total not to exceed 18 x 106 cells) will be administered intradermally as per injection SOP. They will receive up to 3 booster DC injections (total not to exceed 18 x 10 6 cells per injection) at monthly intervals for a total of 4 injections. The booster injections will not contain KLH, as our volunteer studies have shown that priming occurs following a single injection of DCs
46080461|NCT00936793|Drug|Darunavir|
45966503|NCT00124124|Drug|KLH, peptides plus Montanide|Patients randomized to the Montanide arm will also undergo complete baseline evaluation but not leukapheresis. The peptides will be mixed with the adjuvant, Montanide, and administered subcutaneously at a dose of 100 microgram of each peptide +100 microgram KLH mixed with an equal volume of Montanide. They will receive up to 3 booster injections at monthly intervals for a total of 4 injections. The booster injections will not contain KLH.
45966504|NCT00474253|Drug|Sugammadex|Single bolus intravenous (IV) dose of 16.0 mg/kg sugammadex
45966505|NCT00474253|Drug|Succinylcholine|Single bolus IV dose of 1.0 mg/kg succinylcholine
45966506|NCT00474253|Drug|Rocuronium|Single bolus IV dose of 1.2 mg/kg rocuronium
45966507|NCT00124163|Procedure|Imaging procedure of CT colonography|
45966508|NCT00221871|Drug|Different dosages of Ketamine|
45966509|NCT00474058|Drug|Rotigotine|"Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum Rotigotine dose allowed is 16mg/24h"
45966510|NCT00474058|Other|Placebo|Placebo transdermal patches
45966511|NCT00192218|Biological|FluMist|0.5 ml of vaccine intranasally (0.25 ml in each nostril) which contains approximately 107 TCID50 of each type
45667690|NCT02013765|Drug|trastuzumab|Initial dose of 4 mg/kg i.v on Day 1, followed by weekly doses of 2 mg/kg i.v. beginning on Day 8 and continuing for up to 37 weeks.
45667691|NCT02013687|Biological|Pfs25 VLP- FhCMB|
45667692|NCT02013609|Drug|Brexpiprazole|Treatment 12 weeks) - Up to 3 mg/day, once daily dose, tablets, orally
45966512|NCT02277574|Biological|AMP-110|2, 5, or 10 mg/kg
45966513|NCT02277574|Other|Placebo|Placebo
46080462|NCT00936793|Drug|Ritonavir|
45824575|NCT02128932|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Subjects will start on 10 IU once daily and the dose will be adjusted according to fasting plasma glucose.
45824576|NCT02128542|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
45824577|NCT02128542|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
46080463|NCT00936793|Drug|Beclomethasone Dipropionate HFA|
46080464|NCT02805218|Drug|PEG-rhG-CSF|
45667693|NCT01988337|Device|Resin infiltration|The study is a split-mouth design. One tooth with a proximal caries lesion will randomly receive the infiltrating resin (Icon) while the other will receive a placebo, according to the manufactures´ instruction for Icon. In short, teeth will be isolated with a rubber dam and the tooth surface cleaned with non-fluoride prophylactic paste and pumice. The Icon material will be applied following the manufacturer's instructions and light cured, followed by polished using interproximal finishing/polishing strips (Sof Lex, 3M ESPE, St Paul, MN). Subjects will be given a letter to take to their local dentist asking them not to treat the selected lesions without informing the investigator first.
45966514|NCT02962596|Other|ADNEXMR SCORING system|Scoring system used to standardize the imaging report for sonographically indeterminate adnexal masses.
45667694|NCT01988337|Other|Mock treatment|"For the mock treatment the procedure will be identical to the Resin Infiltration intervention, with the exception that a placebo will be used. Essentially, syringes identical to the Icon materials will be supplied by DMG for the placebo procedure. The syringes will be filled with solutions having the same consistency and color as the Icon material."
45667695|NCT02013531|Drug|Brexpiprazole|Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally
45667696|NCT01988103|Drug|Apremilast|20 mg tablet BID for 68 weeks
45966515|NCT02277613|Biological|AMI MultiStem cells|AMI MultiStem cells administration in coronary artery with a micro-infusion catheter.
45966516|NCT02277613|Other|Sham|Sham procedure using Micro-Infusion Catheter in coronary artery without injection.
45966517|NCT02277652|Device|The Miller Laryngoscope|Direct laryngoscopy
45966518|NCT02277652|Device|The Bonfils intubation fibrescope|Optical laryngoscopy
45966519|NCT02277652|Device|The GlideScope Ranger|Videolaryngoscopy
45966520|NCT02277652|Device|The Supraglottic Airway Laryngopharyngeal Tube (SALT)|Blind intubation
45966521|NCT02277730|Device|vasopressor delivery automated system|vasopressor delivery using phenylephrine and ephedrine
45966522|NCT02277730|Drug|phenylephrine|
45966523|NCT02277730|Drug|ephedrine|
45966524|NCT02277730|Device|manual vasopressor delivery|
45966525|NCT00124202|Behavioral|a fatty meal|Approximately one hour before ERCP procedure, patient will have a fatty meal in the study group and normal saline in control group
45966526|NCT00221910|Procedure|Ultrasound|
45966527|NCT04571437|Drug|Capecitabine|Capecitabine metronomic combined with Letrozole
45966528|NCT04571437|Drug|Letrozole 2.5mg|Letrozole daily alone
45966529|NCT00192257|Biological|CAIV-T and TIV|
45966530|NCT00215124|Drug|Filgrastim|
45966531|NCT00473824|Biological|Hepatitis C Immune Globulin Intravenous (Human) 5%|Hepatitis C Immune Globulin Intravenous (Human) 5%, [Civacir]: 18 infusions total, per schedule, of 300 or 400 mg/kg of body weight given with standard post-transplant therapy inclusive of immunosuppressive agents.
45966532|NCT00215163|Drug|Cognitive-behavioral therapy and paroxetine-CR|
45966533|NCT00192335|Biological|CAIV-T|
45966534|NCT00192335|Biological|CAIVT|The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
46080465|NCT02733120|Other|stable isotope infusion|stable isotopes such as 15N2, TRP, 2H3-Leucine, L-[2H3]-3-Methylhistidine, 2H2-Glycine, 2-D-hydroxyproline, 1-13C-ketoisocaproic acid (KIC), L-[Guanido-15N2]-Arginine, L-[ureido-13C-2H2]-Citrulline), L-Glutamine-amide-15N, 1,2-13C2-L-Glutamic acid, 1,2-13C2Taurine, and 13C-Urea is given IV simultaneously
45966535|NCT00192335|Biological|FluMist|The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
45966536|NCT00192374|Biological|CAIV-T, Liquid|
45966537|NCT00215202|Drug|Iressa (ZD1839)|
45966538|NCT00215241|Drug|sertraline and risperidone|
45966539|NCT00124241|Drug|telbivudine|
45966540|NCT00124241|Drug|lamivudine|
45966541|NCT00221949|Device|Ultrasound|
45966542|NCT00124280|Drug|RAD001|
45966543|NCT00215280|Drug|ivermectin and albendazole|
45966544|NCT04727294|Behavioral|Questionnaire|Series of questions covering COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life.
45966545|NCT00215319|Device|Lumbar I/F with cage and pedicle screws|Surgical Titanium Mesh™ with MOSS-Miami™ Pedicle Screws
45667697|NCT01988103|Drug|Apremilast|20 mg tablet BID for 68 weeks
45455625|NCT01226797|Drug|Placebo|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
45667698|NCT01988103|Drug|Placebo|Placebo tablet BID for 16 weeks
45667699|NCT02013375|Procedure|Haploidentical Transplant|All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
45455626|NCT01226797|Drug|PF-04136309|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
45667700|NCT02013375|Drug|Alemtuzumab|On Day -7, the first test dose of alemtuzumab (0.03 mg/kg) will be administered and on Day -6, the second test dose of alemtuzumab (0.1 mg/kg) will be administered. Alemtuzumab (0.3 mg/kg) will be infused daily on Day -5, -4, and -3.
45667701|NCT02013375|Radiation|Total Body Irradiation|A 300cGy dose of TBI will be administered in a single fraction on Day -2.
45667702|NCT02013375|Drug|Cyclophosphamide|Cyclophosphamide (50 mg/kg IBW) IV, over approximately 1-2 hours, is given on Day 3 post-transplantation (ideally between 60 and 72 hours after marrow infusion) and on Day 4 (approximately 24 hours after Day 3 cyclophosphamide).
45824578|NCT02127372|Drug|Docetaxel, Cisplatin and STI571|"Treatment will consist of docetaxel plus cisplatin IV every 21days and oral STI571 given on Days -5 to 2 with each chemotherapy cycle. A maximum of 6 cycles will be given.~Phase 1 dose levels are:~Level 1 Docetaxel/Cisplatin 60 mg/m2, STI571 300mg~Level 2 Docetaxel/Cisplatin 60 mg/m2, STI571 400mg~Level 3 Docetaxel/Cisplatin 70 mg/m2, STI571 400mg~Level 4 Docetaxel/Cisplatin 70 mg/m2, STI571 600mg~Level 5 Docetaxel/Cisplatin 75 mg/m2, STI571 600mg~Level 6 Docetaxel/Cisplatin 75 mg/m2, STI571 800mg~Once the MTD level has been established, the previous dose level will be the dosing schedule for Phase II."
45824579|NCT02127372|Drug|Docetaxel|
45824580|NCT02127372|Drug|Cisplatin|
45966546|NCT00192413|Biological|Cold-adapted influenza vaccine trivalent (CAIV-T)|Liquid CAIV-T vaccine for this study consisted of 3 cold-adapted, attenuated, reassortant strains, representing the HA and NA antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Victoria/504/2000 influenza strains. The vaccine contained no preservatives and had a pH of 7.2 ± 0.5.
45966547|NCT00192413|Biological|Trivalent Inactivated Vaccine (TIV)|Commercially available TIV, inactivated influenza vaccine (Split Virion) BP (Aventis Pasteur MSD, Lyon, France) was administered IM according to the manufacturer's dosing instructions (one 0.5-mL IM dose for adults).
45966548|NCT00222027|Procedure|Collection of treatment-stratefying prognostic factors|
45966549|NCT00192452|Drug|MEDI-507|
45966550|NCT00215358|Drug|Formoterol Fumarate|
45966551|NCT00192491|Biological|FluMist|Nasal Sprayer of one dosage of FluMist and other experimental
45966552|NCT00192491|Biological|FluMist|Nasal sprayer of FluMist
45966553|NCT00192491|Other|Placebo|Nasal Sprayer of Placebo
45966554|NCT00222066|Procedure|Fetal ovarian cyst aspiration|Fetal ovarian cyst aspiration performed under ultrasound guidance and maternal local anesthesia
45966555|NCT00192569|Drug|Pegylated Interferon alfa 2a|PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
45966556|NCT00192569|Drug|Ribavirin (HIV conifected patients only)|"genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing <75kg and 1200mg for patients weighing ≥ 75kg)~Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients"
45966557|NCT00215397|Drug|Formoterol Fumarate|
45966558|NCT00192608|Drug|saquinavir 500 formulation|NRTIs + SQV/RTV 1000/100 mg BID using 200 mg SQV capsules switched at entry to ATV/SQV/RTV 300/1500/100 mg QD using 500 mg SQV tablet for 48 weeks with PK at days 0 and 8.
45667703|NCT02013375|Drug|Sirolimus|Sirolimus will be started on Day +5 (at least 24 hours after the completion of the cyclophosphamide infusion). The starting dose will be 12mg followed by 4mg PO daily. Doses will be adjusted to achieve a whole blood trough level of 4 - 12ng/mL.
45667704|NCT04676217|Procedure|Postoperative positioning advice|The postoperative positioning advice until 3 am the same day.
45667705|NCT02079519|Drug|Bevacizumab|Bevacizumab was provided as a concentrate in vials.
45667706|NCT01987557|Behavioral|rate group|walking with a high cadence (steps per minute)
45824581|NCT04747548|Behavioral|Kurbo Only|Kurbo is a structured behavioral weight management program for youth that focuses on diet, physical activity and mindset skills and is based on the traffic light diet developed at Stanford University. The dietary approach is based on creating an energy deficit diet to produce weight loss while also being attentive to the quality of the calories consumed. Foods are categorized into the colors of a traffic light signal based on their nutritional and caloric content, such that youth are encouraged to eat more of green and yellow foods, and less of red foods. Participants will log their daily food intake and self-monitor dietary and physical activity behaviors, incorporating behavior substitution and habit formation. Participants will also have 15 minute weekly individualized coaching sessions.
45824582|NCT04747548|Behavioral|Kurbo + PolyRules!|In addition to Kurbo, participants will be asked to engage in daily cognitive training using the PolyRules! app for three months. They will be instructed to start with 20-min of daily cognitive training and to progressively increase their training time to 30-min.
45824583|NCT04751682|Biological|BBV154 Vaccine|Replication deficient Adenoviral vector-based (expressing a stabilized spike protein) SARS-CoV-2 vaccine (BBV154) NLT 1X10^10 Virus Particle.
45824584|NCT04751682|Biological|Placebo|Placebo
45824585|NCT02126826|Drug|BI 1026706|Multiple Rising Doses (oral solution, tablet)
45824586|NCT02126826|Drug|Placebo to BI 1026706|Multiple Rising Doses (oral solution / tablet, identical to active treatment)
45824587|NCT02126670|Drug|ACT01|
45824588|NCT02126670|Drug|Comp01|
45824589|NCT02126670|Drug|Comp02|
45824590|NCT02126670|Drug|Comp03|
45824591|NCT02126670|Drug|Comp04|
45966559|NCT00192608|Drug|cross-over arm|either ATV/SQV/RTV 300/1500/100 QD (500 mg SQV tabs) for 7 days then after PK SQV changed to 1600 mg QD (200 mg caps) with PK day 15, or ATV/SQV/RTV 300/1600/100 QD for 7 days with switch to SQV 1500 mg QD. After day 15 PK both groups switch to ATV/SQV/RTV 300/1500/100 QD to week 48
45455627|NCT03671044|Drug|Nanosomal Docetaxel Lipid Suspension (75 mg/m2)|Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.
45667707|NCT01987557|Behavioral|magnitude treadmill group|
45667708|NCT01987557|Behavioral|regular treadmill walking|
45667709|NCT02078817|Drug|Ketamine|IV infusions of 0.5mg/kg of Ketamine hydrochloride over a 40-minute infusion period. Participants will receive a total of 6 doses over a 2-week period.
45667710|NCT02011893|Device|Tonic Stimulation|Prodigy Neurostimulation System with associated components
45667711|NCT02011893|Device|Burst Stimulation|Prodigy Neurostimulation System with associated components
45824592|NCT02125734|Drug|QVA149|QVA149 capsules 110/50 µg for inhalation via Concep-1-inhaler device, taken once a day
45824593|NCT02125734|Drug|Tiotropium|Tiotropium 18 µg capsules for inhalation via HandiHaler device taken once a day
45824594|NCT02124798|Device|Belimumab autoinjector|Single use, disposable autoinjector assembled with the prefilled syringe containing the drug product belimumab with unit dose strength of 200mg/mL and 1 mL will be given as a once weekly SC dose
45824595|NCT04735770|Procedure|Postoperative pain management: LTAP block or local wound anesthesia with levobupivacaine|Postoperative pain management
45824596|NCT02146326|Behavioral|Motivational Interviewing (MI)|MI is a common counseling technique. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to MI. Each session occurred approximately one month apart.
45667712|NCT02011113|Drug|Pomalidomide|4 mg oral pomalidomide once daily Days 1-21 of each 28-day cycle
45667713|NCT02011113|Drug|Dexamethasone|40 mg or 20 mg oral dexamethasone once daily on Days 1, 8, 15, 22 of each 28-day cycle
45667714|NCT01807156|Drug|Tivozanib|Oral medication given daily. No placebo.
45667715|NCT01987479|Drug|Non-Biologic DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study and is at the investigator's discretion.
45667716|NCT01987479|Drug|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 24 weeks.
45824597|NCT02146326|Behavioral|Burnout Reduction: Enhanced Awareness, Tools, Handouts, and Education (BREATHE)|BREATHE is a program developed to attempt to improve or prevent the symptoms of burnout. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to BREATHE. Each session occurred approximately one month apart.
45824598|NCT02146248|Drug|combined oral contraceptive|combined oral contraceptive pill will be dosed continuously for 30 days without cycle interruption
45824599|NCT02146248|Drug|DepoProvera|injectable hormonal contraceptive
45824600|NCT02145468|Drug|Losmapimod 7.5 mg twice daily|Subjects will receive Losmapimod 7.5 mg as film-coated, round, plain faced tablets.
45824601|NCT02145468|Drug|Placebo twice daily|Subjects will receive placebo as film-coated, round, plain faced tablets.
45824602|NCT02145468|Drug|Standard therapy|Subjects will receive standard therapy consistent with the appropriate guidelines from professional societies. The standard therapy includes nitrates, morphine sulfate, beta adrenergic blockers, renin-angiotensin aldosterone inhibitors, other anti-ischemic therapies, and analgesic therapy.
45824603|NCT02124564|Drug|Lacosamide|"Lacosamide (LCM) immediate-release, film-coated tablets at a strength of 50 mg orally administered twice daily in two equally divided doses.~4-week Titration Period: Starting on LCM 100 mg/day increased by 100 mg/day each week until 400 mg/day dose reached at the beginning of Week 4 .~The AED Withdrawal Period and Monotherapy Period (52- week Evaluation Period plus a Follow Up Period): During the AED Withdrawal and Monotherapy Period, the investigator may increase or decrease the dose of LCM to optimize tolerability and seizure control. The LCM dose may be decreased no lower than 200 mg/day or increased, no faster than 100 mg/day per week, up to 600 mg/day."
45966560|NCT00215436|Drug|Formoterol Fumarate|
45824604|NCT02145390|Procedure|Transurethral Resection of the Bladder Tumor & Cystoscopy|"TURBT and Cystoscopy will be performed by the participating urologist prior to start of neoadjuvant chemotherapy, per the study protocol:~Cystoscopic evaluation~Bimanual examination under anesthesia,~Transurethral resection of the bladder tumor,~Biopsy of the prostatic urethra including both mucosa and stroma using a resection loop."
45667717|NCT01987479|Drug|Methotrexate|Methotrexate will be administered per investigator's discretion.
45824605|NCT02145390|Radiation|Intensity Modulated Radiation Therapy|"For subjects with complete response to neoadjuvant chemotherapy. Subjects will receive 25 daily fractions (5 weeks) of radiation therapy for 5 days a week (Monday to Friday) except on weekends or holidays, when remaining fractions will be added to the end of treatment. The overall schema is for IMRT based radiation to the entire bladder, prostate (in men) and the pelvic lymph nodes:~Pelvic lymph nodes: 45 Gy in 25 fractions at 1.8 Gy per fraction.~Whole bladder and prostate: 50 Gy in 25 fractions at 2.0 Gy per fraction.~Tumor boost area: 60-65 Gy in 25 fractions at 2.4-2.6 Gy per day~Final boost dose will be determined at the discretion of the treating physician based on normal tissue exposure and volume."
45824606|NCT02145390|Behavioral|Expanded Prostate Cancer Index Composite Short Form 12|Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
45824607|NCT02145390|Behavioral|International Prostate Symptom Score|Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
45824608|NCT02100696|Drug|Etrozulimab|Participants will receive 105 mg etrolizumab administered by SC injection Q4W.
45824609|NCT02100696|Drug|Placebo|Participants will receive placebo (matched with etrolizumab) administered by SC injection Q4W.
45824610|NCT02145156|Behavioral|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
45824611|NCT02145156|Behavioral|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
45824612|NCT02145156|Behavioral|Survey-only|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
45824613|NCT02123472|Drug|Cephalexin|Administered Orally
45824614|NCT02145078|Drug|docetaxel|Given IV
45824615|NCT02145078|Drug|pemetrexed disodium|Given IV
45824616|NCT02145078|Drug|gemcitabine hydrochloride|Given IV
45824617|NCT02145078|Other|laboratory biomarker analysis|Correlative studies
45824618|NCT02144610|Biological|HGF Plasmid (AMG0001)|IM
45824619|NCT02144610|Biological|Matching Placebo|IM
45824620|NCT02100228|Drug|Apixaban|Oral, 2.5 or 5 mg BID
45824621|NCT02100228|Drug|Parenteral heparin and/or oral Vitamin K antagonist|Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
45824622|NCT02099838|Drug|Pioglitazone and Metformin|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
45824623|NCT02099838|Drug|Placebo|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
45824624|NCT02144220|Other|Virtual care visit|Video-conferencing visit with a Parkinson disease specialist
45667718|NCT01620489|Drug|liraglutide|1.8 mg administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
45667719|NCT01620489|Drug|placebo|Administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
45667720|NCT02076165|Behavioral|Acceptance and the Behavioral Changes to Treat Insomnia|Participants attended 5 individual sessions incorporating behavioral treatment components plus acceptance and commitment therapy (ACT) with a trained instructor.
45824625|NCT02099682|Drug|Lansoprazole|Lansoprazole Capsules 15/ OD Tablets
45824626|NCT05182944|Drug|A：non-pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（2-4 cycles Camrelizumab+Albumin Paclitaxel+Cisplatin and Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
45824627|NCT05182944|Drug|B：non-pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
45824628|NCT05182944|Drug|A：pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
45824629|NCT05182944|Drug|B：pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Best Supportive Care）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
45824630|NCT02142894|Device|CST001|
45824631|NCT02098746|Drug|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
45824632|NCT02122770|Drug|MLN4924|MLN4924 intravenous solution.
45824633|NCT02122770|Drug|Fluconazole|Fluconazole tablets.
45824634|NCT02122770|Drug|Itraconazole|Itraconazole oral solution.
45455628|NCT03671044|Drug|Nanosomal Docetaxel Lipid Suspension (100 mg/m2)|Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.
45455629|NCT03671044|Drug|Taxotere® (100 mg/m2)|Docetaxel Injection Concentrate; 20 mg/0.5 mL
45966561|NCT00192686|Procedure|culture a.m. Kamme-Lindberg|
45966562|NCT00215514|Drug|Epirubicin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
45966563|NCT00215514|Drug|Cisplatin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
45966564|NCT00215514|Drug|5-Fluorouracil (5-FU)|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
45966565|NCT00215514|Procedure|Radiation|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
45966566|NCT00192725|Other|rapid tryptophan depletion|Amino-acid mixture without tryptophan
45966567|NCT00215592|Drug|Zonegran|
45667721|NCT02076165|Behavioral|Cognitive behavioral therapy for insomnia|Participants attended 5 individual sessions incorporating behavioral and cognitive therapy components with a trained instructor.
45966568|NCT00222144|Drug|Gleevec and Taxotere|Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15
45966569|NCT00222183|Drug|Elidel (pimecrolimus)|
45455630|NCT03740425|Procedure|Blood Transfusion|Blood Transfusion in patients who underwent transcatheter aortic valve implantation (TAVI)
45667722|NCT01620255|Drug|Placebo|Placebo delivered subcutaneous injection, 3 doses separated by 4 weeks
45824635|NCT02122770|Drug|Docetaxel|Docetaxel intravenous solution.
45966570|NCT00192764|Drug|high-dose cyclophosphamide|
45966571|NCT00411957|Drug|Atazanavir|ATV/r 300/100mg OD vs ATV/r 200/100 mg OD
45966572|NCT00192803|Drug|candesartan|
45966573|NCT00222222|Procedure|vein puncture|comparison of different inflammatory markers in the blood of septic patients
45966574|NCT00192842|Drug|curcumin (+ gemcitabine)|
45966575|NCT00411996|Drug|indinavir/ritonavir|IDV/r 600/100 mg BID + rifampicin OD for at least 2 weeks
45966576|NCT00192881|Device|Bx Sonic & Cypher stent from Cordis|
45966577|NCT00192920|Behavioral|Transfusion practice|
45966578|NCT00222261|Drug|aspirin|Aspirin 160 mg once daily for two years
45966579|NCT00222261|Drug|clopidogrel|clopidogrel 75 mg once daily for two years
45966580|NCT00192959|Drug|Xenon vs propofol|
45966581|NCT00215631|Drug|tadalafil|
45966582|NCT00222300|Behavioral|Strength training program|
45966583|NCT00193076|Drug|Gemcitabine|Gemcitabine
45966584|NCT00193076|Drug|Carboplatin|Carboplatin
45667723|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 1 delivered subcutaneous injection, 3 doses separated by 4 weeks
45667724|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 2 delivered subcutaneous injection, 3 doses separated by 4 weeks
45667725|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 3 delivered subcutaneous injection, 3 doses separated by 4 weeks
45824636|NCT02122770|Drug|Carboplatin|Carboplatin intravenous solution.
45824637|NCT02122770|Drug|Paclitaxel|Paclitaxel intravenous solution.
45824638|NCT02122380|Drug|Sitagliptin|Sitagliptin 100 mg by mouth daily for 30 Days
45824639|NCT02122380|Drug|Placebo|1 placebo pill by mouth per day for 30 days
45824640|NCT02122146|Drug|PF-06664178|Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined.
45824641|NCT02122146|Drug|PF-06664178|Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.
45966585|NCT00193076|Drug|Trastuzumab|Trastuzumab
45966586|NCT00222339|Behavioral|task-specific training|
45966587|NCT00193115|Drug|Docetaxel|
45966588|NCT00193115|Drug|Doxorubicin|
45966589|NCT00193115|Drug|Cyclophosphamide|
45966590|NCT00193154|Drug|OSI-774|150mg PO, days 1-28, cycle repeated every 28 days
45966591|NCT00193154|Drug|Bevacizumab|10mg/kg, IV infusion, Days 1 and 15, 28 day cycles
45455631|NCT03072134|Biological|Neural stem cells loaded with an oncolytic adenovirus|The primary objectives are to evaluate the safety of the combined therapy and determine the maximum tolerated dose (MTD) for a future Phase II study.
45667726|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 4 delivered subcutaneous injection, 3 doses separated by 4 weeks
45667727|NCT02010567|Drug|CRLX101|CRLX101 is an experimental nanoparticle formulation of the anticancer agent camptothecin manufactured by Cerulean Pharma Inc..
45824642|NCT02121834|Drug|LY3050258|
45824643|NCT02121834|Drug|Placebo|
45966592|NCT00222417|Procedure|myringoplasty|Myringoplasty is an operative procedure to close tympanic membrane perforations.
45966593|NCT00222417|Procedure|Stapes surgery|Operative procedure aimed to replace non-functioning stapes with a synthetic prosthesis
45966594|NCT00193193|Drug|Paclitaxel|
45966595|NCT00193193|Drug|Estramustine|
45966596|NCT00193193|Drug|Carboplatin|
45966597|NCT00222456|Behavioral|Sensitizing parents|
45966598|NCT00193232|Drug|Docetaxel|
45966599|NCT00193232|Drug|Bortezomib|
45966600|NCT00222495|Drug|quetiapine|
45966601|NCT00222495|Drug|olanzapine|
45966602|NCT00222495|Drug|risperidone|
45966603|NCT00193271|Drug|Docetaxel|
45966604|NCT00193271|Drug|Estramustine|
45966605|NCT00222534|Drug|Acetazolamide|
45966606|NCT00222534|Drug|Placebo|
45966607|NCT00193310|Drug|Paclitaxel|
45966608|NCT00193310|Drug|Carboplatin|
45966609|NCT00193349|Drug|Imatinib|
45966610|NCT00193349|Drug|Irinotecan|
45966611|NCT00193349|Drug|Carboplatin|
45966612|NCT00215670|Drug|pegaptanib sodium (Macugen)|
45966613|NCT00193388|Drug|Topotecan|
45966614|NCT00215709|Drug|docetaxel|
45966615|NCT00193466|Drug|Rituximab|
45966616|NCT00193466|Drug|Fludarabine|
45966617|NCT00193466|Drug|CAMPTH-1H|
45966618|NCT00215748|Drug|Dexamethasone|
45966619|NCT00215826|Drug|Alferon LDO|
45966620|NCT00193544|Drug|Arsenic Trioxide|
45966621|NCT00193544|Drug|Thalidomide|
45966622|NCT00215865|Drug|PEGIntron plus ribavirin|
45966623|NCT00124358|Drug|Buprenorphine|
45667728|NCT02010567|Drug|Capecitabine|Capecitabine is an oral fluoropyrimidine pro-drug, metabolically converted to 5-fluorouracil after administration. It is indicated as adjuvant treatment in patients with stage III colorectal cancer (Dukes' C colon cancer), and as first-line treatment of metastatic colorectal cancer.
45667729|NCT02010567|Radiation|Radiotherapy|"This protocol allows physician discretion as to the use of Intensity Modulated Radiation Therapy (IMRT) or 3D conformal planning techniques.~Radiation begins on Day1 of neoadjuvant chemotherapy and continues for 28 (if <T4) or 30 (T4 disease) consecutive weekdays. Patient will receive 1.8 Gy daily fractions of radiotherapy without a break except for weekends and holidays.~Dose is to be prescribed to an isodose surface that encompasses the planning target volume (PTV) and that satisfies the dose uniformity guidelines below. The minimum dose to PTV 1 and PTV 2 shall be no less than 95% of the protocol specified dose for that volume."
45966624|NCT00124358|Behavioral|Integrated HIV care and office-based opioid dependence treatment|
45966625|NCT00215904|Drug|D-serine (~2g/day)|Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (~2g/day). Second arm : adjuvant treatment with placebo (~2g/day).
45966626|NCT00193583|Drug|Topotecan|
45966627|NCT00193583|Drug|Carboplatin|
45966628|NCT00215982|Drug|capecitabine|Capecitabine will be administered at a dose of 825 mg/m2 PO BID, for a total daily dose of 1650 mg/m2. Capecitabine will be administered on days 1-14 followed by 7 day treatment free rest period and days 21-35 followed by a 7 day treatment-free rest period, every six weeks (42 days) of treatment is considered one cycle.
45966629|NCT00215982|Drug|Oxaliplatin|Oxaliplatin will be administered at a dose of 130 mg/m2 IV over 120 minutes in 250-500 ML D5W on day 1, every 42 days.
45966630|NCT00215982|Drug|Irinotecan|Irinotecan will be administered at a dose of 180mg/m2 IV over 90 minutes on day 21 every 42 days.
45966631|NCT00124397|Drug|Atorvastatin|
45966632|NCT00216021|Drug|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
45966633|NCT00216021|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
45966634|NCT00409526|Drug|Inhaled Iloprost|50 micrograms for one hour followed by 100 micrograms for one hour
45966635|NCT00216138|Drug|Docetaxel|Docetaxel 60 mg/m2 for 60 minutes, day 1 of each cycle
45966636|NCT00216138|Drug|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
45966637|NCT00216138|Drug|Premedication|Dexamethasone and antiemetic premedication
45667730|NCT02010567|Procedure|Surgery|Surgery will take place at least 6 weeks post completion of chemoradiotherapy in patients with resectable disease; tissue from surgical resection will be preserved for correlative studies in those patients who do not achieve a pCR.
45667731|NCT01806064|Drug|TRC105 and Axitinib|
45667732|NCT01806064|Drug|Axitinib|
45966638|NCT00409604|Device|Temporary RV VVI pacing|temporary pacing at the onset of revascularisation
45966639|NCT00216177|Drug|Infliximab|Remicade
45966640|NCT00216177|Drug|Adalimumab|Humira
45966641|NCT00216216|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV q 3 weeks
45966642|NCT00473746|Drug|Abiraterone acetate|The first cohort was a abiraterone acetate 250 mg/day orally (by mouth), once daily for 28-day treatment periods , if no dose limiting toxicity (DLT) was documented at this dose, the dose will be escalated to next dose levels 500, 750, and 1000 mg/day. The dose escalation will continue to a maximum of 1000mg/day until Maximum Tolerated Dose (MTD) and a recommended Phase II dose was established.
45966643|NCT00473746|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg daily under fasted conditions upto 10 cycles of therapy.
45966644|NCT00473746|Drug|prednisone/prednisolone or dexamethasone|prednisone/prednisolone (5 mg twice daily) or dexamethasone (0.5 mg once daily) concurrent with abiraterone acetate
45966645|NCT00409643|Drug|valsartan+amlodipine combination|
45966646|NCT00409643|Drug|valsartan|
45966647|NCT00409643|Drug|amlodipine|
45966648|NCT00216294|Drug|RG1068 (Synthetic Human Secretin)|
45966649|NCT00473668|Biological|Zilbrix-Hib|Intramuscular injection, 1 dose
45966650|NCT00473668|Biological|Tritanrix™-HepB/ Hiberix™|Intramuscular injection, 1 dose
45966651|NCT04722497|Other|Sound Education|All physicians and nurses involved in cesarean births will be given an education intervention explaining the impact of noise levels on stress and focus. The SoundEar device will be used as an intervention tool to inform operating room physicians and nurses when the noise level is above the desired level.
45966652|NCT00216333|Drug|combined fixed dose combination|
45966653|NCT00124553|Behavioral|Intensive dietary advice|
45966654|NCT00223119|Device|Absorbable Sutures|
45966655|NCT00409721|Drug|Memantine|
45966656|NCT00223158|Drug|Liothyronine|
45966657|NCT00193622|Drug|Bevacizumab|
45966658|NCT00193622|Drug|Erlotinib|
45966659|NCT00223197|Drug|Pregnenolone|
45966660|NCT00473590|Drug|Bevacizumab|15 mg/kg administered by intravenous infusion
45966661|NCT00473590|Drug|Bortezomib|1.3 mg/m^2 administered by intravenous bolus injection
45966662|NCT00473590|Drug|placebo|Intravenous repeating dose
45966663|NCT00223275|Drug|Naltrexone|
45966664|NCT00124787|Drug|Dimenhydrinate|Dimenhydrinate PO q 6 hours x 4 doses
45966665|NCT00124787|Drug|Placebo|Placebo PO q 6 hours x 4 doses
45966666|NCT00223314|Behavioral|HIV, STD, Pregnancy Prevention Curriculum|The curriculum is designed to change students' knowledge, perceptions of norms, beliefs, self-efficacy, interpersonal skills (i.e., refusal skills), and high-risk behaviors related to HIV. The curriculum included use of facilitators for selected lessons such as role playing. Intervention strategies included demonstrations of skills by role playing, use of role model stories, and other experiential learning techniques. The curriculum was delivered during the school days by facilitators (project staff) who received intensive training prior to implementation and coaching and support during implementation.
45966667|NCT00193661|Drug|Testosterone Gel (1%)|
45966668|NCT00206232|Drug|Spironolactone|Research subjects are randomized to placebo versus spironolactone 25mg daily and followed for 6 months.
45966669|NCT00193700|Drug|Testosterone Gel (1%)|
45667733|NCT01804582|Other|Family Navigator consultation|"Telephone contact from the trained family navigator to the parent participant several times over the 90 day study time period. Components of the service include the following:~(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan."
45824644|NCT02121756|Drug|Dipyridamole|Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
45966670|NCT00206271|Behavioral|neck collar; advice to act-as-usual; active mobilisation|
45824645|NCT02121756|Drug|Placebo, then Dipyridamole|Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
45667734|NCT01787188|Drug|Meloxicam Test Capsules|
45667735|NCT01787188|Drug|Meloxicam Test Capsules|
45667736|NCT01787188|Drug|Placebo Capsules|
45667737|NCT01787032|Drug|BI 113608|tablet
45667738|NCT01787032|Drug|BI 113608|tablet
45667739|NCT01787032|Drug|BI 113608|tablet
45458319|NCT01141543|Drug|Plerixafor (mozobil)|"Cohort 1: Administration of PLERIXAFOR (240mcg/kg sc) before the first dose of FLUDARABINE and BUSULFAN Cohort 2: Administration of PLERIXAFOR (240mcg/kg sc) before the first and second dose of FLUDARABINE and BUSULFAN.~Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN Cohort 4: Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN"
45667740|NCT01787032|Drug|Ketoconazole|tablet
45667741|NCT01787032|Drug|Voriconazole|tablet
45824646|NCT02142504|Biological|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection
45667742|NCT01737268|Drug|FK949E|Oral tablet
45667743|NCT01769404|Biological|LY2605541|
45667744|NCT01769404|Biological|Insulin Glargine|
45667745|NCT04562662|Device|mediVR KAGURA|Approximately 20 min mediVR KAGURA-guided rehabilitation
45667746|NCT01769326|Other|Conventional hand exercise|Conventional hand exercise consists of passive and active range of motion exercise, and simple coordination exercises with the fingers
45667747|NCT01769326|Device|MusicGlove|The MusicGlove is a glove that detects different grip types. Subjects play a musical game by completing different grips.
45667748|NCT01769326|Other|Conventional Arm Exercise|Conventional arm exercise consists of passive and active range of motion exercise, and simple weight bearing exercises
45824647|NCT02142504|Drug|Placebo (Saline)|Placebo-matching norovirus bivalent VLP vaccine
45824648|NCT02121522|Drug|BI 144807|twice daily
45824649|NCT02121210|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
45824650|NCT02141490|Drug|Ferumoxytol|7.5mg/kg intravenous (IV) infusion
45824651|NCT02141490|Diagnostic Test|Magnetic Resonance Imaging (MRI)|3 MRIs: pre-infusion, 24 and 48 hours post-infusion
45824652|NCT02097108|Drug|Raltegravir|
45966671|NCT00124826|Drug|Insulin|
45966672|NCT00223353|Other|Prosthetics, Orthotics and Physical Therapy|Gait Analysis.
45966673|NCT00193739|Drug|NACT|3 cycles of neoadjuvant chemotherapy
45966674|NCT00193739|Procedure|Radical abdominal hysterectomy (class III), BPLND & lower para aortic lymph node sampling|NACT followed by surgery
45966675|NCT00193739|Drug|Inj.Cisplatin|Concurrent chemo radiotherapy
45966676|NCT00193739|Radiation|Concurrent chemo radiotherapy|Radiation therapy will be administered to the whole pelvis region followed by intracavitary brachytherapy.
45966677|NCT00124865|Biological|rFla-MBP|
45966678|NCT00206310|Drug|CRESTOR|
45966679|NCT00193778|Procedure|Surgery for breast cancer|This group will receive standard loco-regional treatment i.e. surgery (modified radical mastectomy (MRM)/ Simple SMAC/BCT) +/- radiotherapy
45966680|NCT00193778|Other|No Loco-regional treatment|This group will not receive any loco-regional treatment
45966681|NCT00223431|Device|all-ceramic fixed partial denture|
45966682|NCT00193817|Procedure|Two field vs Three field lymphadenectomy|
45667749|NCT01769326|Device|Resonating Arm Exerciser|The RAE is a lever that attaches to a manual wheelchair with elastic bands and can be pushed back and forth to exercise the arm.
45966683|NCT00124904|Behavioral|Biofeedback|
45667750|NCT01786330|Device|Procare abdominal binder|
45966684|NCT00124904|Behavioral|Kegel exercises|
45966685|NCT00206388|Drug|Zolendric acid|IV, 2mg/m2/dose on day 0
45966686|NCT00206388|Drug|Cyclophosphamide|fixed dose of 25mg/m2/dose days 0-27
45966687|NCT00125021|Drug|Capecitabine|Given twice a day for 14 days followed by 7 days of no capecitabine (1 cycle is 21 days).
45966688|NCT00125021|Drug|OSI-774|Given once daily
45966689|NCT00193856|Drug|Leuprorelin Acetate|LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).
45966690|NCT00193856|Drug|Zoledronic Acid|Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.
45966691|NCT00193856|Radiation|Conventional external beam therapy|The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with >= 6 MV photons.
45966692|NCT00223509|Drug|Lamotrigine|
45966693|NCT00193895|Drug|Carboplatin|Carboplatin will commence with a dose calculated to target an AUC of 2.0. A maximum of 6 doses of weekly Carboplatin will be given. Carboplatin will be administered intravenously over 20-30 minutes prior to radiation therapy.
45966694|NCT00193895|Radiation|Radiotherapy|60 Gy OR 66Gy in 2Gy/fraction 5days/week
45966695|NCT00223548|Drug|sodium 2-mercaptoethane sulfonate|
45966696|NCT00125060|Drug|Simvastatin (20mg versus 80mg/day)|
45966697|NCT00223587|Other|1 week of treatment discontinuation|1 week of treatment discontinuation during allergic rhinitis season
45966698|NCT00223626|Drug|Topiramate|the maximum topiramate test dose is 200 mg/d.
45966699|NCT00223743|Drug|Zonisamide|study drug initially will taken as one 50-mg tablet a day, then the dose increased by one tablet each two weeks, to no more than 3 tablets (150 mg) taken twice a day.
45966700|NCT00411177|Procedure|post-dilution on-line hemodiafiltration|post-dilution on-line hemodiafiltration, 3 times a week 4 hours
45966701|NCT00411177|Procedure|high flux hemodialysis|High-flux hemodialysis, 3 times a week 4 hours
45667751|NCT01786330|Other|Standard of Care|
45667752|NCT01786174|Drug|Gilenya|0.5mg Gilenya orally by mouth once daily for approximately 28 days
45966702|NCT00411255|Procedure|repetitive transcranial magnetic stimulation (rTMS)|Three arms on three different days 180 stimuli will be delivered to the AC with a sham coil, with the H-coil and with a standard circular coil in separate sessions.
45966703|NCT00125099|Biological|VRC-HIVDNA009-00-VP|
45966704|NCT00193973|Drug|Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C|Idarubicin 15mg/m2 days 1, 22. Filgrastim 5mcg/kg until neutrophil recovery days 2, 23. Methotrexate 1g/m2 days 15, 36 and 50.
45966705|NCT00193973|Radiation|Radiation Therapy|Whole brain Irradiation, 30Gy in 20 fractions over 4 weeks
45966706|NCT00223782|Behavioral|Gait Training with Feedback|
45966707|NCT00223782|Behavioral|Gait Training with no feedback|
45667753|NCT01786174|Other|Placebo|0.5mg placebo (sugar pill) orally by mouth once daily for approximately 28 days
45824653|NCT02097030|Device|filcon II 3|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
45824654|NCT02097030|Device|etafilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
45824655|NCT02097030|Device|nelfilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
45824656|NCT02096952|Drug|Methylphenidate extended-release liquid formulation|
45824657|NCT02120898|Drug|Imiquimod|Cream, generic formulation of the brand product.
45667754|NCT01736566|Other|Family History + Whole Genome Sequencing|"Doctors and their patients receive a Genome Report and a Family History report.~There are two sections of the Genome Report:~The General Genome Report, which include highly penetrant disease mutations, carrier status for recessive disease, and pharmacogenetic associations.~The Cardiac Risk Supplement, which contain genetic information found in the genome regarding cardiac diseases or a risk of cardiovascular diseases that can help with the care of the patient.~Extension Phase: Experimental: Family History + Whole Genome Sequencing~*In the main study participants are randomized to either the Experimental or Other Arm, in the Extension phase of the study all participants are in the Experimental Arm."
45824658|NCT02120898|Drug|Zyclara®|Cream, brand product.
45824659|NCT02120898|Drug|Vehicle Cream|Vehicle cream in the same image of the generic imiquimod. Has no active ingredient.
45824660|NCT02120664|Drug|Florbetapir (18F)|
45824661|NCT02120664|Drug|11C-PiB|
45824662|NCT01627860|Drug|Topiramate add-on therapy|Type=range, unit=mg/day, number=25-200, form=tablet, route=oral use.
45824663|NCT01627860|Drug|Topiramate monotherapy|Type= range, unit= mg/day, number= 25-200, form= tablet, route= oral use.
45966708|NCT00411879|Drug|Vasopressin, Epinephrine, and Steroids|During resuscitation, study group patients receive vasopresssin [20 IU IV maximum dose = 100 IU] and methylprednisolone (40 mg IV). Epinephrine is given to both groups according to guidelines for resuscitation 2005. In the study group, postresuscitation shock is treated with stress-dose hydrocortisone.
45966709|NCT00411879|Drug|Placebo, Epinephrine, Placebo|Epinephrine is given to both groups according to guidelines for resuscitation 2005. Control group patients receive placebo instead of vasopressin and steroids.
45966710|NCT00193505|Drug|Ifosfamide|
45966711|NCT00193505|Drug|Carboplatin|
45966712|NCT00193505|Drug|Etoposide|
45966713|NCT00193505|Drug|Rituximab|
45966714|NCT00193505|Drug|90Y Zevalin|
45966715|NCT00125177|Behavioral|Knack therapy|
45966716|NCT00125216|Behavioral|Response Elaboration Training|Therapist modeling, reinforcement and forward-chaining are used to stimulate verbal descriptions of pictures
45966717|NCT00223860|Drug|Human chorionic gonadotropin (hCG)|
45966718|NCT00223860|Drug|Luteinizing hormone releasing hormone (LHRH)|
45966719|NCT00125255|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel comprising of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. The study drug was applied at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
45966720|NCT00125255|Drug|Placebo Peel|Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
45966721|NCT00223899|Genetic|VCL-IM01 (encoding IL-2) with Electroporation|IL-2-encoding plasmid formulated in phosphate-buffered saline at 0.5 mg/mL, 1.5 mg/mL, and 5.0 mg/mL (VCL-IM01) intratumorally injected and followed by electroporation with Inovio MedPulser® 1.0 cm array with needles up to 3 cm long (one 6-pulse cycle per tumor).
45966722|NCT00223938|Drug|Oral Iron|Oral Iron
45966723|NCT00223938|Drug|sodium ferric gluconate|weekly intravenous injection Dose 1
45966724|NCT00223938|Drug|sodium ferric gluconate|weekly intravenous injection Dose 2
45824664|NCT04745754|Other|Embedded primary care in cancer survivorship model|Primacy care physicians will receive comprehensive training in cancer survivorship care for low-risk, early stage breast and colorectal patients. Training will include continuing medical education (CME) modules, webinars, and in-person discussion and clinical shadowing.
45824665|NCT04732494|Drug|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous injection.
45667755|NCT01736566|Other|Family History Only|Doctors and their patients receive a Family History report.
45667756|NCT01768858|Drug|Adalimumab|Adalimumab administered by subcutaneous injection, via pre-filled syringe or autoinjector pen
45667757|NCT01736254|Drug|Evacetrapib|
45824666|NCT04732494|Drug|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous injection.
45824667|NCT04732494|Drug|Placebo|Ociperlimab placebo injection is a sterile, preservative-free solution for infusion formulated in the same buffer as ociperlimab active drug.
45966725|NCT00125294|Drug|Methadone|
45966726|NCT00206466|Drug|Taxotere|Docetaxel (Taxotere) 100 mg/m2 is to be administered on day 1. A core biopsy is to be performed one day after chemotherapy (day 2) and on days 8, 15 and 22. On day 22, after repeat core biopsy, a second cycle of docetaxel (Taxotere) chemotherapy (100 mg/m2) will be given. Docetaxel (Taxotere) will be given three-weekly for a total of four cycles. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
45966727|NCT00206466|Drug|Adriamycin/cytoxan|Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
45824668|NCT01627782|Drug|Placebo|Form= intravenous infusion, route= intravenous (IV) use. IV infusions of placebo 2 times weekly or IV infusions of placebo 3 times weekly.
45966728|NCT00125333|Drug|NF-kappaB Decoy|
45966729|NCT00224094|Drug|Premarin® (oral) vs. Alora® (transdermal)|
45966730|NCT00125411|Drug|satraplatin and docetaxel|"Satraplatin - oral administration within 2 hours of docetaxel infusion. Subsequent dosing will be on days 2-5 at approximate 24 hour intervals.~Docetaxel will be administered as intravenous infusion over 1 hour followed by saline flush."
45966731|NCT00206505|Drug|Taxotere|
45966732|NCT00206544|Drug|Tamoxifen|40 mg daily of adjunctive tamoxifen in oral capsule
45667758|NCT01736254|Drug|Gemfibrozil|
45667759|NCT01767376|Biological|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid muscle of the arm.
45667760|NCT01767376|Biological|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the right arm (in Co-ad Group) and left arm (in TdapACWY and ACWYTdap Groups).
45824669|NCT01627782|Drug|Ketamine|Type= exact number, unit= mg/kg, number= 0.5, form= intravenous infusion, route= intravenous (IV) use. IV infusions of ketamine 0.50 mg/kg, 2 times weekly or IV infusions of ketamine 0.50 mg/kg, 3 times weekly.
45824670|NCT01598532|Device|MedX Health Phototherapy (light therapy)|The treatment period is 6 weeks (3x per week) for a total of 18 Transcranial LED treatments. Each treatment session is 30 minutes each.
45824671|NCT02119650|Drug|Ruxolitinib|5 mg tablets to be administered by mouth at dose selected from safety run-in phase (Ruxolitinib 15 mg twice daily (BID))
45824672|NCT02119650|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
45966733|NCT00206544|Drug|Progesterone|20 mg daily of adjunctive progesterone in oral capsule
45966734|NCT00206544|Other|placebo|adjunctive placebo daily in oral capsule
45966735|NCT00125450|Procedure|Chest Physiotherapy with Forced Expiratory Technique|Chest Physiotherapy with Forced Expiratory Technique
45824673|NCT02119650|Drug|Pemetrexed|500 mg/m^2 administered as an intravenous infusion over 10 minutes
45824674|NCT02119650|Drug|Cisplatin|75 mg/m^2 infused over 2 hours beginning 30 ± 5 minutes after the end of the pemetrexed infusion
45824675|NCT02119416|Drug|Placebo Administration first|"All participants received each dose on two days and the order of administration was counterbalanced.~Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg"
45824676|NCT02119416|Drug|Low Caffeine Administration first (1mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg"
46080466|NCT04262063|Behavioral|Tell play do technique|it apply the concept of learning by doing .children will enjoy playing with customized dental models
45966736|NCT00125450|Procedure|Nasopharyngeal Aspiration|Nasopharyngeal Aspiration
45966737|NCT00206583|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|GA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)
45966738|NCT00194324|Drug|Miconazole nitrate|
45966739|NCT00194324|Procedure|Magnetic resonance imaging|
45966740|NCT00194324|Behavioral|Moderate levels of exercise|
45966741|NCT00224211|Behavioral|Music|
45966742|NCT00194363|Behavioral|Strength training|13 weeks of supervised strength training (twice weekly for 90 minutes per session), 39 weeks of unsupervised strength training (twice weekly for 90 minutes per session)
45966743|NCT00206622|Drug|Climara PRO (Estradiol / Levonorgestrel transdermal)|2.2mg 17 Beta-estradiol/0.69mg levonorgestrel combination transdermal patch
45966744|NCT00206622|Drug|Menostar (Estradiol transdermal)|1mg 17 Beta-estradiol transdermal patch
45966745|NCT00206622|Drug|Placebo transdermal|Placebo
45966746|NCT00194402|Drug|Slo-Niacin, atorvastatin|Atorvastatin 10 mg qd for 12 or 24 weeks. Time-released niacin 1500 mg qd (titrated from 500mg to 1000mg and then to 1500 mg at 4 week intervals) taken for 12 or 24 weeks.
45966747|NCT00224250|Procedure|One- versus two-layer hysterotomy closure|
45966748|NCT00473512|Drug|Abiraterone acetate|Abiraterone 250 mg (1 capsule) up to 2000 mg (8 capsules) once daily, each dose will be tested in sequential order for 28 days to determine the MTD.
45966749|NCT00473512|Drug|Abiraterone acetate MTD|Abiraterone acetate MTD orally for 12 cycles (28 day each).
45966750|NCT00473512|Drug|Dexamethasone|Dexamethasone 0.5 mg orally will be given (If participants have disease progression) daily up to 12 cycles.
45966751|NCT00125489|Drug|chloroquine sulfate|
45966752|NCT00125489|Drug|sulfadoxine/pyrimethamine|
45966753|NCT00206661|Drug|Sargramostim (Leukine)|4 mcg sargramostim with and without corticosteroids
45458320|NCT03300518|Drug|Follitropin Beta;MSD|Patients will start stimulation with a daily s.c. injection of follitropin beta( 300IU Puregonon;MSD) menstrual cycle day 2 or 3.
45458321|NCT03300518|Drug|Ganirelix|A daily administration of ganirelix (0.25 mg Orgalutran; MSD) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.
45966754|NCT00206661|Drug|Sargramostim (Leukine)|6 mcg sargramostim with and without corticosteroids
45966755|NCT00194441|Other|Bedside display of cerebral perfusion pressure information|Continually updating highly visible color coded bar graph bedside computer display of cerebral perfusion pressure
45966756|NCT00473434|Drug|Paliperidone|3mg or 6mg or 9mg or 12mg once daily for 52 weeks
45966757|NCT00224328|Device|ODISsey Tissue Oximeter|
45966758|NCT00125567|Drug|Stalevo (levodopa/carbidopa/entacapone)|Oral, 50-150 mg levodopa four times daily, for up to 2 years
45966759|NCT00125567|Drug|Levodopa/carbidopa|Oral capsules, 50-150 mg levodopa four times daily, for up to 2 years
45966760|NCT00473083|Drug|Minocycline|Patients will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
45966761|NCT00473083|Drug|Clindamycin 2% in hydrocortisone 1% lotion|"Appropriate amounts of clindamycin and hydrocortisone powder are mixed with corresponding amount of Nutraderm® lotion for this mixture.~If preferred, the appropriate amount of clindamycin powder can be mixed with Emo-Cort® lotion (already contains hydrocortisone 1%), available in 60 mL bottles."
45966762|NCT00473083|Drug|Erlotinib|Erlotinib will be given on an outpatient basis at a fixed dose of either 150 or 100 mg as a single daily oral dose.
45966763|NCT00473083|Drug|Topical clindamycin 2%, triamcinolone acetonide 0.1% soln|Clindamycin 2% in Triamcinolone acetonide 0.1% solution in equal parts propylene glycol and water
45966764|NCT00194480|Drug|Pegylated Interferon|Weekly injections of pegIntereferon
45966765|NCT00125606|Procedure|conditioning for allogeneic HSCT|
45966766|NCT00472420|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv every 3 weeks
45966767|NCT00472420|Drug|First line chemotherapy|As prescribed
45966768|NCT00194519|Drug|Generic acyclovir|400 mg twice-daily oral
45966769|NCT00194519|Drug|Placebo|twice-daily oral
45966770|NCT00206700|Drug|Sargramostim (Leukine)|Open Label, 8 week cycle
45966771|NCT00125645|Drug|Irbesartan Oral Tablet|
45966772|NCT00194558|Behavioral|Internet co-management module|
45966773|NCT00224367|Behavioral|time to first ambulation|
45966774|NCT00125684|Drug|morphine|
45966775|NCT00194597|Drug|Viagra (sildenafil citrate)|
45966776|NCT00206739|Drug|Sulfadoxine (12.5 mg)/Pyrimethamine (250 mg)|
45966777|NCT00125723|Other|PI Discretion|PI Discretion
45966778|NCT00224406|Drug|repertaxin|
45966779|NCT00194636|Procedure|nerve block|
45966780|NCT00206778|Drug|Lamotrigine|
45966781|NCT00206778|Drug|Sodium Valproate|
45966782|NCT00125801|Drug|Subcutaneous hydromorphone delivered by pain pen|Subcutaneous hydromorphone delivered by pain pen during breakthrough pain episodes, at max 4 daily. Dose established by opioid conversion from baseline opioids.
46080467|NCT04262063|Behavioral|tell show do|Tell: your dentist explaining to you what they'd like to do Show: showing you what is involved (e. g. showing the equipment and demonstrating it on a finger) Do: performing the procedure
46080468|NCT02805452|Drug|Succinate of Solifenacin|
46080469|NCT02805452|Drug|Placebo of Succinate of Solifenacin|
45966783|NCT00206817|Device|Triage CardioProfilER (Troponin I, Myoglobin, CK-MB, BNP)|
45966784|NCT00125840|Drug|clofarabine (IV formulation)|
45966785|NCT00224445|Drug|Truvada|Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet) administered orally once daily (QD)
45667761|NCT01767142|Device|The Zeltiq System with Modified Belt Applicator|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
45966786|NCT00224445|Drug|Atazanavir|Atazanavir 300 mg (given as two 150-mg capsules) administered orally QD
45966787|NCT00224445|Drug|Ritonavir|Ritonavir 100 mg capsule administered orally QD
45966788|NCT00194753|Drug|Paclitaxel|80 mg/m2 IV for 12 weeks following completion of doxorubicin and cyclophosphamide
45966789|NCT00194753|Drug|Doxorubicin|24 mg/m2 IV weekly x 12
45966790|NCT00194753|Drug|Cyclophosphamide|60 mg/m2 PO daily for 12 weeks
45966791|NCT00194753|Drug|G-CSF|5 mcg per kg subcutaneously days 2 - 7 during doxorubicin and cyclophosphamide for 12 weeks
45966792|NCT00206856|Device|Triage® B-Type Natriuretic Peptide (BNP) Test|
45824677|NCT02119416|Drug|High Caffeine Administration first (2mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg"
45966793|NCT00125879|Biological|Myozyme|20 mg/kg qow or 40 mg/kg qow
45966794|NCT00206895|Procedure|Photodynamic therapy|
45966795|NCT00125918|Drug|tadalafil|tadalafil 2.5 mg and placebo tablets taken by mouth once a day for 16 weeks.
45966796|NCT00125918|Drug|tadalafil|tadalafil 10 mg and placebo tablets taken by mouth once a day for 16 weeks.
45966797|NCT00125918|Drug|tadalafil|tadalafil 20 mg and placebo tablets taken by mouth once a day for 16 weeks.
45966798|NCT00125918|Drug|tadalafil|tadalafil 40 mg and placebo tablets taken by mouth once a day for 16 weeks.
45966799|NCT00125918|Drug|placebo|placebo tablet taken by mouth once a day for 16 weeks
45966800|NCT00224523|Drug|GW685698X|
45966801|NCT00224523|Drug|mometasone furoate|
45824678|NCT02140164|Drug|Minocycline|Oral dose of 100 mg (or appropriate weight-adjusted pediatric dose) of minocycline twice daily for 12 months.
45966802|NCT00472303|Drug|Tapentadol Extended Release|Tablet taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 100 mg, increasing at a minimum of 3 day intervals by 50 mg, with a maximum dose of 250 mg.
45966803|NCT00472303|Drug|Matching Placebo after Tapentadol in the Titration Phase.|Tablet taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. In the maintenance phase only to participants that were randomized to tapentadol in the titration phase.
45966804|NCT00472303|Drug|Morphine Sulphate Controlled Release|Capsule taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 40 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
45966805|NCT00224562|Drug|TNF-alpha antagonists|
45966806|NCT00125996|Drug|Venofer (intravenous iron sucrose)|
45966807|NCT00224601|Procedure|Colonoscopy with chromoscopy|
45667762|NCT01785628|Dietary Supplement|Sarcosine Capsule|Sarcosine is a glycine transporter-1 (GlyT-1) inhibitor. By blocking glycine uptake, sarcosine increases synaptic glycine concentration to enhance NMDA receptor function.
45667763|NCT01785628|Dietary Supplement|Placebo Capsule|Placebo is dextrin composition.
45966808|NCT00471718|Drug|ABT-751|"Phase I:~Cohort | Number of Patients |Dose (mg) ABT-751 (BID)~-1 | 3-6 |100 mg BID~1 | 3-6 |125 mg BID~2 | 3-6 |150 mg BID~3 | 3-6 |175 mg BID~4 | 3-6 |200 mg BID~Phase II:~Patients receive ABT-751 at 125mg po BID for 7 days on, 7 days off (X2) for a 28 day cycle"
45966809|NCT00194870|Procedure|EEG|computer-assisted analysis of the digitally-recorded EEG signals
45966810|NCT00206934|Drug|Escitalopram|Either 10 mg of escitalopram or placebo will be administered to a group of healthy volunteers
45966811|NCT00206934|Drug|escitaolpram|Either 15 mg of escitalopram or placebo will be administered to healthy volunteers
45966812|NCT00194909|Drug|sildenafil (Viagra)|
45667764|NCT01785472|Drug|LCZ696|LCZ696 200 mg tablet
45667765|NCT01785472|Drug|Olmesartan|Olmesartan 20 mg capsule
45667766|NCT01785472|Drug|Placebo of LCZ696|Placebo tablet of LCZ696 200 mg once daily
45667767|NCT01785472|Drug|Placebo of Olmesartan|Placebo capsule of olmesartan 20 mg once daily
45824679|NCT04745208|Behavioral|Simulation based education|high fidelity simulation with moulage
45824680|NCT02119260|Drug|GSK2798745 solution|Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol
45824681|NCT02119260|Drug|GSK2798745 suspension|Aqueous suspension of GSK2798745 (>=0.5 mg)
45824682|NCT02119260|Drug|GSK2798745 capsule|White Opaque granule filled capsules of GSK2798745 (>=0.5 mg)
45824683|NCT02119260|Drug|Placebo solution|Clear, colourless solution of aqueous citrate buffer with 4% captisol
45966813|NCT00224640|Drug|Iron chelating intervention|Iron chelating intervention
45966814|NCT00194948|Drug|escitalopram|
45966815|NCT00194948|Behavioral|interpersonal psychotherapy|
45966816|NCT00206973|Procedure|mannitol test|
45966817|NCT00126035|Device|Migraid|
45966818|NCT00471445|Drug|ketamine/amitriptyline NP-H cream|Subjects were instructed to apply up to, but not exceeding, 4 g of ketamine/amitriptyline NP-H cream two times per day to each area with pain, numbness, and/or tingling. A measuring device was provided to assist in dispensing the proper amount of the cream.
45966819|NCT00471445|Other|placebo|Applied topically
45966820|NCT00207051|Drug|Brivanib + Cetuximab|Tablets/IV, Oral/IV , Brivanib 800 mg + Erbitux 400 mg/m2 X 1, followed by 250mg/m2, Brivanib QD / Erbitux QW, up to 48 weeks
45966821|NCT00402467|Drug|Rivaroxaban (BAY59-7939)|2.5mg bid
45966822|NCT00402467|Drug|Rivaroxaban, (BAY59-7939)|5mg bid
45966823|NCT00402467|Drug|Rivaroxaban, (BAY59-7939)|10 mg bid
45966824|NCT00402467|Drug|Rivaroxaban, (BAY59-7939)|20mg bid
45966825|NCT00402467|Drug|Enoxaparine|30mg bid
45966826|NCT00402467|Drug|Enoxaparine|30mg bid
45966827|NCT00224679|Drug|Aspirin|
45966828|NCT00224718|Procedure|Endovascular repair (with endograft)|An endovascular stent graft is a tube composed of fabric supported by a metal mesh called a stent. It can be used for a variety of conditions involving the blood vessels, but most commonly to reinforce a weak spot in an artery called an aneurysm. Over time, blood pressure and other factors can cause this weak area to bulge like a balloon and eventually enlarge and rupture. The stent graft seals tightly with your artery above and below the aneurysm. The graft is stronger than the weakened artery and allows blood to pass through it without pushing on the bulge. Physicians typically use endovascular stent grafting to treat abdominal aortic aneurysms (AAAs).
45966829|NCT00224718|Procedure|Open repair|Conventional repair consist in open repair. Different types of surgery can be done : minimal incision aortic surgery (MIAS), transperitoneal approach (TPA), retroperitoneal repair, or conventional median laparotomy.
45966830|NCT00402506|Drug|(MC-1) Pyridoxal 5'-phosphate|
45966831|NCT00195026|Device|Infrared Breast Scan|Patients already scheduled for breast biopsies will receive an additional infrared scan
45966832|NCT00207129|Drug|Ixabepilone|Solution, I.V. infusion, 40 mg/m2, Cycles 1-18: once per cycle (Day 1) cycles 2-18 (6-54 weeks) depending on response.
45966833|NCT00207129|Drug|Capecitabine|Tablets, Oral, 1000 mg/m2, Cycle 1: Once (Day 1) Cycle 2: Twice daily (Days 1-5) Cycles 3-18: None, 2 cycles (6 weeks).
45966834|NCT00402545|Drug|Cetuximab|Given intravenously on days 1, 8 and 15 of each 21-day cycle for three cycles
45966835|NCT00402545|Drug|Docetaxel|Given intravenously on day 1 of each 21-day cycle for 3 cycles
45966836|NCT00402545|Drug|Cisplatin|Intravenously on day 1 of each 21-day cycle for 3 cycles
45966837|NCT00402545|Drug|5-Fluorouracil|Given by continuous infusion pump over a period of 96 hours(dosage wil vary depending upon when participant enrolls in trial)
45966838|NCT00224757|Procedure|Transoesophageal echocardiography|TEE
45966839|NCT00195065|Behavioral|Semi-structured, open-ended interviews|
45966840|NCT04722159|Device|Renal denervation|Catheter-based inhibition of renal sympathetic nerve traffic.
45966841|NCT00126074|Drug|Tedisamil sesquifumarate|
45966842|NCT00224835|Behavioral|Mindfulness Based Stress Reduction Class|Subjects randomized to this condition will attend 120 minute weekly sessions, plus a 7 hour retreat, for training in mindfulness meditation methods.
45667768|NCT01785160|Drug|Raltegravir|low dose oral administration
45667769|NCT01785160|Drug|Raltegravir|low dose oral administration
45667770|NCT01785160|Drug|Faldaprevir|medium dose oral administration
45667771|NCT01736176|Drug|Levodopa-Carbidopa Intestinal Gel|"Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube.~The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours."
45667772|NCT01736176|Procedure|Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)|
45667773|NCT01736176|Drug|Levodopa-carbidopa Immediate Release (LC-IR) Tablets|After LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use.
45966843|NCT00224835|Behavioral|Cardiac Education Class|"Subjects in the disease education control condition will attend 8 weekly 60 minute sessions, plus a 7 hour special experience session, all of which will provide information about CAD in a didactic format."
45966844|NCT00195104|Drug|Arsenic Trioxide (Tricenox)|
45966845|NCT00195104|Drug|Cytarabine|
45966846|NCT00207207|Procedure|Alternate site blood glucose testing|
45966847|NCT00224913|Procedure|Neuromuscular electrical stimulation|
45966848|NCT00224913|Procedure|Voluntary exercise|
45966849|NCT00195143|Genetic|Surgical infusion of AAV-GAD into the subthalamic nucleus|
45966850|NCT00207285|Behavioral|Sleep Hygiene Education|Baseline general meetings with officers in intervention districts, in which we will provide an introductory program on optimal caffeine use (caffeine re-education) and sleep hygiene, as these are cost-effective measures that may effectively address difficulties adjusting to night work, and low-grade sleep disorders such as mild shift work sleep disorder across the cohort as a whole.
46080470|NCT00936949|Procedure|surgical approach|Using a gluteus maximus split, the posterolateral approach remains posterior to the gluteus medius and minimus. Exposure of the hip and proximal femur requires division of the posterior hip capsule and the external rotators. The exposure and dislocation are completed with flexion and internal rotation of the femur. After arthroplasty, the external rotators and posterior capsule was routinely repaired using a heavy absorbable suture.
46080471|NCT00936949|Procedure|modified lateral approach|The operative technique described modified lateral approach as described by Mulliken et al.
46080472|NCT02733198|Other|Prognosis-guided therapy|
45667774|NCT01735630|Drug|ELND005|
45966851|NCT00207285|Procedure|Screening and Treatment of Sleep Disorders|All individuals who screen positive in the questionnaires on the baseline survey will be referred to one of the physicians at Sleep HealthCenters® or other sleep clinics in Massachusetts. Individuals will be paid $40 for attending an initial consultation visit with a sleep clinician and $400 if they are then asked to undergo an overnight sleep study and they complete the sleep study. Individuals will also be asked to wear an ApneaLink device for 2 nights at home and for 1 night during the overnight visit at Sleep HealthCenters®. Subjects may be asked to wear the ApneaLink device for more than 2 nights if there are not 4 hours of usable data each night. If the data is inadequate, subjects will be asked to wear the device until 4 hours of usable data on 2 nights is achieved. The ApneaLink device is an FDA approved sleep-screening tool that is used to identify individuals that are at risk for Obstructive Sleep Apnea Syndrome.
45966852|NCT00195182|Behavioral|Self affirmation and positive affect induction vs. control|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
45667775|NCT01735630|Drug|Placebo|
45667776|NCT04575922|Drug|Nivolumab|Administered into vein by intravenous infusion every 2 weeks over 6 week study cycle.
45966853|NCT00413088|Drug|bemiparin|
45824684|NCT02119260|Drug|Placebo suspension|Visually matching aqueous suspension of hypromellose acetate succinate powder
45966854|NCT00207324|Device|Silver Leaf Dressing|
45966855|NCT00409760|Drug|valsartan+amlodipine combination, valsartan, amlodipine|
45966856|NCT00413127|Drug|lidocaine|administration of lidocaine intravenously or epidural or administration of placebo
45966857|NCT00413127|Drug|NaCl 0,9%|Administration of placebo i.v.
45966858|NCT00126152|Behavioral|Exercise, education and medical management|
45966859|NCT00224991|Procedure|Intensive systematic information (osteoporosis school)|
45966860|NCT00126230|Drug|docetaxel and samarium|
45966861|NCT00207363|Drug|Ribavirin, Peg interferon alfa 2b|Peg interferon alfa 2b 1.5mcg/kg/wk for 48 weeks ribavirin 13+/-2 mg/kg daily for 48 weeks
45966862|NCT00207363|Drug|induction therapy|Peg Intron 3.0mcg/kg/wk for 12 weeks then Peg interon 1.5mcg/kg/week for 36 weeks
45966863|NCT00126269|Drug|cisplatin|
45966864|NCT00126269|Drug|gemcitabine|
45966865|NCT00207402|Drug|rosiglitazone|Infergen 15mcg/ d Avandia qd Ribavirin bid
45966866|NCT00195299|Drug|Temsirolimus|
46080473|NCT04261985|Behavioral|healthy weight behaviors supported by web-based mobile phone application|Chorus is a mobile phone platform that provides texting, a web application, and an online community for mHealth interventions.Content is created using existing templates to insert text, images, pictures, audio, video clips, or any combination of these. Users interface with Chorus by clicking a hyperlink embedded in a text message sent to their phone to then access web-based interactions via prompts and clicks. Content is available in English and Spanish.
46080474|NCT02805374|Drug|ASP1517|Oral
45667777|NCT04575922|Drug|Ipilimumab|Administered into vein by intravenous infusion day 1 of each 6 week study cycle.
45667778|NCT04575922|Radiation|Radiation Therapy|3 radiation treatments, every other weekday or 2 days during week 1 of cycle 1 only of study.
45667779|NCT01735396|Drug|Abiraterone Acetate|Abiraterone acetate 1000 mg orally daily (supplied as four 250 mg tablets) and prednisone 5 mg orally twice daily
45966867|NCT00471328|Drug|Nilotinib|Nilotinib 400 mg twice daily (bid)
45966868|NCT00471328|Other|Best Supportive Care (BSC) +/- imatinib or sunitinib|Can include pain medication, localized radiotherapy, nutritional support, and/or oxygen therapy and blood transfusions. Imatinib or sunitinib can be administered at the last tolerated dose and regimen or at the Investigator's choice.
45966869|NCT00225030|Drug|antihypertensive drugs according to current guidelines|
45966870|NCT00126308|Device|poly-L-lactic acid|immediate injections poly-L-lactic acid (4 bilateral treatments - 8 vials)
45966871|NCT00126308|Device|poly-L-lactic acid|delayed (24 weeks) poly-L-lactic acid injections (4 bilateral treatment - 8 vials)
45966872|NCT00225069|Procedure|Level of sympathectomy|T2 sympathectomy or T2-T3 sympathectomy
45667780|NCT01766206|Biological|MenACWY-CRM (Menveo)|One dose administered intramuscularly preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle in children, adolescents and adults.
45824685|NCT02119260|Drug|Placebo capsule|Matching white opaque placebo blend filled capsule
45824686|NCT02119104|Drug|Prevenar (13v)|Prevenar (13v)
45966873|NCT00195377|Drug|Etanercept|
45966874|NCT00225108|Drug|Tinzaparin|
45966875|NCT00195416|Drug|Etanercept|Etanercept 25mg Injection, 2 times/week
45966876|NCT00207441|Behavioral|Arthritis Self management program|
45966877|NCT00207441|Behavioral|Chronic Disease Self Management Program|
45966878|NCT00225186|Drug|Visanne (SH T00660AA , BAY86-5258)|Daily long-term drug treatment (12 months), and post-treatment observation (6 months) in a subgroup of patients
45966879|NCT00195455|Drug|Trimegestone|
45966880|NCT00195455|Drug|17b Estradiol|
46080475|NCT00937027|Drug|Aminopterin|oral tablets, 1.0 mg dose, once weekly, two weeks
45667781|NCT01734850|Drug|Busulfan|Intravenous busulfan
45667782|NCT01734850|Biological|Cal-1 modified HSPC|Hematopoietic progenitor/stem cells (HSPC) modified with LVsh5/C46 (Cal-1)
45667783|NCT01734850|Biological|Cal-1 modified CD4+ T lymphocytes|CD4+ T lymphocytes modified with LVsh5/C46 (Cal-1)
45824687|NCT02119026|Drug|Capecitabine|"800mg/m2 bid d1-14~± 1000 mg/m2 bid,days 1-14 q3w: maintenance"
45824688|NCT02119026|Drug|Capecitabine|1000mg/m2 bid d1-14,
45824689|NCT02119026|Drug|Bevacizumab|7,5 mg/kg given on d1 q3w
45824690|NCT02119026|Drug|Oxaliplatin|130mg/m2 iv. d 1 q3w
45824691|NCT02119026|Drug|Irinotecan|200mg/m2 iv. d 1 q3w .
45966881|NCT00207480|Behavioral|Brief, motivational interviewing intervention|
45667784|NCT01766050|Drug|Caffeine|
45966882|NCT00126347|Procedure|supplementation with betaine, serine, and folic acid|
45966883|NCT00225225|Drug|Rosiglitazone|
45966884|NCT00225225|Behavioral|dietary recommendation for weight maintenance|
45667785|NCT01766050|Drug|Losartan|
45667786|NCT01766050|Drug|Omeprazole|
46080476|NCT02738502|Drug|darunavir monotherapy|darunavir 600 mg + ritonavir 100 mg 2 times 24 (DRV/r) monotherapy started after checking the tolerance of DRV/r600 mg/100 mg twice daily to replace whatever prior ARVs were used, while maintaining the NRTI backbone for 2 weeks.
46080477|NCT04261907|Drug|ASC09/ritonavir group|ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment
46080478|NCT04261907|Drug|lopinavir/ritonavir group|Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment
46080479|NCT02809352|Biological|Human papillomavirus genotyping|
45824692|NCT04744350|Procedure|Treatment of FFP type IIb and IIc|Patients will either be randomized in the surgical or conservative group.
45824693|NCT02095158|Drug|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% applied to the face once daily for 52 weeks.
45824694|NCT02094612|Device|Quotient®|Patients will be randomized once at the time of ADHD assessment to either usual clinic ADHD care or usual clinic ADHD care plus the Quotient using computer-generated random numbers.
45824695|NCT02094612|Behavioral|Usual Clinic ADHD Care|Usual ADHD care as provided by the clinic
45824696|NCT02139306|Drug|Ataluren (PTC124®)|Oral Ataluren TID
45824697|NCT02139306|Drug|Placebo|Oral Placebo TID
45966885|NCT00126386|Drug|Zoledronic acid (Zometa)|
45966886|NCT00225264|Drug|Pioglitazone|Pioglitazone 15 mg titrated up to 45 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily for up to 72 weeks.
45966887|NCT00225264|Drug|Glimepiride|Pioglitazone placebo-matching tablets, orally, once daily and glimepiride 1 mg titrated up to 4 mg, capsules, orally, once daily for up to 72 weeks.
46080480|NCT00934219|Drug|Omega-3-Acid Ethyl Esters|LOVAZA, 1 g caps; High Dose Arm for 4 months, while on a standard therapy for hypertriglyceridemia (fibrates, +/-metformin). Standard Dose Arm for 3 months, while on a standard, unchanged therapy for hypertriglyceridemia (fibrates +/- metformin).
46080481|NCT05007977|Drug|ZT-01 low dose|Single subcutaneous (SC) injection of ZT-01 3 mg during hypoglycemic clamp
46080482|NCT05007977|Drug|ZT-01 high dose|Single SC injection of ZT-01 20 mg during hypoglycemic clamp
46080483|NCT05007977|Drug|Placebo|Single SC injection of placebo during hypoglycemic clamp
45667787|NCT01766050|Drug|Dextromethorphan|
45667788|NCT01766050|Drug|Midazolam|
45667789|NCT01766050|Biological|Belatacept|
45966888|NCT00126464|Drug|fulvestrant|
45966889|NCT00126464|Drug|tamoxifen citrate|
45966890|NCT00126464|Procedure|conventional surgery|
45667790|NCT02341625|Drug|BMS-986148|
45667791|NCT02341625|Biological|Nivolumab|
45667792|NCT02370095|Drug|Treprostinil Inhalation Solution|Treprostinil inhalation solution administered as blinded marketed product
45667793|NCT02370095|Drug|Placebo|Supplied by the manufacturer and similar to the active drug but containing no Treprostinil
45667794|NCT05370053|Diagnostic Test|ELF Test|Patients receive ELF testing (a blood draw) and their hepatologist receives the result within a week.
45667795|NCT04894877|Procedure|cardiac catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
45667796|NCT04894877|Procedure|coronary artery bypass graft surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said, cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
45824698|NCT02094300|Device|Zenith® Dissection Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
45824699|NCT02118792|Drug|AN2728 Topical Ointment, 2%|
45824700|NCT02118792|Drug|Matching vehicle control|
45824701|NCT02118714|Drug|Atrasentan|Atrasentan
45824702|NCT04743492|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy delivered by clinical psychologists in order to help patients gain coping skills.
45824703|NCT02138916|Drug|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
45824704|NCT02138916|Drug|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
45824705|NCT02138916|Drug|Placebo|Placebo subcutaneously on study week 0 until study week 48 inclusive
45824706|NCT02118012|Drug|Chlorcyclizine HCl|Chlorcyclizine HCl (75 mg twice daily)
45824707|NCT02118012|Drug|Ribavirin|RBV was dosed via a weight-based regimen of 1000 mg daily<75 kg and 1200 mg daily ≥75 kg.
45966891|NCT00126464|Procedure|neoadjuvant therapy|
45966892|NCT00207519|Behavioral|weekly behavioral modification group|
45966893|NCT00207519|Behavioral|liquid meal replacements|
45966894|NCT00195533|Drug|piperacillin-tazobactam|
45966895|NCT00195533|Drug|glycopeptide|
45966896|NCT00207558|Drug|folic acid|
45966897|NCT00195572|Drug|Isovorin|
45966898|NCT00195572|Drug|TS-1|
45667797|NCT04894877|Procedure|percutaneous coronary intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
45966899|NCT00202280|Drug|Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg|
45667798|NCT04894877|Behavioral|Lifestyle|diet, physical activity, smoking cessation
45667799|NCT04894877|Drug|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
45966900|NCT00225303|Drug|TMC125|
45966901|NCT00225342|Drug|Rosiglitazone|
45966902|NCT00225342|Drug|Gliclazide (Comparison drug)|
45966903|NCT00195611|Drug|Prevenar|
45966904|NCT00470470|Drug|imatinib mesylate|Given orally
45966905|NCT00470470|Other|laboratory biomarker analysis|Correlative studies
45667800|NCT01783678|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
45667801|NCT01783678|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
45667802|NCT01734772|Drug|dabigatran etexilate|multiple doses of dabigatran
45667803|NCT01734772|Drug|dabigatran etexilate|medium dose dabigatran
45667804|NCT01734772|Drug|ticagrelor|loading dose of ticagrelor
45667805|NCT01734772|Drug|ticagrelor|multiple doses of ticagrelor
45824708|NCT02093520|Procedure|MILD Procedure|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
45824709|NCT02093520|Drug|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
45966906|NCT00207636|Behavioral|Computer-based prostate cancer screening decision aid|
45966907|NCT00195689|Biological|Human anti-TNF monoclonal antibody/adalimumab|
45966908|NCT00470275|Drug|cytarabine|Given IV
45966909|NCT00225381|Device|connection of measuring device to anesthesia circuit|same as name
45966910|NCT00225381|Procedure|drawing of blood sample through an arterial line, placed according to clinical criteria by primary anesthesia team|same
45966911|NCT00225381|Procedure|changing operating room bed position (head down and up position)|same
45966912|NCT00225381|Procedure|adding PEEP during anesthesia|same
45667806|NCT01734772|Drug|ticagrelor|loading dose of ticagrelor
45824710|NCT02138838|Drug|Cinacalcet HCl|Capsules were opened and either sprinkled onto soft food (≥ 5 mg dose) or suspended into a sucrose syrup (≥ 2.5 mg dose) to create a liquid suspension for administration. Tablets were used for doses of 30 mg and higher in participants who could swallow tablets.
45824711|NCT02138838|Dietary Supplement|Standard of Care|Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
45824712|NCT02138214|Procedure|Thyroidectomy|Undergo total thyroidectomy
45824713|NCT02138214|Procedure|entral lymph node dissection (CLND)|Undergo total thyroidectomy with ipsilateral prophylactic CND
45824714|NCT02138214|Other|Quality-of-life assessment|Voice evaluation, interviews, ancillary studies
45966913|NCT00225381|Procedure|placement of esophageal Doppler for cardiac output measurements|same
45966914|NCT00225381|Device|Humidity sensor|Small conventional anesthesia T piece including tiny 2 thermometer inside
45966915|NCT00225381|Device|A mixing chamber (bymixer)|2 mixing chambers (bymixers) composed of 2 arms where one arm serves as a mixing (passive) arm for the measurement of mixed gas fraction. The bymixer is made of conventional anesthesia supplies and does not influence dead space nor circuit resistance.
45966916|NCT00225381|Device|Pneumotachometer cuvette|The pneumotachometer cuvette is used by many anesthesia monitors to measure gas flow.
45966917|NCT00225381|Device|Mass spectrometer sampling port|Designed for the anesthesia tubing and connected at the airway opening. it has small volume (3 mL) and do not influence circuit resistance.
45966918|NCT00195728|Drug|Hydrocodone/Acetaminophen on Extended Release|2 tablets twice daily
45966919|NCT00470158|Dietary Supplement|iron and zinc combined|Children >= 12 months received an average of 5mg zinc/day, 6.25 Iron/day, and 25IU folic acid/day. children<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
45458322|NCT03300518|Drug|hCG|Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger
45667807|NCT01734772|Drug|dabigatran etexilate|single dose of dabigatran
45667808|NCT02340221|Drug|Taselisib|Taselisib 4 mg was administered as two tablets of 2 mg each as per the schedule specified in the respective arm.
45667809|NCT02340221|Drug|Placebo|Placebo matching to taselisib was administered as per the schedule specified in the respective arm.
45667810|NCT02340221|Drug|Fulvestrant|Fulvestrant 500 mg was administered as two IM injections of 250 mg each as per the schedule specified in the respective arms.
45455632|NCT03664258|Diagnostic Test|Xpert Bladder Cancer Monitor|The Xpert Bladder Cancer Monitor Assay is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer. It should be used in conjunction with other clinical measures to assess disease recurrence. The test provides a fast and accurate result, is non-invasive and easy to perform.The test utilizes a voided urine specimen and measures the level of five target mRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR).
45455633|NCT02290756|Behavioral|Parenting Program|The parenting program is an early childhood stimulation program aimed at newborns from their neonatal period till infancy. The implementation of the parenting program will be conducted through the link workers and parents of the newborns.
45455634|NCT02290756|Behavioral|Low cost evidence based toolkit|"The aim of providing the toolkit is to ensure that all pregnant women in the project are provided the requisite care needed from the antenatal period till delivery to limit complications and insults (both mother and especially the neonate) that can occur during pregnancy, delivery and post partum in both the mother and child. The contents of the toolkit will include:~Clean delivery kit, aspiration bulb, bag and mask, Chlorhexidine, Misoprostol, Nutritional supplements (Iron and folic acid, awareness about breastfeeding) and IEC materials~Trainings for Birth Attendants and Link workers on aspiration and hypothermia management techniques, use of bag and mask APGAR (also to parents), cord care, basic pregnancy and newborn care information"
45455635|NCT05790109|Device|RF track cautery during percutaneous organ biopsy|After biopsy samples are obtained, the physician operator will place a radiofrequency bipolar cautery electrode through the biopsy introducer needle into the biopsy track and cauterize the track using a standardized protocol.
45455636|NCT05790096|Biological|Granulokine|Granulokine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.
45455637|NCT05790096|Biological|Filgrastine|Filgrastine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.
45455638|NCT05790083|Other|Body Lotion and Intensive Care|Body Lotion, applied twice daily on whole body, for 3 months. Intensive Care, applied as needed on affected body areas.
45455639|NCT05790070|Dietary Supplement|Betaine|3g/ twice daily (separated by ~12 hours) betaine anhydrous
45455640|NCT05790070|Other|Placebo|3g/ twice daily (separated by ~12 hours) cellulose placebo
45824715|NCT02092662|Other|stroke|task-oriented therapy: physical and occupational therapy emphasizing integration of the patients needs, environment and context
45824716|NCT02092662|Other|Healthy controls|no treatment
45824717|NCT02092350|Drug|Grazoprevir|Grazoprevir 100 mg tablet
45455641|NCT05790044|Drug|Bupivacaine|intra-oral infra-orbital nerve block with bupivacaine alone
45966920|NCT00470158|Dietary Supplement|iron and zinc on separate days|Children >= 12 months received an average of 5mg zinc/day, alternating daily with 6.25 Iron/day, and 25IU folic acid/day. Children<12 received half that dose. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
45966921|NCT00470158|Dietary Supplement|iron|Children >= 12 months received an average 6.25 Iron/day, and 25IU folic acid/day. Children<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
45455642|NCT05790044|Drug|Clonidine|intra-oral infra-orbital nerve block with bupivacaine and clonidine
45455643|NCT05790018|Device|PREGNANT PILLOW|First of all, questionnaire forms and scales will be applied to the pregnant women included in the experimental group in the pre-test (at 29-30 weeks). Then the pregnant pillow will be given and necessary explanations will be given about its use. Second follow-up 33-34. It will be done at the gestational week and the scales will be repeated. The final test is 37-38. It will be done at the gestational week (before birth) and the research will be completed.
45667811|NCT02339909|Behavioral|Fixed financial incentive|"Participants receiving the fixed financial incentive intervention will be sent a screening appointment letter offering them a fixed amount of £10 if they attend their screening appointment."
45667812|NCT02339909|Behavioral|Probabilistic financial incentive|"Participants receiving the probabilistic financial incentive intervention will be sent a screening appointment letter offering them an entry into a lottery with at least a 1 in 100 chance of winning £1000 if they attend their screening appointment."
45667813|NCT02339909|Behavioral|Control|"Participants receiving the active comparator, (i.e. control) intervention, will be sent the standard diabetic retinopathy screening appointment letter."
45667814|NCT02395133|Drug|Dupilumab|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered.
45824718|NCT02092350|Drug|Elbasvir|Elbasvir 50 mg tablet
45824719|NCT02092350|Drug|Placebo to Grazoprevir|Placebo tablet matched to grazoprevir
45824720|NCT02092350|Drug|Placebo to Elbasvir|Placebo tablet matched to elbasvir
45824721|NCT02117544|Device|Lotrafilcon B multifocal contact lenses (new)|
45824722|NCT02117544|Device|Lotrafilcon B multifocal contact lenses|
45824723|NCT02138136|Drug|Lubiprostone|12 or 24 mcg soft capsules for oral administration
45824724|NCT04726020|Other|Intensive monitoring|periodic and planned monitoring nurse intervention with phone call
45824725|NCT04726020|Other|Standard monitoring|standard monitoring of adverse event reaction
45824726|NCT01626690|Device|Bair-Paws Warming Device|Bair-Paws device to be applied to patient and used for perioperative (including preoperative) warming.
45824727|NCT01626690|Device|Bair-Hugger Warming Device|Bair-Hugger device to be applied to patient and used for intraoperative warming (current standard of care at our institution).
45824728|NCT01626456|Drug|ALKS 9072, Low|IM injection, given monthly
45966922|NCT00470158|Dietary Supplement|Zinc|Children >= 12 months received an average of 5mg zinc/day. Children<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
45966923|NCT00470158|Dietary Supplement|placebo|Children received daily placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
45966924|NCT00475540|Device|synthetic monofilament polypropylene mesh|Vaginal prolapse repair with mesh
45966925|NCT00472186|Drug|Lansoprazole|If weight is less than 30 kg, 15 mg of Lansoprazole twice daily will be administered. If weight is greater than or equal to 30 kg, 30 mg of Lansoprazole twice daily will be administered.
45966926|NCT00472186|Drug|Placebo|Placebo will also be administered based on weight.
45667815|NCT02395133|Drug|Placebo|Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW).
45667816|NCT02395055|Drug|Adalimumab (BCD-057)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
45667817|NCT02395055|Drug|Adalimumab (Humira)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
45966927|NCT00195767|Drug|divalproex sodium|
45966928|NCT00225537|Drug|4-Methylumbelliferone (Heparvit®)|
45966929|NCT00202319|Procedure|Sedation management protocol|
45966930|NCT00207675|Drug|infliximab|
45966931|NCT00202358|Drug|atenolol|
45455644|NCT05789966|Genetic|Genetic Risk Estimate+Health Coaching|The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk). Health coaching will be incorporated through phone or Zoom calls to provide an explanation of each participant's own genetic risk of CHD as well as lifestyle modification measures.
45455645|NCT05789966|Device|Genetic Risk Estimate + Fitbit Functions+Health Coaching|"Intervention: Device: Genetic Risk Estimate + Fitbit Functions The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' or 'no increased genetic risk'.~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate. Health coaching will be incorporated as well"
45455646|NCT05789914|Procedure|Flap surgery+bone graft+guided tissue regeneration|after flap elevation and debridement, intrabony defect was filled with Bio-Oss and covered with membrane.
45667818|NCT02369159|Drug|Peramivir|
45667819|NCT02369159|Drug|Oseltamivir|
45667820|NCT02368691|Drug|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg
45667821|NCT02394665|Radiation|Intensity Modulated Radiation Therapy|IMRT treatment will consist of 60 Gy in 30 fractions to PTV 60
45667822|NCT02394665|Drug|Temozolomide|"Concurrently during radiation therapy. Adjuvant therapy administered daily on days 1 - 5 for 12 cycles. One cycle = 28 days:~Concurrent during Radiation Therapy: 75 mg/m^2 orally for 6 weeks;~Post-radiation, adjuvant therapy: 150 mg/m^2 - 200 mg/m^2 orally daily on days 1 - 5 of each cycle."
45824729|NCT01626456|Drug|ALKS 9072, High|IM injection, given monthly
45824730|NCT04742166|Procedure|Reconstruction|Lateral gastrojejunal Terminolateral gastrojejunal
45824731|NCT02116608|Drug|Betadine|Apply locally as needed.
45824732|NCT02116608|Drug|Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
45824733|NCT02116608|Drug|Hydrocortisone Butyrate Cream, 1.0%|Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
45667823|NCT02394665|Behavioral|Functional Assessment of Cancer Therapy-Brain (FACT-Br)|FACT-Br Quality of Life (QOL) questionnaire to be completed by study patients as protocol specific timepoints
45966932|NCT00202358|Drug|placebo|
45966933|NCT00479713|Drug|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20mg. The treatment duration will be 6 weeks.
45966934|NCT00479713|Drug|Comparator : rosuvastatin calcium|rosuvastatin 10mg. The treatment duration will be 6 weeks.
45966935|NCT00479713|Drug|Comparator: Placebo (unspecified)|rosuvastatin 10mg Placebo. The treatment duration will be 6 weeks.
45966936|NCT00479713|Drug|Comparator: Placebo (unspecified)|ezetimibe/simvastatin 10/20mg Placebo. The treatment duration will be 6 weeks.
45966937|NCT00207753|Drug|albendazole vs. combined albendazole/ivermectin treatment|
45966938|NCT00202397|Drug|Riluzole|capsule-shaped 50 mg tablets bid for 8 weeks
45966939|NCT00202397|Other|placebo|capsule-shaped tablet bid for 8 weeks
45667824|NCT02394665|Radiation|Stereotactic Radiosurgery Boost|"Patients will undergo SRS boost in a single fraction dose prior to IMRT treatment:~HTV Maximum dimension vs. Prescribed Dose to HTV: ≤ 20 mm = 21 Gy; 21 mm - 30 mm = 18 Gy; 31 mm - 40 mm = 15 Gy."
45966940|NCT00479635|Drug|TPI 287|160 mg/m2 every three weeks for six cycles
45966941|NCT00479635|Drug|TPI 287|160 mg/m2 intravenously over 60 minutes every three weeks until toxicity or progression of disease.
45966942|NCT00478972|Drug|Rimonabant|Tablet, oral administration
45667825|NCT02394665|Radiation|Simultaneous Integrated Boost|Treatment shall consist of 60 Gy in 30 fractions to planning target volume (PTV) 60 and 75 Gy in 30 fractions to PTV 75.
45667826|NCT02394665|Device|3D MRSI|Three Dimensional Magnetic Resonance Spectroscopy Imaging (MRSI) during pre-treatment, week 3 during radiation therapy, end of radiation therapy; will include standard gadolinium enhanced MRI prior to cycle 1, 5, 9, and post cycle 12 of adjuvant temozolomide therapy, per protocol.
45966943|NCT00478972|Drug|placebo (for Rimonabant)|Tablet, oral administration
45966944|NCT00478972|Other|Diet and exercise|Target daily caloric intake: Ideal body weight × 25 kcal
45966945|NCT00207792|Drug|filgrastim|
45824734|NCT04742088|Device|ankleSOFT100|During the first two weeks of follow-up, the subject shall not use the device during the sports sessions. The subject shall use the device during the sports sessions for the next 4 weeks (6 weeks of follow-up)
45824735|NCT02092116|Drug|Romidepsin|Latency reversing agent
45824736|NCT02092116|Biological|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
45824737|NCT02092116|Biological|rhuGM-CSF|Granulocyte macrophage colony stimulating factor as a local adjuvant
45824738|NCT02091726|Procedure|Unicirc instrument plus cyanoacrylate tissue adhesive|Volunteers will be circumcised using the Unicirc surgical instrument and the incision will be sealed using cyanoacrylate tissue adhesive
45966946|NCT00195806|Drug|divalproex sodium|
45455647|NCT05789901|Other|MARVIN|Chatbot on Meta (Facebook) Messenger for HIV Patients
45966947|NCT00477529|Drug|ABI-008|nab-docetaxel
45966948|NCT00472693|Drug|Bevacizumab, Abraxane|Bevacizumab, 10 mg/m2 IV days 1 and 15; ABI-007, 100 mg/m2 IV days 1, 8, 15 of each 28 day cycle. Continue treatment until disease progression, patient withdrawal or unacceptable toxicities.
45966949|NCT00195845|Drug|Galantamine|
45966950|NCT00195845|Drug|Placebos|
45455648|NCT05789901|Other|MARVIN-Pharma|Chatbot on Meta (Facebook) Messenger for community pharmacists
45455649|NCT05789901|Other|MARVINA|Chatbot on Meta (Facebook) Messenger for breast cancer patients
45455650|NCT05789888|Genetic|MT-ATP6 mtDNA gene variability in obesity and normal body weight patients.|As part of the research, the MT-ATP6 gene was tested in order to influence the modulation of the amount of fat contained.
45966951|NCT00202436|Procedure|Phlebotomy|Removal of 500 ml whole blood
45455651|NCT05789888|Genetic|SCD gene variability in obesity and normal body weight patients.|As part of the research, the SCD gene was tested in order to influence the modulation of the amount of fat contained.
45966952|NCT00202436|Procedure|Erythrocytapheresis|machinal removal of erythrocytes
46080484|NCT04139876|Procedure|Open Haemorrhoidectomy|Patient operated in the lithotomy position. The external components are grasped by clamps using gentle traction. Diathermy is used for dissection and hemostasis. The skin is incised midway to one-third of the distance from the top of the pedicle, thus, minimizing the skin excision. The subdermal fascia continuing into a submucosal fascia covering the internal anal sphincter is identified as are fibers passing between the hemorrhoid (H) and this fascia. The H is dissected free from the underlying internal sphincter in this plane, leaving the sphincter unharmed. The anal mucosa is incised at the transition from anal mucosa to hemorrhoidal mucosa and only anal mucosa overlying the H is excised. Only the caudal part of the H is excised. With the H held with gentle traction it is divided at the anal orifice. There will thus be a residual part of the H intra-anally with its caudal end 1-2 cm proximal to the anal orifice.
45455652|NCT05789888|Other|Finding TOFI and FOTI phenotypes in participants with obesity and normal weight.|As part of the research, we measured the amount of VAT and SAT and calculate VAT/SAT ratio as a marker to determine the phenotype of fat tissue.
45458323|NCT03300518|Drug|estradiol valerate|Estradiol valerate (progynova,Schering) daily dose of 4 mg (2 mg twice a day) was given orally, started 7 days before the presumed onset of menses and administered up to 2 days of the next menstrual cycle
45667827|NCT02367911|Drug|122-0551 Foam|122-0551 Foam applied twice daily to treat psoriasis
45824739|NCT02091414|Drug|mycophenolate mofetil (MMF)|1.0 g PO BID
45824740|NCT02091414|Drug|cyclosporine A (CsA)|Initial loading dose of 4 to 6 mg/kg within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 ng/mL
45966953|NCT00195884|Behavioral|Aerobic and Resistance Exercise|"Aerobic activities are performed on a cycle ergometer or treadmill. Exercise intensity is standardized using Polar Heart rate monitors that display the subject's heart rate.~Resistance training:Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.~Group A: abdominal crunches, seated row, seated biceps curls, supine bench press, leg press, shoulder press; leg extension Group B: abdominal crunches, lat pulldown, sitting chest press, leg press, upright row, triceps pushdown, leg curls.~Combined aerobic and resistance training group will perform both aerobic and resistance training programs, as described above.~Control: members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program."
45966954|NCT00202475|Procedure|eythrocytapheresis|machinal collection of erythrocytes
45966955|NCT00202475|Procedure|whole blood collection|collection of whole blood
45824741|NCT02091414|Drug|corticosteroids|As per the practice of each participating center
45966956|NCT00225576|Other|Electronic Health Record Implementation|Intervention subjects implemented electronic prescribing as part of an electronic health record implementation
45966957|NCT00202514|Drug|divalproex sodium extended release|
45966958|NCT00207831|Drug|Tegafur and Uracil|
45966959|NCT00195923|Drug|Ampicillin, gentamicin, clindamycin, flagyl, ceftazidime|
45458324|NCT02317198|Drug|Clopidogrel|
45966960|NCT00225615|Drug|sapropterin dihydrochloride|
45966961|NCT00225654|Device|coronary stent|
45966962|NCT00202553|Drug|Perindopril|
45966963|NCT00202592|Drug|Perindopril|
45966964|NCT00196040|Device|PFX Closure System|
45966965|NCT00202631|Device|Surface Functional Electrical Stimulation|
45966966|NCT00196079|Device|Coronary stent|
45966967|NCT00225693|Device|drug eluting coronary stent|
45458325|NCT02317198|Drug|Ticagrelor or Prasugrel|
45667828|NCT02367911|Drug|Vehicle Foam|Vehicle Foam applied twice daily to treat psoriasis
45667829|NCT02339285|Device|tACS (alpha)|
45667830|NCT02339285|Device|tACS (gamma)|
45966968|NCT00196118|Device|Günther Tulip Vena Cava Filter|
45966969|NCT00225810|Drug|Crohn's Disease|
45966970|NCT00411333|Drug|triamcinolone acetonide (Kenalog)|
45966971|NCT00202709|Behavioral|Thought Field Therapy (TFT)|Treatment with TFT twice in one week
45966972|NCT00225849|Drug|Aspirin|
45966973|NCT00196157|Procedure|linear anatomically oriented ablations|linear lesions to ablate persistent atrial fibrillation
45667831|NCT02367833|Drug|Combined Oral Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of combined oral contraceptive (Apri or Reclipsen) on the GH/IGF-1 axis.
45667832|NCT02367833|Drug|Transdermal Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of a transdermal contraceptive (Xulane) on the GH/IGF-1 axis.
45966974|NCT00196157|Procedure|focal electrophysiological oriented ablations|focal electrophysiologically guided ablations to treat persistent atrial fibrillation
45966975|NCT00202748|Behavioral|Increase in activity to control weight|
45966976|NCT00202748|Behavioral|Increase in activity to control weight.|
45966977|NCT00202787|Drug|FOLFOX-4+cetuximab|"Cetuximab; Weekly administration of Cetuximab IV (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes);~FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2"
45824742|NCT04731558|Drug|enoxaparin or tinzaparin or dalteparin|Thromboprophylaxis initiated approximately 14 hours prior to the planned liver resection skin incision. Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function
45966978|NCT00202787|Drug|FOLFOX-4|FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2
45966979|NCT00225888|Behavioral|Digital Photography of meals/snacks and group discussion|Digital Photography of meals/snacks and group discussion
45966980|NCT00424437|Drug|Inhaled human insulin|
45966981|NCT00202865|Biological|infliximab|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6 and every 8 weeks thereafter. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
45824743|NCT04731558|Drug|No intervention|No preoperative thromboprophylaxis.
45824744|NCT02116530|Drug|Olanzapine|oral
45824745|NCT02116530|Drug|Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)|oral or IV
45824746|NCT02116530|Drug|Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)|oral or IV
45966982|NCT00202865|Biological|Placebo|Placebo infusions at Weeks 0, 2, and 6. Subjects will be evaluated at Week 12 after which they will receive infliximab 3 mg/kg at Weeks 16, 18, and 22 then every 8 weeks. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
45966983|NCT00225927|Procedure|radioguided seed localization for nonpalpable breast cancers|radio-labelled (I-125) titanium seed inserted via needle into nonpalpable breast lesion and gamma probe used to guide surgery
45966984|NCT00225966|Device|Device Medtronic InterStim Tined Leads Models 3889 and 3093|
45824747|NCT02116530|Other|Placebo|oral
45966985|NCT00202943|Procedure|TCRFVR and LAUP|
45966986|NCT00226005|Drug|PTK787/ZK222584|One arm: administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
45966987|NCT00196352|Drug|Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets|1 tablet daily
45966988|NCT00226044|Drug|Omeprazole rectally 1mg/kg|A single dose of 1 mg/kg rectally administered omeprazole.
45966989|NCT00202982|Drug|glatiramer acetate 20 mg|glatiramer acetate 20 mg
45966990|NCT00202982|Drug|glatiramer acetate 40 mg|glatiramer acetate 40 mg
45966991|NCT00207948|Drug|Dose adjustment of Kaletra|Adjust the dose by up to +50% of reccomended dosa off the drug to meet target therapeutic concentrations
45966992|NCT00196391|Drug|DR-2021a|1 capsule daily for 10 days
45966993|NCT00196391|Drug|DR-2021b|1 capsule daily for 10 days
45966994|NCT00196391|Drug|DR-2021c|1 capsule daily for 10 days
45966995|NCT00196391|Drug|DR-2021d|1 capsule daily for 10 days
45966996|NCT00196391|Drug|DR-2021e|1 capsule daily for 10 days
45966997|NCT00196391|Other|Placebo|1 matching placebo capsule for 10 days
45966998|NCT00203060|Drug|Rasagiline Mesylate|tablet, 1 or 2 mg, daily, 58 weeks
45966999|NCT00203060|Drug|placebo|tablet, once daily, 58 weeks
45967000|NCT00196430|Device|silver-contained textiles|
45967001|NCT00196430|Drug|corticosteroid|
45967002|NCT00226122|Drug|Indomethacin|Indomethacin capsules 50 mg
45967003|NCT00196469|Drug|heparin|
45967004|NCT00226161|Procedure|Inguinal herniorrhaphy|
45967005|NCT00208065|Drug|almotriptan or pseudoephedrine|
45967006|NCT00203099|Drug|Glatiramer Acetate, N-Acetylcysteine|Subcutaneous glatiramer acetate 20 mg and concomitant oral administration of N-Acetylcysteine divided into two 2.5 g doses.
45967007|NCT00196508|Device|High Viscosity DERMABOND|
45967008|NCT00226200|Drug|Omalizumab|
45455653|NCT05789875|Other|aDOT-CEI|For the design and development of the mobile health app, we have partnered with AiCure to use an existing HIPAA-compliant mobile health app. The app will record video of the participant taking their HIV medication in order to monitor the participant's medication adherence and track incentives for this behavior in real-time.
45824748|NCT02072226|Drug|Alteplase|Single dose of alteplase will be administered at 0.9 milligrams per kilogram (mg/kg) IV (maximal dose of 90 mg).
45824749|NCT02072226|Drug|Alteplase Placebo|Single dose of alteplase placebo will be administered as IV injection.
45824750|NCT02072226|Drug|Aspirin|Single dose of aspirin will be administered at 325 mg orally.
45824751|NCT02072226|Drug|Aspirin Placebo|Single dose of aspirin placebo will be administered orally.
45824752|NCT04730856|Drug|Tinzaparin|"day subcutaneously • Follow-up phase 1 (Day 15 to day 30): The information is obtained at discharge and on day +14, + 28 on 30 days. The latter information is obtained from patients, from medical records or by telephone contact at the patient's home.~• Follow-up phase 2 (At 3 months: Information is obtained from patients, medical records, or by telephone contact at the patient's home."
45967009|NCT00208104|Behavioral|Motivational Interviewing|Trained nurses will interview the group using motivational interview counseling techniques. All sessions will be conducted with the aid of an adapted version of a standardized structured adherence counseling script. This script was specifically developed for use in medication adherence studies of HIV positive patients and has been provided for this trial.
45967010|NCT00203138|Drug|rasagiline mesylate|
45967011|NCT00226278|Drug|ORG 34517|
45967012|NCT00196547|Drug|Montelukast (drug)|
45967013|NCT02962869|Drug|BAY987517|50 μl/ cm*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation number: Z43-078)
45967014|NCT02962869|Other|Untreated skin|One site is patched without treatment as control
45967015|NCT00203177|Drug|rasagiline mesylate|0.5 rasagiline mesylate
45967016|NCT00203177|Drug|rasagiline mesylate 1.0 mg|1.0 mg rasagiline mesylate
45967017|NCT00208143|Drug|Quetiapine|
45967018|NCT00208143|Drug|Risperidone|
45967019|NCT00196586|Drug|Interleukin 2|
45967020|NCT00196586|Drug|pegylated interferon alpha 2a|
45967021|NCT00196586|Drug|ribavirin|
45967022|NCT00226317|Drug|Aripiprazole|
45967023|NCT00226356|Drug|Supplements of L-methionine, betaine and folate|
45967024|NCT00208182|Drug|Risperidone|
45967025|NCT00203255|Drug|Soy Isoflavones|
45967026|NCT00226395|Drug|Oxymorphone immediate release|
45967027|NCT00203333|Device|Medtronic REVEAL|
45967028|NCT00208221|Drug|ramipril|
45967029|NCT00208221|Drug|ramipril-telmisartan|
45967030|NCT00196625|Drug|Amprenavir (drug)|
45967031|NCT00196625|Drug|ABT-378/r (drug)|
45967032|NCT00196625|Drug|Ritonavir (drug)|
45967033|NCT00226434|Procedure|Early antiretroviral treatment|The ARV treatment is started 2 weeks after the diagnosis and the start of the anti-tuberculosis treatment
45967034|NCT00226434|Procedure|Late antiretroviral treatment|The ARV treatment is started 8 weeks after the diagnosis and the start of the anti-tuberculosis treatment
45824753|NCT02090634|Behavioral|Psychoeducation|Participants will also receive daily text messages to evaluate mood, but these messages will not remind participants about medication adherence.
45824754|NCT02090634|Behavioral|individualized Texting for Adherence Building (iTAB)|Intervention is designed to send automated text messages to HIV+ persons who have bipolar disorder (BD+). Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART and psychotropic medications among HIV+/BD+ persons above and beyond an active comparator group.
45967035|NCT00410579|Other|Telephone interview|Telephone interview to assess generic health status, quality of life, comorbidity, impact of cancer, use of medical services, health rating, pain, fatigue, activities of daily living, demographics, functional well-being(C-06 only), and neurotoxicity (C-07 only)
45967036|NCT00208260|Drug|FOLFIRI|FOLFIRI : Irinotecan : 180 mg/m² 90 min continuous perfusion during levorin d1 every 2 weeks
45967037|NCT00208260|Drug|FOLFOX-4|FOLFOX 4 : Oxaliplatine : 85 mg/m² 2h continuous perfusion during levorin d1 every 2weeks
45824755|NCT02114892|Drug|Resveratrol|Resveratrol capsules of 500 mg three times per day before meals with a total dosis of 1500 mg per day.
45967038|NCT00208260|Drug|FOLFIRI-HD|High Dose FOLFIRI : Irinotecan : 260 mg/m² in 90min continuous perfusion during levorin d1 every 2 weeks
45824756|NCT02114892|Drug|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals with a total dose per day of 1500 mg
45967039|NCT00208260|Drug|FOLFOX-7|FOLFOX 7 : Oxaliplatine : 130 mg/m² in 2h continuous perfusion during levorin d1 every 2 weeks
45967040|NCT00208260|Drug|FOLFIRINOX|FOLFIRINOX : Oxaliplatine : 85 mg/m² 2h continuous perfusion followed by 1H rest followed by 90 min continuous perfusion of irinotecan : 180 mg/m² during levorin d1 every 2 weeks
45967041|NCT00226473|Drug|Cisplatin, Vindesine, Dacarbazine (drugs)|
45967042|NCT00208299|Drug|Regadenoson|0.4 mg, bolus intravenous injection
45967043|NCT00208299|Drug|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
45967044|NCT00196664|Drug|Paroxetine|
45967045|NCT00196703|Drug|memantine|
45967046|NCT00196703|Procedure|constraint-induced language therapy|
45824757|NCT02070978|Drug|Atacicept 75 mg|Participants who received atacicept 75 milligram (mg) as once-weekly subcutaneous injection in the core study ADDRESS II continued to receive this dose during this LTE study. Participants in this reporting arm received the medication up to a maximum of 143.7 weeks.
45824758|NCT02070978|Drug|Atacicept 150 mg|Participants who received placebo in the core study ADDRESS II switched to receive atacicept 150 mg as once-weekly subcutaneous injection for up to a maximum of 97.7 weeks during this LTE study.
45824759|NCT02070978|Drug|Atacicept 150 mg|Participants who received atacicept 150 mg in core study ADDRESS II continued to receive atacicept 150 mg as once-weekly subcutaneous injection during this LTE study up to a maximum of 97.9 weeks.
45824760|NCT04725630|Behavioral|Healthy food incentive|$10.50/week/household member for 12 months to purchase healthy foods in participating supermarkets.
45824761|NCT04725630|Behavioral|Healthy food prescription|A one-time healthy food prescription pamphlet
45824762|NCT02114268|Drug|MEDI8897 Intravenous|Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
45824763|NCT02114268|Drug|Placebo|Participants received placebo on Day 1.
45824764|NCT02114268|Drug|MEDI8897 Intravenous|Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
45824765|NCT02114268|Drug|MEDI8897 Intravenous|Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
45824766|NCT02114268|Drug|MEDI8897 Intramuscular|Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
45967047|NCT00208338|Device|RESTORE SIS Patch|Surgical repair of torn rotator cuff with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement
45967048|NCT00208338|Procedure|Rotator cuff repair|Standard surgical repair of torn rotator cuff
45967049|NCT00410618|Procedure|cognitive assessment|
45967050|NCT00410618|Procedure|magnetic resonance imaging|
45967051|NCT00410618|Procedure|management of therapy complications|
45967052|NCT00413322|Drug|belinostat|300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1
45967053|NCT00413322|Drug|5-Fluorouracil (5-FU)|250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.
45967054|NCT00196781|Behavioral|CD-ROM-based prostate cancer treatment education|The goal was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
45967055|NCT00196781|Behavioral|CD-ROM-based prostate ca treatment education+decision tools|The goal of the present study was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
45967056|NCT00413361|Drug|versus hydroxychloroquine|versus hydroxychloroquine
45967057|NCT00410657|Biological|alemtuzumab|
45967058|NCT00410657|Drug|methylprednisolone|
45967059|NCT00410657|Drug|prednisone|
45967060|NCT00410657|Other|flow cytometry|
45967061|NCT00410657|Other|immunologic technique|
45967062|NCT00410657|Other|pharmacological study|
45967063|NCT00196820|Drug|Capecitabine|
45967064|NCT00208377|Device|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
45824767|NCT02114268|Drug|MEDI8897 Intramuscular|Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
45967065|NCT00410696|Drug|Filgrastim|5 mcg/kg/day sc from day +1 after transplantation to hemopoietic reconstitution
45967066|NCT00410696|Drug|Pegfilgrastim|6 mg/day sc at day +1
45967067|NCT00226512|Drug|Campath-1H /ATG|
45967068|NCT00409799|Drug|I-0401 (a new bone graft substitute)|1 time application
45967069|NCT00208416|Procedure|DePuy MI System|A minimally invasive surgical technique used in total hip replacement.
45967070|NCT00208416|Procedure|Conventional surgical technique|A conventional surgical technique used in total hip replacement
45967071|NCT00410735|Drug|Placebo|0 mg BID for 12 weeks
45967072|NCT00410735|Drug|Pranlukast hydrate|225 mg BID for 12 weeks
45667833|NCT02367833|Drug|Contraceptive Vaginal Ring|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of vaginal ring contraceptive (Nuva Ring) on the GH/IGF-1 axis.
45967073|NCT00208455|Device|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
45967074|NCT00203372|Drug|Bevacizumab 7.5 and TAC|Bevacizumab given intravenously at a dose of 7.5mg/kg every 3 weeks, followed by docetaxel, doxorubicin and cyclophosphamide (TAC).
45967075|NCT00203372|Drug|Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)|placebo 7.5 will be adminitered intravenously every 3 weeks followed by TAC
45967076|NCT00203372|Drug|Bevacizumab 15 and TAC|one dose of Bevacizumab (15 mg/kg) will be administered intravenously every 3 weeks followed by TAC.
45667834|NCT02367521|Combination Product|Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)|"LFR rTMS will be delivered at the Brain Stimulation Program at The Johns Hopkins Hospital with a Magstim Super Rapid 2 stimulator with a focal double 70-mm air cooled coil. LFR rTMS will be administered to the Experimental Group.~Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength."
45667835|NCT02367521|Device|Sham Comparator: Sham Treatment|Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
45667836|NCT02338193|Drug|DAPA/MET XR|final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks
45667837|NCT02338193|Drug|DAPA|10 mg dapagliflozin QD for 20-24 weeks
45667838|NCT02338193|Drug|MET XR|1000 mg Metformin XR BID for 20-24 weeks
45667839|NCT01783444|Drug|Capecitabine|Capecitabine, tablets for oral use, 1250 mg/m² twice daily for 2 weeks followed by one week rest (3-week-cycle) (locally supplied)
45667840|NCT01783444|Drug|Exemestane|Exemestane, tablets for oral use, 25 mg per day in (locally supplied)
45667841|NCT01783444|Drug|Everolimus|Everolimus, 5 mg tablets for oral use, 10 mg (2 x 5 mg) per day (centrally supplied)
45967077|NCT00203372|Drug|Placebo 15 and TAC|one dose of placebo 15 will be administered intravenously every 3 weeks followed by TAC.
45967078|NCT00226551|Drug|Isoproterenol|
45967079|NCT00196859|Drug|Ibandronate, Capecitabine|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
45967080|NCT00196859|Drug|Ibandronate|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
45967081|NCT00208533|Drug|Aripiprazole|Aripiprazole 5 mg to 30mg, individually titrated
45967082|NCT00226629|Procedure|Endovascular vs Open Repair|
45967083|NCT00203450|Drug|Zonegran|zonisamide
45667842|NCT02367131|Drug|Jardiance|Empagliflozin
45667843|NCT02394275|Biological|Fecal Microbiota Transplant|All eligible patients will receive fecal microbiota transplant
45667844|NCT01608724|Drug|Saxagliptin|oral, 5 mg once a day (Q.D.)
45667845|NCT02366195|Drug|Talimogene Laherparepvec|The initial dose of talimogene laherparepvec is up to 4.0 mL of 10^6 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 10^8 PFU/mL.
45667846|NCT04905251|Drug|Mifepristone-Misoprostol|Non interventional design.
45824768|NCT02089230|Drug|MEK 162|"Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.~Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I."
45824769|NCT02070744|Drug|VX-661|Tablet, oral use
45824770|NCT02070744|Drug|Ivacaftor|Film coated tablet, oral use
45824771|NCT02070744|Drug|Placebo matched to VX-661|Tablet, oral use
45967084|NCT00203450|Drug|Placebo|Placebo pill
45967085|NCT00226668|Drug|hCRF|hCRF 2mg/day; dexamethasone 4mg/day along with any open-label dexamethasone they may be taking
45967086|NCT00226668|Drug|placebo hCRF|placebo hCRF 2mg/day, dexamethasone 4mg/day and any open-label dexamethasone they may be taking
45667847|NCT02364947|Drug|Nalmefene hydrochloride|As-needed; tablets, orally
45824772|NCT02070744|Drug|Placebo matched to Ivacaftor|Film coated tablet, oral use
45824773|NCT02113956|Behavioral|Guy2Guy (G2G)|"G2G is a text messaging-based healthy sexuality and HIV prevention program specifically for 14-18 year old GBQ adolescent males. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 5 weeks long. A booster is delivered 6-weeks post-intervention end and reviews the topics covered in the intervention. G2G content is tailored based upon whether one is abstinent or sexually active."
45824774|NCT02070588|Device|MRI|MR Diagnostic Imaging will be performed on both TBI subjects and Non TBI subjects
45824775|NCT04741698|Drug|Propranolol|Propranolol 2mg IV
45967087|NCT00208572|Drug|Citalopram|
45967088|NCT00203489|Device|KERLIX A.M.D. Gauze|
45967089|NCT00226707|Drug|Pimecrolimus Cream 1%|
45667848|NCT02364947|Drug|Placebo|As-needed; tablets, orally
45824776|NCT02111850|Biological|Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)|Day 0: cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes
45967090|NCT00203528|Drug|divalproex sodium ER|
45967091|NCT00203528|Drug|risperidone|
45967092|NCT00208611|Dietary Supplement|Vitamin B12 Supplementation|1000 micrograms daily
45967093|NCT00413517|Procedure|Epi-Lasik|A vision correcting surgery
45967094|NCT00203567|Drug|carbamazepine ER|Active study drug, no comparator
45967095|NCT00226746|Drug|Paclitaxel and gemcitabine|"Radiation Therapy: 63.80 Gy (1.1 Gy twice a day X 58 fractions) Paclitaxel: 60 mg/m2 / week by 1- hour IV infusion on days 1, 8, 15, 22, 29, and 36.~Gemcitabine: 75 mg/m2 / week on days 1, 8, 15, 22, 29, and 36."
45967096|NCT00203606|Drug|pegylated interferon alfa-2a ( Roche) and ribavirin|pegylated interferon alfa-2a ( Roche) and ribavirin
45967097|NCT00203645|Behavioral|Self-help treatment|"Workbook Becoming a Winner,"
45967098|NCT02962791|Procedure|Cardiac resynchronization therapy implantation|Cardiac resynchronization therapy implantation will be done for patient with symptomatic heart failure
45967099|NCT02962791|Device|Stimulation of 3 ventricular sites|Cardiac resynchronization therapy with stimulation of 3 ventricular sites
45967100|NCT02962791|Device|Stimulation of 2 ventricular sites|Cardiac resynchronization therapy with stimulation of 2 ventricular sites
45667849|NCT02392481|Procedure|Biofluid sampling|
45667850|NCT02392403|Device|Nucleus CI532 cochlear implant|
45667851|NCT02392247|Device|Coagulation function|Coagulation function assessment tools TEG (standard of practice) vs SEER Quantra (novel coagulation function device)
45667852|NCT05370287|Other|oxygen inhalation|Subjects will breath 100% oxygen through a mask.
45667853|NCT05370287|Device|Adaptive optics imaging|Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
45667854|NCT02337725|Drug|TVP-1012|TVP-1012 1mg Tablets
45667855|NCT02337725|Drug|Placebo|Placebo tablets
45667856|NCT02337491|Drug|Pembrolizumab|
45667857|NCT02337491|Drug|Bevacizumab|
45667858|NCT01765582|Drug|5-fluorouracil|Participants in Arm A will receive 3200 milligrams per square meter (mg/m^2) by 48-hour continuous intravenous (IV) infusion every 2 weeks, during the 4-6 months' induction followed by maintenance therapy including bolus dose of 400 mg/m^2, followed by a 46-hour continuous infusion (2400 mg/m^2) every 2 weeks per investigator's discretion. Participants in Arm B and C will receive a bolus dose of 400 mg/m^2, followed by a 46-hour continuous infusion (2400 mg/m^2) every 2 weeks during the 4-6 months of induction and maintenance per investigator's discretion.
45824777|NCT02111850|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5 % in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hour.
45824778|NCT02111850|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m^2 /day intravenous piggy-back (IVPB) daily over 30 minutes for 5 days.
45824779|NCT02111850|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
45824780|NCT02087904|Biological|ABT-981|
45824781|NCT02087904|Other|Placebo|
45967101|NCT02962791|Device|Echocardiography|Standard Echocardiography will de bone for patient
45967102|NCT00203684|Drug|Flunisolide-HFA|
45967103|NCT00197093|Drug|SB773812|
45967104|NCT00226785|Drug|Dexmedetomidine|
45967105|NCT00197132|Drug|Avandia|
45967106|NCT00208728|Device|PC/SMART cardiopulmonary bypass circuit|
45967107|NCT00208728|Device|PMEA modified cardiopulmonary bypass circuit|
45967108|NCT00208728|Device|Standard of care uncoated cardiopulmonary bypass circuit|
45967109|NCT00197171|Biological|Combined Hepatitis A and B vaccine|
45967110|NCT00226824|Drug|galantamine|
45967111|NCT00197210|Biological|Rotavirus|
45967112|NCT00197249|Biological|Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix|
45967113|NCT00226863|Behavioral|meditation plus education|
45967114|NCT00226863|Behavioral|group psychotherapy with hypnosis plus education|
45967115|NCT00226863|Behavioral|education|
45967116|NCT00203723|Drug|Risperidone|
45967117|NCT00226902|Procedure|Changing hemoglobin concentration|
45967118|NCT00203762|Behavioral|Public sector antiretroviral treatment programmes|
45967119|NCT00226980|Drug|Thalidomide|
45967120|NCT00226980|Drug|Capecitabine|
45967121|NCT00203801|Drug|Sulfadoxine-pyrimethamine|
45967122|NCT00203801|Drug|Artesunate plus sulfadoxine-pyrimethamine|
45967123|NCT00203801|Drug|Artemether-lumefantrine|
45967124|NCT00208806|Other|congestive heart failure patients|observational echo data on congestive heart failure patients
45967125|NCT00227058|Drug|Orotic acid and Glutathione-(Nutritional Supplements)|
45967126|NCT00197288|Biological|Influenza|
45967127|NCT04722588|Other|Introducing clinical pharmacists to the interdisciplinary ED team.|There will be two shifts, one shift from 08.00 - 15.00 and one from 12.00 - 19.00. Consequently, the hours of the day when the majority of patients arrives, are covered and the pharmacist capacity is doubled during the busiest time of the day. Early mornings are normally relatively slowed paced and the pharmacist may use this time to follow up on patients admitted during the night (from 19.00 - 08.00), in particularly those who have been admitted to wards without an assigned pharmacist.
45967128|NCT00203879|Drug|MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug)|draft
45967129|NCT00203879|Drug|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
45967130|NCT00197327|Drug|Epidural bupivacaine (0.25% versus 0.0625%)|
45967131|NCT00227097|Behavioral|Education Notebook for anticoagulant treatment|
45824782|NCT02087670|Other|controlled, supervised exercise protocol|exercise program within a cardiac rehabilitation program
45967132|NCT00208923|Drug|Busulfan, Cyclophosphamide and Fludarabine|"Bulsufan 1mg/kg/dose P.O. every 6 hours for 4 days. If intravenous, busulfan dose will be 0.8 mg/kg every 6 hours for 16 doses.~Fludarabine 40 mg/m2 a day for 5 days via IV over 2 hours, dose based on weight.~Cyclophosphamide given via IV over 1 hour at dose of 60 mg/kg/day for 2 consecutive days."
45967133|NCT02963012|Other|ultrasound examination|
45967134|NCT00227136|Drug|5-Hydroxy-Tryptamine|
45967135|NCT00203918|Behavioral|Survey, interview|A survey is administered to patients visiting the urology clinic to undergo prostate biopsies to validate a method of utility assessment, and understand patients' individual evaluations of treatment-related health states. Medical records will also be reviewed 00 days after the survey was administered to determine whether this data reflects actual treatment decisions.
45967136|NCT00203918|Behavioral|patient utility scores (i.e. patient preference weights)|comparison of patient preferences
45967137|NCT00208962|Procedure|chemotherapy and blood stem cell transplantation|A combination of conventional dose chemotherapy, granulocyte-colony stimulating factor (G-CSF) mobilized HLA-identical related allogeneic PBSC transplant, and post transplant infusions of donor leukocytes.
45967138|NCT00227175|Behavioral|Semi-structured, open ended interview|
45967139|NCT00203957|Drug|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
45967140|NCT00203957|Drug|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
45967141|NCT00209001|Procedure|Acupuncture|Acupuncture using enhanced Ming Men technique for 20 minutes, twice during 1st week, then once during week 2, 3,and 4.
45967142|NCT00209001|Procedure|Sham acupuncture therapy|Sham procedure will be insertion of 5 needles for 20 minutes provided twice during first week, then once per week thereafter.
45967143|NCT00197444|Drug|CDGP/5-FU combined with radiation|Low-dose of Nedaplatin (CDGP) 10 mg/body/day was daily administered on day 1-5, 8-13, 15-19, 22-26 and 5-FU 500 mg/body/day was continuously administered on day 1-5, 8-13, 15-19, 22-26.
45967144|NCT00197444|Radiation|Radiotherapy|Fractionated external radiotherapy was performed from the first day of chemotherapy and a total dose of 50.4-66 Gy was delivered at the rate of 1.8-2.0 Gy per fraction.
45967145|NCT00204074|Drug|17-beta-estradiol (drug)|
45967146|NCT00227292|Drug|Escitalopram|Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
45967147|NCT00227292|Drug|Placebo|Placebo 10mg per day for the first week, then 20mg per day till the end of study.
45967148|NCT00197483|Drug|Pergolide (drug)|
45667859|NCT01765582|Drug|bevacizumab|Participants will receive 5 mg/kg IV every 2 weeks during the first 4-6 months induction phase, followed by 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks during maintenance therapy, and 2.5 mg/kg per week reinduction after disease progression.
45824783|NCT02087670|Other|exercise protocol no supervised|Exercise program at the community
45967149|NCT00230529|Drug|infliximab|
45967150|NCT00204113|Device|Multi-purpose rehabilitation frame|
45967151|NCT00204113|Device|Surface Functional Electrical Stimulation|
45967152|NCT00230568|Drug|Aricept|
45967153|NCT00197522|Biological|CD34+ derived DCs|
45667860|NCT01765582|Drug|capecitabine|Participants will receive 1000 or 850 mg/kg orally twice daily as per investigator's discretion on Day 1 to 14, repeated every 3 weeks in maintenance phase.
45667861|NCT01765582|Drug|irinotecan|Participants will receive IV infusion of 165 mg/m^2 over 1 hour every 2 weeks (Arm A) or IV infusion of 180 mg/m^2 over 1 hour in 2 x 2 weeks cycles alternating months (in Arm B), during 4-6 months induction phase.
45667862|NCT01765582|Drug|folinic acid|Participants will receive IV infusion of 200 mg/m^² (Arm A) or 400 mg/m^2 (Arm B or C) over 2 hours every 2 weeks, during 4-6 months induction phase followed by IV infusion of 400 mg/m^2 in the maintenance therapy.
45824784|NCT04729530|Device|Dyson Pure Cool - Active Purifier|Free standing air purifier
45824785|NCT04729530|Device|Dyson Pure Cool - Placebo purifier|Placebo air purifier
45824786|NCT02086968|Drug|Injectafer|2 doses of Injectafer, at 15mg/kg for a maximum single dose of 750mg given on days 0 and 7 for a total of up to 1500mg
45824787|NCT02086968|Drug|Ferrous Sulfate tablets|325mg (1 tablet) three times a day for 28 days
45824788|NCT04729218|Behavioral|movement imagery ability|Determining the movement imagery ability: internal visual, external visual and kinesthetic imagery
45824789|NCT02086110|Dietary Supplement|Synbiotic|
45824790|NCT02086110|Dietary Supplement|Prebiotic|
45824791|NCT02085252|Drug|Leuprorelin|Solution for injection
45824792|NCT02085252|Drug|Bicalutamide|Bicalutamide tablets
45824793|NCT04417686|Procedure|arterial embolization|arterial embolization of the geniculated arteries for reduction of pain after installation of total knee prosthesis
45667863|NCT01765582|Drug|oxaliplatin|Participants will receive 85 mg/m^2 over 2 hours as IV infusion every 2 weeks (Arm A, C ) or 2 x 2 week cycles alternating months (Arm B), during 4-6 months induction phase .
45967154|NCT00204152|Behavioral|(Condition 1) Behavioral Activation; (Condition 2) Behavioral Activation and Stress Innoculation|
45967155|NCT00227331|Drug|Oral amoxicillin|
46080485|NCT04139876|Procedure|LigaSure Hemorrhoidectomy|Patient is operated in the lithotomy position. The main haemorrhoidal (H) masses are identified and delineated. The H are prolapsed out from the anal canal with Allis clamps or similar pick up forceps. Tension is applied to visualise the junction between the nodule and the mucosal wall (internal) or the perianal tissue (external). A small V-shaped anodermal seal is performed by applying the LigaSure (LS) forceps close to the edge of each pile. The seal is then transacted with scissors along the line of coagulum. Care should be taken to limit the amount of tissue removed to minimize the stricture risk. Repeated applications of the device are performed and the excision is continued into the anal canal, lifting the pile from the internal anal sphincter to the level of the vascular pedicle that is finally sealed by LS and divided.
46080486|NCT02733276|Other|electroacupuncture|Electroacupuncture: Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
46080487|NCT02733276|Other|Sham: Electroacupuncture sham|Sham comparator (Electroacupuncture sham): Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
46080488|NCT02808806|Other|real-time audio-visual feedback|real-time audio-visual feedback to caregivers on TSD (i.e. displaying time, a colour code which will provide an easy-view visualization on whether or not pre-set median time delays between locations are exceeded, and auditory signals indicating the elapsed time), displayed through handhelds and on pre-mounted tablets through the whole trajectory of acute stroke care
45824794|NCT02084238|Drug|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.
45824795|NCT04724694|Behavioral|Brief CBT for Chronic Pain|Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6-12 weeks. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
45967156|NCT00197561|Dietary Supplement|Placebo|Taken orally once per day from randomization through delivery and through the first 6 months after delivery.
45967157|NCT00197561|Dietary Supplement|Selenium|200 ug of selenomethionine taken orally once per day from randomization through delivery and for the first 6 months after delivery
46080489|NCT00930709|Drug|Botulinum toxin type A (Botox®, Allergan)|Two injections of 10-60 units of botulinum toxin type A. Injections are administered with ENMG assisted technique at the baseline and after 13 weeks.
45455654|NCT05789849|Device|Collecting blood pressure measurements with noninvasive blood pressure device|Noninvasive blood pressure measurements will collected based on the recommendations of the International Organization for Standardization (ISO) 81060-2:2018+A1:2020 Non-invasive sphygmomanometers -Clinical investigation of intermittent automated measurement type. This study has only 1 arm; investigational NIBP measurements will be collected using a NIBP Auscultatory Algorithm with alternating NIBP measurements collected using a reference sphygmomanometer.
45455655|NCT05789810|Other|Manuel pressure|10-second manual pressure was applied on the insulin injection area.
45667864|NCT04413838|Drug|NIVOLUMAB|IV injection within 30 minutes of 24ml file (=240 mg) containing NIVOLUMAB BMS(Bristol-Myers Squibb) 10mg/ml (immune check point inhibitor targeting PD-1) on top of routine standard of care for COVID-19 infection
45667865|NCT04413838|Other|Routine standard of care|No intervention is planned in this arm. Patients will follow routine standard of care for the COVID-19 treatment
45667866|NCT01649375|Drug|Secukinumab (75 mg)|Secukinumab 75 mg s.c.
45967158|NCT00227409|Drug|calcium disodium EDTA (edetate calcium disodium)|
45455656|NCT05789810|Other|ShotBlocker|ShotBlocker device was placed in the insulin injection site by contacting the protruding surface with the skin and was kept throughout the injection. The injection was applied through the opening at the middle of the tool.
45455657|NCT05789810|Other|Control|No intervention was performed to reduce pain and fear.
45667867|NCT01649375|Drug|Placebo|Placebo
45667868|NCT01649375|Drug|Secukinumab (150 mg)|Secukinumab 150 mg s.c.
45667869|NCT02336555|Drug|MK-8291|MK-8291 oral tablets
45667870|NCT02336555|Drug|Placebo|Placebo oral tablets
45967159|NCT00197639|Drug|Ritonavir-boosted indinavir|
45967160|NCT00230646|Behavioral|Exercise counseling|
45667871|NCT01648283|Drug|IV racemic methadone HCl|IV racemic Methadone HC1 6 mg
45967161|NCT00197678|Dietary Supplement|Multivitamins-Multiples of RDA|20 mg B1, 20 mg B2, 25 mg B6, 50 mcg B12, 100 mg niacin, 500 mg C, 30 mg E, 0.8 mg folic acid taken orally once per day until 6 weeks after delivery
45667872|NCT01648283|Drug|Oral racemic methadone HCl|oral d5-methadone HCl 11 mg
45667873|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
45967162|NCT00197678|Dietary Supplement|Multivitamins-Single RDA|1.4 mg B1, 1.4 mg B2, 1.9 mg B6, 50 mcg B12, 100 mg niacin, 70 mg C, 10 mg E, and 0.4 mg folic acid taken orally once per day until 6 weeks after delivery
45967163|NCT00227448|Drug|intravenous saline|
45967164|NCT00227448|Drug|intravenous phenylephrine|
45967165|NCT00227448|Drug|intravenous levophed|
46080490|NCT00930709|Behavioral|Active strength training and stretching|Training duration 9 weeks, intensified every 3 weeks in supervision of physiotherapist. Training program includes progressive, slow, repetitive wrist and forearm stretching, eccentric muscle strengthening, occupational exercises and upper limb neural mobilization training.
46080491|NCT02738346|Drug|Carboplatin|Intravenous administration of Carboplatin AUC 5 at Day 1, Every 3 weeks, maximum 6 cycles
46080492|NCT02738346|Drug|Etoposide|Intravenous administration of 100mg/m²/day of Etoposide, Day 1 to Day 3 Every 3 weeks, maximum 6 cycles
46080493|NCT02738346|Drug|Topotecan|Per os administration of 2.3 mg / m2 of Topotecan, Day 1 to Day 5 Every 3 weeks, maximum 6 cycles
46080494|NCT02738346|Device|CT scans|The CT scan evaluations will be conducted during chemotherapy every 6 weeks
46080495|NCT00932165|Drug|Exemestane|"Aromasin® Tablets 25mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dose is 25 mg of exemestane administered orally once daily after a meal."
46080496|NCT02611063|Drug|fostamatinib|100mg qd, 150mg qd, or 100mg bid
46080497|NCT00937183|Biological|autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine|
45667874|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
45667875|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
45667876|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
45667877|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
45667878|NCT01649297|Drug|empagliflozin (low dose qd)|Patients receive Empagliflozin low dose once daily
45667879|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
45824796|NCT04724694|Other|Treatment as usual|Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
45824797|NCT02084082|Drug|Linagliptin/Metformin ER FDC|1x Linagliptin/Metformin FDC tablet
45824798|NCT02084082|Drug|Linagliptin|1x Linagliptin tablet
45824799|NCT02084082|Drug|Metformin ER|2x Metformin ER tablets
45824800|NCT02083926|Drug|Ketamine|Ketamine (a single 0.5mg/kg intravenously over 40 minutes).
45667880|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
45667881|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
45667882|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
45667883|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
45667884|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
45667885|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
45824801|NCT02083926|Other|Saline|Saline (a single 0.5mg/kg intravenously over 40 minutes).
45824802|NCT02083380|Drug|Artefenomel 800mg: piperaquine 640mg|Active, loose combination
45824803|NCT02083380|Drug|Artefenomel 800mg: piperaquine 960mg|Active, loose combination
45824804|NCT02083380|Drug|Artefenomel 800mg: piperaquine 1440mg|Active, loose combination
45824805|NCT02109744|Drug|Decitabine|
45824806|NCT02109432|Behavioral|Self-Directed Pedal Desk|participants will have a pedal desk installed in their office and will have access to their daily recorded data but will not have any other form of feedback or goal-setting
45824807|NCT02109432|Behavioral|Facilitated Pedal Desk|participants are provided with their daily recorded pedal desk data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount
45967166|NCT00227448|Drug|oral midodrine|
45967167|NCT00204191|Drug|tacrolimus|
45967168|NCT00227487|Other|Stool collection|Stool sample will be obtained by parent at home to prevent sample dilution during the cleanout
45967169|NCT00227487|Other|Administration of carbohydrate solution during clinically indicated endoscopy|"A carbohydrate solution (lactulose + rhamnose dissolved in tap water) will be administered during the procedure (upper endoscopy) through a catheter directly into the duodenum to allow for intestinal permeability analysis.~Clinically indicated pinch biopsies will then be obtained.~The endoscopy procedures will take at least 1 - 1 ½ hours.~Children will then typically recover in the endoscopy suite for 2 - 2½ hours or less, if the child is medically cleared to leave the endoscopy suite sooner.~Urine for intestinal permeability analysis will be collected during 5 hours after carbohydrate solution administration. If the child has not voided, an additional 60 minutes will be allowed for the child to void. If the child is not continent for urine, a bag will be applied to catch the specimen."
45967170|NCT00227487|Other|Questionnaires|Parents/legal guardians of subjects will be asked to complete five (5) questionnaires: the Gastrointestinal Symptoms Inventory; a Developmental Screening for Autism - based on the child's age, either the Checklist for Autism in Toddlers (CHAT), Modified Checklist for Autism in Toddlers (M-CHAT), or the Social Communication Questionnaire (SCQ); the Behavior and Sensory Interest Questionnaire (BSI), the Behavior Problems Inventory (BPI), and the Aberrant Behavior Checklist (ABC). It should take parents/guardians no longer than eighty-five (85) minutes to complete all 5 surveys. Results from these questionnaires will be correlated with documented gastrointestinal and/or neurological diagnostic information from subject medical records and with research study test results.
45967171|NCT00204230|Drug|mycophenolate mofetil (drug)|
45967172|NCT00204269|Drug|Testosterone Gel Wolff|
45967173|NCT00227526|Behavioral|Prehabilitation|
46080498|NCT00937183|Biological|autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine|
46080499|NCT00937183|Biological|autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine|
46080500|NCT04261829|Procedure|Autologous Fat Transfer|Female breast cancer patients who were surgically treated with mastectomy could opt for a full breast reconstruction with Autologous Fat Transfer in combination with external expansion.
46080501|NCT02804984|Genetic|ICUS|
46080502|NCT00937261|Drug|Risperidone|2mg - 8mg per day, for the duration of participation in the study
46080503|NCT00937261|Drug|Paliperidone|6mg - 12mg per day, for the duration of participation in the study
46080504|NCT05906459|Diagnostic Test|Anti-HCV antibody and HCV core antigen testing|"HCV antibody screening were carried out with rapid diagnostic testings (RDTs) by colloidal gold method, using fingertip blood or residual blood from other testings.~For samples with positive HCV antibody RDTs screening results, HCV core antigen detection will be carried out subsequently as diagnostic test. HCV core antigen detection will be conducted with chemiluminescent particle immunoassay using residual blood from other testings."
45667886|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
45667887|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
45824808|NCT02109432|Behavioral|Facilitated Pedal Desk with Pedometer|participants will be provided with their daily recorded pedal desk and step count data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount and increase their step count by 3,000 steps/day compared to baseline.
45824809|NCT04723602|Biological|cAd3-Marburg|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10^11 Particle Units (PU) vaccine.
45824810|NCT04723602|Biological|cAd3-EBO-S|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10^11 Particle Units (PU) vaccine.
45824811|NCT02109042|Drug|Blosozumab|Administered subcutaneously
45824812|NCT02066922|Device|Delefilcon A contact lens|Commercially available silicone hydrogel contact lens
45824813|NCT02066922|Device|Narafilcon A contact lens|Commercially available silicone hydrogel contact lens
45824814|NCT02066922|Device|Spectacles|Incremental prescription worn over contact lenses if needed to provide acceptable vision
45824815|NCT02108262|Biological|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
45967174|NCT00197756|Dietary Supplement|Vitamin A alone|30 mg beta-carotene plus 5000 IU preformed vitamin A) taken orally once per during pregnancy and lactation
45967175|NCT00197756|Dietary Supplement|Multivitamins excluding vitamin A|30 mg thiamine, 20 mg riboflavin, 20 mg B-6, 100 mg niacin, 50 ug vitamin B-12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid taken orally once per day during pregnancy and lactation
45967176|NCT00197756|Dietary Supplement|multivitamins including vitamin A|20 mg thiamine, 20 mg riboflavin, 25 mg vitamin B6, 100 mg niacin, 50 ug vitamin B12, 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid taken once per day orally during pregnancy and lactation
45967177|NCT00197756|Other|Placebo|Placebo pill taken orally once per day during pregnancy and lactation
45967178|NCT00227565|Drug|carboplatin|
45455658|NCT05789797|Drug|Remaxol|Remaxol®, solution for infusions, by intravenous drop infusion in the dose of 400 ml/day, on everyday basis for 12 days
45455659|NCT05789784|Other|mymobility Physical Therapy|Physical therapy protocol administered at home through the mymobility application.
45455660|NCT05789784|Other|Standard Office-based Physical Therapy|Physical Therapy protocol administered through exercise handouts and formal office-based therapy directed by physical therapist.
45667888|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
45667889|NCT01649297|Drug|Empagliflozin (high dose qd)|Patients receive Empagliflozin high dose once daily
45667890|NCT01649297|Drug|empagliflozin (high dose bid)|Patients receive Empagliflozin high dose split twice daily
45667891|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
45667892|NCT01649297|Drug|empagliflozin (low dose bid)|Patients receive Empagliflozin low dose split twice daily
45667893|NCT01648205|Drug|Placebo|Matching Placebo will be given for first month.
45667894|NCT01648205|Drug|Ranolazine|Patients will receive ranolazine 1000mg bid for subsequent 5 months.
45667895|NCT04894253|Biological|SRAS-CoV-2 vaccination immunological response|"Follow for 18 months a single group of 30 patients with systemic lupus after their SRAS-CoV-2 vaccination.~Intervention includes immunological analysis on additional volume of blood collected as part of routine care."
45667896|NCT02391545|Drug|Duvelisib|PI3K Inhibitor
45667897|NCT02391545|Drug|Rituximab|monoclonal antibody
45824816|NCT02108262|Biological|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
45824817|NCT04185402|Drug|Azithromycin|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
45824818|NCT02107482|Device|Levia Narrow Band UVB|The device's spectral output is is Narrow Band UVB (NB-UVB) (NB-Levia): 308-312 nm
45967179|NCT00227565|Drug|pemetrexed disodium|
45967180|NCT00227565|Radiation|radiation|
45967181|NCT00204308|Drug|Combination tenofovir-emtricitabine|Tenofovir disoproxil 300 mg / emtricitabine 200 mg taken as a single dose during labor
45824819|NCT02107482|Device|Levia sham/visible-light source|the light spectrum is in the range of 400-700nm, the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
45967182|NCT02963246|Behavioral|Mindfulness|"Mindfulness-based therapy has been used effectively to treat a variety of physical and psychological disorders, including depression, anxiety, and chronic pain. Recently, several lines of research have explored the potential for mindfulness-therapy in treating somatization disorders, including fibromyalgia, chronic fatigue syndrome, and irritable bowel syndrome. Mindfulness-based therapies (MBT) are a clinical application involving the key element of nonjudgmental acceptance of physical pain or psychological distress, thereby reducing the tendency to ruminate over and catastrophise these experiences.~In the present study, we propose a mindfulness intervention of 12 months, with sessions either personalized or online."
45967183|NCT00230724|Behavioral|Exercise Counseling|
45967184|NCT00204347|Drug|risperidone|
45967185|NCT00227682|Dietary Supplement|ascorbic acid|
45967186|NCT00227682|Drug|arsenic trioxide|
45967187|NCT00227682|Drug|dexamethasone|
45967188|NCT00227682|Drug|thalidomide|
45967189|NCT00197795|Biological|"Meningococcal outer membrane vesicle vaccine MenBVac"|
45967190|NCT00230763|Procedure|GSS questionnaire|D0, D30 and D84
45967191|NCT00230763|Procedure|IOP|D0, D30 and D84
45967192|NCT00230763|Drug|LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION|in the evening during 84 days
45967193|NCT00230763|Procedure|Visual acuity|D0 and D84
45967194|NCT00204386|Drug|Topiramate|
45667898|NCT02391545|Drug|Obinutuzumab|monoclonal antibody
45667899|NCT02362451|Biological|Autologus elutriated monocyte placebo vaccine|20x10^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
45967195|NCT04721964|Dietary Supplement|Ferric ammonium citrate and ferrous fumarate syrup (Ranbaxy Ranferon-12 Syrup, Ranbaxy Laboratories, Gurgaon, India)|Daily supplementation with iron syrup for 13 weeks. The dosage will be calculated based on body weight and adjusted after 4 and 8 weeks of intervention
45667900|NCT02362451|Biological|Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine|20x10^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
45667901|NCT01734382|Drug|Tocilizumab|Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants < 30 kg) or 8 mg/kg (for participants >/=30 kg) Q2W/Q3W/Q4W.
45824820|NCT04728360|Drug|BAT2206|45 mg/0.5 mL
45824821|NCT04728360|Drug|Stelara (EU-sourced)|45 mg/0.5 mL
45824822|NCT02066298|Drug|Mometasone 220mcg BID|Mometasone is an ICS
45824823|NCT02066298|Drug|Tiotropium Respimat 5mcg QD|Tiotropium is a LMA
45967196|NCT00197834|Drug|Depakote|
45967197|NCT00230841|Device|nebulized humidity|
45824824|NCT02066298|Drug|Placebo|
45824825|NCT02082912|Drug|D-cycloserine|D-cycloserine 100mg PO twice weekly (Monday and Wednesday) for three weeks
45967198|NCT00197912|Biological|tumor antigen loaded autologous dendritic cells|DC vaccination regime consists of primary 10 intradermal injections of 1-2 weeks interval (q1w x 4 → q2w x 6). HLA-A2 positive patients are treated with p53, survivin and telomerase peptide-pulsed dendritic cells, and HLA-A2 negative patients are treated with allogeneic tumor lysate pulsed dendritic cells. 50 mg cyclophosphamide (Sendoxan®, Baxter A/S) is administered p.o. twice a day bi-weekly and 200 mg celecoxib (Celebra®, Pfizer) is given p.o. every day. From the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.
45967199|NCT02962323|Drug|Torrent's Rosuvastatin Calcium Tablets 40 mg|Oral, crossover
45967200|NCT02962323|Drug|Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA|Oral, crossover
45667902|NCT02391311|Device|transcranial direct current stimulation (tDCS)|tDCS is a low level electrical stimulation that will be applied to F10. The sham group will receive 2 mA (milliamps) for 30 seconds, while the experimental group will receive 2 mA for 20 minutes. Both groups will have 10, 1 hour sessions of playing cognitive remediation games, while receiving the respective level of tDCS for sham vs experimental conditions.
45667903|NCT01765426|Biological|TDV|TDV suspension for intradermal administration
45667904|NCT01765426|Drug|Placebo|Phosphate buffered saline (PBS)
45667905|NCT01765270|Drug|Saxagliptin|one 5-mg saxagliptin tablet daily
45667906|NCT01765270|Drug|Placebo|5mg placebo tablet daily
45824826|NCT02082912|Other|Placebo|Placebo pill PO twice weekly (Monday and Wednesday) for three weeks
45967201|NCT00227838|Behavioral|Behavior Therapy|
45967202|NCT00227916|Behavioral|Behavior Therapy|
45967203|NCT00204425|Dietary Supplement|exercise/soy isoflavone|Exercise 6 days per week, 90 mg/day aglycone isoflavone Exercise placebo (stretching), isoflavone placebo
45824827|NCT02082912|Device|HandMentor Pro|The HandMentor Pro (Kinetic Muscles Inc.) is a robotic device that has recording electrodes. The device gives feedback during various activities requiring varying levels of wrist control. The main goal of the hand robot is to improve active range of motion about the wrist and fingers and wrist control. The robotic therapy will be done over 3 consecutive weeks for 2 hours each session (days 1, 3, 5, 8, 10, 12, 15, 17 and 19, for 18 hours total).
45967204|NCT00204464|Procedure|Exercise|
45967205|NCT00230880|Behavioral|follow-up phone counseling|9 calls over 12 months
45967206|NCT00197951|Drug|Treatment of psychiatric symptoms associated to alcoholism|
45967207|NCT00230919|Behavioral|Diet counseling|
45967208|NCT00204503|Drug|Depakote ER|
45967209|NCT04721847|Other|Pain Neuroscience Education|In first part educational content will be designed to be given in group of patients in six sessions by PNE booklet. The six sessions are 1.5 hours long (9 hours) and will be given at a frequency of 1 session per week. Final session will be given to solve doubts, and to provide additional information to the educational program. Book for additional material will be delivered to participants.
45967210|NCT04721847|Other|Conventional Physical therapy|Control group will be treated by Conventional Physical therapy like TENS, stretching and strengthening exercises. Intervention will be initiated with warm up period (joint mobility exercises) for the duration of 5 mins and ended up with cool down period (relaxing exercises i.e. deep breathing) for the duration of 5 mins.
45967211|NCT00204542|Drug|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 3 months
45824828|NCT02082522|Drug|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin (2 mg/kg) followed by the illumination of the tumor using a fiber optic device during an endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC). Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals.
45824829|NCT02082522|Procedure|Stenting procedure|As per standard medical procedures, stenting procedure consists in the placement of stents above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) when the ERCP approach has been unsuccessful.
45824830|NCT02082522|Drug|Chemotherapy regimen|The regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
45967212|NCT00204542|Drug|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 6 months
45967213|NCT00230958|Drug|Viramidine|
45967214|NCT00230958|Drug|Ribavirin|
45967215|NCT00230958|Drug|pegylated interferon alfa-2b|
45967216|NCT02962856|Drug|BAY987517|50 μl/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. (Formulation: Z43-078)
45967217|NCT02962856|Other|Untreated Skin|This site is patched without treatment as irradiated control
45967218|NCT00227955|Drug|Imipramine|
45967219|NCT00227955|Behavioral|Interpersonal Psychotherapy|
45667907|NCT04605484|Biological|Posoleucel (formerly known as ALVR105) cells|Infusion
45667908|NCT04605484|Biological|Placebo (visually identical to Posoleucel)|Infusion
45667909|NCT01733758|Drug|Albiglutide 30 mg weekly|Albiglutide will be available as a pen injector that delivers 30mg of albiglutide
45667910|NCT01733758|Drug|Albiglutide 50 mg weekly|Albiglutide will be available as a pen injector that delivers 50mg of albiglutide
45667911|NCT01733758|Drug|Placebo|Albiglutide matching placebo will be available as a pen injector
45667912|NCT01733758|Drug|Liraglutide 0.9 mg daily|Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose
45967220|NCT00228033|Drug|Elemental calcium (as carbonate)|
45967221|NCT00230997|Drug|Galantamine|
45967222|NCT00204581|Drug|Interleukin-2 (Proleukin)|6-12 MIE/d 3times a week
45967223|NCT00231075|Drug|Paraplatin|
45967224|NCT00231075|Drug|Paclitaxel|
45667913|NCT01607554|Drug|Irinotecan|"180 mg/m2 Irinotecan intravenously over 60 minutes on day 1 of each cycle~Pre-medication for irinotecan: palonosetron 0.25 mg and dexamethasone 8 - 16 mg, both administered intravenously. Atropine 0.25 - 0.5 mg subcutaneously or IV is at the discretion of the treating physician"
45967225|NCT00198146|Drug|Zenapax|
45967226|NCT00228072|Procedure|Suction-curettage|
45967227|NCT00198185|Procedure|Placement of Platelet Rich Fibrin Matrix During Arthroscopic Rotator Cuff Surgery|
45967228|NCT00204620|Drug|Bendamustin|
45967229|NCT02962518|Device|Pressure Device|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months and they are additionally treated with a non-customized Pressure Device. The standardized clips (K. Egner, Dental Technique, Neu-Ulm, Germany) used in our study is available in two different sizes for smaller or larger defects. According to the guidelines of the German Society of Dermatology, patients are advised to wear the clip at least 16 hours per day. Medically approved transparent acrylate is used so that change in skin color and therefore amount of pressure can be observed at all times. Allergic or toxic skin involvement can be visualized through the transparent surface. Adjusting of the clip is done with one or two screws."
45455663|NCT05789719|Biological|STEM-OA|Combination of autologous or allogeneic MSC(AT)s and fat
45455664|NCT05789706|Behavioral|Dayamed Arthur a novel intelligent medication adherence platform|Novel smart phone adherence application configured with subject pharmacy data providing accurate reminders of when to take medications and providing auditable user feed back to clinical care teams for patient response directed provider intervention.
45667914|NCT01607476|Drug|C11 PiB|One time intravenous administration of 8-22 millicurie (mCi) C11 PiB
45967230|NCT02962518|Procedure|Fillet Technique|"Patients undergo surgery using the fillet technique. To prevent the remaining skin from further damage, the meticulous skin preparation is performed either using the microscope or magnifying glasses. The keloid is peeled out of the excessive skin pocket. If necessary skin trimming is performed and non-resorbable monofilament single sutures are placed."
45967231|NCT02962518|Drug|Triamcinolone|All patients received intra-lesional injections of tiamcinolone 10mg/ml every 4 to 6 weeks for 6 months.
45967232|NCT00198224|Procedure|phlebotomy|
45967233|NCT00228150|Drug|SR57667B|
45967234|NCT00204659|Drug|Rituximab + CHOP chemotherapy|standard Rituximab + CHOP chemo-immunotherapy
45967235|NCT00231192|Drug|Repaglinide and Insulin|
45967236|NCT00409916|Device|BioZ Dx|
45967237|NCT00413556|Biological|ALK Grass tablet|
45967238|NCT00204698|Drug|Aciphex|20 mg of aciphex taken twice daily
45967239|NCT00228189|Biological|CEA-loaded dendritic cell vaccine|Carcinoembryonic antigen (either peptide or mRNA) loaded dendritic cells.
45667915|NCT01607476|Drug|F18 Flutametamol|One time intravenous administration of 3-7 mCi F18 Flutametamol.
45824831|NCT04723446|Drug|Corsodyl® Alcohol free -0.2 % Chlorhexidine digluconate|Corsodyl® Alcohol-free is a clear to slightly opalescent oromucosal solution with an odour of peppermint that contains 0.2% w/v chlorhexidine digluconate which is an antimicrobial preparation for external use. It is effective against a wide range of Gram negative and Gram positive vegetative bacteria, yeasts, dermatophyte fungi and lipophilic viruses. It is active against a wide range of important oral pathogens and is therefore effective in the treatment of many common oral conditions.
45967240|NCT00204737|Drug|prednisone|20mg x 2 weeks
45967241|NCT00204737|Drug|placebo|placebo
45967242|NCT00231231|Device|-PRECISE Nitinol Stent System (5F, 5.5F and 6F)|
45967243|NCT00231231|Device|ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW)|
45967244|NCT00231270|Device|Cordis Nitinol Stent|
45967245|NCT00231270|Device|PRECISE tapered stent|
45967246|NCT00231270|Device|ANGIOGUARD XP Emboli Capture Guidewire (ECGW)|
45455665|NCT05789680|Procedure|Surgical treatment of parathyroid carcinoma|Radical treatment of suspected parathyroid carcinoma should consist of parathyroidectomy and en bloc ipsilateral hemithyroidectomy and central lymph node dissection.
45455666|NCT05789667|Drug|Lenvatinib|Patients will be treated by lenvatinib as recommended by good clinical practice
45455667|NCT05789602|Drug|BPI-460372|Subjects will receive BPI-460372 until disease progression
45455668|NCT05789550|Diagnostic Test|ALL PATIENT DIABETIC IN THIS PERIOD WILL BE INCLUDED IN THE STUDY|"Full clinical history with detailed history about T2DM (its duration and treatment).~Full medical examination, including BMI using the formula: weight (kg)/height (m2).~Laboratory investigation, including the following:~Complete blood picture.~Fasting blood sugar (FBS).~Postprandial blood sugar (PP-BS) (2 h after 75 g glucose orally).~HbA1c.~Kidney function tests (serum creatinine and blood urea).~Liver function tests (serum albumin, ALT, and AST).~Lipid profile, which include cholesterol and triglyceride. 4)H PYLORI Ag IN Stool"
45455669|NCT05789537|Drug|SerpinPC|Participants will receive SerpinPC SC injection.
45455670|NCT05789524|Drug|SerpinPC|Administered as SC injection.
45455671|NCT05789498|Other|In vitro stimulation of Pbmc with tumor antigen nanoparticles|PBMCs were isolated from peripheral blood of cancer patients, and PBMC are co-incubated with nanoparticles loading tumor antigens for specific time in vitro to detect T cells that are related with efficacy of cancer immunotherapy. The content of such T cells are studies the correlation with the efficacy of cancer immunotherapy and patient prognosis.
45455672|NCT05789459|Device|Stapler|Stapler
45455673|NCT05789459|Other|Suture|Suture
45667916|NCT01765192|Drug|Roflumilast|Roflumilast was supplied in tablets.
45824832|NCT04723446|Drug|Colgate Peroxyl® -1.5% Hydrogen peroxide|Peroxyl mouthwash is a clear aqua-blue liquid oromucosal solution which 100ml of solution contains 1.5g of Hydrogen peroxide (as 30% Hydrogen Peroxide solution). It is an oral antiseptic cleanser for external use. The principal action is brought about by contact of hydrogen peroxide with peroxidases and catalases present in tissues and saliva, which causes the rapid release of oxygen. This provides mechanical cleansing which flushes out mouth debris and helps in the treatment of oral irritations. This mouthwash is used as a cleanser in the symptomatic relief of minor mouth and gum irritations.
45967247|NCT00198302|Drug|Aurexis®|
45967248|NCT00228228|Biological|T cell vaccination|
45967249|NCT00198380|Drug|Gefitinib|Gefitinib 250 mg/day, until progression or severe toxicity
45967250|NCT00228267|Drug|Propofol|
45667917|NCT01765192|Drug|Roflumilast placebo|Roflumilast placebo was supplied in tablets.
45667918|NCT01765192|Drug|Montelukast|Montelukast was supplied in tablets.
45667919|NCT01733680|Drug|amiloride|Subjects will take either amiloride hydrochloride or placebo for 8 weeks.
45967251|NCT00198419|Drug|Vitrase|
45967252|NCT00228306|Behavioral|Rehabilitation exercise|Rehab therapy is delivered for 8 weeks.
45967253|NCT00198458|Drug|Vitrase|
45967254|NCT00231348|Drug|Nefazodone|
45967255|NCT00198497|Drug|Placebo|
45967256|NCT00198497|Drug|Vitrase|Hyaluronidase 55 IU in saline solution
45967257|NCT00198497|Drug|Vitrase|Hyaluronidase 75 IU in saline solution
45967258|NCT00231387|Drug|rosiglitazone|
45967259|NCT00198536|Drug|Ecabet 2.83%|
45967260|NCT00198536|Drug|Ecabet 3.70%|
45967261|NCT00198536|Drug|Vehicle|
45967262|NCT00231426|Device|ICD|
45967263|NCT00409955|Procedure|Lamellar transplant with lyophilized corneas|
45967264|NCT00228345|Procedure|Optical coherence tomography,Fluorescein angiography|
45967265|NCT00409994|Drug|Rapamycin|dosis escalation: 2/4/6 mg rapamycin tablets, once daily during 13 days
45667920|NCT01733680|Behavioral|Behavioral|Each week of the study, subjects will complete the AISRS, BRIEF-A, and CGI to measure symptom improvement
45667921|NCT02348216|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg.
45667922|NCT02348216|Drug|Fludarabine|Administered according to package insert
45667923|NCT02348216|Drug|Cyclophosphamide|Administered according to package insert
45667924|NCT04892498|Radiation|Hypofractionated radiotherapy|10-24Gy/5-8Gy/2-3f
45667925|NCT04892498|Drug|PD-1 inhibitor|q3w, until PD
45667926|NCT04892498|Drug|GM-CSF|200μg, D1-D7, ≥8 cycles
45667927|NCT04892498|Drug|IL-2|at a dose of 2 million IU, D8-D14, ≥8 cycles
45967266|NCT00410033|Drug|soluble human insulin|
45967267|NCT00410033|Drug|isophane human insulin|
45967268|NCT00410033|Drug|insulin aspart|
45967269|NCT00228462|Drug|Seroquel (quetiapine)|
45967270|NCT00231504|Procedure|Blood samples|Blood samples
45967271|NCT00198614|Drug|Carvedilol versus Metoprolol|
45967272|NCT00231543|Procedure|Laparoscopic fundoplication|
45967273|NCT00231543|Procedure|open Nissen fundoplication|
45967274|NCT00198653|Behavioral|Newborn Thermal Care Practice|
45967275|NCT00231582|Drug|epirubicin|epirubicin
45824833|NCT04723446|Other|Oral-B® Gum & Enamel Care -Cetylpyridinium chloride|The Oral-B® Gum & Enamel Care mouthwash is an oromucosal solution containing Cetylpyridinium chloride (CPC) and used as an adjunct to oral hygiene.
45967276|NCT00231582|Procedure|high-dose and autologous stem cell transplantation|high-dose and autologous stem cell transplantation
45967277|NCT00231582|Drug|paclitaxel|paclitaxel
45967278|NCT00231582|Drug|etoposide|etoposide
45967279|NCT00231582|Drug|ifosfamide|ifosfamide
45967280|NCT00231582|Drug|carboplatin|carboplatin
45967281|NCT04721574|Device|Philips EnergyUp Energy light HF3418/01|high brightness LED light box
45967282|NCT04721574|Device|Philips EnergyUp Energy light HF3418/01 with filter|high brightness LED light box with filters that reduced lamp output to less than 50 lux
45967283|NCT02963324|Drug|Ivermectin|
45967284|NCT00228540|Drug|Modafinil|
45967285|NCT00198692|Behavioral|self-management|
45967286|NCT00231621|Drug|topiramate|
45455674|NCT05789446|Behavioral|Building a Strong Identity and Coping Skills|Psychoeducational program to teach children coping skills, healthy identity development, and collective social action
45455675|NCT05789407|Diagnostic Test|Detection of PAHs in visceral fat with gas chromatography-isotope dilution mass spectrometry|1 ml sample of visceral fat collected during elective laparoscopy for detection of PAHS by gas chromatography-isotope dilution mass spectrometry
45455676|NCT05789342|Drug|GP681|GP681, tablet, oral
45667928|NCT04887506|Drug|TAVT-45|250 mg abiraterone acetate granules for oral suspension in a sachet, administered twice daily.
45667929|NCT04887506|Drug|Zytiga|500 mg tablet, administered twice daily.
45667930|NCT04887506|Drug|Prednisone|mCSPC patients will receive 5 mg orally once daily. mCRPC patients will receive 5 mg orally twice daily.
45667931|NCT02336165|Drug|Durvalumab|Durvalumab is administered as an IV infusion over 60 ± 5 minutes Q2W.
45667932|NCT02336165|Radiation|Standard radiotherapy|Focal radiotherapy is administered at 2 Gy given daily 5 days per week for a total of 60 Gy over 30 fractions per local institutional guidelines or local prescribing information. On days when radiotherapy and durvalumab overlap, radiotherapy is administered first followed by durvalumab.
45667933|NCT02336165|Biological|Bevacizumab|Bevacizumab is administered as an IV infusion (per local prescribing information) Q2W. When durvalumab and bevacizumab are administered together (i.e., Cohorts B2, B3, and C), durvalumab is administered first followed by a 1-hour observation period, after which, bevacizumab is infused.
45667934|NCT02360111|Drug|Cyclophosphamide|
45667935|NCT02334683|Device|Electrical stimulation|The purpose of this study is to investigate the use of two ways of locating the muscle for botulinum toxin (BoNT) injection for the treatment of focal hand dystonia and upper limb spasticity located by either electrical stimulation using a needle or ultrasound using sound waves.
45824834|NCT04723446|Other|No rinsing|No rinsing
45967287|NCT00198731|Behavioral|Care Seeking for Obstetric Complication|This is a descriptive study of knowledge, practices and outcomes related to maternal morbidity during pregnancy, childbirth and postpartum.
45967288|NCT00474526|Biological|Meningococcal ACWY Conjugate Vaccine|
45967289|NCT00474526|Biological|DTaP-IPV-HBV|
45967290|NCT00474526|Biological|Hib|
45967291|NCT00474526|Biological|Rotavirus|
45967292|NCT00474526|Biological|Pneumococcal 7-valent Conjugate Vaccine|
45967293|NCT00474526|Biological|HAV|
45967294|NCT00474526|Biological|MMR-V|
45967295|NCT00474526|Biological|DTaP|
45967296|NCT00231660|Drug|topiramate|
45967297|NCT00198770|Dietary Supplement|dietary substitution to assess level of caloric compensation|Mushrooms substituted for meat in dishes
45967298|NCT00231699|Procedure|Plastic wrap (study group) and cotton (control group) wrap.|
45967299|NCT00198809|Drug|Biolean + Diet education|
45967300|NCT00198809|Drug|Biolean Free + Diet education|
45967301|NCT00198809|Drug|Placebo + Diet education|
45967302|NCT00231738|Drug|Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)|
45967303|NCT00198848|Drug|Iron-folic acid supplement|
45967304|NCT00228657|Drug|4% Albumin / 0.9% Sodium Chloride|
45967305|NCT00198887|Procedure|Operations research|
45967306|NCT04722081|Other|physical therapy|physical therapy-specific exercises
45967307|NCT00198926|Behavioral|covert v overt nutrition labeling|
45967308|NCT00198926|Behavioral|varying meal nutrition manipulation|
45967309|NCT00478738|Drug|GSK961081|
45967310|NCT00198965|Behavioral|dietary education|
45967311|NCT00198965|Behavioral|dietary education and provided full fat snack foods|
45455677|NCT05789342|Drug|Rosuvastatin|Rosuvastatin, tablet, oral
45455678|NCT05789342|Drug|Digoxin|Digoxin, tablet, oral
45455679|NCT05789342|Drug|Itraconazole|Itraconazole, capsule, oral
45455680|NCT05789342|Drug|Oseltamivir|Oseltamivir, capsule, oral
45455681|NCT05789251|Diagnostic Test|Standardized breakfast|Standardized breakfast to replace in fine oral induced hyperglycemia test
45455682|NCT05789186|Drug|CAVO aromatherapy patch at 3% concentration+Fluoxetine hydrochloride mimetic|CAVO aromatherapy patch at 3% concentration enhances neuroelectrical activity in the brain (especially in the prefrontal cortex), exerting an antidepressant effect.Fluoxetine hydrochloride mimetic without drug treatment effect.
45824835|NCT02082210|Drug|Emibetuzumab|Administered Intravenously (IV)
45824836|NCT02082210|Drug|Ramucirumab|Administered Intravenously (IV)
45824837|NCT02107092|Drug|Sodium Zirconium Cyclosilicate|Oral 10g once daily with breakfast for 11 months.
45824838|NCT02107014|Drug|Low Dose Naltrexone|Naltrexone 4.5 mg p.o. nocte
45824839|NCT01624974|Drug|MK-1029|MK-1029 150 mg tablets taken QD
45824840|NCT01624974|Drug|Placebo|Placebo tablets (matching the MK-1029 150 mg tablets) QD
45824841|NCT01624974|Drug|Montelukast (ML)|ML 10 mg tablets QD
45967312|NCT00198965|Behavioral|dietary education and provided fat free snack foods|
45967313|NCT00228696|Other|none, screening only|Screening protocol with no intervention
45967314|NCT00478426|Drug|Sunitinib Malate|Given PO
45967315|NCT00231855|Drug|Topotecan and Taxotere|
45967316|NCT00199004|Drug|Cyclophosphamide|
45967317|NCT00199004|Drug|Dexamethasone / Prednisolone|
45967318|NCT00199004|Drug|Vincristine|
45667936|NCT02334683|Device|Ultrasound|The purpose of this study is to compare how the muscle is located by either electrical stimulation using a needle or ultrasound using sound waves.
45967319|NCT00199004|Drug|Daunorubicin|
45455683|NCT05789186|Drug|Fluoxetine hydrochloride tablet+CAVO aromatherapy patch at 0.1% concentration|Fluoxetine hydrochloride tablet was widely used selective 5-HT reuptake inhibitor (SSRI) that selectively inhibits the 5-HT transporter, blocks the reuptake of 5-HT by the presynaptic membrane, and prolongs and increases the effects of 5-HT, resulting in antidepressant effects.CAVO aromatherapy patch at 0.1% concentration without drug treatment effect.
45824842|NCT02065518|Device|NMES|Participants will train at 15-20% of maximal voluntary contraction (MVC) during weeks 1-3, 21-30% of MVC during weeks 3-6 and 31-40% of MVC during weeks 6-9, 41-50% of MVC during weeks 9-12, then sustain 50% of MVC during weeks 12-18. Incremental increases will be made at the 3, 6, 9, and 12-week clinic visits.
45667937|NCT02319044|Drug|MEDI4736|MEDI4736 monotherapy
45455684|NCT05789186|Drug|Fluoxetine hydrochloride mimetic+CAVO aromatherapy patch at 0.1% concentration|Placebo without drug treatment effect
45458326|NCT03498274|Device|Fitting System|End users will drive the screening and fitting flow; however, a trained professional is intended to assist them and help with explanations and the actual fitting of the hearing aids on the person. For a first time user the physical act of placing the hearing aid in/on the ear may create confusion. Therefore, the software is designed for an assistant to guide the user through the process and help with specific parts of the fitting or any questions in general.
45667938|NCT02319044|Drug|Tremelimumab|Tremelimumab monotherapy
45667939|NCT02319044|Drug|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
45667940|NCT01649765|Drug|belimumab 10mg/kg|belimumab 10mg/kg IV monthly
45667941|NCT01649765|Other|placebo|Normal Saline 250 ml
45667942|NCT04196738|Other|ventilation strategy|Patients are ventilated in randomised order with three different ventilation strategies: volume assist control (constant flow), Dual Mode or Airway Pressure Released Ventilation
45667943|NCT04902482|Device|iCycle Mark 3|The iCycle Mark 3 is a cycle ergometer, designed to be used by people with SCI while they are seated in their own wheelchairs. The purpose of iCycle is to stimulate the leg muscles in the correct phase for cycling while motivating the person with a Virtual Reality cycling event, perhaps a race, to try to use their muscles.
45824843|NCT02065518|Behavioral|Strength Walking|Strength Walking participants will maintain a daily training log. Pedometer readings will form the basis for setting activity goals. Initial step goals will be 10% above the average 3-day pedometer step count taken at baseline, with a 10% increase every other week, and then a gradual increase when 30% above the baseline step count has been achieved. At week 7, participants will be given a weighted vest to begin the strengthening component. Participants will be instructed to wear the vest during their 30-minute walk, 3 to 4 days a week. The beginning weight load for the vest will be calculated using 2% of baseline body weight and it will be increased by that same amount every week thereafter until the end of the 12 weeks.
45824844|NCT02065518|Behavioral|Standard Rehabilitation Protocol|All participants will receive the current standard of care at the 2 military sites (Walter Reed National Military Medical Center (WRNMMC) and Malcolm Grow Medical Clinics and Surgery Center (MGMCSC)) of the physical therapy rehabilitation protocol for knee injuries. This program includes treatment with a physical therapist at WRNMMC and MGMCSC physical therapy clinic.
45967320|NCT00199004|Drug|Asparaginase|
45967321|NCT00199004|Drug|Methotrexate|
45967322|NCT00199004|Drug|Cytarabine|
45967323|NCT00199004|Drug|Mercaptopurine|
45967324|NCT00199004|Drug|G-CSF|
45667944|NCT02317562|Drug|I10E|Patients who met all eligibility criteria will receive 0.5 g/kg of IMP every 3 weeks during 45 weeks.
45967325|NCT00199004|Drug|Vindesine|
45967326|NCT00199004|Drug|VP16|
45667945|NCT02317016|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
45667946|NCT02317016|Drug|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken from Days 4 to 35. Part B: AZD9291 80mg tablet taken daily for 12 months.
45667947|NCT02317016|Drug|Rosuvastatin|Rosuvastatin (BCRP substrate) 20mg taken once daily on Days 1 and 32 (Part A) .
45667948|NCT02317016|Procedure|Pharmacokinetic sampling - rosuvastatin|Blood sampling to measure rosuvastatin levels
45667949|NCT02317016|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
45967327|NCT00199004|Drug|Adriamycin|
45967328|NCT00199004|Drug|Thioguanine|
45967329|NCT00199004|Drug|VM26|
45967330|NCT00199004|Drug|Rituximab|
45967331|NCT00199004|Procedure|CNS irradiation|
45967332|NCT00199004|Procedure|Mediastinal irradiation (if residual TU)|
45967333|NCT00199004|Procedure|Stem cell transplantation|
45967334|NCT00228852|Drug|Busulfan, Fludarabine and ATG|
45967335|NCT00204776|Drug|Capecitabine and Oxaliplatin|
45967336|NCT00228891|Procedure|Effect of Pulsatile IV insulin on diabetic neuropathy|Control patients with diagnosed diabetic neuropathy will have objective testing at baseline and every six months to compare and measure results to patients receiving pulsatile intravenous insulin therapy.
45824845|NCT01624662|Drug|Fluticasone propionate|Delivered via Optinose Exhalation Delivery System
45667950|NCT02311478|Device|T380A Intrauterine Copper Contraceptive|The T380A is intrauterine device (IUD) that used to prevent pregnancy. It is a soft, flexible T-shaped device made primarily of plastic and copper that is inserted into the uterus.
45824846|NCT02106390|Biological|Meningococcal group B Vaccine, rMenB+OMV NZ|4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
45967337|NCT00228891|Procedure|Effect of Pulsatile IV Insulin on diabetic neuropathy|Patients diagnosed with diabetic neuropathy will be treated with pulsatile intravenous insulin on a weekly basis. Patient's Endocrinologist will determine the dosage of intravenous insulin to be given each week based upon the patient's response and insulin resistance.
45967338|NCT00477412|Drug|Bortezomib|Given IV
45967339|NCT00477412|Drug|Cyclophosphamide|Given IV
45824847|NCT02106390|Biological|Meningococcal ACWY Conjugate Vaccine, MenACWY|4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
45667951|NCT02388932|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45967340|NCT00477412|Drug|Cytarabine|Given IV
45967341|NCT00477412|Drug|Dexamethasone|Given PO or IV
45967342|NCT00477412|Drug|Doxorubicin|Given IV
45967343|NCT00477412|Drug|Methotrexate|Given IV
45967344|NCT00477412|Biological|Rituximab|Given IV
45967345|NCT00477412|Drug|Vincristine|Given IV
45967346|NCT00410774|Biological|bevacizumab|
45667952|NCT02388932|Device|Positron Emission Tomography|Undergo PET/CT
45667953|NCT02388932|Device|Computed Tomography|Undergo PET/CT
45667954|NCT02388932|Other|Quality-of-Life Assessment|Ancillary studies
45824848|NCT02064894|Drug|oral morphine and oral ibuprofen|The combination of oral morphine and oral ibuprofen is one of the Experimental arm group
45824849|NCT02064894|Drug|Oral morphine|Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study
45824850|NCT02064894|Drug|Oral ibuprofen|oral ibuprofen combine to a placebo is the active comparator
45824851|NCT04707768|Drug|Vadadustat|oral tablets
45824852|NCT04707768|Drug|Mircera®|intravenous administration
45824853|NCT02081586|Behavioral|CBT|Therapists will work with patients to identify non-constructive thinking patterns that are serving as barriers to adequate self-management of Type 2 Diabetes.
45824854|NCT02081586|Device|Smartphone app|Smartphone app developed to assist patients practice CBT skills throughout the week
45824855|NCT02081586|Other|Standard Diabetes Care at PCP|Patients receive ADA standard of Care with physician at PCP office
45824856|NCT02081196|Device|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
45824857|NCT02064816|Drug|Rebif®|Rebif® will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week in the morning using RebiSmart® self-injector device for 12 weeks.
45824858|NCT02064816|Drug|Rebif®|Rebif® will be administered at a dose of 44 mcg subcutaneously three times a week in the evening using RebiSmart® self-injector device for 12 weeks.
45967347|NCT00410774|Drug|gemcitabine hydrochloride|
45967348|NCT00410774|Procedure|adjuvant therapy|
45967349|NCT00228930|Drug|Tamoxifen (pharmacodynamic analysis)|Tamoxifen 20mg po daily
45967350|NCT00410852|Procedure|Computer-assisted IV insulin infusion protocol (algorithm A)|Computer assisted insulin protocol (CAIP), with continuous intravenous insulin adjustments aiming blood glucose levels between 100 mg/dl and 130 mg/dl.
45967351|NCT00410852|Procedure|Leuven Strict glycemic control protocol (Algorithm B)|Leuven protocol: continuous intravenous insulin infusion aimiming blood glucose levels between 80mg/dl and 110mg/dl.
45967352|NCT00410852|Procedure|Conventional Intermittent Insulin Protocol (Algorithm C)|Conventional treatment: intermitent subcutaneous insulin according to a sliding scale, starting with blood glucose levels higher than 150mg/dl.
45967353|NCT00231933|Behavioral|Person-centered planning (PCP)|PCP aids participants in discovering a vision of a desirable future and developing a plan for achieving that goal. Techniques include providing direction in the planning process, involving significant others, generating focus on assets and capacities, identifying and providing access to integrated community settings, and promoting acceptance of set backs as part of the path to success.
45967354|NCT00231933|Behavioral|Community integration (CI)|CI includes recovery group sessions and community integration activities.
45967355|NCT00231933|Behavioral|Illness management recovery (IMR)|IMR focuses on nine topic areas: recovery strategies; facts about psychosis; a stress-vulnerability model; building social support; reducing relapses; effective use of medications; coping with stress; coping with problems or symptoms; and meeting health care needs.
45967356|NCT01086982|Drug|Octreotide acetate LAR|30 mg, single dose
45967357|NCT01086982|Drug|Sandostatin LAR ® (octreotide acetate LAR) 30 MG|30 mg, single dose
45967358|NCT00410930|Biological|Subcutaneous immunotherapy - Recombinant birch pollen|
45967359|NCT00228969|Drug|RWJ-333369|
45967360|NCT00410969|Device|ThermoSuit(R) System|The LRS ThermoSuit System is used to cool patients using direct contact of the skin with cold water.
46080505|NCT05906433|Drug|Kenalog with bupivacaine Injection|Indications, relevant for this study include Kenalog injection for knee pain from osteoarthritis or inflammatory arthritis. A single injection to a patient who has no known allergies to anesthetic or corticosteroids would be administered during a scheduled clinical visit.
46080506|NCT05906420|Diagnostic Test|ASTRAL prognostic score|ASTRAL prognostic score
45667955|NCT02388776|Device|ROTEM|A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
45967361|NCT00231972|Behavioral|Project Enhance|The behavioral intervention will be administered by a trained medical social worker on an individual basis. It will include an education component, as well as motivational and behavioral skills enhancement. Treatment will occur for only the first 3 months, after which follow-up sessions will be held every 3 months for the remainder of the year.
45667956|NCT02316548|Radiation|Intensity-Modulated Radiation Therapy|Postoperative adjuvant IMRT radiotherapy 50.4 Gy in 28 fractions. In patients not getting postoperative adjuvant chemotherapy the radiation treatment must begin within 140 days after cystectomy. For patients getting adjuvant chemotherapy radiation treatment must start within 49 days of completing chemotherapy.
45667957|NCT02281760|Drug|Dabrafenib Mesylate|Description: Dabrafenib mesylate (GSK2118436B) is a potent and selective BRAF kinase inhibitor. This inhibition suppresses downstream activity of pERK, a biomarker, and has antiproliferative activity against BRAF mutant tumors.The mode of action is consistent with ATP competitive inhibition.
46080507|NCT05906394|Procedure|Posterolateral Fusion|Posterolateral spinal fusion is a neurosurgical or orthopaedic surgical technique that joins two or more vertebrae. This procedure can be performed at any level in the spine (cervical, thoracic, lumbar, or sacral) and prevents any movement between the fused vertebrae.
46080508|NCT05906381|Dietary Supplement|Probiotics|A specific probiotics capsule product, containing Streptococcus thermophilus will be given to participants for oral intake for 35 days.
46080509|NCT05906381|Dietary Supplement|Placebo|A specific capsule product, containing microcrystalline cellulose will be given to participants for oral intake for 35 days.
46080510|NCT05906368|Diagnostic Test|ClearSight HPI Monitoring system|Continuous blood pressure monitoring for precision hypotensive event response
45667958|NCT02281760|Drug|Trametinib Dimethyl Sulfoxide|Trametinib dimethyl sulfoxide is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Tumor cells commonly have hyperactivated extracellular signal-related kinase (ERK) pathways in which MEK is a critical component. Trametinib dimethyl sulfoxide inhibits activation of MEK by RAF kinases and MEK kinases.
45824859|NCT02080260|Drug|regorafenib|Single agent drug therapy with regorafenib
45967362|NCT00231972|Behavioral|Standard prevention case management (PCM)|Participants will receive standard PCM for HIV prevention.
46080511|NCT05906368|Diagnostic Test|Standard of Care Blood Pressure Monitoring|Blood pressure (BP) monitoring using a conventional arm cuff and inflation after epidural anesthesia as standard procedure. Standard of care blood pressure monitoring includes measurement of blood pressure at the time of epidural test dose delivery, 3-minute cycles of BP monitoring for 30 minutes after epidural placement, and then BP monitoring every 15 minutes per existing clinical standards for at least 4-hours, or until delivery.
45455685|NCT05789160|Behavioral|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
46080512|NCT05906355|Device|the wearable filtrating artificial Kidney Device|the wearable filtrating artificial kidney device rapidly for rapid relief of fluid overload in patients
45667959|NCT02390531|Drug|Bevacizumab|Varying dosages in 10µl
45667960|NCT02390219|Drug|Lumacaftor|
45667961|NCT02390219|Drug|Ivacaftor|
46080513|NCT05906355|Device|traditional hemodialysis machine|the hemodialysis machine currently used in clinical practice to reduce fluid overload in patients
46080514|NCT05906342|Other|20% fat meal|Provided to participants once throughout duration of study, contains 20% fat
45667962|NCT02334215|Drug|Methadone|Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
45824860|NCT01624194|Drug|Oxytocin nasal spray|24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice daily for 4-weeks.
45824861|NCT01624194|Drug|Placebo|3 x 0.1 mL sprays per nostril twice daily for 4-weeks.
45824862|NCT02079636|Drug|Abemaciclib|Administered orally
45824863|NCT02079636|Drug|Pemetrexed|Administered IV
45824864|NCT02079636|Drug|Gemcitabine|Administered IV
45824865|NCT02079636|Drug|Ramucirumab|Administered IV
45824866|NCT02079636|Drug|LY3023414|Administered orally
45824867|NCT02079636|Drug|Pembrolizumab|Administered IV
45967363|NCT00204854|Behavioral|telephone counseling|
45824868|NCT02079246|Drug|Idalopirdine 60 mg|once daily, encapsulated tablets, orally
45667963|NCT02334215|Behavioral|Patient Navigation|A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
45667964|NCT02334215|Behavioral|Enhanced Treatment as Usual (ETAU)|Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
45667965|NCT02359877|Drug|BCD-054|
45824869|NCT02077374|Drug|IDN-6556|25 mg BID for 28 days
45824870|NCT02077374|Other|Placebo|Placebo BID for 28 Days
45824871|NCT02077140|Drug|MDT-10013|
45824872|NCT02077140|Drug|Standard of care for pain|
45667966|NCT02359877|Drug|Rebif|
45824873|NCT02047110|Drug|placebo for risankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
45824874|NCT02047110|Drug|risankizumab|Risankizumab administered by subcutaneous (SC) injection
45824875|NCT02046564|Drug|ASC-01|
45824876|NCT02046564|Drug|Placebo|
45824877|NCT02046174|Biological|RENCA macrobeads|
45824878|NCT02045862|Drug|Solifenacin succinate|Participants received solifenacin 5 mg orally once a day at the same time each day.
45824879|NCT02045862|Drug|Mirabegron|Participants received mirabegron 50 mg orally once a day at the same time each day.
45824880|NCT02045862|Drug|Placebo to match solifenacin|Participants received placebo to match solifenacin 5 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
45824881|NCT02045862|Drug|Placebo to match mirabegron|Participants received placebo to match mirabegron 50 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
45824882|NCT02075658|Device|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal.
45824883|NCT02075658|Device|Conventional Insufflator and Trocar|Conventional insufflator and trocars are used in standard procedures and will serve as the base for comparison of the study device (AirSeal® System).
45824884|NCT02063880|Other|Urgent ART|Children will be started on HAART <48 hours after enrollment.
45824885|NCT02063880|Other|Early ART|Children will be started on ART after stabilization 7-14 days after enrollment.
45824886|NCT02044848|Drug|Secukinumab|
46080515|NCT05906342|Other|40% fat meal|Provided to participants once throughout duration of study, contains 40% fat
46080516|NCT05906342|Other|60% fat meal|Provided to participants once throughout duration of study, contains 60% fat
45667967|NCT02359877|Drug|Avonex|
45667968|NCT02389829|Drug|Hydromorphone|
45667969|NCT02389829|Drug|Prochlorperazine|
45667970|NCT02389829|Drug|Diphenhydramine|
45667971|NCT02358863|Drug|Modified FOLFOX6|Oxaliplatin 85 mg/m2 IV Day 1 every 14 days Leucovorin 400 mg/m2 IV over 2 hours Day 1 5-FU 400 mg/m2 IV over 2 hours Day 1 5-FU 2400 mg/m2 IV over 46 hours Day 1
45667972|NCT02358863|Drug|Docetaxel/Capecitabine|Docetaxel 30 mg/m2 IV Days 1 and 8 Capecitabine 825 mg/m2 PO BID Days 1-14
45667973|NCT02358863|Drug|Cisplatin/Irinotecan|Cisplatin 30 mg/m2 IV Days 1 and 8 every 21 days Irinotecan 65 mg/m2 IV days 1 and 8 every 21 days
45667974|NCT02358863|Drug|Cisplatin/Docetaxel|Cisplatin 75 mg/m2 IV Day 1 every 21 days Docetaxel 75 mg/m2 IV Day 1
45667975|NCT02358863|Drug|IRI/EPI|Irinotecan IV over 90 minutes Days 1 and 8 every 28 days Epirubicin IV over 10-15 minutes Days 1 and 8 every 28 days
45667976|NCT02358863|Drug|EPI/Docetaxel|Docetaxel 75 mg/m2 Day 1 every 21 days Epirubicin 50 mg/m2 IV Day 2
45667977|NCT02358863|Drug|Irinotecan/Docetaxel|Irinotecan 120 mg/m2 Day 1 every 21 days Docetaxel 50 mg/m2 IV Day 1
45824887|NCT02044848|Drug|Placebo|Placebo
45824888|NCT02044458|Device|Stylette|use of stylette for successful insertion of foley catheter for induction of labor
45824889|NCT04180722|Device|aTouchAway™ platform|Participants will receive multi-component Virtual Transition Intervention. The four components of the intervention comprise: (1) routine virtual clinic visits scheduled at the same frequency as usual care; (2) virtual care plan and action plan for respiratory infection/deterioration and management of ventilator issues; (3) remote, weekly and monthly monitoring of ventilator and cough assist metrics, VAI symptoms, and oxygen saturations; and (4) as needed clinical consultations triggered by identification of abnormal parameters or requested by the VAI or family caregiver.
45824890|NCT04182984|Drug|Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil)|Treatment regimens are determined according to the physician's judgment and preferences of the patients.
45824891|NCT02044302|Drug|Bupivacaine|
45824892|NCT02044302|Drug|Botulinum Toxins|
45824893|NCT02044302|Drug|Analgesics|
45824894|NCT02062944|Drug|Sirolimus|SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.
45824895|NCT02062632|Drug|Doxepin Hydrochloride|Given orally
45824896|NCT02062632|Other|Placebo|Given orally
45824897|NCT02062632|Other|Quality-of-Life Assessment|Ancillary studies
45824898|NCT02062632|Other|Questionnaire Administration|Ancillary studies
45824899|NCT02062398|Device|The Reprieve System|BlueWind Medical neurostimulator for the treatment of neuropathic pain
45824900|NCT02061540|Drug|LUM001|LUM001 oral dose
45824901|NCT02043366|Drug|Normal Saline|Normal Saline is intravenously administrated before anesthesia induction
45824902|NCT02043366|Drug|Butorphanol|Butorphanol is intravenously administrated
45824903|NCT02043366|Drug|Flurbiprofen axetil|Flurbiprofen axetil is intravenously administrated
45824904|NCT02043366|Drug|Remifentanil|Remifentanil is intravenously administrated
45824905|NCT02043366|Drug|Sufentanil|Sufentanil is intravenously administrated
45824906|NCT02060370|Drug|Sunitinib|"Starting dose: 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks."
45824907|NCT02060370|Behavioral|Questionnaire|Questionnaire completion on Day 1 of Cycle 1, and on Day 35 of Cycles 2, 4, and 6.
45667978|NCT02358863|Drug|Docetaxel|Docetaxel 60-100 mg/m2 IV day 1 every 21 days
45667979|NCT02358473|Biological|mogamulizumab|Mogamulizumab will be administered by IV infusion.
45824908|NCT01622088|Drug|Dexpramipexole|Oral tablet 150 mg given twice daily (BID)
45824909|NCT01621542|Biological|WT2725|WT2725 injection Study drug will be administered every 1-4 weeks
45824910|NCT02021292|Drug|Macitentan|Macitentan 10 mg, oral tablet, to be taken once daily.
45824911|NCT02021292|Drug|Placebo|Matching placebo oral tablet, to be taken once daily.
45824912|NCT02059980|Behavioral|Response inhibition training|This is a computerized video game that offers 40 training levels, which aims to enhance the individual's response inhibition performance
45824913|NCT02059980|Behavioral|Placebo Control Training|This placebo control training looks very similar to the response inhibition training program in its appearance. However, it does not offer any practice related to response inhibition capabilities.
45824914|NCT02043132|Drug|Tranexamic Acid|Patients randomized to TXA receive an infusion of the standard dose of Tranexamic acid (10 mg/kg) within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
45824915|NCT02043132|Drug|Placebo|Patients randomized to placebo receive an infusion of 10 mg/kg of normal saline within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
45824916|NCT02059434|Drug|LAS190792 Dose 1|
45824917|NCT02059434|Drug|LAS190792 Dose 2|
45824918|NCT02059434|Drug|LAS190792 Dose 3|
45824919|NCT02059434|Drug|LAS190792 Dose 4|
45824920|NCT02059434|Drug|LAS190792 Dose 5|
45824921|NCT02059434|Drug|LAS190792 Dose 6|
45824922|NCT02059434|Drug|LAS190792 Dose 1 (Part 2)|
45824923|NCT02059434|Drug|LAS190792 Dose 2 (Part 2)|
45824924|NCT02059434|Drug|Tiotropium 18 μg|
45824925|NCT02059434|Drug|Indacaterol 150 μg|
45824926|NCT02059434|Drug|Placebo|
45824927|NCT02059278|Drug|T-2345|T-2345 Ophthalmic Solution
45824928|NCT02059278|Drug|Xalatan|Xalatan (latanoprost 0.005% ophthalmic solution)
46080517|NCT05906342|Other|80% fat meal|Provided to participants once throughout duration of study, contains 80% fat
45455686|NCT05789134|Other|self-sampling kits for STI testing in the laboratory|Participants will receive the self-sampling kits and their submitted samples would be sent to laboratory for testing
45667980|NCT02358473|Drug|Docetaxel|Docetaxel will be administered by IV infusion.
45667981|NCT02357459|Drug|FX006|Single 5 mL IA injection
45667982|NCT02357459|Drug|Placebo|Single 5 mL IA injection
45667983|NCT02357459|Drug|TCA IR 40|Single 1 mL IA injection
45667984|NCT04902599|Procedure|Renuvion/j-Plasma procedure using blunt dissection technique|Renuvion/j-Plasma procedure using blunt dissection technique
45667985|NCT04902599|Procedure|Renuvion/j-Plasma procedure using ultrasound-guided dissection technique|Renuvion/j-Plasma procedure using ultrasound-guided dissection technique.
45824929|NCT04680780|Other|Ketogenic diet|Patients will follow a classical ketogenic diet for 3 months
45824930|NCT04680780|Other|3-days water-fasting|Patients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months. In one of the 3 months they are - if required - allowed to split the 3 days into periods of 1 and 2 days. On all other days of the intervention period they are allowed to eat ad libitum.
45824931|NCT04680780|Other|Control|Patients are allowed to eat ad libitum, but will be advised that low salt intake (< 5-7 g/day) and sufficient fluid intake (>3 l/day) which is considered beneficial in ADPKD.
45824932|NCT04722354|Other|Hyperinsulemic euglycemic clamp|Following a 12-hour overnight fast at the CRU (including abstinence from caffeine containing foods and beverages), insulin sensitivity will be measured using the criterion method of the euglycemic clamp. Participants will have not performed vigorous physical activity for at least the previous 24 h, and be free of acute illness for the prior 2 weeks. An intravenous catheter will be placed in an antecubital vein for subsequent insulin (40 mU/m2-min) and glucose infusions and for stable isotope (6, 6-2H2) infusions to measure insulin sensitivity.
45824933|NCT04722354|Procedure|Muscle Biopsy|One biopsy taken prior to clamp and a second biopsy taken 30-45 min after the start of the clamp. A biopsy of the Vastus Lateralis muscle will be performed on the leg/thigh using the Bergstrom technique.
45824934|NCT04722354|Dietary Supplement|Oral abscisic acid (ABA)|Those in this group will receive ABA (95 µg ABA and 300 mg of corn starch)
45824935|NCT04722354|Other|Placebo|Those in this group will receive placebo (300 mg cornstarch)
45824936|NCT02020512|Drug|0.03% Bimatoprost|0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
45967364|NCT00204893|Drug|calcium formate|Calcium formate - Each uncoated white tablet will contain 650 mg of calcium formate, (equivalent to 200 mg elemental calcium). Nephro-Tech, LLC, will formulate and provide the calcium formate tablets for the study.
45967365|NCT00232011|Drug|Pimecrolimus Cream 1%|Pimecrolimus cream 1 %
45824937|NCT02041962|Behavioral|Chronic Care Model for Mood Disorders|"The mood disorders CCM intervention (Life Goals Collaborative Care) consists of: (a) a web-based patient self-management skills enhancement (CCM-1), (b) enhanced information flow and continuity of care via a care manager (CCM-2), and (c) decision support, or situation-specific evidence-based clinical practice guideline recommendations for providers (CCM-3). The CCM will be implemented utilizing telephonic contact with patients and providers by an Aetna care managers.The care managers will also use the Life Goals web portal as a guide for each session."
45967366|NCT00204971|Dietary Supplement|Enteral glutamine powder|nutritional supplement
45667986|NCT02332889|Biological|Vaccine (autologous dendritic cells)|Prior to vaccination, DC will be thawed, washed once with normal saline containing 1% human serum albumin, and viability will be checked (must be > 70%). Peptide pulsed DC will be placed in 1 ml tuberculin syringe(s) and transferred to the study physician for vaccination
45667987|NCT02332889|Drug|Decitabine and Hiltonol|Patients will receive DAC at a dose of 10 mg/m2/d intravenously (IV) over one hour on days 1-5 of week 1. Hiltonol will be given intramuscularly at the same site immediately following vaccine
45667988|NCT02357147|Drug|Placebo|"Combination Phase - Placebo will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Placebo will be administered IV (intravenous infusion) once weekly until disease progression."
45667989|NCT02357147|Drug|Amatuximab|"Combination Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly until disease progression."
45824938|NCT02041962|Other|Educational Control|
45824939|NCT02041494|Device|Ventralight|
45824940|NCT02041494|Device|Strattice|
45824941|NCT04722042|Other|place-based mapping|Adjusting the electric frequency filters to align with the cochlear place frequency
45824942|NCT04722042|Other|default mapping|Default frequency filter assignments
45824943|NCT04699812|Device|ELECTROCARDIOGRAM (ECG) PATCH WEAR|ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION
45824944|NCT04699266|Device|Assigned Intervention (POD F GF)|The investigational lens (POD F GF )will be implanted to both eyes in subjects with bilateral cataract. Registration of patients and the implantation of the investigational lens (POD F GF) will be conducted in consideration of securing 44 eyes in 22 subjects as the analysis subjects
45824945|NCT04698252|Radiation|Radiotherapy|Radiation therapy for oligometastatic sites
45824946|NCT04698252|Procedure|Surgery|Surgery for oligometastatic sites
45824947|NCT04698252|Other|Radiofrequency ablation|Radiofrequency ablation for oligometastatic sites
45824948|NCT02041104|Dietary Supplement|Bread with added beta-glucans|Participants will daily consume bread with high content of beta-glucans. They will approximately consume 6 g beta-glucans per day in 200 g of bread. Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics
45824949|NCT02041104|Dietary Supplement|Placebo Comparator: Bread without added beta-glucans|Participants will daily consume placebo bread without any added beta-glucans (approximately 200 g per day). Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics.
45824950|NCT02019420|Drug|Tedizolid phosphate|Tedizolid phosphate IV 200 mg once daily
45824951|NCT02019420|Drug|Linezolid|Linezolid IV 600 mg twice daily
45824952|NCT02019264|Drug|Lorcaserin hydrochloride|APD356 10 mg twice daily
45824953|NCT02019264|Drug|Placebo|Placebo twice daily
45824954|NCT02019108|Other|Progressive walking program with toe-out gait modification|Participants in this study group will perform continuous treadmill walking for a minimum of 30 minutes at each session, but the emphasis will be to increase toe-out angle by 10 degrees over that exhibited at baseline. A mirror will be provided for biofeedback and participants will be instructed on its use for achieving the target toe-out angle. Increased walking time and distance will be encouraged the same as for the control group.
45824955|NCT02019108|Other|Progressive walking program|At each scheduled visit, participants will perform treadmill walking for a minimum of 30 minutes depending on the individual's baseline activity level and the stage of the intervention. Emphasis will be solely on increasing walking time and distance to achieve the target of a 40% increase in daily activity.
45824956|NCT02018562|Device|Portex Blueline Ultra Suctionaid Tracheostomy Tube|
45824957|NCT02058966|Drug|Entacapone|Entacapone 200 mg oral dose
45824958|NCT02058966|Drug|Methamphetamine|Methamphetamine 20 mg oral dose
45824959|NCT02058966|Drug|Placebo|capsules compounded to be of similar appearance to the active drugs
45824960|NCT04680000|Behavioral|Brief Cognitive Behavioral Therapy for Chronic Pain (BCBT-CP)|BCBT-CP is the standard of care for behavioral management of acute and chronic pain in the Defense Health Agency Stepped Care Pain Pathway. BCBT-CP is a 7-module, CBT-based intervention for the treatment of acute and chronic pain in the primary care setting. The BCBT-CP manual was developed in a collaboration between the Defense Health Agency and the Department of Veterans Affairs as an intervention tailored for use by Behavioral Health Consultants embedded in Military Health System primary care clinics and Patient Centered Medical Homes. Details on BCBT-CP content can be found in the treatment arm description section of this listing.
45967367|NCT00204971|Other|placebo|placebo control
45967368|NCT00232050|Drug|Omalizumab|
45967369|NCT00205010|Procedure|Lymphoscintigraphy|
45967370|NCT00232089|Drug|Tegaserod|
45967371|NCT00229086|Device|Gatekeeper Reflux Repari System (Device)|
45967372|NCT00205127|Procedure|Cardiac PET imaging- rest and pharmacological stress|
45967373|NCT00232128|Procedure|Radiofrequency Ablation of pulmonary neoplasms|
45967374|NCT00205166|Procedure|Cardiac SPECT imaging Rest and Stress|adenosine perfusion scintigraphy
45967375|NCT00205166|Drug|Caffeine|Caffeine 400 mg po
45967376|NCT00205166|Drug|Caffeine|Caffeine 200 mg po
45967377|NCT00205205|Behavioral|peer mentoring|
45967378|NCT00229125|Drug|Gabapentin|
45967379|NCT00229125|Drug|Lorazepam|
45967380|NCT00205244|Behavioral|Healing images, relaxation and distraction materials|
45967381|NCT00229164|Device|Transcutaneous Electric Nerve Stimulation (TENS)|
45967382|NCT00205283|Drug|Nelfinavir|
45967383|NCT00232167|Drug|Indiplon|
45967384|NCT00232167|Drug|Sertraline|
45967385|NCT00205322|Drug|chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)|
45967386|NCT00232206|Drug|Neoadjuvant Therapy with Cisplatin Plus Docetaxel|
45967387|NCT00229242|Drug|Diuretic-Based or Non-Diuretic Based Hypertension Therapy|
45967388|NCT00232245|Drug|Fish oil|
45967389|NCT00205400|Procedure|medical care delivery model|
45967390|NCT00232284|Drug|sertraline|RCT of sertraline/placebo for those young people who fail to respond within first 4 weeks of study entry
45967391|NCT00232284|Behavioral|Cognitive Behavioural Therapy|An integrated 10-week CBT program for depression/anxiety and comorbid substance use
45967392|NCT00229281|Behavioral|Group therapy|
45667990|NCT02357147|Drug|Pemetrexed|Combination Phase - Pemetrexed 500 mg/m^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
45667991|NCT02357147|Drug|Cisplatin|Combination Phase - Cisplatin 75 mg/m^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
45667992|NCT02356211|Other|Multifactorial Falls Assessment|The Geriatric Multifactorial Falls Assessment Clinic is a component of GERIATRIC-PACT, a frail-elderly primary care patient-centered medical home with care provided by an inter-professional teamlet consisting of a geriatrician, geriatric nurse practitioner, clinical pharmacist, licensed practical nurse, nurse care manager, social worker, and dietitian. GERIATRIC-PACT operates with increased ancillary support compared to Primary Care PACT. Falls assessment patients were referred by primary care providers and were evaluated and treated by the GERIATRIC-PACT teamlet, including ordering of tests and medication adjustment, with an average of two visits and active follow-up for one year.
45824961|NCT04680000|Other|BCBT-CP Booster|The BCBT-CP Booster is a telephone or videoteleconference-based booster contact designed to extend the benefits of the standard of care BCBT-CP intervention. BCBT-CP Booster contacts are not clinical interventions (i.e., no new clinical content is provided), but are intended to help motivate patients to use BCBT-CP module content, problem-solve BCBT-CP skills practice and offer reminders for future appointments. BCBT-CP Booster content was developed using feedback from focus groups with patients who completed standard BCBT-CP treatment in a military primary care clinic. Details on BCBT-CP Booster contacts can be found in the treatment arm description section of this listing.
45824962|NCT02017860|Drug|Everolimus|Everolimus was provided by the investigator in 2.5 mg or 5 mg tablets for daily oral administration.
45824963|NCT02040870|Drug|LDK378|750 mg once daily
45824964|NCT04697472|Device|LIFT System|The LIFT System delivers the ARC Therapy to improve upper extremity function in individuals with tetraplegia.
45824965|NCT04720716|Drug|IBI310|IBI310 IV d1, Q6W
45824966|NCT04720716|Drug|Sintilimab|sintilimab IV d1, Q3W
45824967|NCT04720716|Drug|Sorafenib|Sorafenib 400mg po
45824968|NCT04719624|Device|Adaptos®-Si [0.5-1 mm] (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
45824969|NCT04719624|Device|Adaptos®-Si [1-2 mm] (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
45824970|NCT04719624|Device|Geistlich Bio-Oss (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
45824971|NCT04719624|Procedure|Tooth extraction without bone graft material|After screening and enrollment, subjects will undergo tooth extraction of a single tooth and the socket is filled only by clot. Subject will be followed at 2 weeks, 5 months, and 10 months for healing.
45824972|NCT04719624|Device|Adaptos® (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
45824973|NCT04696068|Other|Porcelain plates|The patients will receive the same food in another presentation : porcelain plates instead of plastic trays
45824974|NCT02016300|Device|Unloader Bracing|The bracing arm patients will be randomly selected and will wear an unloader brace post-operatively during the study period.
45824975|NCT02016300|Device|Non-Bracing|Microfracture performed with no post-operative unloader bracing
45967393|NCT00232323|Behavioral|simulation training|
45967394|NCT00205478|Drug|VX-702|
45967395|NCT00205517|Procedure|Daily interruption of sedation versus sedation algorithm|
45967396|NCT00229320|Behavioral|Group therapy|
45967397|NCT00205556|Procedure|on-line hemodiafiltration|addition of convective transport to regular dialysis treatment by using on-line hemodiafiltration
45967398|NCT00205556|Procedure|low flux hemodialysis|standard treatment
45967399|NCT02962206|Device|Point-of-care ultrasound|After the fracture reduction maneouver, the physician will assess residual dorsal angulation using point-of-care ultrasound. If deemed adequate, the physician will progress to immobilization. If the reduction is not adequate, the physician will attempt further reduction at their discretion.
45967400|NCT02962206|Procedure|Closed fracture reduction|The distal radius fracture will be reduced with using a combination of local anesthetic, sedation, reduction maneouvers and immobiliazation at the discretion of the treating physician
45967401|NCT00205595|Device|Positron Emission Tomography|
45967402|NCT00205634|Drug|Biaxin ( clarithromycin)|
45967403|NCT00232362|Drug|Pioglitazone (Actos)|
45967404|NCT00232362|Drug|Anti-diabetic agent other than pioglitazone or rosiglitazone|
45967405|NCT00205751|Drug|Thalidomide/Dexamethasone vs Melphalan/Prednisone|
45967406|NCT00229437|Drug|TAK-128|TAK-128 5 mg, tablets, orally, once daily for up to 6 months.
45967407|NCT00229437|Drug|TAK-128|TAK-128 50 mg, tablets, orally, once daily for up to 6 months.
45967408|NCT00229437|Drug|TAK-128|TAK-128 100 mg, tablets, orally, once daily for up to 6 months.
45967409|NCT00229437|Drug|Placebo|TAK-128 placebo-matching tablets, orally, once daily for up to 6 months.
45967410|NCT00205790|Device|Vascular graft|
45967411|NCT00205829|Device|battery-powered bion(R) microstimulator system|Stimulation on from initial activation and on.
45967412|NCT00229476|Drug|sertraline (Zoloft)|
45967413|NCT00205907|Biological|BLVR Hydrogel|10 mL BLVR Hydrogel
45967414|NCT00232440|Device|BodyFIX|
45967415|NCT00205946|Drug|Bupropion|150 mg of bupropion administered 5 hours before fMRI scanning
45455687|NCT05789108|Diagnostic Test|Blood sample and Ultrasound examination|"The ultrasound examination is a non-invasive procedure with no risks, adverse reactions, or discomforts associated with the examination. The study blood samples are mostly obtained at the same time as clinical blood sample collection in order to avoid unnecessary complications.~The inclusion and ultrasound examiniation is performed by the patient responsible physician at the Emergency Department. Blood samples during the study period are performed by trained study staff."
45455688|NCT05789043|Drug|camrelizumab+apatinib+TMZ|camrelizumab 200mg，q2w+apatinib 250mg，qd+TMZ 200mg/m2，day1-5/28
45967416|NCT00205946|Drug|Placebo|Administered 5 hours prior to fMRI scanning (randomly assigned, double blind)
45967417|NCT00229515|Other|abciximab followed by implantation of bare metal stent|Patients will receive infusion of abciximab at standard regimen before undergoing intervention for STEMI and then bare metal stent implantation in the culprit lesion
45967418|NCT00229515|Other|abciximab and Sirolimus eluting stent|Patients will receive abciximab infusion at standard regimen followed by implantation of sirolimus-eluting stent in the culprit lesion
45967419|NCT00229515|Other|tirofiban and bare metal stent|Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with bare metal stent implantation
45667993|NCT02332655|Drug|Cannabidiol|"Initiation of treatment will begin with 2mg/kg/day. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.~The dose of concomitant antiepileptic drugs will remain unchanged during the first 12 weeks of CBD treatment (or until 8 weeks after steady state at final dose), unless symptoms of toxicity and/or significant changes in blood levels are observed."
45667994|NCT02388737|Drug|Vonoprazan|Vonoprazan tablets
45667995|NCT02388737|Drug|Lansoprazole|Lansoprazole capsules or tablets
45667996|NCT02388737|Drug|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
45667997|NCT02388737|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
45667998|NCT02355743|Drug|rtPA lock therapy|"rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks. rtPA will be given as research intervention as lock therapy in that it will dwell within the catheter of the CVAD for a specified duration of time and then be removed (aspirated); in this setting the medication is not given to the patient as a flush, i.e. in systemic fashion."
45667999|NCT02388347|Drug|Placebo SC|Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
45967420|NCT00229515|Other|tirofiban and sirolimus-eluting stent|Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with sirolimus-eluting stent implantation
45967421|NCT00205985|Device|Scaphoid screw|Conservative treatment versus application of scaphoid screw
45967422|NCT00206024|Drug|Esomeprazole magnesium (Nexium)|
45967423|NCT00206063|Drug|EXANTA|
45967424|NCT00232518|Procedure|Infection with hookworm larvae|
45967425|NCT00206141|Drug|Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)|
45967426|NCT00229593|Drug|Nestorone gel|2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment
45967427|NCT00229593|Drug|Testosterone Gel|100 mg Testosterone gel daily for 3 weeks
45967428|NCT00229632|Drug|Idebenone|Idebenone is a short-chain benzoquinone derivative of similar structure to ubiquinone (coenzyme Q10). This compound was synthesized and developed initially by Takeda Chemical Industries, Ltd. (Osaka, Japan) and designated as CV-2619. The chemical name for idebenone is 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benxoquinone. Santhera Pharmaceuticals (Liestal, Switzerland) LLC, will supply drug for this study as specified by a clinical trial agreement.
45967429|NCT00206180|Drug|esomeprazole magnesium (oral medication)|
45967430|NCT00206219|Drug|Gefitinib|
45967431|NCT00206219|Drug|methotrexate|
45967432|NCT00206258|Drug|Pramlintide and glucagon|
45967433|NCT00206297|Drug|Pramlintide|
45967434|NCT00411047|Drug|gefitinib|oral drug taken daily around the same time
45967435|NCT00229671|Other|Survey 1|During the initial survey, we reviewed dispensed medications by having parents of patients with prescriptions under 21 read the medication label. We then asked questions about potential side effects, method of medication administration, communication regarding the medication with the pharmacist and the health care provider, and demographic information. Research assistants underwent several weeks of training to ensure a standardized approach to surveys.
45967436|NCT00229671|Other|Survey 2|If the parent completed the initial survey, we attempted a second survey 2 months after the index visit to capture persistent symptoms. Surveys were translated and back translated into Spanish and Cambodian and conducted by fluent bilingual interviewers. Surveys were pretested and revised based on 2 focus groups of parents representing a broad array of socioeconomic backgrounds.
45967437|NCT00411125|Drug|Oral salmon calcitonin|
45967438|NCT00229710|Drug|Tesaglitazar|0.5 in combination with insulin (with or without other oral antidiabetic drugs)
45967439|NCT00411164|Drug|OROS hydromorphone HCI (slow release)|
45967440|NCT00411203|Drug|Tamoxifen Citrate|
45455689|NCT05789043|Drug|camrelizumab+apatinib|camrelizumab 200mg，q2w+apatinib 250mg qd
45455690|NCT05789043|Drug|camrelizumab|camrelizumab 200mg，q2w
45668000|NCT02388347|Biological|MEDI7836 Dose 1|Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.
45668001|NCT02388347|Biological|MEDI7836 Dose 2|Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.
45824976|NCT02040090|Drug|Active rabies vaccine (US-FDA approved)|A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.
45967441|NCT00411203|Drug|Placebo|
45967442|NCT00232635|Drug|A-60444|
45967443|NCT00229749|Drug|AVI-4065 Injection|
45967444|NCT00411281|Drug|cytarabine|Given subcutaneously
45967445|NCT00411281|Procedure|observation|No intervention
45967446|NCT00206414|Drug|Iressa Day 1 given with Arimidex and Faslodex|timing of administration of iressa is the study factor
45824977|NCT04719390|Behavioral|TMI Component|The text messaging intervention will include 2 motivational interviewing components and 2 cognitive behavioral therapy components, targeting motivation and coping, and taking a harm reduction approach.
45824978|NCT02058498|Behavioral|Physical activity|Participants will be provided physical activity walking instructions and asked to record their daily activity on an activity log. Participants will be given the International Physical Activity Questionnaire and asked about their quality of life at baseline, at 6 weeks and at 4 months.
45967447|NCT00206414|Drug|Iressa Day 21 given with Arimidex and Faslodex|Timing of Iressa is the study factor
45967448|NCT00232674|Drug|Pulmicort (budesonide) Turbuhaler|
45967449|NCT00206453|Drug|Taxotere|Chemotherapy IV
45967450|NCT00206492|Drug|Iressa|Iressa
45967451|NCT00206492|Drug|Tamoxifen|Tamoxifen
45967452|NCT00413595|Other|No intervention|Observational, epidemiological, prognosis study; no drug tested; only laboratory analysis and diagnostic interventions done.
45967453|NCT00206570|Drug|Estradiol|
45668002|NCT02388347|Biological|MEDI7836 Dose 3|Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.
45967454|NCT00206609|Procedure|Oxygen and air administration|
45967455|NCT00424671|Drug|Licarbazepine|
45967456|NCT00206648|Drug|Betaferon/Betaseron|Betaseron 250 µg SC every other day
45967457|NCT00206648|Drug|Betaferon/Betaseron|Avonex 30 µg IM once per week
45967458|NCT01056159|Drug|Albuterol dry powder inhaler|Albuterol DPI (dry powder inhaler) delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol will be given on two treatment days (3 to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol in a DPI (dry Powder inhaler) and albuterol in an HFA MDI (hydrofluoroalkane metered dose inhaler), ProAir. One inhaler will contain active drug and one inhaler will contain placebo.
45455691|NCT05789030|Drug|Diprospan plus iguratimod|Patients are treated with Diprospan (1mL im) and then with iguratimod (25mg bid) for 12 months.
45967459|NCT01056159|Drug|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler) delivers 90mcg of albuterol with each inhalation. Albuterol will be given on two treatment days (3to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol DPI (dry powder inhaler) and the comparator inhaler, albuterol HFA MDI (hydrofluoroalkane metered dose inhaler).One inhaler will contain active drug and one inhaler will contain placebo.
45967460|NCT00232791|Device|Cypher Select|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
45967461|NCT00232791|Device|Cypher|CYPHER™ Sirolimus-eluting Coronary Stent
45967462|NCT00206765|Drug|Risperidone|
45967463|NCT00206765|Drug|Paroxetine|
45455692|NCT05789030|Drug|Diprospan plus leflunomide|Patients are treated with Diprospan (1mL im) and then with leflunomide (10-20mg qd) for 12 months.
45455693|NCT05789030|Drug|Prednisone plus leflunomide|Patients are treated with prednisone (20 mg qd and taper to ≦ 5mg in 3 months) and leflunomide (10-20mg qd) for 12 months.
45455694|NCT05789017|Drug|Prednisone and Mycophenolate Mofetil|Patients are treated with glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 4 months.
45455695|NCT05789017|Drug|Mycophenolate Mofetil|Patients are treated with low dose mycophenolate (0.5-1g/day) during remission maintenance period for 9 months.
45455696|NCT05789017|Drug|Leflunomide|Patients are treated with leflunomide (10-20 mg/day) during remission maintenance period for 9 months.
45967464|NCT00424710|Drug|ranibizumab intravitreal injection|liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year
45967465|NCT00206843|Device|Triage BNP Test|
45967466|NCT00206882|Drug|corticosteroids|
45967467|NCT00232830|Device|drug-eluting stent|Cypher Sirolimus-eluting Coronary Stent
45967468|NCT00232830|Device|bare-metal stent|any bare-metal stent brand
45967469|NCT00206921|Device|Pulsed dye laser|
45967470|NCT00206921|Device|Intense pulsed light|
45967471|NCT00206960|Drug|zuclopenthixol|Patients will be administered zuclopenthixol orally in doses between 4 -24 mg/day, depending on an effective reduction of symptoms
45967472|NCT00206960|Drug|risperidone|Patients will be administered risperidone orally in doses between 1-6 mg/day, depending on an effective reduction of symptoms
45967473|NCT00232869|Device|drug-eluting stent|Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
45967474|NCT00232869|Device|bare-metal stent|SMART™ bare-metal stent
45967475|NCT00206999|Drug|imipramine|Either 50 mg of imipramine or placebo will be administered to healthy male volunteers
45967476|NCT00229944|Drug|Azithromycin|
45668003|NCT02388347|Biological|MEDI7836 Dose 4|Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.
45668004|NCT02355665|Drug|Nicotine Spray|Nicotine Spray
45668005|NCT02355665|Drug|Placebo|Placebo to match nicotine spray
45668006|NCT02010255|Drug|LDV/SOF|LDV/SOF FDC tablet administered orally once daily
45668007|NCT02010255|Drug|RBV|RBV tablets administered orally in a divided daily dose
45668008|NCT04666701|Drug|Escócia association|Escócia association tablet
45668009|NCT04666701|Other|Placebo Ketorolac|Placebo Ketorolac tablet
45668010|NCT04666701|Other|Placebo Scopolamine|Placebo Scopolamine dragee
45668011|NCT04666701|Drug|Ketorolac Tromethamine|Ketorolac tablet
45668012|NCT04666701|Drug|Scopolamine|Scopolamine dragee
45824979|NCT02039778|Radiation|Stem Cell Radiotherapy (ScRT) and Temozolomide|"Stem Cell Radiotherapy (ScRT) and Temozolomide:~The postoperative surgical bed + edema + margin & the ipsilateral subventricular zone (contoured as a 5mm rim of tissue around the ipsilateral lateral ventricles) will be included within the initial target volume and treated to 46 Gy in 23 fractions. After 46 Gy, the conedown or boost volume (surgical cavity + margin) will be treated to a total of 60 Gy, with seven additional fractions of 2 Gy each (14Gy boost dose).~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays)."
45967477|NCT00207077|Drug|Cetuximab + Erlotinib|IV solution + tablet, IV+ oral, ERB 100 mg/m2, 200 mg/m2, 250 mg/m2 IV + Erl 150 mg tablet, ERB weekly/ Erl once daily, Until disease progression.
45967478|NCT00229983|Behavioral|Motivational Enhancement Therapy|Three 60 minute counseling sessions using a structured, developmentally appropriate approach to identification of drug- and alcohol- related risks and problems, and establishment of goals for behavioral change.
45967479|NCT00207116|Drug|Cetuximab|IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.
45967480|NCT00232908|Drug|ARV regimen|As prescribed
45967481|NCT00232908|Drug|enfuvirtide [Fuzeon]|90mg sc bid for 12 weeks
45967482|NCT00207155|Drug|Cetuximab|IV solution, IV, 400 mg/m2 initial dose + 250-400 mg/m2 weekly, Weekly, Until disease progression.
45967483|NCT00230061|Biological|HBVAXPRO, Hepatitis B (Recombinant) vaccine, 10 mcg/ml|
46080518|NCT05906329|Radiation|Low-dose radiotherapy combined with conventional fractionated radiotherapy|Select the primary lesion, the largest metastatic lesion, or the lesion causing symptoms, and perform routine segmentation (1.8-2Gy/f, 40Gy-60Gy). For the remaining lesions, at least one easily assessable and measurable lesion should be selected as the observation lesion. Unselected lesions (≤ 10) should be given 1.6Gy/f, 1f/w, 4-6 times in total.
46080519|NCT05906290|Other|Multigenerational eHealth Intervention for Grandparents and Grandchildren|Participants in this group will use an online program for 30-45 minutes per week over the course of 2 weeks delivered via smartphone, focusing on increasing physical activity.
45668013|NCT04666701|Other|Placebo Escócia association|Placebo Escócia association tablet
45967484|NCT00232947|Biological|Influenza virus vaccine (Fluviral)|
45967485|NCT00232947|Biological|Influenza virus vaccine (Fluzone)|
45668014|NCT02354417|Biological|Biological: ProHema-CB|Each subject will receive one administration of ProHema-CB unit transplant.
45824980|NCT02015754|Drug|DEBIRI|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in DC Beads and injected in the tumor.
45824981|NCT02015754|Device|LC Bead M1|The LC Bead M1, loaded with irinotecan (DEBIRI-M1) to treat patients with hepatic metastases from colorectal cancer.
45824982|NCT02015754|Procedure|TACE|TACE a minimally invasive procedure performed to restrict a tumor's blood supply.
45824983|NCT04441944|Other|Telemedicine|Use of provider-to-provider telemedicine
45967486|NCT00413673|Procedure|PRK|PRK
45668015|NCT02332187|Device|Active electrical stimulation using an All Stim stimulator|This is an FDA approved stimulator that is used for strengthening the quadriceps muscle.
45668016|NCT02332187|Device|Sham electrical stimulation using an All Stim stimulator|With this intervention the All Stim unit is turned off and no electrical stimulation is provided.
45668017|NCT02330549|Drug|Cenicriviroc 150 mg|Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food.
45824984|NCT02015676|Drug|trastuzumab|Initial loading does of 4 mg/kg IV, followed by 2 mg/kg IV weekly, until disease progression
45967487|NCT00207194|Behavioral|Automated Telephone Program|The intervention incorporated principles of social cognitive theory, the transtheoretical model of behavioral change, and motivational interviewing, and was tailored to the user's values. Content was also adapted to cultural characteristics of culturally African-American adults (i.e., not Caribbean-American, Black-Hispanic, etc.). These participants also received the same health behavior education those in the control condition received.
45967488|NCT00207194|Behavioral|Health Behavior Education|Participants received a 75-page resource manual that described hypertension, listed dietary recommendations, heart healthy food recipes, and local resources for exercise, and provided information to support antihypertensive medication adherence. They received a 20-min education session based on the content of this manual, and were given a pedometer and a digital weight scale (Healthometer, model # HDR900KD01).
45967489|NCT00230139|Device|SPECT/CT|
45967490|NCT00207233|Behavioral|MCT oil hypocaloric liquid diet|"The MCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 34 grams MCT oil (Life Enhancement Products, Inc. Petaluna, CA; 8.3 kcal/gm) added per day to the HMR shakes.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study."
45967491|NCT00207233|Behavioral|LCT hypocaloric liquid diet|"The LCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 31.5 grams LCT oil (corn oil; 9 kcal/gm) per day. Both diets will be isocaloric (1083 kcal/day) consisting of 38% CHO, 28% pro, 34% fat.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study."
46080520|NCT05906277|Diagnostic Test|Biopsy|Liquid biopsy, re-biopsy, tissue biopsy
46080521|NCT05906264|Behavioral|Tele-intervention|Tele-intervention every week to check compliance and encourage the rehabilitation
45668018|NCT02330549|Drug|Placebo|Placebo-matching CVC administered orally once daily and taken every morning with food.
45668019|NCT02009865|Drug|Epanova|Epanova will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
45824985|NCT02015676|Drug|paclitaxel|60 mg/m^2 IV weekly; dose increased to 70 mg/m^2, and subsequently 80 mg/m^2, after 2 treatment cycles with no evidence of DLT until disease progression
45824986|NCT02015676|Drug|Myocet|40 mg/m^2 IV weekly; dose increased to 50 mg/m^2 IV after 2 treatment cycles with no evidence of DLT for 6 cycles
45824987|NCT02015520|Drug|Clazakizumab|
45824988|NCT02015520|Drug|Placebo (Matching with Clazakizumab)|
45824989|NCT02058108|Drug|Telbivudine|Patients of any age and weight< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily
45824990|NCT02058108|Drug|Placebo|Patients of any age and weight < 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
45824991|NCT04678986|Other|ER2|No intervention, data analysis only
45824992|NCT04417374|Other|Description of groups caracteristics|Comparison of the two groups on all the following criterias : age, sex, if the patient lives alone, the matter of hospitalization, its lengh, their primary psychiatric diagnostic, the use of toxics at the moment of the hospitalization and if this psychiatric decompensation happens in a context of treatment interruption.
45824993|NCT04693884|Drug|Cannabis|Cannabis of (~10% THC concentration <1% CBD concentration) will be smoked.
45824994|NCT04693884|Drug|Cannabis|Cannabis of (~10% THC concentration <1% CBD concentration) will be vaporized.
45824995|NCT04693884|Drug|Cannabis|Cannabis of (~10% CBD concentration <1% THC concentration) will be smoked.
45824996|NCT04693884|Drug|Cannabis|Cannabis of (~10% CBD concentration <1% THC concentration) will be vaporized.
45824997|NCT04678362|Drug|Talazoparib + Avelumab|Patients will receive the combined treatment until the investigator considers that the patient no longer obtains benefit from it. The treatment will be continued until disease progression, unacceptable toxicity or discontinuation for any cause.
45824998|NCT02057874|Device|3 Tesla Magnetic Resonance Imaging|3T MRI consists of a series of radiofrequency (RF) pulse sequences optimized for acquiring CEST-, MT-, DW-, and DCE-MRI data in one seamless imaging examination. For DCE, MR contrast agent will be intravenously administered.
45824999|NCT02057874|Drug|Magnevist® (Intravenous (IV) administration of MRI contrast agent)|For the acquisition of DCE-MR data, the FDA-approved contrast agent Magnevist® (gadopentetate dimeglumine, 0.1 mmol/kg) will be delivered intravenously by the MR technologist at a rate of 2 mL/sec (followed by a saline flush) via a power injector after the acquisition of a set of baseline dynamic scans. The entire sequence lasts approximately 8 minutes.
45825000|NCT04678050|Drug|Ketamine/ propofol|ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h.
45825001|NCT04678050|Drug|Dexmedetomidine|Dex solution (4 µg/mL). A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h
45825002|NCT04677426|Drug|Hyperpolarized Xe129|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to assess patients with cHP and IPF.
45825003|NCT02038920|Drug|Vedolizumab|Vedolizumab IV injection
45825004|NCT02038920|Drug|Vedolizumab placebo|Vedolizumab placebo-matching IV infusion
45825005|NCT02038764|Drug|Placebo|Placebo
45825006|NCT02038764|Biological|PF-06342674 Dose A|Multiple SC Doses
45825007|NCT02038764|Biological|PF-06342674 Dose B|Multiple SC Doses
45825008|NCT02038764|Biological|PF-06342674 Dose C|Multiple SC Doses
45825009|NCT02038764|Biological|PF-06342674 Dose D|Multiple SC Doses
45825010|NCT02057718|Drug|LUM001 (Maralixibat)|LUM001 also known as Maralixibat (MRX) oral dose up to twice a day (BID).
45668020|NCT02009865|Drug|Olive Oil|Olive oil will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
45668021|NCT01620177|Drug|Alcohol(oral) and placebo|Subjects will be dosed to an approximate peak BAC of 0.065%. Subjects will be tested on the decline such that subjects will be at or above the goal BAC (0.05%) throughout the drive
45668022|NCT01620177|Drug|Cannabis(THC)(Inhaled) and Placebo|Cannabis vapor is produced from 500 mg either placebo (0% THC), approximately 2.5-3.5% THC (low dose), or approximately 6.0-7.5% THC (high dose) bulk cannabis plant material to yield doses of approximately 0, 12.5-17.5, or 30-37.5 mg THC
45668023|NCT02075541|Biological|NTHi-10-AS01E|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
45668024|NCT02075541|Drug|NaCl Placebo|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
45825011|NCT04693260|Device|Visual Acuity with a Hand-held Device Supported by Mobile App.|The Insight will be compared to a standard ETDRS eyechart
45825012|NCT04177836|Behavioral|Mindfulness intervention|Participants will either complete a mindfulness intervention or active control for 2 weeks on their smartphone
45825013|NCT01622868|Other|Laboratory Biomarker Analysis|Correlative studies
45825014|NCT01622868|Drug|Lapatinib Ditosylate|Given PO
45825015|NCT01622868|Radiation|Stereotactic Radiosurgery|Undergo SRS
45825016|NCT01622868|Radiation|Whole-Brain Radiotherapy|Undergo WBRT
45825017|NCT02014740|Drug|Liraglutide|Liraglutide (Victoza) is an acylated analogue of glucagon-like peptide-1 (GLP-1) indicated for the treatment of type 2 diabetes mellitus• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued. .
45825018|NCT02014740|Drug|Metformin|
46080522|NCT05906251|Genetic|SRP-6004|Single IV infusion of SRP-6004
45967492|NCT00207233|Procedure|Subcutaneous abdominal adipose tissue biopsy|"Subcutaneous adipose tissue biopsies from human subjects will provide tissue samples for ex vivo analysis of adipocytokine production and cell size. Subcutaneous adipose tissue will be sampled by needle biopsy at the suprailiac crest skinfold using standard sterile technique. After a 10 cm area is isolated, cleaned and anesthetized with 1% lidocaine, a small cutaneous incision (1 cm) will be performed. A 50 cc syringe with a 19-gauge needle will be used to aspirate approximately 150 mg of adipose tissue which will require 2 to 6 passes of the needle. Sutures will be used to close the skin incision and a dry sterile dressing applied.~This will be performed at baseline, 6 weeks, and 12 weeks."
45967493|NCT00413712|Drug|Calcium Channel Blocker & Adenosine|
45967494|NCT00207272|Behavioral|1170-1870 kcal/day liquid diet|
45967495|NCT00207272|Procedure|Gastric bypass surgery|
45967496|NCT00207272|Procedure|Biopsy.visceral adipose tissue|
46080523|NCT05906238|Behavioral|STEREOBES Workshops|These workshops are designed to help patients develop appropriate behaviors to deal with stigmatizing situations. They will focus on three main areas: adapted physical activities, nutrition and mental well-being. They will include sessions on developing self-esteem, improving body image and managing emotions. The aim will be to deconstruct the myths and stereotypes surrounding obesity.
46080524|NCT05906238|Behavioral|Un Poids en moins|"Standard intervention proposed by La Vie la Santé"
45825019|NCT02014584|Drug|Dutasteride|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of dutasteride to be administered orally.
45967497|NCT00207272|Procedure|Biopsy.omental adipose tissue|
45967498|NCT00207272|Procedure|Biopsy. subcutaneous abdominal adipose tissue|
45967499|NCT00207272|Procedure|Blood sample|
45967500|NCT00230217|Drug|Rasburicase (SR29142)|
45967501|NCT00207311|Drug|Xenical, Pegasys, Copegus|Xenical 120mg three times daily for 36 weeks or xenical placebo (Arm 1). Pegasys 180 mcg weekly for 48 weeks. Ribavirin daily for 48 weeks.
45967502|NCT00207311|Behavioral|Xenicare Program|Xenicare program for 36 weeks.
46080525|NCT05906225|Procedure|EEG guided anesthesia|Monitoring of electroencephalogram via Sedline probe by MASIMO corporation. Adjust concentration of inhalational sevoflurane during anesthesia, according to component of slow&delta wave and alpha wave, so that slow/delta oscillation (with or without alpha oscillation) is maintained.
45825020|NCT02014584|Drug|Placebo|Dutasteride matching placebo will be supplied as capsules to be administered orally.
45825021|NCT02014272|Drug|RIN 150|Each subject will receive a single oral dose of 4 fixed dose combination tablets (RIN 150) each contains 150 rifampicin and 75 mg isoniazid.
45825022|NCT02014272|Drug|reference drugs|Each subject will receive a single oral dose of 4 x 150 mg rifampicin capsules and 3 x 100 mg isoniazid capsules.
45825023|NCT04963452|Other|Dural puncture epidural|Parturients, between 18 and 45 years of age, with cervical dilation less than 5 cm were consented to receive a DPE technique, with a single dural puncture with a 26-gauge spinal needle. After successful placement of the epidural catheter and puncturing the dura; 20 mL of bupivacaine 0.25% was administered through the epidural catheter and a patient-controlled epidural infusion of bupivacaine was initiated.
45825024|NCT02037984|Biological|Prevnar 13®|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 µg each), and 6B (4.4 µg) in each 0.5 mL dose.
45825025|NCT02037984|Biological|V114 1x:1x:1x|V114 1x:1x:1x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 125 µg of Aluminum Phosphate Adjuvant (APA).
45825026|NCT02037984|Biological|V114 2x:2x:2x|V114 2x:2x:2x contains 4.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
45825027|NCT02037984|Biological|V114 2x:1x:2x|V114 2x:1x:2x contains 4.0 μg of polysaccharide serotypes 6A, 18C, 19A, 19F, and 23F; 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 7F, 9V, 14, 22F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
45825028|NCT02037984|Biological|V114 1x:1x:2x|V114 1x:1x:2x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
46080526|NCT05906225|Procedure|Conventional anesthesia|Adjust concentration of inhalational sevoflurane during anesthesia, according to vital signs, so that mean blood pressure and heart rate are maintained between 80% and 120% of baseline values measured at ward before anesthesia.
46080527|NCT05906212|Procedure|Non-penetrating deep sclerectomy and phacoemulsification and autotransplantation of anterior lens capsule|This group will be undergoing nonpenetrating deep sclerectomy and phacoemulsification with autotransplantation of anterior lens capsule.
45825029|NCT02037984|Biological|V114 0.5x:0.5x:2x|V114 0.5x:0.5x:2x contains 1.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 2.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
45825030|NCT02057406|Drug|2:1 EPA/DHA|400 Eicosapentaenoic acid/200 docosahexaenoic acid fish oil 2 grams
45967503|NCT04721496|Behavioral|Power and Speed|"Analysis of the power and speed of execution in 6 conditions of increasing instability Situation 1 is stable and basic execution. Condition 6 is the most unstable.~The participants performed 2 series of 3 repetitions in each of the situations. All the exercises were executed on the same day."
45967504|NCT00207350|Device|Interstitial Laser Therapy|Device
45967505|NCT00233025|Drug|Duloxetine|
45967506|NCT00233025|Drug|Placebo|
45967507|NCT00207428|Drug|Carbamazepine|
45967508|NCT00207467|Behavioral|Patient-delivered partner treatment|
45967509|NCT00207467|Behavioral|Booklet-enhanced partner referral|
45967510|NCT00233142|Behavioral|Expressive writing|Writing as therapeutic intervention
45967511|NCT00233142|Behavioral|Neutral writing|Non-expressive writing
45967512|NCT00207506|Behavioral|HoMBReS: A lay health advisor approach to STD prevention|
45967513|NCT00230295|Procedure|IMR LAG|
45967514|NCT02962700|Device|muscle microdialysis|Systemic haemodynamics and interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.
45967515|NCT00230334|Drug|Gleevec|
45967516|NCT00207584|Drug|Doxycycline treatment|
45967517|NCT00207623|Behavioral|Arthritis Basics for Change Education program|
45668025|NCT02330081|Device|Mirasol treatment of whole blood|"Subject will be infused with two products at the same time:~radio-labeled platelets derived from subject's stored whole blood which has been treated with Mirasol.~radio-labeled platelets derived from subject's untreated fresh whole blood."
45668026|NCT01986855|Drug|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
45967518|NCT00207662|Drug|infliximab or placebo|
45668027|NCT01986855|Drug|Placebo 5 mg|Placebo to ertugliflozin, oral, tablet, 5 mg tablet once daily for 52 weeks
46080528|NCT05906212|Procedure|Non-penetrating deep sclerectomy and phacoemulsification|This group will be undergoing nonpenetrating deep sclerectomy and phacoemulsification alone.
45668028|NCT01986855|Drug|Ertugliflozin 10 mg|Ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
45825031|NCT02057406|Drug|High EPA|
45668029|NCT01986855|Drug|Placebo 10 mg|Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
45825032|NCT02057406|Other|Placebo|
45825033|NCT02036580|Biological|tralokinumab cohort 1|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
45825034|NCT02036580|Biological|tralokinumab cohort 2|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
45825035|NCT02036580|Other|Placebo|
45668030|NCT02075463|Drug|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863
45825036|NCT02014116|Drug|LY3009120 capsule|Administered orally.
45825037|NCT02057250|Drug|Sarilumab|Pharmaceutical form: Solution Route of administration: Subcutaneous
45825038|NCT02057250|Device|Auto-Injector Device (AID)|
45967519|NCT00233181|Behavioral|Home-based adherence monitoring|
45967520|NCT00207701|Drug|infliximab|
46080529|NCT05906199|Drug|Renexin CR 200/160mg|Single oral administration of Renexin CR 200/160mg, QD
46080530|NCT05906199|Drug|Aspirin 100mg|Single oral administration of Aspirin 100mg, QD
46080531|NCT05906186|Behavioral|kiwifruit|eating two kiwifruits a day
46080532|NCT05906147|Other|Regular follow-up|Follow-up of the population was conducted to track the incidence of fractures
45668031|NCT02075463|Drug|Placebo|Matching placebo tablet for GSK1278863
45668032|NCT02353871|Biological|Botulinum toxin type A|A solution containing 50 U in 0.25 mL (200 U/mL). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL, containing 50 U of BTX-A-HAC NG (i.e. 10 U/0.05 mL) was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
45668033|NCT02353871|Drug|Placebo|A solution containing only the excipients of BTX-A-HAC NG (identical in appearance to the active product). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
45825039|NCT02057250|Device|Pre-filled Syringe (PFS)|
45825040|NCT02057250|Drug|Methotrexate|Dispensed according to local practice.
45825041|NCT02057250|Drug|Sulfasalazine|Dispensed according to local practice.
45825042|NCT02057250|Drug|Leflunomide|Dispensed according to local practice.
45825043|NCT02057250|Drug|Hydroxychloroquine|Dispensed according to local practice.
45825044|NCT04676490|Other|RECORD-ED Card|Low-cost and low-tech recordable audio card containing language-concordant discharge instructions for families of children under age 10 presenting to the ED for asthma exacerbations with no or public insurance and a preference for English or Spanish. Recordable cards allow for multiple audio reviews of the instructions by multiple caregivers without dependence on access to the internet or smartphone technologies.
45825045|NCT04676490|Other|RECORD-ED Patient Portal|Audio recorded, language concordant discharge instructions via patient portal
45825046|NCT02036502|Biological|Pembrolizumab|Intravenous (IV) infusion
45825047|NCT02036502|Drug|Lenalidomide|Oral capsule
45825048|NCT02036502|Drug|Dexamethasone|Oral tablet IV infusion
45825049|NCT02036502|Drug|Carfilzomib|IV infusion
45825050|NCT02056626|Drug|carvedilol|
45825051|NCT02035332|Device|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
45825052|NCT02056392|Drug|Selumetinib|Volunteers will receive 75 mg selumetinib oral dose (Treatment A)
45825053|NCT02056392|Drug|Moxifloxacin|Volunteers will receive 400 mg Moxifloxacin oral dose (Treatment B)
45967521|NCT00233220|Behavioral|Multicomponent, multi-level intervention targeted at physicians and patients|The patient intervention will include an innovative patient education approach known as Self-Paced Programmed Instruction that will be used to educate patients on knowledge of HTN; behavioral counseling by trained C/MHC dieticians on lifestyle modification; and home BP monitoring to activate patients in their own care. The physician intervention comprises online continuing medical education (CME) courses on management of HTN based on the Joint National Committee-7 (JNC-7) guidelines; online HTN rounds or case conferences with HTN specialists; and feedback to physicians on clinical performance measures via computerized decision support systems. The intervention will be delivered to patients every 3 months during regular office visits for 12 months, while the physician intervention will occur every month for the duration of the trial.
45455697|NCT05789004|Procedure|Tooth Bleaching with Whiteness HP Automixx 35%|"Clinical examination and taking the initial shade of the tooth with Vita Easyshade®;~Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~Prophylaxis with a Robson brush and prophylactic paste;~Application of lip balm on the patient's lips;~Placement of the labial retractor;~Application of the gingival barrier;~Application of Whiteness HP Automixx 35% whitening gel;~In the session, a single application of the gel will be carried out and where it will remain on the surface of the tooth for 15 min;~The gel must be removed from the teeth with a sucker and the teeth cleaned with gauze;~Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~The second bleaching session will be carried out 7 days after the first one and, if necessary, a third session can be carried out 7 days after the second one."
45668034|NCT04673175|Drug|Ceftolozane / Tazobactam Injection|Zerbaxa (ceftolozane/tazobactam) for injection is supplied as a white to yellow sterile powder for reconstitution in single-use vials; each vial contains 1 g ceftolozane (equivalent to 1.147 g of ceftolozane sulfate) and 0.5 g tazobactam (equivalent to 0.537 g of tazobactam sodium).
45668035|NCT02009397|Drug|Ipilimumab|
45668036|NCT02009397|Drug|GM-CSF|
45668037|NCT04666311|Diagnostic Test|Accuracy of CAD4TB and Afinion CRP assay for pulmonary TB|"CAD4TB version 6 and 7: Software tool for detecting lung abnormalities in computer tomogram images (pulmonary abnormalities) and frontal chest radiograph images (tuberculosis abnormalities) ; availability is guaranteed by Delft Imaging System; EC 0344 Certificate (vs.6); CE mark pending (vs.7). Will be performed by a registered and qualified radiographer in accordance with national regulations.~Afinion AS100 Analyzer and Afinion CRP: In vitro diagnostic to determine the amount of CRP in human whole blood, serum or plasma; CE-mark ; Will be performed by qualified, GCP-trained study personnel."
45825054|NCT02056392|Drug|selumetinib placebo|Volunteers will receive selumetinib placebo oral dose (Treatment C)
45825055|NCT04717050|Behavioral|Progressive combine training (PCT)|8 month exercise program with 4 month follow up.
45967522|NCT00233220|Behavioral|Usual Care|Patients will receive usual care.
45825056|NCT04717050|Behavioral|Attention Control (AC)|12 month stretching program
45825057|NCT04716270|Procedure|Electrophysiology Study and Ablation|Electrophysiology Study and Ablation of Supraventricular Arrhythmias
45825058|NCT02034708|Drug|Dotarem®|Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
45825059|NCT02034708|Drug|Gadovist®/Gadavist®|Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.
45825060|NCT02034552|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg (55 kBq/kg after implementation of NIST [National Institute of Standards and Technology] update) every 4 weeks x 6 doses intravenous slow bolus
45967523|NCT00207779|Device|heparin impregnated central venous catheters|
45668038|NCT04666311|Diagnostic Test|CAD4COVID+WBC and COVID-19 RDT for SARS-CoV-2 infection|"CAD4COVID: Non-commercial product. Software tool for detecting pneumonia-related features to be expected in COVID-19 patients; availability is guaranteed by Delft Imaging System; CE certified. Will be performed by a registered and qualified radiographer/health professional in accordance with national regulations. Analysis in combination with differential white blood cell count.~SD Biosensor, STANDARDTM Q COVID-19 Ag Test (rapid chromatographic immunoassay for the qualitative detection of specific antigens to SARS-CoV-2)"
45825061|NCT02034552|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) taken orally once daily for up to two years following last dose of radium-223 dichloride
45967524|NCT00233259|Behavioral|Mediterranean Diet|Mediterranean dietary program
45967525|NCT00233259|Behavioral|Physical Activity|Physical activity program
45967526|NCT00233259|Behavioral|Stress Management|Stress management program
45668039|NCT02312219|Drug|Folic Acid|1 mg folic acid once daily
45967527|NCT00233259|Behavioral|Social Support|Social support
45967528|NCT00233259|Behavioral|Smoking Cessation|Smoking cessation program
45967529|NCT00233259|Other|Control group|Usual Diabetes Care Control group
45967530|NCT00207818|Device|self assembled skin substitute (SASS)|Wound care with self assembled skin substitute (SASS)
45967531|NCT00230373|Drug|imiquimod 5% cream (Aldara)|
45967532|NCT00230451|Procedure|Radiation|
45967533|NCT00230451|Drug|Paclitaxel|
45967534|NCT00230451|Drug|Cisplatin|
45967535|NCT00230451|Drug|5-Fluorouracil|
45825062|NCT02034552|Drug|Prednisone|Prednisone 5 mg capsule taken orally twice daily for up to two years following last dose of radium-223 dichloride
45825063|NCT02034552|Drug|Enzalutamide|Enzalutamide 160 mg (four 40 mg capsules) taken orally once daily for up to two years following last dose of radium-223 dichloride
45825064|NCT02034474|Drug|Tocilizumab|8mg/kg intravenously via iv drip over 60 min
45967536|NCT00207935|Behavioral|Swallow instruction|
45967537|NCT00411320|Drug|oral steroid-dexamethasone|2 week steroid trial
45668040|NCT02312219|Drug|Placebo|placebo once weekly
45668041|NCT02312219|Drug|Low Dose Methotrexate|An anti-inflammatory drug
45825065|NCT02034474|Drug|Placebo|intravenously via iv drip over 60 min
45825066|NCT02011542|Drug|VSL#3|This is a probiotic mixture
45967538|NCT00233337|Drug|Co-artemether|
45967539|NCT00230490|Drug|pradefovir mesylate|
45967540|NCT00230490|Drug|adefovir dipivoxyl|
45967541|NCT01089556|Drug|Duloxetine|Administered orally
45967542|NCT01089556|Drug|Pregabalin|Administered orally
45967543|NCT01089556|Drug|Placebo|Administered orally, daily as a blind for duloxetine and/or pregabalin for 8 or 16 weeks
45967544|NCT00411359|Behavioral|Cardiac rehabilitation|Phase III cardiac rehabilitation programme
45967545|NCT00233376|Procedure|Access to an antibiotic decision support system|
45967546|NCT00233376|Behavioral|Distribution of local antibiotic guidelines|
45967547|NCT00424424|Drug|MK0719|
45967548|NCT00233415|Device|Stereotactic Radiosurgery (Cyberknife)|
45967549|NCT00237159|Drug|Zoledronic acid|
45967550|NCT00424541|Drug|SPP100 (aliskiren)|
45668042|NCT01986231|Drug|Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg. Glucagon will be reconstituted immediately prior to administration and each dose will be administered subcutaneously via syringe/needle. The first glucagon dose is at hour 17, second at hour 22, third at hour 24, fourth at hour 27, fifth at hour 29, sixth at hour 31, seventh at hour 33, eighth at hour 35.
45668043|NCT02312063|Drug|Sitagliptin|
45668044|NCT02312063|Drug|Glimepiride|
45825067|NCT02011542|Drug|Placebo|This is a pill with inactive ingredients.
45825068|NCT02011386|Drug|Treatment|
45825069|NCT02010684|Behavioral|Empowerment and CBT Classes|"Participants randomized to the intervention arm will receive a manual with 3 CBT modules and 1 Diabetes Empowerment module. CBT Module 1 covers Understanding Depression and Diabetes, Module 2 How Thoughts Affect Your Mood and Diabetes Care, Module 3 How Activities Affect Your Mood and Diabetes Care. The Diabetes Empowerment Module covers topics including the following: food, exercise, medicine, diabetes and your health, social support, communication skills, and community resources."
45967551|NCT01089127|Drug|Indacaterol|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
45967552|NCT01089127|Drug|Salmeterol 50 μg|Salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
45967553|NCT01089127|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
45967554|NCT01089127|Drug|Placebo to salmeterol|Placebo to salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
45967555|NCT00424580|Drug|Montelukast (10mg) and Desloratadine (5mg)|
45967556|NCT01087957|Device|WalkAide|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
45967557|NCT01087957|Other|Ankle-Foot Orthosis (AFO)|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
45967558|NCT00424658|Procedure|SAHS diagnosis|
45967559|NCT00233532|Drug|Trandolapril|0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).
45967560|NCT00207974|Drug|Marine active|
45967561|NCT00233571|Biological|Adalimumab 40 mg subcutaneous (SC) every other week (EOW)|
45967562|NCT00237198|Drug|Letrozole|
45967563|NCT00233610|Drug|Bicalutamide|
45967564|NCT00233610|Drug|Tamoxifen|
45967565|NCT00208130|Drug|Topiramate|
45967566|NCT00237237|Drug|vildagliptin|
45967567|NCT00208169|Drug|Aripiprazole|
45967568|NCT01087723|Drug|Bivalirudin|
45967569|NCT01087723|Drug|Heparin|
45967570|NCT00208208|Drug|Ziprasidone|
45967571|NCT01087528|Device|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
45967572|NCT00208247|Behavioral|Cognitive behavioral psychotherapy|
45967573|NCT00237276|Procedure|colonoscopy|
45668045|NCT02353169|Drug|Dexmedetomidine|
45825070|NCT02034162|Drug|Mebendazole|Mebendazole will be administered as a single-dose 500 mg chewable tablet. For children 1 year to <36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
45825071|NCT02034162|Drug|Placebo|Matching placebo will be administered as a single-dose chewable tablet. For children 1 year to <36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
45825072|NCT02034006|Drug|Ranibizumab|All patients received a single initial intravitreal injection of ranibizumab 0.5 mg/0.05 ml as per Committee for Human Medicinal Products (CHMP)approval. Further injections might have been required when monitoring reveals disease activity. Disease activity, defined as reduced visual acuity and/or signs of lesion activity, was evaluated based on clinical examination (BCVA, fundus), and/or optical coherence tomography (OCT), and/or fluorescein angiography (FAG). Bilateral treatment was allowed provided at least 14 days of intercurrence.
45825073|NCT02054910|Procedure|Celiac Plexus Block|Patients will receive celiac plexus block during endoscopy.
45825074|NCT02054910|Procedure|Sham|Patients will not receive celiac plexus block during endoscopy.
45967574|NCT00233688|Device|QUANTUM LP™ STENT GRAFT SYSTEM|Stent Graft System for the Treatment of Abdominal Aortic Aneurysms
45967575|NCT00233688|Procedure|Open surgical repair|Open surgical repair
45668046|NCT02353169|Drug|Saline|
45967576|NCT01085812|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.
45967577|NCT01085812|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily.
45967578|NCT00208286|Device|PFC Sigma Fixed Bearing|PFC Sigma Fixed Bearing system for use in total knee arthroplasty
45668047|NCT02009163|Drug|Lisdexamfetamine dimesylate|SDP489 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
45668048|NCT02009163|Other|Placebo|Placebo capsule once per day (double-blind period)
45668049|NCT01983969|Drug|Azacitidine|Starting dose 15 mg/ m2 by vein on Day -11.
45668050|NCT01983969|Drug|Vorinostat|1000 mg by vein on Day -11 through Day -2.
45967579|NCT00208286|Device|PFC Sigma Mobile Bearing|PFC Sigma Mobile Bearing system for use in total knee arthroplasty
45967580|NCT00208364|Device|Pinnacle Acetabular Cup System|A cementless acetabular cup with metal liner for use in total hip replacement
45668051|NCT01983969|Drug|Gemcitabine|Loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8.
45668052|NCT01983969|Drug|Busulfan|Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1.
45668053|NCT01983969|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
45668054|NCT01983969|Drug|Dexamethasone|8 mg by vein twice a day from Day -11 AM to Day -2 PM.
45967581|NCT01085734|Drug|Avastin|1.25mg intravitreally
45967582|NCT01085734|Drug|Osurdex|0.7mg intravitreally
45967583|NCT01085734|Drug|Avastin|1.25mg intravitreally
45668055|NCT01983969|Other|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -9.
45668056|NCT01983969|Drug|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9.
45668057|NCT01983969|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
45668058|NCT01983969|Drug|Rituximab|375 mg/m2 by vein on Days -9.
45668059|NCT02008773|Drug|Valacyclovir HCI 500 mg tablets|Valacyclovir HCI 500 mg capsules 6/day oral for 16 weeks
45967584|NCT00208403|Device|Acryloc™ GHV|A high viscosity bone cement for use in total hip replacement
45967585|NCT00208403|Device|Palacos R|A high viscosity bone cement for use in total hip replacement
45967586|NCT00233727|Procedure|HPV DNA Testing + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women."
45967587|NCT00233727|Procedure|VIA + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women."
45967588|NCT01084603|Drug|Oral Nicotine|A new l mg oral nicotine product
45967589|NCT01084603|Drug|NiQuitinTM Nicotine Lozenge|A marketed 4 mg Nicotine lozenge
45967590|NCT01084603|Drug|Nicorette® Nicotine Gum|A marketed 4 mg Nicotine Gum
45967591|NCT00208442|Device|Marathon™|Moderately cross-linked polyethylene liner in a modular acetabular component
45967592|NCT00208442|Device|Enduron|Standard polyethylene liner in a modular acetabular component
45967593|NCT01084174|Drug|Peanut powder|Delivered orally
45967594|NCT01084174|Drug|Peanut extract|Delivered sublingually
45967595|NCT01084174|Drug|Placebo extract|Delivered sublingually
45967596|NCT01084174|Drug|Placebo powder|Delivered orally
45967597|NCT00237354|Drug|PV-10 (rose bengal disodium 10%)|PV-10 ablation of study lesion
45967598|NCT00233766|Device|Bx VELOCITY Stent containing 45% and 70% of Sirolimus dose|
45967599|NCT00208520|Drug|Carbamazepine|
45967600|NCT00208520|Drug|Lamotrigine|
45967601|NCT00208520|Drug|Levetiracetam|
45967602|NCT00237393|Drug|Quetiapine|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
45967603|NCT00237393|Drug|Placebo|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
45967604|NCT00208559|Drug|Ziprasidone|Ziprasidone 40mg to 60mg per day, individually titrated
45967605|NCT00233805|Device|Sirolimus coated Bx Velocity™|drug-eluting stent
45967606|NCT00233805|Device|Bare metal Bx Velocity™|bare-metal stent
45967607|NCT01084135|Drug|Rivastigmine|At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. Subjects receiving placebo will maintain the same schedule. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
45967608|NCT01084135|Other|Liquid Placebo|Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
45967609|NCT01083316|Drug|Bortezomib|"Induction:~Velcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days~Conditioning:~Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4"
45967610|NCT01083316|Drug|Dexamethasone|"Induction:~Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days"
45668060|NCT02008773|Drug|placebo|placebo capsules 6/day oral for 16 weeks
45668061|NCT02257567|Drug|Bendamustine|Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
45967611|NCT01083316|Drug|Melphalan|"Conditioning:~Melphalan 70-100 mg/m2/day IV on days -2 and -1"
45967612|NCT00208637|Behavioral|moderate carbohydrate, high protein diet (MCHP)|
45458327|NCT03498274|Device|Traditional Fitting System|The trained professional will fit the hearing aids with the traditional software that is currently used on the market. They will not involve the patient except to play demonstration tones.
45668062|NCT02257567|Drug|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) IV on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
45668063|NCT02257567|Drug|Polatuzumab vedotin (Liquid)|Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
45825075|NCT04714398|Behavioral|Opt-In Recruitment|Patients in the opt-in recruitment arm will receive a letter describing the program and inviting them to participate in the remote monitoring program. Along with the letter they will receive an informational brochure and a copy of the informed consent form. Patients in this arm will then receive a recruitment phone call explaining the program and consenting the participant verbally. If the participant consents to participate in the remote monitoring program, to receive text messaging, and to connection to care, the research coordinator will mail a blood pressure cuff and begin the remote monitoring program for the patient 6 days later.
45825076|NCT04714398|Behavioral|Opt-Out Recruitment|Patients assigned to opt-out recruitment will receive a blood pressure cuff with instructions in the mail along with a letter describing the program and opt-out framing regarding their participation, as well as a brochure and a copy of the informed consent form. Patients in this arm will receive a recruitment phone call similar to recruitment arm A, explaining the program and consenting the participant verbally. If the participant consents to participate in the remote monitoring program, to receive text messaging, and to connection to care, the research coordinator will begin the remote monitoring program for the patient immediately.
45825077|NCT02033850|Behavioral|Attention Process Training-II|Rehabilitation of attention using the Attention Process Training-II
45825078|NCT04675788|Drug|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
45825079|NCT04675788|Drug|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to modestly lengthen the QT interval
45825080|NCT04675788|Drug|Testosterone|Subjects will apply transdermal testosterone gel once daily every morning for 3 days
45967613|NCT00208637|Behavioral|high carbohydrate-high fibre (HCHF) diet|
45967614|NCT00208715|Drug|Provigil|
45668064|NCT02257567|Drug|Rituximab|Rituximab standard dose, 375 mg/m^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
45668065|NCT02257567|Drug|Polatuzumab vedotin (Lyophilized)|Participants in the New Formulation (NF) Cohort (Arms G and H) will follow the same schedule and dosing requirements as participants in the other Phase II cohorts (Arms A-F).
45668066|NCT05646043|Behavioral|Physical training|Physical training consists of endurance walking and strength training. The basis for determining the number of steps per day is the baseline value of each patient. This will increase by 10-15% every week until the surgery date. The assumption of a total load increase is 120-180% compared to the baseline.
45967615|NCT01082614|Device|Vigileo|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV > 12%.
45967616|NCT00233844|Procedure|"Venipuncture with cough-trick"|
45967617|NCT00208793|Dietary Supplement|Calcium and vitamin D3 combined|Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with food over 6 months
45967618|NCT00208793|Drug|Placebo|Placebo
45967619|NCT00208793|Dietary Supplement|Calcium|Calcium 2,000 mg/day as calcium carbonate in two divided doses with meals over 6 months
45967620|NCT00208793|Dietary Supplement|Vitamin D3|Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months
45967621|NCT00233883|Drug|enfuvirtide [Fuzeon]|90mg sc bid by Biojector 2000 NFID for 4 weeks
45967622|NCT00233883|Drug|enfuvirtide [Fuzeon]|"90mg sc bid by 27G1/2 needle/syringe for 4 weeks"
45967623|NCT00208832|Procedure|Graphic medication schedule (Pill card)|
45967624|NCT00208832|Procedure|Refill reminder postcard|
45967625|NCT01081873|Drug|leuprolide (Lucrin/Lucrin-Tri-depot)|Subcutaneous or intramuscular administration for all participants
45967626|NCT00237471|Drug|Insulin (tight blood glucose control)|
45967627|NCT00208871|Procedure|Stereoscopic Digital Mammography|screening digital 3D mammogram
45967628|NCT00208910|Behavioral|Odorant Cue|
45967629|NCT00233922|Device|Osteosheet(r)|
45967630|NCT00208988|Procedure|Educational handout about prostate cancer screening|
45967631|NCT00208988|Procedure|Simple cue for patient to talk to doctor|
45967632|NCT00237510|Drug|terazosin|
45967633|NCT01081795|Drug|Topiramate|In the titration period, topiramate 25-mg tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks so that the total daily dose given is 50 mg or 100mg. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
45967634|NCT01081795|Drug|Placebo|In the titration period, matching placebo tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
45967635|NCT00233961|Biological|filgrastim|
45967636|NCT04710186|Procedure|arterial reconstructive open surgery|Patients with peripheral artery disease (PAD) will undergo arterial reconstructive open surgery. Samples obtained from diseased arteries of lower limbs of patients undergoing arterial reconstructive open surgery will be collected and immediately preserved at -80°. Briefly, arterial tissues were excised, homogenized using a motor driven homogenizer and total RNA was isolated using Trizol reagent (Invitrogen, Milan, Italy), in accordance with the manufacturer's instructions. The expression of Androgen Receptor (AR), insulin receptor (IR) and the IGF-I receptor (IGF-IR) will be quantified by real-time PCR using platform Quant Studio7 Flex Real-Time PCR System (Thermo Fisher Scientific, Milan, Italy), following the manufacturer's instructions.
45967637|NCT00234000|Drug|arsenic trioxide|Each 28-day treatment cycle will include dosing for 2 days per week of ATO. Subjects will recieve 1 mg/mL each dosing day.
45668067|NCT05646043|Behavioral|Muscle strength training|Muscle strength training will take place using exercises to strengthen the upper and lower limbs and to strengthen the trunk. There will be a set of 5 exercises in two difficulty variants. The study subjects will perform this set 7 days a week, and will repeat the assembly a total of two times. The total time of strength training is 10 min.
45825081|NCT04675788|Drug|Placebo|Lactose capsules
45825082|NCT04675164|Device|Laser Assisted Immotile Sperm Selection|LAISS will be performed using diode laser system at the lowest working power with a single laser shot at the lower one third of the sperm tail. If sperm tail curling occurred, the sperm is then viable and will be utilized for ICSI after immobilization in PVP.
45825083|NCT04675164|Procedure|Hypo-osmotic Swelling Test|HOST will be performed by transferring immotile sperms from incubation droplet into HOST droplet, with any sperm showing tail swelling will be identified as viable and will be utilized for ICSI after immediate transfer and immobilization.
45825084|NCT02054130|Drug|Placebo|Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
45825085|NCT02054130|Drug|MEDI9929 70 mg|Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
45825086|NCT02054130|Drug|MEDI9929 210 mg|Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
45825087|NCT02054130|Drug|MEDI9929 280 mg|Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
45967638|NCT00234000|Drug|azacitidine|Each 28-day treatment cycle will include dosing the first five days of cycle with Azacitidine. Cohorts of three to six patients will each receive 25, 50, and 75 mg/m2/d injected subcutaneously.
45967639|NCT00209105|Drug|DEX-CRF stimulation test|1 ug/kg body weight of CRF for determining hpa response post dexamethasone ingestion
45967640|NCT00209105|Behavioral|Psychosocial stress induction|Laboratory stress induction, no drug administration
45967641|NCT00209105|Procedure|Brain imaging of sad mood , self-reference, reward|Brain imaging
45967642|NCT00209105|Behavioral|Acoustic startle|No drugs involved
45967643|NCT00234117|Drug|Rabeprazole|
45967644|NCT00209144|Drug|Intensive insulin therapy|
45967645|NCT00234156|Procedure|oral fructose and high fat diet|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
45967646|NCT00209222|Drug|Rituximab|antibody
45967647|NCT00209222|Drug|Cyclophosphamide|chemotherapy
45967648|NCT00209222|Drug|Doxorubicin|chemotherapy
45967649|NCT00209222|Drug|Vincristine|chemotherapy
45967650|NCT00209222|Drug|Prednisone|corticosteroide
45967651|NCT00209222|Drug|Cisplatinum|chemotherapy
45967652|NCT00209222|Drug|Ara-C|chemotherapy
45967653|NCT00209222|Drug|Dexamethasone|corticosteroide
45967654|NCT00209222|Drug|BCNU|chemotherapy
45967655|NCT00209222|Drug|Melphalan|chemotherapy
45967656|NCT00209222|Drug|Etoposide|chemotherapy
45967657|NCT00209222|Drug|G-CSF|growth factor
46080533|NCT05906134|Procedure|Thoracic epidural catheter|The pain service and thoracic surgery attending physician will assess if the patient's pain is not well-controlled using the pain modality they are randomized to. If additional pain control is needed, this will be added as an adjunct to the study arm and will be noted in the data set. This will likely consist of a thoracic epidural catheter.
45967658|NCT00209222|Procedure|chemotherapy: R-CHOP|immuno-chemotherapy
45967659|NCT00209222|Procedure|chemotherapy: R-DHAP|immuno-chemotherapy
45967660|NCT00209222|Procedure|chemotherapy: Dexa-BEAM|chemotherapy
45967661|NCT00209222|Procedure|stem cell harvest|procedure
45967662|NCT00209222|Procedure|total body irradiation|radiation
45967663|NCT00209222|Procedure|high-dose chemotherapy: Cyclophosphamide|chemotherapy
45967664|NCT00209222|Procedure|high-dose chemotherapy: Ara-C /Melphalan|chemotherapy
45668068|NCT04419961|Behavioral|Educational program|"The educational program includes a group discussion and a booklet.~The group discussion lasts for 90 minutes, discussing importance of sexual activity during pregnancy, improving sexual experience during pregnancy, physical and mental changes of pregnant women, and measures to cope with discomfort, anxiety, fear and other issues. It includes a 30-minutes presentation, followed by 1-hour discussion.~The booklet is a color-printed A5-size booklet containing in-depth information of the content given during the discussion. Each participant can only receive one copy of the booklet, and the booklet is not given to the control participants."
45967665|NCT00234195|Drug|bupropion extended release (Wellbutrin XL)|
45967666|NCT00209261|Drug|MINIRIN Oral Lyophilisate|
46080534|NCT05906134|Procedure|Local intercostal nerve block|Patients receiving intercostal blocks will receive a total of 1.0 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.
46080535|NCT05906134|Procedure|Cryo-analgesia and intercostal nerve block|The cryo-ablation will occur 2 cm from the sympathetic chain 2 intercostal spaces above and 2 intercostal spaces below the access incision. The patient will also receive a total of 1.2 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.
46080536|NCT05906134|Procedure|Serratus plane catheter blocks and intercostal nerve blocks|A total of 1.2 cc/kg of 0.25% Bupivacaine + epinephrine will be administered. A total of 20 cc of the weight-based calculation will be reserved for the serratus plane catheter. The remaining local anesthetic will be divided into two-thirds for the chest and one-third for the abdomen. Patients with serratus plane catheters will have an ongoing infusion of 0.2% ropivacaine at 8 ml per hour. The serratus plane catheters will also receive a bolus of 20 ml of 0.25% bupivacaine with epinephrine on POD #1, 2, 3, 4, and 5 by the pain service.
45825088|NCT04673682|Drug|D309|D309(Testosterone) 1 vial, Once, IM injection
45668069|NCT05330299|Behavioral|COMPASS|Participants will be treated with an online CBT program that is specifically tailored to illness-related distress in the context of long-term conditions. It consists of 11 online modules and is therapist-supported.
45668070|NCT05327257|Device|iTBS rTMS|Repetitive transcranial magnetic stimulation (rTMS) intermittent Theta Burst Stimulation (iTBS)
45668071|NCT05645965|Device|ICD insertion|Patients who underwent implantable cardioverter-defibrillator (ICD) insertion between January 2015 and December 2020
45668072|NCT01642615|Drug|Dexlansoprazole|Dexlansoprazole capsules
45668073|NCT01642615|Drug|Dexlansoprazole|Dexlansoprazole capsules
45668074|NCT01642615|Drug|Placebo|Dexlansoprazole placebo-matching capsules
45668075|NCT03571945|Device|Bi-spectral Index (BIS QUATRO REF #186-0106)|GA will be monitored and controlled with Bi-spectral index (BIS).
45668076|NCT03571945|Device|End tidal anaesthesia gas concentration (ETAG)|GA will be monitored and controlled with end-tidal anaesthesia gas concentration
45668077|NCT04853329|Drug|CPO107|CD20-CD47 Bispecific Fusion Protein
45668078|NCT02311361|Biological|Durvalumab|10 mg/kg, mg intravenous (IV), every two weeks, or 1500 mg, IV, every four weeks.
45668079|NCT02311361|Biological|Tremelimumab|75 mg IV, every 4 weeks for 16 weeks
45825089|NCT04673682|Drug|CKD-845|CKD-845(Testosterone) 1 vial, Once, IM injection
45825090|NCT02009046|Behavioral|SEI Classroom Curriculum|Participants receive the 12-session Sexuality Education Initiative (SEI) classroom curriculum. The SEI classroom curriculum covers anatomy, abstinence, contraception and protection, STIs and HIV/AIDS, media messages, gender, relationships, rights and responsibilities, pregnancy, sexuality, peer pressure, negotiation and coercion, and decision making. These sessions are delivered over a two-month period. Each curriculum session is about 45 minutes in length.
45825091|NCT02009046|Behavioral|Control Classroom Curriculum|Participants receive the 3-session basic control curriculum. The control curriculum includes 3 sessions on sexually transmitted infections, anatomy and birth control delivered over a two- or three-week period. Each curriculum session is about 45 minutes in length.
45825092|NCT02009046|Behavioral|SEI Curriculum + 3 School Components|Participants receive SEI classroom curriculum and all three school wide components. The peer education/advocacy component recruits, trains and supervises students through an after-school leadership program to serve as resources to peers, organize health events, and refer students to school-based clinic services. The parent education component provides sessions for parents of students, covering reproductive health, teen pregnancy, and parent-teen communication, together with a parent education booklet for widespread use. The clinical services linkages includes health services on campus, including pregnancy/STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It includes training for teachers and staff to distribute condoms as needed.
45825093|NCT02009046|Behavioral|Control Curriculum + 1 School Component|Participants receive control classroom curriculum and one of the three school wide components, the clinical services linkages. This component includes health services on campus for students, including pregnancy and STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It also includes training for teachers and school staff to distribute condoms to students as needed.
45825094|NCT02052960|Drug|CetuGEX™|60 mg/day 0, 930 mg/day 1, followed by 720 mg i.v. weekly administration
45967667|NCT00209261|Drug|Minirin tablet|
45967668|NCT00237549|Procedure|optimised treatment|"The intervention targeted individual patients and the Primary Care Team. Practitioners were trained in a target driven, intensive multifactorial approach including lifestyle advice (smoking cessation, physical activity 30 min./day and healthy diet) and pharmacological treatment with the aim of reducing the complications of diabetes as described in protocol.~The training included meetings, practice visiting, written feed back reports and reminders on controls."
45967669|NCT00209300|Drug|Pentasa|
45967670|NCT00234234|Drug|Adalimumab|
45967671|NCT00209378|Other|regional anticoagulation with citrate|Regional anticoagulation with trisodium citrate is compared with standard systemic heparinization.
45967672|NCT00209378|Other|HfCitPre|regional anticoagulation with citrate containing replacement solution
45967673|NCT00234273|Procedure|Rehabilitation programme in Adapted Physical Activity (APA)|
45967674|NCT00234273|Behavioral|Therapeutic education primarily focused on dietary|
46080537|NCT05906095|Behavioral|LOCK Falls Program|The LOCK Falls Program helps multi-disciplinary frontline staff teams (nursing, physician, housekeeping, physical therapy, etc.) work together to identify and discuss risk factors for falling and use rapid-cycle QI techniques to pilot and monitor their actions to reduce resident falls.
46080538|NCT05906069|Behavioral|ICBT|The intervention will consist in a structured internet-based intervention with 10 modules that will combine cognitive-behavioral techniques to improve obsessive-compulsive symptoms as well as the emotion regulation ability.
46080539|NCT05906030|Diagnostic Test|Diaphragm ultrasound|Diaphragm ultrasound will be used pre- and postoperatively. Diaphragm dysfunction will be diagnosed using the measurements diaphragm thickening fraction, diaphragm excursion and diaphragm density.
46080540|NCT05906017|Procedure|Open Hernia surgery|primary midline ventral hernia repair - open
46080541|NCT05906017|Procedure|Robotic Hernia surgery|primary midline ventral hernia repair - robotic
46080542|NCT05906004|Device|Pitch-Patch|Pitch-Patch device used for rotator cuff augmentation/ reinforcement.
46080543|NCT05905991|Other|Enhanced Stress Resilience Training|"The ESRT intervention will consist of 1) five weekly one-hour sessions (in-person or virtual) led by a certified instructor; 2) smartphone-based exercises that bring informal practice into daily life; 3) videos on principles and concepts taught each week; and 4) meditation recordings of various lengths and styles supporting the prescribed daily practice of up to 20 min/day. Weekly didactic and experiential activities will cover mindfulness-based intervention concepts and skills, such as cultivating resilience, awareness of the body, managing thoughts, responding versus reacting, transforming circumstances, and advocacy through mindful communication. The ESRT smartphone app (Mindful Brian) houses all course materials (pre-class materials and post-class materials) and sends class reminders and messages. Considering nurses' shifts, ESRT will be offered in two separate sessions each week."
45668080|NCT02311361|Radiation|Sterostatic body radiation therapy (SBRT)|8 Gray (Gy) x 1; 5Gy x 5
45668081|NCT02352779|Dietary Supplement|Omega-3 Fatty Acid|Given PO
45668082|NCT02352779|Other|Placebo|Given PO
45668083|NCT02352779|Other|Questionnaire Administration|Ancillary studies
45668084|NCT02352779|Other|Laboratory Biomarker Analysis|Correlative studies
45668085|NCT04893395|Other|Pharmacogenomic Screening|"First telehealth appointment:~Pharmacogenomics education and informed consent~Medical history~Sample collection~Second telehealth appointment:~Results of pharmacogenomic testing~Utility and limitations of pharmacogenomic testing~Patient-specific potential impacts on current or future medication therapies~Answering of patient questions~Referral to mental health provider(s) for treatment-specific recommendations"
45668086|NCT02257489|Drug|ACE-083|recombinant fusion protein
45668087|NCT05645887|Drug|Human albumin|Human albumin from day 0 to 7 if serum albumin concentrations <35g/l.
45668088|NCT05645887|Other|Saline solution|Saline solution from day 0 to day 7.
45668089|NCT05645809|Device|MONOFIX® PGCL|An absorbable suture made of polyglycapron (PGCL) used for soft tissue suture.
45668090|NCT05645809|Device|Quill Monoderm™|An absorbable suture made of polyglactin used for soft tissue suture.
45668091|NCT02329223|Biological|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
45668092|NCT02329223|Other|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
45967675|NCT00209456|Drug|DatSCAN|
45967676|NCT00237588|Drug|Amlodipine 10 mg or Losartan 100 mg + Amlodipine 5 mg|
45967677|NCT00411437|Drug|Tolterodine ER|
45967678|NCT00411437|Drug|Oxybutynin ER|
45967679|NCT00234312|Drug|escitalopram and sertraline|
45967680|NCT00411515|Drug|Mycophenolate Mofetil 2x 1g|
45967681|NCT00237627|Drug|PS-341|PS-341 will be administered as an intravenous push into a side arm of either a peripheral or central intravenous line infusing normal saline at 100 ml/hr. Patients will be treated twice weekly for two weeks, followed by a one week rest period, such that the typical days of treatment will be days 1, 4, 8, 11 of each three-week cycle. The initial dose level for PS-341 will be 0.9 mg/m2/dose intravenously, while subsequent dose levels will be determined according to a modified Fibonacci schema
45967682|NCT00237627|Drug|Doxil|Doxil will be administered at a dose of 30 mg/m2 as a 1 hour infusion through either a peripheral or central intravenous line every 3 weeks (on day 4 of each 21 day cycle)
45967683|NCT00237627|Drug|Velcade|Velcade will be adminstered intravenously at 1.3 mg/m2 days 1, 4, 8, 11 every 3 weeks
45967684|NCT00209495|Drug|Pregabalin; Dexamethasone|Comparing combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
45967685|NCT00234390|Drug|Pulmicort (budesonide) pMDI|
45967686|NCT00209534|Drug|fospropofol disodium|
45967687|NCT00209573|Drug|fospropofol disodium|
45967688|NCT00414141|Biological|Grass MATA MPL|4 subcutaneous injections
45967689|NCT00414141|Biological|Placebo|4 subcutaneous injections
45967690|NCT01081678|Drug|Placebo|Administered by subcutaneous (under the skin) injection
45967691|NCT01081678|Drug|Romosozumab|Administered by subcutaneous injection
45967692|NCT00209612|Drug|Taxol|Day1,15 X mg/m2, IV (in the vein)
45967693|NCT00209612|Drug|Campt, Topotesin|Day1,15 Y mg/m2, IV (in the vein)
45967694|NCT01081249|Drug|Placebo then intranasal oxytocin|Participant received intranasal placebo spray at first psychotherapy session, and received a single dose of 40 IU intranasal oxytocin at the second session.
45967695|NCT01081249|Drug|Intranasal oxytocin then placebo|Participant received a single dose of 40 IU intranasal oxytocin at the first psychotherapy session, and received a similar dose of intranasal placebo spray at the second session.
45967696|NCT00234429|Drug|Gefitinib, raltitrexed|
45967697|NCT00209651|Drug|Campto, Topotesin|q00 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle.
45967698|NCT00209651|Drug|TS-1|80 mg/m2, PO (oral) on day 1~14 of each 28 day cycle.
45967699|NCT02961855|Drug|anesthesics plus antiinflammatory, CLIFE1|anesthesics plus antiinflammatory, CLIFE1 topical gel containing lidocaine plus diclofenac anesthesics plus antiinflammatory
45967700|NCT02961855|Drug|local anesthesics, CLIFE2|local anesthesics, CLIFE2 topical gel containing lidocaine local anesthesics
45668093|NCT05645419|Behavioral|personalized chronoprevention|Chronobiological variables: dynamic and static position of the planets of the solar system, moon, sun, constellations; angles/degrees of celestial objects above/below the horizon; angular interactions between celestial objects; the moment/time of the patients' birth; moment/time of MI occurrence; latitude / longitude of the place of birth of the patients, as well as the occurrence of MI (event); the degree of influence of celestial objects in relation to the constellations, where they were at a particular personal event / points of the patient.
45967701|NCT00209690|Drug|Taxotere|X mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
46080544|NCT05905978|Procedure|Corneal donors predisposed by CXL|Corneal donors predisposed by CXL and DALK procedure was conducted in patients
46080545|NCT05905978|Procedure|Corneal donors stored in corneal storage media|Corneal donors stored in corneal storage media and DALK procedure was conducted in patients
46080546|NCT05905965|Drug|Empagliflozin 20 mg|Patients receiving empagliflozin 20 mg daily - experimental arm
46080547|NCT05905965|Drug|Empagliflozin 10 mg|Patients receiving empagliflozin 10 mg daily - control arm
46080548|NCT05905952|Diagnostic Test|balance and ROM assessment|assessment of postural stability and ankle range of motion
45825095|NCT02052960|Drug|Cetuximab|400 mg/sqm body surface area (BSA) on day 1, followed by 250 mg/sqm BSA i.v. weekly administration
45825096|NCT02052960|Drug|Chemotherapy|Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
45668094|NCT01641601|Device|Outpatient transcervical Foley balloon|A 30 cc transcervical Foley balloon will be placed in the outpatient setting prior to labor induction.
45668095|NCT02350127|Behavioral|Preventing Loss of Independence through Exercise (PLIE)|PLIE is an integrative group movement program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely between sitting and standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
45825097|NCT02008890|Biological|Secukinumab 300mg|Secukinumab was used as 150 mg pre-filled syringes (PFS) in a double-blinded fashion. Secukinumab 300 mg s.c. (two PFS injections of the 150 mg dose) self-administered
45825098|NCT02008890|Biological|Secukinumab 150mg|secukinumab 150 mg s.c. (one PFS injection of the 150 mg dose + one PFS injection of placebo) self-administered
45825099|NCT02008890|Biological|Placebo|secukinumab placebo s.c. (two PFS injections of placebo) self-administered
45967702|NCT00209690|Drug|5-FU|800 mg/m2, CIV (conti.in the vein) on day 1~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
46080549|NCT05905926|Drug|Tenapanor|Eligible patients from the parent study will continue tenapanor at the same dose assigned in the parent study. Doses can be titrated to either 50 mg BID or 25 mg BID
46080550|NCT05905913|Drug|ANT3310|ANT3310 will be infused over 3 hours
46080551|NCT05905913|Drug|ANT3310-placebo|ANT3310-placebo will be infused over 3 hours
46080552|NCT05905913|Drug|ANT3310|ANT3310 will be infused over 3 hours every 8 hours
46080553|NCT05905913|Drug|ANT3310-placebo|ANT3310-placebo will be infused over 3 hours every 8 hours
46080554|NCT05905913|Drug|ANT3310-placebo|ANT3310-placebo will be infused over 3 hours as a single dose as part of the drug drug interaction study, then every 8 hours as part of the repeat doses study.
45458561|NCT02340026|Other|Dynamic Supported Mobility|Dynamic weight support; Child-directed; No assistive devices, limited use of orthoses, no treadmill; Encourage high degree of error with reduced physical assistance; Encourage frequent variability in motor tasks (no redirection when moving from one activity to another); Physical therapist expertise is focused on designing a salient and challenging environment for the child's specific interests and ability level to encourage engagement, variability, challenge, and error experience, and on determining the appropriate amount of weight assistance
45967703|NCT00209690|Drug|Briplatin|15 mg/m2, IV (in the vein) on day 1~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
45967704|NCT01081132|Drug|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on weight.
45967705|NCT01081132|Other|Placebo|Matching placebo will be provided as 1,2,3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on weight.
45967706|NCT00234468|Drug|Iressa (Gefitinib)|
45967707|NCT01080625|Drug|phenylephrine|100 mcg of phenylephrine (volume 10 ml) iv at the time of reperfusion
45967708|NCT01080625|Drug|epinephrine|10mcg of epinephrine (volume 10 ml) is administered iv at the time of reperfusion
45967709|NCT01080625|Drug|placebo control|10ml of normal saline is administered at the time of reperfusion
45967710|NCT00209729|Drug|Taxotere|X mg/m2, IV (in the vein) on day 1 and 15 of each 28 day cycle.
45967711|NCT00209729|Drug|TS-1|Day 1-14, P.O. everyday
45967712|NCT00414180|Drug|Bupropion SR|
45967713|NCT01089790|Drug|Dutogliptin|400 mg tablet, once daily
45967714|NCT01089790|Drug|Sitagliptin|100 mg capsule (each capsule contains two 50-mg tablets), once daily
45967715|NCT00209768|Device|Filter: NOE96E, ELD96E, NLF1E, TNA1E|
45967716|NCT01089010|Drug|Placebo|Matching placebo in capsules administered as a single oral dose.
45967717|NCT01089010|Drug|250 mg CK-2017357|250 mg CK-2017357 in capsules administered as a single oral dose.
45825100|NCT02052414|Drug|Gabapentin ER|"Patient who are on gralise will report efficacy by rating his or her pain rating on a digital pain scale (11 points) from 0 to 10 on each scheduled clinical visits, which will be compared to their pain level at baseline.~In addition, patients will also record the doses and any adverse effects that might arise during the trial in a diary provided by the study. All information will be recorded in a paper diary that will be followed by coordinator during each follow up visits."
46080555|NCT05905913|Drug|ANT3310|ANT3310 will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
45668096|NCT02350127|Behavioral|Usual Care|Usual care activities will vary between participants. Some will be attending the adult day center and may be engaging in structured physical, mental and/or social activities. Other participants will be living in the community and may engage in physical, mental, and/or social activities on their own or with a caregiver.
45668097|NCT02256553|Biological|MK-3641 12 Amb a 1-U (short ragweed extract)|12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U) extract sublingual tablets
46080556|NCT05905913|Drug|Meropenem|Meropenem will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
46080557|NCT05905913|Drug|Meropenem-placebo|Meropenem-placebo will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
46080558|NCT05905900|Combination Product|Emergent IV Dye Preparation|Diphenhydramine 50 mg IV once, famotidine 20 mg IV once, and dexamethasone 10 mg IV once
46080559|NCT05905887|Drug|Rivoceranib Mesylate, Paclitaxel|"Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).~Rivoceranib 400 mg orally once a day."
46080560|NCT05905874|Other|Machine learning-based prediction model|The machine learning-based prediction model will be used to forecast whether the presence of DVT and/or PTE or not in AECOPD patients after standardized treatment.
45825101|NCT02007954|Device|DEBDOX|DEBDOX, loaded with doxorubicin, is a device that utilizes beads in place of lipiodol to deliver the chemotherapy into the liver tumor. The device allows for continuous elution of doxorubicin into the liver tumor tissue. The advantages of this method of delivery in comparison to conventional TACE are that the beads are able to deliver a greater volume and concentration of the drugs to the tumor because of their unique ability to elute the drug over a period of several days. As a result of this unique delivery, systemic toxicity is significantly reduced. The potential advantages of the smaller beads are deeper penetration into the tumor bed, while avoiding premature proximal occlusion of vessels feeding the tumor, and more consistent dosing. These properties translate into greater potency of therapy and potentially improved patient survival.
45825102|NCT02049450|Drug|ruxolitinib|Ruxolitinib was taken at a starting dose of 10 mg twice daily with dose adjustments within the range of 5 to 25 mg twice daily.
45668098|NCT02256553|Biological|MK-7243 2800 BAU (Timothy grass extract)|2800 bioequivalent allergen units (BAU) of Phleum pratense extract sublingual tablets
45825103|NCT02031432|Drug|Cebranopadol|Film-coated tablet; strengths: 200, 400, or 600 µg
45825104|NCT02031276|Drug|risankizumab IV|risankizumab administered by IV infusion
45825105|NCT02031276|Drug|risankizumab SC|risankizumab administered by SC injection
45825106|NCT02031276|Drug|Placebo|Placebo for risankizumab administered by IV infusion
45825107|NCT04686864|Behavioral|Support Group for Caregivers|"Engage parents in the community via this support group, so they can be supported by other parents who know the system, can advise them on how to proceed, and empower them to help their children. Parents will learn psychoeducation about eating disorders and how to support their children."
45825108|NCT02007720|Drug|Serelaxin|Intravenous infusion
45825109|NCT02007720|Drug|Placebo|Intravenous infusion
45668099|NCT02256553|Drug|Rescue Medication|Self-injectable epinephrine, to be administered for an anaphylactic reaction, including symptoms/signs of upper airway obstruction.
45967718|NCT01089010|Drug|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
45967719|NCT00234507|Biological|Botulinum toxin type A|
45967720|NCT01085266|Drug|Dimebon (latrepirdine)|
45967721|NCT01084330|Drug|AUY922|70mg/m2
45967722|NCT01084330|Drug|Docetaxel|Docetaxel 75mg/m2
45967723|NCT01084330|Drug|Irinotecan|Iriniotecan 350mg/m2
45967724|NCT00209807|Drug|escitalopram|escitalopram 10 mg/d for 6 weeks
45967725|NCT00209807|Drug|Reboxetine|Reboxetine 8 mg/d for 6 weeks
45967726|NCT00209807|Other|No intervention|This group of healthy volonteers will receive no drug and will be a healthy comparator.
45967727|NCT04571671|Other|Collect retrospectively data|Analyse the incidence of Mullerian anomalies in these populations
45967728|NCT00414219|Behavioral|Visual quality of patients with corneal eye injuries|Visual quality of patients with corneal eye injuries
45967729|NCT04571476|Procedure|Ultrathin bronchoscope|Ultrathin bronchoscope (UTB) with an outer diameter no more than 3.0-mm and a 1.7-mm working channel.
45967730|NCT04571476|Procedure|Thin bronchoscope|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel.
45967731|NCT04571476|Procedure|Virtual bronchoscopic navigation combined with endobronchial ultrasound|VBN can create a path to the target lesion automatically when the lesion is depicted in this software.VBN combined with EBUS can improve the diagnostic yield of PPL and shorten the examination time, which has become the standard method for the diagnosis of PPL.
45967732|NCT04571476|Procedure|Guide sheath|GS is a cannula with the thinnest outer diameter of 1.95 mm.
45967733|NCT00209846|Drug|Gaboxadol|
45967734|NCT04571593|Behavioral|Yoga Nidra|The practice of Yoga Nidra, is a scripted and reproducible, guided meditation technique that promotes mental, emotional and physical relaxation while also facilitating the transition between waking and sleeping.
45967735|NCT01082068|Drug|XL147 (SAR245408)|given orally once daily as tablets
45825110|NCT02007720|Other|Standard of CareTherapy|This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
45967736|NCT01082068|Drug|XL765 (SAR245409)|given orally twice daily as capsules
45967737|NCT01082068|Drug|letrozole (Femara)|given orally once daily as tablets
45967738|NCT01086748|Drug|Risperidone|Administered orally.
45967739|NCT01086748|Drug|Placebo|Administered orally.
45967740|NCT01086748|Drug|LY2140023|Administered orally.
45967741|NCT00237705|Drug|metoclopramide|
45967742|NCT00209885|Drug|Gabapentin|
45967743|NCT00209885|Drug|S-ketamine|
45668100|NCT05309083|Behavioral|Mindfulness Based Walking Therapy (MBWT)|MBWT will be a modified form of the typical Mindfulness Based Stress Reduction (MBSR) program that incorporates more walking meditations and is acceptable for people with Parkinson disease and freezing of gait.
45668101|NCT05305807|Other|Postural exercises|Postural correction exercises are effective in improving forward head posture and it effectively decrease neck pain and increase ROM Exercise training and ergonomic guidelines concerning the use of touchscreen smartphones will reduce the risk of developing upper extremity musculoskeletal disorders
45668102|NCT05302297|Drug|Cemiplimab|Pharmaceutical Form: Concentrate solution for injection for intravenous (IV) infusion Route of Administration: Intravenous (IV) infusion
45668103|NCT02349425|Drug|Gefapixant|Gefapixant 7.5 and 50mg tablets administered orally
45668104|NCT02349425|Drug|Placebo (for gefapixant)|Placebo to gefapixant 7.5 and 50mg tablets administered orally
45668105|NCT02310581|Drug|Buprenorphine Sublingual Spray|Buprenorphine sublingual spray delivered via single 100 μL spray
45668106|NCT02310581|Drug|Placebo|Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
45825111|NCT01363440|Drug|Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)|
45825112|NCT01363440|Procedure|Macular Laser Photocoagulation|Laser therapy
45825113|NCT02007252|Drug|ACZ885|ACZ885 150 mg liquid pre-filled syringes were administered s.c..
45825114|NCT02007252|Drug|Placebo|Matching placebo liquid pre-filled syringes were administered s.c..
45825115|NCT02007096|Drug|Transabdominal Plane Block|0.25% bupivacaine injection in 6 different locations in abdomen. Weight <100kg: 50ml total; weight >100kg: 60ml total
45825116|NCT02007096|Drug|Non Transabdominal Plane Block|Saline injection in 6 different locations in abdomen. Weight <100kg: 50ml; weight >100kg: 60ml
45825117|NCT02006706|Drug|rituximab [MabThera/Rituxan]|1000 mg iv Days 1 and 15
45825118|NCT02006706|Drug|methotrexate|10 - 25 mg/week
45825119|NCT02006706|Drug|methylprednisolone|iv administration on Day 1 and 15 prior to MabThera/Rituxan infusion
45825120|NCT02049138|Drug|Upadacitinib|Tablet taken orally
45825121|NCT02049138|Biological|Pneumococcal 13-valent conjugate vaccine (PCV-13)|Administered by intramuscular injection
45967744|NCT00209885|Drug|Lidocaine|
45967745|NCT00209885|Drug|Droperidol|
45967746|NCT04996966|Biological|human umbilical cord-derived mesenchymal stem cells|In the MSCs injection group, 1×10^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
45967747|NCT04996966|Other|saline|In the control group, saline containing 2% albumin (2ml/kg) were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
45967748|NCT04999735|Behavioral|CHDR Monitoring Remotely (MORE)|CHDR MORE is a highly customizable platform which allows remote monitoring of patients and trial subjects, data ingestion, and data management. The current infrastructure includes an Android app to unobtrusively collect data from smartphone sensors, and a connection to the Withings Health online platform to collect wearable data. Data is stored on a secure server in a structured data scheme ensuring clear data management processes, forming a prerequisite for comprehensive data analysis. The Android app enables data collection from multiple smartphone sensors (e.g. location data, accelerometer and ambient light) as well as phone usage logs (e.g. app usage, calls and texts).
45967749|NCT04999735|Behavioral|Withings Steel HR|The Withings Steel HR is a commercially available smartwatch that combines various sensors to measure activity (steps, sleep, etc.) and heart rate (HR). HR is measured using a PPG (photoplethysmogram, i.e. optically obtained volumetric measurement) based on a commercially available sensor (AS7000) incorporating low-noise and high-sensitivity analogue circuitry. The manufacturer supplies the algorithm for converting the PPG signal into HR values. Data is transferred from the watch to the smartphone using the Withings Health Mate app from where it will be uploaded to the output server.
45967750|NCT04999735|Behavioral|Withings Body+ scale|Body composition (weight, BMI and Skeletal Muscle Mass) can be assessed with the Withings Body+ smart scale at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging.
45967751|NCT04999735|Behavioral|Withings Blood Pressure Monitor|Blood pressure can be assessed with the automated Withings Blood Pressure Monitor at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging
45967752|NCT04996693|Diagnostic Test|Imaging on Scanner with Spectral Imaging Capabilities|Patients will undergo imaging on a modern CT scanner with spectral imaging capabilities. A dose neutral spectral acquisition mode will routinely be used. Contrast material protocol and scan ranges are similar in all three arms.
45967753|NCT04996693|Diagnostic Test|CT Scan using an Energy-Integrating Detector CT (128 slice MDCT)|Patients will undergo imaging on a modern 128-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
45967754|NCT04996693|Diagnostic Test|CT Scan using an Energy-Integrating Detector CT (20-slice MDCT)|Patients will undergo imaging on a modern 20-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
45967755|NCT00234546|Biological|Botulinum toxin type A|1 injection, 500 U at day 0. The study will last for 6 months in each patient.
45967756|NCT00234546|Drug|Placebo|1 injection at day 0. The study will last for 6 months in each patient.
45967757|NCT04994002|Drug|CERC-006|Oral solution
45967758|NCT00209924|Drug|Gaboxadol|
45967759|NCT00234585|Device|Renal Artery Stent with Protective Device/Drug|
45967760|NCT00209963|Drug|Gaboxadol|
45668107|NCT04892693|Drug|Talazoparib Oral Capsule|- Patients will receive Talazoparib 1 mg orally once daily continuously, with or without food. Laboratory values will be monitored every 4 weeks until progression or unacceptable toxicity. Dose modifications should be made based on the observed toxicity
45668108|NCT02309723|Device|Beta amyloid imaging|
45967761|NCT04990336|Combination Product|Dachaihu decoction compound|Dachaihu decoction compound includes Bupleurum, Rhubarb, Citrus aurantium, Scutellaria, Pinellia, White Peony, Jujube, Ginger.
46080561|NCT05905861|Procedure|Skin incision with scalpel.|"A Pfannenstiel skin incision will be performed using a scalpel, extending through the subcutaneous tissue and rectus sheath. After separation of rectus muscles, peritoneum will be visualized and opened. Optimal hemostasis will be achieved by applying pressure to skin blood vessels and ligating any subcutaneous bleeding.~Group A: skin incision with a scalpel."
46080562|NCT05905861|Procedure|Skin incision with a diathermy.|"A Pfannenstiel skin incision will be made using a scalpel. Subsequently, a diathermy pen electrode will be employed for the dissection of deeper tissues.~Optimal hemostasis will be achieved by using the same blade pen electrode, set to coagulation mode.~Group B: skin incision with diathermy."
45668109|NCT02309411|Drug|Rivaroxaban (Xarelto, BAY59-7939)|With age and body-weight adjusted twice daily dosing of rivaroxaban as Oral Suspension to achieve a similar exposure as that observed in adults treated with 20 mg rivaroxaban once daily, and no other anticoagulant
46080563|NCT05905848|Drug|administering RASI (the trade name or universal name will not be stipulated) before stenting|"Pre-operative antihypertensive drugs before stenting will be random assigned (RASI or CCB) at least 5 days before stenting. Patients in RASI group will receive RASI (all kinds of RASI will be permited and the trade name or universal name of drugs will not be limited), with or without other antihypertensives except for CCB (any kind of CCB).~Blood pressure of patients should be controlled within the target range (140/90 mmHg); and usage and dosage of antihypertensive drugs will not be stipulated. Grapefruit intaking should be avoid."
45458328|NCT01350830|Procedure|anterior hernia repair|Inguinal incision is made, external oblique divided and the cord is encircled after identifying ilioinguinal and iliohypogastric nerves. The sac is dissected and reduced, in case of direct hernia the posterior wall of inguinal canal is plicated with polypropylene suture; in presence of indirect hernia the sac is reduced and a stitch is passed in manner that the deep ring is snug about the cord. A pre-shaped mesh is positioned on the floor of the canal around the cord with the two tails overlapping laterally; the mesh is then anchored to the pubic tubercle. External oblique is reapproximated with the cord transposed in the subcutaneous space and skin is sutured.
45668110|NCT02008227|Drug|Atezolizumab|1200 mg IV infusion on Day 1 of each 21-day cycle
45825122|NCT04686318|Diagnostic Test|Biomarkers for acute pyelonephritis|"Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of CRP, PCT and suPAR. Laboratory staff will be blinded to participant diagnosis and outcome. CRP and PCT results will be available to the treating physician, but the suPAR result will not be available.~Diagnostic test of CRP. CRP will be measured using an immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi Cobas© systems.~Diagnostic test of PCT: Plasma PCT will be quantified by an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas© within two hours from collection according to standard procedure.~Diagnostic test of suPAR: Plasma suPAR will be quantified by using the commercial available suPARnostic© Tubilatex assay reagents (ViroGates, Denmark) on Cobas© as previously validated (35). Separated plasma is kept refrigerated and analysed for suPAR within 48 hours after collection."
45668111|NCT02008227|Drug|Docetaxel|75 mg/m^2 IV infusion on Day 1 of each 21-day cycle
45668112|NCT04198649|Drug|Non-surgical periodontal treatment and azithromycin treatment|Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Drug: two 250mg azithromycin tablets one time daily for 3 days after scaling and root planning sessions
45668113|NCT04198649|Other|Non-surgical periodontal treatment and placebo treatment|Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Placebo: two 250mg starch tablets one time daily for 3 days after scaling and root planning sessions
45668114|NCT04867551|Drug|KDT-3594|oral administration, dose titration
45825123|NCT02048904|Drug|Sitagliptin|Sitagliptin 100 mg/day for 3 months
45825124|NCT02048904|Drug|Placebo|Placebo 1 pill/day for 3 months
45825125|NCT02006628|Drug|Placebo|Placebo oral solution (0 milligrams [mg]/mL CBD) contained the excipients sesame oil, ethanol, sucralose, and strawberry flavoring.
45967762|NCT04990336|Drug|Rhubarb single medicine|Rhubarb single medicine
45967763|NCT04990336|Combination Product|Regular therapies|Regular therapies, such as fluid therapy, for acute pancreatitis
45967764|NCT04990726|Behavioral|Assessment|Undergo medical assessments
45967765|NCT04990726|Procedure|Biospecimen Collection|Undergo collection of blood samples
45967766|NCT04990726|Other|Quality-of-Life Assessment|Ancillary studies
45967767|NCT04990726|Other|Questionnaire Administration|Complete questionnaires
45967768|NCT04999423|Device|LVIS EVO and HydroCoil Embolic System|Stent assisted Coiling
45967769|NCT00210002|Drug|Darbepoetin alfa (Aranesp®)|
45967770|NCT00210002|Drug|Ferric saccharose(Venofer®)|
45967771|NCT04991272|Other|prewarming and warmed fluid infusion|prewarming with forced air warming system and warmed fluid infusion.
45967772|NCT02277886|Drug|sodium alginate|oral suspension, 50mg/ml, 20ml once at bed time
45967773|NCT02277886|Drug|esomeprazole|40mg/tablet, one tablet once before breakfast
45967774|NCT00413751|Drug|Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)|
45967775|NCT00210041|Drug|Gemcitabine|Gemzar IV infusion 30 minutes Day 1/ Day 15 1250 mg/m²/j
45967776|NCT00210041|Drug|Cisplatin|Cisplatin 50 mg/m²/day 1 h IV infusion at Day 1 / Day 15
45825126|NCT02006628|Drug|GWP42003|GWP42003 was an oral solution containing 100 mg/mL CBD dissolved in the excipients sesame oil, ethanol, sucralose and strawberry flavoring.
45967777|NCT02278042|Other|Beverage Consumption|
45967778|NCT04990804|Drug|Opioid Analgesic|Patients will be provided a prescription for low dose opioids for 5 days postoperatively (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) to be taken every 6 hours as needed for pain. Refills may be provided (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) if requested by the patient at the providers discretion. In addition, patients will also be prescribed Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily and a muscle relaxer (Methocarbamol 750mg BID or Flexeril 5-10 mg TID) as needed for spasms. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
45967779|NCT04990804|Drug|Opioid-Free Postoperative Pain Regimen|Patients will receive no opioids. Pain will be managed with Acetaminophen 1000mg q8 hours, Ketorolac 10mg every 6 hours (for 5 days), Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily, and a muscle relaxer (Methocarbamol 750mg BID or Cyclobenzaprine 5-10 mg TID) all to be taken as scheduled for the first 2 weeks (except Ketorolac - 5 days) postoperatively as side effects permit. Other NSAIDS (Naprosyn 500 mg BID or Ibuprofen 800 mg TID) may be utilized if contraindications to Ketorolac exist. Famotidine (20mg BID) or Omeprazole (20mg daily) will be prescribed along with NSAIDS for GI prophylaxis. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
45967780|NCT00237783|Drug|dialysate sodium (140 mmol/L)|
45967781|NCT00237783|Drug|individualized dialysate sodium|individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
45967782|NCT00210080|Drug|Uridine 5'-Triphosphate (UTP) Solution for Inhalation|
45967783|NCT04991662|Drug|metaraminol|Infusion of metaraminol adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
45668115|NCT04862871|Behavioral|Physical Activity - Pediatric Pain Rehabilitation Center|While admitted to the Pediatric Pain Rehabilitation Center program, patients receive 1-3 hours of individual and group physical therapy 5 times per week and completed a 30-60 minute home exercise program 9 times per week. The median length of stay for the program is 5 weeks. The amount of aerobic exercise prescribed is individualized to each patient and ranged from 10-20 minutes per session. The duration of aerobic exercise prescribed progressed by 5-10 min weekly until the child reached 20-30 minutes. Patients are instructed to reach a moderate to vigorous intensity of exercise (defined at 5-7/10 rate of perceived exertion). The mode of exercise varied dependent on patient ability and interest. Typical modes of exercise included: walking, running, stationary biking, swimming, sports (i.e., soccer, dance), and online aerobic workouts. Patients were prescribed an individualized 30-60 minute discharge home program using the same structure upon completing the program.
45967784|NCT04991662|Drug|Phenylephrine|Infusion of Phenylephrine adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
45825127|NCT02048826|Device|FINGER I|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting I
45967785|NCT04991662|Drug|Norepinephrine|Infusion of Norepinephrine adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
45967786|NCT04997941|Drug|Tamoxifen Oral Product|Experimental arm will have tamoxifen 40mg and active comparator arm will have tamoxifen 20mg for 14 days.
45967787|NCT04997941|Diagnostic Test|Assessment of Ki-67|Paired biopsies (before and after tamoxifen therapy) will be required for the assessment of Ki-67.
45967788|NCT04997941|Procedure|Surgery|The surgery date should be fixed before randomization. The surgery is to be performed within 1 day after the last dose of study treatment.
45825128|NCT02048826|Device|FINGER II|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting II
45825129|NCT04711356|Drug|Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection|Ad26.ZEBOV is a monovalent, replication-incompetent adenovirus serotype 26-based vector that expresses the full-length Ebola virus Mayinga glycoprotein
45825130|NCT02006472|Drug|Pridopidine|22.5 mg and 45 mg capsules
45825131|NCT02006472|Other|Placebo|Capsules matching drug
45967789|NCT00210158|Procedure|Nitrous oxyde|
45967790|NCT00413790|Drug|Darifenacin|Darifenacin tablets 15 mg once daily
45967791|NCT00413790|Drug|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
45967792|NCT00413790|Drug|Placebo|Placebo tablet once daily
45967793|NCT04571710|Drug|SHR1258|Drug: SHR1258 400mg
45967794|NCT04993612|Diagnostic Test|Blood gas analysis|"Two blood samples will be drawn from the wedge position, behind the inflated balloon, during the right heart catheterization, and blood gas analyses will be performed. First sample will be drawn directly after inflating the ballon, and the second one 2 minutes later."
45967795|NCT04995211|Device|Assessment of resting energy expenditure|We will assess the resting metabolic rate and respiratory exchange ratio of twenty healthy adults, with every metabolic cart on two days in the morning. The assessment will last 30 minutes on each metabolic cart, with 15-minute breaks between measurements. The order of the metabolic carts will be randomly selected and replicated the second day.
45967796|NCT00210197|Procedure|Blood collection (pre and postoperative): plasma coagulation parameters|
45967797|NCT04999774|Diagnostic Test|Different diagnostic tests|Each SAC will be tested with all tests
45967798|NCT02962245|Drug|berberine|
45967799|NCT02962245|Drug|regular treatment|such as 5-ASA,immunomodulating/suppressive agents or Anti-TNF therapy
45967800|NCT04992754|Behavioral|psychotherapy, lifestyle counseling|psychotherapy, lifestyle counseling
45967801|NCT04990180|Behavioral|Shared Decision Making Intervention|Decision coaching will be provided to the Pulmonary Rehabilitation Specialists to provide the skills needed to facilitate shared decision making between themselves and patients (and carers). The patient decision aid will be an informational booklet which describes the available Pulmonary Rehabilitation options at the University Hospitals of Leicester. It will detail the risks and benefits of each option and provide interactive sections to engage patients with the content, guide them through it, encourage them to attribute personal meaning and preference to each one so they can make an informed and values-based decision about PR.
45967802|NCT00210236|Procedure|Conventional surgery|
45967803|NCT04571398|Other|ApricityRx mobile application|AE detection and monitoring software
45967804|NCT00237822|Behavioral|Adherence Feedback (AF)|
45967805|NCT00237822|Behavioral|AF + Contingency Management (AF + CM)|
45967806|NCT00237822|Behavioral|AF + Motivational Enhancement Therapy (AF + MET)|
45967807|NCT04571203|Biological|Combined Deceased Donor Kidney and Hematopoietic Cell Transplants|This combined kidney and hematopoietic cell transplants with a conditioning regimen with irradiation and ATG creates an environment of immune-tolerance. This promotes hematopoietic cell engraftment.
45967808|NCT00210275|Behavioral|Printed Educational Message|Three forms of printed educational materials (short or long educational messages and patient reminder notes)
45458329|NCT01350830|Procedure|transinguinal preperitoneal patch repair|Through a 5-cm inguinal incision external oblique fascia is divided, cremasteric fibers are separated and the elements of the cord are skeletonized. Indirect or direct hernia is approached and through the hernia orifice, the sac is reduced, preperitoneal space is accessed and dissected to allow easily placement of the patch facilitated by the memory recoil ring. In case of indirect hernia the lateral part of patch is split and the two tails sutured around vas and gonadic vessels. Hernia orifice is closed with a polypropylene stitch through transversalis fascia and the mesh; external oblique is closed followed by skin approximation.
45967809|NCT04993885|Drug|Avatrombopag|The subjects will receive avatrombopag treatment with an initial dose of 40mg once a day. Platelet counts will be obtained weekly during the first 4 weeks and then every 2 weeks until week 12 after treatment. The dose adjustment range is 20 mg per week to 40 mg per day to maintain the platelet level between 30×10^9/L and 200×10^9/L. If the platelet count does not reach to 30×10^9/L after taking avatrombopag 40mg once a day for 4 consecutive weeks, the treatment will be stopped.
45967810|NCT04998916|Device|Real TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses of continuous theta burst stimulation with the active sham coil (double blinded using the integrated active sham system).
45967811|NCT04998916|Device|Sham TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the integrated active sham system). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the scalp. The electrodes are placed on the left frontalis muscle under the coil for both the real and sham stimulation sessions.
45967812|NCT01059903|Drug|Rotigotine transdermal patch|Rotigotine 4.5 mg/10 cm^2 patch applied for 24 hours
45967813|NCT04996771|Drug|Surufatinib,Etoposide,Cisplatin,Toripalimab|"In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w＋Toripalimab 240mg,d1,q3w was taken orally until the disease progressed."
45967814|NCT04996771|Drug|Surufatinib,Etoposide,Cisplatin|"In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w was taken orally until the disease progressed."
45967815|NCT04996615|Other|no intervention|no intervention
45967816|NCT00210314|Drug|high dose methotrexate|
45668116|NCT02006979|Other|exercise|An acute bout of exercise performed 24 hours prior to every anthracycline infusion.
45967817|NCT00210314|Drug|high dose cytarabine|
46080564|NCT05905848|Drug|administering CCB (the trade name or universal name will not be stipulated) before stenting|"Pre-operative antihypertensive drugs before stenting will be random assigned (RASI or CCB) at least 5 days before stenting. Patients in CCB group will receive CCB (all kinds of CCB will be permited and the trade name or universal name of drugs will not be limited), with or without other antihypertensives except for RASI (any kind of RASI).~Blood pressure of patients should be controlled within the target range (140/90 mmHg); and usage and dosage of antihypertensive drugs will not be stipulated. Grapefruit intaking should be avoid."
46080565|NCT05905809|Device|UniRelieverTM offloading brace (THUASNE)|The patient will be instructed to wear the brace during walking and physical exercise. The investigator will explain to the patient how to adjust it
45668117|NCT02348723|Drug|Warfarin|Patients receiving Warfarin to keep International Normalized Ratio (INR)between 2.0 - 3.0
45668118|NCT02348723|Drug|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)
45967818|NCT00210314|Radiation|radiotherapy|
45967819|NCT04992676|Diagnostic Test|Polysomnograpy|Home polysomnography will be conducted using the scalable, modular Embletta system. Trained staff will instrument the participants in the evening and perform biocalibration to ensure optimal data quality
45967820|NCT04992676|Diagnostic Test|actigraphy|A water resistant accelerometer with light sensor and event marker will be worn on the nondominant wrist for approximately 7 days. Activity counts from the device will be analyzed by proprietary software algorithms for determination of the following: sleep onset, sleep offset, total sleep time, total wake time, and sleep efficiency.16 Daytime sleep periods will be also scored to determine frequency and duration of naps. Daily data will be averaged across the 7-day period, as well as separately for weekdays and weekend, to compute measures of habitual sleep patterns.
45967821|NCT04990024|Other|Dietary Intervention Med Diet|The diet will consist of a calorie-restricted Med diet, with 500 Kcal/d energy restriction. The intervention consists of individual and group educational sessions on Med diet. During the group sessions, the RA will go over the benefits of Med diet, what composition it should have, and how to make appropriate choices for meal planning, in addition to providing food lists, by season. The individual sessions with subjects will also allow to individualize the diet plan.
45967822|NCT04990024|Other|Dietary Intervention HP/LC Diet|This is a non-ketogenic diet consisting of ad libitum intake of proteins, fat, and vegetables, with restriction of daily carbohydrates to <130 g/d. The intervention consists of group educational sessions on HP/LC, same as with Med diet (above). The individual sessions with subjects will also allow to individualize the diet plan.
45967823|NCT04990024|Other|Dietary Intervention LF Diet|In this arm, participants will be advised to follow a calorie restricted LF diet with 500 Kcal/d energy restriction. Group and individual educational sessions will be held at the same frequency as the Med and HP/LC diets, and will have a similar content but targeting LF diet.
45825132|NCT02005692|Device|DynaSense sensor|
45458330|NCT03038347|Behavioral|Training|Six modules containing PDF-files with text-based information, video files, case studies with associated questions and practical exercises. Participants can download the modules and associated materials from an online platform they need to register for. They receive access to modules and associated exercises once a week. After six weeks the training is completed.
45458331|NCT03038347|Behavioral|Education only|Six modules containing only PDF-files with text-based information. Participants can download the modules and associated materials from an online platform they need to register for. They receive access to modules once a week. After six weeks the education is completed.
45668119|NCT01967277|Device|Handi-Dome Laser|One, 30 minute treatment, every other day for 16 weeks.
45668120|NCT01967277|Device|Incandescent red light source.|One, 30 minute treatment, every other day for 16 weeks.
45668121|NCT04411095|Other|Measuring thoracic rotation mobility|Measuring the thoracic rotation mobility with a goniometer, from a standardized position
45967824|NCT04999501|Other|Prolonged resistance-type exercise training|All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
45967825|NCT00210392|Drug|Bortezomib (drug)|Bortezomib 1,3 mg/m2 iv d1,4,8,11 every 21 days. Total 6 cycles
45967826|NCT04990882|Other|Interpretation of FAPI-PET/CT scans|Each observer's Group will be asked to review FAPI-PET/CT scans of patients with representative cancer types.
45668122|NCT02326883|Behavioral|Care Management|The Care Management intervention includes routine outreach to assess ongoing risk of suicide attempt and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
45967827|NCT04998487|Drug|LY3471851|Administered SC.
45967828|NCT00413829|Drug|Intravitreal ranibizumab with photodynamic therapy|Intravitreal injection, photodynamic therapy
46080566|NCT05905809|Device|Unloader One® X brace (Össur)|The patient will be instructed to wear the brace during walking and physical exercise. The investigator will explain to the patient how to adjust it
46080567|NCT05905757|Procedure|Dexmedetomidin + bupivacaine|dexmedetomidine was added as adjuvant to bupivacaine in transversus abdominis plane block (TAP)
46080568|NCT05905757|Drug|Tramadol + Bupivacaine|tramadol was added as adjuvant to bupivacaine in transversus abdominis plane block (TAP)
46080569|NCT05905744|Diagnostic Test|cholangioscopy|cholangioscopy examination and forceps biopsy, followed by brush biopsy from ERCP
45825133|NCT02029638|Biological|anti-thymocyte globulin|An initial dose of 0.5 mg/kg IV will be administered over 6 hours on Day -9. Thereafter the daily dose will be increased to 2 mg/kg IV given over 4 hours on Days -8 and -7. No more than 150 mg of ATG may be administered per day.
45825134|NCT02029638|Drug|Fludarabine|Fludarabine at dose 30 mg/m^2 will be administered daily by intravenous infusion over 30 minutes on Day -6 to Day -2.
45825135|NCT02029638|Drug|Cyclophosphamide|"Low dose pre-transplant cyclophosphamide will be administered intravenously (IV) over 1- 2 hours, (depending on volume) on Days -6 and -5. The dose of pre-transplant cyclophosphamide is 14.5 mg/kg/day.~High dose cyclophosphamide [50mg/kg (Ideal Body Weight)] will be administered on Day 3 post-transplant (within 60 to 72 hours of marrow infusion) and on Day 4 post-transplant. Cyclophosphamide will be given IV over 1-2 hours depending on volume."
46080570|NCT05905731|Biological|TCR-T|"Stage-1: Patients will receive three biweekly HBV-TCR T cell infusions at escalating doses, ranging from 1 x 10^5 cells/kg to 5 x 10^6 cells/kg bodyweight (by IV infusion). Patients are to remain on existing HBV NUC treatment.~Stage-2: Patients will receive three biweekly HBV-TCR T cell infusions at maximum dose as determined in Stage-1 study. Patients are to remain on existing HBV NUC treatment."
46080571|NCT05905705|Diagnostic Test|Electroencephalography (EEG)|High-density EEG will be acquired during resting wakefulness before each ECT session.
46080572|NCT05905705|Diagnostic Test|Quantitative Measurements of Sleep Microstructure|Overnight sleep EEG will be recorded one day before each ECT session using the DREEM device. The DREEM device allows continuous recording of multichannel EEG.
46080573|NCT05905692|Drug|L Carnitine|L carnitine will be given to group 1 (20 mg/kg/day) 3 times per week
46080574|NCT05905679|Dietary Supplement|Dietary Supplement: Probiotics|6 Billion CFU
46080575|NCT05905679|Dietary Supplement|Dietary Supplement: Placebo|0 CFU per day
46080576|NCT05905666|Behavioral|health education and counseling|In the control stage, participants only received standard nursing care. In the experimental stage, intervention measures (health education and counseling) were implemented. The baseline data were the pretest data collected in the control stage. Four weeks later, a posttest was performed, namely the pretest of the experimental stage. Subsequently, 4 weeks of health education and counseling were introduced to smokers according to different stages. After 4 weeks of intervention, participants were asked to fill out the posttest questionnaire again to measure the stages of change for smoking cessation, smoking decisional balance, and self-efficacy of smoking cessation.
46080577|NCT05905653|Drug|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 7 days
46080578|NCT05905640|Other|Method of PrEP delivery and consultation|All core PrEP services that include HIV testing, risk assessment, clinical review PrEP initiation, prescription, dispensing, and follow-up will be performed in a one-stop consultation with a single provider.
45967829|NCT04999267|Other|INVEST|The intervention will consist of 3 primary components: 1) school nurse training and technical support for promoting adolescent vaccination (Tdap, MenACWY, HPV) and strengthening existing school nursing vaccination programming, 2) caregiver-targeted educational materials that are disseminated via school nurses, and 3) tools and resources to facilitate linkage to vaccination providers in the local community. Existing materials will be used in the intervention such as resources available from the Centers for Disease Control and Prevention and Middle School Health Starts Here tool kit from the National Association of School Nurses and the National HPV Roundtable. Technical support includes the study team working with local school nurses to identify educational materials available from national and statewide sources.
45967830|NCT04993534|Behavioral|Stepped-care DWM/PM+|"The DWM program consists of a self-help guide that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. DWM includes five sections (or modules), each of which focuses on a specific skill. In this study, the DWM program will be delivered as an online intervention. The DWM intervention, i.e. both the audios and the self-help guide, have been adapted for use on a smartphone or other device with internet access.~PM+ is a new, brief, psychological intervention program based on cognitive-behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support."
45967831|NCT04993534|Other|Psychological First Aid + usual care (CAU)|All participants, both in the treatment and the comparison group, will be offered individual Psychological First Aid (PFA) through a face-to-face or teleconferencing meeting. In addition to PFA, both the treatment and the comparison group will receive care-as-usual (CAU); they will be allowed to receive any usual care. CAU may include community care, social/legal support, and psychoeducation.
45967832|NCT02210104|Drug|Ipilimumab|Starting Dose of Ipilimumab: 1.0 mg /kg by vein on Days 1, 22, 43, and 64.
45967833|NCT02210104|Drug|Cyclophosphamide|300 mg/m2 administered intravenously 2 days prior to T cell infusion.
45967834|NCT02210104|Biological|CD4+ T cells|Antigen-specific CD4+ T cells administered at a dose of 10^10 cells/m^2 on Day 0.
45967835|NCT00234663|Drug|PTC124|
45967836|NCT02210182|Drug|Oral Pentamidine|Oral pentamidine given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
45967837|NCT02210182|Other|Placebo|Placebo given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
45967838|NCT00210509|Drug|almotriptan malate|
45967839|NCT02210260|Procedure|Spinal and infusion of local anaesthetic|"Spinal anaesthetic will be performed in the lateral position using a midline approach. L3/4 interspace will be identified using Tuffier's as the anatomical landmark. After confirmation of correct placement using a 25G Whitacre needle, 12.5 mg of hyperbaric Bupivacaine in a mixture with 500mcg Diamorphine will be injected intrathecally.~PLUS~Painbuster® catheters will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine."
45967840|NCT02210260|Procedure|Continuous infusion of local anaesthetic|A Painbuster® catheter will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine.
45967841|NCT02210260|Drug|Bupivacaine|
46080579|NCT05905614|Drug|SPH4336 Tablets|Open-label SPH4336 Tablets ：Administered by oral
46080580|NCT05905601|Behavioral|NORTH|NORTH is a native mobile app that provides on-demand content to young adults at risk for psychosis to improve or maintain their well-being, coping skills, and healthy habits, knowledge of psychosis, and provide help-seeking resources.
46080581|NCT05905601|Behavioral|"NORTH Lite"|"NORTH Lite contains the same on-demand lessons, practices and tracking features found in the Full NORTH mobile application but does not include help-seeking resources."
45825136|NCT02029638|Radiation|Total Body Irradiation|Total body irradiation, consisting of 200 centigray (cGy) Anterior-Posterior/Posterior-Anterior (AP/PA) with 4 Megavolts (MV) or 6 MV photons at 8-12 cGy/min at the point of prescription will be administered in a single day on Day -1.
45825137|NCT02029638|Drug|acetaminophen|650 mg orally prior to antithymocyte globulin infusion.
45825138|NCT02029638|Drug|diphenhydramine|25mg diphenhydramine orally prior to antithymocyte globulin infusion.
45825139|NCT02029638|Drug|methylprednisolone|On Days -9 to -7 methylprednisolone 1mg/kg IV 1 hour prior ATG. This dose may be repeated once 3 hours after the first dose of steroids. On Day -6 and -5, methylprednisolone 0.75 mg/kg/ IV as a single dose; on Days -4 and -3, methylprednisolone 0.5 mg/kg/ IV as a single dose; on Day -2 methylprednisolone 0.25 mg/kg/ IV as a single dose.
45825140|NCT02029638|Biological|bone marrow transplant|Unprocessed, unmanipulated bone marrow will be harvested from the donor and infused into the recipient on Day 0.
45825141|NCT02029638|Drug|MESNA|A series of MESNA doses will be administered for each dose of high dose, post-transplant cyclophosphamide. The total daily dose of MESNA is equal to 80% of the total daily dose of cyclophosphamide.
45825142|NCT02029638|Drug|mycophenolate mofetil|MMF will be administered at a dose of 15 mg/kg orally three times per day based upon actual body weight, with the maximum of 3 grams a day from Day 5 to 35. The dose will then be reduced to the standard 1 g twice daily thereafter.
46080582|NCT05905588|Dietary Supplement|Hydrogen-rich water|Patients drink 600mL hydrogen-rich water per day by applying hydrogen-rich water cup (Qingdao Haizhisheng Corp.,LTD, Qingdao, China) for 12 weeks. The dissolved hydrogen concentration is 5 ppm.
45825143|NCT02029638|Drug|prednisone|Prednisone will be administered at a dose of 10 mg orally daily from Day 5 for 12 weeks. Thereafter the dose will be reduced to 5 mg orally daily.
45825144|NCT02029638|Drug|filgrastim|All recipients will receive 5 microgram/kg per day of filgrastim as a single, subcutaneous injection from Day 5 post-transplant until the absolute neutrophil count is greater than 1000/µl on three consecutive measurements over at least 2 days.
45967842|NCT02210260|Drug|Diamorphine|500mcg
45967843|NCT02210260|Device|A Painbuster® catheter|
45967844|NCT02210260|Device|25G Whitacre needle|
45967845|NCT02210299|Other|Exposure study|Sampling of blood, food, water, air and dust and delivery of dietary questionnaire
45967846|NCT02210338|Device|Karl Storz C-MAC|
45967847|NCT02210338|Device|Bonfils Intubation Fibrescope|
45967848|NCT00234702|Drug|Lanthanum carbonate|Lanthanum carbonate 750mg/day, T.I.D. for 2 weeks; titrated at the next 3 weekly visits in order to achieve target serum phosphorus levels, up to a maximum dose of 3000mg/day; 4-week maintenance period where subject receives the final titrated daily dose established during the titration period.
45967849|NCT00234702|Drug|Placebo|Placebo
45967850|NCT00210548|Drug|paliperidone palmitate|
45967851|NCT04571359|Other|Oxalate to creatinine ratio|Comparsion between 24 hours urine oxalate and spot urine oxalate to creatinine ratio
45967852|NCT04570735|Diagnostic Test|MRI|MRI
45967853|NCT04570813|Other|Artistic activies|12 workshops of artictic activities during 12 weeks
46080583|NCT05905588|Dietary Supplement|placebo|Patients drink 600mL tap water per day by applying analogue cup for 12 weeks. This cup has the same appearance as the hydrogen-rich water cup, and the hydrogen-rich water and placebo water were indistinguishable. The dissolved hydrogen concentration is 0 ppm in placebo water.
45825145|NCT04710654|Other|connective tissue manipulation|Individuals in CTM group, will sit on a stool with hips and knees flexed at 90° and their hands free on the thighs. The application will start from the basic area in the first session, and in the other sessions, the lower thoracic, scapular, inter-scapular and cervical regions will be included in the treatment as soon as possible according to the state of the vascular reaction. CTM will be applied three days a week, for four weeks.
45967854|NCT00234741|Drug|STA-5326 mesylate|
46080584|NCT05905562|Other|core stabilization exercises|Core muscles activation exercises will be performed on patients to target the abdominals.
46080585|NCT05905562|Other|Spinal mobilization techniques|lumbar spine joint mobilization techniques will be performed to patient in prone lying.
45455698|NCT05789004|Procedure|Tooth Bleaching with Whiteness HP Automixx 6%|"Clinical examination and taking the initial shade of the tooth with Vita Easyshade®;~Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~Prophylaxis with a Robson brush and prophylactic paste;~Application of lip balm on the patient's lips;~Placement of the labial retractor;~Application of the gingival barrier;~Application of Whiteness HP Automixx 6% whitening gel;~In the session, a single application of the gel will be carried out and where it will remain on the surface of the tooth for 15 min;~The gel must be removed from the teeth with a sucker and the teeth cleaned with gauze;~Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~The second bleaching session will be carried out 7 days after the first one and, if necessary, a third session can be carried out 7 days after the second one."
45668123|NCT02326883|Behavioral|Skills Training|The Skills Training intervention uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.
45668124|NCT02326883|Behavioral|Usual Care|Those assigned to usual care will not be contacted at all by study staff and will continue to receive usual care from treating primary care and mental health providers.
46080586|NCT05905549|Procedure|extended pancreatic transection during laparoscopic pancreaticoduodenectomy|the pancreatic transection was performed at the pancreatic neck beyond the left side of the mesenterico-portal axis during laparoscopic pancreaticoduodenectomy
46080587|NCT05905536|Device|Vitalstream|The device will be placed on the subject and monitoring started in the holding room on the morning of surgery. Monitoring will continue postoperatively until the pulmonary artery catheter (PAC) is removed (Standard of Care) or discharged, or at study team discretion. At Intensive Care Unit (ICU) admittance and again 3 hours later a straight leg raise will be done to monitor for changes in hemodynamics.
45455699|NCT05788991|Drug|Dequalinium Chloride|Fluomizin vaginal tablets (10 mg dequalinium chloride) used once a day for 6 days
45455700|NCT05788991|Drug|Metronidazole Oral|Metronidazole oral tablets (500 mg) taken twice a day for 7 days
45668125|NCT02006667|Drug|trastuzumab|4 mg/kg i.v., Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v., Day 1 of Cycle 2 until disease progression
45668126|NCT02006667|Drug|gemcitabine|1200 mg/m2 i.v. on Days 1, 8, and 15 of Cycle 1 through 6
45668127|NCT02006667|Drug|cisplatin|70 mg/m2 i.v. on Day 2 of Cycles 1 through 6
45668128|NCT01983111|Drug|buprenorphine|Dosage and administration: This one patch should be attached every 7 days.
45967855|NCT00210587|Drug|epoetin alfa|
45967856|NCT04570696|Other|NON INTERVENTIONAL|NON INTERVENTIONAL
45967857|NCT04570540|Diagnostic Test|Sleep Study|Full-night attended in-lab polysomnography with accompanying transcutaneous capnometry
45967858|NCT04570540|Diagnostic Test|Pulmonary Function Test|Bodyplethysmographic assessment
45967859|NCT04570540|Diagnostic Test|Hypercapnic ventilatory response|Measurement of hypercapnic ventilatory response based on the method described by Read in 1967, using a rebreathing bag
45967860|NCT04570540|Diagnostic Test|Cardiopulmonary Exercise Test|Symptom-limited cardiopulmonary exercise test with a ramp protocol according to the ATS/ACCP and ERS recommendations
45967861|NCT04570462|Other|Hypothermia Via Cooling Machine- Arctic Sun 5000|"Initiate hypothermia using the Arctic Sun.The Arctic Sun 5000® is set to a temperature of 34.5 C to lower the body temperature.~Duration of hypothermia will be 48 hours after which the subject will be rewarmed. Metabolic rate, or indirect Calorimetry, will be assessed at baseline, day 1 of hypothermia, day 2 of hypothermia before rewarming, and after full rewarming. CBC, basic metabolic profile, magnesium, phosphorus, coagulation profile, ABG, inflammatory markers would be drawn every 12 hours during hypothermia until subject has achieved full rewarming and once after full rewarming.~The entire hypothermia procedure will last 48 hours. Acceptable rewarming range is a temperature of 36.5C to 37.5C. The subject body temperature rewarming is typically set over 6-8 hours. Therefore, the final 6-8 hours of the 48 hour time period is set to rewarm the subject."
45967862|NCT00234780|Procedure|pediatric nursing used in home to avoid hospitalization|
45967863|NCT00210665|Drug|Trabectedin|Type= exact number, unit= mg/m2, number= 1.5, form= intravenous infusion, route= intravenous use. 1.5mg/m2 as 24hr infusion on day 1 of each 21 day cycle
45967864|NCT04570189|Device|Auscul-X|The Auscul-X System (AusculSciences Canada, Inc.), is novel, professional grade, touch free, multichannel, touch-free electronic stethoscope with disposable elements designed to protect HCPs from exposure to infection diseases by allowing them to auscultate patients from a safe distance (10 feet away). The sensors can stay in place and enable providers to listen on-demand to a patient's heart and lungs over an extended period of time. This practice of distancing in the workplace is a key CDC and PHAC recommendation to protect the frontline HCP from exposure risk to the highly contagious COVID- 19 virus and other communicable diseases. The Auscul-X not only has the potential to better protect HCPs from infection, but also eliminates the potential transmission of pathogens through the use of conventional stethoscopes. In addition, the Auscul-X allows multiple HCPs to listen to the patient's heart and lung sounds simultaneously
45967865|NCT04570345|Drug|ticagrelor monotherapy|• Drug: ticagrelor monothearpy after first 3 months dual therapy
45967866|NCT04570345|Drug|Aspirin with P2Y12 receptor inhibitor|• Drug: aspirin plus ticagrelor dual therapy during 12 months
45967867|NCT04570228|Device|Pulmonary artery denervation|The TIVUS system will be used for pulmonary artery denervation using non focused ultrasound
45967868|NCT04570228|Device|Sham procedure|A sham procedure would be performed using the TIVUS system without delivering the non focused ultrasound
45967869|NCT04570072|Dietary Supplement|Probiotic|Patients receive the formula probiotic for consecutive 8 weeks ( one sachet per day ).
45967870|NCT04570072|Dietary Supplement|Placebo|Patients receive the placebo identical to probiotic for consecutive 8 weeks ( one sachet per day ).
45967871|NCT00234819|Drug|Bazedoxifene/Conjugated Estrogen|
45967872|NCT00210704|Drug|Dapoxetine|
45967873|NCT04570306|Drug|Belimumab|The study will involve 80 adult patients diagnosed with SLE who will be started on belimumab (standard approved dose of i.v. 10 mg/kg or subcutaneous 200 mg/week) due to active disease. The intention to start belimumab will be made by the treating Rheumatologist(s), in accordance to the current standard of care, and on the basis of shared physician-patient decision making.
45967874|NCT04570033|Diagnostic Test|We assessed sensitivity of 18F-FCH PET/CT in preoperative localisation of hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism|We prospectively enrolled 65 consecutive patients with PHPT who underwent neck ultrasound (US) and parathyroid scintigraphy (99mTc/99mTc-MIBI dual phase). Twenty-two patients had unsuccessful parathyroid surgery prior to the study. PET/CT scans were performed 65.0 ± 13.3 min after injection of 218.5 ± 31.9 MBq of 18F-fluorocholine (FCH). Three experienced nuclear medicine physicians assessed the detection rate of hyperfunctioning parathyroid tissue. Response to parathyroidectomy and clinical follow-up served as a reference test. Per-patient sensitivity and positive predictive value (PPV) were calculated for patients who underwent surgery.
45967875|NCT04569721|Device|CT Guided Splanchnic Cryoablation|The patient will be sedated and continuously monitored by the anesthesia team, who will be present for the entire procedure. The puncture site will be anesthetized with 1% Lidocaine infiltration. Following tract anesthesia, and utilizing fluoroscopic CT guidance, four cryoablation probes (Ice Rods®) will be advanced, 2 on each side. In addition, a temperature monitoring probe (Boston Scientific, Multipoint 1.5 Thermal Sensor®) will be advanced on each side. The cryoablation process will include a 10-minute freeze, followed by a 3-minute passive thaw, and a brief active thaw to facilitate probe removal. A final scan will be obtained following removal of the probes. After the procedure, a sterile dressing will be applied, and subjects will be monitored for at least 12 hours in an observation bed in the hospital post-procedure.
45967876|NCT00234858|Drug|trandolapril/verapamil|2/180 mg QD with titration if needed at Week 4 to 4/240 mg QD
45967877|NCT00234858|Drug|(Hyzaar) losartan/hydrochlorothiazide|50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD
45967878|NCT04569955|Behavioral|Knowledge and perception of clinical trial participation|This study aims to get a current picture of the patients' knowledge and perception of clinical trial participation in Breast cancer female patients in Egypt, as an example to Low/Middle income countries
46080588|NCT05905523|Other|Assessing prewriting skills in children|"In this study, your child will be asked to do the following things:~Play a drawing game on a tablet~Copy shapes using a pencil in a paper booklet~Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development"
46080589|NCT05905497|Drug|Bemnifosbuvir (BEM)|BEM administered BID for 4 days and QD on Day 5 (9 consecutive doses)
46080590|NCT05905484|Drug|Bemnifosbuvir (BEM)|A single dose of BEM will be administered.
45668129|NCT01983111|Drug|tramadol/acetaminophen|"Amount of drug ingredients~: Acetaminophen 325 mg and Tramadol hydrochloride 37.5 mg in 1 tablet of this drug.~Dosage and administration:~Adjust dose depending on a patient's pain severity and treatment response. Starting at the initial dose of 2 tablets, usually administer 4 tablets per dose, twice daily. At a dosing interval of at least 12 hr, the daily dose should not exceed 8 tablets."
46080591|NCT05905484|Drug|Placebo|A single dose of matching placebo will be administered.
46080592|NCT05905484|Drug|Moxifloxacin|A single dose of Moxifloxacin will be administered.
46080593|NCT05905458|Drug|HRS9950 tablets|HRS9950 tablets, oral, once a week, low dose
46080594|NCT05905458|Drug|HRS9950 tablets|HRS9950 tablets, oral, once a week, high dose
46080595|NCT05905458|Drug|HRS9950 placebo tablets|HRS9950 placebo tablets, oral, once a week.
45825146|NCT04710654|Other|Interferential current stimulation (100 Hz frequency)|The four electrodes (superficial, self-adhesive, 5x9 cm rectangular) coming out of the two channels will be used. Two of the electrodes will be placed bilaterally at the level of the spinal segment, T9-L2, where the sympathetic fibers of the gastrointestinal tract are innervated, in the posterior region, and the other two will be placed anteriorly on the umbilicus lateral to the abdomen. The current will be applied at the sensory level, increasing to the extent that the patient feels the current effectively but does not reveal pain, discomfort and visible muscle contractions. The application will be made to the individuals at 100 Hz frequency three days a week, for four weeks.
46080596|NCT05905445|Drug|ozone gel|the activity of omega-3 in the ozone gel may be advantageous as a host-modulating agent in the supplemental treatment of periodontitis
46080597|NCT05905419|Other|2 Study Visits with MRI Scanning|Participant undergoes MRI scanning, blood draw(s), urine sample(s)
45455701|NCT05788913|Biological|Heparin|subcutaneous Heparin
45668130|NCT04672941|Drug|Tiotropium bromide plus Olodaterol|Tiotropium bromide plus Olodaterol
45668131|NCT02348489|Drug|SGI-110 (guadecitabine)|Investigational medicinal product
45668132|NCT02348489|Drug|Treatment Choice|Choice of one: cytarabine, decitabine, or azacitidine
45668133|NCT02309099|Device|Cochlear Implant|Cochlear implantation used a treatment for single-sided deafness resultant of labyrinthectomy or a translabyrinthine surgical approach
46080598|NCT05905419|Other|1 Study Visit with MRI Scanning|Participant undergoes MRI scanning, blood draw, urine sample
46080599|NCT05905419|Drug|Opioid Randomization|"Participant is randomized to take their prescribed opioid medication before (peak opioid phase) or after (trough opioid phase) the MRI scan"
46080600|NCT05905406|Other|Electrical estimulation|Electrical estimulation during the fatigue protocol. Frequency = 100 Hz, pulse duration = 500 µs, time ON = 20 s (including rise time = 1.0 s and descent time = 1.0 s) and off time = 20 sec
46080601|NCT05905393|Dietary Supplement|preoperative stimulation of the efferent loop with GABA before ileostomy closure surgery|Foley catheter No.14 Ch connected to an infusion set was introduced through the defunctioned bowel to allow the slow infusion, for 10-20 minutes, of a solution with 3000 mg of GABA diluted in 100 ml of 0.9% physiological saline.
45668134|NCT01966107|Drug|Aclidinium Bromide|400 μg, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
45668135|NCT01966107|Drug|Placebo|Dose matched placebo, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
45668136|NCT01982331|Biological|LAIV H2N2|vaccine is delivered intranasally, .25 cc to each nostril at day 0 and day 28
45668137|NCT01982331|Other|Placebo|placebo delivered intranasally. .25cc to each nostril at day 0 and day 28
45668138|NCT02326025|Drug|Olaratumab|Administered IV
45668139|NCT02326025|Drug|Doxorubicin|Administered IV
45668140|NCT01619865|Drug|68Ga-DOTATOC PET/CT|1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.
45825147|NCT04710654|Other|Interferential current stimulation (0-100 Hz frequency)|The four electrodes (superficial, self-adhesive, 5x9 cm rectangular) coming out of the two channels will be used. Two of the electrodes will be placed bilaterally at the level of the spinal segment, T9-L2, where the sympathetic fibers of the gastrointestinal tract are innervated, in the posterior region, and the other two will be placed anteriorly on the umbilicus lateral to the abdomen. The current will be applied at the sensory level, increasing to the extent that the patient feels the current effectively but does not reveal pain, discomfort and visible muscle contractions. The application will be made to the individuals at 0-100 Hz frequency three days a week, for four weeks.
45825148|NCT04710654|Other|behavioural therapy|"The behavioral therapy includes patient education (description of the disease, symptoms, risk factors, treatment, defecation mechanism and informing about negative attitudes and behaviors towards defecation), lifestyle advices (diet, water consumption, fiber food, etc.), teaching effective defecation posture, timed toilet training, self-abdominal massage.~Constipation Behavioral Therapy Booklet will be prepared within the scope of behavioral therapy."
45825149|NCT04710654|Other|exercise program|"Exercise program consisting of physical activity, core stabilization exercises and pelvic floor muscle exercises.~Exercise Program Booklet will be prepared within the exercise training."
45825150|NCT02047734|Drug|Ozanimod|Oral capsule, daily for 24 months
45825151|NCT02047734|Drug|Ozanimod placebo|Oral capsule, daily for 24 months
45825152|NCT02047734|Drug|Interferon beta-1a|Intramuscular injection, 30 µg, weekly for 24 months
45825153|NCT02047734|Drug|Interferon beta-1a placebo|Intramuscular injection, weekly for 24 months
45825154|NCT02053350|Drug|Alanyl-glutamine|Alanyl-glutamine, 44g, taken by mouth daily for 10 days
45825155|NCT04684914|Biological|HepTcell|Intramuscular injection
45825156|NCT04684914|Drug|Placebo|Intramuscular injection
45825157|NCT04709016|Behavioral|self-questionnaire|self-questionnaire assessing Chemsex's (drug use in a sexual context) consumption over the last 12 months
45825158|NCT04417140|Biological|dHACM (AmnioWrap)|Dehydrated human amnion-chorion membrane (dHACM) is a healing adjunct that has been applied in a broad range of disease, and is FDA registered for wound healing.
45825159|NCT01994850|Drug|brentuximab vedotin|Trade name: Adcetris
45825160|NCT02027844|Behavioral|Cartoon|Cartoon watching by children during inhalational induction of sevoflurane
45668141|NCT02006121|Drug|Apomorphine hydrochloride|Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
45668142|NCT02006121|Drug|Placebo|Sodium chloride 9 mg/ml
45825161|NCT02027844|Behavioral|parental presence|parental presence during inhalational induction of sevoflurane
45825162|NCT04671576|Other|Control Infant Formula|Powder, standard commercial infant formula.
45825163|NCT04671576|Other|Organic Infant Formula|Powder, organic milk-based infant formula.
45825164|NCT01994382|Drug|Cerdulatinib|Oral capsule
45825165|NCT01994382|Biological|Rituximab|IV infusion
45825166|NCT02003898|Device|Medtronic MiniMed 530G Insulin Pump|
45825167|NCT01994226|Drug|Low-dose colchicine|"Route of Administration: Tablet - Oral Use~Dose: 500 mcg (one tablet) every eight hours for four days"
45825168|NCT01994226|Drug|Naproxen 750 mg/250 mg|"Route of Administration: Tablet - Oral Use~Dose: Single initial dose of 750 mg (three tablets) followed by 250 mg (one tablet) every eight hours for up to seven days"
45825169|NCT02002884|Drug|IncobotulinumtoxinA (8 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
45825170|NCT02002884|Drug|IncobotulinumtoxinA (6 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
45825171|NCT02002884|Drug|IncobotulinumtoxinA (2 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
45825172|NCT02002182|Biological|ADXS11-001 (ADXS-HPV)|ADXS11-001 (ADXS-HPV) is a live attenuated Listeria monocytogenes (Lm)-LLO immunotherapy developed for the treatment of HPV-associated dysplasia and malignancy.
46080602|NCT05905393|Dietary Supplement|preoperative stimulation of the efferent loop with only physiological saline|Foley catheter No.14 Ch connected to an infusion set was introduced through the defunctioned bowel to allow the slow infusion, for 10-20 minutes, of 100 ml of 0.9% physiological saline.
46080603|NCT05905367|Drug|Fentanyl|Symptom-inhibited IV fentanyl induction
46080604|NCT05905367|Drug|Methadone|Opioid agonist therapy (OAT) with methadone at starting doses established by symptom-inhibited IV fentanyl induction
46080605|NCT05905367|Drug|Slow-release oral morphine|Opioid agonist therapy (OAT) with SROM at starting doses established by symptom-inhibited IV fentanyl induction
46080606|NCT05905354|Biological|NWRD08|Subjects in dose group 1 and 2 were intramuscularly injected with NWRD08 at week 0, week 4 and week 12 by electric pulse gene delivery instrument, respectively. Subjects in dose group 3 and 4 were intramuscularly injected NWRD08 at week 0, week 2, week 4 and week 12 by electric pulse gene delivery instrument, respectively.
46080607|NCT05905341|Drug|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
46080608|NCT05905341|Combination Product|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
46080609|NCT05905341|Drug|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
45668143|NCT02005887|Drug|triptorelin|Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days)
45668144|NCT02005887|Drug|degarelix|Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)
46080610|NCT05905341|Combination Product|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
45668145|NCT02005887|Drug|letrozole|Letrozole 2.5 mg orally every day for 6 cycles
45668146|NCT01982253|Drug|Fasiglifam|Fasiglifam tablets
45668147|NCT01982253|Drug|Placebo to fasiglifam|Fasiglifam placebo-matching tablets
46080611|NCT05905341|Drug|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
46080612|NCT05905341|Combination Product|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
46080613|NCT05905341|Drug|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
46080614|NCT05905341|Combination Product|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
46080615|NCT05905341|Drug|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
46080616|NCT05905341|Combination Product|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
46080617|NCT05905341|Drug|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
46080618|NCT05905341|Combination Product|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
45668148|NCT01981473|Other|no intervention|
45668149|NCT01981473|Other|no intervention|
45825173|NCT01990950|Device|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneursyms having morphology suitable for endovascular repair
45825174|NCT02001558|Drug|Microcyn|Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily for the earlier of total wound closure or Week 24
45967879|NCT04569838|Drug|Bendamustine hydrochloride injection|Bendamustine is a bifunctional alkylating agent. It cross-links DNA single strand and double strand by alkylation,then destroys the function and synthesis of DNA, and makes the DNA and protein, protein and protein cross-linking, has potential to treat various tumors
45967880|NCT00210743|Drug|epoetin alfa|
46080619|NCT05905341|Drug|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
46080620|NCT05905341|Combination Product|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
45455702|NCT05788900|Biological|Heparin|intravenous Heparin
45455703|NCT05788835|Procedure|DEB-TACE and HAIC|Drug-eluting bead transarterial chemoembolization sequential Hepatic Artery Chemotherapy Infusion
45668150|NCT01981473|Other|no intervention|
45967881|NCT04569916|Radiation|radiotherapy|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
45967882|NCT04569916|Drug|irinotecan liposome|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
46080621|NCT05905328|Drug|CTO1681 10 μg|Administered 3 times daily for 15 days (initial cohort).
45668151|NCT02005029|Drug|Erythromycin|
45668152|NCT02005029|Drug|placebo|
45668153|NCT04672161|Other|Vaccine Education|A baseline educational intervention on vaccination and its role in the health maintenance of patients with IBD will be provided to all participants. Those on immunosuppressive therapies and/or those age 65 or older will also be offered the pneumonia vaccine educational intervention. Finally, patients aged 18-26 and those 27-45 who have never been vaccinated for HPV or those with high risk for HPV will additionally receive the HPV educational intervention.
45967883|NCT04569916|Drug|apatinib|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
45967884|NCT04569916|Drug|PD-1 antibody|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
45967885|NCT04569643|Diagnostic Test|Actigraphy|Participants will undergo overnight leg actigraphy at baseline. Leg movements will be recorded bilaterally by actigraphic method with two ankle-worn recorders.
45967886|NCT04569643|Diagnostic Test|Cardiorespiratory monitoring|All participants will be scanned for presence of sleep-related breathing disorders with a portable monitoring device at baseline. The compact screening device will be attached to the patient's wrist during the night sleep.
45967887|NCT04569643|Diagnostic Test|Neuroimaging|All subjects will undergo brain MRI scanning at baseline and in 1-year follow-up. The imaging protocol will include axial T1, T2, T2*, FLAIR and diffusion-weighted imaging scans that will be made on a 3-Tesla scanner.
45668154|NCT02325791|Drug|Suptavumab 30 mg/kg|Participants received single dose of suptavumab 30 milligram per kilogram (mg/kg) intramuscularly (IM) on Day 1.
45967888|NCT04569643|Other|Assessment of cognitive function|Assessment will take place at weeks 0 (baseline) and 52 (1 year follow-up). The neuropsychological protocol will be consist of Montreal Cognitive Assessment (MoCA), 12-word Verbal Memory Test, Benton Visual Retention Test, Frontal Assessment Battery, Trail Making Test (parts A and B), phonetic (as a part of the MoCA) and semantic verbal fluency assessment, Symbol Digit Modalities Test.
45967889|NCT04569643|Other|Sleep quality and mood questionnaires|Self-reporting scales and questionnaires will be used at baseline to assess sleep quality, daytime functioning and mood. The protocol includes the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, the Geriatric Depression Scale.
45825175|NCT02001558|Other|Sterile saline|Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily for the earlier of total wound closure or Week 24
45825176|NCT02023866|Drug|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release capsules
45967890|NCT04569760|Drug|50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose)|Oral cannabinoid oil preparation dosed in 1ml increments
45967891|NCT04569760|Drug|Placebo Oil|Oral MCT Oil Preparation - No cannabinoids- titrated as tolerated up to a maximum of 8mls twice daily (equivalent to 200 mg- 800 mg total dose of the active product)
45967892|NCT00210782|Drug|topiramate, phenytoin|
45967893|NCT00237861|Drug|risperidone|
45967894|NCT00237861|Drug|olanzapine|
45967895|NCT00237861|Drug|quetiapine|
45668155|NCT02325791|Drug|Placebo Matched to Suptavumab|Participants received 2 IM doses of placebo matched to suptavumab: the first dose on Day 1 and the second dose on Day 57.
45668156|NCT02325791|Drug|Suptavumab 30 mg/kg- 1 Dose|Participants received single dose of suptavumab 30 mg/kg IM on Day 1 and single dose of placebo matched to suptavumab on Day 57.
45668157|NCT02325791|Drug|Suptavumab 30 mg/kg - 2 Doses|Participants received 2 doses of suptavumab 30 mg/kg IM: the first dose on Day 1 and the second dose on Day 57.
45825177|NCT02023242|Device|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
45825178|NCT02023242|Device|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
45825179|NCT01967940|Drug|TAF|25 mg tablet administered orally once daily with food
45825180|NCT01967940|Drug|Placebo|Tablets to match TAF administered orally once daily with food
45825181|NCT01967940|Drug|E/C/F/TAF|150/150/200/10 mg STR administered orally once daily with food
45825182|NCT01967940|Drug|Current failing ARV regimen|Participants will continue taking their current ARV regimen as prescribed in Part 1.
45825183|NCT01967940|Drug|ATV|300 mg tablet administered orally once daily.
45825184|NCT01990560|Drug|Mifepristone|All patients in the study will receive daily Mifepristone for 6 months and primary and secondary outcomes will be assessed before and after the 6 month treatment period
45967896|NCT00237900|Drug|Gefitinib, 5-fluorouracil, leucovorin and radiotherapy|
45967897|NCT04569565|Device|PleurX catheter|Placement of PleurX catheter for refractory cirrhotic ascites, with follow up monitoring
45668158|NCT02004873|Device|Micra Pacemaker Implant|
45668159|NCT04672005|Drug|Folfirinox alternating with Gemcitabine-nab-Paclitaxel|modified Folfirinox every 2 weeks and biweekly Gemcitabine plus Nab-Paclitaxel
45825185|NCT01998984|Drug|ingenol mebutate|
45825186|NCT01998984|Other|Placebo|
45825187|NCT04416594|Other|Data collection|Only data collection
45825188|NCT01967706|Other|mTHS|Single use of Tobacco Heating System 2.2 Menthol (mTHS)
45825189|NCT01967706|Other|mCC|Single use of subject's own menthol cigarette (mCC)
45825190|NCT01967706|Other|NRT|Single administration of 2 mg gum (Nicorette® 2mg)
45825191|NCT01967628|Dietary Supplement|Vitamin D3 (cholecalciferol)|
45825192|NCT01967628|Dietary Supplement|Placebo Sugar Pill|
45825193|NCT01998906|Drug|Trastuzumab|8mg/kg IV on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycle 2 up a maximum of Cycle 17
45825194|NCT01998906|Drug|Doxorubicin|60 mg/m2 IV on Day 1 of Cycles 1 through 3
45825195|NCT01998906|Drug|Paclitaxel|150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7
45967898|NCT04569292|Other|No intervention on patients|No intervention on patients
45967899|NCT04569526|Device|use of intraoperative ultrasound|Ultrasonography guided brain lesions resection intra operatively for good localization
45967900|NCT00210821|Drug|topiramate|
45967901|NCT00237939|Drug|Aripiprazole|
45967902|NCT04569370|Procedure|Laparoscopic Cholecystectomy|Surgical removal of Gall bladder using laparoscopy
45967903|NCT04569019|Other|Vacciantion status in health care workers|Education among HCW about benefits of influenza vaccination. Using posters, email, conversations, informations about vaccination used during vaccination Vaccinating during working hours Vaccinating for free Vaccinating inside departments ( not in special clinic)
45967904|NCT04569214|Drug|PAZ320|Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets Treatment arm C - 4 tablets of PAZ320
45967905|NCT04569214|Other|Placebo|Treatment arm A - 4 tablets of placebo Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets
46080622|NCT05905328|Drug|CTO1681 20 μg|Administered 3 times daily for 15 days (successive cohort).
45668160|NCT02347787|Behavioral|IMPaCT|"The IMPaCT intervention has three stages:~Goal-setting: CHWs will help patients to deconstruct the chronic disease management goal they set with their PCP into patient-driven short-term goals and action plans.~Tailored Support: CHWs will conduct weekly follow-up for 6 months through either telephone or home visit in order to support the achievement of patients' short-term goals.~Connection with longitudinal support: IMPaCT CHWs will also facilitate a weekly patient support group."
46080623|NCT05905328|Drug|CTO1681 30 μg|Administered 3 times daily for 15 days (successive cohort).
45825196|NCT01998906|Drug|CMF|CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10
45455704|NCT05788835|Procedure|DEB-TACE|Drug-eluting bead transarterial chemoembolization
45458562|NCT02340026|Other|Conventional Therapy|"No or static weight support; Therapist-directed (therapist initiates); Traditional early gait training methods: use of assistive devices/orthoses and may use treadmill; Focus on producing typical movement patterns with extensive manual guidance/correction from therapist, prevention of falls; Therapy activities grouped into blocks of practice (i.e. repeated floor to stand practice followed by gait training); Physical therapist expertise is focused on designing and directing the specific practice activities each session, tailored to the individual child"
45668161|NCT02347787|Other|Usual care|
45668162|NCT04416399|Drug|Budesonide dry powder inhaler|Budesonide inhaled via dry powder inhaler, 400 micrograms per inhalation, 2 inhalations twice a day
45668163|NCT01979835|Device|GyneFix Viz|insertion of GyneFix Viz and measurment of the SA distance
45668164|NCT02282345|Other|Laboratory Biomarker Analysis|Correlative studies
45668165|NCT02282345|Drug|Talazoparib|Given PO
45825197|NCT01967550|Drug|diclofenac diethylamine, DDEA 2.32% gel|
45825198|NCT01967550|Drug|Placebo|
45825199|NCT01989546|Drug|BMN 673|Poly (ADP-ribose) polymerase (PARP) inhibitor; has been shown to cause single-agent synthetic lethality in breast cancer 1 and breast cancer 2 (BRCA1/2)- and phosphatase and tensin homolog (PTEN)-deficient cell lines, and has potent antitumor activity in animal models of tumors harboring mutations in deoxyribonucleic acid (DNA) repair pathways.
45825200|NCT01989468|Biological|Secukinumab|Secukinumab 150 mg provided in a 1 mL autoinjector (1 autoinjector for 150 mg dose, 2 autoinjectors for 300 mg dose)
45825201|NCT01989468|Biological|Placebo|Secukinumab placebo provided in 1 mL autoinjector
45825202|NCT01989156|Other|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
45825203|NCT01989156|Other|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
45825204|NCT01989156|Other|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 86 days in an ambulatory setting
45825205|NCT01620762|Drug|Cat-PAD|1 dose every 4 weeks
45825206|NCT01620762|Drug|Placebo|1 dose every 4 weeks
45825207|NCT01966068|Other|MyAsthma Web Portal|Parents will log on to the MyAsthma Web Portal up to three different times over a 6 month period. During each portal visit, parents will be asked to complete a survey which will include questions regarding their views on treatment preferences, goals, asthma control, and medications for their child with asthma.
45825208|NCT01620528|Drug|elagolix|oral tablet
45825209|NCT01620528|Other|placebo|oral tablet
45825210|NCT01965834|Drug|Fenofibrate|Upon screening, registration and enrollment, all subjects will receive Fenofibrate 160 mg orally daily for at least 2 months and may continue receiving study medication for as long as in the opinion of the investigator there is clinical benefit in doing so. Patients with calculated creatinine clearance < 50 mL/min will receive a reduced dose of 54 mg orally daily.
45825211|NCT01965600|Drug|PF-06282999|Tablet, 125 mg, TID, 3 days, 1 of 2 periods
45825212|NCT01965600|Drug|Placebo|Tablet, 0 mg, TID, 3 days, 1 of 2 periods
45825213|NCT01965600|Other|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
45825214|NCT01965600|Drug|PF-06282999|Tablet, 500 mg, BID, 3 days, 1 of 2 periods
45825215|NCT01965600|Drug|Placebo|Tablet, 0 mg, BID, 3 days, 1 of 2 periods
45825216|NCT01965600|Other|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
45825217|NCT01996332|Drug|erlotinib [Tarceva]|150 mg/day until progressive disease or unacceptable toxicity
45825218|NCT04669548|Device|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
45825219|NCT01996254|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
45825220|NCT01987986|Biological|Collagenase Clostridium Histolyticum|injectible intervention
45825221|NCT01987986|Biological|Placebo|
45825222|NCT04659018|Biological|blood collection|A 5ml blood sample will be taken in a dry tube when the venous line necessary for the general anaesthesia for the colonoscopy is placed.
45825223|NCT04658940|Device|AcQBlate® Force Sensing Ablation System|Percutaneous catheter ablation of the cavotricuspid isthmus
45825224|NCT01987908|Drug|Aes-103|The active ingredient in Aes-103 is 5-hydroxymethyl furfural (5-HMF). Aes-103 and matching placebo are administered in a liquid oral formulation.
45825225|NCT01987908|Other|Placebo|
45825226|NCT01995552|Device|External Loop Recorder|
45825227|NCT01987830|Device|MRI-PET|"[11C] temozolomide for PET scan and a contrast dye for the MRI scan~Drawing blood to assess the radioactivity of [11C] temozolomide"
45967906|NCT04569409|Biological|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Wagner grade 2 Foot Ulcer
45458563|NCT02318914|Drug|gevokizumab|
45458564|NCT01365026|Behavioral|PVS: Programa de Vida Saludable|Lifestyle counseling and prescription
45458565|NCT02319070|Other|Survey|Recombinant antihemophilic factor VIII (FVIII) on Secondary Prophylaxis treatment scheduled according to daily routine
45967907|NCT04569409|Procedure|Vehicle Sheet|Application of Vehicle sheet to Diabetic Wagner grade 2 Foot Ulcer
45967908|NCT00210860|Drug|topiramate|
45967909|NCT00237978|Drug|Adapalen|
45967910|NCT00237978|Radiation|VIS and wIRA|
45967911|NCT04568941|Behavioral|Vacuum-Assisted Biopsy|Vacuum-Assisted Biopsy
45967912|NCT04568941|Behavioral|Core Needle Biopsy|Core Needle Biopsy
45967913|NCT04568941|Behavioral|Intraoperative Excisional Biopsy|Intraoperative Excisional Biopsy
45967914|NCT04568668|Device|ActionADE|"ActionADE is a software application that allows healthcare providers to document standardized adverse drug event information in a user-friendly and standardized manner. We integrated ActionADE uni-directionally with PharmaNet, a secure province-wide network that links all pharmacies in British Columbia to a central data system. This allows care providers to pull in demographic information and visualize their patient's medication dispensing history.~In 2020, we enabled bi-directional integration with PharmaNet allowing clinicians to transmit standardized adverse drug event information back to the PharmaNet database. The three dominant community pharmacy systems in the geographic area of the trial will display the adverse drug event information in their systems, and generate patient-specific medication-level alerts when pharmacists attempt to re-dispense a culprit medication."
45967915|NCT04568746|Procedure|emergency vital room|At the arrival of the patient, the qSOFA will be carried out to guide the orientation. Patient with score ≥ 2 will be supported in emergency vital room
45967916|NCT04568746|Procedure|box|patient with score < 2 will be supported in box
45967917|NCT00210899|Drug|ceftobiprole medocaril|
45967918|NCT00210899|Drug|Vancomycin plus Ceftazidime|
45668166|NCT01732822|Drug|Ticagrelor|Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
45668167|NCT01732822|Drug|Clopidogrel|Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
45668168|NCT02004093|Drug|pertuzumab|Loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks
45668169|NCT02004093|Drug|paclitaxel|175 mg/m2 IV every 3 weeks for 6 cycles
45825228|NCT01987830|Device|TMZ-PET|The PET scan will take approximately 90 minutes. You will receive one injection of [11C] temozolomide. Following the injection of the radioactive substance, blood samples will be taken from the second IV line.
45825229|NCT01987596|Biological|filgrastim|Given SC once daily starting on day 1 after chemotherapy in Arm I (fixed) and on any day when ANC drops below 1000/mcl in Arm II (flexible)
45668170|NCT02004093|Drug|gemcitabine|1000 mg/m2 IV Day 1 and 8 of each cycle for 6 cycles
45668171|NCT02004093|Drug|carboplatin|Target AUC of 5 following paclitaxel or AUC of 4 following gemcitabine IV every 3 weeks for 6 cycles
45668172|NCT01641367|Drug|Darunavir|Participants were administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (taken with Ritonavir 100 mg twice a day [200 mg per day])
45668173|NCT01641367|Drug|Etravirine|Patients were administered Etravirine orally as two 100 mg tablets or one 200 mg tablet twice a day (400 mg per day) following a meal.
45668174|NCT01641367|Drug|Emtricitabine/tenofovir disoproxil fumarate|Patients were administered FTC/TDF orally as one fixed dose combination tablet (FTC 200 mg/TDF 300 mg) once daily, with or without food.
45668175|NCT01641367|Drug|Raltegravir|Participants were administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food
45825230|NCT04658316|Behavioral|Iowa Oral Performance Instrument|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure
45825231|NCT01964898|Behavioral|Behavioral Activation (BA)|5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management. BA sessions will occur over the 12 weeks after hospital discharge.
45825232|NCT01964898|Behavioral|Standard Smoking Cessation Counseling|1 hour of in hospital counseling based on clinical guidelines
45825233|NCT01964898|Drug|Nicotine patch|An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
45825234|NCT01964898|Other|Printed Self-help materials for Smoking Cessation|
45967919|NCT04568785|Behavioral|Brief Intervention for Influenza vaccine|Previous to the intervention, patients were asked about the reasons to reject the influenza vaccine. Brief Intervention was performed by the healthcare professional during the consultation. It was given verbally, with written support.
45967920|NCT04568785|Behavioral|Normal advice|In the CG the influenza vaccine advice was the normal advice that professionals used to give their patients and was not asked for the reasons for the rejection of the vaccine to prevent them from influencing the advice.
45967921|NCT04568863|Drug|Melatonin intravenous|7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
46080624|NCT05905315|Drug|Paclitaxel and Carboplatin|Paclitaxel 175 mg/m2, followed by carboplatin 5 area under the curve (AUC). This will be administered in a 3-weekly scheme.
46080625|NCT05905315|Combination Product|Chemoradiation|According to standard treatment.
45825235|NCT01964352|Drug|tiotropium|fixed dose combination
45967922|NCT04568863|Drug|Placebo intravenous|7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
45967923|NCT02210377|Other|Tianjiu|After randomization, patients in Tianjiu and placebo (non-Tianjiu) groups will receive 12 sessions of treatment over a 4-week treatment period.The format of the Tianjiu intervention will be the same as in the treatment group. Participants will be instructed to lie supine before their HD session, and then the bilateral KI1 and CV4
45967924|NCT02210377|Other|Placebo (non-Tianjiu)|The format of the placebo (clay) intervention will be the same as in the treatment group.
45668176|NCT01641367|Drug|Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)|LPV/r and ATV/r were the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC were the most frequent NRTI backbones. Cohort A did not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.
45668177|NCT01641367|Drug|Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available|For Cohort D, in many situations a participant received the same regimen that patients are getting in Cohorts B and C if that was the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there were no further drug options beyond the available study drugs).
45668178|NCT01641367|Other|SOC adherence versus SOC+CPI adherence|"not participating in the adherence randomization; OR~randomized to SOC adherence; OR~randomized to SOC+CPI adherence."
45967925|NCT02210416|Procedure|inguinal hernia surgery|
46080626|NCT05905302|Other|Forced and Voluntary Exercise|Participants will complete a forced exercise (FE) and voluntary exercise (VE) session. Forced exercise is a mode of high intensity exercise in which voluntary exercise rate is augmented, but not replaced. Voluntary exercise is standard stationary cycling. FE and VE exercise sessions will be Off antiparkinsonian medication. The order in which exercise session is conducted first will be randomized. Bilateral neural activity of the STN will be continuously recorded for 130 minutes (pre, during FE or VE and post-exercise).
46080627|NCT05905289|Other|observational study|no intervention as it is an observational study
45967926|NCT00210938|Drug|Doripenem|
46080628|NCT05905276|Other|ERAS Protocol|The ERAS protocol for ambulatory TURBT has been designed based on patient and provider input, a needs assessment of 150 patients in the hours after TURBT, a review of the literature, and experience with other ambulatory ERAS protocols already implemented at Johns Hopkins Hospital. The ERAS protocol for ambulatory TURBT aims to optimize care delivered in the pre, intra and postoperative settings.
46080629|NCT05905276|Other|Standard of Care|Patients in the usual care arm of the EMBRACE trial will experience the present-day care pathway of ambulatory TURBT at Johns Hopkins Hospital.
45668179|NCT02325713|Drug|Oral dispersible tablet of praziquantel (ODT-PZQ)|Treatment A (test): ODT-PZQ (MSC1028703A) at a single dose of 40 milligram per kilogram (mg/kg) orally dispersed in water after meal.
45668180|NCT02325713|Drug|Cysticide|Treatment B (reference): Cysticide tablet at a single dose of 40 mg/kg will be given with water orally after a meal.
45825236|NCT01964352|Drug|placebo|
45825237|NCT01964352|Drug|olodaterol|fixed dose combination
45825238|NCT01964352|Drug|tiotropium|fixed dose combination
45825239|NCT01964352|Drug|tiotropium|
45825240|NCT01964352|Drug|olodaterol|fixed dose combination
45825241|NCT01946412|Drug|Ivacaftor|
45825242|NCT01946178|Device|Mirabilis High-Intensity Focused Ultrasound Treatment System|The intervention consists of a treatment session with the device, during which focused ultrasound energy is applied across the intact abdominal wall to ablate appropriately selected uterine fibroids under ultrasound imaging guidance.
45825243|NCT01945944|Drug|Hypertonic saline (3%)|3mL of HTS given via nebulizer every 6hrs
45825244|NCT01945944|Drug|Placebo (0.9% saline)|3mL of normal saline given via nebulizer every 6hrs
45825245|NCT01945866|Drug|intravitreal ranibizumab 0.3 mg|Intravitreal injection of 0.3mg ranibizumab performed on the day of randomization and up to every 4 weeks using defined treatment criteria
45967927|NCT02278081|Drug|lansoprazole|the lansoprazole will be taken orally.
45967928|NCT02278081|Drug|placebo|the lansoprazole placebo will be taken orally.
45967929|NCT02278159|Procedure|Peritoneal dialysis|
45967930|NCT02278159|Procedure|Home hemodialysis|
45967931|NCT02278276|Drug|sodium polysulthionate|Bioavailable composition of α-sulfur
45967932|NCT02278276|Drug|Placebo|400 mg capsules containing placebo
45967933|NCT02210455|Behavioral|Strongest Families FASD intervention|
45668181|NCT02325713|Drug|ODT-PZQ|Treatment C1 (test): ODT-PZQ (MSC1028703A) at a single dose of 20 mg/kg orally dispersed in water after a meal.
45825246|NCT01945866|Drug|dexamethasone intravitreal implant|The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
45825247|NCT01945866|Procedure|Sham injection|No injection is given. It is a sham injection to keep the participant masked. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first.
45825248|NCT01986114|Drug|SM-13496|
45825249|NCT01945710|Drug|Eribulin-LF|
45668182|NCT02325713|Drug|ODT-PZQ|Treatment C2 (test): ODT-PZQ (MSC1028703A) at a single dose of 60 mg/kg orally dispersed in water after a meal.
45668183|NCT02325713|Drug|ODT-PZQ|Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.
45668184|NCT02325713|Drug|Cysticide|Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.
45668185|NCT04877639|Drug|Esmketamine,Dexmedetomidine|Two different drugs were given to observe which of the two drugs was more suitable for DISE detection
45668186|NCT02325401|Drug|Metformin|Escalating doses of 2000mg, 2550 mg and 3000mg. Starting 1 week prior to the initiation of chemoradiation and ending the final day of chemo or radiation.
45825250|NCT01945242|Drug|Alogliptin|Alogliptin tablets
45825251|NCT01945086|Drug|Ustekinumab|Participants will receive subcutaneous (SC) injections of either ustekinumab 45 mg or ustekinumab 90 mg at Week 0 and Week 4.
45825252|NCT01945086|Drug|Placebo|Participants will receive SC injections of placebo at Week 0 and Week 4.
45668187|NCT02325401|Drug|Cisplatin|Dosed at 100mg/m2 on days 1, 22, and 43
45668188|NCT02325401|Radiation|Radiation Therapy|70 Gy in 2 Gy once daily fractions of 35 fractions
45825253|NCT01945086|Other|Concomitant topical medications for atopic dermatitis|Concomitant topical medications (as defined in the protocol) can be used from 4 weeks prior to randomization and throughout the study. However, the dosage cannot be increased and new medications cannot be added until after Week 12.
45825254|NCT04637802|Behavioral|CBT (SurgeryPal)|The SurgeryPal intervention is a cognitive-behavioral program for youth undergoing major surgery. SurgeryPal is delivered in two 4-week phases: the pre-operative phase, and the post-operative phase. Each phase consists of 3 separate treatment modules for youth and parents, which teach cognitive and behavioral coping skills to target known psychosocial and behavioral risk factors (i.e. anxiety/distress and sleep disturbance) for poorer postsurgical outcomes, and provide training in pain self-management skills. Pre-operative modules include: 1) Preparing for surgery, 2) Coping with stress before surgery, and 3) Getting ready for the hospital. Postoperative modules include: 1) Coping at home after surgery, 2) Return to activities and school, and 3) Long-term recovery. Modules are self-guided and interactive, and focus on phases of preparation and recovery from surgery. The goal of the program is to reduce pain and enhance quality of life following surgery in youth.
45825255|NCT04637802|Behavioral|Education|The patient education website will serve as the active comparator. The purpose is to control for time, attention, and online usage. Youth and parents will be provided access to an education website containing information about pediatric surgery at the same time interval as the active intervention; however, there will be no exposure to cognitive and behavioral coping skills. Similar to the CBT condition, the presurgery period of Education will be administered for one month prior to surgery and the postsurgery period will be administered for one month after the post-discharge assessment.
45825256|NCT04658160|Behavioral|Longitudinal Tracking and Intervention Platform for Medicare Advantage Patients|access to/use of the tracking platform
45825257|NCT01963728|Drug|Insulin, Isophane|daily dosing based on fasting morning glucose levels
45967934|NCT02210455|Other|Psychoeducation|
45967935|NCT00210977|Drug|No intervention|This is an observational study. All participants will be maintained on their regular dose regimen of standard-of-care treatment, under the guidance of the treating physician/investigator.
45668189|NCT02324699|Drug|Prednisone|
45668190|NCT02324699|Drug|Placebo|
45668191|NCT02324699|Drug|Vedolizumab|300mg IV over 30 minutes. Both arms will receive vedolizumab at weeks 0, 2, and 6.
45825258|NCT01963728|Drug|insulin glargine|daily dose based on fasting morning glucose levels
45825259|NCT01963260|Drug|MK-8723|MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
45825260|NCT01963260|Drug|Matching Placebo|Matching placebo to MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
45825261|NCT01962948|Drug|paclitaxel|Given IV
45825262|NCT01962948|Drug|ganetespib|Given IV
45825263|NCT01962948|Other|laboratory biomarker analysis|Correlative studies
45825264|NCT01985334|Drug|Glycopyrronium|Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day
45825265|NCT01985334|Drug|SABA|Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy
45825266|NCT01985334|Drug|LABA|Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy
45825267|NCT01985334|Drug|Indacaterol maleate and glycopyrronium bromide|Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day
45825268|NCT01985334|Drug|LAMA|Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy
45967936|NCT02210494|Drug|Secretrol|
45967937|NCT02210611|Procedure|Intrauterine Insemination 36 hours|Intrauterine insemination 36 hours after ovulation induction
45967938|NCT02210611|Procedure|Intrauterine Insemination 42 hours|Intrauterine insemination 42 hours after ovulation induction
45967939|NCT04568707|Other|blood sample|blood sample for serum (serology, biomarkers) and DNA
45967940|NCT00211016|Drug|doripenem|
45967941|NCT04568512|Diagnostic Test|Control|Brushed biliary samples from a known case of benign biliary stricture were sent for DNA Methylation Biomarker test and cell cytology
45458332|NCT02321020|Procedure|Radiofrequency maze procedure|Radiofrequency energy was used to create continous endocardial and epicardial lesions mimicking most of the left atrial incisions set as described in the Cox Maze III procedure. In the first 70 patients a monopolar technology was employed (Cardioblate Surgical Ablation Pen, Medtronic Inc, Minneapolis, MN, USA - cooled tip cardioblate pen, power ranging from 25 to 35 W), while in the subset of patients who underwent surgery after July 2005 a bipolar device was used (Cardioblate BP2 Irrigated RF Surgical Ablation System, Medtronic Inc, Minneapolis, MN, USA). The tip of both types of RF probe was irrigated with saline at room temperature at a flow rate of 4-6 ml/min.
45668192|NCT01764256|Biological|P2-VP8 subunit rotavirus vaccine|P2-VP8 subunit rotavirus vaccine was made by inserting a codon optimized synthetic gene for the VP8 region of rotavirus VP4 fused to the P2 T-cell epitope of tetanus toxin into the Pj411 proprietary cloning vector developed by DNA 2.0, Menlo Park, CA. The vector carries a kanamycin resistance gene as a selection marker. The vector was transfected into the BL21 strain of E. coli. The fusion protein was purified from Isopropyl β-D-1-thiogalactopyranoside (IPTG)-induced and physically lysed cultures using standard column chromatographic techniques employing Q-Sepharose and Butyl 650 as resins in addition to ultrafiltration and diafiltration.
45668193|NCT01764256|Other|placebo|Sodium Chloride 0.9%, USP for Injection was used to dilute the active P2-VP8 vaccine to final dosing concentration and was used for the Placebo for the study.
45668194|NCT01979523|Other|Laboratory Biomarker Analysis|Correlative studies
45668195|NCT01979523|Other|Pharmacological Study|Correlative studies
45967942|NCT04568512|Diagnostic Test|Cholangiocarcinoma|Brushed biliary samples from a known case of cholangiocarcinoma were sent for DNA Methylation Biomarker test and cell cytology
45967943|NCT04568473|Other|PRG Barrier Coat (By SHOFU Inc., Japan)|PRG Barrier Coat (By SHOFU Inc., Japan) is a bioactive, resin-based varnish based on the proprietary Giomer concept which incorporates the patented bioactive S-PRG (Surface Pre-Reacted Glass ionomer) filler technology, where a unique combination of six beneficial ions are actively gradually released to provide a smart solution to revolutionize dentin hypersensitivity protocol
45668196|NCT01979523|Drug|Trametinib|Given PO
45668197|NCT01979523|Drug|Uprosertib|Given PO
45668198|NCT02255461|Drug|palbociclib isethionate|Given PO
45668199|NCT02255461|Other|pharmacological study|Correlative studies
45967944|NCT04568473|Other|EMBRACE™ Varnish by (Pulpdent Corporation, USA)|5% sodium fluoride with CXP™ (Xylitol-coated Calcium and Phosphate) technology for unsurpassed fluoride release and it is considered as a novel method of delivering remineralizing ions (Calcium and Phosphate) in combination with xylitol. The incorporation of CXP™ in a permeable resin matrix that does not separate, purportedly drives the sustained, time-released properties of this varnish.it has ten times more fluoride release over a 4-hour period than the leading varnish brand, in addition, it also releases bioavailable calcium and phosphate ions which are nano-coated with xylitol.
45967945|NCT04568278|Other|ePRO-CTCAE application|The intervention will be the use of a mobile application for recording symptoms during cancer treatments. Patients in the intervention group will have the mobile application (e-PRO) installed on their smart phones on the first day of cancer treatment (chemotherapy or radiation therapy) and patients will be asked to use the application for 8 weeks. Every week, the application will ask patients to report symptoms they experienced during past 7 days using the pre-specified PRO-CTCAE questions for different types of cancer. Patients also can memo and save photos related symptoms using the application and patients can monitor the progression of the symptoms over time.
46080630|NCT05905263|Other|Application group with virtual reality|Each student will be introduced to the materials to be used for virtual reality and will be informed about the application. After the introduction and information is given, the lens and pupil distances of the virtual reality glasses will be adjusted according to each student and students will be asked to wear them on their heads. Students will then be required to wear gloves. The application will be made one-on-one with each student. The application will be carried out sitting in the laboratory. If the student experiences symptoms such as dizziness and nausea during the application, the application will be terminated. If the student wants to continue the practice after listening, it will be continued. While the students are inside the application, the interface will be introduced through the images projected to the computer simultaneously.
45668200|NCT02255461|Other|laboratory biomarker analysis|Correlative studies
45668201|NCT02255149|Device|Bone/Mesh|A titanium mesh (Ti-Mesh) that is more porous than other materials will be placed in order to hold a spot for the bone particles to grow.
45668202|NCT01764022|Drug|Trastuzumab|Patients will receive 6 courses of trastuzumab in combination with paclitaxel. Trastuzumab will be administered at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations) as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
45668203|NCT01764022|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 every 3 weeks (on Day 1 of each course) as 3 hour intravenous infusion (6 courses totally).
45668204|NCT02003391|Drug|Beta-blocker monotherapy|Per participant's current prescribed therapy
45825269|NCT01985334|Drug|SAMA|Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy
45825270|NCT01985334|Drug|ICS|Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy
45825271|NCT01944774|Drug|Nemonoxacin 500 mg|IV Infusion, once daily for 7~14 days
45825272|NCT01944774|Drug|Nemonoxacin 650 mg|IV Infusion, once daily for 7~14 days
45825273|NCT01944774|Drug|Moxifloxacin 400 mg|IV Infusion, once daily for 7~14 days
45668205|NCT02003391|Drug|Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution|
45668206|NCT04852627|Behavioral|Brisk walking|Walking
45825274|NCT04665648|Drug|Nicorandil|6 mg nicorandil iv. just before coronary intervention, 6mg/h ivgtt. up to 48h after coronary intervention
45825275|NCT04665648|Drug|Placebo|placebo iv. just before coronary intervention, ivgtt. up to 48h after coronary intervention
45967946|NCT04568317|Behavioral|Space from Depression|This is a 7-module internet-based CBT program. The structure and content of the modules follow evidence-based CBT principles; they are structured to incorporate quizzes, videos, psychoeducational content and interactive tools, personalised homework suggestions and summaries. One of the interactive tools is the mood monitor, where users are encouraged to monitor their mood and reflect on several factors that might had influenced it. Clients are allocated to a psychological wellbeing practitioner (PWP). The PWP is responsible for monitoring and guiding the client's progress throughout the intervention. Over the course of the 8 week supported intervention period, on 6 separate occasions the PWP will review participants progress, leaving feedback for them and responding to the work they have completed. The basic share level allows PWP is to view users' goals for the week, key messages and progress points. Each PWP will provide post-session feedback of between 10 and 15 minutes per session.
46080631|NCT05905250|Behavioral|an empirically supported protocol, further refined with evidence-based strategies|The intervention utilizes an empirically supported protocol, further refined with evidence-based strategies targeting the needs of young adult (YA) survivors. Its long-term goal is to promote hopeful thinking, and ultimately enhance other long-term markers of quality of life (QOL) (including mental health and health behaviors). The intervention follows 8 weekly curricula, reinforced through psychoeducation and skill-building, homework/practical application, and self-monitoring. Its 8-week design was informed by cognitive behavioral therapy and positive psychology intervention literature.
46080632|NCT05905250|Behavioral|Health education|Health education regarding maintaining a healthy weight, physical activity, and nutrition, based on American Cancer Society and NCI guidelines/recommendations.
46080633|NCT05905237|Procedure|Cataract surgery, Femtosecond-LASIK, SMILE|Cataract surgery includes both conventional and femtosecond laser assisted. Femtosecond-LASIK and SMILE are options for patients to correct myopia.
46080634|NCT05905211|Other|Observational Tests|The Berg Balance Scale was used to evaluate the balance levels, the Timed Up and Go Test was used to evaluate the functional mobility levels, and the Functional Independence Scale was used to evaluate the activities of daily living. The World Health Organization Quality of Life Instrument-Older Adults Module (WHOQOL-OLD) was used to evaluate the quality of life, the Fear of COVID-19 Scale was used to evaluate the COVID-19 fear levels, the Geriatric Depression Scale was used to evaluate the symptoms of depression.
46080635|NCT05905198|Device|Programming|programming the implanted DBS device to adjust the parameter and switch stimulation mode between Variable-Frequency settings and High-Frequency settings.
46080636|NCT05905185|Drug|Tocotrienol-rich fraction vitamin E (TRF)|The 50 mg of vitamin E isomers in the TRF included 17.1 mg of α-tocopherol ,18.28 mg of α- tocotrienol, 2.02 mg of β-tocotrienol, 22.3 mg of γ-tocotrienol and 7.4 mg of δ-tocotrienol.
45458333|NCT02321020|Procedure|Transthoracic echocardiography|Contemporary to clinical follow up, all patients were evaluated with 2-dimensional transthoracic echocardiography by the same cardiologist at 3,6,12 and 24 months in order to specifically monitor left atrial contractility presence.
46080637|NCT05905185|Drug|Placebo|50mg of Placebo
45668207|NCT04658901|Device|ERA-C70,ERA-C30 and ERA-G5|use endovenous radiofrequency closure catheter (ERA-C70,ERA-C30) and endovenous radiofrequency closure generator (ERA-G5) to treat varicose veins of lower extremity
45668208|NCT04658901|Device|ClosureFast™ and ClosureRFG™|use ClosureFast™ and ClosureRFG™ which has the indication of the treatment of varicose veins of lower extremity approved by NMPA
45458334|NCT03294434|Other|Diffusion tensor Imaging (DTI)|Diffusion tensor Imaging (DTI) is a technique sensitive to the ordered diffusion of water along white matter tracts and can detect subtle disruption. A diffusion tensor signature method was developed that splits the tensor information into isotropic and anisotropic diffusion components. This can differentiate regions of pure tumour from invaded white matter.
45668209|NCT02254681|Drug|Gemcitabine|
45668210|NCT02254681|Drug|Cisplatin|
45668211|NCT02254681|Radiation|low dose radiotherapy|Whole liver and portal lymph node basin low dose radiotherapy
45668212|NCT01965327|Drug|Interferon Gamma-1b|"Subjects will begin by taking 10 mcg/m2 of IFN-g-1b for the first two weeks of the study. Dose will be escalated to 25 mcg/m2 of IFN-g-1b for weeks three and four of the study. Finally, the dose will be escalated to 50 mcg/m2 of IFN-g-1b for the last eight weeks of the study, which is the current dose approved by the FDA for children.~All doses will be administered via subcutaneous injection."
45668213|NCT04872595|Other|Personalized rATG (P-rATG)|P-rATG days (always starting on Day -12 to -10)
45668214|NCT04872595|Radiation|Hyper fractionated total body irradiation|"(1375 - 1500cGy*) Day -9 to -6~*TBI dose in 125cGy fractions (with lung shielding) and total dose to be determined by treating physician/radiation oncology and is based off age, stage of disease, and anesthesia requirements."
45825276|NCT01944462|Behavioral|Pharmacist Pneumococcal Vaccine Program (PPVP)|1.5 hour educational intervention delivered onsite at collaborating senior center consisting of 3 components: presentation about pneumococcal disease and the vaccine given by a infectious disease-certified pharmacist; 2) skits given by volunteer actors at the senior center to illustrate real world scenarios related to pneumococcal disease and the vaccine; 3) action planning to consist of small group breakouts led by licensed pharmacists and 4) vaccination day which is an optional component following the education program, for participants eligible to receive the vaccine. Vaccination to be provided free of charge to eligible participants who opt to receive it.
45967947|NCT04568317|Device|Mood Monitor watch app|"The Mood Monitor watch app will allow in-the-moment self-report of patients' mood and automated monitoring of their sleep and activity level. This data will be integrated into the existing Mood Monitor tool within the participant's Space from Depression program. During the intervention, prompts to record mood data will appear on the watch app; participants will be encourage to choose the frequency and time ranges to receive prompts. The watch app main screen will provide a daily and weekly visualisation of participant's mood, bedtime, hours slept and steps count, and visual cues on their progress. Participants will receive encouragement prompts to reward frequent and consistent self-report of mood over time and a good sleep hygiene. Finally, the app Tips to Stay Well feature will allow participants to go through a list of lifestyle-related tips extracted from the Space from Depression program."
45967948|NCT00238017|Drug|amodiaquine-artesunate versus amodiaquine|
45967949|NCT04567966|Procedure|Split-block technique|Horizontal ridge augmentation using the split-block technique where a cortical bone plate harvested from the external oblique ridge was split in half and fixed at a distance from the atrophied ridge. Then autogenous bone chips were packed in the gap between the plate and the ridge.
45967950|NCT04567966|Procedure|Cortico-cancellous block graft|Horizontal ridge augmentation using a cortico-cancellous block harvested from the chin of the mandible.
45967951|NCT04567927|Other|Ultrasonography|Venous compression ultrasonography using real-time B-mode and colour doppler in transverse and longitudinal views
45967952|NCT02962011|Device|Knotless barbed suture|uterine incision closure
45967953|NCT02962011|Device|polyglactin 910|uterine incision closure
45967954|NCT04568356|Diagnostic Test|Direct Antigen Tests for COVID-19|Rapid Antigen diagnostic device performance comparative to RT-PCR
45967955|NCT04567576|Drug|Disease-modifying antirheumatic drugs (DMARDs)|"Within a non-experimental setting, the routine disease-modifying antirheumatic drugs (DMARDs) prescription will be evaluated as the exposure."
45967956|NCT00211094|Drug|Dapoxetine|
45967957|NCT04567459|Dietary Supplement|Premium Amino Acids|after Chemotherapy ang surgery one pack of Premium Amino Acids in the morning and evening
45967958|NCT04567147|Dietary Supplement|Probiotic|Patients received the formula probiotic for consecutive 8 weeks ( one sachet per day ).
45967959|NCT04567147|Dietary Supplement|Placebo|Patients received the placebo identical to probiotic for consecutive 8 weeks ( one sachet per day ).
45967960|NCT00238056|Drug|domperidone Drug|
45668215|NCT04872595|Drug|Thiotepa|(5mg/kg/day x 2 day) Day -5 to -4
45967961|NCT04722380|Procedure|periodontal regenerative surgery|Procedure/Surgery: open flap debridement Open flap for removal of diseased periodontal tissues and necrotic cementum , using xenogenic bone graft with or without Nigella Sativa oil extract
45967962|NCT04566952|Drug|Anlotinib|Anlotinib will be treated with its minimum dose that is orally 8 mg daily on days 1-14 of a 21-days cycle.
45967963|NCT04566952|Drug|Olaparib|Olaparib will be treated with a total daily dose of 450 or 300mg.
45967964|NCT04567069|Biological|DC vaccine|"Blood samples will be collected twice, 60-120ml/ time. The 1st collection will occur 5 days before the 1st DC vaccine injection, the 2nd collection will occur 15 days after the 1st injection.~Six subcutaneous(ih) injections of DC vaccine will be given at days 1, 8, 15, 21, 28, 35; 1-3×106 cells/time.~Injection site: inguinal lymph nodes."
46080638|NCT05905159|Behavioral|ABM|Direct attention away from pain-related information (i.e., facial expressions) through implicit training procedures
45668216|NCT04872595|Drug|Cyclophosphamide|(60mg/kg/day x 2 days) Day -3 to -2
45668217|NCT04872595|Drug|GCSF|Day +7
45668218|NCT04872595|Drug|Busulfan|Day -9 to -7 doses 2-3 to be adjusted per PK for target cumulative exposure of 65 mg*h/L
45668219|NCT04872595|Drug|Melphalan|(70mg/m2/day x 2 days) Day -6 to -5
45668220|NCT04872595|Drug|Fludarabine|(25mg/m2/day x 5 days) Day -6 to -2
45668221|NCT05651191|Drug|Human CD19 Targeted DASH CAR-T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
45825277|NCT01943292|Drug|Defactinib|
45967965|NCT04567069|Biological|CTL|Four intravenous (iv) drip injections of CTL will be given at days 7, 9, 27, 29; 1-2×109 cells/time.
45458566|NCT02319070|Other|Survey|Recombinant antihemophilic factor VIII (FVIII) On Demand treatment scheduled according to daily routine
45668222|NCT02002689|Drug|LDE225|LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule
45668223|NCT01639729|Drug|Treatment A: Sufentanil IV|Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
45668224|NCT01639729|Drug|Treatment B: Sufentanil NanoTab Sublingual|Single Sufentanil NanoTab 15 mcg given sublingually (SL)
45668225|NCT01639729|Drug|Treatment C: Sufentanil NanoTab Buccal|Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
45967966|NCT04567069|Drug|Sintilimab Injection|The Sintilimab Injection (3mg/kg) will be administered by intravenous (iv) drip injection at days 0, 20。
45967967|NCT04566874|Device|ALIF|Anterior Lumbar Interbody Fusion
45967968|NCT04566796|Drug|Sugammadex|give 2 mg/ kg as muscle reversal drug in premature infants
45967969|NCT04566796|Drug|Neostigmine|give 0.02 mg/ kg atropine and 0.05 mg/kg neostigmine IV. as muscle reversal drug in premature infants
45967970|NCT00238173|Biological|filgrastim|
45967971|NCT00238173|Drug|acetylcysteine|administered i.v. over 30 to 60 minutes
45825278|NCT01961544|Drug|Eribulin mesylate|1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
45967972|NCT00238173|Drug|carboplatin|(200 mg/m2/day; total dose 400 mg/m2) will be infused i.a. over 10 minutes, in 50-180 cc of normal saline.
45967973|NCT00238173|Drug|cyclophosphamide|(330 mg/m2/day; total dose 660 mg/m2) will be infused i.v. in 25-50 cc of normal saline, over approximately 10 minutes.
45967974|NCT00238173|Drug|etoposide phosphate|(200 mg/m2/day; total dose 400 mg/m2) will be infused i.v. in 25-100 cc of normal saline, over approximately 10 minutes, immediately following the cyclophosphamide.
45967975|NCT00238173|Drug|mannitol|(25%) delivered i.a. at a pre-determined flow rate over 30 seconds. The flow rate will be determined by iodinated contrast injection and fluoroscopy as the lowest infusion rate in which there is retrograde flow from the arterial catheter. The rate and volume of mannitol infused will be approximately 4-12 cc/sec x 30 seconds.
46080639|NCT05905159|Behavioral|Control|Direct attention equally towards pain-related and neutral information (i.e., facial expressions) through implicit training procedures
46080640|NCT05905146|Other|personalized pharmaceutical plan|multi-professional intervention around strong opioid treatment with targeted pharmaceutical interview
46080641|NCT05905133|Drug|CBP-201|subcutaneous injection
45668226|NCT01639729|Drug|Treatment D: Sufentanil NanoTab Oral|Single Sufentanil NanoTab 15 mcg swallowed (PO)
45668227|NCT02002533|Behavioral|Brief Behavioral Therapy|Undergo BBT intervention
45825279|NCT01942590|Drug|Clenbuterol|
46080642|NCT05905120|Drug|Toludivenlafaxine hydrochloride sustained-release tablets|80 mg/tablet, 2 tablets each time, once a day, for 4 days, orally at 30 min after the start of meals, 200 mL water to take
45825280|NCT01942590|Drug|Placebo|
45825281|NCT01984242|Drug|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab will be administered according to the dosage schedule mentioned in the arm description.
45825282|NCT01984242|Drug|Bevacizumab|Bevacizumab will be administered according to the dosage schedule mentioned in the arm description.
45825283|NCT01984242|Drug|Sunitinib|Sunitinib will be administered according to the dosage schedule mentioned in the arm description.
46080643|NCT05905107|Other|Neurodynamic Slider Technique from Proximal to Distal|Neurodynamic Slider Technique from proximal to distal at wrist, elbow and neck
46080644|NCT05905107|Other|Neurodynamic Slider Technique from Distal to Proximal|Neurodynamic Slider Technique from proximal to distal at wrist, elbow and neck
46080645|NCT05905094|Other|Postural correction exercises|Exercises to improve posture like shoulder shrugging, chin tuckin, neck isometrics
46080646|NCT05905068|Drug|RN0191 INJECTION|a sterile solution in each bottle for subcutaneous (SC) injection
46080647|NCT05905055|Drug|co-administration of cefepime and nacubactam|2 g cefepime and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes
46080648|NCT05905055|Drug|co-administration of aztreonam and nacubactam|2 g aztreonam and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes
46080649|NCT05905055|Drug|BAT|Dosage of BAT will be based per site's standard of care
45458335|NCT02983357|Radiation|CT, X-Ray|2 anterior-posterior (AP) radiographs of the glenohumeral joint, one in internal rotation and the other in external rotation, along with axillary lateral films, will be completed of the affected operated shoulder. Also, a computed tomographic scan without contrast performed of same shoulder.
45458567|NCT04463134|Drug|NTM drug treatment|NTM drug treatment according to guideline and sensitivity test results
45668228|NCT02002533|Behavioral|Telephone-Based Intervention|Undergo BBT intervention
45668229|NCT02002533|Other|Educational Intervention|Undergo HEAL
45668230|NCT02002533|Behavioral|Telephone-Based Intervention|Undergo HEAL
45825284|NCT01941498|Device|Wavelight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
45825285|NCT01941498|Procedure|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
45825286|NCT04656132|Behavioral|Physical activity assessment, promotion and monitoring in a preventive cardiology clinic|physical activity assessment promotion and remote home step-count monitoring in a clinical cardiology center
45668231|NCT02002221|Drug|Vildagliptin (LAF237)|Corresponds to vildagliptin (LAF237) 50 mg tablets twice daily
45668232|NCT02002221|Drug|Placebo|Matching placebo of vildagliptin 50 mg twice daily
45668233|NCT02002221|Drug|Insulin|"Patients continued their prescribed insulin dose. The dose of insulin remained within a 10% increase of the baseline dose throughout the trial (with no change in frequency or insulin type) unless dose adjustments were required for safety reasons.~The insulin dose was allowed to be decreased for safety reasons at anytime without specific dose limits at the Investigator's discretion."
45668234|NCT02002221|Drug|Metformin|Patients continued their prescribed metformin dose, if applicable.
45668235|NCT01639495|Device|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
45825287|NCT01960998|Behavioral|Pelvic Floor Muscle Training|Evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 2-4 weeks before surgery and continued 2 months after surgery. Content is accessed in daily 10-minute sessions on a secure website
45668236|NCT05651113|Other|SCID Screening|The addition of newborn bloodspot screening for severe combined immunodeficiency
45668237|NCT05642143|Diagnostic Test|Dual Energy X-ray Absorbtiometry scan|Evaluation of body composition and bone mass density
45668238|NCT05642143|Diagnostic Test|High-resolution peripheral quantitative computed tomography|High-resolution peripheral quantitative computed tomography (HR-pQCT) assesses both volumetric bone mineral density (vBMD) and trabecular and cortical microarchitecture.
45967976|NCT00238173|Drug|sodium thiosulfate|STS is available as a 25% (250 mg/ml) solution. The dose of STS administered 4 hours after carboplatin is 16 gm/m2. The dose of STS administered 8 hours after carboplatin is 16 gm/m2. Actual dose to be administered will be determined and mixed with an equivalent amount of sterile water (1 ml:1 ml) for infusion.
45967977|NCT00211133|Drug|epoetin alfa|
45825288|NCT01960998|Behavioral|Perioperative Care and Wetness Management|Telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 1-4 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
45825289|NCT01941186|Other|Patient Decision Aid|Short informational video on developmental delays and early intervention services aimed at helping parents make an informed decision about whether to pursue early intervention services.
45967978|NCT04566913|Procedure|Pontic Shield Technique|• Together the apical and the palatal portions of the root in the esthetic region will be delivered and the buccal part is left for assessment of stability of bucco-palatal dimension of alveolar ridge
45967979|NCT04566835|Other|Standart Care given during normal examination|This is the standart education given by doctor. The child and his/her parents come to the doctor for normal examination. They take their asthma diagnosis or other information about their condition. and then the doctor explain them about what is asthma, what are the drugs or how should they use them. This is the implementation using for the control group.
45668239|NCT05642143|Diagnostic Test|Microindentation|Measures Bone Material Strength Index (BMSi) of cortical bone.
45825290|NCT01960842|Drug|Levodopa-carbidopa intestinal gel|Dose levels will be individually optimized. Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
45825291|NCT01960842|Device|CADD-Legacy® 1400 ambulatory infusion pump|
45825292|NCT01960842|Device|PEG tube|percutaneous endoscopic gastrostomy tube
45967980|NCT04566835|Behavioral|Health Promotion Program with cartoon education for Children with Asthma|First of all, the child and their parents take the routine examination as the same as the control group. Then they take the experimental education called Health Promotion Program with cartoon education for Children with Asthma. The children with asthma were educated within the scope of the program in order to demonstrate the effect of the program on asthma management. Children with asthma were educated with the program, which consisted of 4 units, each of 10 minutes, prepared in the light of the literature and with the current guidelines. Each child received the education in a total of 40 minutes. Every unit has its own cartoon video and comic book material. To sum up The Principal Investigator first give the education about asthma management, then makes them watch the Iggy and the Inhalers videos developed for each unit, and does a colouring activity with comic books at the end of each unit.
45967981|NCT04567030|Device|Dental monitoring (DM)|DM is the first APP system used in orthopedics patients in the world,it has been widely used in Asian countries (Taiwan, Hong Kong, Singapore, Japan, etc.) and has been used by 2140 patients so far. DM allows patients to take in-mouth photos at home, and uses AI as a background analysis to evaluate the patient's current oral condition (including oral hygiene and gum status) based on the photo.
45967982|NCT00211211|Device|Balloon Kyphoplasty|
45825293|NCT01960842|Device|J-tube|jejunal tube
45825294|NCT01984164|Drug|Candesartan|blinded
45967983|NCT00238212|Drug|sorafenib tosylate|Given orally
45967984|NCT00238212|Other|laboratory biomarker analysis|Correlative studies
45967985|NCT04566757|Biological|Umbilical Cord Blood Plasma|Intravenous Infusion of Umbilical Cord Blood Plasma
45668240|NCT05642143|Diagnostic Test|Thermal perception thresholds|Heat and cold perception thresholds
45825295|NCT01984164|Drug|Lisinopril|Blinded
45668241|NCT05642143|Diagnostic Test|Nerve conduction studies|Nerve conduction and amplitude of sural nerve
45668242|NCT05642143|Diagnostic Test|Composite Autonomic Symptom Score 31|A validated self-assessment questionnaire quantifying the severity and distribution of autonomic symptoms across six domains (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder and pupillomotor functions) by scoring 31 clinically selected questions
45825296|NCT01941030|Device|Orbital Atherectomy System|Orbital atherectomy (OA) is performed prior to adjunctive balloon angioplasty (BA)
45668243|NCT05642143|Diagnostic Test|Skin biopsies with quantification of intra-epidermal nerve fibre density|Skin biopsy
45668244|NCT05642143|Diagnostic Test|Perception Threshold Tracking|Transcutaneous stimulation of large and small nerve fibres using weak electrical currents
45668245|NCT05642143|Diagnostic Test|Assessment of cardiovascular autonomic neuropathy|Electrocardiographic recordings at rest and during cardiovascular autonomic reflex tests.
45668246|NCT05642143|Diagnostic Test|Handgrip strength|Evaluation of muscle strength
45668247|NCT05642143|Diagnostic Test|Force plate platform|Evaluation of balance while standing still
45825297|NCT01941030|Device|Balloon Angioplasty|Type of balloon selected is driven by preference of the operator.
45967986|NCT04566523|Other|telerehabilitation|Patients undergo an online exercise training program via a certified host of health data website.
45967987|NCT04566679|Dietary Supplement|Dibuzin|2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10) and 4-week follow-up phase (weeks 11-14)
45967988|NCT04566679|Dietary Supplement|placebo|2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10) and 4-week follow-up phase (weeks 11-14)
45967989|NCT00211250|Drug|Valproic Acid and Depakote ER|
45967990|NCT00238251|Drug|gefitinib|Once daily during days 1-28
45967991|NCT00238251|Drug|temozolomide|Once daily on days 1-21
45967992|NCT00238251|Radiation|radiation therapy|Whole brain radiotherapy
45967993|NCT04566718|Drug|Metformin|metformin cessation
45668248|NCT05642143|Diagnostic Test|Biospecimen collection|Biochemistry including bone turnover markers, glycemic status, inflammation markers i.e
46080650|NCT05904977|Procedure|Type B resection or type C resection of the anterior leaf of vesicouterine ligament during the radical hysterectomy (type C)|The patients with cervical cancer who underwent abdominal radical hysterectomy（type C）plus pelvic lymph node dissection by the same surgical team at the Department of Gynecological Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, were included. According to the resection range of the anterior leaf of vesicouterine ligament (VUL), patients were divided into type C resection group (near the bladder wall) and B type resection group (above the ureter).
46080651|NCT05904951|Device|INVADER™ PTCA Balloon Dilatation Catheter|INVADER™ PTCA Balloon Dilatation Catheter is a single use, EO sterilized, monorail rapid exchange (RX) coronary angioplasty balloon dilatation catheter. The INVADER™ PTCA has been designed to dilate the stenotic atherosclerotic lesions in coronary arteries or bypass grafts. The INVADER™ PTCA is an interventional, non-surgical device, and considered minimally invasive.
45458568|NCT03131960|Device|Paired Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper limb rehabilitation movements.
45668249|NCT05642143|Diagnostic Test|Isometric leg extension strength|Evaluation of muscle strength
45668250|NCT05642143|Diagnostic Test|Michigan Neuropathy Screening Instrument|MNSI is used to assess status of peripheral neuropathy. It includes two separate assessments: a 15-item self-administered questionnaire and a lower extremity examination that includes inspection and assessment of vibratory sensation and ankle reflexes.
45825298|NCT01983930|Behavioral|Kundalini yoga and meditation|Participants will participate in a 60 minute yoga and meditation session weekly for 12 weeks and will be assigned a daily Kirtan Kriya meditation (12 minute duration) for 12 weeks.
45825299|NCT01983930|Behavioral|Memory Training|Participants will attend a weekly memory training class for 12 weeks as well as receive daily memory homework (12 minute duration) for the 12 weeks.
45825300|NCT04636398|Behavioral|MESSAGE - mHealth intervention|A group-based moderated six-week intervention with didactic, discussion, and text communication components.
45825301|NCT01983774|Drug|Esomeprazole|
45825302|NCT01983774|Drug|Placebo|Sugar pill
45825303|NCT01982682|Radiation|Total-Body Irradiation (TBI)|Undergo TBI
45825304|NCT01982682|Biological|Donor Lymphocyte Infusion (DLI)|Undergo DLI
45825305|NCT01982682|Drug|Cyclophosphamide|Given IV
45825306|NCT01982682|Procedure|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo CD34+ selected allogeneic HSCT
45825307|NCT01982682|Drug|Mycophenolate mofetil|Given IV
45825308|NCT01940484|Drug|Methoxy polyethylene glycol epoetin beta|
45825309|NCT01939548|Drug|PF-02545920|PF-02545920 2 mg BID x 7 days, then 5 mg BID until the Week 12 visit
45825310|NCT01939548|Drug|Placebo|Placebo BID until the Week 12 visit
45825311|NCT01939548|Drug|PF-02545920|PF-02545920 5 mg BID x 7 days, then 10 mg BID x 7 days, then 15 mg BID until the Week 12 visit
45825312|NCT01960296|Drug|Clopidogrel|Continue home dose of clopidogrel into surgery
45825313|NCT01960296|Drug|Discontinue Clopidogrel|Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
45825314|NCT01982292|Drug|RLX030 (serelaxin)|RLX030 (serelaxin) was administered according to a weight-range adjusted dosing regimen at a nominal dose of 30 μg/kg/day as a continuous IV infusion for 48 hours.
45825315|NCT01982292|Drug|Placebo|Matching placebo of serelaxin was administered as a continuous IV infusion for 48 hours.
45825316|NCT04652778|Device|Pulsed Field Ablation (PFA) using the Centauri System|cardiac ablation using pulsed electric field energy to cause pulmonary vein isolation; cavo-tricuspid isthmus (CTI) line ablation may be performed as needed
45825317|NCT01939314|Drug|Bupivacaine|Bupivavaine Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
45825318|NCT01939314|Drug|Placebo|Normal Saline Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
45825319|NCT04663152|Behavioral|INSTACARE|CHWs will provide participants with support via phone calls, home-visits, and accompaniment to clinic visits to improve medication management and HIV viral suppression. CHWs will contact participants at least once per week for three months.
45825320|NCT01939158|Biological|Meningococcal vaccine GSK134612|1 or 2 doses administered intramuscularly in the left anterolateral thigh or deltoid region
45825321|NCT01939158|Biological|Prevenar 13™|1 dose administered intramuscularly in the right anterolateral thigh or deltoid region
45825322|NCT01939002|Drug|BIIB017|
45825323|NCT01939002|Drug|naproxen|
45825324|NCT01938846|Drug|BI 860585|BI 860585 multiple dose escalation, once daily
45825325|NCT01938846|Drug|exemestane|exemestane once daily
45825326|NCT01938846|Drug|BI 860585|BI 860585 multiple dose escalation, once daily
45825327|NCT01938846|Drug|BI 860585|BI 860585 multiple dose escalation, once daily
45825328|NCT01938846|Drug|paclitaxel|paclitaxel once weekly
45967994|NCT02210845|Behavioral|Supervised exercise|Supervised exercise intervention is training with professional trainers once a week. It will include aerobic exercise tailored to the individual participant.
45967995|NCT02210845|Behavioral|Financially incentivized weight Loss|Financially incentivized weight loss encourages participants to achieve a monthly goal weight reduction for a 50 dollars prize.
45967996|NCT02210845|Other|Standard Care at BCDiabetes|usual care dictated by GCP at BCDiabetes.ca
45967997|NCT00211289|Behavioral|Education by community pharmacist|
45967998|NCT02210884|Dietary Supplement|Vitamin D|Weekly oral supplementation with 15,000 IU vitamin D
45967999|NCT00238290|Drug|Trastuzumab + Letrozole|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
45968000|NCT02895217|Other|ergocycle|
45968001|NCT02895178|Behavioral|Combined aerobic and strength exercise training|Subjects participate in supervised exercise sessions for 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30 minutes once weekly for 12 weeks.
45458336|NCT02983357|Other|Physical assessment|Physically evaluate for shoulder function and pain using American Shoulder Elbow Score (ASES) Constant score and the Simple Shoulder Test to obtain specific shoulder functional, motion,and strength outcomes.
45668251|NCT05262439|Device|New generation CPAP mask|All participants entered into the study will be couriered a new generation ResMed mask system to be used with their own CPAP machine and in place of their own mask.
45668252|NCT05640661|Device|Oculus Quest II|"active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.~During the realization of the exposure with VRi they will be recorded through an Ipad Tablet, and after performing the entire intervention a terminal visual feedback therapy will be performed by observation of actions in holocentric vision."
45668253|NCT05640661|Device|Oculus Quest II|active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.
45668254|NCT04871971|Dietary Supplement|10 g NUTRALYS®S85 Plus pea protein|To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g NUTRALYS®S85 Plus pea protein.
45668255|NCT04871971|Dietary Supplement|20 g NUTRALYS®S85 Plus pea protein|To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g NUTRALYS®S85 Plus pea protein.
45825329|NCT01960140|Drug|Baricitinib|Administered orally
45825330|NCT01960140|Drug|Simvastatin|Administered orally
45825331|NCT01981356|Behavioral|Acceptance and Commitment Therapy|"The goal of ACT is to help the patient increase psychological flexibility, a core component of mental health and well-being. ACT teaches clients to be mindfully aware but nonreactive to delusions/ hallucinations and to increase willingness to~experience associated distressing emotions while simultaneously engaging in meaningful behavioral actions.~Patients expand their repertoire of behaviors to live according to their values and to pursue valued goals, thereby increasing adaptive functioning and quality of life."
45825332|NCT01981356|Other|Treatment as Usual (TAU)|All patients admitted to the acute psychiatry unit are administered anti-psychotic and/or other psychotropic medication during their inpatient stay. Patients participate in standard milieu therapy on the unit (group and activities therapies, and individual therapy as needed). Therapy on the unit focuses on psycho-education about illness, symptom identification, mood management techniques, stress reduction, and relapse prevention. Patients also receive unstructured individual therapy and case management as appropriate.
45825333|NCT01981122|Biological|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
45825334|NCT01981122|Drug|enzalutamide|Enzalutamide is an androgen receptor inhibitor. It is indicated for the treatment of patients with mCRPC who have previously received docetaxel. The enzalutamide dose used in this study will be 160 mg orally once daily.
45825335|NCT01959672|Procedure|4-Dimensional Computed Tomography|Correlative studies
45825336|NCT01959672|Drug|Fluorouracil|Given IV
45825337|NCT01959672|Drug|Gemcitabine Hydrochloride|Given IV
45968002|NCT00211328|Drug|anecortave acetate|
45968003|NCT02894944|Biological|Theragene®,Ad5-yCD/mutTKSR39rep-ADP|Theragene®,Ad5-yCD/mutTKSR39rep-ADP is Adenovirus-mediated Double Suicide Gene Therapy
45968004|NCT00238329|Biological|PEG-interferon alfa-2b|
45968005|NCT00238329|Drug|thalidomide|
45968006|NCT02894866|Device|hyperbaric oxygen|The hyperbaric oxygen treatment will be administered for 60 min in a baby hyperbaric oxygen chamber pressured with 100% oxygen to 1.5 to 1.8 atm absolute (ATA) and a constant oxygen flow was given to maintain the oxygen. concentration in the chamber at 80% or greater.The treatment will be administered once a day within 7 days after birth, 7 days is a course of treatment, at least for 4 courses.
45825338|NCT01959672|Other|Laboratory Biomarker Analysis|Correlative studies
45825339|NCT01959672|Drug|Leucovorin Calcium|Given IV
45968007|NCT02894905|Drug|AL-335|Participants with various degrees of impaired renal function (mild [Cohort 1], moderate [Cohort 2], severe [Cohort 3]) and normal renal function (Cohort 4) will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
45968008|NCT02894827|Biological|Blood sample|
45968009|NCT02894827|Other|Flow cytometry|
45968010|NCT02894827|Other|western blot|
45968011|NCT00211367|Drug|Anecortave Acetate|
45968012|NCT02894788|Other|ICU admission|
45968013|NCT00238368|Biological|filgrastim|
45968014|NCT00238368|Biological|rituximab|
45968015|NCT00238368|Drug|busulfan|
45968016|NCT00238368|Drug|cisplatin|
45668256|NCT04871971|Dietary Supplement|10 g Whey protein concentrate|To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g Whey protein concentrate.
45825340|NCT01959672|Drug|Nelfinavir Mesylate|Given PO
45668257|NCT04871971|Dietary Supplement|20 g Whey protein concentrate|To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g Whey protein concentrate.
45668258|NCT04871971|Dietary Supplement|50 g Glucose|To determine the glycaemic response and insulinaemic response to 50g Glucose
45668259|NCT05651035|Other|oral feeding|"In experimental group infants: Preterms in this group will be breastfed by their own mother.~In control group infants: Preterms in this group will be fed by the researcher by putting the baby's own mother's milk in the bottle. During feeding, the preterm will be placed on the lap by the researcher in a standing position on the same mother's breast, and will be given a raised side-lying position. In this position, the preterm's head and body will be elevated 45-60 degrees with the help of a small pillow. While the researcher will support the preterm's head, neck and shoulder with one hand, he will control the bottle with the other hand. By touching the preterm's nipple to the preterm's lips, the preterm will be prepared for feeding, and the bottle will be placed in the baby's mouth with the mouth opening and the tongue lowering. During feeding, stimulating movements such as pushing the bottle back and forth in the mouth, which will lead the newborn to suck faster, will not be made."
45825341|NCT01959672|Biological|Oregovomab|Given IV
45825342|NCT01959672|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45968017|NCT00238368|Drug|cyclophosphamide|
45968018|NCT00238368|Drug|cytarabine|
46080652|NCT05904925|Other|Pilates exercises|Sessions will last 60 minutes: five minutes for warming up, 50 minutes for the practice of Pilates exercises, and five minutes for relaxing with the Swiss ball. The exercise protocol will be divided into three gestational phases, covering the entire gestational period, with different and specific objectives for each phase. In all phases, the exercises will be classified into three levels of difficulty: basic, intermediate, and advanced, according to the evolution of each pregnant woman throughout the practice of Pilates. Modifications will be allowed to facilitate or hinder the execution of the movement. The exercises will be performed in one or two sets of seven to 10 repetitions. The number of series, repetitions and exercises and interval time between them, as well as the level of difficulty of the exercises, will be gradually adjusted. The intensity of the exercises will vary between light and moderate and will be controlled by the Borg scale.
45668260|NCT05260177|Device|Light Therapy System (LTS): Active Setting|Exposure for 1 hour á day for consecutive days
45668261|NCT05260177|Device|Light Therapy System (LTS): Sham Setting|Exposure for 1 hour á day for consecutive days
45668262|NCT05431153|Drug|Single dose of PF-07104091 as Tablet Formulation A (Treatment A)|A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.
45825343|NCT01959672|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
45825344|NCT01980888|Drug|Idelalisib|150 mg tablet administered orally twice daily
45968019|NCT00238368|Drug|doxorubicin hydrochloride|
45668263|NCT05431153|Drug|Single dose of PF-07104091 as Tablet Formulation B (Treatment B)|A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.
45825345|NCT01980888|Drug|Bendamustine|Administered intravenously at a starting dose of 90 mg/m^2 for up to 6 cycles. Dosing will be based on mg/m^2 of body surface area.
45825346|NCT01980888|Drug|Rituximab|Single-use vials administered intravenously weekly starting at 375 mg/m^2 on Day 1 (Week 0) and 500 mg/m^2 thereafter for a total of 6 infusions
45825347|NCT01980888|Drug|Placebo|Placebo to match idelalisib administered orally twice daily
45825348|NCT04650282|Combination Product|Lidocaine in SphenoCath device|Participants will receive 2.5 cc of lidocaine 1% solution intranasally via a SphenoCath device into each nares.The portion of the procedure involving this device lasts approximately 30-60 seconds.
45968020|NCT00238368|Drug|etoposide|
45968021|NCT00238368|Drug|methylprednisolone|
45968022|NCT00238368|Drug|prednisone|
45968023|NCT00238368|Drug|vincristine sulfate|
45968024|NCT00238368|Procedure|autologous bone marrow transplantation|
45968025|NCT00238368|Procedure|peripheral blood stem cell transplantation|
45968026|NCT00238368|Procedure|positron emission tomography|
45968027|NCT00238368|Radiation|fludeoxyglucose F 18|
45968028|NCT00238368|Radiation|radiation therapy|
45968029|NCT02894749|Radiation|3D rotational angiography (3DRA)|3DRA allows CT-like reconstructions. It requires less X-rays and contrast medium than standard angioCT-scan. Furthermore, it can be performed in the operative room, during the procedure. Therefore, use of 3DRA should allow reduction of dose, contrast-medium and reintervention when compared to technical success assessment with angioCT-scan.
45968030|NCT02894593|Other|alcohol free essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
45968031|NCT02894593|Other|alcohol essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
45968032|NCT02894593|Other|0.20% chlorhexidine mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
45825349|NCT04650282|Combination Product|Saline Solution in SphenoCath device|Participants will receive saline solution via a SphenoCath device into each nares. The portion of the procedure involving this device lasts approximately 30-60 seconds.
45825350|NCT01937364|Drug|Baclofen|Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
45968033|NCT02894593|Other|Placebo|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
45968034|NCT02894632|Device|MRI compatible motion sensor (MARMOT)|MRI with motion control (several motion sensors placed on the volunteer's body)
45968035|NCT00211406|Drug|Anecortave Acetate Sterile Suspension (15 mg)|
45968036|NCT02894554|Drug|Telbivudine|
45968037|NCT02894554|Drug|Lamivudine|
45968038|NCT00238407|Drug|Docetaxel and Cisplatin|Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71.
45968039|NCT00238407|Radiation|Radiotherapy|Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.
46080653|NCT05904912|Drug|Postoperative analgesia management|Intravenous 0.5 mg/kg tramodol and 1 gr paracetamol will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered iparacetamol iv 1 gr 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
46080654|NCT05904912|Drug|PENG-Bupivacaine|The probe will be placed on the anterior inferior iliac crest in the transverse plane. Then, the pubic ramus will be visualized by rotating 45 degrees. The femoral artery, iliopubic process, and psoas muscle will be visualized. The needle will be punctured with the in-plane method to reach between the pubic ramus and the psoas tendon. After the block area is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
46080655|NCT05904912|Drug|Local infiltration-Bupivacaine|Local infiltration will be applied with 30 ml of a local anesthetic solution containing 0.25% bupivacaine by the surgical team
45458337|NCT02983357|Other|Questionnaire|Rand Short Form Health Survey (Rand SF-36) which is a patient completed quality of life measurement
45668264|NCT05431153|Drug|Single dose of PF-07104091 as Tablet Formulation C (Treatment C)|A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.
45668265|NCT05431153|Drug|Single dose of PF-07104091 as Tablet Formulation D (Treatment D)|A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.
45668266|NCT05431153|Drug|Single dose of PF-07104091 as Tablet Formulation C (Treatment E)|A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.
45668267|NCT05650801|Other|Music Therapy|Therapy using a traditional music originally from Indonesian culture
45668268|NCT05650723|Drug|Zanubrutinib Pill|320 mg once per day by mouth
45825351|NCT01937364|Drug|Placebo|Identical appearing placebo every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
45825352|NCT01979952|Drug|Matching Placebo|twice daily dosing
45825353|NCT01979952|Drug|Nintedanib|gelating capsule
45825354|NCT01999218|Drug|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104
45825355|NCT01999218|Drug|Ertugliflozin 10 mg|Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.
45825356|NCT01999218|Drug|Glimerpiride|Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose
45825357|NCT01999218|Drug|Placebo to Ertugliflozin|Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104
45825358|NCT01999218|Drug|Placebo to Glimepiride|Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.
45968040|NCT02894515|Drug|Idalopirdine commercial tablet (test)|single dose, 10 mg, oral
45968041|NCT02894515|Drug|Idalopirdine clinical tablet (reference)|single dose, 10 mg, oral
46080656|NCT05904886|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
46080657|NCT05904886|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
46080658|NCT05904886|Drug|Tiragolumab|Tiragolumab will be administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
46080659|NCT05904886|Other|Placebo|Placebo matching tiragolumab will be administered by IV infusion on Day 1 of each 21-day cycle.
45825359|NCT01999218|Drug|Metformin|Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin <1500 at screening are up-titrated to >= 1500 daily.
45968042|NCT02894671|Other|blood exams|in serum will be analyzed the level of IMA, iron, transferrin, ferritin, total albumin
45968043|NCT00211445|Procedure|Photodynamic Therapy with Verteporfin|
45968044|NCT00211445|Drug|verteporfin|
45968045|NCT02894710|Drug|Lidocaine 20mg/ml|Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).
45968046|NCT02894710|Drug|Glucose 5% (placebo)|Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.
45968047|NCT00238446|Drug|EC-MPS|
46080660|NCT05904873|Procedure|Mandibular Third Molar Surgery|All surgical procedures were carried out by a single dental(maxillofacial) surgeon different from the clinician performing the cold testing. A total of 4 cc of local anesthetic solution containing 40 mg/ml articaine and 0.005 mg/ml epinephrine was applied to the inferior alveolar and buccal nerve blocks before the surgical procedure. In all cases, the mucoperiosteal flap was raised and bone was removed from the buccal and distal parts of the impacted tooth with burs, while protecting the papilla between the first and second molars during flap design. Before extraction, if necessary, the third molar was divided and tooth extraction was performed with elevators. The flap was brought to its original position and closed with silk suture material.
45825360|NCT01999218|Drug|Sitagliptin|Open label, oral, once daily, rescue medication as required.
45668269|NCT05650723|Drug|Venetoclax Pill|400 mg once per day by mouth following the standard ramp-up schedule (20mg daily PO week 1, 50mg daily PO week 2, 100mg daily PO week 3, 200mg daily PO week 4, followed by 400mg PO daily week 5)
45968048|NCT05428189|Diagnostic Test|Plaque Disclosing Agent|A plaque disclosing agent is applied on teeth to detect plaque. Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.
46080661|NCT05904860|Other|Backward Gait Training|Backward gait training will be provided within parallel bars, a mirror, and on a firm surface. The harness belt will be around the patient's torso to avoid sudden falls.
46080662|NCT05904860|Other|Forward Gait Training|Forward gait training will be provided within parallel bars, a mirror, and on a firm surface. The harness belt will be around the patient's torso to avoid sudden falls.
45668270|NCT05650723|Drug|Obinutuzumab Injection|1000 mg IV given every 28 days
45668271|NCT05636215|Biological|IBI354|Recombinant Anti-HER2 monoclonal Antibody-Camptothecin derivative conjugate for injection
45668272|NCT05249647|Other|Instrument based Fascial abrasion technique|Participants were in a comfortable position during treatment. Emollient (anti-allergic) was applied to prevent skin irritation prior to Fascial Abrasion application. Each session included 1 minute of sweeping (longitudinal strokes performed parallel to the muscle fibers similar to compression with oscillations) directly over the Myofascial trigger points, 2 minutes of fanning (one end of the instrument was held in place & the other end moved through a semicircular pattern similar to petrissage) and concluded with 1 min of sweeping. Fascial Abrasion tool was washed in alcohol-based sanitizer before and after every treatment session and all norms of COVID-19 precautions were maintained. Myofascial trigger points were marked with a 1×1 cm piece of tape/under wrap to confirm consistency of subsequent treatments.
45668273|NCT05249647|Other|Myofascial release technique|All participants will get Conventional therapy i.e heating pad for 10 minutes. For the application of technique, the patient position will be supine lying with head fully supported on therapist hands and therapist places 3 middle fingers just inferior to the nucle line, lifts the finger tips towards the ceiling while resting the head on the table and then therapist applied a gentle upward pull. This procedure done for 2-3 minutes, 5-7 repetitions, 3 sessions per week on alternate days given for 6 weeks.
45668274|NCT05247697|Drug|Mirtazapine 7.5 MG Oral Tablet once daily at bedtime|Mirtazapine 7,5 mg capsule
45825361|NCT01937130|Drug|IDN-6556|
45825362|NCT01937130|Other|Placebo|
45825363|NCT01936974|Drug|Gemcitabine|Patient to receive gemzar
45825364|NCT01936974|Drug|Bevacizumab|Patient to receive avastin
45825365|NCT01936974|Drug|Carboplatin|Patient to receive carboplatin
45825366|NCT01936974|Drug|Cisplatin|Patient to receive cisplatin
45825367|NCT01936974|Drug|Oxaliplatin|Patient to receive Oxaliplatin
45825368|NCT04648644|Other|Application of ERAS protocol|Application of a standardized ERAS protocol for the perioperative perioperative management of patients undergoing emergency surgery
45825369|NCT01959516|Drug|Glycopyrronium|Glycopyrronium capsule for inhalation once per day via SDDPI
45968049|NCT05428189|Device|Airpolishing and ultrasonic debridement|Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.
45968050|NCT00211484|Drug|Anecortave Acetate|
45968051|NCT05428111|Diagnostic Test|flow cytometric immunophynotyping|Expression of programmed death-1 (PD-1) & programmed death ligand-1 (PDL-1) in flow cytometric immunophynotyping
45968052|NCT00238485|Drug|Licarbazepine|
45825370|NCT01959516|Drug|Tiotropium|Tiotropium capsule for inhalation once per day via HandiHaler® device
45968053|NCT05428072|Other|Sugar test|All participants will take two sugar tests ( sugar cocktail consisting of mannitol & lactulose) subjects within 2-3 days of the initial sugar test.
45968054|NCT05428072|Drug|Aspirin Challenge|All participants will take a sugar test after 2 doses of aspirin, 1.3 g each given at 12 & 1 hour before the sugar drink.
45825371|NCT01959516|Drug|Placebo to glycopyrronium|Placebo to glycopyrronium capsule for inhalation once per day via SDDPI
45968055|NCT00211523|Drug|MBI 226 Acne Solutions|
45968056|NCT05427916|Device|Avance Solo|Avance® Solo will include the collective description for a complete device capable of delivering negative pressure to the incision site and managing exudate generated by the incision.
45968057|NCT05427916|Other|Optifoam|Optifoam is a silicone backed foam that is conformable, with a border that is waterproof, flexible and breathable for increased comfort, with a wear time of up to seven days. It is a standard of care product that is given to patients for surgical wounds.
45968058|NCT00238524|Drug|SPM 927|
45968059|NCT05427877|Device|Heating device (Heatwave Technology)|Heating devices will be applied to the trunk and extremities of the body during the first study visit. During each heating cycle, the temperature will increase quickly from room temperature to a high of 45C and then cycle back down. Each heating cycle is 30 minutes with a 3 minute cool down period where no heat is applied. The maximum temperature used in this study is 45 degrees C (113 degrees F). There will be a total of 3 heating cycles at the visit.
45968060|NCT00211562|Drug|Olanzapine, Omega 3, Vitamin E+C|No adverse event nor SAE noted.
45968061|NCT05427799|Dietary Supplement|Honey|A mixed flora honey that will be obtained from local producers. and will be consumed by a daily dose of 0.5 g/kg body weight of honey by each participant and will be divided into two doses.
46080663|NCT05904847|Behavioral|Application of The Theory of Planned Behaviour for Diabetes|In the study, diabetes education consisting of a total of 4 sessions structured according to the Planned Behavior Theory will be applied to the intervention group, and a standard diabetes education consisting of a single session containing information about diabetes on the website of the Ministry of Health will be applied to the control group. The training will be given face-to-face in groups of 10-15 people. After the training, the participants will be monitored for 3 months. To increase patient empowerment and self-efficacy, the intervention group will be followed up by phone calls every 15 days to increase motivation and answer questions.
45668275|NCT05247697|Drug|Placebo oral tablet once daily at bedtime|Matching placebo
45968062|NCT05427799|Dietary Supplement|Other carbohydrate alternatives such as jell-o|A daily dose of 0.5 g/kg body weight of Jell-O will be consumed by each participant and will be divided into two doses. Jell-O was selected as a source of sucrose with negligible phenolic capacity.
46080664|NCT05904834|Other|Flexibility training|Each session consisted of three or four exercises, of which three were static stretches and if there was a fourth, it was dynamic. The duration of each exercise was 20 seconds with 15 seconds rest between sets and 30 seconds rest between exercises.
45968063|NCT05427721|Drug|Thymol|200 mg each 8 hours for 90 days
46080665|NCT05904808|Drug|IV Furosemide|Given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus
46080666|NCT05904808|Drug|IV Furosemide and PO Metolazone|Given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus +5mg PO Metolazone
46080667|NCT05904808|Drug|IV Furosemide and IV Acetazolamide|"Furosemide would be given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus.~500mg IV Acetazolamide would be given in 100cc of saline over half an hour"
45668276|NCT05243797|Drug|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
45968064|NCT00211601|Behavioral|Disease Management Assessment|
45458569|NCT03131960|Other|Rehabilitation|Rehabilitation movements to improve upper limb function after stroke
45668277|NCT05243797|Drug|Lenalidomide|Lenalidomide will be administered orally
45668278|NCT05650489|Other|assessment|correlation between Autistic features, motor function and quality of life
45668279|NCT05238961|Drug|[18F]DPA-714|Investigational PET Tracer [18F]DPA-714
45668280|NCT05232175|Drug|ALT-BB4|Recombinant Hyaluronidase
45668281|NCT05232175|Drug|0.9%NaCl|Normal Saline
45668282|NCT05193331|Drug|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
45668283|NCT05100199|Drug|OnabotulinumtoxinA X|Injection
45668284|NCT05100199|Drug|Placebo|Injection
45668285|NCT05608915|Other|No Cue|There will be no visual cues at all. Will be tested off-medication (after holding morning dopaminergic medications).
45825372|NCT01959516|Drug|Placebo to tiotropium|Placebo to tiotropium capsule for inhalation once per day via HandiHaler® device
45825373|NCT01979016|Drug|Dupilumab|
45968065|NCT05427682|Drug|pyroglutamate rongliflozin capsules|Subjects will receive one 50mg capsule on Day 1
45968066|NCT00238602|Procedure|Stereotactic radiosurgery|
45968067|NCT05427604|Other|Olive oil|ingestion of olive oil (3g) and blood measurement at baseline, after 1h, 2h, 3h, 4h, 5h, 6h
45968068|NCT05427604|Other|Olive Oil|ingestion of olive oil (3g) and blood sampling at the fatty acids pic concentration (for in vitro study)
45968069|NCT05427604|Other|DHA oil|ingestion of DHA oil (3g) and blood measurement at baseline, after 1h, 2h, 3h, 4h, 5h, 6h
45968070|NCT05427604|Other|DHA oil|ingestion of DHA oil (3g) and blood sampling at the fatty acids pic concentration (for in vitro study)
45968071|NCT05427409|Dietary Supplement|Beta-alanine supplementation|In a randomized order, two groups (n=7) was randomly assigned to beta-alanine and placebo during a 4-weeks period
45968072|NCT05427331|Drug|FMT capsule|Patients with insomnia need to take FMT capsules orally in an empty stomach in the morning, 16 capsules once a week, for 4 consecutive weeks
45968073|NCT00238641|Drug|Botulinum Toxin type B|
45825374|NCT01979016|Drug|Placebo|Matching placebo
45825375|NCT01979016|Other|Background treatment|Participants were required to apply stable doses of a topical emollient (moisturizer) twice daily for at least 7 days before the baseline visit and at least 7 days after the baseline visit (day -7 to day 8).
45825376|NCT04648254|Drug|Q702|The study drug Q702 will be administered once daily by mouth on Days 1 through 7 and Days 15 through 21 of every treatment cycle.
45825377|NCT01935336|Drug|Ponatinib|Ponatinib 45mg taken by mouth each day at the same time with or without food
45968074|NCT05427175|Radiation|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
45968075|NCT05427175|Drug|Methotrexate|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
45968076|NCT05427136|Diagnostic Test|Lung function measurements|"All lung function tests are non-invasive and last about 60 minutes per child:~Multiple Breath Washout: The nitrogen multiple-breath-washout test (N2MBW) measures ventilation inhomogeneity of the lung that occurs when smaller airways are damaged.~Spirometry/Bodyplethysmography/DLCO: Spirometry measures dynamic air flows to quantify airway obstruction of large airways and pulmonary restriction. Plethysmography assesses static lung volumes. Diffusing capacity of the lung for carbon monoxide (DLCO) evaluates diffusion deficits."
45825378|NCT01978236|Drug|Dabrafenib 150 mg|Dabrafenib will be provided for oral administration as 50 mg and 75 mg capsules. Dabrafenib will be dosed orally with approximately 200 mL of water, twice a day. Dabrafenib should be administered under fasting conditions.
45825379|NCT01978236|Drug|Trametinib 2.0 mg|Trametinib study treatment will be provided as 0.5 mg and 2.0 mg tablets. should be taken orally with approximately 200 mL of water under fasting conditions, either one hour before or two hours after a meal.
45825380|NCT01934790|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
45825381|NCT01934556|Drug|Ranibizumab 0.3 mg intravitreal injection|
45968077|NCT05427136|Diagnostic Test|Breath Analysis|Patients will exhale into a secondary electrospray-ionization-mass spectrometry (SESI-MS) breath analysis platform. SESI-MS allows real-time breath-printing by detection of both volatile and non-volatile trace components.
45968078|NCT05427136|Diagnostic Test|Magnetic resonance imaging (MRI)|Functional MRI scan assessing regional fractional lung ventilation and relative perfusion, followed by a morphological MRI scan. This technique allows simultaneous assessment of all affected lung components, the airways, alveoli and pulmonary vasculature.
45825382|NCT01934556|Device|Guided Laser Photocoagulation|
45968079|NCT05427136|Other|Standardized interview to assess respiratory symptoms|Short questions on current airway symptoms, recent colds, exercise-related respiratory symptoms, and passive smoking exposure will be assessed. The interview takes about 10 minutes.
45968080|NCT05427136|Other|Data collection for assessment of clinical parameters and cumulative doses to chemotherapy, radiation, surgery and HSCT|Assessment of clinical parameters and cumulative doses to chemotherapy, radiation, surgery and hematopoietic stem cell transplantation (HSCT). Data on cumulative doses of pulmotoxic chemotherapy (carmustine, lomustine, busulfan, bleomycin, methotrexate and cyclophosphamide, fludarabine, ifosfamide, melphalan and thiotepa) and radiation therapy at the region of the chest from patient's hospital charts will be collected. Information on chest wall and lung surgery will be retrieved from the surgical reports. Information about conditioning regimens including cumulative chemotherapy doses and total body irradiation of patients undergoing HSCT will be collected. Further information on the health state of the patient and interventions (e.g. development of pneumonia, antibiotic treatment) will be collected from the hospital charts.
45968081|NCT05427136|Other|Collection of genetic samples|Germline DNA is collected (e.g. through saliva or buccal cell sampling) for later analysis on genetic risk factors for pulmonary complications.
45968082|NCT00211679|Drug|Botulinum Toxin Type A|
45968083|NCT05427058|Procedure|Superior Hypogastric Plexus Block|this procedure uses a transdiscal approach at the level of the L5-S1 vertebrae by injecting 5 ml of 1% lidocaine + 10 ml of 96% alcohol and confirmed by C-arm.
45968084|NCT05427058|Procedure|Ganglion Impar Block|this procedure uses a trans-sacrococcygeal approach by injecting 4 ml of 1% lidocaine + 6 ml of 96% alcohol and confirmed by C-arm.
45968085|NCT00238680|Behavioral|Bladder rehabilitation|
45968086|NCT00238680|Behavioral|Bladder rehabilitation with programmable timer|
45968087|NCT04680091|Drug|Pyrotinib Maleate|single oral dose, 400 mg, fed.
45968088|NCT04680091|Drug|Efavirenz|single oral dose, 600 mg, fasted, at bedtime.
46080668|NCT05904795|Other|PNF strengthening exercises|PNF strengthening exercises 10 repetitions, 1set , 4 days/week along with range of motion exercises total of 4 sessions were given consisting 40 minutes
46080669|NCT05904795|Other|de-lorme and watkins exercises|"The group was given de-lorme and watkins progressive resistance exercises along with range of motion exercises .10 repetitions, 1set, 4 days /week along with range of motion exercises.~total of 4 sessions per week each consisting of 40 minutes."
45668286|NCT05608915|Other|Conventional Cue|Physical lines taped to floor at regular intervals. Will be tested off-medication (after holding morning dopaminergic medications).
45668287|NCT05608915|Other|Constant Cue|The augmented-reality visual cue will always be turned on. Will be tested off-medication (after holding morning dopaminergic medications).
45668288|NCT05608915|Other|Patient hand-triggered|The augmented-reality visual cue will be turned on, intermittently, each time the patient clicks a handheld button. Will be tested off-medication (after holding morning dopaminergic medications).
45668289|NCT05608915|Other|Patient eye-triggered|The augmented-reality visual cue will be turned on, intermittently, each time the patient looks down at the floor near their feet. Will be tested off-medication (after holding morning dopaminergic medications).
45668290|NCT05608915|Other|Examiner-triggered|The augmented-reality visual cue will be turned on, intermittently, by an examiner, whenever they feel the patient is having a freezing episode or at risk of having a freezing episode. Will be tested off-medication (after holding morning dopaminergic medications).
45825383|NCT04415814|Procedure|Unilateral Pedicle Screw Fixation|Pedicle screws are installed unilaterally on the one side of the vertebrae and fixed with rod
45825384|NCT04415814|Procedure|Bilateral Pedicle Screw Fixation|Pedicle screws are installed bilaterally on the both sides of the vertebrae and fixed with rods
45968089|NCT04680364|Other|partnered dance|Dance classes consisted of different choreographies, which include rhythmic and simple movements typically of ballroom/standard dances (Waltz, Tango, Viennese Waltz).
45968090|NCT00211718|Drug|intra-articular botulinum toxin type a|
45968091|NCT04680247|Procedure|VA-LCP|Surgery using the VA-LCP implant
45968092|NCT04680247|Procedure|NCB-PT|Surgery using the NCB-PT implant
45968093|NCT00238719|Drug|Venlafaxine ER|
45968094|NCT04680169|Device|Bronchoscopic intubation through AuraGain LMA|Comparing two different SGAs as conduit for bronchoscopic tracheal intubation
45968095|NCT04680169|Device|Bronchoscopic intubation through I-gel SGA|Comparing two different SGAs as conduit for bronchoscopic tracheal intubation
45968096|NCT04680208|Procedure|Surgical procedure under anesthesia|Different varieties of surgical procedures done under anesthesia
45968097|NCT00211796|Drug|Divalproex Sodium ER|
45968098|NCT00238758|Drug|Omega-3 Polyunsaturated Fatty Acids|
45968099|NCT05426824|Drug|Pegaspargase（P-GOD）|stage I/II) ENKTL patients receiving P-GOD for the first time, gemcitabine 1000 mg/m2 intravenously on day 1 and day 5, oxaliplatin 75 mg/m2 intravenously on day 1, dexamethason 40 mg intravenously on day 1-4, and pegaspargase 3750 IU intramuscularly on day 2. The cycle was repeated every 21 days.The activity of pegaspargase in peripheral blood will be detected on D3, D4, D5, D6, D7, D8, D10, D12, D14, D16, D18 and D21.
45968100|NCT05426824|Drug|Pegaspargase（PEMD）|stage III/IV ENKTL patients receiving PEMD for the first time,methotrexate 3.0 g/m2 intravenously over 6 h on day 1, etoposide 100 mg/m2 intravenously on days 2-4, dexamethasone 40 mg intravenously on days 1-4, pegaspargase 3750 IU intramuscularly on day 2. The activity of pegaspargase in peripheral blood will be detected on D3, D4, D5, D6, D7, D8, D10, D12, D14, D16, D18 and D21.
45968101|NCT05426668|Other|No Intervention|No Intervention
45968102|NCT00211835|Behavioral|Cognitive behavioral therapy|Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
46080670|NCT05904769|Device|LIFELEAF Smartwatch|Noninvasive wearable smartwatch/monitor that utilizes photoplethysmography (PPG) which is a set of measurements acquired from the light flashed from the back of the watch and measuring the intensity of the reflected light from the blood in the blood vessels just below the skin at the wrist. Provides a non-invasive method for measuring blood glucose as well as alternative method for measuring blood pressure, heart rate and rhythm, etc.
45968103|NCT00211835|Behavioral|Supportive psychotherapy|A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
45968104|NCT05426590|Device|Specular biomicroscopy|Specular microscopy will be done before and 3 weeks after cataract surgery
45968105|NCT00238797|Drug|Gefitinib|
45968106|NCT05426551|Other|Dual isotope method|The digestibility of amino acids will be determined within each arm by the collection of ileal digesta owing to naso-ileal intubation device and by plasma samples with the dual isotope method.
45968107|NCT05426317|Other|Blood sample|This study only involves the patient taking 5 additional blood tests (peripheral venipuncture) compared to his usual care, which will be taken when he comes to the hospital. Each sample only requires a blood volume of 5mL (one tube), or a total blood volume of 25mL for the study (one blood test every 3 months for one year).
45968108|NCT00211874|Behavioral|Nurse-management|bilingual nurses counseled patients on diet, medication adherence, and self-management of symptoms through an initial visit and regularly scheduled follow-up telephone calls and facilitated evidence-based changes to medications in discussions with patients' clinicians.
45968109|NCT05426278|Device|Bair hugger and Forces air warmer|The EQUATOR™ (EQ-5000) air-warmer is a convective warmer, with the average and maximum Contact Surface Temperatures of 39℃ & 44℃ Respectively. Temperature on this device can be set at 36℃ , 40℃ , 44℃. The 3M™ Bair Hugger ™ (SW-2003) upper body blanket is used to warm the body from head till the xiphisternum
45968110|NCT00238836|Behavioral|Self-management of chronic illness|
45968111|NCT05426044|Drug|Metformin|"To investigate whether metformin has a neuroprotective effect in patients with primary open-angle glaucoma by comparing the rates of change of average retinal nerve fiber layer ganglion cell inner plexiform layer (RNFL-GCIPL) thickness (primary outcome measure) between patients randomized to receive metformin versus those randomized to receive placebo.~To identify the risk factors associated with progressive RNFL-GCIPL thinning and progressive decline in visual field mean deviation in patients with glaucoma."
45968112|NCT05426044|Device|Placebo|This study takes 24 months. Participants will have 12 visits within 24 months. All of the investigations will be carried out at Grantham Hospital and Hong Kong Eye Hospital. Patients will be randomly assigned in a 1:1 ratio to receive, twice daily, oral metformin 750mg (i.e. 1500mg/day) or identical-appearing oral placebo. The investigators and patients will be blinded to the treatment assignment. Participants will be followed up at 2-month intervals for 24 months.
45668291|NCT02001987|Drug|Tocilizumab|Tocilizumab will be administered at a dose of 162 mg as SC injection once a week.
45668292|NCT02001987|Drug|Methotrexate|Methotrexate will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
45668293|NCT02001987|Drug|csDMARDs|csDMARDs (at investigator's discretion) will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
45668294|NCT01363765|Other|Xpert MTB/Rif|Automatized RT-PCR for the detection of Mycobacterium tuberculosis, the agent of TB, in sputum samples
45668295|NCT01363765|Other|Smear microscopy|Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining. This would be the non-intervention (control) arm.
45668296|NCT02001051|Procedure|Adrenalectomy|Surgery to remove tumor when enrolled in the protocol.
45668297|NCT02001051|Other|Observation|Observation for 6 months prior to surgery
45825385|NCT04411212|Drug|Granulocyte colony-stimulating factor and platelet-rich plasma group|Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Autologous platelet-rich plasma is prepared from the blood using the two step centrifuge process. Under ultrasound guidance and complete aseptic procedures, 1 ml of the PRP is infused inside the uterus while performing the mock embryo transfer. Moreover, G-CSF (Filgrastim®, 300μg/0.5ml) is injected subcutaneously. G-CSF is injected weekly until the 12th gestation week or negative pregnancy test.
45825386|NCT04411212|Other|Control group|Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Mock embryo transfer is performed without injecting anything inside the uterus.
45968113|NCT05425966|Behavioral|CLS-R-FUERTE|The CLS-R-FUERTE program is a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). It contains the same evidence-based service components to improve youth attention/behavior as the in-person CLS-FUERTE program; specifically, it features school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
45968114|NCT05425693|Other|Hybrid Warm-up|Dynamic + stretching exercises
45968115|NCT05425693|Other|Dynamic Warm-up|Dynamic exercises
45825387|NCT01977690|Device|Clavicle Brace|
45968116|NCT05425693|Other|Stretching Warm-up|Stretching exercises
45968117|NCT00238875|Procedure|stereotactic body radiation therapy|Procedure/Surgery: stereotactic body radiation therapy
45668298|NCT05586217|Other|INCENTIVE SPIROMETRY|"Sit up and hold the device.~Then Place the mouthpiece spirometer in mouth and make a good seal over the mouthpiece with lips.~Breathe out (exhale) normally.~Breathe in (inhale) slowly. A piece in the incentive spirometer will rise as you breathe in. And try to get this piece to rise as high as you can.~Usually, there is a marker placed by your doctor that tells you how big of a breath you should take.~A smaller piece in the spirometer looks like a ball or disk.~Your goal should be to make sure this ball stays in the middle of the chamber while you breathe in.~If you breathe in too fast, the ball will shoot to the top.~If you breathe in too slowly, the ball will stay at the bottom. Hold your breath for 3 to 5 seconds. Then slowly exhale."
45968118|NCT05425654|Drug|Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide|The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1. On day 2 you will receive: Methotrexate will be given by vein over 2 to 3 hours and vincristine will be given as a single injection over a few minutes. Procarbazine and Lenalidomide are a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine and Lenalidomide are only given every other cycle. During each cycle, you will be in the hospital. After the second cycle of chemotherapy, PBPCs will be collected. You will be hospitalized again for high-dose chemotherapy and receive supportive medications to help avoid complications, including antibiotics and blood transfusions. Busulfan, carmustine and cyclophosphamide will be given to you for 5 days. After break of 1 day, we will return your PBPC (or bone marrow) to you through a vein. You will be in the hospital for at least 3 weeks.
45968119|NCT05425576|Drug|OT-101|OT-101 in combination of pembrolizumab
45825388|NCT04646148|Behavioral|Yoga classes|All participants are invited to attend weekly yoga classes.
45825389|NCT01934010|Drug|AM-101|AM-101 gel for intratympanic injection
45968120|NCT05425537|Other|Drowning accident|"Drowning is defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid"
45968121|NCT05425381|Behavioral|Enhanced version of Interconnected Systems Framework|"District-community Leadership Team to support district-wide implementation and dissemination (Swain-Bradway et al., 2015)~Detailed memoranda of understanding between schools and collaborating mental health centers~Community mental health clinicians meaningfully participate in MTSS teams~Twice-monthly MTSS meetings using systematic teaming strategies (Newton et al., 2012)~Universal screening of students' social, emotional, behavioral, and academic functioning~Data-based decision-making using screening data and data on school and academic functioning for students with and without disabilities~Student-level discipline and intervention data (Blake et al., 2011; Smolkowski et al., 2016) addressed through iterative problem-solving approaches (McIntosh et al., 2018)~Team fidelity measures taken at the start and end of each school year, augmented with monthly fidelity monitoring of Tier 2 and 3 services~A Community of Practice (Wenger, 2010) among the ISFE schools"
46080671|NCT05904756|Device|framework for implant supported prosthesis, fabricated from metal of polyetherketoneketone|evaluation of patient satisfaction and oral healty related quality of life
46080672|NCT05904717|Drug|PXS-4728 (A)|Participants will receive once daily (QD) for period of 12 weeks
46080673|NCT05904717|Drug|Matching Placebo (B)|Participants will receive once daily (QD) for period of 12 weeks
46080674|NCT05904704|Procedure|Magnetic Resonance Imaging|Undergo MRI
46080675|NCT05904704|Procedure|Oxygen Therapy|Receive supplemental oxygen
46080676|NCT05904691|Drug|OCU-10-C-110 for Injection|OCU-10-C-110 for Injection in one of 3 doses
46080677|NCT05904652|Device|"Fisher and Paykel HealthCare Airvo™ 3 high flow system"|High Flow Nasal Oxygen Delivery Device
46080678|NCT05904652|Device|Conventional Oxygen Therapy|Low flow oxygen delivery device (Flow rate between 2 litres per minute and 15 litres per minute)
46080679|NCT05904626|Drug|ELGN-2112|To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants<3rd percentile* born at 26-32 weeks GA.
46080680|NCT05904626|Drug|Placebo|A placebo formulation consisting of the same inactive ingredients as ELGN-2112.
45825390|NCT01620138|Drug|Pasireotide|"The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at the dosage of 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for six months.~The patients with resistant prolactinomas will be treated with pasireotide at the dosage of 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months."
46080681|NCT05903794|Biological|EXG102-031|EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injecting into one eye of each participant.
45968122|NCT05425381|Behavioral|Positive Behavioral Interventions and Supports with Co-located School Mental Health|"PBIS, including previously established data-based decision making, teaming, and evidence-based practices at three tiers: universal prevention; early identification and intervention for students with emerging risk; and intensive intervention for students with established problems and/or disabilities (Sugai & Horner, 2006; Sugai et al., 2014). Most PBIS schools struggle with intervention (Hawken et al., 2009) and the emphasis is typically on behavior, not internalizing student needs, including depression, anxiety, and trauma (Weist et al., 2018).~SMH using a co-located approach, with clinicians implementing treatment separate from the schools' MTSS (Barrett et al., 2013). Research has shown that even when PBIS and community-supported SMH operate in the same school building, in most cases there is no functional collaboration, (Splett et al., 2014). Under this model, SMH services are provided reactively, and students are often in crisis when referred (Dowdy et al., 2010)."
45968123|NCT00238914|Drug|Naltrexone|50mg of oral naltrexone daily
45968124|NCT00238914|Behavioral|Behavioral Naltrexone Therapy (BNT)|a hybrid of Relapse Prevention, the Community Reinforcement Approach, and Network Therapy
45968125|NCT00238914|Behavioral|Compliance Enhancement (CE)|a controlled therapy intended to simulate outpatient psychiatric care.
45968126|NCT05425342|Device|Smartwatch ECG|Self-recorded 9-lead smartwatch ECGs
45968127|NCT05425225|Other|Low level LASER therapy|Three consecutive treatments will be given in a session, with 5 seconds break in between, giving a total irradiation time of 90 seconds. Two sessions will be given per week for total of 6 weeks.(20)
45968128|NCT05425225|Other|Conventional physical therapy|Hot pack for 15 to 20 minutes followed by 10 repetitions of sustained stretching (10 seconds hold), for 3 days a week for 6 week
45968129|NCT04668976|Device|Medtronic pump and Codman catheter|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
45968130|NCT04668976|Drug|Floxuridine (FUDR)|Please see Detailed Description.
45668299|NCT05586217|Other|Active cycle of breathing|"Breathe in and out gently through your nose if you can. If you cannot, breathe through your mouth instead. If you breathe out through your mouth, it's best to use breathing control with 'pursed lips breathing'. keep your shoulders relaxed.~Try closing your eyes to help you to focus on your breathing and to relax. Breathing control should continue until the person feels ready to progress to the other stages in the cycle. Try to keep your chest and shoulders relaxed.~At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing out. Breathe out gently and relaxed. Repeat 3 - 5 times. Sit up straight with chin tilted slightly up and mouth open.~Take a slow deep breath to fill lungs about three quarters full. Hold breath for two or three seconds. Exhale forcefully, but slowly, in a continuous exhalation to move mucus from the smaller to the larger airways"
45825391|NCT01620138|Drug|cabergoline|"The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for 6 months.~The patients with resistant prolactinomas will be treated with pasireotide at 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months."
45968131|NCT04668976|Drug|Gemcitabine|Please see Detailed Description.
45968132|NCT04668976|Drug|Oxaliplatin|Please see Detailed Description.
45968133|NCT04668976|Drug|Irinotecan (CPT-11)|Please see Detailed Description.
45825392|NCT01977612|Device|4-0 monofilament suture|Skin closure using 4-0 monofilament suture
45968134|NCT04668976|Drug|Fluorouracil|Please see Detailed Description.
45968135|NCT04668976|Drug|Anti-EGFR (Panitumumab or Cetuximab)|Please see Detailed Description.
45825393|NCT01977612|Device|Stainless steel staples|Skin closure using stainless steel staples.
45825394|NCT01932996|Drug|nicotine patch plus nicotine gum/lozenge|12-week treatment with nicotine patch plus nicotine gum/lozenge
45825395|NCT01932996|Behavioral|Intensive Alcohol Intervention|Intensive alcohol abstinence counseling using CBT will include weekly individual sessions for 3 months followed by monthly booster group sessions for 3 months
45968136|NCT00238953|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
45968137|NCT04669366|Drug|sunitinib|As provided in real world
46080682|NCT05902715|Device|oral implant placement with socket shield technique|tooth is split in socket shield configuration, implant is immediately placed
46080683|NCT05902624|Drug|Hepatitis B Virus Vaccine(HBV)|Hepatitis B Virus Vaccine(HBV)
46080684|NCT05902052|Other|Care Protocol|Evaluation of patients' pain in the extubated period with the Visual Anolog Scale Active participation of the patient in pain reporting Regular questioning of the patient's pain Questioning pain at rest and movement Implementing nursing interventions in painful condition (VAS≤ 4)
45825396|NCT01932762|Drug|Grazoprevir|100 mg every day (QD) orally
45825397|NCT01932762|Drug|Elbasvir|50 mg QD orally
45825398|NCT01932762|Drug|Ribavirin|Administered twice daily (BID) orally at a total daily dose of 800 mg to 1400 mg based on participant's weight on Day 1
45968138|NCT04669366|Drug|axitinib|As provided in real world
45968139|NCT04668703|Procedure|Conbercept intravitreal injection|intravitreal injection of 0.5 mg conbercept at the conclusion of cataract surgery
45968140|NCT04669327|Other|gait analysis|Vicon nexus with MTI force plate form
46080685|NCT05905471|Other|Interview|Interview study
46080686|NCT05901792|Other|Virtual Reality Games|Six different Nintendo Wii Fit Plus games will be employed for six weeks, three days a week, for a total of 18 sessions ranging from 40 to 60 minutes. The games will be chosen from those that emphasize shifting the body's center of gravity. In addition, participants will be given basic correction exercises (derotation, deflexion, basic tension, and lateral flexion 3*3) at the beginning of the study and instructed to practice them at home for six weeks.
46080687|NCT05901792|Other|Waiting List|As the control group, the cases on the waiting list will be evaluated. The control group will be given basic elements of corrective exercises (derotation, deflexion, basic tension, and lateral flexion 3*3) at the start of the study and instructed to practice at home for six weeks.
45968141|NCT04721301|Combination Product|Nivolumab plus Ipilimumab plus Maraviroc|In the single treatment arm, all patients receive Nivolumab, Ipilimumab and Maraviroc
45968142|NCT04668625|Behavioral|Participate in a massive musical event|Participate in a massive musical event
45968143|NCT04668508|Drug|Anlotinib|concurrent using anlotinib combined with radiation plus adjuvant anlotinib after radiotherapy until disease progress or develop into serious adverse events.
45968144|NCT04668430|Other|imaging and motion analysis|performing a set of imaging and motion analysis tests before and after orthopedic surgery without modifying the operative indication or the pre- and post-operative management.
45668300|NCT05577013|Other|kinesiotaping|It will be applied by kinesiotape certified physiotherapist on tendons in the direction of extensor muscle to facilitate range of motion by stretching 50%. At first it will be applied on extensor pollicis longus and extensor pollicis brevis muscles of hand, extensor digitorum and extensor indicis of last 4 fingers of hand. Triceps brachii in arm and Supraspinatus and Infraspinatus muscles to stabilize the gelnohumeral joint
46080688|NCT05901753|Device|Laryseal pro supra glottic device|The laryseal pro SP will be advanced at a forward angle aiming for the back of the tongue and soft palate. Then the colored connector will be pushed by index finger till feeling resistance . Device insertion will be considered successful by observing bilateral chest wall movement as well as a stable square-wave capnogram trace
45668301|NCT05577013|Other|motor relearning program|Stacking up blocks Stacking up polystyrene cups Folding piece of cloth Using cutlery Pouring water into glass Closing/opening lid of bottles turning the pages of books or newspaper writing on paper Squeezing of ball Coloring in different shapes
45668302|NCT05429437|Biological|Injectable platelet rich fibrin .|i-PRF with maxillary canine retraction that will be performed two times on intervention sides according to a standardized protocol.
45668303|NCT05429437|Biological|Injectable platelet rich fibrin .|i-PRF that will be performed four times on intervention sides according to a standardized protocol.
45968145|NCT00238992|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
45968146|NCT00556465|Drug|N-acetylcysteine|600 mg of effervescent N-acetylcysteine tablet twice per day for three months
45968147|NCT04668469|Drug|Ivermectin|"evaluation of the anti-parasitic medication efficacy Ivermectin (Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast) plus standard care in the treatment of mild/moderate cases with COVID 19 infection"
45968148|NCT04668469|Drug|Hydroxychloroquine|evaluation of hydroxychlorquine (400 every 12 hours for one day followed by 200 mg every 12 hours for 5 days) plus standard care in the treatment of mild/moderate cases with COVID 19 infection
45968149|NCT04668469|Behavioral|personal protective Measures|evaluation of personal protective Measures (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, wearing masks, and self-isolation) only as a prophylaxis for health care and or household contacts' from COVID-19 disease
45968150|NCT04668547|Device|Hysteroscopic Embryolysis|Hysteroscopic removal of the products of conception for induced abortion using a hysteroscopic morcellator. If this method of induced abortion fails, a traditional Dilation and Curettage procedure is performed
45968151|NCT00211913|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single IM dose totalling 200 mcg of conjugate
45668304|NCT04850677|Other|Observational Cohort|Observational study
45668305|NCT01763164|Drug|MEK162|MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.
45668306|NCT01763164|Drug|Dacarbazine|Patients randomized to dacarbazine will receive an IV infusion of dacarbazine 1000 mg/m2 over the course of 1 hour on day 1 and then every three weeks.
45668307|NCT01782742|Drug|Bexarotene|Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo
45968152|NCT00211913|Biological|placebo|single IM dose
45668308|NCT01782742|Drug|Placebo|
45668309|NCT01782664|Drug|100 mg GSK2586184|100 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
45668310|NCT01782664|Drug|200 mg GSK2586184|200 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
45668311|NCT01782664|Drug|400 mg GSK2586184|400 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
45668312|NCT01782664|Drug|Placebo|Placebo tablets to be taken twice daily with food for up to 84 days.
45668313|NCT04414072|Procedure|sleeve gastrectomy with loop bipartition|operations to decrease weight
45968153|NCT00239031|Drug|Enteric-Coated Mycophenolate Sodium|Enteric-Coated Mycophenolate Sodium
45968154|NCT00239070|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
45968155|NCT00211952|Drug|celecoxib|
45968156|NCT00239109|Drug|Ziprasidone|
45968157|NCT00239109|Drug|Olanzapine|
45968158|NCT00239109|Procedure|Scales|
45968159|NCT00239109|Procedure|measures of the body (Weight...)|
45968160|NCT00239109|Procedure|Serum analysis|
45968161|NCT00211991|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|
45968162|NCT00239148|Drug|E1 and G1|
45968163|NCT00212030|Drug|nicorandil|(0∙067 mg/kg as a bolus, followed by 1∙67 μg/kg per min as a 24-h continuous intravenous infusion
45968164|NCT00212030|Drug|placebo|Control
45968165|NCT00239187|Drug|E1 and G1|
45968166|NCT00212069|Drug|gemcitabine, carboplatin|
45968167|NCT02961777|Other|implementation of care pathway|implementation of a care pathway
45968168|NCT00212108|Drug|celecoxib, gefitinib|The dose of ZD1839 to be administered is 250mg. ZD1839 will be taken once daily in the morning at approximately the same time each day. If the patient inadvertently did not take the dose in the morning, the patient may take that dose anytime up to 10pm that same day. The daily treatment will be resumed the next day at the scheduled morning dose. Celecoxib will be administered at 400 mg bd.
45455705|NCT05788822|Dietary Supplement|Mevalproic acid|Methovalerate pathway is a metabolism of cholesterol and isoprenoid synthesized from acetyl coenzyme A Pathway, which plays a key role in human health and disease, is also necessary for human cells to maintain normal functions. There are a series of important metabolic intermediates in the mevalproate pathway, such as farnesyl diphosphate and incense Folyl vanillin diphosphates, which modify proteins through isoprene, play an important role in regulating cell function. In addition, the latest research shows that valproic acid, the key metabolic intermediate of valproic acid pathway, being the synthetic precursor of cholesterol and isoprene, it can activate insulin growth factor (IGF)1-R and mTOR signals and maintain cell function by mediating histone function
45455706|NCT05788796|Behavioral|Band-aid application|"Before starting the study, cotton and band-aids will be provided to the women in the application group by the researchers.~• Pregnant women in the application group will be asked to take a hazelnut-sized cotton ball before going to bed, put it in the middle of the navel and close it diagonally with a band-aid."
45455707|NCT05788770|Other|FEops HEARTGuide|FEops HEARTGuide added to routine preoperative CT imaging. Results of the computer modelling will be discussed with TAVR implanting team prior to and during the procedure.
45455708|NCT05788744|Diagnostic Test|ctDNA|ctDNA guided surveillance
45455709|NCT05788718|Drug|Sugammadex|As this is a non-interventional study designed to collect data as part of routine clinical practice, the type and dose of neuromuscular blocking agents are all based on the clinician's judgment.
45968169|NCT00239265|Drug|Tamuslosin|
45968170|NCT00212186|Drug|Selenium Supplements (essential nutrient)|
45968171|NCT00414258|Procedure|breastfeeding|See detailed description.
45968172|NCT00414297|Device|ECP Therapy|application of ECP Therapy to CAD Patients
45968173|NCT00212303|Behavioral|Exercise training for 6 months|Exercise 3 times/week for 6 months. Exercise consists of aerobic and resistance exercise
45968174|NCT00414336|Drug|AMA1-C1/Alhydrogel + CPG 7909 Vaccine|
45968175|NCT00212342|Drug|Norethisterone,Ethinylestradiol|
45968176|NCT00212342|Drug|Sugar pill|
45968177|NCT00414375|Procedure|Operation on Admission|Laparoscopic appendectomy on admission
46080689|NCT05901753|Device|Laryngeal Mask Airway- Proseal™|The cuff will be inflated with air and the cuff's pressure will be adjusted to 70 mmHg using a cuff pressure manometer. the device will be lubricated well on both sides, head and neck were placed in neutral position, the proximal firmer part of the device will be compressed between the thumb and two fingers and advanced toward hard and soft palate, the tab will be pulled slightly if needed to increase curvature of the device for better fitting, the device will be advanced till resistance felt.
45668314|NCT04561180|Drug|EG-009A|Administered as an Intramuscular injection
45968178|NCT00414375|Procedure|Drainage and Interval Appendectomy|drainage with interval appendectomy
45968179|NCT00212381|Drug|di indolylmethane (DIM)|This is the agent being studies. Similar agents have been reported to have potential activity.
45968180|NCT00212381|Dietary Supplement|Red rice bran|"this will act as the active comparator. The sponsor provided this as the placebo arm since it is a filler component of their DIM capsules"
45668315|NCT04561180|Drug|EG-009A Placebo|Administered as an Intramuscular injection
45668316|NCT04561180|Drug|Standard of Care|Standard of Care Treatment for COVID-19 Infection
45668317|NCT04561180|Drug|Dexamethasone|The comparator, Administered as an Intravenous infusion
45668318|NCT01732588|Drug|OZ439 120mg PIB|120mg dose (as free base) of OZ439 as a solution made up from powder in bottle (PIB)
45668319|NCT01732588|Drug|120 mg OZ439 caplet|120 mg (as free base) of OZ439 immediate-release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
45825399|NCT04645680|Other|Dietary Intervention|Consume isocaloric whole foods diet higher in fiber
45825400|NCT04645680|Other|Dietary Intervention|Whole foods diet
45968181|NCT00414414|Drug|Prednisone|
45968182|NCT00414414|Drug|placebo|placebo
45968183|NCT00212420|Procedure|parenteral nutrition; enteral nutrition|
45825401|NCT04645680|Other|Quality-of-Life Assessment|Ancillary studies
45825402|NCT04645680|Other|Questionnaire Administration|Ancillary studies
45825403|NCT01618968|Drug|MTX|"Treatment A - 1 dose (4, 6, 8 or 10 tablets respectively to make up 10 mg, 15 mg, 20 mg or 25 mg MTX - per subject's dose group)~Treatment B - SC injection using VIBEX MTX device into abdomen (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)~Treatment C - SC injection using VIBEX MTX device into thigh (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)"
45825404|NCT04645524|Drug|AD182|Oral capsule administered before bed
45968184|NCT00239304|Drug|Gefitinib|
45968185|NCT00239304|Drug|Cisplatin|
45968186|NCT00239304|Procedure|Radiotherapy|
45825405|NCT04645524|Drug|AD504|Oral capsule administered before bed
45968187|NCT00212459|Behavioral|Counseling|Patients are contacted every two weeks after initial counseling to discuss the completion of bleeding records.
45968188|NCT00212459|Behavioral|Control|No more contacts are made with control patients after the initial counseling session.
45968189|NCT00239343|Drug|gefitinib|
45825406|NCT04645524|Drug|Placebo|Oral capsule administered before bed
45968190|NCT00411593|Drug|Bevacizumab|15 g/kg by vein every 3 weeks on day 1 of each cycle.
45968191|NCT00411593|Drug|Bortezomib|"Phase I Starting dose: 1.6 mg/m2 by vein on days 1, 8 of each 3 week cycle.~Phase II: MTD from Phase I."
45968192|NCT00239382|Drug|Meloxicam ampoule|
45968193|NCT00239382|Drug|Meloxicam tablet|
45968194|NCT00411827|Procedure|PRK with conjunctival impression cytology before and after surgery|
45968195|NCT00411827|Procedure|LASIK with conjunctival impression cytology before and after surgery|LASIK with conjunctival impression cytology before and after surgery
45968196|NCT00239421|Drug|Test: Tiotropium 18 µg per day (one inhalation capsule) plus 12 µg formoterol twice daily (two times one inhalation capsule)|
45968197|NCT00239421|Drug|Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d.|
45968198|NCT00212498|Procedure|Develop a bank of blood samples from patients infected with TB for future molecular genetics studies and serological studies|Blood sample
45968199|NCT00239460|Drug|Tiotropium|
45968200|NCT00212576|Behavioral|Video Interaction Project|While waiting to see the primary care provider for well child care, the family meets with a child development specialist, who videotapes the parent and infant interacting together. The videotape is then rewound and watched together by the parent and child development specialist. This leads to a discussion about child development, infant cues and parenting, with the child development specialist building on observed strengths in the interaction. In addition, families are provided with parenting pamphlets developed for the project, and with inexpensive developmentally stimulating toys.
45968201|NCT00212576|Behavioral|Building Blocks Project|This project employs a public health approach to facilitate parental engagement in child development. Families are sent monthly newsletters that focus on child development, infant cues and parenting; included with each newsletter is an inexpensive, developmentally stimulating toy. In addition, families periodically receive Ages and Stages Questionnaires, which they complete and mail back to the program. Based on the questionnaires, the program determines whether the infant has screened positive for possible developmental delay and provides this information to both the family and the primary care provider.
45968202|NCT00239499|Drug|Tiotropium|
45968203|NCT00239499|Drug|Salmeterol plus Fluticasone|
45968204|NCT00212615|Drug|Oxaliplatin (Eloxatin)|
45968205|NCT00212615|Drug|Capecitabine (Xeloda)|
45455710|NCT05788705|Dietary Supplement|"apigenin and glycyrrhizin"|"apigenin will be administered as capsule (10mg,eq 200mg Matricaria chamomilla L extract) two times daily. Also, glycyrrhizin  will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months"
45455711|NCT05788705|Dietary Supplement|"glycyrrhizin and boswellic acid"|"boswellic acid will be administered as capsule (200mg,eq 250mg Boswellia serrata extract) two times daily. Also, glycyrrhizin  will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months"
45968206|NCT00222573|Drug|clopidogrel and metoprolol|
45968207|NCT00212654|Drug|ONO-1101|
45968208|NCT00222612|Other|Reduced intensification|Deletion of one 7 week treatment block containing dexamethasone, vincristine, doxorubicin, Peg-asparaginase, intrathecal methotrexate, cyclophosphamide, cytarabine.
46080690|NCT05901506|Other|a Nurse-led, Motivational Interview|Family member participants will receive three counselling sessions: (1) preparatory session, (2) motivation session, and (3) planning session. The preparatory session will take 10-15 minutes, and the following two sessions at weeks 2 & 3, with 30-45 min, respectively. The sessions can be delivered via face-to-face, zoom meeting, or telephones. Before each session, the nurse will first assess the family member's readiness to engage in ACP based on the State to Change algorithm. Family members who have never thought about ACP will be in the pre-contemplation state. Family members who are willing to discuss end-of-life care will be in the contemplation state. Those who are ready to talk about end-of-life planning will be in the planning state. Readiness-based ACP goals will be established, and state-matched motivational interview counseling will be customized for each participant.
45825407|NCT04645524|Diagnostic Test|Polysomnography|for all arms
45825408|NCT04662216|Procedure|Scaling and root planing|Scaling and root planing will be accomplished with ultrasonic and hand instruments (Gracey curettes).
45825409|NCT04662216|Procedure|"Scaling and root planing + Perisolv +Hyadent BG gels"|"Scaling and root planing will be accomplished with ultrasonic and hand instruments (Gracey curettes), Perisolv gel will adjectively be applied to all pockets with probing depth(PD) ≥ 5 mm, which will be inserted into periodontal pockets before and during SRP (2 times). The nozzle will be placed in the pocket mesially, lingually, distally and bucally. Afterwards, all teeth will be polished and all treated pockets will be filled with hyaluronic acid gel (Hyadent BG)."
45825410|NCT01931670|Other|placebo|
45825411|NCT01931670|Drug|Elagolix|
45825412|NCT01977456|Drug|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
45968209|NCT00222612|Drug|Standard childhood UK ALL protocol|No additional treatment to standard protocol.
45968210|NCT00222612|Drug|Intensified treatment including Capizzi maintenance|Augmented consolidation: vincristine, Peg-asparaginase. Capizzi maintenance: iv methotrexate and peg-asparaginase
45968211|NCT00212693|Drug|ONO-2506PO|
45968212|NCT00212732|Drug|ONO-8025 (KRP-197)|
45968213|NCT00239538|Drug|telmisartan combined with hydrochlorothiazide (80/12.5 mg)|
45968214|NCT00239538|Drug|valsartan combined with hydrochlorothiazide (160/12.5mg)|
45968215|NCT00212810|Drug|Topiramate|
45968216|NCT00222651|Drug|tenecteplase|
45968217|NCT00239616|Drug|iron sucrose injection USP|
45968218|NCT00213005|Drug|Carraguard (PC-515)|
45968219|NCT00239655|Drug|MK0812|
45968220|NCT00213044|Drug|Carraguard (PC-515)|
45968221|NCT00213083|Drug|Carraguard (PC-515)|
45968222|NCT04709406|Drug|deep neuromuscular blockade in bariatric surgery|obese patients who underwent bariatric surgery
45968223|NCT00213122|Drug|miglitol|
45968224|NCT00213161|Drug|iron supplement, iron drops|
45968225|NCT00213200|Drug|morphine, amethocaine|
45825413|NCT01957644|Drug|Azacitidine|
45968226|NCT00239811|Drug|FTY720|
45968227|NCT00213278|Drug|vinblastine sulphate injection|Vinblastine dose: 6 mg/m^2 (10 mg max.) route intravenous administration once a week over a period of 10 weeks. If response at week 10 is greater than or equal to stable, weekly Vinblastine will be continued for 42 weeks.
45968228|NCT00222846|Behavioral|Attention control|Participants attend 3 educational seminars, receive a lay diabetes journal, pedometer, and glucose monitoring supplies.
45968229|NCT00222846|Behavioral|Intervention|Behavioral intervention of diabetes self-management paired with PDA-based monitoring of dietary intake and physical activity. Participants also receive a pedometer and glucose self-monitoring supplies.
45968230|NCT00213317|Procedure|lombo-sacral magnetic stimulation|repetitive lombo-sacral nerve magnetic stimulation active and placebo performed during colonic recordings after bisacodyl instillation
45968231|NCT00239850|Behavioral|lifestyle changes|
45968232|NCT00239889|Drug|Salmon calcitonin|
45968233|NCT00222924|Behavioral|weight loss/ exercise|
45968234|NCT00239967|Drug|Rimonabant (SR141716)|
45455712|NCT05788705|Dietary Supplement|"placebo"|"Placebo capsule will be administered two times daily for 6 months"
45968235|NCT00239967|Drug|Placebo|
45968236|NCT00213395|Device|Interface for noninvasive ventilation|
45455713|NCT05788679|Drug|Azacitidine|Azacitidine
45455714|NCT05788679|Other|Donor lymphocytes|Donor lymphocytes in patients without immune suppression
45968237|NCT00213434|Device|Herbst oral appliance|
45455715|NCT05788679|Other|Tapering of immune suppression|Tapering of immune suppression in patients who are on immune suppressive drugs
45455716|NCT05788614|Device|Reverse shoulder arthroplasty|Reverse shoulder arthroplasty
45668320|NCT01732588|Drug|120mg OZ439 caplet via Enterion capsule|120 mg OZ439 (as free base) in an immediate release (IR) caplet formulation containing nanoparticulate,administered orally via the Enterion capsule and delivered directly to the proximal small bowel (PSB)
45668321|NCT01781962|Other|No Treatment|No Treatment was given in this study.
45668322|NCT04560790|Drug|BD111 Adult single group Dose|3-6 Participants will receive a single group dose administered via corneal injection in the study eye.
45668323|NCT04574830|Other|No Intervention|No Intervention
45668324|NCT01639339|Biological|Placebo plus standard therapy|Placebo plus standard therapy
45668325|NCT01639339|Biological|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
45668326|NCT01639339|Drug|Standard therapy|"The standard therapies allowed in this study are:~- High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy~OR~- High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy"
45825414|NCT01957644|Drug|Volasertib|
45825415|NCT01931202|Drug|Escitalopram|Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is FDA approved for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults and children over 12 years of age.
45825416|NCT01931202|Drug|Placebo oral tablet|Inert substance or treatment which is designed to have no therapeutic value but resemble the active medication in this study
45825417|NCT01930890|Biological|BIIB023|
45825418|NCT01930890|Drug|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
45825419|NCT01930890|Drug|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
45825420|NCT01930188|Drug|semaglutide|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
45825421|NCT01930188|Drug|sitagliptin|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
45968238|NCT00223002|Drug|Chlorhexidine|sample collected at time of procedure and then analysed for bacterial contamination
45968239|NCT00213512|Drug|Mabthera|
45968240|NCT00223041|Drug|Fluvastatin|Arm A receives fluvastatin Arm b receives no fluvastatin
45455717|NCT05788575|Procedure|surgery|any surgery that an inpatient has undergone
45968241|NCT00213551|Drug|Glutamine|
45968242|NCT00213551|Drug|Glucose|
45968243|NCT00213551|Drug|glutamine-antioxidants containing solution|
45968244|NCT00240006|Procedure|Shared Solutions® plus MS Center v. Shared Solutions®|Copaxone
45968245|NCT00213590|Drug|cyclosporine A|The usual-exposure level was based on the mean area-under-the-concentration-time curve (AUC0-12h). In the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L and in the low-exposure group the target was 50% or 2.2 (2.0 to 2.6, range) mg•h/L. Ranges were asymmetrical for safety reasons, i.e., to prevent the occurrence of rejection in the low-exposure arm and nephrotoxicity in the usual-exposure arm.The AUC 0-12h was estimated using a Bayesian estimator and a three-point limited sampling strategy (0, 1, and 3 hours). A computer program was used to calculate the dose adjustment required to reach the therapeutic target. Doses were adjusted in increments of 25% to reach the target within 2 months. Cyclosporine AUC0-12h was determined every 2 months.
45968246|NCT00243633|Procedure|Real-time contrast-enhanced ultrasound sonography|
45968247|NCT00213629|Other|transcriptome analysis|transcriptome analysis from muscle biopsy
45968248|NCT00213629|Other|T cell repertoire analysis|blood T cell repertoire analysis
45968249|NCT00240045|Drug|Midodrine, albumin, octreotide LAR|
45968250|NCT00240045|Drug|midodrine, octreotide, albumin|midodrine up to 12.5 mg tid, octreotide LAR 20 mg im once, albumin 150 mg q weekly
45968251|NCT00213668|Dietary Supplement|glutamine (dipeptiven)|
45968252|NCT00243672|Drug|Atorvastatin|
45968253|NCT00243672|Drug|Gemfibrozil|
45968254|NCT00240084|Drug|nesiritide (Natrecor(TM))|administration of IV nesiritide
45668327|NCT04849507|Device|transcutaneous auricular vagus nerve stimulation|Stimulation of the auricular branch of the left vagus nerve paired with oromotor feeding.
45825422|NCT01930188|Drug|placebo|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
46080691|NCT05899218|Behavioral|Critical Narrative Development|"Participants are asked to answer two prompts (describe an experience where you have felt seen as an LGBTQ+ person of color and describe an experience where you have felt unseen as an LGBTQ+ person of color)."
46080692|NCT05898841|Drug|Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day|DTG/RPV will be administered in combination as 50/25 mg/day tablets or separately as DTG 50 mg/d tablets together with RPV 25 mg/d tablets. There will be no problem if during the course of the study the patient is switched from the combined form to the separate form and vice versa as long as the HAART (Highly Active Antiretroviral Therapy) components are respected.
45458570|NCT02939209|Drug|Hydromorphone Hcl 2Mg Tab|Patients will be given 2 mg hydromorphone (immediate release formulation) in the post anesthetic care unit.
45458571|NCT02939209|Drug|Placebo|Patients may be randomized to placebo.
45458572|NCT02319226|Other|Transplantation from an HLA-identical sibling donor|The study will include a cohort of 60 patients transplanted from an HLA-identical sibling donor.
45458573|NCT01141855|Drug|Champix|"Standard MIMS dosage (including period of titration) will be used. 0.5mg daily for 3 days 0.5mg b.d. for 4 days~1mb b.d. for 70 days (full course 3 months)"
45458574|NCT01141855|Behavioral|Counselling alone|Quit SA 5A counselling over the phone. Maximum 8 calls over a 3 month period
45968255|NCT00243711|Drug|Carboxymethylcellulose sodium and Glycerin|
45825423|NCT01930188|Drug|placebo|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
45968256|NCT00240123|Drug|Benadryl versus Placebo|
45968257|NCT00240279|Drug|Rosuvastatin|
45968258|NCT00240279|Procedure|aortic pulse wave velocity measurements|
45968259|NCT00243750|Drug|Methotrexate|
45968260|NCT00213863|Device|Vocal fold medialization (thyroplasty) prosthesis by insertion of a new implant allowing very easy and quick setting|The porous titanium prosthesis is implanted under local anaesthesia. Neck incision is performed in order to expose the thyroidal cartilage. A window is then opened in this cartilage, and the implant is placed in contact with the vocal muscles. The patient is then asked to speak in order to achieve the implant best setting.
45968261|NCT00243789|Drug|Pentoxifylline|"Participants will be randomized to receive either pentoxifylline or placebo in addition to their stable steroid therapy. Active drug and placebo preparations will be supplied as gel capsules of identical size, appearance and taste. Active drug capsules will contain one 400 mg time-release pentoxifylline tablet and inert filler. Placebo capsules will contain inert filler.~Based on weight at screening, <30 mg will receive 1 400 capsule/day; 30-49 kg will receive two 400 capsules/day; 50 kg or greater will receive three 400 mg capsules/day."
45968262|NCT00213941|Device|Echocardiography|
45968263|NCT00243828|Device|Total Face Mask|
45968264|NCT00214058|Drug|Carboplatin|
45968265|NCT00214058|Drug|Docetaxel|
45968266|NCT00240318|Drug|Rosuvastatin calcium|
45968267|NCT00243945|Drug|Rotigotine|
45668328|NCT05572333|Drug|EP395|Capsule for oral use
45668329|NCT05572333|Drug|Placebo|Capsule for oral use
45668330|NCT02000817|Biological|Otelixizumab|Otelixizumab is available at unit dose strength of 5 milligram/mL provided as 1 mL solution per vial to be diluted to 0.1 mg/mL in 0.9% sodium chloride. The 0.1 mg/mL solution is to be administered by intravenous infusion using a syringe pump and an in-line 0.2 micron filter by study personnel following specified regimens
45668331|NCT02000817|Biological|Placebo|Placebo is available 0.9% w/v sodium chloride
45668332|NCT01641133|Biological|Synflorix (3-Dose)|3 doses administered intramuscularly
45668333|NCT01641133|Biological|Synflorix (2-Dose)|2 doses administered intramuscularly
45668334|NCT01641133|Biological|Synflorix (Single Dose)|1 dose administered intramuscularly
45968268|NCT00214214|Drug|Campath 1H® (Alemtuzumab)|
45968269|NCT00240357|Procedure|Lifestyle Regulation|
45968270|NCT00214253|Drug|Thiazolidinedione|Thiazolidinedione vs. no intervention with standard immunosuppression using Edmonton Protocol
45968271|NCT00240396|Drug|Narcotics alone|
45968272|NCT00240396|Drug|Narcotics and NSAIDS|
45968273|NCT00214292|Procedure|fluorescence spectroscopy and diffuse spectroscopy|
45968274|NCT00214331|Drug|ciprofloxacin|ciprofloxacin 500 mg twice a day for five doses.
45668335|NCT01641133|Biological|Prevenar 13 (Single Dose)|1 dose administered intramuscularly
45668336|NCT01641133|Biological|Prevenar 13 (2-Dose)|2 doses administered intramuscularly
45668337|NCT04849429|Biological|Platelet rich plasma (PRP) with exosomes|Autologous Platelet rich plasma (PRP) with exosomes Following skin disinfection of the back 2 ml from the total PRPex procured will be injected as soon as possible by an fluoroscopy guided lateral approach.
45668338|NCT04849429|Drug|Normal Saline|placebo : 2 ml normal saline para discal administration
45825424|NCT01977222|Device|THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER|Subjects will be provided with noseclips and a threshold impedance device set to 40% of their measured maximal inspiratory pressure and will be trained on using the device. Specifically, subjects will be instructed to breathe through the inspiratory muscle training device while wearing noseclips at a rate of 12 to 16 breaths per minute for 30 minutes a day, 5 days a week for 12 consecutive weeks. Each subject will be provided a customized schedule for increasing resistance by 2 cm H2O every 2 weeks to a maximum resistance of 41 cm H2O.
45825425|NCT01957488|Device|Coloplast Test Product 1|Coloplast Test product 1 is a newly developed 1-piece ostomy appliance
45968275|NCT00214331|Drug|azithromycin|azithromycin 500 mg on day 1 followed by 250 mg on days 2-5
45668339|NCT05112757|Other|Smartphone application use|Use of a smartphone application
45668340|NCT04836637|Dietary Supplement|Maltodextrin|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
45668341|NCT04836637|Dietary Supplement|Calcium-carbonate|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
45668342|NCT04836637|Dietary Supplement|Calcium-enriched permeate|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
45825426|NCT01957488|Device|Coloplast Test Product 2|Coloplast Test product 2 is a newly developed 1-piece ostomy appliance
45825427|NCT01957488|Device|Coloplast SenSura|SenSura 1-piece is the commercial available CE-marked SenSura 1-piece from Coloplast A/S.
45825428|NCT01976364|Drug|Tofacitinib|Tofacitinib 5 mg tablet twice daily
45825429|NCT01976364|Drug|Tofacitinib|Tofactinib 10 mg tablet twice daily
45825430|NCT01976364|Drug|Methotrexate|Methotrexate 7.5-20 mg weekly
45968276|NCT00214331|Drug|gentamicin|a single intravenous dose of gentamicin 1.5mg/kg infused over 60 minutes
45668343|NCT04836637|Dietary Supplement|Calcium-enriched permeate with Inulin|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
45668344|NCT04835467|Device|Dual-modal OCT-FLIm|Intracoronary imaging using dual-modal OCT-FLIm catheter
45825431|NCT01976364|Drug|Placebo Methotrexate|Placebo to match active methotrexate orally once a week
45968277|NCT00243984|Drug|topiramate|
45968278|NCT00214370|Drug|Propofol-Fentanyl|
45968279|NCT00214370|Drug|Propofol alone|
45968280|NCT00240435|Device|5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
45968281|NCT00240435|Device|10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
45968282|NCT00244023|Drug|Testosterone gel|one sachet of 50 mg applied once a day, possibly titrated to two sachets if insufficient improvement of erectile function
45968283|NCT00244023|Drug|testosterone|testosterone gel, one sachet of 50 mg applied once a day, possibly titrated to 100 mg if insufficient effect
45968284|NCT00244023|Other|placebo gel|one sachet of placebo gel once a day possibly titrated to 2 sachets if insufficient efficacy
45968285|NCT02962622|Other|High intensity interval training (HIIT)|Six weeks, three days per week (total of 18 sessions) of HIIT cycle ergometer exercise protocol
45968286|NCT00244062|Behavioral|counseling|
45968287|NCT00214565|Drug|Galida|
45968288|NCT00240474|Drug|Telmisartan 80 mg + hydrochlorothiazide 12.5 mg|
45968289|NCT00240474|Drug|Amlodipine 10 mg + hydrochlorothiazide 12.5 mg|
45968290|NCT00214604|Drug|Rosuvastatin|10mg
45968291|NCT00214604|Drug|rosuvastatin|20mg
45968292|NCT00214604|Drug|pravastatin|40mg
45968293|NCT04720950|Other|Exercise|1 hour of exercise on a motorised treadmill at 70% maximal heart rate
45968294|NCT00214643|Drug|Fosmidomycin|30 mg/kg
45968295|NCT00214643|Drug|clindamycin|10 mg/kg
45968296|NCT00414531|Drug|Atorvastatin|20 to 80 mg per day
45968297|NCT00214682|Drug|Folate (400mcg) and Vitamin B12 (100 mcg)|The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
45825432|NCT01956240|Procedure|Stretching-Asymptomatic subjects|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
45968298|NCT00214682|Behavioral|mediated physical activity promotion|Individuals in the Physical Activity Promotion group received a manual designed to promote older individuals' physical activity participation to the level recommended to gain both physical and mental health benefits. The framework of the physical activity manual was informed by social cognitive theory and the transtheoretical model, and comprised five sections that reflect stages of behaviour change, including; precontemplation, contemplation, preparation, action, and maintenance. The manual contained evidence-based strategies and skills to assist people in increasing their physical activity levels. Participants received a pedometer at the commencement of the intervention as pedometry step / minute values are useful as an indicator of moderate to vigorous physical activity with total number of steps for one week recorded during the brief telephone calls at 1-5 weeks, and 4-, 8-, 13-, 18-, and 22- months.
45968299|NCT00214682|Behavioral|Mental health literacy|Comprises 10 modules, with nine of these specifically written for older adults. Modules 1 to 5 comprised information on depression and the evidence-based treatment for older adults. The additional MHL modules were booklets addressing evidence-based strategies and treatments for depression. It was delivered in a way to foster support and ensure that participants worked through the material systematically. Modules 1 to 5 were delivered in consecutive weeks as previous research indicates that the maximum impact of MHL on depressive symptoms may occur within the first six weeks of the intervention. Telephone interviewers contacted participants once a week for 5 consecutive weeks to motivate and support participants. There were an additional 5 check-in telephone calls, and Modules 6 to 10 of the MHL material that were delivered via postal mail at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10).
45968300|NCT00214682|Drug|placebo|A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
46080693|NCT05898841|Drug|Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day|TDF 245 mg/d or TAF 25mg/d together with FTC 200 mg/d and RPV 25 mg/d. They may be administered as single tablets or in combination forms where one tablet contains TDF/TAF and FTC and another RPV tablet. There will be no problem if during the course of the study the patient is switched from the combined form to the separate form and vice versa as long as the HAART components are respected.
45668345|NCT04419259|Drug|AMG 334|30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
45668346|NCT04835311|Procedure|surgical perineal repair|women who have undergone surgical perineal repair (codes CCAM JMMA002 and/or HKCA005)
45668347|NCT02000427|Drug|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV). A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab followed by a 2-week treatment-free interval.
45668348|NCT05382013|Drug|Avatrombopag|Patients will receive treatment of oral avatrombopag 20mg per day for the first 5 days
45825433|NCT01956240|Procedure|Stretching-Subjects with shoulder pain|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
45825434|NCT01929876|Drug|Cobimetinib|10 milligram (mg) (2* 5 mg capsules) will be administered orally on Day 1 of Period 1 and Day 4 of Period 2
45825435|NCT01929876|Drug|Itraconazole|200 mg oral solution will be administered once daily from Day 1 to Day 14 of Period 2
45825436|NCT04630236|Diagnostic Test|Ultrasound|Using ultrasound control, the central vein catheter is injected with saline solution and the time to detect the saline bolus in the ultrasound is measured.
45825437|NCT01929018|Behavioral|Exercise|Exercise will target muscle strength and joint mobility impairments and will be delivered over a 12 week period.
45825438|NCT01929018|Behavioral|Walking Program|A walking program will be established with the goal of participants walking at least five days per week. Duration of program is 12 weeks.
45968301|NCT00214682|Behavioral|Nutrition information|The attention control intervention for the physical activity intervention was printed nutrition literacy and included information concerning the recommended dietary guidelines for older Australians, as well as strategies and additional information to facilitate beneficial dietary behaviours. The same procedure was adhered to as the physical activity intervention to ensure adequate attention control. Participants in the nutrition promotion intervention received 5 brief telephone calls from an interviewer to facilitate adherence to the intervention, and to offer support and clarification of the materials. Participants received five further brief telephone calls as well as nutrition newsletters that were delivered via postal mail at 4-, 8-, 13-, 18-, and 22- months.
45968302|NCT00214682|Behavioral|pain and arthritis management information|Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
45825439|NCT01929018|Behavioral|Health Self-Management Support|Health self-management support will be delivered with weekly meetings between the researcher and participant over a 12-week period.
45968303|NCT00214721|Drug|Experimental Peritoneal Dialysis Solution|
45968304|NCT00214760|Device|PGET|resolbable liner
45968305|NCT00214760|Device|PMMA|cement liner
45968306|NCT00240513|Drug|Minocycline|100 mg capsules OD for 3 months
45968307|NCT00240513|Drug|Minocycline plus tretinoin|100mg OD Minocycline for 12 weeks plus OD Topical tretinoin 0.01% for 12 weeks Followed by topical tretinoin 0.01% OD for 12 weeks alone
45968308|NCT00214838|Drug|Atiprimod|
45968309|NCT00240552|Drug|fosamprenavir|
45668349|NCT05382013|Other|Artificial Liver Support System|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times. The volume of plasma adsorption in DPMAS is 5000~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.
45668350|NCT05382013|Other|Comprehensive internal medical treatment.|Patients will receive comprehensive internal medical treatment.
45825440|NCT01928940|Drug|dabrafenib|150 mg twice daily
45825441|NCT01928940|Drug|trametinib|2 mg once daily
45968310|NCT00240552|Drug|Telzir®|
45968311|NCT00214877|Drug|Methylene Blue|
45825442|NCT01928862|Drug|Prepopik® ½ Sachet x 2 (9-12 years)|
45825443|NCT01928862|Drug|Prepopik® 1 Sachet x 2 (9-12 years)|
45968312|NCT00214955|Drug|ORAVESCENT Fentanyl Citrate|
45968313|NCT00244179|Drug|interferon-gamma|
45968314|NCT00244179|Drug|infliximab|
45968315|NCT00244179|Drug|dmard|
45968316|NCT00214994|Drug|Gabitril|
45968317|NCT00240630|Drug|sumatriptan succinate/naproxen sodium|Combination Tablet of Treximet
45968318|NCT00240630|Drug|placebo|placebo to match
45968319|NCT00239772|Behavioral|Cognitive Processing Therapy|
45968320|NCT00239772|Behavioral|Prolonged Exposure Therapy|
45968321|NCT00244218|Drug|tetrahydrobiopterin (BH4)|Either placebo or tetrahydrobiopterin (BH4) , 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
46080694|NCT05898841|Drug|Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine.|Patients who are randomised to this treatment arm will continue with the HAART they were receiving prior to signing the informed consent. As in arms 1 and 2, a change in the form of HAART administration (from a combined to a separate form and vice versa) will be allowed as long as the HAART components are respected.
45968322|NCT04721028|Device|Human body component analyzer|The body composition analyzer is a kind of instrument that can measure the body composition health index. It is composed of professional tester, professional consulting management software, color printer A/B machine and so on.
45668351|NCT04678921|Drug|TJ210001|human anti-C5aR monoclonal antibody
45668352|NCT04673851|Device|Horyzons USA|Participants will be oriented to the site (online platform) and how to use it. The site includes curated therapeutic content surrounding issues such as generalized anxiety, social anxiety, social functioning, depression, and distress tolerance. The site also includes a social media function, in which participants and peer support specialists can post text, images, and videos. The site is monitored by graduate students and trained clinicians.
45668353|NCT05425303|Diagnostic Test|Exposure to risk for injury|Athletes will be examined in the preseason stage and will be monitored during the competitive season.
45668354|NCT05044273|Device|Synergy XD stent or Synergy Megatron™ Stent|Percutaneous coronary intervention with Synergy XD stent or Synergy Megatron™ Stent
45668355|NCT04847635|Device|Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan)|The subthreshold laser treatment will be performed using subthreshold laser Pascal Synthesis 577 on a customized macular area.
45825444|NCT01928862|Drug|Oral polyethylene glycol (PEG) based preparation (9-12 years)|
45825445|NCT01928862|Drug|Prepopik® 1 Sachet x 2 (13-16 years)|
45825446|NCT01928862|Drug|Oral polyethylene glycol (PEG) based preparation (13-16 years)|
45825447|NCT01954056|Drug|Hydrocortisone|"• 7 day course of hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line).~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose"
45825448|NCT01954056|Drug|Placebo|"7 days of intravenous or intramuscular placebo (normal saline in equal volume)~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose"
45825449|NCT01953354|Biological|Trichuris suis ova (TSO)|Six doses of TSO orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
45968323|NCT00215111|Behavioral|Low carbohydrate, reduced glycemic load, and a control diet|
45968324|NCT00244257|Biological|GMA161|0.1 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
45968325|NCT00244257|Biological|GMA161|0.3 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
45968326|NCT00244257|Biological|GMA161|0.6 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
45968327|NCT00244257|Biological|GMA161|1.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
45825450|NCT01953354|Biological|Placebo|Six doses of TSO placebo orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
45825451|NCT01975272|Drug|Ferinject|
45825452|NCT01975272|Drug|Ferrous fumarate|
45825453|NCT01975272|Drug|Placebo for ferrous fumarate|
45968328|NCT00244257|Biological|GMA161|3.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
45968329|NCT00215189|Behavioral|In SHAPE (Pilot Health Promotion Intervention)|
45825454|NCT01975272|Drug|Placebo for ferinject|
45968330|NCT00244296|Drug|Duloxetine hydrochloride|
45968331|NCT00244296|Drug|placebo|
46080695|NCT05898126|Procedure|Renin-guided hemodynamic management|If normalization of renin levels is achieved (values within the normal laboratory range), we will continue with usual care according to local protocols.
45968332|NCT00215228|Drug|duloxetine vs. escitalopram|
45968333|NCT00215267|Drug|praziquantel|
46080696|NCT05898126|Procedure|Usual care|Standard of care
45668356|NCT04847635|Device|Pascal Synthesis 577 sham (Topcon Corporation, Tokyo, Japan)|The laser treatment will be performed without any power (only the light beam) using subthreshold laser Pascal Synthesis 577 on a customized macular area.
45668357|NCT04845217|Drug|Peppermint oil|Enteric coated peppermint oil taken by mouth three times daily for 8 weeks.
45825455|NCT04643886|Drug|GEM103|Biological
45968334|NCT00240669|Device|Resorbable device PLLA/PGA|
45968335|NCT00240669|Device|Titanium device|
46080697|NCT05898100|Device|Virtual Reality Distraction|The experimental group will receive the VR video game Dream designed specifically for this study. Pharmaceutical treatment during the procedure such as the use of injected local anesthesia will be used if the procedure requires. Children will be able to play for the entire duration of the dental procedure. Dream aims at reducing anxiety in children aged 6 to 17 years old by mean of immersive distraction. The VR headset offers children with the ability of viewing the game they are playing in real time while simultaneously obstructing the partial view they would normally have of the procedure. In the event of non-cooperation during the appointment, any re-take or re-scheduling appointments will be compiled by the resident dentist. One parent will be allowed in the room during the dental procedure and their presence will be recorded.
45668358|NCT04845217|Drug|Coconut Oil|Enteric coated coconut oil taken by mouth three times daily for 8 weeks
45668359|NCT04419883|Device|McMurray Enhanced Airway|Provider Satisfaction of a New, Flexible Extended-Length Pharyngeal Airway to Relieve Upper Airway Obstructive During Deep Sedation: A Pilot Study
45825456|NCT01951638|Drug|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
45825457|NCT01951638|Drug|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
45825458|NCT01951638|Drug|Placebo|
45825459|NCT01928472|Biological|H7N9c low dose with adjuvant|
45825460|NCT01928472|Biological|H7N9c medium dose with adjuvant|
45825461|NCT01928472|Biological|H7N9c high dose with adjuvant|
45825462|NCT01928472|Biological|H7N9c high dose without adjuvant|
45825463|NCT03563183|Other|Encoding of data collected in Zoster 006 and Zoster 022 studies|Not applicable (disease epidemiology study)
45825464|NCT03565679|Device|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because an arterial sample of blood is not required to make the measurement, the pulse oximeter can provide non-invasive real time information.
45825465|NCT03565679|Device|CO-OXIMETRY SENSORS|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
45825466|NCT03965039|Device|Dipotassium oxalate toothpaste|Experimental dipotassium oxalate (3%) toothpaste
45825467|NCT03965039|Drug|Stannous fluoride toothpaste|Marketed stannous fluoride (0.454%) toothpaste
45825468|NCT03965039|Drug|Potassium nitrate toothpaste|Marketed potassium nitrate (5%) toothpaste
45825469|NCT03965039|Drug|Sodium monofluorophosphate toothpaste|Marketed sodium monofluorophosphate (0.76%) toothpaste
45825470|NCT03961295|Drug|Vedolizumab SC|Vedolizumab SC liquid.
45968336|NCT00215306|Device|CHARITÉ Artificial Disc|
45968337|NCT00215306|Device|Anterior Interbody Fusion with BAK Cage|
45968338|NCT00240708|Drug|risperidone|
45968339|NCT00215345|Drug|Taxotere|
45968340|NCT00215345|Drug|Celecoxib|
45968341|NCT00240747|Drug|Synercid|
45968342|NCT00215384|Drug|Formoterol Fumarate|
45968343|NCT04709523|Procedure|bovine-derived xenograft with i-PRF|Bovine-derived xenograft was mixed with i-PRF and was placed in the augmentation site.
45968344|NCT04709523|Procedure|bovine-derived xenograft alone|Bovine-derived xenograft was placed in the augmentation site.
45968345|NCT00215423|Drug|Formoterol Fumarate|
45968346|NCT04668352|Drug|Dactolisib|TORC1 inhibitor
45968347|NCT04668352|Other|Placebo|Placebo
45968348|NCT00215462|Drug|Vinorelbine|
45968349|NCT04668196|Device|High-flow nasal cannula treatment|Standard operating procedures represented by hihg-flow nasal cannula oxygen therapy
45968350|NCT04668196|Device|Continuous positive airway pressure (CPAP) treatment|Standard operating procedures represented by continuous positive airway pressure (CPAP) therapy
45968351|NCT04668196|Device|Noninvasive ventilation treatment|Standard operating procedures represented by noninvasive ventilation treatment
45668360|NCT05359393|Combination Product|a combination therapy including tislelizumab|"Patients will receive tislelizumab in combination with neoadjuvant radiotherapy and chemotherapy, and will be evaluated 2-3 weeks after completion of the treatment. Those patients who achieve complete clinical regression of the lesion can choose observation, but for those without CCR, surgical resection (TME of the primary lesion, surgical resection of metastases or other destructive local treatment) will be applied. Patients will continue to receive tislelizumab for one year after surgery or during observation.~For liver/pulmonary metastasis, the treatment plan is to implement large fraction radiotherapy for 4-8 times. For primary rectum lesion, short-course radiotherapy regimen through intensity-modulated radiotherapy will be applied with dose of 25Gy/5Fx.~Immunotherapy contains anti-PD-1 monoclonal antibody, Tislelizumab(200mg, d1, q3w x6, i.v). Chemotherapy adopts CAPEOX plan, including Capecitabine(1000mg/m2 bid, d1-14, p.o) and oxaliplatin(130mg/m2, d1, i.v)."
45668361|NCT04833439|Other|Fasting Mimicking Diet|Low-caloric, low-protein, plant-based diet regiment for 3 days
45668362|NCT04178707|Device|OnZurf Probe, Senzime AB, Uppsala, Sweden|Probe is inserted into the fistula and measurements are made of the inner environment.
45668363|NCT04195477|Behavioral|vDPP|The to be developed vDPP curriculum as part of the early stages of this study will be piloted.
45668364|NCT04650919|Procedure|Total laryngectomy and reconstruction by stented aortic allograft (using human tissue and device).|"The procedure consists of 2 operating times:~Surgery S1 (1st surgical procedure): total laryngectomy and placement of the stented aortic graft (human tissue + device: NOVATECH GSS TM (trademark) TD), under tracheotomy cover.~Surgery S2 (2nd surgical procedure) (between S1 +24 weeks and S1 +36 weeks) : opening of the proximal part of the graft by endoscopic way with maintenance of the tracheotomy orifice to ensure patient safety."
45668365|NCT01600885|Drug|Guanfacine|Subjects will be given 3mg of guanfacine before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
45825471|NCT00377897|Procedure|cell therapy|Injection of Bone-Marrow mononuclear cells in the muscles of the calf.
45825472|NCT03567005|Device|Nelfilcon A digital contact lenses|Silicone hydrogel digital contact lenses
45825473|NCT03567005|Device|Nelfilcon A contact lenses|Silicone hydrogel spherical contact lenses
45825474|NCT05313971|Other|Self knowledge course|The online self-knowledge and communication course, created for the purpose of this clinical trial and taught by professionals with certified training in the area by the Shalom Enneagram Institute (https://iesh.pt/), consisted of providing volunteers with mechanisms for self-knowledge using the enneagram. Three modules were carried out between October and December 2020, spaced in time to allow participants to consolidate knowledge: there was 1 month between the first and second module, and between the second and third, 3 weeks.
45825475|NCT03569033|Drug|Gefapixant|Gefapixant 45 mg will be administered orally.
45825476|NCT03569033|Drug|Placebo|Placebo tablet matching gefapixant will be administered orally.
45825477|NCT03955133|Other|Adverse Drug Reaction ADRe Profile for Polypharmacy|PADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the British National Formulary (BNF) and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts. A full description is published (references below).
45825478|NCT03991715|Behavioral|Activity Tracker|Individually tailored daily and weekly physical activity goals established for all participants. Participants sent weekly reports for 6 weeks after cardiac rehabilitation discharge.
45825479|NCT04002791|Device|VasoBand|Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression
45825480|NCT05314049|Procedure|Mckenzie Extension Protocol|Mckenzie Extension Exercise Protocol will be performed by participants in prone position
45825481|NCT05314049|Procedure|Lumbar SNAGs|Lumbar SNAGs will be performed in lumbar flexion and extension in standing Position
45825482|NCT05314049|Device|inferential therapy|4 pole inferential therapy in combination with superficial heating for 20 minutes
45825483|NCT05314049|Device|Heat Therapy|superficial heating for 20 minutes
45825484|NCT03935399|Drug|Oxytocin|10 IU oxytocin (Pitocin) for intramuscular injection
45825485|NCT03935399|Drug|Saline|1.5 ml preservative free saline for intramuscular injection
45825486|NCT03571607|Biological|13-valent pneumococcal conjugate vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
45825487|NCT03993119|Drug|Non-vitamin K antagonist oral anticoagulant|Non-vitamin K antagonist oral anticoagulant
45825488|NCT03574181|Other|Smartwatch to measure Blood Alcohol Level (BAL)|Subjects will wear a wristwatch with a sensor that measures blood alcohol level during a 1-hour period of consuming alcohol followed by a 5 hour observation period.
45825489|NCT03988049|Device|1,550 fracionated photothermolysis laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
45825490|NCT03988049|Device|755 picosecond laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
45825491|NCT03930641|Drug|RTH258|6 mg in prefilled syringe
45825492|NCT03910439|Biological|Avelumab|Avelumab 800 mg intravenous (IV) over 60 minutes (+/- 20 minutes) on days 1 and 15 of each 28-day cycle
45825493|NCT03910439|Radiation|External beam radiotherapy|5 gray (Gy) per fraction will be delivered on 5 consecutive treatment days for a total dose 25 Gy
45968352|NCT04668079|Other|Modified cross body stretch|"Athlete was in side lying positioned. trunk was moved posteriorly 200 to 300 and shoulder is raised to 900 and semi flex both knees. Athlete was ask to passively pull the humerus across the body into horizontal adduction with the opposite hand.~5 reps once daily 3 sets for 4 weeks was given"
45968353|NCT04668079|Other|Modified sleeper stretch|"Athlete was in side lying positioned on the involved side, trunk was rolled posteriorly 200 to 300 and shoulder is raised to 900 and elbow is flexed to 900 and semiflex both knees. athlete was ask to perform internal rotation passively by using the opposite arm.~5 reps once daily 3 sets for 4 weeks was given"
45668366|NCT01600885|Drug|Placebo|Subjects will be given a placebo before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
45968354|NCT00215501|Drug|Capecitabine|Orally twice a day for 14 days (dosage will vary)
45968355|NCT00215501|Drug|5-Fluorouracil (5-FU)|Continuous infusion 24 hours a day for 14 days (Days 1-14) Dosage will vary
45968356|NCT00215501|Drug|Irinotecan|Intravenously weekly for 2 weeks (given after cisplatin) followed by a one-week rest period
45968357|NCT00215501|Drug|Cisplatin|Intravenously weekly for 2 weeks followed by a one week rest period
45968358|NCT04667728|Device|Professional continuous glucose monitoring (CGM) sensor (iPro™2)|Professional continuous glucose monitoring (CGM) sensor (iPro™2) following treatment adjustments and personalized diet plan
46080698|NCT05898100|Behavioral|Dental Clinic's Standard Treatment|The control group will only receive a care-as-usual approach. This includes a television mounted on the wall showing cartoons and the use of pharmaceutical treatment during the procedure such as the use of injected local anesthesia. In the event of non-cooperation during the appointment, any re-take or re-scheduling appointments will be compiled by the resident dentist. One parent will be permitted to be present in the room during the procedure as part of the clinic's usual protocol and their presence will be recorded. Children allocated to the control group will be offered the possibility to try the VR game after the study period if they choose so.
45668367|NCT04625257|Other|Saliva based assay: crude RNA extraction|Crude RNA extraction to inactivate the virus and stabilize the RNA for transport at room temperature. Validation of the crude RNA extraction from saliva in combination with NGS diagnostics and LAMP assays and point of care test (POCT) for rapid detection of viral antigens on patients' samples.
45668368|NCT04625257|Other|Validation of the NGS method|Compare the results obtained with the next-generation sequencing (NGS) method to the nasopharyngeal swabs analysed in a FAMH certified lab.
45668369|NCT04625257|Other|Validation of the LAMP assays|The RNA will be analyzed onsite using the loop mediated amplification (LAMP) assay.
45668370|NCT04625257|Other|Validation of the POCT Antigen and Antibody tests|Rapid point of care tests (POCT) detecting viral protein antigens (Ag) and antibodies (Ab) on patients' samples. POCT are often employed in low income countries, but for COVID-19 they are not yet characterized. Their performance is to be characterized that they can be used as a safe guard if the lab diagnostics fail.
45668371|NCT05011513|Drug|PF-07321332|PF-07321332 (tablet)
45668372|NCT05011513|Drug|Ritonavir|Ritonavir (capsule)
45668373|NCT05011513|Drug|Placebo|Placebo (tablet)
45668374|NCT05011513|Drug|Placebo|Placebo (capsule)
45668375|NCT05369455|Procedure|erector spinae plane block|determine the efficacy and safety of ultra-sound guided erector spine plane block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
45825494|NCT03907241|Drug|Octanorm 16.5%|Human normal immunoglobulin
45825495|NCT03137225|Device|Neurally Adjusted Ventilatory Assist|Neurally Adjusted Ventilatory Assist delivered via RAM cannula .
45825496|NCT03137225|Device|Nasal Intermittent Positive Pressure Ventilation|Nasal Intermittent Positive Pressure Ventilation delivered via RAM cannula
45825497|NCT03927209|Drug|BI 1467335|tablet
45825498|NCT03895307|Other|kinesio tape|two 15 cm I type kinesio tape applied longitudinally
45825499|NCT03895307|Other|local anesthetic|local anesthetic: 18-20 cc %0.5 lidocaine subcutaneous injection
45825500|NCT03895307|Other|local serum physiologic|serum physiologic : 18-20 cc % 0.09 NaCl subcutaneous injection
46080699|NCT05897229|Other|Analysis of costs with patient care during hospitalization|Analysis of direct costs with supplies, medications, diets, laboratory tests and imaging exams, and invasive procedures such as mechanical ventilation, dialysis, and the use of vasoactive drugs.-analysis of costs referring to working hours of physicians, nurses and physical therapists in each unit normalized for the same number of beds.- cost minimization and consequential cost analysis.
45825501|NCT01511081|Radiation|SBRT (stereotactic body radiotherapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.
45825502|NCT01511081|Radiation|SBPT (stereotactic body proton therapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
45968359|NCT04667650|Other|Use of nomogram for predictions of Ocular Mysathenia Gravis generalization|The outcome measure was time to Myasthenia gravis generalization. The explanatory variables were age at onset, sex, first-year anti-acetylcholinereceptor antibody positivity, repetiting nerve stimulation showing electromyogram decrement and steroid use. Kaplan-Meier survival estimations, descriptive and multivariate Cox model analyses were computed. A nomogram combining explanatory vraiables was used to establish a score to predict the probability of OMG generalization.
45968360|NCT04667845|Device|Home Ovulation Test|Digital read home ovulation test
45968361|NCT04668040|Other|Muscle energy technique|Muscle energy technique for illiopsoas, rectus femoris, erector spinae & hamstrings muscles duration of contraction was 10 sec, rest interval was 5 sec, stretch duration was 30 sec, number of repetition of stretch was 5, number of set was 1, frequency per week was 3
45825503|NCT03115853|Drug|Aliskiren 150 mg|Aliskiren 150 mg daily for 2 weeks
45825504|NCT03115853|Drug|Placebo|Placebo tablet for Aliskerin
45968362|NCT04668040|Other|Stretching|Stretching exercises for illiopsoas, rectus femoris, erector spinae & hamstrings muscles duration of stretch was 15 sec, rest interval was 5 sec, number of repetition was 5, number of set was 1, frequency per week was 3
45968363|NCT00240786|Drug|acetaminophen extended release|
45825505|NCT03115853|Drug|HCTZ|HCTZ 25mg every day for 18 weeks
45825506|NCT03115853|Drug|Aliskiren 300 mg|Aliskiren 300 mg for 4 weeks
45968364|NCT00215579|Drug|Depot Risperidone Microsphere (Consta)|
45968365|NCT04667611|Behavioral|Psychosocial interventions|Cognitive behavioural therapy (CBT) based individual and group intervention
45968366|NCT04667806|Behavioral|Questionnaires|Use questionnaires ( SF36 questionnaire (generic score) and St Georges's questionnaire (specific score))
45968367|NCT00556621|Drug|cisplatin|
45968368|NCT00556621|Drug|gemcitabine hydrochloride|
45668376|NCT05369455|Procedure|ultrasound guided caudal block|determine the efficacy and safety of ultra-sound guided caudal block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
45668377|NCT01732510|Drug|MK-8226|MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.
45825507|NCT01498991|Device|AMES Treatment|The AMES device rotates the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the leg. Each participant will receive treatment of both lower extremities. Treatment of the 2 legs will be scheduled to run in the same session. The subject's task is to assist the motion of the device. The AMES treatment device couples assisted movement and tendon vibration (enhanced sensation) in 30 treatments which will each run approximately 40 minutes (20 minutes on the right leg and 20 minutes on the left leg).
45968369|NCT00556621|Procedure|biopsy|
45968370|NCT00556621|Procedure|cystoscopy|
45968371|NCT00556621|Procedure|therapeutic conventional surgery|
45968372|NCT00556621|Radiation|radiation therapy|
45968373|NCT00244452|Drug|Cetrorelix|
45968374|NCT02962583|Other|Weight loss|
45968375|NCT02962583|Drug|Probiotic Formula|
45968376|NCT02962583|Drug|Placebos|
45968377|NCT00556660|Drug|[123I] AV-151|To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects
45968378|NCT00556699|Drug|rituximab|Escalating intravenous repeating dose
45968379|NCT00556699|Drug|SGN-40|Escalating intravenous repeating dose
45968380|NCT00556738|Procedure|Nasal Continuous Positive Airway Pressure ventilation|Nasal Continuous Positive Airway Pressure ventilation
45968381|NCT00556738|Procedure|Intrapulmonary Percussive Ventilation|Intrapulmonary Percussive Ventilation
45968382|NCT00411866|Drug|SB773812|SB-773812 20 mg will be available as white round film coated tablets.
45668378|NCT01732510|Drug|Placebo|Placebo administered IV every 2 weeks for a period of 12 weeks.
45668379|NCT05369377|Drug|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
45968383|NCT00411866|Drug|Ketoconazole|Ketoconazole will be available as 200mg tablets.
45668380|NCT05369377|Drug|Eltrombopag|eltrombopag 50 mg qd for up to 6 weeks. The eltrombopag dose could be increased from 50 mg to 75 mg after 3 weeks in patients whose platelet counts were less than 50 000 per μL. Treatment was discontinued in patients who attained a platelet count greater than 200 000 per μL.
45825508|NCT03895853|Other|Best Practice|Receive standard of care
45825509|NCT03895853|Dietary Supplement|early metabolic resuscitation|Given Intravenous
45825510|NCT03901313|Drug|Treatment A - 400 mg Fasting|Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning under fasting conditions
45968384|NCT00244491|Behavioral|Care Transitions Intervention|
45968385|NCT04667182|Other|Meal-Tagging App and Web-based Portal:|Meal tagging app to capture frequently eaten meals and test meals for 18 weeks.
45968386|NCT04667182|Device|Fitness Tracker|Fitness tracker will be worn around the clock for 18 weeks.
45968387|NCT04667299|Drug|Rabeprazole|20mg bid
45968388|NCT04667299|Drug|Bismuth potassium citrate|0.6g bid
45968389|NCT04667299|Drug|Metronidazole|0.4g qid
45968390|NCT04667299|Drug|Amoxicillin|1g bid
45968391|NCT04720794|Device|Lucira COVID-19 All-In-One test kit|"The Lucira COVID-19 All-In-One Test Kit is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 in nasal swab samples. This test is a single-use test kit that determines whether there is active shedding of the virus which causes COVID-19. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA.~Positive results are indicative of active infection with SARS-CoV-2. Persons who test positive should self-isolate and seek care from their healthcare provider.~Negative results do not preclude SARS-CoV-2 infection. Persons who continue to experience COVID-like symptoms should seek follow up care from their healthcare provider"
45968392|NCT04667143|Drug|Retagliptin, Henagliflozein, metformin XR|Retagliptin-DPP4 inhibitor Henagliflozein-SGLT-2 inhibitor Metformin XR
45968393|NCT04666870|Other|myopia or not myopia|visual acuity, IOL master biometry, the anterior segment with slit lamp, dilated fundus examination and refraction.
45968394|NCT04666753|Dietary Supplement|ImmunoFormulation|The ImmunoFormulation consist of: transfer factors (oligo- and polypeptides from porcine spleen, ultrafiltered at <10 kDa - Imuno TF®) 100 mg, 800 mg anti-inflammatory natural blend (Uncaria tomentosa, Endopleura uchi and Haematoccocus pluvialis - MiodesinTM), 60 mg zinc orotate, 48 mg selenium yeast (equivalent to 96 μg of Se), 20,000 IU cholecalciferol, 300 mg ascorbic acid, 480 mg ferulic acid, 90 mg resveratrol, 800 mg spirulina, 560 mg N-acetylcysteine, 610 mg glucosamine sulphate potassium chloride, and 400 mg maltodextrin-stabilized orthosilicic acid (equivalent to 6 mg of Si - SiliciuMax®).
45968395|NCT00240825|Drug|Ibuprofen|
45968396|NCT00240825|Drug|Placebo|
45668381|NCT04574518|Behavioral|TeaM OUT Intervention|The TeaM OUT Intervention has 2 elements: 1) a letter that a) describes the nodule and the importance of cessation related to the pulmonary nodule (i.e. teachable moment) and b) notification that a Proactive IVR Quit line will initiate contact and 2) call(s) from the Proactive IVR Quit Line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
45968397|NCT00240825|Drug|Acetaminophen|
45455718|NCT05788549|Behavioral|Progressive Muscle Relaxation|The Individual Identification Form, Partial Mayo Score, State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, and IBD-QOL were filled out in person during the first meeting. The first application was done face to face with the researcher. Individuals were asked to perform subsequent applications at home.Educational booklet describing the progressive relaxation exercises with pictures was given to individuals, and a video prepared by the researcher was uploaded to their mobile phones. Individuals were asked to practice progressive relaxation exercises every day, at least once a day, in a quiet and peaceful environment for 30-minute sessions. The researcher sent reminder SMS messages to individuals twice a week for eight weeks to encourage regular practice of the progressive relaxation exercises. Four and eight weeks after the first meeting, forms were transferred to an online environment and sent to individuals via WhatsApp Messenger as a link to be completed
45968398|NCT04666597|Procedure|Modified CariesCare International management|"Management plan will be determined according to 4D cycle of CCI modified system adapted for the pandemic period (non-aerosol generating procedures- Non-AGP).~The baseline data will include:~D-DETERMINE risk assessing the protective and risk factors (social/medical/behavioural and clinical), using remote tools. Additionally, the description of tooth brushing behaviours and consumption of free sugars is included.~D-DETECT & ASSESS: Caries staging and activity: ICDAS-merged visual criteria Caries OUT (without using compressed air, and avoiding radiographs). Clinical risk factors are assessed as well.~D-DECIDE a personalized care plan: individually designed for caries management home and clinical approaches.~D-DO: Appropriate Tooth-preserving & Patient-level caries: Management plan at the Patient and at the Lesion level and the implementation of the Change Behaviour Tool (CBT) designed for this protocol.~The follow-up data will include a T1, T2 and T3 assessment."
45968399|NCT04666675|Drug|Upadacitinib|Oral; Tablet
45968400|NCT04666675|Drug|Placebo for Upadacitinib|Oral; Tablet
45968401|NCT00244530|Drug|Nifedipine|
45668382|NCT04574518|Behavioral|Enhanced Usual Care|The Enhanced Usual Care arm also has two elements: 1) a letter that a) describes the nodule without linking it to smoking cessation (i.e. no teachable moment) with b) wording to contact an Optional IVR Quit line if desired and 2) the Optional IVR Quit line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
45825511|NCT03901313|Drug|Treatment B - 400 mg Fed|Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning within 30 minutes (min) after a low-fat standard breakfast meal
45825512|NCT03901313|Drug|Treatment C - 200 mg Fed|Single oral 200 mg (1 × 200 mg capsule) dose of pexidartinib in the morning within 30 min after a low-fat standard breakfast meal
45968402|NCT04666480|Device|Transcatheter mitral valve repair|Transvenous approach with a transeptal puncture to place the study device
45968403|NCT00411905|Drug|Bortezomib|
45968404|NCT04666363|Other|Lavender oil|the essence was diluted 1:10 with sweet almond oil. A cotton ball soaked in 3 drops of diluted lavender essence was kept at a 10 cm distance from the patients' nose and they were asked to breathe slowly for 5 min.
45968405|NCT00240864|Drug|placebo|
45968406|NCT00240864|Drug|acetaminophen|
45968407|NCT00240864|Drug|ibuprofen|
45968408|NCT00556777|Procedure|axillary lymph node dissection|
45968409|NCT00556777|Procedure|conventional surgery|
45968410|NCT00556777|Procedure|sentinel lymph node biopsy|
45968411|NCT00556777|Radiation|intraoperative radiation therapy|
45968412|NCT00556816|Behavioral|on demand clinic|Outpatient on demand clinic
45968413|NCT00556816|Behavioral|Control|conventional outpatient clinic
45968414|NCT00556855|Other|E-DO|topical lotion, once daily (evening), total duration: 4 weeks
45825513|NCT03900299|Procedure|oncoplastic breast surgery|oncoplastic breast surgery with level 1 or 2 according to the case using intra operative frozen section to assess the margin
45825514|NCT03898349|Other|Annie text messaging system|Annie text messaging system for patient self-management of HCV treatment including medication, lab, and appointment reminders, and motivational messages.
45968415|NCT00556855|Other|Placebo|topical lotion, once daily (evening), total duration: 4 weeks
45968416|NCT00244569|Drug|13C-Methacetin|
45968417|NCT00244569|Device|Breath ID Machine|
45968418|NCT00557011|Drug|NRP104|30 mg, 50 mg or 70 mg capsules taken orally once daily in the morning
45968419|NCT00557011|Drug|Adderall XR|10 mg capsules taken once daily in the morning at dosages of either 1x10mg, 2x10mg or 3x10mg
45968420|NCT00557011|Drug|Placebo|Placebo capsule taken once daily in the morning
45968421|NCT00557050|Other|Training|10-week eccentric hamstring muscle training
45968422|NCT00557089|Drug|rhDNAse|2.5 mg rhDNase will be dispensed in 2.5 ml vials and administered once a day for 28 days. Treatment will be administered by inhalation.
45968423|NCT00557089|Other|Placebo|2.5 mg of the placebo will be dispensed in 2.5 ml vials and administered once a day over 28 days. Treatment will be administered by inhalation.
45968424|NCT04666324|Drug|Simethicone Solution|Oral daily treatment for four weeks
45968425|NCT04666324|Dietary Supplement|Multilac Baby|Oral daily treatment for four weeks
45968426|NCT04720833|Dietary Supplement|dried plum|Dried plum
45968427|NCT04720833|Dietary Supplement|Calcium and vitamin D|Calcium and vitamin D supplement
45968428|NCT04666519|Diagnostic Test|Zonulin Biomarker|During revision hip and knee surgery, discarded fluid/blood will be tested for the presence of zonulin biomarkers
45968429|NCT00215618|Device|Uterine Balloon Therapy|UBT with post procedure curettage
45968430|NCT00215618|Device|Uterine Balloon Therapy|UBT without post procedure curettage
45968431|NCT04666285|Other|Experience of pandemic|Experience of the pandemic will be studied through online questionnaire responses
45968432|NCT00215696|Genetic|BioBypass®|
45968433|NCT00244608|Drug|Budesonide/Formoterol Turbuhaler|
45968434|NCT00244608|Drug|Budesonide Turbuhaler (Pulmicort)|
45968435|NCT00244608|Drug|Terbutaline Turbuhaler|
45668383|NCT04832269|Other|Exposure to methylprednisolone during pregnancy|Exposure to methylprednisolone during pregnancy in the context of an MS relapse therapy
45968436|NCT04666168|Biological|Auto CAR-T|Biological: Auto CAR-T
45968437|NCT04666168|Drug|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
45968438|NCT04666168|Procedure|Leukapheresis|Leukapheresis
45968439|NCT04666090|Drug|Carillizumab|administration regimen: Carillizumab 200mg, IV, D1; Albumin paclitaxel 150mg/m2, D1; Nedaplatin 50 mg/m2, D1; Apatinib 250mg Po D2-4. Preoperative neoadjuvant therapy for 2-3 cycles, one cycle every 14 days.
45968440|NCT04666090|Procedure|Esophagectomy|Laparoscopy combined with thoracoscope radical resection of esophageal carcinoma
45968441|NCT04666090|Other|Samples|Blood, Tumour and Saliva will be Collected from participant. Fate of sample is Destruction after use
45968442|NCT00215735|Device|debridement, dressing, and APC|ebridement, dressing, and APC
45968443|NCT04666207|Diagnostic Test|PCR|RT-PCR for SARS-CoV-2
45668384|NCT05353153|Other|hypnosis|Hypnosis-based intervention with two sessions of hypnosis (focusing on the treatment of anxiety)
45668385|NCT05353153|Other|standart care|no intervention no hypnosis
45668386|NCT04608331|Drug|Dexmedetomidine|Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml) and dexmedetomidine (1.25 microgram/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
45668387|NCT04608331|Drug|Placebo|Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
45825515|NCT03898349|Other|Annie text messaging system with Usual implementation|"Three comparison sites received usual implementation of the automated text messaging system Annie only, which involves an orientation/training meeting and the option of attending twice-monthly Annie clinical adoption calls"
45668388|NCT04589689|Behavioral|Insul-In This Together|Session 1: Introduction to Parental Monitoring Session 2: Advanced Parental Monitoring Session 3: Introduction to Parental Involvement Session 4: Advanced Parental Involvement Session 5: Introduction to Parent-Teen Conflict Management Session 6: Advanced Parent-Teen Conflict Management
45668389|NCT04065295|Drug|BI 1356225|Oral Dose
45668390|NCT04065295|Drug|Placebo|Oral dose
45825516|NCT03898349|Other|Annie text messaging system with Augmented implementation|"Four facilities received the automated text messaging system Annie and our augmented implementation strategy. These facilities had regular facilitation calls, a site visit to assist with implementation, and were given the toolkit, in addition to receiving usual implementation assistance"
45825517|NCT04713917|Device|Hyaluronique Acid Gel|Vaginal gel based on HA with liposomal structure applicated 2 times a week
45825518|NCT04713917|Device|Laser CO2|The laser energy delivered along the vaginal wall heats the tissue without damaging it.
45825519|NCT04713917|Device|Hyaluronique Acid Injection|HA injection performed under the mucosae (2-3mm in depth) following one injection point every 5mm on the 3 first cm of the vagina and on the posterior part of the introitus.
45968444|NCT00240903|Biological|Influenza A/Vietnam/1203/2004 (H5N1; sanofi pasteur)|
45968445|NCT04665661|Behavioral|High-intensity aerobic training|Women will perform treadmill-based aerobic exercise for three days a week, at 70%-85% of MHR for 30 minutes and perceived exertion of 14-16, based on the Borg RPE scale. This range39 is considered to represent HIAT. Aerobic training will be preceded by warm-up exercises for 10 minutes and followed by cool-down exercises for 10 minutes, at a perceived exertion of 11.0 (Borg RPE).
45968446|NCT04665661|Behavioral|Wait-list control|Women in the wait-list control group will be instructed to continue with their usual activities and manage their pain as normal (i.e., with analgesics).
45968447|NCT00244647|Drug|RESTEN-MP|
45968448|NCT00215774|Drug|Flecainide|Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.
45968449|NCT04665505|Behavioral|Educational Workshop|The intervention consists of providing educational content for all ICU care providers concerning building staff knowledge surrounding methods to facilitate cost-effective and evidence-based decision-making about patient care (including tests, treatments, and procedures). The first intervention is an educational workshop to increase staffs' awareness of the current Choosing Wisely Canada Critical Care strategies and recommendations to facilitate cost-effective and evidence-based decision-making about patient care (including tests, treatments, and procedures).
45968450|NCT04665505|Behavioral|Optimizing Staff Scheduling|This initiative will focus solely on the nurse subgroup and concerns schedule optimization to ensure the presence of the appropriate number of nurses per shift, thereby reducing stress, burnout and limiting the need for overtime.
45668391|NCT05348941|Dietary Supplement|TECADRIOL|Food supplement containing an association of D-chiro-inositol and alpha-lactalbumin
45668392|NCT04842097|Behavioral|Mindfulness-based stress reduction|An online mindfulness-based stress reduction intervention will be administered in a group format of maximum 15 participants, once a week for 120 minutes for 8 weeks by an experienced therapist trained in MBSR. Sessions will include sitting and lying meditation, hatha yoga and a body scan where attention is sequentially focused on different parts of the body. Individual autonomous practice between 30-45 minutes, 6 times / week will also be recommended. To support individual autonomous practice, a daily diary and two guided videos (around 35 minutes/each) were created.
45668393|NCT01637077|Drug|pregabalin|Given PO
45825520|NCT03894449|Combination Product|Prebiotic + Iron Forificant|A combination dosage of prebiotic (Inulin or GOS) and Iron Fortificant (FeSO4 or NaFeEDTA) will be given to the study subjects.
45825521|NCT03888755|Drug|Icatibant|Participants will receive icatibant 30 mg SC injection in the abdominal area.
45968451|NCT04665778|Other|hospital bedroom booking|Patient in high risk of hospitalization group benefits a dedicated process to find and book a bedroom
45968452|NCT00240942|Drug|Letrozole|
45825522|NCT00378755|Drug|velcade|
45825523|NCT00378833|Drug|niacin (+) laropiprant|Duration of Treatment: 18 Weeks
45458575|NCT05091736|Diagnostic Test|blood glucose measurement, blood glucose monitor for personal use|measurement of the blood glucose concentration using the blood glucose monitor for personal use (BG-709b)
45668394|NCT01637077|Drug|placebo|Given PO
45825524|NCT00378833|Drug|niacin|Duration of Treatment: 18 Weeks
45825525|NCT02995967|Procedure|Hydrodistention|The hydrodistention will then be performed with the bladder filled at a pressure of 80 cm H2O and noted to be full as evidenced by no further influx of water into the bladder. This volume will be held in the bladder for 5 minutes.
45458576|NCT05091736|Diagnostic Test|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device
45458577|NCT01360736|Behavioral|Safety Planning - Military (SAFE MIL)|The Safety Planning Intervention (SPI) which is delivered in the SAFE MIL condition aims to help individuals lower their imminent suicide risk by having them collaborate with the study clinician to generate a detailed, hierarchically-arranged action plan for managing suicidal thoughts and urges.
45668395|NCT01637077|Other|questionnaire administration|Ancillary studies
45668396|NCT02308163|Drug|Peficitinib|oral
45825526|NCT02995967|Drug|Botulinum toxin-A|Intradetrusor injection of 100 units of botulinum toxin a
45668397|NCT02308163|Drug|Placebo|oral
45668398|NCT02308163|Biological|Etanercept|subcutaneous injection
45668399|NCT02000115|Device|Portico transcatheter aortic valve|St. Jude Medical transcatheter Portico aortic valve
45668400|NCT02000115|Device|Commercially available transcatheter aortic valve|Commercially available transcatheter aortic valve
45668401|NCT05347537|Other|Mulligan mobilization|Mulligan Mobilization designed to reduce pain and improve the patient's range of motion. Mulligan's mobilization with movement at the frequency of 3 sets with 10 repetitions 3 times/ week without the clamshell exercise.
45825527|NCT03888365|Drug|Treprostinil|Treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
45825528|NCT03888365|Drug|Non-Treprostinil PAH Medications|Non-treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
45825529|NCT00377975|Drug|Ephedrine|
45825530|NCT00377975|Drug|Pioglitazone|
45825531|NCT00377975|Drug|Caffeine|
45825532|NCT03870893|Behavioral|hippotherapy|16weeks hippotherapy program
45825533|NCT02994251|Drug|gemcitabine|1000 mg/m^2 of gemcitabine on Day 1 and 8, Dosages may be modified or delayed due to toxicities
45825534|NCT02994251|Drug|Cisplatin|25 mg/m^2 on Day 1 and 8, Dosages may be modified or delayed due to toxicities
45825535|NCT02994251|Drug|Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C|If conventional transarterial chemoembolization (TACE) is warranted based on MRI assessment and the patient meets all the eligibility criteria for TACE therapy, then cTACE will be scheduled to take place during Week 3 of that cycle. Patients will always receive the first cTACE for study; follow-up cTACE will occur on demand.
46080700|NCT05896618|Device|TPA|1. Group I (TPA group).In which patients will receive Transpalatal arch appliance as a space maintainer. Before treatment, dental cast will be made.Lateral cephalometric radiograph and extra-oral and intra-oral photographs will be taken for each patient. After 6 month follow up period, new cast will be made. New lateral cephalometric radiographs and new extra-oral and intra-oral photographs will be taken for each patient.
46080701|NCT05896618|Device|Nance appliance|2. Group II (Nance group).In which patients will receive Nance holding arch appliance as a space maintainer. Before treatment, dental cast will be made.Lateral cephalometric radiograph and extra-oral and intra-oral photographs will be taken for each patient. After 6 month follow up period, new cast will be made. New lateral cephalometric radiographs and new extra-oral and intra-oral photographs will be taken for each patient.
45668402|NCT05347537|Other|clamshell exercise|As a general exercise, the clamshell can help strengthen your medial glutes, bringing more power and stability to your hips. This group treated with mulligan's mobilization with movement and clamshell exercises.
45668403|NCT04819711|Behavioral|Thinking Healthy Programme|The Thinking Healthy Programme (THP) is an evidence-based intervention that is based on principles of cognitive behavioral therapy. It includes strategies that incorporate behavioral activation, active listening, collaboration with the family, guided discovery, and homework. The adapted THP consists of 5 integrated sessions. Session 1 introduces the programme and focuses on engagement of participants, introduction of THP, and breathing exercises. Session 2 focuses on psychoeducation and problem solving. Session 3 focuses on the mother's well-being and introduces activities such as physical exercises, good sleep practices and ensuring a balanced diet. Session 4 focuses on the mother's relationship with the unborn baby. Session 5 focuses on activating social support from family, friends and peers and provides closure of therapy.
45668404|NCT04556851|Drug|HSK7653 10 mg Q2W|HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
45668405|NCT04556851|Drug|HSK7653 25 mg Q2W|HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
45668406|NCT04556851|Drug|Placebo|Placebo 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
45668407|NCT04969081|Behavioral|referral to work focused program|referral to Incentive Therapy or to Other Therapeutic and Supported Employment Services
45668408|NCT04969081|Other|treatment as usual|usual treatment
45668409|NCT04039399|Procedure|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants will receive one session of the intervention (45 minutes total).
45668410|NCT04039399|Procedure|Sham Ischemic Conditioning|There will also be an IC Sham group which is identical to the IC intervention, except the cuff is only inflated to 10 mmHg, which is a high enough pressure to perceive cuff tightness but not high enough to have any physiological effects.
45668411|NCT04419727|Procedure|arterial reconstructive open surgery|Patients with peripheral artery disease (PAD) will undergo arterial reconstructive open surgery. Samples obtained from diseased arteries of lower limbs of patients undergoing arterial reconstructive open surgery will be collected and immediately preserved at -80°. Briefly, the arterial tissues will be excised, homogenized with a motor-driven homogenizer and total RNA will be isolated using Trizol reagent (Invitrogen, Milan Italy), according to the manufacturer's instructions. The expression of ER-alpha, ER-beta,and GPER will be quantified by real-time PCR using the Step One ™ sequence detection system (Applied Biosystems Inc. Milan, Italy), following the manufacturer's instruction
45668412|NCT04554745|Radiation|Ultrasound|ultrasound assessment of pregnant women
45668413|NCT04549363|Drug|Belantamab mafodotin|Belantamab mafodotin is a first-in-class immunoconjugate that targets B cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells.
45825536|NCT03887429|Drug|SXC-2023|SXC-2023 oral capsules
45825537|NCT03887429|Drug|Placebos|Matching Placebo oral capsules
45825538|NCT02978885|Radiation|SPECT-CT imaging|Injection of AxV-128 labeled with 99mTc followed by SPECT CT
45825539|NCT02978885|Drug|AxV-128/Tc|Injection of AxV-128 labeled with 99mTc
45825540|NCT02978885|Procedure|Whipple procedure|"A Whipple procedure - also known as a pancreaticoduodenectomy - is a complex operation to remove the head of the pancreas, the first part of the small intestine (duodenum), the gallbladder and the bile duct.~The Whipple procedure is used to treat tumors and other disorders of the pancreas, intestine and bile duct. It is the most often used surgery to treat pancreatic cancer that's confined to the head of the pancreas. After performing the Whipple procedure, your surgeon reconnects the remaining organs to allow you to digest food normally after surgery. Standard of care."
45825541|NCT02978885|Procedure|Major surgery|Additional surgical procedure(s) that is clinically indicated. Standard of care.
45825542|NCT02936999|Drug|Cholecalciferol|Cholecalciferol 100,000 IU followed by 4000 IU orally once daily for 30 days.
45825543|NCT01385033|Drug|[18F]MK-3328|IV dose of ~150 megabecquerel (MBq) [18F]MK-3328
45825544|NCT02826551|Drug|Marcaine|Pain control medication to theoretically reduce the amount of posterior knee pain that is common after ACL surgery by placing the injection into the posterior capsule of the knee during surgery. This is very easy and safe to accomplish as the surgeon will have direct visualization of the posterior capsule during the surgery.
45825545|NCT02826551|Other|Ice|
45825546|NCT02826551|Drug|Percocet|
46080702|NCT05896397|Procedure|Endovascular Aortic Treatments|Use of Cook's custom-made endovascular grafts to treat complex abdominal, thoracoabdominal aortic diseases, or aortic arch diseases such as aneurysms and dissections.
46080703|NCT05896384|Drug|BI 456906|BI 456906
46080704|NCT05896384|Drug|Microgynon®|Ethinylestradiol (EE) and Levonorgestrel (LNG)
46080705|NCT05896371|Drug|177Lu-PSMA-I&T - escalating renal absorbed dose|Personalized 177Lu-PSMA-I&T injected activity
46080706|NCT05896371|Drug|177Lu-PSMA-I&T - recommended phase 2 regime|Personalized 177Lu-PSMA-I&T injected activity
46080707|NCT05896046|Drug|SHR2554+ SHR1701|SHR2554: 350mg/day, PO, twice a day. SHR1701: recommended dose from phase I trial, IV, over 30 minutes.
45825547|NCT02826551|Device|Knee Brace and Crutches|
45458578|NCT01236859|Drug|Gabapentin|Neurontin®, Pfizer
45968453|NCT04665466|Device|Quantitative Flow Ratio derived PPG|"From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2."
45668414|NCT04038697|Procedure|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants assigned to the IC Only and IC + Treadmill Training groups will undergo twelve sessions of ischemic conditioning over a four-week period.
45968454|NCT00215891|Drug|PEG-Interferon a-2b + Ribavirin|
45968455|NCT04665544|Procedure|SLN side-specific detection rate using radioactive tracer with/without blue dye and ICG tracer.|"The primary objective of this study is to compare SLN detection rate using two types of intracervical tracers (radioactive tracer with or without blue dye vs. ICG).~The null hypothesis is that the detectionrate does not differ between the two techniques."
45968456|NCT02961816|Drug|Palifermin|Palifermin, per standard of care, on Days -13 to -11 and on Days 0, +1, and +2.
45968457|NCT02961816|Drug|Panobinostat|20 mg by mouth daily from Day -9 to -2.
45968458|NCT02961816|Drug|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein followed by prolonged infusion over 4.5 hours of 2,700 mg/m2 (total daily dose 2,775 mg/m2) on Days -8 and -3.
45968459|NCT02961816|Drug|Busulfan|"Busulfan test dose administered on Day -10. Test dose of 32 mg/m2 based on actual body weight administrated over 60 minutes. Busulfan pharmacokinetics performed with the test dose and the first dose on Day-8. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK."
45968460|NCT02961816|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
45968461|NCT02961816|Drug|Rituximab|375 mg/m2 by vein on Day -9 for patients with CD20+ tumors.
45968462|NCT02961816|Drug|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
46080708|NCT05896046|Drug|SHR-1701|Phase I: 30-150 mg/kg, IV over 30 minutes. Phase II: recommended dose from phase I trial, IV over 30 minutes.
46080709|NCT05895292|Device|CAD/CAM Milled Methacrylate Complete Removable Dentures based on bone-support concept.|The patients will receive complete removable dentures designed based on the bone-support concept and digitally manufactured using a milling machine.
45825548|NCT00378443|Drug|prednisone + Inhibace/Cozaar|
45825549|NCT00378443|Drug|Inhibace/Cozaar|
45825550|NCT01337609|Drug|Ganeden BC30|2 billion CFU per capsule; One pill daily for 60 days
45825551|NCT01337609|Other|Placebo (sugar pill)|1 pill daily for 60 days
45825552|NCT01337609|Other|Ganeden BC30, Placebo (sugar pill)|Ganeden BC30 (2 billion CFU per capsule), One capsule daily for 30 days Sugar Pill (placebo), One capsule daily for 30 days
45825553|NCT01340573|Drug|PegIntron Pen|Peginterferon alfa-2b, 1.5 microgram/kg each week, administered subcutaneously.
45825554|NCT01340573|Drug|Ribavirin|Dose is based on body weight. Each tablet of ribavirin is 200mg, and given by oral administration. Participants with body weight of <65 kg were administered 800 mg of ribavirin daily, body weight of 65 kg-85 kg received 1000 mg daily, and participants with a body weight of >85 kg received 1200 mg of ribavirin daily.
45825555|NCT01340885|Drug|Strattera|10-30 mg b.i.d. for 6 weeks
45825556|NCT01340885|Drug|Exelon|1.5-4.5 mg b.i.d. for 6 weeks
45825557|NCT01340885|Other|Placebo|2-6 pills for 6 weeks
45968463|NCT02961816|Drug|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
45968464|NCT02961816|Drug|Glutamine|Oral Glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
45968465|NCT02961816|Other|Oral Cryotherapy (ice chips)|Oral cryotherapy (ice chips) from 30 minutes before until 2 hours after each Melphalan infusion.
46080710|NCT05895292|Device|CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.|The patients will receive complete removable dentures designed based on the neutral-zone concept and digitally manufactured using a milling machine
45458579|NCT05073952|Procedure|Connective tissue graft|Implants will be placed with a flap and a connective tissue graft.
45458580|NCT05073952|Procedure|Flapless|Implants will be placed with a flapless approach
45825558|NCT01326923|Drug|Cetuximab|Single arm phase II study of chemotherapy
45968466|NCT02961816|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
45968467|NCT02961816|Biological|Stem Cell Infusion|Stem cells administered by vein on Day 0.
45968468|NCT02961816|Drug|G-CSF|G-CSF administered as an injection just under the skin, per standard of care ,1 time each day starting on Day +5 until blood cell levels return to normal.
45458581|NCT01360814|Procedure|quality-of-life assessment|Ancillary studies
45458582|NCT01360814|Behavioral|telephone-based intervention|Receive multidisciplinary structured intervention
45458583|NCT01360814|Other|questionnaire administration|Ancillary studies
45458584|NCT01360814|Other|counseling intervention|Receive multidisciplinary structured intervention
45825559|NCT03855059|Drug|Placebos|This will be a saline solution of given IV or perineural.
45825560|NCT03855059|Drug|Dexamethasone Sodium Phosphate|This will be the active drug solution given IV or perineural.
45825561|NCT03863795|Other|Survey Administration|Respond to SurveyGizmo survey online
45825562|NCT03858335|Other|Constraint-induced movement therapy|The constraint-induced movement therapy (CIMT) program requires children to wear forearm splint on the unaffected arm 24 hours for 3 weeks. The program consists of 5 sessions per week for 3 weeks.
45825563|NCT03857243|Device|dual transcranial direct current stimulation|Mild, non-invasive battery powered direct current applied to the head over the motor areas. No shaving or invasive procedures needed.
45825564|NCT01301963|Drug|plerixafor|Given SC
45825565|NCT01301963|Biological|filgrastim|Given SC
45825566|NCT05313737|Other|Automated message|Automated message via phone call (audiocare)
45825567|NCT05313737|Other|Opt-out scheduling|Scheduling via non-automated phone call
45968469|NCT04665427|Other|bilioenteric anastomosis i|The creation of communication between a bile duct and a segment of the digestive tract, often to restore a flow of bile in the digestive tract,
45968470|NCT03454867|Device|Hemofiltration|
45668415|NCT04038697|Procedure|Ischemic Conditioning Sham|Ischemic conditioning sham consists of the same setup as ischemic conditioning, which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 10 mmHg for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. 10 mmHg is a sufficient inflation pressure for study participants to perceive some cuff tightness, but is not high enough to occlude blood flow. In our study, participants assigned to the IC Sham + Treadmill Training groups will undergo twelve sessions of ischemic conditioning sham over a four-week period.
45968471|NCT03454867|Procedure|Standard acute ischemic stroke treatment|
45968472|NCT04665349|Dietary Supplement|Nutricia Pre-op, 400 milliliters, per os|After 10 hours of fasting participants will receive per os 400 milliliters of Nutricia Pre-op
45968473|NCT00244686|Drug|Mepolizumab|open label investigational product
45968474|NCT04665232|Drug|aqueous subcutaneous progesterone|25 mg/die of aqueous subcutaneous progesterone from the day of oocytes retrieval for two weeks.
45968475|NCT00216008|Drug|docetaxel|
45968476|NCT00216008|Drug|cisplatin|
45968477|NCT00216008|Procedure|radiation|
46080711|NCT05894902|Drug|SM-001|The Investigational New Drug SM-001 is formulated as a hot water decoction of two proprietary clonal cultivars of the Peruvian plants, Banisteriopsis caapi (BC) and Psychotria viridis (PV).
46080712|NCT05893069|Drug|Oxandrolone|oral oxandrolone for 12 weeks
45458585|NCT01360814|Behavioral|exercise intervention|Receive multidisciplinary structured intervention
45825568|NCT01298921|Drug|Oxygen|A demand valve delivers oxygen to the user as soon as they try to inhale from an attached mask or mouth tube. As the user starts to inhale, the slight drop in pressure within the mouth piece or mask lifts a valve and starts the oxygen flow. If the user inhales more deeply, more oxygen will flow in response to the increased demand, hence the name demand valve. Unlike a constant flow O2 regulator, a demand valve has no flow meter or flow rate controls, but it is capable of delivering O2 from 0 to 160 liters per minute (LPM). When using a demand valve, O2 dosage is controlled by respiration rate
45825569|NCT01298921|Drug|Oxygen|100 percent continuous oxygen given via a non-rebreather facemask at 7 to 15 liters per minute for 20 minutes
45825570|NCT05313191|Radiation|Pencil Beam Scanning Proton Therapy|Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies
46080713|NCT05893069|Drug|Placebo|oral placebo for 12 weeks
45458586|NCT01360814|Other|educational intervention|Receive multidisciplinary structured intervention
45458587|NCT01360814|Behavioral|telephone-based intervention|Receive standard care
45825571|NCT04331873|Diagnostic Test|Ultrasound|An ultrasound will be obtained prior to obtaining the standard contrast injection to determine if this imaging modality is equivocal.
45825572|NCT00378521|Drug|MQX-503|
45968478|NCT00216008|Procedure|surgery|
45968479|NCT04665076|Biological|Auto CAR-T|Biological: Auto CAR-T
45825573|NCT03870737|Device|Active TNS|Participants will receive 4-weeks nightly treatment with active TNS. Positive responders will be invited to participate in 12-month open-extension study.
45968480|NCT04665076|Drug|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
45968481|NCT04665076|Procedure|Leukapheresis|Leukapheresis
45968482|NCT04665193|Diagnostic Test|Rapid Antigen Test|Antigen Technology Lab-based test and Point of care test
45968483|NCT00241020|Drug|Octreotide|
45968484|NCT00216047|Drug|PTK787|PTK787 daily
45968485|NCT00216047|Drug|Trastuzumab|Trastuzumab 4 mg/kg IV week 1, followed by 2 mg/kg weekly with disease evaluation every other cycle*
45968486|NCT04665310|Drug|Envarsus XR|tacrolimus, extended-release tablets, a calcineurin inhibitor
45968487|NCT04664920|Device|exergame|motor-cognitive training device
45968488|NCT00241059|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
45968489|NCT00216164|Drug|Rituximab|Rituximab 375 mg/m2, day 1 of 21 day cycle
45968490|NCT00216164|Drug|Gemcitabine|Gemcitabine 1000 mg/m2, days 1 and 8 of 21 day cycle
45968491|NCT04664803|Drug|Cefecin Tab.|
45968492|NCT04664803|Drug|Omnicef Cap.|
45968493|NCT04664725|Drug|Repaglinide, Bupropion and SHR3680|Single dose of oral administration of Repaglinide and Bupropion, Multiple dose of oral of SHR3680
45968494|NCT04664764|Drug|Degludec|Basal insulin comparison
45968495|NCT04664764|Drug|Glargine|Basal insulin comparison
45968496|NCT04664764|Drug|NPH insulin|Basal insulin comparison
45968497|NCT00216242|Biological|Influenza virus vaccine (Fluviral)|
45968498|NCT00216242|Biological|Saline placebo|
45968499|NCT04664686|Procedure|AF catheter ablation|Isolation of all four pulmonary veins and additional lesions, considered indicated by the operator
45458588|NCT01360814|Procedure|standard follow-up care|Receive standard care
45668416|NCT04038697|Procedure|Treadmill Training|Participants will perform 3 treadmill training sessions/week for a 4 week period (12 sessions total). Treadmill training will immediately follow IC or IC Sham. Personnel performing the treadmill training will be blinded to the IC treatment group. Subjects will walk on a treadmill for six, 5-minute intervals. Walking speed will be continuously adjusted to maintain heart rate between 50% and 60% of age-adjusted heart rate reserve to minimize the confounder of intensity. If individuals cannot walk at 80% of their overground self-selected walking speed, for 5 minutes, they will be assisted into a body weight support harness. Body weight support will be adjusted (up to 50%) such that individuals can walk at 80% of their over ground walking speed for five minutes and adjusted accordingly throughout the session. Participants assigned to the Treadmill + IC and Treadmill + IC Sham groups will receive Treadmill Training.
45668417|NCT04819477|Behavioral|Fact box|"All physicians surveyed receive a fact box with numerical information on the benefits and harms of chest CT as a screening method.~In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot."
45968500|NCT04664686|Procedure|AV node ablation|AV node ablation
45968501|NCT04664374|Other|MyMood|Users will use the MyMood tool. Each MyMood session consists of a brief survey, followed by a few psycho-educational 'tips'(targeted psycho-educational interventions received from time to time based on symptom severity reports as determined by the software algorithm).
45825574|NCT01269749|Radiation|RAI treatment|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
45968502|NCT00241098|Drug|valsartan|
45968503|NCT00216281|Drug|Clozapine augmented with atomoxetine up to 40 mg or placebo|
45968504|NCT04664296|Other|Review of medical patient file|Review of medical patient file, including patient tracing, brief summary of the disease course, barrier gestures, social distancing.
45968505|NCT04664296|Other|Phone call interview|less than 15 minutes phone call
45968506|NCT04664452|Other|Questionnaire|Participants will be asked to fill the questionnaire
45968507|NCT00241137|Drug|valsartan|
45968508|NCT00216359|Drug|Fuzeon (Enfuvirtide)|
45968509|NCT00216359|Procedure|Laboratory diagnostic (CD4-cells)|
45825575|NCT01269749|Drug|ATD Group|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
45825576|NCT02757053|Device|Guardian Cap|The Guardian Cap is a third party add-on device attached to the facemask of a football helmet that covers the outside of the helmet with a soft material to reduce the initial impact severity, thus reducing the forces transmitted to the brain
45968510|NCT00216359|Procedure|Laboratory diagnostics (HIV-1 viral load)|
45968511|NCT00216359|Drug|antiretroviral co-medication beside Fuzeon|
45968512|NCT04664491|Behavioral|Standardized COPD management|"In standardized management group, patients will receive a multifaceted and integrated disease management that follows recommendations in GOLD 2020 and China Guideline on COPD care. It contains the components below.~Maintenance therapy after initial treatment. In this study, patients' initial therapy is the prescribed inhalers at baseline. Maintenance therapy is the medications (LABA, LAMA, or ICS) prescribed for regular or long-term use after initial therapy.~Long-term follow-up and routine monitoring of symptoms measured by CAT, mMRC and SGRQ.~Regular pulmonary function testing for lung function monitoring~Strengthened COPD education~Behavioral modification, eg. encouragement of influenza/pneumococcal vaccination, providing smoking cessation counseling and pulmonary rehabilitation."
45968513|NCT04664491|Other|Routine COPD management|Patients will undergo usual care according to current clinical practice in study sites. Usual care is the routine care provided to patients. Prescription and dispense of medicine for COPD initial and maintenance therapy will be at the discretion of doctors.
45968514|NCT04664530|Drug|esketamine|The in-hospital intervention process is divided into a titration phase and an effect evaluation phase. After admission, all patients received pregabalin 150mg twice for one day and amitriptyline 12.5mg one piece per night. The treatment group was combined with intranasal esketamine three times per day, and individualized concentration titration was performed within 5 days. Set the initial dosage to 10mg for nasal drops. If the score is less than 5 points compared to the basic value, the dose is increased by 5 mg each time. When the dose reaches 25mg, the increment of the dose will be adjusted to 10mg. If the score is reduced by ≥5 points compared to the basic value, the current dose will be maintained and the titration will end. The titration phase will be finished when the titration dose reaches 35mg or untolerable adverse reactions occurs. Finally, a 7 tesla scan was performed on the right-hand patients with herpes on the body to explore the effect of ketamine on the brain network.
45968515|NCT04664530|Drug|Saline|The titration process in the control group with saline are the same as those in the treatment group with esketamine.
45458589|NCT03493204|Other|Meal delivery|The food will be pre-packaged for storage and patient will prepare these meals at home
45458590|NCT03493204|Other|Standard pamphlet with Dietary Advice|Explains how to maintain a low-sodium diet
45968516|NCT04663984|Behavioral|publication rates|publication rates of theses produced in the Department of Anesthesiology and reanimation
45968517|NCT04664218|Device|HIPEC device|To report the affordability on using the HIPEC machine of our design compared to the standard ones in poor places.
45968518|NCT00216398|Drug|Lanreotide (Autogel formulation)|
45968519|NCT00241215|Drug|Botulinum toxin serotype A|
45968520|NCT04663789|Procedure|reinforcement of the staple line|The operator will perform reinforcement of the staple line with a continuous lock stitch.
45968521|NCT04663789|Procedure|staple only|The operator transect the pancreas with stapler only, without staple line reinforcement.
45968522|NCT04663360|Other|Adverse Drug Reaction (ADRe) Profile|ADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the BNF and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts.
45968523|NCT00216437|Drug|Capecitabine (Xeloda)|
45668418|NCT04819477|Behavioral|Cates plot|In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot.
45668419|NCT04818775|Device|HemaClear|HemaClear Model A
45668420|NCT04818775|Device|Pneumatic Tourniquet|Pneumatic Tourniquet
45668421|NCT04030507|Device|MRI|MRI (which stands for magnetic resonance imaging) provide imaging of the brain which help look for brain metastases (spread of the breast cancer to the brain).
45668422|NCT04966273|Device|Microcatheter|Only to be used if Biosensor Microcatheter does not perform accordingly
45668423|NCT05411029|Diagnostic Test|24 hour blood pressure (BP) monitoring|24-hour ambulatory BP measuring device and blood pressures will be measured every 20 minutes to half hour
45668424|NCT05411029|Diagnostic Test|Polysomnography|Measurements will include electroencephalogram, electromyogram, electrooculogram, electrocardiogram, breathing patterns of chest and abdomen, nasal and oral airflow and oxygen saturation. Sleep stages and apneas will be scored in accordance with validated American Academy of Sleep Medicine standards.
45668425|NCT05344105|Device|Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)|A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in both groups.
45668426|NCT04533373|Procedure|DIEP Flap Neurotization|"We will be performing breast reconstruction using tissue from the patient's abdomen and transferring it to the chest wall to repair the mastectomy defect. Sensory function is restored by using the nerve that supplies the skin of this abdominal tissue (i.e the new source) that is being transferred and attaching it to a nerve in the chest wall."
45668427|NCT04018807|Other|Resource pamphlet|The pamphlet will list violence prevention, mental health, and substance abuse services.
45968524|NCT00244920|Drug|bicalutamide|
45968525|NCT00244920|Drug|leuprolide acetate|
45968526|NCT00244920|Drug|squalamine lactate|
45968527|NCT00244920|Procedure|adjuvant therapy|
45968528|NCT00244920|Procedure|antiandrogen therapy|
45968529|NCT00244920|Procedure|antiangiogenesis therapy|
45968530|NCT00244920|Procedure|conventional surgery|
45968531|NCT00244920|Procedure|neoadjuvant therapy|
45968532|NCT00244920|Procedure|releasing hormone agonist therapy|
45968533|NCT04663477|Diagnostic Test|patient-completed Caprini Risk Score|The participants will be asked to complete patient-completed Caprini Risk Score
45458591|NCT03720925|Procedure|TDI treatment|The TDI treatment was performed according to its complexity. Uncomplicated TDI received minimally invasive treatment (simple restorations and clinical and radiographic follow-up). Complicated TDI received invasive treatment (more complex restorations, endodontic treatment, confection of aesthetic devices, restraints).
45458592|NCT01145365|Procedure|Exam under anesthesia (EUA)|EUA established drainage of perianal fistulas &/or abscesses will be done before patient begins medical therapy with certolizumab (Cimzia)
45668428|NCT04018807|Behavioral|Remote Therapy|Remote therapy sessions will include mindfulness exercises and motivational interviewing techniques.
45668429|NCT04830787|Other|no intervention|there is no intervention, we just chose patients diagnosed with hypertrophic cardiomyopathy and underwent CAG, and patients without hypertrophic cardiomyopathy as control ,the two groups are matched with age, gender and hypertension.
45668430|NCT04018729|Device|Zephyr Endobronchial Valve|Endoscopic lung volume reduction therapy.
45968534|NCT04663438|Drug|Chemotherapy Drugs, Cancer|Other chemotherapy:Irinotecan;topotecan;Enrotinib;Bevacil
45968535|NCT00216515|Drug|galantamine hydrobromide|
45968536|NCT04663516|Other|Exergaming|games provided by the console requiring the movement of upper body, lower body and trunk.
45968537|NCT00244959|Drug|anastrozole|1 mg orally daily for 12 months
45968538|NCT00244959|Procedure|adjuvant therapy|treatment received after breast cancer surgery
45968539|NCT04663672|Other|Experimental Scent|Participants will sleep in the presence of the exposure scent, delivered by an Airwick Essential Oils diffuser
45968540|NCT04663672|Other|Control Scent|Participants will sleep in the presence of a novel scent, delivered by an Airwick Essential Oils diffuser
45968541|NCT04663672|Other|No-Scent Control|Participants will sleep in the presence of an odorless control vehicle, delivered by an Airwick Essential Oils diffuser
45968542|NCT04663672|Behavioral|In-Vivo Exposure|Participants will receive 40 minutes of in-vivo exposure therapy to feared targets in the presence of a distinctive exposure scent.
45458593|NCT03225170|Behavioral|Self Affirmation (SA)|Clients will be asked to rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. They will then be asked to write about the item that is most important to them and why it may be important to them.
45825577|NCT01270919|Device|BioDuct Meniscal Repair Device|"The BioDuct® Meniscal Repair Device is a small, cannulated, arthroscopically implanted, bioabsorbable conduit that has length sizes of 5, 7 and 9 mm. Based on the concept of trephination for treating meniscal tears in the red-white zone, the BioDuct® Meniscal Repair Device is designed to create a vascular access channel between the vascular-rich and cell-rich synovium and the meniscal tear. This channel allows for the flow of blood from the vascular to the avascular tissue to promote repair of the meniscus.~The BioDuct® Meniscal Repair Device is not used across meniscal tears, like other fixation devices. The BioDuct® Meniscal Repair Device is used in conjunction with suturing and helps provide vascular access, while the sutures help provide fixation. Based on the Inclusion Criteria of this protocol, there can be a maximum of three BioDuct® Meniscal Repair Devices utilized for the meniscal tear."
45825578|NCT01262339|Drug|BTX-A|100 units of BTX-A will be delivered subject's hand via iontophoresis and standard of care intradermal injection of 100 units BTX-A will be delivered to the contra-lateral hand
45825579|NCT03861845|Device|Standard off-the-shelf pillbox|Then the participant will receive a store bought one-dose per day pillbox.
45825580|NCT03861845|Device|Custom off-the-shelf pillbox|Then the participant will be administered an off-the-shelf pillbox that was purchased specifically for the participant's preferences, routine, medication regimen, and skills/abilities.
45825581|NCT03861845|Device|Custom designed and manufactured pillbox|Then the participant will describe any design preferences for the pillbox. The researcher will design and manufacture the pillbox using a 3D printer, publically available 3D printing object repository, and computer aided design software.
45825582|NCT03861845|Behavioral|Education & Training|The participant will receive education and training on how to use the pillbox and how to incorporate the pillbox and taking medications into their daily routine.
45825583|NCT03861845|Behavioral|Reflection on medication routines|The participant will reflect on his or her daily routine, medication regimen, and use of existing pillboxes. The participant will also engage in a hands-on standardized pillbox task.
45825584|NCT02708849|Drug|Ketamine|The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
45825585|NCT02708849|Drug|Lamotrigine|lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine
45825586|NCT02708849|Drug|Placebo|oral dose placebo
45825587|NCT03859739|Drug|MK-8558|Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.
45825588|NCT01237613|Device|Artelon|Artelon Tissue Reinforcement
45825589|NCT01234103|Behavioral|Preventing Helath Damaging Health Behaviors in Male and Female Army Recruits|Groups will be randomly assigned to the sexual/substance use prevention intervention or the comparative/control intervention focused on impro risk Involves 10 hours of didactic presentations, interactive group discussions, skills-building exercises, and topic specific videos to reduce participants' risk for and acquisition of STIs, unintended pregnancies and their associated sexual and substance use behaviors.
45825590|NCT01222871|Drug|Triamcinolone|Triamcinolone soaked nasopore dressing
45825591|NCT01222871|Drug|Saline soaked sponge|saline soaked sponge
45825592|NCT01219673|Other|Placebo|1 by mouth twice a day.
45825593|NCT01219673|Drug|Armodafinil|150 mg by mouth once a day.
45825594|NCT01219673|Drug|Minocycline|100 mg by mouth twice a day.
45825595|NCT01219673|Drug|Bupropion|100 mg by mouth twice a day.
45825596|NCT01216631|Drug|methylprednisolone|intra-articular injection of methylprednisolone (80mg given at baseline only)
45825597|NCT01216631|Drug|Infliximab|intra-articular injection of 100mg infliximab given at baseline only
45825598|NCT01216631|Drug|Infliximab|intravenous infliximab at a dose of 5mg/kg (as per patient weight) given at week 0, 2, 6 and 14
45825599|NCT02693717|Other|Laboratory Biomarker Analysis|Correlative studies
45825600|NCT02693717|Drug|Pemetrexed Disodium|Given IV
45825601|NCT03860753|Drug|Pioglitazone|For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by week 2, which is within standard titration parameters as per the investigator's brochure.
45825602|NCT03860753|Drug|Placebo|Pill capsules will look same as that of active drug.
45825603|NCT02687165|Drug|Milnacipran and D-cycloserine|Milnacipran augmented by D-cycloserine
45825604|NCT02672033|Radiation|Hypofractionated Radiation Therapy|Undergo accelerated hypofractionated IMRT
45825605|NCT02672033|Radiation|Intensity-Modulated Radiation Therapy|Undergo accelerated hypofractionated IMRT
45825606|NCT02672033|Other|Laboratory Biomarker Analysis|Correlative studies
45668431|NCT04018729|Biological|Marrow-derived mesenchymal stromal cell|Mesenchymal stem cells have anti-inflammatory, anti-fibrotic, microbicide and repair potential.
45968543|NCT04663048|Procedure|PiXL|Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of low grade myopia.
45968544|NCT04663009|Device|AutoPulse|A band circumflex of the chest that provide chest cage compressions.
45968545|NCT00244998|Drug|fulvestrant|IM
45968546|NCT04663165|Procedure|Periodontal surgery|Flap surgery at teeth with periodontal pocket depth 5 mm or more with additional bleeding or pus on probing. Elimination of dental calculus and granulation tissue as well as scaling of the root surface with scalers and ultrasonic device. Flap closure with non-resorbable sutures.
45968547|NCT04663165|Procedure|Regenerative periodontal surgery|Flap surgery at teeth with periodontal pocket depth 5 mm or more with additional bleeding or pus on probing combined with vertical bone defect of 4mm or more. After elimination of dental calculus and granulation tissue as well as scaling of the root surface with scalers and ultrasonic device, adjunctive treatment with EDTA gel applied to root surface for two minutes, followed by rinsing with saline solution. Finally, application of enamel matrix derivative on a blood free root surface, followed by flap closure with non-resorbable sutures.
45968548|NCT04663243|Behavioral|Thinking healthy Program sessions designed for antenatal period|Low line psychosocial intervention based on the principles of Cognitive Behavior Therapy (CBT), designed for non-specialist will be applied for expectant women experiencing depression during mid to late-pregnancy. It uses the core principles and strategies of the Thinking Healthy Program (THP). Four core sessions and two booster sessions will be applied, designed for antenatal period to prevent antenatal and post partum depression.
45968549|NCT00216554|Drug|risperidone|
46080714|NCT05892679|Other|acupressure|"Acupressure will be formulated according to the standards of the World Health Organization and applied to the determined points in a certain order. Since the reactions of individuals will be different from each other, the stiffness and pressure will be adjusted according to the sensitivity of the individual in order not to cause tissue damage. Pressures will be applied manually by a single practitioner. A total of 8 points with parallel points will be studied, with four points in each lower extremity. There will be a total of 12 minutes of pressure on 8 points, with an average of 90 seconds on each point, and approximately 10-15 seconds of warming and preparatory scrubbing before pressing on the area where the points are located.~Considering the studies done, a person will be given acupressure three times a week for four weeks."
46080715|NCT05890807|Diagnostic Test|Front view photography of the patient's oral cavity with the help of a smartphone in the diabetology department.|The diabetologist will take a photograph of the patient's oral cavity in the diabetology department.
45458594|NCT03225170|Behavioral|Control|Clients will be asked to rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. The control group will rank the list and be asked to write about the 9th ranked item and why it might be important to someone else.
45668432|NCT04817371|Device|Volatile Organic Compounds analysis (e-noses)|VOC analysis in exhaled air with e-noses.
45668433|NCT04817371|Other|Canine odor detection of Volatile Organic Compounds|VOC analysis in sweat by trained dogs.
45668434|NCT04817371|Device|Volatile Organic Compounds analysis (mass spectrometry)|VOC analysis in exhaled air with mass spectrometry.
45668435|NCT04817371|Device|Volatile Organic Compounds analysis in sweat (mass spectrometry)|VOC analysis in sweat with mass spectrometry.
45825607|NCT02672033|Procedure|Therapeutic Conventional Surgery|Undergo pleurectomy/decortication
45825608|NCT02656199|Procedure|Diaphragm Ultrasound|Once on a pressure support weaning trial, enrolled subjects will have an ultrasound of their right hemidiaphragm performed on three levels of pressure support: 15/5 10/5 and 5/5
45825609|NCT03845933|Procedure|Colon polypectomy|Polyp search and resection will be performed during the withdrawal phase in both groups. Insertion polypectomy will not be performed. All proximal colon polyps will be removed irrespective of their size and appearance.
45825610|NCT03817775|Other|Music therapy|"The intervention group will administer U sequence between 10 minutes prior to the beginning of the procedure until its end."
45825611|NCT01169753|Drug|Placebo|Oral tablet every morning for 2 weeks
45825612|NCT01169753|Drug|Armodafinil|Three 50 mg tablets orally every morning for 2 weeks.
45668436|NCT05408533|Device|2-Way Foley Urethral Urinary Catheter|Comparing two types of catheter (silver-coated silicone versus silicone) after Pelvic Reconstructive Surgery (PRS) to compare Urinary Tract Infection (UTI) rates
45668437|NCT04001647|Drug|Acetylcholine|Endothelium-dependent vasodilation will be determined via graded intra-arterial infusions of acetylcholine (ACh). Doses of 1, 4, 8, and 16 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
45668438|NCT04001647|Drug|Sodium Nitroprusside|Endothelium-independent vasodilation will be determined via graded intra-arterial infusions of sodium nitroprusside (SNP). Doses of 0.25, 0.5, 1, and 2 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
45825613|NCT02654639|Drug|TAS-102|TAS-102 Twice a day by mouth day 1-5 and 8-12
45825614|NCT02654639|Drug|Bevacizumab|Bevacizumab by intravenous infusion once every 14 days
45825615|NCT02634827|Drug|Decitabine|Given IV
45825616|NCT02634827|Other|Laboratory Biomarker Analysis|Correlative studies
45825617|NCT02634827|Drug|Midostaurin|Given PO
45825618|NCT02506985|Drug|rivaroxaban|Immediately following completion of alteplase infusion, patients will receive rivaroxaban 15 mg oral bid for 21 days followed by 20 mg oral daily.
45825619|NCT02506985|Drug|warfarin|Immediately following completion of alteplase infusion, patients will continue on unfractionated heparin or low-molecular weight heparin with initiation of warfarin adjusted to INR of 2-3.
45825620|NCT01150409|Drug|hydrocortisone|1) Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
45825621|NCT01150409|Drug|Normal Saline|0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
45825622|NCT01133639|Drug|Ketorolac|30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
45968550|NCT04662892|Drug|Pegfilgrastim-Cbqv|Date, Dose, and cycle for subjects who received Udenyca will be recorded. Other FN prophylaxis such as Neulasta, or other pegfilgrastim biosimilars will be collected.
45968551|NCT00241254|Drug|Cyclophosphamide (drug)|IV cyclophosphamide infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
45968552|NCT00241254|Drug|Methylprednisolone (drug)|Control group : IV methylprednisolone infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
45968553|NCT00216632|Drug|risperidone|
45825623|NCT01133639|Drug|Placebo|Placebo plus standard of care
45968554|NCT04662775|Behavioral|HERizon Project|"1. Participants were asked to complete 3x30-minute physical activity sessions each week & record their sessions using a logbook. They were given the choice of different types of home-based virtual exercise. 2. Behaviour change support calls - participants were allocated an Activity Mentor (trainee sport and exercise psychologists, was supervised by a HCPC-registered Psychologist). Participants had seven weekly videocalls. Each call was based on a pre-planned session outline and was goal orientated, participant centred and focused on physical activity. 3. No reply SMS - Participants received 3 standardised text messages each week, aimed at providing physical activity -related facts, encouragement and study information."
45968555|NCT04662814|Other|shock wave therapy|Intervention group is by shock wave therapy. A radial shock wave device (EME, ITALY) was used. for 4 sessions (one session before the expected day of period and session per day for day1 , day 2 and day 3 of each menstrual cycle) for three successive periods.
45968556|NCT04662814|Other|dietary modification|Participants will receive dietary modification for three consecutive months dietary modification will be low caffeine and high water and liquids intake and reduce the uptake of fast food, should be followed for 3 months
46080716|NCT05888961|Biological|Blood samples|"Fasting at the first session for hormonal measurements of leptin, insulin, acylated and non-acylated ghrelin, serotonin, albumin, protidemia and blood glucose.~Repeated at 6 and 12 months for follow-up"
45825624|NCT01115699|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active 10 Hz rTMS will be applied to the left dorsolateral prefrontal cortex (L-DLPFC) with an intensity of 120% motor threshold. The L-DLPFC location is defined as that area 5 cm anterior to the motor cortex for activation of abductor pollicis brevis. Subjects will receive a total of 3000 stimuli per session. The TMS trains are 4 seconds on and 26 seconds off for a total of 37 1/2 minutes. Treatment will occur 5 days per week for up to six weeks. Subjects will be monitored during rTMS for any side effects or adverse events.
45825625|NCT00378911|Drug|sunitinib malate|Given orally
45968557|NCT04662736|Other|patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy|description of osteo-articular infection managed with tedizolid as a suppressive antibiotic therapy
45968558|NCT04662853|Diagnostic Test|Gut microbiota determination from feces samples.|Determination of the gut microbiota composition by 16S metagenomic and building of a mathematical model, on the basis of the colonoscopies results, able to classify patients without and with color-rectal cancer-related lessions. These latter will be also classified according to the type of lession.
45968559|NCT00216710|Behavioral|Home Visiting|
46080717|NCT05888961|Other|Interviewing the subject and scales|"Collection of sociodemographic data, personal and family neurological history, treatments, MADRS depression scale and CDR autonomy scale.~Carried out at the 1st session"
46080718|NCT05888961|Other|Neurocognitive evaluation|cognitive complaint questionnaire (CCQ), taste, smell, MoCA and MMSE (if not performed in the previous 6 months) Carried out at the 1st session. Repeated at 6 and 12 months for follow-up.
46080719|NCT05888961|Other|Taste tests|"Sweet and salty flavors at the 1st session and acid and umami flavors at the 2nd session. Repeated at 6 and 12 months for follow-up.~Placement of electrodes on the scalp, recording of gustatory evoked potentials, subjective gustatory evaluation by means of visual analogue scales rated from 0 to 10, identification and naming of each of the primary flavors"
45668439|NCT04001647|Drug|Ascorbic Acid|The influence of oxidative stress on arterial stiffness and vasodilation will be assessed by using intravenous ascorbic acid (AA). A single supra-physiological dose of 0.06 g/kg fat-free mass (FFM) will be infused over 20 min followed by a drip infusion of 0.02 g/kg FFM administered over 60 min.
45668440|NCT03989947|Drug|Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.|Modified recombinant human C-type natriuretic peptide (subject to adjustment per protocol)
45668441|NCT04419571|Procedure|Emergency Laparotomy|All adult patients undergoing emergency laparotomy
45668442|NCT04511455|Drug|Cabozantinib|Cabozantinib 60 mg/day peroral
45668443|NCT03958903|Device|Amygdala recording and stimulation using Neuropace RNS|Subjects will undergo a series of different, fear-related, behavioral tasks while undergoing amygdala electrophysiology recording and stimulation using the Neuropace RNS devices.
45825626|NCT03819491|Dietary Supplement|COQUN ORAL FORMULATION|COQUN ORAL FORMULATION is a food supplement based on Coenzyme Q10 MINIACTIVES®
45825627|NCT03801473|Other|robot assisted gait therapy|The Robogait is a fixed lower body hip-knee exoskeleton. The user's weight is supported by a combination of an overhead attached harness and the support from the exoskeleton.
45825628|NCT03801473|Other|Conventional rehabilitation|Conventional rehabilitation program. Exercise and walking education is performed by the physiotherapists.
46080720|NCT05888961|Other|Computerized food preference questionnaires|Performed at the 1st session on a tactile tablet. Repeated at 6 and 12 months for follow-up.
45668444|NCT03958903|Behavioral|Behavioral tasks|Subjects perform a set of fear related behavioral tasks over 2 days, with 3 tasks each day.In addition to amygdala RNS recording and stimulation, recording of electroencephalography (EEG), electromyography (EMG), and electrodermal activity (EDA) will be performed using standard techniques to capture and quantify the fear response across all tasks.
45668445|NCT04816981|Device|EBUS-Elastography|Patients undergoing LN staging for lung cancer with EBUS-TBNA will have digital images and biopsy of every LN obtained in accordance with standards of care. Prior to the lymph node biopsy by EBUS-TBNA, elastography will be performed. The relative strain of tissues in the scanned area of the LNs will be displayed as a colour map, with stiffer areas in blue and softer tissue in red. Elastography and B-mode images will be displayed side by side and images recorded and saved onto an external drive for analysis. Elastography images will be fed to the NeuralSeg algorithm which has a network architecture similar to the standard U-Net for image segmentation. The automatically identified regions of interest will be overlaid onto the EBUS Elastography images to extract the LN stiffness measurements. After overlaying, NeuralSeg will determine the proportion of the LN area within 9 previously defined stiffness thresholds.
45968560|NCT00245076|Behavioral|smoking cessation intervention|
45968561|NCT00245076|Other|internet-based intervention|
45968562|NCT04662541|Other|Mobile Integrated Health (MIH)|MIH leverages paramedics in the community and telemedicine (technology-enabled communication for health purposes) to provide medical care to heart failure patients in the home.
45968563|NCT04662541|Other|Transitions of care coordinator (TOCC)|The TOCC group will receive a follow-up phone call shortly after discharge in which the patient is assessed and connected to clinical and social services as needed and patient education is reinforced.
45968564|NCT04662502|Dietary Supplement|Bifidobacterium longum 35624|Bifidobacterium longum 35624, 1 x 10^9 CFU/capsule, 1 capsule/day over 1 month
45968565|NCT04662658|Drug|Hyperpolarized Xenon -129 MRI|e-cigarette sub-study
45968566|NCT04662424|Other|music in labor|Women in the intervention group will be offered music in labor, defined listening to music from the randomization until the delivery of the baby. Women had the possibility to select the songs at their discretion
45968567|NCT00216788|Drug|Esomeprazole (Nexium) 40 mg/day|
45668446|NCT04490161|Other|intravenous reinstallation of cerebrospinal fluid|10ml of CSF will be taken under sterile conditions from the external ventricular drain and immediately administered intravenously.
45825629|NCT03828149|Combination Product|Drug:OP0201|Drug: OP0201
45668447|NCT04923997|Behavioral|Health Coaching|6 months of integrative health coaching, goal setting, survey administration and physical assessments.
45825630|NCT03828149|Combination Product|Drug: Placebo|Drug: Placebo
45825631|NCT03832907|Device|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay and after hospital discharge for 10 days using the Dexcom Studio software to download the Dexcom receiver data.
45825632|NCT03832907|Diagnostic Test|POC BG - Point-of-Care Blood Glucose monitoring|Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay and after hospital discharge for 10 days.
45968568|NCT04662346|Other|Difficulty score system for robotic pancreatoduodenectomy|calculate the score for patient in you cohort
45968569|NCT00245115|Biological|filgrastim|
45968570|NCT00245115|Drug|busulfan|
45968571|NCT00245115|Drug|cyclophosphamide|
45968572|NCT00245115|Procedure|in vitro-treated bone marrow transplantation|
45968573|NCT00245115|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45825633|NCT03831971|Drug|ANS-6637|Subjects will receive (1) midazolam 5 mg po single dose on Day 1 followed by (2) Drug free period on Day 2 followed by (3) ANS-6637 600 mg po daily (Days 3-7) to reach steady state followed by (4) ANS-6637 600 mg po single dose + midazolam 5mg po single dose on Day 8
45968574|NCT04662385|Drug|aloe vera toothpaste|aloe vera toothpaste have antimicrobial and other multipotential effects.
45968575|NCT04662385|Drug|Colgate Total|Whitening toothpaste that removes and prevents new stains Fights bacteria on teeth, tongue, cheeks and gums for whole mouth healthy Mint toothpaste for long lasting fresh breath Helps prevent plaque, tartar, cavities & gingivitis
45968576|NCT00216827|Drug|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
45968577|NCT04662229|Device|Eco-guided Percutaneous Electrical Stimulation|Pointer 10 hz. A symetric, biphasic current of 10 hz and 240 microsecond. The stimulation intensity will be reaching the excitomotor threshold, producing visible but comfortable contractions.
45968578|NCT04662229|Device|Sham stimulation|Application of the needles only on the median and ulnar nerve of the arm, for 1 minute on each nerve without current intensity and applying a son.
45968579|NCT00241332|Drug|fentanyl|
45968580|NCT00216866|Drug|Dalteparin|
45968581|NCT00216866|Drug|Warfarin|
45968582|NCT00557206|Drug|Oxaliplatin and Docetaxel|"Chemotherapy~Oxaliplatin 130mg/m2 on day 1; and Docetaxel 75mg/m2 on day 1; every 21 days."
45968583|NCT04661917|Drug|BAY2327949|60 mg of BAY2327949 (2 tablets of 30 mg, orally) once daily for 28 days.
45968584|NCT04661917|Drug|Placebo|Matching placebo orally once daily for 28 days.
45968585|NCT00245154|Drug|carboplatin|Given IV
45968586|NCT00245154|Drug|cediranib maleate|Given orally
45968587|NCT00245154|Drug|paclitaxel|Given IV
45968588|NCT00245154|Other|placebo|Given orally
45968589|NCT04661800|Other|Sniffin's stick test|The sniffin's stick test is a three-part test consisting of smelling odor pens: 1) determining a detection threshold, 2) discriminating ability, 3) ability to identify odors. It lasts about 30 minutes, is achievable in the room.
45668448|NCT03939637|Drug|Eltrombopag|"Starting dose for eltrombopag will be based on manufacturer recommendations, and drug will be titrated to effect per guidelines.~Children 1 to 5 years: Initial: 25 mg once daily~Children ≥6 years and Adolescents: Initial: 50 mg once daily (25 mg once daily for patients of East-Asian ethnicity [e.g., Chinese, Japanese, Korean, Taiwanese])~Dose should be titrated based on platelet response. Maximum dose: 75 mg once daily."
45668449|NCT03939637|Drug|Steroids|Prednisone/Prednisolone 4mg/kg/day (Max 120 mg/day) x 4 day
45668450|NCT03939637|Drug|IVIG|IVIG 1 g/kg x1 (no steroids for pre-medication or adjunctive therapy)
45668451|NCT03939637|Drug|Rho(D) Immune Globulin|Anti-D globulin 75 mcg/kg x1 (no steroids for pre-medication or adjunctive therapy)
45968590|NCT04661644|Biological|Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial)|Dose: 1 x 10^7 cells/1 mL/vial (1,000 clusters of adipose-derived mesenchymal stem cells)
45968591|NCT04661644|Biological|Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial)|Dose: 1 x 10^8 cells/1 mL/vial (10,000 clusters of adipose-derived mesenchymal stem cells)
45968592|NCT04661527|Drug|Sarilumab|Treatment with Sarilumab 200 mg IV x 2 doses 24 hours apart for first 5 patients. If no severe AE and no significant improvement within 48 hours, the dose will be increased for subsequent patients to 400 mg IV for the first dose and 200 mg or 400 mg IV for the second dose 24 hours later. Te second dose will be decided at the investigators discretion.
45968593|NCT00216944|Procedure|Tracheal intubation for respiratory care in preterm infants|Premedication with atropine 0.02 mg/kg and morphine 0.03 mg/kg
46080721|NCT05888961|Other|Nutritional status - body composition|Measurement of anthropometric data, bioelectrical impedancemetry (measurement of fat mass, lean mass, water mass and bone mass in kg), measurement of blood pressure and heart rate Performed at the 2nd session Repeated at 6 and 12 months for follow-up.
45825634|NCT03823937|Other|Sniffin' Sticks test and Taste strips|"Sniffin' Sticks test (Burghardt®, Wedel, Germany) is a psychophysical test. It allows semi-objective assessment of the patient's olfactory performance by means of 3 subtests: threshold test, identification test and discrimination test. The Sniffin' Sticks Olfactory Test Kits contain pen like bodies as, for example, in pens used to write on flipcharts or whiteboards.These pen-like bodies, however, contain a fibre stick which is filled with scents. For testing, the cap should be removed so the patient can smell on the tip of the pen.~The taste strips are a validated examination procedure to investigate the taste ability. When testing the whole mouth taste ability, the taste strips are applied by putting them on the tongue and closing the mouth."
45825635|NCT03807089|Device|Conventional Pediatric Colonoscope|
46080722|NCT05887856|Other|comprehensive educational program for reduction of Pre-Operative Anxiety|"BSEP 1 makes use of modern media and aims to educate patients and their carers through educational videos comprising of various aspect of surgical treatment.~Introduction to surgery by consultant surgeon, Patient to receive video of their own surgeon.~Introduction to Anesthesia.~What are different type of breast surgeries in cancer patients (General Video)~Specific video pertaining to the type of surgery patient is undergoing (Mastectomy, Breast Conserving Surgery, Breast Re Construction surgery)~Explanation of Methicillin-resistant Staphylococcus aureus Decolonization protocol~What to expect on Surgery Day~Virtual tour of Holding bay and Operation Room~Post-Operative care including wound care, drain management and common post-operative complications."
45668452|NCT05333029|Biological|Allogeneic mesenchymal stromal cells (MSCs)|Treatment dose 2 x10^6 cells/kg (+/- 20%)
45968594|NCT00216944|Procedure|Tracheal intubation for respiratory care in preterm infants|Premedication with glycopyrronium 0.005 mg/kg, thiopental 2-3 mg/kg (< 2 kg 2 mg/kg), suxamethonium 2 mg/kg and remifentanil 0.001 mg/kg
45968595|NCT00245193|Behavioral|Motivationally-Enhanced Interpersonal Psychotherapy|
45968596|NCT04661488|Device|AI driven triage-system|AI driven triage-system
45968597|NCT04661605|Diagnostic Test|Recurrent Neural Network|We will propose a similar Moiré feature analyzing approach based on Recurrent Neural Network to process the measured Slip Pulse wave-images with 'Chun', 'Guan' and 'Chy' in order to prepare this visualization engineering platform.
45968598|NCT04661722|Other|No intervention|No intervention
45668453|NCT05333029|Biological|Extracorporeal photopheresis (ECP)|Blood is collected through an intravenous (IV) line which is connected to an apheresis machine.The machine adds a chemical that makes the white blood cells sensitive to light. Then the machine shines a light on the cells and then returns the blood to the participant
45968599|NCT04661449|Other|Comprehensive lifestyle intervention|Feeding guidance: promoting exclusive breastfeeding and healthy diet (Pediatrician). Motor development assessment and guidance: Alberta Infant movement scale (AIMS) evaluation, guidance for motor development (Rehabilitation Therapist). Healthcare education: improvement of environmental exposure (Pediatrician).
45968600|NCT00241371|Drug|Clofarabine|
45968601|NCT04661098|Procedure|(Darwish hymenotomy technique)|Formation of an annular hymen in cases of postpubertal imperforate hymen using a laparoscopic trocar (Darwish hymenotomy technique)
45668454|NCT04829461|Device|Ambu® aScope™ 4 Cysto with the aView™ 2 Advance used for stent removal|Procedure using a single-use cystoscope for stent removal
45668455|NCT04829461|Device|Standard of care reusable cystoscope used for stent removal|Procedure using a reusable cystoscope for stent removal
45668456|NCT04479241|Biological|lerapolturev|Lerapolturev (5x10^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).
45668457|NCT04479241|Biological|pembrolizumab|Pembrolizumab (200 mg IV) given every 3 weeks.
45825636|NCT03807089|Device|Short-Turn Radius Colonoscope|
45968602|NCT00217061|Device|Decision Aid Statin Choice|
45668458|NCT03930199|Other|Needs-based intervention (physical, psychological, or both)|Individuals identified as having physical issues (poor prosthesis fit, function, comfort or physical conditioning) will receive prosthetic care and physical therapy. This includes adjusting socket fit, component fit and repair, and in some instances replacement. Rehabilitation strategies include gait and prosthesis use retraining, balance fall-prevention, and range-of-motion training, strengthening, pain management, and activities of daily living training, based on participant-reported mobility goals. Individuals whose prosthesis use is reduced due to psychological issues will be provided with motivational interviewing and other related psychological interventions. During these interventions participant will be asked to set personal goals using a semi-structured interview that explores facilitators and barriers to wearing their prosthesis. If both physical and psychological issues are present, participant may receive both types of interventions simultaneously.
45825637|NCT03822377|Drug|Ticagrelor orodispersible tablets|Ticagrelor loading dose (180 mg) given as two orodispersible tablets (each of 90 mg), to be dispersed in saliva.
45968603|NCT04661371|Procedure|Laparoscopic cholecystectomy|"Method of operation~Surgery was started under general anesthesia~A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
45968604|NCT00245232|Behavioral|Cognitive Therapy|
45968605|NCT00245232|Behavioral|Cognitive Processing Therapy|
45668459|NCT05407285|Drug|cannabis 0 mg, placebo|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
45968606|NCT00245232|Behavioral|Written Exposure|
45825638|NCT03822377|Drug|Ticagrelor standard tablets|Ticagrelor loading dose (180 mg) given as two standard coated tablets (each of 90 mg) to be swallowed with water.
45825639|NCT02501759|Procedure|3 Tesla Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
45825640|NCT02501759|Radiation|Gadodiamide|Given IV
45825641|NCT02501759|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
45825642|NCT02501759|Procedure|Transrectal Biopsy|Undergo transrectal MRI-guided biopsy
45968607|NCT04661020|Drug|CD19 CAR-T cells|Each subject receive CD19 CAR T-cells by intravenous infusion
45968608|NCT04660630|Diagnostic Test|Gene detection of therapeutic drugs for chronic cardiovascular and cerebrovascular diseases|According to the results of drug gene chip detection, we combined with the clinical characteristics of the patient to choose more suitable cardiovascular and cerebrovascular treatment drugs.
45968609|NCT04660630|Behavioral|Regular follow-up and patient education|The subjects received regular follow-up and patient education.
45968610|NCT04660786|Drug|triamcinolone acetonide|local immunosuprresent
45968611|NCT04660786|Drug|vitamin D|local immunomodulator
45968612|NCT00217100|Dietary Supplement|Multivitamin|1 tablet a day
45968613|NCT00217100|Dietary Supplement|Placebo|1 tablet a day
45968614|NCT04660981|Behavioral|Antenatal education|Training Program on Fear of Childbirth Based on Motivational Interview Method
45968615|NCT00241410|Biological|OralvacB2MPL|Comparison of different dosages of drug
45968616|NCT04660825|Other|A resistance band exercise programme|A resistance band based exercise programme lasting six months
45968617|NCT04660825|Other|Control|Maintained usual physical activity
45968618|NCT04660513|Procedure|Bariatric surgery|Subjects with morbid obesity underwent bariatric surgery
45968619|NCT00217139|Drug|Celgosivir|
45968620|NCT04660591|Device|femoral stem in hip arthroplasty|using lateral approach to the hip we will compare the effect of femoral stem length on the oncological and functional outcomes in patients with proximal femoral metastasis.hip arthroplasty is a surgical procedure that involves changing the head of the femur (the ball) with or without replacing the articular surface of the acetabulum (the socket ).and replacing it with metal head based on a stem covered with cement to fix it to the bone of the femur.
45968621|NCT00245310|Procedure|Indocyangreen (ICG) clearance|
45825643|NCT02501759|Procedure|Ultrasound-Guided Prostate Biopsy|Undergo TRUS-guided biopsy
45968622|NCT04660552|Device|Cognilum TM: Light Treatment Condition|The children will wear the CognilumTM device for approximately 15 minutes at a time, twice a week, for a period of 8 weeks.
45825644|NCT03808493|Drug|TAK-438 OD|TAK-438 OD tablet
45825645|NCT03808493|Drug|TAK-438|TAK-438 tablet
45825646|NCT00378989|Behavioral|Consultation at the occupational health services|Consultation at the occupational health services
45825647|NCT02499887|Drug|beclamethasone dipropionate|Inhaler
45825648|NCT02499887|Drug|albuterol|Inhaler
45825649|NCT02499887|Drug|Prednisone|Oral corticosteroid
45825650|NCT02504099|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
45968623|NCT04660318|Device|Remote photoplethysmography for physiological parameters|physiological parameters will be acquired using the Remote photoplethysmography software simultaneously for the conventional parameters measurements (heart rate, respiratory rate, and oxygen saturation)
45968624|NCT04660318|Device|standard acquisition system for physiological parameters|physiological parameters will be acquired using the standard acquisition system for the conventional parameters measurements (heart rate, respiratory rate, and oxygen saturation)
45968625|NCT00217178|Drug|Vitamins: Folic acid, B6, B12|
45968626|NCT04660357|Other|survey study|survey study
45968627|NCT00241449|Drug|Fulvestrant|intramuscular injection 250 mg
45968628|NCT00241449|Drug|Tamoxifen|20 mg oral tablet
45968629|NCT00412100|Drug|Oxycodone naloxone prolonged release tablets (OXN)|
45968630|NCT04659889|Diagnostic Test|Blood sampling (venesection)|"All study participants will have a single blood test to analyse the following parameters:~(i) Serum biochemistry, CRP, Thyroid function and liver enzymes (ii) FBC, d-Dimer, ESR, Blood film (iii) SARS-CoV2 antibody status and serum save (iv) Peripheral blood immunophenotyping."
45968631|NCT04659733|Drug|Anlotinib hydrochloride|Anlotinib are divided into 3 dosage levels, including 8mg, 10mg, 12mg; Oral administration of anlotinib was given, qd, D1-D14; taken on an empty stomach, Every 3 weeks is a cycle, a total of 2 cycles; Starting from the first level of anlotinib, the dose will be ramped up in sequence.
45968632|NCT04660006|Procedure|Cataract surgery|Patients undergoing uneventful cataract surgery were recruited to this study if they met the inclusion criteria of the three groups. Postoperative retinal vasculature measures, as recorded by the optical coherence tomography angiography imaging technique, were compared to baseline measures.
45968633|NCT04659850|Other|low fat, low AGE milkshake|low fat, low AGE milkshake given after an overnight fast
45825651|NCT02504099|Drug|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
45825652|NCT02504099|Drug|ribavirin|Tablet
46080723|NCT05887557|Other|Active Referral|As an implementation science study, all clinical intervention components will be delivered as part of routine clinical care at participating clinical sites. Clinicians and staff at referral sites throughout San Francisco and Alameda counties (emergency departments, psychiatric emergency services, community clinics, care navigation and case management programs, and community-based services) will refer eligible patients who are out of care and are interested in linking to drop-in and/or mobile care services at one of the study sites. Clinical referrals will include basic patient information and contact/locator information to facilitate linkage to care. Referrals will be site-specific based on the site where the patient is interested in accessing care.
45668460|NCT05407285|Drug|Cannabis 20 mg,|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
45668461|NCT05407285|Drug|Cannabis 50 mg|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
45668462|NCT05407285|Drug|Cannabis 100 mg|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
45825653|NCT02450591|Drug|Erlotinib|
45668463|NCT05407285|Drug|Cannabis 200 mg|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
45668464|NCT03916237|Other|Home assessment|Home assessment for environmental hazards according to protocol established by Environmental Health Watch (Healthy Home Audit https://www.ehw.org/healthy-home-audit/)
45668465|NCT03916237|Other|Home remediation|Low level home remediation according to previously established protocol (Kercsmar CM, Dearborn DG, Schluchter M, et al. Reduction in asthma morbidity in children as a result of home remediation aimed at moisture sources. Environ Health Perspect. 2006;114(10):1574-80)
45668466|NCT03916237|Other|Referral to Medical Legal Partnership|Medical Legal Partnership referral as described by the National Center for Medical Legal partnerships and others (Beck AF, Identifying and treating a substandard housing cluster using a medical-legal partnership. Pediatrics. 2012;130(5):831-838)
45668467|NCT03916237|Other|Regular School Based Health Asthma Care|Regular care in the School Health Program
45668468|NCT04829071|Behavioral|Explicit motor learning|Participants will be provided with visual feedback of their right and left step lengths on a screen in front of a treadmill.
45668469|NCT04829071|Behavioral|Implicit motor learning|Participants will walk on a treadmill that drives their right and left legs to move at two different speeds.
45825654|NCT02450591|Other|Local Therapies|Definitive local therapies include surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy
45825655|NCT01094561|Drug|Synthetic Human Secretin|Subjects will each undergo a Secretin-Enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and a Secretin-Enhanced Endoscopic Ultrasound (S-EUS) evaluation, at a dose of 0.2 ucg/kg per exam. Synthetic Human Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
45968634|NCT04659850|Other|low fat, high AGE milkshake|low fat, high AGE milkshake given after an overnight fast
45968635|NCT04659850|Other|high fat, low AGE|high fat, low AGE milkshake given after an overnight fast
45968636|NCT04659850|Other|high fat, high AGE milkshake|high fat, high AGE milkshake given after an overnight fast
45968637|NCT00241488|Drug|Rosuvastatin|
45968638|NCT04659460|Device|Remote Ischemic Conditioning|RIC interventions will be applied to the upper extremity calibrated to induce four, ten-minute cycles of five-minutes-ischemia and five-minutes-perfusion for a total of 20 cumulative minutes of limb ischemia, at a pressure of 250 mmHg.
45968639|NCT04659343|Drug|Medical treatment for metastatic renal cell carcinoma|Medical treatment for metastatic renal cell carcinoma with axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, tivozanib, ipilimumab and nivolumab.
45825656|NCT01094561|Procedure|Secretin-Enhanced Magnetic Resonance Cholangiopancreatography|
45825657|NCT01094561|Procedure|Secretin-Enhanced Endoscopic Ultrasound|
45825658|NCT01074437|Drug|Prednisolone (Corticosteroid)|Oral liquid prednisolone. Dose: 1-2mg/kg/day for 7 days, and then dose will be slowly reduced and then stopped after 3 weeks.
45968640|NCT04659694|Other|Wellness programme provided by Oomph! Wellness company|The Oomph! wellness programme empowers older adults to lead a full life for life. It focuses on building an individual-centred programme that consists of a varied exercise and activity plans including days out. All of these, aims in improving the physical and psychosocial wellness in older adults. This intervention is a three day training session for care home staff to understand and learn how to facilitate care activities within their care home.
45968641|NCT00412178|Device|telecommunication based glucose monitoring system|
45668470|NCT03876457|Device|Endovascular Thrombectomy|Patients randomized to endovascular thrombectomy arm will receive thrombectomy plus medical management. They will be treated with thrombectomy devices (stent-retrievers or aspiration devices) currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke within 24 hours of symptom onset. The devices which will be used are FDA-approved stent retrievers: the Trevo Retriever, the Solitaire Revascularization Device, EmboTrap Revascularization Device and Tigertriever Revascularization Device; and/or the aspiration devices approved by the FDA (e.g. MicroVention SOFIA Catheter, and the Penumbra thrombectomy system). The choice of thrombectomy method, primary approach/technique, whether primary aspiration or primary stent-retriever with or without aspiration, will be left up to the interventionalist, with any of the FDA-approved devices approved in the study protocol or a combination of them.
45968642|NCT04659499|Drug|Nab-paclitaxel in combination with pyrotinib|Nab-paclitaxel I.V. 260mg/m2 every 3 weeks for 12 weeks plus pyrotinib oral 240mg daily for one year
45825659|NCT01074437|Drug|Propranolol|Oral liquid propranolol will be dosed Oral liquid propranolol will be dosed at 2 mg/kg/day.
45668471|NCT03876457|Other|Medical Management|Patients will receive standard AHA guideline-directed medical therapy, which will include IV thrombolytic therapy available for use according to practice guidelines in patients presenting within the first 3 hours from last-seen-normal and meeting other FDA label criteria, or up to 4.5 hours from last-seen-normal and meeting other AHA guidelines. For non-thrombolysis treated patients, this will include aspirin 325 mg on day 1 followed by aspirin 81 mg or 325 mg thereafter, which will be determined by treating physician and standard deep venous thrombosis prevention therapy. Intravenous anticoagulation and dual anti-platelet therapy will be discouraged without clear documented reasoning. Post-thrombolysis patients will be treated based on standard study site protocols for these patients.
45668472|NCT04193917|Diagnostic Test|Conjunctival swab|A conjunctival swab of both eyes will be taken at the same time together with an extensive questionnaire.
45668473|NCT04828681|Diagnostic Test|Cardiac magnetic resonance imaging|Cardiac magnetic resonance imaging was performed 5.0 ± 5.8 days after the primary PCI. MVO, infarct size, and myocardial salvage index were quantitatively assessed in CMR.
45668474|NCT04828369|Procedure|EUS-guided coil embolization combined with endoscopic cyanoacrylate injection|(1) Standard diagnostic endoscopy was first performed. Fundal varices were assessed using the classification of Sarin's. (2) intraluminal water filling of the gastric fundus to use EUS to assess the anatomy of gastric varices, observe the blood flow, scan the portal venous system, left renal vein, confirm the location of the shunt, and measure the diameter of the shunt. (3) Punctured the gastric fundal variceal vein at the lower esophagus near the cardia and placed the coil into the shunt and immediately injected with sclerosant and cyanoacrylate under the guidance of EUS. (4) Sclerosant and cyanoacrylate were injected into the gastric fundal varices by a sandwich method (cyanoacrylate, sclerosant and cyanoacrylate) via endoscope. (5) After the injection, use color Doppler ultrasound to observe the blood flow in the variceal veins to evaluate the embolization effect.
45825660|NCT01074437|Drug|Placebo|Liquid placebo will be given during the two month treatment trial.
45825661|NCT03807245|Biological|GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
45825662|NCT03807245|Biological|Placebo GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
45825663|NCT03807245|Biological|Placebo GBS-NN/NN2 with Alhydrogel® 50|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
45825664|NCT03807245|Biological|GBS-NN/NN2 with Alhydrogel® 50|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
45825665|NCT02461355|Behavioral|Aphasia therapy|Aphasia therapy using a computerized scripting program
45825666|NCT02461355|Device|Anodal tDCS|Anodal transcranial direct current stimulation using the Chattanooga Ionto device
45825667|NCT02461355|Device|Sham tDCS|Sham transcranial direct current stimulation using the Chattanooga Ionto device
45825668|NCT02410577|Drug|89Zr-J591|The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.
45968643|NCT00245349|Procedure|F-18 Fluorothymidine|
45968644|NCT04659304|Drug|Allocetra-OTS|Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.
46080724|NCT05887557|Other|Drop-In Multidisciplinary HIV Care|Each site will independently implement a drop-in multidisciplinary site-based HIV care model. Core intervention features include drop-in care (no appointments), panel management to review clinical progress for all referred patients, and case management. Each site may include adaptations to the care model determined during Aim 1 formative work.
45668475|NCT04828369|Procedure|balloon-occluded retrograde transvenous obliteration|(1)A balloon occlusive catheter was inserted into the shunt via the right femoral vein. (2)Investigators performed angiography to evaluate the size and location of GV and the shunt during balloon occlusion. Shunt was occluded by Fogarty balloon. The diameter of the balloon was chosen according to the diameter of shunt. (3)Then investigators injected sclerosant into the portosystemic shunt. (4)Finally, the balloon left in place for 24 hours was gradually deflated when complete occlusion of blood flow of the target shunt was achieved.
45968645|NCT04659655|Procedure|automated annular suturing|RAM® Automated Suturing Technology. The RAM® DEVICE and SEW-EASY® DEVICE are automated suturing devices indicated for use in the approximation of soft tissue and prosthetic materials when used in conjunction with RAM® COR-SUTURE® QUICK LOAD® surgical suture. Devices will be used for the approximation of respective replacement valves during surgical aortic or mitral valve replacement as described in the study protocol. Cases may include use of the RAM® RING/RAM® RACK devices for suture management and the Aortic Root Retractor (ARR) with delivery device.
45968646|NCT00412256|Drug|Omegaven (10% fish-oil emulsion; Fresenius-Kabi)|
45968647|NCT04649320|Other|questionnaire|"13-item questionnaire about cancer patient's distress and everyday life,~EORTC-QLQ-C30"
45825669|NCT02410577|Device|PET/CT Scan|
45825670|NCT02410577|Device|MRI|
45668476|NCT04408729|Other|PrEP My Way|"Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, and 6 via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 6 and as needed (e.g., treatment for positive tests).~This intervention aims to increase adherence/persistence on PrEP. We hypothesize that removing the structural barriers and stigma associated with going to the clinic, women may be more likely to continue on PrEP."
45825671|NCT02410577|Other|Blood draw|Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection.
45668477|NCT05323591|Drug|Filgotinib|Tablets are administered in accordance with the product label
45825672|NCT01066637|Drug|[18F](+/-)NOS|Injection of radiotracer [18F](+/-)NOS for PET imaging and kinetic data analysis
45825673|NCT03796013|Drug|Entrectinib Form A|Participants will receive a single oral dose of entrectinib form A under fasted conditions.
45825674|NCT03796013|Drug|Entrectinib Form C|Participants will receive a single oral dose of entrectinib form C under fasted conditions.
45825675|NCT02399111|Device|Prevena Incision Management System|The PIMS unit is a single patient use, battery-powered, disposable unit that delivers continuous negative 125 mmHg pressure to the closed surgical incision for a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister. For the purposes of this clinical investigation, canisters can be replaced as often as is needed. A carrying case is also provided with the therapy unit, to allow for patient mobility during the therapy period.
45825676|NCT03793751|Drug|Dexmedetomidine Injection|Dexmedetomidine Injection at a dose of 1 mcg/kg over 10 min, after Spinal Anaesthesia and before start of surgery, followed by a continuous infusion at a rate of 0.4 mcg/kg/h until the end of surgery.
45968648|NCT00241527|Drug|Esomeprazole|
45968649|NCT04649086|Other|Rehabilitation by Eccentric exercises|Participants will perform 24 exercises sessions (30 minutes) with cycloergometer in eccentric mode (while resisting against self-paced pedaling), inducing a greater muscular hypertrophy as compared with concentric mode, the mechanical stimulation being 3 to 4 times greater at the same level metabolic stimulation.
45825677|NCT01030757|Radiation|Tomotherapy treatment|"A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days~Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours~Dose will be prescribed to the isodose line which covers at least 90% of the PTV~Dose homogeneity +/- 5%"
45825678|NCT02351063|Drug|Changes of heart failure medications|Changes in dosage of existing medications or introduction of new medications to improve heart failure condition.
45825679|NCT01016561|Radiation|intracavitary balloon brachytherapy|
45825680|NCT01016561|Radiation|external beam radiation therapy|
45825681|NCT01016561|Radiation|intensity-modulated radiation therapy|
45825682|NCT01016561|Radiation|radiation therapy treatment planning/simulation|
45825683|NCT01016561|Radiation|3-dimensional conformal radiation therapy|
45825684|NCT01016561|Drug|Cisplatin|
45825685|NCT01009931|Drug|12-O-tetradecanoylphorbol-13-acetate|The initial dose of TPA will be 1 mg/week x 3 weeks (Day 1, 8, 15). Up to 6 cycles.
45825686|NCT01009931|Drug|Dexamethasone|Dexamethasone 10 mg PO qid will start 24h prior to TPA and continue for 24h after TPA x 3 weeks. Up to 6 cycles.
45825687|NCT01009931|Drug|Choline magnesium trisalicylate|"Choline magnesium trisalicylate 1500 mg PO TID will begin 24h prior to TPA and continue for 24h post TPA x 3 weeks.~Up to 6 cycles."
45825688|NCT03792191|Radiation|Lumbar Spinal Ultrasonography|Ultrasonography of the lumbar spines using an 8-2 MHz curved array transducer. Identification of the intervertebral space with the best image. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
45968650|NCT04649086|Other|Rehabilitation by Concentric exercises|The control group (concentric) will perform exercise training at an intensity of 60% of the reserve heart rate determined during an initial cardiorespiratory test. The power will be adjusted weekly to stay within the target heart rate range.
45968651|NCT04648735|Other|driving evaluation and practice|"The participants completed the actual driving with a licensed driving instructor on the passenger side in the car and with a dual-control, automatic-transmission car.~Each participant completed three runs of the same route. The first twos were practices to familiarize themselves with the course. The driving instructor graded them on the third run. Each trial took about 10 minutes. The participants were scored according to governmental driver test guidelines. Scoring on individual driving maneuver is weighted. Depending on the type of error, 8, 16 or 32 points were deducted from 100, for example, 32 points for getting too close to pedestrian lane, running a red light or railroad crossing, and 8 points for stopping in S-curve forward and backward. 70 or above is considered as a pass. The occupational therapists in the backseat recorded driving behaviors, including whether the driver checked rear and side mirrors, excessive sweating, distractibility, number of adjustments, etc."
45968652|NCT04648657|Device|Lung Ultrasound|Echography of Lungs based on artifacts study
45968653|NCT04648657|Device|Electric impedance tomography|Low alternating electrical currents (usually <5 milliampere at 50-80 kHz) applied through different pair of electrodes on thorax
45968654|NCT00217217|Device|Echo-Planar Magnetic Resonance Imaging (EP-MRSI)|variable-setting low-frequency MRI
45968655|NCT04648813|Drug|tiotropium bromide monohydrate (Spiriva Respimat)|administered daily, 2 inhalations/5mcg per dose for a total of 8 doses
45968656|NCT04648813|Drug|matching placebo|administered daily, 2 inhalations per dose for a total of 8 doses
45825689|NCT03792191|Radiation|Sham Ultrasound Procedure|Moving the ultrasound probe on the patient's back with the machine in the freeze position.
45968657|NCT04648462|Other|ProTRAIT|The participants are seen at the outpatient clinic by a physician, physician assistant or trial nurse at standard follow-up times at 2.5, 5, 7.5 and 10 years after radiotherapy.
45968658|NCT00245388|Drug|Muraglitazar|
45968659|NCT04648384|Dietary Supplement|Blend Protein Supplementation|Protein supplementation using 20 grams of whey protein or casein mix. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition
45968660|NCT04648384|Dietary Supplement|Placebo Supplementation|Placebo supplementation using 20 grams of Maltodextrin. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition
45968661|NCT04648384|Other|Resistance Exercise|10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise
45968662|NCT04648423|Drug|Sodium Oxybate|solution for oral administration
45968663|NCT04648423|Drug|Placebo|solution for oral administration
45968664|NCT00558181|Drug|rituximab, methylprednisolone|Subjects will receive up-to 6 courses of IV infusion of Methylprednisolone and Rituximab every 21 day.
45968665|NCT00217256|Device|Percutaneous Coronary Stenting|Endeavor Drug Eluting Stent
45968666|NCT00217256|Device|Percutaneous Coronary Stenting|Cypher Drug Eluting Stent
45968667|NCT00241566|Device|implantation of stimulator|
45968668|NCT00558220|Procedure|immunotherapy|"Given together with induction chemotherapy:~Rituximab - 375 mg/m2 iv every 3 weeks, 4-6 doses"
45968669|NCT00558220|Procedure|Induction treatment part 1|"cyclophosphamide 3000 mg/m2 iv every 3 weeks, 3 cycles vincristin 2 mg iv every 3 weeks, 3 cycles doxorubicin 75 mg/m2 iv every 3 weeks, 3 cycles Prednisolone 300 mg/m2 divided into five days po every 3 weeks, 3 cycles pegfilgrastim 6 mg sc every 3 weeks.~3 cycles consisting of combination treatment of above mentioned drugs are given."
45968670|NCT00558220|Procedure|Induction treatment part 2 with PBPC collection|"Starts three weeks after last cycle of Induction part 1.~Etoposide 240 mg/m2 divided into equal doses for four days, together with methylprednisolone 2000 mg divided into equal doses for four days, together with cisplatin 100 mg/m2 divided into equal doses for four days, and together with cytarabine 2000 mg/m2 iv one dose on 4th day of treatment. Filgrastim 10-12 ug/kg from day five after start of chemotherapy untill stem cell collection.~Peripheral blood progenitor cell collection (PBPC) is started when CD34 positive cells are >20/cubic milimeter of blood and continued untill 5 million of CD34 positive cells are collected from peripheral blood."
45968671|NCT00558220|Procedure|Induction treatment part 3|"Part 3 of induction treatment is given approximately one week after the end of Part 2.~Etoposide 240 mg/m2 divided into equal doses for four days, methylprednisolone 2000 mg divided into equal doses for four days, cisplatin 100 mg/m2 divided into equal doses for four days, cytarabine 2000 mg/m2 iv one dose on day 4 of chemotherapy and pegfilgrastim 6 mg on day five of chemotherapy are given twice three weeks apart."
45825690|NCT03792191|Procedure|Conventional Landmark Palpation|Conventional palpation of the anatomical landmarks. The line crossing the iliac crests (Tuffier line) is assumed to cross the spine at L4 spinous process or L3-L4 intervertebral space. Identification of the widest intervertebral space. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
45825691|NCT03792191|Procedure|Spinal Anesthesia|Spinal anesthesia using a 25- or 22-gauge spinal needle
45825692|NCT03792191|Drug|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
45825693|NCT03792191|Drug|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
45825694|NCT03791489|Device|ClariFix|The ClariFix™ device (K162608) is an FDA 510(k) cleared Class II cryosurgical tool indicated for the destruction of unwanted tissue during surgical procedures, including in adults with chronic rhinitis.
45825695|NCT03790865|Drug|Livoletide|Daily subcutaneous injection
45968672|NCT00558220|Procedure|Consolidation treatment part 1: HD-chemotherapy with ASCT|"Consolidation treatment Part 1 starts 4-8 weeks after the second cycle of Induction treatment Part 3.~High dose chemotherapy (HD-chemotherapy) consists of:~BCNU 300 mg/m2 is given on day 1, etoposide 800 mg/m2 divided into four equal doses is given on day 2-5, cytarabine 1600 mg/m2 divided into eight equal doses is given on day 2-5, melphalan 140 mg/m2 is given on day 6.~On day 7, collected stem cells from peripheral blood (see Induction treatment part 1) are infused back to the patient. This is called autologous transplantation (ASCT). Filgrastim 5 ug/kg is given from day 14 (start of the chemotherapy being day 1) until neutrophil recovery."
45968673|NCT00558220|Radiation|Consolidation treatment part 2: Radiotherapy|Radiotherapy is started given 4-8 weeks after the autologous transplantation. It is given to patients with initially bulky disease (>10 cm at diagnosis) or to patients with residual disease after Induction treatment part 1-3 and Consolidation treatment part 1. 30-40 Gy are given in 2 Gy fractions over 3-4 weeks.
45968674|NCT04648345|Procedure|Erector spinal plane block|After induction of general anesthesia, pre-operative ultrasound-guided bilateral erector spinae plane block/ vertebral side block will be performed in the ESPB/VSB group. Local block will be performed at the surgical incisions after the surgery under general anesthesia. All the intervention will be performed without patients' awareness.
45825696|NCT03790865|Drug|Placebo|Daily subcutaneous injection
45825697|NCT00986999|Drug|rosuvastatin|rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years
45968675|NCT00217295|Drug|Avonex and Topamax|
45968676|NCT04648267|Other|Cast and bolster placement duration|The intervention is increasing the duration of cast and bolster placement on split thickness skin graft sites.
45968677|NCT04648267|Other|Standard of care|This will be standard of care - the patient will have his cast and bolster on for 5-7 days
45968678|NCT00245427|Drug|all macrolide antibiotics|Varies based on antibiotic
45968679|NCT00245427|Drug|all beta-lactam antibiotics|Varies based on antibiotic
46080725|NCT05887557|Other|Mobile HIV Care|Each site will independently implement a mobile care model using site-specific resources. At a minimum, the mobile care team will include a clinical nurse with telemedicine (video visit) consultation with a clinician (MD/NP/PA). Mobile teams will also administer medications (including long-acting ART when available) and collect laboratory specimens (e.g. HIV viral loads)
46080726|NCT05887557|Other|Staged Care|Clinical decision rules to escalate/de-escalate care intensity will be finalized developed during Aim 1 formative work, though will be based on a combination of clinical assessment and patient preference.
46080727|NCT05887557|Other|Identify and prepare champions at referral sites|Identify implementation champions at each referral site. Champions will receive marketing materials to promote uptake of clinical referrals to a drop-in/mobile care site by referral site providers/staff. This strategy is aimed at improving referring provider confidence in the value of referral to the care model, reduce perceived referral complexity/improve provider capability to refer, and provide positive peer pressure to promote referrals.
45825698|NCT02345369|Device|Locked Set Screw|Fixation of hip fracture with intramedullary hip screw with locking of the set screw
45825699|NCT02345369|Device|Unlocked Set Screw|Fixation of hip fracture with intramedullary hip screw without locking of the set screw
45825700|NCT03784001|Behavioral|Gratitude + No Expectations Intervention|Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a short gratitude list of up to five items. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest
45825701|NCT03784001|Behavioral|Gratitude + Expectations Intervention|"Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a short gratitude list of up to five items. Participants will have a statement at the top of their Google form about the benefits of gratitude. Examples of these statements are: Practicing gratitude may increase social connectedness and Cultivating gratitude was shown to improve school satisfaction in a UK sample of students. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest"
45825702|NCT03784001|Behavioral|Events Control Intervention|Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a list of up to five items about events from their day. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest.
45825703|NCT03781037|Behavioral|GIVE Module|The GIVE Module is a brief cognitive behavioral intervention targeting youths' beliefs that they are a burden or drain on others. It consists of two sessions embedded within a larger CBT protocol for anxiety or depression.
45968680|NCT00558298|Drug|risperidone|
45968681|NCT04647955|Drug|Itopride|Itopride is a D2 antagonist and cholinesterase inhibitor with prokinetic effects on gastric motility used to treat functional dyspepsia. Patients were treated for 8 weeks.
45968682|NCT04647955|Drug|Placebo|Patients were treated for 8 weeks.
45968683|NCT04647799|Device|smartphone|Samsung A 71
45968684|NCT00217334|Behavioral|Volunteer-led pharmacy sessions with feedback to physicians|
45968685|NCT00245505|Drug|Mesalazine (Mesalamine)|Pentasa (mesalazine) sachets 2 g morning + 2 g evening during 12 weeks treatment
45968686|NCT04647838|Drug|Tepotinib|Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
45968687|NCT00245544|Drug|MK0759|
45968688|NCT00217373|Biological|Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine|Given SC
46080728|NCT05887557|Other|Audit and feedback at referral sites|Investigators will provide monthly reports to implementation champions at each referral site on aggregate number of referrals and the success of referrals (proportion linking to care). This strategy is aimed at improving perceived value of the intervention and increasing provider motivation to refer.
45968689|NCT00217373|Biological|Recombinant Interferon Alfa-2b|Given SC
46080729|NCT05887557|Other|Build a coalition among referral and clinical sites|Investigators will facilitate formation of a coalition of referral and clinic sites to improve cross-site collaboration and promote positive peer pressure to improve intra-site communication and increase referrals.
46080730|NCT05887557|Other|Assess for readiness and identify barriers|Investigators will conduct patient in-depth interviews and clinical team focus group discussions to assess barriers to implementation of the clinical intervention. Findings from interviews and focus group discussions will inform site-specific implementation plans and adaptation of the intervention.
45825704|NCT02319005|Drug|Revusiran (ALN-TTRSC)|
45825705|NCT02319005|Drug|Sterile Normal Saline (0.9% NaCl)|
45968690|NCT00217373|Biological|Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine|Given SC
45668478|NCT04408105|Behavioral|Primary Care Provider Survey|To assess PCP demographics, attitudes, and perceived barriers to BE screening, we have developed a PCP survey using a theoretical model of physician behavior based on Social Cognitive Theory and the Theory of Reasoned Action. This approach has proven effective in colorectal cancer and hepatocellular carcinoma screening. This model includes domains of provider background and experience, screening practices, perceptions of screening, physician influences, and practice environment and practice patterns. To assess PCP knowledge of BE screening, we have designed 9 clinical vignettes that will categorize provider responses into under-, appropriate, and over-use of BE screening. Survey questions and vignettes have been adapted from earlier validated surveys. Prior to distribution, the survey and vignettes will be pretested and refined based on a cognitive interview about the survey among a convenience sample of 10 PCPs.
45668479|NCT04408105|Behavioral|Gastroenterologist Survey|To assess GI demographics, attitudes, and perceived barriers to BE screening, we have developed a GI survey using a theoretical model of physician behavior based on Social Cognitive Theory and the Theory of Reasoned Action. This approach has proven effective in colorectal cancer and hepatocellular carcinoma screening. This model includes domains of provider background and experience, screening practices, perceptions of screening, physician influences, and practice environment and practice patterns. To assess GI knowledge of BE screening, we have designed 9 clinical vignettes that will categorize provider responses into under-, appropriate, and over-use of BE screening. Survey questions and vignettes have been adapted from earlier validated surveys. Prior to distribution, the survey and vignettes will be pretested and refined based on a cognitive interview about the survey among a convenience sample of 10 GIs.
45668480|NCT04408105|Behavioral|Patient Survey|To assess patient knowledge, attitudes, and barriers to completion of BE screening, we will use a theoretical model of patient behavior on the Health Behavior Framework to guide selection of relevant variables for survey development including 4 domains: knowledge about BE and EAC, potential barriers to BE screening completion, patient attitudes and demographic information. Prior to distribution, the survey will be refined and pretested among a sample of 10 patients with each participant completing a cognitive interview prior to distribution.
45668481|NCT04402489|Drug|Placebo|Placebo
45668482|NCT04402489|Drug|MT-7117 Low Dose|MT-7117 Low Dose
45668483|NCT04402489|Drug|MT-7117 High Dose|MT-7117 High Dose
45668484|NCT04827199|Device|Artificial Urinary Sphincter implantation|"Device preparation (recharge, settings, pairing) Patient preparation Calibration procedure (to verify the device is in full working prior to implantation)~Implantation procedure which includes:~Perineal approach and bulbar urethral dissection~Inguinal approach~Cuff implantation around the urethra~Transmission cable passing~Surgery test procedure~Implantation of the Control Unit~Closure of the inguinal incision~Closure of the perineal incision~Implant disabled mode activation"
45825706|NCT03784079|Drug|GSK3640254|GSK3640254 will be available with dosing strengths of 5 mg, 20 mg, and 100 mg to be administered as an oral capsule along with 240 mL of water.
45825707|NCT03784079|Drug|Placebo matching GSK3640254 Mesylate salt|Placebo to match GSK3640254 Mesylate salt will be given as an oral capsule along with 240 mL of water
45825708|NCT00983645|Drug|Prograf|Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID
45825709|NCT00983645|Drug|Neoral|Cyclosporine (Neoral) starting dose 3mg/kg PO BID
45825710|NCT02308475|Device|Somatom Force CT Scanner|Dynamic CT perfusion of the heart
45825711|NCT02234687|Drug|Pomaglumetad Methionil 160mg|Pomaglumetad Methionil 160mg, one dose, one time
45825712|NCT02234687|Drug|Pomaglumetad Methionil 40mg|Pomaglumetad Methionil 40mg, one dose, one time
45968691|NCT00217373|Biological|Sargramostim|Given SC
45968692|NCT04647370|Procedure|remote ischemic preconditioning|3 cycles of 5-minutes inflation of a blood pressure cuff to 200mmHg (or at least to a pressure 50mm Hg higher than the systolic arterial pressure) to one upper arm, followed by5-minutes reperfusion with the cuff deflated
46080731|NCT05887557|Other|Promote adaptability|During a co-design workshop among drop-in/mobile care site teams and site-specific meetings, the study team will collectively finalize core clinical intervention components and outline site-specific adaptations (i.e. adaptable periphery of clinical intervention).
46080732|NCT05887557|Other|Develop a formal implementation blueprint|With each drop-in/mobile care team, develop site-specific implementation plan that includes defining care team and leadership structure, clinic workflow, implementation timeline, and progress measures. This process, and the resulting blueprint, will incorporate site-specific barriers and facilitators to implementation.
45825713|NCT02234687|Drug|Placebo|Placebo, one dose, one time
45825714|NCT00978419|Drug|Rosuvastatin|Loading dose 40mg by mouth first day, then 20 mg by mouth for up to 27 days
45825715|NCT00978419|Drug|Placebo|Placebo administered every day for up to 28 days
45825716|NCT00957827|Drug|keflex|keflex 500 mg BID 5 days
45825717|NCT00957827|Drug|placebo|placebo BID for five days
45968693|NCT04647370|Procedure|Sham remote ischemic preconditioning|3cycles of upper limb pseudo ischemia (low pressure, 5-minutes blood pressure cuff inflation to a pressure of 20 mm Hg and 5-minutes cuff deflation).
45968694|NCT04646980|Dietary Supplement|Biobran/MGN-3|Biobran/MGN3 is defined by the Medicines and Healthcare products Regulatory Agency (MHRA) as a food supplement. Biobran/MGN3 is manufactured by hydrolyzing rice bran with the enzymatic extract of medicinal Shiitake mushrooms. Enzyme hydrolysis of rice bran produces arabinoxylane, a hemi-cellulose compound, which constitutes the active ingredient of biobran/MGN3.
45968695|NCT04646980|Other|Placebo|Placebo, with same appearance and taste as Biobran/MGN-3, was given to control subjects at a dose of 500 mg everyday for 3 months
45968696|NCT04646863|Radiation|laser therapy|performed by MLS® Laser Therapy (ASA Srl, Vicenza, Italy). It is designed to synchronize between two modules. One is emitting at 905 nm, with peak optical power = 25 W; each pulse is composed of a pulse train (single pulse width = 100 ns, maximum frequency 90 kHz). The frequency of the pulse trains varied between 1 and 2000 Hz. The other one is emitting at 808 nm in a continuous mode (power 1.1 W) or pulsed mode (pulses repetition rate 1-2000 Hz).
45968697|NCT04646863|Other|exercise|"The exercises were applied on a floor mat to achieve a full body workout with 10 repetitions for each exercise and rest for one minute before beginning the next exercise to avoid muscle fatigue as the following.~Modified Hundred~Modified Single Leg Stretch~One Leg Circle~Modified Scissors"
45968698|NCT04646863|Other|combination|laser therapy + Pilates exercises
46080733|NCT05887557|Other|Develop educational materials; conduct ongoing training|Compile a manual that includes detailed description of core intervention features, planned local adaptations, and implementation guidance. We will conduct site-specific meetings to provide training on this manual. We will also conduct regular (at least monthly) meetings between the study team and the clinic site to provide technical assistance and coaching.
45825718|NCT00962429|Drug|lipoic acid|Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
45825719|NCT00950183|Device|Iceman® Cold Therapy unit (djOrtho)|postoperative cold therapy
45825720|NCT00950183|Other|Ice|postoperative cold therapy
45825721|NCT00949403|Drug|Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate|injection of C-11 Palmitate and C-11 Acetate during PET/CT to determine Liver metabolism
45825722|NCT03767153|Device|Venus Viva|"The Venus Viva™ fractional RF applicator has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.~Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits."
45825723|NCT03766373|Combination Product|Drug: OP0201 20mg|OP0201
45825724|NCT03766373|Combination Product|Drug: Placebo 0mg|Placebo
45825725|NCT02110277|Device|PAI/ultrasound Diagnostic Group|These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
45825726|NCT03760913|Drug|OLP-1002 (Test): Part A, Single Ascending Dose|Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 µg, 3 µg, 6 µg, 12 µg, 20 µg, 40 μg, 80 μg, 160 μg
45825727|NCT03760913|Drug|OLP-1002 (Test): Part B, Multiple Ascending Dose|Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg
45825728|NCT03760913|Other|Placebo: Placebo Part A, Single Ascending Dose|Subcutaneous Injection: Placebo
45825729|NCT03760913|Other|Placebo: Placebo Part B, Multiple Ascending Dose|Subcutaneous Injection: Placebo x 5
45825730|NCT00920309|Drug|Rapamycin|The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml.
45825731|NCT00920309|Other|Standard of Care-Placebo|
45825732|NCT00928499|Device|Interstim (SNS)|Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy
45825733|NCT02109809|Radiation|total nodal irradiation|Undergo TLI
45825734|NCT02109809|Other|laboratory biomarker analysis|Correlative studies
45825735|NCT02109809|Other|questionnaire administration|Ancillary studies
45825736|NCT02075411|Drug|bupivacaine|"Adolescent males receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Males Single shot peripheral nerve block"
45968699|NCT04647292|Drug|anti-hypertensive|"The recommended target SBP will be 115-125 mmHg in the intervention arm. A medication algorithm based on the SPRINT trial protocol will be provided. The final choice and dose of antihypertensive treatment(s) will be at the discretion of the treating clinicians. If no contra-indications, indapamide or other thiazide diuretic and/or angiotensin-converting enzyme (ACE) inhibitor (perindopril or other) will be encouraged as initial therapy, with long-acting calcium-channel antagonists (eg.amlodipine) encouraged as third-line therapy.~At scheduled face-to-face or remote follow-up, patients will have their home blood pressure monitoring diary reviewed by the study team. If SBP is out of the allocated target range, a prescription to titrate (up or down) antihypertensive medication will be given to the patient."
45825737|NCT02075411|Drug|bupivacaine|"Adolescent females receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Females Single shot peripheral nerve block"
45825738|NCT02075411|Device|continuous perineural infusion catheter|Adolescent males receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
45825739|NCT02075411|Device|continuous perineural infusion catheter|Adolescent females receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
45668485|NCT04399369|Device|SDF|38% silver diamine fluoride solution
45668486|NCT04399369|Device|NaF|5% sodium fluoride varnish
45668487|NCT04840147|Device|JointRep®|JointRep® is a medical device based on a thermogel polymer (Chitosan) for the treatment of chondral lesions, which consists of an injectable aqueous composition that forms a solid and sticky hydrogel in situ within cartilage defect(s). JointRep® is composed of an injectable thermo-gelling aqueous composition. It is used in conjunction with a Bone Marrow Stimulation type of procedure like Microfracture.
45668488|NCT04840147|Procedure|Microfracture|Microfracture is a bone marrow stimulation type of procedure where after debridement of the damaged chondral tissue within the lesion, obtention of stable vertical margins and curettage of the entire calcified layer, multiple holes are created with a variety of instruments (awls, picks, microdills, nanofracture) to establish a communication with the subchondral bone to create a blood clot to elicit the natural healing process
45668489|NCT04419415|Dietary Supplement|Breakfast with high protein dairy|High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) for breakfast.
45825740|NCT03753113|Drug|Topical Herbal Solution|Use Topical Herbal Solution every day in scalp hair loss areas for 36 weeks.
45825741|NCT03753113|Drug|Topical Minoxidil 5%|Use Minoxidil 5% solution every day in scalp hair loss areas for 36 weeks.
45825742|NCT02084147|Device|positron emission tomography|Undergo PET
45825743|NCT02084147|Device|computed tomography|Undergo CT
45825744|NCT02084147|Device|magnetic resonance imaging|Undergo MRI
45825745|NCT02067611|Drug|X0002|Parallel Assignment
45825746|NCT02067611|Drug|Placebo|Parallel Assignment
45668490|NCT04419415|Other|Exercise training|Participants will be asked to participate in organized exercise training 3 times per week.
45668491|NCT04419415|Other|Skipping breakfast|Participants will be asked to skip breakfast.
45668492|NCT04880707|Drug|Twin block local anesthetic nerve block using standard dental anesthetic|2% lidocaine with 1:100,000 epinephrine is the standard dental local anesthetic in universal use. This drug will be administered as the Twin block local anesthetic nerve block targeting the branches of the mandibular nerve supplying the temporalis and masseter muscles.
45668493|NCT04880707|Other|Twin block with placebo|Instead of the standard dental anesthetic, sterile normal saline will be delivered using the Twin block injection
45668494|NCT05369221|Device|ReSpace™|All of the subjects will be injected with ReSpace™ hydrogel.
45668495|NCT04826809|Device|N95 mask|Standard 1870 N95 one time use mask
45668496|NCT04826809|Device|Nordell single E-100 layer mask|Nordell mask design using one layer of E-100 fabric plus cotton fabric overlay
45668497|NCT04826809|Device|Nordell double E-100 layer mask|Nordell mask design using two layers of E-100 fabric
45825747|NCT02075021|Drug|Lenalidomide|
45825748|NCT02075021|Drug|nab-paclitaxel|
45825749|NCT02057237|Drug|Mitotane|Mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance every 3rd day by 0.5 g up to a maximal dose of 5.0 g and then adjusted according to blood concentrations monthly and tolerability, up to a maximum of 10g daily
45825750|NCT03752567|Other|Follow up|like group descriptions
45825751|NCT00378677|Drug|Cyclosporine A dry powder inhalation (Drug)|
45825752|NCT03748979|Drug|TAK-925|TAK-925
45825753|NCT03748979|Drug|Placebo|TAK-925 Placebo
45825754|NCT00850421|Drug|Botulinum Toxin Type A|100 Units - Dilution: 25U/ml (4:1 BOTOX/preservative free saline)
45825755|NCT02017379|Drug|Erythromycin|
45825756|NCT02017379|Drug|Metoclopromide|
45968700|NCT00241605|Drug|rosiglitazone/metformin|
45968701|NCT00217412|Drug|vorinostat|Given orally
45968702|NCT00217412|Drug|isotretinoin|Given orally
45968703|NCT04646941|Other|regular treatment|The patients with or without OSA received regular hypoglycemic drugs.
45968704|NCT04646824|Drug|Almonertinib Pemetrexed/Cisplatin|Pemetrexed/Cisplatin Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
45668498|NCT04815109|Other|Encephalography measurement|Encephalography measurement and partially aggravated sedation.
45968705|NCT00217451|Drug|Fosmidomycin-clindamycin|
45968706|NCT04646707|Drug|Erector Spinae (ESP) Block with Lidocaine/Bupivacaine|Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)
45968707|NCT04646707|Drug|Erector Spinae (ESP) Block with placebo|Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline
45968708|NCT04646629|Device|electroacupuncture treatment|"Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at ST36 (Zusanli) and ST37 (Shangjuxu) twice a day for seven days.After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 ~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of treatment."
45968709|NCT04646629|Device|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at ST36 and ST37(nonacupoints located 1 inch beside acupoints, about20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle for the same time as treatment group"
45968710|NCT04646668|Combination Product|E-cigarette and Heat not burn|Current smokers will be randomized to session order and complete a standardized 10-puff bout (5 minutes) followed by a 60-minute ad libitum session with each product (usual brand cigarette, e-cigarette, heat-not-burn).
46080734|NCT05887557|Other|Create a learning collaborative|Create a cross-site learning collaborative with periodic meetings and workshops throughout the study period to facilitate cross-site communication, sharing of best practices and encourage positive peer pressure to support implementation.
45668499|NCT01999335|Drug|Oprozomib|Extended release (ER) tablets administered orally
45668500|NCT01999335|Drug|Pomalidomide|Capsules for oral administration
45668501|NCT01999335|Drug|Dexamethasone|Tablets for oral administration
45668502|NCT01978119|Drug|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
45668503|NCT01978119|Drug|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
45825757|NCT04332263|Other|Neuromuscular Electrical Stimulation - NMES|NMES will be applied through an alternating biphasic current, with a stimulation frequency of 80 Hz and 1 ms pulse duration. Tetanic evoke forces (EF) at a 50% level of a supra-maximal single-pulse peak EF (i.e., 10-12% of a maximal voluntary isometric contraction) will be used. NMES protocol will be performed five times a week, lasting 20 minutes. Muscle fatigue will be evaluated every 5 min of the intervention, and will be used to determine the NMES protocol termination. A 10 % decrease in the single-pulse evoked torque between the evoked force produced pre- and during the NMES protocol will be used to terminate the fatigue protocol.
45825758|NCT01997567|Drug|Ropivacaine|Subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
45825759|NCT01997567|Drug|Placebo|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
45825760|NCT03742973|Drug|Baricitinib|Administered orally.
45968711|NCT00217529|Biological|pegfilgrastim|
45968712|NCT00217529|Drug|carboplatin|
45968713|NCT00217529|Drug|docetaxel|
45968714|NCT00217529|Drug|erlotinib hydrochloride|
45968715|NCT00245661|Drug|Temazepam|
45968716|NCT04646512|Dietary Supplement|Taurine group and exercise and placebo group and exercise|Both groups supplemented with taurine and / or placebo will perform physical training.
45968717|NCT04646512|Other|Physical training with Deep Water Running|There will be a physical training for eight weeks.
45968718|NCT04646317|Drug|Dexmedetomidine injection|Infusion of dexmedetomidine will be prepared in Four syringes of 50ml containing dexmedetomidine in concentration of 1 microgram per millilitre.
45968719|NCT04646317|Drug|Normal Saline|0.9% as placebo
45968720|NCT00217568|Biological|pegfilgrastim|
45968721|NCT00217568|Drug|carboplatin|
45968722|NCT00217568|Drug|docetaxel|
45968723|NCT04646161|Drug|Misoprostol|misoprostol 200 mcg will be given sublingual 2 hrs before mirena iud insertion
45968724|NCT04646122|Device|Optical Coherence Tomography|Optical Coherence Tomography parameters
45968725|NCT04645888|Procedure|Impacted tooth surgery|Surgical extraction of İmpacted tooth
45968726|NCT00241722|Drug|Alvimopan|
45968727|NCT00241722|Drug|Placebo|
45968728|NCT00558337|Drug|levodopa-carbidopa|novel levodopa/carbidopa formulation or a reference levodopa/carbidopa formulation
45968729|NCT04646278|Drug|Hyperemic stimuli|Hyperemic simuli of coronary flow by adenosine or nicorandil injection
46080735|NCT05887531|Other|Prehabilitation|Patients will be included in a prehabilitation program
46080736|NCT05887492|Drug|TNG260|CoREST inhibitor, administered orally
46080737|NCT05887492|Drug|Pembrolizumab|Pembrolizumab, an anti-PD-1 antibody, administered intravenously
45668504|NCT01999179|Drug|Heparin, Low-Molecular-Weight, or direct oral anticoagulants|Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing obtained by the clinical team or either apixaban, rivaroxaban, dabigatran, edoxaban following a catheter related blood clot
45968730|NCT04645849|Biological|Immunomonitoring|"16 patients will be recruited at the end of treatment: an immunoprofiling analysis will be performed out of a blood sample about 1 month, 5 months and 9 months after treatment.~8 patients will be recruited at diagnosis: a immune profile analysis will be performed before the start of treatment. This will give comparative values for the immune system cells and molecules."
45968731|NCT00558376|Drug|polyethylene glycol|Single time 3 liters PEG, 250 cc every 15 minutes the day before colonoscopy
45968732|NCT00558376|Drug|Sodium phosphate|Sodium phosphate 45cc, 2 doses 4 hours apart the day before colonoscopy
45968733|NCT00217646|Drug|Sorafenib Tosylate|Given orally
46080738|NCT05884359|Diagnostic Test|3D Electroanatomical Mapping (NavX)|To utilize 3D mapping as a tool to explore electro-anatomical and electrocardiographic characteristics of the Left Bundle Branch Area. Patients will undergo placement of standard Left Bundle Area pacing leads for routine indications, during the implantation procedure electro-anatomical map of the target area and neighboring tissues will be created. Map characteristics will be analyzed and used intra-operatively to assist with lead placement along with standard pacing metrics and standard X-ray criteria. We plan on prospectively reviewing the data found from 3D mapping the left bundle branch implantation cases.
46080739|NCT05882877|Drug|Rocatinlimab|Subcutaneous (SC) injection
46080740|NCT05882877|Other|Placebo|SC injection
46080741|NCT05882279|Other|No Intervention|This is a non-interventional study.
45668505|NCT01977729|Drug|Sertraline|"Medication will be administered daily using a fixed-flexible strategy beginning at 25mg, titrating to 200mg across 8 wks (i.e., wks 9-17). We expect patients' medication dose will be adjusted upward in 50 mg/day increments if clinician-rated CGI-S anxiety severity is 3 (mild) or greater. The dose will be held or adjusted downward if patients have few anxiety symptoms (CGI-S<3) or impairing Adverse Events. Patients will be maintained at 200mg per day during wks 18-20."
45668506|NCT01977729|Behavioral|Cognitive Behavioral Therapy|Youth are given instructions in each session that they may stop whenever they want and they do not need to attempt the task unless they so desire. Therapists have been carefully and thoroughly trained in providing reassurance and/or crisis treatments if needed. Therapists also have been trained to contact one of the PIs immediately in the event of a crisis.
45668507|NCT01998477|Biological|TIVc|Madin Darby Canine Kidney (MDCK) cell culture derived subunit influenza vaccine TIVc contained the purified viral envelope glycoproteins, hemagglutinin (HA) and neuraminidase (NA) derived from 3 strains (including HA for each strain [A/H1N1-like, A/H3N2-like, and B-like]) intramuscular (IM) injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere
45668508|NCT01998477|Biological|TIV|A conventional egg derived subunit influenza vaccine (TIV) contained the purified viral envelope-glycoproteins, HA and NA derived from 3 strains (including HA for each strain [A/ H1N1-like, A/H3N2-like, and B-like]) IM injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere.
45668509|NCT01998399|Drug|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
45668510|NCT01998399|Drug|Placebo|Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
45668511|NCT01781572|Drug|LEE011|LEE011 will be administered orally once daily
45668512|NCT01781572|Drug|MEK162|MEK162 will be administered orally twice daily
45825761|NCT03742973|Drug|Placebo|Administered orally.
45825762|NCT03742427|Diagnostic Test|ultrasonography|optic nerve sheath diameter measurement will be done by ultrasonography on both eyes
45825763|NCT03741725|Other|Pay-it-forward|Participants will be offered a gift of free gonorrhea and chlamydia testing made available by donations from previous testers, and asked whether they would like to donate money (pay-it-forward) for future men to receive the same option.
45825764|NCT03741725|Other|Pay-what-you-want|Participants will be offered gonorrhoea and chlamydia testing and told that they can decide and pay any desired amount after receiving the test.
45825765|NCT00825227|Drug|Armodafinil 150 mg/day|"150 mg/day armodafinil~concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents"
45968734|NCT00558454|Drug|Iron|Ferrous succinate mixture
45968735|NCT00558493|Drug|Clevudine|clevudine 30 mg qd for 24 seeks
45668513|NCT01977651|Drug|Enzalutamide|Participants received 4 capsules (40 mg each) of enzalutamide orally once a day, for a total daily dose of 160 mg. Treatment was given with or without food and as close as possible to the same time each day.
45968736|NCT04645615|Device|Cardioblate surgical ablation system|This investigation is a prospective, non-randomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
45968737|NCT04645615|Procedure|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
45968738|NCT00217763|Drug|3APS|
46080742|NCT05881811|Drug|HSK16149，probenecid, cimetidine|40mg HSK16149 single dose, fasted; 500mg probenecid QID from D1~D4 200mg cimetidine QID from D1~D4
46080743|NCT05880628|Other|datas of medical record.|"Analysis datas of medical record:~Feasibility of the technique~Safety of the technique~Efficacity (sclerose of the lesion)"
46080744|NCT05880602|Dietary Supplement|Nettle and Cranberry complex capsules|A specific capsule product, containing nettle and cranberry complex will be given to participants for oral intake for 8 weeks.
46080745|NCT05880602|Dietary Supplement|Placebo(starch)|A specific capsule product, containing starch will be given to participants for oral intake for 8 weeks.
45968739|NCT04645459|Other|low phosphorus meals|All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.
45968740|NCT04645459|Other|control meals|All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.
45968741|NCT00558532|Procedure|Bariatric Surgery|Open roux-en-Y gastric bypass, open banded sleeve gastrectomy, abdominoplasty, other abdominal surgery
45968742|NCT00558649|Biological|Flu Vaccine (FLUARIX®)|Influenza Virus Vaccine, FLUARIX®, 2006-2007 Formula
45968743|NCT00558727|Drug|RH-1|1.5 mg/m2 to 12 mg/m2, depending on protocol cohort, administered via intravenous (IV) infusion over 3 hours once every 21 days.
45968744|NCT00217802|Behavioral|six-session telephone counseling program|
45968745|NCT04645225|Device|. MEFV genetic testing|For mutation analysis, 2 ml blood will be with drawn from both patient and control groups in order to obtain genomic DNA. Extraction of DNA molecule from peripheral blood lymphocytes will be done using standard procedures, then amplification of MEFV gene will be done by polymerase chain reaction(PCR). Reversed hybridization technique will be used for identification of MEFV gene mutation.
45968746|NCT00558805|Behavioral|FISP + Usual Care|
45968747|NCT00558805|Behavioral|Usual Care|
45968748|NCT04645303|Drug|hyaluronic acid (20 mg/2 mL)|A1-Pulley infiltration for trigger finger
45968749|NCT04645303|Drug|Triamcinolone acetonide 10mg/ml|A1-Pulley infiltration for trigger finger
45968750|NCT00217841|Drug|Aurograb|
46080746|NCT05879978|Drug|BI 764532|BI 764532
46080747|NCT05879978|Drug|Ezabenlimab|Ezabenlimab
46080748|NCT05875987|Device|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
46080749|NCT05874895|Procedure|Manual Lymphatic Drainage|Manual lymphatic drainage massage involves gently manipulating specific areas of the body to help lymph move to an area with working lymph vessels.
46080750|NCT05874895|Procedure|Usual Care|Usual care provided for patients in septic shock.
46080751|NCT05873660|Other|No treatment given|No treatment given
46080752|NCT05872620|Drug|Orforglipron|Administered orally
45668514|NCT01998243|Device|Intragastric Balloon (IGB), group A|the intervention was to place An intragastric balloon (BIOENTERICS INTRAGASTRIC BALLOON (BIB) SYSTEM) endoscopically under conscious sedation and was kept in the stomach during minimum 6 months. Patients were also treated with proton bomb inhibitors (PPI), and prokinetics to control gastroesophageal reflux . The balloon was endoscopically removed with the patient under general anesthesia to avoid bronco-aspiration related problems
45668515|NCT01998243|Other|diet, control group B|the intervention in this cotrol group B was only 1200 Kilocalories (Kcal) diet
45668516|NCT01977573|Drug|GSK1278863|Film-coated tablets containing 0.5 mg, 1 mg, 2 mg, 5mg or matching placebo
45668517|NCT01977573|Drug|rhEPO|Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered..
45668518|NCT01963767|Drug|NT-020|"Recommended intake of NT-020 (NutraStem®) is two (2) capsules daily. This comprises Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg). This recommended intake was calculated from doses analyzed in scientific research and based on the dose within the submitted patent.~Scientific description of the ingredients of the product per a 2 capsule dose Vitamin D3 (as cholecalciferol) - 2000 IU BioVin® Grape Extract - 40 mg Proprietary Blend - 900mg Green Tea Extract (Camellia sinensis) Wild Blueberries* (whole fruit) Carnosine VitaBlue® Wild Blueberry Extract*~Vaccinium angustifolium~Other Ingredients:~Magnesium stearate, Cellulose (vegetarian capsules) Contains no yeast, wheat, corn, milk, egg, soy, glutens, artificial colors or flavors, added sugar, starch or preservatives."
45668519|NCT01963767|Dietary Supplement|Placebo|
46080753|NCT05872620|Drug|Placebo|Administered orally
45968751|NCT04644835|Device|Low Energy Shock Wave Treatment|The shock wave applicator (Dornier AR2, shock wave device, Dornier MedTech 2010, Wessling, Germany) will be gently placed directly on the ultrasound transmission gel over the skin surface of the suprapubic region above the urinary bladder at the site of the papillary lesion (ultrasound guided) and at other five points. Points 1 and 2 will be at the level of transverse crease 2 cm above the pubic bone and 5 cm from each, points 3 and 4 will 2 cm above points 1 and 2, and point 5 will be centered of points 1-4. A total of 2000 pulses at 0.25 mJ/mm2 will be delivered with a frequency of 3 pulses per second. The position of the shock wave applicator will be changed after every 400 pulses.
45968752|NCT04644835|Device|Sham Treatment|The patients will be exposed to the same therapy head, which will also be fitted with a stand-off without energy transmission.
45968753|NCT04644913|Behavioral|Quality of life questionnaire|Sending of 2 questionnaires (SF 36 and TESS)
45968754|NCT04644757|Other|Music Listening|The study will employ an individual receptive relaxation music method with participants selecting music based on their preference from a selection of various styles from the MUSIC CARE© app. The music intervention will last 20 minutes per session and will be administered twice daily for 4 consecutive days. Participants will be given an electronic tablet with the MUSIC CARE© app loaded on it and trained on how to access the app to select their preferred style of music.Participants will be instructed to use the provided headphone during all interventions and to sit in a quiet area while wearing an ocular mask to avoid distractions.The PI will remotely monitor each of the music intervention sessions in real-time monitoring via a secured video conferencing interface to ensure adherence to study protocol.
45968755|NCT00217880|Procedure|Bronchoscopy|A bronchoscopy test will occur to view the participant's airways.
45968756|NCT04644523|Other|Dermoscopy|"dermoscopy is currently used in daily practice in dermatology, for melanoma screening. Dermoscopy will be used in this study on peri-ungueal area.~This is a non-invasive and painless exam."
45968757|NCT04644718|Device|Transcranial direct current stimulation (tDCS)|tDCS will be administered using a battery driven stimulator along with intensive SLT. The anode electrode (5-7cm2) will be placed over the left M1 while the cathode will be positioned over the controlateral supraorbital area in both groups ((Lindenberg et al., 2013; Meinzer et al., 2016; Stahl et al., 2019), (based on the 10-20 EEG system) (Darkow et al., 2017). Stimulation will be provided via an electrode using a Soterix device (Soterix Medical Inc., New York, NY). During sham tDCS (control group), the current will be ramped up and remained for 30 s at (2 mA) before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp (Gandiga et al., 2006). Both groups will receive a total of 30 consecutive stimulation sessions over six weeks.
45968758|NCT04644562|Other|Erector Spinae plane block|Ultrasound-guided lumbar Erector Spinae plane block in patients undergoing Lower Limb vascular Surgery
45968759|NCT00217607|Drug|paclitaxel|
45968760|NCT04644484|Biological|SYN023|The finished product of SYN023 is a mixture of 3.0 mg/mL CTB011 and 3.0 mg/mL CTB012 at a ratio of 1:1. SYN023 is a sterile and preservative-free injection, and the excipient contains 25 mM histidine (3.879 mg/mL), 150 mM sodium chloride (8.766 mg/mL) and 0.02% polysorbate 80 (0.2 mg/mL) and pH of 6.0. Each vial contains 2.15 mL of SYN023, or 6.45 mg of monoclonal antibody. The glass bottle was closed with a 13 mm bromobutyl rubber stopper, a 13 mm aluminum crimping cap and a polypropylene flip-open lid.
45968761|NCT04644484|Biological|Human Rabies Immune Globulin (HRIG)|The HRIG is a Chinese licensed Human Rabies Immunoglobulin, which are derived from human plasma, and then purified and filled in the injectable vial form. The HRIG is indicated for the Post-exposure Prophylactic (PEP) of Rabies
45968762|NCT04644484|Biological|Rabies Vaccine|Interventions: The Chinese licensed rabies vaccine should be administered in deltoid muscle Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 0.5 milliliters (mL) before use Dosage: 0.5 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29
45968763|NCT04644250|Drug|Toripalimab|Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45，3 cycles in total.
45968764|NCT04644250|Drug|Paclitaxel liposome/Carboplatin|Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31, 5cycles in total.
45968765|NCT04644250|Radiation|Intensity-modulated radiotherapy|A total of 41.4 Gy, 23 fractions of 1.8 Gy on Day 1 to 31.
45968766|NCT00245739|Drug|TMC-114|600/100 mg tablets of TMC114/rtv BID until commercial available to the subject
45968767|NCT04644211|Drug|Ruxolitinib|Pill taken by mouth.
46080754|NCT05872438|Diagnostic Test|Vaginal, Oral and anal sampling|The patients will take the samples themselves from the 3 sites (vaginal, anal and oral self-sampling) using standard swabs (brand). The sample will immediately be placed in the transport medium in each of the 3 Sigma VCM tubes labeled by the patient, depending on the collection site. The study nurse will register the inclusion of patients, identify the tubes, collect information and send them to the local laboratory for the PCR to be performed.
46080755|NCT05870670|Drug|NNC0519-0130|Administered orally or subcutaneously.
46080756|NCT05870670|Drug|Placebo|Administered orally or subcutaneously.
46080757|NCT05870488|Device|Use of iFuse TORQ|Use of iFuse TORQ for the treatment of SI Joint dysfunction
46080758|NCT05869643|Drug|Low-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
46080759|NCT05869643|Drug|Medium-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
45668520|NCT01761292|Drug|Givinostat|Givinostat, oral suspension 10 mg/mL or oral capsules 50 mg, administered orally under fed conditions at the dose of 25 mg BID, 37.5 mg BID, and 50 mg BID during Part 1 for two weeks, and 25 mg BID and 37.5 mg BID during Part 2 for 12 months. Givinostat, oral suspension 10 mg/mL, administered orally under fed conditions at the dose of 25 mg BID or 37.5 mg BID during Extension 1, and modified as per patient's weight during Extensions 2 and 3 (up to 52 months).
46080760|NCT05869643|Drug|High-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
45668521|NCT01731886|Procedure|Autologous peripheral blood stem cell transplant|Subjects deemed suitable by the principal investigator will undergo autologous peripheral blood stem cell transplantation on day 0.
45668522|NCT01731886|Drug|Lenalidomide|Administered orally at a dose 25 mg daily on days 1-21 of each 28-day cycle.
46080761|NCT05869643|Drug|Placebo|Matching placebo capsule, taken orally once daily after breakfast
46080762|NCT05867654|Drug|Amoxicillin-clavulanate 875mg/125mg q12hrs|Oral antibiotic used based on indication
46080763|NCT05867654|Drug|oral clindamycin 300mg q6hrs|Oral antibiotic used based on indication
46080764|NCT05867654|Drug|Levofloxacin 750mg QID|Oral antibiotic used based on indication
46080765|NCT05867654|Drug|IV Ampicillin-Sulbactam 3g q 12hrs|IV antibiotic used based on indication
46080766|NCT05867654|Drug|clindamycin IV 600mg q12hrs|IV antibiotic used based on indication
46080767|NCT05865886|Drug|BI 1291583|BI 1291583
46080768|NCT05865886|Drug|Placebo|Placebo matching BI 1291583
45668523|NCT01731886|Drug|Dexamethasone|Administered orally at a dose of 40 mg daily on days 1, 8, 15, 22 of each cycle.
45668524|NCT01731886|Procedure|Stem cell collection|Peripheral stem cell collection will be performed at marrow recovery, usually when white blood cell (WBC) is >2500 x 109 cells/liter; platelet count is >20 x 103/mm3.
45825766|NCT00825227|Drug|Placebo,|"placebo~concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents"
45968768|NCT00217919|Behavioral|Health-Counselor Mediated Telephone Counseling Intervention|"A trained health counselor will conduct the TC sessions, which will occur every 6 weeks (total 8 calls). We expect the initial call to last 30 minutes, with subsequent calls lasting 20 minutes. Our intervention for our primary outcome of LDL-C lowering is expected to take most of this time. We will spend approximately 5 minutes addressing physical activity at the end of each session, using methods similar to those in our pilot TC study.~We will use patient-centered counseling to promote adherence to lipid-lowering medication and LDL-C lowering diet. The intervention will also activate patients to discuss initiation or dose increase of lipid-lowering drugs with their physicians. While the focus of our intervention will be on LDL-C lowering, the TC intervention will also devote approximately 5 minutes of the typical 20 minute call to increasing physical activity."
45825767|NCT01978535|Drug|Iron infusion|5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg. Iron sucrose will be diluted to 1 mg of elemental iron in 1 mL of NaCl 0.9% with a maximum volume of 210 mL.
45825768|NCT01978535|Drug|Normal saline infusion|Normal saline (NaCl 0.9%) 5 mL/kg up to a maximum volume 210 mL
45968769|NCT04644445|Dietary Supplement|Bariatric Full Liquid Diet|Patient's will receive a Bariatric Full Liquid Diet (standard bariatric clear liquid diet + protein shakes) to be started 4 hours after surgery
45668525|NCT01731886|Drug|Melphalan|Subjects undergoing autologous peripheral blood stem cell transplant will receive melphalan 200 mg/m2 intravenously on days -2 and -1 or only on day -2.
45968770|NCT00558883|Drug|acarbose|oral application
45968771|NCT04644094|Other|Echocardiography (ECHO) and lung ultrasound (LUS) studies before and after Dexamethasone administration|"A. Electrocardiographic (ECG) leads will be place in the patient for electrocardiogram (ECG) recordings.~B. Echocardiography (ECHO) will be performed by an expert member of the Neonatal Echocardiography team C. Heart Rate Variability (HRV): ECG recordings D. Growth trajectory: body weight, length, head circumference, length/weight ratio at 1-, 2-weeks prior treatment, 1-, 2-, 3-, 4-,6-,8-weeks after treatment, at 36-week PMA."
45968772|NCT04644406|Other|Efficacy of the Pertuzumab-Trastuzumab combination|The efficacy of the pertuzumab in combination with one of the biosimilars of Trastuzumab will be estimated by measuring the PFS at 6 months after the beginning of the treatment.
45668526|NCT01731886|Drug|G-CSF|Subjects will receive G-CSF subcutaneously daily beginning on day 5 and until blood counts recover.
45668527|NCT01731886|Drug|Cyclophosphamide|Subjects may receive up to the maximum recommended high-dose of cyclophosphamide at 4 gm/m2 intravenously.
45668528|NCT01731886|Drug|Mesna|Mesna will be provided with the cyclophosphamide.
45668529|NCT01759420|Drug|Ondansetron|4mg of intravenous ondansetron
45668530|NCT01781026|Drug|Vemurafenib|Single arm trial
45668531|NCT01607398|Drug|ADOAIR250|250 mcg inhalation, twice daily, from week0 -12.
45668532|NCT01607398|Drug|Placebo|Placebo inhalation, twice daily, from week0 -12.
45825769|NCT00808769|Drug|Zegerid®|capsule(20 mg omeprazole/sodium bicarbonate), single dose
45825770|NCT00808769|Drug|Prilosec OTC®|Omeprazole-magnesium 20.6 mg, tablet, single dose
45825771|NCT00378131|Drug|RC-1291|
45825772|NCT00378131|Drug|placebo|
45968773|NCT00217958|Behavioral|SHS reduction intervention based on social cognitive learning theory|
45968774|NCT04643977|Device|mARG-01-17 (mesohyal AGRIBENONE)|Dermal Filler
45968775|NCT04643821|Drug|N-acetylcysteine, NAC, and calcitriol|iv administration of antioxidant and active vitamin D
45968776|NCT04643509|Device|Niccomo|Niccomo monitoring added to pulmonary arterial catheter monitoring
45968777|NCT04643665|Procedure|Double-lung transplantation|
45968778|NCT00558922|Drug|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
46080769|NCT05858164|Drug|BAY2862789|Oral administration, solution or tablets
46080770|NCT05855044|Other|Rosemary oil application|Application of Rosemary oil (10%) to both hands and both feet once a day for 24 weeks
46080771|NCT05846919|Procedure|face-mask preoxygenation|face-mask preoxygenation (flow 2 L/kg/minute, max 6 L/minute) with 100 % oxygen for three minutes.
45968779|NCT04643392|Procedure|Complex decongestive physiotherapy|Each patient received a treatment protocol of Complex decongestive physiotherapy for 5 days a week until they were discharged from the clinic. All patients fully completed all components of the treatment routine daily. The treatment was performed by a physiotherapist who was certified with Manual Lymph Drainage Combined Decongestive Physiotherapy. After the daily treatment protocol was completed, patients wore standard or individually sized compression grade II or III medical compression stockings for the rest of the day.
45968780|NCT04643236|Behavioral|Periodontal health education session|This session comprised of a condensed version of motivational interviewing and a periodontal education view/point. First, patients were analysed in terms of expectations from periodontal treatment/oral hygiene practice, knowledge about periodontal diseases and its consequences, daily oral hygiene routine, awareness of the current periodontal status and the main reasons for not doing proper brushing and interproximal cleaning. The same researcher who did not included in the clinic process informed the patients about how periodontal diseases develops, its aetiology, symptoms, consequences and the relationship with the important systemic disorders verbally and via brochure as well. The importance of the patients' own efforts about daily cleaning of the mouth were emphasized. Finally oral hygiene instructions, including brushing and flossing, were demonstrated to each patient after nonsurgical periodontal treatment.
45968781|NCT04643236|Behavioral|Oral hygiene motivation session|Standard oral hygiene instructions, including brushing and flossing, were demonstrated to each patient after nonsurgical periodontal treatment.
45968782|NCT00218075|Drug|Levodopa|
45968783|NCT00218075|Drug|Carbidopa|
45668533|NCT01779856|Device|REVEAL Insertable Cardiac Monitor (ICM)|
45668534|NCT01729156|Drug|Metformin|1000 mg metformin twice daily in 3 months
45825773|NCT01974635|Device|AMES Therapy|During the therapy session, the AMES device rotates the hand into flexion and extension, while the patient assists with this motion, as possible. At the same time, the AMES device provides sensory stimulation by vibrating the tendons of muscles stretched by the movement. The vibratory stimulus switches from one side of the limb to the other when the rotation reverses direction so that the sensory stimulation remains functionally related to the movement. The subject will receive visual bio-feedback of their contribution to the motor movement.
45968784|NCT00218075|Behavioral|Clinical Management|
45668535|NCT01729156|Drug|Placebo|2 tablets twice daily in 3 months
45668536|NCT01779700|Drug|Fingolimod|0.5mg each day of 8 week cycle
45668537|NCT01779700|Drug|placebo|1 tablet each day of 8 week cycle
45825774|NCT00379067|Drug|Tamsulosin OCAS|Adrenoceptor antagonist
45968785|NCT00218075|Behavioral|Relapse Prevention Therapy|
45968786|NCT00218075|Behavioral|Contingency Management|
45968787|NCT00559000|Behavioral|KIDNET|Narrative Exposure Therapy for Children
45968788|NCT00414570|Drug|[18]F-FLT PET scan|Injection of [18]F-FLT radiopharmaceutical followed by PET imaging.
45968789|NCT00559039|Other|questionnaire administration|
45968790|NCT00559039|Procedure|evaluation of cancer risk factors|
46080772|NCT05846919|Procedure|HFNOC preoxygenation|HFNOC preoxygenation (flow 2 L/kg/minute, max 6 L/minute) with 100 % oxygen for three minutes.
46080773|NCT05846919|Procedure|HFNOC + face-mask preoxygenation|HFNOC (flow 2 L/kg/minute) + face-mask preoxygenation (flow 2 L/kg/minute, max 6 L/minute) - with 100 % oxygen for three minutes.
45668538|NCT04572256|Drug|Montelukast|The novel use of oral montelukast offers the potential of a disease modifying treatment to prevent irreversible cartilage loss after ACL injury. 10mg of oral Montelukast will be taken daily for 6 months post surgery.
45668539|NCT04572256|Drug|Placebo|An oral placebo will be taken daily for 6 months post surgery.
45668540|NCT01778530|Drug|TRC105|Intravenous infusion.
45668541|NCT01778062|Drug|Indacaterol|Indacaterol 150µg once daily oral inhalation
45668542|NCT01778062|Drug|Control|Placebo once daily oral inhalation
45668543|NCT01757704|Procedure|Open pleurae & conventional filling of heart|After completion of the left heart surgery, the heart will be actively filled with blood from the cardiopulmonary bypass circuit and lungs fully ventilated with positive end-expiratory pressure to flush out all air trapped in the lung veins and left heart. When there is no more visible air seen on Trans-esophageal echocardiography, the patient is weaned from cardiopulmonary bypass.
45668544|NCT01757704|Procedure|Intact pleurae & staged filling of heart|After the end of the left heart surgery, the heart is gradually filled with blood from the cardiopulmonary bypass circuit. Cardiac contractions fill the lungs with blood til no more air is seen in left heart on Trans-esophageal Echocardiography. Thereafter the lungs are ventilated with 50% of the estimated lung minute volume and 5 cm positive end-expiratory pressure and cardiac filling and de-airing continued. If no air is seen in the left heart full ventilation is started and the patient is weaned from cardiopulmonary bypass.
45825775|NCT00379067|Drug|Placebo|placebo
45825776|NCT01937507|Drug|HAI with FOLFOX|HAI with FOLFOX q 3 weeks
45825777|NCT00379223|Procedure|vitrectomy with radial optic neurotomy|
45825778|NCT00378287|Drug|rabeprazole sodium|
45825779|NCT01938833|Drug|Romidepsin|
45825780|NCT01938833|Drug|Abraxane|
45968791|NCT00218114|Drug|Divalproex Sodium|Participants are titrated over 2 weeks, as tolerated to 10 mgs / pound, and blood levels are checked to determine that the blood level is between 50-110 micrograms / ml.
45968792|NCT00218114|Drug|Placebo|Participants will be on matching placebo.
45968793|NCT00559078|Other|Interview|Hour-long, qualitative, phone interview
45968794|NCT00559117|Drug|VB-111|A single intravenously infusion of diluted VB-111 should be administered 1 ml/minute
45968795|NCT04643275|Device|BTL-899|Treatment with study device.
45968796|NCT00424788|Procedure|Plasma exchange|
45968797|NCT00424788|Drug|natalizumab treatment|
45968798|NCT04643041|Behavioral|watch and wait|patients with DNA mismatch repair-deficient or microsatellite instability-high distal rectal cancer accessed pathological complete response after 6 courses of PD-1 monoclonal antibody (200mg/Course/Q3w) therapy and start watch and wait.
45968799|NCT00218153|Drug|Naltrexone|
45968800|NCT04642924|Drug|SGM-101|Fluorescence-guided surgery
45968801|NCT04643119|Device|Medial Congruent Insert|The Medial Congruent Bearing (MC Bearing) design was introduced in 2016 for use with the Zimmer-Persona Cruciate-Retaining Femur: the design facilitates greater stability through increased anterior lip height compared to the original Cruciate Retaining Bearing (CR Bearing), allowing for greater anterior constraint and subluxation resistance that aids in full extension and deep flexion. Furthermore, the MC Bearing has been suggested for use in patients presenting with more complicated surgical histories (e.g prior high tibial osteotomies or patellectomies), whereas the original CR Bearing is strictly suggested for use only in patients undergoing knee surgery for the first time, where the posterior cruciate ligament may still be intact.
46080774|NCT05846750|Drug|Obinutuzumab, lenalidomide|"The treatment is divided into two phases: induction therapy and maintenance therapy~Induction: 6 cycles, every 28 days/cycle~Lenalidomide: 20 mg/day, oral. Dosing on Days 2-22 of Cycles 1-6~Obinutuzumab pegol: 1000 mg each time, administered on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6. ( 8 total infusions)~Maintenance: Patients who achieve at least a partial response after 6 months of induction therapy will be eligible to enter the maintenance phase for 2 years~During the first year of maintenance therapy, patients will receive obinutuzumab (1000 mg on Day 1 of each 28-day cycle, every 2 cycles for 6 infusions) and lenalidomide (10 mg on Days 2-22 of each 28-day cycle, 12 cycles) until disease progression or end of treatment~During the second year of maintenance therapy, patients will receive obinutuzumab (6 infusions of 1000 mg) every 2 cycles (28 days each) until disease progression or end of treatment"
46080775|NCT05844007|Behavioral|Trauma-Informed Yoga|Trauma-informed yoga intervention, delivered either in-person or remotely for 6 weeks, twice weekly for 45 minutes sessions
46080776|NCT05843565|Device|Cobalt video laryngoscope blade|Non-standard hyperangulated Cobalt video laryngoscope blade
46080777|NCT05843565|Device|Miller video laryngoscope blade|Standard Miller video laryngoscope blade
46080778|NCT05842967|Biological|Substudy A (Study Intervention)|RSVPreF
46080779|NCT05842967|Other|Substudy A (Placebo)|Placebo
46080780|NCT05842967|Biological|Substudy B|RSVPreF
46080781|NCT05840939|Behavioral|Pranayama|"Pranayama, one of the practices of yoga, is a Sanskrit word consisting of a combination of two words, a technique of rhythmic, controlled breathing. So prana means life breath/life energy and ayama means expansion/regulation/control. Pranayama helps to improve lung capacity, heart and respiratory functions, nervous and hormonal systems, as well as mental activity."
45825781|NCT01893359|Drug|riboflavin ophthalmic solution, 0% dextran|
45668545|NCT01757392|Biological|Candida albicans Skin Test Antigen|0.3 ml injected intralesionally monthly. Number of injections: until wart lesion is resolved or up to 6 injections.
45825782|NCT01893359|Device|UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)|
46080782|NCT05840939|Behavioral|diaphragm breathing exercise|Diaphragmatic breathing is also known as deep breathing or slow abdominal breathing. This breathing exercise uses the diaphragm muscle. The diaphragm is the muscle under the lungs that supports the lungs in up and down breathing.
45825783|NCT01893359|Device|UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)|
46080783|NCT05838703|Drug|tiotropium bromide inhalation powder (Spiriva HandiHaler)|Spiriva HandiHaler is a COPD medication that is available for use.
45825784|NCT01893359|Procedure|Laser-assisted in situ keratomileusis|
45825785|NCT05313503|Other|ketogenic diet|We propose a type of KD named MAD (Modified Atkins Diet) characterized by the following percentages of macronutrients: 65% fats, 27% proteins and 8% carbohydrates.
45825786|NCT00795665|Drug|bevacizumab|Bevacizumab (10 mg/kg) will be given intravenously every other week starting one week before the first dose of BCNU. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
45825787|NCT00795665|Drug|carmustine|BCNU (200 mg/m2), will be given over 4 hours as a continuous intravenous infusion every 8 weeks. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
45968802|NCT04643119|Device|Cruciate-Retaining Insert|The Cruciate-Retaining Bearing (CR Bearing) design was launched together with the use of the Cruciate-Retaining Femoral Components (CR Femur) of the Zimmer-Biomet Persona® Total Knee system. The design not only stabilises the knee through medial conformity and anterior constraint, but also allows for freer and more natural deep flexion through freer movement of the lateral condyle.
45825788|NCT00791843|Drug|Growth hormone releasing hormone/ placebo|12 weeks of drug at max dose of 2mg/day administered in 4 pulses at 11pm, 1am, 3am, and 5am, followed by 6 weeks of washout period, then 12 weeks of placebo or vise versa- 12 weeks of placebo, 6 weeks washout, 12 weeks of drug.
45968803|NCT00241878|Behavioral|Teacher-Delivered Weight Control Intervention|The teacher-delivered weight control intervention (TD-WCI) is implemented over 14 weeks with three lessons per week. Many lessons include the use of colorful, friendly, hand-made puppets that represent the seven food groups of the food pyramid (Miss Grain, Miss Fruit, Mr. Vegetable, Mr. Protein, Miss Dairy, Mr. Fat and Miss Sugar). Please see Appendix IX for complete curriculum and pictures of puppets. There are three 40-minute lessons per week that consist of a 15-20 minutes interactive healthy eating and exercise didactic session and then 20 minutes of ongoing physical activity (5 minutes warm-up, 15 minutes aerobic activity composed of a number of games and dances with music, 5 minutes cool-down). In addition to the child-based curriculum the WCI has parent newsletters. These newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
45968804|NCT00241878|Behavioral|Teacher-Delivered General Health Intervention|The teacher-delivered general health intervention (TD-GHI) serves as the control group in the proposed study. TD-GHI is a general health intervention that is similar in structure and length to TD-WCI. Topics include those related to general health and safety, such as car safety, being a good friend, poison safety, disease prevention, etc. An example of an activity is the 911 emergency call. The children learn what 911 is and what would be an appropriate call. They then practice calling 911 on play telephones and relating the important information: nature of the emergency, their name, their address, etc. They learn also to stay on the phone with the 911 dispatcher until someone comes to help them. In addition to the child-based curriculum the GHI has parent newsletters. Like TD-WCI these newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
45968805|NCT04643197|Device|Barbed PDS suture (STRATAFIX Symmetric PDS Plus)|STRATAFIX Symmetric PDS Plus is a barbed suture.
45968806|NCT04643197|Device|Non-barbed PDS suture (PDS Plus)|Non-barbed suture
45968807|NCT00218192|Behavioral|Behavior Therapy|
45968808|NCT04643314|Other|Guided video-based self-evaluation|"In addition to their usual residency training, participants randomized to this group will undergo the following interventions:~The participants will be asked to review their own operating room recordings (of each of the 5 consecutive submitted laparoscopic cholecystectomy cases that the participant acted as the primary operator) and to assess themselves (within 72 hours (3 days) of the procedure) using validated intra-operative assessment tools. The completion of the self-evaluations is to guide and document video-based self-reflection. The duration of self-assessment/reflection session will be up do the participant. Residents in this group will have unlimited access to their recordings through the web-based platform. On the other hand, they will not be able to access the battery of assessment forms after the third day following the procedure."
45968809|NCT04643080|Other|Yogurt|6 oz. of a commercially available yogurt were provided daily for 12 weeks
45968810|NCT00245817|Behavioral|HINCAB|Psycho-educative intervention performed 2 and 4 weeks after surgery
45968811|NCT00559156|Dietary Supplement|arginine/omega-3 fatty acids/nucleotides oral supplement|
45968812|NCT00559156|Drug|cisplatin|
45968813|NCT00559156|Procedure|adjuvant therapy|
45968814|NCT00559156|Radiation|radiation therapy|
46080784|NCT05838703|Drug|tiotropium bromide (Spiriva Respimat)|Spiriva Respimat is a COPD medication that is available for use.
46080785|NCT05838703|Drug|Hyperpolarized 129XeMRI|Xe129 hyperpolarized with use of MRI for evaluation of lung ventilation has recently been FDA approved
46080786|NCT05831683|Other|Introduction of Standard Operating Procedure regarding lung protective ventilation during general anaesthesia.|The Standard Operating Procedure document will be introduced. The SOP document will cover the theoretical background, definition, and recommendations/criteria of LPV. The SOP document will reflect the most recent LPV guidelines.
46080787|NCT05831358|Other|Multiple Myeloma M-Protein Analysis|Participants will be screened with a blood test for monoclonal protein analysis
46080788|NCT05831358|Other|Multiple Myeloma Knowledge Questionnaires|Participants will complete two questionnaires to share their attitudes toward their screening experience and completion of knowledge questions to gauge community reception and participant multiple myeloma knowledge.
45825789|NCT01836809|Drug|nesiritide|nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
45825790|NCT01836809|Drug|placebo|placebo bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
45825791|NCT00780455|Drug|Interferon beta-1b, FRP within 15 days after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program starting within 6 weeks after randomization
45825792|NCT00780455|Drug|Interferon beta-1b, FRP about 6 weeks after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program about 6 weeks after randomization.
45825793|NCT00755261|Drug|Avastin|Combination of Avastin and doxorubicin. If initial 90 +/- 15 minute infusion of Avastin is tolerated without fever and chills, the 2nd dose may be infused over 60 +/- 10 minutes. If well tolerated, all subsequent infusions may be delivered over 30 +/- 10 minutes.
45825794|NCT00755261|Drug|Doxorubicin|The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.
46080789|NCT05830838|Procedure|Computed Tomography|Undergo PET/CT
46080790|NCT05830838|Radiation|Image-Guided Adaptive Radiation Therapy|Undergo daily adaptive online replanning for SBRT
45825795|NCT00748085|Device|CryoSpray Ablation|Treatment dosimetry will be up to 4, 5-second spray cycles. Subjects will have initial cryospray treatment. Subjects may undergo up to one bronchoscopy with CryoSpray Ablation every seven days for a total of four (4) treatments in the first month.
45825796|NCT03725033|Drug|Subetta|Oral administration.
45825797|NCT03725033|Drug|Placebo|Oral administration.
45825798|NCT03724877|Drug|Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS)|(LABA-LAMA-ICS)
45825799|NCT03724877|Drug|Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)|(LABA-LAMA)
45825800|NCT03724253|Drug|[68Ga]-NeoBOMB1|[68Ga]-radiolabeled bombesin peptide targeting Gastrin Releasing Peptide Receptors
45668546|NCT01756846|Other|usual care|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
45825801|NCT05313113|Behavioral|Experimental|Pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. The training content included topics such as setting a comfortable environment and suitable position for the pregnant, when the fetus is active and asleep during the day, how to count and how to evaluate the movements. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
45825802|NCT01809899|Behavioral|Enhanced consent procedure|Enhanced consent entails a more detailed consent procedure
45458595|NCT01236937|Device|Bellows-based breath hold device|"Bellows-Based breath hold monitoring system:~The bellows-based breath hold system (IBC, Mayo Clinic Medical Devices, USA) contains of 2 elements; one belt which is strapped around the thorax of the patient and a voltage controlled light unit with 8 lights. Belt stretch from respiratory motion is converted into voltage readings and displayed on the light unit giving biofeedback as different lights are activated depending on the dept of the respiration. Patients are instructed to keep respiration constant at a certain dept during the second the guide needle is inserted by controlling their breath with the help of the light unit. The patient is given a brief introduction to the system as to how the lights get turned on and off due to respiration motion before the biopsy is preformed."
45825803|NCT01809899|Behavioral|Consent as Usual|Routine informed consent procedures
45825804|NCT00746603|Drug|Simvastatin|All patients will start at 10mg of simvastatin, and then, based on results of interim evaluation escalated to 20mg and then 40. Patients will stay on maximally tolerated dose of drug until the end of the study at 26 weeks.
45825805|NCT05312957|Other|erector spinae plane block|Group ESP (Arm 1)The probe was placed craniocaudally in the parasagittal plane approximately 3 cm lateral to the T5 spinous process. The T5 transverse process is detected .When the block needle (Stimuplex B. Braun R, Melsungen, Germany) touched the transverse process, 0.5-1 mL of the 0.9% NaCl test dose was administered between the erector spinae muscle fascia and the vertebral transverse process, and the needle location was confirmed.Then, 20 ml of 0.25% bupivacaine was administered to this area, Group Control (Arm 2) :No intervention
45825806|NCT04713527|Diagnostic Test|Cultivation and PCR within 24 hours|During operation for appendicitis peritoneal fluid will be extracted. This is sent to cultivation and PCR analysis to determine if there is bacteria within the peritoneal cavity.
45825807|NCT04713527|Drug|Enteral antibiotics|Patients with complicated appendicitis will receive enteral antibiotics instead of intravenous
45825808|NCT00716807|Drug|nalbuphine plus naloxone|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
45825809|NCT00716807|Drug|nalbuphine plus placebo|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
45825810|NCT00716807|Drug|nalbuphine plus naloxone|Patient group: burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
45825811|NCT00716807|Drug|nalbuphine plus placebo|Patient group: Burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
45825812|NCT03461705|Device|Volcano Verrata Pressure Wire|"Steerable guidewire with a pressure transducer mounted 3cm proximal to the tip. The guidewire has a diameter of 0.014.~and is packaged preconnected to the connector with a torque device to facilitate navigation through the vasculature."
45825813|NCT03461705|Device|St. Jude Medical (SJM) Aeris Pressure Wire System|The pressure wire is a 0.014'' guidewire with a pressure and temperature sensor integrated into the tip to enable measurements of physiological parameters.
45825814|NCT03426137|Drug|Oxycodone|5mg Oxycodone in oral solution given every 3 hours
46080791|NCT05830838|Procedure|Magnetic Resonance Imaging|Undergo MRI
46080792|NCT05830838|Procedure|Positron Emission Tomography|Undergo PET/CT
46080793|NCT05830838|Other|Questionnaire Administration|Ancillary studies
46080794|NCT05830838|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
46080795|NCT05829408|Behavioral|KOPPeling|KOPPeling lasts ten to twelve weeks and will be administered by health care professionals.
46080796|NCT05828901|Other|S1PR analysis on immune cells|S1P receptor 1 and 5 expression will be measured on immune cells
46080797|NCT05825924|Device|E-Cigarette|E-cigarettes have been designed to resemble tobacco cigarettes. They include an aerosol generator, sensor, battery and storage area for liquid. They are either disposable or rechargeable. According to a study, e-cigarettes can deliver an average of 1.3 mg (range 0.4 to 2.6 mg) of nicotine from 15 puffs. Average Cmax after e-cigarette use is recorded as 8.4 ng/mL and Tmax achieved between 2 to 5 minutes
45668547|NCT01756846|Other|use of HEART risk score|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
45968815|NCT04642846|Other|Silver Diamine Fluoride (SDF)|Silver diamine fluoride (SDF) is one of the topical methods for caries arresting. The advantages of using SDF include ease of use, low cost, pain and infection control, minimal requirement of time/training and non-invasive nature of the procedure. SDF can improve oral health, increase access to care and reduce the need for emergency treatment
45968816|NCT04642612|Device|TCD Measurement|"CBFV measurements will be acquired continuously with the patient supine and the head neutral. Analysis of CBFV measurements will be undertaken at 3 timepoints:~Patient awake and supine in the holding area~After sedation~After interscalene nerve block"
46080798|NCT05825924|Drug|Nicotine patch|The nicotine patches are applied on the skin and nicotine is delivered at a steady rate. After administration, the peak blood levels are achieved within 6-10 hours. The levels remain constant, reducing by 25-40% with use of patches once daily. The patch is typically administered every 24 hours for no longer than 12 weeks. The dose of the patches is often determined by daily cigarette consumption and level of addiction.
45825815|NCT03426137|Drug|Ketorolac|toradol intravenous (IV) 30mg. Maintain toradol IV every 8 hours, round the clock. For patients with renal insufficiency, decrease toradol dose to 15mg every 8 hours. For patients over 65 years old, decrease toradol dose to 15 mg every 8 hours. After 24 hours, start oral NSAIDS every 8 hours round the clock when tolerating pain.
45825816|NCT03426137|Other|Placebo|Oral solutions containing only the carrier vehicle - a flavored syrup called OraSweet
46080799|NCT05825079|Behavioral|Weight-Bearing Feedback|Feedback on how much weight patients are exerting on their crutch/injured lower extremity (measured via Smart Crutch Tip) will be delivered to their mobile phones.
46080800|NCT05825079|Device|Smart Crutch Tip|The device is attached to the crutch and measures how much weight-bearing load is exerted onto its axis. The device is capable of transmitting this data into the patient and physicians' user interface.
45668548|NCT01963611|Drug|Plovamer acetate 0.5 milligram (mg)|Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
45968817|NCT04642768|Dietary Supplement|KetoneAid Ketone Ester|Commercially available ketone supplement
45968818|NCT04642768|Dietary Supplement|Maltodextrin|Commercially available maltodextrin supplement
45968819|NCT00241917|Behavioral|Hepatitis C educational video|
45458596|NCT04967092|Drug|Modified Xiao-Feng Powder + Antiallergics|Modified Xiao-Feng Powder granules twice daily for 12 weeks plus Bilastine 20mg once daily for the first 6 weeks, and on-demand for the following 6 weeks.
45968820|NCT00241917|Other|Video|Prevention education video about hepatitis C
45968821|NCT04642495|Diagnostic Test|"Visual acuity testing with SW , Landolt-C and Tumbling-E symbols"|Establish prediction intervals for acuity tests
45968822|NCT04642456|Diagnostic Test|Balance Assessment Scale|The newly developed balance, based on the Balance Evaluation Systems Test (BESTest) and Trunk Control Measurement Scale (TCMS), will be administered by two raters (normative and clinical database + interrater reliability)
45825817|NCT04713683|Device|Percutaneous Patent Foramen Ovale Closure|Patients with well-documented embolic stroke of unknown source (ESUS) and a patent foramen ovale (PFO) are indicated for percutaneous closure of PFO. The intervention is performed through the right femoral vein. The interventional cardiologist introduces the sheath and advances the device via inferior vena cava to right atrium. Then, the catheter is passed through the PFO, the device is deployed and the occlusion is achieved. The procedure is performed under fluoroscopy guidance with or without transesophageal echocardiography guidance.
45825818|NCT04706351|Other|IdFAI questionnaire|The Identification of Functional Ankle Instability (IdFAI) is a newly published questionnaire that was specifically designed to detect whether individuals meet a minimum criteria necessary for inclusion in an FAI population. The IdFAI is intended to give both researchers and clinicians a simple and effective tool to determine an individual's ankle stability status
45825819|NCT05283863|Device|High-frequency stimulation|Patients in this group will receive sub-threshold high-frequency (aka 1200Hz) spinal cord stimulation for 2 weeks.
45825820|NCT05283863|Device|Sham Stimulation|Patients in this group will receive receive sham spinal cord stimulation (aka no stimulation) for 2 weeks.
45825821|NCT05283863|Device|Conventional spinal cord stimulation|Patients will receive conventional spinal cord stimulation (aka 60Hz, aka tonic stimulation, aka paresthesia-based stimulation) for 2 weeks
45825822|NCT01760993|Drug|SPD489|Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks
45968823|NCT04642456|Diagnostic Test|Trunk strength measurement with EMG|A trunk strength protocol in sitting position, using a hand-held dynamometer is developed. During the trunk strength measurements muscle activity of certain muscles of the trunk will be measured using surface electromyography (EMG)
45968824|NCT04642456|Diagnostic Test|MRI spine/pelvis|We will be capturing 3D MR images of the subject lying supine with extended knees, using a T1 weighted SE sequence with interslice distance 3 mm in the area of the hip) extended with full spine MRI images (sagittal full spine T1- and T2- weigthed images as part of the standard sagittal view of full spine to check for significant stenosis or spinal cord pathology) and additional T1-weighted axial slices at level L4, T12 and T8 with interslice distance 4 mm.The field of view covers the full spine, pelvis and hip smaller trochanter.
46080801|NCT05819931|Device|Mechanical In-Exsufflator treatment|"The Mechanical In-Exsufflator (MIE) is a device that alternately inhales and exhales air and amplifies the respiratory cycles in flow and pressure. 15 breathing cycles (about 3 minutes) are recommended each day.~Patients will practice the MIE daily independently and/or carried out by his physiotherapist (PT) during PT sessions.~The MIE is prescribed by the neurologist or pulmonologist and is covered by social security in France. It is gifted by an external service provider.~The Peak-Flow Cough is considered as the standardized score retaining the best of 3 consecutive measurements by Peak-Flow, a small portable device for personal use, which measures the maximum expiratory flow reached by the patient at the moment when the breath is most powerful.~The patient is his own control. At baseline, the patient will be treated as usual. He will be asked to read the Peak-Flow Cough measures. The PT will also perform the Peak flow measurement at each patient visit."
46080802|NCT05814913|Behavioral|CaCBT for psychosis|The CaCBT intervention is based on the intervention manual developed by David Kingdon and Douglas Turkington, and culturally adapted by our group. CaCBT aims to take a collaborative approach to gaining an understanding of the symptoms
45458597|NCT04967092|Other|Placebo + Antiallergics|Placebo granules twice daily for 12 weeks plus Bilastine 20mg once daily for the first 6 weeks, and on-demand for the following 6 weeks.
45825823|NCT00669461|Drug|Lubiprostone|Lubiprostone 24 mcg BID orally for 4 weeks
45668549|NCT01963611|Drug|Copaxone 20 mg|Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
45825824|NCT00673595|Drug|Varenicline|"Smoking cessation assistance: study days 1-3: 0.5 mg once daily, study days 4-7: 0.5 mg twice daily, study days 8-15: 1 mg twice daily; study day 16: 1 mg once. The tablets should be taken orally after food intake with 200 ml of water.~The treatment phase may be prolonged up to a maximum of 2 weeks under the following conditions: 1) the participant voluntarily agrees to the prolongation of the study, 2) both the participant and investigator are confident that the participant will be able to completely refrain from smoking for at least 10 days until the final study day."
45825825|NCT00673595|Drug|Placebo|The pharmacy will prepare tablets that match the varenicline tablets. The tablets should be taken orally after food intake with 200 ml of water.
45968825|NCT04642456|Diagnostic Test|EOS stereoradiographic full body exam|Every subject included in the study will undergo a stereoradiographic full body EOS exam completed with Gravity Line (GL) location, recorded by a force plate on the floor
45968826|NCT04642456|Diagnostic Test|Balance Assessment Scale 2|Repeating the newly developed balance test (test-retest reliability) within 2 weeks after first measurement
45968827|NCT04642456|Diagnostic Test|Trunk strength measurement with EMG 2|Repeating the trunk strength protocol with EMG within 2 weeks after the first measurement (test-retest reliability)
45968828|NCT04642339|Biological|Gam-COVID-Vac|Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization with component I (rAd26-S) and component II (rAd5-S) with 21 days interval
45968829|NCT04642339|Biological|Placebo|Placebo
45458598|NCT03499834|Biological|Immune Killer Cells (IKC)|Autologous cells of the immune system. Intravenous Injection (I.V.) frequency: One injection per week, twenty-four injections on-treatment
45668550|NCT01963611|Drug|Plovamer acetate 3 mg|Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
46080803|NCT05814913|Behavioral|Culturally adapted Family Intervention (CulFI) for psychosis|CulFI intervention comprises of Family psychoeducation; cognitive-behavioural skills training for stress-management, coping and problem solving; crisis intervention and suicide risk management; relapse prevention; education and support regarding the family environment, including communication training. The components are designed to facilitate an understanding about psychosis, the emotional impact of the illness on family relationships, to promote more adaptive coping strategies and minimize relapse risk.
45668551|NCT01963611|Drug|Plovamer acetate 10 mg|Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.
45668552|NCT01963611|Drug|Plovamer acetate 20 mg|Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
46080804|NCT05814848|Drug|Relmacabtagene Autoleucel Injection|For patients who had undergone at least one disease assessment after the first treatment of Relmacabtagene Autoleucel injection and whose disease status was not complete remission, the investigators decided to give the patients a second treatment of Relmacabtagene Autoleucel injection based on clinical practice, and the specific dosage was determined by the investigators according to the patient's condition and dose reserve.
45825826|NCT00670631|Combination Product|tandem autologous transplantation|"DPACE: dexamethasone 20 mg days 1-4 and 8-11, cisplatin 10 mg/m2 days 1-4, Adriamycin 10 mg/m2 days 1-4, cyclophosphamide 400 mg/m2 days 1-4, etoposide 40 mg/m2 days 1-4.~Transplant 1: Dexamethasone 20 mg days -4 to -1 and +2 to +5. Velcade 1mg/m2 on days -4,-1, +2, and +5. Thalidomide 100mg on day -4 to day +5. Melphalan, 100 mg/m2 on days -4 and -1.~Transplant 2: Dexamethasone 20 mg on days -4 to -1 and +2 to +5. BCNU 300mg/m2 on day -4. Melphalan 140 mg/m2 on day -1. Velcade 1mg/m2 on days -4, -1, +2, +5. Gemcitabine 1000 mg/m2 on days -4 + -1.~Maintenance year 1: Bortezomib 1.0 mg/m2 on days 1, 4, 15,18 every cycle. Thalidomide, 100 mg . Dexamethasone,20 mg,on days 1-4 & 15-18 every cycle.~Maintenance year 2: Dexamethasone, 20 mg,days 1-4 every cycle."
45825827|NCT03248141|Drug|Hemophilia B standard half-life|Benefix
45825828|NCT03248141|Drug|Hemophilia B extended half-life|Alprolix
45825829|NCT03248141|Drug|Hemophilia A standard half-life|Xyntha and other standard half-life agents
45825830|NCT03248141|Drug|Hemophilia A extended half-life|Eloctate and Adynovate
45825831|NCT00378365|Procedure|Arsenic trioxide|Arsenic trioxide
45825832|NCT00378365|Procedure|ATRA|ATRA
45825833|NCT05313425|Other|Ectohylo (R) eye drops|using Ectohylo eye drops post operative after PRK in the right eyes of the patients
45668553|NCT04662645|Other|Palliative Therapy|Undergo embedded palliative care
45668554|NCT04662645|Other|Questionnaire Administration|Ancillary studies
45668555|NCT01975701|Drug|BGJ398|Capsule for oral use.
45668556|NCT01962987|Drug|Diclofenac sodium|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
45825834|NCT05600621|Behavioral|Financial Literacy Training (FLT) Workshops|Participants will be assigned to receive FLT workshops which are implemented by community-level agencies in collaboration with the financial institutions. FLT comprises six workshops delivered over 6 weeks. Topics include: a) an introduction to the notion of asset-building; b) coverage of asset-building strategies in detail, e.g., saving; c) coverage of specific topics related to saving, e.g., the importance of saving and how to save, d) an introduction of banking services to participants and e) coverage of basics of borrowing and debt management. Participants from the same location, in this case, clinics are assigned to the same group. Workshops occur on weekends to accommodate participants week-day schedules, including school and/or gardening.
45668557|NCT01962987|Other|Placebo|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
45825835|NCT05600621|Behavioral|Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)|"ALHIV will receive a YSA with a 1:1 matched savings program at a financial institution accredited by the Bank of Uganda. Each YDA will be opened in the name of the adolescent, with their primary caregiver as a co-signer, until the adolescent turns 18 years. The account will then be matched with money from the program on 1:1 rate.~As part of YSA, ALHIV are also trained on investing in income-generating activities (IGA) and are normally allowed to use up to 30% of their matched savings to invest in an IGA to benefit their family. The IGA portion helps promote economic stability for families and enable the ALHIV to afford medical expenses."
46080805|NCT05814107|Drug|CT-996|Capsule of CT-996
46080806|NCT05814107|Drug|Placebo|Capsule of Placebo
46080807|NCT05812261|Other|Creating an electro-anatomical map|After the routine pulsed-field ablation procedure, the operator will create an electro-anatomical map using the ablation catheter and a 3D mapping system.
45668558|NCT01962441|Drug|SOF|400 mg tablet administered orally once daily
45668559|NCT01962441|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45668560|NCT01962441|Drug|Peg-IFN|180 µg administered via subcutaneous injection once weekly
45668561|NCT01638013|Drug|Peficitinib|Oral Tablet
45968830|NCT04642300|Procedure|Holmich Protocol|"Module 1 (1st two weeks):~i)Isometric adduction ii)Abdominal sit-ups iii)Isometric adduction iv)Compound abdominal sit-ups and hip flexion v)Balance exercise on wobble board vi)One-foot exercise on sliding board~Module 2 (from 3rd week):~i)Leg abduction and adduction exercise carried out in side lying ii)Low back extension exercise prone on the end of bench iii)One leg weight pulling abduction/adduction standing iv)Abdominal sit ups v)One leg coordination exercise vi)Training in sideways motion vii)Balance exercise on wobble board"
45968831|NCT04642300|Procedure|Myofascial Release Technique|"Transverse friction massage: 10 mins on painful area of adductor-tendon insertion into pubic bone~Stretching of adductor muscles, hamstrings muscles and hip flexors:3 times and each stretch is 30s with Contract relax technique"
45968832|NCT04642573|Other|non interventional|non interventional
45968833|NCT04642066|Other|Cold water immersion|Full body CWI in open standing, except the head (same location, timing), frequency three times a week in the duration of 7-10 minutes. Swimming was permitted. Volunteers must not use neoprene aids (gloves, shoes), caps were allowed. Volunteers should be in the final phase submerged in water, above which there should only be the head and neck. The upper limbs were below the water surface. Non-neoprene footwear was permitted. Volunteers entered the water continuously without stopping. The time of stay in water was calculated from the first contact of the foot with water. On average, the whole body needed to be immersed in water within 30 seconds.
45968834|NCT04642066|Other|No cold water immersion|People without cold water immersion
45968835|NCT00245895|Drug|Aranesp|Aranesp
45968836|NCT00559195|Biological|epoetin beta|
45968837|NCT00559195|Procedure|quality-of-life assessment|
45668562|NCT01637623|Drug|Losartan|Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.
45668563|NCT01637623|Drug|Allopurinol|Allopurinol 300 mg daily for 6 weeks
45825836|NCT05600621|Behavioral|A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon).|Participants assigned to this component will participate together with her/his caregiving family, in attending sixteen 60 minute sessions hosted within the community over 16 weeks. Each session involves 6-10 families. Participants will learn from the Suubi Cartoon curriculum about their HIV diagnosis and treatment needs, while coping with family loss, stigma, peer relationships, identity, and family functioning.
45968838|NCT00245934|Drug|Enbrel|
45968839|NCT04642144|Other|Yerba mate infusion|"Yerba mate infusion intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of the infusion right before the exercise protocol test, without consumption of a carbohydrate-based meal, keeping the individual fasted.~Yerba mate and carbohydrate intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of a meal based on carbohydrate right before the exercise protocol test with another infusion of yerba mate."
45968840|NCT04642144|Other|Carbohydrate meal|Carbohydrate meal intervention is characterized by the consumption of a carbohydrate-based meal right before the exercise protocol test, without consumption yerba mate infusion.
45968841|NCT00218231|Drug|300 mg/day bupropion-sr|300 mg/day for 1 week
45968842|NCT00218231|Drug|0 mg/day bupropion-sr|0 mg/day bupropion-sr
45968843|NCT04641910|Other|No intervention|No intervention
45968844|NCT04641754|Drug|WX-0593 Tablets|tablets, 60 mg→180mg, quaque die（QD）
45968845|NCT04641676|Diagnostic Test|NGS testing|NGS test will be performed
45968846|NCT00241995|Drug|Anticonvulsants|
45968847|NCT00218270|Drug|Tobacco free snuff|Tobacco free snuff
46080808|NCT05807048|Drug|Daratumumab and Hyaluronidase-fihj|DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection for subcutaneous use. Supplied as individually packaged single-dose vials providing 1,800 mg of daratumumab and 30,000 units of hyaluronidase per 15 mL.
46080809|NCT05807048|Drug|Pre-Intervention Medication|"The following pre-medications will be administered 1-3 hours before each dose of DARZALEX FASPRO:~Acetaminophen 650 to 1,000 mg orally~Diphenhydramine 25 to 50 mg (or equivalent) orally or intravenously~Montelukast 10mg PO prior to DARZALEX FASPRO®.~Methylprednisolone 100 mg (or equivalent) orally or intravenously"
45668564|NCT01637623|Drug|Placebo|Placebo capsule daily for 6 weeks
45668565|NCT01962207|Biological|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm
45668566|NCT04847011|Other|Fasting|Patients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al.
45668567|NCT04844827|Genetic|Conserving routinely performed pleural biopsies in our biological resources center to realize multiomics and bioinformatics analyzes secondarily|Interventions will consist of a diagnostic and symptomatic videothoracoscopy in patients with pleural metastasis under general anesthesia, as part of a standard of care procedure. Fragments of these pleural biopsies (one for routine diagnosis and two for scientific purposes) will enrich the biocollection. Five blood samples will be taken at the time of surgery (3 to 5 ml / tube). These biological samples will be stored in the HCL CRB tumor bank. At the same time, patient demographic data will be collected and anonymized. In the long term, the biological material will be used by IARC for carrying out multi-omics and bioinformatics analyzes
45668568|NCT04841317|Combination Product|Mobile technology intervention|Home blood pressure cuff used by patients twice a week, with blood pressures transmitted to providers remotely
45668569|NCT01995825|Drug|Brand lamotrigine|Brand lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
45968848|NCT04641520|Other|Shoulder clinical testing with isokinetic strength assessment|All the participants had a shoulder clinical testing including shoulder rotators range of motion and isokinetic rotator muscle strength testing
45668570|NCT01995825|Drug|Generic lamotrigine|Generic lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
45968849|NCT04641793|Device|Motion and Emg Control|"We will consider two methods for integrating motions and EMG signals:~Direct methods. Signals extracted from the latent EMG space will directly contribute to the control of the external device. We will integrate EMG and IMU in two ways. In a first scenario, EMG and IMU will be given variable weight in the control. In a second scenario (perturbative method) the distance of ongoing muscle patterns from a desired set of strategies will modulate the mapping from body to cursor motions in the form of assistive (i.e. the cursor moves faster towards the target) or resistive (i.e. the cursor slows down) influences on cursor movement.~Indirect Methods. Signals extracted by EMG will modulate the feedback offered to the learner to penalize deviations from desired muscle patterns. When multiple ways to perform a movement are offered by redundancy, (i.e., by the multiplicity of muscles compared to task demands), the brain chooses solutions that minimize noise and uncertainty."
45968850|NCT00245973|Drug|Bifeprunox|
45968851|NCT04641715|Procedure|OAGB-MGB|One Anastomosis Gastric Bypass - Mini Gastric Bypass as both restrictive and malabsorptive bariatric procedure
45968852|NCT00218309|Drug|Hydromorphone|
45968853|NCT04641598|Procedure|Endometrial Scratch|"An endometrial biopsy pipelle will be used to create endometrial injury in the form of a scratch."
45968854|NCT04641598|Procedure|Sham procedure|Motions of performing an endometrial scratch will be performed including speculum placement and cervix cleansing, however, placement of the tenaculum and the endometrial scratch will not be performed.
45825837|NCT05600621|Behavioral|Engagement with HIV treatment-experienced role models who share lived experiences of HIV|Participants will be assigned to small groups with an average of 3-4 peers from the same health clinic, and each ALHIV stays in the same group -- for 9 sessions - with the same role model. This is intended to build trust and rapport not only between the role model and mentee, but also between all group members. The 9 sessions, to be conducted over a 6-month period, include activities, videos, scenarios, and role-playing to facilitate discussion and learning. This is intended to promote their self-esteem, improve their HIV care engagement, reduce stigma and stress, encourage hopefulness, build stronger communication skills with their caregivers and/or family members, enhance safe sexual decision-making, and decrease sexual risk-taking behavior.
45825838|NCT05600621|Other|Standard of Care (SOC)|SOC consisting of pediatric ART initiation and monitoring outlined by Uganda's Ministry of Health.
45825839|NCT01754987|Drug|Ascorbic Acid + Sorafenib|
45825840|NCT01754987|Drug|Sorafenib|
45825841|NCT01732211|Biological|PD 0360324|100 mg Q2W or 150 mg Q2W via intravenous infusion based on protocol determined dose escalation/de-escalation criteria; 12 weeks Active Therapy;
45825842|NCT01732211|Other|Normal Saline for injection|normal saline Q2W via intravenous infusion for 12 weeks
45825843|NCT05600153|Procedure|implant exchange operation|To perform implant exchange via axillary incision.
45825844|NCT00652457|Drug|Memantine|10 mg BID x 3 months
45825845|NCT00645359|Procedure|diffusion MRI|Diffusion MRI involves using MRI scanning to measure water transport at the cellular level. In this study, dMRI is being used to measure the response of tumors to chemotherapy.
45825846|NCT01681589|Device|Transcranial Direct Current Stimulator (TDCS)|Group will receive active TDCS
45968855|NCT04641364|Drug|recombinant human albumin injection|single dose or multiple doses of intravenous infusion
45968856|NCT04641364|Drug|Placebo|Single dose intravenous infusion of 0.9% sodium chloride injection
45968857|NCT04641364|Drug|human albumin injection|multiple doses of intravenous infusion
45668571|NCT04829929|Device|Omega™LAA Occluder implantation|Left Atrial Appendage closure for patients with non-valvular atrial fibrillation (NVAF) and high bleeding risk by Omega™LAA Occluder using Omega™ Delivery System
45668572|NCT03777943|Procedure|Sampling peritoneal tissue|Resection specimen will be obtained during CRS from normal peritoneum at a distance, normal peritoneum close to a peritoneal metastasis, miliary peritoneal carcinomatosis, and established peritoneal carcinomatosis.
45968858|NCT04641481|Biological|BBV152|BBV152 (6µg-Algel - Imidazoquinoline)
45968859|NCT04641481|Biological|Placebo|Placebo (PBS+Alum, without antigen)
45968860|NCT04720638|Other|Short fiber reinforced flowable resin composite restorations|reinforced flowable resin composite
45968861|NCT04720638|Other|Conventional resin composite restoration|Microhybrid resin composite
45968862|NCT00218348|Drug|Dextro-Amphetamine Sulfate|
45968863|NCT04641130|Other|Exposure to birch pollen in EEC|Patients are exposed to airborne birch pollen allergen. The duration of each exposure is 4h maximum.
46080810|NCT05807048|Drug|Post-Intervention Medication|"The following post-medications will be administered:~Methylprednisolone 20 mg (or an equivalent dose of an intermediate- or long acting corticosteroid) orally for 2 days starting the day after the administration of DARZALEX FASPRO®.~Patients with a history of chronic obstructive pulmonary disease will be prescribed short and long-acting bronchodilators and inhaled corticosteroids.~Antiviral prophylaxis for herpes zoster reactivation must be initiated within one week of daratumumab hyaluronidase-fihj administration and continued for 3 months following the end of treatment."
45668573|NCT01995357|Device|Coloplast Test A|Coloplast Test A is a newly developed ostomy appliance
45825847|NCT01681589|Device|Control Group|This group will receive Sham TDCS
45825848|NCT01681589|Other|Healthy Control Group|Healthy Controls will be involved in the Study. Healthy Controls will receive no Intervention. There will be 1 screening visit and 1 testing visits.
45968864|NCT04641325|Other|Exercise Intervention Group|Patients will be educated on methods of self-evaluating exertion and cardiovascular effort by assessing respiratory rate and perceived exertion. Next, patients will be given options for cardiovascular activities and complete at a moderate level of activity for a minimum of 150 minutes per week. Patients will perform a combination of exercises under the supervision of a physical therapist until a mod intensity level is reached and sustained. Patients will be taught to use the activity tracker to record their heart rate, activity, and PES. Patients will have a phone call every week to assess status, answer questions, and provide guidance on progressing intensity or duration of exercise. At the end of 8 weeks all patients will return for re-assessment.
45968865|NCT00246051|Behavioral|Sleep Hygiene Education|An education program, consisting of materials from experts in the field of fatigue management, will be provided to all police officers in the intervention group. Videotapes, slides, handouts and other educational material will be compiled to create a variety of information sources for police officers. Examples of materials to be incorporated into this training program would be the Operation Healthy Sleep Training Video, powerpoint created by the Harvard Work Hours, Health and Safety Group and pamphlets provided by the American Academy of Sleep Medicine.
45968866|NCT00246051|Other|Expert-Led Sleep Disorders Screening and Treatment|"Expert-led sleep disorder screening and treatment will consist of visiting police stations and presenting an information session about Operation Healthy Sleep. The session will take place during work time. During the session, we will invite officers to take the Operation Healthy Sleep survey. All subjects that answer the survey indicating that they are at high risk on the Berlin Questionnaire will be contacted to arrange an initial appointment at our OSA research clinic. If they don't meet the criteria they will be disempanelled.~Positive on the Berlin Questionnaire~Clinic visit, exam with a physician, given a home diagnostic device (HDD)~High risk on HDD, seen by physician, given a CPAP machine~Follow up visit after 2-3 weeks, CPAP data downloaded and reviewed~Contacted by a sleep health clinic at 3, 6, 12 months~After 12 months subject will be referred to their primary care physician"
45968867|NCT00246051|Other|Online Sleep Disorders Screening|Online sleep disorder screening will be available to all police officers nation-wide through the Operation Healthy Sleep survey. All subjects that answer the survey questions indicating that they are at high risk of a sleep disorder will be notified either online following the completion of the survey or by email or a letter. Treatment and follow up will not be conducted for individuals who screen positive on the online version of the Operation Healthy Sleep survey.
45968868|NCT04641208|Device|mobile phone|The root mean square (RMS) of the signal will be calculated by using electromyography, and were normalized to the EMG data maximum voluntary isometric contraction (MVIC)
45968869|NCT00559312|Drug|fluticasone/salmeterol combination|Diskus inhaler, fluticasone 250μg/salmeterol 50μg, twice daily, 6-week duration
45968870|NCT00559312|Drug|placebo|Placebo Diskus inhaler, twice daily, 6-week duration
45968871|NCT00559351|Procedure|transthoracic esophagectomy 2-field extended lymphadenectomy|right thoracotomy, mobilization of the esophagus, mediastinal lymph node dissection, laparotomy, gastric tube formation, abdominal lymph node dissection, anastomosis in the neck
45968872|NCT00559351|Drug|neoadjuvant chemotherapy (cisplatin, 5-fluorouracil)|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
45968873|NCT00559351|Radiation|neoadjuvant chemoradiotherapy|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 with concurrent external beam fractionated irradiation to a total dose of 30Gy (2Gy fractions on days 1-5, 8-12, 15-19) followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
45968874|NCT00218504|Drug|Tetrahydrocannabinol|Participants will be randomly assigned to receive an oral dose of 10 mg of THC, 20 mg of THC, or placebo.
45968875|NCT00242034|Procedure|CT and MRI with contrast|
45968876|NCT00559429|Drug|Docetaxel|Docetaxel 50mg/m2 IV on day 1 and day 22
45968877|NCT00559429|Drug|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
45968878|NCT00559429|Drug|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
45968879|NCT00559429|Drug|Docetaxel|Docetaxel 75 mg/m2 IV on day 1, 22 and day 43
45668574|NCT01995357|Device|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance.
45668575|NCT01995357|Device|Standard product|Standard product is the subjects usual product. Only subjects that usually use the CE-marked commercially available SenSura 1-piece flat and SenSura Mio 1-piece are included in the investigation.
45668576|NCT04838353|Device|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
45668577|NCT05270239|Behavioral|N-back Cognitive Training|N-back task mainly trains working memory and information processing speed. This training lasts 10 days (1 hour per day).
45825849|NCT00625703|Drug|Linezolid|"Pharmacokinetics~daily dose of linezolid at 15 mg/kg/dose Intravenously (IV) based on subject's weight at study entry, over half an hour period, every 8 hours for a minimum of 7 days to a maximum of 28 days total. The primary doctor may change the route of administration of linezolid from IV to oral (by mouth)after 72 hours on IV formulation and demonstrated clinical improvement based on the clinical evaluation by the primary doctor and comparison of cystic fibrosis exacerbation criteria scores before and after initiating treatment with linezolid."
45825850|NCT00616577|Drug|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
45825851|NCT00616577|Drug|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
45668578|NCT05270239|Behavioral|Virtual Reality Motor and Cognitive Training|"Virtual Reality Ball Task mainly trains inhibitory control, attention, working memory and motor functions. This training lasts 10 days (30 minutes per day)"
45668579|NCT04312399|Procedure|blood take|Blood is taken to analyse degratdation products of the metabolism of amyloid
45825852|NCT00616577|Drug|Ropivacaine|local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site
45825853|NCT00616343|Drug|Zonisamide|100mg tablets once a day for two weeks, then increased to 200mg qhs for two weeks.
45825854|NCT05599997|Drug|Pecavaptan (BAY1753011)|30 mg, immediate release tablet, single dose, oral
45825855|NCT05599997|Drug|Pecavaptan (BAY1753011)|15 mg, immediate release tablet, single dose, oral
45825856|NCT05599919|Drug|Nitric Oxide|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
45825857|NCT05599841|Procedure|PI solution|3,000 cc of <2% concentrated povidone iodine solution will be used as irrigation solution at primary hip/knee arthroplasty. The PI solution was left in the joint for 3 minutes.
45825858|NCT05599841|Procedure|Saline Solution|3,000 cc of 0.9% saline solution will be used as irrigation solution at primary hip/knee arthroplasty. The saline solution was left in the joint for 3
45825859|NCT01681745|Device|Cryo-Touch III|
45825860|NCT05599607|Dietary Supplement|Probiotic mixture|Mixture of strains of lactobacillus and bifidobacteria
45825861|NCT05599607|Dietary Supplement|Placebo|Maltodextrin
45825862|NCT01645709|Drug|Verapamil|
46080811|NCT05799495|Drug|PF-07817883|Arm 1: low dose Arm 2: medium dose Arm 3: high dose
46080812|NCT05799495|Drug|Placebo|Placebo
46080813|NCT05798286|Other|Quantra|The study plans to collect 2 additional 3 mL citrate tubes of venous blood in addition to the platelet and blood counts.
46080814|NCT05798286|Other|Control|The study plans to collect 1 additional 3 mL citrate tubes of venous blood in addition to the platelet and blood counts at each time.
46080815|NCT05798117|Drug|YTB323|Single infusion of YTB323
45668580|NCT04307563|Behavioral|Mindfulness session|1.5 hour weekly session with health educator
45825863|NCT01645709|Drug|Placebo|
45825864|NCT05599529|Other|Differential attainment|Differential attainment related to covid, ethnicity and international graduate status
45825865|NCT05270993|Behavioral|Traditional Centre-based Cardiac Rehabilitation (CBCR) group|A 4-week centre-based outpatient cardiac rehabilitation programme where patients will receive 12 group-based sessions. Patients will also be given access to online educational resources. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
45825866|NCT05270993|Behavioral|I-CREST group|A 6-week home-based cardiac rehabilitation programme where participants will receive an I-CREST app (to deliver education, medication reminders, exercise and vital monitoring) and a wearable smartwatch device (to track physical activity). Participants will be remotely supervised by the cardiac rehabilitation team via an I-CREST web-portal. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
45825867|NCT05267483|Other|No intervention|No intervention
45825868|NCT00608465|Drug|Eplerenone|5 mg x 1 week followed by 10 mg x 9 weeks.
45825869|NCT00608465|Drug|Ramipril|Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.
45825870|NCT00608777|Drug|Calcipotriene/betamethasone|One application to affected areas, once a day for two weeks. The PI may choose to extend treatment until Week 4 if necessary.
45825871|NCT00379301|Procedure|Radiofrequency ablation|Special catheters are inserted into blood vessels in the groin, then advanced into the left atrium of the heart. Radiofrequency (heat) energy is applied to small areas of heart tissue where electrical impulses that generate AF are found.
45825872|NCT00379379|Device|electroacupuncture|
45825873|NCT00379457|Biological|dactinomycin|
45825874|NCT00379457|Drug|carboplatin|
45825875|NCT00379457|Drug|cyclophosphamide|
45825876|NCT00379457|Drug|doxorubicin hydrochloride|
45825877|NCT00379457|Drug|etoposide|
45825878|NCT00379457|Drug|ifosfamide|
45825879|NCT00379457|Drug|topotecan hydrochloride|
45825880|NCT00379457|Drug|vincristine sulfate|
45825881|NCT00379457|Drug|vinorelbine tartrate|
45825882|NCT00379457|Procedure|conventional surgery|
45825883|NCT00379457|Radiation|radiation therapy|
45825884|NCT01643525|Device|Nautilus NeuroWaveTM System|Non-invasive device designed to detect pressure signals from the skull to aid in the diagnosis of ischemic stroke.
45825885|NCT01629329|Drug|Aspirin, Acetaminophen, Caffeine pills|One time dose of 2 pills each containing acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet. Simultaneous administration of placebo(5ml of saline administered IV)
45825886|NCT01629329|Drug|Prochlorperazine 10mg|One time dose of Prochlorperazine 10mg/2ml given IV slow push. Simultaneous administration of 2 unmarked placebo pills.
45825887|NCT01606709|Drug|GnRH agonist|GnRH agonist 1mg one dose
45825888|NCT01606709|Drug|hCG|5,000 IU one dose
45825889|NCT05599139|Behavioral|Low iodine diet|Before ablation and possible subsequent therapy with 131I, patients have to follow a low iodine diet (LID), reducing the iodine intake < 50 mcg per day and thereby depleting the overall iodine store in the body.
45825890|NCT00423059|Drug|bevacizumab|
45825891|NCT00585611|Drug|Atorvastatin|Atorvastatin - 40 mg orally daily for 6 months
45668581|NCT04817761|Drug|Calaspargase pegol (S95015)|"Part 1: S95015 will be administered at dose of 2000 U/m2, 1500 U/m2 or 1000 U/m2 (dose level based on age and BMI) via a 2-hour intravenous infusion at Day 4 (or 5, or 6) of the induction phase, Days 15 and 43 of the consolidation phase, Day 22 of the interim maintenance phase and Days 4 (or 5, or 6) and 43 of the delayed intensification phase. S95015 starting doses for age and BMI groups will be confirmed.~Patients will receive premedication prior to calaspargase pegol administration (acetaminophen, histamine-1 blocker, and corticosteroids to prevent hypersensitivity reaction) and other backbone chemotherapy agents based on the CALGB 10403 protocol treatment regimen.~Part 2: S95015 will be administered at doses as confirmed in part 1."
45968880|NCT04641403|Procedure|The surgeon performed Laparoscopic-assisted TAP (LTAP) block|After the induction of anesthesia, the first port will be inserted through the umbilicus and a 12 mmHg pneumoperitoneum will establish as a standard. Under the direct view of the laparoscopic camera, the block will be performed by inserting a 22-G needle just above the iliac crest through the midclavicular line posteriorly into the triangle of Petit and then inserting the needle below the costal arch through the midclavicular line towards the anterior axillary line into the subcostal plane. The block needle will be advanced under direct view until the two pops were felt and the extraperitoneal space will reach without puncturing the parietal peritoneum, and pulling back the needle 0.5 cm, the area of the thin transversus abdominis muscle fibers wiil be infiltrated. In this area, the correct plane of the needle tip will confirm by observing Doyle's bulge and the spread of the local anesthetic.
45968881|NCT00218582|Behavioral|Double Trouble in Recovery|Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
45668582|NCT03706963|Other|Phone Call|-phone call 7 days (+/- 2 days) into preoperative period
45668583|NCT04267081|Drug|Venetoclax|Ex vivo venetoclax sensitivity testing is used for patient selection.
45968882|NCT00218582|Behavioral|Standard psychiatric day treatment|Individual counseling, groups, medication
45968883|NCT04641169|Procedure|echocardiography|Four measurements in echocardiography performed in addition to standard care
45968884|NCT00242073|Procedure|MRI Prostate|
45825892|NCT00585611|Other|placebo|placebo
45825893|NCT00379535|Drug|potassium iodide|per os
45825894|NCT00379535|Drug|placebo|per os
45968885|NCT04640740|Procedure|hip arthroplasty|two different approaches of total hip arthroplasty
45968886|NCT00218621|Procedure|Buprenorphine / methadone|Parallel study to double blind, double dummy study evaluating safety and efficacy of buprenorphine vs methadone treatment for pregnant opioid dependent women
45968887|NCT00246168|Drug|tramadol hydrochloride + acetaminophen|
45968888|NCT04640584|Device|C-Brace|The C-Brace consists of individually fabricated thigh, calf and foot components. An ankle joint, unilateral or bilateral fitting, or an individual spring element connects the foot and calf components. The sensor system continuously measures the flexion of the knee joint and its angular acceleration. This allows the C-Brace to detect the user's current walking phase, so it can regulate the hydraulic resistances as well as control the flexion and extension of the knee joint.
45968889|NCT00218660|Drug|Naltrexone|150mg/day Naltrexone
45668584|NCT04258267|Procedure|Early mobilization|Patients will wear an adduction sling to immobilize the shoulder during the first 4 weeks post-operative
45668585|NCT04258267|Procedure|Delayed mobilization|Patients will wear an abduction sling to immobilize the shoulder during the first 4 weeks post-operative, followed by an adduction sling for 2 weeks.
45825895|NCT04706195|Behavioral|Person-centred care at distance through an eHealth platform|Person-centred care at distance through an eHealth platform, used by professionals, patients and relatives
45825896|NCT05596253|Procedure|TIPS|TIPS: Established distributary channel between the portal vein and hepatic vein via the jugular vein, portal vein blood directly shunts into the systemic circulation to reduce portal vein pressure to effectively prevent bleeding and refractory ascites.
45668586|NCT05309005|Behavioral|VR TASIT|Consists of a Norwegian adaptation of the 59 videos of social scenes that constitute the A Form in the original TASIT. The stimulus material in the Virtual Reality version is perceived through a head mounted display. This allows the test person to watch the scenes in three dimensions and a 360 degree angle, increasing the sense of social presence.
45668587|NCT05309005|Behavioral|DT TASIT|Consists of a Norwegian adaptation of the 59 videos of social scenes that constitute the A Form in the original TASIT, with identical content as the VR TASIT. The stimulus material in the desktop version is perceived on a two dimensional desktop computer screen.
45825897|NCT01557881|Device|magnetic resonance imaging with positron emission tomography scanning|University Hospitals Seidman Cancer Center [SCC] will house the Philips Ingenuity TF PET/MR, which is a hybrid scanner that merges magnetic resonance imaging with positron emission tomography scanning. University Hospitals is one of only five hospitals in the world with this technology. The PET/MRI system consists of two imaging scanners used sequentially as in PET/CT. The 3Tesla MRI component provides the high resolution that is necessary for soft tissue contrast and functional information on perfusion, diffusion, or metabolism. PET provides information about cellular metabolism and receptor status.
45968890|NCT00218660|Behavioral|BRENDA|Psychosocial Treatment
45968891|NCT00218660|Behavioral|CBT|Cognitive Behavioral Therapy
45968892|NCT00218660|Drug|Placebo|
45968893|NCT04640389|Other|Cross-sectional study/no intervention|Cross-sectional study/no intervention.
45968894|NCT04640467|Diagnostic Test|Biophsical profile|There are five components measured during the biophysical examination. A score of 2 points is given for each component that meets criteria. The test is continued until all criteria are met or 30 minutes have elapsed. The points are then added for a possible maximum score of 10. A total score of 10 out of 10 or 8 out of 10 with normal fluid is considered normal. A score of 6 is considered equivocal, and a score of 4 or less is abnormal.
45668588|NCT04814173|Other|One-jaw mechanic total maxillary arch distalization|A group of patients in which participants will be undergo to the one-jaw mechanic for mini-implants anchored total-maxillary-arch-distalization (the mini-implants will be inserted in the maxillary arch between the roots of 2nd premolar and 1st molar and closer to the molar, then a force of 250 g will be applied from the TAD to a hook lateral to the laterals).
45968895|NCT04640467|Diagnostic Test|Cerebroplacental ratio|CPR is the ratio of the Middle Cerebral Artery Pulsatility Index (MCA PI) to the Umbilical Artery Pulsatility Index (UA PI). The pulsatility indices will be measured from an automated trace of at least three consecutive waveforms of the relevant vessel in the absence of fetal breathing movements or uterine contractions. The angle of insonation will be as close to zero degrees as possible. The UA PI will be recorded from a free-floating section of cord, and the MCA PI will be obtained from the proximal third of the vessel (10, 14).
45968896|NCT04640233|Biological|Gam-COVID-Vac|Vaccine for intramuscular injection
45968897|NCT04640233|Other|Placebo|Placebo comparator
45968898|NCT02961621|Behavioral|Stress Reduction Training for 9-1-1 Telecommunicators|
45968899|NCT00218699|Behavioral|Cognitive-Behavioral Intervention|
45968900|NCT04640116|Procedure|Transjugular intrahepatic portosystemic shunt (TIPS)|A needle punctured the portal vein through the transjugular approach. After a successful puncture, the parenchymal tract was dilated, and covered stents (GORE® VIATORR) were introduced. The specifications of the covered stents were 8 mm × 50 mm, 8 mm × 60 mm, 8 mm × 70 mm, and 8 mm × 80 mm. All of the diameters of the bare stents were 8 mm, and the lengths were 50-80 mm. The portal vein pressure was measured before and after shunt creation. After the insertion of TIPS, all of the patients received a diuretic treatment and a salt-limited diet until the ascites disappeared.
45968901|NCT04640116|Procedure|microwave ablation (MWA)|MWA: After the patient's ascites disappears, MWA therapy will be performed. A MWA antenna was gradually inserted into the tumor along the predetermined angle under the guidance of Computed Tomography (CT). The whole thermal procedure was conducted under intravenous anesthesia. Vital signs were monitored during the procedure. The settings of the ablation parameters depended upon the manufacturer's recommendation and our experience. Ablation volume was determined by physicians according to liver function, tumor invasion site, and tumor stage. An upper abdominal CT scan was carried out immediately after the procedure to evaluate the ablation area and complications.
45968902|NCT00242112|Procedure|MRI Prostate|
45968903|NCT00559546|Drug|montelukast|10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner
45968904|NCT00218777|Behavioral|Comprehensive Behavioral Intervention for Tics|
45968905|NCT00559624|Drug|Acadesine|For part I of the study one 4 hour intravenous infusion will be given. In part II upto five 4 hour intravenous infusions will be given over 20 days.
45968906|NCT04639921|Diagnostic Test|positive test followed by gluten-free diet|DBPCFC with gluten
45668589|NCT04814173|Other|Two-jaw mechanic total maxillary arch distalization|A group of patients in which participants will be undergo to the tow-jaw mechanic for mini-implants anchored total-maxillary-arch-distalization (the mini-implants will be inserted in the mandibular arch between the 2nd premolar and 1st molar, then, a class II elastics 3/16 and 6.5oz will be use from the TAD to the hook of canines brackets).
45668590|NCT04814173|Other|en-mass retraction|A group of patients in which participants will be undergo to the en-mass retraction with first premolars extraction with mini-implants in the maxillary arch inserted between the 2nd premolar and 1st molar, then a force of 250 g will be applied from the TAD to a hook lateral to the laterals .
45668591|NCT04797559|Procedure|SZMN Block|Suprazygomatic Maxillary Nerve (SZMN) Blocks bilaterally near the temples of the patient
45668592|NCT03698071|Biological|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
45668593|NCT03698071|Biological|urine sample|6 ml
45825898|NCT00379613|Drug|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
45825899|NCT00379613|Drug|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
45825900|NCT00379691|Drug|phenylephrine|
45968907|NCT04639921|Dietary Supplement|Placebo|Placebo
45968908|NCT00246207|Drug|CONCERTA (OROS methylphenidate hydrochloride)|
45968909|NCT04639882|Behavioral|Personalized normative feedback|Information presenting perceived and actual drinking norms.
45968910|NCT00218816|Behavioral|Nebulizer Education Intervention|Asthma Education
45968911|NCT00218816|Behavioral|Standard Asthma Education Groups|Asthma Education
45968912|NCT04639804|Drug|Tegoprazan|Tegoprazan 50 mg tablet
45968913|NCT04639804|Drug|Naproxen|Naproxen 500 mg tablet
45968914|NCT04639804|Drug|Aceclofenac|Aceclofenac 100 mg tablet
45968915|NCT04639804|Drug|Celecoxib|Celecoxib 200 mg capsule
45968916|NCT00559663|Dietary Supplement|Green tea|"The green tea group consumed first daily one liter of green tea infusate made of 4 bags left in boiling water during 3 minutes.~After a four week washout-time they were switched over to the dark chocolate treatment, which included consumption of 3.5 ounces 70% dark chocolate.~Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels"
45968917|NCT00559663|Dietary Supplement|70% dark chocolate|"The dark chocolate group consumed 3.5 ounces 70% dark chocolate per day during a one week period.~After a four week washout-time they were given the green tea treatment, which included ingestion of one liter green tea infusate (containing 4 green tea bags).~Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels."
45968918|NCT04639570|Other|KneuroKnits|The KneuroKnits program will be based upon current knitting education practices and leading practices in facilitation of social participation for individuals with neurodevelopmental disorders, physical disabilities, and acquired brain injuries. The program will consist of 4 weekly sessions in which participants will learn knitting fundamentals and have opportunities to socialize over a shared occupation. The 4 weekly sessions of the KneuroKnits curriculum will include related knitting and social skills themes of the week. Each session will begin with a structured lesson on the knitting topic of the day, and will then continue into knitting practice and social interaction. Participants will be encouraged to practice their new skills (knitting and social) between sessions, and will be allowed to keep all materials that they use or create.
45455719|NCT05788549|Behavioral|Relaxative Music|The Individual Identification Form, Partial Mayo Score, State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, and IBD-QOL were filled out in person during the first meeting. Individuals were asked to perform subsequent applications at home.Individuals were provided with a relaxing music file prepared by the researcher and were asked to listen to it at least once a day for 30 minutes in a quiet and calm environment. The researcher also sent reminder SMS messages twice a week for eight weeks to remind individuals. Four and eight weeks after the first meeting, forms were transferred to an online environment and sent to individuals via WhatsApp Messenger as a link to be completed to listen to the relaxing music regularly. At 4 and 8 weeks after the first meeting, the researcher transferred the forms to an online environment via Google Forms and asked individuals to fill them out by accessing the link sent to them via WhatsApp Messenger
45968919|NCT04639687|Behavioral|Food as Medicine Delivery|12 consecutive weeks of home-delivered vegetables plus whole grain foods along with weekly text containing educational video
45455720|NCT05788471|Other|conventional Treatment|It consists of Superficial heat, Ultrasound therapy and stretching exercise to lumbrical muscles of the hand.
45455721|NCT05788471|Other|Neurodynamic mobilization|It is the mobilisation of the nervous system as an approach to physical treatment of pain. The treatment and or assessment relies on influencing pain physiology via the mechanical treatment of neural tissues and non-neural structures surrounding the nervous system.
45668594|NCT03620539|Other|Lifestyle intervention|Sauna bathing
45668595|NCT04792567|Drug|BAF312|taken orally once per day (dose depends on CYP2C9 genotype)
45668596|NCT04792567|Drug|Baseline disease modifying therapies (DMTs)|DMTs: Dimethylfumarate, glatirameracetate, interferon, teriflunomode according to respective SmPC
45668597|NCT04825171|Drug|Bryophyllum 50 % Chewing Tablets|Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g.
45968920|NCT00218855|Drug|thalidomide|tablets thalidomide start 100 mg x 2 escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. The same procedure is repeated by first relapse.
45968921|NCT00218855|Drug|placebo|100 mg x 2 mg tablets escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. This procedure is repeated by first relapse.
45968922|NCT04639609|Other|Characterization of Neuromuscular Function and Fatigue|at inclusion
45668598|NCT03604783|Drug|TP-1287|TP-1287 by oral administration
45668599|NCT04235335|Behavioral|Indigenous Mother's Empowerment Program & Indigenous Kid's Club Program|Weekly groups administered to mothers and children simultaneously but separately for 10 weeks
45825901|NCT01685333|Drug|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Human Recombinant Epoetin) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
45668600|NCT04419025|Drug|N-acetylcysteine|Oral formulation: 600 mg capsules of N-acetylcysteine
45825902|NCT01648907|Other|Imaging exams|"Radiological examinations:~Standard x-ray: they include an x-ray of the cervical, thoracic, and lumbar spine (side-on), of the lumbar spine from the front and an x-ray of the pelvis from the front~MRI scan: are taken of the cervical, thoracic and lumbar spine and sacroiliac joints.~Bone densitometry: evaluation of bone densitometry of the lumbar spine and femoral neck.~Enthesis ultrasound: bilateral evaluation of entheseal insertions for the Achilles tendon, patella tendons and epicondyle tendons.~Biological tests :~Genetic test : DNA will be collected at the first visit from all centers. RNA will be collected at the inclusion visit in AP-HP centres only.~Serum will be collected by all centres at the initial visit, then in M6, M12 and M24 for the first two years of the study, then in M60.~Urine will be collected by all centres at the initial visit, then in M24 for the first two years of the study, then in M60."
45825903|NCT01556009|Drug|Vismodegib|150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
45968923|NCT04639726|Dietary Supplement|Whey Protein Micro Gel|The test product is whey protein microgels 10g, reconstituted in 125ml water.
45968924|NCT04639726|Other|Water without Whey Protein.|A matching placebo (125ml of water without whey protein) will be used as control.
45968925|NCT04639765|Other|CBT without Personalization|Intervention involves a video describing CBT without a message about personalization.
45968926|NCT04639765|Other|CBT with Personalization|Intervention involves a video describing CBT with a message about personalization.
45968927|NCT04639765|Other|ADM without Personalization|Intervention involves a video describing antidepressant medication without a message about personalization.
45968928|NCT04639765|Other|ADM with Personalization|Intervention involves a video describing antidepressant medication with a message about personalization.
45968929|NCT04639765|Other|Combined Treatment without Personalization|Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication without a message about personalization.
45968930|NCT04639765|Other|Combined Treatment with Personalization|Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication with a message about personalization.
45825904|NCT01556009|Drug|Aminolevulinic acid %20 topical solution|20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
45968931|NCT00218894|Procedure|Cataract surgery|surgery one one or two eyes by use of two different types of lenses and correcting for refraction
45968932|NCT00246246|Drug|risperidone|
45825905|NCT04331951|Diagnostic Test|Targeted biopsy within Sydney protocol|Biopsy at suspicious GIM lesions at any area of antrum (both lesser and greater curvature site), body (both lesser and greater curvature site) and incisura. If there is no abnormal mucosa seen at any site, random biopsy will be performed.
45968933|NCT04639375|Biological|Vaccinated with polio vaccine (IPV)|poliovirus vaccine (IPV) manufactured by Sanofi Pasteur for distribution in the United States
45825906|NCT01521143|Biological|Cvac|Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.
45825907|NCT01521143|Biological|Placebo|"Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.~Placebo consisted of the Cvac formulation buffer (5% HSA, 10% DMSO) with 0.9% simethicone provided in 1 mL vials that had been cryopreserved and stored at the manufacturing facility."
45825908|NCT05529953|Dietary Supplement|Oleanolic acid (CAS no. 598-02-1; PubChem CID 10494)|Postprandial study of bioavailability of Oleanolic acid, formulated as functional olive oil, in healthy subjects
45825909|NCT05529953|Dietary Supplement|Control commercial olive oil|Postprandial study of Oleanolic acid bioavailability in healthy subjects
45825910|NCT00546455|Drug|Fenretinide|200 mg/day
45455722|NCT05786261|Device|experimental group MIRT|Task 1a: Assessing the effect of MIRT on cortical plasticity tested with rPAS Task 1b: Assessing the effect of MIRT on structural cortical plasticity and brain connectivity tested with MRI Task 1c: Assessing the effect of MIRT on movement-related beta modulation Task 1d: Assessing the effects of MIRT on motor skills formation with reaching tasks Task 1e: Assessing the effects of MIRT on EEG correlates of motor skills formation Task 2a: Assessing the effect of MIRT on muscle synergies during gait Task 2b: Assessing the effect of MIRT on muscle synergies during reaching movements Task 3a: Assessing the effect of MIRT on sleep microstructure
45455723|NCT05786261|Device|EEG task rTMS, fMRI|EEG task rTMS, fMRI
45455724|NCT05786131|Procedure|Culprit-lesion revascularization|Percutaneous coronary intervention of culprit-lesion
45825911|NCT00546455|Drug|Placebo|2 capsules/day
45825912|NCT01525745|Radiation|Radiosurgery/SBRT|1, 3 or 5 SBRT treatments
45825913|NCT01525745|Radiation|External Beam Radiation Therapy|10 consecutive days of standard radiation
45825914|NCT05231057|Other|Pilates exercises|Mat, Pilates band or elastic bands, and Pilate's ball
45825915|NCT05231057|Other|Conventional physical therapy program|pain relief, increasing flexibility, and mobility, improving muscle strength
45825916|NCT00000737|Drug|Dronabinol|
45825917|NCT00000737|Drug|Megestrol acetate|
45825918|NCT00533351|Drug|AGN201781|AGN201781 50 mg capsules three-times daily for 2 weeks
45968934|NCT04639492|Dietary Supplement|MBS oral solution|Oral BIDAC, twice a day before breakfast and dinner times
45968935|NCT04639453|Diagnostic Test|Trunk strength with hand-held dynamometer|MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various trunk muscle groups in flexion, extension, and lateral (N).
45968936|NCT04639453|Diagnostic Test|Balance Assessment in Sitting and Standing test (BASS)|"The BASS is a test to assess static and dynamic sitting and standing balance, which has been validated for post-stroke hemiparetic patients. Each test is evaluated by a score from 0 (patient needs external support) to 4 (stable without external help) for static condition and from 0 (no possibility to pick up objects) to 3 (objects picked up without external help) for dynamic condition. The maximal score (sitting, standing, static and dynamic) is 14 points."
45968937|NCT04639453|Diagnostic Test|Timed Up and Go test|The participant sits on a chair, gets up, walks 3m, makes a half turn in 1m2, walks 3m and comes back to sit on the chair. The time (s) to complete the task is measured.
45668601|NCT04837417|Diagnostic Test|Pathologic group|"Voluntary Activation level will be determined with the interpolate twitch technique (ITT), both during isometric contractions (knee at 40° flexion) and during isokinetic contraction at angular velocity equal to 100°/s.~Vastus Medialis and Soleous H-reflex will be measured. Cortical excitability and interhemispheric connectivity will be measured through transcranial magnetic stimulation (TMS).~Tests of balance in standing will be performed using the EquiTest platform. Individuals will be requested to perform three different tasks: Sensory Organization test, Adaptation Test upward/downward, Motor Control test backward/forward. Surface electromyography from lower limbs will be recorded.~Through TMS driven by neuronavigation, the cortical representation of the Quadriceps muscle will be studied.~Gait analysis will be performed on a treadmill mounted on force sensors. Participants will walk at increasing velocities from 0.4 m/s to 1.6 m/s. Speed will be increased of 0.2 m/s every 30 s."
45668602|NCT04781647|Drug|ABI-H0731|Participants will receive ABI-H0731 300 mg tablets orally once daily
45668603|NCT04781647|Drug|ETV|Participants will receive ETV 0.5 mg tablets orally once daily
45968938|NCT04639453|Diagnostic Test|Modified Functional Reach Test (MFRT)|The MFRT is a dynamic seated balance test that measures the trunk's ability to move forward, to the paretic and non paretic side (cm).
45968939|NCT04639453|Diagnostic Test|Joint Position sense test (trunk)|The joint positional sense test of the trunk consists in evaluating the positional error of the trunk in the sagittal plane (mm) and in the frontal plane (mm) during a trunk flexion posture (target position).
45968940|NCT04639453|Diagnostic Test|Unstable sitting in a seesaw|This test evaluates the balance capacities of the subject in an unstable sitting position on a seesaw (mediolateral or anteroposterior instability) with forceplate and phone application using center of pressure variables: total displacement (mm), area (mm2), deltas (mm), mean velocity (mm/s) et maximal velocity (mm/s).
45968941|NCT00242190|Drug|oxaliplatin|
45968942|NCT00242190|Drug|gemcitabine|
45968943|NCT00242190|Procedure|radiation therapy|
45968944|NCT00218933|Behavioral|Moderate intensity exercise training|12-weeks, 2-3 times per week moderate exercise-intensity (70% of peak heart rate)
45968945|NCT00218933|Behavioral|High intensity exercise training|12-weeks, 2-3 times per week high-intensity interval-training (95% of peak heart rate)
45968946|NCT04638985|Biological|sIPV+DTaP+MMR|sIPV+DTaP+MMR at the age of 18 month old
45968947|NCT04638985|Biological|sIPV|sIPV at the age of 18 month old
45968948|NCT04638985|Biological|DTaP|DTaP at the age of 18 month old
45968949|NCT04638985|Biological|MMR|MMR at the age of 18 month old
45968950|NCT04638907|Procedure|Assessment of NM block|Observation of resulting course of NM block under teratment and monitoring as described.
45968951|NCT04709718|Procedure|hepatectomy|liver resection taking over the liver hemangioma
45668604|NCT04781647|Biological|Peg-IFNα|Participants will receive Peg-IFNα with a starting dose of 180 µg solution by subcutaneous injection once weekly
45825919|NCT00533351|Drug|placebo|placebo 50 mg capsules three-times daily for 2 weeks
45455725|NCT05786131|Procedure|Non-culprit-lesion revascularization|Complete percutaneous coronary intervention of all angiographically significant non-culprit lesions
45825920|NCT00528437|Drug|temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid|13-cis-retinoic acid, when absorbed, may be subject to first-pass metabolism and subsequent plasma (and tumor) concentrations will depend on the rate of metabolism to the inactive 4-oxo metabolite.
45825921|NCT05480735|Behavioral|Prehabilitation|Multimodal prehabilitation program
45825922|NCT00000743|Drug|Alvircept sudotox|
45825923|NCT00000743|Drug|Zidovudine|
45825924|NCT00506909|Drug|Oxytocin|20 IU BID or 40 IU BID
45968952|NCT00412295|Device|Alcon Ladarvision (Wavefront-guided PRK)|Wavefront-guided PRK using Alcon Ladarvision
45968953|NCT04628884|Drug|Conventional dose|Conventional dose used to calculated the protamine dose
45968954|NCT04628884|Drug|Dosing according residual heparin|In this group the heparin doses will be simulated using a pharmacokinetic model to estimated the residual heparin amount at the end of the surgery, the protamine dose will be calculated using the residual heparin
45668605|NCT04837339|Other|Collection of biological samples|Blood sample, biopsies sample, hair sample.
45825925|NCT00506909|Drug|Placebo|20 IU BID or 40 IU BID
45825926|NCT00500045|Drug|nicotinic acid|niacin 1500 mg po qd
45825927|NCT00000749|Biological|rgp120/HIV-1 SF-2|
45825928|NCT05208359|Behavioral|Supporting Transition Resilience Of Newcomer Groups (STRONG)|10 group sessions that offer skills, strengths, support, and affirmation for newcomer youth
45968955|NCT04629157|Device|Innova Lateral Flow Device|The Innova Lateral Flow Device will be used on anterior nasal swab specimens and RT-PCR will be performed on nose and throat swabs.
45968956|NCT00561262|Other|questionnaire administration|
45968957|NCT00561262|Procedure|high-intensity focused ultrasound ablation|
45968958|NCT00561262|Procedure|quality-of-life assessment|
45968959|NCT00561301|Drug|GemDOx|gemcitabine oxliplatin
45968960|NCT04720755|Device|Low-Intensity Extracorporeal Shock Wave Therapy|Twice-weekly treatments for 6 weeks, of 0.2mL/mm^2 administered for 500 shocks per treatment site, for a total of 3000 shocks per week.
45968961|NCT00412334|Drug|Copegus|1200-1600mg/day po
45968962|NCT00412334|Drug|Copegus|1000-1200mg/day po
45968963|NCT00412334|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly
45968964|NCT00412334|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc twice weekly
45968965|NCT00561379|Drug|CHOP+RITUXIMAB|CHOP-14- Rituximab x 8 courses
45968966|NCT00561379|Drug|CEEP-RITUXIMAB|High dose chemotherapy with rituximab including autologous stem cell support.
45668606|NCT04813003|Other|Functional Brain Imaging and neurobehavioural tasks|"Combination of 3 neurobehavioural tasks:~Task 1 consists in subjective value rating of 64 food items. Participants are asked to rate how much they would want to eat the presented food item while fMRI (functional magnetic resonance imaging ) scanning is performed.~Task 2 consists in rating of subjective nutrient factor of the same 64 food items. Participants will answer the following four categorical questions in randomized order for each item: low or high in added sugar/protein/fat and healthy or unhealthy.~Task 3 consists of a decision-making task. Participants will be presented with two food items (out of the 64 food items), and asked to choose which of the two items they prefer to consume at the end of the experiment."
45455726|NCT05785936|Procedure|Desensitization|Patients that received apheresis and anti-cluster of differentiation antigen 20 for desensitization priori to kidney transplantation
45455727|NCT05785130|Other|background noise|Using sound machine for 3 days at bedtime for 7 hours(11p.m.- 6a.m.) in a decibel of 40-50.
45455728|NCT05784389|Other|Low PRAL|Two weeks on a low PRAL diet compared to 2 week free living
45455729|NCT05784376|Behavioral|Education-based|Nutrition education delivered via text messages through mobile applications (e.g. WhatsApp).
45825929|NCT05404685|Device|Low insufflation pressure (7mm Hg) for Robotic Assisted Partial Nephrectomy|"Use of insufflation pressure at 7 mm Hg. The groups will differ only with respect to the insufflation pressure level set on the AirSeal® system.~The level of pressure will be adjusted at the beginning of the surgery, after placement of the trocars, in accordance with the result of the randomization."
45825930|NCT05404685|Device|Standard insufflation pressure (12mm Hg) for Robotic Assisted Partial Nephrectomy|"Use of insufflation pressure at 12 mm Hg. The groups will differ only with respect to the insufflation pressure level set on the AirSeal® system.~The level of pressure will be adjusted at the beginning of the surgery, after placement of the trocars, in accordance with the result of the randomization."
45825931|NCT05204225|Other|Tablet Application|Participants will receive a tablet app (ReHand) along with face-to-face physiotherapy sessions. The ReHand app includes an exercise program based on current scientific evidence for improving funcional ability and dexterity of the hand with neurological affectation. Those exercises are performed making controlled taps and movements while touching the touchscreen and guided by feedbacks. Also, ReHand app includes a prescription and monitoring web-based system for professionals. Along with this intervention, face-to-face physiotherapy sessions will be performed their respective centres.
45825932|NCT05204225|Other|Conventional Treatment|Participants of this group will receive a home exercise program on paper and face-to-face physiotherapy sessions. This intervention is the conventional approach usually delivered in their respective centres. Those exercises were specifically developed for the rehabilitation of the hand with neurological affectation.
45825933|NCT00000767|Biological|TBC-3B Vaccine|
45825934|NCT00000767|Biological|Smallpox Vaccine|
45825935|NCT05383547|Drug|Bortezomib|Dexamethasone 10mg+ bortezomib (1.3mg /m2 IV) was administered at D1,D4,D8,D11, one month for 1 cycle, for 2 cycles.
45825936|NCT00456989|Drug|Taxotere|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Taxotere is administered on days 1, 8 and 15 (rate: 1 hour). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively.
45825937|NCT00456989|Drug|Doxil|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Doxil is administered on day 1 (rate: 1mg/min). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
45825938|NCT00000773|Drug|Atovaquone|
45825939|NCT00428207|Drug|Insulin Aspart versus Insulin Lispro|Subjects will be randomly assigned to insulin aspart versus insulin lispro via random number generation. Half of the patients will begin with insulin aspart, and then will be crossed over to insulin lispro. The insulin sequence will be reversed for the other half of the patients.
45825940|NCT00428207|Drug|Insulin Lispro versus Insulin Aspart|Subjects will be randomly assigned to insulin lispro versus insulin aspart via random number generation. Half of the patients will begin with insulin lispro, and then will be crossed over to insulin aspart. The insulin sequence will be reversed for the other half of the patients.
45825941|NCT05299151|Other|Vestibular exercises|The vestibular exercise program basically consists of 3 groups of exercises: adaptation, substitution, and habituation exercises. It is aimed to provide vestibular adaptation with adaptation exercises. Exercises that include visual and somatosensory cues to improve gaze and postural stability constitute substitution exercises. Balance exercises can be performed with eyes open and closed, or somatosensory cues can be changed by performing them on soft ground. Removing or reducing clues allows the patient to use other systems as well. The basis of habituation exercises is the reduction of the pathological response as a result of repeated exposure to the provocative stimulus. Habituation is specific to the type, intensity, and direction of stimuli. In most cases, the movement that stimulates the pathological response is less frequently performed during daily activities and promotes compensation for the initially abnormal signal of treatment.
45825942|NCT05299151|Other|Standard neurorehabilitation exercises|A neurorehabilitation program based on stretching, strengthening, posture, mobilization, static and dynamic balance exercises (standing on one leg, tandem, balance board, etc.) will be applied.
45825943|NCT00000791|Drug|Glycovir|
45825944|NCT00000791|Drug|Zidovudine|
45825945|NCT00379847|Drug|conivaptan|IV
45825946|NCT05252741|Other|serum samples and punch skin biopsies|we will take serum samples from psoriasis patients and healthy controls and skin punch biopsies from lesional and non-lesional areas in psoriasis patients.
45825947|NCT00374543|Drug|Ziprasidone|Ziprasidone, flexibly dosed from 40 to 160 mg/day, for 8 weeks.
45825948|NCT00374543|Drug|Placebo|Placebo administered daily for 8 weeks
45825949|NCT00000803|Drug|Delavirdine mesylate|
45825950|NCT00000803|Drug|Zidovudine|
45825951|NCT00000803|Drug|Didanosine|
45825952|NCT00314093|Drug|RFT5pdgA|
45668607|NCT01638559|Drug|Immunosuppression withdrawal|Participants will undergo gradual ISW in no less than 36 weeks and no more than 52 weeks with frequent monitoring of liver tests. All participants will be followed for 48 months ensuring a minimum of 36 months of follow-up after successful ISW.
45668608|NCT04210999|Other|Homebased resistance training|Resistance training at home instructed via a smart phone training app
45968967|NCT04629118|Device|Selution SLR™ 018 Drug Eluting Balloon|Target lesion will be pre-dilated with high pressure non-compliant balloon, then treated with SELUTION SLR™ 018 DEB Balloon.
45968968|NCT00242229|Drug|DVS-233 SR|
45825953|NCT00299195|Drug|sulindac|Sulindac 150 mg po bid x 24 weeks
45825954|NCT00299195|Drug|Placebo|Placebo bid x 24 weeks
45825955|NCT01351415|Drug|Bevacizumab|Participants will receive bevacizumab 7.5 or 15 milligrams per kilogram (mg/kg) intravenously.
45825956|NCT01351415|Drug|Docetaxel|Docetaxel 60 or 75 milligram per meter square (mg/m^2) on Day 1 every 21 days.
45825957|NCT01351415|Drug|Erlotinib|Erlotinib 150 mg daily taken on an empty stomach at least one hour before or two hours after the ingestion of food.
45825958|NCT01351415|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 IV over 10 minutes on Day 1 every 21 days.
45825959|NCT05163275|Diagnostic Test|Video recording and EMG|"The visible and infrared cameras will be positioned in front of the patient (150 cm from the patient's face). EMG electrodes will also be placed on the wings of the nose and the parasternal intercostal muscles. The pressure and flow sensors will finally be positioned at the level of the airways. EMG, respiratory and video recording will begin 15 minutes before the start of the ventilatory weaning trial. Just before the weaning test, a measurement of dyspnea will be carried out. After 15 minutes of baseline recording, patients will be placed in a ventilatory bondage test. Dyspnea will be measured every 5 minutes during the weaning test. After 30 minutes of testing, the ventilatory weaning test is stopped. Patients will then be placed on ventilatory assistance with the same parameters used before the weaning test. An additional 15-minute recording after the end of the ventilatory weaning test will also be made. The recording will therefore last 1 hour in total"
45825960|NCT00281879|Biological|anti-thymocyte globulin|Intravenous, 1.5 mg/kg of body weight daily for 7 to 14 days The first dose should be administered over a minimum of 6 hours and over at least 4 hours on subsequent doses through a high-flow vein.
45825961|NCT00281879|Biological|filgrastim|"Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.~Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion."
45968969|NCT00561496|Drug|Tenofovir gel|Intravaginal (4grams)single dose followed by fourteen days
45968970|NCT00218972|Behavioral|Aerobic interval training|
45455730|NCT05784051|Drug|Experimental group|medical treatment including drug administration ± catheter ablation (Ablation can be performed if the PVC burden remain >10% after 2 lines of AAD treatment).
45455731|NCT05784051|Drug|Control group|patients of this group have no therapeutic or no treatment modification such as drug therapy
45668609|NCT04210999|Other|Supervised heavy slow resistance training|Heavy slow resistance training in the gym instructed by a physiotherapist
45968971|NCT00218972|Behavioral|moderate intensity training|
45968972|NCT00218972|Behavioral|Recommendation of regular exercise|
45968973|NCT00561535|Dietary Supplement|Lactobacillus FARCIMINIS|10.10 UFC of lactobacillus FARCIMINIS
45668610|NCT03593473|Drug|Intranasal Oxytocin|Six intranasal sprays of oxytocin. Each insufflation delivers 4 IUs of oxytocin for a total oxytocin dosage of 24 IUs.
45968974|NCT00561535|Dietary Supplement|placebo (starch)|Once daily
45968975|NCT03454672|Device|Tixel|Tixel treatment. Between 3-5 treatment sessions according to investigator's review of subject response.
45968976|NCT03454672|Device|Laser|Tixel treatment. Between 3-5 treatment sessions according to investigator's review of subject response.
45968977|NCT00246285|Drug|risperidone|
45968978|NCT00219011|Drug|aliskiren|
45825962|NCT00281879|Drug|busulfan|Patients who take the drug PO, busulfan will be administered at 1 mg/kg/ dose given by mouth every 6 hours for 16 consecutive doses. Pediatric patients who receive busulfan IV continuous infusion will receive a dose of 3.0 mg/kg/IBW if under the age of 2.Pediatric patients over the age of 2 will receive busulfan at a dose of 0.8 mg/kg/dose.
45825963|NCT00281879|Drug|carmustine|300mg/m2 IV dissolved in 500 cc NS infused over 2 hours into right atrial catheter on day -6.
45668611|NCT03593473|Drug|Placebo|Six intranasal sprays of placebo manufactured to mimic oxytocin nasal spray containing all equivalent ingredients except oxytocin.
45668612|NCT03588481|Device|DESyne X2|Novolimus-eluting stent
45825964|NCT00281879|Drug|cyclophosphamide|For transplantation, the drug is diluted in 250 to 500 cc of NS or D5W and administered IV over 2 hours.
45825965|NCT00281879|Drug|cyclosporine|Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
45825966|NCT00281879|Drug|cytarabine|400 mg/m2 dissolved in 200cc D5W and infused over 30 minutes into right atrial catheter on days -5, -4, -3, -2.
45825967|NCT00281879|Drug|etoposide|"Etoposide administration 200 mg /m2 dissolved in 1 liter NS and infused over 2 hours into right atrial catheter. Infusion to begin after cytarabine administration on days -5, -4, -3, -2.~Etoposide administration 50 mg/kg IV over 24 hours, divided into 3 doses. Dilute in normal saline at a concentration of 0.4 mg/ml (Observe for precipitation). Administered IV with continuous infusion over 24 hours. Diuretics may be given for fluid overload."
45825968|NCT00281879|Drug|fludarabine phosphate|"Fludarabine administered at 30 mg/m2 IVPB infused over 30 minutes into right atrial catheter on days -4, -3, -2.~Fludarabine administered at 40 mg/m2 IVPB infused over 30 into the right atrial catheter on days -5, -4, -3, and -2."
45825969|NCT00281879|Drug|melphalan|140 mg /m2 in concentration of 0.45 mg/ml of NS infused over 30 minutes into right atrial catheter on day -1.
45825970|NCT00281879|Drug|methotrexate|Administered on days +1, +3, and +7.
45825971|NCT00281879|Drug|methylprednisolone|Methyl-prednisolone is administered IV as a rapid infusion.
45825972|NCT00281879|Drug|mycophenolate mofetil|Mycophenolate may be used as a substitute for Methotrexate
45455732|NCT05770544|Drug|Entrectinib|"Adult and paediatric participants with body surface area (BSA) ≥1.51 m^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day).~Paediatric participants with BSA <1.51 m^2 will receive entrectinib at a dose of 100 mg (BSA=0.43-0.50 m^2) or 200 mg (BSA=0.51-0.80m^2) or 300 mg (BSA=0.81-1.10 m^2) or 400 mg (BSA=1.11-1.50 m^2).~Each cycle of treatment will consist of 28 days and participants may continue until disease progression, unacceptable toxicity or withdrawal of consent."
45455733|NCT05770076|Dietary Supplement|Probiotic lysate (postbiotic and metabiotic)|Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
45455734|NCT05770076|Dietary Supplement|Placebo|Placebo
45668613|NCT05259787|Drug|Sedation Etomidate combined with propofol|Drug IV within 10 second during anesthesia induction.
45668614|NCT05259787|Drug|Sedation Propofol|Drug IV within 10 second during anesthesia induction.
45668615|NCT04196413|Drug|GD2 CAR T cells|Autologous T-Cells transduced with retroviral vector (14g2a-CD8.BB.z.iCasp9) expressing GD2-chimeric antigen receptor
45668616|NCT04196413|Drug|Fludarabine|Fludarabine 25 mg/m2 per day IV for days -4, -3, -2
45668617|NCT04196413|Drug|Cyclophosphamide|Cyclophosphamide 500 mg/m2 per day IV for days -4, -3, -2
45668618|NCT04809571|Other|Photoacoustic imaging and Confocal Raman spectroscopy measurement|All subjects will first have their basic history and clinical measurements taken, followed by skin physiology measurements and photoacoustic mesoscopic imaging as well as confocal Raman spectroscopy measurements.
45825973|NCT00281879|Drug|tacrolimus|A drug used to decrease the risk of graft versus host disease (GvHD).
45668619|NCT03565159|Biological|Prevenar 13|Pneumococcal polysaccharide conjugate vaccine
45668620|NCT03565159|Other|Sodium Chloride 0.9%|Placebo
45825974|NCT00281879|Procedure|peripheral blood stem cell transplantation|The stem cells will be given to you by intravenous injection (through your vein) using a catheter that was placed prior to beginning chemotherapy. The stem cell infusion takes 1-6 hours.
45825975|NCT00281879|Procedure|umbilical cord blood transplantation|The patient will receive ATG to improve the changes of engraftment and decrease their risk of graft versus host disease. The patient may receive ATG 3 times during their transplant regimen on days -3 through days -1
45825976|NCT00281879|Radiation|radiation therapy|Radiation will be given to you 2 times a day for 3 or 4 days.
45825977|NCT05194007|Drug|Frondanol|Frondanol capsule (1000 mg) will be administered orally (Twice daily) in the double blind settings
45668621|NCT01756456|Drug|rhNGF 10 μg/ml|rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
45668622|NCT01756456|Drug|rhNGF 20 μg/ml|one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
45668623|NCT01756456|Other|vehicle|ophthalmic solution of the same composition as the test product without rhNGF
45668624|NCT03329677|Other|Transference-focused Psychotherapy (TFP)|Participants receive 18 months of bi-weekly TFP. Each sessions lasts 45 minutes. During sessions, a therapist employs assorted psychodynamic techniques tailored specially for symptoms and relational difficulties associated with BPD. A participant processes interpersonal experiences with her therapist in sessions alongside her therapist and gains therapeutic insight into her problematic ways of relating to her self and others.
45668625|NCT05226325|Drug|Dexmedetomidine|patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minute followed by infusion
45825978|NCT05194007|Drug|Placebo|Placebo (corn starch) capsule will be administered orally (Twice daily) in the double blind settings
45825979|NCT05153057|Other|Observational study|The goal of the study is purely observational. Treatment decisions will be made by physicians according to the grading of the intraocular inflammation related to birdshot chorioretinopathy and to their consequences on visual function. These treatment decisions will be independent from the observational study.
45825980|NCT05099705|Behavioral|Access to a Family Service Navigator and Treatment Support System|An RCT will be conducted. 40 participants will be randomly assigned to the intervention group and 15 participants to the non-personalized comparison group (i.e., information, training, and referral). The intervention group will have access to a navigator and the treatment support system.
45825981|NCT00000809|Biological|Aluminum hydroxide|
45825982|NCT00000809|Biological|QS-21|
45825983|NCT00000809|Biological|MN rsgp120/HIV-1|
45825984|NCT05091203|Drug|Vitamin D|To investigate role of vitamin D in follicular maturation and number of mature follicles which help in the success of IVF procedure
45668626|NCT04418635|Dietary Supplement|Prosta-OK® Neo or Prosta-OK® Neo-matched placebo|the patient planed to receive Tamsulosin 0.2mg once daily is randomized to the experiment group or placebo group. After randomization, the patient received Tamsulosin therapy with Prosta-OK® Neo or Prosta-OK® Neo-matched placebo 707mg 2 tablets twice daily for 85 days.
45668627|NCT04809259|Device|Isothermal pouch|The study will verify it the use of an isothermal pouch to maintain the content of an elastomeric pump at 10° to 15°C avoids unacceptable meropenem degradation over the 24 hour infusion period.
45668628|NCT05237713|Drug|Canakinumab Injection|Administration for a duration of 6 months for all patients and in case of response further treatment for up to three years
45825985|NCT00000815|Biological|Attenuvax|Measles virus vaccine (attenuate)administered subcutaneously at a single dose of 0.5 mL at 6 months of age
45825986|NCT00000815|Biological|M-M-R-II|Measles-Mumps-Rubella vaccine (attenuated)administered subcutaneously as a single dose of 0.5 mL at 12 months of age
45825987|NCT00240227|Drug|Prazosin|FDA approved medication for hypertension
45825988|NCT00240227|Drug|placebo|
45825989|NCT00205049|Drug|pentoxifylline|daily dosing
45825990|NCT00000833|Drug|Ribavirin|
45825991|NCT00000833|Drug|Didanosine|
45825992|NCT00176501|Biological|therapeutic allogeneic lymphocytes|If a partially HLA-matched donor is identified and other eligibility criteria are met, the patient will receive irradiated lymphocyte infusion(s).
45825993|NCT00000839|Drug|Didanosine|
45825994|NCT00133679|Drug|sildenafil|Sildenafil 0.5 mg/kg every 6 hours orally x 45 d
45825995|NCT00133679|Drug|Placebo|Placebo suspension (equal volume to experimental drug) x 45 days
45968979|NCT03454633|Procedure|the temperature of hypothermic circulatory arrest|Different temperature (mild 30 degree or moderate 25 degree) employed during the hypothermic circulatory arrest on aortic surgery.
45968980|NCT04628923|Other|QUADRATUS LUMBORUM BLOCK|QUADRATUS LUMBORUM BLOCK BY PARASPINOUS SAGITTAL SHIFT APPROACH
45968981|NCT04628611|Device|Video laryngoscopy|Endotracheal intubation using video laryngoscopy
45825996|NCT04994405|Procedure|Tourniquet Pressure|"The procedural intervention will be inflation of a pneumatic tourniquet to a lower than standard pressure as determined by the patient's SBP in hand and upper extremity surgery. The control will be inflation of a pneumatic tourniquet at a standard pressure of 250 mmHg in hand and upper extremity surgery.~The tourniquet used will be the standard tourniquet used for hand and upper extremity surgery at our institutions - a tourniquet 18 inches in length and 3 inches in width manufactured by Stryker (Kalamazoo, MI) used in conjunction with a protective sleeve matched to the size of the tourniquet cuff which is provided by the manufacturer. Both pieces are supplied in a sterile packaging. No other tourniquets will be used."
45968982|NCT04628611|Device|Flexible intubating laryngoscopy|Endotracheal intubation using flexible intubating laryngoscope
45968983|NCT00242268|Drug|Simvastatin|
45968984|NCT04628845|Device|Endo-perio therapy with laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals with using laser 940nm.
45968985|NCT04628845|Device|Endo-perio therapy without laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals
45968986|NCT04628806|Diagnostic Test|CTC isolation by HSP70|patients will receive additional blood examinations with quantification of circulating tumor cells by HSP70 antibodies and EpCAM.
46080816|NCT05796089|Radiation|Thoracic Radiotherapy|"Participants will receive thoracic radiotherapy to a dose of 30 Gray (Gy) in 10 fractions (3 Gy per day) concurrently with cycle 3 or 4 of chemo-immunotherapy (Group 1).~Participants who are unsuitable for concurrent radiotherapy may receive consolidation radiotherapy. Consolidation thoracic radiotherapy will be administered to a dose of 30 Gy in 10 fractions, following 4 cycles of chemo-immunotherapy (Group 2).~Treatment fractions will be delivered daily, where treatment should be completed within 15 days (9-10 fractions a fortnight)."
46080817|NCT05796089|Drug|Etoposide with Carboplatin or Cisplatin|"The chemotherapy in this study is a standard treatment for extensive-stage small-cell lung cancer (EC-SCLC). The combination of chemotherapy (etoposide + carboplatin or etoposide + cisplatin) which the participant will receive is dependent on what is standard at the treatment centre.~Chemotherapy will be administered via an intravenous infusion every 3 weeks (21 days) for 4 cycles."
45668629|NCT04745299|Biological|Lenzumestrocel|Single cycle administration group : injections twice in a 26-day interval Multiple administration group : injections twice in a 26-day interval followed by repeated three times injections every three months
45825997|NCT00000845|Biological|P3C541b Lipopeptide|
45825998|NCT00000875|Drug|Indinavir sulfate|
45825999|NCT00000875|Drug|Diphenhydramine hydrochloride|
45826000|NCT00000875|Drug|Lymphocytes, Activated|
45826001|NCT00000875|Drug|Lamivudine|
45826002|NCT00000875|Drug|Zidovudine|
46080818|NCT05796089|Drug|Durvalumab|"The immunotherapy in this study is a standard treatment for ES-SCLC.~Participants will receive a dose of 1500 mg of Durvalumab via an intravenous infusion every 3 weeks (21 days) for 4 cycles, concurrently with chemotherapy.~A 1500 mg maintenance dose of Durvalumab will administered every 4 weeks after completion of chemotherapy (monotherapy)."
46080819|NCT05795166|Other|No treatment given|No treatment given
46080820|NCT05791864|Genetic|RGX-381|One time subretinal dose in study eye
46080821|NCT05790421|Other|Foot Muscle Energy Technique|Starting from the preparation position, at the restriction barrier, the patient is asked to exert a small effort (no more than 20% of available strength) towards plantarflexion, against unyielding resistance, with appropriate breathing. The patient produces isometric effort contracts either gastrocnemius or soleus (depending on whether the knee is unflexed or flexed). This contraction is held for 7-10 seconds together with a held breath. The exercise was repeated until the full range of movement was obtained.
46080822|NCT05790421|Other|Conventional Physical Therapy Program|Graduated active resisted range of motion exercises for both UL and LL and graduated gait training
46080823|NCT05789992|Drug|Propofol|Propofol (Random:3-5ug/ml)
45668630|NCT04745299|Drug|Riluzole|concomitant administration of Riluzole to all groups, except subjects to whom Riluzole administration is deemed impossible owing to adverse events as determined by medical experts
45668631|NCT04745299|Drug|Placebo Comparator|"Single cycle administration group: Placebo comparator is injected three times every three months after injection of Lenzumestrocel twice in a 26-day interval.~Control group: Placebo comparator is injected twice in a 26-day interval followed by repeated three times injcections every three months"
45826003|NCT00000875|Drug|Acetaminophen|
45826004|NCT00000875|Drug|Aldesleukin|
45826005|NCT04941833|Drug|Desogestrel Oral Tablet|Cerazette is the brand name of the desogestrel which contain of 0.075 mg of desogestrel
45826006|NCT04890041|Drug|TPO-RA|The subjects will receive an initial dose of TPO-RA once daily. Platelet counts were collected weekly until week 6 of the study. Dosage was adjusted to maintain platelet levels between 50×10^9/L and 150×10^9/L according to platelet count. TPO-RA was administered once a day for 4 weeks. If the platelet count dose not reach 30×10^9/L, the treatment was stopped. If the platelet count is more than 400×10^9/L after taking TPO-RA once a day for 2 consecutive weeks, the treatment will be stopped.
45826007|NCT04874909|Other|Blood sample|"Blood sample of 15ml max by subject (case, related individual, control) once time:~subject less than 5 kg : 1.8 to 4.5 ml max~subject 5 kg to 10 kg : 4.5 to 9 ml max~subject 10 kg to 15 kg : 9 to 13.5 ml~subject 15 kg to 20 kg : 13.5 to 15 ml max"
45826008|NCT04874909|Other|Urine sample|Urine sample (500 ml) once time
45826009|NCT04841369|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）|0.5mL,Intramuscular
45826010|NCT04841369|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL,Intramuscular
45968987|NCT04628689|Other|quadratus lumborum block by paraspinous sagittal shift approach|quadratus lumborum block by paraspinous sagittal shift approach
46080824|NCT05789992|Drug|Low Remifentanil|Remifentanil (Random:0-3ug/ml)
45826011|NCT00379925|Behavioral|Physical Activity and Dietary Health Promotion Program|Churches within the intervention group will receive a committee training and church cook training designed to teach them how to do a self-assessment of current practices and develop a plan for their program. The intervention is based on the structural model of health behavior and targets opportunities, mass media (within the church), guidelines and policies, and church environment. Intervention churches also receive monthly intervention mailings to support intervention implementation.
45968988|NCT04628455|Device|Inversion and snaring|"Vertical umbilical 5-mm incision was made for 5-mm trocar. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min keeping intraabdominal pressure between 8-12 mmHg. A two-mm incision was done at a point B [midway between umbilicus and symphysis pubis] for 2-mm port passed under direct vision and a tiny 11-blade scalpel puncture is done at the corresponding Mac-Burney's [Point C] for SGD.~Both SGDs were used to invert the hernia sac by gradual sustained alternating traction on the round ligament. Each SGD hands to the other one till complete inversion occurs, this is known by the hernial sac hanging from internal ring without retracting-back inside the inguinal canal. Then, the MPS is introduced via 2-mm trocar at point. SGD-C passed inside the loop of MPS and re-catches the hernial sac, which is then twisted around its neck several times. MPS was closed at the neck and diathermy current is applied. Detached sac was then pushed antigradely out through the umbilical port."
45968989|NCT00246363|Drug|Silymarin|Silymarin (milk thistle)
45826012|NCT00002975|Drug|aminolevulinic acid|
45826013|NCT02221817|Procedure|Trochanter bursa injections|
45826014|NCT02221817|Device|Ultrasound|
45968990|NCT00246363|Drug|Placebo|Placebo
45826015|NCT00521885|Drug|Arixtra (Fondaparinox) 2.5 mg SC Daily|Patients will be randomized to receive Arixtra 2.5mg once a day if randomized to this arm
45968991|NCT00219050|Drug|aliskiren|
45826016|NCT00521885|Drug|Lovenox 40mg SC Daily|Patients will be randomized to receive Lovenox 40mg SC Daily if randomized to this arm
45826017|NCT05239013|Drug|Nitroglycerin ointment|2 cm (30mg) of 2% nitroglycerin applied 2 cm from the styloid process of the anterior forearm
45826018|NCT00000881|Drug|Cidofovir|
45826019|NCT00000881|Drug|Probenecid|
45826020|NCT00000887|Drug|Nelfinavir mesylate|
45968992|NCT04628533|Behavioral|Four Month Duration Online Behavioral Weight Loss Program|"Participants meet weekly on line with other group participants for 16 weeks. The group-based online behavioral weight control program incorporates the elements of current thinking and empirical data on successful weight loss programs, including restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted, and reinforced throughout the program. Weekly group meetings in a video chat forum led by an experienced group weight control counselor are the venue for the group process, and extensive web-based resources to support behavior changes are offered. The online groups are closed such that those individuals who start the group remain in that group for the duration of their participation. Weight loss counselor will provide feedback and encouragement to participants after reviewing food diaries via weekly emails."
45968993|NCT04628533|Behavioral|Six Month Duration Online Behavioral Weight Loss Program|"Participants meet weekly on line with other group participants for 24 weeks. The group-based online behavioral weight control program incorporates the elements of current thinking and empirical data on successful weight loss programs, including restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted, and reinforced throughout the program. Weekly group meetings in a video chat forum led by an experienced group weight control counselor are the venue for the group process, and extensive web-based resources to support behavior changes are offered. The online groups are closed such that those individuals who start the group remain in that group for the duration of their participation. Weight loss counselor will provide feedback and encouragement to participants after reviewing food diaries via weekly emails."
45968994|NCT04628299|Other|Sham Laser|Sham Laser in plantar fascia
45968995|NCT04628299|Other|Myofascial Induction|Myofascial Induction in plantar fascia
45826021|NCT00000887|Drug|Lamivudine|
45826022|NCT00000887|Drug|Zidovudine|
45826023|NCT05148923|Procedure|Direct current cardioversion (DCCV)|DCCV is a safe and effective method of treating atrial fibrillation.
45826024|NCT03979079|Radiation|external beam radiation therapy|
45826025|NCT02973347|Other|Intermittent enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube less than 30 mins.
45826026|NCT02973347|Other|Continuous enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube for 24 hours.
45826027|NCT04702607|Procedure|contrast enhanced 4DCT|Functional Lung Imaging with DECT and 4DCT
45826028|NCT04618991|Other|Filling the Quebec Sleep Questionnaire|Filling the Quebec Sleep Questionnaire (QSQ) by the pre-surgery patient, then at 3 months post surgery and 1 year post surgery.
45826029|NCT00000119|Device|Heparin Surface-Modified Intraocular Lens|
45826030|NCT00000923|Drug|Indinavir sulfate|
45826031|NCT00000923|Drug|Lamivudine|
45826032|NCT00000923|Drug|Stavudine|
45826033|NCT00000923|Drug|Zidovudine|
45826034|NCT00000923|Drug|Didanosine|
45826035|NCT00000923|Drug|Aldesleukin|
45968996|NCT04628221|Device|OsteoProbe System|"The OsteoProbe® System (OsteoProbe) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation."
45968997|NCT00219089|Drug|aliskiren|
45968998|NCT00246402|Drug|Acipimox|
45968999|NCT00561613|Other|SILCS and lubricant|
45826036|NCT00000161|Drug|Aspirin|
45826037|NCT00000161|Drug|Beta-Carotene|
45969000|NCT00561613|Other|SILCS and spermicide|
45969001|NCT00561691|Drug|nimotuzumab|monoclonal antibody
45826038|NCT00000161|Drug|Vitamin C|
45826039|NCT00000161|Drug|Vitamin E|
45969002|NCT00561769|Drug|Norditropin pen|12 IU per day
45969003|NCT00242307|Drug|Roflumilast|
45969004|NCT00219128|Drug|aliskiren|
45969005|NCT04628143|Drug|Nafamostat Mesilate|Administered intravenously as a continuous infusion
45969006|NCT04627792|Behavioral|IUSECAMH Parent Intervention (Waitlist)|We will use a switching replication design in which fifty guardians will be randomly assigned using a lottery to receive the intervention and fifty will be assigned to a group who will receive the intervention at a later time point
45969007|NCT04627987|Diagnostic Test|Cardiac MRI scan|Cardiac MRI scan pre- and post- aortic valve replacement to assess degree of left ventricular remodelling, fibrosis and myocardial blood flow.
45969008|NCT04627987|Diagnostic Test|Serum biomarkers (High sensitivity troponin, NT-proBNP|Blood tests looking evidence of cardiac structural remodelling and function.
45969009|NCT04627987|Procedure|Implantable Loop Recorder|Determine post-AVR arrhythmia burden
45826040|NCT04474145|Procedure|Comb group|"Patients in the Comb group will receive hydrodilatation of the affected shoulder and subdeltoid bursa injection for 2 times in 2-week interval. Patients also receive mobilization exercise and conventional physical therapy (including physical modalities and stretch exercise), 3 times a week, for 8 weeks.~The injectates for hydrodilation include 10mg triamcinolone, 2cc 1% xylocaine, and 17cc normal saline for both posterior and anterior shoulder joint injection. 10mg triamcinolone and 2cc 1% xylocaine will also be injected into the subdeltoid bursa of the affected shoulder. All injections will be performed under ultrasound guidance. For shoulder joint injection, ａ21 gauge, 3-inch needle will be used; and a 22 gauge, 1.5 inch needle will be applied for subdeltoid bursa injection."
45826041|NCT04474145|Procedure|PT group|The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 8 weeks or until total recovery of the symptoms. The stretching exercise program is similar to the stretching exercise described above. For mimicking injection in the Comb group, patients in the PT group will receive 2cc 1% xylocain injection at the posterior deltoid muscle.
45826042|NCT00000929|Drug|Nonoxynol-9|
45969010|NCT04627987|Diagnostic Test|6 minute walk test|Validated assessment of functional capacity - distance walked over 6 minute time frame.
45826043|NCT04459013|Other|Salivary samples|The salivary samples will be collected at 5 defined times
45969011|NCT04627987|Diagnostic Test|Echocardiogram|Ultrasound assessment of heart structure and function. Standard of care in valve surgery pathway.
45969012|NCT00219167|Drug|aliskiren|
45826044|NCT00000167|Procedure|Low-Intensity Laser Treatment|Initial: 60 barely visible burns, grid pattern. Re-treatment at 12 months: 30 barely visible burns, focal treatment.
45826045|NCT00000935|Biological|Intravenous immune globulin (IVIG)|given at a dose of 20mL/kg Intravenous Immune Globulin (Human) (IVIG 10% solvent/detergent)
45826046|NCT00000197|Drug|Propranolol|
45969013|NCT04627909|Other|Robot|The patient interacts with a robot
45969014|NCT04627909|Other|Medical Personnel|The patient interacts with medical personnel
45969015|NCT04627909|Other|Caregiver|The patient interacts with the caregiver
45969016|NCT04627519|Dietary Supplement|Rhea Health Tone®|Rhea Health Tone® 2 ml twice daily after the meal (every 12 hours)
45969017|NCT04627636|Other|Myofascial trigger points pressure (MTrP) release|Myofascial trigger points pressure (MTrP) release technique, the initial step was to recognize and find the trigger points (TP) , and The second step after TP palpation was the MTrP release technique, as follow, by one or both hands, the thumbs or four fingers of the therapist applied a maintained pressure, pushing internal toward the middle
45969018|NCT04627636|Other|Shockwave therapy application|The JEST-2000 (JOEUN Medical, Dae-Jeon, South Korea) was used for the ESWT. The application of pressure pulses of ESWT was centered around the flexor muscles with hypertonia
45969019|NCT04627636|Other|conventional therapy|Passive ROM exercises performed by the therapist and Bobath Neurodevelopmental Approach (prolonged stretch): The Intervention methods for Bobath involved the activation of key points of control for the reduction of tone
45969020|NCT00242346|Drug|candesartan cilexetil|
45969021|NCT00219245|Drug|Rivastigmine|
45826047|NCT00000947|Drug|Azithromycin|
45969022|NCT04627480|Device|Fisher Wallace Neurostimulation Device|a Cranial Electrotherapy Stimulator Device (CES).
45969023|NCT04627363|Procedure|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 6 weeks
45969024|NCT04627363|Drug|Bevacizumab|15mg/kg intravenously every 3 weeks
45969025|NCT04627363|Drug|Toripalimab|240mg intravenously every 3 weeks
45969026|NCT04627207|Drug|CKD-330 1 Tab. and D085 1 Tab.|Other names: Reference
45969027|NCT04627207|Drug|CKD-333 1 Tab|Other names: Test
45969028|NCT00219323|Drug|Omalizumab|
45969029|NCT00242424|Biological|2005-2006 trivalent inactivated influenza vaccine|Children enrolled at 6-12 weeks to receive first dose, 0.25 ml of trivalent inactivated influenza vaccine, 2005-6 pediatric Fluzone formulation (sanofi pastuer), with concomitant routine pediatric vaccines. Second dose administered 4 weeks later.
45969030|NCT04627324|Device|The smart toothbrush and smart mirror (STM) system (XiuSolution, Gyeonggi-do, Korea)|"The STM system comprises a smart mirror, which is integrated into a computer monitor, and a 3D motion-capture device inside of a modified toothbrush holder. The computer program displays a toothbrushing animation in the mirror. Toothbrush motions detected by sensors embedded inside the holder are captured and sent to the server for analysis.~(used only during the test visits)~Participants had to brush their teeth at home (using toothbrushes with a flat-trimmed nylon bristle of identical type and length.) for 3 min thrice daily, after meals, as recommended by the Korean Dental Association."
46080825|NCT05789992|Drug|Heigh Remifentanil|Remifentanil (Random:3-5ug/ml)
46080826|NCT05789992|Procedure|Intubation|Endotracheal intubation before surgery
46080827|NCT05789992|Procedure|tetanic electrical stimulation|tetanic electrical stimulation before surgery
45668632|NCT05394883|Behavioral|Supervised Exercise|Women randomized to Supervised Exercise group will attend two to three exercise classes/week. Each session will consist of: 5-min flexibility warm-up and cool-down; 40 min of moderate intensity calculated as 40-59% Heart Rate Reserve (HRR) along with Rating of Perceived Exertion (RPE) between 13-14; and 20 minutes of resistance with an additional 30 minutes of unsupervised home aerobic activity per week. The women will be given their choice of aerobic equipment or walking either track/ treadmill to achieve a total of 40 minutes of moderate intensity exercise. The Supervised Exercise group will receive exercise counseling during their first meeting in addition to materials on the benefits of exercise, a log to record additional activity completed each week, goal setting, making time for exercise/making exercise a habit and exercise behavioral strategies.
46080828|NCT05788939|Other|Planned Visual Education Based on Health Belief Model|"The students in IG were administered the planned visual education based on Health Belief Model for a period of seven months.~The education materials were a PowerPoint presentation, a skin cancer model, videos titled Dear 16 years old me, Mr. Sun, a brochure, and 3 posters.~."
46080829|NCT05787561|Drug|Avutometinib (VS-6766)|3.2 mg PO, twice weekly
46080830|NCT05787561|Drug|Defactinib|200 mg PO BID for 3 weeks, followed by a 1 week rest period, in each 4-week (28 day) cycle.
46080831|NCT05779501|Behavioral|Internet-delivered strengths use intervention|"The online strengths use intervention program follows the theorized five stages of strengths use interventions: (1) preparation and commitment, (2) identification, (3) integration, (4) action, and (5) evaluation. To increase participant engagement and motivation, gamification components are embedded in several stages.~The intervention was previously tested through a feasibility and acceptability trial (NCT05474807).~The entire intervention will be delivered online via an LMS software solution."
45455735|NCT05770037|Drug|Alectinib|"Adult participants will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Paediatric participants with a body weight ≥40 kg and who are able to swallow the capsules, will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Each cycle of treatment will consist of 28 days and participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent."
45826048|NCT04300205|Device|High intensity LED light device|Participant wounds are treated with LED light device for 10 minutes, 4 times over the course of 2 months
45455736|NCT05769270|Behavioral|Peer Navigation and Coping Skills|Participants will receive 6 sessions of peer navigation and coping skills
45455737|NCT05769270|Behavioral|Treatment as Usual|Participants will receive referrals for PrEP and services
45455738|NCT05767086|Drug|Gonadotropin releasing hormone antagonist (Cetrotide)|clinical pregnancy rates
45826049|NCT04300205|Device|Sham LED light device|Participants have the light treatment moved off their wound after masking
45826050|NCT04251611|Other|Maintenance of physical exercise|Objectives will be established with the patient to increase the practice of physical exercise and reinforce the control of cardiovascular risk factors (CVRF) and the maintenance of a long-term cardio-healthy lifestyle.
45826051|NCT00000203|Drug|Buprenorphine|
45826052|NCT00000209|Drug|Buprenorphine|
45826053|NCT00000215|Drug|Pergolide|
45826054|NCT00000953|Drug|Sorivudine|
45826055|NCT00000953|Drug|Acyclovir|
45826056|NCT00000983|Drug|Zidovudine|
45826057|NCT00000227|Drug|Buprenorphine|
45826058|NCT00000233|Drug|Buprenorphine|
46080832|NCT05779501|Behavioral|Waiting-list|"The waiting-list arm will serve as the control group, filling in only the outcome measure at the same time as the intervention group participants.~After the intervention group finishes participating in the intervention, the waiting-list participants will benefit from the same internet-delivered strengths use program."
46080833|NCT05776719|Behavioral|Health & Wellness|PowerPoint slide decks will be shown via shared screen. The wellness group will be largely educational in nature and will encourage discussion, setting goals, and making healthy choices. Similar topics covered in this group have been used previously in health promotion classes.
46080834|NCT05776719|Behavioral|Warrior Renew|The group format includes warm-up community building exercises, psychoeducational presentation of material standardized by the use of PowerPoint slides, followed by discussion of the information and interactive exercises, and closes with exercises to improve affect management skills, such as mindfulness or guided imagery.
45455739|NCT05767086|Drug|Medroxyprogesterone Acetate (Tarlusal)|clinical pregnancy rates
45668633|NCT05394883|Behavioral|Home Exercise|Women assigned to Home Exercise group will receive instructions for their home walking program including tips for walking indoors and outdoors, exercise handouts for warm-up/cool-down activities, demonstrations for resistance training activities and an exercise log. Women assigned to Home Exercise group will be contacted once per week to discuss their progress, barriers/challenges faced, ask questions, and strategies to achieve the exercise guidelines. The Home Exercise group will receive exercise counseling during their first meeting in addition to materials on the benefits of exercise, a log to record additional activity completed each week, goal setting, making time for exercise/making exercise a habit and exercise behavioral strategies.
45668634|NCT01756300|Device|Celsius® ThermoCool® RD|The investigational device is designed to transmit radiofrequency (RF) current to the electrodes for ablation purposes, specifically for the treatment of resistant hypertension by renal denervation.
45668635|NCT05393401|Device|VOP1k|Photoplethysmographic records
45668636|NCT04168528|Drug|68GaNOTA-Anti-MMR-VHH2|Injection of the radiopharmaceutical and PET/CT imaging
45668637|NCT03543631|Other|Survey|Online survey
45826059|NCT00000239|Drug|Buprenorphine|
45826060|NCT00000245|Drug|Desipramine|
45826061|NCT00000263|Drug|30% Nitrous oxide|
45826062|NCT00000263|Other|0.25 g/Kg ethanol|
45826063|NCT00000263|Other|0.5 g/KG ethanol|
45826064|NCT00000263|Other|0 g/Kg ethanol|
45826065|NCT00000269|Drug|Pergolide|
45826066|NCT04030559|Drug|Niraparib|Given PO
45826067|NCT04030559|Drug|Niraparib Tosylate Monohydrate|Given PO
45826068|NCT04030559|Procedure|Radical Prostatectomy|Undergo standard of care surgery
45826069|NCT00380003|Drug|EVT 201|
46080835|NCT05774951|Drug|Camizestrant|Camizestrant. Experimental. Administered orally
46080836|NCT05774951|Drug|Tamoxifen|Tamoxifen. Comparator. Administered per local approved label
45455740|NCT05767086|Drug|Dydrogesterone|clinical pregnancy rates
46080837|NCT05774951|Drug|Anastrozole|Anastrozole. Comparator. Administered per local approved label
46080838|NCT05774951|Drug|Letrozole|Letrozole. Comparator. Administered per local approved label
46080839|NCT05774951|Drug|Exemestane|Exemestane. Comparator. Administered per local approved label
45668638|NCT04811131|Drug|ARQ-252 cream 0.3%|ARQ-252 cream 0.3%
45668639|NCT04811131|Drug|ARQ-252 Vehicle cream|ARQ-252 Vehicle cream
45826070|NCT03967223|Drug|Letetresgene autoleucel (lete-cel, GSK3377794)|letetresgene autoleucel will be administered.
45826071|NCT03967223|Drug|Fludarabine|Fludarabine will be used as the lymphodepleting chemotherapy
45826072|NCT03967223|Drug|Cyclophosphamide|Cyclophosphamide will be used as the lymphodepleting chemotherapy.
45826073|NCT00000989|Drug|Zidovudine|
45826074|NCT00000989|Drug|Sargramostim|
45826075|NCT00000989|Drug|Ganciclovir|
45826076|NCT03676439|Device|Magnetic Spinal Stimulation|"Spinal Magnetic Stimulation (TMS) on Lateral Cord Stimulation (LCS), in the search of the improvement of the tone, motor function and speech, in patients with spastic cerebral Palsy.~Due to its non-invasiveness and possible efficacy, the use of Magnetic Spinal Stimulation is proposed to try to prove its therapeutic usefulness.~This is the phase 2/3 clinical test of the method, in the future, and as its use could be extended, if the results were positive, its indications could be extended to other pathological conditions, giving a greater spectrum of spastic patients, potentially benefited."
45826077|NCT00000995|Drug|Zidovudine|
45826078|NCT00000995|Drug|Ganciclovir|
45826079|NCT00001019|Biological|rgp120/HIV-1 SF-2|
45826080|NCT00001019|Biological|MTP-PE/MF59|
45826081|NCT00001025|Drug|Zidovudine|
45826082|NCT00001025|Drug|Didanosine|
45826083|NCT00001031|Biological|rgp120/HIV-1MN|
45826084|NCT00001031|Biological|rgp120/HIV-1 SF-2|
45826085|NCT05440565|Diagnostic Test|Fecal immunochemical test|Fecal immunochemical test can concentrate the high-risk population.
45826086|NCT05440565|Diagnostic Test|APCS score|APCS score can concentrate the high-risk population.
45826087|NCT03121001|Drug|ATG|0.5 mg/kg IV on day -9, and 2 mg/kg on days -8 and day -7
45826088|NCT03121001|Drug|fludarabine|30 mg/m2 IVPB daily for day -6 (6 days before stem cell infusion) through day -2
45826089|NCT03121001|Drug|cyclophosphamide|14.5 mg/kg IV on days -6 and -5 and 50 mg/kg/d on days +3 and +4
45826090|NCT03121001|Radiation|Total body irradiation|3 Gy on day -1
45826091|NCT03121001|Procedure|Stem cell infusion|Stem cell product infused according to BMT unit policy on day 0.
45826092|NCT03121001|Drug|Sirolimus|loading dose of 15 mg followed by 5 mg per day on day +5
46080840|NCT05765266|Device|ACP Max™|Single 4-6 ml intra-articular (IA) injection of the output of ACP Max™
45668640|NCT04811131|Device|NB-UVB phototherapy active treatment|NB-UVB phototherapy active treatment
45969031|NCT04627324|Device|Conventional toothbrush|"toothbrushes with a flat-trimmed nylon bristle of identical type and length.~Participants had to brush their teeth at home for 3 min thrice daily, after meals, as recommended by the Korean Dental Association."
45969032|NCT04627402|Drug|Conbercept and TA|Intravitreous injection of Conbercept and TA
45969033|NCT04627402|Drug|Conbercept|Intravitreous injection of Conbercept
45969034|NCT04627051|Device|Atherectomy and balloon angioplasty|Atherectomy and balloon angioplasty of arterial-venous graft stenosis
45969035|NCT00219362|Biological|one injection of vCP1452 at W0, W4, W8 and W20|
45668641|NCT04811131|Device|NB-UVB phototherapy sham treatment|NB-UVB phototherapy sham treatment
45668642|NCT04724161|Diagnostic Test|ANC surveillance|Clinic-based testing of all pregnant women during antenatal care visits using national standards and commercially available malaria rapid diagnostic tests
45826093|NCT03121001|Drug|mycophenolate mofetil|1 g every 8 h (until day 35) will be started on day 5
45969036|NCT00219362|Biological|one injection of vCP1452 at W4, W8 and W20|
45969037|NCT00219362|Biological|one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20|
45969038|NCT04626895|Device|Paxman Scalp Cooling Device|Paxman scalp cooling device
45969039|NCT04626817|Device|Isokinetic device (Biodex System 4)|The measurement of muscle strength with isokinetic device
45969040|NCT00246597|Drug|epoetin alfa|
46080841|NCT05765266|Device|Depo-Medrol®|Single IA injection of 40 mg of methylprednisolone acetate (1 ml of solution) mixed with 5 ml of Normal Saline for a total of 6 ml.
45668643|NCT05221021|Drug|Vaginal estrogen|0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill
45668644|NCT05221021|Drug|Mirabegron 50 MG [Myrbetriq]|50mg oral Mirabegron once daily
45826094|NCT03118895|Device|BioFreedom™ BA9™ drug-coated stent|Drug-coated stent for coronary arteries
45826095|NCT03055247|Drug|Ibuprofen|Ibuprofen: 3 mg/kg tid (total daily dose: 9 mg/kg); administered orally from day 1 to day 5 and then from day 14 to the day before the last LP.
45826096|NCT03055247|Drug|Myelostim|Myelostim (G-CSF): 5 µg/kg bid (total daily dose 10 µg/kg); administered subcutaneously from day 19 to the day of the last LP.
45668645|NCT03190057|Device|BIOFREEDOM™ FAMILY stent|Percutaneous coronary intervention with BIOFREEDOM™ FAMILY stent
45668646|NCT03169075|Behavioral|Supervised physical exercise programs|"A weekly supervised physical activity session of 60 min at the patient's home is planned for 3 months.~These sessions will be supervised by an educator or physiotherapist trained, with respect to the pathology and the clinical study, specifically for this activity (Fédération Française Sport et Cancer) . The proposed exercises will be normalized and adapted to each patient's profile.~Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT module AC/S, FACT-Gog, HADS, IPAQ, Evaluation by a coach VAE"
45826097|NCT03055247|Drug|Mozobil|Mozobil (Plerixafor): 0,24 mg/kg daily. When CD34+ are ≥ 10 /μL Plerixafor will be administered subcutaneously from the next day (or from day 24 if CD34+ are < 10 /μL) to the day of the last LP.
45826098|NCT00001049|Drug|Zidovudine|
45826099|NCT00001049|Drug|Didanosine|
45826100|NCT00001055|Biological|ALVAC-HIV MN120TMG (vCP205)|
45826101|NCT00001055|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
45826102|NCT00001055|Biological|rgp120/HIV-1 SF-2|
45826103|NCT02911571|Device|MMprofiler SKY92 gene signature|"MMprofiler is a gene expression assay system for detection of the presence (or absence) of the SKY92 high-risk gene signature to aid in the determination of the Multiple Myeloma patient's prognosis"
45969041|NCT04626739|Drug|CD19 CAR-T|CD19 CAR-T for CD19 positive R/R non-Hodgkin lymphoma
45969042|NCT04626739|Drug|CD22 CAR-T|CD22 CAR-T for CD22 positive R/R non-Hodgkin lymphoma
45969043|NCT04626739|Drug|CD19+CD22 CAR-T|CD19+CD22 CAR-T for CD19 positive and CD22 positive R/R non-Hodgkin lymphoma
45969044|NCT04626739|Drug|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
45969045|NCT04626739|Drug|Cyclophosphamide|500mg/㎡ for D-3 and D-2
45969046|NCT00219401|Biological|Pneumococcal 7 valent conjugate vaccine (Prevenar®)|Accelerated PCV vaccinaton.
45969047|NCT04627129|Drug|SHR2554 and Itraconazole|Single dose of oral administration of SHR2554 and Multiple dose of oral of Itraconazole Capsules
45969048|NCT04626856|Biological|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0, 28
45969049|NCT04626856|Biological|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0, 28
45969050|NCT04626856|Biological|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
45969051|NCT04626856|Biological|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
45969052|NCT04626856|Biological|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
45969053|NCT04626856|Biological|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
46080842|NCT05764993|Biological|CUVITRU - Ig subcutaneous human 20%|Subcutaneous Immunoglobin Replacement Therapy, SCigR
46080843|NCT05764993|Other|Standard Medical Therapy|Standard Medical Therapy
46080844|NCT05757986|Other|The presence of nausea and vomiting within 24 hours after surgery|This is a prospective risk prediction model building, thus there is no traditional definition of intervention.
45969054|NCT04626856|Biological|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
45969055|NCT04626856|Biological|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
45969056|NCT04626856|Biological|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
45969057|NCT04626856|Biological|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
45969058|NCT04626856|Biological|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
45969059|NCT04626856|Biological|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
46080845|NCT05756556|Combination Product|T3011 + Cobimetinib|1e8 plaque-forming units (PFU)/mL (up to 10 mL, every 2 weeks [Q2W], 28 days/cycle) T3011 will be administered in combination with 60 mg Cobimetinib (once daily [QD] for the first 21 days of each 28-day cycle)
46080846|NCT05755438|Drug|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the vehicle controlled (DBVC)and open label treatment period (OLE).
46080847|NCT05755438|Drug|Vehicle Cream|Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle controlled period (DBVC).
45668647|NCT03169075|Behavioral|Adapted physical activity|"Program based on the recommendations for performing a physical activity. A booklet containing physical activity recommendations will be given to the patients after randomization.~The weekly sessions at the patients home for the experimental group (Program A) must begin as soon as possible within the 15 days after starting oral targeted therapy.~Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT module AC/S, FACT-Gog, HADS, IPAQ"
45826104|NCT00000275|Drug|Flupenthixol|
45668648|NCT03167437|Drug|Vorinostat|It is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patient with cutaneous T-cell lymphoma (CTCL) who have progress, persistent or recurrent disease on or following two systemic therapies. We are using this drug off label for the purpose of this study
45826105|NCT00001061|Drug|Sevirumab|
45826106|NCT00001061|Drug|Foscarnet sodium|
45826107|NCT00001061|Drug|Ganciclovir|
45826108|NCT00000281|Behavioral|Amantadine|
45826109|NCT02788955|Behavioral|Dietary counselling|
46080848|NCT05750823|Drug|Ruxolitinib Cream|Ruxolitinib cream will be applied twice daily for upto 48 weeks
45826110|NCT02788955|Other|Dietary Protein|
45668649|NCT03167437|Drug|Ustekinumab|Ustekinumab inhibits the bioactivity of human IL-12 and IL- 23 by preventing these cytokines from binding to the IL- 12Rbeta1 receptor protein expressed on the surface of immune cells. It is FDA approved for the treatment of adult patients with active psoriatic arthritis and more recently, in September 2016, ustekinumab has been approved for the treatment of patients with Crohn s disease.
45826111|NCT02577731|Other|Bone marrow collection|Bone marrow will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
45826112|NCT02577731|Other|Blood collection|Blood sample collection will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
45826113|NCT02577731|Other|Clinical data collection|Clinical data collection will encompass demographic information, past and present medical records, laboratory, microbiology, and all other test results, x-ray, CT, MRI, US and all other imaging test results, records about any medication received during admission, records of physical exam during admission, records of all vital signs and hemodynamic monitoring during admission, records of any procedure or intervention during admission, records of any procedure or intervention during hospital admission, condition at the discharge and discharge facility.
45826114|NCT00001067|Drug|Lamivudine|
45826115|NCT00001067|Drug|Stavudine|
45826116|NCT00001067|Drug|Zidovudine|
45826117|NCT02396459|Drug|Triac|Triac, individually titrated dose
45826118|NCT00001079|Drug|Testosterone enanthate|
45826119|NCT00001079|Drug|Megestrol acetate|
45826120|NCT00000293|Drug|Nefazodone|
45826121|NCT00001091|Drug|Ritonavir|
45826122|NCT00001091|Drug|Nelfinavir mesylate|
45826123|NCT00001091|Drug|Nevirapine|
45826124|NCT00001091|Drug|Lamivudine|
45826125|NCT00001091|Drug|Stavudine|
45826126|NCT00000299|Drug|Buprenorphine|
45826127|NCT00000305|Drug|Dextroamphetamine|
45826128|NCT01917929|Device|Secur-Fit Advanced Hip Stem|Straight femoral stem intended for cementless, press-fit application.
45969060|NCT04626856|Biological|Low dosage IRV on a 0- , 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28,56
45969061|NCT04626856|Biological|Medium dosage IRV on a 0- , 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28,56
45969062|NCT04626856|Biological|High dosage IRV on a 0- , 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28,56
45969063|NCT04626856|Biological|Placebo on day 0, 28|Two doses of placebo at the vaccination schedule of day 0,28
45969064|NCT04626856|Biological|Placebo on day 0, 28, 56|Three doses of placebo at the vaccination schedule of day 0, 28,56
45969065|NCT00246636|Drug|Antara (fenofibrate) + Lovaza|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
45969066|NCT00246636|Drug|Antara (fenofibrate)|Antara (fenofibrate) + placebo
45826129|NCT01771679|Biological|Allogeneic Mesenchymal Bone Marrow Cells|Subjects in Part 1, Cohorts 1-3 will receive a 1550 nm Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of 0.5, 1.0, or 1.5 million mesenchymal cells per kg of body weight, not to exceed 150 million cells. Subjects in Part 2 will receive a 1550 Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of mesenchymal cells at the Maximum Tolerated Dose, as determined by the safety results of Part 1. The dose in Part 2 is 1.5 million cells per kg, not to exceed a total of 150 million cells.
45826130|NCT00000311|Drug|Buprenorphine|Medication and Behavioral
45826131|NCT00000311|Drug|methadone|medication and behavioral
45969067|NCT00219440|Other|Actos plus standard diet|Actos plus standard diet
45969068|NCT00219440|Other|Actos plus structured diet|Actos plus structured diet
45969069|NCT00219440|Other|Metformin plus standard diet|Metformin plus standard diet
46080849|NCT05743738|Diagnostic Test|Doppler ultrasound|Control venous Doppler ultrasound
45668650|NCT03164473|Drug|Rituximab|pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)
45668651|NCT03164473|Drug|Azathioprine|oral tablets : 2 mg/kg/day for 24 months
45826132|NCT00000317|Drug|Risperidone|Risperidone (4mg/day)
45668652|NCT03164473|Drug|Placebo-rituximab|4 infusions for 18 months
45668653|NCT03164473|Drug|Placebo-azathioprine|oral tablets for 24 months
45668654|NCT03162289|Other|Fasting|Patients follow a modified fasting regime of 60-72 h (36-48 h before and 24 h after CT) with a dietary energy supply of 350-400kcal per day with vegetable juices during the first four cycles of CT. During the rest of the CT cycles they will observe two days of caloric restriction (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed and the patients are encouraged to follow a pattern of time restricted feeding with 14 h fasting over night at least for six days a week. The patients will receive an individual nutrition training by trained nutritionists.
45826133|NCT00000317|Drug|Placebo|Placebo
45826134|NCT00000317|Behavioral|Relapse prevention counseling|Modified manual guided relapse prevention counseling. Weekly 20 minute sessions consisting of cognitive behavioral skills. Both arms will receive this intervention.
45826135|NCT00001685|Biological|Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase|
45668655|NCT03162289|Other|Vegan|Patients follow a 60-72 h vegan diet with sugar restriction (36-48 h before and 24 h after CT) during the first four cycles of CT. During the rest of the CT cycles they will observe two days of vegan and sugar-restricted diet (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed. The patients will receive an individual nutrition training by trained nutritionists.
45826136|NCT00001115|Drug|Acyclovir|
45826137|NCT00380237|Biological|H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
45668656|NCT05218915|Drug|Dulaglutide|Dulaglutide once weekly subcutaneous
45668657|NCT05218915|Drug|Insulin Degludec|Insulin degludec once daily
45668658|NCT05218915|Device|Continuous glucose monitor|Dexcom G6 CGM system
45826138|NCT00380315|Drug|AG1321001(drug)|
45826139|NCT00001127|Biological|Influenza virus vaccine (CAIV-T)|
45826140|NCT00001757|Drug|Voriconazole|
45826141|NCT00001133|Drug|Indinavir sulfate|
45826142|NCT00001133|Drug|Ritonavir|
45826143|NCT00000329|Drug|Opioid-Related Disorders|
45826144|NCT00000335|Drug|Morphine|
45826145|NCT00000341|Drug|Buprenorphine|
45826146|NCT00000347|Drug|Risperidone|
45826147|NCT00001781|Drug|CGP 77116|
45826148|NCT00001835|Drug|Oxaliplatin|
45826149|NCT00001193|Procedure|high dose melphalan and autologous bone marrow transplantation|
45826150|NCT00000353|Drug|Buprenorphine/naloxone|
45826151|NCT00000377|Drug|Nortriptyline|
45826152|NCT00001865|Drug|Daclizumab|
45826153|NCT00000389|Drug|Fluvoxamine|
45826154|NCT00001271|Drug|IgG-RFB4-SMPT-dgA|
45826155|NCT00000401|Drug|Oral bovine type II collagen|Drug can be interrupted or stopped for suspected adverse events.
45969070|NCT04626700|Device|iNAP|iNAP for the treatment of OSA
45969071|NCT04626700|Device|CPAP|CPAP for the treatment of OSA
45969072|NCT00246675|Drug|Frusemide|
45969073|NCT00219479|Drug|Phenytoin (Dilantin) levels during change in enteral feeding|
45969074|NCT04626778|Drug|Peroxyl Mouthwash|Mouthwash
45969075|NCT04626778|Drug|Placebo Mouthwash|Mouthwash
45969076|NCT04626973|Drug|Ezetimibe/Statin Combination therapy|For statin naive patients, patients would initially receive Ezetimibe 10 mg plus Rosuvastatin 10 mg , For non-statin naive patients, regimens are to be changed to the equivalent dose of ezetimibe+rosuvastatin combination in case of already achieved LDL-cholesterol target (<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
45969077|NCT04626973|Drug|Statin monotherapy|For statin naive patients, patients would initially receive Ezetimibe 10 mg plus Rosuvastatin 10 mg , For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
45668659|NCT05237089|Other|Electroacupuncture|Regular acupuncture will be applied at the main and the additional acupoints with 0.25mm*40mm or 0.30mm*75mm needles. The main acupoints include Shangwan (CV13), Zhongwan (CV12), Jianli (CV11), Xiawan (CV10), bilateral Quchi (LI11), Hegu (LI4), Liangmen (ST21), Tianshu (ST25), Daheng (SP15), Fujie (SP14), Shuidao (ST28), Zusanli (ST36), Fenglong (ST40), Wailing (ST26), Guilai (ST29). Additional acupoints include bilateral Shangjuxu (ST37) and Neiting (ST44), bilateral Yinlingquan (SP9) and Shuifen (CV9), Qihai (CV6) and Guanyuan (CV4). Acupuncturists will use all main acupoints and choose the combined acupoints based on the patients' patterns during each treatment session. The EA apparatus will be connected to the needles at the bilateral ST21, ST25, SP15, using continuous wave type, frequency at 3 Hz, and intensity of 4-5 mA based on the endurance of each patient. Needles will be retained for 30 minutes before removal.
45826156|NCT00000407|Behavioral|Vocational counseling intervention|
45455741|NCT05761964|Behavioral|Harmony & Health|Participants will attend group in-person sessions 2 times each week for 8 weeks. The session will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation. Participants will be asked to complete at-home stretching practices 2 times each week for the 8 week intervention period. Participants will also be asked to complete weekly logs to self-monitor their physical activity.
45826157|NCT00000407|Behavioral|Reading materials for control participants|
45826158|NCT00000407|Behavioral|Standard of care|No education or behavioral intervention
45826159|NCT00001877|Drug|Pentoxifylline|
45826160|NCT00380939|Drug|Atorvastatin|
45969078|NCT04626973|Drug|Ezetimibe/Statin Combination therapy|For statin naive patients, patients would initially receive Ezetimibe 10 mg plus Rosuvastatin 10 mg , For non-statin naive patients, regimens are to be changed to the equivalent dose of ezetimibe+rosuvastatin combination in case of already achieved LDL-cholesterol target (<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
45826161|NCT00380939|Drug|Pravastatin|
45826162|NCT00001889|Procedure|Myocardial contrast echocardiography|
45826163|NCT00001889|Procedure|Stress echocardiography with dobutamine|
45826164|NCT00380549|Diagnostic Test|Blood ion levels|Blood ion levels or the levels of cobalt and chromium ions in the blood and urine will be analyzed.
45826165|NCT00001895|Drug|FDG|
45969079|NCT04626973|Drug|Statin monotherapy|For statin naive patients, patients would initially receive Ezetimibe 10 mg plus Rosuvastatin 10 mg , For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
45969080|NCT00242463|Drug|Nandrolone (anabolic steroid)|
45969081|NCT00242463|Drug|Placebo|
45826166|NCT00001895|Drug|NH(3)|
45826167|NCT00001901|Drug|Etanercept|
45826168|NCT00000431|Drug|PDGF-B/Ad5|This is a dose finding study to evaluate the safety of a single injection of PDGF dna in an adenoviral vector.
45826169|NCT00000437|Drug|Naltrexone Tablet and Nicotine Patch|
45826170|NCT00000437|Drug|Naltrexone Tablet and Placebo Patch|
45826171|NCT00000437|Drug|Placebo Tablet and Nicotine Patch|
45969082|NCT00561808|Other|In-vitro maturation oocytes|Immature oocytes (development stage GV or M1) will be matured in-vitro in IVM culture medium for approximately 28-32 hours. The oocytes will be routinely observed and when they reach maturation (M2) they will be fertilized. The developed embryo will be transferred to the patient 24 hours post-fertilization.
45969083|NCT00219518|Procedure|defecography|insertion of catheter to record pressure. Insertion of barium to outline rectum and fluoroscopy to define change in rectal contour and expulsion of barium during the study.
45969084|NCT00561886|Drug|Formoterol|One inhalation of 24µg Formoterol
45969085|NCT04626622|Drug|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
45969086|NCT04626622|Drug|No one|Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
45969087|NCT00561964|Drug|Irbesartan|Irbesartan capsules strength 150 mg. Irbesartan group will be initiated at one irbesartan and one placebo for 2 weeks and titrated at two capsules if well tolerated after 2 weeks , this dose will be maintained throughout the study without further dose-adjustment (2 capsules daily in the morning will be taken from randomization to study end)
45969088|NCT00561964|Drug|placebo|Placebo group: 2 placebo capsules daily as a single morning intake
45969089|NCT00562003|Procedure|Tenckhoff Catheter placement|'Tenckhoff catheter' will be placed into the abdominal cavity by a minor surgical procedure performed in the Radiology Department.
45969090|NCT00562003|Drug|Ad5-delta24RGD|"Within two weeks before the start of the study, a physical exam, blood tests, removal of fluid from abdominal cavity through the catheter and a CT scan of abdomen and pelvis will be performed.~The procedure will involve receiving the Ad5-delta24RGD virus once a day for 3 days. The virus will be put into the abdominal cavity through a 'Tenckhoff catheter'."
45969091|NCT00219596|Drug|Xalacom|
45969092|NCT00219596|Drug|unfixed Latanoprost and Timolol|
45969093|NCT04626193|Drug|Doxycycline|Doxycylcine 100 mg bid ,esomprazole 20 bid,levofloxacineq.d,Tinadizole 500 bid
45969094|NCT04626193|Drug|Levofloxacin 500mg|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
45969095|NCT00246714|Drug|repeated injections of endotoxin during 5 days|
45969096|NCT04626232|Procedure|N-SLEEVE technique|The N-SLEEVE technique (figure 2) consists of creating a gastric total fundoplication (Nissen technique) before to perform the removal of 2/3 of the stomach (SLEEVE technique).
45969097|NCT04626232|Procedure|SLEEVE|SLEEVE Technique : Removal of 2/3 of the stomach
45969098|NCT00242541|Drug|Octreotide acetate|
45969099|NCT00219635|Drug|UK-390,957|
46080850|NCT05743192|Other|Stop performing an antibiotic susceptibility test|Intervention = Stop performing an antibiotic susceptibility test for enterococcus faecalis in urine cultures. It defines two groups : one before and one after the intervention
45455742|NCT05761964|Behavioral|Health Education|Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and wellbeing topics.
46080851|NCT05742165|Behavioral|Time Restricted Eating (TRE)|TRE involves only consuming food and beverages during a particular consecutive time period - in the case of this study, either 6 hours or 10 hours. Participants will self-select the timing of their first eating occasion of the day, with the provision that their first meal of the day will be consumed within 3 hours of their wake- up time and finished no less than 3 hours prior to bed time. During the fasting period, participants will be encouraged to drink water, and will be permitted to consume zero-calorie beverages. Participants will be instructed to self-monitor all eating occasions using the MyCircadianClock (mCC) smartphone app, which date- and time-stamps all food entries. Participants will also be instructed to self-monitor their body weight daily using a Bluetooth-enabled Renpho scale, which permits remote collection of body weight.
46080852|NCT05739149|Diagnostic Test|Microvessel Ultrasound Examination|Ultrasound to evaluate microvessel formation and elastography or stiffness of the tissues around the ulcer and in an area of unaffected skin
46080853|NCT05739149|Procedure|Skin Biopsy|Dermatology will remove a small piece of skin from the affected ulcer area and control skin
46080854|NCT05727176|Drug|TAS-120|TAS-120 is an oral FGFR inhibitor
45668660|NCT05237089|Other|Sham acupuncture|Patients will receive superficial acupuncture treatment at the same main acupoints as EA group with 0.22*0.25mm needles. The electroacupuncture apparatus will connected to the needles at the bilateral Liangmen (ST21), Tianshu (ST25), Daheng (SP15) without current output. Needles will be retained for 30 minutes before removal. The treatment will be given 3 times a week in week 1-12, 2 times a week in week 13-20, and once a week in week 21-24, totaling 56 sessions of real or sham acupuncture.
45668661|NCT05237089|Other|Health education|The health management brochure will be distributed to all patients in the trial after enrollment, and health education will be arranged online or offline at week 4, 8, 12, 16, 20 and 24 for about 60 minutes, including lifestyle, diet and physical activity. According to the specific situation of each patient, healthier individual lifestyle and behavior will be recommended to all patients, but there will be no strict restrictions on the diet or physical activity.
45668662|NCT03462511|Behavioral|HABIT Intervention|In addition to standard care and education handouts, dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.
46080855|NCT05720325|Drug|Dupilumab|Dupixent is an interleukin-4 receptor alpha antagonist
46080856|NCT05720325|Other|House Dust Mites (HDM)|House Dust Mites used to challenge subjects using an aeroallergen challenge chamber
45668663|NCT03424603|Drug|STRO-001|intravenous antibody drug conjugate
45826172|NCT00000437|Drug|Placebo Tablet and Placebo Patch|
45826173|NCT00000443|Drug|ondansetron (Zofran)|
45826174|NCT00380783|Drug|AGN 203818|
45826175|NCT00000449|Drug|naltrexone (Revia)|
45826176|NCT00000449|Behavioral|cognitive behavioral therapy|
45826177|NCT00000449|Behavioral|cue exposure treatment|
45826178|NCT00000455|Drug|naltrexone|
45826179|NCT00000473|Behavioral|dietary supplements|
45826180|NCT00000473|Drug|fatty acids, omega-3|
45826181|NCT00000473|Behavioral|diet, fat-restricted|
45826182|NCT00001919|Drug|Hypericum (LI-160)|
45826183|NCT00001925|Drug|Alcohol|
45826184|NCT00001307|Drug|Oxygen-15 Water|
45826185|NCT00001307|Drug|Capsaicin|
45826186|NCT00001931|Drug|N-0923|
45826187|NCT04713761|Drug|Toripalimab|"Neoadjuvant treatment stage: Toripalimab 240mg, Carboplatin AUC5+ pemetrexed 500 mg/m ², iv, 3 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: Patients with MPM received surgical treatment (PD/EPP) after neoadjuvant therapy. Patients who were unable to operate or refused surgical treatment due to various reasons were treated with multidisciplinary discussion.~Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: Toripalimab 240mg, Carboplatin AUC5+ pemetrexed 500 mg/m ²,iv, up to 4 cycles (including neoadjuvant stage)."
45668664|NCT04706689|Behavioral|SWADOC tool|"The tool explores some oral and pharyngeal components of swallowing as well as a range of prerequisite and related components of swallowing in DOC patients.~It is composed of an average of 50 qualitative items and a subsection named SWADOC-scored comprising 8 quantitative items."
45668665|NCT04706689|Behavioral|FOTT-SAS|"Facial Oral Tract Therapy Swallowing Assessment of Saliva : the results of the SWADOC-scored in one of the sessions will be compared to the FOTT Swallowing Assessment of Saliva (FOTT-SAS) (27). The test is based on 7 questions under which if items 1-4 are answered Yes and items 5-7 are answered No, oral intake should be initiated. The FOTT-SAS includes items that can be scored based on the administration of the SWADOC tool. In that respect, no additional administration will be required"
45826188|NCT00380471|Device|Bath PUVA|
45826189|NCT00000509|Behavioral|diet, sodium-restricted|
45455743|NCT05756803|Device|Low-intensity acoustic shockwave therapy|The study is being done to find out if low-intensity shockwave therapy can improve penile blood flow and restore sexual function in men with impaired erectile function.
45455744|NCT05755282|Drug|Post-market foam alcohol-based hand sanitizer|Automated dispenser will dispense 1 mL of hand sanitizer product onto hands.
45455745|NCT05751980|Behavioral|Med Wise Rx|The program consists of two 90-minute classes led by trained community site-based facilitators, designed to help older adults communicate more effectively with their pharmacists.
45668666|NCT03398161|Other|Quality-of-Life Assessment|Ancillary studies
45668667|NCT03398161|Other|Questionnaire Administration|Ancillary studies
45969100|NCT04625998|Behavioral|Enhanced CATCH Elementary School Program|Enhanced CATCH Elementary School Program is a Coordinated School Health Program that includes the CATCH Coordination Guide.
45969101|NCT04625998|Behavioral|CATCH Early Childhood (CEC)|Implementation of the CATCH Early Childhood coordinated nutrition and physical activity program for Early Care and Education (ECE) centers.
45969102|NCT04625842|Other|Focus group interview|Group interview with patients who received radiation treatment
46080857|NCT05720325|Other|Placebo|Inert placebo administered to placebo arms of study.
45826190|NCT00000509|Behavioral|diet, potassium-supplementation|
45826191|NCT00000515|Behavioral|diet, reducing|
45826192|NCT00001937|Drug|FK463|
45826193|NCT00001937|Drug|Fluconazole|
45826194|NCT00001325|Drug|18 FDG|
45826195|NCT00000545|Behavioral|exercise|
45826196|NCT00000545|Behavioral|diet|
45826197|NCT04331327|Drug|allogenic lyophilized growth factors|Prior to usage, reconstitution of the product was done using 1-ml saline and 1-ml lignocaine followed by gentle vial rubbing for 3 minutes. Then, the mixture was kept at ambient temperature for 5 minutes to ensure complete protein re-hydration.
45826198|NCT00001955|Drug|Etanercept|
45969103|NCT04720599|Diagnostic Test|ExoDx Prostate(IntelliScore)|The ExoDx Prostate test result supports the biopsy decision process by stratifying patients based on risk for high grade prostate cancer
45969104|NCT04625686|Behavioral|Mental Health Treatment|Treatment of suicidal ideation
45969105|NCT04625920|Device|SootheVR: AppliedVR, Los Angeles, California|a head-mounted display
45969106|NCT00219674|Behavioral|Group I: Video training|"Participants will receive the AED with a video that provides instructional training."
45969107|NCT00219674|Behavioral|Group II: Video training + enhanced self-efficacy (SE)|Partcipants will receive the AED with instructional video, a manikin, and additional training materials by mail.
46080858|NCT05718102|Other|Population-health management|Population-health management
46080859|NCT05714085|Drug|Vericiguat tablet|2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form
46080860|NCT05714085|Drug|Vericiguat suspension|0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form
46080861|NCT05714085|Drug|Placebo tablet|Placebo for vericiguat administered orally once daily in tablet form
46080862|NCT05714085|Drug|Placebo suspension|Placebo for vericiguat administered orally once daily in suspension form
45969108|NCT00219674|Behavioral|Group III: In-person training + enhanced SE|Participants will receive a face-to-face training session in their home as well as the AED with instructional video, manikin and training materials.
45668668|NCT03398161|Radiation|Radiation Therapy|Undergo ultra low dose radiation therapy
45826199|NCT00001955|Drug|Celecoxib|
45826200|NCT00000551|Behavioral|health education|
45969109|NCT00219674|Behavioral|Group IV: In-person training + enhanced SE + support|Participants will receive a face-to-face training session in their home as well as the AED, instructional video, manikin, and a resource manual with information to enhance the family member's confidence in their role as care provider.
45969110|NCT04625959|Behavioral|Behavioral Therapy for Eating Disorders|Change behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).
45969111|NCT04625959|Behavioral|MABT: Mindful Awareness|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically mindful awareness, designed to enhance self-regulation. Mindful awareness strategies include developing inner and outer wisdom, formal meditation, and shifting awareness to the present moment. Mindful awareness skills also include increasing awareness of thoughts, feelings, physical sensations, and hunger and fullness cues.
45455746|NCT05751811|Device|Virtual reality|"The immersive video simulated a magical journey through a calming starry sky on a flying carpet. The headset will play the immersive video content throughout the hysteroscopic procedure; and will stop playing the content as the procedure comes to an end. Participant can adjust the volume of the sound according to her comfort.~The duration of hysteroscopic operation will be 5 to 20 minutes."
45455747|NCT05751811|Procedure|Music therapy|"Relaxing and light music will play throughout the hysteroscopic procedure; and will stop playing as the procedure comes to an end. Participant can adjust the volume of the sound according to her comfort.~The duration of hysteroscopic operation will be 5 to 20 minutes."
45668669|NCT05384197|Drug|Enhanced regimen|"Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 2 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (2 days with the last day of AP course being one day prior to intervention)"
45826201|NCT04943783|Drug|Atorvastatin 20mg|One with the intervention (Atorvastatin, 20mg OD), 20 patients for this arm.
45826202|NCT00000581|Procedure|leukocyte transfusions|
45826203|NCT00000605|Drug|hormone replacement therapy|
45826204|NCT00000605|Drug|estrogens|
45826205|NCT00000605|Drug|medroxyprogesterone|
45826206|NCT00000617|Drug|azithromycin|
45826207|NCT00000623|Drug|Deferoxamine|
45826208|NCT00000623|Drug|Deferiprone|
45826209|NCT00000623|Drug|Arginine|
45826210|NCT00000623|Drug|Sildenafil|
45826211|NCT00000623|Drug|Decitabine|
45826212|NCT00001961|Procedure|MRI|
45826213|NCT00001967|Drug|HAART|
45826214|NCT00001991|Drug|Atovaquone|
45826215|NCT00001997|Drug|Interleukin-2, Polyethylene Glycolated|
45826216|NCT00001997|Drug|Zidovudine|
45826217|NCT00001997|Drug|Didanosine|
45826218|NCT00002003|Drug|Mitoxantrone hydrochloride|
45826219|NCT00002003|Drug|Etoposide|
45826220|NCT00002009|Drug|Sargramostim|
45826221|NCT00000629|Drug|Valproic acid|
45826222|NCT00000629|Drug|Zidovudine|
45826223|NCT00000647|Drug|CD4-IgG|
45826224|NCT00000647|Drug|Zidovudine|
45826225|NCT00000647|Drug|Interferon alfa-n1|
45826226|NCT00000647|Procedure|Peripheral lymphocyte infusion|
45826227|NCT00000647|Procedure|Bone marrow transplant|
45826228|NCT00000653|Drug|Zalcitabine|
45826229|NCT00001409|Drug|Interleukin-2|
45826230|NCT00000659|Drug|CD4 Antigens|
45826231|NCT00000659|Drug|Zidovudine|
45826232|NCT00381017|Drug|Peg interferon alpha-2b|
45826233|NCT00001439|Biological|gp100 human melanoma peptide|
45826234|NCT00002015|Drug|Ganciclovir|
45826235|NCT00002021|Drug|Foscarnet sodium|
45826236|NCT00002027|Drug|Diclazuril|
45826237|NCT00000695|Drug|Interferon beta-1b|
45826238|NCT00000695|Drug|Zidovudine|
45826239|NCT00000701|Drug|Zidovudine|
45826240|NCT00000713|Drug|Ampligen|
45826241|NCT00000725|Drug|Interferon alfa-2a|
45826242|NCT00000725|Drug|Zidovudine|
45826243|NCT00000725|Drug|Interferon alfa-n1|
45826244|NCT00002033|Drug|Zidovudine|
45826245|NCT00002033|Drug|AS-101|
45826246|NCT00002039|Drug|Foscarnet sodium|
45826247|NCT00000731|Drug|Zidovudine|
45826248|NCT00000731|Drug|Acetaminophen|
45826249|NCT00002045|Drug|Zidovudine|
45826250|NCT00001493|Genetic|peripheral blood progenitor cells carrying MDR1|
45826251|NCT00002051|Drug|Thymopentin|
45826252|NCT00001499|Drug|paclitaxel|
45969112|NCT04625959|Behavioral|MABT: Values|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically values, designed to enhance self-regulation. Values skills include identifying and clarifying values, living a values life, making values-consistent decisions, addressing competing values, values awareness, and using values to address negative moods.
45969113|NCT04625959|Behavioral|MABT: Emotion Modulation|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically emotion modulation, designed to enhance self-regulation. Emotion modulation skills include long-term habits for emotion regulation, coping strategies, crisis management, and cognitive reappraisal.
45969114|NCT04625959|Behavioral|MABT: Distress Tolerance|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically distress tolerance, designed to enhance self-regulation. Distress tolerance skills include psychological acceptance, uncoupling, willingness, and dealing with dirty distress.
45969115|NCT00246792|Behavioral|Group treatment|
45969116|NCT04625881|Dietary Supplement|Apple derived fiber|This is a combination of soluble and insoluble fiber
45969117|NCT04625608|Drug|Paracetamol|Standard care of 3 ml/kg water, plus 15 mg/kg oral paracetamol suspension, a minimum of 1 hour prior to the induction of general anaesthesia.
45969118|NCT04625608|Other|Standard care|Standard care of 3.6 ml/kg water, a minimum of 1 hour prior to the induction of general anaesthesia.
45969119|NCT00219713|Drug|nitrous oxide and oxygen|
45969120|NCT04625491|Other|Observational|Observational
45969121|NCT04625335|Other|No Massage Protocol|Participants did not receive therapeutic massage prior to completing the Cold Pressor Test.
45455748|NCT05748769|Behavioral|Practice (UL)|Subjects performed RMs toward the units that were activated in the same order as the tested sequence 1-4-3-5-4-2, and with an activation duration and delay of 1 s. The practice included 16 blocks, each consisting of 30 RM with a 30 s pause after each block
45668670|NCT05384197|Drug|Extended regimen|"Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 7 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (7 days with the last day of AP course being one day prior to intervention)"
45668671|NCT01995201|Drug|DMARD|non-biological disease-modifying antirheumatic drugs at stable dose
45668672|NCT01995201|Drug|methotrexate|stable dose
45826253|NCT00001499|Drug|cisplatin|
45826254|NCT00001499|Procedure|chest radiotherapy|
45826255|NCT00002057|Drug|Nystatin|
45969122|NCT04625335|Other|Prophylactic Therapeutic Massage|Participants received a 5 minute prophylactic therapeutic massage prior to completing the Cold Pressor Test. The massage was completed distally-to-proximally in the following order: superficial strokes to the entire forearm, deep strokes to the entire forearm, one-handed palmar kneading of the entire forearm with participant's forearm stabilized by the massager's the other hand, bilateral thumb kneading of the forearm in strips until the entire forearm was addressed, bilateral transverse thumb motions over palmar surface of the hand, single thumb kneading of thenar and hypothenar eminences simultaneously, bilateral thumb kneading to the dorsum of hand, deep stroking to the entire forearm, and superficial stroking to the entire forearm.
45969123|NCT00219752|Drug|Imatinib mesylate 400 mg|
45826256|NCT00002297|Drug|Inosine pranobex|
45455749|NCT05748769|Behavioral|Observation (SO)|Subjects observed the illuminating switches while avoiding moving. The subjects observed RMs toward the units that were activated in the same order as the practiced sequence 1-4-3-5-4-2, also with an activation duration and delay of 1 s and 30 s pause after each block.
45455750|NCT05748769|Behavioral|Nature Observation (NO)|The video-clip consisted of a 16 min nature movie in cycles of one-minute observation and pausing 30 s, equivalent to the timing of RMs performed by groups UL and SO
45668673|NCT01995201|Drug|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously (SC) qw, Weeks 1-24
45826257|NCT00001535|Drug|Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro|
45969124|NCT04625452|Behavioral|BBCC+5A's+GS|"It is a 5-steps intervention delivered in a motivational interviewing spirit. Clearly the five steps are asking about the behaviour risk factors, assessing the level of risk factors; providing information about the pros and cons of the behaviour in a neutral way; assessing the change by probing about the importance in and the confidence of changing the risk factor; assisting the patient to come-up with a road map about changing the risk factor, connecting the patient to support networks or drugs which can increase the likelihood to change; and arranging for the next visit.~All this given by asking opened question to participant, active listening, summarizing what he is saying, evoking change through concepts or statements, empathy and asking permission to provide further information."
45969125|NCT00242697|Procedure|spinal analgesia and anesthesia for coronary artery surgery|
45826258|NCT00002303|Drug|Epoetin alfa|
45826259|NCT00002063|Drug|Zidovudine|
45826260|NCT00002069|Drug|Ditiocarb sodium|
45826261|NCT00001565|Drug|phenylbutyrate|
45826262|NCT00002309|Drug|Azithromycin|
45826263|NCT00002315|Drug|Netivudine|
45826264|NCT00002315|Drug|Acyclovir|
45826265|NCT00002075|Drug|Flucytosine|
45826266|NCT00002075|Drug|Fluconazole|
45826267|NCT00002075|Drug|Amphotericin B|
45826268|NCT00001577|Procedure|double isolated limb perfusion with melphalan alone|
45826269|NCT00002081|Drug|Zidovudine|
45826270|NCT00002081|Drug|Zalcitabine|
45826271|NCT00001637|Procedure|Blood cell transplantation|
45969126|NCT04625179|Other|Melatonin and hyaluronic acid and sinus membrane elevation|3 mg melatonin powder mixed with 0.2% hyaluronic acid gel will be placed to fill the sinus space and around the implant apex.
45969127|NCT04625179|Procedure|sinus membrane elevation without any materials|No materials will be placed at the sinus space.
45969128|NCT00219791|Drug|glucarpidase (50 Units/kg)|
45668674|NCT01995201|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC qw or q2w, Weeks 24-48
45668675|NCT01995201|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC qw, Weeks 24-48
45969129|NCT04624867|Drug|HP-1050 Patch|Both articles, HP-1050 and XULANE patch, will be applied simultaneously on the back of each subject.
45969130|NCT04624516|Other|self-structured foot exercise|The exercise was done 3 times a week (15x/until they tired x 2set). The exercise used a flexible band with difference thickness (0,5 mm in the first 12 weeks and 0,65 mm in the second 12 weeks)
45969131|NCT02962232|Device|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|treatment group
45969132|NCT02962232|Device|PTA catheter|control group
45969133|NCT04624711|Drug|Eribulin Mesylate|Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.
45668676|NCT05383651|Device|bellavista 1000|observational use of Bellavista 1000 ventilator in adult ventilated patients
45668677|NCT05383651|Device|bellavista 1000 neo|observational use of Bellavista 1000 ventilator in neonatal ventilated patients
45668678|NCT04690699|Biological|Lerapolturev|Lerapolturev administered via intravesical instillation once
45668679|NCT04690699|Other|5% DDM|5% DDM and saline washes
45668680|NCT04783363|Other|Snoezelen session|before one of two repeated invasive care
45668681|NCT04638387|Dietary Supplement|PB125|Nrf2 activator containing active ingredients carnosol, withaferin A, and luteolin.
45668682|NCT04638387|Dietary Supplement|Placebo|Placebo comparator to P125
45668683|NCT01728454|Drug|Placebo|Placebo matching capsules, orally, once daily for 18 weeks.
45668684|NCT01728454|Drug|Telapristone acetate|Telapristone acetate capsules, orally once daily for 18 weeks.
45668685|NCT04568590|Behavioral|educational intervention|If the guardian screens positive for vaccine hesitancy (i.e., vaccine hesitancy score average > 3), they will be given the informational handout along with a brief script.
45668686|NCT04568434|Drug|Olezarsen|Olezarsen will be administered by SC injection.
45668687|NCT04568434|Drug|Placebo|Olezarsen-matching placebo will be administered by SC injection.
45826272|NCT00002087|Drug|Alvircept sudotox|
45668688|NCT04568044|Procedure|Blood sample|Peripheral blood sample will be obtained.
45668689|NCT01636687|Drug|Placebo|2 injections of placebo to secukinumab 150mg per dose
45668690|NCT01636687|Drug|Secukinumab 150mg|Secukinumab 150mg: 1 injection of 150 mg secukinumab and 1 injection of placebo to secukinumab 150mg per dose. After Week 52 database lock, study is open label so only 1 injection of secukinumab 150mg per dose were administered
45668691|NCT01636687|Drug|Secukinumab 300mg|Secukinumab 300mg (2 injections of 150mg secukinumab per dose)
45826273|NCT00002093|Drug|Daunorubicin (liposomal)|
45826274|NCT00002093|Drug|Bleomycin sulfate|
45826275|NCT00002093|Drug|Vincristine sulfate|
45826276|NCT00002093|Drug|Doxorubicin hydrochloride|
45826277|NCT00002099|Drug|Lentinan|
45826278|NCT00002099|Drug|Didanosine|
45668692|NCT03017755|Other|Survey for Patients Treated for Scoliosis and ther Families|Your Scoliosis Journey: A Survey for Patients Treated for Scoliosis and ther Families
45668693|NCT05213377|Procedure|Preoperative warming|Patients enrolled in surgery who will not receive 30 minutes of pulsed air thermal blanket warming prior to induction of anesthesia (3M™ Bair Hugger™ Adult Integral Blanket, Model 300 Dimensions: 213 cm x 91 cm)
45668694|NCT04797169|Behavioral|Noom Health|In Noom Health, participants will be encouraged to use the Noom app multiple times a day to log eating episodes, physical activity and weight. They will also have the ability to interact with coaches to receive advice and feedback specific to weight loss.
45668695|NCT04797169|Behavioral|Noom Digital Health|In Noom Digital Health, participants will use a simplified version to log eating episodes and weight. Both conditions will receive the same weight loss advice content.
45668696|NCT01634659|Device|Delefilcon A contact lenses (DAILIES TOTAL1®)|Commercially marketed silicone hydrogel, single-vision contact lenses for daily wear, daily disposable use
45826279|NCT00002321|Drug|Aldesleukin|
45826280|NCT00002327|Drug|Cidofovir|
45826281|NCT00002333|Drug|Saquinavir|
45826282|NCT00002333|Drug|Zalcitabine|
45826283|NCT00002339|Drug|Fluconazole|
45826284|NCT00002105|Drug|Doxorubicin hydrochloride (liposomal)|
45826285|NCT00002105|Drug|Bleomycin sulfate|
45826286|NCT00002105|Drug|Vincristine sulfate|
45826287|NCT00002345|Drug|Megestrol acetate|
45826288|NCT00002111|Drug|Saquinavir|
45826289|NCT05752643|Other|Online follow up|The online follow up will include screening for HIV and STIs (Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Treponema pallidum (TP)) based in a self-sampling strategy
45826290|NCT00002351|Drug|Indinavir sulfate|
45826291|NCT00002357|Drug|HBY 097|
45826292|NCT00002357|Drug|Zidovudine|
45826293|NCT00002117|Drug|Zidovudine|
45826294|NCT00002117|Drug|Zalcitabine|
45969134|NCT04624711|Drug|Anlotinib hydrochloride|Anlotinib 12mg, administered orally on Days 1-14 of each 21 day cycle.
45969135|NCT00246909|Drug|Pantoprazole|
45969136|NCT04624594|Other|Artificial Intelligence Feedback|AI mobile application provides feedback to participants randomized to artificial intelligence group.
45969137|NCT04624594|Other|Physical Therapist Feedback|PT provides feedback to participants randomized to physical therapist group.
45969138|NCT04624282|Diagnostic Test|different diseases|Patients will be divided into three groups, including chronic superficial gastritis ,chronic atrophic gastritis and gastric carcinoma.
45969139|NCT00219869|Drug|Galantamine|
46080863|NCT05713071|Procedure|Bariatric Endoscopic Antral Myotomy|BEAM will be performed using a standard gastric peroral endoscopic myotomy (G-POEM) technique, however with the myotomy targeting only the antrum and leaving the pyloric ring intact. G-POEM is commonly and widely employed for gastric emptying and nutritional issues and is covered by most insurance plans. This involves injecting fluid into the submucosal space, making a mucosal incision to enter the submucosal space, and tunneling along the antrum to the pylorus. A myotomy is then performed, however, in BEAM the pyloric ring is spared and the myotomy is only performed in the antrum. The incision is then closed with clips. No endoscopic suturing will be performed.
46080864|NCT05712941|Drug|Lerociclib|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice a day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique [FIGO] Stage III versus FIGO Stage IV versus recurrent)~EC tumor grade (Grade 1 versus Grade 2)~Geographic location (US versus Europe versus Rest of World)"
46080865|NCT05712941|Drug|Letrozole 2.5mg|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice daily (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique [FIGO] Stage III versus FIGO Stage IV versus recurrent)~EC tumor grade (Grade 1 versus Grade 2)~Geographic location (US versus Europe versus Rest of World)"
45826295|NCT05752565|Device|SenseWear armband device|"Device: SenseWear armband device Metabolic Holter, Physical Activity and Lifestyle, Portable outpatient multi-sensor energy consumption in calories (EE), movement, physical activity, quality of life"
45826296|NCT00002123|Drug|Delavirdine mesylate|
45826297|NCT00002123|Drug|Didanosine|
45826298|NCT00381329|Behavioral|Motivational Interviewing (MI)|MI is an empirically supported, client-centered, directive method for matching counseling to an individual's readiness to change.
45969140|NCT04624165|Other|Survey|o We plan to hand out copies of a survey to examine patient's perspective on telemedicine.
45969141|NCT00246948|Procedure|Active conservative treatment of sciatica|
45969142|NCT04624360|Drug|Dexamethasone|Intravenous of Dexamethasone 8 mg post clamping of the umbilical cord
45969143|NCT04624360|Other|Placebo|2cc 0.9% Saline
45969144|NCT04624438|Other|Isometric training with electromyostimulation|"Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The force intensity was determined individually during pretest where EMS was delivered at maximal tolerable dose. Electrical stimulation was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Stimulation characteristics were selected among the Compex commercially available strength programs. The stimulation intensity was monitored on-line and determined by the subject at the start of each EMS session according to his/her pain threshold to produce a force corresponding to at least 60% of the pretest MVC score."
45668697|NCT01634659|Device|Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®)|Commercially marketed, silicone hydrogel single-vision contact lenses for daily wear, daily disposable use
45668698|NCT05652985|Behavioral|Inter-professional Collaboration Training|the participated nurses will receive session about Inter-professional Collaboration followed by activity which can boost Inter-professional Collaboration
45668699|NCT04418713|Other|active video-games|An intervention with active video-games to increase physical activity and improve body composition
45826299|NCT00381329|Behavioral|Structured Brief Advice (SBA)|SBA includes the administration of scripted, brief cessation counseling that follows standard health care smoking cessation guidelines.
45826300|NCT00002363|Drug|Peptide Construction 3, Synthetic|
45826301|NCT00381173|Drug|Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)|Patients who meet all entry criteria will be administered 600 mg/m^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).
45826302|NCT05752409|Drug|The median dose of esketamine|1mg•kg-1propofol and 0.5 mg•kg-1esketamine for general anesthesia induction.
45826303|NCT05752409|Drug|The high dose of esketamine|1mg•kg-1propofol and 0.75 mg•kg-1esketamine for general anesthesia induction.
45826304|NCT05752409|Drug|Propofol|2mg•kg-1propofol for general anesthesia induction.
45969145|NCT04624438|Other|Isometric training with voluntary activation|Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). Participants were required to reach the proscribed force level only through voluntary activation of QF. To attain the same contraction/rest ratio as in EMS, automated audible signals were delivered in accordance with the contraction-rest pattern produced by the muscle stimulation device. To ensure participants produced 60% of individual MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
45969146|NCT04624438|Other|Isometric training with combination of electromyostimulation and voluntary activation|Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The proscribed force level was reached by the simultaneous action of EMS and VOLUNTARY. Each contraction was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Electrical stimulation corresponded to 30% of MVC, while the remaining 30% was achieved through voluntary muscle activation. To ensure participants produced a force corresponding to 60% of MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
45826305|NCT00002129|Drug|Vesnarinone|
45826306|NCT00002135|Drug|Ganciclovir|
45969147|NCT00219908|Drug|Mitoxantrone|
45969148|NCT00242736|Drug|Esomeprazole|
45969149|NCT04624048|Diagnostic Test|COVID-19 survey|Participants should complete a survey to analyze the impact of COVID-19 on University population.
46080866|NCT05712941|Drug|Placebo|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique [FIGO] Stage III versus FIGO Stage IV versus recurrent)~EC tumor grade (Grade 1 versus Grade 2)~Geographic location (US versus Europe versus Rest of World)"
45826307|NCT00002141|Drug|Abacavir sulfate|
45826308|NCT00002369|Drug|Indinavir sulfate|
46080867|NCT05712395|Behavioral|Exercise|Non-Ischemic Exercise (NICE), pain-free exercise program will be compared to the Standard painful exercise program.
45826309|NCT00002369|Drug|Lamivudine|
45826310|NCT00002369|Drug|Stavudine|
45826311|NCT00002369|Drug|Zidovudine|
45826312|NCT00002375|Drug|Indinavir sulfate|
45826313|NCT00002375|Drug|Nelfinavir mesylate|
46080868|NCT05712057|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|high frequency rTMS over the right dlPFC
45826314|NCT04636697|Drug|Intramuscular injection|Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
45826315|NCT04636697|Biological|Intramuscular vaccine|Subjects will receive two doses of 3.75 µg of CoVLP adjuvanted with AS03 adjuvant given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
45826316|NCT00002381|Drug|Nelfinavir mesylate|
45826317|NCT00002381|Drug|Nevirapine|
45826318|NCT00002381|Drug|Stavudine|
45826319|NCT05752331|Behavioral|Physical activity behavioural modification|8-week intervention consisting motivational interview, individualised action plan and weekly consultations regarding activities of daily living and symptom management.
46080869|NCT05712057|Device|electrical scalp stimulation|electrical scalp stimulation over the right dlPFC
45826320|NCT00002387|Drug|Indinavir sulfate|
45826321|NCT00002387|Drug|Efavirenz|
45826322|NCT00002393|Drug|Indinavir sulfate|
45826323|NCT00002393|Drug|Efavirenz|
45826324|NCT00002399|Drug|Posaconazole|
45826325|NCT00002399|Drug|Fluconazole|
45826326|NCT00002405|Drug|Amprenavir|
45826327|NCT00002417|Drug|Amprenavir|
45826328|NCT00381407|Behavioral|Organizational Skills Training|Participants in the OST group attend twenty 1-hour sessions over 10 weeks. OST trains children to use a variety of techniques for improving their organizational skills. Both children and their parents attend every OST session.
45826329|NCT00381407|Behavioral|Contingency management (CM)|"Participants in the CM group will attend twenty 1-hour sessions over 10 weeks. CM trains parents and teachers to identify desired end behaviors and to increase the frequency of these behaviors through the use of a structured reward system. Both children and their parents attend every CM session, but the children's participation will be minimal."
45826330|NCT00002423|Drug|Indinavir sulfate|
45826331|NCT00002423|Drug|Abacavir sulfate|
45826332|NCT00002423|Drug|Amprenavir|
45826333|NCT00002423|Drug|Nelfinavir mesylate|
45826334|NCT00002423|Drug|Lamivudine|
45826335|NCT02973581|Drug|Metamizol|in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram
45969150|NCT01580605|Drug|somatropin|"Data are extracted from the French National Registry l'Observatoire National des Prescriptions et Consommations de Médicaments to where physicians report data about growth hormone treatment"
45668700|NCT05165641|Procedure|segmental spinal anesthesia|Spinal anesthesia was performed at a lower thoracic level with the patient in the sitting position. After local anesthesia with 1% lidocaine, the spinal puncture was done in the 10th thoracic intervertebral space (T 10) through a median approach. A 27 Gg pencil-point needle with an introducer was used (marquee). To identify T 10, the vertebra prominens (C7) was palpated and the spinous processes were palpated caudally [ref}. Two senior anesthesiologists performed all the spinal punctures. The progression of the spinal needle was cautious and soft. The effort was made to stop the needle progression just after the tactile perception of the dura mater. Once the flow of cerebrospinal fluid was obtained, 1.5 ml of hyperbaric bupivacaine 5mg/ml (=7.5 mg) mixed with 0.5 ml of fentanyl 50 µg/ml (= 25 µg) was injected and the spinal needle removed.
45969151|NCT04624126|Device|3D-Erect|3D-printed erectile device for intercourse
45969152|NCT04623970|Procedure|Dental Treatment|Comprehensive dental care (restorative treatmen, crowns, pulp therapy, fissure sealant and teeth extraction for pediatric patients under the deep sedation
45969153|NCT00219947|Other|blood draw|"T cell subset enumeration~Serologic reactivity with HIV antigens~Viral load assays by bDNA, PCR, or RT-PCR~Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)~HIV-1 Resistance Testing"
45969154|NCT04623892|Drug|TQB2618 injection|TQB2618 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2618 is diluted to 100 m with normal saline [0.9% (w/v) sodium chloride solution], and the infusion time is 60 ± 10 min.
45969155|NCT00242775|Drug|Budesonide/formoterol Turbuhaler|
45969156|NCT00242775|Drug|Salmeterol/fluticasone Diskus|
45969157|NCT00562081|Behavioral|Education|24/7 access to a Certified Asthma Educator
45969158|NCT00562081|Behavioral|Education|Patient does not have 24/7 access to a Certified Asthma Educator.
45826336|NCT02973581|Drug|Acetaminophen|in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
45826337|NCT02973581|Drug|0,5 % bupivacaine with of 2% lidocaine|in group PBB patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
45668701|NCT04796467|Drug|68Ga-PSMA-617|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
45668702|NCT04796467|Drug|68Ga-P16-093|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-P16-093. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
45668703|NCT05814471|Device|Cable fastening system and 3d printed straps|The participants will wear a Odra knee brace held in place with by a cable fastening system and 3d printed straps for 2 weeks.
45668704|NCT05814471|Device|Velcro straps system|The participants will wear a Odra knee brace held in place with by a velcro straps system for 2 weeks.
45668705|NCT05814458|Device|tDCS|Patients will be receiving twice a day tDCS (applied current at 2mA) stimulation, for 3 weeks on working days (30 sessions in total) and each stimulation will last 25 minutes. The anode will be located on the left, while the cathode- on the right dorsolateral prefrontal area of scalp. The commercially available Soterix 1x1 tDCS mini-CT LTE device (model 1601-LTE) will be used for stimulation.
45668706|NCT05814458|Device|Placebo|Patients will be receiving twice a day sham stimulation, for 3 weeks on working days (30 sessions in total) and each stimulation will last 25 minutes. The anode will be located on the left, while the cathode- on the right dorsolateral prefrontal area of scalp. The commercially available Soterix 1x1 tDCS mini-CT LTE device (model 1601-LTE) will be used for stimulation.
45668707|NCT05814445|Other|Neuromuscular exercise program|Participants will complete a neuromuscular program during 22 weeks. The program consist of isotonic open and closed kinetic chain exercises for the hip and knee, and training to improve hip and knee muscles strength, proprioception, and core stability.
45826338|NCT02973581|Drug|Proxymetacaine|in group T patients will receive topical analgesia using a solution of 0,5% Alcaine
45826339|NCT00002435|Drug|Thymic Humoral Factor|
45826340|NCT00002435|Drug|Zidovudine|
45826341|NCT00002441|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
45969159|NCT00219986|Drug|Potent HAART during acute or early HIV-1 infection|
45826342|NCT00002447|Drug|Ritonavir|
45969160|NCT04623619|Dietary Supplement|Acetyl L-Carnitine|Administering 2 gr of Acetyl L-Carnitine orally in addition to the standard of care therapy for 14 days
45969161|NCT00562198|Drug|entacapone and carbidopa|Entacapone 200mg carbidopa 50mg
46080870|NCT05712057|Behavioral|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal.
46080871|NCT05712057|Behavioral|Emotional Awareness Training|Emotional awareness training is a behavioral intervention through which participants learn how to identify and evaluate their emotions and the components that make up each emotion.
45826343|NCT00002447|Drug|Efavirenz|
45826344|NCT00002447|Drug|Saquinavir|
45826345|NCT00002453|Drug|Tenofovir disoproxil fumarate|
45826346|NCT00002459|Radiation|radiation therapy|
45826347|NCT00002465|Drug|megestrol acetate|
45826348|NCT00002471|Drug|asparaginase|
45826349|NCT00002471|Drug|cyclophosphamide|
45826350|NCT00002471|Drug|cytarabine|
45969162|NCT00562198|Drug|Sinemet 200mg/50mg|Sinemet 200mg/50mg once
45969163|NCT00220025|Device|Phototherapy|The patient begins total body NBUVB that day at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until clearance of disease or maximum efficacy.
45969164|NCT03454594|Device|low level laser hemotherapy|semiconductor laser therapeutic instrument irradiate the circulating blood in the vessels of left hand acupoint and the mucosal tissue in the nasal cavity
45969165|NCT00246987|Drug|Muraglitazar|
45826351|NCT00002471|Drug|daunorubicin hydrochloride|
45668708|NCT05814445|Other|Institutional exercise program|Participants will complete an institutional exercise program during 22 weeks. The program consist of isotonic open and closed kinetic chain exercises for the hip and knee, and concentric and eccentric knee exercises.
45826352|NCT00002471|Drug|dexamethasone|
45826353|NCT00002471|Drug|etoposide|
45826354|NCT00002471|Drug|leucovorin calcium|
45826355|NCT00002471|Drug|methotrexate|
45826356|NCT00002471|Drug|methylprednisolone|
45826357|NCT00002471|Drug|therapeutic hydrocortisone|
45826358|NCT00002471|Drug|thiotepa|
45826359|NCT00002471|Drug|vincristine sulfate|
45826360|NCT00002477|Drug|carboplatin|
45826361|NCT00002477|Drug|cisplatin|
45826362|NCT00002477|Drug|cyclophosphamide|
45826363|NCT00002477|Drug|doxorubicin hydrochloride|
45826364|NCT00002489|Biological|dactinomycin|
45826365|NCT00002489|Biological|filgrastim|
45826366|NCT00002489|Drug|carboplatin|
45826367|NCT00002489|Drug|cyclophosphamide|
45826368|NCT00002489|Drug|doxorubicin hydrochloride|
45826369|NCT00002489|Drug|etoposide|
45826370|NCT00002489|Drug|leucovorin calcium|
45668709|NCT05814432|Drug|Liposomal Amphotericin B|Single high dose (10mg/kg) Standard treatment on 14 days (3mg/kg)
45668710|NCT05814380|Radiation|99mTc-DPD scintigraphy|99mTc-DPD scintigraphy
45668711|NCT05814380|Diagnostic Test|Collection of blood samples and echocardiography|Collection of blood samples from a peripheral vein and TTR sequencing. Transthoracic echocardiography.
45668712|NCT05814354|Drug|SHR-A1811|SHR-A1811 is a lyophilized powder for injection intravenously. Administered according to label, as one option for Physician's Choice.
45668713|NCT05814354|Drug|Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization).
45668714|NCT05814341|Drug|Citrate|Comparison of two dosage adjustment protocols for medication according to different post-filter iCa targets
45826371|NCT00002489|Drug|methotrexate|
45826372|NCT00002489|Drug|vincristine sulfate|
45826373|NCT00002489|Procedure|conventional surgery|
45826374|NCT00002495|Drug|doxorubicin hydrochloride|25 mg/m^2 on days 1 and 15
45826375|NCT00002495|Drug|vinblastine|6 mg/m^2 on days 1 and 15
45826376|NCT00002495|Radiation|standard subtotal nodal irradiation|3600-4000 cGy delivered over 20 fractions
45826377|NCT00002501|Biological|filgrastim|
45826378|NCT00002501|Drug|cyclophosphamide|
45826379|NCT00002147|Drug|Doxorubicin hydrochloride (liposomal)|
45826380|NCT00002153|Drug|A-007|
45826381|NCT00002159|Drug|Itraconazole|
45826382|NCT00002159|Drug|Amphotericin B|
45826383|NCT00002165|Drug|Nelfinavir mesylate|
45826384|NCT04713059|Genetic|FGFR2|Mutation of FGFR2
45826385|NCT00002171|Drug|Nelfinavir mesylate|
45826386|NCT00002177|Drug|Hydroxyurea|
45826387|NCT00002177|Drug|Nelfinavir mesylate|
45826388|NCT00002177|Drug|Stavudine|
45826389|NCT00002177|Drug|Didanosine|
45826390|NCT00002183|Drug|Abacavir sulfate|
45826391|NCT00002183|Drug|Amprenavir|
45826392|NCT00002183|Drug|Lamivudine|
45826393|NCT00002183|Drug|Zidovudine|
45826394|NCT00002189|Drug|Paclitaxel|
45826395|NCT00002195|Drug|Amprenavir|
45826396|NCT00002195|Drug|Lamivudine|
45826397|NCT00002195|Drug|Zidovudine|
45826398|NCT00002201|Drug|Ritonavir|
45826399|NCT00002201|Drug|Nelfinavir mesylate|
45826400|NCT00002213|Drug|Abacavir sulfate|
45826401|NCT00002213|Drug|Amprenavir|
45826402|NCT00002213|Drug|Efavirenz|
45826403|NCT04331405|Biological|Human Allogeneic Umbilical Cord Blood Mononuclear Cells (hUCBMCs) systemic (i.v.) infusions|"HUCBMCs samples were prepared for infusion in the specialized laboratory of Cord Blood Bank (CryoCenter Ltd) and transported to the clinic immediately within 2 hours in the Dry Shipper. All samples were chosen according to patients blood group and rhesus-factor.~All samples were examined for hemotransmissive infections and cell viability prior to the preparation.~Obtained samples were infused through the blood transfusion systems with additional filter after 3 tests for biological and individual compatibility and tolerance.~Each patient of the pilot group received 4 cell infusions (1 infusion per week) with 1 week interval during the in-hospital treatment."
45826404|NCT00381251|Drug|Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg|
45826405|NCT00002219|Drug|Nelfinavir mesylate|
45826406|NCT00002219|Drug|Levocarnitine|
45826407|NCT00002219|Drug|Adefovir dipivoxil|
45826408|NCT00002225|Drug|Efavirenz|
45826409|NCT00002225|Drug|Stavudine|
45826410|NCT00002225|Drug|Didanosine|
45826411|NCT00002231|Biological|APL 400-003|
45826412|NCT00002237|Drug|Peldesine|
45826413|NCT00002243|Drug|Calanolide A|
45826414|NCT00002249|Drug|Levofloxacin|
45826415|NCT00002255|Drug|Filgrastim|
45826416|NCT00002255|Drug|Epoetin alfa|
45826417|NCT00002255|Drug|Zidovudine|
45826418|NCT05752253|Other|Counseling|Counseling is a process which, through positive orientation and the enhancement of personal resources, is aimed at promoting the improvement of the quality of life in the other.
45826419|NCT00002261|Biological|Smallpox Vaccine|
45826420|NCT00002261|Biological|HIVAC-1e|
45826421|NCT00002261|Biological|gp160 Vaccine (MicroGeneSys)|
45826422|NCT00002507|Drug|mitomycin C|
45826423|NCT00002507|Drug|porfiromycin|
45826424|NCT00002507|Radiation|brachytherapy|
45826425|NCT00002507|Radiation|radiation therapy|
45826426|NCT05752175|Drug|WPV01|WPV01 tablets
45826427|NCT05752175|Drug|Placebo|Placebo tablets
45826428|NCT00002519|Drug|chemotherapy|
45826429|NCT00002519|Drug|paclitaxel|
45826430|NCT00002519|Radiation|radiation therapy|
45826431|NCT04673825|Other|Patient initiated care + telemonitoring|See arm/group descriptions.
45826432|NCT00002267|Drug|Rifabutin|
45969166|NCT04623463|Behavioral|Physical activity intervention|Participants included in the present study will benefit from a 4-week physical activity intervention. Upon the initial visit, a physical activity prescription will be defined and they will be equipped with a physical activity monitor that allows feedback. Participants will then exercise one day per week on-site and 4 days/week on their own. Weekly physical activity will be reviewed weekly with the participant during their on-site visit.
45969167|NCT04623814|Other|Food|HEC113995 20mg will be taken orally fasted or with food
45969168|NCT04623814|Drug|HEC113995|HEC113995 will be taken orally fasted (HEC113995 10mg）or with food (HEC113995 20mg and 40mg） for 10 days
45969169|NCT04623814|Drug|placebo|The placebo will be administered fasted or with food for 10 days.
45969170|NCT00220064|Drug|Irinotecan, 5-Fluorouracil, Leucovorin|
45969171|NCT01580644|Drug|GLPG0187 prodrug|
45969172|NCT04623151|Behavioral|Online leaflet about foot care|Short text-based leaflet about foot care, presented online
45969173|NCT04623073|Procedure|Total Hip arthroplasty via a Direct Anterior Approach|Total Hip arthroplasty via a Direct Anterior Approach
45969174|NCT00220103|Drug|epirubicin, capecitabine, cisplatin|
45969175|NCT00220103|Procedure|Surgical resection|
45668715|NCT05814328|Other|Transitional Care|Targeted inhospital intervention of GMT for patient aged 75 ans more with TRST score ≥2 with a follow-up after ED discharge. Transitional Care is defined by a geriatric team having intervention strategies linked to community care: home visits with community professionals and/or multidisciplinary clinical meetings and/or shared professionals and/or shared information systems.
45668716|NCT05814302|Drug|Paracetamol|Emergency physicians were free to administer paracetamol 1000 mg (P), the combination paracetamol 500 mg/ibuprofen 150 mg (PI) or Ibuprofen 600 mg (I)
45969176|NCT04623307|Diagnostic Test|Non-contact DCS-Speckle multi-parameter imaging|The protocol consists of 2-min resting, 6-min stationary state and 2-min resting, with monitoring data continuously by the DCS-Speckle.
45969177|NCT00247026|Drug|curcumin; coenzyme q10|
45668717|NCT05814289|Other|To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.|To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.
45969178|NCT00562237|Biological|S205 placebo|2 i.m. injections per subject (0.5 mL each)
45969179|NCT00562237|Biological|S205 10ugHA|2 i.m. injections per subject (0.5 mL each)
45969180|NCT00562237|Biological|S205 30ugHA|2 i.m. injections per subject (0.5 mL each)
45969181|NCT00562237|Biological|S205 10ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
45969182|NCT00562237|Biological|S205 30ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
45668718|NCT05814276|Behavioral|Training on non-pharmacological therapies' methodology|"The San Rocco study encompasses a training on the non-pharmacological therapies' methodology. It allows the professional caregiver to methodological definition of the non-pharmacological interventions and a comparison of shared readings of the challenging behaviors by the group of colleagues. Participants will follow:~Five meetings, lasting 11 hours overall, on the multidimensional assessment, the shared readings of behavioral disorders of each person and identification of the objectives through the discussion of cases, and administration of non-pharmacological therapies within the framework of the personalization of the interventions~Five meetings, lasting five and a half hours, for the supervision of the staff which implement the non-pharmacological therapies.~As usual control group Participants will continue the usual care activities and non-pharmacological interventions already in use in the Nursing Homes without participating in the training."
45969183|NCT00562237|Biological|S205 10ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
45969184|NCT00562237|Biological|S205 30ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
45969185|NCT00562276|Procedure|Immediate IUD insertion|Insertion of either Paraguard or Mirena IUD within minutes of completing suction aspiration procedure between 5 and 12 weeks gestation
45969186|NCT01580683|Drug|Ascorbic Acid|Two 1 g capsules the evening prior to surgery, followed by one 1 g capsule every 12 hours starting the morning of the first postoperative day for 5 days.
45969187|NCT01580683|Other|Identical Placebo|Two capsules the evening prior to surgery, followed by one capsule every 12 hours starting the morning of the first postoperative day for 5 days.
45969188|NCT04623229|Procedure|MCS|Manual Cataract Surgery
45668719|NCT05814263|Device|HIS/LBB pacing|3830 lead to HIS or LBB
45668720|NCT05814263|Device|LV pacing|LV lead in a CS branch
45826433|NCT00002273|Drug|Ganciclovir|
45969189|NCT04623229|Procedure|ReLACS Early|ReLACS with early administration of anesthesia
45969190|NCT04623229|Procedure|ReLACS Standard|ReLACS with standard time administration of anesthesia
45826434|NCT00002279|Drug|Zalcitabine|
45826435|NCT00002285|Drug|Zidovudine|
45826436|NCT00002531|Drug|asparaginase|
45826437|NCT00002531|Drug|cyclophosphamide|
45826438|NCT00002531|Drug|cytarabine|
45826439|NCT00002531|Drug|daunorubicin hydrochloride|
45826440|NCT00002531|Drug|dexamethasone|
45826441|NCT00002531|Drug|doxorubicin hydrochloride|
45826442|NCT00002531|Drug|etoposide|
45826443|NCT00002531|Drug|ifosfamide|
45826444|NCT00002531|Drug|leucovorin calcium|
45826445|NCT00002531|Drug|mercaptopurine|
45826446|NCT00002531|Drug|methotrexate|
45969191|NCT00242814|Drug|Micardis|
45668721|NCT05814237|Other|Data collection|Data collection from study participants to characterise diagnostic and therapeutic practices.
45826447|NCT00002531|Drug|mitoxantrone hydrochloride|
45826448|NCT00002531|Drug|prednisolone|
45826449|NCT00002531|Drug|teniposide|
45826450|NCT00002531|Drug|thioguanine|
45826451|NCT00002531|Drug|vincristine sulfate|
45826452|NCT00002531|Drug|vindesine|
45826453|NCT00002531|Procedure|allogeneic bone marrow transplantation|
45826454|NCT00002531|Procedure|peripheral blood stem cell transplantation|
45826455|NCT00002531|Radiation|radiation therapy|
45826456|NCT00002537|Drug|topotecan hydrochloride|
45826457|NCT00002537|Radiation|radiation therapy|
45826458|NCT05751941|Drug|Abiraterone|1000 mg of Abiraterone will be given orally daily plus prednisone 5-10 mg daily
45826459|NCT05751941|Drug|Enzalutamide|160 mg of Enzalutamide will be given orally daily ending at week 4
45826460|NCT05751941|Drug|Apalutamide|240 mg of Apalutamide will be given orally daily ending at week 4
45826461|NCT05751941|Drug|Sipuleucel-T|Sipuleucel-T is considered standard of care and will be infused into the participant three times at approximately 2-week intervals starting week 0, 2 and 4.
45826462|NCT00002543|Drug|gallium nitrate|
45826463|NCT00002291|Drug|Pentamidine isethionate|
45826464|NCT00002549|Biological|filgrastim|
45969192|NCT00242814|Drug|Amlodipine|
45969193|NCT00242814|Procedure|Abdominal biopsy|
45969194|NCT04623112|Device|Hearing aid feature: Frequency Compression|FC Deactivated/Activated & set to default/Activated & set to hearing loss
45969195|NCT04623385|Combination Product|Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone|"The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days~The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days"
45969196|NCT04623385|Drug|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
45668722|NCT05814224|Diagnostic Test|Liquid biopsy and CT scan|"CT scan and liquid biopsy blood sample are performed at baseline, after 8 weeks from baseline and, then, every 12 weeks.~Between two subsequent CT scan another liquid biopsy blood sample is performed.~CEA and CA 15.3 will be performed at baseline and then concomitantly to the radiological evaluation"
45826465|NCT00002549|Drug|busulfan|
45826466|NCT00002549|Drug|cyclophosphamide|
45826467|NCT00002549|Drug|cytarabine|
45826468|NCT00002549|Drug|daunorubicin hydrochloride|
45826469|NCT00002549|Drug|etoposide|
45826470|NCT00002549|Drug|idarubicin|
45969197|NCT04623346|Procedure|Observation for study group|Patients with Weber B-type Ankle fractures, extraarticular wrist fractures and proximal humerus fractures were followed with conservative manner( cast or sling)
45969198|NCT04623034|Drug|Ademetionine|
45969199|NCT00220220|Drug|olmesartan medoxomil|
45668723|NCT05814211|Device|Investigational device - newly developed intermittent catheter|Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The investigational device is for single use.
45668724|NCT05814211|Device|Comparator device #1 - SpeediCath Eve|"During comparator study period, subjects will only receive one of the comparator products. Randomization will decide which one.~Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The comparator device is for single use."
45668725|NCT05814211|Device|Comparator device #2 - SpeediCath Compact Plus Female|"During comparator study period, subjects will only receive one of the comparator products. Randomization will decide which one.~Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The comparator device is for single use."
45668726|NCT05814198|Diagnostic Test|HALP score|we will calculate the HALP score with the complete blood count and albumin values in FGR and SGA groups.
45668727|NCT05814185|Device|Periodontal distractor|different activation protocols of periodontal distractor
45668728|NCT05814315|Behavioral|HOPE Intervention|Participants used the Health Checkins Platform for 12 weeks for emotional support and to obtain pain management tools
45668729|NCT05814172|Other|no intervention|no intervention
45826471|NCT00002549|Drug|mesna|
45826472|NCT00002549|Drug|mitoxantrone hydrochloride|
45826473|NCT00002549|Procedure|allogeneic bone marrow transplantation|
45826474|NCT00002549|Procedure|autologous bone marrow transplantation|
45826475|NCT00002549|Procedure|peripheral blood stem cell transplantation|
45826476|NCT00002549|Radiation|radiation therapy|
45826477|NCT05751785|Other|Physical Therapy|All participants may complete a PT program as standard of care (SOC) treatment addressing individual strength, mobility, and flexibility deficits in both proximal (e.g. spine and hip girdle) along with distal (thigh, leg, and foot/ankle) muscle groups. The provider may also use other modalities to address distal issues. To standardize the loading program, all participants will be given an at-home exercise program designed by Dr. Karin Sibernagel for progressive Achilles tendon loading. The participants will also follow the University of Delaware Return to Sport protocol for return to running. This will be completed alongside the standard of care PT participants will be receiving.
45826478|NCT05751785|Device|Shockwave Therapy|A medical provider will conduct SWT on study participants using the OrthoPlus Ultra 100. This Extracorporeal Pressure Activation Treatment device will be used at a radial shockwave of 3000 counts treatment settings of 15 Hz minimum 2 bars with a focus applicator head at mid-portion of Achilles using clinical focusing technique, and 3000 counts at 15 Hz minimum 2.5 bars using broad oscillator to myotendinous region and over symptomatic areas of gastrocnemius and soleus, treatment will be applied distally to proximally to facilitate lymphatic return adjusting treatment air pressure and amount of force applied by applicator head by patient comfort. The maximum setting for each treatment applicator will be 4 bars of air pressure, and the first 500 counts using each applicator will be applied at 1.5 bars to help desensitize the tissue prior to increasing energy settings. The settings used for each participant will be recorded and followed in a similar approach to treatment.
45969200|NCT00220220|Drug|amlodipine|
45826479|NCT05751785|Device|Photobiomodulation Therapy|PBMT is delivered with the LightForce® XPi 25W device through the Smart Hand Piece technology. The therapy is transmitted with a rolling glass massage ball at 10 Joules/cm^2 that is applied in a serpentine manner over the site of injury.
45969201|NCT04622800|Other|Exercise, proprioceptive neuromuscular fasilition (PNF) techniques|PNF applications are defined as the autogenous inhibition, reciprocal inhibition, stress relaxation and gate control theory. Anterior elevation / posterior depression will be performed in the form of repetitive contractions using anterior depression / posterior elevation patterns. There will be 10 repetitions, with a 2-minute rest break between each technique. The treatment will continue twice a week for a total of 6 weeks.
45969202|NCT00242853|Procedure|Power doppler ultrasonography|
45969203|NCT00242853|Procedure|High frequency ultrasonography|
45668730|NCT05814159|Drug|Anakinra|sub cutaneous daily injection
45826480|NCT00002555|Drug|cisplatin|
45969204|NCT00242853|Procedure|Exhaled nitric oxide assessment|
45969205|NCT04622878|Procedure|thrombectomy and PTA|open femoral access with fogarty catheter then PTA with balloon and possible stenting if needed
45969206|NCT04622722|Other|Nutren Diabetes|Nutren Diabetes provides energy at 360 kcal per 360 ml
45969207|NCT04622722|Other|Isocaloric|Isocaloric diet One carton of soy milk (250 ml) and bologna sandwiches (two slices of bread) with mayonnaise
45969208|NCT00220259|Drug|Fluticasone or placebo|
45969209|NCT04622956|Drug|Methotrexate Injectable Solution|"Phase 1:~Level -1: Methotrexate 7.5 mg/m2 on D+6 and D+9*. Level -1 will be explored only if the starting dose is too toxic (reduced dose).~Level 0 [Starting Dose]: Methotrexate 10 mg/m2 on D+6 and 7.5 mg/m2 on D+9~Level +1: Methotrexate 10 mg/m2 on D+6 and D+9~Level +2: Methotrexate 15 mg/m2 on D+6 and 10 mg/m2 on D+9~Phase 2: dose determined in the phase 1 trial"
45969210|NCT00242892|Procedure|Intra coronary measures of pressure|Intra coronary measures of pressure
45969211|NCT04622566|Drug|Lenvatinib, Pembrolizumab|After enrollment, patients receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 6 weeks; Lenvatinib 20mg orally once daily for 6 weeks. Patients conduct surgery within 1-4 weeks after the last dose of Pembrolizumab and Lenvatinib. After complete surgery, Pembrolizumab will be as adjuvant treatment for up to 15 cycles, 200mg IV on day 1 of every 21 day-cycles.
45969212|NCT04622488|Drug|Diclofenac Potassium|- In the form of Insitu gel system can be applied as solution or suspension that undergoes gelation after administration. Applied once inside the root canal after chemo-mechanical preparation.
45969213|NCT00220298|Drug|Testosterone undecanoate (TU) - NebidoTM|Drug treatment with 14 injections of one ampoule of Nebido (1000 mg of testosterone undecanoate) at individually adjusted injection intervals
45455751|NCT05747807|Device|Percutaneous intradiscal radiofrequency treatment|using heat created by radiofrequency electrode to destroy the nociceptive pain fibres and enhance the structural integrity of the disc
45668731|NCT05814159|Drug|Placebo|sub cutaneous daily injection
45668732|NCT05814146|Drug|Dialysate bicarbonate concentration|"Assess how a lower dialysate bicarbonate affects:~QTc duration during and between hemodialysis sessions~PVC burden during and between hemodialysis sessions~Clinically significant arrhythmia during and between hemodialysis sessions~Intradialytic hypotension~Adverse symptoms during hemodialysis sessions"
45668733|NCT05814146|Device|Dialysate bicarbonate concentration - telemetry monitoring|Patients will be monitored with telemetry on both arms of the trial.
45668734|NCT05814120|Behavioral|BLS training program|BLS training program was in accordance with the 2020 AHA cardiopulmonary resuscitation (CPR) guidelines. The BLS training program adopts 4D teaching techniques, namely description (Describe), demonstration (Demo), implementation (Do), feedback (Debriefing).
45668735|NCT05814094|Other|Red Blood Cell Transfusion|Following randomisation, if a patient's Hb concentration reads ≤ 70g/L, one unit of RBC will be transfused within 12 hours of the result becoming available. Additional units can be prescribed if required to raise the Hb concentration to above 70g/L. A transfusion above the restrictive threshold of 70g/L is discouraged.
45826481|NCT00002555|Radiation|low-LET cobalt-60 gamma ray therapy|
45826482|NCT00002555|Radiation|low-LET electron therapy|
45826483|NCT00002555|Radiation|low-LET photon therapy|
45826484|NCT00002561|Biological|bleomycin sulfate|10 units/m2
45969214|NCT04622761|Drug|Cabazitaxel|"Patients will receive Cabazitaxel 25 mg/m2 * intravenously over one hour every 21 days (on Day 1 of each cycle). Treatment will be continued for 4 cycles unless disease progression, unacceptable toxicity or patient request. These patients will have surgery (radical prostatectomy) 4-86 weeks following treatment.~*Cabazitaxel dose should be capped at 50mg (BSA=2)"
45969215|NCT00247104|Drug|Cranberries - Vaccinium macrocarpon|
45826485|NCT00002561|Drug|dacarbazine|375mg/m2
45826486|NCT00002561|Drug|doxorubicin hydrochloride|25mg/m2
45826487|NCT00002561|Drug|vinblastine|6mg/m2
45826488|NCT00002561|Radiation|radiation therapy|35Gy in 20 fractions (daily)
45826489|NCT05751707|Device|High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System|High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System is a clinical device which consists in a pump which generates high frequency oscillations and connected to a jacket worn by the patient, intended to facilitate airway secretions clearance by detaching them from the bronchial wall and moving them upwards in the bronchial system.
45826490|NCT05719649|Dietary Supplement|Lactic acid bacteria NTU 101|"One NTU 101 Lactic Acid Bacteria Vegetable Capsule a day for a total of 12 weeks.~Product ingredients: microcrystalline cellulose, corn starch, NTU 101 Lactobacillus paracasei subsp. paracasei NTU 101 (1.8 x 10^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum."
45969216|NCT04622293|Drug|Solriamfetol Oral Tablet [Sunosi]|Solriamfetol will be given to those participants placed in the experimental group, and given at three possible dosages ( 37.5 mg, 75 mg, and 150 mg). Solriamfetol is already FDA approved for treatment of excessive daytime sleepiness, and has been found safe to use. In this study, we are determining if solriamfetol can also be used to treat chronic fatigue syndrome.
45969217|NCT04622293|Drug|Placebo|A placebo encapsulated to look the same as the experimental drug will be given to the control group.
45969218|NCT04622371|Other|Moderate exercises|Group 1 received 30 minutes of aerobic exercise at 40-60% of maximum heart rate. Group 2,Treated by walking30 minutes daily divided into 5minutes every 2 hours to break sedentary position for 12 hours daily.
45969219|NCT00220337|Drug|lacosamide|Lacosamide film-coated tablets; two times per day; up to 400 mg/day for 2.75 years
45969220|NCT00247143|Drug|Kaletra (drug)|
45969221|NCT04622215|Diagnostic Test|ICIQ questionnaire|questionnaire
45969222|NCT04622137|Procedure|Kinesiotaping therapy|The investigators used kinesiotaping strips in formations such as the Y, I, X, fan, web, and donut formations ove fractured clavicula.
45969223|NCT00412412|Drug|CNF2024|Oral doses of CNF2024 as specified in the protocol.
45969224|NCT00412412|Drug|CNF2024 + trastuzumab|Oral doses of CNF2024 as specified in the protocol Intravenous doses of trastuzumab as specified in the package insert.
45969225|NCT00242931|Other|Nonmyeloablative stem cell conditioning regimen|"Conditioning:~Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0~Hematopoeitic Stem Cell Transplantation:~Infusion of peripheral blood stem cells, day 0~Immunosuppression:~For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop~For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181."
45969226|NCT04622098|Procedure|Endoscopic ultrasound|"this is an endoscopic procedure for the assessment of the lesions, the following will be recorded:~the tumor location,~layer of origin,~maximal diameter,~regularity of extraluminal border,~echopattern,~presence of cystic spaces or echogenic foci."
45969227|NCT00412490|Behavioral|Questionnaire|Written survey at 1 Month & 6 Months post surgery.
45969228|NCT00412490|Behavioral|Interview|One-on-One meeting lasting about one hour, at 1 Month & 6 Months post surgery.
45969229|NCT00247182|Behavioral|Step 1: Minimal Intervention|All participants will receive Step 1, a 15-minute minimal intervention including a discussion of the referral incident and the provision of a booklet containing advice to reduce drinking. Participants will be assessed six weeks later. All students will complete 3, 6, and 9 month follow-up assessments
45668736|NCT05814094|Other|Red Blood Cell Transfusion|Following randomisation, if a patient's Hb concentration reads ≤ 90g/L, one or more units of RBC will be transfused in order to raise the Hb concentration to greater than 90g/L within 12 hours of the result becoming available. A decision not to transfuse below the threshold of 90g/L is discouraged.
45668737|NCT05814081|Procedure|Position/Ventilation|Positioning and ventilation mode adjustments were made to the patients.
45668738|NCT05814068|Drug|antihypertensive drug treatment|Patients with hypertension will be treated for it by their physician
45668739|NCT05814055|Drug|AB-free kava|Participants on this arm will take one kava capsule (each capsule contains 37.5 mg of kavalactones) orally three times daily for 4 weeks.
45668740|NCT05814055|Drug|Placebo|Participants on this arm will take one placebo capsule orally three times daily for 4 weeks.
45969230|NCT00247182|Behavioral|Step 2: Brief Motivational Intervention|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
45668741|NCT05814055|Drug|AB-free kava|Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 4 weeks.
45826491|NCT05719649|Dietary Supplement|Placebo|Maltodextrin was used as a placebo
45826492|NCT00002567|Biological|filgrastim|
45826493|NCT00002567|Drug|etoposide|
45826494|NCT00002567|Procedure|peripheral blood stem cell transplantation|
45826495|NCT00002567|Radiation|low-LET electron therapy|
45826496|NCT00002567|Radiation|low-LET photon therapy|
45826497|NCT00002579|Drug|CMF regimen|
45826498|NCT00002579|Drug|cyclophosphamide|
45826499|NCT00002579|Drug|fluorouracil|
45826500|NCT00002579|Drug|methotrexate|
45668742|NCT05814029|Other|Mobilization with movement for Ankle|The participant will assume a lunge position on a rigid serving table with the relevant extremity in a weight-bearing stance and the foot in a neutral position. An inelastic belt will be placed around the clinician's waist, flush with the lower edge of the medial malleolus, around the distal tibia and fibula. The clinician will stabilize the talus and forefoot with the web spacing of the hands and pressure dimensions on the talus and forefoot, and maintain posterior to anterior sliding of the tibia over the talus using the arch. The clinician will continue to apply pressure while the person is reporting discomfort and/or while the lunge moves, which will continue until the end of the range of motion. Mobilization will be performed as a set of 10 repetitions.
45969231|NCT00247182|Behavioral|Alcohol Assessment|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
45969232|NCT04622059|Behavioral|acoustic stimulation|"An auditive stimulus was produced by hitting a diapason on an acoustic surface, at a distance of 2-3 cm from the mother's skin (in order to avoid mechanical vibration to reach the fetus) in the area near the fetus' head.~The same procedure was repeated three times, waiting 30 seconds between one stimulus and the following one. The total duration of stimulation was about 2 minutes."
45969233|NCT04621903|Other|Shanshamani Vati Plus|Shanshamani Vati Plus was given as combination of Guduchi (Tinospora Cordifolia; 300 mg) and Pipli (Piper Longum 75 mg) twice daily.
45668743|NCT05814003|Drug|hydroxylate flavones solid dispersion application|this drug has the antibacterial and anti inflammatory actions could help the palatal donor sites to promote the wound healing
45668744|NCT05814003|Other|Placebo|Dough inert material without any therapeutic action
45969234|NCT04621942|Other|inertial rehabilitation|Inertial rehabilitation was performed twice a week (Monday and Thursday, between 5:00 and 8:00 PM) for 6 weeks using Cyklotren device (Inerion, Poland). Exercises were conducted by the same 2 researchers. Each training session included warm-up and 4 sets of shoulder ﬂexors, extensors, abductors, and adductors, with the right and left arms worked separately (16 sets for left and 16 sets for right arm). Each set lasted 15 seconds, a 2-minute break occurred between consecutive sets (without rest period between right and left arm). For all trained muscles 5 kg load was applied. During the training participants developed 70% of their maximal force achieved during the strength measurement. Participants observed developed during training force value displayed on-line on the screen. Cyklotren software allows to set the upper and lower limit of force; when developed strength was to low or to high a beep signal was emitted to correct participant force.
45969235|NCT04621942|Other|gymnastic rehabilitation|All women (from T and C group) participated in rehabilitation gymnastics twice a week during experiment (6 weeks). The gymnastics was conducted by a physiotherapist specializing in rehabilitation of women after mastectomy. The trehabilitation session lasted 45 minutes. During the sessions, the women mainly performed exercises involved shoulders, chest and the upper limbs muscles. Moreover, abdomen and back muscles were exercised.
45969236|NCT04621591|Device|Saneso 360° gastroscope|Subjects will have a clinically indicated per standard of care routine EGD procedure performed with the Saneso 360° gastroscope.
45969237|NCT04621474|Diagnostic Test|Narrow band imaging (NBI)|Narrow-band imaging uses specific light wavelengths of 415 nm (blue) and 540 nm (green) due to a special filter which is electronically activated by a switch in the endoscope.
45969238|NCT04621552|Device|WEB embolization|Treatment of intracranial aneurysms with WEB with the use of the virtual simulation before implantation of the device
45826501|NCT00002579|Drug|tamoxifen citrate|
45826502|NCT00002579|Procedure|conventional surgery|
45826503|NCT00002579|Radiation|radiation therapy|
45826504|NCT00002585|Drug|pyrazoloacridine|
45826505|NCT00382187|Biological|MF59 adjuvanted H5N1 influenza vaccine|"MF59 adjuvanted (H5N1) influenza vaccine (Vietnam strain) containing 7.5 mg or 15 mg of H5N1~non-adjuvanted influenza vaccine containing 15 ug of H5N1"
45826506|NCT00002609|Biological|lintuzumab|
45668745|NCT05813977|Device|tritube|The patient is intubated with Tritube® after the removal of the conventional endotracheal tube (ETT) and Tritube® was advanced until proximal to the carina. Before starting the PDT, measurements with ATP bioluminescence-based method (3M Clean-trace®) were made by taking sample from a sterile PVC surface (10 cm2) which is held 50 cm over the operation site. After PDT with Griggs method (Portex), the measurements were repeated by taking sample from surface.
45668746|NCT05813964|Drug|TDF/FTC 300mg/200mg fixed-dose combination tablets|Event-driven dosing regimen
45668747|NCT05813964|Drug|TAF/FTC 25mg/200mg fixed-dose combination tablets|Event-driven dosing regimen.
45668748|NCT05813951|Drug|Linezolid|linezolid either continues infusion or standard intermittent dose
45826507|NCT00002609|Drug|cytarabine|
45826508|NCT00002609|Drug|idarubicin|
45826509|NCT05751395|Device|Central Venous Access|"Critically ill patients in severe MODS need a CVC and in some cases also a second line for e-g- blood purification techniques.~All CVCs are positioned via the ECG method with the CVC tip placed at P-max. Within 24 h a chest radiograph is obtained for assessment of the CVCs, especially their tips."
45826510|NCT00002615|Drug|cisplatin|
45826511|NCT00002615|Drug|epirubicin hydrochloride|
45826512|NCT00002615|Drug|fluorouracil|
45826513|NCT00002615|Procedure|conventional surgery|
45826514|NCT05698199|Drug|ITI-1001|ITI-1001 DNA vaccine represents a multi-antigen nucleic acid cancer immunotherapy encoding 3 CMV antigens. The vaccine is comprised of 2 DNA plasmids: 1 plasmid encoding IE-1 and pp65 antigens as a fusion protein with LAMP1. Another plasmid encodes gB antigen as a fusion protein with LAMP1.
45969239|NCT00412568|Procedure|Photorefractive Keratectomy (PRK)|vision correction with PRK
45969240|NCT00242970|Device|3-Dimensional Color Scanning|Color imaging of the face and neck.
45969241|NCT04621669|Drug|SHR3680|240 mg
45969242|NCT04621669|Drug|digoxin|0.25 mg
45969243|NCT04621669|Drug|Rosuvastatin calcium|10 mg
45969244|NCT04621669|Drug|metformin hydrochloride|500 mg
45969245|NCT00412646|Drug|TMC125|
45826515|NCT05680103|Radiation|lateral cephalometry|lateral x-ray beam to capture lateral cephalometry of patients
45826516|NCT00002621|Biological|recombinant interferon alfa|
45969246|NCT00247221|Behavioral|MI/Family Check-up|The experimental intervention integrates an individual Motivational Interview (MI) for the adolescent with a brief family intervention, the Family Check-Up. Follow-up interviews will be conducted at 3, 6, and 12 months after the baseline intervention.
45969247|NCT00247221|Behavioral|MI only|An individual motivational interview (IMI only) will be conducted at 3, 6, and 12 months after the baseline intervention to assess outcome.
45969248|NCT00562393|Other|Nutritional|Overfeeding high fat diet for 28 days
45969249|NCT00562432|Device|Plexisyl-AF|Plexisyl-AF implants
45969250|NCT00562432|Other|No Treatment|CABG without the experimental treatment
45826517|NCT00002627|Biological|filgrastim|
45826518|NCT00002627|Drug|carboplatin|
45826519|NCT00002627|Drug|cyclophosphamide|
45969251|NCT00562471|Other|Adhibit Adhesion Prevention Gel|A resorbable hydrogel, which adheres to itself and the tissues it contacts, is approved for use in sealing vascular reconstructions. The hydrogel is formed when two synthetic derivatized polyethylene glycol (PEG) polymers are mixed together and applied to tissue. Using a gas-assisted delivery device, the hydrogel is sprayed over all myomectomy suture lines and all surgically treated areas during the myomectomy surgery. The hydrogel is totally resorbed within 30 days post-application.
45969252|NCT00562471|Other|Standard of Care Comparator|standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure
46080872|NCT05711758|Procedure|PSAM Treatment Patients|PSAM is a pylorus-sparing antral myotomy performed under general anesthesia. Endoscopic myotomy is then performed applying the principles of submucosal endoscopy and techniques used during gastric per-oral endoscopic myotomy (G-POEM). A submucosal bleb is created proximal to the pylorus. A longitudinal mucosal incision is made with an endoscopic knife. The endoscope is then introduced into the submucosal space, and the knife is used to dissect the submucosal fibers. Antral myotomy is performed starting proximal to the pyloric ring extending to the mucosal access site. The myotomy entails cutting of the inner circular and oblique muscle bundles or may be full thickness at the discretion of the endoscopist. The mucosal entry is then closed using endoscopic suturing or clips.
45668749|NCT05813938|Device|LabTest Checker|A set of blood laboratory tests is ordered. Test results are recorded in the LabTest Checker. LabTest Checker's diagnostic engine automatically generates a personalized questionnaire that is filled out by the patient. After obtaining all necessary information, including the patient's chronic diseases, medications taken, and symptoms, the tool presents an interpretation of test results.
45668750|NCT05813899|Dietary Supplement|PS23 heat-treated|PS23 heat-treated, 2 caps daily use
46080873|NCT05711381|Drug|HM15912|Drug: HM15912 Active 0.5mg/kg
45969253|NCT00220376|Drug|SPM 907|
46080874|NCT05709834|Other|Autogenic training|"Relaxation procedures will be performed in the following steps: First step - preparation: Each pre-eclamptic woman will be instructed about this method of treatment and its importance for reducing blood pressure to gain her confidence and cooperation during treatment. Second step - AT: The session began with a few minutes of mental relaxation as the patient will be asked to imagine herself in a lovely place that makes her relaxed. Each session include 18 exercises combining both relaxation and auto-suggestion (limb heaviness exercise, limb warmth exercise, cardiac exercise, respiration exercise, solar plexus warmth exercise, and forehead cooling exercise).~About 30 sec will be allowed for each exercise and a further 30-40 sec will allowed for continuing attention focusing by the patient. Third step - termination"
46080875|NCT05709834|Other|Conventional treatment|Patients will receive conventional treatment
45668751|NCT05813886|Other|biodex balance system|The balance tests of the patients were performed 2 to24 WEEKS after their recovery from the disease, which was confirmed by the evaluations of the Covid-19 staff and negative polymerase chain reaction test.
45668752|NCT05813873|Other|Triflow|Triflow
45668753|NCT05813873|Other|Control|Exercise
45826520|NCT00002627|Drug|mesna|
45826521|NCT00002627|Drug|paclitaxel|
45826522|NCT00002627|Procedure|peripheral blood stem cell transplantation|
45826523|NCT00002633|Drug|bicalutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
45826524|NCT00002633|Drug|buserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
45969254|NCT00243009|Drug|cyclosporine|
45969255|NCT00243009|Drug|fludarabine phosphate|
45969256|NCT00243009|Drug|mycophenolate mofetil|
45969257|NCT00243009|Procedure|allogeneic bone marrow transplantation|
45969258|NCT00243009|Procedure|peripheral blood stem cell transplantation|
45969259|NCT00243009|Radiation|radiation therapy|
45969260|NCT00562510|Drug|Raltegravir|Raltegravir 400 mg BID added to stable HAART
45969261|NCT00562510|Drug|Placebo|Placebo BID added to stable HAART
45826525|NCT00002633|Drug|flutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
45969262|NCT00562666|Other|T gamma delta lymphocytes|Single hepatic intra arterial administration of increasing doses of T gamma delta lymphocytes
45969263|NCT00220415|Drug|SPM 927|
45969264|NCT00243048|Dietary Supplement|soy protein isolate|
45969265|NCT00243048|Radiation|radiation therapy|
45969266|NCT04621396|Other|Observational screening study|
45969267|NCT04621513|Device|laser acupuncture (RJ laser S/N 1813458)|use a low-level-laser acupuncture on acupoint
46080876|NCT05705973|Device|Ultimaster Nagomi™|The Ultimaster NagomiTM Sirolimus eluting coronary stent system with Rapid Exchange Balloon Delivery System consists of a balloon expandable intra-coronary L605 cobalt chromium (CoCr) stent with abluminal drug eluting coating, that consists of a blend of Sirolimus and Poly(D,L-lactide-co-caprolactone), pre-mounted onto a high pressure, semi-compliant balloon delivery catheter
46080877|NCT05701501|Drug|Vitamin B5 Tablets|The experimental group was given Vitamin tablets (5mg/tablet) based on the standard IBD treatment.
45668754|NCT05813821|Behavioral|Antimicrobial stewardship in surgery|"Hospitals were invited to form a surgical antibiotic stewardship program (ASP) with surgeons, pharmacists and infectious disease specialists. The interventional ASP relied on an audit and feedback strategy to issue recommendations aimed at reducing the duration of antibiotic treatment and the use of drugs with a particular impact on microbial ecology.~All patients hospitalized in surgical departments were prospectively analyzed weekly. A computerized alert allowed the ASP team to identify patients with antibiotic treatment >7 days. The team meet to discuss the appropriateness of each antibiotic treatment, issuing a written recommendation for each patient. The intervention was performed only once for each patient, except if they had a new focus of infection. The recommendations available for prolonged treatments were: withdraw, maintain, de-escalate, broaden, change route, optimize dose, no recommendation. Adherence to the recommendations was recorded 48 hours later by the ASP team."
45668755|NCT05813808|Diagnostic Test|ultra-low-dose computed tomography|7 ultra-low-dose computed tomography imaging
45668756|NCT05813795|Drug|Ecnoglutide Low Dosage|Subcutaneous Injection
45668757|NCT05813795|Drug|Ecnoglutide Medium Dosage|Subcutaneous Injection
45826526|NCT00002633|Drug|goserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
45826527|NCT00002633|Drug|leuprolide acetate|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
46080878|NCT05701501|Drug|placebo|The control group was given placebo tablets of the same type based on the standard IBD treatment.
46080879|NCT05700812|Procedure|Sound sparing levonorgestrel 52 mg IUD placement|"In phase one, the IUD will be placed in a standard fashion with the use of a uterine sound to obtain baseline data.~In the experimental phases of the study (phase 2 and 3) the levonorgestrel 52 mg IUD will be placed without the use of a uterine sound. In phase 2 the IUD will be placed under abdominal ultrasound guidance. In phase 3 the IUD will be placed without abdominal ultrasound guidance."
46080880|NCT05699538|Behavioral|Minimal-Dose Home-Based Resistance Exercise|8-week home-based resistance exercise performed one day per week.
45668758|NCT05813795|Drug|Ecnoglutide High Dosage|Subcutaneous Injection
45668759|NCT05813795|Drug|Placebo|Subcutaneous Injection with matched volume
45969268|NCT04621513|Drug|western medicine|Montelukast 4mg 1 tablet HS AVAMYS nasal spray 27.5μg QD
45969269|NCT00220454|Drug|Climara|
45969270|NCT00220454|Drug|Hydrocortone|
45969271|NCT00562705|Behavioral|growth hormone- Genotropin or NorditropinSimplex and nutritional intervention|"A combined treatment of growth hormone (Genotropin or NorditropinSimplex or Biotropin) and nutritional intervention"
45969272|NCT00562705|Behavioral|"growth hormone-Genotropin or NorditropinSimplex or Biotropin"|"Growth hormone treatment (Genotropin, or NorditropinSimplex or Biotropin)."
45969273|NCT00247260|Device|32P BioSilicon|
45969274|NCT04621084|Behavioral|Eating habits|Questionnary online
45969275|NCT04621006|Diagnostic Test|Continuously assessment of disease activity|Continuous measures of disease activity and activity in the contact activation system.
45969276|NCT04621162|Behavioral|Positive Expectations (initial)|"A positive expectation of the effect of motor imagery will be given before beginning the mental practice of imagination. This task will generate hypoalgesia"
45969277|NCT04621162|Behavioral|Negative Expectations (initial)|"A negative expectation of the effect of motor imagery will be given before beginning the mental practice of imagination. This task will not generate hypoalgesia"
45969278|NCT04621162|Behavioral|Neutral Expectations (initial)|This group will act as a control. No expectations will be given that will influence the participant.
45969279|NCT04621162|Behavioral|Positive Expectations (during intervention)|"A positive expectation will be given during the performance of the mental practice. This is working very well"
45969280|NCT04621162|Behavioral|Experimental: Negative Expectations (during intervention)|"A negative expectation will be given during the performance of the mental practice. This is working very bad"
45969281|NCT04621162|Behavioral|Neutral Expectations (during intervention)|This group will act as a control. No expectations will be given that will influence the participant.
45969282|NCT00243087|Drug|BI 2536|
45969283|NCT04621357|Radiation|Brain MRI|Brain MRI will include differents sequences.
45969284|NCT04621357|Biological|Biological biomarkers|Biological biomarkers will include a set of systemic inflammatory markers
45668760|NCT05813782|Behavioral|Baby Massage|Baby massage training (30 minutes) was given to primiparous mothers before they were discharged from the hospital. Baby massage training consists of sections that explain the importance of massage, preparation for massage, stages of baby massage and situations that need attention. Primiparous mothers were told to do this massage to their babies in the postpartum period. Baby massage video CD, brochure and baby oil were given to primiparous mothers for an effective baby massage.
45969285|NCT04621123|Biological|Convalescent anti-SARS-CoV-2 MBT plasma|Subjects randomized to combination convalescent anti-SARS-CoV-2 MBT plasma plus SMT will undergo an ABO compatibility test and will receive a single infusion of 200 to 300 ml of ABO-compatible convalescent plasma
45969286|NCT04621123|Other|Control Group|Subjects randomized to placebo plus SMT will receive one infusion of 200 to 300ml of sterile saline solution 0.9%.
45969287|NCT04621240|Behavioral|Online SMART & Stress Solutions|1. On-line SMART - (Strategic Memory Advanced Reasoning Training) is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts. 2. Stress Solutions - provides individuals with practical tools to enhance performance, reduce stress, build resilience and improve quality of life.
45969288|NCT00243126|Behavioral|Family-Based Risk Reduction Intervention|The intervention module topics include five modules and each module is 2 hours in length. The intervention will focus on the elements critical to HIV risk behavior change. These include: risk education (practical understanding of factors responsible for risk and behavior changes needed to reduce risk); threat personalization (accurate appraisal of personal risk based on behavior); self-efficacy (belief that one can implement risk reduction behavior changes and that if changes are made they will have protective value); skills acquisition (e.g., condom use, safer sex guidance, negotiation); cognitive problem-solving skills; and reinforcement.
45969289|NCT04620967|Drug|Insulin aspart|Insulin aspart (Iasp) in insulin pump
45969290|NCT04620967|Drug|Fast-acting insulin aspart|Fast-acting insulin aspart (Fiasp) in insulin pump
45969291|NCT00220493|Drug|Ritalin|
45969292|NCT04620655|Drug|RD13-01 cell infusion|Universal CAR-T cells targeting CD7
45969293|NCT00247299|Device|IPL Quantum Product manufactured by Luminis Ltd.|
45969294|NCT04620538|Diagnostic Test|Breath Analysis|Participants will be asked to provide 500mls of exhaled breath which will be loaded on to thermal desorption tubes and analysed via Mass Spectrometry.
45826528|NCT00002633|Drug|nilutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
45969295|NCT04620616|Other|RELX ENDS Tobacco Flavor|Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
45969296|NCT04620616|Other|RELX ENDS Menthol Flavor|Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
45969297|NCT04620616|Other|Subject Usual Brand ENDS|Ad libitum use of the usual brand product during 8-hour and 5-minute use sessions
45826529|NCT00002633|Procedure|orchiectomy|Optional orchiectomy
45826530|NCT00002633|Radiation|radiation therapy|Radical Radiation Therapy - (65-69 Gy; 35-37 treatments)
45826531|NCT00002639|Drug|chemotherapy|
45826532|NCT00002639|Drug|suramin|
45969298|NCT00247338|Drug|low calorie, low nitrogen parenteral nutrition for patient with NRS score 3|
45969299|NCT00220532|Drug|Folic acid with riboflavin|
45969300|NCT04620694|Device|Choice of arterial cannulation site at the beginning of the surgery|Choice of arterial cannulation site at the beginning of the surgery is at the discretion of the anesthesia physician.
45969301|NCT04620499|Device|EEG|PEER EEG
45969302|NCT00243165|Behavioral|Lifemel honey intake every day|
45969303|NCT04620772|Drug|Cyclophosphamide injection|Cyclophosphamide vs placebo
45969304|NCT00220571|Device|Coronary Angioplasty (PTCA)|
46080881|NCT05697536|Other|Pilates training|"It consists of patients who will receive pilates exercise training sessions 3 times per week for 8 weeks. Every session will be of 45 minutes. Exercise programs follow the basic principles of pilates method but particularly movements with low and medium difficulty levels will be chosen to adapt the program to the physical capacity of the patients.~Protocol will be compromise of 9 modules: postural education, search for neutral position, sitting exercise, antalgic exercise, stretching exercises, proprioceptively improvement exercises and breathing exercises."
46080882|NCT05697536|Other|Aerobic Exercise|"It consists of patients who will receive aerobic exercise sessions 3 times per week for 8 weeks. Every session will be of 45 minutes.~It will include warm up phase, active phase and"
46080883|NCT05696392|Drug|ruxolitinib cream|ruxolitinib cream 1.5% will be applied twice daily as a thin film
45826533|NCT04659005|Other|Nurse-led decision counseling|Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening
45826534|NCT04659005|Other|Usual care|Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises
45826535|NCT05751005|Dietary Supplement|Collagen Peptides vs. Placebo|Participants were randomized into one of three treatment groups.
45826536|NCT00002657|Biological|bleomycin sulfate|5 mg/m^2
45826537|NCT00002657|Biological|recombinant interferon alfa|3.0 x 10^6 IU/m^2
45826538|NCT00002657|Drug|cyclophosphamide|650 mg/m^2
45826539|NCT00002657|Drug|cytarabine|300 mg/m^2
45826540|NCT00002657|Drug|doxorubicin hydrochloride|25 mg/m^2
45826541|NCT00002657|Drug|etoposide|120 mg/m^2
45826542|NCT00002657|Drug|methotrexate|120 mg/m^2
45826543|NCT00002657|Drug|prednisone|dose varies during initial immunosuppression. During chemotherapy, 60 mg/m^2.
45826544|NCT00002657|Drug|vincristine sulfate|1.4 mg/m^2
45668761|NCT05813756|Other|Post-diagnosctic psychoeducational intervention|Participants are randomized to the intervention group. In this group, the participant receives 10 one-hour individual sessions of psychoeducational intervention, bi-monthly, with an evaluation at mid-term (T1:T0+~2.5 months), at the end of the intervention (T2 : T0+~5 months) and 3 months after the intervention (T3 : T0+~8 months). At the same time psychological questionnaires and scales will be completed
45668762|NCT05813704|Device|Coronary Crossing System of Shanghai MicroPort Rhythm|The mechanical vibration generated by the Coronary Crossing System through the piezoelectric effect is amplified and transmitted to the distal end of the guidewire to achieve high-frequency vibration at the tip of the guidewire, and then achieve efficient and safe penetration of the fibrous cap of the CTO.
45969305|NCT04620421|Other|Rhythm-based Multitask Training|Participants will be assigned to a weekly one-hour RYMA session for six months, followed by a six-month follow-up period without training. An experienced instructor will perform the RYMA sessions, which consists of a wide variety of rhythm-based multitask exercises performed to improvised piano music. The RYMA intervention is inspired by Dalcroze eurhythmics and exercises consists of components such as 1) coordination between hands and/or feet, 2) dissociation between hands and/or feet, 3) movements based on musical cues (e.g. follow the tempo), 4) movement inhibition based on musical cues, 5) handling of props (e.g. balls, scarfs, and plates), 6) pair or group-based coordination movements (e.g. clapping each other's hands and mirroring movements), 7) memorizing and repeating of rhythmic patterns, and 8) quick motoric responses to unexpected cues.
45969306|NCT00243204|Drug|talabostat mesylate|
45969307|NCT00243204|Drug|docetaxel|
45969308|NCT04620577|Other|antibiotic|normal saline
45969309|NCT04620850|Device|Acupressure|Acupressure after cesarean section 3 hr and then next 3 hr (duration 10 min per time)
45969310|NCT00562744|Other|Simulation|Use of high-fidelity patient simulator for training and assessment of PALS scenario performance
45969311|NCT00220610|Device|Transcranial magnetic stimulation|
45455752|NCT05747599|Behavioral|Intervention with contingent incentives and text-based support|Contingent incentives on abstinence from alcohol, tobacco, and cannabis; Text-based support based on educational components
45969312|NCT04620460|Device|Low-intensity Focused Ultrasound(LIFUS)|Patients with schizophrenia will be treated with active LIFUS or sham stimulation for 3 weeks on the left DLPFC.
45826545|NCT00002657|Procedure|conventional surgery|Simple excision, for those patients who have resectable disease after initial immunosuppression.
45969313|NCT04620031|Drug|HSK3486|Loading Dose：0.1 mg/kg, infused with 4 min ± 30 s； Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h. Range of maintenance dose: 0.06-0.8 mg/kg/h
45969314|NCT04620031|Drug|Propofol|"Loading Dose：0.5 mg/kg, infused with 4 min ± 30 s~Maintenance Dose：Maintenance is started at 1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5 mg/kg/h. Range of maintenance dose:~0.3-4 mg/kg/h"
45969315|NCT00243282|Behavioral|Relaxation Response (instruction, pocket practice card prov)|
45969316|NCT00243282|Behavioral|Mindfulness training using model developed from UMass|
45969317|NCT04620109|Drug|KDR2-2|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eye drop is in development for the treatment of corneal neovascularization."
45969318|NCT04620109|Drug|Placebo|Placebo : the formulation and the product process of placebo are the same as the KDR2-2 eye drops, but without API .
45969319|NCT00220649|Drug|gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin|
45969320|NCT04620265|Other|Antigravity treadmill training 100% weight bearing|This group received antigravity treadmill training 100% weight bearing and conventional exercise program.
45969321|NCT04620265|Other|Antigravity treadmill training 75% weight bearing|This group received antigravity treadmill training 75% weight bearing and conventional exercise program.
45969322|NCT04620265|Other|Antigravity treadmill training 50% weight bearing|This group received antigravity treadmill training 50% weight bearing and conventional exercise program.
45969323|NCT04620265|Other|Antigravity treadmill training 25% weight bearing|This group received antigravity treadmill training 25% weight bearing and conventional exercise program.
45969324|NCT04620265|Other|The conventional exercise program|This group received the conventional exercise program only.
45668763|NCT05813691|Diagnostic Test|Meridan Bioscience Point of Care test against HCV antibodies|Point of care evaluation of antibodies against HCV obtaining a drop of capillary blood via puncture of the fingertip. If antibodies were detected, HCV RNA assay will be performed.
45826546|NCT00002657|Radiation|radiation therapy|For treatment of localized disease that remains after initial immunosuppression.
45826547|NCT05750927|Procedure|Transcatheter aortic valve intervention (TAVI) and percutaneous coronary intervention (PCI)|TAVI and PCI to be administered as per physician's indication and choice, in one or more stages
45826548|NCT05673785|Drug|Brentuximab Vedotin|Brentuximab vedotin IV infusion
45969325|NCT00243321|Procedure|high dose-rate brachytherapy|High dose-rate brachytherapy
45969326|NCT00243321|Procedure|intensity-modulated radiation therapy|intensity-modulated radiation therapy
45969327|NCT04620226|Other|Quality Improvement|Rapid Point-of-Care testing will provide participants with a HCV antibody and RNA result within 2 hours. If the participant is HCV RNA+, they will receive an inpatient consultation from a liver specialist prior to discharge. We hypothesize that this model will minimize losses in the continuum-of-care and improve linkages to care.
45455753|NCT05743543|Other|Sphenopalatine ganglion block|The block is performed with a nasoscope and the administration of a local anesthetic.
45826549|NCT05673785|Drug|Cyclophosphamide|Cyclophosphamide IV infusion
45826550|NCT05673785|Drug|Doxorubicin|Doxorubicin IV infusion
45826551|NCT05673785|Drug|Prednisone|Prednisone tablets
45826552|NCT00381719|Drug|AGN 203818|3 mg Capsule twice daily for 4 weeks
45826553|NCT00381719|Drug|AGN 203818|20 mg Capsule twice daily for 4 weeks
45826554|NCT00381719|Drug|AGN 203818|60 mg Capsule twice daily for 4 weeks
45826555|NCT00381719|Drug|placebo capsule|Capsule twice daily for 4 weeks
45826556|NCT05750771|Device|DES|Second-generation drug-eluting stents
45969328|NCT04620148|Drug|TAK-242|TAK-242 concentrate solution 80 mg/mL for dilution and infusion
45969329|NCT04620148|Drug|Placebo|Matching placebo concentrate solution
45969330|NCT00220688|Device|Acupressure Wristbands|
45969331|NCT04619641|Device|High Flow Nasal Cannula (HFNC)|HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
45969332|NCT04619641|Device|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
45826557|NCT05750771|Device|DCB|Drug-coated balloon with paclitaxel as drug coating
45969333|NCT04619758|Other|Emollient (sunflower oil)|In group A, mothers will be advised to massage their babies with sunflower oil at a dose of 10 mL/kg/day twice a day in equally divided amounts. They will be called for follow up after six months of application of sunflower oil.
45969334|NCT00247455|Drug|Low fibre breakfast cereal (puffed rice/cornflakes)|
46080884|NCT05695911|Behavioral|Limb Load Biofeedback Training Intervention|Loadsol data will be used to inform the EXP telehealth sessions, as the interventionist guides the participant to self-monitor their movement, problem solve movement patterns that promote asymmetrical limb loading, and create weekly action plans for improving limb load symmetry. Weekly goals will be made in the context of functional task progression over the 40-week intervention.
46080885|NCT05695911|Other|Attention Control|The 12 sessions of EXP group limb-load biofeedback training sessions will be replaced by education-only session in the CTL group. The CTL group sessions will include a review of the standard of care home-exercises, a summary of healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use, home safety).
46080886|NCT05681273|Drug|Chiglitazar|Chiglitazar 48mg
45668764|NCT05813665|Drug|Narlumosbart|Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
45826558|NCT00381875|Biological|E1M184V peptide vaccine|
45826559|NCT00381875|Biological|incomplete Freund's adjuvant|
45826560|NCT00381875|Biological|sargramostim|
45826561|NCT00381875|Other|immunoenzyme technique|
45826562|NCT00002669|Biological|aldesleukin|
45668765|NCT05813665|Drug|Denosumab|Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
45826563|NCT00002669|Biological|recombinant interferon alfa|
45668766|NCT05813652|Other|Pre-pandemic time period (Jun 22, 2018 to March 12, 2020)|The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
45668767|NCT05813652|Other|Peri-pandemic time period (March 13, 2020 to December 3, 2021)|The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
45826564|NCT00002669|Drug|cisplatin|
45826565|NCT00002669|Drug|dacarbazine|
45826566|NCT05750693|Genetic|PIK3CA analysis|"PIK3CA will be investigated together with HER2 in pre-NAD tissue samples, in order to evaluate the correlation with response to NAD chemotherapy, with a 16-gene MYRIAPOD kit. This evaluation will be performed on all 58 patients in the study for group (responders and not responders).~Moreover 10 patient samples (5 responders and 5 non-responders) will be subjected to gene expression profile analysis. Specifically, a transcriptomic analysis will be performed on total RNA from one inch of cells (10-50 cells isolated by LCM from FFPE biopsy, RNA seq) which will allow to have the transcriptional profile for each patient of protein-coding transcripts (coding RNAs) and long non-coding RNAs.~In addition, an NGS analysis by TSO500 will be performed in parallel, on the slide following the previous one, to have the genome sequence (523 genes) on the same 10-50 cells isolated by LCM from FFPE biopsy for the identification of any mutations."
45826567|NCT00002675|Biological|filgrastim|
46080887|NCT05681273|Drug|Empagliflozin|Empagliflozin 10mg
45826568|NCT00002675|Drug|carboplatin|
45826569|NCT00002675|Drug|cisplatin|
45826570|NCT00002675|Drug|cyclophosphamide|
45826571|NCT00002675|Drug|etoposide|
45826572|NCT00002675|Drug|mesna|
45826573|NCT00002675|Drug|vincristine sulfate|
45826574|NCT00002681|Biological|aldesleukin|
45826575|NCT00002681|Biological|daclizumab|
45826576|NCT02973113|Biological|EBVST Cells|EBVST cells in an expected volume of 10-20cc will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
45826577|NCT02973113|Biological|Nivolumab|Nivolumab 3mg/kg (max dose: 240 mg) will be administered as an intravenous infusion over 60 minutes.
45826578|NCT05665439|Radiation|radiation|radiation for patients with newly diagnosed bone metastases or patients with bone metastases after vertebroplasty
45826579|NCT05750615|Other|Uncertain what intervention will be co-created|Uncertain what intervention will be co-created
45969335|NCT00247455|Drug|High fibre cereal (All Bran/Bran Flakes)|
45969336|NCT04619914|Drug|Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt|CLOMID (clomiphene citrate tablets USP) is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-[p-(2-chloro-1,2-diphenylvinyl)phenoxy] triethylamine citrate (1:1)
45969337|NCT04619914|Drug|letrozole (Femara; Novartis pharma AG, Basle, Switzerland)|Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
45668768|NCT05813639|Procedure|Lumbar medial branch cryo ablation neurotomy|The procedure is based on positive lumbar Z- joint testing followed by medial branch neurotomy
45668769|NCT05813639|Procedure|Lumbar medial branch radiofrequency ablation neurotomy|The procedure is based on positive lumbar Z- joint testing followed by medial branch neurotomy
45668770|NCT05813639|Procedure|Endoscopic denervation of fazet joint|The procedure is based on positive lumbar Z- joint testing followed by decapsulation of the facet joint through an endoscopic approach
45826580|NCT00002687|Biological|aldesleukin|
45826581|NCT05750537|Behavioral|EMPACT-Us|A suite of tobacco cessation services supported by patient navigation designed in close partnership with patients, providers, and community stakeholders.
45668771|NCT05813626|Drug|Toripalimab|Toripalimab (240 mg Q3W for 3 cycles) combine with chemotherapy
45668772|NCT05813600|Drug|Nirmatrelvir/Ritonavir|Patients in both groups were given Lianhua Qingwen Capsule orally, 3 times/day, 6 g/time. oral antipyretic (ibuprofen suspension 10ml) and symptomatic supportive treatment for body temperature >38.5 ℃. The study group was given Nirmatrelvir 300mg/Ritonavir 100mg orally, q12h, for 5 days, and the control group not given any antiviral drugs.
45668773|NCT05813561|Drug|DWP14012|DWP14012 40mg
45826582|NCT00002693|Biological|filgrastim|
45826583|NCT00002693|Drug|carboplatin|
45826584|NCT00002693|Drug|topotecan hydrochloride|
45826585|NCT05750381|Other|Micrococcus luteus Blis Q24 balm|Balm formulation containing probiotic bacteria Micrococcus luteus Q24 for topical applications.
45826586|NCT05750381|Other|Placebo balm|Placebo balm formulation for topical applications.
45826587|NCT00002705|Drug|topotecan hydrochloride|
45826588|NCT00002711|Drug|chemotherapy|
45826589|NCT00002711|Drug|cisplatin|
45826590|NCT00002711|Drug|paclitaxel|
45826591|NCT00002711|Radiation|low-LET electron therapy|
45826592|NCT00002711|Radiation|low-LET photon therapy|
45826593|NCT00002717|Drug|cisplatin|
45826594|NCT00002717|Drug|paclitaxel|
45826595|NCT00002723|Drug|suramin|3.192g/square meter total dose given decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65.
45826596|NCT00002723|Drug|suramin|5.320 g/square meter total dose given in decreasing concentrations in 250 cc normal saline via IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65
46080888|NCT05681273|Drug|Atorvastatin|Atorvastatin 20mg
46080889|NCT05681273|Drug|Valsartan|Valsartan 160mg
45668774|NCT05813535|Drug|Sodium bicarb lock|8.4% sodium bicarb locks when off venous nutrition
45668775|NCT05813522|Drug|Furmonertinib Mesilate Tablets|160mg of Furmonertinib mesilate tablets (given as four 40mg tablets) administered orally once daily
45668776|NCT05813509|Device|Organoid culture|Tumor like organ is a kind of organ cultured from tissues of tumor patients, which is a small tumor growing in a culture dish. Compared with the traditional two-dimensional culture system, the most important feature of this technological innovation is that it can directly use the patient's own tissue to culture organ like cells. At the same time, these organ like cells can well replicate some key characteristics of the primary tumor and retain the pathological form and biological mechanism of the patient's tissue
45668777|NCT05813496|Drug|Alpha-Lipoic Acid (ALA)|Oral tablet
45668778|NCT05813496|Drug|Placebo|Microcrystalline cellulose (Ph 101) 427.5 mg, Magnesium stearate 71.25 mg, Sodium laurayl sulphate 6 mg, Croscarmellose sodium 11.25 mg, Silica, colloid anhydrous 11.25 mg, and Purified talc 30 mg.
45668779|NCT05813483|Other|Skinceuticals skin care product(CE)|fraxel laser therapy combined with Skinceuticals skin care product(CE) and routine moisturizing and sun protection
45668780|NCT05813483|Other|fraxel laser therapy|fraxel laser therapy combined with routine moisturizing and sun protection
45826597|NCT00002723|Drug|Suramin|7.661 g/square meter toal dose given in decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,5,58,64,and 65.
46080890|NCT05679674|Radiation|Stereotactic Ablative Body Radiation (SABR)|50 Gy in 5 fractions, once per day for 5 days
45826598|NCT05648123|Behavioral|Supportive Psychotherapy|Supportive psychotherapy is a treatment that uses direct measures to ameliorate symptoms and to maintain, restore or improve self-esteem, ego function, and adaptive skills
45826599|NCT05750147|Other|Blood Sample Collection|Blood for DNA and biomarker analysis
45826600|NCT00002735|Drug|Induction chemotherapy|Cisplatin and 5-Fluorouracil
45826601|NCT00002735|Drug|cisplatin|Cisplatin 100 mg/m2 IV infusion over 90 minutes Day 1 every 21 days for 2 cycles.
45826602|NCT00002735|Drug|fluorouracil|5-Fluorouracil 1,000 mg/m2/day continuous IV infusion over 24 hours Days 1 through 5 every 21 days for 2 cycles.
45826603|NCT00002735|Radiation|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, every week for eight weeks
45826604|NCT00002747|Drug|cisplatin|
45826605|NCT00002747|Drug|fluorouracil|
45826606|NCT00002747|Procedure|conventional surgery|
45826607|NCT00002747|Radiation|low-LET cobalt-60 gamma ray therapy|
45826608|NCT00002747|Radiation|low-LET photon therapy|
45826609|NCT02973035|Drug|Amlodipine|
45826610|NCT02973035|Drug|Valsartan|
45826611|NCT05749991|Device|Dryshield|"DryShield combines the tasks of high-suction evacuator, saliva ejector, bite block, tongue shield, and oral pathway protector in one easy-to-use device.~The DryShield solution® is a patented autoclavable isolation system (MA, USA)"
45826612|NCT05749991|Device|Cotton roll isolation|Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
45826613|NCT00002753|Radiation|iodine I 131 monoclonal antibody 81C6|
45668781|NCT05813470|Biological|Omalizumab (CinnaGen)|Omalizumab (CinnaGen, Iran) was administered via subcutaneous injection
45969338|NCT00220766|Drug|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|
45969339|NCT00220766|Drug|Dextrose, 5% in Water|
45826614|NCT00002759|Drug|cyclosporine|
45969340|NCT04619875|Other|KB5|KB5, a novel glycan, is a Kaleido laboratory code for KB174
45969341|NCT04619875|Other|SG1|SG1 is a novel glycan
45969342|NCT04619875|Other|Lactulose|Lactulose is a synthetic dissacharide
45969343|NCT00243360|Behavioral|diagnostic and treatment clinical algorithms|
45969344|NCT04619290|Drug|Sublingual Methylene blue|Patients will be received the treatment as follow: it will be placed Low Level Light Therapy (LLLT) NocUlite on the ventral side of the wrist on full power. Draw out 1ml of diluted Prexablu into a syringe. Activate this syringe LLLT device for 10 minutes. Then place 1ml of this activated solution of Prexablu sublingually. Patients must keep the solution under the tongue for 10 minutes before swallowing. Keep wrist pads on patients for 50 minutes.
45668782|NCT05813470|Biological|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) was administered via subcutaneous injection
46080891|NCT05679674|Device|Tumor Treating Fields (TTF)|Participant will use the system for at least 18 hours per day starting on the first day of SABR until abdominal disease progression. Short treatment breaks are permitted for personal needs (such as to take a shower) and during radiation therapy. An additional treatment break is permitted for up to 48 hours every 21 days.
45668783|NCT05813457|Other|PRESTO Early Identification Program|"The program combines :~A population-based information component (information campaign aimed at the general population).~A training component for the LPAs (Front Line Actors: general practitioners, school and university medicine, pharmacists, teenagers school and university medicine, pharmacists, teenagers' homes, association networks, SAMU, firemen, etc.).~Facilitated access to care for FPE patients in the form of a pivot mobile team that can directly meet the patient at the request of the LPA, initiate care and ensure the relay within a the relay within 4 weeks to the existing specialized psychiatric structures on the site (CMP, CATTP (CMP, CATTP, day hospital, hospitalization unit, child and adolescent psychiatry services) adolescent psychiatry services)"
45826615|NCT00002759|Drug|irinotecan hydrochloride|
45455754|NCT05743140|Diagnostic Test|CaIMR|Investigators diagnose CMD with CaIMR. Investigators use OCT and OCTA to analyze the fundus microcirculation quantitatively.
45668784|NCT05813431|Other|FRENCH grid (classification for emergency nurses in French hospitals)|Triage tool validated by the French Society of Emergency Medicine (SFMU) which is used to prioritize patients according to standardized criteria and to orient them within the emergency department.
45826616|NCT00002759|Drug|phenobarbital|
45826617|NCT00002765|Biological|LMB-2 immunotoxin|
45826618|NCT00002771|Biological|recombinant interferon alfa|
45826619|NCT00002771|Drug|busulfan|
45455755|NCT05737485|Drug|RCT1100|RCT1100 supplied as varying dose strengths administered using PARI eFlow® Nebulizer System
45455756|NCT05737485|Other|Placebo|Placebo of similar volumes to experimental dose strengths administered using PARI eFlow® Nebulizer System
45668785|NCT05813431|Other|QuickSOFA|Rapid score that consists of an evaluation based on 3 clinical criteria (blood pressure, respiratory rate and consciousness) to quickly establish a severity score.
45826620|NCT00002771|Drug|cytarabine|
45826621|NCT00002771|Drug|hydroxyurea|
45826622|NCT00002771|Drug|idarubicin|
45826623|NCT00002771|Procedure|allogeneic bone marrow transplantation|
45826624|NCT00002771|Procedure|autologous bone marrow transplantation|
45826625|NCT00002771|Procedure|peripheral blood stem cell transplantation|
45969345|NCT04619290|Other|Control patients|Control patients will be received the conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.
45969346|NCT04619563|Drug|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
45969347|NCT04619329|Device|GSMs-TACE|TACE using Lobaplatin (30-40mg/m2) and gelatin sponge microspheres (150-350μm, 350-560μm, 560-710μm or 710-1000μm)
45969348|NCT04619329|Procedure|Surgical Resection|Surgical Resection of HCC
45969349|NCT00220844|Drug|Desipramine|
45969350|NCT00220844|Drug|Amitriptyline|
45969351|NCT04619212|Device|breast pumping as per SoC but on new software for the pump|breast pumping as per SoC but on new software for the pump
45969352|NCT00247494|Drug|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
45969353|NCT04619251|Drug|BI 1323495|BI 1323495
45969354|NCT04619251|Drug|Placebo|Placebo
45969355|NCT04619251|Drug|Itraconazole|Itraconazole
45969356|NCT04619407|Diagnostic Test|Nasopharyngeal swab|SARS-CoV-2 PCR
45969357|NCT04619407|Diagnostic Test|Serum testing|Anti-SARS-CoV-2 antibody testing (IgA and IgG ELISA)
45969358|NCT00562783|Drug|Vitaliver|
45969359|NCT00562783|Drug|Placebo|
45969360|NCT00243399|Drug|Oxandrolone|Subjects will be started on a dose of oxandrolone 0.04 mg/kg/day orally, once/day. After 16 weeks, patients will be assessed for hematologic improvement. If this criteria is not met after 16 weeks, the dose will be escalated to 0.08 mg/kg/day. If no improvement is noted after 16 weeks on the escalated dose, oxandrolone therapy will be discontinued.
45826626|NCT00002771|Radiation|radiation therapy|
45969361|NCT00562822|Procedure|Arthroscopic surgery|Arthroscopic surgery to treat unresolved symptoms of osteoarthritis of the knee
45969362|NCT00562822|Other|Physical and medical therapy|Treatment with physical and medical therapy alone
45969363|NCT00220922|Procedure|Alcohol Wipes vs. No Alcohol Wipes|
45969364|NCT00243438|Device|Multilink Vision™ Stent (CE-labeled)|Patients who have diabetes and/or complex lesions and who have had a Multilink Vision™ Stent placed.
45969365|NCT04618939|Biological|BR-TD-1001|0.5 mL, IM
45969366|NCT04618939|Biological|Td-pur inj|0.5 mL, IM
45969367|NCT00562900|Procedure|robotic assisted cholecystectomy|robotic assisted cholecystectomy
45969368|NCT00562900|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
45969369|NCT04618900|Procedure|Sinus floor elevation with a grafting material|The use of grafting material for sinus floor elevation
45969370|NCT00221000|Drug|Methoxsalen|
45969371|NCT00221000|Procedure|Extracorporeal Photopheresis|
45668786|NCT05813431|Other|Capillary lactate assessment|Collect a drop of blood from the fingertip (less than 1 ml)
45668787|NCT05813405|Other|Experimental: Antihypertensive therapy Hypotension and improved ventilation treatment Intervention treatment for other risk factors|Experimental: Antihypertensive therapy Hypotension and improved ventilation treatment Intervention treatment for other risk factors
45826627|NCT00002777|Drug|exemestane|
45668788|NCT05813379|Combination Product|exosime injection|Treatment- exosome injection
45668789|NCT05813366|Other|Acupuncture|Tony disposable, single-use 0.20×40 mm Chinese needles will be used. The needle penetrates the skin sufficiently to reach the required depth and elicit de qi. The needles remains for 30 min, with gentle rotational movements applied three times during the session.
45668790|NCT05813366|Other|Tryptophan-Rich Diet|"All participants in both groups (A and C) will be treated by high protein foods rich with tryptophan including: chicken , turkey, red meat, salmon, fish, tuna, beans, milk, cheese, seeds, nuts, egg, banana, kiwi, leafy greens, mushroom, broccoli and peas, etc.~Total daily calorie intake will be calculated for each participant in both groups (A and C) before diet description. All females will serve the meals that met their required kilocalorie levels and physical activity levels so that the participants will not lose weight, feel hungry or be over-fed."
45826628|NCT00002777|Drug|tamoxifen citrate|
45826629|NCT04611035|Device|QPOP|QPOP will then be applied to establish the most efficacious drug combination for the specific organoid. Additional drugs other than those listed above may be screened depending on availability of cancer organoids. When patients progress after first-line treatment, QPOP generated second-line options will be informed to treating physicians and the physician will exercise his/her discretion to select the most suitable drug based on patient's comorbidities and organ function after a formal molecular/phenotype tumour board.
45826630|NCT00002783|Drug|cisplatin|
45969372|NCT04619134|Other|NCSR Program|flexibility exercise,strengthening exercise,dynamic strengthening exercise,endurance training,counselling session
45969373|NCT04619134|Other|conventional physical therapy|hot pack,flexibility training,strengthening exercise.
45969374|NCT00243477|Drug|Escitalopram|Escitalopram 10mg or placebo once a day
45969375|NCT04619173|Other|Thoracic manipulation|hot pack ,transcutaneous electrical nerve stimulation and manipulation along with stretching'
45969376|NCT04619173|Other|Conventional physical therapy Program|hot pack ,transcutaneous electrical nerve stimulation and stretching
45969377|NCT04618783|Biological|Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 7.5, 22.5, and 22.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
45969378|NCT04618783|Biological|Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 15, 45, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
45969379|NCT04618783|Biological|Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 22.5, 67.5, and 67.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
45969380|NCT04618783|Biological|Three doses of control wIPV, vaccinated within one-month interval between doses|Antigen content: 40, 8, and 32 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
45969381|NCT04618783|Biological|Three doses of control sIPV, vaccinated within one-month interval between doses|Antigen content: 30, 32, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
45969382|NCT00221039|Drug|Methoxsalen+ECP|UVAdex+ECP will be administered: Treatment consists of two photopheresis treatments on successive days every 4 weeks for six months
45969383|NCT00243516|Device|PREtest Consult|
45969384|NCT00562939|Biological|Pneumococcal vaccines + CPG 7909|Day 0: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 90: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 270: 0.5 ml Pneumo Novum + 1 mg CpG 7909, IM
45969385|NCT00562939|Biological|Pneumococcal vaccines|Day 0: 1 ml Prevenar (double dose) + placebo, IM Day 90: 1 ml Prevenar (double dose) + placebo, IM Day 270: 0.5 ml Pneumo Novum + placebo, IM
45969386|NCT04618510|Device|SEED 1-dayPure EDOF soft contact lens|Centre-distance contact lens with peripheral add power working on extended depth of focus principle to control myopia
45969387|NCT04618510|Device|Single Vision Spectacles|These are the type of glasses that correct vision for a single distance
45455757|NCT05733416|Diagnostic Test|FDG PET/CT|F-fluorodeoxyglucose positron emission/computed tomography
45668791|NCT05813366|Other|Vitamin B6 Supplementation|All participants in all groups (A, B and C) will receive a tablet of vitamin B6 60mg once/day for 8 weeks, starting from the first day of their menstrual cycle, throughout two menstrual cycles.
45969388|NCT04618627|Other|lung ultrasound|Role of lung ultrasonography in prediction of the seveity and the need for surfactant administration in neonates with respiratory distress syndrome.
46080892|NCT05674422|Drug|total neoadjuvant therapy|All patients will be aged 18 years or older, with histologically confirmed rectal adenocarcinoma, located in the mid or distal third (with the inferior margin within 12cm from the anal verge), clinically staged II and III (cT3-T4 and/or any TN+), scheduled to undergo TNT will be eligible. All cases and treatment decisions will be discussed by local Multidisciplinary Boards
46080893|NCT05672147|Biological|Anti-CD33 CAR T-cells|Given IV
45826631|NCT00002783|Drug|floxuridine|
45826632|NCT00002783|Drug|fluorouracil|
45455758|NCT05733416|Diagnostic Test|Usual Care|Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care
45455759|NCT05732077|Drug|Dopamine|A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
45455760|NCT05732077|Diagnostic Test|Fractional Flow Reserve, Renal|Renal FFR will be measured based on SOP
45668792|NCT05813340|Procedure|Vascularized inter-positional periosteal connective tissue flap|It is a vascularized pedicled flap derived from the hard palate that can be used as a barrier to prevent in growth of soft tissue in guided bone regeneration and to increase soft tissue quantity
45668793|NCT05813327|Drug|ADI PEG20|ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m^2 via intramuscular injection into either the deltoid or gluteal muscle.
45668794|NCT05813327|Drug|Ifosfamide|Ifosfamide will be administered intravenously per package insert and institutional practice on Days 1 through 5 of all 3 cycles.
45668795|NCT05813327|Radiation|Radiotherapy|Radiotherapy will begin on C2D1 and will continue as per institutional practice.
45668796|NCT05813327|Drug|Mesna|Mesna will be administered for supportive care either intravenously or by mouth per package insert and institutional practice on Days 1 through 5 of all 3 cycles.
45668797|NCT05813314|Combination Product|BMN 111 administration via Injector Pen|BMN 111 Injection will be given using an injector pen
45826633|NCT00002783|Drug|leucovorin calcium|
45826634|NCT00002783|Procedure|conventional surgery|
45826635|NCT05749757|Device|Acupuncture|For Shangyitang acupoint, the needle will be inserted towards the direction of nasal tip horizontally to a depth of 10-20mm without any manipulation, and a pad will be adhered afterwards. For other acupoints, the needles will be inserted through adhesive pads to 10-20mm. Needles will be lifted, thrust, and twirled for 3 times to achieve deqi sensation, and will be manipulated every ten minutes during 30-minute maintenance.
45826636|NCT05749757|Device|Sham Acupuncture|For all the points, the needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrust and twirled for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
45826637|NCT00002789|Drug|busulfan|
45969389|NCT04618549|Procedure|Direct Anterior Approach Hemiarthroplasty|Hemiarthroplasty to elderly patients with femoral neck fracture through a direct anterior approach
45969390|NCT04618549|Procedure|Mini Posterior Approach|Hemiarthroplasty to elderly patients with femoral neck fracture through a mini posterior approach
46080894|NCT05672147|Procedure|Lymphodepletion Therapy|Undergo lymphodepletion
45969391|NCT04618549|Procedure|Lateral approach|Hemiarthroplasty to elderly patients with femoral neck fracture through a lateral approach (Hardinge)
46080895|NCT05670587|Device|A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection|A wearable cough monitoring device, the Strados Labs Remote Electronic Stethoscope Platform (RESP)ᵀᴹ sensor, with an accompanying mobile application (App) for data collection.
46080896|NCT05669911|Device|Teal Health Self-Collection Device Group|Participants will use the Instructions for Use to perform self-collection of cervicovaginal cells using the Teal Health Self-Collection Device, and will fill out a usability survey and a satisfaction and needs survey. A Pap smear will be performed by a clinician before or after self-collection.
45455761|NCT05732077|Device|Renal artery stenting|Renal artery stenting will be implanted based on the protocol
45455762|NCT05731687|Other|Hybrid DEB approach with drug-eluting balloon|If a patient is randomized to the hybrid DEB approach, lesion preparation of the SB with non-compliant balloon (NC) is mandatory before DEB application. The application of DEB can be performed if acceptable result of the lesion preparation is obtained (at least TIMI III flow and no flow limiting dissection). The drug- eluting balloon used in this study is the CE- marked Magic Touch Sirolimus Coated Balloon Catheter (Concept Medical, Gujarat, India). The size of the DEB is measured on a ratio 1:1 on reference diameter of the SB. The DEB balloon is inflated for 60 seconds, or two times more than 30 seconds if long duration inflations are not possible. Finally low pressure kissing inflation with the same DEB in place, and Proximal Optimization Therapy (POT) are performed. In case of SB occlusion, or flow limiting dissections in non-Left Main (LM) bifurcations and < TIMI 3 flow or 70-99% residual stenosis in LM bifurcations, cross- over to two-stent technique is performed.
45969392|NCT00221078|Device|Neuroprosthesis|The Compex Motion neuroprosthesis, developed by Drs.R. Popovic and Thierry Keller, and company Compex SA, is a flexible device designed to improve grasping function in both SCI and stroke patients. This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp, and holds a number of advantages over the other existing neuroprostesis.
45826638|NCT00002789|Drug|cyclophosphamide|
45826639|NCT00002789|Drug|cyclosporine|
45826640|NCT00002789|Drug|methotrexate|
45826641|NCT00002789|Procedure|allogeneic bone marrow transplantation|
45826642|NCT00002789|Procedure|peripheral blood stem cell transplantation|
45826643|NCT00381953|Drug|Peginterferon alfa-2a|
45826644|NCT00381953|Drug|Interferon alfa-2a|
45969393|NCT04618588|Procedure|Low Window Sinus Lift technique|"Preoperative CBCT of surgical site and Fabrication CAD/CAM surgical stent, Sinus elevation using Low Window Sinus Lift technique, Implant, bone graft and membrane placement"
45969394|NCT00247533|Procedure|Digital subtraction angiography and 24-hour simultaneous recorder of electrocardiograph|
45969395|NCT04618159|Other|lactobacillus reuteri DSMZ 17648|to evaluate if this product can eradicate helicobacter pylori
45969396|NCT04618120|Other|Virtual reality-based exercise|"Virtual reality-based exercises with Microsoft Xbox 360 Kinect and breathing exercises.~Patient education"
45969397|NCT04618120|Other|Exercise|Shoulder range of motion, stretching, posture and breathing exercises. Patient education
46080897|NCT05666115|Dietary Supplement|Probiotic group|During the first 4 weeks, patients will be instructed to take two capsules of Enterelle plus (Bromatech lab, Manno, Switzerland) during morning time, before or after breakfast. Enterelle plus contains specific strains, i.e., S boulardi, E faecium, and acidophilus, that contribute to reduce the mycotic flora and modulate the gastrointestinal transit. For the next 8 weeks, participants will be told to ingest two capsules of Adomelle (Bromatech lab, Manno, Switzerland) at night, during or right after dinner. Adomelle contains several strains, including Bifidobacterium breve, that help to reduce abdominal fat, pain, and gas, and control the frequency of deposition
45455763|NCT05731687|Other|Two-stent strategy|When randomized to the conventional two-stent strategy, TAP/T or Culotte stenting is performed. First lesion preparation of the SB is mandatory. The drug-eluting stent (Supraflex stent) can be placed in the SB if acceptable result of the lesion preparation is obtained and is measured on a 1:1 ratio on reference diameter of the SB. Finally, kissing inflation and POT are mandatory.
45455764|NCT05730504|Other|Mobile app-based self-guided interventions|self-guided, app-based mobile psychological interventions based on CBT, meditation, mindfulness, journaling, and audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation
45668798|NCT05813314|Drug|BMN 111 administration via vial and syringe|BMN 111 Injection will be given using vial and syringe
45969398|NCT00221156|Drug|Acarbose|
45969399|NCT04618276|Other|Photodynamic Therapy|PDT with two different photosensitizers
45969400|NCT04618042|Drug|FX06|FX06 i.v.: 400 mg per day (divided in two injections) during 5 days
45969401|NCT04618042|Drug|Placebo of FX06|Placebo i.v.: 400 mg per day (divided in two injections) during 5 days
45668799|NCT05813275|Drug|AD109|Oral administration at bedtime
45668800|NCT05813275|Drug|Placebo|Oral administration at bedtime
45969402|NCT04618003|Behavioral|Adaptation of autonomic nervous system to activity in virtual reality|heart rate variability assessed at rest and during a physical activity in virtual reality.
45969403|NCT00243555|Procedure|allergy skin testing|
45969404|NCT00243555|Procedure|venepuncture|
45668801|NCT05813249|Drug|Rybelsus Oral Product|Oral Semaglutide
45668802|NCT05813249|Drug|Ozempic Injectable Product|Subcutaneous Semaglutide
45668803|NCT05813249|Drug|Tocopherol and/or Actos|Vitamin E and/or Pioglitazone
45826645|NCT00381953|Drug|Ribavirin|
45826646|NCT05749523|Behavioral|Exercise|Exercise vs non-exercise
45826647|NCT05613881|Other|Education and Telephone Follow-up|The individuals in this group will be given an education and training booklet by the researcher after the pre-tests are applied in the first face-to-face interview. After the first meeting, the individual will be called every 15 days, 5 times in total for 3 months, and the training will be repeated in line with the individual's needs. After 3 months, the final tests will be applied.
45826648|NCT00382343|Drug|Sulfamethoxazole/trimethoprim|Sulfamethoxazole/trimethoprim prophylaxis
45826649|NCT05749445|Drug|Nirmatrelvir-Ritonavir|Nirmatrelvir-Ritonavir
45826650|NCT05749367|Drug|Ropivacaine + saline solution|SIFIB with 30 ml of 0.5% ropivacaine and PENG Block plus LFCNB with 20 ml and 10 ml of saline solution, respectively.
45826651|NCT05749367|Drug|Saline solution + Ropivacaine|SIFIB with 30 ml of saline solution and PENG Block plus LFCNB with 20 ml and 10 ml of 0,5% ropivacaine, respectively.
45826652|NCT05502887|Diagnostic Test|Sublingual in vivo microscopy with the Glycocheck microscope|For the collection of longitudinal microscopy data, sublingual in vivo microscopy with the Glycocheck microscope will be performed at the following timepoints: 2-3 x between day (D) -28 of allogeneic HSCT or CAR T cell therapy and before start of the conditioning regimen, once between D2-D14, once between D15-28, once between D30- D100 and at the onset of endothelial complications such as acute GvHD, TMA, sepsis, VOD and IPS following allogeneic HSCT or CAR T cell therapy. Sublingual microscopy requires 15-30 minutes and is similar to sublingual temperature measurement. To this extent, a tube with a diameter of approximately 1cm carrying a microscope at the tip is inserted into the mouth and under the tongue to measure endothelial structures (blood flow through small capillaries). Biological samples are collected and processed within the established Biobank of the Internal Medicine V of the Heidelberg University Hospital.
45826653|NCT05749289|Drug|Al18F-octreotide|Al18F-octreotide I was injected into the patients before the PET/CT scans
45826654|NCT05602961|Drug|GLB-COV2-043|COVID-19 vaccine, administered as a booster
45826655|NCT05602961|Drug|BNT162b2/COMIRNATY®|active control
45826656|NCT05501249|Behavioral|Aquatic Integrated Cognitive Motor Training|Aquatic exercise class with focus on cognitive and physical exercise
45969405|NCT00221234|Behavioral|Print materials, pedometers/logbooks|
45969406|NCT00221234|Behavioral|Print materials, pedometers/logbooks, telephone counselling|
45969407|NCT04617691|Drug|Guselkumab|Guselkumab will be administered as IV solution derived from FVP or PFS-U.
45668804|NCT05813210|Diagnostic Test|Exercise in combination with biomarkers and pharmacological stress CMR test|A bicycle ergometry combined with pharmacoligical stress test is performed. High sensitive Troponin is taken before and after the stress test.
45969408|NCT04617613|Drug|Omeprazole, Amoxicillin, Metronidazole and Clarithromycin|The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
45969409|NCT04617613|Drug|Omeprazole, Amoxicillin and Clarithromycin|The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
45969410|NCT04617652|Drug|Magnesium sulfate|Patients will receive 1 gm of magnesium in 10 ml over 5 minutes then infusion of 1 gm in 50 ml over one hour.
45969411|NCT04617652|Drug|Normal saline|Patients will receive 10 ml of saline, then infusion of 50 ml of normal saline over one hour.
45969412|NCT02961738|Behavioral|Cognitive Analytic Therapy (CAT)|Cognitive Analytic Therapy (CAT) is a relational, integrative and time-limited psychotherapy. This is a study with two active arms. Therefore in the full CAT arm the participants receive the full therapy, but in the CAT-NR arm participants get CAT with the narrative reformulation aspect removed.
45455765|NCT05723445|Behavioral|Low Glycemic Load Diet|Food delivery service will provide a low glycemic load diet for 8 weeks, followed by a 4-month period of self-adherence to a low glycemic load diet with close nutritionist follow up
45455766|NCT05723406|Drug|Sugammadex 100 MG/ML [Bridion]|8 mg/ml
45826657|NCT05749133|Biological|Anti-GPRC5D CAR-T Cells Injection|"This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells: Initial dose group: 3.0×10^6/kg±20%; Low dose group: 3.0×10^6/kg±20%; High dose group: 6.0×10^6/kg±20%. Dose was weight-based."
45826658|NCT04331171|Device|Web application users|questionnaire of comorbidity and symptoms completed by the patient on his smartphone
45826659|NCT05749055|Drug|ENX-102|Selective GABA-A alpha2,3,5 positive allosteric modulator
45455767|NCT05723406|Other|Placebo|Sodium 0.9% 5 ml
45826660|NCT05749055|Drug|Placebo|Placebo
45969413|NCT00221273|Procedure|ACL surgery|
45969414|NCT04617730|Device|Mepitel® film|This study is a comparative study between the standard procedure, which is to prescribe a hydro-active colloidal gel called Flamigel® to be applied to the irradiated area, and the use of Mepitel® Film.
45969415|NCT04617730|Other|Flamigel®|The control arm will be treated according to the standard of care.
45969416|NCT04617223|Procedure|Endoscopic sinus evacuation|Evacuation of the sinus by using endoscope
45668805|NCT05813197|Behavioral|My Choice - My Way!|Support intervention for adolescents (15+) in out-of-home care (foster care, group home care, supported living, institutional care, etc). 16-19 sessions with a MCMW coach, 4-8 months, weekly to bi-weekly sessions.
45668806|NCT05813197|Behavioral|Usual services|Usual services
45668807|NCT05813184|Drug|Antibiotics|Any antibiotic therapy administered > 7 days
45969417|NCT04617184|Other|NO INTERVENTION|THERE IS NO INTERVENTION TO THIS TRIAL. THIS IS A REGISTRY
45969418|NCT00247572|Drug|NRP104|
45969419|NCT00221312|Drug|Fosamax|
45969420|NCT04616989|Behavioral|Psycho-education|Provide psycho-education to members of the community
45969421|NCT04616989|Behavioral|Comparator|Distribution of COVID-19 leaflets to members of the community
45969422|NCT04617106|Procedure|Radial artery cannulation|cannulation of Radial artery using standard IV cannula (axillary drug port will be taped using opaque adhesive)
45969423|NCT04617145|Other|Aerobic exercise|resistive training which were conducted in the form of a series of exercises using free weights, and dumbles to increase the strength of arms, pectoral muscles, abdominal, back muscles and gluteal region. Patients carried out three sets of 20-30 dynamic repetitions or static isometric exercises for 40-60 seconds for each muscle group and rested 1-2 min between series. Sessions were conducted three sessions/week for eight weeks.
45969424|NCT00221351|Procedure|CRP point of care testing|
45826661|NCT05590481|Device|TIBIAL TRANSCUTANEOUS ELECTROSTIMULATION|The electrodes will be surface (silicone rubber and carbonate), brand Quark®, with dimensions of 5 cm by 3 cm, coupled with conductive gel and fixed to the volunteer's skin with micropore tape. For the placement of the electrodes, the volunteer will be positioned in the horizontal supine position on the stretcher, with the knee in semiflexion and the head supported on a pillow. The electrodes will be positioned one immediately posterior to the medial malleolus of the ankle and the other approximately 10 cm above it, both fixed with micropore tape, on both legs of the patient. To ensure that the electrodes stimulate the tibial nerve, a transcutaneous electrical nerve stimulation (TENS) current with a frequency of 1 Hz will first be applied, with a gradual increase in intensity, to verify a rhythmic movement of flexion of the hallux. The following parameters will be used for TTNS: frequency 10Hz (Hertz), pulse duration 200 μs (microseconds), for 30 minutes.
45455768|NCT05722886|Drug|Alectinib|"Adult participants will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Paediatric participants with a body weight ≥40 kg and who are able to swallow the capsules will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Each cycle of treatment will consist of 28 days and participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent."
45455769|NCT05722886|Drug|Atezolizumab|"Adult participants will receive 1200 mg of atezolizumab intravenously every 21 days.~Paediatric participants will receive atezolizumab at a dose of 15 mg/kg (maximum 1200 mg) every 21 days.~Participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent."
45668808|NCT05813171|Dietary Supplement|Allicor|Participants will take Allicor capsules in addition to standard treatment for a year.
45668809|NCT05813171|Drug|Placebo|Participants will take the placebo capsules in addition to standard treatment for a year.
45668810|NCT05813145|Drug|Placebo|25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week
45668811|NCT05813145|Drug|Fenofibrate 160mg|25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week in addition to 160mg fenofibrate once daily for 3 month.
45668812|NCT05813132|Drug|BEAM Protocol|BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan)
45826662|NCT05590481|Behavioral|behavioral therapy protocol|submitted to a behavioral therapy protocol, which involves bladder training, pelvic floor muscle training and modification of liquid intake. The orientation will be based on the initial evaluation of the patient, in which the responsible researcher will give verbal orientations and deliver booklets on the pathology, behavioral therapy and sleep hygiene.
45668813|NCT05813132|Drug|CEM protocol|CEM (Carboplatin, Etoposide, Melphalan)
45668814|NCT05813106|Drug|Dexmedetomidine Hydrochloride|Intravenous dexmedetomidine 0.2 mcg/kg
45668815|NCT05813106|Drug|normal saline|normal saline
45668816|NCT05813093|Device|rTMS|Accelerated iTBS treatment
45969425|NCT00243594|Biological|Peptide-pulsed dendritic cells|peptide-pulsed dendritic cells
45969426|NCT04616911|Procedure|Rerouting seton|Excision of superficial fistula tract and placment of seton with rerouting of the fistula tract around the internal anal sphincter
45969427|NCT04616911|Procedure|LIFT|Ligation of the intersphincteric fistula tract
45969428|NCT04616638|Behavioral|Resistance Training for Empowerment (RT-POWER)|The EG intervention was designed using the Social Cognitive Theory and its four sources of self-efficacy to promote a participant's (a) involvement in exercise planning, (b) muscular strength, and (c) independent functional performance. It consisted of three phases, which were adapted from the Self-Determined Learning Model of Instruction (Wehmeyer et al., 2000). This model draws from theory and research on self-management and self-control (Bandura, 1986; Martin et al., 1988). Participants were taught by their coaches how to (a) set a goal to meet fitness needs (Phase 1), (b) make a plan to meet goals (Phase 2), and (c) adjust actions to complete the plan (Phase 3).
45668817|NCT05813080|Device|"pronia.ai medical device for high risk psychosis prognosis"|In addition to the computer-assisted prognosis of risk for reaching a psychosis, all patients assigned to the active treatment arm will receive additional in-depth clinical diagnostics including neuropsychological testing. Adapted psychological treatment will be offered consisting of 16 to 24 sessions over a period of six months.
45969429|NCT04616638|Behavioral|A traditional RT intervention|The control intervention also consisted of a three-phase instructional process. Consistent with traditional RT interventions (ACSM, 2009), the coaches rather than the participants, were the primary agents for goal-setting, exercise planning, goal attainment monitoring, and readjusting of the exercise plan. Neither the visual activity schedules nor the system of least-to-most prompts was used in this intervention.
45969430|NCT04616872|Drug|Methotrexate-LDE|MTX-LDE 40mg/m2 (250mL total volume) IV and Folic acid 5mg by mouth (the day after MTX-LDE) weekly for 12 weeks
45969431|NCT04616872|Drug|Placebo-LDE|Placebo-LDE (250mL total volume) IV and Folic acid 5mg by mouth (the day after Placebo-LDE) weekly for 12 weeks
45969432|NCT00221390|Drug|Ropinirole (+ physical therapy)|
45969433|NCT00221390|Drug|(vs.) Placebo + physical therapy|
45969434|NCT00247650|Drug|Zoledronic Acid; Letrozole|
45969435|NCT04616755|Other|Measuring changes of Little´s irregularity index ( sum of 5 contact point discrepancies together) measured in mm 2 years after retention have been I place.|Measuring changes occurred under 2 years which the retention devices have been in place between the groups
45969436|NCT04616716|Drug|FMTN|Single dose of FMTN after high-fat meal,low-fat meal and fast
45668818|NCT05813080|Other|Treatment-as-usual (TAU)|Referral back to the previous care system. Further treatment is left to the referring primary care providers.
45826663|NCT05490017|Drug|KP104|Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.
45969437|NCT04616521|Procedure|Deep brain stimulation|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for moderate-to-advanced stage PD. The targets used in this study are STN and GPi, which are widely accepted and used for symptom control in PD. The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the movement disorder specialist.
45969438|NCT00251043|Behavioral|Interpersonal psychotherapy for depression in pregnancy|IPT-P will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn ways to address emotional stressors associated with childbirth.
45969439|NCT00251043|Behavioral|Parenting education program (PEP)|PEP will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn about the stages of pregnancy, childbirth, and early infant development.
45969440|NCT00221429|Drug|lithium sodium divalproex|
45969441|NCT00563017|Drug|Long-acting Risperidone microspheres injection|
45969442|NCT00563056|Drug|Flutiform|
45969443|NCT00563056|Drug|Flixotide plus Foradil|
45969444|NCT00563095|Procedure|Transcatheter Arterial Chemoembolization (TACE)|
45969445|NCT00563095|Procedure|Transcatheter Arterial Pegylated Interferon Embolization (TAIE)|
45969446|NCT00563134|Drug|GR270774|
45969447|NCT00563173|Drug|CHRONVAC-C®|DNA vaccine, solution for injection, i.m. administration in combination with electroporation
45969448|NCT00221468|Drug|quetiapine|100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
45969449|NCT00563212|Drug|aerosol interferon-gamma|aerosol interferon-gamma-1b 100mcg given via nebulizer three times weekly for one year
45969450|NCT00563251|Drug|Azithromycin|
45969451|NCT00563251|Drug|Placebo tablet|
45668819|NCT05813067|Dietary Supplement|JDS-HF 3.0|Take 2 capsules once daily in the mornings with food
45668820|NCT05813067|Dietary Supplement|Placebo|Take 2 capsules once daily in the mornings with food
45668821|NCT05813054|Dietary Supplement|HA matrix ingredient|1 capsule/day
45668822|NCT05813054|Dietary Supplement|Placebo|1 capsule/day
45826664|NCT05490017|Drug|Placebo|Participants will receive matching placebo which is KP104 vehicle containing sodium phosphate, sodium chloride, and L-Lysine Hydrochloride (L-Lys-HCL).
45826665|NCT05488691|Behavioral|EMDR|The first session consists of recording the patient's history. In the second session the therapist evaluates the presence of coping mechanisms of the patient and, if necessary, suggests extra coping techniques. The following sessions are devoted to the reprocessing process. During these sessions, a target memory is identified and processed using EMDR. After a total of 8-10 sessions, it is expected that the patient will have achieved physiological reconciliation, relieved distress, and the ability to reformulate negative beliefs.
45969452|NCT03454516|Other|telemonitoring|the follow-up of the patient will be performed with Telemonitoring
46080898|NCT05666115|Other|Exercise group|This type of intervention has shown to benefit patients with several chronic conditions 23, including axSpA 13. Exercises combined high knees, lunges, basic burpees, plank, skipping, mountain climbers, and squats with jumps. The training routine will be conducted three times per week, and each session will last around 8 minutes (2 sets of 4 minutes, with a 10 second rest between them). All sessions will be individually tailored and supervised by a senior professional with a degree in Physiotherapy and Sciences of Physical Activity and Sport. Overall, participants will be told to continue exercising if low to moderate bearable pain appeared during training.
46080899|NCT05660850|Drug|GDC-6599|GDC-6599 will be administered Days 1- 14 and on Days 29-42 as film-coated tablets
45969453|NCT02961543|Other|Isokinetic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
45826666|NCT05488691|Behavioral|TAU|treatment as usual for substance use disorders
45826667|NCT05748977|Drug|SABA SAMA ICS Vs LABA LAMA ICs|Short acting agents,long acting agents ,ics
45826668|NCT02972957|Biological|Nasovac-S|one of 0.5ml intranasal dose of trivalent live attenuated vaccine (LAIV)
45826669|NCT02972957|Drug|Azithromycin|a single dose of Azithromycin (liquid formulation - Zithromax) at 20mg/Kg (up to a maximum adult dose 1g) to be given to a subset of subjects
45826670|NCT05748899|Behavioral|Ujjayi pranayama|this group will receive home-based daily ujjayi pranayama for six weeks (fifteen minutes in the morning and 15 min in the evening, this training will be online supervised).
45969454|NCT02961543|Other|Isotonic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
45969455|NCT00221507|Behavioral|Reminder-Recall-Outreach|
45969456|NCT00221507|Behavioral|Case Management|
45969457|NCT00221507|Behavioral|Patient Navigator|
45969458|NCT03454477|Procedure|conventional open surgery|conventional open surgery
45969459|NCT03454477|Procedure|endoscopic thyroidectomy|endoscopic thyroidectomy
45969460|NCT03454477|Device|robotic thyroidectomy|robotic thyroidectomy
46080900|NCT05660850|Other|GDC-6599-matching placebo|GDC-6599-matching placebo will be administered Days 1- 14 and on Days 29- 42. as film-coated tablets
45455770|NCT05722886|Drug|Entrectinib|"Adult and paediatric participants with body surface area (BSA) ≥1.51 m^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day).~Paediatric participants will receive a dose adjusted for BSA. Each cycle of treatment will consist of 28 days and participants may continue until disease progression, unacceptable toxicity or withdrawal of consent."
45668823|NCT05813041|Device|BioCaptis|The BioCaptis is a medical device intended to capture cell-free DNA from peripheral blood for use in liquid biopsy. When used as a cartridge filter during an apheresis procedure in which plasma is passed through the device, the BioCaptis binds cfDNA which can be eluted, concentrated, and used as an input for cancer diagnostic tests.
45668824|NCT05813028|Other|a Mobile Application|Patients will use the mobile application for 6 weeks after receiving the first course of chemotherapy. The Multidimensional Scale of Perceived Social Support, Memorial Symptom Rating Scale, EORTC QLQ-C30 Quality of Life Scale and QLQ-CR29 Module, Beck Anxiety Scale will be administered when they come to the hospital for their 2nd course of chemotherapy. Patients will use the mobile application for 6 more weeks after receiving the second chemotherapy course. 3. The scales will be reapplied when they come to the hospital for a chemotherapy course. Patients will continue to use the mobile application for three more weeks after receiving their 4th and final cure. When the patients come to the outpatient clinic control in the 12th week, the use of the mobile application will be terminated and the Mobile Application Efficiency Evaluation Form will be applied together with the other scales.
45668825|NCT05813015|Drug|Docetaxel|Docetaxel 40mg/m2，every 21 days，6 cycles.
45668826|NCT05813015|Drug|Tegafur-Gimeracil-Oteracil|S-1 40-60mg/m2，p.o, BID, day 1-14, till 1 year postoperation.
45668827|NCT05813002|Other|standard neural mobilization|is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
45826671|NCT05446259|Other|Standard clinical care procedures and outcome measurements.|Standard of care surgical interventions, imaging impressions, laboratory results, and outcome measurements will be collected and analyzed.
45826672|NCT05581043|Dietary Supplement|3-hydroxybutyrate (3-OHB)|The aim of this study was therefore to i) investigate the dose/response relationship between 3-OHB servings of 0, 10, 20 and 40 grams 30 minutes before an OGTT and, ii) investigate the role of timing by serving 25 grams of 3-OHB at different timepoints ahead of an OGTT (0, 30 and 60 minutes).
45826673|NCT05748743|Procedure|glove changing|Surgical gloves were changed prior to abdominal closure during Cesarean section to evaluate its effectiveness in reducing wound complications after surgery
45969461|NCT03454399|Procedure|Suction orogastric tube which is attached to TEE probe|Suction orogastric tube which is attached to TEE probe
45969462|NCT03454360|Device|ACURATE neo™ Aortic Bioprosthesis|TAVI; Transcatheter Aortic Valve Replacement. Transapical Access.
45969463|NCT00251082|Drug|continuous combined estradiol and dydrogesterone|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
45969464|NCT00251082|Drug|continuous combined estradiol and dydrogesterone|1 Mg Estradiol and 5 Mg Dydrogesterone
45969465|NCT00251082|Drug|Placebo|Placebo
45969466|NCT00221546|Drug|Giving DHA-rich supplement|Giving DHA-rich supplement to patients.
45969467|NCT04616092|Drug|FEFINJECT|FEFINJECT injection
45668828|NCT05813002|Other|Distal to proximal neural mobilization|is a distal to proximal movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
45969468|NCT04616482|Behavioral|Digital therapeutic carbohydrate restriction (TCR) program|A 12-week, personalized, online program to teach and coach patients about therapeutic carbohydrate restriction as for obesity and/or T2D (or risk of T2D). The program is intended to enhance the usual clinical care provided for patients.
45969469|NCT04616209|Biological|donor-derived NK cell infusion|PB103 administrations will be separated by 4-week interval
45969470|NCT00221585|Behavioral|Psychosocial treatment/Psychodynamic treatment|
45969471|NCT04616404|Dietary Supplement|500 mg of artichoke extract|Tablets containing 500 mg of artichoke extract (triple standardized to contain caffeoylquinic acids ≥ 5.0%; flavonoids ≥ 1.5%; cynaropicrin ≥ 1.0%, by HPLC)
46080901|NCT05660850|Diagnostic Test|Mannitol|Mannitol challenge tests will be performed during screening and at least 2.5 hours following study drug administration at Study Visits 2, 4, 5 and 7
45969472|NCT04616404|Other|Placebo|Tablets with no active ingredient
45969473|NCT04720482|Diagnostic Test|Somatosensory Evoked Potentials|SSEP performed bilaterally with stimulation of the median nerve
45969474|NCT04720482|Diagnostic Test|Automated Pupillometry|PLR quantified as NPi using a handheld automated pupillometer
45826674|NCT05573009|Behavioral|cognitive behavioral approach-based stress reduction program|"Five days lasting stress reduction program based on cognitive behavioral approach(each session will be an average of 60 minutes) will be initiated in the third day of hospitalisation to the intervention group.~Session main topics are:~Session 1 - Introducing the purpose and content of the program - Stress Psychoeducation Session 2 - Cognitive restructuring Session 3 -Behavioral coping Session 4 - Problem solving training Session 5-Upcoming parenthood"
45969475|NCT00221624|Drug|Peginterferon alfa-2a|
45969476|NCT00221624|Drug|ribavirin|
45969477|NCT00221624|Drug|amantadine|
46080902|NCT05656911|Drug|Zabedosertib (BAY1834845)|Oral administration, two times a day
46080903|NCT05656911|Drug|Placebo to zabedosertib (BAY 1834845)|Oral administration, two times a day
46080904|NCT05656742|Dietary Supplement|Vitamin D|oral vitamin D3
46080905|NCT05653869|Drug|APS03118|Participant received APS03118 orally until evidence of unacceptable toxicity, progressed disease, consent withdrawal or with drawl from the study at the discretion of the investigator.
45969478|NCT04616053|Behavioral|IMPACT intervention|A referent is assigned to the patient. A referent is a health worker (nurse, nutritionist, psychologist …). Patient builds with his referent a free care program (without condition or limit). The patient can choose individual consultation (for example : nutrition, tabacology, psychology …) and/or collective care (for example : patient education, physical activity, relaxation …). A community health worker can help patient with his health administrative procedures. This intervention lasts 6 months.
45969479|NCT04615975|Dietary Supplement|Ketogenic diet with phytoextracts|Patients were provided with an individualized nutritional ketogenic plan during hospitalization
45969480|NCT04615897|Procedure|new tecnology intervention|"The intervention consists of 16 sessions, performed with a frequency of twice a week, the final evaluation was made within three days after the end of the last treatment session. It is used for the motor task, the Fishing Under Zero exercise, included within the balance modality and the so-called Step Plus located in the aerobic exercise folder. Each subject carried out the training taking into account the following methodology: 3 cycles of the Fishing under zero exercise, one cycle of the Step Plus exercise and 3 cycles of the Fishing under zero exercise, the approximate duration of the task being about 30 minutes."
45969481|NCT00221663|Device|surgery techniques (sternotomy for aortic valve replacement)|
45969482|NCT04615741|Behavioral|Trauma Informed Yoga|One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
45969483|NCT04615741|Behavioral|Trauma Informed Psychotherapy|Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
45969484|NCT04615663|Behavioral|Score SMI|the investigator will complete the SMI score
45969485|NCT04615780|Other|mouthwash with green tea|All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The intervention group rinsed the mouth with 100 ml green tea solution for 60 seconds at least twice daily. For the preparation of the green tea mouthwash, green tea solution was made with 5 g (1 teaspoon) of green tea powder dissolved in 100 ml water to produce 5% green tea mouthwash, as described in a previous study (Eshghpour, et al., 2013). The green tea powder was ground from Camelia sinensis leaves and regularly provided by the researcher. The green tea solution is made for a single use and remade before rinsing each time. When patients return to the outpatient monthly, the researcher first confirms patients' compliance, then assists with solving difficulties and gives encouragement.
45969486|NCT04615780|Other|mouthwash with tap water group|All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The control group rinsed the mouth with 100 ml tap water for 60 seconds at least twice daily.
45969487|NCT04720092|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Granules for oral suspension, 10 mg, oral, single dose
45969488|NCT04720092|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Tablet, 10 mg, oral, single dose
45969489|NCT00221702|Drug|PegIntron|100 mcg SC/week for 36 months
45969490|NCT00221702|Drug|intron A|3mui TIWW SC for 18 months
45668829|NCT05813002|Other|proximal to distal neural mobilization|is a proximal to distal movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
45668830|NCT05812963|Diagnostic Test|IVUS-guided PCI group|In IVUS-guided PCI group, the current trial evaluates clinical outcome following IVUS-guided treatment decision for revascularization of non-IRA stenosis.
45826675|NCT05471141|Other|Cognition ECHO|Cognition ECHO is the intervention designed to be used by the study participants who are primary care practitioners. No involvement of patients in this study. The panel will consist of the CI and Co-PIs of this study, a neurologist as a co-moderator, a medical specialist who is the expert on the subject, an occupational therapist, a psychologist, and a speech and language pathologist with experience and expertise in CI. A patient with CI and a caregiver, family member, or community representative who is not a healthcare professional will join the panel because CI is frequently observed with lived experience of family members and loved ones, as two non-clinician panelists. The five topics with the integration of related diagnoses for Cognition ECHO are listed in Table 4. The time allocated for the didactic will be 15-20 minutes and the de-identified case discussion will be 40 - 45 minutes.
45826676|NCT05469191|Other|Group 5 STS|"For 8 weeks, 3 times per week and 3 sets of 5 repetitions during the first month, then 5 sets of 5 repetitions during the second month.~Between each repetition, there will be a rest of 30 to 60 seconds approximately."
45826677|NCT05469191|Other|Group 10 STS|"For 8 weeks, 3 times per week and 3 sets of 10 repetitions during the first month, then 5 sets of 10 repetitions during the second month.~Between each repetition, there will be a rest of 30 to 60 seconds approximately."
45969491|NCT04615702|Diagnostic Test|serum lipase or amylase|"Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits) is helpful in diagnosis~Acute pancreatitis is diagnosed when two of three criteria are present including:~Clinically (abdominal pain consistent with acute pancreatitis),~Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits)~Imaging criteria of acute pancreatitis"
45969492|NCT04615702|Device|ultrasound|helpful in diagnosis of acute pancreatitis and its etiology (Gallstones)
45969493|NCT04615702|Device|CT|helpful in diagnosis of acute pancreatitis and its etiology . assist in detection of type and severity of acute pancreatitis
45969494|NCT04615702|Diagnostic Test|Liver enzymes (Bilirubin, alanine transferase (ALT), aspartate aminotransferase, (AST) and alkaline phosphatase). Calcium. Triglycerides.|help in diagnosis of the etiology of acute pancreatitis elevated Bilirubin, ALT, AST and alkaline phosphatase suggest biliary pancreatitis
45668831|NCT05812963|Diagnostic Test|FFR-guided PCI group|In FFR-guided PCI group, FFR measurement for non-IRA stenosis (>50% visual estimation) will be performed by continuous infusion of adenosine (140~180 ug/kg/min) or intracoronary nicorandil (2 mg bolus) injection. The FFR ≤0.80 will be targeted for PCI. In case of non-IRA stenosis >90%, we will judge FFR value of ≤0.80.
45668832|NCT05812950|Behavioral|GST|Outpatient eating disorder treatment (5 individual pre-group sessions followed by 26 weekly group sessions + 8 optional individual sessions)
45668833|NCT05812950|Behavioral|CBT-E|Outpatient eating disorder treatment (20-40 weekly individual sessions)
45668834|NCT05812937|Procedure|Intraabdominal ultrasound|To assess the diagnostic value of the intraoperative intrabaabdominal ultrasound (IIUS) for endometriosis patients as well as the predictive potential of changing the therapeutic strategy during the surgery based on the ultrasound findings.
45969495|NCT04615702|Device|EUS /Secretin-stimulated magnetic resonance cholangiopancreatography (MRCP)|helpful in idiopathic acute pancreatitis diagnosis
45969496|NCT04615702|Drug|Ringer lactate|"The initial infusion rate for mild cases :~For patients without dehydration is (130-150mL/h).~In case of dehydration: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload.~The initial infusion rate for both severe cases :~For patients without dehydration is (130-150mL/h).~In case of dehydration/ shock: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload d. The target~A mean arterial pressure of 65mmHg or more,~Urine output of 0.5mL/kg per hour or more When these parameters achieved, the infusion rate decreased to the level that maintain these parameters."
45969497|NCT04615702|Combination Product|NSAID / paracetamol +/- opiates+/- epidural analgesia|"Pain control (Modified World Health organization (WHO) analgesia ladder) Step1: NSAID / paracetamol Paracetamol 1gm IV infusion /8h + Diclofenac sodium 75mg /12h.~Step 2: Opiates +/- NSAID/ paracetamol Pethidine 25 mg IV/4h~Step 3: Interventional treatment (epidural analgesia) +/- opiates +/- NSAID/ paracetamol In case of severe pain not responding to the above analgesia"
45969498|NCT04615702|Combination Product|Quinolones + Metronidazole /Carbapenems ± Metronidazole|"Mild attack: no antibiotic prophylaxis administered.~Severe attack:~Timing: Antibiotic prophylaxis administered to cases presented early within 72 hrs of disease onset.~Duration: Not more than 2 weeks~Antibiotics given:~Quinolones + Metronidazole ( the 1st choice in ward) Ciprofloxacin 400mg IV /12 h + metronidazole 500mg IV/8h~Carbapenems ± Metronidazole (the 1st choice in ICU patients and in case of sensitivity to quinolones) Imipenem .5gm IV/6h + metronidazole 500mg IV/8h~b. Therapeutic (in cases with pancreatic or extrapancreatic infections)~In case of pancreatic infection, Carbapenems ± metronidazole were given."
45969499|NCT04615702|Dietary Supplement|Fresubin 2Kcal fiber drink|"Severe cases Timing: Within at least 48 hrs of admission provided that there are no intestinal complications.~Route: Nasogastric tube Nutrients: Polymeric feeding formula~Nutrient: Fresubin 2Kcal fiber drink 200ml (2Kcal/ml)~Total caloric requirements ꞊ body weight (kg) X 30Kcal/day Pattern : Continuous infusion~The nutrition started with small amount and increased gradually over 16hrs~Infusion rate ꞊ Total caloric requirements / 16hrs"
45969500|NCT04615702|Device|nasogastric tube|in case of ileus or vomiting
45969501|NCT04615702|Procedure|retroperitoneal necrosectomy|"General anesthesia , Supine position with 30 degree tilt towards the right side~A left subcostal 5 cm incision is performed one finger below the left costal margin over the midaxillary line and the muscles were divided sequentially~Then, aspiration is done from the possible collection.~After confirmation that it was the site of the collection, the fibrotic thick wall was opened by a scissor, as the collection is opened, pus drained spontaneously.~At first, a wide suction was introduced in the cavity and the friable loose necrotic tissue was aspirated. Then, a circuit of flushing saline was created in the residual cavity by injection of saline through the previously placed PCD followed by aspiration of the saline and detached loose necrotic tissue fragments by the wide suction tube~After completion of the procedure, large bore surgical drain was placed into the collection. The fascia was closed over the drains. The skin closed by interrupted sutures"
45969502|NCT04615702|Procedure|open necrosectomy|"Open necrosectomy was done after failure of the minimally invasive techniques. The procedure was done under general anesthesia under the coverage of Tienam (.5gm/6h IV) following the results of culture and sensitivity of the percutaneous drain effluent Surgical exploration of the peritoneal cavity was done through midline exploratory incision, there were 2 large pus collections extending from the Rt. and Lt. Lumber regions deep down into the pelvis, the intervening septa were divided and the pus was aspirated by a wide suction drain.~The lesser sac was opened and necrosectomy was done The previously placed PCD repositioned in the site of necrosectomy as a port for continuous irrigation while a wide tube drain was placed in the lesser sac for drainage. Another 2 tube drains were placed in the pelvis."
46080906|NCT05651568|Other|Periodized resistance training|"It consists of patients who will receive periodized resistance training 3 sessions per week for 8 weeks. Resistance training has been performed according to FITT principal and as per ACSM recommendation.~Frequency:~Three days in a week~Intensity:~60% intensity with one repetition maximum and 10% intensity were added each the two weeks.4 sets and 8-12 rep as per ACSM criteria. There will be rest of 60 second after every set and 120 seconds after every exercise.~Type:~8 types of resistance exercises were performed. There were 4 set of each exercise with 8 to 12 repetitions. These exercises are smith press, seated press, squat, lying dumbbell leg curls, leg extension, leg press, standing barbell, lying barbell and sit ups.~Time:~40 minutes per session."
46080907|NCT05651568|Other|High intensity interval training|"It consists of patients who will receive high intensity interval training 3 sessions per week for 8 weeks for 30 to 35 minutes.~Active phase: Two weekly sessions of four times four minutes at 90-95% of individual heart rate maximum, separated by three minutes of active rest period and one weekly session of ten times one minute with maximal intensity, separated by one minute of active rest. The exercise mode will be treadmill or outdoor walking/running or cycling (self-selected)."
46080908|NCT05645133|Device|Diagnostic Test|Diagnostic device to monitor coagulation properties of a whole blood sample at the point of care
46080909|NCT05643560|Drug|Damoctocog alfa pegol (Jivi, BAY94-9027)|Intervention is given as part of routine medical practice.
46080910|NCT05639647|Drug|ATM-AVI|A drug specifically designed to treat resistant gam-negative bacterial infections
46080911|NCT05639647|Drug|BAT|BAT will be selected by the investigator and administered iv as appropriate for the selected drug(s)
45826678|NCT05462483|Other|Rice Sock and Instructions to heat the quadriceps.|A rice sock will be provided to the experimental group to heat the quadriceps 3x per day for six weeks. The participants will be encouraged to heat before and after rehabilitation exercises as well.
45826679|NCT04571333|Device|Mi2000 Totally Implantable Cochlear Implant|During the surgery visit, the Mi2000 Cochlear Implant will be implanted according to the general surgical guidelines and the Mi2000 specific surgical guidelines under general anaesthesia.
45826680|NCT05563103|Other|Daily acute intermittent hypoxia|Each participant will be exposed to 8 sessions of daily acute intermittent hypoxia via air generators over the span of two weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02).
45969503|NCT04615702|Procedure|Endoscopic transmural cystogastrostomy|"for pancreatic pseudocyst Antibiotic prophylaxis with Ciprofloxacin 400mg IV /12 hour was administered before the procedure and continued for 5 days after the procedure At first the cyst morphology was evaluated by EUS and color Doppler ultrasound is used to identify nearby vessels The puncture was performed using a 19-gauge needle, which was introduced into the pseudocyst via a therapeutic linear array echoendoscope. Then, a 0.035-inch guidewire was introduced through the needle and coiled within the pseudocyst under fluoroscopic guidance.~The needle was removed and a 10F cystotome was advanced over the guidewire and the tract was dilated by the cystotome, after dilatation, a 10F double-pigtail stent was placed and a sample of the aspirate is sent for chemical and microbiological analysis"
45969504|NCT04615702|Procedure|open cystogastrostomy|"for pancreatic pseudocyst general anesthesia, 1 gm of cefotax was given IV at the induction of anaesthesia, supine position over the operating table A transverse supraumbilical incision was performed. A 5 cm horizontal anterior gastrotomy was performed (Image 23a). Hemostasis of the submucosal vessels was performed before the incision of the gastric mucosa.~First, the cyst was punctured followed by an incision of 5 cm at the posterior gastric wall. Aspiration of the cyst content was done for chemical and microbiological analysis The wall of the pseudocyst is hemmed to the gastric wall with continuous sutures made of a vicryl 2/0 alongside the entire circumference of the orifice Nasogastric tube was placed in the stomach. The procedure was completed by suturing the anterior gastrotomy with a vicryl 2/0 continous sutures in 2 layers A tube drain was inserted at the pelvis with closure of the abdominal wound in a standard way."
45969505|NCT04615702|Procedure|percutaneous catheter drainage (PCD) for infected necrosis|"PCD~The percutaneous drainage catheter placed through peritoneal approach under US guidance, the drain size was 12 F.~After placement of the percutaneous catheter, aspirate was sent for microbiological assessment~The PCD was flushed with 50 ml saline, three times daily to keep the drain open and improve lavage of the collection"
45969506|NCT04615702|Procedure|Endoscopic ultrasound (EUS) guided aspiration for infected necrosis|endoscopic approach it was done to one patient in the form of EUS guided aspiration of pus in a case with infected necrosis followed by percutaneous US guided aspiration of the residual
45969507|NCT04615585|Other|Aloe vera after SRP|Subgingival administration of Aloe vera gel was preceded by flushing the area with saline to wash away any debris. Aloe vera (1cc) gel was applied subgingivally using atraumatic needle. Patients were instructed not to rinse or drink any liquid for at least 30 minutes. The application was performed at baseline and after 1 and 2 weeks.
45969508|NCT04615585|Procedure|Scaling and root planing (SRP)|Removal of supragingival and sub-gingival calculus and debris was performed, followed by smoothing root surfaces and removing cementum or dentine that is impregnated with calculus and toxins.
46080912|NCT05636462|Other|Global postural re-education program|"Different postures of global re-education programs are used and stretch is applied in these postures.~3 sessions per week are given and each session time is 40 minutes. Treatment is given for 4 weeks."
46080913|NCT05636462|Other|Conventional Physical Therapy|Isometrics and stretching is used as conventional treatment. 3 sessions per week are given and each session time is 40 minutes. Treatment is given for 4 weeks.
46080914|NCT05636228|Drug|INV-102|INV-102 Ophthalmic Solution
46080915|NCT05636228|Drug|Vehicle|Vehicle Ophthalmic Solution
45826681|NCT05563103|Other|Room air (SHAM)|Each participant will be exposed to 8 sessions of daily room air via air generators over the span of two weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes of 1.5 minute normoxia (FIO2=0.21±0.02).
45826682|NCT05563103|Other|Walking + tSTIM|Individuals will participate in 45 minutes of gait training while having transcutaneous spinal cord stimulation. Stimulation intensity will be 80% involuntary motor threshold.
45826683|NCT05563103|Other|Walking + Sham transcutaneous spinal stimulation (tSHAM)|Individuals will participate in 45 minutes of gait training while having SHAM transcutaneous spinal cord stimulation. The stimulation will briefly increase to 80% involuntary motor threshold and then brought down to 0 within 30 seconds.
45826684|NCT05545319|Drug|Nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to <60 mL/min) every 12 hours
45826685|NCT05545319|Drug|Ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
45826686|NCT05545319|Drug|Placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to <60 mL/min) every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
46080916|NCT05633186|Behavioral|Moodbuster Life|All participants get access to the Moodbuster Life intervention. Moodbuster Life is an online self-help intervention that contains 5 web-based modules focusing on lifestyle and coping: psycho-education, behavioral activation, physical activity, problem-solving, and worrying. All participants start with module 1, psycho-education. Next, participants can choose what module they wish to continue with. All modules take about 45 minutes to complete and contain text, exercises, video clips and preparing the home-work assignments. Executing the home-work assignments may take 20 minutes each week.
45826687|NCT05446337|Other|Open-Ended Semi-Structured Interview|Examine the participation and engagement in the Diabetic Foot Care and Limb Preservation Pathway design and implementation; identifying barriers and facilitators of the process
45826688|NCT05536427|Biological|IPM001|IPM001 will be used against tumor cells
45826689|NCT05747183|Procedure|ProTaper Ultimate|Root canal preparation using ProTaper Ultimate files.
45826690|NCT05747183|Procedure|ProTaper Gold|Root canal preparation using ProTaper Gold files.
45826691|NCT05526287|Other|Dual-Task Training|"Dual-task training sessions include; walking on treadmill for 10-30 minutes and half of this walking period participants will perform cognitive tasks, cognitive tasks will be repeated on tandem stance position and single leg stance position other half of the session consists of motor-motor dual task activities and gait training on firm and soft surfaces.~Home exercise program includes lower extremity, core stability and balance exercises and will be performed three times a week."
45826692|NCT05526287|Other|Home Exercise Program|Home exercise program includes lower extremity, core stability and balance exercises and will be performed three times a week.
45826693|NCT05526053|Other|Lung volume preservation|Extubate the patient connected to the ventilator and PEEP of 5 cmH2O after a successful SBT also using PEEP.
45969509|NCT04615468|Drug|TQ-B3525|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
45969510|NCT00221741|Drug|Fresh Frozen Plasma (blood product)|
45826694|NCT05523869|Drug|Intravitreal topotecan|Patients meeting all inclusion criteria and not meeting exclusion criteria will be assigned to receive pars plana vitrectomy with or without scleral buckle with intravitreal topotecan 8 µg/0.1mL, administered preoperatively within one week from surgery, intraoperatively during surgery, as well as postoperatively at 2 weeks, 4 weeks, 8 weeks, 12 weeks and 16 weeks, for a total of 7 injections.
45826695|NCT05523869|Procedure|Pars plana vitrectomy with or without scleral buckle|Standard three-port pars plana vitrectomy with or without scleral buckle.
45969511|NCT04615546|Behavioral|Use of Continuous Glucose Monitor (CGM)|Participants will wear CGM
45969512|NCT04615546|Other|Use of Cardea Solo monitoring|Participants will wear a Cardea Solo patch during blinded CGM use
45969513|NCT04615858|Dietary Supplement|Genepro Generation 3 Protein|Generation 3 Genepro Protein. Micronized protein. Zero lactose. No gluten. All Natural. No flavor. No Sugar. FODMAP Certified protein. 11g in weight, scoop.
45969514|NCT04615858|Dietary Supplement|Whey Protein|Nutrition industries number 1 selling whey protein powder. No flavor. Gluten Free. 30g scoop.
45969515|NCT04615351|Drug|Metformin|Medication
45969516|NCT04615156|Drug|18F-2-fluoro-2-deoxy-D-glucose|Administration of 18F-2-fluoro-2-deoxy-D-glucose for the purposes of diagnosis.
45969517|NCT00221780|Device|left ventricular pacing|
45969518|NCT04615312|Drug|a CDK4 / 6 inhibitor and a MEK inhibitor|Participant will receive a CDK4 / 6 inhibitor and a MEK inhibitor treatment to determine the maximum tolerated dose
45969519|NCT04614961|Other|Lifestyle therapy - individual|Individual therapy
45969520|NCT04614961|Other|Lifestyle therapy - group|Group therapy
45969521|NCT04614961|Other|Medical therapy|Medical therapy
45969522|NCT04614961|Procedure|Bariatric surgery|Surgical and endoscopic therapy
45969523|NCT04618666|Procedure|laparoscopic and open surgery intervention|laparoscopic and open surgery to remove an inflammed appendix in chronic appendicitis
45969524|NCT00251121|Other|Mini-invasive electrophysiological study|Transvenous pacing in right heart atrium
45668835|NCT05812898|Other|exercises|strengthening of the gluteus maximus and medius, calf muscles stretching for calf and hamstring muscles
45668836|NCT05812898|Other|myofascial release|myofascial release using instrument assisted soft tissue mobilization
45668837|NCT05812885|Device|TENS|Active TENS
45969525|NCT00251121|Other|Atrial pacing|Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
45969526|NCT04614883|Device|Volatile Organic Compounds analysis|VOC analysis in exhaled air with e-noses and mass spectrometry. VOC analysis in sweat with mass spectrometry.
45668838|NCT05812872|Drug|Toothgraft|Particulate dentin
45668839|NCT05812872|Drug|Allograft|Mineralized corticocancellous allograft
45668840|NCT05812872|Drug|Alloplast|Beta tri-calcuim phosphate
45668841|NCT05812859|Device|Vaginal Orthosis (COSM Medical)|A vaginal orthosis will be 3-D printed by COSM Medical and provided for patients to use from week 2 through week 12 post-operatively. Device will be placed in morning and removed before bed daily.
45668842|NCT05812833|Behavioral|Education|Pregnant women will be given online baby care training
45969527|NCT04614883|Other|Canine odor detection of Volatile Organic Compounds|VOC analysis in sweat by trained dogs.
45969528|NCT00221819|Device|heated humidifier (device)|
45969529|NCT00221819|Device|Heat and moisture exchanger (device)|
45969530|NCT04614727|Combination Product|polymeric nano calcium fluoride containing varnish NANO SEAL|It consists of four components Silicone polymer provides excellent adhesion to enamel and dentine, with transparent formula. NANO-fluoroapatite flows into enamel micro cracks & seals it, penetrating into the dentinal tubules closing them eventually. As for the NANO-calcium fluoride it behaves as a fluoride reservoir, provides gradual and long-term fluoride release. The fourth component Amine fluoride (Olaflur) provides immediate fluoride ion release and accelerates natural remineralization.
45969531|NCT04614415|Device|Autocrosslinked Hyaluronic aid|IAL-SYSTEM ACP gel is an auto-cross-linked HA derivative in the form of highly viscous gel. In this direct formation of ester linkages no foreign substances are introduced into the molecule, thus catabolism of ACP leads only to HA
45969532|NCT04614415|Other|placebo|The placebo consists in an isotonic saline solution (NaCl 0.9%)
45969533|NCT04614688|Behavioral|Patient Education Platform|The patient education platform for hysteroscopy surgery is a website platform which has patient education materials regarding hysteroscopy procedures in the format of pictures, videos, and text. Information on this platform includes anatomy of the surgery area, what to expect, reasons for the surgery, ways to prepare for the surgery, and recovering from the surgery.
45969534|NCT00247923|Procedure|Hysteroscopic resection of endometrial polyps. (TCRP)|
45969535|NCT04614298|Drug|KHK4827-Active|Single SC administration
45969536|NCT04614298|Drug|KHK4827-Placebo|Single SC administration
45969537|NCT04613986|Device|therapeutic plasmaexchnage|established method to exchange plasma (in order to remove injurious disease mediators, e.g. antibodies) or to replace consumed factors (e.g. vWF cleaving proteases)
45969538|NCT04614259|Drug|Bupivacain|"The infraorbital foramen was located at the floor of the orbital rim at about the level of the pupil,The upper lip was folded back and a finger is placed externally at the level of the infraorbital foramen to prevent the needle from the cephalad insertion in the globe of the eye. A 27-gauge needle was bent about 70 degree to ease the insertion through the buccal mucosa over the maxillary process, towards the infraorbital foramen.~After careful aspiration the local anesthetic was injected (injection of 3 ml 0.25% bupivacaine in 1:200.000 adrenaline ,1.5 ml on each side). [104] Pressure was needed to be applied for one minute to the area as there is loose adventitious tissue that can lead to swelling and ecchymosis"
45969539|NCT04614259|Combination Product|i.v. analgesia|"Using inhalational induction with sevoflurane as tolerated , atracurium 0.5mg/kg to facilitate endotracheal intubation and fentanyl 1 mcg/kg ,Mechanical ventilation was adjusted to maintain 30 to 35 mmHg end-tidal carbon dioxide, anesthesia was maintained with 1.5 % isoflurane and atracurium (0.1 mg/kg every 30 minutes) ,all patients were received intraoperative diclofenac sodium 0.5 mg/kg intramuscular .~Blood pressure and heart rate were measured 5 minutes after endotracheal intubation and every 15 minutes till recovery from the anesthesia then every 15 min in the postoperative care unite for 30 minutes"
45969540|NCT00251160|Procedure|Electrothermal arthroscopic capsulorrhaphy (ETAC)|The Oratec Vulcan Generator electro-thermal system (Oratec Interventions Inc., Menlo Park, CA, USA) delivers heat at 75C and 40 watts. An anterior portal is established above the superior border of the subscapularis tendon. For MDI patients, the heat probe is introduced through the posterior portal. The capsule is shrunk using a grid pattern until excess volume is diminished. The extent of the heat probe application is identical to the landmarks used for the open ICS. Care is taken to avoid applying heat to the capsule in the region from 5-7 o'clock within 1cm of the glenoid rim to avoid the axillary nerve. The method of heat application utilizes a grid pattern, which is less likely to cause dissolution of the capsule and subsequent catastrophic capsular loss.
45969541|NCT00251160|Procedure|Open inferior capsular shift (ICS)|MDI: lateral capsule released antero-superiorly from rotator interval to equator, posteriorly on the humeral neck. MDL-AII: release from the rotator interval to 7 o'clock (Right) or 5 o'clock (Left) position on humeral neck, to tighten the 2 bands of the inferior GH ligaments, middle GH ligament and rotator interval. Bone adjacent to the articular surface on the surgical neck of the humerus is roughened to create a bleeding bony bed. With the arm in 0deg flexion, 30deg abduction, 30deg external rotation, the inferior leaflet of the capsule is shifted superiorly and slightly laterally, and sutured to the rim of the capsule using a non-absorbable suture. Superior leaflet is shifted inferiorly and sutured. Subscapularis is repaired at its anatomic length using interrupted sutures.
45969542|NCT00563329|Procedure|Reduction Intervention + Adherence Intervention|
45969543|NCT00563329|Behavioral|Reduction Intervention|
45969544|NCT00563329|Procedure|control|
45969545|NCT04613908|Device|neuro muscular electro stimulation|We used a commercial equipment of electro stimulation with a pulse width of 300 micro seconds, a frequency of 50 Hz, with symmetrical balanced biphasic rectangular wave and with an intensity of up to 80 milliampere.
46080917|NCT05633186|Behavioral|Mobile application|The participants randomized to receive this component will receive access to a mobile application. The aim of this app is two-folded, (1) used for diary ratings, (2) sending out personalized automated messages. First, the participants will rate their mood, sleep and related factors on a daily basis. The participants are prompted to rate the diary ratings three times a day (morning, afternoon, evening). Moreover, the application graphically pictures progression over time. Second, the application will send personalized automated messages. The content of the messages is informative, affirmative or encouraging. The investigators will use reinforcement learning (RL) to find so-called policies that show best long-term engagement and most sustained improvement of participants' mood. To drive choices, the investigators will use the data mentioned in the advising for the modules as well as behavioral data (mood ratings), data across all users is exploited.
46080918|NCT05633186|Behavioral|Guidance by a coach|A coach will provide support once per week at a scheduled time to participants who are allocated to receive support. The coaches are psychologists who are not part of the research team. The support will be provided via the Moodbuster Life messaging system and is focused on helping the participant work through the modules, showing empathy and motivating the participants to continue with the modules. The coaching is not aimed at developing a patient-therapist relationship.
45826696|NCT05523557|Behavioral|Urban Training|1) one-to-one motivational interview for a maximum of 1h; 2) exercise following a dossier containing various maps of Urban Training walking trails, previously used in patients with COPD with a recommendation of doing a minimum of 1 circuit/day; or in case of living faraway from Urban Training walking trails, the instructions will be to walk at least 30 minutes per day ⩾5 days per week, at a pace reaching a dyspnoea Borg scale score of 4 -6; 3) a FitBit Inspire (FitBit, San Francisco, United States) to obtain direct feedback on the step count and intensity of PA; and 4) a motivational follow-up visit, in group, once per month during the follow-up period.
45826697|NCT05522465|Drug|Prednisone|Prednisone 4mg/kg.d, d1-4
45668843|NCT05812820|Combination Product|LiveSpo DIA30|LiveSpo® DIA 30 has a registration number: 6547/2019/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
45668844|NCT05812820|Combination Product|LiveSpo CLAUSY|LiveSpo® CLAUSY has a registration number: 4071/2021/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
45668845|NCT05812820|Other|RO|"Aquafina's distilled water and reverse osmosis (RO) water, produce by PepsiCo, have both obtained ISO 9001:2015 and ISO 22000:2018 certifications, which are internationally recognized standards for quality management and food safety management systems, respectively.~The RO water ampoules are produced using a similar process as the LIVESPO DIA30/CLAUSY but contain 5ml of high-quality distilled water from Aquafina in an opaque plastic bottle"
45668846|NCT05812807|Biological|Pembrolizumab|Given IV
45668847|NCT05812807|Other|Patient Observation|Undergo observation
45668848|NCT05812807|Procedure|Biopsy|Undergo biopsy
45826698|NCT05522465|Drug|Dexamethasone|Dexamethasone 0.6mg/kg.d, d1-4
45826699|NCT04428047|Drug|bintrafusp alfa|bintrafusp alfa will be administered by intravenous infusion over 60 minutes at a dose of 1200 mg on Day1 and Day15
45969546|NCT04613908|Other|Early Mobilization protocol|"The protocol consisted in applying a specific treatment based on different levels of treatment to each subject. Admission to them was carried out according to the maximum capacity of each subject, the conditions of each level being the following:~Level 1: MRC (shoulder) <3 + MRC <3 (hip).~Level 2: MRC (shoulder) ≥ 3 + MRC (hip) <3.~Level 3: MRC (shoulder) ≥ 3 + MRC (hip) ≥ 3 + sitting on the edge of the bed without assistance (minimum 15 minutes).~Level 4: Standing without assistance and walking with or without assistance."
45969547|NCT04613908|Other|standard care or usual rehabilitation|routine, non-protocolized rehabilitation treatment performed by the physiotherapist assigned to intensive care
45826700|NCT05248061|Other|Group A|"Wand exercises; It will be applied to increase the normal range of motion of the joint. Exercises will be performed in the directions of shoulder flexion, abduction, external and internal rotation. Objects such as a round stick, walking stick and towel can be used to assist patients during exercise.~- *Pendulum (Codman) Exercises: These exercises will be applied in 90° flexion of the waist, with the healthy hand resting on a solid place, and turning the arm back and forth, to the sides, clockwise and counterclockwise with circular movements.~*Capsule stretching: Auto stretching (by the patient) will be applied to the posterior region of the shoulder (capsule), pectoralis minor and upper trapezius muscles.~*Isometric shoulder exercises Isometric exercises will be given in the directions of shoulder extension, abduction, external rotation and internal rotation."
45969548|NCT00412763|Drug|Silymarin (Silybum marianum)|
45969549|NCT00251199|Drug|VX-950|
45969550|NCT00251199|Drug|peginterferon|
45969551|NCT04614181|Dietary Supplement|Nestle Resource drink|Beverage (Nestle RESOURCE). Each serving is 237ml containing 53.6g of carbohydrate and 9g of protein. Intervention group will consume two servings of the carbohydrate beverage (53.6g each, total of approximately 100g) on the day before surgery and one serving up to 6 hours prior to scheduled surgery time.
45969552|NCT04614181|Other|Usual care|Usual fracture care as determined by clinical team
45969553|NCT04613635|Device|Stratafix|Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Stratafix USP (United States Pharmacopoe) 2-0 thread
45969554|NCT04613635|Device|Vicryl|Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Vicryl USP 2-0 thread
45969555|NCT00563446|Drug|Darbepoetin alfa|
45668849|NCT05812807|Procedure|Biospecimen Collection|Undergo collection of blood
45668850|NCT05812807|Other|Questionnaire Administration|Ancillary studies
45969556|NCT00563485|Drug|Doxazosin GITS (Cardura XL)|
45969557|NCT00563485|Drug|Terazosin (Hytrin)|
45969558|NCT00251277|Drug|Rituximab|Rituximab will be administered immediately after pheresis to minimize the amount of Rituximab that is removed by the subsequent days pheresis. The guidelines will be that 12 hours must elapse between the end of the first infusion of study drug and the next pheresis. Subsequent infusions would be weekly (plus or minus 2 days) with an attempt made to give study drug infusions after a pheresis that might be the last in a series, i.e. when no pheresis would be scheduled for at least the next day.
45668851|NCT05812807|Other|Quality-of-Life Assessment|Ancillary studies
45668852|NCT05812794|Device|Transcranial Direct Current Stimulation (tDCS)|"Participants will come for 5 sequential days of 2 hour long occupational therapy sessions augmented by tDCS for the first 20 minutes of the session. At arrival, the stimulation safety sheet will be completed by the occupational therapist.The saline soaked electrodes will be placed on the study subjects head and connected to the Soterix 1x1 Limited Total Energy (LTE) enabled tDCS device. Current output through the device will be sham stimulation on day 1 , followed by steady increases to a maximum of 1milliampere (mA) in patients aged 5-12 years old, and 1.5 mA in patients aged 13-19 years old, per the study design flow sheet at the end of this protocol. Blood pressure, pulse rate, and peg-board scores will be recorded as indicated on the stimulation safety sheet during each session.A repeat assessment will be done by the occupational therapist one week post therapy completion.There will be a repeat assessment visit 3 months post intervention."
45969559|NCT00412802|Drug|dose adaptation of Enoxaparin|A same initial dose of 1 mg/kg will be administrated to all patients. According to creatinine clearance, the next doses (every 12 hours subcutaneously) will be adjusted with a 25% dose reduction if creatinine clearance is comprised between 30 and 50 ml/min.
45969560|NCT00412802|Drug|normal injection of Enoxaparine|No dose adaptation of Enoxaparine
45969561|NCT00563524|Drug|ILV-094|SC and IV administration on days 1, 14, 28, and 42
45969562|NCT04613869|Drug|High-dose Esketamine hydrochloride+Hydromorphone|By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
45668853|NCT05812781|Drug|VTX2735|Dose A
45969563|NCT04613869|Drug|Low-dose Esketamine hydrochloride+Hydromorphone|By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
45969564|NCT04613869|Drug|Hydromorphone|No esketamine added
45969565|NCT04613557|Biological|CYAD-211|Allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell
45969566|NCT04613557|Drug|Endoxan|Preconditioning chemotherapy
45969567|NCT04613557|Drug|Fludara|Preconditioning chemotherapy
45969568|NCT00251355|Drug|Gemcitabine|Gemcitabine, IV bolus administered weekly (weeks 1-6) at least 4 hours before that day's radiation therapy.
45969569|NCT00251355|Drug|5-Fluorouracil|5-FU via continuous IV infusion.
45969570|NCT00251355|Procedure|Radiation Therapy|External Beam Radiotherapy (weeks 1-6), Monday through Friday.
45969571|NCT02962388|Drug|Anagrelide|Anagrelide in the study, according to the investigator decision fom day 1 to 48 months
45969572|NCT02962388|Drug|Ruxolitinib (JAKAVI®)|Ruxolitinib (JAKAVI®) - Novartis. Tablets 5 mg. Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing Maximum dose 25 mg BID. fom day 1 to 48 months
45969573|NCT02962388|Drug|IFNα/ PegIFNα|IFNα/ PegIFNα in the study, according to the investigator decision fom day 1 to 48 months
45969574|NCT04613167|Drug|Alirocumab|The first group will receive alirocumab. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
45969575|NCT04613167|Drug|Evolocumab|The second group will receive evolocumab. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
45969576|NCT04613167|Drug|Control group|The third group will receive only optimal guidelines-based secondary preventive treatment. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
45969577|NCT04613284|Drug|Recombinant human endostatin (Endostar)|Continuous intravenous infusion of endostar (Simcere Pharma- ceutical, Nanjing, China) was made over 120 h before the begin- ning of radiotherapy, and then repeated every two weeks. The dose was 7.5 mg/m2/24 h 120 h, 14 days/cycle. ECG monitoring was performed during the first delivery of endostar.
45969578|NCT04613284|Radiation|Thoracic irradiation of 50 Gy with 3DCRT or IMRT|Concurrent thoracic chemoradiotherapy with reduced irradiation dose of 50 Gy will be given to patients with unresectable stage III NSCLC who can not tolerate irradiation dose to 60 Gy.
45969579|NCT00248079|Device|Coronary Artery Stenting|Initial implant of drug eluting stent (zotarolimus)
45668854|NCT05812781|Drug|VTX2735|Dose B
45668855|NCT05812768|Device|Suture-Tight Suture Delivery System|Implantation of the Suture-Tight Suture in the deployment of multiple nitinol sutures to provide augmented fixation and sealing between endovascular aortic graft and the native artery.
45668856|NCT05812742|Behavioral|Early intervention programme|For more information, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).
45668857|NCT05812742|Behavioral|Enhanced usual care|For more information, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).
45826701|NCT05248061|Other|Group B|"The same exercises as in Group 1 will be suitable for the participants.~PRP will be applied in the first session and 2 weeks later. Exercises will be started 2 days after PRP application.~Up to 10 cc of blood will be taken from the PRP group patients by the nurse. 25 mL of venous blood will be collected from each patient at a time, using a syringe containing 2.5 mL of the anticoagulant citrate dextrose solution. After the blood taken is transferred to the special PRP kit and centrifuged for 8 minutes at 3000 rpm, in addition to the 5-6 cc platelet-rich plasma remaining in the upper part of the kit, the entire buffy coat is injected into the syringe from the region compatible with the posterior arthroscopy portal (inferior to the acromion posterolateral bone prominence) by the physician. next, from the end point of the posterior fibers of the deltoid muscle, targeting the subacromial space) will be applied. No buffering or activating agents will be used for PRP."
45826702|NCT05236127|Device|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
45969580|NCT00221858|Procedure|Ultrasound guided blocks|
45969581|NCT04613401|Other|questionnaire (observational study)|questionnaire about hospitalisation rates, complications (bleeding, infection, thrombosis), quality of life (Kansas-Score), depression (PHQ8)
45969582|NCT00563602|Other|Hemodynamic guided therapy|"To switch two or more different treatments for the prevention of variceal rebleeding according to the hemodynamic response. All patients in the experimental group will begin by:~1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)"
45969583|NCT00563641|Other|Very early surfactant and bubble NCPAP|For patients randomized to early NCPAP plus surfactant, 4ml/kg of surfactant were administered through an endotracheal tube in two aliquots, 2 minutes apart followed by positive pressure ventilation administered for one minute with a Neopuff Infant Resuscitator pre-set to give a peak pressure of 20 cm H2O and 5 cm H2O of positive end expiratory pressure. Infant was then extubated and placed on NCPAP of 6 cmH2O
45969584|NCT00563641|Other|bubble NCPAP|"Premature infants randomized to bubble NCPAP alone will continue on NCPAP until they reach yes or no treatment failure criteria."
45969585|NCT00248118|Drug|Bupropion|During treatment phase, participants will take 300 mg bupropion or placebo daily.
45668858|NCT05812729|Behavioral|resiLIR Basic|"Each module contains psychoeducational elements as well as practical exercises.~Week 1: Introduction + Stress and resilience~Week 2: Optimism~Week 3: Mindfulness~Week 4: Sense of coherence and values~Week 5: Acceptance~Week 6: Self-compassion + Conclusion"
45668859|NCT05812716|Behavioral|resiLIR Healthcare Professionals|"Weeks 1 and 2: Theoretical part on stress, resilience, self-care, and self-compassion~Weeks 3 to 6: Training phase of a weekly introduced practical exercise (reflection on living with ease, self-compassionate body scan, planning of positive activities, self-compassionate letter). This phase additionally includes smartphone reminders to apply the exercises in everyday life."
45668860|NCT05812677|Drug|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
45826703|NCT05236127|Procedure|Intermittent Fasting|The purpose of this study is to examine the effect of intermittent fasting on the acute neural responses to subconcussive head impacts. The study is designed to identify the effects of 20 controlled soccer headings in college-aged soccer players in one of four groups (fasted, pre-fasted, post-fasted, or control) through the use of neural-injury blood biomarkers, magnetic resonance spectroscopy, functional, and diffusion MRI, and ocular-motor function across 4 acute time points. Participants will be randomly designed to one of the four groups which consist of an 8 day fast, 5 day fast, 3 day fast, or the non-fasted control group.
45826704|NCT05233865|Behavioral|Water exercise|Participants will be asked to sit and stand multiple times (before, immediately after, and 2 hours after a 15-minute walking session). The walking session will consist of 3 minutes of walking at a light intensity followed by 9 min of walking at a moderate intensity and a 3-minute cool down walking at a light intensity. This walking session will occur in a pool.
45969586|NCT04613011|Device|Ultrasound|Checking vein width snd copression using US
45969587|NCT04612894|Drug|Camrelizumab and Apatinib|All patients will receive Camrelizumab and Apatinib for at least two cycles of neoadjuvant treatment
45969588|NCT04612894|Procedure|surgery|Perform surgery if operable after neoadjuvant therapy
45969589|NCT04612894|Procedure|core needle biopsy|Perform core needle biopsy if inoperable after neoadjuvant therapy
45969590|NCT00251394|Drug|Rituxan|Given intravenously once weekly for four weeks.
45969591|NCT00251394|Drug|1018 ISS|Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given.
45969592|NCT00221936|Behavioral|Self-administration or nurse administered medication|
45969593|NCT04612777|Behavioral|Opening Doors to Recovery|Opening Doors to Recovery (ODR) was created by a large, collaborative group in southeast Georgia as a recovery-oriented approach that navigates clients into services that may in some cases be fragmented and seemingly inaccessible. The team of three Community Navigation Specialists (CNSs) strives to help clients reduce institutional (e.g., hospital, jail) recidivism and embrace recovery. Their process of community navigation is a broader function than traditional case management as it includes mapping out and connecting clients to all available local resources, which requires being embedded in the community. The work of the CNSs benefits from commitments of diverse collaborative ODR partners, including local treatment providers, law enforcement, employers, and housing programs. Each CNS was expected to meet with the client at home or in community settings at least monthly, with the client having contact with at least one CNS weekly.
45969594|NCT04612777|Behavioral|Case Management|Case Management (CM) services, as defined by the State mental health agency, consist of providing essential environmental support and care coordination to assist the individual with improving his/her functioning, gaining access to necessary services, and creating an environment that promotes recovery as identified in his/her Individual Recovery Plan (IRP). The focus of interventions include assisting the individual with: (1) developing natural supports to promote community integration, (2) identifying service needs, (3) referring and linking to services and resources identified through the service planning process, (4) coordinating services identified on the IRP to maximize service integration and minimize service gaps, and (5) ensuring continued adequacy of the IRP to meet his/her ongoing and changing needs. Contact must be made with the individual ≥2 times per month, at least one of which must be in-person, in a non-clinic setting.
45969595|NCT04612777|Behavioral|Intensive Case Management|Intensive Case Management (ICM) is very similar to CM, but four in-person visits are required monthly. Additional contacts may be either face-to-face or via telephone, depending on the individual's needs. At least 60% of total contacts must be face-to-face with the individual, and at least 50% must be delivered in non-clinic/community-based settings. An ICM team includes nine professionals: a licensed clinician, four masters-level clinicians, two bachelors-level clinicians, and two paraprofessionals. The team's maximum case load is 200 in rural settings and 300 in urban settings (22-33 per team member).
45969596|NCT04612543|Device|Genial Posterior Composite with Polyethylene Fiber|Placing restorations,Genial Posterior Composite with Polyethylene Fiber, after bonding procedures, remaining tooth composite resin walls were created and cured for 20 s. Prepared ribbond fiber pieces, 2-mm-wide approximately 12mm-long, (Ribbond Thinner, Higher, Modulus, Ribbond Inc,Seattle) were wetted with an unfilled resin for 2 minutes at a non-light environment. The inner surfaces of the prepared class I cavity were lined with flowable resin. After removing the excess resin, pre-wetted polyethylene fiber was condensed circumferentially and embedded with a hand instrument into the bed of unpolymerized flowable composite and then polymerized for 20 seconds with Light Emitting Diodes. After curing for 20 s, composite resin was applied to the rest of the cavity incrementally, each increment was cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
45969597|NCT04612543|Device|Genial Posterior Composite|Placing Genial Posterior Composite, the enamel and dentin were conditioned with bonding procedure using an applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Genial Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments
45969598|NCT04612816|Other|Prehospital ultrasound|Feasibility of real time PEU transmission in a university affiliated preclinical emergency system.
45969599|NCT02961387|Device|Hydrogen generator treatment|The patients mainly used the hydrogen generator with nebulizer for inhalation of hydrogen-oxygen mixed gas.
45969600|NCT02961387|Device|Oxygen-making machine treatment|The patients mainly used medical molecular sieve oxygen-making machine for oxygen inhalation.
46080919|NCT05633186|Behavioral|Motivational Content|Participants who are randomized to this component, receive access to extra content that is based on the principles of motivational interviewing. This includes an extended first module that contains psychoeducation on the importance of motivations and on how persons can motivate themselves to engage with the interventions. Participants are asked about their life goals (long term) and intervention goals (short time) and are guided in how they should formulate these goals to increase the chance of success. Moreover, in each of the 4 modules a short exercise aimed at increasing motivation is included.
45826705|NCT05233865|Behavioral|Land exercise|Participants will be asked to sit and stand multiple times (before, immediately after, and 2 hours after a 15-minute walking session). The walking session will consist of 3 minutes of walking at a light intensity followed by 9 min of walking at a moderate intensity and a 3-minute cool down walking at a light intensity. This walking session will occur on land.
45969601|NCT04612465|Biological|ASC|"Injection of ASC(Autologous Adipose-derived Mesenchymal Stem Cells) to Crohn's Fistula.~The ASC injection dose is about 1x10^7 cells of ASC per 1cm^2 of the surface area of the fistula, and the additional injection dose is 1.5 times the initial injection dose. and up to 30% of the ASC injection dose is administered in combination with Fibringlu."
45969602|NCT04612465|Drug|Fibringlue|Injection of Fibringlue to Crohn's Fistula. The Fibringlu injection dose is given the size of the fistula that is fill the entire fistula, and the additional injection dose is the same.
45969603|NCT00221975|Drug|Divalproex|Once a therapeutic blood level of lithium was achieved, Divalproex was initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL.
45969604|NCT00221975|Drug|Lamotrigine|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL.
45668861|NCT05812664|Other|enteral feeding|The amount of enteral nutrition that should be given daily was calculated by the nutritionist using the Harris-Benedict formula. Formula at room temperature was given with a nasogastric foley catheter and a feeding pump. The position of the nasogastric Foley catheter in the stomach was confirmed by the PAAC graph when it was first inserted, and by listening before each feeding. Feeding was done in a position with the head at 30 degrees.
45969605|NCT00221975|Drug|Lithium|Subjects who did not respond to the combination of Lithium and Divalproex were then randomly assigned in a 1:1 ratio to adjunctive lamotrigine versus placebo after stratification by illness type (bipolar I versus bipolar II), historical response to lithium (response versus oon-response), and the length of current exposure to the combination treatment with lithium and divalproex (<2 months versus ≥2 months).
45668862|NCT05812664|Procedure|blood glucose measurements|Blood glucose values were measured in all groups at 06:00, 12:00, 18:00 and 24:00, 4 times a day for 7 days. The sample was taken from the patient's cannula and examined in the biochemistry lab. The targeted range in the measurements was accepted as 70-180 mg/dl.
45826706|NCT05230277|Other|the active osteopathic treatment (AOT)|The AOT will first consist of the application of a visceral technique. The patient will lie on their stomach and the osteopath will touch the patient's abdomen with a wide two-handed grip. The action will consist of following the abdominal tissues in directions where tissue mobility is allowed and occurs without restriction, from the surface to the depth of the abdomen. A change in the elasticity of the colon will then be perceived when the mobility restrictions of the tissues are dissipated. The osteopath will then use a technique on the sacrum according toik-g the procedure described by Attali et al. [8] which consists in mobilizing the sacrum between the iliac bones.
45826707|NCT05230277|Other|the sham osteopathic treatment|For SOT, the patient will lie on their stomach and the osteopath will use a wide two-handed grip on the patient's abdomen to deliberately mobilize it in an imprecise manner. Next, a technique with no apparent therapeutic effects, the light touch, first described by Licciardone et al. [13] and proposed by others to perform simulated bone manipulations [14], will be applied to the sacrum
45826708|NCT04835675|Device|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
45826709|NCT05218187|Device|G-EO End-Effector Gait Trainer|The G-EO Gait Trainer uses distal fixation to promote a gait recovery by facilitating a controlled walking environment that includes an over-ground pattern and stair climbing. In addition, the device provides body position control to enable the patient to concentrate on the cyclical motion of walking without the fear of falling. Physical therapists can control different parameters of the gait cycle through computerized adjustments and the training setting can be manipulated to engage patients in active participation.
45826710|NCT05218187|Other|Conventional Physical Therapy Treatment|Therapists will use traditional methods of neurological rehabilitation for improved gait and balance. These approaches will include stretching, strengthening, therapeutic exercises, balance training, and over-ground walking
45969606|NCT04612582|Drug|Thalidomide|Bortezomib (d 1, 8, 15, 22, 1.3mg /m2, subcutaneous injection); thalidomide (d 1-28 50-100mg, oral); dexamethason (d 1, 2, 8, 9, 15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, the patients will complete six courses of treatment after entering the group, and the total observation time is one year after the end of treatment.
45969607|NCT04612582|Drug|Cyclophosphamide|Bortezomib (d 1, 8, 15, 22,1.3mg / m2, subcutaneous injection); cyclophosphamide (d 1, 2,900mg / m2, intravenous drip); dexamethason (d 1, 2, 8, 9,15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, patients will complete six courses of treatment after entering the group, the overall observation time is one year after the end of treatment.
45969608|NCT00248157|Drug|Octreotide acetate in microspheres|
45969609|NCT04612855|Other|Groupwise comparison of primary and secondary outcomes|Statistical comparison of cohorts. Cfr supporting information on statistical plan.
45969610|NCT00222014|Procedure|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
45969611|NCT00222014|Procedure|Paracenthese|Paracenthese
45969612|NCT04612426|Device|Brain-computer Interface-Pedaling Training System|The Brain-computer Interface-Pedaling Training System includes four parts: computer, monitor, EEG testing equipment and pedaling training equipment. The patient wears an EEG detection device, which calculates brain movement participation every 0.5 seconds. The system will provide real-time visual/auditory/somatosensory feedback to patients based on the results of participation, so that patients can participate in motor function training more attentively.
45969613|NCT04612426|Device|Traditional Pedaling Training System|The patient will wear the same EEG equipment that will only collect data, but not guide training.
45969614|NCT04612504|Biological|SynOV1.1|SynOV1.1 will be administered intratumorally.
45969615|NCT03454321|Other|Infiltration|The subacromial injection will be performed under ultrasound guidance to accurately inject the subacromial bursae. After skin disinfection with povidone, the injection will be performed with a 21G needle. The bursae will be injected with 2 ml of lidocaine 2% and 1 ml of betamethasone.
45969616|NCT00251472|Drug|Paclitaxel Albumin Nanoparticle for Injectable Suspension|125mg/m2 by 30-minute IV infusion, once a week.
45969617|NCT04612270|Other|Venous blood collection|Two venous blood collections in within one week. No drug-related intervention in-vivo.
45668863|NCT05812664|Procedure|Evaluation of feeding intolerance with gastric residue|gastric residue assessment; 30 minutes after the feeding was stopped, the N/G tube was drained and the amount coming 30 minutes later was evaluated. Residue positive was defined as the return of more than half of the amount of formula in the last cycle. The same was continued without increasing the amount given. If the incoming amount was less than half, the residue was evaluated as negative and the formula was continued by increasing the predetermined amount.
45668864|NCT05811624|Behavioral|Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy.|"14 weeks, 18 treatment sessions~This includes:~3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~15 sessions which will focus simultaneously on cognition-targeted exercise therapy and behavioral weight reduction. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful. The behavioral weight reduction program includes a lifestyle approach, with changes in diet, behavior, and a physical exercise weight loss program, all aiming for a caloric deficit of 500 to 700 kcal/day."
45668865|NCT05811624|Behavioral|Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone.|"14 weeks, 18 treatment sessions~This includes:~3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~15 sessions which will only focus on cognition-targeted exercise therapy. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful."
45826711|NCT05217953|Device|LovedBy App|The LovedBy solution aims to leverage modern technologies such as smartphones, continuous glucose monitors (CGM), and other smart wearables to assist young sufferers managing their condition. The LovedBy platform offers a mobile application which connects to the user's smart wearables and CGM to monitor data streams that have been linked to long term risk. The mobile application is then able to deliver personally relevant educational content to the user through numerous channels including private social media message
45826712|NCT05215691|Procedure|Group I: TAPA block|Postoperative analgesia will be provided with peripheral nerve block (TAPA)
45969618|NCT00222053|Drug|Thalidomide|Per os thalidomide
45969619|NCT00222053|Drug|Biphosphonates|Biphosphonates
45969620|NCT04612153|Other|Epidemiologic|Epidemiologic study. Observational, transverse study
45969621|NCT00251511|Drug|Arsenic Trioxide|
45668866|NCT05811403|Other|Epigallocatechin gallate (EGCG)|Epigallocatechin gallate (EGCG) is a white powder that can be obtained from tea leaves. It accounts for 50-60 % of catechin content of tea polyphenols with a wide range of biological activities including antioxidant, antimicrobial, anti-inflammatory, immune regulatory, anti-tumour effects.
45668867|NCT05811403|Other|Sodium hypochlorite (NaOCl)|Sodium hypochlorite (NaOCl) is an excellent non-specific proteolytic and antimicrobial agent that provides disinfection of the dentin-pulp interface.
45668868|NCT05811403|Other|Mineral trioxide aggregate (MTA)|Mineral trioxide aggregate (MTA) is the material of choice for pulp capping in vital pulp therapy.
45668869|NCT05811403|Other|Premixed bioceramic putty|Bioceramic putty is a premixed, ready-to-use calcium silicate-based material which can be used as a pulp capping material.
45668870|NCT05811247|Drug|AD109|Oral administration at bedtime.
45668871|NCT05811247|Drug|Placebo|Oral administration at bedtime.
45826713|NCT05215691|Procedure|Group II: IV Morphine|Postoperative analgesia will be provided with opioids
45826714|NCT04831073|Procedure|Surgery on the ascending aorta with or without repair of the aortic root and/or aortic arch|Surgical repair of the ascending aorta with or without surgical repair of the aortic root and/or aortic arch
45826715|NCT05204381|Device|Theta-frequency near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a near-zero phase lag.
45826716|NCT05204381|Device|Theta-frequency anti-synchrony stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a 180 degree phase offset, anti-synchrony.
45826717|NCT05204381|Device|Arrhythmic near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in an arrhythmic pattern with a near-zero phase lag matched in duration to the rhythmic stimulation for that session.
45969622|NCT04611958|Drug|ERCP with Bupivacaine infusion|"Selective cannulation of the pancreatic duct with ERCP scope will be performed. Any contrast dye used will be carefully aspirated and the duct will be flushed with saline as necessary to clear all residual dye. The canula will be taken to the tail of the pancreatic duct, and gradually withdrawn with slow infusion of the bupivacaine solution. Liposomal bupivacaine (13.3 mg/ml of Exparel) will be injected into the main pancreatic duct for a total of 5-10 ml (depending on the length of the pancreatic duct).~Immediately after the procedure, the patient will be monitored for any evidence of acute pancreatitis (worsening abdominal pain, with amylase or lipase x3 upper limit of normal). The patient will be questioned daily after the procedure for common side effects of bupivacaine including nausea, fever, change in taste, dizziness, weakness, palpitations and loss of taste or any other new or unusual symptom."
45668872|NCT05810987|Other|RESTORE|"Virtual educational curriculum organized into the following modules:~Module Specific Communication Strategies~Introduction~Preparing for and introducing a conversation [Consider personal bias /Building rapport /Ask permission]~Assessing understanding [Avoid correcting /Open ended questions]~Giving information [Give a warning shot /Using silence /Wish/worry/wonder]~Explore goals [Reflective listening /Naming, validating emotion~Summarizing and recommending a plan [Values-based recommendation /Aligning with goals /REMAP (Reframe, Expect emotion, Map goals, Align, Propose plan)]"
45969623|NCT00412919|Drug|Azacitidine|
45969624|NCT04612036|Device|Journey II Bi-Cruciate Stabilized TKA|Total Knee Arthroplasty System
45969625|NCT04612036|Device|Journey II Cruciate Retaining TKA|Total Knee Arthroplasty System
45969626|NCT04612036|Device|Journey II Bi-Cruciate Retaining TKA|Total Knee Arthroplasty System
45969627|NCT04611997|Procedure|Indocyanine Green Tracer Using in Laparoscopic Gastrectomy|Indocyanine Green Tracer Using in Laparoscopic Gastrectomy with Lymph Node Dissection for Locally Advanced Gastric Cancer After Neoadjuvant
45969628|NCT04611646|Behavioral|Heat-suit endurance training|Participants (elite cyclists) will conduct five 50-minute low-intensity cycling sessions with heat suit per week for five weeks. These sessions will complement their habitual training routines, which will consist of endurance training with intensities at or below lactate threshold. Participants will ingest 100 mg Fe2+ on a daily basis to support de novo synthesis of hemoglobin
45969629|NCT04611646|Behavioral|Non-heat-suit endurance training|Participants (elite cyclists) will conduct low-intensity cycling without heat suit for five weeks (volume- and intensity-matched to the heat-suit arm). Participants will ingest 100 mg Fe2+ on a daily basis to support de novo synthesis of hemoglobin
45969630|NCT04611490|Procedure|Spine Fusion|Each patient will undergo a spine fusion for a evolutive idiopathic scoliosis with the help of the surgivisio system.
45969631|NCT00222170|Drug|Rabeprazole|
45969632|NCT04611724|Drug|FOLFIRINOX|oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
45969633|NCT00563758|Drug|tegaserod|
45455771|NCT05722886|Drug|Trastuzumab in combination with pertuzumab|"The initial loading dose of trastuzumab is 8 mg/kg body weight administered intravenously every 21 days followed thereafter by a maintenance dose of 6 mg/kg body weight.~The initial loading dose of pertuzumab is 840 mg administered intravenously every 21 days followed thereafter by a maintenance dose of 420 mg.~Participants may continue until disease progression, unacceptable toxicity or withdrawal of consent."
45668873|NCT05810987|Behavioral|Medical Interaction and Coaching|Skills sessions with standardized patients (SPs) along with coaching feedback.
45826718|NCT05204381|Device|Arrhythmic independent stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in different independent arrhythmic patterns matched in duration to the rhythmic stimulation for that session.
45826719|NCT05204381|Device|Alpha-frequency near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a near-zero phase lag.
45826720|NCT05204381|Device|Alpha-frequency anti-synchrony stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a 180 degree phase offset, anti-synchrony.
45826721|NCT05204147|Drug|Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A|Given IV
45826722|NCT05204147|Procedure|Biospecimen Collection|Correlative studies
45826723|NCT04824053|Dietary Supplement|Milk from genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 250 mL of milk. The intervention duration will be 3 months"
45826724|NCT04824053|Dietary Supplement|Conventional milk|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 250 mL of milk. The intervention duration will be 3 months"
45969634|NCT00563836|Drug|Catumaxomab|10 µg Catumaxomab intraoperatively and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
45969635|NCT00222209|Behavioral|Experimental heat pain model|
45969636|NCT00563875|Drug|acetylsalicylic acid|75 mg/d for 7 days (healthy volunteers) and continued treatment with 75 mg/d in patients taking daily aspirin.
45969637|NCT00248196|Device|Reprieve Endovascular Temperature Therapy System|
45969638|NCT04611685|Drug|NSAID|Immediately after the operation, the patient is given (parecoxib 40 mg + sodium chloride 100 ml) intravenously once, and then given (loxoprofen 60 mg) orally twice a day during the first three postoperative days.
45969639|NCT04611685|Drug|Tramadol|Immediately after the operation, the patient is given (tramadol 100 mg) intramuscularly once, and then given (tramcontin 100 mg) orally twice a day during the first three postoperative days.
45969640|NCT04611412|Other|Risk Factors|BMI in children and adolescents was compared with percentile charts developed by who for children from 5 to 19 years of age (WHO Growth Reference, 2007). Body mass index was defined as the ratio of body weight (in kg) to body length in the supine position or height in the standing position (m2).
45969641|NCT00222248|Behavioral|Pelvic floor muscle training and bladder training|
45969642|NCT00248235|Behavioral|Exercise|
45969643|NCT00563914|Drug|ferroquine (SSR97193)|associated with artesunate
45969644|NCT00563914|Drug|amodiaquine|associated with artesunate
45969645|NCT00563953|Drug|Liposomal pegylated doxorubicine|Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
45668874|NCT05810025|Behavioral|RealRisks|RealRisks is a web-based patient-centered decision aid (DA) designed to improve: 1) accuracy of breast cancer risk perceptions; 2) chemoprevention knowledge, and 3) informed choice. The DA includes audio and modules about breast cancer risk (including interactive games on risk communication) and chemoprevention. Through RealRisks, the investigators will collect information on breast cancer risk factors to calculate a patient's BCSC breast cancer risk score and also factors that influenced decision-making about chemoprevention through the preference elicitation game. RealRisks generates an action plan for patients summarizing their personalized breast cancer risk profile and preference elicitation for chemoprevention. Of note, the tool is designed for patients with varying levels of health literacy and numeracy and is available in English and Spanish.
45668875|NCT05809687|Drug|DKP21102_C|Placebo
45826725|NCT04824053|Dietary Supplement|Yogurt made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of one yogurt. The intervention duration will be 3 months"
45826726|NCT04824053|Dietary Supplement|Conventional yogurt|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of one yogurt. The intervention duration will be 3 months"
45826727|NCT04824053|Dietary Supplement|Fresh cheese made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 50 g of fresh cheese. The intervention duration will be 3 months"
45969646|NCT00563992|Drug|Lithium|Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
45969647|NCT00563992|Drug|Valproic acid|Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
45969648|NCT00251550|Drug|Pemetrexed|
45826728|NCT04824053|Dietary Supplement|Conventional fresh cheese|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 50 g of fresh cheese. The intervention duration will be 3 months"
45668876|NCT05809687|Drug|DKP21102_B|Treatment
45668877|NCT05809687|Drug|DKP21102_A|Active Control
45668878|NCT05809570|Diagnostic Test|Clinical examination|"A total of 1057 individuals who applied to Bolu Abant İzzet Baysal University, Faculty of Dentistry, Department of Periodontology and agreed to participate in the study were clinically and radiologically examined.~An intraoral scanner was utilized to capture direct optical intraoral data of a patient."
45668879|NCT05809531|Drug|Pegcetacoplan|Complement (C3) Inhibitor
45826729|NCT05190653|Other|Early palliative and supportive care|The intervention itself will be predominantly the provision of education and information. It is possible that patients in the intervention arm may receive treatment recommendations to help manage symptoms.
45826730|NCT04812197|Procedure|Biospecimen Collection(Punch Biopsy)|Punch Biopsy of Skin
45826731|NCT04811339|Drug|Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable|Pepto bismol (bismuth subsalicylate)
45826732|NCT04811339|Other|Placebo oral tablet without BSS|Placebo Tablet made by P & G to contain everything except active ingredient ( BSS)
45969649|NCT00251550|Drug|Cisplatin|
45969650|NCT04611373|Drug|Acetazolamide Levamisole|Acetazolamide tablet 25mg/ tablet, 2 tablets a day Levamisole 25mg/ tablet, 6 tablets/day Continue treatment until the disease progresses
45969651|NCT00222287|Behavioral|Feldenkrais Movement class|
45969652|NCT04611256|Biological|MSC|Two intravenous infusion of 1*10E6 adipose tissue derived-MSCs /kg body weight reach
45969653|NCT04611256|Drug|Control|Conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.
45969654|NCT04611061|Drug|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
45969655|NCT04611061|Drug|No one|Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
45969656|NCT04610983|Dietary Supplement|Experimental: Control|2 x algal oil gel capsules delivering 400mg DHA in total
45969657|NCT04610983|Dietary Supplement|Experimental: Treatment 1 - Semi-Solid food matrix|"Test Food 1: 200g serve soup + ingredient"
45969658|NCT04610983|Dietary Supplement|Treatment 2 - Solid food matrix|"Test Food 2: 50g serve extruded snack (savoury snack) + ingredient"
45969659|NCT04611178|Device|Mechanical thrombectomy|Stent retriever for treatment of cerebral arterial occlusions
45969660|NCT00222326|Behavioral|Pelvic floor muscle training and lifestyle modification|
45969661|NCT00564031|Drug|Femanest|2mg/day
45969662|NCT00564031|Drug|gestapuran|5mg/day
45969663|NCT00564031|Drug|placebo|daily
45826733|NCT04804631|Device|Enteral feeding tubes|Families within Great Ormond Street Hospital are offered the choice of two enteral feeding tubes prior to admission for bone marrow transplant. Some families choose a gastrostomy to be placed prophylactically in the weeks prior to admission, others choose a nasogastric tube to be placed during the admission.
45826734|NCT05173961|Other|Internet-Based Intervention|Use oncpatient mobile application
45969664|NCT00564031|Drug|Femanest plus Gestapuran|combined daily
45969665|NCT04610632|Diagnostic Test|home pregnancy test|use of home pregnancy test
45969666|NCT00564109|Procedure|retrospective Observation|retrospective Observation
45969667|NCT00222365|Drug|Arnica montana, 5 CH|
45969668|NCT00222365|Drug|Bryonia alba, 5 CH|
45969669|NCT00222365|Drug|Hypericum perforatum, 5 CH|
45969670|NCT00222365|Drug|Ruta graveolens, 3 DH|
45969671|NCT04610437|Procedure|Arthrodesis interphalangeal with intramedullary resorbable fixation system|Interphalangeal arthrodesis of lesser toes with two different fixation systems.
45969672|NCT02961426|Drug|sofosbuvir + ravidasvir|combination of sofosbuvir + ravidasvir
45969673|NCT04610359|Drug|MR-MC-01|Submucosal injection of 2.0 x 10,000,000/5ml (1mL * 5 sites)
45969674|NCT04610281|Device|Inner Garden|"Care actions adapted to the intensity of the states of agitation (The child can be removed from the group while remaining in the same room on a chair with a caregiver. If the problems are too serious, the child can be accompanied to a soothing room where the carer will take care of him/her individually. In units equipped with Inner Garden, the child can use it under semi- supervision of nurses.)"
45969675|NCT04610008|Other|No intervention. Purely observation|Retrospective image analysis of the shape of the optic nerve head in both groups
45969676|NCT04610164|Drug|Tranexamic acid|Prior to surgery, the patient will receive 1 gram of IV TXA
45969677|NCT00222443|Drug|Irinotecan|
45969678|NCT04610203|Dietary Supplement|25 g Nutralys Pea Protein|To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose +25g Nutralys S85 Plus
45969679|NCT04610203|Dietary Supplement|50 g Nutralys S85 Plus.|To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose+50 g Nutralys S85 Plus .
45969680|NCT04610203|Dietary Supplement|50 g Glucose|To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose
45969681|NCT04610398|Drug|Dexamethasone 4mg|s. arm/group description
45969682|NCT04610398|Drug|NaCl 0.9%|s. arm/group description
45969683|NCT04609969|Diagnostic Test|RT-qPCR test|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
45969684|NCT04609969|Diagnostic Test|COVID-VIRO® test|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
46080920|NCT05630521|Behavioral|Medication Adherence Problem Solving for Hypertension|The MASH program is a 12-week intervention containing two components: (1) four education modules on HTN causes, risks, treatment, and barriers to treatment; and (2) telehealth visits every 2 weeks with a registered nurse to deliver evidence-based managed problem solving strategies tailored on patients' responses to assessments of HTN beliefs, medication beliefs, and barriers impacting their medication adherence.
45668880|NCT05809219|Other|1 hour combined intervention ( Exercise and nutrition)|Subjects take oral supplement after exercise in the time period between 1-2 hours. They will take oral supplement during hemodialysis treatment.
45826735|NCT05173961|Other|Survey Administration|Complete survey
45826736|NCT04535921|Other|FCR7 questionnaire|A 7 item questionnaire about fear of cancer recurrence
45826737|NCT05413889|Behavioral|Epic 30-day unplanned readmission risk score|If a patient is identified as having a high risk of readmission defined as readmission risk >20%, a link to transitional and supportive care services (TSC) will be appear in the story board.
45826738|NCT04790123|Procedure|Injection of autologous freshly collected adipose tissue|injection of fresh autologous fat, previously lipoaspirates from the patient's abdomen and centrifugated, into the fistulous tract, after curettage and closure of the internal opening.
45826739|NCT04790123|Procedure|sham|curettage and closure of the internal orifice of the anal fistula and simulated intervention in the abdomen.
45969685|NCT00222482|Drug|Depakote ER|
45969686|NCT04610125|Biological|Auto CAR-T|Biological: Auto CAR-T
45969687|NCT04610125|Drug|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
45969688|NCT04610125|Procedure|Leukapheresis|Leukapheresis
45969689|NCT04610242|Diagnostic Test|skin test|"For skin prick tests (SPT), rituximab solution of 1mg/ml was applied on the volar aspect of the forearm. For intradermal tests (IDT), 0.02 mL of a 1:100 dilution (0.1mg/ml) of full-strength solution (10mg/ml) was injected first. If the result was negative, a 1:10 dilution（1mg/ml）was then used.~As to the desensitization protocol, three solutions with different concentrations are delivered in 12 consecutive steps, each step increasing the rate of drug administration by 2- to 2.5-fold. Solution 1 is a 100-fold dilution (0.01mg/ml) of the final target concentration, solution 2 is a 10-fold dilution (0.1mg/ml) of the final target concentration, and the concentration of solution 3 is the target concentration (1mg/ml). Each step takes 15 minutes until the target rate of 200ml/h is reached, and the final step is prolonged to complete the target dose. The whole procedure takes about 5.5 hours."
45969690|NCT00564148|Drug|Avastin|2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively
45969691|NCT00222521|Drug|Glargine insulin|
45969692|NCT04609774|Other|Severe Acute Respiratory Syndrome CoronaVirus 2 detection|Severe Acute Respiratory Syndrome CoronaVirus 2 Detection by Real-Time Polymerase Chain Reaction and cell culture
45969693|NCT04609540|Drug|Trastuzumab|Dual anti-HER2 therapy
46080921|NCT05628012|Behavioral|Circadian Based Time Restricted Eating|Personalized schedule to restrict eating based on DLMO, approximately ~4h prior to DLMO or sleep onset.
45969694|NCT00564187|Drug|Irbesartan|"Irbesartan: 150mg tablets~Dosage: Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A"
45969695|NCT00564187|Drug|Irbesartan|"Irbesartan: 150mg tablets~Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B"
45969696|NCT00222560|Behavioral|Intensive physical activity counselling by an integrated physical activity counsellor|
45969697|NCT04609462|Procedure|Conventional oxygen therapy|Oxygen therapy by conventional nasal cannula / prongs, venturi mask, or mask with reservoir
45969698|NCT04609462|Procedure|High flow nasal cannula|Breathing support with High-flow nasal cannula
46080922|NCT05625360|Other|eHealth Mindful Movement and Breathing|The self-directed intervention includes an approximately 20-minute eMMB will teach synergistic components: (a) Mindful Meditation - 2 minutes of observing the current state of the body, emotions, thoughts, energy, and breath. Mindful attention may facilitate safe physical movements; (b) Mindful Movement - 10 minutes of gentle movements coordinated with and intended to enhance the breath; (c) Breathing and Relaxation - 3 minutes of placing the hands above the navel (rather than on the belly to avoid discomfort) and noticing them rise and fall with a focus on slightly extending the exhale, which will prepare participants for meditation); (d) Meditation - 5 minutes of observing the natural breath without reacting to it.
45826740|NCT05406713|Drug|Pembrolizumab|400 mg intravenously
45826741|NCT04783415|Drug|Acalabrutinib|Given PO
45826742|NCT04783415|Biological|Ublituximab|Given IV
45826743|NCT04783415|Drug|Umbralisib|Given PO
45826744|NCT00382577|Drug|Itopride|
45826745|NCT00382577|Drug|Placebo|
45826746|NCT05406323|Behavioral|Web-Based Fall Prevention Program|"Health education: This intervention consisted of seven health issues which are Fall among elderly, fall risk factors,  fall prevention interventions-exercise,  fall prevention interventions-healthy diet,  fall prevention interventions- drug use, fall prevention interventions- vision, fear of falling.~Exercise: This intervention is the exercise that is a combination of balance and strengthening exercises (8 exercise). Participants will do the exercises at least three days a week (along 6 week).~Safe home environment: This intervention is aimed at providing a fall-safe home environment for the participants. In this context, the participants will watch the video on creating a safe home environment for falling. Participants will also be asked to answer the Home Safety Check Form for Falls to make their home more fall-proof. In this form, according to the answers given by the participants, suggestions will be given to prevent the risks of falling in the home environment."
45826747|NCT04767347|Other|23.0°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~23.0°C WBGT (29°C, 46% relative humidity) @ 60 min exercise per hour"
45826748|NCT04767347|Other|25.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~25.5°C WBGT (31°C, 52% relative humidity) @ 45 min exercise per hour"
45826749|NCT04767347|Other|27.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~27.5°C WBGT (33°C, 53% relative humidity) @ 30 min exercise per hour"
45826750|NCT04767347|Other|28.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~28.5°C WBGT (34°C, 54% relative humidity) @ 15 min exercise per hour"
45826751|NCT04767347|Other|35.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~35.5°C WBGT (40°C, 65% relative humidity) @ 15 min exercise per hour"
45826752|NCT04767347|Other|26.0°C WBGT - Fixed work-to-rest ratio|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~26.0°C WBGT (31°C, 55% relative humidity) @ 530 W metabolic heat production"
45826753|NCT04767347|Other|30.5°C WBGT - Fixed work-to-rest ratio|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~30.5°C WBGT (36°C, 55% relative humidity) @ 230 W metabolic heat production"
45826754|NCT04767347|Other|30.5°C WBGT - Fixed work-to-rest ratio (high intensity)|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~30.5°C WBGT (36°C, 55% relative humidity) @ 530 W metabolic heat production"
45826755|NCT05400473|Other|Therapeutic exercise|This group will consist of 30 participants. A program consisting of specific therapeutic exercises for the cervical region will be applied.
45969699|NCT04609267|Diagnostic Test|PHQ-9 - Mirror format|The intervention we will be using is a new delivery system of the PHQ-9 using an Amazon Alexa equipped Mirror device. This Mirror device is similar to a smart television with a mirror interface. The device records auditory responses to the PHQ-9. We will be comparing the responses from the Mirror device to those given on the clinically established paper format.
45969700|NCT00222638|Drug|Influenza vaccination|
45969701|NCT04609384|Device|Alcohol rub timer device|A device that should help the surgeon to increase the time spend on surgical rub. Further detail cannot be described due to confidence
45969702|NCT04609150|Other|Bone marrow fat quantification by MRI|Bone marrow fat quantification by MRI at the moment of the diagnosis of vertebral fracture before treatment by vertebroplasty
45969703|NCT00222677|Drug|aspirin|100 mg daily
45668881|NCT05809219|Other|3 hours combined intervention ( Exercise and nutrition)|"All procedures between 1 hour combined intervention and 3 hours combined intervention are the same. The only one different is the time interval between exercise and nutrition. In this arm, the time interval of exercise and nutrition is 2.5 to 4 hours. When we recruiting subjects, all interventions will be clearly introduced to them, including the same and the different parts among them."
45969704|NCT00564343|Other|water based training program to improve balance|The exercise group will meet on 24 occasions over a period of 12 weeks (2 times/week), 45 minute training session.
45969705|NCT00564382|Procedure|Cardiac magnetic Resonance study|Routine cardiac MR study including contrast application
46080923|NCT05625360|Other|Life Impacts Reflection|"This self-directed intervention will focus on active listening, reflection of statements, and avoiding negative judgments. Participants will write brief diary entries daily for four weeks postoperatively and as they choose thereafter. Participants will be given the option of completing diaries on the tablet computer or paper. The instructions for daily diary entries will be, What were some of the events or circumstances that affected you in the past day? Think back over the past day and write down on the lines below up to five events that had an impact on you. A study team member will call participants to encourage diary completion two days (Postop Day 3) and two weeks after the synchronous session."
45826756|NCT05400473|Other|Photobiomodulation|Photobiomodulation will be applied on the cervical region. To perform the photobiomodulation protocol, a low power infrared laser therapy unit will be used.
45826757|NCT04331093|Drug|SHR-1210+Apatinib|"Drug: SHR-1210 SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg~Drug: Apatinib Apatinib tablet will be administered orally,once daily until progression"
45826758|NCT05142917|Device|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
45826759|NCT05142917|Behavioral|Hand motor task|Various type of hand motor tasks are applied to stroke patients.
45826760|NCT04760873|Device|cryotherapy|cryotherapy is a freeze spray that will be applied to GAVE for bleeding
45826761|NCT05130047|Drug|Aldafermin|1 mg solution
45826762|NCT05130047|Drug|Placebo|Aldafermin placebo solution
45826763|NCT04758767|Drug|CID-103|anti-CD38 antibody
45826764|NCT05124977|Drug|Antimicrobial Stewardship|Antimicrobial stewardship based on daily clinical assessment of clinical cure. Discontinuation of appropriate antibiotic therapy antibiotics if criteria of clinical cure of confirmed pneumonia are met. Intensivists will perform clinical assessment daily in order to decide on the pursuit or discontinuation of antibiotic therapy.
45826765|NCT05124977|Drug|Standard management|Standard management: duration of appropriate antibiotic for confirmed pneumonia fixed for 7 days according to guidelines. In the control group, intensivists will perform clinical assessment daily, but the antibiotic will not be discontinued until 7 days whatever the clinical cure.
45826766|NCT05122637|Device|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System with Medtronic React 71 aspiration catheter and a commercially available pump.
45826767|NCT05122637|Device|Standard of Care Aspiration Thrombectomy System|Commercially available aspiration catheter with commercially available aspiration pump
45826768|NCT04742621|Procedure|Liver transplant|Eligibility for liver transplantation will be limited to patients with histologically confirmed metastatic colorectal adenocarcinoma who have achieved stability of liver metastasis on chemotherapy for at least 6 months prior to transplantation. All patients who undergo liver transplantation will start immunosuppressive therapy per protocol. Patients who undergo a successful liver transplant will not receive adjuvant therapy.
45826769|NCT05120297|Drug|AK101|Subjects will receive AK101 subcutaneous injection at week 0 and week 4, and will follow up to week 16.
45969706|NCT00564460|Drug|Finasteride|Finasteride 5 mg PO once daily for 8 weeks prior to TURP
45668882|NCT05809219|Dietary Supplement|Nutrition intervention|"Subjects only take oral supplement during hemodialysis treatment. The oral supplement is the same as the 1 hour combined intervention and 3 hours combined intervention."
45826770|NCT05120297|Drug|Placebo|Subjects will receive placebo subcutaneous injection at week 0 and week 4, and will follow up to week 16.
45826771|NCT05106881|Device|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with device.
45826772|NCT05386043|Drug|FET F-18|PET scan with FET prior to biopsy
45826773|NCT05386043|Drug|O-15 Radioisotope|PET scan with O-15 Water prior to biopsy
45826774|NCT05386043|Procedure|CT scan|CT scan prior to biopsy
45826775|NCT05386043|Procedure|MRI with gadolinium-based contrast|MRI prior to biopsy
45826776|NCT05386043|Procedure|Biopsy Collection|Biopsy collection during standard of care neurosurgery for glioma diagnosis/excision
45826777|NCT04740359|Other|Functional training|The therapy program was planned for 8 weeks and the sessions were performed in 45 minutes (min) for 3 days a week. The functional reach (forward-lateral-cross), trunk rotation exercises were performed in the sitting positions.(25min) Facilitation of trunk extension and elongation in the prone position (10 min). Thoracic mobilization on exercise ball (10min).
45969707|NCT00564460|Drug|Placebo|Placebo once daily for 8 weeks
45969708|NCT04609033|Drug|Bupivacaine|instillation of local anaesthetic in the abdominal cavity at the end of the procedure
45969709|NCT04609033|Drug|isotonic saline|instillation of local anaesthetic in the abdominal cavity at the end of the procedure
45969710|NCT04609033|Drug|Bupivacaine + morphine|instillation of local anaesthetic + morphine sulfate in the abdominal cavity at the end of the procedure
45969711|NCT04609033|Drug|Bupivacaine + morphine + ketamine|instillation of local anaesthetic + morphine sulfate + ketamine in the abdominal cavity at the end of the procedure
45969712|NCT00222716|Behavioral|Problem solving counseling|Telephone nurse counseling behavioral intervention focused on problem solving.
45826778|NCT04740359|Other|Routine training|The therapy program was planned for 8 weeks and the sessions were performed in 45 minutes (min) for 3 days a week. The strengthening exercises were applied on the mat (3x10 for the first 4 weeks and 3x15 repetition for the last 4 weeks). Eyes open-closed perturbation training was performed for trunk control in sitting and standing positions (10 min.).
45969713|NCT04608799|Drug|Perampanel|Efficacy of epilepsy drugs
45969714|NCT04608565|Device|Remote biomonitoring sensor device|Same as described in arm descriptions. Safety was ensured by getting radiant warmer and multichannel probe examined and services by the biomedical engineering department; calibration certificates were obtained and these were used routinely in care of other neonates. An adverse event reporting and resolution protocol for the wearable sensor devices to capture number and severity of adverse events; individual clinical management and feedback for changes into device design. Adverse events recorded were: dermatitis, infection, thermal injury, radiation injury, device leak/burst and others.
45969715|NCT04608604|Other|Physiotherapy|Patients will be randomized in either physiotherapy 1 or physiotherapy 2. Physiotherapy programs are individually tailored based on a structured standardized series. In order to not unblind potential participants, detailed description of both interventions will be provided after recruitment has been finished.
45969716|NCT00248313|Drug|Rapamune®|
45969717|NCT00222755|Behavioral|Disease Management|Self-management, care management, guidelines
45969718|NCT04608760|Drug|Meksibel|2 ml solution
45969719|NCT04608370|Behavioral|Active tPBM session|In this project, taking the method of random, double blindness and control, participants in the active tPBM group will take active tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
45969720|NCT04608370|Behavioral|Sham tPBM session|In this project, taking the method of random, double blindness and control, participants in the sham tPBM group will take sham tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
45826779|NCT05104541|Other|Weight loss|"In addition to standard pharmacological treatment this group would receive diet comprising of 20-25 kcal and 1.2gm protein per kg ideal body weight per day.~The total distribution of the calories would be as 55-60% from carbohydrates, 25% from protein and 20% from fat. The diet would be explained to the patient with the help of individual diet charts."
45969721|NCT04608526|Diagnostic Test|Fractal analysis|Fractal dimension (FD) analysis, which can be measured in panoramic radiographs, is a technique that can be used to measure mandibular trabecular architecture and to determine early periodontal changes in alveolar bone. Fractal analysis method, which has become more and more popular in recent years; has features such as being easily accessible, not being affected by variables such as projection geometry and radiological density and providing objective data about trabecular structures. It can be measured in the patients' existing panoramic images and does not require extra imaging and material.
45969722|NCT00248352|Behavioral|Consultation with Endocrinologist|
45668883|NCT05808582|Drug|chidamide，fulvestrant|chidamide combined with fulvestrant
45668884|NCT05808413|Behavioral|Informational Video|This video emphasizes that vaccination against COVID-19 continues to be important, highlights the importance of seeking accurate information, and provides statistics about the estimated number of lives saved by vaccination and reported adverse events following vaccination in Canada.
45826780|NCT05362097|Other|The reliability and validity of the Chinese version of CC-QoL|Cc-qol, LCQ, and VCD were repeated 1-2 times before and 1-13 weeks after treatment.
45668885|NCT05808413|Behavioral|Altruistic Video|This video presents a vignette about a young adult woman who has many social interactions during her daily life. It shows that her decision to stay up-to-date on COVID-19 vaccination could help to protect those people she comes into contact with, who may be at greater risk from COVID-19 infection. Statistics are used to show that up to one-in-four people in Canada have underlying conditions that make them more vulnerable to COVID-19, and to quantify the number of surgeries that were delayed by pandemic-related disruptions.
45826781|NCT00382421|Drug|bisoprolol|
45826782|NCT00382421|Drug|amlodipine|
45969723|NCT00248352|Behavioral|Counseling from Dietician|
45969724|NCT00248352|Behavioral|Counseling from Diabetes Educator|
45969725|NCT00222794|Drug|Atomoxetine (Strattera)|
45826783|NCT00382421|Drug|molsidomine|
45969726|NCT04608253|Diagnostic Test|11C-choline PET/CT|11C-choline PET/CT
46080924|NCT05625360|Other|PROMIS Questionnaires|Various PROMIS questionnaires will be completed by participants (Pain Interference, Sleep Disturbance, Physical Function, Anxiety and Depression)
46080925|NCT05620836|Drug|Povorcitinib|Oral, Tablet
45826784|NCT00382421|Drug|acetylsalicylic acid|
45826785|NCT04724291|Device|MAGNET|This study will test the accuracy of a single-use ingestible video capsule (NaviCamTM, AnX Robotica) which is remotely controlled to record images of the inside of your stomach. Participants in this research study will have symptoms for which an evaluation by a traditional tube-based endoscopy (EGD) is indicated.
45826786|NCT04712825|Behavioral|Cognitive-behavioural therapy|Cognitive-behavioural therapy sessions during 6 weeks of treatment
45826787|NCT04712825|Device|HypnoVR® device|HypnoVR® sessions during 6 weeks of treatment
45826788|NCT05361551|Procedure|Liver ablation|Ablation needle placement An image-guidance device be used for planning of the procedure and for placement of the ablation needle
45969727|NCT04608643|Diagnostic Test|CBC _inflammatory markers _ platelet function test|CBC , Erythrocte sedimentation rate (ESR) ,CRP, platlet functions tests ( adhesions, 'aggregations ristocetin).
45969728|NCT04608175|Other|Acupuncture|Treatment of disease by inserting needles along specific pathways or meridians. The placement varies with the disease being treated. It is sometimes used in conjunction with heat, moxibustion, acupressure, or electric stimulation.
45969729|NCT00222833|Drug|Aripiprazole|
46080926|NCT05620836|Drug|Placebo|Oral, Tablet
46080927|NCT05617755|Biological|AB-1015|autologous T cell therapy
46080928|NCT05616234|Procedure|Resistance Exercise|Participants will perform a bout of lower body resistance exercise consisting of leg press, leg extension and leg curls.
46080929|NCT05598151|Drug|HM97662|To evaluate the safety, tolerability, preliminary anti-tumor efficacy, PK and PD of HM97662 in solid tumors
45969730|NCT04608097|Behavioral|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
45969731|NCT04608097|Behavioral|Attention Placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
45826789|NCT04713215|Other|Questionnaire|A short (approximately 20-minute) questionnaire will be administered to patients and carers who meet the inclusion criteria and who have expressed and interested, and consented to completing the questionnaire.
45826790|NCT04678271|Behavioral|AFIX-OB Quality Improvement Package|Practices randomized to the intervention arm will be provided with a package of core and supplemental quality improvement interventions to choose from so that the most effective combination for their practice is implemented. Each practice will be required to implement a tablet-based educational app for patients, and evidence based online educational module for providers, standing order protocol, and a reminder/recall protocol. They can then choose to also use flyers and posters in their waiting rooms, standardized talking points for maternal immunization for the providers, educational content for the practice website, and laminated and highlighted CDC Vaccine Information Sheets. The recruited patients and providers at the practice will be given a baseline and follow-up survey to assess their knowledge, attitudes, and beliefs towards maternal immunization.
45826791|NCT05087849|Biological|nonavalent human papillomavirus vaccine|Intralesional injection of nonavalent human papillomavirus vaccine (Gardasil 9) at 0 and 4 weeks
45969732|NCT04607902|Behavioral|Supportive Therapy SSI|Online, 30-minute self-administered program for youth
45969733|NCT04607902|Behavioral|Behavioral Activation SSI|Online, 30-minute self-administered program for youth
45969734|NCT04607902|Behavioral|Growth Mindset SSI|Online, 30-minute self-administered program for youth
45668886|NCT05808413|Behavioral|Individualistic Video|This video presents a vignette about a young adult man who is very health-conscious. He is unsure about staying up-to-date on COVID-19 vaccination until he learns that COVID-19 infection can have serious and disruptive consequences even if someone is younger. Statistics are used to quantify the increased risk of severe symptoms in young adults who are not up-to-date on vaccination.
45969735|NCT00251628|Other|Standard Care|standard care
45969736|NCT00251628|Other|ATC Dosing|ATC dosing of a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours around-the-clock for the first 3 days following surgery
45969737|NCT00251628|Other|Structured Pain Management Program|The structured pain management program consisted of a nurse coaching intervention which included an evaluation of the child's current condition, review of the pain intensity scores, verification that the child was taking the pain medication, re-education regarding the rationale for ATC dosing, review of strategies to facilitate medication administration, and re-education about potential side effects associated with analgesic administration.
45969738|NCT00251628|Other|As needed dosing|"As needed analgesic dosing with a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours as needed for pain."
45969739|NCT04608058|Behavioral|Digital storytelling training|"The digital content in this study is called Diabetes and Bumblebee. It features 35 minutes of animation that provides children with a brief description of the disease, its symptoms and complications, treatment methods, the type of insulin, how to preserve insulin, the importance of nutrition and exercise in treating diabetes as well as efficient communication and collaboration with parents and healthcare providers. Exciting and interactive animations were used to depict the daily life of a adolescence with diabetes."
45969740|NCT04608058|Behavioral|Routine training|The control group received the clinics' routine training include face to face class education.
45969741|NCT00564538|Drug|anti-thymocyte globulin (rabbit)|1.5mg/kg per dose with the first dose initiated in the operating room prior to reperfusion of the transplanted liver. It will then be administered again on post operative day #1, 3 and 5 for a total cumulative dose of 6mg/kg.
45969742|NCT00564538|Drug|tacrolimus|Tacrolimus will be administered orally on post op day #1 as per standard of care.
45969743|NCT00251706|Drug|amiodarone|
45969744|NCT00199121|Drug|Zidovudine (drug)|
45969745|NCT04607824|Behavioral|Duchenne Muscular Dystrophy group|Assessment of heart rate variability at rest and during computational task in people with Duchenne muscular dystrophy
45969746|NCT04607824|Behavioral|Typical Development group|Assessment of heart rate variability at rest and during computational task in people with typical Development
45969747|NCT04607863|Diagnostic Test|Case control|Is a case-control research
45668887|NCT05808400|Biological|MSC-derived exosomes|The total volume of MSC-derived exosomes is 5ml, and exosome concentration in preparation is 1*10^9 particles/ml.
45969748|NCT04607785|Drug|Miswak mouthwash group|Twice daily for seven days for two months
45969749|NCT04607785|Device|Chlorhexidine gluconate mouthwash|Twice daily for seven days for two months
45969750|NCT00248391|Behavioral|upright feeding|
45969751|NCT00199160|Drug|BAY 43-9006|
46080930|NCT05592223|Drug|BCG Vaccine USP|2x10^6 cfu Tice® BCG (ID)
46080931|NCT05592223|Drug|Isoniazid|INH in the dose of 300 mg for three days post BCG injection.
46080932|NCT05592223|Drug|Rifampin|RIF in the dose of 600 mg for seven days post BCG injection.
45826792|NCT05075837|Biological|Virus -specific T cells|The product is obtained by leukapheresis of a family donor responsive to the virus: consists of virus- specific T lymphocytes (both CD4+ and CD8+) resuspended in PBS / EDTA buffer plus 0.5% Albumin Human. The productive process lasts two consecutive days and includes two phases: a brief activation with specific viral peptide followed by immunomagnetic separation using the CliniMACS® CCS (IFNγ) capture system which allows a fast and automated separation of IFNγ secreting lymphocytes
45826793|NCT05343455|Drug|DFD-29|DFD-29 (40 mg) extended release capsules
45969752|NCT04607629|Biological|Genolar® + Symbicort®|The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
45969753|NCT04607629|Biological|Xolair® + Symbicort®|The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
45668888|NCT05807321|Device|Fecobionics|Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry and balloon expulsion test may be used as reference. Anorectal manometry and balloon expulsive test are standard methods for anorectal functional measurement.
45969754|NCT00251784|Drug|Sildenafil|
45668889|NCT05806541|Behavioral|laughter therapy|Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
45668890|NCT05805787|Other|Acupressure|Acupressure will be applied to the elderly in the experimental group once a day, 5 days a week (Monday-Friday) for a week. The application will last for 2 weeks. A total of 10 sessions of acupressure will be applied. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the elderly are in supine position, pressure will be applied to each acupressure point, respectively, Tianshu (ST25), Guanyuan (CV4) and Hegu (LI4) for 2 minutes for a total of 6 minutes.
45668891|NCT05804227|Drug|Ulixertinib|Participants will take ulixertinib by mouth 2 times every day until the night before your surgery.
45668892|NCT05802849|Drug|Acetazolamide|Acetazolamide is a diuretic with a mild diuretic effect. Inhibits the enzyme carbonic anhydrase in the proximal convoluted tubule of the nephron. Increases urinary excretion of sodium, potassium, bicarbonate ions, does not affect the excretion of chlorine ions; causes an increase in urine pH.
45826794|NCT05343455|Drug|Doxycycline|Doxycycline 40 mg capsules
45668893|NCT05800002|Procedure|Intravascular ultrasound|Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on intravascular ultrasound.
45826795|NCT05343455|Drug|Placebo|Placebo capsules
45826796|NCT05335811|Drug|4-[18F]Fluoro-1-Naphthol|By vein (IV)
45969755|NCT04607473|Device|automated breast ultrasound (ABUS)|Both HHUS and ABUS will be performed on each patient for preoperative staging. Breast radiologists each independently will read HHUS and ABUS images obtained from one patient. The radiologists will be blinded to the findings of the other US mode.
45969756|NCT05558852|Procedure|Laparoscopic Meshless Sacrocolpopexy Technique|Meshless sacrocolpopexy: laparoscopic approach to central and anterior compartment prolapse
45969757|NCT04607512|Drug|telaglenastat|glutaminase inhibitor
45969758|NCT04607512|Other|telaglenastat placebo|matching placebo for telaglenastat
45969759|NCT04607512|Other|moxifloxicin|positive control
45969760|NCT04607239|Procedure|Telemonitoring|"A weekly telephone call by the CRA for the collection of home blood pressure measurements (which the patient measures twice a day everyday), for therapeutic education, and for treatment compliance assessment.~A monthly call by the attending physician for treatment titration and side effects check."
45969761|NCT04607239|Procedure|Usual Care without Telemonitoring|"Attending the follow up visits after inclusion at Day 90 (D-90) & Day 180 (D-180) for face to face consultation with the attending physician.~Usual care without any phone calls for therapeutic education, treatment compliance assessment, treatment titration or side effects check."
46080933|NCT05588440|Biological|ONCT-808|"A single infusion of ONCT-808 autologous CAR-T cell infusion will be administered intravenously~Phase 1: Dose Escalation with bridging therapy as needed~Phase 2: Patients with LBCL or MCL will be enrolled into two separate dose expansion cohorts."
46080934|NCT05588440|Drug|Bridging Therapy|Bridging therapy can be oral chemotherapy or IV radiotherapy/chemotherapy per institution's guidelines
45826797|NCT05333939|Dietary Supplement|Moringa leaf powder|capsule ingestion
45826798|NCT05333939|Other|Placebo|capsule ingestion
45826799|NCT05069831|Drug|Abrocitinib|Abrocitinib daily for 4 months
45826800|NCT05068583|Other|Blood Draw|Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.
45826801|NCT05057429|Device|Procellera Bioelectric Dressing|Procellera is single layer, broad-spectrum antimicrobial wound dressing. Embedded in the dressing are microcell batteries made of elemental silver and zinc applied in a dot-matrix pattern. The bioelectric dressing will be applied to surgical site wound with a hydrogel.
45826802|NCT05057429|Other|Standard Gauze Dressing|Standard of care non-adherent gauze dressing will be applied to surgical site with vaseline.
45826803|NCT05049863|Drug|Mycophenolate Mofetil|Mycophenolate mofetil is commercially available.
45826804|NCT05049863|Drug|Allopurinol|Allopurinol is commercially available.
45826805|NCT05049863|Drug|Irinotecan|Irinotecan is commercially available.
46080935|NCT05587296|Drug|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
46080936|NCT05587296|Drug|Placebo|Matching placebo orally once daily.
45969762|NCT04607395|Radiation|pre-operative radiograph|"Three hundred and sixty pre-operative radiographs of deep carious lesions and a contrasted version of the same set have been screened and annotated by 4 evaluators. Annotations were placed at the dentino-enamel junction, at the floor of the carious lesions, and on pulp chamber wall. From these annotations, the ratios residual dentin thickness/ total dentin thickness were derived. First, inter-evaluator agreement and concordance were assessed. A logistic regression that accounted for measurement error was applied to precisely estimate the capacity of the ratio to predict exposure (reported as odds-ratio)."
45969763|NCT00248430|Biological|aldesleukin|
45969764|NCT00248430|Biological|therapeutic allogeneic lymphocytes|
45969765|NCT00248430|Drug|melphalan|
45826806|NCT04652453|Other|Geriatrics Bundle|Enrolled participants in the intervention arm will receive all 3 bundle components: occupational therapy (in addition to physical therapy) upon enrollment in the ICU, a portable amplifying device upon enrollment in the ICU, and a de-prescribing intervention by the ICU pharmacist (in conjunction with the medical team) upon ICU-to-floor transfer.
45668894|NCT05800002|Procedure|Angiography|Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on angiography.
45826807|NCT05314751|Behavioral|Questionnaire and interview|An online survey and an in-depth interview.
45826808|NCT05312255|Behavioral|Behavioral Intervention|Wear a FitBit device and receive prompts for 6 months
45969766|NCT00248430|Procedure|bone marrow ablation with stem cell support|
45969767|NCT00248430|Procedure|peripheral blood stem cell transplantation|
46080937|NCT05583227|Biological|Tezepelumab|Tezepelumab subcutaneous injection
45668895|NCT05799482|Other|Qualitative Interview|Qualitative, semi-structured interview
45826809|NCT05312255|Drug|Beta-Adrenergic Antagonist|Receive beta-blocker regimen as per SOC
45668896|NCT05796804|Procedure|ERECTOR SPINAE PLANE BLOCK|ULTRASOUND GUIDED - ROPIVACAINE 30 ml 0.5%
45668897|NCT05796804|Procedure|Peng block + lateral femoral cutaneous nerve block|ULTRASOUND GUIDED - ROPIVACAINE 20 ml 0.5% + 10 ml 0.5%
45668898|NCT05796804|Procedure|spinal anesthesia|bupivacaine 0.5% 2.2 ml
45668899|NCT05788887|Other|Authentic Ladotyri Mytilinis PDO cheese|Branding PDO cheese from Mytilini, purchasing by E.Thimelis Dairy S.A.
46080938|NCT05583227|Biological|Tezepelumab|Tezepelumab subcutaneous injection
45668900|NCT05788887|Other|Control|Branding Parmesan PDO cheese from Italy, supplied by LIDL Hellas
45668901|NCT05788874|Diagnostic Test|18F-FAPI and 18F-FDG PET/CT|18F-FAPI and 18F-FDG PET/CT for gastrointestinal cancer
45668902|NCT05788289|Drug|Tafasitamab|Participants will receive treatment with intravenous tafasitamab and oral lenalidomide for up to 12 cycles. Each cycle is 28 days in length.
45668903|NCT05788289|Drug|Lenalidomide|Lenalidomide will be self-administered by patients orally on days 1-21 of each 28-day cycle of induction (cycles 1 through 12).
46080939|NCT05583227|Other|Placebo|Placebo subcutaneous injection
46080940|NCT05581641|Biological|BNT165b1|RNA vaccine for active immunization against malaria administered as intramuscular injection
45668904|NCT05787613|Drug|HLX26|Anti-LAG-3 monoclonal Antibody Injection
45826810|NCT05312255|Drug|Propranolol|Given PO
45826811|NCT05312255|Other|Quality-of-Life Assessment|Ancillary studies
45826812|NCT05312255|Other|Questionnaire Administration|Ancillary studies
45826813|NCT05312255|Other|Resistance Training|Undergo strength training for 6 months
46080941|NCT05581641|Other|Placebo|Placebo
45826814|NCT05312255|Other|Short-Term Fasting|Participate in intermittent fasting
45826815|NCT04632485|Device|Ultrasound imaging|Carotid artery ultrasound exam. US imaging will include complete clinical carotid ultrasound examination (B-mode, Doppler and color-flow modes), clinical strain and shear wave imaging study, backscattered and beam-steered radiofrequency (RF) data acquisition using research mode, and reference phantom RF data acquisition.
45826816|NCT04632485|Device|Magnetic Resonance Imaging (MRI)|Head and Neck MRI exam with contrast
45826817|NCT04632485|Other|Neurocognitive testing|Harmonization battery to assess executive function/attention, speeded psychomotor, verbal, and nonverbal memory, language, and visuospatial skills
45668905|NCT05787613|Drug|Serplulimab|anti-PD-1 humanized monoclonal antibody injection
45668906|NCT05787613|Drug|Pemetrexed|non-squamous NSCLC patients will receive Pemetrexed treatment
45668907|NCT05787613|Drug|Nab paclitaxel|squamous NSCLC patients will receive nab-Paclitaxel treatment
45668908|NCT05787613|Drug|Carboplatin|non-squamous and squamous NSCLC patients will receive Carboplatin treatment
45668909|NCT05779202|Other|No intervention is planned.|No intervention is planned.
45668910|NCT05775887|Biological|UQSC2 Vaccine|Subjects will be assigned to treatment group (UQSC2 or NVX-CoV2373) via randomisation. Each treatment group will receive a single dose of either UQSC2 or NVX-CoV2373. The Study will be unblinded after Day 29, to enable subjects who received the investigational vaccine (UQSC2 vaccine) to seek vaccination with a TGA (Therapeutic Goods Administration) approved COVID-19 booster vaccine if indicated by public health authorities.
45668911|NCT05775887|Biological|NVX-CoV2373 vaccine|Subjects will be assigned to treatment group (UQSC2 or NVX-CoV2373) via randomisation. Each treatment group will receive a single dose of either UQSC2 or NVX-CoV2373
45826818|NCT04632485|Device|Transcranial Doppler (TCD)|Use of a TCD system to monitor right and left middle cerebral artery Doppler waveforms in the volunteer for 60 minutes
45826819|NCT05043701|Drug|Personalized drug combination|A personalized drug combination will be prescribed to each patient based on the functional drug screen
45969768|NCT05558189|Device|Vibrotactile Coordinated Reset (vCR)|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants who have refractory Parkinson's disease post surgical treatment
45969769|NCT04607161|Other|no intervention|no intervention
45969770|NCT04607278|Dietary Supplement|Probiotic|Oral probiotic supplementation was provided by iHealth; Cromwell, USA. Each sachet included a 1×1010 CFUs dose of four viable microbial cell preparation strains: there are two strains of lactobacillus genus (Lactobacillus acidophillus L1 (2.9×109) and Lactobacillus rhamnosus liobif (2.9×109)), Bifidobacterium longum (2.9×109) and Saccharomyces boulardii (1.3×109). Each participant took a total daily dose of 4×1010 CFUs.
45969771|NCT04607278|Dietary Supplement|Prebiotic|The prebiotic was made up of inulin from the chicory plant and provided by the Fibrelle (Belgium) company. Five grams packs were given to the participants in boxes. Each participant was requested to take a total daily 10 g dose.
45969772|NCT04607278|Dietary Supplement|Placebo|It was composed of maltodextrin, and provided by the manufacturer Fibrelle; (Belgium). The prescription was similar to probiotics or prebiotics groups.
45969773|NCT00564577|Biological|CFA/I and CS17 challenge strain|Wild type ETEC strain expressing the colonization factor CS17, and heat labile (LT) enterotoxin
45826820|NCT05040581|Behavioral|1-Day CBT-Based Workshop for Preventing PPD|The intervention is a 6-hour long CBT-based workshop. The intervention will be delivered in in modules and contain content on PPD etiology (with a focus on modifiable risk factors), the development of cognitive skills including cognitive restructuring, behavioural skills such as problem solving, sleep strategies, behavioural activation, assertiveness, and self-care, and the final module will involve goal setting and action planning.
45969774|NCT04719975|Other|Mental Fatigue (Stroop task)|"A modified Stroop task of approximately 60 min will be used in order to induce mental fatigue (MF). This will be based on their performance during the max test that was conducted during the familiarization session. In this task, which will be partitioned in 4 blocks of 468 stimuli, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself."
45969775|NCT04719975|Other|Control (Documentary)|In the control task subjects will have to watch a documentary of 60 min on the same computer screen as the one used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several documentaries as proposed by the research team. During the control task physiological and psychological measures will be assessed at the same time points as during the mental fatigue trial.
45969776|NCT05556356|Drug|Acetaminophen|pre-operative acetaminophen (1000mg)
45969777|NCT05556356|Other|Placebo: Multivitamin|pre-operative Multivitamin
45969778|NCT00564616|Device|video cell phone|"the voice group received voice CPR instruction via a voice-only cell phone, and the video group received interactive voice and video instruction via a video cell phone"
45969779|NCT00564655|Procedure|bupivacaine with epinephrine (mid and upper abdomen)|Patients will receive localized infiltration of local anesthesia (0.25% bupivacaine with epinephrine 1:200,000) at the beginning of the procedure as is current standard practice. Localized anaesthetic of the mid and upper abdomen.
45969780|NCT00564655|Procedure|bupivacaine with epinephrine (transversus abdominis plane)|0.6 cc/kg (to a maximum of 20 ccs) of 0.25% bupivacaine with epinephrine 1:200,000 will be injected into the neuro-vascular plane between the internal oblique and transversus abdominis muscles. Regional anaesthetic block of the transversus abdominis plane.
46080942|NCT05579587|Device|Transoral Incisionless Fundoplication|Transoral incisionless fundoplication (TIF) is a minimally invasive, endoscopic fundoplication technique. Transoral Incisionless Fundoplication (TIF) is an FDA approved endoluminal fundoplication technique which utilizes EsophyX device to restore the valve at the gastroesophageal junction. The EsophyX device (EndoGastric Solutions, Redmond, Wash, USA) is an FDA approved procedure for chronic of refractory GERD.
46080943|NCT05577182|Drug|INCA32459-101|solution for infusion
46080944|NCT05573048|Device|Trans-Perineal Grid|A small square piece of plastic with many holes in it placed between the legs to help guide the path of the interventional instruments and to facilitate the prostate intervention. The guide grid will help with needle placement using the grid technology.
45668912|NCT05774431|Other|There was no intervention necessary.|There was no intervention necessary.
45668913|NCT05767034|Drug|Secukinumab 300 mg|Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
45826821|NCT04281719|Other|Mobile Application (working name: Bright Path)|The Bright Path web-based mobile application is designed to target co-occurring problems, enhance patient treatment engagement, and contribute to lasting improvements in teens' mental health. The central hypothesis is that developmentally tailored mobile applications that incorporate evidence-based treatment principles can facilitate increased patient engagement in and between sessions, thus, improving the efficiency, efficacy, and reach of treatments for this highly vulnerable population.
45969781|NCT00564694|Procedure|psychosocial assessment and care|
45969782|NCT00564694|Procedure|quality-of-life assessment|
46080945|NCT05569954|Biological|V116|Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
45969783|NCT04719546|Other|Observation of related perinatal factors|Data described in Primary outcome measures will be collected in both groups
45969784|NCT04607083|Diagnostic Test|Polyp carachterization by combing endoscopist evaluation and Ai output|A polyp characterization (adenoma vs. non adenoma) is provided by endoscopist in light of the results of this own evaluation and of the Ai system output. The confidence level (high vs. low) in polyp characterization is recorded. The combined evaluation is compared with histopathology results.
45969785|NCT04606849|Other|Physician Survey|Our questionnaire includes questions on respondent demographics and Likert-style questions about respondent experiences with ePNa. We will validate our modified questionnaire by calculating component loadings and Cronbach Alphas (i.e., internal consistency) of Likert questions loading onto the same components.
46080946|NCT05569954|Biological|PPSV23|Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
45668914|NCT05767034|Drug|Secukinumab 150 mg|Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
45668915|NCT05767034|Other|Placebo to secukinumab|Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
45668916|NCT05766189|Behavioral|Wastewater vaccine prompts|Social media communications showing levels of SARS-CoV-2 in wastewater
45969786|NCT04606849|Device|ePNa-CheXED|ePNa-CheXED will incorporate Stanford University's artificial intelligence CheXED model to provide electronic classification of chest images in <1 second for elements of pneumonia diagnosis and treatment (radiographic pneumonia, single vs multiple lobes, and pleural effusion).
45826822|NCT05034341|Other|Multimodal Prehabilitation|"In addition to Standard Clinical Care~Behavioral - An exercise program focusing on aerobic exercise as well as strength training. Sessions will be supervised by a physical therapist, 2 times a week for a minimum of 6-8 weeks in addition to home exercise program. They will also participate in a single session of Cognitive-Behavioral Therapy and will receive an educational pamphlet about Pain and Neuroscience Education.~Dietary Supplement - Protein supplements in the form of protein shakes at a dose of 1.2-1.5 gram per kg daily for 6-8 weeks. Protein supplements will be calculated based on ideal body weight and will be given to the patient with instructions on specific use. Diabetic patients will receive protein supplements that are sugar free."
45826823|NCT05034341|Other|Standard Pre-Surgical Clinical Care|"Education related to preoperative activity and home-based exercise program.~Standard preoperative consultation with anesthesiology: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with focus on preoperative cognitive assessment."
45826824|NCT04615325|Drug|RO7303359|RO730359 will be administered as a single intravitreal injection.
45826825|NCT05015621|Drug|Surufatinib plus Toripalimab|Surufatinib is a tablet in the form of 50mg, oral, once a day; Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
45969787|NCT01580722|Procedure|early reconstruction|patients underwent < 8 weeks reconstruction after injury
45969788|NCT01580722|Procedure|delay reconstruction|patients underwent > 8 weeks reconstruction after injury
45969789|NCT05542121|Device|Robot-Assisted Therapy with Rehab CARES system|60 min sessions; 3 sessions per week; for 4 weeks; Patients uses 1 or more affordable robots to exercise the UL with adaptive games assessments as OT; standard of care PT and SLP; Subjects' motor and cognitive impairment will be used to set the game and modes. The game parameters will be adjusted according to motor and cognitive impairment of that station's user while the controller will automatically adjust assisting or resisting torques experienced. The 60 minutes will be broken up into 15-minute training intervals.
45969790|NCT05542121|Other|Standard of Care|60 min sessions; 3 sessions per week; for 4 weeks of OT, PT, and SLP
45969791|NCT04606810|Other|multidisciplinary educational intervention|At randomization, participants in arm 1 received the educational DVD with the instruction to review its contents within the next two weeks. Between 2 and 4 weeks after randomization, reinforcement teleconferences were done in small groups of 10 participants maximum per session with every participant who mentioned having watched the DVD. Each participant attended only to one teleconference. Usual care consisted in regular follow-up with the treating rheumatologist and possibility of asking questions of the rheumatology nurse by phone.
45969792|NCT04606888|Device|Transcutaneous electrical acupoint stimulation|According to the traditional Chinese medicine 15,three acupuncture points were selected as the target points: bilateral Neiguan ,Yintang and bilateral Zusanli.. A transcutaneous electrical stimulator was used to provide an altered frequency 2/100 Hz,disperse-dense waves,and adjusted intensity which was less than 10mA.
45969793|NCT04606537|Drug|Itraconazole|200 mg itraconazole, given orally as 20 mL × 10-mg/mL solution BID on Day 15, followed by QD dosing on Days 16 through 23, inclusive.
45969794|NCT04606537|Drug|Rifampin|600 mg rifampin, given orally as 2 × 300-mg capsules QD on Days 15 through 25, inclusive.
45969795|NCT04606537|Drug|KBP-5074|0.5 mg KBP-5074, given orally as 1 × 0.5-mg tablet on Days 1 and 19 or Days 1 and 21
45969796|NCT00248469|Behavioral|In-school Sexual Health Education|
45969797|NCT00248469|Behavioral|Youth-friendly health services|
45969798|NCT00248469|Behavioral|Youth condom promotion & distribution|
45969799|NCT00248469|Behavioral|Community activities related to adolescent sexual health|
45969800|NCT04606654|Other|Handgrip strength training without Blood flow restriction|Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contract his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training.
46080947|NCT05562947|Device|PDS with ranibizumab (100 mg/mL)|Patients randomized to the implant arm will have the implant (filled prior to implantation with approximately 20 uL of the 100-mg/mL formulation of ranibizumab [approximately 2 mg dose of ranibizumab]) surgically inserted in the study eye at the Day 1 visit following their randomization visit, or at Week 48 visit for patients randomized to the intravitreal arm. After the initial fill of the implant with ranibizumab, patients will receive implant refill-exchanges at fixed 24-week intervals.
45668917|NCT05763797|Behavioral|Individual Interview|"Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist."
46080948|NCT05562947|Drug|Ranibizumab (10 mg/mL)|Patients in the intravitreal arm will receive their first intravitreal injection of 50 uL of the 10 mg/mL ranibizumab (0.5 mg dose) at the Day 1 visit, which will occur at the conclusion of the randomization visit. Afterward, patients will receive intravitreal ranibizumab injections of 50 uL of the 10 mg/mL formulation Q4W at each scheduled study visit until Week 44
45826826|NCT05015621|Drug|5-fluorouracil, Calcium folinate and Irinotecan|Irinotecan 180 mg/m^2, Calcium folinate 400 mg/m^2, 5-FU total 2800 mg/m^2 will be administrated once two weeks.
45826827|NCT05007509|Biological|COVID-19 vaccine HIPRA 10|One sentinel subject and 4 additional subjects will be assigned to COVID-19 vaccine HIPRA 10 µg
45826828|NCT05007509|Biological|COVID-19 vaccine HIPRA 20|One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 20 µg
45826829|NCT05007509|Biological|COVID-19 vaccine HIPRA 40|One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 40 µg
45826830|NCT05007509|Biological|Commercial COVID-19 vaccine|One subject in cohort 1 and 2 subjects in Cohort 2 and 3 will be assigned to Commercial COVID-19 vaccine
45969801|NCT04606654|Other|Handgrip strength training with Blood flow restriction|Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contracts his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training. However, for one of the limbs the pneumatic blood pressure cuff will be placed on the upper arm, 4 cm proximal to the ante-cubital fossa. The decision which arm would receive the occlusion during training will be randomized to avoid a dominant or non-dominant hand bias. During experimental group training blood pressure cuff will be partially inflated (80 mmHg) to ensure venous occlusion. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training while the cuff remained inflated.
45969802|NCT04606147|Procedure|Serratus Anterior Plane Block|The block is performed with full aseptic precautions.in lateral position &arm abduction. US probe placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib.With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, the skin and subcutaneous tissue can be topicalized. Then, using ultrasound guidance, A regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib.Correct location of the needle tip in the fascial plane deep to serratus anterior muscle will be confirmed by injecting 0.5-1 ml normal saline and seeing hydrodissection of fascial plane between SAM and 5th rib. After aspiration to avoid intravascular injection 30 ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle. The entirety of the needle should be visualized at all times throughout the procedure.
45969803|NCT04606147|Procedure|Erector spinae plane block|The block is performed with full aseptic precautions at T5 level. T5 transverse process is identified by us as flat, squared-off acoustic shadows with only a very faint image of the pleura.In longitudinal us view following layers will be visible superficial to transverse processes: skin and subcutaneous tissue, trapezius, erector spinae muscle.Skin is topicalised , then echogenic block needle inserted in- plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration to avoid intravascular injection 30 ml levobupivacaine 0.25% was injected and separation was seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm was used
45969804|NCT00251823|Drug|Eptifibatide facilitated PCI|
45969805|NCT04606225|Drug|Losartan|administration of losartan (50 mg) (oral) Cozaar Oral Tablet
45969806|NCT04606225|Drug|Placebo Oral Tablet|administration of placebo (oral)
45826831|NCT04999085|Other|Supportive care interventions|Subjects will be referred to specialists and/or supportive care interventions based on issues/deficits identified on a baseline geriatric assessment. These interventions will be selected based on deficits or problems identified on baseline assessments. These include referral to physical/occupational therapy for those with physical deficits (Activities of Daily Living impairment, Instrumental Activities of Daily Living impairment, Timed Up and Go, or falls), to optometry/ophthalmology (for visual impairment), to audiology (for hearing impairment), to pharmacist (for polypharmacy), and to cancer center support program (for Mental Health Index 13 criteria).
45668918|NCT05763797|Behavioral|Meditation Exercise|"Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist."
45826832|NCT04997057|Dietary Supplement|Probiotics mixture|"12 weeks of daily supplementation with 1 g of probiotics mixture (4.10exp9 colony forming unit/g) containing:~Bifidobacterium longum LA 101~Lactobacillus helveticus La 102~Lactococcus lactis LA 103~Streptococcus thermophilus LA 104"
45826833|NCT05289167|Drug|Cyclophosphamide|50 mg/kg IV over 1 hour on Day +3 and +4
45826834|NCT05289167|Drug|Abatacept|"Dose level 0: 10 mg/kg IV over 30 minutes on day +5~Dose level 1: 10mg/kg IV over 30 minutes on day +5 and +14~Dose level 2: 10mg/kg IV over 30 minutes on day +5, +14, and +28"
45826835|NCT05289167|Drug|Bortezomib|1.3 mg/m2 IV 6 hours after graft infusion completion and 72 hours thereafter.
45668919|NCT05763628|Device|Control Contact Lens (stenfilcon A Daily Disposable Multifocal Contact Lens)|two weeks of wear
45668920|NCT05763628|Device|Test Contact Lens (senofilcon A Daily Disposable Multifocal Contact Lens)|two weeks of wear
45826836|NCT00382499|Drug|Lidocaine Intravenous Infusion|1.5 mg/kg IV bolus on induction, 3 mg/kg/hr infusion from inducation until fascia closure
45969807|NCT05528549|Other|Exercise|The investigators are looking at how blood flow and blood pressure are regulated in individuals with Down syndrome, who have a reduced ability to do work. This study will compare individuals with Down syndrome to a control group without Down syndrome.
45969808|NCT04606108|Drug|Camrelizumab in Combination With Neoadjuvant Chemotherapy|camrelizumab in combination with Liposome doxorubicin and Ifosfamide
46080949|NCT05558865|Behavioral|somnovia|Participants receive access to the digital health application somnovia
45668921|NCT05760560|Drug|Sugammadex|At the end of surgery, neuromucular blockade will be reversed with 2mg/kg or 4mg/kg sugammadex depending on the depth of neuromuscular blockade.
45826837|NCT04330547|Drug|Analgesic administration|"Level 1 : Paracétamol 1g/Acetaminophène 1g, Ibuprofène 600mg, Diclofénac 50mg.~Level 2: Tramadol 50mg.~Level 3: Oxycodone 5mg, Morphine sulfate 10mg.~Increase of a prior level 3 medication :~1/6 of the total dose of daily level 3 medication (e.g. the patient receives 30mg of oxycodone a day. He will be administered a single dose of 5 mg for the study), defined as a breakthrough dose in the management of chronic pain. To standardize the treatment, the dose of the prior level 3 medication will be converted to oxycodone. Several online tools exist to do the conversion between opioids (e.g. mobile app Orthodose ®).~If the oral intake or the gastrostomy use is not possible, the breakthrough dose will be administered by subcutaneous route. The dose will also be 1/6 of the daily dose and will be converted to injectable morphine. Conversion to injectable morphine will be performed with any equivalence tool (such as the mobile app Orthodose ®)"
45826838|NCT04330547|Drug|Placebo administration|Folavit (folic acid, 0.4 mg)
45826839|NCT05286515|Other|Hybrid Peroperative PT|The intervention will consist of an in-person evaluation assessing the subject's functional level, lower and upper extremities range of motion, strength and endurance. The remaining sessions will be conducted via telehealth. The program will consist of two sessions per week up to six weeks. The program will start approximately 8 to 7 weeks before the scheduled surgery date.
45826840|NCT05286515|Other|Standard Clinical Practice PT|This group will follow the protocols established by the PT facility they chose. They will finish treatment two to three weeks before the surgery date, similar to the intervention group.
45826841|NCT00382655|Procedure|Education and referral|
45826842|NCT00382889|Drug|beclomethasone/salbutamol combination|
45826843|NCT00382889|Drug|beclomethasone|
45826844|NCT00382889|Drug|salbutamol|
45826845|NCT04977167|Drug|HG146|HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
45969809|NCT04719507|Procedure|erector spinae block|ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 3 cm laterally to obtain the appropriate visualization. Under aseptic precautions, the needle is inserted and advanced perpendicular to the skin in all planes to contact the transverse process of the vertebra at a variable depth of 2-4 cm from the skin depending on the build of the individual. At this point, the needle tip lies between the erector spinae muscle and transverse process. After negative aspiration, 20 ml of 0.25% bupivacaine is administered in cephalad and caudal directions.
45826846|NCT04977167|Drug|PD-(L)1 antibody|PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.
45826847|NCT04972799|Other|injection of autologous fat at Day 0 and injection of saline at 6 months|injection into the intersphincter space
46080950|NCT05558267|Dietary Supplement|Standard Table Salt|Standard Table Salt is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis.
46080951|NCT05558267|Dietary Supplement|Salt Substitute|"Salt Substitute is available as a crystalized powder. It substitutes potassium chloride for sodium chloride, and thus contains about 50% less sodium than standard table salt.~Salt Substitute is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis."
45668922|NCT05758090|Procedure|NIPE monitor|Procedure/Surgery: NIPE protocol. Give intraoperative fentanyl according to NIPE value. NIPE score 50-70 indicates optimal narcotic effect. NIPE score > 70 indicated overdosage of narcotic and narcotic should be withheld. NIPE score < 50 indicates inadequate narcotic and narcotic should be given.
46080952|NCT05557942|Drug|AV-101|AV-101 (imatinib) administered via dry powder inhalation
45826848|NCT04972799|Other|injection of saline at Day 0 and injection of autologous fat at 6 months|injection into the intersphincter space
45826849|NCT05273177|Other|Chronic ankle instability|Persistent condition of ankle instability after a first ankle sprain episode.
45668923|NCT05758090|Procedure|Control|Procedure/Surgery: Standard protocol. Give intraoperative fentanyl according to vital signs.
45668924|NCT05757388|Drug|Parecoxib + paracetamol|Administers after induction of anesthesia.
45668925|NCT05757388|Drug|Normal saline|Administers after induction of anesthesia.
45668926|NCT05755334|Drug|Ropivacaine|Administration of Ropivacaine
45668927|NCT05750459|Drug|Artesunate|Participants will receive intravenous (IV) artesunate for severe malaria according to national guidelines. After a minimum of 24 hours and when they can tolerate oral therapy, they will transition to oral artemisinin combination therapy (ACT), also per national guidelines.
45668928|NCT05750173|Other|Streamlining of the pre-procedural patient pathway|"Pre-TAVI ICA is associated with procedural risk, radiation, costs and requires hospitalization (2d).~Show that CTA is a viable alternative to rule out ≥50% left main coronary artery (LM) / prox. left anterior descending artery (LAD) stenosis.~An implementation of a standardized patient pathway which is reproducible, will help to streamline the pre-procedural workup of patients without compromising patient safety."
45668929|NCT05749393|Drug|Heparin sodium|Intravenous heparin was administered during intracranial aneurysm embolization with a guide catheter and discontinued at the end of the procedure.
45668930|NCT05746299|Behavioral|Congruent vs. Incongruent|The Congruent vs. Incongruent intervention relates to the feature-based structure of the novel categories (Modular or non-Modular) and whether there is (Congruent) or is not (Incongruent) a match between what was previously learned and the final target category.
45826850|NCT04482959|Drug|Carbetocin|(1-deamino-1-monocarba-(0-2-methyltyrosine)-oxytocin) is a long-acting synthetic agonist analogue of the human oxytocin
45826851|NCT04482959|Drug|Sodium chloride 0.9%|Physiological solution will be used as placebo
45826852|NCT04581395|Other|non-pretreated Succinylcholine|no pretreatment
45826853|NCT04581395|Drug|succinylcholine 1 minute after rocuronium pretreatment|0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 1 min +/- 10 sec after pretreatment
45826854|NCT04581395|Drug|succinylcholine 2 minutes following rocuronium pretreatment|0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 2 min +/- 10 sec after pretreatment.
45969810|NCT04719507|Procedure|thoracic paravertebral block|ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of pleura, transverse process and paravertebral space, the needle is inserted cranial to caudal direction using in-plane approach . After confirming the displacement of pleura with 0.5-1 ml of local anesthetic (LA), 20 ml of 0.25% bupivacaine is administered for the block.
45969811|NCT04719507|Drug|Pethidine Only Product in Parenteral Dose Form|pethidine (1 mg/kg ) once
45969812|NCT04605757|Other|Clinical, functional and radiological lung involvement evolution|Observational / Clinical, functional and radiological long term evolution of SARS-COV-2 lung involvement
45969813|NCT04605835|Diagnostic Test|ULTRASONIC VISUALIZATION OF OBSTRUCTIVE UROPATHIES IN CHILDREN.|The purpose of this study was to develop proposals and recommendations for improving the safety of urological examination of children with obstructive uropathy by using Doppler ultrasound. Based on the results of a comprehensive urological examination of 665 children with congenital ureteral obstruction, a program for scoring the results of ultrasound examination has been developed, which allows using the safest and most informative methods to reliably determine the functional state of the renal parenchyma and the degree of urodynamic disorders in children with obstructive uropathy.
45969814|NCT04605952|Diagnostic Test|Repeat SARS-CoV-2 IgG antibodies at 45-65 days|All cases who initially tested positive for SARS-CoV-2 IgG antibodies would undergo a repeat test at 45-65 days
45668931|NCT05746299|Behavioral|Immediate vs. Awake vs. Asleep|Immediate, Awake, and Sleep refer to either no break, 2.5 hours awake, or 2 hours asleep plus a 30-minute post-nap break to account for sleep inertia between learning and target category.
45668932|NCT05746299|Behavioral|Targeted memory reactivation (TMR)|Targeted memory reactivation (TMR) is the systematic presentation of sounds during sleep that were associated with certain stimuli during learning and will be administered either during slow wave sleep (SWS) or rapid eye movement (REM) sleep.
46080953|NCT05557058|Device|Gore Glaucoma Device Implant (GORE GDI)|Unilateral implantation of one of two different configurations of the GORE GDI
46080954|NCT05555589|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into study eye(s), five times per day for 28 days
46080955|NCT05555589|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4. Direct instillation into study eye(s), five times per day for 28 days
45668933|NCT05741606|Drug|Sodium pentaborate pentahydrate|Capsules containing sodium pentaborate pentahydrate 200, 400, 600, 800, and 1000 mg
45668934|NCT05741606|Drug|Placebo|Placebo capsules
45668935|NCT05741346|Drug|BCX9930|Taken orally at 400 mg twice daily (BID)
45668936|NCT05738733|Device|MsChief Classic Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
45668937|NCT05738733|Device|MsChief Ylang Ylang Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
45668938|NCT05738733|Device|MsChief Vanilla & Citrus Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
45826855|NCT04571879|Drug|Nebulized Lidocaine|Nebulized Lidocaine for Reducing Pain of Nasogastric Tube Insertion in Children
45826856|NCT04571879|Drug|Intranasal Midazolam|Intranasal Midazolam for reducing anxiety of Nasogastric Tube insertion
45826857|NCT04571879|Other|Placebo|Nebulized normal saline and intranasal normal sline
45826858|NCT04563533|Biological|Low-dose vaccine|"Active ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoV GII.4-VP1 protein and recombinant ReNoV GII.17-VP1 protein each 12.5μg.~Other ingredients: aluminum hydroxide adjuvant 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 1 μg, sodium dihydrogen phosphate: 47 μg, disodium hydrogen phosphate: 87 μg."
45826859|NCT04563533|Biological|High-dose vaccine|"Active ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoV GII.4-VP1 protein and recombinant ReNoV GII.17-VP1 protein each 25μg.~Other ingredients: aluminum hydroxide adjuvant 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg."
45668939|NCT05738733|Device|MsChief Tea & Peach Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
45826860|NCT04563533|Biological|Placebo (containing aluminum)|Active ingredients: none Other ingredients: aluminum hydroxide adjuvant: 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg.
45668940|NCT05733637|Other|No intervention|There will be no intervention apply to study participants.
45668941|NCT05732883|Drug|Dexamethasone|Dexamethasone injection
45668942|NCT05732883|Drug|Normal saline|Placebo
45826861|NCT04563533|Biological|Placebo (without aluminum)|Active ingredients: none Other ingredients: L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg.
45826862|NCT05251259|Drug|AZD5718|Randomised participants will receive AZD5718
45826863|NCT05251259|Drug|Placebo|Randomised participants will receive placebo
45826864|NCT05251259|Drug|Montelukast|Randomised participants will receive montelukast
45668943|NCT05729334|Device|Clinicgram Euclides|"Clinicgram Euclides is a software that allows automated calculation of the area of skin lesions using a mobile device. Three different photographs will be taken of the subject's skin lesion. The area of the skin lesion will be calculated using the photograph of the skin lesion, and:~for EUCLIDES 2D, an external marker. The investigator will outline the skin lesion and the external marker in the photograph prior to the calculation of the skin lesion area.~for EUCLIDES 3D, a two reference points selected by the investigator."
45668944|NCT05720455|Drug|Fexofenadine HCL and pseudoephedrine HCL|Extended-Release Tablets
45969815|NCT04605640|Behavioral|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
45969816|NCT04605562|Drug|GP+DDP|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles; induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
45969817|NCT04605562|Drug|Palbociclib|Administered orally
45969818|NCT04605562|Radiation|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
45969819|NCT04605562|Drug|PD-1 blocking antibody|Administered every 3 weeks
45969820|NCT04605562|Drug|Galunisertib|Administered orally
45969821|NCT00248586|Behavioral|Standard CBT (S-CBT)|Standard CBT (S-CBT) is a skills-based training program delivered to patients in 10 weekly, 1-hour sessions.
45969822|NCT00248586|Behavioral|Minimal contact CBT (MC-CBT)|Minimal contact CBT (MC-CBT) covers the same range of procedures featured in S-CBT but relies extensively on self study materials.
45668945|NCT05720312|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Patterned pulsed magnetic stimulation delivered using an electromagnet. We will use a MagVenture rTMS device and a Cool-B65 coil.
45668946|NCT05717205|Diagnostic Test|technetium scitigraphy|patients will have a technetium scintraphy confirming or ruling out gastroparesis. Then the patients will have a gastroscopy with tissue samples from antrum and fundus. During gastroscopy an endo-flip ballon will meassure the distensibility in pylorus.
45668947|NCT05715814|Drug|Empagliflozin 25 MG|PO once daily
45668948|NCT05710172|Device|Auditory Mirror Therapy|21 days, up to 3 hours per day intervention
45668949|NCT05707182|Drug|18F-rhPSMA-7.3|18F-rhPSMA-7.3 PET/MR
45668950|NCT05704322|Other|Wim Hof Methode|The intervention groups will follow a 7-weeks intervention, with one practice session per week at the rehabilitation center led by Wim Hof or one of his instructors. Besides these joint weekly sessions, the intervention groups have to practice daily at home with the Wim Hof Method app.
45668951|NCT05701891|Combination Product|Physiotherapy with integrated Virtual Reality|A 12-week personalised, VR-integrated physiotherapy intervention.
45668952|NCT05701891|Other|Physiotherapy (usual care)|A 12-week usual physiotherapy care intervention.
45668953|NCT05701111|Behavioral|Start with the Heart Students|The Start with the Heart curriculum includes psychoeducation, lessons, and activities, on mindfulness, neurobiology, meditation, positive thinking, movement, and nutrition to promote well-being. The curriculum will be taught in the classroom to students for 15-20 min per day for 6-8 weeks.
45668954|NCT05701111|Behavioral|Start with the Heart Teachers|Pure Edge Inc will train teachers to deliver the Start with the Heart curriculum. The training emphasizes the neuroscience of stress and educator self-care. The teachers will implement the training in their respective classrooms for 6-8 weeks.
45668955|NCT05701111|Behavioral|Cue Centered Therapy Counselors|The Early Life Stress and Resilience Program team members will train school counselors on Cue-Centered Therapy through self-paced online modules, virtual and in-person live training, and office hours as needed. Counselors will implement the intervention with eligible students for 15-18 weeks.
45668956|NCT05701111|Behavioral|Cue Centered Therapy Students|Students who report a threshold of PTSD symptoms will be offered participation in Cue-Centered Therapy with their school counselors. They will have one-on-one therapy that targets trauma experiences through cognitive behavioral tools, narrative therapy, exposure therapy, psychoeducation, and more. Their caregivers will be involved as needed. They will enroll in treatment for 15-18 weeks.
45826865|NCT04330937|Dietary Supplement|dietetics|90 days of consumption
45826866|NCT04939961|Dietary Supplement|Hericium erinaceus|6 capsules per day, 3 times two after breakfast, lunch and dinner
45826867|NCT04939961|Dietary Supplement|Placebo|6 capsules per day, 3 times two after breakfast, lunch and dinner
45826868|NCT04358705|Other|Aim 1: Online survey|"This survey will evaluate perceptions of flavors on appeal, purchasing and risk perceptions of cigarillo products among young adult and adolescent cigarillo users. This survey will be used to inform survey design for further aims.~As a proxy for biological verification of tobacco use status, data on brand, frequency, and pricing will be collected to confirm user status~Participants will rate the role of flavor and report perceptions of product appeal, health risk, advertising exposure and use intentions. Participants will also complete purchase and substitution tasks."
45969823|NCT00402857|Behavioral|Incredible Years Program|The Incredible Years Program is a 10-week group parenting intervention. Parent training sessions will take place once per week for 10 weeks, and will last approximately 2 hours each. Sessions will focus on teaching positive parenting skills, such as appropriate play and use of praise and rewards, as well as limit-setting techniques, such as ignoring, allowing children to experience the natural consequences of their actions, and assigning time-outs.
45969824|NCT04605523|Procedure|blood withdrawal|Additional blood sample will be taken within blood collection as part of standard care
45969825|NCT04605601|Other|Virtual reality treatment|Tennis, boxing, and baseball games of the Wii Sports package sre used for activating the upper extremity functions of the patients. In the tennis game, patients represent people holding rackets.
45969826|NCT04605601|Other|conventional physiotherapy|As the conventional physiotherapy, neuromuscular electrical stimulation and strengthening exercises for the deltoid, infraspinatus, triceps, biceps, supinator, and wrist extensor muscles, and passive, active, active assistive joint Rage of Motion, and stretching exercises for the shoulder, elbow and wrist joints are applied to the patients in the standardized program for the upper extremity in 10 repetitions.
45668957|NCT05701111|Genetic|iSWAB-DNA|Eligible students will give DNA buccal swabs at 2-3 time points for later analysis of genetic markers.
45668958|NCT05699460|Other|This is an observational study.|This is an observational study.
45668959|NCT05698368|Behavioral|Mindset intervention|Participants receive a digital mindset intervention to improve mindsets about osteoarthritis and exercise.
45668960|NCT05698368|Other|Active comparator|Participants receive a series of osteoarthritis education videos and reflective questions that matches the digital mindset intervention in duration and attention.
45455772|NCT05722886|Drug|Vemurafenib in combination with cobimetinib|"Participants will receive vemurafenib at a dose of 960 mg (4 tablets of 240 mg) orally on a twice daily schedule throughout a 28-day cycle.~Participants will receive cobimetinib at a dose of 60 mg (3 tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break.~Participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent."
45969827|NCT04605367|Device|Transcranial stimulation|For both tasks, the training modalities are the same. After the pre-test, this group will physically repeat the correct sequence as many times as possible, during 12 blocks of 30s. After this training, they will perform the post-test. And immediately after the post-test, they will receive the real anodal stimulation. The intensity of the current will gradually increase for 30s until it reaches 1mA, will remain constant for 15min, then will gradually decrease for 30s until 0mA is reached. The current density during stimulation will be 0.04 mA/cm². For the manual task the anode will be centered above C4 (according to the international 10-20 EEG system) that is located near the hand area of M1. The cathode will be placed on the supraorbital region ipsilateral to the trained hand (Fp1). For the body task, the anode will be placed in the center of the cortex (Cz) and the cathode will be placed at the medial supraorbital region (Fpz).
45668961|NCT05692921|Other|Remote Home Monitoring (RHM)|A Virtual platform will be used to provide education and support for ACS patients within the community after a patient is discharged home
45668962|NCT05692921|Other|Rapid Response Nursing|A Rapid Response Nurse will be used to provide education and support for ACS patients within the community after a patient is discharged home.
45668963|NCT05691140|Other|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy targeting Intolerance of Uncertainty
45668964|NCT05690204|Drug|SAP001|Test the efficacy and safety of SAP 001 versus placebo
45668965|NCT05688735|Other|Isosorbide Diester Moisturizer|Isosorbide Diesters (with 0.1% colloidal oatmeal) + Topical Hydrocortisone 2.5% ointment
45668966|NCT05688735|Other|Control Moisturizer|Topical vehicle (with 0.1% colloidal oatmeal) + Topical Hydrocortisone 2.5 % ointment
45668967|NCT05684887|Other|Digital based contact tracing|"Listing of contacts by SARS-CoV-2 positive individuals in Mamal Pro app + verification and validation by a health care worker.~Immediate access to the contact list in Mamal Pro once validated by the health care worker.~Contacts are immediately notified by text message automatically sent to all contacts with phone numbers and later called by the HCWs responsible for carrying out the contact tracing at the district level.~Contacts will be invited to go to the nearest testing facilities/units to get tested.~Those who are unable or refuse to come for testing are followed up by phone for 10 days for the occurrence of COVID-19 symptoms.~Information about the contact tracing process during communication with contacts are recorded in Mamal Pro digital contact tracing module."
45668968|NCT05680740|Drug|VTAMA® (tapinarof) Cream 1%|VTAMA® (tapinarof) Cream 1% applied topically once daily
45668969|NCT05676580|Procedure|cross-linking surgery or intra corneal ring|After keratoconus diagnosis the patient was assigned to surgery
45668970|NCT05676580|Other|abstention|No surgery
45826869|NCT04358705|Behavioral|Eye Tracking Activity|The eye tracking activity consists of a single in-person eye tracking activity that will take place in a private office where the participant will be seated in a chair within a typical viewing distance from a computer monitor equipped with an infrared camera on the monitor to capture precise eye movements. Participants will have their gaze monitored continuously by the camera on the computer monitor while a randomized set of stimuli (product advertisements) are viewed (n=30) for 10 seconds per image. Following each advertisement, an on-screen closed response question will re-center the participant's gaze for standardization prior to the next image
45826870|NCT04358705|Other|Eye tracking survey|Participants will complete a survey using Qualtrics immediately after the eye tracking activity and one week following completion of the activity via email to measure recall of brand name, product flavors, perceptions of cigarillo harm, and tobacco use behaviors and intentions.
45826871|NCT04358705|Behavioral|Online Experimental Marketplace (ETM)|"Administered online via Qualtrics~Participants are given an account balance for use during their assigned ETM based on their average weekly tobacco use calculated from previous interview. Participants will view all four price conditions and all four flavor conditions in random order for a total of 16 rounds~Cigarillo price conditions: 1) market price 2) ½ market price 3) 2X market price 4) 4X market price~Flavor condition: 1) flavored cigarillos and fruit-flavored disposable-cigarettes available 2) unflavored cigarillos and fruit-flavored ecigarettes available 3) flavored cigarillos and tobacco-flavored e-cigarettes available 4) unflavored cigarillos and tobacco-flavored e-cigarettes available.~Participants will purchase cigarillos with their account balance. During all ETM conditions, constant-priced alternative tobacco products (smokeless tobacco, nicotine lozenges, nicotine gum, and the nicotine patch) will be available in addition to the cigarillos and e-cigarettes."
46080956|NCT05555290|Combination Product|PT027|When administered PT027, participants will receive 2 actuations of albuterol- budesonide per dose administered as oral inhalations.
46080957|NCT05555290|Combination Product|PT007|When administered PT007, participants will receive 2 actuations of albuterol administered as oral inhalations.
46080958|NCT05554159|Behavioral|Standard Fitbit Program|Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
46080959|NCT05554159|Behavioral|Virtual Exercise Program|Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
46080960|NCT05553639|Biological|HB-302/HB-301 Alternating 2-Vector Therapy|Alternating Therapy of HB-302 and HB-301. The first 5 doses will be administered every 3 weeks. The 6th dose will be administered 6 weeks after the 5th dose. Subsequent doses will be administered every 6 weeks.
45668971|NCT05674994|Drug|Methylprednisone/Prednisone|"Patients will be enrolled during their hospitalization in pneumology department, as part of current practice, within 7 days of the screening visit. The investigator will perform randomization by connecting to the eCRF, randomization be stratified for the severity of IPF and the treatment with antifibrotic therapy (Nintedanib or Pirfenidone) (yes/no).~If patient is randomized in Glucocorticoids Group:~Day 1, 2 and 3: Intravenous Methylprednisolone 10 mg/kg/d (without exceeding 1000 mg/d). Vials of injectable solution of methylprednisolone® are diluted in 100 ml of NaCl 0.9% or G5%. Perfusion duration is between 20 to 30 minutes.~From day 4 to Day 30: Oral Prednisone slow tappering~1 mg/kg/d for 7 days~0.5 mg/kg/d for 7 days~0.25 mg/kg/d for 7 days,~10 mg/d until Day 30. For 10mg/kg, 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg; rounding to 5 decimal lower if decimal ≤ 7 and the top ten if decimal ≥ 8."
45969828|NCT05518721|Procedure|Hallux Rigidus Treatment|Participants will receive either a synthetic cartilage implant or dermal interposition arthroplasty
45969829|NCT04605289|Drug|lemongrass essential oil gel|"The lemongrass oil gel will be administered by means of a syringe with a bent, blunt-end needle. The needle will be carefully inserted into the periodontal pocket and the gel will be applied in the test sites in a gentle probing manner, attempting to fill the full extent of the pocket. The gel will be applied up to the gingival margin and the excess gel will be removed with sterile gauze.~Periodontal dressing will be applied after the delivery of the drug, and they will be also asked not to eat for thirty minutes.~After placement of the gel in situ, patients will be instructed to follow strict oral hygiene protocol and not chew hard or sticky foods at the gel placement sites for rest of the week."
45969830|NCT04605289|Drug|Placebo|"The placebo will be administered by means of a syringe with a bent, blunt-end needle. The needle will be carefully inserted into the periodontal pocket and the gel will be applied in the test sites in a gentle probing manner, attempting to fill the full extent of the pocket. The gel will be applied up to the gingival margin and the excess gel will be removed with sterile gauze.~Periodontal dressing will be applied after the delivery of the drug, and they will be also asked not to eat for thirty minutes.~After placement of the gel in situ, patients will be instructed to follow strict oral hygiene protocol and not chew hard or sticky foods at the gel placement sites for rest of the week."
45969831|NCT04605289|Procedure|Scaling and root planing|Conventional mechanical treatment by ultra-sonic scalers
45969832|NCT04605328|Other|Two dimension and three dimension ultrasound|Patient will undergo 2D and 3D ultrasound evaluation after CS for detection of CSD
45969833|NCT00251901|Drug|Esomeprazole|
45969834|NCT04605133|Device|Electrical impedance tomography|Every patient is monitored with electrical impedance tomograpy before, during and after prone position.
45969835|NCT05517278|Other|SurgX Antimicrobial Wound Gel|In addition to standard of care, at time of surgery, SurgX applied on the incision after closure and then re-applied at the time of first bandage change on day of discharge.
45969836|NCT05517278|Other|Standard of Care|The control group will receive standard of care.
45969837|NCT04605250|Other|Respiratory variability before and after surgery|The procedure consist of measuring thoracic chest movement and then calculating the respiratory variability reflected by the coefficient of variation in patients undergoing a surgery. A first recording is done during preoxygenation period using as baseline for further comparisons. (T0, 10 min) The second recording is after extubation during the postoperative recovering period, 30 minutes after interruption of sedations. (T1, 20 min, SSPI ou SIPO) The third recording is before transferring back to classical hospitalization, 1h after T1 (20 min). A fourth recording will be realized 24h after surgery for patients hospitalized in the post operative intensive care unit (T3, 20 min) Optional recordings may be realized if the patient is developing a postoperative respiratory complication during his hospital stay. A follow up for maximum 7 days consisting in consulting the medical file will be realized.
45969838|NCT00564772|Drug|Raltegravir, lopinavir, ritonavir|4 days of raltegravir, then 10 days of Kaletra, then 4 days of both with 12 PK sampling at the end of each period.
45969839|NCT00564811|Dietary Supplement|Agaricus blazei (Murrill) ss. Heinemann (sun mushroom)|Agaricus blazei powder, 10 grams/day, for 5 months
45969840|NCT00564967|Behavioral|CBT via the Internet|15 weeks, patients learn about CBT primarily thru a self-help book published on teh Internet, Minimal therapy contact via e-mail(10 minutes/week),
45969841|NCT00564967|Behavioral|CBT group therapy|15 weeks, 1 session/week, (2,5 hours.)
45969842|NCT03454243|Drug|RXDX-106|Patients will receive continuous daily oral doses of RXDX-106 in 21 day cycles. To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), study drug will be administered in an escalated fashion starting at dose of 10 mg/day and will proceed at the dose levels prespecified by the dose escalation schema. Once daily dosing for RXDX-106 will initially be tested. However, other dosing schedules (eg, every other day, weight based, etc) may be tested based on safety and PK data to optimize drug exposure.
45969843|NCT00251940|Drug|Tesaglitazar 0.5 or 1 mg|
45969844|NCT00251940|Drug|Glibenclamide 2.5, 5, 10 or 15 mg|
45969845|NCT04604977|Behavioral|Mindfulness|Patients are followed with a standardized program including: education and support for behavioral measures, behavioral sessions, by mindfulness, once per week for 45 minutes for 6 weeks which usually delivered in groups of 4 - 8 patients.
45969846|NCT04604938|Drug|Losartan|administration of losartan (50 mg) (oral)
45969847|NCT04604938|Drug|Placebo oral tablet|administration of placebo (oral)
45969848|NCT00248742|Behavioral|Psychological behavioral intervention|3x3 hours group intervention followed by 6-9 hours individual psychotherapy based on cognitive behavioral methods
46080961|NCT05552053|Device|MWSH plus Candlelit Care|Candlelit Care is a virtual perinatal mental health application that builds on cognitive behavioral therapy (CBT) to provide Black, Indigenous and POC women and birthing parents access to culturally affirming mental health support during pregnancy. Driven by an integrated care team, women have access to self-guided therapeutic tools, peer coaching and education about perinatal mood disorders as a primary resource. This convenient and trauma informed app allows parents to see if their mental health symptoms warrant further treatment in a secure setting. The app also provides education of role transitions, discussion of types of interpersonal conflicts common around childbirth (including racial discrimination) and techniques for resolving them, and role-playing with feedback from other parents during groups. The goals are to improve self-advocacy skills; patient communication with medical providers and provide a support network with other Black pregnant women.
45668972|NCT05674994|Other|Placebo|"Patients will be enrolled during their hospitalization in pneumology department, as part of current practice, within 7 days of the screening visit. The investigator will perform randomization by connecting to the eCRF, randomization be stratified for the severity of IPF and the treatment with antifibrotic therapy (Nintedanib or Pirfenidone) (yes/no).~If patient is randomized in Placebo Group:~Day 1, 2 and 3: Intravenous Methylprednisolone-Placebo From Day 4 to Day 30: Oral Prednisone-Placebo The Methylprednisolone-Placebo corresponds to 100 ml of NaCl 0.9 % or G5%. Perfusion duration is between 20 to 30 minutes.~For the Prednisone-Placebo, the placebo was an oral solution formulated with a bittering agent (pharmaceutical excipient). Specifically, in place of prednisone, sucrose octaacetate (defined as a GRAS-'Generally Recognized as Safe' excipient by the EMA) was used at 5 mg/mL."
46080962|NCT05552053|Device|MWSH|The Maternal Wellness Self Help (MWSH) app was created to help individuals to manage perinatal depression and anxiety. The app is designed is to meet the emotional needs of those who are pregnant, want to become pregnant or have given birth. This psycho-educational app informs and normalizes the range of emotional responses throughout the reproductive journey. By learning about perinatal mental health, this app hopes to empower patients to understand and name their experiences.
46080963|NCT05551117|Biological|vobramitamab duocarmazine 2.0 mg (Arm A)|2.0 mg/kg intravenous (IV) every 4 weeks
46080964|NCT05551117|Biological|vobramitamab duocarmazine 2.7 mg (Arm B)|2.7 mg.kg IV every 4 weeks
45458599|NCT01145443|Other|Alternative Intensivist staffing models.|During the study period, each participating ICU alternated between two distinct intensivist staffing formats: (i) in the Discontinuous arm of the study, there was a weekend cross-coverage format wherein an intensivist was responsible for care for a two week or half-month block, but colleagues covered the weekends within each block, or (ii) in the Continuous arm of the study, there was an uninterrupted staffing format, wherein a single intensivist was responsible for the entire two week, or half-month, period. In each ICU the study interval was divided into three phases, so that the models alternated twice in each ICU, beginning with either the weekend cross-coverage or the uninterrupted staffing formats, the four hospitals were randomly assigned between these two patterns.
45668973|NCT05670704|Biological|ARGX-119|Patients receiving ARGX-119 IV or SC
45668974|NCT05670704|Other|Placebo|Patients receiving Placebo IV or SC
45668975|NCT05662397|Drug|HST-1011|Increasing doses of HST-1011 given orally as monotherapy.
45668976|NCT05662397|Biological|Cemiplimab|Cemiplimab administered via intravenous infusion in combination with increasing doses of HST-1011 given orally as monotherapy.
45826872|NCT04358705|Other|Aim 3 survey|"Consists of:~A screener and demographic data collection.~A tobacco product withdrawal scale~Upon completion of the ETM, participants will be asked to respond to a quality assurance question regarding the conditions that varied. Participants will be shown a list of 8 possible conditions and must chose one of the three that varied in order to be eligible to receive compensation.~The tobacco product withdrawal scale again~Measurements of nicotine dependence and flavor preferences"
45826873|NCT04358705|Other|Cognitive Interviews|Cognitive Interviews will be done in-person, using Zoom, or over the phone. Interviews will be video or audio recorded. . The participant will be given a select section of the survey questions from Aim 1. The survey will be uploaded to Qualtrics to reflect the way that survey would be conducted in Aim 1. With the survey questions in front of the participant on the computer screen, research personnel will ask probing questions about each one of the survey questions. If the participant is not able to participate in person or via Zoom, they will be allowed to be interview over the phone with access to the Qualtrics survey or a paper form. If the participant is unable to access the internet, the participant will be read the questions by research personnel. The participant will provide feedback about the questions and walk the research personnel through their thought process for approaching each survey question.
45826874|NCT04332107|Drug|Azithromycin|Participants will be shipped a single 1.2 g dose of oral azithromycin
46080965|NCT05549505|Drug|ARV-471|tablets
46080966|NCT05549505|Drug|Anastrozole|1mg tablet
46080967|NCT05549505|Procedure|Surgical resection of breast tumor|Participants will have surgical resection approximately 5.5 months after starting treatment (C6D18 ± 14 days)
46080968|NCT05548738|Drug|medthylprednisolone|a type of steroids injected in epidural space
46080969|NCT05548738|Drug|prolotherapy|a type of hypertonic glucose
46080970|NCT05546346|Device|wearable magnet tracking system|In this group, wearable magnet tracking system was used.
46080971|NCT05538767|Drug|Emodepside|Treatment with Emodepside 30 mg
46080972|NCT05538767|Drug|Albendazole 400mg|Treatment with Albendazole 400 mg
45668977|NCT05662137|Behavioral|Emotions Recognition and Expression|Emotion recognition and expression program consisting of 8 sessions will be used. In this program, patients will have the opportunity to describe their emotions, explain emotions that are difficult to express such as anger, sadness, shame, guilt, and discuss the consequences of suppressed emotions.
45969849|NCT00565006|Drug|MK0859|
45826875|NCT04332107|Drug|Placebos|Participants will be shipped a dose of matching placebo
45969850|NCT04604587|Drug|1. amyloid PET；2. T807 PET|"Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB~Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807"
45969851|NCT00565123|Drug|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops three times daily to each eye for 5 days
45826876|NCT04329065|Biological|pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|Given ID
45969852|NCT00565123|Drug|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops 2 hours on days 1 and 2, and then every 4 hours on days 3-5 (up to 4 times per day)
45826877|NCT04329065|Drug|Paclitaxel|Given via infusion
45969853|NCT00252018|Behavioral|Daily intake of broccoli sprouts|
45668978|NCT05645588|Behavioral|Pranayama assisted trauma-focused standard psychotherapy (TF-SPT)|To prepare patients for the TF-SPT, they received 5-10 minutes of pranayama at the begin of each of the 10 TF-SPT units.
45668979|NCT05645588|Behavioral|Trauma-focused standard psychotherapy (TF-SPT)|Patients wait for 10 TF-SPT units and then are offered to learn pranayama
45668980|NCT05629117|Behavioral|Personalized Diabetes Text Messaging (DB-TEXT) combined with Peer Support Education|Patients who are assigned to the DB-TEXT+PSE group will receive personalized short text message services twice weekly at approximately noon on Monday and Thursday for three months (12 weeks). Furthermore, they will receive the peer support education weekly from the peer supporter by telephone during three months
45668981|NCT05629117|Behavioral|Personalized Diabetes Text Messaging (DB-TEXT)|Personalized Diabetes Text Messaging (DB-TEXT)
45969854|NCT04604509|Drug|Bupropion Hydrochloride Controlled-release|Given PO
45969855|NCT04604509|Drug|Nicotine Replacement|Given via nicotine patch, lozenges, or gum
45668982|NCT05627596|Behavioral|Ask-Advise-Refer|All patients will be asked if they smoke, advised to quit, and referred to the state quitline
45458600|NCT02319382|Radiation|PET with the tracer 18F-DPA-714|
45458601|NCT02319382|Radiation|PET with the tracer 11C-PE2I|
45458602|NCT02319382|Other|MRI|Magnetic field
45668983|NCT05627596|Drug|Nicotine Patch, 14 Mg/24 Hr Transdermal Film, Extended Release|14 mg transdermal nicotine patch
45668984|NCT05627596|Drug|Nicotine lozenge|4mg nicotine lozenge
45826878|NCT04329065|Biological|Trastuzumab|Given IV
45826879|NCT04329065|Biological|Pertuzumab|Given IV
45826880|NCT04328285|Drug|Hydroxychloroquine|Hydroxychloroquine Oral Tablets
46080973|NCT05529797|Other|Veovita-VR|Veovita-VR is a VR intervention with positive emotional stimuli and positive behavioral activation designed to reduce depressive symptoms in people with at least moderate depressive symptoms. In the VR session, the participants stay in a beautiful environment (island, sandy beach, beautiful scenery). They can engage in activities that are perceived as positive (climbing, treasure hunting, listening to music, building sandcastles). The session has a length of approx. 30 minutes. Participants are free to continue to engage with any treatment they require during the duration of the study.
45668985|NCT05619198|Behavioral|High Intensity Interval Exercise|"High Intensity Interval Exercise:~5 minutes resting phase @ 0 watts.~5-minute warm up phase @ 20 watts.~40 minutes of interval work consisting of eight bouts of 1-minute cycling at a power output corresponding to ~85% of VO2max interspersed with 4-minute recovery periods at 20 watts.~5 minutes resting phase @ 0 watts."
45668986|NCT05619198|Behavioral|Moderate Intensity Continous Exercise|"Moderate Intensity Continous Exercise:~5 minutes resting phase @ 0 watts.~5-minute warm up phase @ 20 watts.~40 minutes of MICE 65% VO2max.~5 minutes resting phase @ 0 watts."
45668987|NCT05602987|Procedure|enema|receiving enema at the night before anal surgery
46080974|NCT05524168|Radiation|SBRT|SBRT for metastatic lesions
45668988|NCT05602987|Procedure|no enema|no enema before anal surgery
46080975|NCT05524168|Drug|Camrelizumab|Maximum 6 cycles for combined therapy. Camrelizumab maintenance for 1 year.
46080976|NCT05524168|Drug|Gemcitabine|Maximum 6 cycles for combined therapy.
45826881|NCT04328285|Drug|Placebo of Hydroxychloroquine|Placebo of Hydroxychloroquine Oral Tablets Placebo manufactured to mimic Hydroxychloroquine tablets
45826882|NCT04328285|Drug|Lopinavir and ritonavir|LPV/r Oral Tablets
45826883|NCT04328285|Drug|Placebo of LPV/r Tablets|Placebo of LPV/r Oral Tablets Placebo manufactured to mimic LPV/r tablets
45826884|NCT04308473|Other|Ultra-processed Food Meal|An ultra-processed diet challenge test utilizing 1) potatoes fried in highly refined and processed vegetable oil, including corn, soybean, or canola oil, with wheat and milk derivatives; 2) a beef patty sandwich containing processed American cheese, enriched refined flour, mold inhibitor, preservatives and oxidation/reduction additives such as ascorbic acid, potassium/calcium iodate, alpha-amylase, and azodicarbonamide; and 3) a beverage composed of carbonated water, high fructose corn syrup and caramel coloring. The ultra-processed challenge meal will be obtained from a local restaurant on the day of the challenge test.
45969856|NCT04604509|Other|Questionnaire Administration|Ancillary studies
45969857|NCT04604509|Other|Tobacco Cessation Counseling|Receive behavioral smoking cessation counseling
45969858|NCT04604509|Drug|Varenicline|Given PO
45969859|NCT05467943|Drug|Tazemetostat|All patients will receive 800 mg of Tazemetostat, BID, administered in continuous 28-day therapeutic cycle
45826885|NCT04308473|Other|Whole Food Meal|A whole food diet challenge test utilizing 1) a side salad comprised of fresh leafy vegetables, and typical whole food toppings including fresh onion, fresh tomato, fresh carrots, and raw walnuts with a pure unrefined olive oil salad dressing; 2) a legume-based main dish including chickpeas, lentils and whole grain quinoa; 3) a fresh berry-rich smoothie beverage consisting of organic blueberries, raspberries, strawberries, bananas, and fresh orange juice. The whole food challenge meal will be made by the study team from readily available commercial foods bought from local grocery stores.
45826886|NCT04928261|Drug|Trastuzumab|Patients with early-stage HER2-positive breast cancer who demonstrate a pathological complete response at time of surgery will be treated with HER2 targeted therapy for a total of 9 treatments every 3 weeks (or its equivalent if given weekly) including the treatment received preoperatively.
45969860|NCT04604392|Procedure|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
45826887|NCT04920539|Drug|Active Delta-9-THC|Active Delta-9-THC (0.03 mg/kg) administered intravenously.
45826888|NCT04911881|Drug|IBI321|Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
45969861|NCT00252096|Device|Nucleic acid amplification test|
45969862|NCT04604470|Other|Decision tool|no intervention.
45969863|NCT00565162|Drug|Insulin Glargine|Insulin glargine administered by subcutaneous injection daily at bedtime for 24 weeks.
45969864|NCT05439707|Device|transaricular vagus nerve stimulation|The transaricular vagus nerve stimulator was placed in the left ear trunk, which is dominated only by the auricular branch of the vagus nerve. Continuous stimulation was performed at a frequency of 25Hz with pulse width of 300 μs. The stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, and the treatment lasted for 9 consecutive days.
45969865|NCT05439707|Device|fake transaricular vagus nerve stimulation|The transaricular vagus nerve stimulator was placed in the same position as the experimental group, covered with an insulating film and placed at the site of the stimulation, so that the patient could not actually receive the electrical stimulation. Continuous stimulation was performed at a frequency of 25Hz and pulse width of 300 μs, and the stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, for 9 consecutive days.
46080977|NCT05524168|Drug|Cisplatin|Maximum 6 cycles for combined therapy.
45826889|NCT04906187|Other|Arm A : intraoperative ANI monitoring of nociception|For the experimental group (arm A), the sufentanil doses are adjusted to maintain an ANI between 50 and 70. Morphine doses are adjusted from 0.05 to 0.05 µg / ml. Intraoperative data will be collected for ANI, TIVA and hemodynamics.
45826890|NCT04906187|Other|Arm B : no specific monitoring of nociception|For the control group (arm B), adjustments to the opioid doses are made in relation to the hemodynamic reactions of the patient and the operating times. Intraoperative data will be collected for TIVA and hemodynamics.
45826891|NCT04354493|Device|Myo-electric Gaming Interface|Non-significant risk, video game controller which maps myo-electric control signals to button presses.
45826892|NCT04299269|Other|Questionnaire|Questionnaire including questions about Quality of life, symptoms and general informations
45826893|NCT04903457|Device|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
45826894|NCT04903457|Behavioral|Motor learning|Sequential finger tapping task training is applied to stroke patients.
45668989|NCT05599386|Diagnostic Test|Preoperative test|Patients are subject to quantitative sensory testing, questionnaires, and biomarker analysis prior to surgery.
45826895|NCT04888247|Device|CLARITY|Trans-septal mitral valve replacement
45826896|NCT04487405|Device|OVAnex|OVAnex is a multivarite index assay assessing ovarian cancer risk
45826897|NCT04882241|Biological|Pembrolizumab|IV infusion
45826898|NCT04882241|Drug|Placebo|IV infusion
45826899|NCT04882241|Drug|Cisplatin|IV infusion
45826900|NCT04882241|Drug|Capecitabine|Oral tablets
45826901|NCT04882241|Drug|5-fluorouracil|IV infusion
45668990|NCT05593588|Drug|Fisetin|20 mg per kilogram (kg) of body weight supplied in 100 mg capsules and administered orally on days 0, 1, 28, and 29
45668991|NCT05593588|Drug|Placebo|Looks exactly like the study drug, but it contains no active ingredient. Administered orally on days 0, 1, 28 and 29
45826902|NCT04882241|Drug|Docetaxel|IV infusion
45826903|NCT04882241|Drug|Oxaliplatin|IV infusion
45826904|NCT04882241|Drug|Leucovorin|IV infusion
45826905|NCT04874519|Behavioral|Questionnaire|The questionnaire will be completed at the time of enrollment, every month, and at the end of study. Regardless of current interventions or lack of, assessments will be completed at enrollment and then monthly for a total of 18 months. In order to provide reasonable flexibility to participants, physicians, and study teams, the assessments can be completed within 30 days of the last assessment. The next month will be recalculated based on last reporting date.
45826906|NCT04869995|Other|Interview|An individual semi-structured interview per surgeon, according to an interview guide.
45826907|NCT04481243|Biological|Pneumovax 23- pneumococcal polysaccharide|Children will receive Pneumovax 23 vaccination. Vaccine response as assessed by Global IgG will be drawn 4-6 months after immunization.
45969866|NCT04604041|Diagnostic Test|1. Clinical testing; 2. Neurophysiological examination (TMS, EMNG); 3. Psychomotor examination; 4. Neuropsychological evaluation; 5. Flow cytometry; 6. ELISA|All groups will not have the same intervention. Interventions are listed and numbered for each group.
45969867|NCT00248820|Procedure|Contrast-enhanced ultrasound|Contrast enhanced ultrasound using Sonovue / 2.4 ml per injection - one or two injections (maximum of 9.6 ml).
45969868|NCT04603885|Behavioral|Aerobic exercise program|A randomized controlled trial will be used to test the feasibility of a home-based exercise program to improve BDNF DNA demethylation among individuals with T2DM. A total of 42 participants will be randomized 2:1 to receive aerobic exercise intervention (n=28) or attention control (n=14) for 3 months. This ratio is used to offset an anticipated attrition imbalance across groups.
45826908|NCT04263779|Behavioral|Order of Options|Relevant providers who are part of the Geisinger preferred provider network will be presented at the top of the otherwise ranked list of SNFs.
45826909|NCT04263779|Behavioral|Default Option|Both the list and the map will present only the P-SNFs, with a button allowing patients to view all results only if they opt to do so. The optional P-SNF advantage video will be included and the link to it highlighted.
45969869|NCT04603885|Behavioral|Stretching exercise|stretching exercise
45969870|NCT04603768|Other|Theraband exercises|Group A performed theraband exercises for 6 weeks.In the first 2 weeks theraband with low resistance was used to perform exercises and then we proceeded gradually with higher resistance therabands.Theraband exercises was performed for Shoulder Flexion,Shoulder Extension Strengthening, Shoulder Internal Rotation Strengthening, Shoulder External Rotation Strengthening, Shoulder Abduction, Empty Can Exercise & Rowing Exercise with 8-10 reps, 3sec hold and 2-3 sets With each of these exercises
45969871|NCT04603768|Other|Co-contraction exercises|"Muscle co-contraction is the simultaneous contraction of the muscles acting around a joint. Subject stood upright & contracted both the groups (agonist and antagonist) simultaneously without bringing movement at shoulder joint with 6-8 reps , 3sets & 5- 15 seconds duration of sustained self-arm bracing or stiffening was maintained.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 3rd and 6th week"
46080978|NCT05522452|Other|Telerehabilitation|Telerehabilitation program: Intervention will be applied by video interview for 12 weeks, 2 days a week, 45 minutes a day through the Zoom application. The application is free and can be installed on desktop or laptop computers, tablets and smartphones. The content of the activities to be done for that session by phone call to the parent before the interventions; Information will be given about the preparations such as keeping the materials on the table, suitable environment for that week's session and camera angle. Instructions and tips for parent support during the intervention will be given before and during the session. Intervention will be focused on upper extremity skills and activities of daily life of the individuals.
46080979|NCT05522452|Other|Face to face rehabilitation|Face to face program: Intervention will be applied by physiotherapist for 12 weeks, 2 days a week, 45 minutes a day in clinic. Intervention will be focused on upper extremity skills and activities of daily life of the individuals.
46080980|NCT05517382|Other|supportED|suicide prevention videogame
46080981|NCT05517382|Other|Control|non-health related videogame
46080982|NCT05512182|Drug|Chemotherapy|Pembrolizumab : 200mg/Q3W/IV infusion/Day 1of each 3-week cycle Neratinib : Week 1: 120 mg, Week 2: 160 mg, Week 3 and onwards: 240 mg/QD/Oral/Once daily Paclitaxel : 175mg/m2 /Q3W/IV infusion/Day 1of each 3-week cycle
46080983|NCT05503264|Drug|Satralizumab|"In Part 1, study drug will be administered after all other study related procedures have been performed at a site visit at Weeks 0, 2, 4, and Q4W thereafter. Participants will receive satralizumab according to body weight. Study drug will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.~In Part 2, participants will be asked to choose from one of the following options:~Option 1: continue on randomized, double-blind study drug; Option 2: start open-label satralizumab based on body weight; Option 3: stop study treatment and continue follow-up assessments"
46080984|NCT05503264|Other|Placebo|Satralizumab placebo PFS is identical in composition to satralizumab PFS, but does not contain the satralizumab active ingredient and will be identical in appearance and packaging to satralizumab. A PFS (assembled with an NSD and extended finger flange) filled with 0.5 mL of solution, corresponding to 60 mg satralizumab, may be used in Part 2 once it becomes available at the study site.
45826910|NCT04437095|Other|Psychological Support Based on Positive Suggestion delivered via pre-recorded MP3 message|Daily administration of audiorecording
45826911|NCT04421573|Procedure|BCPHD with D5W|D5W is injected under the investing fascia of the sternocleidomastoid muscle (SCM) using ultrasound guidance in order to infiltrate the space containing the cervical plexus. This is performed on both sides.
45668992|NCT05591625|Behavioral|Eye Movement Desensitisation and Reprocessing|"EMDR is a trauma-focussed, psychological talking therapy whereby the participant verbally relates a narrative of an emotionally disturbing memory, in brief sequential doses, while simultaneously focusing on an external stimulus, most commonly side-to-side finger movements of the psychological therapist. EMDR aims to enable an individual to process memories of the event in order to reduce psychological morbidity. EMDR is widely practiced, so is scalable. It is also protocolised, so can be taught and tested, and allows for fidelity assessment in controlled studies.~The number of sessions will depend on ongoing presence of disturbing memories. This will be determined by the psychological therapist and participant."
45668993|NCT05591066|Behavioral|PFC I-PASS Intervention|Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
45826912|NCT04421573|Procedure|Waiting period with usual care|Same as previous group description
45826913|NCT04418297|Drug|CT-G20|oral tablet
45826914|NCT04418297|Drug|Placebo|oral tablet
45826915|NCT03575195|Drug|Rifaximin|Rifaximin 550mg orally
45826916|NCT03575195|Other|Placebo|Placebo control
45969872|NCT04603768|Other|Isometric exercises|"Isometric exercises of shoulder were performed in subjects for 6 weeks which included isometric Shoulder flexion, shoulder abduction isometric exercise, isometric shoulder external rotation, isometric shoulder internal rotation & isometric shoulder extension with 8-10 reps, 5 sec hold and 2 sets.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 3rd and 6th week"
45969873|NCT05389553|Other|Ultrasound exam|We included all full-term pregnancies accepted for delivery that received an accurate ultrasound scan before the birth
45668994|NCT05591066|Behavioral|PFC I-PASS+ Intervention|PFC I-PASS+ builds on PFC I-PASS to make it better and focus on the special needs of patients who speak languages other than English. PFC I-PASS+ includes all parts of PFC I-PASS plus having interpreters during and after rounds, cultural humility training, and provider communication skills training.
45668995|NCT05590871|Device|FlashPoint renal denervation system|Radio-frequency ablation of renal arterial sympathetic nerves
45969874|NCT04603963|Device|power breathe|respiratory muscle training 1 time a day with power breathe 3 sets of 10 repetitions
45969875|NCT04604002|Device|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
45826917|NCT04406441|Behavioral|Patient Reported Outcome Well Child Visit|Parents will complete the Family Nutrition and Physical Activity risk assessment (Patient Reported Outcome) prior to scheduled well child visit. Parent reported data is integrated into the child's electronic health record to inform the child's primary care provider and the provision of preventive counseling. The primary care provider documents preventive care provided.
45826918|NCT04406441|Behavioral|Patient Reported Outcome Well Child Visit + Food Care|Adapted Parent Training Program will be delivered via telehealth (video or telephone) to parents by trained Wellness Coaches as 6 individual sessions, distributed throughout a 26-week intervention period. Cooking Matters grocery store tours will be delivered (in-person or virtual) to parents by trained grocery store nutritionists during the 26-week intervention period.
45668996|NCT05588882|Procedure|Wavefront-guided LASIK|Topography-guided utilizes topography mapping to perform the ablation
45668997|NCT05588882|Procedure|Wavefront-guided|Wavefront-guided utilizes aberrometry to perform the ablation
45668998|NCT05585749|Other|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program
45668999|NCT05585294|Behavioral|Exercises|Perturbation exercises: A new protocol of perturbation exercises aimed to disturb static and dynamic posture or equilibrium at primarily at body segments at hip and shoulder level were provided. The perturbation was initially started as anticipatory postural adjustment and progressed to compensatory postural adjustment, where stepping on various directions were challenged. The nature of perturbation or push or nudges applied by physiotherapists were progressed from a) self-generated to therapist applied, anticipated to unanticipated, stable to unstable platforms, static to dynamic postural tasks with loaded extremities and at higher level simple to higher cognitive tasks were also incorporated.
45669000|NCT05582798|Drug|Alpha 1-Proteinase Inhibitor 180mg/kg|alpha1-proteinase inhibitor (human) intravenous infusion
45669001|NCT05582798|Drug|Alpha 1-Proteinase Inhibitor 120mg/kg|alpha1-proteinase inhibitor (human) intravenous infusion
45669002|NCT05582798|Drug|Sodium chloride|Sodium chloride 09.% intravenous infusion
45669003|NCT05575102|Other|Walking Football|"Walking Football (Soccer): Typical football rules apply but without running.~Participants will play at a local sports hall for 6-weeks, (2-hour per week). Time will be split between warm-up, football practice drills, and small-sided games."
45669004|NCT05574322|Other|Progressive foot strengthening protocol|"This interventional group will perform the foot strengthening protocol (PRP) with physical tests as :~Maximum muscle strength of the foot~Foot muscle morphology"
45826919|NCT04391777|Other|Fourth ventricle compression technique (CV-4)|The participant is in the supine position and the principal investigator is seated at the patient's head, with elbows resting on the table. The main investigator overlaps his hands with the thenar eminences, contacting the occipital bone squamous part, between the external occipital protuberance and the participant's occipito-mastoid suture. The technique begins with a maintained compression on the occipital squamous part during a deep thorax exhalation. Throughout the compression of the occipital bone and the participant's voluntary inspirations, the principal investigator feels a gradual pressure increase at the thenar eminences. The technique will be performed until reaching the still point, in which the mobility of the occipital bone, respiratory rate and muscle tone decrease, or until 5 minutes elapsed.
45826920|NCT04391777|Other|Sham|The main investigator uses the technique contact but does not perform any type of tissue traction or compression, maintaining this contact for 5 minutes. At the end of the stipulated time, the contact is removed in a subtle way.
45969876|NCT04604002|Device|Color Fundus Photography|Non-contact white light photography
45969877|NCT04604002|Device|Optical Coherence Tomography|A non-contact test that uses light waves to take cross-sectional pictures of the retina
45969878|NCT04603729|Drug|Dexamethasone 2 MG/ML|Dexamethasone 8mg/day will be given intravenous for 5 days to group 1 participants
45969879|NCT04603729|Drug|Methylprednisolone Injection|methylprednisolone 1mg/kg/day will be given intravenous for 5 days to group 2 participants
45969880|NCT04604080|Other|service of questionnaire|Respondents will be given a survey form only and after filling this will be collected back
45969881|NCT04603924|Drug|Niclosamide|Niclosamide is an antihelmintic with in-vitro antiviral activity
45826921|NCT04382963|Other|High Risk - intensive coaching|"The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education, intensive coaching face-to-face.~Furthermore, this group will receive intensive initiation of the American Heart Association Guidelines for Management of Risk Factors with individual face-to-face coaching meetings on lifestyle change and adherence to treatment on at a least quarterly basis."
45455773|NCT05718427|Behavioral|Ayres Sensory Integration Therapy|Ayres sensory integration theory provides evidence from basic and applied science about the ability to receive, sort, process, and make use of the information originating from the body and the environment and perceived by our senses (touch, gravity, body position and movement, sight, smell, hearing, taste). This sensory information goes to the brain, where it is organized and interpreted. As a result, we form a plan of action that allows us to have an adaptive response appropriate for the demands of the environment. A thorough assessment guides the preparation of goals addressing the referring concerns and the recommendations for intervention. Ayres Sensory Integration intervention is provided within the context of professional practice. It is designed to improve sensory perceptual abilities, self-regulation, motor skills, and praxis. In doing so, it supports the client's ability to show improved behavior, learning, and social participation.
45826922|NCT04382963|Other|High Risk - standard care|The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education.
45455774|NCT05709470|Other|No-intervention|Observational cross-sectional study design with no intervention
45969882|NCT04603924|Drug|Placebo|Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
46080985|NCT05498727|Diagnostic Test|Integration of SARS-CoV 2 Testing in HIV, MNCH and TB Clinics|This study employs a quasi-experimental pre-and-post SARS-CoV-2 Ag-RDT integration design in all facilities implementing the 61 facilities in Cameroon and Kenya in Cameroon and Kenya.
46080986|NCT05496244|Device|Laparoscopy|Laparoscopic surgery
46080987|NCT05496244|Device|Robotic-assisted surgery|Robotic-assisted surgery
46080988|NCT05492500|Drug|Ponsegromab low dose|Ponsegromab low dose subcutaneous injection
45669005|NCT05574322|Other|Control group|The control group will not perform the foot strengthening protocol and will continue with all their daily activities with no change in lifestyle.
46080989|NCT05492500|Drug|Ponsegromab medium dose|Ponsegromab medium dose subcutaneous injection
46080990|NCT05492500|Drug|ponsegromab high dose|Ponsegromab high dose subcutaneous injection
46080991|NCT05492500|Other|Matched placebo|Matched placebo subcutaneous injection
45455775|NCT05702905|Drug|Metformin Hydrochloride 500 MG|Metformin oral tablet (500mg per tablet) will be administered in a dose increasing mode: the initial dose will be 500mg twice daily, which will be increased to 1000mg twice daily after two weeks, and then maintained until the end of treatment in total 12 weeks.
45455776|NCT05702905|Drug|Semaglutide, 1.34 mg/mL|Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and increased to 1.0mg QW after another 4 weeks, and then maintained 1.0mg until the end of treatment in total 12 weeks.
45455777|NCT05702905|Drug|Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG|Both Semaglutide injection and Metformin oral tablet will be administered as described above.
45669006|NCT05574309|Device|Dissociation measure of pelvic and scapular girdles by inertial sensors of accelerometer|Dissociation measure of pelvic and scapular girdles by 2 inertial sensors of accelerometer type (IMU BNO055) during a 10 m walking test
45669007|NCT05574309|Device|GAITRite Device|Walking parameter measured during a 10 m walking test with GaitRite device
45669008|NCT05567640|Behavioral|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)|This is a cognitive behavioral treatment (CBT) for emotional disorders. This transdiagnostic intervention consists of eight modules and can be effectively applied to various disorders and problems.
45669009|NCT05567640|Behavioral|Space for depression|Digital CBT program designed to minimize the impact of depression symptoms. Emphasizes CBT strategies and mindfulness through a series of seven structured modules.
45826923|NCT04382963|Other|Low Risk - control|Control participants will undergo the same study events as the Low Risk group, except without receiving information and advice about eliminating stroke risk factors.
45826924|NCT03481205|Device|Ischemic conditioning device|RLIC will be done using a specialized blood pressure device ( Doctormate) that inflates to 200 mm HG for 5 minutes followed by 5 minutes deflation.
45826925|NCT04159025|Device|CoreDx Pulmonary Mini-Forceps|Manufactured by Boston Scientific
45826926|NCT00002897|Drug|cisplatin|
45826927|NCT00002897|Drug|fluorouracil|
45826928|NCT00002897|Procedure|conventional surgery|
46080992|NCT05491525|Drug|Vibegron|Participants will be administered Vibegron orally, once daily (QD)
46080993|NCT05488847|Drug|Celecoxib|preoperative pain medication given to all patients
46080994|NCT05488847|Drug|Pregabalin|preoperative and discharge pain medication given to all patients
46080995|NCT05488847|Drug|Tramadol|preoperative pain medication given to all patients
46080996|NCT05488847|Drug|Dexamethasone|Intraoperative and discharge pain medication given to all patients
45826929|NCT04144907|Dietary Supplement|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein-free cookies and 4 labeled amino acid experimental meals.
45669010|NCT05567640|Behavioral|Space for resilience|This program is built from positive psychology principles and is designed to promote resilience and well-being through seven modules.
45969883|NCT04603534|Other|Aged Simulation Suit|The aged simulation suit (Sakamoto Model M716, Tokyo, Japan) will be worn by students. The simulation suit consist of a several items such as loads, a soft material band with Velcro, glasses, ear plugs, gloves, belts and a cane. All the items are need to simulate one's posture just like in elderly person. Small, medium and large sizes of suits are provided by the company thereby each suit is suitable for each student related to their wearing size. Prior to this study, a total of three sets of suits will be gathered. Then, each student will perform each pre-defined scenarios step by step after the suit is worn. During the activities no help or leading will be given to the students. However, one of the researchers will supervise the students during the activities so that to integrate a safe platform. In addition, each student will be informed that if he/she can terminate the activity whenever it is required.
46080997|NCT05488847|Drug|Acetaminophen|Intraoperative and discharge pain medication given to all patients
46080998|NCT05488847|Drug|Ropivicaine|Intraoperative pain medication given to all patients
45669011|NCT05562388|Device|Somnodent Classic|The efficacy of the device will be evaluated in regards to the response of nocturia. Once patients report an average of voiding per night of less than 2 in the preceding 2 weeks of the follow up they will be classified as responders in term of nocturia and will be evaluated with a second sleep study. Efficacy of MAD will be assessed by comparing the apnea hypopnea index (AHI) values of pre and post sleep study with MAD, and they will be classified as responders if they have 50% improvement in AHI.
45669012|NCT05562011|Device|Caretaker Device placement|placement of the Caretaker device at preanesthesia visit and again postoperatively
45455778|NCT05702905|Behavioral|calorie-restricted diet|All subjects after randomization will be reviewed and evaluated by a nutritionist, and then will receive diet guidance. The clinical nutritionist will develop a written nutrition plan for each subject. The nutrition plan of this study adopted the method of calorie restriction diet (CRD) to develop a diet, which required 83.68 kJ/kg of energy per day, 1.2 g/kg of protein per day, 40%~55% of carbohydrate energy supply ratio, and 20%~30% of fat energy supply ratio, to ensure the intake of vegetables, fruits and other rich dietary fiber, and drinking more than 1.5 L per day. The nutritionist will explain the method of food exchange in detail to enrich the food types of patients. The diet diary will be distributed to each subject, and the subjects will be required to make a return visit once every four weeks, return the diet diary each time, and receive guidance according to their compliance.
45826930|NCT03420209|Behavioral|Group applying PNF technique|
45826931|NCT00002903|Drug|docetaxel|
45826932|NCT03375203|Drug|Placebo|Matching placebo will be administered once daily based upon dosing group.
45826933|NCT03375203|Drug|JNJ-42847922, 5 mg|JNJ-42847922 will be administered as 5 mg (2*2.5 mg capsule) oral capsules once daily.
45826934|NCT03375203|Drug|JNJ-42847922, 10 mg|JNJ-42847922 will be administered as 10 mg oral capsule once daily.
45826935|NCT03375203|Drug|JNJ-42847922, 20 mg|JNJ-42847922 will be administered as 20 mg oral capsule once daily.
45826936|NCT03375203|Drug|Zolpidem|Zolpidem will be administered as 5 mg or 10 mg (2*5mg capsule) oral capsule once daily based upon the local labeling information.
45826937|NCT00002909|Drug|chemotherapy|
45826938|NCT00002909|Drug|oral sodium phenylbutyrate|
45826939|NCT00002915|Drug|penclomedine|
46080999|NCT05488847|Drug|Epinephrine|Intraoperative pain medication given to all patients
46081000|NCT05488847|Drug|Ketorolac|Intraoperative pain medication given to all patients
46081001|NCT05488847|Drug|Tizanidine|Discharge pain medication given to all patients
45826940|NCT00002921|Drug|suramin|
45826941|NCT00002921|Drug|therapeutic hydrocortisone|
45826942|NCT00383045|Drug|Buprenorphine/Subutex|
45826943|NCT00383045|Drug|Naltrexone|
45826944|NCT00383045|Procedure|Drug counseling|
45826945|NCT00383591|Biological|Hepatitis B adjuvanted vaccine|
45826946|NCT00383591|Biological|Engerix-B|
45826947|NCT00383669|Dietary Supplement|Multivitamins (including B, C and E)|One daily oral dose of 20 mg B1, 20 mg B2, 25 mg B6, 100 mg niacin, 50 μg B12, 0.8 mg folic acid, 500 mg C, and 30 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
45826948|NCT00383669|Dietary Supplement|Multivitamins B, C and E|One daily oral dose of 1.2 mg vitamin B1, 1.2 mg vitamin B2, 1.3 mg vitamin B6, 15 mg niacin, 2.4 μg vitamin B12, 0.4 mg folic acid, 80 mg vitamin C, and 15 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
45826949|NCT00383825|Procedure|Anterior segment indocyanine green angiography|
46081002|NCT05488847|Drug|Magnesium|Discharge pain medication given to all patients
45669013|NCT05560425|Behavioral|Koru Mindfulness (KM) Training|The Koru Basic curriculum consists of four weekly interactive 75-minute classes delivered online through Zoom. Each class consists of an overview of 2-3 skills, group practice of the skills, and group reflection. Topics discussed during each training visit include: belly breathing, dynamic breathing, body scan (week 1); walking meditation, gatha (week 2); guided imagery, labeling thoughts (week 3); eating meditation, and labeling feelings (week 4). Participants are instructed to practice a skill for 10 minutes/day and log any reflection on that practice using the Koru phone application.
45969884|NCT05364125|Other|Olfactory Training|Four aromatic substances will be used (Citrus limon, Eucalyptus radiata, Pelargonium graveolens, Juniperus virginiana)
45969885|NCT05364125|Other|Control|Normal Saline will be used
45969886|NCT00248898|Procedure|Cardiac Surgery|Coronary artery bypass graft surgery, aortic valve replacement, mitral valve replacement, aortic aneurysm repair
45969887|NCT04603378|Other|KB195|KB195 is a novel glycan
45969888|NCT04603378|Other|Polydextrose|Polydextrose is an oligosaccharide
45969889|NCT04603378|Other|Pullulan|Pullulan is an oligosaccharide
45826950|NCT04062461|Other|Multifaceted strategy based on sending text messages(SMS)|"multifaceted strategy based on sending text messages(SMS) to patients with heart failure.~Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity).~The text messages are about how the patient should take your drugs (evem diuretics), measure blood pressure and weight in Kg, and about signals and symptoms (shorthbreathness during the night), and about how important is practice physical exercises and don't drink alcohol."
45826951|NCT04062461|Other|Usual outpatient care|Educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity)
45826952|NCT04329455|Procedure|Endoscopic thyroidectomy|Endoscopic thyroidectomy in Thyroid Nodules
45826953|NCT00002933|Drug|irinotecan hydrochloride|Irinotecan IV at a starting dose weekly for 4 weeks followed by 2 weeks of rest. Treatment continues in the absence of disease progression or unacceptable toxicity. Tumor status is reassessed every 12 weeks during study. Patients attaining a complete response may receive additional courses of treatment. Patients are followed until death.
45826954|NCT00002939|Drug|irinotecan hydrochloride|
45826955|NCT00002939|Drug|paclitaxel|
45969890|NCT04603378|Other|Maltodextrin|Maltodextrin is a digestible carbohydrate
45969891|NCT04603573|Device|fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride )|5% Sodium Fluoride Varnish is a fluoride varnish which is applied to tooth surfaces for sealing dentinal tubules and treatment of hypersensitive teeth. The varnish is applied in a thin layer over the tooth with an applicator brush, and moisture from saliva cures the varnish for adhesion to the tooth surface.
45969892|NCT04603573|Device|Resin based fissure sealant (3M Clinpro sealant )|"teeth will be isolated with coton rolls and saliva ejector then etching for pits and fissure then tooth will be washed then apply resin based fissure sealant on occlusal surface.~resin fissure sealant is a more sensitive for saliva."
45969893|NCT00252213|Drug|Human BNP|
45969894|NCT00565201|Drug|Botox and rehab|Patients will BOTOX® (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
45969895|NCT00565201|Drug|Placebo and rehab|Patients will receive placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
45969896|NCT05361824|Drug|Ketorolac Injection|dosage form: intravenous dosage: 30mg frequency: 8 hours apart (TDS) duration: for 48 hours post operatively
46081003|NCT05488847|Drug|Ibuprofen|Discharge pain medication given to all patients
46081004|NCT05488847|Drug|Oxycodone Hydrochloride 5 Mg|Only given to active comparator group
46081005|NCT05487911|Device|Repetitive Transcranial Magnetic Stimulation|4 weeks of active rTMS (total of up to 20 sessions)
45969897|NCT05361824|Drug|Paracetamol|dosage form: intravenous dosage: 1gm frequency: 6 hours apart (QID) duration: for 48 hours post operatively
45969898|NCT04603612|Procedure|Primary TURBT|"As shown in (Fig. 1), all patients will be thoroughly evaluated by medical history and physical exam, laboratory investigations, abdominal pelvic ultrasound (US). Then, all patients will be managed by cystoscopy and initial complete TURBT. Patients with benign pathology, non-urothelial carcinoma or muscle invasive disease, will be excluded from the study.~After 4-6 weeks, eligible patients will be appointed for repeat resection TURBT."
45969899|NCT00248937|Behavioral|Positive affect and self-affect induction|
45969900|NCT04603222|Device|SUMMIT BRUSH|SUMMIT BRUSH used for the treatment of blepharitis
45969901|NCT04603222|Other|Ocusoft Lid Scrub Original Foaming Eyelid Cleanser|treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser
45969902|NCT04603339|Other|Multidisciplinary rehabilitation programme delivered via telehealth|"12 week programme of;~1) Physiotherapy led aerobic and resistance exercise 2)1:1 Dietetics Counselling 3) Group Multidisciplinary Education Sessions"
45969903|NCT05314829|Other|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is a phase-based evidence-based treatment method for children and adolescents between 6-18 years who experience posttraumatic stress symptoms following trauma exposure. Parents or other close caregivers receive parallel sessions. It is normally provided through 12-16 sessions.
45969904|NCT04603261|Diagnostic Test|Contrast concentration in urine|"Iodinated contrast content of urine samples, collected post-contrast over a period of 5 days at all times of natural excretion within that period, will be assayed.~Serum creatinine will be measured daily before (day 0) and during 5 days post-contrast, and again at 1 month post-contrast."
46081006|NCT05487625|Behavioral|High-ventilated cigarette alone|High-ventilated cigarettes are the only available cigarettes in the Experimental Tobacco Marketplace which increases in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
46081007|NCT05487625|Behavioral|Low-ventilated cigarette alone|Low-ventilated cigarettes are the only available cigarettes in the Experimental Tobacco Marketplace which increases in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
46081008|NCT05487625|Behavioral|High- and low-ventilated cigarette with high-ventilated cigarettes increasing in price|High- and low ventilated cigarettes are available in the Experimental Tobacco Marketplace with high-ventilated cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
45969905|NCT00252252|Device|VPAP non-invasive ventilator|
45969906|NCT00252252|Device|AutoVPAP non-invasive ventilator|
45969907|NCT04603456|Drug|Lacteol fort|Lacteol fort is a drug containing lactobacilli
45826956|NCT03151967|Drug|Lactobacillus crispatus CTV-05|vaginal applicator with medium containing drug
45669014|NCT05560425|Behavioral|Navigating College (NC) Training|With topics discussed from the Freshman Survival Guide book, this training provides a closely matched active control group for KM Training. The training consists of four weekly 75-minute classes delivered online through Zoom. Each class consists of lecture and group discussions on topics related to navigating college. Topics discussed during each training visit include: habits, roommate issues, homesickness, the internet (week 1); strategies when sinking, study skills, getting involved, habit formation (week 2); HALT, gateway habit (week 3); and academic success tips, taking notes, and procrastination (week 4). Participants are instructed to journal about learned information and skills for 10 minutes/day.
45826957|NCT03151967|Drug|Placebo|vaginal applicator with medium containing no drug
45826958|NCT03142919|Biological|Lipopolysaccharide|Lipopolysaccharide (LPS) derived from E. Coli group O 113:H10:K negative
45826959|NCT03142919|Biological|Placebo|Saline solution
45826960|NCT04226027|Behavioral|T2.coach|"T2.coach is a smartphone app for low-burden capture of diet and blood glucose (BG) levels and for reviewing past records, integrated with FitBit for captured of physical activity and sleep. All captured data are sent to the computational inference engine that uses machine learning methods and expert system to formulate personalized behavioral goals. Examples of behavioral goals include the following: For high carbohydrate breakfasts, reduce your carbs to be about 1 carb choice. Examples of 1 carb choice are 1 slice of whole wheat toast, 1 cup of oatmeal, or 1 apple. The T2.coach chatbot companion uses text messages to help individuals set goals that are consistent with evidence based guidelines for diabetes self-management, inferences on data captured with T2.coach, and their own preferences, as well as send individuals goal reminders and prompts for reflection on goal achievement."
45826961|NCT04009967|Drug|Pembrolizumab|Pembrolizumab 200 mg every three weeks for 3 cycles only
45826962|NCT03085823|Device|Sirolimus Coated Balloon|
45826963|NCT04000217|Behavioral|Written Exposure Therapy|In this study, written exposure therapy is delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
45826964|NCT04000217|Behavioral|Imaginal Exposure Therapy|Delivery of imaginal exposure in this study will mirror the procedures used in WET. It will be delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
45826965|NCT00002945|Biological|aldesleukin|IV
45826966|NCT00002945|Biological|filgrastim|IV
46081009|NCT05487625|Behavioral|Low- and high-ventilated cigarette with high-ventilated cigarettes increasing in price|Low- and high-ventilated cigarettes are available in the Experimental Tobacco Marketplace with low-ventilated cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
45969908|NCT04603456|Drug|Standardized Timothy Grass Pollen|SLIT includes 2 phases build up and maintenance phases. (Jubilant HollisterStier LLC 14110 Collections Drive, Chicago USA) .
45969909|NCT04603456|Drug|Lacteol fort and Standardized Timothy Grass Pollen|Lacteol fort is a drug containing lactobacilli and the Standardized Timothy Grass Pollen includes 2 phases build up and maintenance phases.
45969910|NCT05285813|Drug|Vibecotamab|Given by vein (IV)
46081010|NCT05487625|Behavioral|Usual, high- and low-ventilated cigarette with usual cigarettes increasing in price.|Usual cigarette, low- and high-ventilated cigarettes are available in the Experimental Tobacco Marketplace with usual cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
46081011|NCT05487599|Biological|LY3884961|Participants will receive a single dose of LY3884961, administered via IV infusion
46081012|NCT05487599|Drug|Methylprednisolone|1 IV pulse administered as concomitant medication
45969911|NCT05285813|Drug|Dexamethasone|Given by vein (IV) over about 60 minutes before the dose
45969912|NCT05285813|Drug|Acetaminophen|Given by mouth (PO) about 30-60 minutes before the dose
45969913|NCT05285813|Drug|Diphenhydramine|Given by mouth (PO) or Given by vein (IV) about 30-60 minutes before the dose
45669015|NCT05552196|Drug|Ponesimod|Ponesimod tablet will be administered orally.
45969914|NCT00252291|Drug|Aridol|
45826967|NCT00002945|Drug|cyclophosphamide|IV
45669016|NCT05552196|Drug|Carbamazepine|Carbamazepine tablet will be administered orally.
45669017|NCT05538247|Drug|Indomethacin|Immediate release oral capsules 50 mg, 3 times a day for 6 days
45669018|NCT05538247|Dietary Supplement|S. boulardii CNCM I-745|Two 250 mg capsules orally twice daily for 14 days
45669019|NCT05538247|Drug|Placebo|Two 250 mg capsules that contains no active study ingredient orally twice daily for 14 days
45826968|NCT00002945|Drug|cytarabine|IV
45826969|NCT00002945|Drug|etoposide|IV
45826970|NCT00002945|Drug|idarubicin|IV
45826971|NCT00002945|Drug|melphalan|IV
45826972|NCT00002945|Procedure|peripheral blood stem cell transplantation|IV
45969915|NCT00252291|Drug|Methacholine|
45969916|NCT00252291|Procedure|Exercise challenge|
45969917|NCT04602793|Diagnostic Test|ultrasonography|All ultrasonographic examinations were performed by a single physiatrist experienced in musculoskeletal sonography. The full course of the sciatic nerve (SN), tibial nerve (TN), and common peroneal nerve (CPN) was assessed in a craniocaudal direction starting from the subgluteal fold to the popliteal fossa. The probe was placed axially on the nerves (perpendicular to the nerve) and the cross-sectional area (CSA) was measured at the same level proximal to the bifurcation for the SN , and at a point distal to the bifurcation of the SN for the TN and CPN (Figure 2). The values from the normal sides were accepted as controls.
45969918|NCT04602676|Diagnostic Test|Rehydration calculator application with DEP algorithm|4 week period where clinicians will use a rehydration calculator application with the DEP algorithm followed by a 1 week washout period.
45969919|NCT04602676|Diagnostic Test|Rehydration calculator application|4 week period where clinicians will use a rehydration calculator application without the DEP algorithm followed by a 1 week washout period.
46081013|NCT05487599|Drug|Sirolimus|Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
46081014|NCT05487599|Drug|Prednisone|Administered orally as concomitant medication, followed by dose tapering
45669020|NCT05536414|Drug|Centanafadine (328.8 mg)|Oral, extended-release (XR) capsule
45669021|NCT05536414|Drug|Escitalopram|Oral, extended-release (XR) capsule
45669022|NCT05536414|Drug|Placebo|Oral, extended-release (XR) capsule
45669023|NCT05536258|Other|Fluid|The investigators will titrate fluid administration to maintain a RI > 90 over at least 85% of the intraoperative period lasting from induction until the end of anesthesia. Specifically, the investigator will consider titration to have been successful if 85% of patients in the RI group sustain a RI > 90 over at least 85% of the intraoperative period.
45669024|NCT05533632|Drug|Semaglutide|Participants will receive semaglutide s.c. injection once weekly in a dose escalation manner for 24 weeks.
45669025|NCT05531916|Other|Pressurized gloves and foot caps|Using pressurized gloves and foot caps in order to prevent chemotherapy-induced peripheral neuropathy (CIPN).
45669026|NCT05528562|Other|PrEP Rapid Access|'Rapid PrEP Access' is a low-threshold intervention designed to provide on-site access to HIV self-testing at the Victory Program for persons who use opioids.
45669027|NCT05528562|Other|HIV self-testing|After enrollment the research assistant (RA) will provide the participant with a HIV self-test and provide instructions on how to obtain a proper sample for the test. It uses an oral fluid test and yields results within 20 minutes.
45826973|NCT00002945|Radiation|radiation therapy|delivered to the cancer cells
45826974|NCT00002951|Drug|fluorouracil|
45826975|NCT00002951|Drug|hydroxyurea|
45826976|NCT00002951|Procedure|surgical procedure|
45826977|NCT00002951|Radiation|radiation therapy|
45826978|NCT03075839|Other|Cigarette Brand Switching|Adult smokers will be switched from smoking menthol cigarettes to non-menthol cigarettes for a period of two weeks
45826979|NCT03058289|Drug|INT230-6|"INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.~The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.~The drug is stored frozen and must be dosed at room temperature.~The drug dose to be administered is set by the tumor volume of the target lesions - not the subject's body surface area"
45826980|NCT03058289|Biological|anti-PD-1 antibody|The anti-PD-1 antibody will be added concomitantly with INT230-6 as noted in cohort DEC and DEC2
45969920|NCT04602832|Other|Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19|ENHANCE is a 12-session program designed to help improve subjective well-being, especially through the challenges of a pandemic. The ENHANCE program introduces and teaches people about the evidence-based principles and skills that have been shown across decades of research to improve overall health and well-being.
45669028|NCT05528562|Other|Dried blood spot testing|HIV Dried blood spot (DBS) testing provides an accurate method of measuring the HIV viral load in comparison to plasma viral load.
45969921|NCT05285501|Behavioral|Group general fitness training|A single session of general fitness training will be composed of low-intensity, general-fitness exercises. Most of the exercises will be carried out in a sitting position and standing positon. The session will contain aerobic (general warm-up), musculo-articular (strengthening muscles and joints range of motion) and stabilizing exercises (improve spatio-visual coordination). Conducted by a physiotherapist in group form.
45669029|NCT05527405|Device|The MapHabit System|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilizes visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
45669030|NCT05526729|Other|Beovu|Prospective observational study. There is no treatment allocation. Patients prescribed with Beovu for the first time for diabetic macular edema are eligible to enroll into this study.
45669031|NCT05519527|Drug|Part 1 (STI-6129)|Given by vein (IV)
45969922|NCT05285501|Behavioral|Group relaxation and psychoeduaction|A single session of relaxation (10 minutes) psychoeducation (10 minutes) will contain minilectures about mental well-being and psychohygiene. In summary 20 minutes.
46081015|NCT05487235|Drug|GDC-1971|Capsule or tablet administered orally.
46081016|NCT05487235|Drug|Atezolizumab|Administered as IV infusion.
46081017|NCT05487235|Drug|Omeprazole|Administered orally as tablet or capsule in the acid-reducing agent assessment.
45669032|NCT05519527|Drug|Part 2 (STI-6129)|Given by vein (IV)
45669033|NCT05515718|Other|Standard pain management|Patients undergo ultrasound-guided femoral nerve blockperformed by a trained emergency physician, under strict aseptic conditions After the femoral nerve block is performed, the patient is monitored and (BP, HR, SpO2, ECG) during 90 minutes.
45669034|NCT05515718|Other|Femoral nerve block|Patients undergo ultrasound-guided femoral nerve blockperformed by a trained emergency physician under strict aseptic conditions, immediately after oral informed consent is obtained. After the femoral nerve block is performed, the patient is monitored and (BP, HR, SpO2, ECG) during 90 minutes.
45669035|NCT05496192|Drug|Nivolumab/rHuPH20|Specified dose on specified days
45669036|NCT05496192|Drug|Nivolumab|Specified dose on specified days
45669037|NCT05493072|Other|RxConnect|Participants use RxConnect, an on-demand clinical decision support tool that receives medication and patient inputs and uses them to filter an underlying formulary, such as the BNF, and perform dosing calculations, as needed, to return patient-specific dosing recommendations.
45826981|NCT03058289|Biological|anti-CTLA-4 antibody|The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC
45826982|NCT00002963|Drug|aminolevulinic acid hydrochloride|
45826983|NCT00002963|Procedure|conventional surgery|
45826984|NCT00002969|Drug|paclitaxel|
45826985|NCT00002987|Biological|bleomycin sulfate|
45826986|NCT00002987|Drug|cyclophosphamide|
46081018|NCT05483803|Behavioral|Adhera® Caring digital intervention for Type 1 Diabetes|The Adhera® Caring is a mobile based personalized digital intervention for caregivers, lasting for 1 or 3 months (depending on the sub-study).
46081019|NCT05482893|Drug|PT886|PT886 monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47.
45669038|NCT05477758|Behavioral|Collaborative care|Participants in the intervention group were allocated a receive a low-intensity programme of behavioural activation specifically designed for adults ≥65 with subthreshold depression. An allocated case manager (primary care mental health worker/ Improving Access to Psychological Therapy) delivered collaborative care for an intended 8-10 weeks. This ran alongside general practitioner (GP) usual care. Collaborative care in both CASPER and CASPER+ trial included weakly telephone/ face-to-face support, active surveillance and symptom monitoring
45826987|NCT00002987|Drug|doxorubicin hydrochloride|
45826988|NCT00002987|Drug|etoposide|
45826989|NCT00002987|Drug|prednisolone|
46081020|NCT05475392|Other|Traditional Physical Therapy|A 2-week physical therapy program will be arranged. Each patient will be given 60 min session , 10 min for neck ROMS (10 reps for each ROM) , 10 min neck Isometrics (5 reps on each side) , 30 sec static gentle stretch of levator scapulae (3reps) , 30 sec static gentle stretch of trapezius (3reps), 5 min Soft tissue manipulation , 5 min Shoulder shrugging (10reps) , 10 min for PIR
45826990|NCT00002987|Drug|vincristine sulfate|
45826991|NCT00002987|Radiation|radiation therapy|
45826992|NCT02919683|Drug|Nivolumab|
45826993|NCT02919683|Drug|Ipilimumab|
45826994|NCT02919683|Procedure|Standard of Care Surgery|
45826995|NCT03933293|Drug|AK102|450mg, Q4W, subcutaneous injection
45826996|NCT03933293|Drug|Statins|Lipid-lowering therapies
45826997|NCT03933293|Drug|Ezetimibe|Lipid-lowering therapies
45826998|NCT03926741|Drug|GSNO|patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
45826999|NCT00002993|Drug|cisplatin|
45827000|NCT00002993|Drug|doxorubicin hydrochloride|
45827001|NCT00002993|Drug|mitomycin C|
45827002|NCT01928082|Drug|Transdermal estradiol|4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day
45969923|NCT05285501|Device|VRTierOne|"As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VRTierOne Stolgraf® provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the lector (therapist) tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient influences the course of this story, becomes an active participant of the therapeutic process and sees the effects his work."
45969924|NCT04602910|Device|a web-based shared decision-making tool|Five major parts were developed with the use of the action research approach. The Introduction and Options (parts 1 and 2) describe the severity of the cancer treatment and infertility and the knowledge of fertility preservation, respectively. The SDM tool was designed as a step by step process (part 3) that involves the comparison of options, patient's values and preferences, their knowledge regarding infertility and options, and reaching a collective decision. The Resources (part 4) provide information on the hospitals that provide such services, and the References (part 5) list all the literature cited in the website. The results show the web-based SDM meets both the patients' and health providers' needs and helps reproductive-age patients with breast cancer make decisions on fertility preservation.
45669039|NCT05477758|Other|Usual General Practitioner (GP) care|Participants allocated to the control group received usual GP care. Participants did not receive any additional care to their usual primary care management for subthreshold (CASPER) or Major (CASPER+) depression in line with National Institute for Health and Care Excellence (NICE) guidelines as implemented in their GP and local service provision.
45669040|NCT05477758|Behavioral|Behavioral Activation Self-Help guide|Participants in the intervention arm were provided with a self-help booklet based on clear principles of BA for depression. The purpose of the booklet was to introduce simple behavioural strategies for improving mood. Participants were encouraged to (1) re-establish their daily routine, (2) increase meaningful activities and (3) reduce avoidance behaviours. Participants also received 3 phone calls at week 1, 3 and 6 designed to check the booklet had arrived and to encourage the use of the materials. All participants received their usual GP care
45669041|NCT05477368|Dietary Supplement|D-β-hydroxybutyric acid with R-1,3-butanediol|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
45669042|NCT05477368|Other|Inert placebo|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
45669043|NCT05472623|Drug|Adagrasib|Oral Adagrasib 600 mg twice daily for 6 weeks prior to surgery.
45669044|NCT05472623|Combination Product|Adagrasib/Nivolumab|Oral Adagrasib 400 mg twice daily for 6 weeks and IV nivolumab 240mg every 2 weeks for 3 doses prior to surgery.
45669045|NCT05466110|Device|Spinal Cord Stimulation|Epidural application of electrical current to the spinal cord
45669046|NCT05466110|Procedure|Spinal Fusion Surgery|screw-rod system based spinal instrumentation
45669047|NCT05464524|Other|Main questionnaire|10-15 minute questionnaire asking about environmental factors (i.e daily lifestyle questions), quality of life, comorbidities among others.
45669048|NCT05464524|Other|Optional 12-week follow up questionnaire|A 5-minute questionnaire asking about changes to the quality of life and DFU status since the initial questionnaire.
45669049|NCT05442775|Drug|Reldesemtiv|Oral tablet
45669050|NCT05438394|Drug|melphalan hydrochloride for injection|Intravenous (iv) infusion for 20 minutes on Day 1 of a 21-day chemotherapy cycle
45969925|NCT00248976|Behavioral|Net-present value of individual health behaviors in years|
45669051|NCT05434702|Behavioral|Digital Diet Diary|Participants will be asked to complete the Fitbit 3-day food record, which consists of inputting each food and beverage consumed for two weekdays and 1 weekend day into the Fitbit application. This digital diary includes taking photos of each food and beverage consumed during the 3 day food record period on the participant's iphone or ipad.
45669052|NCT05434702|Behavioral|NHANES Food Frequency Questionnaire (FFQ)|Participants will complete the the Food Frequency questionnaire which indicates usual food intake over the past year.
45669053|NCT05434702|Behavioral|Fitbit data collection|Participants will be asked to wear a Fitbit continuously (24/7) for one week to track steps and activity intensity. The Fitbit is worn on the wrist and uses accelerometer and heart rate technology to quantify steps taken and integrated barometric altimeter to measure activity intensity. The resulting Fitbit data will be automatically pulled from the participant's smartphone or study device.
45669054|NCT05434702|Behavioral|Quality of Life questionnaire|The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) includes questions about participant's quality of life during the past week, self-reported general health, self reported chronic conditions and psychological distress using a scale from 1-5, 1=excellent, 5= poor. A lower total score indicates better qualify of life.
45669055|NCT05434702|Behavioral|Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire|The Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
45827003|NCT01972776|Drug|QBM076|Supplied in 25 mg and 75 mg capsules
45827004|NCT01972776|Drug|Placebo|Matching placebo capsules
45827005|NCT00002999|Drug|cisplatin|
45827006|NCT00002999|Drug|fluorouracil|
45827007|NCT00002999|Radiation|radiation therapy|
45969926|NCT04602715|Drug|MET-2|Subjects will take capsules containing MET-2 daily during the trial. There will be a loading dose at the start of dosing, and a daily dose. There will be a booster dose given at week 2 and a second booster dose taken at week 4 for those subjects who have not improved by that time.
45969927|NCT04602715|Drug|Placebo|Placebo Control
45969928|NCT04602403|Procedure|rigid ureteroscopy|endoscopic treatment of ureteric stones by extraction or peumatic desintegration or laser
45969929|NCT05268809|Other|Ketogenic diet|The ketogenic diet is a normo-caloric diet composed of high-fat (70%), low-carbohydrate (10%), and adequate protein (20%) that induces fasting-like effects and the production of ketone bodies.
45969930|NCT00565240|Drug|Marvelon|oral contraceptive
45827008|NCT04330469|Procedure|Periodontal therapy|"Treatment will be performed by a periodontist.~Intensive removal of subgingival and supragingival calculus and plaque biofilm by scaling, root-planing and polishing. The procedures will be carried out with the use of hand scalers and a piezoelectric ultrasonic scaler with universal tips. Disclosing solution will be used to visualize the plaque for the clinician.~One to four sessions of subgingival scaling and root planing by quadrant, under local anesthesia as may be deemed necessary during the study period.~Subgingival irrigation using an antiseptic mouth rinse (chlorhexidine 0.12%).~Polishing of the coronal and radicular surfaces of the teeth."
45969931|NCT00565240|Drug|Nuvaring|contraceptive vaginal ring
45969932|NCT00565240|Drug|Letrozole|Aromatase Inhibitors
45827009|NCT04330469|Procedure|Oral hygiene advice|Oral hygiene advised by Periodontist
45969933|NCT04719780|Behavioral|Emotionally Focused Therapy for Individuals|Emotionally Focused Therapy for Individuals (EFIT) is formulated as a transdiagnostic treatment to treat depression and anxiety, adapted from the well-studied Emotionally Focused Therapy. EFIT has been formulated as an attachment-based alternative to current cognitive approaches (e.g., Cognitive Behavioural Therapy). The strong evidence for insecure attachment as an underlying factor in psychopathology, especially depression and anxiety, positions this theory well as a foundational principle to support psychotherapy for these conditions.
45969934|NCT04719780|Behavioral|Self-Help CBT Training|Individuals in the Waitlist Control Group will receive access to MoodGym, a self-help online program that helps teach CBT interventions. This access will last 15 weeks and is self-driven, meaning participants proceed through the program at their own pace.
45969935|NCT00565279|Drug|ASF1057|Twice daily, topical
45969936|NCT00565279|Drug|ASF1057|Twice daily, Topical
45969937|NCT04602637|Other|Training load|Monitoring training load during covid
46081021|NCT05475392|Other|Post Isometric Relaxation|The exercise will be combined with the baseline treatment 3 sets PIR will be applied per session.The hypertonic muscle is taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle is performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction, the patient is asked to relax and exhale while doing so. Following this, a gentle stretch is applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times.
46081022|NCT05470322|Device|Er: YAG laser|Patients will be treated with laser for their HS scarring.
45669056|NCT05434702|Behavioral|Godin Exercise Leisure-Time questionnaire|The Godin Exercise Leisure-Time questionnaire measures the frequency of strenuous, moderate, and mild exercise for periods of 15 minutes or more during the participant's free time throughout a typical week. The scoring using the formula leisure score index (LSI) which is obtained using the following formula: (frequency of mild × 3) + (frequency of moderate × 5) + (frequency of strenuous × 9).
45669057|NCT05434702|Behavioral|Zoom interviews|A subset of 30 participants (10 African American, 10 Hispanic, 10 non-Hispanic white) will participate in semi-structured interviews to explore (a) sociocultural, environmental, and individual factors associated with lifestyle behaviors; (b) awareness of American Cancer Society (ACS) guidelines, current practices, and essential intervention modules (ex. integrating cultural foods and preferences) to provide study team with information needed to develop healthy behavior interventions for young adult cancer survivors.
45827010|NCT00003005|Drug|Cordycepin|"Dose escalation study using the following doses:~6mg/m2, 12 mg/m2, 24mg/m2, 48mg/m2"
45969938|NCT04602442|Drug|EXO 1 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the first type.
45969939|NCT04602442|Drug|EXO 2 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the second type.
45969940|NCT04602442|Drug|Placebo inhalation|Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
45969941|NCT00249015|Behavioral|Physical exercise|perform exercise program 3 days per week and 5 minutes of warm-up and cool-down exercises before and after the main exercise component
45969942|NCT04602247|Dietary Supplement|SIC|Sodium Iron Chlorophyllin, whose bioavailability is to be studied
45969943|NCT04602247|Dietary Supplement|SIC + AA combined|Sodium Iron Chlorophyllin and ascorbic acid. The ascorbic acid should not have an effect on Sodium Iron Chlorophyllin
45969944|NCT04602247|Dietary Supplement|FeSO4|Ferrous sulfate serves as a positive control, whose iron bioavailability is known
45969945|NCT04602247|Dietary Supplement|FeSO4 + AA combined|Ferrous sulfate serves as a positive control and the addition of ascorbic acid, further enhances its bioavailability
45969946|NCT04602247|Other|EP + FeSO4 combined|Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system
45969947|NCT04602247|Other|EP + FeSO4 + AA combined|Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system. Ascorbic acid is given along with the intervention to see if there is any difference in the fractional iron absorption when compared to EP+ FeSO4
45669058|NCT05432856|Behavioral|Time restricted eating, nutrition education, and sedentary time reduction strategies|"TRE: You will be asked to eating as much as you like but only within an 8-10 hour window and then do not eat, or fast by consuming only water, black coffee or tea without milk/sugar for a window of 16 hours per day. This protocol will be required for 5 or more days in a row each week.~Nutrition education and individualized recommendations: You will receive an assessment, and one-on-one education on healthy eating according to Canada's dietary guidelines, with individualized small goal each to improve your dietary habits.~Sedentary time reduction: Using the provided Fitbit wrist monitor, you will be asked to track and gradually increase your daily step counts, break up periods of inactivity, and try to incorporate ways to decrease sedentary behaviour in everyday life."
45669059|NCT05428358|Diagnostic Test|Preoperative MRI|Preoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection
45669060|NCT05427279|Dietary Supplement|Placebo|The participant will consume a supplemental dose of a placebo (20g maltodextrin with 50mg vitamin C)
45969948|NCT04601896|Other|SF36 questionnaire via telephone interview|SF36 questionnaire via telephone interview
45969949|NCT04602130|Other|Control|"The control group (n: 48) received no intervention except for the routine clinical practices. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
45969950|NCT04602130|Other|Massage|"The researcher applied massage (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
45969951|NCT04602130|Other|Sponge Bathing|"The researcher applied sponge bathing (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
45969952|NCT04602130|Other|Tub Bathing|"The researcher applied tub bathing (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
45969953|NCT00252330|Drug|SR58611A|
45969954|NCT04602052|Procedure|Dilation and evacuation|Abortion is termination of pregannacy by evaccuating the uterus using either medical or surgical technique
45969955|NCT04602208|Procedure|Retrospectively review of medical data in patients treated by focal HIFU for primary localized prostate cancer|This study concern the patients with localized prostate cancer treated by Focal HIFU for low or intermediate risk disease. Three surgeons experienced in HIFU performed the procedures. Patients were treated with the Ablatherm device [EDAP TMS S.A., Vaulx-en-Velin, France] until July 2013 and then with the Focal-One device [EDAP TMS S.A.]. The data of all the patients treated between November 2009 to December 2016, at Edouard Herriot Hospital (Lyon, France), were prospectively maintain within a central database and retrospectively reviewed. The study primary outcome was retreatment-free survival (RFS) defined as any additional further treatment: local (FT/PGA for in-field or out-of-field recurrences or radical prostatectomy or external beam radiotherapy or whole gland HIFU) or systemic salvage treatment, a positive biopsy revealing PCa with an ISUP grade≥ 2 in nontreated patients, PCa metastasis or PCa specific death. The adverse events and functional outcomes were also evaluated.
45969956|NCT04602013|Drug|Sintilimab|Body weight <60kg: 3mg/kg IV Q3W; Body weight ≥60kg: 200mg IV Q3W. Every three weeks is a cycle
45969957|NCT04602013|Drug|Chemotherapy|"Chemotherapy drugs include cisplatin and albumin-bound paclitaxel for injection Paclitaxel for injection (albumin-bound type) dose: 3 dose groups (di=260 mg/m2, di-1=220 mg/m2, di-2=180 mg/m2).~Dosing on the first day, one cycle every three weeks, a total of 2 cycles. Cisplatin (25mg/m2 IV D1-3 Q3W)"
45969958|NCT04602013|Radiation|Radiation Therapy|The total dose is 60-66 Gy, divided into 30-33 times (2.0 Gy/f, 5 f per week).
45969959|NCT04601701|Drug|Bevacizumab Ophthalmic and Intravitreal Dexamethasone.|Pro re nata patients with CRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
45969960|NCT04601701|Drug|Bevacizumab Ophthalmic.|Pro re nata patients with CRVO will receive Bevacizumab. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
45969961|NCT05233748|Device|Stochastic Resonance (SR)|The system consists of six linear isolated stimulators (STMISOLA, Biopac Systems, Inc., Goleta, USA). The SR signal (Gaussian White Noise, zero mean) will be generated through a 16 bit PCI 6733 National Instruments multifunction data acquisition card by a custom LabView program. The stimulation sites include the ankle, lateral soleus, peroneus longus, and tibialis anterior muscles and the hip.
45969962|NCT00252369|Drug|Infliximab|
45969963|NCT00252369|Procedure|Instillation of fibrin glue|
45969964|NCT04601662|Procedure|Corticision|A special instrument will be used to cut the cortex of the alveolar bone at different locations between the lower anterior teeth
45969965|NCT04601662|Other|Traditional Non-accelerated Treatment|The normal sequence of treatment steps will be followed in this group without using any kind of acceleration methods
46081023|NCT05464420|Biological|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
46081024|NCT05464420|Biological|PPSV23|Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
45969966|NCT04601545|Behavioral|Pulmonary rehabilitation|"Three weeks of pulmonary rehabilitation conducted in an outpatient care facility:~5- time a week for 30 minutes a specific respiratory exercises- relaxation exercises for breathing muscles, exercises to increase breathing, prolonged exhalation exercise, chest percussion~5- time a week for 20-30 min training on a cycle ergometer - until the Heart Rate reaches 60% of the HRmax~5- time a week for 30 minutes a fitness and respiratory exercises - coordination and balance exercises, stretching exercises~relaxation by Schultz Autogenic Training. The technique involves the daily practice of sessions that last around 15 minutes. During each session, the practitioner repeats a set of visualisations that induce a state of relaxation."
45969967|NCT04601545|Device|Virtual therapeutic support|"8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.~By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work."
45969968|NCT00565318|Drug|Benfotiamine|3x 300 mg film coated tablet daily (900 mg per day). Duration: 12 weeks.
45969969|NCT00565318|Drug|Placebo|3x 1 film coated tablet daily. Duration: 12 weeks.
45969970|NCT00249054|Device|ASR hip prosthesis|Implantation of resurfacing prosthesis
45827011|NCT00003005|Drug|Deoxycoformycin|Dose escalation using the Fibonacci dose escalation sequence starting dose 2mg/m2, escalating to 3mg/m3 intravenous
45827012|NCT03905603|Drug|ACTH|ACTH (Cosyntropin) 250 mcg will be given once during the study.
45969971|NCT00249054|Device|ReCap hip prosthesis|Implantation of resurfacing prosthesis
45669061|NCT05427279|Dietary Supplement|Hydrolized Collagen|The participant will consume a supplemental dose of Hydrolized collagen (20g with 50mg vitamin C)
45669062|NCT05427279|Dietary Supplement|PrimaColl|The participant will consume a supplemental dose of PrimaColl, a vegan collagen supplementation (20g with 50mg vitamin C)
45669063|NCT05427279|Dietary Supplement|Whey protein|The participant will consume a supplemental dose of whey protein (20g whey isolate with 50mg vitamin C)
45669064|NCT05422326|Biological|aH5N6c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 hemagglutinin (HA) (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume)
45669065|NCT05422326|Biological|aH5N6c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 HA (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume) given 3 weeks after the first aH5N6c vaccination
45827013|NCT03905603|Drug|rhCG|rhCG (Ovidrel) 250 mcg will be given once during the study.
45827014|NCT00003011|Drug|marimastat|10 mg PO BID
45969972|NCT00565357|Device|Silicone Earplugs|Silicone earplugs worn from within 1 week of birth through 35 weeks post-menstrual age or hospital discharge, whichever came first
45969973|NCT00565357|Other|Control|Standard care in the neonatal intensive care unit
45669066|NCT05422326|Biological|Placebo on Day 22|Saline placebo (sterile, 0.5 mL) given 3 weeks after the aH5N6c vaccination
45669067|NCT05410977|Procedure|Biospecimen Collection|Undergo collection of blood and stool samples
45827015|NCT00003011|Drug|Placebo|10 mg PO BID
45669068|NCT05410977|Other|Electronic Health Record Review|Medical records reviewed
45669069|NCT05407610|Procedure|Conventional Radiofrequency ablation of the genicular nerves|Conventional Radiofrequency treatment of the genicular nerves of the knee blocks the transmission of painful stimuli from the sensory genicular nerves of the knee to the central nervous system by means of a thermal lesion created using RF current.
45669070|NCT05407610|Procedure|Cooled Radiofrequency ablation of the genicular nerves|Cooled RF treatment causes a larger lesion size compared to conventional RF by means of internal cooling of the probe.
45669071|NCT05407610|Procedure|Sham procedure|Sham procedure with placing of needles subcutaneously.
45669072|NCT05407129|Behavioral|Family safety reporting intervention|Family safety reporting intervention for patients/families
45827016|NCT03884075|Drug|Semaglutide|Semaglutide injection once weekly
45827017|NCT00003017|Biological|recombinant interleukin-12|
45827018|NCT00003023|Biological|BCG vaccine|
45827019|NCT00003023|Biological|monoclonal antibody A1G4 anti-idiotype vaccine|
45827020|NCT03850067|Drug|CC-90011|CC-90011
45827021|NCT03850067|Drug|Cisplatin|Cisplatin
45827022|NCT03850067|Drug|Carboplatin|Carboplatin
45827023|NCT03850067|Drug|Etoposide|Etoposide
45827024|NCT03850067|Drug|Nivolumab|Nivolumab
45827025|NCT00383279|Other|counseling intervention|
45827026|NCT00383279|Other|study of socioeconomic and demographic variables|
45827027|NCT00003029|Drug|cisplatin|
45827028|NCT00003029|Drug|fluorouracil|
45827029|NCT00003035|Biological|filgrastim|
45969974|NCT05201144|Drug|Sildenafil Oral Suspension|Sildenafil citrate is a highly selective PDE-5 inhibitor found in pulmonary vascular smooth muscle cells. Sildenafil acts by increasing cGMP levels in the nitric oxide pathway, leading to smooth muscle relaxation and an anti-proliferative effect within the pulmonary vasculature.
45969975|NCT05201144|Other|Placebo|Equal volume of placebo
45969976|NCT00252408|Drug|Hormone replacement therapy|
45969977|NCT04601389|Biological|"Omalizumab (JSC GENERIUM, the Russian Federation)"|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
45669073|NCT05386108|Drug|Elacestrant|300 mg, 400 mg
45669074|NCT05386108|Drug|Abemaciclib|100 mg, 150 mg
45669075|NCT05386030|Combination Product|saypha® VOLUME Lidocaine|Crosslinked hyaluronic acid (HA) 23 mg/mL + 0.3% lidocaine hydrochloride.
45969978|NCT04601389|Biological|Xolair® (Novartis Pharma AG, Switzerland)|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
45969979|NCT04600843|Other|Physical therapy with Patient education|patient manual was translated and validated in Urdu which was provided to patients so that they can follow it at home
45969980|NCT04600843|Other|Physical Therapy without patient Education|Group B was only treated with proper physical therapy treatment protocol according to patient presenting condition
45827030|NCT00003035|Drug|doxorubicin hydrochloride|
45827031|NCT00003035|Drug|paclitaxel|
45669076|NCT05386030|Combination Product|Juvéderm® Voluma™ XC|Crosslinked HA 20 mg/mL + 0.3% lidocaine hydrochloride
45669077|NCT05368493|Other|MRI task|Task fMRI (Simon) [ Time Frame: Children will undergo MRI scans when they are 6-11 years of age. ] Children will also complete a task, which will allow exploratory analyses of the functionality of attention-related neural circuits. The Simon fMRI task is a non-verbal task equivalent to the Stroop that tests sustained attention and inhibitory control and discriminates children with and without ADHD. Exploratory fMRI time-series data for each participant will be modeled using a general linear model with 3 predictors: congruent correct, incongruent correct, and incorrect. Contrast images for each participant (e.g., incongruent-minus-congruent) will be generated and entered into a group-level random-effects model. Analyses are exploratory, and will focus on frontal lobe activity during each type of trial.
45669078|NCT05367609|Diagnostic Test|Preoperative Genotyping|Genotype based risk prediction and personalized pain management
45669079|NCT05349331|Procedure|Liver Resection|Surgical resection treatment: laparoscopic or open liver resection is performed, and targeted and immunotherapy are not continued after surgery.
45669080|NCT05345730|Diagnostic Test|3 DImensional Late Enhanced Gadolinium cardiac MRI scan|A cardiac MRI scan is made using late gadolinium enhancement to detect atrial fibrosis in the left atrium.
45827032|NCT00003035|Drug|tamoxifen citrate|
45827033|NCT00003035|Procedure|surgical procedure|
45827034|NCT00003035|Radiation|radiation therapy|
45827035|NCT02579525|Other|Hemodynamical treatment TTP|Based on capillary refilling time, peripheral temperature, mottling, diuresis, MAP safety limit monitoring
45827036|NCT02579525|Other|Hemodynamical treatment MCG|Based on MAP, CVP, urine output monitoring
45969981|NCT00565396|Drug|Fosinopril and Losartan|Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
45969982|NCT00252447|Procedure|Pre-Operative Conformal Radiotherapy|
45969983|NCT04600765|Diagnostic Test|hsCRP serum measurement of inflammation|hsCRP inflammation change as result of non-contaminated diet
45969984|NCT05197790|Device|FDA approved pulse oximeter and DOVE device prototype|The objective is to assess reasonable detection of hypoxic episodes
46081025|NCT05458856|Drug|Triptorelin embonate 22.5 mg|A prolonged release formulation of triptorelin pamoate 22.5 mg 6-month formulation in D, L-lactide-co-glycolide polymers for single subcutaneous injection on Day 1 and Day 169
45669081|NCT05342064|Other|patient-centered TB preventive therapy|The intervention phase includes i) enrolling participants who have had TB disease excluded and allowing participant selection of a preferred TPT regimen, and ii) randomizing participants to one of two participant adherence support modalities.
45827037|NCT03837431|Diagnostic Test|Skin slit|Skin slit microscopy, RDT and PCR
45827038|NCT03837431|Diagnostic Test|Dental broach|Dental broach RDT and PCR
45827039|NCT03837431|Diagnostic Test|Tape disc|Tape disc PCR
45827040|NCT00003041|Drug|pyrazoloacridine|
45827041|NCT00383903|Biological|HRV vaccine|Two or three oral doses
45827042|NCT00003053|Drug|cisplatin|
45827043|NCT00003053|Drug|etoposide|
45827044|NCT00003053|Procedure|adjuvant therapy|
45827045|NCT04329689|Other|The Septal myectom|"The Septal myectomy is the preferred treatment of most patients with HOCM, and many studies have documented relief of symptoms and satisfactory late patient survival after relief of outflow tract gradients.~valve repair or replacement may be necessary"
45969985|NCT04601116|Drug|Atorvastatin 80 Mg Oral Tablet|Atorvastatin 80 mg per day for 2 years
45969986|NCT04601116|Drug|Placebo oral tablet|Placebo 1 tablet per day for 2 years
45969987|NCT04600687|Other|Placebo tablets|Participants will take placebo tablets identical to the commercial versions of the two combination antiretroviral single tablet regimens of bictegravir/emtricitabine/tenofovir alanfenamide and dolutegravir/abacavir/lamivudine.
45969988|NCT00249093|Drug|oxygen|
45969989|NCT04600726|Other|no intervention|no interventioni
45969990|NCT05174624|Other|No intervention|No intervention
45969991|NCT04600453|Other|Physical Exercise|The intervention will consist of a multicomponent exercise training programme24, which will be composed of supervised progressive resistance exercise training, balance-training and walking for 4 consecutive days. During the training period, patients will be trained in 20 min sessions twice a day. The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM combined with balance and gait retraining exercises that progressed in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.
45669082|NCT05342064|Other|TB preventive therapy adherence support|As part of this study, enhanced adherence support will be provided via bi-directional messaging and/or via clinic phone calls. All participants randomized to enhanced adherence support will receive a weekly text reminder beginning seven days after the initiation. Each message will ask participants if they would like to be contacted to discuss any questions and will prompt participants to ask questions by text if more convenient or preferable. All text-based questions from participants will be answered by a trained nurse with back up from a physician.
45669083|NCT05330611|Device|Cryoneurolysis of Intercostal Nerves|"Patients will be offered a minimally invasive intervention procedure for pain control called cryoneurolysis using an ultrasound-guided device called the Iovera Smart Tip 190.~The direct application of cold to the intercostal nerves via Iovera device produces lesions in peripheral nervous tissue to block the pain caused by rib fractures.~This procedure is particularly beneficial for patients who are not candidates for surgical stabilization of their rib fractures.~Application of cryoneurolysis as an analgesic will reduce the amount of narcotics patients might need and instead provide them short- or long-term pain control with minimal risk.~Follow up includes pain surveys administered in Chest Wall clinic or via telephone at 30, 90, 365 days post discharge."
45669084|NCT05330611|Other|Standard of Care|"Patients will be provided regular standard of care at the Stanford Hospital with short- or long-term follow-up provided at the Stanford Center for Reconstruction after Chest Wall Injury.~Standard of care for patients with rib fractures that are not eligible for surgical stabilization includes multi-modal pain therapy and pulmonary toilet.~Follow up includes pain surveys administered in Chest Wall clinic or via telephone at 30, 90, 365 days post discharge."
45827046|NCT04329845|Procedure|open splenectomy|open splenectomy for treatment of splenic injury
45827047|NCT04329845|Procedure|laparoscopic splenectomy for splenic injury in trauma|laparoscopy as a technique for removal of the spleen in injury
45827048|NCT00003065|Biological|filgrastim|
45827049|NCT00003065|Drug|paclitaxel|
45827050|NCT00003065|Drug|topotecan hydrochloride|
45827051|NCT04329611|Drug|Hydroxychloroquine|COVID19
45827052|NCT00383357|Drug|zolpidem|
45969992|NCT04600297|Device|ELS Even Stronger (3D Printed Resin Composite)|Missing of one premolar cases will be restored using the 3D Printed resin composite (ELS Even Stronger, Saremco, Switzerland). The steps of the procedure: Preparation, scanning, colour determination, design of the restoration, printing the restoration, adjusting occlusion, finishing and polishing, cementation.
45969993|NCT04600024|Diagnostic Test|Ultrasound guided diagnostic injection|4 cc lidocaine %2 injection into the piriformis muscle was performed for the diagnosis of piriformis syndrome. It was performed by the ultrasound-guidance to increase the accuracy of the injection.
45969994|NCT00249132|Drug|risperidone|
45827053|NCT03763331|Device|Control/Sham Treatment|Thermoneutral water will be circulated through water-circulating trousers to maintain skin temperature at baselines levels daily for 90 minutes for 8 weeks.
45827054|NCT03763331|Device|Heat Therapy|Water at 110 degrees F will be circulated through water-circulating trousers daily for 90 minutes for 8 weeks.
45969995|NCT05154461|Other|Alginate|BHB covered in alginate will be realised in stomach-duodenum
45969996|NCT05154461|Other|Pea-protein|BHB covered in pea-protein will be released in ileum-colon
45827055|NCT00003077|Dietary Supplement|omega-3 fatty acid|
45827056|NCT03759665|Drug|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
45827057|NCT00003089|Drug|amifostine trihydrate|
45827058|NCT00003089|Drug|carboplatin|
45827059|NCT00003089|Drug|paclitaxel|
45827060|NCT00003089|Radiation|radiation therapy|
45827061|NCT02070575|Other|blood draw|Venous blood will be collected in an EDTA Vacutainer tubeup to 10 mL and will be immediately put on ice. This sample may be drawn as a stand-alone blood draw. Samples will be centrifuged at 1900g (3000-3200 RPM) for 15 Minutes and the serum aliquoted into freezer vials and stored at -80°C until analysis. In addition patients who have not received treatment for biochemical recurrence after their first draw are eligible for subsequent draws to determine the reproducibility of the test over time.
45827062|NCT03713801|Drug|Metformin|Total daily dose titrated up to 1500 mg po q day over the course of 3 weeks and continued for a total exposure of 12 weeks.
45827063|NCT03713801|Drug|Placebo|Placebo tablets titrated up to 3 tablets over the course of 3 weeks and then continued as 3 daily for a total exposure of 12 weeks
45827064|NCT00003101|Biological|filgrastim|
45827065|NCT00003101|Drug|busulfan|
45827066|NCT00003101|Drug|lomustine|
45827067|NCT00003101|Drug|procarbazine hydrochloride|
45827068|NCT00003101|Drug|thiotepa|
45827069|NCT00003101|Drug|vincristine sulfate|
45827070|NCT00003101|Procedure|autologous bone marrow transplantation|
45827071|NCT00003101|Procedure|peripheral blood stem cell transplantation|
45969997|NCT00565474|Drug|Fluvastatin|Graft vasculopathy
45969998|NCT04599907|Device|Roll-In Cohort: Single Application of N-SWEAT Patch|Single Application of N-SWEAT Patch in both axillae for 10 subjects
45969999|NCT04599907|Device|Randomized Cohort: Single Application of N-SWEAT Patch|Single Application of N-SWEAT Patch in both axillae for subjects randomized to the treatment group
45970000|NCT04599907|Device|Randomized Cohort: Single Application of Sham Patch|Single Application of Sham Patch in both axillae for subjects randomized to the control group
45669085|NCT05324852|Drug|Intranasal midazolam|Midazolam, 5 mg, injectable solution in 5mg/ml, intranasal administration, atomize into nose with Mucosal Atomizer Device (MAD) 5mg(1ml) up each nostril , one time
45970001|NCT00252486|Drug|Flax oil|Flax oil and olive oil placebo were analyzed for quality and purity; sufficient bioactivity was confirmed for the flax oil independently at the University of Massachusetts mid-way through the study. Each capsule of omega -3 fatty acid concentrate contained 550 mg of α-linolenic acid (α-LNA) from flax seed oil.A stepped but flexible dose-titration schedule was carried out with doses increased by 1-2 grams at each visit as tolerated, to an attempted total dose of 6 capsules twice per day, as requested by the FDA (up to 6.6 grams of daily α-linolenic acid).
45970002|NCT04600492|Drug|Riociguat Oral Tablet|Take any dose of Riociguat from 0.5mg to 2.5mg, or placebo
45970003|NCT00402935|Other|laboratory biomarker analysis|Patients undergo blood collection at the same time points for follicle-stimulating hormone, estradiol, and inhibin B levels.
45970004|NCT00402935|Procedure|fertility assessment and management|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
45970005|NCT00402935|Procedure|management of therapy complications|Patients are also asked to fill out questionnaires on estrogen-depletion symptoms at those times. Patients also keep a calendar of menstrual bleeding and hormonal medications.
45970006|NCT00402935|Procedure|ultrasound imaging|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
45970007|NCT04600063|Procedure|Isolation procedure (RAMPS procedure)|In the Isolation procedure group, the transection of the root of the splenic artery and the pancreatic transection are performed first, followed by the transection of the splenic vein (mandatory procedure). At that time, the branch from the splenic artery (dorsal pancreatic artery), the branch to the splenic vein (left gastric vein, inferior mesenteric vein), and short gastric arteriovenous are also disconnected as soon as possible (recommended procedure). An operation to lift up the pancreatic neck from the dorsal portal vein or superior mesenteric artery to expose the splenic vein (so-called tunneling) is allowed. After that, lymph node dissection such as hepatoduodenal mesentery (No12), common hepatic artery perimeter (No8), lymph node dissection around SMA (No14p) was performed (recommended procedure), and at the end of the resection operation, the pancreas body/tail and spleen are mobilized and removed (required procedure).
45970008|NCT04600063|Procedure|Conventional procedure|In the conventional procedure group, first, the pancreatic body and tail and spleen are mobilized (mandatory procedure), and the regional lymph nodes of the body and tail of the pancreas, such as the hepatoduodenal mesentery (No12 lymph node) and the common hepatic artery perimeter (No8), are removed. (Recommended procedure) and dissection of lymph nodes (No14p) around SMA (Recommended procedure), and after dissection of the gastro-splenic ligament and pancreas, transection of the splenic vein at the end of the resection procedure (required procedure) . However, in order to prevent bleeding and secure a safe field of view, early pancreatotomy is allowed.
45669086|NCT05324852|Drug|Intramuscular loxapine|Loxapine, 100mg, injectable solution in 50mg/2ml intramuscular, intra muscular administration, one time
45669087|NCT05293041|Drug|Argipressin|Infusion of Argipressin 0.8 U/ml, 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the treatment arm.
45669088|NCT05293041|Drug|Placebo|Infusion of Normal Saline 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the placebo arm.
45669089|NCT05289089|Behavioral|Positive Psychology Intervention|Participants will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Participants will independently complete PP exercises between phone sessions and review them with their study trainer during phone sessions. A total of 9 sessions will be completed over the course of the program.
45669090|NCT05287568|Drug|Venetoclax|Venetoclax is a potent, selective and orally bioavailable small molecule inhibitor of BCL-2 that binds with > 1,000-fold higher affinity to BCL-2 (Ki < 0.010 nM) than other apoptotic pathway proteins BCL-XL (Ki = 48 nm) or MCL-1 (Ki > 444 nM). Leukemia stem cells (LSCs) overexpress BCL-2, and BCL-2 overexpression has been associated with worse outcomes in AML.
45669091|NCT05287568|Drug|CC-486|An oral formulation of azacitidine currently being developed for the treatment of hematological and solid malignancies.
45669092|NCT05287191|Drug|Magnesium sulfate and then Digoxin|We will test MgSO4 and then digoxin IV (in 3 divided dose) as second line therapy with amiodarone IV as third line. Digoxin will be protocolised to commence between 30 minutes and 12 hours after MgSO4 if fast AF persists as initially designated (dose 1). Undiluted IV digoxin (12 mcg/kg) will be administered in 3 divided doses (6, 3 and 3 mcg/kg) separated by approximately 6 hrs (i.e. dose 1 at 30 mins - 12 hours after MgSO4, followed by dose 2 at -6 hrs and dose 3 at the approximately 12 hrs). Patients with renal dysfunction (creatinine clearance <60 ml/min measured by the MDRD formula) will receive a reduced dose of 8 mcg/kg in 3 divided doses (4, 2, and 2 mcg/kg) separated by the same time intervals. In the trial intervention group, amiodarone will be given approximately 120 mins after digoxin if necessary whilst completing the digoxin dose. Amiodarone will be administered as a 150 mg infusion over 10 minutes followed by 900 mg over 24 hours.
45827072|NCT03692273|Procedure|Luminis ultrapulse fractional ablative carbon dioxide laser|This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.
45827073|NCT03692273|Procedure|0.5mm punch biopsy|punch biopsies will be performed to remove approximately equivalent volumes of tissue compared to the laser
46081026|NCT05449496|Behavioral|Dietary Education Curriculum|Curriculum of dietary education and group-based counseling to encourage whole-food plant-based eating
46081027|NCT05440448|Device|Patch-free occlusion therapy|Use of filters in glasses to provide occlusion therapy
45827074|NCT03690869|Drug|cemiplimab (monotherapy)|To be administered intravenously as monotherapy in Phase 1
45827075|NCT03690869|Drug|cemiplimab (maintenance)|To be administered intravenously in combination with radiation and then used as maintenance therapy
45827076|NCT03690869|Radiation|Conventional or hypofractionated|Combined with cemiplimab IV administration
45827077|NCT03690869|Radiation|Re-irradiation|Combined with cemiplimab IV administration
45669093|NCT05287191|Drug|Amiodarone|We will test Amiodarone (150mg IV then 900mg IV over the next 24 hours ) as first line treatment in the standard of care group. No more than 2g MgSO4 be delivered over 2 hours maximum for this group in the first 24 hours after randomisation unless clinically indicated for measured hypomagnesaemia (a value below the index hospital laboratories lower limit of normal).
45669094|NCT05285527|Device|MiSight 1 Day|Subjects will wear MiSight 1 day lenses for three years.
45669095|NCT05280652|Behavioral|Nutritional and culinary intervention|Participants will attend 6 two-hours nutritional-culinary workshops between May 2022 and February 2023. All of the workshops will be held in a kitchen, and will be given in groups of 2 dyads or parents according to the intervention group. In addition, during the intervention families will be given access to a web page with nutrition and culinary education materials (infographics, videos).
45970009|NCT04599985|Other|star excursion balance training (SEBT)|The SEBT is aimed to be maintained the single limb stance on one leg while reaching farthest possible with the swing leg. An individual can reach farthest with the swing leg while maintaining the balance on the stance leg
45669096|NCT05280652|Behavioral|Nutritional intervention|Participants will attend 6 1-hour nutritional workshops between May 2022 and February 2023. The workshops will be held in person, and will be given in groups of 10-12 families. In addition, during the intervention families will be given access to a web page with nutrition education materials (infographics, videos).
45970010|NCT04599985|Other|Simplified star excursion balance training (SSEBT)|It is one of the training protocols, in a simplified way, with respect to star excursion balance test. It consists a series of reaching tasks for the lower limbs in three-directions i.e., anteromedial, medial and posteromedial.
45827078|NCT04330313|Procedure|Traction|Intermittent traction will be applied to the cervical region in a supine position with the neck at 25-30 ° flexion. The target weight is determined as 10% of the patient's weight. Traction pulling force applied to the target weight will be achieved gradually increasing from low. Traction therapy will be applied intermittent traction for 15 minutes in each session as 60 seconds retention and 60 seconds rest. The therapy will be held for 18 sessions, 3 days / week.
45669097|NCT05279417|Drug|ATI-450 50mg oral tablet BID|Oral, small molecule MK2 inhibitor
45669098|NCT05279417|Drug|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
45669099|NCT05279417|Drug|Methotrexate|15 mg to 25 mg weekly
45669100|NCT05279417|Drug|ATI-450 20mg oral tablet BID|Oral, small molecule MK2 inhibitor
45669101|NCT05278052|Radiation|Local consolidative radiation therapy|Local consolidative radiation therapy (LCRT) to all oligo-metastatic sites in addition to primary disease site
45669102|NCT05278052|Drug|Standard maintenance therapy as decided by the treating medical oncologist|Standard maintenance therapy/Observation
45669103|NCT05274347|Behavioral|Muti-faceted virtual, remote intervention|Patients will be provided with tablets with internet connectivity and Aetonix software, along with a blood pressure cuff, weigh scale and pulse oximeter with blue tooth capability. These will be used to deliver virtual CBT sessions as well as remote monitoring of vital signs, symptoms and enhanced communication. The intervention duration will be 10 weeks.
45669104|NCT05268094|Device|Ductal Arterial Stent|Drug-eluting ductal arterial stents will be placed by transcatheter method.
45669105|NCT05268094|Procedure|Systemic-to-Pulmonary Artery Shunt|A surgical connection will be made between a systemic artery and the pulmonary artery.
45669106|NCT05259046|Dietary Supplement|Menaquinone-7 (MK-7) tablet (333 µg)|One MK-7 tablet containing 333 µg MK-7 per day
45669107|NCT05259046|Dietary Supplement|Placebo tablet|One placebo tablet per day
45827079|NCT04330313|Procedure|Laser therapy|Laser therapy will be applied to the participants with a GaAs laser with 904 nm wavelength, 6 points transforaminally, 120 seconds to each point, at 2 J / cm² density, total dose of 12 J laser therapy by keeping the probe in constant contact with the skin.
45827080|NCT04330313|Procedure|Hot pack|The hot pack, which is the superficial heat agent, will be held in the neck area of the participants for 20 minutes in each session.The therapy will be held for 18 sessions, 3 days / week.
45970011|NCT04599712|Drug|Amivantamab|Amivantamab will be administered intravenously at the recommended doses based on weight (1050 milligram [mg] or 1400 mg) once weekly for the first 4 week cycle (1 cycle equals to 28 days), then every 2 weeks thereafter.
45970012|NCT00414648|Drug|Sirolimus|A sirolimus dose of 2 mg will be given in the form of 2 tablets (1 mg/tablet) per day for 1 year.
45970013|NCT00414648|Drug|Placebo sirolimus|A placebo dose of 2 mg will be given in the form of 2 tablets (1 mg/tablet) per day for 1 year.
45827081|NCT04330313|Procedure|Stretching|Stretching exercises will be repeated 3 times a day in total, 2 times a day self-stretching at home and 1 time under the supervision of a physiotherapist. Exercises for upper trapezius muscle, sternokleudomasteudeus (SCM) muscle and the scalene muscle to be applied in a 3 repeat by waiting 30 seconds, stretching under tension.The therapy will be held for 18 sessions, 3 days / week.
45827082|NCT01866371|Procedure|Retinal imaging|Retinal imaging procedures include adaptive optics imaging, optical coherence tomography and fundus photography.
45970014|NCT05099978|Genetic|NGS analysis of ctDNA|Diagnostic Test: plasma circulating tumor DNA
46081028|NCT05440448|Device|Adhesive patch|Standard-of-care occlusion therapy with an adhesive patch
46081029|NCT05439200|Device|Asynchronous 3D movies|3D movies streamed at home for viewing on a handheld lenticular 3D screen
45669108|NCT05242770|Other|Control Arm|Participants randomized to this arm will only receive educational pamphlets with resources for sexual dysfunction and will not participate in physical therapy. Participants will be contacted at 3 months and 6 months to fill out two questionnaires about sexual function and quality of life. After 6months, if participants desire a referral to physical therapy, investigators will provide a referral.
46081030|NCT05439200|Device|Patching|Adhesive patch to cover the fellow eye
46081031|NCT05432804|Procedure|Magnetic Resonance Imaging|Undergo MRI
46081032|NCT05432804|Drug|Selinexor|Given PO
45669109|NCT05242770|Other|Physical Therapy Arm|Participants will receive a referral to begin a pelvic physical therapy regimen. Participants will complete the sexual function and quality of life questionnaires after completion of the physical therapy regimen and again 3 months after. There will be a brief exit interview.
45970015|NCT04599673|Drug|AMNIOGEN|"AmnioGen® amnion matrix allograft is a bioactive tissue matrix processed from 100% human amniotic tissue. The allograft is processed with advanced technology so the graft can be suspended in liquids and applied through needles and syringes.~Amniotic tissue is composed of structural extracellular matrix, which is rich in various types of collagen, growth factors, cytokines, and specialized proteins. Thus, the application of amniotic tissue is known to modulate localized tissue inflammation, reduce scar tissue formation and promote the healing of soft tissue."
45970016|NCT04599673|Other|normal saline|10 ml normal saline
45970017|NCT04599595|Device|Peristeen (Coloplast)|"Patients with severe intestinal dysfunction impairment (PAC QoL score ≥ 32) will be offered the adoption of the TAI (Transanal Irrigation) with Peristeen Device as a way to manage their own evacuation, replacing any other measure used until that moment (suppositoires, clisms exceptionally cc) with the exception of the possible intake of macrogols and/or prebiotics and/or probiotics which instead patients can continue. This treatment will be proposed to all patients with severe impairment of intestinal function.~The TAI training with Peristeen will be carried out at the surgical clinic of the Surgical Department of the Ferrara University Hospital, Italy, by the health personnel involved in the study, usually in a single session, but more sessions may be necessary, with the continuation of the TAI for 4 weeks or with patient's exclusion from the study if the guarantees of appropriate use of the device will not be reached."
45970018|NCT00565513|Procedure|blood test|cord blood and maternal milk test
45970019|NCT00565552|Drug|Silicone gel (Dermatix®)|The half one the scar to treat was randomised among patients. After regular cleaning of the skin around the scar one half was thinly creamed with the silicone gel from medial to lateral and let dry for 5 minutes. It was done twice daily.
45970020|NCT04599439|Diagnostic Test|Cardiac magnetic resonance imaging|All patients will undergo a cardiac magnetic resonance test to calculate their border zone channel (BZC) mass. This will not be used to decide further interventions, but all the patients will be treated according to standards of care.
45970021|NCT00414687|Drug|Ventavis (Iloprost, BAYQ6256)|
45970022|NCT04599244|Other|emergency pulpotomy|removal of coronal pulp
45970023|NCT04599283|Device|MenHealth Uroflowmeter|MenHealth Uroflowmeter is a mobile application and FDA cleared medical device that analyzes the sound of urine hitting the toilet water when a male urinates and generates voiding data (maximum flow, average flow, and voided volume) and a flow curve. All test results are saved in an automated voiding diary.
46081033|NCT05432804|Drug|Temozolomide|Given PO
46081034|NCT05431582|Drug|ZN-c3|Given by PO 1 time a day with a glass (about 8 ounces) of water
45669110|NCT05242770|Other|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)|Questionnaire designed to measure cancer patients' physical, psychological and social functions
45669111|NCT05242770|Other|Female Sexual Function Index (FSFI)|19-item self-report inventory designed to assess female sexual function.
45669112|NCT05242770|Other|Exit Interview|11-item questionnaire for participants to give feedback to investigators about teir experience with the intervention.
45669113|NCT05240352|Device|active tDCS|Subjects will receive active dose (constant current intensity of 2mA) from the tDCS device for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later
45669114|NCT05240352|Device|sham tDCS|"Subjects will receive a dose from a sham-tDCSthat is, a device which delivers a different pattern of electric current for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later"
46081035|NCT05431582|Drug|Bevacizumab|Given by vein over about 30-60 minutes on Day 1 of each cycle
46081036|NCT05431582|Drug|Pembrolizumab|Given by vein over 30-60 minutes on Day 1 of each cycle.
46081037|NCT05430113|Device|Spinal Cord Stimulator (octopolar Medtronic Vectris Leads)|2-4 leads FDA-approved for treatment of symptoms of refractory pain
46081038|NCT05427201|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique designed to alter network function
46081039|NCT05427201|Behavioral|Acceptance and Commitment Therapy|ACT is a mindfulness-based cognitive behavioral intervention that has demonstrated efficacy for chronic pain.
45970024|NCT04599322|Other|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle
45970025|NCT04599205|Drug|Tranexamic acid|fractional co2 laser, microneedling and topical tranexamic acid gel
45970026|NCT04599127|Other|Mobilization with movement|The physical therapist will adjust the active movement of the shoulder joint during the arm elevation or abduction and shoulder external rotation
45970027|NCT04599127|Other|Conventional physical therapy|The exercise is tailor-made and each participant will be performing some of the exercises based on the list that physical therapist prescription
46081040|NCT05426564|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
46081041|NCT05425420|Drug|methadone hydrochloride 0.1mg/kg|Single dose of methadone hydrochloride administered via intravenous (IV)
45827083|NCT01805609|Behavioral|Working with the Caregiving Family (WCF) training|Training curriculum will be comprised of 2 phases to be attended sequentially: (l) The Didactic Phase will consist of 6 twice a month seminars, administered over a 3 month period. Each seminar includes a 1 hour lecture & discussion followed by 1 hour of role-play exercises; Lecture segments may include short training videos which Dr. Zaider uses in the nurses' training module she teaches through the Communication Skills Laboratory. The teaching portion of the didactic sessions of the training may also be videotaped as a reference point for curriculum review. Will explain to the providers that videotapes will only be available to study staff & that the role play portion will not be recorded; (2) Consolidation Phase will consist of 6 twice a month peer-group supervision meetings for ongoing consultation on family cases, also held across a 3 month period. Length of these consolidations sessions will be up to 2 hours.
45669115|NCT05236790|Diagnostic Test|Detection and classification and size measurement of polyp by Artificial Intelligence (Cad eye) and the Scale Eye|Detection and classification and size measurement of polyp by Artificial Intelligence (CADeye) and Scale Eye This study will be conducted in multiple phases: phase 1 (pilot phase, n=40 polyps, about 60 patients) to evaluate the feasibility of applying Scale Eye in real-time practice, training endoscopists to work with CADe and CADx and determining the sample size and reference standard to evaluate SCALE-EYE during the second phase of the study (randomized controlled trial), phase 2 will evaluate the performance of SCALE-EYE and CAD-eye in real-time practice. The sample size for phase 2 (RCT comparing visual with scasle eye) will be based on the pilot data allowing to compare relative accuracy of size measurement with scale eye versus visual size estimation. After completion of phase 2 later phases will use instruments such as snare and/or forceps as reference measurement devices compared to relative accuracy of measurement when using scale eye.
45970028|NCT05070260|Drug|Intravenous glenzocimab (ACT017) 1000 mg|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
45669116|NCT05230212|Other|Pecan Breakfast Shake|The pecan breakfast shake contains 68 grams of blended raw pecans. Participants will consume this shake at either visit 1 or visit 2 depending on randomization procedures.
45669117|NCT05230212|Other|Cream Breakfast Shake|The cream breakfast shake contains 138 grams of heavy whipping cream. Participants will consume this shake at either visit 1 or visit 2 depending on randomization procedures.
45669118|NCT05221632|Device|Accelerated transcranial magnetic stimulation with real coil|The stimulation mode of TMS is accelerated continue theta-burst stimulation.
45669119|NCT05221632|Device|Transcranial magnetic stimulation with real coil|The stimulation mode of TMS is 1-Hz repetitive Transcranial magnetic stimulation .
45669120|NCT05221632|Device|Transcranial magnetic stimulation with sham coil|The stimulation mode of TMS is accelerated continue theta-burst stimulation, but without active stimulation.
45827084|NCT01805609|Behavioral|questionnaires|
45827085|NCT01788839|Behavioral|surveys|A survey including the Female Sexual Function Index (FSFI), the Modified Female Sexual Function Index (FSFI-M), the Modified Female Sexual Function Index Follow-Up (FSFI-M Follow-Up) the Sexual Activity Questionnaire (SAQ), the Female Sexual Distress Scale (FSDS-R), the Menopausal Symptom Check List (MSCL), Patient-reported Outcomes Measurement Information System Sexual Function Instrument (PROMIS-SF), Abbreviated Dyadic Adjustment Scale for Relationships (ADAS), Reproductive Health Survey-baseline (RHS-B). Reproductive Health Survey-followup and (RHS-F1)Reproductive Health Survey-followup (RHS-F2) will be conducted at the following intervals: baseline/before chemotherapy +/- 1 month, 3 months after baseline +/- 1 month, 6 months after baseline +/- 1 month, 1 year after baseline +/- 1 month, and at intervals during survivorship that include yearly for 5 years +/- 2 months.
45970029|NCT05070260|Drug|Intravenous Placebo|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
45970030|NCT04599400|Other|There is no intervention in our study|There is no intervention in our study
45970031|NCT04598737|Procedure|Ultra-translucent multilayer zirconia|Ultra-translucent multilayer zirconia laminate veneer treatment
45970032|NCT04598737|Procedure|Lithium disilicate|Lithium disilicate laminate veneer treatment
46081042|NCT05424484|Device|Self-Gripping Resorbable Mesh|Self-Gripping Resorbable Mesh used for suture line reinforcement after midline laparotomy in clean and clean-contaminated fields (CDC Classification I and II).
46081043|NCT05423730|Other|White Wine|One serving (5 ounces) of white wine daily for 3 weeks
45970033|NCT05055128|Drug|X842|Patients will receive X842 tablets.
45970034|NCT05055128|Drug|X842 Dummy|Patients will receive matching placebo tablets for X842.
45970035|NCT05055128|Drug|Lansoprazole|Patients will receive Lansoprazole capsule.
45970036|NCT05055128|Drug|Lansoprazole Dummy|Patients will receive matching placebo capsules for Lansoprazole.
46081044|NCT05423730|Other|Grape Juice|One serving (6 ounces) of white grape juice daily for 3 weeks
46081045|NCT05419687|Behavioral|Training in de-escalating violence|"Individual educational component through a de-escalating violence training for health care workers (verbal and non-verbal de-escalating techniques)~Refreshment training in the form of collaborative learning"
45970037|NCT00565591|Drug|Albuterol sulfate|Single dose dry powder by inhalation
45970038|NCT00252603|Drug|Galantamine|
45970039|NCT00565630|Device|Vigamox delivered via the device in spray form|Vigamox delivered 4 times, 1 hour prior to cataract surgery
45669121|NCT05217537|Drug|Omadacycline Injection [Nuzyra]|Single dose of 100 mg omadacycline IV in 100 mL of normal saline
45669122|NCT05217537|Drug|Omadacycline Oral Tablet|Single dose of 300 mg omadacycline PO (2 x 150 mg tablets)
45669123|NCT05216042|Dietary Supplement|Study diet|Participants will consume the study diet for 5 days provided by the clinical research unit's metabolic kitchen (at UAB)
45669124|NCT05216042|Other|Exercise capacity VO2 max determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.
45970040|NCT00565708|Other|placebo|Placebo Comparator
45970041|NCT00565708|Drug|Acetylsalicylic acid|Adjuvant Therapy
45970042|NCT05011526|Biological|MVC-COV1901|Approximately 471 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
45970043|NCT05011526|Biological|AZD1222|Approximately 471 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
45970044|NCT00565786|Device|ArCom® Polyethylene|Argon packaged compression molded polyethylene
46081046|NCT05419687|Behavioral|Code of conduct delivered via a warning board|A publicly displayed code of conduct (a co-designed set of rules) for both HCWs and clients, delivered via a warning board at the level of the health facilities and secondary hospitals
46081047|NCT05418556|Drug|aspirin|DAPT strategy
45669125|NCT05216042|Other|Exercise Challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.
45669126|NCT05216042|Other|Glucose Challenge|Participants will come in fasting state on day 6th and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
45669127|NCT05208216|Device|Geko device|A small battery powered device that provides neuromuscular stimulation to the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
45669128|NCT05208216|Device|Flowtron DVT|A pneumatically powered pair of calf boots device that intermittently compress the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
46081048|NCT05413122|Drug|Varenicline|At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician.
45669129|NCT05207891|Device|Intervention mattress|The intervention mattress, Tidewave, will be compared to the regular care mattress, CuroCell 4AD. Primary outcome will be change in pressure injury occurence, assessed according to the NPIAP 2019 Clinical Guidance, and marked up on pressure injury body-map figures. Secondary outcomes will be experienced quality of life, assessed with the Spinal Cord Injury Quality of Life Basic Data Set. Further mattress comfort, assessed with the Mattress Comfort Scale, sleep-wellness, assessed with the Insomnia Severity Index, and pain, assessed with the Brief Pain Inventory. Satisfaction in the participants and in the nursing staff will be assessed with custom made Likert scales. Resource use and experienced stain in the nursing staff will be assessed with custom made forms asking for number of persons needed in position change, number of position changes needed during bed-rest, and experienced strain related to the position changes.
45669130|NCT05206682|Drug|Leuprorelin|Leuprorelin will be used to postpone period after vaginal repair.
45669131|NCT05204082|Device|Single Use Vein Entry Indicator Device|Electronic pressure sensing device, integrated to a conventional needle catheter, and which indicates continuously during intravenous cannulation whether the tip of the needle is inside or outside of a vein, to assist a clinician in intravenous cannulation.
45669132|NCT05201937|Drug|JNJ-64281802|JNJ-64281802 tablets will be administered orally as per the defined regimens.
45827086|NCT01788839|Other|Blood draw|Those patients receiving chemotherapy who consent to the optional blood draw will provide blood at baseline (before start of chemotherapy), 12 months after baseline (+/-1 month) and 24 months after baseline (+/-2 months). All patients in the subset of the premenopausal cohort receiving tamoxifen only will have required blood draws at baseline (before they begin taking tamoxifen), at 6 months post-baseline/start of tamoxifen (+/- 2 weeks), 12 months post-start of tamoxifen (+/-1 month) and 24 months post-start of tamoxifen (+/-2 months). We will ask these participants for blood draws on day 1, 2, 3 or 4 of their menses at baseline and 6 months post-baseline/start of tamoxifen and during months 1 through 5 post-baseline/start of tamoxifen.
45970045|NCT00565786|Device|ArComXL® Polyethylene|Highly crosslinked Ultra High Molecular Weight Polyethylene
45970046|NCT00252642|Drug|Peginterferon Alpha-2a|
45970047|NCT00565942|Procedure|Integrative care|In short, integrative care was up to 10 complementary therapy treatments delivered to the patient in addition to the usual care over an intervention period of up to 12 weeks. The integrative care was provided by a multidisciplinary team coordinated by a gate keeping general practitioner with clinical knowledge and experience of CTs and senior licensed/certified CT providers representing Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong.
45970048|NCT00565942|Procedure|Usual care|The usual care treatment was coordinated by the patient's general practitioner and complied with the clinical practice routines at the participating primary care units. Conventional procedures included but were not exclusive to advice, prescription of drugs, sick leave and physiotherapy/physical therapy. There were no constraints to the provided usual care as the study aimed to pragmatically reflect the general practitioners' standard care and treatment as usual.
45970049|NCT04598542|Drug|Lorecivivint (LOR)|0.07 mg
45970050|NCT04598542|Drug|Triamcinolone acetonide (TA)|40 mg
45970051|NCT04995263|Behavioral|Sueña component 1: Sleep Hygiene Promotion|The nursery staff will be instructed to promote sleep hygiene. Nurse technicians will: inform patients of the efforts to ensure a healthy sleep environment, verify the minimization of light and noise after 23:00 PM, favour natural light after 07:00 AM, and foment patient's activities and participation in group therapy. Nurses will: reduce sleep interruptions to a minimum, to only perform actions (i.e. blood testing, clinical controls, medicine administration) deemed strictly necessary between 23:00 PM and 07:00 AM. A list of commonly used medications with their pharmacodynamic and pharmacokinetic properties tailored by a pharmaceutical chemist will be provided, to ensure optimal medication administration while protecting the guaranteed sleep hours, to be coordinated with the treating physician.
45970052|NCT04995263|Behavioral|Sueña component 2: Periodic Anxiety and Pain Screening|Every night, nursery staff will include anxiety and pain screenings as part of vital signs assessments, using visual analog scales for each one. If any screening is altered, clinical actions will be performed to alleviate symptomatology if deemed necessary, using clinical judgement.
45970053|NCT04995263|Behavioral|Sueña component 3: Hypnotics and Caffeine Regulation|The use of hypnotics will be standardized to be administered no later than at 22:00 PM; in the case of melatonin, its administration will be suggested at sundown, at 20:00 PM. Caffeinated drinks will be prohibited after 15:00 PM.
45970054|NCT04995263|Behavioral|Sueña component 4: Sleep Masks and Ear Plugs|Sleep masks and ear plugs will be available to all patients if they wish to use them. The nursery team will reinforce its use between 23:00 PM and 07:00 AM.
45970055|NCT04995263|Other|Sueña component 5: Personalized Psychoeducation|Two individualized, nurse-led psychoeducation PowerPoint presentations on sleep hygiene will be presented to patients, supported by educational material aimed at the patient and their families.
45970056|NCT04995263|Device|Sueña component 6: Sleep Reports|Objective and subjective reports of sleep quality will be handed to attending psychiatrist, using data gathered with wearable devices (Fitbit Charge 4) and self-report questionnaires regarding perceived sleepiness and overall sleep. The psychiatrist in charge uses said information in the routine case management
45970057|NCT04598581|Radiation|Low Dose Radiation Therapy (LD-RT)|Low Dose Radiation Therapy (LD-RT) of both lungs with 1 Gray
45970058|NCT04598581|Other|Sham irradiation|Sham irradiation
45970059|NCT00252681|Procedure|laparotomy|
45455779|NCT05702905|Behavioral|physical exercise|All subjects after randomization will be reviewed and evaluated by a trainer, and then will receive guidance of physical exercise.The trainer will formulate an exercise plan for each subject. The exercise plan consists of 30 minutes of moderate and low intensity continuous aerobic exercise every day, with a frequency of 5-7 days/week. The form of exercise can be determined according to personal hobbies, such as fast walking, jogging, climbing, swimming, etc. The exercise diary will be distributed to each subject, and the subjects are required to make a return visit once every four weeks, return the exercise diary each time, and the trainer will provide guidance to the subjects according to their compliance.
45669133|NCT05199480|Other|Tobacco flavored liquid type 1|A commercially available cartridge-based device with tobacco flavored liquid.
45669134|NCT05199480|Other|Tobacco flavored liquid type 2|A commercially available cartridge-based device with tobacco flavored liquid.
45827087|NCT01788839|Device|Transvaginal ultrasounds|Transvaginal ultrasounds are used to determine the number of antral follicles in each ovary. They will be performed to evaluate both the number and size of antral follicles of premenopausal women on Tamoxifen as antral follicle count is a good predictor of ovarian reserve and response. All patients in the subset of the premenopausal cohort receiving tamoxifen only will also have required transvaginal ultrasounds at baseline (before they begin taking tamoxifen) and at 6 months post-start of tamoxifen (+/- 2 weeks).
45827088|NCT00003107|Biological|recombinant interleukin-12|
45970060|NCT00252681|Procedure|primary peritoneal drainage|
45970061|NCT04598503|Other|full history and clinical examination|For each case, a detailed perinatal and maternal and family history were obtained by interviewing questionnaire. Diagnosis of congenital anomalies was based on clinical evaluation of newborn babies by the neonatologist and other appropriate investigations such as radiography, ultrasonography, echocardiography and chromosomal analysis etc... Classification of anomalies is done by systems according to WHO international classification of diseases (ICD10) [10]. Data was entered into excel data sheet and appropriate statistical analysis was performed. The prevalence was calculated by dividing the number of CA during the 6 months (173) by the total number of admission during this period (753).
45669135|NCT05197842|Drug|BDB-001 injection|Intravenously administered
45669136|NCT05197842|Drug|Cyclophosphamide|Intravenously administered
45669137|NCT05197842|Drug|Glucocorticoids|Orally administered
45827089|NCT00383201|Device|OptiFree Multi-Purpose Disinfecting Solution|
45827090|NCT00003113|Biological|filgrastim|Filgrastim (granulocyte colony-stimulating factor; G-CSF) is given subcutaneously on days 5-21 and 33-42 of each cycle.
45455780|NCT05698563|Diagnostic Test|Magnetic resonance imaging|MRI scan with contrast of the foot or feet
45455781|NCT05698563|Diagnostic Test|Ultrasound|Ultrasound scan of the feet
45455782|NCT05698563|Drug|Corticosteroid injection|Administered ultrasound guided to patients with intermetatarsal bursitis
45455783|NCT05698563|Other|Clinical foot evaluation|An examination of the feet
45455784|NCT05698563|Other|Picture of the feet|To evaluate the presence of V-sign/spreading toes
45455785|NCT05697471|Drug|Dienogest|Dienogest 2 mg per day
45455786|NCT05697471|Drug|Danazol|Danzol 200MG per day
45669138|NCT05197842|Drug|BDB-001 injection|Intravenously administered
45669139|NCT05197842|Drug|Cyclophosphamide|Intravenously administered
45669140|NCT05197842|Drug|Glucocorticoids|Orally administered
45669141|NCT05197842|Drug|Cyclophosphamide|Intravenously administered
45669142|NCT05197842|Drug|Glucocorticoids|Orally administered
45827091|NCT00003113|Drug|cyclophosphamide|Cyclophosphamide are given on days 22-31 of each cycle.
45827092|NCT00003113|Drug|etoposide|Etoposide is given on days 1-3.
45827093|NCT00003113|Drug|lomustine|Lomustine is given on day 1 of cycles 1 and 3 only.
45669143|NCT05194098|Device|TMS: single session intermittent theta burst stimulation (iTBS) to dorsomedial prefrontal target in individuals with major depressive disorder, via MagVenture MagPro R30 device / Cool-DB80 A/P coil|Active Session: Single session of standard iTBS of 50Hz triplet bursts, 5 times each second with a 2 s on / 8 s off duty cycle for 600 pulses per hemisphere (1200 pulses total) will be applied for a total stimulation time of 6:40 minutes
45669144|NCT05194098|Device|SHAM (inactive) TMS stimulation|Sham neurostimulation (SHAM) entails use of the sham side of the D-B80 A/P placed over the same anatomical target, without any active stimulation.
45669145|NCT05192564|Other|Exercise for bilateral or unilateral vestibular hypofunction patients|Physical Activity intervention with balance exercises, multidirectional displacements, and strength with postural control, implementing 8-10 exercises integrating the main muscle groups and motor patterns, aerobic exercise on bicycle (15 min) developed progressively in intensity (R1-mild, R2-moderate, R3-vigorous) implementing an intervallic design in low volume.
45970062|NCT04598191|Drug|Iloprost|"Participants in Iloprost group will be administered aerosolized 20 μg iloprost in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done."
45970063|NCT04598191|Drug|Control (Normal saline)|"Participants in Control group will be administered aerosolized 5 ml of normal saline in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done."
45827094|NCT00003113|Drug|procarbazine hydrochloride|Procarbazine are given on days 22-31 of each cycle.
45827095|NCT00003113|Radiation|radiation therapy|Following the third cycle of chemotherapy, if residual disease is confined to 1 or 2 nodal sites, patients receive radiation therapy.
45827096|NCT01545557|Device|Hyaluronic acid dermal filler gel|1 Emervel Volume injection per indication and 1 touch-up injection if necessary
45827097|NCT00003119|Biological|filgrastim|
46081049|NCT05413122|Drug|Nicotine patch|A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package.
46081050|NCT05413122|Drug|Nicotine gum|A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package.
46081051|NCT05413122|Behavioral|Intensive Behavioral Counselling|Participants randomized to the Intensive Behavioural Counselling condition will receive in-person intensive (~45 minutes) behavioural counselling in the clinic at screening and at weeks 2, 4, 8, and 12. Additionally, on non-clinic visit weeks participants will receive (1) one phone call each week from the clinic counsellor, and (2) two text messages each week providing encouragement and advice.
46081052|NCT05413122|Behavioral|Peer Counselling|Participants randomized to the Peer Support condition will be engaged by a peer counsellor over weeks -2 to 12. Peer counselling will follow a flexible framework for contact with participants, which will include in-person and phone-based check-ins, depending upon individual participant preference. Peer counsellors will visit the counsellors' assigned participant in-person at participants' home, workplace, or other setting based on participant preference at least during weeks -2, 2, 4, 8 and 12; additional in-person contact will be provided upon participant request.
46081053|NCT05412030|Biological|Prevnar 13|PCV13 administered intramuscularly 4 times within 12 months
46081054|NCT05412030|Biological|AFX3772|AFX3772 administered intramuscularly 4 times within 12 months
46081055|NCT05407662|Other|sMRA therapies|No drug will be provided to participants. Patients follow routine clinical practice/administration.
46081056|NCT05405660|Biological|barzolvolimab|Subcutaneous Administration
46081057|NCT05405660|Drug|Matching Placebo|Subcutaneous Administration
46081058|NCT05390801|Other|Survey|Survey developed by ophthalmologists from the Ophthalmology Department of the Necker-Enfants Malades Hospital, fill out only once by patients with congenital aniridia in order to identify eye and systemic manifestations in congenital aniridia and to determine the patients' knowledge of their own disease.
46081059|NCT05387889|Behavioral|Mindfulness Meditation for Pulmonary Hypertension (MMPH)|Eight weeks of Mindfulness Meditation practice for patients with Pulmonary Hypertension condition. The content will focus on how to apply Mindfulness concepts to the everyday management of symptoms and stress.
46081060|NCT05384756|Drug|Alemtuzumab|Given IV
45827098|NCT00003119|Biological|sargramostim|
45827099|NCT00003119|Drug|carboplatin|
45827100|NCT00003119|Drug|cyclophosphamide|
45827101|NCT00003119|Drug|doxorubicin hydrochloride|
45827102|NCT00003119|Drug|etoposide|
45827103|NCT00003119|Procedure|adjuvant therapy|
46081061|NCT05384756|Procedure|Hematopoietic Cell Transplantation|Undergo HCT
45827104|NCT00003119|Procedure|conventional surgery|
45827105|NCT00003119|Radiation|radiation therapy|
45827106|NCT00003395|Drug|arsenic trioxide|
45827107|NCT00003401|Drug|carmustine|
45827108|NCT00003401|Drug|cisplatin|
45827109|NCT00003401|Drug|cyclophosphamide|
45827110|NCT00003401|Drug|dexamethasone|
45827111|NCT00003401|Drug|etoposide|
45827112|NCT00003401|Drug|gemcitabine hydrochloride|
45827113|NCT00003401|Drug|melphalan|
45827114|NCT00003401|Drug|paclitaxel|
45970064|NCT04598113|Device|Cervical Traction Device|"While The patient is lie on the back his or her head is housed within the specific head portion of the device. The investigator inflate progressively the device using a valve and ensuring the patient's relaxation. The process of inflation is continued until the level of 12 Kg of pressure is reached. This maximum level of traction is maintained for 10 minutes then the process of deflation is started until the pressure decreased to 0 Kg. This maneuver is reproduced once again after 5 minutes of rest.~The balance assessment using the force plate-from is done just before the intervention and 5 minutes after its end."
45827115|NCT00003401|Procedure|bone marrow ablation with stem cell support|
45827116|NCT00003401|Procedure|peripheral blood stem cell transplantation|
45827117|NCT00003125|Biological|ALVAC-CEA vaccine|
45827118|NCT00003125|Biological|aldesleukin|
45827119|NCT00003125|Biological|sargramostim|
45827120|NCT00003125|Biological|vaccinia-CEA vaccine|
45827121|NCT04130555|Device|CELLIS Rectopexy (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in Laparoscopic Ventral Rectopexy (LVR) or robotic assisted rectopexy
45669146|NCT05192564|Other|Conventional rehabilitation treatment|Vestibular rehabilitation exercises counseling
45827122|NCT00003131|Drug|chemotherapy|
45970065|NCT04956848|Device|iDAScore®|Images of all the embryos reaching at least developmental stage of 3BB will be analyzed by iDAScore®. The embryo with the highest iDAScore® will be proposed for transfer.
45970066|NCT04598308|Diagnostic Test|absolute flow and resistance measurements|"This registry only collects all measurement data from normal/routine physiologic assessment in the cathlab. These measurements are performed on a daily basis~Short description of the procedure Coronary angiography, PCI (if indicated), and physiologic measurements are performed completely according to normal routine. Physiologic measurements may include FFR, NHPR, IMR, CFR, absolute flow (Q) and microcirculatory resistance (Rmicro or MRR) measurement.~Intention to measure Q and Rmicro are mandatory to be included in this registry.~Use of drugs either during or after the procedure should also exactly identical to normal routine."
45970067|NCT04598230|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants randomized to this arm will receive up to 20 sessions of evidence based cognitive behavioral therapy (CBT) of extended duration, with more exposure tasks and greater family involvement than has been studied in the past.
46081062|NCT05384756|Radiation|Intensity-Modulated Radiation Therapy|Undergo TMLI
46081063|NCT05384756|Drug|Sirolimus|Medication to prevent the development of graft-versus-host disease (GVHD)
46081064|NCT05382130|Diagnostic Test|Test all|"In the test all arm, SARS-CoV-2 infection screening questions will be administered to all clinic attendees followed by SARS-CoV-2 Ag-RDT testing irrespective of screening results."
46081065|NCT05376462|Diagnostic Test|Quantra System with the QStat Cartridge|Whole blood viscoelastic test system that provides an assessment of the patient's coagulation status.
45669147|NCT05189457|Drug|Luteinizing Hormone Releasing Hormone|During the first strike, LHRH will be administered for 12 to 18 weeks. During the second strike, participants will receive 4 cycles of LHRH
45827123|NCT00003131|Drug|gemtuzumab ozogamicin|
45827124|NCT00384371|Drug|Botulinum Toxin A|Botulinum Toxin A
45827125|NCT00384371|Drug|Placebo|Placebo
45827126|NCT00423215|Drug|Insulin glargine (LANTUS)|"The patients will receive Lantus administered by subcutaneous injection, once daily at any time but at the same time each day.~Treatment duration: 4 months."
46081066|NCT05376462|Diagnostic Test|Standard Laboratory Tests|Laboratory tests that provide information about a patient's coagulation status.
45970068|NCT04598230|Drug|Combination therapy (COMB)|Participants randomized to this arm will receive cognitive behavioral therapy comparable to that in the cognitive behavioral therapy arm, plus one of three selective serotonin reuptake inhibitors (SSRI) medications (fluoxetine, sertraline, escitalopram)
46081067|NCT05373485|Biological|COVID-19 mRNA vaccine|2 doses of vaccine on Day 0 and Day 21
46081068|NCT05373485|Biological|Placebo|2 doses of placebo on Day 0 and Day 21
46081069|NCT05373472|Biological|COVID-19 mRNA vaccine|2 doses of vaccine on Day 0 and Day 21
45669148|NCT05189457|Drug|New Hormonal Agent|During the first strike, if Abiraterone is chosen 1000mg of Abiraterone will be taken orally. If Enzalutamide is used, 160 mg will be taken orally every 24 hours.
45970069|NCT04955366|Drug|Belatacept|Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg monthly
45455787|NCT05695950|Drug|GLPG3667|GLPG3667 capsules will be administered per dose and schedule specified in the arm description.
45669149|NCT05189457|Drug|Docetaxel|"During the second strike, participants will receive 4 cycles of Docetaxel at 75mg/m2 given intravenously at day 1 of ever 21 days. For participants with positive prostate biopsy or detectable PSA, the second strike will receive 2 additional cycles of docetaxel."
45827127|NCT00003413|Biological|filgrastim|
45970070|NCT04955366|Drug|Abatacept|Abatacept is an immunosuppressive medication and will be given SQ at a dose of 125 mg s.c. weekly
45970071|NCT00249171|Drug|risperidone|
46081070|NCT05373472|Biological|Placebo|2 doses of placebo on Day 0 and Day 21
45827128|NCT00003413|Drug|carmustine|
45827129|NCT00003413|Drug|cisplatin|
45455788|NCT05695950|Drug|Placebo|Placebo matching to GLPG3667 capsules will be administered per schedule specified in the arm description.
45455789|NCT05695482|Other|Neuromuscular training exercises|The 6-week exercise intervention consists of 25-minute group sessions of Neuromuscular training supervised by a researcher.
45827130|NCT00003413|Drug|melphalan|
45827131|NCT00003413|Drug|paclitaxel|
45827132|NCT00003413|Procedure|peripheral blood stem cell transplantation|
45827133|NCT00003413|Procedure|surgical procedure|
45827134|NCT00003137|Drug|irinotecan hydrochloride|
45827135|NCT00003419|Procedure|antiviral therapy|
45827136|NCT00003425|Biological|filgrastim|
45827137|NCT00003425|Drug|amifostine trihydrate|
45827138|NCT00003425|Drug|cyclophosphamide|
45827139|NCT00003425|Drug|melphalan|
45827140|NCT00003425|Procedure|peripheral blood stem cell transplantation|
45827141|NCT00534131|Procedure|Standard abdominal approach for rectal excision|Standard abdominal approach for rectal excision
45827142|NCT00534131|Procedure|APPEAR Procedure|Perineal incision to reach the distal rectum
45827143|NCT00534131|Procedure|Proctectomy|standard rectal excision which does not preserve the anal canal
45827144|NCT00330551|Drug|Oral Risperidone|Patients will be treated with oral risperidone daily, with the dosage determined by treating psychiatrist.
45827145|NCT00330551|Drug|Risperidone in Long-Acting Injectable Form (Consta)|Participants will take a 25 mg dosage of injectable risperidone (Risperidone in Long-Acting Injectable Form (Consta)) once every 2 weeks. Dosage will be adjusted if needed.
45970072|NCT04598464|Other|Home based exercise|The home-based training program included posture and stretching exercises, strengthening exercises, balance training, and a walking regimen 3 days per week for 3 months.
45970073|NCT00565981|Drug|Fludarabine phosphate|orally, 40 mg/m2 d1-3 q4w, x4 cycles
45970074|NCT00565981|Drug|Alemtuzumab|subcutaneous, starting dose 3 mg and escalation to 10 mg, then 30 mg, followed by 30 mg thrice weekly for 16 weeks in escalated dose
45970075|NCT04952519|Drug|Amantadine|Patients are treated with high doses of amantadine.
45970076|NCT04598035|Diagnostic Test|Diagnostic Tests|"Blood and Urine laboratory tests~ECG and blood pressure for cardiovascular measurements~Self-report questionnaires about pain"
45970077|NCT00414921|Drug|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults
45970078|NCT00414921|Drug|methylphenidate|Methylphenidate is known to safely and effectively treat many ADHD symptoms.
45970079|NCT00414921|Other|placebo|inactive substance
45827146|NCT00001259|Drug|Leuprolide|Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly
45970080|NCT04597762|Drug|Cyclosporin|Cyclosporin eyedrops
45970081|NCT04597762|Drug|Hydrocortisone|Hydrocortisone eyedrops
45970082|NCT04597645|Other|Therapeutic elastic band resistance training|A16-week therapeutic program using Elastic Thera Band will be taught. The exercises are designed to train specific major muscle groups, strengthen the motivation of participants, and facilitate home-based compliance. The program will be performed two times per week (once supervised and guided by a trained physical therapist and the other supervised by educational trainers) over 16 weeks for a total of 32 sessions. Each session supervised by a physical therapist last for 60 minutes, including a 5-minute warm-up consisting of light-intensity aerobic and dynamic stretching exercises, followed by 50 minutes of EB exercise and a 5-minute period of cool-down and static stretching exercises.
45970083|NCT00249210|Drug|levofloxacin|
45970084|NCT04597957|Dietary Supplement|Fresh Rx Intervention group|"Fresh Rx Intervention participants will be able to fill their prescription at the FQHC based Farmers Market for fresh produce up to eight times during the 15-week Fresh Rx program. The provided debit cards will be loaded with the $10 stipend at each visit. At each market session, cooking demonstrations will take place that reinforce healthy food options and how to prepare foods that were available at the Mercado.~All control group participants will be given flyers describing all the health and wellness programs at the FQHC including the Mercado. Control group participants will receive a $10 gift card to a national brand pharmacy (no fresh produce available). The enrollment time for the control group will overlap with the Fresh Rx group. After a 3-month time period, the control group will follow up and be given a $20 gift card to the same national brand pharmacy."
45970085|NCT04597723|Drug|oxygen|Patients will be given different concentrations of oxygen.
45970086|NCT00252798|Drug|Gefitinib|
45970087|NCT00252798|Drug|Carboplatin|
45970088|NCT00252798|Drug|Paclitaxel|
45970089|NCT00252798|Procedure|Radiation|
45669150|NCT05189457|Drug|Tislelizumab|During the second strike, participants will receive 6 doses of Tislelizumab at 200 mg, given intravenously once every 3 weeks.
45669151|NCT05188469|Drug|EG-COVID-003|"Subjects will receive one, two or three single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-003 0.5mL (mRNA 100μg)~Route of administration: Intramuscular injection"
45970090|NCT04597567|Procedure|Metal removal|Implant removal after fracture consolidation after posterior fixation of thoracolumbar spine fractures
45970091|NCT04597216|Device|sample of blood and saliva|sample of 3ml of blood by veinous puncture, of 1 drop of blood by needlestick, and of saliva by spitting
45970092|NCT04597255|Device|Holographic optical coherence tomography|Descriptive wavefront analysis with holographic optical coherence tomography
45970093|NCT04597489|Procedure|Fractional flow reserve|Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.
45970094|NCT04597489|Procedure|Angiography-only|Patients were stratified into the angiography-only group if a coronary angiography without adjunctive FFR measurement was performed.
45669152|NCT05188469|Drug|EG-COVID-001|"Subjects will receive one, two or three single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-001 0.5mL (mRNA 200μg)~Route of administration: Intramuscular injection"
45669153|NCT05188469|Drug|A: EG-COVID|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 0.5mL (mRNA 400μg)~Route of administration: Intramuscular injection"
45827147|NCT00001259|Drug|Estradiol Patches|Transdermal Estradiol, 100mcg/day by skin patch
45827148|NCT00001259|Drug|Progesterone|Progesterone suppository, 200mg vaginally twice/day
45827149|NCT00001259|Drug|Placebo patch|Placebo by skin patch
45827150|NCT00001259|Drug|Placebo injection|Placebo given intramuscularly monthly
45827151|NCT00001259|Drug|Placebo suppository|Placebo vaginal suppository
45827152|NCT00003143|Drug|Amifostine|
45669154|NCT05188469|Drug|B: EG-COVID|"Subjects will receive two single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 1mL (mRNA 800μg)~Route of administration: Intramuscular injection"
45827153|NCT00003143|Drug|DHAP|
45827154|NCT00003431|Biological|recombinant flt3 ligand|
45827155|NCT00003149|Biological|recombinant interleukin-12|
45827156|NCT00003437|Drug|asparaginase|
45827157|NCT00003437|Drug|cyclophosphamide|
45827158|NCT00003437|Drug|cytarabine|
45970095|NCT02961660|Drug|Odalasvir|Participants will receive odalasvir 25 mg tablet, orally.
45970096|NCT04870151|Procedure|Anterolateral approach|Cemented hemiarthroplasty using an anterolateral approach.
45970097|NCT04870151|Procedure|Direct lateral approach|Cemented hemiarthroplasty using a direct lateral approach.
45970098|NCT04597177|Radiation|ST-IMRT SW-IMRT|
45970099|NCT04596904|Other|Lavender oil application group|Individuals, for 10 days, 3 drops of cotton drops of lavender oil, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
45970100|NCT04596904|Other|Distilled water application group|Individuals, for 10 days, 3 drops of cotton drops of distilled water, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
45970101|NCT04596787|Procedure|Bilateral Thoracic paravertebral block|The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
45970102|NCT00252837|Drug|Tesaglitazar|
45970103|NCT00252837|Behavioral|Dietary and Lifestyle counseling|
45970104|NCT04596748|Dietary Supplement|Probiotic|Bacillus Subtilis, Bacillus Clausii, Bacillus Coagulans, Bacillus Indicus HU36, MCC 102
45970105|NCT04596748|Dietary Supplement|Placebo|Placebo caps
45970106|NCT00403013|Procedure|Positioning and anesthesia|Positioning during axillary plexus block
45669155|NCT05188469|Drug|C: EG-COVARo|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVARo 0.5mL (mRNA 800μg)~Route of administration: Intramuscular injection"
45970107|NCT04597060|Device|Thermomechanical system with corticosteroids|The device in this study using Novoxel - Tixel®
45970108|NCT04597060|Other|corticosteroid injection|corticosteroid injection using TA 10mg/ml
45970109|NCT00566176|Device|Surgical Ablation using the AtriCure Bipolar System|Surgical Ablation using the AtriCure Bipolar System
45970110|NCT00566215|Procedure|Duodenal exclusion plus omentectomy|"Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.~Additionally, total omentectomy is performed."
45669156|NCT05173415|Device|Sirius Pintution|The intervention studies a metal Clip (Sirius Pintution) to localize axillary lymph nodes during TAD. Intraoperative localization of the lymph node will be conducted using a hand-held probe identifying the clip.
45827159|NCT00003437|Drug|daunorubicin hydrochloride|
45827160|NCT00003437|Drug|dexamethasone|
45669157|NCT05173415|Device|HydroMARK (C) Clip|The control intervention is a metal clip (HydroMARK© Clip), which will be localized and extracted during the tailoring surgery. Intraoperative Ultrasound is used to localize the clip. This method is considered as standard practice today.
45827161|NCT00003437|Drug|doxorubicin hydrochloride|
45827162|NCT00003437|Drug|mercaptopurine|
45827163|NCT00003437|Drug|methotrexate|
45970111|NCT00566215|Procedure|Duodenal exclusion without omentectomy|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
45827164|NCT00003437|Drug|pegaspargase|
45827165|NCT00003437|Drug|prednisolone|
45827166|NCT00003437|Drug|thioguanine|
45827167|NCT00003437|Drug|vincristine sulfate|
45970112|NCT00566332|Drug|Chlorambucil|Chlorambucil 8 mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months By oral route
45970113|NCT00566332|Drug|Fludarabine|Fludarabine 40 mg/m² (30 mg/m² if patient aged more than 75 years old) 5 days every 28 days during 6 cycles By oral route
45970114|NCT00403052|Drug|1018 ISS immunostimulatory oligonucleotide|6 weekly subcutaneous (under the skin) injections
45970115|NCT04596943|Diagnostic Test|[68Ga]Ga-DOTA-(RGD)2 PET/CT|We have developed a dimeric cyclic RGD peptide conjugated with DOTA as a chelator. If labeled with the positron emitting radionuclide Gallium-68 (68Ga), [68Ga]Ga-DOTA-(RGD)2 can be used to visualize αvβ3 integrin expression with PET
45970116|NCT00252876|Drug|tesaglitazar|
45970117|NCT04597021|Device|use of a wiresless US transducer|to (evaluate the practicability of applying a wireless US transducer for central venous catheter-placement in these patients.
45970118|NCT04596709|Dietary Supplement|Vitalose|dissolved in water
45970119|NCT04596709|Dietary Supplement|isomaltulose|dissolved in water
45970120|NCT04596709|Dietary Supplement|sucrose|dissolved in water
45970121|NCT04596709|Dietary Supplement|glucose|dissolved in water
45970122|NCT04596358|Other|Observational|Evaluation of adherence to the Mediterranean diet through the administration of the Med Diet Score questionnaire.
45827168|NCT00003437|Radiation|radiation therapy|
45827169|NCT00003443|Drug|bryostatin 1|
45827170|NCT00003449|Drug|dexamethasone|
45827171|NCT00003449|Drug|gemcitabine hydrochloride|
45827172|NCT00003449|Drug|paclitaxel|
45827173|NCT00002801|Drug|leucovorin calcium|
45669158|NCT05153629|Device|TENS|TENS device used four times a day for 60 minutes each time
45669159|NCT05153226|Drug|Cyclophosphamide|50 mg/kg (AIBW) i.v. d+3, d+4 post transplant
45669160|NCT05153226|Biological|ATG|10 mg/kg i.v. d-3, d-2, d-1 pre-transplant
45669161|NCT05137236|Biological|mRNA-1283|Sterile liquid for injection
45669162|NCT05137236|Biological|mRNA-1283.211|Sterile liquid for injection
45669163|NCT05137236|Biological|mRNA-1273|Sterile liquid for injection
45669164|NCT05137236|Biological|mRNA-1283.529|Sterile liquid for injection
45669165|NCT05136612|Other|conventional physiothrapy|Conventional physiotherapy program will be applied to the control group for 6 weeks, 3 days a week, 45 minutes a day. Strengthening, dynamic stretching, coordination and balance exercises and functional exercises for upper and lower extremities will be applied in this treatment program.
45669166|NCT05136612|Other|robotic rehabilitation|The study group will be included in the rehabilitation program with the Hocoma brand Armeo Spring pediatric upper extremity robot for 30 minutes a day, 3 days a week, for 6 weeks at hospital. Armeo spring robot enables the individual to perform active movement by carrying the weight of the upper extremity of children who have active movement in their upper extremities but do not have enough strength to overcome gravity with their upper extremities. The individual is actively involved in the study during the study. With the adjustments made, it becomes suitable for use for right and left extremities. In the process of working; The games named High Flyer, Frisbee, Balloons, Goalkepper, Save the Monster, Fishing, Helicopter Rescue, which are included in the Armeo Spring robot and created to increase shoulder, elbow and wrist movements, will be used.
45827174|NCT00002801|Drug|tegafur-uracil|
45827175|NCT00002801|Radiation|radiation therapy|
45827176|NCT00002807|Radiation|radiation therapy|45 Gy in 25 fractions over 5 weeks
45827177|NCT04329533|Other|"Calm is a mindfulness meditation mobile app"|"Mindfulness meditation is a self-management strategy that can be utilized to assist with the management of stress. Mindfulness meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time."
45827178|NCT00002813|Drug|cisplatin|
45827179|NCT00002813|Drug|vinorelbine tartrate|
45827180|NCT00002819|Drug|carboplatin|
45827181|NCT00002819|Drug|cyclophosphamide|
45827182|NCT00002819|Drug|mitoxantrone hydrochloride|
45970123|NCT00566371|Drug|atomoxetine|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
45970124|NCT00566371|Drug|placebo|placebo
45970125|NCT04825769|Device|LLLT（Low Level Laser Therapy）|2 times a day, 3 minutes each time, with an interval of more than 4 hours. During the semester: From Monday to Friday, set up an intervention room in the school; For winter and summer vacation: everyday at home
45970126|NCT04596397|Other|Inpatient setting|These women stay at the hospital.
45669167|NCT05135910|Drug|Hallux Terbinafine Subungual Gel|Hallux Terbinafine Subungual Gel (HSG) administered every 1 to 2 months over 44 weeks.
45970127|NCT04596397|Other|Outpatient setting|These women can leave the hospital.
45970128|NCT00252915|Biological|GM-CSF (verum)|sagramostim
45827183|NCT00002819|Drug|paclitaxel|
45669168|NCT05130177|Drug|Zimberelimab|Zimberelimab is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets the human programmed cell death-1 (PD-1) immune checkpoint.
45669169|NCT05130177|Drug|Domvanalimab|Domvanalimab is a humanized immunoglobulin G1 (IgG1) mAb that targets immune checkpoint TIGIT.
45669170|NCT05129748|Drug|Sodium Thiosulfate + Mannitol|Drug delivery will be sequential, where Mannitol will be infused over 30 minutes and Sodium Thiosulfate will be infused over 15 minutes.
45669171|NCT05127746|Drug|Aricept 5mg Tablet|1 tablet once daily
45669172|NCT05127746|Drug|Aricept 10mg Tablet|1 tablet once daily
45669173|NCT05127746|Drug|DA-5207 A|1 patch once weekly
45669174|NCT05127746|Drug|DA-5207 B|1 patch once weekly
45669175|NCT05127174|Drug|Fedratinib Pill|Fedratinib is taken orally once per day, in 100 mg capsules. Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).
45970129|NCT04596280|Procedure|Colonic Resection|Resection of the colonic tract which has been interested by the acute diverticulitis
45669176|NCT05110456|Behavioral|Telephone support|"Participants will receive 10 telephone counseling calls by trained coaches: 9 during pregnancy (one call/week) and 1 at 6 weeks postpartum. We have included individual telephone calls by a trained coaches aimed to :~encourage the use of online material;~identify strategies for overcoming obstacles;~help apply content to real-life settings; and~underscore the participants' success in using effective coping strategies"
45669177|NCT05109234|Drug|Brivaracetam Film-coated tablet|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Brivaracetam film-coated tablet [10, 25 or 50 mg] will be administered twice per day in equal doses."
45669178|NCT05109234|Drug|Brivaracetam oral solution|"Pharmaceutical form: Oral solution~Route of administration: Oral use~Brivaracetam oral solution [10 mg/mL]) will be administered twice per day in equal doses."
45669179|NCT05072080|Biological|CHIKV VLP/adjuvant|PXVX0317 vaccine is comprised of chikungunya virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide (Alhydrogel®) adjuvant 2%
45669180|NCT05072080|Biological|Placebo|Placebo is comprised of formulation buffer
45669181|NCT05067335|Drug|Romosozumab|Subjects will receive romosozumab in a specified sequence during the treatment Period.
45827184|NCT00002819|Procedure|autologous bone marrow transplantation|
45970130|NCT04595929|Procedure|Staging laparoscopy|All patients undergo staging laparoscopy and peritoneal lavage.
45970131|NCT04595929|Drug|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
45970132|NCT04595929|Drug|Leucovorin|Day 1 q2w: 200 mg/m² IV over 30 minutes
45827185|NCT00002819|Procedure|peripheral blood stem cell transplantation|
45827186|NCT00002825|Biological|filgrastim|
45827187|NCT00002825|Drug|docetaxel|
45827188|NCT00002831|Biological|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to the first stem cell collection and before DAC infusion.
45827189|NCT00002831|Drug|Busulfan|Administered orally every 6 hours on consecutive days -6 through -4.
45970133|NCT04595929|Drug|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
45970134|NCT04595929|Drug|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
45970135|NCT04595929|Procedure|Radical surgery|Radical gastrectomy with D2 - lymph node dissection.
45970136|NCT04595929|Procedure|PIPAC|Intraoperative Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin 7,5 mg/m², doxorubicin 1,5 mg/m².
45970137|NCT04595929|Drug|Adjuvant chemotherapy|Adjuvant chemotherapy according to indications.
45827190|NCT00002831|Drug|Cyclophosphamide|Given intravenously (IV) over 1 hour on consecutive days -3 and -2.
45970138|NCT04802564|Other|regular hand therapy|edema control, scar management, stretching regimen, tendon gliding exercise, blocking exercise, muscle strengthening protocols
45970139|NCT00249327|Behavioral|education|
45669182|NCT05067335|Drug|Placebo|Subjects will receive Placebo in a specified sequence during the treatment Period.
45669183|NCT05062824|Behavioral|Baby Feed|Baby Feed web portals can (1) Quickly and easily evaluate infant diet using a validated Infant Food Frequency Questionnaire (infant FFQ) developed by our group14. [Parental FFQ portal]; (2) Provide automatic results to healthcare professionals on nutrients and foods/beverages consumed above or below the recommended levels to discuss with parents for improving the infant's diet. Also, to provide recommendations for amounts of foods/beverages that the infant should be consuming by age [Clinician Portal]; (3) Give online access to parents to these diet recommendations to implement at home, with an easy tracking component [Parent's Portal].
45669184|NCT05054998|Radiation|Fludeoxyglucose F-18|Given IV
45669185|NCT05054998|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
45669186|NCT05054998|Procedure|Positron Emission Tomography|Undergo PET/MRI
45669187|NCT05054218|Biological|mRNA-1273|Participants will receive a 0.5 mL injection of the vaccine that contains a 100-μg dose of mRNA1273. The vaccine will be administered into the deltoid muscle.
45669188|NCT05048316|Behavioral|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
45827191|NCT00002831|Drug|Cyclosporine|Patients intolerant to tacrolimus receive cyclosporine IV beginning on day -2, then orally following tolerance and engraftment.
45669189|NCT05030675|Drug|Fostamatinib|Given PO
45669190|NCT05024552|Drug|Gilteritinib|Gilteritinib is an oral inhibitor of FLT3-ITD and FLT3-TKD. Dose cohort 1 will receive 120mg daily on days 6-19 of induction and days 4-17 of re-induction and consolidation
45669191|NCT05024552|Drug|Vyxeos|Vyxeos is a liposomal encapsulation of cytarabine and daunorubicin. It is given as an intravenous infusion over 90 minutes on days 1, 3 and 5 of induction and days 1 and 3 of re-induction and consolidation. The induction and reinduction dose is 44mg/m2 daunorubicin and 100mg/m2 of cytarabine with each infusion. The consolidation dose is 29mg/m2 daunorubicin and 65mg/m2 of cytarabine with each dose.
45970140|NCT04596085|Dietary Supplement|Investigational Product - ViraCide|Viracide
45669192|NCT05007808|Drug|G001 Topical Gel|Non-steroidal anti-inflammatory drug for topical administration
45669193|NCT05007808|Drug|Vehicle|Vehicle Gel for topical administration
45455790|NCT05695482|Other|Hip abductors muscular strength exercises|The 6-week exercise intervention consists of of 20-minute group sessions of progressive resistance training, supervised by a researcher.
45455791|NCT05693909|Drug|SP-420|Capsules for oral intake
45455792|NCT05693363|Device|AURA10 Specimen Imager|High-resolution specimen imaging using the AURA10 PET-CT specimen imager during thoracic surgery.
45827192|NCT00002831|Drug|Decitabine (DAC)|IV over 4 hours on days -8 and -7.
45827193|NCT00002831|Drug|Methotrexate|Given intrathecally or intraventricularly monthly, beginning on the second month through the eighth month of treatment.
45827194|NCT00002831|Drug|Methylprednisolone|Given according to clinical grade of GVHD procedures.
45827195|NCT00002831|Drug|Tacrolimus|IV beginning one day before stem cell infusion, then orally following tolerance to tacrolimus.
45827196|NCT00002831|Procedure|Allogeneic Bone Marrow Transplantation|Infusion of stem cells on Day 0.
45827197|NCT00002831|Procedure|Peripheral Blood Stem Cell Transplantation|Stem cell infusion on Day 0.
45827198|NCT00002837|Biological|Filgrastim (G-CSF)|
45970141|NCT04596085|Other|Placebo - Starch Powder Soft gels|Starch Powder Soft gels
45970142|NCT00566410|Drug|Dichloroacetate|Continuous daily oral dosage (bid).
45970143|NCT04758533|Biological|AloCELYVIR|Mesenchymal allogenic cells + ICOVIR-5: 500.000 cells/kg
45970144|NCT04596007|Drug|HEC83518 tablets|Each dose of HEC83518 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
45970145|NCT04596007|Drug|Placebo|placebo
45970146|NCT00252954|Drug|Levetiracetam|Tablets 2000-3000 mg per day
45970147|NCT04595812|Drug|Misoprostol 200mcg Tab vaginal|2 tablets vaginally 1 hour before surgery
45970148|NCT04595812|Drug|Oxytocin|30 IU oxytocin in 500 ml normal saline at a rate of 120 ml/h
45970149|NCT04595812|Drug|Carbetocin|100 μg IV Carbetocin (1ml) in 5 ml saline over 1 minute
45970150|NCT04595812|Procedure|pericervical hemostatic tourniquet|a Foley catheter size 18, which will be firmly tied at the level of the cervico-isthmic junction of the uterus before the uterine incision,The time of tourniquet administration will be recorded, and will be released not later than 45 minutes after its application. For those requiring multiple applications, the tourniquet will be reapplied after a period of at least 15 minutes.
45970151|NCT04596046|Procedure|steroid injecting|Group L: Triamcinolone acetonide was administered to the patients through injecting inside the lesion.Group S: Oral methylprednisolone was administered to the patients.
45827199|NCT00002837|Drug|Cyclophosphamide|
45970152|NCT04595890|Biological|Autologous Nucleated Cells|For each participant, bone marrow will be aspirated from the iliac crest, and then processed to achieve a concentrated dose of autologous, nucleated cells. These cells will be injected into the same participant's knee that is affected by knee OA.
45669194|NCT05006040|Device|Hybrid Closed Loop System|Participants will utilize the Tandem Control-IQ Professional Hybrid Closed Loop artificial pancreas system [25, 26]. This device consists of the Dexcom G6 Continuous glucose monitor (or a more recent interoperable CGM), the Tandem t:slim X2 continuous subcutaneous insulin infusion pump, and the Control-IQ professional hybrid closed loop control algorithm. The CGM is generally replaced by parents or patients and then replaced after sensor expiration or if it falls off. This CGM, like all future iCGMs, is factory calibrated and approved for direct dosing of insulin. In addition, while the system is in use, patients will conduct blood glucose level checks at least four times a day with a fingerstick and calibrate the CGM if the measurements differ by more than 20 mg/dL of fingerstick blood glucose level. The t:slim X2 insulin pump delivers rapid acting insulin via a subcutaneous cannula which is placed by parents or patients and then replaced every 3 days [30].
45827200|NCT00002837|Drug|Doxorubicin Hydrochloride|
45827201|NCT00002837|Drug|Paclitaxel|
45970153|NCT00252993|Drug|DDP225|
45970154|NCT04595539|Behavioral|Behavioral Activation treatment with Attention Training Technique|"The BATD includes the development of a shared formulation, psychoeducation, self-monitoring of daily activities, identifying depressed behaviours, developing alternative goal orientated behaviours, scheduling of valued activities, and problem solving around difficulties implementing scheduled activities.~Wells's Attention Training is a task designed to train selective attention to specific information by training individuals to attend to multiple auditory external sources. In addition to auditory exercices, the ATT sessions included psychoeducation, discussion around rumination (e.g. controllability, usefulness), self-report evaluation of self-focused before and after the auditory exercices, and transfer to everyday life."
45970155|NCT00566566|Other|sample without DNA|family history, anthropometric measurements and blood sampling
45970156|NCT04595695|Behavioral|Transparent mask|A transparent mask worn by the surgeons in customary fashion will be used.
45970157|NCT04595695|Behavioral|Typical surgical covered mask|A standard covered surgical mask worn by the surgeons in in customary fashion will be used.
45970158|NCT04595578|Device|Cerebellar repetitive transcranial magnetic stimulation|rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
45970159|NCT00249366|Drug|Lorazepam (drug)|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
45970160|NCT00249366|Drug|Lorazepam|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
45455793|NCT05693051|Other|Prone position ventilation|Turning the patient prone for 16 hours
45827202|NCT00002837|Procedure|Peripheral Blood Stem Cell Transplantation|
45827203|NCT00003455|Drug|antineoplaston A10|
45827204|NCT00003455|Drug|antineoplaston AS2-1|
45827205|NCT00003455|Procedure|alternative product therapy|
45827206|NCT00003455|Procedure|biological therapy|
45827207|NCT00003455|Procedure|biologically based therapies|
45827208|NCT00003455|Procedure|cancer prevention intervention|
45827209|NCT00003455|Procedure|complementary and alternative therapy|
45827210|NCT00003455|Procedure|differentiation therapy|
45827211|NCT00003461|Procedure|surgical procedure|
45827212|NCT00003461|Radiation|astatine At 211 monoclonal antibody 81C6|
45827213|NCT00003467|Drug|carmustine|
45827214|NCT00003467|Drug|polifeprosan 20 with carmustine implant|
45827215|NCT00003467|Procedure|surgical procedure|
45970161|NCT04595461|Other|Video Education|Patients receive four short YouTube videos explaining chronic rhinosinusitis and endoscopic sinus surgery
45970162|NCT04595461|Other|Control|Standard patient education with verbal and written education
45970163|NCT04595227|Device|Computerized pupillary light reflex assessment device|CPLRAD may serve as an effective screening tool for glaucomatous optic neuropathy, since they can dynamically detect abnormal pupillary responses from a novel sequence of light stimuli and functionally-shaped stimuli. CPLRAD can collect the clinical examination data and objectively measure the pupil dynamic parameters monocularly and/or binocularly as indicators from the retina and optic nerve in glaucoma patients.
45970164|NCT04635683|Drug|Lenalidomide|Given PO
45970165|NCT04635683|Biological|Ublituximab|Given IV
45970166|NCT04635683|Drug|Umbralisib|Given PO
45970167|NCT04595383|Device|ti.care|Electronic platform for doctor-patient communication
45970168|NCT04595110|Other|Observational study|Coagulation factors, Hypercoagulation biomarkers, Endothelial, Fibrinolysis and neutrophil activation biomarkers
45970169|NCT00253032|Device|PRIMA|
45970170|NCT04595344|Other|Listening to Pure Binaural Beats|"The patients in DCG ((binaural beat group) ) and USRG (binaural beat group) listened to binaural beats.The binaural beats were produced using a software program (Audacity®, version win. 2.3.2, 2019 Audacity Team) at frequency of 10 Hz (a tone of 200 Hz in the right ear and a tone of 210 Hz in the left ear). The binaural beats that the patients in DCG-1 and USRG-1 listened to were pure frequencies, with no background music or waves."
45970171|NCT04595344|Other|Listening to classical music|The patients in DCG (classical music group) and USRG (classical music group) listened to classical music.The classical music that those in DCG-2 and USRG-2 listened to was Mozart's 40th Symphony.
45970172|NCT04595344|Other|No audio only headphone|The patients in DCG (placebo group) and USRG (placebo group) sat in a quiet room with headphones on but no audio playing
45970173|NCT00403091|Behavioral|Internet Intervention|Internet-based intervention aims to improve guideline adherence by rural physicians caring for adult patients with type 2 diabetes.
45970174|NCT00403091|Behavioral|Control|The comparison group will receive a text-based, non-interactive Internet posting of publicly available resources.
45970175|NCT00566605|Procedure|Penetrating keratoplasty with IntraLase|penetrating keratoplasty with femtosecond laser shaped incisions- IntraLase TM (IntraLase Enabled Keratoplasty [IEK])
46081071|NCT05371665|Behavioral|Culturally Adapted Compass for Courage|COMPASS is an indicated prevention and early intervention program for 8-13-year-old youth with higher anxiety. Our CAB has decided to adapt it as a universal prevention and early intervention for all NA youth in the tribal community. It is delivered across six weeks with 30 min weekly sessions. Youth engage in games (e.g., WorryHeads Board Game) and role-play reducing anxiety and stress in mildly challenging situations to provide in-vivo exposure. Session 1 involves introductions, relaxation training, and discussing emotions. Session 2 teaches youth about worries and how to handle them. Session 3 focuses on having conversations with others. Session 4 teaches youth how to be assertive (CAB identified this as an area of adaption in initial meetings). Session 5 teaches youth how to face their fears. Session 6 is a review session. Parents and teachers are sent notes of what youth learned in each session and asked to encourage youth to practice their learned skills.
46081072|NCT05368285|Biological|barzolvolimab|Subcutaneous Administration
46081073|NCT05368285|Drug|Matching Placebo|Subcutaneous Administration
46081074|NCT05366751|Drug|SAGE-324|SAGE-324 oral tablets
46081075|NCT05364866|Drug|Antiarrhythmic drug Therapy|Propafenone, Sotalol and Amiodarone
46081076|NCT05364866|Device|cryoballoon ablation|Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters including 23mm and 28mm.
45970176|NCT00566605|Procedure|Penetrating keratoplasty with vacuum trephine|Group 2 - penetrating keratoplasty with vacuum trephine
45970177|NCT04594954|Dietary Supplement|Diet|A high-protein low carbohydrate diet (HPLC) diet would be prescribed to the patients. HPLC (high-protein low carbohydrate) diet would comprise of energy as 20-25 Kcal/Kg IBW/day (amounting to 700- 800 Kcal less than the usual dietary intake), Protein as 1.2-1.5 gm/Kg IBW/day i.e. 30% of the total calories as proteins, 52% of carbohydrates 18% of fats with dietary fiber as 25 g/day. The protein requirements would be met with modular high protein, low calorie supplements.
45970178|NCT04594954|Other|FMT|"Stool Administration Procedure (ILBS FMT Protocol)~500 mL filtrates will be delivered through the UGI Endoscopy into proximal jejunum [(2 to 3 minutes per 50 ml).]~The recipient will be kept nil per oral for at least 4 hours prior to the stool instillation.~100 mL freshly thawed sample will be given once in 15 days for 3 doses~Non-absorbable antibiotics will be avoided in the patient from the time of enrollment into the study and therapy initiation.~Intravenous antibiotics will be continued as per institutional protocol in the event of active sepsis based on culture and sensitivity.~The patient will be allowed to consume liquid diet two hours after the procedure."
45970179|NCT04594954|Other|Physical Activity|"Physical Activity:~The exercise program would consist of brisk walking. Brisk walking is defined as the walking intensity of 60-70% of their respective age-predicted maximum heart rate (target heart rate) 27,28. Speed of 5- 6 kmph considered as a brisk walking in most of the studies preferably on a treadmill for a duration of 30-45 minutes30 or brisk walking (walking faster than normal pace, measure 5000 steps continuously by pedometer). Same amount of physical activity would be prescribed to both the groups for 5 days a week for 30 -45 min."
45970180|NCT00253071|Behavioral|Prophylactic combined medical and psychological treatment|"Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy."
45970181|NCT04626674|Genetic|SRP-9001|Single IV infusion of SRP-9001
45669195|NCT05004662|Behavioral|Smartphone-delivered automated treatment|An interactive smartphone-based intervention that comprises content delivered via audio/video clips and text content automatically each week to the participant
45827216|NCT00003485|Drug|antineoplaston A10, antineoplaston AS2-1 (ANP)|"Patients with metastatic or unresectable Colon Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45970182|NCT04594876|Other|Flouroscopic guidance cervical epidural versus cervical facet injection|The patients are classified in two groups group P for cervical epidural and group F for facet injection. The skin will be prepared with an antiseptic solution. The midline of the selected interspace will be identified under fluroscopic guidance.
45970183|NCT00249405|Drug|Citalopram + MI|14-week citalopram treatment + Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
45970184|NCT00249405|Behavioral|Placebo + MI|placebo + single Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
45970185|NCT00566644|Device|levonorgestrel-releasing intrauterine system|
45970186|NCT00566644|Other|questionnaire administration|
45827217|NCT00003491|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45827218|NCT00003497|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
45827219|NCT00003167|Biological|Ad5CMV-p53 gene|Given intravesically
45827220|NCT00003515|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45827221|NCT00003521|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Soft Tissue Sarcoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45827222|NCT00002849|Biological|recombinant interferon alfa|first 2 years
46081077|NCT05364424|Drug|Glofitamab|Participants will receive intravenous (IV) glofitamab for up to 3 cycles.
45827223|NCT00002849|Drug|dexamethasone|40 mg*/d PO 1 - 4, 9 - 12, 17-20 q 35 days for 3 cycles*
45827224|NCT04329377|Diagnostic Test|blood test|complete blood count and platelet function
45669196|NCT05004662|Drug|Nicotine patch|Participants will be provided with a 10-week supply of nicotine patches
45827225|NCT00002855|Drug|Bicalutamide|
45827226|NCT00002855|Drug|Doxorubicin hydrochloride|
45827227|NCT00002855|Drug|Estramustine Phosphate Sodium|
45827228|NCT00002855|Drug|Flutamide|
45827229|NCT00002855|Drug|Ketoconazole|
45827230|NCT00002855|Drug|Nilutamide|
45827231|NCT00002855|Drug|Therapeutic Hydrocortisone|
45669197|NCT05004662|Behavioral|Counceling|Phone counseling with the Florida Quitline
45827232|NCT00002855|Drug|Vinblastine|
45970187|NCT00566644|Procedure|observation|
46081078|NCT05364424|Drug|Obinutuzumab|Participants will receive IV obinutuzumab on Cycle 1 Day 1.
46081079|NCT05364424|Drug|Tocilizumab|Participants will receive IV tocilizumab as necessary to manage cytokine release syndrome (CRS) events.
46081080|NCT05364424|Drug|Rituximab|Participants will receive up to 2 doses of IV rituximab.
46081081|NCT05364424|Drug|Ifosfamide|Participants will receive IV ifosfamide for up to 3 cycles.
46081082|NCT05364424|Drug|Carboplatin|Participants will receive IV carboplatin for up to 3 cycles.
46081083|NCT05364424|Drug|Etoposide|Participants will receive IV etoposide for up to 3 cycles.
46081084|NCT05363709|Drug|Balstilimab|Given by Vein (IV)
45669198|NCT05004662|Drug|Nicotine lozenge|Participants will be provided with a 10-week supply of nicotine lozenges
45669199|NCT04988477|Behavioral|Chronic care management|Quarterly brief provider intervention (the 5As) and 3 quarterly outreach calls over 3 months.
45827233|NCT00002855|Procedure|Conventional Surgery|Surgical castration
45827234|NCT00003173|Biological|filgrastim|
45827235|NCT00003173|Drug|thiotepa|
45827236|NCT00003173|Procedure|autologous bone marrow transplantation|
45827237|NCT00003173|Procedure|peripheral blood stem cell transplantation|
45827238|NCT00003533|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Metastatic Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45827239|NCT00003179|Drug|medroxyprogesterone|
45827240|NCT00003545|Drug|nelarabine|
45827241|NCT00003551|Drug|aminocamptothecin colloidal dispersion|
45827242|NCT00002873|Radiation|brachytherapy|
45669200|NCT04974619|Behavioral|Online survey|Aim 1 Participants will be asked to complete a Qualtrics survey to identify knowledge gaps, health beliefs, attitudes, and educational learning preferences.
45827243|NCT00002879|Drug|cladribine|
45669201|NCT04974619|Behavioral|Focus groups|Focus groups will be conducted in-person or remotely to evaluate the newly created educational materials about HPV vaccination. Individual interviews and/or focus groups (n=24) with young Latino men who have sex with men (YLMSM) (12 in Puerto Rico and 12 in Florida) will be conducted to gain feedback on the education intervention. The purpose will be to gain feedback on the acceptability, accessibility, content, delivery preference and aesthetics of the theoretically informed, HPV education target for Spanish-speaking YLMSM.
45827244|NCT00003185|Biological|autologous tumor cell vaccine|
45827245|NCT00003185|Biological|sargramostim|
45827246|NCT00003185|Biological|tumor-draining lymph node lymphocyte therapy|
45827247|NCT00003185|Drug|cyclophosphamide|
45970188|NCT04625660|Device|PQ Bypass System|Intended use from CLN232 Rev A (CLN232 is the DETOUR2 Continued Access Protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis.
45970189|NCT04594447|Device|Physica Kinematic Retaining knee replacement|modular knee prosthesis with a Kinematic Retaining (KR) mechanism and posterior cruciate ligament (PCL) preservation
45669202|NCT04974619|Behavioral|Interviews|In-depth interviews (n=20) will be conducted with key stakeholders (10 in PR and 10 in FL) eliciting feedback to inform intervention content and delivery methods and identify potential facilitators and barriers to intervention implementation.
45827248|NCT00003185|Procedure|conventional surgery|
45827249|NCT00003557|Drug|dolastatin 10|
45970190|NCT04594447|Device|Physica Cruciate Retaining knee replacement|modular knee prosthesis with posterior cruciate ligament (PCL) preservation
45970191|NCT04594720|Other|Identification group|papillary thyroid cancers (n=10) and benign thyroid tumors (n=10)
45827250|NCT00003935|Drug|etoposide|
45970192|NCT04594720|Other|Validation group|papillary thyroid cancers (n=45) and benign thyroid tumors (n=35)
45970193|NCT04594330|Drug|virgin coconut oil (VCO)|15 mL of VCO twice a day for 14 days
45970194|NCT04594330|Other|placebo|15 mL of placebo twice a day for 14 days
46081085|NCT05362760|Drug|Abemaciclib + Aromatase Inhibitor|Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)
45827251|NCT00003935|Drug|vincristine sulfate|
45827252|NCT00003935|Radiation|radiation therapy|
45827253|NCT00003191|Drug|fenretinide|
45827254|NCT00003941|Biological|bleomycin sulfate|
45827255|NCT00003941|Biological|filgrastim|
45827256|NCT00003941|Drug|cisplatin|
45827257|NCT00003941|Drug|etoposide|
45827258|NCT00003941|Drug|ifosfamide|
45827259|NCT00003941|Procedure|bone marrow ablation with stem cell support|
45827260|NCT00003941|Procedure|peripheral blood stem cell transplantation|
45827261|NCT00384527|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily plus one vancomycin-placebo capsule four times daily for 10 days.
45970195|NCT04618133|Behavioral|Early time-restricted eating|Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from 6am to 2pm, with a 1-hour allowance according to their daily routine
45970196|NCT04618133|Behavioral|Late time-restricted eating|Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from noon to 8pm, with a 1-hour allowance according to their daily routine
45970197|NCT04618133|Behavioral|Active control|Participants will be advised to eat a minimum of 3 meals over the 24-hour cycle, i.e. breakfast from 6am to 9am, lunch from 11am to 2pm, dinner from 6pm to 10pm. Snacks will be allowed between meals
46081086|NCT05362760|Drug|Abemaciclib + Fulvestrant|Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)
46081087|NCT05356702|Other|Brain Health Assessment|Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. They will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.
46081088|NCT05355701|Drug|PF-07799933|Tablet
46081089|NCT05355701|Drug|binimetinib|Tablet
46081090|NCT05355701|Biological|cetuximab|Injection for intravenous use
45827262|NCT00384527|Drug|Vancomycin|One vancomycin 125 mg capsule four times daily plus one nitazoxanide-placebo twice daily for 10 days.
45827263|NCT00003197|Dietary Supplement|green tea extract|
45827264|NCT00003563|Radiation|WBRT|3 GY of WBRT daily for a total of 10 days
45827265|NCT00003563|Drug|MGd|5.0 mg /kg MGd plus WBRT
45827266|NCT00003569|Drug|cisplatin|
45827267|NCT00003569|Drug|dimesna|
45827268|NCT00003569|Drug|paclitaxel|
45827269|NCT00003953|Biological|filgrastim|Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each 2 week course.
45827270|NCT00003953|Drug|CMF regimen|Stratum I and II: receive cyclophosphamide, methotrexate, and fluorouracil (CMF) for 4 courses
45827271|NCT00003953|Drug|docetaxel|Docetaxel IV over 1 hour on days 43, 57, and 71.
45827272|NCT00003953|Drug|doxorubicin hydrochloride|Doxorubicin IV on days 1, 15, and 29.
45970198|NCT04594057|Behavioral|Gaze and Postural Retraining Exercise|"Gaze and Postural Stability The duration and content of the Gaze and Postural Stability (GPS) intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.~The target duration of each in clinic visit will be 90 min (15 min of gaze stability exercises, 15 min of postural stability exercises and approximately 60 min for the standard care control intervention with rest interspersed throughout the exercise session.~Gaze stability exercise will consist of progressive Vestibular-occular training.~Postural stability exercises will consist of progressive static and dynamic postural training."
46081091|NCT05349188|Dietary Supplement|Melatonin 3 mg|Participants will be provided with a smart pill bottle containing a 4-week supply of 3 mg melatonin pills.
46081092|NCT05349188|Dietary Supplement|Melatonin 0.5 mg|Participants will be provided with a smart pill bottle containing a 4-week supply of 0.5 mg melatonin pills.
45970199|NCT04594135|Drug|anti-CD5 CAR T cells|anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells
46081093|NCT05349188|Other|Cellulose placebo pill|Participants will be provided with a smart pill bottle containing a 4-week supply of cellulose placebo pills.
46081094|NCT05345054|Other|no intervention|This study will not involve an intervention of any sort. Participants will either take a survey or undergo an interview, and those taking the survey will have clinical data captured.
46081095|NCT05344989|Drug|APNmAb005|Administered by IV infusion
46081096|NCT05344989|Drug|Placebo|Administered by IV infusion
45827273|NCT00003953|Drug|tamoxifen citrate|Patients with positive estrogen or progesterone receptors receive oral tamoxifen daily for 5 years.
46081097|NCT05340621|Drug|OKI-179 + binimetinib|"Phase 1b: With a 3+3 dose escalation design, enrollment in Phase 1b will proceed until the MTD has been defined or the highest dose level has been reached. OKI-179 will be administered on a 4-days-on/3-days-off schedule, while binimetinib will be administered BID continuously.~Phase 2: Patients will be treated with the RP2D."
45827274|NCT00003953|Procedure|autologous bone marrow transplantation|Stratum III:may receive high dose chemotherapy with stem cell support
45827275|NCT00003953|Procedure|surgical procedure|Fourteen to 21 days following preoperative chemotherapy, patients undergo a radical, modified radical, or breast sparing surgery plus axillary lymph node dissection.
45827276|NCT00003953|Radiation|radiation therapy|Radiotherapy is administered 5 days a week for 5.5 weeks.
45827277|NCT00003959|Biological|ras peptide cancer vaccine|
45827278|NCT00003959|Biological|sargramostim|
45827279|NCT02972723|Drug|Metformin|Oral Metformin 1g bd. (total = 2g per day) for 14 days
46081098|NCT05334368|Drug|Depemokimab|Depemokimab will be administered.
46081099|NCT05334368|Other|Placebo|Matching placebo will be administered.
46081100|NCT05331378|Device|Test myopia control lenses|A myopia control spectacle lenses (test lenses) will be given to 1 arm to wear for 12 months.
46081101|NCT05331378|Device|Single vision lenses|A single vision spectacle lenses (control lenses) will be given to 1 arm to wear for 12 months.
46081102|NCT05331027|Drug|Desflurane|After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±5.
46081103|NCT05331027|Drug|Sevoflurane|After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±5.
46081104|NCT05330429|Drug|Magrolimab|Administered intravenously
45455794|NCT05688397|Dietary Supplement|Experimental 1|L. gasseri oral capsule once a day (1 x 10^9 CFU/day) for 18 days starting the next day after menstruation is over
45827280|NCT00003203|Biological|filgrastim|Given IV
45827281|NCT00003203|Drug|carboplatin|Given IV
45827282|NCT00003203|Drug|cisplatin|Given IV
45827283|NCT00003203|Drug|cyclophosphamide|Given IV
45827284|NCT00003203|Drug|vincristine sulfate|Given IV
45827285|NCT00003203|Procedure|adjuvant therapy|
45827286|NCT00003203|Radiation|radiation therapy|1.8 Gy/fx x 20fx=36Gy Craniospinal XRT*
45970200|NCT00253110|Drug|risperidone|
45970201|NCT00253110|Drug|haloperidol|
45970202|NCT04594252|Drug|ALXN1840|Administered orally as tablets.
46081105|NCT05330429|Drug|Bevacizumab|Administered intravenously
46081106|NCT05330429|Drug|Irinotecan|Administered intravenously
46081107|NCT05330429|Drug|Fluorouracil|Administered intravenously
46081108|NCT05330429|Drug|Leucovorin|Administered intravenously
46081109|NCT05323253|Device|DaRT seeds|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed.
46081110|NCT05322005|Procedure|partial meniscectomy|Arthroscopic procedure
46081111|NCT05322005|Device|Condrotide® (polynucleotides gel: class III medical device)|Condrotide® Polynucleotide gel is a joint lubricating and viscosizing agent, given by intraarticular and intra-meniscal injection
45827287|NCT00003575|Biological|filgrastim|
45827288|NCT00003575|Biological|recombinant interleukin-12|
45827289|NCT00003575|Drug|etoposide|
45827290|NCT00003575|Drug|ifosfamide|
45669203|NCT04969887|Drug|Ipilimumab|CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.
45827291|NCT00003539|Biological|trastuzumab|
45827292|NCT00003539|Drug|paclitaxel|
45827293|NCT00003209|Biological|bleomycin sulfate|
45827294|NCT00003209|Drug|cisplatin|
45827295|NCT00003209|Drug|fluorouracil|
45827296|NCT00003209|Drug|ifosfamide|
45970203|NCT04594174|Procedure|Fluid administration|"Patients will be treated in accordance with the criteria of the responsible physician and the hemodynamic data obtained with the Mostcareup monitor will be recorded and used for decision-making according to the hemodynamic management protocols of each center.~If the patient has a PPV ≥ 14%, for 3 minutes and a MAP <65 mm Hg or a Systolic Blood Pressure <90 mm Hg, a bolus volume load of 3 ml / kg weight of a balanced crystalloid solution in a time of 10 minutes36,37. The start of the volume charge (T1) will be noted by an event mark on the MostCareup monitor. The end of the volume charge (T2) will be noted by an event mark on the MostCareup monitor. Five minutes after the completion of the volume charge a new event will be marked on the MostCare monitor (T3). Both brands will serve as a reference for the analysis of hemodynamic data. Patients will be considered responders to the administration of fluids if the cardiac index (CI) increase."
45970204|NCT04598672|Behavioral|Cognitive behavioral therapy for insomnia (CBTi)|Patients will undergo a 7 sessions course in cognitive behavioral therapy for insomnia.
45970205|NCT00566683|Drug|diazemuls, pethidine|5mg Diazemuls and 25mg Pethidine one min. before procedure followed by bolus doses of 2.5mg Diazemuls / 12.5mg Pethidine at the discretion of endoscopists Maximal dose of 0.2mg/kg Diazemuls and 1mg/kg Pethidine
45970206|NCT00566683|Drug|Propofol and Alfentanil|Loading dose of 40-60mg or 0.8mg/kg Propofol one min. before procedure Propofol 200mg + Alfentanil 0.5mg, 1.5ml per bolus (bolus dose of 14.3mg Propofol + 35ug Alfentanil) via PCA pump No maximal dose Zero lockout time
46081112|NCT05314712|Behavioral|Sleep intervention|Participants will receive a 9-week sleep intervention through text and Facebook that include traditional Blackfoot cultural components combined with scientifically validated strategies for sleep.
46081113|NCT05312125|Procedure|backward downhill walking|Children in the intervention group will take backward downhill walking program plus to routine physiotherapy.
45669204|NCT04969887|Drug|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
45669205|NCT04959526|Diagnostic Test|Shear-wave elastography|Ultrasound based imaging of diaphragm muscle activity
46081114|NCT05312125|Procedure|routine physiotherapy|Children in one of the groups will take routine physiotherapy programme
45827297|NCT00003209|Drug|methotrexate|
45827298|NCT00003209|Drug|mitomycin C|
45827299|NCT00003209|Drug|vinblastine sulfate|
45827300|NCT00003209|Drug|vindesine|
45970207|NCT00566761|Drug|bevacizumab and triamcinolone|three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2
45970208|NCT00566800|Drug|erlotinib hydrochloride|
45970209|NCT00566800|Other|laboratory biomarker analysis|
45970210|NCT00566800|Procedure|biopsy|
45827301|NCT00003209|Radiation|radiation therapy|
45827302|NCT00003587|Drug|carboplatin|AUC=5.5 day 1 every 21 days X 3
45827303|NCT00003587|Drug|cisplatin|IV cisplatin 100 mg/m^2 day 1 every 21 days X 3
45827304|NCT00003587|Drug|docetaxel|IV docetaxel 75 mg/m^2 day 1 every 21 days X 3
45827305|NCT00003587|Drug|gemcitabine|IV gemcitabine 1,000 mg/m^2/day, days 1 and 8 every 21 days X3
45827306|NCT00003587|Drug|paclitaxel|IV paclitaxel 225 mg/m^2/day, day 1 every 21 days X 3
45827307|NCT00003587|Drug|vinorelbine|IV vinorelbine 25 mg/m^2/day, days 1 and 8 every 21 days X 3
45827308|NCT00003977|Biological|human papillomavirus 16 E7 peptide|
45827309|NCT00003977|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45827310|NCT00003215|Biological|filgrastim|
45827311|NCT00003215|Drug|CHOP regimen|
45827312|NCT00003215|Drug|cyclophosphamide|
45827313|NCT00003215|Drug|cytarabine|
45827314|NCT00003215|Drug|doxorubicin hydrochloride|
45827315|NCT00003215|Drug|etoposide|
45827316|NCT00003215|Drug|leucovorin calcium|
45827317|NCT00003215|Drug|melphalan|
45827318|NCT00003215|Drug|methotrexate|
45827319|NCT00003215|Drug|methylprednisolone|
45827320|NCT00003215|Drug|mitoxantrone hydrochloride|
45827321|NCT00003215|Drug|prednisone|
45827322|NCT00003215|Drug|therapeutic hydrocortisone|
45827323|NCT00003215|Drug|vincristine sulfate|
45827324|NCT00003215|Procedure|bone marrow ablation with stem cell support|
45827325|NCT00003215|Procedure|peripheral blood stem cell transplantation|
45827326|NCT00003215|Radiation|radiation therapy|
45827327|NCT00003989|Biological|ISIS 3521|
45827328|NCT00003995|Biological|trastuzumab|
45827329|NCT00003995|Drug|irinotecan hydrochloride|
45827330|NCT00003593|Drug|asparaginase|Given IV
45827331|NCT00003593|Drug|cytarabine|Given IT
45827332|NCT00003593|Drug|daunorubicin hydrochloride|Given IV
45827333|NCT00003593|Drug|methotrexate|Given IV
45827334|NCT00003593|Drug|therapeutic hydrocortisone|Given IT
45827335|NCT00003593|Drug|thioguanine|Given IV
45970211|NCT04593589|Other|Submandibular Gland Stem Cell Transplantation|Autologous transplantation of salivary stem cells (salisphere derived cells) cultured in vitro as obtained from submandibular glands after postoperative radiotherapy
45827336|NCT00003599|Dietary Supplement|Vitamin E (AT)|Orally daily
45970212|NCT04593706|Drug|Betamethasone acetate + Betamethasone sodium phosphate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
45970213|NCT04593706|Drug|Dexamethasone sodium phosphate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
45970214|NCT04593706|Drug|Methylprednisolone acetate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
45970215|NCT04593706|Drug|Triamcinolone acetonide|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
45970216|NCT04593667|Device|hm-P bandage|hm-P bandage will be placed over the puncture site with the TR band positioned over the hemostatic bandage. The TR band will then be inflated per device specific instructions and to the group instructions. The arterial sheath will be removed from the body with slight device rotation.
45970217|NCT04593238|Drug|Double Antibiotic paste|Metronidazole and Ciprofloxacin
45970218|NCT04593238|Drug|Calcium Hydroxide Paste - Non-Setting|Calcium hydroxide paste to be delivered inside the canal as an intra-canal medication
45970219|NCT04593316|Other|Saliva collection|A saliva sample will be collected before physical exercise.
45669206|NCT04944784|Drug|Reldesemtiv|Reldesemtiv Oral Tablet
45669207|NCT04944784|Drug|Placebo|Placebo Oral Tablet
45669208|NCT04936750|Other|Analysis of body composition|The cross section of the third lumbar spine in the CT scan images of the patients was analyzed to obtain the parameters related to the body composition of the patients
45669209|NCT04933084|Behavioral|Pre-operative Opioid Education|"The pre-operative education in the text handout and pre-recorded video will include the topics of:~Description of expected postoperative pain after robotic prostatectomy and typical opioid consumption after RARP.~Efficacy of non-opioid multimodal analgesia and recommendation to take nonopioid alternatives prior to prescribed opioids.~Adverse short- and long-term effects of opioids including nausea, vomiting, sedation, hypoventilation, hypotension, dizziness, constipation, depression, and addiction."
45669210|NCT04932486|Device|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation of the upper airway muscles
45827337|NCT00003599|Drug|Isotretinoin|Orally daily
45827338|NCT00003605|Biological|rituximab|
45827339|NCT00003605|Drug|cyclophosphamide|
45827340|NCT04329299|Diagnostic Test|blood-based biomarkers analyses|Analyses of H. pylori antibodies/pepsinogen levels, micro RNAs (miRNAs) or blood-based protein markers levels in participants' blood samples
45970220|NCT04593316|Behavioral|Questionnaires|The participant will fill in questionnaires relative to his heath status and psychological and motivational resource questionnaires before physical exercise.
45970221|NCT04593316|Other|Ingestible core temperature capsule intake|The participant will ingest a capsule before physical exercise in order to continuously monitor core temperature during physical exercise.
45827341|NCT00003611|Drug|acitretin|
45970222|NCT04593316|Other|Physical exercise|The participant will perform a walk/run test.
45970223|NCT04593316|Other|Heart rate monitoring|Heart rate will be monitored during physical exercise thanks to a chest belt.
45970224|NCT04593316|Other|Core temperature monitoring|Heart rate will be monitored during physical exercise thanks to an ingestible core temperature capsule.
45827342|NCT00003611|Other|placebo|
45827343|NCT00003617|Drug|chlorambucil|
45827344|NCT00003617|Drug|clarithromycin|
45827345|NCT00003617|Drug|omeprazole|
45827346|NCT00003617|Drug|tinidazole|
45827347|NCT00003623|Dietary Supplement|multivitamin|
45827348|NCT00003623|Other|Placebo|
45827349|NCT00003635|Drug|nelarabine|
45970225|NCT04593433|Other|Museum virtual guided tours|The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 5 participants. They meet online one time per week for a 20 to 25 min of a visit tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
45970226|NCT04593511|Drug|LY03009 F1|a single dose of LY03009 F1
45970227|NCT04593511|Drug|LY03009 F2|a single dose of LY03009 F2
45970228|NCT04593511|Drug|LY03009 F3|a single dose of LY03009 F3
45970229|NCT04593511|Drug|LY03009 F4|a single dose of LY03009 F4
45970230|NCT00566839|Procedure|awake nonresectional LVRS|Thoracoscopic nonresectional lung volume reduction surgery carried out in awake patients under sole epidural anesthesia through plication of most emphysematous target areas of the lung
46081115|NCT05311176|Biological|IMU-131|IMU-131 will be administered intramuscularly into the deltoid region of the arm on Day 1, 15, 29 and 57 and then every 63 days until disease progression or treatment discontinuation.
46081116|NCT05311176|Drug|Ramucirumab plus Paclitaxel|Chemotherapy to be administered every 3 weeks (Q3W) starting on Day 1.
45827350|NCT00004001|Drug|docetaxel|
45827351|NCT00004001|Drug|estramustine|
45827352|NCT00004001|Drug|mitoxantrone|
45827353|NCT00004001|Drug|prednisone|
45827354|NCT00004013|Biological|trastuzumab|
45827355|NCT00004013|Drug|paclitaxel|
45827356|NCT00004025|Biological|aldesleukin|
45827357|NCT00004025|Biological|dendritic cell-gp100-MART-1 antigen vaccine|
45827358|NCT00004037|Drug|docetaxel|
45827359|NCT00004043|Dietary Supplement|calcitriol|
45827360|NCT00004049|Drug|apomine|
45827361|NCT00004055|Biological|filgrastim|
45827362|NCT00004055|Drug|paclitaxel|
45970231|NCT00566839|Procedure|Nonawake resectional LVRS|Thoracoscopic lung volume reduction surgery carried out under general anesthesia and one-lung ventilation through nonanatomic resection of the most emphysematous target areas of the lung
45669211|NCT04930887|Drug|Exparel (Bupivacaine Liposome)|Non-opioid postsurgical analgesic used in the management of postsurgical pain; 133 mg/10 mL (13.3 mg/mL) single-dose vial (per Pacira), study administers 3cc bilaterally
45827363|NCT00004055|Drug|topotecan hydrochloride|
45970232|NCT04593160|Drug|Diclofenac potassium- acetaminophen combination|Preoperative single dose of diclofenac potassium(50mg)- acetaminophen(1000mg) combination
45970233|NCT04593160|Drug|Diclofenac potassium|Preoperative single dose of diclofenac potassium(50mg)
45970234|NCT04593160|Drug|Placebo|Preoperative single dose of placebo
45970235|NCT04592965|Behavioral|Clinical and neuropsychological assessments|The assessment of disease state, clinical condition, and of cognitive and neuropsychological attributes.
45970236|NCT04592965|Behavioral|Induction of PH and associated bodily states|Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls
45970237|NCT04592965|Other|Resting-state fMRI acquisition|Investigation of neural mechanisms at rest, that are potentially disrupted at different degrees, for the different clinical groups of PD patients, compared to the healthy aged-matched controls
45970238|NCT04592965|Other|Induction of PH and associated bodily states (MRI)|Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls Assessment and comparison of the neural mechanisms responsible for the induction of the PH and associated bodily illusions, in different groups of PD patients and healthy aged-matched controls
45669212|NCT04930887|Drug|Saline|Prescription medicine used for fluid and electrolyte replenishment for intravenous administration; Exparel-matched Placebo treatment
45970239|NCT00253149|Drug|risperidone|
45970240|NCT04592926|Device|Accuro SpineNav3D|The intervention will consist of a pre-procedural scan of the lumbar spine using the handheld image guidance device, Accuro, to determine spinal landmarks and anticipated depth of the intrathecal space.
45970241|NCT04592926|Other|Sham|The sham group will receive a pre-procedure sham scan (the handheld image guidance Accuro device will be placed on the back, but it will be turned off) followed by sham marking on the subject's back.
45970242|NCT00566917|Procedure|Anterior colporrhaphy|Standardised colporrhaphy of the anterior vaginal wall
45970243|NCT00566917|Procedure|Anterior PROLIFT|Transvaginal mesh surgery of the anterior vaginal wall
45970244|NCT04539236|Drug|Lenalidomide|Administered daily by mouth on a 21 day cycle. Doses will be administered at 2.5 mg, 5 mg and 10 mg.
45669213|NCT04930666|Other|BRief intervention to Enhance Adherence to Treatment and HEalth advice in Advanced Lung Disease|BREATHE-ALD utilizes the patient's nurse practitioner (NP) to deliver a brief intervention using motivational interviewing and shared decision making, in a one-time 9-minute intervention. The NP will follow a 4-step script tailored to specific ALD self-management discussed during the most recent visit with the patient's pulmonologist. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
45669214|NCT04915612|Drug|Gemtuzumab Ozogamicin|Given IV
45669215|NCT04915612|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
45669216|NCT04907357|Device|rTMS|Each rTMS session will consist of 75 rTMS trains of 10 Hz for 4 seconds (40 pulses per train) with inter-train interval (ITI) of 11 seconds (a total of 3000 stimuli per session) over the left dorsolateral prefrontal cortex (DLPFC).
45827364|NCT00004061|Biological|filgrastim|
45970245|NCT04539236|Drug|Luspatercept|Administered subcutaneously in the upper arm, thigh and/or abdomen on Day 1 of a 21 day cycle. Starting dose will be at 1.0 mg/kg and can be titrated, dependent on participant response, to doses of 1.33 mg/kg, and 1.75 mg/kg.
45970246|NCT00249483|Drug|Venlafaxine|Venlafaxiine 300mg/day
45970247|NCT00249483|Drug|Placebo|Placebo
45970248|NCT00566956|Procedure|Hydrosalpinx needle aspiration to arm 1|For those assigned to Group I, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side. The hydrosalpinx fluid is discarded
45970249|NCT00567034|Drug|naltrexone|50mg naltrexone, 1 tablet a day for 12 weeks.
45970250|NCT00567034|Drug|placebo|lactose placebo, 1 capsule every day for 12 weeks
46081117|NCT05311176|Biological|Pembrolizumab|Pembrolizumab will be administered every 3 weeks (Q3W) starting on Day 1 until disease progression or treatment discontinuation.
46081118|NCT05310279|Other|GAIMplank|The GAIMplank video game controller will be used to play active video games.
45827365|NCT00004061|Biological|palifermin|
45827366|NCT00004061|Drug|cyclophosphamide|
45827367|NCT00004061|Drug|etoposide|
45827368|NCT00004061|Drug|ifosfamide|
45827369|NCT00004061|Procedure|peripheral blood stem cell transplantation|
45827370|NCT00004061|Procedure|quality-of-life assessment|
45827371|NCT00004061|Radiation|radiation therapy|
45827372|NCT00004067|Biological|herceptin|4 mg/kg loading dose then 2 mg/kg weekly for 1 year.
45827373|NCT00004067|Drug|adriamycin|60 mg/m2 IV push every 21 days for 4 cycles.
45827374|NCT00004067|Drug|cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
45827375|NCT00004067|Drug|taxol|175 mg/m2 IV every 21 days for 4 cycles
45827376|NCT00004073|Drug|suramin|
45827377|NCT00004073|Radiation|radiation therapy|
45827378|NCT00004079|Drug|SarCNU|Given PO
45827379|NCT00004079|Other|pharmacological study|Correlative studies
45827380|NCT00004079|Other|laboratory biomarker analysis|Correlative studies
45827381|NCT00004085|Biological|filgrastim|as prescribed by physician
45970251|NCT03454126|Drug|BIIB095|Administered as specified in the treatment arm.
45970252|NCT03454126|Drug|Placebo|Administered as specified in the treatment arm.
45970253|NCT04484909|Other|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT
45669217|NCT04907357|Device|Sham (Placebo)|Each sham rTMS session will consist of 75 rTMS trains of 10 Hz for 4 seconds (40 pulses per train) with inter-train interval (ITI) of 11 seconds (a total of 3000 stimuli per session) over the left dorsolateral prefrontal cortex (DLPFC). In the placebo condition the magnetic field will be delivered in the opposite direction (away from the brain).
45669218|NCT04875065|Behavioral|Engage coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
45455795|NCT05688397|Dietary Supplement|Experimental 2|L. gasseri and L. crispatus oral capsule once a day (1.5 x 10^9 CFU/day) for 18 days starting the next day after menstruation is over
45455796|NCT05688397|Dietary Supplement|Placebo|One maltodextrin-containing capsule a day for 18 days starting the next day after menstruation is over
45455797|NCT05677893|Drug|MBS-COV|MBS-COV is a potent siRNA treatment for mild to moderate COVID-19.
45669219|NCT04863248|Drug|Trilaciclib|Trilaciclib administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
45455798|NCT05677893|Other|Placebo|Normal saline
45455799|NCT05670561|Drug|Esketamine|PCIA formula#100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min.The PCIA pump was commenced at the beginning of TACE. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
45669220|NCT04863248|Drug|Placebo|Placebo administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
45970254|NCT04484909|Radiation|Radiation Therapy|Undergo radiation therapy
45970255|NCT04593043|Drug|Warfarin|Warfarin dispensing claim is used as the reference
45970256|NCT04593043|Drug|Dabigatran|Dabigatran dispensing claim is used as the exposure
45970257|NCT04592263|Other|EPD Questionnaire|A 44 items questionnaire (4 point likert scale) was distributed. Included dimensions where: experience with your physician, provision of care, barriers, outcomes of care, symptoms, patient engagement, health literacy and patient empowerment.
46081119|NCT05299242|Drug|Adalimumab Injection|40mg in 0.8ml preparation in vials from Fresenius Kabi Ltd
46081120|NCT05299242|Drug|Placebo|Saline [0.9% NaCl]
46081121|NCT05299125|Drug|Amivantamab|Low fucose, fully human immunoglobulin gamma-1-based bispecific antibody directed against EGFR and MET tyrosine kinase receptors. It shows clinical activity against tumors with the primary activating EGFR mutations Exon 19del or Exon 21 L858R substitution, EGFR Exon 20ins mutations, the EGFR resistance mutations Threonine790Methionine (T790M) or Cysteine797Serine (C797S), and activation of the Mesenchymal Epithelial Transition (MET) pathway.
46081122|NCT05299125|Drug|Lazertinib|It selectively inhibits both primary activating EGFR mutations (Exon 19del, Exon 21 L858R substitution) and the EGFR T790M resistance mutation, while having less activity versus wild-type EGFR.
46081123|NCT05299125|Drug|Pemetrexed 500 mg|Inhibits enzymes involved in folate-dependent metabolism, thereby disrupting cellular replication.
45669221|NCT04863248|Drug|Docetaxel|Docetaxel administered IV on Day 1 of each 21-day cycle.
45669222|NCT04832698|Other|Survey Administration|Complete survey
45669223|NCT04815902|Drug|Fisetin|Oral Fisetin 20 mg/kg taken for 10 days total.
45669224|NCT04815902|Drug|Losartan|12.5 mg oral Losartan taken for 30 days total.
45827382|NCT00004085|Procedure|autologous bone marrow transplantation|1-2 weeks prior to treatment
45827383|NCT00004085|Procedure|peripheral blood stem cell transplantation|1-2 weeks prior to treatment
45827384|NCT00004085|Radiation|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min, single dose
45827385|NCT00004091|Other|Papanicolaou test|
45827386|NCT00004091|Other|cytology specimen collection procedure|
45669225|NCT04815902|Drug|Placebo - Losartan|Losartan appearance-matched microcrystalline cellulose placebo. 12.5 taken for 30 days total.
45827387|NCT00004091|Other|fluorescent antibody technique|
45827388|NCT00004091|Procedure|colposcopic biopsy|
45827389|NCT00004091|Procedure|study of high risk factors|
45827390|NCT00004097|Drug|fluorouracil|
45827391|NCT00004097|Drug|gemcitabine hydrochloride|
45970258|NCT02961309|Drug|THC|1 High-Potency THC (Dosage = 10mg) cigarette (oral smoking) on one day and 1 Placebo on the other day.
45970259|NCT04484363|Drug|Pevonedistat|Pevonedistat 20 milligram per square meter (mg/m^2), intravenous infusion, on Days 1, 3, and 5 of repeated 28-day cycles.
45970260|NCT04484363|Drug|Azacitidine|Azacitidine 75 mg/m^2, intravenous or subcutaneous infusion, on Days 1 to 5, Days 8 and 9 of repeated 28-day cycles or Days 1 through 7 of repeated 28-day cycles.
45970261|NCT04592302|Diagnostic Test|Blood Draw|2-4 weeks before surgery a blood draw will be taken to test for nicotine levels in the body
45970262|NCT04592146|Device|Frailty multicomponent intervention supported by POSITIVE|This technology mainly consists in a home monitoring kit periodically measuring gait speed, involuntary weight loss and power in the lower limb. Furthermore, through a tablet device, other relevant information (e.g. state of mind, activities of daily living-ADLs, etc.) is collected. The same device is used to enhance communication with the clinical team and follow the tailored intervention
45970263|NCT04592146|Other|Frailty multicomponent intervention|This intervention is based on 3 main pillars: medication review (to avoid polypharmacy), tailored nutritional recommendations and a tailored physical activity plan based on the VIVIFRAIL program.
45970264|NCT04592380|Drug|Stage 1: Clevidipine (double-blinded)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
45827392|NCT00004097|Drug|paclitaxel|
45827393|NCT00004097|Radiation|radiation therapy|
45827394|NCT00004103|Drug|cisplatin|
46081124|NCT05292781|Other|CHOICES|An innovative web application to provide interactive information about reproductive health options for people with SCD or SCT. CHOICES is a multimedia intervention that provides targeted and tailored information for participants to become informed ns about their reproductive health options. Targeted to their sex and tailored to their SC reproductive health knowledge, reproductive health behavior during the previous 6 mo, and parenting plan (e.g., intention to have child with SCD or not), CHOICES presents information about options to help the participant achieve their parenting plan through reproductive partner selection based on sickle cell status, prenatal testing, ovum and sperm donation, advanced reproductive technologies, and options to avoid pregnancy or adopt. The website will be housed on secure UF servers and accessible via computers or mobile devices (e.g., tablets, smart phones); device capture will inform plans for long-term dissemination.
45827395|NCT00004103|Drug|floxuridine|
45669226|NCT04815902|Drug|Placebo Fisetin|Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 10 days total.
45827396|NCT00004103|Drug|irinotecan hydrochloride|
45827397|NCT00004103|Procedure|adjuvant therapy|
45669227|NCT04807140|Drug|Toripalimab, nab-paclitaxel, carboplatin|"Patients receive Toripalimab IV on day 1, nab-paclitaxel IV on day 1 and carboplatin IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity."
45669228|NCT04807140|Drug|Toripalimab|"Patients receive Toripalimab IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity."
45827398|NCT00004103|Procedure|conventional surgery|
45827399|NCT00004103|Procedure|neoadjuvant therapy|
45827400|NCT00004109|Drug|Doxorubicin Hydrochloride|Doxorubicin dose will not exceed 20 mg/m2 per week IV over 4 days every week for 5 weeks
45669229|NCT04807140|Procedure|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
45827401|NCT00004109|Radiation|Radiation Therapy (RT)|External-beam radiotherapy at a dose of 50 Gy (2.0 x 25 fractions, weeks 1-5).
45827402|NCT00003239|Biological|Recombinant Interferon Alfa|Daily by subcutaneous injection.
45827403|NCT00003239|Drug|Cytarabine|Daily by subcutaneous injection.
45827404|NCT00003239|Drug|Omacetaxine Mepesuccinate|Homoharringtonine is administered by continuous infusion on days 1-5.
45827405|NCT00004115|Radiation|yttrium Y 90 monoclonal antibody HMFG1|
45827406|NCT00003245|Drug|irinotecan hydrochloride|
45827407|NCT00004127|Drug|FOLFOX regimen|
45827408|NCT00004127|Drug|fluorouracil|
45827409|NCT00004127|Drug|leucovorin calcium|
45827410|NCT00004127|Drug|oxaliplatin|
45669230|NCT04804566|Other|This is a non-interventional study|This is a non-interventional study
45669231|NCT04791839|Drug|Zimberelimab|Zimberelimab will be supplied by Arcus Biosciences.
45669232|NCT04791839|Drug|Domvanalimab|Domvanalimab will be supplied by Arcus Biosciences.
45669233|NCT04791839|Drug|Etrumadenant|Etrumadenant will be supplied by Arcus Biosciences.
45669234|NCT04781140|Drug|100mg SPN-812|100mg SPN-812 will be administered once daily and compared to Placebo
45669235|NCT04781140|Drug|Placebo|Placebo will be administered once daily
45827411|NCT00003251|Drug|amifostine trihydrate|
45827412|NCT00003251|Drug|cisplatin|
45827413|NCT00003251|Drug|paclitaxel|
45827414|NCT00003251|Radiation|radiation therapy|
45827415|NCT00004139|Drug|docetaxel|
45827416|NCT00004139|Drug|gemcitabine hydrochloride|
45827417|NCT00004139|Drug|irinotecan hydrochloride|
45827418|NCT00003257|Biological|Ad5CMV-p53 gene|
45827419|NCT00004145|Biological|anti-thymocyte globulin|
45827420|NCT00004145|Drug|cyclophosphamide|
45827421|NCT00004145|Drug|fludarabine phosphate|
45827422|NCT00004145|Procedure|peripheral blood stem cell transplantation|
45827423|NCT04212923|Behavioral|Medical Dashboard based self-management intervention|Before the start of the intervention, chronic kidney disease patients and care providers will receive a face-to-face training session on the use of Medical Dashboard. To avoid contamination, Medical Dashboard will only be made accessible for participants in the intervention group via a secure password-protected registration process.
45827424|NCT00004151|Drug|acridine carboxamide|
45827425|NCT00003263|Biological|recombinant interferon alfa|vaccine
45827426|NCT00003263|Drug|cisplatin|
45827427|NCT00003263|Procedure|surgical procedure|
45827428|NCT00003263|Radiation|radiation therapy|
45827429|NCT00004157|Biological|filgrastim|
45827430|NCT00004157|Biological|recombinant interleukin-11|
45827431|NCT00003269|Biological|sargramostim|
45827432|NCT00003269|Drug|amifostine trihydrate|
45827433|NCT00003269|Drug|cisplatin|
45827434|NCT00003269|Drug|cyclophosphamide|
45827435|NCT00003269|Drug|etoposide|
45970265|NCT04592380|Drug|Stage 1: Placebo (double-blinded)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded placebo infusion, an oral antihypertensive agent may be administered. The placebo infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
46081125|NCT05292781|Other|eBook|e-Book contains information typically shared in clinical SCD care, including stick figure representation of inheritance because the investigator considers it unethical to withhold this basic information. It does not include other information related to the SCKnowIQ knowledge items or any of the behaviors needed to implement a parenting plan. Although not as long as CHOICES, the e-Book is sufficiently long, attractive, and engaging to retain participants randomized to the usual care control group; key factors for an adequate control condition. Interestingly, during the study and in interviews after the study, many e-Book participants commented that they were pleased to be assigned to the intervention group (they had not), which indicates that the control condition is sufficient for its intent--2-yr longitudinal retention of the sample. Also, human contact is the same for both groups, and the time-on-task on the computer is unlikely to influence study knowledge and behavior endpoints.
45669236|NCT04773691|Device|Active rTMS|"Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: 10 Hz, 1000 pulses per session, 110% of SM, cortical target: right DLPFC"
45669237|NCT04773691|Device|Placebo rTMS|"Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation."
45827436|NCT00004163|Drug|Trastuzumab|
45827437|NCT00003281|Drug|paclitaxel|
45827438|NCT00003281|Drug|topotecan hydrochloride|
45827439|NCT00003281|Radiation|radiation therapy|
46081126|NCT05292482|Procedure|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
46081127|NCT05292482|Procedure|physical therapy|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions.
46081128|NCT05290727|Other|Aquoral Lipo (Esteve)|15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products
46081129|NCT05290727|Other|Hyabak (Thea)|15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products
46081130|NCT05282706|Drug|Lavender Oil|A hydrogel lavender oil infused aromatherapy patch
46081131|NCT05282706|Drug|Mandarin Oil|A hydrogel mandarin oil infused aromatherapy patch
46081132|NCT05282706|Drug|Peppermint oil|A hydrogel peppermint oil infused aromatherapy patch
46081133|NCT05282706|Other|Placebo|A placebo patch containing no aromatherapy oil
46081134|NCT05282394|Procedure|Abdominal massage|abdominal massage
46081135|NCT05282394|Other|Reading|guidance given to parents about reading with baby
45669238|NCT04773691|Other|Questionnaires|questionnaires for craving assessment: EVA, OCDS, CGI and ADS and signs of physical withdrawal by CIWA
45669239|NCT04773691|Device|Breathalyzer|estimation of blood alcohol level
45827440|NCT00003287|Drug|FOLFOX regimen|
45827441|NCT00003287|Drug|fluorouracil|
45827442|NCT00003287|Drug|leucovorin calcium|
45827443|NCT00003287|Drug|oxaliplatin|
45827444|NCT00004187|Drug|capecitabine|
45827445|NCT00004187|Drug|oxaliplatin|
45827446|NCT00384137|Drug|Tacrolimus|Immunosuppression
45827447|NCT00384215|Drug|insulin glargine [rDNA origin] injection|
45827448|NCT00004193|Drug|ISIS 2503|
45827449|NCT00003293|Drug|leflunomide|
45827450|NCT00003293|Drug|procarbazine hydrochloride|
45827451|NCT00004199|Drug|cisplatin|
45827452|NCT00004199|Drug|gemcitabine hydrochloride|
45827453|NCT00004199|Drug|prinomastat|
45827454|NCT00384995|Drug|0.9% (154 mEq/L) IV Sodium Chloride|Saline solution
45827455|NCT00384995|Drug|1/6 M (166 mEq/L) IV Sodium Bicarbonate|Bicarbonate solution
45827456|NCT00003299|Drug|cisplatin|
45827457|NCT00003299|Drug|etoposide|
45827458|NCT00003299|Drug|paclitaxel|
45827459|NCT00004205|Drug|letrozole|Letrozole 2.5 mg daily oral administration.
45827460|NCT00004205|Drug|tamoxifen citrate|Tamoxifen 20 mg daily oral administration.
45827461|NCT00003305|Drug|aminopterin|
45827462|NCT00003305|Drug|leucovorin calcium|
45827463|NCT00004211|Biological|PSA RNA-pulsed dendritic cell vaccine|
45827464|NCT00003311|Biological|filgrastim|
45827465|NCT00003311|Drug|cyclophosphamide|
45827466|NCT00003311|Drug|cytarabine|
45827467|NCT00003311|Drug|dexamethasone|
45827468|NCT00003311|Drug|doxorubicin hydrochloride|
45827469|NCT00003311|Drug|methotrexate|
45827470|NCT00003311|Drug|vincristine sulfate|
45827471|NCT00003317|Drug|carboplatin|
45827472|NCT00003317|Drug|paclitaxel|
45827473|NCT00003317|Radiation|radiation therapy|
45970266|NCT04592380|Drug|Stage 2: Clevidipine (open-label)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
45970267|NCT04592380|Drug|Stage 2: Standard of Care (open-label)|Transition to oral antihypertensive medication from SOC IV antihypertensive is per institutional practice.
45827474|NCT00003317|Procedure|surgery|
45970268|NCT00253188|Drug|galantamine hydrobromide|
45970269|NCT04471220|Device|High-flow nasal cannula|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
45970270|NCT04592497|Procedure|AF ablation|Prospective, single-center, non-randomized, open label, two arm study. After informed consent, 60 consecutive subjects who are scheduled to undergo AF ablation will be enrolled in the study in two equally sized groups of 30 subjects each. One group will undergo the procedure with assistance THERMOCOOL SMARTTOUCH SF-5D QDOT system and the other with the standard Thermocool Smartouch SF system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Data will be anonymized by removing patient protected health information, only initials will be used.
45970271|NCT00249522|Behavioral|Contingency management|
45970272|NCT04591990|Drug|Administration of AVP|Administration of AVP
45970273|NCT04591990|Drug|Administration of placebo AVP|Administration of placebo AVP
46081136|NCT05269667|Drug|Satralizumab 120 mg|Satralizumab 120 mg will be administered as monotherapy (SC) in the abdominal or femoral region at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Weeks 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).
45669240|NCT04761575|Other|Validation of the FFQ65+ via eNutri app|All participants will provide two eNutri FFQ datasets within a 14-day interval along with three 24-hour dietary recalls and dried blood spot samples.
45827475|NCT00004217|Biological|filgrastim|5 μg/kg/day IV or SC
46081137|NCT05267665|Behavioral|Brief Family Intervention (BFI)|A 2-session psychoeducational and skills-based family intervention.
45669241|NCT04759248|Drug|Atezolizumab + Trastuzumab + Vinorelbine|"Atezolizumab IV 1200 mg in combination with~Trastuzumab sc 600mg or IV 6mg/kg every 3 weeks and~Vinorelbine 25 mg/m² IV or 60 mg/m2 PO on days 1 and 8, every 3 weeks during the first cycle and if there are no toxicity signs dose will be increased to 80 mg/m2 PO o 30 mg/m2 IV."
45669242|NCT04756726|Drug|CFT7455|oral CFT7455
45827476|NCT00004217|Biological|sargramostim|5 μg/kg/day IV or SC starting d 15
45827477|NCT00004217|Drug|cytarabine|Ara-C continuous IV: Hours 2.5 - 170.5 before PSC-833
45827478|NCT00004217|Drug|daunorubicin hydrochloride|continuous IV: Hours 2 - 74 before PSC-833
45827479|NCT00004217|Drug|valspodar|2 mg/kg load IV over 2 hrs (loading); 10 mg/kg/day Continuous hours 0 - 96
45970274|NCT04591990|Drug|Administration of placebo hydrocortisone|Administration of placebo hydrocortisone
45970275|NCT04591990|Drug|Administration of hydrocortisone|Administration of hydrocortisone
45970276|NCT04438265|Drug|levobupivacaine|local anesthetic
45970277|NCT04438265|Device|ultrasound device|scream
45970278|NCT04592068|Device|Retinal multi-diseases diagnosed by DL algorithm|DL algorithm automatically classify multi-diseases from fundus photography and differentiate major vision-threatening conditions and other retinal abnormalities.
45970279|NCT04592068|Other|Retinal multi-diseases diagnosed by expert panel|Expert panel classifies multi-diseases from fundus photography and differentiate major vision-threatening conditions and other retinal abnormalities.
45669243|NCT04756726|Drug|Dexamethasone Oral|oral dexamethasone [ ≤75 years old: 40 mg once per week (QW) on days 1, 8, 15, and 22; >75 Years old: 20 mg QW on days 1, 8, 15, and 22]
45669244|NCT04754932|Other|Cognitive Stimulation Therapy|Group-based therapy for people living with mild to moderate stage dementia, delivered by two trained facilitators.
45669245|NCT04746833|Behavioral|SUMMIT|multicomponent web-based application focused on pain self-management skills
45669246|NCT04746833|Behavioral|control|My Pain Diary app
45827480|NCT00003323|Drug|finasteride|5 mg/d PO
45827481|NCT00003323|Drug|flutamide|250 mg PO tid
45827482|NCT00003323|Other|quality-of-life assessment|Assessment survey administered at baseline, and 3 & 6 months post initiation of treatment
45827483|NCT00004229|Biological|recombinant human endostatin|
45827484|NCT00004235|Drug|docetaxel|
45827485|NCT00004235|Drug|irinotecan hydrochloride|
45827486|NCT00003335|Biological|anti-thymocyte globulin|antithymocyte globulin IV for three days on days -3 to -1
45827487|NCT00003335|Drug|busulfan|If TBI is not tolerated, busulfan is substituted and administered orally every 6 hours for 4 days on days -8 to -5.
45827488|NCT00003335|Drug|cyclosporine|Cyclosporine begin on day -2 and continue for 6 months.
45669247|NCT04725188|Biological|Pembrolizumab/Vibostolimab coformuation|Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
45669248|NCT04725188|Drug|Docetaxel|Docetaxel 75 mg^m2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity. Docetaxel will serve as part of an experimental treatment in Arm 1, and as an active comparator in Arm 3.
45669249|NCT04725188|Drug|Placebo|Normal saline IV infusion Q3W up to approximately 2 years
45827489|NCT00003335|Drug|melphalan|melphalan IV for three days on days -4 to -2
45827490|NCT00003335|Drug|methylprednisolone|Methylprednisolone IV for three days on days -3 to -1. Methylprednisolone begin on day -2 and continue for 6 months.
45827491|NCT00003335|Procedure|umbilical cord blood transplantation|On day 0, patients receive umbilical cord blood infusion.
45970280|NCT04595071|Device|Voice Activated Prosthetic Interface (VAPI) Controller|A device installed between a subjects socket quick disconnect wrist connection and multi-articulating hand which enables the use of voice as a control modality in addition to their standard two-site myoelectric control.
45970281|NCT04592107|Diagnostic Test|eGFR|estimated glomerular filtration rate
45970282|NCT00249561|Behavioral|Recovery by Choice|"The experimental condition, the modified TC, was a 6- to 9-month program located in a separate 72-bed housing unit within the prison. Inmates progressed through four program stages with upper level inmates functioning as peer mentors for newer members. The modified, comprehensive TC treatment program focused on increasing awareness and understanding of female roles and relationships as they relate to addiction and drugs used and abused, and emotional and behavioral coping skills. Program elements addressed issues of substance abuse, relapse prevention, mental health, criminal thinking and behavior, coping with trauma and abuse, and parenting skills. All treatment staff received special training related to working with women exposed to trauma and abuse, making the program trauma informed and trauma sensitive."
46081138|NCT05265312|Other|START diabetes prevention clinical pathway|"The diabetes prevention clinical pathway will focus on the following steps:~Screen/test - testing of eligible patients for prediabetes/diabetes~Education - PCPs will be encouraged to take an online learning module and in-person group training on prediabetes management and patients with prediabetes will receive a handout about prediabetes prior to their upcoming PCP visit~Action - PCPs will use a shared decision-making guide and treatment algorithm to discuss options with patients at their visit~Referral - patients may be referred to DPPs and/or medical nutrition therapy (MNT)~Treat - patients will be scheduled for a follow-up visit within 3-9 months with their PCP or care team to continue addressing prediabetes."
46081139|NCT05262764|Drug|JARDIANCE®|JARDIANCE®
46081140|NCT05261399|Drug|Savolitinib|300 mg savolitinib (3 × 100 mg tablets twice daily) Administrative route : oral
46081141|NCT05261399|Drug|Osimertinib|"80 mg osimertinib~(1 × 80 mg tablet once daily) Administrative route : oral"
45669250|NCT04708275|Procedure|PaCT|Manualized Psychoanalytic short-term therapy (PaCT) for children with internalizing disorders, 20-25 sessions (1, 2). PaCT helps the child to resolve rigid conflictual internal representations/ working models by using interpretative and mentalizing techniques and drawing on therapeutic transference relationship with the child and the parent.
45669251|NCT04704505|Radiation|radium-223|Radium-223 is an alpha-particle-emitting bone-targeted therapy. All patients will receive Treatment with Radium-223 at a dose of 55 kBq per kilogram of body weight IV every 28 days, for 6 cycles,
45669252|NCT04704505|Drug|Bipolar Androgen Therapy (BAT)|All Patients will receiveTestosterone Cypionate 400mg IM every 28 days, until progression or unacceptable toxicity.
45669253|NCT04699435|Other|Control|"All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 3-minute pre-oxygenation for the Control group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
45827492|NCT00003335|Radiation|radiation therapy|9 fractions of total body irradiation (TBI) on days -9 to -5
45827493|NCT00004241|Drug|tanespimycin|Given IV
45669254|NCT04699435|Other|PreOx_3min|"Patients with a BMI between 30 kg / m² and 40 kg / m² are distributed according to a random allocation in the group PreOx_3min.~All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 3-minute pre-oxygenation for the PreOx_3min group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
45827494|NCT00004241|Other|pharmacological study|Correlative studies
45827495|NCT00003341|Biological|epoetin alfa|
45827496|NCT00003341|Procedure|quality-of-life assessment|
45827497|NCT00004253|Drug|carboplatin|
45827498|NCT00004253|Drug|paclitaxel|
45827499|NCT00004253|Radiation|radiation therapy|
45827500|NCT00004265|Drug|paclitaxel|
45827501|NCT00003359|Drug|batabulin sodium|
45827502|NCT04195061|Procedure|Cardiopulmonary exercise test (CPET)|CPET studies will be performed in the Cardiovascular Performance Program exercise lab at MGH. Subjects will undergo CPET on an upright cycle ergometer with continual measurement of metabolic gas exchange via a commercially available metabolic cart as well as heart rate and blood pressure. Exercise will proceed according to a maximal effort clinical protocol. Subjects will then undergo a standardized 30-min work load on the upright cycle ergometer based on the results of the maximal effort clinical protocol.
45827503|NCT00003365|Dietary Supplement|curcumin|
45970283|NCT00249561|Behavioral|The Intensive Outpatient Program (IOP)|The control condition, known at the prison as the Intensive Outpatient Program (IOP), was designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism. The IOP substance abuse treatment curriculum, designed for delivery over 15 weeks, consisted of a 90-hour manual-driven course (Strategies for Self-Improvement and Change, Wanburg & Milkman, 1998), which employed a cognitive behavioral format to address underlying issues of substance use/abuse and criminal behavior.
45970284|NCT04591756|Other|Qualitative Fit Testing|Qualitative fit testing with denatonium benzoate
45970285|NCT04591795|Drug|Sahastara remedy extract|The concentration of SHT extract is 100 mg per capsule
45970286|NCT04591795|Drug|Diclofenac|Diclofenac sodium, 25 mg enteric-coated tablets
45970287|NCT04591639|Drug|Dapagliflozin 10 milligrams [Farxiga]|Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
45970288|NCT04591639|Drug|Placebo|Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
45970289|NCT04719585|Drug|Duloxetine vs. Opioid|Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine or opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
45827504|NCT00003365|Dietary Supplement|rutin|
45669255|NCT04699435|Other|PreOx_6min|"Patients with a BMI between 30 kg / m² and 40 kg / m² are distributed according to a random allocation in the group PreOx_6min.~All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 6-minute pre-oxygenation for the PreOx_3min group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
45827505|NCT00003365|Drug|quercetin|
45827506|NCT00003365|Drug|sulindac|
45827507|NCT00004307|Behavioral|Protein and calorie controlled diet|
45827508|NCT00004307|Genetic|Ornithine transcarbamylase vector|
45827509|NCT00004829|Drug|tobramycin|
45970290|NCT04592029|Drug|TACE combined with sintilimab and bevacizumab|Sintilimab and bevacizumab are administered at 3-7 days after the first TACE. The study includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then, Sintilimab 200mg/kg IV. q3w+ select specific dose of bevacizumab (7.5mg/kg or 15 mg/kg IV. q3w), expand to 36-39 patients for the further safety and efficacy study. The study treatment of sintilimab and bevacizumab lasts up to 24 months. TACE can be repeated when indicated clinically.
45970291|NCT04409873|Drug|Oral-B Mouth Sore mouthwash|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
46081142|NCT05261399|Drug|Pemetrexed|Pemetrexed (500 mg/m2) Administrative route : IV infusion
46081143|NCT05261399|Drug|Cisplatin|Cisplatin (75 mg/m2) or Administrative route : IV infusion
45827510|NCT00004313|Drug|dehydroepiandrosterone|
45827511|NCT00004853|Biological|Filgrastim|5 microgram/kg/dose SC daily starting 24-36 hours after last dose of chemotherapy until post-nadir ANC >=10,000/microliter
45827512|NCT00004853|Biological|Filgrastim-SD/01|100 microgram/kg SC 24-36 hours after last dose of chemotherapy (single dose)
45827513|NCT00004865|Biological|cetuximab|
45827514|NCT00004865|Drug|cisplatin|
45827515|NCT00004865|Drug|fluorouracil|
45827516|NCT00004865|Drug|paclitaxel|
45827517|NCT00004361|Drug|calcium gluconate|
45827518|NCT00004361|Drug|sodium citrate|
45827519|NCT00004367|Procedure|Clinical vestibular tests|
45827520|NCT00004373|Drug|alprazolam|
45970292|NCT04409873|Drug|Crest Pro-Health Multi-Protection mouthwash|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
45970293|NCT04409873|Drug|CloSYS Ultra Sensitive Rinse mouthwash|Rinse and gargle 4 times daily, for 45 seconds, for 4 weeks.
46081144|NCT05261399|Drug|Carboplatin|Carboplatin (AUC5) Administrative route : IV infusion
45970294|NCT04409873|Drug|Distilled water|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
46081145|NCT05254834|Diagnostic Test|Freenome Test|Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.
46081146|NCT05250180|Other|Animal Assisted Therapy|Patients enrolled in the study will be randomly scheduled to have a dog be a part of their PT and OT sessions on two days (one in the first week and one in the second week) during their stay. On these days, the therapist will lead the therapy session and integrate the dog at whatever level is appropriate based on the patient's level of functioning and therapy goals.
46081147|NCT05250180|Other|Control|treatment as usual as dictated by their treatment team
45970295|NCT04409873|Drug|Listerine Zero Mouthwash Product|Rinse and gargle 4 times daily, for 30 seconds, for 4 weeks.
46081148|NCT05244733|Behavioral|Social Engage (S-ENGAGE)|S-ENGAGE uses the process of action planning to foster sustained behavior change. Action planning involves: 1) select a goal; 2) develop ideas to meet this goal; 3) choose one or more of these ideas; 4) identify concrete steps to implement the goal (i.e., form an action plan); 5) identify and address barriers if needed.
45669256|NCT04689555|Procedure|Novel method without manual compression|Novel method for femoral artery hemostasis without manual compression. After sheath removal, four or five sterile gauzes were overlaid layer by layer and then bandaged without the procedure of manual compression.
45827521|NCT00004871|Drug|azacitidine|
45827522|NCT00004871|Drug|sodium phenylbutyrate|
45827523|NCT00004397|Drug|heme arginate|
45827524|NCT00004397|Drug|tin mesoporphyrin|
45827525|NCT00004877|Drug|BMS-214662|
45827526|NCT00004883|Biological|trastuzumab|Given IV
45827527|NCT00004883|Other|laboratory biomarker analysis|Correlative studies
45827528|NCT00004403|Drug|albendazole|
45827529|NCT00004403|Drug|dexamethasone|
45827530|NCT00004403|Drug|phenytoin|
45827531|NCT00004409|Drug|collagenase|
45827532|NCT00004415|Device|Medlink spinal cord electrode|
45827533|NCT00004421|Device|implanted pulse generator|
45827534|NCT00004889|Biological|rituximab|375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
45827535|NCT00385307|Drug|amibegron (SR58611A)|
45827536|NCT00004901|Drug|ethynyluracil|
45827537|NCT00004901|Drug|fluorouracil|
45827538|NCT00004901|Drug|hydroxyurea|
45827539|NCT00004901|Radiation|radiation therapy|
45827540|NCT00004433|Drug|pergolide|
45827541|NCT00004913|Drug|cisplatin|
45827542|NCT00004913|Drug|docetaxel|
45827543|NCT00004913|Drug|fluorouracil|
45827544|NCT00004913|Drug|leucovorin calcium|
45827545|NCT00004451|Drug|Glucose|
45827546|NCT00004919|Drug|cisplatin|Given IV
45827547|NCT00004919|Drug|irinotecan hydrochloride|Given IV
45827548|NCT00004919|Drug|amifostine trihydrate|Given IV
45827549|NCT00004919|Other|pharmacological study|Correlative studies
45827550|NCT00004925|Biological|trastuzumab|
45827551|NCT00004925|Drug|pegylated liposomal doxorubicin hydrochloride|
45669257|NCT04689555|Procedure|Standard method with manual compression.|Standard method for femoral artery hemostasis with manual compression.After sheath removal, manual compression was continued for at least 10 minutes or until hemostasis. After that four or five sterile gauzes were overlaid layer by layer and then bandaged without the procedure of manual compression.
45827552|NCT00004481|Procedure|genetic testing|
45827553|NCT00004931|Drug|leucovorin calcium|Given IV
45827554|NCT00004931|Drug|fluorouracil|Given IV
45827555|NCT00004931|Drug|oxaliplatin|Given IV
45827556|NCT00004931|Other|laboratory biomarker analysis|Correlative studies
45970296|NCT04591951|Behavioral|I2-ART|Based on the Parent Empowerment Program model, I2-ART will use methods of adult learning, direct instruction to share knowledge or techniques for practice, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). The research team will provide the family navigators with 3 months of I2-ART training, including 40 hours of didactic and interactive sessions (10 sessions of 4 hours each). Following training, the family navigators will implement the 3-month I2-ART intervention with the caregivers, including a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
45669258|NCT04683692|Device|Magnetic Resonance Imaging (MRI)|Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation
45970297|NCT04591951|Other|Usual care|Care as usual
45827557|NCT00004487|Drug|chondrocyte-alginate gel suspension|
45970298|NCT00253227|Drug|galantamine hydrobromide|
45970299|NCT04591678|Drug|nusinersen|SPINRAZA (nusinersen) is FDA approved to treat spinal muscular atrophy (SMA) through intrathecal injection.
45970300|NCT04591444|Drug|Fluoride Varnish|Following the manufacturer's recommendations, it was not necessary to moisten or dry the treated surface beforehand or afterwards. The product was dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush, flowing into interproximal areas, and quickly adhering to the tooth surface in the presence of saliva.
45970301|NCT04591444|Drug|Glass Ionomer Sealant|Following the manufacturer's recommendations, prophylaxis and prior drying of the treated surface was carried out, the product was also dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush and light-cured for 20 s.
45970302|NCT04591444|Other|Placebo Group|4 weeks after the simulation of the treatment application, participants in the placebo group received DH treatment with the product that had the best effect in the first 4 weeks.
45970303|NCT04404335|Diagnostic Test|Crevicular fluid analysis by using ELISA testing.|Samples of crevicular fluid (fluid existing in the space between the gums and the roots of the teeth) will be obtained from healthy and periodontal patients. In periodontal patients, samples will be taken before and after receiving a routine course of periodontal treatment (root scale and polish) to assess the levels of a peptide called LL-37 and inflammatory cytokines (IL-4, IL-6, IL-10): Samples will then be analysed using laboratory procedures (ELISA)
46081149|NCT05244733|Behavioral|The Healthy Lifestyles Education Program|The healthy lifestyles education program is a self-guided psychoeducational program, including a notebook containing evidence-based educational material on mental health, physical activity, and information on community resources.
46081150|NCT05243511|Device|Digital ACT|Participants in this arm receive Digital ACT as well as standard of care.
45827558|NCT00004937|Drug|acridine carboxamide|
46081151|NCT05243511|Other|Digital Symptom Tracker|Participants in this arm complete a digital symptom and function tracker and monitor, are provided access to digital fibromyalgia and health education, and receive standard of care.
46081152|NCT05239039|Drug|spesolimab|spesolimab
45669259|NCT04683692|Other|Laboratory Testing|Laboratory blood testing to include high sensitivity CRP (hs-CRP), interleukin-6 (IL-6), NT-proBNP and high sensitivity troponin prior to and post-ablation
45669260|NCT04671186|Dietary Supplement|Culturelle (Lactobacillus rhamnosus strain GG)|Culturelle probiotics are typically sold over the counter as dietary supplements Probiotics group will take 1 capsule of probiotics orally once daily
45669261|NCT04671186|Other|Placebo|Placebo group will take 1 capsule of placebo orally once daily
45669262|NCT04651270|Device|SurroundScope|The study will evaluate standard laparoscopic surgery using the 270Surgical system. The procedure will be performed according to the institution's standard of care, using the SurroundScope for visualization.
45669263|NCT04617197|Device|Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy|Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy using (Dragon Waves Resonant Home Care Electronic Nerve Stimulator (DW-1330), Taiwan Resonance Wave Research Co., Taiwan R.O.C,)
45669264|NCT04592250|Other|Survey Administration|Complete survey
45669265|NCT04588038|Biological|Efineptakin alfa|Given via intramuscular injection
45827559|NCT00385229|Drug|induction of labor|Misoprostol, Dinoprostone, amniotomy, Oxytocin
45827560|NCT00004979|Drug|paclitaxel|
45827561|NCT00004979|Drug|topotecan hydrochloride|
45827562|NCT00004493|Drug|sodium dichloroacetate|
45827563|NCT00004985|Drug|Capravirine|
45827564|NCT00004985|Drug|Nelfinavir mesylate|
45827565|NCT00004559|Behavioral|dietary polyunsaturated fatty acid|
45827566|NCT00004997|Drug|Leucovorin|
45827567|NCT00005009|Biological|Varivax®|Each participant will receive 2 doses of Varivax 6 to 8 weeks apart.
45827568|NCT00004583|Drug|Lopinavir/Ritonavir|
45827569|NCT00004583|Drug|Nelfinavir mesylate|
45827570|NCT00004583|Drug|Lamivudine|
45827571|NCT00004583|Drug|Stavudine|
45827572|NCT00005015|Drug|Fluoxetine|
45827573|NCT00004637|Drug|Vitamin E|
45827574|NCT00005021|Biological|filgrastim|
45827575|NCT00005021|Drug|carboplatin|
45827576|NCT00005021|Drug|paclitaxel|
45827577|NCT00005021|Drug|topotecan hydrochloride|
45827578|NCT00004643|Drug|cytarabine|
45827579|NCT00005027|Drug|becatecarin|
45827580|NCT00005033|Biological|trastuzumab|
45827581|NCT00005033|Procedure|conventional surgery|
45970304|NCT04591522|Other|Healthy fecal bacteria liquid|Fecal bacteria liquid were obtained from healthy people by a feces processor, and perfused into the patient's intestine.
45669266|NCT04558918|Drug|LNP023|Taken Orally b.i.d. Dosage Supplied: 200 mg Dosage form: Hard gelatin capsule Route of Administration: Oral
45827582|NCT00005039|Biological|recombinant fowlpox-prostate specific antigen vaccine|Given IM
45970305|NCT00249600|Behavioral|Contingency management|
45970306|NCT03453970|Behavioral|Therapeutic Education Program|The total duration of the program will be 12 weeks with a maximum of 6 sessions of 30 minutes each. In the first session, through the EBADE questionnaire, the needs will be identified by grouping them by the 4 constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention). The interventions and the number of sessions will be adapted depending on the areas identified with barriers. These interventions will be applied in both face-to-face and telephone modalities, using the Nursing Intervention Classification and their respective activities. The interventions will be carried out by nurses who have previously received training on the proposed program. Follow-ups will be carried out every 15 days.
45970307|NCT04591327|Procedure|The Effect of General Anesthesia and Spinal Anesthesia on Postoperative Atelectasis by Lung Ultrasonography in Cesarean Sections|Preoperative lung ultrasound will be performed on all patients and baseline values will be recorded. The sensory block level under T10 of the patients who underwent spinal anesthesia in the postoperative period lung ultrasonography will be done after regression. In the postoperative period, lung ultrasonography will be performed in patients undergoing spinal anesthesia when the sensory block level is below T10. In the general anesthesia group, when the neuromuscular block is completely reversed and the Aldrete score is> 9, lung ultrasonography will be performed. The degree of atelectasis will be determined according to the modified LUS score.
45970308|NCT04396730|Drug|Cannabidiol Oil|400 mg Cannabidiol oil will be administered daily along with oral contraceptives daily for 24 days.
45970309|NCT04396730|Drug|Placebo|Placebo will be administered daily along with oral contraceptives daily for 24 days.
45970310|NCT04396730|Drug|Combined oral contraceptive pill|All participants will receive oral contraceptives
45970311|NCT04591132|Device|kinematic analysis|motor tasks appropriate for each diagnosis will be recorder with wearable inertial sensors
45970312|NCT00253266|Drug|Venlafaxine|Venlafaxine XR up to 450 mg/d during the complete trial (8 weeks)
45970313|NCT00253266|Drug|Quetiapine|Quetiapine up to 200 mg/d for four weeks
45970314|NCT04591288|Other|Functional Electrical Stimulation protocol|FES-assisted treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age-predicted maximum heart rate. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Each treadmill bout consists of alternating one- minute intervals of FES on and FES off. For the last walking bout, the first three minutes will be FES-assisted on the treadmill and the last three minutes will be overground walking without FES assistance to promote carryover effects. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
45970315|NCT04591288|Other|Treadmill only protocol|We will implement a 12-wk Treadmill training protocol consisting of treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
45970316|NCT00253305|Drug|Organogel of naftifine, 2%|
45970317|NCT00253305|Drug|Organogel of terbinafine, 2%|
45669267|NCT04558918|Drug|Eculizumab|"Administered as intravenous infusion every 2 weeks as per the stable regimen, the maintenance dose is a fixed dose.~Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion"
45970318|NCT00253305|Drug|Organogel of naftifine, 6%|
45970319|NCT00253305|Drug|Organogel of terbinafine, 6%|
46081153|NCT05232825|Drug|Ocrelizumab IV|IV Injection
45669268|NCT04558918|Drug|Ravulizumab|"Administered as intravenous infusion every 8 weeks, the maintenance dose is based on body weight.~Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion"
46081154|NCT05232825|Drug|Ocrelizumab SC|SC Injection
46081155|NCT05232825|Drug|Methylprednisolone IV|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
46081156|NCT05232825|Drug|Diphenhydramine IV|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
46081157|NCT05232825|Drug|Dexamethasone given orally|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
45669269|NCT04548479|Device|PEP bottle|PEP bottle: it will be performed with a bottle of distilled water and a plastic tube, where the patient breathes against a resistance during expiration.
45669270|NCT04529278|Drug|Liraglutide|"Liraglutide is initiated at 0.6 mg / day during week S1 (initiation D1) during weekly hospitalization in the diabetology department. Then the dose of liraglutide is increased to 1.2 mg / day on week S2 (increase in dose on D8) then to 1.8 mg / day on week S3 (increase in dose on D15).~The daily dose is then 1.8 mg until week W26."
45669271|NCT04526730|Drug|Tavo|Tavo will be injected on Days 1 and 8 every 4 weeks at a dose volume of ¼ of the calculated lesion volume with a minimum dose volume per lesion of 0.1 mL for lesions of volume <0.4 cm3
45669272|NCT04526730|Drug|Nivolumab|Nivolumab will be administered 480 mg every 4 weeks over 30 minute infusions
45827583|NCT00005039|Biological|recombinant vaccinia prostate-specific antigen vaccine|Given intradermally
45827584|NCT00005039|Other|laboratory biomarker analysis|Correlative studies
45827585|NCT00004667|Drug|von Willebrand factor|
45827586|NCT00004685|Drug|albuterol|
45827587|NCT00005045|Drug|carboxyamidotriazole|
45827588|NCT00005051|Drug|carboplatin|
45827589|NCT00005051|Drug|cisplatin|
45827590|NCT00005051|Drug|paclitaxel|
45827591|NCT00005051|Drug|topotecan hydrochloride|
45827592|NCT00004697|Drug|choline chloride|
45827593|NCT00004727|Drug|aspirin|
45827594|NCT00004727|Drug|ticlopidine|
45455800|NCT05670561|Drug|Sufentanil|PCIA formula#100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously.No obvious adverse reactions were observed for 10min. The PCIA pump was commenced at the beginning of TACE. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
45970320|NCT04591600|Drug|Ivermectin and Doxycyline|Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.
45970321|NCT04591600|Drug|Standard of care|"Standard care~Acetaminophen 500mg on need~Vitamin C 1000mg twice/ day~Zinc 75-125 mg/day~Vitamin D3 5000IU/day~Azithromycin 250mg/day for 5 days~Oxygen therapy/ C-Pap if needed~dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed~Mechanical ventilation, if needed"
45970322|NCT04591405|Biological|Attenuated Mumps vaccine (KMB-17) in phase II and III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.3 logCCID50/ml] in 360 children (5-11 years old) on 0 day
45970323|NCT04591405|Biological|Placebo in phase II|Freeze-dried stabilizer and diluent without mumps virus antigen in 360 children (5-11 years old) on 0 day
45827595|NCT00004733|Drug|levodopa|
45827596|NCT00004739|Drug|Antiretroviral therapy|
45827597|NCT00005057|Biological|adenovirus RSV-TK|
45455801|NCT05667649|Biological|RB-ADSC|Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs)
45669273|NCT04526730|Device|OncoSec Medical Electroporation Therapy System|"The OMS (OncoSec Medical Electroporation Therapy System), a medical EP device system, consists of 3 components: 1. an Electroporation Generator that generates electric pulses, 2. a sterile Applicator Tip containing needle array, and 3. an Applicator Handle that connects to the Electroporation Generator at the proximal end and connects to the Applicator Tip at the distal end.~Upon user activation of the attached Foot Switch, the OMS Electroporation Generator delivers controlled electrical pulses in a square wave pulse pattern yielding optimal transmembrane potential for electroporation to occur. EP pulses occur between 6 hexagonal opposing needle electrodes. After the first pulse, the polarity between the opposing needle electrode pairs is reversed and the needle pair is pulsed again. After the initial paired pulse, the pulse delivery is rotated clockwise to the next opposing needle pairs until a total of 6 pulses are delivered to complete the EP sequence."
45827598|NCT00005057|Drug|ganciclovir|
45827599|NCT00004751|Procedure|Surgery|
45970324|NCT04591405|Biological|Attenuated Mumps vaccine (KMB-17) in phase III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.3 logCCID50/ml] in 5640 children (5-11 years old) on 0 day
45669274|NCT04515810|Other|Internet-Based Intervention|Use smartphone application
45669275|NCT04515810|Other|Best Practice|Engage in standard care
45669276|NCT04515810|Other|Questionnaire Administration|Ancillary studies
45669277|NCT04503148|Drug|Propofol|Propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia
45669278|NCT04503148|Drug|Inhaled General Anesthetics|Sevoflurane or desflurane for induction and maintenance of anesthesia
45970325|NCT04591405|Biological|Placebo in phase III|Freeze-dried stabilizer and diluent without mumps virus antigen in 5640 children (5-11 years old) on 0 day
45970326|NCT04590742|Drug|melatonin 6mg|6 weeks of melatonin (6mg) given to patient
45970327|NCT04590742|Drug|Placebo|Patient given 6 weeks of placebo tablet
45970328|NCT00253344|Drug|docetaxel|Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days until disease progression or unacceptable toxicity.
45970329|NCT00253344|Drug|lenalidomide|Oral lenalidomide on days 1-14. Courses repeat every 21 days until disease progression or unacceptable toxicity.
45970330|NCT04590859|Procedure|Block performed|Comparing block performed with penile blood flow
45970331|NCT04590859|Device|LMA placement|Placement of LMA for airway securement
45970332|NCT00567346|Drug|Oralgen|Patients will receive drops of grass pollen immunotherapy sublingually
45970333|NCT00567346|Drug|grass pollen extract|Patients will receive matching placebo sublingually
45970334|NCT00567385|Drug|somatropin|
45455802|NCT05662566|Procedure|Epidural replacement|"Insufficient analgesic effect of epidural anesthesia to the extent were replacement of the catheter is needed.~Defined as insertion of a new epidural catheter"
45669279|NCT04498832|Biological|High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
45827600|NCT00004751|Procedure|Physical therapy|
45827601|NCT00004757|Drug|acyclovir|
45827602|NCT00005069|Drug|arsenic trioxide|
45827603|NCT00004763|Drug|leuprolide|
45827604|NCT00004763|Drug|Ethinyl estradiol/norethindrone|
45827605|NCT00005075|Procedure|high-intensity focused ultrasound ablation|
45827606|NCT00004787|Drug|filgrastim|
45827607|NCT00005081|Drug|O6-benzylguanine|
45827608|NCT00005081|Drug|carmustine|
45827609|NCT00005087|Biological|filgrastim|
45827610|NCT00005087|Drug|cisplatin|
45827611|NCT00005087|Drug|paclitaxel|
45827612|NCT00005087|Procedure|conventional surgery|
45827613|NCT00005087|Radiation|radiation therapy|
45827614|NCT00004799|Biological|whole-cell pertussis vaccine|
45827615|NCT00004799|Biological|diphtheria-tetanus vaccine|
45827616|NCT00004805|Behavioral|CPR instruction|
45827617|NCT00005093|Drug|gemcitabine hydrochloride|
45827618|NCT00005093|Drug|tacedinaline|
45827619|NCT00004811|Drug|itraconazole|
45827620|NCT00004817|Drug|phenytoin|
45827621|NCT00004817|Drug|valproate sodium|
45827622|NCT00005117|Drug|pravastatin|
45827623|NCT00005555|Behavioral|Exercise|
45669280|NCT04498832|Biological|Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: SC
45827624|NCT02972489|Device|3D OFDI guidance arm|Subjects randomized to 3D-guidance arm will undergo optical frequency domain imaging (OFDI) assessment in the main vessel after re-wiring into the jailed side branch following stent implantation. If the position of the wire is not located in the optimal cell, further attempts to redirect the wire to the optimal cell will be performed, with subsequent OFDI acquisitions to confirm position in 2D and off-line 3D reconstruction. After procedure, OFDI is performed in the main branch.
45827625|NCT02972489|Device|Angio guidance arm|In angiography-guidance group, wire recrossing into the side branch will be performed using conventional fluoroscopic/angiographic guidance. After finishing the procedure, OFDI is performed in the main branch but the results will be blinded to the operators.
45827626|NCT00385385|Drug|Rifalazil|
45970335|NCT00253383|Other|counseling intervention|
45970336|NCT00253383|Other|educational intervention|
45970337|NCT00253383|Procedure|psychosocial assessment and care|
45970338|NCT00253383|Procedure|quality-of-life assessment|
45669281|NCT04493203|Drug|Nivolumab|Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1. It is a type of Immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
45669282|NCT04493203|Drug|Axitinib|Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor.Its primary mechanism of action is thought to be vascular endothelial growth factor receptor 1-3, c-KIT and PDGFR inhibition, this, in turn, enables it to inhibit angiogenesis (the formation of new blood vessels by tumours)
45827627|NCT00005567|Behavioral|Parental knowledge and beliefs about infant sleep position|
46081158|NCT05232825|Drug|Desloratadine given orally|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
46081159|NCT05231213|Device|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
45827628|NCT00385463|Drug|Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID|
45827629|NCT00386165|Drug|larazotide acetate|larazotide acetate 4 mg capsules
45827630|NCT00423371|Device|sodium hyaluronate|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
45827631|NCT00423371|Device|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
45827632|NCT00005579|Drug|dolastatin 10|
45827633|NCT00005585|Drug|cyclophosphamide|Given IV
45970339|NCT00567424|Drug|GW273225|
45970340|NCT00567463|Device|Fluticasone|Fluticasone 250mcg for 3 months followed by 100mcg for 9 months, one puff once a day at supper time
46081160|NCT05231213|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
46081161|NCT05228002|Other|sFlt-1/PlGF ratio - Active Comparator: Standard|"Blood test for biomarkers (sFlt-1/PlGF ratio) For patients in the standard group, the biomarker results will be masked and then revealed afterwards for statistical analysis.~For the biomarkers group, the monitoring decision will be made based on the ratio calculation"
46081162|NCT05228002|Other|sFlt-1/PlGF ratio - Experimental: Biomarkers|"Blood test for biomarkers (sFlt-1/PlGF ratio) For patients in the standard group, the biomarker results will be masked and then revealed afterwards for statistical analysis.~For the biomarkers group, the monitoring decision will be made based on the ratio calculation."
45827634|NCT00005585|Drug|cytarabine|Deoxycytidine analogue which is metabolized to ARA-CTP, a substance which inhibits DNA polymerase.
45827635|NCT00005585|Drug|daunorubicin hydrochloride|Given IV
45827636|NCT00005585|Drug|dexamethasone|Dexamethasone is a synthetic fluorinated glucocorticoid devoid of mineralocorticoid effects.
45827637|NCT00005585|Drug|leucovorin calcium|Synthetic d,l-5 CHO tetrahydrofolate, which is used to bypass the inhibition of dihydrofolate reductase by Methotrexate (MTX)
45827638|NCT00005585|Drug|mercaptopurine|An analogue of the nucleic acid constituent adenine and the physiological purine base hypoxanthine
45970341|NCT00253422|Drug|anastrozole|
45970342|NCT00253422|Drug|exemestane|
45970343|NCT00253422|Drug|fulvestrant|
45970344|NCT04590703|Biological|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
45970345|NCT04590703|Procedure|Vehicle sheet|Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
45970346|NCT04590937|Drug|BI 730357|Film-coated tablet
45970347|NCT04590937|Drug|CRESTOR®|Film-coated tablet
46081163|NCT05225584|Drug|KT-333|KT-333 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined frequency and dose level.
46081164|NCT05222984|Drug|Decitabine|Given IV
46081165|NCT05222984|Biological|Navitoclax|Given PO
45970348|NCT04590937|Drug|Lenoxin®|Tablet
45970349|NCT04590937|Drug|MetfoLiquid GeriaSan®|Oral solution
45970350|NCT04590937|Drug|Lasix®|Oral solution
45970351|NCT04590625|Drug|Apatinib Mesylate|apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd
45970352|NCT04590625|Drug|Abraxane|abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1
45970353|NCT04590625|Drug|Cis Platinum|cis-platinum one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1
45970354|NCT04590625|Drug|Carboplatin|carboplatin one course will last 21 days.carboplatin intravenous injection at a dose of AUC=5-6,d1
45970355|NCT04590469|Other|COVID WHELD|COVID WHELD is a COVID-19 adapted version of an established nursing home training intervention that confers benefits in well-being and neuropsychiatric symptoms for people with dementia. The adaptations include the development of digital resources to support the programme and virtual coaching.
45827639|NCT00005585|Drug|methotrexate|A folate analogue which inhibits the enzyme dihydrofolate reductase, haltin g DNA, RNA, and protein synthesis
45669283|NCT04484766|Other|Primary data collection|"Primary data collection takes place via questionnaires outside the study centre.~All other investigations take place at the study centre:~Physical examination: height, weight, BMI, blood pressure~Cardiac examination: cardiac output~Vascular measurements: Carotid intima media thickness, total peripheral resistance, blood pressure, flow-mediated vascular dilatation, critical flicker frequency, pulse wave velocity, augmentation index~Serum analysis: basic laboratory, multiplex analysis (human vascular inflammation, human angiogenesis and adhesion molecule panel)"
45827640|NCT00005585|Drug|pegaspargase|E-Coli asparaginase deaminates asparagine, thus, is lethal for cells which cannot synthesize asparagine.
45827641|NCT00005585|Drug|thioguanine|Given orally
45827642|NCT00005585|Drug|vincristine sulfate|Given IV
45827643|NCT00005591|Biological|cetuximab|
45970356|NCT00253461|Procedure|computed tomography|Within 4 weeks after initial imaging, patients also undergo a CT scan.
45970357|NCT00253461|Procedure|positron emission tomography|"Phase I: IV over 10 minutes followed immediately by a 1-2 hour positron emission tomography (PET) scan.~Phase II: fludeoxyglucose F 18 IV and, 1 hour later, undergo a PET scan."
45970358|NCT00253461|Radiation|11C topotecan|Phase I and II: IV over 10 minutes
46081166|NCT05222984|Drug|Venetoclax|Given PO
46081167|NCT05221840|Drug|Durvalumab|Durvalumab IV (intravenous infusion)
46081168|NCT05221840|Drug|Oleclumab|Oleclumab IV (intravenous infusion)
46081169|NCT05221840|Drug|Monalizumab|Monalizumab IV (intravenous infusion)
46081170|NCT05221840|Other|Placebo|Placebo IV (intravenous infusion)
46081171|NCT05215886|Behavioral|Surgery|Study subjects scheduled for or have already completed weight loss surgery and have already completed psychological screening as part of their pre-surgery work up
46081172|NCT05215223|Device|whole body vibration|the patients will stand on whole body vibration device with maintaining squatting position while keeping their trunk extended. The first training session will be consisted of three sets of 1 min and will be separated by a 1-min of standing rest. intensity will 1 mm. Then one set will be added every session
46081173|NCT05215223|Device|Treadmill|Females will be asked to perform moderate intensity aerobic exercise for 45 minutes for 3 times per week for 8 weeks
46081174|NCT05211037|Diagnostic Test|Kidney function assessment|kidney clearance measured by scintigraphy
46081175|NCT05201456|Device|LithoVue Elite System|The LithoVue Elite System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
46081176|NCT05199688|Drug|Satralizumab|Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period.
46081177|NCT05199272|Drug|23ME-00610|23ME-00610 given by IV infusion
45669284|NCT04484220|Device|Ellipsys Vascular Access System|The Ellipsys System is indicated for the creation of a proximal radial artery to perforating vein anastomosis via a retrograde venous access approach in patients with a minimum vessel diameter of 2.0mm and less than 1.5mm of separation between the artery and vein at the fistula creation site who have chronic kidney disease requiring dialysis.
45669285|NCT04482582|Radiation|Cryoneurolysis|Patients will be offered a minimally invasive solution known as cryoneurolysis. By directly applying a cold cryoneurolysis probe to the nerves the axon is destroyed, resulting in Wallerian degeneration of the distal nerve without distorting epineurial or perineurial tissue. Application of cryoneurolysis will help reduce the amount of narcotics the patient would need to take and instead provide them longer term pain control with minimal risk.
45970359|NCT00253461|Radiation|fludeoxyglucose F 18|Phase II: fludeoxyglucose F 18 IV
46081178|NCT05198063|Biological|Recombinant novel coronavirus vaccine (CHO cells)|At 6 months after the basic immunization (window period ± 1 month), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
45827644|NCT00005591|Drug|gemcitabine hydrochloride|
45827645|NCT00005195|Procedure|Catheter ablation|
45827646|NCT01926444|Drug|GIC-1001|GIC-1001 oral tablet, white-coated, to be taken with water
45827647|NCT00005597|Drug|temozolomide|200 mg/m^2/day, PO, on Days 1-5 of each 28 day cycle.
45827648|NCT04172844|Drug|Azacitidine|75mg/m^2 Days 1-7 given IV
45827649|NCT04172844|Drug|Venetoclax|100 mg on cycle 1 day 1, 200 mg daily on cycle 1 day 2, 400 mg on cycle 1 day 3 and thereafter from cycle 1. Venetoclax is given for a minimum of 21 days and a maximum of 28 days. Administered orally.
45827650|NCT04172844|Drug|Pevonedistat|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
45827651|NCT00005603|Drug|asparaginase|
45827652|NCT00005603|Drug|cyclophosphamide|
45827653|NCT00005603|Drug|cytarabine|
45827654|NCT00005603|Drug|daunorubicin hydrochloride|
45827655|NCT00005603|Drug|dexamethasone|
45827656|NCT00005603|Drug|doxorubicin hydrochloride|
45827657|NCT00005603|Drug|mercaptopurine|
45827658|NCT00005603|Drug|methotrexate|
45827659|NCT00005603|Drug|prednisone|
45970360|NCT04272242|Drug|Dolutegravir (DTG)|Administered orally
45970361|NCT04272242|Drug|Isoniazid (INH)|Administered orally
45970362|NCT04272242|Drug|Rifapentine (RPT)|Administered orally
45970363|NCT04272242|Drug|Antiretroviral Therapy (ART)|Participants will remain on DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. NRTIs will not be provided by the study. Arm 1 participants will take non-study supply of DTG for morning doses, and will take study-supplied DTG for evening doses. For Arm 2 participants, DTG will be from non-study ARV supply.
45970364|NCT04272242|Dietary Supplement|Pyridoxine (Vitamin B6)|All participants must receive 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH, based on the current local, national, or international dosing guidelines. Pyridoxine is not provided by the study.
45827660|NCT00005603|Drug|thioguanine|
45827661|NCT00005603|Drug|vincristine sulfate|
45970365|NCT04590313|Procedure|Arthrodesis|MTPJ I arthrodesis
45970366|NCT04590352|Procedure|nasopharyngeal and throat swab|diagnostic specimens via nasopharyngeal swab and throat swab were collected following the current standard operating procedures.
45669286|NCT04482582|Other|Standard of Care|Patients will be provided regular standard of care at the Stanford Hospital with long-term follow-up provided at the Stanford Center for Reconstruction after Chest Wall Injury.
45669287|NCT04458545|Drug|Placebo|Intranasal placebo 0mg
45827662|NCT00005609|Biological|rituximab|
45970367|NCT04590352|Procedure|collection of mucosal lining fluid|MLF will be collected via nasal absorption at the inclusion visit by study staff and four more time points by the parents or by the children themselves. Nasal absorption is performed by maneuvering a strip of synthetic absorptive matrices (SAM) into the lumen of the nostril, avoiding rubbing against the nasal mucosa. The outside of the nose is then pressed with a finger to cause apposition of the SAM against the mucosa.
45970368|NCT04590352|Procedure|blood collection via fingerprick|Participants will be asked to wash their hands with soap and warm water. The procedure involves cleaning the ball of the fingertip with an alcohol swab, then using a sterile disposable lancet to pierce the skin (BD Microtainer Lancet or similar). The lancet is placed in a spring-loaded device, which propels the lancet a fixed distance (a few mm) into the skin when the trigger is pressed. Approximately 10-20 drops of blood (0.3 ml) will then be collected with a sterile capillary tube. The participant is given a cotton wool pad to mop up any extra blood, and an elastoplast-type bandage is placed over the finger if necessary. Fingerprick blood samples will only be collected from participants older than 6 months at 28-32 days after the first home visit (d0). Lancet length will be adjusted for age (2.0 mm for participants 8 years and older, 1.5 mm for participants older than 6 months and younger than 8 years).
46081179|NCT05197309|Dietary Supplement|Metabolic Diet|Metabolic Diet includes increasing the amount of foods high in fat and decreasing the amount of foods that may cause increased flux in blood glucose levels. Food logs and ketone logs will be reviewed weekly during the 8 weeks of the intervention.
46081180|NCT05193162|Other|No any intervention|have no any intervention
45669288|NCT04458545|Drug|Oxy 25 mg|Intranasal oxycodone 25mg
45669289|NCT04458545|Drug|OXY 50 mg|Intranasal oxycodone 50mg
46081181|NCT05189925|Biological|gp91 Grans|Adults with gp91phox-deficient CGD without systemic infection will participate in a dose escalation trial to identify the MTD (the most effective yet safe dose) of gp91 Grans IV infusion.
45669290|NCT04458545|Drug|OXY 100 mg|Intranasal oxycodone 100mg
45669291|NCT04458545|Drug|Heroin|Intranasal heroin 100mg
45669292|NCT04443608|Drug|Patiromer Powder for Oral Suspension [Veltassa]|Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink
45669293|NCT04443608|Drug|Placebo|Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink
45827663|NCT00005615|Biological|Interferon alfa|Interferon alfa as outlined in treatment arm.
45827664|NCT00005615|Radiation|Radiation therapy|Radiation therapy as outlined in treatment arm.
45827665|NCT00005627|Drug|carboplatin|
45827666|NCT00005627|Drug|docetaxel|
45827667|NCT00005627|Drug|estramustine phosphate sodium|
45827668|NCT00005633|Biological|OVA BiP peptide|
45827669|NCT00005633|Biological|gp209-2M antigen|
45827670|NCT00005633|Biological|recombinant 70-kD heat-shock protein|
45827671|NCT00005633|Biological|tyrosinase peptide|
45827672|NCT00005639|Drug|Azacitidine Injection|subcutaneous injection (SC)
45827673|NCT00005639|Drug|sodium phenylbutyrate|continuous intravenous (CIV)
45827674|NCT00005645|Drug|ILX-295501|
45827675|NCT00005663|Drug|Valacyclovir hydrochloride|
45827676|NCT00385775|Drug|AEG35156|weekly IV solution infused over 2 hrs
45827677|NCT00005675|Drug|Oral bovine type I collagen|500 mcg of CI daily for 15 months
45827678|NCT00005675|Drug|Placebo|CI placebo daily for 15 months
45827679|NCT00385853|Drug|PTK787/ZK 222584|Twice daily for each 28-day cycle
45827680|NCT00385853|Drug|Temozolomide|Daily for each 28-day cycle
45669294|NCT04429516|Drug|Morphine Sulfate|over-encapsulated Morphine Sulfate prolonged release 5mg tablet, twice daily for 14 days. Patients will then crossover after a 7 day wash out period.
45669295|NCT04429516|Drug|Placebo oral tablet|capsule containing Microcrystalline Cellulose Ph. Eur, 5 mg twice daily
45827681|NCT00385853|Procedure|Radiation Therapy|For 7 weeks beginning on day 5 of the first treatment cycle
45970369|NCT04720560|Diagnostic Test|regulatory B cell by flow cytometry|"4-Evaluation of the Frequency of regulatory B cells (Bregs) by Flow Cytometry Using flow cytometry, circulating Bregs will be detected using FITC-conjugated-CD38, PE-conjugated-CD24 (Bioscience, USA), and PerCP-conjugated CD19 (BD Bioscience, USA). Briefly, 100 µl of blood sample will be incubated with 10 µL of CD24, CD38 and CD19 for 20 minutes at 4 °C in the dark. Following incubation, RBCs will be lysed and washed. Cells will be fixed and permeabilized then stained with APC-conjugated IL-10 (BD Bioscience, San Jose, CA, USA) and analysis will be done by FACS Calibur flow cytometry with CellQuest software (Becton Dickinson Biosciences, San Jose, CA, USA).~An isotype-matched negative control will be used for each sample. Forward and side scatter histograms will be used to define the lymphocytes population. CD19+ IL-10+ B cells will be gated, then the expression of CD38 and CD24 on the CD19+B cells will be detected. Bregs will be identified as CD19+ IL-10+CD24+hiCD38+hi cells."
45970370|NCT04590391|Device|Visual and Auditory Breathing-swallowing Coordinated Training device|This device has a structure in which a band wrapped around the chest detects the respiratory phase from changes in the lung volume, and the connected device lights a signal and sounds a sound.
45970371|NCT04244552|Biological|ATRC-101|ATRC-101 is an engineered, fully-human IgG1 antibody derived from a naturally-occurring human antibody.
45669296|NCT04417452|Other|Basic data collection (online survey or written form)|Basic data collection is carried out by means of a questionnaire that participants can fill in outside the study centre. It contains questions about the current life situation, sleep and activity behaviour.
45970372|NCT04244552|Biological|Pembrolizumab|Pembrolizumab (Keytruda®) is a humanized immunoglobulin G4 monoclonal antibody with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
45455803|NCT05661721|Other|Sweet licorice|Ecologic, vegan and gluten free, low-sodium sweet licorice pastilles made from Glycyrrhiza glabra, with a manufacturer specified content of 4% sugars, 2% glycyrrhizin and 0.03% salt, will be used as intervention. The exact glycyrrhizin content will be determined before the study begins, and participants will be instructed to consume a daily licorice dose that is equivalent to 100 mg of glycyrrhizin.
45455804|NCT05661721|Other|Salty licorice|A vegan and gluten free salty licorice without glycyrrhizin, flavored with ammonium chloride, with a manufacturer specified content of 0% sugars and 0.05% salt, will be used as control. The amount of salty licorice will be the same as for sweet licorice, and thus determined after the glycyrrhizin content analysis of the sweet licorice.
45669297|NCT04417452|Other|Physical examination|The physical examination takes place at the study centre and includes the measurement of height, current weight and body fat, as well as the recording of heart and circulation parameters (e.g. blood pressure measurement or determination of vascular health by means of ultrasound). General metabolic and hormonal parameters are analysed by means of a blood sample. In addition, a sugar test for diabetes diagnosis will be carried out.
45455805|NCT05659641|Device|PerMed Stent Graft System In Surgical Operation|PerMed Branch Stent Graft
45455806|NCT05659641|Device|Endovastec CRONUS® Intraoperative stent system|CRONUS® Branch Stent Graft
45669298|NCT04417452|Behavioral|Psychometric examination|Psychometric examination is carried out at the study centre with the help of a RIAS (Reynolds Intellectual Assessment Scales and Screening) test.
45669299|NCT04417452|Diagnostic Test|Recording of the adrenergic stress reaction (saliva test)|The adrenergic stress reaction is recorded by a saliva test.
45669300|NCT04412096|Drug|Timolol 0.5% ophthalmic solution|1 drop BID
45669301|NCT04412096|Drug|Latanoprost 0.005% Ophthalmic Solution|1 drop QD
45669302|NCT04410042|Drug|Tranexamic Acid|Given IV
45669303|NCT04410042|Other|0.9% sodium chloride|Given IV
45669304|NCT04405167|Drug|Tasquinimod|Tasquinimod will be supplied as oral capsules.
45827682|NCT00386321|Drug|Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)|
45827683|NCT00005711|Behavioral|Asthma self-management education|"Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma (triggers), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish."
45827684|NCT00005765|Drug|nicotine|
45827685|NCT00005765|Drug|alcohol|
45827686|NCT00005771|Device|Visual utrasound feedback|
45827687|NCT00005771|Procedure|Abdominal Hollowing Exercise|
45827688|NCT00005777|Procedure|Minimal mechanical ventilation management|Partial pressure of carbon dioxide (PCO2) target (>52 mm Hg)
45827689|NCT00005777|Procedure|Routine mechanical ventilation management|Partial pressure of carbon dioxide (PCO2) target <48 mm Hg)
45827690|NCT00005777|Drug|Dexamethasone|Treatment with the study medication was initiated within 24 hours after birth. The dexamethasone-treated infants received a 10-day tapered course (0.15 mg of dexamethasone per kilogram per day for three days, followed by 0.10 mg per kilogram for three days, 0.05 mg per kilogram for two days, and 0.02 mg per kilogram for two days), with the daily dose divided in half and given at 12-hour intervals intravenously or orally, if an intravenous catheter was no longer in place.
45827691|NCT00005777|Drug|Placebo|The infants in the placebo groups received equal volumes of saline.
45970373|NCT04244552|Drug|Pegylated liposomal doxorubicin (PLD)|Pegylated liposomal doxorubicin (PLD) is doxorubicin hydrochloride (HCl), an anthracycline topoisomerase inhibitor that can bind DNA and inhibit nucleic acid synthesis. PLD is doxorubicin HCL encapsulated in liposomes formulated with surface-bound methoxypolyethylene glycol
45970374|NCT04590157|Device|Low Level Laser Therapy|Laser Acupuncture application on Neurogenic Acupoints: the treatment based upon the use of low power laser light to stimulate acupuncture points
45970375|NCT04590157|Other|Pelvic floor muscle training|exercise prodram as follow: from supine lying position with legs slightly apart the patient asked to contract the pelvic muscles as hard as possible and hold for 10 seconds
45970376|NCT00567658|Drug|Esomeprazole|Esomeprazole or Nexium 40 mg BID is given for four months.
45970377|NCT04589884|Other|Hyperspectral Imaging|Hyperspectral images of the operative field will be collected at several time points during the surgical procedure. The device used is the TIVITA® compact Hyperspectral imaging system (Diaspective Vision GmbH, Germany). It is a CE (European Economic Area) mark approved device. The acquisition takes roughly 10 seconds, is contrast-free and contact-free.
45970378|NCT04589806|Procedure|2-stage ridge splitting|two-stage alveolar ridge splitting technique using piezoelectric device with simultaneous implant placement in order to treat narrow posterior mandibular ridges avoiding the risks of malfracture and necrosis of the split part
45970379|NCT00567697|Drug|ranibizumab|0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection. Monthly injection for 3 months, followed by reinjection if edema for a total of 6 months.
45970380|NCT00567697|Drug|ranibizumab|Sham injection with an empty, sterile 3-ml stopped glass vial. # monthly sham-injections, followed by reinjection for 3 months if present edema.
45970381|NCT04589416|Other|Dental adhesive materials.|It is used to bond the composite resin to the dental tissues. That is, it is used to bond dental filling materials to dental tissues.
45970382|NCT04589455|Dietary Supplement|Hennep extract|Hennep extract from Becanex containing 70 mg CBD
45455807|NCT05658653|Other|Educational Materials for Chronic Disease Management Test (CDMT)|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
45455808|NCT05652218|Device|LB-CRT|LB-CRT (DDD 60-130, LV lead turned off) (active intervention #1)
45455809|NCT05652218|Device|BIV-CRT|BIV-CRT (DDD 60- 130, LV lead turned on) (active intervention #2).
45455810|NCT05650463|Device|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
45455811|NCT05649098|Drug|Dupilumab|The treatment period will include a 16-week open-label phase and a 20-month long-term extension phase for those who qualify and wish to continue.
45669305|NCT04405167|Drug|IRd chemotherapy|IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone
45669306|NCT04391114|Procedure|Traditional HoLEP|Holmium laser enucleation of the prostate (HoLEP), first reported by Fraundorfer et al in 1998, is a more recent step in the evolution of holmium laser prostatectomy. HoLEP is a safe and effective procedure which has demonstrated comparable results to TURP and open prostatectomy for patients with symptomatic enlarged prostate, with low morbidity and short hospital stay [4]. The improvement in outcome parameters is durable, and the late complications and reoperation rates reported are very low [5]. HoLEP is equally suitable for small, medium and larger prostate glands, with clinical outcomes that are independent of prostate size, unlike TURP. HOLEP offers patients the alterative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay [6].
45827692|NCT00005783|Drug|Recombinant-methionyl human stem cell factor|
45827693|NCT00385931|Drug|Valsartan and simvastatin|
45827694|NCT00386087|Drug|Enzastaurin Hydrochloride|
45827695|NCT00386399|Drug|Mitomycin-C|Mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour antibiotic activity.
45827696|NCT00005801|Biological|therapeutic allogeneic lymphocytes|
45455812|NCT05647980|Other|TACTIC|Participants execute the three steps of TACTIC Participants fill in questionnaires Participants take laboratory and biometric tests to measure their cardiovascular risk
45827697|NCT00005801|Procedure|peripheral blood stem cell transplantation|
45827698|NCT00005801|Radiation|radiation therapy|
45827699|NCT00005807|Drug|BMS-247550|anticancer agent for the treatment of patients with malignant tumors.
45827700|NCT00005813|Biological|bispecific antibody MDX447|
45827701|NCT00005813|Biological|lymphokine-activated killer cells|
45827702|NCT00005813|Procedure|conventional surgery|
45827703|NCT00005399|Other|No interventions|No interventions
45827704|NCT04567433|Drug|Hydroxyethyl starch|Hydroxyethyl starch compared to 0.9% saline
45827705|NCT04567433|Drug|Hydrocortisone|Hydrocortisone compared to Placebo
45970383|NCT04589494|Drug|Tramadol Hydrochloride|tramadol hydrochloride 100 mg three times daily , morphine sulphate 30 mg twice daily
45970384|NCT04589299|Biological|Immunoglobulin|Randomization 1:1 to the same total dose of either SCIG or IVIG for 26 weeks of stable dose + 60 weeks of redcution.
45970385|NCT00253500|Biological|pegfilgrastim|6 mg in a syringe
45970386|NCT00253500|Drug|epirubicin hydrochloride|120 MG q 2 weeks for 4 cycles
45970387|NCT00253500|Procedure|conventional surgery|to remove small piece of cancer
45970388|NCT04588909|Procedure|Colorectal resections|All patients admitted with colorectal cancer were subjected to various types of colorectal resections
45970389|NCT04213469|Biological|PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells|Gene editing autologous T cells with anti-CD19 ScFv expression and knockout of PD1
45970390|NCT04589026|Drug|Cosentyx|Cosentyx injection will be administered subcutaneously.
45970391|NCT04589026|Drug|Candin|Candin will be administered interadermally along with NaCl solution.
45827706|NCT04567433|Procedure|Early Goal Directed Therapy|Early Goal Directed Therapy compared to Usual Care
45669307|NCT04391114|Procedure|Top-Down HoLEP|The main difference between the Top-Down and Traditional approach is that the direction of lateral dissection begins from upwards to downwards. This could help in avoiding the overtraction of the mucosal strip overlying the posterior urethral sphincter, which theoretically leads to a decrease in the incidence of postoperative stress incontinence. Moreover, using the Top-Down approach should lead to a decrease in the incidence of lost enucleation planes, which results in decreasing the intraoperative time and decreasing the number of cases required to master the HoLEP technique.
45827707|NCT04569929|Other|(DLP)-printed photo-polymerizable PMMA Nextdent mandibular implant overdenture|The bite registration records with their corresponding master casts were digitalized using an extra oral desktop 3D scanner (3shape D850) and then stored as standard triangulation language (STL) files (Figure 1). The STL files were then imported to Dental system PREMIUM3 design software (3Shape Dental System 2018) for model analysis, surveying and blocking out, designing full permanent denture bases, and for virtual teeth set-up following the recorded inter-arch space
45970392|NCT04589143|Drug|Agomelatine|Oral tablets of agomelatine at a dose of 25-50 mg/d for 8 weeks
45970393|NCT04589143|Drug|Placebos|Oral tablets of placebos at a dose of 25-50 mg/d for 8 weeks
45669308|NCT04388852|Biological|Ipilimumab|Given IV
45669309|NCT04388852|Drug|Valemetostat|Given PO
45827708|NCT00003647|Drug|allovectin-7|
45970394|NCT04589182|Device|MHSL- SleepBand|The MHSL-SleepBand (sleep headband) is easy to apply and only involves attachment of sticky electrodes on different locations on the face/behind ear to be able to measure EEG (electroencephalogram), EOG (electrooculogram) and EMG (electromyogram). Brief tones at a low volume (around 60 dB, comparable to conversation) will be applied, when slow waves are present in the course of the sleep period and other criteria are fulfilled. Auditory stimulation will start with a specific volume that has been adjusted to the individual hearing capacity (usually between 45-65 dB; maximum 80 dB). The stimulation is performed in a way that the general structure of sleep (e.g. duration, sleep cycling, etc.) is unchanged.
45970395|NCT04589182|Device|Sham|Playing no tones during non- Rapid Eye Movement (NREM) sleep but wearing the device and recording the biosignals over a period of 3 nights, every night.
45970396|NCT00249639|Behavioral|Contingency management|Rewards valued $1-$100
45827709|NCT00003647|Drug|allovectin-7/dacarbazine|
45970397|NCT04588987|Biological|PD-1|Neoadjuvant PD-1 and Apatinib for rHGG. Adjuvant PD-1 and Apatinib for rHGG
45827710|NCT00003647|Drug|dacarbazine|
45827711|NCT05895695|Procedure|levator muscle resection|resection of levator muscle in congenital unilateral ptosis
45827712|NCT05895695|Procedure|levator muscle plication|plication of levator muscle in congenital unilateral ptosis
45970398|NCT04589104|Behavioral|Expressive writing|"The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows:~Week 1: Writing to expressive difficult emotions~Week 2: Writing to release & integrate difficult emotions~Week 3: Writing to nurture gratitude~Week 4: Writing to enhance strengths & resources~Week 5: Writing to cultivate positive meaning & savor goodness~Week 6: Writing to invite insight, perspective, & growth"
45970399|NCT04588558|Device|Flywheel exercise|Flywheel training is a strength training modality that offers the possibility of performing exercises with eccentric overload and variable resistance as compared to conventional gravity-based resistance training. Flywheel exercise applied three days a week for 8 weeks
45669310|NCT04388839|Drug|Vincristine|IV push over 1 minute with dosing ranging from 0.24mg up to 1.5mg
45669311|NCT04388839|Drug|Cyclophosphamide|IV over 60 minutes with dosing ranging from 220mg to 1200mg
45669312|NCT04388839|Drug|Vinorelbine|IV push over 6-10 minutes with dosing ranging from 4mg-25mg
45669313|NCT04388839|Drug|Actinomycin D|Actinomycin D should not be given with radiation. Will be administered through IV over 3-5 minutes with dosing ranging from 0.025mg-0.045mg
45669314|NCT04388839|Drug|Cyclophosphamide Pill|Based on Body Surface Area (BSA) round to nearest 25mg
45669315|NCT04373720|Procedure|Magnetic Resonance Elastography|Undergo MRE
45669316|NCT04373720|Procedure|Magnetic Resonance Imaging|Undergo standard of care MRI
45970400|NCT04588558|Other|Home exercise|The active ROM exercise was performed via knee in extension to full-flexion, then knee in flexion to full-extension exercises, repeated 10 times. The strengthening exercises consisted of quadriceps strengthening by holding maximal isometric contractions for 10 s and performing 10 repetitions. Stretching targeted the gastrocnemius- soleus and hamstring muscle and was performed by asking the patient to stretch the muscle for 30 s and to complete three repetitions for each muscle group.
46081182|NCT05184478|Drug|Medicinal cannabis (MC): THC 10mg/mL : CBD 15mg/mL, manufactured by Cann Group Ltd.|"Each 1mL contains 10mg tetrahydrocannabinol (THC),15 mg cannabidiol (CBD), and 0.004mL peppermint oil in medium chain triglyceride (MCT) oil.~All participants will start at 0.1 mL per day, and will gradually increase in 0.1mL increments until day 21 when a dose of 0.5mL (participants weighing <50kg) or 1mL (participants weighing ≥50kg) is reached. At day 29, an assessment of treatment response will be conducted. Participants who meet criteria for a treatment response will remain on the same dose for the remainder of the treatment period. Participants who do not meet criteria for a treatment response will gradually increase the dose in 0.1mL increments until day 49 when a daily dose of 1mL (participants weighing <50kg) or 2mL (participants ≥50kg) is reached."
45669317|NCT04371263|Other|Emotional Change of Nursing Manpower in Emergency and Critical Unit After Keen Election And What's The Influence of Emotional Change|use the emotion regulation questionnaire (ERQ) to realize the influence in duty work
45669318|NCT04357951|Drug|d-cycloserine|D-cycloserine is an FDA-approved antibiotic medication that has been shown to enhance extinction learning in several studies. It will be paired with 4 sessions of behavior therapy.
45669319|NCT04357951|Drug|Placebo pill|A pill placebo serves as an active comparator. It will be paired with 4 sessions of behavior therapy.
45669320|NCT04357951|Behavioral|Behavior Therapy|All participants will receive 4 sessions of behavior therapy for tics (e.g., habit reversal training, comprehensive behavioral intervention for tics).
45669321|NCT04323293|Other|Cold Water Bath|immersion of the hand for 2-5min in 2-10°C water
45669322|NCT04323293|Other|Neutral Water Bath|immersion of the hand for 2-5min in 32±2°C water
45669323|NCT04304872|Behavioral|Gamification|"Participants sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. At 6 weeks, we have a follow up call if the participant is stuck in a lower level and restart them back at the middle level."
46081183|NCT05184478|Drug|Placebo|"The placebo contains MCT oil and peppermint flavoring solution, which is indistinguishable from the active medication in appearance, smell and taste.~The dose will be matched for volume to the medicinal cannabis, and will follow the same dosing schedule as the medicinal cannabis treatment phase."
46081184|NCT05183360|Drug|BI 706321|BI 706321
46081185|NCT05183360|Drug|Placebo|Placebo
45669324|NCT04304872|Behavioral|Loss-Framed Financial Incentives|Participants are informed that each week $14 is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that $2 was taken away.
45669325|NCT04285229|Drug|Ixekizumab|Administered SC
45669326|NCT04285229|Drug|Placebo|Administered SC
45669327|NCT04282668|Drug|TAS1440|Form: Capsule or Tablet Route of Administration: Oral
45827713|NCT05895682|Device|mobiCARE +Pulse (MP100W)|Volunteers were monitored using end-tidal carbon dioxide partial pressure and fraction of inspired oxygen. Each volunteer was placed in a semi-Fowler's position and connected to a breathing circuit to administer the nitrogen-air-carbon dioxide mixtures. A nose clip was applied to prevent breathing of room air. For frequent blood sampling, an arterial cannula was placed in the radial artery of each volunteer. Pulse oximeter probes were simultaneously attached to each volunteer's fingers. Each volunteer was exposed to various levels of induced hypoxia from 70~100% of SaO2. Each plateau of oxygen saturation was maintained for at least 30 s until stabilization, after which 1 ml of arterial blood was drawn into a heparinized syringe. The study period consisted of two rounds of hypoxia, and the volunteers were maintained on room air between each round. SaO2 measurements using a CO-oximeter were used as a reference for the SpO2 accuracy.
45827714|NCT05895656|Other|7 Tesla MRI|Performing an additional 7 Tesla MRI examination as part of the initial treatment pathway.
45827715|NCT05895630|Behavioral|Interactive physical exercise|Interactive remote sessions of physical exercise in groups of 10 patients. The sessions are categorized by level 1, 2 or 3 and the allocation to this level is decided according to a decision tree taking into account the mobility profile (balance and cardiomuscular health). The intervention will last 12 weeks. The sessions will be delivered 3 times per week (Monday, Wednesday, Friday) offering a total of approximately 180 min/week.
45455813|NCT05645796|Other|Adopted contrast media amount by using different approaches|Using different contrast media approaches recommended by literature to explore the impact on the contrast enhancement in chest CT
45455814|NCT05643118|Genetic|OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)|Clear colorless solution dissolved in 1X PBS and injected intravitreally
45455815|NCT05642598|Behavioral|Pivot for Vape|"Pivot for Vape vaping cessation smartphone app and program"
45455816|NCT05640414|Other|Weekly Family Food Packages|Families receive weekly family food packages for 6 months
45669328|NCT04282668|Drug|TAS1440 + ATRA|Form: Capsule or Tablet Route of Administration: Oral
45669329|NCT04279028|Behavioral|Adapted CBT|"ACBT is derived from traditional CBT principles, but eliminates the text-heavy requirements. Traditional CBT incorporates the use of complex worksheets and a lengthy workbook, whereas ACBT replaces these skill learning activities with simpler, straightforward exercises that are practiced in session along with the therapist. This real world practice eliminates the need for reading and writing as part of CBT while simultaneously recapitulating how the patient would actually implement CBT procedures. In session exercises will mirror that of standard CBT practices. For example, they could include lessons in goal setting, distinguishing situations, moods, and thoughts, and experiments to test underlying assumptions. Participants will be assigned paper-free homework assignments."
45669330|NCT04279028|Behavioral|Standard CBT|CBT involves the therapist and client working to identify and change negative beliefs and thoughts, replacing them with more accurate and balanced thoughts. CBT for Depression will be conducted according to standard manuals and incorporate the use of a common workbook used within CBT sessions. As per standard practice, participants will be assigned worksheets from their workbook used both in session and as homework assignments.
45669331|NCT04263454|Drug|Endotoxin, Escherichia Coli|Endotoxin is a purified lipopolysaccharide prepared from E. coli O:113 and vialed under good manufacturing practice guidelines.
45669332|NCT04263454|Procedure|Magnetic Resonance Spectroscopy|MRI is a non-invasive imaging technique and does not utilize ionizing radiation.
45827716|NCT05895630|Behavioral|Video physical exercise|Individual remote sessions of physical exercise based on pre-recorded videos. The video sessions are categorized by level 1, 2 or 3 and the allocation to this level is decided according to a decision tree taking into account the mobility profile (balance and cardiomuscular health). The videos will be delivered 3 times per week (Monday, Wednesday, Friday) offering a total of approximately 180 min/week.
45970401|NCT04588558|Device|Electrotherapy group|"The participants in the electrotherapy group received TENS (Intellect; Chattanooga Group, Hixson, TN), therapeutic ultrasound (Intellect 340 Combo) and exercise. TENS was applied via four electrodes around the knee joint: two on the medial and two on the lateral aspect on either side of the joint line for approximately 20 min. For pain relief, the devices were set to a continuous mode (110 Hz, 50 μ). Electrical pulses were asymmetric and biphasic.~Therapeutic pulsed ultrasound therapy was administered using a 1-MHz frequency, 0.8 W/cm power ultrasound device with a sound-head area of 5 cm2 and effective radiating area of 3.5-5 cm2 . Ultrasound was applied to the medial and lateral parts of the knee in circular movements for a duration of 5 min with the patient in a supine position.~All participants received the same standardized exercise program. The exercises included aerobic, active ROM, strength, and stretching exercises"
45827717|NCT05895604|Behavioral|Nurse-Family Partnership|Nurse-Family Partnership is a prenatal and infancy home visiting program providing regular visits to first-time mothers until the child is two years old
45669333|NCT04259060|Drug|Hydroxocobalamin with Butyrate|"In phase 1, patients will take hydroxocobalamin at 1g daily for four weeks. This will be in the form of 1 500mg capsule twice a day. Butyrate will be 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, the dose of hydroxocobalamin will be increased to 2g daily (1g twice a day) for four weeks pending FDA approval. Butyrate will remain at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day. Patients will undergo flexible sigmoidoscopy at baseline and at week four in phase 2."
45669334|NCT04259060|Drug|Placebo with Butyrate|"In phase 1, patients will take 1 placebo capsule twice a day. Butyrate will be taken at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, patients will take 2 placebo capsules twice a day, along with butyrate at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day."
45827718|NCT05895591|Other|Anti-aging cosmetic care product|"frequency of application: Once a day (in the morning)~modalities of application: Apply the cream on face (according to normal conditions of use) and on treated forearm, massage until complete penetration~area: The whole face, neck, neckline and one randomized forearm (external photo-exposed area) the other forearm is untreated~duration of investigational product application: 56 days (a window of + 72 hours is allowed)~quantity: 2 pressures of product for the whole face, neck and neckline and 1 pressure of product for the treated forearm"
45827719|NCT05895565|Drug|PMG1015|Strength: 100 mg/2 mL/vial. Dosage and Administration: Intravenous infusion of PMG1015 at 15 mg/kg, 30 mg/kg and 40 mg/kg for 30 min (±5 min), once every 4 weeks, for 3 doses.
45827720|NCT05895565|Drug|PMG1015 placebo|The placebo injection of PMG1015 contains the same excipients as PMG1015 Injection, only without the active substance. Strength: 2 mL/vial. Dosage and Administration: A single dose of placebo. Intravenous infusion for 30 min (±5 min), once every 4 weeks, for 3 doses.
45970402|NCT04588831|Device|Mouthguard|Protective device for orofacial complex for patients playing contact sports
45970403|NCT00567736|Drug|Disci/Rhus toxicodendron comp.®|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites verum group 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
45970404|NCT00567736|Drug|placebo solution|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
45970405|NCT00253539|Drug|arzoxifene hydrochloride|Given orally
45970406|NCT00253539|Drug|tamoxifen citrate|Given orally
46081186|NCT05180981|Device|Transcutaneous vagal nerve stimulation|Noninvasive stimulation vs sham stimulation will be delivered via an auricular device.
45827721|NCT05895552|Drug|RTA 901|RTA 901 capsules will be administered once daily during a fasted state in either Dose 1 or Dose 2.
45827722|NCT05895552|Drug|Placebo|Matching placebo capsules will be administered once daily during a fasted state.
45455817|NCT05640414|Behavioral|Family Health Group Sessions|Families with children aged 6-17 years who have overweight or obesity attend 6 monthly group sessions with cooking demonstrations
45827723|NCT05895539|Other|An automated patient-reported outcome data collection and adverse event surveillance tool|Patients received a short prompt to provide information on treatment satisfaction and side effects
45827724|NCT05895526|Procedure|Self etch dentin adhesive, Fluoride varnish|After an informed consent, in one group 5% sodium fluoride varnish will be applied in affected area, while the other group will receive self etch dentin adhesive.
45827725|NCT05895513|Drug|Pimavanserin 34 mg|5HT-2a receptor antagonist
46081187|NCT05180981|Behavioral|Breathing task|Participants will be asked to breathe in specific patterns.
46081188|NCT05177848|Other|All nicotine/ tobacco products at market price|Nicotine/tobacco products available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
45455818|NCT05640297|Behavioral|KMC with Massage therapy|investigator will provide tactile and kinesthetic massage
45827726|NCT05895513|Drug|Placebo|Inactive Comparator
45970407|NCT00253539|Other|placebo|Given orally
45970408|NCT04180163|Drug|Lanadelumab|Lanadelumab solution, SC
45970409|NCT04588636|Behavioral|behavioral and self-care therapy|It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses behavioral and self-care techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state
45970410|NCT04588636|Device|rigid occlusal splint (ROS)|Occlusal splint formed in a vacuum from rigid individual sheets of 2 mm thick polyethylene terephthalate (Biolon, Dreve, Unna, Germany).
45970411|NCT04588636|Device|soft occlusal splint (SOS)|Occlusal splint formed in a vacuum from 3 mm thick individual soft sheets of ethyl vinyl acetate (Drufosoft, Dreve, Unna, Germany).
45970412|NCT04588636|Device|non-occlusive splint (NOS)|non-occlusive splint formed under vacuum from individual sheets of rigid polyethylene terephthalate 2 mm thick (Biolon, Dreve, Unna, Germany), from which the occlusal surfaces were cut and incisal edges, allowing the usual occlusal contact of each subject.
45669335|NCT04251195|Behavioral|Cognitive Intervention|Participants will undergo 15 minutes of a cognitively challenging activity in the Virtual Reality environment. (More details about each condition will be added after study completion to protect the blinding of our participants).
45669336|NCT04251195|Behavioral|Active Control Intervention|Participants will undergo 15 minutes of a cognitively challenging activity in the Virtual Reality environment. (More details about each condition will be added after study completion to protect the blinding of our participants).
45970413|NCT04588675|Diagnostic Test|MRI|the patients will underwent dobutamine stress cardiac MRI
45970414|NCT04720365|Device|play-based rehabilitaion|usual re-education treatment by their physiotherapist
45970415|NCT00567775|Drug|human insulin|
45669337|NCT04219904|Other|Fludeoxyglucose F-18|Given IV
45455819|NCT05635877|Drug|Esmolol|The treatment group was given Esmolol 0.5mg/kg load and 10μg /kg/min continuous pump
45669338|NCT04219904|Drug|Gadobutrol|Given IV
45669339|NCT04219904|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
45669340|NCT04219904|Procedure|Positron Emission Tomography|Undergo PET/MRI
45669341|NCT04218240|Drug|Pregabalin 200 MG capsules|oral pregabalin 200 mg capsules given with a taper on day 5
45669342|NCT04218240|Drug|Placebo oral tablet|oral Placebo
45669343|NCT04218240|Drug|Lofexidine 0.18Mg Tab|lofexidine 0.18 tab given with a taper starting on day 5
45669344|NCT04212793|Drug|Bevacizumab-IRDye800CW|Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to endoscopic transsphenoidal surgery
45669345|NCT04212793|Device|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the Surgvision explorer endoscope. During surgery, three imaging moments are defined in which the fluorescence molecular endoscopy system will detect the fluorescent signal
45669346|NCT04212260|Behavioral|Oropharyngeal exercises|Oro-pharyngeal exercises that improve oro-pharyngeal and tongue strength. Instructions will be delivered via a tablet-based app.
45827727|NCT05895474|Device|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
45827728|NCT05895461|Behavioral|BWLI-College|"Behavioral modifications are based on empirically-supported principles for weight loss.~Diet recommendations follow a small change approach in which participants will make a series of small, self-selected dietary changes each day (~100-200 calories) that they build on over the course of the intervention.~Physical activity recommendations are to achieve 150-250 weekly minutes of moderate-to-vigorous physical activity with specific goals and rate of progression that are individualized to each participant."
45970416|NCT00567775|Drug|inhaled human insulin|
45970417|NCT00567814|Drug|Metyrapone|Twice daily
45970418|NCT00567814|Drug|Oxazepam|Twice Daily
45970419|NCT00567814|Drug|Placebo|Twice daily
45970420|NCT04588753|Other|active isolated stretch|"Active Isolated Stretch (AIS);~The shortened hamstring muscle will be isolated.~The hamstring will be stretched.~This Stretches will be Repeated eight to 10 times.~Stretch will be hold for no more than two seconds.~Exhale on the stretch; inhale on the release. Other amputees training exercises;~weight-shifting~Dynamic balancing activities~Stool stepping~Braiding~Gait exercises~Climbing/descending the stairs"
45970421|NCT04588753|Other|Post Facilitation Stretch|"Participants of this group will receive Post Facilitation Stretch (PFS);~The shortened hamstring muscle will be placed between a fully stretched and a fully relaxed state.~The patient will be asked to contract the hamstring using a maximum degree of effort for 5-10 seconds while the therapist will resists thepatients force.~The patient will be then asked to relax and release the effort, whereas the therapist will apply a rapid stretch to a new barrier and is held for 10 seconds.~The patient relaxes for approximately 20 seconds and the procedure will be repeated to five times (8) (18).~2. Other amputees training exercises;~weight-shifting~Dynamic balancing activities~Stool stepping~Braiding~Gait exercises~Climbing/descending the stairs"
45970422|NCT04588090|Procedure|The concurrent 3 weeks TP regimen|paclitaxel + cisplatin regimen (TP-TAX: 150mg/m^2, DDP: 70mg/m^2 (35mg/m^2, d1, d2), 1 time/3 weeks) chemotherapy for 2 cycles.
45970423|NCT04588090|Procedure|The concurrent weekly TP regimen|paclitaxel + cisplatin regimen (TP regimen: TAX 50mg/m^2, DDP: 25mg/m^2) 6 cycles of chemotherapy
45827729|NCT05895448|Drug|velpatasvir and sofosbuvir once daily for 12 weeks (brand or branded generic) .|Directly active antiviral therapy (velpatasvir 100 mg+sofobuvir 400 mg) once daily
45827730|NCT05895435|Device|radiofrequancy|"Power of device: 150 W~Duration of the session: 40 minutes~Frequency: 2 sessions per week for 8 week.~Heating temperature: According to patient tolerance."
45827731|NCT05895435|Other|aerobic exercise|The program include five minutes for warming-up in the form of range of motion and stretching exercises, thirty minutes of walking on treadmill with high speed (60-70% of maximum heart rate) and five minutes of cooling down (on treadmill with low speed and without inclination
45827732|NCT05895370|Biological|HPV-T|Participant will receive HPV-T iv on day 0. One time of cell infusion constitute a cycle, each participant receives up to four cycles of treatment
45827733|NCT05895370|Drug|Interleukin-2|500,000IU/m^2 SC, after each cell infusion, IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.
45827734|NCT05895305|Combination Product|Paclitaxel-Coated Pulmonary Balloon Catheter|Subjects with benign airway stenosis will be treated by Airiver pulmonary DCB at index procedure
45970424|NCT04588090|Radiation|External radiation plus intraluminal after-loading irradiation|External radiotherapy of linear accelerator, CT simulation positioning, and intensity modulated radiotherapy will be applied for external radiotherapy. The prescribed dose is 95% PTV 45-50.8Gy/25-28 times (1.8Gy/time), the maximum and minimum in the target area do not exceed ±10% of the prescribed dose, and the increase in enlarged lymph nodes will reach 50-66GY. At the same time, the total dose of 192Ir high-dose rate intraluminal after-loading irradiation is 30-36Gy (EQD2: 40-48GY), and external pelvic irradiation is not available on the day of intraluminal after-loading irradiation.
45669347|NCT04212260|Behavioral|Sham control|Simple mouth movements that have no impact of oro-pharyngeal strength. Instructions will be delivered via a tablet-based app.
45827735|NCT05895279|Other|Media Intervention|Watch MiCaP Research Digest video
45827736|NCT05895279|Other|Media Intervention|Watch alternate video
45827737|NCT05895279|Other|Survey Administration|Complete survey
45669348|NCT04187547|Drug|Tricaprilin|"Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of AC-SD-03 contains 20 g of the active ingredients (tricaprilin)"
45669349|NCT04187547|Drug|Placebo|Matching placebo to AC-SD-03 will be mixed with 240 mL water and shaken until fully dispersed.
45669350|NCT04175678|Other|Diet|Participants will receive delivered meals every 4 weeks for three months of a variety of foods for breakfast, lunch, dinner, two snacks, and an additional snack or dessert for each day.
45827738|NCT05895240|Drug|Ulinastatin|Nine MiU Ulinastatin in three divided doses 8 hourly for 3-5 days
45669351|NCT04175678|Other|Exercise|Training will be supervised, individualized, and periodized, incorporating 3 sessions per week, 45-60 min per session for 36 sessions.
45669352|NCT04175678|Other|Standard care|Observational
45669353|NCT04159662|Behavioral|Cognitive Intervention|In each of the 6 visits, participants will be completing some computerized tasks for a period of about 40 minutes. At the end of each session, there will be 10-15 minutes of bridging discussion between the research therapist and the participants. (More details about each condition will be added after study completion to protect the blinding of our participants) .
45827739|NCT05895227|Procedure|Oocyte retrieval|
45827740|NCT05895214|Procedure|oncological relevance of the mesopancreas|Invasion status Invasion depth in mm Depth of mesopancreas in mm Treitz fascia intact (histopathological examination)
45970425|NCT00253578|Drug|sorafenib tosylate|Given PO
45970426|NCT00253578|Other|laboratory biomarker analysis|Correlative studies
45970427|NCT04588285|Drug|Ambroxol|Oral ambroxol medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
45970428|NCT04588285|Drug|Placebo|Oral placebo medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
45827741|NCT05895201|Drug|Sitagliptin|600 or 400 (or MTD) mg PO every 12 hours on days -1 to +14 depending on dose level assignment.
45827742|NCT05895201|Drug|Bortezomib|1.3 or 1.0 mg/m2 (or MTD) IV push 6 hours after graft infusion completion (day 0), and 72 hours thereafter depending on dose level assignment.
45827743|NCT05895201|Drug|Cyclophosphamide|50 mg/kg IV over 1 hour on days +3 and +4
45827744|NCT05895188|Device|Virtual Reality Glasses|From the beginning to the end of the procedure, women will watch the selected nature video.
45970429|NCT04153565|Drug|Pembrolizumab|Participants will receive Pembrolizumab 200 mg IV every 3 weeks (Q3W) until disease progression, or until participant has received 35 administrations of Pembrolizumab (approximately 2 years).
45970430|NCT04153565|Drug|Pemetrexed|Participants will receive Pemetrexed 500 mg/m^2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks
45970431|NCT04153565|Drug|Cisplatin|Participants will receive Cisplatin 75 mg/m^2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks
45827745|NCT05895175|Other|Questionnaires|Questionnaires
45970432|NCT04588324|Drug|SHR2150|Patients will receive escalating doses of SHR-2150 (starting dose 2 mg) in 3-week treatment cycles.
45970433|NCT04588324|Drug|Anti-Cancer Agent|The previously resistant first-line cytotoxic regimens, anti-PD-1 antibody and/or anti-CD47 antibody will be administered intravenously Q3W.
45827746|NCT05895149|Other|Flying buttress technique|With the volunteer in a supine position, the researcher who applied the technique positioned himself standing at the head of the massage table, supporting the patient's head. He contacted the occipital region, near the occipital-mastoid suture, with the thenar and hypothenar region of his right hand. He contacted the mastoid process of the contralateral temporal bone with the thenar and hypothenar region of his left hand. The forearms were positioned in a straight line. After a slight initial compression, the researcher applied a rhythmic pumping motion with both upper limbs in a convergent direction. The pressure applied was due to the rhythmic movement of the researcher's body. The technique was performed bilaterally and each one lasted for 2 minutes
45827747|NCT05895149|Other|Placebo technique|With the volunteer in a supine position, the researcher placed the palms of their hands on the patient's shoulders. The palm of the hand rested on the acromioclavicular joint with the rest of the hand relaxed. The placebo technique was performed for 4 minutes.
45827748|NCT05895136|Drug|Human albumin|"Human albumin solution is made from pooled human plasma. It is widely used as a plasma-expander in several disease conditions, such as liver cirrhosis and critically ill patients.~ATC-Code: B05AA01"
45827749|NCT05895136|Drug|Enoxaparin|Enoxaparin is a drug that belongs to the group of anticoagulants. It exerts its antithrombotic activity by binding to antithrombin III (AT III). ATC-Code: B01AB05
45970434|NCT04588324|Drug|SHR2150|Patients will receive SHR-2150 at RP2D in 3-week treatment cycles.
45827750|NCT05895136|Drug|Standard medical treatment|SMT will be considered non-study medication and is not specified in the protocol.
45827751|NCT05895123|Drug|Rosuvastatin 20 mg ,40 mg|patients will receive one tablet rosuvastatin 20-40 mg every night
45669354|NCT04159662|Behavioral|Active Control Intervention|In each of the 6 visits, participants will be completing some computerized tasks for a period of about 40 minutes. At the end of each session, there will be 10-15 minutes of bridging discussion between the research therapist and the participants. (More details about each condition will be added after study completion to protect the blinding of our participants) .
45827752|NCT05895123|Drug|Atorvastatin 40mg,80mg|patients will receive one tablet Atorvastatin 20-40 mg every night
45827753|NCT05895110|Biological|Recombinant Novel Coronavirus vaccine (CHO Cells)|The experimental vaccine dose used in this study is 25μg/0.5mL. All subjects recruited should have received two doses of novel Coronavirus inactivated vaccine on the market for 6-9 months, and all eligible subjects will receive one dose of recombinant Novel Coronavirus vaccine (CHO cells).
45970435|NCT04587895|Behavioral|VITAAL Exergame|12 weeks training with the VITAAL Exergame. The VITAAL exergame is an individualized multicomponent exergame training based mostly on the prevention and slowing of physical and cognitive decline and its consequences. It mainly consists of three (four with UI) components; strength training, balance training, cognitive training and pelvic floor muscle training (PFMT) when suffering from UI.
45669355|NCT04155463|Other|Organic Diet|Participants receive one week of organic food. Organic food is certified through the USDA's National Organic Program as produced without the use of synthetic pesticides, including glyphosate.
45669356|NCT04155463|Other|Conventional Diet|Participants receive one week of conventionally grown (non-organic) food.
45669357|NCT04129125|Device|Zoom Reperfusion System|Thrombectomy
45827754|NCT05895097|Device|Left bundle branch pacemaker|Left bundle branch pacing (LBBP) will be the pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Final lead position will be confirmed according to ECG parameters. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory.
45827755|NCT05895097|Device|Conventional pacing|Right ventricular pacing in patients with LVEF ≥ 40% and cardiac resynchronization therapy in patients with LVEF < 40 %
45970436|NCT04587895|Behavioral|Conventional Training UI|12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The PFM training booklet is based on exercises that showed a reduction of incontinence in older adults while performing group pelvic floor muscle training (PFMT) and mobility exercises.
45827756|NCT05895084|Behavioral|Group Yoga|Yoga is delivered as described in an earlier section in a group format. Classes are an hour in duration and occur once per week for 8 weeks, and they are led by an adaptive yoga specialist.
45669358|NCT04117347|Device|Light therapy A via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
45827757|NCT05895071|Drug|5%potassium hydroxide|. In group-A 30 patients were given topical 5% potassium hydroxide solution on affected area once at night for upto 4 weeks
45827758|NCT05895071|Drug|Liquid nitrogen|in group-B 30 patients treated with cotton bud method of cryotherapy with liquid nitrogen once every two weeks. Patients were reassessed at every two weeks. The treatment carried out upto 12 weeks or until complete recovery from warts.
45970437|NCT04587895|Behavioral|Conventional Training MI|"12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The exercises are based on recommendations from the Beratungsstelle für Unfallverhütung (bfu)."
45970438|NCT00249678|Behavioral|Behavior Therapy|
45970439|NCT04588168|Drug|Chemotherapy|Patients with muscle invasive bladder cancer will receive modified gemcitabine-cisplatin neoadjuvant chemotherapy prior to radical cystectomy for a period of two months (three 21 day cycles) as part of standard clinical routine.
45827759|NCT05895058|Device|Gastric bypass surgery with 2D 4K laparoscopic imaging|All patients involved in the investigation will receive a laparoscopic Roux-en-Y gastric bypass (LRYGB). The interventions are performed by three defined surgeons.
45970440|NCT04588168|Diagnostic Test|Immediate Multiparametric MRI|Within 24 hours after the use of cisplatin during the first course of modified GC neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive an immediate mpMRI scan.
45970441|NCT04588168|Procedure|Cystectomy and Lymphadenectomy|The patient with muscle invasive bladder cancer will undergo radical cystectomy and pelvic lymph node dissection followed by a urinary tract reconstruction.
45827760|NCT05895058|Device|Gastric bypass surgery with 3D HD laparoscopic imaging|All patients involved in the investigation will receive a laparoscopic Roux-en-Y gastric bypass (LRYGB). The interventions are performed by three defined surgeons.
45970442|NCT04588168|Diagnostic Test|conventional Multiparametric MRI|After two and three course of neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive a conventional mpMRI scan.
45970443|NCT04588168|Diagnostic Test|Baseline Multiparametric MRI|Patient considered muscle invasive bladder cancer will receive a baseline mpMRI scan within one week before neoadjuvant chemotherapy.
45970444|NCT04146545|Behavioral|"Community Rx-Dementia CRxD Caregiver Resources"|A tailored list of resources addressing health-related social needs (HRSN) for caregivers and access to an online community resource finder.
45669359|NCT04117347|Device|Light therapy B via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
45669360|NCT04117347|Device|Light therapy C via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
45827761|NCT05895045|Behavioral|Yoga|Restorative Vinyasa Yoga
45970445|NCT04587817|Combination Product|camrelizumab+hyperfractionated radiotherapy|Immunotherapy combined with hyperfractionated radiotherapy
45970446|NCT00253617|Drug|porfimer sodium|
45970447|NCT00253617|Procedure|adjuvant therapy|
45669361|NCT04097145|Device|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL System in patients on optimal medical therapy
45669362|NCT04097145|Drug|Optimal Medical Therapy|Optimal Medical Therapy alone in patients with tricuspid regurgitation
45669363|NCT04097145|Device|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL System in conjunction with OMT
45827762|NCT05895032|Other|Exercise|12-week exercise intervention
45827763|NCT05895032|Other|Usual Care|usual care
45827764|NCT05895006|Device|alpha-frequency tACS|The investigators will apply a 2 mA sinusoidal current oscillating at individual participants' baseline peak alpha frequencies (PAF; 7-13 Hz), which will be determined by a 3-min resting state EEG recording during the setup.
45827765|NCT05895006|Device|Random noise stimulation|The investigators will apply a 2 mA sinusoid current oscillating at random frequency (1-200 Hz).
45827766|NCT05894993|Device|transient elastograghy|is a non-invasive method proposed for the assessment of hepatic fibrosis in patients with chronic liver disease by measuring liver stiffness. It can be easily performed at the bedside or in the outpatients clinic with immediate results and good reproducibility.
45827767|NCT05894980|Device|active tDCS stimulating left DLPFC|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the left DLPFC
45970448|NCT00253617|Procedure|laser therapy|
45970449|NCT00253617|Procedure|photodynamic therapy|
45970450|NCT00253617|Procedure|phototherapy|
45970451|NCT04587778|Drug|Ketamine Hydrochloride|intravenous infusion
45669364|NCT04084951|Biological|SQZ-PBMC-HPV|antigen presenting cell therapy; therapeutic vaccine consisting of peripheral blood mononuclear cells (PBMCs) manufactured with immunogenic epitopes of HPV16
45827768|NCT05894980|Device|active tDCS stimulating right OFC|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the right OFC
45669365|NCT04084951|Drug|Atezolizumab|programmed cell death ligand 1 (PD-L1) blocking antibody
45669366|NCT04084951|Drug|Ipilimumab|cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody
45827769|NCT05894980|Device|sham tDCS|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 0 mA) applied to the left DLPFC
45827770|NCT05894967|Behavioral|C1 - Standard Perceptual Learning (SPL)|Each trial starts with a fixation point (500ms) after which a Gabor (1° radius, at cut-off SF of 25% accuracy, estimated from Pre-Test CSF, at either 45° or 135°) appears for 128ms. The task is to indicate whether the Gabor was tilted left or right. Gabor contrast will be controlled by a 3/1 staircase (converging on approximately ~80% contrast threshold) across all training sessions.
46081189|NCT05177848|Other|Nicotine vaping products at 1/2 market price|Availability of nicotine vaping products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
45827771|NCT05894967|Behavioral|C2 - Long Training (LT)|Will be the same as the SPL with the exception that each session in LT will be twice as long as in SPL.
45827772|NCT05894967|Behavioral|C3 - Short Staircases (SS)|"Will be largely the same as SPL with the only difference being a change to the adaptive procedure. SS will use so-called short-staircases, which are initialized at 60% contrast with steps of .05 log units and employs a 3/1 staircase that after every 40 trials is reset (the short in short-staircases) back to 60% contrast."
45827773|NCT05894967|Behavioral|C4 - Mixed Difficulty (MD)|This condition will be identical to SPL with the exception that two staircases - one a 2/1 staircase producing difficulties centered around 60-70% accuracy, the other a 4/1 staircase producing difficulties centered around 85-95% accuracy - will be utilized to control the stimuli.
45827774|NCT05894967|Behavioral|C5 - Noise Training (NT)|The NT condition will be the same as SPL with the exception that contrast thresholds will be estimated in 5-different levels of external noise (10%, 15%, 20%, 25%, 30%).
45970452|NCT04587778|Drug|Esketamine|intravenous infusion
45669367|NCT04084951|Drug|Nivolumab|programmed cell death 1 (PD-1) blocking antibody
45669368|NCT04083898|Biological|Isatuximab|Isatuximab will be administered on a 28-day cycle
45669369|NCT04083898|Drug|Bendamustine|Bendamustine will be administered on a 28-day cycle as follows
45669370|NCT04083898|Drug|Prednisone|Prednisone will be administered on a 28-day cycle as follows
45669371|NCT04082637|Behavioral|Mindful Awareness in Body-oriented Therapy|A mind-body intervention designed to teach interoceptive awareness skills for emotion regulation and self-care. Delivered individually in 75 minute sessions once a week for 8 weeks.
45669372|NCT04058665|Device|Floseal|Hemostatic agent
45970453|NCT04587778|Drug|Placebo|intravenous infusion
45970454|NCT04139564|Device|EaseVRx headset|EaseVRx is a virtual reality therapy intended to treat chronic pain
45970455|NCT04139564|Device|Active control VR sham program|VR, 2d visual wildlife scenes similar to some EaseVRx content
45970456|NCT04587505|Procedure|Epidural anesthesia with light general anesthesia|Epidural anaesthesia: mixture of ropivacaine 6.5 mg/ ml and fentanyl 8.3 μg/ml. Light general anesthesia: isoflurane in mixture of 50/50 of nitrous oxide and oxygen to achieve Minimum alveolar concentration between 0.6 and 0.8.
45970457|NCT04587505|Drug|Postoperative epidural analgesia|Before the end of operation was given 4 ml of the mixture of ropivacaine 4.4 mg/ml and morphine 0.8mg/ ml. Epidural analgesia was continued for next 24 hours with a mixture of ropivacaine 2.2 mg/ml and morphine 0.4 mg/ml.
45970458|NCT04587505|Procedure|General anesthesia|Maintaining general anesthesia: nitrous oxide and oxygen in mixture 50/50 and isoflurane to achieve minimum alveolar concentration between 0.8 and 1. Fentanyl loading dose: 6-8 μg/kg. Additional fentanyl doses were given incrementally.
46081190|NCT05177848|Other|Nicotine vaping products at 2x market price|Availability of nicotine vaping products in the Experimental Tobacco Marketplace at 2x market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
45827775|NCT05894967|Behavioral|C6 - Training with Flankers (TWF)|TWF will be reasonably different from the standard SPL task. Here, on 50% of trials a target Gabor will be presented at either 45° or 135° (as in SPL) and will be flanked by two collinear Gabors. On the remaining 50% of trials, flankers will be present without a target. TWF is thus a yes/no detection task, which is necessary since the collinear flankers fully indicate the target orientation. In different 20-trial mini-blocks the flankers will appear either lambda, 1.5 lambda, or 2 lambda from the target (i.e., closer or further from the target) and target contrast will be controlled by a 3/1 staircase separately for each spacing.
45970459|NCT04587505|Drug|Continuous intravenous analgesia|Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
45970460|NCT00249717|Behavioral|Contingency management|Receive rewards (prizes) abstinence and attendance
45970461|NCT04587544|Behavioral|Cold Water Immersion|The participants maintained their daily activities during the intervention. When daily activity ended, the intervention was begun. CWI therapy by immersed the whole part of inflamed target joints in the water at 20-30C for 20 minutes/day. The intervention was continued for four weeks. The researchers work together with the nurses of community health services to give the intervention.
45970462|NCT04128683|Drug|amisulpride|Dopamine D2 antagonist to test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
45970463|NCT04128683|Drug|bromocriptine|Dopamine D2 receptor agonist test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
45669373|NCT04056611|Drug|JNJ-53718678 250 mg|JNJ-53718678 250 mg will be administered orally.
45669374|NCT04056611|Drug|Placebo|Matching placebo will be administered orally.
45669375|NCT04056611|Drug|JNJ-53718678 125 mg|JNJ-53718678 125 mg will be administered orally.
45970464|NCT00249756|Behavioral|Re-entry Modified Therapeutic Community (Re-entry MTC)|In general, the MTC program model applies three fundamental adjustments - increased flexibility, decreased intensity, and greater individualization. The central TC feature is retained; the MTC, like all TC programs, seeks to develop a subculture where clients learn through self-help and affiliation with the community to foster change in themselves and others. From this base (as elaborated below), further adaptations for the population of offenders with MICA disorders were incorporated to include an emphasis on modifying criminal thinking and behavior; on recognizing and responding to the interrelationship of substance abuse, mental illness, and criminality (triple recovery); and on using strategies for symptom management.
45669376|NCT04040686|Drug|Injection of 99mTc-NM-02|Patient will be injected with microdose (<100ug) of 99mTc-NM-02 radiotracer
45669377|NCT04035837|Drug|pegylated interferon-alfa|All the patients in this study will receive pegylated interferon for all course.
45827776|NCT05894967|Behavioral|C7 - Parafoveal Training (PT)|The PT condition is the baseline for C8-C11 (all of which involve parafoveally presented targets). In PT, we utilize the same task as in SPL, however, in PT, in addition to central training, targets will also appear in one of two peripheral locations (5° eccentricity; angles = 135° and 270°). The location of targets will be randomized trial-wise so as to discourage eye-movements and independent 3/1 staircases will be run at each location. By training only 2 peripheral locations we can measure the extent to which training gives rise to location transfer (e.g., in transfer tasks examining performance at 8 different locations - 2 trained locations and 6 untrained locations). Furthermore, training at the central location facilitates comparisons between PT and SPL.
45970465|NCT00249756|Behavioral|Parole Supervision and Case Management|Recognizing the complexity of issues facing offenders returning to the community, and the importance of continuity of care, the CDOC established a system of aftercare substance abuse services for offenders on parole or placed in Community Corrections facilities. The statewide treatment options for the offenders consist of a network of community-based clinics and halfway houses throughout Colorado that provide substance abuse services and mental health services. Parole officers and Community Corrections case managers monitor treatment compliance to support participation in prescribed services.
45970466|NCT04105634|Drug|FNOS|The imaging drug used for this group is called 18F-NOS, it is an experimental imaging drug that has not yet been approved by the Food and Drug Administration (FDA) for use except in a research study. Subject will not receive the results or feedback from the study participation, the images may be reviewed with subject or her/his doctor upon request but will not be used to make decisions about subject medical care.
45970467|NCT04105634|Drug|Florbetaben|The imaging drug used for this group is called Florbetaben, it is an FDA approved radioactive PET tracer used to image amyloid plaques in the body. Although not yet FDA approved for this purpose, it has already been used clinically to image amyloid in other parts of the body. Subject will not receive the results or feedback from the study participation, the images may be reviewed with subject or her/his doctor upon request but will not be used to make decisions about subject medical care.
45669378|NCT04024462|Drug|Pertuzumab IV|Pertuzumab will be administered as a fixed non-weight-based loading dose of 840-milligrams (mg) IV and then a 420-mg IV maintenance dose Q3W.
45669379|NCT04024462|Drug|Trastuzumab IV|Trastuzumab will be administered as an 8-milligram per kilogram of body weight (mg/kg) IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
45669380|NCT04024462|Drug|Pertuzumab and Trastuzumab FDC SC|The pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.
45669381|NCT04024462|Drug|Doxorubicin|Doxorubicin 60 milligrams per meter squared of body surface area (mg/m^2) will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
45669382|NCT04024462|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m^2 will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
45827777|NCT05894967|Behavioral|C8 - Stimulus Variety (SV)|"The base task for SV is the PT condition. However, SV employ 20 trial mini-blocks of different SFs (.75, 1.5, 3, 6, 12, 24 cpd) and locations (45°, 135°, 225°, 315° - i.e., more locations than PT, but not the full set tested in the transfer battery) with separate staircases for each SF and location. Orientations will also be drawn from a larger set (22.5°, 45°, 67.5° - for which participants respond clockwise and 112.5°, 135°, 157.5° - for which participants respond counter-clockwise) and will vary on a trial-by-trial basis. This design holds-out 4 locations and 2 orientations to address transfer."
45827778|NCT05894967|Behavioral|C8a - Complex Features (CF)|This is the same as C8, however we will use band-pass filtered stimuli similar to what has been done by a number of groups including Hussein et al.
45827779|NCT05894967|Behavioral|C9 - Exogenous Attention Training (ExAT)|Stimuli will be presented in a similar manner as in PT. However, in ExAT, a 100% valid cue, a small black dot - 48ms duration with an 96ms SOA prior to stimulus onset - will appear above the target location on each trial.
45827780|NCT05894967|Behavioral|C10 - Endogenous Attention Training (EnAT)|Stimuli will be presented in a similar manner as in PT. However, in EnAT, a 100% valid cue (letter UL, LR; standing for upper left and lower right, respectively) - 150ms duration with an 500ms SOA prior to stimulus onset - will appear at the fixation point.
45827781|NCT05894967|Behavioral|C11 - Multisensory Facilitation (MF)|MF utilizes the same basic task structure as in ExEAT, however, rather than a visual cue, an auditory cue will be used (50ms, 1000hz tone with sound location determined by convolving sound with generic head-related transfer function, kemar large ears.
45827782|NCT05894967|Behavioral|No Contact Control|"While not a training condition one type of experience that could be part of a condition is a no contact control (i.e., where participants do no training activities over the same rough time span as for the other training tasks)."
45827783|NCT05894954|Dietary Supplement|Precision Medicine Approach|Precisions Medicine Approach involves a combination of medicines, dietary supplements, lifestyle changes, and diagnostics
45827784|NCT05894954|Combination Product|Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises|"Tailored Medications and Devices to address imbalances per lab results, known to affect cognitive function:~Potential Devices: Oura Ring, Continuous Glucose Monitor, Keto-Mojo, and Heartmath Inner Balance. Few may receive Hyperbaric Oxygen Treatment, neurostimulation, neurofeedback, neurostimulation to reduce stress and relax the body), photobiomodulation (light therapy), or CPAP.~Atrophic subtype support may include: estradiol, progesterone, testosterone, DHEA, pregnenolone, levothyroxine, liothyronine, hydrocortisone.~Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine Penicillin G, Methylene Blue, Nystatin, Clotrimazole, Metronidazole, Valacyclovir, Acyclovir, Famciclovir, Shingles Vaccine Vascular treatments may include: antihypertensives, Ubrelvy, aspirin, Eliquis"
45827785|NCT05894954|Behavioral|Standard-of-Care|Participate in cognitively stimulating and social activities, exercise, sleep, control risk factors, adhere to a health diet, consult physician if conditions worsen
45827786|NCT05894954|Behavioral|Lifestyle including diet, exercise, stress management|Combining a tailored diet, exercise and stress management program supported by coaching specialists
45827787|NCT05894941|Other|Corrective Exercises|A total of 6 evidence-based exercises and stretches namely; Upper trapezius stretch, Sternocleidomastoid stretch, pectoral stretch; Chin tuck exercise, YTWL exercise, and resisted/isometric neck extension exercise will be prescribed to the exercise group while the postural education group will follow the guidelines provided by National Institutes of Health (NIH) for using computers and other sources. The control group will receive no intervention.
45827788|NCT05894941|Other|Postural Education|Postural guidelines for doing daily activity especially sitting for prolonged periods and using electronic devices like computers and other electronic devices.
45827789|NCT05894928|Drug|LOXO-783|Administered orally.
45827790|NCT05894928|Drug|Cholestyramine|Administered orally.
45827791|NCT05894915|Procedure|open surgery|Open surgery is a traditional surgery method.
45827792|NCT05894915|Procedure|laparoscopic surgery|Laparoscopic surgery is a newly developed minimally invasive method.
45827793|NCT05894889|Biological|Pembrolizumab 200 mg IV infusion|"Biological: Pembrolizumab 200 mg IV infusion~Drug: nab-paclitaxel IV infusion~Drug: Carboplatin IV infusion~Drug: Pemetrexed IV infusion"
45970468|NCT04587349|Other|Neurorehabilitation|Neurorehabilitation - 2 years-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (2/ week)
45970469|NCT04587349|Other|Neurorehabilitation|Neurorehabilitation - 2 years-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (3/ week)
45970470|NCT04587349|Other|Physiotherapy|Physiotherapy 2-years-long (3/week)
45669383|NCT04024462|Drug|Docetaxel|Docetaxel 75 mg/m^2 will be administered IV on Day 1 of Cycle 5. At the investigator's discretion the dose may be escalated to 100 mg/m^2 IV for Cycles 6-8 (Q3W) provided no dose-limiting toxicity occurs.
45669384|NCT04024462|Procedure|Surgery|Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.
45669385|NCT04024462|Radiation|Post-Operative Radiotherapy|If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).
45827794|NCT05894876|Other|No treatment is given|No treatment is provided to the participants as part of this study.
45827795|NCT05894863|Device|Smart flex stent|Smart flex stent will be used for femoropopliteal occlusive lesions.
45669386|NCT04024462|Drug|Hormone Therapy|For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
45827796|NCT05894850|Other|AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through by telephone .|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients by telephone.
45827797|NCT05894850|Other|AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through message.|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients through message.
45827798|NCT05894850|Other|Manually remind the patients|Medical staff remind patients manually .
45827799|NCT05894837|Drug|Serplulimab+Regorafenib|Serplulimab: once every two weeks; Regorafenib: from the first day to the 21st day
45827800|NCT05894837|Drug|Hepatic Artery Bicarbonate Infusion|hepatic artery bicarbonate infusion: once every four weeks
45827801|NCT05894824|Drug|T-Dxd(Trastuzmab deruxtecan), Ramucirumab|"Phase Ib will use a standard 3+3 scheme with the planned doses of T-DXd (4.4~6.4 mg/kg) once every 3 weeks in combination with Ramucirumab 8mg/kg administered once every 2 weeks.~Dosing Regimen~Trastruzumab deruxtecan : One IV infusion every 3 weeks on Day 1 of each 21-day cycle~Ramucirumab : One IV infusion on every 2 weeks on Day 1,15 of each 28-day cycle"
45827802|NCT05894811|Diagnostic Test|oral glucose tolerance test|Nine blood samples were collected from subjects within 4 hours of oral glucose administration, 0 min before oral glucose administration, and 10, 20, 30, 60, 90, 120, 180, 240 min afterwards, and 4 mL of venous blood was collected at each time point for glucose, C-peptide and insulin concentrations.
45827803|NCT05894811|Diagnostic Test|MRI|Using MRI to quantify of fat content in the liver and pancreas of the subjects
45827804|NCT05894798|Other|Acupuncture|Acupuncture at point LI 4 in the thumb grip on the upper side of the hand, bilaterally, with a sterile disposable needle of dimension 0.20 x 13 mm. The stitch is approximately three mm deep. The needle is allowed to remain in place for about 30 seconds
45827805|NCT05894785|Procedure|External cephalic version|An ECV attempt is made on the study group
45827806|NCT05894772|Behavioral|Power over Pain Portal|Youth from different ages, sexes, gender, sexual orientations, races, dwelling and school/employment status will receive access to the Power over Pain Portal for 4 months. The portal consists of self-assessment tools (bi-weekly check-ins to provide users with feedback on their mood, anxiety, pain, and sleep and guide decision making on choice of interventions), evidence-based virtual educational (pain neuroscience) and cognitive behavioural therapy (CBT) pain interventions that are delivered in a stepped care manner based on participant needs/preference. The overall objective is to determine the implementation (guided by Proctor's implementation conceptual framework) and clinical effectiveness of the PoP Portal in a sample of youth (12-18 years of age) who are on the waitlist for tertiary care consultation at any pediatric CP clinic in Canada.
46081191|NCT05177848|Other|Heated tobacco products at 1/2 market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
45669387|NCT04023227|Drug|Sacubitril/valsartan|50 (24/26) mg, 100 (49/51) mg and 200 (97/103) mg will be available for dose adjustments.
45669388|NCT04023227|Drug|Enalapril|5 mg and 10 mg will be available for dose adjustments.
45669389|NCT04022135|Dietary Supplement|Folic acid|Participants will supplement with 0.6mg/day for 16 weeks.
45669390|NCT04022135|Dietary Supplement|(6S)-5-methyltetrahydrofolic acid|Participants will supplement with 0.625mg/day for 16 weeks.
45669391|NCT04017130|Drug|MT-0169|MT-0169 intravenous infusion.
45669392|NCT04011254|Procedure|haemodialysis|Routine haemodialysis session
45669393|NCT04003038|Procedure|Negative Pressure Wound Therapy|Receive wound care with NPWT
45669394|NCT04003038|Procedure|Wound Care Management|Receive wound care with a standard dressing (bandage)
45827807|NCT05894746|Dietary Supplement|gluten-free|see info in arm description
45827808|NCT05894746|Dietary Supplement|probiotic|see info in arm description
45827809|NCT05894746|Dietary Supplement|gluten|see info in arm description
45827810|NCT05894733|Other|study group|Calling with phone frequently(15.th day, 1 month , 3 month, 6 month ) and face to face interwiew on first, 3 th and 6th month
45827811|NCT05894733|Other|control group|first and sixth month face to face interwiew
45970471|NCT00253695|Device|Wrist Actigraphy|Wrist actigraph will record participants' sleeping patterns.
46081192|NCT05177848|Other|Heated tobacco products at 2x market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 2x market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
45970472|NCT04587310|Diagnostic Test|Laparoscopic Sleeve Gastrectomy|bariatric surgery
45970473|NCT00403208|Procedure|Analgesia based sedation in ICU patients|
45827812|NCT05894720|Other|Thrower's Ten Exercise Group|"the athletes were subjected to Thrower's Ten exercise program under the supervision of the same physiotherapist 3 days a week for a period of 6 weeks in addition to their routine practice programs."
45827813|NCT05894707|Drug|SCT650C|Recombinant anti-IL-17A antibody
45827814|NCT05894694|Drug|palliative care group first-line scheme+compound kushen injection|FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab+compound kushen injection Compound kushen injection: intravenous infusion, 20ml at a time, diluted with 200ml sodium chloride injection, once a day, each cycle of chemotherapy should reach the cumulative dose of 200ml, at least 4 cycles of chemotherapy.
45970474|NCT04586998|Device|"Exhaled drug monitor Edmon"|Taking samples of exhaled breath every minute during elective surgery in comparison to blood samples taken at predefined time points.
46081193|NCT05177848|Other|Nicotine pouch products at 1/2 market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
45970475|NCT00253734|Biological|Fluzone® (IM)|15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.
45669395|NCT04001803|Drug|CAB LA+RPV LA|Subjects will receive one tablet of CAB 30 milligram(mg) + RPV 25 mg once daily from Day 1 for 1 month. During month 1, subjects will receive 600 mg of CAB LA injection+ 900 mg of RPV LA injection. Following Month 1, subjects will receive 400mg of CAB LA + 600mg of RPV LA at each subsequent injection.
45970476|NCT00253734|Biological|Fluzone®|9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).
45669396|NCT04001777|Drug|APG-1252|Multiple dose cohorts, 30 minute IV infusion, weekly for 3 weeks of a cycle with 21days.
45669397|NCT04001777|Drug|Osimertinib Mesylate Tablets|Osimertinib Mesylate Tablets 40mg/80 mg, one time a day until disease progression
45970477|NCT04587115|Drug|Risperidone|Risperidone 1mg to be used in combination with other drugs
45970478|NCT04587115|Drug|Ziprasidone|Ziprasidone 80mg to be used in combination with other study drugs
45970479|NCT04587115|Drug|Oxycodone|Oxycodone alone in a capsule will be considered the control. Oxycodone 15 mg will also be used in combination with other study drugs
45970480|NCT00403247|Dietary Supplement|Capsule with folate, Vitamin B12 & pyridoxine|
45669398|NCT03994913|Biological|CAR-CD19 T Cells|"The CAR- CD19 T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting CD19.~Fludarabine and Cyclophosphamide are used for lymphodepletion."
45669399|NCT03987802|Drug|Faster-acting insulin aspart|Faster-acting insulin aspart given as subcutaneous (s.c., under the skin) injections according to routine clinical practice. The decision to initiate treatment with commercially available Fiasp® must be made by the patient and the treating physician before and independently from the decision to include the patient in this study.
45669400|NCT03984994|Other|Aerobic exercise training|3 months of center-based, supervised treadmill exercise
45669401|NCT03984994|Other|Strength training|3 months of center-based, supervise strength training
45669402|NCT03983668|Drug|CMP-001|Immunostimulatory therapeutic agent
45669403|NCT03983668|Drug|Pembrolizumab|Humanized antibody used in cancer immunotherapy
45669404|NCT03977012|Drug|Buprenorphine|5~20 mcg
45827815|NCT05894694|Drug|palliative care group first-line scheme|FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab
45827816|NCT05894681|Other|THE EFFECT OF WATSON MODEL-BASED PSYCOEDUCATIONAL INTERVENTIONS ON PREVENTION OF POSTPARTITION DEPRESS|THE EFFECT OF WATSON MODEL-BASED PSYCOEDUCATIONAL INTERVENTIONS ON PREVENTION OF POSTPARTITION DEPRESS
45827817|NCT05894668|Other|ECIRS|Endoscopic Combined Intrarenal Surgery
45827818|NCT05894655|Behavioral|COVID-19 walk-up, on-site testing strategy|This strategy is a no-appointment, walk-up point-of-care PCR and rapid testing strategy for clinic patients and community members. It will be offered 5 days/week for 7 hours during the first 3 months of the trial at Clinic 1. The intensity will decrease over the trial ending with 1 SYH Medical Assistant overseeing the testing protocol. Bilingual research staff will be trained to oversee onsite testing.
45970481|NCT00403247|Other|placebo|placebo capsule
45827819|NCT05894655|Behavioral|Community Health Worker (CHW) leading testing navigation and general preventive care reminders|This strategy provides health counseling about when COVID-19 testing is recommended, which test to use, testing instructions, and how to interpret results. Community Health Workers (CHW) will also offer general preventive health care reminders such as flu shots, blood pressure checks, and A1c screenings. This strategy will be available full-time during the first 3 months of roll-out at each clinic and after 3 months, the CHW will be available as needed. Trained bilingual CHW will be supervised by a SYH employee.
45827820|NCT05894655|Behavioral|No-cost self-testing kit vending machines|This strategy includes vending machines that will provide interactive instructions for accessing free self-testing COVID-19 kits located outside of clinics for patients and community members to use anytime. The vending machines will be available 24 hours/day, 7 days a week.
45827821|NCT05894642|Behavioral|0|It is a case-control study, cross-sectional, so there is no intervention possible.
45827822|NCT05894629|Behavioral|Pain Neuroscience Education (PNE)+ Therapeutic Exercise (TE)|12-week program consisting of PNE and TE
45827823|NCT05894629|Behavioral|Active Comparator: Usual treatment|12-week program consisting of home exercises, performed 3 days/week.
45827824|NCT05894577|Other|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
45827825|NCT05894577|Drug|Montelukast|Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.
45827826|NCT05894564|Drug|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
45827827|NCT05894564|Other|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
45827828|NCT05894551|Other|Evaluation of q angles different positions|Q angle evaluation in two different static postures (upright and supine position) and dynamic posture during the midstance phase of the gait
45827829|NCT05894551|Other|Physical examination|"With goniometric evaluations, the femoral anteversion angle will be measured. Pelvis width and thigh length will be measured with a tape measure. Quadriceps muscle strength, hamstring muscle strength, Hip abduction, adduction, internal and external rotation and extension muscle strength will be measured with hand-held dynamometer.~Joint mobility will be assessed with the Beighton score and foot posture will be evaluated with the foot posture index-6 (FPI-6)."
45827830|NCT05894551|Other|Functional mobility assessment|10-meter walking test will be conducted to understand functional mobility.
45827831|NCT05894538|Drug|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
45827832|NCT05894538|Other|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
45827833|NCT05894486|Drug|Lutetium[177Lu] Oxodotreotide Injection|Lutetium[177Lu] Oxodotreotide InjectionFour administrations of 7.4 GBq (200 mCi) Lutetium[177Lu] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity
45827834|NCT05894460|Device|Chocolate balloon|Vascular preparation with chocolate balloons prior to drug-coated balloon angioplasty
45827835|NCT05894447|Drug|Naptumomab Estafenatox|5 or 10 µg/kg IV naptumomab estafenatox will be given on the first four days of every 21-day treatment cycle for 6 cycles
45827836|NCT05894447|Drug|Pembrolizumab|200 mg IV pembrolizumab will be given on day 2 of each 21 day cycle for up to 24 cycles
45970482|NCT04587037|Procedure|fascia lata allograft|underwent superior capsule reconstruction using fascia lata allograft
45970483|NCT04587037|Procedure|human dermal allograft|underwent superior capsule reconstruction using human dermal allograft
45970484|NCT04586725|Other|Encouragement a one minute intervals|Patients will perform the six exercise tests with encouragement at one minute intervals
45970485|NCT04586725|Other|Encouragement a two minute intervals|Patients will perform the six exercise tests with encouragement at two minute intervals
45970486|NCT00253773|Drug|acetominophen, sulfer amino acids; cysteine and methionine|
45970487|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation suspension for nebulization 1000/20 mcg bid for 2 weeks
45970488|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 1000/10 mcg bid for 2 weeks
45970489|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/20 mcg bid for 2 weeks
46081194|NCT05177848|Other|Nicotine pouch products at 2x market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 2x market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
45970490|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/10 mcg bid for 2 weeks
45970491|NCT00403286|Drug|Fluticasone Propionate|Inhalation Suspension for nebulization 1000 mcg bid for 2 weeks
45970492|NCT00403286|Drug|Formoterol Fumarate|Inhalation Solution for nebulization 20 mcg bid for 2 weeks
45970493|NCT00403286|Drug|Fluticasone Propionate/Salmeterol Xinafoate|Inhalation Powder delivered by Diskus device 250/50 mcg bid for 2 weeks
45970494|NCT00403286|Drug|Placebo|Inhalation Solution for nebulization 2 mL bid for 2 weeks
45970495|NCT04587232|Diagnostic Test|Turkish version of Mini Osteoarthritis Knee and Hip Quality of Life Questionnaire|Turkish version of Mini Osteoarthritis Knee and Hip Quality of Life Questionnaire (Mini-OAKHQoL) was derived from the Turkish version of OAKHQoL questionnaire, which was developed to assess the quality of life (QoL) in subjects with lower limb osteoarthritis. It includes five subscales: physical activities, mental health, pain, social support, social functioning; with three additional independent items addressing sexual life, professional life, and fear of being dependent. The numerical rating scales in the items range from 0 (worst) to 10 (best). Scores were obtained by computing the means of the item scores in each subscale. The last three items' score (independent items) becomes the corresponding score.
45970496|NCT04587232|Diagnostic Test|Nottingham Health Profile|Standardized questionnaire to investigate the health-related quality of life. NHP is a general is used to measure health problems perceived by the patient. It comprises 6 sections. The sum of the items within each section ranges from 0 to 100, and the total score ranges from 0 to 600. The higher score shows a worse quality of life.
45669405|NCT03968055|Other|Integration with Epic|Participants will have CGM data connected to our medical record through an already established pathway (Dexcom app on iOS device to Apple HealthKit to Epic MyChart to Epic)
45669406|NCT03940066|Device|Biomonitor-2 and Kardia mobile|Implantable cardiac monitor and Smart-phone based electrocardiogram recording
45970497|NCT04587232|Diagnostic Test|Short form 36|Standardized questionnaire to investigate the general health-related quality of life. The SF-36 questionnaire is a generic quality of life questionnaire and consists of 8 subscales, with 36 items. The scores ranges from 0 to 100 and the high score indicates good health.
45970498|NCT04587232|Diagnostic Test|Western Ontario and McMaster|Standardized questionnaire to investigate the health status of patients with osteoarthritis. The WOMAC OA index assesses the symptomatic severity and disability with pain, stiffness, and physical function domains. Each subscale was summated to a maximum score of 20, 8, and 68, respectively, with the higher scores corresponding worst health status.
46081195|NCT05176639|Drug|VRDN-001|Multiple ascending doses of VRDN-001, ranging from 3 mg/kg to 20 mg/kg
46081196|NCT05176639|Drug|VRDN-001|Multiple doses of VRDN-001 using dosing regimen 1
46081197|NCT05176639|Drug|VRDN-001|Multiple doses of VRDN-001 using dosing regimen 2
46081198|NCT05176639|Drug|Placebo|Multiple doses of placebo
46081199|NCT05169008|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular injection
46081200|NCT05169008|Biological|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Nebulized inhalation through the mouth
45669407|NCT03940066|Other|No Intervention|No intervention
45669408|NCT03922724|Drug|IOC|e-ATG40 mg/kg/day IV on days -14 and -13. Pentostatin 4 mg/m2/day IV on days -9 and -5. Cyclophosphamide 5 mg/kg orally daily on days -9 through -2
45669409|NCT03922724|Drug|GVHD prophylaxis|High-dose, post-transplantation cyclophosphamide (PTCy) on days +3 and +4 ( 25 mg/kg/day on both arms), sirolimus on days +5 through +60, and mycophenolate mofetil (MMF) on days +5 through +25.
45669410|NCT03922724|Drug|RIC|e-ATG 40 mg/kg/day IV on days -14 and -13. Pentostatin 4mg /m2/day IV on days -11 and -7. Cyclophosphamide 5 mg/kg orally daily on days -11 through -4. Busulfan IV, pharmacokinetically dosed, on days -3 and -2.
45669411|NCT03922724|Procedure|allo HCT|Stem cell transplant
45669412|NCT03922724|Drug|mRIC|e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, lowdose cyclophosphamide (5 mg/kg) orally daily on days -11 through -4; busulfan IV, pharmacokinetically dosed, on days -3 and -2, G-CSF 5 mcg/kg/day subcutaneous on days -12, -8, and -4.
45669413|NCT03922724|Drug|ATL-RIC|e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, low-dose cyclophosphamide (5 mg/kg) orally daily on days -11 through -4; busulfan IV, pharmacokinetically dosed, on days -3 and -2, G-CSF 5mcg /kg/day subcutaneous on days -12, -8, and -4, ruxolitinib 45 mg/day from day -12 through day -2, and zidovudine 300mg orally three times a day from day -1 through day +50.
45827837|NCT05894447|Drug|Obinutuzumab|Two doses of 1,000 mg IV obinutuzumab given prior to starting pembrolizumab and naptumomab estafenatox
45827838|NCT05894434|Behavioral|Multisensory Training|The procedure involves repeatedly presenting identical visual-auditory stimuli at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°). The visual (a 500 ms flash) and auditory (500 ms broadband noise burst) stimuli are in spatial and temporal congruence.
45827839|NCT05894434|Behavioral|Unisensory Training|The procedure involves repeatedly presenting identical auditory stimuli (500 ms broadband noise burst) at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°).
46081201|NCT05159453|Biological|Human Insulin|International Unit for International Unit exchange of transdermally delivered Human Insulin for injected Human Insulin or combinations of basal and fast-acting insulins.
46081202|NCT05159453|Device|Finger-actuated, Metered Pump Sprayer|Stock, pharmaceutical grade High Density Polyethylene (HDPE) bottle and HDPE nylon and stainless steel finger-actuated pump sprayer delivering 0.2 mL per pump.
45970499|NCT00253812|Procedure|flexible sigmoidoscopy|
45970500|NCT04586764|Device|Non-Invasive Cardiac System|Non-Invasive Cardiac System (NICaS, NI Medical, Israel) is a non-invasive hemodynamic monitoring system that records various cardiovascular parameters including stroke volume, cardiac output, cardiac index (CI), total peripheral vascular resistance, body water content, and cardiac power index, a marker of myocardial contractility by employing the principles of the whole body impedance cardiography.
45970501|NCT04586803|Drug|SHR4640|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
45970502|NCT04586608|Dietary Supplement|MCT/ω-3 fatty acids|The provision of ω-3 fatty acids to premature neonates in the Parenteral Nutrition.
45970503|NCT04586608|Dietary Supplement|soybean oil-based IVFE|soybean oil-based IVFE
45970504|NCT04586491|Combination Product|Oral care protocol|Oral care protocol
45970505|NCT00223067|Drug|TAIZ|
45970506|NCT04719429|Dietary Supplement|Cricket-derived Protein|Beverage containing 25 g cricket-derived protein
45970507|NCT04719429|Dietary Supplement|Beef-derived Protein|Beverage containing 25 g beef-derived protein
45970508|NCT04586218|Behavioral|Computer guided vasopressor infusion|automated titration of vasopressor infusion to maintain a mean arterial pressure > 65mmHg
45970509|NCT04586218|Behavioral|Manual control of vasopressor infusion|manual adjustments of noradrenaline infusion
46081203|NCT05155254|Drug|IO102-IO103|IO102-IO103 comprises IDO peptide antigen (IO102) and PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) administered subcutaneously
46081204|NCT05155254|Drug|Pembrolizumab|Pembrolizumab administered intravenously
46081205|NCT05155085|Drug|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1)monoclonal antibody directed against Siglec-8
46081206|NCT05155085|Other|Placebo|Placebo
45669414|NCT03915964|Drug|Baricitinib|Administered orally.
45669415|NCT03915964|Drug|TNF Inhibitor|Administered SC
45669416|NCT03907423|Drug|Rosuvastatin10 mg tablet|Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
45669417|NCT03907423|Drug|Placebo Oral Tablet|Diabetic patients treated with Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
45669418|NCT03906409|Other|Constant|Participants will be provided with their daily energy requirements in a continuous drip across the day (1 ml/minute).
45827840|NCT05894408|Other|this is no intervention|this is no intervention
45827841|NCT05894382|Device|Double Helix Design Defocus Lens Spectacle (RACE)|Double Helix Design Defocus Lens Spectacle wearing more than 10h/day.
45827842|NCT05894382|Device|single-vision spetacle lens|single-vision spetacle lens wearing more than 10h/day.
45827843|NCT05894356|Other|Study chart review|Evaluation of 4250 sperm DNA fragmentation samples with the goal of defining a cut-off age beyond which SDF levels increase significantly
45827844|NCT05894343|Genetic|AAV-GAD|Bilateral infusion of AAV-GAD
45827845|NCT05894291|Other|Swimmer Prone Position|"Patients will be positioned with the head rotated. This rotation is followed by shoulder elevation/abduction, then 90° elbow flexion for the arm opposite to the head rotation. The hand is placed flat on the bed.~A 60° to 90° flexion is performed on the hip homolateral to head rotation, combined with knee flexion.~The position is changed to the mirror position every 4 hours."
45970510|NCT04585867|Drug|Exparel|The injections will be performed under direct guidance by the cardiac surgeon at bilateral sternal-costal interspaces 1.5 cm lateral the sternal boarder at levels 2-6 in divided doses (2 ml/injection) just before the closure of the sternum near the end of the surgical procedure. The final 20 ml will be injected into the skin incision after closure
45970511|NCT04585867|Drug|Bupivacaine|The injections will be performed under direct guidance by the cardiac surgeon at bilateral sternal-costal interspaces 1.5 cm lateral the sternal boarder at levels 2-6 in divided doses (2 ml/injection) just before the closure of the sternum near the end of the surgical procedure. The final 20 ml will be injected into the skin incision after closure
45970512|NCT00223106|Device|Vaginal Sling|
45970513|NCT04585828|Device|Phototherapy with double sided fiber optic pads with blue light at irradiance 30 uW/cm2/nm using Bili Cocoon|The baby will be treated with Bilicocoon for 24 hours. Decrease of total serum biliurubin will be evalueated hereafter.
45970514|NCT04585828|Device|Phototherapy from above using NeoBlue at irradiance of 30 uW/cm2/nm|The baby will be treated with phototherapy from above for 24 hours. Decrease of total serum bilirubin will be evaluated hereafter.
46081207|NCT05149755|Device|Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT)|Patients will have a Transcatheter Aortic Valve Replacement (TAVR) with either an Evolut PRO+ TAVR, or Evolut FX TAVR, heart valve, and given clinical site-determined guideline-directed management and therapy (GDMT).
46081208|NCT05147662|Biological|Damoctocog alfa pegol (Jivi, BAY94-9027)|"Part A: 40 IU/kg (up to 60 IU/kg at the investigator's discretion), two times per week (2x/week) with the first 4 infusions under medical supervision. Thereafter, participants will continue their treatment as home treatment. Dose may be increased up to 60 IU/kg if needed at any time during the study at the investigator's discretion.~Part B: Each participant may continue on prophylaxis dose regimen as prescribed in part A (40 - 60 IU/kg, 2x per week) or adjustments to prophylaxis dose / dose frequency can be made at the investigator's discretion (based on the bleeding events and individual needs): Dose frequency may be decreased to every 5 days with a prophylaxis dose of 60 IU/kg."
45970515|NCT00253851|Drug|unfractionated heparin|Five minutes prior to tourniquet inflation, patients will receive 0.1 ml/kg/minute of intravenous (IV) unfractionated heparin (1000 units/ml) or placebo (normal saline solution). Five minutes will be allowed to elapse to ensure complete systemic heparinization. The operated limb will then be elevated and exsanguinated using an Esmarch bandage. Following cuff inflation, the contents of a second syringe will be administered IV over a 5 minute period. The second syringe will contain either protamine sulfate (1.0 mg/kg) to reverse the systemic heparin for patients in the treatment group, or normal saline for the control group. Study drugs will be administered by the anaesthesiologist via a peripheral IV. This new method of intraoperative regional heparinization has been used in two previous studies (Giachino et al., 2001; Giachino et al., 1985) with no adverse effects noted.
46081209|NCT05140252|Behavioral|Breast cancer decision aid|The decision aid is tailored from a previously published aid, specific to women ≥70 with early-stage breast cancer. The aid will be delivered via mail or electronically per patient preference before the patient's initial appointment with a surgeon.
46081210|NCT05271409|Drug|Satralizumab|Study drug will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
46081211|NCT05271409|Other|Placebo|Placebo will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
45669419|NCT03906409|Other|Bolus|Participants will be provided with their daily energy requirements in two bolus feeds. One at 08:00-08:15 and one at 20:00-20:15
45827846|NCT05894291|Other|Prone position with arms alongside the body|"The head will be positioned either straight or rotated to one side, depending on ICU habits. The arms are positioned symmetrically along the body, palms up. The lower limbs are positioned symmetrically and parallel, knees extended or slightly flexed if a cushion is used on the front of the feet.~Head rotation, if applicable, is performed every 4 hours."
45669420|NCT03903874|Behavioral|Deep south Interactive voice response system supported Active Lifestyle (DIAL)|12 months of automated telephone physical activity counseling with community health worker support
45827847|NCT05894278|Other|Prescription data collection|Prescription data collection
45669421|NCT03897621|Drug|Tranexamic Acid|tranexamic acid will be administered intravenously after induction of anesthesia (a bolus of 10 mg/kg or maximal dose of 1g).
45669422|NCT03897621|Drug|Placebo|Patients in the placebo group will receive normal saline (a bolus of sodium chloride 0.9%, 0.1 mL/kg or maximal dose of 10 mL).
45669423|NCT03896269|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
45669424|NCT03882671|Device|EpiTel Epilog|EEG recording device
45669425|NCT03882671|Device|Empatica E4|PPG, sweat level, temperature and accelerometry recording device
45669426|NCT03882671|Device|GENEActiv|Temperature, light level and accelerometry recording device
45669427|NCT03880656|Biological|Intramuscular administration of autologous BM-MNCs|Intramuscular administration of autologous BM-MNCs at either a low or high cell dose.
45827848|NCT05894265|Other|ActiveMatrix® Dosage A|This group will receive ActiveMatrix® (AM) product dosage A (1cc AM diluted to 3cc with saline)
45827849|NCT05894265|Other|ActiveMatrix® Dosage B|Group 2 will receive ActiveMatrix® product dosage B (2cc AM diluted to 3cc with saline)
45827850|NCT05894265|Procedure|Saline injection|Group 3 will receive saline injection
45827851|NCT05894252|Other|Walking Interventions|"Participants in the intervention group will be required to complete a 30-minute walk five days a week for 12 weeks. This will be in addition to any regular walking or exercise they are currently doing, which will be assessed via a questionnaire at baseline. In the control group, participants will be asked to continue with their daily routines and usual level of physical activity.~The baseline measurements will be taken before the intervention at week zero. Subsequently, all the participants will attend a virtual meeting (screening visit) to learn about the key aspects of the research, including the required actions of the control and intervention groups, how to use the act watch and report the required data. All participants in the intervention group and the control group will be required to wear acti watches, which will be given to them for free."
45827852|NCT05894226|Procedure|laparoscopic ventral mesh rectopexy|patients are treated by laparoscopic ventral mesh rectopexy for anterior rectocele
45827853|NCT05894200|Other|Glass Ionomer cement pit and fissure sealant, Silver Diamine Fluoride|GC Fuji 7, e-SDF
45970516|NCT04585672|Other|Ammonia infusion|Ammonia metabolism investigated in healthy individuals and patients with cirrhosis with and without ammonia lowering agent: glycerolphenylbutyrat (healthy) and Lactulose + Rifaximin (Cirrhosis)
45669428|NCT03874507|Other|Virtual Reality/Augmented Reality Headset|"A virtual reality (VR) headset is a device the participant will wear over his/her head and eyes like a pair of goggles. It blocks out all external light and shows him/her an image on high-definition screens in front of his/hers eyes. It implies a complete immersion experience that shuts out the physical world.~Augmented reality (AR) headset is a device that the participant will wear over his/hers head and eyes and it adds digital elements to a live view."
45669429|NCT03859167|Other|Stress Test|Participants will reach maximum exercise on a treadmill and results will be collected and recorded.
45669430|NCT03849118|Diagnostic Test|89Zr-girentuximab|Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
45669431|NCT03846726|Procedure|standard TME surgery|radical resection for rectal cancer
45970517|NCT04585555|Device|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
45970518|NCT04585282|Behavioral|Plus Cognitive behavioral therapy of insomnia（CBT-I plus）|Cbt-i plus program is an enhanced version of cbt-i program, which increases the response to depression and anxiety symptoms.
45827854|NCT05894161|Other|Exercise training program|"The designed exercise program will be distributed on everyone. The recommendations will be to train from 30 to 45 minutes, 3 days per week for 6 weeks in addition to walking 30 minutes on the ground surface daily.~Diaphragmatic Breathing Exercises: Diaphragmatic breathing (DBRT) or abdominal deep breathing is an expansion of the abdominal area rather than the thoracic area when breathing.~Progressive Muscle Relaxation (PMR): The physical element includes the tensing and relaxing of all muscle groups over the face, arms, trunk (abdomen & chest) and legs.~A combination of stretching, stabilization and strengthening exercises of the pelvic-lumbar region:~Walking exercise: Walking on the ground surface for 30 minutes every day."
45970519|NCT04585282|Behavioral|Cognitive behavioral therapy of insomnia（CBT-I）|Cognitive behavioral therapy of insomnia is mainly aimed at correcting the bad behaviors and beliefs among the maintenance factors of insomnia, which is considered as the first-line treatment program of insomnia disorder. Cognitive behavioral therapy of insomnia mainly includes five important components: sleep restriction, secondary control, cognitive therapy, relaxation therapy and sleep hygiene.
45970520|NCT00249912|Drug|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
45827855|NCT05894148|Drug|Genakumab injection|Group 1: 120mg Q4W，group 2: 200mg Q4W
45970521|NCT00249912|Drug|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
45970522|NCT00249912|Drug|Rosuvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
45970523|NCT04585438|Drug|Diclofenac Potassium|The drug will be used as a transparent disc applied to the mucosa
45970524|NCT00567853|Device|Implantation of the MEMO 3D Annuloplasty Ring|Implantation of the MEMO 3D Annulopalsty Ring for mitral valve repair.
45970525|NCT00223223|Drug|Levetiracetam, Keppra|
45970526|NCT00567931|Drug|1-methyl-d-tryptophan|Given orally
45970527|NCT00567931|Other|pharmacological study|Correlative studies
45970528|NCT00567931|Other|laboratory biomarker analysis|Correlative studies
45970529|NCT00567970|Procedure|quality-of-life assessment|
45970530|NCT00567970|Radiation|stereotactic body radiation therapy|
45970531|NCT00568009|Drug|SLV320|1, 2.5, 5, 10 and 20 mg twice daily and placebo group. Duration of treatment 84 days
45970532|NCT00223301|Drug|Mycophenolate Mofetil (cellcept)|
45970533|NCT04585516|Procedure|endoscopy|Colonoscopy or gastroscopy
45970534|NCT04585321|Drug|Diclofenac Sodium 140mg Medicated Plaster|"Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day."
45970535|NCT04585321|Drug|Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac|"Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day."
45970536|NCT00249951|Drug|Alkaline citrate|Prophylactic alkaline citrate medication during the first 8 weeks of life versus placebo solution to prevent nephrocalcinosis of prematurity.
45970537|NCT04585360|Other|Questionnaires evaluating anxiety and depression symptoms, tiredness, and quality of life|"Realization of specific questionnaires evaluating:~psychiatric symptoms (self-assessment according to the SLC-90R questionnaire and hetero-assessment by the internist doctor of the center according to the M.I.N.I. questionnaire)~fatigue (Multidimensional Fatigue Inventory (MFI-20), French version, in self-assessment)~quality of life (SF36 self-assessment questionnaire)"
45455820|NCT05635877|Drug|Placebo Comparator: Placebo Comparator:normal saline(0.9%)|The control group received the same volume of 0.9% normal saline, which was continuously pumped until the end of the operation before extubation.Patient-controlled analgesia pump (sufentanil 2 μg/kg, 2 mL/h, for 48h) was used as the postoperative analgesia regimen in the two groups. If the VAS score was >3, analgesic adjuvant drugs were given intravenously and recorded. If repeated treatment is ineffective, the study will be excluded.
45669432|NCT03821506|Device|Dynamic Light|Dynamic Lighting system
45669433|NCT03821506|Device|Usual care|Standard lighting system
45669434|NCT03819192|Diagnostic Test|microbiome analysis|"From all full age pregnant women with PPROM enrolled in this study vaginal smear samples will be taken at three time points:~directly after hospitalization~5-7 days after beginning of antibiotic treatment~24 h before birth~The microbiome of the neonates of these women will be analysed out of pharyngeal and rectal swabs and umbilical cord blood taken directly after birth and additionally out of the first Meconium."
45669435|NCT03819192|Diagnostic Test|Conventional cultures|For every sample taken for microbiome analysis, a conventional culture is taken as control.
45970538|NCT00412997|Drug|LBH589|
45970539|NCT04585048|Behavioral|Integrated Behavioral Therapy for Selective Mutism|Cognitive Behavioral treatment including 24 weekly sessions
45970540|NCT00253929|Drug|Intra-arterial infusion of adenosine|
45970541|NCT00253929|Drug|intra-arterial infusion of caffeine|
45970542|NCT00253929|Drug|intra-arterial infusion of acetylcholine|
45827856|NCT05894148|Drug|placebo|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection.
45970543|NCT00253929|Drug|intra-arterial infusion of sodium nitroprusside|
45970544|NCT00253929|Procedure|Occlusion of arm-circulation by inflation of upper-arm cuff to 200mmHg for 2, 5 and 13 minutes|
45970545|NCT04584931|Procedure|coronally advanced flap|flap surgery to achieve root coverage at gingival recession defect
45970546|NCT04584931|Procedure|restorative intervention|colored composite restoration to camouflage the gingival recession defect
45970547|NCT00223340|Behavioral|Patient Activation and Diabetes Registry|
45970548|NCT04585126|Drug|Intermediate cervical block|Local anesthesia performed in addition to the general anesthesia
45970549|NCT00568048|Biological|bevacizumab|10 mg/kg i.v., on day 1 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
46081212|NCT05139342|Device|expiratory muscle strentgh training (EMST)|"All patients undergo EMST training, and results will be compared between groups.~After individual adjustment of the EMST device for each patient, the patient receives speeach adn instruction from a speech and language pathologist on the correct use of the EMST device. The intervention regime then consists of 5x5 breaths per day for 14 consecutive days."
45669436|NCT03819192|Diagnostic Test|CAAP48 measurement|CAAP48 is an identified sepsis marker in adult patients. The samples are taken dependent on clinical monitoring to compare CAAP48 with established inflammation markers (CRP, IL-6, White blood cell count, Procalcitonin).
45669437|NCT03809884|Behavioral|Dietary Counselling|Individually tailored strategy to increase potassium in the diet.
45669438|NCT03809884|Drug|Potassium Citrate|Dosing of 50 to 100 mmol of potassium citrate per day (as 25 to 50 ml of the liquid solution).
45669439|NCT03805594|Drug|Lutetium Lu 177-PSMA-617|Given IV
45669440|NCT03805594|Biological|Pembrolizumab|Given IV
45669441|NCT03804619|Device|Accelerated intermittent theta-burst stimulation (aiTBS)|aiTBS is an effective form of non-invasive brain stimulation which has been FDA-approved for the treatment of Major Depressive Disorder (MDD)
45669442|NCT03804138|Other|Anti-influenza and DTp pertussis vaccinations|Anti-influenza and DTp pertussis vaccinations will be performed during the visit by the clinical research nurse. The vaccine has been prescribed as part of the care either by the patient's physician (pulmonologist or general practitioner).
45827857|NCT05894135|Drug|BG2109 100mg|One tablet of BG2109 100mg , oral , once daily
45970550|NCT00568048|Drug|temozolomide|150 mg/m2 p.o., on days 1-7 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
45970551|NCT00249990|Drug|9-NC in aerosol reservoir|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks (45-47).
45970552|NCT04584775|Other|Treatment modalities of Traditional Chinese Medicine (Acupuncture, Chinese herbal medicine, Tunia, Chinese dietetics)|"Acupuncture is a physical treatment modality that uses thin needles to stimulate specific points on the body in order to manipulate neurologic mechanisms to control specific symptoms and/or physiologic processes.~Chinese herbal medicine is a phytotherapeutic treatment modality that uses herbs, minerals and rarely animal products which are orally administered.~Tuina is a form of massage and physical therapy. Chinese dietetics is a nutritional therapy according to the theoretical principle of traditional Chinese medicine."
45970553|NCT04584775|Other|Standard care|Standard care includes any medical intervention in palliative care that aims to promote and/or sustain the quality of life of patients suffering from advanced disease (in this case cancer). These may be of pharmaceutical, surgical, psychological and/or spiritual nature.
45827858|NCT05894135|Drug|BG2109 200mg|One tablet of BG2109 200mg, oral , once daily.
45827859|NCT05894135|Drug|ABT(E2 1 mg / NETA 0.5 mg)|One tablet of ABT(E2 1 mg / NETA 0.5 mg), oral, once-daily
45827860|NCT05894135|Drug|BG2109 100mg Placebo|One tablet of BG2109 100mg Placebo, oral , once daily.
45827861|NCT05894135|Drug|BG2109 200mg Placebo|One tablet of BG2109 200mg Placebo, oral , once daily.
45455821|NCT05633940|Behavioral|Implementation of the service delivery model primary care behavioral health|The research project will study a real-world implementation of PCBH in routine primary care. The implementation is facilitated by a regional implementation group of psychologists with special training in PCBH. The active implementation period for each intervention center is 12 months, where continuous support, materials and training are offered by the implementation group.
45827862|NCT05894135|Drug|ABT Placebo|One tablet of ABT Placebo, oral, once-daily
45827863|NCT05894109|Dietary Supplement|zinc citrate 50 mg|will take zinc citrate 4 days before and 1 week after botulinum toxin injection
45827864|NCT05894109|Other|Placebo Microcrystalline Cellulose|will take placebo 4 days before and 1 week after botulinum toxin injection
45970554|NCT00223379|Procedure|Endodontic procedure with varied apical preparation size|Comparison of two commonly used techniques for performing root canal treatment: 1) Lightspeed method 2)Buchannan method
45970555|NCT00568165|Procedure|Mobile team|a mobile team including a cardiologist with mobile echocardiography, systematic follow up à 3 days, a dietician advice in patients hospitalized for acute heart failure in a non cardiology ward
45970556|NCT00568165|Procedure|Standard care|Standard care
45970557|NCT04584424|Other|The study does not required|The study is prospective multi-center COVID-19 patient cohort
45970558|NCT04584580|Drug|low-molecular-weight heparin|low-molecular-weight heparin administered via subcutaneous injection
45970559|NCT00250029|Drug|Oxaliplatin|"Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2 hour intravenous infusion on day 1 of a three week cycle, prior to the 1st dose of capecitabine. 5-HT3 antagonists with or without dexamethasone premedication are strongly recommended. Oxaliplatin may be infused either through a peripheral vein or a central venous line. The infusion lines must be adequately flushed with 5% dextrose solution (D5W) between oxaliplatin infusion & the administration of any other drug.~Capecitabine is to be administered orally within 30 mins. after the end of a meal. Tablets should be swallowed with approximately 200 mL water (not fruit juices). The first dose of each cycle will be administered as the evening dose on day 1 & the last dose of each cycle is scheduled the morning of day 15, followed by a 7 day rest period. This provides for a total of 28 single doses per cycle over 15 calendar days."
46081213|NCT05128669|Procedure|CPIP|CPIP is an innovative Child-Parent Individualized Psychotherapy, consisting of 25 sessions, designed by the PI and his clinical collaborators for children with internalizing disorders in the aftermath of childhood neglect. It is informed by Short-term Psychoanalytic Child Therapy, elements of psychoanalytic parent work, videofeedback and Child-Parent Psychotherapy (CPP) and. CPIP supports the child-caregiver relationship and helps the child to resolve rigid conflictual internal representations/working models and improve interpretative and mentalizing techniques.
46081214|NCT05128669|Procedure|ECS|"Enhanced Caregiving Support (ECS) will serve as the control condition provided by the Allgemeine Sozialdienst (ASD - Community Social Services) of the two participating cities. According to German law (§ 27 SGB VIII), caregivers are entitled to receive caregiving support (CS; Hilfe zur Erziehung) in cases where the child's wellbeing is jeopardized. CS generally includes supportive work across all child-relevant systems (family, neighborhood, (pre-)school, peer group etc.). Appointed social workers and educators provide parenting counseling, family support, and intensive child support according to an individualized helping plan (Hilfeplan). In more severe cases, children are placed in (temporary) day-care centers, children's homes, foster families etc. Within the context of the trial, we will appoint an additional multi-systemic case manager to each case to enhance the quality of case coordination (enhanced CS; ECS). All children and families will receive ECS."
46081215|NCT05123703|Drug|Ocrelizumab|Ocrelizumab will be administered at a dose of 600 mg by IV infusion on Day 1 and Day 15 (half the dose, 2 weeks apart) and every 24 weeks thereafter.
46081216|NCT05123703|Other|Ocrelizumab Placebo|Ocrelizumab placebo will be administered by IV infusion on day 1 and Day 15 and every 24 weeks thereafter.
46081217|NCT05123703|Drug|Fingolimod|Fingolimod will be administered daily as 0.5 mg capsule.
46081218|NCT05123703|Other|Fingolimod Placebo|Fingolimod placebo will be administsred daily as a capsule.
46081219|NCT05122676|Behavioral|More Individualized Care: Assessment and Recovery through Engagement (MI-CARE)|"This study evaluates whether offering nurse collaborative care management for 12 months by telephone or video can improve depression-related symptoms, increase access to evidence-based medication treatment for opioid use problems, as well as decreasing adverse health events. Participants randomized to the nurse support arm can work with the nurse at no cost for up to 12 months via phone or video visits.~The nurse asks questions about stress, mood, worry, pain, sleep, and medication and substance use; participants choose what to focus on. The nurse meets weekly with clinical consultants who may recommend treatment options, tailored to the patient. The participant and their regular provider(s) can discuss the options and decide which to try. The nurse and primary care provider can then help the patient access selected options. The nurse can also offer behavioral activation to help build skills to increase day-to-day positive adaptive experiences and support broader treatment gains."
46081220|NCT05120349|Drug|Osimertinib|The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease recurrence, unacceptable toxicity or other discontinuation criteria are met.
46081221|NCT05120349|Drug|Placebo|Matching placebo. Initial dose of 80mg once daily can be reduced to 40mg once daily.
46081222|NCT05108246|Behavioral|Dual-Task Exercise Training|Simultaneous cognitive-motor training
45669443|NCT03785366|Drug|VeraCept|VeraCept Intrauterine Device (IUD)
45835876|NCT04696224|Drug|Tranexamic acid|The surgical technique consists in patient in supina position with previous reduction with lower limb traction (on a traction table or manual) associated or not with the use of percutaneous reduction clamps. Longitudinal lateral incision of 3-5 cm proximal to the greater trochanter, approximately 5 cm long, will be performed. After the skin and subcutaneous incision, the fascia lata will be incised in the same direction, with exposure of the gluteal muscles and the proximal femur. The awl will be introduced at the tip of the greater trochanter and then, at the same location, an intramedullary guidewire, towards the proximal shaft, crossing the fracture. A 3 cm incision to the thigh and inferior to the initial incision with template to introduce the screw in the center of the femoral head. Then, a 2cm incision will be made at the distal end of the nail, and a hole in the femur for the distal lock in dynamic nail hole with a 4.5mm drill where a cortical screw will be inserted.
45455822|NCT05633706|Device|fluid biopsy capsule|Collection of a fluid biopsy from the small intestine via ingestible capsule
45669444|NCT03785366|Drug|ParaGard|ParaGard intrauterine copper contraceptive
45669445|NCT03768427|Combination Product|EZ 10 mg/Ator 10 mg|FDC of EZ10 mg/Ator 10mg
45669446|NCT03768427|Combination Product|EZ 10 mg/Ator 20 mg|FDC of EZ10 mg/Ator 20mg
45455823|NCT05630183|Drug|Botensilimab|A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
45455824|NCT05630183|Drug|Gemcitabine|Standard-of-care chemotherapy administered intravenously.
45455825|NCT05630183|Drug|Nab-paclitaxel|Standard-of-care chemotherapy administered intravenously.
45669447|NCT03768427|Drug|Atorvastatin|Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets
45669448|NCT03768427|Drug|Placebo for FDC EZ/Ator|A single placebo tablet administered orally QD for 84 days
45669449|NCT03768427|Drug|Placebo for atorvastatin|Two placebo tablets matching atorvastatin administered orally QD for 84 days
45669450|NCT03758781|Drug|IRX 2|IRX-2 Regimen: 21 day regimen of cyclophosphamide on Day 1 and subcutaneous IRX-2 injections for 10 days between Days 4 and 18. This 21 day regimen will be given every 12 weeks.
45669451|NCT03758781|Drug|Nivolumab|Nivolumab 240 mg will be given via IV infusion once every 2 weeks.
45970560|NCT04584658|Diagnostic Test|Fibreoptic Endoscopic Evaluation of Swallowing (FEES)|This is the use of endoscopy during feeding trials. The patient is fed different consistencies of food and drink while an endoscope is in place (usually passed through the nasal passage and down into the throat). The endoscope provides a bird's eye view to the transit of food through the upper aero-digestive tract. This provides information from the point of food bolus formation in the mouth to the movement of the base of the tongue; the movement of pharyngeal muscles; the deflection of the epiglottis to protect the airway including the closure of the vocal cords and the passage of food into the oesophagus. Any abnormality in these steps are noted during FEES. Liquids, thickened fluids, semi-solids and solids are some of the food textures that are tested.
45970561|NCT04584658|Diagnostic Test|Videofluoroscopy|A radio opaque dye is used to label the test food and drink items offered to the patient. Following this, x-ray technology is used to create a video of the outline of the patient and the structures responsible for chewing and swallowing as they injest the test materials. The study is carried out in real time in the radiology department in conjunction with a radiographer and an SLT.
45970562|NCT04584658|Other|Dysphagia Handicap Index (DHI)|This is a 25-item questionnaire assessing three domains: physical (9 items), functional (9 items), and emotional aspects (7 items) of the Quality of Life (QOL) in patients suffering with dysphagia. For each statement the patient checks if it applies to him/her all the time, some of the time or never. The suggested scores are 0, 2 and 4, respectively. Using this scoring system amounts to a DHI score range of 0 - 100. The higher the score, the worse the dysphagia related QOL. The patient is also asked to provide a rating of their own impression of the severity of the dysphagia experienced on a scale from 1 (normal) to 7 (severe problem).
45827865|NCT05894070|Other|Voice recording, ENT (Ear, Nose and Throat) examination including transnasal fiberendoscopy, and VHI-30-questionnaire|"The following speech samples will be recorded from the study participants:~Standardized, phonetically balanced text~Sustained, modulated production of five vowels~Picture description~Diadochokinetic exercise.~Before starting speech recording, the participant fills in a questionnaire consisting of:~Health barometer~Self-rating in terms of stress/fatigue/emotional status.~An Ear, Nose and Throat examination incl. transnasal fiberendoscopy is performed at each visit. The investigators will assess the vocal folds/aryepiglottic folds for the presence of paralysis or reduced mobility, as well as the presence of scar/synechia, edema, erthyro-/leukoplakia, or a cancer-suspicious lesion/mass in the larynx/hypopharynx or a chondroradionecrosis in the larynx.~Additionally, it will be assessed, if a tracheotomy canula or a nasogastric tube is in place or was used since the last visit.~Furthermore, the investigators will ask the patients to fill out the VHI-30."
45455826|NCT05629910|Device|O2Matic|During the interventional period the O2Matic will operate in automatic mode using the Neonatal Study Profile. O2Matic will continuously adjust the O2 flow to adjust SpO2 within range based on readings from the pulse oximeter connected to O2Matic, while AIRVO-2 will adjust the flow of ambient air to keep the total gas flow constant.
45455827|NCT05629832|Procedure|mechanical ventilation strategy guided by transpulmonary pressure|Mechanical ventilation parameters adjust guided by transpulmonary pressure monitoring. For pressure assist control or volumn assit control mode; inspiratory pressure or volumn setting needs to maintain Ppeak less than 25 cm H2O; PEEP was set at such a level that expiratory Ptp stayed between 0 and 5 cm H2O.
45827866|NCT05894057|Other|Data collection on acceptability of midazolam administration by 2- to 10-year-old pediatric patients at UKBB|On the day of entry to the Anesthesiology Unit for an elective surgery, or before an intervention at the Emergency Unit, all children, irrespective of their participation to the present study, will receive standard midazolam dose of 0.3-0.5 mg/kg as prescribed by the treating clinician at UKBB in line with clinical practice (as oral syrup, rectal suppository or ODMT). The children's spontaneous reactions after intake of midazolam (e.g., positive comments, spitting out of medication, crying) will be observed and recorded by the research staff. Children who are able to understand the Hedonic Scale (FHS) will be questioned on how they liked the medication by pointing to the appropriate face of a Facial Hedonic Scale (FHS) at the time of midazolam intake.
45669452|NCT03747718|Biological|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
45970563|NCT04584658|Other|Voice Symptom Scale (VoiSS)|This is a 30-item validated quality of life tool that is also a self-reporting tool. It appraises the impact of the patient's abnormal voice from an emotional perspective, related physical symptoms and stratifies the impairment itself in context of day to day activities. VoiSS is currently the most psychometrically robust voice outcome measure. Each item is scored 0 - 4 on the frequency responses: never, occasionally, some of the time, most of the time, always. The total score of 120 measures general voice pathology which is made up of Impairment = maximum score of 60; Emotional = maximum score of 32; Physical = maximum score of 28.
45970564|NCT00223418|Drug|aripiprazole|
45970565|NCT04584697|Biological|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb).
45970566|NCT04584697|Drug|Placebo|Diluent solution
45970567|NCT04584736|Drug|Livalo, Ezetrol|Pitavastatin+Ezetimibe Pitavastatin
45970568|NCT00250068|Drug|Liposomal 9-Nitrocamptothecin|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks
45970569|NCT04584268|Behavioral|mindfulness|in person and smart phone application mindfulness practice
45970570|NCT04584268|Other|standard medical education|standard medical education / control
45970571|NCT04584307|Drug|Elotuzumab|Elotuzumab 10-20mg/kg
45970572|NCT04584307|Drug|Pomalidomide|Pomalidomide 2mg
45970573|NCT04584151|Procedure|regional analgesia|Insertion of bilateral ESP catheters
46081223|NCT05097963|Device|Endoscopic Ultrasound Shear Wave Elastography|Software to determine stiffness of liver for evaluating liver fibrosis.
46081224|NCT05096195|Drug|Denosumab 60 mg/ml|Details described in intervention arm/group description section.
46081225|NCT05096195|Other|Calcium and vitamin D prophylaxis|Details described in intervention arm/group description section.
45669453|NCT03747718|Other|Placebo|Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
45827867|NCT05894044|Other|Russian current 10%|Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
45669454|NCT03746080|Drug|Plerixafor|Plerixafor will be administered via infusion at 400 micrograms per kilogram per day for four weeks beginning one week before the end of radiation
45970574|NCT00223457|Behavioral|Factors that influence compliance|
45827868|NCT05894044|Other|Aussie current 10%|Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
45970575|NCT04720521|Diagnostic Test|OE+white light|Firstly use white light to observe from esophagus to duodenum and then switch OE mode to observe from antrum to esophagus
45827869|NCT05894044|Other|Pulsed current 500 µs phase|Pulsed current, modulated in 50 Hz, 500 µs
45827870|NCT05894044|Other|Pulsed current 200 µs phase|Pulsed current, modulated in 50 Hz, 200 µs
45827871|NCT05894031|Behavioral|Wim Hof Method|The intervention followed the guidelines provided by Wim Hof. The intervention comprised three components: cold water exposure, breathing exercise, and meditation.The participants were instructed to perform the WHM daily over the course of 15 days. The participants could choose when to do so throughout the day, however, the components were to be performed in a strict, sequential order: breathing exercises, followed by meditation, and then cold exposure. Participants were asked to complete a daily log in which they documented whether they performed the procedure and for how long. Altogether, the procedure lasted about 15 minutes.
45970576|NCT04584034|Drug|Salbutamol|Salbutamol will be delivered using a Babyhaler spacer device. Ventolin will be used, brandname for Salbutamol sulfate. Ventolin contains the propellant HFA 134a.
45827872|NCT05894018|Drug|Fluzoparib|150mg, orally, bid
46081226|NCT05096195|Diagnostic Test|Monitoring of post-injection calcium and phosphate|Details described in intervention arm/group description section.
45827873|NCT05894018|Procedure|Radioactive particle implantation|Radioactive iodine-125 seeds implantation
45827874|NCT05893992|Device|Hearing aids (omnidirectional)|Device for hearing loss compensation with microphone sensitivity all around the listener.
45827875|NCT05893992|Device|Hearing aids (directional)|Device for hearing loss compensation with microphone sensitivity in front of the listener.
45827876|NCT05893992|Other|Unaided|Control condition
45669455|NCT03746080|Drug|Temozolomide|Temozolomide (TMZ) will be administered concurrently with the radiation for 42 days and 6-12 cycles of monthly adjuvant Temozolomide (TMZ) after completion of Plerixafor infusion.
45669456|NCT03746080|Radiation|Whole-Brain Radiotherapy (WBRT)|Undergo Whole brain radiotherapy (WBRT) - Radiotherapy consists of 30 Gy in 15 fractions of whole brain radiations
45827877|NCT05893979|Device|Spectacle Lenses|Standard Spectacle Lenses
45827878|NCT05893966|Radiation|Whole breast irradiation +/- tumor bed boost|Postoperative whole breast irradiation (3D-conformal radiation therapy or IMRT) with or without tumor bed boost (sequential or simultaneous integrated boost)
45827879|NCT05893953|Device|immediately feedback device|Sitting in a standard chair with immediate feedback device
45827880|NCT05893953|Device|Unstable chair|sitting in an unstable chair
45827881|NCT05893953|Other|Standard chair|Sitting in a standard chair
45827882|NCT05893927|Other|Diabetes education web site application|The Diabetes education website application will contain informational videos for this protocol. The videos will include a welcome video and the categorical topics of Healthy Coping, Healthy Eating, Staying Active, Medications (Use and Safety), Problem Solving in Diabetes, and Disease Pathophysiology. Each category contains several videos providing education about a different component of diabetes care.
45970577|NCT04584034|Drug|Placebo|The placebo will be delivered using a Babyhaler spacer device. The placebo will contain only the propellant HFA 134a.
45970578|NCT04584229|Other|Intervention|Intervention: comprehensive individual or collective interview, recorded and transcribed
45970579|NCT04584073|Procedure|Adenoidectomy alone or with Myringotomy or with Myringotomy and Tympanostomy Tube application|Adenoidectomy with or without tonsillectomy when indicated will be performed. simple Myringotomy incision will be done in the antero-inferior quadrant of pars tensa of both tympanic membranes. Middle ear fluids will be aspirated. Tympanostomy tube application will be done.
45970580|NCT00223535|Behavioral|Cognitive Remediation|
45970581|NCT00223535|Behavioral|Social Skills Training|
45970582|NCT00250146|Behavioral|Gluten (behaviour)|
45970583|NCT04583722|Dietary Supplement|AX-olive oil-PP emulsion|single dose and plasma samples
45970584|NCT04583683|Behavioral|Very low calorie diet with Fortimel (Nutricia) supplementation|Patients will undergo a very low calorie diet
45970585|NCT04583683|Procedure|Metabolic Surgery|Patients will undergo metabolic surgery
45835877|NCT04696224|Other|Saline solution|30 patients who will not receive the TXA, but will receive a 100ml intravenous saline solution 0,9% after anesthetic induction and before incising the skin (such as group 1) and a compress soaked in saline solution as used in group 2
45970586|NCT04583605|Device|PREVENA|A negative pressure wound closure therapy is used after lymph node dissection
46081227|NCT05067933|Drug|VXA-CoV2-1.1-S|COVID-19 (SARS-CoV-2) E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant Oral Tablet Vaccine
46081228|NCT05067933|Other|Placebo Tablets|Placebo tablets matching the active vaccine tablets
45970587|NCT04583566|Genetic|COVID-19 Diagnostic and Assessment Tests|Complete Blood Count (CBC), Differential leukocytes, D-dimer, C-Reactive Protein, Polymerase Chain Reaction (PCR) Test, Ferritin level, Cytokines Profile, Transcriptome Analysis, miRNA Analysis.
45970588|NCT04583410|Drug|Nicotine patch|"NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day"
45970589|NCT04583410|Drug|Placebo patch|"PLACEBO OF NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day"
45970590|NCT00223574|Drug|Control - high carbohydrate, high glycemic index foods|
45970591|NCT00223574|Drug|high carbohydrate, low glycemic index foods|
45669457|NCT03746080|Radiation|Radiation Therapy|Radiotherapy consists of 30 Gy in 15 fractions
45669458|NCT03741543|Other|A 12-week health promotion course|The Health Promotion intervention consists of 12 weekly 2-hour sessions with a group of up to six participants and two course facilitators. Teaching methods includes lecture, questions- and answer periods, and interactive hands-on learning. During the class sessions, the facilitators encourages the participants to ask questions and make comments about the lecture at any time. During the first class session, each participant receives a booklet with the course material.
46081229|NCT05067634|Drug|Xcopri|Age groups 12 to <18 will enroll once dosing data is received from Cohort I of the PK analysis of YKP3089C039 study. Age groups 6 to <12 will enroll once dosing data is received from Cohort IIa of the PK analysis of YKP3089C039 study. Age groups 4 to <6 will enroll once dosing data is received from Cohort IIb of the PK analysis of YKP3089C039 study. Age groups 2 to <4 will enroll once dosing data is received from Cohort III of the PK analysis of YKP3089C039 study.
46081230|NCT05059860|Device|Tandem Control IQ Hybrid Closed Loop Insulin Delivery System|The Tandem Control IQ hybrid closed loop insulin delivery system is made up of an externally worn Tandem insulin pump which communicates wirelessly to the Dexcom G6 CGM worn as a patch on the skin. The CGM measures glucose levels transmitting them into the computer within the pump. The computer then calculates how much insulin is required then dose delivery completes the cycle. The Control-IQ™ advanced technology adjusts insulin delivery to avoid glycaemic excursions, while still allowing the user to manually bolus at mealtimes.
46081231|NCT05059327|Drug|Basimglurant with crossover to Placebo|Basimglurant with crossover to Placebo
46081232|NCT05059327|Drug|Placebo with crossover to Basimglurant|Placebo with crossover to Basimglurant
46081233|NCT05041166|Drug|Hyperpolarized [13C] Pyruvate|Will be injected at a dosage of 0.43 ± 0.05 mL/kg body weight
45669459|NCT03737994|Drug|Alectinib|Given PO
45669460|NCT03737994|Drug|Brigatinib|Given PO
45669461|NCT03737994|Drug|Carboplatin|Given IV
45669462|NCT03737994|Drug|Ceritinib|Given PO
45970592|NCT00223574|Drug|low carbohydrate, high monounsaturate fat foods|
46081234|NCT05037929|Drug|Astegolimab|Participants will receive SC astegolimab Q2W or Q4W.
46081235|NCT05037929|Drug|Placebo|Participants will receive SC placebo Q2W.
46081236|NCT05036135|Drug|AV-101|AV-101 (imatinib) administered via dry powder inhalation
46081237|NCT05036135|Drug|Placebo|Placebo administered via dry powder inhalation
46081238|NCT05032430|Behavioral|ATIENDE|A mix of mindfulness-based stress reduction, mindful eating, and mindful parenting strategies.
46081239|NCT05032430|Behavioral|Enhanced Usual Care|Consists of strategies meant to enhance health and well-being (e.g., health education, strategies to get more physical activity) but does not include mindfulness as an active ingredient.
46081240|NCT05022524|Dietary Supplement|Acetate (Apple Cider Vinegar)|Consumer-grade apple cider vinegar (ACV) capsules will have extra enteric coating applied for delivery further into the GI tract.
45669463|NCT03737994|Drug|Cisplatin|Given IV
45669464|NCT03737994|Drug|Crizotinib|Given PO
45835878|NCT04693494|Other|Training program|Training program consisting in 4 sessions with information about milestones to achieve and advices for motor development. Triptychs and short videos containing the main points containing the main points.
45835879|NCT04690452|Behavioral|Compassion Cultivation Training|The Compassion Cultivation Training (CCT©) is an 8-week standardized meditation program conducted in groups of 15-20 participants and consisting of weekly 2 hour on-line sessions with 20-30 minutes of daily formal meditation practices and informal compassion practices. The CCT© program will be guided by a certified instructor form the Center for Compassion and Altruism Research and Education at Stanford University. The CCT© program comprises six sequential steps: 1) Settling the mind; 2) Loving-kindness and compassion for a loved one; 3) Self-directed loving-kindness and compassion; 4) Common humanity; 5) Cultivating compassion for others; and 6) Active compassion (Tonglen).
45669465|NCT03737994|Drug|Ensartinib|Given PO
45669466|NCT03737994|Drug|Lorlatinib|Given PO
45669467|NCT03737994|Drug|Pemetrexed|Given IV
45669468|NCT03724149|Drug|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
45669469|NCT03724149|Drug|Epclusa|Epclusa (sofosbuvir 400mg and velpatasvir 100mg once daily) is taken by mouth for 12 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
45970593|NCT00254007|Drug|citalopram (celexa)|20(1 tablet)-50(2 1/2 tablets) mg/day for a period of 6 or 10 weeks
45970594|NCT04583098|Other|fecal microbiota transplantation|frozen stool from donors who had already finished recommended blood & stool screening for stool donors
45970595|NCT00223613|Drug|daily intranasal administration of insulin|
45970596|NCT04583293|Other|No intervention|This study does not involve any intervention or new treatment.
46081241|NCT04999852|Device|Safe and Sound Protocol|SSP is a non-invasive acoustic vagus nerve stimulator consisting of 5 hours of filtered and processed music designed to promote efficient regulation of autonomic state, and available through an app. The SSP is delivered via a mobile app and may fall under the heading of medical devices under the category of software functions/mobile medical applications.
45669470|NCT03720002|Dietary Supplement|HF2|placebo
45970597|NCT04583371|Other|MECHANICAL PULMONARY HYPERINFLUATION|For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique. In the participants of the intervention group, the calculation of the ideal tidal volume of each patient will be performed, after which they will be positioned in the same way as baseline aspiration, in assisted-controlled pressure ventilation, increasing 10 cmH2O in inspiratory pressure and, in ventilatory mode. -controlled by volume, we will increase 50% of the tidal volume for a period of 10 minutes, observing the peak that cannot exceed 40 cmH2O in both ventilation modes, and then three aspirations will be performed for 15 seconds and with an interval of 30 seconds.
45970598|NCT04583332|Other|Rhymes|"Participants will be provided with a choice of 3 Nursery rhymes (Wheels on the bus, Old McDonald and Twinkle Twinkle Little Star) Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects."
46081242|NCT04999852|Behavioral|Psychotherapy|All participants, regardless of study arm, will be recruited from the pool of Spencer Psychology clients who are actively recieving psychotherapy. Participants will continue to recieve psychotherapy during the course of the study.
46081243|NCT04998851|Drug|Ocrelizumab|Women will receive the ocrelizumab dose regimen as per the locally-approved label. The ocrelizumab dose will be administered as an initial split dose of two 300 mg infusions separated by 14 days or a single 600 mg infusion according to the local prescribing information.
46081244|NCT04998812|Drug|Ocrelizumab|Post-partum dosing and treatment duration are at the discretion of the physicians, in accordance with local clinical practice and local labelling.
45669471|NCT03702270|Other|Penicillin Allergic Risk Stratification Best Practice Alert|Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
45669472|NCT03637816|Drug|Anamorelin Hydrochloride|Given PO
45669473|NCT03637816|Other|Placebo|Given PO
45669474|NCT03637816|Other|Questionnaire Administration|Ancillary studies
45669475|NCT03598309|Drug|Curcumin C3 complex®|Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
45669476|NCT03598309|Drug|Lovaza®|Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
45669477|NCT03598309|Other|Placebo|Groups B and Placebo as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
45835880|NCT04689438|Diagnostic Test|gingival crevicular fluid|GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.
45835881|NCT04688580|Drug|XW10172|Various formulations
45835882|NCT04753008|Drug|Dopamine administration|Administration of dopamine (3 mcg/kg/min) as part of cardiac support therapy after the cardiopulmonary bypass. Administration of dopamine is a subject of clinical decision based on the cardiovascular status of the patients.
45835883|NCT04771494|Other|Power and execution speed as a function of instability experience|"Each subject performed 3 repetitions for the light load (40% RM; VMP > 1.0 m/s), with 1 minute rest; 2 repetitions for the medium load (60% RM; 0.65 m/s ≤ VMP ≤ 1.0 m/s) with 2 minutes rest and 1 repetition for the heavy load (80% RM; VMP < 0.65 m/s) with 4 minutes rest. A metronome was used for the start countdown and to time the eccentric and concentric portions of the exercise.~Subjects began the bench press with their elbows fully extended, maintaining a grip distance slightly greater than shoulder width. The bar was then lowered to their chest and then applying as much thrust as possible until full elbow extension on a 2-1-0 count. The timing sequence involved 2 seconds for the eccentric phase, a 1 second hold (to minimise the contribution of the rebound effect and allow for more reproducible and consistent measurements) and for the concentric up phase the highest possible execution speed, until the bar returned to the starting position."
46081245|NCT04997018|Radiation|Radiation Therapy|"Patients enrolled in this study will undergo ultra-hypofractionated radiation utilizing MR guided, daily online adaptive planning. Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously-delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm, as determined on the pretreatment diagnostic T2 MRI imaging. In the setting of two similarly-sized dominant lesions, both will be boosted."
45827883|NCT05893888|Drug|PRV211 (Intraoperative Cisplatin System)|PRV211 system is comprised of two parts, a liquid permeation enhancer (PE) and cisplatin patch. The permeation is brushed onto the resected tumor bed and after 5 minutes the patch can be applied directly over the same area. Apply up to 2 layers of the PRV211 system to the tumor bed post-resection. The duration of the PRV211 treatment takes approximately 10-20 minutes and then the surgeon can continue as planned with the rest of the standard of care procedure. The proposed starting dose is 0.5 mg/cm2 of cisplatin on the tumor bed. This approach can be safe and effective in preventing locoregional recurrence after surgery and eliminating high-risk factors for local recurrence, such as dysplasia at the margins.
45827884|NCT05893862|Drug|MK-8189|Oral Tablet
45970599|NCT04583332|Other|Individual Items in Rhymes|"Participants will be provided with a choice of 3 pictures within the initial choice making of the 2 Nursery rhymes (Wheels on the bus and Old McDonald ) Wheels on the Bus will include - mama/wipers/horn McDonalds - cow/dog/cat Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects."
45970600|NCT04583332|Other|Objects|Participants will be provided with 2,3 and 4 sensory objects. Participants will opt for an object by making a choice between these objects, if this is achieved then the child will be moved to picture level and symbol.
45970601|NCT04583137|Drug|Lidocain|Layngeal direct fiberoptic examination transnasaly
46081246|NCT04982224|Drug|REGN5093-M114|Administered by intravenous (IV) infusion
46081247|NCT04976556|Device|Histolog Scanner|imaging of fresh lumpectomy specimens with the Histolog Scanner, confocal microscopy scanning medical imaging device
45669478|NCT03595228|Biological|BN-Brachyury plus radiation|MVA-BN-Brachyury injections will be given on day 0 and 14. FPV-Brachyury injection will be given on day 28, followed by radiation on days 42 through approximately day 70. FPV-Brachyury will then be given two weeks after radiation then every 6-12 weeks through 110 weeks after radiation is complete.
45669479|NCT03572933|Drug|ganaxolone|active drug
45669480|NCT03572933|Drug|Placebo|inactive
45669481|NCT03558152|Drug|UTTR1147A|UTTR1147A will be administered intravenously (IV) at dose levels 1, 2, or 3 in Part A, and at the maintenance dose level in Part B, per the respective arm descriptions.
45669482|NCT03558152|Drug|UTTR1147A Placebo|The matching placebo to UTTR1147A (UTTR1147A Placebo) will be administered IV.
45669483|NCT03558152|Drug|Vedolizumab|Vedolizumab will be administered IV, as specified in the prescribing information.
45669484|NCT03558152|Drug|Vedolizumab Placebo|The matching placebo to vedolizumab (Vedolizumab Placebo) will be administered IV.
45669485|NCT03768999|Diagnostic Test|Non-contrast magnetic resonance coronary angiography (MRCA)|Scan non-contrast MRCA and compare the image with clinically scanned coronary computed tomography angiography (CTA).
45669486|NCT03537963|Other|mHealth Stepped-care Intervention|Test of the feasibility and acceptability of an mHealth stepped-care intervention for sleep disturbance in HCT survivors, to compare with the control group.
45669487|NCT03537963|Other|Educational Control Condition|General health education for cancer survivors provided in NCI booklets entitled Facing Forward: Life After Cancer Treatment and Coping With Advanced Cancer.
45970602|NCT00223691|Drug|Atomoxetine|10-50 mg, PO. Single dose. Alone or in combination with Yohimbine or Mestinon.
45970603|NCT00223691|Drug|Acarbose|25-100 mg, PO. Single dose.
45970604|NCT00223691|Drug|Pyridostigmine Bromide|30 mg-180 mg PO. Single dose. Alone or in combination with Yohimbine or atomoxetine.
45970605|NCT00223691|Drug|Yohimbine|2.7, 5.4 or 10.8 mg PO. Single dose. Alone or in combination with Atomoxetine or Pyridostigmine.
45970606|NCT00223691|Drug|Midodrine HCl|2.5, 5.0, 7.5, 10 mg PO. Single dose
45970607|NCT00223691|Drug|placebo|PO.Single dose.
45970608|NCT00223691|Drug|Modafinil|50-400 mg PO. Single dose
45970609|NCT00223691|Drug|Octreotide|5-50 µg, S.C. Single dose.
46081248|NCT04963270|Drug|Satralizumab|Satralizumab will be administered as a subcutaneous injection
46081249|NCT04963270|Other|Placebo|Satralizumab placebo will be administered as a subcutaneous injection
46081250|NCT04959175|Drug|Mycophenolate Mofetil|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
46081251|NCT04959175|Procedure|Allogeneic HSCT|Stem cell transplant
46081252|NCT04959175|Drug|Fludarabine|30 mg/m2 IV infusion over 30-60 minutes once daily for 5 days (Pre-Transplant days -6 through -2).
45827885|NCT05893862|Drug|Moxifloxacin|Oral Tablet
45827886|NCT05893862|Drug|Placebo|Oral Tablet
45970610|NCT00223691|Other|water intake|Tap water 2 onz., 8 oz., 16 oz. PO, alone or in combination with any of the above medications. Single dose.
45970611|NCT00223691|Drug|Diphenhydramine Hydrochloride|12.5 mg-100 mg PO. Single dose. Alone or in combination with Ranitidine
45827887|NCT05893849|Drug|Clinical probes|Inpatients taking one or more clinical probes of CYP2C19 (omeprazole, rabeprazole, pantoprazole), CYP2D6 (metoprolol, carvedilol), CYP3A4 (rivaroxaban, finasteride, amlodipine, simvastatin), OAT (meropenem), OATP1B1 (atorvastatin, rosuvastatin) and OCT (metformin) will be included in the study.
45827888|NCT05893810|Drug|Mupirocin Ointment|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares
45835884|NCT04771104|Dietary Supplement|Amino Acid Challenge (AAC)|The AAC contains 54 g banana flavoured amino acid mixture added 200-300 mL of water. The AAC simulates the composition of haemoglobin in approximately 400 mL of blood.
45827889|NCT05893784|Other|Use of progressive relaxation exercises education|Progressive relaxation exercises education It starts with deep breathing exercises along with music. Then stretching and relaxation exercises are performed. After the education, an 8-minute video in which the progressive relaxation exercises was explained practically to the individuals was sent to their mobile phones. The participants were asked to perform these exercises regularly for 4 weeks, each day one hour before going to bed, simultaneously with the video.
45970612|NCT00223691|Drug|Ranitidine HCL|150-300 mg PO. Single dose. Alone or in combination with Diphenhydramine.
45970613|NCT00223691|Drug|Tranylcypromine|5 - 40 mg PO. Single dose
45970614|NCT00223691|Drug|Ergotamine/ Caffeine|Ergotamine: 1.0 mg PO. Single dose. Caffeine 100 mg PO.Single dose
45970615|NCT00223691|Drug|Celecoxib|50-200 mg PO. Single dose
45970616|NCT00223691|Drug|Pseudoephedrine|15, 30 or 60 mg, PO. Single dose.
45970617|NCT00223691|Drug|Methylphenidate|5 or 10 mg PO. Single dose.
45669488|NCT03537963|Other|Questionnaire|After the intervention, participants will be asked to complete a questionnaire to provide feedback on the intervention.
45970618|NCT00223691|Drug|Indomethacin|25, 50 or 75 mg, PO. Singe dose.
45970619|NCT00223691|Drug|Ibuprofen|300, 600 or 900 mg, PO. Single dose.
45970620|NCT00223691|Drug|Oxymetazoline 0.05% nasal solution|1-2 sprays/ nostril. Single dose.
46081253|NCT04959175|Drug|Sirolimus|Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, max initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +60 with no taper. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
45970621|NCT00223691|Dietary Supplement|Bovril|6-10 g, PO. Single dose.
46081254|NCT04959175|Drug|Filgrastim|begins on day +5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously, until the absolute neutrophil count is > 1,000/mm3 over the course of three days or > 5,000/mm3 on one day. Rounding to the nearest vial is allowed. G-CSF may be stopped early or not administered if required by the clinical circumstance. Additional G-CSF may be administered as warranted.
45669489|NCT03537963|Other|Interview|Qualitative interviews will be gathered after the participants have completed participation in the new intervention to gather data to inform future refinements of the intervention.
45827890|NCT05893758|Device|The Cera™ PFO Occluder|The Cera™ PFO Occluder is a percutaneous, transcatheter closure device for the non-surgical closure of Patent Foramen Ovale (PFO).
45827891|NCT05893745|Other|Supervised Exercise Program|Participants in the control group will receive a supervised exercise program that consists of three weekly sessions in addition to home exercises, over the course of four weeks. This program will include stabilization, flexing, extension, and rotation exercises for the cervical region and self-mobilization targeting the deep neck muscles. Participants will be instructed to perform the exercises at home three times a week in a manner that did not cause pain.
45970622|NCT00223691|Drug|Acetazolamide|125-1000 mg PO. Single dose. Alone or in combination with yohimbine or midodrine
45970623|NCT00223691|Drug|Rivastigmine tartrate|1.5-6 mg PO. Single dose.
45970624|NCT00223691|Drug|Carbidopa/levodopa|10mg/100mg or 25mg/100mg. 1-2 tab PO. Single dose. Alone or in combination with carbidopa (Lodosyn) 25-175 mg
45970625|NCT00223691|Device|Inflatable abdominal binder|External abdominal compression (20-40 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
45970626|NCT00223691|Device|inflatable abdominal binder (sham)|External abdominal compression (5 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
45970627|NCT04583020|Drug|Camrelizumab|Neoadjuvant Camrelizumab 200mg IV, adjuvant Camrelizumab 200mg IV (once every two weeks, until progress)
45970628|NCT04583020|Radiation|radiation|60Gy/30
45970629|NCT04583020|Drug|Temozolomide|Given PO during RT 75mg/m2/d; 4 weeks post RT 150-200mg/m2/d days 1-5, 4 weeks/cycle, 6 cycles
45970630|NCT04583059|Other|Taping|A hard-preventive Zinc oxide tape was used in this study. Taping procedure consists of three separate steps: First step involved application of the anchor tape, which achieved by applying the tape circumferentially just above the malleolar level at the lo
45970631|NCT04582552|Drug|PARP inhibitors|Ovarian cancer patients with PARP inhibitors according to the NCCN guideline and their instructions.
45970632|NCT00568204|Device|Mexyn-A|Atomised topical self-chilled pressurised spray
45970633|NCT04582747|Diagnostic Test|Urinary Biomarkers (NGAL, DKK-3, IGFBP-7/TIMP-2, KIM-1)|"Validation of Urinary biomarker tests for the rapid prediction of AKI.~No intervention is being proposed as part of the study. Concentrations of Urinary biomarkers will be obtained post operatively. These concentrations will be assessed to ascertain their predictive ability for the development of Acute Kidney Injury post-operatively."
45970634|NCT00223730|Drug|Citrulline|Oral provision of amino acid citrulline to support impaired urea cycle function during escalated dose chemotherapy for stem cell transplant
45970635|NCT00223730|Drug|Placebo|
45970636|NCT04582630|Dietary Supplement|omega 3 fatty acid|Participants will take 0.1-0.2 g/kg/day of omega 3 fatty acids for 7 days.
45970637|NCT04582786|Drug|Morphine|Repeated bolus according to pain score
45970638|NCT04582786|Drug|Morphine HCl|Infusion of morphine HCl solution for intravenous administration
45970639|NCT04582786|Drug|STR-324|Infusion of solution for intravenous administration
45970640|NCT04582513|Other|AnCHor-Checklist implementation|a standardized checklist using the SBAR concept according to the recommendations of the DGAI
45970641|NCT00223769|Drug|Oxandrolone|
45827892|NCT05893745|Other|Supervised Exercise Program plus Dermoneuromodulation Techniques|Participants in the study group will receive the same supervised exercise program as the control group, with home exercises, in addition to two dermoneuromodulation techniques for the Dorsal Cutaneous Nerve (C3-T1), which are the skin stretch technique and kitten technique. Patients in this group will receive 3 sessions/week for a total of 4 weeks.
45970642|NCT04583449|Behavioral|Mental imagery|"Mental imagery involves the mental representation of a future event, action, or task. By imitating or rehearsing this mental event or series of events (Taylor et al., 1998, p. 430) mental imagery interventionists theorise that an individual's preparation for, and motivation toward, a future action can be made more likely. Mental imagery involves an individual following a set of pre-defined exercises involving thinking about, visualising and writing about a health-related action. Mental imagery exercises can involve focusing on anticipated positive/beneficial outcomes of an action (outcome imagery) or imagery relating to the anticipated strategies/preparation that would be required to successfully execute a pre-defined action (process imagery)."
45970643|NCT04582474|Other|Dengue module and rapid diagnostic tests|Digital platform providing clinical decision support for Dengue, Dengue rapid diagnostic tests and training will be deployed at study sites for Dengue screening, diagnosis, case management as well as reporting to surveillance system following local guidelines
45827893|NCT05893732|Device|High-Intensity Laser Therapy (HILT)|Participants will undergo HILT treatment using a diode laser device (wavelength: 1064 nm; power: 12 W; peak power: 50 W; energy density: 600 J/cm²; spot size: 1 cm²; pulse duration: 200 μs; pulse frequency: 10 Hz) applied in continuous mode. The laser probe will make contact with the skin over the LFCN entrapment site at three specific points: (a) the inguinal ligament, (b) the point of maximum tenderness along the nerve pathway, and (c) the mid-point between the ASIS and the lateral border of the patella. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
45970644|NCT04582123|Procedure|crossed pin configuration|comparison of two crossed pin fixation methods
46081255|NCT04959175|Drug|Cyclophosphamide|Pre-transplant: 14.5 mg/kg/day IV daily for 2 days pre-transplant (Pre-Transplant days -6 and -5). Post-transplant: 25 mg/kg/day or 35 mg/kg/day (Post-transplant days +3 and +4).
45970645|NCT04582084|Drug|Etanercept|Patients received biosimilar etanercept 25 mg twice weekly or 50 mg once weekly.
46081256|NCT04959175|Drug|Mesna|25 or 35 mg/kg (equal to the cyclophosphamide dose) as IV infusion concomitant with cyclophosphamide. Mesna may or may not be given with the pre-transplant cyclophosphamide depending on institutional practice.
46081257|NCT04959175|Procedure|Total Body Irradiation (TBI)|400 centigray (cGy) to be delivered in 2 fractions as 200 cGy per fraction twice daily. Pre-Transplant Day -1 (or Day 0 prior to graft administration)
46081258|NCT04958785|Drug|Magrolimab|Administered intravenously
46081259|NCT04958785|Drug|Nab-Paclitaxel|Administered intravenously
46081260|NCT04958785|Drug|Paclitaxel|Administered intravenously
46081261|NCT04958785|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
45970646|NCT00254046|Drug|TMC125|2 X100 mg tablets b.i.d.96 weeks
45970647|NCT00254046|Drug|Placebo|2 tablets b.i.d.96 weeks
45970648|NCT00568360|Device|Oximeter|
45970649|NCT00223847|Behavioral|Constraint Induced Language Therapy|
45970650|NCT04582162|Other|Unsplinted implants|Patients received ball abutments on each implant without splinting for retaining an implant retained mandibular overdenture.
45970651|NCT04582162|Other|Splinted implants|Patients had their implants splinted using Rhein bars with ball extension for retaining an implant retained mandibular overdenture.
45970652|NCT04582396|Procedure|stellate ganglion block injection|A stellate ganglion block (SGB) is an injection of local anesthetic (numbing medicine) to block the nerves located on either side of the voice box in the neck. It will be administered in an inpatient monitored setting.
45970653|NCT04582396|Procedure|Normal saline injection|An injection of normal saline will be injected into muscle on either side of the voice box in the neck. It will be administered in an inpatient monitored setting.
46081262|NCT04955405|Other|The seven visit telemedicine protocol|The transition of care team (pharmacist, advanced practice provider, social worker) will conduct an initial visit as a team with the patient using the telemedicine platform. During the visit, the team will assess the clinical, social, and pharmaceutical needs of the patient. The transition of care team will then meet to discuss the specific needs of the patient and to develop a care plan for the next 6 telemedicine visits. Either the social worker or the advanced practice provider will conduct the next 6 visits. The pharmacist will provide medication counseling as needed and recommended by the entire care team. The next 3 visits will occur weekly, the following 2 visits will occur biweekly, and the remaining 1 visit will occur at some point during the third month.
46081263|NCT04951466|Behavioral|Mindfulness-based therapy for insomnia (MBTI)|Participants randomly assigned to either the MBTI or healthy lifestyle intervention will receive 2 hours weekly session of mindfulness meditation and behavioral sleep strategies for 8 weeks.
46081264|NCT04951466|Behavioral|Healthy lifestyle intervention|Participants randomly assigned to either the MBTI or healthy lifestyle intervention will receive 2 hours weekly session of mindfulness meditation and behavioral sleep strategies for 8 weeks.
46081265|NCT04938830|Biological|Clesrovimab|IM injection
46081266|NCT04938830|Biological|Palivizumab|IM injection
46081267|NCT04938830|Biological|Placebo|IM injection
46081268|NCT04934306|Other|Nasometry|Repetition of several stimuli (syllables, sentences ) in the microphones of the Nasometer
45455828|NCT05629546|Biological|Memory-like natural killer cells|Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core Facility (BTCF).
45455829|NCT05629546|Biological|Relatilmab|Standard of care
45455830|NCT05629546|Biological|Nivolumab|Standard of care
45970654|NCT04582396|Behavioral|Psychoeducation|"The session will be 30 minutes in duration, to be administered by a health professional with experience working with CA patients, the goal will be to establish rapport and help patient identify anxious situations, thoughts, and bodily feelings related their recent CA that could lead to avoidant behavior.~Explain how many of these feelings are common in CA survivors, and they are often unrelated to their risk of its recurrence. Explain how the body has a fight-or-flight system that is controlled in part by the stellate ganglion and explain how blocking the action of this part of the body can reduce the feelings of anxiety that commonly occur. Discuss how certain activities such as exercise can increase feelings of anxiety around bodily sensations, but continued engagement could reduce that fear and that exercise is helpful for recovering from CA"
45970655|NCT04582240|Other|no intervention|no intervention
45970656|NCT04581772|Drug|DNL343|Multiple oral doses
45970657|NCT04581772|Drug|Placebo|Single oral dose
45970658|NCT04581772|Drug|DNL343|Single oral dose
45669490|NCT03537963|Other|Qualitative Interviews|To conduct qualitative interviews with patients, caregivers, and clinicians regarding sleep disturbance in HCT survivors and on preferences for a new mHealth intervention for sleep disturbance. Separate panels of 10 HCT survivors, 10 caregivers who were the primary caregiver of an HCT survivor during or after the inpatient HCT hospitalization, and 5-10 HCT clinicians will be recruited for individual qualitative interviews via telephone or in person.
45970659|NCT00223925|Drug|Maribavir|
45970660|NCT00223925|Drug|Placebo|
45970661|NCT00254085|Drug|Insulin Aspart|
45970662|NCT04582006|Procedure|Bariatric surgery|Surgical treatment of morbid obesity.
45669491|NCT03537963|Other|Virtual Reality|The intervention will comprise six 360º videos of relaxing natural landscapes from which patients can choose (i.e., beaches, tropical scenes, calm thunderstorms, snowfall). Participants will also choose an audio accompaniment: a progressive muscle relaxation script, a deep breathing exercise script, a mindfulness meditation script, or scene-relevant audio (e.g., waves crashing for the beach scene).
45669492|NCT03533543|Device|CEM|All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital will receive 24-hour cardiac monitoring until discharge.
45970663|NCT04581967|Genetic|polymorphism analysis|"DNA will be purified from whole blood samples by commercial DNA isolation kits.~Genotyping and genetic polymorphism detection for some metabolic enzymes genes will be performed by real time PCR."
45970664|NCT04581967|Drug|Doxorubicin-Cyclophosphamide regimen|Treatment with a combination of Doxorubicin and Cyclophosphamide, This regimen comprises 60 mg/m² Doxorubicin and 600 mg/m² Cyclophosphamide administered intravenously on day 1 of each 21-day cycle, and repeated for a total of four cycles.
45970665|NCT04581577|Other|Semi-structured telephone questionnaire|Semi-structured telephone questionnaire
46081269|NCT04932278|Procedure|Osteopathic manipulative treatment|Osteopathic manipulative treatment (OMT) is hands-on care provided by an osteopathic physician (D.O.). During osteopathic manipulative treatment, an osteopathic physician may move participants' muscles and joints using osteopathic techniques including stretching, gentle pressure and resistance, as well as thrust techniques that apply a quick, therapeutic force of brief duration that travels a short distance.
46081270|NCT04932278|Procedure|Usual care|Routine concussion management with healthcare professionals.
45827894|NCT05893732|Device|Sham High-Intensity Laser Therapy (Sham HILT)|Participants will undergo sham HILT treatment using an identical laser device with no active laser output, following the same treatment protocol as the HILT group. The laser probe will make contact with the skin over the LFCN entrapment site at the same three specific points as the HILT group. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
45669493|NCT03511196|Drug|Adaptive Androgen Deprivation Therapy (ADT)|ADT with Leuprolide, Goserelin, or Triptorelin, as GnRH agonist, every 4 weeks as outlined in study arm description.
45827895|NCT05893719|Device|iNedit, iNdeep, iNtercept|Patients to undergo mechanical thrombectomy with iNedit, iNdeep and iNtercept
45970666|NCT00223964|Drug|Ferrlecit (sodium ferric gluconate complex in sucrose injection)|
45970667|NCT04581694|Diagnostic Test|TAVI without contrast|TAVI without contrast
45970668|NCT00254124|Device|The Diet Plate (R) TM portion control plate and bowl|
45970669|NCT04581421|Other|High Carb Low Fat Diet|The participants will be randomized to a diet of low carb/ high fat og high carb/low fat
45455831|NCT05621512|Other|Preventive sessions|Preventive sessions between the pregnant employee, her manager and a midwife.
45455832|NCT05612724|Device|Testing for SARS CoV2 Antigen|Device: Testing for SARS CoV2 Antigen Antigen testing: Rapid Antigen testing (Point-of-care)
45827896|NCT05893693|Other|Biological|CT0594CP
45827897|NCT05893654|Drug|Melphalan Injection|7.5mg of melphalan injected via intra-arterial catheterization of the ophthalmic artery.
45970670|NCT04581421|Other|Low Carb High Fat Diet|The participants will be randomized to a diet of low carb/ high fat og high carb/low fat
45970671|NCT00224081|Drug|Sodium ferric gluconate,|Sodium ferric gluconate, 125 mg IV given at 8 consecutive hemodialysis sessions
45970672|NCT04581265|Drug|albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin|Participants received a single dose of albumin-bound paclitaxel (nab-PTX) 270mg/m2/d, administered intravenously (IV) on Day 1; Ifosfamide 1.2g/m2/d administered intravenously (IV) on Day 2-6; Cisplatin 20mg/m2/d administered intravenously (IV) on Day 2-6.
45970673|NCT04581187|Other|Quality of life assessment|Quality of life questionnaires
45970674|NCT00414999|Drug|TG100801|
45970675|NCT04580875|Procedure|Minimally invasive surgery (laparoscopy and laparoscopic-assisted procedures) in both diagnosis and treatment of penetrating abdominal trauma in Children|
45970676|NCT04581109|Biological|Blood sample|Twenty ml of blood will be drawn from each patient : 10 ml of blood will be drawn on CellSave tubes (fixed cells) for CTC detection using the FDA-cleared CellSearch system (gold standard) and 10 ml of blood will be drawn on EDTA tubes (viable cells) for the detection of functional CTCs using the EPIDROP.
45970677|NCT02962466|Other|CC-Test|classification of the oocyte based on the expression pattern observed in the cumulus cells
45970678|NCT04580797|Drug|PF-06700841 IR|Immediate release formulation
45970679|NCT04580797|Drug|PF-06700841 MR1|Modified release formulation 1
45970680|NCT04580797|Drug|PF-06700841 MR2|Modified release formulation 2
45970681|NCT04580797|Drug|PF-06700841 MR3|Modified release formulation 3
45970682|NCT04580797|Other|Placebo|Matching placebo
45970683|NCT00415038|Drug|Rostafuroxin|1 capusle of 50 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
45970684|NCT00415038|Drug|Rostafuroxin|1 capusle of 150 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
45970685|NCT00415038|Drug|Rostafuroxin|1 capusle of 500 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
45827898|NCT05893654|Radiation|Plaque brachytherapy|Brachytherapy will be performed using a 24-mm notched plaque with Ruthenium-106 seeds.
45970686|NCT00415038|Drug|Rostafuroxin|1 capusle of 1.5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
45970687|NCT00415038|Drug|Rostafuroxin|1 capusle of 5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
46081271|NCT04929678|Device|Braive™ Growth Modulation System (Braive™ GMS)|"The Braive™ GMS is designed as a growth-modulation, non-fusion technique, which utilizes patients' remaining growth potential to limit further progression of the curve, to provide correction of the thoracic spine, and allow continued growth while maintaining mobility.~The system consists of the following components: Braid, Fixed Angle Screws (FAS), Plate, and Break-Off Set Screw."
46081272|NCT04926857|Other|Non-Interventional|Non-Interventional
45970688|NCT00224159|Behavioral|Drug and Dietary behavior|
45669494|NCT03511196|Drug|Abiraterone|Prednisone 5 mg once a day with food.
45669495|NCT03511196|Drug|Prednisone|Abiraterone 1000 mg daily with empty stomach.
45970689|NCT00568477|Drug|MabThera|"Rituximab (MabThera):~375 mg/m² as IV infusions over >=6h each at time point 0 and 2 weeks. Initial infusion rate of 50 mg/h, stepwise rise is possible after 30 minutes"
45970690|NCT04580836|Procedure|Magnetic Resonance Imaging|Undergo MRI
45970691|NCT04580836|Other|Questionnaire Administration|Ancillary studies
45970692|NCT04580836|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45970693|NCT00415077|Procedure|PRK|PRK
45970694|NCT00415077|Procedure|MMC PRK|mitomycin C PRK
45669496|NCT03502668|Drug|ASTX727 LD|oral decitabine (LD) + cedazuridine (E7727)
45669497|NCT03502668|Drug|ASTX727 SD|oral decitabine (SD) + cedazuridine (E7727)
45669498|NCT03501368|Drug|Ceritinib|Participants will take ceritinib by mouth (PO) once daily at a dose of up to 450 mg (3 capsules of 150 mg)
45669499|NCT03501368|Drug|Trametinib|Participants will take trametinib by mouth at a dose of 2 mg daily
45970695|NCT00415077|Procedure|LASEK|LASEK
45970696|NCT00568516|Drug|ASP3550|subcutaneous administration
45827899|NCT05893641|Behavioral|A regular training volume|Participate will maintain their training volume of 35 h/week
45970697|NCT00224198|Procedure|Lung Disease|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. In the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways.In the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently to obtain epithelial cells lining the airway. Certain individuals may have bronchial wall biopsy carried out. In this procedure, a small biopsy forceps is passed through the bronchoscope and a small biopsy is obtained from the bronchial wall.
45970698|NCT00568711|Drug|doxycycline|a 5-day course of 100 mg bid doses of doxycycline
45970699|NCT00568711|Drug|rifampin|a 5-day course of daily 600-mg doses of rifampin
45970700|NCT04580758|Combination Product|Fractional laser with PRP fluid or PRP gel|20 participants divided into 2 groups of 10 10 participants will do Fractional laser with PRP fluid sessions and 10 participants will do Fractional laser with PRP gel
46081273|NCT04913753|Procedure|CBEU|Patients in the control group will have bacterial culture and double J removal will be performed as usual. .
45827900|NCT05893641|Behavioral|A lower exercise volume group|Participate will conduct 85% of the control group weekly training volume (i.e., 30h/week)
45827901|NCT05893641|Behavioral|A longer rest group|Participate will maintain the 35 h/week of exercise training
45827902|NCT05893628|Other|muscle length and muscle endurance assessment|Pectoralis Minor Length and muscle endurance evaluation
45835885|NCT00060606|Procedure|Prenatal Myelomeningocele Repair Surgery|Fetal surgery to repair spina bifida defect performed prior to 26 weeks of gestation with delivery by C-section at approximately 37 weeks of gestation.
45835886|NCT00060606|Procedure|Postnatal Myelomeningocele Repair Surgery|Standard postnatal surgical closure of the spina bifida defect
45970701|NCT04580641|Other|Questionnaire|A self-administered questionnaire will be completed by each study subject
45970702|NCT00415116|Drug|carboplatin|
45970703|NCT00415116|Drug|docetaxel|
45970704|NCT00415116|Drug|lenalidomide|
45970705|NCT00568750|Drug|dasatinib|Dasatinib is given orally 70 mg BID. Dasatinib will be continued until progression, unacceptable toxicity and up to 2 years (26 cycles, each cycle lasting 4 weeks).
45970706|NCT00568789|Drug|Ramelteon, zolpidem and placebo|"Ramelteon 8 mg, tablets, orally, one night only during Period 1, 2 or 3~Zolpidem 10 mg, tablets, orally, one night only during Period 1, 2 or 3~Ramelteon/Zolpidem placebo-matching tablets, orally one night only during Period 1, 2 or 3"
45970707|NCT00254202|Drug|iloperidone|
45669500|NCT03482141|Device|Whole Exome Sequencing (WES)|The Investigators will enroll pregnant women with fetal anomalies detected by ultrasound. Patients will be approached by a maternal-fetal specialist, who has counseled the patient regarding the fetal anomaly that has been detected. Written informed consent will be obtained by the study prenatal genetic counselor. Many patients will have undergone prenatal diagnostic testing in an outside laboratory; in such cases, cells or extracted DNA from the original fetal sample will be used for the purpose of this study. The consent process for prenatal WES will include pre-test counseling and the option of choosing whether or not to receive uncertain results and secondary findings. After conducting whole exome sequencing, the findings will be shared with the parent(s). Routine medical care will be provided to patients. The research will study the effectiveness of sequencing as a tool for providing genetic information to parents when a prenatal study reveals a fetus with a structural anomaly.
45827903|NCT05894083|Procedure|Surgery|Cohort A will undergo initial surgical resection of the primary and neck dissection with pathologic features directing predetermined adjuvant treatment. Pathology of the primary and nodal specimens will then be reviewed as to determine the next intervention per protocol. Based on operative findings including degree of nodal involvement, extracapsular spread, perineural invasion, and lymphovascular involvement, patients will be designated to adjuvant treatment arms consisting of observation, adjuvant radiation, or adjuvant chemoradiation.
45455833|NCT05611736|Other|cold saline|After standard chemo-mechanical preparation of the root canal, final irrigation will be performed using 20 milliliters of cold (at 2.5 degrees Celsius temperature) saline solution.
45669501|NCT03477175|Drug|E7080|Oral Administration.
45970708|NCT00254202|Drug|active comparator|
45970709|NCT00254202|Drug|placebo|
45970710|NCT00568945|Drug|Capadenoson (BAY68-4986)|4 mg BAY68-4986 for five days
45970711|NCT00568984|Drug|repaglinide|
46081274|NCT04913753|Procedure|No CBEU|Patients in the experimental group will have bacterial culture and double J removal will be performed as usual. .
46081275|NCT04902365|Other|neurofeedback|(based on real-time functional magnetic resonance signals)
45669502|NCT03477175|Drug|Comparator Drug|Per parent study.
46081276|NCT04895189|Other|No intervention|There is no intervention for this observational study. The investigators are observing the changes in participants before and after the participants receive the COVID-19 vaccine, which participants will receive outside of the study.
45669503|NCT03477175|Drug|Comparator Drug: Sorafenib|Per parent study.
45669504|NCT03461406|Biological|Fibrin Sealant Grifols|The FE Grifols solution was applied topically via drip or spray application.
45827904|NCT05894083|Combination Product|Chemoradiation|Patients will receive an initial plan with a single prescription of 30 Gy in 15 fractions to PTV_High and PTV_Low with RT given once daily, 5 days a week (Monday through Friday). After analysis of mid-treatment PET/CT, the remaining radiation treatment will be delivered as a conedown to the gross disease only. Patients will be planned to receive a total dose of 70 Gy, 54 Gy, or 44 Gy to PTV_High in 2 Gy per fraction.
45669505|NCT03461406|Biological|EVICEL|The EVICEL solution was applied topically via drip or spray application.
45669506|NCT03431974|Drug|LD-Aminopterin oral capsule|anti-folate treatment
45669507|NCT03431974|Drug|Placebo oral capsule|Microcrystalline filled capsule to mimic capsule containing aminopterin tablets
45835887|NCT04771338|Behavioral|VR-JIT/KF-STRIDE|Treatment group will receive 12 sessions of job interview training protocol.
45835888|NCT04771026|Drug|Dexamethasone|Pre-operatively nebuliser dexamethasone 8mg prior to induction of anesthesia
45835889|NCT00063570|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 14 days, until disease progression
45970712|NCT00568984|Drug|metformin|
45970713|NCT00568984|Drug|glicazide|
45970714|NCT00254241|Drug|Seroquel and Risperidone|
45970715|NCT00569023|Dietary Supplement|alga Dunaliella bardawil|"Each patients will be treated with four capsules daily of Dunaliella bardawil for 90 days.~Alga Dunaliella bardawil containing 15 mg approximately 50% all-trans beta-carotene and 50% 9-cis beta-carotene isomers"
45970716|NCT00224315|Drug|ziprasidone|
45970717|NCT00224315|Drug|risperidone|
45970718|NCT00569101|Drug|tacrolimus|during the first 2 months : tacrolimus 0.1 mg/kg + prednisolone 0.8 mg/kg p.o. ,then after : tacrolimus 0.1 mg ~0.02 mg/kg + prednisolone tapering
45970719|NCT00569140|Drug|E10030|Intravitreal injection
45970720|NCT00569179|Device|CliniMACS CD34 Reagent System|Alloreactive NK cells will be purified by a two-step immunomagnetic selection (CD3 depletion followed by CD56 selection) using the CliniMACS device.
45970721|NCT00569257|Drug|AEZS-108|intravenous infusion at a dose of 267 mg/sqm every 3 weeks, up to 6 treatment cycles
45970722|NCT00224354|Biological|IL-2 secreting and hCL4OL-expressing autologous B-CLL cells|Patients will be treated with six subcutaneous injections of their IL-2-secreting and hCD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window
45970723|NCT00224354|Biological|IL-2|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
45970724|NCT00224354|Biological|CD40L|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
45970725|NCT00224354|Drug|ONTAK|an interleukin-2 immunotoxin directed to the CD25 antigen (denileukin diftitox, ONTAK
45970726|NCT00224354|Biological|immunotoxin dose|Days 0, 2, and 4 (18 ug/kg) i.v
45827905|NCT05894083|Other|Observation|Cohort A will undergo initial surgical resection of the primary and neck dissection with pathologic features directing predetermined adjuvant treatment. Pathology of the primary and nodal specimens will then be reviewed as to determine the next intervention per protocol. Based on operative findings including degree of nodal involvement, extracapsular spread, perineural invasion, and lymphovascular involvement, patients will be designated to adjuvant treatment arms consisting of observation, adjuvant radiation, or adjuvant chemoradiation.
45970727|NCT00254280|Procedure|Intense Pulsed Light + paring versus paring alone|
45970728|NCT00569296|Biological|EGFRBi-armed autologous activated T cells|Dose escalation, dosage depends on when entered in study. 8 infusions (twice a week over 4 weeks. Each infusion will be over at least 1 hour.
45970729|NCT00569296|Biological|aldesleukin|300,00IU/m2/day beginning 3 days before the first Activated T-cell infusion and ending 1 week after the last infusion
45970730|NCT00569296|Biological|sargramostim|250 micrograms/m2/twice weekly beginning 3 days before the first activated T-cell infusion and ending 1 week after the last Activated T-cell infusion
45970731|NCT00569335|Drug|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).~Irinotecan 150 mg/m2 is administered by intravenous infusion on day 1. Bevacizumab 7.5 mg/kg (body weight) is administered by intravenous infusion on day 1."
45970732|NCT00254319|Drug|Avastin, Alimta|
45970733|NCT00569452|Device|Accu-Chek Spirit Insulin Pump|One basal rate
45669508|NCT03426748|Radiation|Low dose rate prostate brachytherapy|Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance
45970734|NCT00569452|Device|Accu-Chek Spirit Insulin Pump|Multiple basal rates
45970735|NCT00569491|Device|TAXUS Express 2™|TAXUS Express™ Paclitaxel-Eluting Coronary Stent System
45970736|NCT00569569|Drug|juxtascleral depot injection of Retaane|juxtascleral depot injection of Retaane
45455834|NCT05611736|Other|saline|After standard chemo-mechanical preparation of the root canal, final irrigation of the root canal will be done using normal saline solution at room temperature
45455835|NCT05607043|Device|Testing for SARS CoV2 RNA|Device: Testing for SARS CoV2 RNA- lab-based RNA RT-PCR testing
45669509|NCT03426748|Radiation|High dose rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
45669510|NCT03416335|Drug|DSP-0509|Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump.
45669511|NCT03416335|Drug|DSP-0509, Pembrolizumab|Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (200 mg IV q3w)
45669512|NCT03416335|Drug|DSP-0509, Pembrolizumab|Each patient treated will receive DSP-0509 at the Recommended Phase II Dose (RP2D) level as determined in Part B. It is given as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (400 mg IV q6w)
45827906|NCT05894083|Radiation|Post-operative radiation|Patients will receive adjuvant radiation based on pathologic features.Total radiation treatment doses and prescriptions will include 36 Gy in 18 fractions, 50 Gy in 25 fractions and 60 Gy in 30 fractions.
45827907|NCT05893615|Behavioral|Cognitive Behaviour Therapy|The CBT module was adjusted as follows: (1) Health education about paroxysmal atrial fibrillation; (2) Self-awareness training; (3) Exposure training; (4) Habitual reversal training；(5) Correcting cognitive distortion; (6) Behavioral activation (7) Specific training for anxiety; (8) Practice and feedback; (9) Relapse prevention; (10) Review.
45827908|NCT05893602|Other|Blood sample analysis|Blood sample analysis on Cobalt and Chrome will be performed during the period under study.
45970737|NCT00224432|Drug|probiotics: Lactobacillus GG, lactobacillus Rhamnosus|
45970738|NCT00569608|Other|Early Discharge|Application of an early discharge protocol from the neonatal intensive care unit.
45970739|NCT00569647|Device|Virtual Reality Hypnosis|Use of virtual reality headset to induce hypnotic state
45970740|NCT00569647|Device|Placebo|no use of device
45970741|NCT00569686|Drug|lovaza|lovaza 4 gm po daily
45970742|NCT00569686|Drug|placebo|placebo
45970743|NCT00569881|Drug|gatifloxacin and moxifloxacin|Comparison of wound healing between drugs
45970744|NCT00224471|Biological|GSK208141 vaccine|3 IM doses
45970745|NCT00569920|Drug|dexamethasone|IV dexamethasone 0,15 mg/kg bodyweight. Single-dose bolus injection after start of anesthesia. Medication is opened and administrated to the patient from a coded ampoule by the physician. The medication is diluted in such a way that 1 mL is equivalent to 10 kg body weight (1,5 mg/mL).
45970746|NCT00569920|Drug|natriumchloride 0,9%|iv natriumchloride 0,9% (placebo). 1 mL is equivalent to 10 kg body weight.
45970747|NCT00569920|Drug|dexamethasone|IV dexamethasone 0,30 mg/kg body weight. Drug diluted to 3,0 mg/mL and administrated in same way as arm 2.
45970748|NCT00569959|Other|fasting 12+ hours|fasting 12+ hours
45970749|NCT00569959|Other|Non-fasting|Non-fasting
45970750|NCT00569998|Device|NovoPen™ 4|
45970751|NCT00569998|Device|NovoPen® 3|
45970752|NCT00224510|Drug|lamotrigine|
45970753|NCT00570193|Drug|verteporfin (Visudyne)|Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1
45970754|NCT00570193|Drug|ranibizumab (Lucentis)|ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33&37 per study protocol
45970755|NCT00570271|Other|Placebo with BP dec (written form)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects in written form.
45970756|NCT00570271|Other|Placebo with BP dec (doctor)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects by doctor.
45970757|NCT00570271|Other|Placebo with BP inc (written)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects in written form.
45970758|NCT00570271|Other|Placebo with BP inc (doctor)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects by doctor.
45970759|NCT00570271|Other|Placebo info given (written)|Subject informed about receiving placebo. Information provided to subjects in written form.
45970760|NCT00570271|Other|Placebo info given (doc)|Subject informed about receiving placebo. Information provided to subjects by doctor.
45669513|NCT03408899|Drug|PC-1005 gel|PC-1005 (0.002% MIV-150/0.3% zinc acetate in 3.0% carrageenan gel) in 4 mL, 16 mL, and 32 mL doses administered rectally.
45827909|NCT05893589|Other|test group|Women in the intervention group participated in face-to-face and virtual meetings based on social cognitive theory structures for 4 weeks
45970761|NCT00570388|Drug|Prometa Treatment Program|"Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion. Flumazenil infusion.~Day 1•Gabapentin 300 mg po 9PM w/ hydroxyzine HCL 50 mg PRN for sleep.~Day 2•Gabapentin 600 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Day 3•Gabapentin 900 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Days 4 through 28•Gabapentin 1200 mg po 9 PM~Days 29 through 31•Gabapentin 900 mg po 9 PM~Days 32 through 34•Gabapentin 600 mg po 9 PM~Days 35 through 38•Gabapentin 300 mg po 9 PM~Flumazenil Dosing Schedule~2 mg flumazenil is given as a slow IV push. Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine; subjects in the active group will receive flumazenil, gabapentin, and hydroxyzine per protocol."
45970762|NCT00570427|Behavioral|Problem Solving Therapy (PST)|Counseling
45669514|NCT03363711|Other|AYA STEPS|a mobile health application
45669515|NCT03348956|Diagnostic Test|EPR Oximetry|Subjects will have up to five EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
45669516|NCT03328546|Other|Dietary intake|Dietary intake converted into dietary pattern scores.
45669517|NCT03317496|Drug|Avelumab 800 mg in combination with pemetrexed / carboplatin|Avelumab Pemetrexed Carboplatin
45669518|NCT03317496|Drug|Avelumab 800 mg in combination with gemcitabine / cisplatin.|Avelumab Gemcitabine Cisplatin
45669519|NCT03317496|Drug|Avelumab 1200 mg in combination with pemetrexed/carboplatin|Avelumab Pemetrexed Carboplatin
45827910|NCT05893563|Other|Standard Post-Operative Clinic Visit|In clinic, the joint will be assessed (ROM, stability testing), standard X-rays will be taken of the joint, and patient reported outcomes (questionnaires) will be completed by patient (WOMAC, UCLA, VR12, EQ5D, Oxford Hip).
45827911|NCT05893563|Other|Study-Specific Outcomes|Patients will complete additional questionnaires (SF12 and HHS), will undergo RSA and CT imaging for implant stability analysis, and will provide a stool sample for gut microbiome analysis.
45827912|NCT05893550|Dietary Supplement|Smartfish Omega|Fruit juice drink containing Omega-3: the experimental condition
45827913|NCT05893550|Dietary Supplement|Smartfish Fruit Juice Only|this is a fruit juice drink with no omega-3 added. it is the placebo condition
45970763|NCT00570427|Behavioral|Medication Management|If a participant chooses to receive antidepressant medication while in the study, a depression care specialist works with the participant's usual primary care provider to initiate an appropriate prescription and to follow-up with side effects, adherence, efficacy, etc. on a monthly or biweekly basis.
45970764|NCT00570466|Behavioral|Video Games|Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit,vegetable,water intake + physical activity + decrease TV viewing.
45970765|NCT00570466|Behavioral|Web and DVD knowledge|Web and DVD based knowledge games
45970766|NCT00224549|Drug|irbesartan, amlodipine and hydrochlorothiazide|irbesartan, amlodipine and hydrochlorothiazide
45970767|NCT00570544|Drug|tiotropium|18ug capsule daily for 30 days
45970768|NCT04580329|Procedure|neuromuscular electrical stimulation (NMES) in addition to routine hospital care|"Patients in the NMES group will receive NMES sessions as the electrodes will be placed around the bilateral femoral quadriceps muscles and at the site of renal arteries.~NMES(>100 Hz, 50-80 μ sec) will be performed for 55 min including 5 minutes for warm up and 5 minutes for recovery .~The intensity of electrical stimulation will be adjusted to suit the comfort level of each individual patient without producing discomfort or pain."
45970769|NCT04580329|Procedure|routine hospital care without NMES|routine hospital care include all the routine intervention done for post partum women with AKI including fluid resuscitation, diuretics, hemodialysis
45970770|NCT00254436|Drug|Procrit (epoetin alfa)|Weekly dose
45970771|NCT00224588|Drug|Ketamine (or placebo : isotonic saline solution)|
45970772|NCT00570622|Drug|Pioglitazone|Patients receive 60mg of pioglitazone once a day orally for 9 days
45970773|NCT00570622|Drug|Placebo|Patients receive placebo once a day orally for 9 days
45970774|NCT00254475|Drug|simvastatin|
45970775|NCT00254475|Drug|valsartan|
45970776|NCT00570817|Other|12 hours of prehydration|12 hours of prehydration with an infusion rate of 150 ml/m2/hour with a solution of 5% glucose with 40 mmol sodium bicarbonate/L and 20 mmol potassium chloride/L.
45970777|NCT00570856|Drug|Folic acid|Folic acid 5 mg/day
45827914|NCT05893537|Drug|Active Comparator CT1812|123 participants will receive a single daily dose of CT1812 (200 mg)
45970778|NCT00570856|Drug|Placebo|Placebo similar to the folic acid tablets, 1/day
45970779|NCT00570895|Dietary Supplement|Vitamin C|"Visit 1: Subjects will receive 1mg iron-58 sulfate as an aqueous solution with 50mg ascorbic acid.~Visit 2: Subjects will consume a meal of a bread muffin labelled with 4mg of iron-57 as ferrous fumarate, and a glass of apple juice containing 0 or 25mg ascorbic acid.~Visit 3: During this admission the apple juice will contain either 0 or 25mg ascorbic acid, the opposite of what was given to the subject in visit 2."
45970780|NCT00254514|Drug|somatropin|
45970781|NCT00570934|Dietary Supplement|Cholecalciferol|2000IU Cholecalciferol P.O. Q.D.
45970782|NCT00570934|Dietary Supplement|Calcium|1 gm calcium as calcium carbonate
45970783|NCT00570934|Dietary Supplement|Calcium and cholecalciferol|2000IU cholecalciferol and 1 gm calcium P.O. Q.D. for 6 months
45970784|NCT00570934|Drug|Placebo|Placebo
45970785|NCT00570973|Procedure|endoscopic band ligation|Endoscopic Band ligation of esophageal varices, performed every 2-4 weeks until resolution of varices
45970786|NCT00570973|Procedure|TIPS-Implantation|Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent, placed once, under fluoroscopic control,
45970787|NCT00571051|Behavioral|Mindfulness Based Stress Reduction|8 week course in mindfulness training
45970788|NCT00571090|Procedure|Thyroid ultrasonography|Ultrasound-guided thyroid fine-needle aspiration biopsy
45970789|NCT00254553|Drug|Testim 1% (testosterone gel)|Testim_ 100 mg: two tubes of 50 mg of Testim_per day
45970790|NCT00254553|Drug|Placebo|two tubes of placebo per day
45669520|NCT03317496|Drug|Avelumab 1200 mg in combination with gemcitabine/cisplatin|Avelumab Gemcitabine Cisplatin
45827915|NCT05893537|Drug|Placebo Comparator|123 participants will receive a single daily dose of placebo
45827916|NCT05893524|Diagnostic Test|Timed Up-and-Go (TUG single-task)|The TUG test is a well-established clinical test of one mobility sequence: rising from an armchair, walking straight ahead, passing a line marked on the floor, turning around, walking back, and sitting down again.
45827917|NCT05893524|Diagnostic Test|Timed Up-and-Go dual-task (TUGdt)|Two dual-task tests including TUG (TUGdt) were carried out: TUGdt naming animals and TUGdt months backwards. The outcomes registered were: time scores for TUG single-task and both TUGdt tests, TUGdt costs (relative time difference between TUG single-task and TUGdt), number of different animals named, number of months recited in correct order, number of animals per 10 s, and number of months per 10 s.
45835890|NCT00063570|Drug|Gemcitabine|1500 mg/m2, intravenous (IV), every 14 days, until disease progression
45970791|NCT00571129|Procedure|DCR with no tubes or mitomycin|"The patients were randomized into the two study groups, either with or without the insertion of a bicanalicular silicone tube after primary DCR.~In revision group patients were randomized into the two groups,ether with or without application of mitomycin C after DCR"
45970792|NCT00224627|Procedure|Capsule GIVEN IMAGING LTD|
45970793|NCT03453931|Drug|Corticosteroid injection|Intravenous high dose corticosteroids
45970794|NCT00571168|Drug|Emend|125 mg/d on day 1; 80 mg/d on day 2-4
45970795|NCT00571168|Drug|Placebo|Placebo capsules on day 1-4
45970796|NCT00571207|Device|On-site oral fluid screening devices|Comparison of screening device results to oral and/or blood sample results
45970797|NCT00571207|Behavioral|Checklist: drug recognition expert|Correlation of drug recognition expert observations to findings for drugs in non-suspected/suspected cases
45970798|NCT00571246|Drug|Topiramate|Participants are randomized to take Topiramate (250mg/day) 2 times a day
45970799|NCT00571246|Drug|lamotrigine|Participants are randomized to take Lamotrigine (250 mg/day) 2 times a day
45970800|NCT00571246|Other|Placebo|Participants are randomized to take placebo
45970801|NCT00254631|Drug|Oxycodone hydrochloride|
45970802|NCT00571285|Dietary Supplement|Vitamin D3|600 IU Vitamin D3 capsule daily
45970803|NCT00571285|Dietary Supplement|Vitamin D3 - high dose|50,000 IU Vitamin D3 capsule once a week
45970804|NCT00571285|Dietary Supplement|Placebo|Placebo capsule given once a week
45970805|NCT00224666|Device|Cortex stimulation|
45970806|NCT00571363|Procedure|standard surgery|excision with 4 mm margins
45970807|NCT00571363|Procedure|Mohs micrographic surgery|excision of basal cell carcinoma with 2 mm margins and immediate examination of margins for residual tumour. residual tumour was excised until complete tumour removal was achieved.
45970808|NCT00571402|Behavioral|Family-focused therapy for adolescents|FFT includes 25 sessions of psychoeducation, communication enhancement training, and problem-solving skills training plus ongoing pharmacological maintenance.
45970809|NCT00571402|Behavioral|Enhanced care|Enhanced care includes 3 sessions of family psychoeducation plus ongoing pharmacological maintenance.
45827918|NCT05893524|Diagnostic Test|Clinical functional assessment|The diagnostic procedure was part of the clinical routine for patients undergoing memory assessment and involved a geriatrician's careful evaluation of the patient's history and cognitive testing including Mini-Mental State Examination (MMSE), Clock Drawing Test, Verbal Fluency Test, and Trail Making Test A and B. In addition, all participants carried out short versions of the Geriatric Depression Scale and the General Motor Function Assessment Scale, as well as static balance according to the Bohannon Method, and hand grip strength using a dynamometer.
45970810|NCT00571480|Other|acupuncture|ear acupuncture needles will be inserted into three preselected acupuncture points which are thought to be specific for low back pain
45970811|NCT00571480|Other|Sham acupuncture|ear acupuncture needles are inserted into three preselected acupuncture points which are thought not specific to low back pain
46081277|NCT04888494|Device|Transcranial Magnetic Stimulation|For the brain stimulation the investigators will use Repetitive Transcranial Magnetic stimulation (rTMS). Different stimulation conditions (hippocampal or sham) will be delivered in each round of stimulation (5 days). Repetitive TMS will be applied at 100% resting motor threshold intensity, 20 Hz pulse trains separated by 28-s inter-train intervals (~20 minutes for the entire daily stimulation session). Stimulation parameters will be identical in both groups
45970812|NCT00571480|Other|standard of care|participants can take acetaminophen 650 mg no more than every 6 hours and frequent rest and topical warm/cold compress
45970813|NCT00224705|Device|Molecular Adsorbent Recirculating System (MARS®)|
46081278|NCT04888494|Device|Sham rTMS|Sham rTMS
46081279|NCT04880070|Device|Shockwave Treatment|Self-controlled, single-arm group using the Shockwave device.
46081280|NCT04869319|Behavioral|MyChart message|Message subjects through MyChart to follow-up with their provider to schedule a follow up HbA1C test.
46081281|NCT04868474|Behavioral|Training program and decision aid|1) a one-time, in-person, 2.5-hour training program encouraging participating GPs to present quitting smoking with a quit aid as the default choice to their eligible patients, and 2) access to an electronic decision aid that presents available quit aids. The 2.5-hour training program consists of: 1.5 hours of didactic teaching, with information about pharmacologic quit aids, electronic cigarettes, presenting quitting as a default choice, the decision aid, and a video of a model consultation. This is followed by 1 hour of role plays to practice presenting quitting as a default choice using the decision aid.
45970814|NCT00571558|Drug|aminolevulinic acid hydrochloride|Given PO
45970815|NCT00571558|Drug|photodynamic therapy|Undergo photodynamic therapy
45970816|NCT00571558|Other|laboratory biomarker analysis|Correlative studies
45970817|NCT02961231|Biological|PCV 2p+1|introduction of PCV in a reduced dosing 2p+1 schedule
45970818|NCT02961231|Biological|PCV 3p+0|introduction of PCV in a reduced dosing 3p+0 schedule
45970819|NCT02961231|Biological|PCV 1p+1|introduction of PCV in a reduced dosing 1p+1 schedule
45970820|NCT02961231|Biological|PCV 0p+1|introduction of PCV in a reduced dosing 0p+1 schedule
45970821|NCT00571636|Drug|Fentanyl|"The experimental drug will be diluted according to each NICU scheme and administered as an attach dose of 1 mcg/kg in 30' followed by continuous i.v. infusion of 1 mcg/kg/h. Infusion of the experimental drug has to begin within 24 hrs from the beginning of MV and has to be continued until the end of MV and not after 7 days of life. If the newborn is still on MV after the 7th day of life he/she will be treated for pain according to local protocols.~Open label boluses of Fentanyl during the study phase will be administered, in both groups when the EDIN pain score is > 6 and before performing the following invasive procedures:Peripherally inserted central venous catheter positioning;Re-intubation;Lumbar puncture;Pneumothorax or hydrothorax drainage."
46081282|NCT04868474|Behavioral|Refresher course|A 45-minute refresher training about smoking cessation that does not aim to change GP behaviour. It will include the same information about pharmacologic quit aids and electronic cigarettes.
45835891|NCT00063570|Drug|Gemcitabine|1000 mg/m2, intravenous (IV), on Days 1 and 8 of 21-day cycle, until disease progression
45970822|NCT00571636|Drug|5% glucose solution|ev continuous infusion
45970823|NCT00224744|Device|ultracision|Surgery by Ultracision
45970824|NCT00224744|Device|classical lymphadenectomy|classical lymphadenectomy
45970825|NCT00571675|Drug|AT-101, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour on day 1, every 21 days [one cycle]), oral prednisone (5mg BID on days 1-21), and oral AT-101 on cycle days 1-3
45970826|NCT00571675|Drug|placebo, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour every 21 days [one cycle]), oral prednisone (5mg BID on days 1-21), and oral placebo on cycle days 1-3
45970827|NCT00571714|Drug|Peginterferon alpha-2a and ribavirin|Peginterferon alpha-2a 180mcg by subcutaneous injection every week and weight based ribavirin, 800 to 1400mg/day by mouth in two divided doses every day for 48 weeks
45970828|NCT00571714|Drug|Peginterferon alpha-2a , ribavirin and betaine|Peginterferon alpha-2a 180mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400 mg/day by mouth in divided doses twice a day plus betaine 10 gm dissolved in juice twice a day for twelve weeks followed by peginterferon alpha-2a 180 mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400mg/day by mouth in divided doses twice a day for 36 weeks.
45669521|NCT03311308|Drug|Pembrolizumab Injection [Keytruda]|200mg, IV, every three weeks, up to two years; After the first three doses, dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
45669522|NCT03311308|Drug|Metformin|500 mg, by mouth, twice a day for nine weeks.
45669523|NCT03308006|Biological|Stem cells|Participants will be exposed to e abdominal liposuction procedure under local anesthesia for stem cells harvesting. Stem cells will be separated from fat cells in the adipose tissue then activated in Tissue Culture Lab at Research Center- Jeddah. The activated stem cells will be injected into the knee joint via 22G spinal needle. The intra-articular stem cells injections will be performed under Ultrasound guidance at the theater under spinal anesthesia. Each patient will receive 1.0× 108 stem cells in 3 mL of normal saline.
45669524|NCT03288545|Drug|enfortumab vedotin (EV)|Intravenous (IV) infusion on days 1 and 8 every 21 days
45827919|NCT05893511|Procedure|Endoscopic ultrasound-guided gallbladder drainage|Prior to the procedure, the patients would be kept fasted for 6 hours and antibiotics would be commenced (2nd generation cephalosporin or equivalent). EUS-GBD would be performed by either the conventional or direct method. A 10mm stent system would be used if the largest gallstone is smaller than 10mm in size and a 16mm stent is used if the largest gallstone is larger than 10mm. The distal flange of the stent would be deployed under EUS guidance, followed by deployment of the proximal flange under endoscopic guidance. Once deployed, the gallbladder is completely emptied by suction and irrigation until the effluent through the stent is clean. The need of inserting an additional double pigtail plastic stent through the LAMS would be decided by the endosonographer. A course of antibiotics will be continued for 7 days after the procedure .
45669525|NCT03288545|Drug|pembrolizumab|IV infusion on day 1 every 21 days
45669526|NCT03288545|Drug|cisplatin|IV infusion on day 1 every 21 days
45669527|NCT03288545|Drug|carboplatin|IV infusion on day 1 every 21 days
45669528|NCT03288545|Drug|gemcitabine|IV infusion on days 1 and 8 every 21 days
45669529|NCT03279393|Drug|fluorodeoxyglucose (FDG)-PET/MRI|Innovative PET combined with magnetic resonance imaging (PET/MRI) to simultaneously study the hematopoietic system, the artery wall, and the brain's fear system, which comprises the amygdala and anterior cingulate cortex (ACC)
45827920|NCT05893511|Drug|Antibiotics first|Patients randomized to antibiotics first would be given intravenous antibiotics 2nd generation cephalosporin or equivalent). Antibiotics would first be given parenterally and then switched to oral form when patient can tolerate diet or when sepsis subside. It will be continued for at least a total of 7 days.
45827921|NCT05893485|Behavioral|Music Therapy Intervention|Music Therapy Sessions. There will be 4 scheduled music therapy sessions, and a postpartum follow up.
45827922|NCT05893472|Combination Product|combination of venetoclax and HAA regimen|Using the combination of venetoclax and HAA regimen as induction therapy in young, newly diagnosed adult acute myeloid leukemia patients under the age of 60.
45827923|NCT05893459|Behavioral|Debrief|Post-Stressor Discussion with a Friend
45827924|NCT05893446|Dietary Supplement|Nutrition care by RDN, medical nutrition therapy -stepped wedge cluster-randomized trial design. Everyone gets the intervention so no arms.|RDNs in the community will provide MNT and meals for three months post discharge from the hospital
45827925|NCT05893355|Behavioral|Acupressure group|"Application to Acupressure Group~Participants in this group will be interviewed for the first time at postpartum week 1, and for the second time between 4-6 weeks postpartum. The application will be explained and a voluntary consent form will be signed.~Participant Information Form will be filled in by the researcher by face-to-face interview.~The VAS, which will be applied to the puerperant women for the first time in the first week of the postpartum week and for the second time between the 4th-6th weeks, will be filled by the participant just before the application to evaluate the back pain.~The VAS Evaluating Back Pain after the application will be filled in by the participant.~The participant will be informed that the study has been completed."
45827926|NCT05892978|Other|Vascular imaging|"Experimental group - Vascular imaging device with the infrared light group: Before PIVC, infrared light will be directed to the vein area and the procedure will be started after vein visibility is achieved.~Experimental group - Vascular access transillumination group: Before PIVC, a transilluminator will be inserted to the vein area and the procedure will be started after vein visibility is achieved"
45827927|NCT05892913|Drug|Slow dose preemptive Atropine|it will planned to administer 0.4 mg/4mL diluted atropine in 20 seconds(10mcg/kg), as a slow bolus as bradycardia would expected (10% reduction in peak heart rate after spinal anesthesia)
45827928|NCT05892913|Drug|Ephedrine|For sympathetic blockade (SBP<90) developed in patients in the ephedrine group, a bolus dose of 5 mg/mL ephedrine was used and repeated if necessary.
45827929|NCT05892432|Drug|Semaglutide 3 MG [Rybelsus]|Semaglutide 3 mg will be taken for the first 4 weeks of the 8-week trial.
45827930|NCT05892432|Drug|Semaglutide 7 MG [Rybelsus]|Semaglutide 7 mg will be taken for the second 4 weeks of the 8-week trial.
45827931|NCT05892432|Drug|Placebo|A medically inert placebo medication will be taken for 8 weeks.
45827932|NCT05892302|Behavioral|Access to Asma Guardian website/app|The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
45827933|NCT05892302|Behavioral|Delayed Access to Asma Guardian website/app|Delayed access to the website/app. The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
45835892|NCT00063570|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days, until disease progression
45835893|NCT04770714|Diagnostic Test|Breast MRI|Standard of Care Breast MRI
45835894|NCT04770714|Diagnostic Test|Contrast Enhanced Mammography|Standard of Care Contrast Enhanced Mammography
45835895|NCT01897038|Drug|Onartuzumab|Onartuzumab intravenous infusion at a starting dose of 10 or 15 milligram per kilogram body weight administered every 3 weeks (Q3W) until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
45970829|NCT02961270|Drug|Icotinib|Icotinib will be given orally 250 mg thrice per day until disease progression, or untolerated toxicity
45970830|NCT00571753|Drug|isoniazid|modified daily isoniazid dose according to NAT2 genotype (appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively).
45970831|NCT00571753|Drug|isoniazid|Treatment with a standard isoniazid dose of isoniazid (appr. 5 mg/kg b.w.)
45827934|NCT05892211|Diagnostic Test|Polysomnography|Polysomnography is performed by 3-channel electroencephalography ((EEG; F4-M1, C4-M1, O2-M1), 2-channel electrooculography (EOG), chin electromyography (EMG), surface EMG recording from tibialis anterior muscles of the right and left leg, body position, oronasal thermal airflow sensor, nasal pressure sensor, thoracic and abdominal respiratory belts for assesing the respiratory effort, electrocardiography (ECG), pulse, recording of respiratory sounds, oxygen saturation and synchronous video recording. The sleep stages are scored by the current criteria of American Academy of Sleep Medicine.
45970832|NCT00224783|Biological|CAIV-T|Trivalent cold adapted temperature sensitive attenuated Types A and Type B influenza virus live vaccine (CAIV-T)
45970833|NCT00224783|Biological|Placebo|0.2 mL of 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2).
45970834|NCT04580173|Diagnostic Test|metabolomics analysis|Targeted and untargeted metabolomics-based analysis will be performed using Gas Chromatography tandem Mass Spectometry and Liquid Chromatography tandem Mass Spectrometry, in order to quantify serum biomarkers.
45970835|NCT00254709|Drug|Sirolimus|
45970836|NCT00571831|Procedure|intraocular lens implantation|Intraocular lens implantation
45970837|NCT00224822|Drug|Aripiprazole|
45970838|NCT00571870|Drug|cetrorelix acetate|The GnRH antagonist, cetrorelix acetate (Cetrotide; Serono) 0.25 mg was added daily, starting when the leading follicle reached 14 mm in diameter during ovarian stimulation for IVF. When the leading follicle reached a mean diameter of 18 mm or two follicles or more reached a diameter of 17 mm, 250 μg of recombinant hCG (Ovidrel; Serono) SQ was injected. In Group A, the GnRH antagonist continued to be used until the day of hCG administration. In Group B, the GnRH antagonist was not administrated on the hCG day
45970839|NCT00254748|Drug|Quetiapine fumarate|flexible doses from 200 mg to 600 mg
45970840|NCT00254748|Drug|Placebo|placebo
45970841|NCT00571909|Procedure|video thorascopic splanchnicectomy (VSPL)|VSPL is a minimally invasive technique using 1-2cm incisions through which a camera and surgical tools are placed inside the thoracic cavity and the idea of the procedure is to cut the pain pathway linking the splanchnic ganglion with pain centers in the hypothalamus
45970842|NCT00224861|Behavioral|Self-Management|
45970843|NCT00224861|Behavioral|Adherence|
46081283|NCT04867681|Behavioral|Psycho-education programme|4 individual sessions (S1, S2, S3, S4) of one hour each spread over 2 weeks, i.e. 2 sessions per week. S1 explains the different clinical signs and discusses the prognosis of the disease, S2 deals with the question of drug treatments, their different forms and their mechanisms of action. S3 discusses the evolution of the disease and the organisation of the care pathway. Finally, S4 looks at the aspects of quality of life, lifestyle and the fight against addictive co-morbidities, and concludes with a review of the patient's motivation and involvement in the subjects covered.
46081284|NCT04853251|Device|SUSVIMO (ranibizumab injection)|The ranibizumab 100 mg/mL will be administered to participants via the SUSVIMO Ocular Implant (IMP)
45827935|NCT05892211|Diagnostic Test|Skin conductance|The sympathetic skin response recordings are performed with a four-channel electromyography apparatus (Nihon-Kohden). They are recorded from both sides of the sternum with the active and reference electrodes placed 2 cm apart from the midline.
45827936|NCT05892211|Genetic|ALU and LINE-1 DNA methylation analysis|2 cc peripheric venous blood is drawn from the participants to the test tubes with EDTA. DNA isolation is done by Nucleospin Blood Kit (REF:740951.250, Macherey-Nagel). Epitect Fast DNA Bisulfite Kit (REF:59824, Qiagen) is used to do DNA bisulfite modification. ALU and LINE-1 site specific methylation primer is designed and the methylation patterns are compared between the groups by Epitect Methylight PCR Kit (Cat. No:59496, Qiagen).
45827937|NCT05892211|Diagnostic Test|The Menopause-Specific Quality of Life Questionnaire (MENQOL)|The Menopause-Specific Quality of Life Questionnaire (MENQOL) is filled by each participant to assess the health related quality of life before the polysomnography test.
45827938|NCT05892211|Diagnostic Test|Pittsburgh Sleep Quality Index (PSQI)|Pittsburgh Sleep Quality Index (PSQI) is done by each participant to assess the sleep quality and disturbances before thepolysomnography test.
45827939|NCT05891795|Drug|Clascoterone 1% Top Cream|Apply a thin layer to the affected area twice daily.
45827940|NCT05891795|Drug|Vehicle|Apply a thin layer to the affected area twice daily.
45835896|NCT01897038|Drug|Sorafenib|Sorafenib 400 milligram (mg) tablets (2 tablets of 200 mg each) orally once daily or twice daily depending on the cohort assigned until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
45970844|NCT00572026|Drug|Methylphenidate Transdermal System|Daytrana wear time up to 15 hours
45970845|NCT00572065|Drug|arsenic trioxide|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Triseonx will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
45970846|NCT00572065|Drug|cytarabine|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Trisenox will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
45970847|NCT00234897|Drug|adalimumab|
45970848|NCT00572104|Other|resistance exercise|12 month training intervention of weight resistance exercise. All participants receive a daily calcium and vitamin D supplement
45970849|NCT00572104|Other|plyometric exercise|12 month training intervention of plyometric exercise. All participants receive a daily calcium and vitamin D supplement
45970850|NCT00572143|Other|ca coli follow-up by GP|patients randomized to follow up by GP
45970851|NCT00572182|Drug|MK-0752|This is a dose escalation study. Patients may receive 150, 200, 260 or 325 mg/m2 orally for 3 consecutive days of every 7 days for 28 days (dosing regimen 1 - closed to accrual 2/23/2010) or 800, 1000, 1400, or 1800 mg/m2 orally once weekly for 28 days (1 course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 6 courses.
45970852|NCT02961153|Other|death|
45970853|NCT00224939|Drug|Potassium Chloride|
45970854|NCT00572221|Behavioral|Continuing Quality Improvement and Quality Assurance system|The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation.
45970855|NCT00572221|Behavioral|CQI and QA System with Best-Practice Care Protocols|A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions.
45970856|NCT00572299|Drug|alendronate|70 mg of alendronate orally per week for at least three months in patients receiving at least 10 mg/day or oral prednisone for at least three months
45827941|NCT05891743|Diagnostic Test|Patch Test|The Patch Test will include the European baseline series, as well as the epoxy and isocyanate series. Additionally, specific products commonly used in the workplace, such as glues, resins, and paints, will be prepared and included in the testing.
45970857|NCT00572338|Other|No drugs are involved|No treatment or drugs are involved in this research. Participating in this study requires that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of participant's multiple myeloma. Bone marrow/peripheral blood samples will be collected at the same time for research purposes. Data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.
45669530|NCT03270098|Behavioral|Aerobic Exercise|Trainer-led one hour aerobic exercise sessions, three times per week, over 12 weeks.
45827942|NCT05891522|Procedure|portable scanner|performing a portable cranial scanner on cerebro-injured intensive care patients
45827943|NCT05891522|Procedure|fixed scanner|performing a conventional fixed cranial scanner on cerebro-injured intensive care patients
45970858|NCT00234936|Drug|Adalimumab|
45970859|NCT00234936|Drug|Methotrexate|
45970860|NCT00572377|Drug|FemLife Gel|the gel or placebo (240 mcg)applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
45970861|NCT00572377|Drug|Placebo|the gel or placebo (240 mcg) applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
45970862|NCT00413075|Drug|oral belinostat|oral belinostat dosed once or twice daily at continuous and discontinuous dosing schedules.
45970863|NCT00572416|Behavioral|Individual Sleep Promotion Plan|Four components, including activity-rest, sleep-wake, psychological distress, and symptom management. Sleep-wake component has four strategies: stimulus control, sleep restriction, relaxation, and sleep hygiene
45970864|NCT00572416|Behavioral|Healthy Eating Control|Equal time and attention and information about healthy eating
45970865|NCT00572494|Device|MAGIC EXPLORER (Biotronik AG)|The lesion is pre-dilated with the PLEON EXPLORER balloon with a length of 10 mm or 15 mm or 20 mm under angiographic control. After dilation, the stenosed area is treated by one AMS implant. If the implanted stent is not fully apposed to the vessel wall or if initial angiography reveals a residual stenosis, the stent may be post-dilated with the delivery system balloon. If necessary, a high-pressure, non-compliant balloon catheter may be used.
46081285|NCT04853251|Drug|LUCENTIS (ranibizumab injection)|Ranibizumab (intravitreal 0.5-mg injections of 10 mg/mL formulation) will be used in the study eye as supplemental treatment. If a study patient discontinues study treatment, he/she may start receiving intravitreal ranibizumab injections in the study eye, per investigator's discretion.
46081286|NCT04852068|Biological|Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 5-dose program|Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
45827944|NCT05891314|Procedure|Botox Injectable Product|one group will have botox injection in the internal sphincter
45669531|NCT03270098|Behavioral|Stretching and Toning Exercise|Trainer-led one hour stretching-and-toning exercise sessions, three times per week, over 12 weeks.
45669532|NCT03266471|Diagnostic Test|Baseline blood sample|Blood sample for cytokine measurements and genetics.
45669533|NCT03266471|Diagnostic Test|Baseline intestinal biopsies|Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.
45669534|NCT03266471|Other|Crohn's disease activity index (CDAI)|To determine response, a Crohn's Disease Activity Index (CDAI) score will be obtained at time point 1 and time point 2 in all enrolled CD patients. The CDAI is a well validated symptom index for CD which assesses 8 factors including stool frequency, abdominal pain, general well being, CD complications, HCT, and deviation from ideal body weight.
45669535|NCT03266471|Diagnostic Test|Post treatment blood sample|Blood sample for cytokine measurements after patients have been on therapy for at least 6 weeks but no more than 52 weeks.
45669536|NCT03266471|Diagnostic Test|Post treatment intestinal biopsies|Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy at least 6 weeks but no more than 52 weeks after initiation of therapy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.
45669537|NCT03266471|Diagnostic Test|Baseline stool sample|Stool sample for inflammatory markers or microbiome analysis.
45669538|NCT03266471|Diagnostic Test|Post treatment stool sample|Stool sample for inflammatory markers or microbiome analysis.
46081287|NCT04852068|Biological|Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 4-dose program|Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
46081288|NCT04852068|Biological|Freeze-dried human rabies vaccine (Vero cells) Chengda - 5-dose program|Inoculate 1 dose of control vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
45970866|NCT00572494|Device|PLEON EXPLORER (Biotronik AG)|The lesion is dilated with the PLEON EXPLORER balloon with lengths of 10 mm or 15 mm or 20 mm, respectively. In case that the PTA procedure results in a residual stenosis of >50%, the AMS implant should be used to improve the result. A flow-limiting dissection does not qualify for stenting. Best effort must be made to obtain a satisfactory result (e.g. multiple and prolonged inflations) before a patient in the PTA group can be treated with a stent.
46081289|NCT04852068|Biological|Freeze-dried human rabies vaccine (Vero cells) Chengda - 4-dose program|Inoculate 1 dose of control vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
46081290|NCT04839042|Biological|SC-Ad6-1|SC-Ad6-1, I.M., single or multiple-dose
46081291|NCT04839042|Biological|SC-Ad6-1|SC-Ad6-1, I.N., single or multiple-dose
46081292|NCT04839042|Biological|SC-Ad6-1|SC-Ad6-1, I.H., single or multiple-dose
46081293|NCT04835441|Drug|ALPN-101|Blinded ALPN-101 will be administered
45669539|NCT03232411|Other|Questionnaires|Participants will be asked to complete a baseline questionnaire that asks questions about their demographic information, medical history, and smoking habits when they first enroll in the study. They will also be asked to complete a follow-up questionnaire 2 years later. The questionnaires will each take about 25 minutes to complete.
45669540|NCT03232411|Other|Saliva Samples|Participants will be asked to provide a saliva sample using the saliva kit that will be mailed to them. Detailed instructions for collection will be included in the saliva collection packet.
45827945|NCT05891314|Procedure|Internal sphincterotomy|this group will have internal sphincterotomy
45827946|NCT05891028|Drug|68Ga-EB-ss-CPT|68Ga-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
45827947|NCT05891028|Drug|64Cu-EB-ss-CPT|64Cu-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
45827948|NCT05890950|Drug|K-757 and K-833|Both administered orally
45827949|NCT05890950|Drug|Matching placebo to K-757 and K-833|Both administered orally
45827950|NCT05890716|Diagnostic Test|AI-powered ECG analysis to detect cardiac arrhythmic episodes|ECG recording and processing by AI platform
46081294|NCT04835441|Drug|Placebo|Blinded placebo matching ALPN-101 will be administered.
46081295|NCT04826003|Drug|RO7122290|RO7122290 will be administered using a QW (Part I) or Q3W (Part I or Part II) schedule in combination with 100 mg cibisatamab Q3W with obinutuzumab pre-treatment. The maximum dose of RO7122290 to be explored in combination with cibisatamab with obinutuzumab pre-treatment in this study is 500 mg for the QW dosing interval (Part I) or 1500 mg for the Q3W dosing interval (Part I or Part II).
46081296|NCT04826003|Drug|Cibisatamab|Cibisatamab will be administered to participants at a fixed dose of 100 mg Q3W (100 mg on Day 1 of each 21-day cycle).
46081297|NCT04826003|Drug|Obinutuzumab|"Obinutuzumab will be administered (IV) as pre-treatment on Day - 8/- 7 (split dose) or~- 8 (single dose) prior to C1D1 of cibisatamab and as re-treatment every 6 months if the participant is still receiving cibisatamab"
46081298|NCT04825223|Drug|Multicomponent Meningococcal B Vaccine|Pharmaceutical form:Liquid suspension for injection in a single vial Four liquid suspensions and one diluent (only for Stage 1) Route of administration: Intramuscular
46081299|NCT04825223|Drug|Meningococcal Group B Vaccine MenB|Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
46081300|NCT04825223|Drug|Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)|Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
45827951|NCT05890690|Diagnostic Test|Urea|"Diagnostic test with a single weight-adapted dose of oral urea dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The investigators will make use of the lemon-lime flavor to soften the bitter taste of urea.~- Dose calculation: 0.5 g urea/kg body weight (rounded to no decimal places), with a minimal dose of 30g and a maximal dose of 45g."
45827952|NCT05890690|Diagnostic Test|Placebo|"Diagnostic test with a single weight-adapted dose of placebo dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The placebo will contain a mixture of bitter herbal substances to mimic the taste of urea.~- Dose calculation: 22 ml of placebo containing 20 ml Ergytonyl®, 1 ml Carmol®, and 1 ml Bitter Liebe®."
45827953|NCT05890430|Biological|Blood draw, Urine draw|Collection of an additional volume of blood at each follow-up time in addition to the standard blood test performed during the patient's follow-up Collection of an additional volume of urine at each follow-up time
45827954|NCT05890352|Procedure|Biospecimen Collection|Undergo optional collection of blood
45970867|NCT00572611|Drug|[14C]-bilastine|Single oral dose of 20 mg [14C]-bilastine. 1 capsule. 1 day dosing only
45970868|NCT00572650|Drug|vildagliptin|16 volunteers in each group of mild renal impairment patients and their matched healthy volunteers will receive once daily doses of 100mg LAF237 for 14 days.
45970869|NCT00413270|Drug|nilotinib|
45970870|NCT00572689|Drug|Exenatide|10 microgram injected sub-cutaneously once
45970871|NCT00572689|Genetic|Buccal/blood Sample Collection|Buccal/blood Sample collection for TCF7L2 polymorphism genetic testing
45827955|NCT05890352|Procedure|Computed Tomography|Undergo PET/CT and CT
45827956|NCT05890352|Drug|Lenalidomide|Given PO
45827957|NCT05890352|Procedure|Magnetic Resonance Imaging|Undergo MRI
45827958|NCT05890352|Procedure|Positron Emission Tomography|Undergo PET/CT
45970872|NCT00572767|Drug|Dextro-Amphetamin|After a two week baseline phase the patients will receive a dose of 10mg Dexamphetamine on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.
45970873|NCT00572767|Other|Glucose|"After a two week baseline phase the patients will receive a dose of 10mg of a placebo (same appearance as the experimental drug) on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.~The treatment of the control group will be the same as for the experimental group except the content of the drug capsule."
45970874|NCT00572806|Drug|insulin aspart|
45970875|NCT00572845|Other|Weaning of Antispasticity Medication|Weaning of antispasticity medication over a three day period and then titration back to previous dose over a three day period.
45970876|NCT00224978|Drug|Chloroquine|
45970877|NCT00572884|Other|permethrin insecticide|25 mg neat carbon-14 labelled permethrin applied dermally in isopropyl alcohol, once for 8 hours containing 1 microcurie of carbon-14
45970878|NCT00573001|Drug|Tenofovir/Emtricitabine (Truvada) and Nevirapine|Tenofovir/Emtricitabine(Truvada) 245/200mg 1cp/day ; Nevirapine 200mg 2cp/day after first 14 days
46081301|NCT04825223|Drug|Placebo|Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
45970879|NCT00573001|Drug|Tenofovir/Emtricitabine/Efavirenz (Atripla)|Tenofovir/Emtricitabine/Efavirenz (Atripla) 300/200/600mg 1cp/day
45970880|NCT00573001|Drug|Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia)|Tenofovir (Viread) 300mg 1cp/day ; Lopinavir/Ritonavir (Aluvia) 400/100mg 4cp/day
46081302|NCT04825223|Drug|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine|Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
46081303|NCT04812925|Biological|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
46081304|NCT04811040|Drug|Oral Lenacapavir|Tablets administered without regard to food
46081305|NCT04811040|Drug|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
45669541|NCT03232411|Other|Tumor Tissue|Participants will be asked for permission to obtain a sample of their tumor tissue. Participants will receive a medical release form. Once they complete it and mail it back, investigators will request a small amount of tissue collected during the participant's prostate biopsy (or during their surgery, if they had surgery) from their health care provider.
45669542|NCT03229499|Drug|Anastrozole|"Anastrozole is an aromatase inhibitor indicated for:~adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer~first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer~treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy."
45827959|NCT05890352|Other|Quality-of-Life Assessment|Ancillary studies
45827960|NCT05890352|Other|Questionnaire Administration|Ancillary studies
45827961|NCT05890352|Biological|Tafasitamab|Given IV
45970881|NCT00573001|Drug|Tenofovir/Emtricitabine (Truvada) and Zidovudine|Tenofovir/Emtricitabine (Truvada) 245/200mg 1cp/day ; Zidovudine 300mg 2cp/day
45970882|NCT00254787|Drug|IR (Immediate-Release) quetiapine fumarate (drug)|
45970883|NCT03453853|Device|Mitral Loop Cerclage Annuloplasty|Atrial Functional mitral regurgitation Response In mitral loop Cerclage Annuloplasty
46081306|NCT04811040|Biological|Teropavimab|Administered intravenously
46081307|NCT04811040|Biological|Zinlirvimab|Administered intravenously
46081308|NCT04807205|Device|RF Non-Invasive Treatment|Self-controlled single-arm group using the Elite IQ device
46081309|NCT04806100|Device|Malleo-Lok|The Malleo-Lok is a novel, low-profile carbon fiber device with two laterally positioned struts aligned in the sagittal plane.
45669543|NCT03229499|Drug|Placebo Oral Tablet|matching placebo tablet
45827962|NCT05890352|Drug|Tazemetostat|Given PO
45827963|NCT05890352|Drug|Zanubrutinib|Given PO
45827964|NCT05890248|Procedure|Technique|Paravertebral block versus Erector spinea block versus quadratus lamborum block
45827965|NCT05889741|Drug|Ropivacaine injection|6.5cc of Ropivacaine hydrochloride (HCl) 0.5%, one time into the stellate ganglion
45827966|NCT05889741|Drug|Normal saline|6.5cc of Normal Saline one time into the stellate ganglion.
45827967|NCT05889637|Diagnostic Test|Gastric ultrasound|Patient will be scanned first in the supine position and then in the right lateral decubitus position. The ultrasound probe will be placed in a sagittal plane in the epigastric region at the left subcostal margin and then will be moved past the midline in a fan like manner to the right subcostal region. Qualitative and quantitative assessments will be done.
45835897|NCT04770792|Other|2% chlorhexidine gluconate with mineral trioxide aggregate.|2% chlorhexidine gluconate with mineral trioxide aggregate.
45970884|NCT03453775|Device|Ultrasound guided periradicular lumbar infiltration|Once position of the needle is confirmed, the mixture Depomedrol 40mg + Lidocaine 2% (1ml) is injected, under neurostimulation with an intensity of 0.2 milliampere (identifies a distance of 1mm from the nerve root allowing the protection of the root of a lesion by the needle).
45970885|NCT03453775|Device|Fluoroscopy guided periradicular lumbar infiltration|Once position of the needle is confirmed, the mixture Depomedrol 40mg + Lidocaine 2% (1ml) is injected, under neurostimulation with an intensity of 0.2 milliampere (identifies a distance of 1mm from the nerve root allowing the protection of the root of a lesion by the needle).
45970886|NCT00225056|Drug|docetaxel and capecitabine|
45970887|NCT03453736|Other|No intervention|This is a qualitative study involving staff interviews and observations. No intervention is being applied.
45827968|NCT05887830|Drug|Nivolumab|Single administration of Nivolumab on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. The active drug Nivolumab will be administered at a standard dose (5mg/kg) dissolved in 100ml 0.9%NaCl solution. Nivolumab was given at a rate of 15-25 drops per minute, and the intravenous infusion time exceeded 1 hour.
45970888|NCT00254826|Biological|YF-VAX® plus saline|YF-VAX® plus saine
45970889|NCT00254826|Biological|17D YF Vaccine plus Ig,|17D YF Vaccine plus Ig, one vaccine on day 0
45970890|NCT03453697|Device|acute intermittent hypoxia|Adjust the proportion of nitrogen and oxygen, through increasing the suction nitrogen concentration, the subject's blood oxygen saturation could decrease to 80%~90% within 30 seconds and also lasts 30 seconds; then quickly reduce the concentration of nitrogen gas suction to make the subject's blood oxygen saturation gradually return to normal level (consistent with the air inhalation), and then continue breathing air about 60 seconds to enter the next round of hypoxic state.
45970891|NCT00225173|Drug|Doxorubicin|Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11
45827969|NCT05887830|Other|Placebo|Single administration of Placebo on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. Patients assigned to the placebo treatment group will receive an intravenous infusion of 100 ml 0.9% NaCl solution at a rate of 15-25 drops/min for an IV infusion duration of more than 1 hour.
45970892|NCT00225173|Drug|Vinblastine|Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11
45970893|NCT00225173|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV w 1, 5, 9
45970894|NCT00225173|Drug|Etoposide|Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11
45970895|NCT00225173|Drug|Vincristine|Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)
45970896|NCT00225173|Drug|Bleomycin|Bleomycin 5 u/m2 IV w 2,4,6,8,10,12
45970897|NCT00225173|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 IV w 13,15,17,19
45970898|NCT00225173|Drug|Vinorelbine|Vinorelbine 25 mg/m2 IV w 13,15,17,19
45970899|NCT00225173|Drug|Prednisone|Prednisone 40 mg/m2 PO qod w 1-10, taper
45970900|NCT00234975|Drug|Lopinavir/Ritonavir|400 mg/ 100 mg BID. Both arms use Kaletra 400/100 mg BID, plus NRTI chosen by the investigator
45970901|NCT00573196|Radiation|Far infrared|Far infrared radiation (5μm to 15μm wavelength)
45970902|NCT00573274|Device|Physioflow Impedance|6 ECG leads applied to the neck and thorax for the duration of surgery (approximately 1 hour).
45970903|NCT00235014|Drug|trandolapril|2 mg QD
46081310|NCT04802174|Drug|Lurbinectedin|Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.
46081311|NCT04802174|Drug|Berzosertib|Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.
46081312|NCT04799275|Drug|Cyclophosphamide|Given IV
46081313|NCT04799275|Drug|Doxorubicin Hydrochloride|Given IV
46081314|NCT04799275|Drug|Oral Azacitidine|Given PO
46081315|NCT04799275|Drug|Prednisone|Given PO
45669544|NCT03215810|Procedure|Tumor-infiltrating Lymphocytes (TIL)|Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.
45669545|NCT03215810|Drug|Nivolumab|Nivolumab will be administered intravenously at a fixed dose of 240 mg for 4 doses every 2 weeks prior to TIL. Nivolumab dose will be fixed at 480 mg every 4 weeks up to 12 months after TIL.
45669546|NCT03215810|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS) over approximately 2 hours. Cyclophosphamide will be initiated seven days prior to the anticipated TIL transfer, and the precise timing will depend on the rate of in vitro TIL growth. The dose will be based on the patient's body weight, but to prevent undue toxicity, it will not exceed a dose greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company, Height and Weight Table.
45827970|NCT05885230|Procedure|pecto intercostal fascial block using bupivacaine 0.25%|patients will receive bilateral ultrasound-guided pecto-intercostal fascial block using 20 ml of bupivacaine 0.25% for each side.
45835898|NCT04770792|Other|Mineral trioxide aggregate.|Mineral trioxide aggregate.
45835899|NCT00064038|Drug|dexamethasone|Given orally
45970904|NCT00235014|Drug|trandolapril/verapamil|180/2 mg QD
45970905|NCT00235014|Drug|placebo|1 tablet QD
45970906|NCT00235014|Drug|verapamil|SR 240 mg QD
45970907|NCT00225290|Drug|Thalidomide(Thado)|
45970908|NCT00573352|Radiation|Far Infrared|Far Infrared Radiation (5μm to 20μm wavelength). Duration is 30 to 40 minutes per session
45970909|NCT00573547|Drug|Fluoxetine|Fluoxetine will be dosed at 90 mg once a week
45970910|NCT00573586|Device|Sonablate 500 (SB-500)|Sonablate 500 (SB-500)
45970911|NCT00225329|Procedure|Labour assessment and support|
45970912|NCT00573664|Drug|Gabapentin|single oral dose of 600mg gabapentin
45970913|NCT00573664|Other|lactose|Single dose
45970914|NCT00573703|Procedure|Laparoscopic Burch colposuspension|Lapaparoscopic approach. One or two nonadsorbable sutures are placed at the level of the midurethra without penetrating the vaginal mucosa and fixed to Cooper's ligament with a tension free knotting technique.
45970915|NCT00573703|Procedure|Transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of needle. Application of resorbable tensioning suture that maintains the mesh and enables fine adjustments in mesh tension during the procedure and in the immediate postoperative period.
45970916|NCT00573742|Drug|Candesartan Cilexeotil 16mg|
45970917|NCT00254865|Drug|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).|
45970918|NCT00573781|Dietary Supplement|Diet with increased intake of rye bread, berries and fish|Dietary modification with commercial food items
45970919|NCT00573781|Dietary Supplement|Increased intake of whole grain and rye bread|Dietary modification with commercial food items
45455836|NCT05603702|Drug|Lacosamide|Study Visit 1: Baseline study assessments will be made and questionnaires completed in person, on day 0. Drug treatment days will then occur on days 1-7. Study Visit 2: Following completion of the 7-day drug treatment period, participants will have a face-to-face clinic visit on day 8 (with a 3 day grace period), where similar assessments and questionnaires will again be completed. Participants will return all unused drug at this visit, for disposal and to monitor compliance. A follow-up phone visit will occur on day 21 (with a 3 day window) to assess for adverse events and medication changes
45455837|NCT05599906|Other|questionnaires|Completion of 3 questionnaires (HADS; SF-12; FAS) at the beginning and end of the rehabilitation and after 3 months
45827971|NCT05885230|Drug|lidocaine infusion|1.5 mg/kg lidocaine will be administered after induction of anesthesia, then 2mg/kg/h lidocaine will be administered with continuous intravenous infusion until the end of the surgery.
45455838|NCT05598658|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
45455839|NCT05598658|Procedure|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
45455840|NCT05596006|Drug|ASIMOMMY®|ASIMOMMY 500 mg
45827972|NCT05881408|Genetic|SRP-9001|Single IV infusion of SRP-9001
45827973|NCT05881408|Genetic|Placebo|Single IV infusion of matching placebo
45827974|NCT05879159|Behavioral|Questionnaires|Survey
45827975|NCT05877027|Other|Exercise|The first 3 weeks of the exercise program will include range of motion exercises, isometric and isotonic strengthening exercises for the muscles around the knee and hip, and stretching exercises. In the following 3 weeks, resistance strengthening exercises and closed kinetic chain exercises will be added to the program.
45827976|NCT05877027|Other|Topical Diclofenac|They will apply it around the knee joint 4 days a week, 2 times a day (every 12 hours), morning and evening for 6 weeks.
45827977|NCT05877027|Other|Platelet-Rich-Plasma (PRP)|8 ml of blood will be taken from each patient in tubes containing 0.9 ml of 3.2% sodium citrate. Swing-out rotor (open-swing type) will be placed in the centrifuge with the tubes facing each other. After centrifugation, 2.5 cc of PRP product will be collected from each tube and the resulting PRP will be administered to patients by injection under sterile conditions.
45827978|NCT05876000|Device|Corheart 6 Ventricular Assist System|Implantation of ventricular assist device for hemodynamic support
45827979|NCT05867121|Drug|RO7496353|RO7496353 will be administered as per the schedules specified in the respective arms.
45827980|NCT05867121|Drug|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
45827981|NCT05867121|Drug|Capecitabine|Capecitabine will be administered as per the schedules specified in the respective arms
45827982|NCT05867121|Drug|S-1|S-1 will be administered as per the schedules specified in the respective arms.
45827983|NCT05867121|Drug|Nivolumab|Nivolumab will be administered as per the schedules specified in the respective arms.
45827984|NCT05867121|Drug|Oxaliplatin|Oxaliplatin will be administered as per the schedules specified in the respective arms.
45827985|NCT05867121|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered as per the schedules specified in the respective arms.
45827986|NCT05867121|Drug|Gemcitabine|Gemcitabine will be administered as per the schedules specified in the respective arms.
45827987|NCT05865028|Drug|APG-157|Participants will take 200mg (2 x 100mg pastilles) of APG-157 therapy orally (PO) three times daily during each 4-week cycle for up to three cycles. Cycle three is optional.
45827988|NCT05861258|Drug|Minocycline|Patients with M. avium complex pulmonary disease will receive 200 mg of minocycline for 5 days before starting rifampicin and after 1 month (±1 week) of receiving rifampicin. Antimycobacterial drugs other than rifampicin can be started prior to or simultaneous with the first minocycline dosing period as part of standard care. At day 5 of both minocycline dosing periods, blood will be sampled for minocycline plasma concentration measurements at T = 0, 1, 2, 3, 4, 6, 8 and 24 hours.
45455841|NCT05596006|Drug|Domperidon|Domperidone capsule 10 mg
45455842|NCT05596006|Drug|Placebo|Capsules of placebo 500mg.
45455843|NCT05595213|Device|Wrist cooling device with cooling plate|This device is worn like a watch and pressing the button activates the cooling function to begin to col the wrist skin temperature to 47 degrees. Pushing the device button again cools the skin to 60 degrees and a third time to 77degrees.
45827989|NCT05857800|Other|Observation|Analysis of dynamic changes of lung cancer microenvironment in neoadjuvant therapy using bio-omics information collected in clinical trials.
45827990|NCT05854628|Procedure|skin biopsy|Skin biopsies will be obtained at different time points.
45827991|NCT05850598|Device|sham rTMS|The coil was held while disconnected from the stimulator, and rTMS noise was presented with computer loudspeakers with recorded sound from a real stimulation (20 minutes for each side of the lateral cerebellum everyday for 2 weeks).
45827992|NCT05850598|Device|active rTMS|Low-frequency (1 Hz) rTMS at with a stimulation intensity of 95% of the motor threshold will be delivered over the bilateral cerebellum for patients with Parkinson's disease (20 minutes for each side of the lateral cerebellum everyday for 2 weeks).
45835900|NCT00064038|Drug|lenalidomide|Given orally
45835901|NCT00064038|Other|placebo|Given orally
45669547|NCT03215810|Drug|Fludarabine|After administration of Cyclophosphamide, Fludarabine will then be infused at 25 mg/m^2 intravenous piggyback (IVPB) daily over approximately 30 minutes starting 5 days prior to TIL transfer. To prevent undue toxicity with fludarabine, the dose will be based on body surface area (BSA), but will not exceed a dose calculated on surface areas based on body weights greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company Height and Weight Tables.
45970920|NCT00573781|Dietary Supplement|Control diet with decreased intake of rye bread, berries and fish|Dietary modification with commercial food items
45669548|NCT03215810|Other|Tumor-infiltrating Lymphocyte Therapy|On day 0, all patients will receive TIL administered according to the current Moffitt Cell Therapy TIL Standard Operating Procedure (SOP). Eight (8) to twelve (12) hours after completing the TIL infusion, all participants will begin intermediate-dose decrescendo interleukin-2 (IL-2).
45669549|NCT03215810|Drug|Interleukin-2 (IL2)|Interleukin-2 (IL-2) - a drug used to help the body's response to treatment on the immune system. A high dose regimen of IL-2 will be given after the infusion of the T-cells.
45669550|NCT03181516|Biological|Bifidobacterium animalis subsp. lactis BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
45669551|NCT03181516|Other|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12
45827993|NCT05847478|Other|Auricular acupressure of traditional Chinese Medicine|"The participants will be randomly assigned to receive the auricular point patch therapy.~The selected acupoints include Shenmen, hungry point, endocrine, stomach, mouth and subcortical. The opaque patch with vaccaria seed is used for acupoint pressing. Pressing the acupoints once a day before and after eating, each time for 1 minute, lasting for 2-3 days, follow up visit once a week. The intervention period is 3 months."
45827994|NCT05847478|Behavioral|Intermittent low carbohydrate diet|"The participants will be randomly assigned to the intermittent low carbohydrate diet group.~The intermittent carbohydrate diet includes 7 days of low carbohydrate diet within 2 weeks (consecutive or nonconsecutive, carbohydrate intake be controlled as ≤ 50g per day). The study duration is 3 months, including 1-month intervention period and 2-month self-maintenance period."
45827995|NCT05847478|Behavioral|Health education|Health education is conducted once a week during 3-month intervention for all participants. Health education including the understanding of childhood obesity and cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
45827996|NCT05847309|Other|Delayed extubation|Patients randomized to delayed extubation, will be extubated 6-12 hours after endovascular treatment under general anesthesia.
45827997|NCT05847309|Other|Early extubation|Patients randomized to early extubation, will be extubated < 6 hours after endovascular treatment under general anesthesia.
45827998|NCT05845177|Procedure|Primary Total Hip Arthroplasty|All patients surveyed have undergone primary total hip arthroplasty approximately 1 year prior to survey distribution
45827999|NCT05844085|Other|Non-polar lipids|The shame comparator lipid intervention product contains no polar lipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of lipids are15g, and the total amounts of available carbohydrates are 50 g.
45970921|NCT00225368|Device|Insecticide treated bednets|
45970922|NCT00573820|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each treatment session.
45970923|NCT04579822|Biological|influenza vaccine|quadrivalent influenza vaccination in the flu seasons
45970924|NCT00235053|Drug|fluticasone/salmeterol DISKUS 250/50|
45970925|NCT04579861|Other|Prospective data collection following gynaecological oncology surgery|Prospective data collection and entry on database following gynaecological oncology surgery
45669552|NCT03179449|Diagnostic Test|Diagnostic (ferumoxytol-enhanced MRI)|Undergo ferumoxytol-enhanced MRI
45669553|NCT03179449|Procedure|Surgery|Undergo surgical resection
45669554|NCT03179449|Drug|Ferumoxytol|Given IV
46081316|NCT04799275|Other|Questionnaire Administration|Ancillary studies
45669555|NCT03179449|Other|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
45669556|NCT03132454|Drug|Decitabine|Given IV
45669557|NCT03132454|Drug|Dexamethasone|Given IV or PO
45669558|NCT03132454|Drug|Palbociclib|Given PO
45669559|NCT03132454|Drug|Sorafenib|Given PO
45828000|NCT05844085|Other|No lipids|The placebo comparator contains no added lipids. The product contains a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of available carbohydrates are 50 g.
45828001|NCT05844085|Dietary Supplement|Polar lipids low|The experimental intervention product contains 7,5 g plant based lipids polar lipids and 7.5 g plant based lipids non polarlipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. TThe total amounts of available carbohydrates are 50 g.
45970926|NCT00225407|Drug|Smoking of cannabis cigarettes (different strength)|
45669560|NCT02978196|Procedure|Injection of 99m-Tc-NM-01|Patient is injected with micro-dose of 99m-Tc-NM-01
45828002|NCT05844085|Dietary Supplement|Polar lipids high|The experimental intervention product contains15 g plant based polar lipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of available carbohydrates are 50 g.
45970927|NCT04580056|Procedure|Uterine fundus endometrial incision during hysteroscopy|Uterine fundus endometrial scratching during hysteroscopy by incision
45970928|NCT04719468|Other|Dance with ballet elements|Ballet-based dance sessions will be delivered by trained artists within the English National Ballet group in a professional dance space/ delivered remotely, COVID-19 permitting.
45828003|NCT05842434|Device|Felix|Felix is a wrist-worn, noninvasive, transcutaneous neurostimulation system intended for daily use to suppress hand tremors. An artificial intelligence (AI) algorithm will automatically adjust the stimulation based on each patient's tremor throughout the day.
45970929|NCT04579744|Other|EuroQol 5D questionnaire|EuroQol questionnaire (EQ-5d) facilitates to obtain values of health in the physical, psychological, and social dimensions. It is a standardized non-disease specific instrument to describe and value the health-related quality of life.
45970930|NCT00225446|Device|MicronTracker|MicronTracker is a Third Generation Optic Repositioning System in orthognatic surgery.
45970931|NCT00574015|Drug|hydrocodone/acetaminophen|oral hydrocodone 10 mg/acetaminophen 650 mg
45970932|NCT00574015|Drug|bupivacaine (supraperiosteal nerve block)|Administration of Bupivacaine 0.5% 2 ml adjacent to tooth root
45970933|NCT00574054|Radiation|Far Infrared|Far infrared radiation (5 μm to 20 μm wavelength) for 30 to 40 minutes per treatment session.
46081317|NCT04799275|Biological|Rituximab|Given IV or SC
45828004|NCT05840211|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
45828005|NCT05840211|Drug|Paclitaxel|Administered intravenously
45828006|NCT05840211|Drug|Nab-paclitaxel|Administered intravenously
45828007|NCT05840211|Drug|Capecitabine|Administered orally
45970934|NCT00255021|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib Vac|0.5 mL, IM
45970935|NCT00225485|Drug|Effexor XR|
45669561|NCT02964078|Drug|Pembrolizumab|Pembrolizumab: 200 mg every 3 weeks, 12 doses planned. This is considered the investigational part of the combination. The infusion time is 1 hour.
45970936|NCT00574093|Drug|Ranibizumab; Verteporfin|Patients will be administered Lucentis™ 0.5 mg on Day 1, at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
45970937|NCT00574210|Drug|Bilastine|Bilastine Tablets, administered at a dosage strength of 10 mg or 20 mg, once or twice per day.
46081318|NCT04799275|Drug|Vincristine Sulfate|Given IV
45828008|NCT05834127|Other|Aerobic exercise|"Group A will receive aerobic exercise in the form of warm up and cool down (both for 5 min)~Treadmill (30 min) based on Target Heart Rate (calculated using Karvina formula at 60%-70% of heart rate reserve).~Treatment will be given 3 times a week for 1 month"
45828009|NCT05834127|Other|Yoga Exercises|"Group B will receive yoga movements for 40 min, 3 times a week for 1 month.~They will be given yoga movements, including 10 min of Kapalbharti Pranayama which includes automatic inhalation with short and forceful exhalations.~20 min of yoga movements (Cat-cow pose, Child's pose, Plank pose, Cobra pose - each for 5 min).~10 min of meditation/relaxation in Savasana pose"
45970938|NCT00574210|Drug|Placebo|Placebo Tablets administered twice per day
45828010|NCT05834088|Other|Myofascial release techniques|12 treatment sessions will be given in 12 weeks
45828011|NCT05834088|Other|Thiele massage|12 treatment sessions will be given in 12 weeks
45970939|NCT00574366|Drug|erlotinib|"Levels:~1 Erlotinib 50 mg/d~2 Erlotinib 50 mg/d~1 Erlotinib 100 mg/d~2 Erlotinib 100 mg/d~3 Erlotinib 150 mg/d~4 Erlotinib 150 mg/d"
45828012|NCT05829655|Drug|Drug A (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
45828013|NCT05829655|Drug|Drug B (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
45970940|NCT00574366|Drug|RAD001|"Levels~minus 1: RAD001 2.5 mg/d~minus 2: RAD001 2.5 every other day~RAD001 2.5 mg per day~RAD001 5 mg per day~RAD001 10 mg per day~RAD001 10 mg per day"
45970941|NCT00225524|Drug|Effexor XR|
46081319|NCT04789096|Drug|Tucatinib|Oral tablet
46081320|NCT04789096|Drug|Pembrolizumab|Intravenous
45828014|NCT05829655|Drug|Drug C (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
45970942|NCT00574444|Procedure|transvaginal diagnostic peritoneoscopy|For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
45970943|NCT00574483|Drug|quinacrine|100 mg day
46081321|NCT04789096|Drug|Trastuzumab|Intravenous
46081322|NCT04789096|Drug|Capecitabine|Oral tablet
46081323|NCT04785794|Biological|Sing2016 M2SR H3N2 influenza vaccine|This group will receive a dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally on Day 1 followed by IIV at least 28 days later.
46081324|NCT04785794|Other|Placebo|This group will receive saline placebo administered intranasally on Day 1 followed by IIV at least 28 days later.
46081325|NCT04782895|Biological|Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Three doses administered intramuscularly at 0, 45 day and 6 month.
46081326|NCT04782895|Biological|Gardasil®9|Three doses administered intramuscularly at 0, 45 day and 6 month.
45970944|NCT00235092|Device|Cypher Sirolimus-Eluting Stent|
45455844|NCT05595213|Device|Wrist fan activating device without cooling plate|This device is worn like a watch and pressing the button activates the cooling fan for 5 minutes.
45970945|NCT00235092|Device|Taxus Paclitaxel-Eluting Stent|
45828015|NCT05829655|Drug|Drug D (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
45828016|NCT05829655|Drug|Suvorexant (20mg/day)|Double blind administration of suvorexant once per day during residential stay until discharge.
45970946|NCT00574522|Radiation|Far infrared|Far infrared radiation with the wavelength between 5μm and 20μm for 30 to 40 minutes per session.
45970947|NCT00225563|Device|Electronic Health Record|e-prescribing methods
45828017|NCT05829655|Drug|Placebo|Double blind administration of placebo once per day during residential stay until discharge.
45828018|NCT05827003|Other|Exercise|Supervised exercise program with a physiotherapist for 6 weeks, two days a week
45828019|NCT05827003|Other|Exercise&Topical Agent|Diclofenac gel application to the knee joint twice a day, four days a week, in addition to a supervised exercise program under the supervision of a physiotherapist for 6 weeks.
45828020|NCT05827003|Other|Topical Agent|Application of diclofenac gel to the knee joint twice a day, four days a week, for 6 weeks
45970948|NCT00574600|Biological|SAAVI DNA-C2 vaccine|DNA vaccine
45970949|NCT00574600|Biological|SAAVI MVA-C vaccine|Boost vaccine
45970950|NCT00574600|Biological|Placebo|Placebo vaccine
46081327|NCT04777331|Drug|Prasinezumab|Prasinezumab will be administered as an IV infusion to participants Q4W.
46081328|NCT04777331|Drug|Placebo|Prasinezumab placebo will be administered to participants.
46081329|NCT04774094|Drug|Zavicefta, Ceftazidime-Avibactam|Participants will receive CAZ-AVI (2000 mg of ceftazidime and 500 mg of avibactam) administered by IV infusion in a volume of 100 mL at a constant rate over 2 hours.
46081330|NCT04773782|Drug|avapritinib|oral administration
46081331|NCT04767789|Dietary Supplement|NZ-GHMH-01|Each randomized subject will consume 1 capsule daily bringing 100 mg (≥ 2 x 109 CFU) of active ingredient during 16 weeks (from V2 to V5 visits).
46081332|NCT04767789|Dietary Supplement|Placebo|Each randomized subject will consume 1 capsule with no active ingredient daily during 16 weeks (from V2 to V5 visits).
46081333|NCT04767373|Biological|Clesrovimab|Clesrovimab solution
46081334|NCT04767373|Drug|Placebo|Placebo (0.9% sodium chloride [NaCL]) solution
45970951|NCT00574639|Drug|Alprazolam|1 mg given orally prior to morning and afternoon clamps on Day 1
45970952|NCT00574639|Drug|Placebo|1 mg given orally prior to glucose clamps on Day 1 (morning and afternoon)
45828021|NCT05824273|Behavioral|LungTalk|LungTalk is a 10-15 minute long computer-tailored health communication and decision-making tool.
45828022|NCT05824273|Behavioral|Non-tailored intervention - Standard of practice|ACS Lung Screening Informational Video
45828023|NCT05824195|Other|Bread products|Four intervention products were included in the study. Three experimental breads (quinoa 1, quinoa 2, quinoa 3) were developed, and consisted of white wheat breads substituted with the differrent quinoa types. The reference product included was a white wheat bread without quinoa. All intervention products contain 50 g available starch.
45828024|NCT05821530|Device|HFIT|At least 1 hour daily for 4 weeks
45970953|NCT00574678|Other|Tear collection|"A tear sample (~75 microliters in a tuberculin syringe with the needle removed) will be taken at time of the initial clinic visit. After collection, the tears will be put directly on ice and taken to the lab. If it is not possible to obtain natural tears, an eye wash method using sterile saline will be employed and the fluid collected using the aforementioned technique. The SELDI-MS process will be conducted on the specimen immediately. The remainder of the tear specimen will be stored in a -80ºC freezer until completely analyzed."
45970954|NCT00574717|Procedure|Spectacles|Infants will receive spectacles with 3.00D of under-correction relative to the spherical equivalent in each eye as measured by the cycloplegic retinoscopy performed at baseline. They will also receive the full amount of measured astigmatism in their glasses. Changes in spectacle lens power will be made as needed at follow-up visits to keep the level of under-correction within 0.50D of the target 3.00D. A program of visual engagement is also provided to encourage the normal development and use of accommodation. Treatment will continue for 15 months (until 18 months of age) or until the infant reaches a spherical equivalent refractive error of +3.00D or less hyperopia.
45970955|NCT00225602|Behavioral|Assertive Community Treatment|
45970956|NCT00225602|Behavioral|Treatment in Community Mental Health Center|
45970957|NCT00255255|Drug|Budesonide/Formoterol|
45970958|NCT00574756|Drug|ranolazine|extended release 500 mg twice a day for two weeks
45828025|NCT05821530|Device|TENS|At least 1 hour daily for 4 weeks
45970959|NCT03453658|Procedure|Manual instrumentation|Manual conventional files will be used in endodontic treatment of primary teeth
45970960|NCT03453658|Procedure|Reciprocating Instrumentation|Reciprocating files system will be used in endodontic treatment of primary teeth.
45970961|NCT03453424|Procedure|TEA+DEX|intra and post operative TEA infusion of (bupivacaine +fentanyl 2 mic/ ml+ dexmedetomidine 0.5 mic/ ml) Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 inter space was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.
45970962|NCT03453424|Procedure|TEA|"Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 interspace was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.~then, intra and post operative TEA infusion of bupivacaine 0.125%+fentanyl 2 mic/ ml."
45970963|NCT00225641|Procedure|CT-scan, CEA, X-ray of lungs|Arm 1: 6, 12, 18, 24 and 36 months after surgery
45828026|NCT05821530|Other|Control|Users will continue to use the digital MSK program as needed
45970964|NCT00225641|Procedure|CT-scan, CEA, X-ray of lungs|Arm 2: 12 and 36 months after surgery
45970965|NCT00235131|Device|Smart Stent|Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System
45970966|NCT00235131|Device|Luminexx Stent|Bard® Luminexx™ 6F Vascular Stent
45970967|NCT03453346|Drug|Sofosbuvir|Generic sofosbuvir tablet 400 mg
45970968|NCT03453346|Drug|Ribavirin|Ribavirin was provided in 100-mg tablets.
45970969|NCT00575068|Drug|IDEC-114|Phase 1-A Group 1 - 125 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 2 - 250 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 3 - 375 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-B Group 4 - 500 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase II-A & II-B - Dosage start at the MTD (up to 375 mg/m2)
45970970|NCT00575107|Other|Exercise|Velocity-controlled variable resistance protocols enable trainees to load their muscles more optimally along the entire ROM in either or both of the shortening (VSC) and lengthening (VLC) phases of a training repetition
45455845|NCT05595213|Other|Hot Flash Diary|Participants will be instructed to daily document each hot flash experience and indicate if it was mild, moderate, or severe and whether they activated the wrist cooling device.
45835902|NCT04770558|Other|Interactive Exergame|The one-to-one supervised training session consists of 10 min warm-up exercise, 40 min interactive exergame, and 10 min cool-down exercise. Both physical (muscle strength, coordination and balance in lower limbs) and cognitive functions (visuospatial, attention, short-term memory, calculation, reaction and executive function) will be trained through the interactive exergame.
45970971|NCT00575107|Other|Exercise|Standard training of leg extension
45970972|NCT00225680|Device|drug eluting coronary stent|
45970973|NCT00575224|Drug|Pegylated interferon and ribavirin|180 ug of peg-IFN per week and 1000-1200 mg of ribavirin per day (weight-dependent). Treatment duration is determined by treatment arm.
45970974|NCT00235170|Device|drug-eluting stent|Cypher Sirolimus-eluting Coronary stent
45970975|NCT00590941|Procedure|Blood draw|Sample Collection for Genotyping prior to cycle 1 treatment of R-CHOP, if patient is enrolled after cycle 1, sample for genotyping should be collected prior to cycle 2.
45970976|NCT00225719|Drug|rHDL|
45970977|NCT00255294|Drug|Cellulose sulfate vaginal gel|
45970978|NCT00591058|Drug|TM-601|TM-601, administered intravenously (IV), once/week for 3 weeks
45835903|NCT04770948|Device|19 gauge needle|EBUS-TBNA performed using 19G needle
45835904|NCT04770948|Device|22 gauge needle|EBUS-TBNA performed using 22G needle
45835905|NCT01960530|Drug|Hydrocortisone granules|Multi-particulate granules
45970979|NCT00225797|Drug|Oxymorphone Extended Release|
45970980|NCT00591136|Drug|indibulin|Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months
45970981|NCT00591292|Drug|indibulin|Dose escalation of indibulin given twice daily for up to 6 months
45828027|NCT05818787|Behavioral|Vestibular Perceptual Learning|The participants will be tilted and asked to indicate their perceived direction of self-motion (e.g., left or right). Feedback will be provided to promote learning (i.e., improved perception of motion). Feedback will only be provided after the subject response, and thus vestibular (i.e., self-motion) perception is required to judge the direction of the tilt stimulus. After each trial, a 3 second period of rest will be given. Each day of training will include three blocks of one-hundred trials each. Testing will take place in the dark (except for aims where a visual cue is provided). Subjects will be seated on a motion platform with a 5-point harness and the head restrained. Noise cancelling earpieces (along with a white noise signal) will be used to reduce external noise. Subjects will always be asked to make a decision (e.g. left versus right) by pressing buttons with their left or right hands. If not certain, subjects are instructed to provide their best guess.
45835906|NCT01960530|Drug|Hydrocortisone Tablet|Standard hydrocortisone tablets
45835907|NCT01960530|Drug|i.v. Hydrocortisone Injection|Standard hydrocortisone solution for intravenous injection
45835908|NCT01960530|Other|Dexamethasone|Challenge agent
45970982|NCT00591331|Drug|Spinosad (the active ingredient in NatrOVA)|This is a patch test in which the test material is applied to the patch and the patch applied to the skin.
45970983|NCT00591331|Drug|placebo|
45970984|NCT00591448|Other|Virtual Reality (VR)|See above
45970985|NCT00235209|Device|Collagen ORC Antimicrobial Matrix (CAM)|
45970986|NCT00225836|Device|OVA (TENS apparatus)|
45970987|NCT00591487|Drug|Lidocaine|Subcutaneous infiltration with Active/Placebo solutions with tumescent technique previous to suction assisted lipectomy. Patient abdomen and back will be divided in 4 zones anterior and posterior, one side (left or right) will be infiltrated with active solution and the other with placebo. The allocation of the side will be made with random numbers.
45970988|NCT03452215|Behavioral|Mobile Phone Application Educational Resources|Mobile Phone Application Educational Resources
46081335|NCT04764357|Device|Paxman Scalp Cooling System|Scalp cooling will begin at least 30-45 minutes prior to administration of each chemotherapy (45 minutes for those with thick or coarse hair types). Scalp temperature will be maintained at +3°C (37°F) throughout drug administration and for at least 120-180 minutes after discontinuing the infusion. Scalp cooling will occur with each dose of chemotherapy.
45970989|NCT03452215|Behavioral|Mobile Phone Application GWG Tracker|Mobile Phone Application GWG Tracker
45455846|NCT05589610|Drug|EQ101|EQ101, 2 mg/kg, once weekly dosing, for a total of 24 doses
45835909|NCT01897350|Other|Cardiac magnetic resonance imaging|
45835910|NCT01737060|Device|Reverse total shoulder arthroplasty|
45970990|NCT00255333|Drug|INNO-105|
45970991|NCT03452059|Device|AiLegs, AiWalker and HKAFO|5 days. Using their own control method, each morning using AiLegs, AiWalker AiWalker and HKAFO for 6 minutes walk test, three kinds of appliance between at least 30 minutes to determine heart rate, blood pressure and breathing back to quiet level. Repeat the same procedure in the afternoon ，the order is also random. Each participant will complete 10 groups of lower limb exoskeleton rehabilitation Training robot (including AiLegs, AiWalker two models) and HKAFO 6 minutes walking test
45970992|NCT00225875|Drug|Mabthéra|
45970993|NCT03452020|Device|Temperature measurementsusing the Tyto thermometer, the standard of care thermometer and the predicate thermometer|Temperature measurements using the Tyto thermometer, the standard of care thermometer and the predicate thermometer
45970994|NCT03451981|Procedure|mechanical debridement and chemical decontamination|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with chlorhexidine.
45970995|NCT03451981|Procedure|Er:YAG laser|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Chlorhexidine. Furthermore, Er:YAG laser treatment will be provided on the implant surface.
45970996|NCT03451981|Procedure|Air Powder|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Clorhexidine. Furthermore, an Air-Powder treatment will be provided on the implant surface.
45970997|NCT03451942|Drug|FLOT regimen chemotherapy|FLOT regimen chemotherapy
45970998|NCT03451942|Procedure|D2 gastric and imaging metastases resection|After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)
45970999|NCT00255372|Drug|PEG 4000 (Forlax®)|Powder for oral solution. 2 sachets of 4g, from baseline every two weeks over a 4 week treatment period.
45971000|NCT00255372|Drug|Lactulose active and Lactulose placebo|Powder for oral solution. 1 sachet of 3.3g lactulose active and 1 sachet of lactulose placebo. From baseline every two weeks over a 4 week treatment period.
45971001|NCT00225914|Drug|Paroxetine|Paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability
46081336|NCT04764357|Other|Alopecia Assessments|Photographs of the hair will be taken before initiation of chemotherapy (baseline) and at a visit 4 weeks (3-6 week window) after the last dose of chemotherapy for those being treated for a non-cancerous condition. Patient with solid tumors will have photographic documentation at baseline, 2-5 weeks after every 2 cycles of chemotherapy, and at end of study (approximately 4 weeks following the last chemotherapy treatment with a range of 3-6 weeks).
45971002|NCT00225914|Drug|placebo|Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
45971003|NCT03451903|Drug|Actilyse|Actilyse is the intra-venous agent used for intra-venous thrombolysis in the acute phase of cerebral infarction.
46081337|NCT04764357|Other|Patient Reported Outcomes Questionnaires|"Selected questions from NCI PRO-CTCAE™, Chemotherapy-Induced Alopecia Distress Scale (CADS), and PediQUEST Memorial Symptom Assessment Scale, at the following time points: baseline, end of chemotherapy administration, and 4 week follow up.~Tolerability Questionnaire each time the cooling cap is used and at the end of study"
45971004|NCT03451903|Procedure|Mechanical thrombectomy|Mechanical thrombectomy is an endovascular procedure by which an arterial clot is retrieved, in order to reperfuse the brain.
45971005|NCT03451864|Procedure|Vaginal delivery|classic vaginal delivery
45971006|NCT03451864|Procedure|Cesarean Section|routine lower segment cesarean scetion
45971007|NCT00235248|Drug|Warfarin|Warfarin
46081338|NCT04761822|Biological|Moderna COVID-19 Vaccine|Intramuscular injection
46081339|NCT04761822|Biological|Pfizer-BioNTech COVID-19 Vaccine|Intramuscular injection
45971008|NCT00235248|Drug|Clopidogrel-aspirin|Clopidogrel-aspirin
46081340|NCT04761822|Biological|Placebo|Intramuscular injection
45971009|NCT04574323|Radiation|Curative radiotherapy|Standard curative radiotherapy
46081341|NCT04757194|Diagnostic Test|openTriage - Alitis algorithm|A machine learning algorithm (Gradient boosting) applied to structured data collected in the Alitis Clinical Decision Support system, patient demographics, and free-text notes.
46081342|NCT04754399|Drug|Cannabidiol (CBD)|"week 1: 25 mg twice daily, approximately 12 hours apart, with food~week 2: 50 mg twice daily, approximately 12 hours apart, with food~week 3: 75 mg twice daily, approximately 12 hours apart, with food~week 4+: 100 mg twice daily, approximately 12 hours apart, with food"
46081343|NCT04730791|Diagnostic Test|Algo(s)rithm/ IASP clinical criteria|IASP clinical criteria for identifying nociplastic pain. The criteria is completed by the healthcare professional and includes questions about the patient's clinical picture.
46081344|NCT04730791|Diagnostic Test|Pressure Pain Threshold|The pain pressure threshold (PPT) is used to measure pain sensitivity in body areas. The test quantifies the minimum amount of pressure in a given area, during an increasing skin pressure stimulus, which is capable of altering the feeling of pressure in pain.
46081345|NCT04727554|Drug|AMG 994|Administered as an intravenous (IV) infusion.
46081346|NCT04727554|Drug|AMG 404|Administered as an intravenous (IV) infusion.
46081347|NCT04716725|Drug|68Ga-PSMA-11|Given IV
45669562|NCT02964078|Drug|Interleukin-2|Interleukin-2: 8 admissions to hospital, each with 5 doses planned. This is considered the standard part of the combination. The standard interleukin-2 dose is 600,000 international units per kilogram per dose, with a maximum of 66,000,000 (for patients over 110 kg, which is 242 pounds). The dose is usually set at the start of the treatment and not adjusted. The infusion time is 15 minutes.
45669563|NCT02960659|Drug|Metformin and Liraglutide|Randomized controlled trial of metformin + liraglutide vs. metformin alone over 3 months in youth with type 2 diabetes.
45669564|NCT02960659|Drug|Metformin|Paired study of metformin over 3 months in youth with type 2 diabetes compared to controls (youth with prediabetes or type 2 diabetes not treated with metformin).
45669565|NCT02915744|Drug|NKTR-102|
45669566|NCT02915744|Drug|Eribulin|
45669567|NCT02915744|Drug|Ixabepilone|
45669568|NCT02915744|Drug|Vinorelbine|
46081348|NCT04716725|Procedure|Positron Emission Tomography (PET)|Undergo PET
46081349|NCT04714086|Drug|Avapritinib|Avapritinib will be administered orally at 300 mg QD.
46081350|NCT04708470|Drug|Bintrafusp Alfa|"Subjects will receive bintrafusp alfa via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. Bintrafusp alfa will be administered as a flat dose of 300 mg independent of body weight. Bintrafusp alfa is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter."
45669569|NCT02915744|Drug|Gemcitabine|
45669570|NCT02915744|Drug|Paclitaxel|
45669571|NCT02915744|Drug|Docetaxel|
45669572|NCT02915744|Drug|Nab-paclitaxel|
45669573|NCT02885363|Other|Clinical examination|
45669574|NCT02885363|Other|Blood sample|
45669575|NCT02885363|Procedure|Echocardiography|
45835911|NCT04389372|Behavioral|Mindfulness|Mindfulness by smartphone combined to video calls for clinical evaluation in patients with chronic migraine and medication overuse after withdrawal program
45835912|NCT04770168|Behavioral|Cognitive Behavioral Therapy Curriculum|"The 3-month Harry Potter curriculum is delivered by trained teachers and includes lessons on a) risk factors that can contribute to emotional distress, b) how depression and anxiety manifest and how to access support/treatment, c) cognitive distortions, how they differ from rational thoughts and basic cognitive restructuring techniques, d) crisis planning including personalized stressbusters and hope kits, and e) how to be resilient."
45971010|NCT04574323|Other|Paleolithic lifestyle intervention|This intervention consists of daily outdoor walks or bike rides of at least 30 min duration, preferably done at noon to maximize vitamin D production, and the adoption of a Paleolithic diet. For the outdoor activity, patients were told to not use sun screen. The Paleolithic diet prescription emphasized the consumption of fatty meats and organ meats from humanely raised animals, wild-caught fish, eggs, nuts and seeds, algae, spices, vegetables and fruits. Excluded were processed foods, grains of all types, legumes, vegetable oils except for native coconut and olive oil and dairy products except for ghee. No dietary supplements were allowed.
45971011|NCT00225992|Drug|Arsenic Trioxide|
45971012|NCT03451513|Behavioral|Pride Body Project|"PBP is a 2-session eating disorder prevention program. Each session is 2 hours, and separated by a week. Groups have 4 to 7 participants and are led by a peer and a clinician. This program allows a forum for young men to critique the appearance ideal. These exercises should induce cognitive dissonance, which subsequently lead to a reduction of internalization of the ideal. In session 1, participants: (1) define the ideal body type in the gay community, (2) discuss its origin and perpetration, (3) brainstorm its costs, (4) participate in a verbal challenge where they counter the ideal, and (5) are asked to complete three assignments. In session 2, participants: (1) review homework, (2) engage in role-plays to counter pursuit of the ideal, (3) discuss ways to challenge body talk statements, (4) list ways to resist the pressure to pursue this ideal (body activism), (5) discuss barriers to body activism and how to overcome those barriers, and (6) select an exit activity."
45828028|NCT05818787|Behavioral|Placebo Intervention|The placebo (or control) task will consist of oculomotor exercises that the subject will complete at home (i.e., outside of the lab). The oculomotor exercises will include saccadic eye movements performed in the horizontal and vertical planes. All movements will be completed within a limited, comfortable range of motion with the head remaining stationary. As the control intervention will be performed with the head stationary and in a seated position, no change in self-motion perception or balance is expected to result from the control (i.e., placebo) task.
45828029|NCT05812924|Biological|Platelet-rich plasma (PRP)|0.1-0.2 mL injections of platelet-rich plasma (PRP) will be injected to the vulvovaginal area. The injections will be placed every 5mm and at an angle of 60° into the mucosa and lamina propria of the posterior wall of the vagina.
45828030|NCT05810480|Diagnostic Test|polyreactive immunoglobulin G|Polyreactive immunoglobulin G will be tested centralized in Hannover as published (Taubert, Engel et al., Hepatology, 2022). The current standard diagnostic autoantibodies (e.g. ANA, anti-SMA, anti-LKM, anti-LC1, anti-SLA/L) will be tested centrally in Hannover according to current guidelines.
46081351|NCT04708470|Drug|NHS-IL12|NHS-IL12 will be administered at as dose of 4, 8, 12, or 16.8 micrograms/kg by SC injection every 2 or 4 weeks. The dose of NHS-IL12 will be calculated based on the weight of the subject determined within 72 hours prior to the day of drug administration. The dose of NHS-IL12 used for the previous administration can be repeated if the change in the subject's weight is 10% or less than the weight used for the last dose calculation.
45828031|NCT05807204|Dietary Supplement|Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
46081352|NCT04708470|Drug|Entinostat|The entinostat used in this study is a self-administered investigational agent and will be given orally at a designated dose once a week or as directed. Number of entinostat tablets will be calculated based on the dose for the participant.
46081353|NCT04707235|Drug|Hydroxycarbamide|Patients, aged ≥ 2 years old, with symptomatic SCD, treated with Siklos®.
46081354|NCT04702893|Drug|Nintedanib|Nintedanib
46081355|NCT04696861|Behavioral|IDEAS for Hope|Participants will receive three counseling sessions at two week intervals, delivered by telehealth by a trained psychiatric nurse, focused on managing suicidal ideation and enhancing HIV care engagement.
46081356|NCT04696861|Behavioral|Enhanced Standard of Care (Safety Planning)|Participants will receive a brief, 10-15 minute counseling session, delivered by telehealth by a trained psychiatric nurse, focused on safety planning.
45828032|NCT05807204|Dietary Supplement|Placebo|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
45828033|NCT05804786|Device|3D electromagnetic navigation guided bronchoscopy|It is performed when a pulmonary lesion with a possibility of malignancy is found on chest CT and histological diagnosis and differentiation are required.
45828034|NCT05799313|Other|At home removal|Removal of PNE lead at home
45828035|NCT05799313|Other|In office removal|Removal of PNE lead in the office
45828036|NCT05791877|Device|pneuRIP|Respiratory sensor to measure pulmonary function
45828037|NCT05788237|Biological|RSVpreF+qIRV|RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B combined with Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)
45828038|NCT05788237|Biological|qIRV|Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)
45828039|NCT05788237|Biological|RSVpreF|RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B
45828040|NCT05788237|Drug|Placebo|0.9% saline for injection
45971013|NCT03451513|Behavioral|Media Advocacy|We will use a media advocacy (MA) intervention as an active, time- and attention-matched control. MA is a 2 session, group-based program with co-leaders (1 peer and 1 clinician). The MA content centers on acknowledging and discussing the role the media has on shaping body image ideals. In session 1, there is a discussion on describing the ideal body in the gay community and how the media impacts this ideal. Following this, participants will watch a video on how the media influences body image among gay men, and the consequences of internalizing these messages. In session 2, participants will watch a second video. Next, the group discusses other forms of media (e.g., pornography, social media) and how it impacts body image.
45971014|NCT03451435|Drug|N acetyl cysteine|N acetyl cysteine at 20mM will be utilized as the final stage of irrigation prior to induction of bleeding during endodontic revascularization procedure.
45971015|NCT04719195|Other|Meniscus extrusion ultrasonogrphic evaluation|This study will enroll the patients with knee medial compartment osteoarthritis of the knee joint who undergo open proximal tibial osteotomy. The degree of medial and lateral meniscus extrusion will be measured through ultrasound measurements before and after surgery. Also, demographic factors and radiographic measurements will be also investigated before and after surgery. In addition, preoperative, postoperative 3, 6, and 1 year clinical results including meniscus extrusion will be compared and judged, and the evaluation will be evaluated by an orthopedic surgeon who has not participated in the operation among registered researchers.
45971016|NCT04574596|Other|no Intervention|This is an observational study. There is no intervention
45828041|NCT05788237|Biological|RSVpreF + qIRV 1.0 mL formulation|RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains) plus sterile water as diluent for injection
45971017|NCT04575064|Other|Standard of Care (SoC)|Standard supportive care is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
45828042|NCT05788237|Biological|RSVpreF + qIRV 0.5 mL formulation|RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains)
45971018|NCT04575064|Drug|Remdesivir|Remdesivir 200mg IV on day 1, followed by 100 mg IV daily infusion for 9 days or until discharge from hospital, whichever occurs first
45971019|NCT03451318|Drug|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray NASONEX
45971020|NCT03451318|Procedure|tonsillar adenoidectomy|tonsillar adenoidectomy
46081357|NCT04687072|Biological|Efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
45971021|NCT03451318|Procedure|Maxillary expander plus Twin-Block|Twin-block appliance combined with maxillary expander
45828043|NCT05784571|Other|Body Composition Assessment|Assessment of body composition using bioelectrical impedance analysis.
45828044|NCT05784571|Other|Modified Physical Performance Test|A test of physical functioning
46081358|NCT04687072|Other|Placebo PH20 SC|Subcutaneous injection with placebo PH20 SC
46081359|NCT04680637|Drug|Efavaleukin Alfa|Administered as a subcutaneous (SC) injection.
45828045|NCT05784571|Other|Hand grip strength|A test of hand grip strength using a hand dynamometer.
46081360|NCT04680637|Drug|Placebo|Administered as a subcutaneous (SC) injection.
46081361|NCT04680637|Other|Standard of Care|Standard of care procedures and therapies for managing active systemic lupus erythematosus will be carried out according to each investigator's standard procedures.
45971022|NCT03451240|Behavioral|Corporate Athlete® Resilience|"The product Corporate Athlete® Resilience Training Program (CAR Training), is a one day training program aimed to educate participants about stress management and stress recovery techniques.~The content of the training program is divided into two parts:~Introduction to stress and resilience: an overview of stress and its impact on wellbeing, combined with the definition of resilience and its linking to daily performance.~Introduction and implementation of stress management and resilience techniques: an overview of applicable stress management and resilience tools, combined with real time application methods. These activities aim to help individuals recover and grow from a stressful state into meaningful life engagement. The desired overall effect is better performance at home and at work."
45828046|NCT05784571|Other|6-minute walk test|Self-paced test of walking capacity.
45828047|NCT05784571|Procedure|Measurement of blood glucose and insulin|Blood will be drawn for measurement of glucose and insulin.
45828048|NCT05779943|Drug|Furosemide|Given IV
45828049|NCT05779943|Other|F18-rhPSMA-7.3|Given IV
45828050|NCT05779943|Procedure|Positron Emission Tomography|Undergo PET/CT scan
45828051|NCT05779943|Procedure|Computed Tomography|Undergo PET/CT scan
45835913|NCT04769934|Device|Penguin RFA|to evaluate the peri-implant bone level changes (marginal bone level) around the implant platform.
45835914|NCT01897428|Drug|Test-Bepotastine salicylate 9.64 mg|
45835915|NCT01897428|Drug|Reference-bepotastine besilate 10 mg|
45835916|NCT05606562|Procedure|Dental care|Participants will be offered free dental care
45835917|NCT00067236|Drug|PG-116800 (given as PG-530742)|200 mg tablet of PG-116800 (given as PG-530742)twice a day for 90 days
45835918|NCT00067236|Drug|Placebo tablet|placebo tablet, twice a day for 90 days
45828052|NCT05779774|Behavioral|WayToServe Plus In-service Component|Investigators will test WayToServe Plus in-service component's ability to increase refusal of service to intoxicated patrons in a randomized trial. A two-group randomized field trial (WayToServe training only [comparison control] v. WayToServe training plus WayToServe Plus in-service component [intervention]) with 2 assessment rounds (Baseline, Posttest) will yield a 2 factorial design. Investigators will randomly assign premises to WayToServe training and WayToServe Plus after baseline in Month 18, stratified by state and location. Remaining premises will receive WayToServe Training Only. All premises will be recruited to have servers complete WayToServe training. Servers in intervention group will be accepted into a Facebook private group after WayToServe training to receive in-service component with ~3 posts per week for 12 months. In Months 30-32, all premises will be posttested with PiP assessments (blind to condition).
45971023|NCT04573894|Diagnostic Test|Procalcitonin dosage|Plasma PCT levels measured by automated enzyme immunoassay (Kryptor).
45971024|NCT04574284|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
45828053|NCT05779774|Behavioral|WayToServe Training Only|Investigators will test WayToServe Plus in-service component's ability to increase refusal of service to intoxicated patrons in a randomized trial. A two-group randomized field trial (WayToServe Training Only [comparison control] v. WayToServe Plus In-service Component [intervention]) with 2 assessment rounds (Baseline, Posttest) will yield a 2 factorial design. Investigators will randomly assign premises to WayToServe Traiing Only after baseline in Month 18, stratified by state and location. In Months 30-32, all premises will be posttested with PiP assessments (blind to condition).
45971025|NCT04574284|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
45828054|NCT05779007|Drug|Pirfenidone|Pirfenidone
45828055|NCT05779007|Drug|Nintedanib|Nintedanib
45828056|NCT05778942|Device|Eyestil SYNFO|Instillation of study drug in both eyes: preservative-free ophthalmic solution based on sodium hyaluronate and xanthan gum
45828057|NCT05778903|Other|Nerve block|Suprazygomatic maxillary nerve block
45828058|NCT05776797|Procedure|Atrioventricular junction ablation in patients with cardiac resynchronization therapy (CRT)|Ablation of the atrioventricular (AV) node is a procedure used to disrupt or break the electrical connection between the upper heart chambers (the atria) and the lower heart chambers (the ventricles).
45971026|NCT04574050|Other|SELF-BREATHE|A self -guided, internet -based intervention for patients with chronic breathlessness
45971027|NCT00255450|Drug|ferumoxytol or placebo|
45971028|NCT04574128|Procedure|No retransfusion of cardiotomy blood|No retransfusion of cardiotomy blood via heart- and lung mashine
45971029|NCT00226031|Procedure|Educational Material and Reminder|Family practices were randomly assigned to intervention or usual care. The intervention was a mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the GP and a letter and educational package for the women.
45971030|NCT04573855|Biological|Anti-SARS-CoV-2 immunoglobulin|Treatment with Anti-SARS-CoV-2 immunoglobulin
45971031|NCT04574206|Behavioral|Elaborative Reminiscence (ER)|Parents will be trained to use elaborative communication techniques in conversations with their child.
45971032|NCT04574206|Behavioral|Present Tense Talk (PTT)|Parents will be trained to engage their children in conversations, describing activities as they are actually happening.
45971033|NCT04574011|Diagnostic Test|Passive leg raising|Raise the patient's lower limb at a 45 degree angle while lying down
45971034|NCT04721379|Behavioral|Meditation|"Group 1 participants with unguided session simply close their eyes for 10 minutes while EEG and EKG recordings are performed. Following 10 minutes, after briefly opening their eyes, they will be asked to relax with eyes closed for 30 minutes. After finishing the session, they fill out meditation depth questionnaire.~Group 2 participants with guided sessions close their eyes for 10 minutes while EEG and EKG recordings are performed. Following 10 minutes, after briefly opening their eyes, they will be guided through relaxation and meditation session for 30 minutes with a Heartfulness trainer with continued recording. After finishing the session, they also fill out meditation depth questionnaire."
45971035|NCT04573543|Diagnostic Test|Evaluation of the degree of fibrosis and steatosis|The degree of steatosis will be estimated using the controlled attenuation parameter (CAP), a method for grading steatosis by measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of fibrosis.
46081362|NCT04678752|Other|Weight management care path|"Documentation and data capture built in the Electronic Health Record~Clinical data support that suggests weight loss approach(es)~Tracking of weight loss progress and weight loss maintenance during patient visits to guide the patient-clinician conversation~Diagnosis and billing in EHR automatically adds the diagnosis of overweight or obesity and links the most common weight-related co-morbidities to ensure adequate provider reimbursement~Evidence-based online training on weight management for clinicians~Practice quality improvement and training for use of PATHWEIGH for weight-prioritized visits through practice coaches/facilitators~Consultation support by practice facilitators with implementing PATHWEIGH and by obesity providers for clinicians with creating patient treatment plans"
45455847|NCT05587374|Drug|Cadonilimab|Cadonilimab 10mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 14 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.
45455848|NCT05587374|Drug|Gemcitabine|Gemcitabine 1g/m2, d1 & 8 of every cycle, every 3 weeks for 3 cycles before radiation.
45455849|NCT05587374|Drug|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
45971036|NCT04573543|Diagnostic Test|Screening for the components of metabolic syndrome|"Anthropometric measures including body mass index (BMI), waist circumference (WC), waist hip ratio (WHR), and waist height ratio (WHtR) will be measured in all patients.~Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: bilirubin, AST, ALT, GGT, ALP, albumins, WBC, neutrophil-to-lymphocyte ratio, hemoglobin, platelet count, fasting glucose, triglycerides, cholesterol, HDL and LDL. Non-invasive scores of steatosis/fibrosis will be calculated (APRI, FIB4, NAFLD score). Patients will be screened for the components of metabolic syndrome."
45828059|NCT05776797|Drug|Optimal medication treatment in patients with cardiac resynchronization therapy (CRT)|Optimal medication therapy according to the prescription of the physician.
45828060|NCT05775471|Procedure|Biopsy|Undergo tissue biopsy
45669576|NCT02875301|Behavioral|150 Minutes Week|This group will complete aerobic based exercise 150 minutes per week. Participants will obtain minutes through supervised on site exercise and home based exercise. An exercise duration of 30 minutes will be achieved by the forth week of the program and be maintained for the duration of the intervention. Heart rate will be monitored to ensure proper intensity levels. Participants will also be instructed to exercise at home for 30 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone. During the Covid-19 pandemic shutdown, all intervention exercise was been shifted to home based.
45971037|NCT04573543|Diagnostic Test|Measurement of serum semaphorin concentrations|Semaphorin concentration will be measured in patient sera by ELISA.
45971038|NCT04573543|Diagnostic Test|Identification of semaphorin gene polymorphisms|Semaphorin genes will be sequenced to identify semaphorin gene polymorphisms associated with NAFLD.
45828061|NCT05775471|Procedure|Biospecimen Collection|Undergo blood and urine collection
45828062|NCT05775471|Drug|Enfortumab Vedotin|Given IV
45828063|NCT05775471|Procedure|MR Urography|Undergo MRU
45828064|NCT05775471|Procedure|Nephroureterectomy|Undergo nephroureterectomy
45828065|NCT05775471|Biological|Pembrolizumab|Given IV
45828066|NCT05768516|Other|Implementation of best practice for low back pain in primary care|"Stratified care: GPs will use a simple algorithm based on the risk of chronicity to determine the management plan. The risk level bas will be based on the Start Back Tool (SBT) and other variables that have been shown to improve the classification, such as work capacity.~Healthcare professional education: GPs will receive education to improve their knowledge about low back pain guidelines, diagnostic triage, patient education, stratified care and best practice.~Patient education: An education booklet Understanding My Low Back Pain will be used by GPs during their consultations. Second, GPs, PTs and OTs will provide similar reassuring messages and direct patients to the website www.infomaldedos.ch.~Interprofessional collaboration: A structured assessment form and a facilitated contact will be implemented between healthcare providers."
45828067|NCT05768347|Biological|Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)|Tissue samples are harvested, prepared and cryopreserved from post Bacillus Calmette-Guerin (BCG) bladder biopsies.
45828068|NCT05767047|Drug|Apremilast|Oral tablets or liquid suspension
45971039|NCT00226109|Drug|spironolactone|100 mg once daily. Can be reduced to 50 mg a day still maintaining the doubled-blinded status
45971040|NCT04573426|Drug|Acetaminophen|1,000mg liquid acetaminophen
45971041|NCT04573426|Drug|Placebo|Liquid placebo solution
45971042|NCT04573426|Behavioral|Weight stigma vignette|Short vignette meant to induce weight stigma by describing one's rejection for a promotion due to their weight
45971043|NCT04573426|Behavioral|Control vignette|Short vignette meant to have no effect on emotion describing a generic promotion process
45971044|NCT00235287|Drug|Candesartan and enalapril|24 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), where Enalapril is added in incremental doses (5,10 and 20 mg)the last 8 weeks.
45971045|NCT00235287|Drug|candesartan and enalapril|24 weeks of treatment with Enalapril in incremental doses (5, 10, 20 mg), where Candesartan is added in incremental doses (4,8,16 mg) in the last 8 weeks.
45971046|NCT00235287|Drug|candesartan and enalapril|8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), followed by 8 weeks of treatment with Enalapril in incremental doses (/5,10,20 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan in incremental doses (4,8,16 mg) and Enalapril 20 mg.
45828069|NCT05765396|Device|imPulse™ Una infrasound-to-ultrasound e-stethoscope|The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
45835919|NCT04753398|Device|Blood Pressure Monitor, medication dispenser, telemonitoring technology|The telemonitoring interference in the telemonitoring arm consists of an automatic blood pressure device and medication dispenser that transmit data to a central platform.
45971047|NCT00235287|Drug|candesartan and enalapril|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg), followed by 8 weeks of treatment with Candesartan (4,8,16 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
45971048|NCT00226148|Procedure|Use of a membrane to cover bonedefects around implant|
45971049|NCT00226148|Device|Use of bonechips to fill up defects around implant|
45835920|NCT04617678|Other|Prehabilitation Program|We will assess whether prehabilitation intervention helps mitigate adverse symptoms (e.g., anxiety, depression, suicidality, distress, nutritional status, dysphagia, sarcopenia, and well-being) on a sample of head and neck cancer patients. Subjects will attend a Prepare for Surgery Heal Faster session and meet with a physical therapist, registered dietician, speech language pathologist, and masters of social work at pre-treatment, 6-8 weeks post-treatment, and 5-6 months post-treatment completion.
45971050|NCT00226148|Procedure|Use of membrane and bonechips to manage defects|
45971051|NCT04573348|Diagnostic Test|Savicell's ImmunoBiopsy™|ImmunoBiopsy and ELISA
45971052|NCT04573621|Procedure|Pelvic drain|A pelvic drain is placed
45669577|NCT02875301|Behavioral|225 Minutes Week|This group will complete aerobic based exercise 225 minutes per week. Participants will obtain minutes through supervised on site exercise and home base exercise. A walking duration of 45 minutes will be achieved by the seventh week of the program. This will be maintained for the duration of the intervention and heart rate will be monitored to ensure proper intensity levels. Participants will be instructed to exercise at home for 45 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone. During the Covid-19 pandemic shutdown, all intervention exercise has been shifted to home based.
45971053|NCT04573621|Other|No pelvic drain is placed|A pelvic drain is not placed
45971054|NCT04573465|Behavioral|Phone Coaching|Participants receiving phone coaching receive one 10-15 minute phone call each week from their randomly assigned peer-support coach. During coaching calls, the peer-support coach will discuss ACT Guide usage with the participant (e.g., asking how many modules the participant completed, asking what the participant liked/disliked about the modules, etc.).
45971055|NCT04573465|Behavioral|Text Message Coaching|Participants receiving text message coaching receive text messages on a weekly basis from their randomly assigned peer-support coach. Text messages from the peer-support coach will discuss ACT Guide usage with the participant (e.g., asking how many modules the participant completed).
45971056|NCT04573465|Behavioral|ACT Guide|ACT Guide is an online self-help program based on acceptance and commitment therapy (ACT), targeting acceptance, mindfulness, and values-based processes. It is intended to be used for 20 to 40 minutes at time, a few times a week. While using ACT Guide, participants will read about concepts relevant to ACT and engage in guided experiential exercises, with additional exercises being assigned to be completed in between sessions as homework.
45971057|NCT00255489|Drug|Gefitinib|
45971058|NCT00255489|Procedure|palliative thoracic radiotherapy|
45971059|NCT04573153|Drug|Hydroxychloroquine + Metabolic cofactor supplementation|Treatment arm will include dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside + standard therapy (hydroxychloroquine).
45971060|NCT04573153|Drug|Hydroxychloroquine + Sorbitol|Placebo comparator will include sorbitol as placebo + standard therapy (hydroxychloroquine).
45971061|NCT00226187|Procedure|Supplement of fatty acid (DHA and AA)|
45971062|NCT02277418|Device|VAVL|Videolaryngoscope
45971063|NCT02277418|Device|MIL|Direct laryngoscopy
45971064|NCT00255528|Drug|metoprolol succinate|
45971065|NCT04573270|Biological|PrimePro|Intravenous Injection
45971066|NCT04573270|Other|Placebo|Intravenous Injection
45971067|NCT00226226|Procedure|Peripherally Inserted Central Catheter Placement|
45971068|NCT04572919|Procedure|lateral advancement flap|Patients were randomly assigned to undergo either lateral advancement flap or classic Limberg flap for treatment of non-complicated pilonidal sinus
45835921|NCT00007644|Procedure|Radical prostatectomy|Surgical removal of the prostate
45835922|NCT00068718|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
45835923|NCT00024102|Drug|Standard Treatment|Cyclophosphamide 100 mg/sq m PO d 1-14 + MTX 40 mg/sq m IV push d 1 & 8 and 5-FU 600 mg/sq m IV push d 1 & 8 q 28 days for 6 cycles OR doxorubicin 60 mg/sq m IV d 1 + cyclophosphamide 600 mg/sq m IV d 1 q 21 d for 4 cycles
45971069|NCT04572919|Procedure|classic Limberg flap|Patients were randomly assigned to undergo either lateral advancement flap or classic Limberg flap for treatment of non-complicated pilonidal sinus
45971070|NCT04572685|Drug|Paliperidone Palmitate|A long acting extended release injectable suspension intended for monthly intramuscular administration
45971071|NCT04572724|Drug|Sacubitril / Valsartan Oral Tablet|Sacubitril/Valsartan will start at 50mg bid, when blood pressure can be tolerable, the dose will be gradually increased to 100mg bid after taking for 2-4 weeks, and then the target dose is gradually add to the 200mg bid after another 2-4 weeks. Ensure BP>90/60mmHg, the minimum dose is 50mg bid if the patient can't tolerate higher dose but the blood pressure is stable at low dose.
45971072|NCT04572724|Drug|RAS Inhibitors|RAS inhibitor group allows the use of a monodose of any ACEi or ARB. Ensure BP>90/60mmHg, the minimum dose is half dose if the patient can't tolerate monodose but the blood pressure is stable at half dose.
45971073|NCT00255567|Drug|Sodium Stibogluconate|Sodium Stibogluconate 20mg/kg/day for 30 days
45971074|NCT00255567|Drug|Paromomycin sulphate|Paromomycin sulphate
45971075|NCT00255567|Drug|SSG and Paromomycin sulphate|SSG and Paromomycin Sulphate 17 days
45971076|NCT04572607|Dietary Supplement|The consumption of avocado honey was analyzed|The subjects of honey group consumed 25 g of honey each day for 4 weeks.
45971077|NCT03450967|Drug|Durvalumab Plus Tremelimumab|Durvalumab 1500mg plus tremelimumab 75mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination until progression.).
45971078|NCT03450928|Procedure|Peroral Endoscopic Myotomy (POEM)|"Peroral endoscopic myotomy (POEM) is a minimally invasive intervention for the treatment of esophageal achalasia.~POEM includes different steps:~Lifting of the esophageal mucosa, with the injection of saline solution, and mucosal incision on the esophageal body (approximately 12 or 7 cm above the esophagogastric junction, for about 1-2cm)~Advance of the endoscope into the submucosa, repeated submucosal injection and dissection of a submucosal tunnel into the distal esophagus up to 3 cm into the gastric wall.~Myotomy of the distal esophagus, cardia and gastric wall, starting 3 cm below the mucosal incision~After the completion of myotomy, and check for mucosal integrity, the mucosal incision is closed using endoscopic clips"
45971079|NCT00235365|Behavioral|meta-cognitive therapy|Meta-cognitive therapy
45971080|NCT00235365|Other|waiting list|waiting list control
45971081|NCT03450889|Procedure|Colonoscopy|"Patients will undergo surveillance colonoscopies, with intervals of 1 or 2 years depending on the amount and type of polyps resected during last colonoscopy.~In case patients underwent subtotal colectomy, the term 'colonoscopy' should be replaced with 'sigmoidoscopy'."
45971082|NCT03450616|Device|PICO Negative Pressure Wound Therapy|Negative Pressure Wound Therapy Device
45971083|NCT03450616|Procedure|Compression Dressing|Standard of Care Compression Dressing
45971084|NCT04572529|Procedure|Cardiac Valve replacement|Open heart surgery to replace the valvular infective endocarditis
45669578|NCT02875301|Behavioral|Stretch and Tone|The control condition will focus on improving balance, flexibility, and strength. This group will obtain 150 minutes per week via in person sessions, zoom sessions and home based stretching. Resistance bands, balance disks, yoga blocks, and exercise mats will be used to engage in non-cardiorespiratory activities. These are progressive in nature and include modifications to accommodate injuries, physical difficulties, etc. A new set of similar, yet slightly more challenging activities will be introduced every four weeks. During the first two weeks, participants are introduced to the new activities, and, during the second two weeks, they are encouraged to increase intensity by using more weight or more repetitions. During the current Covid-19 pandemic, all intervention exercise has been shifted to home based.
45828070|NCT05760092|Combination Product|Institutional standard treatment for xerostomia and Long Covid|(Medical follow-up at the general outpatient clinic for prescription and control of medications, underlying diseases, clinical status and routine short, medium and long-term care follow-up, standard guidelines for the use of aerobic physical activity in those who do not have contraindications, stretching exercises, ergonomics, home adaptation to maximize functionality and energy savings, emotional cognitive support psychotherapy, socio-educational measures, sleep hygiene, Nutritional follow-up and monitoring, dentistry follow-up at the University's odontological team, guidance on proper oral hygiene, use of low-sugar diets, daily topical use of fluoride and antimicrobial mouthwash to prevent dental caries, oral hydration, guidance on avoiding cigarette use or intake of caffeine-containing beverages . When necessary, measures such as oral lubricants, artificial saliva, measures to prevent aspirations, as well as the careful use of liquids during meals, can be instituted ) +
45971085|NCT04572334|Other|Auto and Subjective Refraction|All patients will be measured with three autorefractometers and two independent observes will perform subjective refraction
45971086|NCT00255606|Drug|docetaxel|Given in 3- or 4- week courses
45971087|NCT00255606|Drug|prednisone|Given in 3- or 4- week courses
45455850|NCT05587374|Radiation|Intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
45971088|NCT03450577|Procedure|PCI of bifurcation lesions|Different approaches for treatment of bifurcation coronary artery disease.
45971089|NCT00226343|Drug|Depakote-ER|
45828071|NCT05760092|Radiation|Photobiomodulation Therapy|Application of Red LED in the 3 pairs of major salivary glands (parotid, submandibular and sublingual) extraorally, transcutaneously, 3 J/cm2, for 36 seconds, twice a week for 06 weeks.
45971090|NCT03450499|Drug|Ketamine|the analgesic affects of ketamine will be compared between the experimental and placebo group.
45971091|NCT03450499|Drug|Placebo|the analgesic requirement will be calculated in placebo group.
45971092|NCT03450460|Behavioral|Peer support|The Program matches volunteer Mentors and Partners for a series of one-to-one interactions that focus on the discussion and resolution of problems or issues (i.e., problem solving) related to one or several key topic areas including family and friends, resources, life changes or challenges, (health care) professionals, social/recreational activities, work/employment/training/volunteering, the brain injury itself, emotions or feelings, and other issues.27 Once the match is established, the Mentor and Partner communicate with one another primarily by telephone until the problems or issues are either resolved or a referral to another service is made (i.e., counselling or community support services). For some partnerships, communication by email or video conferencing is used.27 Most telephone calls last between 20 and 40 minutes (personal communication) and are held weekly.
45971093|NCT03450421|Device|Actamax™Adhesion Barrier|Actamax™Adhesion Barrier is a degradable hydrogel to be sprayed directly on surgically traumatized tissue. The aim of using the Actamax™ Adhesion Barrier (AB) in this way is to allow damaged and apposing tissue surfaces the opportunity to heal separately without becoming abnormally attached.
45971094|NCT00235404|Other|Multicomponent treatment|Specialized care in preparing recharge to home
45971095|NCT00235404|Other|usual care|Usual recharge directly from hospital to home
45455851|NCT05586529|Dietary Supplement|Cholecalciferol|Cholecalciferol is vitamin D derivative and as our population already vit D deficient so post-operative hypocalcemia can be prevented.
45669579|NCT02853643|Drug|ASN002|Single dose study with food effect
45669580|NCT02835638|Device|Adaptative Servo Ventilation|the ASV treatment will be observed during this study on the patients included
45669581|NCT02827955|Device|Gamma Knife® radiosurgery bilateral|
45669582|NCT02823327|Genetic|Laboratory Biomarker Analysis|Correlative studies
45971096|NCT00226382|Drug|Pegylated Interferon-alfa-2a|Pegasys once weekly
45971097|NCT01580839|Drug|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
45971098|NCT01580839|Drug|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
45669583|NCT02823327|Other|Medical Chart Review|Medical chart review is performed
45455852|NCT05579847|Other|mHealth Smart Phone Application|The mHealth interactive application consists of educational intervention geared towards eligible patients who are receiving Nivolumab/ Pembro with Axitinib/Cabozantinib/Lenvatinib. These patients commonly experience immune-related side effects, higher rate of fatigue, high blood pressure, and palmar-plantar erythrodysesthesia. The educational intervention will consist of multiple modules covering relevant information on treatment and adverse events and provided over a six-week period through an mHealth platform. This educational intervention includes a patient-friendly algorithm for early detection and management of the most common adverse events in patients with advanced renal cell carcinoma receiving combination immunotherapy.
45828072|NCT05760092|Radiation|Placebo Photobiomodulation Therapy|All parameters as the number of points, dose and place of application of the PBM will be the same as described in the item PBM therapy Intervention Group, however in the placebo PBM equipment will be turned off. The device activation noise will be recorded and used to mimic the irradiation.
45828073|NCT05759208|Drug|OK-101|Ophthalmic Solution
45828074|NCT05759208|Other|Placebo|OK-101 Placebo Ophthalmic Solution (vehicle)
45971099|NCT03450382|Other|Hans Kai Education|9 weeks of health education classes preceding social group formation into Hans Kai. Peer led support focused on behavioural change.
45971100|NCT03450265|Device|Hemopatch|Applied according to the current instruction for use (IFU). According to the IFU, a maximum of 7 Hemopatch 45 x 90 mm patches can be used in adults.
45971101|NCT03450265|Device|Tachosil|Applied according to the current instruction for use (IFU).
45669584|NCT02803125|Behavioral|Psychosocial intervention|This intervention is to be developed during the study. It will likely include modules that provide anger management strategies, communication skills, and education about interpersonal relationships and social support. In addition, psychoeducation about behavioral activation and stress management will likely be included
45828075|NCT05756569|Procedure|Biospecimen Collection|Undergo collection of blood
45971102|NCT00235482|Drug|Coxsackievirus A21|
45669585|NCT02803125|Behavioral|Support group control|The support groups will be process-oriented in nature with core elements manualized to facilitate consistency of the intervention. In particular, group leaders will facilitate a check-in with the group, and the agenda will be open to topics brought in by group members
45828076|NCT05756569|Procedure|Computed Tomography|Undergo CT
45828077|NCT05756569|Drug|Enfortumab Vedotin|Given IV
45828078|NCT05756569|Procedure|Magnetic Resonance Imaging|Undergo MRI
45971103|NCT03450226|Drug|stellate ganglion block|After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 or C7. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
45971104|NCT00226421|Drug|Oxymorphone Extended Release|
45971105|NCT04572373|Dietary Supplement|SMOFlipid|
45971106|NCT03450148|Other|Pavlok wristband with electric stimulus|it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Device has maximum voltage of 0-500 volts, delivers a electric stimulus for a maximum of 1 sec and average duration of 0.2 secs
45971107|NCT03450148|Other|Pavlok wristband without electric stimulus|it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Participants will not receive any electric stimulus since this feature will be turned off.
45971108|NCT03450109|Drug|LY01005|One gluteal IM injection
45971109|NCT03450109|Drug|Zoladex|One Subcutaneous injection in the abdominal wall
45971110|NCT03450031|Other|NAC (no drug/no device)|Nasal allergen challenge (NAC) with mixed grass pollen: a bolus NAC with mixed grass pollen will be conducted
45971111|NCT00226460|Drug|Fetal porcine cells, Neurocell-PD|
45669586|NCT02782949|Drug|Curcumin|Given PO
45669587|NCT02782949|Other|Laboratory Biomarker Analysis|Correlative studies
45669588|NCT02782949|Other|Placebo Administration|Given PO
45669589|NCT02782949|Other|Quality-of-Life Assessment|Ancillary studies
45669590|NCT02736656|Drug|SPN-812|
45669591|NCT02528643|Drug|Enzalutamide|Oral capsule
45669592|NCT02528643|Drug|Placebo|Oral capsule
45669593|NCT02506933|Other|Laboratory Biomarker Analysis|Correlative studies
45669594|NCT02506933|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
45669595|NCT02506933|Other|Placebo|Given IM
45828079|NCT05756569|Biological|Pembrolizumab|Given IV
45828080|NCT05756569|Other|Questionnaire Administration|Ancillary studies
45828081|NCT05755711|Device|Shockwave Medical Coronary IVL System|Coronary Intravascular Lithotripsy (IVL)
45828082|NCT05752123|Biological|ET-01|Recruited participants will receive ET-01 IV infusion after conditioning.
45828083|NCT05748197|Biological|ADCLEC.syn1 CAR T cells|There are 4 planned flat-dose levels: 25 × 10^6, 75 × 10^6 , 225 × 10^6 , and 450 × 10^6 CAR T cells and 1 de-escalation dose: 10 × 10^6 CAR T cells.
45828084|NCT05748197|Drug|Conditioning chemotherapy|Fludarabine 30 mg/m2 daily for 3 days and cyclophosphamide 500 mg/m2 daily for 3 days.
45828085|NCT05746611|Biological|Recombinant Mycobacterium tuberculosis fusion protein for injection|For the suction test, EC0.1ml was injected into the palmar skin of the forearm by the Mondu's method
45828086|NCT05746611|Biological|TB-PPD was injected|For the aspiration test, 0.1ml TB-PPD was injected into the palmar skin of the forearm by the Mondu's method
45835924|NCT00024102|Drug|capecitabine|2000 mg/sq m PO d 1-14, 7 day rest then repeat for a total of 6 cycles
45971112|NCT03459781|Behavioral|Cognitively-Based Compassion Training|CBCT® was designed at Emory University by Lobsang Tenzin Negi. CBCT® is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. Over the course of 8 weeks there will a total of 8 CBCT® sessions, one session per week, led by the CBCT® instructor. Dyads will attend the weekly CBCT® classes together. Each weekly session will last for 90 minutes and will begin with brief meditation to focus attention. The instructor will then articulate content and goals of the current week, after which a group discussion led by the instructor will take place. A session will end with a 20-30 minute meditation. Dyads will be encouraged to practice a minimum of 10 minutes per day at home, and together as a dyad if possible.
45971113|NCT03459781|Behavioral|CHE (Cancer Health Education)|The cancer health education (CHE) intervention is an adaptation of the in-person program called Health Discussion, a protocol used by our group previously. The CHE will focus on relevant topics to health and cancer including 1) cancer advocacy, 2) health and cancer biology, 3) nutrition, 4) lifestyle interventions such as physical activity and goals for physical activity, 5) the importance of good sleep, 6) the impact of stress, and 7) mental health and social support. CHE will also discuss current events related to cancer. Over the course of 8 weeks there will be a total of 8 sessions, one session per week. Each session will last for approximately 90 minutes.
45971114|NCT03458767|Behavioral|Eight weekly 90-minute group educational sessions|Eight weekly 90-minute group educational sessions, originally developed for the MAPSS-MS intervention, adapted for remote web-based delivery.
45971115|NCT00413309|Procedure|Video Capsule Endoscopy|Noninvasive pill endoscopy is undertaken after 90 days of Aspirin/Clopidogrel in patients who have had percutaneous coronary intervention with drug-eluting stents.
45971116|NCT03457519|Device|Children's Automated Respiration Monitor (ChARM)|The Philips CHARM (children's automatic respiratory monitor) is specifically designed to detect pneumonia in low resource areas. The lightweight measuring device sits on a child's or infant's chest, secured by a strap and measures respiration rate (fast breathing) through an ingenious algorithm. In this study ChARM will be used as a self monitoring and teaching aide by the CHWS.
45971117|NCT03451552|Behavioral|Patient Navigator|Navigators will support patients to access community based resources for healthy living and self-management, rather than providing specific information about health issues. Navigators will teach patients how to identify available and relevant programs to meet their health-related goals, in their language of choice. The navigator will ensure that the individual understands the reason for referral and potential benefits. They will discuss social barriers potentially affecting patients' access to community health resources, and assist patients to prioritize their health goals and relevant resources to achieve these. The navigator will then assist patients to access the community-based services in the language of their choice to which they have been referred. The navigator may assist the patient in making appointments, coordinating transportation, and/or accompaniment to resources as required).
45971118|NCT00413348|Drug|Lactobacillus acidophilus NCFM|
45971119|NCT00413387|Drug|beclomethasone dipropionate plus formoterol fumarate combination|100mcg beclomethasone diproprionate plus 6 mcg formoterol
45971120|NCT00413387|Drug|budesonide plus formoterol combination|200mcg budesonide plus 6 mcg formoterol
46081363|NCT04678752|Other|Control|"Within primary care the option to select Obesity brief HPI, this is a brief historical intake of a patient's weight - when either they or their clinician decides to have a weight-prioritized visit. It is intended to initiate a discussion regarding potential strategies for weight loss (often eat less, exercise more). The provider has the discretion to augment or add support as they see fit."
46081364|NCT04668157|Drug|TAK-536|TAK-536 granule formulation
45669596|NCT02491632|Drug|Dexamethasone|Given PO
45828087|NCT05743387|Other|T2D care package|T2D care package including lifestyle counselling, firstline antidiabetic (metformin) and lipid-lowering (statin) treatment for uncomplicated T2D and treatment support and regular check-ups for complicated T2D at village-level. Guidance will be provided via the ComBaCaL app. In case of complicated disease referral to the closest health facility for further management.
45828088|NCT05743387|Other|Referral to the responsible health facility|CC-VHWs will refer participants to the responsible health facility for therapeutic management. The ComBaCaL app supports clinical decision making and documentation for screening, diagnosis and referral, but not prescription/provision and monitoring of antidiabetic or lipid-lowering medication for uncomplicated T2D patients or treatment support for complicated T2D patients.
45828089|NCT05737706|Drug|MRTX1133|KRAS G12D Inhibitor
45828090|NCT05732831|Drug|TNG462|TNG462, a selective PRMT5 inhibitor, will be administered orally
45828091|NCT05727098|Drug|Bupivacaine Hydrochloride|injection of Bupivacaine 0.25% in ESPB
45669597|NCT02491632|Behavioral|Exercise Intervention|Complete a graded resistance exercise program and a walking regimen
45669598|NCT02491632|Other|Laboratory Biomarker Analysis|Correlative studies
45828092|NCT05727098|Drug|Bupivacaine Hydrochloride and dexmedetomedine|injection of Bupivacaine 0.25% and dexmedetomedine in ESPB
45828093|NCT05727098|Drug|Bupivacaine Hydrochloride and ketamine|injection of Bupivacaine 0.25% and ketamine in ESPB
45828094|NCT05720806|Other|Weight Bearing as tolerated (WBAT) immediately following surgery.|Subject will be provided standard of care physical therapy following surgical intervention, except will be able to self-select weight bearing based on pain and confidence.
45828095|NCT05720806|Other|Flat foot weight bearing (FFWB) immediately following surgery|Subject will be provided standard of care physcial therapy following surgical intervention except
46081365|NCT04667234|Drug|AMG 510|Administered as an oral tablet.
45669599|NCT02491632|Other|Quality-of-Life Assessment|Ancillary studies
45669600|NCT02491632|Other|Questionnaire Administration|Ancillary studies
45669601|NCT02476734|Other|There is no intervention|Subjects undergo FDG-PET CT scans in order to determine lesional FDG intake and changes in lesional FDG uptake.
45669602|NCT02409810|Drug|Dexmedetomidine|Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10 minutes by nursing staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg. This dosage is within the FDA-approved package insert parameters. Heart rate, blood pressure and oxygen saturation will be closely monitored by a staff RN already trained to provide care in the procedure room. 1 hour prior to- and after completion of the burn dressing change each day using a 100-mm visual analog scale. Patients will both rate their satisfaction with PCA-DEX for anxiety management after each completion of the burn dressing change.
45971121|NCT04572490|Diagnostic Test|periapical radiograph|alveolar bone loss measurement on standardized parallel periapical radiograph
45971122|NCT03458845|Diagnostic Test|Computed Tomography Scan|The results of the CT scan and the hand-grip test will be used for diagnosis of sarcopenia. The Royal Free Hospital-Global Assessment (RFH-GA) results will classify the nutritional status of the patient.
45971123|NCT00413426|Drug|Darifenacin (DAR328)|
45669603|NCT02325804|Behavioral|Lifestyle Counseling|In both arms life style counseling: Low calorie diet- 30% reduction of weight maintenance calories (TDEE); and recommended moderate exercise 3 times per week 45 minutes.
45828096|NCT05720182|Device|Compremium Compressibility Measurement|"CPM#1 measurements:~Step 1: Manual investigation to identify the compartment for compressibility measurements~Step 2: Marking the location for compressibility measurements~Step 3 - Examination with CPM#1~Place the probe on the target area~Identify correct landmark~Compress the compartment~Increase steadily the pressure applied by the CP probe to 80 mmHg."
45828097|NCT05720182|Procedure|Treadmill Running|"Exercise:~Step 1: Participants will walk on a treadmill with standardized walking speed (5.0 km/hour) and slope (15%) for 5 minutes.~Step 2: Immediate, one minute, and five minutes post-exercise CPM#1 measurements will be performed at one leg.~Exercise and post-exercise CPM#1 measurements will be repeated for the other leg."
45828098|NCT05720182|Other|Questionnaire|"Questionnaires NIAPS questionnaire: Baseline NIAPS questionnaire with one additional question about leg dominance.~Experience questionnaire: Scores 1-5, questioning the intensity, how painful, the nuisance, the duration of the study and the non-invasive pressure measurements."
45828099|NCT05717062|Drug|Varespladib intravenous form|This is a lyophilized drug contained in 100 mg vials to be reconstituted in Water for Injection (WFI), followed by dilution into 0.9% Sodium Chloride Injection.
45828100|NCT05717062|Drug|varespladib-methyl- oral form|Varespladib-methyl (LY333013) is an immediate-release, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration.
45828101|NCT05717062|Drug|Placebo intravenous form|The intravenous placebo will be saline (0.9%). Blinding will be ensured by covering the bag containing the investigational product with opaque covers.
45828102|NCT05717062|Drug|Placebo - oral form|Oral placebo is supplied as a white film-coated oval tablet to match the appearance of the LY333013 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate
45828103|NCT05716048|Behavioral|KF-mSMT Plus Aerobic Exercise Training|Participants will undergo this combinatory intervention 3 days per week for 12 weeks. The combined session duration will begin with 15 minutes and last up to 2 hours by the end of the 12th week
45828104|NCT05716048|Behavioral|KF-mSMT Plus Stretching Exercise Training|Participants will undergo this combinatory intervention 3 days per week for 12 weeks. The combined session duration will begin with 15 minutes and last up to 2 hours by the end of the 12th week
45828105|NCT05710224|Biological|V181|0.5 mL SC dose of V181
45828106|NCT05710224|Biological|Butantan-DV|0.5 mL SC dose of Butantan-DV
45828107|NCT05698823|Device|Lumoral Treatment|The Lumoral treatment -device is a CE-marked antibacterial home-use device for the treatment and prevention of oral diseases caused by bacteria. It is used in combination with a CE-marked mouth rinse called Lumorinse.
45828108|NCT05695183|Device|IV SafeLock|Designed to prevent patient access to intravenous lines in the hospital setting. The device locks with an institution specific key and protects the hub as well as all tubing access points.
45828109|NCT05694520|Other|pistachios consumption of 1.5 oz thrice per week|According to the Chinese nutritional guidelines for GDM women, the energy intake of 1500-1800 kcal/d will be recommended for all the included participants with pregestational BMI≥24 kg/m2. Standard care and a balanced diet will be recommended to the women in CG incorporating the total nuts intake of less than 2.5 oz per week). While the women in the IG will be offered the otherwise same diet as their counterparts in the CG, except for the extra intake of pistachios of 1.5 oz thrice per week.
45828110|NCT05692492|Drug|ZSP1601|50mg BID
45828111|NCT05692492|Drug|ZSP1601|100mg BID
45828112|NCT05692492|Drug|Placebo|Placebo
45828113|NCT05691699|Drug|ABBV-903|Capsule; oral
45828114|NCT05691699|Drug|Placebo for ABBV-903|Capsule; oral
45828115|NCT05691699|Drug|Itraconazole|Capsule; oral
45828116|NCT05689814|Device|Paraffin based Denture Fixative|Denture fixative applied in strips to secure dentures in place
45828117|NCT05687058|Drug|Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing|Participants in Group I will be asked to take empagliflozin 25 mg after each hemodialysis session under direct observation by a trained health care worker.
45828118|NCT05687058|Drug|Empagliflozin 10 mg daily dosing|Participants assigned to Group II will be asked to take empagliflozin 10 mg each morning between 8:30 and 9:30 a.m. at home.
45828119|NCT05685433|Device|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
45828120|NCT05684367|Behavioral|Center-Based Walking Exercise|Each exercise session will begin with a short warm-up followed by 30 min of walking. Participants will initially be instructed to walk at a moderate intensity, equivalent to a 5-6 on Borg category-ratio (CR) scale. Participants will be encouraged to, if possible, incorporate brief periods of vigorous walking (7-8 on CR10 scale) with a goal of achieving at least 10 min of vigorous walking per session.
45971124|NCT00255762|Drug|carboplatin|Given IV
45971125|NCT00255762|Drug|paclitaxel|Given IV
45971126|NCT00255762|Biological|bevacizumab|Given IV
46081366|NCT04665037|Drug|Posaconazole IV 6 mg/kg|POS 6 mg/kg of body weight by IV infusion in a single dose on Day 1
45971127|NCT00255762|Other|laboratory biomarker analysis|Correlative studies
46081367|NCT04665037|Drug|Posaconazole IV TBD|POS at a dose to be determined (TBD) by IV infusion twice daily on Day 1; and then once daily on Day 2 to a maximum 84 days
45669604|NCT02324608|Biological|cetuximab|Given IV
45828121|NCT05684367|Behavioral|Home-Based Walking Exercise|Participants will be asked to walk for exercise in their community five days/week. Participants will be instructed to begin with 10-15 minutes of walking exercise/session in the first month of the intervention and to increase exercise duration by five minutes/session each week, facilitating reasonable but steady progress toward the goal of 30 minutes per session.
45669605|NCT02324608|Other|laboratory biomarker analysis|Correlative studies
45669606|NCT02286726|Other|Laboratory Biomarker Analysis|Correlative studies
45669607|NCT02286726|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
45828122|NCT05683730|Other|Intermittent caloric restriction|"Intermittente caloric restriction:~st month: restriction of 50% of the caloric intake previously determined by the dietician 1 day per week~nd month: restriction of 50% of the caloric intake 2 days per week~rd month: restriction of 60% of the caloric intake 2 days per week~th month: restriction of 75% of the caloric intake 2 days per week"
45828123|NCT05681884|Drug|Faricimab|Faricimab is a humanized bispecific antibody binding to human Ang-2 and VEGF. For Phase III studies, the Ro 686-7461 drug product is provided in single-dose 2-mL glass vials (6 mg/0.05 mL) with L-histidine/acetate buffered solution (approximately pH 5.5) containing sodium chloride, sucrose, L-methionine, polysorbate 20, and water for injection.
45828124|NCT05681624|Other|Maternal oxygen supplementation|Maternal oxygen supplementation 10 liters/minute via nonrebreather mask
45828125|NCT05681624|Other|Room air|Room air, no mask
45828126|NCT05680415|Biological|Mycobacterium Vaccae for Injection|The experimental group was alternately injected with 1 dose of microcard every two weeks (0-2-4-6-8-10 weeks) in the left and right hip muscle deep, and a total of 6 doses were injected.
45828127|NCT05677451|Drug|LOU064 (blinded)|LOU064 (blinded) active treatment
45828128|NCT05677451|Drug|placebo|matching active drug
45828129|NCT05664737|Biological|Luspatercept|Specified dose on specified days
45828130|NCT05664737|Drug|Placebo|Specified dose on specified days
45828131|NCT05664737|Other|Best Supportive Care|Specified dose on specified days
45828132|NCT05656352|Device|Masimo Total Hemoglobin SpHb® Continuous Non-invasive Hemoglobin Monitoring Device|Masimo Radical-67® Pulse CO-Oximeter and rainbow® sensors.
45828133|NCT05656352|Diagnostic Test|Complete Blood Count|The test will be done using venous blood collected in EDTA tubes. Samples will be analyzed within 6 hours of collection or stored at 2 to 8C and analyzed within 24 hours. Analysis will be done using a five-part differential hematology analyzer.
45828134|NCT05655299|Drug|VTX958|Dose A
45828135|NCT05655299|Drug|VTX958|Dose B
45828136|NCT05655299|Drug|VTX958|Dose C
45828137|NCT05655299|Drug|VTX958|Dose D
45828138|NCT05655299|Drug|Placebo|Placebo
45828139|NCT05650229|Drug|KL1333|Twice daily
45828140|NCT05650229|Drug|Placebo|Twice daily
45828141|NCT05649865|Diagnostic Test|Blood sample|Blood samples for analysis of circulating tumour HPVDNA
45828142|NCT05645718|Drug|Cyclophosphamide|Given by (IV) vein
45828143|NCT05645718|Drug|Vincristine|Given by (IV) vein
45828144|NCT05645718|Drug|Blinatumomab|Given by (IV) vein
45828145|NCT05645718|Drug|Methotrexate|Given by (IV) vein
45828146|NCT05645718|Drug|Cytarabine|Given by (IV) vein
45828147|NCT05645718|Drug|Mercaptopurine|Given by (IV) vein
45828148|NCT05645718|Drug|Prednisone|Given by PO
45828149|NCT05645718|Drug|Pegfilgrastim|Given by (IV) vein
46081368|NCT04665037|Drug|Posaconazole PFS TBD|POS at a dose TBD, orally by PFS starting on Day 8 once daily for a maximum 84 days
45669608|NCT02206815|Drug|Ticagrelor+Warfarin|Ticagrelor 90mg/bid + Warfarin (maintain INR 2.0-2.5)
45669609|NCT02206815|Drug|Clopidogrel+Aspirin+Warfarin|Clopidogrel 75mg/day + Aspirin 100mg/day + Warfarin(maintain INR 2.0-2.5)
45669610|NCT02186691|Other|MRI|
45669611|NCT02175680|Drug|PRO 140|CCR5 Antagonist
45669612|NCT02175680|Other|Historical data|Historical data (i.e., time to HIV-1 RNA viral load > 500 copies/mL of 29 days).
45669613|NCT02151175|Device|LIFUP|
45669614|NCT02140021|Procedure|Biospecimen Collection|Undergo anal, cervical, vaginal, and oral sample collection
45669615|NCT02140021|Other|Laboratory Biomarker Analysis|Correlative studies
45669616|NCT02125981|Drug|Limaprost|taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day
45828150|NCT05645718|Drug|Inotuzumab ozogamicin|Given by (IV) vein
45828151|NCT05645718|Drug|Rituximab|Given by (IV) vein
45828152|NCT05645718|Drug|Dexamethasone|Given by (IV) vein
45828153|NCT05641142|Other|monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease|"Monitoring:~hemoglobin and ferritin levels~transfusion or intravenous iron~hospitalization for bleeding or thrombose~digestive bleeding and/or another haemorrhagic accident~severity of epistaxis~quality of life"
45828154|NCT05638620|Drug|stellate ganglion block with 0.5% bupivacaine|"The stellate ganglion block is being done on both sides of the neck. The stellate ganglion block will be performed on the right side at the first visit. The procedure will be repeated on the left side one week after the first injection.~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for use nor intended to be used to support any other significant change in the labeling for the drug. Similar to a phase 1 clinical trial, the main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms. As a general rule, phase 1 studies require a low number of patients, typically 12-20 subjects. There is considerable uncertainty regarding long COVID as a disease state, so data from even small numbers of patients in a well-designed clinical trial will make steps towards reducing that uncertainty."
45828155|NCT05635578|Behavioral|sleep|reiki
45828156|NCT05635110|Drug|VX-548|Tablets for oral administration.
45971128|NCT03456583|Device|Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
45828157|NCT05635110|Drug|Omeprazole|Tablets for oral administration.
45828158|NCT05635110|Drug|Rifampin|Capsules for oral administration.
45971129|NCT03455998|Other|questionnaires|
45971130|NCT02277457|Radiation|PET-Adaptive RT|All patients will be treated with response-driven PET-adaptive RT. The radiation dose will be delivered in greater than or equal to 2.2 Gy per daily fraction to FDG-PET/CT-guided target volumes with the treatment duration limited to 30 fractions and total radiation dose limited to 66-80.4 Gy.
45971131|NCT02277457|Drug|Erlotinib|150 mg once daily
45971132|NCT02277457|Drug|Crizotinib|250 mg twice daily
45971133|NCT00255879|Drug|Quetiapine|
45971134|NCT00255879|Drug|Risperidone|
45971135|NCT00255879|Drug|Olanzapine|
45971136|NCT00195052|Diagnostic Test|Intrinsic signal imaging of human cortex|Light is shined on the brain at 540 nm and 610 nm and images are acquired at 10 frames per second.
45971137|NCT00413465|Drug|Escherichia Coli Endotoxin|
46081369|NCT04657289|Drug|Ranibizumab|"Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals~Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals"
45828159|NCT05632809|Drug|NKTR-255|Given by IV (vein)
45828160|NCT05632809|Drug|Durvalumab|Given by IV (vein)
45828161|NCT05631990|Drug|AD-209|PO, Once daily(QD), 8weeks
45828162|NCT05631990|Drug|AD-209-1A|PO, Once daily(QD), 8weeks
45828163|NCT05631990|Drug|AD-209-1B|PO, Once daily(QD), 8weeks
45971138|NCT04572178|Behavioral|Cash payment and brief behavioral counseling|"The intervention consists of: (i) in person brief behavioral counseling, (ii) the evaluation of the smoking status using breath carbon monoxide, and (iii) cash payment of 25 Euro if the reading does not exceed a carbon monoxide value 3 ppm ( ppm = parts per million) on two consecutive measurements per week. The intervention starts at the earliest in pregnancy week 15 and lasts until the delivery. If they relapse, the reward is not paid. However, in the following week they have the opportunity to quit smoking and being rewarded again."
45971139|NCT00199888|Drug|124-Iodine-cG250 (124I-cG250)|
45971140|NCT00413504|Drug|Fondaparinux|
45971141|NCT04721223|Drug|JAB-3068|JAB-3068 administrated orally as a tablet.
45971142|NCT04721223|Drug|PD1 inhibitor|JS001 administrated as an intravenous(IV) infusion.
45971143|NCT04710498|Drug|Atezolizumab|Atezolizumab administered intravenous (IV) infusion at a fixed dose of 1200 mg
45971144|NCT00226538|Drug|Phenytoin|
45971145|NCT00226538|Drug|Rifampicin|
45971146|NCT00226538|Drug|Diclophenac|
45669617|NCT02125981|Drug|Placebo|taking placebo drug
45669618|NCT02114944|Device|NIV|Patients treated, as per attending physician's decision, with noninvasive ventilation
45971147|NCT00226538|Drug|Fluconazole|
45971148|NCT00255918|Drug|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose
45971149|NCT00255918|Drug|Placebo|Placebo dosed to match active medication
45971150|NCT00255918|Drug|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose
45971151|NCT04710264|Other|AURORA-Rec|Explorative study of cumulus cells gene expression in relation to the patient treatment and oocyte competence.
45971152|NCT00226616|Drug|Zinc|
45971153|NCT00199849|Biological|NY-ESO-1 Plasmid DNA Cancer Vaccine|NY-ESO-1 Plasmid DNA Cancer Vaccine administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.
45971154|NCT00255957|Drug|HES administration|
45971155|NCT00255957|Drug|Hydroxy Ethyl Starch administration to stroke patients|
45971156|NCT00226694|Drug|Citalopram|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
45669619|NCT02114944|Device|CPAP|Patient treated, as per attending physician's decision, with CPAP
45669620|NCT02114944|Device|Standard oxygen|Patient treated, as per attending physician's decision with standard oxygen therapy either as primary respiratory therapy or rest therapy during breaks off CPAP or NIV
45669621|NCT02114944|Device|HFNC|Patients treated, as per attending physician's decision, with high-flow nasal cannula either as primary therapy or rest therapy during breaks off NIV or CPAP
45669622|NCT01983462|Drug|Clonidine|
45669623|NCT01983462|Drug|Hydrochlorothiazide|
45669624|NCT01983462|Drug|Placebo|
45669625|NCT01936883|Radiation|HDR|High dose rate brachytherapy
45669626|NCT01936883|Radiation|LDR|Low dose rate brachytherapy boost
45669627|NCT01919086|Drug|Bortezomib|Bortezomib SC (or IV if SC not tolerated) 1.5 mg/m^2, days 1, 8, 15 and 22
45669628|NCT01919086|Drug|Dexamethasone|Dexamethasone 40 mg PO or IV days 1, 4, 8,15 and 22 or on a split-dose regimen. (20mg BIW).
45828164|NCT05631990|Drug|AD-209-1C|PO, Once daily(QD), 8weeks
45828165|NCT05631990|Drug|AD-209 placebo|PO, Once daily(QD), 8weeks
45828166|NCT05631990|Drug|AD-209-1 placebo|PO, Once daily(QD), 8weeks
45828167|NCT05631093|Drug|ART|Standard of care ART, per approved product list, taken orally
45971157|NCT00226694|Other|Placebo|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
45971158|NCT00255996|Drug|linezolid|
45971159|NCT00226733|Behavioral|Exercise training|Interval exercise training with high intensity five days per week for four weeks.
45828168|NCT05631093|Drug|DOR/ISL|Combination of 100 mg doravirine (DOR) with 0.25 mg Islatravir (ISL) in tablet form, taken orally, once daily.
45828169|NCT05626985|Diagnostic Test|GAMAD|Blood samples are tested for tumor markers including PIVKA-II (DCP),AFP, ctDNA methylation and biochemical tests.
45828170|NCT05617833|Combination Product|MLT+EPO|Melatonin component will be a single daily dose of 30 mg/kg enteral administered in the evening. EPO component is a two-stage regimen with high dose EPO (1000 U/kg/dose q 48 hrs ± 2hr IV) for 10 doses followed by maintenance dose EPO (400 U/kg/dose q Monday, Wednesday, Friday IV/SC) to 33-6/7wk. Maintenance EPO dosing will begin on the day closest to completing the high dose series.
45455853|NCT05579847|Behavioral|eHEALS digital literacy test|"The eHEALS digital literacy test is an 8-item measure of eHealth literacy developed to measure the participants combined knowledge, comfort and perceived skills at finding, evaluating and applying electronic health information to health problems. The test is measured with a 5-point Likert scale with response options ranging from strongly disagree to strongly agree. Total scores of the eHEALS are summed to range from 8 to 40, with higher scores representing higher self-perceived eHealth literacy."
45455854|NCT05579847|Behavioral|Weekly Quiz|Participants will take a weekly true/false quiz to assess knowledge of their diagnosis, expected outcome and treatment associated adverse effects at baseline and longitudinally. Each quiz will be administered at the beginning of the week before the weekly educational content is available, then the same quiz will be administered after the educational content is reviewed by the patient. Each quiz will be scored based on the number of correct answers.
45669629|NCT01919086|Drug|Lenalidomide|Lenalidomide may be added to the patient's regimen at any time if there is evidence of hematologic disease progression
45828171|NCT05617833|Other|Placebo|Placebo enteral and IV
45669630|NCT01868711|Behavioral|Cognitive Behavior Therapy|
45669631|NCT01849575|Behavioral|Intervention|"Information about carotid ultrasound results to the participant and his/her primary care physician in the form of atherosclerosis highlighted graphically in color against normal vascular age patterns and as plaque formation. General information about atherosclerosis as a dynamic modifiable process and recommendation to follow clinical guidelines for risk factor control. After 2-4 weeks a follow-up call by a research nurse, to give additional information and reassurance, if needed. Identical information to the study participant is sent by post after 6 months.~CVD risk factors are managed according to clinical guidelines within primary health care during the entire study period."
45828172|NCT05610527|Device|ENG Implant|This is an FDA approved contraceptive device
45828173|NCT05610527|Device|LNG IUD|This is an FDA approved contraceptive device
45828174|NCT05608525|Device|transcranial current stimulation|A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
45828175|NCT05608525|Behavioral|GRASP|A standardized occupational therapy- GRASP will be performed daily together with tDCS over the period between the Pre Assessment and the Post Assessment. GRASP exercise will be administered concurrently with or immediately after tDCS stimulation. GRASP is a self-directed arm and hand exercise program for which is supervised by a therapist, but done independently by the participant (and with their family if possible). GRASP has been shown to improve arm and hand function and strength in stroke patients in community [22-27]. The versions of the program- Home GRASP will be used. All occupational tasks will be selected from the GRASP task pool and be progressed according to the GRASP protocol (https://neurorehab.med.ubc.ca/grasp). Each GRASP session will take about 1 hour. A total of 20 GRASP sessions will be administered.
45828176|NCT05608369|Drug|Cisplatin|Cisplatin (100 mg/m2 every 3 weeks)
45828177|NCT05608369|Radiation|Radiation therapy|Radiation therapy (70 Gy) for total of 7 weeks
45828178|NCT05608369|Drug|Vorinostat|Pre-treatment; 300 mg every other day
45828179|NCT05608291|Drug|Fianlimab|Fianlimab will be administered by intravenous (IV) infusion every (Q) 3 weeks
45828180|NCT05608291|Drug|Cemiplimab|Cemiplimab will be administered by IV infusion Q 3 weeks
45828181|NCT05608291|Drug|Pembrolizumab|Pembrolizumab will be administered by IV infusion Q 3 weeks
45828182|NCT05608291|Drug|Placebo|Matching placebo co-infused with pembrolizumab IV, will be administered by IV infusion Q 3 weeks
45828183|NCT05604521|Biological|PfSPZ Vaccine|PfSPZ vaccine consists of radiation-attenuated, aseptic, purified Plasmodium falciparum (NF54) sporozoites (SPZ) cryopreserved in liquid nitrogen vapor phase (LNVP) at -150C to - 196C. PfSPZ Vaccine is composed of PfSPZ derived from the NF54 strain of Pf, which is thought to be from West Africa. PfSPZ Vaccine is diluted in phosphate buffered saline (PBS) with human serum albumin (HSA) to achieve the correct dosage and is administered by DVI.
45828184|NCT05604521|Biological|PfSPZ Challenge (7G8)|PfSPZ Challenge (7G8) is similar to PfSPZ Vaccine but has not been attenuated by radiation and is therefore infectious.PfSPZ Challenge (7G8) is composed of PfSPZ derived from the 7G8 clone of Pf, which is from Brazil.
45669632|NCT01779375|Drug|Metformin|
45669633|NCT01779375|Drug|Glargine|
45828185|NCT05604521|Other|Normal Saline|0.9% sodium chloride
45828186|NCT05604053|Behavioral|Motivation Manipulation|On some trials, participants have lower motivation and on other trials participants have higher motivation.
45828187|NCT05595915|Dietary Supplement|COMP-4|COMP-4 is a novel compound that consists of ginger extract, L-citrulline, and the herbal components Paullinia cupana and muira puama.
45828188|NCT05594979|Dietary Supplement|TOTUM-070|2.5-g dose of TOTUM-070 diet supplement; Four capsules per day to consume orally in two intakes
45828189|NCT05594732|Behavioral|Weak outdoor light|Stay and stare far on the balcony or under the tree
45828190|NCT05594732|Behavioral|Strong outdoor light|Stay and stare far in the sunlight
45828191|NCT05590468|Dietary Supplement|Nicotinamide Riboside|Vitamin B3 derivative; a total of 1000 mg/day in a regimen of 500mg every 12 hours by mouth (either fasting or fed)
45669634|NCT01594723|Drug|120 mg LY2784544|Administered orally
45669635|NCT01559935|Drug|carfilzomib|45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles.
45669636|NCT01559935|Drug|Dexamethasone|20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
45828192|NCT05590468|Drug|Placebo|Looks exactly like the study drug, but it contains no active ingredient
45971160|NCT00226733|Behavioral|Exercise training|Exercise training with moderate intensity, five days per week for four weeks.
45971161|NCT00415155|Drug|LY2181308|"Phase 1: 250mg, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle. (dose escalation)~Phase 2: phase 1 recommended dose, maximum 750mg dose, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle."
45971162|NCT00226850|Behavioral|hypnosis|
45971163|NCT00226889|Drug|bosentan|
45971164|NCT00415272|Behavioral|Pulmonary Rehabilitation|
45971165|NCT00226928|Behavioral|Supportive-Expressive Group Therapy plus education|
45971166|NCT00226928|Behavioral|Education|
45971167|NCT04710225|Procedure|Upper limb fracture surgery and arterial occlusion pressure (AOP) estimation based tourniquet pressure (TP) setting|"Upper limb fracture surgery will be performed with the aid of a pneumatic tourniquet.~The cuff (11 cm) of the tourniquet will be placed around the arm with the distal edge 5 cm above the olecranon. AOP estimation formula according to initial systolic blood pressure (SBP) and Tissue Padding Coefficient (KTP) values (AOP= [SBP+10]/KTP) from a list (Table 1) will be used to calculate AOP (17). After calculation of AOP, a safety margin of 20 mmHg will be added to AOP to determine the TP (TP=AOP+20 mm Hg). Exsanguination of the limb will be provided with an Esmarch bandage and the cuff will be inflated to the predetermined TP. TP will be manually raised in response to each 10 mmHg increase in SBP during the surgical procedure."
45971168|NCT00226967|Drug|Sandostatin|Calculated per patient
45971169|NCT04709913|Drug|HU6|HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
45971170|NCT00199381|Drug|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily.
45971171|NCT00227006|Behavioral|Behavioral lifestyle/weight-loss intervention|
45669637|NCT01559935|Drug|Clarithromycin|500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
45971172|NCT04710069|Behavioral|POINT|Patients randomized to the POINT program will be given preoperative counseling on adverse effects of opioids and expectations will be set that most patients do not require opioids for pain control after endocrine surgery, they will receive the info in writing afterwards as well. These patients will also be shown a short instructional video reiterating the counseling provided in the preoperative clinic visit. Information in the video will pertain to the expected pain after surgery, the over-the-counter options for pain control, the risks and side effects of using opioids, and reassurances that opioids may be prescribed at any time after discharge if pain is unmanageable. After the video, the patient will be provided with paperwork, requiring patient consent/signature to receive opioids if they opt into narcotic treatment. They will not be provided with a narcotic prescription if consent is not explicitly provided.
45971173|NCT04709991|Procedure|Endovascular procedure|Creation of a bone and arterial panorama using EndoNaut® software. The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.
45971174|NCT00227084|Drug|Arista AH hemostasis powder|
45971175|NCT04709952|Device|Transcranial direct current stimulation_High real|Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in high real stimulation group (2mA).
45971176|NCT04709952|Device|Transcranial direct current stimulation_Low real|Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in Low real stimulation group (1mA).
45971177|NCT04709952|Device|Transcranial direct current stimulation_Sham|Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in sham stimulation group (0mA).
45669638|NCT01559935|Drug|Lenalidomide|25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
45669639|NCT01559935|Drug|Dexamethasone|40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
45669640|NCT01559935|Drug|Lenalidomide|10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.
45828193|NCT05574244|Procedure|Partial surgery preserving the prostatic apex|Partial Endoscopic resection of prostate to conserve apex
45828194|NCT05574244|Procedure|Conventional endoscopic prostatic surgery|Endoscopic resection of prostate.
45828195|NCT05572658|Biological|mRNA-1345|Sterile liquid for injection
45828196|NCT05572658|Biological|Placebo|0.9% sodium chloride (normal saline) injection
45828197|NCT05565560|Drug|Apremilast|Oral tablets
45835925|NCT05606250|Other|Ultrasound-Guided Percutaneous Neuromodulation|Ultrasound guided percutaneous neuromodulation in femoral nerve. Patients were placed in supine lying with the anterior aspect of the hip uncovered. The intervention consisted of the application of a biphasic square wave electric current, with a frequency of 2 Hz, a phase duration of 250μs, and a maximum tolerable intensity to cause an exacerbated muscle contraction for 15minutes in total
45669641|NCT01358877|Drug|5-Fluorouracil|5-Fluorouracil will be administered as per the schedule specified in the respective arm.
45669642|NCT01358877|Drug|Carboplatin|Carboplatin will be administered as per the schedule specified in the respective arm.
45828198|NCT05564546|Procedure|FeNO (fractional exhaled nitric oxide)|"FeNO measurement is a marker of airway inflammation. It is a non-invasive examination for the patient, easy to perform for healthcare personnel, the measurement of NO in exhaled air is one of the only non-invasive and reproducible examinations allowing the detection of inflammation airways.~The FeNO will be measured by an electrochemical NO analyzer of the NiOx Vero type (Circassia, The Surgical Company) and expressed in particles per billion (ppb). The objective and reproducible measurement of NO production by the bronchial mucosa is a reflection of the degree of airway inflammation. The measurement of exhaled NO is part of diagnostic health technologies aimed at quantifying airway inflammation, especially in asthmatic patients.~FeNO is considered normal for values of 16-25 ppb. A FeNO value > 25 ppb will be a reason for consultation at the Martinique Hospital for additional assessment."
45971178|NCT00227123|Drug|quetiapine, risperidone|Flexible dose titrations to 'treat-to-symptoms'
45971179|NCT00256035|Procedure|Measuring IL-4 levels|
45971180|NCT00227162|Behavioral|Group 1|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive positive affect intervention.
45971181|NCT00227162|Behavioral|Group 2|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive the self-affirmation intervention.
45971182|NCT00227162|Behavioral|Group 3|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive both positive affect and self-affirmation intervention.
45971183|NCT00235521|Drug|aerosolized iloprost|
45971184|NCT00227201|Behavioral|Self-affirmation intervention|
45971185|NCT00235560|Drug|rapamycin|sirolimus
45971186|NCT00256074|Procedure|Enteral feeding formula|
45971187|NCT00227279|Biological|ALK Grass tablet|Tablets, 75,000 SQ-T or matching placebo. Daily administration for 3 years
45971188|NCT00235599|Procedure|IGFBP-3 Stimulation Test|
45971189|NCT00227318|Drug|ATACAND|
45971190|NCT00227357|Drug|On-site - buprenorphine/naloxone (Suboxone)|Tablet, sub-lingual, 8/2 mg, 1-3 daily
45971191|NCT00227357|Drug|Off-site - methadone or no agonist|
45971192|NCT00198133|Drug|Premetrexed (Alimta)|Pemetrexed will be 500 mg/m2 IV every 3 weeks
45971193|NCT00256113|Drug|Saredutant succinate (SR48968C)|
45971194|NCT00227435|Drug|val-mCyd|
45971195|NCT00235677|Procedure|Endoscopic gastroplication|
45971196|NCT00227474|Drug|recombinant modified vaccinia Ankara-5T4 vaccine|
45669643|NCT01358877|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per the schedule specified in the respective arm.
45971197|NCT00227474|Procedure|adjuvant therapy|
45971198|NCT00227474|Procedure|recombinant viral vaccine therapy|
45971199|NCT00197236|Biological|Havrix™|2 intramuscular injections, 6 months apart
45971200|NCT00197236|Biological|Infanrix™|1 intramuscular injection
45971201|NCT00197236|Biological|ActHIB™|1 intramuscular injection
45971202|NCT00256152|Device|AF Suppression Pacing Algorithm|
45971203|NCT00227513|Drug|bortezomib|Given IV
45971204|NCT00227513|Drug|vorinostat|Given orally
45971205|NCT04709445|Diagnostic Test|ICG-NIRF Imaging plus ingress and egress analysis|intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) before and after anastomosis formation, postoperative analysis of ingress and egress for specific regions of interest
45971206|NCT00256191|Drug|TPI 287 Injection|
45971207|NCT00227630|Drug|cisplatin|
45971208|NCT00227630|Drug|pemetrexed disodium|
45971209|NCT00227630|Procedure|adjuvant therapy|
45971210|NCT00227630|Procedure|conventional surgery|
45669644|NCT01358877|Drug|Docetaxel|Docetaxel will be administered as per the schedule specified in the respective arm.
45669645|NCT01358877|Drug|Doxorubicin|Doxorubicin will be administered as per the schedule specified in the respective arm.
45669646|NCT01358877|Drug|Epirubicin|Epirubicin will be administered as per the schedule specified in the respective arm.
45669647|NCT01358877|Drug|Paclitaxel|Paclitaxel will be administered as per the schedule specified in the respective arm.
45669648|NCT01358877|Drug|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm.
45669649|NCT01358877|Drug|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
45971211|NCT00227630|Procedure|neoadjuvant therapy|
45971212|NCT00227630|Radiation|radiation therapy|
45971213|NCT00256230|Drug|Disulfiram (DSF)|DSF pills at 250 mg will be given orally, two times a day. If this dose is tolerated, the dose will be escalated until the maximum tolerated dose is reached. Treatment will continue every day for 3 months or longer unless the disease gets worse, the side effects are too dangerous for the subject, or the subject decides to discontinue treatment.
45971214|NCT00227669|Drug|docetaxel|
45971215|NCT00227669|Drug|gemcitabine hydrochloride|
45971216|NCT00235794|Drug|temsirolimus|
45971217|NCT00256269|Drug|Oxaliplatin|40 mg/m2 IV over 60 minutes Every 21 days
45971218|NCT00256269|Drug|Irinotecan|60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days
45971219|NCT00197002|Biological|GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix)|Two doses, administered intramuscularly in the right anterolateral thigh.
45971220|NCT00197002|Biological|Prevnar™|One dose, administered intramuscularly in the left anterolateral thigh.
45971221|NCT00227708|Drug|docetaxel|
45971222|NCT00227708|Procedure|quality-of-life assessment|
45971223|NCT00235911|Drug|budesonide/formoterol Turbuhaler|
45971224|NCT00196105|Device|6 mm Nitinol Zilver Stent|
45971225|NCT00196105|Device|10 mm Nitinol Zilver Stent|
45971226|NCT00196105|Device|10 mm Stainless Steel Wallstent|
46081370|NCT04657289|Device|Port Delivery System with Ranibizumab|"Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals~Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals"
45669650|NCT01358877|Drug|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm.
45669651|NCT01284699|Procedure|Gamma Knife radiosurgery|For patients presenting a contraindications for anaesthesia or electrode implantation, operate their brain without opening the skull without infection or bleeding risk.
45669652|NCT00981058|Biological|Necitumumab|"800 milligrams (mg) Intravenously IV infusion on Days 1 and 8 of every 3 week cycle.~Continues until progressive disease, toxicity, noncompliance, or withdrawal."
45828199|NCT05564546|Procedure|Spirometry|"Spirometry tests will assess lung function. It is a safe and painless test to measure lung volumes and expiratory flows.~Ventilatory function is assessed by simple spirometry parameters such as forced expiratory volume in the first second (FEV1, in litres), vital capacity (CV, in litres), and the FEV1/CV ratio.~The results of the spirometry will be compared with the theoretical or predicted values calculated according to age, sex, height.The FEV1/CV ratio as a percentage is an indicator of the level of bronchial obstruction.~Spirometry is considered normal for CV values ≥80% and FEV1/FVC ≥0.70 of the predicted value. A value of CV <80% or FEV <80% of the predicted value will be a reason for consultation at the Martinique hospital for additional assessment."
45669653|NCT00981058|Drug|Gemcitabine|"1250 mg/m2 on Days 1 and 8 of every 3 week cycle.~Continues for a maximum of six cycles."
45828200|NCT05564546|Other|Physical examination|"A pulmonary clinical examination will be carried out by the investigator, including:~Cough,~Sputum,~Vesicular murmur (MV),~Added noises (BSA),~Vocal vibrations (VV),~Tympanism,~Dullness,~Signs of acute respiratory distress (ARD),~…"
45971227|NCT04722068|Other|Kinetics test|Subjects will participate in two study visits to evaluate lipoprotein kinetics before and after administration of evinacumab.
45971228|NCT00256347|Drug|intramuscular injections of morphine|
45669654|NCT00981058|Drug|Cisplatin|"75 mg/m2 IV on Day 1 of every 3 week cycle.~Continues for a maximum of six cycles."
45669655|NCT00979043|Behavioral|Dietary Weight-loss|The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.
45971229|NCT00227747|Drug|capecitabine|
45971230|NCT00227747|Drug|oxaliplatin|
45971231|NCT00227747|Procedure|conventional surgery|
45971232|NCT00227747|Procedure|neoadjuvant therapy|
45669656|NCT00979043|Behavioral|Exercise|Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
45669657|NCT00667069|Drug|triptorelin|
45669658|NCT00667069|Procedure|adjuvant therapy|
45669659|NCT00667069|Radiation|3-dimensional conformal radiation therapy|
45669660|NCT00565851|Biological|Bevacizumab|Given IV
45669661|NCT00565851|Drug|Carboplatin|Given IV
45669662|NCT00565851|Drug|Docetaxel|Given IV
45669663|NCT00565851|Drug|Gemcitabine Hydrochloride|Given IV
45669664|NCT00565851|Other|Laboratory Biomarker Analysis|Correlative studies
45669665|NCT00565851|Drug|Paclitaxel|Given IV
45669666|NCT00565851|Other|Quality-of-Life Assessment|Ancillary studies
45669667|NCT00305227|Drug|Lactin-V|
45669668|NCT00305227|Drug|Placebo|
45669669|NCT00238563|Drug|Triamcinolone injection, sub-tenon|
45971233|NCT00227747|Radiation|radiation therapy|
45971234|NCT00235950|Drug|Rosuvastatin or atorvastatin or simvastatin and clopidogrel|
45971235|NCT00227786|Behavioral|smoking cessation intervention|
45971236|NCT00227786|Other|counseling intervention|
45971237|NCT02962089|Dietary Supplement|Branched chain amino acids (BCAA)|
45971238|NCT02962089|Dietary Supplement|Placebo|
45971239|NCT00256386|Device|Electronic Medical Record (EMR) to clinician's in-basket|
45971240|NCT00256386|Device|Automated Voice Message (AVM) reminder to patient's phone|
45971241|NCT00256386|Procedure|Pharmacy Team phone call-letter followup|
45971242|NCT00227825|Behavioral|Motivational interviewing|
45971243|NCT00227864|Behavioral|Behavior Therapy|
45971244|NCT00227864|Other|Treatment as Usual|
45971245|NCT00256425|Behavioral|Cognitive rehabilitation|
45971246|NCT04721990|Device|Automatic Sound Management 3.0|The investigational front-end features include those within Automatic Sound Management 3.0 (i.e., Ambient Noise and Transient-Noise Reduction, and Adaptive Intelligence). Automatic Sound Management 3.0 will be accessed in the MAESTRO system software. The investigational front-end features within Automatic Sound Management 3.0 will be programmed in the SONNET2EAS processor.
45971247|NCT00256464|Behavioral|Multi-component Yoga Intervention|
45971248|NCT00227942|Drug|Estrogen Replacement Therapy|17-b-Estradiol Patch, .05 mg/day; applied for 7 days
45971249|NCT00227942|Drug|Zolpidem|10 mg/day, po qhs
45971250|NCT00227942|Drug|placebo|placebo
46081371|NCT04655248|Device|Transcatheter Aortic Valve Implantation/Replacement|The device is placed in patients heart at the level of aortic valve through a transfemoral access from femoral groin as indicated in device IFU
45669670|NCT00001070|Drug|Oral Vitamin C|
45669671|NCT04601467|Drug|AZD5718|Oral dose of AZD5718 (tablet) once daily for 12 months
45828201|NCT05564546|Other|Interrogation|"Participants will undergo an interview with the medical team to collect the following information in particular:~Age, size, sex, medical history, smoking status, current treatments, potential symptoms, date of first symptoms, clinical manifestations experienced (respiratory, digestive, neurological, cardiac, psychiatric, visual, skin disorders, etc.) place of residence, concentration H2S in ppm on the site, presence of sand mist in the environment, etc."
45828202|NCT05564325|Device|Deflectable guidewire|A deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.
45971251|NCT00256503|Behavioral|Cognitive-Behavioral Therapy for Insomnia|Insomnia Subjects receive CBT-I
45971252|NCT00227981|Behavioral|Interpersonal Psychotherapy|
45971253|NCT00227981|Drug|Fluoxetine|
45971254|NCT00236028|Drug|Infliximab|
45971255|NCT00256542|Drug|Alkalinized Lidocaine-Heparin|
45971256|NCT00228020|Drug|basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent)|
45971257|NCT00228020|Drug|MMF, cyclosporine, steroids|
46081372|NCT04652804|Behavioral|Low intensity HCV treatment adherence support|A 28-day supply of medication will be dispensed to participants at entry, 4 weeks, and 8 weeks. Participants will receive standard adherence counseling at entry and every refill pickup/home or field delivery. Participants will have access to all of the services available at the ICC including facilitated linkage to referrals as needed. Site staff will routinely track clients who miss refill appointments in real-time using standard tracking measurements
45669672|NCT04601467|Drug|Placebo|Oral dose of matching placebo (tablet) once daily for 12 months
45669673|NCT01599793|Drug|cabozantinib|Given PO
45669674|NCT01599793|Other|laboratory biomarker analysis|Correlative studies
45669675|NCT01599793|Procedure|magnetic resonance imaging|Undergo MRI
45669676|NCT05209633|Drug|Granules Dendrobii|6g each, 3 times per day, total 18 weeks
45669677|NCT05209633|Drug|Placebo|placebo
45669678|NCT04499677|Drug|Favipiravir|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
45669679|NCT04499677|Drug|Lopinavir/ Ritonavir|Dosage and method of administration: Day 1: 400mg/100 mg twice daily; Day 2 to Day 7: 200mg/50mg four (4) times daily
45669680|NCT04499677|Other|Favipiravir Placebo|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
45669681|NCT04499677|Other|Lopinavir/ Ritonavir Placebo|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
45971258|NCT00236067|Drug|Gabitril|
45971259|NCT00228059|Drug|Licarbazepine|
45971260|NCT00195715|Biological|Adalimumab|Adalimumab 40 mg by subcutaneous injection every other week or every week
45971261|NCT00236106|Drug|tacrolimus ointment 0.1%|
45971262|NCT00236106|Drug|mometasone furoate 0.1%|
45971263|NCT00228098|Behavioral|Smoking cessation|
45971264|NCT00236145|Drug|ACTIQ (Oral transmucosal fentanyl citrate)|
45971265|NCT00413543|Other|early pulmonary lung rehabilitation|early pulmonary rehabilitation, 10 days after discharge
45971266|NCT00256581|Procedure|Additional rest and stress image sets on new camera|
45971267|NCT00228215|Behavioral|TIPS Intervention|A behavioral-educational sleep intervention and support from a nurse in the immediate postpartum
45971268|NCT00228254|Drug|Zinc (12.5 mg/day)|
45971269|NCT00228254|Drug|vitamin A 10,000 IU per week|
45971270|NCT00228293|Device|investigational monitor/defibrillator with CPR feedback|
45971271|NCT00195676|Drug|adalimumab|40 mg every other week or 40 mg every week by subcutaneous injection
45971272|NCT00228332|Drug|Administration of zinkgluconaat or placebo|
45971273|NCT00194077|Drug|Aripiprazole|dosing will occur at 2mg, 5mg, 7mg, 10 mg, 12mg, or 15 mg based on weight, side effects and efficacy
45971274|NCT00194077|Drug|Placebo|subjects in phase 2 will be randomized to active abilify or placebo
45971275|NCT00228371|Device|Neurostimulation|High frequency neurostimulation of subthalamic nucleus : quadrupolar electrode, type 3389, n° : I7 02 08 39709 158, Medtronic, Minneapolis, USA
45971276|NCT00193609|Drug|Oxaliplatin|130 mg/m2 IV day 1 of 21 day cycle
45669682|NCT05652751|Drug|nerve growth factor|The patient first received an intramuscular injection of NGF or saline into the gluteus maximus.The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.
45828203|NCT05564325|Device|Standard of care guidewire (different models may be used)|The control device is any standard of care guidewire as per hospital routine indicated for neuro-interventional procedures.
45828204|NCT05563194|Device|Heating prototype (Prototype 1)|A wearable that heats and vibrates to help distract from pain. It can be wrapped around any joint with temperature and vibration settings allowing CYP to set the device to their needs.
45828205|NCT05563194|Device|Physio tool (Prototype 2)|A motivational physiotherapy tool that incrementally lights up as the CYP do their prescribed stretches, emphasising a sense of progression and making it a more engaging activity.
45828206|NCT05563194|Device|Communication tool (Prototype 3)|A wearable to help communication in the classroom between the teacher and pupil. The child can alert the teacher if they need help, through vibration, without attracting the attention of their classmates, reducing embarrassment.
45828207|NCT05555615|Drug|Pimavanserin|Pimavanserin given once daily, as capsule of 10, 20, or 34 mg dose strength, respectively, according to the patient's age
45828208|NCT05553366|Drug|VX-548|Tablets for oral administration.
45971277|NCT00193609|Drug|Capecitabine|1000 mg/m2 by mouth twice daily on days 1-14 of each 21 day cycle
45971278|NCT00228410|Drug|Tigecycline|
45971279|NCT00228410|Drug|vancomycin with aztreonam|
45971280|NCT00228449|Drug|peginesatide|
45971281|NCT00193180|Drug|Imatinib|Imatinib
45971282|NCT00193180|Drug|Docetaxel|Docetaxel
45971283|NCT00193063|Drug|Trastuzumab|Trastuzumab
45971284|NCT00193063|Drug|Gemcitabine|Gemcitabine
45971285|NCT00228488|Drug|Gefitinib|
45971286|NCT00228527|Drug|Esomeprazole (Nexium)|
45971287|NCT00191854|Drug|gemcitabine|2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles
45971288|NCT00191854|Drug|paclitaxel|150 mg/m2, IV, every 14 days x 8 cycles
45971289|NCT00191854|Drug|carboplatin|Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles
45971290|NCT00191854|Drug|cisplatin|50 mg/m2, IV, every 14 days x 8 cycles
45971291|NCT00228605|Drug|OraVescent Fentanyl|
45669683|NCT05652751|Drug|physiological saline|Other patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
45971292|NCT00191815|Drug|Gemcitabine|Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).
45828209|NCT05553366|Drug|HB/APAP|Capsules for oral administration.
45828210|NCT05553366|Drug|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
45828211|NCT05553366|Drug|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
45828212|NCT05548062|Other|Hydroxyurea|Prospective observational study. There is no treatment allocation. Patients prescribed with Hydroxyurea are eligible to enroll into this study.
45971293|NCT00191815|Drug|cisplatin|Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).
45971294|NCT00191386|Drug|Atomoxetine hydrochloride|0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
45971295|NCT00228683|Procedure|Biology Study and Tissue Banking|Collection of specimens from Hepatoblastoma patients.
45971296|NCT00191308|Drug|pemetrexed|500 mg/m^2 IV q 21 days for 3 cycles unless disease progression occurs
45971297|NCT00191308|Drug|cisplatin|75 mg/m^2 IV q 21 days for 3 cycles unless disease progression occurs
45971298|NCT00191308|Procedure|Radical Non-Small Cell Lung Cancer (NSCLC) surgery|All participants proceeded to surgery within 4-8 weeks from the last dose of pemetrexed.
45971299|NCT00256620|Procedure|Mean arterial pressure during cardiopulmonary bypass 80 mmHg vs. customized|
45971300|NCT00228839|Drug|Infliximab|
45971301|NCT00191269|Drug|gemcitabine|1000 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
45971302|NCT00191269|Drug|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
45971303|NCT00256659|Behavioral|Early assessment and referral to ancillary care services vs. standard care|
45971304|NCT00228878|Procedure|Effects of Pulsatile IV insulin on Diabetic Quality of Life|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment and their insulin resistance.
45971305|NCT00413868|Procedure|LASIK|
45971306|NCT00413868|Procedure|PRK|
45971307|NCT00413868|Behavioral|Small target contrast sensitivity and disability glare|
45971308|NCT00228956|Drug|pharmacodynamic analysis|Exemestane 25mg po daily or Letrozole 2.5mg po daily
45971309|NCT00228995|Drug|epoetin alfa|
45971310|NCT04709640|Other|Tailored Medication Management Intervention|This research study involved an initial 1.5 hour visit and 2-3 follow up home visits (each lasting 60 minutes). Participants received 2-3 home visits during which they received recommendations on strategies which will improve medication management. Level II occupational therapy fieldwork students made the recommendations, after approval from their supervising licensed OT. The OT fieldwork students provided assistance to the individual in implementing strategies, obtaining adaptive equipment at little or no cost to the individual.
45669684|NCT05652751|Device|EA|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day."
45669685|NCT05652751|Device|sham EA|The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.
45669686|NCT02915263|Drug|IGIV-C|Gamunex-C [immune globulin injection (human) 10% caprylate/chromatography purified] is a sterile solution of human immune globulin protein.
45669687|NCT02915263|Drug|0.9% Sodium Chloride|Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
45828213|NCT05548062|Other|Ruxolitinib|Prospective observational study. There is no treatment allocation. Patients prescribed with Ruxolitinib are eligible to enroll into this study.
45828214|NCT05546580|Drug|Iadademstat|iadademstat oral solution
45828215|NCT05546580|Drug|Gilteritinib Oral Tablet|120 mg Gilteritinib
45828216|NCT05545072|Drug|Dupilumab 300 MG/2 ML Subcutaneous Solution|150 mg/mL in pre-filled syringe to deliver 300 mg in 2 mL given Subcutaneously every 2 weeks during the treatment period
45828217|NCT05545072|Drug|Placebo|Pre-filled syringe to deliver 2 mL given Subcutaneously every 2 weeks during the treatment period
45828218|NCT05543187|Drug|TAK-625|TAK-625 orally, twice daily (BID)
45828219|NCT05543174|Drug|TAK-625|TAK-625 200 mcg or 400 mcg per kilogram, orally, once daily
45828220|NCT05541341|Other|tisagenlecleucel|Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting are eligible to enroll into this study.
45971311|NCT00413946|Drug|Recombinant human Erythropoietin|3 doses 3000 units (1 ml) of recombinant human erythropoietin per kg body weight
45971312|NCT00413946|Drug|saline|three doses of 1.0 ml saline per body weight
45971313|NCT00229073|Drug|dapoxetine|
45971314|NCT00413985|Drug|Nutrient-enriched human milk|
45971315|NCT00229112|Drug|MK0826, ertapenem sodium / Duration of Treatment - 24 weeks|
45971316|NCT00229112|Drug|Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks|
45971317|NCT00256737|Drug|Omeprazole|
45971318|NCT00191191|Drug|Pemetrexed 500 mg/m2|500 mg/m2, intravenous (IV), every 21 days, one year from registration date
45971319|NCT00191191|Drug|Pemetrexed 1000 mg/m2|1000 mg/m2, intravenous (IV), every 21 days, one year from registration date
45971320|NCT00229151|Behavioral|Sleep deprivation and sleep phase advancement|Total sleep deprivation from 0800 to 1700 next day, and three day sleep phase advancement following sleep deprivation.
45971321|NCT00229151|Other|usual treatment|Treatment as usual in the psychiatric ward. Patients in this group will be offered treatment with sleep deprivation and sleep phase advancement after five weeks if they still meet inclusion criteria
45669688|NCT02909335|Drug|Tacrolimus|"Tacrolimus is administered at an initial dose of 0.040 mg / kg twice a day on Day 5.~The doses are then adjusted to maintain trough levels :~between 6 and 10 ng / ml during the first 2 months,~between 5 and 8 ng / ml from the start of the end M3 and M6,~and between 4 and 6 ng / ml between the beginning and the end of M7 M12."
45669689|NCT02909335|Drug|Everolimus|"Everolimus is administered at an initial dose of 1.5 mg twice a day on Day 5.~The doses are then adjusted to maintain trough levels:~between 6 and 10 ng / ml during the first 2 months,~between 5-8 ng / ml from the start of the end M3 and M6,~and between 4 and 6 ng / ml between the beginning and the end of M7 M12."
45828221|NCT05528874|Dietary Supplement|Same intervention for both groups: glycaemic index assessment of 3 biscuits recipes|Following International standards ISO 26642 guidelines, subjects (at fasting) will have their glycemia measured and after will consume a solution containing 50g of glucose and 100g of water. In the following 2 hours, glycemia and other blood parameters will be taken 6 times (at 15, 30, 45, 60, 90, and 120 minutes). This protocol is repeated twice within 3 months. After these 2 days, with the same methods, they will come to our clinic to test 3 different recipes of biscuits (characteristics are presented on request). Subjects and investigators are not blinded to these biscuits characteristics.
45828222|NCT05528874|Dietary Supplement|Crossover: Recipe 4 before recipe 5|"After the assessment of fasting parameters, subjects will consume recipe 4 (chocolate biscuits) and perform a 180 min curve with blood taken at 15, 30, 45, 60, 90, 120, and 180 minutes. In this case, both investigators and patients are blinded to the presence of an additional non-nutritive, non-toxic and without taste encapsulated bitter compound (artemisia absinthium), that could be present in recipe 4 or recipe 5. On the second day (with at least a week gap), patients will consume recipe 5. Questionnaires and a food diary will also be requested for subjects for lunch and dinner."
45828223|NCT05528874|Dietary Supplement|Crossover: Recipe 5 before recipe 4|Same as previous group, but starting with recipe 5
45828224|NCT05527808|Drug|Tislelizumab|200 mg ,intravenous injection ,Q3W 2-4 cycles
45828225|NCT05527808|Drug|pemetrexed|500 mg/m2,intravenous injection ,Q3W 2-4 cycles
45828226|NCT05527808|Drug|cis-platemum|60-75mg/m2 ,intravenous injection ,Q3W 2-4 cycles
45828227|NCT05527808|Drug|or carboplatin|AUC(4-5) ,intravenous injection ,Q3W 2-4 cycles
45828228|NCT05523895|Drug|Pimavanserin|Pimavanserin
45828229|NCT05523895|Drug|Placebo|Pimavanserin matching placebo
45828230|NCT05523700|Other|Mobile Application|Intervention is a mobile application than combines patient data via EMR with PROMIS outcome measures.
45828231|NCT05519397|Diagnostic Test|Immune checkpoint measurement|Measurement of sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9
45828232|NCT05516108|Behavioral|Mindfulness|The mindfulness intervention includes 14 daily 20-minute audio lessons plus brief daily practice prompts. Lessons train specific meditation techniques through didactic explanation and guided practice. Based on the Unified Mindfulness system, lessons train 3 mindfulness skills: concentration, sensory clarity, and equanimity. Concentration, a state of stable attention on the intended target, enables participants to monitor present-moment physical and emotional body experiences. Sensory clarity, the monitoring of momentary experiences, involves detecting subtle sensations and discriminating between different experiences. Equanimity, an attitude of acceptance toward momentary experiences, is trained through 3 strategies: (a) body relaxation, (b) mental welcoming, and (c) a gentle tone of voice. Practice prompts build on the skills trained in each lesson, encouraging participants to practice brief moments of mindful awareness, mindfulness while doing daily tasks, or formal meditation.
45828233|NCT05516108|Behavioral|Coping|The coping intervention includes 14 daily 20-minute audio lessons plus brief daily practice prompts. Lessons train specific coping techniques through didactic explanation and guided practice. Lessons train coping skills (reflection, reappraisal, and problem solving) without encouraging focus on or acceptance of present experience (i.e., mindfulness skills). Participants are instructed to: (1) reflect and let their minds drift, (2) reframe or reappraise past and anticipated events, and (3) analyze and solve personal problems. Practice prompts build on the skills trained in each lesson, encouraging participants to take brief reflection breaks or to practice reappraisal or problem-solving skills.
45828234|NCT05515432|Drug|Single oral dose of BAY3283142 IR (immediate release) tablet|Single oral dose of BAY3283142 in participants with renal impairment compared to an age, gender and weight matched control group in an open-label study design
45828235|NCT05515341|Device|Commercially Approved Interventional Medical Device/Therapy for Chronic Pain|Commercially Approved Interventional Medical Device/Therapy
45828236|NCT05506449|Device|Impella CP®|"Subjects randomized to the Treatment Arm will undergo Impella CP placement prior to PCI. Right heart catheterization will be performed prior to or immediately after PCI.~Use of IABP will not be allowed in the Treatment Arm."
45828237|NCT05506449|Other|Standard of Care|This may include inotropes and/or vasopressors. An IABP may or may not be used according to local practice and the specific condition of each individual patient. If an IABP is used, it may be placed prior to or after PCI, and its timing of explant is left to the discretion of the Investigator.
45828238|NCT05499663|Behavioral|POSTHOC app|The POSTHOC app is a smartphone application that will deliver the Survivorship Care Plan and promote healthy lifestyle behaviors consistent with the individual's Care Plan
45828239|NCT05496868|Drug|Reparixin 600mg|Reparixin will be administered through a nasogastric tube at the dose of 1200 mg (2 x 600 mg tablets) TID every 8 hours (6 tablets daily) for 14 days. All patients will receive therapy in line with current standard-of-care as it pertains to ARDS management (protocolized ventilator management will be made available to all sites in accordance with currently accepted standard of care).
45971322|NCT00414024|Drug|Tegaserod|
45971323|NCT00229190|Procedure|Nasal lavage|
45669690|NCT02909335|Drug|Mycophenolate mofetil|mycophenolate mofetil is administered similarly in the two groups at the dose of 1.5 g for the first two months and then 1 g twice a day. The doses may be adjusted according to the tolerance of the product.
45669691|NCT02909335|Drug|Prednisolone, Prednisone or Methylprednisolone|Corticosteroid is similarly administered in both groups between baseline and the end of M6 and adjusted in case of acute rejection
45669692|NCT02893267|Device|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
45971324|NCT00229190|Procedure|Allergy skin testing|
45971325|NCT00229190|Procedure|Peak nasal inspiratory flow|
45971326|NCT00229190|Procedure|Acoustic rhinometry|
45971327|NCT00229190|Procedure|Nasal examination|
45971328|NCT00229190|Procedure|Quality of Life Questionnaire|
45828240|NCT05496868|Other|Matching Placebo|Placebo will be administered through a nasogastric tube at the dose of 1200 mg (2 x 600 mg tablets) TID every 8 hours (6 tablets daily) for 14 days. All patients will receive therapy in line with current standard-of-care as it pertains to ARDS management (protocolized ventilator management will be made available to all sites in accordance with currently accepted standard of care).
45828241|NCT05496335|Drug|AGN-151586|Intramuscular Injection
45828242|NCT05496335|Drug|BOTOX|Intramuscular Injection
45971329|NCT00229190|Procedure|Physical examination|
45971330|NCT00256815|Drug|chemotherapy|
45971331|NCT00256815|Procedure|Radiation|
45971332|NCT00229229|Other|Low glycemic load diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
46081373|NCT04652804|Behavioral|Medium intensity HCV treatment adherence support|The medium intensity intervention will include standard of care dispensation of a 28-day supply of medication at entry, 4 weeks and 8 weeks. Participants will be assigned to a patient navigator (PN) and receive tailored patient navigation support for medication reminders, picking up medication refills (or home or field delivery of study medications), overcoming barriers as well as service linkage. Participant will be contacted by the PN at least once every two weeks.
46081374|NCT04652804|Behavioral|High intensity HCV treatment adherence support|The high intensity intervention will involve patient-centered DOT with flexibility in terms of the frequency of pickup and the site of DOT (ICC, field-based) with a minimum of at least 1 observed dose per week. Participants in this arm will also receive PN support for overcoming barriers and service linkage similar to participants in Arm 2. The main differences between Arms 2 and 3 are: (i) medications will not be dispensed for more than one week at a time (to coincide with opioid agonist therapy (OAT) dosing, where applicable); and (ii) ≥1 dose/week will be observed.
46081375|NCT04639466|Drug|Placebo Administration|Given IM in the non-dominant upper arm
45828243|NCT05496335|Drug|Placebo|Intramuscular Injection
45828244|NCT05487378|Dietary Supplement|PKU GOLIKE|AA protein Substitute for the dietary management of PKU, PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
45828245|NCT05480098|Drug|Brimonidine Topical|Topical brimonidine intraoperatively for hemostasis
45828246|NCT05439031|Radiation|Stereotactic Arrhythmia Radiotherapy|Single radiation treatment of 25 Gy with external beam radiation therapy to the pro-arrhythmic region as determined by the cardiologist-electrophysiologist and radiation-oncologist combined
45828247|NCT05438511|Behavioral|Focus group|A semi-structured focus group discussion guide will be developed with question probes that cover 1) contextual factors, 2) barriers to implementation, and 3) facilitators to implementation, with secondary probing questions.
45828248|NCT05438511|Behavioral|Organizational Readiness for Implementing Change|measures the extent to which organizational members are prepared to implement organizational change. The ORIC tool asks participants to rate their level of agreement with 12 statements pertaining to organizational readiness for change (change commitment and change efficacy) on a 5-point Likert Scale.
45828249|NCT05434364|Other|Facilitated Tucking|giving facilitated tucking before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
45828250|NCT05434364|Other|Swaddling|swaddling before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
45828251|NCT05434364|Other|Prone Position|giving prone position before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
45971333|NCT00229229|Other|Canada Food Guide Diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
45971334|NCT00229229|Other|Low glycemic index diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
45971335|NCT00229229|Other|Low carbohydrate diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
45971336|NCT00414102|Drug|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 28 days.
45971337|NCT00414102|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 28 days.
45971338|NCT00229307|Behavioral|Prolonged Exposure (PE) therapy|20 minutes exposure
45971339|NCT00229307|Behavioral|Prolonged Exposure (PE) therapy|40 minutes exposure
45971340|NCT00256893|Drug|ropinirole|
45971341|NCT00229385|Drug|Ziprasidone|40-80 mg BID
45971342|NCT00236223|Drug|Gabapentin + dexamethasone + ketamine|Comparing analgesic effect of gabapentin 1200 mg + dexamethasone 8 mg + ketamine 0.15 mg/kg
45971343|NCT00236223|Drug|Placebo|Matching placebo
45971344|NCT00229424|Drug|Lafutidine|Oral administration of lafutidine by 20mg/day along with famotidine placebo
45971345|NCT00229424|Drug|Famotidine|Oral administration of famotidine by 40mg/day along with lafutidine placebo
45971346|NCT00229424|Other|Placebo|Oral administration of lafutidine placebo along with famotidine placebo
45971347|NCT00256932|Drug|alvimopan|0.5 mg
45971348|NCT00256932|Drug|Placebo|
45971349|NCT00256971|Procedure|meniscectomy|
45971350|NCT00229541|Procedure|Counselling and 3-week medical in-patient rehabilitation|Counselling and 3-week medical in-patient rehabilitation in IG
45971351|NCT00236262|Device|ventilatory strategies with pressure|
45971352|NCT00191152|Drug|gemcitabine|1000 mg/m2, intravenous (IV) day 1 and day 8 every 21 days until disease progression
45828252|NCT05430438|Other|dialysis with low dialysate sodium concentration|Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 137 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
45971353|NCT00191152|Drug|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression
45971354|NCT00191152|Drug|capecitabine|1000 mg/m2, by mouth (PO) twice a day (BID), days 1-14, every 21 days until disease progression
45971355|NCT00229580|Behavioral|3 session brief intervention with health behavior feedback|
45971356|NCT00229580|Other|treatment as usual|
45971357|NCT00257049|Drug|levofloxacin|
45971358|NCT01059188|Drug|cetuximab|400 mg/m2 initial dose on day 1 250 mg/m2 weekly starting on day 8 and for 12 weeks
45971359|NCT01059188|Drug|cisplatin|50 mg/m2 on day 1 and 2 of 21 day cycles, for 3 cycles
45971360|NCT01059188|Drug|docetaxel|85 mg/m2 day 1 of 21 day cycles, for 3 cycles
46081376|NCT04639466|Biological|Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1|Given IM in the non-dominant upper arm
46081377|NCT04624568|Device|PAPILOCARE|"Papilocare® is a self-administered vaginal gel. Its single-dose cannula contains hyaluronic acid and pre-biotics (Coriolus Versicolor) that would improve the re-epithelialization of the uterin cervix. By creating a protective film on the cervix, this gel could induce a favorable environment for regression of the cervical intraepithelial lesions 1 and for clearance of Human Papillomavirus.~The specific approach related to our study would be to apply Papilocare® vaginal gel for 6 months for the treated group.~Smear and HPV test will be perform by all patients at 6 and 12 months."
45669693|NCT02893267|Other|Physical Therapy|Participants will receive 8 60-minute sessions of outpatient therapy over a 4 week period concurrent with PNS or sham-PNS treatment. Therapy may include: Proper Positioning and Handling, Therapeutic positioning and Strengthening Exercises, Mirror Therapy, Task-specific Therapy, Home Exercise Program, and a Mental Practice program.
45971361|NCT01059188|Radiation|Radiotherapy|44 Gy (PTV1=30 Gy, PTV2=14 Gy), for 3 weeks, after the 3 cycles of Cisplatin / Docetaxel treatment
45971362|NCT01059188|Procedure|Surgery|Ipsilateral formal mediastinal lymphadenectomy. In case of involved N3 lymph nodes, resection of the precarinal and contralateral nodes.
45971363|NCT00236301|Drug|CLIMASTON (drug)|CLIMASTON(drug)
45971364|NCT00236301|Drug|17 Beta-estradiol (2mg/day)and (1mg/day)|17 Beta-estradiol (2mg/day)and (1mg/day)
46081378|NCT04609046|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspirate and biopsy
46081379|NCT04609046|Procedure|Computed Tomography|Undergo CT and PET/CT
45669694|NCT02893267|Other|Sham-PT|Participants randomized to sham-PT will receive 8 60-minute sessions with therapists with the goal of controlling for the effect of regular contact with a therapist and study staff in a therapeutic environment. Participants will undergo a hands-on evaluation and re-evaluation before and after treatment. Therapists will provide sham ultrasound therapy and light application of inert gel to the shoulder for 10 minutes, Pre-Gait Training or Gait training, Exercise therapy, and relaxation therapy.
45669695|NCT02893267|Device|Sham-PNS|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source.The stimulator will appear to function as normal though will not deliver electrical current to the electrode. The subjects will be prescribed 6 hours of sham-stimulation per day for 3 weeks.
45669696|NCT04471909|Device|NEXUS Aortic Stent Graft System|"Arch Stent Graft, whose cranial narrow end is intended to be deployed into the Brachiocephalic artery and whose distal end is intended to be deployed into the Descending Thoracic Aorta.~Ascending Stent Graft intended to be deployed in the Ascending Aorta.~OPTIONAL: Descending Extension can be used in case the aortic lesion elongates further distally and out of the covered length offered by the Arch Stent Graft. Multiple Descending Extensions can be used if needed to cover the entire length of the lesion."
45669697|NCT04417699|Drug|TAS 102|Oral medication over Days 1-5
45828253|NCT05430438|Other|dialysis with standard dialysate sodium concentration|Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 140 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
45828254|NCT05426031|Drug|Protamine fixed dose|250 mg of protamine intravenously (IV), one time use
45828255|NCT05426031|Drug|Protamine ratio dose|1mg of protamine per 100 units of heparin given intravenously (IV), one time use
45828256|NCT05424328|Procedure|ALTF (Anterolateral thigh flap) with preoperative virtual planning|In this study group, using preoperative CTs (head & neck and thigh ) to virtually plan a guide that can be used during the surgery, this guide will determine the design and dimensions of the Alt flap to be harvested and restore the defect left on the tongue due SCC resection and hemi glossectomy.
45971365|NCT00236301|Drug|placebo|placebo
45971366|NCT00236340|Device|syringe aspiration|
45971367|NCT00236340|Device|Wall suction|
45971368|NCT00229697|Drug|Gefitinib|
45971369|NCT00229697|Drug|Tamoxifen|
45971370|NCT00236379|Drug|Olanzapine|Target oral dose of 20 milligrams per day for 6 months
45971371|NCT00236379|Drug|Risperidone|Target oral dose of 6 milligrams per day for for 6 months
45971372|NCT00229736|Genetic|AAV-hAADC-2|9 x 10^10 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
45971373|NCT00229736|Genetic|AAV-hAADC-2|3 x 10^11 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
45971374|NCT00257088|Behavioral|whole day first grade program|
45971375|NCT00229775|Drug|artemether/lumafantrine vs chloroquine/sulfadoxine-pyrimethamine|
45971376|NCT00257127|Biological|Pneumococcal 7-valent conjugate vaccine|0.5 mL administered intramuscularly
45971377|NCT00257127|Biological|Pneumococcal polysaccharide vaccine|0.5 mL administered intramuscularly
45971378|NCT00257127|Biological|Hepatitis B vaccine|0.5 mL administered intramuscularly
45971379|NCT00257127|Biological|Measles, mumps, and rubella virus vaccine, live|0.5 mL administered subcutaneously
46081380|NCT04609046|Procedure|Echocardiography|Undergo ECHO
45828257|NCT05424328|Procedure|ALTF (Anterolateral thigh flap) with conventional method|ALTF (Anterolateral thigh flap) will be harvested with conventional method which depends on surgeon's own experience in determining the flap design and dimensions needed to reconstruct and restore the defect left on the tongue due SCC resection and hemi glossectomy.
46081381|NCT04609046|Drug|Lenalidomide|Given PO
45669698|NCT04417699|Drug|Oxaliplatin|Administered by intravenous infusion over 2 hours on day 1
45669699|NCT02805517|Device|Percuvance™ Percutaneous Surgical System|Patients will undergo percutaneous externally-assembled laparoscopic donor nephrectomy where one or more 3 mm instruments are added or substituted for conventional 5 or 12 mm trocars.
45669700|NCT02797561|Other|5 year Follow-up|
45669701|NCT05652595|Drug|GP40141|Once, at a dose of 3 mcg/kg, Subcutaneously in the shoulder area
45669702|NCT05652595|Drug|Nplate|Once, at a dose of 3 mcg/kg, Subcutaneously in the shoulder area
45669703|NCT04418323|Procedure|Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula|Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula
45828258|NCT05423106|Drug|JNJ-64457744|JNJ-64457744 will be administered as oral solution.
45828259|NCT05423106|Drug|Placebo|Placebo will be administered as an oral formulation.
45828260|NCT05423106|Drug|Tenofovir Disoproxil Fumarate (TDF)|TDF tablet will be administered orally
45828261|NCT05423106|Drug|Tenofovir Alafenamide (TAF)|TAF tablet will be administered orally.
45828262|NCT05423106|Drug|Entecavir (ETV)|ETV tablet will be administered orally.
45828263|NCT05423106|Drug|JNJ-64457744|JNJ-64457744 will be administered as oral tablet.
45828264|NCT05422222|Drug|VX-121/TEZ/D-IVA|Fixed-dose combination for oral administration.
45828265|NCT05421091|Other|Asciminib|Prospective observational study. There is no treatment allocation. Patients prescribed with asciminib are eligible to enroll into this study.
45828266|NCT05415761|Behavioral|iCanQuit|iCanQuit is a smoking cessation smart phone application that uses acceptance and commitment therapy (ACT) approach, a cognitive behavioral treatment
45828267|NCT05415761|Behavioral|iCanQuit+Motiv8|iCanQuit + Motiv8 is a integrated version of iCanQuit (Cognitive Behavioral Therapy smoking cessation therapy application) with Motiv8 (a contingency management program that rewards decreased smoking determined by measuring CO levels of participant)
45971380|NCT00190684|Drug|atomoxetine|0.5-1.8 mg/kg/day, by mouth (PO), for up to 5 years
45971381|NCT00236418|Drug|topiramate|
45971382|NCT00257283|Drug|Omega-3-acid ethyl esters 90|
45971383|NCT00236457|Drug|risperidone|
45971384|NCT04721834|Device|Low-intensity Extracorporeal Shockwave Therapy|Low intensity shockwave energy would be delivered to stimulate angiogenesis in corporal tissue. Therapy would be delivered through a linear probe in 6 sessions. It would be conducted as a day procedure.
45971385|NCT04721834|Device|Sham Therapy|Same device as the active treatment arm would be used, with the addition of sham probe which block all shockwaves.
46081382|NCT04609046|Procedure|Lumbar Puncture|Undergo lumbar puncture
45669704|NCT05652517|Procedure|Vein of Marshall ethanol infusion|Vein of Marshall ethanol infusion performed during the radiofrequency catheter ablation of persistent or long-standing persistent atrial fibrillation.
45669705|NCT05163847|Biological|Cam2020 M2SR H3N2 influenza vaccine|Administered intranasally on Day 1
45669706|NCT05163847|Biological|Fluzone HD IIV|Administered intramuscularly on Day 1
45669707|NCT05163847|Other|IN Placebo|Administered intranasally on Day 1
45669708|NCT05163847|Other|IM Placebo|Administered intramuscularly on Day 1
45828268|NCT05415761|Behavioral|Florida quit line|An evidence-based, existing smoking cessation healthcare option recommended by the U.S. clinical practice that connects active smokers to trained quit coaches via referral by their providers.
45828269|NCT05412277|Other|VIA Disc Nucleus Pulposus Allograft|A single dose, intradiscal injection of 100mg of VIA Disc NP mixed with 2ml sterile saline administered to the affected 1 to 3 levels, L1-S1.
45828270|NCT05399277|Drug|Rivaroxaban|15mg oral daily for 7 days
45828271|NCT05395858|Other|No intervention|Retrospective analysis using database without any intervention assigned in the study.
45828272|NCT05377944|Drug|BAT2306|150 mg/1 ml/injection (2 injections/visit)
45828273|NCT05377944|Drug|EU-approved Cosentyx|150 mg/1 ml/injection (2 injections/visit)
45828274|NCT05371964|Drug|Imetelstat|Imetelstat sodium will be administered as intravenous (IV) every 28 days.
45828275|NCT05371964|Drug|Ruxolitinib|Ruxolitinib will be administered, orally (PO), twice daily (BID) as the standard of care per local prescribing guidelines.
45828276|NCT05371145|Biological|Carnosine|Determine whether carnosine supplementation (2 g/day) for 3 months in peripheral arterial disease patients improves 6MWT ability.
45828277|NCT05362409|Drug|5 Aminolevulinic Acid|5-aminolevulinic acid [5-ALA] administered orally 20 mg/kg every 4 weeks
45828278|NCT05362409|Device|CV01-delivered ultrasound|CV01-delivered ultrasound every 4 weeks
45828279|NCT05348733|Drug|Kerendia (Finerenone, BAY94-8862)|Decision will taken by the treating physician to initiate treatment with finerenone.
45828280|NCT05342636|Biological|Pembrolizumab|200 mg administered via intravenous (IV) infusion every 3 weeks (Q3W)
45971386|NCT00236496|Drug|topiramate|
46081383|NCT04609046|Procedure|Magnetic Resonance Imaging|Undergo MRI
46081384|NCT04609046|Drug|Methotrexate|Given IV or PO
46081385|NCT04609046|Biological|Nivolumab|Given IV
46081386|NCT04609046|Procedure|Positron Emission Tomography|Undergo PET/CT
46081387|NCT04609046|Biological|Rituximab|Given IV
46081388|NCT04609046|Procedure|Ultrasound Imaging|Undergo testicular ultrasound
45828281|NCT05342636|Biological|Coformulation favezelimab/pembrolizumab|800 mg favezelimab + 200 mg pembrolizumab administered via IV infusion on day 1 and then Q3W
45971387|NCT00199277|Drug|i.v. iron sucrose|
46081389|NCT04603807|Drug|Entrectinib|Entrectinib will be self-administered orally at a dose of 600 mg (three 200 mg capsules per day) once daily with or without food.
46081390|NCT04603807|Drug|Crizotinib|Crizotinib will be self-administered orally at a dose of 250 mg twice daily with or without food.
46081391|NCT04590872|Biological|Tolerogenic Dendritic Cell Vaccine|PIpepTolDCs
46081392|NCT04584099|Device|Radiofrequency device treatment|TempSure firm
45669709|NCT05203393|Device|Harmony Headset|"The Harmony headset is a non-invasive nonsignificant risk observational device to collect intracranial waveform data. The headset will be placed on normal study participants to collect data for a period of 3 minutes and transferred to investigators for analysis."
45669710|NCT04196569|Device|Alcon Trifocal and Trifocal Toric Intraocular Lenses|"Panoptix Model #TFAT00 for the UV Absorbing Trifocal IOL. Torics:~TFAT30, TFAT40, TFAT50, TFAT60"
45828282|NCT05342636|Drug|MK-4830|800 mg administered via IV infusion Q3W
45828283|NCT05342636|Drug|Lenvatinib|20 mg administered via oral capsules each day
45828284|NCT05342636|Drug|Irinotecan|180 mg/m^2 administered via IV infusion on day 1 of every 14-day cycle.
45828285|NCT05342636|Drug|Paclitaxel|80-100 mg/m^2 administered via IV infusion on Days 1, 8 and 15 of every 28 day cycle
45828286|NCT05336071|Drug|INS068 injection|Group A subjects were injected formulation T and formulation R of INS068 injection at Day1 and Day8.
45828287|NCT05336071|Drug|INS068 injection|Group B subjects were injected formulation R and formulation T of INS068 injection at Day1 and Day8.
45971388|NCT00199277|Drug|Oral iron|
45669711|NCT04806373|Drug|Cathflo Activase|Cathflo Activase 4mg in 50ml normal saline given through chest pleural catheter
45669712|NCT04806373|Drug|Talc Slurry Pleurodesis|Talc, 5 gm in 50 ml Normal Saline given through chest pleural catheter
45669713|NCT02619253|Drug|Pembrolizumab|
45669714|NCT02619253|Drug|Vorinostat|
45828288|NCT05333679|Device|UTRA|Collect urine on intervention participants and screen for presence of TFV.
45828289|NCT05333679|Behavioral|UTRA feedback|Feedback will be provided to the participant based on the UTRA results on their adherence with provision of standard adherence counseling.
45828290|NCT05327244|Other|Real-world vibration feedback gait retraining|Participants will walk with a vibration feedback tool attached to their shoelaces. A small force sensing resistor is taped to the foot bed of the shoe under the lateral foot and a vibration motor is placed over the outside of the ankle with a strap. When a participant walks on the outside of their foot, they will exceed the pressure threshold and activate the feedback which signifies an incorrect foot placement. The feedback is intended to prompt a correct foot placement on the subsequent step. Participants will use the same feedback tool for 6 real world training sessions.
45828291|NCT05325034|Behavioral|Early Intervention|"Participant and clinician lipid score card to increase the likelihood of effecting guideline-directed change in lipid lowering therapy through two key actors - both the patient and their clinician(s).~The Score Card documents four key fields to be completed by the participant, study team and participant's regular clinician including 1) 'current' LDL-C level, 2) participant's level of adherence to lipid-lowering therapy using modified Voil's criteria, 3) lipid-lowering management decisions made at the clinician's appointment and 4) currently prescribed lipid-lowering therapies."
45971389|NCT00236535|Drug|tramadol HCl + acetaminophen; hydrocodone bitartrate + acetaminophen; placebo|
45971390|NCT00193219|Drug|Bevacizumab|5 mg/kg IV
45971391|NCT00193219|Drug|Cetuximab|400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8
45971392|NCT00193219|Drug|5-fluorouracil|400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)
45971393|NCT00193219|Drug|Leucovorin|350 mg IV
45971394|NCT00193219|Drug|Oxaliplatin|85 mg/m2 IV
45971395|NCT00199316|Drug|spinal morphine|
45971396|NCT00196339|Drug|Cyproterone acetate 5|Cyproterone acetate 5 mg
45971397|NCT00196339|Drug|Placebo|Matching placebo
45971398|NCT00196339|Drug|Cyproterone acetate 15|Cyproterone acetate 15 mg
45971399|NCT00196339|Drug|Cyproterone acetate 25|Cyproterone acetate 25 mg
45669716|NCT04795141|Drug|ABY-035|ABY-035 Duration: 52 weeks
45828292|NCT05324878|Other|Training|Social workers/nurses participants are agreeing to participating in the training program (3 sessions of 2 hours over a period of six weeks - one session every 2 weeks), follow up training sessions (occurring monthly), mentorship calls with social worker faculty on the project team, recording one conversation between social worker and a patient for quality improvement purposes, and completing evaluation of the project interventions (5-minute questionnaire after each education session, 15-minute questionnaire at end of participation in project).
45828293|NCT05321264|Behavioral|Educational nursing intervention|Four weekly individualized intervention sessions, with a duration of 40 minutes.
45828294|NCT05320198|Drug|DISC-0974|DISC-0974 is administered subcutaneously.
45828295|NCT05319873|Drug|Carboplatin|Given IV
45828296|NCT05319873|Drug|Docetaxel|Given IV
45828297|NCT05319873|Drug|Fulvestrant|Given SC
45828298|NCT05319873|Biological|Pertuzumab|Given IV
45828299|NCT05319873|Other|Quality-of-Life Assessment|Ancillary Studies
45828300|NCT05319873|Drug|Ribociclib|Given PO
45828301|NCT05319873|Biological|Trastuzumab|Given IV
45828302|NCT05319873|Drug|Tucatinib|Given PO
45828303|NCT05300906|Behavioral|personalized 2-week mobile wellbeing intervention|"For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the personalized condition will receive the optimal combination of content, feedback and design, based on their baseline engagement scores.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages."
45828304|NCT05300906|Behavioral|non-personalized 2-week mobile wellbeing intervention|"For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the non-personalized condition will receive a random version of the intervention.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages."
45828305|NCT05296070|Drug|Loncastuximab tesirine 150 µg/Kg|Participants will be treated with loncastuximab tesirine at a dose of 150 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 1 - 2.
45828306|NCT05296070|Drug|Loncastuximab tesirine 75µg/Kg|Participants will be treated with loncastuximab tesirine at a dose of 75 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 3 - 6.
45828307|NCT05293470|Other|Piqray|There is no treatment allocation. Patients administered Piqray by prescription will be enrolled.
45828308|NCT05291884|Device|Impella BTR|Subjects will be prepared for pump insertion procedure according to clinical site standard of care. Procedural preparations for insertion of the Impella BTR are identical to the insertion of the Impella 5.0/5.5 via the axillary artery. The Impella BTR remains in situ until the patient is sufficiently recovered for removal or is transitioned to another form of support. It is expected that the Impella BTR is in situ for a maximum of 28 days.
45828309|NCT05289180|Other|Questionnaires|A questionnaire will be administered post-procedure to assess for pain and anxiety. This questionnaire will be administered by study personnel delegated to administer questionnaires, namely the study coordinator or PI.
45828310|NCT05288439|Diagnostic Test|Resting-state functional connectivity MRI|participants will undergo functional MRI
45828311|NCT05288439|Other|Neurocognitive battery with quality-of-life assessment|Cognitive and quality of life assessments performed by a trained neuropsychologist
45828312|NCT05281458|Procedure|Early drainage of peripancreatic fluid collections|Participants will undergo EUS guided drainage earlier (≤1 weeks) in the disease course.
45828313|NCT05276297|Drug|GSK3228836|2 doses of GSK3228836 study intervention administered subcutaneously once per week for 12 weeks (Day 1 up to Day 78) to participants in ASO12-TI and ASO12 groups, or for 24 weeks (Day 1 up to Day 162) to participants in ASO24-TI and ASO24 groups, plus loading doses administered at Day 4 and Day 11 (2 doses each day) to participants in all groups during Treatment 1 period.
45971400|NCT00257361|Drug|D-Cycloserine|
45971401|NCT00199355|Drug|Istradefylline (KW-6002)|
45669717|NCT04795141|Drug|Normal saline|Dosage form: Solution for injection; Duration: 52 weeks
45669718|NCT05652361|Other|Additional visualisation of surgical assistance during surgery|Robot-assisted anterior rectal resection using daVinci® system as CE-marked gold standard with additional visualization of surgical assistance functions based on machine learning techniques
45971402|NCT00179959|Drug|Sodium hypochlorite (bleach) baths|Sodium hypochlorite (bleach) baths twice weekly for 3 months
45971403|NCT00179959|Drug|Mupirocin ointment|Intranasal mupirocin 2% ointment BID x five days (3 times total for subjects; one time only for family members)
45971404|NCT00179959|Drug|Water|Water baths twice weekly for three months
45971405|NCT00179959|Drug|Petrolatum Ointment|Intranasal petrolatum ointment twice daily for five days
46081393|NCT04579445|Other|Education on tailored Quality Improvement measures|Centers will undergo an education on defined Quality of Care measures, with the aim to implement a standardized pathway which is reproducible, scalable and which will allow increased access. The implementation of these measures will help to reduce resource requirements, intensive care bed occupancy and overall length of hospital stay with uncompromised patient safety.
45971406|NCT00199394|Drug|Istradefylline (KW-6002)|
46081394|NCT04573972|Behavioral|Social Incentive|Receiving half the monetary incentive conditional on meeting a step goal and half the monetary incentive conditional on walking together
45669719|NCT05651971|Behavioral|measurement group|Measurement of the distance between the origin of LCA (left colonic artery，LCA) and IMA (inferior mesenteric artery，IMA) root and the distance between IMA and IMV (inferior mesenteric vein，IMV) at the origin of LCA in rectal cancer patients
45828314|NCT05276297|Biological|GSK3528869A|"The GSK3528869A chronic Hepatitis B targeted immunotherapy (CHB-TI) consisting of 4 doses administered intramuscularly as follows:~1 dose of the Chimpanzee adenovectored HBV vaccine (ChAd155-hIi-HBV) at Day 1 of Treatment 2 period.~1 dose of the Modified Vaccinia Virus Ankara HBV vaccine (MVA-HBV) at Day 57 of Treatment 2 period.~2 subsequent doses of the AS01B-4-adjuvanted HBc-HBs proteins (HBc-HBs/AS01B-4) administered at Day 113 and Day 169 of Treatment 2 period."
45971407|NCT02961933|Other|Apneic oxygenation|Nasal cannula apneic oxygenation
45971408|NCT02961933|Other|Pre-oxgenation with NRB, NIPPV, BVM|Pre-oxygenation with non-rebreather mask, non-invasive positive pressure ventilation, or bag-valve mask
45971409|NCT00257400|Behavioral|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy
45971410|NCT00257400|Behavioral|Individual Psychotherapy|Individual Psychotherapy
45971411|NCT00236574|Drug|Galantamine hydrobromide|
45971412|NCT00199433|Drug|Istradefylline (KW-6002)|
45971413|NCT00199472|Procedure|Dynamic Contrast Enhanced CT & Diuretic Renogram|
45971414|NCT02961972|Dietary Supplement|monohydrate and micronized creatine|oral supplementation with creatine
45971415|NCT02961972|Other|placebo|oral supplementation with maltodextrin (control group)
45971416|NCT00199511|Drug|Administration of Hypertonic Solution 7.5% vs Mannitol 20%|
45971417|NCT00236613|Drug|topiramate|
46081395|NCT04573972|Behavioral|Standard Incentive|Receiving the full monetary incentive conditional on meeting a step goal and not conditional on walking together
46081396|NCT04567849|Behavioral|message|patient portal message
46081397|NCT04567849|Behavioral|provider|nudging calling the patient's provider
45669720|NCT04137211|Behavioral|Prolonged sitting with social break|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a short social break. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
45828315|NCT05276297|Drug|Control|4 doses of non-active control administered intramuscularly in the deltoid region of the non-dominant arm at Days 1, 57, 113 and 169 to participants in ASO24 and ASO12 control groups during Treatment 2 period.
45828316|NCT05264740|Behavioral|Motivational interviewing|The intervention group will receive motivational interviewing sessions with a trained study nurse plus educational material
45828317|NCT05264740|Behavioral|Educational materials|The control group will receive educational material only.
45828318|NCT05260242|Other|Disparities Conversation|The study intervention will be a scripted interaction delivered by an anesthesia healthcare provider to an individual patient admitted to the labor/delivery unit for labor epidural placement and obstetric care. The discussion will highlight current data relating to healthcare disparities in obstetric anesthesia care within underserved groups and will explain various aspects of obstetric anesthesia care in a culturally-sensitive manner.
45828319|NCT05254002|Drug|Finerenone (Kerendia, BAY94-8862 )|oral administration, once daily
45828320|NCT05254002|Drug|Empagliflozin|oral administration, once daily
45971418|NCT00257478|Drug|YM155|
45971419|NCT00199550|Procedure|Bipolar Transurethral Resection of the Prostate|Bipolar TURP
45971420|NCT00199550|Procedure|Monopolar Transurethral Resection of the Prostate|Monopolar TURP
45971421|NCT04721340|Other|Test Group|Individuals who meet the inclusion criteria will be evaluated for manual dexterity, performance, muscle strength and fatigue, respectively, on a predetermined day.
45971422|NCT04721340|Other|Control Grup|Individuals who meet the inclusion criteria will be evaluated for manual dexterity, performance, muscle strength and fatigue, respectively, on a predetermined day.
45971423|NCT00199589|Drug|Botulinic toxin (Botox)|Patients may benefit, depending on the draw, in addition to their orthosis, intramuscular injections of botulinum toxin.These injections are among 6 in the muscles posterior (rear) of the leg paralyzed with tracking electromyographic to ensure the accuracy of the injection.
46081398|NCT04567849|Behavioral|tele-nurse|nudging calling the tele-nurse
45971424|NCT00236652|Drug|levofloxacin|
45971425|NCT00257595|Drug|Cetirizine Dry Syrup|
45971426|NCT00199667|Drug|Mycophenolate Mofetil|
46081399|NCT04566003|Drug|[18F]GTP1|Participants will receive a bolus IV of approximately 7mCi of [18F]GTP1 radiotracer.
46081400|NCT04566003|Drug|[18F]PI-2620|Participants will receive a bolus IV of approximately 5mCi of [18F]PI-2620 radiotracer.
46081401|NCT04566003|Drug|[18F]MK-6240|Participants will receive a bolus IV of approximately 5mCi of [18F]MK-6240 radiotracer.
46081402|NCT04549142|Other|There is no intervention|There is no intervention
46081403|NCT04548999|Drug|Ocrelizumab|The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (participants's body weight <75 kg) or 1800 mg (participant's body weight >/=75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg intravenous (IV) infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion every 24 weeks.
46081404|NCT04548999|Drug|Ocrelizumab|Ocrelizumab will be administered at a dose of 600 milligram (mg) every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg intravenous (IV) infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
45971427|NCT00236691|Drug|topiramate|
45971428|NCT00199706|Drug|7.2% NaCl in 6% hydroxyethyl starch solution|
45828321|NCT05254002|Drug|Placebo|oral administration, once daily
45828322|NCT05249452|Other|Preconditioning with azathiprine and hydroxyurea (3 months)|Preconditioning with azathiprine and hydroxyurea (3 months) before alemtuzumab/TBI conditioning and matched sibling donor allogeneic stem cell transplantation.
45828323|NCT05244499|Other|Evidence-based leadership training|7-modules online training over six months mentored by tutors. Independent familiarisation of reading material, peer-group discussions, self-reflection, assignments, tutor's feedback.
45828324|NCT05244499|Other|Conventional training|7-modules online training over six months. Independent reading only.
45828325|NCT05239741|Biological|Pembrolizumab|Intravenous (IV) infusion
45828326|NCT05239741|Drug|Oxaliplatin|85 mg/m^2 given as an intravenous infusion (IV) on Day 1 in each 14-day cycle (Q2W) as part of the mFOLFOX6 regimen
45828327|NCT05239741|Drug|Leucovorin|400 mg/m^2 given as an IV on Day 1 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
45828328|NCT05239741|Drug|5-fluorouracil|400 mg/m^2 given as an IV bolus on Day 1 and then 1200 mg/m^2/day IV over 2 days for a total dose of 2400 mg/m^2 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
45828329|NCT05239741|Drug|Irinotecan|180 mg/m^2 IV on Day 1 Q2W as part of the FOLFIRI regimen
45828330|NCT05239741|Biological|Bevacizumab|IV infusion
45828331|NCT05239741|Biological|Cetuximab|IV infusion
45828332|NCT05238311|Drug|Elranatamab|
45828333|NCT05218772|Other|Questionnaires|Each eligible participant will receive a questionnaire to complete concerning: objective health status; perceived health status (QoL assessed by the WHOQOL-Old questionnaire); demographic data; social data; psycho-cognitive data (anxious symptoms, depressive symptoms, use of coping strategies, time perspective)
45828334|NCT05211895|Drug|Durvalumab|Durvalumab IV (Intravenous infusion)
45828335|NCT05211895|Drug|Domvanalimab|Domvanalimab IV (Intravenous infusion)
45828336|NCT05211895|Other|Placebo|Placebo IV (Intravenous infusion)
45828337|NCT05210790|Drug|Placebo|Placebo
45828338|NCT05210790|Drug|Rusfertide|Experimental drug
45828339|NCT05206266|Other|Turmeric|Three amounts of dietary turmeric will be tested: 1) turmeric 300 mg/day, 2) turmeric 1 g/day, 3) turmeric 3 g/day.
45828340|NCT05206266|Other|Turmeric+Black Pepper|Three amounts of dietary turmeric (300mg/day, 1g/day or 3g/day) with black pepper (300 mg) added to the turmeric.
45828341|NCT05201703|Drug|Fycompa|Fycompa 4 mg daily
45828342|NCT05201703|Drug|Fycompa with a boost|Fycompa 4 mg daily with a boost to 6 mg daily a week before the start of your menstruation cycle until Day 4 of your cycle.
45828343|NCT05200338|Drug|Engerix-B|Subjects are vaccinated with an accelerated scheme at 0, +1, +2 months with a booster at +12 months.
45828344|NCT05195125|Procedure|Direct Peritoneal Resuscitation|Direct peritoneal resuscitation involves the abdominal infusion and drainage of a peritoneal dialysate in high-risk liver transplant patients, for up to 24 hours after surgery.
45828345|NCT05193019|Other|Parenteral antiplatelet agents|Patients undergoing PCI and receiving parenteral antiplatelet agents, cangrelor or glycoprotein IIb/IIIa inhibitors (GPIs), during the procedure as per clinical practice
45828346|NCT05188326|Drug|Vidaza 100 milligram (mg) injection|1st cycle 50 mg/sqm s.c. or i.v. for 7 days (5 + weekend off + 2) every 28 days and increase dosing after 1st cycle, if well tolerated, to 75 mg/ m2 for further 5 cycles, followed by cycles every 56 days for 4 years and six months post-remission.
45828347|NCT05188326|Other|Best Supportive Care|Best supportive care includes antibiotics, transfusions and fluids
45828348|NCT05186974|Drug|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
45828349|NCT05186974|Drug|Pembrolizumab|Administered intravenously
45828350|NCT05186974|Drug|Carboplatin|Administered intravenously
45828351|NCT05186974|Drug|Cisplatin|Administered intravenously
45828352|NCT05182918|Other|Substance use disorder treatment|The study followed a heterogenous sample of patients in opioid maintenance treatment (OMT) and other substance use disorder treatment. The main focus was on health related problems in this cohort, with focus on tobacco use and substance use.
46081405|NCT04548999|Drug|Antihistamine|Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
45828353|NCT05180942|Drug|Atorvastatin Calcium 40Mg Tab|One tablet daily
45828354|NCT05171075|Biological|Abelacimab|Abelacimab 150 mg
45828355|NCT05171075|Drug|Dalteparin|Dalteparin 200 IU/kg/day followed by 150 IU/kg/day
45828356|NCT05171049|Biological|Abelacimab|Abelacimab 150 mg
45828357|NCT05171049|Drug|Apixaban|Apixaban 10 mg followed by 5 mg
45828358|NCT05165108|Device|Vagal Nerve Stimulator|A handheld device which consists of a battery powered portable stimulator with a digital control user interface that controls signal amplitude and two steel contact electrodes will deliver the nVNS electrical stimulation to the cervical Vagus nerve. The device has been approved by the U.S. Food and Drug Administration (FDA) for non-invasive Vagus nerve stimulator therapy for adjunctive use for the prevention and treatment of migraine and cluster headaches in adult patients.
45828359|NCT05164653|Drug|Sacubitril Valsartan Sodium Hydrate|"Switch from the ACE inhibitor or ARB that was taken before the allocation, and start oral administration twice daily with a starting dose of 50 mg of sacubitril valsartan. The duration of administration of the ACE inhibitor or ARB before allocation does not matter, but when switching from the ACE inhibitor, administration of sacubitril valsartan should be started at least 36 hours after the final administration of the drug.~After the start of administration, the dose is gradually increased to 100 mg and 200 mg once at intervals of 2 to 4 weeks, referring to the latest package insert and safety and tolerability standards. At that time, if the doctor in charge determines that the dose is not tolerated after the dose is increased, the dose may be reduced to the previous dose or the drug may be suspended depending on the medical situation."
45828360|NCT05164653|Drug|Standard treatment|Standard treatment, other than Sacubitril Valsartan Sodium Hydrate, for HF
45971429|NCT00236730|Drug|topiramate|
45971430|NCT00199745|Drug|atorvastatin|
45971431|NCT04709172|Drug|Cefditoren pivoxil 400mg|Cefditoren pivoxil 400mg bid for 7 days
45971432|NCT00199784|Drug|Phenylephrine|
45971433|NCT00236769|Drug|norelgestromin + ethinyl estradiol|
45971434|NCT00199823|Genetic|Intracoronary aotologous stem cell transplantation|
45971435|NCT00415311|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
45971436|NCT00415311|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
45971437|NCT00415311|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
45971438|NCT00199940|Drug|Ziprasidone|
45971439|NCT00236808|Drug|levofloxacin|
45669721|NCT04137211|Behavioral|Prolonged sitting with walk break|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform a brisk walk for about three minutes on a treadmill at a predetermined speed and grade based on the fitness test performed during the familiarization session. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
45669722|NCT04137211|Behavioral|Prolonged sitting with simple resistance activities|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
45669723|NCT05651815|Device|Graphene spectrum light wave therapy room|Undergo 30-min of graphene adjuvant therapy every day for 7 d.
45669724|NCT04136275|Biological|CAR-37 T cells|CAR-37 is an investigational treatment that uses the participant own immune cells, called T cells, to try to kill the cancerous cells
45669725|NCT04132219|Behavioral|eHealth Intervention|Every week, each dyad member will receive a tailored text message that provides a new fun fact or that encourages them to log-on to the website to access findings of new research and how the results might apply to them. They will be directed to specific pages in the Web-based program and asked to select strategies from a list that they will practice during the upcoming week. Graphic displays of their progress will be provided along with SCT-based feedback. They will be directed to the website to record their behavioral goals for the upcoming week. Tips also will be provided for effective communication to enhance couple efficacy. All usage will be tracked to assess adherence.
45669726|NCT03998293|Drug|Somatostatin|infused to block endogenous insulin secretion over a 4 hour period
45971440|NCT00199979|Drug|Nevirapine|
45971441|NCT02961114|Procedure|Microcannula Harvest Adipose|Use of closed syringe microcannula harvest of autologous AD-tSVF from subdermal adipose deposits to create a AD-cSVF
45971442|NCT02961114|Device|Centricyte 1000|Use of Centricyte 1000 closed system digestion, incubation/agitation, and centrifugation to acquire a concentrated pellet of AD-cSVF
45669727|NCT05651503|Dietary Supplement|Prodilac Oral, Frezyderm|In our study oral probiotics Lactobacillus salivarius Oral S1 11 (Prodilac Oral, Frezyderm) will be tested in two Experimental groups
45828361|NCT05161260|Behavioral|Yoga Breathing|"For the12 weeks, participants will be asked to use the mobile study app, completing 3, 10 minute exercises, 5 days a week. Participants in the Yoga Breathing group will practice a breathing exercise guided by the mobile study application. The application will also send nudges and reminders throughout the day. Participants will engage with the research study app along with other participants in groups of 2-7 at their own convenience. Participants may practice their breathing activity with either a group of participants, through the video conferencing feature of the app, or on their own. The study instructor may join sessions on a random basis to ensure compliance with the technique and to clarify any questions participants may have."
45971443|NCT02961114|Biological|IV Sterile Normal Saline|Sterile Normal Saline deployment of AD-cSVF in suspension of 500cc in IV pathway
45971444|NCT00200018|Device|Enterra Therapy System (H9900014)|
45971445|NCT00257634|Drug|dexamethasone to injury site|
45971446|NCT00236847|Drug|topiramate|
45971447|NCT00410228|Drug|AHT956|
45971448|NCT00257673|Drug|MEM 1003|30 mg twice a day
45971449|NCT00257673|Drug|MEM 1003|90 mg MEM 1003 twice a day
45971450|NCT00257673|Drug|Placebo for MEM 1003|Placebo twice a day
45971451|NCT00410306|Drug|Testosterone Undecanoate (Nebido, BAY86-5037)|Patients from routine practice
45971452|NCT00257712|Drug|TH9507 human growth hormone releasing hormone (GHRH)|1mg subcutaneous injection given daily for 20 weeks
45971453|NCT00179647|Drug|lenalidomide|Lenalidomide, 5 mg to 25 mg, QD, orally, for 21 days every 28 days, with or without dexamethasone
45971454|NCT00179647|Drug|dexamethasone|Dexamethasone, 20 mg to 40 mg, QD, orally, administered under a variety of dosing regimens
45971455|NCT00257751|Procedure|Aprotinine|
45455855|NCT05579847|Behavioral|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire|"The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30) comprises 30 single questions, 24 of which are aggregated into nine multi-item scales, that is, five functioning scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting) and one global health status scale. The remaining six single-item (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea and the financial impact) scales assess symptoms. No item occurs in more than one scale.~Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the patient), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the patient)."
45455856|NCT05579847|Behavioral|Patient Post Intervention Survey|The Patient Post Intervention Survey is a 7 question survey to help determine the effectiveness of the mHealth app. 3 questions are open fields for patient feedback, and 4 questions ask how often the app was used, how often the educational module was used and if the patient found it useful.
45455857|NCT05575284|Procedure|Robot-assisted urological surgery|Patient with programmed robot-assisted urological surgery
45828362|NCT05161260|Behavioral|Attention Control|"For the12 weeks, participants will be asked to use the mobile study app, completing 3, 10 minute exercises, 5 days a week. Participants in the Attention Control group will practice a mindfulness exercise guided by the mobile study application. The application will also send nudges and reminders throughout the day. Participants will engage with the research study app along with other participants in groups of 2-7 at their own convenience. Participants may practice their mindfulness activity with either a group of participants, through the video conferencing feature of the app, or on their own. The study instructor may join sessions on a random basis to ensure compliance with the technique and to clarify any questions participants may have."
45828363|NCT05160896|Drug|Raltitrexed|Raltitrexed 2 mg/m² iv, 15min. day 1
45828364|NCT05160896|Drug|Irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min. day 1
45828365|NCT05160896|Drug|Bevacizumab|Bevacizumab 5 mg/kg, iv, day 1
45828366|NCT05160896|Drug|Cetuximab|cetuximab 500 mg/ m² , iv, day 1
45828367|NCT05156125|Drug|VTX002|Dose A tablet administered orally once daily
45828368|NCT05156125|Drug|VTX002|Dose B Tablet administered orally once daily
45828369|NCT05156125|Drug|Placebo|Placebo Tablet for VTX002 administered orally once daily
45828370|NCT05150210|Device|Robotic-Assisted Surgery|da Vinci SP Surgical System, instruments, and accessories in pulmonary lobectomy and thymectomy for benign and malignant disease.
45828371|NCT05148962|Biological|GRT-R910 10 mcg Dose (after AZ)|10 mcg vaccine by intramuscular (IM) injection on Day 1 (required) and on Day 113 (optional)
45828372|NCT05148962|Biological|GRT-R910 30 mcg Dose (after AZ)|30 mcg vaccine by intramuscular (IM) injection on Day 1 (required) and on Day 113 (optional)
45828373|NCT05148962|Biological|GRT-R910 10 mcg Dose (After Adenovirus based vaccine)|GRT-R910 10 mcg vaccine by intramuscular (IM) injection on Day 1 and on Day 29
45828374|NCT05148962|Biological|GRT-R910 10 mcg Dose (after mRNA based vaccine)|GRT-R910 10 mcg vaccine by intramuscular (IM) injection on Day 1 and on Day 29
45828375|NCT05145881|Dietary Supplement|Low dose probiotics|Taking 1 package of low dose probiotic powder (B. breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) twice daily before meals (BIDAC).
45828376|NCT05145881|Dietary Supplement|Normal dose probiotics|Taking 1 package of normal dose probiotic powder (B. breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) twice daily before meals (BIDAC).
45971456|NCT00200096|Procedure|Acupuncture and questionnaires|"Acupuncture once weekly for six weeks Brief Fatigue Inventory, Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Treatment scale. Patients will repeat the BFI and FACT-G at seven and eight weeks after randomization, approximately one and two weeks after their final treatment. HADS will be repeated at week seven. At the end of the study, patients will be asked to state whether they were thought they on true or placebo acupuncture and why.~On the day of the final session of acupuncture treatment (approximately day 35), blood samples will be collected and tested for hemoglobin, thyroid function tests, as described in pretreatment evaluation. The results will be designated posttreatment values. Actigraphic monitoring will be conducted in week seven. Patients will be asked to wear the device for seven days just like during baseline evaluation."
46081406|NCT04548999|Drug|Methylprednisolone|Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
45828377|NCT05140915|Behavioral|Peer Messaging|Peer messages, written by current and former adolescent e-cigarette users and tailored by age and readiness-to-quit.
45828378|NCT05140915|Behavioral|Peer Coaching via Text|Peer coaching, facilitated by texting
45828379|NCT05140915|Behavioral|Gamification|Gamification, designed to motivate participation
45669728|NCT05651503|Dietary Supplement|placebo lozenges|In order to avoid possible bias, probiotics will be compared with placebo lozenges/no probiotic in two Control groups
45971457|NCT00200096|Procedure|placebo acupuncture|"During the placebo phase, placebo acupuncture needles (68) will be applied a few mm away from the points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. However, the needle does not penetrate the skin and instead moves upward inside the handle. Needles will be applied after sterile swabbing of the skin and kept in place for 20 minutes in both group.Patients in the placebo group will be offered true acupuncture after receipt of the week seven and eight fatigue diaries.~Patients will complete the BFI, HADS and FACT-G at baseline, approximately two weeks before randomization and their first treatment. The BFI and FACT-G will be repeated after seven days, that is, one week before randomization. The use of repeat measurement decreases intrapatient variability and hence increases the precision of the baseline measure."
45971458|NCT00179413|Drug|PEG -Intron|
45971459|NCT00179413|Drug|Colchicine|0.6mg twice a day
45971460|NCT00236886|Drug|topiramate|
45971461|NCT00178633|Procedure|Bariatric surgery|Bariatric surgery was not part of this trial. This was observational trial of persons post-bariatric surger.
45971462|NCT04571866|Other|Beta-glucan bread|Beta-glucan is a dietary fiber with beneficial health effects, both on cholesterol levels and potentially blood glucose levels.
45971463|NCT00257790|Drug|Tobramycin once a day|
45971464|NCT00178399|Procedure|Stereotactic Body Radiation Therapy|
45971465|NCT00200174|Drug|Raloxifene followed by combination therapy|Patients will be randomized to either Raloxifene at 60mg P.O. (each day) for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
45971466|NCT00200174|Drug|Exemestane followed by combination therapy|Patients will be randomized to Exemestane at 25mg P.O. for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
45971467|NCT00178126|Device|Skin Protection Wheelchair Seat Cushion|Cushion receiving CMS code for Skin Protection Wheelchair Cushion
45455858|NCT05574088|Procedure|Apical patency with file|After an informed consent , One group will receive apical patency intervention with k file number 10 while the other will be control group
45669729|NCT04793737|Radiation|Precision Radiation (SBRT)|Precision radiation of melanoma metastases
45828380|NCT05140915|Other|E-Cigarette Cessation Materials|Written e-cigarette cessation materials by the Research Coordinator at the time of study enrollment. The written materials will consist of two pamphlets from Journeyworks, selected based on: (1) their clear and attractive layout designed for a low-literacy audience, and (2) their providing both information re: e-cigarette use with a strong message about nicotine and nicotine addiction, E-Cigarettes: 8 Things Everyone Should Know, and support in quitting, How to Quit Vaping.
45669730|NCT01755598|Biological|GSK Biologicals' investigational TB vaccine (GSK692342)|2 doses administered intramuscularly in the deltoid region of the arm.
45669731|NCT01755598|Biological|Placebo|2 doses administered intramuscularly in the deltoid region of the arm.
45669732|NCT01606306|Drug|daily fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily
45669733|NCT01606306|Drug|Montelukast|Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening
45828381|NCT05138939|Other|Red wine A|8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
45828382|NCT05138939|Other|Red wine B|8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
45669734|NCT01606306|Drug|as-needed fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms
45669735|NCT01754194|Procedure|Gastric Sleeve Resection|Laparoscopic Gastric Sleeve Resection
45669736|NCT01754194|Procedure|Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
45828383|NCT05138939|Other|Control|8 oz (237 ml) of control beverage is a beverage that has similar calories to red wines.
45828384|NCT05137054|Drug|Linvoseltamab|Linvoseltamab is administered by intravenous (IV) infusion
45828385|NCT05137054|Drug|Daratumumab|Daratumumab is administered by IV infusion and/or subcutaneous (SC) injection; SC injection may be used after a minimum of 2 cycles of IV administration at the investigator's discretion.
45971468|NCT00178126|Device|Segmented Foam Wheelchair Seat Cushion|General use class wheelchair seat cushion
45971469|NCT00236925|Drug|Low dose Hydrocortisone|Hydrocortisone 10 mg daily
45971470|NCT00236925|Drug|Placebo|Placebo
45971471|NCT00200213|Behavioral|portion or unportioned food|
45971472|NCT00236964|Drug|Iron Sucrose + Erythropoietin|
45971473|NCT00236964|Drug|Ferrous Sulfate + Erythropoietin|
45971474|NCT00200252|Drug|oxytocin|
45971475|NCT00177307|Drug|Bevacizumab|Bevacizumab 5 mg/kg by 90-30 minute IV infusion IV q 2 weekly Until disease progression or unacceptable toxicity
45971476|NCT00177307|Drug|Capecitabine|Capecitabine will be administered orally at twice daily 1250 mg/m2 (equivalent to a total daily dose of 2500 mg/m2) as intermittent therapy (1 week of treatment followed by one week without treatment) and this cycle repeated every 14 days. The first dose of capecitabine will be given on day 1 of each cycle as evening dose and the last dose will be given on day 8 as morning dose (for a total of 14 single doses per cycle).
45971477|NCT00177307|Drug|Oxaliplatin|Oxaliplatin will be administered at the dose of 85 mg/m2 given as a 2-hour intravenous infusion on day 1 of a two-week cycle, prior to the first dose of capecitabine
45971478|NCT00257829|Drug|Methazolamide|
45971479|NCT00257829|Drug|Cisplatin|
45971480|NCT04571983|Other|Blood Eosinophil counts - comparing historical with stable state|Comparing historical blood eosinophil counts over 24 months to stable state eosinophil count.
45971481|NCT00200291|Behavioral|hypocaloric, low-fat diet|hypocaloric, low-fat diet
45828386|NCT05137054|Drug|Carfilzomib|Carfilzomib is administered by IV infusion
45971482|NCT00176644|Drug|Transdermal Estradiol|"application of 4 transdermal estradiol patches, each patch releases a dose of 0.1 mg/day for a total dose of 0.4 mg/day. All four patches will be changed every 7 days. This continuous weekly schedule will be followed until the patient goes off-study.~The patch will be applied to a clean, dry, intact area of the lower abdomen or the upper quadrant of the buttock. The sites should be rotated weekly. If a patch falls off during the 7 days, a new patch will be applied for the remainder of the 7 day period. At the end of the 7 days all four patches will be changed."
45971483|NCT00237003|Behavioral|motivational interviewing|Assessment plus motivational interview condition -- two motivational interview sessions are conducted during the first month of this six month study participation.
45971484|NCT02277535|Other|Feedback/Reminder email.|
45971485|NCT02484664|Drug|Celecoxib|We will perform a pilot clinical trial to investigate the safety and tolerability of celecoxib therapy as a single agent for patients with LAM. LAM subjects who are not taking everolimus or rapamycin will be treated with celecoxib at 200mg PO QD for 6 months. They will be monitored for respiratory function and angiomyolipoma size. At the end of the 6 month period, celecoxib will be discontinued, and subjects will be monitored for another 6 months.
45828387|NCT05137054|Drug|Lenalidomide|Lenalidomide is administered by mouth (PO) as a capsule
45828388|NCT05137054|Drug|Bortezomib|Bortezomib is administered by IV infusion or SC injection
45971486|NCT00200330|Behavioral|Behavioral weight loss treatment|
45971487|NCT00200330|Behavioral|Behavioral and home environment weight loss treatment|
45971488|NCT00257868|Drug|Rivastigmine prevention of delirium|
45971489|NCT00176605|Drug|Etoposide|50 mg per day of Etoposide orally for 21 consecutive days. Etoposide will be alternated with oral cyclophosphamide. The drug is administered at night just prior to bed. Week 1 of each cycle will begin with etoposide.
45971490|NCT00176605|Drug|Cyclophosphamide|50 mg per day of cyclophosphamide orally for 21 consecutive days. Cyclophosphamide will be alternated with oral etoposide. The drug is taken 2 hours after breakfast. The patient will be asked to increase hydration throughout the day. Recommendation is at least 6, 8oz glasses of water or other non-caffeinated beverage. Week 4 of the each cycle will begin with cylcophosphamide. Chronic administration of cyclophosphamide at this dose has been well tolerated
45971491|NCT00200369|Device|MEMS cap|
45971492|NCT00176488|Drug|epirubicin|Epirubicin (100 mg/m2) will be given on Day 1
45828389|NCT05137054|Drug|Pomalidomide|Pomalidomide is administered by mouth (PO) as a capsule
45828390|NCT05137054|Drug|Isatuximab|Isatuximab is administered by IV infusion
45828391|NCT05137054|Drug|Fianlimab|Fianlimab is administered by IV infusion
45828392|NCT05137054|Drug|Cemiplimab|Cemiplimab is administered by IV infusion
45828393|NCT05137054|Drug|Nirogacestat|Nirogacestat is administered by mouth (PO) as a tablet
45828394|NCT05135000|Drug|LTP001|LTP001 will be administered orally once daily in the morning
45828395|NCT05135000|Drug|Placebo|Placebo to LTP001 will be administered once daily in the morning
45971493|NCT00176488|Drug|vinorelbine|Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17.
45971494|NCT00200447|Drug|carbidopa/l-dopa|
45971495|NCT00200447|Drug|carbidopa/l-dopa/entacapone|
45971496|NCT00200447|Drug|Stalevo|
45971497|NCT00200447|Procedure|[123I]-IBZM imaging|
45971498|NCT00237120|Drug|Imatinib|
45971499|NCT00175825|Other|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 7-week Treatment Period
45971500|NCT00175825|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam over the 7-week Treatment Period
45971501|NCT04710329|Drug|Ascorbic acid|The daily administration of 6 grams of vitamin C intravenously in 4 equal doses every 6 hours occurred and the treatment lasted 96 hours. Vials containing 1.5 gr vitamin C were placed in 100 cc 5% dextrose and infused intravenously in 30-60 minutes. Prepared serum bottles and sets are wrapped with aluminum foil in order to protect them from sunlight.
45971502|NCT00257946|Procedure|Repair of CDH w/SIS Gold|
46081407|NCT04548661|Procedure|Intraoperative incisional wound irrigation with povidone-iodine solution|Participants randomized to the povidone-iodine irrigation group will have all incisions irrigated once with povidone-iodine diluted in 0.9% sterile normal saline (to a final concentration of 5% povidone-iodine (0.5% available iodine)) delivered through a bulb syringe. The povidone-iodine irrigation should be left on for 60 seconds and then dried with sterile gauze. Irrigation will be performed after any/all deep tissue layers are closed, prior to skin closure. The volume used will be left to the discretion of the clinician and irrigation will be administered until saturation is achieved.
46081408|NCT04548661|Procedure|Intraoperative incisional wound irrigation with saline|Participants randomized to the saline irrigation group will have all incisions irrigated once with 0.9% sterile normal saline delivered through a bulb syringe. Irrigation will be performed after any/all deep tissue layers are closed, prior to skin closure. The volume used will be left to the discretion of the clinician and irrigation will be administered until saturation is achieved.
45971503|NCT00257946|Procedure|Repair of CDH w/Alloderm|
45971504|NCT00257985|Drug|GTN|
45971505|NCT00200525|Drug|apomorphine HCl injection|
45971506|NCT00174967|Drug|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.
45971507|NCT00174967|Drug|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily for up to 4 weeks.
45971508|NCT00174967|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 4 weeks.
45971509|NCT00174967|Drug|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily for up to 4 weeks.
45971510|NCT00200564|Drug|ketamine|
45971511|NCT00174265|Drug|asenapine|5-10 mg sublingually twice daily for 26 weeks
45971512|NCT00174265|Drug|olanzapine|5-20 mg by mouth once daily for 26 weeks
45971513|NCT00200603|Device|calcium phosphate macroporous bioceramics|
45971514|NCT00258024|Drug|IPT-sulphadoxinepyrimethamine|
45971515|NCT00200642|Device|Stretta® System|
45971516|NCT00200681|Drug|Velcade|
45971517|NCT00258063|Drug|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).|
45669737|NCT04567108|Behavioral|Maintain SSBs (Control)|Instruction/guidelines to maintain baseline intake of SSBs; select from approved beverages for a monthly at-home delivery; engage with a motivational mobile app to track beverage intake
45971518|NCT00200720|Behavioral|Atkins diet (low carbohydrate diet)|
45971519|NCT00200720|Behavioral|DASH diet (high carbohydrate diet)|
45971520|NCT00258102|Drug|Levofloxacin|
45971521|NCT00200759|Drug|Cranberry juice and capsules|
45971522|NCT00265278|Drug|Modafinil|
45971523|NCT00258141|Drug|Rupatadine|
45971524|NCT00258141|Drug|Placebo|
45971525|NCT00265356|Procedure|PET diagnostic imaging|PET diagnostic imaging
45971526|NCT00200876|Procedure|Hypertonic saline|To elicit pain
45971527|NCT00200876|Procedure|Isotonic saline|Non-painful control
45971528|NCT00258258|Drug|paricalcitol|
45971529|NCT00258258|Drug|zoledronic acid|
45971530|NCT00200954|Dietary Supplement|Probiotic bacteria|3 x 10e9 CFU of a mixture of probiotic bacteria, once daily to the pregnant mothers last 6 weeks of pregnancy.To their offspring during the first year of life.
45971531|NCT00200954|Dietary Supplement|Placebo|The placebo consists of the carrier of the probiotic bacteria mixture, i.e. rice starch and maltodextran
45971532|NCT00265434|Drug|Pulmozyme|
45971533|NCT00172042|Drug|Zoledronic acid 4 mg|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride or 5% glucose solution).
45971534|NCT00200993|Behavioral|physical activity|
45971535|NCT00258297|Drug|gefitinib|
45971536|NCT00258297|Procedure|conventional surgery|
45971537|NCT00258297|Procedure|enzyme inhibitor therapy|
45455859|NCT05570591|Device|2RT subthreshold nanosecond laser - active|The 2RT™ Q-switched YAG laser (532nm) delivering 3 nanosecond pulses; 400 um spot size, is a pulsed subthreshold nanosecond (SNL) laser, which uses low energy levels to produce limited effects that selectively target melanosomes within the pigmented retinal pigment epithelial (RPE) cells.
45669738|NCT04567108|Behavioral|Substitute Aspartame ASBs|Instruction/guidelines to eliminate SSBs and replace, where possible with beverages artificially sweetened with aspartame; select from approved beverages for a monthly at-home delivery; engage with a motivational mobile app to track beverage intake
45669739|NCT04567108|Behavioral|Substitute Sucralose ASBs|Instruction/guidelines to eliminate SSBs and replace, where possible with beverages artificially sweetened with sucralose; select from approved beverages for a monthly at-home delivery; engage with a motivational mobile app to track beverage intake
45669740|NCT04567108|Behavioral|Substitute Water|Instruction/guidelines to eliminate SSBs and replace with water; select from approved beverages for a monthly at-home delivery; engage with a motivational mobile app to track beverage intake
45828396|NCT05129670|Device|Calcite chewing gum|The calcite chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
45971538|NCT00258297|Procedure|neoadjuvant therapy|
45971539|NCT00258297|Procedure|protein tyrosine kinase inhibitor therapy|
45971540|NCT00258297|Procedure|surgery|
45971541|NCT00201110|Behavioral|Problem Solving Skills|Intensive Intervention: CVD Risk Self-Management Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)
45971542|NCT00201110|Behavioral|Problem Solving Skills|Brief Intervention: CVD Risk Self-Management Education (1 session) + Brief Problem-Solving Training (1 session)
45971543|NCT00201149|Behavioral|Patient-centered Counseling|To improve patients' adherence with prescribed anti-hypertensive medication, improve blood pressure control and doctor-patient communication, we propose a three-armed randomized controlled trial in the internal medicine clinics of a large metropolitan teaching hospital which serves a large percentage of poor African American and white patients. We will implement an intervention strategy by teaching clinicians to counsel patients about hypertension control through the use of patient-centered counseling and by providing office-based support; critical to facilitating clinicians' use of this strategy. Through this intervention we will provide clinicians with communication skills that are proven to help patients change risk-related behaviors, and which will enhance doctor-patient communication.
45971544|NCT00201188|Behavioral|Status Reports|Interpreted Analysis of Peak-Flow Monitoring Trends
45971545|NCT00258336|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
45971546|NCT00258336|Biological|rituximab|
45669741|NCT01753570|Drug|MP-424|MP-424: 750mg every 8 hours (q8h) for 12 weeks
45669742|NCT01753570|Drug|RBV(24 weeks)|RBV: 600 - 1000mg/day based on body weight for 24 weeks
45669743|NCT01753570|Drug|IFN beta(24 weeks)|IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 24 weeks
45828397|NCT05129670|Device|Unmatched Placebo chewing gum|The placebo chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
45971547|NCT00258336|Biological|sargramostim|
45971548|NCT00171925|Drug|Zoledronic acid|Zoledronic acid administered via normal saline intravenous infusion (over 15 minutes) every 4 weeks. Dosage was according to calculated creatinine clearance: patients with baseline creatinine clearance > 60 ml/min received 4 mg; for patients with mild to moderate renal impairment, doses were calculated to achieve the same AUC as that achieved in patients with creatinine clearance of 75 ml/min, assuming target AUC of 0.66 (mg*hr/l).
45455860|NCT05570591|Device|2RT subthreshold nanosecond laser - sham|Application of sham laser (i.e. flashing lights which replicate the look of active laser to the participant) from the 2RT subthreshold nanosecond laser device.
45669744|NCT01753570|Drug|RBV(48 weeks)|RBV: 600 - 1000mg/day based on body weight for 48 weeks
45669745|NCT01753570|Drug|IFN beta(48 weeks)|IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 48 weeks
45669746|NCT01753336|Biological|Botulinum toxin type A|Dysport® (intramuscular injection), Up to 500 units (U)/vial using 2mL dilution, 3 treatment cycles
45828398|NCT05128617|Drug|Epirubicin-cyclophosphamide|1 cycle of Epirubicin-cyclophosphamide
45828399|NCT05128617|Drug|Paclitaxel|1 cycle of Paclitaxel
45828400|NCT05110261|Drug|Nirsevimab|Drug: injection, 100 mg/mL, a single fixed IM dose of 50 mg (if weight < 5 kg) or 100 mg (if weight ≥ 5 kg)on day 1 only.
45971549|NCT00171925|Dietary Supplement|Calcium / Vitamin D|Patients on zoledronic acid received 500 mg calcium and 400-500 IU vitamin D combination tablet daily.
45971550|NCT00258375|Drug|custirsen sodium|
45971551|NCT00258375|Drug|docetaxel|
45971552|NCT00201227|Other|practice guideline adherence|Project facilitator assist primary care practice clinicians and staff work in effective quality improvement teams through the use of facilitated collaborative meetings.
45971553|NCT00258453|Other|metabolic assessment|
45971554|NCT00258453|Other|physiologic testing|
45971555|NCT00258453|Procedure|biopsy|
45971556|NCT00258453|Procedure|computed tomography|
45971557|NCT00258453|Procedure|conventional surgery|
45971558|NCT00258453|Procedure|magnetic resonance imaging|
45971559|NCT00258453|Procedure|management of therapy complications|
45971560|NCT00258453|Procedure|psychosocial assessment and care|
45971561|NCT00258453|Procedure|quality-of-life assessment|
45971562|NCT00258453|Radiation|radiation therapy|
45971563|NCT00201266|Procedure|Screening|Characterization tests including blood group typing, measures of lung function, measures of allergy, and collection of DNA.
45971564|NCT00201305|Drug|Gemcitabine+5FU+Leucovorin|
45669747|NCT01777282|Drug|Albiglutide|Albiglutide is a fixed-dose, fully disposable pen injector system for delivery of albiglutide from a prefilled dual chamber glass cartridge that is an integral part of the pen. It is intended for single use by the subject. It is designed for manual reconstitution of the dose, priming, and insertion of the pen needle, and manual injection by the subject. The subject will inject albiglutide 30 mg weekly for 52 weeks (with optional uptitration to 50 mg weekly) subcutaneously into the abdomen, alternating between left and right sides. The pen is designed to work with standard pen needles.
45828401|NCT05110261|Drug|Placebo|Commercially available 0.9% (w/v) saline (sterile for human use) fixed IM dose of 0.5 mL (if weight <5 kg) or 1.0 mL (if weight >=5 kg)
45828402|NCT05107375|Biological|Tetravalent influenza virus lysis vaccine|Influenza virus lysis vaccine, one dose at a time, each dose 0.5mL, containing each influenza virus strain hemagglutinin 15μg.
45828403|NCT05107375|Biological|Recombinant new coronavirus vaccine (CHO cell) group|One dose of recombinant Novel Coronavirus vaccine (CHO cells) was administered at 0.5mL each dose, containing 25μg nCP-RBD protein.
45828404|NCT05101213|Biological|Virus-specific Cytotoxic T-lymphocytes|Given IV
45828405|NCT05101148|Drug|Selumetinib|The dosing regimen for selumetinib (25 mg/m2 bid) will be based on BSA, during T1 and T2 the dose will be 25mg/m2, consistent with the approved prescribing information in the US. If T3 is required, appropriate dose of selumetinib will be defined by Data Review Committee for T3.
45828406|NCT05094128|Drug|Upadacitinib|Tablet; Oral
45828407|NCT05090033|Other|ofatumumab|There is no treatment allocation. Patients administered ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
45828408|NCT05084391|Device|stereotactic ablative radiotherapy (SABR)|is safe for treating heart arrhythmias (irregular heartbeat
45828409|NCT05084391|Other|Standard of Treatment|Standard of care
45828410|NCT05083442|Device|Low Level Laser Therapy|Non-surgical cosmetic treatment which can be used by individuals intending to reduce size of the mid-section
45828411|NCT05083442|Other|Sham (placebo)|Use of sham (placebo) option
45828412|NCT05070858|Drug|Pozelimab + Cemdisiran|Subcutaneous administration as described in the protocol
45971565|NCT00258492|Behavioral|Aerobic exercise|
45971566|NCT00265551|Drug|SCA-136 (200 mg)|
45971567|NCT00265551|Drug|SCA-136 (400 mg)|
45669748|NCT01777282|Drug|Sulfonylurea|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
45669749|NCT01777282|Drug|Biguanide|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
45971568|NCT00265551|Drug|olanzapine (15 mg)|
45971569|NCT00265551|Drug|placebo|
45971570|NCT00201344|Drug|Cisplatin,5-FU,Leucovorin|
45971571|NCT00265629|Device|RF catheter ablation|RF ablation using mesh device
45971572|NCT00201383|Drug|cisplatin|
45971573|NCT00201422|Other|Omeprazole, Amoxicillin, Clarithromycin|Omeprazole20 mg,Clarithromycin500 mg b.i.d.,Day 1-14 plus Amoxicillin 500 mg q.i.d.,Day 1-14 plus
45971574|NCT00258531|Device|Olympus ScopeGuide®, 3-dimentional magnetic imager|
45971575|NCT00201461|Device|STARFlex septal closure system|transcatheter placement of STARFlex device to close a patent foramen ovale
45971576|NCT00201461|Drug|Best medical therapy|aspirin (325 mg daily) and/or warfarin (target INR = 2.5)
45971577|NCT00258609|Drug|Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection|
45971578|NCT00265707|Device|Blood pressure measurement|
45971579|NCT04709367|Other|3D optical scan|The clinical protocol consisted of four test sessions in four different days for an overall duration of 3 weeks. During the 1st session, amputees' residual limb volume was measured 7 times at intervals of 10 minutes after the prosthesis removal. During the subsequent sessions, the residual limb volume was measured immediately after the prosthesis doffing and after the amputee's stabilization time, before and after 15-min of walking on a treadmill, both in the morning and in the afternoon.
45971580|NCT00265746|Drug|Metformin|
45971581|NCT00265746|Behavioral|Lifestyle intervention - diet, physical activity|
45971582|NCT00201539|Drug|single dose Morphine|
45971583|NCT00201539|Drug|double dose Morphine|
45971584|NCT00201539|Drug|placebo|purchased from the manufacturer of morphine tablets (Nycomed Pharma, Oslo, Norway)
45971585|NCT04709055|Other|Co-management|Personalized and intensive geriatric peri-operative care
45971586|NCT04709055|Other|Usual care|Pre-operative and post-operative geriatric care as per usual practice
45971587|NCT00201617|Device|Bone-anchored hearing aid|
45971588|NCT04709328|Drug|SCTA01|Diluted by 0.9% normal saline，IV
45971589|NCT04709328|Other|Placebo|IV
45971590|NCT00258687|Biological|GVAX|4 vaccines every two weeks
45971591|NCT00201656|Procedure|Retention of Cerclage|Retain Cerclage until clinical removal is indicated by protocol
45971592|NCT00201656|Procedure|Removal of Cerclage|Immediate removal of Cerclage following randomization
45971593|NCT00201656|Procedure|Removal vs. Retention of Cervical Cerclage|Immediate removal of cerclage following randomization vs. retention of cerclage until labor, chorioamnionitis, or fetal distress
45971594|NCT00265824|Drug|bevacizumab|bevacizumab 7.5mg/kg every 3 weeks until disease progression or limiting toxicity
45971595|NCT00265824|Drug|bevacizumab, erlotinib|bevacizumab 7.5mg/kg and oral erlotinib 150 mg/day continuously Cycles every 3 weeks until disease progression or limiting toxicity
45828413|NCT05070858|Drug|Cemdisiran|SC administration as described in the protocol
45971596|NCT00201695|Drug|Doxil®|40 mg/m2 IV day 1
45971597|NCT00201695|Drug|Vincristine|1.4 mg/m2 (maximum 2 mg) IV day 1
45971598|NCT00201695|Drug|Dexamethasone|40 mg PO days 1-4
45971599|NCT00201695|Drug|Arsenic Trioxide|0.25 mg/kg IV over 1-4 hours twice per week, week 1-4 of each cycle (i.e., days 1 and 4; 8 and 11; 15 and 18; 22 and 25)
45971600|NCT00258726|Biological|MMR-II|
45971601|NCT00258726|Biological|Pro-Quad|
45971602|NCT00258726|Biological|Varivax|
45971603|NCT00410345|Drug|Mifepristone|
45971604|NCT00265863|Drug|mitomycin C|Mitomycin C is infused into the abdominal cavity by hyperthermic perfusion over 60 minutes.
45971605|NCT00410462|Drug|brostallicin|
45971606|NCT00410462|Drug|doxorubicin hydrochloride|
45971607|NCT00258765|Drug|Zoledronic Acid|
45971608|NCT00258765|Drug|Docetaxel|
45971609|NCT00410501|Drug|Indacaterol (QAB149)|
45971610|NCT00265902|Procedure|diagnostic imaging|
45971611|NCT00410540|Drug|OROS hydromorphone HCL ; Morphine sulfate|
45828414|NCT05070858|Other|Placebo|SC administration as described in the protocol
45971612|NCT00258804|Drug|Insulin glargine|
45971613|NCT00201812|Drug|Etanercept|7 days prior to treatment with docetaxel. Administered twice weekly throughout the study.
45971614|NCT00201812|Drug|Docetaxel|Administered intervenously (IV) over 30 minutes through an infusion pump once a week (every 7 days). A cycle will comprise six weekly treatments followed by 2 weeks of rest.
45971615|NCT00201812|Drug|Dexamethasone|Administered orally 8 mg 12 hours prior to docetaxel, immediately prior to docetaxel (two hours after etanercept), and 12 hours after docetaxel to complete a total of 3 doses (total dose 24 mg/week) on treatment weeks.
45971616|NCT00258843|Biological|Inactivated Poliomyelitis vaccine|0.5 mL, intramuscular (IM)
45971617|NCT00258843|Biological|Inactivated Poliomyelitis vaccine|0.5 mL, IM
45971618|NCT00201890|Procedure|Lymphatic Massage (Decongestive Lymphatic Therapy) (Arm 1)|20 weeks of lymphatic massage therapy by a certified LMT in the Vodder technique Elastic Compression Sleeve and GLove
45971619|NCT04709094|Drug|Danicopan|Danicopan was dosed as 2 x 100 milligram (mg) tablets.
45971620|NCT04709094|Drug|Warfarin|Warfarin was dosed as 2 x 10 mg and 1 x 5 mg warfarin sodium tablets (Coumadin or generic equivalent).
45828415|NCT05070858|Drug|Pozelimab|SC administration as described in the protocol
45828416|NCT05065957|Drug|D07001-softgel capsules + Xeloda (or TS-1)|"D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle).~Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)"
45828417|NCT05065957|Drug|mFOLFOX|intravenous infusion on Day 1 for 14-day cycle
45828418|NCT05051241|Drug|GFH018|Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen.
45828419|NCT05046808|Drug|Famitinib Malate Capsules|Famitinib Malate Capsules 10mg single dose
45828420|NCT05046808|Drug|Famitinib Malate Capsules|Famitinib Malate Capsules 15mg single dose
45828421|NCT05046808|Drug|Famitinib Malate Capsules|Famitinib Malate Capsules 20mg single dose
45971621|NCT04709094|Drug|Bupropion|Bupropion was dosed as Wellbutrin (or generic equivalent) as 1 x 100 mg tablet.
45971622|NCT04709094|Drug|Ethinyl Estradiol/Norethindrone|EE/NET (0.035 mg/1 mg) was dosed as Ortho-Novum-1/35 (or generic equivalent) fixed-dose combination tablets.
45971623|NCT00201929|Procedure|Standard Decision Board|
45971624|NCT00201929|Procedure|Computer Decision Board|
45971625|NCT00201929|Procedure|Paper Decision Board|
45971626|NCT00171340|Drug|Zoledronic acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.
45971627|NCT00171340|Drug|Letrozole|Letrozole tablets 2.5 mg/day taken orally for 5 years.
45971628|NCT00266019|Behavioral|Weight Management (diet, exercise, and behavior modification)|
45971629|NCT00201968|Device|Compex Motion Stimulator|Functional Electrical Stimulation applied to the lower limbs of SCI individuals in order to stimulate walking while on Body Weight Support Treadmill
45971630|NCT00201968|Device|Compex Motion Stimulator|Specific functional electrical stimulation program developed for each individual applied while walking on the treadmill.
45971631|NCT00201968|Other|Conventional Exercise|An aerobic and resistance training program.
45971632|NCT00202007|Drug|Aripiprazole tablet, 5-30mg/day, oral, 6 weeks|
45971633|NCT00202007|Drug|Risperidone tablet, 1-6mg/day, oral, 6 weeks|
45971634|NCT00171301|Drug|Deferasirox|Deferasirox was administered orally once daily. Deferasirox was available as 125 mg, 250 mg, and 500 mg tablets.
45971635|NCT00266058|Drug|Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine|participants receive a total of 6 doses of artemether(80mg)/lumefantrine(480mg)for baseline PK evaluation. This is followed by a 26-day course of either efavirenz(600mg) once daily or lopinavir/ritonavir (400mg/100mg) twice daily and additional 6 doses of artemether/lumefantrine to determine the pharmacokinetics of the antimalarial medications in the context of antiretrovirals. The participants undergo at least a 14 day washout period (between the last baseline PK blood draw and the initiation of antiretrovirals)
45971636|NCT00171223|Drug|STI571|STI571 oral capsules or tablets.
45971637|NCT00202124|Drug|Tryptophan|
45971638|NCT04571905|Device|Osteosynthesis with resorbable Material|Osteosynthesis with Magnezix screws in fractures of the Epicondylus ulnaris and Condylus radialis under General anaesthesia
45971639|NCT00266097|Drug|erlotinib hydrochloride|Cohort (-1) = 50 mg daily Cohort 1 = 50mg daily Cohort 2= 75 mg daily Cohort 3 = 100mg daily Cohort 4 = 100mg daily Cohort 5 = 150mg daily
45971640|NCT00266097|Drug|gemcitabine hydrochloride|Gemcitabine will be given at a dose of 100 mg/m2 for the first cohort and escalated to a fixed dose of 200 mg/m2 for the remaining 3 cohorts
45971641|NCT00266097|Drug|oxaliplatin|Oxaliplatin will be given at 30 mg/m2 weekly for the first two cohorts and then will be dose-escalated to 45 mg/m2 and 60 mg/m2 for the next 2 in cohorts
45971642|NCT00266097|Radiation|radiation therapy|5040 cGy, every week, up to 6 weeks
45971643|NCT00266097|Drug|gemcitabine hydrochloride|Given weekly at a starting dose of 100mg/m2 in the first 3 cohorts and dose escalated to 200 mg/m2 for the remaining 2 cohorts
45971644|NCT00266097|Drug|Oxaliplatin|The Part II dose of oxaliplatin will be determined by Part I of the study. The dose for Part II will be one dose level increase from the MTD determined in Part I.
45971645|NCT00470236|Radiation|Standard WB fractionation|A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
45971646|NCT00470236|Radiation|Shorter WB fractionation|A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
45971647|NCT00470236|Radiation|Standard WB fractionation+Boost|"Whole Breast: A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).~Tumour bed: A total dose of 10 Gy in 5 fractions in 2-Gy daily fractions, 5 fractions per week."
45971648|NCT00470236|Radiation|Shorter WB fractionation + Boost|"Whole breast: A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).~Tumour bed: A total dose of 10 Gy in 4 fractions in 2.5-Gy daily fractions, 4 fractions per week."
45828422|NCT05046808|Drug|Famitinib Malate Capsules|Famitinib Malate Capsules 10mg*2 single dose
45971649|NCT00202163|Drug|DHEA|
45971650|NCT00202163|Drug|Testosterone|
45971651|NCT00258999|Device|Skin Cholesterol Testing|
45971652|NCT00476554|Drug|Sapacitabine|Sapacitabine
45828423|NCT05046808|Drug|Famitinib Malate Capsules|Famitinib Malate Capsules 25mg single dose
45971653|NCT00476125|Behavioral|Dietary manipulation ketogenic diet|Subjects will consume a ketogenic diet for 3 days.
45971654|NCT00476125|Behavioral|Dietary Manipulation - 12 day ketogenic diet|Subjects will consume a ketogenic diet for 12 days.
45971655|NCT00476125|Behavioral|16 Hour Fast|Subjects will fast for 16 hours.
45971656|NCT00202202|Procedure|consultation format|
45828424|NCT05043090|Drug|savolitinib|Tablets : 3 × 200 mg tablets once daily
45828425|NCT05043090|Drug|durvalumab|Concentrate for solution for IV infusion : 1500 mg durvalumab every 4 weeks
45828426|NCT05043090|Drug|sunitinib|Capsules : 2 x 25mg capsules once daily 4 weeks on, 2 weeks off
45971657|NCT04709289|Other|Aminolevulinic acid, photodynamic therapy|Aminolevulinic acid, photodynamic therapy
45971658|NCT00202241|Procedure|testosterone injection|
45455861|NCT05570227|Other|[U-13C]Glucose Infusion|Peri-operative infusion of [U-13C]glucose
45828427|NCT05036278|Biological|Damoctocog alfa-pegol (Jivi, BAY94-9027)|"Dosage Levels:~40 IU/kg/dose two times per week~50 IU/kg/dose every 5 days, total recommended maximum dose/infusion is 6000 IU~60 IU/kg/dose, Less frequent dosing (e.g. every 7 days), the total recommended maximum dose/infusion is 6000 IU."
45828428|NCT05031520|Procedure|Coronary computed tomography angiography (CCTA)|Participants will undergo CCTA. CCTA performed in this study will be technically identical to CCTA that is commonly performed in clinical practice, for which safety profiles are well defined. Guidelines implemented by the National Institutes of Health Radiation Exposure Committee will be followed. Major risks of CCTA include exposure to ionizing radiation, the requirement for intravenous catheter placement and contrast media administration, and side effects of beta-blockers and nitrates that may be used for vasodilation and heart rate control to optimize CCTA image quality.
45828429|NCT05031520|Drug|Isovue|CCTA requires intravenous catheter placement and the administration of iodinated contrast media (Isovue).
45828430|NCT05031520|Drug|Nitroglycerin|Medication to promote coronary vasodilation during the CCTA may be administered immediately prior to CCTA to optimize image quality
45971659|NCT00266136|Drug|Cytarabine|see protocol
45971660|NCT00266136|Drug|Thioguanine|see protocol
45971661|NCT00266136|Drug|Daunorubicin|see protocol
45971662|NCT00266136|Drug|Cyclophosphamide|see protocol
45971663|NCT00266136|Drug|G-CSF|see protocol
45971664|NCT00266136|Procedure|Autologous stem cell transplantation|for details see protocol
45971665|NCT00266136|Procedure|Allogeneic stem cell transplantation|for details see protocol
45971666|NCT00230555|Behavioral|professional support model|
45971667|NCT00259038|Drug|Carperitide|
45971668|NCT00259038|Drug|Placebo|
45971669|NCT00230594|Drug|desmopressin|desmopressin 120 mcg melt tablet; 120 mcg, 240 mcg or 360 mcg administered once daily before bedtime
45971670|NCT00230594|Drug|placebo|placebo melt tablet; 1 to 3 placebo melt tablets administered once daily before bedtime
45971671|NCT00259077|Drug|Omeprazole|
45971672|NCT00479674|Drug|Abraxane|100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..
45971673|NCT00479674|Drug|Bevacizumab|10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.
45971674|NCT00479674|Drug|Carboplatin|area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death.
45971675|NCT02962310|Drug|Torrent's Rosuvastatin Calcium Tablets 40 mg|oral, crossover
45971676|NCT02962310|Drug|Crestor 40 mg Tablets of AstraZeneca LP, USA|oral, crossover
45669750|NCT01777282|Drug|Glinide|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
45971677|NCT00259116|Drug|Relaxin|
45971678|NCT00415779|Drug|docetaxel|given IV in subsequent cohorts of patients at 30, 40, or 50mg/m2
45971679|NCT00415779|Drug|zoledronic acid|2 mg IV every 2 weeks
46081409|NCT04544436|Drug|Ocrelizumab|The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (participants's body weight <75 kg) or 1800 mg (participant's body weight >/=75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg intravenous (IV) infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion every 24 weeks.
45828431|NCT05031520|Drug|Metoprolol|Medication to promote heart rate reduction during the CCTA may be administered immediately prior to CCTA to optimize image quality
45971680|NCT00230711|Behavioral|Physical activity counseling|
45971681|NCT00259155|Drug|Rifaximin|
45971682|NCT00230750|Biological|Influenza A/H5N1 Vaccine|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 90-mcg/mL. Dosages: 45 mcg or 90 mcg administered intramuscularly.
45971683|NCT00230750|Drug|Placebo|Saline placebo.
46081410|NCT04544436|Drug|Ocrelizumab|Ocrelizumab will be administered at a dose of 600 milligram (mg) every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg intravenous (IV) infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
46081411|NCT04544436|Drug|Antihistamine|Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
45669751|NCT01777282|Drug|Thiazolidinedione|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
45669752|NCT01777282|Drug|Alpha-glucosidase inhibitor|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
45828432|NCT05027906|Drug|AT-1501|Investigative Arm
45828433|NCT05021133|Behavioral|Tele-Navi LCS|Tele-Navi of LCS includes: telehealth coaching from a Tele-Navigator for patients undergoing LCS to access a patient portal and a video-call system.
45828434|NCT05019950|Drug|NIM-1324|Once daily oral tablet
45828435|NCT05019950|Drug|Placebo|Once daily oral tablet
45971684|NCT00479401|Drug|Pramipexol Extended Release|
45971685|NCT00479401|Drug|Pramipexol Immediate Release|
45971686|NCT00479401|Drug|Placebo|
45971687|NCT00415818|Biological|MVA-MUC1-IL2|"MVA-MUC1-IL2:~Dose of 10exp8 plaque forming units (pfu).~Chemotherapy:~Arm 1 and Arm 2 Intravenous CT: cisplatin (75mg/m² at Day 1) and gemcitabine (1250mg/m² at Days 1 and 8) every 3 weeks, for up to six cycles or until progressive disease, whichever occurred first."
45971688|NCT00415818|Drug|1st line Chemotherapy|
46081412|NCT04544436|Drug|Methylprednisolone|Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
46081413|NCT04537156|Biological|Nonavalent HPV vaccine|Nonavalent HPV vaccine (270μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
46081414|NCT04537156|Biological|Bivalent HPV vaccine|Bivalent HPV vaccine (60μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
45828436|NCT05018650|Device|Route 92 Medical Reperfusion System|Mechanical thrombectomy for acute ischemic stroke patients with large vessel occlusions will be performed with direct aspiration consisting of navigating a large-bore catheter up to the face of the clot and initiating vacuum suction.
45828437|NCT05018585|Biological|Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®|Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®
45828438|NCT05018585|Dietary Supplement|Colecalciferol 2000 IU|Colecalciferol (vitamin D3) 2000 IU (equivalent to 50 microgram vitamin D3).
45828439|NCT05018585|Biological|Placebo for recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®|Placebo for Diamyd, Alhydrogel® only
45828440|NCT05012813|Other|Aromatherapy with Essential Oils|Participate in SFIT this is one intervention with aroma therapy with essential Forest oils
45971689|NCT00230789|Drug|Tolterodine ER 4 mg QD|
45971690|NCT00230789|Behavioral|OAB Patient Behavioral Training Material|
45971691|NCT00230828|Drug|bifeprunox|
45971692|NCT02962544|Procedure|FS-SMILE|The procedure will be performed using an established technique. the patient's eye will be centered and docked with the curved interface cone before application of suction fixation.The laser will be activated for photo-dissection in the following sequence: first the posterior surface of the refractive lenticule then the lenticule border then The anterior surface of the refractive lenticule which extended beyond the posterior lenticule diameter by 0.5 mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the cap near the hinge before the cap is separated. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula. The lenticule is then grasped with forceps through the small incision.
45971693|NCT02962544|Procedure|FS- LASIK|LASIK procedure Each LASIK procedure will be performed using a standard, established technique. Under topical anesthesia and standard draping, a lid speculum is used to retract the eyelids. A superiorly hinged 100 μm thick flap will be created using the WaveLight FS200 (Alcon Laboratories, Inc.) With inverted side cut (115 ̊) .Excimer laser ablation is then performed using WaveLight EX500 excimer laser (Alcon Laboratories, Inc.).After ablation, the flap will be carefully repositioned, and postoperative medications are commenced.
45971694|NCT02962544|Device|Visumax device|
45971695|NCT02962544|Device|FS 200 device|
45971696|NCT00415896|Device|positive pressure ventilation|
45971697|NCT00478777|Drug|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression.
45971698|NCT00478777|Drug|dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4 (approximately months 1-4). Beginning cycle 5 (approximately month 5) dexamethasone is reduced to 40 mg daily for days 1-4 every 28 days.
45971699|NCT00477607|Drug|alpha-lipoic acid|Supplements (1200mg once a day) or placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
45971700|NCT00477607|Behavioral|Audiology|otoscopy, immittance screening, noise exposure questionnaire and individualized behavioral pure-tone in the convention and high-frequency ranges.
45971701|NCT00477607|Biological|laboratory biomarker analysis|Plasma concentrations of Malondialdehyde (MDA) will be measures as an indicator of oxidative stress.
45971702|NCT00477607|Drug|Placebo|Placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
45971703|NCT00259194|Behavioral|Moving|The patients are allowed to lift their head, arms and legs during the 2 hours.
45971704|NCT00259194|Behavioral|No Moving|The patients are told not to move, to keep their legs and upper arms down and not to lift the head from the pillow in these 2 hours.
45971705|NCT00259233|Drug|peripheral Peptide YY administration|
45971706|NCT00230867|Device|iontophoretic acyclovir|
45971707|NCT00259311|Drug|LY2422347|
45971708|NCT00259311|Drug|placebo|
45971709|NCT00230906|Procedure|Haemodialysis with either low or high flux membranes|
45971710|NCT00266214|Drug|lidocaine patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime
45828441|NCT05007431|Other|Questionnaires|Data collection will be carried out by hetero-questionnaire carried out in the presence of the questioned.
45971711|NCT00259350|Drug|Skin disinfection|
45828442|NCT05003167|Device|Expiratory Muscle Strength Training (EMST-150)|All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure).
45455862|NCT05568329|Device|Hearing Aid Program|"Each subject will listen to recordings of music processed by seven different hearing aid brands set to the default Speech in Quiet program and the default Music program. Recordings (hearing aid brand x program x music sample) will be randomized from trial to trial."
45669753|NCT04169776|Device|Transcutaneous Auricular Vagus Nerve (taVNS) stimulation|Participants in this study will perform home transcutaneous auricular vagus nerve stimulation (taVNS) for 5 minutes a day for a 6-month period. The device that will be used is the commercially available Roscoe Medical TENS 7000 vagus nerve stimulator. The device will be attached to the Cymba Concha of the ear via an electrode ear clip. The intensity of the stimulation will be slowly increased and adjusted to individual tolerability for each treatment. TaVNS will be performed for 5 minutes daily for a period of 6 months.
45971712|NCT00230945|Behavioral|education and support intervention|The patient-oriented education and support intervention (PES) is based on the Arthritis Self-Management Program, a group intervention that consists of 6 weekly 2 hour sessions shown to successfully reduce pain severity and depressive symptomatology and to enhance a sense of efficacy in managing arthritis pain and other symptoms. The couple-oriented education and support intervention (CES) is a group education and support intervention that consisted of 6 weekly 2 hour sessions attended by individuals with OA and their spouses. All components of the PES are covered in the CES using the standard format, and topics are framed as couples' issues whenever possible.
45971713|NCT00266253|Drug|GK Activator (2)|Escalating doses, po bid or qd for 12 weeks.
45971714|NCT00266253|Drug|Metformin|As prescribed, for 12 weeks
45971715|NCT00230984|Behavioral|education|
45828443|NCT04994197|Other|Observational study only - no intervention|Observational study only - no intervention
45828444|NCT04989829|Drug|SHR6390、Omeprazole|SHR6390 tablet single dose、Omeprazol single dose.
45828445|NCT04988035|Drug|Danicopan|Danicopan is a small molecule, orally administered complement factor D (FD) inhibitor
45828446|NCT04988035|Other|Placebo|Danicopan matching placebo tablet
45828447|NCT04988035|Drug|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
45971716|NCT00230984|Drug|Oral dietary supplements (563 kcal/d), RESPIFOR|
45971717|NCT00230984|Behavioral|exercises on an ergometric bicycle 3 to 5 times a week|
45971718|NCT00230984|Drug|160 mg/d of oral testosterone undecanoate in men, 80 mg/d in women|
45971719|NCT00266292|Behavioral|Fish oil (Bio-Marine, Pharma Nord)|
45971720|NCT00266292|Behavioral|n-6 PUFA intake (Margarine+sunflower oil vs. butter product+rapeseed oil)|
45971721|NCT04721678|Behavioral|Interpersonal psychotherapy|Internet-based interpersonal psychotherapy aimed at reducing symptoms of depression. The content of the intervention is divided into three parts: the assessment phase (the first four weeks), the focus phase (the following five weeks), and the end phase (the last week).
45971722|NCT00415350|Drug|Azithromycin|Azithromycin Tablet 250 mg daily
45971723|NCT00415350|Other|Placebo|Placebo tablet 1 daily
45971724|NCT00231023|Drug|Peribulbar Triamcinolone Acetonide|
45971725|NCT00266331|Drug|Reduced glutathione|
45971726|NCT00231101|Drug|Quetiapine|
45971727|NCT00231140|Drug|Thalidomide (drug)|
45971728|NCT00415389|Behavioral|interactive educational program|2-session interactive stroke educational program
45971729|NCT00415389|Behavioral|usual medical care|standard educational materials and usual care
45971730|NCT00231218|Drug|dietary supplement--echinacea, propolis, and vitamin c|
45971731|NCT02961192|Behavioral|Supportive social incentive|A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
45971732|NCT02961192|Behavioral|Competitive social incentive|Participants in this intervention will be competing against each other in the game.
45971733|NCT02961192|Behavioral|Collaborative social incentive|Participants in this intervention will be working with each other in the game.
45971734|NCT00231296|Device|Cardiac CryoCor Cryoablation System|Treatment with CryoCor Cardiac Cryoablation system
45971735|NCT00231296|Drug|Medical management|Medical management- treatment with standard medical therapy, which includes anti-arrhythmic medications
46081415|NCT04536298|Dietary Supplement|vitamin D|Vitamin D softgel capsules; each capsule contains 3200 IU of vitamin D3. Three capsules per day (9600 IU/day) will be taken on days 1 and 2, and one capsule per day (3200 IU/day) will be taken on days 3 through 28
46081416|NCT04536298|Dietary Supplement|Placebo|Placebo softgel capsules. Three capsules per day will be taken on days 1 and 2, and one capsule per day will be taken on days 3 through 28
46081417|NCT04526990|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
45669754|NCT04571632|Drug|Avelumab|"Avelumab (200mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 40 mg (= 2 ml of a 200mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of avelumab (200mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions < 0,5 cm to 2.0 mL for lesions > 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required."
46081418|NCT04526990|Biological|Placebo|Intramuscular administration
46081419|NCT04526106|Drug|RLY-4008|RLY-4008 is an oral inhibitor of FGFR2
46081420|NCT04524208|Drug|Cabozantinib|Cabozantinib is administered orally at the dose of 60 mg per day..
46081421|NCT04522102|Drug|Start antiplatelet monotherapy|Start one antiplatelet drug, be available in local standard clinical practice, chosen by patient's physician pre-randomisation
46081422|NCT04512040|Behavioral|At-Home Yoga|At-home yoga practice over 12 weeks.
46081423|NCT04509674|Drug|Empagliflozin|Empagliflozin
46081424|NCT04509674|Drug|Placebo|Placebo
46081425|NCT04502030|Biological|Panzyga|Panzyga is a 10% IVIG produced from a pool of human fresh frozen plasma donations
46081426|NCT04502030|Other|Placebo|Placebo
45669755|NCT04571632|Drug|Ipilimumab 5 MG/ML|"Ipilimumab (50mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 10 mg (= 2 ml of a 50mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of ipilimumab (50mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions < 0,5 cm to 2.0 mL for lesions > 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required. Determination of ipilimumab (50mg/10mL solution) injection volume based on lesion size"
45971736|NCT00266448|Drug|Chlorhexidine solution 4%|
46081427|NCT04494256|Drug|BIIB105|Administered as specified in the treatment arm.
46081428|NCT04494256|Drug|Placebo|Administered as specified in the treatment arm.
46081429|NCT04483947|Drug|AZD2693|Subcutaneous administration of AZD2693 multiple ascending doses in participants with NASH and who are carriers of the PNPLA3 148M risk allele(s).
46081430|NCT04483947|Other|Placebo|Participants randomised to placebo will receive the corresponding dose volume of solution as participants receiving AZD2693 within the same cohort
46081431|NCT04476043|Drug|INCB054707|Oral; Tablet
46081432|NCT04476043|Drug|Placebo|Oral; Tablet
46081433|NCT04472429|Drug|carboplatin|carboplatin will be administered intravenous on Day 1 of each 28 day cycle
46081434|NCT04472429|Drug|paclitaxel|paclitaxel will be administered intravenous on Days 1,8, and 15 of each 28 day cycle
46081435|NCT04472429|Drug|retifanlimab|retifanlimab will be administered intravenous on Day 1 of each 28 day cycle
46081436|NCT04468607|Drug|BLYG8824A|BLYG8824A will be administered at a flat dose independent of body weight.
46081437|NCT04465318|Other|E-cigarette (EC)|NJOY Daily E-cigarettes are self-contained and non-refillable. Each DAILY provides approximately 300 puffs, comparable to a full pack of cigarettes.
45971737|NCT00415428|Behavioral|Patient adherence to national educational guidelines.|
45971738|NCT00231335|Drug|escitalopram|
45971739|NCT00266487|Drug|Folic acid|
45971740|NCT00266487|Drug|Vitamin B12|
45971741|NCT00266487|Drug|Vitamin B6|
45971742|NCT00231374|Procedure|Myelogram|
45971743|NCT00415467|Device|GliaSite Radiation Therapy System|Radiation delivery system that provides brachytherapy targeted to a specific site in the brain, to see its effects to the surrounding area where the tumor was located.
45971744|NCT00231452|Drug|Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)|Monthly chemoprophylaxis with SP (Fansidar® 500/25 mg) plus Artesunate (AS, Arsumax® 50 mg) or placebo (provided by Roche and Sanofi-Aventis) was administered according to the following age-based dosing schedule: ½ tablet of SP or placebo and ½ tablet of AS or placebo on the first day and ½ tablet of AS or placebo on the second and third days.
45971745|NCT00266526|Biological|Recombinant birch pollen|
45971746|NCT00231491|Drug|Botulinum Toxin A (Botox )|
45971747|NCT00477490|Drug|desmopressin acetate|Oral lyophilisate of desmopressin acetate placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime in the assigned dosage: 10, 25, 50 or 100 μg
45971748|NCT00477490|Drug|Placebo|Oral placebo placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime.
45971749|NCT00415545|Behavioral|Fluid Watchers LITE Educational Intervention|Patients in Fluid Watchers LITE will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written material, a diary, a scale and a telephone follow-up to answer any questions they might have about the educational session.
45971750|NCT00415545|Behavioral|Fluid Watchers PLUS Educational Intervention|Patients in Fluid Watchers PLUS will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written materials, a diary, a scale, an audio tape of the session and telephone followup. Participants in the PLUS program will receive additional counseling, audio tapes, and follow-up telephone calls on a biweekly basis, as compared to participants in the LITE program.
45971751|NCT00231530|Drug|topiramate|
45971752|NCT00259389|Behavioral|Directly observed therapy (DOT)|
45669756|NCT04571632|Drug|Pembrolizumab 100 MG in 4 ML Injection|The first administration of pembrolizumab 200 mg (100 mg/4mL solution) by the intravenous route during 30 minutes will be administered on day 1. The second administrations of pembrolizumab 200 mg will be administered by a 30 minutes intravenous infusion on day 21, and thereafter every 21 days (or up to ± 3 days before or after the scheduled date if necessary) days.
45828448|NCT04987138|Device|Zenflow Spring System|The Zenflow Spring Implant is an electropolished and passivated nickel titanium alloy (nitinol) implant. The implant is constructed from a single wire strand formed into ring elements connected by spine sections. There are four sizes of implants ranging from 16 mm to 24 mm in length and 14 mm to 16 mm in diameter to implant in the subject's prostatic urethra. The implant is placed in the urethra using a custom delivery catheter and cystoscope (Spring Scope). The implant is intended to be permanent but can be removed if necessary.
45828449|NCT04987138|Device|Sham Procedure|A18 Fr Foley Catheter is placed into the patient's bladder. To mimic the Treatment Arm procedure, the Foley Catheter balloon will be inflated in the bladder. Once inflated, slight tension will be applied against the subject's bladder neck. While tension is being applied the site staff will follow a script to simulate the Zenflow procedural steps. Additionally, devices will be used to produce mock deployment sounds of the Zenflow procedure. Once complete, the balloon will be deflated and the catheter will be removed, completing the procedure.
45971753|NCT00231569|Drug|ISIS 301012 or Placebo|30 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
45971754|NCT00231569|Drug|ISIS 301012 or Placebo|100 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
45971755|NCT00231569|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
45971756|NCT00231569|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
45971757|NCT00231569|Drug|ISIS 301012 or Placebo|400 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
45971758|NCT00231569|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
45971759|NCT00231569|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
45971760|NCT00477334|Drug|Famciclovir|oral; two 500 mg tablets twice a day; single day treatment
45828450|NCT04986423|Drug|ZEN003694|72 mg PO QD
45828451|NCT04986423|Drug|Enzalutamide|160 mg PO QD
45971761|NCT00477334|Drug|Placebo|oral; two tablets twice a day; single day treatment
45971762|NCT00266565|Drug|Mepolizumab|10mg/kg (max 750 ml) once a month for 3 months
45971763|NCT02211859|Drug|BI 2536|
45971764|NCT00231608|Drug|topiramate|
45971765|NCT00266604|Drug|Topiramate|
45971766|NCT04560985|Other|Hydrophilic fissure sealant|Hydrophilic fissure sealant on first molars
45971767|NCT04560985|Other|Hydrophobic fissure sealant|Hydrophobic fissure sealant on first molars
45971768|NCT04721483|Procedure|Ramicotomy|We will selectively lesion the gray rami communicantes from T3 and T4 thoracic sympathetic ganglia
45971769|NCT04560946|Behavioral|Personalized Augmented Cognitive Training (PACT)|Personalized Augmented Cognitive Training (PACT) group. Intervention: Behavioral: The study neuropsychologist will use a portion of the TBI education session to describe available treatment modules and make recommendations for module selection based on results from baseline assessment. After discussion, five 60-minute CogSMART modules will be selected. PACT participants will receive guidance to complete 2 modules per week of the CogSMART app. PACT participants will also receive guidance to complete BrainHQ exercises of their choice for 30 minutes a day, 5 days per week, for a total training time of 15 hours.
46081438|NCT04465318|Other|Nicotine Replacement Therapy (NRT)|Participants in the NRT arm will receive 21 mg nicotine patch (for those with CPD >= 20) or 14 mg nicotine patch (for those with CPD < 20) + 4 mg nicotine gum. CPD stands for Cigarettes Per Day.
45828452|NCT04948268|Behavioral|Adaptive messaging intervention|Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Content and messages will be tailored using machine learning.
45971770|NCT04560946|Behavioral|Enhanced Treatment As Usual|"Enhanced Treatment As Usual (ETAU) group. Intervention: Behavioral: The ETAU condition was designed to replicate treatment as usual following neuropsychological assessment of post-TBI cognitive problems. Treatment as usual for mTBI patients at the VA hospital usually consists of: 1) A general evaluation by the polytrauma clinic, 2) Possible neuropsychological assessment evaluation by the TBI Cognitive Rehabilitation Clinic, and 3) If impairments are present, cognitive rehabilitation is offered. The current study's condition is considered enhanced treatment as usual because standard of care for chronic mTBI does not always involve neuropsychological assessment with feedback and psychoeducation or the provision of self-directed tools such as the CogSMART app or BrainHQ cognitive training software."
45971771|NCT04561024|Diagnostic Test|AI model|Deep Learning CNN model
45971772|NCT04561336|Drug|Avelumab|avelumab in combination with cetuximab
45971773|NCT04561336|Drug|Cetuximab|avelumab in combination with cetuximab
45971774|NCT00259428|Drug|Dronedarone (SR33589)|oral administration
45971775|NCT00259428|Drug|placebo|oral administration
45971776|NCT04560907|Procedure|Aquablation|"By means of a high-pressure saline stream, parenchymal tissue of the prostate is removed endoscopically through a heat-free mechanism called hydrodissection. The intervention is supported by live ultrasound guidance and the required depth as well as the angle of the resection is planned out prior to the resection. The bladder is accessed using a 24-Fr hand-piece, which accommodates the scope. The handpiece is supported by an articulating arm attached to the operation table. Once placed in the optimal position, the system automatically adjusts the alignment as necessary.~Hemostasis is consecutively achieved through diathermy and post procedure, a threeway catheter is inserted and bladder irrigation is initiated."
45971777|NCT04560907|Procedure|HoLEP|This is done endoscopically under general anesthesia the three lobes of the prostate that are cored out intact with the laser are pushed into the bladder before being morcellated by a special instrument inserted through the telescopic camera. A catheter is placed into the bladder to drain the urine while the raw surface heals, then left in place for around 24 hours before being removed on the day of discharge from hospital. Sterile saline fluid is also irrigated into the bladder through the catheter to dilute any blood in the urine and prevent clots from forming.
45971778|NCT00231647|Drug|topiramate|
45971779|NCT02211898|Drug|BNS003|
45455863|NCT05561582|Other|Seated knee extension exercise|Participants will be seated in a resistance exercise machine. Weight corresponding to the assigned group will be added to the machine. Participants will extend the dominant knee for 3 sets of 10 repetitions.
45455864|NCT05560529|Behavioral|DBT|Applying DBT modules in group format over 20 weeks
45455865|NCT05560529|Drug|TAU|Giving TAU (usual pharmacotherapy in BED) over 20 weeks
45455866|NCT05560529|Diagnostic Test|Plasma Ghrelin|Measuring fasting plasma ghrelin pre and post treatment in both arms
45828453|NCT04948268|Behavioral|Non-personalized messaging intervention|Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Psychological content will center on a single psychological strategy each week. There will not be any tailoring of messaging and content based on group or individual level data.
45828454|NCT04948268|Behavioral|Coaching|Human coaching to support intervention use and engagement via telephone calls, text or email
45828455|NCT04948268|Behavioral|Psychoeducational links|SMS messages with URLs containing brief psychoeducational information.
45828456|NCT04939792|Drug|Vitamin D|Capsules ingested orally
45828457|NCT04939792|Drug|Placebo|Capsule ingested orally
45828458|NCT04939792|Drug|Vitamin D + L-cysteine|Capsule ingested orally
45828459|NCT04939792|Drug|L-cysteine|Capsule ingested orally
45828460|NCT04939220|Procedure|TEE with SGA|SGA Placement and maintenance with inhalational anesthetic or propofol
45828461|NCT04939220|Procedure|TEE with Deep Sedation|Deep sedation with propofol and natural airway
45828462|NCT04921358|Drug|Tislelizumab|administered intravenously
45828463|NCT04921358|Drug|Docetaxel|administered intravenously
45828464|NCT04921358|Drug|Sitravatinib|administered orally
45828465|NCT04899310|Biological|mRNA-3705|A sterile liquid for injection
45828466|NCT04894903|Other|Diabetes Care Gaps Patient Portal Intervention|The Diabetes Care Gaps Patient Portal Intervention is embedded within an existing patient web portal (My Health at Vanderbilt). The intervention (a) notifies patients when selected, clinically meaningful, evidence-based diabetes monitoring & preventative care (e.g., annual urine microalbumin) are due and (b) allows patients to initiate orders for the care.
45971780|NCT04560322|Drug|Venetoclax|Tablet, taken by mouth
45971781|NCT04560322|Drug|Obinutuzumab|Intravenous infusion
45971782|NCT04560322|Drug|Acalabrutinib|Capsule, taken by mouth
45971783|NCT04560751|Drug|Lenvatinib|Lenvatinib capsules will be administered orally, once daily (for patients <60kg, lenvatinib 8mg po; for patients ≥60kg, lenvatinib 12mg po)
45971784|NCT04560751|Procedure|TACE|TACE will be performed as needed.
45971785|NCT00259467|Behavioral|Home-Based Behavorial Intervention|
45971786|NCT00231686|Behavioral|Supervised aerobic training|
45971787|NCT00231686|Behavioral|Supervised strength training|
45971788|NCT00231686|Behavioral|Unsupervised training|
45971789|NCT04560478|Device|Pro Seal Sealant|Sealant was reapplied every 3 months
45971790|NCT04560478|Device|MI Varnish|Fluoride varnish was applied every 4-6 weeks
45971791|NCT04560244|Drug|SHR1701|PD-L1 / TGF-β RII double antibody
45971792|NCT04559854|Behavioral|Mindful After Cancer|The intervention includes eight weekly sessions (1.5-2 hours each), plus participant educational materials and audio recorded meditations, and is delivered to women in their homes via group videoconference led by a trained facilitator. Participants are asked to complete activities and mindfulness practice between sessions.
45971793|NCT00266643|Drug|duloxetine hydrochloride|
45971794|NCT00231725|Drug|insulin lispro injection [rDNA origin] Low Mix|
45669757|NCT04571632|Other|CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC|"CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be administered by intratumoral injection in the lesions that were injected by avelumab en ipilimumab on day 1 (approximately 24 hours after intratumoral injection of avelumab en ipilimumab).~The total administered CD1c (BDCA-1)+/ CD141 (BDCA-3)+ myDC volume will be up to 4.0 mL per intratumoral treatment session. Injected volume per lesion (skin-, soft tissue or lymph-node metastases) will range from 0.1 mL for lesions < 0,5 cm to 4.0 mL for lesions > 5 cm in longest diameter. Injection of all lesions in an individual patient will not be required.~The determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume is based on lesion size.~When lesions are clustered together, they are injected as a single lesion according to the table for determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume based on lesion size."
45971795|NCT04560205|Drug|Tocilizumab|"4-8mg/kg with 400mg maximum dose of Tocilizumab will be given in 60 minutes I/V infusion, and dose will be repeated after 12-24 hours according to clinical as well as laboratory parameters.~Customized decision for Tocilizumab usage will be made by attending infectious diseases physician, comfort with Tocilizumab usage, bacterial co-infection and duration of Ventilation."
45669758|NCT01975389|Drug|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
45828467|NCT04894591|Drug|Zepzelca|Zepzelca is administered by intravenous infusion over 60 minutes every 21 days. Date, dose prescribed and received will be collected at each Zepzelca infusion.
46081439|NCT04465318|Behavioral|Smoking Harm Reduction Counseling Sessions|Counseling will cover health education, social support issues, and motivational enhancement to improve self-efficacy while addressing other aspects know to contribute to smoking among people with COPD (e.g., tips on dealing with depression)
46081440|NCT04462523|Drug|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
45828468|NCT04887584|Other|Control diet|The control Typical American Diet (TAD) diet pattern will mimic the level of intake of fruits, vegetables, whole grains, added sugars, saturated fats and sodium in the general U.S. population. This diet will feature no servings of pulses per day.
45828469|NCT04887584|Other|Low Pulse diet|The Low Pulse diet will be designed based on the TAD with substitution of pulses for lean meat and grains. This diet will feature 0.2 cups of pulses per day at 2,000 kilocalories (kcals).
45971796|NCT04559971|Drug|SLN124|SLN124 for subcutaneous (s.c.) injection
45971797|NCT04559971|Drug|Placebo|Sodium chloride for s.c. injection
45971798|NCT04560049|Drug|Silver Nitrate|application of silver nitrate to sinus tract
45971799|NCT04560049|Drug|Phenol|phenolisation of sinus tract
45971800|NCT04559425|Drug|Dexamethasone|All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
45971801|NCT04559425|Other|No Dexamethasone|All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
46081441|NCT04462523|Drug|Topical Prednisolone|Standard of care topical drop treatment
46081442|NCT04461210|Diagnostic Test|Thermographic Imaging and Mechanical Pain Assessment|Assessment of pain sensitivity with mechanical stimulus (cotton swab) and thermographic imaging with infrared camera
46081443|NCT04457336|Drug|Tildacerfont/Placebo|Tablet, administered daily
46081444|NCT04455620|Biological|BNT151|intravenous
45455867|NCT05558280|Drug|Dinutuximab beta|The study treatment will be administered with a continuous intravenous infusion at a dose of 14 mg/mq/day, days 1-5, a total of 60 hours (cumulative dose/cycle: 70 mg/mq). Each cycle lasts 28 days.The treatment phase foresees 5 cycles of Dinutuximab Beta.
45971802|NCT00231764|Drug|daclizumab|
45971803|NCT00259506|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|
45971804|NCT04559503|Other|Progressive relaxation exercises|Progressive relaxation exercises are those involving the voluntary, regular and consecutive relaxation of the muscles until there is relaxation all over the body. PMR are consisted of taking a deep breath and then tensing and relaxing muscles in both hands and arms, shoulders, chest, abdomen, hips, legs, feet, and face regions. The training was given in line with the CD that was prepared by the Turkish Psychologists Association as three-part relaxation exercises. The first part of the CD contains the definition, purpose and applications to consider when doing the exercises and a definition of 10-minute deep relaxation. In the second 30-minute section, relaxation exercises are explained accompanied by the sound of streams and oral instructions. The last section, which consists of 30 minutes, contains only relaxation music without instructions.
45971805|NCT04559776|Other|gait analysis|gait analysis with 3D optoelectronic system and surface EMG
45971806|NCT04559308|Drug|Metformin|first-line anti-diabetic drug
45971807|NCT04559308|Drug|Chemotherapy|First line neoadjuvant chemotherapy protocol
45455869|NCT05555745|Device|Audio-based behavioral activation intervention|Access to audio-based behavioral activation intervention
45828470|NCT04887584|Other|High Pulse diet|The High Pulse diet will be designed based on the TAD with substitution of pulses for lean meat and grains. This diet will feature 1.5 cups of pulses per day at 2,000 kilocalories (kcals).
45828471|NCT04867837|Drug|Octaplex|Four-factor prothrombin complex concentrate (4F-PCC)
45971808|NCT00266682|Device|Pacing Lead|
45971809|NCT04559191|Device|continuous glucose monitoring (CGM)|CGM (FreeStyle Libre Pro®, Abbott, Chicago, Illinoi, the United States)
45971810|NCT00231803|Other|Combined CKD and CVD Prevention|Perindopril, Lisinopril, Captopril, Candesartan, Losartan, Amlodipine, Verapamil, Chlorthalidone
45971811|NCT00231803|Other|Cardiovascular Disease prevention|Atorvastatin, Rosuvastatin, Simvastatin, Aspirin, Clopidogrel
46081445|NCT04452188|Other|Normoxia (with controlled re-oxygenation)|"Participants will receive lower levels of oxygen during surgery and after surgery on the ventilator.~As cardiopulmonary bypass is being weaned, anesthesia will initiate mechanical ventilation with an FiO2 of 50% or less (unless clinically necessary) to achieve oxygen saturation and PaO2 goals that fit within the expected range for the patient's physiology:~Single ventricle patients (PaO2:35-45 and oxygen saturation 75%-85%)~Two ventricle patients (PaO2: 60-100 and oxygen saturation >92%)"
46081446|NCT04452188|Other|Standard of care ventilation|As cardiopulmonary bypass is being weaned, anesthesia will initiate mechanical ventilation per standard protocols. Ventilation will be continued in the ICU and adjusted per standard goals per the intensivist.
46081447|NCT04437108|Procedure|Li-SWT (suprapubic approach)|The patient will be asked to lie in flat dorsal position. A commercially used gel for sonography will be applied to the suprapubic region. The applicator will be placed on suprapubic region with two fingers apart from the symphysis pubis tilting to 45°. Shock waves will be directed to 3 different sites; the midline (over the bladder dome) and 3 cm right and left to the midline (over bilateral bladder walls). The patient will receive 3000 shocks (1000 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
46081448|NCT04437108|Procedure|Li-SWT (perineal approach)|The patient will be asked to lie in lithotomy position. A commercially used gel for sonography will be applied to the perineum. The applicator will be placed on perineal region. Shock waves will be directed to 3 different sites: the midline and 2 cm above and below the midline. The patient will receive 3000 shocks (1000 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
45455870|NCT05555745|Device|Audio-based self-monitoring intervention|Access to audio-based self-monitoring intervention
45669759|NCT01975389|Drug|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
45669760|NCT01974141|Drug|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
45828472|NCT04864249|Device|SNOO|The SNOO is a commercially available device which is a responsive bassinet for neonates. The bassinet is designed to respond to the infant's cries and automatically respond by emitting engineered white noise sounds and providing a rhythmic rocking motion. The infant is also swaddled to remain securely back-down. The SNOO automatically increases the emitted sound and motion if the infant is still crying. However, if the infant does not settle within 3 minutes, the SNOO will shut off and alert the adults for additional assistance. Parents can also modify the SNOO settings to meet the baby's need for sound and/or motion.
45669761|NCT01974141|Drug|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
45669762|NCT01945593|Biological|BAX855|Antihemophilic Factor (Recombinant), PEGylated
45669763|NCT01945281|Drug|Caspofungin|
45669764|NCT01945281|Drug|Amphotericin B Deoxycholate|
45828473|NCT04864249|Other|Safe sleep education in the postpartum period|Comprised of education from the postpartum clinical nurse with a corresponding educational handout to take home
45828474|NCT04850495|Drug|Cyclophosphamide|Given IV
45971812|NCT00231803|Other|Treatment of Chronic Kidney Disease complications|Calcitriol, Calcium carbonate, Erythropoietin, Sodium bicarbonate
45971813|NCT00231803|Other|Usual care|No prescribed intervention, just those that the patient's own family physician thought indicated
45669765|NCT01961349|Drug|Intralipid|Treated by Anaesthesiologist. (Intralipid is being used as a placebo for Diprivan.)
45669766|NCT01961349|Drug|ICI35,868 (Diprivan)|Treated by Anaesthesiologist
45669767|NCT01961349|Drug|ICI35,868 (Diprivan) + EES0000645/A (SDS)|Treated by Endoscopist with EES0000645/A(SDS)
45828475|NCT04850495|Drug|Doxorubicin Hydrochloride|Given IV
45828476|NCT04850495|Drug|Prednisone|Given PO
45828477|NCT04850495|Biological|Rituximab|Given IV
45828478|NCT04850495|Drug|Vincristine Sulfate|Given IV
45828479|NCT04850495|Drug|Zanubrutinib|Given PO
45971814|NCT04559113|Drug|Methylprednisolone Injectable Product|"0.5mg to 1mg/Kg methylprednisolone or equivalent dexamethasone dose (to a maximum of 20mg) given daily x 5 to 7-days or~Methylprednisolone 1 mg/kg daily IV for 5 days followed by 40 mg daily x 3 days, followed by 10 mg daily x 2 day."
45971815|NCT02211937|Drug|BI 44847 solution, low dose|
45971816|NCT02211937|Drug|BI 44847 suspension, high dose|
45971817|NCT02211937|Drug|BI 44847 tablet, low dose|
45971818|NCT02211937|Drug|BI 44847 tablet, high dose|
45971819|NCT02211937|Other|high fat breakfast|
45971820|NCT00266721|Drug|Pancrelipase (Creon) 2 tablets with each meal|
45971821|NCT04559269|Other|No intervention|patients have benefited from maintenance wakefulness tests as part of their clinical evaluation
45971822|NCT04559074|Drug|Amlodipine|Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry; starting dose equivalent to current dose for patients on amlodipine at entry or at next 1-2mg dose step (according to clinical need based on the Investigator's judgement). Investigation of whether gradually increasing the dose of liquid amlodipine (can be an add-on to existing amlodipine tablets) in small increments (e.g. 1-2mg) will enable blood pressure control within the sequence 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg to a maximum of 10mg amlodipine per day.
45971823|NCT04559152|Dietary Supplement|Zinc Supplementation Group|Enrolled subjects received zinc capsule 20mg daily in the morning after meal for 12 weeks
45971824|NCT04559152|Dietary Supplement|Placebo Group|Enrolled subjects received placebo tablet, which was inserted into capsule of the same shape and color as zinc capsule, daily in the morning after meal for 12 weeks
45971825|NCT00231920|Biological|Fluzone|
45828480|NCT04847674|Drug|TEV-53275 Dose A|subcutaneous (sc) injection
45971826|NCT00259545|Drug|Retarded Release Phosphatidylcholine (rPC)|
45971827|NCT02211976|Drug|Bisacodyl|
46081449|NCT04437108|Procedure|Li-SWT (combined approach)|The patient will receive 3000 shocks; 1500 shocks through suprapubic approach (500 shocks per site) and another 1500 shocks through perineal approach (500 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
46081450|NCT04437108|Procedure|Sham treatment|The same technique of Li-SWT will be used but the applicator of the shock wave device will be turned off.
46081451|NCT04437108|Drug|Solifenacin|The patients will be treated by antimuscarinics (solifenacin) which are considered as the conventional treatment of storage symptoms after prostatectomy.
46081452|NCT04421768|Behavioral|cervical exam training|Each nurse will then examine 1 sets of 10 high-fidelity silicone task trainers approximately three per week for a maximum of 20 sessions (200 repetitions total). For each set of 10 exams, the estimates will recorded on an answer sheet. A cumulative summation analysis will be performed on each participant. When an individual nurse achieves competence her training will be suspended
45455871|NCT05555303|Drug|Amikacin|"In addition to the all-oral RR-TB treatment, add two intramuscular doses each consisting of 30 mg amikacin/kg, a first dose on day 1 and a second dose on day 4, all in the first week of treatment.~The amikacin solution will be admixed with a lidocaine solution in the syringe before administration."
45455872|NCT05552066|Other|Standard follow up|Patients enrolled into front phase will be followed in a standard way without any additional procedure except satisfaction questionnaire
45669768|NCT01973595|Dietary Supplement|Almonds, Then no almonds|Whole, raw almonds with skin, or whole, raw almonds with skin that have been ground into a paste.
45828481|NCT04847674|Drug|TEV-53275 Dose B|subcutaneous (sc) injection
45828482|NCT04847674|Drug|Placebo|Matching subcutaneous (sc) placebo injection
45828483|NCT04847557|Drug|Tirzepatide|Administered SC
45828484|NCT04847557|Other|Placebo|Administered SC
45828485|NCT04828785|Other|MTM|weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 6-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
45828486|NCT04828785|Other|Food Subsidy|$40/month food subsidy
45828487|NCT04825613|Biological|HB-adMSCs|Hope Biosciences adipose derived Mesenchymal Stem Cells
45828488|NCT04817007|Drug|BMS-986158|Specified dose on specified days
45828489|NCT04817007|Drug|Ruxolitinib|Specified dose on specified days
45828490|NCT04817007|Drug|Fedratinib|Specified dose on specified days
45828491|NCT04815252|Behavioral|CHIME|CHIME is a professional development program to provide knowledge and skills for nurturing early childhood educator mindfulness, compassion and socio-emotional learning. CHIME is a manualized curriculum delivered by a trained facilitator. The intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Sessions can be delivered online or in-person.
45828492|NCT04813796|Biological|mRNA-1283|Sterile liquid for injection
45828493|NCT04813796|Biological|mRNA-1273|Sterile liquid for injection
45828494|NCT04813796|Biological|Placebo|0.9% sodium chloride (normal saline) injection
45971828|NCT02211976|Drug|Simeticone|
45971829|NCT04558606|Device|Sonic Toothbrush|Sonic Toothbrush (Philips Sonicare Flexcare Platinum Toothbrush®)
45971830|NCT04558606|Device|Manual Toothbrush|Manual brushing (Technique Pro - GUM® Sunstar Italiana SRL)
45971831|NCT04558645|Other|Online Survey|Online surveys will be applied to all participants
45971832|NCT04558684|Drug|Chemotherapy|CAPOX (6 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine: Dose of 2000mg/m2,14 days, q3w
45971833|NCT04558684|Drug|Immunotherapy|Camrelizumab (6 cycles): 200mg on day 1 of each cycle, q3w
45669769|NCT01973595|Other|No Almonds, Then almonds|No almonds will be consumed by participants for 3 weeks.
45971834|NCT04558684|Radiation|IMRT|Radiotherapy (5 Gy x 5 fractions)
45971835|NCT04558528|Diagnostic Test|Novel in vitro diagnostics and medical applications|Novel in vitro diagnostics and medical applications
45971836|NCT00231959|Drug|Pramipexole (Mirapex)|pramipexole 0.5mg tablets qd and titrated per protocol
45971837|NCT00231959|Drug|Placebo|sugar pill
45971838|NCT02278393|Other|1-Fermented Dairy Product with Phytosterols (test)|1- 3 bottles of test product/day
45971839|NCT02278393|Other|2-Fermented dairy Product with No Phytosterols (control)|2-3 bottles of control product/day
45971840|NCT00259584|Behavioral|Management and Outcome of SVCO|
45971841|NCT04558411|Behavioral|Dialectical Behavioral Therapy (DBT) Skills|14 brief videos that teach DBT skills.
45971842|NCT00231998|Drug|Pimecrolimus|Pimecrolimus cream 1 %
45971843|NCT04558333|Other|blood and exhaled breath specimens|identification of possible biomarkers
45971844|NCT02212054|Behavioral|conservative|anal dilatation; colonic lavage; oral probiotic
45971845|NCT02212054|Procedure|operative|one stage pull through radical colectomy
45971846|NCT00266838|Drug|Maxidex; Lacrystat|6 times daily, for 20 weeks.
45971847|NCT00232037|Drug|Tegaserod|
45971848|NCT02212132|Other|behavioral assessments|Neuropsychological evaluation, psychopathological assessment and fatigue
45971849|NCT02212171|Other|TRIAP|"The primary healthcare professionals organised in healthcare mini-teams, composed of 2 doctors, 2 nurses and 1 member of the administrative staff.~Administrative staff:~Following a flow chart, they will refer patients with mild self-limiting illnesses as well as consultations regarding chronic disorders in adults to the nurses. They will also perform administrative tasks such as the printing of prescriptions, sick leave reports and medical notes (justifying absence), etc.~Nursing staff:~They will carry out activities focused on health promotion, self-management and de-medicalisation during visits from patients with mild self-limiting illnesses as well as appointments for chronic diseases in adults.~GP:~They will develop the new portfolio of services: health promotion, joint review of patient medical records by doctors and nurses to improve the management of certain groups of patients, and organization of minor surgery services, etc."
45971850|NCT02212210|Drug|Methylprednisolone|
45971851|NCT02212210|Drug|Normal saline|
45971852|NCT00232076|Drug|ciclosporin|
45971853|NCT04558099|Behavioral|MBSR|Described previously
45971854|NCT04558255|Diagnostic Test|A machine-learning method which can robustly discriminate early-stage lung cancer patients from controls|In our study, we intend to integrate molecular features obtained through liquid biopsy and clinical data of lung cancer patients, and develop and prospectively validate a machine-learning method which can robustly discriminate early-stage lung cancer patients from controls.
45971855|NCT00259623|Device|Radiofrequency ablation|
45971856|NCT04558060|Other|Virtual Standardized Patient|Computer program that presented a virtual human patient
45971857|NCT04558060|Other|Academic Study|Study of a summary of motivational interviewing concepts and techniques.
45971858|NCT00232115|Drug|Pimecrolimus|Pimecrolimus cream 1 %
45971859|NCT00232115|Drug|Placebo|Vehicle cream (placebo)
45971860|NCT02212249|Biological|soluble Ve cadherin|dosage of soluble VE cadherine in each arms
45971861|NCT04558372|Other|exhaled breath sampling|The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.
45971862|NCT04558372|Other|exhaled breath sampling|The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.
45971863|NCT04558372|Other|exhaled breath sampling|The participants breath normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume through an e-nose tube connected to the Hepa-filter at the inlet.
45971864|NCT04558021|Drug|Niclosamide suspension|200mg/10ml
45971865|NCT04558021|Other|Placebo|10ml placebo(absent of niclosamide)
45971866|NCT00232154|Drug|Zithromax&#153; (azithromycin) 500mg tablets|
45971867|NCT00232154|Procedure|Endoscopic Sinus Surgery|
45971868|NCT00232154|Procedure|Blood sampling for hematology|
45971869|NCT00232154|Procedure|Blood sampling for plasma chemistry profile|
45971870|NCT00232154|Procedure|Serum pregnancy test (for women of child-bearing potential)|
45971871|NCT02212288|Other|Blood sample|Blood samples are for metabolic and genetic and biological investigation
45971872|NCT02212288|Other|Urine sample|Urine sample for biological investigation
45971873|NCT04557826|Device|RD19|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens
45971874|NCT00259662|Drug|atorvastatin|
45971875|NCT04557982|Procedure|A painful procedure (peripheral venepuncture)|The child will undergo a peripheral venepuncture during a scheduled visit to a hospital clinic and routinely provided care.
45971876|NCT04557943|Drug|Prolotherapy|"Prolotherapy injection is performed intra-articularly and extra-articularly by a physician. Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the 10-mL syringe, then 5 mL are injected with the superolateral approach. An extra-articular injection with 15% dextrose will be carried out with the following details:~in the 10-mL syringe 4 mL of 40% dextrose, 2 mL lidocaine, and 4 mL of distilled water are injected, to make a total of 30-40 mL injections. Treatment will be carried out on day 1st, 29th, and 57th."
46081453|NCT04420949|Behavioral|Sensory re-weighting|During training, sensory re-weighting is driven by priming upregulation of somatosensory cues. Two rounds of training, each lasting 15 minutes and block-randomized in sets of 10 trials, are conducted per training visit. In each training trial, participants must determine the direction of gravity and then indicate if the rod being displayed is aligned with gravity or if it needs to rotate clockwise or counterclockwise for that to be so. Participants will be instructed to pay attention to what they feel from their feet, legs, and gut during training and to use that pressure, stretch, movement, and muscle tension feedback to help them sense gravity. Immediate auditory and non-orienting, visual feedback is provided after each trial. A staircase method is used to adapt the level of difficulty based on response accuracy. After two consecutive correct responses, the difficulty increases. After each incorrect response, the difficulty decreases. This process is repeated in each round.
45669770|NCT01944969|Drug|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 0.5 mg/day (patients ≥65) or 1 mg/day (patients 18-64 years)
46081454|NCT04406792|Behavioral|DPP only|Participation in the online DPP only with a mixed group of participants at risk for type 2 diabetes and doula divas are not the team leaders.
45669771|NCT01961115|Drug|Epacadostat|Given PO
46081455|NCT04406792|Behavioral|Diabetes Prevention Program (DPP) online + doula divas|Participation in the DPP online intervention with doula divas as team leaders.
45455873|NCT05552066|Other|short circuit|"Patients included in the post phase will have to complete the cem@santé application. If no contraindications are identified by the plateform with the remote PRO collection, patients will undergo chemotherapy directly the next day (without any medical validation)."
45669772|NCT01961115|Biological|MELITAC 12.1 Peptide Vaccine|Given ID/SC
45828495|NCT04804735|Device|REV : local anesthesia and virtual reality|REV : local anesthesia and virtual reality in Implanted Venous Access Device (IVAD) procedure under local anesthesia
45828496|NCT04804735|Device|MUS : local anesthesia and music therapy|MUS : local anesthesia and music therapy in Implanted Venous Access Device (IVAD) procedure under local anesthesia
45828497|NCT04804553|Drug|Apremilast|Participants will receive apremilast orally.
45828498|NCT04804553|Drug|Placebo|Participants will receive the matching placebo orally.
45828499|NCT04782856|Drug|Levothyroxine|levothyroxine sodium tablet for oral use
46081456|NCT04405583|Device|Occlutech Atrial Flow Regulator|The Occlutech Atrial Flow Regulator is an interatrial shunt device for transcatheter delivery.
46081457|NCT04401761|Drug|Rivaroxaban (BAY59-7939, Xarelto)|2.5 mg twice daily
46081458|NCT04401761|Drug|Acetylsalicylic acid|75 - 100 mg once daily at the discretion of the investigator
46081459|NCT04396002|Diagnostic Test|Life Space Questionnaire|This 9-item questionnaire is interested in finding out how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame.
45669773|NCT04661397|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally as per assigned treatment sequence.
45669774|NCT04661397|Drug|Darunavir|Participants will receive a single dose of Darunavir orally as per assigned treatment sequence.
45828500|NCT04782856|Drug|Liothyronine|Liothyronine sodium tablets for oral use treatment of hypothyroidism
45828501|NCT04782856|Drug|Placebo|inert sugar tablets for oral use blinding for treatment of hypothyroidism
45828502|NCT04763200|Device|Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®|Impella CP / Impella CP with SmartAssist will be used in most patients randomized to the Impella arm. Impella 2.5 may be used in patients with small body size (BMI <20 kg/m2 or body weight <60 kg) or if the iliofemoral vasculature is able to accommodate the smaller Impella 2.5 device but not the Impella CP device.
45828503|NCT04763200|Device|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
45971877|NCT04557943|Drug|Sodium Hyaluronate|Hyaluronan sodium injection is performed intra-articularly using 2 mL of Adant® Disposable. The treatment will be given five times, on day 1st, 8th, 15th, 22nd, and 29th
45971878|NCT04709133|Procedure|multi-ligament knee surgery|a chart review will be performed to identify patients who underwent surgical treatment for multi-ligamentous knee injuries at Assiut University Hospital performed by one of sports medicine orthopaedic surgeons at Assiut arthroscopy and sport unit.
45971879|NCT00232232|Drug|Fish oil|
46081460|NCT04396002|Diagnostic Test|Low Luminance Questionnaire|This 32-item questionnaire is interested in finding out problems that involve vision under different lighting conditions or feelings that people have about your vision under different lighting conditions.
46081461|NCT04396002|Diagnostic Test|Contrast sensitivity under dim illumination|Participants will be presented with visual targets of different contrast under dim illumination and asked to report when they see the target.
45669775|NCT04661397|Drug|Emtricitabine/Tenofovir Alafenamide|Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally as per assigned treatment sequence.
45455874|NCT05551286|Other|A rehabilition programme for young adult cancer survivors|The programme consists of 22 sessions focusing on; 1) everyday life (energy conservation, cognitive challenges, fatigue); 2) Physical activity; 3) psychological issues; 4) work and study d; 5) sexuality and relationship; 7) rights and finance, and 8) goal setting. The sessions include both education, workshops, and engagement in different activities and will be delivered by a multidisciplinary team.
45455875|NCT05550935|Device|High-flow Nasal Cannula|HFNC is a device that, in this study, will give the maximum flow (60 L/min), with minimum adjusted temperature (31°C) and FiO2 of 21% or room air.
45669776|NCT04661397|Drug|Cobicistat|Participant will receive a single dose of Cobicistat tablet orally as per assigned treatment sequence.
45669777|NCT01973439|Other|Intervention 1: PK assessment while on Twice Daily Abacavir|Week 0
45669778|NCT01973439|Other|Intervention 2: PK assessment while on Once Daily Abacavir|Week 4
45828504|NCT04763135|Drug|Mirtazapine|"Orally disintegrating tablets of mirtazapine introduced at the dose of 15 mg and increased up to 45 mg per day during 56 days.~Doses escalation: based on symptom management and side effect assessment."
45669779|NCT01973283|Drug|Antidepressant Medication|If patient has a history of non-response or cannot tolerate escitalopram and/or duloxetine, then they will be treated openly with an approved antidepressant.
45828505|NCT04763135|Drug|Escitalopram|"Orally disintegrating tablets of escitalopram introduced at the dose of 10 mg (or 5 mg for patients older than 65) and increased up to 20 mg per day during 56 days.~Doses escalation: based on symptom management and side effect assessment."
45828506|NCT04762979|Drug|Alpelisib|Alpelisib 300mg, PO, days 1-28 of each cycle.
45828507|NCT04762979|Drug|Fulvestrant|Fulvestrant 500mg, IM, once monthly
45828508|NCT04762979|Drug|Aromatase inhibitor|Aromatase Inhibitor, administered per standard of care
45828509|NCT04762069|Drug|Berubicin|Berubicin HCl is a novel synthetic anthracycline with a chemical structure similar to doxorubicin HCl, a cytotoxic anthracycline topoisomerase II inhibitor isolated from cultures of Streptomyces peucetius var. caesius.
45828510|NCT04762069|Drug|Lomustine|"Lomustine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an alkylating agent."
45828511|NCT04755816|Behavioral|Sodium intervention|The sodium dietary intervention provides uses location services to determine when a participant is at home, arrives at a grocery store or arrives at a restaurant. The user receives a tailored message to assist with making dietary choices based on sodium content.
45828512|NCT04755816|Behavioral|Clinical worsening intervention|The intervention adapts to the participant's reported symptoms and provides feedback with a global health status indicator (HSI). Users will receive tailored push notification based on their HSI status.
45828513|NCT04755816|Behavioral|Educational content|Standard heart failure educational information and a daily symptom survey.
45828514|NCT04750941|Drug|Copanlisib|Copanlisib will be infused intravenously on days 1, 8, 15 of each cycle, over 1 hour, of 28-day cycles.
46081462|NCT04396002|Diagnostic Test|Visual field under dim illumination (MAIA)|Sensitivity in the central visual area will be assessed under dim illumination
45455876|NCT05549752|Drug|Flecainide Injectable Solution|Intravenous Flecainide at a dose of 2.0mg/kg (maximum dose: 150mg) in 100ml D/W 5% for 10 minutes.
45455877|NCT05549752|Drug|Amiodarone Injectable Solution|Intravenous Amiodarone at a dose of 5.0-7.0 mg/kg for 1 hour, and maintenance dose of 50mg/h (maximum dose: 1000mg) for up to 24 hours.
45669780|NCT01943799|Biological|GS-4774|Administered as a subcutaneous injection every 4 weeks for a total of 6 doses
45669781|NCT01943799|Drug|OAV Regimen|Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)
45669782|NCT01972659|Drug|placebo|Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion
45828515|NCT04750941|Other|Ketogenic Diet|"In cycle 1, patients will first start the ketogenic diet for 7 days (Day -6 to Day 0).~Only the patients who demonstrate compliance and tolerance with the ketogenic diet, as confirmed by pertinent blood and urine tests and a diary of diet, will be allowed to continue the study and start copanlisib on Day 1. The ketogenic diet will continue daily throughout the treatment days.~In cycle 2 and beyond, patients will start the ketogenic diet and copanlisib on day 1.~The ketogenic diet will then continue daily throughout the treatment days."
45669783|NCT01972659|Drug|Magnesium Sulphate|"Experimental :~50 mg/kg bolus plus 15 mg/kg continuous infusion"
45669784|NCT01972659|Drug|sugammadex|4 mg/kg iv bolus at the end of the surgery
45828516|NCT04747613|Drug|Iptacopan|Taken orally b.i.d. Dosage supplied: 200 mg Dosage form: hard gelatin capsule Route of administration: oral
45828517|NCT04739436|Device|Hearing amplification|Bilateral vs. unilateral hearing aids for hearing loss
45828518|NCT04723134|Combination Product|Folinic acid calcium salt|Folinic acid (2.5%) by combination with Placebo
45828519|NCT04711135|Drug|Lutetium [177Lu] oxodotreotide/dotatate|Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
45828520|NCT04700072|Biological|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
45828521|NCT04700072|Biological|Pembrolizumab/Quavonlimab|Administered via IV infusion at a specified dose on specified days
45828522|NCT04700072|Drug|Lenvatinib|Administered via oral capsule at a specified dose on specified days
46081463|NCT04396002|Diagnostic Test|Macular Pigment Optical Density (MPOD)|Participants will be asked to look at a fixation target and the density of their macular pigment will be assessed.
45455878|NCT05546892|Procedure|Full bowel preparation prior to colon resection for cancer|Mechanical bowel preparation and oral antibiotics
45455879|NCT05546892|Procedure|No bowel preparation|Omission of any bowel preparation
45669785|NCT01971723|Other|T+ Supplement|Randomized, placebo-controlled, double blind protocol with two treatment groups (matched by lean body mass). Group 1 will receive the recommended serving of one scoop (11g) of T+ supplement. This serving will be taken 45 minutes before the beginning of working out on an empty stomach (>1 hour after meal). On non-training days, the participants will also take a serving at the same time as on training days. This will continue for four weeks (28 days).
45669786|NCT01971723|Other|Placebo|The placebo group will consume a calorie-match placebo in the same manner as the supplement group (one serving 45 minutes prior to work outs on an empty stomach). The placebo group will also follow the same supplementation patterns and workout as their counterparts in the supplement group.
45669787|NCT01942785|Drug|Brexpiprazole|2-3 mg/day, once daily dose, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgement.
45669788|NCT04416165|Diagnostic Test|18F-FDG and 68Ga-DOTA-FAPI -04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI-04, and undergo PET/CT imaging within the specified time.
45828523|NCT04683718|Device|Permanent implant of a BIOTRONIK Prospera™ SCS (Spinal Cord Stimulation) System with HomeStream™ Remote Management|The Prospera™ SCS System is a rechargeable, 16-electrode, MRI conditional Spinal Cord Stimulation system that delivers electrical stimulation to the dorsal column of the spinal cord for the treatment of chronic intractable pain of the trunk and/or limbs.
45828524|NCT04676334|Drug|Rucaparib|Rucaparib will be administered daily.
45828525|NCT04675450|Drug|Placebo|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
45828526|NCT04675450|Drug|NBP Softgel Capsules|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
45828527|NCT04673292|Behavioral|Fixed site standard of care testing|This arm includes all three Johns Hopkins (JHMI) ambulatory outdoor testing sites across Baltimore City. Each site represents a traditional appointment-based scheduling system. Participants will be given a choice of 1 of 3 outdoor testing locations based on their preferences. Study staff will make an appointment for testing based on testing availability and participant schedule.
45828528|NCT04673292|Behavioral|Community-based, mobile van testing|This arm offers the convenience of highly accessible testing and with the flexibility of no fixed appointment time. Each of the 12 geographic strata will have a single, centrally located testing site within the area, providing similar geographic access across households. The testing location will be published on the study website and social media so that participants can visit the location at a time convenient to them.
45828529|NCT04673292|Behavioral|Self-collected, home-based testing|Individuals will receive a home-based testing kit delivered by a courier service as soon as the randomization of the household is complete. The kit will include provisions for contacting the courier service for pick up. Appropriate biohazard precautions are included. Each of the testing components of this kit will include FDA Emergency Use Authorization approved collection methods. Easy to use instructions with options to view pre-recorded videos and/or virtual 'on demand' coaching sessions with members of the study team via a HIPAA-secure Zoom session will be available.
45828530|NCT04666272|Drug|dabrafenib|There is no treatment allocation. Patients administered dabrafenib alone by prescription that have started before inclusion of the patient into the study could be enrolled.
45828531|NCT04666272|Drug|trametinib|There is no treatment allocation. Patients administered trametinib alone by prescription that have started before inclusion of the patient into the study could be enrolled.
45828532|NCT04652687|Biological|VIA Disc NP|VIA Disc NP - Allograft tissue injection
45828533|NCT04651998|Diagnostic Test|MMSE, MoCA, functional near-infrared spectroscopy|MMSE and MoCA are used for cognitive test before carotid artery stent implant and 6 months later. Cerebral blood oxygenation is evaluated by functional near-infrared spectroscopy under the mental task before and after revascularization within one week, 6 months later respectively.
45828534|NCT04649060|Drug|Melflufen|Powder for solution for i.v. infusion
45828535|NCT04649060|Drug|Dexamethasone|Oral tablets
45828536|NCT04649060|Drug|Daratumumab|Solution for s.c. injection
45828537|NCT04640272|Drug|RBM-007|Intravitreal injection
45828538|NCT04639050|Drug|RO7126209|RO7126209 will be administered via IV infusion, Q4W for a total of seven doses during 28 weeks of treatment.
45828539|NCT04639050|Drug|Placebo|Matching placebo will be administered via IV infusion, Q4W for a total of seven doses during 28 weeks of treatment.
45828540|NCT04638829|Drug|Avatrombopag Oral Tablet|Avatrombopag 20 mg given daily for 90 days. Initial dose and dose adjustments will be determined by the physician along with the Doptelet prescribing information
45828541|NCT04623008|Behavioral|Goal-Oriented Episodic Future Thinking|Individuals in the intervention group will receive a 20-week web-based intervention and individual health coaching focused on stress management, healthy eating and physical activity.
45828542|NCT04608487|Drug|Fludarabine|Intravenous infusion
45828543|NCT04608487|Drug|Cyclophosphamide|Intravenous infusion
45828544|NCT04608487|Biological|Axicabtagene Ciloleucel|Intravenous infusion
45828545|NCT04607746|Device|Capsule Endoscope|Capsule endoscope used to view colonic mucosa
45828546|NCT04602767|Drug|Vasopressin|Vasopressin titrated 0.01 U/min up to 0.04 U/min for MAP < 65 mmHg
45828547|NCT04602767|Drug|Phenylephrine|Phenylephrine titrated 0.25 mcg/kg/min up to 1.0 mcg/kg/min for MAP < 65 mmHg
46081464|NCT04396002|Diagnostic Test|Dark Adaptation|After adapting to a dark environment, participants will be exposed a bright flask of light. the time needed for them to recover their sensitivity will be measured.
46081465|NCT04395079|Biological|Durvalumab|Given IV
46081466|NCT04395079|Radiation|Internal Radiation Therapy|Undergo brachytherapy
45669789|NCT01774786|Drug|5-Fluorouracil|Participants will receive 5-fluorouracil 800 milligrams per meter square (mg/m^2)/24 hour IV infusion for 120 hours (Days 1-5) q3w for 6 cycles.
45971880|NCT04557904|Other|Craniocervical flexion exercises|Command the subject to be in crook lying position. Lock their finger to place their finger below the skull and retract the lower jaw and retract chin as far as possible. Subject has to slightly raise his/he skull a few centimeters. Fingers should be touching the cranium but not supporting it. Subject had to respire and hold the position. Subject has the move out the chin. Stop exercise and restart again. Perform this exercise for 10 times by holding this position for 20 sec at the start of the exercise, increasing it by 10 seconds every session commonly underwent pectoralis minor stretching before every session of exercise of 4 sets with 30 second's hold
45971881|NCT04557904|Other|Scapular stabilization exercises|The scapular stabilization exercises were made up of four stages: (1) In supine position, the patient was commanded to deep respire for the sake of relaxation by maintain the cervical and shoulder in relaxing position to take a deep breath to relax the body while holding her shoulders and neck in relaxing position. (2) The patient then flex her knees and placed her feet flat on the plinth, and maintain the pose without any cervical movement. Then the patient asked to raise her dominant arm to 90° shoulder flexion with full elbow extension and scapular protraction. This position was sustained for 10 seconds before going to initial position. Three laps of 10 repetitions with one-minute interval in between were performed. (3) In quadruped position, the patient raise her arms alternatively with shoulder abduction and 120 ° flexion. That posture was held for 10 seconds before returning to the starting position. (4) In sitting position
45971882|NCT04557475|Drug|Aspirin|Two tablets daily with dinner
45971883|NCT00232271|Drug|Clexane|
46081467|NCT04395079|Biological|Tremelimumab|Given IV
46081468|NCT04391309|Biological|anti-CD14|4 mg/kg on Day 1, 2 mg/kg on Days 2-4 administered intravenously (IV)
46081469|NCT04391309|Other|Placebo|Placebo administered intravenously on Days 1-4
46081470|NCT04391309|Drug|remdesivir|Remdesivir administered intravenously for 5 days beginning with a 200 mg loading dose on Day 1, followed by 100 mg/day on Days 2-5.
45828548|NCT04590521|Biological|Gardasil®, Merck|Gardasil® (4vHPV) is a recombinant protein particulate (VLP) vaccine. Each 0.5 mL monodose pre-filled syringe or vial contains approximately 20 μg of HPV 6 L1 protein, 40 μg of HPV 11 L1 protein, 40 μg of HPV 16 L1 protein, and 20 μg of HPV 18 L1 protein as well as approximately 225 mcg of aluminum (as Amorphous Aluminum Hydroxyphosphate Sulfate adjuvant). It has completed phase III trials and is licensed for use in over 100 countries around the world including the United States, Australia and countries in the European Union (EU) for girls aged 9-26 years. Vietnam currently offer this vaccine in private health clinics, as a 3-dose schedule (0, 2 and 6 months).
45669790|NCT01774786|Drug|Capecitabine|Participants will receive capecitabine 1000 mg/m^2 orally twice daily, evening of Day 1 to morning of Day 15 (28 doses) q3w for 6 cycles.
46081471|NCT04385745|Procedure|Biodegradable Intramedullary Nailing (BIN)|Unstable forearm shaft fractures are treated by the study method (BIN) or the control method (ESIN).
46081472|NCT04381897|Drug|N-acetyl cysteine|Oral solution for N-acetyl cysteine is prepared in syringes and provided to the participants along with instructions on how to administer them.
46081473|NCT04381897|Other|Placebo|NAC Placebo-matching solution is prepared in syringes and provided to the participants along with instructions on how to administer them.
46081474|NCT04378751|Behavioral|Decision aid video|Decision aid video
46081475|NCT04378751|Behavioral|Genetic counseling informational brochure|Genetic counseling informational brochure
46081476|NCT04362592|Device|In Utero Endoscopic Correction of Myelomeningocele IDE - Percutaneous Technique|The percutaneous approach uses endoscopes through a closed maternal abdomen and closed uterus to perform the spina bifida correction.
46081477|NCT04362592|Device|In Utero Endoscopic Correction of Myelomeningocele IDE - Laparotomy/Uterine Exteriorization Technique|The laparotomy/uterine exteriorization technique uses endoscopes through an open abdomen and closed, exteriorized uterus to perform the spina bifida correction.
46081478|NCT04356690|Drug|Etoposide|Etoposide 150 mg/m2 administered intravenously once daily on Days 1 and 4.
46081479|NCT04353661|Drug|Azithromycin|Azithromycin will be administered orally.
46081480|NCT04353661|Other|HP xenon (¹²⁹XE)|HP xenon (¹²⁹XE) will be administered at specified timepoints and the total dose bag volume should target 20% of the patient's forced vital capacity followed by a breath hold of up to 15 seconds
45828549|NCT04586894|Diagnostic Test|Cardiac MRI|Gadolinium-enhanced magnetic resonance imaging of the heart before the first cycle of chemotherapy
45828550|NCT04586894|Device|Smart cloth|A smart cloth recording cardiac and hemodynamic parameters will be worn by patients during 42 days. Replaced by a holter monitor if the smart cloth is refused or not tolerated by the patient.
46081481|NCT04352205|Drug|Bortezomib|Given SC
45971884|NCT04557397|Drug|Fruquintinib|oral VEGFR inhibitor
46081482|NCT04352205|Biological|Daratumumab|Given IV
46081483|NCT04352205|Drug|Dexamethasone|Given PO and IV
45669791|NCT01774786|Drug|Cisplatin|Participants will receive cisplatin 80 mg/m^2 IV q3w for 6 cycles.
45971885|NCT04557397|Drug|Itraconazole|a synthetic triazole antifungal agent
46081484|NCT04352205|Drug|Lenalidomide|Given PO
45669792|NCT01774786|Drug|Pertuzumab|Participants will receive pertuzumab 840 mg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
45669793|NCT01774786|Drug|Placebo|Participants will receive placebo (matched to pertuzumab) IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
45971886|NCT04557397|Drug|Rifampin|a semisynthetic antibiotic derivative of rifamycin SV
45971887|NCT04557241|Behavioral|Brief informational infographic|The primary intervention in this study will be an infographic that is designed to build trust in the scientific process. Infographics are preferable to narratives or text because they center visuals as part of the storytelling process and facilitate cognitive information processing, knowledge absorption, and enhanced persuasion. The study's infographic design will follow best practices in health communication. The message will be simple and jargon free. Visuals will include individuals (scientists), charts, text, and numbers. Attention will be paid to images, color, frames, representation, and composition (e.g., how the elements in the infographic are organized to show their relationship to each other).
45971888|NCT04557241|Behavioral|Placebo control (non-behavioral infographic)|"The comparator in this study will be a control (placebo) infographic that is completely unrelated to science (e.g., about cats), but that is developed using the same communication and graphical style."
45971889|NCT04557319|Biological|GNR-038, 25 МЕ/kg|25 МЕ/kg once per study
45971890|NCT04557319|Biological|GNR-038, 50 МЕ/kg|50 МЕ/kg once per study
45971891|NCT04557319|Biological|GNR-038, 100 МЕ/kg|100 МЕ/kg once per study
45971892|NCT00232310|Drug|CELIVARONE (SSR149744C)|
45971893|NCT04557514|Procedure|platelet rich plasma injection in post burn facial scar|"2 spins>>>~st spin (separate plasma from blood) 2500 for 10 minutes~nd spin (separate platelet rich part of plasma) 1500 for 10 minutes Taking lower part (platelet rich plasma ) Injection under scar after rigotomy"
45971894|NCT04557514|Procedure|fat injection in post burn facial scar|Anesthesia : general or local Lipoaspirate from abdomen or thigh using adrenaline(1\1000000) + ringer lactate + zylocaine Liposuction by canula no4 Sediment 3 layers : taking mid layer of fat and omit uppermost and lowermost layers Lipoinjection in fan shaped manner 10-20 cc according to site affected by canula no 1 .
45971895|NCT02212366|Device|Active TDCS|Active Stimulation
45971896|NCT02212366|Device|Sham TDCS|Sham Stimulation
45971897|NCT04557202|Drug|Tamsulosin Oral Capsule|To assess the efficacy of peri-operative alpha1 blockers on improving the success rate and decreasing complications of non-stented ureteroscopic laser lithotripsy for ureteric stones.
45971898|NCT04557202|Drug|Placebo|Placebo - control group
45971899|NCT00232349|Drug|galantamine|open label galantamine, dosed at 4-12 mg/b.i.d., with a target dose of 12 mg/b.i.d.
45971900|NCT00259701|Device|Laser Doppler Flowmetry with topical acetylcholine and nitroglycerin|
46081485|NCT04352205|Drug|Thalidomide|Given PO
46081486|NCT04339140|Drug|Zafirlukast|Oral tablets, 2x daily for 28 day cycle up to 1 year
46081487|NCT04337827|Drug|Rituximab|"Weekly x 4 weeks.~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto Long Term Follow Up (LTFU)."
45669794|NCT01774786|Drug|Trastuzumab|Participants will receive 8 mg/kg IV initial dose on Day 1, followed by 6 mg/kg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
45669795|NCT01960725|Biological|RV5 (Pentavalent Rotavirus Vaccine)|
45669796|NCT04654845|Procedure|Pulpotomy|"Access to pulp chamber. Removal of the pulp chamber tissue. Use of Sodium Hypochlorite (5.25% NaCl) during the whole procedure and in the amount considered appropriate by each operator.~Wait until confirmation of absence of bleeding from the conducts. Placement of polytetrafluroethylene in pulp chamber. Placement of temporary filling. Reduction of the occlusal surface of the tooth until there is no contact with the articulating paper from 200μ."
45669797|NCT04654845|Procedure|Pulpectomy|"Access to pulp chamber. Removal of the pulp chamber tissue. Use of Sodium Hypochlorite (5.25% NaCl) during the whole procedure and in the amount considered appropriate by each operator.~Establishment of working length by means of Electronic Apex Locator and a number 8 K file.~Access to all conducts with a number 10 K file. Rotary instrumentation with one reciprocating system up to working length and up to an apical diameter of 25.~Placement of polytetrafluroethylene in pulp chamber. No intermediate medication will be filled into the conducts.~Placement of temporary filling. Reduction of the occlusal surface of the tooth until there is no contact with the articulating paper from 200μ."
45669798|NCT01942161|Drug|Aripiprazole Low (2 mg/day)|administered 2 mg once daily for 6 weeks
45669799|NCT01942161|Drug|Aripiprazole Mid (6 - 12 mg/day)|administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg
45669800|NCT01942161|Drug|Aripiprazole High (24 - 30 mg/day)|administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg
45669801|NCT01971645|Drug|Dexamethasone|Patients may receive 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) either perineurally or intramuscularly.
45971901|NCT02212405|Device|repetitive Transcranial Magnetic Stimulation|Each participant will participate in all three arms to receive sham, 1hz and 10hz rTMS as well as PET imaging.
45971902|NCT02212405|Other|repetitive Transcranial Magnetic Stimulation Sham|The sham coil is built in the same helmet of the active coil. The sham coil is has a circular shape and placed perpendicular to the scalp within the same helmet. This coil produces a similar sound and scalp sensation as the real coil.
46081488|NCT04337827|Drug|Acalabrutinib|"100mg twice per day (BID) x 4 weeks (28 day cycle)~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto LTFU."
45455880|NCT05541003|Drug|NBT-NM108|All patients will consume NBT-NM108 in the form of 2 muffins daily.
45828551|NCT04586894|Other|Biobanking|Blood samples (plasma, serum, DNA, stem cells, immune cells) taken as part of the study will be stored in a biological sample collection. These samples may be used for further analysis not described in the initial protocol but which may be useful for investigation or in light of advances in scientific knowledge.
45828552|NCT04586231|Drug|Belzutifan|Immediate-release 40 mg tablet
45828553|NCT04586231|Drug|Lenvatinib|Capsule available in 4 mg and 10 mg dosages
45828554|NCT04586231|Drug|Cabozantinib|Tablet available in 20 mg, 40 mg and 60 mg dosages
45828555|NCT04582916|Drug|11C-MCI|Injected IV followed by PET scanning
45828556|NCT04582916|Drug|11CPS13|Injected IV followed by PET scanning
45828557|NCT04581447|Drug|Metformin|Metformin will start at dose of 850 mg once daily and, at one month increased to 850 mg twice daily
45828558|NCT04581447|Other|Standard Care|Standard Care
45828559|NCT04581447|Dietary Supplement|Standardized meal|Measurements of metformin-induced enterohormones secretion will be done after standardized meal test in a subgroup of patients (ancillary study)
45828560|NCT04580485|Drug|INCB106385|INCB106385 will be administered orally QD
45828561|NCT04580485|Drug|INCMGA00012|INCMGA0012 will be administered IV once every 4 weeks (Q4W)
45828562|NCT04563793|Device|Superion™ IDS|All patients to receive IDS for the treatment of moderate Lumbar Spinal Stenosis symptoms.
45828563|NCT04552665|Device|KODEX-EPD system|To evaluate the performance of the KODEX-EPD system and collect procedural data and medical images for Philips' internal research and development activities (R&D)
45828564|NCT04524689|Drug|SAR408701 (Tusamitamab ravtansine)|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
45828565|NCT04524689|Drug|Pembrolizumab|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
45828566|NCT04524689|Drug|Cisplatin|Pharmaceutical form: Lyophilized powder for reconstitution in solution Route of administration: Intravenous
45828567|NCT04524689|Drug|Carboplatin|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
45828568|NCT04524689|Drug|Pemetrexed|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
45828569|NCT04520685|Drug|Oral cannabidiol 100mg/mL|In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
45828570|NCT04520685|Drug|Placebo|In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
45828571|NCT04519151|Drug|Pembrolizumab|200 mg administered by IV infusion on Day 1 of each 21-day cycle.
45828572|NCT04519151|Drug|Lenvatinib|20 mg administered orally (PO) QD during each 21-day cycle.
45828573|NCT04511650|Drug|Razuprotafib Subcutaneous Solution|Up to 3 daily dose levels of Razuprotafib Subcutaneous Solution will be evaluated. Doses will be administered subcutaneously three times daily (Q8H) for 7 days.
45828574|NCT04511650|Drug|Placebo Subcutaneous Solution|Matched vehicle-controlled placebo solution will be administered subcutaneously three times daily (Q8H) for 7 days
45828575|NCT04506372|Drug|Perioperative withdrawal of angiotensin converting enzyme inhibitors and angiotenin receptor blockers|Withdrawal from 24 hours before surgery until 24-48 hours after surgery. The ACEI/ARB medication is resumed on the second or third day after surgery, as soon as the clinical condition allows based on judgement by the attending physician.
45828576|NCT04506372|Diagnostic Test|Blood draw|Blood will be drawn to measure creatinin and troponin: once before surgery, on the first and second postoperative day, and within 4-8 weeks after surgery
45828577|NCT04506372|Behavioral|Diary to register drug adherence|To register medication adherence, patients will be asked to fill out their medication intake (of ACEI/ARB) in a diary from a week before surgery until surgery.
45828578|NCT04506372|Behavioral|Quality of life questionnaire|Patients are asked to fill out a quality of life questionnaire (EQ-5D) before surgery and at three months after surgery
45828579|NCT04506372|Behavioral|WHODAS questionnaire|Patients are asked to fill out a questionnaire about disabilities (WHO Disability Assessment Schedule 2.0) before surgery and at three months after surgery
45828580|NCT04497012|Drug|2mg/kg/day Iron Sulfate|Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
46081489|NCT04337827|Diagnostic Test|CT scans|2 weeks (day 36 ± 5 days) after end of cycle 1 treatment.
45828581|NCT04497012|Drug|6 mg/kg/day Iron Sulfate|Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
45669802|NCT01971645|Drug|Ropivacaine|Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.
45669803|NCT01941537|Drug|ILV-094|IV infusion of ILV-094
45669804|NCT01941537|Drug|Placebo Comparator|Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of a placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
45669805|NCT01971567|Device|HIRREM|
45669806|NCT01960413|Drug|Montelukast added to Hydroxyurea|
45669807|NCT01960413|Drug|Placebo added to Hydroxyurea|
45828582|NCT04493424|Drug|Spesolimab|Spesolimab
45828583|NCT04484259|Drug|Ticagrelor monotherapy|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
45828584|NCT04484259|Drug|Ticagrelor plus aspirin|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
45828585|NCT04484259|Drug|Clopidogrel with aspirin|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
45828586|NCT04463693|Drug|Etonogestrel implant|Insertion of the contraceptive implant at an alternative insertion site located over the scapula
45828587|NCT04450264|Behavioral|African Immigrant Breast Cancer Education Program|African immigrant women are at significant risk for not participating in preventive screening, such as for breast cancer. Thus, this project will culturally adapt an existing evidenced-based, the Witness Project, by identifying potential barriers and guided by the Health Belief Model incorporate those findings into a group-based narrative education program for English and French-speaking African immigrant women. The program content will include: (1) information about the benefits of early detection of breast cancer screening, (2) education about disparities in breast cancer, (3) disparities in breast cancer screening among African immigrant women, and (4) will address the unique barriers and facilitators of African immigrant women identified in Aim 1 of this study. The program will use a culturally matched peer approach to educate and model successful experiences with mammography screening.
45828588|NCT04423302|Dietary Supplement|TOTUM-63 3 intakes per day|5-g dose of TOTUM-63 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in three intakes (3 in the morning, 2 at lunch and 3 at dinner)
45828589|NCT04423302|Dietary Supplement|Placebo 3 intakes per day|Placebo. Eight capsules per day to consume orally in three intakes (3 in the morning, 2 at lunch and 3 at dinner)
45828590|NCT04423302|Dietary Supplement|TOTUM-63 2 intakes per day|5-g dose of TOTUM-63 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in two intakes (4 in the morning and 4 at dinner)
45828591|NCT04417621|Drug|LXH254|LXH254 will be supplied as tablet for oral use.
45828592|NCT04417621|Drug|LTT462|LTT462 will be supplied as hard gelatin capsule for oral use.
45828593|NCT04417621|Drug|Trametinib|Trametinib will be supplied as film-coated tablet for oral use
45828594|NCT04417621|Drug|Ribociclib|Ribociclib will be supplied in tablets and hard gelatin capsules.
45828595|NCT04405024|Diagnostic Test|Hepatitis C testing|Hepatitis C Screening
45828596|NCT04404985|Procedure|Surgical AVF|"Surgical fistula creation is standard surgical procedures, where a small cut through the skin is made to create a channel directly between a vein and artery .~The study procedures are standard clinical practice, and not considered an experimental procedure."
45828597|NCT04404985|Procedure|Endo-vascular AVF|Endovascular fistula creation is a minimally invasive procedure used to create a canal between close artery and vein at the forearm. A magnet attached to a catheter is passed over a guidewire into the artery while another magnet passed over the guidewire into the vein. The two magnets are aligned close to each other, then the radiofrequency electrode is released from the venous catheter and energized for 2 seconds, creating a channel between the vein and the artery.
45971903|NCT04556929|Diagnostic Test|Intra-operative imaging of 5-ALA fluorescence using ultra-high sensitivity camera|An ultra-high sensitivity camera attached to the side arm of the operative microscope will be used to take images of the anterior, posterior, lateral and inferior walls of the resection cavity on completion of tumour resection.
46081490|NCT04308785|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg intravenously on the first day of each 21-day cycle.
46081491|NCT04308785|Drug|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg intravenously on the first day of each 21-day cycle.
45669808|NCT04661241|Other|Automatic DRT/VIM target-recognition method using MR-SISET and ML approaches|The proposed sequence (<15 minutes) will be added as a supplementary sequence only for the preoperative imaging for subjects who agree to participate: a 3D multi-echo GRE sequence will be performed during a preoperative MR imaging, using the following parameters: field of view = 220x170x75 mm3, matrix = 176x136x60, 1.25-mm isotropic resolution, flip angle = 22 degrees, TR = 92 ms, 20 TEs = 1.90 - 45.98 ms with echo spacing of 2.32 ms, bandwidth = 840 Hz/pixel.
45669809|NCT04661241|Other|Routine clinical MRI protocol|MRI will be performed using 3T scanner (Skyra, Siemens, Erlangen, Germany). All patients will undergo preoperative MRI of the brain including routine clinical MRI protocol (T1-/T2-weighted and diffusion imaging) under general anesthesia to reduce movement artifacts.
45828598|NCT04392011|Drug|Midazolam HCl|Oral syrup, 2 mg/mL
45828599|NCT04392011|Drug|Dextromethorphan HBr|Oral liquid capsules, 15 mg
45828600|NCT04392011|Dietary Supplement|Kratom|Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two g of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Subjects will drink the tea within 10 minutes of administration.
45828601|NCT04390529|Other|quality-of-life questionnaire: BREAST-Q|quality-of-life questionnaire: BREAST-Q
45828602|NCT04370301|Drug|Cyclophosphamide|Given IV
45828603|NCT04370301|Drug|JAK Inhibitor|Given PO
45828604|NCT04370301|Drug|Fludarabine|Given IV
45828605|NCT04370301|Biological|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
45828606|NCT04370301|Drug|Melphalan|Given IV
45828607|NCT04370301|Drug|Mycophenolate Mofetil|Given PO
45828608|NCT04370301|Procedure|Peripheral Blood Stem Cell Transplantation|Given IV
45828609|NCT04370301|Drug|Tacrolimus|Given IV and PO
45828610|NCT04370301|Radiation|Total-Body Irradiation|Undergo TBI
45828611|NCT04348916|Biological|ONCR-177|Intratumorally administered oncolytic immunotherapy comprised of a genetically engineered HSV-1
45828612|NCT04348916|Biological|pembrolizumab|Anti-PD-1 monoclonal antibody
45828613|NCT04326153|Drug|Sintilimab Injection|"Preoperative:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of two cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total~Postoperative:~Patients began to receive postoperative adjuvant treatment within 21-60 days after the operation. Specific medication plan:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of 8 cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total."
45828614|NCT04310163|Other|Natural history|Parent interview and video capture
45828615|NCT04305041|Biological|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
45828616|NCT04305041|Biological|Quavonlimab|Administered via IV infusion at a specified dose on specified days
45828617|NCT04305041|Biological|Vibostolimab|Administered via IV infusion at a specified dose on specified days
45828618|NCT04305041|Drug|Lenvatinib|Administered via oral capsules at a specified dose on specified days
45828619|NCT04305041|Drug|ATRA|Administered via oral capsules at a specified dose on specified days
45828620|NCT04299113|Drug|Vinorelbine|Given IV
45828621|NCT04299113|Drug|Mocetinostat|Given PO
46081492|NCT04308785|Other|Placebo|Placebo matching to tiragolumab will be administered at a dose of 600 mg intravenously on the first day of each cycle.
46081493|NCT04279847|Drug|INCB057643|INCB057643 dose escalation and dose expansion.
45828622|NCT04295603|Other|Toucher Massage (TM) on the feet|The intervention for the Experimental Group (EG) includes a massage time of about 15 minutes (according to current Geneva Hospital practice) on the foot area. At least four sessions will be delivered and spread over two weeks. The TM will be provided by the care team. The training time for the workers corresponds to 2 times 2 hours. In order to be as close as possible to a standardized session, practitioners will benefit from an intervention guide.
45828623|NCT04295603|Other|Homedics HM MP RELEX 90 device|"The Control Group (CG) will benefit from an intervention of identical duration. The treatment consists of a foot massage with a Homedics HM MP RELEX 90 device, a heat-free shiatsu program, which lasts about 15 minutes. The use of the Homedics device is no more a common treatment than the practice of Touch-Massage. TM involves a therapeutic relationship between caregiver and patient. It is for this reason that we need a comparator that should allow us to keep the aspect of the massage while decreasing the aspect of the therapeutic relationship and therefore offer us an adequate comparator."
45828624|NCT04295499|Device|soft (hydrophilic) contact lens|The intervention is a daily wear soft contact lens
45828625|NCT04291001|Device|ENG implant|This is an FDA-approved contraceptive device
45828626|NCT04291001|Drug|oral ulipristal acetate|This is an FDA-approved oral emergency contraceptive
45828627|NCT04285580|Drug|Bimatoprost SR|Consists of 1 Bimatoprost SR administration in the study eye.
45828628|NCT04285580|Drug|LUMIGAN|Treatment with LUMIGAN 0.01% begins on Day 1. The drop will be instilled once daily in the evening to the study eye throughout the duration of the study.
45828629|NCT04272606|Drug|Tranexamic Acid|Antifibrinolytic Agent
45828630|NCT04272606|Drug|Saline Solution|Placebo
45828631|NCT04272606|Diagnostic Test|Visual Acuity Exam|Supplemented into standard of care daily neurological exam on day of surgery and day after
45828632|NCT04272606|Diagnostic Test|3 Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)|3D-CAM is a brief verbal assessment tool that can be used to test patients and study patients for delirium.
45828633|NCT04265430|Other|Contrast Agent|Given IV
45828634|NCT04265430|Procedure|Magnetic Resonance Imaging|Undergo MRI
45828635|NCT04265430|Other|Quality-of-Life Assessment|Ancillary studies
45828636|NCT04265430|Other|Questionnaire Administration|Ancillary studies
45669810|NCT01970475|Biological|ABP 501|Solution for subcutaneous injection in pre-filled syringe
45828637|NCT04259905|Behavioral|Active video game teleconference support group|12 sessions of teleconferenced support group meetings, including active video game play + self-paced walking monitored by Fitbit wearable device
45828638|NCT04259905|Behavioral|Standard support group + pedometer|3 monthly sessions of in-person standard support group meetings + self-paced walking monitored by pedometer
45828639|NCT04258969|Behavioral|Pedaling|Participants will pedaling at a low-moderate intensity using a stationary pedal ergometer concurrent to their chemotherapy (FOLFOX or FOLFIRI) infusion. Participants will cycle for 30 min within the first 2 hours of their infusion.
45828640|NCT04254926|Behavioral|Revie ⊕|Revie ⊕ is a positive approach centered on the resources and strengths of the patient, and it consists of an intervention that focuses on the individual's life review. Revie ⊕ allows specialist nurses to discuss life events with cancer patients, to identify the significant elements, and to explore how the diagnosis has changed their values and preferences. The intervention is geared toward working with the patient to discover their potential, to identify their strategies for coping with the events of their life, and to thereby accompany them in achieving a better understanding of themselves and what defines their identity. The intervention also allows their concerns surrounding death to be addressed, in addition to providing clarity in regard to the life projects. In the end, as a conclusion to the intervention, the patient is provided a booklet recounting the salient features of their life review along with photographs, quotes, or images.
45828641|NCT04245371|Drug|Lidocaine 1.8%|Topical Patch
45828642|NCT04245371|Drug|Placebo|Matching Placebo Patch
45828643|NCT04241185|Drug|Pembrolizumab|400 mg of IV (intravenous) pembrolizumab once every 6 weeks.
45828644|NCT04241185|Radiation|Conventional Radiotherapy (Bladder only)|64 Gy of radiation administered to participant's bladder only. Thirty-two fractions will be administered over 6.5 weeks.
45828645|NCT04241185|Radiation|Conventional Radiotherapy (Bladder and pelvic nodes)|64 Gy of radiation administered to participant's bladder and pelvic nodes. Thirty-two fractions will be administered over 6.5 weeks.
45828646|NCT04241185|Radiation|Hypofractionated Radiotherapy (Bladder only)|55 Gy of radiation administered to participant's bladder only. Twenty fractions will be administered over 4 weeks.
45828647|NCT04241185|Drug|Cisplatin|35 mg of cisplatin per cubic meter of body volume, administered once weekly via IV infusion.
45828648|NCT04241185|Drug|Fluorouracil (5-FU)|5-FU administered via IV infusion at a dose of 500 mg per cubic meter of body volume on Days 1-5 and 22-26.
45828649|NCT04241185|Drug|Mitomycin C (MMC)|MMC administered via IV infusion at a dose of 12 mg per cubic meter of body volume on Day 1.
45828650|NCT04241185|Drug|Gemcitabine|Gemcitabine administered via IV infusion at a dose of 27 mg per cubic meter of body volume twice weekly.
45828651|NCT04241185|Drug|Placebo to Pembrolizumab|Placebo to intravenous (IV) pembrolizumab administered once every 6 weeks.
45828652|NCT04231539|Drug|Nicotine|Vape different flavor nicotine products
45828653|NCT04231539|Device|Vaporizer Device|Take puffs from vaporizer filled with different flavors
45669811|NCT01970475|Biological|Adalimumab|Solution for subcutaneous injection in pre-filled syringe
45669812|NCT04653753|Device|kneeSOFT500|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use a knee support device.
45669813|NCT01939977|Drug|Paricalcitol|1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours.
45669814|NCT01939977|Drug|Calcifediol|5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.
45669815|NCT01939899|Drug|IXAZOMIB|Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days.
45669816|NCT01970397|Device|JUVEDERM® Ultra XC|Up to 3.0 mLs JUVEDERM® Ultra XC injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
45828654|NCT04201821|Biological|fecal microbial transplantation (FMT)|Fecal microbial transplantation (FMT) is the infusion of intestinal microbiota from healthy donors.
46081494|NCT04279847|Drug|Ruxolitinib|Ruxolitinib will be administered twice a day using the dose designated as the stable dose at the time of the screening visit for each subject. Acceptable doses are 5 mg BID to 25 mg BID.
46081495|NCT04272762|Procedure|Cryoablation|Pulmonary vein isolation with cryoablation
46081496|NCT04272762|Procedure|Placebo|Placebo procedure
46081497|NCT04266301|Drug|MBG453|A dose of MBG453 800 mg will be administered intravenously (IV) every 4 weeks (Q4W).
45669817|NCT01970397|Device|Belotero Balance®|Up to 3.0 mLs Belotero Balance® injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
45971904|NCT04556929|Diagnostic Test|Intra-operative imaging of 5-ALA fluorescence using in-built operative microscope camera|In-built camera of the operative microscope will be used to take images of the anterior, posterior, lateral and inferior walls of the resection cavity on completion of tumour resection.
45971905|NCT04556929|Diagnostic Test|Biopsies|Following image capture, biopsies (approx 5x5x5mm size) will be taken from regions of the anterior, posterior, lateral and inferior walls of the resection cavity corresponding to the imaged areas.
45971906|NCT04566406|Procedure|Laparoscopic adrenalectomy|Preoperative staging in all cases consisted of computed tomography or/and magnetic resonance imaging. Prior to surgery, a routine panel of laboratory tests was carried out. The catecholamines metabolites (metanephrine, normetanephrine, and methoxytyramine) were measured from 24-hour urine collection. All patients were preoperatively treated with phenoxybenzamine or alternative doxazosin.Additionally, beta-blockers in case of coexisting tachycardia were given. In the morning of the operation, preinduction blood pressure was measured. Pneumoperitoneum was achieved by insufflating CO2 gas to an intraperitoneal pressure of 12 mmHg. The operative method in our department was laparoscopic transperitoneal lateral total adrenalectomy. Intraoperatively SBP and diastolic blood pressure (DBP) were measured and recorded every 10 minutes. To treat hypertensive and hypotensive episodes, intravenous doses of urapidil, ephedrine, nitrates, MgSO4, norepinephrine, or ß-blockers were administered.
45971907|NCT00232388|Procedure|Blood draw|
45971908|NCT04566367|Diagnostic Test|blue laser imaging|The intervention is the push on demand activation of blue laser imaging technique during gastroscopy.
45971909|NCT00267033|Procedure|injection of orthopaedic cement into vertebral bodies|injection of orthopaedic cement into vertebral bodies
45971910|NCT04566055|Device|AlloSure|Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause.
45971911|NCT04566211|Drug|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
45971912|NCT04566211|Drug|pantoprazole+bismuth+amox+clar|pantoprazole 40 mg twice daily, bismuth subcitrate 240 mg twice daily, and amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days
45971913|NCT00232427|Procedure|Hemodynamic monitoring system PiCCO|
45971914|NCT04565626|Other|Additional weekend physiotherapy|Patients randomized to intervention would receive a Medical Exercise Bike Pedal Exerciser Mini Peddler to allow for an additional 20 minutes a day of unsupervised physiotherapy both during the week and on weekends.
45971915|NCT04565587|Other|Xanthan-gum based thickener|Participants will undergo a screening procedure (V-VST) with two of the viscosities levels determined and prepared with mineral water and Tsururinko Quickly (200 and 800mPa·s). After the V-VST, a Videofluoroscopy (VFS) will be performed with thin liquid and 5 viscosity levels prepared with X-Ray contrast (Omnipaque), mineral water and Tsururinko Quickly (100, 200, 400, 800, 1600mPa·s). Participants swallow will be studied with VFS in a lateral projection and images will include the oral cavity, pharynx, larynx and cervical oesophagus. Swallows will be analysed by equipment developed to capture and digitize the swallowing sequences to assess VFS signs of safety and efficacy according to accepted definitions and to measure the timing and spatial events of the swallow response.
45971916|NCT00232466|Procedure|Vertebroplasty|"Procedure:~The treatment consists of a transpedicular injection of polymethylmethacrylate bone cement into the collapsed vertebral body (maximal 2 vertebrae in 1 treatment session) using fluoroscopic guidance. The procedure is performed under the use of local anesthetics and the patient can be discharged the same day or after 1 night of hospital stay."
45971917|NCT02211040|Behavioral|My Plan|"The intervention consists of three sessions for each behaviour (ie., physical activity, fruit and vegetables intake) and is available on a website and tablets to deliver it in general practice.~Adults can start session one on a tablet in general practice or on their own computer at home, after receiving a flyer in general practice.~In this first session adults receive general information, monitor their behaviour and receive tailored feedback to increase awareness.~Adults are also guided to set goals and self-efficacy is increased by modeling and problem solving methods.~In the second and third session, adults can evaluate if they reached their goals, make coping plans and adapt their action plans."
45669818|NCT01970241|Drug|NPH|NPH given per study table based on steroid dose and patient weight in kg.
45971918|NCT00259779|Drug|budesonide/formoterol|
45971919|NCT00259779|Drug|Prednisolone|
45971920|NCT02211079|Drug|JNJ-54861911|JNJ-54861911, 50 mg (2*25 mg tablets) orally once daily from Day 2 to Day 9.
46081498|NCT04266301|Drug|Azacitidine|A dose of Azacitidine 75 mg/m2 will be administered IV or subcutaneously (SC) on Day 1-7, or Day 1-5, 8 and 9.
46081499|NCT04266301|Drug|Placebo|A dose of Placebo 800 mg will be administered intravenously every 4 weeks (Q4W).
46081500|NCT04263922|Drug|Huaiqihuang granules|Huaiqihuang granules, 2 bags at a time, 3 times a day. Valsartan capsule simulant, 80mg at a time, once a day. Oral administration.
45455881|NCT05540691|Device|Wear noise-cancelling earphones|Intervention of wearing noise-canceling earphones after general anesthesia
45669819|NCT01970241|Drug|Correction Factor|Given at 2 units per 50 mg/dl over 200 mg/dl and increased to 3 units/50 mg/dl over 200 if glucose rises to over 300 mg/dl. Administered qid during study duration.
45669820|NCT01939353|Drug|CTN SR|CTN SR tablets
45669821|NCT01939353|Drug|Placebo|CTN SR-matching placebo tablets
45669822|NCT01970007|Device|Zilver Vena Venous Self-Expanding Stent|stenting
45669823|NCT01728376|Drug|Daptomycin|Intravenous daptomycin given at 7 mg/kg (ages 12-17 years); 9 mg/kg (ages 7-11 years); 12 mg/kg (ages 1-6 years) infused once daily, intravenously, over 30 or 60 minutes. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
45828655|NCT04200313|Combination Product|Bionic Pancreas (BP) with Aspart or Lispro|iLet Bionic Pancreas System, which consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls insulin delivery based on glucose values obtained by communicating with a Dexcom G6 sensor using lispro or aspart insulin.
45828656|NCT04200313|Combination Product|Bionic Pancreas with Fiasp (BPFiasp)|iLet Bionic Pancreas System, which consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls Fiasp insulin delivery based on glucose values obtained by communicating with a Dexcom G6 sensor.
45455882|NCT05539859|Procedure|Endoscopic surgery|Subjects will receive surgical hematoma evacuation using neuroendoscope, followed by medical management
45455883|NCT05539859|Other|Medical management|Subjects will initially receive the standard medical therapies for the treatment of intracerebral hemorrhage, according to the latest available guideline.
45455884|NCT05538286|Device|ClearFit implant|The ClearFit implant is an FDA cleared implant in regular use in the United States. The ClearFit implant and other PMMA cranioplasty implants manufactured by Longeviti have been reported to be safe and effective as cranial implants that permit transcranial ultrasound to be performed. The PMMA cranioplasty implant (Longeviti Neuro Solutions, Hunt Valley, MD) is clear, sonolucent, and was recently shown to be safe and effective in transcranial ultrasonography for bypass patency assessment. The ClearFit cranioplasty being used in this study is industry standard of care.
45455885|NCT05538286|Procedure|transcranial ultrasonography through sonolucent cranioplasty|The implantation of the ClearFit PMMA sonolucent implant permits TUSC to be performed at the bedside for patients in both the in-patient and outpatient settings. While the patient is an inpatient, the clinical or research teams will attempt to perform TUSC within 1 hour of neuroimaging if that neuroimaging is performed at a time when a trained ultrasound operator is present.
45828657|NCT04200313|Other|Usual Care (UC)|Using pre-study insulin regimen with the Dexcom G6 CGM
45828658|NCT04200313|Other|BP Guidance Insulin Dosing|Pre-study insulin delivery method with SMBG and blinded CGM with dosing guidance by the BP
46081501|NCT04263922|Drug|Valsartan capsule|Valsartan capsule, 80mg at a time, once a day. Huaiqihuang granules simulant, 2 bags at a time, 3 times a day. Oral administration.
46081502|NCT04252625|Drug|Q-Urol|Q-Urol is an over-the-counter herbal supplement manufactured by Farr Laboratories. It is a combination product composed of quercetin, pollen extract, bromelain, and papain.
46081503|NCT04252625|Drug|Placebo|placebo capsule
46081504|NCT04251117|Biological|GNOS-PV02|GNOS-PV02 delivered by intradermal injection and electroporation
46081505|NCT04251117|Biological|INO-9012|INO-9012 delivered by intradermal injection and electroporation
46081506|NCT04251117|Drug|Pembrolizumab|Pembrolizumab administered as an intravenous (IV) infusion
45828659|NCT04200248|Drug|RBM-007 Injectable Solution|RBM-007 Injectable Solution
45828660|NCT04200248|Drug|Aflibercept|EYLEA® (aflibercept) Injection, for Intravitreal Use
45828661|NCT04200248|Drug|Sham|Sham intravitreal injection
45971921|NCT02211079|Drug|Caffeine|Single oral dose of caffeine 100 mg (2*50 mg tablets), on Day 1, 2, and 9.
45971922|NCT02211079|Drug|Midazolam|Single oral dose of midazolam 2 mg (1 mL, 2 mg/mL solution), on Day 1, 2, and 9.
45828662|NCT04199689|Biological|9vHPV Vaccine|9-valent human papillomavirus vaccine (9vHPV) is an aluminum-adjuvanted recombinant protein vaccine prepared from the highly purified virus-like particles (VLPs) of the recombinant major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 given as a 0.5 mL intramuscular injection.
45971923|NCT02211079|Drug|Tolbutamide|Single oral dose of Tolbutamide 500 mg tablet, on Day 1, 2, and 9.
45971924|NCT04565860|Other|Bulk-fill composite resin. (Dental Composite Resin Materials) (Dental filling materials)|"Bulk-fill composites that were introduced in recent years are dental filling materials. Traditionally, the composite resins are placed in increments of 2 mm that are cured separately (incremental technique). Bulk-fill composites can be described as composites that are sufficiently polymerizable in a single layer up to 4 mm thick.~In this study, each bulk-fill composite resin was used both in bulk-filing and incremental techniques for the same patient. The study set to 4 groups and 20 restorations in each group (a total of 80 restorations)."
45971925|NCT00232622|Drug|Streptokinase|Accelerated infusion of streptokinase
45971926|NCT00232622|Drug|Streptokinase|Standard dose streptokinase
45971927|NCT04565938|Procedure|Application of adhesive for the restoration of dental lesions with resin composite|"Mechanical removal of sclerotic dentin with a round bur~Enamel beveling~Enamel (30sec) and dentin (15sec) etching with phosphoric acid~Application of ExciTE (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec with 800mW/cm2 light intensity (Cure TC-01, Spring Health Products, Inc, Norristown, PA, USA)~Composite-resin application using a transparent cervical matrix (Kerr-Hawe, Orange, CA, USA) and curing for 40sec~Finishing and polishing"
45971928|NCT04565938|Procedure|Application of adhesive for the restoration of dental lesions with resin composite|"Mechanical removal of sclerotic dentin with a round bur~Enamel beveling~Application of AdheSE One (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec~Composite-resin application using a transparent cervical matrix and curing for 40sec~Finishing and polishing"
45971929|NCT04565938|Procedure|Application of adhesive for the restoration of dental lesions with resin composite|"Mechanical removal of sclerotic dentin with a round bur~Enamel beveling~Enamel (30sec) etching with phosphoric acid~Application of AdheSE One and curing for 10sec~Composite-resin application using a transparent cervical matrix and curing for 40sec~Finishing and polishing"
45971930|NCT04565548|Other|Educational program for hypertensive patients|The theory-guided program consisted of one session of health education, self-developed leaflet, and weekly text messaging for 12 weeks.
45971931|NCT04565548|Other|Usual care|One standardized health education and a leaflet developed by the Health Bureau. As similar as the intervention group, weekly text messaging will be delivered, but the content is not related to the blood pressure control.
45971932|NCT04565314|Dietary Supplement|Plumpy'Mum|Mothers will consume Plumpy'Mum (one packet daily) from enrollment (child age 0-3 months) for 3 months.
45971933|NCT04565002|Device|Transcutaneous Electrical Diaphragmatic Stimulation|The procedure consists of electrical stimulation in the region of the motor points of the diaphragm. Its configurations contribute to produce involuntary muscle contractions. There are four electrodes positioned superficially on the skin.
45971934|NCT00259818|Drug|EM-1421|
45971935|NCT04565197|Biological|convalescent plasma|"Transfuse 2 aliquots of plasma (200 mL x 2) per patient.~Transfuse first aliquot for 2-3 hours (~1.4 to 2 mL/min)~Transfuse second aliquot at same rate 2 hours after completion of first aliquot"
45971936|NCT00232661|Drug|ARIMIDEX (anastrazole)|
45971937|NCT00232661|Drug|NOLVADEX (tamoxifen)|
45971938|NCT04564924|Radiation|DXA|Bone mineral density was examined in all cases and controls
45828663|NCT04199689|Other|Placebo (Saline for Injection)|0.9% sodium chloride given as a 0.5-mL intramuscular injection
45828664|NCT04192591|Device|Superion™ IDS device|The Superion™ IDS is a minimally-invasive spinal implant that treats LSS symptoms by limiting extension at the symptomatic level that compresses the neural elements and is designed for percutaneous surgical placement.
45828665|NCT04189432|Biological|SCM-CGH|SCM-CGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
45971939|NCT00267267|Drug|torcetrapib/atorvastatin|
45971940|NCT00267267|Drug|ezetimibe/simvastatin|
45971941|NCT04564729|Other|Shared Decision Making|The intervention group will receive a shared decision-making intervention including a decision aid and conversation with a study investigator. The intervention group will have the opportunity to choose the number of opioid pills they receive at discharge from hospital after total knee arthroplasty.
45455886|NCT05538091|Drug|Vismodegib|A small-molecule SMO inhibitor designed to specifically target the hedgehog pathway, a known driver of BCC. It systemically inhibits hedgehog pathway signaling. Following mutation, SMO is released from the inhibitory effect of PTCH and moves to the cell surface, activating GLI. GLI travels to the nucleus and initiates transcription of target genes that regulate basal cell growth and proliferation.
45828666|NCT04189432|Other|Placebo|Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
45828667|NCT04189419|Biological|SCM-AGH|SCM-AGH will be administrated once a day for 3 days(D0, D1 and D2).
45828668|NCT04189419|Other|Placebo|Placebo will be administrated once a day for 3 days(D0, D1 and D2).
45828669|NCT04188522|Diagnostic Test|Magnetoencephalography (MEG)|Participants will undergo MEG at the University of Maryland (College Park) to measure cerebral activity while performing a visual naming task. The Montreal Cognitive Assessment (MOCA) will also be administered.
45971942|NCT04564651|Other|platelet transfusion|when the ADP inhibition >70%, give one unit platelet tansfusion
45971943|NCT04564690|Dietary Supplement|QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein)|Consumption of three QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein) per day for three weeks
45971944|NCT04564690|Dietary Supplement|Regular hen eggs|Consumption of three regular hen eggs per day for three weeks
45971945|NCT00232700|Drug|Escitalopram|
45971946|NCT04564456|Drug|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test oproduct in one study period
45971947|NCT04564456|Drug|ADVAIR DISKUS® 500/50|2 inhalations Reference product in one study period
45971948|NCT04564144|Drug|Meclizine Hydrochloride|A study will be conducted on the three tested orodispersible tablets and the commercial one (control). 6 volunteers are asked to cease any medication 7 days prior to blood sampling at least. Each volunteer will undergo 4 study sessions with one week of washout period in between (cross-overed to receive the other formulation). All volunteers are asked to fast overnight before taking the tablet. The tablet should be kept for 10 min in the mouth before swallowing without water. Just before taking the tablet, three milliliters of venous blood samples will be drown (predose, 0 h) and at 30, 60, 90, 120, 240, 360, 480, 720 min and 24 h postdose and stored in tubes coated with sodium heparin. Separation of plasma from Blood samples will be carried out by centrifuging at 5000 rpm for 10 min, then, it will be frozen at -20°C until analysis. By employing high-performance liquid chromatography (HPLC), the plasma concentration of MCZ will be assayed
45971949|NCT00267306|Drug|Visilizumab|
45971950|NCT04563949|Other|Repeat Testing|Repeat Testing with the PLA will be conducted
45971951|NCT00232778|Device|GAMMA-Iridium-192 catheter|
45971952|NCT04674787|Other|Peripheral nerve stimulation provocation study|Study which measures stimulation thresholds in volunteers induced by low frequency electromagnetic gradients used in MRI scanners.
45971953|NCT04563910|Other|young mania rating scale|questionnaires to the patients and their family after their written consent
45971954|NCT00259896|Drug|exenatide|
45971955|NCT04721795|Drug|Atorvastatin with standard anti tuberculosis drugs|Participants will receive oral 30/40mg of atorvastatin daily for 2 months together with oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
45828670|NCT04179760|Biological|SCM-AGH|SCM-AGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
45828671|NCT04179760|Other|Placebo|Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
45455887|NCT05538091|Drug|Atezolizumab|Atezolizumab is a humanized monoclonal antibody immune checkpoint inhibitor that selectively binds to PD-L1 to stop the interaction between PD-1 and B7.1 (CD80 receptors). The antibody still allows interaction between PD-L2 and PD-1.
45828672|NCT04178096|Other|Quality Improvement Intervention|The investigators will assess the effectiveness of empirically determined implementation strategies that are associated with increasing cirrhosis evidence based practices and thus improving outcomes of Veterans with cirrhosis by introducing a bundle of these strategies to four new 'low-performing' hospitals every six months during and eighteen month period in this stepped wedge cluster randomized trial.
45828673|NCT04178018|Device|Photoacoustic imaging|-Emerging technique in which a short-pulsed laser beam penetrates diffusively into a tissue sample
45828674|NCT04178018|Device|Ultrasound|-The ultrasound is being used in conjunction with the photoacoustic imaging
45828675|NCT04153422|Drug|Panzyga IVIG|Immune Globulin Infusion 10% (Human)
45971956|NCT04721795|Drug|Anti tuberculosis drugs only|Participants will receive oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
45971957|NCT04675021|Drug|AZD6094 (Savolitinib) film coated tablets 600 mg|AZD6094 (Savolitinib) ilm Coated Tablet 200 mg x 3
45971958|NCT04675021|Drug|[14C]-AZD6094 (Savolitinib) Solution for Infusion, 20 μg/mL (NMT 37.0 kBq/5 mL)|14C AZD6094 (Savolitinib) Solution for Infusion (20 μg/mL (NMT 37.0 kBq/5 mL)
45971959|NCT04675021|Drug|[14C] AZD6094 (Savolitinib) Oral Solution, 300 mg (NMT 4.1 MBq)|14CAZD6094 (Savolitinib) Oral Solution (300 mg NMT 4.1MBq)
45971960|NCT04564066|Biological|efgartigimod IV|intravenous infusions of efgartigimod
45971961|NCT04564066|Biological|efgartigimod PH20 SC|subcutaneous injections of efgartigimod PH20 SC
46081507|NCT04251117|Device|CELLECTRA®2000 EP Device|CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.
46081508|NCT04249622|Other|Best Practice|Given standard of care pertuzumab-based chemotherapy
46081509|NCT04249622|Other|Questionnaire Administration|Ancillary studies
46081510|NCT04249622|Drug|Rifaximin|Given PO
45828676|NCT04153422|Drug|Placebo|0.9% NaCl prepared as the calculated dose equivalent volume to IVIG.
45828677|NCT04142177|Other|Pain EASE|The internet-based pain self-management program consists of open access to the Pain EASE program (Pain E-health for Activity, Skills, and Education) for the duration of participation in the trial. Pain EASE has 10 pain coping skill modules: pain education, setting personal goals, planning meaningful activities, physical activity (stretching, body mechanics, and a pedometer-based walking program), relaxation, developing healthy thinking patterns, pacing and problem-solving, improving sleep, effective communication, and future planning.
45828678|NCT04142177|Procedure|Tailored exercise|Findings from the initial examination and the Keele STarT Back Screening Tool (Hill, et al., 2011) will be used by the physical therapist to guide and tailor the intervention to individual participants which will involve up to 8 treatment sessions with ongoing home exercise. For most participants, exercise and physical activity will focus on walking in addition to motor control and stabilization exercises for the low back with flexibility exercises when lumbar spine stiffness is present.
45971962|NCT04564222|Dietary Supplement|Micronutrient Enriched Crackers (MECs)|"MECs are manufactured according to the Standard Operational Procedures which have been developed taking into account the Hazard Analysis and Critical Control Point (HACCP) to maintain quality and safety and ensure the Ready-to-eat MEC products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detectable) in the MEC products have been obtained from analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of MEC products will be repeated at the middle and the end of the RCT to check on the quality and safety of the MEC product."
45971963|NCT04564222|Dietary Supplement|Placebo|"Placebo crackers are manufactured according to SOPs which have been developed taking into account the HACCP to maintain quality and safety and ensure the Ready-to-eat placebo products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detected) in the placebo have been obtained based on the analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of placebo samples will be repeated at the middle and the end of the RCT to check on the quality and safety of the placebo product."
45971964|NCT00232817|Drug|Nicotine (drug)|nicotine nasal spray (3mg) before surgery
45971965|NCT04674865|Other|Standardized Physical therapy protocol|Standardized Phase 1 protocol without for 7 days without ANB sessions.
45971966|NCT04674865|Other|Alternate nostrils breathing|Alternate nostrils breathing 2 sessions per day
45669824|NCT01728376|Drug|Comparator|Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin: administered per standard of care. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
45669825|NCT01708174|Drug|LDE225|Sonidegib for oral suspension was supplied in amber glass bottles. Sonidegib oral suspension was combined with the supplied reconstitution vehicle to a final concentration of 50 mg/mL.
45669826|NCT01708174|Drug|TMZ|Temozolomide capsules were obtained locally by the Investigator
45669827|NCT02488759|Drug|Nivolumab|
45669828|NCT02488759|Drug|Ipilimumab|
45669829|NCT02488759|Drug|Relatlimab|
45971967|NCT04674943|Other|Breathing exercises|Breathing exercises as well as Buteyko technique and Papworth relaxation method was performed as relaxation technique. All exercises were performed 15rep 3 sets for 15 min.
45971968|NCT00267384|Drug|Oral N-Acetylcysteine|
45971969|NCT04674904|Other|Dry Needling|Dry needling on Upper trapezius, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids for 10 min
45971970|NCT04674904|Other|Hot pack , TENS , Stretching|"Treatments are~Hot Pack for 15 minutes~TENS for 10 minutes~Stretching~The third treatment which is Stretching will be given one time on each muscle (tight upper trap, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids) of upper spine"
45971971|NCT04675060|Drug|TQ-B3139 capsules|TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.
45971972|NCT04674982|Device|a vibrating device|vibrating device (Mini vibrator, 8.5 cm, 92-100 Hz)
45971973|NCT00259935|Drug|topotecan|topotecan
45971974|NCT00424736|Procedure|whole body CT scan|
45828679|NCT04142177|Other|Continued Care and Active Monitoring|CCAM will not be standardized keeping in line with the pragmatic nature of this trial. CCAM may be variable across sites and for individual participants reflecting de facto clinical practice for cLBP. Clinical practice may involve pharmacological and non-pharmacological treatments for cLBP. Current analgesics (including opioids, acetaminophen, NSAIDs, topical analgesics (capsaicin), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, skeletal muscle relaxants, and alpha-2-delta ligands (gabapentin-like drugs)) and non-pharmacological treatments may be continued by participants. CCAM participants will be encouraged to discuss pain problems with their treating physician, but not begin new treatments if possible. Patients will specifically be discouraged from starting CBT, chiropractic, or yoga. Other than this, there will be no attempt by study personnel to influence pain management.
45971975|NCT04674709|Drug|Oleander 4X - single|Cohort 1 receive 4 doses of Oleander 4X in a 24-hour period for a period of seven days.
45971976|NCT04674709|Drug|Oleander 4X - double|Cohort 2 receive 2 doses of either active drug or placebo 4 times per day in a 24-hour period for a period of seven days.
45971977|NCT04674709|Drug|Oleander 4X - quadruple|Cohort 3 receive 4 doses of either active drug four times per day in a 24-hour period for a period of seven days.
45971978|NCT04674709|Drug|Placebo|The placebo group receives 4 doses of placebo in a 24-hour period for a period of 7 days
45971979|NCT00555841|Drug|ALC and Placebo|ALC and Placebo
45971980|NCT00232856|Device|drug-eluting stent|PCI
45971981|NCT00259974|Drug|Rituximab|Rituximab
45971982|NCT00555919|Drug|Lonaprisan (ZK 230211, BAY86-5044)|25 mg daily oral treatment
45971983|NCT00555919|Drug|Lonaprisan (ZK 230211, BAY86-5044)|100 mg daily oral treatment
45971984|NCT00555958|Device|Active, implantable, intra-abdominal vagal blocking medical device|Intermittent, programmable, intra-abdominal vagal blocking
45971985|NCT04674475|Device|Pressure guidewire, optimal coherence tomography|Pressure guidewire, optimal coherence tomography
45971986|NCT00232895|Drug|lipuro propofol|
45971987|NCT00232895|Drug|standard formulation propofol|
45971988|NCT04674280|Procedure|aHSCT|Autologous haematopoietic stem cell transplantation
45669830|NCT02488759|Drug|Daratumumab|
45971989|NCT04673968|Other|prehabilitation|inhospital exercise training 5 times/week, 5~6 weeks during nCRT; home exercise 5 times/week, 5~6 weeks, between completion of nCRT and before surgery
45971990|NCT04674046|Device|Nonoperative treatment|Patients where the ankle is evaluated as stable using arthroscopy will be treated with conservative treatment using a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.
45971991|NCT04674046|Procedure|Operative treatment|Patients where the ankle is evaluated as unstable using arthroscopy will be operated on. Standard operative treatment is open reduction and internal fixation (ORIF) of the fracture using plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.
45971992|NCT04674046|Behavioral|Standardized education|All participants, regardless of group allocation, will receive education focusing on basic self- management. A physiotherapist will be responsible for the education. The intention will be to increase self-efficacy and encourage self-management. Participants will learn about crutch walking, cast or orthosis usage, loading principles, be advised to stay physically active within proper restrictions and how to rest and reduce pain and swelling of the ankle in the acute phase. Participants will also receive a standard information brochure about the condition, treatment and basic self-management.
45971993|NCT00260013|Procedure|program of care delivery|
45971994|NCT00232934|Drug|Thalidomide|
45971995|NCT04673812|Drug|Bupivacaine-fentanyl|"Bupivacaine-Fentanyl (BF) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and (0.5 mL) normal saline added in the same syringe in a total volume of 3.5 mL.~Bupivacaine-Fentanyl-Naloxone (BFN) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and 20 µg Naloxone (prepared in 0.5 mL normal saline) added in the same syringe in a total volume of 3.5 mL."
45971996|NCT04673461|Drug|STA363 containing 90 mg (60 mg/mL) lactic acid|STA363 containing 90 mg (60 mg/mL) lactic acid will be injected into the center of up to two intervertebral discs.
45971997|NCT04673461|Drug|STA363 containing 180 mg (120 mg/mL) lactic acid|STA363 containing 180 mg (120 mg/mL) lactic acid will be injected into the center of up to two intervertebral discs.
45971998|NCT04673461|Other|Placebo|Placebo will be injected into the center of up to two intervertebral discs.
45971999|NCT00260052|Drug|Erythropoietin administration|
45972000|NCT00232973|Drug|ICXP007|
46081511|NCT04246047|Drug|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate
45669831|NCT01605916|Drug|AZD6244|Tablet Oral bid
45669832|NCT02416609|Radiation|LDR|LDR will be delivered during each cycle of Gem-based doublets
45669833|NCT02416609|Drug|Gem-based doublets|4 cycles of Gem-based doublets
45669834|NCT02416609|Radiation|SBRT|SBRT will be administered after the fourth Gem-based doblet cycle, if no progression; three fractions will be administered
45669835|NCT02321137|Procedure|Surgical closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease. The operation as well as the pre and post-operative care will be performed according to local surgical policies.
45972001|NCT04673500|Drug|Propofol lidocaine through large vein|A mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given through a large antecubital vein to assess pain severity on propofol injection during general anesthesia induction
45972002|NCT04673500|Drug|Propofol lidocaine through small vein|A mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given through a small vein on the dorsum of hand to assess pain severity on propofol injection during general anesthesia induction
45972003|NCT04673695|Drug|Lixiana(D006)|NOAC(Factor Xa inhibitor)
45972004|NCT04673695|Drug|CKD-344|NOAC(Factor Xa inhibitor)
45972005|NCT04673305|Other|Cognitive Assessment, Cytokine dosage|Once the patient's informed consent has been acquired, a neurological examination is carried out, with functional tests required by the protocol. The patient carries out, as per clinical practice, the treatment provided for the cure of his disease. The evaluation of the tests is repeated at 6 months and 12 months after enrollment in the study. In conjunction with a venipuncture performed for the exams required by clinical management, a blood sample is taken to measure the cytokines involved in inflammatory processes.
45972006|NCT04673344|Device|Regeneten Collagen Patch|Partial rotator cuff repair surgery with the addition of the Regeneten scaffold
45972007|NCT00233012|Drug|Topiramate|
45972008|NCT04673110|Diagnostic Test|Neutrophil to Lymphocyte Ratio and C-reactive protein|Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
45972009|NCT00267540|Behavioral|cholecalciferol (D3) (vitamin)|
45972010|NCT04672954|Drug|BI 474121|BI 474121
45972011|NCT04672954|Drug|Placebo|Placebo
45972012|NCT04672993|Device|Urine collection device for men|Use of urine collection device for men
45972013|NCT04673188|Procedure|Reconstruction of MPFL with or without tibial tuberositas osteotomy|Reconstruction of the medial patellofemoral ligament with autologous grafts with or without osteotomy and transfer of tibial tuberosities.
45972014|NCT00233051|Drug|Salmeterol or Salmeterol/Fluticasone|
45972015|NCT04673227|Diagnostic Test|Blood draw|Blood draw and the analysis of blood in laboratory
45972016|NCT00260091|Procedure|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
45669836|NCT02321137|Procedure|No closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
45669837|NCT02217709|Drug|phenelzine sulfate|Given by mouth
45669838|NCT02217709|Other|laboratory biomarker analysis|Correlative studies
45669839|NCT02217709|Other|questionnaire administration|Ancillary studies
45828680|NCT04142177|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants randomized to CBT in Step 2 will receive treatment with a trained therapist using the VA's CBT-chronic pain (CBT-CP) protocol involving one planning session and 9 treatment sessions (10 total) over 3 months. The VA's CBT-CP protocol consists of 11 core CBT-CP modules that can be completed in up to 10 sessions. Weekly, individual sessions of 45-50 minutes are recommended, although it is recognized that bi-weekly or other arrangements are often made to fit practical needs.
45972017|NCT00260091|Procedure|infertility|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
45972018|NCT04673071|Other|Thread Embedding Acupuncture (TEA)|"TEA in 1 month for 4 months The six TEA points used in this study are GV20, BL15, BL18, ST40, GV14 and GB34.~Acupuncture point Procedure Baihui (GV20) oblique insertion toward nose, 3cm Both Xin Shu (BL15) perpendicular insertion, 3cm Both Gan Shu (BL18) perpendicular insertion, 3cm Both Fenglong (ST40) perpendicular insertion, 3cm Dazhui (GV14) perpendicular insertion, 3cm Both Yanglingquan (GB34) perpendicular insertion, 3cm"
45972019|NCT04673071|Other|Sham-TEA (STEA)|STEA in 1 month for 4 months All procedure of Sham-TEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
45972020|NCT04672642|Device|SpyGlass DS|Detection by the SpyGlass DS of residual pancreatic stones not detected by the standard method (CT scan and ERCP)
45972021|NCT00233129|Behavioral|Top Down|Six months
45972022|NCT00233129|Other|cognitive rehabilitation day treatment program|six months
45972023|NCT00260130|Other|food in fluid form|dietary intake of fluid forms of vegetables
45972024|NCT00260130|Other|food in solid form|dietary intake of solid forms of vegetables
45972025|NCT04672603|Procedure|Complete Preservation of Denonvilliers' Fascia|Patients accept L-PANP surgery with complete preservation of Denonvilliers Fascia
46081512|NCT04246047|Drug|Daratumumab|Anti-cluster of differentiation 38 [CD-38] monoclonal antibody
46081513|NCT04246047|Drug|Bortezomib|Proteasome Inhibitor
46081514|NCT04246047|Drug|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity
45669840|NCT03921541|Drug|Pegzilarginase|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
45669841|NCT03921541|Drug|Placebo|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
45669842|NCT03921541|Drug|Pegzilarginase|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
45669843|NCT02161783|Drug|Fludarabine|Fludarabine 30 mg/m2 IV over 1 hour given on days -6 through -2 of transplant.
45972026|NCT00233168|Behavioral|Adherence Program|14 counseling sessions focusing on INH adherence conducted over 6 months, starting once per week and decreasing in frequency to once a month.
45972027|NCT00233168|Behavioral|Life Skills and Self-Esteem Training Program (Attention Control Arm)|Peer counseling session covering life skills (e.g., communication skills, goal setting, self-esteem) training, 14 sessions over 6 months beginning once per week and decreasing in frequency over time to once per month.
45972028|NCT04672837|Procedure|Pediatric Integrative Manual Therapy and educational therapy|Pediatric Integrative Manual Therapy is a soft Orthopedic Manual Therapy approach por infants and children. It integrates joints soft mobilisation, myofascial release and neurodynamic mobilisation. Also the educational therapy.
45972029|NCT04672837|Procedure|Stretching and educational therapy|It is a protocol of stretching based on literature research. Also the educational therapy with counter positioning, stimulation in prone position, positional care, etc.
45972030|NCT00267579|Behavioral|Strongest Families (formerly Family Help Program): Behaviour Disorder Program|Evidence-based psychological and behavioural Distance Intervention
45972031|NCT04672759|Drug|Durvalumab|Patients receive durvalumab as an intravenous infusion over 60 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
45972032|NCT04672759|Drug|Durvalumab|Durvalumab monotherapy or combined with chemotherapy and/or radiotherapy.
45972033|NCT04672408|Device|His bundle pacing|Pacing with capture of the His bundle
45972034|NCT04672408|Device|Right ventricular pacing|Pacing from the right ventricular lead (septal or apical)
45972035|NCT04672096|Device|Neuronoff BASMATI Injectrode|The 28 day temporary placement of a Basmati Injectrode does not result in unexpected levels of inflammation or encapsulation.
45972036|NCT00260169|Behavioral|Collaborative care treatment|Patients receiving collaborative care treatment choose 12 weeks of CBT and/or medication management (antidepressants prescribed by patients' primary care provider) from the study depression care specialist (DCS).
45972037|NCT00260169|Behavioral|Enhanced usual care|Usual care participants are assigned to a 16-week wait-list for the study treatment, during which they are free to receive treatment elsewhere. A letter is given to participants' primary care providers (PCP) that indicates they screened positive for depression. In addition, patients receive an information booklet about depression and a community resource list.
45972038|NCT04672330|Drug|Tislelizumab|Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) before radical nephroureterectomy and lymphadenectomy.
45972039|NCT00233207|Drug|IC14|
45972040|NCT04672057|Other|assessment of gait parameters|Gait parameters have been recourded with the use of BTS G-Walk Wireless Digital Walking Analysis System on a 10-meter smooth walking area.
45972041|NCT00260247|Drug|carbamazepine oxcarbazepine|
45972042|NCT04671979|Diagnostic Test|Lactate Dehydrogenase|All the patients that arrived at the hospital with symptoms of mesenteric ischemia, had a registered lactate dehydrogenase. We compared the value with the patient's outcomes.
45972043|NCT00233246|Procedure|FFP Infusion|
45669844|NCT02161783|Drug|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours given on days -6 and -5 from transplant. And Cyclophosphamide 50 mg/kg IV over 2 hours given on days +3 and +4 from transplant.
45669845|NCT02161783|Radiation|Total Body Irradiation|TBI 200cGy in a single fraction on day -1 from transplant.
45669846|NCT02161783|Biological|Hematopoietic stem cell infusion|Hematopoietic stem cell infusion given on day 0.
45972044|NCT04671745|Behavioral|Music|patient receiving care with interactive music
45972045|NCT04671745|Behavioral|No music|patient receiving care without interactive music
45669847|NCT02158507|Drug|Combination of Veliparib + Lapatinib|Treatment cannot be in administered conjunction with other chemotherapy, targeted therapy, radiation therapy, or other investigational drugs.
45669848|NCT04791553|Drug|Cenobamate|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
45669849|NCT04192747|Device|Percutaneous Coronary Intervention|Percutaneous coronary intervention of de novo native coronary artery lesions
45669850|NCT05651347|Other|Placebo|Tablets, visually identical to the melatonin tablets, but containing no active ingredient are administered three times a day.
45972046|NCT00260286|Behavioral|Energy availability|
45972047|NCT04671940|Other|DNA Analysis|Molecular analysis includes DNA analysis on the blood/saliva and on the cancer specimens from the biopsies & subsequent resections
45972048|NCT04671589|Drug|Meropenem Injection|"Administration Intravenous meropenem 1gram every 8 hours together with standard care;~."
45972049|NCT04671199|Other|MP 3000 monitor|Additional monitoring
45669851|NCT05651347|Drug|Melatonin 10 MG|Melatonin 10 mg tablets will be administered three times a day, up to a maximum of 30 mg daily
45669852|NCT05651269|Drug|Milciclib Dose: 150 mg/day Mode of administration: oral|milciclib plus gemcitabine
45972050|NCT00260325|Drug|valdecoxib|
45972051|NCT04671277|Other|Chewing of breads|"During the video recording session, participants were asked to place the whole sample (5-6 g) in the mouth (e.g. single bite) and chew naturally until the bolus is ready for swallowing.~During the second section, participants were asked to place the whole sample in the mouth and chew naturally. After 5 chewing cycles, participants checked all the attributes that describe the texture sensations perceived at the beginning of mastication. A list of attributes and their definitions were provided to guide the participants. Participants proceeded with chewing until the swallowing point when they again checked all the attributes that characterize the texture sensations perceived at the end of mastication. The food bolus was then spat in a container."
45972052|NCT00233441|Drug|CELIVARONE (SSR149744C)|
45972053|NCT04671160|Diagnostic Test|Assessment the activity of anti-Xa factor.|Assessment the activity of anti-Xa factor in patients treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis, patients treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis, patients not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis and patients not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
45972054|NCT04671394|Procedure|FMUD + DLIG|Full-Mouth Ultrasonic Debridement + Diode Laser and Indocyanine Green solution
45972055|NCT04671394|Procedure|FMUD + ST|Full-Mouth Ultrasonic Debridement + Sham Treatment
45972056|NCT04671550|Diagnostic Test|questionnaire|"Questionnaire on Driving performances and Visual Field"
45972057|NCT00233558|Drug|adalimumab (up to 9 months exposure)|
45972058|NCT00233558|Drug|methotrexate|
45972059|NCT00267618|Behavioral|FHP Pain|Evidence-based psychological and behavioural Intervention
45972060|NCT04670926|Diagnostic Test|TruGraf|"TruGraf results will be available in real-time and used by the physician in conjunction with other standard of care labs to guide management of immunosuppression as follows:~Patients with a stable serum creatinine and eGFR of > 45 mL/min who also have a TruGraf TX result at month 3 will have their Mycophenolate Mofetil or Mycophenolate Sodium decreased from a standard dose of 1000 mg twice daily to 500 mg twice daily or 720 mg twice daily to 360 mg twice daily respectively.~Patients with a stable serum creatinine and estimated eGFR of > 45 mL/min who also have a TruGraf TX result at months 4, 5, and 6 will have their Tacrolimus target trough level decreased to a target between 3 and 6.~Patients with TruGraf not-TX will have no further immunosuppression reduction and continued to be monitored."
45972061|NCT04670926|Other|Standard of Care|Patient's immunosuppression will be managed per the current CPMC standard of care that includes continuation of Mycophenolate Mofetil or Mycopheonolate Sodium at 1000 mg bid or 720 mg bid respectively. The dose may be decreased at the discretion of the physician for drug adverse effects such as diarrhea or other gastrointestinal side-effects or neutropenia as is the standard of care. Patients will be maintained on Tacrolimus at target levels that are considered standard of care by the managing physician.
45972062|NCT00233636|Drug|Iressa (Gefitinib)|
45972063|NCT00233636|Procedure|Radiotherapy|
45972064|NCT04670887|Procedure|Delayed surgery|Delayed surgery is performed if cystic mass radiologically upgrades into Bosniak 4 or solid mass in the active surveillance.
45828681|NCT04142177|Procedure|Spinal Manipulation Therapy (SMT)|After examination by a qualified Doctor of Chiropractic (DC), a SMT intervention consisting of up to 10 sessions over 3 months will be designed focusing on spinal manipulation and/or mobilization of the lower thoracic, lumbar and/or sacroiliac joints. Adjunctive use of myofascial and/or stretching techniques are allowed as they are commonly used along with SMT, and can be considered a standard accompaniment to SMT.
45972065|NCT04670887|Procedure|Immediate surgery|Partial or radical nephrectomy is performed as treatment of Bosniak 3 cystic mass
45972066|NCT04671121|Procedure|Standart pressure pneumoperitoneum|CO2 insufflation pressure was kept at 14 mmHg throughout the surgery.
45972067|NCT04671121|Procedure|Low pressure pneumoperitoneum|CO2 insufflation pressure was kept at 8 mmHg throughout the surgery.
45972068|NCT04671316|Drug|DA-5209 60mg Tab|"single oral administration of 1 tablet of DA-5209 60mg Tab with 150mL water"
45972069|NCT04671316|Drug|DA-5209 60mg Tab|"single oral administration of 1 tablet of DA-5209 60mg Tab without water"
45972070|NCT04671316|Drug|Lixiana 60mg Tab|"single oral administration of 1 tablet of Lixiana 60mg Tab with 150mL water"
45972071|NCT04670614|Procedure|Nerve Block with ropivicaine 0.5% Injectable Solution|Peripheral nerve blocks using 0.5% ropivicaine
45972072|NCT04670614|Procedure|Nerve Block with Placebo sham control of 0.9% Normal Saline|Peripheral Nerve Block with placebo 0.9% normal saline
45669853|NCT05650255|Other|A Digital Twin for Exoskeleton Pilot|The purpose of this project is to establish a digital twin of this driving, which will perform the driving action in parallel, and calculate in parallel in the virtual environment the torque required to provide each joint torque to maintain stable walking without falling, and this torque can be used as a monitoring basis for the auxiliary torque of each axis for the exoskeleton. When the exoskeleton's movements are out of range of a stable gait, the controller can warn and attenuate the output of auxiliary forces, and on the other hand, it has the opportunity to analyze whether the intention of driving is to switch the movement mode - such as stopping, or sitting, squatting, etc.
45669854|NCT05647525|Diagnostic Test|Perform autoimmune encephalitis titer tests|We only follow up without intervention.
45972073|NCT04670692|Other|5G-MCE examination|The endoscopist (W.Z.) manipulated the two joysticks on the remote console (based in Shanghai). Then the remote control software and remote connection software takes the endoscopist's input and translates it into a control signal. After network transmission, the patient side cart (based in Yinchuan) translates the control signal into actual instrument manipulation and mobilize the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric and duodenum examination. Meanwhile, the images captured by the capsule are simultaneously sent back to the screen of the remote console, and thus provide guidance for better control of the capsule.
45669855|NCT04791163|Device|Socket evaluation|The subject will wear the socket for 4 weeks, and then reply questionnaires and achieve a 2-minute walking test
45828682|NCT04142177|Procedure|Yoga|The Yoga for Veterans with cLBP program consists of up to 10 weekly, 60-minute instructor-led sessions along with 15-20 minutes of yoga practiced at home each non-session day. The initial session is 75 minutes (15 minutes longer than the other sessions). The yoga program can be considered classical hatha yoga with influences from Iyengar and Viniyoga yoga. These styles emphasize modifications and adaptations including the use of props such as straps and blocks to minimize the risk of injury and make the poses accessible to people with health problems and limitations (Iyengar, 1979). The instructor leads participants through a series of 23 yoga poses (32 total variations) at a slow-moderate pace.
45828683|NCT04137887|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
45828684|NCT04137887|Biological|Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
45972074|NCT04670692|Other|MCE examination|The endoscopist (W.Z.) performs the MCE examination procedure conventionally. And communicate with the volunteer face to face in the same examination room.
45972075|NCT00267657|Drug|Reserpine|
45669856|NCT05638009|Dietary Supplement|Salt substitute 66%33%|Salt substitute composed of 66% potassium chloride and 33% sodium chloride
45455888|NCT05537389|Device|In-line filter|"All infusions, with the exception of some solutions (eg blood products), will be subjected to filtration. The aqueous solutions (parenteral therapy and drugs) will be administered through 0.2 μm filters which will be replaced every 96 h; the lipid emulsions will be administered through 1.2 μm filters which will be replaced every 24 h.~In case of emergency, life-saving drugs will be administered with bolus modality though the infusion line closer to the patient without the need for filtration.~In case of drugs/solutions not supported by filtration (eg blood products), they will be administered through a dedicated unfiltered access, which will be removed as soon as the drug is no longer needed."
45669857|NCT05638009|Dietary Supplement|Salt substitute 33%/66%|Salt substitute composed of 33% potassium chloride and 66% sodium chloride
45669858|NCT05636683|Procedure|Root surface debridement|subjects will be examined for clinical periodontal parameters, their saliva samples will be collected, and then receiving full scaling using ultrasonic device, and oral hygiene instructions and motivation. After one week, the same clinical parameters, saliva sampling will be taken, and received full root surface debridement (RSD) using curette hand instruments (Gracey, USA) (First visit). One month and three months after first visit, the same clinical measurements, saliva will characterize as second and third visits, respectively.
45669859|NCT01635283|Biological|tumor lysate-pulsed autologous dendritic cell vaccine|Given ID
45669860|NCT01635283|Other|laboratory biomarker analysis|Correlative studies
45669861|NCT01707004|Drug|decitabine|Given IV
45828685|NCT04120402|Drug|EP-104IAR 25 mg|Single 5 mL intra-articular injection
45828686|NCT04120402|Drug|Vehicle|Single 5 mL intra-articular injection
45828687|NCT04113382|Drug|CLENPIQ|"CLENPIQ consists of sodium picosulfate 10.0 mg + magnesium oxide 3.5 g + citric acid, anhydrous 12.0 g.~Supplied as a pre-mixed, ready-to-drink oral solution in two bottles, each containing 160 mL."
45828688|NCT04113382|Drug|MIRALAX|MIRALAX powder for oral solution, supplied in a 8.3 oz multi-dose bottle containing 238 g of laxative powder (polyethylene glycol [PEG] 3350).
45828689|NCT04097821|Drug|Ruxolitinib|5 mg tablets for oral use
45828690|NCT04097821|Drug|Siremadlin|10 mg, 20 mg, or 40 mg capsules for oral use
45828691|NCT04097821|Drug|Crizanlizumab|100 mg/mL concentrate for infusion for intravenous use
45828692|NCT04097821|Drug|Sabatolimab|100 mg/mL or 400 mg/4 mL concentrate for infusion for intravenous use
45828693|NCT04097821|Drug|Rineterkib|100 mg capsule for oral use
45828694|NCT04097821|Drug|NIS793|700 mg/7 mL concentrate for intravenous use
45828695|NCT04096196|Behavioral|Safe City game|The game intervention uses a game-based learning approach to teach players how to recognize and remove injury hazards from different homes and sports areas. It also highlights the need to pay attention to traffic and safety facilities to prevent injuries in a real-world environment. Players will create their own avatar to assume the duties of safety inspectors in the game. Point, level and reward systems will be included to increase player motivation to engage in the game.
45828696|NCT04096196|Other|Health education|All students in the health education group will receive a comprehensive package on safety information. The information package includes both printed and electronic promotional materials regarding safety and a comprehensive list of relevant website and information sources. The information from these relevant websites and information sources are similar to those used in setting the safety case scenarios for the Safe City game. As a result, both intervention arms will have comparable accessibility to safety-related information and the major contrast between the two groups will be the method of presentation (game-based learning vs traditional health promotion approach, i.e. unidirectional information package).
45669862|NCT01707004|Drug|fludarabine phosphate|Given IV
45669863|NCT01707004|Drug|busulfan|Given IV
45828697|NCT04095273|Drug|Elimusertib (BAY1895344)|Study drugs will be administered as scheduled
45828698|NCT04095273|Drug|Pembrolizumab|Study drugs will be administered as scheduled
45828699|NCT04086771|Behavioral|Navigation|Weekly phone-calls, personal messages, and American Cancer Society Pap test and mammography test reminder post card
45828700|NCT04086771|Other|Information only|American Cancer Society breast and cervical cancer screening information and Pap test and mammography test reminder post card
45828701|NCT04074590|Drug|LYS006|capsule for oral use
45828702|NCT04074590|Drug|Placebo|capsule for oral use
45669864|NCT01707004|Drug|cyclophosphamide|Given IV
45669865|NCT01707004|Drug|tacrolimus|Given PO or IV
45669866|NCT01707004|Drug|mycophenolate mofetil|Given PO
45669867|NCT01707004|Biological|filgrastim|Given SC
45669868|NCT01707004|Radiation|total-body irradiation|Undergo total-body irradiation
45669869|NCT01707004|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
45669870|NCT01707004|Other|laboratory biomarker analysis|Correlative studies
45669871|NCT01939197|Drug|ABT-450/r/ABT-267|tablet
45669872|NCT01939197|Drug|ABT-333|tablet
45669873|NCT01939197|Drug|ribavirin|tablet
45669874|NCT04778761|Behavioral|Home ACP Video|A video focused on Advance Care Planning and Hospice for patients with serious illness
45828703|NCT04068844|Behavioral|Exercise training|Exercise training, either whole body or isolated single leg
45972076|NCT04670809|Drug|Clevidipine Butyrate Injection|Initiate the intravenous infusion of Clevidipine Butyrate Injection at 2 mg/hour. The dose should be doubled every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 32 mg/hour. The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
45972077|NCT04670809|Drug|Ncardipine Hydrochloride Injection|Dilute the Ncardipine Hydrochloride Injection to 0.1mg/ml. Initiate the intravenous infusion at 0.5μg/(kg•min). A 0.5-1μg/(kg•min) dose should be added every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 6μg/(kg•min). The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
45669875|NCT05182645|Behavioral|lifestyle-modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of crohn's disease patients.
45828704|NCT04023487|Behavioral|Resilient, Empowered, Active Living-Telehealth (REAL-T)|REAL-T is an individually-tailored occupational therapy intervention that focuses on incorporating diabetes self-care into participants' daily habits and routines. Participants receive approximately 12 hours of intervention, delivered via telehealth over 6 months by a licensed occupational therapist with training in diabetes education, motivational interviewing, and the REAL Diabetes intervention protocol.
45972078|NCT04670575|Procedure|Cataract Surgery with Implantation of Vivity Extended Range of Vision IOL|Patients with early stage glaucoma implanted with Vivity or Vivity Toric IOL
46081515|NCT04241627|Behavioral|Cell Phone Support|Cell Phone Support includes short phone calls (<5 minutes) made each weekday by a human AF to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services. Cell Phone Support calls focus on assisting AYAs in identifying and accessing resources and support from their natural environments, such as finding ways they can receive needed help from their families, peers, medical teams, and communities. Live Text Support will deliver the same intervention, by text message.
46081516|NCT04222062|Drug|Carmustine 7.7Mg Wafer|GLIADEL wafers will be placed to cover tumor bed immediately after tumor removal.
46081517|NCT04221529|Drug|Atezolizumab|1200 mg i.v. on day 1 of each cycle
45669876|NCT05182645|Behavioral|waiting control group|Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
45669877|NCT01969851|Drug|Lacosamide|"Oral intake twice daily of tablet (100 mg or 50 mg) or syrup formulation (10 mg/ml).~Total daily dose will be titrated over a period of 6 weeks with starting dose of 100 mg/day or 2 mg/kg/day up to doses not exceeding 600 mg/day or 12 mg/kg/day tablet or syrup, respectively. Followed by a 12 week maintenance period with stable dosing of at least 200 mg/day or 4 mg/kg/day tablet or syrup, respectively."
45669878|NCT04661085|Diagnostic Test|Broader Medical history and clinical tests|Patients will be treated with standard care plus additional blood tests, urine culture and urine flow cytometry,
45669879|NCT04659759|Other|COVID-19 exposure|COVID-19 exposure during pregnancy
45972079|NCT04670341|Other|chewing tapioca pearls in bubble tea drinks|Saliva was collected on the first day before bubble tea consumption (pretest) and on the third day after bubble tea consumption (posttest); collection was conducted in the morning (09:00 a.m.-12.00 p.m.).
45669880|NCT04659759|Biological|COVID-19 vaccine|Receipt of any COVID-19 vaccine
45669881|NCT05560243|Behavioral|Tobacco cessation|Tobacco cessation program consisting of cognitive-therapy sessions and pharmacological management
45972080|NCT04670341|Other|drink tea without chewing tapioca pearls|Saliva was collected on the first day before drink tea without tapioca pearl (pretest) and on the third day after tea consumption (posttest); collection was conducted in the morning (09:00 a.m.-12.00 p.m.).
45972081|NCT00267735|Behavioral|Use of Computerized Decision Aid on Childbirth|
45669882|NCT05553847|Other|Automated oxygen titration based on the oxygen saturation during activity|A device will be used, which automatically adjusts the oxygen flow to the dosage necessary for keeping the saturation at the recommended level (90-94%). If the saturation falls below 90%, oxygen flow will increase, and if the saturation increases above 94%, oxygen flow decreases in order to stay on target.
45828705|NCT03997773|Behavioral|Face-it Intervention|The Face-it intervention is a health promotion intervention consisting of 3 major components: 1) active involvement of health visitors, 2) digital health technology and coaching, and 3) a structured cross-sectoral communication system in the healthcare system. The intervention will begin at time approx. 3 months (after the baseline data collection, i.e. 10-14 weeks postpartum), and continues until 12 months
45455889|NCT05537116|Behavioral|Personalized feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
45669883|NCT01938573|Drug|Cisplatin|Given IV
45669884|NCT01938573|Drug|Gemcitabine Hydrochloride|Given IV
45669885|NCT01938573|Drug|Sirolimus|Given PO
45669886|NCT01938573|Procedure|Cystectomy|Undergo cystectomy when appropriate
45828706|NCT03992131|Drug|Rucaparib|Oral rucaparib will be administered twice daily
45828707|NCT03992131|Drug|Lucitanib|Oral lucitanib will be administered once daily
45828708|NCT03992131|Drug|Sacituzumab govitecan|IV Sacituzumab govitecan will be administered Days 1 and 8 every 21 days
45828709|NCT03972969|Behavioral|Facility-based structured exercise|Structured exercise program in a facility with instruction and encouragement
45828710|NCT03972969|Behavioral|Home-based structured exercise|Structured exercise program in the home with instruction and encouragement
45828711|NCT03972969|Behavioral|Health education|Provision of general information about a variety of topics
45669887|NCT05546515|Drug|Suvorexant (dual orexin receptor antagonist)|Participants will be prescribed up to 30 days of SUVO.
45828712|NCT03954366|Drug|Rucaparib|Rucaparib 600 mg BID commencing on Day 5 until Day 23.
45828713|NCT03954366|Drug|Rosuvastatin|Single dose of 20mg oral rosuvastatin on Day 1 and Day 19 only.
45828714|NCT03954366|Drug|Oral Contraceptives|Single dose of combined oral contraceptive (30 μg ethinylestradiol and 150 μg levonorgestrel) on Day 1 and Day 19 only.
45828715|NCT03940703|Drug|Tepotinib|Participants will be administered Tepotinib orally once daily at an initial dose of 500 milligram (mg). A safety monitoring committee (SMC) may decide to confirm or adapt the dose.
45828716|NCT03940703|Drug|Osimertinib|Participants will receive Osimertinib at a dose of 80 mg orally once daily.
45828717|NCT03936569|Drug|Marketed Toothpaste|Marketed stannous fluoride (0.454%) toothpaste
45828718|NCT03936569|Drug|Marketed Cavity Protection Toothpaste|Marketed sodium monofluorophosphate (0.76 %) toothpaste
45972082|NCT00233714|Device|CYPHER Sirolimus-Eluting Coronary Stent|Single dose Sirolimus-Eluting coronary stent
45972083|NCT00233714|Device|CYPHER Sirolimus-Eluting Coronary Stent|Double-dose Sirolimus-Eluting coronary stent
45972084|NCT04670497|Procedure|bupivacaine 0.5% with 1:200000 adrenaline|regional anesthesia to block lumbar plexus for analgesia of lower limb
45972085|NCT04670302|Procedure|Tendon repair procedure|"Tendon repair procedure:~Single senior surgeon (HS) will perform mini-open surgery to decompress the acromioplasty and repair the supraspinatus tendon.~Splicing is achieved by installing screw-type anchors on the insertional footprint of the humeral head greater tuberosity.~Then, double suturing of the supraspinatus tendon is performed."
45972086|NCT04670302|Procedure|Tendon repair augmented with AAdMSC-HAM composite|After double suturing of the supraspinatus tendon, the composite comprising freeze-dried HAM (2 cm x 2 cm x 0.002 cm) and AAdMSC (20 million cells) is placed on the upper surface of the splice and fixed with stitches at all four corners.
45972087|NCT04670107|Drug|Anlotinib in combination with Immune checkpoint inhibitors|Enrolled patients received anlotinib plus Pembrolizumab treatment (anlotinib, 8-12mg, qd, 2 weeks in a row and 1 week off; anti-PD1 injection or anti-PDL1 injection, Following instructions, iv.)
45669888|NCT05546515|Drug|Placebo|Participants will be prescribed up to 30 days of placebo medication.
45455890|NCT05537116|Behavioral|Personalized feedback and text messages|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions.
45455891|NCT05537116|Behavioral|Information Only|Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message.
45669889|NCT05496907|Behavioral|Diabetes specialist nurse-led collaborative care intervention|10 sessions with a diabetes nurse to help improve physical and mental health outcomes
45828719|NCT03935932|Device|nasal delivery of heated and humidified air|Subjects will receive nasal delivery of heated and humidified air (plus oxygen if needed) at 30 liters/minute from the Fisher and Paykel myAirvo2 heater/humidifier using an Optiflow nasal cannula.
45828720|NCT03934255|Other|Constant Routine Protocol|Constant routine protocols are used in circadian research to examine underlying circadian rhythms in the absence of light, activity, and meals
45828721|NCT03923270|Drug|Durvalumab|Participants in all arms will be administered 1500 mg of Durvalumab intravenously every 4 weeks.
45669890|NCT04777513|Procedure|CCTA (Coronary Computed Tomography Angiography)|Per the protocol, patients had a coronary computed tomography angiography within standard of care before the enrollment to the study.
45669891|NCT04777513|Procedure|ICA (Invasive Coronary Angiography)|Per the protocol, patients will have an Invasive Coronary Angiography within standard of care.
45669892|NCT04777513|Procedure|FFR (Fractional Flow Reserve)|Per the protocol, patients will have a Fractional Flow Reserve procedure within standard of care.
45669893|NCT04777513|Device|CNBP measurement|Per the protocol, patients will have the measurement of the resting Continuous Non-Invasive Blood Pressure (CNBP). The signal is required for iSIL-FFR technology.
45828722|NCT03923270|Drug|Tremelimumab|Participants in arm B will be administered 75 mg of Tremelimumab intravenously every 4 weeks for up to 4 doses.
45828723|NCT03923270|Drug|Olaparib Pill|Participants in arm C will be self-administer 300 mg of Olaparib orally.
45972088|NCT00260364|Drug|Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle|
45972089|NCT00260364|Drug|Capecitabine orally days 1 -21|
45972090|NCT00260364|Drug|Erlotinib 100 mg orally days 1-28|
45972091|NCT00260364|Drug|Bevacizumab 5 mg/kg intravenously every 2 weeks|
45972092|NCT00233753|Device|Cordis Neurovascular Self-Expanding Stent|
45972093|NCT04557007|Drug|Pembrolizumab|Drug trough-level will be measured in patients on Pembrolizumab with or without additional chemotherapy in routine care.
45972094|NCT04670458|Other|no intervention|no intervention
45972095|NCT00233792|Device|sirolimus coated Bx VELOCITY stent - fast release|
45972096|NCT00233792|Device|sirolimus coated Bx VELOCITY stent - slow release|
45972097|NCT00260403|Procedure|Photodynamic therapy versus Transpupillary thermotherapy|
45972098|NCT04556812|Procedure|Four-in-one procedure|"four-in-one surgical technique centered on tibial tuberosity osteotomy and proximal displacement"
45972099|NCT04556812|Procedure|soft-tissue surgery|traditional soft-tissue surgery
45972100|NCT04670380|Other|Posture and movement analysis during a simulated forceps vaginal operative delivery|It will be request from each volunteer to perform a vaginal operative delivery using a Suzor's forceps on a mannequin. The condition will be standardized (anterior occiput low fetal presentation). Each participant will be equipped with 34 reflecting markers allowing to record their movement using infra red cameras (VICON system).
45972101|NCT00556153|Drug|[F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical|A single dosage of the diagnostic drug will be administered to individuals who meet inclusion criteria after informed consent.
45972102|NCT00556192|Drug|rituximab|"Rituximab of 1000 mg given 2 weeks apart. On day the of rituximab, and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5.~A treatment dose rituximab of 1000mg given 2 weeks apart and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5, and 'pulse' cyclophosphamide 500mg/m2 at baseline and day 14.~Sequential therapy with oral cyclophosphamide (50 to 100 mg/day) for 6 months followed by azathioprine (up to 2.5mg/kg/day) for maintenance up to 12 months. Oral prednisolone will be given at 0.5 mg/kg/day (up to 30 mg daily) for 4 weeks, tapered by 5 mg every 2 weeks thereafter until 5mg /day for the rest of the study period."
45972103|NCT00233831|Device|Generator of electromagnetic millimeter waves|
45669894|NCT04777513|Device|Cardiolens FFR-CT Pro|Per the protocol, non-invasive FFR measurements will be perfomed via Cardiolens FFR-CT Pro technology for the enrolled patients.
45669895|NCT05169931|Biological|RegenerEyes|Biologic eye drop
45972104|NCT00260442|Behavioral|Resistance Training|12 weeks, 3 times a week whole body resistance training
45972105|NCT00260442|Behavioral|Sedentary|Absence of physical activity
45669896|NCT04789837|Drug|Cilostazol 50 MG|Cilostazol 50 mg twice daily plus Celecoxib 200mg capsule
45455892|NCT05535192|Behavioral|THRIVE|"The THRIVE Intervention will involve:~1) two in-person exercise sessions, followed by twice-weekly, home-based exercise sessions, supervised remotely through telehealth, and 2) a remotely delivered dietary assessment and recommendations to support protein intake throughout the study"
45669897|NCT04789837|Drug|Placebo|Placebo tablet twice daily plus Celecoxib 200mg capsule
45669898|NCT03522259|Drug|Rivaroxaban 10 MG Oral Tablet [Xarelto]|Rivaroxaban 10mg per os is started on the first postoperative day. Patients receive Rivaroxaban 10mg QD for 7days (short arm) or 28 days (long arm)
45669899|NCT04789681|Drug|Canakinumab|Given SC
45669900|NCT04789681|Other|Quality-of-Life Assessment|Ancillary studies
45669901|NCT05167669|Device|HIFU-MRI guided|HIFU application under MRI guiding to deliver hypothermia to eligible bone metastases before clinical indicated radiotherapy
45669902|NCT05167201|Device|Nasal High Flow|High flow nasal cannula (NHF) is a device that delivers warmed and humid air through a high air flow rate, through the nose. It is used as a non-invasive ventilatory approach, which is relatively comfortable, in the management of respiratory failure and has been investigated in several studies evaluating the outcomes as domiciliary treatment in patients with COPD.
45669903|NCT04788901|Other|REThink therapeutic game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
45828724|NCT03923270|Radiation|Thoracic Radiotherapy|Thoracic Radiotherapy will be administered at 3 Gray units X 10 fractions
45972106|NCT00556270|Drug|Matrifen|as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)
45972107|NCT00260481|Drug|Prometa|Medication protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient medications for 39 days
45972108|NCT00260481|Drug|Placebo|Placebo protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient placebo medications for 39 days.
45828725|NCT03923270|Drug|Tremelimumab|Participants in arm D will be administered 300 mg of Tremelimumab intravenously in 1 single dose
45828726|NCT03919929|Drug|Semaglutide 3mg and 7mg [Rybelsus]|Once daily oral tablet of semaglutide for 4 months
45828727|NCT03919929|Other|Weight loss diet|Prescribed weight loss diet to match weight loss in Drug arm
45828728|NCT03912220|Drug|Nicotinamide riboside|The experimental arm will investigate the effects of nicotinamide riboside on nerve degeneration and regeneration.
45972109|NCT00233870|Drug|Agalsidase beta (recombinant form)|agalsidase beta 1.0 mg/kg body weight infused every 2 weeks as an intravenous infusion
45972110|NCT00260520|Drug|Dalteparin|
45972111|NCT00233909|Drug|Zosuquidar|
45972112|NCT00233909|Drug|gemtuzumab ozogamicin|
46081518|NCT04219774|Procedure|Endovascular intervention|Endovascular angioplasty of the occluded carotid using balloon angioplasty and reconstruction with stents: coronary stents distally (Rebel, Boston Scientific; Vision, Abbott Vascular) and carotid stents proximal (Acculink and Xcat, Abbott Vascular) Patients will stay on their aspirin 325 mg and clopidogrel 75 mg
45455893|NCT05535192|Behavioral|Health Education Support Program|Participants will receive a tablet with information and resources regarding mediation, stretching and gentle movement, relaxation and creative arts during chemotherapy
45828729|NCT03912220|Drug|Placebo Oral Tablet|Placebo drug that looks like the experimental drug, nicotinamide riboside tablets.
45828730|NCT03898167|Behavioral|Telephone Recall|Participants receive a scripted telephone recall from a trained patient navigator.
45828731|NCT03898167|Behavioral|Mailed HPV Self-Sampling Kit|Participants receive a mailed kit that allows them to self-collect a cervical sample in their home and return it to a laboratory for human papillomavirus (HPV) testing.
45828732|NCT03898167|Behavioral|Patient Navigation|Participant receives telephone call from patient navigator within 3-5 days of receipt of self-collection kit. Patient navigator provides one-on-one education on cervical cancer screening and self-collection of cervical sample.
45828733|NCT03889912|Drug|Cemiplimab|Each patient will receive intralesional injections of cemiplimab every week (QW) or every other week (QOW) into the lesion at the assigned dose level for 5-12 weeks prior to scheduled surgery
45828734|NCT03872791|Biological|KN046|KN046 at a dose level of 3 or 5 mg/kg via intravenous infusion on Days 1 and 15 of 28-day cycle
45828735|NCT03872791|Drug|Nab-paclitaxel|Nab-paclitaxel at dose level of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of 28-day cycle
45828736|NCT03866187|Biological|ChAd155-hIi-HBV low dose formulation|Subjects in group A1 receive one dose of ChAd155-hIi-HBV low dose formulation at Day 1, by intramuscular injection in the deltoid of the non-dominant arm.
45828737|NCT03866187|Biological|ChAd155-hIi-HBV high dose formulation|"Subjects in groups B1 and B3 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in groups C1 and C2 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm."
45828738|NCT03866187|Biological|HBc-HBs/AS01B-4 low dose formulation|Subjects in group A1 receive two doses of HBc-HBs/AS01B-4 low dose formulation, one at Day 113 and one at Day 169 and subjects in group A2 receive four doses of the low dose formulation, one dose each at Days 1, 57, 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
45828739|NCT03866187|Biological|HBc-HBs/AS01B-4 high dose formulation|Subjects in group B1 receive two doses of HBc-HBs/AS01B-4 high dose formulation, one at Day 113 and one at 169; subjects in group B2 receive four doses, one dose each at Days 1, 57, 113 and 169; subjects in group C1 receive four co-administered doses at Days 1, 57, 113 and 169 and subjects in group C2 receive two co-administered doses at Days 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
45828740|NCT03866187|Biological|MVA-HBV low dose formulation|Subjects in group A1 receive one dose of MVA-HBV low dose formulation at Day 57, by intramuscular injection in the deltoid of the non-dominant arm.
45828741|NCT03866187|Biological|MVA-HBV high dose formulation|"Subjects in groups B1 and B3 receive one dose of MVA-HBV high dose formulation at Day 57 and Day 169 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in group C1 receive three co-administered doses of the vaccine at Days 57, 113 and 169 and subjects in group C2 receive one co-administered dose of the vaccine at Day 169, by intramuscular injection in the deltoid of the dominant arm."
45828742|NCT03866187|Drug|Placebo|Subjects in group A3 receive four doses of placebo, one each at Days 1, 57, 113 and 169 and subjects in group B3 receive two doses of placebo one each at Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Subjects in group C2 receive 2 co-administered doses of placebo at Days 1 and 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.
45828743|NCT03864042|Drug|losartan|taken orally
45828744|NCT03864042|Drug|dextromethorphan|taken orally
45828745|NCT03864042|Drug|caffeine|taken orally
45828746|NCT03864042|Drug|omeprazole|taken orally
45828747|NCT03864042|Drug|midazolam|taken orally
45828748|NCT03864042|Drug|rosuvastatin|taken orally
45828749|NCT03864042|Drug|bupropion immediate release (IR)|taken orally
45828750|NCT03864042|Drug|encorafenib|taken orally
45828751|NCT03864042|Drug|binimetinib|taken orally
45828752|NCT03864042|Drug|modafinil|taken orally
45828753|NCT03858361|Device|Atrial Flutter Ablation|Catheter-based electrophysiological (EP) intervention.
45828754|NCT03827798|Drug|CFZ533|s.c.
45828755|NCT03827798|Drug|Placebo to CFZ533|s.c.
45828756|NCT03827798|Drug|LYS006|p.o.
45828757|NCT03827798|Drug|Placebo to LYS006|p.o.
45828758|NCT03827798|Drug|MAS825|s.c.
45828759|NCT03827798|Drug|Placebo to MAS825|s.c.
45828760|NCT03827798|Drug|LOU064 25mg|p.o.
45828761|NCT03827798|Drug|LOU064 100mg|p.o.
45828762|NCT03827798|Drug|Placebo to LOU064|p.o.
45828763|NCT03769506|Combination Product|ASP-1929 Photoimmunotherapy|Use of ASP-1929 PIT therapy
45828764|NCT03769506|Drug|Physician's Choice SOC|docetaxel, cetuximab, methotrexate, paclitaxel
45828765|NCT03737604|Drug|Ropivacaine Continuous Infusion Catheter|For those randomized to the TAP catheter group, ultrasound guidance will be used for TAP block and 5mls 1% lidocaine will be used for skin infiltration. A peripheral nerve catheter will be placed approximately 3-5 cm into the TAP space after injection of the ropivacaine solution. A bolus dose of 2.5 mg/kg of ropivacaine will be administered in a volume of 30 ml up to a maximum of 150 mg. An infusion with a programmable pump will be initiated at a rate of 8 ml/hr of 0.2% ropivacaine on the inpatient floor.
45828766|NCT03737604|Drug|Single Dose Liposomal Bupivicaine|TAP block will be performed using ultrasound guidance. 12ml of 0,25% plain bupivacaine will be used for skin infiltration and to open up the TAP. Liposomal bupivacaine 266 mg (1.3% in 20 ml) will be diluted to 40 ml volume with 20 ml of preservative free normal saline. 20 ml (133mg) of liposomal bupivicaine will then be injected into the TAP.
45669904|NCT03329521|Other|Multi-component quality improvement intervention|Patients in 13 of the 26 CKD programs will receive a quality improvement intervention or usual care. The intervention has four main components: (1) support for local quality improvement teams and administrative needs; (2) tailored education and resources for staff, patients, and living kidney donor candidates; (3) support from kidney transplant recipients and living kidney donors; and (4) program-level performance reports and oversight by program leaders.
45972113|NCT00267813|Drug|Bupropion (Zyban)|1 tablet a day increasing to 2 tablets a day after a week
45972114|NCT00234026|Drug|gemcitabine hydrochloride|
45972115|NCT00267852|Other|as clinical practice|Dosage, form, frequency and duration as per ordinary clinical practice
45972116|NCT00234143|Behavioral|Darbepoetin and Filgrastim|Aranesp and Neupogen G-CSF (Neupogen) 300 mcg s.c. twice a week, 3-4 days apart and EPO (Aranesp) 500 mcg s.c. once every 2 weeks until week 24, titrate depending of response
45972117|NCT00234143|Drug|Darbepoetin|Aranesp EPO (Aranesp) 500 mcg s.c. once every 2 weeks until 24 weeks, titrate depending of response
45972118|NCT04670419|Other|Viral clade|Disease outcomes are compared for patients infected with 2 different clades of a HEV gt 3 infection
45669905|NCT01937871|Drug|5 mg Tadalafil|Administered orally
45669906|NCT01937871|Drug|Placebo|Administered orally
45669907|NCT01937871|Drug|0.2 mg Tamsulosin|Administered orally
45669908|NCT03220477|Drug|Pembrolizumab|Pembrolizumab will be administered at 200mg IV on day 1 of each 21 day cycle.
45669909|NCT03220477|Drug|Guadecitabine|Guadecitabine will be administered subcutaneously given daily on days 1-5 of each cycle with escalating doses by cohort.
45828767|NCT03730519|Device|Baroreflex Activation Therapy with Barostim Neo|Baroreflex activation therapy (BAT) delivers electrical field stimulation at the carotid sinus to lower BP.
45828768|NCT03726879|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
45828769|NCT03726879|Drug|Placebo|Placebo matched to atezolizumab will be administered as per the schedule specified in the respective arm.
46081519|NCT04219774|Drug|Aspirin and Clopidogrel (maximal medical Therapy)|Best Medical Management: daily dual antiplatelet therapy (aspirin: 325 mg p.o. qd and Clopidogrel: 75 mg p.o. qd), optimization of systolic blood pressure (120 -140 mmHg), and smoking cessation.
46081520|NCT04218838|Device|CornerLoc SI Joint Stabilization Procedure|CornerLoc minimally invasive SI Joint Stabilization System
45455894|NCT05531149|Drug|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days
45972119|NCT04670185|Behavioral|BIP SAMBA|Behavioral parent management training
45455895|NCT05531149|Drug|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days
45669910|NCT03220477|Drug|Mocetinostat|Mocetinostat will be administered orally with escalating doses on days 8, 10, 13, 15, 17 and 20 of each cycle with escalating doses by cohort.
45972120|NCT04670146|Diagnostic Test|ultrasound of the masseteric muscle|Ultrasound of the masseteric muscle to evaluate the thickness and rigidity of the masseteric muscle before and after oral cancer treatment. There will be no invasive investigation of the muscle.
45669911|NCT04775875|Device|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory wave form confirmation of cerebral arteries, and optical tracking technology (eg, AntNeuro Visor2 system) may be used in tandem with the Brainsonix Pulsar 1002 ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
45669912|NCT01747447|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
45669913|NCT01747447|Dietary Supplement|Fish oil placebo|Fish oil placebo
45972121|NCT00234182|Drug|Interferon alpha-2b|
46081521|NCT04218838|Drug|Intra-articular Sacroiliac Joint Steroid Injection|Standard of Care - Steroid injection into the sacroiliac joint
46081522|NCT04218539|Drug|Psilocybin|10mg Psilocybin
46081523|NCT04218539|Drug|Placebo|25mg Diphenhydramine
46081524|NCT04202965|Drug|PTG-300|Active treatment with PTG-300 injected subcutaneously.
45669914|NCT01747447|Dietary Supplement|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
45669915|NCT01747447|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
45669916|NCT02947633|Drug|Single-injection sciatic PNB|Single-injection sciatic PNB is a regional anesthetic technique employed to anesthetize the sciatic nerve with a single dose of local anesthetic. This technique offers pain control for a limited amount of time based on the volume and concentration of local anesthetic used.
45828770|NCT03726879|Drug|Doxorubicin|Doxorubicin will be administered as per the schedule specified in the respective arm.
45828771|NCT03726879|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per the schedule specified in the respective arm.
45828772|NCT03726879|Drug|Paclitaxel|Paclitaxel will be administered as per the schedule specified in the respective arm.
45972122|NCT04669873|Radiation|Active Comparator: Standard|Radiation: Whole Breast Irradiation + Boost Whole breast, either 40Gy, in 15 fractions, in 3 weeks
45972123|NCT04669873|Radiation|Experimental 1: Hypofractionated radiotherapy|Radiation: Hypofractionated irradiation Whole Breast Irradiation 26Gy in 5 fractions in one week
45972124|NCT04669873|Radiation|Experimental 2: Accelerated Partial Breast Irradiation|Radiation: Accelerated partial breast irradiation Tumor bed 26Gy in 5 fractions, in 5 days.
45972125|NCT04669756|Procedure|ovariopexy|if endometriosis was removed from the pelvic side wall or the ovary or both leading to an open wound adjacent to the ovary, ovariopexy was performed on both sides using a transabdominal-transovarian suture being tied extracorporeally on the patients Skin leading to uplifting of the ovary to the abdominal wall
45972126|NCT04669756|Procedure|placebo operation|in arm D sutures are transabdominal only
45972127|NCT00260598|Procedure|LIFE Bronchoscopy|The first LIFE Bronchoscopy is performed at least 6 months following surgical resection of primary NSCLC. Timing of subsequent bronchoscopies is dependent on pathology from first bronchoscopy.
45972128|NCT04669912|Other|glucose control and sensor usage|Data related to glucose control and sensor usage collected from the Libreview platform
45972129|NCT04669795|Drug|Cissus Quadrangularis|Drug with osteogenic potential given to the patients after consolidation period. dose was two capsules once /day with meals for 6 weeks
45972130|NCT04670029|Other|Adapted physical activity|APA sessions during chemotherapy with aerobic and anaerobic sessions on site and at home (+ home exercises book if the patient so wishes)
45972131|NCT04669951|Other|uPAR immunohistochemistry|Resected esophageal cancer will be qualitatively and semi-quantitatively analyzed for uPAR expression
45972132|NCT00234221|Behavioral|Strengths Based Case Management|
45972133|NCT00234221|Behavioral|Motivational Enhancement Therapy|
45828773|NCT03726879|Drug|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm.
45828774|NCT03726879|Drug|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm.
45972134|NCT00234221|Behavioral|Brief Informational Feedback|
46081525|NCT04197583|Device|Boston Scientific Ureteral Stents, Urinary Diversion Stent|A BSC Ureteral Stent is an implantable device that is used to restore flow of urine from the kidney to the bladder in obstructed ureters. A BSC Urinary Diversion Stent is an implantable device that is used to restore flow of urine from the kidney.
46081526|NCT04195139|Drug|Nivolumab|Participants will receive Nivolumab intravenous infusions (240 mg days 1 and 15 every 28 days for cycles 1-4; then 480 mg day 1 every 28 days for cycles 5-6).
46081527|NCT04195139|Drug|Temozolomide|Participants will receive temozolomide (TMZ) tablets days 1-5, every 28 days for 6 cycles. TMZ will be dosed at 150mg/m2 for the first cycle. If well tolerated TMZ is then given at 200mg/m2 for cycles 2 - 6.
46081528|NCT04193891|Other|Modified Atkins Diet|The ketogenic diet, where individuals restrict their carbohydrate intake and significantly increase their intake of fats, was initially primarily used in children with severe epilepsy, often due to genetic syndromes. Recently, with the advent of slightly less restrictive forms of ketogenic dietary therapy (e.g. the modified Atkins diet), it has begun to be used in adults with intractable seizures who are not surgical candidates.
46081529|NCT04191824|Diagnostic Test|APOL1 status|Participants will be randomized to immediate versus delayed return of results for positive or negative APOL1 status.
46081530|NCT04174352|Drug|Tamoxifen|estrogen modulator
45669917|NCT02947633|Drug|Continuous sciatic PNB|"Continuous sciatic PNB entails placing a continuous perineural infusion (CPI) catheter so that local anesthetic may be released slowly but continuously adjacent to the sciatic nerve (perineural) for several days postoperatively. The continuous PNB has the ability to reliably provide analgesia on subsequent postoperative days.~Participants my be randomized to receive an additional experimental continuous pain ball during surgery which can provide up to 48 hours of pain relief."
45669918|NCT01341535|Radiation|Adaptive dose-painting-by-numbers|Adaptive dose escalation by dose-painting-by-numbers.
45669919|NCT01341535|Radiation|standard intensity-modulated radiotherapy (IMRT)|Standard radiotherapy for head and neck cancer.
45669920|NCT04775407|Procedure|blood sampling|IgM og IgG analysis
45828775|NCT03726879|Drug|Trastuzumab Emtansine|Participants without pCR have the option of receiving adjuvant atezolizumab/placebo combined with Trastuzumab Emtansine 3.6 mg/kg IV Q3W.
45828776|NCT03713554|Procedure|FNIRS Observational|In addition to completing an Informed Consent and survey questions, fNIRS Imaging and Electroencephalography (EEG) will take place will take place:The fNIRS imaging is experimental technology that has not been approved by the FDA. EEG is a noninvasive way to record electrical activity of the brain. The recording device is made up of electrodes that are fixed to a snug-fitting elastic cap. An MRI and EEG will follow the fNIRS procedure. The MRI will be performed before participants undergo fNIRS or EEG. The MRI will be done to show there are no lesions in the inner ear and therefore is a recruitment clearance tool.
45828777|NCT03695380|Drug|Cobimetinib|Cobimetinib will be administered at a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle (Stage 1) and PO QD on Days 1-21 (21/7 schedule) at the established dose for the doublet regimen in Stage 1 (Stage 2).
45828778|NCT03695380|Drug|Niraparib|Niraparib will be administered at a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle (Stage 1) and PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1 (Stage 2).
45828779|NCT03695380|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle (Stages 1 and 2).
45828780|NCT03682068|Drug|Durvalumab|Durvalumab IV (intravenous infusion)
45972135|NCT04669990|Drug|Remdesivir|The objective of this Registry study is to continue to collect safety and outcome data for COVID-19 patients who are treated with Remdesivir and convalescent plasma therapy (CPT).
45972136|NCT00267930|Drug|Vernakalant (oral)|
45972137|NCT00267930|Drug|Placebo comparator|
45972138|NCT04669405|Device|High intensity laser therapy|A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
45972139|NCT04669405|Other|Therapeutic Exercise|A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
45972140|NCT02962271|Device|Musculoskeletal Ultrasound|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
45972141|NCT00556348|Drug|bevacizumab|1.25mg
45972142|NCT04556539|Drug|SC10914|400mg TID, oral admination on fasting condition
45972143|NCT00556387|Drug|saline|1 mg/kg IV bolus slowly over 1-2 minutes followed by 0.5 mg/kg IV continuous infusion over 48 hours or until discontinuation of ICP monitor (whichever occurs first)
45972144|NCT00556387|Drug|Ketamine|1 mg/kg IV bolus slowly over 1-2 minutes, followed by 0.5 mg/kg IV continuous infusion for 48 hours or until discontinuation of ICP monitor (whichever occurs first)
45972145|NCT00260637|Procedure|Acupuncture|
45972146|NCT04556422|Other|Aerobic exercise|15 minutes of aerobic exercise using stationary bicycle
45972147|NCT04556422|Other|Sauna bathing|Passive heat exposure
45972148|NCT04669483|Other|evidence-based informed consent form|Evidence-based informed consent forms for total knee arthroplasty and related anesthesia procedures will be developed. The design of the evidence-based informed consent forms will be guided by an existing guideline on how to present evidence-based health information (guideline evidence-based health information) and nocebo research. The information will be presented in plain language. Benefits and harms of the procedures will be presented in absolute risk formats and in comparison with other interventions or placebo. Verbal presentations of risks lead to overestimations of risks and therefore, will not be applied exclusively. Gain and loss framing will be combined. To visualize important aspects, pictograms will be used. Information on uncertainty, missing or low quality evidence will be provided.
45972149|NCT04552093|Drug|Floxuridine|Administration of intra-arterial floxuridine via the HAIP (HAIP chemotherapy) to the liver with concomitant Dutch standard of care systemic FOLFOX (5-FU, leucovorin and oxaliplatin) or FOLFIRI (5-FU, leucovorin and irinotecan).
45972150|NCT04552093|Device|Tricumed IP2000V infusion pump|Surgical implantation of hepatic artery infusion pump (HAIP) followed by administration of the combined chemotherapy (HAIP and systemic).
45972151|NCT00260676|Procedure|change ventilation|reduction of tidal volume, increase of PEEP, recruiting maneuver, apnea test during CPAP
45972152|NCT04556110|Drug|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
46081531|NCT04174352|Diagnostic Test|FES PET/CT|Radiolabeled estrogen [18F]-fluoroestradiol (FES) in combination with Positron Emission Tomography / Computed Tomography is a molecular imaging technique for measuring pharmacodynamic effects of endocrine therapy. The injected dose of 18F-FES will be 6 mCi (185 MBq) ± 20% with a specific activity greater than 170 Ci/mmol at the time of injection for an activity dose of 6 mCi. Participant will receive baseline imaging and repeat imaging after 3-4 weeks to evaluate for FES blockade as assigned dose level.
46081532|NCT04151498|Behavioral|Reengagement and Assessment Mobile Program|Participants will participate in mobile clinic visit that will include an educational interview, adherence counseling, and standard blood draws for HIV reengagement. The goal of this intervention is to motivate participants to become reengaged in traditional HIV care by making an in person clinic appointment.
46081533|NCT04151498|Other|Qualitative Interview|Qualitative interview about barriers and facilitators to HIV care, and experience at most recent clinic visit.
46081534|NCT04150289|Drug|Farydak|non-interventional study
46081535|NCT04141150|Drug|[18F]APN-1607|In this study, all patients will receive one injection of [18F]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 7 mCi IV as a bolus injection. [18F]APN-1607 injection will be followed by a 10 ml saline flush.
45828781|NCT03682068|Drug|Tremelimumab|Tremelimumab IV (intravenous infusion)
45828782|NCT03682068|Drug|Cisplatin + Gemcitabine|Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
46081536|NCT04136756|Drug|NKTR-255|NKTR-255 administered by IV infusion every 21 or 28 days to establish safety and tolerability
46081537|NCT04136756|Drug|NKTR-255 Q21|NKTR-255 administered by IV infusion every 21 days to establish safety and tolerability
45669921|NCT05380063|Drug|De-escalated Dual Antiplatelet Therapy|ticagrelor (90mg twice daily) + aspirin (100 mg once daily) during first 3 months post CABG, then switching to aspirin (100 mg once daily) + placebo (twice daily) for 9 months.
45828783|NCT03682068|Drug|Carboplatin + Gemcitabine|Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
45669922|NCT05380063|Drug|Dual Antiplatelet Therapy|Ticagrelor (90mg twice daily) + aspirin (100 mg once daily) for 1 year post CABG.
45669923|NCT02740699|Drug|Rosuvastatin|Participants will receive 20-40 mg once daily
45828784|NCT03676504|Biological|CD19.CAR T Cells|Dose Level 1: 1×10^6 transduced cells/m^2; Dose Level 2: 5×10^6 transduced cells/m^2; Dose Level 3: 20×10^6 transduced cells/m^2; Dose Level 4: 5x10^7 transduced cells/m^2; Dose Level 5: 10x10^7 transduced cells/m^2; Dose Level 6: 20x10^7 transduced cells/m^2
45828785|NCT03676504|Drug|Fludarabine|3 days of fludarabine 30 mg/m^2/day
45828786|NCT03676504|Drug|Cyclophosphamide|3 days of cyclophosphamide 500 mg/m^2/day
45828787|NCT03637764|Drug|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45828788|NCT03637764|Drug|Atezolizumab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45669924|NCT02740699|Drug|Atorvastatin|Participants will receive 40-80 mg once daily.
45669925|NCT02740699|Radiation|Cardiac Computed Tomography (CT)|Cardiac CT angiography (CCTA) provides a non-invasive method of evaluating both calcified and noncalcified plaque volume. Performed at baseline, 12 months 24 months, and 36 months.
45669926|NCT02740699|Radiation|Cardiac Magnetic Resonance Image (MRI)|Provides a non-invasive method of evaluating both calcified and noncalcified plaque volume. Cardiac MRI may be performed at baseline, and 24 months (optional).
45669927|NCT01287091|Drug|GDC-0980|Oral tablet dose
45669928|NCT01287091|Drug|GDC-0980|Oral capsule dose
45669929|NCT01287091|Drug|GDC-0980|Oral tablet dose in fed state
45669930|NCT01287091|Drug|GDC-0980|Oral repeating dose in fasting state
45669931|NCT01287091|Drug|GDC-0980|Oral repeating dose in fed state
45669932|NCT01287091|Drug|GDC-0980|Oral tablet in a fasting state
45669933|NCT01287091|Drug|rabeprazole|Oral repeating dose
45972153|NCT04556110|Drug|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
45972154|NCT00234299|Drug|Aspirin|325mg, one tablet orally, six months
45972155|NCT00234299|Drug|Placebo|325mg, one tablet orally every day, 6 months
45972156|NCT04556227|Behavioral|Simultaneous Cycle/Cognitive Training|Two weeks after discharge from the hospital the intervention group will complete recumbent cycle for 1 hour, 2x/wk. for 12 weeks (24 sessions). 10-minute cycle warm-up, 40-minute simultaneous cycling and cognitive training, 10-minute cool down. Cycling based on provider prescription and progression of physical recovery. Cognitive training program from Posit Science, Brain HQ (TM) progressive level of difficulty. Total duration of 60 minutes.
45972157|NCT04556032|Dietary Supplement|L-Ergothioneine 10 mg/d|L-Ergothioneine 10 mg/d
45972158|NCT04556032|Dietary Supplement|L-Ergothioneine 25 mg/d|L-Ergothioneine 25 mg/d
45972159|NCT04556032|Other|Placebo|0 mg/d L-Ergothioneine
45972160|NCT00260715|Behavioral|Community-Popular Opinion Leader Model|
45972161|NCT00260715|Behavioral|Diffusion of Innovations|
45972162|NCT04556149|Device|imPulse™ Una e-stethoscope|The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
45972163|NCT04556149|Device|Philips Lumify Ultrasound System|Point-of-care ultrasound
45972164|NCT04556071|Drug|Niraparib|Niraparib will be administered orally once a day continuously throughout each 21-days cycle. The initial dose will be based on the participant's basal body weight or platelet count. Participants with basal body weight≥77 kg and basal platelet count of≥150,000/microliter (μL) will take 300 mg daily. While participants with basal body weight<77 kg and/or basal platelet count <150,000/μL will take 200 mg daily.
46081538|NCT04136756|Drug|Rituximab|Rituximab administered intravenously at specified dose on specified days
46081539|NCT04136756|Drug|Daratumumab|Daratumumab administered subcutaneously at specified dose on specified days
46081540|NCT04128761|Behavioral|Scarcity Narrative|Participants are presented with a hypothetical scarcity narrative and asked to read and consider the scenario.
45669934|NCT01269463|Drug|Methylphenidate Hydrochloride Extended Release Capsule|An optimized dose of Methylphenidate Hydrochloride Extended Release Capsules 15, 20, 30 or 40 mg to be dosed once daily
45828789|NCT03637270|Dietary Supplement|Dietary supplementation|Before and after each exercise session, the research assistant will give subjects protein supplement or carbohydrate supplement according to the treatment assignment and ask them to drink it down right away.
45828790|NCT03637270|Other|Exercise training|Including aerobic cycling training and progressive resisted exercise
46081541|NCT04128761|Behavioral|Neutral Narrative|Participants are presented with a hypothetical neutral narrative and asked to read and consider the scenario.
46081542|NCT04123366|Drug|Olaparib|Oral tablet
46081543|NCT04123366|Biological|Pembrolizumab|Intravenous infusion
46081544|NCT04118062|Behavioral|Questionnaires|Questionnaires
45455896|NCT05527990|Device|Multimodal PO|Mixed methods diagnostic accuracy and implementation of multimodal PO
45455897|NCT05524935|Drug|Pembrolizumab|Pembrolizumab Day 1 of each 21 day (3 week) cycle
45669935|NCT01269463|Drug|Placebo|Capsule without active drug
45669936|NCT05362825|Drug|Neo-adjuvant Chemotherapy FOLFOXIRI Regimen|Oxaliplatin 85mg/m2 IV; Irrinotecan 165mg/m2 IV; Leucovorin 400mg/m2 IV; 5-Fluorouracil 2400mg/m2 continuous infusion in 46 hours - every 2-week cycle, up to 12 cycles.
45669937|NCT05362825|Procedure|synchronous resection surgery|Patients undergoing colorectal primary and liver resection in a single operation or staged curative procedure or no surgery
45669938|NCT02539459|Drug|Everolimus|10 mg tablets
45669939|NCT01706926|Biological|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks
45828791|NCT03626974|Biological|Venipuncture|Venipuncture for blood collection
45828792|NCT03626974|Device|Diffuser spreading odor|Diffuser will place under a Hood with an air-flow
45972165|NCT04556071|Drug|Bevacizumab|The dose of Bevacizumab will be 15 mg/kg that administered via a 30-minute intravenous infusion on day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death.
45972166|NCT04563871|Drug|80mg Osimertinib|One tablet of 80mg Osimertinib for oral administration per day
45972167|NCT04563676|Biological|blood test|covid19 infected patient will have a blood test in order to make an autoimmune assessment (antinuclear antibodies, soluble nuclear anti-antigen, ANCA, antiphospholipid antibodies, FT3, FT4 , TSH, antithyroid antibodies, ACTH cortisol, and creation of a serotheque).
45972168|NCT00234377|Drug|Seroquel SR|
46081545|NCT04118062|Behavioral|Semi-structured individual interviews|Semi-structured individual interviews
46081546|NCT04118062|Other|Focus Group|Focus Group
46081547|NCT04118062|Other|DELPHI Consensus Method|DELPHI Consensus Method
45669940|NCT01706926|Biological|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks.
45669941|NCT01706926|Biological|Mavrilimumab 150 mg|Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks.
45972169|NCT04563754|Diagnostic Test|mHRME (Mobile High resolution microendoscope)|"SOC (standard of care) HRA with Lugol's iodine will be performed. Unstained (abnormal) area will be evaluated with mHRME for optical biopsy diagnosis:~contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)).~The mHRME will then be inserted and imaging of abnormal tissues will be performed. This will add 2 to 6 minutes per procedure.~This is a single-arm study where all subjects will receive both standard of care HRA (High resolution anoscopy) and experimental mHRME imaging."
45972170|NCT04563754|Drug|Proflavine Hemisulfate|Contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)) to use with the mHRME
45972171|NCT04563754|Diagnostic Test|High resolution anoscopy|SOC (standard of care) HRA with Lugol's iodine will be performed.
46081548|NCT04098419|Behavioral|Science for Life|The implementation for both school years will follow the same procedures with different cohorts. Sixteen adolescents will be recruited through existing after-school programs at each location (32 total each year). College interns will facilitate food literacy lessons after school once per week with high school-aged adolescents. Beginning in January, adolescents will participate in training led by project staff and college interns to become competent cross-age teachers for garden-enhanced nutrition curricula. This training will consist of instruction in utilization of inquiry-based teaching practices and will be followed by adolescents practicing facilitating the curricula in teaching pairs. Up to 32 younger youth participants at each location (up to 64 total each year) will be recruited from local elementary schools while adolescents complete the cross-age teaching training. With mentorship from college interns, adolescents will facilitate curricula in pairs with younger youth.
46081549|NCT04092647|Drug|Ashwagandha|Ashwagandha 350 mg po BID
46081550|NCT04092647|Drug|Placebo|Placebo 350 mg po BID
46081551|NCT04092270|Procedure|Biospecimen Collection|Undergo blood sample collection
45669942|NCT01706926|Other|Placebo|Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks.
45669943|NCT01634113|Drug|tiotropium-bromide|IMP
46081552|NCT04092270|Procedure|Computed Tomography|Undergo CT scan
46081553|NCT04092270|Procedure|Echocardiography|Undergo ECHO
45669944|NCT01634113|Drug|tiotropium-bromide|IMP
45669945|NCT01634113|Drug|placebo|placebo matching tiotropium
46081554|NCT04092270|Procedure|Magnetic Resonance Imaging|Undergo MRI
46081555|NCT04092270|Procedure|Multigated Acquisition Scan|Undergo MUGA scan
45669946|NCT01706770|Device|enfilcon A|
45669947|NCT01706770|Device|galyfilcon A|
45669948|NCT01016899|Radiation|electronic brachytherapy|Post market observational study recording data form patients with skin cancer treated with electronic brachytherapy. Treatment is standard of care, and can vary in dose and fractionation schedule from patient to patient depending on radiation oncologist's judgement for best treatment for the patient.
45828793|NCT03602521|Other|Interpersonal stress|"Through an interview the evaluator will make a 1 to 2 pages script, written in first-person and in present tense. It will involve an interpersonal conflict between the participants and the person who once trigger their feeling of abandonment.~After reading the script the participants will have to close their eyes and imagine the event as if was happening to them, now, in real time, and think about it during 3 minutes.~To evaluate the stress efficiency, the evaluator will ask 2 questions :~1) from 0 (no distress at all) to 10 (maximal unimaginable distress), to wich point this script bring distress to you?~2) from 0 (I can not at all) to 10 (I can completely), to wich point are you able to imagine the scenario in real time, as if you were living it?"
45828794|NCT03600155|Biological|Ipilimumab|Given IV
45828795|NCT03600155|Biological|Nivolumab|Given IV
45828796|NCT03597594|Drug|Anti-thymocyte globulin (rabbit)|given intravenously
45828797|NCT03597594|Drug|Busulfan|given intravenously
45828798|NCT03597594|Drug|Fludarabine|given intravenously
45828799|NCT03597594|Drug|Thiotepa|given intravenous infusion
45828800|NCT03597594|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
45828801|NCT03597594|Other|Donor Lymphocyte Infusion|given intravenous infusion
45972172|NCT04563286|Other|questionnaire on life quality|Two sets of 30 PROMs questions will be created. The v-ATTR and wt-ATTR questionnaires will be critically evaluated by the whole panel, taking into account observations and feedback from patients. The 2 scores will be administered to consecutive patients evaluated at dedicated ambulatory clinics of the 4 Institutions. To confirm score reliability and responsiveness, 2 distinct patient cohorts will be recruited. The reliability cohort will be assembled to demonstrate the instrument's test-retest reliability. A second cohort of patients (responsiveness cohort) will be assembled to demonstrate the instrument's responsiveness to changes in clinical status. Patients experiencing a heart failure hospitalization within 6 months will enter the responsiveness cohort at the time of hospital admission.
45972173|NCT00260754|Behavioral|Community-Popular Opinion Leader Model|
45669949|NCT04497454|Other|EIT-Group|A mechanical ventilation strategy with the main goal to maintain DP < 16 cmH2O
45669950|NCT04497454|Other|ARDSNet|Low PEEP-FiO2 table ARDS Network ventilation protocol
45669951|NCT01937715|Drug|PF-05212384|PF-05212384 at the Recommended phase 2 dose (RP2D/MTD) weekly
45669952|NCT01937715|Drug|FOLFIRI regimen|The RP2D/MTD dose of FOLFIRI regimen every 2 weeks
45669953|NCT01937715|Biological|Bevacizumab|5 mg/m^2 every 2 weeks or 7.5 mg/m^2 every 3 weeks
45669954|NCT01937715|Drug|FOLFIRI|Full dose FOLFIRI regimen every 2 weeks
45669955|NCT01937559|Biological|Tranexamic acid (TXA)|1.5g of TXA in 100ml normal saline solution
45669956|NCT01937559|Drug|Normal saline|
45669957|NCT04634331|Behavioral|Augmented Reality Multi-Modal Training|Training administered via an augmented reality headset.
45669958|NCT04634331|Behavioral|Traditional Multi-Modal Training|Training administered via a 1:1 physical therapy session
45972174|NCT00260754|Behavioral|Diffusion of Innovations|
45972175|NCT02211118|Drug|Intranasal dexemdetomidine (IN-DEX)|
45972176|NCT02211157|Drug|BIBR 796 BS|
45972177|NCT02211157|Drug|Placebo|
45972178|NCT02211157|Other|high fat breakfast|
45972179|NCT00234416|Drug|Gefitinib|
45972180|NCT00234416|Drug|Gemcitabine|
45669959|NCT01960257|Device|Digital Health Feedback System|This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their TB medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their TB medications.
45828802|NCT03595657|Biological|CS1001|monoclonal antibody
45972181|NCT02211196|Behavioral|smoking cessation intervention|Receive evidence-based tobacco cessation strategies
45972182|NCT02211196|Other|survey administration|Ancillary studies
45972183|NCT02211196|Other|questionnaire administration|Ancillary studies
45828803|NCT03591887|Biological|ABY-035|ABY-035 solution for injection
45972184|NCT04563364|Other|Interdisciplinary hospital-home intervention|The intervention will start in NICU and to be continued at home with the support of ICT. The NICU intervention will have theoretical and practical components, the theoretical one will be about motor development in premature infants, and practical one will have strategies for motor early intervention, it will be demonstrated with pediatric simulator and parents should be demonstrate it with a infant: 1Sensorial motor stimulation, visual and auditory follow-6up; Tactile integration 3Extension muscle activation 4Middle line integration 5Alignment reaction stimulation in prone position 6Flexor muscle activation with transition to lateral position 7Flexor muscle activation with transition to sitting position 8Facilitation of reciprocal flexion and extension lower limbs. All parents will receive a motor sensorial kit that will include roller, visual tags, blankets and rattles, it will be for apply the strategies for motor early intervention, and will be supported by ICT
45972185|NCT04563364|Other|Convencional treatment|Control group will receive a conventional treatment given by the institutions
45972186|NCT04562857|Behavioral|Moderate intensity interval training (MITT)|interval exercises (intervention) on bicycle for patients with AF and OSA or AF with CSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
45972187|NCT04563052|Behavioral|Educational Program on Air Pollution as a Health Risk Reduction Strategy|A power point presentation about the health impact of exposure to fine particulate matter (PM2.5) on health. Pm2.5 is found outdoors and indoors. Information will be reviewed about steps to take for the participants to locate the information using a smart phone and steps to take to decrease exposure to prevent illness such as heart disease or strokes.
45972188|NCT00234455|Device|drug eluting-stent|PCI
45972189|NCT00234455|Device|drug-eluting stent|PCI
45972190|NCT04563169|Other|Video consultation|The first video consultation with a nurse was planned one week after start with CPAP. Three focus points were discussed during the consultations: 1) adherence (>6 hours per night); 2) rest AHI < 5 (or <10 if age >70), and 3) (improvements in) complaints. If these objectives were achieved after one week, a new consultation was planned three weeks later (four weeks after start). As long as these objectives were not achieved, video consultations were planned weekly (until after four weeks).
45669960|NCT01960257|Other|SOC DOT|
45669961|NCT01918371|Drug|Anti-VEGF|Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.
45828804|NCT03591887|Biological|Placebo|Placebo to ABY-035 solution for injection
45828805|NCT03563690|Other|treatment1|"Acupoints：Liangqiu（ST34）,Xuehai（SP10）,Neixiyan（EX-LE4）,Dubi(ST35),Yanglingquan (GB34)and Yinlingquan (SP9)~operation: the needles will be manipulated using techniques including lifting, thrusting, twisting, and rotating, until De Qi is achieved for 30 minutes."
45828806|NCT03563690|Other|treatment2|"Acupoints：Needling points are the same to the above group~operation: The electrode will be connected Neixiyan (EX-LE4) and Dubi (ST35) and electrode wire will be connected to the electro-acupuncture apparatus using dilatational wave with a frequency of 2/100 Hz, the current intensity is within participants'tolerance, for 30 minutes."
45828807|NCT03563690|Other|treatment3|"Acupoints：treating points are the same to the above group~Operation: During treatment, participants will choose to sit with knee buckling natural 90 degrees ,with the affected knee(s) exposed. Mild moxibustion are applied at the distance of 2-3 cm away from the skin of both the Neixiyan (EX-LE4) and Dubi (ST35) for 30 minutes."
45828808|NCT03563690|Other|treatment4|"Acupoints：Needling points are the same to the above group~Operation: Warm-needling acupuncture are applied at both Neixiyan (EX-LE4) and Dubi (ST35). That is to insert one zhuang(about 2cm)of Huai Qing Ai on the top of the needle, and burn the moxa at the lower end ,each acupoint applied 2 Zhuang for 30 minutes."
45828809|NCT03563690|Other|treatment5|"points：Sham Liangqiu（ST34）,Sham Xuehai(SP10), Sham Neixiyan(EX-LE4), Sham Yanglingquan(GB34),Sham Yinlingquan (SP9)~Operation: Sham acupuncture with non-meridian and non-acupoint needling method, respectively acupuncture 1cm away lateral to the above sham acupoints with a 0.18 * 25mm single-use needle with the depth of 1-2mm."
45828810|NCT03563690|Drug|Celebrex|Drug: Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd), which will be applied 1 time daily( taken 0.2g one time orally ) Time of treatment :4 weeks Other Name: celecoxib
45972191|NCT04563091|Device|Hemodialysis with online HFR|"Hemodialytic therapy using 240-minute online HFR on Flexya® hemodialysis machine (Medtronic, Mirandola, Italy). The blood flow from vascular access will be maintained at values > 250 ml/minute, the flow of dialysis fluid will be 500 ml/minute. Weight loss during dialytic treatment will be prescribed according to the patient's clinical needs.~Assess potassium (intra and extra cellular), sodium, bicarbonatemia, calcemia, urea, blood sugar values and ECG every 30 minutes during dialysis and every 60 minutes after dialysis.~Body impedance analysis at time 0 at 240 minutes, after 60 minutes after the end of dialysis and after 7 hours after the end of dialysis.~Use of the Natrium sensor (Medtronic, Mirandola, Italy) during HFR dialytic treatment."
45972192|NCT00234572|Drug|Lanreotide (Autogel formulation)|
45972193|NCT04562818|Diagnostic Test|Diagnosis|Determine the number of center that are able to process PCR or FISH/Karyotype for PML/RAR or t(15;17)
45972194|NCT04562818|Diagnostic Test|Molecular and Karyotype|To realize the need of having more center we the technology to perform all of these tests
45972195|NCT04562818|Diagnostic Test|Leucocytes|
45972196|NCT00260793|Drug|Ropinirole Hydrochloride|
45828811|NCT03557684|Dietary Supplement|leucine|amino acid leucine in powder
45828812|NCT03557684|Other|PO placebo|maltodextrin
45972197|NCT04562506|Device|rTMS with H-coil|Deep repetitive transcranial manetic stimulation or sham stimulation with H-coil
45972198|NCT04562506|Device|Sham rTMS stimulation with H-coil|Sham rTMS stimulation
45972199|NCT04562545|Device|Modified Twin Block|a modified twin block design including jack screws to facilitate incemental advancement
45828813|NCT03557684|Biological|lipopolysaccharide (LPS)|purified bacterial wall component as an inflammatory challenge
45972200|NCT04562545|Device|Twin Block Appliance set to maximum bite|a traditional twin block set to maximum bite advancement at start of treatment
45972201|NCT00234611|Procedure|Echocardiogram guided left ventricular lead placement|
45972202|NCT00415935|Drug|methotrexate|
45972203|NCT02211274|Other|Everyday Competence Assessment and Planning for Community Transitions|The Everyday Competence Assessment and Planning for Community Transitions (ECAP-CT) toolkit will allow CLC interdisciplinary team members to 1) assess the Veteran's everyday competence for safe and independent living; 2) develop personally meaningful rehabilitation goals that facilitate successful transition out of the CLC based on everyday competence; and 3) conduct structured treatment planning to support resident goals around transitioning back into the community. By considering everyday competence and goal-setting in this context, Veterans will have optimal P-E fit upon returning to the community, ensuring a successful transition.
45972204|NCT02211352|Drug|Korean Red Ginseng Capsules|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
45972205|NCT02211352|Drug|Placebo|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
45972206|NCT00413738|Device|Antiseptic-coated central venous catheters|
45972207|NCT02211391|Other|Casein Protein|The effect of casein protein consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
45972208|NCT02211391|Other|Non-caloric placebo|The effect of a non-caloric placebo consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
45669962|NCT01917747|Behavioral|Patient Navigator|The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed. In the second part of the study, further educational tools are given to parent(s) and discussion of additional follow up mechanisms, including community hearing services and types of interventions for pediatric hearing loss is imparted.
45669963|NCT01917747|Behavioral|Standard scheduling and follow-up|The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test, as is standard practice.
45828814|NCT03557684|Other|IV placebo|0.9% saline
45972209|NCT02211469|Drug|BMS-986104|
45972210|NCT02211469|Drug|Placebo|
45669964|NCT04633551|Dietary Supplement|Anti-inflammatory supplement|commercially available combination of curcumin, quercitin, resveratrol, and green tea
45972211|NCT00415974|Behavioral|Physician Counseling|Physician-patient visits will occur in the primary care setting and are scheduled at study onset (beginning of step 1) and at the end of the first year. An extra physician visit will occur for patients who do not progress from step 1 after two attempts. At study entry, physicians will discuss the purpose and importance of the intervention and encourage participation. Physicians will underline the value of attending all study visits and complying with study protocol and instructions. Subsequent physician visits will focus on weight loss progress and overcoming barriers.
46081556|NCT04092270|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
45828815|NCT03557008|Biological|Rabies Vaccine|A 1.0 milliliter (mL) dose of Imovax® will be given to participants on Day 0 and Day 28 of the study.
45828816|NCT03557008|Drug|Metronidazole|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Flagyl taken by mouth three times a day.
46081557|NCT04092270|Drug|Peposertib|Given PO
45455898|NCT05524935|Drug|Olaparib|Olaparib by mouth days 1-21 of each 21 day (3 week) cycle
45828817|NCT03557008|Drug|Vancomycin|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 125 mg of Vancocin taken by mouth four times a day.
45828818|NCT03557008|Drug|Neomycin Sulfate|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Neomycin sulfate taken by mouth three times a day.
45828819|NCT03556683|Device|3% Hypertonic Saline|4 mL of 3% hypertonic saline
45828820|NCT03556683|Device|7% Hypertonic Saline|4 mL of 7% hypertonic saline
46081558|NCT04091386|Drug|Damoctocog alfa pegol (Jivi, BAY94-9027)|Intervention is given as part of routine medical practice
46081559|NCT04090411|Drug|50 mg Induction/Chronic|PF-06480605
46081560|NCT04090411|Drug|450 mg Induction/Chronic|PF-06480605
46081561|NCT04090411|Drug|150 mg Induction/Chronic|PF-06480605
46081562|NCT04090411|Other|0 mg Induction ONLY|0 mg Placebo
46081563|NCT04084730|Radiation|Accelerated Partial Breast Irradiation|Treatment will consist of APBI delivered using external beam RT techniques to a dose of 24 Gy in 3 fractions of 8.0 Gy delivered on consecutive weekdays
46081564|NCT04084249|Diagnostic Test|ctDNA-analysis|Minimally-invasive blood-based analysis of circulating tumor DNA (ctDNA).
45669965|NCT01597791|Device|Foley catheter|Foley catheter placement after CSE.
45669966|NCT01597791|Other|No foley catheter|Spontaneous Micturation/ Post Void Residual. the spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
45669967|NCT01916967|Drug|Desloratadine|Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks
45669968|NCT01916967|Drug|Placebo|Placebo tablets, given orally, once daily in the evening for 2 weeks
45828821|NCT03543852|Behavioral|SurvivorLink|SurvivorLink (www.cancersurvivorlink.org) was developed in 2010 as a HIPAA compliant web-based communication tool to enable survivors to learn about survivorship care, store their SHP and other important health documents, and share their SHP and other health documents with their various healthcare providers. Once the registrant creates their health record, they can upload and store their important health documents and electronically share their health record with their providers. Other key features include a provider directory for patients to find physicians knowledgeable of survivor care, additional patient/parent material available in English/Spanish, and additional continuing medical education (CME) modules for providers to learn about survivor care.
45828822|NCT03520881|Other|Pediatric ASTHMA-Educator mobile application|This intervention represents a mobile application (accessible by iOS and Android devices) that provides asthma education through games and videos.
45828823|NCT03509012|Drug|Durvalumab|IV (intravenous)
45828824|NCT03509012|Drug|Tremelimumab|IV
45828825|NCT03509012|Drug|Cisplatin (dose level 4)|IV
45828826|NCT03509012|Drug|Cisplatin (dose level 3)|IV
45828827|NCT03509012|Drug|Carboplatin (dose level 1)|IV
45828828|NCT03509012|Drug|Carboplatin (dose level 2)|IV
45828829|NCT03509012|Drug|Etoposide (dose level 1)|IV
45828830|NCT03509012|Drug|Etoposide (dose level 2)|IV
45828831|NCT03509012|Drug|Paclitaxel|IV
45828832|NCT03509012|Drug|Pemetrexed|IV
45828833|NCT03509012|Radiation|External beam radiation (dose level 1)|radiation therapy
45828834|NCT03509012|Radiation|External beam radiation (dose level 2)|radiation therapy
45828835|NCT03509012|Radiation|External beam radiation (hyperfractionated)|radiation therapy
45828836|NCT03509012|Drug|Cisplatin (dose level 1)|IV
45828837|NCT03509012|Drug|Cisplatin (dose level 2)|IV
45828838|NCT03509012|Radiation|External beam radiation (standard)|radiation therapy
45828839|NCT03481413|Device|Ablation|Ablation therapy for cardiac arrhythmias
45828840|NCT03443323|Behavioral|Organizational Skills Training - School Based (OST-S)|OST-S is a small group skills training intervention, with parents and teachers supporting children's use of new skills. The program manual includes strategies for training and coaching school staff, referred to as school partners, to effectively implement OST-S and guidelines to modify the program for implementation in diverse schools with diverse students. Each student session includes: (a) homework review to assess completion of between-session skills implementation; (b) skill-building activities, which include the use of modeling, shaping, guided practice, and reinforcement for organized behavior; and (c) activities to promote generalization of skills. Sessions address four organizational challenges: (a) tracking assignments, (b) managing materials, (c) managing time, and (d) planning for long term assignments.
46081565|NCT04084249|Other|Intensified Follow-up Schedule|PET/CT-scans every 3. month
46081566|NCT04078672|Procedure|NOTAL-OCT V3.0|AMD and DR patients
45669969|NCT01936623|Behavioral|Computerized Brief Intervention|No additional information needed.
46081567|NCT04075266|Drug|Ocrelizumab|"Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks.~Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg"
45669970|NCT04625127|Device|Treadmill gait training with GaitBetter|Participants will receive gait training with the GaitBetter solution for a total of 15 sessions (3 days a week for 5 weeks) each lasting approximately 45 minutes.
45828841|NCT03413254|Other|Routine follow-up|Patients visit the outpatient clinic twice a year during the first two to three years and annually thereafter, until five years postoperative. CEA-levels are determined at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48 and 60 months after primary resection. Detection of liver metastases with ultrasound or CT is performed at 12, 24, 36, 48 and 60 months postoperative. At 6 and 18 months postoperative, a CT-scan is part of the study protocol, but ultrasound of the liver is allowed for other time intervals during follow-up. Colonoscopy is performed at 12 and 48 months postoperative.
45828842|NCT03413254|Procedure|Second look DLS|Second look DLS is performed within one month from negative CT at 6-9 months (depending last date of adjuvant chemotherapy) and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
45828843|NCT03413254|Procedure|Third look DLS|Third look DLS is performed within one month from negative CT at 18 months and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
45828844|NCT03404193|Drug|Decitabine|Given IV
45828845|NCT03404193|Other|Laboratory Biomarker Analysis|Correlative studies
45828846|NCT03404193|Drug|Venetoclax|Given PO
45828847|NCT03395847|Biological|Pembrolizumab|Given IV
45828848|NCT03367637|Other|Standard palliative care|Standard care includes regular follow-up phone calls and home visits by the RPCHO staff for all advanced cancer patients at RPCHO, though the timing of these calls is variable and is selected by the discretion of the team. In addition, patients can contact providers on a landline number available during business hours and staffed by an on-call palliative care provider as and when needed. For after-hours emergency assistance, patients have the option of contacting the on-call palliative-care physicians for assistance.
46081568|NCT04056624|Dietary Supplement|High carotenoid juice|Juice with high carotenoids
45828849|NCT03367637|Other|Smart Phone based symptom evaluation application|In addition to the standard palliative care currently provided at the RPCHO, patients will receive biweekly reminders to fill out the African Palliative Care Outcomes Scale (APCA POS) on the new smartphone application on their phones. It is a short symptom assessment questionnaire with responses on 5-point severity scale. In addition to bi-weekly frequency, patients can complete the symptom assessment at any time they feel their symptoms are poorly controlled. The team at RPCHO will be able to track all enrolled patients on a desktop dashboard. Any score of 2 or higher will be flagged. The providers at RPCHO will respond to such patients during business hours via call or text and will advise the patients as indicated or triage to a fellow team member.
45828850|NCT03347617|Drug|Ferumoxytol|Given IV
45828851|NCT03347617|Other|Laboratory Biomarker Analysis|Correlative studies
45828852|NCT03347617|Procedure|Magnetic Resonance Imaging|Undergo ferumoxytol MRI
45828853|NCT03347617|Biological|Pembrolizumab|Given IV
45828854|NCT03328273|Drug|Ceralasertib|An ATP competitive, orally bioavailable inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR).
45828855|NCT03328273|Drug|Acalabrutinib|An experimental anti-cancer drug and Bruton's tyrosine kinase (BTK) inhibitor.
45828856|NCT03315871|Biological|PROSTVAC-V|Recombinant vaccinia virus vector vaccine of the genus Orthopoxvirus. Administered by subcutaneous injection.
45828857|NCT03315871|Biological|PROSTVAC-F|Recombinant fowlpox virus vector vaccine of the genus Avipoxvirus. Administered by subcutaneous injection.
45828858|NCT03315871|Drug|MSB0011359C (M7824)|Fully human bifunctional fusion protein that combines IgG1 anti-PD-L1 and TGFbetaRII as a monoclonal antibody. Administered via IV infusion over 1 hour.
45828859|NCT03315871|Biological|CV301|Recombinant vaccinia virus vaccine of the genus Avipoxvirus. Administered subcutaneously.
45828860|NCT03310957|Drug|ladiratuzumab vedotin|Given into the vein (IV; intravenously)
45828861|NCT03310957|Drug|Pembrolizumab|IV infusion every 3 weeks
45828862|NCT03291470|Biological|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1
45828863|NCT03291470|Biological|Placebo Control|2 mL normal saline intraarticular injection
45828864|NCT03281369|Drug|5-Fluorouracil (5-FU)|5-FU 2400 milligrams per square meter (mg/m^2) by continuous intravenous (IV) infusion over 46 hours on Days 1 and 2 and Days 15 and 16 of every 28-day cycle.
45828865|NCT03281369|Drug|Leucovorin|Leucovorin: 100 mg/m^2 IV over 2 hours on Days 1 and 15 of every 28-day cycle.
45828866|NCT03281369|Drug|Oxaliplatin|Oxaliplatin: 100 mg/m^2 administered by IV infusion over 2 hours on Days 1 and 15 of every 28-day cycle.
45828867|NCT03281369|Drug|Atezolizumab|Atezolizumab: 840 mg by IV infusion on Days 1 and 15 of every 28-day cycle.
46081569|NCT04056624|Dietary Supplement|Placebo control - Apple juice|Juice with negligible carotenoids
46081570|NCT04052880|Drug|Daratumumab|Daratumumab 1800 mg will be delivered by subcutaneous injection given through a syringe and needle by a manual push over approximately 3 to 5 minutes. Doses will be administered at alternating locations on the abdomen. Daratumumab will be administered weekly during treatment in Cycles 1 to 2, every 2 weeks during cycles 3-6, and every 4 weeks thereafter.
46081571|NCT04052880|Drug|Bortezomib|Subjects will receive 1.3 mg/m2 bortezomib as a subcutaneous infusion on Days 1, 8, and 15 during the 28-day cycles.
45828868|NCT03281369|Drug|Cobimetinib|Cobimetinib: 60 mg by mouth once a day on Days 1-21 of every 28-day cycle
45828869|NCT03281369|Biological|Ramucirumab|Ramucirumab: 8 mg/kg administered by IV infusion over 60 minutes on Days 1 and 15 of every 28-day cycle.
45828870|NCT03281369|Drug|Paclitaxel|Paclitaxel: 80 mg/m^2 administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
45828871|NCT03281369|Biological|PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20: 3 micrograms per kilogram (mcg/kg) administered by IV infusion on Days 1, 8, and 15 of every 21-day cycle.
45828872|NCT03281369|Drug|BL-8040|BL-8040: 1.25 mg/kg administered by subcutaneous (SC) injection on Days 1-5 during the 5-day priming period prior to Cycle 1; 1.25 mg/kg administered by SC injection three times a week (Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of every 21-day cycle).
45828873|NCT03281369|Drug|Linagliptin|Linagliptin: 5 mg orally once a day of every 21-day cycle.
45828874|NCT03281369|Drug|Atezolizumab|Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle
45828875|NCT03281369|Drug|Cobimetinib|Cobimetinib: 40 or 60 mg (depending on the recommended dose determined during the safety run-in phase) by mouth once a day on Days 1-21 of every 28-day cycle.
45828876|NCT03281369|Drug|Cisplatin|Cisplatin: 80 mg/m^2 administered by IV infusion on Day 1 of each 21 day cycle. Treatment will be capped after 6 doses.
45828877|NCT03281369|Drug|Tiragolumab|Tiragolumab: 600 mg administered by IV infusion on Day 1 of every 21 day cycle.
45828878|NCT03281369|Drug|5-Fluorouracil (5-FU)|5-FU 800 mg/m^2 administerd by IV infusion on Days 1-5 of each 21 day cycle.
45828879|NCT03258593|Drug|Durvalumab|Durvalumab 1500 mg is administered intravenously (IV) once every 4 weeks for 12 months with an option to continue therapy for an additional 12 months (total of 24 months) provided that patient is tolerating therapy and remains free of recurrent high grade NMIBC (see Treatment Period below). The dose of durvalumab is 1500 mg. If optional maintenance therapy continued in the second year, durvalumab 1500 mg will be administered intravenously once every 3 months to provide an immune boost.
45455899|NCT05523180|Dietary Supplement|Probiotic|"Active ingredients:~Lactobacillus plantarum RSB11, 5 Billion colony forming units (CFU) Lactobacillus acidophilus RSB12, 5 Billion CFU Lactobacillus rhamnosus RSB13, 5 Billion CFU Holy basil leaf extract, 42.0 mg Turmeric root extract, 30.0 mg Vasaka leaf extract, 48.0 mg~Inactive ingredients:~Microcrystalline Cellulose, Vegan Capsule (Hypromellose), Magnesium Stearate, Silicon Dioxide"
45828880|NCT03258593|Drug|Vicineum|Vicineum is administered in a 12-week Induction Phase followed by a Maintenance Phase for at least one year with an option for a total of up to 2 years of treatment. During the Induction Phase, Vicineum is administered once weekly for 12 weeks. During the Maintenance Phase, Vicineum is administered every other week. The dose of Vicineum is 30 mg in 50 mL of saline.
45828881|NCT03235271|Device|BrainPulse Device|"The BrainPulse is used on a patient's head to non-invasively detect, amplify and capture the skull motion caused by pulsatile cerebral blood flow from the cardiac cycle.~The BrainPulse consists of a reusable headset that contains the accelerometers used to measure motion caused by pulsatile cerebral blood flow. The system is powered by a rechargeable battery pack. The headset is placed on the subject's head and outputs data to a data collector that forwards the data to the computer. Each accelerometer has an attached tip that makes contact with the subject's head through hair. The headset also includes a photoplethysmograph (PPG) that simultaneously captures the subject's heart-rate information. There is no energy delivered to the brain or subject by these highly sensitive sensors."
45828882|NCT03203330|Biological|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.
45828883|NCT03203330|Biological|Placebo Control|2 mL normal saline injection
45828884|NCT03178149|Drug|ASP7317|subretinal injection
45828885|NCT03178149|Drug|tacrolimus|oral
45828886|NCT03136029|Dietary Supplement|Antioxidant|Daily consumption of over-the-counter vitamins (600mg alpha lipoic acid, 1000mg vitamin c, 600IU vitamin E)
45828887|NCT03136029|Dietary Supplement|Tetrahydrobiopterin (BH4)|Daily consumption of BH4 (10mg/kg)
45828888|NCT03136029|Other|Exercise training|Aerobic exercise training program (3x/week for 8 weeks, 1 hour per session)
45828889|NCT03071120|Behavioral|Parent-Mediated Intervention|Children with ASD will participate in a 6-month parent-mediated intervention that will include direct intervention and parent education.
45828890|NCT03040999|Biological|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
45828891|NCT03040999|Drug|Placebo|Normal saline or dextrose solution administered as an IV infusion Q3W
45828892|NCT03040999|Drug|Cisplatin|100 mg/m^2 administered as an IV infusion Q3W
45828893|NCT03040999|Radiation|Accelerated Fractionation (AFX) Radiotherapy|70 Gray (Gy) given in 35 fractions over 6 weeks
45828894|NCT03040999|Radiation|Standard Fractionation (SFX) Radiotherapy|70 Gy given in 35 fractions over 7 weeks
45828895|NCT02990338|Drug|Isatuximab|Pharmaceutical form: solution for infusion Route of administration: intravenous
45828896|NCT02990338|Drug|Pomalidomide|Pharmaceutical form: capsule Route of administration: oral
45828897|NCT02990338|Drug|Dexamethasone|Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous
45828898|NCT02971956|Drug|Pembrolizumab|Immune checkpoint inhibitor
45828899|NCT02885142|Procedure|Local excision for early rectal cancer|
45828900|NCT02861300|Drug|CB-839|Patients will receive CB-839 orally twice daily during each cycle. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
45828901|NCT02861300|Drug|Capecitabine|capecitabine will be given orally twice daily for 14-21 days of cycles. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
45828902|NCT02848235|Other|Standard of Care + EMMA|Mother Mentors will provide enhanced care, above that of the standard of care, to include clinic visit exit discussions, visit reminder messages, and patient follow-up in the event that a clinic visit is missed.
45828903|NCT02787369|Drug|ACY-1215|
45828904|NCT02787369|Drug|Ibrutinib|
45828905|NCT02787369|Drug|Idelalisib|
45828906|NCT02576509|Drug|Nivolumab|Specified Dose on Specified Days
45828907|NCT02576509|Drug|Sorafenib|Specified Dose on Specified Days
45835926|NCT05606016|Behavioral|Facilitated Self-Sampling Intervention (FSSI)|CHWs will consent and enroll participants to the FSSI from the randomized PBGs. FSSI will consist of Community Health Worker (CHW) delivered education intervention about COVID-19 testing at a home visit. In addition, the participant will receive a batch of 4 rapid antigen tests which can be shared with people in the household or other close contacts if needed. The CHWs will provide low-literacy instructions for administering the tests, including print and video. The CHWs will also provide guidance if they tested positive (e.g. quarantine, notify contacts, wearing a mask). The CHWs will also be available by phone to the participants for any follow-up questions. CHW will follow-up via text and phone with the participants during the two months post intervention. In addition to the intervention, the participants will be asked to complete the pre and post test surveys. Post surveys will be administered online or over the phone two months after the initial intervention.
45835927|NCT05606016|Behavioral|Testing Navigation Intervention (TNI).|CHWs will consent and enroll participants to the TNI from the randomized PBGs. The TNI will consist of CHW-led intervention at a home visit where they will provide low health literacy materials about how and when to conduct a COVID 19 test (including antigen and PCR) using a decision tree model and provide navigation to nearby PCR testing sites, locations to purchase antigen tests and support in accessing federal government antigen tests if not already obtained by the participant. In addition to the intervention, the participants will be asked to complete the pre and post-test surveys. Post surveys will be administered online or over the phone two months after the initial intervention.
45835928|NCT05606016|Behavioral|Control|Participants in the Control arm will receive CDC-designed COVID-19 testing brochures, and pre and post surveys only.
45972212|NCT00415974|Behavioral|Health Educator|Health education sessions are held with teens and parents at the primary care setting. These include information on nutrition, physical activity, and weight loss. Behavioral approaches are used to enhance the home environment, food preparation, and planned physical activity to elicit weight loss, including discovery of perceived and actual barriers to modification of eating and physical activity behaviors. The Health Educator focuses on problem-solving and tailored selection of behavior change skills to help participants overcome difficulties. In addition to reviewing the assessment and generating solutions to barriers, sample meal plans (including strategies for restricting calories) and pedometers will be distributed at the initial health educator visit. Pedometers are encouraged to monitor progress with physical activity goals. An initial binder is distributed to teen and parent participants at the initial session and subsequent materials are added with each visit.
45828908|NCT02567877|Procedure|thyroidectomy|Patients enrolled in the study will undergo a clinically-indicated thyroidectomy performed as standard of care.
45972213|NCT00415974|Behavioral|Phone Counseling|Brief counseling calls will occur between PACE-PC participants and assigned counselors during all steps. In general, these calls occur on a bi-weekly to monthly basis in steps 1 and 2, and monthly in step 3. Such calls are intended to encourage continued goal attainment and progression and to promote healthy eating and physical activity behaviors. Counselors will review progress since the last clinical interaction (e.g., health educator visit, phone call, or physician visit) and help adolescents set new goals that are appropriate and attainable. Data from pedometers may be discussed during these sessions as an interim assessment of progress on physical activity behaviors between formal study measurement visits. After speaking with the adolescent, the counselor will talk with the parent (when feasible) to reinforce parental involvement and emphasize the importance of the healthy changes in the home environment to encourage goal attainment.
45972214|NCT00415974|Behavioral|Health promotion materials on physical activity and nutrition|PACE-PC adolescents and their families will receive information regarding healthy eating and physical activity behaviors on a weekly basis via mail. These behavioral-based materials will educate participants and their families on healthy behaviors that are necessary for successful weight management. Topics will coincide with the intervention goals and include supplemental information to enhance quality of life and improve body image. Topics will include realistic goal-setting and attainment, how to handle holidays and celebrations, eating fast food, grocery shopping and food preparation, and relapse prevention, etc.. Topics will include specific strategies related to the adolescent's readiness to change to reflect processes that are most appropriate. Content from these materials will be addressed by the phone counselors to ensure that participants received and understood intervention messages.
45972215|NCT04562584|Device|MyHomeDoc|MyHomeDoc device SpO2 measurements and parallel blood gas analysis to determine oxyhemoglobin saturation (SaO2) using an ABL-90 multi-wavelength oximeter.
46081572|NCT04052880|Drug|Lenalidomide|"In Cycles 1 through 12, lenalidomide will be self-administered at a dose of 15 mg orally each day on Days 1 through 21 of each 28-day cycle.~For subjects with CrCl 30-60mL/min, lenalidomide will be reduced to 10mg daily, and for subjects with CrCl 15-30 mL/min, lenalidomide will be reduced to 5mg daily.~In maintenance phase: lenalidomide will be administered at one dose level below Cycles 1-12 dosing ie 10 mg orally daily.~In maintenance, for subjects with CrCl 30-60 mL/min, lenalidomide will be reduced to 5 mg daily during maintenance treatment, and for subjects with CrCl 15-30 mL/min, lenalidomide will be reduced to 5 mg every other day during maintenance treatment."
45828909|NCT02567877|Drug|levothyroxine in thyroidectomy patients|Patients will initiate levothyroxine treatment after surgery consistent with standard of care. The drug dosage will be titrated to TSH goal that matches the pre-surgery TSH (+/- 1 mIU/L)
45828910|NCT02548351|Drug|Obeticholic Acid|
45828911|NCT02548351|Drug|Placebo|
45828912|NCT02366728|Biological|Unpulsed DCs|Patients in Group I will receive 1 x 10^6 autologous unpulsed DCs in saline administered to a single side of the groin intradermally 1 day before the fourth vaccine.
45828913|NCT02366728|Biological|Td|Patients in Groups II and III will receive a single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally 1 day before the fourth vaccine.
46081573|NCT04052880|Drug|Dexamethasone|"Dexamethasone will be self-administered orally at a total dose of 20 mg weekly during cycles.~However, the dexamethasone 20 mg oral or IV (only if oral is not available) dose administered as a preinfusion medication on daratumumab infusion days replaces the oral dexamethasone dose for that day. Dexamethasone will be administered until the subject experiences disease progression or unacceptable toxicity.~In the maintenance phase, dexamethasone/steroid premedications may be tapered or discontinued in the absence of daratumumab related infusion reactions/based on patient tolerance. In the event of persistent daratumumab related infusion reactions, the least amount of steroid premedications needed to prevent the same may be used."
45828914|NCT02366728|Biological|Human CMV pp65-LAMP mRNA-pulsed autologous DCs|2x10^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
45828915|NCT02366728|Biological|111In-labeled DCs|111In-labeled DCs are 2 x 10^7 pp65-LAMP mRNA loaded mature DCs will be labeled with 111In (50 μCi / 5 x 10^7 DCs) and given i.d. as fourth vaccine for Groups I and II only.
46081574|NCT04052880|Drug|Ixazomib|During maintenance treatment, if choice of maintenance therapy includes ixazomib, ixazomib will be administered at 3 mg orally daily on Days 1,8, and 15 of each cycle. For subjects with CrCl 15-30 mL/min, ixazomib will be reduced to 2.3 mg once per week during maintenance treatment.
45669971|NCT04625127|Other|Treadmill gait training with GaitBetter + Standard of care|Participants will receive gait training with the GaitBetter solution for a total of 15 sessions (3 days a week for 5 weeks) each lasting approximately 45 minutes. In addition, the investigators will record the number and duration of therapy sessions followed by the participant during standard of care.
45669972|NCT04625127|Other|Standard of care|Participants will follow their standard of care. The investigators will record the number and duration of therapy sessions followed during standard of care.
45669973|NCT01959243|Drug|Brimonidine Tartrate|Ophthalmic solution to be applied as directed.
45669974|NCT01959243|Drug|Vehicle|Ophthalmic solution to be applied as directed.
45669975|NCT01959243|Drug|Sodium Fluorescein|For use as needed during the study for evaluating corneal damage.
45828916|NCT02366728|Drug|Temozolomide|Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 5 (± 1) weeks for a total of 6 to 12 cycles at the discretion of the treating oncologist.
45828917|NCT02366728|Drug|Saline|0.4mL of saline given in the opposite groin 1 day before the fourth vaccine in all groups
45972216|NCT04562350|Other|XatJove Anoia Aplication|All students (age 12-16 years) from middle school and high school in the sanitary region of Anoia, province of Barcelona, will access a Platform ( ABH Health), where the users will enter specific registration data ( age, sex..etc), after every visit the users will be provided with a 6 multiple choice questionary and asked to punctuate in a scale from 1 to 10, the satisfaction of the service provided. Appart from this data, researchers will use a software to register specific Health-related words and classify them as Health-problems. While Osona students will attend face-to-face consultations as usual, apart from this data,Registrations will be reviewed later and specific search techniques and strategies will be coded. A qualitative review will be performed too.
46081575|NCT04051216|Behavioral|Education information system|Participants will receive a mobile tablet as an educational intervention
45669976|NCT01959243|Drug|Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP|For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
45828918|NCT02366728|Drug|Basiliximab|Group III will receive basiliximab infusions (20 mg I.V) 1 week before the first vaccine and 1 week before the second vaccine.
45972217|NCT04562311|Drug|Chidamide with tislelizumab|Chidamide: 30mg orally BIW. Immunotherapy: tislelizumab,the fixed dose of 200 mg IV. Treatment cycles are repeated every 3 weeks.
45828919|NCT02361554|Device|Medtronic Percept with SensSight Deep Brain Stimulation System|
46081576|NCT04051216|Other|Activity monitor|Participants will receive at least 1 of 4 activity monitoring devices
46081577|NCT04051216|Other|Interview|Participants will be interviewed about their experience using the device(s)
45455900|NCT05523180|Other|Placebo|"Active ingredients:~N/A~Inactive ingredients:~Microcrystalline Cellulose, Vegan Capsule (Hypromellose), Magnesium Stearate, Silicon Dioxide"
45455901|NCT05515029|Combination Product|GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor|Cyclophosphamide 100 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +45, +60, +90, +120 Vedolizumab 10 mg/kg/day, max. 300 mg on the days -1, +14, +28
45455902|NCT05510674|Diagnostic Test|OWL-EVO1|EVOC probe
45669977|NCT01959165|Drug|MEDI7183 low dose|MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
45669978|NCT01959165|Drug|MEDI7183 medium dose|MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
45669979|NCT01959165|Drug|MEDI7183 high dose|MEDI7183 will be administered by SC on Day 1, and placebo for MEDI7183 at Week 2, 4, and 8
45828920|NCT02355002|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
45828921|NCT02352896|Drug|EPI-743|EPI-743 100 milligrams/milliliter (mg/mL) oral solution will be administered per dose and schedule specified in the arm.
46081578|NCT04051216|Other|Survey Administration|Participants will receive surveys
46081579|NCT04051216|Other|Laboratory Biomarker Analysis|Correlative studies
45669980|NCT01959165|Drug|Matching Placebo|Placebo will be administered by SC on Day 1, Week 2,4, and 8
45669981|NCT01916109|Drug|Gemcitabine|
45669982|NCT01916109|Drug|Carboplatin|
45669983|NCT01916109|Drug|Panitumumab|
45669984|NCT01916109|Procedure|radical cystectomy|
45828922|NCT02333370|Drug|LEE011|LEE011 as 50 mg and 200 mg hard gelatin oral capsules as individual patient supply packaged in bottles. LEE011 will be taken QD - days 1-21 of each 28 days cycle.
45828923|NCT02333370|Drug|Letrozole|25mg
45828924|NCT02333370|Drug|Tamoxifen|20 mg
45828925|NCT02333370|Drug|Fulvestrant|500 mg
45972218|NCT00234650|Procedure|Colonoscopy|
45972219|NCT02211547|Device|Epic 10 Diode Laser by Biolase Inc.|
45972220|NCT02211547|Other|Placebo|Single blind lack of laser treatment (the laser will be positioned and operated as if applying the treatment, but the energy transfer will not take place).
45972221|NCT04562272|Procedure|LV mechanical unloading by Impella-CP|The patients will receive Impella-CP for 36-48 hours. The pump speed and LV unloading will be guided by PCWP (Swan-Ganz catheter)
45972222|NCT04561843|Diagnostic Test|pelvic floor ultrasound|2D and 3D trans-perineum ultrasound examinations will be performed by single examiner who was blind to clinical data, using a GE Voluson 730 machine (GE Medical System Kretz Technik, Zipf, Austria) with a RAB 4-8 MHz curved array volume transducer. In the supine position, with flexed and slightly abducted hips after urine voiding. The transducer was placed on the perineum, in the mid sagittal plane with minimal pressure being applied after covering it with an un-powdered glove or thin plastic wrap for hygienic reasons
45972223|NCT00234689|Drug|Naltrexone|
45972224|NCT04561960|Drug|Fluoride toothpaste|Fluoridated paste containing 1450ppm NaF
45972225|NCT04561960|Drug|Toothpaste Product|Non Fluoridated toothpaste with extract of miswak ( Dabur, miswak tooth paste)
45972226|NCT04561960|Device|Toothbrush|Colgate classic clean Soft bristled toothbrushes, 19.05 x 1.27 x 1.91 cm
45972227|NCT04561960|Device|Miswak Stick|A miswak stick of 15 cm length
45972228|NCT04561804|Procedure|laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB)|"The participants will receive nutritional recommendations for a low carbohydrate, low glycemic load, and isocaloric diet. The diet will be composed of carbohydrates (CHO;35%), fats (40-50%), and proteins (20-25%), and will be tailored to individual preferences and calorie requirements. The number of CHO, protein and fat servings will be determined based on the recommended total energy requirements for age, calculated on the basis of dietary reference intake (DRI). Participants will not be instructed to restrict calories, but to reduce carbohydrate based on their glycemic load.~The subjects will be instructed about appropriate food choices, and each subject was provided a diet information booklet containing food list, sample menus and recipes"
45972229|NCT00234728|Device|Occlusive dressing|
45972230|NCT04561921|Drug|Magnesium sulfate|patients will be given an IANB injection by adding 0.18 mL of 10% magnesium sulphate to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
45972231|NCT04561921|Drug|Mepivacaine-Levonordefrin Hydrochloride|patients will be given an IANB injection by adding 0.18 mL of sterile distilled water to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
45972232|NCT04561882|Device|Transcatheter exclusion of atrial septal aneurysm|"Through transseptal perforation, transcatheter reconstruction of atrial septum was achieved with PFO occluder to cover the whole ASA.~Device: Cardi-O-Fix™ patent foramen ovale occluder (Starway Medical Technology, Inc. Beijing, CN)"
45972233|NCT04561999|Device|Elastography|Performance of Ultrasound, Elastography
45972234|NCT04561687|Drug|Montelukast|Montelukast and nasal budesonide
45972235|NCT04561687|Drug|Azelastine|Azelastine and nasal budesonide
45972236|NCT04561687|Drug|Budesonide|To all groups
45455903|NCT05502354|Device|removal of transanal drainage tube|removal of transanal drainage tube after laparoscopic anterior resection for rectal carcinoma according to postoperative CRP trajectory
45972237|NCT04561687|Drug|Placebo|Placebo and nasal budesonide
45972238|NCT00234767|Device|Pulmonary Artery Catheter|
45972239|NCT00234767|Behavioral|Protocolized Fluid Management|
45828926|NCT02333370|Drug|goserelin|
45828927|NCT02303444|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients can get sorafenib at any time during study.
45828928|NCT02303444|Drug|Other Multikinase inhibitors|Patients can get MKIs at any time during study.
45828929|NCT02267564|Procedure|MPFL reconstruction|to correct patellar dislocation with medial patellofemoral ligament reconstruction
45972240|NCT04561414|Device|LED light source system for endoscope|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use LED light source system for endoscope.
45828930|NCT02267564|Procedure|tibial tubercle transfer|to correct patellar dislocation with tibial tubercle medial transfer
45972241|NCT04561414|Device|Ureteral stent (Cook Ireland Ltd.)|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use Ureteral stent (Cook Ireland Ltd.).
46081580|NCT04035005|Drug|Ocrelizumab|The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg infusion every 24 weeks. A minimum interval of 20 or 22 weeks, depending if the previous dose was administered in one or two infusion, should be maintained between each infusion.
45455904|NCT05500339|Other|M-health App|Pregnant women receive the App designed for the support of the first 1000 days of life
45455905|NCT05500339|Other|Standard care|Pregnant women receive standard supportive and educational methods.
45669985|NCT01915095|Device|rTMS|small magnetic pulses will be given to the brain in a non invasive manner.
45669986|NCT01915095|Device|Sham rTMS|sham or fake stimulation (TMS or rTMS) will be given to the brain in a non invasive manner
45828931|NCT02264678|Drug|Administration of ceralasertib|An oral formulation of ceralasertib will be used. In Module 2 Part A1, patients will receive a single dose of ceralasertib on Day 1, followed by 4 to 6 days washout, before multiple dosing.
45972242|NCT04561726|Other|Connective Tissue Manipulation|Connective tissue manipulation is a soft tissue manipulative technique and also a reflex therapy which is characterized by localised and specific strokes performed in where the fascia is superficial or palpable. A shear force is created between the skin-underlying fascia or dermis-hypodermis and angulatory force is applied to the collagen fibers to produce reflex and mechanical effects.
45972243|NCT04561726|Other|Exercise|The purpose of the given home exercises is to increase motor ability in activities such as standing, walking and posture, to increase muscle strength and also to elongate muscles. Exercises progressed day by day according to the adaptation of the motor system and muscle strength to the exercises.
45972244|NCT04561531|Other|3%NaCl|Intervention is infusion of 3%NaCl which is defined in arms of experiment.
46081581|NCT04035005|Drug|Placebo|The first dose of placebo will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, placebo will be administered as a single 600 mg infusion every 24 weeks, with a minimum interval of 20 or 22 weeks, depending if the previous dose was administered in one or two infusion, should be maintained between each infusion.
45972245|NCT00234806|Other|Health-e-Access|telemedicine intervention
45972246|NCT04561219|Drug|Nitazoxanide|Nitazoxanide 500mg three times a day for 5 days
45972247|NCT04561219|Drug|Placebo|Placebo three times a day for 5 days
45972248|NCT04561609|Other|Transcutaneous CO2 application|"Patients lie on examination tables. Lower extremities of the patients are isolated in a therapeutic wrap (single use, low-density, made from biocompatible polyethylene), sealed at the waist. After this, air is first pumped out of the therapeutic wrap, then the wrap was filled with 99.9% CO2 gas. The therapy lasts for 45 minutes.~Each patient from the study group will receive CO2 therapies - four weeks (meaning 20 CO2 therapies that were performed on workdays only)."
45972249|NCT04561609|Other|Placebo treatment|Each patient from control group will have therapeutic wrap filled with air instead of CO2. Patients from control group will also receive 20 therapies (4 weeks on workdays only), that will also last 45 minutes.
45972250|NCT00424866|Drug|FGF-1|"Doses of FGF-1: 3 ug/kg; 10 ug/kg; 30 ug/kg~Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg"
45972251|NCT00424866|Drug|Placebo|Vehicle: 0 µg/kg
45972252|NCT04561492|Drug|[68Ga]Ga-PentixaFor|Tomography by emission of positons (PET) with theradiopharmaceutic [68Ga]Ga-PentixaFor
45972253|NCT04561570|Device|Study Group|Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens
46081582|NCT04015609|Behavioral|Meaning Centered Psychotherapy for Latinos|MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span ot 7-14 weeks.
46081583|NCT04015609|Behavioral|Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale|Determines the degree of spiritual well-being
45669987|NCT01915095|Other|Training|at the direction of the researcher the participant will be instructed to do repetitive motor movements with their arm, hand or leg. this is called training
45669988|NCT01915095|Other|Motor Task|participants will be asked to perform specific motor tasks or movements with their fingers, hands, arms or legs.
45669989|NCT01958619|Drug|1440mg PQP tablets|Piperaquine phosphate tablets (1440mg)
45828932|NCT02264678|Drug|Administration of ceralasertib in combination with olaparib|An oral formulations of ceralasertib and olaparib will be used. In Module 2 Part A2, patients will receive either a single or twice daily dose of ceralasertib followed by 4 to 6 days washout, before multiple dosing with ceralasertib and olaparib. In Module 2 Part B, patients will receive ceralasertib and olaparib at the dose, frequency and schedule recommended from Module 2 Part A2. Cycle 0 may be omitted at the discretion of the sponsor.
45828933|NCT02264678|Drug|Administation of ceralasertib in combination with durvalumab|An oral formulation of ceralasertib will be used. Durvalumab is given via IV infusion. In Module 3 Part A, patients will receive an initial single dose of ceralasertib on Day 1, followed by multiple dosing in combination with durvalumab. In Module 3 Serial Tumour Biopsy Extension and Part B expansion cohorts, patients will receive ceralasertib at the dose, frequency and schedule recommended from Module 3 Part A, in combination with durvalumab.
45835929|NCT00074802|Drug|Paroxetine|Treatment with paroxetine will consist of an immediate release, flexible dosage of 20 to 50 mg per day.
45972254|NCT04561570|Device|Control Group|Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens
45972255|NCT00234845|Drug|adalimumab|
45972256|NCT00234845|Drug|methotrexate|
45669990|NCT01958619|Drug|960mg PQP tablets|Piperaquine phosphate tablets (960mg)
45669991|NCT01958619|Drug|800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension
45669992|NCT01958619|Drug|960mg PQP granules|Piperaquine phosphate granules for oral solution (960mg)
45669993|NCT01752634|Drug|Secukinumab (AIN457)|Secukinumab (AIN457)
45669994|NCT01752634|Drug|Placebo|Placebo PFS for s.c. administration.
45972257|NCT02211625|Drug|Open-label TRV734 125 mg|125 mg
45972258|NCT02211625|Drug|TRV734 blinded|blinded, multiple ascending dose
45972259|NCT02211625|Drug|Oxycodone IR 10 mg|
45972260|NCT02211625|Drug|Placebo|TRV734-matched and oxycodone placebo
45972261|NCT02211664|Device|Passeo-18 balloon|
45972262|NCT02211664|Device|Passeo-18 Lux drug releasing balloon|
45972263|NCT02211664|Device|Pulsar-18 stent|
45972264|NCT00234923|Drug|lopinavir/ritonavir|400 mg lopinavir/ 100 mg ritonavir, BID
45972265|NCT00234923|Drug|lamivudine/zidovudine|300mg lamivudine/150mg zidovudine, BID
45972266|NCT04551937|Other|Lactose Free 1% Milk|8 oz of study beverage daily
45972267|NCT04551937|Other|Lactose Free 1% Milk + 10 g prebiotic|8 oz of study beverage supplemented with 5 grams of fructooligosaccharide and 5 grams of galactooligosaccharide
45972268|NCT00268125|Device|Acupression's bracelet|
45972269|NCT00268125|Behavioral|Hygiene and dietetic advices|
45972270|NCT04552054|Device|Mixed Reality+ 3D printing guided localization|Researchers project a three-dimensional reconstructed image of the patient's chest through MR glasses, then overlay the virtual chest with the actual chest. Finally, researchers put the three-dimensional printing navigational template on the surface of the body to guide for percutaneous lung puncture localization.
45972271|NCT04552054|Device|Computerized Tomography guided localization|CT-guided percutaneous lung puncture staining marker localization.
45972272|NCT02213887|Drug|Pantoprazole|40 mg PO QAM
45972273|NCT02213887|Drug|Pantoprazole|0 mg PO QAM
45972274|NCT00234962|Drug|Lopinavir/Ritonavir|
45972275|NCT04551859|Other|Dynamic Pelvic Floor MRI|6 months after surgery, a Dynamic Pelvic Floor MRI is performed
45972276|NCT00424905|Drug|Bacillus clausii|2 Enterogermina vials/day for 12 to 17 days (i.e. during the 5 to 10-days antibiotic treatment and for 7 days thereafter.
45669995|NCT01933113|Device|Deep Brain Stimulation of the Lateral Hypothalamic Area|Deep Brain Stimulation of the Lateral Hypothalamic Area
45828934|NCT02264678|Drug|Administration of ceralasertib monotherapy|Module 4 Part A and Module 4 Part B Cohort 3: During C0, patients will receive ceralasertib monotherapy orally once a day on 3 non-consecutive days and ceralasertib twice a day on 5 consecutive days. After the patients have completed C0 (Part A) they may transition to Module 4 Part B cohort 3 where they will continue to receive ceralasertib monotherapy
45828935|NCT02264678|Drug|Administration of ceralasertib and olaparib|"Module 4 Part B Cohort 1:~After completion of Part A (C0), the patient may transition to Part B and be allocated to receive ceralasertib in combination with olaparib as decided by the investigator."
45972277|NCT04551703|Drug|Adrenaline saline irrigation|The surgical field is flushed with 20 cc of Adrenaline saline irrigation. This is in contrast to the standard of care, normal saline irrigation.
45972278|NCT04551976|Behavioral|Mindfulness|Pay attention to the present moment, on purpose, in a nonjudgemental way.
45972279|NCT00235001|Drug|trandolapril/verapamil|180/2 mg QD
45972280|NCT04551781|Drug|20 Mg Prednisone for 14 days|20 Mg Prednisone for 14 days
45972281|NCT04551781|Drug|control|symptomatic ttt
45972282|NCT00424944|Biological|GMZ2 (malaria vaccine)|100 micrograms of GMZ2 in each vaccination
45972283|NCT00424944|Biological|GMZ2 malaria vaccine|100 micrograms of GMZ2
45669996|NCT01726270|Drug|tamsulosin|0.4 mg
45669997|NCT00942331|Biological|Bevacizumab|Given IV
45835930|NCT00074802|Behavioral|Cognitive behavioral therapy (CBT)|CBT will consist of 16 weekly treatment sessions.
45972284|NCT00424944|Biological|Verorab vaccine|Anti-rabies vaccine
45972285|NCT04551625|Device|High Resolution Colonic Manometry and 3D-Transit system.|Not performed as an intervention, the study is observational.
45972286|NCT02214004|Drug|Trastuzumab|"- Eight times IV administration of trastuzumab per 3 weeks~Trastuzumab 8mg/kg on Day 1 of Cycle 1~Trastuzumab 6mg/kg from Day 1 of Cycle 2 to Day 1 of Cycle 8"
45972287|NCT02214004|Drug|Letrozole|- Daily letrozole 2.5 mg/day for 24 weeks
45972288|NCT04551274|Behavioral|Music Therapy|Music Therapy interventions involve the use of live music (performed or created by the therapist and/or patient), and a process that includes patient-specific assessment, treatment, and evaluation
45972289|NCT00268164|Drug|lactobacilus acidophilus & bifidobacterium animalis/lactis|
45972290|NCT04551118|Device|Transcranial alternating current stimulation (tACS) -active|Transcranial alternating current stimulation (tACS) is a non-invasive neuromodulation technique of the brain with an AC micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive 20 min sessions of 1.5 mA alternating current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
45972291|NCT04551118|Device|Transcranial direct current stimulation (tDCS)-active|Transcranial direct current stimulation (tDCS) is a non- invasive neuromodulation technique of the brain with a DC micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive 20 min sessions of 1.5 mA direct current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
45972292|NCT04551118|Device|Transcranial electrical stimulation (TES)-sham|Transcranial electrical stimulation (TES) is a non-invasive neuromodulation technique of the brain with micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min for 7 consecutive days.
46081584|NCT04015609|Behavioral|Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients|Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
46081585|NCT04015609|Behavioral|Pre-assessment questionnaire|Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
46081586|NCT04013984|Other|Accupuncture|In experimental groups (A), acupuncture will be applied for 30 minutes in each session and will be started from the month prior to onset of ovarian stimulation (two sessions of a weekly), and during the ovarian stimulation cycle (two sessions of a weekly), totally 7 acupuncture sessions will be carried out. Acupuncture will be performed using sterile needle on specific points (CV 3 (Zhongji), CV 4 (Guanyuan), ST 25 (Tianshu), ST 28 (Shuidao), ST 29 (Guilai), and LR 3 (Taichong), BL 23 (Shenshu), BL 32 (Ciliao), GV 20 (Baihui), GV 24 (Shenting), GB 13 (Benshen), ST 36 (Zusanli), SP 6 Sanyinjiao), SP 8, SP 10 and KI 3 (Taixi)). The needles were inserted to a depth of 15-30 mm, depending on the region of the body. No sham acupuncture is considered in the control group for ethical and practical reasons
46081587|NCT04007276|Drug|brimonidine tartrate ophthalmic solution 0.025%|Single dose of brimonidine tartrate ophthalmic solution 0.025% applied as an eye drop to the eye surface.
46081588|NCT04007276|Other|sterile balanced saline solution|Single dose of sterile balanced saline solution applied as an eye drop to the eye surface.
46081589|NCT03985098|Behavioral|Motivational interviewing intervention arm|The intervention will be a phone call by a pharmacy student that will use MI strategies to identify and address the adherence barrier(s) and 5 monthly follow up calls
45669998|NCT00942331|Drug|Cisplatin|Given IV
45669999|NCT00942331|Drug|Gemcitabine Hydrochloride|Given IV
45670000|NCT00942331|Other|Laboratory Biomarker Analysis|Correlative studies
45670001|NCT00942331|Other|Placebo Administration|Given IV
45670002|NCT02102269|Device|actimove sling|
45670003|NCT02102269|Device|shoulderlift|
45670004|NCT00630565|Biological|sargramostim|Given subcutaneously (SC) 10 μg/kg/day from day +3 until apheresis is completed
45972293|NCT04551079|Drug|TAK-994|TAK-994 tablets.
45670005|NCT00630565|Drug|busulfan|4 mg/kg po in 4 divided doses (.8 mg/kg/dose orally every 6 hours) on days -7 through -4.
45828936|NCT02264678|Drug|Administration of ceralasertib and durvalumab|"Module 4 Part B Cohort 2:~After completion of Part A (C0), the patient may transition to Part B and be allocated to receive ceralasertib in combination with durvalumab as decided by the investigator."
45828937|NCT02264678|Drug|Administration of ceralasertib in combination with AZD5305|An oral formulations of ceralasertib and AZD5305 will be used. In Module 5 Part A, patients will receive a single dose of ceralasertib on cycle 0 Day1 followed by 6 days washout, before multiple dosing with ceralasertib and AZD5305. In Module 5 Part B, patients will receive ceralasertib and AZD5305 at the dose, frequency and schedule recommended from Module 5 Part A.
46081590|NCT03969446|Drug|Decitabine|Given IV
45972294|NCT04551079|Drug|Placebo|TAK-994 placebo-matching tablets.
45972295|NCT00235040|Behavioral|Smart Form|Computer Decision Support System
45972296|NCT00260949|Procedure|Arthroscopic repair of rotator cuff tear|Patients will undergo arthroscopic shoulder surgery in the standard fashion
46081591|NCT03969446|Biological|Pembrolizumab|Given IV
46081592|NCT03969446|Drug|Venetoclax|Given PO
46081593|NCT03955627|Behavioral|Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN)|Self-management program which includes supervised exercise sessions in groups and group discussions for 8 weeks conducted by Zoom video, followed by an 8-week home-based version of the same program participants do on their own with bi-weekly coaching calls.
46081594|NCT03952039|Drug|FEDRATINIB|A potent and selective inhibitor of JAK2 kinase activity
46081595|NCT03952039|Drug|Best Available Therapy (BAT)|Best available therapy (BAT)
46081596|NCT03939858|Procedure|Cognitive Assessment|Tests have been selected to represent a range of cognitive functions affected by cancer and radiotherapy including basic attention, recent memory, executive functions (spanning verbal fluency, cognitive set-shifting, and abstract reasoning), and visual perceptual/spatial skills.
46081597|NCT03939858|Diagnostic Test|Blood Collection|16 ml of blood will be collected before 10 a.m. and after the participant has fasted for 8 hours. White blood cells and platelets will be used for respirometric analysis. Plasma will be additionally processed and saved in 500uL aliquots(x2) and the remainder in 1mL aliquots at -80°C.
46081598|NCT03939858|Diagnostic Test|Bioenergetic Profiling|Peripheral blood mononuclear cells (PBMCs) and platelets will be separated from the blood. Primary respirometric parameters will be measured with high-throughput respirometry using the Agilent Seahorse 24XFe. Additional parameters will be collected with high-resolution respirometry using the OROBOROS Oxygraph-2k. Both methods will report a variety of mitochondrial parameters resulting in 48 measures per participant, creating robust profiles of bioenergetic health. Additional analysis will include western blots to enumerate protein density for the five major mitochondrial complexes, mtDNA copy number analysis, and citrate synthase activity as these assays provide different but complementary data to respirometry for a more dynamic picture of mitochondrial metabolism.
45670006|NCT00630565|Drug|cyclophosphamide|4 gm/m^2 x 1 (day 0) and 60 mg/kg intravenous (IV) over 2 hours on days -3 and -2.
45670007|NCT00630565|Drug|dexamethasone|20 mg/m^2 x 4 doses every 12 hours given intravenously (IV) push before cytoxan on day 0 and then every 12 hours
45670008|NCT00630565|Drug|etoposide|300 mg/m^2/day x 2 days (day 0-1) over 3 hours intravenously (IV)
45670009|NCT00630565|Procedure|bone marrow transplantation|Day 0 infusion of bone marrow cells
45670010|NCT00630565|Procedure|hematopoietic stem cell transplantation|Stem cell infusion (>48 hours after the last dose of cyclophosphamide)
45670011|NCT00630565|Procedure|peripheral blood stem cell transplantation|Day 0 infusion of peripheral blood stem cells
45670012|NCT00630565|Radiation|total-body irradiation|165 cGy/dose given twice a day on days -7 through -4.
45670013|NCT01914393|Drug|Lurasidone 20, 40, 60, 80 mg, flexibly dosed|Lurasidone 20, 40, 60, 80 mg once daily, flexibly dosed
45835931|NCT02505750|Radiation|3D conformal EBRT|External Beam Radiation Therapy
45835932|NCT02505750|Device|Contact X-ray brachytherapy 50 kV|
45670014|NCT01545271|Drug|xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.
45670015|NCT01545271|Device|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
45972297|NCT02214082|Other|Same Day Discharge|This group will be discharged home, on the same day after their elective angioplasty
45972298|NCT00235079|Drug|Colchicine|Colchicine 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
45972299|NCT00235079|Drug|Placebo|Placebo comparator
45972300|NCT00268281|Device|Left Ventricular Capture Management Software|
45972301|NCT04550689|Device|Bone graft|Bone grafts produced by Straumann LLC
45972302|NCT04550923|Combination Product|Z-Brace interbody fusion device|Use non-rigid (Titanium Alloy, Z-Brace, Baui Biotech) interbody fusion device in Anterior Cervical Discectomy and Fusion (ACDF) surgery
45972303|NCT04550923|Combination Product|PEEK interbody fusion device|Use rigid (PEEK) interbody fusion device in Anterior Cervical Discectomy and Fusion (ACDF) surgery
45972304|NCT00235118|Device|Cordis AAA Bilateral Device|
45972305|NCT04550884|Diagnostic Test|neuromascular ultrasound|neuromascular ultrasound of foot and ankle
45972306|NCT00260988|Drug|Fragmin (dalteparin)|200 IU/Kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
45972307|NCT00260988|Drug|Innohep (tinzaparin)|175 IU/kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
45972308|NCT04550416|Other|ProMark Information and Test Results|Participants in the intervention arm will receive information (both print and webinar format) about ProMark in between Round 1 and Round 2 data collection, as well as appropriate ProMark test results for each of the vignette-based simulated patients that they care for in the second round of data collection.
45972309|NCT04550533|Other|Therapeutic Adherence|To measure adherence to treatment in oncohematological patients in treatment with oral anti-cancer drugs
45828938|NCT02264678|Drug|Administration of ceralasertib in combination with carboplatin|An oral formulation of ceralasertib will be used. In Module 1 Part A, patients will receive a single dose of ceralasertib on Day 1, followed by multiple dosing in combination with carboplatin. A maximum of 6 cycles (21 days per cycle) of treatment will be given. In Module 1 Part B, patients will receive ceralasertib and carboplatin at the dose, frequency and schedule recommended from Module 1 Part A.
45972310|NCT00235157|Device|Sirolimus-eluting Palmaz Genesis peripheral stent|treatment of renal artery stenosis with a renal stent
45972311|NCT04550338|Drug|Tranexamic acid|Oral administration of blinded medications
45972312|NCT04550338|Drug|Placebo|Oral administration of blinded medications
45972313|NCT02214199|Other|Manipulative Therapy Techniques|
45972314|NCT02214199|Other|Home Exercises|
45972315|NCT00268320|Device|Cardiac Resynchronization Therapy+Implantable Cardioverter Defibrillator|
45972316|NCT04550611|Other|Mini-pool Intravenous Immunoglobulin (MP-IVIG)|The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
45972317|NCT04550611|Other|plasma exchange|plasma exchange (plasmapheresis ) in a regimen of removing of 1.3 plasma volumes in each cycle for total of five cycle for five consecutive days within four weeks of onset of symptoms.
45972318|NCT00235196|Device|Collagen ORC Antimicrobial Matrix (CAM)|
45972319|NCT04550182|Procedure|Positioning schedule|"The Braden scale will be collected every morning. Patients' care will be friction and repositioning applied at a frequency defined by the Braden scale:~6 ≥ Braden ≤ 8: alternate positioning every 2 hours 9 ≥Braden ≤ 13: alternate positioning every 4 hours 14 ≥ Braden ≤ 17: No alternative of the positioning required, but a friction and an evaluation of the cutaneous state every 6 hours.~18 ≥Braden ≤ 23: No alternative of the positioning required, but a friction and an evaluation of the cutaneous state every 12 hours.~Positioning will alternate semi-lateral decubitus at 30, semi-Fowler 30° -30°, half-sitting position 45° with elevation of the lower limbs.~A medical prescription as part of the daily reassessed care will ensure the absence of absolute contraindication to the mobilization or contraindication to certain positions.Friction will be performed during repositioning."
45455906|NCT05499832|Drug|Tenecteplase|Patients randomized to IA treatment will receive IA TNK via a standard approved microcatheter positioned as close as possible to the residual occlusion site or as distal as possible in the originating vessel if multiple residual occlusions exists.
45670016|NCT00559819|Drug|placebo|Placebo (orange juice), same volume as alcohol
45670017|NCT00559819|Drug|Alcohol|Dose with Alcohol (Vodka) to make blood alcohol concentration 0.08%
45670018|NCT01931865|Drug|IncobotulinumtoxinA|Subject will receive Xeomin, injected into the area of reported focal pain associated with prior cancer treatment. The total dose will depend on the extent of the area involved by pain. botulinum toxin which is marketed under the trade name of Xeomin. Xeomin is approved by FDA for certain conditions.
45670019|NCT04646889|Drug|AR882 Single Dose|A single dose of AR882
45670020|NCT04646889|Drug|AR882 Multiple Dose|AR882 taken once daily for 14 days
45670021|NCT04646499|Device|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) will be applied at 40 Hz (gamma band) during eight sessions over the course of a month.
45670022|NCT01617447|Drug|Placebo of Aripiprazole|administered orally once daily
45828939|NCT02253238|Behavioral|Quality of Life Survey|Quality of life survey completed at baseline, 7 days after radiation therapy (RT) and at 6 - 8 weeks after RT.
45972320|NCT04550026|Other|HTP inhalation|Sham inhalation for 30 minutes
45972321|NCT04550299|Other|Surgical technique combined with a specific choice of the material for the ligament reconstruction|The surgical procedure is done as standard of care. The intervention is to randomize the participant into the study arms, which none of those has been proved yet to be a superior choice
45972322|NCT00261027|Drug|Exemestane|
45972323|NCT00235235|Procedure|Biopsy|core biopsy
46081599|NCT03933631|Drug|Pilocarpine|pilocarpine hydrochloride ophthalmic solution 2% (20 mg/mL)
45670023|NCT01617447|Drug|Aripiprazole|Flexibly dose administered orally once daily
45670024|NCT00432679|Drug|Rosiglitazone (BRL49653C)|study drug
45670025|NCT04798027|Biological|SARS-CoV-2 mRNA vaccine formulation 1|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
45670026|NCT04798027|Biological|SARS-CoV-2 mRNA vaccine formulation 2|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
45670027|NCT04798027|Biological|SARS-CoV-2 mRNA vaccine formulation 3|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
45972324|NCT00235235|Procedure|Serum Collection|serum collection
45972325|NCT00235235|Procedure|Urine Collection|urine collection
45972326|NCT00235235|Drug|Doxorubicin|Doxorubicin 60 mg/m2 day 1 of every 21-day cycle
45972327|NCT00235235|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle
45670028|NCT04798027|Biological|Placebo (0.9% normal saline)|Pharmaceutical form: Liquid Route of administration: Intramuscular injection
45670029|NCT05238025|Biological|MVA-BN-RSV vaccine|One injection, suspension for injection, intramuscular use, 0.5mL MVA-BN-RSV virus with a titer of at least 3 x 10E8 infectious units (Inf.U)/0.5mL in a Tris buffer at pH 7.7.
45828940|NCT02253238|Behavioral|Health Management Surveys|Confidence in health management survey; completed at baseline and 6 - 8 weeks after RT.
45828941|NCT02253238|Other|Monitoring Devices|Home use of CYCORE devices (blood pressure monitor, weight scale, electronic tablet, palm-sized plug-in computer)
45670030|NCT05238025|Biological|Tris Buffered Saline (TBS)|One injection, solution for injection, intramuscular use, 0.5mL TBS, pH 7.7.
45670031|NCT05232487|Other|Swiss low back acupuncture (SLBA)|"Participants are placed in the prone position (if required with a pillow under the abdomen). Then acupuncture is applied to the back of the body. The treatment takes place for the duration of 9 weeks (2x per week from week 1 to 6 and 1x a week from week 7 to 9). One treatment session lasts about 50-60 minutes.~Swiss low back pain acupuncture The SLBA method is a further developed method from the Jiu Gong acupuncture technique, also known as the Nine Palace-Points on the spine. The following acupuncture points will be used: LV3/ LV5, Tai Xi (Kl 3), Fe Yang (BL 58), Tai Chong (LR 3), Guang Ming (GB 37), Tai Xi (Kl 3) and Fe Yang (BL 58)."
45972328|NCT00235235|Drug|Capecitabine|Capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle
45828942|NCT02253238|Behavioral|Symptoms Surveys|"Behavioral: Symptoms survey 1; completed at weeks 1, 3, 5, and 7 days after RT, and at 6 - 8 weeks after RT.~Behaviorial: Symptoms survey 2; completed at baseline, weeks 1, 3, 5, and 7 days after RT, and at 6 - 8 weeks after RT."
45972329|NCT00235235|Drug|Vinorelbine|Vinorelbine 25mg/m2 days 1, 8, 15 of every 28-day cycle
45972330|NCT00235235|Drug|Gemcitabine|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
45972331|NCT04549714|Procedure|High AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with high AI value, the AI target value for the front wall and the top wall is 550, and the rear wall and the lower wall are 400.
45972332|NCT04549714|Procedure|Middle AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with middle AI value, the AI target value for the front wall and the top wall is 500, and the rear wall and the lower wall are 350.
45972333|NCT04549714|Procedure|Low AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with low AI value, the AI target value for the front wall and the top wall is 450, and the rear wall and the lower wall are 300.
45972334|NCT04549909|Other|collect retrospectively data|Analyse the incidence of BPL in these populations
45972335|NCT04549675|Behavioral|Sun Safe Partners Online|Sun Safe Partners Online has 4 individual-focused modules and 4 couple-focused modules focusing on skin cancer prevention education and sun protection.
45455907|NCT05494164|Other|Nigella sativa nasal oil drops|in addition to the standard treatment, the study group will receive one nasal drop of the prepared N. sativa nasal oil drops in each nostril twice daily which are equivalent to a daily dose of 100 milligram of a pure N. sativa oil for four weeks. N. sativa oil was prepared from N. sativa seeds and it was mixed in Sesame oil with a ratio of 1 to 1. The prepared drops will then be placed in dark containers with a specific dropper. Each participant will be instructed regarding the dose, proper position and steps, assisted by a flyer which will be developed by the researcher.
45455908|NCT05494164|Drug|standard treatment|intranasal corticosteroids in addition to nasal irrigation with sea water; for patients with allergy the standard treatment is oral antihistamines with or without oral corticosteroids.
45828943|NCT02253238|Behavioral|Device Usability Survey|Device usability survey; completed at weeks 1, 3, 5, and 7 days after RT.
45828944|NCT02246920|Drug|Fluticasone propionate|50 mcg/actuation Nasal Spray
45828945|NCT02246920|Drug|Flonase®|50 mcg/actuation Nasal Spray
45828946|NCT02246920|Drug|Placebo|Inactive Nasal Spray
45972336|NCT04549675|Behavioral|Generic Online Sun Safety Information intervention|4 links to sent to participants from (1) The Skin Cancer Foundation's Skin Cancer Prevention guidelines, (2) the Centers for Disease Control and Prevention's information on risk factors for skin cancer, (3) the American Academy of Dermatology's information on how to select an appropriate sunscreen, and (4) The Skin Cancer Foundation's information on sun protective clothing. Participants were emailed a link to one of the resources each week for 4 weeks.
45972337|NCT04549948|Procedure|0.017X0.025 Stainless steel|Leveling curve of Sppe using 0.017X0.025 SS archwire
45972338|NCT04549948|Procedure|0.019X0.025 Stainless steel|Leveling curve of Sppe using 0.019X0.025 Stainless steel archwire
45972339|NCT04549948|Procedure|0.021X0.025 B-Titanium archwire|Leveling curve of Sppe using 0.019X0.025 B-Titanium archwire
45972340|NCT00268359|Biological|bevacizumab|
45972341|NCT00268359|Drug|irinotecan hydrochloride|
45972342|NCT00235274|Drug|Subcutaneous Secretin|
45972343|NCT04549987|Device|Space closure without changing working archwire monthly|Upper premolar space closure using the same 0.019X0.025 stainless steel archwire every month
45835933|NCT02505750|Drug|Capecitabine|
45972344|NCT04549987|Device|Space closure withchanging working archwire monthly|Upper premolar space closure using new 0.019X0.025 stainless steel archwire every month
45972345|NCT04549636|Other|V/Q SPECT-CT|At visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan.
45972346|NCT04549636|Other|St. George's Respiratory Questionnaire (SGRQ)|At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ).
45972347|NCT04549636|Other|mMRC (Modified Medical Research Council) Dyspnea Scale|At visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale.
45972348|NCT04549636|Other|Six-minute walk test (6MWT)|At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).
45972349|NCT04549636|Other|Spirometry|At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.
45972350|NCT04549636|Other|Plethysmography & DLCO|At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
45972351|NCT04549636|Other|Airwave Oscillometry|At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.
45972352|NCT04549441|Procedure|Distal radius fracture plating surgery|We performed open reduction and plating surgery for the distal radius fracture.
45972353|NCT00268398|Drug|oxaliplatin, folinic acid, fluorouracil|folinic acid 200 mg/m² (day 1&2) oxaliplatin 85 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1&2) continuous 5FU 600mg/m² (day 1 to 2)
45972354|NCT00268398|Drug|oxaliplatin, irinotecan, folinic acid, fluorouracil|"FOLFOX7 folinic acid 400 mg/m² (day 1) oxaliplatin 130 mg/m² (day 1) continuous 5FU 3000mg/m² (day 1 to 2)~FOLFIRI folinic acid 400 mg/m² (day 1) irinotecan 180 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1) continuous 5FU 2400mg/m² (day 1 to 2)"
45972355|NCT00235313|Procedure|Dose adjustment of nicotine replacement therapies|Dose adjustment of nicotine replacement therapies
45972356|NCT00235313|Drug|nicotine patch|normal following with a nicotine patch
45972357|NCT04549285|Biological|Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs)|"Human Umbilical Cord Tissue-derived Mesenchymal Stromal Cells (hCT-MSC):~hCT-MSCs is an allogeneic cell product manufactured from donated umbilical cord tissue that is digested and expanded in culture, cryopreserved and banked. Doses contain 2x10^6 cells/kg (up to a maximum dose of 100x10^6 cells) diluted in plasmalyte-A with 5% HSA to a volume of 20-40mL."
45455909|NCT05487755|Drug|Tadalafil 20Mg Oral Tablet|Tadalafil is a phosphodiesterase type 5 enzyme (PDE5) inhibitor used mainly in erectile dysfunction and pulmonary hypertension by a mechanism involving increase(NO-cGMP-PKG) signaling pathway.(8) Tadalafil is a powerful pleiotropic drug that it can be used in DN as it can target more than pathway involved in pathogenesis of DN include hyperglycemia and endothelial dysfunction through increase (NO-cGMP) signaling pathway as well as hyperlipidemia
45972358|NCT04549753|Device|Transcranial direct current simulation|Four sessions of stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system
45972359|NCT02214316|Other|Hypertonic Saline|
45670032|NCT05232487|Other|Standard acupuncture (SA)|Participants are placed in the prone position (if required with a pillow under the abdomen). Then acupuncture is applied to the back of the body. The treatment takes place for the duration of 9 weeks (2x per week from week 1 to 6 and 1x a week from week 7 to 9). One treatment session lasts about 50-60 minutes. The SA method is described in the acupuncture textbook for TCM in China and all acupuncture points are selected based on TCM principles, international literature, and the opinion of national and international TCM experts. The following points have been selected: Ming Men (GV 4), Zhi Shi (BL 52), Tai Xi (KI 3) Yao Guan (GV 3), Guan Yuan Shu (BL 26), Ge Shu (BL 17), Ci Liao (BL 32), Wei Zhong (BL 40), Ji Zhong (GV 6), Yao Yang Guan (GV 3), Shen Shu (BL 23), Da Chang Shu (BL 25) and A-Shi points.
45972360|NCT04549519|Other|No intervention|No intervention / Compare the difference in batting mechanics and bat-swing velocity in baseball players with good and poor lumbopelvic control
45835934|NCT05605938|Drug|Tenoten for children|Oral administration
46081600|NCT03933631|Drug|Prednisolone|Prednisolone acetate ophthalmic suspension 1%
45835935|NCT05605938|Drug|Placebo|Oral administration
45835936|NCT00156390|Device|echo-guided left ventricular lead placement|placement of the LV lead of the biventricular pacing device under echocardiographic guidance
45835937|NCT00156390|Other|LV lead placement as per standard of care (without echo guidance)|
45835938|NCT00029172|Other|case management|
45972361|NCT00235352|Drug|CX516 (Ampakine)|
45972362|NCT04555876|Device|high tone external muscle stimulation- stationary bicycle|high-tone external muscle stimulation (HTEMS), with Frequencies continuously will be scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 mW to be introduced 3 times per week, for 10 weeks
45972363|NCT02212444|Device|Dynamic elastomeric fabric orthoses (DEFO)|A patient customised dynamic elastomeric fabric orthoses (DEFO)
45972364|NCT02212444|Device|Off -the-shelf triplanar orthoses|
45972365|NCT00235469|Drug|SPM 927|
45972366|NCT04549012|Drug|Tranexamic acid|comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS
45972367|NCT04549012|Drug|Oxytocin|Oxytocin
45972368|NCT04555954|Other|surveys and questionnaires|The study practised the physical activity levels of healthy adults aged 18-65 years in Turkey during the novel type of coronavirus pandemic by the International Physical Activity Questionnaires-Short Form (IPAQ-SF). Communication with the participants of the study was conducted via online survey software (Google Forms) and social media communication application (WhatsApp).
46081601|NCT03933631|Drug|Ofloxacin|Ofloxacin Drops
46081602|NCT03927690|Drug|LKA651|LKA651 IVT
46081603|NCT03927690|Drug|LKA651|LKA651 IVT
46081604|NCT03927690|Drug|Lucentis|Lucentis IVT
46081605|NCT03927690|Drug|Lucentis|Lucentis IVT
46081606|NCT03901833|Behavioral|Telemedicine Support|Telemedicine intervention
45972369|NCT02214394|Other|High-performance liquid chromatography Analysis|Blood samples will be collected for HPLC analysis to compare with the breath samples.
45972370|NCT02214394|Device|SMART Device|Breath collection for GC-MS analysis to compare with Blood collection.
45972371|NCT00261105|Drug|telithromycin|
45972372|NCT00235508|Drug|Eszopiclone (Lunesta)|Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime
46081607|NCT03901833|Other|Standard of Care|Standard of Care
45972373|NCT04548856|Procedure|Microsurgical clipping|Subjects randomized to surgical therapy will receive treatment from one neurosurgeon expert in surgery for ruptured aneurysms.
45972374|NCT04548856|Procedure|Endovascular embolization|Subjects randomized to endovascular therapy will be treated by one endovascular expert in such treatment. Endovascular treatment will include all modern accepted surgical techniques.
45972375|NCT04548895|Device|Observational measurement of biometric data. No change to health care provided.|"Emfit devices will be installed once after enrollment under each participant's mattress and left to record automatically without further intervention. The participants will wear their Biostrap wristbands consistently, ideally 24 hours a day, 7 days a week, for 2 months.~A virus panel will be upon enrollment (baseline) and then every two weeks (± 3 days, or on the closest convenient sampling day if the LTCF is testing all residents on the same day) for a maximum of 5 times during the two-month period. Using polymerase chain reaction or next generation sequencing, the virus panel will detect COVID-19 and 12 other common respiratory viruses that may cause similar symptoms and similar biometric signatures. These include influenza A and B, parainfluenza types 1 through 4, respiratory syncytial virus, non-COVID coronavirus, rhinovirus, adenovirus, bocavirus and metapneumovirus."
45972376|NCT04548934|Device|Personal protective equipment (PPE)|Wearing of PPE (FFP3 mask, gloves, eye protection, long-sleeved gown)
45972377|NCT04548934|Device|No Personal protective equipment (PPE)|Standard CPR without wearing PPE
45972378|NCT00268515|Drug|cyclosporine|
45972379|NCT00268515|Drug|tacrolimus|
46081608|NCT03900715|Drug|Luspatercept|Luspatercept
46081609|NCT03870763|Drug|Dimethyl Fumarate|Administered as specified in the treatment arm.
46081610|NCT03870763|Drug|Peginterferon Beta-1a|Administered as specified in the treatment arm.
46081611|NCT03870763|Drug|Placebo|Administered as specified in the treatment arm.
45972380|NCT00268515|Drug|prednisone|
45972381|NCT00268515|Drug|azathioprine|
45972382|NCT04548700|Drug|Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 15 mg/m2, 18 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28-day cycle."
45670033|NCT01600105|Drug|Perfusion MRI|1) Assess the role of a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus) for the measurement of liver MR Perfusion, compared to extra-cellular contrast agents.
46081612|NCT03862911|Radiation|palliative radiotherapy|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Patients in this arm should not receive stereotactic doses or radiotherapy boosts. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
45972383|NCT04548700|Drug|Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|"Drug: Liposomal mitoxantrone hydrochloride (at RP2D) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28- or 21-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28- or 21-day."
45972384|NCT02214433|Drug|Placebo IV Solution|A sterile IV solution of 5% dextrose in water
46081613|NCT03862911|Radiation|Stereotactic ablative radiotherapy|"Lung: Tumors 5 cm or less surrounded by lung parenchyma 48 Gy/4#, or 54 Gy/3#, daily or every second day Within 2 cm of mediastinum or brachial plexus 60 Gy/8#, daily~Bone: Any bone 35 Gy/5#, or 24 Gy/2#, daily~Brain: Stereotactic lesions (no whole brain RT) <2cm 20-24 Gy/1#, once 2-3 cm 18 Gy/1#, once Metastases only: 35Gy/5# to PTV, daily Whole brain + Mets: 35Gy to metastases, daily 20 Gy whole brain, daily~Liver: 54 Gy/3#, every second day~Adrenal/Pancreas: 40 Gy/5# / 35Gy/7#, daily~Lymph Node: 40 Gy/5#, daily"
46081614|NCT03858231|Drug|Norco 5Mg-325Mg Tablet|1 tablet up to 4 times per day for 7 days
46081615|NCT03858231|Drug|Ibuprofen 600 mg|1 tablet up to 4 times per day for 7 days
46081616|NCT03858231|Drug|Acetaminophen 325Mg Tab|1 tablet up to 4 times per day for 7 days
46081617|NCT03856515|Drug|Nicotine Replacement|Received NRT (Electronic Cigarette - With Nicotine)
46081618|NCT03856515|Other|Questionnaire Administration|Ancillary studies
46081619|NCT03856515|Device|Electronic Cigarette|Electronic Cigarette - with Nicotine
46081620|NCT03856515|Device|Electronic Cigarette|Electronic Cigarette -without Nicotine
46081621|NCT03853954|Device|Methoxyflurane|Methoxyflurane (Penthrox) inhaler, 3mL inhalation vapour, liquid
46081622|NCT03850782|Drug|Bimatoprost (SR)|"Study Eye: Cycles 1 - 3 administrations through the PRN treatment period.~Fellow Eye: Standard of care or Bimatoprost SR."
45972385|NCT02214433|Drug|Debio 1450 IV Solution|A white to off-white powder (40 mg Debio 1450 per vial) to be reconstituted and formulated in a sterile IV solution of 5% dextrose in water
45972386|NCT02214433|Drug|Placebo Tablet or Capsule|Placebo tablet or capsule, matching Debio 1450 coated tablet or capsule
45972387|NCT02214433|Drug|Debio 1450 Tablet|Debio 1450 40 mg coated tablets
45972388|NCT02214433|Drug|Debio 1450 Capsule|Debio 1450 40 mg capsules
45670034|NCT01077895|Procedure|CVVH|"CVVH is started using following parameters:~Blood flow is started at 150 mL/min~Anticoagulation: none, heparin or low molecular weight heparin according to local protocols in study centers.~In both groups: dialysis dose of 25 mL/kg body weight administered using both pre- and postdilution~Substitution fluid temperature is started at 37°C and adjusted in function of patient body temperature (which is maintained at 35-37°C)"
45972389|NCT02214433|Drug|Debio 1450 Oral Solution|Lyophilized Debio 1450 (40 mg per vial) reconstituted in 5% dextrose in water
45972390|NCT02214433|Drug|Pantoprazole|Pantoprazole 40 mg orally
45972391|NCT04710407|Drug|TBPM-PI-HBr|TBPM-PI-HBr (2 x 300mg tablets) a total of five doses
45972392|NCT00261144|Drug|Collagenase|One 0.58mg injection every two weeks for six weeks (total three 0.58mg injections)
45972393|NCT00261144|Biological|Biological|Collagenase injection
45972394|NCT04555681|Diagnostic Test|Collection of subgingival dental plaque|Identification and quantification using q-PCR of the 21 bacteria most frequently found in the dental plaque (including the periopathogenic bacteria) and Candida albicans.
45972395|NCT04548622|Device|Magstim Rapid 2 system triggering Magstim Super Rapid system|Week 1 treatment includes rTMS for 5 sessions to both the left and right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
45972396|NCT04710251|Device|Speedometer|We will measure and monitor the withdrawal time of colonoscopy with a speedometer.
45828947|NCT02129244|Other|NCM-Plus|"The NCM will follow the domains of the chronic care model by:~Assuring effective, efficient clinical care and self-management support~Promoting clinical care consistent with scientific evidence and patient preferences~Organizing data to facilitate efficient, effective care~Empowering and preparing patients to manage their health and health-care needs~Mobilizing community resources to meet the needs of patients"
45828948|NCT02086890|Device|Electro-acupuncture|
45828949|NCT02086890|Device|Laser Acupuncture|
45828950|NCT02086890|Device|Transcorneal Electrical Stimulation|
45828951|NCT02086890|Device|Sham Electro-acupuncture|
45972397|NCT02212561|Drug|Selinexor|Given orally on days 1,3,8,10,22 and 24 of each cycle
45972398|NCT02212561|Drug|Fludarabine|Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
45828952|NCT02086890|Device|Sham laser acupuncture|
45828953|NCT02086890|Device|Sham transcorneal electrical stimulation|
45828954|NCT01972919|Radiation|Radiation Therapy|Radiation therapy dose escalation to an MR-defined gross tumor volume (GTV) of up to 69.75 Gy at 2.25 Gy per fraction.
45828955|NCT01972919|Drug|Concurrent chemotherapy (Gemcitabine, Capecitabine)|Gemcitabine 400mg/m^2 IV weekly x 6 doses. Capecitabine 825 mg/m^2 by mouth twice daily Monday-Friday on days of radiation use 500 mg tablets.
45972399|NCT02212561|Drug|Cytarabine|Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
45972400|NCT02212561|Drug|methotrexate/hydrocortisone/cytarabine|Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
45972401|NCT00268554|Drug|dipyridamole|
45972402|NCT00268554|Drug|caffeine|
45972403|NCT04555993|Procedure|lower abdominal surgery|Patients will undergo lower abdominal surgery under general anesthesia.
45972404|NCT04555993|Other|Erector spinae plane block|patients will receive erector spinae plane block using 20 mL levobupivacaine (0.25%).
45972405|NCT04555993|Other|Transversus abdominis plane block|patients will receive transversus abdominis plane block using 20 mL levobupivacaine (0.25%).
45972406|NCT00235586|Procedure|10 vit. D deficient subjects take vit. D for 3 months.|
45828956|NCT01832402|Drug|Fentanyl Pectin Nasal Spray|Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
45828957|NCT01832402|Drug|Placebo Nasal Spray|Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
45972407|NCT00268593|Drug|PI-88|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
45972408|NCT00268593|Drug|docetaxel|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
45972409|NCT00268593|Drug|prednisone|5 mg twice a day orally
45972410|NCT04555525|Drug|sarecycline|sarecycline tablet
45972411|NCT04555525|Dietary Supplement|Centrum Adult Multivitamin|Centrum Adult Mulltivitamin tablet
46081623|NCT03845036|Behavioral|DASH Diet plus Home-Based Exercise|The DASH dietary program consists of a diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy, in which patients record daily servings of fruits and vegetables. The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
45972412|NCT00235625|Drug|Curcuminoids C3 Complex®|
45670035|NCT01077895|Procedure|ultrafiltration|"ultra filtration is started at 100 mL/h and increased according to following protocol~Ultrafiltration is increased by 100 mL/h after 2h and subsequently by 100mL/h (until a maximum of 500mL/h) every 4h unless:~Vasopressor or inotrope medication dose is increased by > 25% (provided mean arterial pressure remains constant at 65 mmHg or another target value specified by treating physician according to standard of care)~When above condition is not met UF should be kept constant and a passive leg raising test or stroke volume variation measurement should be performed. If SVV > 10% or PLR is positive 100mL of albumin 20% solution or 250 mL of Hydroxyethyl Starch 130/0.4 solution is administered according to treating physician at a maximum of 4 times per 24h~If there is no improvement after 2 colloid administration rounds, UF should be stopped for 4h and restarted at half the rate it was set at when discontinued."
45972413|NCT02212600|Other|Observational|observational cohort of proximal humerus fractures
45972414|NCT04555486|Drug|DCR-PHXC|Intervention, drug, DCR-PHXC
45670036|NCT01077895|Procedure|ultrafiltration control group|ultrafiltration is set at 100 mL/h (and fluid administration is titrated to approach 100 mL /h)
45455910|NCT05487755|Drug|Pentoxifylline 400 MG Oral Tablet|Pentoxifylline is a methyl xanthine derivative, non selective phosphodiesterase enzyme inhibitor used mainly to treat peripheral vascular diseases by improve blood flow
45828958|NCT01832402|Other|Walk Test|Walk test administered before first dose of drug/placebo nasal spray. Participant will rest for 30 minutes after walk test. Drug/placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Drug/placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes.
45828959|NCT01832402|Behavioral|Questionnaires|Questionnaires completed at baseline, before each walk test, and at end of final walk test.
45828960|NCT01832402|Behavioral|Mental Ability Tests|Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
45828961|NCT01737827|Drug|INC280|INC280 will be administered orally and continuously on a twice a day dosing schedule.
45828962|NCT01661881|Drug|Rituximab|
45828963|NCT01661881|Drug|Bendamustine|
45828964|NCT01661881|Drug|Cytarabine|
45828965|NCT01619488|Device|Adjustable Gastric Band|"Surgical placement of an adjustable gastric band around the upper portion of the stomach.~Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction."
45972415|NCT04555486|Drug|Sterile Normal Saline (0.9% NaCl)|Placebo comparator
45972416|NCT04555213|Drug|NOX66|NOX66 Suppository
45972417|NCT04555369|Genetic|ct-DNA|The enrolled mCRC patients will perform ct-DNA testing to evaluate drug efficacy of chemotherapy, at the time of baseline and after the first cycle of chemotherapy.
45972418|NCT00261183|Drug|Melatonin|
45972419|NCT00235664|Procedure|Collection of stool and endotracheal aspirate samples|collection of samples
45972420|NCT04555447|Dietary Supplement|Agavins (prebiotic fiber)|Agavins contained in ready-to-use sachets were dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.
45972421|NCT04555447|Dietary Supplement|Placebo|Maltodextrin contained in ready-to-use sachets was dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.
45972422|NCT00268632|Drug|risedronate|
45972423|NCT04554979|Drug|Hydroxychloroquine Pill|hydroxychloroquine 400 mg twice daily first day and maintained on 200 mg twice daily for 6 days in mild cases and 10 days in moderate cases. Also they received anticoagulants, vitamin c and zinc. In case of secondary bacterial infection, empiric antibiotics are started
45972424|NCT00235703|Device|Antimicrobial Prescribing Decision Support|
45972425|NCT04555057|Procedure|Music therapy|Music selected according to the patient's individual preferences.
45972426|NCT04554901|Dietary Supplement|Cocoa|2-week, once-daily 70%, 50g cocoa bar manufactured by The UWI Cocoa Research Institute (14 bars)
45972427|NCT00261222|Drug|Amodiaquine|
45972428|NCT04554628|Diagnostic Test|ELISA test in urine|enzyme linked immunosorbent assay technology for detection of UNGAL and UKIM1 in urine in postoperative ICU patients
45972429|NCT00235781|Drug|Thymoglobulin|
45972430|NCT04554823|Behavioral|Health Education|Will attend lectures on health education about Health and Physical Education, healthy eating, overcoming barriers, Back to routine, Physical Activity Options and Dealing with Stress and Depression
45972431|NCT04554823|Behavioral|Physical Exercise|Supervised physical training program of combined exercises for 24 weeks, with frequency of 3 times weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week.
45972432|NCT04554589|Drug|Glycopyrrolate 0.2 MG|injections
45972433|NCT04554589|Drug|normal saline|normal saline
45972434|NCT00268671|Drug|Docetaxel|
46081624|NCT03845036|Behavioral|Home-Based Exercise|The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
45972435|NCT04554433|Drug|Ethanol with Asprin|"Group ( A ) which will receive the new protocol will be categorized into sub-groups according to the medical conditions , inclusion criteria , investigations and symptoms .~Inhaling alcohol vapor through nostrils .~Inhalation of Alcohol vapor driven by Oxygen .~Inhalation of Alcohol vapor driven by oxygen in case of ARDS.~Ethyl Alcohol infusion into the airway . Investigations will be made before starting the protocol and follow up data will be collected every day .~Follow up test will be done according to the schedule . PCR test will be done according to the duration of each technique to evaluate the final results ."
45972436|NCT04721054|Drug|Thoracic epidural effect on heart rate in Laparoscopic Cholecystectomy (bupivacaine and lignocaine)|patients in epidural anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
45670037|NCT04785079|Procedure|Graston Instrument assisted Soft tissue Mobilization|Instrument assisted soft tissue mobilization using the Graston tool and technique for 3 minutes on each of the three locations
45670038|NCT04797481|Procedure|Exercise|Group A participants will be invited to attend up to 24 exercise sessions (2 sessions per week and a 3rd optional) and 2 virtual (online; a 3rd will be optional) HF workshops over 8 weeks. All sessions will be delivered via online platforms, with 1 facilitator supporting up to 8 participants simultaneously in each session.
45972437|NCT04721054|Drug|general anesthesia effect on heart rate in Laparoscopic Cholecystectomy|patients in general anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
45972438|NCT02212639|Drug|digoxin|All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients <75 years and between 0.5-0.8 ng/ml in patients older than 75 years
45972439|NCT02212756|Drug|DW1029M 1200mg and Metformin 1000mg|Metformin 500mg 1 Tablet and DW1029M 300mg 2 Tablets b.i.d. for 7days
45972440|NCT02212756|Drug|Metformin 1000mg|Metformin 500mg b.i.d. for 7 days
45972441|NCT02212795|Drug|Zabofloxacin 183mg|Zabofloxacin 183mg single dose
45972442|NCT02212795|Drug|Levofloxacin 250mg|Levofloxacin 250mg single dose
45972443|NCT02212795|Drug|Zabofloxacin 367mg|Zabofloxacin 367mg single dose
45670039|NCT04797481|Procedure|Self-managed exercise|Group B participants will be provided with a self-care exercise programme. The exercise programme will be home-based with a mixture of online video calls and telephone support contacts, alternating once every other week. The video or telephone contacts will be mutually agreed by the patient and the facilitator at a mutually convenient time and will aim to support Group B participants, by offering advice and tracking progress. Patients will be provided with two exercise programmes: I) a chair-based exercise programme (DVD will be provided), and ii) a progressive walking training programme (a manual will be provided). Patients will be advised to exercise ≥3 times per week, starting from their own personal level and gradually building up over 8 weeks in session's duration, frequency of sessions per week, and walking pace.
45670040|NCT04797325|Drug|Vedolizumab|Repeatedly vedolizumab infusion at week 0, 2, 6, 14, 22
45670041|NCT04797325|Drug|Prednisolone|tablet prednisolone plus infliximab in severe cases.
45828966|NCT01588392|Behavioral|Short bouts of structured physical activity|Short bouts of structured physical activity preschools will be asked to implement age-appropriate 10 minute structured physical activity routines within the classroom setting followed by 20 minutes of usual unstructured playtime activities. Intervention will be implemented for a total of 30 minutes during both morning and afternoon gross motor playtime 5 days/week for 6 months.
45828967|NCT01588392|Behavioral|Unstructured physical activity|Unstructured physical activity intervention will consist of 30 minutes of supervised unstructured free playtime twice. intervention will be delivered during both morning and afternoon gross motor playtime for 5 days/week for 6 months.
45828968|NCT01588379|Behavioral|Girls and mothers Afro-centric dance program|African-American girls and their mom's will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
45670042|NCT02246647|Diagnostic Test|Permeability measurement|Saccharide excretion was compared between IBS-C and healthy volunteers
45670043|NCT02246647|Procedure|Esophagogastroduodenoscopy|Duodenal biopsies were collected from IBS-C and healthy volunteers
45828969|NCT01588379|Behavioral|Girls, alone|African-American girls (without their mom's) will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
45828970|NCT01588379|Other|Newsletter|Both girls and the mothers will receive weekly newsletter containing various health information.
45828971|NCT01473628|Other|Clinical Observation|Undergo observation
45828972|NCT01473628|Radiation|Radiation Therapy|Undergo radiation therapy
45972444|NCT00261261|Behavioral|ADVANCE|
45972445|NCT00261261|Drug|Midazolam|
45972446|NCT00261261|Procedure|Parental presence|
45972447|NCT00235820|Drug|adalimumab|40 mg every other week following an 80 mg dose
45972448|NCT00235820|Drug|MTX|MTX 7.5 to 25 mg once weekly
45972449|NCT00235820|Drug|placebo adalimumab, placebo MTX|placebo injections once every other week after 2 injections at Baseline (adalimumab) placebo capsules once weekly (MTX)
45972450|NCT04554199|Device|Flexible partial denture|removable partial dentures (RPDs) were fabricated using thermoplastic resins (flexible RPDs). EEG and MMSE were evaluated before denture delivery and after one month of denture wear.
45972451|NCT04554355|Behavioral|School-based PA intervention|Provide moderate to vigorous fun-game based exercises for adolescents with ID in schools to help them reduce obesity and improve fitness levels.
45972452|NCT04554238|Device|Armeo spring|Armeo spring is an exoskeleton that allows intensive therapy aimed at upper extremity tasks, which can be regulated according to the anthropometric measurements of the child and the objective of the session. The software contains an extensive library of game-like exercises that are run in a motivating and informative virtual reality training environment, clearly showing the functional task to be performed through immediate feedback in a 3D work space.
45972453|NCT04554238|Other|Occupational Therapy|This treatment includes passive stretching exercises, weight bearing, stimulation of protective reactions, muscle strengthening exercises and different types of motivating bimanual games, favoring reaching, grasping, exploration and manipulation.
45972454|NCT00268710|Drug|docetaxel|
45972455|NCT02212873|Other|MyBFF@school program|Students will be required to participate in all 3 components of MyBFF@school (SSG, nutrition and psychology sessions) for 16 weeks under the supervision of trained researchers, then for another 16 weeks supervised by their respective teachers-in-charge of physical education and/or co-curriculum activity. Each SSG session will be for an hour, thrice weekly while the nutrition or psychology session will be for 30-45 minutes once a week.
45972456|NCT04554082|Procedure|laparoscopic sleeve gastrectomy|bariatric surgery to loss weight
45972457|NCT02212912|Behavioral|improvement intervention|"Evidence-based clinical pathway: It contained general guideline-based recommendations about acute stroke management. Standard operating procedures (SOP) of performance indicators. A quality coordinator:The role of the quality coordinator includes interacting with physicians once gaps in the incorporation of evidence-based interventions are identified, ensuring that all components of the quality improvement intervention are being used for every acute ischemic stroke (AIS) patient.Monitoring and feedback system of performance measures.~The system could view the level of implementation of prespecified performance measures at any time (per week recommended) , compare with the previous record of own study site and level of other clusters."
45972458|NCT02212912|Behavioral|no intervention|No intervention indicated that the physicians among control hospital provide routine
45670044|NCT02246647|Procedure|Flexible sigmoidoscopy|Colonic biopsies were collected from IBS-C and healthy volunteers
45972459|NCT04554394|Device|CellFX Device|The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
45972460|NCT00261300|Drug|Pantoprazole|Long term Pantoprozole trial
45972461|NCT02212990|Other|Acetaminophen Arm|Blinded Therapy
45972462|NCT02212990|Other|Placebo Arm|Blinded Therapy
45972463|NCT02212990|Other|Ibuprofen Arm|Open Label Therapy
45972464|NCT00235859|Drug|adalimumab|
45670045|NCT00752245|Procedure|Dialysis during 4 hours|Blood and dialysate sampling
45972465|NCT00235859|Drug|methotrexate|
45670046|NCT00752245|Procedure|Dialysis during 6 hours|Blood and dialysate sampling
45670047|NCT00752245|Procedure|Dialysis during 8 hours|Blood and dialysate sampling
45670048|NCT04771351|Biological|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
45670049|NCT04771351|Drug|Placebo|Diluent solution
45828973|NCT01473628|Biological|Rituximab|Given IV
45828974|NCT01370447|Drug|EPI-743|EPI-743 (oral solution [100 mg/mL] or liquid-filled capsules [100 mg or 200 mg]) will be administered per dose and schedule specified in the arm.
45828975|NCT01210625|Dietary Supplement|Nutrabiotix|Fiber supplement: 9mg or 12mg
45670050|NCT04770727|Behavioral|CBT workshop|The CBT based intervention for adolescents will include psychoeducation on food allergy and anxiety and also focus on providing skills, knowledge and support.
45670051|NCT05107687|Behavioral|Smoking cessation|"Assisted Smoking Cessation- Subject is provided professional support provided by tobacco cessation specialist.~Unassisted Smoking Cessation- Subject provided resources and attempts to quit smoking without professional support.~The subject selects their preferred intervention."
45670052|NCT04773067|Biological|UB-612|Around 3300 adult subjects and 330 adolescent subjects will receive 2 doses of 100 µg UB-612 vaccine. The subjects will be invited to have the 3rd dose after unblinded.
45828976|NCT01210625|Dietary Supplement|Psyllium|12g total per day (4 capsules containing 1 gram psyllium fiber 3 times a day)
45828977|NCT01009190|Drug|PF-01367338|Increasing doses of single lead-in (Day -10) intravenous and daily oral PF-01367338 administered from Day 1 to Day 14 every 3-week cycle
45828978|NCT01009190|Drug|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
45828979|NCT01009190|Drug|PF-01367338|RP2 doses of oral PF-01367338 administered daily from Day 1 to Day 14 every 3-week cycle
45828980|NCT01009190|Drug|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
45828981|NCT00667628|Drug|TAC-101|Participants received TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
45972466|NCT02213029|Drug|Epelsiban|White to off white Oral tablets with unit dose strength of 5 mg or 25 mg for dose level of 25 mg, 150mg or >150mg
45972467|NCT02213029|Drug|Placebo|White to off white oral placebo tablets to match 5mg epelsiban
45972468|NCT02213029|Drug|Oxytocin|Oxytocin for IV infusion (at doses of 5, 10, and 20 milliunits), IV bolus (5 IU administered IV as a bolus over 15 seconds) and IM (5 IU administered IM).
45972469|NCT02213029|Drug|Ortho-Cylcen (21)® tablet|White, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson & Johnson
45972470|NCT02213146|Drug|BioChaperone human insulin|Single dose of 0.2 U/kg body weight injected subcutaneously
45972471|NCT02213146|Drug|Huminsulin® Normal|Single dose of 0.2 U/kg body weight injected subcutaneously
45972472|NCT02213146|Drug|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
45972473|NCT00268749|Drug|glycine|0.8 g/kg/day
45972474|NCT04553887|Drug|Almonertinib|single agent, 110mg p.o once daily until disease progressed
45972475|NCT00235898|Drug|CoFactor|
45670053|NCT04773067|Biological|Placebo|Around 550 adult subjects and 55 adolescent subjects will receive 2 doses of normal saline 0.9%.
45972476|NCT00235898|Drug|5-FU|
45972477|NCT00235898|Drug|Leucovorin|
45972478|NCT02213185|Other|EMLA patches|EMLA patches 1.5 hrs before sterile water injections
45972479|NCT02213224|Drug|Perindopril|Perindopril is a kind of angiotensin converting enzyme inhibitors (ACEIs) which has been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
45972480|NCT02213224|Drug|Telmisartan|Telmisartan is a kind of angiotensin receptor blockers (ARBs) which has also been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
45972481|NCT02213224|Drug|Amlodipine|Amlodipine is also a kind of widely used first-line drugs for the treatment of hypertension, and there is no evidence showing that it is effective for NAFLD.
45972482|NCT00268788|Drug|Subcutaneous immunoglobulin|Individually dosed, given twice a week.
45972483|NCT00268788|Drug|Intravenous immunoglobulin|Individual dose and frequency
45972484|NCT00235937|Drug|Anastrozole and goserelin|
45972485|NCT02213341|Procedure|Skin prick allergen test|To test for hypersensitivity to milk, egg, or peanut
45972486|NCT02213341|Procedure|Blood draw|
45972487|NCT04553614|Behavioral|Home-based HIIT|Home-based HIIT uses body-weight equipment free exercises. Participants complete all exercise in their own own at a time of their choosing. This potentially removes many of the barriers preventing at risk-individuals from engaging with the current exercise referral scheme, such as cost, time or intimidating gym environment.
45670054|NCT04784845|Biological|N. lactamica Y92-1009|Lyophilised N. lactamica reconstituted in phosphate-buffered saline
45828982|NCT00667628|Drug|Placebo|Participants received placebo (two matching tablets) at same frequency and duration of active treatment.
45670055|NCT04784455|Drug|nomacopan (rVA576)|The study population will consist of paediatric patients who have undergone allogeneic or autologous HSCT and develop HSCT-TMA within 100 days of HSCT
45670056|NCT02244619|Drug|Oral acetaminophen|Subjects randomized to the Oral acetaminophen arm will receive 2 Tylenol 500mg capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving Oral acetaminophen will also receive 100ml of IV Normal Saline similar to the delivery method of the IV acetaminophen arm. The Normal Saline IV placebo will be given not as an intervention but rather as a method to maintain study integrity.
45828983|NCT00597636|Behavioral|Questionaire, blood sample|Provide 30ml blood for laboratory assays Complete Health Questionnaire
45972488|NCT04553614|Other|Control|Usual exercise referral scheme procedure.
45972489|NCT04553224|Other|Clinical evaluations|SCORAD and target SCORAD
45972490|NCT04553224|Other|Non-invasive instrumental measurements|TEWL, cutaneous hydration, skin lipidic analysis, colorimetry, hydration index
45972491|NCT04553224|Other|Subject's evaluations|PO-SCORAD, target PO-SCORAD and subject's questionnaire
45972492|NCT00261339|Drug|Pantoprazole|
45972493|NCT04553653|Other|checklist|The checklist will be implemented and healthcare providers use the checklist to manage the patients.
45972494|NCT00235976|Drug|Gantacurium Chloride for Injection (AV430A)|
45972495|NCT04553380|Drug|basic insulin|"Initial dose of basic insulin: 0.2U/kg/d.~Dose titration regimens: the dose is titrated by increments of 0.07U/kg daily until the fasting blood glucose（FBG）≤7 mmol / L, and if the FBG≤ 3.9mmol/L, the 0.07U/kg is reduced.~Injection time: subcutaneous injection before going to bed every night."
45670057|NCT02244619|Drug|IV acetaminophen|Subjects randomized to the IV acetaminophen arm will receive Ofirmev 1000mg in 100ml Normal Saline IV plus 2 placebo capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving IV acetaminophen will also receive 2 placebo capsules similar to the delivery method of the oral acetaminophen arm. The placebo capsules will be given not as an intervention but rather as a method to maintain study integrity.
45670058|NCT02243371|Biological|CRS-207|1 × 10^9 CFU administered IV on Day 2 of Cycles 3-6
45972496|NCT04553302|Other|This study does not contain any intervention.|This study does not contain any intervention.
45828984|NCT00597636|Behavioral|Questionaire, Blood sample|Provide 30ml blood for laboratory assays Complete Health Questionnaire
45828985|NCT00321555|Drug|Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin|LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% Sodium Chloride (NaCl) and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
45972497|NCT04553497|Device|Interferential current|"Interferential current or sham were applied to the patients before the each exercise session. Pre-modulated bipolar method with the currier frequency of 4 kHz by a combination therapy unit (Sonopuls 692, Enraf-Nonius) with two electrodes (8×6 cm) was used. One electrode was placed on the lateral part of the deltoid muscle; the other was placed on the trapezium muscle close to the shoulder. Subjects were told that in order to produce an effect, the intensity of the stimulator must be maintained at a strong but comfortable level at all times. The sham interferential current therapy consisted of the placement of the same pads for the same time but no electrical stimulation was applied to the probes."
45972498|NCT04553497|Other|Rehabilitation program|Rehabilitation program carried out under the guidance of same physiotherapist 3 times a week for 6 weeks. First phase of the rehabilitation (0-3 weeks) began with elbow, wrist and hand active range of motion (ROM) and pendulum (clockwise and counter clockwise) exercises in the 0-2 weeks of the nondisplaced fracture. During second phase (3-6 weeks), active forward elevation in supine were carried out, and then progressed to sitting and standing position. At the end of 6 weeks', the physiotherapist described the home training program involving the resistance exercises by using therabands of progressive strengths for internal and external rotation, flexion, extension and abduction. Flexibility and stretching exercises were also given to progressively increase ROM in all directions. At each visit, the patients were instructed to regularly perform their exercises.
46081625|NCT03835702|Other|SAM Clinic Intervention|SAM Clinic is a sleep provider led team comprised of either a sleep clinician or sleep nurse practitioner along with sleep nurses and or durable medical equipment representative. The provider interacts with each patient personally. Various modes of trouble shooting of PAP related issues are tailored to solve PAP adherence issues including mask complaints, nasal issues, pressure intolerance, anxiety, and other related barriers to PAP adherence. When the provider is seeing patients individually other patients have the opportunity to interact and offer informal interpersonal support to other participants in dealing with similar PAP issues. The provider makes an individualized follow-up plan for each patient, which may include another SAM visit or referral back to the non-sleep provider.
45828986|NCT00003653|Drug|bicalutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
45670059|NCT02243371|Biological|CRS-207|1 × 10^9 CFU administered IV on Day 1 of Cycles 3-6
45670060|NCT02243371|Drug|nivolumab|3 mg/kg administered IV on Day 1 of Cycles 1-6
45670061|NCT02243371|Biological|GVAX|5x10^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2
45670062|NCT02243371|Drug|CY|200 mg/m^2 administered IV on Day 1 of Cycles 1 and 2
45972499|NCT00236015|Drug|Gabitril|
45972500|NCT00261378|Device|Transarterialchemoembolisation (TACE)|
46081626|NCT03822572|Other|endurance exercise|defined exercise program
46081627|NCT03822572|Other|control|habitual physical activity before the diagnosis
45670063|NCT01931475|Drug|Duloxetine|Administered orally
45670064|NCT01931475|Drug|Placebo|Administered orally
45972501|NCT00261378|Device|DC Bead with Doxorubicin|
45972502|NCT04555408|Device|blue light|Patients receive exposure to 100lux blue light, which dominant wave-length is 468nm for 30 minutes in the morning.
45972503|NCT04555408|Device|bright light|Patients receive exposure to 1000lux bright light, which dominant wave-length is 490nm for 30 minutes in the morning.
45972504|NCT04555408|Device|dim light|Patients receive exposure to 100lux dim light, which dominant wave-length is 490nm for 30 minutes in the morning.
45972505|NCT04553458|Device|Radiofrequency ablation|Radiofrequency ablation of the tumour
45972506|NCT04553458|Drug|Trance-arterial chemoembolization|Trance-arterial chemotherapy
45972507|NCT04553458|Procedure|Liver resection|non-anatomical or anatomical liver resection
45972508|NCT04553458|Combination Product|Combined radiofrequency ablation + percutaneous ethanol injection|combined therapy
45972509|NCT04553458|Drug|Percutaneous ethanol injection|Percutaneous ethanol injection of HCC
45972510|NCT04553458|Drug|Systemic chemotherapy|Systemic chemotherapy
45972511|NCT04553458|Drug|Sorafenib|Sorafenib
45972512|NCT04553458|Dietary Supplement|Viscum|Viscum for HCC
45972513|NCT04553458|Drug|Symptomatic treatment|Symptomatic treatment
45972514|NCT00236054|Drug|Gabitril|
45972515|NCT00268827|Drug|Kaletra soft-gel capsules switched to Kaletra tablets|
45972516|NCT00268827|Device|MOS-HIV Health and Medication Satisfaction Survey, Global Conditioning Improvement and Therapy Preference Questionnaire|
45972517|NCT04552756|Diagnostic Test|Seizure Diary|"The patients keep a seizure diary during the period of radiotherapy and up to 6 weeks following radiotherapy. Every day, the patients document the number (and type) of seizures and intake of anti-epileptic medication. The seizure diary will be used to assess the rate of patients with progression of seizure events during the course of radiotherapy compared to baseline.~To obtain an objective assessment of seizure activity in addition to patient reported outcomes, an electroencephalography (EEG) is performed during the first and the sixth week of radiotherapy, as well as during the sixth week following radiotherapy. Activity typical for epilepsy includes spike waves, sharp waves and/or sharp slow waves and is classified as absent or present."
45972518|NCT04553029|Other|No intervention|This is a cross-sectional survey study evaluating prevalence, severity and associated factors in women with moderate-to-severe menopause-related vasomotor symptoms (MR-VMS).
46081628|NCT03816345|Procedure|Biospecimen Collection|Undergo collection of blood, CSF, tissue, stool and urine samples
45828987|NCT00003653|Drug|buserelin|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
45972519|NCT04552951|Drug|Cholecalciferol|Single doe of 100.000 IU
45972520|NCT02213419|Drug|Endoscopic ultrasonography-guided double ethanol lavage|"A radial echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration and ethanol lavage.~The 80 percent volume of cyst fluid was aspirated, and the pure ethanol was injected into the collapsed cyst until the original shape was restored. After 3-5 minutes, the reaspiration of the injected ethanol was then performed. The pure ethanol was reinjected into the collapsed cyst, followed by reaspiration of maximal possible volume for 3-5 minutes."
45972521|NCT00268866|Behavioral|Education|
45972522|NCT00236093|Drug|ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])|
45972523|NCT04552483|Drug|Nitazoxanide|Nitazoxanide 500mg 8/8 hours for 5 days in the early clinical phase of COVID-19.
45972524|NCT04552483|Drug|Placebo|Placebo 8/8 hours for 5 days in the early clinical phase of COVID-19.
45972525|NCT02213536|Radiation|VMAT (Volumetric Modulated Arc Therapy)|Delivering a prescribed radiation dose to the whole brain using VMAT to reduce dose to hair follicles on scalp.
45972526|NCT00261417|Drug|Tesaglitazar|
45972527|NCT02213614|Dietary Supplement|Lithium Water|Supply daily doses of Lithium water in form bottled mineral water
45972528|NCT02213614|Dietary Supplement|placebo: spring mineral water|Drink spring natural water a placebo 3 times a day
45972529|NCT02213614|Other|natural spring water|A group will drink natural spring water for 4 months
45972530|NCT02213653|Drug|ARM A : IV iron + epoietin zeta|"Epoietin zeta at a dose of 450 IU / kg per week subcutaneously~Carboxymaltose ferric (Ferinject ®) at week 1; Intravenous infusion not exceeding 1000 mg (administered once if weight> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~Renewable with a minimum of 4 weeks depending on the iron status (if CST <20% and absence of serum ferritin> 800) in the same manner as week 1."
45972531|NCT02213653|Drug|ARM B: IV iron + epoietin zeta sequence|"Epoietin zeta at a dose of 450 IU / kg per week subcutaneously started in week 7~carboxymaltose ferric (Ferinject ®) at week 1~Intravenous infusion not exceeding 1000 mg (administered once if weight> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~Renewable with a minimum of 4 weeks depending on the iron status (if CST <20% and absence of serum ferritin> 800) in the same manner as week 1."
45972532|NCT02213653|Drug|ARM C : single epoietin zeta|Epoietin zeta at a dose of 450 IU / kg per week subcutaneously begun in week 1
45972533|NCT02213731|Other|Holter monitoring|Subjects will wear holter monitors at baseline, 6 months and 12 months.
45972534|NCT00268944|Biological|Myozyme|20 mg/kg qow
45972535|NCT04721093|Device|Photobiomodulation device|In this study, PBM was applied using a machine made to be attached to the subject in the form of a probe. In this clinical trial, a low-intensity irradiation device (Color-DNA-WSF U) from Color seven was used to deliver visible light (610nm± 10nm wavelength, 3.0mW/㎠±20%) irradiation. PBM was applied 5 times a week for 8 weeks, 30 minutes per session.
45972536|NCT04552444|Drug|Biapenem|In the course of CRKP treatment, double dose biapenem was selected.
46081629|NCT03816345|Biological|Nivolumab|Given IV
46081630|NCT03806985|Drug|Placebo oral capsule|microcrystalline cellulose capsule
45972537|NCT04552600|Drug|Nuvastatic|Phase 1b Interventional, multi-centered, double-masked, randomized
45972538|NCT04552600|Other|Placebo|Phase 1b Interventional, multi-centered, double-masked, randomized
45972539|NCT04552561|Behavioral|My MS Toolkit|My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.
45972540|NCT04552678|Behavioral|Healthy Eating, Active Play, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
45972541|NCT04552678|Behavioral|Healthy Eating, Active Play, Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
45972542|NCT04552678|Behavioral|Healthy Eating, Active Play, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
45972543|NCT04552678|Behavioral|Healthy Eating + Active Play|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy.
45972544|NCT04552678|Behavioral|Healthy Eating, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
45972545|NCT04552678|Behavioral|Healthy Eating + Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
45972546|NCT04552678|Behavioral|Healthy Eating + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
45972547|NCT04552678|Behavioral|Healthy Eating Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum. Parents will receive access to web-based resources on food literacy.
46081631|NCT03806985|Drug|Low Dose Psilocybin|0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin capsule (fixed-dose option)
46081632|NCT03806985|Drug|High Dose Psilocybin|0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option)
46081633|NCT03806452|Drug|Hydroxycarbamide|Hydroxycarbamide tablets of 100 and 1000 mg
46081634|NCT03806452|Drug|Placebo Oral Tablet|Placebo tablets of 100 and 1000 mg to mimic hydroxycarbamide tablets
46081635|NCT03800394|Other|Observational PK study|Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations
45455911|NCT05485857|Procedure|Arrangement of small intestine order before close the abdomen|After the completion of laparoscopic-assisted colorectal cancer surgery, the chief surgeon performed laparoscopic small bowel arrangement before closing the abdomen, straightening the small bowel from the colon-small bowel anastomosis or the ileocecal valve to the ligament of Trevor, and restoring the original position of the small bowel. Afterward, close the abdomen.
46081636|NCT03761173|Device|FlowTriever System|Thrombectomy
46081637|NCT03761173|Drug|Anticoagulation Agents|Anticoagulation medication
46081638|NCT03750903|Behavioral|Aerobic Exercise|Participants will engage in an aerobic exercise program meeting thrice weekly for a period of 12 weeks.
46081639|NCT03750903|Behavioral|Stretching and Balance Training|Participants will engage in a balance and stretching comparator condition meeting thrice weekly for 12 weeks.
46081640|NCT03742414|Combination Product|Tri-lipid skin barrier cream (Epiceram)|The aim is to compare the effect of proactive sequential skin care, including the twice daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone proprionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
46081641|NCT03742414|Combination Product|Fluticasone propionate Cream 0.05%|Proactive use of fluticasone proprionate cream for inflammation of the skin, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
45972548|NCT04552678|Behavioral|Active Play, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
46081642|NCT03742414|Combination Product|Moisturizer|The aim is to compare the effect of proactive sequential skin care, including the twice daily use of a moisturizer and proactive use of fluticasone proprionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
46081643|NCT03742414|Other|Standard of Care|Participants' eczema will be managed by their primary physician, i.e. standard of care with routine reactive topical products for atopic dermatitis flares.
46081644|NCT03733028|Behavioral|Mobile Intervention for Reducing Anger (MIRA)|This is a mobile intervention that uses interpretation bias modification (IBM) techniques to reduce the hostile interpretation bias. Participants will be given a mobile device with the MIRA app and instructed to complete 5 treatment sessions each week for a period of 4 weeks. Each session takes approximately 10 minutes. The app also includes a Nightly Diary to track symptoms, a calendar to program session reminders, and a My Progress feature to track use and performance.
46081645|NCT03733028|Behavioral|Mindfulness Intervention|"This is a mobile intervention that uses the Mindful Breathing and Body Scan exercises from the Mindfulness Coach app. These audio-guided exercises take approximately 10 minutes each. Participants will be given a mobile device with the Mindfulness app and instructed to complete 5 exercises (i.e., Body Scan or Mindful Breathing) each week for a period of 4 weeks. The app also includes a Nightly Diary to track symptoms, a calendar to program reminders, and a My Progress feature to track use and performance."
46081646|NCT03731260|Drug|Avapritinib|Avapritinib tablet
46081647|NCT03731260|Drug|Placebo|Placebo tablet
46081648|NCT03728556|Biological|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months
46081649|NCT03728556|Biological|CS1001 placebo|Participant will receive CS1001 placebo by intravenous infusion every 3 weeks, for up to 24 months
45828988|NCT00003653|Drug|cyproterone acetate|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
45828989|NCT00003653|Drug|flutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
45828990|NCT00003653|Drug|goserelin|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
45828991|NCT00003653|Drug|leuprolide acetate|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
45972549|NCT04552678|Behavioral|Active Play + Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
46081650|NCT03715894|Procedure|transcatheter valve implantation|aortic transcatheter valve implantation using Edwards SAPIEN 3 valve
45972550|NCT04552678|Behavioral|Active Play + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
45972551|NCT04552678|Behavioral|Active Play Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy.
45972552|NCT04552678|Behavioral|Self-Regulation + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
45972553|NCT04552678|Behavioral|Self-Regulation Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
45972554|NCT04552678|Behavioral|Food Literacy + Parent Education|Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
45972555|NCT04552678|Behavioral|Food Literacy Only|Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy.
45972556|NCT00236171|Drug|Protopic, Advantan|
45972557|NCT00236171|Procedure|Blood and Urine Test|
45972558|NCT00236171|Procedure|coherence tomography|
45972559|NCT04552639|Behavioral|Newbridge Eating disorders Activity Treatment group|A compulsive exercise cognitive-behavioural based group, for children and adolescents diagnosed with an eating disorder. It was devised for eating disorders including Anorexia Nervosa, Bulimia Nervosa and Other Specified Feeding or Eating Disorder. This treatment is semi-structured and problem-oriented, which focuses on tackling the factors and processes that maintain compulsive exercise behaviour.
45972560|NCT04552639|Behavioral|Newbridge House treatment as usual|Multi-disciplinary eating disorder treatment (including; psychiatry, individual therapy, group therapy, dietetic support, occupation therapy and nursing excluding NEAT group).
45972561|NCT04552405|Dietary Supplement|Anti-inflammatory Diet|FAP individuals followed for 3 months a low-inflammatory diet
45972562|NCT00269022|Drug|SB-705498|
45972563|NCT00236210|Behavioral|Action Score|Improvement in a novel 100-point score summarizing cardiovascular risk.
45972564|NCT00236210|Behavioral|VIP program|Risk assessment, lifestyle counselling, exercise program
45972565|NCT04552210|Diagnostic Test|blood sample|Whole blood was collected on EDTA (1mg/ml) to prevent clotting and DNA degradation.
45972566|NCT02213848|Drug|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
45972567|NCT02213848|Drug|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
45972568|NCT00413855|Procedure|laparoscopic appendectomy or not (surgery)|
45828992|NCT00003653|Drug|nilutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
45828993|NCT00003665|Biological|dendritic cell-MART-1 peptide vaccine|
45828994|NCT00003665|Biological|gp100 antigen|
45828995|NCT00003665|Biological|therapeutic tumor infiltrating lymphocytes|
45828996|NCT00003665|Biological|tyrosinase peptide|
45828997|NCT00003671|Drug|asparaginase|
45828998|NCT00003671|Drug|cyclophosphamide|
45828999|NCT00003671|Drug|cytarabine|
45972569|NCT04548544|Behavioral|Training for Awareness, Resilience, and Action (TARA)|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
45829000|NCT00003671|Drug|daunorubicin hydrochloride|
45670065|NCT04622787|Other|Knowledge translation|"A. Healthcare Providers Observational Study - measure of the effectiveness of the International Guidelines training courses (face to face and online) delivered to medical professionals (involves all clinical partners).~The International Guidelines training courses on the evidence-based principles of Early Detection (ED), Early surveillance (ES), and Early intervention (EI) will be delivered to healthcare providers.~Face-to-face professional trainings will be set up at each Consortium partner location. E-learning platform will allow for training and follow-up resources will be available to clinicians in all languages that are spoken/written in the locations of the Consortium partners.~Clinicians will be assessed on their knowledge and standard clinical practices in survey format before trainings and after the trainings."
46081651|NCT03694015|Radiation|SUPR|simple unplanned palliative radiotherapy-(either 8 Gy in 1 fraction or 20 Gy in 5 fractions), chosen pre-randomization at ROs or centres discretion
45972570|NCT04548388|Other|rehabilitation|"A specialist physiotherapist in neurological rehabilitation provided the Bobath approach individually to each patients in both groups. Bobath approach included 3 days a week over a total of 12 sessions for four weeks. The Bobath approach consisted of about individual one hour session.~In addition to the Bobath approach, the subjects in the study group received WBV for 20 minutes a day, 2 days a week. The frequency of the device was increased by 5 Hz every week, starting the treatment with 30 Hz. Whole body vibration application was performed on a platform (Power Plate Pro5®) that provides vertical vibration. Two different practice positions were chosen as standing and semi-squatting. In order to prevent muscle fatigue, the set consisting of 1 minute of application - 1 minute of rest in each position was applied for a total of 10 minutes with 5 repetitions"
45972571|NCT00261573|Drug|galantamine hydrobromide|
45972572|NCT04548466|Device|PEP bottle|
45972573|NCT04548427|Drug|CKD-352|Eye Drop
45972574|NCT04548427|Drug|Diquafosol Sodium 3%|Eye Drop
45972575|NCT00413933|Procedure|Comprehensive Multidisciplinary Intervention|Comprehensive Multidisciplinary Intervention
45972576|NCT04548271|Drug|Camrelizumab|Anti-PD-1 targeted immunotherapy
45972577|NCT04548271|Drug|Apatinib|A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor
45972578|NCT04541719|Drug|Patient-controlled remifentanil analgesia|Patient controlled remifentanil analgesia with a regimen to provide a bolus of 40 μg remifentanil with a lockout interval of 2 min
46081652|NCT03694015|Radiation|VMAT|volumetric modulated arc therapy--(either 8 Gy in 1 fraction or 20 Gy in 5 fractions), chosen pre-randomization at ROs or centres discretion
45829001|NCT00003671|Drug|dexamethasone|
45829002|NCT00003671|Drug|leucovorin calcium|
45829003|NCT00003671|Drug|mercaptopurine|
45829004|NCT00003671|Drug|methotrexate|
45829005|NCT00003671|Drug|thioguanine|
45829006|NCT00003671|Drug|vincristine sulfate|
45829007|NCT00003677|Drug|Dolastatin 10|IV bolus once every 21 days.
45829008|NCT00384605|Drug|taranabant|taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
45829009|NCT00384605|Drug|placebo|Placebo capsule once daily. Treatment for 52 weeks.
45829010|NCT00003683|Drug|doxorubicin hydrochloride|
45829011|NCT00003683|Drug|ifosfamide|
45829012|NCT04329143|Procedure|open completion cholecystectomy|open excision of cystic duct remnant
45972579|NCT04541719|Drug|Epidural analgesia|Patients will receive continuous epidural analgesia using bupivacaine 0.125% in conjunction with fentanyl 2 ug/ml at a rate of 8-15 ml/hr
45972580|NCT04548115|Behavioral|ARTISAN Condition|Youth and senior participants will be randomly paired and engage in the 5-weekly, 3-hour ARTISAN intervention as dyads (totaling 15 hours of intervention). In the first four weeks of the ARTISAN, dyads will engage in themed museum tours facilitated by a docent (45min), guided storytelling (45 min) and professionally-led art-making (45 min). The remaining time (45 min) is allocated for session breaks, session introduction/closing, and buffer time for movement around the gallery. The final week involves an exhibition where participants share their artworks with the public and reflect on their experiences and artworks. The weekly session themes are as follows: Week 1: Discovering our National Heritage (Art medium: Clay); Week 2: Strengthening Social Bonds (Art medium: Acrylic Paints); Week 3: Overcoming Adversities and Resilience (Art medium: Beads); Week 4: Building Dreams and Aspirations (Art medium: Recycled Materials); Week 5: Sharing our Stories and Legacies (Community Showcase)
46081653|NCT03687671|Other|Animal-assisted therapy|Animal-assisted occupational therapy, animal-assisted physiotherapy and animal assisted speech therapy with different animals. All animals are trained for the specific service with vulnerable patients. There are guinea pigs, rabbits, miniature pigs, sheeps, goats, chicken, dogs, cats and horses.
46081654|NCT03687671|Other|Treatment as usual|Speech therapy, occupational therapy or physiotherapy
45972581|NCT04548115|Behavioral|Intergenerational Participatory Arts Condition|Youths and senior participants in this condition will be randomly paired and engage in a 5-weekly 45-minute group-based art activity conducted in a community space with 15 minutes of preparation/break time (totaling 5 hours of intervention). A professional artist or art therapist will facilitate art-making sessions with the participants in a community space, utilizing the same mediums that were used in ARTISAN. The weekly session themes are as follows: Week 1: Discovering our National Heritage (Art medium: Clay); Week 2: Strengthening Social Bonds (Art medium: Acrylic Paints); Week 3: Overcoming Adversities and Resilience (Art medium: Beads); Week 4: Building Dreams and Aspirations (Art medium: Recycled Materials); Week 5: Sharing our Stories and Legacies (Community Showcase)
45972582|NCT04548115|Behavioral|Intergenerational Art-space Condition|Youths and senior participants in this condition will engage in a 5-weekly 45-minute group-based curated museum tour that follow the ARTISAN themes with 15 minutes of preparation/break time, and conducted by a trained docent at the National Museum Singapore (totaling 5 hours of intervention).The weekly session themes are as follows: Week 1: Discovering our National Heritage; Week 2: Strengthening Social Bonds; Week 3: Overcoming Adversities and Resilience; Week 4: Building Dreams and Aspirations; Week 5: Sharing our Stories and Legacies.
45972583|NCT04548115|Behavioral|Intergenerational Storytelling Condition|Youths and senior participants in this condition will be paired to engage in a 5-weekly 45 minute group-based storytelling activity conducted in a community space with 15 minutes of preparation/break time (totaling 5 hours of intervention). Storytelling sessions will be conducted by a trained facilitator, and conversation starters from ARTISAN intervention will be used. The weekly session themes are as follows: Week 1: Discovering our National Heritage; Week 2: Strengthening Social Bonds; Week 3: Overcoming Adversities and Resilience; Week 4: Building Dreams and Aspirations; Week 5: Sharing our Stories and Legacies.
45972584|NCT04548115|Behavioral|Control Condition|Participants in this condition will engage in a 5-weekly 45 minute group-based physical activity session conducted in the community with 15 minutes of preparation/break time (totaling 5 hours of intervention). Physical activity was selected over basic psychosocial care to test the effects of inter-generational contact independent of arts and heritage-based engagements.
45972585|NCT00414089|Drug|90Y-ibritumomab tiuxetan (Zevalin)|
45972586|NCT00261612|Drug|bortezomib|
45972587|NCT00261612|Drug|rituximab|
45972588|NCT00261612|Drug|dexamethasone|
45972589|NCT00261612|Procedure|treatment protocol|
45972590|NCT04547764|Drug|triple antibiotic paste (TAP)|root canal treatment of pulpally involved teeth.
45972591|NCT04547764|Drug|Vitapex (calcium hydroxide/iodoform paste)|root canal treatment of pulpally involved teeth.
45972592|NCT04547647|Radiation|X- Ray|X-Ray with A-P and lateral view of the whole spine.
45972593|NCT04547608|Other|The difference of the timing of rocuronium administration after propofol injection|The difference of the timing was rocuronium was administered immediately after propofol injection or when BIS score became below 60 after propofol administration.
45829013|NCT04329143|Procedure|lap completion cholecystectomy|lap excision of cystic duct stone
45829014|NCT00003695|Drug|chemotherapy|
45829015|NCT00003695|Procedure|surgical procedure|
45829016|NCT00003707|Drug|gemcitabine hydrochloride|
45829017|NCT00003707|Drug|tipifarnib|
45972594|NCT00236249|Drug|Lidocaine|
45972595|NCT00269061|Drug|pioglitazone|
45972596|NCT02214472|Behavioral|Biofeedback|
45972597|NCT02214472|Drug|Placebo|
45972598|NCT04547452|Radiation|Stereotactic body radiation therapy|Sintilimab Combined with SBRT
45972599|NCT04547452|Drug|Anti-PD-1 antibody drug named Sintilimab|Sintilimab
45972600|NCT04547335|Drug|Voriconazole|This is an observational study and only the patients already on voriconazole treatment will be included in the study.
46081655|NCT03682042|Other|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
45829018|NCT00003713|Drug|intoplicine|
45972601|NCT00236288|Drug|Bupropion and intensive behavioral therapy|To prescribe bupropion and behavioral therapy to patients and/or their families, who are currently receiving radiation.
46081656|NCT03677141|Drug|Mosunetuzumab|Participants will receive intravenous (IV) mosunetuzumab.
46081657|NCT03677141|Drug|Polatuzumab Vedotin|Participants will receive polatuzumab vedotin via IV.
46081658|NCT03677141|Drug|Rituxumab|Participants will receive rituxumab via IV.
46081659|NCT03677141|Drug|Cyclophosphamide|Participants will receive cyclophosphamide via IV.
45670066|NCT01929993|Procedure|SWETZ|Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
45670067|NCT01929993|Procedure|LLETZ cone|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth. The loop is applied to the cervix outside the lateral margin of the transformation zone and brought slowly to the controlateral transformation zone margin.
45829019|NCT00003719|Drug|irinotecan hydrochloride|
45829020|NCT00003725|Drug|valrubicin|
45829021|NCT00003725|Procedure|conventional surgery|
45829022|NCT00003731|Drug|temozolomide|
45829023|NCT00003737|Drug|becatecarin|
45829024|NCT00003743|Biological|aldesleukin|
45829025|NCT00003749|Procedure|adjuvant therapy|
45972602|NCT04547296|Drug|Sodium Bicarbonate Ringer's Solution|After the participants enter the operating room, radial artery puncture and catheterization were performed. The blood gas in the non-oxygen state was used as the basic value. A peripheral venous access was established in one upper limb, and the two groups were pre-dilated with sodium bicarbonate Ringer's solution or acetate Ringer's solution (30 min, 8 ml/kg). For laparoscopic surgery, adjust the PaCO2 value to 35-45 mmHg again 10 minutes after the establishment of the pneumoperitoneum. After the operation started, the two groups of participants were maintained with 4-5 ml/kg/h Ringer's solution during the operation. Blood gas was measured every hour after tracheal intubation during the operation, and the last blood gas was measured when the skin was sutured. When the blood gas pH <7.2, 5% sodium bicarbonate injection was given to correct it.
46081660|NCT03677141|Drug|Doxorubicin|Participants will receive doxorubicin via IV.
46081661|NCT03677141|Drug|Vincristine|Participants will receive vincristine via IV.
45972603|NCT02214511|Behavioral|emotional facial stimuli|Subjects watch passively dynamic facial emotions obtained by emotionnal faces photos morphing. Their rapid facial reactions are recorded by faciel EMG device as eye movement by occulometric device.
45972604|NCT02214511|Behavioral|Cyberball game|Ball tossing computer game to manipulate social inclusion status : rejection or inclusion. Social behavior, social pain and inflammatory modification will be assessed after the game.
45972605|NCT00236327|Drug|fentanyl|
45972606|NCT00269139|Behavioral|Crisis resolution|
45972607|NCT02214589|Other|Oral glucose, facilitated tucking, NNS|
45972608|NCT02214589|Other|Oral glucose and NNS|
45972609|NCT02214589|Other|Facilitated tucking and NNS|
45972610|NCT04546984|Drug|HEC96719|Part 2：Mulltiple doses up to 10 days
45670068|NCT04630821|Other|Dilute Sodium Hypochlorite solution|"Subjects will be treated with the dilute bleach compresses daily for the first 3 weeks of therapy.~While these subjects are undergoing radiation therapy, they will be assessed weekly before the day's compress treatment by a physician investigator on the study team. Subjects will be evaluated and photographs will also be taken at study visits 1-3. The subjects will also complete a subject questionnaire addressing patient-reported outcomes at baseline and each weekly check-in during these two weeks. They will be also interviewed about ease of use and treatment tolerability. Subjects will complete interview questions at the end of the study to determine if they would continue the treatment and any obstacles or barriers."
45829026|NCT00003749|Procedure|conventional surgery|
45972611|NCT00236366|Drug|fentanyl|
45972612|NCT04546789|Drug|M2951 (BTK inhibitor)|Participants will receive a single oral dose of M2951 (BTK inhibitor).
45670069|NCT04645953|Combination Product|3mg AZ-010|Subject will receive a single inhaled dose (3mg)
45670070|NCT04645953|Combination Product|1mg AZ010|Subject will receive a single inhaled dose (1mg)
45829027|NCT00003749|Radiation|brachytherapy|
45829028|NCT00003749|Radiation|radiation therapy|
45670071|NCT04645953|Combination Product|Staccato Placebo|Subject will receive a single inhaled dose (Staccato Placebo)
45829029|NCT00003755|Drug|MKC-1|
45829030|NCT00003761|Biological|rV-DF3/MUC1|"- The starting dose for this Phase I study of rV-DF3/MUC1 will be 4.76 x 106 PFU.~-- Dose escalation will proceed with cohorts of at least 6 patients as follows: Per vaccination~Level 1 4.76 x 106 PFU~Level 2 4.76 x 107 PFU~Level 3 4.76 x 108 PFU"
45829031|NCT00003773|Drug|oglufanide disodium|
45829032|NCT00003779|Biological|Connaught|Compare two strains of BCG
45829033|NCT00003779|Biological|Tice|Compare two strains of BCG
45829034|NCT00384917|Drug|Ketoconazole|
45829035|NCT05444153|Drug|Semaglutide|Participants will receive 1 tablet of oral semaglutide once daily.
45829036|NCT05444153|Drug|Empagliflozin|Participants will receive 1 tablet of empagliflozin once daily.
45829037|NCT00003797|Biological|trastuzumab|
45829038|NCT00003797|Drug|gemcitabine hydrochloride|
45829039|NCT00003803|Drug|cisplatin|
45829040|NCT00003803|Drug|gemcitabine hydrochloride|
45829041|NCT00003803|Radiation|radiation therapy|
45829042|NCT02972879|Procedure|Therapeutic modalities: Orthotic (Group 1)|participants will be instructed to remove the orthosis only two hours in the morning, two hours in the afternoon and two hours at night to avoid joint stiffness
45972613|NCT00261690|Behavioral|Virtual Reality Distraction|Using virtual reality distraction during a procedure
45972614|NCT04547179|Drug|Fremanezumab-Vfrm|Patients will receive three injections of Ajovy® if in the corresponding arm of the study.
45972615|NCT04547179|Device|BLAfit®|Usage of the BLAfit device, a fixed orthotic appliance that allows users to tone facial muscles with one minute usage per day
45972616|NCT04547179|Other|Saline|Patients will receive three injections of saline if in the corresponding arm of the study. This is a placebo meant to simulate the Ajovy® injection.
45972617|NCT04547101|Drug|AK104|AK104，6 mg/kg IV，every 2 weeks (Q2W)
45972618|NCT04546906|Biological|CD22 CAR-T|Biological: CD22 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
45972619|NCT00236405|Drug|epoetin alfa|
45972620|NCT00269178|Behavioral|Peer Health Education Programme|
45972621|NCT04546438|Device|miraDry®|"MiraDry is a noninvasive method that uses microwave technology to destroy sweat glands.~In this study we evaluate a higher energy level with a newer generation device, in respect with side effects and number of treatments (one or two interventions)."
45972622|NCT00236444|Drug|risperidone|
45972623|NCT00269217|Drug|niacin (+) laropiprant (+) simvastatin|Duration of Treatment 12 Weeks
45972624|NCT00269217|Drug|Comparator: niacin (+) laropiprant|Duration of Treatment 12 Weeks
45972625|NCT00269217|Drug|Comparator: simvastatin|Duration of Treatment 12 Weeks
45972626|NCT04546204|Other|vaginal delivery|normal vaginal spontaneous delivery
45972627|NCT04546282|Other|Description of the molecular alterations detected in blood samples of patients treated by osimertinib|Description of the molecular alterations detected in blood samples of patients treated by osimertinib. This test is usualyy performed routinely to detect conventional mutations including EGFR T790M. We performed panel of genes screeining based on next generation sequencing. Thius, iIn some cases, new mutations can be detected by this assay.
45972628|NCT04546321|Other|serum L carnitine level measuring|The serum level of total L carnitine was measured for both HIE and TTN cases
45972629|NCT00236483|Drug|tramadol hydrochloride + acetaminophen|
45972630|NCT04546048|Behavioral|Strength Exercise Training|The 8-week exercise-training program consisted of two 30-min sessions a day for 5 days/week and conducted by elastic exercise bands in 2-3 sets, 6-10 repetitions, with 1-2 min rest between sets (M. Deltoideus and M. Quadriceps are trained as major muscle groups). The 8-repetition maximum(8RM) is used to determine training loads with the rated perceived exertion(RPE) lower than 5-7 on the Modified Borg scale(MBS). The program consisted functional exercises by half squat to squat and sit-to-stand chair exercises. Exercise sessions were supervised twice daily during the 1st week, the 2nd week training included one supervised and one unsupervised daily sessions. The remaining 6-week training program conducted at home individually after discharge. Patients instructed for the ongoing 8-week training program and a patient-specific schedule delivered to subjects. Phone calls are provided weekly and training load is assessed while generating 4th week evaluations.
45972631|NCT04546165|Procedure|manipulation plus exercise|HLVA manipulation was performed for 8 sessions (twice a week for four weeks) using a segment-specific technique for segmental dysfunctions of the upper cervical spine. . By bringing the cervical spine to light flexion and about 15-20º lateral flexion without any rotational motion, the middle finger of the manipulating hand provided deep contact, and an HVLA thrust was applied out of the rotational slack by applying a deep force from the dorsal to the ventral direction
45972632|NCT04546165|Procedure|suboccipital inhibition plus exercise|Suboccipital inhibition was performed for 8 sessions (twice a week for four weeks) as a combined muscle and soft tissue inhibition technique. While the patient was in the supine position, the physician sitting at the top end of the table placed the fingers of both hands on the patient's suboccipital region
45829043|NCT02972879|Procedure|Therapeutic modalities: LLLT (Group 2)|"The LLLT parameters are:~LASER 904nm~P: 1.5W/cm²~30mV/cm²~Area 2 cm²~1 Joule por ponto ( in the A1 pulley)"
45829044|NCT02972879|Procedure|Therapeutic modalities: Paraffin (Group 3)|"Paraffin will be heated and maintained at 50 ° C. Participants will immerse their affected hand 10 times in heated paraffin, then they will roll up their affected hand in a towel that they will bring, after 20 minutes timed by a trained professional, the subjects will remove the towel and paraffin glove:"
45972633|NCT04546165|Procedure|exercise|Patients were asked to exercise at least three days a week during treatment. The exercise program, which lasted 20 to 30 minutes, included cervical range of motion (ROM) exercises to warm-up and cool-down, and then stretching exercises of cervical and upper thoracic spine muscles (trapezius, levator scapula, sternocleidomastoid) and strengthening exercises (cervical isometric contraction and concentric contraction of the deep cervical flexor muscles).
45972634|NCT04545970|Combination Product|Facial cleanser|Facial cleanser to be used by study participants
45972635|NCT04545970|Combination Product|Facial moisturizer|Bland moisturizer to be used by study participants after serum in the evening.
45972636|NCT04545970|Combination Product|Sunscreen|Sunscreen to be applied after application of serum in the morning.
45972637|NCT04545931|Device|Posterior tibial nerve stimulation|34-gauge stainless steel needle is inserted about three finger breadths cephalad to the medial malleolus. In children, previous administration of a topical anesthetic agent (e.g. lidocaine) can help to reduce pain and fear associated with needle insertion. The goal is to place the tip of the needle close to the PTN without actually touching it. The negative electrode is placed on the same leg near the arch of the foot. The needle and the electrode are connected to a low voltage (9 V) stimulator
45972638|NCT04545931|Drug|Desmopressin Acetate|0.2 mg, single evening dose ) for 12 weeks, tapering to half of the dose daily for two weeks before discontinuation
45972639|NCT00236522|Drug|levofloxacin|
45972640|NCT00261729|Drug|Paroxetine|paroxetine 20 mg
45829045|NCT02972879|Procedure|Corticosteroid injection (Group 4)|The injection solution is composed of 1 ml of betamethasone and 1 ml of 2% lidocaine.This group may repeat the procedure in two weeks if they report that there was no improvement of the triggering or pain.
45829046|NCT00003815|Biological|bleomycin sulfate|
45670072|NCT01912599|Device|Sensimed Triggerfish|IOP will be measured with the Sensimed Triggerfish, which is a disposable silicone contact lens embedded with a wireless sensor. The sensing resistive gauge in the device is circular around the center of the lens and is placed over a circumference of 11.5 mm in diameter. This corresponds to the corneoscleral junction position, where maximum corneal deformation occurs as a result of changes in IOP. A soft patch containing the receiving antenna will be applied around the eye and transmits the information via wire to the recorder that the patient will wear around the waist. The patient can continue to wear spectacles during monitoring. The device records a total of 144 measurements over a 24-hour period.
45670073|NCT01912599|Device|Blood Pressure|Patients in both groups will be fitted with a blood pressure cuff that will measure pressures for 24 hours.
45829047|NCT00003815|Drug|carmustine|
45829048|NCT00003815|Drug|cyclophosphamide|
45972641|NCT00261729|Drug|Prazosin|Prazosin
45972642|NCT00261729|Drug|placebo|placebo capsules
45972643|NCT04541836|Diagnostic Test|18F-PMPBB3|single intravenous injection 5mCi 18F-PMPBB3 per scan
45972644|NCT04541758|Procedure|surgical treatment|surgical treatment and Conservative treatment
45829049|NCT00003815|Drug|cytarabine|
45829050|NCT00003815|Drug|doxorubicin hydrochloride|
45829051|NCT00003815|Drug|etoposide|
45829052|NCT00003815|Drug|melphalan|
45829053|NCT00003815|Drug|prednisolone|
45829054|NCT00003815|Drug|vincristine sulfate|
45972645|NCT04541758|Procedure|Conservative treatment|Conservative treatment
45972646|NCT04541641|Procedure|New Reverse Drilling technique|a new technique of dental implant drilling that promote osseodensification by rotating the drills anti-clockwise rather than clockwise to promote bone condensation rather than bone cutting
45972647|NCT04541641|Procedure|osteotome technique|a technique for dental implant placement by using the osteotome to condense the bone and create an osteotome rather than cutting the bone
45972648|NCT00236561|Drug|topiramate, propranolol|
45972649|NCT02215330|Drug|Eplerenone|
45972650|NCT02215330|Drug|Maltodextrin|
45972651|NCT00261768|Behavioral|Digital noise reduction|
45972652|NCT02214667|Behavioral|Dual-diagnosis motivational interviewing (DDMI)|DDMI is an evidence-based adaptation to motivational interviewing. DDMI incorporates an integrated framework and accommodates cognitive impairments and disordered thinking associated with co-occurring substance use and mental disorders.
45972653|NCT02214667|Behavioral|Integrated group therapy (IGT)|IGT is an evidence-based practice for treating co-occurring disorders. IGT focuses on relapse prevention by reducing substance use and stabilizing psychiatric symptoms.
45972654|NCT02214667|Behavioral|Jail and community-based behavioral health services|Existing behavioral health service programs
45972655|NCT02278510|Drug|Topotecan|Topotecan is a chemotherapy that is approved by the FDA to treat cancers. It is normally given by an intravenous injection, and not directly into a tumor. That is why it is considered to be an investigational drug for this study
45670074|NCT04645017|Behavioral|Intergenerational Music Program|Music activities will be lead by adolescent musicians for older adult participants.
45670075|NCT01929681|Device|Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic technique. It uses low strength electric fields operating at a high frequency.
45670076|NCT01646177|Drug|Placebo|Administered SC
45670077|NCT01646177|Drug|50 mg etanercept|Administered SC
45670078|NCT01646177|Drug|80 mg ixekizumab|Administered SC
45829055|NCT00003815|Procedure|autologous bone marrow transplantation|
45829056|NCT00003815|Radiation|radiation therapy|
45670079|NCT01912287|Behavioral|Cognitive Behavioral Therapy|CBT focused on Generalized Anxiety Disorder (12 sessions)
45829057|NCT00003821|Drug|aminopterin|
45829058|NCT00003827|Drug|amifostine trihydrate|
45972656|NCT02278510|Drug|Gadolinium DTPA|Gadolinium DTPA is a contrast agent which will be added to topotecan to allow the investigators to observe where topotecan goes in tumors. Gadolinium DTPA is approved by the FDA for intravenous injection during an MRI scan. It is not approved by the FDA for administration directly into a tumor.
45972657|NCT02278510|Device|Cleveland Multiport Catheter|The Cleveland Multiport Catheter is a device that is not approved by the FDA and so it is classified as an investigational device. It has been designed to deliver drugs and other agents intended to treat cancers directly into the affected tissues. The Cleveland Multiport Catheter can be placed into a brain tumor only in the operating room. It is placed during an operation to perform a biopsy of brain tumors. Following the biopsy, a surgeon will place two catheters into the tumor with use of an image guided navigation system. Once each catheter has been placed, it will be secured into the scalp and the incision will be closed. The Cleveland Multiport Catheter will be left in place until the completion of the topotecan treatment.
45972658|NCT04546243|Procedure|resection group|patients received VATS
45972659|NCT04546243|Radiation|radiotherapy group|patients received radiotherapy
45670080|NCT01912287|Behavioral|Stress Education|Active control group (12 sessions)
45670081|NCT01912287|Behavioral|Yoga|12 sessions, mindfulness components
45670082|NCT01929135|Drug|Medicated 2% atorvastatin dentifrice|Non surgical periodontal therapy accompanied by medicated 2% atorvastatin dentifrice (20 mg per ml) 2 times a day for two minutes each time, for 30
45972660|NCT02278627|Other|manual lymphatic drainage|
45972661|NCT04545892|Drug|Capsaicin|One milliliter of each dilution was pipetted on to 2 cm filter paper squares. Then, the filter papers were let dry. Immediately before application, they were rehydrated with 1 milliliter of distilled water
46081662|NCT03677141|Drug|Prednisone|Participants will receive oral prednisone.
46081663|NCT03677141|Drug|Tocilizumab|Participants will receive tocilizumab via IV.
45670083|NCT01929135|Drug|Non-medicated dentifrice|Non surgical periodontal therapy accompanied by non medicated dentifrice 2 times a day for two minutes each time, for 30 days.
45670084|NCT01911819|Procedure|Sinus augmentation|
45670085|NCT01911819|Drug|Equimatrix|Equimatrix cancellous particle size 0.2-1mm approximately 2g (4cc)
45670086|NCT01911819|Drug|OSSIF-i sem|OSSIF-i sem Mineralized Cancellous Bone Allograft SP 0.25-1.0mm approximately 2cc x 2
45670087|NCT01911819|Drug|Bio-oss|Bio-oss small granules cancellous 0.25-1mm, approximately 2g (4cc)
45670088|NCT02280863|Device|Medtronic Hybrid Closed-loop System - Android Platform|A continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm using an Android controller.
45670089|NCT02280863|Device|Medtronic Hybrid Closed-loop Integrated System|A fully integrated continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm
45670090|NCT01911429|Drug|Lurasidone 40 mg|Lurasidone 40 mg once daily
45829059|NCT00003827|Drug|cytarabine|
45829060|NCT00003827|Drug|topotecan hydrochloride|
45829061|NCT00003833|Genetic|DNA stability analysis|
45829062|NCT00003833|Genetic|gene mapping|
45829063|NCT00003851|Biological|proteolytic enzymes|
45829064|NCT00003851|Drug|gemcitabine hydrochloride|
45829065|NCT00003851|Procedure|Gonzalez regimen|
45829066|NCT00003863|Genetic|comparative genomic hybridization|
45829067|NCT00003863|Genetic|cytogenetic analysis|
46081664|NCT03672331|Other|Mammogram|Every 1-4 years according to the national/regional guidelines or personalised schedule according to risk assessment
46081665|NCT03672331|Other|Ultrasound|As required according to the national/regional guidelines or personalised schedule according to risk assessment
46081666|NCT03672331|Other|MRI|As required according to the national/regional guidelines or personalised schedule according to risk assessment
46081667|NCT03672331|Other|Tomosynthesis|As required according to the national/regional guidelines or personalised schedule according to risk assessment
46081668|NCT03666741|Device|AVR with or without CABG|Surgical aortic valve implantation with INSPIRIS RESILIA Aortic Valve™
46081669|NCT03647501|Device|Interbody cage (titanium)|Subject will be implanted with a 3D-printed titanium cage during their lumbar interbody fusion surgery.
46081670|NCT03647501|Device|Interbody cage (PEEK)|Subject will be implanted with a poly-ether-ether-ketone (PEEK) cage during their lumbar interbody fusion surgery.
46081671|NCT03639025|Device|OCS Lung System|"The OCS™ Lung System is a portable organ perfusion, ventilation, and monitoring medical device intended to preserve donor lungs in a near physiologic, ventilated, and perfused state prior to transplantation. This technology was designed to overcome the limitation of cold storage and has the potential to expand the utilization of donor lungs. The OCS™ Lung System accomplishes this by performing 3 key functions:~Reducing ischemic injury through the use of warm, oxygenated blood based perfusion.~Optimizing the lung condition by ventilatory recruitment maneuvers and high-oncotic perfusion solution supplemented with hormones and nutrients.~Allowing for ex-vivo functional assessment of the donor lung during preservation and prior to transplant."
46081672|NCT03634228|Drug|Cytarabine|Given SC
46081673|NCT03634228|Drug|Milademetan Tosylate|Given PO
46081674|NCT03634228|Drug|Venetoclax|Given PO
45829068|NCT00003863|Genetic|fluorescence in situ hybridization|
45829069|NCT00003863|Genetic|gene rearrangement analysis|
45670091|NCT01911429|Drug|Lurasidone 80 mg|Lurasidone 80 mg once daily
45670092|NCT01911429|Drug|Placebo 40 or 80 mg|Placebo 40 or 80 mg once daily
45670093|NCT02324465|Device|King Vision Video Laryngoscope|Intubation via King Vision Video Laryngoscope
45670094|NCT02324465|Device|Glidescope Video Laryngoscope|Intubation via Glidescope Video Laryngoscope
45670095|NCT04630197|Behavioral|e-CBT|The description is provided in the treatment arm description.
45670096|NCT02324153|Drug|Ramelteon|1 pre-operative and 2 nightly postoperative doses of Ramelteon/placebo will be administered
45670097|NCT02324153|Drug|Microcrystalline Cellulose|Placebo Comparator
45670098|NCT02324153|Drug|Riboflavin 100 mg|Riboflavin will be added to both placebo and active intervention capsules in order to track adherence to dose while taken as an outpatient (i.e. only the first preoperative dose)
45829070|NCT00003881|Biological|trastuzumab|
45829071|NCT00003881|Drug|carboplatin|
45829072|NCT00003881|Drug|paclitaxel|
45829073|NCT00003887|Biological|peripheral blood lymphocyte therapy|
45829074|NCT00003893|Drug|CMF regimen|
46081675|NCT03617783|Drug|Prebiotin|Prebiotin (12g/day), an oligofructose-enriched inulin (OEI)
46081676|NCT03617783|Drug|Placebo|placebo-OEI
46081677|NCT03612973|Diagnostic Test|lipid profile|Serum samples will be withdrawn after fasting 12 hours then performed on Siemens Dimension Max: Total cholesterol and triglyceride concentrations will be estimated using enzymatic methods ( Roche Diagnostics, Mannheim, Germany). High density lipoprotein cholesterol will be determined after precipitation with phosphotungstic acid/magnesium chloride. Low density lipoprotein(LDL) cholesterol will be measured directly with a commercially available direct LDL-C assay (LDL-C Plus assay; Roche Diagnostics)
46081678|NCT03612973|Diagnostic Test|fasting insulin|serum samples used for doing the test by ELISA after fasting for 8 h
46081679|NCT03612973|Diagnostic Test|fibro scan|liver stiffness by fibro scan before and after treatment
46081680|NCT03611972|Dietary Supplement|Sugar-sweetened beverage|Sugar-sweetened koolaid-flavored water.
46081681|NCT03603223|Biological|Pembrolizumab|Given IV
45972662|NCT04541524|Device|Santen Preserflo Microshunt|The PMS is 8.5 mm long has an outer diameter of 350 μm and a lumen diameter of 70 μm. It has a fin sized 1.1 mm located 4.5 mm distally from the internal tip of the device and it consists of poly(styrene-b-isobutylene-b-styrene) SIBS. The device was implanted 1 year prior to the present study via an ab externo approach. At the beginning of the surgery, the conjunctiva was opened. In the first group of patients (group 1) we made a fornix based conjunctival opening, prepared a 1mm wide and long scleral pocket in 3mm distance from limbus and placed the PMS in the anterior chamber via a 25G needle track. In the second group (group 2) the conjunctival opening was 3.5 mm from the limbus, the scleral pocket was prepared at 3.5 mm distance from the limbus and a 27G needle was used. PMS guides aqueous humor from the anterior chamber to the subconjunctival space. The forming filtering bleb absorbs aqueous humor which leads to IOP reduction.
45670099|NCT02280473|Drug|Refresh Optive® Gel Drops|Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
45670100|NCT02280473|Drug|REFRESH LIQUIGEL®|REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
46081682|NCT03599245|Drug|Ocrelizumab|Participants will receive a 600-mg infusion of Ocrelizumab every 24 months for two years.
46081683|NCT03593590|Drug|Ocrelizumab|Ocrelizumab is administered as an intravenous infusion in accordance with the approved labelling.
46081684|NCT03587142|Drug|Buspirone|Buspirone tablet
45670101|NCT04644471|Diagnostic Test|CT scanner|1 conventional low dose inspiratory acquisition and 1 ultra-low-dose inspiratory acquisition
45670102|NCT04644471|Diagnostic Test|Lung MRI|3 UTE sequences (free breathing, inspiratory and expiratory) and 1 T2 sequence
45670103|NCT04420481|Drug|Somatropin|Dose: 1,4 mg (4,2 IE) every other day Dosage: 9 month treatment period and a 3 month follow-up period Administration: One subcutaneous injection of somatropin or corresponding placebo in the thigh or abdomen given in the evening given every other day.
45670104|NCT04420481|Drug|Placebo|Placebo
45670105|NCT01911273|Drug|PF-03446962|PF 03446962 7 mg/kg, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
45670106|NCT01911273|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
45670107|NCT01911273|Other|Placebo|Placebo will consist of Saline (0.9% w/v Sodium Chloride Injection, USP or NS)
45670108|NCT01911273|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
45670109|NCT02308007|Drug|Terconazole|
45670110|NCT02308007|Drug|Metronidazole|
45829075|NCT00003893|Drug|cyclophosphamide|
45829076|NCT00003893|Drug|doxorubicin hydrochloride|
45829077|NCT00003893|Drug|epirubicin hydrochloride|
45829078|NCT00003893|Drug|fluorouracil|
45829079|NCT00003893|Drug|methotrexate|
45829080|NCT00003893|Drug|mitomycin C|
45829081|NCT00003893|Drug|mitoxantrone hydrochloride|
45829082|NCT00003893|Procedure|adjuvant therapy|
45829083|NCT00003893|Radiation|radiation therapy|
45829084|NCT00003899|Biological|filgrastim|
45829085|NCT00003899|Drug|cyclophosphamide|
45829086|NCT00003899|Drug|melphalan|
45670111|NCT02308007|Drug|Terconazole/metronidazole|
45670112|NCT02278367|Drug|Flortaucipir F18|IV injection, 370 MBq (10 mCi), up to two doses
45670113|NCT02278367|Procedure|Brain PET scan|positron emission tomography (PET) scan of the brain
45670114|NCT04886141|Behavioral|Virtual Reality Headset|To determine if virtual reality headsets can reduce a patients pain level instead of using the standard Nitrous. This may provide a alternate to patients who cannot receive nitrous if pain or anxiety can be reduced effectively.
45670115|NCT01910181|Drug|Vemurafenib|Participants will receive vemurafenib at a dose of 960 mg twice daily orally.
45670116|NCT04885907|Biological|mRNA-1273 vaccine|COVID vaccine 3rd dose
45670117|NCT04885907|Other|Normal Saline Placebo|Normal Saline Placebo
45829087|NCT00003899|Drug|paclitaxel|
45829088|NCT00003899|Drug|thiotepa|
45829089|NCT00003899|Procedure|autologous bone marrow transplantation|
45829090|NCT00003899|Procedure|peripheral blood stem cell transplantation|
45829091|NCT00003911|Radiation|stereotactic radiosurgery|
45829092|NCT00003917|Drug|topotecan hydrochloride|
45829093|NCT00003923|Drug|porfimer sodium|
45829094|NCT02973191|Drug|JCAR015|
45829095|NCT00003929|Biological|filgrastim|Filgrastim (G-CSF) is administered subcutaneously daily on days 12-21 and days 33-42, until absolute neutrophil counts recover. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
45829096|NCT00003929|Drug|lomustine|Oral lomustine on day 1. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
45829097|NCT00003929|Drug|procarbazine hydrochloride|Oral procarbazine on days 1-10 and days 22-31. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
45829098|NCT00003929|Radiation|radiation therapy|Whole brain radiotherapy is administered daily for 28 days beginning 1-3 weeks following chemotherapy.
45829099|NCT02210507|Other|Biofortified cassava gari|Cassava, bred to contain high amounts of vitamin A-forming carotenoids (primarily beta-carotene and its cis-derivatives).
45829100|NCT02210507|Other|White cassava gari|Non-biofortified (white) cassava and a retinyl palmitate reference dose.
45829101|NCT02210507|Other|White cassava gari + red palm oil|Non-biofortified (white) cassava gari containing red palm oil.
45829102|NCT02210663|Drug|veliparib (ABT-888)|Subjects will be given veliparib twice daily on Days 1-28 every 28 days orally.
45829103|NCT04568525|Diagnostic Test|Passive Microwave Radiometry|The MWR2020 (ormer RTM-01-RES) device is a unique commercially available CE marked device. It is registered in UK MHRA MDN 40802 as Microwave thermography system for clinical studies. The device is already registered in Kyrgyzstan for breast cancer diagnostics. During the 1980-90s there were several works on identification of excess of microwave emission due to fluid in lungs (on phantoms) which could be indication of inflammatory, process, cancer and other lung disorders.Later results were confirmed by clinical studies for lung cancer
45972663|NCT04541563|Device|Fisher Wallace Cranial Electrotherapy Stimulator Device|Fisher Wallace Stimulator®, a patented cranial electrotherapy stimulation device that was cleared by the FDA in 1991 for the treatment of depression, anxiety and insomnia.
45670118|NCT04622241|Other|Eave Tubes|The eave tubes are PVC tubes with a diameter of 15 cm installed in the outer wall of occupied rooms (e.g. bedrooms and living rooms but not storage rooms) at 1.5-2 m intervals, fitted with electrostatic mesh inserts coated with insecticides. No additional screening will be done. All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
45972664|NCT02214706|Drug|Sirolimus|sirolimus (40 µl) will be applied under occlusion, using van der Bend patch-test chambers (size: 1cm2), and left in situ for 7 days.
45972665|NCT02214706|Other|Erbium yag laser|Er:Yag laser ablation of the stratum corneum
45972666|NCT02214706|Device|Pulsed Dye Laser|
45670119|NCT04622241|Other|Eave Ribbons|"Eave ribbons are 15 cm-wide triple-layered hessian fabrics (burlap-line fabric woven from sisal fibres, procured locally), in lengths starting 1 m that can be attached to houses using nails, adhesives or Velcro, without completely closing eave-spaces. The eave ribbons will be treated by study staff with a commonly used spatial repellent, transfluthrin. Eave ribbons will be retreated by study staff after 6 months (only in Phase II, if selected for inclusion in the cluster-randomised trial).~All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents."
45972667|NCT04541485|Drug|DWRX2003|Intramuscularly injection at pre-defined injection sites
45972668|NCT04541485|Drug|Placebo|Intramuscularly injection at pre-defined injection sites
45972669|NCT02214745|Other|Questionnaire|Questionnaire developed for this purpose by the investigators
45972670|NCT02214784|Device|Active Neurotech Vital|12 weeks treatment for 30 minutes per day, 5 days out of 7.
45972671|NCT02214784|Device|Modified Neurotech Vital Device|12 weeks treatment for 30 minutes per day for 5 days out of 7.
45972672|NCT02214862|Drug|[F18]-FDDNP|radiopharmaceutical tracer
45972673|NCT00236600|Drug|topiramate|
45972674|NCT00269295|Biological|Ty800|Live attenuated Ty800 S typhi oral vaccine is co-administered with a sodium bicarbonate buffer solution. Dosages: 5 X 10^7 cfu, 5 X 10^8 cfu, and 5 X 10^9 cfu.
45972675|NCT00269295|Drug|Placebo|150 mL of the prepared sodium bicarbonate buffer solution. Placebo will look and taste essentially like the study product.
45972676|NCT04541134|Drug|Pelubiprofen 45mg|Pelubiprofen 45mg 1 tab for moderate or severe menstrual pain, bid for 3days(prn)
45972677|NCT04541134|Drug|Placebo|Placebo1 tab for moderate or severe menstrual pain, bid for 3days(prn)
45972678|NCT00236639|Drug|topiramate|
45829104|NCT04568837|Drug|Prednisone 20 Mg|20 mg of Prednisone or 1 mL of 4 mg/mL Dexamethasone Sodium Phosphate will be administered each day for participants in the intervention group
45829105|NCT04568291|Other|model treatment|the treatment decisions were decided by Machine Learning （ML） model in model treatment group
45829106|NCT04568291|Other|routine treatment|the treatment decisions were decided by multi-disciplinary team （MDT）
45829107|NCT04569617|Other|Resistance Training - UL endurance protocol|UL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
45829108|NCT04569617|Other|Resistance Training - UL strength protocol|UL strength protocol - 2 series of 8 repetitions, elbow flexion at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
45829109|NCT04569617|Other|Resistance Training - LL endurance protocol|LL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test strength of 1 maximum repetition, (recovery 1 minutes between sets).
45972679|NCT04541368|Drug|CS1 Targeted CAR T-cells|Each subject receive CS1 Targeted CAR T-cells by intravenous infusion
45972680|NCT00261924|Device|Transfusion of Pathogen Inactivated Platelets stored for 6-7 days|pathogen inactivation of platelets for transfusion
45972681|NCT04545463|Dietary Supplement|FIBRACEP|A total intake of 7 g/day of FIBRACEP (provided in 6 cookies of 15 g/each) during two months
45972682|NCT04545463|Dietary Supplement|INSOLUBLE|A total intake of 7 g/day of wheat bran (provided in 6 cookies of 15 g/each) during two months
45972683|NCT04545463|Dietary Supplement|SOLUBLE|A total intake of 7 g/day of psyllium plantago (provided in 6 cookies of 15g/each) during two months
45972684|NCT04545697|Other|Medcorder|Medcorder is a smartphone app that is HIPAA compliant for the use of on patient recordings of consults with healthcare providers.
45972685|NCT02214901|Drug|BIBW 2948 BS for oral inhalation|
45972686|NCT02214901|Drug|Placebo|
45972687|NCT00236678|Drug|Epoetin alfa|
45972688|NCT00269334|Drug|Using Citalopram(drug) or Paroxetine(drug)|
45972689|NCT04541251|Drug|Camrelizumab + Nab-paclitaxel + Carboplatin|The patients will receive three cycles (one cycle is defined as every 21 days +/- 3 days) of neoadjuvant therapy with camrelizumab 200 mg, nab-paclitaxel 260 mg/m2, and carboplatin AUC 5. This will then be followed by surgery.
45972690|NCT04540783|Device|Transcranial direct current stimulation (tDCS)|10 sessions of 2mA and 20 minutes tDCS. Sponges size 5x7 cm. For the sham condition, the patient will receive just 30 seconds of stimulation.
45972691|NCT04545034|Other|water aerobic exercise|The EP would be formed by continuous session of dynamic water aerobic exercise which consisted of a dynamic warm-up period (5 minutes), an active exercise period at the established intensity of HR (35 minutes), and a cooldown period (5 minutes) to total 45 minutes, with a intensity of 75%HR.
45972692|NCT00236717|Drug|Topiramate; Carbamazepine; Valproate|
45972693|NCT00269373|Procedure|PET-CT|no drugs included
45972694|NCT04540549|Behavioral|exercise|Jogging or cycling ≥5 days/week, 30-60 min/d
45972695|NCT04545073|Device|PanOptix|Trifocal IOL with ORA in post refractive patients
45972696|NCT00236756|Drug|topiramate|
45972697|NCT04545307|Biological|Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis|The implant of BM-MSC/MSC-Endo/PRP in a clean and shaped root canal from patients with immature apexes and pulpal necroses and apical periodontitis
45972698|NCT00269412|Drug|Rifaximin|
45972699|NCT04545190|Dietary Supplement|Glucose|To investigate the effects of glucose intake during resistance training on muscle biological adaptations
45972700|NCT00236795|Drug|norelgestromin + ethinyl estradiol; triphasil.|
45972701|NCT04545268|Device|Neuromuscular electrical stimulation (NMES)|"NMES will carried out with four-channel myostimulator Beurer EM80 (Germany). Self-adhesive electrodes locates above the quadriceps, the duration of the NMES session was 60 minutes, including 5-minute periods of heating and hitch. Throughout the series, rectangular pulses with a frequency of 45 Hz will modulate. As a result, tonic contraction of these muscles will induce for 12 seconds, followed by a pause of 5 seconds. The amplitude of electrical exposure will select separately for each of the four channels until good muscle contraction (visually or by palpation) without pain. Electrical stimulation will start from the second day after the admission to preoperative department and will carried out during the entire preoperative period (about 10 days)."
45670120|NCT04622241|Other|Full House Screening|"Full house screening includes screening eaves/ceilings, ventilation openings, and windows. Eaves/ceiling, air vents, and windows of eligible houses will be screened with wire mesh or other locally available screening materials. or ceilings, if eaves are closed and ventilation openings. We are also filling in any gaps in the walls. All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents."
45670121|NCT04622241|Other|Partial House Screening|Partial screening will include either screening of the eaves or installing a screened ceiling, where no ceiling is present. In traditional houses, a netting (either insecticide-impregnated or untreated) may be either fixed in multiple places in the rafters or by hanging from a single central point and attached to the walls. No other screening or filling of the gaps will be done in partially screened houses.All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
45829110|NCT04569617|Other|Resistance Training - LL strength protocol|LL strength protocol - 2 series of 8 repetitions, knee extension at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
45670122|NCT01957215|Drug|Indomethacin|Topical indomethacin
45670123|NCT01957215|Drug|Placebo|Placebo patch
45829111|NCT04567199|Other|Observational, retrospective|retrospective analysis of observed results, for both study groups.
45829112|NCT04567043|Behavioral|MORE+JITAI|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse. JITAI involves stress-triggered reminders to practice mindfulness skills.
45829113|NCT04567043|Behavioral|Supporive Psychotherapy|A supportive psychotherapy group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
45829114|NCT04569071|Device|Sinovation Laser Ablation System|In the present single arm study. All eligible subjects will undergo MgLiTT with the Sinovation Laser Ablation System.
45829115|NCT04568057|Device|NIR Transcranial phototherapy device|1068 nm NIR helmet
45829116|NCT04568057|Device|Placebo Transcranial Device|The placebo device looks like the active device.
45829117|NCT04568135|Other|survey|survey
45829118|NCT04567901|Other|Death|Mortality group
45829119|NCT04567901|Other|Survive|Survival group
45829120|NCT04566809|Other|FES+CBA|The experimental treatment was formerly composed by 20 sessions of FES for the hand in combination with a structured cognitive therapy
45670124|NCT02322749|Drug|selumetinib 75mg single dose|3 blue capsules of 25 mg given as a single dose
45670125|NCT02322749|Drug|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
45670126|NCT02322749|Drug|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
45670127|NCT01957137|Device|InterStim® (Device Programming)|
45670128|NCT01928433|Drug|Finafloxacin 800 mg i.v. once daily|Infused over 60 mins [i.v. pump]) for at least 3 days.
45829121|NCT04566809|Other|FES|The control treatment was formerly composed by 20 sessions of FES for the hand
45829122|NCT04569305|Procedure|Negative Pressure Wound Therapy|NPWT technique was applied to injured area of the foot and ankle after debridement and cleaning of the necrosed tissue and using Vacuum Assisted Closure (VAC) consisting of evacuation tube, vacuum pump, collecting canister and a multiporous polyurethane sponge. VAC dressings were changed every 72 hours.
45829123|NCT04569305|Procedure|Conventional treatment|In conventional treatment moist gauze dressings were applied and change of dressings were done daily.
45829124|NCT04567823|Dietary Supplement|Smoothie with microalgae|Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae
45829125|NCT04568447|Device|IMOOVE|Imoove® is a device dedicated to rehabilitation and fitness and has the capacity to increase muscle tenfold.
45829126|NCT04566107|Behavioral|mHealth intervention|The intervention promotes self-management and adherence to treatment regimens in patients with multimorbidity. This 8-week SM intervention uses mobile health (m-Health) technology for daily messages and reminders to promote self-monitoring activities. Bluetooth devices provided will depend on the participant's need for self-management; heart failure (scale), diabetes (glucometer), COPD (pulse oximeter) or hypertension (BP machine).
45972702|NCT04545268|Device|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same site, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
45972703|NCT04544644|Drug|AK104+anlotinib|AK 104 is given by intravenous infusion and anlotinib is given by oral.
45972704|NCT00261963|Device|ultraviolet light|
45972705|NCT04540627|Drug|Palivizumab|Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg or 15mg/kg, administered at a rate of 1mL/min
45972706|NCT04540627|Drug|Placebo|Sodium Chloride 0.9% Solution (Normal Saline), intravenous infusion, single dose of 0mg/Kg, administered at a rate of 1mL/min
45972707|NCT04540627|Other|RSV-A Memphis 37b virus|Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU)
45455912|NCT05483972|Behavioral|Whole Prediabetes Diet Intervention|Participants will be instructed by RDN on how to adhere to the diet intervention and will be provided menus and recipes. For the enrolled adults in the study, the goal is to maintain complete diet adherence during the two-week intervention. The focus for children/adolescents will be on encouragement and exposure of the diet by the index parent and any additional household parent/guardian/caregiver. Participants will receive groceries that are tailored specifically to the prescribed diet menus/recipes for each week. Foods will be distributed using either a grocery delivery service or via participant pick-up. Each household will receive enough groceries to feed a household of four-persons for each week of the intervention.
45455913|NCT05480761|Biological|Sucraid (sacrosidase) Oral Solution 8500 IU/mL|Sucraid is a pale yellow to colorless, clear solution of glycerol, water, and citric acid, with a pleasant, sweet taste. Each milliliter of Sucraid contains 8,500 IU of the enzyme sacrosidase, the active ingredient.
45670129|NCT01928433|Drug|Finafloxacin placebo i.v. once daily|Infused over 60 mins [i.v. pump]) for at least 3 days.
45829127|NCT04566107|Behavioral|mHealth Plus|The intervention promotes self-management and adherence to treatment regimens in patients with multimorbidity. This 8-week SM intervention uses tailored self-management strategies (action planning, goal setting, and individual identified support needs) and mobile health (m-Health) technology for virtual visits, daily messages, and self-monitoring activities. The investigators will test the additive impact of having the nurse practitioner/community health worker (NP/CHW) team with the m-health platform. The NP will evaluate physiological and psychosocial status while the CHW will assist in recognizing possible solutions to challenging social determinants of health by identifying community resources and guidance in overcoming barriers. Bluetooth devices provided will depend on the participant's need for self-management; heart failure (scale), diabetes (glucometer), COPD (pulse oximeter) or hypertension (BP machine). Participants will receive reminders through the platform.
45670130|NCT01928433|Drug|Finafloxacin 800 mg tablets once daily|Administered as four 200 mg tablets
45670131|NCT01928433|Drug|Finafloxacin placebo tablets once daily|Administered as four tablets
45829128|NCT04568915|Other|Dry Needling|TENS 10 minutes, Stretching, Strengthening(girdle),Neck Isometrics, DN
45829129|NCT04568915|Other|Maitland Mobilization|TENS 10 minutes, Stretching, Strengthening(girdle),Neck Isometrics, Maitland joint mobilization
45829130|NCT04569227|Drug|EC-18|2000 mg PO daily
45829131|NCT04569227|Drug|Placebo|PO daily
45829132|NCT02210819|Drug|Rivaroxaban (Xarelto, BAY59-7939)|"Cohort participants are classified as rivaroxaban patient, if the patient receives initial rivaroxaban VTE treatment. Dosing according to daily clinical routine"
45972708|NCT00236834|Drug|levofloxacin; imipenem/cilastitin|
45972709|NCT04540393|Biological|AZD1222|Participants will receive 2 doses of AZD1222; the first dose will be administered on Day 1 and the second dose on Day 29. Unit dose strength(s) > 0.7 × 1011 vp/mL. Dosage level(s) 5 ×1010 vp (nominal). Route of administration Intramuscular injection
45972710|NCT04544722|Behavioral|Jianfei Kangfu Cao|The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.
45972711|NCT04544722|Behavioral|lung rehabilitation training|The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.
45670132|NCT01928433|Drug|Ciprofloxacin 400 mg i.v. twice daily|Infused over approximately 60 mins [i.v. pump]) for at least 3 days
45670133|NCT01928433|Drug|Ciprofloxacin placebo i.v. twice daily|Infused over approximately 60 mins [i.v. pump]) for at least 3 days
45670134|NCT01928433|Drug|Ciprofloxacin 500 mg oral twice daily|Administered as two 250 mg capsules.
45670135|NCT01928433|Drug|Ciprofloxacin placebo oral twice daily|Administered as two capsules.
45670136|NCT02322281|Drug|Rociletinib|
45670137|NCT02322281|Drug|Pemetrexed or gemcitabine or paclitaxel or docetaxel|
45972712|NCT00236873|Drug|topiramate|
45972713|NCT04544566|Device|Test product A|one new adhesive material which is applied to the baseplate and the subjects peristomal skin
45972714|NCT04544566|Device|Test product B|one new adhesive material which is applied to the baseplate and the subjects peristomal skin
45972715|NCT04544566|Device|Comparator|Already CE- marked product as a comparator which is applied to the baseplate and the subjects peristomal skin
45972716|NCT00269490|Behavioral|Yoga Nidra|
45670138|NCT02322125|Device|ReWalk|Intensive training with the ReWalk to negotiate smooth ground, rough terrain indoors and outdoors, ascending and descending slopes and steps, in a home setting and in the community.
45972717|NCT04540510|Device|OPEP therapy|Oscillatory Positive Expiratory Pressure therapy
45972718|NCT04540510|Other|Standard care|Standard pneumonia care
45972719|NCT00236912|Drug|levofloxacin; metronidazole|
45972720|NCT00269529|Procedure|femoral nerve block|
45972721|NCT00269529|Procedure|knee infiltration and injection via catheter|
45972722|NCT04540471|Other|music|MT group receives additional music therapy
45972723|NCT04540471|Other|comprehensive in-patient education program|comprehensive in-patient education program
45972724|NCT04544605|Other|Individualized-Chinese herbal medicine|"I. Lung and spleen qi deficiency syndrome Clinical manifestations: shortness of breath, fatigue, fatigue, anorexia, nausea, fullness, weak stool, and uneasiness. The tongue is pale and greasy. Recommended prescription: French Pinellia 9g, Chenpi 10g, Codonopsis 15g, Sunburn Astragalus 30g, Stir-fried Atractylodes 10g, Poria 15g, Huoxiang 10g, Amomum villosum 6g (later), and Licorice 6g~II. Qi and Yin deficiency syndrome Clinical manifestations: fatigue, shortness of breath, dry mouth, thirst, palpitations, sweating, poor appetite, low or no lever, dry cough and little sputum; dry tongue, fine or weak pulses. Recommended prescription: North and south radix salviae 10g, 15g ophiopogonis, 6g American ginseng, 6g schisandra, 6g gypsum l5g, 10g light bamboo leaves, 10g mulberry leaves, 15g reed root, 15g salviae miltiorrhiza, 6g raw liquorice."
45455914|NCT05467059|Other|Napping|Patients are already equipped with electrodes when they pass a test battery before the nap to evaluate mechanisms potentially correlated with tinnitus modulation. Then they do a nap, the nap is stopped when several periods of sleep are seen on EEG (electroencephalogram). Then the test battery is done backwards to evaluate the same measures.
45829133|NCT02210819|Drug|Recommended VTE pharmacological treatments according to international guidelines|"Cohort participants are classified as Standard of care patients, if the patient receives recommended VTE pharmacological treatments according to international guidelines, e.g. unfractionated heparin, LMWH, fondaparinux, VKA, if these are also approved pharmacological treatments for VTE in the respective country. Dosing according to daily clinical routine."
45829134|NCT04564469|Drug|Furosemide|A number of different protocols exist in terms of the timing of furosemide injection, (F+0) protocol in which furosemide is injected at the same time of radiotracer administration &( F - 15)protocol in which furosemide is administered 15 min before tracer administration
45972725|NCT04540237|Diagnostic Test|Flow-cytometric analysis|Flow-cytometric analysis of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33
45972726|NCT02215447|Drug|NAB paclitaxel|100 mg/m2 i.v. every week (d1,8,15) in three weekly cycle Number of Cycles: until progression or unacceptable toxicity develops.
45972727|NCT02215447|Drug|Carboplatin|
45972728|NCT00236990|Drug|pentosan polysulfate sodium|
45455915|NCT05466942|Device|Pulse Oximeter, Respiratory Rate, Heart Rate|Measurement of physiological parameters
45455916|NCT05461755|Combination Product|Fractional radiofrequency and topical Tretinoin|Treatment of striae with fractional radiofrequency and topical tretinoin in combination
45455917|NCT05461755|Drug|Topical Tretinoin|Treatment of striae with topical tretinoin alone
45455918|NCT05461755|Device|Fractional radiofrequency|Treatment of striae with fractional radiofrequency alone
45670139|NCT02243293|Drug|ABT-493|Tablet
45670140|NCT02243293|Drug|ABT-530|Tablet
45670141|NCT02243293|Drug|ribavirin (RBV)|Tablet
45829135|NCT04565639|Device|Powered Hand Orthosis|A prototype powered hand orthosis system designed to improve grip strength and improve ability to perform tasks of daily living.
45829136|NCT04564235|Genetic|genome-wide analyses|genome-wide analyses will be done in patients and parents (father, mother)
45829137|NCT04564235|Genetic|Search for de novo mutations in paternal sperm samples|Sperm analysis will be done in paternal samples
45670142|NCT02243293|Drug|ABT-493/ABT-530|Tablet; ABT-493 co-formulated ABT-530
45829138|NCT04564001|Drug|Infliximab|Patients will receive infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 in arm A
45829139|NCT04564001|Drug|Tocilizumab|Patients will receive tocilizumab 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 in arm B
45829140|NCT04565873|Diagnostic Test|TSH|retrospective TSH level
45670143|NCT02322047|Drug|Prazosin|Prazosin Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
45670144|NCT02322047|Drug|Naltrexone|Naltrexone Dosing Days 1-42: 50mg @ 9PM
45670145|NCT02322047|Drug|Placebo (Prazosin)|Placebo Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
45670146|NCT02322047|Drug|Placebo (Naltrexone)|Placebo Dosing Days 1-42: 50mg @ 9PM
45829141|NCT04565561|Device|Neovas BRS or DCB|"All STEMI patients were predilated (including predilated balloon or cutting balloon) before randomization. Thrombus aspiration was determined by the surgeon according to the specific situation.~Sufficient predilation criteria: the following two conditions must be met: A. residual stenosis < 30%; B. no flow limiting dissection or TIMI grade 2-3."
45829142|NCT04565405|Other|Detergent|The tracheostomy inner cannulas will be washed with detergent.
45829143|NCT04565405|Other|Sterile water|The tracheostomy inner cannulas will be washed with sterile water.
45972729|NCT02215486|Other|Head Massage Therapy|Intervention consists of administering head massage therapy according to the Chinese head massage protocol for approximately 10 minutes.
45972730|NCT02215486|Other|Simple relaxation (No Head Massage)|Consists of a simple relaxation in the same sitting position as the head massage therapy session.
45972731|NCT04540276|Drug|Inspiratory oxygen fraction|Median inspiratory oxygen fraction during general anesthesia
45972732|NCT04544371|Device|gastric ultrasound|Focused gastric ultrasound was performed in semi-sitting position then right lateral position mindray curved transducer for examination of abdomen with low frequency (2-5 MHz) by a trained physician. The antrum of the stomach was located in the epigastrium after a sweep of the probe from left to right subcostal margins. This could be done using left lobe of liver as an anterior landmark and descending abdominal aorta as a posterior landmark
46081685|NCT03587142|Drug|Placebo|"Sugar pill manufactured to mimic buspirone 10 mg tablet"
45829144|NCT04565093|Procedure|iPACK|"Interspace between the popliteal artery and the capsule of the posterior knee (iPACK):~This is basically ultrasound guided peripheral nerve block performed by the anesthesiologists at the posterior side of the knee to control pain after TKA."
45829145|NCT04565093|Procedure|Periarticular local infiltration analgesia (LIA)|A mixture of Bupivacaine 0.25% 20 ml + epinephrine 100 mics ± lornoxicam 8 mg ± morphine 10 mg ± tranexamic acid 1 gm in 40 ml normal saline (NS) will be injected into the posterior capsule and the medial and lateral ligaments just before implantation: after insertion of the implants and into the capsule and retinacular tissues. The remaining solution (approximately 20 mL) will be used to infiltrate the muscle and subcutaneous tissues. This intervention is commonly performed by the operating orthopedic surgeon to control pain after TKA.
45455919|NCT05461456|Drug|Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)|"Intervention:~The amount of study lotion (OP2101) used is 11 grams per subject, equivalent to 22 fingertip units (FTU). The lotion is applied to the subject on back and front of the trunk, both hands (palm and back) and both arms. An SOP for handling and application of the lotion ensures the 11 grams covers 54% of the body surface area (BSA) evenly without residue.~Comment:~The treatment is single-dose and single-treatment. The FTU is used to standardize the amount of cream being applied in clinical research. It is also used in clinical practice and hence connects the objectiveness of the trial to the clinical situation."
46081686|NCT03576924|Behavioral|MICT|Individuals randomized to MICT will be asked to engage in only MICT 5 times/week for 30 min/session at 60-70% of heart rate max, consistent with physical activity guidelines of 150 min/week of moderate activity. Individuals are asked to engage in only MICT exercise during the 4-week supervised and unsupervised exercise sessions. During the supervised exercise the intensity will be based on the heart rate (HR) monitors and psychophysiological responses of perceived exertion. The exercise training is paired with 30-50 minutes of behavioral counselling that is identical for all three interventions.
45455920|NCT05460650|Behavioral|App Promoting Healthy Behaviours|Women on the study will receive two months access to the app.
45670147|NCT02254291|Drug|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks). Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
45670148|NCT02254291|Drug|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks) followed by 0.5 mg for 4 weeks. Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
45670149|NCT02254291|Drug|sitagliptin|Daily doses of 100 mg sitagliptin. Total duration of treatment is 30 weeks. Administered as oral tablets.
45829146|NCT04564937|Drug|SCT510A|SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT
45972733|NCT04544371|Procedure|nasogastric tube insertion|Nasogastric tube (18-french) was inserted after induction of anaesthesia and endotracheal intubation. Aspiration of gastric contents was performed through gentle suction using 50 ml syringe with synchronous epigastric massage and gentle movement of nasogastric tube in and out for 10 minutes after confirmation of nasogastric tube position.
45972734|NCT00237068|Drug|Lansoprazole; Solutab|15 and 30 mg doses of dissolvable tablet, 2 tablets daily for one year
45972735|NCT04539925|Other|Acute coronary syndrome|The effect of air pollution on acute coronary syndrome
45972736|NCT00269568|Drug|mifepristone and misoprostol|
45972737|NCT02215603|Behavioral|Breaking prolonged sitting with physical activity|
45972738|NCT04544215|Biological|Dosage 1 of MPCs-derived exosomes|7 times aerosol inhalation of MPCs-derived exosomes (8.0*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
45972739|NCT04544215|Biological|Dosage 2 of MPCs-derived exosomes|7 times aerosol inhalation of MPCs-derived exosomes (16.0*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
45972740|NCT04544215|Biological|No MPCs-derived exosomes|No aerosol inhalation of MPCs-derived exosomes
45972741|NCT04540081|Other|Epic Healthy Planet Population Health Module|Electronic population health module which is tailored to increased adherence to USPSTF and CDC recommendations
45972742|NCT00237107|Procedure|Curretage|
45972743|NCT00262197|Behavioral|Customized Physician Intervention|
45972744|NCT00262197|Behavioral|Customized Patient Intervention|
45972745|NCT02215681|Device|acupuncture|
45972746|NCT00237146|Drug|Zoledronic acid|
45972747|NCT04544137|Behavioral|BOKS|BOKS is an evidence-based physical activity program developed by Reebok to get kids active and establish a lifelong commitment to health and fitness. It was originally developed and tested as a 12-week program offered before or after school. In the present study, BOKS will be offered four days per week for eight weeks over the summer at a public park in one low-income community. The program will run one-hour prior to lunch service by the USDA's Summer Food Service Program. The BOKS curriculum includes lesson plans for 40-45 minute classes that follow the same daily format and focus on a functional fitness skill of the week (squat, plank, push up, etc) and engage participants in team-oriented games.
45972748|NCT04544059|Drug|Lenalidomide|Lenalidomide orally 25 mg per day was administered on days 1 through 10 of each cycle and delivered concomitantly with standard dose R-CHOP-21 regimen (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2 or Liposome doxorubicin 30mg/m2, vincristine 1.4 mg/m2 [capped at 2.0 mg], all on day 1; prednisone 100 mg per day on days 1 through 5). All patients received aspirin 100mg per day prophylaxis throughout, unless they were on therapeutic dose warfarin or low molecular weight heparin for intercurrent conditions. The treatment continued for a maximum of six to eight cycles or until disease progression. Tumor lysis prophylaxis, antiemetics, and supportive care were standard of care.
45972749|NCT00269607|Drug|Implantation of naltrexone implants|
45972750|NCT04544176|Other|Observational|There will be no interventions in this study, it is purely observational using data already collected.
45455921|NCT05459779|Device|Electric wheelchair with activated assistance module|This evaluation will be carried out in 1 standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 with activated assistance.
45829147|NCT04568603|Drug|Islatravir|ISL 30 mg x 2 (60 mg total) capsules taken by mouth.
45829148|NCT04568603|Drug|Methadone|Methadone 20 to 200 mg QD taken by mouth.
45829149|NCT04563689|Other|CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)|rinse 15 ml during 1 min during 5 days, twice daily
45829150|NCT04563689|Other|placebo rinse|destilled water rinse 15 ml during 1 min during 5 days, twice daily
45829151|NCT04563221|Device|Prostatic artery embolization|Prostatic artery embolization is performed using LC Bead LUMI, which is the investigational device. The particles are administered to the prostatic arteries using either a balloon occlusion or standard microcatheter. Follow-up is performed at 1 month, 6 months, 12 months, and 24 months after intervention.
45829152|NCT04564859|Device|Heated Humidified High-Flow Nasal Cannula|Participants using of invasive ventilator more than 14 days, maybe considered transferred to the Respiratory Care Center(RCC), participants enrolled to this study and also written informed consent from participants or their family; After extubation, the difficult weaning patients were allocated to two treatment groups, and randomly assigned to Heated Humidified High-Flow Nasal Cannula or Noninvasive Ventilation devices.
45829153|NCT04562051|Other|prophylaxis regimen|All recipients were divided into two groups: stratified prophylaxis group based on donors' and recipients' characteristics and routine prophylaxis group based on clinical experience
45829154|NCT04563767|Procedure|Infinitome|Added sequence of rs-fMRI.
45972751|NCT04539769|Procedure|conventional BI|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with conventional Billroth I gastroduodenostomy.
45972752|NCT04539769|Procedure|long-limb BII|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Billroth II gastrojejunostomy using 100 cm-long biliopancreatic limb.
45972753|NCT04539769|Procedure|long-limb RY group|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and standard biliopancreatic limb.
45972754|NCT00237224|Drug|Letrozole|
45972755|NCT04543747|Device|HeartWare Ventricular Assist Device|The Medtronic HVAD® System is comprised of three major components: the HVAD Pump with inflow and outflow conduits, a Controller and power sources. In addition to these components, the system includes a Monitor, Battery Charger, AC and DC power adapters, and a Carrying Case. The HVAD® System is indicated for hemodynamic support in patients with advanced, refractory left ventricular heart failure; either as a bridge to cardiac transplantation (BTT), myocardial recovery, or as destination therapy (DT) in patients for whom subsequent transplantation is not planned.
45972756|NCT04539847|Device|High-end hearing aid|hearing aid with premium level of technology
45972757|NCT04539847|Device|Basic hearing aid|hearing aid with basic level of technology
45972758|NCT00262236|Drug|Aliskiren|
45972759|NCT04539886|Device|CellFX System|CellFX System consists of a console combined with a handpiece and coupled with a sterile single patient-use treatment tip (1.5 x 1.5mm, 2.5 x 2.5mm, and 5.0 x 5.0mm)
45972760|NCT04539886|Device|Intralesional Electrodesiccation|Hyfrecator electrosurgical unit with a non-insulated needle-shaped electrode
45972761|NCT04543981|Diagnostic Test|Diagnostic Criteria for Tempro-mandibular Disorders(DC/TMD)|diagnostic sheet include questions to be answered by the patients and others include examinations will be done by the investigator
45972762|NCT00237263|Drug|Entacapone|
45972763|NCT04543864|Device|Electric intraoral welding device|welding metal framework to the implants in completely edentulous maxilla by electric welding device intraorally
45972764|NCT04543864|Device|casting|casting the metal framework
45972765|NCT04539613|Drug|HPFSH & HMG|. Various gonadotropin preparations
45670150|NCT04191811|Behavioral|Internet-delivered cognitive behavioral therapy for major depressive disorder|Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.
45972766|NCT00269646|Behavioral|Low-carbohydrate and high-carbohydrate diets|Each subject will consume two different ad libitum diets, each for four weeks, with a 4-week washout period inbetween each diet.
45972767|NCT04543669|Biological|Adacel®|Vaccine for TdaP-Tetanus, diphtheria, acellular pertussis
45972768|NCT00237302|Drug|topiramate|
45972769|NCT04539691|Device|Magnet|Magnet or Sham is worn by subject in close proximity to their described maximum pain site
45972770|NCT02214940|Drug|BI 11634|
45972771|NCT02214940|Drug|Placebo|
45972772|NCT00262275|Drug|Aspirin, Clopidogrel|
45972773|NCT04539652|Drug|Experimental|Experimental group are treated with TenofoBell®
45972774|NCT02214979|Drug|Telmisartan/Ramipril|fixed dose combination tablet
45972775|NCT02214979|Drug|Telmisartan|
45972776|NCT02214979|Drug|Ramipril capsule|
45972777|NCT02214979|Drug|Ramipril tablet|
45670151|NCT04191811|Behavioral|Internet-delivered cognitive behavioral therapy for insomnia|Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.
45670152|NCT04191811|Behavioral|Internet-delivered cognitive behavioral therapy for social anxiety disorder|Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.
45972778|NCT00237341|Drug|fentanyl|
45972779|NCT04539496|Drug|XZP-3287|a small molecular, oral potent, selective CDK4/6 inhibitor
45972780|NCT04539301|Diagnostic Test|Estimated anticoagulant level (conversion factor x anti-Xa activity)|Estimated anticoagulant level (conversion factor x anti-Xa activity)
45972781|NCT04539535|Other|General Movements Assessment on two different surfaces in infants with DS and typically infants on the same day|Different surface
45972782|NCT00237380|Drug|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
45972783|NCT04543708|Procedure|Incision drainage|"Oropharyngeal pre-anesthesia is performed with 10% xylocaine spray, then submucosal anesthesia of the anterior pillar of the tonsil is performed with 2 ml of Rapidocaine or Rapidocaine 1 or 2% adrenaline. A scalpel incision is made with the search for the abscess pocket with a crile. If pus is present, a NaCl / Betadine rinse is performed. A syringe puncture can help locate the abscess if needed. The duration is approximately 15 minutes.~If no purulent pouch is found, the procedure is completed with tonsillectomy under general anesthesia."
45972784|NCT04543708|Procedure|Tonsillectomy|Under general anesthesia, in dorsal decubitus, an autostatic mouth opener is placed, an incision of the anterior pillar of the tonsil allows the opening of the capsular space, along which the entire tonsil is dissected until complete extraction, hemostasis is performed, then the patient is awakened. The duration is approximately 30 minutes.
45972785|NCT00262353|Device|Dialysis with different artificial devices|
45972786|NCT04539145|Device|Chocolate PTA Balloon|Chocolate PTA Balloon
45972787|NCT04539145|Device|conventional balloon angioplasty|conventional bal-loon angioplasty
45972788|NCT04543318|Procedure|Deep temporal nerves|"Surgical procedure:~Group A Exploration on the affected side a facelift-type incision will be performed, and an anterior subcutaneous flap is then will be lifted for several centimetres. In the inferior zygomatic region, the plane of elevation is deepened into the sub-SMAS plane and a composite flap elevated for several centimetres. Following elevation in this plane, the distal facial nerve branches will be identified. The distal portion of the zygomatic nerve is usually located midway between the oral commissure and the helical root. and was confirmed by nerve stimulator.~The deep temporal fascia and temporalis muscle will be incised along the temporal fusion line and will be reflected from the skull to expose the divisions of the deep temporal nerves and the longest branch was traced and prepared for anastomosis end to end with the zygomatic branch after confirming the eyelid supply."
45972789|NCT04543318|Procedure|massteric nerve|group B The same procedure as group A except tracing the masseteric nerve related to masseter muscle and anastomosis will be the same
45972790|NCT00237419|Drug|infliximab|Infliximab infusions 5 mg/kg body-weight each 6 to 8 weeks
45972791|NCT04539340|Biological|GNR-055|Single intravenous administration
45972792|NCT04539106|Drug|intravitreal injection of Ranibizumab|intravitreal injection of 0.25 mg/0.025 ml ranibizumab with a 30-gauge needle 1.5mm from limbus
45972793|NCT04543552|Device|Bladder scan|Bladder Scanner, or Biocon-900 is an ultrasonic imaging device that has been developed to measure post-void residual volume of the bladder non-invasively. The images and measurements are obtained by applying a probe onto the abdomen (i.e. bladder). As it scans, the scanner constructs 12 cross-sectional images at 15 degree interval using the reflection signals from urine in the bladder and extracts the position of the bladder wall as well. During urodynamic studies, the bladder scan will measure the infused volume in order to assess difference between the infused and scanned volumes.
45972794|NCT04543474|Other|Low Lactose Diet|First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
45972795|NCT04543474|Other|Low FODMAP Diet|First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
45972796|NCT00237497|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 28 nights.
45455922|NCT05459779|Device|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 1 standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 without activating assistance.
45829155|NCT04563299|Drug|Dextenza 0.4Mg Ophthalmic Insert|All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive a sham dilation.
45972797|NCT00237497|Drug|Zopiclone|Zopiclone 7.5 mg, tablets, orally, once daily for up to 28 nights.
45972798|NCT00237497|Drug|Placebo|Placebo-matching tablets, orally, once daily for up to 28 nights.
45972799|NCT00416130|Drug|Vorinostat|MK-0683 capsules, 100 mg, 400mg once a day, continuously (at dose level 0 - Phase 1 part of the study)
45972800|NCT04538716|Procedure|transconjunctival lower blepharoplasty|transconjunctival lower blepharoplasty associated with stromal vascular fraction gel (SVF-gel)
45972801|NCT04539028|Procedure|Emergency Abdominal surgery|Emergency Abdominal surgery
45972802|NCT04543084|Behavioral|Logbook|Participants will record practice in a logbook.
46081687|NCT03576924|Behavioral|HIIT|Individuals randomized to HIIT will be asked to engage in only HIIT 5 times/week for 4 weeks. HIIT consists of 5 repeated vigorous intervals of 1-min duration at 80-90% of heart rate max interspersed with 1-min recovery periods. A 3-min warm-up and 2-min cool-down are also included, for a total session duration of 15 minutes. This matches the guidelines of 75 min of vigorous exercise per week. During the supervised exercise sessions, intensity will be based on HR monitors and psychophysiological responses of perceived exertion. The exercise training is paired with 30-50 minutes of behavioral counselling that is identical for all three interventions.
45829156|NCT04563299|Drug|Prednisolone Acetate|All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).
45829157|NCT04561895|Genetic|DNA extraction|investigation of DNA polymorphism in patients suffering from NAFLD
45972803|NCT00416169|Drug|galantamine hydrobromide|
45972804|NCT00237536|Drug|Lonidamine|
45972805|NCT04543240|Device|Integra™ dermal regeneration template|Integra a biologic dressing for deep wounds or large soft tissue defects that penetrate to the level of bone
45972806|NCT02215720|Drug|Cetuximab|
45972807|NCT02215720|Drug|Temsirolimus|
45972808|NCT02215759|Drug|BI 44370 TA|
45972809|NCT02215759|Drug|Placebo|
45972810|NCT00416208|Drug|Bortezomib|1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
45972811|NCT02215798|Drug|Cymbalta|
45972812|NCT02215018|Drug|BI 44370 TA solution|
45972813|NCT02215018|Drug|BI 44370 TA tablet|
45972814|NCT02215018|Drug|Placebo solution|
45972815|NCT02215018|Drug|Placebo tablet|
45972816|NCT02215837|Drug|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
45972817|NCT02215837|Biological|Ag-D-CIK|8×10^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
45972818|NCT02215057|Drug|topical anesthesia|topical anesthetic drops and Group 2
45972819|NCT02215057|Drug|topical anesthesia plus intracameral lidocaine 1%|received topical anesthesia plus intracameral lidocaine 1%
45972820|NCT00269685|Drug|vasopressin|
45972821|NCT04710095|Behavioral|Brief Alcohol Intervention|Brief alcohol intervention uses a motivational interviewing approach and covers the following components: giving information about the possible health risks associated with alcohol use, placing the responsibility for change on the individual, discussing the reasons for drinking and downsides of drinking, and setting a goal and change plan if the participant is receptive.
45972822|NCT04710095|Behavioral|Control Condition|The attention-matched control condition consisting of a 30-min video about astronomy.
45972823|NCT02215135|Drug|Corifollitropin alfa|In GnRH antagonist protocol, ovarian stimulation with single dose of 100μg (BW≦60 kg) or 150μg (BW> 60 kg) corifollitropin alfa (Elonva, SC), followed 1 week later (stimulation day 8) by a daily dose of rFSH to the day of GnRH agonist triggering final oocyte maturation.
45972824|NCT04543123|Device|tDCS treatment|Participants visited the hospital four times (biweekly for two weeks). During their second visit, a research nurse instructed each participant on use of home-based tDCS equipment (YDS-301N; Ybrain Inc., Seongnam-si, Korea) and all participants thereafter conducted tDCS treatment at home once a day for 30 minutes (five times per week).
45972825|NCT04543123|Drug|Antidepressant Drug(escitalopram)|Participants in both active and sham groups were prescribed escitalopram in combination with tDCS treatment.
45972826|NCT04539418|Drug|Vitamin K 2|Patients will be monitored during the whole protocol.
45972827|NCT00269724|Drug|OROS® oxybutynin|
45972828|NCT04538638|Procedure|Mesenteric sparing ileocolic resection|Mesentery left in situ
45972829|NCT04538638|Procedure|Central mesenterectomy ileocolic resection|Mesentery is taken up to the level of the ileocolic trunk
45455923|NCT05458141|Behavioral|FYA-003|FYA-003: It is a gamified health education module for children aimed at promoting healthy nutrition, physical activity, health hygiene, and infectious diseases risk reduction within the clinically proven app fooya!
45972830|NCT04542928|Behavioral|nurse facilitated face care group|The experimental group is required to receive a nurse leading 50- minute face care group every two week
45972831|NCT04543006|Diagnostic Test|serology|blood sample of 10 ml twice (6 and 12 months after the Covid-19)
45972832|NCT04710017|Drug|Tranexamic acid|will be given Tranexamic acid at 500 mg four times daily (2 g/day) during the bleeding episodes for 5 days. The dose is 250 mg.
45972833|NCT04710017|Drug|Medroxyprogesterone Acetate 150 MG/ML|will be given MPA at 150 mg once intramuscular injection
45972834|NCT04538521|Dietary Supplement|Niacin|The dose for a slow-released form of niacin will be 500-1000 mg/day. The daily niacin dose, 250 mg/day, is gradually escalated by 250 mg/month so that the full dose is reached after 2 months. The intervention time with the full niacin dose is 8 months and subsequently total intervention time 10 months.
45972835|NCT00269763|Drug|Fentanyl Transdermal Therapeutic System (TTS)|
45972836|NCT04543630|Procedure|Sinus floor augmentation|Sinus floor augmentaion using the lateral window technique
45972837|NCT04542967|Biological|Biological|"An administration unit of 200 ml convalescent plasma intravenous infusion every 24 hours for two doses.~If a third dose of convalescent plasma is necessary, it may be used, as long as an evaluation of the research team is carried out."
45972838|NCT00237575|Drug|gemcitabine|
45972839|NCT00237575|Drug|cisplatin|
45972840|NCT00237575|Drug|sargramostim|
45972841|NCT00237575|Drug|filgrastim|
45972842|NCT04542811|Other|Acupuncture|Acupuncture is a complementary therapy modality which is used by needle inserted the specific points on the body.
45972843|NCT00269802|Drug|OROS methylphenidate HCl|
45972844|NCT00269802|Drug|Ritalin|
45972845|NCT00269802|Drug|Placebo|
45972846|NCT02215174|Drug|Rosuvastatin|Rosuvastatin 20mg po x1
45972847|NCT00237614|Drug|intravenous and oral N-acetylcysteine|
45972848|NCT04538326|Behavioral|Exercise|Participants performed stepping movements that were either cued by the investigator or interacted with a video game. There were three video game exercises that all involved stepping in either a repeated or a random pattern that was either self-paced or game paced.
45972849|NCT00269841|Drug|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
45972850|NCT00269841|Drug|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
45972851|NCT00269841|Drug|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
45972852|NCT04538443|Other|functional capacity|impact of hemodialysis on functional capacity in children with CKD
45972853|NCT04538443|Other|muscle strength|impact of hemodialysis on muscle strength in children with CKD
45829158|NCT04561583|Device|LED light source system for endoscope|"This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period."
45972854|NCT04538443|Other|Quality of life of children|impact of hemodialysis on Quality of life in children with CKD
45972855|NCT04538443|Other|Quality of life of families|impact of hemodialysis on Quality of life of families of children with CKD
45972856|NCT04538404|Procedure|Colon Surgery|Right, left colon surgery, transverse colon surgery, multiple colon surgery in open and minimally invasive surgert
45972857|NCT04538872|Behavioral|StraDiMS implicit|participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up. Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task. The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task. The latter group will get more knowledge on the task than the former.
45972858|NCT04538872|Behavioral|StraDiMs explicit|participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up. Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task. The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task. The latter group will get more knowledge on the task than the former.
45670153|NCT02253433|Other|Enhanced Clinic Care|The intervention includes a standard clinical appointment including spirometry, as well as collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies, and a customized asthma self-management plan developed using motivational interviewing.
45670154|NCT02253433|Other|Enhanced Clinic Care + Home Intervention|The home-based component includes environmental exposure assessment (observed and measured) and a multicomponent exposure reduction and asthma control intervention (five home visits over approximately 12 months).
45670155|NCT04784143|Drug|MDMA|3,4-methylenedioxymethamphetamine
45670156|NCT04784143|Behavioral|Psychotherapy|Standardized non-directive psychotherapy performed by therapist team
45670157|NCT02242981|Drug|LY2623091|Administered orally
45670158|NCT02277743|Drug|Dupilumab|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
45829159|NCT04561583|Device|Pinpoint Endoscopic Fluorescence Imaging System|"This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period."
45972859|NCT00414128|Drug|mycophenolate mofetil|2-3g/day for 3-6 months, in tablet, capsule or liquid form
45670159|NCT02277743|Drug|Placebo (for Dupilumab)|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
45972860|NCT00414128|Drug|cyclophosphamide|intravenous cyclophosphamide, 15mg/kg with dose reductions according to age and renal function, for 3-6 months (6-10 doses total)
45972861|NCT04538677|Device|Video consultation|A two-way audio and visual connection between patients and surgeons
45972862|NCT04538365|Drug|Triclosan 0.5 % Topical Solution|Hand antisepsis by scrub Surgical Hand scrubbing using triclosan 0.5% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
45972863|NCT04538365|Drug|propanolol|Hand antisepsis by scrub Surgical Hand scrubbing using Propanolol 60% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
45972864|NCT00414245|Drug|metformin|
45972865|NCT04542772|Other|Mirror Therapy|Participants will receive the standard-of-care; multidisciplinary rehabilitation intervention based on their needs and tolerance, and will receive an additional 30 min of Mirror Therapy education. During Mirror Therapy education, the patients will be educated or shown how to perform MT and the patients will complete the recommended exercises on their own for 30 minutes/day for 5 days a week/ for 4 weeks. Standard Mirror Therapy Protocol will be followed.
45670160|NCT02242903|Drug|LY3079514|Administered SC
45670161|NCT02242903|Drug|LY3079514|Administered IV
45670162|NCT02242903|Drug|Placebo|Administered SC
45670163|NCT02242903|Drug|Placebo|Administered IV
45670164|NCT02320721|Drug|Insulin Glargine (HOE901 - U300)|Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
45670165|NCT02320721|Drug|Insulin Glargine (HOE901 - U100)|Self-administered by SC injection in the evening using a pre-filled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
45972866|NCT04542772|Other|Regular Rehabilitation|Participants will receive the standard-of-care, multidisciplinary rehabilitation intervention based on their needs and tolerance.
45972867|NCT00269880|Drug|Placebo|Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.
45972868|NCT00269880|Drug|Heparin|Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.
45972869|NCT00269880|Drug|Abciximab|Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.
45972870|NCT04542655|Other|Ergometer Cycling followed by treadmill running|The participants undergo ergometer cycling, treadmill running and rest.
45670166|NCT02320721|Drug|Background therapy|Non-insulin anti-diabetic drugs with the exception of thiazolidinediones.
45670167|NCT02320487|Drug|Bendamustine|Bendamustine was administered as an intravenous infusion at a dose of 90 milligrams per square meter (mg/m^2) on Days 2 and 3 Cycle 1; and on Days 1 and 2 Cycles 2-6.
45670168|NCT02320487|Drug|Obinutuzumab|Obinutuzumab was administered as an intravenous infusion at a dose of 100 milligrams (mg) on Day 1 Cycle 1; at a dose of 900 mg on Day 2 Cycle 1; at a dose of 1000 mg on Days 8 and 15 Cycle 1, and Day 1 Cycles 2-6.
45670169|NCT04197479|Drug|Placebo|Matching tablets
45829160|NCT04561505|Procedure|Holmium laser enucleation of prostate|surgical management of BPH by Holmium laser enucleation using 0.9% saline fluid for irrigation
45829161|NCT04561505|Procedure|monopolar transurethral resection of prostate|surgical management of BPH by monopolar TURP using distilled water for irrigation
45829162|NCT04561817|Drug|Ipatasertib|400mg PO daily: day 1-21 of 28 day cycle
45829163|NCT04561817|Drug|Paclitaxel|80 mg/m2 IV weekly: day 1, 8, 15 of 28 day cycle
45829164|NCT04561349|Other|Task oriented training|Task oriented training consisted of different functional tasks for lower limbs to improve balance and walk. Each task was given 5 minutes Tasks were progressed according to each child's performance. These progressions included increase of repetitions, speed and switching between the tasks. One hour practice of these tasks was advised for home plan
45829165|NCT04561349|Other|Conventional rehabilitation treatment|"Conventional rehabilitation treatment includes mat activities and ROM of all limbs, Lower limb strengthening and stretching, walking, cycling.~Each exercise was performed for 5 minutes. One hour practice of above exercises and thermotherapy for the spastic muscles advised for 10 minutes once a day at home was advised."
45829166|NCT04561271|Other|foot reflexology|Patients will receive one session of foot reflexology with a nurse who received a specific formation. The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. A neutral oil will be used. The technique associates specific movements of foot reflexology. The session is accompanied by relaxing music.
45829167|NCT04561271|Other|toucher massage|one session of toucher massage with a nurse (this technique is taught during the formation of every nurse in palliative care units). The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. It consists in a simple massage and effleurage, with fluid and progressive movements. Almond oil will be used. The session is accompanied by relaxing music.
45829168|NCT02211833|Drug|BI 2536|
45829169|NCT02211833|Drug|Pemetrexed|
45670170|NCT04197479|Drug|Resmetirom|Tablet
45670171|NCT04884659|Other|Time restricted feeding arm|80% of calories consumed before 2PM, remaining 20% consumed by 4PM. Fasting for 14-16 hours
45670172|NCT04884659|Other|usual feeding pattern arm|All meals consumed ad lib with 50% of calories consumed after 4PM
45670173|NCT02277119|Device|Maestro|OCT machines used for diagnostic purposes
45670174|NCT02277119|Device|iVue|OCT machines used for diagnostic purposes
45670175|NCT02320253|Behavioral|In Person Group (IP)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via in-person groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success.
45972871|NCT04542655|Other|Treadmill Running followed by ergometer cycling|The participants undergo treadmill running, ergometer cycling and rest.
45972872|NCT04542655|Other|Rest|The participants undergo ergometer cycling, treadmill running and rest.
45972873|NCT04542538|Other|No intervention, observational study|
45972874|NCT04539067|Drug|HHMG|Induction of ovulation from the 2nd day of cycle to 5th day then follow the diameter of follicle Use transvaginal ultrasound When diameter of follicle 18 to 22 patients receiving HMG
45972875|NCT00237653|Drug|Valganciclovir|
45972876|NCT00269958|Drug|epoetin alfa|
45972877|NCT04538248|Other|Combined rehabilitation during hemodialysis|Combined rehabilitation during hemodialysis
45972878|NCT04538014|Drug|Lu AF88434|Oral solution
45972879|NCT04538014|Drug|[11C]-Lu AF88434|[11C]-Lu AF88434, and a radioactive dose not exceeding 400 MBq at each PET examination, intravenous bolus injection
45972880|NCT04538209|Radiation|Abdominal computed tomography with angiography.|technique of combing a Computed Tomography scan with the injection of dye to create pictures of the portal circulation and portosystemic collaterals veins.
45972881|NCT02215876|Drug|Doxorubicin|Doxorubicin 60mg/m2 administered intravenously over 5 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
45972882|NCT02215876|Drug|Cyclophosphamide|Cyclophosphamide 600mg/m2 administered intravenously over 60 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
45972883|NCT02215876|Drug|Eribulin|Eribulin 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
45972884|NCT00269997|Drug|epoetin alfa|
45972885|NCT00237731|Drug|morphine|morphine 0.05
45972886|NCT00237731|Drug|morphine|morphine 0.10
45972887|NCT04542226|Drug|Polyoxidonium|Polyoxidonium (azoximer bromide) is administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections)
45972888|NCT00270036|Drug|epoetin alfa|
45972889|NCT01641874|Procedure|Exercise|Directional specific exercise
45972890|NCT01641874|Procedure|Evidence based exercise|Quadriceps exercises and advice on aerobic exercises. Exercises are based on current evidence for the best exercises for osteoarthritic knee
45972891|NCT00237848|Drug|D-serine|
45972892|NCT00237848|Behavioral|Cognitive retraining|
45670176|NCT02320253|Behavioral|Telephone Conference Call Group (TCC)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via telephone conference call groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. Dietitians will deliver the adapted Look AHEAD lifestyle intervention.
45670177|NCT02320253|Behavioral|Medical Nutrition Therapy (MNT)|Participants are referred to meet with a registered dietitian for individual medical nutrition therapy sessions up to 3-4 times per year.
45670178|NCT04197089|Drug|Vitamin D|First dose of 10.000 IU Vitamin D at baseline visit for all patients; stratification of treatment (10.000 or 50.000 IU Vitamin D) depending base 25(OH)Vitamin D levels. Treatment weekly during 4 weeks before scheduled cystectomy
45670179|NCT02276807|Behavioral|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques.
45829170|NCT04562909|Device|Neurocom balance master device|With the Modified Sensory Balance Interaction Clinical Test, the static balance will be examined by measuring the torso oscillation velocities while the eyes are open and the eyes closed on the stable rigid and unstable foam floors, and the dynamic balance will be examined with the sit-stand test, which is the basic motor activity in daily life, and the parameters will be measured on the same device.
45972893|NCT04537975|Device|C2Rx|Hemofiltration
45972894|NCT04537975|Other|Standard of Care (SOC)|Standard of care that excludes any protocol restrictions.
45972895|NCT04538131|Device|sensor-driven position-adaptive SCS|Medtronic sensor-driven position-adaptive SCS is capable to monitor the position change and change the parameters accordingly, so as to reduce the position change related side effects.
45972896|NCT04538131|Device|conventional SCS|Conventional SCS can not change the parameter when the body position changes.
45972897|NCT00262392|Drug|Pamidronate (AREDIA)|Pamidronate (AREDIA) vs radiation
45972898|NCT04537780|Other|Placebo|Placebo tabled every day
45670180|NCT02276807|Other|Usual Care|Primary care patients will be referred to the integrated behavioral health provider to receive brief treatment in primary care.
45670181|NCT02252965|Drug|Metformin IR|Subjects will receive Metformin Immediate Release (IR) tablets, orally once daily at a dose of 500 milligram (mg) for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
45829171|NCT04562675|Behavioral|LHA intervention|For the IG, a 4-hour lesson consisting of 4 chapters and leaflets was delivered over 4 weeks, with one chapter per hour per week. Each LHA visited the assigned mother in the IG four times in a 4-week period.
45829172|NCT04562675|Other|brochure-only|brochure-only for control group (CG)
45829173|NCT02211443|Biological|Recombinant full human Anti-EGFR Monoclonal Antibody|
45829174|NCT04562753|Procedure|Maïa® TMC Prosthesis (Lépine Groupe)|Patients undergoing thumb basal joint arthroplasty using Maïa® TMC prosthesis as treatment of osteoarthritis.
45829175|NCT04562753|Procedure|APL Suspensionplasty|Patients undergoing thumb basal joint arthroplasty using APL Suspensionplasty as treatment of osteoarthritis.
45972899|NCT04537780|Drug|Montelukast|Montelukast 10 mg daily at bed time.
45972900|NCT00237887|Drug|adalimumab|
45972901|NCT04537858|Device|Virtual reality therapy first|First day of the protocol with Virtual Reality intervention in the morning and conventional intervention in the afternoon
45972902|NCT04537858|Device|Conventional therapy first|First day of the protocol with conventional intervention in the morning and Virtual Reality intervention in the afternoon
45972903|NCT04537819|Drug|Imupret in addition to local NAID|Additional prescription of Imupret oral drops to conventional therapy with local NAID (Benzydamine hydrochloridy), elimination of irritating factors in the diet and acetaminophen (if necessary)
45972904|NCT04537819|Drug|Local NAID (Benzydamin)|(Benzydamine hydrochloridy) and acetaminophen (if necessary), elimination of irritating factors in the diet
45972905|NCT02215915|Procedure|Angiography|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
45972906|NCT02215915|Procedure|IVUS|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
45972907|NCT02215915|Procedure|DES implantation|
45972908|NCT00262431|Procedure|Tracheostomy on day 3-5 in early group and 10-12 in late group|Upon admission to ICU, acute respiratory failure patients requiring at least 3 days of mechanical ventilation and defined by a SAPS II score between 35 and 65, will be randomly assigned to either arm A or B of the study.
45972909|NCT00237926|Behavioral|Exercise|aerobic or resistance training
45972910|NCT02215993|Drug|Prasugrel|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
45972911|NCT02215993|Drug|Ticagrelor|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
45972912|NCT04537546|Device|OBESINOV elasto-compressive belt|It is a customised medical device, using a technique for calculating the compression ratio adapted to each patient according to his morphology
45972913|NCT04537702|Behavioral|Streamlined Education|After completion of the baseline surveys, the SG subjects will watch an approximately eight minute long genetics education video. This video will be made with the assistance of Duke University genetic counselors and gynecologic oncology providers. It will consist of a discussion of genes and mutations, the recommendation of universal testing for high grade epithelial ovarian cancer, a review of genes associated with ovarian cancer predisposition, the possibility of uncertain results including variants of undetermined significance, the potential for undetected mutations in known or unknown cancer susceptibility genes, the potential impact on personal treatment and on family members, the possibility of genetic discrimination and the legal protection of genetic information.
45670182|NCT02252965|Drug|Metformin XR|Subjects will receive Metformin Extended Release (XR) tablets, orally once daily at a dose of 500 mg for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
45829176|NCT04562519|Device|TENS|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
45670183|NCT02242435|Biological|4 mL injection of Ampion|4 mL injection of Ampion
45670184|NCT02242435|Drug|4 mL Injection of Placebo|
45829177|NCT02211521|Biological|PRP|3ml of PRP
45829178|NCT02211521|Drug|Hyaluronic acid|3ml hyaluronic acid
45829179|NCT01597908|Drug|Dabrafenib|Dabrafenib 150 mg twice daily orally
45829180|NCT01597908|Drug|Vemurafenib|Vemurafenib 960 mg twice daily orally
45829181|NCT01597908|Drug|Trametinib|Trametinib 2 mg once daily orally
45829182|NCT04415970|Other|Flotation therapy sensory deprivation tank|Participants will float for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with sleep pod every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short safety questionnaire and an anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
45829183|NCT04415970|Other|Sleep Pod|Participants will utilize the sleep pod for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with float every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
45829184|NCT01951170|Drug|Tocilizumab|162 milligrams (mg) tocilizumab was administered subcutaneously once weekly for 24 weeks
45670185|NCT02251717|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
45670186|NCT02242201|Drug|PNB Bupivacaine|Infusion
45670187|NCT02242201|Drug|PAI Ropivacaine|Injection
45670188|NCT02242201|Drug|PAI liposomal bupivacaine|Injection
45670189|NCT02242201|Drug|Epinephrine|Injection, weight-based dosage of 100 mcg - 300 mcg
45670190|NCT02242201|Drug|Ketorolac|Injection, 30 mg
45829185|NCT01951092|Other|Text messaging|
45829186|NCT04640922|Device|Gedea Pessary pHyph|Vaginal tablet
45829187|NCT04640922|Device|Placebo|Vaginal tablet
45829188|NCT01949532|Drug|Carfilzomib|Carfilzomib was administered by IV injection.
45972914|NCT04537702|Behavioral|Traditional Education|The TG subjects will then meet with the genetic counselor at the previously scheduled appointment time. During this visit, they will receive approximately thirty to sixty minutes of counseling regarding genetic testing and potential results. The discussion is based on the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines of informed consent for genetic testing. After counseling, participants will be given the option to undergo a multi-gene panel genetic test either via saliva or blood sample. Those who agree to testing will also complete the standard genetic testing consent form. As per standard practice of the clinical genetic service at DCI, patients will also be asked to provide consent for somatic tumor testing of surgical specimen (non-cytologic).
45972915|NCT04719351|Behavioral|The DIARY mobile application|The mobile application has two main functionalities. First, it will remind the user to report in regular time periods on their mental health status (e.g., sleep disturbances, stress). The assessment is done daily for four weeks. Second, some completed assessments will be combined with a behavioral prompt i.e. short message encouraging the user to engage in one of the strategies that can help coping with stress at work, e.g. remember to take short breaks, exercise in daylight, summarize a day with a colleague after a finished shift.
45972916|NCT04537585|Combination Product|Tomeka®|Tomeka® is a farine mixte made by soy, sorghum, maze and mushrooms
45972917|NCT04537585|Drug|"Vernonia amygdalina"|"Vernonia amygdalina is the Intervention that was pre-specified to be administered as part of the protocol as a particular intervention of not of interest because the World Health Organization doesn't support its use due to two reports case of toxicity in Kinshasa in a child and Mbandaka in an adult in the Democratic Republic of the Congo that why investigators would like review its usage in a large community and update that intervention of not of interest as appropriate (using randomisation on the follow up of participants who will take by themselves those herbs called Congo Bololo to compare, as necessary, to the ones who are afraid to take them because of reported cases of toxicity)."
45972918|NCT00237965|Behavioral|Mole Mapping Diagram|
45972919|NCT02216110|Procedure|Surgery|Surgery for early gastric cancer includes distal gastrectomy, total gastrectomy, proximal gastrectomy, and wedge resection
45972920|NCT02216149|Drug|S-1|S-1 25 mg/m2/day BID d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
45972921|NCT02216149|Drug|Capecitabine|capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
45972922|NCT02216149|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 D1 every 3 weeks
45972923|NCT00238004|Drug|Nicotinic acid|
45972924|NCT04537468|Other|Skin squame collection|Subjects underwent skin squame collection by scraping. The investigator gently scraped the surface of a lesional skin area for patients with psoriasis, and of a non-lesional skin area for healthy volunteers to collect superficial cells. These samples were analyzed by gene expression analyses.
45972925|NCT04537468|Other|Tape strip collection|The first subjects had up to 35 tape strips from a maximum of 4 areas (4 X 35 strippings) on the trunk or limbs (excluding the genital area). Patients with atopic dermatitis or psoriasis had tape stripping performed on lesional skin areas and the control subjects had tape stripping performed on nonlesional skin areas. The next subjects were used to determine the optimal number of tape strips required to obtain a good signal by gene expression analyses.
45972926|NCT04537468|Other|Tape strip and skin biopsy collection|Subjects had tape stripping on up to 3 different skin areas (2 areas on lesional skin and one area of nonlesional skin for patients with atopic dermatitis or psoriasis, and 2 areas of healthy skin for control subjects) using the optimal number of tape strips, as determined in the previous part. One 4-mm skin biopsy on a tape stripped area plus one 4-mm biopsy on non-tape-stripped skin (2 biopsies per subject) were also collected.
45972927|NCT00262548|Drug|Rosuvastatin; improvement of lipid profile|
45972928|NCT04537390|Diagnostic Test|Blood sample collection|Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development
46081688|NCT03576924|Behavioral|CHOICE|Participants will first be familiarized with HIIT and MICT in a randomized, counter-balanced order during supervised sessions 1 and 2, and will subsequently self-select the exercise type for the supervised and unsupervised exercise sessions. The HIIT and MICT protocols will match to the parallel imposed conditions. During the supervised exercise, intensity will also be based on HR monitors and psychophysiological responses of perceived exertion. The exercise training is paired with 30-50 minutes of behavioral counselling that is identical for all three interventions.
46081689|NCT03564938|Drug|Regorafenib (Stivarga, BAY73-4506)|The recommended dose of regorafenib is 160 mg (consisting of 4 tablets, each containing 40 mg of regorafenib) for 3 weeks of every 4 week cycle, (ie. 3 weeks on therapy, 1 week off therapy).
45455924|NCT05455814|Behavioral|Shambhavi Madamudra Kriya|The intervention is taught at the Inner Engineering program offered by non-profit Isha Foundation as online as well as in-person formats. It incorporates a combination of different breathing patterns and meditative components. The intervention training provides precise, step by step and easy to follow instructions on how to perform this practice. Performed in a seated posture, this is a simple, safe and accessible intervention that requires no previous experience of meditation. The intervention selected for this study was shown to significantly reduce perceived stress, enhance self-reported general well-being, improve positive emotions, mindfulness, sleep, engagement, relationships, and may promote enhanced Heart Rate Variability and Sympathovagal balance.
45670191|NCT02242045|Drug|Idelalisib|150 mg tablet(s) administered orally twice daily
45670192|NCT02241889|Device|Insulin pump therapy|Subject's own insulin pump will be used to manage blood glucose.
45670193|NCT02241889|Device|Closed-loop Artificial Pancreas Controller|Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
45670194|NCT02241733|Behavioral|Breathing retraining plus exercise|Patients will participate in a 12-week exercise program with breathing retraining. They will also participate in an adherence program.
45670195|NCT02241733|Behavioral|Exercise only|Patients will participate in a 12-week exercise program . They will also participate in an adherence program.
45670196|NCT02241343|Device|Venous occlusion (leg tourniquet, made in-house)|Leg occlusion applied via a blood pressure cuff. Venous occlusion checked using duplex ultrasound
45670197|NCT04191577|Drug|CVN424 Low Dose|CVN424
45972929|NCT04536883|Procedure|microscopy confocal|"At this stage, the confocal microscopy procedure begins:~Taking pictures for post-procedure analysis in 4 different territories. For each territory, the investigator need to get a snapshot of a vascular structure and a snapshot of an alveolus.~Analysis per procedure: the same operator analyzes the alveoli deemed to be representative in real time. It determines the presence of intra-alveolar inflammatory cells and answers the question of the main criterion: possible interpretation in confocal microscopy? YES / NO, the clinical researcher immediately notes the answer in the CRF. Based on this per-procedure analysis, if he deems the interpretation possible, the operator declares if he concludes that pulmonary inflammation is present YES / NO, the response is noted immediately in the CRF.~The fibroscopy procedure is then resumed as usual in the department, namely:"
45972930|NCT00238043|Drug|Biogeneric Epoetin|
45972931|NCT04536844|Device|Mobile application MyDignio (follow disease activity by assigning questionnaires to participants)|An electronic application available both on Apple store and Android play which the patients can download for free will be used to collect data from the Telehealth follow up group. This group will be compared to conventional outpatient clinic follow-up group.
45972932|NCT04536844|Other|Conventional prescheduled follow-up|Patients will be followed in the outpatient clinic by prescheduled follow-up
45455925|NCT05441930|Drug|Levofloxacin Ocular Implant|Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
45670198|NCT04191577|Drug|CVN424 High Dose|CVN424
45972933|NCT00415584|Drug|Cinacalcet HCl|
45972934|NCT04537273|Other|Descriptive and analytical|
45972935|NCT04536922|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg /day over 1 hour x 2 days.
45972936|NCT04536922|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.
45972937|NCT04536922|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
45972938|NCT04536922|Drug|Pembrolizumab (KEYTRUDA(R))|Pembrolizumab 2 mg /kg IV over approximately 30 minutes on Days -2, 21, 42, and 63.
45972939|NCT04536922|Biological|Individual Patient TCR-Transduced PBL|Day 0: Cells will be infused at a dose not to exceed 1.5e11 in 400 mL intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
45972940|NCT04536961|Drug|Reference Treatment- BMS-986165-01|Specified dose on specified days
45972941|NCT04536961|Drug|Prototype BMS-986165|Specified dose on specified days
45670199|NCT04191577|Drug|Placebo|Placebo
46081690|NCT03559647|Drug|Atezolizumab|Atezolizumab will be administered per the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA).
46081691|NCT03535688|Drug|D-cycloserine|200 mg twice daily
46081692|NCT03535688|Drug|Placebo|twice daily
45670200|NCT04966741|Drug|Setmelanotide|All patients will begin treatment at a dose of 0.5 mg of setmelanotide per day. Patients will then increase their dose by 0.5 mg increments, every 2 weeks, until reaching their target maximum dose (not to exceed 2mg daily). The target maximum dose of setmelanotide used in this study will be based on the weight bands.
45670201|NCT02241187|Drug|PEGPH20|
45670202|NCT02241187|Drug|Cetuximab|
45829189|NCT01949142|Drug|OTO-201|Single, intratympanic injection
45829190|NCT01949142|Drug|Sham|Simulated single, intratympanic injection
45829191|NCT01948908|Drug|Intranasal midazolam|Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).
45829192|NCT01925274|Drug|PF-05212384|30 minute IV infusion of PF-05212384 on days 2, 9, 16 and 23 of each cycle. Intra-patient dose escalation will commence with 110mg and will increase depending on tolerability.
45972942|NCT04536961|Drug|Famotidine|Specified dose on specified days
45972943|NCT04536961|Other|Alcohol|Specified quantity on specified days
45972944|NCT04537117|Other|Questionaire|Questionnaire addressing pediatric dentists behaviors and practices during the COVID-19 pandemic
45972945|NCT04542265|Combination Product|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
45972946|NCT00415662|Device|Pulsed Signal Therapy (PST)|
46081693|NCT03532139|Drug|Enoxaparin|Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness
45455926|NCT05441930|Drug|Control|Commercially available topical medications as per LEVO-CS102 Surgical Therapy Procedure.
45455927|NCT05438732|Device|smaller incision, new generation implantable miniature telescope (SING-IMT)|The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)
45670203|NCT02241187|Device|DW & DCE-MRI|
45670204|NCT02241187|Other|blood draws|Blood samples will be drawn at various time points.
45670205|NCT02249767|Drug|Tretinoin|Treatment of acne once daily in evening
45670206|NCT02239939|Behavioral|Vest|light weight, adjustable, vest to be worn underneath clothes that weight can be added to
45670207|NCT02239939|Behavioral|Diet|Participants will undergo a 22 week dietary weight loss intervention which will incorporate dietary practices for achieving weight loss while minimizing muscle and bone loss. Participants will be instructed by the Registered Dietitian to follow a low calorie diet. Individual calorie goals will be adjusted during the study if necessary to achieve a targeted weight loss goal of at least 8%, but no more than 12%, within the intervention time frame.
45670208|NCT04783675|Drug|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after remission
45829193|NCT01925274|Drug|irinotecan|90 minutes IV infusion of irinotecan 180mg/m^2 on days 1 and 15 of each cycle
45829194|NCT01925274|Drug|Cetuximab|120 minute IV infusion of cetuximab 400mg/m^2 on cycle 1 day 1; 60 minute IV infusion of cetuximab on days 8, 15, and 22 of each cycle, and on day 1 of each cycle after cycle 1
45972947|NCT04536610|Behavioral|Providing structured osteoporosis education|The OP education was performed in groups of 4-5 people by a single physician with a single session in the form of verbal expression via slide, with a duration of 20 minutes.
45972948|NCT04536610|Behavioral|Giving informative leaflet|Leaflets containe the same information as the OP education program
45972949|NCT00238160|Drug|cisplatin|
45972950|NCT00238160|Drug|fluorouracil|
45972951|NCT00238160|Procedure|adjuvant therapy|
46081694|NCT03532139|Drug|Enoxaparin + Rosuvastatin|"Rosuvastatin is an anti-cholesterol medication that is FDA (the U.S. Food and Drug Administration) approved to lower cholesterol and reduce the risk of arterial blood clots. There is evidence that rosuvastatin can lower the risk of venous blood clots in healthy individuals~Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness"
45455928|NCT05435118|Other|EMONO + audiovisuals tool|EMONO + use of audiovisuals tool on smartphone or tablet
45455929|NCT05424068|Behavioral|In-person rehabilitaiton group|participants who have chosen to complete the study intervention by coming in for their 8 week education and exercise sessions.
45455930|NCT05424068|Behavioral|Virtual rehabilitation group|Participants who have chosen to complete the study virtually instead of in-person sessions.
45455931|NCT05415527|Other|Presence of sarcopenia evaluated prior to neoadjuvant chemotherapy and during chemotherapy as part of optimised management(dietician and APA).|"Sarcopenia will be evaluated by CT-scan. This method will be combined with a bone mineral density test which is also a way of entering into a more specific approach to sarcopenia screening.~The patients will receive optimised treatment by nutritional monitoring and adapted physical activity (APA) in addition to follow-up for sarcopenia."
45455932|NCT05405829|Other|Health education|theoretical-practical hygienic-dietary training, with visual support and work materials where three specific interventions are explained: textures for solids and liquids, safety postures to reduce the risk of bronchial aspiration, and oral hygiene. In addition, tools are offered to caregivers so that they can identify situations of anxiety and overload, as well as guidelines for social support.
45455933|NCT05394727|Device|Needle-free injection device, Then traditional insulin pen|Patients first received needle-free syringe for insulin injection 3~4 times per day for 2 weeks. After the period of 2 weeks, they then received conventional insulin pen for insulin injection 3~4 times per day for 2 weeks.
45455934|NCT05394727|Device|Traditional insulin pen , Then Needle-free injection device|Patients first received conventional insulin pen for insulin injection 3~4 times per day for 2 weeks. After the period of 2 weeks, they then received needle-free syringe for insulin injection 3~4 times per day for 2 weeks.
45972952|NCT00238160|Procedure|chemotherapy|
45972953|NCT00238160|Procedure|conventional surgery|
46081695|NCT03532139|Other|Thromboprophylaxis|standard of care therapy
45829195|NCT01925274|Drug|Irinotecan|90 minutes IV infusion of Irinotecan 180mg/m^2 on days 1 and 15 of each cycle
45455935|NCT05391243|Procedure|LLETZ|Large loop excision of the transformation zone
45972954|NCT00238160|Procedure|hepatic arterial infusion|
45972955|NCT00238160|Procedure|surgery|
45972956|NCT04536649|Radiation|Radiotherapy|Multimodal brain imaging-guided radiotherapy using different beams
45455936|NCT05387499|Drug|NP-011 (Single Ascending Dose Phase)|The participants will receive assigned single dose of NP-011 after a minimum 8 hour fast on Day 1
45829196|NCT01948830|Drug|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
45829197|NCT01948830|Drug|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
45829198|NCT01972464|Drug|Progesterone|oral micronized progesterone
45829199|NCT01972464|Drug|Placebo|
45670209|NCT02248675|Behavioral|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions.
45670210|NCT02248675|Other|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
45670211|NCT02207725|Biological|Andexanet|
45670212|NCT02207725|Other|Placebo|
45670213|NCT04892953|Drug|Carboplatin|Given IV
45670214|NCT04892953|Biological|Durvalumab|Given IV
45670215|NCT04892953|Drug|Gemcitabine|Given IV
45829200|NCT01948050|Device|non-invasive transcranial direct current stimulation (tDCS)|
45829201|NCT01947894|Other|Non Interventional Study|Non Interventional Study
45972957|NCT04536454|Drug|[18F]FPyGal|Radiotracer for PET-imaging
45972958|NCT00415701|Drug|Etomidate|Single induction dose of etomidate 0.2%; total dose 0.15 mg/kg
45972959|NCT00415701|Drug|Propofol|Single induction dose of propofol 2%; total dose 1.5 mg/kg
45972960|NCT00415701|Drug|Hydrocortisone|Hydrocortisone 100 mg/2 ml: day of operation 3x, POD 1 2x, POD 2 1x
45972961|NCT00415701|Drug|NaCl 0.9%|NaCl 0.9% 2 ml; day of operation 3x, POD 1 2x, POD 2 1x
45972962|NCT00415701|Other|Tetracosactin|Diagnostic test, Tetracosactin 250 microg iv
45972963|NCT02961998|Drug|Celecoxib|Patients from experimental group will take celecoxib, except for sorafenib
45972964|NCT02961998|Drug|Sorafenib|Each group will receive sorafenib as basic treatment.
45972965|NCT04536727|Behavioral|Fit & Strong!|The 8-week intervention will consist of the Fit & Strong! program adapted to address the impact of exercise on enhancing positive affect and reducing negative affect and depressive symptoms. Exercise classes will meet three times per week for 90 minutes per session for eight weeks. Each class is divided into 60 minutes of strength training, flexibility, and cardiovascular exercise and 30 minutes of group education/discussion, which has been adapted to include affect-oriented content
45829202|NCT01947582|Device|Ankle foot orthosis|The ankle foot orthoses (AFOs) that will be used are designed to provide assistance with anterior tibial advancement during stance and dorsi flexion assistance during swing. The device(s) are polypropylene and are custom-fabricated.
45829203|NCT01924806|Device|WoundWand™ Debridement Device|Group I - Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound
45829204|NCT01924806|Device|Standard of Care sharp debridement|Group II - Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound
45972966|NCT04536727|Behavioral|Wait list|Participants randomized to the wait list group receive the 8-week Fit & Strong! intervention after the intervention group has competed it and after the wait list group has provided their post-outcomes.
45670216|NCT04892953|Procedure|Local Consolidation Therapy|Undergo LCT
45670217|NCT04892953|Drug|Nab-paclitaxel|Given IV
45829205|NCT01924182|Device|SynchroMed Infusion System and Intrathecal Morphine Sulfate|Following a successful test of Intrathecal Morphine Sulfate, subjects will undergo surgery to implant the drug pump (SynchroMed Infusion System) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control.
45972967|NCT04536415|Drug|Oseltamivir Phosphate 75 mg capsules|Capsules, 75 mg, single, oral dose
45972968|NCT04536415|Drug|Tamiflu capsules 75 mg|Capsules, 75 mg, single, oral dose
45455937|NCT05387499|Drug|NP-011 (Multiple Ascending Dose Phase)|The participants will receive assigned dose of NP-011 after a minimum 8 hour fast once daily for 7 days
45670218|NCT04892953|Drug|Paclitaxel|Given IV
45670219|NCT04892953|Drug|Pemetrexed|Given IV
45670220|NCT04892953|Other|Quality-of-Life Assessment|Complete questionnaire
45670221|NCT04892953|Other|Questionnaire Administration|Complete questionnaire
45670222|NCT04783441|Device|Dexcom G6|access to continuous glucose monitoring in the Dexcom G6 arm 24/7
45670223|NCT04783441|Device|Dexcom G6 blinded sensor|retrospective access to continuous glucose profile after 10 days of wear
45670224|NCT02238379|Drug|Oxytocin|24 International Units of Oxytocin in a Nasal Spray
45670225|NCT02238379|Other|Placebo|Placebo will contain all ingredients except the active oxytocin in the Nasal Spray.
45670226|NCT02238067|Drug|ESA|Participants will continue to receive their ESA treatment, as per physician's discretion. The study protocol does not specify any particular ESA drug.
45829206|NCT01924182|Other|Conventional Medicine|Subjects will continue to use pain medications as prescribed by their doctor.
45829207|NCT01972308|Behavioral|Patient Advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to accomplishing medical advice, and transfer of information between provider and patient.
45972969|NCT04536220|Diagnostic Test|Endoscopic Ultrasound (EUS), Fine Needle Aspiration|Endoscopic Ultrasound (EUS), Fine Needle Aspiration, which are routine clinical operations
45972970|NCT00262587|Drug|Seretide|Combination of inhaled corticosteroids (250 microgr) and inhaled long-acting beta2-agonists (25 microgr)
45972971|NCT00262587|Drug|Placebo|Inhaled sugar powder in a placebo inhaler
45972972|NCT00238199|Dietary Supplement|calcitriol|
45972973|NCT00238199|Drug|docetaxel|
45972974|NCT04536259|Behavioral|Video Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation by video.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend a video consultation. B) If possible, I would rather attend the appointment in person."
45972975|NCT04536259|Behavioral|In-Person Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend an in-person consultation. B) If possible, I would rather attend the appointment by video."
45972976|NCT04536259|Behavioral|Active Choice|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend a consultation by video or in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) I would prefer a video consultation. B) I would prefer an in-person consultation."
45972977|NCT04536064|Procedure|LVA and liposuction|"Tumescent technique in lymph-sparing fashion was adopted. Areas were infiltrated with a mix of a standard tumescent solution consisting for each liter of in 1000 ml of saline solution, 50 ml lidocaine 1%, 1 ml epinephrine 1:1000, 10 ml bicarbonate 8,4%. Infiltration volume was approximately from 0,5 to 1 liter for the upper extremities and 1-2 liters for lowers. Three to 4 mm 3 holes blunt cannulas were employed. Aspiration technique was as parallel as possible along the lymphatic network pattern and from superficial to deep layers.~Lymphatic vessels identified at ICG lymphography were spared. Volume of the aspirate was aimed to approximate 80 percent of the volume difference between the affected and non affected side.~The number and type of anastomosis were recorded as well as amount of removed lipoaspirate versus the excess limb volume."
45972978|NCT04536493|Drug|LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (1 application)|1 application of LET topical anesthetic gel
45972979|NCT04536493|Drug|LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (3 applications)|3 applications of LET topical anesthetic gel
45670227|NCT02238067|Other|Satisfaction Survey Questionnaire|Each participant will be interviewed to complete treatment satisfaction questionnaire survey at baseline and at 6-month follow-up visit.
45670228|NCT02237911|Other|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
45670229|NCT02237911|Other|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
45670230|NCT04769167|Other|Stool and Blood Specimen Collection|Stool and Blood specimens will be collected at 3 designated time points
45670231|NCT04769167|Other|Follow-up Medical Record Review|Participant medical records as well as the medical records of infants during study enrollment will be reviewed up to 3 years from the date of enrollment.
45670232|NCT02234479|Biological|Hydrophor (Group A)|"Rehydrates dry, chapped or chafed skin~May be used alone as a skin lubricant or protectant"
45670233|NCT02234479|Biological|MediHoney (Group B)|"It helps the body's natural healing processes in three key ways which have been shown to have healing benefits:~Maintain a balanced environment for healing.~Aids in reducing dermatitis.~Reduce affected area pH.2-3"
45829208|NCT01972308|Behavioral|Usual Care|Subjects receive asthma care from their proivders in the participating practices which generally follow asthma guidelines
45829209|NCT01946880|Drug|Mycophenolate Mofetil|Subjects will enter the trial on 1000-3000 mg/day of MMF and will be randomized to remain on MMF treatment or to be tapered off MMF within 12 weeks.
45670234|NCT02207491|Drug|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
45670235|NCT02207491|Drug|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
45972980|NCT04536181|Drug|Prednisolone|12 weeks prednisolone treatment
45972981|NCT04536181|Drug|Placebo|12 weeks simulated tablets
45670236|NCT02207491|Other|Placebo|1 drop QD, AM, OU
45670237|NCT04797715|Drug|AXS-05|AXS-05 tablets, taken twice daily
45670238|NCT04797715|Drug|Placebo|Placebo tablets, taken twice daily
45829210|NCT01946880|Drug|Hydroxychloroquine or Chloroquine|Subjects will be on concurrent anti-malarial agents (hydroxychloroquine or chloroquine). Hydroxychloroquine is approved by the FDA for the treatment of SLE. Hydroxychloroquine has been shown to help prevent flare in SLE, and to improve skin and musculoskeletal activity in particular.Even lupus nephritis outcomes appear improved on a background of hydroxychloroquine therapy
45972982|NCT00262626|Drug|Intraocular pressure reduction|
45972983|NCT00262626|Procedure|Argon laser trabeculoplasty|
45972984|NCT00262626|Procedure|Trabeculectomy|
45972985|NCT04535869|Drug|Sofosbuvir 400 MG plus Daclatasvir 200mg|This group which receive sofosbuvir and daclatasvir for 14 days plus standard therapy
46081696|NCT03527719|Other|Village-doctor-led multifaceted intervention|"Establishing a network including hypertension specialists at city/county hospitals, primary care physicians at township hospitals, and village doctors to collaboratively manage hypertension~Using hypertension control rate as one of the metrics for incentive supplements to village doctors~Providing discounted or free antihypertensive medications to patients with hypertension~Training village doctors to measure blood pressure according to a standard protocol~Training village doctors to use a simple stepwise protocol for hypertension treatment~Training village doctors to conduct health coaching on lifestyle change (e.g., lowering sodium and alcohol intake) and medication adherence~Providing free blood-pressure monitor and training to patients for home blood pressure measurement~Encouraging lifestyle change and medication adherence~Connecting patients through WeChat or telephone for group social support"
46081697|NCT03527277|Other|Naturally-sweetened orange juice|Commercially-available ready-to-serve refrigerated orange juice
46081698|NCT03527277|Other|Sugar-sweetened beverage|Sugar-sweetened water flavored with Kool-Aid (TM)
45670239|NCT02315066|Drug|PF-04518600|Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined
46081699|NCT03524352|Other|fecal microbiota|fecal microbiota in suspension
46081700|NCT03524352|Other|Placebo|sterile saline
45829211|NCT01946880|Drug|Prednisone|Once the subject is randomized into the trial, the prednisone (or other corticosteroid) dose must be stable through Week 36 (24 weeks following protocol taper of MMF), in the absence of flares as described in Section 3.2 of the study protocol, Description of Primary Endpoint. Further taper of prednisone after that point is by the investigator's discretion based on the subject's clinical status.
45829212|NCT01972152|Drug|G-Pen(TM) 1 mg|
45829213|NCT01972152|Drug|Lilly Glucagon(TM) 1 mg|
45829214|NCT01972152|Drug|G-Pen(TM) 0.5 mg|
45972986|NCT02216188|Biological|AFFITOPE® PD01A|s.c. injection
45972987|NCT02216188|Other|Control|Untreated control group
46081701|NCT03522142|Drug|INCB081776|INCB081776 administered once or twice daily orally with water after a fast of at least 2 hours before and at least 1 hour after the dose.
46081702|NCT03522142|Drug|INCMGA00012|INCMGA0012 administered intravenously according to the label as 500 mg every 4 weeks
45972988|NCT02216227|Drug|Mupirocin|Patients with known positive MRSA or MSSA and patients who have unknown status will decolonize BID x 5 days
46081703|NCT03509584|Radiation|hypofractionated radiotherapy|Stereotactic hypo-fractionated irradiation (3 x 8 Gys) radiotherapy fraction
46081704|NCT03509584|Drug|nivolumab|administration of nivolumab
46081705|NCT03509584|Drug|Ipilimumab|administration of ipilimumab
45670240|NCT02315066|Drug|PF-04518600|Part A2 - patients with hepatocellular carcinoma will be randomized to receive treatment with PF-04518600 at various doses administered intravenously
45670241|NCT02315066|Drug|PF-04518600 plus PF-05082566|Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.
45829215|NCT01972074|Drug|Memantine|Capsule
45829216|NCT01972074|Other|Placebo|Capsule
45829217|NCT01970982|Other|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
45829218|NCT01970982|Other|Smoking abstinence (SA)|SA for 5 days in confinement
45829219|NCT01970982|Other|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
45972989|NCT02216227|Drug|Chlorhexidine gluconate|"Patients that are MRSA or MSSA positive or have unknown status will bathe in CHG daily x 5 days.~Patients that are MRSA or MSSA negative will bathe with CHG the night before and morning of surgery."
45972990|NCT02216227|Drug|Cefazolin|All patients will receive Cefazolin during surgery
45972991|NCT02216227|Drug|Vancomycin|Patients who are positive for MRSA, or have unknown MRSA status, will receive vancomycin along with cefazolin during surgery.
45670242|NCT02315066|Drug|PF-04518600 plus PF-05082566|Part B2 - patients with select tumor types (ocular melanoma, cutaneous/acral melanoma or non-small cell lung cancer) will be treated at dose levels based on the OBD selected in Part 1.
45670243|NCT02207413|Biological|Influsplit Tetra™ vaccine produced by investigational process (IP)|Influsplit Tetra™ vaccine using a new manufacturing process administered intramuscularly (IM) in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
45670244|NCT02207413|Biological|Influsplit Tetra™ vaccine produced by licensed process (LP)|Influsplit Tetra™ vaccine using a licensed manufacturing process administered IM in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
45670245|NCT02309372|Behavioral|Beating the Blues|Computerized depression treatment intervention
45972992|NCT02216227|Drug|Nasal Povidone Iodine|The purpose of this research is to evaluate a SSI checklist. This checklist includes decolonizing a patient's nose and skin and optimizing antibiotics prior to surgery. At the time that we wrote it, the predominate product to decolonize patient's noses was mupirocin. However, in 2017, an FDA final monograph stated that nasal povidone-iodine may be used for pre-surgical decolonization. Nasal povidone-iodine should be able to overcome barriers to checklist implementation that we identified in Aim 3. We now plan to replace the nasal agent mupirocin with the nasal agent povidone-iodine at 3 participating medical centers (Iowa City VA, Minneapolis VA and Portland VA) to assess whether this overcomes the barriers to our SSI checklist.
45670246|NCT02276027|Drug|BYL719|BYL719 was dosed as 350 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take BYL719 exactly as prescribed.
45670247|NCT02276027|Drug|INC280|INC280 was dosed as 600 mg (tablet) or 400mg(Capsule) twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to takeINC280 exactly as prescribed.
45670248|NCT02276027|Drug|LDK378|LDK378 was dosed as 750 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take LDK378 exactly as prescribed.
45670249|NCT02276027|Drug|MEK162|MEK162 was dosed as 45 mg twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take MEK162 exactly as prescribed.
45670250|NCT02309294|Device|Novel lubricant Miami w/ fragrance|0.2 ml aliquot on occlusive patch
45670251|NCT02309294|Device|Novel lubricant Miami no fragrance|0.2 ml aliquot on occlusive patch
45670252|NCT02309294|Device|KY Liquid lubricant|0.2 ml aliquot on occlusive patch
45670253|NCT02309294|Device|Astroglide Gel lubricant|0.2 ml aliquot on occlusive patch
45670254|NCT02309294|Device|Wet Platinum lubricant|0.2 ml aliquot on occlusive patch
45670255|NCT02233543|Drug|QVA149|Delivered once daily via single-dose dry powder inhaler
45670256|NCT02233543|Drug|QVA149 Placebo|Placebo delivered once daily via single-dose dry powder inhaler
45670257|NCT02309138|Diagnostic Test|Gestational diabetes screening with fasting 3 hour 100 gm|Participants receive fasting 3 hour 100 gm oral glucose tolerance test
45670258|NCT02309138|Diagnostic Test|Gestational diabetes screening with fasting 2 hour 75g|Participants receive fasting 2 hour 75 gm oral glucose tolerance test
45670259|NCT04761133|Drug|Povidone-Iodine pleural irrigation|Irrigation of the infected pleural cavity with an antiseptic solution to reduce microbial load
45829220|NCT01946802|Device|Frontal 4 channel EEG|Simultaneous conventional EEG and SEDline monitoring for 30 minutes during and after therapeutic hypothermia
45829221|NCT01618266|Drug|dexamethasone intravitreal implant|dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
45829222|NCT01919112|Device|tDCS|Anodal tDCS will be administered with swallowing exercises
45972993|NCT00238277|Drug|temozolomide|
45670260|NCT02233309|Other|Monitoring of pressures during caudal anesthesia|The caudal itself is a separate procedure not covered by this observational study. This study simply attaches a monitoring device to the needle used for the caudal to measure pressures. The caudal takes place whether the observation of pressures is agreed to or not, as per standard protocol.
45829223|NCT01918332|Drug|Valsartan 160mg|
45829224|NCT01918332|Drug|Rosuvastatin 20mg|
45829225|NCT01918332|Drug|Valsartan 160mg placebo|
45829226|NCT01918332|Drug|Rosuvastatin 20mg placebo|
45972994|NCT00238277|Procedure|adjuvant therapy|
45670261|NCT04779697|Drug|GLP-1 analogue - semaglutide|GLP-1 analogue - semaglutide - administered once weekly for a total of 12 weeks
45670262|NCT04779697|Other|Placebo|Placebo - administered once weekly for a total of 12 weeks
45670263|NCT02204917|Drug|OPTISON|Contrast enhanced Voiding Urosonography (ceVUS) with intravesical administration of OPTISON for vesicoureteral reflux detection and urethral imaging in children. Voiding Cystourethrography (VCUG) examination will be subsequently performed as part of the standard care.
45670264|NCT02280044|Biological|Rifaximin intervention|Rifaximin administered then Challenge with C jejuni
45670265|NCT02280044|Biological|Placebo intervention|Placebo administered then Challenge with C jejuni
45670266|NCT04748653|Behavioral|Multi-component reintegration intervention|The intervention incorporates health education, psychosocial counseling, physiotherapy and economic investment.
45829227|NCT04628832|Behavioral|PMP Use Mandate Letter|A letter with reminders about the mandate to check the PMP when prescribing opioids.
45829228|NCT04628832|Behavioral|Prescribing Information Letter|A letter with information about the prescriber's patients who received co-prescriptions. The letters will provide clinical background on the harms of co-prescribing and encourage prescribers to avoid co-prescribing in the future.
45829229|NCT04628832|Behavioral|Prescribing Information + PMP Use Mandate Letter|A letter combining the content of the PMP Use Mandate Letter and the Prescribing Information Letter. This letter will remind prescribers about the PMP use mandate and provide information about the prescriber's patients who received co-prescriptions.
45829230|NCT01922934|Behavioral|Commercial weight loss program|vouchers for Weight Watchers
45829231|NCT01922934|Behavioral|Colorado Weigh|Group behavioral weight loss program
45829232|NCT01922934|Dietary Supplement|Meal replacements|Health Management Resources meal replacement products (shakes and entrees)
45829233|NCT01922934|Drug|Obesity pharmacotherapy|Phentermine or phentermine-topiramate (Qsymia)
45829234|NCT01922934|Behavioral|Recreation center passes|1 year pass to a Denver recreation center
45829235|NCT01970592|Behavioral|POWER training|Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be ~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking
45829236|NCT04661124|Device|SPECTRALIS|ophthalmic imaging device with head and chinrest
45829237|NCT04661124|Device|SPECTRALIS with Flex Module|ophthalmic imaging device on mobile instrumentation stand
45829238|NCT01921140|Drug|Olaparib tablets|Olaparib dosing (2X 150mg tablets) following allocated meal
45829239|NCT01921140|Procedure|Pharmacokinetic sampling|Blood samples taken pre and post dosing with 2x 150 mg olaparib tablet
45829240|NCT01921140|Other|Dietary Fasted|2x 150 mg olaparib tablet formulation taken in fasted state. 5-14 days washout period
45829241|NCT01921140|Other|Dietary High Fat|2x 150 mg olaparib tablet formulation taken 30 minutes after allocated meal. 5-14 days washout period.
45829242|NCT01920594|Drug|GSK1278863|White, round biconvex, film coated tablet with unit dose strength of 100 mg for oral administration
45829243|NCT01920594|Drug|Placebo|White, round biconvex, film coated GSK1278863 matching placebo tablet for oral administration
45829244|NCT01917084|Other|Passive range of motion (ROM) exercise|After their Norwood surgery, stable subjects will undergo passive ROM exercise therapy for up to 21 consecutive days or until hospital discharge, whichever comes first. Subjects will have completed the study after their anthropometric measurements are collected at 3 months of age
45829245|NCT01917006|Drug|OnabotulinumtoxinA|OnabotulinumtoxinA injected into specified muscle per protocol on Day 1.
45670267|NCT02308748|Drug|Dofetilide|"8 am: Placebo~12 pm (noon): 250 µg~5:30 pm: 250 µg"
45829246|NCT01917006|Drug|Normal Saline|Placebo (normal saline) injected into specified muscle per protocol on Day 1.
45972995|NCT00238277|Procedure|chemotherapy|
45972996|NCT00238277|Procedure|radiation therapy|
45972997|NCT00262665|Drug|ORG 24448|flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
45972998|NCT00262665|Drug|Placebo|matching placebo pill - flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
45670268|NCT02308748|Drug|Mexiletine|"8 am: weight x 4 mg/kg~12 pm (noon): Same as at 8 am~5:30 pm: Same as at 8 am"
45670269|NCT02308748|Drug|Lidocaine|"9 am : 30 µg/min per kg (loading) for 60 minutes and 10 µg/min per kg (maintenance) for 30 minutes~2 pm: 55 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes~7:30 pm: 52 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes"
45670270|NCT02308748|Drug|Moxifloxacin|"9 am: 5.63 mg/h per kg (loading) for 1 hour and 0.26 mg/h per kg (maintenance for 30 minutes)~2 pm: 6.14 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)~7:30 pm: 2.23 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)"
45670271|NCT02308748|Drug|Diltiazem|• 7:30 pm: 330 µg/h per kg (loading) for 60 minutes and 61 µg/h per kg (maintenance) for 30 minutes
45670272|NCT02308748|Drug|Placebo|Placebo (#2 Gelcap or IV saline)
45670273|NCT04745689|Drug|Durvalumab|"IV infusions through induction phase.~IV infusions through maintenance phase until PD or other discontinuation criteria."
45670274|NCT04745689|Drug|AZD2811|IV infusions through maintenance phase until PD or other discontinuation criteria.
45670275|NCT04745689|Drug|Carboplatin|IV infusions through induction phase if chosen by Investigator.
45670276|NCT04745689|Drug|Cisplatin|IV infusions through induction phase if chosen by Investigator.
45670277|NCT04745689|Drug|Etoposide|IV infusions through induction phase.
45670278|NCT04768543|Device|Upper airway stimulation (Inspire Medical Systems, Inc.)|phasic hypoglossal nerve stimulation device
45972999|NCT02216266|Drug|Physostigmine|
45973000|NCT02216266|Other|Sodium Chloride solution|
45973001|NCT04535830|Device|Flash Glucose Monitoring System|During the three months experimental period,participants at the FSL group will be asked to wear a flash glucose monitoring sensor for a period of 2 weeks and have a care visit every month while people at SMBG group will receive a care visit every month.
45670279|NCT04768153|Biological|Serology|Serological diagnosis of COVID-19 in patients with cancer from a sample of cancer patients, at 3 and 6 months after implementation of confinement in France
45973002|NCT00262704|Behavioral|Simulated case-based customized learning|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback
45973003|NCT00262704|Behavioral|Simulated case based customized learning + leader feedback|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback + Physician Opinion Leader Feedback Tailored to Provider's Specific Practice Style
45973004|NCT04535752|Drug|ANX009|Single or multiple ascending dose
45973005|NCT04535752|Drug|Placebo|Single or multiple ascending dose
45973006|NCT00238316|Drug|letrozole|2.5 mg PO daily for 1 year
45829247|NCT04625790|Device|Repetitive transcranial magnetic stimulation|"Transcranial Magnetic Stimulation(TMS) has been used for diagnostic and therapeutic purposes in the treatment of many neurological and psychiatric diseases such as stroke, multiple sclerosis, myelopathy, amyotrophic lateral sclerosis, movement disorders, epilepsy, and depression. It is a way to stimulate the targeted areas in the cerebral cortex without invasive methods. The application of TMS in the aphasia usually consists of repetitive stimulations, in order to activate or deactivate the target area.~In this study, 10 sessions of 1-Hz low frequency rTMS for 20 minutes will be applied to the inferior frontal gyrus of the right frontal lobe."
45973007|NCT00238316|Other|Placebo|2.5 mg PO daily for one 1 year
45973008|NCT04535518|Drug|IVIG|IVIG at a single dose of 2 g/kg
45973009|NCT04535518|Drug|Aspirin|Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
45973010|NCT04535518|Drug|Infliximab|Intravenous infliximab at single dose of 5 mg/kg, given more than 2 hours.
45973011|NCT02216383|Drug|Carbetocin|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Carbetocin, listed here, is one of the of the three study drugs.
45973012|NCT02216383|Drug|Syntocinon|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntocinon, listed here, is one of the of the three study drugs.
45973013|NCT02216383|Drug|Syntometrine|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntometrine, listed here, is one of the of the three study drugs.
45973014|NCT00262782|Drug|Fludarabine|Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
45973015|NCT00238394|Drug|cediranib maleate|Given orally
45973016|NCT00238394|Other|laboratory biomarker analysis|Correlative studies
45973017|NCT04535284|Behavioral|Coaching|"Health Coaching-in-Context that consists of up to 10 sessions, arranged once-a-week or multiple times a week based on convenience of scheduling for up to 10 weeks. The program targets improved caregiver health through occupational therapy coaching."
45973018|NCT02216461|Drug|Low dose of BIBW 2948 BS for oral inhalation|
45973019|NCT02216461|Drug|Medium dose of BIBW 2948 BS for oral inhalation|
45973020|NCT02216461|Drug|High dose of BIBW 2948 BS for oral inhalation|
45973021|NCT02216461|Drug|Placebo|
45973022|NCT00238472|Drug|nateglinide|
45670280|NCT01646216|Behavioral|Split belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to move at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same or slightly different speeds.
45670281|NCT02308124|Drug|Midodrine|
45829248|NCT04625790|Other|Speech therapy|Speech therapy will be given to each patient by the same therapist, and the treatment will last 10 days, 60 minutes a day. It will consist of exercises to improve the articulation and comprehension.
45829249|NCT01916304|Drug|Levothyroxine sodium new formulation|Levothyroxine tablets
45973023|NCT04535206|Diagnostic Test|Venous blood collecting and test and ultrasound screening|To collect the venous blood samples before the PICC catheterization, and perform ultrasound examination before and after the catheterization at the specified time point in follow-up.
45973024|NCT04534621|Other|Electronic survey|Brazilian chiropractors will be invited by email and social media to answer an electronic survey.
45973025|NCT00262899|Behavioral|counseling intervention|
45973026|NCT00262899|Other|educational intervention|
45973027|NCT00262899|Procedure|psychosocial assessment and care|
45973028|NCT04534855|Drug|Treprilimab|Treprilimab 240mg Q3W until progression or unacceptable toxicity
45973029|NCT00238511|Drug|SPM 927|
45670282|NCT02308124|Drug|Pyridostigmine Bromide|
45829250|NCT01916226|Drug|FPNS|Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.
45829251|NCT01916226|Drug|FPNS Placebo|Bottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.
45973030|NCT04534699|Drug|KBP-5074|KBP-5074 tablet
45973031|NCT02216539|Behavioral|Self-hypnosis|Patients will be trained to self-hypnosis prior to surgery, in order to be able to use self-hypnosis as a pain-management tool after surgery
45973032|NCT02216539|Procedure|Lung transplantation|
45670283|NCT02308124|Drug|Midodrine + pyridostigmine|
45829252|NCT01916226|Drug|Cetirizine|Over-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).
46081706|NCT03494049|Procedure|Veil sparring HoLEP|"Early mucosal incision; lateral to the Veru and proximal to the apical bulge of the adenoma, followed by early separation of the adenoma from the sphincter ring after identification of the plane of enucleation, this minimizes sphincter stretch.~Furthermore, more proximal incision of the 12 O'clock mucosal strip sparring a veil of mucosa covering the sphincter ring."
45829253|NCT01916226|Drug|Cetirizine Placebo|Over-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).
46081707|NCT03494049|Procedure|Standard HoLEP|Holmium laser enucleation of the prostate in the standard approach described by Elhilali et al 2010
45670284|NCT02232061|Drug|Fingolimod|Fingolimod 0.5 mg tablet
45670285|NCT02275481|Drug|Arformoterol tartrate inhalation solution|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
45670286|NCT02275481|Drug|Tiotropium|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
45670287|NCT02204449|Behavioral|Cardiac Rehabilitation Peer Mentorship|
45829254|NCT01969500|Behavioral|Mobile Application|
45829255|NCT01969500|Behavioral|Treatment as Usual (TAU)|
45829256|NCT04624074|Behavioral|Teen Marijuana Check Up|Teen Marijuana Checkup will be adapted for youth and young adults with first episode psychosis. The Teen Marijuana Checkup includes two intervention sessions. In Session 1, the interventionist uses motivational interviewing skills to hear the adolescent's history and current concerns with marijuana. The personalized feedback report generated from the baseline assessment is reviewed. In Session 2, the interventionist elicits change talk and guides discussion on making changes to reduce or stop marijuana use.
45829257|NCT05120154|Other|Online educational materials|The CAPACITI program is comprised of three independent modules, taken separately (each constituting an intervention): (1) Identify and Assess; (2) Enhance Communication Skills; (3) Enhance Skills for Ongoing Care (including involvement of family and specialists). Each module addresses a critical component of implementing a palliative care approach into primary care practice. The CAPACITI program emphasizes practice supports in each module, integrating two components: 1) clinical education in the form of expert advice and tips, and 2) evidence-based tools with action steps.
45829258|NCT05120154|Behavioral|Facilitated online webinars|Intervention participants will be invited to participate in facilitated online discussions. These discussions review the online materials and share strategies for problem-solving.
45829259|NCT01915914|Drug|Fluticasone propionate|All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient (Physiogel) twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient (Physiogel) twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient (Physiogel) twice daily up to 12 weeks.
45829260|NCT01919970|Other|Cognitive Behavioral Therapy|This condition involves 12 weekly CBT sessions.
45829261|NCT01919970|Other|Treatment as usual|This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
45829262|NCT01919814|Dietary Supplement|Appethyl™|Four hours after breakfast participants will be given a small amount of liquid to drink that will contain Appethyl™. They will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. Participants are not expected to eat all of the pizza.
45829263|NCT01919814|Other|Placebo|Four hours after breakfast, participants will be given a small amount of liquid to drink that will contain a placebo (inactive liquid). Participants will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. They are not expected to eat all of the pizza.
45829264|NCT01968954|Drug|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
45829265|NCT01968954|Other|Placebo|subcutaneous injection, every 2 weeks for 12 months
45829266|NCT01919190|Drug|EXPAREL|TAP with EXPAREL
45829267|NCT01919190|Drug|Placebo|Placebo
45829268|NCT01620060|Drug|Lurasidone|Lurasidone 20, 40,80, 120 or 160 mg/day oral single and multiple does of lurasidone for 12 days
46081708|NCT03493945|Biological|M7824|1,200 mg IV once every 2 weeks
46081709|NCT03493945|Drug|N-803|8-15 mcg/kg subcutaneous every 2 weeks
46081710|NCT03493945|Biological|MVA-BN-Brachyury|MVA-BN-Brachyury will be administered subcutaneously (2 doses 2 weeks apart).
46081711|NCT03493945|Biological|FPV-Brachyury|FPV-Brachyury will be given 2 weeks after second dose of MVA-BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.
46081712|NCT03493945|Drug|Epacadostat|600 mg orally twice daily (1200 MG total)
46081713|NCT03493854|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of ddAC Q2W or AC Q3W) for Cycles 1-4.
46081714|NCT03493854|Drug|Doxorubicin|Doxorubicin 60 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of either ddAC Q2W or AC Q3W) for Cycles 1-4.
45670288|NCT02308046|Drug|Terconazole|
45670289|NCT02308046|Drug|Placebo|
45670290|NCT02318693|Drug|Sitagliptin|Sitagliptin 50 mg orally once a day before breakfast for 14 days
45670291|NCT02318693|Drug|Glibenclamide|Glibenclamide 1.25 mg orally twice a day (2.5 mg/day) before breakfast and dinner for 14 days
45670292|NCT02230891|Drug|Carvedilol|Carvedilol is a non selective beta blocker
45670293|NCT02230891|Drug|Spironolactone|Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure
45973033|NCT02216539|Other|Standard post-operative pain management|Post-operative pain management treatments as per usual protocols in the hospital
45973034|NCT04534816|Diagnostic Test|Indocyanine Green|Perfusion assessments
45973035|NCT00262938|Behavioral|behavioral dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
45973036|NCT00262938|Other|counseling intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
45670294|NCT02230891|Other|Usual care|standard care as per primary care provider
45973037|NCT00262938|Other|educational intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
45670295|NCT01646138|Biological|Ca/04/2009/H1N1 Vero Grown Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
45829269|NCT04615182|Device|Transplant|To enable continued clinical access to DCD heart transplantation in the U.S. and to continue to collect additional data on the performance of the OCS Heart System to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.
45973038|NCT00262938|Other|preventative dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
45973039|NCT00262938|Procedure|quality-of-life assessment|Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
45973040|NCT04534894|Diagnostic Test|fluorescence lifetime imaging microscopy|collect 2mL of venous blood and use fluorescence lifetime imaging microscopy to exam NADH fluorescence characteristics of it
45829270|NCT01914666|Drug|Duloxetine|Administered orally
45829271|NCT01913340|Drug|Erythropoietin|1000 U/kg/dose IV x 5 doses
45829272|NCT01913340|Drug|Normal saline|placebo: NS IV x 5 doses
46081715|NCT03493854|Drug|Docetaxel|As part of one of the two investigator's choices of chemotherapy (AC followed by docetaxel), docetaxel 75 mg/m2 will be administered IV on Day 1 of Cycle 5 and then 100 mg/m2 IV at the discretion of the investigator for Cycles 6-8 (Q3W), if no dose-limiting toxicity occurs.
45670296|NCT02204371|Drug|Pazopanib|Pazopanib is available as 50 mg and 200 mg tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
45670297|NCT02204371|Drug|Placebo|Pazopanib matching placebo is available as tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
45829273|NCT01864200|Biological|Crotalidae polyvalent immune fab (ovine)|crotalidae antivenom
45973041|NCT00238628|Drug|Bexarotene|
45670298|NCT02274857|Procedure|Standard PVI Ablation|Standard PVI procedure without FIRMap.
45670299|NCT02274857|Procedure|FIRM-Guided Procedure and PVI|FIRM-guided procedure followed by conventional ablation including PVI.
45670300|NCT02302859|Drug|Nicotine Patch|Participants receive an 8 week supply of Nicotine patches.
45973042|NCT00238628|Drug|Iressa|
45973043|NCT02216617|Drug|Taxotere, Cisplatin, Afatinib|
45973044|NCT04534777|Other|repeated neurological, behavioral assessments and conventional, quantitative and functional brain imagery|Based on the collected data, we will evaluate the respective diagnostic accuracy of all the markers acquired in clinical practice regarding the clinical outcome at 2 years.
45973045|NCT00262977|Behavioral|Electronic prompt plus patient-directed intervention|
45973046|NCT00262977|Behavioral|Electronic prompt to clinician to prescribe aspirin|
45973047|NCT04534504|Procedure|SG-JJB|Base on SG-JJB procedure, the jejunum was not transected, only 200-cm jejunum 20-cm distal to Treiz ligament was measured and side-to-side jejunojejunal anastomosis was made. And the jejunum 3-5cm distal to the anastomosis was ligated with 10# suture.
45670301|NCT02302859|Behavioral|Questionnaires|Questionnaire completion at baseline on laptop, then weekly for 8 weeks on smartphone, then 3 months after smartphone intervention.
45670302|NCT02302859|Other|Pamphlet|Pamphlet given to participant describing health and financial reasons to quit smoking.
45829274|NCT01864200|Biological|Placebo|Saline placebo
45829275|NCT01912872|Drug|Omalizumab|Subcutaneous injection dose according to the IgE level and body weight.
45829276|NCT01912872|Drug|Budesonide|Budesonide (400 μg, 200 μg or 100 μg) tablets taken orally according to maximum daily dose.
45829277|NCT01912872|Drug|Formoterol|Formoterol 12ug tablets taken orally according to maximum daily dose.
45829278|NCT01912872|Drug|Budesonide|Budesonide (400 μg, 200 μg or 100 μg). Patients were instructed to take the inhaled budesonide doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
45829279|NCT01912872|Drug|Formoterol|Formoterol 12ug. Patients were instructed to take the inhaled formoterol doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
45829280|NCT01912404|Drug|IDN-6556|25 mg BID for 28 days
45829281|NCT01912404|Drug|Placebo|Placebo controlled
45829282|NCT01911780|Drug|placebo|placebo matching amlodipine capsule
46081716|NCT03493854|Drug|Paclitaxel|As part of one of the two investigator's choices of chemotherapy (ddAC followed by paclitaxel), paclitaxel 80 mg/m2 will be administered IV QW for 12 weeks.
46081717|NCT03493854|Drug|Pertuzumab IV|Pertuzumab will be administered as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.
45670303|NCT02302859|Behavioral|Phone Counseling Sessions|"Standard Treatment (ST) Group: Participants receive 8 phone counseling sessions (one session per week) for support in quitting smoking. The calls should last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief video clips with advice on how to quit smoking over smartphone, as well as interactive text and picture messages once a week for 8 weeks. The video clips will be about 5 minutes long.~Participants also have access to additional counseling content on the smart phone, which can be used at any time."
45455938|NCT05387499|Other|NP-011 (Placebo)|The participants will receive single dose of NP-011 after a minimum 8 hour fast on Day 1 in Single Ascending Dose part and will receive once daily for 7 days after a minimum 8 hour fast in Multiple Ascending dose part of the study
45455939|NCT05382039|Device|Transcutaneous Electrical Nerve Stimulation|High frequency sensory transcutaneous electrical nerve stimulation
45829283|NCT01911780|Drug|telmisartan + HCTZ|FDC tablet
45829284|NCT01911780|Drug|telmisartan + HCTZ|FDC tablet
45829285|NCT01911780|Drug|amlodipine|capsule
45829286|NCT01911546|Drug|everolimus + low-dose tacrolimus|Patients are supplied everolimus (Zortress) + prograf
45829287|NCT01910298|Procedure|Breast Reconstruction, Direct to Implant (DTI) with Strattice™|
45829288|NCT01910298|Procedure|Two Stage Breast Reconstruction|
45829289|NCT05116878|Dietary Supplement|Omega-3|One capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative
45829290|NCT05116878|Dietary Supplement|Placebo|One cellulose capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative
45829291|NCT01909674|Device|Switch CPAP mask type|
45829292|NCT05114694|Procedure|early APM|Early APM group were patients have knee syndrome within 3 to 6 months
45829293|NCT05114694|Procedure|delayed APM|delayed APM group recruit participants who received delayed APM surgery within 6 to 12 months
45829294|NCT01908816|Drug|ranibizumab|One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)
45829295|NCT01908582|Drug|Evacetrapib|Administered orally
45829296|NCT01908582|Drug|Rifampin|Administered orally
45829297|NCT04621188|Drug|Lorlatinib|100 mg once daily
45829298|NCT01908426|Drug|Cabozantinib tablets|
45829299|NCT01908426|Drug|Placebo tablets|
45829300|NCT01907100|Drug|Nintedanib|triple kinase inhibitor; 200mg starting dose
45829301|NCT01907100|Drug|Pemetrexed|backbone chemo
45829302|NCT01907100|Drug|Cisplatin|backbone chemo
45455940|NCT05378048|Drug|PDO-guided treatment|"A biopsy of the tumour will be performed for PDO culture and Genome-guided drug screening.~An Multidisciplanary Tumour Board will review the drug screen results and recommend the use of a drug with a response in a PDO."
45670304|NCT02302859|Other|Saliva Test|Participants complete saliva cotinine test 3 months after intervention.
45829303|NCT01907100|Drug|Cisplatin|backbone chemo
45829304|NCT01907100|Drug|Pemetrexed|backbone chemo
45829305|NCT01907100|Drug|Placebo|Nintedanib matching placebo
45829306|NCT01889862|Drug|BMN165 20mg/day|BMN165 20mg/day self-administered daily
45829307|NCT01889862|Drug|BMN165 40mg/day|BMN165 40mg/day self-administered daily
45829308|NCT01889862|Drug|Placebo|Non-drug placebo, self-administered daily
45829309|NCT01887912|Biological|C. difficile Toxoid Vaccine|0.5 mL, Intramuscular
45829310|NCT01887912|Biological|Placebo: 0.9% normal saline|0.5 mL, Intramuscular
45829311|NCT04415346|Biological|HU-014 Inj|Clostridium botulinum type A
45829312|NCT01887678|Drug|Traumeel® / Zeel® Injectable Solution|Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one IA injection) on treatment days 1, 8 and 15.
45829313|NCT01887678|Drug|Placebo|Placebo is an injection of Saline
45829314|NCT01887600|Drug|Roxadustat|Roxadustat was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with > 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
45829315|NCT01887600|Drug|Placebo|Placebo was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with > 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
45829316|NCT01887288|Drug|Capecitabine|650 mg/m^2 PO b.i.d.
45829317|NCT01887288|Drug|Digoxin|0.25 mg once daily
45829318|NCT01887210|Behavioral|IMB Gaming Adherence Intervention|Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
45829319|NCT01887210|Behavioral|Enhanced treatment as usual|Smart pill bottle cap and mobile phone but no game
45829320|NCT03405714|Drug|Brivaracetam|"Pharmaceutical form: Solution for iv injection~Route of administration: intravenous use~Concentration: 10 mg/ml"
45829321|NCT01885182|Drug|Oxycodone/Naloxone|
45829322|NCT01885182|Drug|Oxycodone|
45973048|NCT00238667|Drug|Antiplatelet (Aspirin, Dipyridamole, clopidogrel)|
45973049|NCT00238667|Drug|Anticoagulant (Unfractionated Heparin, LMW Heparin, Warfarin)|
45973050|NCT04534426|Drug|: Arnica montana|In Arnica group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
45973051|NCT04534426|Drug|Mucopolysaccharide polysulfate|In Arnica group and MPSP group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
45973052|NCT04534426|Other|Control group|In Control group, only standard therapy was performed after surgery
45973053|NCT00263016|Drug|Docetaxel|
45973054|NCT00238706|Device|Radiofrequency ablation|
45973055|NCT04534465|Drug|Polyethylene glycol (MiraLAX, BAY81-8430)|Oral solution, 17g polyethylene glycol, one time
45973056|NCT04534465|Drug|Mannitol|Oral, 2g, 4g, 6g, 8g and 10g mannitol, one time
45973057|NCT02216656|Drug|Placebo|Oral administration
45973058|NCT02216656|Drug|KHK7580 low dose|Oral administration
45973059|NCT02216656|Drug|KHK7580 middle dose|Oral administration
45973060|NCT02216656|Drug|KHK7580 high dose|Oral administration
45973061|NCT02216656|Drug|KRN1493|Oral administration
45973062|NCT00263055|Drug|oxaliplatin|
45973063|NCT00238745|Drug|Bazedoxifene|
45973064|NCT00238745|Drug|Placebo|
45973065|NCT04534348|Device|70% isopropyl alcohol-impregnated catheter caps|Implementation of 70% isopropyl alcohol-impregnated catheter caps in order to assess the number of CLABSI diagnosed during 1 Year
45973066|NCT04534231|Drug|Nicotine patch|Nicotine transdermal patches as per product monograph
45973067|NCT00263094|Drug|Rofecoxib|
45973068|NCT04534192|Device|JADE Balloon|Suitable TASC C and D lesions will be treated with non-compliant high pressure JADE balloon.
45670305|NCT02302859|Device|Smart phone|"Standard Treatment (ST) Group: Participants receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone."
45670306|NCT02274311|Drug|Clomiphene Citrate|Clomiphene citrate, 50 mg, orally for three months
45670307|NCT02316353|Biological|C1-esterase inhibitor|
45973069|NCT00238784|Drug|Budesonide/formoterol Turbuhaler|
45973070|NCT04534036|Dietary Supplement|PDS-08|PDS-08 is a novel synbiotic comprised of nine probiotic bacterial strains and FOS-inulin as a prebiotic.
45973071|NCT04534036|Other|Placebo|Placebo sachets will contain potato or tapioca maltodextrin.
45973072|NCT00263133|Drug|Sertraline|
45973073|NCT04533724|Drug|Amisulpride|The amisulpride treatment group was given amisulpride tablets. The dose: the initial dose was 50 mg/d. The doctor titrated the dose to the therapeutic amount within 1 to 2 weeks according to the patient's condition. The maximum dose was 300 mg/d, taken with a single meal. Observe for 8 weeks.
45973074|NCT04533685|Behavioral|Portal Reminders for Influenza Vaccination: Direct scheduling link|Patients receive reminder/recall messages via the patient portal to get an influenza vaccination that include a direct scheduling link, enabling the patient to directly schedule a flu vaccination only visit
45973075|NCT04533685|Behavioral|Portal Reminders for Influenza Vaccination: No direct scheduling link|Patients receive reminder/recall messages via the patient portal to get an influenza vaccination (no direct scheduling link included)
45973076|NCT04533685|Behavioral|Pre-Commitment Prompt|Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination
45973077|NCT04533685|Behavioral|Pre-Appointment flu vaccine reminders|Patients receive modified pre-appointment reminders for upcoming scheduled appointments that include language encouraging patients to ask the provider for the flu vaccine
45973078|NCT00263172|Behavioral|behavior modification for weight loss|
45973079|NCT00238901|Drug|Basiliximab|
45670308|NCT02273141|Drug|NER1006, Day Before-Only Dosing|The subject will self-administer both doses of NER1006 in the evening of Day 1 with 1-2 hours interval. Subject will take mandatory additional clear fluid after each dose.
45670309|NCT02273141|Drug|SP+MS, Day Before-Only Dosing|The subject will self-administer SP+MS in the morning of Day 1 and afternoon of Day 1. Subject will take mandatory additional clear fluid after each dose.
45670310|NCT02314052|Drug|DCR-MYC|"Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.125mg/kg/dose~Number of cycles: until progression or unacceptable toxicity develops.~PHASE 1b Dose escalation: 50% or 25% increase in subsequent cohorts depending upon toxicity until maximum tolerated dose (MTD) is identified.~PHASE 2 Cohort expansion at the MTD: Additional patients to be treated at the highest dose tolerated to assess efficacy and further assess safety"
45670311|NCT04870580|Diagnostic Test|Fluorodopa PET tracer|PET/CT scan using fluorodopa tracer
45973080|NCT04533490|Drug|SHR-1210|After the subjects were enrolled in the study, the patients were treated with SHR-1210 200mg igvtt q3w from 1 to 2 months after operation until disease progression or intolerable toxicity, and the longest medication period was no more than 12 months
45973081|NCT00263250|Procedure|watchful waiting or tension-free hernia repair|
45973082|NCT00238940|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
45973083|NCT04533139|Drug|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season antigens: A/New Caledonia/20/99(H1N1)-like, A/Wyoming/3/2003(H3N2), and B/Shanghai/361/2002-like antigens~2005-2006 season antigens: A/New Caledonia/ 20/00(H1N1)-like, A/California/7/2004 (H3N2)-like, and B/Shanghai/361/2002-like antigens"
45973084|NCT04533256|Procedure|CytoSorb|three consecutive sessions of hemoadsorption in patients with sepsis
45973085|NCT04533217|Procedure|Vertebroplasty|Injection of cement into vertebral lesion(s)
45973086|NCT04533178|Device|soft spinal brace|Use of a soft spinal brace 16 hours per day during the 6 week treatment period.
45973087|NCT04533178|Other|Resting from all sports activities|Resting from all sports activities
45973088|NCT00263289|Procedure|preprocedural fasting|
45973089|NCT00238979|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
45829323|NCT01885104|Drug|Polyethylene Glycol (PEG 3350)|Oral 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
45455941|NCT05378048|Drug|standard of care|the standard of care will include all treatments that have been reported to improve survival or quality of life in randomized trials.
45670312|NCT02279732|Biological|Paclitaxel|
45670313|NCT02279732|Biological|Carboplatin|
45670314|NCT02279732|Biological|Ipilimumab|
45670315|NCT02279732|Other|Placebo|0.9% sodium chloride injection, USP, or 5% dextrose injection
45670316|NCT05650034|Radiation|Elective nodal de-escalation arm|Omission of elective nodal irradiation in N0 hemi-neck of well lateralized H&N SCCs ( pN0 or by PETCT). Dose de-escalation of elective nodal irradiation in N0 hemi-neck of midline H&N SCCs ( pN0 or by PETCT).
45829324|NCT01885104|Drug|Placebo|Oral 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
45829325|NCT01885104|Drug|Bisacodyl laxative tablets (rescue medication)|5.0 mg tablets, 1 to 3 tablets in a single daily dose, to be provided for use as rescue medication if participant has not had bowel movement for 72 hours after start of treatment.
45829326|NCT04614324|Device|RhinAer ARC Stylus|The RhinAer procedure incorporates use of the RhinAer Stylus (Model FG815), which is a cleared (FDA - K192471) disposable handheld device capable of delivering bipolar radiofrequency energy to tissue. RhinAer has CE Marking in EU. The Aerin Console (Model FG226) RF generator with temperature control capable of delivering very low doses of energy was cleared for use in the US (FDA - K162810) and has CE Marking in the EU (CE639608).
45829327|NCT04613232|Device|Wearable sensor|The patients will be asked to wear an Apple Watch during their treatment course. The watch will pasively collect sensor data (heart rate and physical activity)
45829328|NCT04612374|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
45829329|NCT04612374|Behavioral|Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
45829330|NCT01881750|Behavioral|Pivotal Response Training (PRT)|12 week program on instruction of Pivotal Response Training, consisting of group meetings and individual sessions.
45829331|NCT01881750|Behavioral|Parent Education Group (PEG)|12 week program consisting of offering/discussion information for parents. No pivotal response training provided.
45829332|NCT01906008|Drug|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for 4 months beginning at chemotherapy initiation.
45829333|NCT01906008|Drug|Placebo|1 placebo by mouth for the first day of chemotherapy, then 1 dose every 12 hours for 4 months beginning at chemotherapy initiation.
45829334|NCT01906008|Behavioral|Questionnaires|Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit.
45829335|NCT01906008|Behavioral|Sensory Test|Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
45829336|NCT01863732|Biological|Secukinumab|Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
45829337|NCT01863732|Other|Placebo (Pbo)|Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
45829338|NCT01905540|Drug|SSP-004184AQ|Magnesium salt
45829339|NCT01905540|Drug|SSP-004184SS|Disodium salt
45829340|NCT01904760|Drug|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
45829341|NCT01904760|Drug|Saline placebo|Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day
45829342|NCT01904604|Biological|Placebo Viaskin® Patch|Placebo (e.g., no peanut) patch in an epicutaneous application for 24 hours every 24 hours.
45829343|NCT01904604|Biological|Low-dose DBV712 Viaskin® Patch|100 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
45829344|NCT01904604|Biological|High-dose DBV712 Viaskin® Patch|250 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
45829345|NCT01904058|Drug|LUM001|
45829346|NCT01904058|Drug|Placebo|
45829347|NCT01904058|Drug|Ursodeoxycholic Acid|
45829348|NCT01881126|Drug|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
45829349|NCT01881126|Drug|travatan 0.004%|Travatan 0.004% administered to both eyes once daily for 12 weeks.
45829350|NCT01881126|Drug|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
45829351|NCT01881126|Drug|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
45829352|NCT03357588|Other|Intensified monitoring|Intensified virological monitoring during first-line ART with viral load monitoring at month 6 of ART and 3-monthly thereafter, followed-up consecutively by point-of-care qualitative drug level testing and drug resistance testing in case of a viral load >1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.
45829353|NCT03357588|Other|Standard of care monitoring|Standard-of-care virological monitoring during first-line ART as described by WHO and South African National Department of Health ART guidelines, consisting of viral load monitoring at month 6 and 12 of ART and annually thereafter, followed-up by a repeat measurement within 3 months after a viral load >1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.
45829354|NCT01614600|Device|Nelfilcon A contact lenses|Commercially marketed hydrogel contact lenses for daily wear, daily disposable use
45455942|NCT05376540|Procedure|Direct gallbladder injection of ICG intraoperatively|Patients randomized to this arm will have 2.5 mg ICG injected directly into the gallbladder intraoperatively.
45670317|NCT02279498|Drug|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
45670318|NCT02279498|Drug|porcine (pig) PERT|oral, enterically-coated, pancreatic replacement enzymes prepared from a porcine source
45973090|NCT04533295|Device|acupuncture and IVF|Acupuncture was performed three times a week for 30 minutes each time, starting from the 5th day of menstruation and ending within 24 hours after embryo transfer.
45973091|NCT04533295|Device|sham acupuncture and IVF|Sham acupuncture was performed three times a week for 30 minutes each time, starting from the 5th day of menstruation and ending within 24 hours after embryo transfer.
45829355|NCT04611672|Diagnostic Test|Assessment of CA|As part of our routine stroke work up, each patient receives an initial CT scan with CT perfusion to indicate thrombolysis therapy (intravenous, mechanical, or both, depending on the time since first stroke symptoms and perfusion-mismatch), an MRI within 2 days, extracranial and transcranial Duplex ultrasound, echocardiography, continuous Monitoring of BP, O2, body temperature, NIHSS and Glagow Coma Scale (GCS) every 6 hours. Assessing CA by continuous recording of blood pressure, cerebral blood flow velocity, end-tidal CO2. Analysis via Transfer function estimates
45973092|NCT04532944|Diagnostic Test|imaging of energy dysfunction|7T sodium imaging, phosphorus spectroscopy and 3T diffusion-weighted spectroscopy
45973093|NCT04533061|Drug|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season contains: A/New Caledonia/20/99 (H1N1)-like, A/Fujian/411/2002 (H3N2-like), and B/Shanghai/361/2002-like antigens~2005-2006 season contains: A/New Caledonia/20/99 (H1N1)-like, A/California/7/2004 (H3N2), and B/Shanghai/361/2002-like antigens"
45973094|NCT00239018|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
45973095|NCT04532905|Other|Strength Training Exercises Therapy|Five type of exercises: dumbbell bent row over, deadlift, lunge, shoulder press, and squat with each three sets and 10 repetitions. Between each set there will be 2-3 minute rest period and 8-10 minute rest period among each exercise type.
45973096|NCT02216734|Behavioral|Mother support groups for HIV+ mothers|Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
45973097|NCT02216890|Drug|SGN-CD70A|Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks)
45973098|NCT04532983|Procedure|fixation of mesh prosthesis|in the first group mesh was fixed in position with laparoscopic tacks
45455943|NCT05376540|Procedure|Intravenous injection 2.5 mg|Patients randomized to this arm will have 2.5 mg ICG injected intravenously 1 hour prio to surgery
45455944|NCT05376540|Procedure|Intravenous injection and direct gallbladder injection|Patients randomized to this arm will have 2.5 mg ICG injected intravenously 1 hour prior to surgery and another 2.5 mg ICG injected directly into the gallbladder, intraoperatively.
45455945|NCT05376540|Procedure|Intravenous injection 5 mg|Patients randomized to this arm will have 5 mg ICG injected intravenously 0-8 hours prior to surgery
45973099|NCT04532983|Procedure|mesh placement without fixation|mesh placement in preperitoneal space without fixation
45973100|NCT04532866|Behavioral|Isolation and Confinement|Eight months of isolation and confinement in the spaceflight analog NEK in Moscow
46081718|NCT03493854|Drug|FDC of Pertuzumab and Trastuzumab SC|The FDC of pertuzumab and trastuzumab will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.
46081719|NCT03493854|Drug|Trastuzumab IV|Trastuzumab will be administered as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
45670319|NCT05649956|Drug|Letrozole|Letrozole 2.5 mg PO daily
45670320|NCT02307266|Behavioral|Standard of care + supplementary education|
45829356|NCT04611672|Diagnostic Test|Assesment of CA only|Assessing CA by continuous recording of blood pressure, cerebral blood flow velocity, end-tidal CO2. Analysis via Transfer function estimates
45670321|NCT02307266|Behavioral|Standard of care + additional visits|
45670322|NCT02307266|Behavioral|Standard of care|
45670323|NCT02279420|Device|g-Cath EZ™ Suture Anchor Delivery Catheter|This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
45670324|NCT04877132|Drug|olipudase alfa (GZ402665)|Patients will receive intravenous (IV) infusion of olipudase alfa
45829357|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
45455946|NCT05374837|Behavioral|Infant and young child feeding voice messaging intervention|A mobile voice and text messaging intervention aimed at improving IYCF practices will be delivered to mothers and fathers with young children (6-23 months). A total of 16 voice and text message, with the same content, will be sent over a 16-week period (1 voice + 1 text messages (with same content) per week x 16 weeks). Two types of messages will be included: 1) eight scripted and 2) eight unscripted messages from positive deviants. The content of the messages include: breastfeeding until two years of age, consuming a variety of foods within a given meal, the consistency of porridge (thick rather than thin), limiting sweets and fried foods, the importance of animal source foods, consuming vitamin A rich fruits and vegetables, consuming leafy greens, handwashing and feeding infants and young children fruits and vegetables produced by the household.
45455947|NCT05374291|Drug|Dapagliflozin 10 mg/day (oral)|Patients take 10 mg dapagliflozin or matching placebo once daily in the morning
45455948|NCT05374291|Drug|Placebo|Patients take 10 mg dapagliflozin or matching placebo once daily in the morning
45973101|NCT04532476|Device|Low level laser therapy|"Diode laser (Laser HF, Hager-Werken GmbH & Co., Duisburg, Germany) was applied to the RIGHT side. Laser was set at PDT mode (660nm) acupuncture therapy. The power of the laser was set at 90 mW in intervals of 80 seconds as recommended by the manufacturer.~The laser was applied perpendicular in contact with the mucosa on 1 point of the buccal and 1 point on the palatal side of the first molar approximately on the middle part of the root, with the 10mm distance from the laser to the mucosa. Each point was treated in 3 intervals, 80s each, in total 240s on vestibular and 240s on the palatal side per tooth. The treated surface was 1cm2. The power of the laser was 90mW, wavelength 660n, beam area 1 cm2, irradiance per target 0.09 W/cm2, during 240 seconds of treatment interval per point- 21.6J/cm2 of energy was delivered.~The same laser treatment was performed the next day, as the pain was noted to be highest within 24 hours after the placement of separators."
45973102|NCT04532671|Other|Poly ether ether ketone (PEEK)|PEEK has been used in dentistry so far in certain fields as for, removable and fixed dental prostheses, implants, and implant abutments as well as orthodontic devices, whereas in literature, it is mostly mentioned in relation to prosthetics. PEEK was predominantly processed out of CAD/CAM-supported milled out of prefabricated blanks. Producing dental restorations via Additive manufacturing is still hardly widespread
45973103|NCT04532671|Other|CADCAM Poly ether ether ketone (PEEK)|Increased demand for long-lasting restoration's properties have led to many improvements in the production techniques of posterior restorations such as CAD/CAM systems. This technique simplifies the production of indirect restorations and make it possible to use advanced materials as PEEK
45973104|NCT04532671|Other|indirect resin composite|CADCAM resin composite blocks using milling process
45973105|NCT00239057|Drug|Enteric-Coated Mycophenolate Sodium|
45973106|NCT04532593|Procedure|autologous adipose stem cell injection|Abdominal or buttock fat will be aspirated under local anesthesia or general anesthesia by conventional methods (0.5 ml fat was aspirated per 1 cm2 of skin graft area). The matrix component rich in adipose stem cells will be obtained by chopping, washing and centrifugation. The intervention treatment will be performed after the skin graft sutured. The stem cell components will be injected underneath the skin graft (0.05 ml/cm2).
45973107|NCT04532593|Procedure|saline injection|saline will be injected underneath skin graft (0.05 ml/cm2).
46081720|NCT03493854|Drug|Trastuzumab SC|After surgery (from Cycle 9 onwards), participants in Arm A will be allowed to switch from trastuzumab IV to trastuzumab SC, at the discretion of the investigator, in the countries where trastuzumab SC is routinely used. For participants who switch, a fixed dose of 600 mg trastuzumab SC (irrespective of the patient's weight) will be administered in the adjuvant phase.
45829358|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
45829359|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.
45829360|NCT01880424|Drug|Placebo|matching Placebo Capsules, Oral, once daily
45670325|NCT02278328|Drug|STX209 (15mg)|"A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (15mg) intervention is the low dose"
45670326|NCT02278328|Drug|placebo|A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The placebo intervention is the non-active placebo control dose
45670327|NCT02278328|Drug|STX209 (30mg)|"A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (30mg) intervention is the high dose"
45455949|NCT05369429|Behavioral|My Wellbeing Guide|The intervention includes cognitive behavioral therapy management strategies for health-related stress in the form of animated videos, interactive activities, and written content. The intervention will be delivered via an online application over an 7-week period. Intervention participants will also complete four assessments: baseline (at the beginning of the research study), post-intervention (7 weeks after baseline), a 6-month follow-up, and a 12-month follow up.
45829361|NCT01880424|Drug|Linaclotide|Linaclotide 290 ug Capsules, Oral, once daily
45829362|NCT01862874|Biological|V501|Formulated with aluminum hydroxyphosphate sulfate (AAHS) adjuvant
45829363|NCT01862874|Biological|Placebo|Formulated with AAHS adjuvant
45829364|NCT01879722|Drug|TAK-063|TAK-063 tablets
45829365|NCT01879722|Drug|TAK-063 Placebo|TAK-063 placebo-matching tablets
45829366|NCT01879410|Drug|UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI|The drug is administered via NDPI as one inhalation once daily in the morning. NDPI has two strips, each containing 30 blisters of medication. The first strip has UMEC blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 62.5 mcg per blister and the second strip has VI blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 25 mcg per blister.
45455950|NCT05364580|Biological|PROTOXIN|Botulinum toxin Type A
45455951|NCT05364580|Biological|Botox®|Botulinum toxin Type A
45670328|NCT04884152|Procedure|Home Exercise Group|Educational training program about bruxism and the other oral parafunctional activities in patients with myofascial temporomandibular disorders.
45973108|NCT02216968|Behavioral|Increase vegetable intake in pre-school children|"6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
45973109|NCT00238082|Drug|HFA-134A Beclomethasone DIpropionate (QVAR)|
45973110|NCT02217007|Drug|SNC-102 sustained release tablet|SNC-102 is an 800 mg tablet. It will be administered twice daily (morning and evening) for a total of 8 weeks: the initial 4 weeks will be 1 tablet in the morning and 1 tablet in the evening; the next 4 weeks will be 2 tablets in the morning and 1 tablet in the evening.
45973111|NCT02217046|Procedure|device replacement(pocket capsule removal)|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
45973112|NCT02217124|Other|dried apples|120 calories
45973113|NCT02217124|Other|muffin|120 calories
45973114|NCT05897931|Other|Connective tissue massage|Connective Tissue Massage will be applied by starting from the lumbosacral region, continuing from the lower thoracic region, and finishing by applying it to the scapular region, interscapular region, and cervico-occipital region.
45973115|NCT05897931|Other|Kinesio Tape Application|"Taping will be applied to the levator scapula and upper trapezius muscles in a Y shape, with 25% tension and while the participants were in an upright position. Again in the same position, this time the C shaped taping technique will be adhered with 50% tension from the middle fibers of the trapezium to the last rib."
45973116|NCT05897905|Behavioral|Personalised, holistic follow-up appointments underpinned by self determination theory|"Appointment 1 (two weeks after discharge):~Address participants knowledge gaps as regards their stroke, medication and secondary prevention.~Detailed biopsychosocial review.~Understand participant priorities and jointly set goals.~Agreeing onward referrals if needed.~Written summary sent to GP with copy to participant.~Appointment 2 (six weeks):~Review priorities identified in post stroke review checklist.~Review goals and plans from first appointment.~Address any new or persistent information gaps.~Review hidden impairments that may be impacting on return to work, activities of daily living, relationships or general well-being.~Agreeing onward referrals and action plan.~Written summary and plan sent to GP."
45973117|NCT05897879|Biological|Nasopharyngeal swab|"For hospitalized patients :~Nasopharyngeal swab (1 aspiration or 2 swabs (1 in each nostril))~For ambulatory patients :~Deep nasal swab: 2 swabs (1 in each nostril), or 1 swab only for children for whom taking 2 swabs is complicated."
45973118|NCT05897879|Biological|Blood samples|For hospitalized patients : 3 to 7.5 ml For ambulatory patients: Fingertip blood sampling
45973119|NCT05897840|Device|Fiber-optic probe CeVOX|Installation of the fiber-optic probe within the existing central venous catheter for continuous monitoring of SvcO2
45829367|NCT01879410|Drug|FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS|The drug is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains a single strip with 60 blisters of medication. The strip has 250 mcg of fluticasone propionate and 50 mcg of salmeterol per blister in the form of dry white powder.
45973120|NCT05897827|Behavioral|PLANTS|PLANTS intervention is an online-delivered training program, including asynchronous and synchronous activities. This intervention was informed by the Information-Motivation-Behavior theory to target skills, self-efficacy, knowledge, and outcome expectations. There are 3 asynchronous online modules that cover a variety of topics including lessons on LGBTQ+ terminology, names and pronouns, resources, antibullying, gender neutral bathrooms, student confidentiality, active empathic listening, and school policies. Module include recorded presentations, student testimonials, activities, and downloadable resources for future reference. Every month, 7-9 lessons are opened. There are 2 synchronous group events delivered via Zoom and are 1.5 hours each.
45973121|NCT05897827|Behavioral|EMAILS|The active control arm is an email-based intervention, EMAILS, in which existing public resources for supporting, affirming, and protecting LGBTQ+ students are emailed to participants.
45973122|NCT05897814|Other|Location of the epidural analgesia catheter|Research of the location of the epidural analgesia catheter using M-mode and color Doppler (cD) ultrasonography.
45829368|NCT01879410|Drug|Placebo DISKUS|Placebo is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains 1 strip with 60 blisters of placebo in the form of dry white powder.
45829369|NCT01879410|Drug|Placebo NDPI|Placebo is administered via NDPI as one inhalation once daily in the morning. The inhaler contains 2 strips with 30 blisters of placebo per strip in the form of dry white powder.
46081721|NCT03493854|Procedure|Surgery|Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.
45829370|NCT04415268|Behavioral|Exercise|Surpervised exercise program: Includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions.
45670329|NCT04884152|Procedure|Telerehabilitation Group|Telerehabilitation program combined with educational training program about bruxism and the other oral parafunctional activities in patients with myofascial temporomandibular disorders.
45829371|NCT04415268|Behavioral|Unsupervised exercise|Unsupervised exercise program: The same exercise program learned during the supervised phase will be practiced at home.
45670330|NCT02314637|Drug|Teneligliptin|Teneligliptin for 52 weeks
45670331|NCT02314637|Drug|Teneligliptin + Sulfonylurea|Teneligliptin for 52 weeks in combination with sulfonylurea
45670332|NCT04877054|Behavioral|Adherence Treatment Program|4 telehealth sessions including a combination of psycho/medical education plus a motivational interviewing component.
45670333|NCT04877054|Behavioral|Education only|The control group will receive an education-only session. Education will include medication purpose and adherence strategy recommendations delivered in a single telehealth session.
45670334|NCT04876430|Drug|Meropenem|Meropenem 2g every 8h for patients with glomerular filtration rate (GFR) equal or higher that 50 mL/min. Dose adjustment is recommended for patients with GFR < 50mL/min.
45670335|NCT01646645|Biological|CMV-pp65 CTLs|Patients will be treated with CMVpp65-CTLs derived from their transplant donor. These will be patients with CMV seropositive transplant donors who have previously provided leukocytes for generation of CMVpp65-CTL and for whom such CMVpp65-CTL are available. The T-cells to be infused will be selected based on criteria mentioned in section 4.0 from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 106 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
45670336|NCT02272985|Other|[15O]H2O PET-CT scan|All participants will undergo 3 [15O]H2O PET-CT scans during the hemodialysis study session
45670337|NCT02272985|Other|NIRS (Invos)|All participants will undergo near infrared spectroscopy (NIRS) during the hemodialysis study session.
45670338|NCT01644149|Device|Stratis Jet Injector|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
45829372|NCT04415268|Drug|CFTR Modulators|"Standard of care: Lumacaftor with Ivacaftor or Tezacaftor combined with Ivacaftor.~For children between 6 and 11 years of age, Lumacaftor 400 mg combined with Ivacaftor 500 mg in total per day, divided into 2 doses per day; for those over 11 years of age, Tezacaftor 100 mg combined with Ivacaftor 150 mg in the morning, adding a dose of Ivacaftor 150 mg at night.~https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000833-37/ES"
45829373|NCT05114148|Device|Holmium-166 radioembolization|Individualized 166Ho-RE will be performed via a catheter during angiography. Dosimetry-based treatment planning will be individualized based on Q-Suite™ software.
45829374|NCT01903434|Drug|Evacetrapib|Administered orally
45829375|NCT01903356|Drug|Trajenta duo|Linagliptin and Metformin
45829376|NCT04618770|Device|Triathlon PSR Tibial Insert|The Triathlon PSR Tibial Insert is intended to be used as a component in primary TKA and is designed to reduce rotational constraint at deep flexion.
45829377|NCT01862796|Behavioral|Underfeeding diet|Heart healthy diet with 35% reduced calories
45829378|NCT01862796|Behavioral|Weight maintaining diet|Heart healthy weight-maintaining diet
45829379|NCT01878084|Other|bioactive glass (sol-gel)|Extraction sockets will be augmented using bioactive glass (sol-gel)
45829380|NCT01878084|Other|empty extraction socket|Extraction socket will be left empty
45829381|NCT01862640|Drug|Brexpiprazole, OPC-34712|Once-daily, tablets
45829382|NCT01862640|Drug|Placebo Oral Tablet|Once-daily, tablets
45829383|NCT01902966|Drug|Propranolol|Starting dose: 20 mg is taken by mouth twice a day (40 mg/day).
45829384|NCT01902966|Behavioral|Diary|Patients record study medication taken each day in a pill diary. Relaxation diary completed after listening to audio sessions twice a week.
45829385|NCT01902966|Behavioral|Relaxation Audio Recording|Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes.
45829386|NCT01902966|Behavioral|Questionnaires|Questionnaires completed at baseline, 2 months, and 4 months.
45829387|NCT01862484|Dietary Supplement|Restricted Diet|Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
45829388|NCT01862484|Dietary Supplement|Ruse Diet|Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet
45829389|NCT01902888|Device|GORE® VIABAHN® Endoprosthesis|
45829390|NCT01862328|Drug|MLN4924|"MLN4924 (intravenously [IV]) in participants in a 21-day cycle:~MLN4924 on Days 1,3,5 of each cycle"
45829391|NCT01862328|Drug|Paclitaxel|"Paclitaxel (IV) in a 21-day cycle:~Paclitaxel on Day 1 of each cycle"
45829392|NCT01862328|Drug|Gemcitabine|"Gemcitabine (IV) in participants in a 28-day cycle:~-Gemcitabine on Days 1,8,15 of each cycle"
45829393|NCT01862328|Drug|Docetaxel|"Docetaxel (IV) in participants in a 21-day cycle:~- Docetaxel on Day 1 of each cycle"
45829394|NCT01862328|Drug|Carboplatin|"Carboplatin (IV) in participants in a 21-day cycle:~- Carboplatin on Day 1 of each cycle"
45829395|NCT01862250|Drug|Clonidine (Duraclon®)|"Clonidine at dosing intervals of 6, 8, 12, 18 or 24 hours. If the following is observed the event will be recorded, and no additional clonidine will be given and blood will be drawn to measure plasma level of clondine.~10 mm Hg reduction in MAP or MAP ≤ 40 mm Hg sustained for ≥30 min after administration~20% drop in HR from the infant's baseline, sustained for ≥30 min after administration~HR ≤70/min, sustained for ≥30 min after administration"
45829396|NCT01901874|Device|Carotid Artery Stenting|Carotid Artery Stenting with the GORE® Carotid Stent
45829397|NCT01860534|Behavioral|eye covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and unpatched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
45829398|NCT01901328|Drug|CB-5945|
45829399|NCT01901328|Drug|Placebo|
45973123|NCT05897801|Diagnostic Test|MeMed BV®|One blood sampling of 3ml will be drawn on the first day for the performance of the MeMed BV® test. Two rectal swabs will be taken for determining the MDRO gut colonization. Patient information regarding the specific respiratory tract infection and the treatment regimen being prescribed will be recorded in the eCRF made specifically for this trial.
45973124|NCT05897788|Behavioral|Text Message Check-ins|Patients will receive automated text-message check-ins up to once per day for 30 days to see if the patient needs help with anything AND patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week.
45973125|NCT05897788|Behavioral|Contingency Management|Patients will receive incentives for engagement with treatment. Participant will receive compensation for filling their buprenorphine scripts at discharge and attending their follow-up care appointments.
45973126|NCT05897775|Device|Deep brain stimulation|"Thalamic coordinated reset DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS that uses continuous high amplitude, high frequency stimulation.~Each participant will receive both the new intervention and the standard of care intervention, each for a week."
45973127|NCT05897762|Behavioral|Tele rehabilitation Group|It has been determined that the telerehabilitation method applied in chronic hemiplegic patients increases daily living activities, upper extremity functionality, and spasticity levels decrease.
45973128|NCT05897749|Other|Brucea javanica oil emulsion injection|Drug: Brucea javanica oil emulsion injection Brucea javanica oil emulsion injection: intravenous drip, 30ml each time (add 250ml sterile physiological saline),once a day, 14 consecutive days as a cycle, at least 2 cycles completed. The best supportive treatment:According to the NCCN Best Palliative Treatment Guidelines (2022. V1), provide the best supportive treatment
45973129|NCT05897749|Other|The best supportive treatment|The best supportive treatment:According to the NCCN Best Palliative Treatment Guidelines (2022. V1), provide the best supportive treatment
45973130|NCT05897723|Device|Fractional Radiofrequency|Fractional Radiofrequency (RF) delivering nano-fractional RF energy, causing fractional ablation and coagulation at the treatment site.
45973131|NCT05897710|Other|Virtual World-Based Cardiac Rehabilitation (VWCR)|12-week virtual world technology-based program via Second Life platform. Weekly virtual visits with nurse coach and exercise physiologist, weekly education sessions, and social support group discussions within the virtual world environment.
45973132|NCT05897710|Other|Center-Based Cardiac Rehabilitation (CBCR)|Traditional 12-week in-person cardiac rehabilitation program; standard of care at participant's cardiac rehabilitation facility
45973133|NCT05897658|Drug|Levetiracetam|Tablets
45973134|NCT05897658|Other|Placebo|Tablets
45973135|NCT05897645|Other|Registration|collect clinical date, assess the morphologic characteristics of plaque
45973136|NCT05897632|Behavioral|Outpatient Evaluation|Subjects will receive an outpatient evaluation within 72 of being discharged from the ED.
45670339|NCT01644149|Device|Needle and Syringe|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
45670340|NCT01644149|Biological|2011-2012 Fluzone trivalent inactivated influenza vaccine|
45670341|NCT02313233|Dietary Supplement|Umooze|Umooze is consisted of Astragalus radix extracts and soy extracts. Astragalus radix (AR) is the dried root of Astragalus membranaceus Bge. Var. mongholicus and is used as a tonic in the traditional Chinese medicine. According to the reports submitted by the National Cancer institute of American, people who eat soybean products can reduce the incidence rate for prostate cancer. The composition of Umooze is invented by Golden Biotechnology Corp. against prostatic hyperplasia.
45829400|NCT01859988|Drug|Dupilumab|
45829401|NCT01859988|Drug|Placebo|
45829402|NCT01876446|Other|Laboratory Biomarker Analysis|Correlative studies
45973137|NCT05897632|Behavioral|Hospitalization Evaluation|Patients randomized to this arm receive evaluation for their symptoms in a hospital ward, observation unit, or emergency department boarding.
45973138|NCT05897606|Combination Product|Multiviamins and minerals|The intervention group received one capsule of multivitamin and minerals supplements every day, one hour after breakfast, for 12 weeks.
45973139|NCT05897606|Combination Product|Placebo|Placebo
45973140|NCT05897580|Behavioral|Heart Rate Variability - Biofeedback (HRV-BF)|"The HRV-BF was delivered over 30 minutes once weekly for 8 weeks by our nurse-led Community Health Worker (RN/CHW) team trained to deliver scripted material created by a trained biofeedback practitioner on our study team. The weekly sessions included the use of a tablet device to share a 10-minute video which teaches the basic techniques and breathing practices of HRV-BF and guiding the participant through a 20-minute practice, using the techniques while watching their heart rate data in real time using an HRV-BF device, the EmWave Pro (HeartMath).~Participants were also asked to complete daily practices on their own, without the HRV-BF device, for 10 minutes, twice a day, to reinforce topics and skills taught in videos. Practices logged by the participant were collected weekly by the CHW and referral to resources were provided."
45829403|NCT01876446|Drug|Pegylated Irinotecan|Given IV
45829404|NCT01876446|Other|Pharmacological Study|Correlative studies
45829405|NCT04599660|Other|Treatment of Low Risk GISTs according clinical practice (includes drugs, surgery or any other received treatments)|This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments
45973141|NCT05897580|Behavioral|Health Promotion (HP)|The HP active control group was delivered over 30 minutes, once weekly for 8 weeks by our nurse-led Community Health Worker team, trained to deliver scripted materialized content created. In the HP program, PEH were educated on common physical chronic diseases PEH experience, including hypertension, diabetes, heart disease and arthritis, along with referrals provided based on needs expressed by PEH.
45973142|NCT05897567|Other|resistance training|All participants perform a four-day resistance training aimed to stimulate a hypertrophic response.
45973143|NCT05897567|Other|ketogenic diet|Subjects allocated to the ketogenic diet arm (KD group) consume less than 50 g of carbohydrates per day.
45973144|NCT05897567|Other|western diet|Subjects allocated to the western diet arm (WD group) consume a standard diet based on 55% of their daily calories from carbohydrates.
45973145|NCT05897528|Other|No Intervention|Difference in outcomes in patients with COVID-19 diagnosis and diabetes mellitus groups
45973146|NCT05897515|Diagnostic Test|LIAISON NES FLU A/B & COVID-19|The LIAISON® NES FLU A/B & COVID-19 assay used on the LIAISON® NES instrument is a real-time PCR system that enables the direct amplification, detection and differentiation of Flu A viral RNA, Flu B viral RNA and SARS-CoV-2 RNA from dry nasal swabs. Nasal Swabs can be professionally collected by a Healthcare Provider or self-collected by the patient under the supervision of the healthcare provider. The collected nasal swab can then be directly loaded into the cartridge without nucleic acid extraction.
45973147|NCT05897502|Behavioral|multimedia education|"The experimental group use multimedia education, 20 minute nutrition education courses each time, a total of 8 courses.~The control group use routine education."
45973148|NCT05897476|Other|ultrasound|brief external ultrasound will be proceed on each patient included searching signs of aortic dissection
45973149|NCT05897424|Drug|INBRX-101|A1PI, Recombinant, Bivalent Fc Fusion Protein
45973150|NCT05897411|Behavioral|Unmasking previous conditioning procedure|An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will be provided.
45973151|NCT05897411|Behavioral|No unmasking of previous conditioning|An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will not be provided.
45973152|NCT05897398|Other|Data collection|Data collected at initiation, 6 months and 12 months of WEGOVY® treatment will be retrospectively extracted from the WEGOVY® ATU/AP2 eCRF.
45973153|NCT05897398|Other|Blood sampling|Blood sampling for routine care (max 15mL) and constitution of a plasma bank (28 mL)
45973154|NCT05897398|Other|Questionnaires|"Completion of questionnaires for the entire cohort:~To assess hyperphagia and eating behaviour: BES, DEBQ and Hunger Score questionnaire To assess physical activity: short IPAQ To assess sleep behaviour: MCTQ To assess quality of life: EQ5D5L To assess digestive system disorders: GIQLI To assess anxiety and depression: HAD"
45973155|NCT05897385|Drug|Lignocaine|Intraperitoneal lignocaine 200mg/20mls + epinephrine 1:200,000
45973156|NCT05897385|Drug|Normal Saline|Intraperitoneal 20ml of 0.9% normal saline
45973157|NCT05897372|Drug|ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib|Standard of care for diabetic kidney disease.
45670342|NCT02313233|Dietary Supplement|Placebo|Placebo is consisted of cornstarch and is provided by by Golden Biotechnology Corp.
45670343|NCT02305238|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Aflibercept 2mg is intravitreally injected.
45670344|NCT02313155|Drug|Subcutaneous injection of TAK-850|TAK-850 0.5 mL, Subcutaneous injection
45973158|NCT05897359|Behavioral|bCBTMI|This experimental group involves 4 weekly 30-45 minute sessions using the brief CBT and the brief MI models by trained nursing students.
46081722|NCT03493854|Radiation|Post-operative Radiotherapy|If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).
45670345|NCT02313155|Drug|Intramuscular injection of TAK-850|TAK-850 0.5 mL, Intramuscular injection
45973159|NCT05897359|Behavioral|Control|The control group will receive health talks about internet addiction consequences and impacts on young people by nursing students who are not involved in the intervention group to mimic the time and attention spent on the intervention group. These health talks are considered routine care for IA health promotion.
45973160|NCT05897346|Other|'Learning while serving' training program|The training program will involve training workshops, hands-on sessions, and a smoker referral competition.
45973161|NCT05897346|Other|Usual care|A 3-hour training workshops in the control group are regarded as usual care since the training workshops are also conducted regularly to other secondary or tertiary schools.
45973162|NCT05897307|Drug|Ropivacaine|dexmedetomidine
45973163|NCT05897294|Drug|Voriconazole Inhalation Powder|dry powder inhalation of voriconazole
46081723|NCT03493854|Drug|Hormone Therapy|For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
46081724|NCT03473223|Biological|Apolipoprotein A-I [human] (apoA-I)|Apolipoprotein A-I [human] (apoA-I) purified from human plasma for intravenous administration
46081725|NCT03473223|Other|Placebo|25% albumin solution diluted to 4.4%
45670346|NCT02204293|Drug|Canakinumab|Canakinumab, single-dose 4 mg/kg up to 300 mg administered subcutaneously.
45670347|NCT02204293|Drug|Placebo|Matching placebo administered subcutaneously.
45670348|NCT02304926|Drug|Simvastatin|simvastatin (40 mg/day) for 4 weeks
45670349|NCT02304926|Drug|Ezetimibe|ezetimibe (10 mg/day) for 4 weeks
45670350|NCT02304926|Drug|Simvastatin + Ezetimibe|combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period
45670351|NCT01646255|Drug|Rotigotine|"Transdermal Patch~Content:~4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)~For advanced-stage Parkinson's Disease, subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 12 week maintenance period"
45670352|NCT01646255|Drug|Placebo Patch|"Transdermal Patch~Size:~20 cm^2, 30 cm^2, 40 cm^2~Subjects randomized to placebo received matching placebo patches"
45973164|NCT05897281|Procedure|SHOOT exercise group|In addition to routine training, the experimental group will be done a progressive resistance band exercise program (SHOOT) created for shooters, 3 days a week for 8 weeks, accompanied by a physiotherapist.
45973165|NCT05897281|Procedure|routine training group|The control group will continue their routine training
45973166|NCT05897255|Device|Surface EMG Biofeedback|Surface EMG activity will be recorded from the left and right abdominal muscles while the exercises will be performed in different positions. Electrical signals in the muscle are measured and displayed on the screen and are amplified into sounds that the patient can hear. This feedback increases patient effort and participation and provides the data and documentation required to measure patient outcomes and quantify progress. Electrical activity from Rectus Abdominis muscle, External Oblique muscle and Transversus Abdominis muscle will be recorded with their specific exercises. SEMG Biofeedback protocol of a series of ten second contractions, each contraction preceded by a ten second rest period will be followed. Starting with shorter work/rest periods as needed to build-up to these intervals are acceptable; for example, starting with 3-second contractions and 6-second rest periods, and then gradually increasing the duration of each.
45973167|NCT05897242|Behavioral|Smartphone app|Use ACT on Vaping smartphone app
45973168|NCT05897242|Other|Text Message|Receive text messages
45973169|NCT05897242|Other|Survey Administration|Ancillary studies
45973170|NCT05897216|Drug|CKD-383|QD, PO
45973171|NCT05897216|Drug|CKD-501, D745, D150, D029|QD, PO
45973172|NCT05897203|Drug|TAZCOV|Herbal Syrup
45973173|NCT05897203|Drug|Vidicine|Herbal Syrup
45973174|NCT05897112|Drug|Group A received cryotherpay|Group A were subjected to weekly cryotherapy with a cotton stick dip ped in Liquid Nitrogen for 02 Freezes and Thaw Cycle of 07 seconds with each cycle 10 seconds apart for 3 weeks
45973175|NCT05897112|Drug|Group B received 10% Potassium Hydroxide Solution|Group B applied 10% potassium hydroxide aqueous solution twice daily with the help of a cotton tip applicator until lesion showed signs of inflammation or clearance for 3 weeks
45973176|NCT05897086|Drug|Polyethylene Glycol 3350|Topical irrigation with approximately 2 ccs of a 190 mM solution of 50% PEG 3.35 kD in sterile water
45973177|NCT05897073|Behavioral|Time-restricted eating intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window.
45973178|NCT05897073|Behavioral|Exercise intervention|The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion >7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at >85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
45973179|NCT05897073|Behavioral|Time-restricted eating plus exercise intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window. The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion >7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at >85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
45973180|NCT05897060|Device|Venus Jugular O2 Saturation optical fiber|A continuous measurement of VjO2S, the usual reference measurement of the marketed devices, will be performed by implanting an optical fiber (CEVOX, PULSION Medical Systems) through an internal jugular catheter in addition to the classical catheter of the external electro-systolic drive probe. The following parameters will be recorded every 2 seconds: invasive blood pressure (systolic, mean and diastolic), heart rate, SaO2 on the pulse wave. VjO2S will be recorded continuously during the entire implantation procedure. The time of the beginning of the surgical incision, of the beginning of sinus tachycardia (overdriving) induced by external electro-systolic stimulation, of the beginning of inflation of the intravalvular aortic balloon, of the maximum occlusion of the balloon, of the end of complete deflation of the balloon, of the end of stimulation and of the end of skin closure will be recorded.
45973181|NCT05897047|Combination Product|Additional interventional telemedical management|Predefined additional telemedical management including regular telemedicine visits and automatic data transfer (e.g. vital signs, well-being, medication plan laboratory data and chat) between the patient at home and KTC through a certified smartphone application.
45973182|NCT05896995|Other|Pilates Exercise|Pilates exercises target the deep muscles of the core, including the abdomen, lower back, hips, and glutes, while also engaging the whole body.
45973183|NCT05896995|Other|Mckenzie Exercise|The McKenzie Method emphasizes self-treatment and active patient involvement in the management of their condition. It involves a systematic assessment process to determine the most appropriate exercises and interventions for an individual based on their specific symptoms and movement responses.
46081726|NCT03470155|Procedure|mitral valve repair|operative reconstruction
46081727|NCT03459456|Behavioral|Provocation OC task (Provoc)|used to evoke OC-related distress
45670353|NCT01646255|Drug|L-dopa|Subject must be on a stable dose of L-dopa (either short-acting or sustained release [in combination with benserazide or carbidopa]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.
45670354|NCT04870229|Drug|Carnosine|
45670355|NCT04870229|Drug|Placebo|Placebo
46081728|NCT03459456|Behavioral|Trier Social Stress Test (TSST)|used to evoke anxiety unrelated to OCD (e.g., performance anxiety)
45973184|NCT05896982|Other|Care as usual with information support|Comprises of additional visual information in the form of two videos that show details about the procedure on both days of the MPI diagnostic procedure. Each of these two videos are approximately 5 minutes long and are made available to the patients before the first day (video 1), and in between the first and second day (video 2).
45973185|NCT05896982|Other|Care as usual with supportive coaching|Patients receive coaching from one person who is present throughout the complete diagnostic process. The coach is available for answering questions as well as comforting the patients when necessary (e.g., to reassure patients if they are anxious or stressed).
45973186|NCT05896982|Other|Care as usual with information support and supportive coaching|This intervention comprises additional visual information in the form of two videos and coaching throughout the diagnostic process as described above.
45973187|NCT05896969|Drug|SNK-396 - SAD cohort|A single dose of SNK-396 within the dose range of 25 to 800 mg, or matching placebo.
45829406|NCT01900626|Drug|epidural catheter|epidural catheter with 0.3% ropivacaine
45973188|NCT05896969|Drug|SNK-396 - MAD Cohort|Multiple doses of SNK-396 within the dose range of from 25 to 800 mg, or matching placebo.
45973189|NCT05896956|Other|no interventions|no interventions
45973190|NCT05896943|Drug|Ustekinumab|Patients with ulcerative colitis treated with ustekinumab
45973191|NCT05896930|Drug|Meropenem 6g IV over 6 hours|Meropenem 6g intravenously over 6 hours once daily on days 1-14.
45973192|NCT05896930|Drug|Ertapenem 1g IM|Ertapenem 1g intramuscularly once daily on days 1-14.
45973193|NCT05896930|Drug|Meropenem 3g IV|Meropenem 3g intravenously twice daily over 60 minutes on days 1-14.
45973194|NCT05896930|Drug|Ertapenem 1g IV|Ertapenem 1g intravenously once daily on days 1-14.
45973195|NCT05896930|Drug|Amoxicillin/CA twice daily|Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally 12-hourly on days 1-14.
45973196|NCT05896930|Drug|Rifampicin 35 mg/kg|Rifampicin 35 mg/kg once daily on days 1-14.
45973197|NCT05896930|Drug|Meropenem 6g IV over 60 minutes|Meropenem 6g intravenously once daily over 60 minutes on days 1-14.
45973198|NCT05896930|Drug|Rifafour e-275|Rifafour e-275 will be supplied as fixed dose combination tablets and administered orally once daily for 14 days as The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.
45973199|NCT05896930|Drug|Meropenem 4g IV|Meropenem 4g intravenously once daily over 60 minutes on days 1-14.
45829407|NCT04414800|Drug|Placebo|Distilled water
45829408|NCT04414800|Drug|Ketamine|1 mg/kg intranasal ketamine
45973200|NCT05896930|Drug|Amoxicillin/CA once daily|Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally once daily on days 1-14.
45973201|NCT05896904|Diagnostic Test|Echocardiography|Echocardiography
45973202|NCT05896891|Diagnostic Test|esophagogastroduodenoscopy (EGD), buccal swab, blood withdrawal|During routine EGD, byopsy, blood and buccal saliva samples will be withdraw and stored at San Raffaele Hospital
45973203|NCT05896852|Behavioral|physical activity|Participants will increase their physical activity through walking.
45973204|NCT05896839|Procedure|Biopsy|Undergo tumor biopsy
45829409|NCT04414800|Drug|Fentanyl|1μg/kg intranasal fentanyl
45829410|NCT01900314|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the sham arm.
45829411|NCT01899768|Drug|GSK2339345|Clear colorless solution in clear glass vial for oral inhalation via aqueous droplet inhaler with unit dose strength of 1000 microgram (mcg) inhaled in two actuations.
45973205|NCT05896839|Procedure|Biospecimen Collection|Undergo blood sample collection
45973206|NCT05896839|Procedure|Computed Tomography|Undergo CT scan
45973207|NCT05896839|Biological|Ipilimumab|Given IV
45973208|NCT05896839|Procedure|Kidney Biopsy|Undergo kidney biopsy
45973209|NCT05896839|Procedure|Magnetic Resonance Imaging|Undergo MRI
45973210|NCT05896839|Biological|Nivolumab|Given IV
45973211|NCT05896839|Drug|Prednisone|Given PO
45973212|NCT05896839|Drug|Sirolimus|Given PO
46081729|NCT03459456|Behavioral|Exposure provocation task|used to elicit overt OCD rituals
45973213|NCT05896826|Device|Magnetometer|inspection equipment for magnetocardiography
46081730|NCT03448042|Drug|Runimotamab|Runimotamab will be administered via IV infusion until disease progression, intolerable toxicity, or any other discontinuation criteria are met.
46081731|NCT03448042|Drug|Trastuzumab|Trastuzumab will be administered via IV infusion
45973214|NCT05896813|Drug|CMOP+Chidamide|Cyclophosphamide: 750 mg/m2, d1; Mitoxantrone Hydrochloride Liposome: 20 mg/m2, d1; Vincristine: 1.4 g/m2, d1 (maximum dose of 2 mg), or vindesine 3 mg/m2, d1; Prednisone: 60 mg/m2, d1-d5; Chidamide:20 mg, biw. The treatment is administered every 3 weeks as a cycle and lasts for a total of 6 cycles.
45973215|NCT05896800|Device|Nitric Oxide Generation and Delivery System|The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
45973216|NCT05896787|Drug|AK104, nab-paclitaxel, carboplatin|AK104 plus nab-paclitaxel and carboplatin as neoadjuvant therapy，and AK104 as adjuvant therapy for those who do not achieve pCR;
45973217|NCT05896774|Drug|Maplirpacept|Study drug will be administered intravenously with adjustment for body weight weekly over 28-day cycles.
45973218|NCT05896761|Drug|Cabotegravir Injectable Suspension|CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 milligrams per milliliter (mg/mL) of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.
45973219|NCT05896761|Drug|Rilpivirine Injectable Suspension|RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
45973220|NCT05896748|Drug|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
45973221|NCT05896748|Drug|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
45973222|NCT05896722|Other|Core muscle endurance|Trunk flexion, trunk extension, side bridge exercises and prone bridge test developed by McGill will be used to evaluate core muscle endurance.
45973223|NCT05896722|Other|Upper extremity muscle strength|Isometric muscle strength assessment of the shoulder, elbow and wrist muscles will be performed with a hand-held dynamometer.
45973224|NCT05896722|Other|Grip strength|Grip strength will be evaluated with a hand dynamometer in the position recommended by the American Association of Hand Therapists.
45973225|NCT05896722|Other|Pinch strength|Pinch strength will be evaluated with a pinchmeter in three positions.
45973226|NCT05896722|Other|Alternate hand-wall toss test|To measure hand-eye coordination, it is performed by changing hands by throwing and catching the ball against the wall.
45973227|NCT05896709|Other|MK-RS|The embryos are assessed by the AI-enhanced MK analysis together with RS analysis.
45973228|NCT05896683|Drug|Lazertinib|Lazertinib will be administered orally.
45973229|NCT05896670|Biological|Licaminlimab ophthalmic suspension 60 mg/mL|Screening phase, an artificial tears run-in phase, a 6-week treatment phase, and a 2-week follow-up.
45973230|NCT05896670|Other|placebo (vehicle of Licaminlimab ophthalmic suspension)|Screening phase, an artificial tears run-in phase, a 6-week treatment phase, and a 2-week follow-up.
45973231|NCT05896657|Dietary Supplement|Ligilactobacillus salivarius CECT5713|Oral administration of a capsule containing 9 log10 cfu of the strain.
45973232|NCT05896657|Dietary Supplement|Placebo|Oral administration of a capsule containing maltodextrin.
45973233|NCT05896631|Other|7.5 mg hyperbaric bupivacaine|Spinal anesthesia with 7.5 mg hyperbaric bupivacaine after preoperative peng (pericapsular nerve group) block
46081732|NCT03448042|Drug|Tocilizumab|Participants will receive IV tocilizumab if needed
46081733|NCT03440567|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplantation
46081734|NCT03440567|Drug|Avelumab|Given IV
46081735|NCT03440567|Drug|Carboplatin|Given IV
46081736|NCT03440567|Drug|Etoposide Phosphate|Given IV
46081737|NCT03440567|Drug|Ibrutinib|Given PO
46081738|NCT03440567|Drug|Ifosfamide|Given IV
46081739|NCT03440567|Other|Laboratory Biomarker Analysis|Correlative studies
45973234|NCT05896631|Other|5 mg hyperbaric bupivacaine|Spinal anesthesia with 5 mg hyperbaric bupivacaine after preoperative peng (pericapsular nerve group) block
45973235|NCT05896605|Drug|Azathioprine|Before medication, TPMT activity was normal, and AZA was started at small doses and added every two weeks after no AEs, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid.
45973236|NCT05896553|Drug|intranasal Oxytocin(24IU)|Administration of intranasal Oxytocin(24IU)
45973237|NCT05896553|Drug|intranasal Placebo|Administration of intranasal Placebo
46081740|NCT03440567|Biological|Rituximab|Given IV
46081741|NCT03440567|Biological|Utomilumab|Given IV
45973238|NCT05896540|Behavioral|ENFOCATE|ENFOCATE is a comprehensive program of sexual education for adolescents. Its design follows the guidelines of the Intervention Mapping Approach and the orientations proposed by the Framework for Gender-Transformative Health Promotion. The intervention has a participative focus, thus the activities are designed to promote processes of knowledge, understanding, application and reflection in the adolescents. The activities aim to improve the capacity for critical thinking, increase the motivation to listen and learn actively, and to improve interpersonal abilities. The execution of the intervention uses three pillars: (i) preventive sexual behavior; (ii) gender equity; and (iii) mental health. The intervention consists of ten weekly sessions, each lasting one hour. The teams that will perform the intervention will be composed of at least two professionals of the psychosocial area (mainly psychologists, social workers and/or guidance counsellors) of the schools included in the study.
45973239|NCT05896527|Drug|DC-806|DC-806 will be supplied as tablets to be administered orally.
45973240|NCT05896527|Other|Placebo|Matching placebo will be supplied as tablets to be administered orally.
45973241|NCT05896462|Other|10% povidone iodine|The apposed skin edge was covered with 10% povidone iodine-soaked gauze dressing
45973242|NCT05896449|Diagnostic Test|[68Ga]Ga-PSMA-11 PET/CT|The PET/CT image acquisition was performed from the skull to the mid-thigh (3-min per bed position, 3 iterations, 21 subsets) with a CT scan (120 kV, 170mAs reference) with dose modulation for anatomic correlation (CARE dose 4D) and attenuation correction on a Biograph 64 TruePoint (Siemens Medical Solutions Inc., USA) 60 min post injection of [68Ga]Ga-PSMA-11 (2 MBq per kg body weight).
45670356|NCT05649761|Drug|QL1604 injection|Participants will receive QL1604 injection 0.3 mg/kg,1mg/kg, 3mg/kg,10mg/kg, or 200mg intravenous every 2 weeks or every 3 weeks and will be continued until disease progression or unacceptable toxicity.
45829412|NCT01899768|Drug|Placebo|Clear colorless solution of 0.9% sodium chloride for oral inhalation via aqueous droplet inhaler inhaled in two actuations.
45670357|NCT05649566|Device|Virtual Reality game|"The game consists of cutting mobile targets, using lightsabers while avoiding obstacles that approach the user. This game is a reference for immersive play since, while distracting, it recreates a physical activity similar to what would be done in reality. It has been shown that the same energy expenditure, on the part of the user, practicing tennis in real life, is what he does playing Beat Saber playing the same period of time."
45829413|NCT01898598|Drug|Placebo|Participants will receive matching placebo to vismodegib for 12 weeks.
45829414|NCT01898598|Drug|Vismodegib|Participants will receive vismodegib 150 mg oral capsule once a day for 12 weeks
45829415|NCT01898442|Drug|Ticagrelor 180mg|Rndomization to standard or high ticagrelor loading dose regimens
45973243|NCT05896436|Behavioral|Emotion Focused Therapy|12 sessions of Emotion Focused Therapy (EFT). The focus in EFT is to promote the individual's experiencing and facilitate participants' self-disclosure and openness to their own experience, rather than the therapist's agenda or techniques. Key processes within EFT include helping people overcome their avoidance of emotion, maintaining a collaborative focus on emotions, and exploring emotions in therapy.
45973244|NCT05896345|Device|SWL|Shockwave Lithotripsy (SWL) For Paediatrics Radiolucent Renal Stone
45973245|NCT05896345|Combination Product|SWL and ODT|Shockwave Lithotripsy (SWL) and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone
45973246|NCT05896332|Device|Active, Open Label iTBS-rTMS|Participants in this group will receive 10 sessions of iTBS-rTMS per day, 5 days per week for one week (50 sessions total)
45973247|NCT05896319|Device|Hyaluronic acid gel|"Post-operative application of Hyaluronic acid gel 3 times per day (8 hours distance between each application) for 7 days after oral hygiene and without swallowing, eating or drinking for one hour after the application, as follows: wash your hands thoroughly before each application, apply a layer of gel on the injured mucosa, massage with a finger in order to facilitate spreading of the product over the treated area."
45973248|NCT05896306|Other|No intervention|No intervention
45973249|NCT05896293|Drug|kisspeptin 112-121|SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)
45973250|NCT05896280|Procedure|EST|Stones are taken by cutting the papillary sphincter
45973251|NCT05896280|Procedure|ECPP|During ERCP, a generous biliary sphincterotomy (>1 cm) will be performed to facilitate large stone extraction by use of a lithotripsy basket and a stone extraction balloon. After all stone fragments were cleared from the bile duct, this group will undergo ECPP after EST. A single-pigtail biliary stent will be placed (suspended overlength biliary stent, 7F × 20 cm). Then the rotatable repeatable opening and closing of soft tissue clamps (referred to as harmony clips, Mico-Tech, ROCC-D-26-195) should be applied to extend the bile duct axially, linear clamp the incised duodenal papilla, taking care to avoid clamping the bile duct stent, and removing the bile duct stent 3 weeks after ECPP.
45973252|NCT05896254|Drug|MAR001|Subcutaneous injection
45973253|NCT05896254|Drug|Placebo|Subcutaneous injection
45973254|NCT05896241|Other|non-interventional study|non-interventional study
45670358|NCT02203591|Drug|3M CHG/IPA Prep C|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
45670359|NCT02203591|Drug|3M CHG/IPA Prep CH|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
45670360|NCT02203591|Drug|ChloraPrep|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
45829416|NCT01898442|Drug|Ticagrelor 270mg|Randomization to standard or high loading dose regimen
45829417|NCT01898442|Drug|Ticagrelor 360mg|Randomization to standrad or high loading dose regimen
45829418|NCT01898286|Drug|DiaPep277®|1 mg of DiaPep277® subcutaneously in the upper arm at 0, 3, 6, 9, 12, 15, 18, and 21 months, for a total of 8 administrations
45829419|NCT01898208|Device|FilmArray testing|FilmArray Blood Culture Identification (BCID) Panel is a polymerase chain reaction (PCR) panel that identifies 19 types of bacteria, 5 types of fungi, and select antimicrobial-resistance genes.
45973255|NCT05896228|Drug|Iberdomide|"Participants will receive Iberdomide (Iber) therapy orally (PO) in capsules as follows:~Combination therapy: Cycles 1 to 8: 1 mg per day*, Days 1 to 21 every 28 days.~Monotherapy: Cycles 9 to 20: 1 mg per day*, Days 1 to 21 every 28 days.~(*) The first 6 patients will begin at 1 mg/day as lead-in with option to increase to 1.3 mg with dose-escalation cohort after two (2) cycles tolerated therapy"
45973256|NCT05896228|Drug|Carfilzomib|"Participants will receive Carfilzomib (K) therapy intravenously (IV) as follows:~Cycle 1: 20 mg/m2 per dose on Day 1; 56 mg/m2 per dose on Days 8 and 15~Cycles 2 to 8: 56 mg/m2 per dose on Days 1, 8, and 15."
45973257|NCT05896228|Drug|Daratumumab|"Participants will receive Daratumumab (D) therapy subcutaneously (SC) or intravenously (IV) as follows:~Cycles 1 and 2: 1800 mg SC or 16 mg/kg IV on Days 1, 8, 15, and 22~Cycles 3 through 6: 1800 mg SC or 16 mg/kg IV on Days 1 and 15~Cycles 7 and 8: 1800 mg SC or 16 mg/kg IV on Day 1."
45973258|NCT05896228|Drug|Dexamethasone|"Participants will receive Dexamethasone (d) therapy either orally (PO) or intravenously (IV) as follows:~Cycles 1 and 2: 40 mg/dose on Days 1, 8, and 15; 20 mg/dose on Day 22~Cycles 3 and 4: 40 mg/dose on Days 1, 8, and 15~Cycles 5 through 8: 20 mg/dose on Days 1, 8, and 15."
45973259|NCT05896228|Drug|Acetaminophen|"Participants will receive Acetaminophen orally (PO) prior to Iber-KDd therapy as follows:~Cycles 1 and 2: 650 mg/dose on Days 1, 8, 15, and 22~Cycles 3 through 6: 650 mg/dose on Days 1 and 15~Cycles 7 and 8: 650 mg/dose on Day 1."
45973260|NCT05896228|Drug|Diphenhydramine|"Participants will receive Diphenhydramine either orally (PO) or intravenously (IV) prior to Iber-KDd therapy as follows:~Cycles 1 and 2: 25 mg/dose on Days 1, 8, 15, and 22~Cycles 3 through 6: 25 mg/dose on Days 1 and 15~Cycles 7 and 8: 25 mg/dose on Day 1."
45973261|NCT05896228|Drug|Montelukast|"Participants will receive Montelukast orally (PO) prior to Iber-KDd as follows:~Cycle 1 only: 10 mg/dose, Days 1, 8, 15, and 22, to be administered prior to the first 4 doses of Daratumumab (D)."
45973262|NCT05896202|Other|taVNS Video|One third of the participants will see the taVNS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.
45973263|NCT05896202|Other|Educational materials|Participants will receive sample consent forms and brochures for taVNS, TMS, and tDCS. These materials will be reviewed with each participant once on site, and they will have the opportunity to ask questions. participants will take these materials home and have the opportunity to review further at their leisure.
45973264|NCT05896202|Other|TMS Video|One third of the participants will see the TMS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.
45973265|NCT05896202|Other|tDCS Video|One third of the participants will see the tDCS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.
45973266|NCT05896189|Behavioral|Arm 1: Attention Control|The program will includes 8 non-speeded exercises that include spin-offs of such games as breaking hex, lineup four, battleship, gems swap, double klondike, solitaire, reversi, word search, and sudoku. These games are well matched for time on task, novelty, and progression across levels. These are strategy-based games without adaptive, speeded, or accuracy-based algorithms underlying their personalization.
46081742|NCT03407079|Other|Sucralose|Sucralose is an organochlorine and is approximately 600 times sweeter than sucrose. Participants will receive sucralose (approximately 4mg/kg/day) or placebo by mouth in a capsule for 28 days. This dose corresponds to the amount of sucralose contained in approximately 3 or 4 twelve ounce cans of commercially-available diet soda for a 70 kg adult.
45670361|NCT02203591|Drug|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
45670362|NCT01642277|Drug|Solifenacin|5 mg for 4 weeks with option to increase to 10 mg for an additional 8 weeks
46081743|NCT03407079|Other|Placebo|Placebo capsules will be taken orally for 28 days
45670364|NCT04869956|Other|Dietary pattern : High-fiber diet rich in PUFA|High-fiber diet rich in PUFAs (total dietary intake of at least 30 grams of fiber per day, and of at least 3 grams of PUFAs per day from food, not supplements) at least 4 weeks before surgery
45670365|NCT04869956|Other|Dietary pattern: Standard diet|standard nutritional recommendations
46081744|NCT03390686|Drug|Bevacizumab|15 mg/kg IV every 3 weeks on Day 1
46081745|NCT03390686|Drug|HD204|15 mg/kg IV every 3 weeks on Day 1
46081746|NCT03390686|Drug|Carboplatin|Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
46081747|NCT03390686|Drug|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
45670366|NCT02230189|Biological|Segmental airway allergen challenge|
45670367|NCT02230189|Procedure|Bronchoscopy|
45670368|NCT02230189|Diagnostic Test|Methacholine challenge test|
45670369|NCT02230189|Diagnostic Test|Spirometry|
45670370|NCT02230189|Diagnostic Test|Allergen skin prick test|
45670371|NCT04196348|Procedure|Short BPL RYGB|Alimentary limb (AL) with 120 cm and BPL with 100 cm.
45973267|NCT05896189|Behavioral|Arm 2: Computerized Training (BrainHQ)|Cognitive training exercises include Double Decision (targets visual speed of processing and useful field of view), Target Tracker (targets visuospatial working memory capacity), Visual Sweeps (targets speed of processing), Syllable Stacks (targets auditory memory), Eye for Detail (targets eye movement speed and visuo-spatial working memory), Mind Bender (targets mental flexibility), Divided Attention (a shape-color-pattern inhibitory control exercise that focuses on rapidly determining whether flashing colors, shapes, or patterns meet a pre-specified rule), Right Turn (targets spatial reasoning).
45829420|NCT01898208|Behavioral|Antimicrobial Stewardship|Real time antimicrobial stewardship: an infectious diseases pharmacist or physician will provide patient-specific recommendations to modify antimicrobial therapy.
45973268|NCT05896176|Diagnostic Test|a clinical examination and anamnesis|The investigators compare the results of the PSQ alone with the elements provided by the clinical examination regarding the referral of patients to the Otolaryngologist (ENT) consultation.
45973269|NCT05896163|Drug|maplirpacept (PF-07901801)|Intravenous infusion
46081748|NCT03385577|Behavioral|Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer|'Stilling the waters,' the prominent theme of this program, is drawn from the core principle in yogic philosophy. It uses breath techniques and physical postures to cultivate inner peace and an ability to live in the present moment. The emphasis on stilling the fluctuations of uncertainty is a direct allusion to the intrusive and inherently unknown future, which characterizes the core experience of Fear of Cancer Recurrence (FCR). This is especially true among gynecologic, gastrointestinal (GI), or thoracic cancer patients for whom the likelihood of recurrence is quite high. An additional motif throughout the program is the lotus flower. The symbolic importance of the lotus in yogic culture is due to its requiring thick muddy waters for ideal growth. The metaphor of cancer as the muddy waters will be used to cultivate benefit-finding and acceptance regarding the mental and physical challenges participants endured during their initial diagnosis and treatment.
45973270|NCT05896163|Drug|Glofitamab|Intravenous infusion
45973271|NCT05896163|Drug|Obinutuzumab|Intravenous infusion
45973272|NCT05896150|Procedure|Cryoanalgesia AND single-injection paravertebral block|CO2 Cryoanalgesia AND paravertebral block with Bupivacaine 0.5%
45973273|NCT05896150|Procedure|Single-injection paravertebral block|Paravertebral block with Bupivacaine 0.5%
45973274|NCT05896137|Drug|CS0159 2mg|Oral QD
45973275|NCT05896137|Drug|Placebo|Oral QD
45973276|NCT05896124|Drug|2mg CS0159|Oral QD
45973277|NCT05896124|Drug|Placebo|Oral QD
46081749|NCT03384277|Drug|Steroid|Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）
45829421|NCT01898208|Other|Bacterial culture|This test identifies the pathogen responsible for an infection.
45973278|NCT05896111|Procedure|Physical therapy exercises.|Exercises to treat hemiparetic cerebral palsy
45973279|NCT05896085|Other|REThink game|The Rethink therapeutic game is an online game developed based on Rational-Emotive Behavioral Therapy and has two versions: for children and adolescents and for adults. The Rethink therapeutic game for adults is available in 3D and VR version and consists of four levels, each of them training a specific emotion regulation ability such as: emotional awareness, mindfulness, cognitive change
46081750|NCT03384277|Drug|Rituximab|375mg/m2 for one dose
46081751|NCT03384277|Drug|Cyclophosphamide|cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)
46081752|NCT03370367|Drug|13-cis retinoic acid|Taken daily.
46081753|NCT03370367|Other|Placebo|Placebo
46081754|NCT03363243|Other|STOP Therapy Treatment group|Testing of the STOP Therapy protocol
46081755|NCT03363243|Other|Treatment as usual (TAU) group|Treatment as usual in the community through group therapy
46081756|NCT03341689|Drug|High Dose Psilocybin|0.143 mg/kg psilocybin capsule
46081757|NCT03341689|Drug|Low Dose Psilocybin|0.0143 mg/kg psilocybin capsule
45829422|NCT01898208|Other|Susceptibility testing|Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics. Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics.
45973280|NCT05896072|Procedure|Erector Spinae Plane Block|"Application of ultrasound-guided erector spinae plane block for perioperative analgesia for elective inguinal hernia repair. Erector spinae plane block will be administered under general anesthesia before the surgery~Drug: Bupivacaine (Block Drug)~For block performances, 0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc)."
45973281|NCT05896072|Procedure|Caudal Block|"Application of caudal block for perioperative analgesia for elective inguinal hernia repair. The caudal block will be administered under general anesthesia before the surgery.~Drug: Bupivacaine (Block Drug)~0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc) for block performances"
45973282|NCT05896059|Drug|Tislelizumab|Tislelizumab，200mg，D1, intravenous，Q3W；
45829423|NCT01898130|Biological|bevacizumab|Given IV
45829424|NCT01898130|Procedure|quality-of-life assessment|Ancillary studies
45829425|NCT01876368|Drug|LCZ696|
45829426|NCT01876368|Drug|Olmesartan|
45829427|NCT01876368|Drug|Placebo of LCZ696|
45829428|NCT01876368|Drug|Placebo of Olmesartan|
45973283|NCT05896059|Drug|Anlotinib|Anlotinib，12mg，oral administration，QD.
46081758|NCT03341689|Drug|Placebo|microcrystalline cellulose capsule
46081759|NCT03324425|Drug|Simvastatin 80mg|Participants will receive simvastatin 80 mg by mouth daily at bedtime
46081760|NCT03317457|Biological|Durvalumab and Tremelimumab|immun checkpoint inhibitor
46081761|NCT03317457|Drug|Doxorubicin|Anthracycline
45829429|NCT01874340|Drug|Placebo|Placebo will be administered at predefined visits over the 6-month treatment phase.
45973284|NCT05896033|Behavioral|Non-Menthol Cigarettes|Ppts will be randomly assigned to a group that receives non-menthol cigarettes
45973285|NCT05896033|Behavioral|Tobacco Flavored E-cigarettes|Ppts will be randomly assigned to a group that receives tobacco flavored e-cigarettes
45973286|NCT05896033|Behavioral|Menthol Cigarettes|Ppts will be randomly assigned to a group that receives menthol flavored cigarettes
45973287|NCT05896033|Behavioral|Menthol Flavored E-cigarettes|Ppts will be randomly assigned to a group that receives menthol flavored e-cigarettes
45973288|NCT05896007|Drug|Zanubrutinib|160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 1st year in 2 years of follow-up
45829430|NCT01874340|Drug|AIN457|AIN457 will be administered at predefined visits over the 6-month treatment phase.
45829431|NCT04597242|Drug|Exebacase|Patients will receive a single IV infusion of exebacase in addition to antistaphylococcal antibiotics prescribed by the treating physician. Patients with normal renal function or mild renal impairment will be administered a dose of 18 mg of exebacase; patients with moderate or severe renal impairment will be administered a dose of 12 mg; patients with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg.
45973289|NCT05896007|Drug|Rituximab|375 mg/m^2 ivgtt, D0 of each 28-day cycle
45670372|NCT04196348|Procedure|Long BPL RYGB|AL with 120 cm and BPL with 200 cm.
45973290|NCT05896007|Drug|Methotrexate|3.5 g/m^2 ivgtt, D1 of each 28-day cycle
46081762|NCT03313622|Behavioral|Beads Task|Participants will be asked to make a series of decisions that involve combining information about the value and probability of potential rewards. Subjects will sit in front of a computer monitor and place their hand over a box with orange and blue button that they will be asked to press based on their idea of which one will be the majority in a jar full of orange and blue beads. This task should take 15-20 minutes to complete, not including EEG setup.
45670373|NCT02304302|Drug|Memantine|Encapsulated Namenda 10 mg bid (after four-week standard dose titration protocol)
45670374|NCT02304302|Drug|Placebo|Identically looking placebo capsules bid (after a four-week regimen designed to mimic standard dose titration protocol)
45670375|NCT02276612|Drug|E/C/F/TAF|150/150/200/10 mg fixed-dose combination (FDC) tablet administered orally once daily with food
45829432|NCT01897896|Drug|SD-809|SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.
45670376|NCT02301143|Drug|nab-Paclitaxel|
45670377|NCT02301143|Drug|Gemcitabine|
45670378|NCT02301143|Drug|Chemoradiation|
45670379|NCT02301143|Drug|Capecitabine|
45670380|NCT02301143|Procedure|Surgery|Surgical intervention
45670381|NCT02276222|Drug|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
45670382|NCT02276222|Drug|Spiriva® 18 mcg QD Handihaler|Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
45670383|NCT02275364|Device|Test strip|Class I device for the application to the nose to facilitate better air flow through the nose
45670384|NCT02275364|Device|Placebo strip|Placebo strip
45670385|NCT02275364|Other|Nasal spray|Nasal decongestant to be used on a single occasion (one spray per nostril), 20 minutes prior to commencing the third MRI scanning sessions.
45973291|NCT05896007|Drug|Temozolomide|150 mg/m^2 ivgtt, D1-D5 of each 28-day cycle
45973292|NCT05895994|Drug|RD13-02 cell infusion|CAR-T cells
45973293|NCT05895981|Device|G132 system, Beijing PINS Medical Co., China|Neuromodulation was performed according to the usual protocol
45973294|NCT05895968|Procedure|posterior cervical surgery|The patients were operated by the posterior cervical surgery, which were used with the barbed to suture the deep fascia.
45973295|NCT05895942|Drug|Imatinib|The control group, before and after imatinib treatment, and patients with different efficacy of imatinib treatment were collected, and the correlation analysis was performed to screen the key flora and metabolites that affect the efficacy of imatinib
45973296|NCT05895916|Behavioral|High-volume road cycling|1,144 km of road cycling performed on seven consecutive days with an increase in energy intake to maintain a stable body weight
45973297|NCT05895890|Genetic|Sequential sampling (stool, saliva, serum) .|Sequential sampling (stool, saliva, serum) prior to the occurrence of AAH episodes in heavy drinking patients to identify protective or deleterious profiles.
45973298|NCT05895877|Drug|Goofice®|Once daily before breakfast.
45973299|NCT05895877|Drug|Goofice® Placebo|Once daily before breakfast.
45973300|NCT05895864|Drug|utidelone injection|utidelone monotherapy in patients with recurrent or metastatic urothelial carcinoma by utidelone
45973301|NCT05895851|Radiation|head and neck radiation|RON and non-RON: nasopharyngeal carcinoma patients recieved head and neck radiation; Normal: normal individuals.
45973302|NCT05895812|Drug|Deuremidevir Hydrobromide Tablets|JT001 single dose, 0.3g
45829433|NCT01858194|Device|Renal sympathetic denervation|"The ablation catheter is placed within a long vascular sheath and advanced into the renal artery. The sheath is advanced over the catheter to engage the renal artery ostium and allow for contrast injection and visualization of the vessel during catheter manipulation.~After completion of the measurement, no more than six radiofrequency ablation lesions separated both longitudinally and rotationally (a spiral pattern, see figure) will be placed per renal artery. The power will be started at 10 W and titrated to a maximum 20 W, as deemed appropriate by the impedance drop (goal 10% drop). Each lesion should be between 30-120 seconds in duration (no more than 120 seconds per lesion)."
45973303|NCT05895799|Other|Tuition from a expert clinical trainer|Each group was initially provided with an online tutorial on the complete physical examination of the cardiovascular system as performed on a standardized patient by the trainer. At the beginning of each session, the trainer performed the examination on a hybrid patient wearing the auscultation vest and provided additional teaching, explanations, and rationale. Following the demonstration, each participant was invited to perform repeated physical examinations in front of their peers with real-time one-to-one feedback from the trainer. After each performance, the participant was encouraged to critique their own performance(s), peers were invited to provide some insights, and the trainer gave some overall feedback. At the end of the session and after each participant had had the opportunity to perform the complete examination at least once, the participants were taken through a range of abnormal signs using the auscultation vest with explanations provided by the trainer.
45973304|NCT05895760|Other|Multi-component physical exercise online intervention|"A multicomponent exercise program was implemented consisting of a combined program of endurance, strength, coordination, balance, and flexibility exercises depending on the level of functional capacity.~Three types of physical exercise programs were designed according to the physical performance level of each participant. The first type of exercise program training was performed for frail adults with an SPPB score of 4 to 6, the second was for the pre-frail adults with an SPPB score of 7 to 9 and the third for robust adults with an SPPB of 10 to 12."
45973305|NCT05895721|Other|Virtual Reality|Virtual Reality as adjunct treatment
45973306|NCT05895708|Other|Specific strengthening and stretching exercise|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretching (cervical extensors and pectoral muscles) exercises based on Harman and Mostafa et al's approach. This exercise program will be repeated 4 times per week for 10 weeks, and each session lasted for 30 minutes.
45973307|NCT05895708|Other|General Exercise|The program will consist of regular general postural exercises such as postural awareness exercises as well as general strengthening exercises such as range of motion exercises for the upper quadrant. The program will also be repeated 4 times per week for 10 weeks, with each session lasting 30 minutes
45973308|NCT05895422|Procedure|pyeloplasty|repair of the uPJO
45973309|NCT05895357|Other|Musictherapy|The patients were asked about the type of music they wanted to listen to. Especially in the last meta-analyses, it was determined that listening to the music that patients chose was more effective (Witten 2020). For this reason, after the intervention group is asked about the music they want to listen to, the music they want will be played from the music application.
45973310|NCT05895331|Diagnostic Test|Thiol/Disulphide Homeostasis|An automated analysis quantitatively measuring serum native and total thiol, and disulfides has been recently described as a method to determine dynamic Thiol/Disulfide Homeostasis (TDH).
45973311|NCT05894759|Behavioral|Psychological stress relief techniques|Psychological stress relief techniques
45973312|NCT05894187|Other|animated video|Participants randomized to the intervention group will receive a link to a short survey gauging parent anxiety levels three days prior to their childs surgery date. If randomly assigned to watch the informative animated video, the survey will be followed by a link to a video which families are free to watch prior to your child's surgery date. Once participants and there family watch the video, they will be asked to rate the quality of the video on a scale of 0 (very bad) to 10 (excellent). Responses to this question will be used to confirm that participants watched the video to the end.
45973313|NCT05894122|Diagnostic Test|DM-DIV MITRA®|Comparison of phenylalanine concentrations in the new device with those in the current device (blotter).
45973314|NCT05893914|Procedure|Dry Needling and intramuscular electrical stimulation to trigger points|Dry needling will be applied to trigger points in at least two of the following posterior cervical muscles; splenius capitis, splenius cervicis, semispinalis capitis/cervicis, cervical multifidi (from C2-4) and obliquus capitis inferior. Following elicitation of a local twitch response, needles will be left in place and connected to a charge generating device for intramuscular electrical stimulation.
45973315|NCT05893771|Drug|Methylprednisolone Injection|Ultrasound-guided genicular nerve block comparing Methylprednisolone combined with Bupivacaine to bupivacaine alone. All patients will undergo TKA and will receive spinal anesthesia.
45973316|NCT05893771|Drug|Bupivacaine Hcl 0.5% Inj_#2|Ultasound- guided genicular nerve block using 5 ml bupivacaine 0.5% in 15 ml saline
45973317|NCT05893771|Drug|normal saline|Ultrasound guided genicular nerve infiltration with 20 ml normal saline as a placebo control.
45973318|NCT05893576|Drug|HRS9531|Receive a single dose of HRS9531 of original formulation.
45973319|NCT05893576|Drug|HRS9531|Receive a single dose of HRS9531 of new formulation.
45973320|NCT05892965|Other|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
45973321|NCT05892640|Other|Low-Salt Diet|Low-salt diet (LS diet) according to DASH eating plan, with sodium intake of 1500 mg (3.75 g of salt), within the period of 14 days
45973322|NCT05892497|Other|Tecartherapy|The tecartherapy intervention was with a deep diathermy machine applied to the patient's lower extremity for 30 minutes.
45829434|NCT01858194|Device|VT ablation alone|Placebo arm will receive standard VT ablation using current techniques
45973323|NCT05892458|Behavioral|Abdominal massage|To perform abdominal massage, patients should keep their upper body in an upright or semi-decumbent position. Using their right four fingers or palm, they should apply pressure to the middle point of the lower margin of the right upper abdominal ribs, which corresponds to the opening of the gallbladder and common bile duct. The pressure should be firm, with a depth of approximately 3-4 cm and a length of 5-10 cm, and should be applied at least once a day for 10-15 minutes per session.
45973324|NCT05892419|Other|No intervention|There is no intervention
45973325|NCT05891015|Behavioral|Mindfulness Intervention for Emotional Distress(MIED)|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
45973326|NCT05887752|Other|Standard rehabilitation|"Carried out 3h/day, 5 days/week at the Montecatone Institute. It implies a multiprofessional approach through:~physiotherapy;~occupational therapy;~sports rehabilitation."
45973327|NCT05887752|Device|Hunova® rehabilitation|Performed in a dedicated gym of the Montecatone Institute, 1 hour/day, 5 days/week, in the presence of a physiotherapist. Depending on the improvement of the person and of his skills acquisition, the degree of tilting of the Hunova® seat in the various planes may vary.
45973328|NCT05886673|Other|cosmeceutical cream|cosmeceutical cream
45973329|NCT05886673|Other|Placebo|Placebo
45973330|NCT05883748|Drug|DISC-1459|DISC-1459 dose level 1
45973331|NCT05883748|Drug|DISC-1459|DISC-1459 dose level 2
45973332|NCT05882552|Diagnostic Test|Tilted Gaze Target Tast|Tilted gaze target tast is playing a small animated video with a visual mobile device at a distance of 33 cm and 3 m, respectively, to determine the optimal angle of head position improvement and the spatial tilt angle of the screen relative to the orthostatic position.It will be conducted during the first visit. Preoperative intervention will also be conducted before surgery. Postoperative interventions will be conducted at one day, one month, and six months after surgery.
45973333|NCT05882552|Diagnostic Test|Conventional Examination Methods|The conventional examination methods include oculomotor examination, Bielschowsky head tilt test, alternate prism cover test, prism adaptation test, and monocular cover test. They will be conducted during the first visit. Preoperative intervention will also be conducted before surgery.Postoperative interventions will be conducted at one day, one month, and six months after surgery.
46081763|NCT03313622|Behavioral|PROVOC Tasks|Three tasks will be developed collaboratively with the participant and independent evaluator that involve the participant being exposed to triggers that are considered by him/her impossible to confront without ritualizing. There will also be a similar process involving objects that should not cause any distress to be used as a control. Sessions will be videotaped with AFAR system concurrent to recording of LFPs from VS and scalp EEG.
46081764|NCT03288207|Device|Bluetooth-enabled glucometer|Bluetooth-enabled glucometer
46081765|NCT03288207|Device|Bluetooth-enabled scale|Bluetooth-enabled scale
46081766|NCT03288207|Device|Global Positioning System (GPS) Device|Global Positioning System (GPS) Device
46081767|NCT03288207|Device|Step it Up mobile app|Step it Up mobile app
45670386|NCT02275052|Drug|UMEC/VI DPI|The DPI will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
45670387|NCT02275052|Drug|Placebo DPI|The placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
45670388|NCT02275052|Drug|Albuterol/salbutamol MDI|Albuterol/salbutamol MDI (metered-dose inhaler) or nebules will be permitted throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline. Nebules will not be supplied.
45973334|NCT05882084|Dietary Supplement|Astaxanthin 6 mg daily|Astaxanthin at 6 mg is given for daily ingestion and compared against placebo.
45973335|NCT05882084|Dietary Supplement|Placebo|Placebo
45973336|NCT05879692|Procedure|focused ultrasound|"focused ultra sound cavitation using a device of Mabel6 DUO Ultra Cavitation Technology system produced by DAEYANG MEDICAL COMPANY, KOREA will be applied on the abdominal region which extending bilaterally from the line extending from mid axilla to iliac crest, and above from center of diaphragm to the line extending between two iliac crest below.~the session of Focused Ultra Sound will take 25- 30 minutes, twice/week and with about three day intervals for 12 weeks."
45973337|NCT05879692|Behavioral|Low Caloric Diet (LCD) and a low (FODMAPs) diet|"The Low caloric diet (LCD) diet will be an equilibrated diet that had a caloric value 10% below the total metabolic expenditure (total energy expenditure) of each individual.~The low FODMAPs diet (LFD) is a diet low in fermentable oligo-, di-, mono- saccharides and polyols (FODMAPs)."
46081768|NCT03275103|Drug|Cevostamab|Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.
46081769|NCT03275103|Drug|Tocilizumab|Tocilizumab will be administered as premedication during Cycle 1.
46081770|NCT03267836|Drug|Avelumab|-10mg/kg IV
46081771|NCT03267836|Radiation|Proton Therapy|-Proton therapy will start concurrently with the first dose of avelumab (up to 3 days before or after is permissible) and will be administered once daily during weekdays (Monday through Friday).
46081772|NCT03267836|Procedure|Surgery|-Standard of care
46081773|NCT03197506|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
46081774|NCT03197506|Other|Laboratory Biomarker Analysis|Correlative studies
46081775|NCT03197506|Biological|Pembrolizumab|Given IV
46081776|NCT03197506|Radiation|Radiation Therapy|Undergo radiation therapy
46081777|NCT03197506|Drug|Temozolomide|Given PO
46081778|NCT03197506|Procedure|Therapeutic Conventional Surgery|Undergo surgery
46081779|NCT03188705|Drug|Clopidogrel|Participants will receive 300 mg of clopidogrel on the first day, then 75 mg per day for the next 6 days. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
46081780|NCT03188705|Drug|Aspirin|Participants will receive a single dose of 324 mg aspirin on the last day of clopidogrel administration.
45670389|NCT05649020|Drug|Dose of prilocaine|With the patient in the sitting position, spinal anesthesia was performed using the midline approach at the L3-L4; L4-L5 interspace with a spinal needle. The dose of HP that a patient received was determined by the previous patient's response. If successful anesthesia was obtained, the next patient's dose was decreased. The first patient will receive a dose of 20 mg. The dose decrement/increment for each subsequent patient will be set at 2 mg. A nurse blinded to the dose, will assess the sensitive level achieved with each block. Furthermore, all patients will be unaware of the injected dose of HP. For purposes of the study, anesthesia was considered successful when there was complete loss of pinprick and cold sensation at the L1 dermatome. Values of ED 50 will be determined by calculating the midpoint concentration after at least 8 crossover points sufficient/insufficient anesthesia will be obtained. A single measurement will be obtained from each patient.
45670390|NCT04869488|Drug|Fluzoparib|Fluzoparib Orally twice daily（Cohort 1、Cohort 4）
45670391|NCT04869488|Drug|Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets|Enzalutamide OR abiraterone acetate Orally once daily（Cohort 1）
45670392|NCT04869488|Drug|Fluzoparib Combined With Apatinib|Fluzoparib Orally twice daily; Apatinib Orally once daily（Cohort 2、Cohort 3、Cohort 4）
46081781|NCT03113487|Biological|Modified Vaccinia Virus Ankara Vaccine Expressing p53|Given SC
45670393|NCT05648942|Diagnostic Test|Anemia testing|Patients will undergo a point of care test to identify possible anemia
45829435|NCT01873950|Drug|Ranolazine|
45829436|NCT01873950|Drug|Dofetilide|
45829437|NCT01873950|Drug|Verapamil|
45829438|NCT01873950|Drug|Quinidine sulfate|
45829439|NCT01873950|Drug|Placebo|
45829440|NCT01857102|Device|etafilcon A|Soft contact lens to be worn in a daily wear, daily disposable modality for one week
46081782|NCT03113487|Biological|Pembrolizumab|Given IV
46081783|NCT03072238|Drug|Ipatasertib|Oral tablets, 400 mg, given once daily (QD) beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.
46081784|NCT03072238|Drug|Abiraterone|Oral tablets of abiraterone, 1000 mg QD, taken on an empty stomach and swallowed whole with water.
46081785|NCT03072238|Drug|Placebo|Oral tablets (matched to ipatasertib appearance), given QD beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.
46081786|NCT03072238|Drug|Prednisone/Prednisolone|Oral tablets of 5 mg, taken twice daily (BID) until disease progression or intolerable toxicity.
45829441|NCT01857102|Device|etafilcon A for Astigmatism|Soft contact lens to be worn by participants in a daily wear, daily disposable modality for one week.
45829442|NCT01872078|Drug|AZD4901 (oral)|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
45829443|NCT01872078|Drug|Placebo to match AZD4901|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
45829444|NCT04618458|Behavioral|Power to Prevent|Lifestyle diabetes prevention intervention based on the National Diabetes Prevention Program and tailored for African American families. The intervention will be delivered using telehealth and small group videoconferencing.
45829445|NCT01896726|Drug|Baricitinib|Administered orally
45829446|NCT01896726|Drug|Microgynon|Administered orally
45829447|NCT01856790|Device|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
45829448|NCT01856790|Drug|liraglutide|Liraglutide is a long-acting analog of human glucagon like peptide-1 (GLP-1) that works as a GLP-1 receptor agonist
45829449|NCT01856322|Drug|Sulindac|one tablet 150mg twice daily
45829450|NCT01856322|Drug|Placebo|One tablet twice daily
45829451|NCT01856322|Other|Validate assays and shipping methods|
45973338|NCT05879692|Other|aerobic exercise|aerobic exercise program under direct supervision at a frequency of 3 times/week for 12 weeks, in the form of walking on a treadmill for 30 minutes with moderate intensity (12-14) according to The Borg Rating of Perceived Exertion (RPE) scale.
45973339|NCT05876715|Drug|Lurbinectedin|This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered intravenously.
45973340|NCT05871892|Diagnostic Test|18F-FDGal PET/CT or PET/MRI|All patients suspected of or diagnosed with HCC will be offered an initial 18F-FDGal PET/CT or PET/MRI scan. Moreover, patients who undergo loco-regional treatment (resection, ablation (radiation or microwave), chemo- or radio-embolization) are re-examined with 18F-FDGal. The scans will be performed 1-2 months and 3-5 months after the loco-regional treatment. The images will be analyzed by an experienced PET specialist and the CT or MR images by an experienced radiologist for focal lesions and compared to other imaging modalities. The investigators expect approximately 25 patients per year during a 5-year period and as such aim at a total of 125 patients
45973341|NCT05867849|Drug|Cannabidiol|Cannabinoid
45973342|NCT05867849|Other|Placebo|Inactive substance
45973343|NCT05864846|Drug|Cannabidiol Oral Solution [Epidiolex]|100 mg/ml Cannabidiol Oral solution
45973344|NCT05860296|Drug|SLC-391|SLC-391 is an AXL inhibitor
45973345|NCT05860296|Biological|Pembrolizumab|Immunotherapy
45973346|NCT05859048|Diagnostic Test|NT-proBNP|blood sample to measure N-terminal prohormone of B-type natriuretic peptide at local laboratory
45973347|NCT05859048|Diagnostic Test|AI echocardiogram|Artificial intelligence driven transthoracic echocardiogram
45973348|NCT05859048|Diagnostic Test|electrocardiogram|tracing of electrical cardiac activity of the heart
45973349|NCT05859048|Other|Cardiovascular physical examination|basic physiological measurements to include height (cm), weight (kg) and hip circumference (cm) and blood pressure (mmHg)
45973350|NCT05853445|Other|Jakavi|Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
45973351|NCT05853120|Drug|Doxycycline|Doxycycline is used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections. Doxycycline (DOX) will be given orally at 100 and 200 mg doses.
45973352|NCT05847686|Other|Counseling|Participate in therapy visits
45973353|NCT05847686|Drug|Psilocybin|Given PO
46081787|NCT03032484|Drug|Bevacizumab|Bevacizumab is FDA approved as a treatment for recurrent Glioblastoma following failure of radiation therapy and temozolomide.
45670394|NCT02274038|Drug|Baseline 18F-thymidine (FLT) PET/CT|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This baseline scan will be used to compare post-therapy FLT-PET/CT in order to assess change in tumor accumulation of FLT.
45670395|NCT02274038|Drug|"Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT flare"|"FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed on the day of starting pemetrexed therapy (within 24hrs of starting pemetrexed) and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for early pemetrexed induced changes in tumor accumulation of FLT known as FLT flare."
45829452|NCT01896102|Genetic|Lenti-D Drug Product (eli-cel)|Participants received a single IV infusion of Lenti-D Drug Product.
45829453|NCT01871532|Drug|Gonal-f®|
45829454|NCT04606992|Procedure|CELS|CELS resection for early colon cancer is a compromised resection performed in frail patients
45829455|NCT01855074|Drug|Risperidone|Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
45973354|NCT05847686|Other|Questionnaire Administration|Ancillary studies
45973355|NCT05842512|Drug|ADI-PEG20|Treatment for NASH
45973356|NCT05842512|Other|Placebo|Treatment for NASH
45973357|NCT05841160|Drug|Ecopipam Hydrochloride|oral tablets
45973358|NCT05841160|Drug|Moxifloxacin|oral tablet
45973359|NCT05841160|Drug|Placebo|oral tablet
46081788|NCT03032484|Drug|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme.
46081789|NCT03013946|Behavioral|Concomitant coaching|"The corner stones of the pro-active coaching are as follows:~Patient education:~Information on nature and severity of treatment emergent AEs~information about remedies for TEAEs~propagation and explanation of tests and treatment decisions~Patient instruction on self-care and preventive measures~Preemptive AE treatment strategies~Supervision of reported ADR severity, ADR mitigation strategies according to recommendations of the PREPARE protocol and cancer treatment modification by treating physician in close collaboration with the coach"
46081790|NCT03003546|Other|Laboratory Biomarker Analysis|Correlative studies
46081791|NCT03003546|Drug|Nab-paclitaxel/Rituximab-coated Nanoparticle AR160|Given IV
45973360|NCT05839873|Device|FlexAbility SE Ablation Catheter|Subjects receive ablation treatment.
45973361|NCT05816382|Drug|TAK-861|TAK-861 tablets
45829456|NCT01871142|Drug|Placebo|100 mL
45973362|NCT05815758|Drug|rimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)|rimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)
46081792|NCT03003546|Other|Pharmacological Study|Correlative studies
46081793|NCT02996825|Drug|Gemcitabine|Given IV
46081794|NCT02996825|Drug|Gemcitabine Hydrochloride|Given IV
45829457|NCT01871142|Drug|Aes-103|Single dose of 1000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
45829458|NCT01871142|Drug|Aes-103|Single dose of 3000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
45829459|NCT04606290|Device|O2matic HOT|Automated oxygen titration with O2matic HOT
45973363|NCT05815758|Drug|Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution|Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
45973364|NCT05813613|Other|Squatting with the aid of Kynapsis Virtual Training apparatus.|Squatting exercise was performed using a virtual reality (VR) machine (kynapsis) for guidance in both groups. Squats were performed while the hands were kept in front of the bodies and the knees flexed to 90 degrees following a rhythm of two seconds for descent, two second ascent mimicking the movement done on the VR machine.
45973365|NCT05811364|Device|Stenting of the Common and/or External Iliac Arteries with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis|Treatment of target lesions in the common and/or external iliac arteries by stenting with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis.
45973366|NCT05811364|Device|Stenting of the Common and/or External Iliac Arteries with Bare Metal Stent|Treatment of target lesions in the common and/or external iliac arteries by stenting with a commercially available bare metal stent that is approved for treatment of the disease.
46081795|NCT02996825|Other|Laboratory Biomarker Analysis|Correlative studies
46081796|NCT02996825|Biological|Mirvetuximab Soravtansine|Given IV
46081797|NCT02996825|Other|Pharmacological Study|Correlative studies
46081798|NCT02981173|Drug|0.143 mg/kg Psilocybin or 10 mg Psilocybin|0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option) ingested on each of three test days (5 days apart +/- 1-2 days)
46081799|NCT02981173|Drug|0.0143 mg/kg Psilocybin or 1 mg Psilocybin|0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin (fixed-dose option) ingested on each of three test days (5 days apart +/- 1-2 days)
46081800|NCT02981173|Drug|Placebo|Microcrystalline cellulose capsule ingested on each of three test days (5 days apart +/- 1-2 days)
46081801|NCT02975349|Drug|Evobrutinib|Participants received Evobrutinib 75 milligrams (mg) orally, twice daily (BID) up to Week 48
46081802|NCT02975349|Drug|Evobrutinib|Participants received Evobrutinib 25 mg orally, once daily (QD) up to Week 48
46081803|NCT02975349|Drug|Evobrutinib|Participants received Evobrutinib 75 mg orally, QD up to Week 48
46081804|NCT02975349|Drug|Placebo|Placebo were administered for 24 weeks
45455952|NCT05350501|Drug|EO2040|"EO2040, is a therapeutic peptide vaccine composed of two microbial-derived peptides mimicking cytotoxic T cell (CD8+ T cell) epitopes from the Tumor Associated Antigens (TAAs) combined with the helper peptide (CD4+ T cell epitope) Universal Cancer Peptide 2 (UCP2).~The peptide mix EO2040, i.e. drug product (DP), will be emulsified with the adjuvant Montanide.~EO2040 will be given in combination with nivolumab, which is an anti-PD1. Nivolumab is approved for use for the treatment of multiple cancer types, including subtypes of CRC (mismatch repair deficient or microsatellite instability-high metastatic disease after prior treatment). However, it is not currently approved for ctDNA defined MRD of CRC."
45829460|NCT04606290|Device|Oxygen concentrator|Fixed dose oxygen flow from concentrator
45455953|NCT05346081|Device|Electrical impedance tomography|Electrical impedance tomography (EIT) is a potential alternative non-invasive diagnostic screening measure to spirometry.
45455954|NCT05344898|Procedure|Subscap Tenotomy|Group will not have their subscapularis tendon repaired following a reverse shoulder replacement.
45670396|NCT02274038|Drug|Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed 2-4 weeks after starting pemetrexed therapy and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for pemetrexed induced changes in tumor accumulation of FLT as a surrogate measure of tumor proliferation.
45670397|NCT02300558|Drug|Eleclazine|Tablets administered orally
45670398|NCT02300558|Drug|Eleclazine placebo|Tablets administered orally
45829461|NCT04411056|Other|Barrier box|Placement of barrier box ( a plastic box for shielding)
46081805|NCT02975349|Drug|Tecfidera|Tecfidera; 120 mg hard capsule BID for 7 days then 240 mg hard capsule BID for duration of treatment (48 weeks).
46081806|NCT02975349|Drug|Evobrutinib|Following Placebo for 24 weeks, participants received Evobrutinib 25 milligram (mg) orally, once daily (QD) from Week 24 to 48 weeks.
46081807|NCT03645681|Device|InnAVasc arteriovenous graft surgical implant|An InnAVasc AVG will be surgically implanted into the upper arm or forearm of enrolled participants
46081808|NCT02974582|Behavioral|Exposure to smoking advertising with coupon|Direct mail marketing of smoking advertising with discount coupon
46081809|NCT02974582|Behavioral|Exposure to smoking advertising without coupons|Direct mail marketing of smoking advertising without discount coupon
45670399|NCT04882046|Other|Blood collection|Blood samples (8ml) at three times of the study: at baseline, 3 hours and 6 hours after treatment
45829462|NCT01895322|Drug|OPC-41061|
45829463|NCT01894776|Drug|Rifabutin|Substance: Rifabutin Daily dose: oral, 300 mg once daily (8:00 am) for 10 days
45829464|NCT01894776|Drug|Maraviroc|Substance maraviroc daily dose 300 mg twice daily (8:00 am and 8:00 pm) for 15 days
45829465|NCT01894620|Device|rTMS real-sham|In this intervention patients receive 4 weeks of rTMS treatment with real coil and then 4 weeks of treatment with sham coil; there will be 4 weeks of break between the two blocks of treatment.
45829466|NCT01894620|Device|rTMS sham-real|In this intervention patients receive 4 weeks of rTMS treatment with sham coil and then 4 weeks of treatment with real coil; there will be 4 weeks of break between the two blocks of treatment.
45670400|NCT04882046|Other|Data collection|collection of socio-demographic, clinical and biological data.
45670401|NCT02273960|Drug|BMS-986004 75 mg IV|BMS-986004 (75 mg) infusion (50 ml) administered in 120 minutes
45670402|NCT02273960|Drug|BMS-986004 225 mg IV|BMS-986004 (225 mg) infusion (100 ml) administered in 120 minutes
45670403|NCT02273960|Drug|BMS-986004 675 mg IV|BMS-986004 (675 mg) infusion (100 ml) administered in 120 minutes
45670404|NCT02273960|Drug|BMS-986004 1500 mg IV|BMS-986004 (1500 mg) infusion (100 ml) administered in 120 minutes
45973367|NCT05810181|Other|Interview|"The following three groups of stakeholders will be interviewed to assess the beliefs, attitudes, and informational needs around gene therapy for rare pediatric diseases:~(1) patients and families of children with rare genetic diseases who have received gene therapy (to assess their perspectives and understand their informational needs around participating in a clinical trial using gene therapy), (2) patients and families of children with rare genetic diseases who were offered but have decided against receiving gene therapy or ultimately did not qualify for a trial (to elicit feedback and to evaluate whether their informational needs and communication expectations about participating in a clinical trial using gene therapy were met), and (3) healthcare workers who provide care to patients receiving gene therapy (to assess their perspective regarding patient/family needs for gene therapy education and communication)."
45973368|NCT05795582|Device|POPMETRE® (Axelife , France)|Measurement with 2 devices
45973369|NCT05793801|Other|Dressing change|"The patient circuit corresponds to that of usual care.~Not part of usual patient management:~The rhythm of PICCline dressing changes, which differed between the two groups.~The collection of pain on a visual analog scale at each dressing change."
45973370|NCT05793619|Device|Prototypes (816-v1 301) to (816-v1 355) every week|Application on brown spots located on the face (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face. Subjects will be lying down, and the prototypes will be administered upside down. During applications, subjects will wear diving goggles protecting the eyes from cryogenic gas.
45973371|NCT05793619|Device|Prototypes (816-v1 301) to (816-v1 355) every two weeks|Application on brown spots located on the face (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face. Subjects will be lying down, and the prototypes will be administered upside down. During applications, subjects will wear diving goggles protecting the eyes from cryogenic gas.
45455955|NCT05344898|Procedure|Subscap Repair|Group will have their subscapularis tendon repaired following a reverse shoulder replacement.
45455956|NCT05336162|Other|Self etch giomer based fissure sealant (BeautiSealant, Shoufu, USA)|A fissure sealant providing a physical barrier that inhibits microorganisms and food particles accumulation, preventing caries initiation, and arresting caries progression
45670405|NCT01646021|Drug|Ibrutinib|560 mg once daily continuous (without interruption) by mouth for 21-day cycles
45670406|NCT01646021|Drug|Temsirolimus|175 mg once daily intravenous infusion on Days 1, 8, 15 of the first cycle followed by 75 mg on Days 1, 8, 15 of each 21-day cycle
45670407|NCT01750918|Drug|Dabrafenib|Each capsule contains 50 mg or 75 mg of GSK2118436; 50 mg strength capsules are Swedish orange (dark red) opaque hypromellose size 2 capsules and 75 mg strength capsules are pink opaque hypromellose size 1 capsules. The initial dosing regimen will be twice daily (BID) continuous oral daily dosing.
45973372|NCT05788978|Other|Scale development|Scale development
45973373|NCT05782179|Biological|GBS-NN/NN2|GBS-NN/NN2 bound to alhydrogel as an adjuvant
45973374|NCT05782179|Biological|Placebo|Normal Saline 0.9 %
45973375|NCT05774600|Behavioral|SSW Works|SSW Works is a behavioral, culturally tailored online intervention for skin cancer prevention amongst outdoor workers in the United States.
45973376|NCT05774600|Behavioral|Minimal Information Control|Provision of online materials for skin cancer prevention.
45973377|NCT05763732|Behavioral|Rhythmic Auditory Stimulation (RAS)|"Rhythmic auditory stimulus (RAS) is a Neurologic Music Therapy (NMT) technique that utilizes an auditory rhythmic cue to entrain gait to a specific rhythm.~RAS, as an anticipatory time cue, can be used as both an immediate entrainment stimulus, providing rhythmic cues during movement, and as a facilitating stimulus for planning and executing a movement to achieve more functional gait patterns. Cadence, gait velocity, and stride length are the commonly used parameters to monitor changes in a patient's gait."
45973378|NCT05758766|Dietary Supplement|Plant-based omega-3-FA|Plant-based omega 3 Fatty Acids
45973379|NCT05755373|Other|No treatment given|No treatment given
45973380|NCT05742009|Device|iCare ST500|Measurement of Intraocular Pressure (IOP)
45455957|NCT05332860|Procedure|Congenital Cardiovascular Surgery|Relationship between perioperative and postoperative hemodynamics, laboratory, oxygenation parameters and demographic data with extubation times in pediatric cardiac surgery cases taken in our hospital.
45455958|NCT05326048|Other|cytof analysis|cytof analysis of biological samples of CIS patients. Genomic analysis
45455959|NCT05324553|Procedure|Tissue Collection|Research tissue specimen will be obtained during the patient's clinical biopsy or clinical tumor resection, if feasible.
45670408|NCT01750918|Drug|Trametinib|Each tablet contains 0.5mg or 2.0 mg GSK1120212; 0.5 mg is yellow modified oval biconvex film-coated tablets of size 4.8 mm X 8.9 mm and 2 mg as pink round biconvex film coated tablets;7.5 mm in diameter. The initial dosing regimen will be once daily continuous oral daily dosing.
45973381|NCT05742009|Device|GAT|Measurement of Intraocular Pressure (IOP)
45973382|NCT05742009|Device|iCare IC200|Measurement of Intraocular Pressure (IOP)
45973383|NCT05740241|Other|Elderly|A group of participants with physical activity (protocolized)
45973384|NCT05729997|Other|Listening to live classical music|The group of musicians perform music in the hemodialysis room while patients receive treatment.
46081810|NCT02974582|Behavioral|Exposure to non health related images|Control group
46081811|NCT02955394|Drug|Enzalutamide|160mg of Enzalutamide will be given daily in conjunction with Fulvestrant.
45455960|NCT05324553|Diagnostic Test|Blood Collection|Up to 50 mL of research blood will be drawn around the time of the procedure. Additional blood may be collected in selected cases, as warranted, to monitor disease recurrence/remission or perform additional
45455961|NCT05324553|Diagnostic Test|Buccal Swab|Buccal swab may be requested, if necessary, to generate germline data.
45455962|NCT05323370|Other|24h urine|Urine samples will be collected at home over 24 hours
45670409|NCT01750918|Drug|Panitumumab|Panitumumab is a sterile, colorless, translucent-to-white amorphous, proteinaceous powder available as 100 mg panitumumab in 5 mL (20 mg/mL) single-use vial; 200 mg panitumumab in 10 mL (20 mg/mL) single-use vial; 400 mg panitumumab in 20 mL (20 mg/mL) single-use vial; to be administered as an intravenous infusion over 60 minutes, every 14 days. Doses higher than 1000 mg should be administered over 90 minutes.
45670410|NCT01750918|Device|5-fluorouracil|5-fluorouracil-based chemotherapy
45670411|NCT02300987|Drug|LEE011|
45670412|NCT02300987|Drug|LEE011 Placebo|
45973385|NCT05727059|Device|The Elevate™ System|The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
45973386|NCT05726604|Other|Respiratory gating|10 minutes breathing motion monitoring during an additional CT scan to establish a more accurate cardiac and LAD dosimetry compared to reality
45973387|NCT05726058|Device|XyCAM with oxygen|After the standard imaging protocols, participants will be asked to inhale 100% oxygen through a mask and will be re-imaged using the XyCAM RI or XyCAM FC.
45670413|NCT01750840|Device|Biomet® EBI Bone Healing System|A pulsed electromagnetic fields electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 3-10 hours per day with a recommended use of 10 hours per day.
45829467|NCT04605198|Behavioral|Modified Mindfulness-based Stress Reduction|Participants will be trained in mindfulness meditation and the applicability of mindfulness practices to daily life. During MBSR programming, teachers will lecture about key topics in mindfulness and lead class discussions. Participants are given homework assignments, such as listening to guided meditations. Participants are given opportunities to ask the instructor questions and to share their experiences with each other. Each session focuses on a different key topic. Topics are: Session 1: Introduction; Session 2: Understanding Perceptions; Session 3: Hatha Yoga, Sitting Meditation, Walking Meditation; Session 4: Concentration & Awareness; Session 5: Unhealthy Patterns &Getting Unstuck; Session 6: Transformational Coping Strategies; Session 7: Mini-retreat; Session 8: Maintaining Discipline & Flexibility; Session 9: Course Review.
45829468|NCT04605198|Behavioral|Health Promotion Wellness Classes|Sessions will cover the following general wellness topics: Session 1; Introduction; Session 2: Envisioning Health Through Art; Session 3: Chronic Disease 1 (Heart Health); Session 4: Chronic Disease II (Diabetes); Session 5: Nutrition and Hydration; Session 6: Infectious Disease Prevention; Session 7: Skin Care; Session 8: Oral Health; Session 9: Promoting Social Integration & Course Graduation.
45829469|NCT01854918|Biological|Evolocumab|Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen
45455963|NCT05323370|Other|urine sample|A urine sample of 20cc will be collected
45829470|NCT01854918|Drug|Standard of Care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
45829471|NCT01894230|Genetic|SLCO1B1*5 allele testing, results reported at randomization|Genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at randomization
45973388|NCT05724849|Drug|Venlafaxine|See arm/group description.
45973389|NCT05724849|Drug|Placebo|See arm/group description.
45973390|NCT05723913|Dietary Supplement|Dietary Supplement: A package containing a mix of functional foods|Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein, agave extract and genistein.
45973391|NCT05711576|Other|Non surgical peri-implant mucositis therapy with one-stage full-mouth scaling|Patients were treated with full mouth non surgical peri-implant mucositis therapy performed with only full mouth scaling and root planing
45973392|NCT05711576|Other|Non surgical peri-implant mucositis therapy with one-stage full-mouth scaling and chlorexidine|Patients were treated with full mouth non surgical peri-implant mucositis therapy performed with only full mouth scaling and root planing and chlorexidine
45973393|NCT05709743|Behavioral|Experimental: Within-Subjects Attentional Information|Behavioral: Visual Search Information Type (target or distractor information) Participants will have information about targets, distractors, or neither in different trials of the intervention.
45973394|NCT05705258|Drug|Aflibercept (Eylea, BAY86-5321)|Treatment with Intravitreal (IVT)-AFL must be made by the treating ophthalmologist
45973395|NCT05694533|Drug|INDV-2000|Capsules administered orally twice a day
45973396|NCT05694533|Drug|Midazolam|Midazolam syrup administered orally on Days 1 and 15
45973397|NCT05693129|Drug|Leniolisib|The doses selected will range from 10 to 50 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 100 mg per day).
45455964|NCT05322850|Biological|Orca-Q|All transplant recipients enrolled on this study in both the phase I and phase II portions will receive Orca-Q (Orca-Q Prime and Orca-Q Supplement) intravenously following myeloablative conditioning.
45455965|NCT05322525|Drug|ON101 Cream|"Test drug:~Name: ON101~Dosage form: Topical cream~Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica~Dose(s): Apply 1 cc per 5 cm2 ulcer size (not exceeding 2 mm in thickness)~Dosing schedule: Apply once a day"
45455966|NCT05322512|Drug|18F-FDG|All enrolled participants will be allocated to undergo one 18F-FDG PET/CT scan.
45455967|NCT05321771|Other|Family caregiver application of HELP principles|The family caregiver will apply the principles of the HELP program in a structured manner following training by a nurse clinical specialist in geriatrics. These principles include engaging patients in conversation, particularly emphasizing orientation to time and place, encouraging eating and drinking, and assisting with early mobility.
45455968|NCT05311150|Device|Narrow band imaging bronchoscopy guided endobronchial biopsy|Examination of the airways will be performed with the narrow band imaging mode using a flexible video-bronchoscope (BF-1T 180, Olympus Medical, Japan). Endobronchial biopsies will be performed from the abnormal areas as deemed by the operator.
45670414|NCT01750840|Device|Biomet Orthopak® Non-Invasive Bone Growth Stimulator System|A capacitive coupling electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 24 hours per day.
45670415|NCT01750840|Device|Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator|A capacitive coupling electrical stimulation device used as an adjunctive treatment to lumbar spinal fusion. Designed to be used for 24 hours per day.
45829472|NCT01894230|Genetic|SLCO1B1*5 allele testing, results reported at end of study|Genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at end of study
45973398|NCT05692401|Behavioral|Nutrition and Exercise Instruction|Eating and exercise patterns. Educational handouts and instructions will be provided, which are intended as a guide for subjects in intervention group. Subjects will also be given a Patient Diary to complete their daily meal intake and physical exercises. Use of and return of the diary is optional but encouraged. It has been found that use of a patient diary to record food intake keeps one from eating more than they planned and can be a useful tool in weight control.
45973399|NCT05687916|Drug|TAK-861|TAK-861 tablets.
45973400|NCT05687916|Drug|Placebo|TAK-861 placebo matching tablets.
45829473|NCT01894230|Genetic|Genetic testing for SLCO1B1*5 allele|Blood test for SLCO1B1*5 allele
45829474|NCT01894152|Device|XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)|Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
45973401|NCT05685290|Other|Pushing with saline technique|Peripheral venous catheter placement by pushing with saline technique
45829475|NCT04597008|Drug|Treatment group|Standard of Care + Local Vancomycin + Local Tobramycin: Participants in the treatment group will receive a dose of 1000mg of Vancomycin powder AND a dose of 1200mg of Tobramycin powder in their wound bed immediately before wound closure.
45829476|NCT04597008|Drug|Control group|Standard of Care + Local Vancomycin: Participants in the control group will receive a dose of 1000mg of Vancomycin powder in their wound bed immediately before wound closure.
45829477|NCT04596930|Procedure|Laser ablation thermal therapy|The Visualase Thermal Therapy System is used to necrotize or coagulate soft tissue through interstitial irradiation under MRI guidance
45829478|NCT01854528|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
45829479|NCT01854528|Drug|Ribavirin|Tablet
45829480|NCT01854528|Drug|Pegylated Interferon a-2a (PegINF)|Pre-filled syringe
45829481|NCT01854528|Drug|Telaprevir|Film-coated tablet
45829482|NCT01853982|Drug|Ceftolozane/Tazobactam|
45829483|NCT01853982|Drug|Piperacillin/Tazobactam|
45829484|NCT01853280|Drug|L-methylfolate|15mg/day L-methylfolate.
45829485|NCT01853280|Drug|OROS-Methylphenidate|All subjects will be treated with open-label OROS-MPH
45973402|NCT05685290|Other|Traditional method|Peripheral venous catheter placement with the traditional method by nurses in the clinic routinely.
45973403|NCT05682378|Drug|Inclisiran|Inclisiran sodium 300mg (equivalent to 284mg inclisiran*) in 1.5mL solution administered subcutaneously in pre-filled syringe
45973404|NCT05681390|Drug|Tislelizumab|Tislelizumab 200mg iv drip, d1, Q3W;Anlotinib tablet : 10mg, PO, QD; Chemotherapy: selected by investigator following CSCO or NCCN pancreatic adenocarcinoma guideline; Tislelizumab and Anlotinib continue unless disease progression or intolerance to toxicity, chemotherapy continue upto 8 cycles unless disease progression or intolerance to toxicity
45973405|NCT05676450|Diagnostic Test|cell-free DNA|Given by IV (vein)
45973406|NCT05671874|Behavioral|Web/mobile/tablet-based digital decision aid + communication (DA+C) tool|The web/mobile/tablet-based digital DA+C toll is designed to enhance communication and shared decision making between clinicians and surrogates of critically ill severe acute brain injury (SABI) with four goals: to 1) prepare families for their surrogate role and discussions with clinicians; 2) provide balanced information to families on prognosis and all available treatment options; 3) provide tailored information about the patient and family to clinicians in advance of family meetings; and 4) serve as a communication guide for clinicians in the clinician-family meeting to facilitate shared decision-making.
46081812|NCT02955394|Drug|Fulvestrant|500mg Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
46081813|NCT02882321|Drug|Oxidative Phosphorylation Inhibitor IACS-010759|Given PO
46081814|NCT02882321|Other|Pharmacological Study|Correlative studies
45670416|NCT01606228|Drug|Paliperidone ER|Type= range, unit= mg/day, number= 3 to 12, form= tablet, route= oral use. Paliperidone ER 6 mg orally administered once daily for the first five days. Thereafter, flexible dosing in a range of 3 to 12 mg/day.
45670417|NCT01706536|Drug|Placebo|EP-101 Placebo AM + EP-101 Placebo PM
45670418|NCT01706536|Drug|EP-101 12.5 mcg|EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
45670419|NCT01706536|Drug|EP-101 25 mcg|EP-101 25 mcg AM + EP-101 25 mcg PM
45670420|NCT01706536|Drug|EP-101 50 mcg|EP-101 50 mcg AM + EP-101 50 mcg PM
45670421|NCT01706536|Drug|EP-101 100 mcg|EP-101 100 mcg AM + EP-101 100 mcg PM
45670422|NCT02269943|Drug|CC-486|
45829486|NCT01853280|Drug|Placebo|15 mg matched placebo comparator, with open-label OROS-Methylphenidate
45829487|NCT04415736|Other|No intervention, observational study|
45973407|NCT05669547|Device|dual hormone fully closed loop (DHFCL)|dual hormone fully closed loop consisting of an algorithm, sensors and both insulin and glucagon infusion.
46081815|NCT02864953|Drug|BIIB093|Administered as specified in the treatment arm.
46081816|NCT02864953|Drug|Placebo|Administered as specified in the treatment arm.
45973408|NCT05669261|Procedure|Adipose Tissue Harvest|"Local Anesthesia will be administered. A Stab wound will be created at the harvest site through which a 3.0 or 2.5 mm cannula will be inserted to suction fat using the syringe (i.e. manual) technique. A total of 100 cc of lipoaspirate will be collected by manual draw of the adipose tissue into syringes."
45973409|NCT05669261|Biological|ATCell|Infusion of the study medication at the rate of 575 mL/HR (500ml of LRD5 plus 75ml of ATCell suspended in LRD5) and continue until all received trial medication has been delivered.
45829488|NCT01892436|Drug|Secukinumab|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
45973410|NCT05669079|Drug|decitabine|15 mg/m2 daily intravenously for consecutive 3 days
45973411|NCT05669079|Biological|umbilical cord blood|MNC ≥ 3*108 cells; HLA compatibility ≥ 5/6
45670423|NCT04882319|Drug|HP-5000 Topical Patch|HP-5000, placebo and saline will be administered simultaneously
45670424|NCT04882319|Drug|HP-5000 Placebo Patch|HP-5000, placebo and saline will be administered simultaneously
45829489|NCT01892436|Drug|Placebo|Placebo
45829490|NCT04415580|Other|Vestibular Rehabilitation (VR)|"VR consisted of two types of exercises, i.e., those for gaze stability and those for postural stability~Gaze stability exercises The patients will perform the exercises while holding their gaze on a firm target (VORx1) during active horizontal and vertical head movements (one minute for each axis).~Postural stability exercises March in Place Each patient will ask to get on a foam cushion of 10 cm in height and then will blindfold. Treadmill Training As preparation for training, all subjects underwent a 1-minute walk on treadmill with open eyes using preferred walking speed. Immediately after preparation, patients will blindfold and will ask to walk on treadmill without support of hands for 4 minutes.~When patients made the mistake of changing direction, the physiotherapist help them to keep the right position using verbal cues (e.g., you are turning left or right)."
45973412|NCT05669079|Drug|Granulocyte-colony stimulating factor|Granulocyte-colony stimulating factor will be used when absolute neutrophil count ≤ 1.5 × 109/L
45670425|NCT04882319|Drug|Saline Patch|HP-5000, placebo and saline will be administered simultaneously
45670426|NCT01706458|Biological|sipuleucel-T|Given IV
45829491|NCT04415580|Other|Conventional Neurorehabilitation|muscles stretching, active and assisted limbs mobilization, four limbs coordination exercises, balance training on instable platform and gait training
45973413|NCT05669079|Drug|Recombinant human thrombopoietin / thrombopoietin receptor agonist|Recombinant human thrombopoietin or thrombopoietin receptor agonist will be used when platelet count ≤ 30 × 109/L
45973414|NCT05669079|Drug|Recombinant human erythropoietin|Recombinant human erythropoietin will be used when hemoglobin ≤ 85 g/L
45670427|NCT01706458|Biological|DNA Vaccine|Given ID
45670428|NCT02269787|Behavioral|Enhanced Telephone Monitoring|Detox inpatients in the ETM condition will be expected to complete one session while in detox and one 15-minute telephone call per week for 12 weeks (plus usual care).
45670429|NCT01605370|Drug|Nebivolol|Nebivolol 2.5 mg once daily
45670430|NCT01605370|Drug|Metoprolol succinate|Metoprolol succinate 50 mg once daily
45973415|NCT05661188|Drug|Atezolizumab plus Tiraglolumab|All patients receive atezolizumab (1200mg) plus tiragolumab (600 mg) for 2 cycles (Q3W) in concomitance with the 6 weeks of standard scheduled chemoradiotherapy (cisplatin: 60 mg/m² on days 1 and 29; 5-FU: 1000 mg/m² per day on days 1-4 and 29-32; radiotherapy: 1.8 Gy per day / total dose 54 Gy). After the concomitant phase, patients receive atezolizumab and tiragolumab for 6 additional cycles (consolidation phase).
45973416|NCT05658510|Drug|BXCL501|Sublingual Film
45973417|NCT05658510|Drug|Matching Placebo|Sublingual Placebo Film
45973418|NCT05650021|Device|SpaceOAR Vue|CBCT images acquired during the first five fractions of radiotherapy
45829492|NCT01853046|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days)
45829493|NCT01891890|Drug|Oxcarbazepine|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
45973419|NCT05641766|Drug|THC|Participants will receive THC into a rapidly flowing IV infusion.
45973420|NCT05641766|Other|Placebo|Participants will receive an equivalent amount (about 1-2 ml) of placebo (sterile 190 proof USP ethanol). The placebo does not produce any measurable blood alcohol levels or subjective/behavioral effects.
45973421|NCT05630625|Behavioral|Drinking Dashboard|Day-level feedback on alcohol use and consequences
45973422|NCT05628350|Other|No UPF controlled diet|Following a two-week eucaloric lead-in diet, participants will be provided and consume a diet without UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein), matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
45973423|NCT05628350|Other|Standard UPF controlled diet|Following a two-week eucaloric lead-in diet, participants will be provided and consume a diet maintaining usual UPF intake (59% energy). Diets will be eucaloric (50% carbohydrate, 35% fat, 15% protein), matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
45973424|NCT05623059|Drug|Slow Release DHEA|DHEA is a hormone produced by the body's adrenal gland. In drug form, it is available as an over-the-counter supplement that is available on the market without prescription.
45455969|NCT05311150|Device|White light bronchscopy guided endobronchial biopsy|Examination of the airways will be performed with the white light bronchoscopy mode using a flexible video-bronchoscope (BF-1T 180, Olympus Medical, Japan). Endobronchial biopsies will be performed from the abnormal areas as deemed by the operator.
45670431|NCT02269709|Device|ARFI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI). This is a new ultrasound technology in which unique sound waves create the images/pictures of the liver beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
45670432|NCT02269475|Drug|MEDI3250|MEDI3250
45670433|NCT02269475|Drug|Placebo|Placebo
45829494|NCT01891890|Drug|Levetiracetam|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
45829495|NCT01891890|Drug|Lamotrigine|Titration to target dose starting at week 11. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
45829496|NCT01852812|Drug|Montelukast Oral Granules (OG)|Montelukast 4 mg in one sachet
45829497|NCT01852812|Drug|Montelukast Chewable Tablets (CT)|Montelukast 5 mg in one tablet
45829498|NCT04617834|Other|Quality Surveillance Data Collection|Data will be retrospectively collected through EHR queries
45829499|NCT04602624|Drug|SAGE-718|SAGE-718 oral tablets.
45829500|NCT01869348|Behavioral|Monitor intervention|"Investigators will lend each participant 1 Jawbone Up activity monitor and 1 mini tablet device. Participants will receive weekly brief phone calls with counseling related to self-efficacy and self-regulation. The monitors will be programmed to provide idle alerts that vibrate when participants have reached a cut point for a bout of sedentary behavior (e.g., 30 minutes). Participants will monitor their progress using an app on the tablet that provides graphical feedback on physical activity and sedentary behavior."
45829501|NCT01869192|Drug|Epirubicin|Epirubicin 90 mg/m2 d1 q3w
45829502|NCT01869192|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 d1 q3w
45973425|NCT05611905|Combination Product|11C-para-aminobenzoic acid PET/CT|A bolus of 20 mCi of 11C-PABA followed by PET/CT
45973426|NCT05611905|Drug|Probenecid|Oral dose of 500 mg (tablet) 2 hours before IV dose of 11C-PABA will be administered.
45973427|NCT05607173|Drug|Fexinidazole (HOE239)|Route of administration: oral; pharmaceutical form: tablet
45973428|NCT05593445|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
45973429|NCT05593445|Drug|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
45973430|NCT05592743|Drug|Vorasidenib|Oral therapy
45973431|NCT05586373|Drug|medication 1|Ibuprofen pills, identical to the intervention (dipyrone pills), will be administered every 6 hour for a maximum of five days
45973432|NCT05586373|Drug|medication 2|Dipyrone pills, identical to the intervention (ibuprofen pills), will be administered every 6 hour for a maximum of five days
45973433|NCT05583019|Device|GENEActiv Accelerometry Device|a watch like wearable sensor
45973434|NCT05583019|Device|Centrepoint Insights Watch (CPIW) Accelerometry Device|a watch like wearable sensor
45973435|NCT05583019|Device|Apple Watch Accelerometry Device|a watch like wearable sensor
45973436|NCT05583019|Device|Polysomnography|Sleep monitor
46081817|NCT02780583|Drug|kineret|anakinra administered subcutaneously every 6 hours x 72 hours along with intravenous methylprednisolone
46081818|NCT02780583|Drug|placebo|placebo injection administered every 6 hours along with intravenous methylprednisolone
46081819|NCT02777892|Other|Sapien S3|Patients that have undergone percutaneous implantation of an Edwards SAPIEN S3 Transcatheter Heart Valve in the pulmonic position at the time of data collection
45670434|NCT01605136|Drug|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
45670435|NCT01605136|Drug|Placebo|One placebo subcutaneous implant every 2 months for 6 months
45670436|NCT01706146|Drug|Non-coumadin Oral Anticoagulant|Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
45973437|NCT05583019|Device|Videography|Thermal Camera
45973438|NCT05579626|Drug|high-intensity statin arm|•high-intensity statin strategy (standard arm): rosuvastatin 20 mg PO qd, once daily
45973439|NCT05579626|Drug|low-intensity statin plus ezetimibe|•low-intensity statin plus ezetimibe strategy (experimental arm): rosuvastatin 5mg /ezetimibe 10mg PO qd), once daily
45973440|NCT05568134|Diagnostic Test|Oral glucose tolerance test|"An oral glucose tolerance test will be completed. A fasting glucose will be measured.~Participants will drink 1.75 g/kg of dextrose (up to a maximum of 75 grams) within 10 minutes. Glucose values will be measured at 1 hour and 2 hours."
45973441|NCT05556772|Procedure|Biospecimen Collection|Collection of blood; urine; cervical, anal, vaginal samples
45973442|NCT05556772|Other|Interview|Attend interview
45973443|NCT05551754|Dietary Supplement|Ketone Supplement|Drink a single dose of ketone supplement 25g
45973444|NCT05551754|Other|Alcohol Beverage|Subjects will drink about 2 ½ standard alcohol beverages, based on their weight to reach a breath alcohol level of 0.050%
45973445|NCT05551741|Biological|IBC-Ab002|An anti-PD-L1 monoclonal antibody
45973446|NCT05551741|Other|Placebo|Normal Saline
45973447|NCT05549401|Drug|CKD-348(4) F1|QD, PQ
45973448|NCT05549401|Drug|CKD-348(4) F2|QD, PQ
45973449|NCT05549401|Drug|CKD-828, D097, D337|QD, PQ
45973450|NCT05543252|Drug|UCB0599|UCB0599 Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive UCB0599 in a pre-specified sequence during the Treatment Period.
46081820|NCT02768532|Drug|Vedolizumab|"During each 8 visits (screening, V0, V1, V2, V3, V4, V5, V6) at weeks-1, 0, 2, 6, 10, 14, 22, 54, respectively), the following parameters will be systematically recorded: Crohn's disease Activity Index (CDAI), adverse events.~Blood and fecal samples will be systematically collected at weeks 0, 2, 6, 10, 14, 22 and 54 for routine serum ultrasensitive CRP (C-Reactive Protein) and fecal calprotectin assessments and for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-Vedolizumab antibodies. In case of loss of response, an additional measurement of serum CRP (C-Reactive Protein), fecal calprotectin and Vedolizumab pharmacologic parameters will be performed."
46081821|NCT02765074|Drug|subcutaneous tocilizumab|162 mg subcutaneous, once a week during 12 months
46081822|NCT02739776|Device|Thermographic imaging|Using infrared-recording camera will obtain thermographic images of the lower extremities before and after the epidural blockade
46081823|NCT02710851|Biological|low dosage HPV Vaccine(1:1)|"Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
46081824|NCT02710851|Biological|low dosage HPV Vaccine(1:2)|"Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:2 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
45670437|NCT04168450|Other|WiSAT System, Passive Feedback|The WiSAT system is installed in the participant's wheelchair cushion and a smartphone application is installed on his/her cellphone. Participants are able to view the application as they please and they will receive no notifications from the app regarding their movement goals.
45829503|NCT01869192|Drug|Docetaxel|Docetaxel 75 mg/m2 d1 q3w
45670438|NCT04168450|Other|WiSAT System, Active Feedback|The WiSAT system is installed in the participant's wheelchair cushion and smartphone application is installed on his/her cellphone. Participants receive notifications from the app to help them meet their movement goals.
45829504|NCT01869192|Drug|Capecitabine|Capecitabine 1000 mg/m2/dose bid x 14d q3w
45829505|NCT01869192|Radiation|Radiation Therapy|Standard dosing, fields depending on clinical findings
45829506|NCT04415190|Other|early palliative care|early palliative care
45829507|NCT04595682|Drug|Placebo|Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol (or placebo) effects on disinhibition and impulsive choice. The placebo consists of 300 ml of lemon-flavored soda with a small amount (3 ml) of alcohol floated on top.
45829508|NCT04595682|Drug|Alcohol|Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol effects on disinhibition and impulsive choice. The alcohol dose consists of 0.60 g/kg absolute alcohol that produces a peak blood-alcohol concentration of 80 mg/dl. Doses will be mixed with a carbonated, non-caffeinated, lemon-flavored soda and consumed within 10 minutes.
45973451|NCT05538910|Other|Placebo Nicotine Patch|Comparator
45670439|NCT02269241|Drug|LF111 (drospirenone)|One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
45670440|NCT01750684|Drug|AC105|
45670441|NCT01750684|Other|Placebo|
45670442|NCT01750294|Drug|Chlorthalidone|
45670443|NCT01749982|Other|Placebo|
45670444|NCT01749982|Drug|Choline bitartrate|
45973452|NCT05538910|Drug|Nicotine Patch|Study drug: 7.5 mg Nicotine Patch which will be administered in a double blind, randomized manner
45973453|NCT05537220|Drug|N-acetylcysteine|After randomization, participants will be given about 10-months supply of study drug (intervention), with instructions to take 3 effervescent tablets in water twice a day. They will return to the clinic at M4.5 for evaluation and then at M9, M18, M27, M36, M40.5 and M45. At each in-clinic visit, drug reconciliation will occur. At each visit at Baseline, M9, M18, M27, M36, that is, every 9 months, participants will be given another 10-month supply of study drug.
45973454|NCT05537220|Drug|Placebo|After randomization, participants will be given about 10-months supply of placebo, with instructions to take 3 effervescent tablets in water twice a day. They will return to the clinic at M4.5 for evaluation and then at M9, M18, M27, M36, M40.5 and M45. At each in-clinic visit, efficacy and safety assessments will be done and drug reconciliation will occur. At baseline, M9, M18, M27, and M36 participants will be given another 10-month supply of placebo.
45973455|NCT05526391|Drug|TAK-341|TAK-341 IV infusion
45973456|NCT05526391|Drug|Placebo|TAK-341 placebo-matching IV infusion
45973457|NCT05513586|Drug|TAK-771|Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
45670445|NCT01749982|Drug|Betaine|
45670446|NCT01749982|Drug|Choline bitartrate + Betaine|
45973458|NCT05512871|Behavioral|Personalized mHealth intervention to promote short-term metabolic and mental health among women with a history of Gestational Diabetes Mellitus (GDM)|The study aim to conduct lifestyle intervention trials to examine the feasibility, efficacy, and cost-effectiveness of the mHealth approach in preventing them from developing Type 2 Diabetes in the future. This pilot study will primarily aim to determine the feasibility of our intervention approaches as well as enhance health literacy and promote healthy lifestyle in the study participants. In the longer term, we hope that the proposed mHealth intervention can be translated to include women from the community setting and involve wider healthcare setting to come together and reduce the burden of Type 2 Diabetes in Singapore.
45973459|NCT05507658|Drug|Tislelizumab combined with Oxaliplatin and Capecitabine|"Drugs:~Tirelizumab 200mg, iv.gtt, D1, Q3W;~Chemotherapy (XELOX) : oxaliplatin (130 mg/m2), iv.gtt, D1, Q3W; Capecitabine (1000mg/m2), P.O.B.I.D., D1-D14, Q3W.~Neoadjuvant therapy:~Tislelizumab combined with XELOX for 3 weeks;~D2 radical gastrectomy within 3-6 weeks after neoadjuvant therapy, with more than 15 lymph nodes dissected.~Adjuvant therapy:~From 4 to 8 weeks after surgery, the treatment dose was the same as above;~Patients who achieved pCR and non-PCR on pathological evaluation were treated with tirelizumab +XELOX 6-8 cycles;~Tumor evaluation performed every 3 cycles;~The maximum duration of adjuvant therapy was not more than 8 cycles."
45973460|NCT05506423|Device|CycloPen Cyclodialysis System|The CycloPen Micro-Interventional Cyclodialysis System is a manual surgical instrument for ab-interno supraciliary intervention to enhance uveoscleral outflow. The CycloPen may be used to deliver allograft tissue and/or viscous material to reinforce and maintain the cyclodialysis cleft.
45973461|NCT05495633|Other|Collection and evaluation of clinical (CROMs) and patient-reported outcomes (PROMs)|"The study uses a web-based German-language registry database called heartbeat ONE by heartbeat medical solutions GmbH (Berlin, Germany) that provides both clinical reported outcome measures (CROMs) and patient-reported outcome measures (PROMs). PROMs are investigated by validated questionnaires: IPSS/QoL, ICIQ-MLUTS, MSHQ, ICIQ-MLUTSsex, QoR-15GE, PROMIS Global Health 10, ICIQ-S, NRS, and by home urine flow measurement (iUFlow) as well as by self-designed questionnaires to assess patients´ preferences and expectations for Rezum and for surgical therapy of the prostate, satisfaction with the Rezum therapy, side effects of the Rezum therapy, (re)medication to treat BPO and LUTS, and reoperations after Rezum therapy."
45973462|NCT05495633|Other|Analysis of uroflowmetry data by Kesem Health iUFlow medical uroflowmetry device|If patients have a smartphone with app function (Android or Apple), they will be provided with a certified and approved home uroflowmetry medical device (iUFlow from Kesem Health) at study entry. This should enable patients to measure their urine flow conveniently from home and thus be independent of the medical consultation (automated home bladder monitoring solution). iUFlowTM is marketed by Kesem Health Pty Ltd, 5A Hartnett Cl, Mulgrave VIC 3170, Australia. The Device is FDA and CE approved and is approved to be used in the EU and Switzerland. Every time a patient is using the device urine flow measurement data and additional voluntary parameters entered by the patient (micturition protocol, drinking protocol) will be sent to the study database.
45973463|NCT05491668|Diagnostic Test|Non-hyperemic pressure ratio assessment pre and post PCI|Pre and post PCI invasive physiologic assessment
45973464|NCT05488509|Drug|Cannabis|Participants will inhale vapor from cannabis containing either 20mg THC or 40mg THC.
45973465|NCT05488509|Drug|Placebo|Participants will inhale vapor from a placebo product.
45973466|NCT05488431|Drug|Bempedoic acid|Bempedoic Acid is an oral first-in-class small molecular adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor which lowers LDL-C by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Inhibition of ACL by bempedoyl-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of LDL receptors and concomitant suppression of hepatic fatty acid biosynthesis. BA has been studied in >4300 individuals and is currently being studied in >14,000 individuals in CLEAR Outcomes (NCT02993406).
45973467|NCT05488431|Other|Placebo|Placebo
45973468|NCT05486793|Behavioral|Written Exposure Therapy (WET)|5 individual sessions that cover psychoeducation about PTSD, the rationale for exposure treatment, and directing patients to write in session for 30 minutes about their traumatic experience using scripted instructions. Each session includes unique writing instructions. Earlier sessions focus on describing the details of a traumatic stressor linked to their symptoms, with particular attention to felt emotions and thoughts. Later writing sessions focus on writing about the meaning of the traumatic event and how the event has changed their life and how they relate to other people. After writing, therapists spend ~10 minutes processing the patient's experience with the writing. WET does not include between session assignments.
45973469|NCT05486793|Behavioral|Emotion Focused Supportive Therapy (EFST)|5 individual sessions where patients choose what problems to discuss in each session. Therapists validate and clarify patients' emotions and engage in problem solving during sessions.
45670447|NCT02269163|Biological|Immune Globulin Intravenous|Gammargard, Gammaplex,Gamunex, or Octogam IGIV Product
45670448|NCT02269163|Biological|Prometic's Immune Globulin Intravenous 10%|Liquid formulation of Prometic Immune Globulin Intravenous 10% (human) in 50 mL vials containing 100 mg/mL of immunoglobulin G (IgG)
45670449|NCT01749826|Drug|Morphine Sulfate|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
45973470|NCT05485012|Drug|Marijuana|Double-blind administration of marijuana
45670450|NCT02300129|Drug|CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo|"Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
45670451|NCT02300129|Drug|Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo|"Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
45670452|NCT02300129|Drug|CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47|"Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
45670453|NCT02300129|Drug|Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47|"Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
45829509|NCT04615884|Dietary Supplement|Chinese herbs formula: Shu Yu Wan|Shu Yu Wan Formula is a combination of 23 natural chinese herbs.This formula may be used to relieve chemotherapeutic side effects or cancer-related symptoms.
45829510|NCT04615884|Other|Placebo capsules|Placebo
45829511|NCT01868646|Drug|Subetta|"Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type II diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
45829512|NCT01868646|Drug|Placebo|"Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type II diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
45829513|NCT01852110|Drug|MK-7622|MK-7622 capsule
45829514|NCT01852110|Drug|Placebo|Matching placebo to MK-7622 capsule
45829515|NCT01852110|Drug|AChEI|"One of the following AChEIs, as prescribed by the participant's primary care physician:~Donepezil: 10 mg total daily dose, administered orally~Rivastigmine: 9.5 or 13.3 mg/24 hours, administered by transdermal patch; or 6-12 mg total daily dose administered orally~Galantamine: 16-24 mg total daily dose, administered orally"
45829516|NCT01851720|Drug|Low dose fentanyl PCA|
45829517|NCT01851720|Drug|Standard IV fentanyl bolus|
45829518|NCT01851330|Drug|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
45829519|NCT01851330|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45829520|NCT01868022|Drug|GSK3052230|A clear to opalescent, colorless to pale yellow solution for IV infusion once weekly (Day 1, Day 8, Day 15) in each 21-day cycle with unit dose strengths/dose level of 5, 10, 15, and 20 mg/kg supplied in a sterile 25 mL glass vial.
45829521|NCT01868022|Drug|paclitaxel|paclitaxel will be from commercial stock.
45829522|NCT01868022|Drug|carboplatin|carboplatin will be from commercial stock.
45829523|NCT01868022|Drug|docetaxel|docetaxel will be from commercial stock.
45829524|NCT01868022|Drug|pemetrexed|pemetrexed will be from commercial stock
45829525|NCT01868022|Drug|cisplatin|cisplatin will be from commercial stock
45829526|NCT01850004|Drug|Dasatinib|
45829527|NCT01867710|Drug|Abiraterone Acetate|Type = exact number; unit = mg; number = 1000; form = tablet; route = oral; taken as four 250 mg tablets once daily at least 2 hours after eating and no food should be eaten for at least 1 hour after taking the tablets.
45829528|NCT01867710|Drug|Prednisone 5 mg twice daily|type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
45829529|NCT01867710|Drug|Prednisone 5 mg once daily|type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken once daily, in the morning after a meal
45829530|NCT01867710|Drug|Prednisone 2.5 mg twice daily|type = exact number; unit = mg; number = 2.5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
45829531|NCT01867710|Drug|Dexamethasone 0.5 mg once daily|type = exact number; unit = mg; number = 0.5; form = tablet; route = oral; taken once daily, in the morning after breakfast
45829532|NCT01849848|Drug|SyB L-0501|The administration of SyB L-0501 at 90 mg/m^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.
45973471|NCT05485012|Drug|Opioid|Double-blind administration of an opioid agonist
45973472|NCT05477953|Drug|Nifurtimox (BAYA2502)|At least 1 dose of nifurtimox
45973473|NCT05473715|Drug|Aflibercept(BAY86-5321, Eylea)|2mg, intravitreal (IVT) injection
45973474|NCT05472584|Other|Electrophysiology assessment - corticospinal tract|Kinematics and cortical spinal motor excitability
45973475|NCT05472584|Other|Electrophysiology assessment - reticulospinal tract|Kinematics and reticular spinal motor excitability
45973476|NCT05472584|Other|Electrophysiology assessment - spinal motoneuron|Kinematics and spinal motoneuron excitability
45973477|NCT05472584|Other|Activity-based training|Motor task
45973478|NCT05472584|Other|Transcutaneous spinal cord stimulation|Non-invasive spinal cord stimulation
45973479|NCT05472519|Biological|blood samples|"Only one visit for each participant: A large majority of visits will be part of patients' usual care.~Medical examination : weight, gender, blood pressure, medical history~Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma"
45670454|NCT02267135|Biological|Secukinumab 300 mg|Secukinumab 300 mg will be provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab will consist of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 20 inclusive. In order to maintain the blinding, patients will receive additional placebo injections at Weeks 13, 14 and 15. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur of days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
45973480|NCT05472519|Biological|blood samples|"Only one visit for each participant:~Medical examination : weight, gender, blood pressure, medical history~Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma"
45973481|NCT05467891|Drug|Ribociclib|600 mg orally once daily Days 1-21 (28 day Cycle)
45973482|NCT05467891|Drug|Fulvestrant|500 mg intramuscularly on Day 1 and 15 of Cycle 1 then Day 1 of Cycle 2+
45973483|NCT05467891|Drug|Anastrozole|1 mg orally once daily
45670455|NCT02267135|Biological|Placebo|Placebo will be provided in 1 mL prefilled syringe. Each placebo dose will consist of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3 and 4), then after four weeks at Week 8. At Week 12, PSSI responders will continue on placebo and receive their injections once weekly for five weeks (Weeks 12, 13, 14, 15 and 16), then followed by dosing after four weeks at Week 20. PSSI non-responders will be switched to receive 300 mg secukinumab at Weeks 12, 13, 14, 15 and 16, then after four weeks at Week 20. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur on days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
45829533|NCT04594512|Other|Fresh corneal lenticule and autologous serum in advanced keratoconus using ReLex Smile surgery|A 19-year-old female patient with keratoconus and chronic hydrops cornea referred to the cornea department of our clinic with thin cornea and hydrops in chronic stage and minimal dry eye symptoms. Minimum corneal pachymetry in the right eye was 378 µm as measured by optical coherence tomography(AS-OCT-Zeiss). Atlas corneal topography showed steep K-values 82.60 ax.37 and flat K 75.15 D ax 127 with -7.45 corneal astigmatism. Her best corrected visual acuity was 0.0.5 in right eye and 1.0 in the left eye. Slit lamp examination showed intense punctate epitheliopathy (Figure 1), tear film break-up time (TBUT) was measured as 7-8 sec and Schirmer test was 10 mm in right eye, and the other eye examinations were determined normally
45973484|NCT05467891|Drug|Letrozole|2.5 mg orally once daily
45973485|NCT05467891|Drug|Exemestane|25 mg orally once daily
45973486|NCT05456191|Drug|Asciminib|Asciminib 80 mg QD administered under fasting conditions.
45973487|NCT05456191|Drug|Nilotinib|Nilotinib 300 mg BID administered under fasting conditions.
45973488|NCT05455658|Biological|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given IV
45829534|NCT01849458|Device|BioFiber|Subjects implanted with BioFiber or BioFiber-CM Scaffold
45670456|NCT02299427|Behavioral|dog safety|use of dog safety website at home for about 2 weeks
45973489|NCT05455658|Biological|Sargramostim|Given ID
45973490|NCT05455606|Other|Best Practice|Receive usual care
45973491|NCT05455606|Other|Chart Abstraction|Ancillary studies
45973492|NCT05455606|Other|Educational Intervention|Physicians access genomic testing education materials
45670457|NCT02299427|Behavioral|transportation safety|use of transportation safety website at home for about 2 weeks
45829535|NCT04415034|Other|VAS and 5-D itch pruritus assessment|All subjects were evaluated for presence of pruritus using VAS and 5-D itch scale
45829536|NCT01832766|Drug|Dronabinol|dronabinol 10 mg one capsule by mouth at 8:00 a.m.
45829537|NCT01832766|Other|Placebo Comparator|one capsule given by mouth at 8:00 a.m.
45829538|NCT01832532|Drug|liraglutide|daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose
45829539|NCT04414956|Diagnostic Test|AFP-L3|AFP-L3 will be tested using serum sample every 6 months.
45829540|NCT04414956|Diagnostic Test|AFP|AFP will be tested using serum sample every 6 months.
45829541|NCT04414956|Diagnostic Test|PIVKA-II|PIVKA-II will be tested using serum sample every 6 months.
45973493|NCT05455606|Procedure|Genomic Profile|Patients undergo genomic testing
45973494|NCT05455606|Other|Interview|Ancillary studies
45973495|NCT05455606|Other|Questionnaire Administration|Ancillary studies
45973496|NCT05455606|Other|Tumor Board Review|Patients undergo genomic tumor board review
45973497|NCT05445843|Drug|JDQ443|JDQ443 orally administered
45973498|NCT05442567|Drug|Vedolizumab IV|Vedolizumab IV infusion
45973499|NCT05442567|Other|No Intervention|Participants will not receive any intervention in the Observational Cohort.
45973500|NCT05442515|Drug|fludarabine|Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose)
45973501|NCT05442515|Drug|cyclophosphamide|Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion.
45973502|NCT05442515|Biological|CD19/CD22-CAR-transduced T cells|CD19/CD22-CAR-transduced T cells on D0 after lymphodepleting preparative regimen
45973503|NCT05434546|Drug|Sepranolone|Treatment with 10 mg Sepranolone s.c. twice weekly for 12 weeks alongside patient's standard of care Tourette treatment.
45973504|NCT05433090|Behavioral|Inpatient serious illness care program|Inpatient advance care planning intervention that will be delivered by advanced care practitioners or hematology/oncology fellow physicians. The intervention will be an adapted version of the serious illness care program.
45973505|NCT05432193|Drug|[Ga-68]-PNT6555|[Ga-68]-PNT6555 IV administered as imaging agent for PET/CT
45829542|NCT04414956|Diagnostic Test|Sonography|Sonography will be tested by experts every 6 months.
45670458|NCT05649371|Other|Prehabilitation|A multiphasic exercise prehabilitation program for alloHSCT candidates across each treatment phase, that includes behaviour change support
45670459|NCT05649215|Other|No intervention will be applied.|This is a questionnaire study.
45670460|NCT01724866|Drug|SPI-2012|SPI-2012 SC injection.
45670461|NCT01724866|Drug|Pegfilgrastim|Pegfilgrastim SC injection, per manufacturer's Prescribing Information.
45670462|NCT01724866|Drug|Docetaxel|Docetaxel given based on standard dose for chemotherapy.
45670463|NCT01724866|Drug|Cyclophosphamide|Cyclophosphamide given based on standard dose for chemotherapy.
45670464|NCT04874441|Diagnostic Test|Diagnosis strategy based on C. glabrata / krusei PCR|For diagnosis, a blood cultures and blood tubes for PCR will be collected and patients will be treated with echinocandins in the first instance with an early switch to fluconazole if the C. glabrata / krusei PCR is negative
45670465|NCT04419935|Procedure|lymphadenectomy|Lymphadenctomy according with ESTS guidelines
45829543|NCT04414956|Diagnostic Test|CT|Contrast-enhanced CT will be tested annually.
45829544|NCT04589910|Diagnostic Test|diaphragm thickness and thickening fraction|Ultrasound measurement of the diaphragm will be performed with the use of a Sono Site SII, portable system in B mode with the child in a 30-degree supine position. The diaphragm thickness will be measured with a high frequency (4-10 MHz) linear array transducer placed in the ninth or tenth intercostal space between the anterior and midaxillary lines in the zone of apposition between lung and liver.
45829545|NCT04415112|Behavioral|Mediterranean Diet|A list of foods high consumption of vegetables, fruits, non-refined cereals, legumes and potatoes, moderate consumption of fish and poultry and low consumption of full fat dairies, red meat and its products and homemade sweets.
45829546|NCT04415112|Behavioral|Low Fat Diet|These children are forbidden to eat high-fat foods such as fried foods, butter, cream cheese, while foods such as fruits, vegetables (starchy and non-starch), cereals, poultry, lean meat and low-fat dairy products are allowed.
45829547|NCT01848990|Drug|Commercial Hylenex® recombinant (hyaluronidase human injection)|
45829548|NCT01848990|Drug|Precommercial Hylenex recombinant (hyaluronidase human injection)|
45829549|NCT01848990|Drug|Insulin lispro|
45829550|NCT01848990|Drug|Insulin aspart|
45829551|NCT01848990|Drug|Insulin glulisine|
45829552|NCT01867086|Biological|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 3 weeks.
45829553|NCT01867086|Drug|Carboplatinum|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
45829554|NCT01867086|Drug|Carboplatinum and Taxol|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
45829555|NCT01831596|Device|ciSNaP|SNaP disposable, mechanically powered Negative Pressure Wound Therapy System
45829556|NCT01848834|Biological|Pembrolizumab|IV infusion
45829557|NCT01867008|Device|Nucleus CI422 Cochlear Implant with N6 Sound Processor|
45829558|NCT01848756|Drug|SNX-5422|Capsule(s) dosed every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle.
45829559|NCT04594434|Other|Scale SUD|Subjective Units of Distress Scale ou Subjective Units of Disturbance Scale is a scale of subjective appreciation of emotions
45829560|NCT04594434|Other|VOC scale|The VOC (Validity Of Cognition) scale is a scale of value given to cognition.
45829561|NCT04594434|Other|DES II scale|The Dissociative Experiences Scale (DES), which is translated as the Dissociative Experiences Scale, is a self-questionnaire to assess the frequency of various dissociative symptoms in the patient's daily life.
45973506|NCT05432193|Drug|[Lu-177]-PNT6555|Patients with FAP-avid disease as determined by the [Ga-68]-PNT6555 screening PET/CT will receive [Lu-177]-PNT6555 at a fixed dose level for up to 6 doses at an interval of 6 weeks between each dose.
45973507|NCT05419622|Biological|bronchial biopsies|This fibroscopy will make it possible to perform 4 bronchial biopsies at the level of the 4th bronchial generation (subsegmental bronchi), using suitable pediatric forceps.
45973508|NCT05416814|Dietary Supplement|Kefir|Oral route (via feeding tube in intubated patients). Serving size 240mL to be given in an ascending dosing regimen if tolerated starting at 60 mL/day, 120 mL/day until single 240 mL/day; if evidence of intolerance, dose will be reduced to previously tolerated dose.
45973509|NCT05407844|Other|Community Health Worker (CHW) based palliative care|Those in the intervention group will receive support from a dedicated CHW trained in motivational interviewing, components of palliative care communication, and social determinants of health.
45973510|NCT05405998|Other|Proactive care pathway|"Patient participation in a specific therapeutic education program, as soon as the therapeutic decision is made.~The reinforced cooperation of the expert centers with the homecare providers on 2 different times:~before the installation of the pump, i.e. before the episode of hospitalization dedicated to the starting of the treatment;~after the installation of the pump following the above mentioned hospitalization."
45973511|NCT05401838|Behavioral|Group Brief Cognitive-Behavioral Therapy (G-BCBT)|G-BCBT comprises 12, 90 minute sessions organized in three phases: (1) emotion regulation, (2) cognitive flexibility, and (3) relapse prevention. The first session will be a tailored individual session focusing on person-specific crisis response planning and developing the participant's suicide mode. Sessions 2 through 5 feature treatment goal setting, followed by teaching skills in stimulus control, mindfulness, relaxation, a reasons for living task, and survival kit. Sessions 6 through 10 provide opportunities for improving cognitive flexibility via cognitive-behavioral exercises such as ABC worksheets, challenging questions, patterns of problematic thinking worksheets, coping cards, and activity planning. The third phase of treatment focuses on relapse prevention, and encompasses the last two sessions of treatments where group participants demonstrate mastery of the skills learned in treatment and practice successfully navigating a future stressful situation.
45973512|NCT05401838|Behavioral|Dialectical Behavior Therapy (DBT) Skills Group|DBT comprises 24 weekly group therapy sessions each lasting 90 minutes. DBT sessions include worksheets and skills practice activities. The DBT protocol entails three phases as follows. Phase I (8 weeks) covers a two-week mindfulness orientation and a six-week distress tolerance module. Distress tolerance skill building includes paired muscle relaxation, distraction, and radical acceptance. Phase II (nine weeks) entails a two-week mindfulness module followed by seven weeks of emotion regulation skill building. Emotion regulation content includes a model of describing emotion and a pleasant events checklist. Phase III (7 weeks) includes two-week mindfulness and orientation module, followed by five weeks of interpersonal effectiveness training. Interpersonal effectiveness training approaches include clarifying goals in interpersonal situations, guidelines for keeping relationships, and self-respect. Mindfulness, cutting across modules, addresses review of concepts such as Wise Mind.
45973513|NCT05400122|Drug|Vactosertib|Vactosertib is a highly selective, potent inhibitor of the protein serine/threonine kinase activity of transforming growth factor (TGF)-β receptor type 1 (TGFBR1; also known as activin receptor-like kinase 5 [ALK5]). Vactosertib inhibits the phosphorylation of the ALK5 substrates Smad2 and Smad3, as well as the intracellular signaling of TGF-β.
45973514|NCT05400122|Drug|Fludarabine Phosphate|Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoroara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
45670466|NCT02266433|Drug|Ketorolac|"The proposed use of ketorolac in this study is outside of the FDA-approved indication and is the investigational agent in this study~Ketorolac is a non-steroidal anti-inflammatory drug (NSAID). The approved indication for Ketorolac is for the short-term (≤5 days) management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. It is highly protein bound (99%) and is largely metabolized by the liver. In it's approved indication it is contraindicated for those with renal impairment, active peptic ulcer disease, pregnant or nursing females, individuals with NSAID hypersensitivity, or individuals at high risk for bleeding/clotting disorders."
45829562|NCT04600362|Drug|Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Subcutaneous
45829563|NCT01830972|Drug|SA-ER 500 mg|oral tablets
45829564|NCT01830972|Drug|SA-IR 500 mg|oral capsules
45829565|NCT01848288|Device|CENTURION® Vision System (CVS)|Phacoemulsification aspiration platform, with configuration consisting of Centurion® Vision System Phaco Emulsifier Aspirator, 45° Balanced ultrasonic tip, and INTREPID Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
45829566|NCT01848288|Device|INFINITI® Vision System (IVS)|Phacoemulsification aspiration platform, with configuration consisting of Infiniti® Vision System Phaco Emulsifier Aspirator, 45° Mini Flared Kelman tip, and Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
45829567|NCT01848210|Drug|Coumarin/troxerutin|Coumarin + troxerutin fixed-dose combination tablets
45829568|NCT01848210|Drug|Placebo|Coumarin + troxerutin placebo-matching tablets
45829569|NCT01830816|Drug|Ixazomib|Ixazomib capsules
45829570|NCT01846416|Drug|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle until disease progression.
45973515|NCT05400122|Drug|Cyclophosphamide|Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity.
45829571|NCT04589754|Drug|Sintilimab plus chemotherapy|AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks; sintilimab (10ml; 100mg) was administered intravenously every 3 weeks;
45973516|NCT05400122|Drug|IL-2|"Proleukin® (aldesleukin) has been shown to possess the biological activities of human native interleukin-2. In vitro studies performed on human cell lines demonstrate the immunoregulatory properties of Proleukin, including: a) enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines; b) enhancement of lymphocyte cytotoxicity; c) induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and d) induction of interferon-gamma production.~The in vivo administration of Proleukin in animals and humans produces multiple immunological effects in a dose dependent manner. These effects include activation of cellular immunity with profound lymphocytosis, eosinophilia, and thrombocytopenia, and the production of cytokines including tumor necrosis factor, IL-1 and gamma interferon. In vivo experiments in murine tumor models have shown inhibition of tumor growth"
45973517|NCT05400122|Drug|Natural Killer Cells|Adoptive NK cell therapy has demonstrated the potential for cancer immunotherapy in various malignancies with particular potential in hematologic malignancies including acute myeloid leukemia (AML), and colon cancer [14, 19-23]. This therapeutic approach is extremely well tolerated in patients even when massive numbers of cells are utilized (~109 NK cells/kg). In fact, studies suggest that high doses of NK cells are not only well tolerated but have potential to lead to higher levels of efficacy.
45829572|NCT01865448|Dietary Supplement|Omega-3 DHA|Patients take daily 2 tablets of Docosahexaenoic Acid
45829573|NCT01865448|Other|Placebo|Patients in control group take daily 2 placebo capsule
45829574|NCT04414878|Device|VitaFlow™ II Transcatheter Aortic Valve System|VitaFlow™ II Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System, loading tools, and a guide-wire
45829575|NCT01846104|Biological|50-μg booster dose RVEc|Subjects will be recruited from the 10 subjects who received three 50-μg doses of RVEc during the Phase 1 trial. Subjects will receive a single booster dose only and will be followed for 6 months after vaccination.
45829576|NCT01803282|Drug|Andecaliximab|Administered intravenous infusion
45829577|NCT01803282|Drug|Gemcitabine|Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
45829578|NCT01803282|Drug|Nab-paclitaxel|Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
45829579|NCT01803282|Drug|Carboplatin|Administered intravenously on Day 1 of each 21-day treatment cycle
45829580|NCT01803282|Drug|Pemetrexed|Administered intravenously on Day 1 of each 21-day treatment cycle
45829581|NCT01803282|Drug|Leucovorin|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
45973518|NCT05386472|Drug|nirmatrelvir|Nirmatrelvir (tablets) administered by mouth every 12 hours for 5 days (10 doses total)
45973519|NCT05386472|Drug|ritonavir|Ritonavir (capsules) administered by mouth every 12 hours for 5 days (10 doses total)
45973520|NCT05384626|Drug|NVL-655|Oral Tablet of NVL-655
45973521|NCT05376917|Device|Zeiss CT Asphina / Zeiss CT Asphina|Monovision with refractive target of -1.50D on the dominated eye
45829582|NCT01803282|Drug|Oxaliplatin|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
45829583|NCT01803282|Drug|5-FU|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
45829584|NCT01803282|Drug|Bevacizumab|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
45829585|NCT01803282|Drug|Irinotecan|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
45829586|NCT01803282|Drug|Paclitaxel|Administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle (Breast cancer) or on Day 1 of each 21-day treatment cycle (NSCLC)
45829587|NCT01844778|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).
45829588|NCT01844778|Drug|Tobramycin inhalation solution|Tobramycin inhalation solution was administered via nebuliser
45829589|NCT01844778|Drug|Colistimethate|Colistimethate was administered via nebuliser.
45973522|NCT05376917|Device|Zeiss AT Lara/ Zeiss AT Lisa Tri|Zeiss AT Lara (dominant eye) / Zeiss AT Lisa Tri (non-dominant eye)
45973523|NCT05376917|Device|Zeiss CT Asphina/ Zeiss AT Lara|Zeiss CT Asphina/ Zeiss AT Lara (non-dominant eye)
45973524|NCT05376917|Device|Zeiss AT Lara / Zeiss AT Lara|Micromonovision with refractive target of -0.75D on the non-dominant eye
45670467|NCT02266433|Drug|Dexamethasone|"Dexamethasone is a synthetic corticosteroid and possesses glucocorticoid activity, and will be used within its labeled indication for this study: intra-articular or soft tissue injection for: synovitis of osteoarthritis, epicondylitis, acute nonspecific tenosynovitis. It is the active comparator in this study.~In its approved indication there use limitations for immunocompromised individuals, pregnant females, persons with allergy to steroids, individuals with systemic fungal infections, and individuals with cerebral malaria. It is contra-indicated in systemic fungal infections, and hypersensitivity to any component of this product, including sulfites."
45829590|NCT01802580|Behavioral|Internet Survey|
45829591|NCT01802580|Drug|fluocinonide 0.05% ointment|
45829592|NCT01802346|Dietary Supplement|dietary intervention|Consume a low-calorie diet
45829593|NCT01802346|Procedure|nutritional support|Receive dietary advice
45829594|NCT01802346|Other|laboratory biomarker analysis|Correlative studies
45829595|NCT01611090|Drug|Ibrutinib|Type=exact number, unit=mg, number=420 , form=capsule, route=oral use. Capsule is taken once daily continuously.
45829596|NCT01611090|Drug|Bendamustine hydrochloride|Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.
45829597|NCT01611090|Drug|Rituximab|Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.
45829598|NCT01611090|Drug|Placebo|Form=capsule, route=oral use. Capsule is taken once daily continuously.
45829599|NCT01844700|Drug|Ziprasidone|random assignment to ZIP (20-160mg/d, bid dosing)
45829600|NCT01844700|Drug|aripiprazole, quetiapine, or risperidone|random assignement to Usual Care antipsychotic UC antipsychotic (aripiprazole 2-30mg/d, quetiapine 25-800mg/d or risperidone 0.1-8mg/d)
45829601|NCT01827384|Drug|Adavosertib|Given by mouth (PO)
45829602|NCT01827384|Drug|Carboplatin|Given intravenous (IV)
45829603|NCT01827384|Drug|Everolimus|Given by mouth (PO)
45829604|NCT01827384|Drug|Temozolomide|Given by mouth (PO)
45829605|NCT01827384|Drug|Trametinib|Given by mouth (PO)
45829606|NCT01827384|Drug|Veliparib|Given by mouth (PO)
45829607|NCT01844076|Drug|Quinacrine and Capecitabine|The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
45829608|NCT01826604|Device|Alexis O C-Section Retractor|The Alexis O C-section retractor will be used.
45829609|NCT01826604|Other|Control- Conventional retractors|Conventional hand-held retractors will be used. A self-retaining barrier retractor will not be used.
45829610|NCT01843842|Drug|Ergoferon|Safety and Efficiency of liquid dosage form
45829611|NCT01843842|Drug|Placebo|Safety and Efficiency of liquid dosage form
45829612|NCT01826448|Drug|PLX3397|
45829613|NCT01826448|Drug|vemurafenib|
45829614|NCT01826370|Drug|Linagliptin|tablet
45829615|NCT01826214|Drug|LDE225|LDE225 will be supplied as 200 mg capsules by Novartis. Patients will receive study treatment on an outpatient basis. LDE225 will be dispensed every two weeks for the first four weeks and at the start of every four weeks thereafter, as needed.
45829616|NCT04582344|Biological|CoronaVac|Two doses at 14-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (each prefilled syringe of the vaccine contains 600 SU of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,14
45829617|NCT04582344|Biological|Placebo|Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, two doses given 14 days apart.
45829618|NCT01843062|Drug|Selumetinib|3 capsules of 25 mg strength orally twice a day for approximately 5 weeks treatment period
45829619|NCT01843062|Drug|Placebo|3 capsules ( to match Selumetinib capsules) orally twice a day for approximately 5 weeks treatment period
45829620|NCT01843062|Drug|Radioactive Iodine Therapy|A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization. Additionaly, Thyrogen (Recombinant human TSH) will be used to stimulate iodine uptake according to the manufacturer's recommendation(0.9 mg intramuscular injection once a day for the 2 days prior to the dose of radioactive iodine)
45829621|NCT01842438|Behavioral|Behavioral: psychosexual intervention|6 session manualised intervention, This manual-based family-relational-psychosexual support was based on systemic principles combined with techniques from sex therapy, i.e. sensate focus. The manual offered an intermediate level of specificity, enabling practitioners to use their own therapeutic style and take some lead from the couple while meeting the objectives of the intervention. Specialist training in delivery of the intervention was provided to practitioners holding accredited counselling or psychotherapy qualifications. Practitioners engaged in routine clinical supervision with one additional team supervision session offered by one of the practitioners
45829622|NCT01799226|Other|Toothpaste without triclosan|this intervention will use a toothpaste without triclosan
45829623|NCT01799226|Other|Triclosan|this intervention will use Colgate Total which contains triclosan
45829624|NCT01798992|Drug|Carvedilol|
45829625|NCT01798992|Drug|Metoprolol succinate|
45829626|NCT01798992|Drug|Metoprolol succinate + doxazosin|
45829627|NCT01825200|Biological|Flublok|A Biologics Licensing Application (BLA) for Flublok was approved by the FDA for influenza immunization of adults 18-49 years of age. Flublok is produced using recombinant technology under serum-free conditions.
45829628|NCT01825200|Biological|Afluria|Afluria is approved for use in persons 5 years of age and older and is produced by inactivation and disruption of live influenza virus grown in embryonated chicken eggs.
45829629|NCT01824576|Device|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
45829630|NCT01824498|Other|Low Fat diet|Low fat diet = 20% fat
45829631|NCT01824498|Other|Low Fat high n3 diet|Low Fat high n3 diet = 20% fat + 3% n3
45829632|NCT01824498|Other|High Fat Diet|High Fat Diet = 40% fat
45973525|NCT05372055|Other|Semi-structure interviews|Semi-structured interview focusing on psychosocial impact of living with an IPC to be performed at 2 weeks and 6-8 weeks post IPC insertion
45973526|NCT05367778|Drug|HS-10370|HS-10370 will be administered orally once daily in a continuous regimen
45973527|NCT05362981|Other|CAT|2 group programs, led by trained speakers, addressing specific ED topics through written, verbal and/or behavioral exercises,
45973528|NCT05360784|Drug|Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation|Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation. Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
45973529|NCT05360784|Drug|Lumify® (brimonidine tartrate ophthalmic solution 0.025%)|Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
45973530|NCT05359939|Diagnostic Test|18F-FDGal PET/CT versus 18F-choline PET/CT|Fifty patients with known HCC are investigated with two PET/CT-scans with 18F-FDGal and 18F-choline. In some of the cases one of the CT-scans will be altered to a contrast-enhanced MRI scan. A contrast-enhanced CT scan will be performed as part of the standard diagnostic work-up. We include patients with known HCC as the aim is to compare the diagnostic performance of the two tracers. Images will be analyzed for focal lesions and compared to other modalities by an experienced specialist in PET and an experienced radiologist.
45973531|NCT05355766|Drug|CN128 Tablets|Iron chelator, oral tablets
45973532|NCT05354934|Other|quetionnaire|"The questionnaire includes the following modules~Demography and socio-economic conditions~Screening and modalities of discovery and announcement of HIV infection~Time and modalities of introduction of antiretroviral drugs after diagnosis~Knowledge of HIV infection~The perception of follow-up in the health care service~Experiences of stigma~Barriers to accessing care~Periods of loss of sight and reasons for this~Perceived health status, mental health (PHQ4), chronic illness, functional limitations~Addictions~Social network and support~Clinical data Date of HIV diagnosis Date of introduction of antiretrovirals CD4 count at diagnosis Viral load at diagnosis Period without follow-up for more than 12 months CD4 nadir Last CD4 count Last viral load Antiretroviral treatment at last consultation Comorbidities Initial hospitalisation Recent hospitalization"
45973533|NCT05353985|Drug|TAK-062|TAK-062 tablets.
45973534|NCT05353985|Dietary Supplement|Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar|SIGE gluten bars.
45973535|NCT05353985|Drug|TAK-062 Placebo|TAK-062 placebo-matching tablets.
45973536|NCT05353985|Dietary Supplement|Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar|SIGE gluten-free bars.
45973537|NCT05351775|Device|Smartphone application|Patient is asked to do the first recording at hospital to test the device and then preferably twice daily for 1 minute period of time during the 3-month study period.
45973538|NCT05351775|Device|Bed sensor|The Emfit bed sensor will be used during the index hospitalization and in home-based monitoring after hospital discharge up to 3 months.
45973539|NCT05351775|Device|Wrist-worn photoplethysmography (PPG) and accelerometer data logger.|Data collection with PDL is continued during initial hospitalization in the intervention group where the gold standard ECG is obtained and data can be used in algorithm development but will not be used to monitor treatment or for diagnosis.
45973540|NCT05351775|Device|Patch-holter ECG|The patch-holter will be used during the index hospitalization and also in home if the home-based monitoring devices are signalling of a possible AF and it is not detected in the consequent ECG.
45973541|NCT05350072|Biological|VAY736|ianalumab s.c.
45973542|NCT05350072|Other|Placebo|placebo s.c.
45973543|NCT05338151|Behavioral|Brief Negotiated Interview (BNI)|Brief Negotiated Interview (with referral and telephone booster) alone
45973544|NCT05338151|Behavioral|BNI+facilitated provision of MAUD|Brief Negotiated Interview (BNI)+ Medication for Alcohol Use Disorder (MAUD)
45670468|NCT01748890|Device|Sonoelastography|Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
45973545|NCT05338151|Behavioral|Brief Negotiated Interview BNI+facilitated provision of MAUD+CBT4CBT|Brief Negotiated Interview (BNI)+Medication for Alcohol Use Disorder (MAUD)+Computer Based Treatment for Cognitive Behavioral Treatment (CBT4CBT)
45973546|NCT05335044|Drug|CKD-331|QD, PO
45973547|NCT05335044|Drug|EX5619|QD, PO
46081825|NCT02710851|Biological|high dosage HPV Vaccine(1:1)|"Participants would intramuscularly receive high dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
46081826|NCT02710851|Biological|Hepatitis E vaccine,Hecolin®|Participants would intramuscularly receive Hepatitis E vaccine for 3 doses at 0, 1, 6 month.
46081827|NCT02703207|Device|Positive airway pressure|CPAP will be applied as standard of care for diagnosis of moderate to severe OSA
46081828|NCT02703207|Device|NIPPV and /or oxygen|supplemental oxygen will be applied to PAP/non-invasive positive pressure therapy
45973548|NCT05332275|Behavioral|Intervention Arm - T.E.C.H. Parenting|"Intervention Arm participants will enroll in a web-based psychoeducational group (15 parents per group across 4 groups). Participants will receive psychoeducational information on media parenting, and they will be invited to participate in an online group discussion board to share their experiences with other parents in the intervention. In weeks 2-5, participants will learn about 4 domains of media parenting: 1) Talk to your child about media; 2) Educate your child about media-related risks; 3) Co-View/Co-Use media and technology actively with your child; and 4) establish House rules for media usage. Week 6 will review information and provide an expert clinician to support parent problem solving. Participants will receive 2-3 weekly push messages via text messaging prompting practice of skills learned in the group setting. Participants will be assessed at baseline, immediately following the 6 week intervention, and 3 months after the intervention is completed."
45670469|NCT05648981|Other|Inferior Alveolar Nerve Block administration with laser irradiation|Patients will receive inferior alveolar nerve block local anesthesia followed by laser irradiation after completion of the operative procedure.
46081829|NCT02675829|Drug|ado-trastuzumab emtansine|Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
45829633|NCT04593888|Behavioral|Gluten reduced diet|Dietary advice focusing on reducing gluten intake in children
46081830|NCT02645019|Device|Cuffed ETT|Cuffed endotracheal tube.
45829634|NCT01798134|Device|TANDEM™|
46081831|NCT02645019|Device|Cuffed LMA|Cuffed laryngeal mask airway.
46081832|NCT02609880|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is used to optimize sleep, pain, and mood in women with gynecologic cancers and will be provided 2 hours once a week for six weeks.
46081833|NCT02609880|Behavioral|Psychoeducation|Psychoeducation is used to provide information, resources, and non-specific support related to adapting well to cancer. Sessions will be provided 2 hours once a week for 6 weeks.
46081834|NCT02588651|Drug|Brentuximab vedotin|study drug given intravenously to determine efficacy in study diseases
45670470|NCT05648981|Other|Inferior Alveolar Nerve Block administration|Patients will not receive any laser irradiation after administration of inferior alveolar nerve block local anesthesia.
45670471|NCT04869215|Other|EverVita Pro|EverVita Pro is composed of barley and corn, grown and mechanically processed in Europe, with non-GMO grains.
45670472|NCT04869215|Other|Control bread|Bread baked with normal Bakers flour
45670473|NCT01747876|Drug|LEE011|LEE011 is a small molecule inhibitor of CDK4/6.
45670474|NCT02273726|Drug|Epoetin Alfa|Epoetin alfa will be administered per dose and schedule specified in the arm.
45670475|NCT02273726|Drug|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm.
45670476|NCT04557358|Other|COVID-19 survey|A questionnaire locally developed to explore access to medical care and to medications, access to communication with their primary rheumatologist, and patients risk perception about COVID-19 disease
45829635|NCT01798056|Biological|GSK 1437173A|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
45829636|NCT01798056|Drug|Placebo|2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.
45829637|NCT01824342|Biological|Denosumab|Administered by subcutaneous injection
45829638|NCT01841970|Device|HET Bipolar System|The HET Bipolar System is used to treat hemorrhoids by bipolar ligation of the superior hemorrhoidal blood supply.
45829639|NCT01823328|Drug|Ketamine|Subjects will receive ketamine for sedation prior to rapid sequence intubation.
45829640|NCT01823328|Drug|Etomidate|Subjects will receive etomidate for sedation prior to rapid sequence intubation.
45829641|NCT01840410|Drug|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
45973549|NCT05332275|Behavioral|Control Arm - General Positive Parenting|The Control Arm of the RCT is the attention control group. These participants will enroll in a web-based psychoeducational group (four groups of 15 parents each). They will receive 6 weeks of online psychoeducational material, including 2-3 push messages prompting skill practice. Parents will have access to an online discussion board to share experiences with other parents. This group will match the intervention arm of the study in number of study staff contacts, time of start/duration of the group, peer support, and availability of a professional in week six for consultation on parenting issues. Control participants will not receive information on media parenting. Participants in this group will be assessed at baseline, immediately following the six-week intervention period, and 3 months after intervention completion. Participants will be asked about exposure to TECH Parenting content at baseline and followup to address potential contamination effects across study arms.
45973550|NCT05321368|Behavioral|LINKED-HEARTS Program|The intervention arm will include training on home blood pressure monitoring, Sphygmo blood pressure telemonitoring app, Community Health Worker visit for education, counseling on lifestyles modification and Pharmacist to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.
45973551|NCT05313321|Device|Primary total hip arthroplasty receiving the Insignia Stem|Patients receiving the Insignia Stem and associated Stryker Acetabular Component for total hip arthroplasty
45973552|NCT05312047|Procedure|Pelvic organ prolapse surgery|Vaginal surgery of any compartment for pelvic organ prolapse
45973553|NCT05286177|Procedure|Volume-based EN|Bedside nurses will receive a total daily feed volume prescription to be administered to the participant over a 24-hour period. The bedside nurse will calculate the initial hourly rate by dividing the total daily feed goal by 24 hours at approximately 0700 hours. In this intervention group, they will be instructed to titrate the rate of feeds to accommodate for any feeding interruptions as follows: When feeds are held for > 1 hour, the remaining daily feed volume will be divided by the remaining number of hours. A maximum infusion rate will be set at 2 times the patient's baseline 24-hour feed rate to ensure that a large bolus volume of feed is not administered over a too short period of time.
45973554|NCT05286177|Procedure|Rate-based EN|Bedside nurses will receive an hourly feed rate prescription to administer the tube feedings over a 24-hour period. If feeds are held, they will be restarted at the same consistent hourly rate that was previously ordered. Nurses will not adjust feed rates to compensate for feed interruptions
45973555|NCT05280756|Device|Home-based transcranial direct current stimulation (tDCS)|Each participant will be asked to do ten home-based tDCS sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive active home-based tDCS (constant current intensity of 2mA) anodal-left and cathodal-right prefrontal for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
45973556|NCT05280756|Device|Sham home-based transcranial direct current stimulation (tDCS)|Each participant will be asked to do ten home-based sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive sham home-based tDCS for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
45973557|NCT05277051|Drug|GSK4381562|GSK4381562 will be administered.
45973558|NCT05277051|Drug|Dostarlimab|Dostarlimab will be administered.
45973559|NCT05277051|Drug|GSK4428859A|GSK4428859A will be administered.
45973560|NCT05261139|Drug|nirmatrelvir|PF-07321332
45973561|NCT05261139|Drug|ritonavir|ritonavir
45829642|NCT01840410|Other|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
45829643|NCT01797432|Drug|Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp
45829644|NCT01797432|Device|Restylane|Intralesional injections of 2mLs of Restylane on one side of the scalp
45829645|NCT01797120|Drug|Fulvestrant|"Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles).~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity."
45829646|NCT01797120|Drug|Everolimus|"Everolimus 10 mg (2 tablets) daily x 12 cycles.~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity."
45829647|NCT01797120|Drug|Placebo|Placebo for Everolimus (2 tablets) daily x 12 cycles. Placebo manufactured to mimic everolimus tablet.
45829648|NCT01796964|Drug|ESBA1008 solution|For intravitreal (IVT) injection
45829649|NCT01796964|Drug|Aflibercept|For intravitreal (IVT) injection
45829650|NCT01838694|Biological|Ala-Cpn10|
45829651|NCT01838694|Drug|Placebo|
45829652|NCT01795638|Drug|Sodium chloride|
45829653|NCT01795638|Drug|Placebo|sterile water, 0.4 ml/kg every 6 hours on days of life 7-35.
45829654|NCT01794780|Drug|LABA based treatment: indacaterol|LABA based treatment: indacaterol
45829655|NCT01794780|Drug|LAMA based treatment: tiotropium|LAMA based treatment: tiotropium
45829656|NCT01794780|Drug|LABA/ICS based treatment: salmeterol/fluticasone|LABA/ICS based treatment: salmeterol/fluticasone
45829657|NCT01794780|Drug|LABA/ICS based treatment: budesonide/formoterol|LABA/ICS based treatment: budesonide/formoterol
45670477|NCT04557358|Other|RAPID-3|The instrument measures function, pain, and patient global estimate of status, with correspond to activity disease
45670478|NCT04557358|Other|WHOQOL-BREF|The instrument measures the patient´s quality of life (4 dimensions: physics, phycological, social, and environment)
45670479|NCT04557358|Other|DASS-21 instrument (depression and anxiety)|The instrument measures the presence of depression and anxiety
45670480|NCT04557358|Other|IER-R (posttraumatic stress)|The instrument measures the presence of posttraumatic stress
45829658|NCT01794780|Drug|theophylline based treatment|theophylline based treatment
45829659|NCT01794780|Drug|Other treatment|"non-long-acting bronchodilators for COPD treatment, such treatments were classified as other treatments"
45670481|NCT01723228|Drug|Rasagiline|
45670482|NCT01723228|Drug|Placebo|
45670483|NCT05648630|Dietary Supplement|PB125|PB125 is a naturally-derived plant-based supplement that activates the Nuclear Factor Erythroid-2-like 2 (Nrf2) system to stimulate induction of endogenous antioxidants and anti-inflammatory pathways.
45670484|NCT05648630|Dietary Supplement|Placebo|A placebo will be used in combination with exercise rehabilitation allowing for a double blinded placebo controlled design.
45670485|NCT05648630|Behavioral|Exercise Rehabilitation|A 12-week treadmill based supervised rehabilitation
45829660|NCT04587726|Behavioral|Girl's room video|"Girls Room, a body image mini-series, developed in collaboration with Lena Waithe, Dove and CAR.~Video content was informed by empirical evidence related to body image prevention and intervention. The series consists of five, 3-minute videos.~The videos follow the lives of a 5 best friends, and each video targets a key risk factor for body image:~Appearance comparison~Body appreciation~Body talk~Body functionality~Appearance teasing & bullying~Appearance focus~The five videos aired on Instagram TV (IGTV) in March 2020."
45829661|NCT04587726|Other|Control video - Chicken Girls|Chicken Girl's Episode - appearance neutral episode matched for target audience and video length
45973562|NCT05251909|Biological|Benralizumab|Benralizumab is a humanized, afucosylated, monoclonal antibody that binds specifically to the IL-5Rα on the target cell and thus directly depletes eosinophils through antibody-dependent cell-mediated cytotoxicity. Benralizumab has been widely approved for treatment of asthma.
45973563|NCT05251909|Biological|Placebo|Placebo will be injected as a comparator to injection with Benralizumab to examine effect on both the signs and symptoms of EG/EGE and the underlying eosinophilic inflammation, with dual primary outcome variables
45973564|NCT05250947|Device|Angel® Concentrated Platelet Rich Plasma System|Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP.
45973565|NCT05250791|Drug|Lidocaine hydrochloride 2% for injection|An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.
45973566|NCT05250791|Drug|0.9% sterile Sodium Chloride solution for injection|Administered as lidocaine
45973567|NCT05241873|Drug|BLU-451|BLU-451 will be administered orally by tablet QD or BID on a 21-day treatment cycle
45670486|NCT02273180|Drug|SAR342434|SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by deep subcutaneous (SC) injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour post prandial plasma glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
45670487|NCT02273180|Drug|Humalog|Humalog 100 U/mL (dose range of 1 unit to 60 units) self-administered by deep SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycaemia.
45973568|NCT05241873|Drug|Carboplatin|Carboplatin will be administered intravenously (IV) on Day 1 of each cycle (every 3 weeks) for 4 to 6 cycles
45973569|NCT05241873|Drug|Pemetrexed|Pemetrexed will be administered prior to carboplatin as an IV infusion on Day 1 of each cycle (every 3 weeks)
45973570|NCT05238922|Drug|INCB0123667|25 mg tablets
45670488|NCT02273180|Drug|Insulin glargine HOE901|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
45670489|NCT01746862|Drug|Saizen®|Subjects in the Saizen test group will receive Saizen (recombinant-human growth hormone [r-hGH]) subcutaneously 6 days per week at a weight based dose of 0.067 milligram per kilogram of body weight per day (mg/kg/day) for 12 months.
45670490|NCT01746862|Drug|Saizen®|Subjects in the Saizen control group will receive no treatment for the first 6 months and thereafter will receive Saizen (r-hGH) subcutaneously 6 days per week at a weight based dose of 0.067 mg/kg/day for the next 6 months.
45670491|NCT01745848|Drug|Roflumilast|
45670492|NCT01745380|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|The study drug is regional anesthetic delivered intranasally on the same side as the operative tooth
45829662|NCT01838616|Drug|Tapentadol Prolonged Release|All participants started with 50 mg tapentadol hydrochloride prolonged release (twice daily). The dose of tapentadol hydrochloride prolonged release will be adjusted in increments of 50 mg to a level that provided adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants are permitted a maximum dose of 250 mg twice a day (500 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
45829663|NCT01838616|Drug|Oxycodone/Naloxone Prolonged Release|All participants start with 10 mg/5 mg oxycodone/naloxone (twice daily). The dose of oxycodone/naloxone may be adjusted in increments of 10mg/ 5 mg oxycodone/naloxone to a level that provide adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants will be permitted a maximum dose of 50 mg/ 20 mg oxycodone/naloxone twice daily a day (100 mg/40 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
45973571|NCT05230342|Dietary Supplement|A package containing a mix of functional foods|Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein and genistein.
45670493|NCT01745380|Drug|Placebo|The placebo spray was identical in appearance to and was administered in the same volume and manner as the active ingredient.
45670494|NCT01745146|Behavioral|ASMT|8-session, individual, psycho-educational intervention based on principles of self-monitoring and problem-solving training Significant other (friend or relative) invited to participate in 3 of 8 sessions
45670495|NCT01745146|Behavioral|PRE|8-session, individual, psycho-educational intervention based on principles of education and personal readjustment to TBI Significant other (friend or relative) invited to participate in 3 of 8 sessions
45670496|NCT02272634|Drug|YPL-001 80 mg|twice daily [BID]
45973572|NCT05230342|Other|Placebo ingredient group|The control group will receive a comparable set of food items that contain an equivalent number of calories per portion but without the added functional ingredients
45973573|NCT05229146|Behavioral|Episodic Future Thinking|Episodic future thinking (EFT) includes a focus on generating detailed and vivid descriptions of future events. For the current intervention, EFT will be modified to have mothers describe specific events with their children.
45973574|NCT05221866|Behavioral|Empowering patient to steer their pain management after surgery|Prior to discharge from the hospital, patients will be approached regarding interest in the study with an introductory letter that describes the content and purpose of the study. Following informed consent, patients will be randomized to receive the consumer health informatics app (UControlPain) versus provision of an app with only data collection function (no educational components) in an intent-to-treat design. Randomization will be implemented via REDCap by the study coordinators so that all investigators will remain blind to group assignment. Further, information on which type of app was installed will not be shared with providers or patients.
45973575|NCT05221866|Behavioral|Provider-facing prescription aid|Providers will be given information to inform a patient-centered post-discharge pain management plan.
45973576|NCT05202327|Drug|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as the active ingredient.
45973577|NCT05202327|Drug|Placebo|The placebo contained corn starch.
45829664|NCT01611792|Other|Stabilization exercise protocol|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles as well as deep dorsal trunk muscles. Then patients were progressed to exercises that added leverage of the limbs while maintaining the co-contraction of the deeper abdominal muscles and deep dorsal trunk muscles while breathing normally. Various positions (e.g., supine and quadruped positions) were used to challenge the patients based on their tolerance. Finally, patients were progressed to exercises in more functional positions that included tasks/activities that were reported as challenging and/or painful; patients performed the tasks at the speed demanded by the particular task. Maintenance of the co-contraction of deep trunk muscles was emphasized during these functional activities.
45973578|NCT05201898|Other|control:usual medical management|with regular doctor visits every 3 months
45973579|NCT05201898|Behavioral|intervention 1:usual medical management+individual dieting consultation|with regular doctor visits every 3 months and dietitian visits every 3 months
45973580|NCT05201898|Behavioral|intervention 2:usual medical management+individual dieting consultation+ daily tea drinking|with regular doctor visits every 3 months and dietitian visits every 3 months and daily tea drinking
45973581|NCT05200520|Behavioral|Appetite Self-Regulation Intervention|The intervention will consist of content from Appetite Awareness Training (AAT), a cognitive-behavioral intervention to promote intuitive eating and the Diabetes Prevention Program (DPP)20, a behavioral lifestyle intervention. The goal of AAT is to enable participants to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. AAT has been successful in helping participants to reduce binge and overeating. Participants are taught to respond to external cues to eat (e.g., social gatherings), self-monitor the participant's adherence to biological signals of hunger and satiety, and to develop appropriate coping skills to manage urges to eat when not physically hungry.
45973582|NCT05197322|Drug|Pembrolizumab|Dose: 200mg by IV infusion on Day 1 of each treatment cycle
45670497|NCT02272634|Drug|YPL-001 160 mg|twice daily [BID]
45670498|NCT02272634|Drug|Placebo|twice daily [BID]
45973583|NCT05193552|Drug|Hizentra|subjects level of IGRT will be adjusted for bioavailability as per manufacturer's instructions
45973584|NCT05192356|Drug|CKD-348(3)|QD, PO
45973585|NCT05192356|Drug|CKD-828, D097, D337|QD, PO
45973586|NCT05187000|Device|individualized repetitive transcranial magnetic stimulation|During the rTMS-active stage, treatment will be given for 10 consecutive sessions (one session daily). The participants will be placed in the semi-reclining position on either a normal chair or a wheelchair and each stimulation session will last 20 minutes with a frequency of 10 Hz (train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 2000 pulses at 90% of RMT).
45973587|NCT05187000|Device|Sham repetitive transcranial magnetic stimulation|The sham coil will be used which has no magnetic field to send to the cerebral cortex while appearing to be the same shape as the active coil, with good approximation of auditory feedback.
45973588|NCT05181878|Device|The AcQMap 2.1 System with Electro-Magnetic Tracking Feasibility System|Demonstrate the ability of the AcQMap 2.1 System to support EMT in conjunction with the existing impedance localization capabilities. The new EMT technology is expected to continuously provide fully synchronized and similar localization information to the impedance-based localization information associated with the location of the catheter's magnetic sensor position.
45973589|NCT05176665|Drug|EMB-01|EMB-01 at the RP2D of 1600 mg will be administered as an IV infusion once weekly (QW) throughout the study. One cycle is defined as 4 weeks (4 doses). All patients will be premedicated with a histamine-1 (H1) receptor antagonist diphenhydramine (25 or 50 mg) intravenously 30-60 minutes prior to dosing in the first two cycles. Premedication for subsequent treatment cycles will depend on whether the patient develops infusion-related reactions (IRR), at the discretion of the investigator.
45670499|NCT04550104|Radiation|Radiotherapy|Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.
45670500|NCT04550104|Drug|Olaparib Oral Tablet [Lynparza]|Oral tablet
45670501|NCT04550104|Drug|AZD1390|Oral tablet
45670502|NCT04550104|Drug|TBD Compound 1|
45670503|NCT04550104|Drug|TBD Compound 2|
45670504|NCT04550104|Drug|TBD Compound 3|
45670505|NCT05648474|Diagnostic Test|Somatosensory evoked potential [SSEP] intraoperative monitoring|No study specific intervention is performed. Intraoperative neuromonitoring system that is observed in this study is for assessing the health of the lumbar plexus during lateral lumbar interbody fusion surgery
45670506|NCT05648396|Other|FFRangio|Assessing the physiologic significance of an intermediate coronary lesion/lesions using FFRangio - a non invasive method to calculate the fractional flow reserve (FFR) of the assessed lesion.
45670507|NCT05648318|Drug|Lactulose oral solution|In the LOS group, patients were instructed to drink 200ml lactulose (Duphalac, Olst, the Netherlands; 200ml/bottle) diluted with clear water into 1L 4-6h before colonoscopy at a rate of 250ml every 30min.
45973590|NCT05160012|Behavioral|Peer Comparison Message|"In addition to usual care, PCPs will receive a monthly report as an EPIC in basket message describing what category they are in:~If HTN control rate <50th percentile, PCP is told they are below median~If HTN control rate is between 50-89th percentile , PCP is told they are below top performer~If HTN control rate is between 90-100th percentile, PCP is told they are a high performer"
45829665|NCT01611792|Other|Strength and conditioning exercise protocol|This protocol contained trunk strengthening and endurance exercises. It consisted of 3 phases: 1) initial strengthening of trunk flexors/extensors in single plane movements, 2) trunk and lower-extremity stretching as well as progression of trunk-strengthening exercises to include multi-planar trunk movements. Aerobic exercises were progressed as tolerated and patient education about body biomechanics were reinforced, and 3) trunk-strengthening exercises under dynamic conditions (e.g., unstable support surface and in multi-planar trunk movements). During the 10 week protocol, exercises became more challenging, and each subject had to complete at least the first phase before moving onto the next phase in order to be included in post-testing analyses. There was no specific focus on the deep abdominal or deep dorsal trunk muscles during any of these exercises.
45829666|NCT01820364|Drug|LGX818|BRAF inhibitor. LGX818 was administered QD orally on a daily schedule (21-day cycles) as a flat-fixed dose and not by body weight or body surface area. LGX818 100 mg capsules and 50 mg capsules.
45670508|NCT05648318|Drug|PEG|patient in the PEG group were instructed to drink 2L of PEG (each liter containing 59g PEG 4000, 1.46g sodium chloride, 5.68g sodium sulfate, 0.74g potassium chloride, 1.68g sodium bicarbonate; WanHe Pharmaceutical Co, Ltd., China) 4-6h before colonoscopy at a rate of 250ml every 15min
45670509|NCT02203513|Drug|LY2606368|105 mg/m^2 intravenous (IV) once every 14 days of a 28 day cycle
45670510|NCT04881890|Behavioral|Low-Carbohydrate Diabetes Prevention Program|LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits
45829667|NCT01819506|Behavioral|Task Practice Physical Rehabilitation Therapy|Similar to stroke rehabilitation occupational therapy.
45829668|NCT01794000|Drug|Prasugrel|Administered orally
45829669|NCT01794000|Drug|Placebo|Administered orally
45829670|NCT01609296|Device|IN.PACT Admiral™ Drug Eluting Balloon|IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon.
45829671|NCT01609218|Drug|LY2140023|
45829672|NCT01609218|Drug|Aqueous activated charcoal|
45829673|NCT01609062|Drug|BMN 110|Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 192 weeks.
45829674|NCT01609062|Drug|BMN 110|Weekly IV infusions of BMN 110 at 4.0 mg/kg/week over a period of approximately 4 hours per infusion for 27 weeks, and will eventually transition to 2.0 mg/kg/week for up to an additional 166 weeks.
45829675|NCT04580472|Drug|Cephalexin|If randomized to the antibiotic group, a single dose of cephalexin or clindamycin hydrochloride (if concern for previous allergy to Cephalexin) will be given prior to surgery.
45829676|NCT04580472|Other|Placebo capsules|Patients will receive 4 placebo capsules prior to surgery if randomized to placebo group.
45829677|NCT01819272|Drug|Met DR|metformin delayed-release tablets
45829678|NCT01819272|Drug|Met XR|metformin extended-release tablets
45829679|NCT01819272|Drug|Placebo|placebo delayed-release tablets
45829680|NCT01819194|Device|senofilcon A|
45829681|NCT01611558|Biological|Ipilimumab|
45829682|NCT04579926|Other|Pinpoint app|Tablet and smartphone app with pain assessment and communication education, and pain assessment tool.
45829683|NCT04593186|Procedure|Trans-oral magnifying endoscopy with NBI|"Endoscopic procedures would be performed by endoscopists with expertise on performing magnifying NBI endoscopy. Topical local anaesthetic will be applied to the oropharynx and nasopharynx. In addition, intravenous sedation by use of Midazolam and Fentanyl would be given. Endoscopes with magnification and NBI function would be used (GF-H290Z, Olympus Medical Corporations, Tokyo, Japan). A soft black hood would be attached to the tip of the endoscope for better focal length adjustment.~Upon insertion through a mouthpiece, the scope will then be retroflexed into the nasopharynx and the lateral walls into the Fossa of Rosenmuller and the posterior nasopharyngeal wall will be systematically examined with white light and NBI. Target suspicious areas would be examined by use of magnification with the power up to 80X. Biopsy would be taken if suspicious lesion is identified during the procedure."
45973591|NCT05158738|Other|Patients with inherited cardiac condition, onset <16 years old and Parents|Patients with a confirmed diagnosis of an inherited cardiac condition, onset <16 years old and Parents will have samples that undergo whole genome sequencing and biomarker analysis
45973592|NCT05149131|Drug|ADT (Eligard®*) with or without treatment intensification|"Abiraterone acetate (Zytiga®) Enzalutamide (Xtandi®) Apalutamide (Erleada®) Docetaxel (Taxotere®)~*may be substituted with leuroprolide gel, buserelin, goserelin, triptorelin, histrelin, cyproterone or degarelix"
45829684|NCT04579068|Behavioral|Screening and Brief Intervention of Problematic Alcohol Use|Provide/enhance knowledge, screening and detection, modify attitudes, motivate and provide skills and resources to reduce alcohol related risk and consumption.
45973593|NCT05148065|Device|BIS|Bispectral index monitoring
45973594|NCT05148065|Device|PSi|Patient state index monitoring
45973595|NCT05145764|Drug|Suvorexant|Encapsulated suvorexant (matched for color, weight, and size)
45973596|NCT05145764|Drug|Placebo|Encapsulated placebo (matched for color, weight, and size)
45973597|NCT05142826|Behavioral|Relative Age Effect Intervention|School-based consultation to establish a developmentally appropriate daily behavior report; teacher education regarding developmentally appropriate behaviors; teacher consultation to promote positive behavior supports.
45973598|NCT05142826|Other|School as Usual|Interventions and supports as provided through usual care
45973599|NCT05132075|Drug|JDQ443|JDQ443 tablets, orally administered
45973600|NCT05132075|Drug|docetaxel|docetaxel concentrated solution for infusion, intravenously administered
45973601|NCT05130216|Other|Genicular Nerve Radiofrequency Ablation|Radiofrequency Ablation (RFA)
45973602|NCT05128812|Dietary Supplement|PLX|Intake of natural food supplement of vegetable origin based on lemon verbena extract (Lippia citriodora). To study the anxiolytic effects in subjects with high perceived stress levels and low sleep quality.
45973603|NCT05128162|Drug|Psilocybin|Two oral doses of psilocybin in a capsule formulation taken approximately 2 weeks apart.
45973604|NCT05128162|Behavioral|Psychotherapy|1. Pre-dose preparatory sessions; 2. Dosing day monitoring; and, 3. Post-dose integration sessions.
45973605|NCT05123235|Behavioral|Physical Activity|the participants will be encouraged to set their own physical activity goals weekly and using behavioral strategies work towards meeting those goals. The behavioral strategies will be discussed weekly for 30 minutes a telehealth method.
45973606|NCT05116189|Biological|Pembrolizumab|IV infusion
45973607|NCT05116189|Drug|Paclitaxel|IV infusion
45973608|NCT05116189|Drug|Bevacizumab|IV infusion
45973609|NCT05116189|Other|Placebo for pembrolizumab|IV infusion
45670511|NCT02299934|Diagnostic Test|Magnetic Resonance Imaging (MRI)|MRI sequences for visualisation of the blood supply of liver without contrast agent.
45670512|NCT02299934|Diagnostic Test|Compurtized Tomgraphy (CT)|CT including CT Angiography (CTA) for the evaluation of hepatic vasculature.
45670513|NCT01703260|Drug|Roflumilast|Roflumilast dose
45829685|NCT04577976|Device|SMBG|Subjects and/or their caregivers will utilize capillary SMBG for managing diabetes for 6 months.
45829686|NCT01818726|Drug|ICL670|ICL670 was supplied in registered packages as 250mg or 500mg dispersible tablets.
45973610|NCT05116189|Drug|Docetaxel|IV infusion
45973611|NCT05276973|Procedure|Biopsy|Undergo biopsy
45670514|NCT01703260|Drug|Pioglitazone|Pioglitazone dose
45670515|NCT01703260|Drug|Placebo|Pioglitazone placebo-matching dose
45670516|NCT01703260|Drug|Placebo|Roflumilast placebo-matching dose
45670517|NCT02203357|Biological|Hepatitis B vaccine|Hepatitis B vaccine, 60 μg/1ml recombinant hepatitis B vaccine,20 μg/1ml recombinant hepatitis B vaccine, Shenzhen Kangtai Biological Products Co, LTD.
45670518|NCT02299388|Drug|Liraglutide or Placebo|All subjects will be advised a low sodium diet. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval.
45829687|NCT01818726|Drug|Chelation|Main group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment (immunosupressant - Cyclosporine A) and received chelation with ICL670 (deferasirox).
45829688|NCT01818726|Drug|No chelation|Comparative group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment ( immunosupressant -Cyclosporine A)
45829689|NCT01818336|Drug|Penicillin skin test kit|Allergy skin testing is done by puncture and intradermal. If all tests negative, subjects receive an oral amoxicillin challenge.
45973612|NCT05276973|Drug|Carboplatin|Given IV
45973613|NCT05276973|Drug|Ipatasertib|Given PO
45973614|NCT05276973|Drug|Paclitaxel|Given IV
45973615|NCT05113693|Drug|CKD-393|QD, PO
45973616|NCT05113693|Drug|CKD-501, D759, H053|QD, PO
45973617|NCT05106647|Behavioral|Reduce screen time|The intervention is information provided via email on how to set up an automated response to emails received during their weekend off, reduce screen time for duration of leisure time, and uninstall work applications from their mobile device.
45973618|NCT05099848|Drug|Camrelizumab|"Procedure:~Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 1st day 30minutes after meals, once a day, for continuous medication.~On the 2nd day of treatment, intravenous infusion of Camrelizumab 200mg every 3 weeks.~On the 3rd to 4th day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX, oxaliplatin 85 mg/m2 in 0-2 hours, folinic acid 400 mg/m2 in 2-3 hours, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 8 times.~The cumulative maximum drug use period is up to 8 cycles. Patient will be administratied radical resection if possible during treatment. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
45973619|NCT05087342|Drug|Semaglutide 2.4mg|The intervention drug, semaglutide 2.4mg will be given to the Intervention Group per the schedule outlined in the armed description.
45973620|NCT05087342|Drug|Placebo|A placebo will be given to the control group per the schedule outlined in the armed description.
45973621|NCT05086432|Other|Sputum-guided management|As previously described.
45973622|NCT05086432|Other|Standard of Care|As previously described.
45670519|NCT02202577|Drug|Chlorhexidine - Isopropyl alcohol|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
45670520|NCT02202577|Drug|Povidone-Iodine Scrub and Paint|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
45670521|NCT02299076|Behavioral|Behavioral economics incentives|Behavioral economics-informed incentives to promote engagement and outcomes in a smoking cessation intervention.
45670522|NCT02299076|Other|Minimal incentives|Minimal financial incentives to promote engagement and outcomes in a smoking cessation intervention.
45670523|NCT01723072|Biological|Omalizumab|Humanized monoclonal antibody against human IgE
45670524|NCT01723072|Drug|Placebo|Placebo to omalizumab
45670525|NCT01722994|Device|Polyglactin 910 sterile synthetic absorbable suture (Ethicon)|Half of punch biopsy wounds are closed with each absorbablesuture
45670526|NCT01722994|Device|Chromic Gut Sterile absorbable Suture (Ethicon)|
45829690|NCT04592640|Other|Human amniotic mesenchymal stem cells|"Intravenous infusion of hAMSCs: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance).~Injection of hAMSCs to local skin lesions: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance)."
45829691|NCT01818258|Drug|ZDV+3TC+LPV/r|
45829692|NCT01817790|Drug|Fluticasone propionate|Nasal spray formulation (200 mcg/day)
45829693|NCT01817790|Drug|Placebo|Vehicle for Fluticasone propionate aqueous nasal spray
45829694|NCT01793688|Drug|Sulbactam Sodium/Ampicillin Sodium|"Intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection or drip infusion. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).~Kit for intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection after dissolved in an accompanying reconstitution diluent. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency))."
45829695|NCT01793142|Drug|Viviant|Viviant (Bazedoxifene) 20mg once daily
45829696|NCT01792830|Drug|Metformin|"Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels will be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient.~Patients without a history of diabetes and admission HbA1c < 7% requiring SC insulin therapy in the hospital will be discharged on metformin monotherapy.~Treatment naïve patients with an HbA1c between 7% and 9% prior to admission will be discharged on metformin monotherapy or a combination of metformin and a single dose of subcutaneous insulin."
45829697|NCT01792830|Drug|Glargine insulin|"Glargine is a recombinant human insulin analog that exhibits a constant glucose-lowering profile over 24 hours and permits once-daily dosing. It is administered subcutaneously once a day at the same time every day.~Patients with an HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of glargine insulin at 50% of total daily hospital dose.~Patients with an HbA1c > 9% will be discharged on oral metformin and a single dose of glargine insulin at 80% of total daily hospital dose."
45829698|NCT01792830|Drug|Glulisine|Glulisine is an injectable, recombinant insulin analog. The total daily dose varies between 0.5 to 1 unit/kg/day depending on the levels of blood glucose. Glulisine will be given within 15 minutes before a meal or within 20 minutes after starting a meal.
45829699|NCT01792518|Drug|Placebo|
45829700|NCT01792518|Drug|Linagliptin 5mg|
45829701|NCT01792284|Drug|LY2605541|
45829702|NCT01792284|Drug|Insulin Lispro|All participants will be administering insulin lispro SQ as their pre-meal insulin during the course of the trial.
45829703|NCT04414566|Drug|gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil|Patients receive GP gemcitabine (1000 mg/m^2 d1,8) and cisplatin (80mg/m^2 d1) or TPF docetaxel (60mg/m^2 on day 1), cisplatin (60mg/m^2 on day 1) and fluorouracil (600mg/m^2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
45829704|NCT04414566|Radiation|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
45829705|NCT04414566|Radiation|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m^2 every 3 weeks for 3 cycles.
45829706|NCT01837914|Procedure|Maxillary expansion|
45829707|NCT01837914|Procedure|Adenotonsillectomy|
45829708|NCT01791894|Drug|arsenic trioxide|Given IV
45829709|NCT04592016|Drug|Voltaren - Diclofenac sodium gel 1% (GSK, USA)|Topical application in dermal-sampling visit
45829710|NCT04592016|Drug|Pennsaid 2 % Topical Solution (Horizon Therapeutics, USA)|Topical application in dermal-sampling visit
45973623|NCT05085496|Biological|Atezolizumab|Given IV
45670527|NCT02228395|Drug|PF-04958242|Administered as specified in treatment arm
45973624|NCT05085496|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45973625|NCT05084053|Drug|TAK-771|Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
45973626|NCT05078476|Other|Manchester Short Splint|3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
45973627|NCT05078476|Other|Relative Motion Flexion|3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
45670528|NCT02228395|Drug|Placebo|Administered as specified in treatment arm
45670529|NCT02170051|Behavioral|CBSST-CCT|
45670530|NCT02170051|Behavioral|Goal focused supportive contact|
45829711|NCT04592016|Drug|Diclofenac sodium gel 1% (Perrigo, USA)|Topical application in dermal-sampling visit
45829712|NCT04592016|Device|Dermal open flow microperfusion - Pilot|Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess diclofenac concentration in the dermis. Interstitial fluid (ISF) sampling: 1 hour pre-dose and 24 hours post-dose.
45670531|NCT02169739|Device|Ischemic Preconditioning|Patients will undergo ischemic preconditioning once or twice daily for up to four 5-minutes cycles of bilateral upper extremity ischemia separated by 5-minute periods of reperfusion.
45670532|NCT02169505|Drug|Brentuximab Vedotin|Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose increased to 1.8 mg/kg by vein after the second cycle for all subsequent cycles.
45670533|NCT01909791|Procedure|Prompt Laser|Focal/grid laser performed at baseline and as needed during follow-up
45670534|NCT01909791|Drug|Prompt aflibercept|Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
45670535|NCT01909791|Procedure|Deferred laser|Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
45829713|NCT04592016|Device|Dermal open flow microperfusion - Pivotal|Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess diclofenac concentration in the dermis. Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose.
45829714|NCT04592016|Procedure|Blood sampling - Pilot|1 sample is taken pre-dose and 24 samples are taken post-dose.
45829715|NCT04592016|Procedure|Blood sampling - Pivotal|1 sample is taken pre-dose and 12 samples are taken post-dose.
45829716|NCT01837680|Drug|Insulin|
45829717|NCT01836276|Drug|Varenicline|1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
45829718|NCT01790568|Drug|Vorinostat|administered at a dose of 100 mg orally, twice daily starting on day -10 in order to achieve steady-state prior to beginning the conditioning chemotherapy, and continued after transplant (day 0) until day +100.
45829719|NCT01790568|Drug|Tacrolimus|
45829720|NCT01790568|Drug|Methotrexate|
45829721|NCT01610076|Other|Code Status Video|"10 minute video about Code Status"
45829722|NCT04587024|Other|mHealth intervention|Subjects will receive mHealth direct observation of therapy for 12 weeks
45829723|NCT04587024|Other|standard of care|Subjects will receive standard of care observation for 12 weeks
45829724|NCT01836198|Drug|LY2409021|
45829725|NCT01836198|Drug|Gemfibrozil|
45829726|NCT01836198|Drug|Ketoconazole|
45829727|NCT01836198|Drug|Clarithromycin|
45829728|NCT04590846|Behavioral|Constipation Health Education Intervention Course|"The 4-weeks health education includes three dimensions. The first is Causes and Hazards of Constipation. The second is Constipation Symptoms and Criteria. The third is Constipation Treatment Strategies and Prevention.~Health education leaflets with 3 to 5 test questions in the weekly are distributed once a week, students will bring them back to parents, and parents need to complete the answers and sign after reading them."
45829729|NCT04590846|Behavioral|General Health Course|General courses about health issues according to the curriculum of each primary school.
45973628|NCT05074810|Drug|avutometinib (VS-6766) and sotorasib|The RP2D of avutometinib(VS-6766) + sotorasib determined in Part A will be used in Part B dose expansion
45670536|NCT01909791|Drug|Deferred aflibercept|Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria
45670537|NCT02202499|Drug|Varenicline|All participants will take the following dose of varenicline: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day through week 16 of the study. Arm descriptions show specific details for each group.
45670538|NCT02202499|Other|Counseling and Support Materials|Counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided.
45829730|NCT01816074|Drug|Vyvanse (lisdexamphetamine)|Active ADHD drug, Vyvanse, is administered to mother.
45829731|NCT01816074|Behavioral|Behavior Parent Training|Mother is given 8 weeks of individual sessions of behavioral parent training
45829732|NCT01815918|Drug|Hydrocortisone|Patients randomized to treatment arm will three doses of 100 mg of hydrocortisone at the following times: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
45829733|NCT01815918|Drug|Placebo|Patients receive placebo prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
45829734|NCT01789476|Drug|CR845|CR845 dosage = 0.005 mg/kg per dose, IV bolus. The initial dose was administered upon reaching a qualifying pain intensity score and followed by a supplemental dose, if requested by patient for pain. Additional doses could be administered every 8 hours up to 48 hours.
45829735|NCT01789476|Drug|Placebo|Matching placebo administered using same dosing algorithm as the active arm
45829736|NCT01789320|Drug|triamcinolone acetonide (Triesence®)|4 mg of TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space
45829737|NCT01815840|Drug|Vismodegib|Vismodegib 150 mg hard gelatin capsule orally once daily
45829738|NCT01815840|Drug|Placebo|Vismodegib placebo orally once daily
45829739|NCT01774110|Other|Early standardized task training|Early standardized task training is a treatment approach using treadmill training applied very early after stroke onset.
45829740|NCT01788228|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|2 doses administered intramuscularly (IM) in deltoid region of arm at the Day 0 and Day 21 visits.
45829741|NCT01607346|Drug|ezogabine/retigabine|Starting dose of 300mg/day, titrate up to a targeted maximum dose of 1200 mg/day. Dose can be reduced to a minimum of 600 mg/day if unable to tolerate higher doses
45829742|NCT01787838|Other|Focused Health Education|"A two-phase quality improvement study was designed to modify staff and patient behaviors. The project incorporated evidence-based strategies of staff education, feedback and incentives for performance and patient education.~The staff received monthly feedback on departmental immunization rates, and incentives for performance. A one-page patient education flyer, written at 3rd grade reading level, was added to encourage patients to inquire about it."
45829743|NCT01787760|Device|Test Soft Contact Lens B|Test lenses to be worn in daily wear modality
45829744|NCT01787760|Device|Test Soft Contact Lens C|Test lenses to be worn in a daily wear modality
45829745|NCT01787760|Device|Active Comparator|Control spectacle lenses to be worn in a daily wear modality
45829746|NCT01815138|Drug|hCG|Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger
45829747|NCT01815138|Drug|hCG|Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger
45829748|NCT01606800|Drug|PEG-IFN alfa-2b|Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week
45829749|NCT01606800|Drug|ribavirin|Ribavirin 200 mg capsules administered orally daily based on weight
45829750|NCT04414488|Procedure|Thoracic paravertebral block (ThPVB)|Before the induction of general anaesthesia a single-shot ThPVB was performed at the Th3 to Th4 level, approximately, 2.5 to 3 cm lateral to tip of a spinous process. A preblock ultrasound examination was undertaken to assess the depth of the transverse process and the pleura. An insulated 10 cm long needle was used and this was connected to a peripheral nerve stimulator with a set current of 2.5 milliampere(mA). The current was gradually reduced as the needle was inserted until the appearance of visible intercostal muscles activity with a current of 0.3 to 0.5mA (paravertebral space identification). Plain bupivacaine (0.3 ml*kg-1) was then injected after a negative aspiration test for air or blood. The efficacy of the blockade to cold was checked after 20 min with a plastic ampoule of saline kept in the freezer. Testing was symmetrical on both sides of thorax. A difference in sensation to cold between the blocked and unblocked sides was taken to indicate an effective block.
45829751|NCT01772550|Device|20GA BD Nexiva Diffusics|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If the Inserter is unsuccessful in the second attempt, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
45829752|NCT01772550|Device|18GA Conventional Catheter|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If after the first attempt, there is no vein in the contralateral arm that can accommodate an 18 gauge catheter, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
45829753|NCT01787292|Behavioral|Stretching Exercise Intervention|A. Light stretching and balance exercises under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted to be under 50% of age-related maximum.
45829754|NCT01787292|Behavioral|Aerobic Exercise Intervention|Supervised weekly exercise. 3 bouts of 45 minutes weekly on a cycle ergometer. HR will be kept at 75% of age-related maximum.
45829755|NCT01787292|Behavioral|Self Monitoring|6 month self-monitored training phase during which time participants will exercise according to prescribed regimen (cycling)
46081835|NCT02554851|Drug|recombinant human Epidermal Growth Factor (rhEGF)|The Heberprot-P® is a parenteral formulation, which is in a lyophilized powder vial presentation containing 75μg of recombinant Epidermal Growth Factor (rhEGF) for local application (intralesional) with the therapeutic potential to promote granulation and wound healing of DFU. The rhEGF is a polypeptide of 53 amino acids and has the ability to stimulate fibroblasts, keratinocytes and vascular endothelial cells proliferation. Then it contributes to its properties in scar tissue formation. The action mechanism is based on the interaction with specific receptors located on specifics cell membranes. The rhEGF was developed through recombinant DNA technology and it has been produced by biotechnological methods in Saccharomyces cerevisiae yeast line.
46081836|NCT02554851|Other|Placebo|This group will receive the standard medication and the placebo drug. The placebo drug has the same formulation, except for the fact that it does not contain the recombinant human Epidermal Growth Factor (rhEGF).
46081837|NCT02552628|Device|"Medtronic, Activa® PC on"|
46081838|NCT02552628|Device|"Medtronic, Activa® PC off"|
46081839|NCT02530164|Device|Transcranial direct current stimulation (tDCS)|active/sham tDCS as adjunctive treatment with a SSRI
45973629|NCT05060146|Other|Structured medico-pharmaceutical collaboration|Reconciliation of drug treatments; Writing of the prescription for discharge from hospital for the pneumococcal vaccine; Pharmaceutical interview at discharge; Drafting of the discharge letter and transmission to the attending physician; Writing of the pharmaceutical discharge letter and transmission to the pharmacist; Pharmaceutical dispensing in the pharmacy; Administration of the vaccine by the attending physician or a nurse at home.
45670539|NCT02202499|Other|Laboratory Assessments|The first laboratory assessment will consist of completion of questionnaires and a cue-reactivity test. The second laboratory assessment will be scheduled for the end of the week before the participant's quit date. It will involve completion of questionnaires and another cue reactivity test. A follow-up session conducted by research staff will occur one month after the target quit date to collect information about each participant's current smoking status, smoking rate, varenicline use, and opinion about the treatment. A second follow-up session will be conducted by telephone and will occur three months after the target quit date, at the end of varenicline use. At the end of the study, participants will be asked to complete a brief survey asking basic information, similar to the questions during the screening period.
45670540|NCT02202109|Behavioral|CHW and Self-sampling for Cervical Cancer|Behavioral: CHW and Self-sampling for Cervical Cancer The intervention strategies will involve one home visit: 1) provide brief health education on cervical cancer screening, 2) provide and collect self-sampler test. We envision visits lasting no more than 60 minutes.
45973630|NCT05044715|Behavioral|Treatment as Usual|"Treatment as usual-TAU groups include:~Mood Groups - General Process Groups~Anxiety Groups - Cognitive Behavioral Therapy~Body Image and Eating Concerns Groups~Reconciling Faith and Sexuality Groups"
45973631|NCT05044715|Behavioral|Compassion-Focused Therapy (CFT)|The CFT protocol assumes that participants have no prior experience with meditation, mindfulness, and self-compassion and teaches principles of each as well as skills such as guided meditations.
45973632|NCT05038735|Drug|Alpelisib|Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.
45973633|NCT05038735|Drug|Fulvestrant|Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle (each cycle is 28 days).
45973634|NCT05038735|Drug|Alpelisib-matching placebo|Alpelisib-matching placebo (tablets) administered orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.
45973635|NCT05035095|Drug|Oral semaglutide|Participants will receive a daily dose of oral semaglutide.
45973636|NCT05035095|Drug|Placebo (semaglutide)|Oral placebo (semaglutide) once daily. Planned treatment duration will be 68 weeks.
45973637|NCT05031416|Combination Product|LTQ|The investigators will test the LTQ-Connect application and a standard 10-week course of nicotine replacement therapy (NRT) nicotine patches, and Facebook groups, which will run for a total of 3 months with research study participants
46081840|NCT02522611|Drug|Resiniferatoxin|Resiniferatoxin (RTX) is an ultrapotent agonist analog of capsaicin that targets a receptor expressed on specific dorsal root sensory ganglia (DRG) neurons and is expected to reduce pain within the targeted zone.
46081841|NCT02520141|Other|Laboratory Biomarker Analysis|Correlative studies
46081842|NCT02520141|Biological|Ramucirumab|Given IV
46081843|NCT02513875|Dietary Supplement|vitamin D|60,000 IU per week for 8 weeks
46081844|NCT02513875|Dietary Supplement|Placebo|placebo +diet and lifestyle
46081845|NCT02513394|Drug|Palbociclib|
46081846|NCT02513394|Drug|Standard Adjuvant Endocrine Therapy|
46081847|NCT02474160|Other|Cytology Specimen Collection Procedure|Procurement of tissue and blood samples
46081848|NCT02407405|Drug|Selumetinib|orally 50 mg/dose, every 12 hours every day continuously (1 cycle = 28 days)
46081849|NCT02405351|Behavioral|Adaptive Working Memory Training|"The working memory training task will consist of an online adaptive working memory program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember."
46081850|NCT02365090|Other|patching|covering the sound eye with a patch to force use of the amblyopic eye
46081851|NCT02365090|Other|binocular games|playing iPad games 1 hour per day 5 days per week to allow the child to use the amblyopic eye and the sound eye together
46081852|NCT02329847|Drug|Ibrutinib|Participants will receive oral capsule of ibrutinib once daily as either 420 mg or 560 mg or at recommended Phase 2 dose in any of the cohort.
46081853|NCT02329847|Drug|Nivolumab|Participants will receive nivolumab intravenously as 3 mg/kg on Day 1 every cycle of 14 days.
45670541|NCT02202109|Behavioral|Mailed Self Sampler|Mailed Self Sampler. Women randomized to this intervention arm will receive a self-sampling kit via mail. This kit will include: 1) the self-sampler; 2) the vial for collecting and storing the specimen; 3) a pre-addressed, stamped envelope for returning the vial; 4) a brief introductory letter/postcard which includes a picture of the CHE and the CHW and serves to re-orient the participant to the focus of the study; 5) instructional guide that visually depicts the steps for self-sampling;
45670542|NCT02227849|Drug|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 52 weeks
45670543|NCT02227849|Drug|GLP-1 analogue|
45829756|NCT04414644|Behavioral|Eating Condition|Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
45829757|NCT01814748|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly
45829758|NCT01814748|Drug|Placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly
45829759|NCT01814748|Drug|Metformin|Open-label metformin (dosed daily according to the country-specific product label) was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
45829760|NCT01814670|Biological|botulinum toxin Type A|20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
45829761|NCT01814046|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses) (only for cohort A).
45829762|NCT01814046|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
45829763|NCT01814046|Drug|Fludarabine|Fludarabine 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
45829764|NCT01814046|Biological|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL and high dose aldesleukin (Cohort A) or no aldesleukin (Cohort B). On day 0,cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
45829765|NCT01813890|Drug|Tapentadol IR 50 mg|Tapentadol IR 50 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
45829766|NCT01813890|Drug|Tapentadol IR 75 mg|Tapentadol IR 75 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
45829767|NCT01813890|Drug|Placebo|Placebo will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
45829768|NCT01772316|Drug|tocilizumab|162 mg subcutaneously weekly or every two weeks, 96 weeks
45829769|NCT01813422|Biological|Evolocumab|Administered by subcutaneous injection
45829770|NCT01813422|Drug|Placebo|Administered by subcutaneous injection
45829771|NCT01786668|Drug|Tofacitinib 2 mg|4 blinded tablets (two 1 mg tablets of tofacitinib along with two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
45829772|NCT01786668|Drug|Tofacitinib 5 mg|4 blinded tablets (one 5 mg tablet of tofacitinib, one 5 mg and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
45973638|NCT05028062|Drug|XR-NTX 380 mg, intramuscular injection|Two doses of XR-NTX 380 mg, intramuscular injection.
45973639|NCT05028062|Behavioral|Medical Management|All subjects will receive 8 weeks of medical management (Pettinati et al. 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
45973640|NCT05028062|Drug|Placebo intramuscular injection|Two doses of XR-NTX 380 mg, intramuscular injection.
46081854|NCT02314624|Behavioral|Behavioral Activation for Depression, Cognitive Behavior Therapy for Insomnia, Collaborative Assessment and Management of Suicidality|Evidence-based interventions for treating depression and concurrent problems
45670544|NCT01927497|Procedure|Biological mesh assisted perineal closure|The eAPR procedure will be performed in an identical way as described for the control arm of the study, and this is preferably followed by an omental plasty. The intervention in the experimental arm consists of suturing an acellular biological mesh derived from porcine dermis in the pelvic floor defect (Strattice™, 6x10 cm). The mesh will be sutured at each side of the coccyx or distal sacrum with Prolene or PDS to the discretion of the surgeon. Laterally, the mesh is attached to the remainings of the levator complex and, anteriorly, to the transverse perineal muscle or posterior vaginal wall. A suction drain will be inserted and positioned on top of the mesh. The perineal subcutaneous fat and skin will be subsequently closed in layers similar to primary simple closure as performed in the standard arm.
45829773|NCT01786668|Drug|Tofacitinib 10 mg|4 blinded tablets (two 5 mg tablets of tofacitinib and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
45829774|NCT01786668|Drug|Placebo|4 blinded tablets (two 1 mg and two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
45829775|NCT01786512|Drug|Omecamtiv Mecarbil Matrix F1 Formulation|Modified release tablets for oral administration
45829776|NCT01786512|Drug|Omecamtiv Mecarbil Matrix F2 Formulation|Modified release tablets for oral administration
45829777|NCT01786512|Drug|Placebo|Modified release tablets matching to omecamtiv mecarbil
46081855|NCT02314624|Behavioral|Care-as-Usual Psychotherapy|Usual care psychotherapy for depression and concurrent problems
46081856|NCT02289781|Device|posterior crowns|teeth will be prepared to receive posterior crown made of either zirconia or metal-ceramic material
46081857|NCT02287428|Radiation|Radiation Therapy|Standard radiotherapy (approximately 60 Gy over 6 weeks)
46081858|NCT02287428|Biological|Personalized NeoAntigen Vaccine|NeoVax will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.
46081859|NCT02287428|Drug|Pembrolizumab|Pembrolizumab will be administered every 3 weeks at a flat dose of 200 mg intravenously. Pembrolizumab should be administered as a 30 minute IV infusion (Pembrolizumab treatment cycle intervals may be increased due to toxicity per protocol).
46081860|NCT02287428|Drug|Temozolomide|Concurrent Temozolomide (TMZ) = 75 mg/m2/day for 6 weeks, administered with XRT
46081861|NCT02287428|Drug|Temozolomide|Adjuvant Temozolomide (TMZ) = 150 mg/m2/day on days 1-5 of each 28-day cycle for up to 6 adjuvant cycles
46081862|NCT02286687|Other|Laboratory Biomarker Analysis|Correlative studies
45455970|NCT05305521|Procedure|transcrestal sinus floor elevation|Under local anesthesia (articaine 4% with epinephrine 1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest. Clinicians were left free to choose their preferred transcrestal antrostomy technique. After checking sinus membrane integrity with visual inspection and Valsalva maneuver, pre-heated (40°C) xenogeneic porcine bone substitute in gel form (Gel 40, Tecnoss, Giaveno, Italy) was injected through the crestal antrostomy in order to elevate the membrane and fill the sub-antral space. Duration of graft injection (in seconds) was recorded using a digital chronometer. Periapical intraoperative radiographs were taken to confirm membrane elevation of at least 10 mm.
45455971|NCT05305521|Procedure|Implant placement|"Simultaneous implant placement was performed when it was possible to achieve adequate primary stability in the residual crestal bone, otherwise crestal antrostomy was sealed by collagen sponges (Hemocollagene, Septodont, Saint-Maur-des-Fossés, France) and implant insertion was postponed.~Flaps were sutured with Sentineri technique and single stitches using synthetic monofilament"
45455972|NCT05295342|Behavioral|No Means No intervention Girls' Curriculum|"The No Means No (NMN) Girls' Curriculum is a violence prevention program designed for adolescent girls and young women 10-20 years old. This curriculum has been designed specifically for safer implementation during the COVID-19 pandemic. NMN Girls' programming is deeply rooted in Empowerment Self-Defense, which is a uniquely holistic, survivor-centered, feminist approach to self-protection skills. Youth educators called Instructors deliver the curriculum to young people in schools. This 8-hour intervention is comprised of classes that teach young people mental, verbal and physical self-defense skills that can be used to prevent sexual assault and other forms of gender-based violence."
45829778|NCT01786512|Drug|Omecamtiv Mecarbil Swellable Core Technology F2|Modified release tablets for oral administration
45829779|NCT04414254|Drug|Cefprozil 125mg/5ml Susp; Cefprozil granule (125mg)|"Subjects were allocated to one of two groups randomly and equally with a 3-day washout interval between the two periods.Cefprozil for Suspension® (125mg/5mL, 50mL/bottle, batch no. F701087, manufactured by Lupin Pharmaceuticals, Inc.) and cefprozil granule (125mg, batch no. 8G001F07, manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study."
46081863|NCT02286687|Other|Pharmacological Study|Correlative studies
46081864|NCT02286687|Drug|Talazoparib|Given PO
46081865|NCT02255227|Biological|Prevenar 13|one dose for arm 1 and 2 doses for arm 2
46081866|NCT02255227|Biological|Pneumo 23|one dose
46081867|NCT02205294|Other|Osteopathic Treatment|The osteopathic treatment will be a gentle hands treatment using myofascial release techniques.
45829780|NCT01772160|Other|Data collection|HZ/PHN booklet, HZ/PHN file and logbook. HZ/PHN booklet will be completed by the patient and the HZ/PHN file and logbook will be completed by the participating general practitioner.
45829781|NCT01770912|Drug|Lactated Ringers|Solution used for TMJ arthrocentesis procedure. 1 cc of Lactated Ringers solution injected once after the TMJ rinsing procedure.
45829782|NCT01770912|Drug|Triamcinolone hexacetonide|1 cc of triamcinolone hexacetonide (5 mg) injected once after the TMJ rinsing procedure.
45829783|NCT01811706|Drug|Dalfampridine|Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks period
45829784|NCT01811706|Drug|Placebo|Placebo will be administered orally every 12 hours, for a 4 week period.
45829785|NCT01811472|Drug|LCQ908|LCQ908 5 mg, 10 mg, 20 mg tablets
46081868|NCT02192359|Biological|Carboxylesterase-expressing Allogeneic Neural Stem Cells|Given intracranially
46081869|NCT02192359|Drug|Irinotecan|Given IV
46081870|NCT02192359|Drug|Irinotecan Hydrochloride|Given IV
46081871|NCT02192359|Other|Laboratory Biomarker Analysis|Correlative studies
46081872|NCT02192359|Other|Pharmacological Study|Correlative studies
46081873|NCT02169310|Device|tDCS|There is no study intervention for Experiment 1. The study intervention for Experiment 2 is tDCS. tDCS is a non-invasive brain stimulation technique that uses electrodes attached to the scalp to deliver very low intensity direct current to the brain. This intervention has been demonstrated to result in neuromodulatory effects.
45973641|NCT05013099|Biological|zirconium Zr 89 crefmirlimab berdoxam|Up to three zirconium Zr 89 crefmirlimab berdoxam PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 3.0 mCi ± 20% and 4.5 mg API) as an IV infusion or slow bolus injection as follows: First (PETbaseline) within 14 days prior to the onset of IOT, and a second (PETEOC1) 4 to 6 weeks after start of immunotherapy. The second zirconium Zr 89 crefmirlimab berdoxam administration and scan (PETEOC1) should be completed prior to the start of the third cycle of IOT. Subjects who are determined by the treating physician to have PD on immunotherapy can receive the optional third zirconium Zr 89 crefmirlimab berdoxam PET scan at the principal investigator's (PI's) discretion.
45973642|NCT04999202|Drug|BAY2416964|Oral, twice or three times daily
45973643|NCT04999202|Drug|BAY2416964|The highest dose determined safe in combination with pembrolizumab in the dose escalation part or a lower dose. More than one dose may be explored in the dose expansion.
45973644|NCT04999202|Drug|Pembrolizumab|Administered as a dose of 200 mg using a 30-minute IV infusion every 3 weeks
45973645|NCT04997811|Drug|Sodium Valproate, Bezafibrate, Medroxyprogesterone|Sodium valproate tablet 1 x 500mg bd, (starting 1 x 200mg bd) Bezafibrate standard release tablet 2 x 200mg tds, (starting 1 x 200mg tds) Medroxyprogesterone acetate tablet 1 x 400mg bd (starting 1 x 400mg od)
45973646|NCT04997811|Drug|Danazol|Danazol 1 x 200mg capsules tds, (starting 1 x 200mg od)
45973647|NCT04983836|Procedure|Serratus anesthesia technique|locoregional anaesthesia allowing analgesia of the hemi-thorax by ultrasound guided single injection of naropeine 5mg/ml
45973648|NCT04983836|Procedure|Paravertebral anesthesia technique|Ultrasound guided single injection of of naropeine 5mg/ml dose into the paravertebral space next to the thoracic spine
45973649|NCT04972318|Procedure|Positive end-expiratory pressure titration with driving pressure control|Positive end-expiratory pressure will be tailored during a decremental maneuver (without a formal alveolar recruitment maneuver). The best positive end-expiratory pressure will be defined as the one associated with the higher respiratory system compliance, up to 20 cmH2O. Plateau pressure limit will be 30 cmH2O. If driving pressure remains elevated after optimal PEEP setting, tidal volume will be reduced to keep driving pressure below 14 cmH2O.
45973650|NCT04972318|Procedure|ARDSNet ventilatory strategy|Positive end-expiratory pressure will be set according to fixed inspired oxygen fraction values.
45973651|NCT04971967|Combination Product|Crowdsourced partner services intervention|The intervention includes the provision of provider referral and dual referral services, crowdsourced materials such as postcards and an HTML aiming to promote PS, as well as free take-home HIV self-testing kits.
45973652|NCT04965909|Other|Online physiotherapy protocol based on pain neuroscience education and gradual exposure to movement.|Online group therapeutic program (small groups), applied for 3 months.
45973653|NCT04953884|Drug|wilate|wilate is a plasma-derived, stable, highly purified, double virus inactivated concentrate of freeze-dried active VWF and factor VIII (FVIII) prepared from cryoprecipitate and intended for the treatment of patients with von Willebrand disease (VWD) and/or haemophilia A
45973654|NCT04952753|Drug|NIS793|Investigational drug NIS793 will be administered intravenously (IV) at the dose and schedule determined in the safety run-in part.
46081874|NCT02169310|Drug|[11C] Raclopride|[11C] Raclopride is administered under an IND 054135. This IND is sponsored by the NIH Clinical Center and [11C] Raclopride is dispensed by the NIH PET Department. Quality Assurance for Radioactive Drug: [11C] Raclopride, is assayed for radiochemical purity under the supervision of the NIH PET Department prior to dispensing the drug for administration. Given that IND PET drugs manufactured at the NIH PET Department are used in a single site and that there is no intent for their commercialization, submission of IBs has not been required by FDA for any of the NIH Office of Research Support and Compliance-sponsored IND applications.
45455973|NCT05295342|Behavioral|No Means No intervention Boys' Curriculum|"The No Means No (NMN) Boys' Curriculum is a violence prevention curriculum that has been designed specifically for implementation during the COVID-19 pandemic. Designed for adolescent boys and young men age 10-20. Like the girls program it is delivered by youth educators called Instructors in schools. This 8-hour intervention is comprised of classes that teach young people gender equitable attitudes, skills to defend equality and how to avoid violence as a power paradigm."
45670545|NCT01927497|Procedure|Primary perineal closure|The perineal phase of the APR will be performed according to the principles of an extralevator APR, which means that the levator muscles will be laterally transected in order to leave a muscular cuff around the tumour. The coccyx will not be routinely resected, but only if indicated based on surgical exposure or oncological principles. The extent of excision of perineal skin and ischioanal fat will be as limited as oncologically justified. Preferably, an omental plasty is positioned in the pelvic cavity following resection. Closure of the perineum in the control arm consists of stitching the perineal subcutaneous fat together using interrupted Vicryl sutures in one or two layers. Subsequently, the skin will be closed using interrupted sutures according to the preference of the surgeon. Placement of a transabdominal or transperineal drain will be at the discretion of the surgeon.
45455974|NCT05295342|Behavioral|Active comparator: Life Orientation|The standard school-based Life Orientation curriculum
45670546|NCT02169271|Drug|Aspirin|Given PO
45973655|NCT04952753|Drug|Bevacizumab|Bevacizumab will be administered IV
46081875|NCT02145143|Drug|Vemurafenib|
46081876|NCT02145143|Device|serial 124I PET/CT|
46081877|NCT02145143|Drug|thyrotropin alpha|
46081878|NCT02133196|Drug|Aldesleukin|Aldesleukin 720,000 (Arm 1) or 72,000 (Arm 2) IU/kg IV (based on total body weight) over 15 minutes every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to a maximum of 9 doses in Arm 1 and 12 doses in Arm 2.
46081879|NCT02133196|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
46081880|NCT02133196|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hour.
46081881|NCT02133196|Biological|Young TIL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
46081882|NCT02122835|Behavioral|aerobic exercise training|12 weeks of supervised aerobic exercise training
46081883|NCT02122328|Procedure|Sequential laser photocoagulation of communicating vessels.|
46081884|NCT02122328|Procedure|Selective laser photocoagulation of communicating vessels|
45973656|NCT04952753|Drug|Modified FOLFOX6|5-fluorouracil [continuous infusion], leucovorin [administered IV] (or levoleucovorin [administered IV]), and oxaliplatin [administered IV]
45973657|NCT04952753|Drug|FOLFIRI|5-fluorouracil [continuous infusion], leucovorin [administered IV] (or levoleucovorin [administered IV]), and irinotecan [administered IV]
45973658|NCT04952753|Drug|Tislelizumab|Investigational drug tislelizumab will be administered intravenously (IV).
45973659|NCT04950985|Other|Observational Study|Observational study
45973660|NCT04948333|Drug|ABL001 40mg BID|One tablet of 40 mg will be taken orally twice a day (BID)
45973661|NCT04948333|Drug|ABL001 80mg QD|Two tablets of 40 mg will be taken orally once a day (QD)
45829786|NCT01811472|Drug|placebo|Matching placebo of LCQ908 5 mg, 10 mg, 20 mg tablets.
45973662|NCT04948333|Drug|ABL001 200mg QD|Five tablets of 40 mg will be taken orally once a day (QD)
45973663|NCT04933383|Drug|AQ001S 0.125 mg/ml|administered by nebulization once daily
45973664|NCT04933383|Drug|Budesonide 0.125 mg/ml inhalation suspension|administered by nebulization once daily
45973665|NCT04925752|Drug|Oral Lenacapavir (LEN)|Tablets administered orally without regard to food
45973666|NCT04925752|Drug|F/TDF|Tablets administered orally
46081885|NCT02119611|Device|Deep Brain Stimulation management|The DBS surgery will be performed according to standard of care in the centers of referral. If performed at the NIH, this will be done under protocol 11-N-0211 or other protocols permitting DBS surgery depending on future availability.
46081886|NCT02119468|Drug|ixazomib citrate|Given orally
46081887|NCT02119468|Drug|dexamethasone|Given orally
45829787|NCT01811238|Drug|Oxycodone/naloxone|Targin 5mg, 10mg, 20mg up to 40mg b.i.d
45829788|NCT01769508|Drug|5-Fluorouracil|5-FU, 225 mg/m2 IVCI, during XRT.
45829789|NCT01769508|Drug|Oxaliplatin|Oxaliplatin, 85 mg/m2 IV, Days 1, 15, 29.
45829790|NCT01769508|Drug|Lapatinib|Lapatinib, Continuous PO daily dosing during XRT, dose determined during lead in portion
45829791|NCT01769508|Radiation|Radiation Therapy|Radiation therapy, 50.4 Gy (1.8 Gy/day or 28 fractions) M-F, Weeks1-6
45829792|NCT04585308|Device|transShield Embolic Protection System|Used for embolic protection during TAVR.
45829793|NCT04576260|Behavioral|Cognitive Behavioural Therapy for Insomnia|Weekly CBTI training
45973667|NCT04925752|Drug|Sub-cutaneous (SC) Lenacapavir (LEN)|Administered via SC injections
45973668|NCT04925752|Drug|Placebo SC LEN|Administered via SC injections
46081888|NCT02119468|Drug|pomalidomide|Given orally
46081889|NCT02112565|Drug|RNR inhibitor COH29|Given PO
46081890|NCT02112565|Other|laboratory biomarker analysis|Correlative studies
46081891|NCT02112565|Other|pharmacological study|Correlative studies
46081892|NCT02039934|Other|High intensity interval training|"The intervention consists of 30 minute sessions of high-intensity interval training on a bicycle ergometer three times per week.~Training program: After 5 minutes of warm-up the subject cycles for 10 intervals of 60 s. at 90 % maximum effort separated 60 s at 20% maximum effort, based on a previously performed spiroergometry, followed by 5 minutes of cool-down."
46081893|NCT02017717|Biological|Nivolumab|specified dose on specified days
46081894|NCT02017717|Biological|Bevacizumab|specified dose on specified days
46081895|NCT02017717|Biological|Ipilimumab|specified dose on specified days
46081896|NCT01976091|Genetic|SRP-9004|Isolated Limb Infusion (ILI)
45829794|NCT01810380|Drug|Placebo|Once daily as tablets and capsules, orally
45829795|NCT01810380|Drug|Brexpiprazole|2-4 mg/day, once daily, tablets, orally
45829796|NCT01810380|Drug|Quetiapine extended release|400-800 mg/day, once daily, encapsulated tablets, orally
45829797|NCT01769196|Drug|Simtuzumab|125 mg/mL single-dose vials administered subcutaneously once a week
45829798|NCT01769196|Drug|Simtuzumab placebo|Simtuzumab placebo single-dose vials administered subcutaneously once a week
45829799|NCT01810302|Drug|Nicardipine hydrochloride|Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
45829800|NCT01810302|Drug|Preservative-free normal saline|Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
45829801|NCT01783938|Biological|Nivolumab|
45829802|NCT01783938|Biological|Ipilimumab|
45829803|NCT01768572|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form: solution Route of administration: subcutaneous
45829804|NCT01768572|Drug|tocilizumab|Pharmaceutical form: solution Route of administration: intravenous
45973669|NCT04925752|Drug|PTM F/TDF|Tablets administered orally
45973670|NCT04925752|Drug|PTM Oral LEN|Tablets administered orally
45973671|NCT04925752|Drug|F/TAF (for US participants only)|F/TAF tablets administered orally once daily
45973672|NCT04923906|Drug|Aumolertinib|"Aumolertinib 110 mg QD in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of every 21-day cycles up to 4~6 cycles, followed by Aumolertinib daily with pemetrexed maintenance (500 mg/m2) on Day 1 of every 21-day cycles.~Dose may be reduced to allow for the management of investigational drug related toxicity."
45973673|NCT04923906|Drug|Placebo Aumolertinib|Placebo Aumolertinib 110 mg QD Dose may be reduced to allow for the management of investigational drug related toxicity.
45973674|NCT04923776|Drug|Carboplatin|The dosage for this drug is area under the curve (AUC) 5 mg/ml/min intravenous, Day 1, every 21 days for 4 cycles. This is standard of care.
45973675|NCT04923776|Drug|Etoposide|The dosage for this drug is 100 mg/m2 Intravenous, Days 1-3, every 21 days for 4 cycles. This is standard of care.
45973676|NCT04923776|Drug|Atezolizumab|The dosage for this drug is 1200 mg Intravenous, Day 1, every 21 days until disease progression. This is standard of care.
45973677|NCT04923776|Radiation|Stereotactic Body Radiation Therapy (SBRT)|This radiotherapy is given within +/-3 days of cycle 2, 10 Gy 3 doses on alternating days. This is not standard of care and considered interventional.
45973678|NCT04913285|Drug|KIN-2787|KIN-2787 will be administered orally twice daily in 28-day cycles
45973679|NCT04913285|Drug|KIN-2787 and binimetinib|KIN-2787 and binimetinib will be administered orally twice daily in 28-day cycles
45973680|NCT04908943|Behavioral|RENEW|RENEW is a 12-week, peer-led, web-based program to help people with scleroderma learn skills that can be used to manage disease symptoms and improve well-being.
45973681|NCT04903691|Behavioral|Cardiac Exercise Program|Participants who enrolled in cardiac exercise program
45973682|NCT04902521|Device|Transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (TMS) is a safe non-invasive technique that stimulates the brain using repetitive magnetic pulses to enhance neuroplasticity. TMS has been shown to produce lasting modulation of cortical activity and improve clinical symptoms of children with neurodevelopmental disorders including CP
45973683|NCT04902521|Device|Sham Transcranial Magnetic stimulation|Sham Transcranial Magnetic stimulation will be given to the control group. During the Sham procedure patients will sit near the TMS but will not receive any magnetic pulses.
45973684|NCT04902144|Other|Electronic Health Record Review|Medical data collected
45973685|NCT04902144|Other|Questionnaire Administration|Complete questionnaires
45973686|NCT04902144|Behavioral|Behavioral Intervention|Receive coaching
45973687|NCT04899583|Device|Sirolimus Coated Balloon Catheter|a Sirolimus Coated Balloon Catheter designed and produced by Acotec
46081897|NCT01935921|Biological|Cetuximab|Given IV
46081898|NCT01935921|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45670547|NCT02169271|Other|Laboratory Biomarker Analysis|Correlative studies
45670548|NCT02169271|Other|Placebo|Given PO
45670549|NCT02202031|Behavioral|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
45670550|NCT02202031|Behavioral|Music Therapy|Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
45670551|NCT01644188|Drug|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
45670552|NCT01644188|Drug|Placebo (for alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
45670553|NCT01644188|Drug|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
45829805|NCT01768572|Drug|hydroxychloroquine|Dispensed according to local practice.
45829806|NCT01768572|Drug|methotrexate|Dispensed according to local practice.
45829807|NCT01768572|Drug|sulfasalazine|Dispensed according to local practice.
45973688|NCT04899583|Device|a Paclitaxel Coated Balloon Catheter|a Paclitaxel Coated Balloon Catheter(trade name:Bingo)
45973689|NCT04898894|Drug|Venetoclax|Given orally (PO)
45973690|NCT04898894|Drug|Selinexor|Given Orally (PO)
45973691|NCT04898894|Drug|Cytarabine|Given in to the vein (IV) or intrathecal (IT)
45973692|NCT04898894|Drug|Fludarabine|Given in to the vein (IV) - Because of the ongoing nationwide shortage of fludarabine, this agent may be omitted during the dose expansion phase of the trial.
45973693|NCT04898894|Biological|Filgrastim|Given subcutaneous (SubQ, SC)
46081899|NCT01935921|Biological|Ipilimumab|Given IV
46081900|NCT01935921|Other|Laboratory Biomarker Analysis|Correlative studies
46081901|NCT01927731|Drug|Eltrombopag Olamine|Given PO
46081902|NCT01927731|Other|Laboratory Biomarker Analysis|Correlative studies
46081903|NCT01909492|Procedure|Blood Draw|Patients will provide a serum sample for research.
46081904|NCT01909492|Procedure|Lumbar Puncture|Patients will have a lumbar puncture to obtain CSF.
46081905|NCT01863550|Drug|Bortezomib|Given SC or IV
46081906|NCT01863550|Drug|Carfilzomib|Given IV
46081907|NCT01863550|Drug|Dexamethasone|Given PO
46081908|NCT01863550|Other|Laboratory Biomarker Analysis|Optional correlative studies
46081909|NCT01863550|Drug|Lenalidomide|Given PO
45670554|NCT01644188|Drug|Placebo (for ezetimibe)|One capsule once daily orally at approximately the same time of the day with or without food.
45973694|NCT04898894|Drug|Methotrexate|Given intrathecal (IT)
45973695|NCT04898894|Drug|methotrexate/hydrocortisone/cytarabine|Given intrathecal (IT)
46081910|NCT01863550|Other|Quality-of-Life Assessment|Ancillary studies
46081911|NCT01824836|Drug|anastrozole|Given PO
46081912|NCT01824836|Other|questionnaire administration|Ancillary studies
46081913|NCT01824836|Other|laboratory biomarker analysis|Correlative studies
46081914|NCT01824836|Other|pharmacogenomic studies|Correlative studies
46081915|NCT01810913|Drug|Atezolizumab|Given IV
46081916|NCT01810913|Procedure|Biospecimen Collection|Undergo collection of blood
46081917|NCT01810913|Biological|Cetuximab|Given IV
46081918|NCT01810913|Drug|Cisplatin|Given IV
46081919|NCT01810913|Procedure|Computed Tomography|Undergo CT
46081920|NCT01810913|Drug|Docetaxel|Given IV
45670555|NCT01644188|Drug|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose.
45670556|NCT05648162|Device|Electrical acupuncture|Electrical acupuncture (2Hz, 150 μs) once daily
45829808|NCT01768572|Drug|leflunomide|Dispensed according to local practice.
45829809|NCT01768572|Drug|subcutaneous placebo|Pharmaceutical form: solution Route of administration: subcutaneous
45829810|NCT01768572|Drug|intravenous placebo|Pharmaceutical form: solution Route of administration: intravenous
45829811|NCT01783548|Drug|BDP Nasal Aerosol|
45829812|NCT01783548|Drug|Placebo|
45973696|NCT04886531|Drug|Neratinib|120mg for 7 days; 160mg for 7 days ; 240mg for 7 days. 240 mg (up to a maximum of 24 weeks) orally daily*.
45973697|NCT04886531|Drug|Letrozole (L) or Anastrozole (A)|L: (2.5 mg) OR A: (1 mg) orally daily (up to a maximum of 24 weeks)*
45973698|NCT04886531|Drug|Trastuzumab|All Arms 8mg/kg loading dose followed by 6mg/kg every 3 weeks administered every 3 weeks by IV starting wk 4. Trastuzumab biosimilars may be used per institutional guidelines.
45973699|NCT04884308|Biological|BCG TICE Vaccine|Intradermal vaccination with BCG TICE
45973700|NCT04871542|Procedure|Biospecimen Collection|Undergo collection of blood sample
45973701|NCT04871542|Other|Questionnaire Administration|Complete questionnaires
45973702|NCT04868565|Drug|Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]|"after randomization, caffeine citrate will be contineously prescribed to those patients assigned to the ongoing caffeine with oxygen supplement (group 2) with a medication regimen of 10mg/kg.dose, once daily, and weekly adjustment based on the working weight."
45973703|NCT04867616|Other|Placebo|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous infusion~Participants will receive Placebo during the Double-blind Treatment Period."
45973704|NCT04867616|Biological|Bepranemab|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous infusion~Participants will receive pre-specified doses of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period."
45973705|NCT04865770|Drug|Semaglutide|Semaglutide given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
45973706|NCT04865770|Drug|Placebo (Semaglutide)|Placebo (Semaglutide) given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
45973707|NCT04855734|Behavioral|FAmily CEntered (FACE) pACP Intervention|The (approximately) weekly 3-session FACE-Rare intervention of approximately 45-60 minutes each is comprised of the CSNAT approach [Sessions 1 & 2] and Respecting Choices [Session 3].
45973708|NCT04849364|Drug|Capecitabine|Capecitabine 1000 mg/m2 BID Orally 14 days on and 7 days off Cycle = 21 days; Total of 8 cycles
45973709|NCT04849364|Drug|Talazoparib|Talazoparib Cycle 1: 0.75 mg then Cycle 2-8: 1 mg Cycle = 21 days; Total of 8 cycles
45973710|NCT04849364|Drug|Atezolizumab|Atezolizumab 1200 mg IV over 1 hour Cycle = 21 days; Total of 9 cycles
45829813|NCT01809210|Drug|selumetinib|2 x 25mg capsules bd continuously in cohort 1 (with gemcitabine and cisplatin). If tolerated - next cohort 3 x 25mg capsules bd continuously. if higher doses are explored, required number of capsules will be provided. Option to administer on D2-19 of each 21 day cycle if required to assess tolerability of combinations with chemotherapy
45829814|NCT01809210|Drug|gemcitabine|1250 mg/m2 iv on Day 1 and 8 of each 21 day cycle. If combination not tolerated, option to give 1000 mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
45973711|NCT04849364|Drug|Inavolisib|Inavolisib Cycle 1: 6 mg then Cycle 2-8: 9mg Orally 21 days on Cycle = 21 days; Total of 8 cycles
45973712|NCT04849364|Other|Treatment of Choice|Treatment of patient and physician's choice will be given with strong consideration for capecitabine given the data from CREATE-X and KEYNOTE 522. Dose, schedule and duration of treatment to be determined by treating physician.
45973713|NCT04844294|Behavioral|Brief Cognitive Behavioral Therapy (BCBT)|BCBT is divided into three phrases. In phase I (5 sessions), the therapist conducts a detailed assessment of the patient's most recent suicidal episode or suicide attempt, identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills such as relaxation and mindfulness. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
45973714|NCT04844294|Behavioral|Present-Centered Therapy (PCT)|PCT includes (1) psychoeducation about the typical symptoms and features associated with suicidal thoughts and behaviors; (2) normalization of symptoms; (3) experience of receipt of support and feedback from a licensed professional; and (4) positive interpersonal interactions. PCT differs from BCBT in several key ways including less structure (i.e., patients are allowed to have more input into PCT session agendas) and no systematic training in behavioral or cognitive strategies for managing emotions and changing suicide-focused thoughts. PCT will be used as an active comparator because it is an empirically supported treatment for depression and PTSD that also reduces suicidal ideation (Bryan et al., 2016; Resick et al., 2017), but contains unique elements that distinguish the treatment from BCBT.
45973715|NCT04826718|Other|Questionaire|"A questionnaire will be administered to all participants to evaluate exposures related to infection at the baseline (enrollement) - Baseline questionnaire. A Follow-up questionnaire to all participants will be done after 3 and 6 months.~Capillary blood collection, for diagnosis of anti-SARS-CoV-2 Antibodies by rapid test, will be done at the first interview, for all participants (cases and controls).~Collection of peripheral venous blood, for analysis of the presence and duration of anti-SARS-CoV-2 Antibodies (N and S) will be done at the first interview, and after 6 months for all participants (cases and controls)."
45973716|NCT04822311|Behavioral|Experimental: Investigate the effects of an exercise intervention on retired APF players|Enrolled participants will perform a 18 months exercise intervention which involves 90 exercise rehabilitation training visits. In addition, participants will also be tested on various measures of health and function both at baseline (prior to intervention), at 6 months, 12 months, and 18 months (post intervention).
46081921|NCT01810913|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
46081922|NCT01810913|Other|Laboratory Biomarker Analysis|Correlative studies
46081923|NCT01810913|Procedure|Magnetic Resonance Imaging|Undergo MRI
46081924|NCT01810913|Other|Quality-of-Life Assessment|Ancillary studies
45670557|NCT05648162|Device|Acupuncture|Electrical acupuncture (no electricity) once daily
45670558|NCT05648162|Device|tDCS|tDCS (1mA) once daily
45670559|NCT05648162|Device|sham tDCS|tDCS (no electricity) once daily
45670560|NCT02201953|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
45670561|NCT02201953|Drug|SOF|400 mg tablet administered orally once daily
45670562|NCT02201953|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45829815|NCT01809210|Drug|cisplatin|75 mg/m2 iv on Day 1 of each 21 day cycle. If combination not tolerated, option to give 50 mg/m2 iv on Day 1 or 25mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
45829816|NCT01809210|Drug|carboplatin|If it is not possible to identify a tolerable combination of selumetinib, gemcitabine and cisplatin, cisplatin may be replaced with carboplatin (AUC5) iv on Day 1 of each 21 day cycle
45829817|NCT01809210|Drug|pemetrexed|Gemcitabine may be replaced with pemetrexed 500 mg/m2 iv on Day 1 of each 21 day cycle.
45829818|NCT01809132|Drug|Anakinra|Anakinra, interleukin-1 receptor antagonist; 100 mg/0.67 mL solution for subcutaneous injection.
45973717|NCT04815824|Behavioral|Exercise Mode|Stationary cycling or treadmill walking
45973718|NCT04794101|Biological|Genetic: AAV5-RPGR 4e11|Bilateral, subretinal administration of AAV5-RPGR - deferred treatment group
45973719|NCT04794101|Biological|Genetic: AAV5-RPGR 2e11|Bilateral, subretinal administration of AAV5-RPGR - deferred treatment group
45973720|NCT04791215|Other|Observational|All patients will be treated with standard of care pembrolizumab. After obtaining written informed consent, NSCLC participants will have serial blood collection. The blood collection (26 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. If additional biopsies or tumor resection are performed as part of routine standard of care throughout the course of the study, an additional 26 ml blood collection may be drawn for the study. Participants will remain on the study for as long as they are being followed or treated at Columbia University Irving Medical Center. Participants can withdraw from the study at any time.
45973721|NCT04772989|Drug|AB308|Administered intravenously (IV) as specified in the treatment arm
45973722|NCT04772989|Drug|Zimberelimab|Administered IV as specified in the treatment arm
45973723|NCT04744051|Drug|50 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 50 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
45973724|NCT04744051|Drug|150 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 150 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
45973725|NCT04744051|Drug|300 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 300 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
45973726|NCT04744051|Drug|Placebo Infusion|Each participant in this arm will receive a single dose of placebo. Upon completion of the study each placebo participant will with be given the option to be treated with their cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Dosage for the crossover will be determined by the PI following review of data collected from the other arms of the study.
45973727|NCT04743856|Behavioral|ActiveGOALSv2|13 weekly self-guided sessions on problem solving and goal setting related to increasing physical activity, and weekly remote coaching support. Once a month support materials sent monthly from months 4-12 of intervention.
45973728|NCT04743856|Behavioral|PAT|Participants will receive a physical activity tracker and encouragement to increase activity.
45973729|NCT04738942|Drug|Vedolizumab|Vedolizumab 300 mg, IV infusion
45973730|NCT04716881|Drug|Naltrexone 380 MG|Vivitrol (naltrexone) 380 mg delivered intramuscularly every 28 days
45973731|NCT04715074|Behavioral|Interviews|We will understand the impact psychosocial, lifestyle, and familial aspects play on an EOCRC diagnosis through 20 one-hour interviews with EOCRC patients and survivors.
45973732|NCT04715074|Behavioral|Pilot|Utilizing the Behaviour Change Wheel in conjunction with results gathered from Aims 1 and 2 we will develop a theory-driven, multi-media campaign intervention to increase awareness of EOCRC, risk factors, and early detection benefit.
45973733|NCT04711824|Drug|Olaparib|Olaparib 100-300 mg twice daily up to 28 days concurrently with stereotactic radiosurgery. Three dose levels of olaparib will be explored in the Phase I portion. Olaparib will start one week prior to SRS and continue during and following SRS for up to 28 days total. One cycle will be given.
45973734|NCT04711824|Radiation|Stereotactic Radiosurgery|SRS 1-5 fractions will be given per institutional standards
45973735|NCT04711824|Drug|Durvalumab|Durvalumab 1120 mg IV over 60 minutes Day 1 of each cycle 21 day cycle.
45670563|NCT02271854|Drug|Diclofenac sodium gel 1%|Diclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
45973736|NCT04711824|Drug|Physicians Choice systemic chemotherapy|Olaparib: 300mg PO BID; Days 1-21 Paclitaxel: 80 mg/m2 IV over 60 min; Day 1 and 8 Nab-paclitaxel:100 mg/m2 IV over 30 min; Day 1 and 8 Eribulin: 1.4 mg/m2 IV over 2-5 min; Day 1 and 8 Carboplatin: AUC 2 mg/ml/min IV over 30-60 min; Day 1 and 8 Cisplatin: 75 mg/m2 IV over 30-60 min; Day 1 Capecitabine: 1000 mg/m2 PO BID; Days 1-14 Gemcitabine: 1000 mg/m2 IV over 30 min; Day 1 and 8 Gemcitabine + Carboplatin: 1000mg/m2 IV over 30-60 min; Day 1 and 8
45829819|NCT01809132|Drug|Pentoxifylline|Pentoxifylline, generic
45829820|NCT01809132|Drug|Zinc Sulfate|Zinc Sulfate, nutritional supplement
45829821|NCT01809132|Drug|Methylprednisolone|Methylprednisolone, corticosteroid
45829822|NCT01808508|Device|Continuous positive airway pressure|Continuous positive airway pressure is a machine used with sleep which compresses air delivered via a nasal mask and thus helps stent the airway open.
45829823|NCT01808508|Device|Sham or placebo continuous positive airway pressure|Sham or placebo CPAP is a machine used instead of therapeutic CPAP. This machine is similar to a therapeutic CPAP machine but has built in leaks and does not deliver pressure. It is not effective in treating OSAS.
45829824|NCT01766778|Drug|LAF237 (vildagliptin)|Vildagliptin 50mg capsule
45829825|NCT01766778|Drug|Metformin|Metformin maximum tolerance dose
45973737|NCT04681066|Drug|CM-4620 Injectable Emulsion or CM-4620-IE|Auxora is to be administered as an IV infusion and is supplied as a translucent, white to yellowish colored, sterile, non-pyrogenic emulsion containing 1.6 mg/mL of the active pharmaceutical ingredient CM4620. CM4620-IE is supplied as an 80 mL fill in a 100 mL, single-use glass vial. The drug product is formulated as an emulsion due to the low solubility of CM4620 in aqueous solution. CM4620-IE contains egg phospholipids, medium chain triglycerides, glycerin, edetate disodium salt dehydrate (EDTA), sodium hydroxide (as needed to adjust pH), and sterile water for injection.
45973738|NCT04681066|Other|Placebo|Matching Placebo is to be administered as an IV infusion and is supplied as a translucent, white to yellowish, sterile, non-pyrogenic emulsion carrier containing no active pharmaceutical ingredient. Placebo is supplied as an 80 mL fill in a 100 mL single-use vial. Placebo contains the same ingredients as Auxora except that it does not contain CM4620.
45973739|NCT04673032|Device|Radiofrequency Ablation|Radiofrequency Ablation for treatment of chronic pain or other disorders
45973740|NCT04671433|Biological|Genetic: AAV5-RPGR|Bilateral, sub-retinal administration of AAV5-RPGR - immediate treatment group
45973741|NCT04671433|Biological|Genetic: AAV5-RPGR|No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-RPGR to be administered in the follow-up study)
45973742|NCT04655937|Other|Acceptance and Commitment Therapy|none two hour remote sessions (50 minutes activity + 20 minute break + 50 minutes activity). Acceptance and Commitment Therapy (ACT) is a third wave transdiagnostic cognitive-behavioural therapy that supports clients to adjust to current experiences and 'commit' to behaviours that are congruent with their personal values, in order to promote psychological well-being and prevent future mental health crisis. ACT uses a variety of experiential techniques to support this process including: mindfulness practices; exercises to identify personal values; commitment to goals for valued living.
45973743|NCT04652479|Drug|Avexitide|Avexitide (exendin 9-39) is a competitive antagonist of GLP-1 at its receptor
45973744|NCT04644237|Drug|Trastuzumab deruxtecan|Trastuzumab deruxtecan 100 mg will be provided as a sterile lyophilized powder and reconstituted with 5 mL water for injection (final concentration 20 mg/mL [ie, 100 mg/5 mL]). The study drug will be administered as an intravenous (IV) infusion over 30 to 90 min Q3W ± 2 days. The initial dose of study drug will be infused for 90 ± 10 min.
46081925|NCT01736202|Biological|fat orally|Oral ingestion of palm oil or canola oil or water at timepoint zero
46081926|NCT01729858|Device|Ceramic-Ceramic|"Zirconia computer aided design and computer milled cores with press on veneers with different thicknesses, gingival embrasure diameters and connector heights.~Fifty percent of the recruited subjects will be given a ceramic-ceramic bridge at baseline."
45670564|NCT02271854|Drug|Placebo|Placebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
45670565|NCT05296993|Dietary Supplement|Extracts found in the Extended Longevity supplements|Ingredients found in these serums are all naturally occurring, and extracted from a variety of plant species.
45670566|NCT02296892|Drug|Remimazolam|For induction and maintenance of sedation
45670567|NCT02296892|Drug|Placebo|Inactive control arm
45670568|NCT02296892|Drug|Midazolam|For induction and maintenance of sedation
45670569|NCT02270684|Device|StepRite|The StepRite device uses an insole to monitor motion, and relays this information to the physical therapist via a smart phone app and web link. Set exercises can be programmed into the app for the participant to complete
45829826|NCT01808196|Drug|Losartan Potassium|The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.
46081927|NCT01729858|Device|Metal-Ceramic|"Metal Ceramic prosthesis with press on veneer with different thicknesses, different diameters of curvature of gingival embrasure and connector heights.~Fifty percent of the recruited subjects will receive the metal-ceramic bridges at baseline."
46081928|NCT01670227|Behavioral|PARENTCORPS|ParentCorps is a culturally-informed, universal intervention (for all children enrolled in Pre-K within an elementary school) designed to promote positive behavioral supports for children at home and in the classroom. ParentCorps includes two complementary components: 1) parent and child group intervention (13 2-hour sessions after school) for Pre-K students and their families; 2) professional development and individual consultation for early childhood teachers.
46081929|NCT01552434|Biological|Bevacizumab|Given IV
45829827|NCT01808118|Biological|adalimumab|40 mg every other week
46081930|NCT01552434|Biological|Cetuximab|Given IV
45829828|NCT01808118|Biological|Placebo|every other week
45829829|NCT01807650|Drug|Oleogel-S10, non-adhesive wound dressing|1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
45829830|NCT01807650|Device|Non-adhesive wound dressing only|Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
45829831|NCT01782690|Drug|erlotinib|Study participants will receive erlotinib according to Summary of Product Characteristics (SmPC)
46081931|NCT01552434|Other|Laboratory Biomarker Analysis|Optional correlative studies
46081932|NCT01552434|Other|Pharmacological Study|Optional correlative studies
46081933|NCT01552434|Drug|Temsirolimus|Given IV
46081934|NCT01552434|Drug|Valproic Acid|Given PO
46081935|NCT01534819|Device|EndoAnchor™|Use of the EndoAnchor™ in conjunction with endograft
46081936|NCT01534819|Procedure|endovascular treament|implantation of a device inserted through an artery
46081937|NCT01482455|Other|Elevation of FFA during OGTT|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1"
46081938|NCT01482455|Other|Elevation of FFA during Clamp|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1."
46081939|NCT01468883|Procedure|M|Modified radical mastectomy
46081940|NCT01468883|Radiation|X|Excisional biopsy plus radiation
45973745|NCT04642599|Device|Bimanual motor skill learning with the REAplan® rehabilitation robot|REAplan® rehabilitation robot: training to perform complex, coordinated, bimanual movements
45973746|NCT04635111|Drug|TURALIO™|This is a non-interventional, observational study to evaluate long-term risk of hepatic failure associated with TURALIO™ (pexidartinib) treatment. No study medication will be provided to the participants.
45973747|NCT04634617|Other|Questionnaire Administration|Complete questionnaires
45973748|NCT04616781|Dietary Supplement|"Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate"|nutritional ketone ester
45973749|NCT04616781|Drug|Isocaloric dextrose placebo|Drink indistinguishable from ketone ester
45670570|NCT04868396|Procedure|Tumor biopsy|Tumor material will be derived from 'left-over' tumor tissue that is not needed for standardised diagnostics (immune histochemistry and molecular testing).
45670571|NCT05647928|Other|no intervention|no intervention
45670572|NCT02168803|Drug|Evacetrapib|Administered orally
45670573|NCT02201329|Drug|Azacitidine|Azacitidine (subcutaneous)
45670574|NCT02201329|Drug|Volasertib|Volasertib escalating doses (intravenous)
45670575|NCT01927419|Drug|Nivolumab|
45670576|NCT01927419|Drug|Ipilimumab|
45670577|NCT01927419|Drug|Placebo|Matching nivolumab
45829832|NCT01782690|Drug|gemcitabine|Study participants will receive gemcitabine according to Summary of Product Characteristics (SmPC)
45973750|NCT04616781|Other|Alcohol drinks|drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
45973751|NCT04609943|Drug|BAY1211163|Participants will receive one of the drug doses of BAY1211163 solution three times per day (TID) by inhalation for seven days.
45973752|NCT04599088|Other|Brain functional MRI with simplified urodynamics|"Structural:~MPRAGE provides a structural image, which is used for coregistration of subjects. Structural scans are then performed including Diffusion Spectrum Imaging (DSI; microstructural), and Fluid-attenuated inversion recovery (FLAIR; white matter specific) scans.~Functional:~With about 50 ml in the bladder, resting state functional BOLD measurements are made, followed by functional whole-brain images while a small amount of saline is infused and withdrawn from the bladder, in 2 blocks of 4 repetitions each. Each repetition starts with a 12-scan pause, followed by infusion (6 scans = 12 s), pause (6 scans), and withdrawal (6 scans). Each block of 4 repetitions is completed by a 6 scan pause during which scanning continues. 24 ml is infused at 120 ml/min, and slightly less is withdrawn to avoid accommodation.This is repeated on an empty and full bladder along with a resting state image."
45973753|NCT04596878|Biological|GBS-NN/NN2|GBS-NN/NN2 bound to Alhydrogel as an adjuvant.
45973754|NCT04596878|Biological|Placebo|Normal Saline 0.9%
45973755|NCT04589845|Drug|Entrectinib|Adults and pediatric participants with a BSA >/= 1.51 m2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA < 1.51 m2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m2) or 300 mg/day (BSA=0.81-1.10 m2) or 200 mg/day (BSA=0.51-0.80 m2) or 100 mg/day (BSA=0.43-0.50 m2).
46081941|NCT01421524|Drug|CC-122|CC-122 dose in both arms will increase by 1 mg increments starting with 3 mg 5/7 days using the 3+3 design in dose escalation phase. A dose-level -1, with a starting dose of 2mg, may also be evaluated if the opening dose level is not tolerated. At all dose levels in MM-2b arm, DEX will be combined with CC-122 at a starting dose dependent on the subject's age: for subjects who are ≤ 75 years of age, DEX 40 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle and for subjects who are > 75 years of age, DEX 20 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle. Approximately 33 subjects will be enrolled in the dose escalation phase (15 in each treatment arm). An additional intermittent schedule of 21/28 days may be evaluated per Safety Review Committee (SRC) decision. Following dose escalation, one or two arms will be expanded at or below the MTD in up to 28 subjects (14 subjects in each arm).
46081942|NCT01421524|Drug|CC-122|One or more intermittent schedules of CC-122 either given 5 continuous days out of 7 per week (5/7 days) or 21 continuous days out of 28 days per cycle (21/28 days). Following dose escalation, one or more of these intermittent schedules will be evaluated at a starting dose of 4 mg.
46081943|NCT01421524|Drug|CC-122|Dose escalation on a continous schedule will be evaluated at a starting dose of 4 mg. Specifically, dose levels with 1 mg increments (eg 4mg, 5mg, 6mg etc.) will be evaluated using a 3+3 design as detailed in Part A of the protocol .
46081944|NCT01421524|Drug|CC-122|Up to 10 subjects with relapsed or refractory PCNSL will be enrolled to a PCNSL cohort to evaluate intermittent schedules of CC-122 and to further explore preliminary signals of efficacy and biomarker hypotheses.
46081945|NCT01415752|Biological|rituximab|Given IV
46081946|NCT01415752|Drug|bendamustine hydrochloride|Given IV
46081947|NCT01415752|Drug|bortezomib|Given IV or SC
46081948|NCT01415752|Drug|lenalidomide|Given PO
45670578|NCT02168491|Drug|Lixisenatide|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
45973756|NCT04589845|Drug|Entrectinib|Adults and pediatric participants with a BSA >/= 1.51 m2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA < 1.51 m2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m2) or 300 mg/day (BSA=0.81-1.10 m2) or 200 mg/day (BSA=0.51-0.80 m2) or 100 mg/day (BSA=0.43-0.50 m2).
45973757|NCT04589845|Drug|Alectinib|Alectinib will be administered orally BID (twice a day) with food at a dosage of 600 mg (four 150-mg capsules).
45973758|NCT04589845|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg for participants aged >/=18 years, and 15 mg/kg (maximum 1200 mg) for participants aged <18 years on Day 1 of each 21-day cycle.
45455975|NCT05295238|Behavioral|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
45829833|NCT01782378|Device|Real LED Treatment|"PhotoMedex Helmet: 12 Pods, 4.5 x 4.8cm (21.6 cm2); 20 diodes; 830nm; Power Output (PO) 665.3 mW; Power Density (PD)/LED 30.8 mW/cm2; CW; Time/session 28m 10s*; Dose: Energy Density 26 J/cm2.~MedX Device: 1 Cluster Head/ear, 2 inch diameter (22.48 cm2); 870nm; PO 90 mW; PD/LED 4 mW/cm2; CW; Time/session 4m; Energy Density 4 J/cm2; 2 Vielight Intranasal Devices: Red, 633nm diode; PO 6.5 mW; PD/LED 7.6 mW/cm2; CW; Time/session 25m; Energy Density 11.4 J/cm2 and NIR, 810nm diode; PO 6.5 mW; PD/LED 7.6 mW/cm2; Pulse frequency 10Hz; Duty Cycle 50%; Time/session 25m; Energy Density 11.4 J/cm2 Thor Photomedicine Helmet: 10 Pods, 6cm diameter (28.3 cm2); 35 diodes; Wavelength 850nm; PO 1050 mW; PD/LED 50 mW/cm2; CW; Time/session 23m, 24s; Energy Density 26 J/cm2 2 Placement sets: 1) midline, 6 cluster heads; 2) L&R side of head 12 cluster heads (14m, 5s, each set); 1) midline, 5 cluster heads; 2) L&R side of head 10 cluster heads (11m, 42s, each set) CW, Continuous Wave"
45455976|NCT05285969|Behavioral|Motivational interview|The new CR program with MI will be structured in 4 sessions and an optional fifth during the six months after discharge. The methodology of the MI sessions will follow the four phases logical sequence of MI proposed by Rollnick and Millner. 1) engage in a collaborative relationship, 2) focus on a particular change, 3) evoke intrinsic motivations for change, and 4) plan an immediate step for change
45670579|NCT02168491|Drug|Insulin glargine|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
45829834|NCT01782378|Device|Sham LED Treatment|Intervention for Real and Sham are Identical, but sham has power output of 0, no photons emitted.
45829835|NCT01766310|Drug|Folic Acid|yellow tablet contained 5mg of folic acid, manufactured from the Government Pharmaceutical Organization, Ministry of Public Health, Thailand
45829836|NCT01766310|Drug|placebo|sugar tablet manufactured to mimic folic acid tablet
45829837|NCT01765920|Drug|Ergoferon|5 ml 3 times a day
45829838|NCT01765920|Drug|Placebo|5 ml 3 times a day
45829839|NCT01782222|Drug|Rotigotine|"Rotigotine, transdermal patches:~10 cm^2 (2 mg / 24 hours); 20 cm^2 (4 mg / 24 hours); 30 cm^2 (6 mg / 24 hours); 40 cm^2 (8 mg / 24 hours)~The maximum Rotigotine dose allowed is 8 mg / 24 hours or 16 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours or 8 mg / 24 hours for those with early Parkinson's Disease Duration: up to 21 weeks (including de-escalation)"
45829840|NCT01782222|Other|Placebo|"Placebo, matching transdermal patches~Duration: up to 21 weeks (including de-escalation)"
45973759|NCT04589845|Drug|Ipatasertib|For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants < 35 kg, 300 mg for participants >/= 35 and < 45 kg, 400 mg for those >/= 45 kg orally QD, beginning of Cycle 1, on Days 1-21 of each 28-day cycle until the participant experiences disease progression, intolerable toxicity, or withdraws consent.
45973760|NCT04589845|Drug|Trastuzumab emtansine|Trastuzumab emtansine will be administered at 3.6 mg/kg by IV infusion every 21 days until disease progression or unacceptable toxicity. The dosage and administration method also applies for pediatric participants 12-17 years of age.
45973761|NCT04589845|Drug|Idasanutlin|"Idasanutlin will be administered at 250 mg QD (daily) PO for Days 1-5 of each 28-day cycle. Idasanutlin may be given without regard to meals and water can be given as often as necessary or desired. The daily doses should be administered 10-14 hours apart.~Note: Cohort G has been closed for enrollment."
45973762|NCT04589845|Drug|Inavolisib|GDC-077 will be administered QD at a starting dose of 9 mg PO in repeated 28-day cycles. The dosage and administration method also applies for pediatric participants 12-17 years of age.
45973763|NCT04589845|Drug|Belvarafenib|Belvarafenib will be administered at a dose 400 mg (PO) BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.
45455977|NCT05285969|Behavioral|Active Comparator: Standard care group|All patients in the control group will receive a kit with informative material with the actions and procedures to follow (diet, physical activity, smoking cessation, and other recommendations about secondary prevention).
45455978|NCT05274412|Other|hypotension prediction index(HPI)|Implementing hypotension prediction index (HPI) in perioperative goal-directed hemodynamic therapy. Keep HPI < 85; pulse pressure variation >12%; keep cardiac index >2L/min/cm^2; keep mean arterial pressure > 65mmHg.
45973764|NCT04589845|Drug|Pralsetinib|Pralsetinib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric patients ≥ 12 and < 18 years of age. A treatment cycle consists of 4 weeks (28 days).
45973765|NCT04589845|Drug|GDC-6036|GDC-6036 will be self-administered by patients orally at home (except on clinic days) on a continuous daily dosing regimen for both adult and pediatric patients. A treatment cycle consists of 3 weeks (21 days).
45973766|NCT04589845|Drug|Camonsertib|Camonsertib will be self-administered by patients orally at home (except on clinic days). A treatment cycle consists of 3 weeks and will be given on days 1-3 and days 8-10 of every 21-day cycle.
45973767|NCT04582266|Drug|Remdesivir|RDV was not provided as part of the study. Participants were administered RDV intravenously once daily for up to 10 days per clinical care.
45670580|NCT04766749|Other|RIPC|RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times
45670581|NCT02225743|Other|Observation Of Temperature|Participants temperature will be recorded perioperatively.
45829841|NCT04414098|Drug|INC424 / Ruxolitinib|"Ruxolitinib 5 mg orally every 12 hours during 14 days.~Total Follow-up time will be of 45 days.~The reduction of ruxolitinib dose will be considered in cases of drug-related cytopenias.~During hospitalization, clinical and laboratory evolution parameters will be recorded daily in the medical history of the patient and in the data collection table of the study. Upon patient's discharge, a follow-up will be conducted until day +45~During hospitalization, adverse events will be monitored daily by means of clinical assessment and laboratory data.~After discharge, monitoring of adverse events will continue during the outpatient follow-up.~Pro-inflammatory parameters will be assessed at baseline, after one week (day +7) and at the end of treatment (day +14)~Ruxolitinib will be associated to the standard of care for COVID-19 of each center.~In case of an adverse effect or a need to discontinue the treatment, ruxolitinib should be suspended."
45973768|NCT04577755|Drug|Pomalidomide|Given PO
45973769|NCT04577352|Drug|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
45973770|NCT04577352|Drug|Placebo|Placebo will be administered per schedule specified in the arm.
45829842|NCT01781832|Device|ARFI-Derived Shear Wave Velocities|An ultrasound based scan uses ARFI, an acoustic radiation force impulse to estimate shear wave velocities during scanning of the urinary bladder. The research ultrasound scan lasts about 10 to 15 minutes.
45829843|NCT01807182|Biological|Aldesleukin|Given IV
45973771|NCT04535648|Other|Non-invasive detection method: CRISPR techonology|This study was a laboratory diagnostic study without any intervention.
45973772|NCT04533022|Drug|C21|C21 b.i.d.
45973773|NCT04528134|Device|Extended Contact RMGI (Resin-modified Glass Ionomer) Varnish|This is a light-cured, durable coating that forms an immediate layer of protection that releases fluoride, calcium and phosphate and can be recharged with fluoride by using fluoride-containing products over the 6-month life of the product.
45973774|NCT04528134|Device|5% Sodium Fluoride Varnish|This is a 5% Sodium Fluoride varnish that hardens on the teeth upon contact with saliva.
45973775|NCT04521920|Drug|Suboxone|Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
45973776|NCT04521920|Drug|PrEP|Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
45973777|NCT04521894|Device|Positron emission tomography/computerized tomography (PET/CT)|"Genetic factors and age:~Epidemiological studies have shown that if an immediate family member (brother or father) suffers from prostate cancer, the risk of prostate cancer will be more than doubled. Age is a relatively strong risk factor for PCa.~Prostatitis: Prostatitis is related to PCa. Cancer is usually found in the tissues where inflammation is found.~Obesity: Research has found that obese patients have a low grade of PCa, but their risk of developing aggressive cancer is higher.~Infection:~Exercise: Most studies have found that exercise does not reduce the risk of prostate cancer, but some studies have shown that.~Daily diet: The corrective mechanism of diet in PCa is not very clear.~Drinking history:"
45973778|NCT04496739|Behavioral|Cancer Educational Materials|Receive educational materials about breast cancer risk and chemoprevention via RealRisk
45973779|NCT04496739|Other|Decision Aid|Given patient-centered decision support via an action plan
45973780|NCT04496739|Other|Decision Aid|Given decision support and action plans based on patient's interactions with RealRisks via the BNAV support tool
45829844|NCT01807182|Drug|Cyclophosphamide|Given IV
45973781|NCT04496739|Other|Interview|Participate in audio-recorded interview via telephone or video conference
45829845|NCT01807182|Drug|Fludarabine Phosphate|Given IV
45829846|NCT01807182|Other|Laboratory Biomarker Analysis|Correlative studies
46081949|NCT01368055|Radiation|70 Gy/CGE|Low Risk
45670582|NCT01721746|Biological|BMS-936558|
45670583|NCT01721746|Drug|Dacarbazine|
45973782|NCT04496739|Other|Questionnaire Administration|Ancillary studies
45973783|NCT04491136|Drug|ACEI/ARB|initative ACE/ARB drug for 6 months in this study
45973784|NCT04491136|Drug|ARNI|initative ARNI drug for next 6 months in this study
46081950|NCT01368055|Radiation|72.5 Gy/CGE|Intermediate Risk
46081951|NCT01237093|Other|1. Meat, no fish or soda|weight maintaining diet with meat but no fish or soda
46081952|NCT01237093|Other|2. Meat and soda, no fish|weight maintaining diet with meat and soda but no fish
46081953|NCT01237093|Other|3. Meat and fish, no soda|weight maintaining diet with meat and fish but no soda
45670584|NCT01721746|Drug|Carboplatin|
45670585|NCT01721746|Drug|Paclitaxel|
45670586|NCT02225665|Genetic|SB-728mR-T|-SB-728mR-T infusions of 2 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
45670587|NCT02225665|Genetic|SB-728mR-T|- SB-728mR-T infusions of 3 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
45670588|NCT02225665|Drug|Cyclophosphamide|- IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion
45670589|NCT01721200|Other|Decision Support Tool|Educational decision support tool for patients with rheumatoid arthritis
45670590|NCT01721200|Other|Usual Care|Subjects randomized to the Usual Care Group will receive their biologic drug teaching from the rheumatologist as part of their routine care.
45973785|NCT04482621|Drug|Decitabine|"Study duration is 6 weeks after the last dose of study drug. Number of study visits is dependent on Length of hospitalization of study participant. Study visits are scheduled on days 0-7, 11, 15, 29, and may occur via telemedicine or inpatient assessment or outpatient assessment in COVID recovered participants.~Decitabine will be administered via Intravenous Administration 10/mg/m^2/day Dosage: 10mg/m^2/day IV day x 5 days (1 cycle only)"
45829847|NCT01807182|Biological|Therapeutic Tumor Infiltrating Lymphocytes|Undergo TIL infusion
45973786|NCT04482621|Other|Placebo Saline|Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)
45973787|NCT04475510|Other|Antiplatelet treatment discontinuation|All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.
45973788|NCT04459338|Biological|Exendin-9,39|Exendin-9,39 is a competitive antagonist of GLP-1 actions at the GLP-1 receptor
45973789|NCT04459338|Other|Saline|Placebo comparator
45973790|NCT04457687|Drug|Lorcaserin|Lorcaserin 10 milligram (mg) tablets orally.
45973791|NCT04455841|Drug|INCB000928|INCB000928 Dose Escalation
45973792|NCT04455841|Drug|ruxolitinib|INCB000928 +ruxolitinib Dose Expansion
45973793|NCT04452877|Drug|Dabrafenib|Dabrafenib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Dabrafenib will be administered orally twice daily (150 mg BID) for Days 1-21 of a 21-day cycle.
45973794|NCT04452877|Drug|Trametinib|Trametinib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Trametinib will be administered orally once daily (2 mg QD) for Days 1-21 of a 21-day cycle
45973795|NCT04435756|Other|Biomarker Analysis|Correlative study
45973796|NCT04435756|Procedure|Blood Product Collection|Undergo collection of blood
45973797|NCT04431479|Procedure|Biospecimen Collection|Undergo collection of blood sample
45670591|NCT02225587|Biological|Prevnar 13™|Pneumococcal vaccine containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Injections are to be administered into the deltoid muscle of the upper arm.
45670592|NCT02225587|Biological|Pneumovax™ 23|Pneumococcal vaccine containing serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Injections are to be administered into the deltoid muscle of the upper arm.
45670593|NCT02225587|Biological|Placebo|Injections are to be administered into the deltoid muscle of the upper arm.
45829848|NCT04584762|Device|Automated Variable Pressure Insufflation|Acute migraine treatment
45829849|NCT01806714|Other|Text-based reminder for recommended HPV vaccine or WCC|Patients due for a well visit or HPV vaccine received a text reminder
45829850|NCT01806714|Other|Non-specific text-based reminder (general health tip)|Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
45829851|NCT01765764|Drug|bimatoprost solution|Bimatoprost solution once a day or twice a day applied to each eyebrow for 7 months.
45829852|NCT01765764|Drug|Vehicle to bimatoprost solution|Vehicle to bimatoprost solution once or twice a day applied to each eyebrow for 7 months.
45829853|NCT01806168|Device|rTMS|Magstim Super Rapid-2
45829854|NCT01804842|Drug|Met DR|metformin delayed-release tablets
45829855|NCT01781286|Behavioral|High Protein|250 kcal; 40% Protein; 40% Carbohydrate; 20% Fat
45829856|NCT01781286|Behavioral|Low Protein|5% Protein; 50% Carbohydrates; 45% Fat
45973798|NCT04431479|Other|Medical Chart Review|Review of medical chart
45973799|NCT04431479|Other|Quality-of-Life Assessment|Ancillary studies
46081954|NCT01237093|Other|4. Meat and fish and soda|weight maintaining diet with meat, fish and soda
46081955|NCT01237093|Other|5. Fish, no meat or soda|weight maintaining diet with fish but no meat or soda
46081956|NCT01237093|Other|6. Fish and soda, no meat|weight maintaining diet with fish and soda but no meat
46081957|NCT01237093|Other|7. No meat, fish or soda|weight maintaining diet with no meat, no fish, and no soda (vegetarian)
46081958|NCT01237093|Other|8. Soda, no meat or fish|weight maintaining diet with soda but no meat or fish (vegetarian + soda)
46081959|NCT01231100|Other|HCUE-guided care|Care directed by hand-carried ultrasound echocardiography
46081960|NCT01230346|Other|questionnaire administration|Ancillary studies
46081961|NCT01230346|Other|survey administration|Ancillary studies
46081962|NCT01230346|Other|counseling intervention|Telephone intervention
46081963|NCT01230346|Other|educational intervention|Telephone intervention
45670594|NCT02296424|Drug|ACZ885 150 mg (Canakinumab)|Active canakinumab in individual 2 mL glass vials, each containing 150 mg canakinumab liquid in vial.
45670595|NCT02296190|Drug|Etripamil|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
45670596|NCT02296190|Drug|Placebo|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
45670597|NCT04875026|Drug|5-fluorouracil 4% (Tolak)|Application of Tolak once daily in the evening for 4 weeks
45670598|NCT04875026|Device|Dexeryl|Application of Dexeryl once daily in the morning for 8 weeks
45670599|NCT02296112|Drug|trametinib|Given PO
45670600|NCT02296112|Other|laboratory biomarker analysis|Correlative studies
45670601|NCT02296112|Other|pharmacological study|Correlative studies
45829857|NCT01780974|Drug|Lipoic Acid plus Omega-3 Fatty Acids|alpha lipoic acid (racemic) and fish oil concentrate
45829858|NCT01780974|Drug|Placebo|placebo capsules
45829859|NCT01780662|Drug|Brentuximab Vedotin|Given IV
45829860|NCT01780662|Drug|Gemcitabine Hydrochloride|Given IV
45829861|NCT01780584|Drug|Oral T3 Low dose|Comparison of different dosages of drug. Low dose group oral T3 is 0.5 mcg/kg q24h
45829862|NCT01780584|Drug|Placebo|Comparison of different dosages of drug. In low dose group, placebo was given alternately with oral T3 every 12h with a total 3 doses for placebo and 3 doses for oral T3
45829863|NCT01780584|Drug|Oral T3 high dose|Comparison of different dosages of drugs. Oral T3 high dose is 0.5 mcg/kg q12h
45670602|NCT02295644|Device|Ultrasound Sonicator 740|Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1MHz, 5 minutes
45829864|NCT01780506|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
45829865|NCT01780506|Drug|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
46081964|NCT01224704|Other|Hypertonic saline infusion|Three percent saline (0.1ml/kg of the lean mass/min) will be infused for 120 minutes.
46081965|NCT01224704|Other|Water deprivation|24 hour water deprivation
46081966|NCT01212029|Behavioral|Behavioral measures|Behavioral tasks/ questionnaires
45670603|NCT05647772|Behavioral|UseIt! App|The UseIt! app is a parenting app with evidence-based parent management content. The app runs on both Android and iOS devices. It includes a digital library of parent management skills, a trouble-shooting guide, a behavior diary, a point counter, and a skills-alarm.
45670604|NCT05647772|Behavioral|Coach|The coach is be a bachelor's level paraprofessional with a degree in psychology or an allied discipline (e.g., social work) who provides support to parents. The coach will provide motivation and accountability but will not provide therapeutic/clinical support. The primary goal of the coach is to increase participant engagement with the UseIt! mHealth system.
45829866|NCT01780506|Drug|E/C/F/TDF Placebo|Tablet administered orally once daily
45829867|NCT01780506|Drug|E/C/F/TAF Placebo|Tablet administered orally once daily
46081967|NCT01212029|Device|fNIRS Devices &amp; Application|Device 1- fNIRSoft and Device 2 - NIRScout
46081968|NCT01212029|Other|Physiological measures|A set of tasks.
46081969|NCT01174108|Device|Miltenyi CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations.
46081970|NCT01174108|Other|Donor derived G-CSF mobilized PBC|Cell Therapy
46081971|NCT01164228|Drug|Gemcitabine|Given IV
46081972|NCT01164228|Drug|Sunitinib|Given PO
46081973|NCT01087346|Behavioral|Reading Information|Reading information about risk factors for obesity among children
46081974|NCT01036581|Device|MagPro X100 Magnetic Stimulator|Concurrent TMS-MRI acquisition allows us to investigate the acute effects of induced brain activity on BOLD signal and evaluate interference of the TMS pulse with the BOLD signal measurement.
46081975|NCT01036581|Device|Transcranial Rotating Magnetic Stimulator|Participants will undergo transcranial rapid rotating permanent magnetic stimulation (TRPMS), with the aim of evaluating the prolonged effect of TRPMS on motor cortex excitability. In another experiment, participants will undergo TRPMS with the aim of evaluating cortical excitability changes with TRPMS. These experiments will help interpret subsequent experiments investigating the effect of TRPMS on BOLD signal.
46081976|NCT01036581|Device|Magnetom Prisma Fit 3T Scanner|Type: MRI Name: Magnetom Prisma Fit 3T Scanner (Siemens) Description: Functional and structural magnetic resonance imaging techniques are used for noninvasive mapping of brain physiology and pathology and to develop advanced magnetic resonance imaging and spectroscopy (MRI and MRS) techniques for neuroimaging studies related to addiction.
46081977|NCT00950846|Drug|Busulfan|"Day -9, -8, -7 and -6~Patients less than or equal to 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients >12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses."
46081978|NCT00950846|Drug|Cytoxan|(50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 2 hours (can be given over 1 to 4 hours as determined by the treating physician). The total dose to be given over 4 days is 200 mg/kg.
46081979|NCT00950846|Drug|Fludarabine|40 mg/m2/day IV over 1 hour for patients greater than 10 kg, or 1.3 mg/kg/day for patients less than or equal to 10 kg.
46081980|NCT00950846|Procedure|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on Day 0.
46081981|NCT00924027|Radiation|HDR Brachytherapy|Brachytherapy, the placement of a radioactive source close to a tumor, is a well-established part of the treatment of many malignancies, both for palliative and definitive applications. High dose brachytherapy is useful in many malignancies in order to deliver a high dose of radiation therapy to tumor in a conformal fashion with a rapid dose fall-off with the objective of sparing normal surrounding tissue.
46081982|NCT00923013|Drug|Cladribine|Cladribine 0.15 mg/Kg/day by 2-hour i.v. infusion days 1-5. The infusion time may be changed to 1 hour at the discretion of the PI.
46081983|NCT00923013|Drug|Rituximab|Rituximab 375 mg/m2 i.v. infusion every week x8, begin day 1 in half of randomized patients and in all HCLv patients, and then again in all patients at least 6 months later when HCL is detected by blood FACS.
46081984|NCT00804154|Drug|Intrathecal Resiniferatoxin|phase I, single-site, non-randomized, open-label, dose-escalation study to determine the safety and efficacy of IT RTX in subjects with severe refractory pain due to advanced malignancy
45670605|NCT05647772|Behavioral|SmilingMind App|The control app is a mindfulness app called SmilingMind. It is available for both Android and iOS devices.
45670606|NCT02269670|Drug|everolimus|Given PO
46081985|NCT00774254|Behavioral|A|Intervention
45670607|NCT02269670|Drug|anastrozole|Given PO
46081986|NCT00774254|Behavioral|B|Intervention
46081987|NCT00641030|Drug|clofarabine|Administered at the appropriate dose level(dose level one = 30 mg/m2, dose level two and three = 40 mg/m2)on days -9 to day -5 from transplant
46081988|NCT00641030|Drug|melphalan|Administered at the appropriate dose level (dose level one and two = 100 mg/m2, dose level three = 140 mg/m2) on day -4 from transplant
45829868|NCT01779648|Device|DVT-3000|
45829869|NCT01779648|Device|SCD Express|
45829870|NCT01762800|Drug|fluticasone propionate/salmeterol 50/250mcg|Active, 50/250mcg, Twice daily (morning and evening)
45829871|NCT01762800|Drug|fluticasone propionate/salmeterol placebo|Placebo, Twice daily (morning and evening)
45829872|NCT01762800|Drug|tiotropium bromide 18mcg|Active, 18mcg, Once daily(morning)
45829873|NCT01762800|Drug|tiotropium bromide placebo|Placebo, Once daily(morning)
45829874|NCT01762800|Drug|fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg|Active. The randomized treatment may be switched to TRIPLE therapy when COPD symptoms are uncontrolled or the subject is not satisfied with the randomized treatment at each scheduled or unscheduled visit.
45973800|NCT04431479|Other|Questionnaire Administration|Complete questionnaire
45973801|NCT04405778|Biological|TAK-102|TAK-102 intravenous infusion
45973802|NCT05050916|Dietary Supplement|Vitamin D|"This is a Phase II randomized, dose-ranging clinical trial including 1) a within-woman comparison of hormones pre-and post-supplementation and 2) a comparison across women on a Vitamin D and a placebo. After recruitment, there will be two phases: Phase 1 will follow all women for one menstrual cycle prior to supplementation; blood will be assayed for 25OHD. Phase 2 includes only: 1) women with less than 20 ng/ml 25OHD (deficient) OR 2) a sample of women with >20 ng/ml 25OHD (sufficient) as the placebo group. During Phase 2, deficient women will be assigned to receive a blinded dose of 50,000 IU of vitamin D supplementation per week and followed for three more menstrual cycles. Hormone levels will be compared between the pre-and post-supplementation cycles as the primary analysis. The primary aim will test: if mid-luteal progesterone, rate of estrogen rise and pre-ovulatory LH are higher in vitamin D supplemented cycles."
45973803|NCT04613596|Drug|MRTX849 Monotherapy|MRTX849 Inhibitor will be administered orally twice daily in a continuous regimen (Cohort 1b).
45973804|NCT04613596|Drug|MRTX849 in Combination with Pembrolizumab|"MRTX849 Inhibitor will be administered orally twice daily in a continuous regimen.~Pembrolizumab is administered as an intravenous infusion at a 200 mg dose once every 3 weeks then after 9 months patients may switch to a 400 mg dose administered every 6 weeks. Pembrolizumab treatment may continue up to 24 months (Cohort 2)."
45973805|NCT04613596|Drug|MRTX849 in Combination with Pembrolizumab|MRTX849 Inhibitor will be administered orally twice daily in a continuous regimen. Pembrolizumab is administered as an intravenous infusion at a 200 mg dose once every 3 weeks then after 9 months patients may switch to a 400 mg dose administered every 6 weeks. Pembrolizumab treatment may continue up to 24 months (Cohort 3).
45973806|NCT04613596|Drug|Phase 3 comparator arm|Pembrolizumab + platinum (cisplatin 75 mg/m2 OR carboplatin area under the curve (AUC) 5 mg/mL/min on Day 1 every 3 weeks for 4-6 cycles) + pemetrexed 500 mg/m2 (with vitamin supplementation) every 3 weeks for 4-6 cycles, followed by pembrolizumab 200 mg plus pemetrexed 500 mg/m2 every 3 weeks until progression. After 9 months, patients may switch to a pembrolizumab 400 mg dose administered every 6 weeks.
46081989|NCT00641030|Genetic|gene expression analysis|Peripheral blood draw on day -9 and day -4 prior to transplant
46081990|NCT00641030|Genetic|reverse transcriptase-polymerase chain reaction|Peripheral blood draw on day -9 and day -4 prior to transplant
46081991|NCT00641030|Other|flow cytometry|Bone marrow aspirate and biopsy to confirm diagnosis prior to transplant, day -9 pre-transplant, day 30 post-transplant, day 100 post-transplant, 6 months post-transplant, one year post-transplant, then yearly through year 5 post-transplant
46081992|NCT00641030|Other|laboratory biomarker analysis|Peripheral blood draw day -9 or earlier pre-transplant, day 14 post-transplant, day 30 post-transplant, day 60 post-transplant, day 100 post-transplant, 6 months and one year post-transplant.
46081993|NCT00641030|Procedure|allogeneic hematopoietic stem cell transplantation|Infusion of allogeneic hematopoietic stem cells on day 0 of transplant
46081994|NCT00554515|Drug|HD IL2|
45670608|NCT02269670|Drug|letrozole|Given PO
46081995|NCT00490581|Other|case management and supportive housing|patients randomized to the study group are offerred respite care/interim housing and case management upon discharge from enrolling hospitalization. They are also offerred stable housing within 90 days of enrolling hospital discharge, with case management at all 3 stages - hospital, respite care/interim housing, and stable housing.
46081996|NCT00329043|Drug|LHRH Agonist|Intramuscular injection either monthly for 3 months or in a single 3-month dose.
46081997|NCT00329043|Drug|Sunitinib Malate|25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles.
46081998|NCT00329043|Procedure|Radical Prostatectomy|Radical prostatectomy after completion of Sunitinib and LHRH agonist.
46081999|NCT00209586|Drug|fospropofol disodium|
45670609|NCT02269670|Drug|tamoxifen citrate|Given PO
45670610|NCT02269670|Drug|fulvestrant|Given IM or PO
45829875|NCT01597596|Biological|alglucosidase alfa|Intravenous (IV) infusion of alglucosidase alfa (4000 L material) 20 mg/kg every other week (QOW)
45829876|NCT01597596|Biological|alglucosidase alfa|IV infusion of alglucosidase alfa (160 L material) 20 mg/kg QOW.
45829877|NCT01778556|Biological|Metreleptin|Recombinant analog of the human hormone, leptin
46082000|NCT00160771|Behavioral|Joint Motion Analysis|Joint motion will be recorded for analysis.
46082001|NCT00107289|Radiation|iobenguane I 131|"Patients receive a single dose of iodine I 131 metaiodobenzylguanidine (^131I-MIBG) IV over 30 minutes to 4 hours on day 0. Patients undergo radiation dosimetry following the first dose of ^131I-MIBG to determine if a second dose can be safely administered. Some patients may receive a second dose of iodine I 131 metaiodobenzylguanidine (^131I-MIBG) 6-8 weeks after the first dose if response is achieved and patients do not experience major toxicity. After blood radioactivity has fallen below 1 μCi/mL, patients may undergo autologous stem cell transplantation.~After completion of study treatment, patients are followed at 4-6 weeks after ^131I-MIBG administration and then every 3 months for up to 1 year."
46082002|NCT00102544|Device|EM Tracking|Utilizing electromagnetic tracking technology as a fusion and navigation tool for minimally invasive interventional procedures.
46082003|NCT00090974|Procedure|quality-of-life assessment|
45670611|NCT02269670|Drug|megestrol acetate|Given PO
45670612|NCT02225353|Drug|Progesterone Cervical Pessary 6.3 g|Progesterone Cervical Pessary low dose
45670613|NCT02225353|Drug|Progesterone 200 mg vaginal capsules|Progesterone 200 mg vaginal capsules daily
45670614|NCT02225353|Drug|Progesterone Cervical Pessary 7.7 g|Progesterone Cervical Pessary high dose
45670615|NCT01641926|Biological|PEG-Intron™|PEG-Intron subcutaneously (SC) once weekly for a total of 48 weeks
45670616|NCT01641926|Biological|PEGASYS™|PEGASYS subcutaneously (SC) once weekly for a total of 48 weeks
45670617|NCT02295020|Drug|Standard treatment only|Standard treatment such as NSAIDs and injections
45670618|NCT02295020|Device|Standard treatment plus Bioskin Ten-7 knee brace|Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace.
45670619|NCT02200939|Device|Bioinductive implant|
45829878|NCT04562532|Device|Microport Firehawk stent|MicroPort Firehawk biodegradable polymer rapamycin target eluting stent
45829879|NCT04562532|Device|2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)|"Everolimus eluting stents (Xience family - Abbott Vascular, Promus family- Boston Scientific, Synergy - Boston Scientific)~Zotarolimus eluting stents (Resolute/Onyx family and Endeavor- Medtronic)~Sirolimus eluting stents (Orsiro- Biotronik)"
45455979|NCT05274412|Other|ordinary goal-directed hemodynamic therapy|Keep pulse pressure variation >12%; keep cardiac index >2L/min/cm^2; keep mean arterial pressure > 65mmHg.
45455980|NCT05273970|Other|Behavioral testing under intracranial monitoring|After standard of care surgery to implant the electrodes is complete and patients have have recovered satisfactorily from the procedure, they will be asked to perform some computer based tasks to answer questions about pretend financial decisions, pay attention to certain images, watch videos, look at images, listen to sounds, or move a joystick.
45670620|NCT02200939|Device|Surgical repair|Surgical repair with commercially-available sutures/suture anchors.
45829880|NCT04562376|Other|High-intensity resistance training|The program consists of high-intensity resistance training for 60 minutes twice a week (group A) during 12 weeks
45973807|NCT04404660|Biological|AUTO1|Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with a total target dose of 410E+6 of CD19-positive CAR T cells as a split dose on Day 1 and on Day 10 (±2 days).
45973808|NCT04402632|Procedure|Surgical Management|SDH Evacuation (Control)
45973809|NCT04402632|Device|Surgical Management + Treatment|SDH Evacuation + Onyx™ LES Embolization
45973810|NCT04402632|Other|No Treatment|Observation Only (Control)
46082004|NCT00082797|Drug|leucovorin calcium|
45455981|NCT05273216|Diagnostic Test|Transcranial Duplex Sonography|Immediately after mechanical thrombectomy, patients will be investigated with bedside neurosonography (including TCD) at the stroke unit or neurointensive care unit. Apart from routine assessment of brain-supplying vessels, experienced sonographers will especially focus on intracranial blood flow velocities and determine the MCA mean blood flow velocity index (recanalized divided by contralateral artery). To assess potential dynamic blood flow changes, these investigations will be repeated at 24-48 hours after thrombectomy and at day 7 when we expect a (more) stable stroke phase. During these neurosonographic assessments, other important and potentially influential (hemodynamic) parameters such as blood pressure, heart rate and use of vasoactive medications will be documented. Assessment of intracranial blood flow will be standardized to dedicated measuring points.
45670621|NCT05152381|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
45829881|NCT04562376|Other|Low frequency of high-intensity resistance training|The program consists of high-intensity resistance training for 60 minutes once a week (group B) during 12 week
45829882|NCT04562298|Biological|LCAR-M23 cells|Prior to infusion of LCAR-M23, subjects will receive a premedication regimen (intravenous infusion of cyclophosphamide 300 mg/m2 and fludarabine 30 mg/m2 once daily for 3 days; fludarabine dose reduction to 25 mg/m2 and cyclophosphamide to 250 mg/m2 are allowed if the subject' s creatinine clearance is 50-70 mL/min/1.73 m2). A single dose, single Infusion of LCAR-M23 is scheduled 5 to 7 days after the initiation of the premedication regimen.
45670622|NCT02294786|Drug|Lapatinib|Lapatinib was supplied as 250mg tablets that are oval, biconvex, and orange film-coated with one side plain and the opposite side debossed, or as 250mg tablets that are oval, biconvex, and yellow film-coated with one side plain and the opposite side debossed. Each tablet contained 405mg of Lapatinib ditosylate monohydrate, equivalent to 250mg Lapatinib free base
45670623|NCT02294786|Drug|Capecitabine|Capecitabine (Xeloda™) was supplied as a biconvex, oblong, light peach or peach colored film-coated tablet for oral administration. Each light peach colored tablet contained 150mg Capecitabine and each peach colored tablet contained 500mg Capecitabine. Generic versions of capecitabine may have been used within the study if Xeloda cannot be provided. XELODA™ is a trademark of Hoffmann-La Roche AG.
45829883|NCT04562064|Device|corneal tomography scans|corneal tomography scans of the two corneal surfaces were obtained preoperatively and postoperatively with a rotating Scheimpflug imaging system
45829884|NCT01761162|Device|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
45829885|NCT01761162|Other|Magnetic Resonance Imaging (MRI) scan|MRI scan of head and lower back.
45829886|NCT01778010|Drug|Modafinil 0 mg|Modafinil (0 mg/day)
45829887|NCT01778010|Drug|Modafinil 200 mg|Modafinil (200 mg/day)
45829888|NCT01778010|Drug|Modafinil 400 mg|Modafinil (400 mg/day)
45973811|NCT04402632|Device|Treatment|Onyx™ LES Embolization
45973812|NCT04381650|Drug|TAK-981|TAK-981 IV infusion.
45973813|NCT04381650|Drug|Pembrolizumab|Pembrolizumab IV infusion.
45973814|NCT04381143|Drug|Aspirin 100 mg Oral Tablet|Aspirin 100 mg tablets daily
45973815|NCT04373343|Behavioral|16-week Food Addiction Clinical Treatment (FACT) Program|16-week Food Addiction Clinical Treatment (FACT) Program, first session will be 120 mins, all subsequent sessions will be 90 mins. Treatment will be led, at a minimum, by a full licensed psychologist
45973816|NCT04370093|Drug|Pioglitazone 45 mg|45 mg/day- one pioglitazone tablet once daily throughout the 24 weeks of the study
46082005|NCT00082797|Drug|methotrexate|
46082006|NCT00060398|Biological|epoetin alfa|
46082007|NCT00060398|Drug|dexamethasone|
46082008|NCT00054561|Biological|recombinant interferon alfa|
46082009|NCT00054561|Dietary Supplement|vitamin E|
46082010|NCT00054561|Drug|isotretinoin|
46082011|NCT00054561|Procedure|adjuvant therapy|
46082012|NCT00049517|Biological|sargramostim|Given IV or as an injection
46082013|NCT00049517|Drug|busulfan|Given IV
46082014|NCT00049517|Drug|cyclophosphamide|Given IV
46082015|NCT00049517|Drug|cytarabine|Given as a continuous infusion
45829889|NCT01778010|Drug|Cocaine 0 mg|Cocaine (0 mg/day)
45829890|NCT01778010|Drug|Cocaine 12 mg|Cocaine (12 mg/day)
45829891|NCT01778010|Drug|Cocaine 25 mg|Cocaine (25 mg/day)
45829892|NCT01778010|Drug|Cocaine 50 mg|Cocaine (50 mg/day)
45829893|NCT04568928|Device|OLTP/PE + FES|12 sessions OLTP/PE + FES
45829894|NCT01777854|Drug|Omeprazole|The principal investigator will be contacted and will work with the research pharmacist to obtain the omeprazole (20 mg PO daily for patients >20kg) and placebo. The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look. The medication will be locked in the designated medication cabinet at each office. It will be prepackaged for a 28 day course. The patient will start the treatment 4 weeks prior to tonsillectomy and stop the day before surgery. The medication will be given to the patient once the consent and assent are signed. This will avoid an unnecessary office visit to improve patient compliance.
45973817|NCT04370093|Behavioral|Weight Loss|Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
45973818|NCT04370093|Other|Pioglitazone + Weight Loss|Pioglitazone + Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
45973819|NCT04340193|Drug|nivolumab|Specified dose on specified days
45973820|NCT04340193|Drug|ipilimumab|Specified dose on specified days
45973821|NCT04340193|Procedure|TACE|TACE (Trans-arterial ChemoEmbolization)
45973822|NCT04313881|Biological|Magrolimab|Administered intravenously
45973823|NCT04313881|Drug|Azacitidine|Administered either subcutaneously (SC) or intravenously (IV) according to region-specific drug labeling
45973824|NCT04313881|Biological|Placebo|Placebo to match magrolimab administered intravenously
45973825|NCT04308590|Drug|relacorilant|Relacorilant is supplied as 100 mg capsules for oral dosing.
45973826|NCT04308590|Other|Placebo|Placebo is supplied as 100 mg capsules for oral dosing.
45973827|NCT04298229|Drug|Dapagliflozin 10 MG|SGLT2 inhibitors being investigated for its diuretic and natriuretic effects on top of protocolized diuretic therapy.
45973828|NCT04298229|Other|Protocolized Diuretic Therapy|Structured usual care arm with protocolized diuretic therapy based on urine output.
45973829|NCT04298086|Other|Exercise Treatment|Exercise treatment will consist of individualized walking delivered up to 7 times weekly to achieve the patient-specific goal energy expenditure. Training sessions will be performed on a treadmill at under remote surveillance using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service.
45973830|NCT04298086|Other|Plant-Based Diet|Pre-prepared meals, including 6 dinners and 6 lunches per week, will be shipped to the partipant's home during the intervention.
45973831|NCT04298086|Other|Physical activity|Treadmills and low-calorie recipes will be provided to patients in the counseling arm.
45973832|NCT04298086|Other|Nutrition counseling|Nutrition program including regular counseling by exercise physiologists and registered dieticians (RDs).
45973833|NCT04298086|Other|Replication Exercise Test|Exercise capacity will be reassessed by a replication exercise test at week 6 in the intervention group only.
46082016|NCT00049517|Drug|gemtuzumab ozogamicin (GO)|Given IV
45455982|NCT05273216|Diagnostic Test|Brain MRI|The investigators will use magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) routinely performed on day 1 after thrombectomy to assess (1) the size and location of acute ischemic damage including (vasogenic) cerebral edema formation, (2) hemorrhagic transformation, (3) concomitant chronic ischemic and hemorrhagic brain changes, and (4) patency of intracranial vessels. Contrast-enhanced or arterial spin labeling perfusion MRI will be used to (5) measure cerebral perfusion status. Findings from perfusion MRI will be correlated with blood flow information from TCD. MRI including MRA and perfusion sequences will be interpreted centrally in Graz as successfully demonstrated in previous large multicenter stroke studies.
45670624|NCT02294786|Drug|Octreotide|Octreotide (Sandostatin LAR™) was supplied as sterile 5milliliter (mL) vials delivering 20mg Octreotide as the free peptide. When mixed with diluent (approximately 2mL or 2.5 mL) it becomes a suspension that is given as an intramuscular injection. Two 20mg intramuscular injections were given to deliver a total dose of 40mg. The Octreotide is uniformly distributed within the microspheres which are made of a biodegradable glucose star polymer, D,L-lactic and glycolic acids copolymer. Sterile mannitol was added to the microspheres to improve suspendability
45670625|NCT04880876|Drug|25mg Eluxadoline|Oral Tablets
45829895|NCT01777776|Drug|LEE011|LEE011 will be administered orally, once daily for 21 consecutive days followed by a 7-day planned break (28-day cycle).
45829896|NCT01777776|Drug|LGX818|LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).
45829897|NCT01777620|Biological|onabotulinumtoxinA|BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
45670626|NCT04880876|Drug|100mg Eluxadoline|Oral Tablets
45670627|NCT05647694|Other|V-NAV indoor navigation prototype|Users will use the V-NAV prototype as an augmentation to their indoor navigation activities.
45670628|NCT02269124|Device|Hearing aid|The subject will wear a hearing aid at all times for a 3-month period. At school, he/she will wear this hearing aid in addition to using conventional measures (FM system and preferential seating).
45829898|NCT01777620|Drug|Normal Saline|Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
45829899|NCT01777542|Drug|Recombinant Human Insulin Growth Factor 1 (rhIGF-1)|Subjects will receive twice daily subcutaneous injections of IGF-1.
45670629|NCT01927341|Drug|MEK162|Tablet for oral use, 45 mg (three 15 mg tablets), BID
45670630|NCT01927341|Drug|Panitumumab|Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)
45973834|NCT04294641|Drug|Ibrutinib|140 mg capsules for a dose of 420 mg daily for up to 12 months.
46082017|NCT00049517|Drug|Daunorubicin|Given intravenously daily for 3 days at a dose of either 45 or 90 mg/m2.
46082018|NCT00049517|Procedure|Autologous HCT|Autologous hematopoietic cell transplantation
46082019|NCT00049517|Procedure|Allogeneic HCT|Allogeneic hematopoietic cell transplantation
45829900|NCT01777542|Drug|Placebo|Subjects will receive twice daily subcutaneous injections of a saline solution (placebo).
45973835|NCT04278118|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
45973836|NCT04278118|Radiation|Photon Beam Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
45973837|NCT04278118|Radiation|Proton Beam Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
45973838|NCT04278118|Other|Quality-of-Life Assessment|Ancillary studies
45973839|NCT04278118|Other|Questionnaire Administration|Ancillary studies
45973840|NCT04273269|Genetic|LYS-GM101|LYS-GM101 is an adeno-associated viral vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene, formulated as a suspension for injection
45973841|NCT04266093|Drug|GeneTherapy|Observation/ Gene Therapy Long-term Follow-up. Subjects who have received treatment on an applicable NCI CIO gene therapy protocol.
45829901|NCT01736124|Other|computerized cognitive training|A variety of computer games tailored to address their personal cognitive deficits.
45973842|NCT04250025|Procedure|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation
45973843|NCT04241666|Diagnostic Test|renal scintigraphy|Technetium-99m-dimercaptosuccinic acid scintigraphy of both kidneys
45829902|NCT01736124|Other|control games|A variety of computer games that are engaging but not designed to enhance cognitive skills
45829903|NCT01759446|Drug|Placebo taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
45829904|NCT01759446|Drug|Generic H/A taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
45829905|NCT01759446|Drug|Vycavert taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
45973844|NCT04241666|Diagnostic Test|renal doppler sonography|doppler ultrasound of both kidneys
45973845|NCT04234646|Behavioral|Patient Navigation (PN) 2.0 Checklist|The PN 2.0 Checklist intervention is centered on a learning health system checklist that enumerates a patient's Social Determinants of Health (SDoH) related barriers and tracks completion of services to address SDoH (at community oncology and community social service settings) as well as completion of USPSTF recommended cancer-related screenings, behavioral counseling, and immunizations.
45973846|NCT04234646|Behavioral|One-on-one Patient Navigation (PN)|The one-on-one Patient Navigation will be based on a Case Management Model where PNs perform appointment scheduling and reminders; facilitate communication between patients and care teams; and identify and reduce patient barriers through education, outreach, and referrals to community, local, and state resources
45670631|NCT02294474|Drug|SAR342434|SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by subcutaneous (SC) injection, immediately (within 5 -10 minutes) before meals intake. Dose adjusted to achieve 2 hour post prandial glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
45670632|NCT02294474|Drug|Humalog|Humalog 100 U/ml (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meals intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
45670633|NCT02294474|Drug|insulin glargine HOE901|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
45973847|NCT04209660|Drug|Lenvatinib|Lenvatinib 20mg daily (two 10mg lenvatinib capsules) taken orally will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day.
45973848|NCT04209660|Drug|Pembrolizumab|Pembrolizumab (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes are acceptable on C1D1.
45973849|NCT04205955|Other|Best Practice|Receive healthy living education via phone call
45973850|NCT04205955|Dietary Supplement|Dietary Intervention|Receive diet modification coaching via phone call
45973851|NCT04205955|Other|Message|Receive motivational messages via email and/or text message
45973852|NCT04205955|Other|Quality-of-Life Assessment|Ancillary studies
45973853|NCT04205955|Other|Questionnaire Administration|Ancillary studies
45973854|NCT04205487|Behavioral|Motivational Interviewing (MI)|Two motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered via Zoom.
45973855|NCT04205487|Behavioral|Contingency Management (CM)|CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
46082020|NCT00044304|Drug|Imatinib|The dosing regimen to be used initially (400 mg po qd in adults and 260 mg/m2/day in children with food and a glass of water) is identical to that recommended by the FDA for the treatment of the chronic phase of chronic myelogenous leukemia (CML) (Prod Info Gleevec ). In patients with ANC <1500/mm3, platelet counts < 75,000mm3 or abnormal liver function tests (ALT or AST > 2.5 or bilirubin > 3 times the upper limit of normal), the starting dose will be reduced to 300 mg po qD.
45670634|NCT02168101|Drug|MLN9708|"Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive MLN9708 orally (PO) as monotherapy on Days 1, 8, and 15 of each 28-day cycle for 6 cycles. Up to 18 patients will be enrolled in a dose-escalation phase to determine the maximum tolerated dose (MTD).~Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy. Dosing will start at 2.3 mg. If acceptable tolerability is demonstrated, escalations will be made to 3 mg and to a maximum-planned dose (MPD) of 4 mg."
45670635|NCT01956123|Drug|Follitropin Delta (FE 999049)|
45670636|NCT01956123|Drug|Follitropin Alfa (GONAL-F)|
45670637|NCT02298179|Biological|RSV F subunit 45 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
45829906|NCT01759446|Drug|Generic H/A plus i taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
45829907|NCT01759446|Drug|Generic H/A plus p taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
45973856|NCT04202445|Drug|Ingenol mebutate|Topical field treatment as prescribed by dermatologist
45973857|NCT04190225|Behavioral|Digital/social media intervention|Participants will receive individual counseling, access to an individually tailored website, guided goal setting via texts, access to a study Instagram account, and a wearable tracker (Fitbit)
45973858|NCT04177433|Drug|Depo-Medrol Injectable Product|Corticosteroid
46082021|NCT00044304|Drug|Ruxolitinib|The dosing regimen to be used initially (15 mg po bid) is identical to that recommended by the FDA for the treatment of myelofibrosis with platelet counts of 100-200,000/mm3 (Prod Info ruxolitinib). In patients with platelet counts <100,000/mm3, moderate renal impairment (CrCl <60 mL/min) or abnormal liver function tests (ALT or AST > 2.5 or bilirubin > 3 times the upper limit of normal), the starting dose will be reduced to 10 mg bid. The recommended guidelines for dose adjustment during therapy and discontinuation of therapy in myelofibrosis will be followed.
45670638|NCT02298179|Biological|RSV F subunit 45 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
45670639|NCT02298179|Biological|RSV F subunit 45 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
45670640|NCT02298179|Biological|RSV F subunit 90 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
45829908|NCT01777308|Biological|Meningococcal conjugate vaccine GSK134612|Single dose to be administrated intramuscularly in the deltoid of the non-dominant arm
45829909|NCT04571736|Other|access to the internet information platform|This platform contains, among other things, an explanatory video of thyroid surgery and allows the patient to have access to information on surgical management at any time.
45973859|NCT04177433|Drug|Saline|Placebo
45973860|NCT04166643|Behavioral|WHHIP PLUS|Worksite health promotion and occupational health and safety (total worker health)
45973861|NCT04166643|Behavioral|Education only control|Education at the start of the project
45973862|NCT04166383|Biological|Vascular Biogenics (VB)-111|1E13 or 0.7E13 VP via intravenous (IV) infusion on Day 1 of cycle 1 and continue every 6 weeks
45973863|NCT04166383|Drug|Nivolumab|240 mg of nivolumab via intravenous (IV) infusion on Day 1 of each cycle starting on cycle 2 and continue every 2 weeks
45973864|NCT04150497|Biological|UCART22|Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen
45973865|NCT04150497|Biological|CLLS52|A monoclonal antibody that recognizes a CD52 antigen
45973866|NCT04142437|Drug|larotrectinib(Vitrakvi, BAY2757556)|In the study, patients treated under local standard of care clinical practice; all decisions in terms of diagnostic procedures, treatments, management of the disease, and resource utilization are fully dependent on mutual agreement between the patient and the attending physician, without interference by the study initiator or study protocol
45973867|NCT04141748|Device|Symphonie Aqua SystemTM|a water filled cylinder that can be pressurized around the residual limb to support body weight
45973868|NCT04141748|Procedure|Hand Casting|plaster of Paris or fiberglass bandages are wrapped around the residual limb
45670641|NCT02298179|Biological|RSV F subunit 90 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
45973869|NCT04132895|Other|observational only, no interventions are prescribed in protocol.|"Treatment will be given as per usual standard of care.~No treatments are specified by this protocol."
45670642|NCT02298179|Biological|RSV F subunit 90 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
45670643|NCT02298179|Biological|RSV F subunit 135 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
45670644|NCT02298179|Biological|RSV F subunit 135 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
45670645|NCT02298179|Biological|RSV F subunit 135 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
45670646|NCT02298179|Drug|Placebo|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
45670647|NCT02298023|Biological|allogenic adipose stem cell injection|Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.
45670648|NCT02298023|Biological|fibrin glue/normal saline injection|Total 1cc of fibin glue and normal saline mixture injection and range of motion exercise
45973870|NCT04131842|Other|External focus of attention visual feedback|Patients will receive external focus of attention visual feedback during the impairment-based rehabilitation program.
45973871|NCT04131842|Other|External focus of attention auditory feedback|Patients will receive external focus of attention auditory feedback during the impairment-based rehabilitation program.
45973872|NCT04131842|Other|Internal focus of attention video feedback|Patients will receive internal focus of attention visual feedback during the impairment-based rehabilitation program.
46082022|NCT00041314|Drug|carboplatin|
45670649|NCT02298023|Biological|normal saline injection|Total 1cc of normal saline injection and range of motion exercise
45670650|NCT02296931|Other|Saline|Standard IV Saline Fluids
45670651|NCT02296931|Drug|Magnesium Sulfate|The standard drug used to prevent and treat convulsions for women with pre-eclampsia and eclampsia is magnesium sulfate (MgSO4)
45670652|NCT02166697|Drug|candesartan cilexetil|candesartan cilexetil tablets
45670653|NCT01909479|Drug|MOD-4023|Individualized once weekly dose of MOD-4023
45670654|NCT01909479|Other|Placebo|Once weekly administration of placebo
45670655|NCT04764721|Device|18F-FDG PET-CT|Enrolled patients in Neurocog-Covid will receive a 18F-FDG PET-CT
45670656|NCT04764175|Behavioral|Telephone All Nations Breath of Life|Same as described above.
45973873|NCT04131842|Other|No feedback|Patients will receive no feedback during the impairment-based rehabilitation program.
45973874|NCT04130711|Other|Visual virtual Conditions|"The objective is to evaluate if certain virtual visual conditions can increase the illusion of movement induced by the tendon vibration of the upper limb.~Thirty healthy volunteers and 20 post-stroke subjects will test 3 different situations of vibration applications, with no EEG Neurofeedback session. It will be applied to the subject (healthy and post-stroke) according to a randomized order a vibrator for a few minutes on his non-dominant (or deficit) hand hidden from view, with a screen representing a static virtual hand, then a vibrator on his hand hidden with a screen representing an animated virtual hand, then a vibrator on his hand hidden with a screen representing an empty background."
46082023|NCT00041314|Drug|exisulind|
46082024|NCT00041314|Drug|gemcitabine hydrochloride|
46082025|NCT00028990|Drug|bevacizumab|10 mg/kg following paclitaxel treatment on weeks 1 and 3 of every 4-week cycle
46082026|NCT00028990|Drug|Paclitaxel|90 mg/m2 IV infusion over 1 hour every week for 3 weeks followed by 1 week rest
46082027|NCT00027859|Drug|docetaxel|
46082028|NCT00027859|Drug|estramustine phosphate sodium|
46082029|NCT00027859|Drug|ketoconazole|
46082030|NCT00027859|Drug|therapeutic hydrocortisone|
45670657|NCT04764175|Behavioral|Comparison Program|Same as described above.
45670658|NCT04760977|Drug|Drugs administration|Antifibrinolytics, analgesics, sedatives, neuromuscular blocking agents
45973875|NCT04130711|Other|Standard EEG|Twenty healthy volunteers test 3 separate electroencephalographic recording conditions without Neurofeedback. It will be applied to the subject an EEG headset recording brain activity during the application of vibration stimulation producing the illusion of movement on the non-dominant hand or during a task Mental imagery of the upper limb, or during the joint application of vibratory stimulation and a mental imaging task on the affected upper limb in a randomized order.
45973876|NCT04130711|Other|Neurofeedback Training Stroke Patients|The post-stroke subject is evaluated on clinical tests (FMA, ARAT, MAL, NHPT, Finger Tapping test) during the first visit. Then, he performs 12 sessions of NFB (on his deficit member) lasting 45 minutes, spread over 6 weeks, depending on the feedback modality that has been drawn randomly (visual or visuo-vibratory). A second visit after the first NFB session and a third visit after the last NFB session evaluates the motor skills of the trained upper limb (FMA, ARAT, MAL, NHPT, Finger Tapping test) and a satisfaction questionnaire is given to the subject for evaluate tolerance and satisfaction with the feedback modality assigned. Evaluation of changes of EEG sensorimotor rhythms at the end of the program.
45670659|NCT04760977|Device|Resuscitative endovascular balloon occlusion of the aorta|Resuscitative technique for exsanguinating traumas
45973877|NCT04120285|Behavioral|remote internet-based cognitive behavior therapy (eCBT)|Provide access to online psychotherapy program to participants in rural WV areas at no expense to them.
45973878|NCT04116151|Combination Product|Cosmetic cream (Alantel (R): aloe vera, chamomile and thime)|Application on the affected skin of the cream to be tested
45973879|NCT04116151|Combination Product|Usual treatment|Application on the affected skin of the emollient and moisturizing substance
45973880|NCT04108897|Drug|Doxycycline|The investigators will administer doxycycline to rosacea patients according to the dose of patients' assigned study arm.
45973881|NCT04108897|Drug|Ivermectin Topical|1% topical ivermectin.
45670660|NCT04760977|Biological|Blood transfusions|Transfuion of transported blood products for exsanguinating traumas
45973882|NCT04101877|Drug|Bevacizumab Injection|25 mg/ml
45973883|NCT04101877|Drug|Aflibercept Injection|40 mg/ml
45973884|NCT04101838|Drug|Fluzone|inactivated seasonal influenza vaccine
45973885|NCT04101838|Drug|Flucelvax|inactivated seasonal influenza vaccine
45973886|NCT04101838|Drug|Fluzone High-Dose|inactivated seasonal influenza vaccine
45973887|NCT04101838|Drug|Fluad|inactivated seasonal influenza vaccine
45973888|NCT04075747|Drug|CPX-351|Up to 2 induction and 2 consolidation courses will be offered
45973889|NCT04075747|Drug|Venetoclax|Will be administered over specified duration during induction and consolidation courses
45670661|NCT04760977|Other|Prehospital management|Stay and play strategy vs scoop and run
45670662|NCT04760977|Device|Prehospital eFAST|Prehospital thorax/abdomen extended focused assessment sonography for trauma
45670663|NCT01955733|Drug|BI 695500|
45670664|NCT02197897|Drug|Tamoxifen Citrate|Single-center, two-stage phase-II clinical trial (Simon design)
45670665|NCT02223793|Behavioral|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will be informed about their measured levels of the different cardiovascular risk factors. They will also receive information on how to lower their levels in 8 weeks
45670666|NCT02223793|Behavioral|No information on high risk factor levels but lifestyle advice|In this arm, participants will have delayed information on their risk factor levels, but they will receive general advices on how to lower levels in 8 weeks
45670667|NCT02223793|Behavioral|No information on high risk factor levels, nor lifestyle advice|In this arm, participants will have delayed information on both their risk factor levels and general information on how to lower risk factor levels.
45670668|NCT01926015|Biological|RotaTeq™ (V260)|Live, oral, pentavalent vaccine containing 5 human-bovine reassortant rotavirus strains
45670669|NCT01926015|Biological|DTP-IPV|Diphtheria, tetanus, pertussis, inactivated polio vaccine used as part of the Japanese vaccination schedule
45670670|NCT02223715|Other|CDI Pts|
45670671|NCT02196259|Drug|Anesthetics, Dissociative|The subject will receive intravenous anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
45670672|NCT02294396|Drug|Mirabegron tablet|orally administered at a dose of 1 tablet once daily after breakfast
45973890|NCT04075747|Drug|Midostaurin|Will be administered over specified duration during induction and consolidation courses
45973891|NCT04075747|Drug|Enasidenib|Will be administered over specified duration during induction and consolidation courses
45973892|NCT04069273|Drug|Pembrolizumab Monotherapy|Pembrolizumab 200 mg IV
45973893|NCT04069273|Drug|Ramucirumab|Ramucirumab 10 mg/kg IV
45973894|NCT04069273|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV
45973895|NCT04061044|Drug|Ophthalmic Insert|Travoprost, 0.32 mg
45973896|NCT04054648|Other|Bedtime administration of the participant's pre-existing antihypertensive medications|Changing the administration time of once daily blood pressure lowering medications, one at a time as tolerated, from morning to bedtime.
45973897|NCT04049994|Drug|Uro-Vaxom|Uro-Vaxom® (OM Pharma SA, Meyrin, Switzerland) is a lyophilized lysate of 18 E. coli strains.
45973898|NCT04049994|Drug|Placebo oral tablet|Placebo oral tablet
45973899|NCT04034030|Device|Transcranial Magnetic Stimulation|"Each patient will receive a 10 minute treatment of one time stimulation of the Epileptogenic Cortical Area (ECA). The TRPMS cap will be worn over the previously fixed scalp EEG electrodes. The procedure during this treatment session will consist of positioning a device microstimulator component centered on an area of focal epileptiform discharges (identified with EEG electrode placement) with the patient relaxing in a chair.~The stimulus parameters used will be 120 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 10 min. . The investigators will measure the subject for adequate placement of the device prior to stimulation. Once the placement of the device is confirmed, the study technician administrating the treatment will turn on the device using the app downloaded on an electronic device connected by Bluetooth to the device."
45973900|NCT04032470|Device|Deep Brain Stimulation Systems (DBS)|Subjects receiving DBS implant for treatment of Essential Tremor
45973901|NCT04026958|Drug|Clarithromycin|Clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
45973902|NCT04026958|Drug|Placebo|A placebo to match clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
45973903|NCT04024254|Drug|Folic Acid Tablet|Folic Acid 1 mg by mouth daily
45973904|NCT04023331|Drug|67Cu-SARTATE|67Cu-labelled MeCOSar-Tyr3-octreotate
45829910|NCT01759368|Device|Telemonitoring assisted self-care|Telemonitoring group was given a home-care package including a weight scale, a blood pressure meter, a mobile phone and self-care instructions. The measurements taken at home to be uploaded were: diastolic and systolic blood pressure, pulse, body weight and an assessment of symptoms. The symptom assessment concerned the patient's feelings of dizziness, dyspnea, palpitation, weakness and, oedema. Patients were also asked to evaluate their overall condition- whether their condition had deteriorated, improved or remained unchanged. The patients were advised to carry out and report the measurements together with the self-assessment once a week. The responsible nurse followed patients' status and the data once a week or more frequently if needed. Based on the reported measurements, the nurse could invite the patient for a control visit. In case a patient did not make self-measurements as planned , the nurse contacted the patient and reminded him/ her to continue with monitoring
45973905|NCT04023331|Drug|64Cu-SARTATE|64Cu-labelled MeCOSar-Tyr3-octreotate
45973906|NCT04016376|Drug|PVB Protocol|Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
45973907|NCT04016376|Drug|PECS-1|For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor
45670673|NCT02294396|Drug|Solifenacin tablet|orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 2 tablets)
45670674|NCT02294396|Drug|Propiverine tablet|orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 1 tablet twice daily after breakfast and after dinner)
45670675|NCT02294396|Drug|Imidafenacin tablet|orally administered at a dose of 1 tablet (0.1 mg tablet) twice daily after breakfast and after dinner (could be increased to 2 tablets twice daily after breakfast and after dinner)
46082031|NCT00026286|Drug|conjugated estrogens|
45670676|NCT02294396|Drug|Tolterodine capsule|orally administered at a dose of 1 capsule once daily after breakfast (could not be increased)
45670677|NCT01721044|Drug|Placebo|Administered orally
45670678|NCT01721044|Drug|Baricitinib|Administered orally
45973908|NCT04016376|Drug|Serratus|For the serratus block, the patient will be placed in the supine or lateral decubitus position and with an ultrasound probe, in the parasagittal plane, the serratus muscles will be identified. Injections will be done in-plane below the serratus anterior.
45670679|NCT01721044|Drug|cDMARD|Participants will continue to take background cDMARD therapy throughout study.
45670680|NCT02164981|Drug|sodium nitroprusside|intravenous
45670681|NCT02164981|Other|Placebo|Placebo
45973909|NCT03994601|Drug|BMS-986288|Specified dose on specified days
45973910|NCT03994601|Drug|Nivolumab|Specified dose on specified days
45973911|NCT03994601|Drug|Regorafenib|Specified dose on specified days
45670682|NCT02195869|Drug|Ibrutinib|
45670683|NCT01908699|Drug|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration
46082032|NCT00026286|Drug|medroxyprogesterone|
46082033|NCT00014118|Drug|carboplatin|
45670684|NCT01908699|Drug|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR
45670685|NCT01599637|Drug|IGE025|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
45670686|NCT01599637|Drug|placebo|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
45670687|NCT02264639|Drug|Pegcetacoplan|Complement (C3) Inhibitor
46082034|NCT00014118|Drug|paclitaxel|
46082035|NCT00014118|Procedure|conventional surgery|
46082036|NCT00014118|Radiation|radiation therapy|
46082037|NCT00006004|Drug|carboplatin|
45973912|NCT03978936|Behavioral|Medication Therapy Management (MTM) Video Telehealthcare|"MTM is an individualized approach to optimize medication use for improved patient outcomes and is designed to empower patients to take an active role in managing patients' medications thus, providing a favorable strategy for addressing adherence issues. Five core elements define MTM: complete medication therapy review (CMR), creation of a personal medication list (PML), development of a medication action plan (MAP), intervention and/or referral for drug therapy problems, and documentation and follow-up"
45973913|NCT03978936|Behavioral|Electronic Adherence Self-Management (EAM)|Participants will have a sensor which monitors their adherence to medication use
45973914|NCT03975829|Drug|dabrafenib|dabrafenib oral, twice daily
45973915|NCT03975829|Drug|trametinib|trametinib oral, once daily
45973916|NCT03939481|Drug|Chemotherapy|Given chemotherapy regimen
45973917|NCT03939481|Other|Functional Assessment|Functional and sensory clinician assessments
45973918|NCT03939481|Other|Questionnaire Administration|Patient and physician reported responses
45973919|NCT03939182|Drug|Abexinostat|Two doses of the abexinostat will be tested: 30 mg/m2 and 45 mg/m2 orally twice daily, 7 days/week given every other week during a 28-day cycle.
45973920|NCT03939182|Drug|Ibrutinib|Ibrutinib will be given at the FDA-approved dose for mantle cell lymphoma (MCL) of 560 mg orally daily for 28 day cycle.
45973921|NCT03935633|Drug|CN128 Tablets|Iron chelator， oral tablets
45670688|NCT04881461|Drug|5-grass mix SLIT-drops|Sublingual allergy immunotherapy drops, for daily administration
45670689|NCT04881461|Drug|Placebo|Placebo
45829911|NCT01777152|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles
45455983|NCT05273216|Diagnostic Test|Blood biomarkers|"Apart from the assessment of outcome-relevant routine blood parameters of inflammation, coagulation, glucose metabolism, renal and liver function, the investigators will also investigate novel biomarkers of interest that could be indicative of endothelial damage / blood brain barrier disruption. Candidate markers for this purpose are interleukins (i.e., interleukin-6) and matrix metalloproteinases (i.e., MMP-9). Furthermore, the investigators will also measure neurofilament light chain protein as a marker for neuro-axonal damage that has been shown to indicate cerebral tissue destruction including vascular brain lesions with a very high sensitivity.~For analysis, peripheral blood will be taken by venipuncture on day one and at follow- up three months after MT. Serum will be immediately stored at -80°C according to international consensus guidelines. Markers will be centrally analyzed in the neurological laboratory of the Department of Neurology, Medical University of Graz."
45670690|NCT05648903|Other|Total diet replacement|The TDR intervention involves a low-calorie, nutritionally complete diet for 12 weeks consuming four meal replacement products exclusively per day, followed by a 4-week food-based reintroduction period; and then weight loss maintenance support monthly to 12 months. The TDR products will be provided to participants free of charge. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a TDR for an additional 4 weeks but participants would have to self-fund these products.
45973922|NCT03934372|Drug|Ponatinib|Ponatinib administered as a tablet or age-appropriate formulation for pediatric participants according to age-based cohort assignment.
45829912|NCT01777152|Drug|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
45829913|NCT01777152|Drug|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles
45829914|NCT01777152|Drug|vincristine|1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles
45829915|NCT01777152|Drug|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
45973923|NCT03908437|Drug|buprenorphine/naloxone|"A mobile team will be led by a nurse practitioner (able to prescribe buprenorphine/naloxone in PA) and include a peer recovery specialist (PRS), and a case manager. The team will rapidly confirm opioid use disorder and risk of overdose, complete informed consent, and begin induction procedures for a transitional (one month) course of buprenorphine/naloxone treatment. During this time, the dedicated case manager and PRS will work with the participants to help them become engaged in existing medication assisted treatment programs"
45973924|NCT03901807|Device|Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge|TORAYMYXIN PMX-20R (PMX) is an extracorporeal hemoperfusion cartridge intended for the selective removal of endotoxin from circulating blood through direct hemoperfusion (DHP). Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute).
45829916|NCT01759290|Device|Absorb Bioresorbable Vascular Scaffold|Subjects receiving the Absorb Bioresorbable Vascular Scaffold
45829917|NCT01758900|Device|CO2 insufflation regulator|The CO2 insufflation regulator is Olympus UCR(Olympus Optical Co., Ltd., Tokyo, Japan). The device connect the medical gas pipe joints and CO2 cylinders, then the CO2 gas will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
45829918|NCT01758900|Device|Air insufflation|The air will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
45829919|NCT01757184|Drug|Sebelipase Alfa|IV infusions of sebelipase alfa
45829920|NCT01757184|Drug|Placebo|IV infusions of matched placebo
45829921|NCT01775904|Drug|LY2886721 in a Capsule|Administered orally.
45973925|NCT03887702|Other|Best Practice|Receive best practice
45973926|NCT03887702|Drug|Entecavir|Given PO
45973927|NCT03887702|Drug|Tenofovir Alafenamide|Given PO
45973928|NCT03887702|Drug|Tenofovir Disoproxil Fumarate|Given PO
46082038|NCT00006004|Drug|cisplatin|
46082039|NCT00006004|Drug|gemcitabine hydrochloride|
46082040|NCT00006004|Drug|paclitaxel|
46082041|NCT00004860|Drug|leucovorin calcium|
45973929|NCT03878589|Drug|Oxytocin (OT)|During the 4 week intervention, participants will self-administer twice daily 24 IUs intranasal oxytocin (OT) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
45973930|NCT03878589|Drug|Placebo (P)|During the 4 week intervention, participants will self-administer twice daily 24 IUs intranasal placebo (P) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
45973931|NCT03876262|Drug|Moxidectin|2mg tablets, encapsulated for blinding
45973932|NCT03876262|Drug|Ivermectin|3mg tablets, encapsulated for blinding
45973933|NCT03875326|Device|1 mA HD-tDCS|Participants will receive HD-tDCS at 1 mA for 30 minutes, for between 5-30 sessions.
45973934|NCT03875326|Device|2 mA HD-tDCS|Participants will receive HD-tDCS at 2 mA for 30 minutes, for between 5-30 sessions.
45973935|NCT03875326|Device|3 mA HD-tDCS|Participants will receive HD-tDCS at 3 mA for 30 minutes, for between 5-30 sessions.
45973936|NCT03875326|Device|Sham|Participants will receive sham (placebo) HD-tDCS for 30 minutes, for between 5-30 sessions.
45973937|NCT03875287|Drug|Decitabine|"DOSING REGIMEN(S):~Level -1 10mg daily days 1-4~Level 1 10mg daily days 1-5~Level 2 15mg daily days 1-5~Level 3 20mg daily days 1-5"
45973938|NCT03875287|Drug|Cedazuridine|"DOSING REGIMEN(S):~Level -1 100mg daily days 1-4~Level 1 100mg daily days 1-5~Level 2 100mg daily days 1-5~Level 3 100mg daily days 1-5"
45973939|NCT03860168|Other|PICU Up!|The PICU Up! intervention is a multifaceted mobility program incorporating the ABCDEF bundle components into routine PICU care through multidisciplinary staff education and a structured pathway to determine a patient's daily mobility goal. PICU Up! was developed by a collaborative multidisciplinary team approach, and the central components include the consultation and involvement of physical therapy/occupational therapy (PT/OT) by PICU Day 3, sleep hygiene promotion and routine delirium screening for all PICU patients utilizing a validated tool.
45973940|NCT03846193|Biological|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
45973941|NCT03846193|Biological|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
45973942|NCT03846193|Biological|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
45973943|NCT03846193|Biological|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
46082042|NCT00004860|Drug|tegafur-uracil|
46082043|NCT00003864|Drug|carboplatin|
46082044|NCT00003864|Drug|docetaxel|
46082045|NCT00003810|Drug|docetaxel|
46082046|NCT00003810|Drug|gemcitabine hydrochloride|
45670691|NCT05648903|Other|Low-carbohydrate diet|Participants who choose this intervention will be supported to undertake a low-carbohydrate diet. During the first 12 weeks of the programme patients will be supported to consume below 100g carbohydrate per day, whilst being encouraged to increase protein, choose predominantly unsaturated fats alongside a high intake of non-starchy vegetables and low-carbohydrate fruits. After 12 weeks patients will be able to increase their carbohydrate intake up to 130g per day. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a 100g carbohydrate for an additional 4 weeks.
45829922|NCT01775904|Drug|LY2886721 in an orally disintegrating tablet (ODT)|Administered orally.
46082047|NCT00003701|Drug|carboplatin|
46082048|NCT00003701|Drug|cisplatin|
46082049|NCT00003701|Drug|doxorubicin hydrochloride|
46082050|NCT00003701|Drug|methotrexate|
46082051|NCT00003701|Drug|paclitaxel|
46082052|NCT00003701|Drug|vinblastine sulfate|
45829923|NCT01775670|Device|Off-the-shelf splint|Subjects will use an off-the-shelf splint
45829924|NCT01775670|Device|OT Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists.
45829925|NCT01775124|Drug|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
45829926|NCT01733316|Drug|RP103|
45829927|NCT01733316|Drug|Cystagon®|
46082053|NCT00003615|Biological|denileukin diftitox|
45829928|NCT01732926|Drug|Idelalisib|150 mg tablet administered orally twice daily
45829929|NCT01732926|Drug|Rituximab|375 mg/m^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)
45829930|NCT01732926|Drug|Bendamustine|90 mg/m^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)
45829931|NCT01732926|Drug|Placebo|Tablet administered orally twice daily
45829932|NCT01755858|Drug|Bendavia|
45829933|NCT01755858|Drug|Placebo|
45829934|NCT01732770|Biological|Denosumab|Denosumab 60 mg administered by subcutaneous injection once every 6 months.
45829935|NCT01732770|Drug|Zoledronic Acid|Zoledronic acid 5 mg administered by intravenous infusion once a year
45829936|NCT01732770|Drug|Placebo to Denosumab|Administered by subcutaneous injection once every 6 months
46082054|NCT00003614|Drug|estramustine phosphate sodium|
45973944|NCT03846193|Device|GT005/ Device: Orbit™ Subretinal Delivery System|"A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System"
45973945|NCT03846193|Device|GT005/ Device: Orbit™ Subretinal Delivery System|"A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System"
45973946|NCT03846193|Device|GT005/ Device: Orbit™ Subretinal Delivery System|"A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System"
45973947|NCT03843190|Behavioral|Take of Pounds Sensibly (TOPS)|Experimental arm: Dietician-facilitated Wait-list control arm: Peer-led
45973948|NCT03833206|Drug|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
45973949|NCT03832829|Device|Indirect composite restoration|Restoration of tooth with extensive substance loss
45973950|NCT03832010|Drug|Crisaborole|Participants will be instructed to apply crisaborole to affected areas with eczema.
45973951|NCT03832010|Drug|Hydrocortisone Ointment|Participants will be instructed to apply hydrocortisone to affected areas with eczema on face, armpits or groin.
45973952|NCT03832010|Drug|Triamcinolone ointment|Participants will be instructed to apply triamcinolone to affected areas on the body excluding face, armpits or groin.
45973953|NCT03832010|Drug|Aquaphor|Participants will be instructed to moisturize all over the body with Aquaphor.
45973954|NCT03827850|Drug|ERDAFITINIB|Daily in a range from 3 mg to 9 mg
45973955|NCT03813836|Drug|Pembrolizumab|Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
45973956|NCT03801330|Other|Usual Care Pulmonary Rehabilitation Program|Participants in the Usual Care Pulmonary Rehabilitation Program group will complete an 8 week clinic based Pulmonary Rehabilitation Program (usual care).
45973957|NCT03801330|Other|Pulmonary Rehabilitation Software-Based Home Program|Participants in the Pulmonary Rehabilitation Software-Based Home Program group will complete an 8-week home-based Pulmonary Rehabilitation Program using a software app (software)
45973958|NCT03796988|Device|Autologous Regeneration of Tissue (ART) device|This device will harvest hundreds of full-thickness columns of skin tissue (500 micrometer diameter) using single-needle, fluid-assisted harvesting technology.
46082055|NCT00003614|Drug|paclitaxel|
46082056|NCT00003519|Drug|cyclophosphamide|
46082057|NCT00003519|Drug|docetaxel|
46082058|NCT00003519|Drug|doxorubicin hydrochloride|
46082059|NCT00003329|Genetic|gene mapping|
46082060|NCT00003283|Drug|octreotide acetate|
46082061|NCT00003283|Drug|prednisone|
46082062|NCT00003235|Drug|carboplatin|
46082063|NCT00003235|Drug|paclitaxel|
46082064|NCT00003235|Radiation|radiation therapy|
46082065|NCT00003206|Drug|carboplatin|
46082066|NCT00003206|Drug|paclitaxel|
46082067|NCT00003153|Biological|therapeutic allogeneic lymphocytes|
45973959|NCT03757949|Other|Laboratory Biomarker Analysis|Correlative studies
45973960|NCT03757949|Dietary Supplement|Nutritional Intervention|Receive SIM PO
45973961|NCT03757949|Other|Placebo Administration|Given PO
45973962|NCT03757949|Other|Quality-of-Life Assessment|Ancillary studies
46082068|NCT00003010|Drug|marimastat|
46082069|NCT00003008|Drug|indinavir sulfate|
46082070|NCT00003008|Drug|nelfinavir mesylate|
45973963|NCT03757949|Other|Questionnaire Administration|Ancillary studies
45973964|NCT03740048|Other|Hemodialysis|Hemodialysis frequency will differ in the first six weeks of hemodialysis therapy between the two treatment arms.
45973965|NCT03740048|Drug|Patiromer Oral Product|Participants in the intervention group who develop hyperkalemia, during the first six weeks of receiving hemodialysis twice per week, will be treated with Patiromer.
46082071|NCT00003008|Drug|paclitaxel|
46082072|NCT00003008|Drug|ritonavir|
46082073|NCT00003008|Drug|saquinavir mesylate|
46082074|NCT00002997|Procedure|cryosurgery|
46082075|NCT00002996|Drug|flecainide acetate|
46082076|NCT00002878|Drug|dexamethasone|
46082077|NCT00002878|Drug|doxorubicin hydrochloride|
46082078|NCT00002878|Drug|valspodar|
46082079|NCT00002878|Drug|vincristine sulfate|
46082080|NCT00002632|Drug|paclitaxel|
46082081|NCT00002520|Drug|nicotine|
46082082|NCT00002520|Behavioral|Usual Care|
46082083|NCT00001721|Drug|Cholesterol Suspension|
46082084|NCT00001721|Drug|CRH|
46082085|NCT00001721|Drug|Cholesterol|
46082086|NCT00001230|Drug|Diethylcarbamazine|
46082087|NCT00609557|Drug|duloxetine|Weeks 0-2 placebo Weeks 2-3 30mg duloxetine Weeks 3-4 60mg duloxetine Weeks 4-12 60-90mg duloxetine Week 13 30 mg duloxetine Week 14 stop
46082088|NCT02812082|Other|web-based patient education|
46082089|NCT02812082|Behavioral|questionnaire|
46082090|NCT04014673|Behavioral|Behavioral : Characterization|Behavioral scales and neuropsychological tests; MRI, SPECT/PET
46082091|NCT02738190|Drug|Albumin|Albumin 5% added to blood priming solution
46082092|NCT02738190|Biological|Fresh Frozen Plasma|Fresh Frozen Plasma added to blood priming solution
45973966|NCT03733951|Drug|KN046|"Phase Ia：Intravenous (IV) infusions, 1,3 and 5 milligrams per kilogram (mg/kg) every 2 weeks.~Phase Ib：Intravenous (IV) infusions, 1 ,3 or 3, 5 milligrams per kilogram (mg/kg) every 2 weeks, the dose of phase Ib based on the result of phase Ia."
45829937|NCT01732770|Drug|Placebo to Zoledronic Acid|Administered by intravenous infusion once a year
45973967|NCT03733197|Behavioral|Culture Specific|We anticipate the culture-specific arm developed minimally will include two core components: barbers as motivational interviewers, and (2) fecal immunochemical test (FIT) kits distributed by barbers. If we choose this route for the culture-specific arm, preliminary data from our barbers suggest I teach the barbers the MI technique using content that stems from Aim 1 findings. Additional components for this arm may be developed during the APEASE process.
45973968|NCT03733197|Behavioral|Control|the (control) arm will include an informational CRC screening brochure developed by the American Cancer Society plus a FIT kit distributed by the barbers.
45973969|NCT03730649|Drug|Sulforaphane (broccoli sprout extract)|Participants will topically apply Sulforaphane for a period of time
45973970|NCT03730649|Radiation|UV or visible light|Participants will have 2 test areas irradiated with up to 5 UV or visible light treatments
45973971|NCT03723928|Other|Usual care disease monitoring|Imaging and serum tumor markers are at the discretion of the treating physician (however imaging must be performed at least every 12 weeks).
45973972|NCT03723928|Other|Serum Tumor Marker directed disease monitoring|Serum tumor markers every 4-8 weeks without imaging
45973973|NCT03723928|Other|Quality-of-Life Assessment|Ancillary studies
45973974|NCT03723928|Other|Anxiety Questionnaire Administration|Ancillary studies
45973975|NCT03697109|Drug|Relacorilant|Relacorilant is supplied as 100 mg capsules for oral dosing.
45973976|NCT03697109|Other|Placebo|Placebo matched to study drug
45973977|NCT03683355|Radiation|18F-FDG PET/CT|18F-FDG PET/CT and blood cultures will be performed at 3-month follow-up after TAVR Patients with positive 18F-FDG PET/CT (moderate or intense radiolabeled tracer uptake) will be scheduled for a second 18F-FDG PET/CT at 6-month follow-up.
45973978|NCT03645031|Other|Acute Intermittent Hypoxia|AIH entails continuous breathing as the level of oxygen in the air is decreased, then returned to normal. Participants will alternate between breathing normal air and breathing hypoxic air (air that has less oxygen). Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH). Breathing, muscle activity and heart activity will be monitored before, during and after the procedure. The intervals will last 1 minute each.
45455984|NCT05268926|Drug|Dapagliflozin 10Mg Tab|dapagliflozin 10 mg/d or matched placebo
45973979|NCT03645031|Other|Sham Acute Intermittent Hypoxia|Participants will complete the sham acute intermittent hypoxia, consisting of a single 45 minute session of breathing air with normal oxygen levels. All aspects of this procedure will otherwise be the same as for the AIH procedure. Breathing, muscle activity and heart activity will be monitored before, during and after the procedure.
46082093|NCT02805140|Behavioral|Virtual exercise|Using videoconferencing, mothers assigned to intervention arm will participate in daily (weekdays) virtual exercise sessions for 6 weeks with other mothers.
45455985|NCT05268926|Drug|Placebo|Placebo
46082094|NCT02805140|Behavioral|Mobile apps|During virtual exercise sessions, mothers assigned to intervention arm will follow exercise routines using mobile exercise apps that are recommended by study staff.
46082095|NCT02805140|Behavioral|Exercise resources and information|For all mothers, the investigators will provide standard information on the benefits of exercise and link to existing public health resources on how to start and stay active.
45973980|NCT03632720|Biological|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine|Pharmaceutical form: solution for injection; route of administration: intramuscular, 0.5 mL
45973981|NCT03632720|Biological|Meningococcal group B vaccine|Pharmaceutical form: suspension for injection; route of administration: deep intramuscular, 0.5 mL
45973982|NCT03632720|Biological|Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine|Pharmaceutical form: powder and suspension for suspension injection; route of administration: deep intramuscular, 0.5 mL
46082096|NCT05122481|Dietary Supplement|Vitamin C|Vitamin C (also known as ascorbic acid and ascorbate) is a vitamin found in various foods and sold as a dietary supplement.Vitamin C is a water-soluble vitamin, with dietary excesses not absorbed, and excesses in the blood rapidly excreted in the urine, so it exhibits remarkably low acute toxicity. More than one gram may cause indigestion, flatulence and stomach pain.
45829938|NCT01732692|Drug|MOVIPREP|MOVIPREP solution
45829939|NCT01774968|Drug|Human Regular U-500 Insulin|
45829940|NCT01774344|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib, 40 mg tablets
45829941|NCT01774344|Drug|Placebo|Placebo tablets matching in appearance
45829942|NCT01732536|Drug|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
45829943|NCT01732536|Procedure|Sham procedure|In-office bilateral sham procedure
45829944|NCT01732536|Drug|Mometasone furoate nasal spray|Two sprays in each nostril once daily, totaling 200 mcg of mometasone furoate throughout Day 90
45829945|NCT01755702|Drug|Placebo|Placebo
45829946|NCT01755702|Drug|Experimental paracetamol + caffeine formulation|experimental paracetamol + caffeine formulation
45829947|NCT01755702|Drug|ibuprofen marketed formulation|ibuprofen marketed formulation
45829948|NCT01755702|Drug|Paracetamol marketed formulation|Paracetamol marketed formulation
45829949|NCT01732458|Drug|Aprepitant|Administered as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia. Aprepitant was supplied in a sachet containing a powder for suspension (PFS) that was reconstituted up to total volume of 5 mL using potable water.
45973983|NCT03632720|Biological|Human rotavirus RIX4414 strain vaccine|Pharmaceutical form: oral suspension; route of administration: oral, 1.5 mL
45829950|NCT01732458|Drug|Placebo to Aprepitant|
45829951|NCT01732458|Drug|Ondansetron|Administered IV at a dose of 4 mg for participants >40 kg in weight and 0.1 mg/kg for participants ≤40 kg in weight. In participants <1 month of age, the dose of ondansetron was administered per the product label or based on local standard of care. Ondansetron was supplied by the Sponsor as vials or ampules, depending on the country.
45973984|NCT03632720|Biological|Pneumococcal 13-valent polysaccharide conjugate vaccine|Pharmaceutical form: suspension for injection; route of administration: intramuscular, 0.5 mL
45973985|NCT03622788|Biological|Anti-Thymocyte Globulin|Given IV
45973986|NCT03622788|Drug|Cyclophosphamide|Given IV
45973987|NCT03622788|Biological|Cytokine-treated Veto Cells|Given IV
45973988|NCT03622788|Drug|Fludarabine|Given IV
45973989|NCT03622788|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT
45973990|NCT03622788|Radiation|Total-Body Irradiation|Undergo TBI
45829952|NCT01732458|Drug|Placebo to match ondansetron|Participants in the aprepitant regimen received normal saline IV (provided by the site) as the placebo for ondansetron on Day 1, immediately prior to induction of anesthesia.
45973991|NCT03612596|Behavioral|Narrative visualization|Participants use narrative visualization procedures to connect their step data to important events or feelings that occurred at the same time, then reflect on their behavior
45973992|NCT03612596|Behavioral|Standard self-regulation|Participants self-monitor steps using a wearable device, app, and a hand-written step log
45973993|NCT03598426|Drug|Dexamethasone|Conventional arm will only use oral dexamethasone as intervention; Short-Course arm will only use intravenous dexamethasone as intervention; Combined arm will use both oral and intravenous dexamethasone as intervention
45973994|NCT03581487|Biological|Durvalumab|Given IV
45973995|NCT03581487|Drug|Selumetinib|Given PO
45670692|NCT05648903|Other|Intermittent fasting 5:2|"Participants will have the option to follow a 5:2 dietary approach whereby calories are significantly reduced on two days of the week to 500 calories per day for women and 600 calories per day for men. The placement of the fasting days can vary each week, but there must be two fasting days in each seven-day period. After 12 weeks, patients will have the option of continuing with the 5:2 approach for further weight loss or adopting a 6:1 approach whereby patients would only fast on 1 day in each seven-day cycle for weight maintenance. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a 5:2 approach for an additional 4 weeks."
45829953|NCT01731990|Drug|Canakinumab (ACZ885)|Dosage form: solution for injection Strength: 150 mg/1 mL Mode of administration: subcutaneous use.
45829954|NCT01731990|Drug|Placebo|Matching placebo of Canakinumab
45670693|NCT01363011|Drug|E/C/F/TDF|E/C/F/TDF (150/150/200/300 mg) STR administered orally once daily
45670694|NCT01363011|Drug|COBI|COBI 150 mg tablet administered with food orally once daily
45829955|NCT01708902|Drug|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
45829956|NCT01708902|Drug|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
45829957|NCT01708902|Drug|linagliptin 5mg|linagliptin 5mg once daily
45829958|NCT01708902|Drug|Metformin 500mg|Metformin 500mg BID
45973996|NCT03581487|Biological|Tremelimumab|Given IV
45973997|NCT03568890|Drug|Rivaroxaban, dabigatran, apixaban, or edoxaban|Duration of treatment: 8 weeks
45973998|NCT03568890|Drug|Clopidogrel -75 mg/day|Duration of treatment: 8 weeks
45670695|NCT01363011|Drug|ATV|ATV 300 mg tablet administered orally once daily
45829959|NCT01708902|Drug|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
45829960|NCT01708902|Drug|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
45829961|NCT01708902|Drug|linagliptin 5mg|linagliptin 5mg once daily
45829962|NCT01708902|Drug|Metformin 1000mg|Metformin 1000mg BID
45829963|NCT01755546|Drug|EN3409|Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily
45973999|NCT03568890|Drug|Low dose aspirin -80 to 125 mg/day-|Duration of treatment: 8 weeks
45974000|NCT03561805|Device|ECG monitoring|Prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure
45974001|NCT03558204|Procedure|Denervation of the thumb CMC joint|Removal/disconnection of the nerve branches to the joint from their attachments to the joint
45974002|NCT03558204|Procedure|trapeziectomy with ligament reconstruction (LRTI)|excision of the trapezium and suspension of the thumb metacarpal with the flexor carpi radialis tendon
45974003|NCT03549507|Drug|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
45974004|NCT03521037|Drug|Rucaparib camsylate|In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by intensive plasma PK sampling up to Day 7 (hour 144). In Part II, patients may continue to receive continuous oral rucaparib in 28 day cycles.
45974005|NCT03507777|Device|Coronary PCI guided by OCT|Stent implantation in high-risk or complex lesions in patients with coronary artery disease using OCT guidance
45974006|NCT03507777|Device|Coronary PCI guided by Angiography|Stent implantation in high-risk or complex lesions in patients with coronary artery disease using angiography guidance
45974007|NCT03499444|Drug|Rucaparib|Rucaparib will be administered twice daily
45974008|NCT03494322|Drug|Avelumab|Avelumab 10 mg/kg given IV
45974009|NCT03494322|Drug|Cetuximab|"Cetuximab 500* mg/m2 given IV~*Cetuximab dose will be dependent on outcome of safety run-in."
45974010|NCT03480191|Drug|Daptomycin|Daptomycin will be given by intravenous infusion and administered over a 30 minutes infusion, daily, for 8 days and at the dosis of 10mg/kg/day.
45670696|NCT01363011|Drug|DRV|DRV 800 mg tablet administered orally once daily
45829964|NCT04413864|Other|Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration|"Assigned Interventions:~Blood samples collection at inclusion (D0) and follow-up visits (D2, D7 and M6)~CAM-ICU scores during ICU hospitalisation, neurological questionnaires at M6 (GOAT, GOSE, MOCA, Barthel Index, PTSD, GDS, Rankin score, HADS)"
45974011|NCT03478878|Drug|Vitamin A Palmitate|Provide vitamin A to participants with pre/post assessments of vision.
45670697|NCT01363011|Drug|NRTI|Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC, 3TC, tenofovir disoproxil fumarate (TDF), or FTC/TDF, administered according to prescribing information.
45670698|NCT05648825|Device|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device. Using this device, myectomy could be performed in the beating heart via a mini-thoractomy approach. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. We are now conducting the study to explore the feasibility, the safety, and the efficacy of transapical beating-heart myectomy for the treatment of apical hypertrophic cardiomyopathy.
45974012|NCT03467958|Drug|Ozanimod|Specified dose on specified days
45974013|NCT03459079|Drug|Lanifibranor|The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation. Participants receive 800mg/ day
45974014|NCT03459079|Other|Placebo|Film-coated tablets with a core containing 900 mg of a physical mixture of lactose monohydrate, microcrystalline cellulose, pre-gelatinized starch and magnesium stearate serve as placebo.
45829965|NCT04560504|Other|Control Group|Leisure activities
45829966|NCT04560504|Other|Oculomotor Training Group|Eye movement training
45829967|NCT01755234|Drug|Sevoflurane|Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube
45829968|NCT01755234|Drug|Propofol|Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
45829969|NCT01731912|Drug|Degarelix|Given SC
45829970|NCT01731912|Radiation|External Beam Radiation Therapy|Undergo standard EBRT
45829971|NCT01731912|Other|Laboratory Biomarker Analysis|Correlative studies
45974015|NCT03441633|Drug|apixaban|current or new medication
45974016|NCT03441633|Drug|dabigatran|current or new medication
45974017|NCT03441633|Drug|VKA|current or new medication
45974018|NCT03441633|Drug|rivaroxaban|current or new medication
45974019|NCT03436862|Drug|Nivolumab|Nivolumab 240 mg IV infusion over 60 minutes given every 2 weeks for up to 6 months.
45974020|NCT03424005|Drug|Capecitabine|Capecitabine will be administered 1250 mg/m^2 orally twice daily on Days 1-14, of each 21 day cycle.
45974021|NCT03424005|Drug|Atezolizumab|"For Atezolizumab (Atezo) + SGN-LIV1A, Atezo + Sacituzumab Govitecan, or Atezo + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.~For Atezo + Nab-Paclitaxel, Atezo + Selicrelumab + Bevacizumab, Atezo + Ipatasertib, or Atezo + Nab-Paclitaxel + Tocilizumab: atezolizumab will be administered IV, 840 mg on Days 1 and 15, of each 28-day cycle."
45974022|NCT03424005|Drug|Ipatasertib|Ipatasertib will be administered by mouth 400 mg once a day, on Day 1-21 of each 28 day cycle.
45670699|NCT05648747|Other|impact of COVID-19 on Health-Seeking Behaviors|The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Italy's government rapidly established diverse public actions, which helped maintain the medical supply. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether pelvic inflammatory disease rates were affected by the COVID-19 pandemic.
45670700|NCT05648669|Drug|Elagolix|200 mg tablet
45670701|NCT05648669|Drug|Elagolix placebo|Elagolix-matched Placebo tablet
45974023|NCT03424005|Drug|SGN-LIV1A|SGN-LIV1A will be administered IV, 2.5 mg/kg (maximum calculated dose 250 mg), on Day 1 of each 21 day cycle.
45670703|NCT02263547|Drug|teriflunomide|
45829972|NCT01731678|Procedure|Transcranial Magnetic Stimulation|The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
45829973|NCT01731600|Drug|turoctocog alfa pegol|Fixed dose of turoctocog alfa pegol for intravenous injections (i.v.) twice weekly for prophylaxis. In addition, turoctocog alfa pegol will be administered to treat bleeding episodes during the trial period. Bleeding episodes will be treated with doses of 20-75 U/kg body weight.
45829974|NCT01730586|Drug|Abraxane|220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
45829975|NCT04413942|Biological|FB825|Humanized monoclonal IgG1 specifically targeting the CεmX domain of membrane-bound IgE
45829976|NCT04413942|Other|Placebo|Formulation buffer
45829977|NCT01707030|Other|Web-Based Brief Alcohol Intervention|Participants report their alcohol use and problems on line and receive feedback comparing them to national norms.
45829978|NCT01707030|Other|Usual Care|All patients will be receiving care in a Hepatitis C clinic. In some cases clinicians may counsel them on alcohol problems.
45829979|NCT01755156|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly (preferably on the same day of each week)
45974024|NCT03424005|Drug|Bevacizumab|Bevacizumab will be administered IV, 10 mg/kg, on Days 1 and 15 of each 28 day cycle.
45974025|NCT03424005|Drug|Chemotherapy (Gemcitabine + Carboplatin or Eribulin)|"Gemcitabine will be administered by IV, 1000 mg/m^2, along with carboplatin, by IV, AUC 2, on Days 1 and 8 of each 21 day cycle.~Or~Eribulin will be administered by IV, 1.4 mg/m^2 on days 1 and 8 of each 21 day cycle."
45974026|NCT03424005|Drug|Selicrelumab|Selicrelumab will be administered by subcutaneous (SC) injection at a fixed dose of 16 mg on Day 1 of Cycles 1 to 4 and every third cycle thereafter (cycle = 28 days).
45974027|NCT03424005|Drug|Tocilizumab|Tocilizumab will be administered IV, 8 mg/kg infusion on Day 1 of each 28 day cycle.
45974028|NCT03424005|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered by IV, 100 mg/m^2, on Days 1, 8, and 15 of each 28-day cycle.
45455986|NCT05267366|Drug|PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed|PD-1 inhibitor (pembrolizumab) 200mg iv, d1; bevzcizumab 15mg/kg, iv, d1; Carboplatin 5/AUC or Cisplatin 75mg/m2 iv d1; Pemtrexed 500mg/m2 iv, d1; every 21 days a cycle.
45455987|NCT05267288|Drug|afatinib|afatinib 40mg oral, bevacizumab 15mg/kg iv, every 21days, until progression disease, untolerated toxicities, or patient death.
45670704|NCT02263547|Drug|Colestipol|
45670705|NCT04620759|Drug|Psilocybin|The psilocybin used in this study is synthetically manufactured and formulated under current good manufacturing practices (cGMP). The active drug is encapsulated using a size 0 blue gelatin capsule and contains 25 mg of psilocybin.
45974029|NCT03424005|Drug|Sacituzumab Govitecan|Sacituzumab govitecan will be administered by IV, 10 mg/kg, on Days 1 and 8 of each 21-day cycle.
45670706|NCT04620759|Drug|Placebo|The placebo used in this study is microcrystalline cellulose, an inert substance, encapsulated using a size 0 blue gelatin capsule.
45974030|NCT03424005|Drug|Abemaciclib|Abemaciclib tablets will be administered at a dose of 150 mg twice daily by mouth on Days 1-28 of each cycle (cycle=28 days).
45974031|NCT03424005|Drug|Fulvestrant|Fulvestrant IM injection at a dose of 500 mg will be administered on Days 1 and 15 of Cycle 1, and then on Day 1 of each cycle thereafter (cycle=28 days).
45974032|NCT03424005|Drug|Ribociclib|Ribociclib tablets of 400 mg will be administered by mouth on Days 1-21 of each 28-day cycle.
45974033|NCT03424005|Drug|Inavolisib|Inavolisib tablets will be administered at a dose of 9 mg by mouth on Days 1-28 of each cycle (cycle = 28 days).
45974034|NCT03424005|Drug|Inavolisib (9 mg)|Inavolisib tablets will be administered at a dose of 9 mg by mouth on Days 1-21 of each cycle (cycle = 21 days).
45974035|NCT03424005|Drug|Inavolisib (6 mg)|Inavolisib tablets will be administered at a dose of 6 mg by mouth on Days 1-21 of each cycle (cycle = 21 days).
45974036|NCT03424005|Drug|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan will be administered at a dose of 5.4 mg/kg by IV infusion on Day 1 of each 21-day cycle.
45974037|NCT03418961|Drug|Carvedilol|Given PO
45974038|NCT03418961|Other|Laboratory Biomarker Analysis|Correlative studies
45974039|NCT03418961|Other|Patient Observation|Undergo observation
45974040|NCT03400176|Drug|VAY736|Experimental
45974041|NCT03400176|Drug|ibrutinib|Approved medication
45974042|NCT03397394|Drug|Rucaparib|Rucaparib will be administered daily.
45974043|NCT03395080|Drug|Paclitaxel|Administered by IV infusion
45974044|NCT03395080|Drug|300mg DKN-01|Administered by IV infusion
45829980|NCT01755156|Drug|Matching placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once weekly (preferably on the same day of each week)
45455988|NCT05266430|Other|Standard of Care|Patients who are planned to receive plaque radiotherapy for the treatment of IL/CM based on the expert judgment of the investigator
45455989|NCT05266430|Drug|AU-011|Previously received
45670707|NCT05648513|Behavioral|Motivational Interwiev|Parent Attitudes About Childhood Vaccines Survey (PACV) will be implemented to the patients consulting to Atatürk City Hospital. Subjects with vaccine hesitancy will be randomly distributed to groups, and in this way, experimental (n=26) and control (n=26) groups will be formed. Routine antenatal monitoring will be kept with the control group. With the experimental group, on the other hand, motivational interviewing method will be implemented for 4 sessions of about 45 minutes each. Interviews will be held at 4 separate weekends, 1 session for each. Interviews will be performed via online means or face to face.
45670708|NCT01925703|Drug|Sodium ferric gluconate|Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
45829981|NCT01755156|Drug|Glimepiride|Glimepiride 1 or 2 mg tablet/capsule administered orally once daily and up-titrated to a maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
45829982|NCT01755156|Drug|Matching placebo to glimepiride|Matching placebo to glimepiride tablet/capsule administered orally once daily and up-titrated to a mock maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
45974045|NCT03395080|Drug|600mg DKN-01|Administered by IV infusion
45974046|NCT03373760|Biological|Durvalumab|Given IV
45974047|NCT03373760|Other|Laboratory Biomarker Analysis|Correlative studies
45974048|NCT03373760|Biological|Tremelimumab|Given IV
45974049|NCT03354728|Other|Laboratory Biomarker Analysis|Correlative studies
45974050|NCT03354728|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
45974051|NCT03354390|Biological|cell infusion|This is a single-arm, phase 1 trial of HERV-E TCR transduced CD8+/CD34+ T cells in HLA-A*11:01 positive patients with metastatic ccRCC. The study is planned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a dose limiting toxicity (DLT). Patients with evaluable advanced/metastatic ccRCC will be recruited in up to 4 dose levels.
45974052|NCT03325946|Behavioral|ACQUIRE Therapy|Intensive therapy services combined with operant conditioning during treatment delivered by trained OT or PTs
45974053|NCT03324880|Biological|rhPTH (1-84)|rhPTH (1-84) SC injection.
45974054|NCT03324880|Biological|Placebo|Placebo QD SC injection.
45974055|NCT03307980|Biological|PF-06838435 (formerly SPK-9001)|Gene Therapy: A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
45974056|NCT03290794|Drug|Aflibercept (Eylea, BAY86-5321)|Intravitreal Aflibercept as prescribed by the treating Physician
45974057|NCT03283878|Drug|Cefazolin|"Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA for Group 1.~Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA. In addition, two weight based doses of cefazolin will be administered within 24 hours postoperatively for Group 2."
45974058|NCT03217422|Biological|VAY736|VAY736
45974059|NCT03217422|Other|Placebo|Placebo control with conversion to active VAY736
45974060|NCT03128359|Drug|Busulfan|Given IV
45974061|NCT03128359|Drug|Cyclophosphamide|Given IV
45974062|NCT03128359|Drug|Fludarabine Phosphate|Given IV
45974063|NCT03128359|Procedure|Hematopoietic Cell Transplantation|Undergo PBSC HCT
45974064|NCT03128359|Other|Laboratory Biomarker Analysis|Correlative studies
45974065|NCT03128359|Drug|Melphalan Hydrochloride|Given IV
45974066|NCT03128359|Drug|Mycophenolate Mofetil|Given IV or PO
45974067|NCT03128359|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC HCT
45974068|NCT03128359|Other|Quality-of-Life Assessment|Ancillary studies
45974069|NCT03128359|Drug|Tacrolimus|Given IV
45829983|NCT01755156|Drug|Insulin glargine|During Phase B of the study, participants who received a maximum up-titration of open-label glimepiride or blinded glimepiride/matching placebo to glimepiride, may be rescued with open-label insulin glargine.
45974070|NCT03128359|Radiation|Total-Body Irradiation|Undergo TBI
45974071|NCT03107897|Other|Pre-habilitation|Eight - Twelve visits to physical therapy prior to their TAVR procedure.
45974072|NCT03059342|Procedure|single event multilevel surgery|
45974073|NCT03053440|Drug|BGB-3111|160 mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
45974074|NCT03053440|Drug|Ibrutinib|420 mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
45974075|NCT03005418|Biological|Human Acellular Vessel (HAV)|The investigational medicinal product (IMP) - the Human Acellular Vessel (HAV) is a sterile acellular tubular graft composed of human collagen types I and III and other extracellular matrix proteins, including fibronectin and vitronectin which can be used for arterial bypass or reconstruction in patients with life or limb threatening vascular trauma. The vessel is 6 mm in diameter and approximately 42 cm in length. The product is supplied on a silicone mandrel immersed in sterile phosphate buffered saline in a sealed and labeled plastic container. The Humacyte HAV is implanted using standard vascular surgical techniques similar to placement of predicate peripheral vascular prostheses.
45974076|NCT02986100|Drug|C-14 labeled Rucaparib|Each dosage unit consists of a hard gelatin capsule filled with cold rucaparib camsylate and [14C]-rucaparib camsylate salt. Each capsule contains approximately 150 mg rucaparib (free base weight) and approximately 35 µCi of [14C]-rucaparib. Each patient will ingest four capsules in the fasted state for a total dose of 600 mg rucaparib (free base weight) with approximately 140 µCi of [14C]-rucaparib
45974077|NCT02986100|Drug|Rucaparib|200 & 300 mg tablet
45974078|NCT02985684|Device|GORE® CARDIOFORM ASD Occluder|Percutaneous Atrial Septal Defect Closure
45829984|NCT01755156|Drug|Metformin|Participants continue stable pre-study dose of metformin tablet(s) administered orally (>= 1500 mg daily) throughout the study.
45829985|NCT01754766|Drug|AGN-229666|One drop of AGN-229666 into each eye on Day 1 and Day 15.
45829986|NCT01754766|Other|vehicle of AGN-229666|One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
45974079|NCT02965027|Drug|Prazosin|
45974080|NCT02965027|Drug|Placebos|
45974081|NCT02959450|Dietary Supplement|Modified consistency and volume diet|Modified consistency diet, with a certain viscosity and controlled volume, which was designed from recommendations based on the review of different studies. A Chef and a Nutritionist developed and determined the viscosity of the menus with a Brookfield Viscometer (model RV). All the menus were prepared and evaluated at the Food Technology Department of this Institute to achieve the viscosity required with a food thickener. The nectar consistency had a viscosity of 51 to 350 centiPoises (cP) and the pudding consistency menus with a higher viscosity at 1,750 cP. The patient and/or their caregivers in the intervention group must attend to a training workshop to explain how to use the food thickener.
45974082|NCT02952534|Drug|Rucaparib|Rucaparib will be administered daily
45974083|NCT02949934|Drug|Tolcapone|
45974084|NCT02949934|Drug|Placebo|
45455990|NCT05249816|Biological|NVX-CoV2373|A single booster injection of NVX-CoV2373 with Matrix-M adjuvant. 0.5 mL injection volume at a dose of 5μg of antigen with 50 μg Matrix-M adjuvant
45455991|NCT05249816|Biological|BBIBP-CorV vaccine|BBIBP-CorV vaccine administered per manufacturer instructions.
45829987|NCT01754376|Drug|Aldesleukin|Intravenous therapy given every 8 hours for up to 14 doses per week.
45829988|NCT01754376|Drug|Vemurafenib|Tablets given twice daily.
45829989|NCT01605396|Drug|Ridaforolimus|Ridaforolimus 10 mg tablet, administered PO at a dose of 10 mg (triplet) or 30 mg (doublet) depending upon randomization, on Days 1-5, 8-12, 15-19, & 22-26 of 28-day cycle.
45829990|NCT01605396|Drug|Dalotuzumab|Dalotuzumab administered 10 mg/kg IV weekly on Days 1, 8, 15, and 22 of 28-day cycle.
45829991|NCT01605396|Drug|Exemestane|Exemestane 25 mg tablet administered PO QD.
45974085|NCT02935634|Biological|Nivolumab|Specified dose on specified days
45974086|NCT02935634|Biological|Ipilimumab|Specified dose on specified days
45974087|NCT02935634|Biological|Relatlimab|Specified dose on specified days
45974088|NCT02935634|Biological|BMS-986205|Specified dose on specified days
45974089|NCT02935634|Drug|Rucaparib|Specified dose on specified days
45974090|NCT02927236|Device|TMS|TBS is a type of TMS protocol.To administer the iTBS treatment, a MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 coil will be used.
45974091|NCT02921256|Drug|Capecitabine|Given PO
45974092|NCT02921256|Drug|Fluorouracil|Given IV
45974093|NCT02921256|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity modulated radiation therapy
45974094|NCT02921256|Drug|Leucovorin|Given IV
45974095|NCT02921256|Drug|Oxaliplatin|Given IV
45974096|NCT02921256|Biological|Pembrolizumab|Given IV
45829992|NCT04559802|Procedure|Transmucosal Technique|Dental implant will be placed in transmucosal manner (Healing abutment is exposed in the mouth).
45829993|NCT04559802|Procedure|Submerged Technique|Dental implant will be installed in submerged manner (implant is completed covered by soft tissue).
45974097|NCT02921256|Drug|Veliparib|Given PO
45974098|NCT02864992|Drug|Tepotinib|Subjects will receive 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
45974099|NCT02825160|Drug|Ventavis (Iloprost, BAYQ6256)|The treatment of Ventavis should comply with the local product information
45974100|NCT02807636|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
45974101|NCT02807636|Drug|Carboplatin|Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
45974102|NCT02807636|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
45974103|NCT02807636|Other|Placebo|Placebo matched to atezolizumab will be administered by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
45974104|NCT02807636|Drug|Cisplatin|Cisplatin will be administered at a dose of 70 mg/m^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
45974105|NCT02788045|Biological|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
45974106|NCT02788045|Biological|Ad26.Mos4.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 4 Ad26 vectors, 2 containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5mL injection administered intramuscularly.
45974107|NCT02788045|Biological|Clade C gp140|Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
45670709|NCT02195011|Device|SIR-Spheres|Radioembolization will be administered once by injection through a trans-femoral catheter into the hepatic artery.
45829994|NCT01730118|Biological|Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine|autologous AdHER2 transduced dendritic cell vaccine manufactured under Good Manufacturing Practices (GMP) conditions from cryopreserved patient monocytes here at the National Institutes of Health (NIH) Clinical Center (CC) Department of Transfusion Medicine (DTM). Vaccine is administered intradermally at assigned dose level at weeks 0, 4, 8, 16 and 24 of the study.
45829995|NCT01730040|Drug|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
45829996|NCT01730040|Drug|Atorvastatin|Atorvastatin over-encapsulated tablets orally.
45829997|NCT01730040|Drug|Ezetimibe|Ezetimibe over-encapsulated tablet orally.
45974108|NCT02788045|Drug|Placebo|Normal saline 0.9 percent (%), 0.5 mL injection administered intramuscularly.
45974109|NCT02746081|Drug|BAY1436032|The selected starting dose of BAY1436032 is 300 mg/day (150 mg BID) to be administered orally continuously in tablet form in 21-day cycles. Adjustments to this schedule may be made if warranted by information collected during the course of the study. The maximum feasible dose of BAY1436032 is expected to be 3000 mg/day.
45974110|NCT02740712|Drug|Caffeine|200 mg (4 x 50mg) Tablet
45974111|NCT02740712|Drug|Warfarin|10 mg (2 x 5mg) Tablet
45974112|NCT02740712|Drug|Omeprazole|40 mg Tablet
45974113|NCT02740712|Drug|Midazolam|5 mg/mL
45974114|NCT02740712|Drug|digoxin|.25 mg Tablet
45670710|NCT02195011|Drug|Regorafenib|All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.
45670711|NCT01617681|Drug|VAL489|Valsartan 3mg/kg oral solution
45670712|NCT01617681|Drug|VAL489 matching placebo|Valsartan 3 mg/kg oral solution
45670713|NCT02263079|Drug|Entecavir|Participants will receive entecavir, either as a film-coated tablet or oral solution, once daily at a dose of 0.015 milligrams per kilogram (mg/kg) (maximum daily dose of 0.5 mg).
45670714|NCT02263079|Drug|Lamivudine|Participants will receive lamivudine, either as a film-coated tablet or oral solution, once daily at a dose of 3 mg/kg (maximum daily dose of 100 mg).
45829998|NCT01730040|Drug|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
45829999|NCT01730040|Drug|Placebo|Placebo for alirocumab and ezetimibe.
45830000|NCT01706328|Drug|FF/VI 100/25 Inhalation Powder NDPI|Subjects randomized to the FF/VI Inhalation Powder Novel Dry Powder Inhaler (NDPI) arm will receive a single inhalation of 100 mcg FF and 25 mcg VI via NDPI every morning for 12 weeks.
45974115|NCT02740712|Drug|Vitamin K|10 mg Tablet
45974116|NCT02740712|Drug|Rucaparib|200 & 300 mg tablet
45830001|NCT01706328|Drug|Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of 250 mcg Fluticasone Propionate and 50 mcg Salmeterol via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
45830002|NCT01706328|Drug|Placebo Inhalation Powder NDPI|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of placebo inhalation powder via NDPI every morning for 12 weeks.
45974117|NCT02686125|Device|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their dystonia symptoms will be offered participation in this registry.
45974118|NCT02684578|Drug|Metformin|
45974119|NCT02612129|Drug|arimoclomol|
45974120|NCT02612129|Drug|Placebo|
45974121|NCT02580305|Drug|SUVN-502|Once-daily, tablets, orally
45974122|NCT02580305|Drug|Placebo|Once-daily, tablets, orally
45974123|NCT02580305|Drug|Donepezil|Donepezil HCl (10 mg, once a day)
45974124|NCT02580305|Drug|Memantine|Memantine HCl (10 mg, twice a day or 28 mg extended-release, once a day).
45974125|NCT02379416|Drug|Nilotinib + Paclitaxel|The BCR-Abl kinase inhibitor nilotinib demonstrated greater than additive activity in combination with the anti-tubulin agent paclitaxel in preclinical xenograft models, justifying the clinical evaluation of this combination for its antitumor activity
45974126|NCT02311374|Other|Brain connectivity and physiology|Two MRI scanning session will be obtained for each participant both at the same time of day (9AM 12 PM). In one occasion they will be scanned after a night of rested sleep while awake and on another day they will be scanned after one night of sleep deprivation while sleeping in the scanner. In addition to the most sensitive technique selected in the development phase (either DWI or MT), each imaging MRI session will include (1) a resting-state functional connectivity (RSFC; 10 minutes) scan using single-shot T2*-weighted EPI; and (2) quantitative T1 relaxometry (T1) in a CSF voxel (1mL; cubic) using an inversion recovery experiment with increased interpulse intervals (TI = 200, 300, 400, 500, 700, 1000, 1500, 2000, 3000, 5000, 10000 ms) and a long TR (10000 ms; scan time 2 min) to assess the level of solutes in CSF.
45974127|NCT02311374|Other|Brain Wave|ECG will be used to monitor heart rate variability (HRV), which differ significantly between the waking state and the different sleep stages
45974128|NCT02294877|Drug|Vimizim® (elosulfase alfa)|Recombinant human N acetylgalactosamine 6 sulfatase (rhGALNS)
45974129|NCT02279394|Drug|Elotuzumab|10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8
45974130|NCT02279394|Drug|Lenalidomide|25 mg Oral; Days 1-21 days Cycles 1-24
45974131|NCT02279394|Drug|Dexamethasone|40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8
45974132|NCT02229578|Drug|Lidocaine|Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
45974133|NCT02229578|Drug|Placebo|Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
45974134|NCT02153307|Device|Implantable loop recorders system Reveal ICM LINQ®,|
45670715|NCT02263079|Drug|Pegylated Interferon Alfa-2A|Participants will receive pegylated interferon-alfa-2A at a body surface area (BSA) based dose of 180 micrograms per 1.73 square meter (mcg/1.73m^2) BSA.
45974135|NCT02151513|Device|Intrathecal Pump Placement|
45974136|NCT02141438|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|This is a non-interventional study, the drug is used in its authorized indication from commercial supply. The decision to treat with Radium-223 will be agreed upon between the physician and the patient independently and prior to providing the patient study information. Treatment with Radium-223 should follow the approved local product information.
45974137|NCT02108054|Device|7T MRI|Modifying, refining, and verifying the feasibility and applicability of tasks for functional magnetic resonance imaging (fMRI) to measure intended concomitant brain activation
45455992|NCT05246605|Other|change in body position|changing from supine to prone position and the back to supine
45455993|NCT05240547|Other|Spinal Manipulation|Spinal manipulative therapy delivered to the cervical spine by a chiropractor
45455994|NCT05240547|Other|Placebo|Sham manipulative treatment delivered to the cervical spine by a chiropractor
45670716|NCT04869059|Device|Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
45974138|NCT02054741|Other|Comprehensive Geriatric Assessment|Complete geriatric assessment
45974139|NCT02054741|Other|Quality-of-Life Assessment|Ancillary studies
45974140|NCT02054741|Other|Survey Administration|Ancillary studies
45974141|NCT01915212|Biological|HSV529|The vaccine was administered intramuscularly (deltoid muscle) as a 0.5 mL solution containing 1 x 10(7) plaque forming units on day 0, one month after the first dose (day 30) and then six months after the first dose (day 180).
45974142|NCT01915212|Other|Placebo|Sodium Chloride 0.9%
45670717|NCT04869059|Device|sham tDCS|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
45974143|NCT01821781|Drug|Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan|Between days -23 and -15: alemtuzumab test dose, 3mg IV or SQ Day -14: alemtuzumab, 10mg IV or SQ Day -13: alemtuzumab, 15mg IV or SQ Day -12: alemtuzumab, 20mg IV or SQ Days -8 to -4: fludarabine, 30mg/m2 IV Day -4: thiotepa 4mg/kg IV q 12 hours Day -3: melphalan, 140mg/m2 IV Day 0: stem cell infusion Day +7: G-CSF
45974144|NCT01555463|Drug|Azelaic acid foam, 15% (BAY39-6251)|Azelaic acid twice daily topical application
45455995|NCT05230732|Device|Tragus stimulator|Active LLTS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 12 weeks
45974145|NCT01555463|Drug|Vehicle foam|twice daily topical application
45974146|NCT01534104|Procedure|preoperative fMRI. DTI and DSI with tractography|W/I approx 4-6 weeks of the fMRI, DTI & DSI, neurological/physical testing & brain MRI showing tumor &/or edema located in or near (<2 cm) the motor cortex (precentral gyrus), motor pathway (corticospinal tract), language cortex (Broca's area, Wernicke's area), &/or language pathway (arcuate fasciculus) Preoperative MRI for surgical planning (approximately <48 hours before surgery*) fMRI to localize gray matter DTI, DSI & tractography to localize white matter, DSI & updated fMRI (Optional) Most patients will undergo surgery w/i 48 hrs of their preoperative MRI. For some patients, the MRI results will be used for preoperative counseling. In this subset of patients, we expect that surgery will occur w/i 3-4 months of the MRI. Brain tumor resection as per the treating neurosurgeon Electrical stimulation to localize gray &/or white matter structures if clinically necessary according to the standard of care at MSKCC Postoperative neurological/physical examination (<48 hours after surgery)
45974147|NCT01511614|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS), a type of Non-invasive Brain Stimulation (NIBS), has the potential to modify neuronal circuits by application of a subthreshold conductive current through the scalp. Two potential targets for tDCS as a smoking cessation aid are the dorsolateral pre-frontal cortex (dlPFC), a node of the ECN, and the ventromedial prefrontal cortex (vmPFC), a node of the DMN. tDCS can potentially strengthen the control of the ECN through excitatory stimulation of the dlPFC, and weaken the influence of the DMN (Lerman et al 2014) by inhibitory stimulation of the vmPFC. The tDCS model we will use is the neuroConn DC-Stimulator MR (neuroCare Group GmbH, Munchen, Germany).
45974148|NCT01511614|Device|sham|Sham Comparator
45974149|NCT01482715|Drug|Rucaparib|Oral tablets administered daily with 8 oz (240 mL) of water on an empty stomach or with food; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day (once a day); doses and dosing frequency(e.g. twice a day or three times a day) will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 and Part 3 will receive the RP2D for continuous 21-day treatment cycles until disease progression.
45974150|NCT01398085|Radiation|I131 1.1 GBq|Radio-iodine
45974151|NCT01378871|Drug|IMTOX-25|"This agent is supplied as a sterile solution at 0.5 mg/ml. Thus a vial with 5 mL contains 2.5 mg IMTOX-25~IMTOX-25 is an immunotoxin. It is an antibody that is bound to a piece of the poison ricin. This antibody have been shown to bind to leukemia cells and kill them because of the ricin.~15 mg/m²/cycle IV. The calculated total dose for the cycle will be divided by four and given on Days 1, 3, 5 and 7."
46082097|NCT00937339|Device|Whole body vibration therapy|Experimental group: One session per day, 3 sessions per week, for consecutive 8 weeks. The total duration of whole body vibration therapy will be about 10 minutes per session.
46082098|NCT00937339|Device|Exercise on the vibration platform with the device turned off|Control group: One session per day, 3 sessions per week, for consecutive 8 weeks. The subjects will perform the same exercises on the vibration platform but no vibration will be applied.
46082099|NCT02805062|Procedure|Digital Pleural Manometry|Measurement of intra-pleural pressure and the removal of pleural fluid.
46082100|NCT02805062|Procedure|Magnetic Resonance Imaging|Subject lies a long tunnel shaped scanner and images are recorded.
46082101|NCT02733354|Device|watch viedo|
46082102|NCT00937417|Drug|docetaxel|
46082103|NCT00937417|Drug|vandetanib|
46082104|NCT00937417|Genetic|proteomic profiling|
46082105|NCT00937417|Other|laboratory biomarker analysis|
46082106|NCT00937417|Other|pharmacological study|
46082107|NCT02728440|Drug|human chorionic gonadotropin, human menopausal gonadotropin|drug for the treatment of male hypogonadism
45455996|NCT05230732|Device|SHAM|Sham LLTS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour daily for 12 weeks
45455997|NCT05227924|Device|Total hip arthroplasty (primary or revision)|Total hip arthroplasty with at least one medical device from the SYMBOL range
45670718|NCT02295995|Behavioral|Exercise as an Adjuvant Therapy for Veterans with PTSD|Methods: Approximately 50 Veterans 60 years and older with PTSD will be recruited to participate in a 12-week physical activity program consisting of aerobic and strength-training activities. Participants will be randomized to an intervention arm or usual care wait-list control. Outcomes: Changes in physical function, PTSD symptom severity, and aerobic endurance will be assessed between the two study arms. Secondary outcomes include compliance with the intervention, pain, sleep, and psychological well-being.
45670719|NCT02294981|Device|Excimer laser phototherapy|Excimer laser phototherapy is a type of ultraviolet light that is applied to psoriatic plaques. It is administered using a laser in a targeted way so that only the plaques are treated (normal skin is not treated).
45830003|NCT01706328|Drug|Placebo Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the FF/VI Inhalation Powder NDPI arm will receive a single inhalation of placebo inhalation powder via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
45830004|NCT01706328|Drug|Salbutamol as needed|Salbutamol inhalation powder
45830005|NCT01753518|Device|Subcuticular suture|subcuticular Monocryl suture closure
45830006|NCT01753518|Device|Subcuticular staple|subcuticular staple wound closure with INSORB 20 device
45830007|NCT01706250|Other|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
45830008|NCT01706250|Other|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
45830009|NCT01706250|Other|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
45830010|NCT01706250|Other|PROACTIV (2.5% BPO) Renewing Cleanser|Available over the counter.
45830011|NCT01706250|Other|PROACTIV (2.5% BPO) Repairing Lotion|Available over the counter.
45455998|NCT05218629|Drug|Anlotinib, PD-1 inhibitor|Anlotinib, 8-12 mg/day, orally, day 1-14; PD-1 inhibitor 200 mg iv, every 21 days one cycle
45974152|NCT01360606|Radiation|Stereotactic Body Radiation Therapy|"SBRT:~Patients will receive one of the following radiation regimens:~50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period.~60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period.~75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period."
45974153|NCT01306019|Drug|Palifermin|Mucositis prophylaxis commenced- Infusion of keratinocyte growth factor (palifermin) at 60 mg/kg/day before (Days -6 to Day -4) administration of busulfan
45974154|NCT01306019|Drug|Busulfan|3mg/kg per day with drug levels obtained on Day -3. Busulfan dose on day -2 will be adjusted (if busulfan AUC result is available) to achieve targeted busulfan AUC 4500 min*umol/L/day. If result is not available in time to make an adjustment, then proceed to give the standard 3mg/kg on the second day
45974155|NCT01306019|Biological|Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector|Transduced cell product administered intravenously over <30 minutes by a PI or designated Associate Investigator at the NIH Clinical Center.
45455999|NCT05214651|Procedure|novel double row|The large - massive rotator cuff tears in in this group will be treated using a novel double row repairing techniques.
45974156|NCT01257919|Drug|Azelaic Acid Foam|Dermal application of Azelaic Acid Foam
45974157|NCT01257919|Drug|Azelaic Acid Gel|Dermal application of Azelaic Acid Gel
45974158|NCT01081951|Drug|olaparib|Tablets Oral BID
45974159|NCT01081951|Drug|paclitaxel|175mg/m2 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
45456000|NCT05214651|Procedure|suture bridge double row|The large - massive rotator cuff tears in in this group will be treated using a suture bridge double row repairing techniques.
45456001|NCT05205785|Dietary Supplement|Human Milk Oligosaccharide Mix|Subjects takes 5.5 g of powder mixed in water once a day for 12 weeks.
45456002|NCT05205785|Other|Placebo|The placebo to be used in this trial is 5.5 g of powdered dextrose powder in a single-serve stick pack. The participants will be instructed to mix the product in a 4-6 oz glass of water and consume in the morning once a day for 12 weeks.
45670720|NCT02262377|Behavioral|Integrative Medicine Group Visits|Patients with chronic pain and depression attend group medical visits and use website and virtual patient advocate as part of the curriculum.
45974160|NCT01081951|Drug|carboplatin|AUC6 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
45974161|NCT01081951|Drug|paclitaxel|175mg/m2 iv for up to 6 cycles (18 weeks)
45456003|NCT05205330|Drug|CR6086|oral CR6086, twice a day for 14 days
45456004|NCT05205330|Biological|AGEN2034|AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle
45456005|NCT05203653|Behavioral|Resistance exercise only|Participants will perform 3 sets of 8 repetitions of 7 different exercises while in a fasted state.
45456006|NCT05203653|Behavioral|Resistance exercise plus cool down|Participants will perform 3 sets of 8 repetitions of 7 different exercises while in a fasted state followed by a 10-minute light aerobic cool down
45670721|NCT02260817|Drug|11C-choline Injection|"Choline C11 Injection for PET/CT Imaging Protocol:~15 - millicuries (mCi) 11C-choline IV Injection~PET images skull base to mid thigh with 3 min per bed position~Use of IV contrast based on American College of Radiology (ACR) IV contrast guidelines for a renal function screening protocol~Fusion of PET and CT images~Choline C11 Injection for PET/MRI Whole Body Imaging Protocol:~No IV contrast~High resolution axial T2 prostate bed, axial Diffusion Weighted Image (DWI) pelvis, coronal T2 skull base to mid thighs~Fusion of coronal and PET images"
45974162|NCT01081951|Drug|Drug: carboplatin|AUC4 iv for up to 6 cycles (18 weeks)
45974163|NCT00915837|Drug|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; slow release formulation approximately 1-3 mcg/day
45974164|NCT00915837|Drug|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; fast release formulation approximately 3-5 mcg/day
45974165|NCT00004847|Drug|([18F]-DOPA)|is L 3, 4 dihydroxyphenylalanine (L-DOPA) labeled with the radioactive isotope 18F. In general, PPGLs belong to the group of neuroendocrine tumors. This heterogeneous group of tumors takes up amino acids, transforms them into biogenic amines (dopamine and serotonin) by decarboxylation and stores the amines in vesicles. L DOPA is a precursor of catecholamines (dopamine, norepinephrine and epinephrine). Epinephrine conversion to dopamine is catalyzed by the aromatic amino acid decarboxylase. According to previous and current studies, [18F]-DOPA PET is highly sensitive and specific for detection of PHEO/PGL67-69. However, there are only a few reports in the literature using [18F]-DOPA as a PET agent and particularly for patients with metastatic PPGLs. PET imaging will be done together with either a CT, an MRI or both modalities.
45974166|NCT00004847|Drug|([18F]-6F-DA)|is an imaging agent developed at the NIH, that may improve specificity and sensitivity in the localization of PPGLs. [18F]-6F-DA enters cells via the membrane norepinephrine transporter. Once inside cells, [18F]-6F-DA is translocated via the vesicular monoamine transporter into storage vesicles, where the radioactivity is concentrated. After injection of [18F]-6F-DA, the much faster disappearance of [18F]-6F-DA-derived radioactivity from the bloodstream and non-neuronal cells than from chromaffin cells should enable rapid visualization of PPGLs by PET scanning.
45974167|NCT00001309|Other|Vitamin C|Outpatient subjects will be encouraged to consume vitamin C in foods. As inpatients, vitamin C deficiency will be induced by placing subjects on a tightly restricted scorbutic diet. Plasma vitamin C will be monitored several times per week. When subjects have achieved a plasma ascorbate concentration of 5-10 micromolar, blood sampling and urine collection over 24 hours will be performed. After platelets and leukocytes are collected, ascorbate repletion will begin. Escalating doses of ascorbate will be administered orally and intravenously for the remainder of their inpatient admission. Total daily doses of 30mg, 60mg, 100mg, 200mg, 400mg, 1000mg and 2500mg will be given in two divided doses. Bioavailability of ascorbate will be determined at each dosage increment. When plasma ascorbate concentration reaches steady state for each dose, subjects will undergo 36 hr plasma sampling and a timed 48 hr urine collection.
46082108|NCT04119986|Device|drug coated balloon|Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for >30 seconds.
45456007|NCT05200182|Device|Neurofeedback with functional near infra-red spectroscopy|"the neurofeedback protocol will last 15 minutes per session, and during each session, the volunteer will have to increase the brain activity of his/her dorsolateral prefrontal cortex using a visual gauge representing the activity level of his/her own dorsolateral prefrontal cortex. No specific instructions will be given to the volunteer so that he/she can develop his/her own internal strategy to increase this activity level."
45456008|NCT05200182|Device|Sham Neurofeedback|the participants will receive the same instruction but will be shown a random signal
45670722|NCT05647967|Diagnostic Test|Ultrasound|Each patient underwent ultrasound after admission of ICU.
45830012|NCT01706250|Other|PROACTIV (2.5% BPO) Revitalizing Toner|Available over the counter.
45670723|NCT04873193|Device|Leo device|Children's respiratory flow and volume measurements will be continuously recorded using the Leo device during oscillometry and pneumotach procedures.
45670724|NCT01642589|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)|0.5 mL, Intramuscular
45670725|NCT01642589|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
45830013|NCT01729728|Drug|Tapentadol|Tapentadol oral solution single dose (1mg/kg body weight)
45830014|NCT01729026|Other|Shelter Dog Adoption|Veterans will choose a dog from the San Antonio Humane Society with the help a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
45830015|NCT01728792|Biological|TDV|TDV IM or SC injection
45830016|NCT01752036|Radiation|Post-operative, Stereotactic Body Radiation Therapy (SBRT)|All participants received SBRT at 600 cGy x 5 fractions
45830017|NCT01728324|Drug|BI 207127-placebo: 8-week treatment|8 weeks of placebo treatment
45830018|NCT01728324|Drug|Ribavirin: 24-week treatment|24 weeks of active treatment
45830019|NCT01728324|Drug|BI 207127: 24-week treatment|24 weeks of active treatment
45830020|NCT01728324|Drug|Faldaprevir: 24-week treatment|24 weeks of active treatment
45830021|NCT01728324|Drug|Faldaprevir: 24-week treatment|24 weeks of active treatment
45830022|NCT01728324|Drug|Ribavirin-placebo: 8-week treatment|8 weeks of placebo treatment
45830023|NCT01728324|Drug|BI 207127: 24-week treatment|24 weeks of active treatment
45830024|NCT01728324|Drug|Faldaprevir-placebo: 8-week treatment|8 weeks of placebo treatment
45830025|NCT01728324|Drug|Faldaprevir: 16-week treatment|16 weeks of active treatment
45830026|NCT01728324|Drug|Ribavirin: 16-week treatment|16 weeks of active treatment
45830027|NCT01728324|Drug|RBV: 24-week treatment|24 weeks of active treatment
45830028|NCT01728324|Drug|BI 207127: 16-week treatment|16 weeks of active treatment
45974168|NCT00001168|Behavioral|Balanced diet|
45974169|NCT00001160|Drug|68-Gallium Dotatate|For evaluation risk/benefit evaluation
45974170|NCT00239096|Drug|losartan (drug)|
46082109|NCT04119986|Device|drug eluted stent|with regular techniques
45974171|NCT04532398|Other|Gugging swallowing screen - ICU (GUSS-ICU) index test|"Gugging swallowing screen - ICU (GUSS-ICU) index test:~Screening for post-extubation dysphagia: GUSS-ICU performed by 2 speech therapists independently. The GUSS-ICU model contains the core features of the original GUSS tool with the added assessment items specific to the ICU Patient (RASS score (Richmond Agitation and Sedation Scale)).~Stage one of the screen focuses on the preliminary investigation of indirect swallowing. Stage two is comprised of varying steps that directly test swallowing. This would include the administration of semisolids, water and bread with four distinct signs that were being assessed for - deglutition, coughing, drooling and voice change. The GUSS test is evaluated using a points system (0-10) which determines the severity of dysphagia and recommends a diet form that largely minimizes the risk of aspiration. (e.g. 10 points: No dysphagia = normal food)."
45974172|NCT04532398|Other|Flexible Endoscopic Evaluation of Swallowing (FEES) reference test|"Flexible Endoscopic Evaluation of Swallowing (FEES) reference test:~Flexible Endoscopic Evaluation of Swallowing (FEES) is a technique to directly view the pharynx, larynx and esophagus during swallowing. The swallowing test is carried out first with saliva and then with different consistency (liquid, pulpy, solid) and different sized swallowing portions. This reference test is performed independently from the GUSS-ICU index test."
45670726|NCT04868357|Behavioral|Hypnosis|Two 45-minute group sessions in which patients experience hypnosis and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. First session is introductory. Second session addresses concerns that patients may have identified after using self-hypnosis. Both sessions include group hypnosis exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, eye closure, relaxation, nodding). Patients are asked to concentrate in nature-themed metaphors and hypnotic suggestions of pure air entering their lungs. Both sessions end with a round of questions, instructions and motivation to use self-hypnosis throughout the duration of the PRP and beyond.
45670727|NCT04868357|Behavioral|Relaxation|Two 45-minute group sessions in which patients experience dynamic relaxation and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. Both sessions include group relaxation exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, stretching, breathing exercises, nodding). Both sessions end with a round of questions, instructions and motivation to use relaxation throughout the duration of the PRP and beyond.
45974173|NCT04532554|Drug|Growth Hormone|Recombinant growth hormone will be used
45974174|NCT04532554|Drug|Placebo|Saline injection with the same amount
45670728|NCT05647499|Behavioral|The Back 2 School program for problematic school absenteeism|We will use the Danish version of the revised manual developed within the B2S study in Aarhus, Denmark. The B2S program consists of a 3 to 3,5 -hour initial clinical assessment, a clinical conference, 11 sessions where the youth and/or parent are attending, and a booster session after three months including youth and parent. The B2S manual comprise four school meetings with the child, parents, school staff and therapists present. In the Norwegian pilot study, we will add an extended school module to the B2S-program. The school module includes a pre-meeting interview with the schools in week 1 and session 1 with the school in week 2 or 3. The B2S counselor and the school will decide whether there is a need for an additional meeting between school meetings 1 and 2. There is also a booster session with the child, parents, the school and the B2S team 3 months after the program.
45670729|NCT05647421|Device|IOL implantation|after phacoemulsification of the cataract , implantation of Acrysof IQVIVITY IOL .
45670730|NCT05647421|Device|IOL implantation|after phacoemulsification of the cataract , implantation of TECNIS Synergy™ Intraocular Lens (Model ZFR00V )
45830029|NCT01728246|Drug|Tramadol/Paracetamol (APAP)|Celecoxib 200 milligram (mg) once daily for 4 weeks and fixed dose combination of Tramadol 37.5 mg/Paracetamol 325 mg thrice daily for 4 weeks as add-on therapy.
45830030|NCT01728246|Drug|Non-Tramadol/APAP|Celecoxib 200 mg alone once daily for 4 weeks.
45830031|NCT04414020|Drug|Progesteron|intramusculer progesterone
45830032|NCT04559178|Other|Fluid challenge|fluid challenge administration when patient is in the gray zone
45830033|NCT04559022|Procedure|Fat Grafting|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.
45974175|NCT04532281|Drug|Murine CD19 CAR-T cells|Each subject receive murine CD19 CAR T-cells by intravenous infusion
45456009|NCT05200182|Other|oral microbiota collection|an examination and oral swab for oral microbiota analysis will be performed by a dentist
45830034|NCT01705236|Drug|Fingolimod|All subjects received an oral dose of 0.5 mg fingolimod (FTY720) per capsule (hard gelatin capsules) once daily according to local label for the treatment of their MS.
45830035|NCT01705080|Device|EnligHTN|Renal artery ablation with EnligHTN system used for all groups
45830036|NCT01704846|Drug|BI 201335 NA 120 mg capsule|1capsule of BI 201335 NA 120 mg capsule
45974176|NCT00239135|Drug|PEP005|
45974177|NCT04532086|Diagnostic Test|Uterocervical angle|Transvaginal ultrasound examination will be performed at 18-28 weeks gestation in (197) pregnant women with live singleton fetuses, attending routine prenatal care services. Measuring length of uterine cervix at (18-28) weeks & evaluation of dilatation of internal os & measurement of uterocervical angle between(18-28)weeks gestational age.
45974178|NCT04532203|Drug|CAR-T cells|Each subject receive CAR T-cells by intravenous infusion
45974179|NCT04532203|Procedure|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
45974180|NCT02217163|Drug|Carfilzomib, , Cyclophosphamide, Dexamethasone|Carfilzomib is administered intraveneously over 30 minutes. For cycle 1 only, Carfilzomib is administered at 20mg/m2 on Day 1 and 2, dose will be escalated to 36mg/m2 on Day 8,9,15 and 16 of the 28-days cycle. Patients who tolerate the 36mg/m2 dose are kept at this dose for the subsequent cycles on Day 1,2,8,9,15,16 on a 28 days cycle. Cyclophosphamide is given at a fixed dose of 500mg once per week orally, along with dexamethasone which is given on the days of Carfilzomib administration, 30 minutes to 4 hours prior to Carfilzomib infusion.
45974181|NCT02217202|Device|Aquacel Ag dressing|Participants will have their knee arthroplasty wound dressed using the Aquacel Ag dressing instead of the standard Aquacel dressing.
45974182|NCT00239174|Drug|SR147778|
45974183|NCT04531852|Other|CALSTI - Complex Active Lifestyle Intervention|"A group-based exercise (EX) and health empowerment program (HEP) conducted in the local area.~Structured, progressive resistance (55-60%), balance (10-15%), endurance (10-15%) exercise was delivered twice weekly for 12 weeks under supervision of a trained instructor.~HEP consists of 8 group sessions aiming to facilitate long-term behaviour change, by empowering older citizens to act on current risk behaviours (i.e. low physical activity/exercise, high sedentary behaviour, social isolation, poor dietary habits, incontinence). Four sessions were conducted during the exercise intervention period (phase 1 - intensive), and four sessions in the following 12 weeks (phase 2 - maintenance)."
45974184|NCT04531852|Behavioral|SEMAI - Self-Management Intervention|A low-cost enhancement of the existing preventive service where citizens are information about relevant health resources. Citizens allocated to SEMAI intervention are offered the health-empowerment program as outlined above, including four extra sessions dedicated to practical experiences with exercising. 24 weeks duration in total, with eight sessions in phase 1 and four sessions in phase 2
45974185|NCT04531774|Behavioral|RECHARGE|"RECHARGE is an abbreviated and adapted version of Problem Management Plus (PM+), an evidence-based intervention that helps to cope with stress in times of crisis. Recharge is specifically developed for HCWs as a brief psychological intervention for adults affected by adversity emerging from stress exposure and teaches people three well-documented strategies to manage acute stress. The strategies are: a) managing stress, b) managing worry, c) meaningful activity. It includes psychoeducation, arousal reduction techniques, managing worries and problem-solving skills, behavioural activation, enhancement of meaningful activities, and relapse prevention, which are all based on the principles of cognitive-behavioural therapy.~RECHARGE is delivered online in a 1 to 1 setting between coach and participant. Trained peers (medical doctors, nurses, psychologists) act as coaches."
45974186|NCT04531774|Behavioral|Self Study|HCWs are referred to a few recommended webpages that outline well-validated, adaptive coping strategies for managing stress.
45974187|NCT00239213|Drug|catechin extracts (health food)|
45974188|NCT04531930|Procedure|surgery|Colorectal surgery, mainly total proctocolectomy.
45974189|NCT04531930|Procedure|enhanced colonoscopy|Colonoscopic treatment and surveillance in every 3 months.
45974190|NCT04531930|Other|self choosed methods|A patient chooses a method for himself other than surgery.
45974191|NCT04532008|Behavioral|Group based treatment|12 sessions of group based therapy that included cognitive restructuring, behavioral activation, and interpersonal therapy
45974192|NCT00263367|Other|Hyperbaric Oxygen|Hyperbaric Oxygen at 1.3 ATA for one hour
45974193|NCT04531423|Drug|SSRI + golimumab|Golimumab will be administered at the dose of 50mg every month during the acute phase.
45974194|NCT04531423|Other|SSRI + placebo|placebo
45974195|NCT04531657|Drug|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly during 2008-2009 season for measurement of A/Brisbane/59/2007(H1N1)-like, A/Brisbane/10/2007(H3N2)-like, and B/Florida/4/2006-like antigens
45974196|NCT00239252|Drug|Interferon alfacon-1|
45456010|NCT05200182|Other|Questionnaires|questionnaires for pre-intervention behavioral characterization
45456011|NCT05200182|Device|resting-state fMRI|characterize the brain function of volunteers by resting-state fMRI
45456012|NCT05200182|Device|Electro gastrogram|Volunteers will also be equipped with an MRI-compatible electro-gastrogram device to correlate gastric signals with brain activity during rsMRI acquisition.
45456013|NCT05200182|Behavioral|Emotional Stroop task|an emotional Stroop task adapted to food and body image representation
45830037|NCT01704846|Drug|BI 201335 NA 120 mg capsule|1 capsule of BI 201335 NA 120 mg capsule
45830038|NCT01704846|Drug|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
45830039|NCT01704846|Drug|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
45830040|NCT01751802|Drug|Ecopipam|Antagonist of the dopamine D1 receptor
45830041|NCT01751802|Drug|Placebo|Placebo for Ecopipam
45830042|NCT01704456|Behavioral|Mindfulness-based Cognitive Therapy|The MBCT intervention will be administered in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
45974197|NCT04531306|Other|Kinesio® Tape|Fascial taping technique for myofascial trigger points on the iliotibial band
45974198|NCT00263406|Drug|Administration of an ACE-inhibitor or not|
45974199|NCT04531267|Dietary Supplement|Individualized dosage of calcium and magnesium|Participants' diet will be assessed by food frequency questionnaire to obtain calcium and magnesium intake. Individualized dosage of dietary supplements will be provided to maintain a calcium/magnesium ratio as 2.3. Participants will stay with the original medication plan.
45974200|NCT04531228|Procedure|TACE-HAIC plus lenvatinib|chemo-lipiodolization with EADM (30mg/m2), followed by FOLFOX-based chemotherapy artery infusion (Oxa 85mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2). Lenvatinib was administrated two or four days after TACE-HAIC, with 8mg for patients weight <60kg, or 12mg for patients weight more than 60Kg.
45974201|NCT04531150|Drug|INV-101|Subjects will be randomized to receive INV-101 tablets
46082110|NCT00609713|Behavioral|Comprehensive behavioral weight control program|Participants will meet weekly for 12 weeks, then every other week for 12 weeks, and once a month thereafter through week 52. Adolescents and parents will receive manuals that provide lessons and homework assignments for each meeting. The program for the first 22 weeks includes the following topics: 1) the causes of obesity; 2) components of healthy nutrition; 3) self-monitoring of calories, physical activity, and inactivity; 4) stimulus control procedures; 5) coping with high-risk social or psychological situations that trigger excess eating; 6) increasing physical activity; and 7) minimizing inactivity. At each session, participants will submit their self-monitoring diaries and completed homework. Incentives for completion of self-monitoring tasks are an integral part of the behavior modification program and a small gift certificate will be given to subjects for successful completion at each intervention session.
45456014|NCT05196763|Behavioral|the Supplemental Nutrition Assistance Program-Education|The Supplemental Nutrition Assistance Program-Education is federal nutrition education provided in all U.S. states to the SNAP-eligible population.
45456015|NCT05193149|Behavioral|Inspiratory muscle training|Training of respiratory muscles
45456016|NCT05193149|Behavioral|Exercise training|Supervised aerobic exercise intervention
45456017|NCT05191667|Drug|AN0025|250 mg or 500 mg Q.D., oral administration
45670731|NCT01954251|Biological|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
45670732|NCT01954251|Biological|GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A|2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.
45670733|NCT01644617|Drug|Placebo|Placebo rapidly dissolving tablets administered sublingually once daily
45670734|NCT01644617|Drug|MK-8237 6 DU|MK-8237 6 DU rapidly dissolving tablets administered sublingually once daily
45670735|NCT01644617|Drug|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablets administered sublingually once daily
45830043|NCT01704456|Behavioral|Cognitive Behavioural Therapy|The CBT intervention will be administered to women in small group format (8-9 women). Each session will be 2.25-hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
45830044|NCT04166526|Device|FDNIRS-DCS|FDNIRS-DCS measurements will be performed at the same time as all MRI scans. Participants in Group 4 will have additional measurements before, during, and after the their scheduled transfusion.
45830045|NCT04166526|Device|MRI|Participants in Groups 1-3 will receive a single, hour-long MRI. Participants in Group 4 will receive two, one hour long MRI scans: one within a week prior to their transfusion and one within a week after their transfusion.
45830046|NCT01703988|Drug|Nusinersen|Single IT injection for each dose
45830047|NCT01703832|Drug|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
45830048|NCT01703286|Drug|Placebo|Placebo matching Glimepiride
45830049|NCT01703286|Drug|Linagliptin|given once daily for 28 days
45830050|NCT01703286|Drug|Placebo|Placebo matching Linagliptin
45830051|NCT01703286|Drug|Placebo|Placebo matching Linagliptin
45830052|NCT01703286|Drug|Placebo|Placebo matching Glimepiride
45830053|NCT01703286|Drug|Glimepiride|1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)
45974202|NCT04531150|Drug|Placebo|Subjects will be randomized to receive placebo tablets
45974203|NCT00414284|Drug|Increased dose of Kaletra|
45974204|NCT04531345|Diagnostic Test|Flow cytometric analysis|IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokine analysis of COvid-19 patients and healthy volunteers
45974205|NCT04531072|Drug|Artemether-lumefantrine|Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
45974206|NCT04531072|Drug|Atazanavir-ritonavir 300/100 mg|Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
45974207|NCT04530955|Device|Prometra II Programmable Pump - Flowonix Medical|The valve gated Prometra II Programmable Pump will be replacing the prior peristaltic Synchromed II pump and a 20% dose decrease will be performed at the time of the replacement.
45974208|NCT00414323|Drug|Duloxetine|
45974209|NCT00414323|Drug|Escitalopram|
45974210|NCT00414323|Drug|Placebo|
45974211|NCT00263484|Drug|dexamethasone|20 mg, PO (orally) on days 1-4, 8-11 and 15-18 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
45974212|NCT00263484|Drug|thalidomide|100 mg, PO (orally) on days 1-21 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
45974213|NCT00263484|Drug|zoledronic acid|4 mg, IV (in the vein) on day 1 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
45974214|NCT04531033|Dietary Supplement|Lactobacillus acidophilus MPH734|After supplementing with oral probiotics, it has been suggested that select probiotics capable of expressing Beta-glucosidase enzyme activity may likewise be effective treatment for lactose intolerance.
45974215|NCT04531033|Dietary Supplement|Placebo|placebo made to match dietary supplement being tested.
45974216|NCT04530448|Drug|Sodium bicarbonate|Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.
45974217|NCT04530448|Other|Standard of Care|Standard of Care treatment
45974218|NCT04530721|Other|no intervention|we don't do any intervention
45974219|NCT00263523|Drug|[11C] (-)-RWAY|
45974220|NCT04530370|Biological|recovered covid 19 patients plasma|we transfused 150 ml of recovered covid 19 plasma to severely ill patients with confirmed covid 19 disease
45974221|NCT00414401|Behavioral|Clinical Reminder|
45670736|NCT02294318|Behavioral|HealthCall+Motivational Interviewing|HealthCall is a technology-based enhancement to brief MI to improve behavior outcomes. It is introduced to patients by the study counselor at the end of the MI session.
45456018|NCT05185128|Behavioral|PEERS social skills intervention|The PEERS treatment program consists of 90-minute sessions, delivered once a week over the course of 16- weeks. Parents and children/adolescents attend separate concurrent sessions that instruct them on key elements about making and keeping friends. Among others, this parent-assisted, social skills intervention provides explicit instruction to target verbal and nonverbal communication skills, appropriate use of humor and resolving peer conflict, as well as expanding and developing friendship networks38. The candidate, Dr. Nair, has been trained on the PEERS social skills intervention extensively for the past five years, and is a certified provider for the adolescent program. The PEERS program will be provided by Dr. Nair's research team (consisting of Dr. Nair, lab co-ordinators, and clinical psychology doctoral students) through the LLU Department of Psychology.
45456019|NCT05182710|Behavioral|Stress Inoculation Training|"The SIT programme/intervention will involve~30 minute educational phase of preparatory information to allow participants to conceptualise the types of stressors they are likely to face and the role of stress on performance~30 minutes of skills acquisition which will involve discussion of and teaching participants techniques to reduce stress in simulated resuscitation events~Inoculation through the application of acquired skills in 1-2 resuscitation scenarios"
45670737|NCT02294318|Behavioral|Motivational Interviewing|Motivational Interviewing is a client-centered counseling approach for eliciting behavior change.
45670738|NCT04643925|Drug|Ovitrelle|Ovitrelle 260 IE once daily for 8 weeks prior to IVF/ICSI
45670739|NCT02293499|Behavioral|PLASMA|"A structured asthma self-management manual (Let's Talk about Asthma [LTAA],developed by the study team will be utilized in a camp like setting and administered by either peers or adults medical professionals. The manual adheres to the 2007 NAEPP Guidelines Training strategies will involve didactic sessions, discussion, demonstrations, and role-play. Group learning activities will closely align with the program manual (LTAA) that consists of three sessions. Participants will also learn and practice skills in using the peak flow meter, spacer and inhaler, daily symptom diary and asthma action plan. Besides instructional activities, participants will engage in recreational activities that each camp site."
45830054|NCT04166448|Other|Fetal MRI|The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus(es)
45830055|NCT01703208|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly
45830056|NCT01703208|Drug|Placebo|Matching placebo to omarigliptin capsule or tablet administered orally once weekly
45830057|NCT01727700|Drug|Aripiprazole|Once-daily, tablet
45974222|NCT04530331|Behavioral|Nutrition education|Dietitians visited the worksites of the intervention group once a week to deliver a nutrition education session and provide dietary advice for each participant.
45974223|NCT02217319|Drug|Sevoflurane|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min). After induction of anesthesia the propofol infusion is stopped and patients receive 1 MAC Sevoflurane over 30 min. Then the propofol infusion is restarted and Sevoflurane is washed out.
45974224|NCT02217319|Drug|TIVA|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min).
45974225|NCT00263601|Biological|Allergovit 6-grasses|Subcutaneous injections
45830058|NCT01727700|Drug|Placebo|
45830059|NCT01727154|Biological|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
45974226|NCT00263601|Other|Placebo|Subcutaneous injections
45974227|NCT02217397|Device|OA, CPAP, combination therapy|
45974228|NCT00414479|Drug|praziquantl, iron, ACT|
45830060|NCT01725750|Device|Bright White Light (BWL)|"Participants will self-administer bright white light daily. Litebooks used for Bright White Light and Dim Red Light are identical except for the light which they emit. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box."
45974229|NCT02217514|Drug|Midazolam|
45974230|NCT02217514|Drug|BI 44370 low dose|
45974231|NCT02217514|Drug|BI 44370 medium dose|
45974232|NCT02217514|Drug|BI 44370 high dose|
45974233|NCT02217553|Drug|Cholecalciferol|The study participants will receive 180 soft gel cholecalciferol capsules, to be taken 2 capsules once a day for 90 days
45974234|NCT04719312|Procedure|Y modification of transconjunctival approach|"Section of the orbital septum is done at the Arcus Marginalis and subperiosteal dissection done to expose the infraorbital rim and orbital floor.~Subsequently, canthotomy of the superficial limb of the lateral canthal ligament is performed and subperiosteal dissection is carried out to expose the fracture at the frontozygomatic region.~The cutaneous Y will transform into a box when retracting its corners, increasing the working area and allowing access of the frontozygomatic (FZ) suture, lateral orbital wall, body of the zygoma, infraorbital rim, and floor of the orbit with a single approach.~A small upper vestibular incision is placed to expose the fracture at the zygomatic buttress. Reduction and fixation of fractures in a regular fashion are accomplished."
45974235|NCT02217631|Drug|BI 653048 BS H3PO4|
45974236|NCT02217631|Drug|Prednisolone low dose|
45974237|NCT02217631|Drug|Prednisolone high dose|
45974238|NCT02217631|Drug|Placebo|
45974239|NCT04530292|Behavioral|Intervention by a pediatric nurse at the child's home|"The intervention will consist of a coordinated intervention by a pediatric nurse at the child's home to support the parents in the implementation of the theoretical knowledge acquired at the hospital.~Three home visits will be set up by a nurse during the first six months of the discovery of diabetes in the child. These visits will be organized during the first, fourth and sixth months after the discovery of diabetes and last about 2 hours each time. An additional visit may be set up according to the needs of families."
45974240|NCT02217670|Drug|Metformin 1000 mg granules|
45974241|NCT02217670|Drug|Metformin 1000 mg film-coated tablets|
45974242|NCT00239291|Drug|Gefitinib, radiotherapy|
45974243|NCT02217748|Other|Survey questionnaire|
45974244|NCT00263640|Biological|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
45974245|NCT00263640|Drug|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients were treated according the same dosing schedule of active group. Children received lifestyle counselling.
45974246|NCT02217826|Drug|DG3173|
45830061|NCT01725750|Device|Dim Red Light (DRL)|"A device that appears identical to BWL Litebook but that uses red LEDs emitting DRL. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box."
45974247|NCT02217826|Drug|Saline|
45974248|NCT02217826|Drug|Octreotide|
45974249|NCT02278666|Procedure|aortic valve replacement|aortic valve replacement with either biological prosthetic valve or mechanical valve
45456020|NCT05182710|Behavioral|Alternative Training|"30 minutes of teaching on management of a drowning patient (in order that both control and intervention perceive they have had teaching of the same length as the other group)~1-2 resuscitation simulation events (same scenario and tasks as in the intervention group)"
45456021|NCT05179226|Drug|Ferric Derisomaltose|All subjects will be treated with Ferric derisomaltose 20 mg/kg at baseline visit except for 12 subjects included in the PK-group, who will be treated with 10 mg/kg
45456022|NCT05177653|Other|Intravenous infusion|GIP receptor antagonist (GIP(3-30)NH2)
45830062|NCT01725282|Drug|quetiapine extended release (XR)|Extended release tablets
45830063|NCT01725282|Drug|Placebo|matching tablets
45830064|NCT01725126|Drug|GSK2890457|Provided as powder and capsule.
45830065|NCT01725126|Drug|Metformin|"Tablet~Part A: Single doses on Day 1 and Day 42 orally~Part B: Subject continues usual metformin dose through Run-in, and resumes after Treatment Period completed~Part C: Subject continues usual metformin dose throughout study"
45830066|NCT01725126|Drug|Placebo|Provided as powder and Capsule.
45830067|NCT01725126|Drug|Liraglutide|"Provided as Injection. 6mg/mL, 3mL injector pen that permits doses of 0.6mg, 1.2mg, and 1.8mg~Subcutaneous injection 18 weeks dosing (Stabilization and Treatment Periods, Part B only"
45830068|NCT01751724|Drug|Caffeine citrate|"Enrolled subjects will be randomized to receive a study drug consisting of either blinded Caffeine citrate.~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
45974250|NCT02278666|Device|biological prosthetic valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
45974251|NCT02278666|Device|Mechanical valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
45974252|NCT00239330|Drug|Rosuvastatin|
45974253|NCT00239330|Drug|Atorvastatin|
45974254|NCT04530097|Procedure|RFA|Radiofrequency ablation was performed immediately after enrollment, and melatonin treatment was given for 6 months after 1 week after radiofrequency.
45974255|NCT02218021|Drug|Samidorphan|
45974256|NCT02218021|Drug|Placebo|
45974257|NCT02218021|Drug|Oxycodone|
45974258|NCT04719234|Device|lung ultrasonography|Application of 12 zone lung ultrasonography protocol using the konvex ultrasound probe (2-6 MHz)
45974259|NCT02218060|Procedure|Coronary CT angiography on SOMATOM Force|Coronary CT angiography using iodinated contrast; metoprolol and/or nitroglycerin may also be administered on a per-patient basis
45974260|NCT02218060|Procedure|Previous coronary CT angiography on 2nd generation CT scanner|Clinically indicated coronary CT angiography previously performed on a 2nd generation CT scanner
45974261|NCT00239369|Drug|Fixed dose combination telmisartan 80 mg + HCTZ 25 mg|
45974262|NCT00239369|Drug|Fixed dose combination telmisartan 80 mg + HCTZ 12.5 mg|
45974263|NCT04529746|Behavioral|EVERYbody Project|Brief behavioral intervention (4 hours across two meetings)
45974264|NCT04529668|Drug|vitamin D supplementation|vitamin D supplementation
45974265|NCT04529668|Drug|usual therapy for nasal polyposis|steroids ( systemic and local )
45974266|NCT00263679|Biological|Prophylaxis: Diphtheria, tetanus and pertussis|
45974267|NCT02218099|Drug|ASP8232|Oral
45974268|NCT02218099|Drug|Placebo|Oral
45974269|NCT00239408|Device|Pulmonary function Testing|
45974270|NCT00239408|Drug|tiotropium bromide|
45974271|NCT02218138|Behavioral|Learning 2 BREATHE|Mindfulness-based group program
45974272|NCT02218138|Behavioral|Colorado Blues|Colorado Blues, Cognitive-behavioral depression prevention group
45974273|NCT02218177|Drug|Aflibercept|anti-VEGF treatment for wet age related macular degeneration
45974274|NCT02218177|Drug|Ranibizumab|anti-VEGF treatment for wet age related macular degeneration
45974275|NCT02218177|Procedure|Combination Photodynamic Therapy|Use of cold laser with an intravitreal injection of dexamethasone to treat wet age related macular degeneration
45974276|NCT00263718|Drug|Calcipotriol plus betamethasone dipropionate (LEO 80185) gel|
45670740|NCT04628949|Device|aScope™ Duodeno endoscope and aBox™ Duodeno|"The aScope™ Duodeno endoscope is a sterile single-use disposable duodenoscope indicated for endoscopic retrograde cholangiopancreatography (ERCP) procedures.The aScope™ Duodeno endoscope is designed to be used with aBox Duodeno, endoscopic accessories and other ancillary equipment for ERCP procedures.~The aBox Duodeno is the console that is necessary for processing the endoscope camera´s video image, regarding the remote switches and output video and recorder data. The aBox Duodeno is designed to be used with the aScope™ Duodeno endoscope."
45974277|NCT02218255|Device|Eeva™ results|
45974278|NCT02218294|Drug|BCX4161|
45974279|NCT02218333|Dietary Supplement|Milk|4 dl milk will be consumed daily with breakfast and supper for 12 weeks
45974280|NCT02218333|Dietary Supplement|Placebo|
45974281|NCT02218528|Dietary Supplement|Plant-based ingredient|
45974282|NCT02218528|Dietary Supplement|No Plant-based ingredient|
45974283|NCT02218567|Behavioral|questionnaire qualilty of life|
45974284|NCT02218567|Behavioral|psychological interview|
45974285|NCT02218567|Behavioral|psychological tests|
45456023|NCT05177653|Other|Intravenous infusion|GLP-1 receptor antagonist (exendin(9-39)NH2)
45830069|NCT01751724|Other|Normal saline|"Enrolled subjects will be randomized to receive a study drug consisting of blinded Placebo (equivalent volume of normal saline).~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
45830070|NCT01751646|Dietary Supplement|Vitamin D3 50,000 IU|Group A: Vitamin D3 50,000 IU orally every four weeks by DOT
45830071|NCT01751646|Dietary Supplement|Vitamin D3 placebo|Group B: Vitamin D3 placebo orally every four weeks by DOT
45830072|NCT01751568|Drug|Raltegravir|Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) orally twice daily.
45974286|NCT02218567|Other|Motor evaluation|
45974287|NCT02218567|Behavioral|Behavioral evaluation|
45974288|NCT02218567|Behavioral|cognitive tests|
45456024|NCT05177653|Other|Intravenous infusion|GIP(3-30)NH2 and exendin(9-39)NH2
45456025|NCT05177653|Other|Intravenous infusion|Saline
45456026|NCT05176197|Other|Almond|Participants will consume almonds every day for 16 weeks.
45456027|NCT05176197|Other|Control|Participants will consume pretzels every day for 16 weeks.
45670741|NCT04620603|Radiation|Low Dose Rate Brachytherapy (LDR)|LDR on treatment day 1
45670742|NCT04620603|Drug|Standard-of-Care Immunotherapy|Every 28 days, 12 cycles total
45830073|NCT01751412|Radiation|Proton Radiation|
45830074|NCT04556682|Device|Rotational atherectomy|Device used for severely calcified coronary lesion preparation before stent implantation.
45830075|NCT04556682|Device|Intravascular lithotripsy|Device used for severely calcified coronary lesion preparation before stent implantation.
45830076|NCT01751178|Drug|Chlorhexidine Digluconate Mouthwash with Alcohol|0.2% w/v Chlorhexidine Digluconate, alcohol containing - UK Marketed Mouthwash
45974289|NCT02218645|Drug|WE 941 OD tablets|
45974290|NCT02218645|Drug|Brotizolam|
45974291|NCT02218684|Drug|Telmisartan|
45974292|NCT02218684|Drug|Lacidipine|
45974293|NCT02218684|Drug|Placebo|
45974294|NCT02278822|Other|Low dose oral liposomal glutathione supplementation|Low dose oral liposomal glutathione supplementation
45974295|NCT02278822|Other|High dose oral liposomal glutathione supplementation|High dose oral liposomal glutathione supplementation
45974296|NCT02278861|Drug|Oral isotretinoin|Oral isotretinoin - 10mg/day (one pill) after lunch for six months
45974297|NCT02278861|Drug|Tretinoin 0,05% cream|Topical tretinoin 0,05% cream - applied every other night in the face and forearms for six months
45974298|NCT02278861|Drug|Sunscreen FPS 60|Sunscreen FPS 60 applied on sun exposed areas every 3 hours daily
45974299|NCT02278900|Other|Communication aids|Question Prompt list Audiofile
45974300|NCT01641913|Other|Absorbable sugars|Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
45974301|NCT01642030|Drug|Placebo|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
45974302|NCT01642030|Drug|Hydromorphone|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
45974303|NCT01642030|Drug|Buprenorphine|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
45974304|NCT01642069|Other|laboratory biomarker analysis|Correlative studies
45974305|NCT00239447|Drug|Tiotropium|
45974306|NCT00239447|Device|HandiHaler|
45974307|NCT00239447|Device|Respimat SMI|
45974308|NCT00263796|Drug|Oxytocin|10 international units = 1 cc, IV over 4 hours
45974309|NCT00263796|Drug|Placebo|Normal Saline, IV over 4 hours
45974310|NCT01642108|Drug|Sitagliptin|50 mg once per day
45974311|NCT01642264|Behavioral|WeBREATHe Training Program|The WeBREATHe Training Program is a web-based, interactive training program to teach pediatric respiratory therapists, nurses and nurse practitioners how to help their patients' parents to quit smoking.
45974312|NCT01642303|Other|vodcasting|listening to downloaded vodcasting files
45974313|NCT01642303|Other|no intervension|Listen to student book listening files
45830077|NCT01751178|Drug|Chlorhexidine Digluconate Mouthwash without Alcohol|0.2% w/v Chlorhexidine Digluconate, without alcohol - UK Marketed Mouthwash
45974314|NCT00250185|Drug|Sodium Nitrate|
45974315|NCT00250185|Drug|Acetylcholine|
45974316|NCT01642381|Behavioral|"Full Motivational Interviewing (FMI)"|Relational and technical technical (directive) strategies in counselling sessions to significantly increase commitment strength to reduce drinking.
45974317|NCT01642381|Behavioral|"Spirit Only Motivational Interviewing (SOMI)"|Empathic and non-directive counselling based on Rogerian psychotherapy model.
45670743|NCT02257385|Drug|UMEC/VI|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains Umeclidinium bromide (unit dose strengths 62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate 0.6% weight/weight (w/w) of total drug product and second strip contains Vilanterol (unit dose strengths 25 mcg per blister) blended with lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
45670744|NCT02257385|Drug|UMEC/VI matching placebo|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains lactose monohydrate and magnesium stearate 0.6% w/w of total drug product and second strip contains lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
45830078|NCT01606254|Drug|Paliperidone palmitate|Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.
45670745|NCT02257385|Drug|Tiotropium|Tiotropium (as bromide monohydrate) inhalation capsules 18 mcg per dose will be supplied along with HANDIHALER inhalers manufactured by Boehringer Ingelheim
45830079|NCT01750242|Device|Medtronic DBS system|Advanced Parkinson's disease patients implanted with the Medtronic Deep Brain Stimulation (DBS) system.
45830080|NCT01723254|Biological|IGE-1|Intramuscular, multiple dose
45830081|NCT01723254|Biological|IGE-2|Intramuscular, multiple dose
45974318|NCT00239486|Drug|Pramipexole|
45974319|NCT01642459|Other|Same direction cannulation|The puncture direction of the arterial needle is same as the blood flow in every hemodialysis session.
45974320|NCT01642459|Other|Opposite direction cannulation|The puncture direction of the arterial needle is opposite to the blood flow in every hemodialysis session.
45974321|NCT01642498|Device|ROX COUPLER|The COUPLER will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
45974322|NCT01642537|Device|Rhythmia Mapping System and the Rhythmia Mapping Catheter|Patients will undergo a diagnostic assessment with the Rhythmia Mapping System and the Rhythmia Mapping Catheter as part of the Electrophysiology Ablation Procedure.
45670746|NCT02257385|Drug|Tiotropium matching placebo|Tiotropium matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with HANDIHALER inhalers
45830082|NCT01723254|Biological|Saline|Saline (0.9% sodium chloride)
45830083|NCT01722162|Drug|Bevacizumab|
45830084|NCT01722162|Drug|Capecitabine|
45830085|NCT01722162|Drug|Levocetirizine|
45830086|NCT01721772|Biological|BMS-936558 (Nivolumab)|
45830087|NCT01721772|Biological|Placebo matching BMS-936558 (Nivolumab)|
45974323|NCT00263835|Behavioral|Empowerment|
45456028|NCT05172323|Device|3DCT-scan|A contrast CT-scan of the coronary arteries will be performed and 3D analyzed to determine the best angle for the C-arm during Percutaneous Coronary Intervention (PCI) for stent implantation. Furthermore determining the amount and localization of calcium in the right coronary artery (RCA) and diameter and length of RCA. The use of IVUS will be used to determine the degree of calcium.
45670747|NCT02257385|Drug|Indacaterol|Indacaterol inhalation capsules 150 mcg per dose will be supplied by GSK along with BREEZHALER inhalers manufactured by Novartis
45670748|NCT02257385|Drug|Indacaterol matching placebo|Indacaterol matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with BREEZHALER inhalers manufactured by Novartis
45456029|NCT05172323|Other|Angiography guided PCI|Standard of care is angiography guided PCI of the ostium of the RCA. The use of IVUS will be used to determine the degree of calcium.
45456030|NCT05171712|Device|Transcatheter Aortic Valve Replacement|Transcatheter Aortic Valve Replacement for the treatment of patients with severe aortic stenosis
45670749|NCT02257385|Drug|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules for as needed use will be issued throughout the study. Albuterol/salbutamol will be sourced from local commercial stock. If not available locally, GSK will source centrally
45670750|NCT05647265|Biological|Nivolumab|Given IV
45830088|NCT01721772|Drug|Dacarbazine|
45830089|NCT01721772|Drug|Placebo matching Dacarbazine|
45830090|NCT01702428|Biological|Priorix|Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
45830091|NCT01702428|Biological|M-M-R II|Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
45830092|NCT01702428|Biological|Varivax|Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.
45830093|NCT01702428|Biological|Havrix|Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.
45830094|NCT01702428|Biological|Prevnar 13|US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.
45456031|NCT05170997|Dietary Supplement|Cows' milk|Intervention groups will receive a free 12 week supply of cows' milk equating to a pint a day for study participants. Milk is provided by Lakeland dairies.
45456032|NCT05170997|Other|British Dietetic Association Iodine Fact Sheet.|All participants will receive the British Dietetic Association Iodine fact sheet which discusses the importance of iodine and the dietary sources.
45670751|NCT05647265|Biological|Ipilimumab|Given IV
45670752|NCT05647265|Procedure|Surgical Procedure|Undergo surgery
45670753|NCT05647265|Procedure|Computed Tomography|undergo CT
45830095|NCT01701258|Drug|Amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride during the fMRI session only
45830096|NCT01701258|Drug|Placebo|single-dose placebo capsule during the fMRI session only
45830097|NCT01700946|Drug|dexamethasone|given intravenously or orally
45830098|NCT01700946|Drug|vincristine sulfate|given intravenously
45830099|NCT01700946|Biological|rituximab|given intravenously
45830100|NCT01700946|Drug|clofarabine|given intravenously
45830101|NCT01700946|Drug|cyclophosphamide|given intravenously
45830102|NCT01700946|Drug|etoposide|given intravenously
45830103|NCT01700946|Biological|aldesleukin|given subcutaneously
45830104|NCT01700946|Drug|pegaspargase|given intravenously
45830105|NCT01700946|Drug|methotrexate|given intrathecally or intravenously
45830106|NCT01700946|Drug|mercaptopurine|given orally
45830107|NCT01700946|Drug|cytarabine|given intrathecally or intravenously
45830108|NCT01700946|Drug|mitoxantrone|given intravenously
45830109|NCT01700946|Drug|teniposide|given intravenously
45830110|NCT01700946|Drug|vinblastine|given intravenously
45830111|NCT01700946|Biological|natural killer cell infusion|undergo allogeneic natural killer cell infusion
45830112|NCT01700946|Other|laboratory biomarker analysis|correlative studies
45830113|NCT01700946|Drug|therapeutic hydrocortisone|given intrathecally
45670754|NCT05647265|Procedure|Magnetic Resonance Imaging|Undergo MRI
45670755|NCT05647265|Procedure|Positron Emission Tomography|Undergo PET
45830114|NCT01700946|Procedure|allogeneic hematopoietic stem cell transplantation|undergo allogeneic HSCT
45670756|NCT01629667|Biological|Tralokinumab|Participants will receive Tralokinumab 400 mg IV infusion Q4W for 68 Weeks.
45670757|NCT01629667|Biological|Tralokinumab|Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
45670758|NCT01629667|Other|Placebo|Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
45670759|NCT01645280|Drug|Placebo + methotrexate (MTX) (Group 1)|Placebo: form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
45670760|NCT01645280|Drug|Ustekinumab + MTX (Group 2)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
45670761|NCT01645280|Drug|Ustekinumab + MTX (Group 3)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 12 weeks (Weeks 16 and 28) + MTX (pre-study dose)
45670762|NCT01645280|Drug|CNTO 1959 + MTX (Group 4)|CNTO 1959: type = exact number, unit = mg, number = 200, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
45670763|NCT01645280|Drug|CNTO 1959 + MTX (Group 5)|CNTO 1959: type = exact number, unit = mg, number = 50, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28)+ MTX (pre-study dose)
45830115|NCT01700946|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
45830116|NCT04565886|Device|Diode laser application|After mechanical debridement, the pockets around the implant will be rinsed with sterile saline solution. Adjunctive diode laser (settings: 810 nm, 2.5 W, 50 Hz, 10 ms) will be applied 3x for 30 s (i.e., 90 s per appointment) using a 400-lm thick fiber (WhiteStar, Orcos Medical AG, Küsnacht, Switzerland) in the test group. In the control group, non-activated (= placebo) adjunctive diode laser will be applied. The entire treatment procedure, including mechanical debridement, will be performed at Day 0 (= baseline), 7 and 14. The laser decontamination procedure will occur by systematically moving the laser tip along the subgingival implant surface in a vertical and horizontal scanning way. The laser tip will be checked after 4-5 s for coagulation to prevent hotspots in the soft tissues.
45830117|NCT04565886|Device|Sham Diode laser|After mechanical debridement, the pockets around the implant will be rinsed with sterile saline solution. Non-activated (= placebo) adjunctive diode laser will be applied. The entire treatment procedure, including mechanical debridement, will be performed at Day 0 (= baseline), 7 and 14. The laser decontamination procedure will occur by systematically moving the laser tip along the subgingival implant surface in a vertical and horizontal scanning way.
45830118|NCT04548804|Diagnostic Test|ECG-Imaging|A body surface potential mapping and a cardiac + low dose CT-scan
45830119|NCT01748994|Drug|Pioglitazone|30mg per day for four months
45830120|NCT01748994|Drug|Placebo|
45830121|NCT01721070|Drug|Sufentanil NanoTab (SUF NT) 15 mcg|Period 1: One dose of SUF NT 15 mcg administered sublingually
45830122|NCT01721070|Drug|Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg|Period 2: Ketoconazole 400 mg administered daily for three days, SUF NT 15 mcg co-administered sublingually on the third day
45830123|NCT01748760|Behavioral|CLASP-A intervention|Three individual sessions with adolescent patient using acceptance based strategies and motivational interviewing techniques. Sessions focused on identifying personalized risk factors for suicidal behavior, identifying values and goals, and development of personalized safety plan.
45830124|NCT01748760|Other|Treatment as Usual|Referral to outpatient treatment as part of routine discharge planning.
45830125|NCT01748292|Drug|0.5 mg ranibizumab|Subject will receive drug (ranibizumab) via intravitreal injections (IVT) at every visit.
45670764|NCT02256917|Biological|Human cl rhFVIII|
45830126|NCT01720602|Drug|vorinostat|Given PO
45974324|NCT00239525|Device|3-D ultrasound scanner|The availability of color flow Doppler combined with effective ultrasound contrast agents in transcranial sonography serves as a low cost, bedside method for evaluation and management of patients with cerebrovascular disease in spite of the image degrading properties of the skull.
45974325|NCT00239525|Drug|Perflutren Protein-Type A Microspheres for injection|Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.Bolus: The recommended dose for activated DEFINITY® is 10 microliters (μL)/kg of the activated product by intravenous bolus injection within 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 microliters (μL)/kg dose followed by a second 10 mL saline flush may be administered 30 minutes after the first injection to prolong contrast enhancement. Infusion: The recommended dose for activated DEFINITY® is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute.
45974326|NCT01642576|Behavioral|weight loss counselling|Diet counselling with or without sports trainers, over 8 months
45974327|NCT01642654|Other|Exercise|The WG was submitted to a 16-week WEP, with combined aerobic and resistance exercises in three weekly sessions. Water temperature was approximately 30º C with an average ambient temperature of 34° C. The pool had water levels ranging between 1,20 and 1,40 meters deep.
45974328|NCT01642654|Other|Educational lectures|Educational lectures
45974329|NCT01642693|Radiation|Low power laser in teeth after intrusive movement|Low power laser was aplied to premolar teeth under an intrusive movement to study histological changes and root resorption
45974330|NCT01642693|Other|Simulated laser in teeth with intrusive movements|Simulated laser in teeth with intrusive movements for histological and root resorption changes
45974331|NCT01642810|Behavioral|Acceptance-based behavioural therapy|Behavioral intervention focusing on acceptance, mindfulness and values-based living instead of focus on symptom control
45974332|NCT01642810|Other|Will vary per participant|Participants will continue pre-study treatment under their current licensed practitioners. Intervention may include drug treatment, physical therapy, or other
45974333|NCT00239564|Drug|IPX054 100 mg|IPX054 containing 25 mg carbidopa and 100 mg levodopa
45974334|NCT00239564|Drug|IPX054 150 mg|IPX054 containing 37.5 mg carbidopa and 150 mg levodopa
45974335|NCT00239564|Drug|IPX054 200 mg|CD-LD CR containing 50 mg carbidopa and 200 mg levodopa
45974336|NCT00239564|Drug|IPX054 250 mg|CD-LD CR containing 62.5 mg carbidopa and 250 mg levodopa
45974337|NCT00239564|Drug|IPX054 300 mg|CD-LD CR containing 75 mg carbidopa and 300 mg levodopa
45670765|NCT01629589|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)|0.5 mL, Intramuscular
45670766|NCT01629589|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)|0.5 mL, Intramuscular
45670767|NCT04188223|Biological|Recombinant Hepatitis B (Bio Farma) Vaccine|Recombinant Hepatitis B vaccine produced by Bio Farma
45670768|NCT04188223|Biological|Recombinant Hepatitis B (Bio Farma) Vaccine®|Registered Recombinant Hepatitis B vaccine produced by Bio Farma
45670769|NCT02256839|Device|CST_001|
45830127|NCT01720602|Drug|anastrozole|Given PO
45830128|NCT01720602|Drug|letrozole|Given PO
45974338|NCT02961036|Other|Group 1 information|Group 1 prize draw information for participants to win 100% of an Amazon gift card (or currency equivalent) in invitation letter.
45830129|NCT01720602|Drug|exemestane|Given PO
45830130|NCT01720602|Procedure|positron emission tomography|Correlative studies
45830131|NCT01720602|Radiation|F-18 16 alpha-fluoroestradiol|Correlative studies
45670770|NCT02220907|Drug|Teneligliptin/Canagliflozin|Co-administration of Teneligliptin and Canagliflozin orally once daily for 52 weeks.
45670771|NCT02255981|Other|Acupuncture and massage|"Treatment consists in to put needles on specific points of skin one day each week initially, then with longer spaces of time according to improvement.A total of 11 Chinese needles stainless steel, 25 x 40 were used by manual insertion and left for 12-15 minutes.~Periocular massage is taught and is practiced daily by the patient him or herself."
45670772|NCT01601873|Device|PROPATEN|Heparin-bonded graft implantation for hemodialysis vascular access
45670773|NCT01601873|Device|Standard Graft|non-heparin bonded conventional hemodialysis vascular access graft
45670774|NCT02194933|Drug|Brexpiprazole|Brexpiprazole 2 mg/day, once daily dose, tablet, orally, for 6 weeks - Brexpiprazole 4 mg/day, once daily dose, tablet, orally, for 6 weeks
45830132|NCT01720602|Radiation|fludeoxyglucose F 18|Correlative studies
45974339|NCT02961036|Other|Group 2 information|Group 2 prize draw information for participants to win 75% of an Amazon gift card (or currency equivalent) in invitation letter.
45974340|NCT02961036|Other|Group 3 information|Group 3 prize draw information for participants to win 50% of an Amazon gift card (or currency equivalent) in invitation letter.
45974341|NCT02961036|Other|Group 4 information|Group 4 prize draw information for participants to win 25% of an Amazon gift card (or currency equivalent) in invitation letter.
45830133|NCT01720602|Other|laboratory biomarker analysis|Correlative studies
45830134|NCT01746732|Drug|Ortho-Cyclen|Oral administration
45830135|NCT01746732|Drug|Evacetrapib|Oral administration
45830136|NCT01720524|Drug|placebo|IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.
45830137|NCT01720524|Drug|iv sildenafil|loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.
45830138|NCT01720446|Drug|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
46082111|NCT00609713|Other|Individual 12-month nutrition education program|The other half of the participants (44 subjects) will be randomized to this arm of the intervention (usual care), which will also start in five waves. In contrast to the comprehensive behavioral weight control program, the nutrition education program will take place through individual appointments with a clinical dietician to reflect usual care and mimic the present approach used for the treatment of obese adolescents at the Children's Hospital of Philadelphia (CHOP) Nutrition Consultation. Parents will be required to take part in the consultations. The first consultation will last 60 minutes and the following consultations of 30 minutes will take place once a month for the first six months, then every other month for the second six months, as is the usual practice in our clinical setting.
45830139|NCT01720446|Drug|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg followed by 0.5 mg dose escalation as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
45830140|NCT01720446|Drug|placebo|Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin).
45974342|NCT02961036|Other|Group 5 no information|Group 5 no Information for participants to enter a draw to win an Amazon gift card (or currency equivalent) in invitation letter.
45670775|NCT04865783|Procedure|Saline spray|The saline spray will be applied twice for 1-2 seconds.
45830141|NCT01746108|Biological|Synflorix™|1 or 2 doses depending on the priming status, intramuscularly in the non-dominant deltoid muscle or the thigh.
45830142|NCT01717638|Biological|1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose
45830143|NCT01717638|Biological|2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, two doses, two months apart
45974343|NCT02961036|Other|Group A Reminder|One survey reminder at 14 days
45974344|NCT02961036|Other|Group B Reminders|Two survey reminders one at 14 days and one at 28 days
45974345|NCT01642849|Dietary Supplement|high protein diet|6 months on HP diet
45974346|NCT01642849|Dietary Supplement|high carbohydrate diet|12 subjects will be placed on a hig carbohydrate diet for 6 months
45974347|NCT01642888|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
45974348|NCT01642888|Biological|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
45974349|NCT00239603|Device|OV-Watch|
45974350|NCT01642966|Drug|Prasugrel|Prasugrel 10mg/day for 15 days
46082112|NCT00934453|Biological|Lactobacillus rhamnosus GG ATCC 53103|Study drug capsules (1x10^10 LGG/capsule) are to be taken orally twice a day every day dissolved in cow's milk or soy milk on an outpatient basis for six months.
46082113|NCT00934453|Biological|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis for six months.
45670776|NCT04865783|Procedure|Cryospray|The cryospray will be applied twice for 1-2 seconds.
45670777|NCT05647109|Other|No intervention|No intervention
45670778|NCT04420247|Drug|Chloroquine|5 days of treatment with Chloroquine + Standard Care
45670779|NCT04420247|Drug|Hydroxychloroquine|5 days of treatment with Hydroxychloroquine + Standard Care
45670780|NCT04420247|Other|standard care|Standard Care according to Brazilian Guidelines for treating COVID-19
45670781|NCT01644890|Drug|NK105|IV, Weekly
45670782|NCT01644890|Drug|Paclitaxel|IV, Weekly
45830144|NCT01745094|Drug|mirabegron|oral
45830145|NCT01745094|Drug|solifenacin|oral
45974351|NCT01642966|Drug|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
45670783|NCT04868006|Procedure|End-range Maitland mobilization + proprioception training|End-range Maitland mobilization performed in end position of internal rotation of the shoulder accompanied with 8--week long proprioception training
45670784|NCT04868006|Procedure|Non end-range Maitland mobilization + proprioception training|Non end-range Maitland mobilization performed in loose position of the shoulder accompanied with 8--week long proprioception training
45974352|NCT01643005|Behavioral|Relationship Strengthening HIV Prevention Intervention|The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.
45974353|NCT01643005|Behavioral|Parenting Program Intervention|Nurturing Parenting curriculum delivered in a group format.
45974354|NCT04529317|Dietary Supplement|Quinoa and quinoa-based food|"Products created replaced grains, legumes, tubers, also farinaceous commonly consumed by the participants and only the cereal fraction was modified, similar products based on quinoa flour were created.~Thus, apart from delivering quinoa, quinoa flakes and quinoa flour to the participants, they were given products created with ≥70% quinoa flour and were biscuits, crackers, brioche, sponge cake, baguette bread, sliced bread and pasta. Moreover, a quinoa-based recipe was delivered with eight commonly consumed recipes that replaced the tuber, legume or grain of the recipe. Each subject received the equivalent of what they consumed according to their regular diet dietary records."
45974355|NCT01643083|Drug|Rifaximin|Rifaximin 400mg tid for 2 wk
45974356|NCT01643083|Drug|Placebo|Placebo for 2 week
45974357|NCT01643122|Other|No drug|Patients with expected stable endometriosis management status (EMS), i.e. patients who have not planned a change in endometriosis treatment or a therapeutic surgical procedure in the next 12 weeks and have had no change in endometriosis treatment or therapeutic surgical procedure in the previous 4 weeks.lease specify as free-text; for drugs include daily dose, dosage form dosage frequency and duration (if appl. and possible for the OS/NIS).
45974358|NCT01643122|Other|No drug|Patients with expected change in endometriosis management status (EMS), i.e. patients who have planned a change in endometriosis treatment or a therapeutic surgical procedure during the next 12 weeks or have undergone a change in endometriosis treatment or a therapeutic surgical procedure in the previous 4 weeks.
45974359|NCT01643161|Behavioral|Treatment As Usual|Communicating the diagnosis to the patient's primary care doctor and neurologist. May include referrals for physical therapy or psychiatric evaluations, or referrals to community therapists or doctors.
45974360|NCT01643161|Behavioral|Guided Self-Help|A self-help workbook based on cognitive behavioral therapy, and four half-hour guidance sessions over a three-month period.
45974361|NCT01643239|Other|Hospital-based mCIT restraint of the unaffected arm and practice of the affected arm|the mCIT group with individualized intervention
45974362|NCT01643239|Other|Hospital-based mCIT|the mCIT group with individualized intervention
45974363|NCT01643239|Other|Hospital-based TR|OT or PT or therapist-based training
45974364|NCT01643278|Drug|Dasatinib|Given PO
45974365|NCT01643278|Biological|Ipilimumab|Given IV
45974366|NCT01643278|Other|Laboratory Biomarker Analysis|Correlative studies
45974367|NCT01643278|Other|Pharmacological Study|Correlative studies
45974368|NCT01643356|Behavioral|Intervention to reduce excess weight gain during pregnancy|Intervention includes meetings with a nutrition counselor and/or psychologist where individualized eating plans will be developed and reviewed, and regular group meetings during which information about healthy eating for weight management will be discussed.
45974369|NCT01643395|Other|vertebroplasty|Vertebroplasty consists in the injection of cement (PMMA) in the damaged vertebral body to prevent further collapse
45974370|NCT01643395|Other|conservative therapy|The study is a prospective, randomized trial comparing conservative treatment (brace) and vertebroplasty in acute (less than 15 days after trauma) traumatic vertebral compression fracture (VCF) type A according Magerl classification.
45974371|NCT01643590|Biological|JVS-100 15 mg dose Injection|Intramyocardial Injection
45974372|NCT01643590|Biological|Placebo Injection|Intramyocardial Injection
45974373|NCT01643590|Biological|JVS-100 30 mg dose injection|Intramyocardial Injection
45974374|NCT01643629|Biological|Autologous Human Platelet Lysate (HPL)|Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
45670785|NCT04868006|Procedure|Sham manual therapy technique + proprioception training|Placebo performed in loose position of the shoulder accompanied with 8--week long proprioception training
45670786|NCT04865237|Biological|SARS-CoV-2 Virus|SARS-CoV-2, intranasally, (1x10^1 TCID50, 1x10^2 TCID50 and 1x10^3 TCID50 or higher, as necessary)
45670787|NCT04865237|Drug|Remdesivir|VEKLURY™
45670788|NCT01628965|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
45974375|NCT01643629|Other|2 % Minoxidil and /or Finasteride|Control arm B subjects will receive Standard therapy (2% Minoxidil and/or Finasteride)
46082114|NCT05358912|Drug|Vasopressor Agent|"Patients will receive vasopressor agents according to Surviving Sepsis Campaign Guidelines 2021"
45830146|NCT01697748|Device|Silver-impregnated dressing|Silver-impregnated dressing placed over Cesarean wound after skin closure; the dressing will be changed to saline-treated dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
45830147|NCT01697748|Device|Telfa pad dressing|Telfa pad dressing placed over Cesarean wound after skin closure; the dressing will be changed to a new Telfa pad dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
45830148|NCT01717326|Drug|Grazoprevir|100 mg tablet orally QD
45830149|NCT01717326|Drug|Elbasvir|Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD
45830150|NCT01717326|Drug|Placebo to Elbasvir|Placebo to Elbasvir 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)
46082115|NCT05358912|Drug|Crystalloid Solutions|"Patients will receive crystalloid solutions according to Surviving Sepsis Campaign Guidelines 2021"
46082116|NCT05358912|Procedure|Invasive Blood Pressure Monitoring|Invasive blood pressure monitoring will be performed through an intra-arterial cannula placed in the radial artery. Philips Intellivue mx 500 monitors will be used for bedside monitoring.
45830151|NCT01717326|Drug|Ribavirin|Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight
45830152|NCT01697592|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
45830153|NCT01697592|Drug|Matching placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
45974376|NCT01643746|Device|Supera Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
45974377|NCT01643746|Device|Life Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
45974378|NCT04529200|Other|electrotherapy treatment|physical therapy management like EMS IFT
45974379|NCT01643785|Drug|Second-line quadruple therapy with endonase|Compare Second-line quadruple therapy w/o pronase (endonase)
45974380|NCT01643824|Radiation|Proton Beam Therapy|"- Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 <40%, and/or RLV30 <30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30<50% and RLV30<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30<60%, and/or RLV30<50%~- Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
45974381|NCT04529161|Dietary Supplement|Fasting Mimicking Diet (FMD)|The treatment consists in the self-administration of FMD at home - closely followed by the neuropsychologist by phone and by a properly trained nutritionist in the FMD sector - for 5 days a month for 6 consecutive months.
45974382|NCT04529161|Dietary Supplement|Routinary diet habits|Subjects will follow their routinary eating habits for 6 consecutive months
45974383|NCT04528966|Other|Whole-Body Vibration|Whole-Body Vibration Treatment for 3 sessions in a week for 8 weeks. Each sessions takes 15 minutes.
45974384|NCT04528966|Other|Conventional Physiotherapy|conventional physiotherapy for 2 sessions in a week for 8 weeks. Each sessions takes 45 minutes.
45974385|NCT01644019|Procedure|Teleconsultation|Teleconsultation of an EMS physician in cases of suspected acute stroke
45974386|NCT01644097|Dietary Supplement|Lactobacillus plantarum strain 299v|Given PO
45974387|NCT01644097|Dietary Supplement|Lactobacillus acidophilus probiotic|Given PO
45974388|NCT01644097|Dietary Supplement|placebo|Given PO
45974389|NCT01644097|Other|laboratory biomarker analysis|Correlative studies
45974390|NCT01644097|Other|questionnaire administration|Ancillary studies
45974391|NCT01644097|Procedure|quality-of-life assessment|Ancillary studies
45974392|NCT01644097|Dietary Supplement|Bifidobacterium lactis probiotic supplement|Given PO
45974393|NCT01644136|Procedure|robot-assisted laparoscopic surgery|Undergo standard robotic assisted laparoscopic prostatectomy
45974394|NCT01644136|Procedure|regional lymph node dissection|Undergo pelvic lymph node dissection
45974395|NCT01644136|Device|microsphere-mediated lymphocele prevention|Undergo microsphere-mediated lymphocele prevention
45830154|NCT01744782|Drug|RP103|Cysteamine Bitartrate Delayed-release Capsules (RP103) were administered twice daily, orally or via gastrostomy tube (G-tube), after a 2-hour fast. The starting dose was one-quarter of the RP103 targeted maintenance dose based on age, weight, and body surface area. The recommended targeted maintenance dose for children up to 6 years old was 1 gram/m²/day, in 2 divided doses given Q12H. The dose was gradually escalated, in 10% steps, based on monitoring of WBC cystine levels 30 minutes after the morning RP103 dose collected every 2 weeks, until the participant's WBC cystine level was <1 nmol ½ cystine/mg protein.
45974396|NCT01644253|Biological|20 mg/kg TRU-016 + Rituximab|"TRU-016: 10 mg/kg for first dose, all subsequent doses 20 mg/kg, IV once weekly for 8 weeks followed by 4 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV once weekly for 8 weeks followed by 4 monthly doses"
45974397|NCT01644253|Biological|10 mg/kg TRU-016 + Rituximab|"TRU-016: 6 mg/kg for first dose, all subsequent doses 10 mg/kg, IV on Day 1, 8 and 15, followed by 5 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV following TRU-016 schedule"
45974398|NCT01644253|Biological|TRU-016 20 mg/kg + Obinutuzumab|"TRU-016: 6 mg/kg on Day 1, 20 mg/kg on Day 8 and 15, then 20 mg/kg once a month for 5 months~Obinutuzumab: 100 mg on Day 1, 900 mg on Day 2, 1,000 mg on Day 8 and 15, then 1,000 mg once a month for 5 months"
45974399|NCT01644253|Biological|TRU-016 6-20 mg/kg + idelalisib + rituximab|TRU-016: 6 mg/kg on Days 15-36 weekly, 10 mg/kg on Days 43 and 50, then 20 mg/kg once a month for 5 months.
45974400|NCT01644253|Biological|TRU-016 10-20 mg/kg + ibrutinib|TRU-016: Dosed weekly for 8 weeks followed by 4 monthly intravenous (IV) infusions. The first dose will be 10 mg/kg and all subsequent doses will be 20 mg/kg.
45830155|NCT01744392|Behavioral|education intervention|Each patient will receive instructions on how to use the medication calendar to help them adhere to their medication regimen. The Meducation Calendar is developed by the clinical pharmacist participating in the research study). The clinical pharmacist will enter the medication regimen for each participant into the application for Meducation Calendar Development.
45830156|NCT01604850|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.
45830157|NCT01604850|Drug|RBV|Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
45830158|NCT01604850|Drug|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
45830159|NCT01604850|Drug|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
45670789|NCT05647460|Procedure|computer guided screw holes locating guide and custom-made plates|"Virtual planning and guide fabrication for the study group:~Preoperative CT.~Virtual reduction of broken segments on software.~Gain occlusion.~Design surgical screw holes locating guide.~Design the custom-made plates.~Print the screw holes locating guide and the custom-made plate.~Surgical guiding tools: screw holes locating guide and custom-made plates.~Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the custom-made plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa."
45670790|NCT05647460|Procedure|conventional plates|mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
45670791|NCT05647382|Diagnostic Test|blood cell analysis, blood gas surveillance, chest radiograph and echocardiography|Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
45670792|NCT01644734|Drug|Spiriva HandiHaler|
45670793|NCT02255279|Biological|Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29)|A 0.25 mL (for children 6 to <36 months old) and 0.5 mL (for children ≥36 months to < 72 months old) dose of aTIV, a trivalent (surface antigen, formaldehyde-inactivated) influenza virus vaccine, adjuvanted with MF59C.1, administered at day 1 (for all subjects) and day 29 (for naïve subjects).
45830160|NCT01742286|Drug|Ceritinib|"LDK378 is a capsule taken by mouth, contents can be mixed with food for pediatric patients or mixed with water and given via nasogastric/gastric (NG/G) tube. For patients in fasted group: 1-2 tablespoons (15-30 mL) of an appropriate food such as apple sauce or non-fat yogurt and a glass of water were allowed.~For patients in the fed cohort: LDK378 was taken with, or within 30 minutes after finishing a low-fat light snack containing 100-300 calories and 1.5-2 grams of fat."
45830161|NCT01697358|Device|Spinal Cord Stimulation (SCS)|Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead. Subjects will undergo an SCS screening test and, if successful, an implantable neurostimulation system implant. Any SCS group subject not implanted will continue to be treated with OMM and will be followed as part of the SCS group.
45830162|NCT01697358|Drug|Optimal Medical Management (OMM)|The investigator and subject will determine an individual OMM treatment plan, which should include non-investigational pharmacologic agents and/or therapies.
45974401|NCT01644253|Biological|TRU-016 10-20 mg/kg + bendamustine|TRU-016 dosed 10 mg/kg for the first dose and then 20 mg/kg weekly for 2 cycles, followed by dosing every other week for an additional 4 cycles (cycle = 28 days). Bendamustine (90 mg/m2 on days 2 and 3 of cycle 1 and then days 1 and 2 of cycles 2 to 6) will be infused after completion of TRU-016. If a patient is benefiting with stable disease or better, then TRU-016 may continue to be dosed every 3 weeks after the first 6 cycles; bendamustine will not be dosed beyond 6 cycles.
45974402|NCT01644370|Drug|HAART|as per Thai HIV Treatment guidelines
45974403|NCT01644448|Other|Autologous Human Platelet Lysate|Subjects will receive one dose of 5 ml of HPL with simultaneous micro-needling on day 2
45974404|NCT01644448|Other|Standard Therapy|Topical Applications as directed by the investigator
45974405|NCT01644487|Device|self-expanding nitinol stent|A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
45974406|NCT01644487|Device|balloon angioplasty|A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
45974407|NCT01644526|Device|Hemoaccess Valve System|Device that allows blood to selectively flow into an arteriovenous graft to provide vascular access for dialysis then turn off the flow of blood to the graft in between dialysis sessions.
45974408|NCT01644604|Device|MDT-2211 Renal Denervation System|A percutaneous system that delivers radiofrequency (RF) energy through the luminal surface of the renal artery.
45830163|NCT01716234|Drug|Posaconazole 12 mg/kg/day BID|Posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) (maximum 800 mg/day)
45830164|NCT01716234|Drug|Posaconazole 18 mg/kg/day BID|Posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) (maximum 1200 mg/day)
45670794|NCT02255279|Biological|Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).|A 0.25 mL (for children 6 to <36 months old) and 0.5 mL (for children ≥36 months to < 72 months old) dose of TIV , an egg-derived trivalent split influenza vaccine licensed in Mexico, administered at day 1 (for all subjects) and day 29 (for naïve subjects)
45974409|NCT01644682|Other|IWFPL|Indoor house walls and floors will be plastered with lime (a traditional method known in the study areas) including treatment of outdoor breeding places with lime and bleaching powder to inhibit sandfly breeding
45974410|NCT01644682|Other|IDWL|Install durable wall lining containing deltamethrin to kill immature stage and as well as adult sand flies
45974411|NCT01644682|Other|ITN|Impregnation of existing bed-nets available in the community with slow release insecticide, deltamethrin
45974412|NCT01644760|Procedure|Ultrasounds with controlled breathing|The patient will have cardiac, abdominal and thoracic ultrasounds with controlled and monitored inspiratory effort. This gesture takes about 40 minutes.
45974413|NCT01644799|Drug|idelalisib|oral
45974414|NCT01644799|Drug|lenalidomide|oral
45974415|NCT01644838|Drug|Hyoscine|The samples were randomly allocated to inject of 20 mg of hyoscineIM in dilatation 3-5cm.
45670795|NCT01643798|Procedure|Sham rTMS|The eSham system was implemented in conjunction with a specialized Neuronetics sham TMS coil. This coil has a metal plate hidden inside of it that blocks the magnetic field from affecting the brain. Scalp electrodes were used to mimic the feel of real rTMS. This approach has been validated in previous studies.
45670796|NCT01643798|Procedure|Real rTMS|An iron-core, solid-state figure-of-8 coil was used to stimulate the dorsolateral prefrontal cortex. The site of stimulation was estimated using the Beam F3 method based on the 10-20 EEG system.
45830165|NCT01716234|Drug|Posaconazole 18 mg/kg/day TID|Posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) (maximum 1200 mg/day)
45974416|NCT01644838|Drug|Promethazine|The samples were randomly allocated to inject of 25 mg of promethazine IM in dilatation 3-5cm.
45670797|NCT04865159|Drug|Tipifarnib|Cardiac Safety of Tipifarnib
45830166|NCT01716234|Drug|Posaconazole 12 mg/kg/day TID|Posaconazole oral suspension 12 mg/kg/day divided into 3 doses (TID) (maximum 800 mg/day)
45830167|NCT01716156|Drug|Grazoprevir|Grazoprevir, tablet, orally, 100 mg, once per day for 12 or 24 weeks, depending on Arm assignment
45830168|NCT01716156|Drug|Ribavirin|Ribavirin capsules, orally, twice per day, at a total daily dose from 800 to 1400 mg based on participant weight
45974417|NCT01644877|Drug|DAS181 dry powder, formulation F02|
45974418|NCT01644877|Drug|Lactose Placebo|
45974419|NCT01644955|Drug|carboplatin|Carboplatin in a volume of 54 ml will be administered intracerebrally by convection enhanced delivery
45974420|NCT01644955|Procedure|Surgery|Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room.
45974421|NCT01644994|Combination Product|intracavitary cisplatin-fibrin|single dose, local intracavitary application of cisplatin-fibrin after pleurectomy/decortication
45974422|NCT00263874|Drug|UK-500,001|
45974423|NCT01645033|Other|computerized Cognitive Behavioral Therapy (CBT)|Standard treatment (as described in TAU) plus a short session using a computer program containing CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
45456033|NCT05164718|Behavioral|Supervised home-based exercise|150-300 minutes of moderate intensity activity (55-75% of maximum heart rate in sinus rhythm or RPE 12-13 on the Borg Scale) or 75-150 minutes of vigorous intensity activity (75-90% of maximum heart rate or 14-16 on the Borg Scale) per week, or an equivalent combination of both, according to current general recommendations, including also those with established CVD. To maximize the potential for improvements in cardiorespiratory fitness, we encourage that at least 40-60 minutes per week (i.e. 2 sessions á 20-30 minutes) should be of vigorous intensity.
45456034|NCT05164718|Other|Usual care|Standard management according to usual practice at the respective participating centers, including medical therapy as per guidelines. Prior to randomization all will be provided an ICM (Confirm RX™). The UC group will receive information about general PA recommendations as per guidelines at study enrollment. No further supervision is given.
45456035|NCT05156515|Diagnostic Test|68Ga-THP-APN09|APN09, nanobody targeting PD-L1, labeled with PET radio-nuclide (68Ga) will be used as a molecular imaging tracer for PET/CT scan.
45670798|NCT05647031|Other|Qualitative study. Pain in competitive athletes with physical disabilities and techniques for its management.|"This study used a qualitative, exploratory and descriptive methodology, with a semi-structured interview technique. The purpose was to respond to the specific objectives set out in this research from the perspective of competitive athletes and sports agents (physiotherapist, coach and psychologist). The thematic cores that served as a script for the interview were for the athletes and sports agents 1) sporting characteristics of the professionals; 2) perception of how pain affects this type of athlete and what repercussions it has on the development of their sporting career, and 3) knowledge of techniques and/or strategies for pain management (athlete, coach and psychologist).~The interviews were conducted via skype. After transcription of all the interviews, validation by the interviewees was applied for the reliability of the research. Two types of triangulation were applied to ensure the quality of the data."
45974424|NCT01645033|Other|Treatment as Usual (TAU)|"This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~Teaching about the treatment program~Teaching important ideas about sexual behaviors risks~Increasing knowledge about specific sexually transmitted diseases~Discussions of ways to reduce or minimize spread of diseases related to drug use [for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)]"
45974425|NCT01645150|Behavioral|Progressive strength training|12 weeks of supervised progressive strength training
45974426|NCT01645189|Biological|Hunterase|once weekly, 0.5mg/kg IV infusion
45456036|NCT05152524|Device|Tigertriever 13|patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO) will be treated with the Tigertriever 13 device.
45456037|NCT05140187|Biological|CMV-TCR-T cells|The patients with CMV infection after HSCT will receive one to three doses of donor-derived CMV-TCR-T cells, with the escalated doses including 1×10^3/kg, 1×10^5/kg, and 5×10^5/kg CMV-TCR-T cells per dose.
45670799|NCT05647304|Device|RGn550 5 Hz-PWM|RGn550 with a 5 Hz-pulsed wave mode light emission
45670800|NCT05647304|Device|RGn550 10 Hz-PWM|RGn550 with a 10 Hz-pulsed wave mode light emission
45670801|NCT05647226|Combination Product|Digital therapeutic and intensive lifestyle programme|Initial 12-week LED and behaviour education app.
45830169|NCT04555512|Other|Progressive High Intensity Interval Training (PRO-HIIT)|Individual exercise training sessions, involving two weeks of moderate intensity continuous exercise and 10 weeks of interval exercise training. This protocol involves progression of training of 3 stages: 1) six high-intensity intervals (at an RPE of 15-18) of 1-min separated by five low-intensity intervals of 2-min; 2) three high-intensity intervals of 2-min separated by two low-intensity intervals of 4-min, and a further 2-min of low intensity following the last interval before cool-down; and 3) three high-intensity intervals of 3-min separated by two low-intensity intervals of 3-min, and a further 1-min of low intensity following last interval before cool-down.
45974427|NCT04528888|Drug|Enoxaparin|Enoxaparin will be administered subcutaneously at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.
45670802|NCT05647226|Other|Standard of care|Standard of care.
45830170|NCT04555512|Other|Constant High Intensity Interval Training (CON-HIIT)|Individual exercise training sessions, involving two weeks of moderate intensity continuous exercise and 10 weeks of interval exercise training. This protocol involves a constant protocol of training, including six high-intensity intervals (at an RPE of 15-18) of 1-min separated by five low-intensity intervals of 2-min.
45974428|NCT04528888|Drug|Methylprednisolone|Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.
46082117|NCT05358912|Procedure|Intra-Abdominal Pressure Monitoring|"IAP will be measured indirectly by monitoring the pressure in the bladder.~Bladder pressure will be measured through an indwelling Foley catheter every twelve hours. Twenty-five mL of sterile normal saline will be injected in each measurement and readings will be recorded with a pressure transducer."
46082118|NCT05358912|Other|Abdominal Perfusion Pressure|APP will be calculated with the following formula: (Mean arterial pressure) - (Intra-abdominal Pressure)
45974429|NCT04528888|Drug|unfractionated heparin|Patients in this group will receive unfractionated heparin and methylprednisolone. Unfractionated heparin will be administered intravenously at therapeutic doses. The infusion will be started at an infusion rate of 18 IU/kg/hour and then modified to attain APTT Ratio in the range 1.5-2.0. aPTT will be periodically checked at intervals no longer than 12 hours. The treatment with unfractionated heparin will be administered up to ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with LMWH in the destination ward up to clinical judgement of the attending physician.
45974430|NCT00250224|Device|Radiotherapy stent|
45974431|NCT04528615|Behavioral|CCK In-Person Sessions|This group attended eight weeks of nutrition education-focused experiential learning.
45974432|NCT04528615|Behavioral|CCK Printed Materials|This group did not attend any in-person sessions and was only provided with select CCK written materials.
45974433|NCT01645267|Procedure|Hydroxyapatite|Use of artifical bonegraft material
46082119|NCT02812316|Device|HI-BRITE Large Diameter Rigid Gas Permeable Contact Lens|Approximately At least one hundred and forty (140) subjects (280 eyes) will be enrolled in this study at approximately two (2) clinical sites in Taiwan. All subjects will be fitted for and dispensed study lenses by each Investigator.
45830171|NCT04555278|Device|Active rTMS|"A figure-of-8 coil connected to a biphasic Magstim Rapid 2 stimulator (The MagstimCo, Whitland, UK) will be used. Coil orientation and position will be guided throughout the experiment by a neuronavigation system (Brainsight, Rogue research, Montreal, QC, Canada). The intensity of rTMS will be set at 95 % of the first dorsal interosseous (FDI) resting motor threshold (RMT).~Active rTMS will consist of 40 trains of 5 seconds each at 10 Hz (25-s intertrain interval) applied over M1 (on FDI cortical representation), for a total of 2000 stimulations lasting 20 minutes."
46082120|NCT04261517|Drug|Hydroxychloroquine|Subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments
45456038|NCT05127603|Behavioral|Cognitive behavioral intervention|Individually tailored physiotherapy that fits within the guideline non-specific neck pain (KNGF, 2016) with a focus on influencing dysfunctional illness perceptions and dysfunctional movement/ pain behavior, by means of communication, body awareness exercises, functional movements and exposure techniques. Tools are supplied to create an appropriate explanatory model for the pain, for functional movement behavior and active coping in a patient's daily lives.
45456039|NCT05112263|Drug|Tofacitinib|For the tofacitinib the dose of 10 mg BD will be administered for 8 weeks (10 mg TDS for initial three days) and then reduced to 5 mg BD for the period of study
46082121|NCT00930865|Drug|Bumetanide|Tablets, Oral, 1 mg, Single Dose, 7 Days
45456040|NCT05112263|Drug|Cyclosporine|: Intravenous Cyclosporine 2 mg/kg continuous infusion for 5-7 days and then shifted to oral cyclosporine 4 mg/kg/day in two divided doses for 12 weeks.Those who respond with intravenous cyclosporine will be shifted to oral cyclosporine 4 mg/kg for 12 weeks while the thiopurine dose is adjusted to the patient's weight
45830172|NCT04555278|Device|Sham rTMS|A sham coil will be use (e.g. equipped with a magnetic shield that blocks the magnetic field). The sham stimulation will last the same duration as the active rTMS (30 min).
45830173|NCT04555278|Other|Motor Control Exercises|The rehabilitation program will consist of a 30-minute session of motor control exercises following the rTMS (Active or Sham) intervention. This approach aims to improve spine health through the optimization of spine loading. The first session will be preceded by an individualized evaluation of the participant's abilities and deficiencies to tailor the training program to each participant.
45974434|NCT01645345|Device|Alma Lasers Accent RF Pixel handpiece|Treatment with fractionated RF Pixel device
46082122|NCT00930865|Drug|Dapagliflozin|Tablets, Oral, 10 mg. Single Dose, 7 Days
45456041|NCT05104281|Drug|osimertinib oral and bevazizumab intravenously|osimertinib 80mg, oral daily and bevacizumab 15mg/KG body weight intravenously infusion every 21 days.
45456042|NCT05103605|Drug|Osimertinib|Single arm treated by osimertinib
45456043|NCT05100823|Procedure|Nasal cells sampling|Nasal epithelium brushing in intermediate turbinate using a specific curette following a local anesthesia with Xylocaine 5% nebulizer.
45456044|NCT05100823|Procedure|Rectal biopsy sampling|Forceps Biopsy Procedure (Servidoni et al., 2013) Only for volunteer patients included in the Montpellier center.
45974435|NCT00263952|Biological|bee venom|
45974436|NCT01645384|Drug|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
45974437|NCT00239798|Drug|FTY720|
45974438|NCT01645423|Drug|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
45974439|NCT01645774|Procedure|10s injections duration|10s injections duration
45974440|NCT01645774|Procedure|10s injection duration and waiting 10s before withdrawing the needle|10s injection duration and waiting 10s before withdrawing the needle
45670803|NCT04874714|Biological|MM09-MG01(30.000-30.000)|Mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 30,000 AU / mL and grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne and Dactylis glomerata) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
45830174|NCT04554420|Behavioral|Youth Participatory Action Research-Mental Health Curriculum|The mental health curriculum will focus on enhancing the knowledge, critical consciousness (i.e., exploration of systemic/racial problems), research self-efficacy, and other skills of youth to integrate their lived experiences and identity to learning about the intersection of system and community level issues in mental health. Activities will center on participatory action approaches to engaging youth in culturally/community responsive ways.
45974441|NCT01645774|Procedure|15s injection duration and waiting 5s before withdrawing the needle|15s injection duration and waiting 5s before withdrawing the needle
45830175|NCT01739790|Drug|N-Acetylcysteine|1800 mg twice daily for 8 weeks
45830176|NCT01739790|Drug|Placebo|Identical placebo manufactured to mimic appearance of intervention drug with identical frequency and duration.
45974442|NCT01645774|Procedure|5s injection duration and waiting 15s before withdrawing the needle|5s injection duration and waiting 15s before withdrawing the needle
45974443|NCT00263991|Device|EEC-techniques|
45974444|NCT01645852|Dietary Supplement|Optifast 800|Five units of Optifast 800 plus an unlimited volume of calorie-free fluids per day for one week prior to hepatic resection.
45974445|NCT00239876|Drug|FTY720|
45974446|NCT01646008|Other|To measure carbon dioxide by capnography and arterial blood|Three times per day will be measured exhaled carbon dioxide and obtained in arterial blood sample.
45974447|NCT01646008|Other|to measure carbon dioxide by capnography and arterial blood|three times per day we will obtained arterial blood samples and measurements of carbon dioxide by capnography
45974448|NCT01646047|Dietary Supplement|multi-component nutritional supplement capsules|two capsules containing nutritional supplements per day for 6 months (vitamin C, mixed tocopherols/tocotrienols, vitamin D, fish oil, lutein, zeaxanthin, pine bark extract, benfotiamine, green tea extract, curcumin)
45830177|NCT01696032|Drug|SGI-110|
45830178|NCT01696032|Drug|Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)|Investigator chose to treat with either topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine
45830179|NCT01696032|Drug|Carboplatin|
45974449|NCT01646047|Dietary Supplement|multi-component dietary supplement|placebo capsules
45456045|NCT05100771|Other|Pediatric brain MRI|Routine brain MRI with automated quantitative information (brain volumetry and T1 relaxometry)
45830180|NCT01695954|Drug|Pitavastatin|Pitavastatin 2 mg tablets taken at bedtime in Arm A and in the morning in Arm B.
45830181|NCT01695954|Drug|Darunavir|Darunavir 400 mg tablets x 2 taken daily in Arm B
45830182|NCT01695954|Drug|Ritonavir|Ritonavir 100 mg tablets taken daily in Arm B
45974450|NCT00264030|Device|Angioguard distal protection device|PTCA with the Angioguard distal protection device.
45974451|NCT00264030|Other|PTCA|PTCA
45974452|NCT01646086|Behavioral|12 month behavioral weight loss intervention|The intervention for all groups will follow a standard behavioral weight loss protocol. Participants will meet in groups of up to 20 persons; groups will meet weekly for the first six months, then biweekly for two months and monthly for the remaining four months of the 12-month treatment period. Session content will be centered on behavioral goal setting and attention to caloric intake and physical activity. Participants will be asked to keep daily diet and physical activity logs.
45974453|NCT04709510|Diagnostic Test|Duplex Ultrasound|Duplex Ultrasound was performed for every participants for the diagnosis of symptomatic or asymptomatic deep vein thrombosis
45974454|NCT01646242|Procedure|removal of eligible polyps using cold snare polypectomy technique|Snare polypectomy using a mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
45974455|NCT01646242|Procedure|removal of eligible polyps using double biopsy technique|Cold forceps polypectomy using a standard- capacity forceps with double biopsy technique (two bites per one forceps pass)
45974456|NCT02961075|Other|local surface anesthesia|Airway anesthesia for Bronchoscopy
45974457|NCT02961075|Device|Laryngeal tube|
45974458|NCT01646281|Drug|Vernakalant|10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given.
45974459|NCT01646281|Drug|Flecainide|10-minute infusion of 2 mg/kg (maximal 150 mg)
45974460|NCT01646359|Device|1.Esophageal doppler monitor|1.Esophageal doppler monitor (CARDIO Q®, DELTEX MEDICAL. Brighton, U. K.)-inserted into the esophagus and positioned approximately 35-40 cm from the teeth. The position of OED prove was confirmed by continuously measuring blood flow velocity in the descending thoracic aorta and focused to find the optimum peak velocity and waveform signal.
45974461|NCT01646359|Device|2. philips Intelivue MP70 monitors|2.philips Intelivue MP70 monitors (Intellivue MP70, philips medical Systems, Suresnes, France) -a radial arterial cannula was inserted and arterial pressure waveforms were monitored through Philips Intelivue MP70 monitors. In the monitor, PPVauto was displayed in real-time. It based on automatic detection algorithms, kernel smoothing, and rank-order filters.
45974462|NCT00239915|Drug|Pagoclone|
45456046|NCT05099484|Drug|The MedMilk study|This observational, pragmatic PK study will enroll lactating women who are taking medications that were prescribed by their treating medical provider or as an over-the-counter medication.
45670804|NCT04874714|Biological|MG01(30.000)|Grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne and Dactylis glomerata) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
45974463|NCT01646476|Device|Covered stent (Bona stent pyloric/duodenal covered) insertion|self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
45974464|NCT01646476|Device|Uncovered stent (Bona stent, pyloric/duodenal) insertion|Self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
45974465|NCT01646554|Drug|Modified FOLFOX6|
45974466|NCT01646554|Biological|Aflibercept|Targeted therapy
45974467|NCT01646554|Procedure|Surgery|
45974468|NCT00250263|Drug|(agent for immunotherapy) Staloral|"Immunotherapy agent for sublingual daily use. First week (vial containing the concentration 10 IR/ml) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing the concentration 300 IR/ml) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily~The first year will be followed by a second year open label period (optional)- 8 pressures daily"
45974469|NCT00250263|Drug|Placebo|"Matching placebo for sublingual use. Same schedule used for the intervention ACTIVE group.~First week (vial containing placebo) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing placebo) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily"
45974470|NCT02279368|Behavioral|Family Counselling and safeguarding|
45974471|NCT02279446|Other|Intermediate Visual acuity (IVA) assessment|Intermediate visual acuity (IVA) will be assessed with the Intermediate Visual acuity chart which is similar to the prevalent Jaeger chart. It consists of short blocks of text in various type sizes.The computer screen is set at a specific reading distance (1 meter) and the patient is asked to read the passage with the smallest type he/she can see. According to the smallest text he/she can read, IVA is classified from IVA1 (which is considered the equivalent of 20/20 distance visual acuity) to IVA5
45974472|NCT02279485|Drug|Perampanel|
45974473|NCT01646593|Drug|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off
45974474|NCT00264069|Drug|antipsychotic|as prescribed
45974475|NCT00264069|Drug|antidepressants|as prescribed
45974476|NCT01646632|Behavioral|Physical exercise intervention|the experimental intervention included group- based progressive resistance training, balance training, and functional training, two times a week, one hour sessions, lasting 16 weeks.
45456047|NCT05098015|Behavioral|Game Changers|8-session group intervention that uses didactic instruction, role plays and experience sharing to empower participants to engage in HIV prevention advocacy.
45456048|NCT05096884|Drug|Metoprolol Succinate|The beta blocker metoprolol succinate will be initiated at a starting low dose of 25 mg daily for two weeks and will be escalated if well tolerated every 2 weeks to a maximum dose of 400 mg po daily.
45456049|NCT05094102|Device|OnLume Imaging System|for fluorescence-guided surgery with ICG dye
45456050|NCT05094102|Drug|Indocyanine green|Indocyanine green is a cyanine dye used in medical diagnostics
45456051|NCT05092295|Device|Head and Intraocular Trauma Tool|HITT device to scan eyes of participants up to 3 times (~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.
45670805|NCT04874714|Biological|MM09(30.000)|Mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
45830183|NCT01695954|Drug|Efavirenz|Efavirenz 600 mg tablets taken at bedtime in Arm A
45830184|NCT01694706|Drug|faldaprevir|medium dose of faldaprevir
45830185|NCT01694706|Drug|faldaprevir|medium dose of faldaprevir
45830186|NCT01694706|Drug|omeprazole|medium dose of omeprazole
45830187|NCT01694706|Drug|faldaprevir|medium dose of faldaprevir
45456052|NCT05092295|Diagnostic Test|SCAT-5|Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.
45670806|NCT04874714|Biological|Placebo subcutaneous|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
45670807|NCT02194699|Biological|Experimental: Tralokinumab|Tralokinumab subcutaneous injection
45670808|NCT02194699|Other|Placebo|Placebo subcutaneous injection
45670809|NCT04867070|Diagnostic Test|NAS score|Participants will be recorded according to the NAS and W-BAS pain scores
45830188|NCT01693692|Drug|TD-9855 Group 1|
45830189|NCT01693692|Drug|TD-9855 Group 2|
45830190|NCT01693692|Drug|Placebo|
45830191|NCT01693614|Drug|Buparlisib|100 mg hard gelatin capsules administered orally, once daily in cycles of 28 days
45830192|NCT01715298|Drug|NVA237|NVA237 (Glycopyrronioum bromide) as a powder for inhalation in single-dose capsules
45974477|NCT01646632|Behavioral|Lifestyle counseling|the control intervention included recreational sessions, including talks, video's, music, board games etc. No physical activity was involved in the control intervention.
45974478|NCT01646710|Behavioral|Pretesting food based recommendations|
45974479|NCT01646788|Device|NMB Paclitaxel Drug Ejecting Balloon|NMB's PTA Balloon catheter with drug
45974480|NCT01647178|Procedure|TORQ assisted sternal closure|
45974481|NCT01647178|Procedure|Conventional closure|
45974482|NCT02961699|Device|Transpose ® RT System|adipose-derived stem cell therapy
45974483|NCT02961699|Other|debridement/dressing of wound|standard of care debridement and wound dressing
45974484|NCT01647256|Drug|Nikkomycin Z|Capsule, 500 mg, single-dose
45974485|NCT00239954|Drug|Escitalopram|
45670810|NCT04866524|Other|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages & Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy to use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
45670811|NCT04866524|Other|Physical development and General Health|Physical development and General health examination
45974486|NCT04528927|Drug|HCQ|600 mg on the 1st day as a starting dose then 200 mg * 2 /D for 9 days
45974487|NCT04528927|Drug|Azithromycin|500 mg (1st day) then 250 mg / D for 4 days
45974488|NCT04528927|Drug|Doxycycline|200 mg per day for 10 days
45974489|NCT04528927|Dietary Supplement|Zinc|220 mg per day for 10 days
45974490|NCT04720287|Drug|bupivacaine/ neostigmine.|will receive bilateral ultrasound guided QLB
45974491|NCT04720287|Drug|bupivacaine/ neostigmine.|will receive ultrasound guided CB.
45974492|NCT04528654|Other|Mobile Health Application|The participants will be given instructions to use their smartphone or tablet to download the hypertension tracking app. They will follow the instructions provided within the app and use it to track their blood pressure over the next six months.
45974493|NCT00239993|Drug|glatiramer acetate|
45974494|NCT00239993|Procedure|Warm compress prior to injection of glatiramer acetate|
45974495|NCT01647334|Radiation|Adaptive radiotherapy|
45974496|NCT00264108|Drug|Darbepoetin alfa|Either 150 ug once weekly or 500 ug once every 3 wks, variable treatment length.
45974497|NCT00264108|Drug|Epoetin alfa|40,000 IU once weekly, variable treatment length.
45974498|NCT01647412|Drug|Growth Hormone|Humatrope will be administered daily to patients in a dose of .18-.20 mg/kg/week.
45974499|NCT01647412|Dietary Supplement|Nutraceutical Combination|
45974500|NCT01647412|Other|Exclusion Diet|Patients on the exclusion diet will adhere from consumption of all grain, corn, dairy, and carrageenan containing products.
45974501|NCT01647412|Other|Placebo Growth Hormone|
45974502|NCT01647529|Drug|Ganciclovir|Treatment with topical ganciclovir ointment
45974503|NCT00240032|Drug|glatiramer acetate injection with oral cetirizine hydrochloride|Copaxone® injection 20 mg, Oral Zyrtec® 10 mg tablet
45974504|NCT00240032|Drug|glatiramer acetate with placebo|Copaxone® injection 20 mg, oral placebo
45974505|NCT01647607|Behavioral|Young Women's Intervention (YWI)|This educational intervention uses print and web-based materials to focus on issues unique to young women with breast cancer, including career development, starting/raising a family, body image, and genetic predispositions to breast cancer.
45974506|NCT01647607|Behavioral|Physical Activity Intervention (PAI)|This educational intervention uses print and web-based materials that focus on developing and/or maintaining a healthy lifestyle for young women with breast cancer, including the benefits of exercise and resources to enhance physical activity after diagnosis.
45974507|NCT00250302|Procedure|autologous mesenchymal stem cells implantation|
45974508|NCT04528849|Drug|Gonadotropin dose increment timing|Gonadotropin dose increments of 25 IU will be utilized on 7th and 14th day of ovulation induction for each study group.
45974509|NCT00240149|Drug|Regular Insulin via Insulin-Glucose Algorithm|
45974510|NCT01647646|Drug|Seretide|Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety
45974511|NCT01647685|Drug|Nanocort|Two weekly IV infusions of 150 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
45974512|NCT01647685|Drug|Methylprednisolone|Two weekly infusion iv methylprednisolone sodium succinate 125 mg infusion.
45670812|NCT04866524|Other|Developmental Red flags|Developmental Red flags Questionnaires
45974513|NCT01647685|Drug|Placebo|Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
45974514|NCT00240188|Procedure|Open mesh repair of ventral incisional hernia|For the open procedure, the technique, as described by Chevrel and others was adopted.
45974515|NCT00240188|Procedure|Laparoscopic mesh repair of ventral incisional hernia|For the laparoscopic repair, the method of Gagner was adopted
45974516|NCT01647802|Device|"Standing attempts with the Vertic'Easy Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes.
45974517|NCT01647802|Device|"Standing attempts with the Turner Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
45974518|NCT01647802|Device|"Standing attempts with the Tina device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
46082123|NCT02804906|Behavioral|Home-based physical therapy|"Participants will be visited by a physical therapist 3 times a week for approximately 1 hour each day, for a duration of 4 weeks. These visits will serve to encourage adherence to the intervention, reinforce activities recommended at discharge, monitor safety under direct supervision, and adjust the exercise prescription if/as needed (e.g. advance recommended activity level) if necessary. Patients will also be provided with a tablet computer device installed with software, Moving Analytics, that will reinforce the cardiac rehabilitation program through daily reminders and easily accessible visual activity plans. This program will be updated by the physical therapist during home visits as the program advances. Daily patient-reported health status (Your Activities of Daily Living) 26 will be ascertained on the same tablet device by participants three times per week using open source software designed."
45830193|NCT01715298|Drug|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
46082124|NCT02804906|Behavioral|Usual Care|"Participants in the control arm will be provided with a 30-minute counseling session on risk factor modification prior to discharge. Participants will be provided with a tablet computer device to complete patient-reported health status (Your Activities of Daily Living) 26 three times per week using open source software designed. Participants will be visited by the Research Coordinator or member of the study team at one month post-hospital discharge to perform a follow-up assessment that will include ADLs, IADLs, SF-12 PCS, frailty measures, and questions on healthcare utilization (hospital readmissions)."
46082125|NCT02738112|Device|Encore System|Hyo-mandibular suspension
46082126|NCT02812004|Device|Ultra Q Reflex YAG laser (Ellex)|"Group 1 receives up to 2 sessions of vitreolysis performed with the Ultra Q Reflex YAG laser (Ellex). There is no cut off for total energy per treatment session.~For the sham treatment in group 2, the physician quickly manipulates the light switch of the laser's slit lamp to create light flashes and simulate laser pulses."
45670813|NCT05647148|Behavioral|Progressive Relaxation Exercises|"In the first part of this audio material, which consists of three parts; The definition of deep relaxation, its purpose and points to be considered during exercise are included.~The second part, consisting of an average of thirty minutes, includes the explanation of relaxation exercises with verbal commands accompanied by the sound of the stream.~In the last part, there is only relaxation music without any commands."
45670814|NCT05369858|Drug|[14C] SKLB1028|A single 150 mg oral dose of [14C] SKLB1028 containing approximately 120 microcurie of [14C] SKLB1028
45670815|NCT02293538|Drug|FID 114657 eye drops (10 ml)|Lubricating eye drop for temporary relief of burning and irritation due to dryness of the eye
45830194|NCT01713582|Drug|OTX015/Birabresib|OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally
45830195|NCT01739400|Drug|Macitentan 10 mg tablet, once daily.|Macitentan 10 mg tablet, once daily.
45830196|NCT01713348|Device|FreeStyle Navigator|Masked CGM day 1 to 15, unmasked CGM days 15 to 100
45830197|NCT01713348|Device|Standard SMBG|Masked CGM days 1 to 15, standard SMBG days 15 to 86, masked CGM day 86 to 100
45830198|NCT01737996|Drug|BI 207127 + faldaprevir|fixed dose combination
45670816|NCT02293538|Drug|Saline control eye drops (15 ml)|Saline eye drops (15 ml)
45974519|NCT01647919|Dietary Supplement|cogniVida™ 100 mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
45974520|NCT01647919|Dietary Supplement|Placebo|4 capsules of placebo identical to cogniVida™ once a day
45974521|NCT00240266|Drug|Rosuvastatin|
45974522|NCT01648036|Drug|Unfractionated heparin|Dose: 18 IU/kg/hr, continuous intravenous infusion. Duration: up to 7 days or until ICU discharge or death
45974523|NCT01648036|Drug|Dalteparin|Dose 5000 IU, subcutaneous, daily
45974524|NCT01648075|Dietary Supplement|Experimental: Probiotic enriched milk|Milk will be enriched with lactobacillus rhamnosus for the experimental group.
45974525|NCT01648114|Other|Antenatal Breastfeeding Intervention|The intervention will include a 20 to 30-minute one-to-one educational talk by a lactation expert explaining the facts of breastfeeding and answering participant questions. The educational intervention will focus on: (1) the importance of exclusive breastfeeding, (2) milk supply/demand and feeding on demand, (3) frequency of feedings, feeding cues, how to know an infant is getting enough milk, (4) avoiding artificial nipples until the infant is nursing well, (5) the importance of a good latch, (5) where to seek breastfeeding help and support, and (7) returning to work and continuing breastfeeding
45974526|NCT04528537|Other|questionnaire|16-item quality of recovery questionnaire for the postanesthesia care unit (QoR-PACU)
45974527|NCT00240305|Drug|Rosuvastatin|
45974528|NCT01648192|Drug|Losmapimod for single dose|Film coated white tablet
45974529|NCT01648192|Drug|Losmapimod for repeat dose|Film coated white tablet
45974530|NCT01648231|Drug|Reference Treatment: 1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state
45974531|NCT01648231|Drug|Fixed Dose Combination 1: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
45974532|NCT01648231|Drug|Fixed Dose Combination 2: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
45670817|NCT02293538|Device|Habitual contact lenses|Commercially marketed biweekly or monthly replacement soft contact lenses as prescribed by eye care practitioner, brand and power
45974533|NCT01648309|Other|Neuropsychological testing|This is an observational study
45974534|NCT01648504|Other|eGuide to Colonoscopy and in office ipad education|The investigators will follow patients who receive in office Ipad video education and at home web portal access to the Johns Hopkins eGuide to Colonoscopy.
45974535|NCT01648543|Procedure|lumbar sympathetic ganglion block|
45974536|NCT01648660|Dietary Supplement|Lutein/ Zeaxanthin + Omega- 3- Fatty Acids|capsule with Lutein, Zeaxanthin, Omega-3-FA for two years
45456053|NCT05092282|Device|Head and Intraocular Trauma Tool|HITT device to scan eyes of participants up to 3 times (~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.
45456054|NCT05092282|Diagnostic Test|SCAT-5|Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.
45456055|NCT05086731|Other|Best Practice|Receive standard of care
45456056|NCT05086731|Other|Informational Intervention|Receive reminders
45974537|NCT00264186|Drug|LPS 2 ng/kg intravenous (IV) bolus|
45974538|NCT00264186|Drug|rhSOD 82,000 IU (8.2 mg)/min intraarterially|
45974539|NCT00264186|Drug|Norepinephrine 60, 120, 240 pmol/min intraarterially over 5 min/dose level (two times; pre-dose and +3.5 hrs)|
45974540|NCT00264186|Drug|Acetylcholine 6.25, 12.5, 25 nmol/min intraarterially over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
45974541|NCT00264186|Drug|Glyceroltrinitrate (nitroglycerine) 4, 8, 16 nmol/min over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
45974542|NCT01648738|Other|Spa therapy, exercise and educational therapy|During 5 days: Spa therapy (2 hours/day), exercises (30 min/day), educational therapy (45 min/day) including education on physical activities, work, and pain management
45974543|NCT01648738|Other|Usual care|Information, counseling, treatment usually provided for sub-acute and chronic low back pain and the back book
45974544|NCT01648855|Other|Biological samples|To measure the levels of sFlt1, angiogenic and antiangiogenic factors at birth in maternal blood, umbilical cord blood and in the amniotic fluid
45456057|NCT05086731|Other|Medical Device Usage and Evaluation|Receive a SMRxT smart pill bottle
45456058|NCT05086731|Other|Quality-of-Life Assessment|Ancillary studies
45974545|NCT01648933|Radiation|Rubidium PET|Myocardial Perfusion Imaging
45974546|NCT01648972|Drug|Gastrografin|
45670818|NCT02194621|Drug|Total Flavor option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM complex 1 ingredient -Total Flavor Option 1
45974547|NCT01648972|Drug|Placebo|
45974548|NCT00240422|Drug|Telmisartan|
45974549|NCT00240422|Drug|Ramipril|
45974550|NCT00264225|Drug|Lamaline® , 3 different doses, Dafalgan codeine|
45974551|NCT01649011|Behavioral|Application of the initial evaluation|Initial evaluation involves the application of the previously spanish validated Rolland Morris Questionnaire and the new spanish Oswestry Disability Index
45974552|NCT01649011|Behavioral|Final application of scales|Application of the previously spanish validated version of the RMQ and the new spanish translation of the ODI 2 weeks after initial evaluation
45974553|NCT01649050|Drug|BGG492|
45974554|NCT01649050|Drug|Placebo|
45670819|NCT02194621|Drug|Total Flavor option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride and new OM complex 2 ingredient. Total Flavor option 2
45670820|NCT02194621|Drug|Placebo toothpaste: Crest Cavity Protection toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste w/sodium fluoride (currently marketed)
45670821|NCT02220205|Other|PelvicSim|
45670822|NCT02220205|Device|Manufacturer model|
45830199|NCT01713036|Drug|Pimasertib|Part A: Subjects will receive unlabeled pimasertib capsules orally at a single dose of 60 milligram (mg) on Day 1. One hour after administration of the oral unlabeled pimasertib dose, the intravenous (IV) tracer dose of 9 kilobecquerel (kBq) [14C] pimasertib will be administered as a bolus injection. On Days 3-21 (except Day 8), subjects will receive unlabeled pimasertib capsules orally at a dose of 60 mg twice daily (BID). In the morning of Day 8, subjects will receive 60 mg unlabeled pimasertib capsules spiked with a dose of 2.6 megabecquerel (MBq) (70 microcuries [mcgCi]) of [14C] pimasertib orally. In the evening of Day 8, subjects will receive the evening dose of 60 mg pimasertib as unlabeled pimasertib capsules orally. Part B : Subjects will be administered with 60 mg BID unlabeled pimasertib as oral capsules continuously in cycles of 21 days until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow-up or death.
45974555|NCT02279563|Drug|Azelastine HCl and Fluticasone Propionate Nasal Spray, 137 µg/50 µg per spray|"During the placebo lead-in period, the placebo nasal spray was administered via nasal inhalation with one spray in each nostril twice daily for 7days.~During the randomized treatment period, the investigational products (experimental, active comparator and placebo nasal spray) were administered via nasal inhalation with one spray in each nostril twice daily for 14 days"
45974556|NCT02279563|Drug|Dymista™ Nasal Spray|
45974557|NCT02279563|Drug|Placebo|
45974558|NCT00240461|Dietary Supplement|COLD-fX natural health product|200 mg/COLD-fX natural health product - 2 capsules twice daily for 6 months
45974559|NCT00240461|Dietary Supplement|COLD-fX|400 mg COLD-fX natural health product 2 times daily for 6 months
45974560|NCT00240461|Other|Placebo|crystalline substance 200 mg twice daily for 6 months
45974561|NCT02279680|Device|Electroencephalography|
45974562|NCT02279680|Behavioral|Neuropsychological assesments|
45974563|NCT02279758|Drug|Metformin|
45974564|NCT00264264|Procedure|Closure Device|
45974565|NCT00264264|Procedure|Direct Compression|
45974566|NCT01649206|Procedure|Percutaneous Radiofrequency Thermal Ablation|Percutaneous Radiofrequency Thermal Ablation (RTA) by using a RITA© StarBurst Talon needle (RITA Medical Systems, Fremont, CA). RTA is performed in each patient at Time 0.
45974567|NCT01649245|Drug|Reiferon retard|Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is >75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses.
45974568|NCT04721210|Other|Transcranial magnetic stimulation|"The investigated method is called transcranial magnetic The impact on the SMA will be made using a special inductor of the double conical coil type. Navigation will be carried out through the use of the international system 10-20%. The threshold of motor response will be determined by stimulating the motor area of the legs with the intensity of stimulation necessary to trigger a motor response with an amplitude of more than 50 mv."
45456059|NCT05086731|Other|Survey Administration|Ancillary studies
45974569|NCT01649284|Drug|afatinib|40, 30, and 20 mg film-coated tablets
45974570|NCT00250419|Biological|V930|
45974571|NCT01649401|Device|Standard nebulizer|"Nebulizer sessions for the patients will be administerd using our standard nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical."
45830200|NCT01712334|Drug|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari eRapid nebulizer.
45974572|NCT01649401|Device|PARI LC Sprint Sp nebulizer|"Nebulizer sessions for the patients will be administerd using the PARI LC Sprint Sp nebulizer.~Manufacturer: PARI GmbH Germany"
45974573|NCT00415740|Drug|ELC200 (carbidopa+levodopa+entacapone)|
45974574|NCT01649479|Biological|Antiphospholipid antibody tests|Each patient will be tested for antiphospholipid antibodies.
45974575|NCT01649479|Biological|Thrombophilia bloodwork|"Bloodwork will be drawn up for:~antithrombin, protein C, protein S~Factor V Leiden polymorphisms (F5 1691A)~prothrombin 20210A gene polymorphism (F2 20210A)~JAK2 617F Mutation~Homocysteine~Factor VIII"
45974576|NCT01649479|Other|Psychiatric evaluation|During this consultation, the Mini International Neuropsychiatric Interview will be used to screen for psychiatric symptoms. Should the latter be detected, a further consult with a psychiatrist or a psychologist will be organized; this second consult will include the Mood Disorder Questionnaire (MDQ), the Beck Depression Inventory (BDI), the Inventory for Depressive Symptomatology - Clinician (IDS-C) and the Structured Clinical Interview for Disorders (SCID, DSM-IV).
45974577|NCT01649635|Drug|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
45456060|NCT05084378|Drug|Povidone-Iodine Lavage Solution|0.35% povidone-iodine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.35% povidone-iodine and sterile isotonic saline solution may also be used.
45670823|NCT02266706|Drug|Ceftolozane/Tazobactam 1000/500 mg|A fixed dose combination (FDC) of 1000 mg ceftolozane and 500 mg tazobactam as a 60 minute infusion.
45670824|NCT02266706|Drug|Ceftolozane/Tazobactam 30/15 mg/kg|A FDC of 30 mg/kg of ceftolozane and 15 mg/kg of tazobactam as a 60 minute infusion.
45974578|NCT01649635|Drug|Prednisone|Pharmaceutical form: tablet Route of administration: oral
45974579|NCT01649635|Drug|Ciprofloxacin|Pharmaceutical form: tablet Route of administration: oral
45974580|NCT01649635|Drug|G-CSF (Granulocyte colony-stimulating factor)|Pharmaceutical form: solution Route of administration: subcutaneous
45670825|NCT02266706|Drug|Ceftolozane/Tazobactam 20/10 mg/kg|A FDC of 20 mg/kg of ceftolozane and 10 mg/kg of tazobactam as a 60 minute infusion.
45670826|NCT02266706|Drug|Ceftolozane/Tazobactam 18/9 mg/kg|A FDC of 18 mg/kg of ceftolozane and 9 mg/kg of tazobactam as a 60 minute infusion.
45670827|NCT02266706|Drug|Ceftolozane/Tazobactam 12/6 mg/kg|A FDC of 12 mg/kg of ceftolozane and 6 mg/kg of tazobactam as a 60 minute infusion.
45830201|NCT01712334|Drug|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari LC Plus jet nebulizer.
45974581|NCT00250536|Drug|nandrolone decanoate|
45974582|NCT00250536|Behavioral|resistance exercise training|
45974583|NCT00240617|Drug|sumatriptan succinate/naproxen sodium|comparator
45974584|NCT00240617|Drug|placebo|placebo to match
45974585|NCT01649713|Drug|Fluval AB vaccination|Vaccination with Fluval AB suspension for injection
45974586|NCT01649752|Biological|Differentiated stem cells to endometrium is deposited in the uterine cavity through an IUI catheter|
45974587|NCT01649752|Biological|Undifferentiated MSC is deposited in the uterine cavity through an IUI catheter.|
45974588|NCT01649830|Radiation|Radiotherapy|External beam radiation: 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
45974589|NCT01649830|Drug|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
45974590|NCT04708743|Diagnostic Test|Automatic Tongue Diagnosis System|tongue image capture tongue images by Automatic Tongue Diagnosis System
45974591|NCT01649986|Behavioral|Non-pharmacologic intervention|Diet and physical exercise
46082127|NCT04014439|Diagnostic Test|Ratio of Neutrophil to Lymphocyte|Each patient was examined for a blood sample of 6 ml of venous blood taken from the cubital vein using a vacuum tube without anticoagulants. Blood samples were centrifuged at a speed of 3500 rpm for 20 minutes. Samples are processed with abbott® devices, to obtain neutrophil and serum lymphocyte levels. Plasma samples are stored in the refrigerator -20 C. The patient's diaphragm thickness was measured on days 0, 3, 5 and then the measurement was compared. Diaphragm thickness was measured in patients using mechanical ventilation in intensive care rooms.
46082128|NCT04014439|Diagnostic Test|Level of Prealbumin Serum|Each patient was examined for a blood sample of 6 ml of venous blood taken from the cubital vein using a vacuum tube without anticoagulants. Blood samples were centrifuged at a speed of 3500 rpm for 20 minutes. Samples are processed with abbott® devices, to obtain neutrophil and serum lymphocyte levels. Plasma samples are stored in the refrigerator -20 C. The patient's diaphragm thickness was measured on days 0, 3, 5 and then the measurement was compared. Diaphragm thickness was measured in patients using mechanical ventilation in intensive care rooms.
45456061|NCT05084378|Drug|Chlorhexidine Lavage Solution|0.05% chlorhexidine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.05% chlorhexidine and sterile isotonic saline may also be used.
45456062|NCT05084378|Drug|Topical Antibiotic|2 grams Vancomycin powder
45670828|NCT02293460|Drug|I10E|"Patients who meet all eligibility criteria will receive one dose of IMP at 2g/kg over 2-5 days followed by 7 doses of IMP at 1g/kg over 1-2 day(s), every 3 weeks.~Duration of treatment period: 21 weeks +/- 7 days."
45670829|NCT04880642|Drug|C21|C21
45830202|NCT01712256|Biological|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
45830203|NCT01712178|Biological|Adalimumab, current formulation|Current formulation adalimumab 40 mg every other week
45830204|NCT01712178|Biological|Adalimumab, new formulation|New formulation adalimumab 40 mg every other week
45830205|NCT01693068|Drug|Pimasertib|Subjects will receive pimasertib orally as monotherapy at a dose of 60 milligram (mg) twice daily continuously. Treatment will consist of repeated 21-day cycles which will continue until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first.
45830206|NCT01693068|Drug|Dacarbazine|Subjects will receive dacarbazine intravenously at dose of 1000 milligram per square meter (mg/m^2) of body surface area every 3 weeks on Day 1 of each 21-days cycle until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first. Eligible subjects with documented tumor progression on dacarbazine will offer to switch to pimasertib treatment.
45830207|NCT01691898|Drug|Obinutuzumab|Obinutuzumab 1000 mg will be administered by IV infusion on Days 1, 8, 15 of first 21-Day cycle and on Day 1 of subsequent 21-day cycles for up to 8 cycles.
45974592|NCT01649986|Drug|Nutraceuticals (Armolipid Plus)|Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
45670830|NCT04880642|Drug|Placebo|Placebo
45974593|NCT00240656|Drug|spironolactone captopril carvedilol|
45974594|NCT01645696|Device|BD CGM with Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring for 72 hours.
45974595|NCT01645696|Device|BD CGM without Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring over 72 hours.
45974596|NCT01645696|Device|Medtronic iPro2 Professional CGM|continuous subcutaneous glucose monitoring for 72 hours
45974597|NCT01647451|Drug|NNC0114-0006|Two i.v. (intravenous) doses administered 6 weeks apart.
45670831|NCT04419974|Diagnostic Test|Molecular Diagnosis|Double-blind molecular diagnosis for the SCA3/MJD mutation.
45670832|NCT04419974|Diagnostic Test|Clinical Scales - Baseline|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied on baseline.
45670833|NCT04419974|Diagnostic Test|Blood Draw - Baseline|"Blood collection on baseline for evaluation of~Candidate genes expression~Serum proteins~Lymphocytic proteins"
45670834|NCT04419974|Diagnostic Test|Quality of Life Assessment - Baseline|Participants fill out 2 self-reported quality of life questionnaires.
45670835|NCT04419974|Diagnostic Test|Clinical Scales - Follow-up 12 months|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 12 months after baseline for prospective evaluation.
45830208|NCT01691898|Drug|Pinatuzumab Vedotin|Pinatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
45830209|NCT01691898|Drug|Polatuzumab Vedotin|Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
45830210|NCT01691898|Drug|Rituximab|RTX 375 mg/m^2 administered by IV infusion on Day 1 of every 21-day cycle.
45974598|NCT01647451|Drug|placebo|Two i.v. (intravenous) doses administered 6 weeks apart.
45974599|NCT00250575|Drug|Clozapine|
45974600|NCT01640899|Device|Shoe Insoles|Shoe insoles is an orthotic devices which are used to prevent, relieve, or reduce pain in lower extremities. The insoles give a mechanical support for the body by put it in a good alignment.
45670836|NCT04419974|Diagnostic Test|Blood Draw - Follow-up 12 months|"Blood collection 12 months after baseline for prospective evaluation of~Candidate genes expression~Serum proteins~Lymphocytic proteins"
45670837|NCT04419974|Diagnostic Test|Quality of Life Assessment - Follow-up 12 months|Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
45974601|NCT00240695|Drug|galantamine hydrobromide|
45830211|NCT01737840|Drug|Pantoprazole|33 patients
45974602|NCT04528381|Procedure|Laparoscopy|Laparoscopic orchiopexy
45974603|NCT00250614|Drug|Saredutant succinate (SR48968C)|
45830212|NCT01737840|Drug|Ranitidine|33 patients
45830213|NCT01691820|Procedure|Blood collection|Samples collected at Months 0, 4, 8, 12, 16, 20, 24, 28, 32, and 36.
45830214|NCT01691820|Procedure|Urine collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
45974604|NCT04528186|Diagnostic Test|Maternal thyroid volume|Maternal thyroid volume measurement
45830215|NCT01691820|Procedure|Saliva collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
45830216|NCT04547400|Other|assessment|Assessments of balance, gait, lower extremity position sense, and foot sole sense
45830217|NCT04167930|Other|electronic medical record(EMR) Data and patient survey|"Retrospective Data Collection (1) Neck Disability Index (NDI), Oswestry Low Back Disability Index(ODI), euroqol-5 dimension(EQ-5D) scores during hospitalization (2) symptom onset date, symptom onset motive, past history, accident occurrence date, accident treatmen termination agreement date, etc.~Question items (consistent with the case record) according to the purpose of the investigation (1) General: Demographic sociological characteristics (gender, age, occupation, income, etc.) (2) Matters concerning the correlation between traffic accident agreements and symptoms"
45830218|NCT01711866|Drug|Rotigotine|Rotigotine up to 16 mg / 24 hours, 4 weeks.
45830219|NCT01737762|Biological|HP802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x106 cells per mL every 14 days.
45830220|NCT01737762|Biological|Vehicle|
45830221|NCT01691508|Drug|Mepolizumab|Mepolizumab is a fully humanised Immunoglobulin G antibody (IgG1, kappa) with human heavy and light chain frameworks.
45830222|NCT01691508|Drug|Placebo|Will be available as an equivalent volume of 0.9% sodium chloride.
46082129|NCT04115696|Device|Percutaneous placement of biodegradable biliary stents|The bening biliary strictures stents used in this register are made of polydioxanone (PPDX) (Ella-DV biliary stent, ELLACS, Hradec Králové, Czech Republic). The stents are implanted using a percutaneous transhepatic cholangiography using the standard micropuncture technique. Before stent implantation, balloon bilioplasty may be performed.
45974605|NCT00240734|Drug|Epoetin alfa|
45974606|NCT01645072|Other|Low glycemic index diet|Diet modification in addition to ongoing anti epileptic drug treatment. Medium and high-GI carbohydrates (GI >55) will be eliminated from the diet and only food items with low glycemic index (GI <55) will be allowed. Parent will be given a list of low glycemic index food items. They will also be given a list of food items (medium and high glycemic index) which should be avoided.
45974607|NCT01645072|Other|Control group|The ongoing anti epileptic drug treatment will be continued without change.
45974608|NCT01645891|Device|CDO electrochemical tissue oxygenation system|The TransCu O2® device is a non-invasive, electrochemical tissue oxygenation system intended for use with lower-cost wound dressings for the treatment of chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and other skin wounds through the continuous diffusion of oxygen (CDO). The goal of CDO therapy is to continuously supply pure oxygen to an oxygen-compromised wound to aid in wound healing
45974609|NCT01645891|Device|Moist Wound Therapy|Moist Wound Therapy in combination with sham or deactivated device
45974610|NCT04720248|Drug|Metamizole|Patients will receive metamizole intraoperatively and throughout 48h postoperatively.
45974611|NCT01646515|Drug|Placebo|"Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company.~Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks"
45974612|NCT01646515|Drug|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
45974613|NCT00240773|Drug|acetaminophen|4 grams daily for six months
45670838|NCT04419974|Diagnostic Test|Clinical Scales - Follow-up 24 months|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 24 months after baseline for prospective evaluation.
45670839|NCT04419974|Diagnostic Test|Blood Draw - Follow-up 24 months|"Blood collection 24 months after baseline for prospective evaluation of~Candidate genes expression~Serum proteins~Lymphocytic proteins"
45670840|NCT04419974|Diagnostic Test|Quality of Life Assessment - Follow-up 24 months|Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
45830223|NCT01691508|Drug|OCS (prednisone/prednisolone)|Oral Corticosteroid (prednisone/prednisolone)
45830224|NCT01682460|Drug|Refresh Tears Lubricant Eye Drops (Allergan)|Eye drops QID for 1 month
45830225|NCT01691430|Dietary Supplement|2 cranberry capsules|Two cranberry capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
45830226|NCT01691430|Dietary Supplement|Placebo|Two placebo capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
45670841|NCT05647070|Procedure|Autologous rectus Fascia TOT|"A sterile Foley catheter is placed to drain the bladder, following this, injectable normal saline is utilized using 10 cc syringe for hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through Pfannestiel incision, ~1 cm× ~5 cm rectus fascia strip is isolated from the anterior rectus sheath. Two stay sutures are secured to the corner of the fascial segment on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration"
45830227|NCT04413708|Behavioral|P3-T PrEP Adherence App|"P3-T provides daily PrEP reminders, a medication tracker and calendar, personalized medication adherence strategies, refill reminders, and tailored adherence support messages; social support via a social wall that includes daily discussion prompts; daily quests to build knowledge and skills; a multimedia knowledge center; interactive narrative collections; personalized adherence counseling provided by an adherence counselor via in-app messaging; in-app rewards; a bank account that rewards daily app use by adding or subtracting a small financial reward based on daily app use; and, a user profile that includes a user-selected avatar."
45974614|NCT00240773|Drug|naproxen|750 mg daily for 12 months
45830228|NCT01709838|Drug|deferasirox|Deferasirox dispersible tablets at strengths of 125 mg, 250 mg, and 500 mg were administered by oral daily dosing.
45830229|NCT01682226|Device|CliniMACS Fractionation system (Arm A)|"7 days before transplant Admit to hospital. Line insertion 6 days before transplant Fludarabine (chemotherapy) Cyclophosphamide (chemotherapy) 5 days before transplant Fludarabine Thiotepa 4 days before transplant Fludarabine Thiotepa 3 days before transplant Fludarabine Start CSA and MMF 2 days before transplant Fludarabine and TBI (radiation therapy)~1 day before transplant TBI (radiation therapy) Day of transplant Transplant day (infuse cord blood) Day after cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF"
45974615|NCT00240773|Drug|acetaminophen|4 grams daily for 12 months
45974616|NCT00240773|Drug|naproxen|750 mg daily for six months
45974617|NCT02279797|Behavioral|survey|Survey about Knowledge, Attitude and Practice About bone marrow donation
45974618|NCT01688401|Drug|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).~Standard dose: Cycle 1: 1 mg, intra-arterial (IA) delivery. Cycle 2: 2 mg, intra-arterial (IA) delivery.~Duration of treatment: Eight weeks total - two cycles of IA chemotherapy, separated by four weeks."
45974619|NCT04708821|Drug|Dexamethasone ophthalmic insert 0.4Mg|Dextenza 0.4Mg Ophthalmic Insert
46082130|NCT02737800|Procedure|endometrioma aspiration|Transvaginal ultrasound guided aspiration
46082131|NCT02737800|Drug|GnRh agonist ( Decapeptyl )|3 monthly doses of Decapeptyl 7.5mg intramuscular
46082132|NCT02737800|Procedure|standard long stimulation protocol|Decapeptyl 3.75mg in the mid luteal phase followed by human menopausal gonadotropins(HMG);fostimon, or merional injections after bleeding, doses are individualization according to each patient, monitored by follicular size &serum estradiol.
46082133|NCT00934531|Drug|Donepezil|"Participants with MCI will be randomized to either the experimental (donepezil) or placebo arm of the study.~Experimental Arm: Participants with MCI will receive 5 mg/day of donepezil p.o. for 4 weeks, and thereafter 10 mg/day of donepezil p.o. for a period of 5 months, yielding a total period of intervention of 6 months from baseline.~Placebo Arm: Participants with MCI will receive a matched placebo p.o. for 4 weeks, and thereafter will receive a new matched placebo p.o. for the next 5 months, yielding a total period of intervention of 6 months from baseline."
45974620|NCT04708821|Drug|0.2% loteprednol etabonate ophthalmic suspension|0.2% loteprednol etabonate ophthalmic suspension
45670842|NCT04865276|Behavioral|Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system|Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system
45974621|NCT04708821|Drug|olopatadine hydrochloride ophthalmic solution 0.7%|olopatadine hydrochloride ophthalmic solution 0.7%
45974622|NCT01688440|Other|#1 Respiratory Care Solution|Respiratory care solution.
45830230|NCT01682226|Device|CliniMACS Fractionation system (Arm B)|"8 days before transplant Admit to hospital. Line insertion 7 days before transplant Fludarabine 6 days before transplant Fludarabine Cyclophosphamide 5 days before transplant Fludarabine Cyclophosphamide 4 days before transplant Rest 3 days before transplant TBI x 3 Start CSA and MMF 2 days before transplant TBI x 3~1 day before transplant TBI x 3 Day of transplant TBI x 2 then infuse cord blood~1 day after the cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF"
45974623|NCT00240812|Drug|ibuprofen; pseudoephedrine HCl|
45974624|NCT01688479|Drug|Calendula Weleda cream (Weleda AG, Sweden) contains extracts of marigold plant (Calendula Officinalis 10%), wool fat and sesame oil|
45974625|NCT01688479|Drug|Essex® cream (Schering-Plough), aqueous cream without parabens|
45974626|NCT01688518|Drug|Heated Lidocaine/Tetracaine Patch|
45830231|NCT01682226|Biological|Haploidentical donor CD34+ cells|CB grafts will consist of two CB units 4-6/6 HLA-matched to the patient to augment graft cell dose and additional T-cell depleted PBSC from a haplo-identical donor.
45974627|NCT01688518|Drug|5% Lidocaine Patch|
45974628|NCT00250653|Drug|Saredutant succinate (SR48968C)|
45670843|NCT02266004|Device|Transcranial Direct Current Stimulation (tDCS)|Anodal tDCS will be applied for the duration of the walking training at 2 milliamps with IOMED Phoresor.
45974629|NCT05140681|Procedure|FibReORS with apically positioned flap (apical position)|Periodontal surgery including flap elevation. root surface scaling, bone remodeling and suture of the flap at 2 mm subcrestal position
45830232|NCT04167618|Drug|177Lu-DTPA-omburtamab|Biological, radiolabeled DPTA-omburtamab
45974630|NCT05140681|Procedure|FibReORS with apically positioned flap (crestal position)|Periodontal surgery including flap elevation. root surface scaling, bone remodeling and suture of the flap at either a crestal position
45974631|NCT00240851|Drug|acetaminophen extended release|
45456063|NCT05084378|Drug|Saline Lavage Solution|1 litre of sterile isotonic saline
45456064|NCT05076591|Drug|IMM2902|a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47
45670844|NCT02266004|Other|locomotor training|An individualized dual-task walking program for approximately 30 minutes.
45670845|NCT04864652|Device|CHILLS Procedure|CHILLS Cryotherapy procedure
45670846|NCT02292719|Drug|OBV/PTV/r|Tablet
45670847|NCT02292719|Drug|Sofosbuvir|Tablet
45670848|NCT02292719|Drug|Ribavirin (RBV)|Tablet
45830233|NCT01688466|Drug|Pomalidomide|0.5 mg/day with and/or without Dose Escalation and 0.5 mg/day- 2.0 mg/day by mouth (PO) QD(every day) of each 28 day cycle
45974632|NCT01688557|Device|Innovative colonoscopy (Olympus CF-HQ190F, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Sano and Kudo classifications.
45974633|NCT01688557|Device|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
45974634|NCT01688674|Drug|10% dextrose|
45974635|NCT04708977|Procedure|One-level lateral lumbar interbody fusion with Indirect Decompression|One-level lateral lumbar interbody fusion, with or without percutaneous posterior instrumentation. Thorough discectomy will be performed using lateral access. Fusion will then be performed using lateral access interbody cage and allograft bone graft with or without use of recombinant human bone morphogenic protein 2.
45974636|NCT04708977|Procedure|One-level lateral lumbar interbody fusion with Direct Decompression|"One-level lateral lumbar interbody fusion, with or without percutaneous posterior instrumentation. Thorough discectomy will be performed using lateral access instruments. Fusion will then be performed using lateral access interbody cage and allograft bone graft with or without use of recombinant human bone morphogenic protein 2.~Additionally, direct decompression through midline or parasagittal approach will be utilized. A unilateral laminotomy or complete bilateral laminectomy may be performed."
45974637|NCT05140486|Procedure|Rehabilitation: shortwave diathermy and perceptual training|All subjects in the rehabilitation group received shortwave diathermy therapy 5 days per week for 4 weeks and perceptual training 5 days per week for 10 weeks.
45974638|NCT00240929|Drug|MEDI-493|Active Comparator
45974639|NCT05140447|Other|preheating of resin composite|evaluate the effect of preheating BIS-GMA free resin composite at different temperatures on temperature change of the pulpal floor and restorations and compare it with BIS-GMA containing resin composite.
45974640|NCT01688713|Drug|Icotinib|The patients will receive Icotinib in doses of 250mg thrice per day until disease progression or undue toxicity.
45974641|NCT00250692|Drug|Nitrous Oxide|
45974642|NCT01688791|Drug|Vintafolide|
45974643|NCT01688791|Drug|Carboplatin|
45974644|NCT01688791|Drug|Paclitaxel|
46082134|NCT04202094|Diagnostic Test|Physical examination|A physical examination to measure the patients' weight, height, body mass index, blood pressure and testicular volume using a Prader orchidometer and to determine the patients' Tanner stage (secondary sexual development).
45670849|NCT02291861|Drug|SD-809|SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks. Tablets were swallowed whole with water and taken with food.
45670850|NCT02291861|Drug|Placebo|Placebo tablets taken twice daily for 12 weeks. Tablets were swallowed whole with water and taken with food.
45670851|NCT02291549|Drug|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
45974645|NCT01688908|Procedure|Endoscopic Screening|"Upper G.I. endoscopic examination with Lugols Iodine in esophagus~Biopsy at the visually abnormal sites~Pathologic examination of all biopsy tissue specimens~Subsequent re-examination and further medical services among individuals who already have high-grade lesions found at screening.~Advises of endoscopic or surgical treatment will be given to participants who are diagnosed of high grade upper G.I. lesions."
45974646|NCT00240968|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|A monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit¿¿dose vials containing either 30-mcg/mL A/H5N1 HA or 90-mcg/mL A/H5N1 HA. Subjects will receive 1 of 4 dose levels of vaccine (7.5, 15, 45, or 90 mcg) administered intramuscularly.
45974647|NCT01688947|Drug|V116517 50-mg tablets|Taken orally twice daily
45974648|NCT01688947|Drug|V116517 30-mg tablets|Taken orally twice daily
45974649|NCT01688947|Drug|Pregabalin capsules|1-2 capsules taken orally twice daily
45974650|NCT01688947|Drug|Placebo|Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily
46082135|NCT04202094|Diagnostic Test|Scrotum ultrasound|A scrotum ultrasound to measure the patients' testicular volume and to investigate potential abnormalities in the testicular parenchyma.
46082136|NCT04202094|Diagnostic Test|Blood sample|A morning blood sample to evaluate the serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (T), estradiol (E2), inhibin B (INHB), thyroid-stimulating hormone (TSH), free thyroxine (FT4), insulin-like growth factor 1 (IGF1), prolactin (PRL), cortisol and adrenocorticotropic hormone (ACTH). Upon approval by the patient himself, a spare blood sample will be collected and retained for 5 years for subsequent research purposes limited to the context of the present study.
45670852|NCT02291549|Drug|Mometasone furoate nasal spray|Mometasone furoate nasal spray (200mcg) once daily
45830234|NCT01682148|Biological|Botulinum toxin type A|
45830235|NCT01681992|Biological|Priorix|Subjects receive one dose of either minimum (Inv_MMR_Min) or medium (Inv_MMR_Med) potency lot at Day 0 and a dose of separate potency lot (Inv_MMR_Release) at Day 42, administered subcutaneously in the triceps region of the left arm.
45830236|NCT01681992|Biological|M-M-R II|Subjects receive two doses of either Lot 1 or Lot 2, one at Day 0 and one at Day 42, administered subcutaneously in the triceps region of the left arm.
45830237|NCT01681992|Biological|Varivax|Subjects receive one dose co-administered subcutaneously with the study vaccines (Priorix and M-M-R II), in the triceps region of right arm, at Day 0.
45830238|NCT01681992|Biological|Havrix|Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the right thigh, at Day 0.
45830239|NCT01681992|Biological|Prevnar 13|US Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the left thigh, at Day 0.
45830240|NCT01687998|Drug|Evacetrapib|Administered Orally
45830241|NCT01687998|Drug|Placebo|Administered Orally
45830242|NCT01681836|Drug|15Nitrogen(15N)-labeled sodium nitrite|15Nitrogen(15N)-labeled sodium nitrite 20 mg once
45974651|NCT00250731|Behavioral|telephone support and behavior change|Diabetes self-management education provided over the telephone either for individuals or couples
45974652|NCT00250731|Other|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
45830243|NCT01681836|Drug|15Nitrogen(15N)-labeled sodium nitrate|15Nitrogen(15N)-labeled sodium nitrate 1,000 mg once
45830244|NCT01681368|Drug|Birinapant (TL32711)|47mg/m^2 intravenous (IV) on days 1, 8 and 15 of each 28 day cycle
45830245|NCT01681212|Drug|Ipilimumab|
45974653|NCT00241007|Drug|VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE|
45974654|NCT01689025|Drug|NNC0114-0006|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
45974655|NCT01689025|Drug|placebo|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
45974656|NCT01689142|Drug|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
45974657|NCT01689142|Drug|Insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
45974658|NCT00241046|Drug|Letrozole|
45974659|NCT01689220|Drug|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
45974660|NCT01689220|Drug|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
45670853|NCT02291549|Procedure|Sham|In-office bilateral sham procedure, consisting of advancement of a delivery system with the S8 Sinus Implant into the ethmoid sinuses followed by removal without deployment.
45670854|NCT05651165|Device|Pharmacoactive balloon angioplasty. Lutonix®|Percutaneous transluminal angioplasty with paclitaxel-coated balloon in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
45670855|NCT05651165|Device|Mimetic stent.Supera®|Multiple intertwined nitinol wires that provide greater radial resistance and allow for even stress distribution. Implanted through percutaneous transluminal angioplasty in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
45670856|NCT02264990|Drug|Paclitaxel|Administered by Intravenous infusion on Day 1 of each 21-day cycle
45830246|NCT01681212|Drug|Dacarbazine|
45830247|NCT01687296|Drug|fluticasone propionate inhalation solution|2×0.5mg/2ml twice daily nebulized to treat an acute exacerbation of asthma for 7 days
45830248|NCT01687296|Drug|oral prednisone|once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) to treat an acute exacerbation of asthma for 7 days
45830249|NCT01687296|Drug|placebo inhalation solution|4ml 0.9% saline nebulized twice daily
45830250|NCT01687296|Drug|placebo tablet|placebo soluble tablet, oral ,once daily
45974661|NCT01689259|Drug|SL TNX-102 at 2.4 mg|1 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
45974662|NCT01689259|Drug|SL TNX-102 at 4.8 mg|2 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing them.
45974663|NCT01689259|Drug|SL TNX-102-A at 2.4 mg|1 TNX-102-A SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
45974664|NCT01689259|Drug|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
45974665|NCT01689298|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
45830251|NCT01687296|Drug|salbutamol|Salbutamol MDI 2 puffs twice daily or Nebules twice daily, and can be increased up to every 4 hours on an as-needed basis, through the treatment period.
45974666|NCT01689298|Drug|Carbetocin|Carbetocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
45974667|NCT00241085|Drug|valsartan|
45974668|NCT01689376|Drug|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off drug
45974669|NCT02272075|Device|Mobile OCT M3 scope|
45974670|NCT00241124|Drug|valsartan|
45974671|NCT00241124|Drug|lisinopril|
45974672|NCT00250809|Procedure|Placement of a central venous catheter|Placement of a central venous catheter
45974673|NCT00241163|Procedure|Fibrinogen (human) + thrombin (human) (TachoSil)|
45974674|NCT00241202|Behavioral|Symptom Management Manual|Participants receive the Symptom Management Manual, and are shown an example. They are given the Manual to take home with them and use.
45670857|NCT02264990|Drug|Carboplatin|Administered by Intravenous infusion on Day 1 of each 21-day cycle
45974675|NCT02277106|Drug|SAGE-547|
45974676|NCT02277106|Drug|Placebo|
45974677|NCT00241241|Drug|pegylated interferon-alfa 2a|
45974678|NCT00241319|Drug|R89674 (generic name not yet established)|
45974679|NCT00414804|Device|Precision SCS|Precision Spinal Cord Stimulation (SCS) Therapy
46082137|NCT04202094|Diagnostic Test|Semen analysis|A semen analysis to evaluate the ejaculate volumes, sperm concentration, sperm motility and sperm morphology. If sperm is found in the semen sample, an antisperm antibody test ((in)direct mixed anti-globulin reaction test) and a sperm DNA fragmentation test (Halosperm test) will be performed. Upon approval by the patient himself, the surplus of the semen sample will be retained for 5 years for subsequent research purposes limited to the context of the present study.
46082138|NCT00934609|Behavioral|Endurance training|45 min ergometer cycling at the ventilatory anaerobic threshold 4 times per week for 12 weeks
45830252|NCT04410432|Biological|Blood sample collection|"Additional blood volumes taken during a routine care blood test:~1 dry tube 5 mL for isolation and freezing of serum~1 x 5 mL EDTA tube to isolate and freeze plasma~8 heparinized 6 mL tubes for flow cytometry study"
45830253|NCT02071914|Drug|CT-P27|Influenza A treatment drug.
45830254|NCT02071914|Drug|Placebo|Placebo.
45830255|NCT01568892|Drug|Dolutegravir 50 mg twice daily|Active dolutegravir plus failing background regimen (Day 1 to Day 7). Open label dolutegravir plus optimized background regimen (from Day 8)
45974680|NCT00414804|Procedure|Nerve Blocks and PT|Pain therapy utilizing Nerve Blocks with Physical Therapy
45974681|NCT02279602|Drug|fosbretabulin|fosbretabullin, 60 mg/m2 weekly for up to 1 year
45974682|NCT02276209|Drug|Dasotraline|Dasotraline 4 mg once daily
45974683|NCT02276209|Drug|Dasotraline|Dasotraline 6 mg once daily
46082139|NCT02732886|Device|Medifoam®|Foam Dressing
46082140|NCT02732886|Device|Betafoam®|Foam dressing including Betadine iodine
46082141|NCT05531006|Other|retrospective cohort study|retrospective patient file review
46082142|NCT00937651|Drug|Placebo|Placebo
46082143|NCT00937651|Drug|Fimasartan (BR-A-657•K) 20 mg|Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
45456065|NCT05072249|Drug|Naloxone|Take Home Naloxone for reversing opioid overdose
45456066|NCT05071209|Drug|Elimusertib|Given PO
45670858|NCT02264990|Drug|Cisplatin|Administered by Intravenous infusion on Day 1 of each 21-day cycle
45670859|NCT02264990|Drug|Veliparib|Oral capsule, administered twice daily for 7 days in each 21-day cycle
45974684|NCT02276209|Other|Placebo|Placebo once daily
45974685|NCT01689493|Behavioral|patient education and daily SMS|The proposed intervention will be based on several conceptual frameworks (Chronic Care Model and Medication Adherence Model) and adapt elements of prior successfully adherence interventions, including: collaborative care, patient education, tailoring of medication regimens, and daily mobile phone short message service (SMS).
45974686|NCT01689571|Drug|CHF6001|
45974687|NCT01689571|Drug|Placebo|
45974688|NCT00241436|Drug|Anastrozole (ARIMIDEX™)|
45974689|NCT00264420|Drug|zoledronic acid|At baseline 4 mg IV zoledronic acid over 15 min. every 4 weeks for 6 months plus radiation therapy 30 Gy in 10 fractions (5 times per week for first two weeks)
45974690|NCT01689766|Drug|Technetium Tc 99m EC20|
45974691|NCT00241475|Drug|Gefitinib|
45974692|NCT01689844|Behavioral|DASH Plus|DASH diet advice and guided shopping for high postassium foods at a local supermarket
45670860|NCT02264990|Drug|Pemetrexed|Administered by Intravenous infusion on Day 1 of each 21-day cycle
45670861|NCT05646914|Other|Complex training exercises|Squats and drop jumps, Barbell step-ups and hops, Bench press and plyometric press-up, Barbell lunge and box jumps were performed.
45670862|NCT05646914|Other|Plyometric training exercises|Drop Jumps, Hops, Plyometric press-up, Box Jumps were performed.
45670863|NCT02291237|Drug|Eleclazine|Tablet (s) administered orally once daily
45670864|NCT02291237|Drug|Placebo|Placebo to match eleclazine administered orally once daily
45830256|NCT01568892|Drug|Dolutegravir placebo twice daily|Dolutegravir placebo plus failing background regimen (Day 1 to Day 7)
45974693|NCT01689844|Behavioral|DASH - C|Brief DASH dietary advice, No shopping guidance at the local supermarket.
45974694|NCT01689883|Device|Current stimulator|This is a device developed by the investigators to produce sub-sensory electrical stimulation delivered via subcutaneous electrodes placed on the skin.
46082144|NCT00937651|Drug|Fimasartan (BR-A-657•K) 60 mg|Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
45974695|NCT01689922|Other|AlterG|All patients will begin an early postoperative rehabilitation program and standard PT no later than 4 weeks following surgery and continue for at least 6 weeks. The duration of standard PT program could be extended depending on the patient needs. The patients randomized to undergo (LBPP) treadmill training will have an additional 7-week 3 times a week training on the antigravity
45974696|NCT01689961|Behavioral|Structured + monitored nutrition and exercise intervention|The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence.
45974697|NCT01686061|Other|No intervention- only one time survey|
45974698|NCT01685359|Drug|Epoetin Alfa|Intravenous administration for 4 weeks, three times a week (monday, wednesday, friday)
45974699|NCT01682824|Other|Nutritional Assessment|Complete dietary intake assessment
45974700|NCT01682824|Other|Questionnaire Administration|Complete TFEQ-R18v2 questionnaire
45974701|NCT01682824|Other|Questionnaire Administration|Complete EQ-EMA questionnaire
45974702|NCT01687738|Other|communication intervention|Because of the gaps between documented outcomes of lung cancer surgery and patient communication barriers identified in our recent work, our communication intervention will focus on improving presentation of risk information and confirmation of understanding of patient medical.
46082145|NCT00937651|Drug|Fimasartan (BR-A-657•K) 180 mg|Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
46082146|NCT00931021|Drug|Varenicline (Chantix)|2 mg
45670865|NCT02292446|Drug|Ruxolitinib|supplied as 5 mg, 10 mg and 20 mg tablets to be taken orally
45670866|NCT02290925|Drug|Kothala Himbutu Biscuit|Kothala Himbutu biscuit (containing Salacia reticulata extract) as a snack. This herb has been used by traditional physicians to control blood sugar.
45670867|NCT02290925|Dietary Supplement|Placebo Biscuit|Placebo biscuit without the herbal extract of Kothala Himbutu (Salacia reticulate)
45670868|NCT05651087|Drug|LACUDY|LACUDY:Insert 2mL twice a week for 4 weeks before going to bed
45670869|NCT02290691|Biological|Influenza Vaccine|Influenza Vaccine
45830257|NCT01568112|Drug|BG00012 (dimethyl fumarate)|Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.
45830258|NCT01568112|Drug|BG00012 placebo|Placebo matching BG00012
45670870|NCT02292212|Device|ViE-21|The subjects will be undergone three times KUF measurement sessions and three times blood sampling sessions during study period.
45670871|NCT02291510|Drug|Met DR|metformin delayed-release tablets
45670872|NCT02291510|Drug|Met XR|metformin extended-release tablets
45670873|NCT02291510|Drug|Met IR|metformin immediate-release tablets
45830259|NCT01568112|Drug|ASA|325 mg microcoated aspirin (ASA)
45830260|NCT01568112|Drug|ASA placebo|Placebo matching aspirin
45830261|NCT04116840|Drug|MT1002 for injection|Study drug will be administered by an intravenous bolus dose followed by an infusion of 4 hours.
45830262|NCT01568034|Drug|BIA 9-1067|BIA 9-1067 - 25 mg single-dose
45830263|NCT01568034|Drug|BIA 9-1067|BIA 9-1067 - 50 mg single-dose
45830264|NCT01568034|Drug|BIA 9-1067|BIA 9-1067 - 100 mg single-dose
45830265|NCT01568034|Drug|Placebo|single-dose
45830266|NCT01568034|Drug|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
45974703|NCT01687738|Other|Real Time Registry and data feedback only|This group of patients will not received the enhanced communication intervention
45974704|NCT02278978|Drug|BIBF1120|BIBF1120 200 mg two times per day orally
45974705|NCT02218723|Drug|FF UD-DPI|A blister containing a small quantity of powder comprising of a blend of FF (micronised) and excipient(s) will be administered using UD-DPI. It is available in following dosages: 80mcg/Blister (0.8% Blend); 100mcg/Blister (0.8% Blend); 140mcg/Blister (0.8% Blend); 100mcg/Blister (0.6% Blend)
45974706|NCT02218723|Drug|FF ELLIPTA DPI|A blister strip contained within the ELLIPTA device. Each blister contains a small quantity of powder comprising of a blend of FF and excipient(s) in dose 100mcg/Blister (0.8% Blend)
45974707|NCT02218762|Drug|Fluticasone Propionate/Salmeterol Xinafoate DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of powder comprising of a blend of fluticasone propionate (micronized)(100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One blister to be administered twice daily via DISKUS inhaler
45974708|NCT02218762|Drug|Placebo to Match DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of lactose and powder comprising of excipient(s). One blister to be administered twice daily via DISKUS inhaler
46082147|NCT00931021|Drug|Nicotine Patch|21 mg
45830267|NCT01568034|Drug|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
45830268|NCT01687218|Drug|Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)|
45830269|NCT01687218|Drug|Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)|
45974709|NCT02218762|Drug|Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS|A capsule containing a small quantity of powder comprising of a blend of fluticasone propionate (micronized) (100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
45974710|NCT02218762|Drug|Placebo to Match ROTACAPS|A capsule containing a small quantity of lactose and powder comprising of excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
45974711|NCT00264459|Biological|Grass pollen formulation|"Solution for sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter."
45974712|NCT00264459|Other|Comparator|Solution for sublingual application containing Placebo. The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter.
45974713|NCT00241514|Drug|Esomeprazole|
45974714|NCT02218879|Drug|Tecfidera|Oral Tecfidera 240 mg bid
45974715|NCT02218918|Behavioral|Ground walk training|3 times a week and 6 weeks
45974716|NCT02218918|Behavioral|Supervised Treadmill Walk training|3 times a week and 6 weeks
45974717|NCT02218957|Procedure|Extended Pouch RYGB|
45974718|NCT02218957|Procedure|Standard RYGB|
45974719|NCT00241553|Drug|Esomeprazole|
45974720|NCT02219074|Device|Sebacia microparticle and laser treatment|
46082148|NCT02732808|Drug|Ovulation stimulation|"Double stimulation in 2 phases:~Phase I: Clomiphene citrate (Ovumid®) 25 mg/day with co-treatment of Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. human menopausal gonadotrophin (HMG) Menopur®150 IU every other day beginning on cycle day 6. triptorelin (Decapeptyl®) 100 μg follows by ibuprofen 600 mg.~Phase 2:A total of 225 IU HMG(Decapeptyl®) and letrozole (Letrofem®) 2.5 mg is administered daily .Daily administration of medroxyprogesterone acetate (Progestrone®)10 mg. . the final stage of oocyte maturation is induced again with triptorelin (Decapeptyl®)100 μg by injection."
45670874|NCT02290223|Behavioral|Behavioral Based Treatment Model|Behavioral based treatment consists of four 90 minute group sessions, one meeting per week. The sessions addressed: empowering patients to take an active role in pain management and overall health; pain management lifestyle practices; use of health information technology resources for active self-care; education on neurobiology of pain and opioids; and improving communication with providers.
45670875|NCT05651009|Procedure|TKA|Total knee artroplasty with medial parapatellar incision and mechanical alignment without navigation
45830270|NCT01687218|Drug|Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)|
45830271|NCT01686828|Drug|Acyline|300 mcg/mL administered subcutaneously (at Day 0, Week 2)
45670876|NCT05646407|Device|Honeywell HT-900 Turbo Force Air Circulator|This is a basic, portable, household fan with a single cost of CDN$21.99.
45974721|NCT02219074|Device|Vehicle and laser treatment|
45974722|NCT00250887|Drug|Gefitnib|
45974723|NCT02219113|Procedure|Arthroscopic surgery|
45974724|NCT02219113|Procedure|Liposuction|
45974725|NCT02219113|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
45974726|NCT02219113|Other|Intraarticular administration of autologous ADRC|
45974727|NCT02279017|Behavioral|mHealth Texting for Weight Loss|
45830272|NCT01686828|Drug|Testosterone 1.62% gel|Transdermal Testosterone Gel (either 1.25g or 5g/d) for 4 weeks
45830273|NCT01686828|Drug|Letrozole|Letrozole oral aromatase inhibitor 5mg daily for 4 weeks
45974728|NCT02219152|Drug|tranexamic acid|
45974729|NCT02219152|Drug|saline|
45974730|NCT00264615|Drug|lamotrigine extended-release|
45974731|NCT02219191|Drug|puerarin tablet 50 mg|
45974732|NCT02219191|Drug|Atorvastatin tablet 20 mg|Approval No.: H19990258
45974733|NCT02219347|Drug|DMARD cessation|Complete cessation of non-biologic DMARD therapy (single or combination of methotrexate, sulphasalazine and/or hydroxychloroquine)
45974734|NCT04529512|Drug|DEXTENZA®|DEXTENZA® is a corticosteroid implant indicated for the treatment of ocular pain following ophthalmic surgery. DEXTENZA® is inserted into the lower lacrimal punctum into the canaliculus by the physician following ophthalmic surgery. A single DEXTENZA® releases a 0.4 mg dose of dexamethasone for up to 30 days following insertion. DEXTENZA® is preservative free, resorbable and does not require removal. Saline irrigation or manual expression can be performed to remove the insert, if necessary.
45974735|NCT00241592|Drug|Cannabis|
45974736|NCT04720131|Drug|Camrelizumab|Camrelizumab was administered 200mg iv every 3 weeks.
45974737|NCT04720131|Drug|apatinib|"Apatinib A safety-run-in was conducted in the first cycle to identify the recommended dose of Apatinib, the initial dose was administered 250mg orally daily every 3 weeks (Day 1-14 of a treatment cycle) The dose of Apatinib increase and reduction was 250 mg orally q.d. and 250 mg orally q.o.d. every 3 weeks respectively according to the number of doses limiting toxicity events (DLTs) in the initial group.~The final dose of Apatinib for the extension stage was detemained by the result of safety-run-in stage."
45974738|NCT04720131|Drug|Capecitabine|Capecitabine was administered 1000mg/m2 orally, b.i.d. every 3 weeks (Day 1-14 of a treatment cycle)
45670877|NCT02289833|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered intravenously (IV) at a dose of 3.6 mg/kg on Day 1 of every 21-day cycle until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the sponsor, whichever occurs first.
45830274|NCT01686828|Drug|Placebo gel (for Testosterone 1.62% gel)|placebo gel manufactured to mimic Testosterone 1.62% gel
45830275|NCT01686828|Drug|Placebo pill (for Letrozole)|Oral placebo aromatase inhibitor to mimic Letrozole 5mg/d
45830276|NCT01686438|Behavioral|Cognitive behavioral therapy for insomnia|A behavioral modification program consisting of 6 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
45974739|NCT02219386|Other|Group 1. Deep dry needling|Deep dry needling and stretch. The intervention included DDN of every active MTrP found in the trapezius muscle using a 4 cm x 0.32 mm acupuncture needle as described by Simons et al. (Simons et al., 1999). Once the needle was inserted into the MTrP previously marked by the blinded assessor, local twitch responses (LTRs) were obtained by using Hong's fast-in and fast-out technique, which involves rapid movements of the needle in and out of the MTrP. After four LTRs, the needle was withdrawn and the area was disinfected with alcohol again (Simons et al., 1999). Then, passive stretch was performed on the trapezius muscle.
45974740|NCT02219386|Other|group 2. Passive analitical stretch (performed in both groups)|
45974741|NCT02219425|Procedure|endometrial biopsy|
45974742|NCT02219542|Drug|transversus abdominis plane block|transversus abdominis plane block with 20 mL saline
45974743|NCT02219542|Drug|transversus abdominis plane block|transversus abdominis plane block with 20 mL 0.25% ropivacaine
45974744|NCT02219620|Behavioral|Music, Imagery, Movement|Implementation of music, art and imagery activation, and movement in group modality
45974745|NCT02219620|Behavioral|Social Control|social conversational group facilitated by care counselor
45974746|NCT00241670|Drug|5-aminolevulinic acid (5-ALA)|1.5 grams 5-ALA dissolved in 50 ml water, single dose, orally, 2-4 hours prior to surgery
45974747|NCT02219737|Drug|Carboplatin|Given IVPB
45974748|NCT02219737|Drug|Etoposide|Given IVPB
45974749|NCT02219737|Drug|Ibrutinib|Given PO
45974750|NCT02219737|Drug|Ifosfamide|Given IV
45974751|NCT02219737|Other|Laboratory Biomarker Analysis|Correlative studies
45974752|NCT02219737|Other|Pharmacological Study|Correlative studies
45974753|NCT02219737|Biological|Rituximab|Given IV
45974754|NCT02219854|Procedure|Laparoscopic gastrectomy|
45974755|NCT02219854|Procedure|Open gastrectomy|
45670878|NCT05646329|Behavioral|Motivational Interview|The motivational interview to be held with the experimental group was planned as 4 sessions together with the follow-up session.
45670879|NCT01702558|Drug|Capecitabine|Capecitabine will be administered at de-escalating doses (starting from 750 mg/m^2) to determine the MTD.
45974756|NCT02219893|Drug|MOC31PE Immunotoxin|Patients who meet inclusion criteria will be treated with a single intraperitoneal MOC31PE immunotoxin instillation for 6 hours on the first day after CRS and HIPEC
45974757|NCT02219971|Drug|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
45974758|NCT04720170|Procedure|Revascularization|Angiogram and IVUS with revascularization of the lateral plantar artery and pedal arch on target foot.
45670880|NCT01702558|Drug|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg via IV infusion every 3 weeks.
45670881|NCT01702558|Drug|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine will be administered at a dose of 2.4 mg/kg via IV infusion every week.
45670882|NCT01702558|Drug|Capecitabine|Capecitabine will be administered at the MTD determined in Cohort 1.
45670883|NCT05650931|Procedure|Implantation of PNS electrodes during surgery, mapping to select sites with the best effect and pain modulation.|PNS electrodes are implanted in the area of peripheral nerves of the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate peripheral nerves at different sites in the stump. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
45974759|NCT02218801|Other|Evaluation of treatment for liver metastasis|
45974760|NCT02217865|Behavioral|Interviews - Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
45830277|NCT01593696|Biological|Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)|Cells extracted, followed by induction chemotherapy before Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR) infusion (dose escalation.)
45830278|NCT01592760|Device|air-Q SP|air-Q SP placement for airway maintenance.
45830279|NCT01592760|Device|air-Q|air-Q placement for airway maintenance.
45830280|NCT01592760|Device|i-gel|i-gel placement for airway maintenance.
45830281|NCT03901014|Other|Standard American diet|Standard American diet with 50% energy from carbohydrate, 30% from fat, and 20% from protein.
45830282|NCT03901014|Other|Very low carbohydrate diet|Ketogenic diet with <50g carbohydrate, 60-75% energy from fat, and 20% from protein
45830283|NCT01696188|Device|interscalene nerve catheter|
45830284|NCT02985762|Drug|EXPAREL|
45974761|NCT02217865|Behavioral|Questionnaire|Questionnaire completion asking general health and demographic questions.
45974762|NCT02217865|Behavioral|Focus Groups|Focus groups conducted with participants and caregivers. Up to 4 focus groups conducted with up to 30 participants each. Focus groups expected to take 30 to 60 minutes.
45974763|NCT02217865|Behavioral|Interviews - Caregivers of Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
45974764|NCT02210650|Procedure|Symptomatic stone removal|Symptomatic stone removal by the surgical procedures called Ureteroscopy or Percutaneous Nephrolithotomy
45974765|NCT02210650|Procedure|Asymptomatic kidney stones and ureteral stone removed|Asymptomatic kidney stones and symptomatic stone removal by the surgical procedure called Ureteroscopy
45974766|NCT04720014|Behavioral|SMART-3RP Group Intervention|"Nine 1.5 hour group sessions focusing on developing:~an understanding of stress physiology and the physiology of the relaxation response;~a regular practice of eliciting the relaxation response; and~cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice."
45974767|NCT02218606|Drug|Abiraterone acetate 1000 mg po daily|
45974768|NCT02218606|Drug|Cabazitaxel 25 mg/m2 IV|
45974769|NCT02218606|Drug|prednisone 5 mg po BID|
45974770|NCT02212951|Drug|BIOD-531|
45974771|NCT02212951|Drug|Humalog Mix 75/25|
45974772|NCT02212951|Drug|Humulin R U-500|
45974773|NCT02211508|Device|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
45974774|NCT00250965|Drug|intravenous magnesium|Subjects will be randomized prior to surgery (1:1) to receive 5 g magnesium or placebo (saline) bolus by the anaesthesiologist upon removal of the crossclamp. On postoperative days 1 through 4, subjects will receive either IV MgSO4 (5g in 250 ml normal saline) or IV placebo (250 ml normal saline) infusion over 4 hours daily.
45974775|NCT00241826|Procedure|Magnetic Resonance Angiography|Participants will undergo magnetic resonance angiography.
45974776|NCT00241826|Procedure|Magnetic Resonance Venography|Participants will undergo magnetic resonance venography.
45974777|NCT02210806|Drug|A006 DPI|Single dose 110 mcg, 1 inhalation
45974778|NCT02210806|Drug|A006 DPI|Single dose 220 mcg, 1 inhalation
45974779|NCT02210806|Other|Placebo DPI|Placebo, 1 inhalation
45974780|NCT02210806|Drug|Proventil® MDI|Single dose 90 mcg, 1 inhalation
45974781|NCT02210806|Drug|Proventil® MDI|Single dose 90 mcg, 2 inhalations
45974782|NCT02210026|Device|Seattle-PAP|We propose to test the hypothesis that by introduction of variation in airway pressure Seattle bubble nasal continuous positive airway pressure (Seattle-PAP) reduces work of breathing in very low birth weight infants more effectively than standard bubble nasal continuous positive airway pressure.
45974783|NCT00264654|Drug|BRL29060A|
45974784|NCT00264654|Drug|paroxetine hydrochloride hydrate|
45974785|NCT00241943|Procedure|Hepatitis C educational video|
45974786|NCT02219230|Device|Active knee (Ossur Power Knee II)|Prosthetic knee with active control system.
45974787|NCT02219230|Device|Adaptive knee (Ossur Rheo)|Prosthetic knee with adaptive control system.
45974788|NCT02219230|Device|Passive knee (Various manufacturers)|Prosthetic knee with mechanical control system.
45974789|NCT02219659|Drug|Sedation Protocol with Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning both infusions are stopped and when the patient is awake and met the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
45974790|NCT02219659|Drug|Sedation Protocol Without Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
45670884|NCT05650931|Procedure|SCS electrode implantation at surgery, mapping to select sites with the best effect and pain modulation.|SNS electrodes are implanted in the area of targeted peripheral nerves in the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate the spinal cord at different sites in the cervical thickening (C5-T1). Stimulation starts at a specific site at a frequency of 1 Hz and increases by 0.1 Hz until the patient no longer feels phantom pain. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
45670885|NCT05650931|Procedure|EEG to search for phantom pain biomarkers|This procedure uses the method of electroencephalography (EEG). EEG signals are recorded during the entire experiment. First, the patient is recorded at rest with stimulator on (PNS/SCS) with eyes open and then closed, in the stimulator off state (eyes open, then closed) when patient's pain returns to its preoperative state. The stimulation is then turned back on to the original level of pain suppression. The moments of pain suppression are fixed by marking.
45974791|NCT02219659|Drug|Fentanyl Push First|Fentanyl 25 mcg intravenous push (IVP) every 5 min up to 4 doses hourly as needed to target pain score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when patient's RASS is 0 to -2 and passes the SBT safety screen, 120-min CPAP trial is performed. If patient meets CPAP passing criteria, the physician will be notified for determination of extubation. If patient does not pass, it is repeated next morning. If target RASS is not achieved with fentanyl IV push alone, study team is notified and fentanyl infusion at 50 mcg/hr titrated by 25 mcg/hr every 30 min to target pain score (max 6 hrs). If target RASS score is not achieved with the fentanyl IV, propofol infusion is started at 5 mcg/kg/hr titrated by 5 mcg/kg/hr every 15 min to target RASS score (max 6 hrs).
45974792|NCT00241982|Drug|long-circulating liposomal prednisolone|
45974793|NCT02212015|Drug|Pazopanib + Paclitaxel|pazopanib in combination with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.
45974794|NCT04720859|Drug|Canagliflozin 300 MG Oral Tablet|Patients diagnosed with PHH following bariatric surgery by 100g glucose OGTT were prescribed 300mg canagliflozin during two weeks. 100g glucose OGTT response was evaluated after canagliflozin treatment.
45974795|NCT00272727|Behavioral|Dialog tool for caregivers|
45974796|NCT02279056|Behavioral|Self-help book for insomnia|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
45974797|NCT02279056|Behavioral|Sleep hygiene advice|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
45974798|NCT00272766|Drug|pegaptanib sodium|
45974799|NCT00242060|Procedure|MRI|
45974800|NCT02961842|Drug|500 mL Colloid Preload|6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 500 mL will be rapidly infused before spinal anesthesia
45974801|NCT02961842|Procedure|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
45974802|NCT02961842|Drug|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
45974803|NCT02961842|Drug|Intrathecal Fentanyl|Fentanyl 15 µg will be administered in the subarachnoid space
45974804|NCT02961842|Drug|500 mL Crystalloid Coload|Ringer acetate 500 mL will be rapidly infused immediately after intrathecal injection
45974805|NCT02961842|Drug|1000 mL Crystalloid Coload|Ringer acetate 1000 mL will be rapidly infused immediately after intrathecal injection
45974806|NCT02961842|Procedure|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
45830285|NCT04768374|Other|Virtual Reality with Kinect|"In the study it was conducted a 12 week-intensive VR intervention (twice a week, 45 minutes each) and compared the results in the 12th week to investigate the effects of rehabilitation and follow-up assessments were made in the 16th and 24th weeks. From the beginning of the VR intervention, each game was played in equal durations by each participant. However, the difficulty of the games varied depending on the child's performance.~Microsoft Kinect Games-Carnival Games was used as VR intervention. In meeting held with the authors to determine which games would be used in the VR program, 5 games were chosen and the remaining games were removed from the program because of their similar contents."
45830286|NCT04768374|Other|Conventional Occupational Therapy (COT)|"The COT based on neurodevelopmental treatment was carried out by the same occupational therapist. The treatment goals aimed at increasing the use of participant's extremities and improving the independence in ADL. The activities in the treatment were chosen in view of children's motor skills and daily living activities such as getting dressed, solving puzzles, and writing etc.~Both groups received COT while the control group received COT only for 12 weeks."
45974807|NCT02961842|Radiation|Ultrasound Assessment of the Inferior Vena Cava|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 5-2 MHz curved array ultrasound probe placed longitudinally in the subxiphoid region
45974808|NCT02961842|Drug|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
45974809|NCT00272805|Drug|carvedilol|
45670886|NCT05650775|Drug|Concerta|3-week trial of oral methylphenidate extended release
45974810|NCT00242099|Procedure|Monitoring - blood samples drawn to test for HHV-6 and HHV-7|
45974811|NCT00242138|Behavioral|Erectile Dysfunction|
45974812|NCT00242177|Drug|ACTOS (Pioglitazone)|
45974813|NCT00264888|Drug|PTC124|
45974814|NCT00416481|Behavioral|quality of life questionnaires|
45974815|NCT00264927|Drug|SR121463B|
45974816|NCT00242294|Drug|Roflumilast|
45974817|NCT00242333|Drug|AD 237|
45974818|NCT00416559|Other|clinical observation|
45974819|NCT00264966|Drug|ASM8|
45974820|NCT00242372|Drug|Tesaglitazar 0.5|
45974821|NCT00242372|Drug|Insulin at least 30 units/day|
45974822|NCT00265005|Drug|alteplase|Iv administration of 1 mg/ml up to two times and 2 mg/ml if needed.
45974823|NCT00242411|Drug|Budesonide/Formoterol Turbuhaler|
45974824|NCT00242411|Drug|Conventional Best Asthma Therapy|
45974825|NCT00272922|Device|hernia repair|
45670887|NCT05650775|Drug|Adderall-XR|3-week trial of oral mixed amphetamine salts, extended release, administered only to children who do not show at least 30% improvement during the Concerta/Methylphenidate trial.
45670888|NCT02287883|Other|Observational: Patient Activation and Engagement (PAE)|Observational: Patients receive care from clinics with either low or high levels of patient activation and engagement activities.
45974826|NCT00265044|Behavioral|Provider Education|
45974827|NCT00265044|Behavioral|Hypertension Alert|
45974828|NCT00265044|Behavioral|Patient Education|
45974829|NCT02962037|Other|Melatonin and light therapy|
45974830|NCT00273000|Drug|GLP-2|
45974831|NCT04720586|Procedure|lower eyelid blepharoplasty , retractor plication and wedge resection|combined lower eyelid blepharoplasty , retractor plication and wedge resection
45974832|NCT04720586|Procedure|lower eyelid blepharoplasty and retractor plication|combined lower eyelid blepharoplasty and retractor plication procedures
45974833|NCT00282399|Drug|Subcutaneous Decitabine|
45974834|NCT00242450|Drug|Metoclopramide|
45974835|NCT00273039|Drug|paroxetine|
45974836|NCT04718883|Biological|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|JWCAR029 will be administered at dose level: 1 x 10^8 CAR+T cells
45974837|NCT00242528|Drug|Zoledronic acid|
45974838|NCT00273117|Procedure|transnasal gastroscopy|
45974839|NCT00273156|Behavioral|Telephone quitline|
45974840|NCT00242606|Drug|Lamotrigine|titrate to 200mg over 10 weeks and maintained until end of week 26
45974841|NCT00242606|Drug|Levetiracetam|titrate to 2000mg/day over 22 days, maintain until the end of week 26
45670889|NCT01743040|Diagnostic Test|CADence|"Patients with chest pain and two or more coronary risk factors and who were already indicated for nuclear stress test were enrolled in the study. The CADence was performed prior to nuclear stress test. Patients underwent standard angiogram based upon normal clinical judgement. In all other patients a CT angiogram followed.~CADence is a handheld equipped with acoustic sensor technology, a patient booklet, remote algorithm and final report."
45974842|NCT00242645|Behavioral|Health Information|
45670890|NCT02194465|Drug|LY2623091|Administered orally
45670891|NCT02194465|Drug|Tadalafil|Administered orally
45670892|NCT02194465|Drug|Spironolactone|Administered orally
45670893|NCT02194465|Drug|Placebo|Administered orally
45670894|NCT02287025|Drug|Regorafenib (Stivarga, BAY73-4506)|Dose(s) 160 mg tablet (4 tablets per day at 40 mg) daily for 3 weeks on / 1 week off
45670895|NCT02287025|Other|iPAD application|Investigators were supported with enhanced drug-specific information via an iPad application (SMART).
45670896|NCT02287025|Other|Bayer specialist|The treating investigator will have access to the prescribing information and have ability to consult a Bayer specialist, should questions arise.
45670897|NCT01720264|Drug|Sitagliptin|Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
45670898|NCT04564846|Drug|ORMD-0801|8 mg capsules of ORMD-0801 (Oral Insulin)
45830287|NCT01603602|Biological|botulinum toxin Type A|Intramuscular injections of botulinum toxin Type A into specified muscles of the upper limb on Day 1.
45830288|NCT01603602|Drug|Normal Saline (Placebo)|Intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1.
45830289|NCT01684878|Drug|Gemcitabine (Chemotherapy)|Participants administered gemcitabine at a dosage of 1000 milligrams per square meter (mg/m^2) intravenous (IV) infusion on Days 1 and 8 every 3 weeks.
45830290|NCT01684878|Drug|Paclitaxel (Chemotherapy)|Participants administered paclitaxel at a dosage of 80 mg/m^2 as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.
45830291|NCT01684878|Drug|Pertuzumab|Participants administered pertuzumab 840 milligrams (mg) IV infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.
45830292|NCT01684878|Drug|Placebo|Participants administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.
45830293|NCT01684878|Drug|Topotecan (Chemotherapy)|Participants administered topotecan at a dosage of 1.25 mg/m^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.
45830294|NCT01684722|Dietary Supplement|Vitamin D|Vitamin D3 (cholecalciferol), 2000 IU per day.
45830295|NCT01684722|Drug|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
45830296|NCT01684722|Dietary Supplement|Vitamin D placebo|Vitamin D3 placebo
45830297|NCT01684722|Dietary Supplement|Fish oil placebo|Fish oil placebo
45830298|NCT04799106|Behavioral|Community Based Strategies for Early Detection of Melanoma|"The main procedures of this study include educational sessions about melanoma and how to detect it at its earliest stages with the help of a community health worker, conducting a self-skin examination every three months, helping to perform a skin examination every three months for a family member or friend who would be selected as a partner, and completing short questionnaires at the beginning of the study, at month three during the study, and at completion of the study."
45830299|NCT01592292|Drug|Rituximab|Rituximab as per physician's discretion.
45830300|NCT01592292|Drug|Adalimumab|Adalimumab as per physician's discretion.
45830301|NCT01592292|Drug|Etanercept|Etanercept as per physician's discretion.
45974843|NCT00242645|Behavioral|Preventive Services|
45974844|NCT00242645|Behavioral|Computer tailored information|
45670899|NCT04564846|Other|Placebo|Placebo capsule (Fish Oil)
45974845|NCT00273195|Device|Implantable Cardioverter Defibrillator|
45974846|NCT00242762|Drug|ZD1839 (IRESSA™)|
45974847|NCT00242762|Drug|Docetaxel|
45670900|NCT05645939|Other|Diasgnosis of hypertrophic cardiomyopathy|Patients diagnosed with hypertrophic cardiomyopathy during study period
45670901|NCT01702246|Drug|Simvastatin|40 mg, orally, once daily for 3 months
45974848|NCT00242762|Drug|Cisplatin|
45974849|NCT00282516|Procedure|In-home telemonitoring of pediatric patients with persistent asthma|
45974850|NCT00242801|Drug|Gefitinib|
45974851|NCT00273234|Procedure|Autologous Platelet Gel (APG)|
45974852|NCT00282555|Drug|S-Tenatoprazole-Na (STU-Na)|
45974853|NCT00242840|Drug|No intervention; Observational study|
45974854|NCT00273273|Procedure|blood draw|
45974855|NCT00242879|Drug|Physician determined comparator PI + ritonavir|
45974856|NCT00242879|Drug|GW640385 + ritonavir|
45974857|NCT00282594|Drug|Novolin R (human recombinant Insulin)|
45974858|NCT00242918|Drug|docetaxel|
45974859|NCT00242918|Drug|ZD1839|
45974860|NCT00282633|Device|Dermabond|
45974861|NCT00242957|Behavioral|Intervention with Microfinance for AIDS and Gender Equity|
45974862|NCT00273312|Drug|Patupilone|Patupilone was in dosage strength of 10 mg/4 mL as a clear, colorless concentrate for solution for injection in individual 10 mL glass vials
45974863|NCT00242996|Biological|filgrastim|
45974864|NCT00242996|Biological|rituximab|
45974865|NCT00242996|Biological|sargramostim|
45974866|NCT00242996|Drug|carmustine|
45974867|NCT00242996|Drug|cyclophosphamide|
45974868|NCT00242996|Drug|etoposide|
45974869|NCT00242996|Procedure|adjuvant therapy|
45974870|NCT00242996|Procedure|bone marrow ablation with stem cell support|
45974871|NCT00242996|Procedure|peripheral blood stem cell transplantation|
45974872|NCT00273390|Drug|Remicade (infliximab)|
45670902|NCT01631227|Drug|Eprosartan|Eprosartan 450 mg
45830302|NCT01592292|Drug|Infliximab|Infliximab as per physician's discretion.
45830303|NCT01590888|Drug|PBT2|250mg capsules administered orally once per day for 26 weeks
45974873|NCT00243035|Drug|bortezomib|Given IV
45974874|NCT00243035|Drug|tipifarnib|Given orally
45670903|NCT01631227|Drug|Eprosartan Mesylate|Eprosartan mesylate 600 mg
45830304|NCT01590888|Drug|PBT2|100mg capsules administered orally once per day for 26 weeks
45830305|NCT01590888|Drug|Placebo|Matching capsules administered orally once per day for 26 weeks
45830306|NCT01565928|Drug|MDV3100|4 x 40 mg capsules, orally, once per day
45830307|NCT01565850|Drug|D/C/F/TAF|DRV 800 mg/COBI 150 mg/FTC 200 mg/TAF 10 mg FDC tablet administered orally once daily
45974875|NCT00243035|Other|laboratory biomarker analysis|Correlative studies
45974876|NCT00243113|Drug|docetaxel|
45974877|NCT00243113|Radiation|radiation therapy|
45974878|NCT00273429|Drug|timolol maleate 0.5%|
45974879|NCT00273429|Drug|dorzolamide/timolol maleate fixed combination|
45974880|NCT00273429|Drug|latanoprost 0.005%|
45974881|NCT00273429|Drug|placebo|
45974882|NCT00243308|Drug|Serine proteinase-1 (Serp-1)|
45974883|NCT00273468|Drug|Granisetron|
45974884|NCT00243425|Procedure|Standard Quality Improvement|
45974885|NCT00243425|Procedure|Patient-centered Intervention|
45974886|NCT00282750|Device|Bar coded sponge and scanner|
46082149|NCT02808884|Genetic|Circulating tumor DNA assay|Blood samples will be separated into plasma and cellular fraction including erythrocytes and buffy coat.The plasma fraction will be placed in a separate tube and frozen for subsequent analysis. Frozen plasma samples, de-identified, will be delivered to Pathway Genomics where DNA content will be analyzed with a circulating tumor DNA assay employing the UBC/Boreal Genomics enrichment technology. All of the participants' plasma will be sent to Pathway, where it will be used up in the assay. Circulating tumor DNA assay results (raw sequencing data) from Pathway Genomics will be returned to UBC and analyzed for the presence of cancer mutations. Any samples showing activating mutations above the assay's technical Limit of Detection (LOD) will be called positive. One exception will be made for TP53 mutations that are known to exist in some normal individuals at low levels. For these mutations, a level of 0.1% will be set, above which the sample will be called positive.
45670904|NCT01631227|Drug|Placebo Eprosartan mesylate|Placebo Eprosartan mesylate
45670905|NCT01631227|Drug|Placebo Eprosartan|Placebo Eprosartan
45670906|NCT05645861|Procedure|Blood pressure management of Systolic Blood Pressure to maintain target range +/- 10 mmHg|Techniques used to target SBP will not be controlled for and will be at the discretion of the procedural anaesthetist to manage blood pressure, this can include vasopressors, intravenous fluids, titration of anaesthetic maintenance drugs and use of other vasoactive drugs.
45670907|NCT01719172|Device|Veriset™ Hemostatic Patch|Topical Hemostat
45670908|NCT02286947|Drug|Eteplirsen|Eteplirsen solution for IV infusion
45830308|NCT01565850|Drug|DRV|DRV 800 mg (2 × 400 mg tablets) administered orally once daily
45974887|NCT00243464|Drug|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
45974888|NCT00282789|Device|bilevel positive airway pressure|
45974889|NCT00282789|Device|bilevel positive airway pressure (Device)|
45974890|NCT00243542|Drug|ACZONE Gel, 5%|
45974891|NCT00243542|Drug|Vehicle|
45974892|NCT00282906|Device|hybrid PET-CT imaging system|15 mCi of FDG
45974893|NCT00243581|Behavioral|Dean Ornish Heart Disease Reversing Program|
45974894|NCT00273507|Drug|Carboplatin and Paclitaxel|
45974895|NCT02962154|Radiation|Coronary CT Angiography|The coronary CT angiography will assess for coronary artery stenosis, plaque characteristics, calcifications, and other factors.
45974896|NCT02962154|Other|Mood Symptom Scale|"Some or all of the following questionnaires will be conducted to assess mood symptoms:~Beck Depression Inventory, Hamilton Depression Rating Scale (24-item), Montgomery Asberg Depression Rating Scale (MADRS), Mood and Anxiety Symptom Questionnaire (MASQ), QIDS, Young Mania Rating Scale"
45974897|NCT02962154|Other|Anxiety Symptom Scale|"Some or all of the following questionnaires will be conducted to assess anxiety symptoms:~Beck Anxiety Inventory, Spielberger State/Trait Anxiety Inventory (STAI), GAD-7 Anxiety Questionnaire, Penn State Worry Questionnaire (PSWQ)"
45974898|NCT02962154|Other|Chronic Stress Inventories|"Some of all of the following questionnaires will be conducted to assess chronic stress:~Chronic stress inventories: Cohen Perceived Stress Scale, Holmes and Rahe Stressful Life Events Scale, Karasek Job Strain Questionnaire, Conner-Davidson Resilience Scale, PTSD Checklist"
45974899|NCT02962154|Other|Psychosocial Function Questionnaires|"Some of all of the following questionnaires will be conducted to assess psychosocial function:~Type A Personality Scale, NEO Personality Inventory, Positive and Negative Affect Schedule (PANAS), Behavioral Inhibition/Behavioral Approach Scale (BIS/BAS)"
45974900|NCT02962154|Other|General Health and quality of life questionnaires|"Some of all of the following questionnaires will be conducted to assess quality of life:~EQ-5D Health Questionnaire, Seattle Angina Questionnaire, International Index of Erectile Function (ILEF-5), Pittsburgh Sleep Quality Scale, Morningness Eveningness Questionnaire"
45974901|NCT02962154|Other|Magnetic Resonance Imaging|First, subjects will undergo a resting cardiac MR perfusion study to establish baseline (pre-stress) measures of cardiovascular function. Second, subjects will undergo a series of brain magnetic resonance imaging studies (T1-weighted anatomical MRI, diffusion tensor imaging, resting state functional MRI) to establish baseline (pre-stress) measures of brain function and structural correlates. Third, investigators will use a well-validated cognitive task to induce mental stress by testing subjects' working memory for a series of emotionally arousing or neutral images, while repeating the functional MRI scan. Finally, subjects will undergo a repeat cardiac MR perfusion study while being tested on the same mental stress task.
45974902|NCT00282945|Drug|Rosiglitazone|
45974903|NCT00282945|Drug|Metformin|
45974904|NCT00243620|Device|Vacuum therapy (device)|
45974905|NCT00273546|Drug|XRP6976 (Docetaxel/Taxotere)|
45974906|NCT00273585|Device|Personally-tailored educational software program|
45670909|NCT02286713|Behavioral|Patient Decision Aid|Participants will receive study materials including a video to watch about lung cancer screening
45670910|NCT02286713|Behavioral|Standard Educational Information|Participants will receive study materials including a booklet to read about lung cancer screening.
45670911|NCT02286713|Behavioral|Follow-Up Assessments: Questionnaires|Follow up questions administered via phone and/or mail at 1-week, 3-month, and 6-month
45670912|NCT05650385|Drug|B1962|B1962 is a PD-L1/VEGF bispecific antibody fusion protein.
45974907|NCT00283023|Procedure|Oligodendrocyte progenitor cell culture/craniotomy|Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply
45974908|NCT00283101|Drug|SGN-40 (anti-huCD40 mAb)|1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6.
45670913|NCT02285855|Drug|Metformin|Metformin treatment given at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week.
45974909|NCT00243698|Drug|SonoVue (sulphur hexafluoride microbubbles)|One contrast enhanced ultrasonography using sonovue / 4.8 ml per injection (maximum of 3 injections)
45974910|NCT00273663|Device|TCES|
45974911|NCT00243737|Drug|Artesunate-Mefloquine|
45974912|NCT00273702|Drug|N-Acetyl Cysteine|
45974913|NCT00243815|Drug|ibuprofen|
45974914|NCT00283179|Drug|Aripiprazole|
45974915|NCT00283179|Drug|Risperidone|
45974916|NCT00243854|Drug|Tarceva|Tarceva: 100mg/day x 2 weeks (Days 1-14) +
45974917|NCT00273741|Drug|methylphenidate|methylphenidate per os 20mg per day 7 days, 20mg or 40mg per day 7 days and 20, 40 or 60mg per day 14 days
45974918|NCT00273741|Drug|placebo comparator|placebo capsules
46082150|NCT02809040|Other|Electrocardiogram/Echocardiography|"Electrocardiogram (ECG) is a non-invasive (does not require an incision into the body) test that records the electrical activity of the heart.~Echocardiography is a non-invasive scanning of heart images using standard two-dimensional, three-dimensional, and Doppler ultrasound to create images of the heart."
46082151|NCT02809040|Other|Portable digital auscultation|"Traditional Stethoscope :An acoustic medical device for auscultation, or listening to internal sounds of human body.~Digital Stethoscope :Electronic stethoscope is a passive heart sound recording device. The heart sound listening and recording will be performed by trained personnel in a way very similar to that of using conventional cardiac auscultation"
46082152|NCT00926783|Procedure|CFAE ablation|CFAE ablation (targeted vs. generalized)
45670914|NCT02285855|Other|Placebo|Placebo treatment given 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day.
45670915|NCT02285855|Radiation|Stereotactic body Radiotherapy (SBRT)|SBRT delivered per standard of care practice as determined by participant's physician.
45670916|NCT02285777|Biological|Meningococcal ABCWY|One dose administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
46082153|NCT03615690|Other|Fasting Mimicking Diet|5 day reduced calorie diet
46082154|NCT03615690|Other|Regular Diet|Regular Diet
45670917|NCT02285777|Biological|Placebo|One dose of placebo administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
45830309|NCT01565850|Drug|COBI|COBI 150 mg tablet administered orally once daily
45830310|NCT01565850|Drug|FTC/TDF|FTC 200 mg/TDF 300 mg FDC tablet administered orally once daily
45830311|NCT01565850|Drug|D/C/F/TAF Placebo|D/C/F/TAF placebo tablet administered orally once daily
45830312|NCT01565850|Drug|DRV Placebo|DRV placebo tablet administered orally once daily
45830313|NCT01565850|Drug|COBI Placebo|COBI placebo tablet administered orally once daily
45670918|NCT02285153|Drug|Acetylsalicylic acid lysinate|100mg intravenously administered Acetylsalicylic Acid lysinate per day
45670919|NCT02285153|Drug|0.9% sodium-chloride solution|Placebo, intravenously administered, daily
45670920|NCT02284373|Other|Flexitouch for 1 month in addition to routine wound care|simultaneous wound care and pneumonic compression
45670921|NCT02284373|Other|Routine wound care for venous ulcers and lymphedema|wound care /dressings
45830314|NCT01565850|Drug|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
45830315|NCT01565694|Drug|Solifenacin succinate|Oral suspension administered once a day via syringe.
45830316|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells 1 day following IV cyclophosphamide 200 mg
45830317|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 0.5 g/m2
45830318|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.0 g/m2
45974919|NCT02279134|Radiation|Adjuvant Chemoradiation|Patients receive Paclitaxel 135-150mg/m2 (D1 and D29) and Cisplatin or Nedaplatin 50-75mg/m2 (D1 and D29) every 4 weeks, concurrent with radiotherapy. Prophylactic polyethylene glycol recombinant human G-CSF is administered 48 hours after chemotherapy. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.
45670922|NCT02284373|Device|Flexitouch pneumonic compression|pneumonic compression only
45670923|NCT04878575|Other|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
45974920|NCT02279134|Radiation|Adjuvant Radiation|Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.
45974921|NCT02279134|Drug|Paclitaxel|135-150mg/m2 (D1 and D29)
45974922|NCT02279134|Drug|Cisplatin or Nedaplatin|50-75mg/m2 (D1 and D29)
45974923|NCT00243893|Drug|minocycline|Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
45974924|NCT00243893|Drug|doxycycline|Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
45974925|NCT00243971|Drug|SPM 962|
45974926|NCT00283218|Drug|NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70|
45974927|NCT00244049|Behavioral|counseling|Physicians discussed high-risk/binge drinking with college-aged individuals in a health care setting.
45670924|NCT04878575|Other|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
45974928|NCT00244049|Other|Brief Intervention|Physicians discussed effects of high-risk/binge drinking with college-aged individuals in a health care setting.
45974929|NCT00273780|Behavioral|Adherence counseling|Three adherence counseling sessions will be given to participants in the trial. Two sessions will occur prior to initiation of antiretroviral medications and one session will be given one month after drug administration.
45974930|NCT00273780|Device|Alarm device|This pocket alarm device will be set to ring at designated times during the day that the participant should take their antiretroviral medication.
45974931|NCT04718844|Drug|SLN124|SLN124 for subcutaneous (s.c.) injection
45670925|NCT04878185|Other|Exercise|Preoperative exercise
45974932|NCT04718844|Drug|Placebo|Sodium chloride for s.c. injection
45830319|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 2.0 g/m2
45830320|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.5 g/m2
45830321|NCT01590810|Drug|MK-8150 2.0 mg|Single oral 2.0-mg dose of MK-8150
45830322|NCT01590810|Drug|MK-8150 10 mg|Single oral 10-mg dose of MK-8150
45830323|NCT01590810|Drug|MK-8150 40 mg|Single oral 40-mg dose of MK-8150 without food (fasted) and with food (fed)
45974933|NCT00244127|Drug|Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP)|
45974934|NCT00273819|Procedure|CT angiography|
45974935|NCT00414557|Procedure|Quadriceps strengthening|
45830324|NCT01590810|Drug|MK-8150 90 mg|Single oral 90-mg dose of MK-8150
45830325|NCT01590810|Drug|MK-8150 5.0 mg|Single oral 5.0-mg dose of MK-8150
45830326|NCT01590810|Drug|MK-8150 20 mg|Single oral 20-mg dose of MK-8150
45830327|NCT01590810|Drug|MK-8150 60 mg|Single oral 60-mg dose of MK-8150
45974936|NCT00273897|Device|Phoresor II|
45670926|NCT01632241|Biological|Placebo plus standard therapy|Placebo plus standard therapy
45830328|NCT01590810|Drug|MK-8150 120 mg|Single oral 120-mg dose of MK-8150
45830329|NCT01590810|Drug|MK-8150 160 mg|Single oral 160-mg dose of MK-8150
45830330|NCT01590810|Drug|MK-8150 320 mg|Single oral 320-mg dose of MK-8150
45670927|NCT01632241|Biological|Belimumab 10 mg/kg plus standard therapy|Belimumab 10mg/kg plus standard therapy
45974937|NCT00244166|Drug|prednisolone|
45670928|NCT01632241|Drug|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
45670929|NCT02263508|Drug|Talimogene Laherparepvec|Talimogene laherparepvec administered by intratumoral injection
45670930|NCT02263508|Drug|Pembrolizumab|Administered at a dose of 200 mg as an intravenous infusion over approximately 30 minutes.
45670931|NCT02263508|Drug|Placebo|Administered by intratumoral injection
45670932|NCT02291432|Biological|autologous muscle-derived cells (AMDC)|Cell treatment
45670933|NCT05369780|Dietary Supplement|Hydrolyzed Collagen Peptide|Dietary Hydrolized Collagen Peptide sourced from bovine
45670934|NCT02290340|Drug|Placebo|Participants will receive placebo intramuscularly.
45670935|NCT02290340|Drug|MEDI8897 10 mg|Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
45670936|NCT02290340|Drug|MEDI8897 25 mg|Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
45670937|NCT02290340|Drug|MEDI8897 50 mg|Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
45830331|NCT01590810|Drug|MK-8150 600 mg|Single oral 600-mg dose of MK-8150
45830332|NCT01590810|Drug|MK-8150 900 mg|Single oral 900-mg dose of MK-8150
45830333|NCT01590810|Drug|MK-8150 1200 mg|Single oral 1200-mg dose of MK-8150
45974938|NCT00273936|Drug|AVN-944 capsules for oral administration|
45974939|NCT00244205|Procedure|Identifying genes methylated in urine|
45974940|NCT00283257|Behavioral|Patients and caregivers are taught problem solving skills|
45974941|NCT00244244|Drug|arimoclomol|
45974942|NCT00273975|Drug|Nevirapine|
45974943|NCT00273975|Drug|Lamivudine|
45974944|NCT00273975|Drug|Zidovudine|
45974945|NCT00244283|Drug|Sevoflurane|
45974946|NCT00244283|Procedure|High thoracic epidural analgesia|
45974947|NCT00283335|Drug|gemfibrozil|
45974948|NCT00283335|Other|Placebo|Matching placebo tablets taken once per day
45974949|NCT00244322|Drug|LY450139 dihydrate|
45974950|NCT00244322|Drug|placebo|
45974951|NCT00283374|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
45974952|NCT00244361|Drug|rituximab|
45974953|NCT00274014|Drug|Tiotropium|
45974954|NCT00244439|Drug|MALG|30 minute application
45974955|NCT00244439|Drug|Ovide (malathion) lotion 0.05%|8-12 hour application
45974956|NCT00244439|Drug|Permethrin 1%|10 minute application
45974957|NCT00417144|Drug|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
45974958|NCT00417144|Drug|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
45974959|NCT00244478|Dietary Supplement|Soy Protein Dietary Supplement|The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
45974960|NCT00244478|Dietary Supplement|Placebo|The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
45974961|NCT00274053|Drug|tiotropium|
45974962|NCT04709588|Dietary Supplement|placebo group|subjects drank 50 ml every night for 14, 28 days
45974963|NCT04709588|Dietary Supplement|collagen drinkss|subjects drank 50 ml every night for 14, 28 days
45974964|NCT00417183|Drug|Arvekap 0.1 mg (Triptorelin, Ipsen, France)|
45974965|NCT00417183|Drug|Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)|
45974966|NCT00244517|Drug|TTE measurements under anesthesia with sevoflurane, isoflurane, desflurane, and remifentanyl|TTE measurements were performed during remifentanil 2 ng/ml TCI end-organ concentration, 1 MAC of either anesthetic gas under spontaneous ventilation and 1 MAC of either anesthetic under IPPV
45458603|NCT01141933|Other|Cognitive-existential intervention|Over the past 2 years we developed a 12-week cognitive-existential intervention consisting of 12 modules. The first three modules essentially involve cognitive and behavioral techniques proposing reinforcement of the use of active behavioral (e.g., relaxation, activation) and emotional (cognitive reframing) strategies. This content comes from classical cognitive-behavioral techniques. The next 3 modules, inspired by empirically-tested interventions further explore emotional strategies. The last six modules specifically address the existential dimension. They are adapted from logotherapy techniques, which are also empirically-based, and have been adapted to a French-Canadian culture by our team. They aim to improve meaning-based and emotional coping strategies.
45830334|NCT01590810|Drug|Placebo for MK-8150|Single oral dose-matched dose of Placebo for MK-8150
45830335|NCT01590810|Drug|MK-8150 50 mg|Single oral 50-mg dose of MK-8150
45830336|NCT01590810|Drug|MK-8150 100 mg|Single oral 100-mg dose of MK-8150
45974967|NCT00244517|Drug|Sevoflurane, Isoflurane, Desflurane|1 MAC
45974968|NCT00274092|Drug|tiotropium inhalation capsules (18 mcg once daily)|
45974969|NCT00274092|Drug|Atrovent MDI (2 puffs of 20 mcg(q.i.d.) in patients|
45974970|NCT00244556|Drug|Methotrexate plus ENBREL or ENBREL alone|
45974971|NCT00283413|Device|Covered Stent System|Self-expanding, polytetrafluoroethylene(PTFE)-covered, stent system
45974972|NCT00283413|Device|Bare metal stent|Any commercially available bare metal stent for coronary indication
45974973|NCT00244595|Drug|candsartan cilexetil|
45974974|NCT00274131|Drug|Pramipexole 0.125 mg tablets|
45830337|NCT01590810|Drug|MK-8150 200 mg|Single oral 200-mg dose of MK-8150
45974975|NCT00274131|Drug|Pramipexole 0.5 mg tablets|
45974976|NCT00244634|Drug|candsartan cilexetil|
45830338|NCT01590810|Drug|MK-8150 400 mg|Single oral 400-mg dose of MK-8150
45830339|NCT01590810|Drug|MK-8150 500 mg|Single oral 500-mg dose of MK-8150
45830340|NCT01542528|Behavioral|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
45830341|NCT01565148|Drug|iCo-007 350 mcg|iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4
45830342|NCT01565148|Drug|iCo-007 700 mcg|iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4
45830343|NCT01565148|Drug|iCo-007 350 mcg and Laser|iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation
45974977|NCT00274170|Drug|Octreotide|
45974978|NCT00244673|Biological|DTP3/4+OPV+MV versus OPV+MV or DTP4+OPV4 versus OPV4|Trial of not providing 3. and/or 4. DTP together with or after MV at 9 to 18 month of age.
45830344|NCT01565148|Drug|Ranibizumab and iCo-007 350 mcg|Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later
45830345|NCT04410354|Drug|Merimepodib|400 mg (total daily dose of 1200 mg) for 10 days
45974979|NCT00244790|Behavioral|Diet|crossover low vs high protein diet before and after weight loss
45974980|NCT00283452|Behavioral|Phone counseling with written materials|Participation in phone/mail counseling to maintain physical activity
45974981|NCT02961530|Other|Isokinetic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
45974982|NCT02961530|Other|Isotonic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
45974983|NCT00283491|Behavioral|Active Lactobacillus plantarum 299v|10^11 cfu/meal in 2 meals on 2 consecutive days
45974984|NCT00283491|Dietary Supplement|Inactive Lactobacillus plantarum 299v|Inactive form of the active treatment but with the fermentation products in the same concentration
45974985|NCT00244829|Drug|imatinib mesylate|
45974986|NCT00244829|Procedure|adjuvant therapy|
45974987|NCT00283530|Procedure|Tumor biopsy|
45974988|NCT00244868|Other|counseling intervention|
45974989|NCT00244868|Other|educational intervention|
45974990|NCT00274209|Procedure|Chromoendoscopy with magnification|A blue dye (indigo carmine) will be sprayed prior to imaging the bowel lining using a zoom colonoscope. The dye is not absorbed and is safe for human use.
45974991|NCT00244907|Dietary Supplement|Genistein vs Risedronate|Gensitein (100 gm) from soy protein isolate Risedronate (5 mg)
45974992|NCT00283569|Other|Mouth Swab, Toe Nail Clippings, Questionnaires|The objective of this study is to establish a clinic based case control study for examination of potential risk factors for primary adult brain tumors.
45974993|NCT00274248|Drug|MLN518|
45974994|NCT00244946|Biological|therapeutic autologous lymphocytes|Lymphocytes collected by standard apheresis technique either prior to or post stem cell mobilization and collection
45974995|NCT00244946|Drug|carmustine|
45974996|NCT00244946|Drug|cytarabine|
45974997|NCT00244946|Drug|etoposide|
45974998|NCT00244946|Drug|melphalan|
45974999|NCT00244946|Procedure|peripheral blood stem cell transplantation (PBSCT)|
45975000|NCT00283608|Genetic|Single nucleotide polymorphism (SNP)|Evaluating SNP association with traits.
45975001|NCT00283608|Other|high performance liquid chromatography|analysis of plasma concentrations of drugs
45670938|NCT05647187|Diagnostic Test|Serum Interleukin 17 levels|Serum Interleukin 17 levels will be measured pre and post treatment by NB-UVB by performing an enzyme-linked immune sorbent assay (ELISA)
45830346|NCT04410354|Drug|Matching Placebo|0 mg (total daily dose of 0 mg) for 10 days
45830347|NCT04410354|Drug|Remdesivir|200 mg loading dose on Day 0 followed by 100 mg daily dose for 4 days. If a subject does not demonstrate clinical improvement, 100 mg daily dose may be extended for up to 5 additional days (for a total of up to 10 days)
45975002|NCT00283608|Other|measurements by DXA|determine bone mineral density (BMD)
45830348|NCT01564758|Drug|Linezolid|"Vancomycin-resistant, E. faecium, including concurrent bacteremia: Linezolid for 600mg (IV or oral) every 12 hours for 14-28 days~Nosocomial infection, cSSTI: Linezolid for 600mg (IV or oral) every 12 hours for 10-14 days~Uncomplicated SSTI: Linezolid for 400mg oral every 12 hours for 10-14 days"
45830349|NCT01541826|Dietary Supplement|Chokeberry Extract|Consumption of 2 x 250 mg chokeberry extract capsules daily for 12 weeks.
45670939|NCT05647187|Radiation|NB-UVB|patients will be exposed to narrow band UVB twice weekly for three months
45830350|NCT01541826|Dietary Supplement|Placebo capsule|Color-matched rice powder pill, 2 x 250 mg/day for 12 weeks
45830351|NCT01541826|Dietary Supplement|Chokeberry extract capsule, acute|Chokeberry extract capsule, 2 x 250 mg, one-time dose.
45830352|NCT01541748|Other|Axis|Coloplast's Axis™ Allograft Dermis is used for anterior, posterior or combined (anterior and posterior) pelvic organ prolapse repair.
45830353|NCT01589094|Drug|Gemcitabine and Cisplatin (DD GC)|Patients will receive six cycles of GC administered every 14 days. Gemcitabine 2,500 mg/m2 will be administered intravenously on day 1 and cisplatin 35 mg/m2 will be administered intravenously on days 1 and 2 of a 14 days cycle (with Peg GCSF). A total of six cycles of therapy will be administered followed by radical cystectomy with bilateral pelvic lymph node dissection (PLND)
45830354|NCT01563978|Drug|fostamatinib|fostamatinib 100 mg twice daily
45975003|NCT00283608|Other|questionnaire administration|determine attitude changes
46082155|NCT00937807|Drug|xenon|Inhalational gas; dose allowed: 60 % Xenon; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
46082156|NCT00937807|Drug|sévoflurane|Inhalation gas; dose allowed: 1,4 %; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
45458604|NCT01141933|Other|Usual care|This group receive the usual treatment only.
45670940|NCT02290028|Device|Sentus QP left ventricular lead|Implantation of quadripolar left ventricular lead in patients with CRT-D indication
45670941|NCT01741792|Drug|Blinatumomab|Administered by continuous intravenous infusion over 8 weeks in the first cycle and 4 weeks in the second cycle.
45670942|NCT02289950|Drug|Farletuzumab|Farletuzumab will be administered intravenously (IV) weekly
45830355|NCT01563978|Drug|placebo|placebo
45830356|NCT04114344|Procedure|TAPP|Trans Abdominal Pre Peritoneal approach
45830357|NCT04114344|Procedure|TEP|Total Extra Peritoneal approach
45830358|NCT01563354|Drug|Pasireotide LAR|60 mg was administered as an intra muscular depot injection once every 28 days starting at Day 1
45830359|NCT01563354|Drug|Everolimus|10 mg tables administered orally once a day
45975004|NCT00245024|Drug|sulindac|
45975005|NCT00245024|Other|laboratory biomarker analysis|
45975006|NCT00274326|Drug|SR121463B|
45975007|NCT00245141|Biological|dactinomycin|
45975008|NCT00245141|Drug|cyclophosphamide|
45975009|NCT00245141|Drug|vincristine sulfate|
45975010|NCT00245141|Radiation|radiation therapy|
45975011|NCT00245180|Behavioral|Diet|
45975012|NCT00245180|Behavioral|Exercise|
45975013|NCT00416637|Biological|Bevacizumab (Avastin)|
45975014|NCT00245258|Drug|Sildenafil Citrate|
45975015|NCT00283725|Other|No intervention|Patients will be prescribed either galantamine or no AD treatment (ie, neither an acetylcholinesterase inhibitor [AChEI] nor memantine).
45975016|NCT02961803|Drug|MD1003 100 mg capsule|
45975017|NCT02961803|Drug|Placebo|
45975018|NCT00274365|Procedure|videoconference|
45975019|NCT00245297|Drug|Kogenate FS, reconstituted in a suspension of liposomes|
45975020|NCT00274404|Drug|valacyclovir|
45975021|NCT00283764|Drug|Xalatan|
45975022|NCT00245336|Biological|rThrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
45975023|NCT00245336|Drug|bovine thrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
45975024|NCT00274443|Drug|ABI-007 (Abraxane) and Carboplatin|ABI-007 plus Carboplatin will be administered intravenously over 30 minutes in cycles of 3 weeks
45975025|NCT00245375|Drug|Tylenol #3|
45975026|NCT00245375|Drug|Combination Tylenol and Ibuprofen|
45975027|NCT00245414|Drug|Pegasys®|180μg for s.c./week for 48 weeks
45975028|NCT00245414|Drug|Pegasys®|180μg for s.c./week for 24 weeks
45975029|NCT00274521|Drug|Tiotropium|
45975030|NCT00245453|Drug|azithromycin|250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5
45975031|NCT00245453|Drug|telithromycin|400 mg tablets; 2 tablets once daily (QD) for 5 days
45975032|NCT00245453|Drug|Clarythromycin|500 mg extended release tablets; 2 tablets QD for 7 days
45975033|NCT00245492|Procedure|Chromocolonoscopy|Indigocarmine dye applied to entire colon to highlight mucosal detail and enhance detection of flat lesions.
45975034|NCT00274560|Drug|Tiotropium|
45975035|NCT00274560|Drug|Salmeterol|
45830360|NCT01563354|Drug|Pasireotide LAR and Everolimus Combination|Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily
45975036|NCT00283920|Drug|[(11)C] PBR28|
45975037|NCT00245609|Drug|Pregabalin|
45975038|NCT00245609|Drug|Alprazolam|
45975039|NCT00245609|Drug|Placebo|
45975040|NCT00283998|Procedure|surgical versus conservative treatment|Surgical treatment of fractures versus conservative stabilization
45975041|NCT00245648|Drug|fibrinolytic therapy or combination reduced fibrinolytic therapy|
46082157|NCT00934687|Drug|clostridium botulinum toxin type A neurotoxin complex|A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.
46082158|NCT00934687|Other|0.9% NaCl solution|0.9% NaCl solution will be injected in analogy to clostridium botulinum toxin type A neurotoxin complex as a placebo comparator.
46082159|NCT02808728|Drug|Pain Cocktail with Exparel|pain cocktail: bupivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 80cc preparation as well as an injection of Exparel (bupivacaine liposome injectable suspension), 20cc of 1.3% Exparel, to total 100cc.
46082160|NCT02808728|Drug|Pain Cocktail with Ropivacaine|pain cocktail: ropivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 100cc preparation.
46082161|NCT05331053|Drug|Atorvastatin|Simvastation acts as a systemic LOX inhibitor.
46082162|NCT02732730|Drug|Truvada|400 women who accept to initiate PrEP
46082163|NCT00934765|Behavioral|weight loss|self-directed weight loss, guided weight loss, weight loss by gastric by-pass surgery
46082164|NCT02808650|Other|Laboratory Biomarker Analysis|Correlative studies
45830361|NCT01588548|Drug|AZD1208|Dose of AZD1208 will be escalated from 120mg to a maximum tolerated dose
45830362|NCT01587924|Drug|GSK1278863|tablet
46082165|NCT02808650|Other|Pharmacological Study|Correlative studies
46082166|NCT02808650|Drug|Prexasertib|Given IV
45830363|NCT01587924|Drug|rhEPO|injection
45830364|NCT04113408|Other|FABIR sequence|The FABIR sequence with a duration of 8 minutes is added to the imaging protocol.
45830365|NCT03028038|Drug|Platelet Rich Plasma|"Platelet Rich Plasma (PRP) will be injected beneath the buccal periosteal of the first molar and premolar in one mouth side with a split-mouth design before the beginning of Rapid Maxillary Expansion and after 7 days of it.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed."
45975042|NCT00274599|Drug|Telmisartan|
45975043|NCT00274599|Drug|Ramipril|
45975044|NCT00245687|Device|Tiger Tube|
45975045|NCT00245726|Device|FES Cycle|Subjects will use electrical stimulation of the leg muscles to pedal a cycle for 1 hour / 3x week
45975046|NCT00245726|Device|ES therapy|Subjects will electrically stimulate the leg muscles for 1 hour/ 3x week
45975047|NCT00245726|Device|Passive (Motor Assist) Cycle|Subjects will use a cycle that moves the legs for 1 hour/3x per week
45975048|NCT00274638|Drug|Telmisartan & Hydrochlorothiazide|
45975049|NCT00274638|Drug|Losartan & Hydrochlorothiazide|
45975050|NCT00274638|Procedure|ABPM|
45975051|NCT02961569|Procedure|sputum collection for acid fast bacilli|spontaneous or post fiberoptic bronchoscopy sputa
45975052|NCT00274677|Drug|Placebo|Experimental treatment arm
45975053|NCT00274677|Drug|lamotrigine|Experimental treatment
45975054|NCT00245843|Behavioral|Mother Infant Transaction Program (MITP)|Psychosocial intervention. 11-session one hour standardized intervention program. The aim of the MITP is to help parents to appreciate their infant's unique characteristics,temperament and developmental potential.
45975055|NCT00284037|Device|continuous positive airway pressure therapy|
45975056|NCT00245882|Behavioral|Care Coordination|Care coordination with monthly follow-up by a diabetes nurse educator
45975057|NCT00245882|Behavioral|Home Telemedicine|Active care management by a nurse practitioner using home telemedicine
45975058|NCT00274755|Drug|chemotherapy|
45975059|NCT00274755|Procedure|conventional surgery|
45975060|NCT00274755|Procedure|magnetic resonance imaging|
45975061|NCT00274755|Procedure|magnetic resonance spectroscopic imaging|
45975062|NCT00274755|Radiation|radiation therapy|
45975063|NCT00245921|Drug|Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg|
45975064|NCT00284076|Drug|L-arginine|
45975065|NCT00246038|Device|Boston Scientific ENOVUS AAA Endograft|
45975066|NCT00274794|Biological|filgrastim|10mcg/kg/d subcutaneously, beginning 48 hours after completion of Etoposide
45975067|NCT00274794|Biological|rituximab|375 mg/m2, IV, Once per week for 3 weeks.
45975068|NCT00246155|Biological|Botulinum toxin type A|
45975069|NCT00284193|Drug|rFVIIa-FEIBA therapy for hemophilia A inhibitors|DOses tailored per ex vivo spiking thrombin generation
45975070|NCT00284193|Drug|FEIBA- Activated Prothrombin Complexes|
45975071|NCT00246194|Drug|risperidone (RISPERDAL CONSTA)|Long-acting injectable of risperidone given as per the prescription from the prescribing physician.
45975072|NCT00284232|Behavioral|Use and interpretation of blood glucose results|
45975073|NCT00284232|Drug|Insulin dosing based on SMBG chart and education|
45975074|NCT00246233|Drug|methylphenidate|
45975075|NCT00274833|Drug|erlotinib hydrochloride|Erlotinib is available as 25 mg, 100 mg, and 150 mg tablets. It should be administered orally once daily at the prescribed dose specified in the clinical study protocol per dose escalation schema. Preferably, erlotinib should be taken in the morning with up to 200 mL of water at least 1 hour before or 2 hours after a meal.
45975076|NCT00274833|Drug|temozolomide|TMZ is supplied in white opaque, preservative-free, two piece hard gelatin capsules of the following sizes: 100mg capsules, 20mg capsules, and 5mg capsules. TMZ will be a once a day orally administered (75 mg/m2 x BSA x 42 days)set of capsules taken at least two hours after and one hour before a meal.
45670943|NCT02289950|Drug|Placebo|Placebo will be administered intravenously (IV) weekly
45975077|NCT00274833|Radiation|radiation therapy|Concomitant focal RT will be delivered once daily at 2 Gy per fraction, 5 d/wk, for a total of 60 Gy. (6 weeks) as mentioned in therapeutic modalities.
45975078|NCT04709666|Procedure|Endsocopic Retrograde ColangioPancreatography (ERCP)|
45975079|NCT00274872|Drug|fluorouracil|
45975080|NCT00274872|Drug|leucovorin calcium|
45975081|NCT00274872|Drug|oxaliplatin|
45975082|NCT00246272|Drug|risperidone|
45975083|NCT00284271|Drug|Cyclophosphamide|
45975084|NCT00284271|Drug|Adramycin|
45975085|NCT00284271|Drug|Procarbacine|
45975086|NCT00284271|Drug|Prednisone|
45975087|NCT00284271|Drug|Vincristine|
45975088|NCT00284271|Drug|Bleomycin|
45975089|NCT00284271|Drug|Erythropoietin beta|
45975090|NCT00284115|Device|Gait trainer|Mechanical gait repetitive training
45975091|NCT00284115|Device|Conventional rehabilitation|Physiotherapeutic conventional rehabilitation
45975092|NCT00246350|Procedure|massage|8 light massage treatments and hot pack
45830366|NCT03028038|Drug|No Platelet Rich Plasma|"No Platelet Rich Plasma (PRP) will be injected in the other mouth side with a split-mouth design during Rapid Maxillary Expansion.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed."
45830367|NCT03027960|Drug|Empagliflozin|10mg empagliflozin for a 2-week period
45830368|NCT03027960|Drug|Placebo Oral Capsule|10 mg placebo for a 2-week period
45830369|NCT03028194|Procedure|Curettage|Postpartum uterine curettage with a sharp curette # 14 or #16, immediately after delivery of the placenta.
45830370|NCT03028194|Procedure|Placebo|No procedure after delivery of the placenta
45830371|NCT03027882|Other|No Intervention|This is a reliability/validity study of a functional clinical test. There is no intervention
45975093|NCT00246350|Procedure|massage|16 light massage treatments and hot packs
45975094|NCT00246350|Procedure|spinal manipulation|8 high velocity, low amplitude spinal manipulation treatments and hot pack
45975095|NCT00246350|Procedure|Spinal manipulation|16 high velocity, low amplitude spinal manipulation treatments and hot pack
45975096|NCT00246389|Drug|cyclobenzaprine hydrochloride|
45670944|NCT01741012|Drug|Gardasil|0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6
45670945|NCT02288312|Drug|BIA 2-093|
45830372|NCT01539642|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
45830373|NCT01539642|Drug|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
45830374|NCT01586364|Drug|Ospemifene 60Mg Oral Tablet|
45830375|NCT01538628|Device|SpaceOAR System|Fiducial marker placement followed by randomization to treatment group, i.e., 10mL SpaceOAR hydrogel injection, or control group, i.e., no injection of SpaceOAR hydrogel.
45975097|NCT00274911|Drug|cisplatin|
45975098|NCT00274911|Drug|lomustine|
45975099|NCT00274911|Drug|vincristine sulfate|
45975100|NCT00274911|Procedure|adjuvant therapy|
45975101|NCT00274911|Radiation|radiation therapy|
45975102|NCT00246428|Behavioral|Motivational Interviewing|Experimental manipulations will be evaluated 6, 9, and 12 months
45975103|NCT00284349|Device|Use of a rehabilitation brace instead of a plaster|
45975104|NCT00246467|Biological|Alhydrogel|
45975105|NCT00246467|Biological|rF1 and rV protein antigens|
45975106|NCT00277173|Behavioral|Adoption of Crew Resource Management approach|
45458605|NCT01365104|Drug|desferrioxamine|intravenous infusion at 10mg/kg/hr for a total of 6 hours at final infused doses of 60mg/kg.
45670946|NCT01740388|Drug|Besifloxacin|one drop of besifloxacin ophthalmic suspension 0.6% administered to infected study eye(s) BID for 3 days.
45670947|NCT01740388|Drug|Vehicle|one drop of the vehicle of besifloxacin ophthalmic suspension administered to infected study eye(s) BID for 3 days.
45670948|NCT01740154|Procedure|transcranial magnetic stimulation|Undergo TMS
45670949|NCT01740154|Procedure|electromyography|Undergo EMG
45670950|NCT01740154|Other|survey administration|Ancillary studies
45670951|NCT01740154|Drug|sunitinib malate|Given PO
45975107|NCT00246506|Procedure|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
45975108|NCT00246506|Procedure|in vitro fertilization|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
45975109|NCT00246545|Behavioral|exercise|
45975110|NCT00277251|Drug|Alendronate|
45975111|NCT00246584|Drug|SPP100|
45975112|NCT00416676|Drug|carboplatin|
45975113|NCT00416676|Drug|cisplatin|
45975114|NCT00416676|Drug|cyclophosphamide|
45975115|NCT00416676|Drug|etoposide|
45975116|NCT00416676|Drug|vincristine sulfate|
45975117|NCT00416676|Procedure|adjuvant therapy|
45975118|NCT00416676|Procedure|conventional surgery|
45975119|NCT00416676|Procedure|neoadjuvant therapy|
45458606|NCT03492970|Biological|Hourly dosing of the nychtemeral secretion of melatonin|Hourly dosing of the nychtemeral secretion of melatonin links and with sleep disorders and behavior of adult patients with SMS
45975120|NCT00416676|Radiation|radiation therapy|
45975121|NCT00284388|Procedure|Simultaneous controlled power measurement|
45975122|NCT00284388|Procedure|Surface EMG measurement|
45975123|NCT00246623|Drug|Exubera (inhaled insulin)|
45975124|NCT00246623|Procedure|8-point glucose diary (to assess pre- and post prandial glucoses)|
45975125|NCT00246623|Procedure|Meal Tolerance Test|
45975126|NCT00246623|Procedure|24-hour continuous glucose monitoring (at select sites)|
45975127|NCT00246623|Procedure|Pulmonary Function Testing|
45975128|NCT00246623|Procedure|Hypoglycemic Event Monitoring|
45975129|NCT00246623|Procedure|Laboratory Assessments|
45670952|NCT02287922|Biological|ALX-0061|
45975130|NCT00246623|Behavioral|Nutritional Counseling and Diabetes Education|
45975131|NCT00284427|Drug|vitamin C|IV Vitamin C given 2-3 times a week
45975132|NCT00246662|Drug|Vosaroxin|All patients receive vosaroxin Injection
45975133|NCT00277290|Drug|XL999|Treatment was administered on an outpatient basis. XL999 was administered at 2.4 mg/kg as a 4 hour intravenous (IV) infusion. Subjects received a XL999 infusion once a week for 8 weeks of treatment unless drug-related toxicity required a dosing delay
45458607|NCT01362374|Drug|5-FU|5-FU at a dose level of 400 mg/m^2 as intravenous (IV) injection followed by a dose of 2400 mg/m^2 as IV infusion over 46 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
45670953|NCT02287922|Biological|Placebo|
45830376|NCT01538472|Drug|Y Zevalin|Starting dose: 0.4 mCi/kg by vein after Rituxan infusion on Day -14.
45830377|NCT01538472|Drug|In Zevalin|Imaging dose: 5 mCi by vein following Rituxan infusion on Day -21.
45670954|NCT02287922|Biological|Tocilizumab|
45670955|NCT02287610|Drug|RAYOS (delayed-release prednisone)|Physicians may prescribe any dosage of RAYOS based on what is appropriate for the treatment of the patient's condition as determined by performing standard of care assessments.
45670956|NCT05646446|Behavioral|REACH Program|The REACH program addresses alcohol use, sexual assault risk, and experiences relating to harm among bisexual women.
45670957|NCT05646212|Other|Project ECHO|Project Extension for Community Healthcare Outcomes® (ECHO): This EBP, tested originally to facilitate HCV care into non-specialty settings, is based on established educational theories of social learning & behavior change in where non-specialists collaborate with specialists, resulting in an innovative healthcare delivery model that results in equivalent quality care for patients in non-specialty settings.
45670958|NCT05646212|Other|Payment for Performance|"P4P in healthcare, endorsed by 3 IOM reports, gives financial incentives to clinicians for adhering to clinical guidelines and achieving better health outcomes. One 2007 IOM report recommended physician incentives so that profitability and improved healthcare delivery is aligned with patient safety goals and strengthen the business case for healthcare quality and safety."
45670959|NCT05646134|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive brain stimulation therapy that modulates brain excitability.
45830378|NCT01538472|Drug|Rituxan|"250 mg/m2 by vein on Day -21 and on Day -14.~1000 mg/m2 by vein on Days +1 and +8."
45830379|NCT01538472|Drug|BCNU|300 mg/m2 by vein on Day -6.
45830380|NCT01538472|Drug|VP -16|200 mg/m2 by vein every 12 hours on Days -5, -4, -3, and -2.
45830381|NCT01538472|Drug|Ara-C|200 mg/m2 by vein every 12 hours on Days -5, -4, -3,and -2.
45830382|NCT01538472|Drug|Melphalan|140 mg/m2 by vein on Day -1.
45975134|NCT00246701|Drug|Simvastatin|Simvastatin
45975135|NCT00246701|Drug|Simvastatin + Lovaza|Simvastatin + Lovaza (omega-3-acid ethyl esters)
45975136|NCT00284466|Procedure|MS-CT Coronary Angiography|MS-CT Coronary Angiography done
45975137|NCT00246779|Procedure|Modified ultrafiltration|
45975138|NCT00277329|Drug|XL999|• The Study Treatment Period, in which subjects received a once-weekly, 4-hour intravenous (IV) infusion of XL999 at 2.4 mg/kg as outpatients for 8 weeks. Treatment was to be stopped at the occurrence of disease progression or unacceptable toxicity.
45975139|NCT00246818|Procedure|Tai Chi Chuan|
45830383|NCT01538472|Procedure|Stem Cell Infusion|Autologous stem cell infusion on Day 0.
45975140|NCT00277368|Other|A structured questionnaire for seizure-related headache|A structured questionnaire for seizure-related headache
45975141|NCT00246896|Behavioral|care management|
45975142|NCT00284505|Drug|thalidomide|
45975143|NCT00246935|Drug|Roflumilast|
45975144|NCT00277407|Procedure|NAET with acupressure and/or chiropractic procedures|
45975145|NCT00246974|Drug|Gemcitabine|intravenous
45975146|NCT00246974|Drug|Cisplatin|intravenous
45975147|NCT00246974|Drug|Gefitinib|oral
45975148|NCT00284583|Drug|Injection of Steroid into Foot|
45975149|NCT00284583|Drug|Injection of Alcohol into Foot|
45975150|NCT00284583|Drug|Injection of Lidocaine into Foot|
45975151|NCT00247013|Behavioral|Breast Cancer Screening Compliance|
45975152|NCT00277563|Device|reduction of pain scores by magnetic energy|
45975153|NCT00247052|Drug|diclofenac|diclofenac 50 mg bid versus placebo bid
45975154|NCT00247052|Drug|diclofenac|diclofenac 100 mg per day for 14 days
45975155|NCT00247052|Drug|matching placebo|
45975156|NCT00284622|Procedure|Arthroscopy|HTO with pre-scope
45975157|NCT00247091|Biological|standard-titer measles vaccine|
45975158|NCT00277602|Drug|Riluzole|
45975159|NCT00277641|Drug|Lamotrigine|25 mg or 100 mg
45975160|NCT00277641|Drug|placebo|identical tablets to study drug
45975161|NCT00284661|Procedure|FAST FIX|Fast fix repair of a meniscal tear
45975162|NCT00284661|Procedure|Meniscal suturing|standard suturing of meniscal tear
45670960|NCT05646134|Device|Sham Transcranial Magnetic Stimulation|During Sham Transcranial Magnetic Stimulation the coil will be facing the wall making the stimulation inactive
45670961|NCT05646056|Device|Software|Observation only
45670962|NCT05645978|Device|Pacemaker insertion|Patients who underwent pacemaker insertion between January 2015 and December 2020
45670963|NCT04873466|Dietary Supplement|Enzyme-rich malt extract|Enzyme-rich malt extract (ERME) is a by-product of the malting process in which the cereal grain barley is dried. The ingredients are 100% barley malt extract. It smells and tastes sweet, with a runny jam-like texture. Malt extract has been used as a food stuff in baking and cookery for many years, but ERME is extracted by means which retains more active enzymes, such as amylase.
45670964|NCT02262728|Drug|Simeprevir|Simeprevir 150 milligram (mg) capsule orally once daily for 12 weeks
45975163|NCT00247130|Drug|Omeprazole|
45975164|NCT00247130|Drug|Ranitidine|
45975165|NCT00277680|Procedure|Laparoscopic bilateral occlusion of uterine artery|
45975166|NCT00277680|Procedure|Radiological embolization (UFE)|
45975167|NCT00247169|Drug|progesterone|Micronized progesterone 400mg 1x daily for 10 days/month from menstrual cycle day 16-25
45975168|NCT00247208|Device|Taxus polymer-based paclitaxel-eluting stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
45975169|NCT00247208|Device|Express 2 bare metal stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
45975170|NCT00284778|Drug|Alimta®|
45975171|NCT00284778|Drug|Taxotere®|
45670965|NCT02262728|Drug|Daclatasvir|Daclatasvir 60 mg tablet orally once daily for 12 weeks
45670966|NCT02262728|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet orally once daily for 12 weeks
45670967|NCT02262260|Drug|Labeled regime arm|Treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month.
45670968|NCT02262260|Drug|Wait and Extend regime arm|Lucentis (ranibizumab) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
45975172|NCT00247247|Drug|Comtess®|
45670969|NCT02285270|Device|FDG PET/CT|PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.
45670970|NCT01717768|Drug|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
45670971|NCT02260934|Biological|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2
45670972|NCT02260934|Drug|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
45670973|NCT02260934|Drug|Prednisone|"Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~Continue prednisone 10 mg/day to week 96"
45670974|NCT02260934|Drug|Methylprednisolone|"Week 0 and Week 2:~Solumedrol (100 mg) IV"
45670975|NCT02260934|Drug|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
45670976|NCT02260934|Drug|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
45975173|NCT00277758|Biological|Interleukin 2|Interleukin-2 at 1.2 mU/M2 administered subcutaneously daily
45975174|NCT00277758|Drug|Ribavirin|Ribavirin @ 800 mg daily (< 65 kg body weight), 1000 mg (65-85 kg), and 1200 mg (> 85 kg)
45975175|NCT00277758|Biological|Pegylated Interferon Alpha|Pegylated-Interferon-alpha 1.5 ug/kg weekly subcutaneously.
45975176|NCT00277758|Biological|Inteleukin-2|Interleukin-2 administered as a daily subcutaneous injection at 1.2 mU/M2 BSA
45975177|NCT00277758|Drug|Ribavirin + Pegylated interferon-alpha|Pegylated interferon-alpha administered 1.5 ug/kg weekly. Ribivirin 800 mg daily for body weight <65 kg, 1000 mg for body weight 65-85 kg, and 1200 mg for body weight >85 kg.
45975178|NCT00247286|Behavioral|weighted vaginal cones|
45975179|NCT00247286|Behavioral|Biofeedback|Pelvic floor muscles exercises performed with a biofeedback machine
45975180|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 1 mg/kg for 51 weeks.
45975181|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
45975182|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; 6 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
45975183|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; on Study Day 0 followed by weekly maintenance doses of 3mg/kg for 51 weeks.
45975184|NCT00284817|Drug|MEDI-522|The next cohort of patients will be treated after at least 3 of 4 patients treated in the previous cohort receive at least 3 weeks of treatment and experience no dose-limiting toxicity (DLT).
45975185|NCT00247325|Drug|Iodixanol(Drug)|
45975186|NCT00277797|Device|Biowave Targeted Non-Invasive Electronic Pain Control Device|"This device is a non-invasive non-pharmacologic treatment for pain. It sends a premixed modulated envelope of two high frequency electronic wave forms (Feed Signals) between two electrodes."
45975187|NCT00277797|Device|TENS (Transcutaneous Electrical Nerve Stimulation) device|This device features a bisourced, biphasic waveform. The combined constant voltage, constant-current waveform provides a strong stimulus that allows the clinician to prescribe a treatment program.
45975188|NCT00247364|Drug|Levetiracetam (Keppra)|
45975189|NCT00247403|Drug|2-deoxyglucose (2DG)|Addition of 2DG to stereotactic radiosurgery. Dose escalation study.
45670977|NCT02260934|Biological|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2.
45670978|NCT02260934|Drug|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
45975190|NCT00277836|Drug|MST-997|
45975191|NCT00247442|Behavioral|Decision aid|
45975192|NCT00277875|Drug|ALT-711 (alagebrium chloride)|
45975193|NCT00424814|Drug|Kaletra (lopinavir/ritonavir)|(200/50 mg x2)x 2/d= 2 pills twice daily
45975194|NCT00424814|Drug|Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)|Kaletra (lopinavir/ritonavir): (200/50 mg x2)x 2/d= 2 pills twice daily Combivir (zidovudine/lamivudine): (300/150mg) x 2/d=1 pill twice daily
45830384|NCT01538472|Drug|G-CSF|5 mg/kg by vein daily starting Day 0 till recovery of granulocytes of 4.0 x 109/L.
45830385|NCT01562028|Drug|Erlotinib|Patients will be treated with erlotinib, 150 mg p.o., daily
45830386|NCT01562028|Drug|Bevacizumab|Patients will be treated with bevacizumab 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days)
45975195|NCT00284973|Biological|Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720|
45975196|NCT00247481|Drug|Gefitinib|
45975197|NCT00247481|Drug|Docetaxel|
45975198|NCT00277914|Drug|Flibanserin|flibanserin flexible dosing
45975199|NCT00247520|Drug|topical nasal rEV131|
45456067|NCT05070338|Behavioral|Guideline-Based (Injunctive Norm) Nudges|"Surgeons in this arm will receive an email with the following content at the end of each month in which at least two of their patients are discharged with an opioid prescription that exceeds the prescribing guideline for the procedure performed.~Dear Dr. [Name],~In [month], at least XX of your patients were discharged with opioid prescriptions exceeding the amounts recommended by safety guidelines for these procedures.~For patient safety, Sutter Health recommends prescribing within the ranges below for these procedures. Doing so will also meet best-practice safety guidelines for post-operative opioid prescribing.~We will continue to send you opioid prescribing safety reports.~Sincerely, [Signature]~[Table displaying recommended ranges of 5mg oxycodone tablets for each procedure]"
46082167|NCT04996667|Drug|inhaled nitric oxide (iNO)|"Inhaled nitric oxide (iNO), which is known mainly from the pulmonary hypertension literature for its therapeutic role in pulmonary arterial hypertension, has been proposed as a potential pharmacologic adjunct to standard anticoagulation in acute PE.~Inhaled nitric oxide (iNO) will be administered at 30 ppm for 3 minutes. The measurements will be obtained/calculated before, during iNO administration, and after iNO has been withheld for 2 minutes."
46082168|NCT00931177|Other|weight|weight and dehydration scores
46082169|NCT00931177|Other|weight and dehydration score|weight and dehydration score
45670979|NCT02260934|Drug|Prednisone|"Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~Continue prednisone 10 mg/day to week 96"
45670980|NCT02260934|Drug|Methylprednisolone|Week 0 and Week 2: Solumedrol (100 mg) IV
45670981|NCT02260934|Drug|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
45670982|NCT02260934|Drug|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
45670983|NCT02260934|Biological|Belimumab|The RCB Group will receive IV belimumab 10mg/kg at weeks 4, 6, 8, and then every 4 weeks through week 48
45830387|NCT04112316|Drug|liothyronine or placebo|Each treatment period of liothyronine or placebo will be approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo or LT3.
45975200|NCT04719039|Behavioral|Restorative Yoga Internvention|Participants in the intervention group will receive links to two 60-min videos per week for 8 consecutive weeks. Each video will include a yoga practice guided by a certified yoga instructor. The intervention group is required to perform the yoga practice at least two times per week. If preferred, they can do additional sessions with the videos and record their total hours of self-practice.
45975201|NCT00247559|Biological|Botulinum toxin type A|
45975202|NCT00285051|Drug|inhaled delta-8-THC 300mcg or 600mcg per dose|"drugs to be used to prevent/treat nausea and/or vomiting due to cancer chemotherapy drug Patients will receive chemotherapy on day 0 and receive study medication, return on day 1or 2 and again on day 4 to return medication. There will be at least 10 days between the last dose of study medication from the first cycle and the first dose for the 2nd cycle..~Patients will receive for each chemotherapy cycle either IV Ondansetron and Placebo inhalation, or IV Placebo and delta-8-THC inhalation. The patients will be randomized to receive one of 2 doses of the THC, either 300mcg or THC or 600mcg of THC"
45975203|NCT02961725|Biological|UCMSC|UCMSC: umbilical cord mesenchymal stem cells 3-5*10^7/5 ml
45975204|NCT00247715|Drug|algeldrate/magnesium oxide|
45975205|NCT00247715|Drug|ranitidine|
45975206|NCT00247715|Drug|pantoprazole|
45975207|NCT00247754|Behavioral|Cognitive Behaviour Treatment|
45975208|NCT00285090|Dietary Supplement|Calcium, Vitamin D|
45975209|NCT00285090|Dietary Supplement|Calcium,Vitamin D|
45975210|NCT00285090|Dietary Supplement|Calcium, VitaminD|
45975211|NCT00285090|Other|Sugar Pill|
45975212|NCT00247793|Drug|Oral Impact (preoperative enteral nutritional supplement)|
45975213|NCT00417222|Drug|olmesartan medoxomil|5 to 40mg P.O. daily until the end of the study
45975214|NCT00247832|Behavioral|Self-directed motivation|Post-lobectomy patients are provided with a booklet that outlines expected physical activities (sitting up, walking arm exercises) to aim for each day after surgery. It also provides room for the patients to record what they have accomplished.
45975215|NCT00247832|Behavioral|Personal motivational interviewing|Post-lobectomy patients receive daily visits from a study coordinator aimed to motivate the patient to complete various physical activities each day after surgery. The study coordinator goes through the same booklet that is given to Group 2 and helps patients set goals and record their accomplishments.
45670984|NCT04879862|Combination Product|Epidural stimulation + Stand Training|Participants may use a standing apparatus or a less assistive device such as walker or cane. In case of upper limbs and trunk control insufficient for safely using the standing apparatus, participants will be placed on the treadmill, and a body weight support system. In this case, the level of body weight support will be continuously reduced as the individuals increase their ability to bear weight. A trainer positioned behind the participant will aid in pelvis and trunk stabilization. Trainer(s) positioned at the lower limb will provide manual facilitation for knee extension during standing. Manual facilitation at the trunk-pelvis and at the legs will be used only when needed.Participants will be encouraged to stand for as long as possible throughout the training session, with the goal to stand for 60 minutes with the least amount of assistance.
45975216|NCT00278070|Drug|vinorelbine oral formulation|Patients will take three times a week [Monday, Wednesday and Friday] by mouth, a standard dose of soft capsules of vinorelbine given at dose ascribed by randomization procedure
45975217|NCT00417261|Drug|ATF936|
45975218|NCT00417261|Drug|AXT914|
45975219|NCT00424983|Drug|Zoledronic acid|
45975220|NCT00247910|Drug|Hydrochlorothiazide|Not recorded in detailed description.
45670985|NCT04879862|Combination Product|Epidural stimulation + Step Training|Participants may be placed on the treadmill in an upright position and suspended in a harness. All trainers are careful to provide manual assistance only when needed. A trainer positioned behind the research participant will aid in pelvis and trunk stabilization, as well as appropriate weight shifting and hip rotation during the step cycle. Trainers positioned at each limb will provide manual assistance to promote knee extension and knee flexion and toe clearance. Research participants will step at various body weight load and speed. Research participants will take a break and rest at any time they feel the need to during the session. If independence is achieved during stepping, some training might be performed overground with appropriate assistive device and manual assistance to maintain participant safety. Participants will be encouraged to step for 60 minutes with the least amount of assistance. Seated or standing resting periods will occur when requested by the individuals
45670986|NCT04879862|Combination Product|Epidural stimulation + Bladder Capacity Training|We will initially conduct daily training for capacity in a supervised on-site lab setting. Optimal configurations will be used. The storage phase configuration will be used until the time for voiding/catheterization. The training procedure will be repeated for up to 8 hours daily on-site until three consecutive stable days of maintaining a consistent capacity values are achieved and deemed safe. In the home setting, participants will record blood pressure values, voided and residual volumes. Participants will return to the lab the following day for monitoring and testing. If assessments show stable outcomes, participants will be allowed to train at home for 7 consecutive days, prior to returning to the lab for clinical evaluation (urodynamics and questionnaires). On the return visit, if their storage/voiding outcomes remained stable over the 7 days, they will be able to start the home-based training for bladder capacity.
45975221|NCT00278187|Biological|volociximab|
45975222|NCT00278187|Drug|erlotinib hydrochloride|
45975223|NCT04718610|Other|Osteopathic intervention|Nerve vagus stimulation
45975224|NCT04718610|Biological|CRP assessment|Blood CRP will be assessed during trial
45975225|NCT04718610|Behavioral|QLQ-C30 questionnaire|Completion of QLQ-C30
46082170|NCT02732496|Behavioral|Targeted Cognitive Training (TCT)|The instructors have selected a set of computer exercises designed to specifically target working memory, which is a cognitive construct relevant to ADHD and Tourette Syndrome. The tasks were designed to benefit subjects through principles of learning-dependent plasticity.
45458608|NCT01362374|Drug|Docetaxel|Docetaxel will be administered at dose level of 75 mg/m^2 as IV infusion over 1 hr on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
45458609|NCT01362374|Drug|Enzalutamide|Enzalutamide will be administered orally at a dose level of 160 mg once daily continuously as per schedule defined in respective arm until disease progression or unacceptable toxicity.
45975226|NCT00247988|Drug|Weekly Taxotere with weekly carboplatin|
45975227|NCT00425022|Procedure|thoracoscopy|
45975228|NCT00248066|Drug|RESTEN-MP|
45975229|NCT00285129|Device|ceramic-on-ceramic total hip replacement versus metal-on-metal hip resurfacing|
45975230|NCT00248105|Behavioral|Lifestyle Physical Activity Management|Lifestyle Physical Activity Promotion as given by Physical Activity Advocates. Advocates will meet with participants at baseline and every 3 months throughout the study to promote increase in lifestyle physical activity reached through goal setting and Motivational Interviewing (MI)
45975231|NCT00278226|Behavioral|smoking cessation intervention|
45975232|NCT00278226|Other|educational intervention|
45975233|NCT00248144|Drug|Famciclovir|
45975234|NCT00278265|Drug|MTX followed by fludarabine|MTX should be administered with 10-20mg weekly, calculated according to the body weight. Fludarabine should be administered with 25mg/m2 on day 1-3 of 28 days, up to 4 cycles
45975235|NCT00248183|Drug|PRX-00023|
45975236|NCT00278304|Radiation|brachytherapy|
45975237|NCT00278304|Radiation|radiation therapy|
46082171|NCT02732496|Other|Youth Appropriate Online Games|Engaging games not designed to improve cognition.
45975238|NCT00248222|Behavioral|Supervised aerobic training|
45975239|NCT00278343|Drug|cediranib maleate|30mg given PO, daily
45975240|NCT00278343|Other|laboratory biomarker analysis|Correlative studies
45975241|NCT00248261|Drug|ziprasidone, sertraline|
45975242|NCT00285168|Behavioral|Bone Density Decision Aide|Absolute 10-year Fracture Risk Report
45975243|NCT00248300|Other|Chlorhexidine|Chlorhexidine, 5 ml swab to the oral cavity within 12 hours of endotracheal tube intubation
45975244|NCT00278382|Drug|sorafenib tosylate|Given orally
45458610|NCT01362374|Drug|Ipatasertib|Ipatasertib will be administered orally (in escalating doses during Stage 1 followed by at a dose decided during Stage 1) as per schedule defined in the respective arms.
45975245|NCT00278382|Other|laboratory biomarker analysis|Correlative studies
45975246|NCT00248339|Drug|Peginterferon-alpha-2b (PEG-Intron)|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin ~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
45975247|NCT00248339|Drug|Ribavirin|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin ~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
45975248|NCT00248339|Drug|Epoetin-alpha (Procrit)|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
45975249|NCT00278421|Biological|rituximab|
45975250|NCT00278421|Drug|cyclophosphamide|
45975251|NCT00278421|Drug|doxorubicin hydrochloride|
45975252|NCT00278421|Drug|prednisone|
45975253|NCT00278421|Drug|vincristine sulfate|
45975254|NCT00248378|Drug|Smoked Cannabis|
45975255|NCT00248456|Drug|Calcipotriol plus betamethasone dipropionate ointment|
45975256|NCT00285285|Device|Point of Care Device; i-Stat Analyzer|
45975257|NCT00248690|Device|ICP mean wave amplitude|Appropriate measures when ICP mean wave amplitude is to high, e.g. CSF drainage
45975258|NCT00278460|Drug|docetaxel|40 milligrams per meter squared infused over 30 minutes on day 1 and 8, repeated every 21 days
45975259|NCT00278460|Drug|gemcitabine hydrochloride|800 milligrams per meter squared intraveneously for two consecutive weeks followe by one week of no treatment then repeated.
45975260|NCT00248729|Drug|Etomidate (20mg) or Midazolam (7mg)|
45975261|NCT00248768|Device|Transcranial magnetic Stimulator|a device which produces intense magnetic fields in the brain and activates cerebral neurons
45975262|NCT00278499|Behavioral|Cross-sectional surveys|Cross-sectional surveys will occur at study entry, Month 6, and Month 12. Every fourth participant enrolled in the FSW cross-sectional survey, all FSWs found to be HIV infected, and all FSWs who are intravenous drug users will participate in a substudy lasting 12 months.
45975263|NCT00278499|Behavioral|Questionnaire/counseling|An initial questionnaire and counseling will occur once in addition to post-test counseling.
45670987|NCT04879862|Combination Product|Epidural stimulation + Bladder Voiding Efficiency Training|We will conduct training for voiding efficiency in a supervised on-site lab setting while the participant continues his/her training for capacity. Voiding without catheterization will be attempted. The training procedure will be repeated for up to 8 hours on-site until three stable days of maintaining a consistent voiding efficiency are achieved and deemed safe. The participant will be sent home for one day to perform the stimulation at home. In the home setting, participants will record blood pressure values, voided and residual volumes. Participants will return to the lab the following day for monitoring and testing. If assessments show stable outcomes, participants will be allowed to train at home for 7 consecutive days, prior to returning to the lab for clinical evaluation and questionnaires. On the return visit, if their storage/voiding outcomes remained stable over the 7 days, they will be able to start the home program integrating bladder training for capacity and voiding
45975264|NCT00248846|Behavioral|Intervention Group|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
45975265|NCT00278577|Biological|Immune Ablation and Hematopoietic Stem Cell Support|Autologous Hematopoietic Stem Cell Transplant
45975266|NCT00248885|Procedure|Regulating Mean Arterial Pressure during cardiopulmonary bypass|Patients were randomized to one of two groups. In the first group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB. In the second group (High), the goal was to maintain MAP between 80-100 mm Hg. In both groups, CPB flow was held constant at 1.6 L/min/M2 (cool) and 2.4 L/min/M2 (warm) and vasoactive drugs (nitroglycerin or phenylephrine) were used to maintain MAP in the desired range. MAP was controlled in this fashion from the onset of CPB through separation from CPB began.
45975267|NCT00285402|Drug|AST-726 Low dose|
45975268|NCT00285402|Drug|AST-726 High dose|
45975269|NCT00285402|Drug|AST-726 Placebo|
45975270|NCT00248924|Behavioral|Social Services|
45975271|NCT00278616|Biological|Stem Cell Transplantation|Autologous Stem Cell Transplantation
45975272|NCT00278694|Drug|Oxaliplatin|
45975273|NCT00278694|Drug|Chemoradiation|
45975274|NCT00278694|Drug|5-FU|
45975275|NCT00278694|Radiation|Preoperative chemoradiation|
45975276|NCT00278694|Procedure|Pelvic surgery|
45975277|NCT00278694|Drug|Neoadjuvant oxaliplatin|
45975278|NCT00248963|Drug|Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg|
45975279|NCT00278733|Behavioral|Brief intervention (physician advice)|
45975280|NCT04720508|Diagnostic Test|blood sample collection.|venipuncture procedure
46082172|NCT05523362|Device|Dexcom continuous glucose monitor|The investigational device used in this study is the Dexcom G6 Pro/Personal Continuous Blood Glucose Monitoring system.
46082173|NCT00937885|Behavioral|Implementation of reminiscence|
45975281|NCT00249041|Drug|50 mg Etanercept|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
45975282|NCT00249041|Drug|Enbrel liquid|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
45975283|NCT00285519|Drug|Doxazosin (drug)|
45975284|NCT00278772|Drug|Divalproex|oral, 15mg/kg/day - 30mg/kg/day
45975285|NCT00278772|Other|Placebo|oral dose, placebo
45975286|NCT00249119|Drug|risperidone|
45975287|NCT00278811|Procedure|mobile crisis team|
45975288|NCT00285558|Behavioral|CBT with peer-enhanced activities|
46082174|NCT00937963|Dietary Supplement|Palm DAG Oil|Use of Palm DAG Oil to replace palm oil traditionally used in foods
45670988|NCT04420052|Other|Osteopathic manipulative treatment|"Osteopaths will executed several high velocity low amplitude (HVLA) techniques on the upper thoracic spine and cervical spine. These techniques are assumed to modulate the sympathetic cervical ganglia and reduce inflammation in chronic rhinosinusitis.~This procedure takes around 15 minutes."
45458611|NCT01362374|Drug|Leucovorin|Leucovorin at a dose level of 400 mg/m^2 as IV infusion over 2 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
45458612|NCT01362374|Drug|Oxaliplatin|Oxaliplatin at a dose level of 85 mg/m^2 as IV infusion over 2 hours will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
45975289|NCT00285558|Behavioral|CBT with supervised aerobic exercise|
45975290|NCT00414713|Procedure|red blood cell transfusion|red blood cell transfusion
45975291|NCT00278850|Behavioral|Educational|three 1 hour long educational seminars
45975292|NCT00414752|Drug|AFQ065|
45975293|NCT00285597|Drug|Ursodeoxycholic Acid|
45975294|NCT00249158|Drug|Risperidone|
45975295|NCT00278928|Drug|Liposyn III 20% (lipid infusion)|
45975296|NCT00278928|Drug|Intralipid 20% (lipid infusion)|
45975297|NCT00249197|Drug|levofloxacin|
45975298|NCT00278967|Drug|HalfLytely with Bisacodyl Tablets Bowel Prep Kit|
46082175|NCT05247281|Diagnostic Test|Culture-based treatment|Medications to treat prosthetic joint infection will be chosen based on results of traditional cultures alone
46082176|NCT05247281|Diagnostic Test|Next Generation Sequencing (NGS) with Culture|Medications to treat prosthetic joint infection will be chosen based results of NGS and culture
45670989|NCT04420052|Other|Placebo manipulation|"The osteopath will lay hands without movement on the nose, the throat and the thorax of patients.~This procedure takes around 15 minutes."
45670990|NCT02260388|Drug|Nortriptyline|
45670991|NCT02260388|Drug|Duloxetine|
45830388|NCT03028662|Behavioral|Retrieval-Extinction Learning|The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
45670992|NCT02260388|Drug|Pregabalin|
45670993|NCT02260388|Drug|Mexiletine|
45670994|NCT04878458|Procedure|phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy|The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy.
45670995|NCT04878458|Procedure|phacoemulsification with intraocular lens implantation combined with trabeculectomy|The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with trabeculectomy.
45670996|NCT02260154|Drug|Mebeverine|Subjects treated by Duspatalin (mebeverine) 200 mg BID (bis in die = twice a day) upto 6 weeks in accordance with routine practice will be observed
45830389|NCT04767828|Drug|PYRROTINI|CAPECITABINE: 800 mg/m2 twice daily, taken orally within 30 minutes after meal (one in the morning and one in the evening, 12 hours apart, equal to a daily dose of 1600 mg/m2, with one dose in the morning and one dose in the morning) .
45830390|NCT04767828|Radiation|Brain radiation therapy|Brain radiation therapy: the dose and frequency of brain radiation therapy are determined by the doctor according to the patient's condition.
45975299|NCT00278967|Drug|HalfLytely - Reformulation|
45975300|NCT00249236|Drug|Risperidone, oral tablets|
45975301|NCT00249275|Device|spectacles|
45975302|NCT00279006|Procedure|Percutaneous coronary intervention|
45975303|NCT00285675|Drug|DN-101 (calcitriol) - Drug|
45975304|NCT02215096|Drug|GSK2636771|GSK is available as 100 mg hard gelatin oral capsule to be taken once daily/continuous until treatment withdrawal under fasting conditions for at least 1hour (h) before and 2h after dosing with approximately 200 mL of water
45975305|NCT02215096|Drug|Enzalutamide|Enzalutamide will be sourced locally from commercial stock for sites in countries where it is approved
45975306|NCT02961647|Procedure|Mitral valve repair|The intervention is NOT related to the study design. It is a description of patients undergoing surgery vs. not undergoing surgery and this decision is made according to current guidelines (patients are not randomized).
45975307|NCT00279045|Drug|Rosiglitazone|
45975308|NCT00279045|Drug|glyburide|
45975309|NCT00279045|Drug|metformin|
45975310|NCT00249353|Drug|methylphenidate hydrochloride|
45975311|NCT02215408|Behavioral|CVRS Intervention|A clinical pharmacist working in the University of Iowa CVRS followed each patient for 12 months, working on lifestyle modification and recommending medication changes to the patient's clinical pharmacist in the local clinic.
45975312|NCT02216032|Other|TMW Curriculum|
45975313|NCT02216032|Other|Nutrition Curriculum|
45975314|NCT00249431|Drug|Sertraline|Patients will be started on 25mg/day of Sertraline, and their dose will be increased to 50 mg/day by week two, and then weekly by 50mg/day based on clinical response and emergence of side effects. The maximum dose will be 200mg/day
46082177|NCT02732574|Device|Oscilatory Positive Expiratory Pressure (OPEP) device|OPEP devices will be set to the highest pressure setting tolerated on POD #1. If the highest pressure setting is not achieved on POD#1, the PT will increase the pressure daily with the aim to achieve the highest pressure setting as soon as tolerated by the patient or POD#3, whichever comes first. Patients will be instructed to complete 15 breaths in a seated position with the OPEP device twice per waking hour. This will occur in addition to usual care.
46082178|NCT02732574|Device|SHAM Device Group|SHAM devices will be provided to patients on POD #1 and set to the highest pressure setting externally, however no positive expiratory pressure will be provided as the internal pressure regulating mechanism has been removed. Patients will be instructed to complete 15 breaths in a seated position with the sham device twice per waking hour. This will occur in addition to usual care.
45975315|NCT00249431|Behavioral|Relapse Prevention Therapy|Patients will have a weekly one-hour session for medication evaluation, relapse prevention therapy and answer questionnaires.
45975316|NCT00285714|Procedure|3D stereophotogrammetric imaging|
45975317|NCT00285714|Procedure|3D CT-imaging with cone-beam CT|
45975318|NCT00285714|Procedure|Case report form|
45975319|NCT00249509|Drug|Nefazodone|
45975320|NCT00249509|Drug|Bupropion|
45975321|NCT00279084|Drug|GROUP A: if necessary, martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 110 to 129 g/L.|
46082179|NCT02804516|Behavioral|the nurse did early mobilization|the nurses know and do what is the early mobilization in ICU
46082180|NCT02804516|Behavioral|the nurse do not do early mobilization|the nurses do not know and do what is the early mobilization in ICU
45456068|NCT05070338|Behavioral|Peer-Based (Social Norm) Nudges|"Surgeons in this arm will receive an email with the following content at the end of each month in which at least two of their patients are discharged with an opioid prescription that exceeds the prescribing guideline for the procedure performed.~Dear Dr. [Name],~In [month], at least XX of your patients were discharged with opioid prescriptions exceeding the amount prescribed by YY% of your peers for these procedures.~YY% of [specialty] surgeons at Sutter Health prescribe within the ranges below for these procedures.~We will continue to send you opioid prescribing safety reports.~Sincerely, [Signature]~[Table displaying recommended ranges of 5mg oxycodone tablets for each procedure]~The ranges of 5mg oxycodone tablets displayed will be the same as the ranges stipulated by the prescribing guidelines, but this nudge will not mention guidelines."
45670997|NCT02284178|Other|Enhanced oropharyngeal suction|Deep oropharyngeal suction with catheter every 4 hours
45830391|NCT01585584|Drug|Boceprevir|All patients will receive a 4-week lead-in with Peginterferon and Ribavirin therapy, followed by 24 weeks of Pegetron 1.5microg/kg + weight-based ribavirin + boceprevir 800mg tid. HCV RNA (Cobas TaqMan) will be measured at baseline and at treatment weeks 4, 6,8,12,16,20,24 and 28, and post-treatment weeks 12 and 24 (to obtain SVR-12 and SVR-24 results).
45830392|NCT01561560|Device|Delefilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
45830393|NCT01561560|Device|Narafilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
45830394|NCT04111536|Drug|liothyronine or placebo|Each treatment period of liothyronine or placebo will be approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo or LT3.
45830395|NCT01537068|Drug|Desvenlafaxine|Desvenlafaxine oral dose ranging from 50 to 100 mg/day
45670998|NCT02284178|Other|Usual Care|Oral suction with suction swab every 4 hours
45670999|NCT01643408|Drug|asparaginase Erwinia chrysanthemi|
45830396|NCT01537068|Drug|Placebo|Matching placebo pills
45830397|NCT01585428|Drug|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
45830398|NCT01585428|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml in 5% dextrose in water (D5W) over 1 hr.
45830399|NCT01585428|Biological|Young TIL|Cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
45671000|NCT02283788|Drug|BIA 2-093|
45671001|NCT02283788|Drug|Moxifloxacin|
45830400|NCT01585428|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
45830401|NCT01585272|Drug|ENA713|
45830402|NCT01585194|Biological|Ipilimumab|Given IV
45830403|NCT01585194|Other|Laboratory Biomarker Analysis|Correlative studies
45830404|NCT01585194|Biological|Nivolumab|Given IV
45830405|NCT03028116|Biological|influenza vaccine|"A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains:~NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes)."
45830406|NCT03028116|Biological|Placebo|water for injection
45830407|NCT01560780|Drug|Prasugrel|one 10 mg tablet by mouth daily
45830408|NCT01560780|Drug|Placebo|placebo similar in appearance to prasugrel
45830409|NCT01585038|Drug|Efavirenz|600mg orally every evening
45830410|NCT01585038|Drug|Rilpivirine|25mg orally once daily
45830411|NCT01560234|Drug|AZD8848|Single dose, oral inhalation (nebuliser solution)
45975322|NCT00279084|Drug|GROUP B: martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 130 to 149 g/L|
45975323|NCT00249548|Behavioral|Contingency management|
45671002|NCT02283788|Drug|Placebo|
45975324|NCT00285753|Behavioral|support groups|cognitive behavioral intervention with psychoeducation
45975325|NCT00249587|Drug|Methadone|dosed to effect, every six hours
45975326|NCT00279123|Drug|pantoprazole infusion|
45975327|NCT00279123|Drug|pantoprazole bolus|
45975328|NCT00279123|Drug|no treatment|
45975329|NCT00249626|Behavioral|Contingency management|Rewards (prizes) for abstinence
45975330|NCT00279162|Drug|Calcipotriene/betamethasone gel and ointment|
45671003|NCT01739764|Drug|Vemurafenib|Vemurafenib was given based on the last dose of the antecedent study (minimum 480 mg orally BID).
45671004|NCT01700530|Drug|Statin|Statins (40mg/day)for 12 weeks
45671005|NCT01700530|Other|Exercise only|12 weeks of exercise training (5 days a week for 45-50 min a session)
45671006|NCT01700530|Other|Statins + Exercise|Statins (40mg/day of simvastatin) plus exercise training (5 days/wk for 45-50 min a session) for 12 weeks
45671007|NCT01700140|Drug|SyB D-0701|Study drug patches [Low dose group (18.75 mg): SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 patch, High dose group (30.00 mg): SyB D-0701 15 cm2 patch + SyB D-0701 25 cm2 patch] assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
45830412|NCT01560234|Drug|Placebo|Single dose, oral inhalation (nebuliser solution)
45975331|NCT04720352|Device|Active treatment|Active treatment delivers radiofrequency and cryogen
45975332|NCT04720352|Device|Sham|Sham delivers non therapeutic levels of radiofrequency and cryogen
45975333|NCT00285792|Behavioral|Physical Activity|
45975334|NCT00249704|Drug|Vitamin D + Sham Exercise|1000 IU per day of Vitamin D + Sham (equivalent to placebo) Exercise
45671008|NCT01700140|Drug|Placebo|Study drug patches (Placebo group: SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 placebo patch) assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
45456069|NCT05067868|Biological|Replagal|Participants will receive Replagal 0.2 mg/kg, intravenous infusion at Day 1 and every 2 weeks.
45975335|NCT00249704|Procedure|Vitamin D Placebo + Exercise|Vitamin D placebo + Exercise
45975336|NCT00249704|Procedure|Vitamin D Placebo + Sham Exercise|Vitamin D placebo + Sham (equivalent to placebo) Exercise
45975337|NCT00249704|Drug|Vitamin D + Exercise|1000 IU per day of Vitamin D + Exercise
45975338|NCT00249743|Device|FallSaver (formerly called NOCwatch)|
45975339|NCT00249782|Drug|Vehicle control, 2x/day|
45975340|NCT00249782|Drug|ACZONE (dapsone) Gel, 5%, 2x/day|
45975341|NCT00249782|Drug|ACZONE (dapsone) Gel, 5%, 1x/day|
45975342|NCT00249782|Drug|MetroGel® (metronidazole gel), 1.0% 1x/day|
45975343|NCT00249782|Drug|ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)|
45975344|NCT00279240|Drug|Metformin|
45975345|NCT00249860|Drug|Interferon-beta-1a|Interferon-beta-1a will be administered subcutaneously at a dose of 44 microgram (mcg), three times a week up to Week 24
45975346|NCT00249860|Drug|Placebo|Matching placebo will be administered subcutaneously three times a week for 12 weeks. The placebo responders will continue the study off-treatment after Week 12 up to Week 24
46082181|NCT00929669|Drug|pasireotide LAR|pasireotide LAR 80 mg IM once a month
45671009|NCT01717456|Other|Education|Patient and caregiver will be taught which muscles are used in continence and defecation through the use of a training manual and anatomical drawings.
45671010|NCT01717456|Dietary Supplement|Fiber supplements|Patients and caregivers will be taught to use fiber supplements to normalize stool consistency if patient reports diarrhea or constipation. Fiber supplements will be in the form of Metamucil beginning with 3.4 grams per day and increasing up to 13.6 grams per day if needed to control stool consistency.
45671011|NCT01717456|Drug|Laxatives or anti-diarrheals|"Miralax at a dose of one packet (17 grams) daily may be used for constipation if unresponsive to fiber. Dose may be titrated up to two packets (34 grams) daily if needed.~Imodium at a starting dose of 2 mg/day may be used for diarrhea if unresponsive to fiber. Dose of Imodium may be titrated down to 1 mg or up to 4 mg if needed."
45830413|NCT04124328|Procedure|ALINE + VoM infusion|In patients assigned to the ALINE + VoM infusion group, extended ablation will be performed according to the ALINE criteria. Additionally, the vein of Marshall will be infused with ethanol.
45830414|NCT04124328|Procedure|ALINE only|In patients assigned to the ALINE only, extended ablation will be performed according to the ALINE criteria.
45830415|NCT01559844|Drug|Sofosbuvir|Sofosbuvir 400 mg (2 x 200 mg tablets) administered orally once daily
45830416|NCT01559844|Drug|Ribavirin|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
45975347|NCT00249860|Drug|Ribavirin plus Interferon-beta-1a|Placebo non-responders at Week 12 will receive ribavirin at a dose of 1000 milligram (mg) or 1200 mg orally once daily in combination with Interferon-beta-1a, administered subcutaneously at a dose of 44 mcg three times a week, from Week 16 up to Week 24
45975348|NCT00249899|Drug|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
45975349|NCT00249899|Drug|Stable statin therapy|Lapaquistat acetate placebo-matching, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
45975350|NCT00249938|Drug|Minute Maid Heart Wise orange juice|
45975351|NCT00249938|Drug|Welchol|
45975352|NCT00279279|Device|Implanted Device|
45975353|NCT00249977|Drug|Capecitabine in Combination with Cisplatin and Irinotecan|"Cisplatin 50 mg/m2 on day 1 (course 1) or day 11 (subsequent courses) Irinotecan 50 mg/m2 on day 1, 8, and 15 (course 1) or day 11, 18 and 25 (subsequent courses).~Capecitabine will be administered from day 1 to day 10 PO starting on course 2."
45975354|NCT00285909|Behavioral|Alcohol: 25 gday (white wine)|
45975355|NCT00285948|Device|Primary Birmingham hip resurfacing arthroplasty using a metal-on-metal couple|
45458613|NCT01362374|Drug|Paclitaxel|Paclitaxel at a dose of 90 mg/m^2 as IV infusion over 1 hr will be administered on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
45830417|NCT01584648|Drug|Dabrafenib|Dabrafenib 150 mg twice daily
45830418|NCT01584648|Drug|Trametinib|Trametinib 2 mg once daily
45830419|NCT01584648|Drug|Trametinib placebo|Dabrafenib 150 mg twice daily and trametinib placebo
45830420|NCT01559454|Drug|Methadone|10-60 mg/day divided by 2-4 times a day for 6 months
45830421|NCT01559454|Drug|Buprenorphine/naloxone|4-16 mg/day divided by 2-4 times a day for 6 months
45830422|NCT03028584|Behavioral|Survey|Subjects (cancer patients and clinicians) will complete up to 2 surveys.
45830423|NCT01584024|Device|Resin infiltration|"Baseline treatment of one caries lesion with resin infiltration therapy, in addition to preventative measures and behavioral modification.~ICON product: FDA-510(k): K100062"
45975356|NCT00250055|Procedure|Colposcopy, Spectroscopy, and Biopsy|During the colposcopy or LEEP (Loop Electrical Excision Procedure) procedure, or during pelvic exams before surgery after the doctor applies 3% acetic acid to the cervix, the doctor then positions the colposcope to take pictures of the patient's cervix. Digital pictures are taken of the patient's cervix under white light using a colposcopy imaging system. These pictures are annotated by the doctor during the appointment to mark the spectroscopy sites.
45975357|NCT00279357|Procedure|Narrow Band Imaging|
45975358|NCT00250094|Drug|Topotecan and VP16|"Course 1A: On day 1 treatment will start with a continuous infusion of TPT at 0.4 mg/m2/day for 21 days. A pump will be used to deliver the TPT. The bag in the pump will be replaced every week for sterility precautions.~Course 1B: On day 28, if ANC is >1,500 and platelets > 100,000, VP-16 will be administered orally at 50 mg/day for 14 days."
45975359|NCT00285987|Procedure|Reconstruction of the cruciate ligament|
45975360|NCT00250133|Procedure|Blood draws|
45975361|NCT00279435|Drug|visilizumab|
45975362|NCT00286026|Drug|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg. One dose vs 2 doses given 30 days apart.
45975363|NCT00250172|Drug|[C-11](R)-rolipram|
45975364|NCT00279474|Behavioral|cognitive-behavior groups|
45975365|NCT00286065|Drug|AeroLEF|
45975366|NCT00250211|Procedure|Functional MRI imaging and tomotherapy|
45975367|NCT00279513|Drug|Traumeel S|
45975368|NCT00250250|Drug|ZOMACTON|
45975369|NCT00279552|Drug|Recombinant human intrinsic factor|
45975370|NCT02961608|Drug|Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)|Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)
45975371|NCT00286104|Device|Antibiotics-impregnated ventricular catheter (Bactiseal®)|Antibiotics-impregnated ventricular catheter (Rifampicin- and Clindamycin-impregnated)
45975372|NCT00286104|Device|Plain ventricular catheter (Codman EDS II/III)|Plain ventricular catheter
45975373|NCT00250289|Device|a mucosal sticker with herbal formula|
45975374|NCT00286143|Drug|Fentanyl|Fentanyl is added to epidural Bupivacaine to be administered to neonates having thoracotomy for lung resections.
45975375|NCT00250328|Device|LapCAC Laparoscopic Compression Anastomosis Clip|
45458614|NCT01142011|Drug|Belimumab|"The first cycle of Belimumab (10mg/kg by intravenous (IV) infusion) is a loading cycle of 3 doses over 28 days (days 1, 15, 29). After the first cycle, additional cycles of belimumab (10mg/kg by intravenous (IV) infusion) will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles).~The infusion will be administered over a minimum period of 1 hour."
45975376|NCT00286260|Drug|levetiracetam|Levetiracetam tablet 500 mg, daily dose titrated to 3000 mg, 6 weeks
45975377|NCT00250367|Drug|risperidone|
45975378|NCT00279630|Procedure|Orthoses and Exercise|orthrose and exercise - daily
45975379|NCT00250406|Device|Ureteral Stent|triclosan-eluting ureteral stent
45975380|NCT00250406|Device|Ureteral Stent|Percuflex Plus Stent as the control
45975381|NCT02960841|Other|Intracavitary Manual Lymphatic Drainage|
45975382|NCT02960841|Other|Conventional treatment|
45975383|NCT04720235|Device|Lucira COVID-19 All-In-One test kit|"The Lucira COVID-19 All-In-One Test Kit is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 in nasal swab samples. This test is a single-use test kit that determines whether there is active shedding of the virus which causes COVID-19. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA.~Positive results are indicative of active infection with SARS-CoV-2. Persons who test positive should self-isolate and seek care from their healthcare provider.~Negative results do not preclude SARS-CoV-2 infection. Persons who continue to experience COVID-like symptoms should seek follow up care from their healthcare provider"
45975384|NCT00279669|Procedure|Ultrasound examination|contact ultrasound examination
45975385|NCT02960724|Other|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan.
45975386|NCT00250562|Drug|valsartan plus hydrochlorothiazide|
45975387|NCT00286299|Other|Aerobic high-intensity interval training (AIT)|The AIT group trains 4x4 minute interval training on a treadmill at 85-95 % HRpeak interspersed with 3 minutes of active resting periods at a work load corresponding to 70% HRpeak between each interval. All training sessions are monitored and start with a 6 minute warm-up and end with a 5 minute cool-down period at a work load corresponding to 70% HRpeak. Intervals are performed walking or running on a treadmill with a minimum of 5% inclination, 3 times per week for 8 weeks.
45975388|NCT00286299|Other|Computer game training (CG)|The CG spend the same amount of time (36 minutes), training to improve their ability in the computer game, Tetris. Tetris is a game where small shapes called Tetraminoes fall from the top of the Playfield to the bottom. Players must rotate the Tetraminoes as they fall and fit them together to complete lines. When the player fills an entire line with blocks, that line is removed from the screen. If the player cannot complete lines, the blocks will eventually rise past the top of the screen, and the game ends.
45975389|NCT00286299|Other|Maximal strength training|Training starts with a 10 minute warm-up on the treadmill. Maximal strength training is then performed in an inclined leg press machine. The subject lifts 4 maximal repetitions that are repeated 4 times after a 2 minute rest period. Subjects are instructed to lift the weight with an intention of maximal mobilization of force. Training load is increased each time the subject manage to perform 4x4 maximal repetitions. Training is carried out 3 times per week in 8 weeks.
45975390|NCT02960880|Drug|Rivaroxaban (Xarelto, BAY597939)|15mg, 20mg
45975391|NCT02960880|Drug|Phenprocoumon (branded and generics)|Individually adjusted dose
45975392|NCT00279747|Drug|meloxicam 0.25 mg/kg|
45975393|NCT00279747|Drug|meloxicam 0.125 mg/kg|
45975394|NCT00279747|Drug|naproxen 10 mg/kg|
45975395|NCT00250601|Drug|Saredutant succinate (SR48968C)|
45975396|NCT00286377|Drug|prosaptide|
45975397|NCT02961686|Radiation|Patients affected by prostate cancer|Patients affected by prostate cancer and treated with a multidisciplinary approach: it includes exclusive radiotherapy, psychological and andrologic evaluation.
46082182|NCT02737644|Other|observation|This is an observational study
46082183|NCT02804360|Device|dexamethasone injection|intravitreal dexamethasone in retinitis pigmentosa cystoid macular edema
46082184|NCT02727738|Dietary Supplement|Selenium|Selenium 80 mg bid for 90 days
45975398|NCT00250640|Drug|Iloprost (Ventavis, BAYQ6256)|The recommended dose is 2.5 micrograms or 5.0 micrograms of inhaled iloprost (as delivered at the mouthpiece of the nebuliser). Dosing should follow the recommendations of the current package leaflet
45975399|NCT00250796|Drug|Thalidomide, alpha interferon|If the patient SSR status is negative, patients will not be given subcutaneous injections of octreotide (Sandostatin LAR) but will receive the thalidomide and alfa interferon only.
45975400|NCT00250796|Drug|Thalidomide, interferon, Octreotide|If SSR status is positive or unknown, patients will receive oral doses of thalidomide starting at 200mg a day and increasing to 800mg at increments of 200 per week depending on tolerance. They will also receive injections three times a week of alpha interferon and monthly injections of octreotide (Sandostatin LAR) 30 mg into their buttocks muscle..
45975401|NCT00286416|Drug|omalizumab (Xolair)|
45975402|NCT00279786|Procedure|Blood draw|blood drawn
45975403|NCT00250874|Drug|Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab|
45975404|NCT00279825|Drug|IPX054 200 mg|IPX054 tablet containing 50 mg carbidopa and 200 mg levodopa
45975405|NCT00279825|Drug|IPX054 250 mg|IPX054 tablet containing 62.5 mg carbidopa and 250 mg levodopa
45975406|NCT00279825|Drug|CD-LD IR|Active comparator containing 25 mg carbidopa and 100 mg levodopa
45975407|NCT00279825|Drug|CD-LD CR|Active comparator containing 50 mg carbidopa and 200 mg levodopa
45975408|NCT00279825|Drug|IPX054 200 mg Placebo|Placebo to match IPX054 200 mg
45975409|NCT00279825|Drug|IPX054 250 mg Placebo|Placebo to match IPX054 250 mg
45671012|NCT01717456|Behavioral|Pelvic floor muscle exercises|Patients will be taught how to perform pelvic floor muscle contractions during digital rectal examination by a nurse. They will be asked to squeeze 100 times daily.
45830424|NCT01584024|Device|Sham treatment|Baseline treatment of one caries lesion with sham treatment, in addition to preventative measures and behavioral modification.
45830425|NCT01583166|Drug|Bupivacaine|10ml 0.5% bupivacaine
45830426|NCT01583166|Drug|Saline|10ml 0.9% sodium chloride
45830427|NCT01583166|Drug|Epinephrine|1:200,000 epinephrine
45830428|NCT01535274|Other|Inspired oxygen fraction / end tidal carbon dioxide|"Following induction of anesthesia, FIO2 and minute ventilation will be sequentially adjusted to achieve:~FIO2 30% (70% nitrogen), PETCO2 30mmHg - supine position.~FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position.~FIO2 100%, PETCO2 30mmHg - beach chair position.~FIO2 100%, PETCO2 45mmHg - beach chair position.~FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position."
45830429|NCT01558752|Device|Total hip replacement with titanium shell and CORAIL stem|Patients that are randomized into Group 1 will receive a total hip replacement with the following components: CORAIL (impaction broach) titanium stem and a monoblock cup with ceramic on ceramic bearing (DELTA motion).
45830430|NCT01558752|Device|Total hip replacement with Modular Titanium Femoral Stem|Patients that are randomized into Group 2 will receive a total hip replacement with the following components: the Trilock-Pinnacle system (titanium stem and titanium cup with polyethylene insert).
45975410|NCT00279825|Drug|CD-LD IR Placebo|Placebo to match CD-LD IR
45975411|NCT00279825|Drug|CD-LD CR Placebo|Placebo to match CD-LD CR
45975412|NCT00250913|Behavioral|Telephone-based physical activity counseling program|
45458615|NCT02319460|Biological|Kcentra®|Kcentra®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product that contains coagulation Factors II, VII, IX and X, and antithrombotic Proteins C and S as a lyophilized concentrate.
45975413|NCT00250952|Drug|Botox Cosmetic™|
45975414|NCT00250991|Drug|activase|
45458616|NCT02319460|Biological|Plasma|
45671013|NCT01717456|Behavioral|Tips on how to prevent fecal incontinence|"Examples of behavioral tips are Walk, don't run to the toilet and Squeeze before you lift objects or sneeze."
45671014|NCT01717456|Behavioral|Daily diary|Both groups will keep a daily diary, but amount of detail differs: Active comparator group records bowel accidents, bowel movements, Bristol Stool ratings of stool consistency, number of times they do pelvic floor exercises, study medications, and comments for the nurse to read. Placebo comparator group records only bowel accidents, bowel movements, and Bristol Stool scores.
45830431|NCT01582854|Drug|Actovegin|Actovegin solution for infusion and Actovegin tablets
45830432|NCT01582854|Drug|Placebo|Actovegin placebo-matching solution for infusion and Actovegin placebo-matching tablets
45975415|NCT00250991|Drug|integrilin|
45975416|NCT00416754|Other|counseling intervention|subjects will receive genetic counseling
45975417|NCT00286611|Procedure|Blood and salivary sampling of amifostine|Sampling of blood and saliva to test for amifostine levels.
45975418|NCT04719962|Procedure|Targeted proteomics in skin +/- cerebrospinal or synovial fluid to diagnose disseminated Lyme disease|"Following a 2-days course of local daily clobetasol propionate 0,05% cream application, a skin biopsy (3 mm punch-biopsy ) of healthy-looking skin of the upper part of the thigh will be performed in all patients,.~Arthrocentesis (in patients with Lyme arthritis only) and lumbar puncture to collect cerebrospinal fluid (in patients with neuroborreliosis only) will be performed in the usual care setting as appropriated.~All biological samples will be subject to Borrelia culture, PCR and SRM-MS proteomics."
45975419|NCT00416832|Drug|cyclophosphamide|
45975420|NCT00416832|Drug|dacarbazine|
45975421|NCT00416832|Drug|doxorubicin hydrochloride|
45975422|NCT00416832|Drug|etoposide|
45975423|NCT00416832|Drug|prednisone|
45975424|NCT00416832|Drug|procarbazine hydrochloride|
45975425|NCT00416832|Drug|vincristine sulfate|
45975426|NCT00416832|Radiation|radiation therapy|
45975427|NCT00251030|Drug|Nelfinavir and Omeprazole|
45975428|NCT00286650|Procedure|3rd molar teeth extraction|
45975429|NCT00251069|Drug|Glucosamine sulphate|
45975430|NCT02214160|Drug|UX007|Administered orally (PO) with food or by gastrostomy tube, at the target dose range of 25-35% of total calories.
45975431|NCT00286689|Drug|Growth Hormone|
45975432|NCT00286689|Procedure|Whole body Protein turnover|
45975433|NCT00286689|Procedure|DEXA scan|
45975434|NCT02961491|Drug|Ultratrace Iobenguane I131|Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 whole body scans. If the scans indicate tumor avidity for AZEDRA, the subjects will receive up to 2 therapeutic doses of AZEDRA each at 500 mCi (or 8 mCi/kg, for subjects weighing 62.5 kg or less) approximately 90 days apart.
45975435|NCT01640002|Drug|Propantheline Bromide|15MG OF PROPANTHELINE BROMIDE, THREE TIMES DAILY FOR 02 MONTHS.
45975436|NCT01640002|Drug|Placebo|PLACEBO CAPSULE, 03 TIMES DAILY FOR 02 MONTHS
45975437|NCT01640041|Device|Radio-frequency Microstiumulator|All participants will receive leg implants and will be trained first in the clinical and subsequently perform stimulation-assisted exercises in the home - for an overall duration of 6 months post-implant. Subsequently, exercise programs will continue without stimulation. Patient condition will be assessed at 9, 12 and 24 months post-implant.
45975438|NCT00279903|Drug|Botulinum toxin type A (Btx-A)|Participants randomized to Btx-A will be given either a low dose of 100 units or a high dose of 200 units. The Btx-A dose (100U or 200U) will be resonstituted with 4 cc of sterile non-preserved 0.9% sodium chloride solution.
45975439|NCT00279903|Drug|Cortisone|1 cc of 40 mg/cc methylprednisolone will be drawn up in 22 gauge needles with 3 cc of sterile non-preserved 0.9% sodium chloride solution.
45975440|NCT02961452|Other|Cross reaction detection|
45975441|NCT01640275|Drug|Propofol|patients randomized to the propofol arm of the study will receive general anesthesia with propofol
45975442|NCT01640275|Drug|Isoflurane|patients randomized to the isoflurane arm of the study will receive general anesthesia with isoflurane
45975443|NCT01640392|Behavioral|MyLife MyStyle group-level intervention|Three 1.5-hour HIV behavioral risk-reduction group sessions conducted with up to 12 young African American/Black men (ages 18-29 years) over a 1-3 week period.
45975444|NCT01640470|Device|Assistive Technology Provision and Tune-Up Intervention|"The home based AT Provision, Updating and Tune-Up (ATPUT) Intervention will consist of 5 components: 1) identification and prioritization of problematic activities by the assistance user and his/her principal, cohabitating caregiver; 2) in-residence assessment of the daily activities and social participation and preferences of the assistance user; 3) detailed review of the AT and human assistance that are currently being used; 4) recommendations by an occupational therapist for possible changes in the personal assistance strategy; 5) negotiation of an ATPUT Personal Plan with the assistance user and her/his principal caregiver.~The intervention occurs over a six week period and involves 3 to 6 visits from an occupational therapist."
45975445|NCT01640470|Device|Customary Care|Participants in the customary care group receive normal occupational therapy services.Occupational Therapy
45975446|NCT01640509|Radiation|treated by synchrotron radiation|treated by synchrotron radiation
45975447|NCT04719923|Behavioral|Children with autism spectrum disorders|Subjects affected by autism spectrum disorders
45975448|NCT04529356|Device|Transcranial magnetic stimulation|By using different frequency of TMS, the device can generate different effects. For low frequency, such as 1HZ, it mainly generates inhibition on the brain cortex; while high frequency (usually higher than 10HZ) can generate stimulation effects. The later one could be used to treat different central nervous disease.
45975449|NCT04529356|Drug|Acetaminophen|Acetaminophen is used as the painkiller to alleviate patients' headache before and during the clinical trial. In order to decrease the medication bias, we required these patients to only use acetaminophen instead of other non-steroid anti-inflammatory drugs. In the meantime, participants are requested to recorder the frequency and dosage of acetaminophen they used during the treatment course.
45671015|NCT01717456|Other|Protective pads or garments|In both groups, patients will be permitted to use pads or protective garments to avoid embarrassment. They will be told that fecal leakage that is stopped by a pad or protective garment should still be recorded as fecal incontinence.
45671016|NCT01699750|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses, Phase 2
45671017|NCT01699750|Device|Senofilcon A contact lenses|Silicone hydrogel contact lenses, Phase 2
45830433|NCT03884400|Procedure|Specimens obtained from surgical, phlebotomy or other non-invasive procedure|Biospecimen Collection
45830434|NCT04102644|Other|Observation|Documentation of course and outcome of hospitalization, labor, delivery, and postpartum period
45830435|NCT01582308|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
45975450|NCT04529083|Device|Mr. MAPP|Mixed reality device to provide virtual mirror therapy to patients with phantom pain
45975451|NCT01640626|Other|Health Education package|Health Education package that covers key health messages about the proper personal hygiene practices will be given to school children in the intervention school. The package consisted of many items such as posters, comic book, song video, competitions, drawing activities, puppet show, etc.
45975452|NCT00279942|Dietary Supplement|Soy|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
45975453|NCT00279942|Other|Placebo|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
45975454|NCT01640665|Drug|Sorafenib|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses.
45975455|NCT01640665|Drug|Capecitabine|Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days.
45830436|NCT01582308|Drug|Saxagliptin 5 mg|Saxagliptin 5 mg: one saxagliptin 5 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
45975456|NCT00251108|Procedure|Cardiorespiratory fitness training|
45975457|NCT01640704|Behavioral|Computerized reminders about treatment guidelines to providers who care for hypertensive patients|
46082185|NCT02727738|Drug|Methimazole|Methimazole starting dose depending on FT3 values (15 mg/day or 20 mg/day or 30 mg/day, for FT3 values <10 pg/ml, 10-15 pg/ml, >15 pg/ml, respectively) to be tapered by 5 mg/day every 15 days down to values sufficient for FT3 to be normal
45671018|NCT01699750|Device|OPTI-FREE® PUREMOIST® MPDS|Contact lens care system, Phase 2
45671019|NCT01699750|Device|BIOTRUE®|Contact lens care system, Phase 2
45671020|NCT01699750|Device|Balafilcon A contact lenses|Silicone hydrogel contact lenses worn for 30 days, Phase 1
45671021|NCT01699750|Device|ReNu® Multiplus®|Contact lens care system used for 30 days, Phase 1
45671022|NCT01716754|Drug|QGE031|QGE031 was supplied as 120 mg liquid in vial per 1 mL
45671023|NCT01716754|Drug|Omalizumab|Omalizumab was supplied as 150 mg lyophilisate in vial
45671024|NCT01716754|Drug|Placebo|Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL
46082186|NCT02804048|Other|superficial heat pelvic floor muscle|Superficial heat application in the pelvic floor muscle
45671025|NCT01698814|Drug|AL-4943A Ophthalmic Solution|
45671026|NCT01698814|Drug|AL-4943A Ophthalmic Solution Vehicle|Inactive ingredients used as placebo
45671027|NCT01738984|Behavioral|MomZing Web Program|Online web platform that is accessed via a television connected to internet
45458617|NCT04722952|Drug|Visilizumab|Azacytidine 75mg/(m2.d) by IV on days 1-7 of every cycle. Anti-PD-1 mAb 200mg by IV on day 8 of every cycle. Homoharringtonine(HHT) 2mg/(m2.d) by IV on days 1-6 of every cycle Cytarabine 10mg/(m2.d) by SC on days 1-7 of every cycle Granulocyte colony-stimulating factor(G-CSF) 300ug/d by SC on days 1-7 of every cycle，until absolute neutrophil count(ANC) > 5X109／L or white blood cell（WBC）> 20X109／L.
45671028|NCT01738984|Behavioral|Standard Exercise DVD|Standard exercise DVD that demonstrates exercises a women does with an infant.
45671029|NCT01738594|Drug|carfilzomib|Given IV
45671030|NCT01738594|Drug|romidepsin|Given IV
45671031|NCT01738594|Other|laboratory biomarker analysis|Correlative studies
45671032|NCT01738438|Drug|Cabozantinib|
45671033|NCT01716520|Device|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
45671034|NCT01716520|Device|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
45671035|NCT01716520|Device|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
45671036|NCT04548310|Other|Muscles Fatigue|An exhaustion protocol that reduces knee joint flexor and extensor torque will be applied.
45671037|NCT04548232|Procedure|Laparoscopic sleeve gastrectomy|bariatric surgery
45975458|NCT01640782|Drug|Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin|"Irinotecan (CPT-11) 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by~Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 4 administrations.~After 3 weeks from last infusion:~Docetaxel (TXT) 75 mg/m2, given as a 1h i.v. infusion on day 1 followed by~Cisplatin (CDDP) 75 mg/m2, given as a 1h i.v. infusion on.day 1, every 3 weeks, for 3 cycles."
45975459|NCT01640782|Drug|Leucovorin, 5-Fluorouracil|"Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 9 administrations."
45671038|NCT01698268|Procedure|TAP block|TAP Block will be performed under ultrasound guidance via Sonosite device with an in-plane technique by the anesthesiologist.
45671039|NCT01698268|Procedure|Local Infiltration|Local infiltration of 0.5 cc/kg of 0.25% ropivacaine will be administered by the surgeon.
45671040|NCT04555564|Procedure|Technicium 99 MAA infusion|4mci of Technicium 99 MAA will be infused into the bronchial artery via a catheter prior to a standard therapy (bronchial artery embolization). The patient will undergo nuclear medicine imaging following this intervention to quantify MAA distribution within the lung tumor and adjacent lung tissue.
45830437|NCT01582308|Drug|Vildagliptin 50 mg|Vildagliptin 50 mg: one vildagliptin 50 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
45830438|NCT01582308|Drug|Vildagliptin 50 mg BID|Vildagliptin 50 mg BID: one vildagliptin 50 mg tablet BID (twice daily), once in the morning following a fast of at least approximately 8 hours and once in the evening on Days 1 through 5 in one out of five treatment periods.
45830439|NCT01582308|Drug|Placebo|Placebo: one placebo for sitagliptin tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
45830440|NCT01558674|Drug|MK-7145|
45975460|NCT00279981|Device|Diagnostic|
46082187|NCT02804048|Other|superficial heat low back|Superficial heat application in the low back
46082188|NCT02804048|Other|Pelvic Floor Muscle Training|Pelvic floor muscle training exercises
46082189|NCT02804048|Other|Manual therapy in iliopsoas, diaphragm and piriformis|Manual therapy in iliopsoas, diaphragm and piriformis for 10 minutes
45671041|NCT04555330|Device|Physical activity measurement|"To assess physical activity two small tri-axial accelerometers embedded in medical Band-Aids will be used. The accelerometers are discretely worn on the lateral aspect of the thigh.~The accelerometers sample accelerations continuously during hospitalisation and are connected wirelessly to a tablet that via an inbuilt algorithm classify the recordings as bedridden (lying down), sitting, standing, and walking."
45671042|NCT04555330|Device|Visual Feedback|The tablet will be placed on the patients bedside table and provides feedback on the amount of physical activity and motivational imagesand texts that will be visible for the patients, the health care staff and visitors.
45456070|NCT05065918|Behavioral|sexual violence and alcohol use harm reduction text message content|The multi-target sexual violence harm reduction and alcohol use intervention will use a similar model to the alcohol use reduction intervention previous developed and implemented. Students will be: 1) queried via TM prior to typical drinking days regarding both alcohol use and SV harm reduction goal setting; 2) provided with goal reminders during drinking period; and 3) assessed for goal attainment and given feedback following drinking episodes. As with the control condition, post-drinking assessment happens weekly on Sundays. Monday thru Saturday participants will randomly receive or not receive one appropriate message pathway from the message library using the pre-determined pathways for messages.
45458618|NCT05187572|Behavioral|Group intervention|This intervention was developed during 14 sessions, held twice a week, with a duration of 45 to 60 minutes each. The sessions were developed as group-based interventions, facilitated by a leader and a co-leader from each community institution.
45458619|NCT01352390|Behavioral|Planning Prompt|A prompt to have their child their health test reminder mailing to color
45458620|NCT01352390|Behavioral|Control Condition|A basic reminder mailing will prompt each subject to get a health test as specified on the mailing
45458621|NCT02319538|Procedure|Total thyroidectomy performed|Surgery combined with standard thyroxine treatment
45671043|NCT01697956|Drug|BDP|Beclomethasone dipropionate (BDP) 80 mcg/day (40 mcg/spray, 1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
45671044|NCT01697956|Drug|Placebo|Placebo (1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
45671045|NCT01697800|Drug|Tadalafil|
45671046|NCT01697800|Drug|Placebo|
45671047|NCT04553770|Drug|Anastrozole|Given PO
45671048|NCT04553770|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45671049|NCT04553770|Biological|Trastuzumab Deruxtecan|Given IV
45671050|NCT01644500|Drug|Dulaglutide|Administered SC
45671051|NCT01644500|Drug|Glimepiride|Administered orally
45671052|NCT01644500|Drug|Placebo as Capsules|Placebo for glimepiride is administered orally as one to three capsules daily.
45671053|NCT01644500|Drug|Placebo as SC Injection|Placebo for dulaglutide is administered as one SC injection.
45830441|NCT01558674|Drug|Furosemide|
45830442|NCT01558674|Drug|Torsemide|
45830443|NCT01558596|Procedure|Preconditioning|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
45830444|NCT01558596|Procedure|Control|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
45830445|NCT01535040|Drug|memantine hydrochloride|Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.
45975461|NCT00251147|Procedure|Open acromioplasty with rotator cuff repair|A standard vertical incision was made over the anterolateral aspect of the acromion. The deltoid muscle was split and stripped off the anterior aspect of the acromion. The anterior and inferior aspect of the acromion was removed. The coracoacromial ligament was excised. Repair of the tear in the cuff tendon(s) was accomplished by suturing leading edge of the tear into the greater tuberosity of the humerus at or near the original site of insertion of the cuff to bone. Trans-osseous sutures, suture anchors and tendon to tendon suture repair techniques were employed for a secure repair with the arm at the side. The surgeon was allowed to use whatever method(s) to create a secure repair. The deltoid was securely reattached to the acromion with the deltoid fascia repaired down the split.
45671054|NCT04877834|Drug|Dexlansoprazole|Dexlansoprazole capsule prepared by SAMI Pharmaceuticals will be administered to this arm.
45975462|NCT00251147|Procedure|Arthroscopic acromioplasty with mini-open repair|A standard arthroscopic gleno-humeral arthroscopy was performed followed by an arthroscopic acromioplasty. Three standard arthroscopic portals were used. The lateral portal was centered in line with the cuff tear, and incorporated into the mini-open incision. Initially, a partial bursectomy was performed to improve visualization. The inferior surface of the anterior acromion and the coracoacromial ligament were removed. Following the arthroscopic acromioplasty, a 3-4cm lateral incision was performed in the area of the lateral portal. The deltoid muscle was split longitudinally to expose the tear in the rotator cuff. The tear was repaired in a similar manner to the open repair with tendon to tendon sutures, trans-osseous sutures and with suture anchors.
45975463|NCT01640821|Behavioral|CdM? program|The program is conducted in small groups of 12 to 15 women for 14 weekly sessions (13 3h-evening sessions and 1 intensive-day session of 6 hours). Two health professionals (a registered dietician and a social worker or psychologist) lead the group. Sessions include lectures, guided self-examination and observations, group discussions, and practical exercises. Different topics are discussed during sessions such as enjoyment of physical activity and healthy nutrition, setting realistic objectives with regard to weight loss, and acceptation of their own and others' body image. A weekly food diary and group discussions are used to facilitate the recognition of internal cues of hunger and satiety and the identification of external influences on eating behaviors and food intake.
45975464|NCT01640977|Procedure|Open PLIF (posterior lumbar interbody fusion)|The PLIF procedure achieves access to the degenerated disc from the back of the spine.
45975465|NCT01640977|Procedure|MAS PLIF|The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach.
45671055|NCT04877834|Drug|Dexlansoprazole|Dexlansoprazole capsule prepared by Takeda Pharmaceutical Company will be administered to this arm.
45975466|NCT00251186|Drug|Capecitabine and Cetuximab|
45975467|NCT01641172|Procedure|Dexa scan|"the DEXA scan to measure bone and fat will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have a DEXA scan at baseline, 1 month after the end of chemotherapy and after 1 year."
45975468|NCT01641172|Procedure|audiogram|"the audiogram will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an audiogram at baseline, 1 month after the end of chemotherapy and after 1 year."
45975469|NCT01641172|Procedure|measurement of heart rate variability and baroreflex sensitivity|"the measurements (continuous assessment of heart rate and blood pressure using an non-invasive Finapress device) during 30 minutes will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have those measurements taken at baseline, 1 month after the end of chemotherapy and after 1 year."
46082190|NCT02804048|Other|Intra Vaginal Manual therapy|Intra Vaginal Manual therapy in the pelvic floor muscles
46082191|NCT02804048|Other|Electromyographic biofeedback|Electromyographic biofeedback in the pelvic floor muscles
45456071|NCT05065918|Behavioral|alcohol use reduction content|"The control condition will be a previously tested TM-delivered alcohol use reduction intervention. Prior to typical drinking occasions, individuals planning a drinking event are prompted to consider committing to a drinking limit goal, i.e.: Would you be willing to set a goal to drink less than X drinks when drinking?. Based on willingness to commit to the goal, a feedback message is provided. During typical drinking periods, individuals receive a goal reminder. Each week, the program provides goal success/failure feedback or drinking quantity feedback. For example, those occasions where an individual committed to a drinking limit goal triggers either messages to reinforce goal successes or reframe goal failures. When an individual did not commit to a drink limit goal, they are provided feedback based on alcohol quantity (e.g. high risk drinking feedback)."
45456072|NCT05059652|Device|Ischemic Preconditioning|The Ischemic Preconditioning (IPC) is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff.
45830446|NCT01535040|Drug|placebo|Placebo by mouth through completion of 12 weeks.
45830447|NCT04410510|Drug|P2Et (Caesalpinia spinosa extract)|P2Et active extract capsule equivalent to 250mg of P2Et every 12 hours for 14 days + Standard Care
45830448|NCT04410510|Other|Placebo|Placebo capsule equivalent to 250mg of excipients of P2Et every 12 hours for 14 days + Standard Care
45830449|NCT04767672|Dietary Supplement|Non digestible carbohydrates|the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
45975470|NCT01641172|Procedure|Glucose tolerance assessment|"Glucose tolerance will be assessed by drinking glucose water and measuring glucose at baseline and 2 hours later. It will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an assessment at baseline, 1 month after the end of chemotherapy and after 1 year."
45975471|NCT01641172|Dietary Supplement|oral nutrition supplements|a set of 10 Oral Nutrition Supplements (ONS) will be offered combined with a questionnaire to measure appreciation and preference for these food products. All these tests and questionnaires will be performed longitudinally (before the first chemotherapy, on day 7 of the first course, before the second course, on day 7 of the second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy) and cross-sectional (1, 3, 5 and 7 years after chemotherapy).
45975472|NCT01641172|Behavioral|Two day food records|Two day food records will be used to investigate the actual dietary intake before the first and second course, during (on day 5 and 6) first and second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy.
45975473|NCT01641172|Behavioral|Food Frequency Questionnaire|A Food Frequency Questionnaire (FFQ) will be used to investigate the usual dietary intake before the start of the first course, before and after the second course, 1 month after start of the last course, seven months after the start of chemotherapy, and 1 year after the start of chemotherapy (longitudinal), and 1, 3, 5 and 7 years after chemotherapy (cross-sectional).
45975474|NCT00286845|Drug|Standard Chemotherapy|physician determined
45975475|NCT01641211|Behavioral|Meducation device technique video|2-minute video that displays proper inhaler, diskus, and turbuhaler technique. The video will only be watched once at the medical visit. Children in this group will be given a wallet card so they can access the video via the Internet after leaving the asthma clinic.
45671056|NCT05645822|Other|Screen&treat|Study participants will be tested with an RDT to prove the presence of antibodies against Trypanosoma brucei gambiense. Should the RDT be positive, they will be offered the 10-day treatment with fexinidazole, and an additional blood sample will be taken for the post hoc confirmation of the disease.
45671057|NCT05645120|Other|Education|All participants attended to a two-part nutrition education program. The education intervention program was administered in two sessions, one week apart. Before the intervention, a pre-test was administered to determine the knowledge and beliefs attitudes of participants. After the pre-test each session consisted of a PowerPoint presentation of about 20 minutes. Education topics included components of adequate-balanced nutrition and its relationship with COVID-19, introduction of food groups, the association between COVID-19 and dietary supplements, herbal foods in the prevention/treatment of COVID-19, considerations regarding DS/HF, food-drug interactions, and COVID-19 drugs and food interactions. The presentation was concluded with the nutritional recommendations for COVID-19. The post-tests were shared with the participants at the end of the second session of the education intervention.
45671058|NCT01604824|Drug|Alirocumab|SC injection in the abdomen
45671059|NCT01604824|Drug|Placebo|SC injection in the abdomen
45671060|NCT01716052|Drug|placebo|Lactulose
45671061|NCT01716052|Drug|Ibuprofen|
45830450|NCT04767672|Dietary Supplement|Placebo|the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
45830451|NCT01534962|Drug|Ranolazine|Oral administration, BID; for a maximum of 112 days.
45830452|NCT01534962|Drug|Ranolazine|Oral administration, BID; for a maximum of 112 days.
45830453|NCT01534962|Drug|Ranolazine|Oral administration, BID; for a maximum of 112 days.
45830454|NCT01534962|Drug|Placebo|Oral administration, BID; for a maximum of 112 days.
45830455|NCT04758234|Drug|LY3549492|Administered orally.
45830456|NCT04758234|Drug|Placebo|Administered orally.
45830457|NCT01582152|Drug|TPI287|"Phase I Starting Dose: 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle.~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
45830458|NCT01582152|Drug|Bevacizumab|Arm A + B: 10 mg/kg by vein every 2 weeks of a 42 day cycle.
45830459|NCT01581684|Drug|BI 411034|Low dose solution for oral administration
45830460|NCT01581684|Drug|Placebo|Solution for oral administration
45830461|NCT01581684|Drug|BI 411034|Medium dose solution for oral administration
45830462|NCT01581684|Drug|BI 411034|Low dose solution for oral administration
45830463|NCT01581684|Drug|BI 411034|High dose solution for oral administration
45830464|NCT01581684|Drug|BI 411034|High dose solution for oral administration
45830465|NCT01581684|Drug|BI 411034|Medium dose solution for oral administration
45830466|NCT01581684|Drug|BI 411034|High dose solution for oral administration
45830467|NCT01581684|Drug|BI 411034|Medium dose solution for oral administration
45830468|NCT01557582|Device|Ventripoint Medical System|"The subjects will undergo a 2D echocardiography according to standard of care. An additional 5 - 10 minutes of scanning using VMS transducer attached to the echocardiography system to acquire images for 3-D reconstruction is required.~Within one day of the VMS image acquisition the subjects will also undergo cMRI according to hospital standards of care plus an additional 5 minutes to capture the PSSS required images."
45830469|NCT01557504|Drug|Sitagliptin/metformin XR|Fixed dose combination tablet of immediate-release sitagliptin 50 mg and extended-release (XR) metformin 1000 mg (total daily dose, sitagliptin 100 mg and metformin XR 2000 mg).
45830470|NCT01557504|Drug|Placebo|Matching placebo to fixed dose combination tablet of sitagliptin and metformin. Matching placebo tablets are same size, shape and color as the active product, but do not contain any markings.
45830471|NCT01557504|Drug|Metformin|Concomitant use of metformin is permitted during the study provided the participant has been receiving a stable metformin dose for at least 12 weeks prior to the dose of study drug. Administration of metformin will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
45975476|NCT01641211|Other|Nutrition video|Children in this group will watch a 2-minute nutrition video.
45975477|NCT01641250|Drug|RO5429083|Multiple escalating doses
45975478|NCT01641250|Drug|cytarabine|1000 mg/m2 iv daily for 5 consecutive days, up to 4 cycles
45975479|NCT00251264|Procedure|Open stabilization|"Following examination under anesthesia, a 5cm standard deltopectoral incision is made. Dissection is continued exploiting the deltopectoral internervous plane. The conjoined tendon is retracted medially. The underlying subscapularis tendon is identified and incised horizontally or split vertically in its midsubstance. If required for adequate exposure, the subscapularis split may be extended by incising the inferior component of the subscapularis tendon near its insertion on the lesser tuberosity. The shoulder is entered by performing a T shaped arthrotomy with retractors for full exposure of the glenoid. Shoulder pathology is addressed with suture anchor repair of any capsulolabral detachment (ie.Bankart lesion) and/ or a capsular plication for repair of capsular redundancy."
45671062|NCT01641692|Drug|GSK573719 Active treatment or Placebo|Eligible subjects will be randomised to a sequence of three treatments from 8 possible arms: 7 active drug doses (15.6mcg, 31.25 mc, 62.5mcg 125mcg or 250mcg GSK573719 once daily; 15.6mcg or 31.25 mcg GSK573719 taken twice daily) or matched placebo.
45830472|NCT01557504|Drug|Thyroid hormone|Concomitant use of thyroid hormone (eg, levothyroxine) is permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to study drug administration and is euthyroid as documented by thyroid stimulating hormone testing at prestudy. Administration of thyroid hormone will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
45830473|NCT01580670|Drug|TA-650|TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Week 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 46. If the criteria for a dosage escalation are met, TA-650 will be administered at a dosage of 10 mg/kg.
45671063|NCT01641692|Procedure|GSK573719 (Sub-group cohort)|Subjects at selected Sub-group sites (approximately 30% of the total population) will have additional serial assessments and procedures (including blood and urine samples for pharmacokinetic analysis) at the start (Day 1) and at the end (Days 14 and 15) of each treatment period. On Day 14 of each treatment period subjects will remain overnight at the clinic for 24-hour assessments, including spirometry, ECGs, and 24-hour Holter monitoring.
45671064|NCT01641692|Drug|Salbutamol/Albuterol|Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods
45671065|NCT04859816|Other|Metabolic test|Iv and oral administration of stable isotope tracers during fasting and a high-fat liquid mixed meal
45671066|NCT04859816|Other|DXA-scan|Dual energy X-ray Absorptiometry scan of whole-body fat
45830474|NCT04748484|Device|KCC Active or inactive|Depending of the randomization, the KCC will be active or inactive, and will provide heat when active, but the patient won't know if the medical device is active or not. The battery charge indicator will work the same whether the device is operating or not.
45830475|NCT01534260|Drug|sorafenib, vorinostat and bortezomib|Escalating dose cohorts of sorafenib, vorinostat and bortezomib. The first cohort will receive sorafenib from day 1 to 14, vorinostat will be given on days 1-4 and 8-12, and bortezomib will be given on days 1 and 8. This will be followed by 7 days of rest. Therefore each cycle will be 21 days.
45830476|NCT01534182|Drug|Fingolimod|0.5 mg orally once a day
45830477|NCT01534182|Drug|Interferon beta - 1a (IFN)|44 mcg subcutaneously three times a week
45830478|NCT01534182|Drug|Glatiramer acetate (GA)|20 mg subcutaneously once a day
45671067|NCT04859816|Other|MRS|Magnetic resonance spectroscopy of liver fat content
45671068|NCT04859816|Other|Feces collection|4-day feces collection
45671069|NCT01682512|Drug|BI 695500|
45671070|NCT01682512|Drug|BI 695500|
45671071|NCT01682512|Drug|Rituxan®|
45671072|NCT01682512|Drug|Rituxan®|
45671073|NCT01682512|Drug|MabThera®|
45671074|NCT02256488|Biological|TIVc_LOT A|Single IM (Intramuscular) administration dose of 0.5 mL of TIVc
45671075|NCT02256488|Biological|TIVc_LOT B|Single IM administration dose of 0.5 mL of TIVc
45671076|NCT02256488|Biological|TIVc_LOT C|Single IM administration dose of 0.5 mL of TIVc
45671077|NCT02256488|Biological|TIVf|Single IM administration dose of 0.5 mL of TIVf
45975480|NCT00251264|Procedure|Arthroscopic stabilization|With the examination under anesthesia completed, the arthroscope is introduced through a standard posterior arthroscopy portal. A diagnostic arthroscopy is performed and the intraarticular pathology identified and documented. Any labral detachment (i.e. Bankart lesion) is repaired using suture anchor fixation and arthroscopic tying techniques. Capsular redundancy is addressed with the use of thermal electrocapsulorrhaphy or arthroscopic suture repair of the redundant capsule. With the repair complete, 40 cc of 0.5% Bupivicaine is introduced into the joint. A sterile dressing is applied over the wounds and the operated shoulder placed in a shoulder immobilizer.
45975481|NCT01641289|Drug|Paracetamol|>50kg: Paracetamol 1gm PO/NG q6hourly for 72hours and afebrile for 24h (maximum total dose 4g/24 hours) plus intravenous Artesunate <50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72hours and afebrile for 24h (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate
45975482|NCT01641289|Drug|No Paracetamol|"No paracetamol + Intravenous Artesunate~If temperature > 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen."
45975483|NCT01641328|Behavioral|Cogntive Activation Training|Mindfulness-based stress reduction - 30 minutes / class x 3 classes / week; optional home practice Tai Chi - 30 minutes / class x 3 classes / week; optional home practice Computer-based cognitive training - 20 minutes / class x 3 classes / week; optional home practice
45975484|NCT01641328|Behavioral|Waitlist Control / Home-based training|Computer-based cognitive training - 20 minutes / day Daily walking - 20 minutes / day Biofeedback relaxation Training - 20 minutes / day
45975485|NCT00280020|Behavioral|Tai Chi Chih (TCC)|Participants will learn and practice 20 movements in 1 hour sessions twice per week for 16 weeks
46082192|NCT02737488|Behavioral|Trauma Systems Therapy (TST)|Treatment will be delivered by clinicians and trainees working at the CSC who have been trained in delivering TST. Participants who begin treatment in the safety-focused phase will have their treatment sessions in their homes. Whenever a child enters a different phase of treatment, he or she will go to the site for office visits. At the beginning of treatment, TST clinicians will do a brief diagnostic assessment. All documentation that is completed by the clinician as part of TST treatment at the NYU Langone Medical Center will be documented using Epic, a standard of care integrated health information system for patient safety. Although we are not providing the CSC's standard of care in this study,we are replicating standard care as TST is standard care in other settings. Providing medication is part of standard TST treatment and conforms to good usual practice integrated with psychotherapy. Medication will not be prescribed for research purposes.
45671078|NCT05560646|Drug|OG-6219|OG-6219 Dose 1, Dose 2, Dose 3 BID: Participants will receive (orally) OG-6219 during treatment cycles.
45671079|NCT05560646|Drug|Placebo|Participants will receive (orally) OG-6219 Placebo tablets BID during treatment cycles.
45671080|NCT05558384|Behavioral|Aerobic Exercise|"A 15-week standardized aerobic exercise intervention.~Frequency: 5 days/wk (2 supervised)~Intensity: 50-59% heart rate reserve~Time: 40 min/session (ramp up from 25-40 during first 4 weeks)~Type: Aerobic exercise (e.g. treadmill, walking/jogging, cycling, elliptical)"
45830479|NCT01579812|Drug|Metformin|"Patients receiving primary surgical debulking followed by adjuvant chemotherapy will initiate metformin prior to primary surgery. Following surgery patients will be initiated on metformin prior to the initiation of chemotherapy.~Patients treated with neoadjuvant chemotherapy will be initiated on metformin prior to the initiation of chemotherapy. Following surgery patients will be initiated on metformin prior to the re-initiation of chemotherapy."
45975486|NCT00280020|Behavioral|Cognitive Behavior Therapy (CBT)|For each 2-hour session held once a week for 16 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
45671081|NCT05644886|Behavioral|FP Training and Technical Support|Same as in Intervention arm description
45671082|NCT04863794|Drug|RO7248824|A single dose of 10 mg RO7248824 will be used for this PET study in healthy participants.
45975487|NCT00280020|Behavioral|Sleep Seminar (SS)|Each 2-hour session, held once a week for 16 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion.
45975488|NCT01641406|Drug|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER-(Triple Negative and ER-PR+Her-2-):Patients who respond to the first 4 courses of TEC with a Complete Remission will receive 4 more courses of TEC. Patients who respond to the first 4 courses of TEC with a Partial Remission or Stable Disease will then have their treatment changed to the non-cross resistant NAX regimen.Courses will be repeated every 21 days according to blood counts.A total of 4 courses will be given.
45671083|NCT04863716|Procedure|Erector Spinae Plane Block|Erector Spinae Plane Block will be administered before the surgery.
45671084|NCT04863716|Procedure|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
45671085|NCT05644418|Device|Flow Controlled Ventilation (FCV)|FCV is started with the same settings as PCV (PEEP, Ppeak, FiO2) and after 30 minutes FCV is optimized concerning the driving pressure and PEEP using the dynamic compliance. After a total of 60 minutes the flow is adjusted based on the arterial blood gas.
45830480|NCT01533714|Biological|CDP6038 (olokizumab)|Biological/Vaccine: CDP6038 (olokizumab) 100 mg/mL solution for subcutaneous (sc) injection
45830481|NCT01533246|Drug|linsitinib|Oral Linsitinib 150mg, twice a day, days 1- 28
45975489|NCT01641406|Drug|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|"Her-2 positive cases:Patients who respond to 4 courses of TEC with either a partial or complete remission will then receive 4 additional courses of Docetaxel plus Herceptin, and upon completion of the 4th course of DH they will undergo definitive surgery.A total of 4 courses will be given. Courses will be repeated every 21 days according to blood counts. Patients whose response after 4 courses of TEC is either stable disease or progression, will be treated with NTX."
45975490|NCT01641406|Drug|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER+ Cases(ER+PR+Her-2- and ER+PR-Her-2-):After the first course of TEC if the SUV of the primary tumor is >5%, treatment will be TEC x 4 courses. If the Oncotype is low, patients will be switched to hormonal therapy x 6 months. If the Oncotype result is intermediate/high, patients will be NAX chemotherapy x 4 courses. If the SUV post course #1 TEC is <5%, subsequent treatment will depend on the Oncotype.If the Oncotype is low, the treatment will be hormonal therapy x 6 months. If the Oncotype is intermediate/high , the treatment will be NAX chemotherapy x 4. Surgery will be performed 6 weeks after the 4th course of NAX chemotherapy.
45975491|NCT01641484|Procedure|local control at 19.8Gy|Day 14, full body TEP and pelvis MRI
45975492|NCT01641523|Device|CustomBone Service|customized hydroxyapatite cranial prosthesis
45671086|NCT04135352|Drug|200 mg of pembrolizumab|Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.
45671087|NCT04135352|Biological|V938|Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.
45671088|NCT04862312|Behavioral|VideoDine|Participants will VideoDine with a dining partner at least six times during an eight week period. VideoDining involves sharing a meal with someone not physically present using video chat technology. Dining partners will be recruited, trained and paired with participants. Participants will be provided Amazon Echo Show devices for video chat.
45830482|NCT01533246|Other|laboratory biomarker analysis|Correlative studies
45830483|NCT01579578|Drug|AZD8931|40 mg, oral dose twice daily
45975493|NCT00417339|Procedure|hemodialysis|individualised
45975494|NCT00251342|Procedure|Edinburgh Postnatal Depression Scale|
45975495|NCT01641796|Drug|Paromomycin|Paromomycin Topical Cream applied to all lesions once a day for 20 days
45975496|NCT00280098|Drug|docetaxel|Docetaxel 75mg/m2/q3wx10 cycles with Prednisone 10mg/d/bid
45671089|NCT01715896|Biological|Golimumab 50 mg|Participants received alternating doses of golimumab 50 mg (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
45975497|NCT01681147|Behavioral|2 online nutrition and exercise education classes|Two online nutrition and physical activity classes will accessed from a computer, android phone or a tablet. Each class is estimated to last about 1.5- 2 hours and will be accessed 6 weeks-3 months and 9 months
45975498|NCT01681147|Behavioral|Self monitoring of blood glucose levels|Self monitoring of blood glucose levels four times a day for four consecutive days once a month from 6 weeks-3 months through 9 months post partum
45456073|NCT05054504|Device|Butterfly iQ|The primary intervention under study is the Butterfly iQ point-of-care ultrasound device, embedded in a larger program of training, iterative ANC service delivery design, and a final program evaluation.
45671090|NCT01715896|Biological|Mavrilimumab 100 mg|Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
45671091|NCT02255552|Drug|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
45671092|NCT05642780|Drug|SKB264|be administrated as an intravenous (IV) infusion on Day 1,15, 29 of each 42-day cycle;
45671093|NCT05642780|Drug|Pembrolizumab|be administrated as an intravenous (IV) infusion on Day 1 of each 42-day cycle;
45975499|NCT00251381|Drug|Cetuximab|
45975500|NCT01685827|Drug|Fexinidazole|
45975501|NCT01685827|Drug|Nifurtimox|
45975502|NCT01685827|Drug|Eflornithine|
45456074|NCT05054296|Behavioral|Educational Intervention|Receive general education exercise packet
45671094|NCT01714726|Drug|MEDI2070|1 iv infusion on Week 0 and Week 4
45671095|NCT01714726|Drug|placebo|1 iv infusion on Week 0 and Week 4
45671096|NCT02255474|Device|Biofinity Multifocal D +1.50 add|This is a monthly disposable contact lens commercially available from CooperVision
45830484|NCT01579578|Drug|Placebo|Placebo, oral dose twice daily
45830485|NCT01579578|Drug|Paclitaxel|IV once weekly for 3 weeks followed by a week off.
45830486|NCT01578486|Drug|salsalate|open-label trial of salsalate 3g/day for 12 weeks.
45830487|NCT01532934|Behavioral|motivational enhancement therapy|Four 45-minute MET sessions
45830488|NCT01532934|Other|standard care|
45975503|NCT00251420|Procedure|writing about disease|writing about physical or emotional consequences of pulmonary disease
45975504|NCT05108584|Procedure|PPE Level 3 and Video Laryngoscope|The operator used level 3 PPE and video laryngoscope for the intubation process
45456075|NCT05054296|Behavioral|Exercise Intervention|Participate in supervised and self-directed exercise sessions
45456076|NCT05054296|Device|FitBit|Wear FitBit for activity tracking
45830489|NCT01532388|Behavioral|eScreen|Web based self-monitoring of problematic alcohol and drug use.
45830490|NCT01555164|Drug|Ranolazine|Ranolazine tablet(s) administered orally
45975505|NCT05108584|Procedure|PPE Level 3 and Direct Laryngoscope|The operator used level 3 PPE and direct laryngoscope for the intubation process
45975506|NCT05108584|Procedure|PPE Level 2 and Direct Laryngoscope|The operator used level 2 PPE and direct laryngoscope for the intubation process
45975507|NCT01686841|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
45975508|NCT00417378|Device|Left Ventricular Assist Device Impella LP 2.5|Left Ventricular Assist Device
45975509|NCT00417378|Device|Intraaortic Balloon Pump|Counterpulsation
45975510|NCT05140096|Drug|Acalabrutinib|"Modify as Participants will receive a single oral dose of 100 mg (1 X 100 mg capsule) acalabrutinib either on Day 1 of Period 1 (Treatment A) and Day 1 of Period 2 (Treatment B) or Day 5 of Period 2 (Treatment C)."
45975511|NCT05140096|Drug|Fluconazole|Participants will receive 400 mg fluconazole (2 × 200 mg tablets) on Day 1 Period 2 (Treatment B).
45975512|NCT05140096|Drug|Isavuconazole|Participant will receive oral dose of 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) three times daily on Day 1 and 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) once daily on Days 2 to 5 in Period 2 (Treatment C).
45671097|NCT02255474|Device|Biofinity Multifocal D +2.50 add|This is a monthly disposable contact lens commercially available from CooperVision
45671098|NCT02255474|Device|Biofinity|This is a monthly disposable spherical contact lens commercially available from CooperVision
45975513|NCT00251459|Drug|rhuFab V2 (ranibizumab)|
45975514|NCT04823065|Drug|Loperamide Pill|4 mg Imodium, per os
45975515|NCT04823065|Drug|hyoscine-n-butylbromide|3 X 20 mg Buscopan, intravenous
45671099|NCT05642702|Other|Peptide complexed HA Age Defying Gel with Vitamin C & Niacinamide|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
45830491|NCT01555164|Drug|Placebo to match ranolazine|Placebo to match ranolazine for the duration of the study
45830492|NCT01555164|Drug|Metformin|Metformin tablet(s) administered orally once daily
45975516|NCT00280176|Drug|bortezomib|0.7mg/m2 - 1.5mg.m2 given during Weeks 1, 2, 4 and 5 on a Monday/Thursday or Tuesday/Friday schedule, up to six weeks
45975517|NCT00280176|Drug|fluorouracil|225mg/m2 given weekly, up to 6 weeks
45975518|NCT00280176|Radiation|radiation therapy|180 cGy, every 5 days, up to six weeks
45975519|NCT02961179|Behavioral|Increased dairy product|
45671100|NCT05642702|Other|Peptide complexed HA Age Defying Gel with Natural Extracts|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
45671101|NCT05642702|Other|Peptide complexed HA Age Defying Gel with Vitamin C & Natural Extracts|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
45830493|NCT01555164|Drug|Placebo to match metformin|Placebo to match metformin for the duration of the study
45830494|NCT01555164|Behavioral|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
45830495|NCT01555164|Behavioral|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
45671102|NCT05642702|Other|1% w/v Sodium Lauryl Sulphate (SLS) solution|1g of Sodium Lauryl Sulphate will be dissolved in distilled water and made up to 100 mL solution using distilled water. A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
45830496|NCT03028428|Biological|Placenta Derived Mesenchymal Stem Cell|1ml 1*10^7 Placenta Derived Mesenchymal Stem Cell administered into the knee joint once
45830497|NCT03028428|Drug|Sodium Hyaluronate|Sodium hyaluronate administered into the knee joint once
45975520|NCT02961179|Behavioral|Dietary counselling|
45975521|NCT04829305|Drug|SHR2285|SHR2285 is a selective inhibition of human FXIa small molecule compound.
45975522|NCT00280215|Drug|ACEI / Angiotensin converting enzyme inhibitor|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker, Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
45975523|NCT00280215|Drug|ARB /Angiotensin Receptor Blocker|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker,Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
45975524|NCT00280215|Drug|Placebo|Patients will receive placebo for 24 months
45975525|NCT04720118|Other|No Intervention|There is no intervention for this study.
45830498|NCT01578330|Drug|Fingolimod|Fingolimod 0.5mg orally once a day without food.
45830499|NCT01577160|Drug|Paliperidone ER|Participants will receive paliperidone ER 6 milligram (mg) orally once daily up to Week 12. Dose adjustment will be done at Week 2, 4 and 8 as per investigator's discretion based upon participant's CGI-I score.
45830500|NCT01554618|Drug|Exenatide Once Weekly|2 mg exenatide once weekly
45830501|NCT01554618|Drug|Placebo|Placebo
45830502|NCT04108728|Diagnostic Test|BRIEF SCORE AT INCLUSION|BRIEF SCALE evaluation
45830503|NCT01531998|Drug|Lenalidomide|Induction Phase: 25 mg by mouth daily on Days 1-14. Maintenance Phase: at last tolerated dose from Induction Phase day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.
45456077|NCT05054296|Other|Quality-of-Life Assessment|Ancillary studies
45975526|NCT04826029|Other|Standard strategy|In the standard arm, patients will complete CA 125 (+/- HE4) at 3 months, 6 months, 12 months, 18 months and 24 months (+/- 15 days), complete the HAD and EQ5D self-questionnaires, and be managed according to INCa 2018 recommendations. If clinical symptoms, marker elevation, and/or imaging workup occur, the patient will be referred to the multidisciplinary consultation meeting (MDC) for management according to INCa 2018.
45975527|NCT04826029|Other|Follow-up strategy|In the interventional arm, patients will perform at 3 months, 6 months, 12 months, 18 months and 24 months (+/- 15 days) a CA125 assay (+/- HE4 assay), a thoracoabdominal CT scan after contrast injection and a whole body MRI (T2, DW and T1 sequences after fat saturation before and after gadolinium injection) with a maximum delay of 15 days between the two examinations, and will complete the HAD and EQ5D self-questionnaires. A senior radiologist from each center will perform a prospective reading of each of the images. For any suspicious anomaly identified, the following criteria will be analyzed: Size, location, number, evolution, contrast after injection, MRI signal (T2, Diffusion, Dynamic Enhancement Curve). The RECIST criteria (version 1.1) will be applied.
45975528|NCT00251498|Drug|Cetuximab|Cycle 1:400 mg/m2, administered as a 120-minute iv infusion on Day 1 and 250 mg/m2 administered as a 60-minute iv infusion on Days 8 and 15, subsequent cycles:250 mg/m2 administered as a 60-minute iv infusion on Days 1, 8, 15
45975529|NCT00417456|Other|Evisit|Asynchronous,remote care delivery via a secure web platform
45975530|NCT00417456|Other|Office visit|Conventional office-based care
45975531|NCT00280254|Procedure|Hemodynamically Oriented Echocardiography-based Strategy|
45975532|NCT02275351|Drug|SM04554|Topical solution, applied once a day
45975533|NCT02275351|Drug|Vehicle|Topical solution, applied once a day
45975534|NCT04720040|Device|Mind STIM|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
45975535|NCT04825834|Other|Blood Sample Collection|Subjects enrolled in the DELFI-L101 will have blood specimens collected (~40 mL) at enrollment.
45975536|NCT04826653|Other|Suture removal|Suture removal after coronally advanced flap plus a connective tissue graft
45830504|NCT01531998|Drug|Bortezomib|"Induction Phase: 1.3 mg/m2 by vein daily on Days 1, 4, 8 and 11.~Maintenance Phase: 1.3 mg/m2 by vein or last tolerated dose on Day 1 and Day 8."
45975537|NCT00417495|Behavioral|Sentinel Lymph Node Technique|
45975538|NCT05140057|Combination Product|Moviprep|Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings
45975539|NCT00251537|Drug|LTB4|
45975540|NCT02271334|Drug|A006 DPI|Single dose 110 mcg, 1 inhalation
45975541|NCT02271334|Drug|A006 DPI|Single dose 220 mcg, 1 inhalation
45975542|NCT02271334|Drug|Proventil® MDI|Single dose 90 mcg, 1 inhalation
45975543|NCT02271334|Drug|Proventil® MDI|Single dose 90 mcg, 2 inhalations
45975544|NCT00280332|Procedure|colonoscopy|proform a follow up colonoscopy in the 5 year period from index colonoscopy
45975545|NCT02276755|Dietary Supplement|Cholecalciferol (vitamin D3)|14000 IU vitamin D3 weekly Experimental group will receive vitamin D supplement (Tishcon, USA).
45830505|NCT01531998|Drug|Siltuximab|"Induction Phase Starting Dose: 11 mg/kg by vein on Day 1.~Maintenance Phase: 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy."
45830506|NCT01531998|Drug|Dexamethasone|"Induction Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12.~Maintenance Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12. If participant still on Dexamethasone, when entering Maintenance Phase, dose reduced to 20 mg a week."
45830507|NCT01531998|Behavioral|Questionnaires|M. D. Anderson Symptom Inventory Module (MDASI-MM) completed Day 1, Day 8 of Cycle 1 - 8, and on Day 1 of Cycle 9 and beyond.
45830508|NCT01576146|Drug|Etelcalcetide|Administered as an intravenous bolus three times a week at the end of each hemodialysis session at dosages up to a maximum of 15 mg.
45830509|NCT01553916|Drug|Lithium Carbonate|
45975546|NCT02276755|Other|Placebo|Placebo group will receive placebo (Tishcon, USA) weekly.
45975547|NCT02278198|Drug|rhTSH|Intramuscular injections of rhTSH (Thyrogen) will be given on days 1 and 2.
45975548|NCT00286884|Procedure|Monitoring of heart rate variability|
45975549|NCT02279290|Behavioral|Healthy Mind Intervention (HMI)|Healthy Mind Intervention (HMI) is a flexible cognitive-behavioral resilience building program. Participants will receive 8 weekly, 60-minute individual sessions of HMI. In HMI, participants will be able to select 3 areas of resilience that they want to work on.
45975550|NCT02279290|Behavioral|Healthy Body Intervention (HBI)|The 8 weekly, 60-minute individual sessions will include the following topics: the mind-body connection, nutrition, exercise, unhealthy substances, sleep, preventing illness, and preventive care. Each session is spent providing didactic information on these topics and strategies for how to engage in behavior change in these areas.
45975551|NCT04826419|Other|ozone therapy|The treatment session of oxygen-ozone was 80 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) five times a week for the first week.The treatment session of oxygen-ozone was 40 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) twice a week after first week.
45975552|NCT00280371|Drug|Formoterol Fumarate|
45975553|NCT04822480|Behavioral|Diabetes Prevention Program (DPP)|Individuals with prediabetes can mitigate the risks and costs of diabetes by taking preventative action, such as participation in a National Diabetes Prevention Program (DPP). The DPP began as a multisite randomized controlled trial demonstrating the effectiveness and cost-benefit of a 12-month intensive lifestyle intervention over pharmaceutical treatment for preventing or delaying diabetes among prediabetic participants. In 2010, Congress authorized the Centers for Disease Control and Prevention to lead the dissemination of the DPP as a targeted approach (high risk populations) and population-based strategy to reduce the incidence of diabetes and diabetes-related healthcare costs. The goal is to achieve modest weight loss (7%) by developing and implementing behavior change skills resulting in lifestyle modifications such as physical activity (150 minutes per week) and dietary and nutritional practices.
45975554|NCT04826926|Procedure|Procedure/Surgery: Non Surgical Periodontal Therapy|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
45975555|NCT04825132|Other|Geriatric assessment tools|Multidimensional Prognostic Index (Living status, medications, ADL, IADL, MMSE mental evaluation, ESS pressure sores, chronic disease, nutritional assessment)
45975556|NCT00280410|Drug|E7337|
45975557|NCT04900246|Procedure|Visual Inspection|"The examiners will evaluate the surfaces included in the study independently and without knowledge of the results of the other examiner, after prophylaxis, using a mouth mirror and a WHO probe or Ball point. The evaluations will be carried out in a dental chair with the aid of a reflector. The teeth will be examined moist, and afterwards, they will be dried for 5 seconds with the use of a triple syringe.~For visual inspection, the International Caries Detection and Assessment System (ICDAS) evaluation system will be used. Complete ICDAS has seven categories, the first for healthy teeth (code 0) and the next two for limited enamel caries, white/brown stain (codes 1 and 2). The following two categories (codes 3 and 4) are considered to be caries that extend to the enamel without exposed dentin. And the two remaining categories (codes 5 and 6), are considered caries with exposed dentin."
45975558|NCT04900246|Radiation|BWX Radiographic Assessment|Participants will be radiographed with a digital X-ray device (DIOX-602, Micro Imagem, Indaiatuba, Brazil) with a regulation of 60 kV and 2 mA and exposure time of 0.10s. The technique used will be the interproximal/bitewing (BWX), with the FIT T1 Digital Sensor (external dimensions: 36.7mm x 24.3mm/sensitive area dimensions: 30.0mm x 20.0mm - 600mm²) and the sockets will be standardized with use of Han-Shin radiographic positioners (Jon, São Paulo, Brazil).
45975559|NCT04900246|Device|Assessment of the iTero Element 5D scan|For scanning, the iTero 5D (Align Technology) equipment featuring NIRI Technology will be used. The Infrared Imaging Technology (NIRI) is a diagnostic tool that allows the detection of interproximal and occlusal caries in several stages, from the initial enamel caries to lesions in the amelo-dentin junction, without the use of ionizing radiation. Infrared is the region of the electromagnetic spectrum between 0.7 and 2.0 micrometers (µm). The iTero Element 5D imaging system uses wavelength light (= 850 nm) in an electromagnetic spectrum that, in interaction with the hard tooth tissue, provides additional data on its structure.
45975560|NCT04455139|Drug|Topotecan|intravitreal or intra-arterial administration of topotecan
45975561|NCT04455139|Drug|Melphalan|intravitreal or intra-arterial administration of topotecan
45975562|NCT00280449|Behavioral|strengths-based case managed proactive service model|
45975563|NCT00251654|Procedure|perineural block (anesthesia)|continuous peripheral regional anesthesia ropivacaine 0.33% for 3 to 5 days
45975564|NCT04335019|Other|Pulmonary ultrasound|Pulmonary ultrasound results: quotation in 8 fields (right antero-superior, left antero-superior, right antero-inferior, left antero-inferior, right postero-superior, left postero-superior, right postero-inferior and postero-upper left).
45671103|NCT05642702|Other|Sodium chloride (Isotonic Saline Solution) Injection IP 0.9 % w/v|A 0.04 mL of 0.9% w/v solution of Isotonic Saline Solution will be dispensed on the center of an appropriately sized filter paper, which will be further placed in the designated IQ/Finn chambers prefixed to a micropore tape.
45671104|NCT05544734|Drug|Hydrocodone 5Mg/Acetaminophen 325Mg Tab|5 mg/325 mg tablet
45830510|NCT01553916|Radiation|Prophylactic cranial irradiation|
45830511|NCT01553136|Drug|Varenicline|0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day
45830512|NCT03028506|Other|Carbohydrate intake|By calculating carbohydrate amounts at meals and snacks, as well as classifying meals and snacks as high fat, the investigators will examine the correlation to higher preprandial blood glucose values and large for gestational age infants.
45975565|NCT00286923|Drug|Topiramate|
45975566|NCT04822168|Other|MySafeRx™|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of B/N medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
45975567|NCT04822168|Other|Standard Care|Standard Care through office-based opioid treatment with B/N dosing, on-site counseling and regular urine toxicology screening
45456078|NCT05054296|Other|Questionnaire Administration|Ancillary studies
45456079|NCT05048017|Drug|Regorafenib|Regorafenib, 120 mg, once a day, 3 weeks on/1 week off
45671105|NCT05544734|Drug|Acetaminophen 1000mg|1000 mg tablet
45830513|NCT04836468|Diagnostic Test|Tape application|Magnetic Tape or Kinesiology tape will be applied randomly with both the examiner and the subjects blinded.
45830514|NCT01552902|Drug|Lisdexamfetamine dimesylate|Daily oral dosing in the AM ranging from 30- 70 mg. 4 week forced dose titration, 2 week dose maintenance
45830515|NCT01552902|Drug|Methylphenidate Hydrochloride|Daily oral dosing in the AM ranging from 18-72 mg. 4 week force dose titration, 2 week dose maintenance
45830516|NCT01552902|Drug|Placebo|Daily oral dosing in the AM for 6 weeks
45830517|NCT03923790|Behavioral|Educational Packet|The patient will receive an educational packet.
45830518|NCT03923790|Behavioral|Phone call at 72 hours by discharge nurse navigator|Patients will receive a phone call at 72 hours by the discharge nurse navigator (standard of care) to assure that they have received their medications and follow-up appointments
45975568|NCT00251732|Drug|Standard dose (once daily) PPI plus low-dose antidepressant|20 mg. rabeprazole plus low dose tricyclic antidepressant(TCA)
45671106|NCT05544734|Drug|Ibuprofen 400 mg|400 mg tablet
45975569|NCT00251732|Drug|Double dose PPI plus evening placebo|20 mg. twice daily with a placebo
45975570|NCT00251732|Drug|Rabeprazole , placebo, placebo|20 mg rabeprazole(PPI) once daily -a.m. placebo -p.m. placebo -bedtime
45975571|NCT04088539|Behavioral|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date)
45975572|NCT04088539|Behavioral|Video-based health education|Educational videos on smoking and health will be developed to improve the knowledge of CSD smokers. The videos aim to raise their awareness on these important health topics and acquire effective cessation methods. The effectiveness of the educational videos will be evaluated by pre- and post-tests through a self-administered survey that assess the changes in knowledge related to smoking hazards, benefits of quitting, and methods to quit smoking.
45975573|NCT04042792|Other|pharmacokinetics (PK) measurement|two ADA-PK samples will be collected during routine rheumatology visits in case of medical indicated blood draw (1 trough PK sample and 1 random PK sample per subject)
45975574|NCT00286962|Device|MIP 2007C implantable insulin pump|Intraperitoneal insulin infusion delivered by an implantable pump: MIP 2007c
45975575|NCT00286962|Device|continuous subcutaneous insulin infusion (CSII) or MDI|
45975576|NCT04011826|Device|Device: Trial nasal mask (F&P)|This trial nasal mask will serve as the participant's primary PAP/BPAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial nasal mask as their primary PAP/BPAP therapy mask for 6 months after Visit 3.
45975577|NCT04006756|Behavioral|Online cognitive training 1|Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.
45975578|NCT04006756|Behavioral|Online cognitive training 2|Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
45975579|NCT00251771|Procedure|catheter-directed venous thrombolysis|catheter-directed continuous intravenous infusion of alteplase 0.01mg/kg/h and low-dose heparin. Max dose 20mg/24 h and up to 96 hrs.
45671107|NCT02254772|Biological|Ipilimumab|A dose of 10 mg in cohort 1 or 25mg in cohort 2 via intratumoral injection on day 2, week 1.
45671108|NCT02254772|Drug|SD-101|Started on day 2 week 1, then once every week x 4 successive weeks for a total of 5 injections.
45671109|NCT02254772|Radiation|Radiation therapy|Undergo low-dose radiation therapy to 1 site of disease
45671110|NCT02254460|Dietary Supplement|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
45671111|NCT02254460|Other|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
45671112|NCT05540054|Other|Inspiratory muscle training|Respiratory muscle strengthening training will be given with a resistive threshold inspiratory muscle strengthening device.
45830519|NCT03923790|Behavioral|Telehealth visit at 7 days, 1 month, 3 months, and 5 months after discharge|A stroke prevention trained nurse practitioner or MD or social worker will review the participant's hospital records and depression, dietary, and sleep apnea screens,will reinforce the care plan based on patient-specific needs.They will counsel patients on salt reduction, the Mediterranean diet, and the importance of diet and exercise for stroke prevention.Along with the pharmacist they will also review the BP data to determine the need for medication adjustment and will discuss the side effects and interactions.The social worker will assess the need for medication assistance and other resources. The care plan will be shared with primary care providers (PCP)and patients will be referred to a PCP if they do not have one. The social worker will also will assist uninsured patients in applying for Texas County Indigent Care programs.
45830520|NCT03923790|Behavioral|Educational messages every other week|The messages will be sent to the participants cellular phones and will contain one of the following: a reminder to monitor BP, information from about lifestyle and diet for BP reduction, or a message from the pharmacist about medication adherence
45830521|NCT03923790|Diagnostic Test|BP monitoring by QardioARM with periodic transmission of BP data|Participants will be prompted to transmit BP logs through the telemonitoring device every 2 weeks until average BP is < 130/80, then monthly thereafter. Uncontrolled BP will prompt a call from the pharmacist to discuss medication adherence and the need for further titration.
45975580|NCT03946462|Drug|NO gas delivered during cardiac surgery|intra-operative NO gas at 20ppm blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system.
45975581|NCT03946462|Other|placebo gas delivered during cardiac surgery|placebo blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system. The placebo gas in this study will be 21% (or atmospheric) oxygen.
45975582|NCT00280488|Behavioral|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
45671113|NCT05540054|Other|Standard pulmonary rehabilitation programme|The standard PR consisted of breathing exercises, peripheral muscle strengthening and self walking training.
45671114|NCT01682044|Biological|pegfilgrastim|Given SC
45671115|NCT01682044|Biological|rituximab|Given IV
45671116|NCT01682044|Other|flow cytometry|Correlative studies
45671117|NCT01682044|Procedure|biopsy|Correlative studies
45671118|NCT01682044|Other|immunohistochemistry staining method|Correlative studies
45671119|NCT01682044|Genetic|western blotting|Correlative studies
45671120|NCT05640986|Behavioral|BART-EEG at V1 + V2|Balloon Analogue Risk Task coupled to Electroencephalogram (BART-EEG) at V1 + V2 for Parkinsonian patients
45671121|NCT05640986|Behavioral|BART-EEG at V1 only|Balloon Analogue Risk Task coupled to Electroencephalogram (BART-EEG) at V1 only for healthy volunteers
45671122|NCT05651204|Diagnostic Test|GABA Blood Level|Blood specimens will be collected by a registered phlebotomist according to hospital's specimen collection procedures.
45671123|NCT05640596|Drug|Betamethasone|
45671124|NCT05651126|Drug|Psilocybin 5 mg|Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin
45671125|NCT05651126|Drug|Psilocybin 2 mg|Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin
45671126|NCT05651126|Drug|Placebo|Inactive placebo
45975583|NCT00280488|Behavioral|Assessment|In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
45975584|NCT00280488|Behavioral|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
45975585|NCT03658486|Other|Exercise|Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be assigned a moderate intensity walking and strengthening program to complete at home. At baseline, 12 and 24 weeks patients will wear an accelerometer to determine activity levels. At these time points, patients will also complete a physical fitness assessment (timed sit-to-stand and six minute walking tests) and a range of quality of life questionnaires. At baseline, patients will receive a behaviour change consultation and continued support throughout the intervention. Each patient will receive a pedometer during the home-based, unsupervised regime to monitor step count and they are expected to complete a daily physical activity diary. Upon completion of the 24 week follow-up, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.
45975586|NCT00251810|Device|Cerebral State Monitor|All patients monitored with BIS and CSM, results hidden for the anesthesiologist.
45975587|NCT03531580|Device|Magnetic Resonance Imaging|Brain imaging using magnetic resonance imaging, using several MRI sequences: structural imaging (grey matter, using T1-imaging), cerebral perfusion using arterial spin labeling), functional and effective connectivity (using resting-state functional MRI), white matter tracts (using diffusion imaging), white matter lesions (using Fluid-attenuated inversion recovery MRI (FLAIR)) and microbleeds (using Susceptibility weighted imaging (SWI))
45975588|NCT03488641|Diagnostic Test|ex-vivo drug response assay|drug sensitivity testing of primary patient derived cancer cells
45975589|NCT00287001|Device|Cold air cooling|
45671127|NCT01696942|Drug|Cimzia|400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks
45975590|NCT03439930|Other|Balance training|6 weeks lasting balance training program
45975591|NCT04719650|Drug|Zoledronic Acid Injection|Infusion 1mg zoledronic acid once.
45975592|NCT04719650|Drug|Zoledronic Acid Injection|Infusion 2.5mg zoledronic acid once.
45975593|NCT04719650|Drug|Zoledronic Acid Injection|Infusion 5mg zoledronic acid once.
45671128|NCT01696942|Drug|Mesalamine|mesalamine 800 mg orally three times daily
45830522|NCT04102254|Procedure|ANT recording and stimulation|In this study, the investigator aims to perform sEEG recordings during simultaneous ANT recording and stimulation to better understand the following: 1) how the ANT is involved in various seizure types; 2) which cortical regions are modulated by established ANT stimulation patterns; and 3) how novel ANT stimulation patterns modify epileptogenic cortical activity.
45975594|NCT04719650|Drug|Placebo|Infusion normal saline once.
45975595|NCT03406312|Diagnostic Test|Post Prandial Hypoglycemia test|three test assessing hypoglycemia will be used: liquid mixed meal tolerance test, solid mixed meal tolerances test, continuous glucose monitoring
45975596|NCT03218605|Other|physical activity|Subjects performed five activities: running, static stretch, dynamic stretch, cycling and rope skipping
45975597|NCT00251849|Drug|Rifalazil|
45671129|NCT05494814|Other|Child Care Centers Served Meals Prepared by Central Kitchen|The child care centers who are served by the central kitchen will receive meals that include locally sourced fresh fruits and vegetables to serve their staff and children.
45671130|NCT05651048|Other|Control Group|Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
45671131|NCT05651048|Other|BEMER Group|BEMER therapy and Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
45671132|NCT05651048|Other|Kinesiotape Group|Kinesiotape application and Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
45671133|NCT05493566|Biological|Aldesleukin|Given SC
45830523|NCT02072928|Biological|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) prescribed as standard of care in clinical practice.
45671134|NCT05493566|Biological|Pembrolizumab|Given IV
45671135|NCT05493020|Other|Questionnaires set|"At baseline, the children's demographics, disease-related data, characteristics of Mukbangwatching behavior, appetite, nutritional status, and quality of life data were collected. From the first day of radiotherapy or chemotherapy, 3 meals a day for 5 consecutive days were followed to track the children's appetite status and the characteristics of Mukbangwatching behavior. Their nutritional status and quality of life were tracked at the end of treatment or when they were discharged from the hospital."
45671136|NCT05485922|Device|Investigational device - intermittent catheter with a micro-hole zone|The investigational device was a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
45830524|NCT01529346|Drug|PF-05089771|A single dose of PF-05089771 1600 mg oral solution administered once to the subject on Day 1 postoperatively
45830525|NCT01529346|Other|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
45830526|NCT01529346|Drug|PF-05089771|A single dose of PF-05089771 450 mg oral solution administered once to the subject on Day 1 postoperatively
45975598|NCT03189862|Behavioral|Motor Skills Intervention|"The behavioral motor skills intervention (CHAMP) is an intervention strategy that uniquely addresses differences in children's developmental levels on an individualized basis. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to develop improvements in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP will be implemented 4x/week for 30 minutes across ≈30 weeks for ≈3000 minutes of intervention time."
45975599|NCT02960802|Procedure|kidney transplantation|
45975600|NCT04822597|Drug|Lidocaine patch|Lidocaine is a local anesthetic.
45975601|NCT04822597|Device|Buzzy(R)|Buzzy provides non-invasive pain relief by vibrating and cooling the skin which distracts from pain sensations.
45975602|NCT04822597|Other|Ice pack|Ice cools the skin and can provide some numbing for pain.
45975603|NCT00251888|Drug|campto (irinotecan)|
45975604|NCT00251888|Drug|cisplatin (cisplatyl)|
45975605|NCT04823221|Device|Rezūm System|The basic principle of the Rezūm System is to deliver a controlled amount of sterile water vapor directly into the hyperplastic tissue in the transition zone of the prostate using a transurethral approach .The stored thermal energy in the vapor is transferred directly onto the cell membranes as the vapor condenses and releases the heat of condensation, causing cell death. Inaddition, this thermal energy transfer collapses the vasculature within the treatment zone, resulting in a bloodless procedure. During procedure the water vapor is created by a heating element in the Rezūm Delivery Device,Saline flush during vapor delivery protects and preserves the urethra.
45975606|NCT01600027|Procedure|Fascia iliaca compartment block|Fascia iliaca compartment block was performed as described by Dalens et al technique.
45975607|NCT01600027|Procedure|Fascia iliaca block|Fascia iliaca compartment block was performed as described by Dalens et al technique.
45975608|NCT00251966|Drug|Esomeprazole|
45975609|NCT02699086|Drug|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
45671137|NCT05485922|Device|Comparator device -VaPro intermittent catheter|The comparator device is a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
45830527|NCT01529346|Other|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
45975610|NCT00252044|Drug|Pergolide|
45975611|NCT01805284|Drug|Linezolid|600 mg linezolid as a 1 hour controlled infusion (acceptable time frame is between 30 and 120 minutes), twice, at least 3 days.
45975612|NCT01337128|Procedure|Carotid endarterectomy (CEA)|Carotid endarterectomy (CEA) will be performed on the patients
45975613|NCT01337128|Procedure|Carotid stenting (CAS)|Carotid Stenting (CAS) will be performed on these patients.
45975614|NCT01337128|Procedure|Neurocognitive functions|Neurocognitive functions will be measured pre-operatively and after 3 weeks, 6 months and 1 year.
45975615|NCT01337128|Procedure|Levels of biomarkers|Levels of biomarkers (Protein S100B) will be examined pre- , peri- and post-operatively after 2 hours, 6 hours and 24 hours.
45975616|NCT01337128|Procedure|Detection of peri-operative embolization|A Transcranial Doppler Ultrasonography will be used to detect peri-operative embolization.
45975617|NCT01337128|Procedure|Validation results|On a subgroup of 20 patients a MRI-scan will be done pre- and post-operatively after 48 hours and 3 weeks.
45975618|NCT04719884|Procedure|Perioperative fluid optimisation|"In case of stroke volume variation (SVV) >10% and SI and CI >10% below the starting value, fluid challenge was performed with approximately 2 ml/kg of colloid over maximum of 5 minutes. The response was monitored.~If there was a fall in SVV and an increase in SI of >10% and the SVV still >10%, the second fluid challenge was performed.~If there was still a reduction in SVV after the second fluid challenge, but an increase in nSI <10% and decrease in systemic vascular resistance (SVR), no additional fluids were given. Vasoactive drugs were used instead."
45975619|NCT01191073|Device|CAD/CAM fabricated RPD's|group receiving Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM)fabricated removable partial dentures (double blind)
45830528|NCT01529346|Drug|PF-05089771|A single dose of PF-05089771 150 mg oral solution administered once to the subject on Day 1 postoperatively
45830529|NCT01529346|Other|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
45830530|NCT01529346|Drug|Ibuprofen|2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively
45830531|NCT01529346|Other|Placebo|Placebo solution for PF-05089771: A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
45830532|NCT01529346|Other|Placebo|Placebo solution for PF-05089771:A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
45830533|NCT01529346|Other|Placebo|Placebo tablets for Ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
45975620|NCT01191073|Device|traditional fabricated RPD's|group receiving traditional fabricated dentures (double blind)
45975621|NCT00280605|Drug|Alfuzosin|
45975622|NCT01134601|Procedure|Radiation Therapy|
45975623|NCT01134601|Drug|Capecitabine|
45975624|NCT01134601|Drug|AZD6244|
45975625|NCT00252083|Behavioral|Popular Opinion Leader|
45975626|NCT00287040|Behavioral|Tailored, interactive intervention for mammography screening|Follow ups will occur at 6-, 12-, and 21-months in order to determine effectiveness of intervention as well as cost effectiveness and variation based on participant characteristics to facilitate a more effective program for mammography screenings
45975627|NCT00252122|Drug|Ketamine|Ketamine. 0.2 mg/kg, intravenously
45975628|NCT00287157|Drug|Sublingual Tizanidine HCl|
45975629|NCT00252161|Procedure|Gastrectomy with more than D2 dissection|Gastrectomy with more than D2 dissection
45671138|NCT05626244|Behavioral|Being a Parent|Being a Parent (BaP) is a group parenting intervention for parents of children (2-11 years old) with behavioral problems. It consists of 2-hour sessions facilitated by psychologists for between 8-12 parents. Based on attachment, family systems, and cognitive-behavioral theories, BaP successfully integrates knowledge acquisition, behavior change with adult learning and social support. Each course session is highly interactive involving an engaging blend of small and large group discussion, role play, demonstrations, information sharing and reflection. This enables parents to practice and use new skills to achieve specific goals (Day et al., 2020).
45456080|NCT05048017|Drug|PD-1 inhibitor|"Camrelizumab: 200mg (BW ≥ 50 kg) or 3 mg/kg (BW < 50 kg) Toripalimab: 240mg is given through intravenous drip every 3 weeks on Day 1 of each course of treatment.~Pembrolizumab: 200mg is given through intravenous drip every 3 weeks."
45456081|NCT05046951|Behavioral|Should I Screen website|The Should I Screen educational website, developed by our consultant, Rafael Meza, PhD, is available at no cost, is written at an 8th grade reading level, requires 15 minutes to use, and undergoes regular updates (https://shouldiscreen.com). The goal is to increase lung screening awareness and to encourage a shared decision making visit with a provider. Sections of the website include the benefits (the reduced likelihood of dying from lung cancer) and harms (false alarms, overdiagnosis, more testing, and invasive procedures) of screening, causes of lung cancer, methods to reduce lung cancer risk, and the lung cancer risk calculator. Improvements in knowledge have been demonstrated with individuals eligible for screening.
45975630|NCT00252161|Drug|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
45975631|NCT00280644|Drug|Leflunomide|
45975632|NCT00252200|Drug|Neseritide|Dose of Nesiritide infusion will be 0.005 ug/Kg/min
45975633|NCT00280722|Behavioral|patient information leaflet|
45975634|NCT00252278|Drug|atomoxetine|
45975635|NCT00287196|Radiation|Radiotherapy|48 Gy reference dose in 20 fractions at 5 fractions per week, with a maximum overall treatment time of 30 days.
45975636|NCT00252317|Drug|Captopril and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
45975637|NCT00252317|Drug|Captopril Test Dose and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
45975638|NCT01118026|Drug|ABVD|doxorubicin 25 mg/m^2 IV bleomycin 10 units/m^2 IV vinblastine 6 mg/m^2 IV dacarbazine 375 mg/m^2 IV
45975639|NCT01118026|Drug|BEACOPP|bleomycin 10 units/m^2 IV on Day 8 etoposide 200 mg/m^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m^2 IV on Day 1 cyclophosphamide 1250 mg/m^2 IV on Day 1 vincristine 1.4 mg/m^2 IV on Day 8 procarbazine 100 mg/m^2 orally on Days 1-7 prednisone 40 mg/m^2 orally on Days 1-14
45975640|NCT01118026|Radiation|radiation therapy|
45975641|NCT00280800|Device|constant CPAP devices|different CPAP mode
45456082|NCT05046951|Behavioral|Should I Screen print booklet|The Should I Screen print-based education will be developed in Aim 1 and compared to the Should I Screen website in Aim 2. It will also be at the 8th grade level and will require 15 minutes to read. Although it will contain the same topics as the website, there is one inherent difference - it is not possible to include the interactive risk calculator in the print version. The print-based version will list all of the risk criteria that are included in the algorithm so that participants can see which ones apply to them. However, the risk calculator requires the computer algorithm to calculate a person's 6-year risk of developing lung cancer.
45671139|NCT04871204|Drug|Octreotide Injection|10 mg Sandostatin LAR intramuscular injection
45830534|NCT02073162|Procedure|Major Abdominal Surgery|•All types of open or lap-assisted abdominal or pelvic surgery with an expected duration of at least 2 hours, and an expected hospital stay of at least 3 days (for example, oesophagectomy, gastrectomy, pancreatectomy, colectomy, aortic or aorto-femoral vascular surgery, nephrectomy, cystectomy, open prostatectomy, radical hysterectomy, and abdominal incisional hernia repair)
45830535|NCT01529268|Drug|DR cysteamine bitartrate capsule|"600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~750 mg/day (five 75 mg capsules twice daily) for patients >65 - 80 kg at baseline~900 mg/day (six 75 mg capsules twice daily) for patients >80 kg at baseline"
45830536|NCT01529268|Other|DR cysteamine bitartrate placebo|"600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~750 mg/day (five 75 mg capsules twice daily) for patients >65 - 80 kg at baseline~900 mg/day (six 75 mg capsules twice daily) for patients >80 kg at baseline"
45830537|NCT01529112|Drug|Lenvatinib|
45830538|NCT01529112|Drug|Lenvatinib matched placebo|
45830539|NCT01529112|Drug|BSC|
45975642|NCT00280800|Device|automatic CPAP devices|different CPAP mode
45975643|NCT00252356|Drug|SR58611A|
45975644|NCT01648153|Biological|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration
45975645|NCT01648153|Other|Placebo (saline)|To compare the efficacy and biomarker changes between placebo and active groups
45975646|NCT01648153|Biological|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
45975647|NCT02753998|Combination Product|Additional angioplasty with paclitaxel-coated balloon|Additional angioplasty with paclitaxel-coated balloon after conventional angioplasty
45975648|NCT02753998|Combination Product|Additional angioplasty with placebo balloon|Additional angioplasty with placebo balloon after conventional angioplasty
45671140|NCT05650970|Other|routine therapy|Routine treatment program including massage, ice and activity training applied to hand thumb osteoarthritis patients
45975649|NCT02753998|Procedure|Conventional angioplasty|
45975650|NCT02279836|Device|SC20 Colonoscope|Single Arm Post-Marketing Study of SC20 Colonoscope
45975651|NCT00287235|Device|MARS|
45975652|NCT00287235|Drug|Standard Medical Therapy|
45975653|NCT00252395|Device|PDA-based Electronic Prescribing Software|
45975654|NCT02759731|Drug|Baricitinib|Cycle=28 days: Baricitinib: 1mg-4mg PO QD
45975655|NCT02753452|Behavioral|Residential Immersive Life Skills programming|
45975656|NCT02753452|Behavioral|Non-residential life skills programming|
45975657|NCT02754154|Drug|Warfarin|
45975658|NCT02754154|Drug|Apixaban|
45975659|NCT02754154|Drug|Dabigatran|
45975660|NCT02754154|Drug|Rivaroxaban|
45975661|NCT00252434|Behavioral|Cognitive Behavioral Therapy Development for Methamphetamine Abuse|
45671141|NCT05650970|Other|radial nerve mobilization exercise|Radial nerve mobilization exercise in addition to the routine treatment program applied to patients with hand thumb osteoarthritis
45671142|NCT05619770|Drug|101-PGC-005|Bolus Injection containing 30mg of 101-PGC-005 will administered intravenously once daily for 3 consecutive days
45975662|NCT00280839|Drug|Topiramate|
45975663|NCT00280839|Drug|Placebo|
45975664|NCT04719728|Diagnostic Test|Aided pure tone audiometry|aided response, speech, evoked potential
45975665|NCT00287274|Device|computerized physician order entry|
45975666|NCT00414869|Drug|NCX-1000|500 mg powder sachets to be taken as 1, 2, or 4 sachets twice daily, PO x 16 days
45671143|NCT05615948|Drug|VTS-K|Proprietary oral formulation of 486mg aspirin and 80mg ketamine
45671144|NCT05612828|Behavioral|Conventional versus simulation manikin training|Two approaches to training Combat Life Savers will be employed and performance of participants will be evaluated.
45975667|NCT00414869|Drug|Placebo|Inactive powder matching NCX-1000
45975668|NCT00280878|Drug|gemcitabine|
45975669|NCT00280878|Drug|vinorelbine|
45975670|NCT00280878|Drug|ifosfamide|
45975671|NCT00280878|Drug|rituximab|
45830540|NCT01551420|Device|Advanced upper limb prosthetic device IMU controlled|Advanced upper limb prosthetic IMU controlled
45830541|NCT01551420|Device|Advanced upper limb prosthetic EMG-PR controlled|Advanced upper limb prosthetic EMG-PR controlled
45830542|NCT01575054|Biological|botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
45830543|NCT01575054|Drug|Normal Saline|Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles.
45975672|NCT02758717|Drug|Brentuximab Vedotin|Given IV
45975673|NCT02758717|Biological|Nivolumab|Given IV
45975674|NCT00252473|Device|MedTec S-frame Immobilization Masks|
45975675|NCT00287313|Drug|Vitamin K|
45975676|NCT01680133|Other|Hyperinsulinemic euglycemic clamp|
45975677|NCT01680211|Dietary Supplement|Salacia bark extract|
45975678|NCT01680211|Dietary Supplement|Salacia leaf extract|
45975679|NCT01680211|Dietary Supplement|Sesame seed extract|
45975680|NCT01680211|Behavioral|TLC|Lifestyle changes include diet, exercise, weight loss, etc.
45975681|NCT01680211|Other|Placebo|
45975682|NCT01680250|Drug|Sirolimus|Sirolimus administration for 12 months followed by conventional therapy alone for additional 12 months
45975683|NCT00280956|Drug|natalizumab|
45975684|NCT02279875|Drug|Linezolid|
45975685|NCT02279875|Drug|HRZE (isoniazid rifampicin,pyrazinamide,ethambutol)|isoniazid (H) 75 mg plus rifampicin (R) 150 mg plus pyrazinamide (Z) 400 mg plus ethambutol (E) 275 mg
45975686|NCT04827901|Drug|XEN1101|two 10 mg capsules
45975687|NCT04827901|Drug|Placebo|matching placebo
45975688|NCT04824508|Behavioral|position|teamleaders are instructed to allocated position
45975689|NCT00252551|Procedure|Osteosynthesis|
45975690|NCT00252551|Procedure|Simple surgery|Surgery without device
45975691|NCT00280995|Drug|ISIS 301012|100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
45975692|NCT00280995|Drug|ISIS 301012|200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
45975693|NCT00280995|Drug|ISIS 301012|300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64,71, 78, and 85
45975694|NCT00280995|Drug|ISIS 301012|50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
45975695|NCT04822675|Procedure|Percutaneous mitral valve repair|Percutaneous mitral repair will be performed using the MitraClip system.
45975696|NCT04822675|Procedure|Surgical mitral valve repair/replacement|All mitral valve surgeries will be performed either via sternotomy or right thoracotomy, and with cardioplegic arrest and cardiopulmonary bypass. Mitral valve repair may include annuloplasty and adjunctive procedures as determined by the operating surgeon. For mitral valve replacement, the choice of mitral valve prosthesis will be left at the surgeon's discretion.
45975697|NCT04821349|Device|Capsule endoscopy|"A consecutive series of patients recruited by 12 European centers based on the indication of OGIB will undergo capsule endoscopy examination.~Capsule endoscopy will be performed in each site according to local rules and requirements, and the study protocol will concern only the post-procedure analysis on reading modalities for each patient."
45975698|NCT05139667|Drug|Corticosteroid Topical|topical tacrolimus and corticosteroids
45975699|NCT02271061|Device|Kinesio tape|Elastic therapeutic tape is one type of elastic tape that is widely used for various treatment including rehabilitation and sports injuries . The elastic therapeutic tape has different characteristics from other kind of tape. It has ability to stretch around 130 - 140% from original length and recoil back to starting length after applying the tape. Tape produces pulling force on skin which lifts and folds layers of epidermis . Pulling force provides an appropriate alignment which can facilitate and inhibit muscle contraction.It has been claimed for several benefits such as supportingly injured muscles, increased proprioception, stimulated and inhibited muscle activity, relieved pain, increased range of motion, and improved blood and lymph flow.
45975700|NCT02271061|Device|Control tape|Apply tape in same technique without tension.
45975701|NCT00287352|Drug|Olanzapine, Amantadine|Olanzapine continuing as clinically indicated, Amantadine 100 mg tid
45975702|NCT00287352|Drug|Olanzapine and placebo|Olanzapine continuing as clinically indicated
45975703|NCT04823962|Drug|rhGM-CSF + hydrogel|The active substance: molgramostim (rhGM-CSF)
45671145|NCT04857710|Device|Wide-pulse neuromuscular electrostimulation (WP NMES)|The WP NMES program consists of electrical stimulation trains of 1000 symmetrical biphasic pulses (1 ms, 100 Hz). The duration of a train is of 10 s and the rest between trains is of 30 s. A WP NMES session includes 30 evoked contractions. The stimulation intensity is monitored online and adjusted to the highest tolerable by the subjects.During the stimulation, subjects are seated with the knee joint fixed a 60° angle. Three self-adhesive electrodes are placed over the right thigh. The positive electrodes, measuring 25 cm² (5 x 5 cm), are placed as close as possible to the motor point of the vastus lateralis and vastus medialis muscles. The negative electrode, measuring 50 cm² (10 x 5 cm), is placed 5-7 cm below the inguinal ligament. Electrical stimulations are delivered by a stimulator BioStim (Mazet Santé).
45671146|NCT04857710|Device|Conventional neuromuscular electrostimulation (CONV NMES)|"The CONV NMES program consists of electrical stimulation trains of 500 symmetrical biphasic pulses (0.2 ms, 50 Hz). The duration of a train is of 10 s and the rest between trains is of 30 s (duty cycle: 1/3). A WP NMES session includes 30 evoked contractions. The stimulation intensity is monitored online and adjusted to the highest tolerable by the subjects.~During the stimulation, subjects are seated with the knee joint fixed a 60° angle. Three self-adhesive electrodes are placed over the right thigh. The positive electrodes, measuring 25 cm² (5 x 5 cm), are placed as close as possible to the motor point of the vastus lateralis and vastus medialis muscles. The negative electrode, measuring 50 cm² (10 x 5 cm), is placed 5-7 cm below the inguinal ligament. Electrical stimulations are delivered by a stimulator BioStim (Mazet Santé)."
45671147|NCT04857710|Device|Control (CONT) modality|Control (CONT) modality is used as a reference and is representative of a sedentary behaviour regularly observed in our populations.
45975704|NCT04823962|Drug|Placebo hydrogel|Placebo hydrogel
45975705|NCT04823962|Other|Standard care|Compression therapy and neutral dressings
45975706|NCT00252668|Drug|Etanercept|
45975707|NCT00252668|Drug|Methotrexate|
45975708|NCT02271997|Drug|Ferrous fumarate|treatment with ferrous fumarate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
45975709|NCT02271997|Drug|Ferrous gluconate|treatment with ferrous gluconate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
45671148|NCT05478746|Device|BioNourish, a component of the Flourish HEC kit|BioNourish is a vaginal moisturizing gel which obtained FDA 510k clearance in 2020. It is one component of the full system being tested. The main intervention is to use this kit to improve the vaginal microbiome.
45671149|NCT05478746|Other|Control - no intervention|No intervention; participants only receive routine care.
45671150|NCT05465798|Drug|MC 3x3|Patients allocated to this arm will receive MC 3x3, an oral supplement containing 25mg of 1,3 beta-Glucans of fungal origin (Trichoderma sp.) daily for up to three consecutive days.
45975710|NCT02271997|Drug|Iron(III)carboxymaltose|treatment with Iron(III)carboxymaltose and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
45975711|NCT04821076|Other|Diet intervention - caloric restriction|Energy restriction is set to 25 kcal / kg fat-free mass
45975712|NCT04821076|Other|Exercise intervention|Exercise will consist of supervised resistance training, interval training and moderate intensity cycling
45975713|NCT04821076|Other|Diet intervention - Energy balance|Energy balance is set to 50 kcal / kg fat-free mass
45975714|NCT05139394|Procedure|emergency pancreaticoduodenectomy|Emergency pancreaticoduodenectomy (EPD) is a complex surgical procedure, that can be performed for complex pancreaticoduodenal injuries, that cannot be controlled through less invasive procedures. EPD can be performed either as a classical Whipple procedure, or as a pylorus-preserving procedure. A one stage procedure implies the reconstruction step being done in the same surgical intervention, while a two step procedure implies the reconstruction being done in a later stage, through a second surgical intervention.
45975715|NCT05139082|Drug|TQB3616 capsules＋ TQB2450 injection|"TQB3616 is a highly active CDK4/6 inhibitor. Preclinical studies have shown that it has a strong inhibitory effect on the kinase activity of CDK4/6.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
45975716|NCT04719767|Device|visual laryngeal mask|After anesthesia induction, visual laryngeal mask airway was placed in the visual group and tracheal intubation was guided under visual conditions. In the non-visual group, laryngeal mask airway was inserted, after clinical judgment of good counterpoint of the laryngeal mask, endotracheal intubation was inserted blindly through LMA. Selection of laryngeal mask airway (LMA) model: the ideal body weight of the patient was calculated.
45975717|NCT05138926|Other|Cervical Manipulation|high speed, low amplitude cervical manipulation
45975718|NCT05138926|Other|Sham Cervical Manipulation|Cervical mobilization without performing spinal manipulation
45975719|NCT00287391|Drug|Rabeprazole|
45975720|NCT05138536|Procedure|Pan-Computer Tomography|trauma centers use the pan-computed tomography (CT) scan (head, neck, chest, and abdomen/pelvis) for the evaluation of blunt trauma.
45975721|NCT04826770|Drug|BNT162b2|vaccination against COVID-19
45975722|NCT04826770|Drug|AZD 1222|vaccination against COVID-19
45975723|NCT04826770|Drug|mRNA-1273|vaccination against COVID-19
45975724|NCT00252707|Drug|Gefitinib or Docetaxel|
45975725|NCT01680367|Procedure|wound care management|Receive transparent film dressing or Xeroform petroleum gel impregnated gauze dressing
45975726|NCT01680367|Procedure|wound care management|Receive native collagen wound dressing
45975727|NCT01680367|Other|questionnaire administration|Ancillary studies
45975728|NCT00281073|Device|Intra-Cardiac Echocardiography guided Cardioversion|Intracardiac Echo and TEE
45975729|NCT00281073|Device|Intracardiac Echo|Intracardiac Echo Viewmate
45975730|NCT00281073|Device|ICE|ICE or TEE
45975731|NCT01680406|Drug|Artemether-lumefantrine combination|
45975732|NCT01680406|Drug|Primaquine|
45671151|NCT05465798|Drug|Placebo|Patients allocated to this arm will receive a matching placebo similar to MC 3x3 pills used in the intervention arm. Placebos will be delivered orally every day for up to three consecutive days.
45671152|NCT04860596|Behavioral|collaborative health management model|nursing education program
45975733|NCT01680406|Drug|Chloroquine|
45975734|NCT00252746|Drug|ZD6474 (vandetanib) 100mg|once daily oral dose
45975735|NCT00252746|Drug|ZD6474 (vandetanib) 200mg|once daily oral dose
45975736|NCT00252746|Drug|ZD6474 (vandetanib) 300mg|once daily oral dose
45671153|NCT05650424|Other|Abdominal massage training|please refer to group description
45830544|NCT04748328|Procedure|ACL Reconstruction surgery and Rehabilitation Treatment|ACL Reconstruction surgery is a procedure to treat ACL injury by replacing the torn ligament with another. ACL Rehabilitation treatment is a procedure to treat ACL injury by muscle strengthening and exercise
45975737|NCT01680484|Dietary Supplement|Bitter chocolate|
45975738|NCT01680484|Dietary Supplement|Orange juice|
45975739|NCT01680523|Procedure|Radical hysterectomy|Piver-Rutledge type III hysterectomy New classification type C2 hysterectomy Open, vaginal, laparoscopic assisted, laparoscopic, robotic radical hysterectomy are all allowed
45975740|NCT01680523|Radiation|Tailored adjuvant therapy|After radical hysterectomy, intermediate risk group according to GOG protocol 92 criteria will receive adjuvant radiation therapy. High risk group will receive adjuvant chemoradiation therapy with weekly cisplatin (40mg/m2, IV for 6 cycles). Extended filed radiation therapy is allowed in case of common iliac lymph node or para-aortic lymph node metastasis. Intracavitary brachytherapy and nodal or parametrial boost is not allowed.
45671154|NCT05650268|Drug|Vitamin D3|Receiving 576000 international units in single oral dose of liquid vitamin D 3~7 days prior to the surgery.
45671155|NCT05650268|Other|95% MCT|95% MCT supplement 3-7 day before surgery
45671156|NCT05434598|Device|ChromoSeq|Novel, streamlined whole genome sequencing approach
45671157|NCT05577494|Other|Questionnaire online|"Questionnaire online: all subjects will receive an online questionnaire and complete the Clinician Questionnaire.~Semi-structured interviews: semi-structured interviews are conducted with the clinician interviewers using the Clinician Interview Guide.~Focus group discussion: Focus group discussions are conducted with patients according to the Patient Focus Group Symposium Manual."
45830545|NCT01528254|Drug|Placebo of vildagliptin|
45830546|NCT01528254|Drug|vildagliptin|One tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.
45830547|NCT01528254|Drug|Metformin|Twice daily (bid) regimen during or after meals at the same time as vildagliptin.
45830548|NCT01574352|Behavioral|Small intervention|The control group are offered a weekly 1 hour training or activity session during six weeks. Furthermore two sessions where the parents are invited to participate in information about diet and exercise.
45975741|NCT01680523|Radiation|Primary chemoradiation therapy|Patient will receive primary radiation therapy including external pelvic irradiation, intracavitary brachytherapy, and parametrial or nodal boost. Extended filed radiation therapy is allowed in case of common iliac lymph node enlargement. Patients will receive concurrent weekly cisplatin (cisplatin 40mg/m2 for 6 cycles) during external radiation therapy.
45975742|NCT00287430|Drug|Growth Hormone|
45975743|NCT00287430|Procedure|Whole body Protein Turnover Study|
45975744|NCT00287430|Procedure|Dual Energy X-ray Absorptiometry (DEXA)|
45975745|NCT01680562|Other|in-vivo skin tumor imaging via optical coherence tomography|optical coherence tomography imaging of skin lesion; digital dermoscopy imaging of skin lesion
45975746|NCT04528147|Behavioral|Yi Jin Jing Tiger Roaring Speech Rehabilitation|A traditional Chinese medicine treatment
45975747|NCT04528147|Behavioral|Conventional Speech Rehabilitation|A active speech rehabilitation method recommended by the Parkinson's Foundation of America
45975748|NCT01680601|Procedure|Remote ischaemic preconditioning (RIPC)|RIPC will be performed by 3 cycles of 5 minute leg ischaemia induced by inflation of a blood pressure cuff to 40 mmHg above the patient's systolic pressure. This protocol will be performed at two phases: 24 hours before surgery and during anaesthesia immediately prior to surgery.
45830549|NCT01574352|Behavioral|Intervention camp|The children are participating in a 6 week day camp. The camp contains social activities, physical activity training, usual school classes and health education. All meals (healthy food) are consumed during the camp day.
45975749|NCT01680601|Procedure|Placebo|
45458622|NCT01238419|Device|Physiotulle|Physiotulle is a non adherent dressing, composed of a polyester fabric impregnated with hydrocolloid particles (CMC) suspended in vaseline
45830550|NCT01527006|Drug|perampanel|During the titration period, participants started at a set daily dose of 0.015 mg/kg and had doses up-titrated at 1-week intervals (6 titration steps) to a maximum daily dose of 0.18 mg/kg. During the Maintenance Period, participants continued taking perampanel oral suspension once daily at the dose level they achieved at the end of the Titration Period. During the extension phase, participants continued taking perampanel oral suspension once daily, at the dose level achieved at the end of the treatment phase of the core study to a maximum daily dose of 0.18 mg/kg. The maximum total daily dose a participant was allowed was 12 mg.
45671158|NCT05092178|Behavioral|calorie restricted diet and exercise|The CR diet and exercise group received a balanced diet with an energy consists carbohydrates 45-65%; fat 20-35%; and protein 10- 35% and a deficit of 600 kcal/day from their daily energy requirement.The exercise intervention consists of aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for≥2 d•wk for six months. The aerobic exercises included walking on a treadmill, stationary cycling for at least 30 minutes for≥2 d•wk, while, resistance exercises included nine upper-extremity and lower-extremity exercise with weighting lift machines for ≥2 d•wk, while, flexibility exercise including the major muscle-tendon groups (a total of 60 s per exercise) for ≥2 d•wk. Participants performed 1 or 2 sets with 8-12 repetitions of each exercise. The exercise sessions were monitored by telephone video.
45671159|NCT05092178|Behavioral|exercise alone|In exercise alone group, participants then underwent their usual habitual dietary diet and the above exercise intervention during the program.
45671160|NCT01640366|Device|PICO|Single-use Negative Pressure Wound Therapy System
45671161|NCT01640288|Drug|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, < 1 hour
45671162|NCT01640288|Other|High Resolution CT of the Chest|High Resolution CT of the Chest, single visit
45830551|NCT01526928|Drug|Rociletinib|Phase 1: Rociletinib <900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
45830552|NCT01526928|Drug|Rociletinib|Phase 1: Rociletinib 900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
45830553|NCT01526928|Drug|Rociletinib|"Phase 1: Rociletinib 500 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 500 mg BID HBr will be administered daily"
45830554|NCT01526928|Drug|Rociletinib|"Phase 1: Rociletinib 625 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 625 mg BID HBr will be administered daily"
45830555|NCT01526928|Drug|Rociletinib|"Phase 1: Rociletinib 750 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 750 mg BID HBr will be administered daily"
45830556|NCT01526928|Drug|Rociletinib|"Phase 1: Rociletinib 1000 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 1000 mg BID HBr will be administered daily"
45830557|NCT01549860|Device|MIST Therapy|Non-contact low frequency ultrasound therapy
45830558|NCT01549392|Device|DECT|DECT at tumor progression and 3 months later
45830559|NCT01549392|Device|MR spectroscopy|MR spectroscopy at tumor progression and 3 months later
45830560|NCT01526148|Drug|Lithium|Lithium will be initiated at 300 mg per day and titrated in 300 mg increments every 7days as tolerated with blood lithium levels > 0.6mEq/L.
45975750|NCT01680679|Biological|Inactivated Trivalent Influenza Vaccine (TIV)|
45975751|NCT01680679|Biological|Inactivated poliovirus vaccine (IPV), trivalent|
45975752|NCT01680718|Drug|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
45975753|NCT01680718|Drug|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
45975754|NCT01680718|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010).
45975755|NCT01680757|Device|LARIAT Suture Delivery Device and Accessories|
45975756|NCT01680796|Drug|Dovitinib|"Dose Level 0: 200 mg daily~Dose Level 1: 300 mg daily~Dose Level 2: 300 mg daily~Dose Level 3: 400 mg daily~Dose Level 4: 500 mg daily"
45975757|NCT01680796|Drug|Bortezomib|"Dose Level 0: 1.3 mg/m2 IV on days 1 and 8~Dose Level 1: 1.3 mg/m2 IV on days 1 and 8~Dose Level 2: 1.6 mg/m2 IV on days 1 and 8~Dose Level 3: 1.6 mg/m2 IV on days 1 and 8~Dose Level 4: 1.6 mg/m2 IV on days 1 and 8"
45975758|NCT01680796|Drug|Dexamethasone|Dexamethasone 20 mg will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle.
45671163|NCT04688996|Diagnostic Test|Lateral Flow Assay for Pathogens of the Plague|A dipstick type of rapid test for antigens of the plague bacterium Yersinia pestis in samples from enrolled participants from both a known geography of plague activity (Madagascar) as well as samples from a geographically separated population of likely plague free status (US Naval Health Research Center, San Diego, CA).
45671164|NCT04835870|Drug|Zanubrutinib|Zanubrutinib-160mg bid PO d0-d20(1-21d)
45671165|NCT04835870|Drug|Rituximab|Rituximab-375 mg/m2 i.v d0 (/21d)
45830561|NCT01526148|Drug|Quetiapine|Quetiapine will be started at 50 mg per day at bedtime and titrated up to 300 mg as tolerated over 1 week.
45671166|NCT04835870|Drug|Cyclophosphamide|Cyclophosphamide-750 mg/m2 i.v d1 (/21d)
45671167|NCT04835870|Drug|Doxorubicin|Doxorubicin-50 mg/m2 i.v d1 (/21d)
45671168|NCT04835870|Drug|Vincristine|Vincristine-1.4 mg/m2 i.v d1 (/21d)(2 mg max)
45671169|NCT04835870|Drug|Prednisone|Prednisone-100 mg p.o d1-d5 (/21d)
45671170|NCT01639040|Drug|Dupilumab|Dupilumab 300 mg once weekly (QW) for 4 weeks
45671171|NCT01639040|Drug|Placebo (for Dupilumab)|Placebo (for Dupilumab) once weekly (QW) for 4 weeks
45671172|NCT01639040|Other|Topical Corticosteroid (TCS)|TCS such as methylprednisolone aceponate 0.1%, mometasone furoate 0.1%, or betamethasone valerate 0.1%
45830562|NCT01572948|Drug|roflumilast|The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
45830563|NCT01572948|Drug|placebo|The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient
45830564|NCT01525602|Drug|PLX3397|PLX3397 tablets, 200mg
45830565|NCT01525602|Drug|Paclitaxel|Paclitaxel IV
45671173|NCT04687904|Behavioral|Mindfulness meditation training|Patients will be able to benefit from mindfulness meditation training at the rate of 1h30 in the morning and 1h30 in the afternoon. During this training, patients will be invited to share with the psychologist their vision of mindfulness meditation and their expectations of this practice. The psychologist will then introduce what mindfulness is and how the sessions will take place. Several sessions guided by the psychologist will then be offered to the patient (body scan, focused attention, mindfulness movements...).
45830566|NCT04749966|Other|This is an observational study, there are no interventions|This is an observational study, there are no interventions
45830567|NCT01549002|Drug|Intranasal Fentanyl|Drug: Fentanyl 50 micrograms/mL Dosage: 2 micrograms per kilogram (maximum 100 micrograms) Drug delivery: Intranasal via mucosal atomization device (MAD® Nasal, Wolfe Tory Medical Inc., Salt Lake City, UT) Frequency: one-time dose
45830568|NCT01549002|Drug|Intravenous Morphine|Drug: Morphine Dosage: 0.1 milligrams/kilogram (maximum 8 milligrams) Drug delivery: Slow IV push Frequency: one-time dose
45975759|NCT00252785|Drug|Budesonide/Formoterol|
45975760|NCT00252785|Drug|Budesonide|
45975761|NCT00252785|Drug|Theophylline|
45975762|NCT01680874|Dietary Supplement|Probiotic|The intervention will consist of the subject taking the study medication once a day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
45456083|NCT05046873|Drug|Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL|Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
45671174|NCT04687904|Behavioral|Therapeutic education|"Patients will benefit from a 2-hour interview which will be conducted by the psychologist associated with the project.~The aim of this interview is to help patients better understand their disease in order to adopt the right behaviors on a daily basis. This session will inform patients about their disease, its origins, its treatment, the difficulties it causes and the means to remedy it. The objective of this session is to better understand and manage epilepsy and to enable patients to take an active part in the process of care and management of the disease.~No specific instructions will be given at the end of this interview."
45671175|NCT04685486|Other|Virtual Reality|Immersive and interactive game played through a portable head-mounted display as a distraction mechanism
45671176|NCT05421338|Drug|BI 456906 (C-14)|BI 456906 (C-14)
45456084|NCT05046873|Drug|semaglutide 1.34 mg/mL (placebo)|Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
45456085|NCT05046873|Drug|Semaglutide 1.34 mg/mL|The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
45456086|NCT05046873|Drug|NNC0480-0389 A 10 mg/mL|The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
45456087|NCT05042258|Drug|Dupilumab|12 week dupilumab administration
45975763|NCT01680874|Dietary Supplement|Placebo|The intervention will consist of the subject taking the placebo once a day for 4 weeks. day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
45975764|NCT01680913|Procedure|Ultrasound guidance|The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
45975765|NCT01680913|Procedure|Palpation of Tuffier's line|Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.
45830569|NCT01548768|Drug|TNF inhibitors|"TNF inhibitors are an FDA approved class of medications indicated for the treatment of RA when initial treatment (usually with methotrexate) has failed to achieve remission of RA disease activity. TNF inhibitors are part of the standard of care management of RA.~The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi."
45975766|NCT01680913|Procedure|Spinal anesthetic|Subcutaneous local infiltration with a 25g needle we be performed prior to the spinal. Neuraxial technique will be attempted midline with a 25 gauge whitacre needle in the sitting position. Spinals will be attempted on either L2-L3, L3-L4, L4-L5 interspaces. The amount and type of local anesthetic/intrathecal narcotic will be left to the discretion of the Anesthetist.
45975767|NCT00287508|Device|Carotid artery stenting with filter (interventional)|
45975768|NCT01680952|Drug|A) TEST|"Extended Release Tacrolimus (Advagraf®)~① Living The day before surgery: 0.2 mg/kg(morning dose) po, qd Morning on the day of surgery: 0.1 mg/kg po, qd After surgery, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~② Cadaveric Before surgery at once : 0.1 mg/kg within 12hours before surgery. After surgery : 0.2mg/kg po. in the morning After that, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~Sirolimus (Rapamune®):~After surgery : 2mg/kg po. within 24hrs after reperfusion. After that, the capacity is adjusted according to the trough level."
45456088|NCT05040984|Drug|Solifenacin Oral Tablet|Solifenacin 1 tablet per day
45456089|NCT05040984|Drug|Mirabegron 25mg|Mirabegron 1 tablet per day
45671177|NCT05400746|Biological|Pfs48/45 in Matrix-M|Three doses of Pfs48/45 in Matrix-M at different doses
45671178|NCT04834388|Drug|Anakinra|Anakinra treatment is started within 8 hours of symptom onset
45671179|NCT04834310|Drug|Cefazolin|All patients will receive an intraoperative dose of IV Cefazolin 2 g (re-dose after 4 hours) or IV Clindamycin 600mg (re-dose after 6 hours) for penicillin allergic patients.
45830570|NCT01548768|Drug|DMARDs|Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.
45830571|NCT01572792|Drug|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose, twice per day
45830572|NCT01572792|Drug|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose, twice per day
45975769|NCT01680952|Drug|B) CONTROL|"Extended Release Tacrolimus (Advagraf®)~: Same as above.~Mycophenolate mofetil : After surgery : 500mg/kg po. within 24hrs after reperfusion. After that, daily dose: 1000mg bid"
45671180|NCT04834310|Drug|Cephalexin|The experimental group will receive a postoperative 5-day course of Cephalexin 500 mg QID or Clindamycin 300 mg QID for penicillin allergic patients. All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.
45671181|NCT04834310|Other|Placebo|The placebo group will receive a postoperative 5-day course of placebos (sugar capsules). All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.
45975770|NCT01681108|Behavioral|Lifestyle counseling|Individualized meal planning and exercise regimen sessions will be developed for each participant
45975771|NCT01681303|Drug|AST-120|
45975772|NCT00252824|Drug|Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy|
45975773|NCT04528420|Other|optimised management|"At the inclusion , the patient will benefit from an early consultation with a nutritionist, a pain doctor and a social worker.~During the preparation phase for radiotherapy the patient will benefit from weekly consultations with a pain nurse and a dietician.~During the radiotherapy the patient will be weighed daily and have an assessment of their nutritional needs and a weekly consultation with a pain nurse and dietician and then twice a month until three months post-radiotherapy."
45975774|NCT01681381|Device|Tivoli® DES|Device:Tivoli® DES The Tivoli® DES drug eluting stent(Tivoli® DES) is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug releasing in 1 week and approximately 80% releasing in 28 days. The polymer may be degraded in 3 to 6 months in human body. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 10、15、18、21、25、30、35 mm and diameters of 2.5、2.75、3.0、3.5、4.0 mm.
45975775|NCT01681381|Device|Firebird2® DES|The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug elutes in 1 week and approximately 90% elutes in 1 month. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 13, 18, 23, 29, 33 mm and diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm.
45975776|NCT01681420|Behavioral|HIV Counseling and Testing|HIV counseling and testing in lieu of blood donation.
45975777|NCT01681420|Behavioral|Blood Donation|Blood donation without HIV counseling
45975778|NCT00281190|Procedure|Blood drawing|blood will be drawn at the time of starting the intravenous (IV) line for the procedure.
45975779|NCT00281190|Procedure|Bronchoalveolar lavage during indicated bronchoscopy|A small amount of liquid will be introduced and immediately sucked back out of portions of the lung, and the cells that are recovered will be analyzed in the laboratory. All test will be solely for research, and there will be no results reported to the subject from that fluid.
45975780|NCT00252863|Drug|Symbicort, used twice daily (b.i.d) and as needed (prn)|
45975781|NCT00252863|Drug|Budesonide Turbuhaler 200 µg|
45975782|NCT00252863|Drug|Fluticasone Discus 250 µg|
45975783|NCT00252863|Drug|Formoterol Turbuhaler 4.5 µg|
45975784|NCT00252863|Drug|Terbutaline Turbuhaler 0.5 mg|
45975785|NCT00252863|Drug|Salbutamol pressurized metered dose inhaler (pMDI) 100 µg|
45975786|NCT00252863|Drug|Salmeterol Discus 50 µg|
45975787|NCT00252863|Drug|Budesonide/Formoterol Turbuhaler 160/4.5 µg|
45975788|NCT00252863|Drug|Fluticasone/Salmeterol Discus 250/50 µg|
45975789|NCT00252863|Drug|Fluticasone/Salmeterol Discus 500/50 µg|
45975790|NCT00252863|Drug|Theophylline 200 mg|
45456090|NCT05038930|Device|Mobilisation using the Sara Combilizer|The mobilisation with the Sara Combilizer, will be done one time either 24 or 48 hours after stable intracranial pressure
45456091|NCT05038527|Device|ABM/P-15 bone graft|RCT (single blinded) where the patients will be randomized into two groups. One group receiving the standard bone graft which is a mix of locally autologous harvested bone and a morselized femoral head (allogenic) and the other group will receive bone graft of anorganic bovine bone mineral coated with a bioactive peptide (ABM/P-15).
45671182|NCT05397782|Device|BioNourish, a component of Flourish HEC|BioNourish, one of three parts of the Flourish HEC system, is a vaginal moisturizing gel - a Class II medical device with FDA 510k clearance obtained in 2020.
45671183|NCT05060042|Other|Whole body vibration group|WBV will be provided with a frequency of 6-26Hz with amplitude of 1-3mm 4-5 bouts(60 sec each) for 3 times a week
45671184|NCT05060042|Other|Bilateral proprioceptive training|"Static balance training will be provided in first week for 3-4 times for 10 mints of single session. 3 times a week In 2nd and 3rd week dynamic balance training for 3 times with a session of 10 mints.~In 4th week progressive balance training will be done with same frequency and duration.~Tai chai exercises will be given for 20 mints 3 times a week"
45671185|NCT04848116|Drug|Nivolumab|Nivolumab is an investigational drug in this study.
45671186|NCT04848116|Drug|HuMax-IL8|HuMax-IL8 is an investigational drug in this study.
45830573|NCT01572792|Drug|Aclidinium bromide|Inhaled Aclidinium bromide 400 μg, twice per day
45830574|NCT01572792|Drug|Formoterol Fumarate|Inhaled Formoterol Fumarate 12 μg, twice per day
45830575|NCT01572792|Drug|Placebo|Inhaled dose-matched placebo, twice per day
45830576|NCT03028272|Other|Skye Barrier|Substrate derived from amniotic tissue that is FDA-approved for human implantation
45830577|NCT03028272|Other|Fascia|Autologous donor substrate. Examples include tragal cartilage, perichondrium, temporalis fascia, and temporoparietal fascia
45830578|NCT01547598|Drug|travoprost ophthalmic solution 0.004%|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks.
45975791|NCT00252863|Drug|Theophylline 300 mg|
45975792|NCT00252863|Drug|Singulair 10 mg|
45975793|NCT01681537|Drug|Lenalidomide|
45975794|NCT01681537|Drug|Mitoxantrone|
45975795|NCT01681537|Drug|Etoposide|
45975796|NCT01681537|Drug|Cytarabine|
45975797|NCT00287625|Procedure|Pulmonary rehabilitation|Pulmonary rehabilitation
45975798|NCT01681654|Behavioral|Lifestyle Intervention|Participants in the Lifestyle Intervention will receive a 12-week individualized exercise and dietary program based on their exercise assessment and dual energy x-ray absorptiometry (DXA) scan results, will attend twice weekly group exercise classes, and perform their individualized at-home program an additional two times per week. In addition, participants will be required to attend six education sessions during the 12-week intervention.
45975799|NCT01681654|Behavioral|Maintenance Intervention|Patients randomized to receive the Maintenance Program Intervention following treatment will receive a Survivorship Care Plan outlining their physical activity, dietary, and health behaviour progress throughout the program, future goals, individualized maintenance strategies, and optional drop-in exercise sessions.
45975800|NCT01681693|Drug|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
45975801|NCT01681732|Other|Personalized Care Plan|We will develop a personalized plan based on info collected in the primary visit
45975802|NCT01681732|Other|Control Standard Care|This is the standard care arm
45975803|NCT01681888|Device|Sanger EMG Biofeedback Device|
45975804|NCT00252902|Behavioral|Behavior change counseling|
45975805|NCT04528264|Device|Intraoperative ultrasound guided|Samsung Mysono U6 machine with LN 15 linear (https://www.samsunghealthcare.com/en/products/UltrasoundSystem/MySono%20U6/General%20Imaging/transducers) probe capable of Musculoskeletal imaging will be used for visualization and location of fracture after which elevation and reduction of fracture will be attempted. The ultrasound probe will be used as described by McCann. Radiographic continuity of periosteal shadow without any step will be taken as end point for reduction and the procedure will be terminated.
45975806|NCT04528264|Other|Conventional blind reduction technique|Conventional blind reduction technique
45975807|NCT01681966|Drug|PRF110- oily solution (Ropivacaine)|Post operative application of PRF110-oily solution (Ropivacaine)
45975808|NCT01682161|Drug|Paliperidone palmitate|Paliperidone palmitate will be administrated in accordance with each product's information. Recommended initial loading doses are 150 mg equivalent on Day 1 and 100 mg equivalent on Day 8, followed by subsequent once-monthly administration with 75 mg equivalent or flexible dose between 25 mg and 150 mg equivalent.
45975809|NCT01682200|Drug|ProOxy|Clean the face with ProOxy facial wash before spraying ProOxy on the face enough to wet it twice daily, upon waking up and before bedtime.
45975810|NCT01682395|Procedure|Resection and anastomosis|Resection of sigmoid colon with primary anastomosis
45975811|NCT01682395|Procedure|Resection and colostomy|Resection of sigmoid colon with end colostomy and Hartmann's pouch, followed at a later date by Hartmann's reversal as a second surgical procedure
45975812|NCT01682395|Procedure|Mesosigmoidopexy|Mesosigmoidopexy--the fixation of the sigmoid colon to lateral abdominal wall with concomitant shortening of the mesosigmoid length.
45975813|NCT01682434|Procedure|Laser in situ keratomileusis (LASIK)|Wavefront guided treatment in one eye, conventional in the other.
45975814|NCT01682473|Drug|ZSTK474|Two arms, each with serial cohorts receiving escalating doses.
45975815|NCT00252941|Device|Memokath 028SW Urethral Stent|
45975816|NCT01682551|Drug|Chinese Medicine|"The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day."
45975817|NCT01682551|Drug|Acetalozamide|"If the participators have the history of AMS, he/she will be randomized to take Wu Zhu Yu Tang plus placebo of Acetalozamide or Acetalozamide plus placebo of Wu Zhu Yu Tang."
46082193|NCT02737488|Behavioral|Treatment as Usual (TAU)|"Youth in the control group will be referred to a mental health clinic in close proximity to their residence, in order to receive an evaluation and trauma treatment as usually provided. It cannot be specifically determined, in advance, the nature of this treatment.~The clinics will be contacted after the family enrolls to determine if there was a specific protocol followed. An NYU CSC research coordinator will contact the clinic and assist in scheduling the subject's first visit. Families who do not enroll in any community treatment or dropout of treatment will be followed according to the research protocol for data collection. At the 3, 6, and 9 month assessments, the research coordinator will request the patient's records from the community treatment clinic they are attending in order to track and keep record of the youth's treatment modality, progress, and visit frequency."
46082194|NCT05102513|Procedure|Unilateral Cleft Lip Repair: Hybrid Technique|The rotation flap of the Millard II technique was expanded by extending the incision into the columella - similar to the well-known Mohler technique. The caudal part of the advancement flap of the Millard II technique was lengthened by a wave cut as known from the Pfeiffer procedure. For the vermillion a Noordhoff plasty is applied.
45830579|NCT01547598|Drug|travoprost 0.004% / timolol 0.5% combination ophthalmic solution|DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
45671187|NCT04848116|Drug|Cabiralizumab|Cabiralizumab is an investigational drug in this study.
45671188|NCT05392868|Device|SDF|38% silver diamine fluoride solution
45671189|NCT05392868|Device|KNO3|5% potassium nitrate solution
45830580|NCT01547598|Drug|Bimatoprost ophthalmic solution 0.01%|LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
45830581|NCT01547286|Biological|Standardized Cat Allergen Extract and Standardized Dust Mite Allergen|The route of administration will be topical application of the titrated allergen via nebulized droplets to the lungs. The starting dose of allergen will be 3 dose dilutions below the estimated provocative concentration of allergen that causes a 20% fall in Forced Expired Volume in 1 second delivered for 5 minutes at tidal breathing, followed by Forced Expired Volume in 1 second at 10-minute intervals until the lowest Forced Expired Volume in 1 second is established. If the percent of Forced Expired Volume in 1 second fall is < 20%, the next concentration is given, until the Forced Expired Volume in 1 second falls ≥ 20 percent. When this happens the Forced Expired Volume in 1 second will be followed at 10, 20, 30, 45, and 60 minutes, then hourly for 7 hours. The early asthmatic response is the maximum percent of Forced Expired Volume in 1 second fall between 0 and 3 hours and the late asthmatic response between 3 and 7 hours post allergen challenge.
45830582|NCT01547286|Radiation|Computed Tomography imaging, functional Positron Emission Tomography imaging|Physiology study using Computed Tomography and Positron Emission Tomography imaging with Nitrogen-13 saline as radiotracer; images obtained during the early and late phases after allergen challenge
45975818|NCT00281268|Procedure|pulmonary artery catheter|
45975819|NCT00281268|Procedure|central venous catheter|
45975820|NCT00281268|Procedure|fluid management|
45975821|NCT02279914|Drug|Misoprostol 400 mcg 3 hours prior to procedure|Misoprostol 400 mcg 3 hours prior to D&E procedure
45975822|NCT02279914|Drug|Misoprostol 600 mcg 90 minutes prior to procedure|Misoprostol 600 mcg 90 minutes prior to D&E procedure
45975823|NCT01682590|Procedure|Renal Remplacement Therapy|"Investigators of each center will have the choice of the RRT technique based on their usual practice: intermittent hemodialysis, intermittent hemodiafiltration, continuous hemodialysis, continuous hemofiltration, continuous hemodiafiltration (typically the continuous techniques in the acute phase, followed by intermittent techniques after stabilization).~In case of life threatening conditions within the 48 hours after randomisation (hyperkalemia, metabolic acidosis or pulmonary edema) the RRT will be initiated as soon as possible.~In case of improvement of renal function within the 48 hours after randomisation (defined as the return of spontaneous urine output > 1000ml/24 hr or >2000ml/24hr with diuretics), RRT is not mandatory."
45975824|NCT00281307|Drug|RRR-alpha-tocopherol 1,000 IU/mL|Intranasal application three times daily vs. placebo (inert excipient)
46082195|NCT05102513|Procedure|Unilateral Cleft Lip Repair: Millard 2 Technique|A curved incision is marked skirting the philtral ridge. If more length is required a back-cut incision can be performed. The C-flap is outlined by the incision just marked and the incision along red-white border up to the base of the columella. On the cleft side an advancement flap is designed. For the vermillion a Noordhoff plasty is applied.
46082196|NCT04111952|Device|CO2 laser|A single session of CO2 vaginal laser treatment
46082197|NCT04111952|Device|Sham laser|A single session of sham laser treatment.
46082198|NCT02727426|Other|Low Salt (LS) diet|Intake of less than 2.3 g of salt per day for 7 days.
46082199|NCT02727426|Other|High Salt (HS) diet|Intake of 11.2 g of salt per day for 7 days.
46082200|NCT00610025|Procedure|Transgastric access to the abdomen|Upper endoscopy, gastrotomy created with a needle knife followed by lower endoscopy.
46082201|NCT02811770|Other|kidney biopsy|
46082202|NCT02732418|Drug|Depo-Provera CI|The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA)
46082203|NCT02732418|Drug|Depo-subQ 104|The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA). Depo-subQ provera 104® (medroxyprogesterone acetate injectable suspension, 104 mg/0.65mL) for subcutaneous injection
46082204|NCT05099393|Dietary Supplement|Non Nutritive Sweeteners|"The 2 arms will participate in 3 periods and each of these periods will correspond to the intake of either sucralose, AceK or a placebo.~The order will be defined randomly. There will be 3 periods and each period will last 4 weeks. 7 to 14 days of break will be respected between each period."
46082205|NCT02811692|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
46082206|NCT02732340|Procedure|triple-branched stent graft|place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
46082207|NCT04259723|Other|VR during TAVI|Virtual Reality (VR) glasses
45671190|NCT05390606|Combination Product|Flourish HEC and BioGenesis|Flourish HEC is a 3-component system, including: 1) Balance feminine wash, used daily; 2) BioNourish vaginal moisturizer, used daily before bed except if having intercourse; 3) BiopHresh homeopathic vaginal suppository with probiotics, used once every 3 days before bed except if having intercourse. BioNourish is a class II medical device with FDA 510k clearance, on the market for 2 years. BioGenesis is also a class II medical device with FDA 510k clearance, and is designated as a fertility lubricant, safe for sperm and embryos.
45671191|NCT05372198|Drug|Chohort 1: Surufatinib|Surufatinib 300mg, qd, every 3 weeks as a cycle
45671192|NCT05372198|Drug|Chohort 2: Immunotherapy|Refer to the instructions for the use of immunotherapy, every 3 weeks as a cycle
45671193|NCT05372198|Drug|Chohort 2: Surufatinib|Surufatinib 250mg, qd, every 3 weeks as a cycle
46082208|NCT04104854|Device|drug coated balloon|Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for >30 seconds
45671194|NCT04854980|Other|Blood Sample|Blood sample, 2- to 5 tea spoon full (between 10 to 25 mL approximately) between 43 to 96 days after first dose of the vaccine.
45671195|NCT05048732|Drug|18F-FluorApoTrace|-The dose of 18F-FluorApoTrace to be given is 5 mCi
45830583|NCT01547286|Drug|Nebulized methacholine inhalation|Standard methacholine challenge performed once to determine the subject's dose that causes a 20% fall in Forced Expired Volume in 1 second from baseline.
45830584|NCT01547130|Drug|Normal (0.9%) saline|A total of 2L solution at lukewarm temperature (37.2-38.8 degrees Centigrade)consumed as bolus intake (8-16 oz in one to two minutes) alternating with yoga exercises.
46082209|NCT05330897|Procedure|Implantation of an eCLIPs™ device|Implantation of an eCLIPs™ device and coiling of the bifurcation aneurysm
46082210|NCT05330897|Device|eCLIPs™ Electrolytic Bifurcation Systems|Implantation of an eCLIPs™ device and coiling of the bifurcation aneurysm
45830585|NCT01547130|Drug|HalfLytely|A total of 2L solution prepared as per manufacturers instructions and sipped until bowel movements are clear.
46082211|NCT02737410|Behavioral|Gut-directed Hypnotherapy|The GHT protocol used was the Manchester protocol of GHT and consisted of 10 weekly sessions (45 min), with six patients per group over a treatment period of 12 weeks. GHT was performed at the University Hospital by two experienced physicians trained in Manchester (UK).
45830586|NCT01524978|Drug|cetuximab|Escalating doses administered on Day 1 and then once weekly by intravenous infusion.
45830587|NCT01524978|Drug|vemurafenib|Escalating doses given orally twice a day starting on Day 2
45830588|NCT01524978|Drug|vemurafenib|960 mg vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.
45830589|NCT04410120|Other|Interview|Semi-structured 45 minute interviews regarding impact of asthma attacks
45830590|NCT01524198|Drug|Budesonide|500 mcg budesonide plus Albuterol plus ipratropium bromide (IB) nebulization, 3 doses back to back
45830591|NCT01524198|Drug|Normal saline|0.5 ml to 1.5 ml normal saline (to complete 3 mls total volume), plus albuterol plus ipratropium bromide nebulizations 3 doses back to back
46082212|NCT04004078|Device|other antifungal agents,breathing machine|If treatment failure for patients in group A，group B，group C and group D，change other antifungal agents(Amphotericin B for Injection,25mg,North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation((EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
45671196|NCT05359406|Combination Product|a combination therapy including tislelizumab|"For liver/pulmonary metastasis, the treatment plan is to implement large fraction radiotherapy for 4-8 times. For primary rectum lesion, short-course radiotherapy regimen through intensity-modulated radiotherapy will be applied with dose of 25Gy/5Fx. Immunotherapy contains anti-PD-1 monoclonal antibody, Tislelizumab(200mg, d1, q3w, i.v). For patients with RAS or BRAF mutation, chemotherapy adopts FOLFOX+BEV plan. For patients without RAS or BRAF mutation, chemotherapy adopts FOLFIRI+CET plan.~Patients will be followed for safety during the study. The safety follow-up period is defined as 90 days after the last dose of tislelizumab. Safety related data will be collected from the time of signing the informed consent until the end of the safety follow-up period or the start of new therapy."
45671197|NCT05038904|Drug|Acalabrutinib|100 mg oral capsule
45671198|NCT01640054|Drug|Fostamatinib|Fostamatinib 100mg once daily
45830592|NCT01523886|Drug|Rocuronium|Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h
45830593|NCT01523886|Drug|Rocuronium|Intravenous use: 0,3 mg/kg followed by NaCl-infusion
45671199|NCT04654208|Drug|palbociclib|patients on palbociclib combination treatment
45830594|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28-days.
45830595|NCT01546038|Drug|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
46082213|NCT02732262|Drug|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 1.00 mg.
46082214|NCT02732262|Drug|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.03 mg/kg.
46082215|NCT02732262|Drug|Oxycodone, 0.02 mg/kg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.02 mg/kg.
46082216|NCT00566995|Drug|ZACTIMA (Vandetanib) (ZD6474)|
45671200|NCT04652960|Drug|Duvelisib|Given PO
45671201|NCT04652960|Biological|Nivolumab|Given IV
45671202|NCT04652960|Procedure|Punch Biopsy|Undergo punch biopsies
45671203|NCT05360420|Diagnostic Test|Immediate CEUS|Subjects will receive CEUS examination immediately for the suspicious lesion detected by US.
45671204|NCT05357846|Drug|Sintilimab|Sintilimab 200mg, IV (in the vein) on day 1 and day 22
45671205|NCT05357846|Radiation|Preoperative radiotherapy|External radiation with a total dose of 40.0 or 45.0 Gy is given in 20 fractions,5 fractions a week.
45671206|NCT05357846|Drug|Paclitaxel|50mg/m2, IV (in the vein) on day 1,day 8,day 15 and day 22
45671207|NCT05357846|Drug|Cisplatin|25mg/m2,IV DRIP on day 1,day 8,day 15 and day 22
45830596|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days.
45830597|NCT01546038|Drug|Decitabine|Decitabine given at 20 mg/m2 over 1 hour infusion for 5-days
45830598|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days
45830599|NCT01546038|Drug|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
45830600|NCT01546038|Drug|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
45830601|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days
45830602|NCT01546038|Drug|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
45830603|NCT01546038|Drug|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
45830604|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days (if randomized to receive PF-04449913)
45975825|NCT01682629|Other|Debriefing Script|"A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. It was developed in iterative steps: (a) review of PALS learning objectives; (b) categorization of script content; (c) development of scripted language; (d) formatting into a cognitive aid and (e) pilot testing script for usability with subsequent edits before implementation in the study.~All novice instructors received the scenario 2 weeks prior to the study session. Instructors randomized to scripted debriefing were also given the script with no instruction on how to use it except on the day of the study, to use and follow the script as closely as possible during the debriefing session. All instructors held a clipboard while observing the simulation session; to hold the debriefing script and/or take notes. This allowed for blinding of the video reviewers as to which study arm the team had been randomized. Debriefing sessions were limited to 20-minutes in duration."
45975826|NCT01682629|Other|High Physical Realism Simulation|"High vs. Low Physical Realism Simulators A pre-programmed infant simulator was used for all simulation sessions. To create high physical realism (HiR), full simulator functions were activated (turned on) including vital sign monitoring, audio feedback, breath sounds, chest rise, heart sounds, palpable pulses, and vocalization. Low physical realism (LoR) groups had the identical simulator but the compressor was turned off, thus eliminating physical findings described above. In addition, the LoR simulator was connected to a monitor, but it only displayed the cardiac rhythm, and not pulse oximetry, respiratory rate, blood pressure, temperature and audio feedback present in the HiR group. All other aspects of the simulated resuscitation environment were standardized for all groups."
45975827|NCT01682746|Drug|Photofrin (porfimer sodium) & photodynamic therapy.|"Intravenous (IV) Photofrin~This is a dose escalation study. Patients will receive Photofrin via an IV infusion approximately 24 hours prior to their tumor resection surgery and Photodynamic Therapy (PDT). Patients will be light sensitive immediately upon receiving the Photofrin and must observe photosensitivity & light precautions for a minimum of 30 days after the infusion.~Photodynamic Therapy (PDT)~After tumor resection, an optical fiber will be placed in the approximate center of the surgical cavity. Intralipid will be infused into the open tumor cavity while PDT is performed. The Intralipid will diffuse the light and ensure uniform delivery. Photoactivation of Photofrin is controlled by the total light dose delivered over the treatment time."
45975828|NCT00287664|Drug|terlipressin|
46082217|NCT05625984|Device|Fascigel|The product is a Class III Medical Device. Structure is made by 1% sodium hyaluronate polysaccharide in normal saline solution.
46082218|NCT00926393|Drug|Quetiapine Immediate Release|Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
46082219|NCT00926393|Drug|Quetiapine Extended Release|Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
45671208|NCT05357846|Procedure|esophagectomy|McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 6-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
45671209|NCT05358470|Other|Exercise therapy and adapted physical activity-based program|Exercise therapy and adapted physical activity program based on racket sports
45671210|NCT05031494|Drug|YH003|YH003 will be dosed at RP2D every 3 weeks. The first infusion of YH003 should be administered over 60 minutes.
45671211|NCT05031494|Drug|Toripalimab|Toripalimab will be administered at a dose of 240 mg every 3 weeks.
45830605|NCT01546038|Drug|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
45830606|NCT01571232|Drug|dexamethasone intravitreal implant|Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)
45458623|NCT01238419|Device|URGOTUL|Urgotul is an non occlusive dressing comprising of a polyester mesh impregnated with hydrocolloid particles dispersed on a petroleum jelly matrix
45458624|NCT01365260|Device|MM-II|Single intraarticular (knee) injection of MM-II
45458625|NCT01365260|Device|DurolaneTM|Single intraarticular (knee) injection of DurolaneTM
45458626|NCT03492892|Device|Acupuncture|Stimulate acupoint with filiform needles to restore the healthy condition of patients
45671212|NCT05031494|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered each 21-day cycle.
45671213|NCT05031494|Drug|Gemcitabine|Gemcitabine will be administrated each 21-day cycle.
45830607|NCT01571232|Drug|intravitreal bevacizumab|Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.
45830608|NCT01544478|Biological|V501|HPV types 6, 11, 16, and 18 vaccine 0.5 mL by intramuscular injection at Day 1, Month 2, and Month 6
45830609|NCT02985528|Other|further diagnostic|further diagnostic procedures - mainly CHEST CT -
45830610|NCT01522950|Drug|Nebivolol|5 mg daily or 10 mg daily
45830611|NCT01522950|Drug|atenolol|25 mg daily or 50 mg daily
45830612|NCT01522950|Drug|placebo|one tablet daily
45830613|NCT01522404|Drug|Atomoxetine|Subjects in this intervention will receive Atomoxetine up to 29 weeks, crossover, dose escalating (up to a maximum dose of 100 mg per day) of oral atomoxetine
45671214|NCT04845542|Behavioral|ReStoreD|ReStoreD is a remotely-administered behavioral intervention in which couples coping with stroke learn and practice goal-setting, communication strategies, and positive psychology activities, such as expressing gratitude, finding meaning, and fostering connections. Participants are provided with 8 weekly modules, each featuring two components: 1) psychoeducational materials, such as an informational video and resources/links about a general topic related to resilience, coping, and/or overall well-being of the individual and couple, and 2) examples of positive psychology activities that relate to the week's theme or topic. Participants are asked to complete at least two positive psychology activities alone and two together each week.
45671215|NCT04844216|Device|STYLAGE® L Lidocaine|An injection of maximum 2 mL on one nasolabial fold is planned at Day 0. A touch-up of maximum 1 mL on the same nasolabial fold is possible 1 month after D0 (month 1).
45975829|NCT01682902|Drug|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
45975830|NCT01682902|Drug|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
45975831|NCT01682902|Drug|insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
46082220|NCT02737254|Drug|Oxytocin|40 IU/ML nasal spray. One administration: children <40kg administer 12IU, children >40kg administer 24IU.
45671216|NCT04844216|Device|Active control|An injection of maximum 2 mL on one nasolabial fold is planned at Day 0. A touch-up of maximum 1 mL on the same nasolabial fold is possible 1 month after D0 (month 1).
45830614|NCT01522404|Drug|Placebo|Subjects in this intervention will receive inactive compound up to weeks 29 and will cross over to the other group
45830615|NCT01570686|Drug|Aliskiren|Aliskiren 300 mg once daily
45830616|NCT01522248|Biological|Trivalent Inactivated Influenza vaccine|0.5 ml IM once only
45830617|NCT04120584|Device|Forma Eye Applicator|"Eligible subjects will receive up to 3 treatments (2-3 weeks interval) with the Forma Eye Applicator according to the study protocol.~The subject will return for 3 follow up visits: four weeks (4wk FU), 12 weeks (12wk FU), twenty-four weeks (24wk FU) after the last treatment."
46082221|NCT02737254|Drug|Placebo|NaCl 0,9 % nasal spray.
45830618|NCT01543776|Drug|abiraterone acetate|Given PO
46082222|NCT02737254|Other|Secure CBM training|Children are trained to interpret ambiguous maternal behavior in a secure way.
45975832|NCT01683097|Other|Standardized explanation|Standardized explanation provided on code status, advance directives and end of life care
45975833|NCT01683136|Device|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|"on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities.~From the third treatment all subjects will recive a real stimulaitiobn: a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 10 Hz to the supplementary motor cortex and then a 20 seconds recess.each subject would undergo 5 sessions a week for 4 weeks"
45975834|NCT01683175|Drug|Erlotinib|
45975835|NCT01683175|Drug|cis-platinum|
45975836|NCT01683175|Drug|Vinorelbine|
45975837|NCT00252980|Behavioral|Psychotherapy|
45975838|NCT00281346|Procedure|Doppler echocardiography|Echocardiography
45975839|NCT01683253|Drug|Levodopa/Carbidopa(200mg/50mg)|
45830619|NCT04119414|Behavioral|Spear and Shield (S&S) Program|The S&S Program is a comprehensive sexual risk reduction intervention consisting of 4 weekly 90-minute manualized group sessions conducted by a trained Community Health Center (CHC) facilitator.
45975840|NCT01683253|Drug|Dopaminergic Agonists|Treated for at least 6 months after diagnosis of Parkinson's Disease.
45975841|NCT01683292|Drug|Inhaled VR040|
45975842|NCT01683292|Drug|Placebo for VR040|Placebo arm
45975843|NCT00253058|Drug|Cetirizine Dry Syrup|
45830620|NCT04119414|Behavioral|Like Father Like Son (LFLS) Program|The LFLS Program is a private 2 90-minute session conducted by a trained CHC facilitator. The sessions will be focused on exploring issues relevant to parental decision making related to voluntary medical male circumcision (VMMC) and early infant male circumcision (EIMC). Session 1 will be conducted antenatal and Session 2 will be immediately post-partum.
45975844|NCT00281385|Behavioral|traditional vs. lifestyle exercise|
45975845|NCT01683487|Procedure|Observation|Observational study only, no intervention.
45975846|NCT01683682|Drug|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
45830621|NCT01518192|Drug|doxycycline|100 mg bid; 15 days
45458627|NCT03492892|Device|Sham Acupuncture|Stimulate non-acupoint with filiform needles to treat the condition of patients
45830622|NCT01518192|Drug|cefuroxime axetil|500 mg bid; 15 days
45830623|NCT01569594|Device|CorMatrix ECM for Carotid Repair|Subjects must be undergoing carotid endarterectomy with patch angioplasty closure
45975847|NCT01683682|Drug|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
45975848|NCT01683682|Drug|Carboplatin|AUC 5 i.v. on day 1 (three-week cycle)
45975849|NCT00287703|Device|Pulsating Electro-Magnetic Fields|5 days a week for 5 weeks 30 minutes
45975850|NCT00287703|Device|Pulsating Electro-Magnetic Fields sham|sham PEMF
45975851|NCT00253097|Behavioral|Intervention|Patients allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
45975852|NCT01683799|Behavioral|Cognitive Behavioral Therapy for Insomnia|6-week behavioral treatment for insomnia
45975853|NCT01683877|Procedure|FloSeal application|After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)
45975854|NCT01683877|Procedure|Electrocautery|After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
45975855|NCT00287742|Drug|risperidone|
46082223|NCT02737254|Other|Neutral CBM training|Children receive a training unrelated to the interpretation of maternal behavior.
46082224|NCT00938197|Drug|Fimasartan|Fimasartan (1d~7d) Amlodipine (12d~14d) Fimasartan + Amlodipine(15d~21d)
46082225|NCT00938197|Drug|Amlodipine|Amlodipine (1d~10d) Amlodipine (25d~27d) Fimasartan + Amlodipine(28d~34d)
46082226|NCT02727504|Device|Electrocardiogram|ECG at inclusion and M12
46082227|NCT02727504|Device|2D and 3D echocardiography|2D and 3D echocardiography at inclusion and M12
45975856|NCT04527640|Dietary Supplement|Synbiotics containing Lactobacillus acidophilus & Bifidobacterium longum 5x10^9 CFU and FOS 60 mg|Patients will undergo baseline examination including medical history and physical examination, blood samples will be collected for hemoglobin, WBC, platelet, urea, creatinine, albumin and indoxyl sulfate level. Patients will be asked to complete 2 questionnaires the PAC-SYM and PAC-QOL questionnaires, and will undergo food recall evaluations by a nutritionist. They will then be given 2 capsules of synbiotics per day for 30 days. After 1 month of intervention, the patients will be evaluated for food recall and side effects. Afterwards, the patients will receive 2 capsules of the same synbiotics per day for the next 30 days. After 2 months of intervention, the patients' history will be taken, they will be asked to complete the PAC-SYM and PAC-QOL questionnaires, undergo food recall examination, and side effects evaluation. Blood samples will be taken for indoxyl sulfate examination.
45975857|NCT04527640|Other|Placebo|Patients will undergo baseline examination including medical history and physical examination, blood samples will be collected for hemoglobin, WBC, platelet, urea, creatinine, albumin and indoxyl sulfate level. Patients will be asked to complete 2 questionnaires the PAC-SYM and PAC-QOL questionnaires, and will undergo food recall evaluations by a nutritionist. They will then be given 2 capsules of placebo per day for 30 days. After 1 month of intervention, the patients will be evaluated for food recall and side effects. Afterwards, the patients will receive 2 capsules of the same placebo per day for the next 30 days. After 2 months of intervention, the patients' history will be taken, they will be asked to complete the PAC-SYM and PAC-QOL questionnaires, undergo food recall examination, and side effects evaluation. Blood samples will be taken for indoxyl sulfate examination.
45975858|NCT04527562|Drug|Colchicine|Participants in this group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
45975859|NCT04527562|Drug|Placebo|Participants in this group will be given a starting dose of 2 tablets of Placebo, single or 12 hourly divided dose. After that, they will take one placebo tablet daily for 13 days.Placebo tablet will be identical with the Colchicine tablet. If patients develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
45975860|NCT00281424|Device|pedometer|gave pedometer and info
45975861|NCT01684072|Biological|vaccine without gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
45975862|NCT01684072|Biological|vaccine with gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
45975863|NCT01684111|Drug|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
45975864|NCT01684111|Drug|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
45975865|NCT01684189|Other|Patient registry|Patient registry without study intervention
45975866|NCT00253136|Drug|risperidone|
45671217|NCT05349422|Behavioral|Electronic Health Record (EHR) Enabled Teamlets|The intervention consist of four components: 1) patients with hypertension will be automatically screened for low medication adherence using linked EHR-pharmacy data at the time of a PCP encounter; 2) MAs will deliver a validated, rapid, survey of common causes of non-adherence; 3) MAs and/or RNs will address barriers to adherence tailored to survey response, including delivery of brief health coaching based on motivational interviewing; and 4) PCPs will address specific barriers to adherence based on survey response.
45975867|NCT02960529|Procedure|extra-peritoneal high ligation of hernia|
45975868|NCT02960529|Procedure|intraabdominal high ligation of hernia|
45975869|NCT01684267|Device|Robotic Gait Rehabilitation (RGR) Trainer|
45975870|NCT01684306|Drug|Modafinil|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
45975871|NCT01684306|Drug|Placebo|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
45975872|NCT01684345|Drug|Placebo|Solution for subcutaneous injection
45975873|NCT01684345|Drug|Dose 1 gevokizumab|Solution for subcutaneous injection
45975874|NCT01684345|Drug|Dose 2 gevokizumab|Solution for subcutaneous injection
45975875|NCT00287781|Drug|Lidocaine|
45975876|NCT01684384|Radiation|Functional Respiratory Imaging|HRCT scan at FRC and TLC as taken during an episode of exacerbation and after recovering.
45975877|NCT01684462|Biological|Human Serum Albumin 20|Human Serum Albumin 20% 100cc albumin 1.25g/kg up to 100g (500ml) intravenously infused over 4~8h, commencing within 12 hours of stroke onset
45671218|NCT05345678|Drug|Durvalumab|Dose: 1500mg Route: IV
45671219|NCT05345678|Drug|Tremelimumab|Dose: 300mg Route: IV
45671220|NCT05345288|Device|BrainHQ cognitive training|"Posit Science's BrainHQ exercises are based on the science of neuroplasticity, also called brain plasticity. Brain plasticity is your brain's natural ability to remodel itself throughout life. The brain is always changing, sometimes for better, and sometimes for worse. What BrainHQ's exercises do is harness that change and direct it in ways that can enhance your overall performance and improve the quality of your life. BrainHQ exercises are grouped into six categories: Attention, Memory, Brain Speed, Intelligence, People Skills, and Navigation."
45975878|NCT01684462|Drug|0.9 % Normal Saline|Infusion of 100 mL of 0.9% Normal Saline ( equivalent volume of Albumin ) over 4~8h, commencing within 12 hours of stroke onset
45975879|NCT00416871|Biological|aldesleukin|
45975880|NCT00416871|Biological|recombinant interferon alfa|
45975881|NCT01684540|Other|Medical Device, Drug-like|Ectoin Rhinitis Nasal Spray
45975882|NCT01684540|Drug|Sinupret forte|
45671221|NCT05345288|Device|BrainHQ control games|BrainHQ also offers control games for research studies. The control activities will be games similar to candy crush, connect four, gem swap and battleship.
45671222|NCT05357222|Behavioral|Straw phontion|"Pitch Glides: (1 minute) Vocalize through the straw starting from as low as possible to as high as possible. As the participant you will want to get as much as your vocal range as possible. But, don't let the voice get growly at the bottom or press it into a painful range at the top.~2. Accents: (1 minute) Vocalize progressive little hills or accents. It sounds like a revving engine of the car.~3. Song: (1 minute) Pick a favorite song and vocalize it through the straw. Examples: National Anthem, Happy Birthday, Mary had a Little Lamb. These are great songs because they have a range of pitches and one can build some accents in, as well.~4. Reading passage: (1 minute) Vocalize a reading passage through the straw. Be as dramatic as possible, using a lot of inflection."
45671223|NCT05353556|Device|Inspiratory Muscle Training (IMT)|The IMT protocol will consist of home-based high-intensity daily training - two cycles of 30 breaths with a 1-min rest between sets, twice a day for 8 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to 50% of each patient's maximal inspiratory pressure measured every week and was adjusted weekly based on the modified Borg scale from 4 to 6 regarding respiratory effort performed during the session.
45671224|NCT05353556|Device|Sham IMT|The IMT protocol will consist of home-based daily training - two cycles of 30 breaths with a 1-min rest between sets, twice a day for 8 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to the lowest intensity of the IMT Threshold device.
45671225|NCT05335070|Drug|Temporo-masseteric Nerve Block|Following lower third molar extraction under intravenous sedation, the patient will receive the TMNB local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine on the side/s of the lower wisdom molar (third molar) extraction/s
45671226|NCT05327738|Biological|Atezolizumab|Given IV
45975883|NCT01684579|Behavioral|Resistance Exercise|Resistance exercise will be performed 2 days per week for 18 weeks. The resistance training protocol will follow the Resistance Training Strategies for Individuals With Cancer (RTSFIC). The goals will be to keep intensity levels low at the outset (having lighter weights and more reps) and progress slowly and safely. Training prescriptions will be modified based on the training level of the patients and their progress.
45456092|NCT05032885|Other|physiotherapy|"Patients in the intervention group will receive early physiotherapy treatment. This intervention will consist of exercises and physiotherapy techniques commonly used and aimed at improving the patient's respiratory and motor conditioning.~At the respiratory level: diaphragmatic and costal targeted ventilation, pursed-lip breathing and bronchial hygiene techniques if required.~At the motor level: passive, active-assisted kinesitherapy and analytical and global potentiation of the upper and lower limbs that will allow the maintenance and improvement of the articular pathway and will prevent muscle weakness; retraining of transfers and balance; gait reeducation."
45456093|NCT05032378|Behavioral|Kinesthetic Awareness Training|One physical or occupational therapy session per week for 8 weeks during which the participant with disordered movement will attempt to perform desired movements while wearing the KAT device
45671227|NCT05327738|Procedure|Biopsy|Undergo biopsy
45671228|NCT05327738|Drug|Cabozantinib S-malate|Given PO
45671229|NCT05327738|Radiation|Yttrium Y 90 Glass Microspheres|Given intra-arterially
45671230|NCT05325788|Other|e-Covery|Through the e-Covery app, participants will receive place-specific messages, sent when participants pass locations identified as triggers.
45671231|NCT05325788|Other|Comparator Condition|Through the e-Covery app, participants will receive a single general message sent daily in the morning.
45671232|NCT05008874|Other|Natural History Observation|Data collection on progression of disease
45671233|NCT04419662|Drug|Phenylephrine|"Three time points: before, during and 20-30 minutes after infusion of phenylephrine.~Patients will receive an infusion of up to 1 mcg/kg/min phenylephrine intravenously to raise mean arterial pressure with 20 mmHg for 10 minutes. Infusion of phenylephrine will start at 0.1 mcg/kg/min with subsequent titration to effect."
45671234|NCT04419662|Other|Combination of PEEP and positioning|"Six time points based on combinations of the following:~Three different levels of PEEP (as set on the ventilator): 0, 6 and 12 mmHg. Two different positions: 1) torso elevated 30 degrees, legs horizontal and 2) torso horizontal, legs elevated 30 degrees."
45671235|NCT04614740|Drug|VC004|25 mg capsules,50 mg capsules,100 mg capsules.
45975884|NCT01684579|Behavioral|Aerobic Exercise|A 20-week aerobic walking exercise program will be developed for each participant based on results of initial exercise testing and prescribed to be done 5 or more days per week designed to progress from moderate exercise intensity, (50-70% maximum heart rate), to vigorous exercise intensity (75-85% maximum heart rate). Maximum heart rate (HR max) will be determined as the peak heart rate achieved during initial cardiopulmonary exercise screening. Heart rate during exercise will be monitored by participants using wrist monitors, already available through TREC Program. Patient progress will also be evaluated using a six minute walk test (6MWT), which will be conducted at TGP at baseline, 6, 12 and 18 weeks and, after completion of the intervention.
45975885|NCT01684579|Behavioral|Behavioral Group Counseling|The psychosocial component of the 20-week exercise program includes a 1 ½ hour support group offered prior to one of the weekly exercise classes.
45975886|NCT01684618|Procedure|Cerebral NIRS Oximetry + CPAP|CPAP flow pressure is increased for 5 minutes then 15 minutes with CPAP pressure at baseline. Repeated once
45975887|NCT01684657|Drug|Asenapine|This is an atypical antipsychotic that blocks dopamine and increase the serotonin level.
45975888|NCT00416910|Biological|Filgrastim|
45975889|NCT00416910|Drug|Fludarabine|
45975890|NCT00416910|Drug|Cyclophosphamide|
45975891|NCT00416910|Drug|Mitoxantrone|
45975892|NCT01684696|Behavioral|Virtual experience|
46082228|NCT02727504|Device|Dobutamine stress echocardiography|dobutamine stress echocardiography at inclusion
46082229|NCT02727504|Biological|Blood tests|Blood test electrolytes, creatinine, hemoglobin, NT-proBNP, CRP, ST-2 at inclusion and M12
46082230|NCT02727504|Device|Cardiac MRI|Cardiac MRI at inclusion
45456094|NCT05032378|Behavioral|Provision of KAT-assisted physical or occupational therapy|Physical or occupational therapy professionals will provide one KAT-assisted therapy session per week for 8 weeks to one or more participants with movement disorder.
45671236|NCT05353088|Other|scapular stabilization|Scapular stabilization exercise aims to restore scapular position, orientations, motor control of muscles, and movement pattern, thereby attaining stability of scapula for better kinematics of shoulder.scapular stabilization exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of four exercise programs (Scapular retraction; Scapular mobilization, Scapular dynamic stabilization I and Scapular dynamic stabilization II)
45975893|NCT01684696|Behavioral|Videos|
45975894|NCT01684774|Drug|Bupivacaine|
45975895|NCT02279992|Drug|Vardenafil|
45975896|NCT02279992|Drug|Carboplatin|
45671237|NCT05353088|Other|Thoracic extension exercises|Thoracic extension involves concurrent posterior rotation (external torsion) and depression of the posterior ribs with elevation of the anterior ribs. Bending to the side is a combination of spinal segments side bending, ribs on the same come together while ribs on the opposite side separate.Group B performed thoracic extension exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of three exercise programs.
45975897|NCT00253175|Drug|topiramate|
45975898|NCT00287820|Drug|Olanzapine|olanzapine 5-40 mg/day
45671238|NCT05351918|Other|acupuncture|Acupuncture points are punctured with needles.
45975899|NCT00287820|Drug|olanzapine|olanzapine 5-40 ,mg/day
45975900|NCT00287820|Drug|risperidone|risperidone 1-12 mg/day
45975901|NCT02272348|Other|Training course to functional insulin therapy|Carbohydrate counting, carbohydrate/insulin ratio, sensitivity to insulin factor
45975902|NCT02272348|Other|Usual diabetes management.|
46082231|NCT02727504|Device|Cardiac scanner|Cardiac scanner at inclusion
46082232|NCT02727504|Other|6-minutes walking test|6-minutes walking test at inclusion and M12
45456095|NCT05032274|Other|Home-based Exercise Program|The exercise program will include chink tuck and shoulder retraction exercises. The chin tuck exercise will be performed in standing position. The shoulder retraction exercise includes activation and strengthening components. The activation component will be performed in standing position and strengthening component will be performed in prone position.
45975903|NCT02278744|Radiation|single-fraction radiation|Patients enrolled on this study will be registered into a dose tier and undergo 1 session of image-guided SRS using techniques previously. Three escalating SRS spinal cord/cauda maximum dose (Dmax) levels (14 Gy, 16 Gy, and 17 Gy) will be evaluated to determine the safety of this approach. A minimum of three patients will be treated per dose tier. Toxicity based on NCI CTCAE (v4). Post treatment followup at 2 and 4 months (+/- 2 weeks) post-treatment, at 6 months (+/- 4 weeks) and then every 3 months until 2 years (± 4 weeks). Followup schedule based on last day of treatment. No schedule adjustments based on early or delayed visits.
45975904|NCT02278744|Device|MRI and/or CT|
45975905|NCT02279095|Drug|Palovarotene dose level 1|Palovarotene was taken orally once daily at approximately the same time each day.
45975906|NCT02279095|Drug|Palovarotene dose level 2|Palovarotene will be taken orally once daily at approximately the same time each day.
45975907|NCT02279095|Drug|Palovarotene dose level 3|Palovarotene will be taken orally once daily at approximately the same time each day.
45975908|NCT02279095|Drug|Palovarotene dose level 4|Palovarotene will be taken orally once daily at approximately the same time each day.
45975909|NCT01684852|Other|Medical device, drug-like|
45975910|NCT00253214|Drug|galantamine hydrobromide|
45975911|NCT00287859|Drug|topotecan hydrochloride|intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29.
45975912|NCT01684891|Drug|RG1662|multiple doses of RG1662
45975913|NCT01684969|Drug|Haloperidol|0.5 mg iv x one dose
45975914|NCT01684969|Drug|Placebo|0.5 mg iv , one dose
45975915|NCT01685125|Drug|abiraterone acetate|Given PO
45975916|NCT01685125|Drug|dasatinib|Given PO
45975917|NCT01685125|Drug|prednisone|Given PO
46082233|NCT02727504|Other|Duke Activity Score|Duke Activity Score at inclusion and M12
46082234|NCT00931333|Procedure|non percutaneous vertebroplasty|The patient will undergo general anaesthetic. With a low invasive approach, 4 screws will be placed in pedicles of vertebra under and above the fractured vertebra. The reduction of the fracture will be realised by a smooth movement, and screws positions will be verified by a radio control, with a guided navigation system. The stems will be placed and locked. After the screw positioning, the fractured vertebra pedicles will be reached by a low invasive approach, using a 6 mm trocar, to raise, if necessary, the vertebral plate. Then the cement will be injected in the vertebral body, under radio control. When the maximal volume (6 to 8 ml) is reached, or if an extra vertebral leak is detected, the cement injection is stopped. Then the incision is closed. The next day, the patient will be placed in a corset for a 2 months period.
45975918|NCT00416988|Other|educational intervention|
45975919|NCT04527679|Drug|GC combined Lenvatinib|"GC chemotherapy D1 Cisplatin 25mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 8 courses.~Lenvatinib (<60kg: 8mg /d; ≥60kg, 12mg)."
45975920|NCT01685164|Other|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.
45975921|NCT01685281|Drug|Metadoxine (MG01CI)|MG01CI is an orally administered extended release formulation of metadoxine. Doses: 1400 mg and 700 mg and Placebo
45975922|NCT01685281|Drug|Placebo|Placebo tablets will be similar in appearance (color and size) to the investigational product
45975923|NCT00417066|Drug|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
45975924|NCT00417066|Drug|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
45975925|NCT04527952|Behavioral|Online handouts describing how to follow each diet for 1 week each|Participants will receive handouts via email about how to follow each diet
45975926|NCT01682005|Other|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
45975927|NCT01685398|Drug|0.5% timolol maleate eye drop|
45975928|NCT01685398|Drug|Normal saline|
45975929|NCT01685476|Device|Echodia® hand-held equipment|
45975930|NCT01685515|Drug|Oral Decitabine and Tetrahydrouridine|Oral Decitabine and Oral Tetrahydrouridine (THU) given 1-2 hours apart on 2 consecutive days over 8 weeks
45975931|NCT01685515|Drug|Placebo|Plain water will be dispensed at a similar volume and in the same containers as study drug. The water placebo has a similar appearance and taste to the study drug, since the study drug is highly diluted in water.
46082235|NCT04259489|Behavioral|Shared Care diabetes management|After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
46082236|NCT02727348|Procedure|Sciatic with or without femoral block|Sciatic with or without femoral block performed either with ultrasound and/or nerve stimulator on the patient with 3mg/kg of ropivacaine
46082237|NCT02727348|Procedure|Spinal anaesthesia|Spinal anaesthesia with up to 3mls of 0.5% bupivacaine
45671239|NCT04589546|Drug|Nicotinamide treatment|Nicotinamide (500 mg) will be mixed in 50 ml of 0.9% saline and administered intravenously every 12 h for a total of 72 h.
45671240|NCT04589546|Drug|placebo treatment|For the placebo group, an identical volume of 0.9% saline will be administered in the same manner.
45671241|NCT01600586|Device|Pacifier-Activated-Lullaby system (PAL).|Pacifier-Activated-Lullaby system (PAL).
45671242|NCT04411238|Other|interview|interview
45975932|NCT00281502|Drug|Rifaximin (drug)|Rifaximin 400mg three (3) times daily
45975933|NCT00253331|Drug|topical organogel with nitroglycerin|
45975934|NCT04527250|Drug|ASC41|ASC41,1mg/table;5mg/table
45975935|NCT04527250|Drug|ASC41 placebo|ASC41 placebo,1mg/table;5mg/table
45975936|NCT04527484|Drug|SHR-1314|each group subjects will be given different formulations of SHR-1314
45975937|NCT04527835|Diagnostic Test|ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.|ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.
45975938|NCT01685554|Device|hypothermic CPB|maintenance of mild hypothermia during cardiopulmonary bypass
45975939|NCT01685554|Device|normothermic CPB|maintenance of normal body temperature during cardiopulmonary bypass
46082238|NCT02804126|Procedure|TAP (transversus abdominis plane block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
46082239|NCT02804126|Procedure|QL (quadratus lumborum block)|ultrasound-guided regional block between abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
46082240|NCT02804126|Drug|Bupivacaine|In both groups (TAP&QL) 0.25% bupivacaine will be given (0.2 mL/kg)
45975940|NCT01685593|Device|abdominal binder|
45975941|NCT01685593|Other|no binder|
45975942|NCT00253409|Drug|chemotherapy|
45975943|NCT00253409|Procedure|adjuvant therapy|
45975944|NCT00253409|Procedure|conventional surgery|
45975945|NCT00253409|Procedure|neoadjuvant therapy|
45975946|NCT00253409|Radiation|radiation therapy|
45975947|NCT01685632|Procedure|Surgery with IPCH|"surgical debulking and extensive tumoral resection after laparotomy under general anesthesia~7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum , each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
45975948|NCT01685632|Procedure|Without surgery and without IPCH|"The patients is opened and recused during the surgery because of extended carcinosis and closed without resection neither IPCH.~7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery (2 hours before IPCH, 1.5hours after IPCH, 4 hours after IPCH) and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum, each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
45975949|NCT00281541|Drug|YM155|
45975950|NCT01685671|Drug|NESP 60μg|Administrated NESP 60μg once subcutaneously
45975951|NCT01685671|Drug|CKD-11101 60μg|Administrated CKD-11101 60μg once subcutaneously
45975952|NCT01685710|Drug|GTN patch|
45975953|NCT01685710|Drug|placebo comparator|This arm will be a placebo patch to the active drug patch to blind the trial.
45975954|NCT00253487|Drug|O6-benzylguanine|
45975955|NCT00253487|Drug|busulfan|
45975956|NCT00253487|Drug|temozolomide|
45975957|NCT00253487|Procedure|adjuvant therapy|
45975958|NCT00253487|Procedure|autologous bone marrow transplantation|
45975959|NCT00253487|Procedure|conventional surgery|
45975960|NCT00253487|Procedure|peripheral blood stem cell transplantation|
46082241|NCT02804126|Device|Needle|Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
46082242|NCT02804126|Drug|Paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
46082243|NCT02804126|Drug|Metamizol|Intravenous metamizol will be used (1.0 gram), up to 4 grams per day
46082244|NCT02804126|Drug|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
45975961|NCT00253487|Radiation|radiation therapy|
45975962|NCT01685788|Other|No intervention|
45975963|NCT00281619|Drug|CellCept (mycophenolate mofetil)|
45975964|NCT00281619|Behavioral|Dietary Monitoring|
45975965|NCT00281619|Behavioral|Drug Diary|
45975966|NCT00281619|Procedure|Blood Sampling|
45975967|NCT04527211|Drug|Ivermectin|Oral administration of ivermectin 200 mcg/kg every week for seven weeks
45975968|NCT01685866|Device|Vein-Viewer Vision|A medical device called Vein-Viewer Vision
45975969|NCT00253526|Drug|bevacizumab|
45975970|NCT00253526|Drug|gemcitabine hydrochloride|
45975971|NCT00253526|Procedure|adjuvant therapy|
45975972|NCT00253526|Procedure|anti-cytokine therapy|
45975973|NCT00253526|Procedure|antiangiogenesis therapy|
45975974|NCT00253526|Procedure|antibody therapy|
45975975|NCT00253526|Procedure|biological therapy|
45975976|NCT00253526|Procedure|chemotherapy|
45975977|NCT00253526|Procedure|conventional surgery|
45975978|NCT00253526|Procedure|growth factor antagonist therapy|
45830624|NCT04099056|Device|Neurostimulation|"Participants will be seated comfortably in a chair and asked to complete simple computer tasks. Participants will receive neurostimulation in the form of Transcranial Magnetic Stimulation (TMS) or Temporal Interference (TI).~TMS: Either during, or just before any of the tasks, participants will receive either repetitive transcranial magnetic stimulation (rTMS) or single pulse TMS. During this, the researchers place a small plastic coil next to the participant's head. The coil will then generate a magnetic pulse, and stimulation will occur during presentation of the visual stimuli on which subjects will conduct behavioral or cognitive tasks.~TI: Either during, or just before, any of the above tasks, participants will receive stimulation with TI. To do so, commercially available gel-based electrodes will be placed on the scalp to target the relevant brain region. The position targeted by the electrodes will be guided by previously defined coordinates."
45671243|NCT01639742|Device|New texture round breast implants|Breast implant surgery
45671244|NCT05416736|Procedure|The bladder stimulation technique|The bladder stimulation technique consists of two consecutive maneuvers. In the first maneuver, the bladder is stimulated by tapping the suprapubic region for 30 seconds at a frequency of 100 touches per minute. In the second maneuver, circular massage is applied to the paravertebral region for 30 seconds. The two stimulation maneuvers will be repeated alternately for 3 minutes (180 seconds) until micturition begins. Maneuvers will be performed by the researcher. Infants in both groups will be held under the armpit by a parent, male infants will be held in the drooping legs, and female infants will be held in the hip flexion position.
45671245|NCT05416736|Procedure|Steril urine bag|Steril urine bag are attached to the genital area to collect urine samples
45830625|NCT01517802|Drug|Abiraterone acetate|Type=exact number, unit=mg, number=1000, form=tablet, route=oral, abiraterone acetate once daily
45975979|NCT00253526|Procedure|monoclonal antibody therapy|
45975980|NCT00253526|Procedure|surgery|
45975981|NCT01685944|Dietary Supplement|Live Pediococcus pentosaceus LP28|
45975982|NCT01685944|Dietary Supplement|Heat-killed Pediococcus pentosaceus LP28|
45975983|NCT01685944|Dietary Supplement|Placebo|
45975984|NCT01686022|Other|Immunoblot|serum specific IgE binds to grass extract by immunoblot
46082245|NCT02804126|Drug|Morphine|Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
45975985|NCT01686217|Drug|ASP015K ER|oral extended release (ER) at three dosing levels
45456096|NCT05027607|Procedure|Bascom's pit-pick|Pit-pick procedure of simple pilonidal sinus disease in the natal cleft in a day-surgery setting.
45456097|NCT05022602|Device|Imagio|Imagio - both ultrasound probe and Duplex OA probe
45671246|NCT04995380|Procedure|Early Cholecystectomy|Cholecystectomy performed within 10 days from onset of symptoms
45975986|NCT01686217|Drug|ASP015K IR|oral immediate release (IR)
45975987|NCT04719572|Other|Basic treatment group|A total of 60 subjects were recruited in the group.
45975988|NCT04719572|Other|Basic treatment+ anti-osteoporosis drug group|A total of 60 subjects were recruited in the group.
45975989|NCT04719572|Other|Basic treatment + non-drug treatment group|A total of 60 subjects were recruited in the group.
45975990|NCT01686295|Device|iRestore Hair Rejuvenation System|This study is to evaluate the effectiveness of the iRestore Hair Rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
45975991|NCT01686295|Device|sham device|This shame device will be a sham comparator to evaluate the effectiveness of the iRestore Hair rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
45975992|NCT04528030|Device|WAVE device|WAVE applies a transcutaneous vibration to the soles of the foot and palms of the hand to elicit nerve signalling from pressure and other limb proprioceptor sensors to pontine, cerebellar, and medullary brain areas that coordinate limb movement and reflexively activate brain areas controlling breathing. The WAVE device is a battery-operated product to reduce the episodes of Apnoea of Prematurity by vibratory stimulation to the hand and foot.
45975993|NCT01686412|Device|Electromagnetic Fields of Low Energy (EEFLE)|Are employed three sets of programs of different frequencies are modulated specifically for each group of patients in accordance with diagnostic (hepatocellular carcinoma, breast carcinoma and healthy subjects). These frequencies ranging between 0.1 and 114.000Hz.
45975994|NCT01686490|Behavioral|Video/workbook for patients about to receive an AICD|will view the 3 completed sections of the video/workbook
45975995|NCT01686490|Behavioral|LiveSkills Video/Workbook for patients about to receive an AICD|This exploratory intervention first met in a focus group with healthcare professionals and another focus group with patients who already had received an automatic implantable cardiac defibrillator to learn more about what video and accompanying workbook material it would be helpful for patients to receive pre-inplantation. Another focus group was held with post-implantation patients asking them what additional knowledge would have been helpful. Three sections of the video with accompanying workbook were then produced and given to pre-inplantation patients. A focus group was then held with these patients after their procedure to ask them what had and had not proved helpful.
45975996|NCT00281736|Drug|HPPH|Given IV
45456098|NCT05017272|Other|Opioid Addiction Recovery Support Software Platform|OARS (Opioid Addiction Recovery Support) is used by providers of MAT programs to improve insight into a patient's recovery progress while promoting ownership and adherence to treatment plans. OARS also provides extensive tools to support patients with recovery from Opioid Use Disorder.
45456099|NCT05009459|Behavioral|eVIS|To facilitate individualized physical activity levels within the Swedish IPRP setting, an eVISualisation (eVIS) of physical activity and pain intervention has been systematically developed. eVIS is designed to target facilitating mechanisms for behavior change, such as outcome expectations, self-monitoring, self-evaluation, and self-efficacy, which are theoretically framed by the Social Cognitive Theory by Bandura. In eVIS, objectively measured physical activity tracking using a wrist-worn activity tracker (Fitbit Versa 2) is combined with a daily activity goal (steps/day) and daily patient reports of known important clinical outcome assessments: pain intensity and its affect on daily activities30-34 and pharmaceutical consumption. Data is collected and visualized in a purpose-developed web application, Pin And TRaining ON-line (PATRON), which can be used by the patient and the IPRP-team to follow and adjust individual physical activity levels.
45671247|NCT05369468|Drug|dexmedetomidine as adjuvant with bupivacaine|to assess efficacy of adding dexmedetomidine as adjuvant with bupivacaine in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
45671248|NCT05369468|Drug|Bupivacain only|to assess efficacy of bupivacain alone in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
45456100|NCT05008965|Biological|FB825|A humanized monoclonal immunoglobulin G1 (IgG1) targeting the CεmX domain on human B lymphocytic cells expressing membrane-bound IgE (mIgE).
45456101|NCT05008965|Other|Placebo|Formulation buffer
45671249|NCT05291468|Radiation|FDG-PET/CT|Patients will be randomized in a 1:1 ratio to either receive a combination of doxycycline and azithromycin or placebo during 3 months, after which the inflammatory state of disease is measured by FDG-PET/CT and serum biomarkers. If patients have cutaneous sarcoidosis, a skin biopsy will be performed at baseline and at the end of the study.
45671250|NCT05278130|Other|Additional vaginal swabs|Every 2 weeks from 16 weeks gestational age to 34 weeks gestational age
45975997|NCT00253565|Drug|capecitabine|
45975998|NCT00253565|Drug|imatinib mesylate|
45975999|NCT01686529|Procedure|Autoconjunctival grafting|The pterygium head was lifted off the corneal surface by blunt dissection. The pterygium body was dissected from the underlying sclera and thereafter excised. A thorough removal of Tenon's capsule was performed in an area much greater than the pterygium body. Free conjunctival autografting after pteryigum excision was performed as follows: the desired size of the conjunctiva under the upper eyelid was marked and excised. No limbal tissue was included in the graft. The excised tissue was placed on the bare sclera and tightly sutured to the sclera and the limbal area. Finally the autograft edges were sutured to the conjunctiva all around.
45976000|NCT01686529|Drug|Subconjuntival bevacizumab injection|The subconjunctival injection of bevacizumab was applied adjacent to the site of pterygium separation inside the healthy conjunctiva. The half of the dose (1.25 mg/0.05ml) was applied in the nasal inferior quadrant, and the other half of the dose was applied in the nasal superior quadrant.
45976001|NCT01686607|Drug|Parenteral micafungin application|Parenteral
45976002|NCT01686607|Drug|Other parenteral antifungal drugs|Parenteral
45976003|NCT05140720|Biological|PNEUMOSIL®|"Study subjects will be vaccinated PNEUMOSIL® with the primary doses as described below:~Group 1: 3 doses, 4 to 8 week interval Group 2: 2 doses, dose interval > 1 month Group 3: 2 doses, dose interval > 2 months"
45976004|NCT00281814|Procedure|psychosocial assessment and care|psychosocial assessment and care
45976005|NCT01686724|Behavioral|Collaborative Life Skills Intervention (CLS)|CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
45976006|NCT01686724|Other|Business As Usual|
45830626|NCT01517802|Drug|Prednisone|Type=exact number, unit=mg, number=5, form=tablet, route=oral, prednisone or prednisolone twice daily
45830627|NCT04099992|Behavioral|Mindfulness-based stress reduction (MBSR)|Mindfulness-based stress reduction (MBSR) is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session. MBSR teaches to become more aware of thoughts, feelings, and sensations, and to skillfully respond to stressors. Each of the sessions includes education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. Participants learn formal mindfulness practices (e.g., meditation, yoga, body scan, body scan) as well as informal such as awareness of breath, thoughts, or emotions, and mindfulness of daily activities. Participants will receive digital audio (MP3) downloads with guided MM practices, a home practice manual, and handouts with each week's assignments. Daily home practice will consist of 40-45 minutes of recorded practice. Participants will log their daily practice. If a participant misses a class, it is possible to make up the class on a different day.
45830628|NCT04099992|Behavioral|Health enhancement program (HEP)|"8-week health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP matches MBSR in structure and content, and in parallel to MBSR, consists of music therapy, nutritional education, posture and balance movements, walking and stretching. Work with all practices with group discussion and exercises during an all-day spa day will match the all-day retreat in MBSR. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions. Participants will receive MP3 downloads on an MP3 player with recordings of health education topics, a home listening manual, and weekly handouts with each week's listening assignments. Participants will listen to these MP3 recordings daily for 40-45 minutes and log their daily adherence."
45976007|NCT01686802|Drug|oral morphine|
45976008|NCT01686802|Drug|Ibuprofen|
45976009|NCT00281853|Procedure|management of therapy complications|Patients undergo a 1-hour peripheral nerve function assessment, including hearing, vibratory sensation, and blood pressure testing, at baseline and then at 4, 8, and 12 weeks during treatment with chemotherapy or biologic therapy.
45976010|NCT01686880|Device|Sirsphere trans-arterial radioembolization|Patients will receive Sirsphere trans-arterial radioembolization before surgery
45976011|NCT00253721|Drug|Melphalan|"All levels: Every 4 weeks for up to one year~Dose Escalation Plan:~Level 1: 4mg/m2/day x 2 days~Level 2: 6mg/m2/day x 2 days~Level 3: 8mg/m2/day x 2 days~Level 4: 10mg/m2/day x 2 days~Level 5: 12mg/m2/day x 2 days"
45976012|NCT01686919|Dietary Supplement|milk-free|milk-free diet during 8 preoperative weeks
45976013|NCT01686997|Procedure|Roux-en-Y Gastric Bypass|
45976014|NCT01687075|Device|CR8 a drug eluting coronary stent|a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
45976015|NCT00253760|Drug|dietary amino acids; cysteine and methionine|
45976016|NCT00281892|Biological|Fludarabine plus Darbopoetin|Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks
45671251|NCT05274854|Behavioral|a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing|Pre consultation interventions consist of one of four intervention a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing
45671252|NCT05274854|Behavioral|a) consultant-led outpatient clinic or b) a integrated care clinic|Consultation intervention consists of one of two interventions a) consultant-led outpatient clinic or b) a integrated care clinic
45671253|NCT05347550|Other|Graduated Compression Stockings - Thromboembolic deterrent stockings|Centres randomised to the intervention arm will consist of participants receiving GCS.
46082246|NCT04013815|Procedure|erector spinae plane block with ropivacaine|The block is performed immediately before surgery. by an ultrasound guide, with the probe positioned longitudinally, the spinous process of T5 is identified. A peripheral block needle is inserted in the cephalo-caudal direction (caliber 21G and length 10 cm) and 3 ml of physiological solution are injected to confirm the injection site: fascial plane between the erector spinae muscle and the large rhomboid, near the tip of the transverse process of T5. Once the correct position of the needle tip has been confirmed, ropivacaine 0.75% 20 ml is injected.
46082247|NCT04013815|Procedure|Intercostal nerve block with ropivacaine|The intercostal nerve block will be performed by the surgeon at the time of thoracotomy from the 4th to the 8th intercostal space, by injecting 20 ml of 0.75% ropivacaine (4 ml for each space). The injection is performed at about 2-3 cm from the spine.
46082248|NCT00610103|Drug|apomorphine hydrochloride|Apomorphine hydrochloride (started at 1 mg and titrated to a maximum of 6 mg) is subcutaneously administered.
46082249|NCT05624190|Drug|Recombinant Human tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA)|The administration of rhTNK-tPA will be infused constant and slowly over 15min (0.125 mg/kg, Max 12.5mg) through a microcatheter.
46082250|NCT05624190|Other|Best Medical Management|Best Medical Management
45671254|NCT05415098|Drug|APG-5918|"The investigational drug product is formulated as oral tablets of 50 mg or 200 mg that contain APG-5918 as the active ingredient. APG-5918 will be orally administered once every day on 28-day cycles.~The dosage of APG-5918 depends on the dose level to which the patient is assigned. Each dose of APG-5918 will be taken orally in fasted condition in the study."
45671255|NCT02164513|Drug|fluticasone furoate (FF)|FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg
46082251|NCT02804204|Drug|Anti-TNF|
45671256|NCT02164513|Drug|vilanterol (VI)|VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg
45830629|NCT04099992|Device|Transcutaneous Vagus Nerve Stimulation (tVNS)|Transcutaneous Vagus Nerve Stimulation (tVNS) is delivered using gammaCore (Electrocore), a multi-use, hand-held, rechargeable portable device consisting of a rechargeable battery, signal generating and amplifying electronics, and a button for operator control of the stimulation intensity. Conductive gel is applied to the stainless steel round discs on the device and placed vertically on the skin overlying the vagus nerve under the angle of the mandible, between the trachea and sternocleidomastoid muscle. A low-voltage electrical signal is delivered consisting of 5-kilohertz (kHz) sine wave series for 1 ms and repeated every 40 ms, with a maximum delivery of 24 V and 60 milliampere (mA) output. Stimulation amplitude is adjusted by the user and is increased until there is a vibration and slight muscle contraction in the lower face or neck. Stimulation is delivered for 2 minutes on the left side of the neck, and 2 minutes on the right side of the neck, for a total 4 minutes per one dose.
45671257|NCT02164513|Drug|umeclidinium bromide (UMEC)|UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg
45671258|NCT04562246|Diagnostic Test|Serologic assays for antibodies to SARS-CoV-2|Beckman Coulter and Roche automated immunoassays
45671259|NCT04969094|Other|Neuromuscular electrical stimulation (NMES)|Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 3-months
45671260|NCT04969094|Other|Multi-Modality Balance Intervention (MMBI)|Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 3-months
45671261|NCT05369078|Drug|THR-1442 20mg Single dose|THR-1442 20mg is administrated 1 dose on Day 1, then follow till day 7.
45671262|NCT05369078|Drug|THR-1442 20mg Multiple dose group|THR-1442 20mg is administrated QD for 7days, then follow till day 14.
46082252|NCT04261283|Other|Experimental|"The Circuit Training will be consisting of:~Habituation Exercises~Exercises for the gaze stability (The two exercises are specifically for the patients who reported a high score on oscillopsia severity questionnaire~Exercises to improve Saccade Latency.~Adaptation Exercises~Substitution Exercises~Postural Control Exercises~General Conditioning Activities~Cawthorne-Cooksey Exercises~Ocular Motor Exercises~Gait Exercises~Treatment to Decrease Sensitivity to Motion in the Environment"
46082253|NCT04261283|Other|Active Comparator|Medicines as prescribed by the ear, nose, and throat (ENT) specialist and Home-based exercise Programme (Simple and general vestibular rehabilitation exercises) will be recommended to the patients to perform. ( Not under the supervision of neuro-therapist)
45671263|NCT04540016|Drug|[14C]HSK7653|25 mg of [14C]HSK7653 (radioactivity of 80 µCi) capsules are taken under fasted condition.
46082254|NCT00938275|Drug|0.5g SRT2104|"SRT2104 will be supplied in two forms: as 0.5g powder which will be prepared by the pharmacist/designee into a liquid suspension and as two hard gelatin capsules, each containing 0.25g SRT2104. The dosing vehicle for the liquid suspension is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104.~Each formulation of test material will be administered orally, in a single dose to the subjects in the fasted state and following consumption of a standard meal. Neither the investigator nor the subjects enrolled will be blinded to treatment assignment."
45671264|NCT04852562|Procedure|Modified radical endoscopic sinus surgery|Modified radical endoscopic sinus surgery was performed to remove the mucosa including ethmoid sinus and maxillary sinus, as well as a completly middle turbinate.
45976017|NCT00281892|Drug|Fludarabine mono|"Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa."
45976018|NCT02276443|Drug|Chemotherapy|Receive standard chemotherapy
45976019|NCT02276443|Other|Immunotherapy|Receive standard immunotherapy
45671265|NCT04852562|Procedure|functional endoscopic sinus surgery|Full maxillary antrostomy, ethmoidectomy, sphenoidotomy and frontal sinusotomy, but with the middle turbinate preservation.
45976020|NCT02276443|Other|Laboratory Biomarker Analysis|Correlative studies
45976021|NCT02276443|Procedure|Lymph Node Biopsy|Undergo baseline lymph node evaluation
45976022|NCT02276443|Procedure|Ultrasonography|Undergo standard ultrasound
45830630|NCT04099992|Device|Sham-transcutaneous Vagus Nerve Stimulation (tVNS)|Sham stimulation will be delivered using a sham device that is identical in appearance and function, but programmed to produce a lower frequency biphasic signal that can be felt by the participant without actually stimulating the vagus nerve.
45830631|NCT04714710|Drug|IV Potassium Canrenoate|"Administration of 200 mg of IV potassium canrenoate (diluted in sodium chloride 0.9%) in brain-dead donors within 10 hours after the diagnosis of brain death and before the departure to the operating room.~Second administration of potassium canrenoate 6 hours after first administration if the patient is not YET admitted IN the operating room"
45976023|NCT02274571|Drug|TSEC (Tissue-selective estrogen complexes)|Duavee™, combination of CE(conjugated equine estrogens) and BZA (bazedoxifene)
45830632|NCT04714710|Drug|IV Sodium Chloride 0.9 %|"Administration of IV sodium chloride 0.9% (placebo) in brain-dead donors within 10 hours after the diagnosis of brain death is made and before the departure to the operating room.~Second administration of IV sodium chloride 0.9% (placebo) 6 hours after first administration if the patient is not YET admitted IN the operating room."
45830633|NCT01520922|Biological|Ofatumumab|Ofatumumab (ARZERRA™) is an immunoglobulin G1κ (IgG1κ) human monoclonal antibody that specifically recognises a distinct epitope encompassing both large and small extracellular loops on the human CD20 molecule expressed on B cells and binds to this site with high affinity with a dissociation half-life of approximately 3 hours. Ofatumumab induces more efficient complement-dependent cytotoxicity (CDC) mediated cell lysis in vitro, compared to rituximab, especially in low CD20 density cells.
45976024|NCT02274571|Other|Placebo|non active
45671266|NCT05412290|Drug|Mosunetuzumab|"Mosunetuzumab is administered intravenously in a step-up dosing strategy. The doses will be 1 mg on C1D1, 2 mg on C1D8, 60 mg on C1D15, 60 mg on C2D1, and 30 mg for all doses following."
45976025|NCT00253799|Device|Hylan GF-20|
46082255|NCT00934999|Procedure|Burch urethropexy|Patients will undergo a Burch modified Tanagho procedure (in which the anterior vagina is suspended to Cooper's ligament bilaterally using two non-absorbable sutures).
45830634|NCT01520922|Drug|Bendamustine|Bendamustine is a cytostatic drug which structurally combines a purine-like benzamidazol nucleus and a bifunctional alkylating nitrogen mustard group.
46082256|NCT00934999|Procedure|Synthetic mid-urethral sling (TVT)|Patients will undergo a polypropylene mid urethral sling as described by the manufacture (Align, Bard Urological, Covington, GA).
45830635|NCT01569438|Drug|Gefapixant|50 or 300 mg tablets for a total daily dose of 50, 100, 150, 200, 250 or 300 mg BID, orally with food for 4 weeks
45830636|NCT01569438|Drug|Placebo|Dose matched placebo tablets, BID, orally, with food for 4 weeks
45830637|NCT01517412|Drug|Lixisenatide (AVE0010)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
45830638|NCT01517412|Device|Self-injector pen device (OptiClik®)|
45830639|NCT01517412|Drug|Metformin|To be kept at stable dose (≥1.5 g/day) throughout the study.
45976026|NCT01687231|Other|Non-neutropenic Diet|Non-neutropenic diet is without restriction.
45976027|NCT00281931|Biological|rituximab|
45976028|NCT00281931|Drug|cyclophosphamide|
45976029|NCT00281931|Drug|fludarabine phosphate|
45976030|NCT01687309|Drug|GSK2586184 800mg single and repeat dose|GSK2586184 800mg single dose and then twice daily dosing for 13 days
46082257|NCT04263623|Drug|Dexmecamylamine HCl|Investigational drug
46082258|NCT04263623|Other|Placebo|Oral tablet containing no active drug.
45456102|NCT05005533|Other|Observational|Chronic Obstructive Pulmonary Disease Severity of Individuals by Chronic Obstructive Pulmonary Disease Assessment Test, shortness of breath Modified Medical Research Council scale, cough related quality of life Leicester Cough Questionnaire, respiratory muscle strength with Maximum Inspiratory and Expiratory Pressure, Posture with Spinal Mouse device, pain with Visual Analog Scale, severity of fatigue Fatigue Physical performance of the lower extremities will be evaluated with the Short Physical Performance Test, functional mobility will be evaluated with the Time Up and Go Test, and balance will be evaluated with the Biodex Balance System
45671267|NCT05255744|Device|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
45671268|NCT04532372|Other|Best Practice|Receive standard of care drugs
45671269|NCT04532372|Drug|Leflunomide|Given PO
45671270|NCT04532372|Drug|Placebo Administration|Given PO
45976031|NCT01687309|Drug|Placebo-to-match GSK2586184|Placebo-to-match GSK2586184
45976032|NCT01687309|Other|GSK2586184 single dose taken with food|GSK2586184 single dose taken with FDA approved high fat, high calorie breakfast
45976033|NCT01687309|Other|GSK2586184 single dose taken without food|GSK2586184 single dose taken in a fasted state
45976034|NCT01687348|Drug|lidocaine aguettant|
45976035|NCT01687426|Drug|Brimonidine Tartrate 0.025%|1 drop in each eye daily four times a day for 14 days
45976036|NCT01687426|Drug|Vehicle|1 drop in each eye daily four times a day for 14 days
46082259|NCT05602220|Behavioral|Brain training|Participants will play a few brain training games using an online interface each day. These games train attention, memory and other cognitive functions.
45976037|NCT04719689|Other|Dry needling|Experimental group 1 got this intervention containing Dry needling for 10 mins, followed by conventional physiotherapy treatment (hot pack and stretching) for 15 mins. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus lumborum
45976038|NCT04719689|Other|Dry cupping|Experimental group 2 got this intervention containing Dry cupping for 10 mins, followed by conventional physiotherapy treatment (hot pack and stretching) for 15 mins. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus Lumborum
45976039|NCT01687543|Dietary Supplement|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|A suspension of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v together with maltodextrin is distributed to the patients twice a day.
45976040|NCT01687543|Other|Maltodextrin|A suspension of maltodextrin (as placebo control) is distributed to the patients twice a day.
45976041|NCT00287898|Behavioral|Telephone Genetic Counseling|Participants will receive all genetic counseling via telephone
45976042|NCT00287898|Behavioral|Usual Care|subjects will receive standard in-person genetic counseling
46082260|NCT05602220|Behavioral|Paced breathing|After completing brain training, they will then immediately do one 15-minute session of paced breathing, followed by a second 15-min session of paced breathing later in the day. During the paced breathing sessions, participants will clip a pulse monitor to their ear lobe and try to inhale and exhale in synchrony with a ball that moves up and down on the screen. They will receive heart rate biofeedback regarding whether they are achieving their relaxation/alertness goal.
45456103|NCT05004935|Dietary Supplement|beetroot juice|single intake of beetroot juice containing 800mg nitrates
45456104|NCT05004935|Other|nitrate|single intake of 800mg nitrates
45671271|NCT04953338|Other|Exposure of mental health condtion of interest|Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder.
45671272|NCT04524104|Behavioral|Lumen Treatment|the virtual AI agent, Lumen, via an iPad-based application. Each participant will receive a locked, encrypted study iPad installed with Lumen. They will complete 8 problem solving therapy (PST) sessions beginning with 4 weekly and then 4 biweekly intervals over 12 weeks on their assigned iPad.
45671273|NCT05232188|Procedure|Percutaneous nephrolithotomy|percutaneous nephrolithotomy surgery, 22F amplatz sheath is used in one group, while 28F amplatz sheath is used in the other group.
45830640|NCT01517178|Device|New ostomy base plate (SS)|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
45830641|NCT01517178|Device|Standard Care base plate|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
45830642|NCT01489956|Biological|Immucothel Alone (Part A)|100 ug at day 0 (priming dose) and day 9(booster dose)
45830643|NCT01489956|Biological|Immucothel+Montanide (Part A)|100 ug SQ Immucothel plus Montanide at day 0 (priming dose) and day 9 (booster dose)
45830644|NCT01489956|Biological|Immucothel Alone or Immucothel+Montanide (Part B)|50 mg of native KLH on days 0-4 and 10-14 (total of 500 mg). Immunization on days 26 and 35.
45976043|NCT01687582|Drug|GLP-1 analog|GLP-1 analog treatment
45976044|NCT01687621|Procedure|Diagnostic Algorithm for Community Based Worker for Omphalitis|After obtaining guardian informed written consent, newborns aged 1-10 days presenting to the health facility for routine or sick visits would undergo 2 independent, parallel evaluations; first, by a ZamCAT Field Monitor (community level worker from our existing study) and the second by a Zambian medical doctor (gold standard). A US board of pediatrics-certified pediatrician will perform a third independent assessment of a photo of the cord remotely. Using the on-site clinician as the gold standard, the community-based algorithm and the photo assessment will be tested for concordance and the sensitivity and specificity of the algorithm will be generated. Likewise, the remote pictorial assessment will be compared to the gold standard to determine reliability of diagnosis from photographs alone.
45976045|NCT01687660|Other|acupuncture|apply acupuncture to prevent the migraine attack
45976046|NCT01687699|Drug|Spironolactone|
45976047|NCT00287937|Drug|vorinostat|Given orally
45976048|NCT00287937|Drug|paclitaxel|Given IV
45976049|NCT00287937|Drug|carboplatin|Given IV
45976050|NCT00287937|Other|laboratory biomarker analysis|Correlative studies
45976051|NCT00287937|Other|pharmacological study|Correlative studies
45976052|NCT01687855|Device|Ultrafast Magnetic Resonance Imaging|MRI was performed with a 1.5 superconducting magnet (Gyroscan Intera type, Philips Co. Holland) in a posterior and anterior neck coil. The sequence used to perform the ultrafast MRI was a fast gradient- echo plus sequence. Technical parameters included: echo time, 12 msec; repetition time, 2.3 msec; flap angle, 250; matrix, 192 × 512; section thickness, 7 mm. The imaging time per slice for this sequence was 0.92 sec. A total of 120 consecutive images were obtained as a single section, with a total imaging time of 110.4 seconds. MRI scanning was carried out with the subject first asleep, then whilst awake after 20 minutes in quiet respiration. All images were inputted to the PACS workstation.
45671274|NCT04950920|Drug|Y-2 sublingual tablets|30mg Edaravone+6mg d-borneo OR， Bid
45671275|NCT04950920|Drug|d-borneol|60 μg d-borneol OR， Bid
45671276|NCT05337020|Other|Survey|Each patient will be asked to fill in the questionnaire to assess their vision on telemedicine
45456105|NCT05000372|Drug|68Ga-grazytracer|68Ga-grazytracer PET/CT: after intravenous injection of 2.96 MBq/kg body weight of quality-controlled 68Ga-grazytracer, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
45671277|NCT05410418|Drug|Mosunetuzumab|"Mosunetuzumab is administered subcutaneously using a step-up dosing strategy. The initial dose on C1D1 will be 5 mg, and doses thereafter will be 45 mg."
45671278|NCT05410418|Drug|Polatuzumab vedotin|Polatuzumab vedotin is administered intravenously over 90 minutes for the initial dose, and over 30 minutes thereafter.
45671279|NCT05230706|Other|Cephalic helmet|An acrylic headgear (length: 27 cm; width: 27 cm; height: 17.5 cm; opening: 17x12 cm) was placed on the patient's head. The helmet was covered with surgical cloth (green or blue) folded into 50x60cm rectangles, leaving the front part open to maintain adequate airflow.
45671280|NCT05220488|Other|Assessment|Parameters such as physical activity and fear of covid will be evaluated in asthmatic and healthy children and adolescents.
45671281|NCT04513184|Drug|IV Dexamethasone|6 mg from Day 1 to 10 after randomization
45671282|NCT04513184|Drug|Nasal Dexamethasone|0.12 mg/kg/daily for 3 days from day 1, followed by 0.06 mg/kg/daily from day 4 to 10 after randomization.
45671283|NCT04756531|Drug|PF-07321332 Dose 1|PF-07321332 Dose 1 or Placebo
45671284|NCT04756531|Drug|PF-07321332 Dose 2|PF-07321332 Dose 2 or Placebo
45671285|NCT04756531|Drug|PF-07321332 Dose 3|PF-07321332 Dose 3 or Placebo
45671286|NCT04756531|Drug|PF-07321332 Dose 4|PF-07321332 Dose 4 or Placebo
45671287|NCT04756531|Drug|PF-07321332 Dose 5|PF-07321332 Dose 5 or Placebo
45671288|NCT04756531|Drug|PF-07321332 Dose 4 or Placebo (Fed)|PF-07321332 Dose 5 or Placebo with high fat meal
45830645|NCT03027726|Behavioral|lifestyle and psycho-educational program|The family-based healthy lifestyle education and psychological education program will be followed once every two weeks (11 sessions over 22 weeks) for 90 minutes (45 minutes in the healthy lifestyle education program and 45 minutes in the psycho-educational intervention). The sessions of the healthy lifestyle education and psycho-educational interventions will be developed simultaneously and delivered to both parents (or caregivers) and children, separately. The family-based healthy lifestyle education program will be conducted by experienced nutritionists and the psycho-educational program by experienced psychologists in behavior changes
45830646|NCT03027726|Other|Exercise plus lifestyle and psycho-educational program|The intervention group will attend the same lifestyle education and psycho-educational program plus the exercise program. The exercise group will do exercise 3 days/week, 90 minutes per session, over a 22-week period. The program will be offered to the families five days per week to choose a total of three days/week. Sessions will be designed and supervised by exercise specialists. The duration of training sessions will be 90 minutes of exercise, including warm-up, moderate to vigorous aerobic activities, and strength exercises
45830647|NCT01516008|Drug|Tapentadol IR 50 mg|Type= exact number, unit= mg, number= 50, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.
45830648|NCT01516008|Drug|Tapentadol IR 75 mg|Type= exact number, unit= mg, number= 75, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.
45830649|NCT01516008|Drug|Placebo|Form= tablet, route= oral use. Placebo tablets will be administered as a single oral dose every 4 to 6 hours, for a period of 72 hours.
45830650|NCT01489254|Drug|Glatiramer Acetate (GTR)|Glatiramer Acetate (GTR) 20 mg daily, for 9 months (Part 1) followed by additional 15 month treatment period (Part 2)
45830651|NCT01489254|Drug|Glatiramer Acetate (Copaxone®)|Glatiramer Acetate (Copaxone), 20 mg daily, for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
45830652|NCT01489254|Drug|Placebo|Placebo (daily) for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
45830653|NCT01489020|Biological|subcutaneous immunotherapy with DPT extract|Increasing doses of subcutaneous immunotherapy in three different scales up to the maximum dose of 500 TSU (Treatment Standardized Units)
45830654|NCT01489020|Biological|Subcutaneous depot placebo|Increasing doses of subcutaneous depot placebo in three different scales
45830655|NCT03027024|Device|Implantation of IOL: PhysIOL POD F GF|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
45830656|NCT01514760|Other|Mobile-based Asthma Action Plan|"The participant will be distributed a mobile phone (iPhone or Android) at the time of consent. The mobile-based Asthma Action Plan application will be provided on the mobile device. The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts. Participants will receive 3 daily messages from the Asthma Action Plan mobile application. A fourth rotating message will be sent twice weekly."
45830657|NCT01514682|Drug|Anti-inflammatory Combination Therapy|"salsalate: target dose 4 gm/day, administered in two divided doses of 2 gm in the morning and 2 gm in the evening~fluvastatin: target dose 40 mg/day, administered in a single evening dose~combined omega-3-fatty acid preparation of EPA and DHA; target dose EPA 2 gm/day and DHA 2 gm/day administered in a single evening dose"
45830658|NCT01514682|Drug|Placebo|Non-medication pills; To be taken in morning and evening intervals.
45830659|NCT01514448|Drug|Everolimus (RAD001)|Everolimus was used as commercially available formulated tablets of 10 mg strength
45976053|NCT00253838|Procedure|Restoration HA stem|The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating to be applied to the entire length of the stem.
45976054|NCT00253838|Procedure|Solution stem|The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
45976055|NCT01687894|Drug|Vasopressins|Vasopressins propofol vasopressins sevoflurane
45976056|NCT01687894|Drug|Placebo|Placebo propofol & placebo sevoflurane
45976057|NCT01687894|Drug|propofol|vasopressin propofol & placebo propofol
45976058|NCT01687894|Drug|sevoflurane|vasopressins sevoflurane placebo sevoflurane
45976059|NCT00287976|Drug|irinotecan hydrochloride|
45976060|NCT01687933|Device|three-dimensional glasses(manufactor Vuzix,wrap 920)|The samples were randomly allocated to use three-dimensional glasses for 30 minutes in order to reliving labor pain.
45976061|NCT01687933|Other|usual care|Women in Control group did not use the glasses.
45976062|NCT01688089|Drug|ODM103|
45976063|NCT01688089|Drug|Placebo|
45976064|NCT01688089|Drug|Entacapone|
45976065|NCT01688089|Drug|Levodopa/carbidopa|
46082261|NCT02737176|Other|Tobacco cessation intervention|"The nicotine dependence status is evaluated by the Fagerstrom Test for Nicotine Dependence test; those who 3 or more score are eligible for the intervention.~During the study, attending doctors implement a tobacco cessation intervention with standard treatments for above oral diseases.~Even if the subjects failed to abstain from smoking, the treatment is continued.~In case of the use of the nicotine replacement therapy, The investigators supply NRTs (nicotine patch or gum) for 2 weeks as a free of charge, and later the subjects themselves purchase it as over the counter (OTC) drugs at a pharmacy."
45976066|NCT00253877|Other|Complication rate|All patients in the active comparator group received the Conserve Plus Hip Resurfacing System, manufactured by Wright Medical Technology. The complication rate and clinical efficacy will be recorded and compared to the Total Hip Replacement historical control group.
45671289|NCT02218489|Drug|KPI-121|KPI-121 drug product will be supplied in 0.25% strength as a suspension in opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arm will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
45671290|NCT02218489|Drug|Vehicle|The vehicle control has the same composition as KPI-121 0.25% ophthalmic suspension except it does not contain loteprednol etabonate. The vehicle is essentially isotonic and is buffered to maintain pH 5.0 - 7.0. It is a sterile, aqueous solution supplied in the same white, low-density polyethylene plastic dropper bottle with the same white, controlled-drop polyethylene tip and white polypropylene closure as KPI-121 0.25% ophthalmic suspension.
45671291|NCT05205512|Other|Exercise Intervention|Maintain current levels of physical activity
45671292|NCT05205512|Other|Questionnaire Administration|Ancillary studies
45976067|NCT01688128|Device|Phase I U-SMART (4 wks)|Intervention_Control Group, 4-weeks U-SMART(2 session/week); Control_Intervention Group, no intervention
46082262|NCT04014127|Diagnostic Test|Coronary flow reserve assessment|Coronary flow reserve will be assessed using Doppler transthoracic echocardiograpy and myocardial contrast echocardiography.
46082263|NCT04014127|Diagnostic Test|Sphygmocor|Pulse wave analysis and pulse wave velocity will be assessed using the Sphygmocor device
46082264|NCT04014127|Diagnostic Test|Electrocardiogram|An electrocardiogram will be performed prior to administration of adenosine to ensure no resting conduction disease
46082265|NCT04014127|Other|Blood test|Blood tests will be performed for markers of renal function, bone mineral metabolism and myocardial stretch and injury
46082266|NCT04014127|Other|Urinary albumin/creatinine ratio|Urine will be analysed for albumin/creatinine ratio
45830660|NCT01514370|Drug|IFN beta 1a 44 mcg TIW|Subjects received IFN beta 1a 44 microgram (mcg) subcutaneously TIW for 24 months.
45830661|NCT01514370|Drug|Curcumin|Subjects received 500 milligram (mg) curcumin orally twice a day for 24 months.
46082267|NCT04260893|Device|Tixel|Peri-Orbital fractional treatment on the Eye-Lid to assess the effect on Dry Eye symptoms
45671293|NCT05205512|Other|Telemedicine|Participate in telehealth exercise intervention
45671294|NCT04419740|Behavioral|Mindfulness based psychological intervention|Women in the intervention group will have to use an application during 1 month. They will do meditation during 15 minutes each day.
45830662|NCT01514370|Drug|Placebo|Subjects received placebo matched to curcumin orally twice a day for 24 months.
45830663|NCT04705974|Procedure|Fascia iliaca block|Fascia iliaca block will be performed under ultrasound guidenance.
45830664|NCT04705974|Procedure|Femoral nerve block|Femoral nerve block will be performed under ultrasound guidenance.
45976068|NCT01688128|Other|Washout (2 wks)|2-weeks wash out period in both arms
45976069|NCT01688128|Device|Phase II U-SMART (4 wks)|Intervention_Control Group, no intervention; Control_Intervention Group, 4-weeks U-SMART(2 session/week, Crossover design)
45976070|NCT01688206|Biological|Atezolizumab [TECENTRIQ]|Participants will receive atezolizumab at a fixed dose of 840 mg, intravenously every 2 weeks.
45976071|NCT01688206|Biological|Vanucizumab|Participants will receive escalating doses of vanucizumab (starting dose: 3 milligram [mg] per kilogram) and fixed dose of vanucizumab (MTD/RP2D: 30 mg/kg), intravenously every 2 weeks.
45976072|NCT01688245|Behavioral|SMS Assessments & Feedback|Weekly pre-weekend drinking plan and post-weekend drinking outcome assessments with personlaized feedback
45976073|NCT01688245|Behavioral|SMS Assessments|Weekly post-weekend drinking outcome assessments
45976074|NCT01688284|Device|office hysteroscopy|Endometrial wash and biopsy is taken at the day around implantation window (day 14_to day 22)of the menstrual cycle from patients of recurrent miscarriages to evaluate the levels of uterine natural killer cells compared to control of females of normal reproductive outcome
45976075|NCT01688323|Other|Collect Blood and Survey Instruments|Each subject will be administered the appropriate surveys and blood draws over the course of the study.
45976076|NCT00288093|Radiation|3-Dimensional Conformal Radiation Therapy|
45976077|NCT00288093|Drug|Triapine|
45976078|NCT04525339|Procedure|TAVI and Off pump CABG|Concomitant Transcatheter aortic valve implanatation and off pump coronary artery bypass grafting
45976079|NCT00288132|Behavioral|Intervention|A 12-month diabetes self-management intervention delivered via telemedicine, with opportunity to receive telemedicine-based screening eye exam, was conducted.
45976080|NCT00288132|Behavioral|Usual Care|Upon randomization, received one 15-minute diabetes self-management individual session, using American Diabetes Association materials. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
45976081|NCT04519840|Other|nill|nill
45976082|NCT04519372|Diagnostic Test|Testing for SARS-CoV-2|All Patients admitted to the hospital were routinely tested for SARS-CoV-2 within 72 hours of admission by nasopharyngeal swabs.
46082268|NCT02803814|Procedure|Superior mesenteric artery approach for pancreatoduodenectomy|Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the superior mesenteric artery approach
46082269|NCT02803814|Procedure|Classic approach for pancreatoduodenectomy|Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the classical approach
46082270|NCT02727114|Other|Echographic measurement of skin thickness|"(Epi)Dermal thickness at the proximal forearm, the deltoid region and medial site of the thigh (till 2 years) will be measured using imaging technology, more specifically high-frequency ultrasound (20-70 MHz) in B-mode (VEVO 2100® & VEVO 3100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid and medial thigh region, and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging."
46082271|NCT04236752|Radiation|Stereotactic Ablative Body Radiation (SBRT)|
45671295|NCT05202626|Diagnostic Test|Nasopharyngeal Endoscopy image-guided Biopsy|For each participant with suspicious nasopharyngeal lesion, three biopsy specimens will be obtained from the lesion, including one sample inside the lesion, one sample 5-8 mm outside the lesion, and one sample 8-10 mm outside the lesion. All of these specimens will be pathologically confirmed as carcinoma or non-carcinoma.
45830665|NCT04705974|Procedure|Pericapsular nerve group block (PENG block)|Pericapsular nerve group block (PENG block) will be performed under ultrasound guidenance.
45830666|NCT01519674|Drug|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) twice daily. Individually adjusted dose.
45976083|NCT00253916|Behavioral|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
45976084|NCT00253916|Behavioral|Resistance Exercise Program|Resistance Exercise Program
45976085|NCT00288171|Drug|Placebo|placebo capsule twice daily for one month
45976086|NCT00288171|Drug|Allopurinol|Allopurinol 200mg twice daily for one month
45976087|NCT00253955|Drug|Levofloxacin|
45976088|NCT00253955|Drug|Piperacillin/Tazobactam|
45976089|NCT00288210|Procedure|Primary angioplasty in acute myocardial infarction|
45976090|NCT00253994|Procedure|Acupuncture|
45976091|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
45976092|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|12 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
45976093|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-minute i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
45976094|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
45976095|NCT00254033|Drug|Dextroamphetamine|
45976096|NCT00254033|Drug|Methylphenidate|
45976097|NCT01600573|Drug|pazopanib in combination with weekly topotecan|"Topotecan as an IV infusion over 30 minutes on days 1, 8, and 15 of a 28 day cycle and~Pazopanib orally once daily continuous dosing in the following dose levels:~Phase I Trial:~Dose level -I: Topotecan weekly 3mg/m2, Pazopanib 400 mg Dose level I: Topotecan weekly 4mg/m2, Pazopanib 400 mg Dose level II: Topotecan weekly 4mg/m2, Pazopanib 600 mg Dose level III: Topotecan weekly 4mg/m2, Pazopanib 800 mg~Phase II Trial:~Phase II will either use the MTD as determined in Phase I or a lower dose if deemed necessary."
45976098|NCT01600612|Drug|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
46082272|NCT04260971|Device|Abbott St Jude Medical Infinity 7 neurostimulator|The stimulator has the capability to deliver both continuous and cyclical modes of stimulation which is being investigated in this study
46082273|NCT00938353|Drug|beclomethasone dipropionate suspension for nebulisation 800 mcg/2 ml|Single dose 1600 mcg/4 ml
45671296|NCT02192905|Behavioral|Diabetes Prevention Program Lifestyle Intervention|
45671297|NCT01713946|Drug|RAD001|Everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
45671298|NCT01713946|Drug|Placebo|Placebo tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
45830667|NCT01519674|Drug|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) once daily. Individually adjusted dose.
45830668|NCT01519674|Drug|sitagliptin|Subjects will continue on their pre-trial sitagliptin treatment.
45830669|NCT01519674|Drug|metformin|Subjects will continue on their pre-trial metformin treatment.
45830670|NCT01519518|Drug|unfractionated heparin|70 units/kg body weight intravenous
45976099|NCT01600612|Drug|misopristol|600 ug of misopristol will be given sublingually to patients with atonic postpartum hemorrhage
45976100|NCT01600612|Drug|oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
45976101|NCT01600651|Other|Recruitment Maneuver (RM) sham group|It 's when RM sequence precedes a shame evaluation period
45976102|NCT01600651|Other|Sham recruitment maneuver (RM) group|Group in which patients receive a sham sequence before the RM sequence
45976103|NCT00288288|Procedure|Epicardial left ventricular lead placement|Epicardial left ventricular lead placement
45976104|NCT00288288|Procedure|Transvenous left ventricular lead implant|Transvenous left ventricular lead implant
45976105|NCT00254111|Device|Ultra Probe Laser System|
46082274|NCT00938353|Drug|Placebo solution for nebulisation 2 ml|single dose: 4 ml
46082275|NCT03076476|Device|Bioresorbable Vascular Scaffolds (BVS)|Bioresorbable Vascular Scaffold. Introduced after the interim analysis (phase 2) for comparison with DES-slow.
46082276|NCT03076476|Device|Drug-Eluting Stent (DES) - slow|"Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.~After the interim analysis DES-slow to be compared with BVS."
46082277|NCT03076476|Device|Drug-Eluting Stent (DES) - standard(std)|Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.
46082278|NCT04263701|Other|Therapeutic exercises|Conventional physiotherapy exercises for children with cerebral palsy
45830671|NCT01519518|Drug|Bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
45830672|NCT01519206|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
45830673|NCT01518972|Drug|Prazosin|"Form: Prazosin will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
45830674|NCT01518972|Drug|Placebo medication|"Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
46082279|NCT04263701|Other|Dual Task Training|Dual task training in addition to conventional physiotherapy exercises for children with cerebral palsy
45830675|NCT01514136|Device|Ostomy appliance: convex 1-piece drainable|8 variations of an ostomy devices are tested
45830676|NCT01513590|Drug|insulin degludec/insulin aspart|Administered s.c. (under the skin) twice daily. Dose individually adjusted. Pre-trial metformin treatment to be continued.
45830677|NCT03027570|Behavioral|Control|Five-month interdisciplinary program, including: twice a week one-hour group exercise activity sessions, 3-5 group meetings with a dietician, 12-13 parent sessions with a social worker, and a healthy cooking workshop, each child will take part in individual sessions including: two appointments with a pediatrician, three sessions with a dietician and two sessions with a physical therapist serving as a consultant for physical activity.
45830678|NCT03027570|Behavioral|Exergame activity_EXG|"In addition to the treatment given to the control group (as described above), the EXG group will obtain home access to the app Just Dance Now and part of a weekly exercise session will include a group activity with the app."
45830679|NCT03027570|Other|Application activity|"The application - Just Dance Now will be downloaded to the cellular phone of the child or parent. Exercise using the app will be used by cell phone connection to the child's home computer and as part of exercise group activity."
45976106|NCT01600690|Other|Statin withdrawal|Patients are instructed to stop taking statin pills for the duration of the study. The rest of therapy will remain unchanged.
45976107|NCT01600768|Drug|Beta-Lactams|infusion time: 30 mins or 1 hr
45976108|NCT01600768|Drug|Beta-Lactams|infusion time 4 hrs
45976109|NCT00288327|Behavioral|Lifestyle behavior change program|Intervention included a six-month intensive intervention of 2 individual counseling sessions, 3 group sessions, and 3 phone calls from a peer counselor followed by a maintenance phase (6 months) including 1 individual counseling session and 7 monthly peer counselor calls.
45976110|NCT00288327|Behavioral|Pamphlets|Nutritional and physical activity pamphlets from American Heart Association
45976111|NCT04467112|Device|Breath Biopsy face masks with removable filters and fitted PVA strip|Device developed for collection of breath samples
45976112|NCT00414947|Drug|Vildagliptin (LAF237)|
45976113|NCT04465747|Other|Publications|Reviewing published evidence
45976114|NCT04464772|Device|FreeStyle Libre 3|FreeStyle Libre 3 Continuous Glucose Monitoring System
45976115|NCT00288405|Device|Cordis Self Expanding Stent|
45976116|NCT04462744|Other|educational program|an oral health educational program regarding the emergency management of traumatic dental injuries.
45976117|NCT00414986|Behavioral|Standard CQI intervention|In-practice change facilitator assists the practice in implementing a chronic disease registry
45976118|NCT00414986|Behavioral|Chronic Care Improvement (CCI) Intervention|An in-practice change facilitator will assist the Improvement Team in enhancing the relationship infrastructure of the practice and in implementing diabetes and depression office systems.
45976119|NCT00414986|Behavioral|Self-directed practice comparison|Practices will have access to all tools used in Arm 1 via a project website
45976120|NCT00288444|Drug|Lonafarnib|
45976121|NCT00288444|Drug|Docetaxel|
45976122|NCT04460716|Procedure|Major noncardiac surgery|Vascular, thoracic, visceral, orthopedic, gynecologic, urologic, ENT, maxillo-facial, plastic and reconstructive surgery
45976123|NCT00415025|Procedure|adjuvant therapy|
45976124|NCT00415025|Procedure|management of therapy complications|
45976125|NCT00415025|Procedure|quality-of-life assessment|
45976126|NCT00415025|Radiation|intensity-modulated radiation therapy|
45976127|NCT04460404|Behavioral|Lifestyle consultation|"Collect relevant data of patients included in the study through outpatient consultation, telephone follow-up, questionnaire follow-up, etc., including:~Basic information~Digestive tract symptoms:~A constipation-related symptoms B abnormal symptoms~Fecal traits~Lifestyle habits~Others"
45976128|NCT04459819|Other|Respiratory physiotherapy|"Respiratory physiotherapy consists of:~early mobilization (passive and active mobilization, muscle-strengthening exercises, mobilization out of bed, standing, walking, ADL)~patients positioning~non-invasive mechanical ventilation / CPAP~tracheostomy management~invasive mechanical ventilation weaning~airway clearance~oxygen titration"
45976129|NCT00417573|Drug|IV Gamunex 10%|
45976130|NCT00415064|Drug|Perifosine|Perifosine given in either 50 mg or 100 mg / day
45976131|NCT00415064|Drug|Lenalidomide|Lenalidomide given in either 15 or 25 mg / day
45976132|NCT00415064|Drug|Dexamethasone|Dexamethasone given in 20 mg / day
45976133|NCT04456465|Other|Pain diabetic peripheral neuropathy|Neuropathic pain is the focus of current clinical research, clinical identification, and treatment. It is unique from nociceptive pain and requires evaluation of the relevance and utility of common pain measures created for other painful conditions.
45976134|NCT04455685|Other|anonymised data collection|The population of the present study corresponds to a sample of previous market research. Data from participants from the five main regions of Brazil (North, Northeast, Midwest, South, Southeast) will be selected at random and according to the sample size calculation.
45976135|NCT04455217|Other|data collection from patients with FAI (occuring January 2000 until December 2019)|data collection from patient files (data regarding surgery, adverse events, infections, demographic data)
46082280|NCT00610181|Procedure|MRI|MRI of both breasts, results used for surgery, then MRI repeated in 1 year as part of routine follow-up after surgery.
46082281|NCT02727036|Dietary Supplement|Pumpkin seed oil|1 gram capsule of Pumpkin seed oil.
46082282|NCT02727036|Dietary Supplement|Pumpkin seeds|4.1 grams (1½ teaspoons/~0.15ounces) of pumpkin seeds
46082283|NCT00935077|Other|PPCM Asthma|Pharmacists collaborate with physicians to manage asthma
46082284|NCT00935077|Other|24 Month PPCM BP|Pharmacists collaborate with physicians for 24 months to manage hypertension.
46082285|NCT00935077|Other|9 Month PPCM BP|Pharmacists collaborate with pharmacists for 9 months to manage hypertension
45830680|NCT04672512|Drug|CORT125329 lipid capsule formulation|CORT125329 lipid capsule formulation 1 or 2 for oral administration
45830681|NCT04672512|Drug|Placebo|Placebo matching CORT125329 lipid capsule formulation 1 or 2 for oral administration
45671299|NCT01713946|Drug|Antiepileptic drug (1 to 3 only)|no more than any 3 of the listed antiepileptic drugs could be taken with the study drug or placebo. List of allowed antiepileptic drugs were: valporic acid, carbamazepine, clobazam, N-desmethylclobazam, topiramate,TRI477, TRI476, clonazepam, zonisamide, phenobarbital, phenytoin
45671300|NCT01713946|Drug|open label RAD001 (only used for post-extension phase)|everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister backs in boxes with open label design and were taken during the Post-Extension phase, where all the participants, including those who were previously on placebo, took the 2mg tablets.
45830682|NCT04672512|Drug|Prednisone|Prednisone tablet for oral administration
45830683|NCT01512264|Device|Magstim SuperRapid|This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
45830684|NCT01512108|Drug|liraglutide|0.9 mg/day liraglutide was injected once daily subcutaneously (s.c., under the skin).
45830685|NCT01512108|Drug|oral anti-diabetic drug|An additional oral anti-diabetic drug (OAD) with a different mechanism of action than the pre-trial OAD. The type and dosage of the additional OAD should be chosen by the investigator within the Japanese labelled dose.
45830686|NCT01486758|Drug|Azithromycin|Oral azithromycin 10 mg/kg once daily for 7 days followed by 5mg/kg once daily for additional 7 days.
45830687|NCT01486758|Drug|Placebo|
45976136|NCT00415103|Drug|Aprepitant|Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days
45976137|NCT00415103|Drug|Palonosetron|Palonosetrón: 0.25 mg iv every 48 hours, starting day 1
45976138|NCT00415103|Drug|Granisetron|Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment
45976139|NCT00417690|Drug|4-Aminosalicylic acid|Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
45976140|NCT00417690|Drug|PASER placebo granules|Oral granules administered administered as one packet three times daily for two weeks followed by one packet two times daily for two weeks
45976141|NCT04454320|Other|INTUSSUSCEPTION IN CHILDREN|the seasonal variation and management outcomes of childhood intussusception.
45976142|NCT04453540|Diagnostic Test|FilmArray PCR on respiratory samples|Molecular test performed on respiratory samples realized for microbiological routine testing as part of the care
45976143|NCT00254150|Procedure|Increase oxygen extraction rate|
45976144|NCT04452994|Drug|JNJ-68284528|JNJ-68284528 will be administered as a single intravenous (IV). The target dose will be the recommended Phase 2 dose (RP2D) of 0.75*10^6 chimeric antigen receptor (CAR)-positive viable T cells per kilogram (cells/kg) (range: 0.5 to 1.0*10^6 CAR-positive viable T cells/kg).
45976145|NCT00417729|Drug|Acarbose|After an 8-week period of metformin monotherapy (500 mg t.i.d.), all patients were randomised to add on either acarbose or glibenclamide. The doses of acarbose and glibenclamide were 50 mg t.i.d. and 2.5 mg t.i.d., respectively, for 4 weeks and force-titrated to 100 mg t.i.d. and 5 mg t.i.d., respectively, for the last 12 weeks.
45976146|NCT00254189|Drug|Levonorgestrel|
45976147|NCT00254189|Drug|Ethinyl Estradiol|
45976148|NCT01600807|Drug|Gemcitabine, Erlotinib, OSI-906|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD, OSI-906 dose to be determined BID
45976149|NCT01600807|Drug|Gemcitabine, Erlotinib|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD
45976150|NCT00288483|Drug|Policosanol|
45976151|NCT00254228|Device|Electrotactile sensory substitution|
45976152|NCT01600963|Drug|Arm A Double-blind Phase: TMC207|Type=exact number, unit=mg, number=400 mg for the first 2 weeks and 200 mg 3 times per week for the remainder of the treatment period, form=tablet, route=oral administration.
45976153|NCT01600963|Drug|Arm B Double-blind Phase: Placebo|Form=tablet, route=oral administration, taken once daily for 2 weeks then 3 times per week for the remainder of the treatment period.
45976154|NCT01600963|Drug|Treatment Failure During Double-blind Phase: TMC207|Type=exact number, unit=mg, number=200 mg 3 times per week, form=tablet, route=oral administration.
45976155|NCT01600963|Drug|Treatment Failure During Follow-up Phase: TMC207|Type=exact number, unit=mg, number=400 mg once daily for 2 wks and 200mg three times per week for 22 weeks, form=tablet, route=oral administration.
45976156|NCT01606969|Drug|scalp infiltration solution|Dex group: Dexmedetomidine 2mcg/ml-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
45976157|NCT01606969|Drug|scalp infiltration solution|1:100000 epinephrine-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
45976158|NCT00288522|Drug|Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days|
45976159|NCT00254267|Drug|AMG 706|AMG 706 125mg, oral, once a day
45976160|NCT02277028|Behavioral|priming and task specific training|This task specific training protocol has been used in several clinical trials.
45976161|NCT01601002|Drug|Mirtazapine|Mirtazapine 7.5 to 45 mg/day, once daily, 12 weeks open label
45976162|NCT00288561|Drug|ranibizumab|
45976163|NCT01607086|Drug|Cherry lamotrigine ODT|25mg, taken orally on one study visit
45830688|NCT01463982|Drug|Oratecan and Capecitabine|"Oratecan in combination with Capecitabine~Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1~Day5~HM30181AK Tablet - Fixed dose 15 mg, Day1~Day5~Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1~Day14"
45830689|NCT01486446|Drug|XPF-002|XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
45830690|NCT01486446|Drug|Placebo|XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
45830691|NCT03027180|Device|Noninvasive positive airway pressure with different levels|
45830692|NCT04655352|Dietary Supplement|Bacillus subtilis MB40|1-week placebo (maltodextrin and excipients) lead-in followed by 250 mg capsule (5 billion CFU/capsule) administered twice daily for 21 days
45830693|NCT04700280|Drug|GLPG3970|GLPG3970 film-coated tablet.
45830694|NCT04700280|Drug|Placebo|Placebo film-coated tablet.
45830695|NCT01485354|Device|Armeo Spring training|Upper-limb training using the Armeo system for a period of 6 weeks
45830696|NCT01510158|Drug|Lesinurad|Tablets, 200 mg once daily (qd)
45830697|NCT01510158|Drug|Lesinurad|Tablets, 400 mg qd
45830698|NCT01510158|Drug|Placebo|Tablets, Placebo qd
45830699|NCT01510158|Drug|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
45976164|NCT01607086|Drug|Cherry Placebo|Taken orally on one study visit
45976165|NCT01607125|Drug|Vortioxetine (Lu AA21004)|encapsulated 20 mg tablets, orally, once daily for 13 to 14 days
45976166|NCT01607125|Drug|Placebo|capsules, orally, once daily for 13 to 14 days
45976167|NCT00288678|Procedure|Health Education|
45976168|NCT00254345|Procedure|coating a dental restoration material ,polymethylmethacrylate, with liquid polish resin|
45976169|NCT01607164|Behavioral|Healthy Mood Project Website|Self-help automated online mood management course based on cognitive-behavioral methods to control depressed mood.
45976170|NCT01601041|Other|sonographic assessment of residual urine, urine culture|residual urinary volume assessed by ultrasound after bladder catheterization urinary cultures taken before and after prostate massage
45976171|NCT00254618|Drug|mesalamine|oral tablet, 30 mg mesalamine/day for 28 days
45976172|NCT00254618|Drug|mesalamine|oral tablet, 60 mg mesalamine/day for 28 days
45976173|NCT00254618|Drug|mesalamine|oral tablet, 90 mg mesalamine/day for 28 days
45976174|NCT00288717|Drug|Candesartan|
45976175|NCT00288717|Drug|Telmisartan|
45976176|NCT01601119|Drug|Rebif|The subjects will receive Rebif as per the current practices or as directed by the physician.
45976177|NCT01601119|Other|Other: Disease modifying therapies (DMT)|The subjects will receive other DMTs as per the current practices or as directed by the physician.
45976178|NCT01601158|Biological|Umbilical Cord Blood administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
45976179|NCT01601158|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
45976180|NCT01601197|Behavioral|Tactile stimulation|Immunizer will rub the ipsilateral limb before, during and after immunization injection(s)
45976181|NCT01601314|Drug|Magnesium Sulfate|"At the beginning of the neurosurgery, the subjects are going to receive one 4gr bolus in Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Magnesium Sulfate 20 gr, in Sodium Chloride 1000 mL, lasting 24 hours, will be started."
45976182|NCT01601314|Other|Sodium Chloride|"At the beginning of the neurosurgery, the subjects are going to receive a bolus of Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Sodium Chloride 1000 mL, lasting 24 hours, will be started."
45976183|NCT00254657|Drug|Levetiracetam|Started with one 500 mg tablet/day and titrated upward as tolerated over 6 weeks by 500 mg/week to a maximum dose of 3000 mg/day.
45976184|NCT00254657|Drug|Placebo|
45976185|NCT00288756|Procedure|lv injection of contrast|
45976186|NCT01607515|Other|Impedance cardiography|noninvasive measure of cardiac index by impedance cardiography.
45976187|NCT02482753|Drug|Chidamide|30 mg, administered orally twice per week (BIW)
45976188|NCT02482753|Drug|exemestane|25 mg, PO daily
45976189|NCT02482753|Drug|placebo|Administered orally twice per week (BIW)
45976190|NCT00254696|Drug|Extended-Spectrum-Lactamases (ESBLs)|
45976191|NCT00288795|Other|Massage Therapy|Therapeutic Touch
45976192|NCT00288795|Other|Polarity Therapy|Use of energy fields to alleviate distress and achieve balance in the body
45456106|NCT04998110|Other|Ambulatory Supportive Care|Ambulatory supportive care visits monthly for six months - a monthly visit with an ambulatory palliative care provider educated in kidney disease
45671301|NCT05332262|Diagnostic Test|Assessment of platelet reactivity|Assessment of platelet reactivity and HPR status will be performed post-PCI. Platelet reactivity will be measured by VerifyNow P2Y12 and HPR status will be defined using a cut-off value of platelet reactivity units (PRU)>208.
45830700|NCT01510158|Drug|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
45830701|NCT01510158|Drug|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
45830702|NCT04080882|Biological|AbobotulinumtoxinA dose 1|Treatment of platysmal bands
45830703|NCT04080882|Other|Placebo|Treatment of platysmal bands
45830704|NCT04080882|Biological|AbobotulinumtoxinA dose 2|Treatment of platysmal bands
45830705|NCT04080882|Biological|AbobotulinumtoxinA dose 3|Treatment of platysmal bands
45830706|NCT03027336|Dietary Supplement|Coleosoma|patients will take one tablet of 500mg daily for 12 weeks. No dose titration is foreseen.
45830707|NCT03027336|Dietary Supplement|Placebo|patients will take one tablet daily for 12 weeks.
45830708|NCT01485120|Device|BP monitoring using two methods|BP readings from participant using invasive radial arterial line, Non-invasive cuff with SuperSTAT NIBP algorithm, and Non-invasive cuff with Classic NIBP algorithm.
45976193|NCT01607632|Behavioral|loving-kindness meditation|A 12-week duration, 90 minute per session loving-kindness meditation course
45976194|NCT00254735|Drug|quetiapine fumarate|
45976195|NCT00254735|Drug|SSRI/Clomipramine|
45671302|NCT05332262|Diagnostic Test|Troponin measurement|Measurement of high sensitivity troponin for the assessment for the presence of myocardial infarction/myocardial injury will be performed post-PCI.
45976196|NCT00288834|Behavioral|dysphagia rehabilitation|
45976197|NCT01607827|Procedure|Polyp removal upon insertion and withdrawal|"Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist removed all visible polyps instantly regardless whether advancing the instrument to the cecum or pulling back."
45976198|NCT01607827|Procedure|Polyp removal upon withdrawal only|"Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist advanced the endoscope to the cecum without removing polyps. Upon withdrawal, all visible polyps were removed successively by standard techniques."
45976199|NCT01607866|Procedure|Quadrant parotidectomy|Excision of one quadrant of the parotid gland which is comparable to half of the superficial lobe of the gland
46082286|NCT00610259|Behavioral|brief behavioral therapy for insomnia (bBT-I)|4 50-minute individual sessions every week for 4 weeks
46082287|NCT00610259|Other|Treatment as usual (TAU)|The psychiatrist-in-charge sees the patient once every 2 weeks for approximately 10 minutes each to monitor pharmacotherapy.
45671303|NCT04918784|Device|Restrata®|Restrata® is a sterile, single use device intended for use in local management of wounds. Restrata® is a soft, white, conformable, non-friable, absorbable matrix that provides a moist environment for the body's natural healing process to occur. Restrata® is made from synthetic biocompatible materials and was designed to include a fibrous structure with high porosity, similar to native extracellular matrix.
45976200|NCT01607866|Procedure|Superficial parotidectomy|Excision of the whole superficial lobe of the parotid gland
45976201|NCT00288873|Drug|Ergocalciferol|
45976202|NCT00288873|Drug|Cholecalciferol|
45976203|NCT01608022|Drug|PF804|45 mg p.o. daily and continuously (28-day treatment as one treatment cycle)
45671304|NCT04918784|Device|Wound Dressing|Alginate or Foam wound dressing is intended to manage wounds.
45976204|NCT04719494|Other|Dynamic balance walking training|Participants in the training group will walk on an elevated treadmill that will move side-to-side in a pseudorandom manner, thereby increasing the difficulty to their balance. Participants are asked to walk independently for 30-minutes per session, for 12 days over 4 weeks.
45671305|NCT04916444|Device|rTMS|repetitive transcranial magnetic stimulation is a painless, noninvasive form of neurostimulation. This study uses an accelerated protocol in which the neurostimulation pulses are delivered in 4 sessions per day over 4 consecutive days (16 total sessions). Active or sham rTMS will be provided at 9 weeks following botox injections.
45671306|NCT04465136|Device|CES, Alpha-Stim stimulator (Electromedical Products International, Inc., Mineral Wells, Texas, USA)|CES is a brain stimulation device with 2 electrodes on the bilateral earlobe. It uses Alternating current to stimulate the brain including thalamus, vagus nerve system and influence EEG and neurotransmitters like gamma-aminobutyrate. Stimulation was applied at a current intensity that can be adjusted continuously to provide between 10 and 600 micro-ampere and frequency of 0.5Hertz for 60 minutes, everyday for 6 weeks, total 42 sessions.
45671307|NCT05329688|Procedure|novel nutrition program|Give nutrition health education every two weeks and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease.
45830709|NCT03027258|Other|mHealth|"HBI participants who consent will be enrolled in this study and will have data collected from their community screening stored in a secure, web-based database. The stored data will be encrypted into a Quick Response code embedded in a smart card. A unique identification number and participant's blood group type will be on the outside of the card. There will be no names or any other identifiers. Each participating center will identify a dedicated delivery room staff that will be trained to read the contents of the card using the cell phone application as well as enter new data in the participant's profile. When a participant presents at delivery without the card, information can still be obtained from the secure, web-based database and confirmed using the participant's name, date of birth and cell phone number. This information is provided to the clinician to guide management of the infant."
45830710|NCT01484496|Biological|Placebo|Placebo
45830711|NCT01484496|Biological|Belimumab 200 mg SC|Belimumab 200 mg SC
45830712|NCT01484496|Drug|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
45830713|NCT03027102|Biological|DNT cells|DNT cells will be expanded (increased in numbers) in the laboratory, in order to enhance their tumour destroying potential before infusion into AML patients.
45976205|NCT01608139|Drug|Curcumin|Starting dose: 4 grams by mouth per day. During the first cycle only, Curcumin given on Day 1. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
45976206|NCT01608139|Drug|Sorafenib|Starting dose: 200 mg by mouth daily. During the first cycle only, Sorafenib given on Day 5. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
45671308|NCT04464512|Drug|Sufentanil|IV buprenorphine plus IV sufentanil treatment group.
45671309|NCT04899908|Radiation|Stereotactic Radiation|Focused radiation beams to treat tumors
45671310|NCT04899908|Drug|AGuIX gadolinium-based nanoparticles|Intravenous injection
45671311|NCT04899908|Other|Placebo|Intravenous infusion
45671312|NCT04897412|Drug|CBL-514 Injection|Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
45830714|NCT04097340|Device|Attentional Bias Retraining (ABR)|Participants randomized to this intervention will receive 2 weeks of ABR for opioids delivered via a mobile device.
45976207|NCT01608139|Drug|Vorinostat|Starting dose: 100 mg by mouth daily. During the first cycle only, Vorinostat given on Day 3. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
45830715|NCT04097340|Device|Control Training|Participants randomized to this intervention will receive 2 weeks of training without ABR, delivered via a mobile device.
45671313|NCT04897412|Other|Placebo|Sodium Chloride (0.9% NaCl) placebo for injection
45830716|NCT01509846|Biological|Vaccine: 2.6±0.8 x 10^8 vp/mL, 1 dose|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10^8 vp/mL administered on Day 0
45830717|NCT01509846|Biological|Vaccine: 2.6±0.8 x 10^9 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10^9 vp/mL administered on Days 0, 28, and 56
45830718|NCT01509846|Biological|Vaccine: 2.6±0.8 x 10^10 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10^10 vp/mL administered on Days 0, 28, and 56
45830719|NCT01509846|Biological|Vaccine: 2.6±0.8 x 10^11 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10^11 vp/mL administered on Days 0, 28, and 56
45830720|NCT01509846|Biological|Placebo: 1-3 doses|Placebo administered on Day 0 (if 1 dose) or Day 0, 28, and 56 (3 doses)
45830721|NCT01462344|Drug|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
45830722|NCT01462344|Drug|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
45830723|NCT01462344|Drug|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
45830724|NCT01462344|Drug|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
45830725|NCT01484028|Device|etafilcon A control lens (1DM)|A marketed daily disposable contact lens
45830726|NCT01484028|Device|etafilcon A with print and PVP for light eyes (EALE)|A daily disposable contact lens
45830727|NCT01484028|Device|etafilcon A with print and PVP for dark eyes (EADE)|A daily disposable contact lens
45830728|NCT01462266|Drug|Sitagliptin|Sitagliptin 100 mg tablet once daily for 24 weeks
45830729|NCT01462266|Drug|Comparator: Placebo|Placebo to sitagliptin once daily for 24 weeks
45830730|NCT01462266|Biological|Insulin Glargine|Participants on insulin glargine or another insulin regimen for at least 10 weeks prior to screening will continue or switch to open-label insulin glargine once-daily in the evening for the duration of the study.
45671314|NCT04849130|Procedure|Static reconstruction technique according to Schöttle|In static MPFL reconstruction, a graft (harvested autologous gracilis tendon or allogen transplant) is attached to the femoral and patellar bones using tunnels, screws, and/or anchors.
45830731|NCT01462266|Drug|Metformin|Participants on metformin oral tablet(s) at a dose of at least 1500 mg/day for at least 10 weeks prior to screening will continue receiving metformin at their current dose for the duration of the study.
45830732|NCT01508910|Biological|Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of Auto-CD34+ cells
45830733|NCT01508910|Biological|Placebo: Diluent used to suspend Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of placebo
45830734|NCT01508910|Other|Standard of care|Standard of care for refractory angina
45830735|NCT01462110|Device|19416-154-1|0.15% ethyl lauroyl arginate HCl-containing mouthrinse
45830736|NCT01462110|Device|W002194-0221P|5% hydroalcohol mouthrinse
45830737|NCT04087590|Drug|Formoterol-glycopyrronium co suspension (PT003)|Formoterol-glycopyrronium co suspension (PT003) in a Metered Dose Inhaler, 2 puffs twice daily
45830738|NCT04078854|Behavioral|Diabetes education|Both presentations are identical in educating patients how to control diabetes and the risk of future amputations in diabetes, but the experimental arm presentation will also include information regarding sexual dysfunction in diabetes.
45830739|NCT01508676|Drug|Pennsaid|
45830740|NCT01508676|Drug|Placebo (2.3% DMSO solution)|
45830741|NCT04095546|Other|routine psychotherapy for Borderline Personality Disorder (BPD)|Routine psychotherapy as treatment for patients with Borderline Personality Disorder
45830742|NCT02985372|Drug|Decitabine|All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).
45830743|NCT02985372|Drug|Cytarabine|
45830744|NCT04087512|Other|Training on perturbation treadmill|Perturbations into different directions are induced during static and dynamic tasks on a treadmill. Perturbations include announced and unannounced perturbations. Intensity and number of perturbations increases over the course of the intervention based on judgement of participant. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 30 minutes.
45671315|NCT04849130|Procedure|Dynamic reconstruction technique according to Becher|Dynamic MPFL procedure by detaching and reinserting only the distal part of a hamstring muscle to the patella and leaving the proximal tendon attached to its muscle. This way the patella position can be adjusted dynamically by hamstring contraction.
45671316|NCT05369234|Dietary Supplement|100% Aloe Vera Juice|George's 100% Aloe Vera Liquid Supplement
45671317|NCT05369234|Combination Product|Magic Mouthwash|Magic Mouthwash
45671318|NCT05369234|Combination Product|Salt and Baking soda rinse|Mouth rinse made with salt and baking soda
45830745|NCT04087512|Other|Exercises of dynamic stability under unstable conditions|The mechanisms of dynamic stability recovery are trained under unstable conditions. Different unstable undergrounds are used to stand on, perform lunges or jumps. Additionally, balance is challenged by different restrictions (e.g. decreased base of support, closed eyes) or therapist-applied perturbations. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 45 minutes.
45830746|NCT02985216|Drug|YHD1119|"YHD1119 150mg, PO YHD1119 300mg, PO~YHD1119 600mg, PO"
45830747|NCT02985216|Drug|Lyrica|Lyrica 75mg, PO Lyrica 150mg, PO Lyrica 300mg, PO
45830748|NCT01482312|Device|lotrafilcon A contact lenses|Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
45830749|NCT01482312|Device|comfilcon A contact lenses|Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
45671319|NCT05369234|Drug|Carafate|Carafate taken as a slurry
45671320|NCT05179148|Behavioral|Motivational Interviewing|MI is a client-centered counselling style for strengthening a person's own motivation and commitment to change. MI helps evoke the person's own motivation for changes through reflective listening, engaging, evoking, and planning
45830750|NCT01482312|Other|Glasses|Glasses per habitual prescription
45830751|NCT01461096|Biological|Quadrivalent HPV Vaccine|Participants were prescribed one intramuscular (IM) injection of the quadrivalent HPV vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
45830752|NCT01461096|Biological|Placebo Vaccine for Male Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
45830753|NCT01461096|Biological|Placebo Vaccine for Female Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
45830754|NCT04077294|Other|Cardiac risk stratification using preoperative BNP measurement, followed by postoperative cardiac monitoring|Patients undergoing non-cardiac surgery risk stratified using BNP measurements according to CCS guidelines.
45830755|NCT04077294|Other|Use of traditional perioperative cardiac risk stratification only|Patients undergoing non-cardiac surgery risk stratified using tools other than BNP measurement such as revised cardiac risk index (RCRI).
45830756|NCT01507896|Biological|Recombinant factor IX|Following a loading dose with BAX326, participants will receive BAX326 as a bolus infusion. The treatment regimen will be determined by the intensity and duration of the hemostatic challenge and the institution´s standard of care. The dose will be tailored to raise FIX concentration to at least 80%-100% of normal for major surgeries and to at least 30%-60% of normal for minor surgeries.
45830757|NCT01507662|Behavioral|Bone Mineral Density Result Letter and Bone Health Brochure|Letter mailed to patient to include - Date of DXA, T-score, impression, 10 year major fracture risk with visual depiction of risk, basic bone health guidelines, instructions to follow-up with their healthcare provider. The brochure will include information on osteoporosis, calcium, vitamin D, medicines, exercise, tobacco and alcohol cessation and where to find more information.
45830758|NCT01506960|Device|InfraReDx Lipiscan IVUS|Near Infrared Spectroscopy/Intravascular Ultrasound will be performed following OCT imaging.
45830759|NCT01480674|Drug|Trastuzumab|
45830760|NCT01506882|Drug|Levetiracetam (LEV)|"Active Substance: Levetiracetam~Pharmaceutical Form: Film-coated tablet~Concentration: LEV 250 mg, LEV 500 mg~Frequency: Twice daily~Route of Administration: Oral use"
45830761|NCT01506726|Drug|Salsalate|Salsalate 750mg tablet 1 pill bid for one month followed by Salsalate 750mg tablets 2 pills (1500mg) twice a day for a further 5 months (total duration of treatment will be 6 months)
45830762|NCT01506726|Drug|Placebo|Placebo tablet - one pill twice daily for one month, followed by 2 pills twice daily for a further 5 months. Total duration of treatment is 6 months
45830763|NCT01505868|Drug|Cabazitaxel|Given IV
45830764|NCT01505868|Drug|Carboplatin|Given IV
45830765|NCT01505868|Other|Laboratory Biomarker Analysis|Correlative studies
45830766|NCT01505634|Drug|Relebactam 250 mg|Participants randomized to receive relebactam 250 mg will be administered a 250 mg dose of relebactam IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval.
45830767|NCT01505634|Drug|Relebactam 125 mg|Participants randomized to receive relebactam 125 mg will be administered a 125 mg dose of relebactam IV in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval.
45830768|NCT01505634|Drug|imipenem/cilastatin 500 mg|A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
45976208|NCT01607671|Drug|Timolol maleate|Timolol 0.5% 1 drop twice daily to the effected eye for 4 weeks.
45976209|NCT00288951|Drug|Travoprost 0.004% with and without BAK|
45976210|NCT00254774|Drug|quetiapine fumarate or valproate|
45976211|NCT01608334|Drug|Fentanyl|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
45671321|NCT04839692|Drug|Hyaluronic acid filler|Hyaluronic acid filler treatment of the lips with Restylane Kysse, which is a FDA approved treatment for lip augmentation.
45830769|NCT01505634|Drug|Placebo to relebactam|Participants randomized to receive imipenem/cilastatin alone will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
45830770|NCT01505634|Drug|Ciprofloxacin|After at least 96 hours of IV treatment, participants may be switched, at the discretion of the investigator, to 500 mg ciprofloxacin, administered orally, twice daily
45830771|NCT04409730|Other|Photographic Posture Analysis|Postural evaluation was done using the photographic method. All measurements were made by two researchers experienced in postural analysis evaluation. Canon camera and national geographic tripod with double spirit level were used for evaluation. The camera was placed on a 115 cm high tripod, 1.5 m away from the subjects. Spirit levels have been adjusted so that the tripod is completely flat on the ground. The tripod was taped to the floor to maintain the same distance between the camera and the participants. Six photographs of each child whose feet on the ground, in a free-sitting position, 3 from the front and 3 sides were taken by the researchers.
45830772|NCT01460628|Drug|Armodafinil|Women who are eligible will receive 4 weeks of treatment with armodafinil. Armodafinil will be titrated from 50-mg/day up to 150-mg/day. For exploratory reasons only, at the end of the 4-week treatment period, participants will enter a discontinuation phase in which they will be randomized to double-blind treatment with armodafinil 150-mg/day or matching placebo for 2 weeks in a 1-to-1 ratio. No primary outcomes were studied in the discontinuation phase.
45830773|NCT01480596|Biological|Belimumab|10mg/kg IV infusion
45830774|NCT01480596|Other|Placebo|placebo IV infusion
45671322|NCT05173766|Other|ergonomic principls|Ergonomic principles for posture correction in office for computer users.
45976212|NCT01608334|Drug|Sufentanil|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
45456107|NCT04989452|Diagnostic Test|Recordings of cough sounds from adults|Smartphone recordings of the cough sounds of participants who enrol in the study and obtain a COVID-19 rt-qPCR result.
45671323|NCT02163499|Drug|Sodium Zirconium Cyclosilicate|Acute Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) for 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) based on i-STAT potassium measurements up to 12 months.
45671324|NCT04827446|Other|Wearable Sensor|Patient is given a wearable device to wear for 12 weeks.
45671325|NCT04827446|Other|Blue-blocking glasses|Patient is given blue-blocking glasses to wear at instructed times.
45671326|NCT04827446|Other|Clear glasses|Patient is given glasses that block no visible light.
45456108|NCT04981912|Drug|HDMP + rituximab as a means of debulking prior to initiating venetoclax.|"Patients will receive HDMP + Rituximab for 1 cycle, followed by reassessment of Tumor Burden,~If Tumor Burden classification is low after HDMP + Rituximab (lymph nodes < 5cm in diameter AND absolute lymphocyte count < 25k/uL), patients will initiate venetoclax dose ramp-up, with ramp-up schedule according to venetoclax package insert.~Patients who still have a disease burden (lymphadenopathy > 5 cm or ALC > 25k/iL) that meets criteria for medium or high risk of TLS after 1 cycle of HDMP + Rituximab are given the option to repeat a 2nd cycle of HDMP + Rituximab prior to venetoclax dose ramp-up."
45456109|NCT04974879|Drug|Osimertinib Oral Tablet|Osimertinib, 80mg, oral daily; bevacizumab (avastin), 15mg/KG body weight, erery 21 days, intravenously.
45456110|NCT04974866|Drug|EGFR-TK Inhibitor|epidermal growth factor receptor tyrosine kinase inhibitors
45671327|NCT04827446|Other|Full SYNC app|Patient downloads the SYNC app and is given light interventions designed to have a targeted, personalized effect on the circadian clock.
45671328|NCT04827446|Other|"Dummy SYNC app"|Patient downloads the SYNC app and is given light interventions designed to have minimal impact on the circadian clock.
45830775|NCT01480284|Drug|GSK548470 300 mg tablet|Blue tablets, each tablet containing 300 mg of tenofovir disoproxil fumarate
45830776|NCT01480284|Drug|ETV 0.5 mg capsule|Brown capsules, each capsule containing 0.53 mg of entecavir hydrate
45830777|NCT04409028|Procedure|Coronal restoration|A restorative material like composite resin is condensed into the cavity of teeth.
45671329|NCT04827368|Other|Breath Test|Research Breath Test
45671330|NCT02163187|Device|Implantation of the InterStimTM|
45671331|NCT02163187|Behavioral|MSK BFI questionnaires|
45671332|NCT02163187|Behavioral|The Low Anterior Resection Score (LARS) questionnaires|
45830778|NCT01459614|Drug|Gemcitabine|IV on Days 4 and 11
45830779|NCT01459614|Drug|Taxotere|IV on Days 4 and 11
45458628|NCT03634904|Drug|Drug bood sampling|"Total: 6 per patient~after the first administration of ceftazidime (loading dose): sampling #1: at trough before 1st dialysis; sampling #2: after the end of the dialysis session;~after the second administration of ceftazidime (maintenance dose): sampling #3: at trough before 2d dialysis session;~after the third administration of ceftazidime (maintenance dose): sampling #4: at trough before 3d dialysis session;~after the fourth third administration of ceftazidime (maintenance dose): sampling #5: at trough before 4th dialysis session; sampling #6: after the end of the dialysis session"
45671333|NCT02163187|Behavioral|The EuroQOL5D questionnaires|
45671334|NCT02163187|Behavioral|The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires|
45671335|NCT05145452|Dietary Supplement|Fish-oil derived n-3 polyunsaturated fatty acids|4.2 g/d (7 pills with 600 mg each)
45830780|NCT01459614|Drug|Xeloda|orally, twice a day Days 1-14
45830781|NCT01459614|Drug|Cisplatin|IV Days 4 and 11
45830782|NCT01459068|Behavioral|Common Elements Treatment Approach|"CETA components include:~Engagement (encouraging participation)~Psychoeducation (introduction)~Anxiety Management Strategies (relaxation)~Behavioral Activation (getting active)~Cognitive Coping/Restructuring (thinking in a different way, part I and part II)~Imaginal Gradual Exposure (talking about difficult memories)~In Vivo Exposure (Live exposure)~Suicide/Homicide/Danger Assessment and Planning (safety)~Screening and Brief Intervention for Alcohol (alcohol intervention)"
45976213|NCT01608373|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr
45976214|NCT01608373|Drug|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc. 50cc of irrigation fluid will be spread below diaphragm and 50cc of irrigation fluid will be spread around the gall bladder.
45671336|NCT04419116|Procedure|tibial preservation bone cut|tibial preservation bone cut: removing of proximal tibial less than conventional tibial bone cut with 2mm.
45671337|NCT04839614|Other|CONCURRENT LAPAROSCOPIC HYSTERECTOMY AND WEIGHT LOSS SURGERY-Referral|See arm description
45671338|NCT02191579|Biological|onabotulinumtoxinA|155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks.
45671339|NCT02191579|Drug|Topiramate|Topiramate up to a maximum oral dose of 100 mg/day.
45671340|NCT05138510|Behavioral|Focus Group|"Providers with extensive training and expertise in the subject will lead the virtual focus groups over Zoom using a semi-structured guide. Topics will focus on education received from the health care team, information received from outside sources, and patient recommendations on the type and timing of information preferred.~We will create an analytic report based on the focus group findings, which will be used to inform the development of educational material.~Sexual well-being is currently measured longitudinally on a 0-100 point scale as a component of a validated patient-reported outcome measures (PROM) survey (BREAST-Q) distributed to all breast cancer patients. These scores will be analyzed in patients with and without educational interventions for comparison."
45671341|NCT04756141|Device|Continuous Glucose Monitor (CGM)|A CGM will be placed on patients with DM and COVID-19 infection and interstitial glucose will be monitored continuously while the patients are in the hospital.
45830783|NCT01458522|Drug|fPHT|"If after initial treatment with fPHT any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments."
45976215|NCT01608373|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
45976216|NCT01608412|Drug|Tacrolimus|TACROLIMUS (C0 = 5-10 ng/mL) + MPS 1440 mg + Pred
45671342|NCT05125250|Other|Motor Control Group|will received treatment which comprises of therapeutic exercises, During the first 4 weeks, motor control and ROM exercises will be prescribed in order to improve muscular endurance of deep flexors muscles and to improve the ROM of cervical spine in flexion, extension, rotation and side bending and lateral rotation in. These exercises will be performed at a rate of 3 sets and an intensity of 15 repetitions per day .
45976217|NCT01608412|Drug|Everolimus|Everolimus (C0 = 6-10 ng/mL) + MPS 1440 mg + Pred
46082288|NCT02737098|Other|Enhanced Implementation Strategy|The enhanced implementation strategy will add external facilitation to the standard VA implementation strategies. External facilitation will begin with an assessment of the current workflow at the VHA Medical Center and the affiliated CBOCs using System Redesign methods. The external facilitation team will then generate a clinical workflow chart that describes the current process of care. With advice from the external facilitation team, the local champion will then incorporate the clinical process of the TOP intervention into the current clinical workflow chart, making changes to the TOP intervention and/or current clinical workflow as needed. The local champion will also meet monthly with external facilitators to troubleshoot and make refinements.
46082289|NCT02737098|Other|Standard Implementation Strategy|Standard VA implementation strategies will include disseminating a clinical intervention manual, a local champion guide, care manager training materials, PTSD case-finder tool, and technical support from the facility level telehealth technician. Internal facilitation will be conducted by the designated local champion. In addition, each VAMC will receive funds to hire a full time telephone care manager.
46082290|NCT04259333|Drug|Celecoxib 200mg|Celecoxib tablet
45671343|NCT05125250|Other|Vestibular Group|will receive vestibular exercises which comprises of postural awareness training, balance board exercises, Foveal vision exercises .
45671344|NCT04414514|Drug|Ruxolitinib 1.5% Cream|Topical Ruxolitinib 1.5% Cream
46082291|NCT04259333|Drug|Acetaminophen, Codeine Drug Combination|acetaminophen-codeine-caffeine tablet
46082292|NCT02736942|Procedure|Laparoscopic TME|Laparoscopic Total Mesorectal Excision
46082293|NCT02736942|Procedure|TaTME|Transanal Total Mesorectal Excision
45671345|NCT05324462|Drug|IDegLira|Collecting data reported in medical records of patients with T2D, who had initiated treatment with commercially available IDegLira according to the routine clinical practice and local label at the discretion of the treating physician
45671346|NCT04873856|Dietary Supplement|Intervention|"The four dimensions of MINDNUT are described below:~Nutritional plan: is conducted in collaboration with the participant based on nutritional registration and information about routines and habits to reach a daily protein target of 1.5 g/kg/day. The nutritional plan is adjusted at the regular contact, and nutritional supplementation will be handed out to the participant.~Friendly reminder/informal caregiver: is a friendly reminder that encourage the participant to follow the nutritional plan and to ask for support (a note to hang on the refrigerator). The informal caregiver is a person with close contact to the participant.~Regular contacts: The participant will be contacted on regular basis (with an interval of 7-14 days) via phone and besides nutritional plan, this conversation will be used to talk about well-being, compliance and potential side-effects.~Weight diary: participants is instructed in keeping a weight diary which include registration of a daily weight."
45671347|NCT04838756|Other|AI screening modality|Screen exam will be analysed with an AI system (Transpara, ScreenPoint, Nijmegen, The Netherlands) that assigns exams with a cancer-risk score from 1 to 10, as well as presenting CAD-marks at suspicious findings. Exams with risk score 1-9 will be single read and exam with score 10 will be double read. Risk scores and CAD-marks are provided to the reader(s). The reader(s) will decide whether to recall the woman for work-up or not (as per standard of care). In addition, exams with the highest 1% risk will by default be recalled with the exception of obvious false positives.
45976218|NCT00254813|Drug|Quetiapine|
45976219|NCT01608529|Device|Feel Breathe, restriction device ventilatory nasal|The Feel Breathe (FB) consisted of a small adhesive strip that is placed across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacturer's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. Each subject was required to perform three identical submaximal exercises with intensity at 50% VT1-VT2 under different breathing conditions. The breathing conditions were: oronasal, nasal and FB breathing. All participants performed three trials of stable load (50% VT1-VT2) for 10 minutes in the three conditions mentioned above, setting the cadence at 70-75 rpm, and controlling the same in all three exercise conditions.
46082294|NCT02726724|Other|5 observers|
45976220|NCT04718454|Device|dental attachment|This research aimed to evaluate the retentive power and wear of the smart box attachment use with tilted two implant assisted mandibular overdenture
46082295|NCT02726724|Other|1 observer|
46082296|NCT00926237|Device|Sham rTMS - Sham repetitive transcranial magnetic stimulation|Sham rTMS will be delivered using a commercially available sham coil and targeted to the same brain site in the temporal lobe and in a manner identical to that for active rTMS except that scalp electrodes are used to stimulate the temporalis muscle electrically during sham stimulation to replicate the feel of active TMS.
45671348|NCT04838756|Other|Conventional screening modality|Screen exams will be read by two radiologists without the support of AI.
45671349|NCT01363700|Drug|DE-114 ophthalmic solution|
46082297|NCT00926237|Device|Active 1 Hz rTMS - Active repetitive transcranial magnetic stimulation delivered at 1 Hz frequency|Active rTMS will be targeted either to the mid-superior temporal gyrus opposite the ear with loudest tinnitus or to the same region in the left hemisphere if no asymmetry in tinnitus is present. 1 Hz active rTMS will be delivered at 110% of motor threshold (MT) for a total of 1800 magnetic pulses per session, 4 sessions per week.
45671350|NCT01363700|Drug|Placebo ophthalmic solution|
45976221|NCT01608568|Device|Device is the type of suture used: Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during robotic assisted laparoscopic sacrocolpopexy (RALSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
45976222|NCT01608646|Drug|S-1 plus oxaliplatin|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
45458629|NCT01235455|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
45671351|NCT01363700|Drug|Olopatadine Hydrochloride 0.1% Ophthalmic Solution|
45671352|NCT04822688|Procedure|Biospecimen Collection|Undergo collection of tissue and blood samples
45671353|NCT04838678|Drug|Neuropeptide Y|intra-arterial infusion of neuropeptide Y
45671354|NCT04372706|Drug|RTX-240|Engineered red cells co-expressing 4-1BBL and IL-15TP
45976223|NCT00254852|Procedure|Posterior Lateral Fusion (PLF)|Posterior lateral fusion (PLF) of the lumbar spine
45976224|NCT00254852|Procedure|Anterior Lumbar Interbody Fusion (ALIF)|Anterior lumbar interbody fusion (ALIF)
45976225|NCT00254852|Procedure|Transforaminal lumbar interbody fusion (TLIF)|Transforaminal lumbar interbody fusion (TLIF)
45976226|NCT00254852|Procedure|Posterior lumbar interbody fusion (PLIF)|Posterior lumbar interbody fusion (PLIF)
45671355|NCT04372706|Drug|Pembrolizumab|Humanized immunoglobulin G4 programmed death receptor-1 blocking antibody
45671356|NCT04178642|Drug|percutaneous destruction of the tumor + Idarubicin-Lipiodol treatment|Patients will receive the standard treatment protocol consisting of a percutaneous destruction of the tumor. In addition they will receive an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin (Zavedos®, Pfizer), which is an anthracycline antineoplastic agent, mixed with Lipiodol (Lipiodol Ultra-Fluid®, Guerbet), which is a contrast agent.
45671357|NCT04178642|Procedure|Percutaneous destruction of the tumor|Patients will received the standard treatment protocol consisting of a percutaneous destruction of the tumor.
45671358|NCT04157894|Other|Standard long-lasting insecticidal net|Interceptor® (BASF) contains a pyrethroid insecticide
45671359|NCT04157894|Other|Chlorfenapyr insecticide treated net|Interceptor® G2 (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.
46082298|NCT00926237|Device|Active 10 Hz rTMS - active repetitive transcranial magnetic stimulation delivered at 10 Hz frequency|Active rTMS will be targeted either to the mid-superior temporal gyrus opposite the ear with loudest tinnitus or to the same region in the left hemisphere if no asymmetry in tinnitus is present. 10 Hz active rTMS will be delivered at 110% of motor threshold (MT) for a total of 1800 magnetic pulses per session, 4 sessions per week.
45671360|NCT04157894|Other|Piperonyl butoxide long-lasting insecticidal net|PermaNet®3.0 (Vestergaard) contains deltamethrin, a pyrethroid insecticide, and piperonyl butoxide, an insecticide synergist.
45671361|NCT04838288|Drug|Change from Prograf to Envarsus XR|Change from Tacrolimus taken twice a day to Envarsus XR taken once a day
45671362|NCT04821752|Behavioral|Avoidance Education|Dietary modification and lifestyle interventions
45976227|NCT00254852|Procedure|Extreme lateral interbody fusion (XLIF)|Extreme lateral interbody fusion (XLIF)
45976228|NCT01608763|Behavioral|Check Your Drinking (CYD) personalized feedback intervention|The CYD provides problem drinkers with a personalized summary of their drinking that compares his or her drinking with that of the general population. The CYD also provides an assessment of the severity of the person's drinking problem.
45976229|NCT01608802|Other|Palliative care|Regular appointments with an existing clinic nurse who has been trained in palliative care, the patient is asked about their physical, psychological, social and spiritual problems, and a care management plan devised with referral as necessary.
45976230|NCT01608802|Other|Standard care|Patients attend monthly for their ART monitoring and prescription filling, and a multiprofessional team is available as necessary.
45671363|NCT04815278|Behavioral|Immediate Chronic Disease Prevention Program (CDPP)|The CDPP is an adaptation of the Diabetes Prevention Program (DPP). It will take place over a 24 week period and involve online instruction and individualized lifestyle coaching sessions. The online classroom curriculum includes 8 modules: Goal setting, self-monitoring and problem solving (M1), Managing stress and negative thoughts (M2), Healthy eating (M3), Taking more steps (M4), Keeping alcohol in check (M5), Lifestyle change (M6), Taking charge of what (and who) is around you (M7), and Staying motivated (M8). The lifestyle coaches will meet in person and over the phone intermittently over the 24 week period (Weeks 2, 4, 6, 10, 12, 16, 24).
45671364|NCT04815278|Behavioral|Workplace Equity, Job and Health Supports Employer Intervention|The employer intervention combines implicit bias awareness training for supervisors of hired DSS-E clients, and regular, structured, interactions between supervisors and DSS-E hires.
45830784|NCT01458522|Drug|LCM|"If after initial treatment with LCM any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments."
45976231|NCT01608841|Drug|Erlotinib|Erlotinib 100 mg 1# PO qd till disease progression
45830785|NCT01505010|Procedure|Renal denervation|Renal denervation in the intervention group
45830786|NCT03026946|Drug|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
45976232|NCT00254930|Drug|risperidone|
45976233|NCT01608919|Other|blood tests|thromboelastogram platelet mapping
46082299|NCT02721576|Drug|Sodium Glycididazole|Sodium Glycididazole 800mg/m2.Three times a week (once every other one day),before radiation therapy, total 5-6 weeks.
45976234|NCT00289029|Drug|Iopamidol 370 mgI/mL|
45976235|NCT00254969|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, Im
45976236|NCT00289068|Procedure|Phacoemulsification Sleeve surgery|Group 2.2 mm surgery setting
45976237|NCT00289068|Procedure|Phacoemulsification Sleeves surgery|Group 2.8 mm surgery setting
45976238|NCT00289068|Procedure|Phacoemulsification Sleeves|Group 3.0 mm surgery setting
45671365|NCT04815278|Behavioral|Delayed, attenuated Chronic Disease Prevention Program (CDPP)|Participants will have access to a delayed, attenuated online-only version of the CDPP at the time they complete the 12 month data collection. This version will provide all modules, self-monitoring options (including through use of a Fitbit contingent on the completion of the 12 month data collection) but will not include face-to-face or phone lifestyle coach sessions.
45671366|NCT04821674|Biological|DS-5670a|DS-5670a (10, 30, 60 or 100 µg) administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
45671367|NCT04821674|Biological|Placebo|Placebo administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
45671368|NCT04367480|Device|Placebo Administration|Wear placebo TENS device
45671369|NCT04367480|Other|Questionnaire Administration|Ancillary studies
45671370|NCT04367480|Device|Transcutaneous Electrical Nerve Stimulation|Wear active TENS device
45671371|NCT04340180|Drug|Standard of Care (SOC) gadolinium Breast MRI|Standard of Care (SOC) gadolinium Breast MRI
45671372|NCT04340180|Drug|reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.|reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.
45671373|NCT04327934|Drug|GnRH antagonist|GnRH antagonist up to 16 days.
45671374|NCT04327934|Drug|GnRH antagonist + MethylTESTOSTERone 5 MG|GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.
45671375|NCT04791566|Drug|Dexamethasone 1 mg/kg|Dexamethasone 1 mg/kg administered as a single preoperative i.v. infusion over 10-15 min prior to general anaesthesia
45671376|NCT04791566|Drug|Physiologic saline|100 mL Physiologic saline administered as a single preoperative i.v., infusion over 10-15 min prior to general anaesthesia
45976239|NCT02273440|Drug|BIIL 284 BS|
45976240|NCT02273440|Drug|Theophylline|
45456111|NCT04972773|Behavioral|Mindfulness meditation (MM)|"Towards this additional MM practice, participants will be able to use any combination of the MM apps: Insight timer, which focuses on community/group-like therapy, Healthy minds, which focuses on resilience that is essential in disability adjustment, and Smiling mind, that reminds patients of their family/support structures. These three options were chosen for delivering free MM with different focuses that would cater to the variety of SCI patients needs. Participants will be alerted if they are not achieving 30 minutes of additional MM per week. This will guarantee that the treatment group have a higher time spent on MM for dose-response analysis. Participants will receive a reminder email (see attached) on the Sunday evening of a week with <30 minutes of additional MM encouraging them to use their mindfulness app."
46082300|NCT04162782|Procedure|obstetric and gynaecological surgeries|surgeries for gynecologic and obstetric diseases
45456112|NCT04969640|Other|Optical coherence tomography|Anterior segment optical coherence tomography examination of corneas with infective keratitis
45456113|NCT04944615|Procedure|The guidewire successfully passed the CTO lesion|"The successful passage of the guide wire through the CTO lesion was defined as: the guide wire successfully passed through the CTO lesion and reached the distal true lumen as confirmed by angiography.~Aspirin load dose (300 mg), clopidogrel load dose (300 mg), or ticagrelor load dose (180 mg) is recommended for all subjects prior to stent implantation and is recommended to be taken at least 6 hours prior to surgery."
45456114|NCT04933058|Drug|IV acetaminophen|Pain management
45456115|NCT04933058|Drug|IV fentanyl|Pain management
45456116|NCT04929821|Device|Biliary Duct Stenting|UNITY-B Balloon-expandable Biodegradable Biliary Stent deployment in obstructed biliary ducts.
45456117|NCT04928612|Drug|CBP-1018|CBP-1018 for injection, IV infusion
45456118|NCT04926766|Radiation|External Beam radiotherapy using IMRT technique|2600cGy/ 5 fractions / 1 weeks to ipsilateral whole breast and a sequential tumor bed boost of 5.2 Gy in 2 fractions at the discretion of radiation oncologist
45976241|NCT02273440|Drug|Placebo|
46082301|NCT04259099|Other|Testing the Quality of Life Questionnaire of the European Foundation for Osteoporosis-31(QUALEFFO-31)|Administer the questionnaires to 150 participants to classify their status of quality of life.
45976242|NCT01588678|Drug|DS-3078a|DS-3078a will be administered as oral capsules once daily and will be supplied in 5, 20, 50, and 150 mg capsules.
46082302|NCT02721420|Drug|dihydroartemisinin-piperaquine|
46082303|NCT02721420|Other|message(SMS) reminder|
46082304|NCT02721420|Other|Health worker reminder|Health surveillance assistants reminders prior to each treatment course
46082305|NCT02721420|Other|short message(SMS) reminder|
45830787|NCT03026946|Drug|cyclosporin A|Oral cyclosporine A start dose 5 mg/kg/day (split in 2 doses), decreasing the dose after 8 weeks to 3 - 3.5 mg/kg/day (split in 2 doses). The treatment period is 24 weeks.
45830788|NCT01458366|Drug|Bendamustine|"Phase 1: Given via IV at the following dose levels:~Level 1: 70 mg/m2~Level -1: 50 mg/m2~Level 2: 90 mg/m2~Level 3: 120 mg/m2~Phase II: Given via IV on Days 1 and 2 of each cycle at the maximum-tolerated dose level found in the Phase I portion of the study."
45830789|NCT01458366|Drug|Ofatumumab|"Phase II~Cycle 1: 300 mg via IV on Day 1 and 1000 mg via IV on Day 3~Cycles 2 and 3: 1000 mg via IV on Day 1"
45671377|NCT04129736|Drug|Teriflunomide 14 MG|Blood and cerebrospinal fluid is obtained from teriflunomide treated patients with multiple sclerosis
45830790|NCT01458366|Drug|Carboplatin|Phase II: AUC 5 via IV on Day 2 of each cycle
45830791|NCT01458366|Drug|Etoposide|Phase II: 100 mg/m2 via IV on Days 1, 2, and 3 of each cycle
45830792|NCT01458366|Procedure|CT Scan|CT Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
45976243|NCT04719455|Behavioral|Adherence Improving self-Management Strategy|An in-person delivered intervention imbedded in regular follow-up care during 9-months. Patients will receive an electronic monitoring System to track medication intake and a pedometer to count daily amount of steps. During the baseline visit, the health care professional (HCP) will use pre-tested materials for informing and motivating patients; and collaboratively set goals and plans for medication adherence and physical activity. During regular follow-up consultations with the HCP, personalized visual reports of medication intake and amount of steps will be evaluated to enhance patients awareness of their (non-)adherence and (in)activity and identify any problems and solutions to reduce undesired behaviour. The control group will receive usual treatment only.
45976244|NCT04719455|Other|Regular care|Treatment as usual (appointments with nurse/nurse practioner with regular content)
45671378|NCT04115540|Device|TENS penile nerve stimulation|The electrode pads of the transcutaneous electrical nerve stimulation (TENS 7000) will be placed at the base of the penis (and perineum) to stimulate the penile nerves.
45671379|NCT05301218|Procedure|angioplasty|Coronary angioplasty, also called percutaneous coronary intervention, is a procedure used to open clogged heart arteries. Angioplasty uses a tiny balloon catheter that is inserted in a blocked blood vessel to help widen it and improve blood flow to the heart
45830793|NCT01458366|Procedure|PET Scan|PET Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
45830794|NCT01458366|Genetic|Stem Cell Transplant (STC)|"For potential transplant candidates:~Autologous STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee~Allogeneic STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee"
45830795|NCT01458210|Drug|Ortho-Cyclen|Administered orally
45830796|NCT01458210|Biological|Dulaglutide|Administered subcutaneously
45830797|NCT01478958|Dietary Supplement|SFA diet|Volunteers are following a high saturated fat diet for a 4-month period
45456119|NCT04925492|Radiation|Positron Emission Tomography|An imaging method that uses radiotracers to view changes in the metabolic process.
45456120|NCT04925492|Drug|Cu-64]-LLP2A|A radioactive tracer used in PET imaging.
46082306|NCT00608699|Drug|GSK256073A tablets + IR niacin tablets|single dosing for 4 to 5 sessions
46082307|NCT05330819|Other|Non-interventional|Blood thrombogenicity in patients with previous history of myocardial infarction will be studied using Badimon perfusion chamber, SEM and TEG.
45830798|NCT01478958|Dietary Supplement|MUFA diet|Volunteers are following a high monounsaturated fat diet for a 4-month period
45830799|NCT01478958|Dietary Supplement|n-6 PUFA diet|Volunteers are following a high n-6 polyunsaturated fat diet for a 4-month period
45830800|NCT01457352|Drug|SPARC0921|
45830801|NCT01457352|Drug|Placebo0921|
45830802|NCT01457118|Drug|NKTR-102 145 mg/m2|A 90 minute IV infusion of 145 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
45830803|NCT01457118|Drug|NKTR-102 120 mg/m2|A 90 minute IV infusion of 120 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
46082308|NCT05193396|Drug|Hydrocortisone|hydrocortisone
46082309|NCT05193396|Drug|Placebo|placebo tablets
45671380|NCT04418960|Diagnostic Test|Magnetic resonance imaging (MRI)|MRI pre- and postoperatively for detailed analysis of the ventricle and the mitral annulus. The first MRI will be performed on the admission day before surgery. The second MRI will be performed during the hospital stay, between 3 and 7 days after the operation. The MRI images are interpreted through a specialized cardiologist and radiologist.
45830804|NCT01457118|Drug|NKTR-102 95 mg/m2|A 90 minute IV infusion of 95 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
45830805|NCT01457118|Drug|NKTR-102 50 mg/m2|A 90 minute IV infusion of 50 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
45671381|NCT04769960|Diagnostic Test|MRI Studies|MRI scans will be performed on a 1.5T MRI scanner. Department of Radiology MRI SafetyGuidelines will be followed except regarding breast tissue expanders. Conventional MRIstudies will be performed using the standard of care clinical sequences.
45830806|NCT01501110|Drug|N-acetylcysteine|in infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours
45830807|NCT01500720|Drug|Cabazitaxel|Cabazitaxel 25 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 every 3 weeks (21-day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
45830808|NCT01500720|Drug|Topotecan|Topotecan 1.5 mg/m^2 IV on Day 1 to Day 5 every 3 weeks (21-Day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
45830809|NCT04408872|Diagnostic Test|Esophago-gastro-duodenoscopy (EGD)|EGD: ENDOSCOPIC PROCEDURE DURING WHICH THE ESOPHAGUS, STOMACH AND DUODENUM ARE VISUALISED WITH A TINY CAMERA IMPLANTED AT THE END OF AN ENDOSCOPE.
45830810|NCT04408872|Diagnostic Test|Endoscopic ultrasound (EUS)|EUS: SAME AS EGD, BUT IN ADDITION HAS AN INTEGRATED ULTRASOUND PROBE WHICH ALLOWS TO EXAMINE THE PANCREAS, LIVER AND BILIARY SYSTEM.
45830811|NCT01500252|Device|Patellar Replacement Prosthesis|The Profix™ Total Knee System, a posterior cruciate retaining prosthesis manufactured by Smith and Nephew, Inc. was utilized in all subjects. Subjects randomized to the Resurfaced group received an all polyethylene patellar implant
45671382|NCT04769960|Behavioral|Patient Reported Outcomes|Participants will fill out questionnaires before, immediately after, and approximately 3 months following the MRI examination +/- 1 month to evaluate for any pain or perceived changes with the breast tissue expander. The first questionnaire will obtain background participants information as well as establish a baseline pain level, the second questionnaire will evaluate any changes in pain after undergoing the MRI examination, and the last questionnaire will evaluate long term changes in pain. The patient reported outcome questionnaire will be optional at 3 months post-MRI +/-1 month.
45671383|NCT01637402|Drug|Abiraterone Acetate|"Standard dose participants:~1,000 mg, once daily, oral administration.~Dose escalation participants:~1,000 mg, twice daily, oral administration"
45671384|NCT01637402|Drug|Prednisone|5 mg, twice daily, oral administration
45830812|NCT01500252|Device|Profix TKR with Patellar Retention|All subjects received a Profix TKR. Subjects in the Patellar Retention group retained their native patellar surface.
45830813|NCT01476696|Drug|Prasugrel|Administered orally
45830814|NCT01500096|Drug|American ginseng|American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
45830815|NCT01500096|Dietary Supplement|Placebo for American ginseng|"Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.~Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day"
45830816|NCT04767438|Other|Pregnant women|All pregnant women that present to the 12-week scan in the Obstetrics Unit
45976245|NCT01588717|Drug|Glycopyrrolate|glycopyrrolate 2 to 6mg/day
45456121|NCT04918810|Drug|Docetaxel intermittent|After 3 cycles of docetaxel chemotherapy (75mg/m^2 every 21) in combination with an undetectable mGSTP1 level, patients randomised to this arm will stop docetaxel treatment. Plasma mGSTP1 is measured every 21 days and docetaxel treatment will be recommenced if it mGSTP1 becomes detectable again.
45456122|NCT04918810|Drug|Docetaxel standard of care|After 3 cycles of docetaxel chemotherapy (75mg/m^2 every 21) in combination with an undetectable mGSTP1 level, patients randomised to this arm will continue with standard Docetaxel treatment (75mg/m^2 every 21)
45456123|NCT04908215|Drug|INM-755 (cannabinol) cream|topical cream containing cannabinol for dermal application
45456124|NCT04908215|Drug|Vehicle Cream|topical cream base for dermal application containing no active agent
45671385|NCT04419350|Procedure|Microneedling|One session of microneedling will be performed by using dermaroller 1.5 mm. The microneedling done from the edge of the normal skin towards the center of the hypopigmented lesion in all the directions (horizontal, vertical. diagonal).
45671386|NCT04419038|Procedure|conjunctival autografting augmented with topical application of Mitomycin C|Group A included 32 eyes of 32 patients who underwent conjunctival autografting augmented with topical application of Mitomycin C (0.2 mg/mL).
45671387|NCT04419038|Procedure|conjunctival autografting augmented with Ologen implantation|Group B included 31 eyes of 31 who underwent conjunctival autografting augmented with Ologen implantation.
45671388|NCT04739852|Other|Fasting|Patients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al.
45976246|NCT00270075|Drug|epoetin alfa|
45671389|NCT04825730|Drug|JOINTSTEM|JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
45830817|NCT01455012|Drug|Rotigotine|Rotigotine 1 mg/24 h, 2 mg/24 h, and 3 mg/24 h. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
45830818|NCT01455012|Drug|Placebo|Matching Placebo. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
45976247|NCT01588756|Drug|AcSDKP-NH2 inuline|Once intravenous administration of 100 µg or less
45671390|NCT04824638|Biological|3 doses of BNT162b2 vaccine|Administration of BNT162 b2 vaccine (30µg in 0.3mL) at D1 D29 and M8, intramuscularly (participants without antecedent of SARS-CoV-2 infection)
45671391|NCT04824638|Biological|2 dose of BNT162b2 vaccine|Administration of BNT162 b2 vaccine (30µg in 0.3mL) at D1 and M8, intramuscularly (participants with antecedent of SARS-CoV-2 infection)
45671392|NCT04219670|Diagnostic Test|Wearable sensors|Utilizing wireless wearable sensors, to capture quantitative biometric and movement-based data.
45976248|NCT01588756|Drug|AcSDKP-NH2 Cr-EDTA|Once intravenous administration of 100 µg or less
46082310|NCT02732964|Other|Pandora Music|Patients enrolled will be exposed to Pandora music for 30 minutes prior to their spinal anesthesia and cesarean delivery, and throughout their surgery.
45671393|NCT05306834|Procedure|Retinal Imaging|Auto-Refractometry / Adaptative Optics (OA) / Swept Source Optical Coherence Tomography (SS-OCT-A) / Globe Axial length measurements / Color Retinophotography of the retina.
45671394|NCT05306834|Genetic|Blood sample|Analyses of molecular biomarkers including
45671395|NCT05306834|Procedure|Evaluation of cardiovascular risks|Measurement of blood pressure and arterial stiffness
45456125|NCT04904861|Behavioral|Videoconference intervention group|A short face-to-face dyadic group workshop focused on increasing maternal sensitivity was adapted to be carried out virtually by videoconference. The intervention considers 4 sessions, with a weekly frequency, with a minimum of 3 and a maximum of 6 dyads per group led by a monitor (psychologist). The activities are protocolized in a manual and are designed to be carried out by the mother with the baby under one year of age. .
45671396|NCT05306834|Procedure|Brain imaging (MRI)|3DT1 / 3DFLAIR / T2GRE / DTI 15 directions (and B0MAP)
45830819|NCT04408716|Procedure|Ablation Index Guided High-Power Short-Duration Strategy|Point-by-point circumferential pulmonary vein ablation will be performed using the advanced STSF catheter under ablation index guided high power short duration strategy (Radiofrequency energy is set up at a power of 50 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 20 mL/min; Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
45830820|NCT04408716|Procedure|Standard Radiofrequency Ablation Technique|Point-by-point circumferential pulmonary vein ablation will be performed using the ST catheter under standard radiofrequency ablation settings (Radiofrequency energy is set up at a power of 30 to 35 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 17 to 30 mL/min. Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
45976249|NCT04719104|Device|Transcutaneous Bilirubin Meter - 'Bilimeter'|Taking a transcutaneous (TcB) measurement will involve using a 'biliflash'. This is a non-invasive measurement that involves flashing a light against the helix of the infant's ear and can be done at the cotside. This process takes approximately 1-2 minutes and does not cause the baby discomfort. The meter gives an immediate bilirubin level.
45671397|NCT05306834|Other|Cognitive Tests|Mini Mental State Examination (MMSE) / Montreal Cognitive Assessment (MoCA) / 16 items Free and Cued Recall (RL/RI 16 items) / Trail Making Test A et B (TMT A et B) / Frontal Assessment Battery (FAB) / Phonemic (letter P) and semantic (animals) verbal fluency tests / Digit Symbol Substitution Test (DSST)
45671398|NCT05306834|Other|Geriatric Depression Scale (GDS)|15 items
45671399|NCT05306834|Other|Instrumental Activities of Daily Living (IADL)|Instrumental Activities of Daily Living (IADL)
45671400|NCT05306834|Diagnostic Test|Unipodal standing test|Unipodal standing test
45976250|NCT01588795|Procedure|Percutaneous renal denervation and TMNS|Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications
45671401|NCT05306834|Other|Walking speed measurement|over 5 meters
45671402|NCT02217475|Drug|Cenicriviroc|CVC 150 mg, administered orally once daily and taken every morning with food.
45671403|NCT02217475|Drug|Placebo|Placebo administered orally once daily and taken every morning with food.
45671404|NCT04213820|Device|Transcranial magnetic stimulation|TMS (theta burst) will be administered consisting of bursts containing 3 pulses at 50 Hz and an intensity of 80% motor threshold repeated at 200 ms intervals (i.e., at 5 Hz) and a 10 s between burst triplet interval for a total for 190 s (600 pulses). The intervention will be given daily 5 times/week during 4 weeks.
45976251|NCT01588795|Drug|Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin|Patients are maintained on Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the eGFR), 25OH vitamin D3 and a statin (atorvastatin 20mg)
45976252|NCT01588834|Procedure|breast biopsy|ultrasound-guided core needle biopsy of healthy, mammographically dense breast tissue
46082311|NCT02732964|Other|Mozart Music|Patients enrolled will be exposed to Mozart music for 30 minutes prior to their spinal anesthesia and cesarean delivery, and throughout their surgery.
46082312|NCT02726568|Drug|Icotinib|375 mg Tid (1125 mg per day) until intracranial PD.
46082313|NCT02726568|Radiation|SRS|If intracranial PD, then the subjects get stereotatic radiosurgery （30Gy/3f) combined with Icotinib 375mg Tid.
45830821|NCT01454778|Drug|Paclitaxel|"Paclitaxel in addition to angioplasty, stenting or atherectomy Dosing will be based on the lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm^3~Paclitaxel Dosage:~Superficial Femoral/Common Femoral: 2.4 mg/inflation of balloon* Popliteal: 1.8 mg/inflation of balloon* Tibial: 1.4 mg/inflation of balloon*~not to exceed 10mg total dose"
45830822|NCT04408404|Procedure|Acute aortic dissection|Acute aortic dissection treatment include Bentall procedure, Tyrone David procedure, Yacoub procedure or ascendant aortic replacement with or without aortic valve replacement, ascendant aortic root remodelling (all are standard of care procedures)
45830823|NCT01454076|Drug|Ixazomib 2.5 mg|Ixazomib 2.5 mg Capsule B (Cycle 1 only)
45830824|NCT01454076|Drug|Ixazomib 4 mg Capsule A|Ixazomib 4 mg Capsule A (Cycle 1 only)
46082314|NCT05078021|Diagnostic Test|Bronchoscopy|Bronchoscopy will be performed in all groups with endobronchial biopsies, brushings and bronchial washing performed.
45671405|NCT04213820|Behavioral|Body Image Intervention|Body image interventions delivered directly after TMS will include body exercises that target disturbed body image and psychoeducation about the body. Together with a therapist the participants with anorexia nervosa will explore and estimate their body size through feedback.
45671406|NCT04213820|Behavioral|Treatment as usual|Treatment as usual at the eating disorder unit, Child and adolescent psychiatric clinic and Psychiatric clinic is delivered during 4 weeks
45671407|NCT05296148|Device|Transcatheter Tricuspid Valve Implantation|Implantation of a tricuspid coaptation valve through a transcatheter approach.
45830825|NCT01454076|Drug|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 2 and beyond )
46082315|NCT02726490|Drug|Glyburide|glyburide 2.5milligrams (mg) at bedtime (qhs) increased as needed to a maximum of 20mg/day usually taken twice a day (BID)
46082316|NCT02726490|Drug|Glucovance|glucovance (2.5/500) 1 taken orally (PO) at bed time (QHS) increased as needed to a maximum dose of (20/2000)/day usually taken twice a day (BID)
45671408|NCT02191267|Radiation|[F18]-T807|[F18]-T807 PET Scan to measure tau deposition in the brain.
45671409|NCT02191267|Radiation|[F18]-Florbetapir|[F18]-Florbetapir PET scan to measure Beta-amyloid deposition in the brain.
45671410|NCT02191267|Device|MRI/MRS|Two scans (structural, diffusion tensor imaging, and susceptibility weighted imaging scanned as part of one MR protocol, and a one-dimensional and two-dimensional spectroscopy examination as part of the other MR protocol.
45671411|NCT02191267|Genetic|Genetic Analysis for Genetic Risk Score for Tau.|DNA will be extracted from previously acquired and de-identified frozen blood specimens using a standard protocol (Gentra Puregene Kit, Qiagen 158422). Genotyping will be performed using the iPLEX Sequenom MassARRAY platform and samples will be genotyped for single nucleotide polymorphisms (SNPs) associated with the deposition of neurofibrillary tangles.
45671412|NCT05293886|Other|Classical Pelvic Floor Muscle Training|In the first 2 weeks of classical pelvic floor muscle training, individuals will perform 3 sets of 10 maximal voluntary pelvic floor muscle contraction exercises and 20 submaximal voluntary pelvic floor muscle contraction exercises per day. In every 2-week control, the number of sets will be increased by one set.
45830826|NCT01454076|Drug|Ketoconazole|Ketoconazole 400 mg tablets (Cycle 1 only)
45830827|NCT01454076|Drug|Rifampin|Rifampin 600 mg capsule (Cycle 1 only)
45830828|NCT01454076|Drug|Clarithromycin|Clarithromycin 500 mg tablets (Cycle 1 only)
46082317|NCT02716350|Dietary Supplement|B-GOS|comparison versus placebo
46082318|NCT02716350|Dietary Supplement|Maltodextrin|placebo
45456126|NCT04904861|Other|Control group|Psycho-educational intervention : They will receive brochures with information on parenting (once a week for 4 weeks) in addition to the usual care in their primary care center
45830829|NCT01454076|Drug|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 1 and beyond)
45830830|NCT01453998|Biological|Infanrix hexa|Single dose, licensed formulation, intramuscular into right thigh
45830831|NCT01453998|Biological|Prevenar 13|Single co-administered dose, intramuscular into left thigh
45830832|NCT01453998|Biological|GSK217744|Single dose, investigational formulation A or B, intramuscular into right thigh
45830833|NCT01453374|Drug|VIVITROL 380mg|380 mg IM injection given once monthly
45830834|NCT01453296|Drug|GW642444|GW642444 25 μg; Novel dry powder inhaler
45671413|NCT05293886|Other|Functional Pelvic Floor Muscle Training|Functional pelvic floor muscle training will be started with 3 exercises (toe tap, bridge and clamshall exercises), each exercise will be performed with 1 set and 30 repetitions. In every 2-week control, the number of exercises will be increased by one. Cat-cow exercise will be added at 3-4th weeks, squats will be added at 5-6th weeks, and lunges will be added at 7-8th weeks.
45456127|NCT04896281|Dietary Supplement|Phenylalanine-free milk|Intervention protocol Phenylalanine-free milk will be fed for 3 days after enrollment. The milk is purchased from ABBOTT company. The content of the whole nutrition for a daily need is also personalized based on the calculation by our dieticians. After the completion of the study, diet will be back to normal diet for all patients.
45456128|NCT04894864|Drug|Opioid-Based Anesthesia-Analgesia Strategy|A perioperative Opioid-Based multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Based arm of the study.
45456129|NCT04894864|Drug|Opioid-free Anesthesia-Analgesia Strategy|A perioperative Opioid-Free multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Free arm of the study.
45671414|NCT04418245|Diagnostic Test|Imaging by thoracic scanner|Low-dose computed tomography
45456130|NCT04894435|Biological|mRNA-1273 SARS-CoV-2 vaccine|Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.
45456131|NCT04894435|Biological|BNT162b2|A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.
45671415|NCT04818944|Drug|Tirofiban Hydrochloride|Tirofiban Hydrochloride will be dosed for 24 hours post MT via continuous IV
45456132|NCT04894435|Biological|ChAdOx1-S [recombinant]|A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).
45671416|NCT04818944|Drug|Placebo|Saline will be dosed for 24 hours post MT via continuous IV
45671417|NCT04818866|Diagnostic Test|SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase|Biomarkers of inflammation
45456133|NCT04894435|Other|0, 28 day schedule|Second injection administered 28 days post first injection
45671418|NCT02189941|Drug|Deferiprone sustained-release|Deferiprone sustained-release tablets
45671419|NCT02189941|Drug|Deferiprone immediate-release|Deferiprone immediate-release tablets
45671420|NCT04194476|Diagnostic Test|StatStrip blood glucose meter and strips|We'll use a drop of heel-stick blood to test blood glucose on the glucose meter. About 200-300 ul of blood from the same stick site will be collected, centrifuged to get plasma for testing of glucose level in a laboratory biochemistry analyzer.
45830835|NCT01453296|Drug|Placebo|Matching placebo; Novel dry powder inhaler
45671421|NCT02216773|Procedure|Radiofrequency assisted liver partition with portal vein ligation (RALPP)|
45671422|NCT02216773|Procedure|Portal vein embolization (PVE)|
45671423|NCT01601132|Drug|theophylline|300mg (80mg/15ml elixir)
45671424|NCT01601132|Drug|colchicine|colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
45671425|NCT04818398|Drug|DS-6016a|DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
45671426|NCT04818398|Drug|Placebo|Placebo will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
45456134|NCT04894435|Other|0, 112 day schedule|Second injection administered 112 days post first injection
45671427|NCT04824482|Other|Robot-assisted treadmill gait training (RTGT)|Locomotor training guided by the robotic device (Lokomat Hocoma) according to a pre-programmed gait pattern with the help of robot-driven exoskeleton orthoses. The process of gait training is automated and controlled by a computer under supervision of a physiotherapist.
45830836|NCT01453140|Drug|Cyclophosphamide and Sirolimus|"On the first day of treatment, cyclophosphamide will be administered at a dose of 4g/m2 IV x 1 dose. Patients who are >40% above ideal weight will be dosed based on adjusted weight and adjusted BSA.~One day after the administration of cyclophosphamide, patients will receive sirolimus 6 mg PO x 1 and on the following day will start sirolimus at a dose of 2 mg PO daily."
45671428|NCT04824482|Other|Therapist-assisted treadmill gait training (TTGT)|Locomotor training via a repetitive execution of walking movements manually guided by a physiotherapist during treadmill gait training.
45671429|NCT04836962|Drug|normal saline|2cc of normal saline is administered to patient instead of dexamethasone.
45671430|NCT04836962|Drug|dexamethasone|dexamethasone is administered 0.5mg/kg (up to 10mg) which is diluted with normal saline to make a total of 2cc.
45671431|NCT04199702|Other|Same day discharge|Patients will be discharged the same day they undergo catheter ablation of atrial fibrillation.
45671432|NCT05289440|Drug|Low-dose esketamine infusion|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 2 µg/kg/min until before suture the skin.
45671433|NCT05289440|Drug|High-dose esketamine infusion|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 4 µg/kg/min until before suture the skin.
45671434|NCT05289440|Drug|Saline infusion|Patients received a bolus infusion of the same volume saline before cutting the skin, and then the same volume saline was infused until before suture the skin.
45671435|NCT04718870|Drug|Dupilumab SAR231893|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
45830837|NCT01453140|Drug|Low dose IL-2 with Cytoxan + Sirolimus|"Patients in treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus.~IL-2 will be administered at a dose of 0.5E6 IU/m2 SQ daily x 8 weeks followed by 4 weeks off, starting 14 days after the cyclophosphamide."
45830838|NCT01453140|Drug|Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus|"Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza). The Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.~The dose administered will be 10 mg SQ daily for 5 days followed by 3 weeks off."
45671436|NCT04709900|Diagnostic Test|CT angiography, FFR-CT and stress CT myocardial perfusion|The study intervention team consists of a specialist in Cardiac CT imaging, an invasive cardiologist, a thoracic surgeon and a cardiology nurse specialist. Treatment strategy defined by the study team based on CT findings involve referral for percutaneous coronary intervention, Coronary Artery Bypass surgery and/or initiation of optimal medical therapy, in addition to potential supplementary diagnostic procedures.
45671437|NCT04016168|Biological|Blood sample collection|Three additional blood tubes (3 x 8mL) will be collected for this study. They will be added to the traditional diagnostic assessment carried out for their IPF, during their consultation at the competence centre for rare lung diseases. These samples will be taken by a registered nurse in the presence and under the responsibility of the investigator.
45830839|NCT01453140|Drug|Cyclophosphamide and Sirolimus|Day 1: Cyclophosphamide Day 2: Sirolimus
45830840|NCT01453140|Drug|Low dose IL-2 with Cytoxan + Sirolimus|treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus
45830841|NCT01453140|Drug|Low dose IL-2, Vidaza, Cytoxan & Sirolimus|Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.
45671438|NCT04016090|Dietary Supplement|Folic Acid|Folic acid (5 mg)
45830842|NCT01499940|Drug|Vitamin D3|Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.
45671439|NCT04016090|Other|Placebo|Placebo capsule
45830843|NCT01499160|Drug|letrozole|Drug is are to be taken orally. 2.5 mg once daily
45830844|NCT01499160|Drug|lapatinib|Drug is to be taken orally. 1,500 mg once daily in the first part of the study and then 1,250 mg once daily in the second part of the study (after initial progression)
45830845|NCT01499160|Drug|everolimus|Drug is to be taken orally. 5 mg once daily.
45830846|NCT01498692|Device|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating)
45830847|NCT01498068|Drug|Telaprevir|Telaprevir Type = exact number, unit = mg, number = 750, form = tablet, route = oral. Telaprevir 750 mg (2 oral tablets) is taken every 8 hours for 12 weeks
45671440|NCT04809974|Drug|Niagen|The intervention consists of taking Niagen and completing all tasks divided into 6 visits.
45671441|NCT05226884|Diagnostic Test|Visual Acuity|Measurement of distance and intermediate visual acuity at variety targeted correction.
45456135|NCT04894435|Biological|Covifenz|COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration
45456136|NCT04880395|Drug|Intervention Arm: dolutegravir/lamivudine|1 pill QD
45671442|NCT05226884|Diagnostic Test|Defocus Curve|Measurement of a defocus curve
45671443|NCT03329612|Procedure|Remote Ischemic Preconditioning|Serial inflations and deflations as detailed in the arm/group descriptions.
45830848|NCT01498068|Drug|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a type = exact number, unit = microgram, number = 180, form = injection, route = subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks
45830849|NCT01498068|Drug|Ribavirin|Ribavirin Type = exact, number = 1000 or 1200, unit = mg, form = tablet, route = oral. 1000mg (if participant's weight is < 75kg) or 1200mg (if participant's weight is >= 75kg) per day for 24 or 48 weeks.
46082319|NCT02726802|Other|physical therapy vs. primary care interventions|Subjects with acute (< 3 months onset) will be randomized to see either a physical therapist or a primary care provider as their initial entry into the healthcare system
45456137|NCT04880395|Drug|Comparator ARM: TDF/XTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine)|1 pill of each QD
45456138|NCT04870593|Behavioral|Information|Elder informed about vaccination.
45456139|NCT04870593|Behavioral|Buddy|"Elder encouraged to get vaccinated using buddy system, whereby he/she is accompanied to the vaccination site by another adult who could also get the vaccine. A potential buddy also given vaccination information and encouraged to help the elder get to the vaccination site so they could both be vaccinated."
45830850|NCT01497366|Drug|Sofosbuvir|Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
45830851|NCT01497366|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
45671444|NCT03317990|Procedure|NeuroSAFE procedure|When the prostate is removed from within the patient as it is disconnected from its attachments. The specimen will then be painted (right=blue, left =black) by the operating surgeon and delivered expediently to the pathologist who will perform frozen section analysis of the painted areas. The pathologist will remove the pre-painted surface of the gland (which had been in contact with the neurovascular bundles) using a sharp blade. The tissue sample will be snap frozen and embedded in OCT. If a positive margin is reported by the pathologist, the entire neurovascular bundle on the affected side will be removed and sent for formal pathological examination.
45671445|NCT03317990|Procedure|Standard RARP|Patients will undergo the standard intervention - RARP without NeuroSAFE Frozen section analysis
45671446|NCT04691960|Other|Ketogenic Diet|Ketogenic diet is high-fat, low carbohydrate diet. Ketogenic diet will be maintained on a continuous basis. The diet will begin at an approximately 3:1 fat to carbohydrate + protein ratio for 5 days. If the patient does not show urine ketosis (1.5 mmol/L or 27.0 mg/dL), the ketosis diet will be advanced to approximately 4:1 ratio for 5 days. If the patient still does not attain ketosis a 24 hour fast will be done to promote ketosis. The diet will encourage at least 30 ml per day of Medium Chain Triglycerides (MCT) oil to enhance ketosis.
45456140|NCT04870593|Behavioral|Gossip intervention|"Members of elder's community asked who in the community is good at spreading information. These gossips then asked to spread information about vaccination of elders. If buddy intervention assigned in community, gossips also asked to encourage their communities to use the buddy system to get elders vaccinated."
45671447|NCT04691960|Drug|Metformin|Metformin will be administered as a single 850 mg dose P.O. at Week 8, then titrated up to 850 mg P.O. BID at Week 10, and then 850 mg T.I.D. at Week 12, as tolerated.
45671448|NCT04796792|Device|Break Wave Lithotripsy and Ultrasonic Propulsion|Novel ultrasound technologies to facilitate passage of stones.This includes Burst Wave Lithotripsy (BWL), a technology to noninvasively fragment urinary calculi within the kidney and ureter, and ultrasonic propulsion, a technology to non-invasively reposition stones within the kidney and ureter. BWL uses short multi-cycle bursts of low amplitude ultrasound to induce stone fracture. This is in contrast to traditional extracorporeal shock wave lithotripsy (SWL), which employs a brief single compression/tensile cycle of high amplitude (shock) waves to achieve stone fracture. Ultrasonic propulsion uses long multi-cycle bursts of low amplitude ultrasound to move stones within the collecting system.
45830852|NCT01497366|Drug|RBV|"Ribavirin (RBV) administered as 200 mg tablets up to 1200 mg in a divided daily dose~Dose of sofosbuvir+RBV group based on baseline weight: < 75kg = 1000 mg and ≥ 75 kg = 1200 mg~Dose of PEG+RBV group: 800 mg"
45830853|NCT01496976|Drug|High Dose Methylprednisolone (HDMP)|HDMP will be administered at 1 gm/m^2 IV over 90 minutes daily with ofatumumab infusions 1-8.
45830854|NCT01496976|Drug|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP.
45456141|NCT04870593|Behavioral|Information assigned in community|Information intervention assigned for other elders in community.
45456142|NCT04870593|Behavioral|Buddy assigned in community|Buddy intervention assigned for other elders in community.
45830855|NCT01496976|Drug|Lenalidomide|The Lenalidomide Starting Dose (Cycle 4) Based on Renal Function Prior to Cycle 4 of Treatment.
45456143|NCT04857281|Device|nVNS (gammaCore)|The treatment will be self-administered using nVNS and will be applied for 4 weeks; a member of the study will provide the proper training on the correct use of nVNS. The patient will be instructed to use the nVNS in place of the rescue medications. When the nauseas gets bad enough that they feel to use a rescue medication they will first use the device on one side of the neck for two 2-minute stimulations and wait fifteen minutes to check if the stimulation works. If this does not help either, they will stimulate with an additional 2 stimulations and wait for another fifteen minutes. If there is no improvement rescue medication will be used. nVNS can be used up to, but no more than, 8 times a day.
45456144|NCT04852016|Behavioral|Consent process with the addition of Digital educational platform (DEP)|In-patients being consented for laparoscopic cholecystectomy will be provided with a Digital Educational Platform (DEP), in the form of modules on an iPad. These participants will still undergo the usual standard verbal consent (SVC). Multiple choice questionnaires will be given pre and post consent to determine acquisition and retention of the information provided using DEP.
45671449|NCT05225012|Other|Acceptance and Commitment Therapy|Participants will then commence the intervention for the next 4 weeks. They will be sent the workbook via post. This will not be a standalone self-help intervention; participants will progress through the workbook alongside weekly emotional support sessions. These will either be over the phone or using an online video-call software, depending on participants preference. The first session will be an hour long to set-up the workbook, answer questions and go through goal setting. The following three weekly sessions will be half an hour to revisit exercises in the workbook, answer questions and review how the workbook progress is going. All sessions will be delivered by a trainee clinical psychologist who will receive standardised training and ongoing supervision from an experienced clinical psychologist.
45830856|NCT01475838|Drug|PI|PI administered according to prescribing information; allowed PIs include atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)
45830857|NCT01475838|Drug|RTV|RTV administered according to prescribing information FTC/TDF administered according to prescribing information
45830858|NCT01475838|Drug|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
45830859|NCT01475838|Drug|Stribild|Stribild (E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
45456145|NCT04852016|Behavioral|Consent process using the standard verbal consent (SVC)|In-patients being consented for laparoscopic cholecystectomy will go through the SVC. Multiple choice questionnaires will be given pre and post consent to determine acquisition and retention of the information provided using SVC.
45830860|NCT01451814|Behavioral|Positive Psychotherapy for smoking cessation|6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
45830861|NCT01451814|Drug|Nicotine polacrilex|8 weeks of nicotine patch
45830862|NCT01451814|Behavioral|Relaxation training|Instructions in progressive muscle relaxation
45830863|NCT01451814|Behavioral|Behavioral smoking cessation treatment|Counseling on techniques to manage triggers and avoid smoking
45830864|NCT01475370|Drug|OCV-501|"Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001.~After the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the recommended dose."
45830865|NCT04091646|Drug|ARQ-154 foam 0.3%|experimental
45830866|NCT04091646|Drug|ARQ-154 vehicle foam|experimental
45830867|NCT01496430|Drug|Placebo|
45830868|NCT01496430|Drug|Azilsartan medoxomil|
45830869|NCT01496430|Drug|Azilsartan medoxomil|
45976253|NCT00107614|Drug|DT PACE + Rituxan|INDUCTION PHASE DT PACE + Rituxan DT PACE + Rituxan + PBSC Collection Response Assessment TRANSPLANT PHASE Transplant 1 (MEL 200 (patients with < 50% response to induction) OR MEL-DT PACE (Patients with > 50% response to Induction) Transplant 2 (identical to the first, except patients with progressive or proliferative disease, will receive BEAM) MAINTENANCE PHASE Rituxan every 3 months x 1 year
45456146|NCT04849013|Drug|Placebo|Drug: Placebo Capsules containing mannitol looking identical to the other drugs Other: Placebo Capsules containing mannitol looking identical to the other drugs
45456147|NCT04849013|Drug|Mescaline 100mg|"Drug: 100mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
45976254|NCT00255242|Drug|Simvastatin treatment for 28 days|40 mg / day
45976255|NCT00270114|Drug|epoetin alfa|
45456148|NCT04849013|Drug|Mescaline 200mg|"Drug: 200mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
45456149|NCT04849013|Drug|Mescaline 400mg|"Drug: 400mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
45456150|NCT04849013|Drug|Mescaline 800mg|"Drug: 800mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
45456151|NCT04849013|Drug|Mescaline 800mg + Ketanserin 40mg|"Drug: 800mg Mescaline per os, single dose~Other: 40mg Ketanserin per os, single dose"
45671450|NCT05279612|Radiation|Short-term neoadjuvant chemoradiotherapy|Short-term radiotherapy ( 25 Gy, 5f ) + XELOX regimen was performed before operation for two cycles. After the condition was evaluated by enhanced CT, whether the patients belonged to PD, SD, PR and CR was analyzed (reference RECIST 1.1). Surgery was performed four weeks after chemotherapy.
45671451|NCT03948854|Other|Registered dietitian|Education on low FODMAP diet is provided in person by a registered dietitian who is an expert on the low FODMAP diet
45671452|NCT03948854|Other|On-line video program|Education on low FODMAP diet is provided by an on-line program via a link sent through email
45671453|NCT03948854|Other|Printed handout|Education on low FODMAP diet is provided through printed handout material at the initial visit.
45671454|NCT03948854|Other|Dietitian-led group|Education on low FODMAP diet is provided in a dietitian-led group setting
45671455|NCT04816916|Drug|AXA1665|AXA1665 administered TID with food
45671456|NCT04816916|Drug|Placebo|Matching placebo administered TID with food
45976256|NCT00255281|Drug|AZD7009, no generic name available|
45976257|NCT00107380|Biological|rituximab|
45976258|NCT00107380|Drug|cyclophosphamide|
45976259|NCT00107380|Drug|doxorubicin hydrochloride|
45976260|NCT00107380|Drug|prednisone|
45976261|NCT00107380|Drug|vincristine sulfate|
45976262|NCT00107380|Radiation|tositumomab and iodine I 131 tositumomab|
45976263|NCT00270153|Drug|enalapril|5mg enalapril daily for 6 months
45976264|NCT00270153|Drug|Placebo|5mg enalapril-matching placebo daily for 6 months
45976265|NCT00255320|Drug|VIP|
45671457|NCT04809038|Other|dry needling|Patient will be placed in a comfortable prone position and encouraged to maintain complete relaxation. The selected active MTrPs was prepared by wiping the area with alcohol pad, and a gauge needle with its plastic guide tube in place will be palced over the active MTrPs .a tapping motion will be used to advance the needle to a depth of 5 to 10 mm for 30 seconds
45830870|NCT04408326|Drug|Angiotensin II|Exogenous angiotensin II acts on angiotensin II type 1 receptor and raise blood pressure by vasoconstriction, salt and water retention, and stimulation of aldosterone hormone
45830871|NCT04408326|Drug|Interleukin-1 receptor antagonist|Interleukin-1 receptor antagonist is an immunomodulating drug aiming to mitigate cytokine storm in COVID-19 patients
45830872|NCT01451424|Drug|Proellex|vaginal suppository, daily, for 12 weeks
45830873|NCT01475214|Dietary Supplement|potassium bicarbonate|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
45830874|NCT01475214|Dietary Supplement|potassium bicarbonate|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
45830875|NCT01475214|Other|Inactive placebo capsule|microcrystalline cellulose
45830876|NCT01496274|Biological|rIX-FP|Recombinant IX-FP (rIX-FP) is a fusion protein linking coagulation factor IX with albumin, and will be administered by intravenous administration
45830877|NCT01475136|Drug|LY2140023|
45830878|NCT01474746|Drug|Sertraline|Liquid sertraline (20 mg/mL) will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid sertraline once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid sertraline once per day for a period of six months.
45830879|NCT01474746|Drug|Placebo|The placebo will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid placebo once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid placebo once per day for a period of six months.
45830880|NCT01450800|Drug|Nitrofurantoin|Nitrofurantoin 100mg po daily to be taken every day the patient uses a catheter for up to one week post-operatively
45830881|NCT01450800|Drug|Placebo|Participants randomized to placebo will be instructed to take placebo one tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
45830882|NCT03026634|Behavioral|Sleep-disordered breathing|Prevalence and dynamic of sleep-disordered breathing after heart transplantation
45830883|NCT01474512|Drug|80 mg Ixekizumab Dosing Regimens 1, 2, and 3|Administered SC
45830884|NCT01474512|Drug|Placebo|Administered SC
45830885|NCT01474434|Drug|pradigastat (LCQ908)|pradigastat tablets were supplied to the investigators at dose strengths of 10 mg and 20 mg as individual patient packs.
45830886|NCT01474434|Drug|Placebo|matching placebo tablets
45830887|NCT04074798|Behavioral|assessment of hyperventilation, postural control and psychological behavior|assessment of hyperventilation, postural control and psychological behavior
46082320|NCT02726646|Drug|Doxycycline|Application of 1 mg of doxyxycline microspheres at 4 sites (two means and two deep periodontal pockets) after mechanical debridement.
46082321|NCT02726646|Procedure|Mechanical debridement|Mechanical debridement (full mouth) of 45 minutes associated with the application of 1 mg of microspheres placebo in selected periodontal pockets.
46082322|NCT02726646|Drug|Placebo|The application of 1 mg of microspheres placebo
46082323|NCT02811458|Behavioral|Transdiagnostic Cognitive-Behavioral Therapy|Treatment in the Transdiagnostic CBT condition will consist of 12 weekly 2-hour sessions following the manualized treatment protocol including psychoeducation, cognitive restructuring, exposure and relapse prevention.
46082324|NCT02726412|Procedure|Acute vs elective|non-intverention study
46082325|NCT03913208|Procedure|Priority to freeze|Priority for cryopreservation and later on embryo transfer in artificial cycle with endometrium preparation by the exogenous administration of estrogen-progesterone.
46082326|NCT03913208|Procedure|Fresh embryo transfer|usual strategy of giving the priority for fresh embryo transfer
46082327|NCT02803892|Drug|rapamycin|Rapamycin will be administered at an initial dose 0.2 mg/kg on day 0, followed by 0.1 mg/kg/die. The daily dose will be adjusted to the whole blood 24-hr trough to target, as tolerated, 8-10 ng/mL
46082328|NCT02803892|Drug|Vildagliptin|Vildagliptin will be administered at a dose of 50 mg x2/die starting from day 0.
45830888|NCT02985606|Other|Caffeine powder -60|
45830889|NCT02985606|Other|Caffeine powder -30|
45830890|NCT02985606|Other|Caffeine powder 0|
45830891|NCT02985606|Other|Placebo powder -60|
46082329|NCT02803892|Drug|Placebo 1|Placebo 1 will be titrated according to a random schedule alternating plausible doses of placebo. After 4 weeks of treatment patients will discontinue placebo 1
45671458|NCT04809038|Other|magnesium sulphate iontophoresis|The subjects in the iontophoresis group received MgSO4 iontophoresis using an iontophoretic drug delivery system (Phoresor_IIAuto,ModelPM850,IOMED. MTrPs were examined using pincer palpation and marked by pin. MgSO4 was applied to the active positive electrode using a syringe with a concentration of 100 mg/cm2. The active electrode was placed directly over the marked area where the sensitive MTrPs were located. The dispersive electrode was applied to the skin 6 inches distal from the active electrode.
45671459|NCT04809038|Other|stretching exercise|The patient will be placed in a comfortable and relaxed sitting position with his back supported ; one hand was placed on the side of the head applying the stretching force, while the other hand was placed on the patients shoulder applying shoulder stablization . The direction of stretched force was in flexion , side bending to the opposite side and rotation to the same side . The stretched position will be sustained for 30 seconds , then a relaxation period of 30 seconds . This procedure was repeated 3 times .
45671460|NCT05652998|Biological|C. albicans antigen|a test dose (0.1 ml) of the C. albicans antigen will be injected intradermally into the skin of the forearm. A reaction will be considered positive in presence of ≥5 mm erythema and induration after 48-72 hr. Only reactors will be included. patients will receive intralesional injection of candida antigen at a dose 0.1 ml of 1/1000 solution into the largest wart at 3 weekly intervals for a total of 3 doses.
45671461|NCT05652998|Other|autologous PRP|patients will receive intralesional autologous PRP injection every month until a complete clearance or for a maximum of 2 sessions. 20 cc blood will be collected under a complete aseptic condition in citrate tubes . The lower 2-4 cc of the plasma will be provided as PRP concentrate after centrifugation. 0.1 ml of PRP will be injected intralesional with an insulin syringe.
45830892|NCT02985606|Other|Placebo powder -30|
45830893|NCT02985606|Other|Placebo powder 0|
45830894|NCT01473732|Drug|Everolimus|Starting dose 1.5 mg bid, target trough level 6-10 ng/ml.
45830895|NCT01473732|Drug|Tacrolimus|Target trough level of Tacrolimus 3-5 ng/ml.
45976266|NCT04050085|Biological|Nivolumab|Given IV
45830896|NCT01473732|Drug|Mycophenolic acid|Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Used in both arms. Used for one year.
45830897|NCT01450098|Drug|LY2484595 Reference Formulation (RF)|Administered orally
45830898|NCT01450098|Drug|LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)|Administered orally
45830899|NCT01449708|Drug|TIVA NoNarc|"patients in both groups receive antiemetic prophylaxis~patients in the TIVA NoNarc group will receive propofol, dexmedetomidine, ketamine, ketorolac and acetaminophen intraoperatively~postop management in both groups is similar in both groups"
45830900|NCT01449630|Drug|LY3031207|Administered orally
45830901|NCT01449630|Drug|Placebo|Administered orally
45830902|NCT01449630|Drug|Celecoxib|Administered orally
45830903|NCT01493778|Drug|turoctocog alfa|Patients will be scheduled to receive treatment with turoctocog alfa for at least 100 exposure days. In most cases, treatment will be given at home with intravenous (i.v., into the vein) self-injection by the parent/caregiver/support person.
45830904|NCT01473420|Biological|Epoetin Hospira|Variable dose
45830905|NCT01473420|Biological|Epogen Amgen|Variable dose
45830906|NCT04674774|Drug|Tegoprazan|oral administration of tegoprazan-based bismuth quadruple therapy(tegoprazan 50 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 days
45976267|NCT04050085|Radiation|Radiation Therapy|Undergo radiation therapy
45976268|NCT04050085|Drug|TLR9 Agonist SD-101|Given intratumorally
45976269|NCT00289224|Biological|bivalent killed whole cell oral cholera vaccine|"Given as 1.5 mL dose, given orally in 2 doses 14 days apart, each dose contains:~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
45976270|NCT00289224|Biological|Placebo|Heat Killed E. coli K12 in an optical turbidity identical to killed oral cholera vaccine, in 1.5 mL oral dose given twice, at least 14 days apart.
45976271|NCT00255359|Drug|XTL-2125|
45976272|NCT04054843|Diagnostic Test|Afamin|Plasma maternal afamin levels
45671462|NCT05652998|Other|saline|patients will receive intralesional saline at a dose of 0.3ml into the largest wart at 2-week intervals until complete clearance is achieved or for a maximum of five treatment
45830907|NCT04674774|Drug|Lansoprazole|oral administration of PPI-based bismuth quadruple therapy(lansoprazole 30 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 day
45830908|NCT01492686|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
45456152|NCT04837846|Other|Differing Tube Voltage Administration|Subjects will undergo CCTA utilizing a scan and contrast media injection protocol that will be tailored to individual body habitus.
45456153|NCT04836416|Other|Observational|Observational
45976273|NCT04055038|Drug|Platinum-Based Drug|Reintroduction of platinum-based chemotherapy
45976274|NCT04055038|Drug|Conventional chemotherapy|Conventional chemotherapy
45976275|NCT00270192|Behavioral|individual lactation counseling and educational material|
45830909|NCT01492686|Drug|Placebo|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
45830910|NCT01492686|Drug|MCI-186 in open label phase|All patients after the double blind phase may receive MCI-186 in 7th until 12th treatment - observation cycles at the patients' will.
45830911|NCT04409496|Behavioral|Chat-based instant messaging support|"Subjects will receive personalised instant messaging support for 12 weeks after baseline, address the five problems that contributed to smoking relapse:~(1) lack of support for cessation, (2) negative mood or depression, (3) strong or prolonged withdrawal symptoms, (4) weight gain, and (5) smoking lapses. Updated information about the negative effect of smoking on risk of COVID-19 infection and prognosis will also be delivered."
45456154|NCT04834505|Other|Diagnostic imaging modalities for validation sample|Endoscopic ultrasound and other imaging modalities such as CT, MRI, or PET-CT are performed.
45671463|NCT05362136|Procedure|perforation of the sinus floor|perforation of the cortical layer of the sinus floor prior to inserting the augmentation material during sinus floor elevation
45671464|NCT05362136|Procedure|no perforation of the sinus floor|standard procedure for sinus floor elevation
45671465|NCT05221190|Procedure|Single buccal infiltration|injecting local anaesthetic solution into the soft tissues of the buccal sulcus adjacent to the target tooth.
45830912|NCT04409496|Behavioral|SMS message support|Subjects will receive regular SMS on generic smoking cessation for 3 months.
45830913|NCT04409496|Behavioral|Self-help booklet|Subjects will receive a standard self-help booklet on smoking relapse prevention.
45976276|NCT00270192|Behavioral|educational material alone|
45976277|NCT00270192|Behavioral|routine antenatal care without educational intervention|
45976278|NCT04054609|Diagnostic Test|FAZA PET/MRI scan|PET/MRI scan using radio tracer named 18F-Fluoroazomycin Arabinoside (FAZA) pre and post standard of care endovascular treatment for critical limb ischemia patients
45976279|NCT04054531|Biological|KN046|IV infusion
45976280|NCT04054531|Drug|Paclitaxel|IV infusion
45976281|NCT04054531|Drug|Pemetrexed|IV infusion
45976282|NCT04054531|Drug|Carboplatin|IV infusion
45976283|NCT00289263|Drug|Paclitaxel|
45976284|NCT04054336|Behavioral|Inhibit AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
46082330|NCT02803892|Drug|Placebo 2|Placebo 2 will be administered BID starting from day 0. After 8 weeks of treatment patients will discontinue placebo 2
45671466|NCT05221190|Procedure|Inferior alveolar nerve block|Injection of local anesthetic solution into the pterygomandibular space to access the inferior alveolar nerve before it enters the mandible.
46082331|NCT04236128|Other|Mobile App|"The app will be provided to patients in hospital on post-operative day 3. On the day of discharge, the patient will be emailed a Daily Health Check and receive subsequent Daily Health Check emails on Day 1-14, 21 and 30 days following discharge. The Daily Health Check is a tailored questionnaire to elicit their symptoms and status of post-operative recovery. After the patient has completed the Daily Health Check, a Daily Health Check Summary is emailed to the patient that summarizes their responses and provides appropriate action recommendations based on their responses ranging from: (i) suggestions for educational modules, (ii) expect a call from your health care team in the next 24 hours, (iii) call your surgeon's office today or (iv) go to the nearest emergency room. The patient's Daily Health Check responses are displayed in real time on a secure website that automatically red flags extreme responses to alert the health care team to contact the patient by telephone."
46082332|NCT02803502|Device|Chronometric method|Chronometric method of FVIII dosage on STA-R PLC automate (reactive Cephascreen STAGO, Unicalibrateur STAGO, plasma deficient Cryopep, Controls STAGO)
46082333|NCT02803502|Device|Chromogenic method|"Chromogenic FVIII assay method ( BIOPHEN FVIII: C and BIOPHEN Factor IX of the firm Hyphen BioMed)"
45456155|NCT04834505|Other|EUS for derivation sample|Endoscopic ultrasound was performed.
45456156|NCT04832282|Device|Napoleon|The Micro-Tech Endoscopic Measurement Device named Napoleon is a small catheter with a 30mm ruler calibrated at 1mm intervals with 5mm demarcations. It is classified as a Class 1, 510(k) exempt device by the FDA. The device was originally intended to measure polyps. However, it is used off-label in this study and is considered investigational.
45671467|NCT04816682|Drug|Silymarin|Silymarine tablets will be provided irrespective of meal by a registered nurse T.I.D
45671468|NCT02162719|Drug|Ipatasertib|Participants received ipatasertib orally 400 milligrams (mg) daily on Days 1-21 of each 28-day cycle.
45671469|NCT02162719|Drug|Paclitaxel|Participants received paclitaxel 80 milligrams per square meter (mg/m^2) intravenously (IV) on Days 1, 8, and 15 of each cycle.
45671470|NCT02162719|Drug|Placebo|Participants received oral placebo matched to ipatasertib, daily on Days 1-21 of each 28-day cycle.
45456157|NCT04832282|Other|Visual estimation|For each case, endoscopists will first visually estimate the diameter of the GJA by comparing its size to the upper endoscope.
45671471|NCT03939728|Radiation|Chest radiography and lung ultrasound|We'll include all patients which have, during their stay in pediatric intensive care unit, in order to have a pleural or pulmonary diagnosis, a chest radiography and then a lung ultrasound, at less than 2 hours interval.
45671472|NCT05652842|Behavioral|Work-type|Participants are categorized by the type of work hours they must maintain. For example, regular work hours, shift work, and rotational work.
45976285|NCT04054336|Behavioral|classical AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
45976286|NCT04054336|Behavioral|Control Group|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
46082334|NCT02803502|Device|Thrombin generation test (TGT)|"Briefly: the measurement of thrombin generation is performed by the technique of calibrated and automated Thrombinography (CAT) developed by Hemker HC. This technique allows the simultaneous analysis of multiple samples using a fluorometer (Fluoroscan Ascent, ThermoLabsystems OY, Helsinki, Finland) and a Thrombinoscope® software that converts the fluorescence intensity obtained by concentration of active thrombin. The reagent PPP-reagent Low respectively containing 1pm FT and 4μM phospholipid (PL) as a final concentration will be used."
46082335|NCT04189380|Other|HLQ (Health literacy questionnaire)|each patient complete survey and self-assessment questionnaire before or after his medical consultation
46082336|NCT04189380|Other|MoCA (Montreal Cognitive Assessment)|each patient complete survey and self-assessment questionnaire before or after his medical consultation
45671473|NCT03180086|Other|Breast cancer risk report|An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
45671474|NCT02161549|Device|Motus Gl CleanUp System|
45671475|NCT05652530|Drug|Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)|This product is allogeneic NK cells which are cryopreserved after in vitro CAR genetic modification and scale-up manufacturing. Subjects are enrolled and treated with lymphocyte clearance chemotherapy (including pre-clearance evaluation), pre-infusion evaluation and BCMA CAR-NK cells infusion.
46082337|NCT02800382|Other|Take samples|Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
45671476|NCT02189863|Device|Lotrafilcon B MF|Multifocal contact lenses worn in both eyes
45671477|NCT02189863|Device|Lotrafilcon B MV|Spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near
45830914|NCT01449006|Drug|Maraviroc|Maraviroc oral tablet. Dosage: 150 mg twice daily, 300 mg twice daily, or 600 mg twice daily. Dosing will be dependent on the participant's background HAART therapy, and will be in accordance with the product information sheet.
45671478|NCT02189863|Device|Lotrafilcon B SVD|Spherical contact lenses worn with both eyes corrected for distance
45671479|NCT02189863|Device|Comfilcon A MF|Multifocal contact lenses worn in both eyes
45671480|NCT02189863|Device|Habitual contact lenses|Contact lenses worn in both eyes per subject's habitual prescription
45671481|NCT05274776|Device|EOS calculator|For this study the EOS calculator was developed as a mobile application (by everywhereIM), including CE marking. It is concerned a medical device for health care professionals.
45830915|NCT01448850|Biological|MEDI8968 600 mg IV, 300 mg SC|MEDI8968 600 mg as IV infusion on Day 1 followed by 300 mg injection SC every 4 weeks up to Week 53.
45830916|NCT01448850|Other|Placebo|Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
45830917|NCT04748406|Device|Extracorporeal Shock Wave Therapy(ESWT)|Group 2 (n = 35) will be applied 1 session per week for 3 weeks, 3 sessions of ESWT (1.8 bar, 10.0 Hz, 2000 beats) + cold application + home exercise program will be applied.
45830918|NCT04748406|Other|Peloid therapy|Group 1 (n = 35) will be given 15 sessions of peloid therapy + cold application + home exercise program for 3 weeks, 5 days a week
45976287|NCT00289302|Device|Cardiac resynchronization therapy device|
45671482|NCT04808882|Drug|Tinzaparin, Low dose prophylactic anticoagulation|"Participants randomized to the LD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: LD-PA : 3500 IU/24h. Depending on the type of tinzaparin pre-filled syringe available in the participating center, the dose of 4000 IU/24h will be allowed in place of 3500 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: LD-PA: 4000 IU/24h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
45830919|NCT04748406|Other|Home Workout Program|Patients will be given a home exercise program consisting of eccentric strengthening exercises and stretching exercises, which are planned to increase resistance every week. The patients will be taught strengthening exercises for forearm pronation-supination with wrist extensors and a home exercise program will be started 3 sets of 10 repetitions per day.
45830920|NCT04748406|Other|Cold application|At the beginning of each treatment, gel ice packs are wrapped with a moist towel and placed around the elbow joint for 15 minutes. will be applied.
45830921|NCT04083534|Drug|REGN5459|Administered by intravenous (IV) infusion
45830922|NCT01491672|Drug|RAD001|Study drug was supplied as 5 mg tablets in blister packs.
45830923|NCT01447446|Drug|Peg-IFN Alfa-2a|Peg-IFN Alfa-2a according to standard of care and in line with local labeling.
45830924|NCT01447446|Drug|Peg-IFN Alfa-2b|Peg-IFN Alfa-2b according to standard of care and in line with local labeling.
45830925|NCT01447446|Drug|Ribavirin|Ribavirin according to standard of care and in line with local labeling.
45830926|NCT01447446|Drug|Boceprevir|Boceprevir according to standard of care and in line with local labeling.
45830927|NCT01447446|Drug|Telaprevir|Telaprevir according to standard of care and in line with local labeling.
45976288|NCT04516486|Other|retrospective metagenomics on clinical samples collected during hospitalization|Massive sequencing of respiratory samples (restrospective)
45830928|NCT01490814|Procedure|Electrical isolation of the pulmonary veins|Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
45456158|NCT04824768|Device|Tecar Therapy|"CRet is a non-invasive diathermy technique that provides high frequency energy generating a thermal effect on soft tissues. Functional massage (FM) is a non-invasive manual therapy technique that combines rhythmical passive joint mobilization with compression of the muscular belly with the muscle-tendon insertions to be treated.~In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (80-100W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (100-120 W) on the hamstrings. Then a 5 min F.M with passive ankle dorsiflexion and CRet on resistive mode (110-120 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (180-250VA) on the mentioned area.~In supine position, a 5 min FM with passive knee flexion and CRet on resistive mode 8.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes"
45456159|NCT04824768|Device|Sham Tecar Therapy|"In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (0 W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (0 W) on the hamstrings. Then a 5 min FM with passive ankle dorsiflexion and CRet on resistive mode (0 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (0 VA) on the mentioned area.~In supine position, a 5 min FM with passive knee flexion and CRet on resistive mode 0.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes"
45830929|NCT01490814|Procedure|Electrical isolation of pulmonary veins|Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
45458630|NCT01143961|Device|CSC100 - Verso airway access adapter CareFusion|Following randomisation patients will have a one-way valve inserted into the ventilator circuit (CSC100 - Verso airway access adapter CareFusion) prior to a non-directed bronchoalveolar lavage (NBL) being performed. Changes in regional ventilation will be recorded by electrical impedance tomography during the NBL. Recordings of ventilation will take place for upto four hours. One-way valve will stay in place until ventilator circuit is changed.
45830930|NCT01471782|Biological|Blinatumomab|Administered by continuous intravenous infusion
45830931|NCT01490580|Drug|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants < 1000g - Renewable once 2.5 mg/kg for infants > 1000G - Possible additional dose of 1 mg/kg
45830932|NCT01490580|Drug|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants < 1000g 0.2 µg/kg for infants > 1000g
45830933|NCT01490190|Drug|Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)|Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.
45830934|NCT01446042|Drug|Testosterone|Intranasal testosterone
45830935|NCT01446042|Drug|Testosterone|Intranasal testosterone
45830936|NCT01445886|Drug|Indigo Naturalis Extract in Oil|The participants applied indigo naturalis extract in oil topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
45976289|NCT04516525|Device|cardiac resynchronisation therapy (CRT) implantation|In a group of 100 patients with chronic cardio-renal syndrome, the blood and urine biomarkers are tested before CRT implantation and after 48 hours, 3 months and 1 year of follow-up.
45976290|NCT00255437|Drug|ferumoxytol or oral iron|
45976291|NCT04515940|Dietary Supplement|acceptability, tolerance and palatability study|prospective acceptability study
45976292|NCT00255476|Drug|gefitinib|
45830937|NCT01445886|Drug|Calcipotriol Solution|The participants applied calcipotriol solution topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
45976293|NCT00255476|Drug|cisplatin|
45976294|NCT00255476|Drug|5-flourouracil|
45976295|NCT04513249|Diagnostic Test|dynamics of coagulation parameters|the effects of fresh frozen plasma administered during a plasma exchange therapy on viscoelastic tests
45976296|NCT00270270|Drug|epoetin alfa|
45456160|NCT04812665|Behavioral|mHealth solution based on emotional and behavioral change techniques|"Adhera supports the empowerment of patients with chronic conditions by supporting the acquisition of healthier lifestyles, improved mental wellbeing and grounded on the principles of behavioral change.~The solution is based on incorporating the principles of personalized health education into a mobile platform which is achieved by applying the Integrated Model of Behavioral Change which is further adapted using recommender systems. Emotional and mental health elements, such as stress, resilience, are crucial part in the acquisition of self-management behaviors and will be the main focus of this intervention. Adhera adapts to provide tailored support to specific users' needs."
45458631|NCT04676698|Behavioral|Three Good Things|"The treatment phase will last 3 weeks. However, participants will complete surveys at baseline and up to 6 months. At the end of the trial the study team will also select a limited number of entries from participants to share some of the good things which people listed. These will be edited to ensure writer anonymity and participants will be informed of this plan in the study introduction."
45671483|NCT04808882|Drug|Tinzaparin, High dose prophylactic anticoagulation|"Participants randomized to the HD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: HD-PA : 7000 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: HD-PA: 4000 IU/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
45671484|NCT04808882|Drug|Tinzaparin,Therapeutic anticoagulation|"Participants randomized to the TA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: TA : 175 IU/kg/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: TA: 100 IU/kg/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
45671485|NCT02189473|Radiation|radiotherapy|external beam radiotherapy (5 x 4 Gy versus 10 x 3 Gy)
45830938|NCT01470612|Drug|CP-690,550|5 mg tablets, BID, for at least 12 months
45830939|NCT01470612|Drug|CP-690,550|10 mg tablets, BID, for at least 12 months
45830940|NCT01445730|Dietary Supplement|Fructose|3 month fructose diet 75 g/day
45830941|NCT01445652|Device|nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
45830942|NCT01445652|Other|Spectacles|Spectacles per current prescription
45830943|NCT04073316|Drug|Rivaroxaban 20 MG|Rivaroxaban intake, 20mg/day
45830944|NCT04073316|Drug|Warfarin|Warfarin intake, with target INR range between 2 and 3
45830945|NCT04089852|Drug|Nitrous oxide gas for inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. Environmental safety will be maintained with an N2O scavenger system and Porter Miniature Vacuum System. The treatment group will receive inhaled N2O/O2. The N2O will be gradually up-titrated to a goal ratio of 70/30 N2O/O2 and will be administered as outlined in the treatment arm description.
45976297|NCT04512118|Diagnostic Test|PET-CT of 18F-FDG|Whole-body 18F-FDG-PET/CT was performed on a digital hybrid system (Vereos, Philips®)
45976298|NCT04511143|Other|muscle strength and ultrasound imaging measurement|hamstring muscle strenght measured by hand held dynamometer. The long head of Biceps Femoris, Semitendinosus, Semimembronosus were evaluated by B-mode ultrasound imaging.
45976299|NCT00255515|Drug|Quetiapine fumarate|oral
45976300|NCT00255515|Drug|conventional treatment for schizophrenia|various standard therapies
45976301|NCT00270309|Behavioral|Self-management|
45976302|NCT00289419|Drug|Epidural Ropivacaine, morphine|Infusion rate 4 ml/h in 48 h Solution 200 ml Ropivacaine 2mg/ml added 1 ml morphine 10 mg/ml
45976303|NCT00289419|Drug|Ropivacaine, Ketorolac and Adrenaline|Wound infiltration: 100 ml Ropivacaine 2 mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml Bolus injection: 20 ml Ropivacaine 7,5mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml
45976304|NCT01600144|Other|digital mammography|data collection
45976305|NCT00255554|Behavioral|Dialectical Behavioral Therapy|
45830946|NCT04089852|Drug|Oxygen Gas for Inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. The control group will receive inhaled O2 alone. Control group participants will receive 100% O2 for two minutes prior to speculum placement. Inhaled oxygen will be administered continuously throughout the procedure as outlined in the control arm description.
45976306|NCT00255554|Drug|Escitalopram|
45830947|NCT03026244|Dietary Supplement|Milk protein, prebiotics, vitamin D|3 weeks supplementation with milk protein only, followed by 3 weeks milk protein + prebiotics, followed by 3 weeks milk protein + prebiotics + vitamin D
45830948|NCT03026244|Dietary Supplement|Placebo product|3 periods of 3 weeks placebo product
45976307|NCT00270348|Drug|ciclesonide|
45976308|NCT00255593|Drug|rituximab|
45976309|NCT00289497|Device|TempTouch®|
45976310|NCT04497337|Procedure|Complete excision to superficial lesions around the ear|Complete excision of these lesions and histopathology
45830949|NCT03026322|Other|Manual Ventilation|Beginning after the administration of sedation/neuromuscular blockade, manual ventilation will be provided by bag-valve-mask until the initiation of laryngoscopy. In patients requiring more than one attempt at laryngoscopy, bag-valve-mask ventilation will resume between laryngoscopy attempts.
45976311|NCT04496869|Other|Online questionnaire|the investigators sent by email a Googleform online questionnaires to women followed in ART center of HFME (Hospital Femme-Mère-Enfant) . Questions are about demographic characteristics, ART history, feeling during the lockdown. To evaluate psychological impact, the investigators use PSS10 and HADS scales. Both scales are worldwide validated and used in recent COVID19's research. the investigators add some quantitative questions about de feeling during the look down, ART interruption, pregnancy desire.
45976312|NCT00255671|Other|Questionnaire|Patients complete questionnaires about the side effects they experience from radiosurgery. The questionnaires are completed at baseline and at 1 week, 1 month, and 2 months after radiosurgery.
45976313|NCT04496206|Other|No intervention|No intervention, it is retrospective study.
45976314|NCT00270387|Drug|Natrecor (nesiritide)|
45976315|NCT00255710|Biological|filgrastim|
45976316|NCT00255710|Drug|cyclophosphamide|
45830950|NCT03026322|Other|No Manual Ventilation|Between the administration of sedation/neuromuscular blockade and intubation, ventilation will not be provided unless the patient experiences an arterial oxygen saturation less than 90%. For patients who experience an oxygen saturation less than 90% after induction, bag-valve-mask ventilation may be provided.
45830951|NCT01470144|Drug|Epoprostenol|Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit
45830952|NCT01443858|Drug|Meclizine|Pre-Quit Period: In this group, participants will take meclizine daily during the three week pre-quit period. The meclizine will be taken in two doses daily, one capsule with breakfast and one with dinner.
45830953|NCT01443858|Drug|Nicotine Patch|"Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily.~Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week."
45830954|NCT01443858|Drug|Placebo|Pre-Quit Period: In this group, participants will take placebo capsules daily during the three week pre-quit period. The placebo will be taken in two doses daily, one capsule with breakfast and one with dinner.
45830955|NCT01443078|Drug|pemetrexed|
45830956|NCT01443078|Drug|cisplatin|
45830957|NCT01443078|Drug|Carboplatin|
45830958|NCT01443078|Drug|Gemcitabine Hydrochloride|
45830959|NCT01443078|Drug|Vinorelbine Tartrate|
45830960|NCT01443078|Drug|Docetaxel|
45830961|NCT01439880|Biological|Evolocumab|Administered by subcutaneous injection
45830962|NCT01439880|Other|Standard of care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
45830963|NCT01469364|Drug|Aztreonam Lysine for Inhalation (AZLI)|The intervention will involve open label treatment with AZLI inhaled 75mg TID self-administered intermittently for 28 days on study drug and 28 days off study drug over a study period of 5 consecutive months (on/off/on/off/on AZLI)
45830964|NCT01469364|Procedure|Status Post Lung Transplant|Bronchoscopy, pulmonary function testing, and laboratory testing will be performed on a regular basis during study enrollment consistent with each center's usual standard clinical care.
45830965|NCT01439724|Device|Low Level Laser Therapy- (DMC, São Paulo, Brazil)|Diode laser (DMC,São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100 mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
45830966|NCT01439724|Device|Placebo (DMC, São Paulo, Brazil)|The placebo (DMC, São Paulo, Brazil) was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
45830967|NCT01439568|Drug|LY2510924|Administered subcutaneous injection
45830968|NCT01439568|Drug|Carboplatin|Administered intravenously
45830969|NCT01439568|Drug|Etoposide|Administered intravenously
45830970|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state
45830971|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (20 mg twice a day) in the fed state
45830972|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fed state
45830973|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (15 mg once a day) in the fed state
45458632|NCT04676698|Behavioral|Wait list control arm and then Three Good Things|Surveys will be completed for 3 months prior to treatment and then after treatment.
45458633|NCT01365338|Drug|Placebo|Administered as specified in the treatment arm
45830974|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fasted state
45830975|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state
45830976|NCT01468818|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
45830977|NCT01468818|Drug|Fludarabine|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
45830978|NCT01468818|Biological|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL. On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
45830979|NCT01442376|Drug|Palonosetron|Single dose Palonosetron IV 10 mcg/kg up to a maximum total dose of 0.75 mg
45830980|NCT01442376|Drug|Palonosetron|Single dose Palonosetron IV 20 mcg/kg up to a maximum total dose of 1.5 mg
45830981|NCT01442376|Drug|Ondansetron|Single three (every 4 hours) Ondansetron IV doses 0.15 mg/kg up to a maximum total dose of 32 mg
45830982|NCT01442376|Drug|Placebo to Ondansetron|
45830983|NCT01442376|Drug|Placebo to Ondansetron|
45830984|NCT01442376|Drug|Placebo to Palonosetron|
45671486|NCT05652452|Other|Neurodynamics|Subjects in the neurodynamic group performed the 'Seated Straight Leg Slider' (SSLS) (Fig.1). To execute this sliding technique, subjects assumed a seated slump position (thoracic and lumbar flexion) which they needed to maintain throughout the exercise. This SSLS consisted of alternating movements towards knee extension and ankle dorsiflexion (increase of neural tension) combined with cervical extension (decrease of neural tension) on one hand, and knee flexion and ankle plantar flexion (decrease neural tension) combined with cervical flexion (increase of neural tension) on the other. During this 6-week period, each subject in this neurodynamic slider group was instructed to perform 3 sets of 20 repetitions on a daily basis for 6 weeks.
45830985|NCT01442064|Drug|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).
45830986|NCT03026868|Procedure|quadrilateral surface plate|Both anterior and posterior approaches were always conducted to manage the fragments of quadrilateral surface. Novel quadrilateral surface plate was used in this study to examine whether the fragments could be fixed through single Stoppa approach.
45830987|NCT01441596|Drug|Vinorelbine|Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course
45830988|NCT01441596|Drug|Investigator's choice of treatment|Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
45830989|NCT01441596|Drug|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
45830990|NCT01441596|Drug|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
45830991|NCT01441440|Drug|venlafaxine ER 75 mg/day (fixed dose)|Treatment phase: 8 weeks (37.5 mg/day for 1st week and 75 mg/day for 7 weeks), oral administration Tapering phase: 2 weeks (37.5 mg/day for the 1st week and placebo for the 2nd week), oral administration
45830992|NCT01441440|Drug|venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|Treatment phase: 8 weeks (37.5 mg/day for the 1st week, 75 mg/day for the 2nd weeks, 75-150 mg for the 3rd week, 75-225 mg/day for the rest of 5 weeks), oral administration Tapering phase: 2 weeks (75/37.5 mg/day for the 1st week and 37.5 mg/day/placebo for the 2nd week), oral administration
45830993|NCT01441440|Drug|Placebo|Treatment phase: 8 weeks (placebo), oral administration Tapering phase: 2 weeks (placebo), oral administration
45830994|NCT03026400|Procedure|Transumbilical incision|While both types of incision were considered equal regarding the potential clinical outcome, the investigators considered the transumbilical incision to be the ''intervention'' and the subumbilical incision to be the ''standard care comparator'' since the transumbilical incision take a few more minutes to be completed.
45830995|NCT03026400|Procedure|Subumbilical incision|Considered here as the ''control'' intervention.
45976317|NCT00255710|Drug|fludarabine phosphate|
45458634|NCT01365338|Drug|PF-04958242|Administered as specified in the treatment arm
45458635|NCT01144039|Drug|LG-group|
45458636|NCT01144039|Drug|HG-group|
45458637|NCT01144039|Drug|Placebo-group|
45458638|NCT04656730|Drug|Iberogast® and Iberogast® N|Oral intake of the investigation drug 20 drops three times per day (TID) for 14 days,
45458639|NCT04676282|Other|Hypothetical Scenario|Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.
45458640|NCT01145677|Drug|Topiramate|Topiramate 100-300 mg/day orally twice per day
45671487|NCT05652452|Other|Static stretch|Subjects in the control group were instructed to perform a standard standing static stretch with the heel of the dominant leg taking support on a chair. Then they had to move the pelvis into anteversion, simultaneously inducing a forward lean of the trunk, until the clear sensation of hamstring stretch was perceived at the posterior aspect of the thigh. Again, the execution of the exercise was thoroughly explained and evaluated by the researchers and subjects sent home with a comprehensive instruction guide and supporting pictures. Each subject was instructed to do 3 repetitions of 30 second static stretches on a daily basis during the 6-week intervention.
45671488|NCT05164796|Device|IVUS assessment of coronary ostia|"For coronary arteries at high-risk of obstruction during TAVI in native valves or valve-in-valve TAVI:~IVUS analysis before valve implantation (+ coronary angiogram) to detect any leaflet interference with the coronary ostium, existing prior to the transcatheter heart valve (THV) placement~IVUS analysis (+ coronary angiogram) after valve implantation in absence of acute coronary occlusion, to assess the patency of the ostium at-risk, the presence of native or degenerated surgical leaflet adjacent to the ostium, and the interaction of THV-frame with the coronary ostium.~In case of CHIMNEY stenting, re-assessment of the stent expansion and coronary ostia patency with IVUS."
45830996|NCT01438476|Procedure|Intravenous Patient-Controlled Analgesia (IVPCA)|Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures.
45976318|NCT00255710|Drug|mycophenolate mofetil|
45458641|NCT03499522|Other|Observational group|"The dependent variables (pain, quality of life, anxiety and coping strategies) and the outcome measures used to measure these variables will be:~Numerical scale of pain~Short Form 36 Health Survey [SF-36].~State-Trait Anxiety Inventory [STAI].~Tampa Scale of Kinesiophofia [TSK-11SV].~Pain catastrophizing scale [PCS].~Coping Strategies Questionnaire [CSQ]."
45671489|NCT03081806|Drug|X0002|Subjects will complete 22 weeks of double-blind treatment and then enter into 30 weeks open-label treatment.
45671490|NCT02188849|Other|Resistance exercise training|All participants will be subjected to resistance training of upper and lower limbs, using elastic bands and tubing and free weights. Training will be calibrated at 60% of one repetition maximum for each muscle group with three sets of 15 repetitions with one minute rest between each set. All exercises will be additionally calibrated to be of moderate intensity according to the Borg scale. The exercise load will be adapted according to the progression of each participant.
45671491|NCT02188849|Drug|Creatine|Creatine powder 5 g day
45830997|NCT01438476|Procedure|Thoracic Epidural Analgesia (TEA)|Thoracic epidurals (needle inserted into the space between the covering of spinal cord and the cord itself) placed preoperatively in either the holding area or in the operating room.
45830998|NCT01438476|Behavioral|Questionnaires|Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
45830999|NCT01438476|Behavioral|Pain Assessment|Hourly post surgery rating level of pain on a scale of 0-10.
45831000|NCT03026478|Drug|Betamethasone Dipropionate|
45831001|NCT03026478|Drug|Clobetasol Propionate|
45831002|NCT01467570|Dietary Supplement|oral rehydration solution Hipp ORS Apple 200|"Volume of the solution calculated by weight:~fast oral rehydration in 3-4 hours by mouth~ORS given for ongoing losses until diarrhea stops (maintenance phase)"
45831003|NCT01467570|Dietary Supplement|ESPGHAN ORS|"Volume of the solution calculated by weight:~fast oral rehydration in 3-4 hours by mouth~ORS given for ongoing losses until diarrhea stops (maintenance phase)"
45831004|NCT04066764|Drug|Rivaroxaban|15mg twice daily for 3 weeks after operation, later 20mg once daily until 3 months after the filter is removed. Application: oral
45831005|NCT04066764|Drug|Warfarin|3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until until 3 months after the filter is removed. Frequency: once daily Application: oral
45831006|NCT04066764|Drug|Nadroparin|Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
45831007|NCT01437540|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg, high dose twice per day
45831008|NCT01437540|Drug|Formoterol Fumarate|Inhaled formoterol fumarate 12 μg, twice per day
45831009|NCT01440972|Other|partial blood flow restriction (PBFR)|low intensity resistance training with partial blood flow restriction 3 times/week for 4 weeks.
45831010|NCT01440972|Other|low intensity resistance training|low intensity resistance training without partial blood flow restriction
45831011|NCT01420536|Procedure|Occlusal scheme|"Before enrollment, all participants will receive conventional complete dentures adjusted according to the bilateral balanced occlusion concept.~Following randomization, canine guidance will be achieved by adding composite resin (Restorative Z100, 3M Brazil, Sumaré, SP, Brazil) on the lingual surface of the maxillary canines. A sham comparator will also employ the addition of composite, but without changing eccentric contacts."
45976319|NCT00255710|Drug|tacrolimus|
45976320|NCT00255710|Procedure|allogeneic bone marrow transplantation|
45458642|NCT01237015|Device|Infant Flow nasal CPAP|Infant Flow nasal CPAP 5 cm H2O
45671492|NCT05164484|Device|Transpulmonary thermodilution|Through the analysis of the thermodilution curve recorded at the tip of an arterial catheter after the injection of a cold bolus in the venous circulation, transpulmonary thermodilution intermittently measures cardiac output.
45671493|NCT05652374|Device|Ialuril 50ml Prefill|Bladder instillations weekly for 6 weeks, followed by monthly maintenance therapy for 1 year
45976321|NCT00255710|Procedure|peripheral blood stem cell transplantation|
45976322|NCT00255710|Radiation|radiation therapy|
45976323|NCT04493866|Other|Messages to departmental employees to improve quality of consent form completion|All interventions directed to members of the plastic surgery department: Intervention 1: Poster illustration common mistakes on consent forms. Intervention 2: Group message explaining Quality Improvement Project to the department. Intervention 3: Email from Consultant lead in support of project. Intervention 4: Further group message illustrating gains and ongoing goals of the project.
45976324|NCT00270426|Drug|Benazepril|
45976325|NCT00255749|Biological|epoetin alfa|
45671494|NCT05652374|Drug|Nitrofurantoin|100mg daily (1dd100mg or 2dd50mg) for 1 year. ( In case of resistance/intolerance/allergy for nitrofurantoin alternatively trimethoprim 100mg daily)
45831012|NCT01420068|Drug|SPP100|
45831013|NCT01467492|Drug|Telaprevir|Tablet
45976326|NCT04491214|Other|quality of live assessment|quality of live assessment 3 moth and 6 moth after ointensive care hospitalisation using SF36.
45976327|NCT04491448|Behavioral|Social needs screening|Interview and referral for non-medical health-related social needs
45831014|NCT01467492|Drug|Ribavirin|Tablet
45831015|NCT01467492|Biological|Pegylated Interferon Alfa-2a|Subcutaneous Injection
45831016|NCT01466790|Drug|TMC435|TMC435 will be administered as one oral capsule of 150 mg once a day.
45831017|NCT01466790|Drug|PSI-7977 (GS7977)|PSI-7977 (GS7977) will be administered as oral tablets (2 tablets of 200 mg for Cohort 1 and 1 tablet of 400 mg for Cohort 2) once a day.
45831018|NCT01466790|Drug|Ribavirin|Ribavirin will be administered according to body weight. For patients with body weight less than 75 kg daily dose (1000 mg) will be administered as 400 mg (2 oral tablets of 200 mg) in the morning and 600 mg (3 oral tablets of 200 mg) in the evening. Body weight more than or equal to 75 kg daily dose (1200 mg) will be administered as 600 mg twice a day (3 tablets of 200 mg per intake, morning and evening).
45831019|NCT01418352|Drug|Aripiprazole|Aripiprazole tablets once weekly for 8 weeks.
45976328|NCT00289575|Device|MBCP|
45976329|NCT01600183|Device|UNFO-s|The UNFO-s is a foot orthosis used to treat congenital foot malformations in infants
45976330|NCT01600183|Procedure|cast|casting of the infant legs
45976331|NCT04489030|Other|Magnifying narrow-band imaging endoscopy|During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.
45976332|NCT00255788|Drug|everolimus|
45976333|NCT00270465|Drug|VRC-HIVDNA016-00-VP|
45976334|NCT00270465|Drug|VRC-HIVADV014-00-VP|
45671495|NCT04815668|Other|Acupuncture group|Sterile single-use stainless steel needles (size 0.35 mm × 55 mm) (YiDaiFu brand, Suzhou Tianyi Acupuncture Instrument Co., Ltd., Suzhou, China) will be utilized. Participants in lateral position, the acupoints area will be sterilized with 75% alcohol. To stimulate SPG, the needles will be inserted in the medial superior anterior direction to a depth of approximately 55 mm33 until the participants report a special sensation radiating toward the nose or the upper teeth. After that, the needle will be withdrew slightly. The needles will be retained for 30 minutes after three stimulation. Rescue medication are permitted when participants feel that their symptoms are intolerable.
45831020|NCT01418352|Drug|Placebo|Aripiprazole matching-placebo once-weekly for 8 weeks.
45671496|NCT04815668|Other|Placebo acupuncture group|The acupuncture procedure will be similar to that of the acupuncture group. After sterilizing the skin, the 0.35 × 25 mm disposable needle will be vertically inserted at SPG acupoint about 3-5 mm. No needle manipulation will be conducted to avoid the deqi response. Rescue medication are permitted when participants feel that their symptoms are intolerable.
45671497|NCT04815668|Other|Rescue medication group|Participants in the rescue medication group do not receive acupuncture treatment during the study period. They will be only allowed to use rescue medication. They have the option of 4 weeks (up to 8 sessions) of acupuncture free of charge at the end of the follow-up period.
45831021|NCT01436370|Biological|Trivalent inactivated influenza vaccine|Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® High Dose [60 mcg x 3 strains]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
45671498|NCT01636076|Drug|QMF149|delivered via Concept1 device
45671499|NCT01636076|Drug|Salmeterol|delivered via Accuhaler®
45671500|NCT04794842|Drug|Tetracaine 5% drops|same as information in the arm/group description
45671501|NCT04794842|Drug|Phenol 90% concentration|same as information in the arm/group description
45831022|NCT01436370|Biological|Trivalent inactivated influenza vaccine|Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® [15 mcg x 3 strains]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
45831023|NCT01465464|Drug|Orantinib (TSU-68)|200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
45831024|NCT01465464|Drug|Placebo|1 tablet was administered orally twice per day after meals, morning and evening.
45831025|NCT03026010|Procedure|central blood pressure|SphygmoCor XCEL will be used to measure both standard blood pressure in the arm and central pressure, the blood pressure at the heart.
45458643|NCT01360970|Biological|hepatitis A vaccine ( HAVRIX or EPAXAL)|1.0 ml im ( Havrix) and 0.5 ml im (Epaxal. Both vaccines are given two times with 6 months interval
45671502|NCT01635998|Device|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
45671503|NCT01635920|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
45671504|NCT01635920|Device|Lotrafilcon B contact lens|Silicone hydrogel contact lens
45671505|NCT04793984|Device|Carragelose|inhalation 3 times a day
45831026|NCT01417104|Drug|Aliskiren|150 mg/300mg
45831027|NCT01417104|Drug|Placebo|150mg/300mg
45831028|NCT01465386|Drug|bortezomib|Given SC
45831029|NCT04082364|Biological|margetuximab|margetuximab: Fc-modified anti-HER2 monoclonal antibody: 15 mg/kg IV, Day1 of each 3-week cycle
45831030|NCT04082364|Biological|Retifanlimab|Retifanlimab: anti-PD-1 checkpoint inhibitor 375 mg IV, Day 1 of each 3-week cycle.
45831031|NCT04082364|Biological|Tebotelimab|Tebotelimab: anti PD-1, anti-LAG3 bispecific DART (R) molecule 600 mg IV, Day 1 of each 3-week cycle.
45831032|NCT04082364|Biological|Trastuzumab|Anti-HER2 monoclonal antibody 8 mg/kg loading dose and then 6 mg/kg administered IV on Day 1 of each 3-week cycle
45831033|NCT04082364|Other|Chemotherapy|"Investigator choice of 1 of 2 chemotherapy regimens: XELOX or mFOLFOX6~Chemotherapy~XELOX chemotherapy Capecitabine: 1000 mg/m2 as oral capsules twice a day Days 1-14 of each cycle, Oxaliplatin: 130 mg/m2 of Day 1 of each 3-week cycle as IV infusion~mFOLFOX6 chemotherapy: Leucovorin: 400 mg/m2 every 2 weeks as IV infusion, 5-FU bolus: 400 mg/m2 every 2 weeks as IV infusion, 5-FU continuous infusion: 2400 mg/m2 every 2 weeks as a 46 hr infusion, Oxaliplatin: 85 mg/m2 every 2 weeks as IV infusion."
45831034|NCT01465230|Drug|Maintenance lenalidomide|Daily maintenance treatment, oral lenalidomide
45831035|NCT04767516|Other|no intervention|no intervention
45831036|NCT04050072|Other|Childhood Cancer Survivors (CCSS)|To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in adult survivors of childhood cancer vs. non-cancer controls, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
45831037|NCT04050072|Other|SJLIFE|To use the current PRO-CTCAE to conduct a symptom content creation process for the PRO-CTCAE-SCC by identifying clinically meaningful symptomatic AEs for adult survivors of childhood cancer, to create symptomatic AE items not included in the current PRO-CTCAE, and to perform comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation to clinically validate the PRO-CTCAE-SCC.
45831038|NCT04050072|Other|Community non-cancer control|To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in non-cancer controls vs. adult survivors of childhood cancer, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
45831039|NCT04048668|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation technique by which very small electrical currents (2 mA) are applied to the scalp.
45831040|NCT04500132|Drug|EC-18|EC-18 QD
45831041|NCT04500132|Drug|Placebo EC-18|Placebo EC-18 QD
45831042|NCT03820830|Drug|Palbociclib 125mg|Palbociclib 125 mg oral tablet taken daily for 3 years from randomization
45831043|NCT03820830|Drug|Standard endocrine therapy|Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
45831044|NCT01435356|Biological|recMAGE-A3 + AS15 ASCI|5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
45831045|NCT01435356|Biological|Placebo|5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
45458644|NCT03492814|Procedure|partial wound closure|3 sutures distal to second molar and leaving the vertical releasing incision open without any sutures.
45458645|NCT03492814|Procedure|total wound closure|5 interrupted sutures with 2 sutures closing the vertical releasing incision and 3 sutures distal to second molar leading to a complete hermetic closure of the wound.
45671506|NCT04793984|Device|NaCl|inhalation 3 times a day
45671507|NCT03029000|Drug|Tbo-filgrastim|solution for subcutaneous injection
45671508|NCT03023150|Other|Ischemic Preconditioning|
45671509|NCT03023150|Other|Sham|
45671510|NCT03799562|Drug|Pregnenolone|Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial. Placebo will be identical to the pregnenolone arm, except placebo will be dispensed.
45671511|NCT03799562|Drug|Placebo|Same as pregnenolone (active study medication), except placebo dispensed.
45831046|NCT01435122|Drug|Axitinib|Axitinib Administration as outlined in Arm description
45976335|NCT04486807|Diagnostic Test|Elite badminton players|The population was all the elite badminton players followed in a University Hospital Centre and the National Institute of Sport, Expertise, and Performance. We excluded players who had SSI in the 3 months prior to the isokinetic test or had shoulder surgery. They were included and followed during the badminton season (Nineteen elite badminton players and followed over the badminton season (from september 2018 to may 2019 or from september 2019 to may 2020)
45976336|NCT00255827|Biological|HyperAcute-Pancreatic Cancer Vaccine|
45976337|NCT00270504|Device|Memokath stenting|Urethral Stenting
45831047|NCT04048122|Behavioral|MultiContext for PD Strategy Training|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper & pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions. Graded task practice with OT feedback on performance accuracy is used to produce neurocognitive improvement (or possibly independent strategy development). The OT assigns practice of specific cognitively challenging everyday life activities for homework (but without action plans).
45671512|NCT03783182|Drug|Betamethason Sodium Phosphate|Glucocorticoid
45976338|NCT00255866|Behavioral|Skills training for the care of dementia patients|
45976339|NCT00289614|Drug|Iopamidol 370 mgI/dL|
45976340|NCT04482361|Diagnostic Test|Presence of specific anti-SARS-CoV-2 antibodies|Presence of specific anti-SARS-CoV-2 antibodies
45976341|NCT00255905|Behavioral|Cognitive behavioral therapy (CBT) for insomnia|
45671513|NCT03783182|Drug|10% glucose solution|Glucose solution that can be used for injection, but in this case it is used perorally (one ml)
45671514|NCT03780920|Procedure|manual therapy/osteopathy|"In this group, children will benefit from early osteopathic treatment over a period ranging from the third day to 4 months. The number of sessions will not be fixed, on average, 3 sessions will be carried out during this period at the University Hospital of Montpellier.~The duration of the session will be between 20 minutes to 30 or even 40 minutes"
45671515|NCT05652062|Device|Prizvalve® system|Transcatheter valve-in-valve replacement
45976342|NCT00255905|Behavioral|Clinician monitoring|
45976343|NCT00270543|Drug|Taxotere, Fluorouracil, Leucovorin|
45456161|NCT04809207|Other|CF Wellness Program Sessions|The intervention will last approximately 12 weeks. During this time, up to 9 coaching sessions will be delivered. Each will last approximately 45 - 60 minutes. Sessions will be delivered either by web-based video chat (e.g., Zoom) or by telephone. Sessions will cover content such as understanding the physiological, cognitive, affective, behavioral contributors to CF fatigue; understanding the role of physical activity/exercise and fatigue including the importance of balancing activity and rest periods; cognitive restructuring; addressing attention and interpretation processes contributing to fatigue; teaching techniques such as mindfulness meditation relaxation strategies, good sleep hygiene, and activity scheduling and behavioral activation; and engaging social support. Physical activity goals will be set each session. Participants will be encouraged to use the provided fitness tracker and to sync weekly prior the coaching session so that the results can inform session content.
45976344|NCT04480684|Diagnostic Test|Three-dimensional Endoanal Ultrasound|"Three-dimensional endoanal ultrasound is the gold standard diagnostic tool in the assessment of obstetric anal sphincter injury. The anorectal transducer is inserted directly into the anal canal which allows assessment of the anal sphincter complex.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed."
45456162|NCT04808245|Drug|Tecentriq 1200 MG in 20 ML Injection|One vial of Tecentriq® (1200 mg) will be administered as an intravenous (i.v.) infusion over 60 minutes every 3 weeks starting 4 weeks after radiotherapy. If the first infusion is tolerated, all subsequent infusions will be delivered over 30 minutes.
45456163|NCT04808245|Biological|H3K27M peptide vaccine|The H3K27M peptide vaccine is injected subcutaneously (s.c.). For a single vaccination 300 μg of the peptide will be emulsified in a total volume of 1 ml.
45456164|NCT04808245|Other|Imiquimod (5%)|One sachet of Aldara® cream (250 mg) will be applied to an area of 5 x 5 cm around the injection site of the H3K27M peptide vaccine 15 min after vaccination and left on the skin for approximately 8 hours according to the instructions in the SmPC. 24 hours after the vaccination a second sachet of Aldara® will be applied by the patient as instructed above and left on the skin for approximately 8 hours.
45456165|NCT04804033|Drug|BHV-3500 (zavegepant)|BHV-3500 (zavegepant) softgel capsule.
45671516|NCT05651984|Device|Comparison between communication board and eye tracking|The comparison between the communication board and eye tracking, conducted as a crossover, generates a randomization of the patients (from the cross-sectional part) into two groups and the communication interfaces were divided into two time periods: group A received eye tracking/communication board sequence and group B received communication board/eye tracking sequence.
45456166|NCT04804033|Drug|Placebo|Matching placebo softgel capsule.
45671517|NCT05651906|Procedure|Kidney Transplantation|Kidney transplantation as the best option for patients with end-stage kidney disease.
45671518|NCT03760484|Drug|Fidaxomicin 200 mg|Each cycle consists of fidaxomicin 200 mg PO bid x 7-10 days till clinical efficacy is achieved, to a max of 4 cycles.
45671519|NCT03760484|Biological|fecal microbiota transplantation (FMT)|Each cycle consists of FMT per rectum daily x 3 days till clinical efficacy is achieved to a max of 4 cycles
45671520|NCT04807868|Procedure|Standard of care liver biopsy|Patients undergoing a standard of care liver biopsy for any reason who are willing to participate will be consented for collecting additional biopsy tissue for research purposes. 1-2 additional biopsy tissue cores will be collected for research. Liver tissue will be biobanked for future use.
45671521|NCT04807868|Other|Fibroscan|A FibroScan will be performed to evaluate longitudinal changes in liver fat and fibrosis.
45456167|NCT04802395|Diagnostic Test|KidneyIntelX|KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).
45456168|NCT04800783|Diagnostic Test|Swallowing ultrasound|Ultrasound assessment of the tongue movement and thickening, the geniohyoid and suprahyoid muscles echogenicity, thickness and thickening, the hyoid bone elevation, and the number of swallowing trial.
45456169|NCT04799119|Behavioral|Do As I Do (DAID) dog training|Children and their family dog will participate in this dog training program.
45831048|NCT04048122|Behavioral|Standard of Care|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper & pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. Therefore, this is a standard-of-care approach that includes all but the proposed critical elements of MC4PD. The OT reviews pre-treatment cognitive test scores with the client but without discussion to build awareness. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions.
45831049|NCT01434810|Device|Filtered-sunlight phototherapy|Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using window tinting film. Window tinting films by Solutia, Inc., and V-KOOL, Inc.
45831050|NCT01434810|Device|Conventional phototherapy|Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.
45831051|NCT01393626|Drug|Placebo|oral tablets twice daily
45976345|NCT04480684|Diagnostic Test|Transperineal Ultrasound(multiplanar)|"If endoanal ultrasound is declined or not tolerated, the anal sphincter will also be assessed using three-/four-dimensional (3D/4D) transperineal ultrasound with the probe placed externally on the area of the fourchette.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed."
45976346|NCT04480684|Diagnostic Test|The MolecuLight i:X: Bacterial autofluorescence camera|"The bacterial load of the perineal wound will be measured every week using the MolecuLight i:X. This is a system, which uses fluorescent illumination to capture and document the presence of bacteria.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed.~These findings will be supported by microbiological analysis of the wound fluid with swab culture and sensitivity."
45456170|NCT04798430|Drug|lerodalcibep|PCSK9 inhibitor
45456171|NCT04793581|Device|Atherectomy|Directional atherectomy of lesions below the knee.
45671522|NCT04807868|Other|Biospecimen Collection|Blood and urine will be collected.
45671523|NCT05651750|Drug|Montelukast|receiving 2 months treatment with Montelukast once a day
45671524|NCT05651750|Drug|Fluticasone Furoate|receiving 2 months treatment with Fluticasone Furoate nasal spray once a day
45671525|NCT02917460|Genetic|Genomic sequencing and molecular diagnostic results, if any|Samples will be stored in the pediatric genomic Biorepository. A subset of samples will undergo genetic/genomic analysis.
45671526|NCT03754790|Drug|Fitusiran|Pharmaceutical form:solution for injection Route of administration: subcutaneous
45671527|NCT05651672|Drug|Pemigatinib|13.5mg, po, 2 weeks on/1 week off, Q3W
45671528|NCT02895230|Other|Standard care|An extraction from French Health Reimbursement Agency database and French hospital discharge database will be performed using a simplified request based on inclusion criteria but the extraction will encompass a 4-year period to ensure sufficient follow-up.
45976347|NCT04480684|Device|Silhouette® 3D camera: Three-dimensional wound measuring camera|For wound that have superficially dehisced, the wound surface area, depth, volume and healing progress will be precisely measured using the Silhouette® 3D camera. This is a system that uses 3D laser technology to track wound healing progression.
45671529|NCT02160145|Drug|Tolvaptan (OPC-41061)|Tolvaptan tablets (15 or 30 mg) will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later.
45671530|NCT02160145|Drug|Placebo|Matching placebo tablets will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
45671531|NCT04807478|Drug|Omegaven® (fish oil triglycerides) Injectable Emulsion|Dose, frequency and duration is a decision of the Investigator
45671532|NCT01696396|Drug|Abrilumab|Administered by subcutaneous injection.
45671533|NCT01696396|Drug|Placebo|Placebo matching to abrilumab administered by subcutaneous injection
45671534|NCT04793906|Other|Iron supplement with a lunch meal containing beef|Participants will consume a lunch meal containing beef with an iron supplement for 8 weeks.
45671535|NCT04793906|Other|Iron supplement with a lunch meal containing plant-based alternative|Participants will consume a lunch meal containing plant-based alternative with an iron supplement for 8 weeks.
45671536|NCT02836262|Device|HIT Hip Replacement System|HIT Hip Replacement System
45671537|NCT05269784|Procedure|Minimally Invasive Lung Surgery Under ERAS With Completely Tubeless Protocol|Minimally Invasive Lung Surgery Under ERAS With Completely Tubeless Protocol
45671538|NCT05269784|Procedure|Minimally Invasive Lung Surgery Under ERAS With partially Tubeless Protocol|Minimally Invasive Lung Surgery Under ERAS With partially Tubeless Protocol
45831052|NCT01393626|Drug|CP-690,550|oral tablets twice daily
45671539|NCT04793750|Diagnostic Test|Cepheid GeneXpert HIV-1 Qual POC HIV VL test|POC Nucleic acid-based test for HIV RNA.
45831053|NCT01393626|Drug|CP-690,550|oral tablets twice daily
45831054|NCT04059666|Other|Investigational|Cow's milk-based Infant Formula with whey protein-lipid concentrate
45831055|NCT04059666|Other|Control|Cow's milk-based Infant Formula
45831056|NCT04059276|Diagnostic Test|MRI|We will examine chronic (>3 months post stroke) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
45831057|NCT04059276|Diagnostic Test|MRI|We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
45831058|NCT01393158|Drug|Apremilast|20mg of Apremilast taken orally BID for 3 months or 30 mg of Apremilast taken orally BID for 6 months.
45831059|NCT01413360|Drug|High dose vitamin C|Vitamin C, 3g per day (tid), with meal, per oral with water 100mL
45831060|NCT01413204|Drug|TA-7284 Low|The patients will receive TA-7284-Low orally for 24 weeks.
45831061|NCT01413204|Drug|TA-7284 High|The patients will receive TA-7284-High orally for 24 weeks.
45831062|NCT01413204|Drug|Placebo|The patients will receive Placebo orally for 24 weeks.
45831063|NCT03815448|Drug|Methotrexate|Participants randomized to methotrexate group will receive active drug, methotrexate. Starting from 5 mg/week, the dosage will be adjusted to 10 mg/week if the participants can tolerate for 2 weeks. After 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study if the participants can tolerate.
45831064|NCT03815448|Other|Placebo|Participants randomized to placebo group will receive placebo tablets. Starting from 5 mg/week for 2 weeks, the dosage will be adjusted to 10 mg/week; after 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study.
45831065|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
45831066|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
45976348|NCT00255983|Drug|Faropenem medoxomil|600 mg BID for 5 days
45976349|NCT00255983|Drug|placebo|placebo tablets BID for 5 days
45671540|NCT04793750|Diagnostic Test|DPP HIV-Syphilis test system|POC Tests for antibodies to HIV 1/2 and Treponema pallidum.
45671541|NCT04793750|Diagnostic Test|OraQuick|POC oral fluid swab test for HIV 1/2 antibodies.
45831067|NCT01392378|Drug|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
45831068|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
45831069|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
45831070|NCT01392378|Drug|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
45831071|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
45671542|NCT03654638|Combination Product|Dietary Intervention|The dietary intervention requires men to consume 2 slices soy bread each day for 20 weeks while initiating hormone therapy
45671543|NCT03654638|Combination Product|Dietary Intervention|The dietary intervention requires men to consume 2 slices wheat bread each day for 20 weeks while initiating hormone therapy
45831072|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
45976350|NCT04480060|Diagnostic Test|COVID-19 diagnostic PCR|Nasopharyngeal swab samples will be analyzed by PCR for COVID-19 DNA existence.
45976351|NCT02960919|Drug|oral amoxicillin or parenteral ampicillin/ penicillin and gentamicin|
45976352|NCT02960919|Drug|parenteral ampicillin/ penicillin|
45976353|NCT02960919|Drug|gentamicin|
45976354|NCT04479124|Diagnostic Test|COVID-19 PCR|Nasopharyngeal samples were analyzed by PCR for the detection of Novel Coronavirus 2019 DNA
45976355|NCT04478383|Procedure|a new transosseous suture technique|a new technique using the spur base on the insertional site to drill the suture tunnel to repair Achilles sleeve avulsion.
45976356|NCT00415220|Procedure|Spinal Manipulation, Microdiscectomy|
45976357|NCT00270582|Drug|Taxotere, Cisplatin, Gemcitabine|
45456172|NCT04791423|Biological|GRAd-COV2|GRAd-COV2 is a replication-defective gorilla adenoviral vector (GRAd) encoding the SARS-CoV-2 surface glycoprotein (S, Spike) antigen under the control of CMV immediate early promoter. The encoded Spike antigen is stabilized in pre-fusion conformation by introducing 2 proline residues
45456173|NCT04791423|Other|Placebo|Saline solution
45456174|NCT04790513|Biological|lerodalcibep|anti-PCSK9 small binding protein
45456175|NCT04790513|Biological|evolocumab|monoclonal antibody to PCSK9
45456176|NCT04790513|Biological|alirocumab|monoclonal antibody to PCSK9
45456177|NCT04788459|Biological|COVID-eVax|Plasmid DNA Vaccine for COVID-19
45671544|NCT03654638|Other|Questionnaire Administration|Ancillary studies
45456178|NCT04788459|Device|Cliniporator® and EPSGun|IGEA Electroporation Device
45456179|NCT04787666|Procedure|Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet|Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet for tackling the problem of respiratory failure
45671545|NCT02216071|Drug|Ciprodex®|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
45671546|NCT02216071|Drug|EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
45671547|NCT04418570|Behavioral|cognitive remediation|
45671548|NCT04418570|Other|attendance to an Early Intervention Service for Psychosis|
45671549|NCT01681576|Drug|Valsartan|Valsartan 320mg tablet once daily
45671550|NCT01681576|Drug|LCZ696|LCZ696 400mg tablet once daily
45671551|NCT04418726|Other|Intensified Monitoring|Apart from clinical assessment, use non-invasive devices to check for the haemodynamic consequences of stenosis by measuring Qa, using either indicator dilution techniques or duplex ultrasound every month.
45456180|NCT04786353|Other|LongCOVIDkidsDK|Exposure: To be identified as an exposure for the current study, children from 0-18 years with at least one positive SARS-CoV-2 test will be identified from COVID-19 data from January 2020 until the last updated version. To be able to identify the parents who will receive the questionnaires we will also need CPR-data on the children's parents.
45456181|NCT04777071|Procedure|Computed Tomography|Undergo PET/CT scan
45456182|NCT04777071|Drug|Gallium Ga 68 Gozetotide|Given IV
45456183|NCT04777071|Procedure|Positron Emission Tomography|Undergo PET/CT scan
45456184|NCT04772937|Procedure|LLETZ|LLETZ is one of several possible surgical interventions for treating cervical dysplasia. The transformation zone of the cervix is completely removed
45831073|NCT01392378|Drug|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
45831074|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
45831075|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
45831076|NCT01392378|Drug|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
45456185|NCT04772937|Procedure|LEEP|LEEP is one of several possible surgical interventions for treating cervical dysplasia. Only the dysplastic lesion is removed without removing the whole transformation zone.
45831077|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
45831078|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
46082338|NCT02721108|Behavioral|Mindfulness meditation|The meditation content is a structured and progressive course, layering in new techniques and concepts over successive sessions. The course was created and narrated by a former monk - Andy Puddicombe - drawing on a secularised version of the techniques he was taught over 10 years' experience in monasteries around the world. The first 30 days cover basic techniques, assuming no previous experience of meditation. The second 30 days focus specifically on the use of these techniques with respect to pain. The duration of individual sessions builds over time. Days 1-10 are 10 minutes in duration, days 11-20 are 15 minutes in duration, and days 21-60 are 20 minutes in duration.
46082339|NCT02721108|Behavioral|Relaxation app|The Active Control group will use the same app, but the app will be configured so that they will hear a series of non-meditative progressive muscle relaxation instructions, also narrated by Andy Puddicombe. These sessions will be identical every day, except that their duration will increase to mirror the increasing duration of the meditation content being listened to by the Intervention group.
46082340|NCT02803658|Behavioral|smoking behavior|
45831079|NCT01412424|Drug|Octreotide capsules|Octreotide was provided in hard gelatin capsules.
45831080|NCT01433250|Drug|AIN457|(10mg/kg i.v.).
45831081|NCT01433250|Drug|AIN457|(10mg/kg i.v.).
45831082|NCT01433172|Biological|Phase I - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase I: Participants receive the GM.CD40L.CCL21 vaccine in a standard 3+3 design."
46082341|NCT02803658|Biological|Sperm collection|
45456186|NCT04771572|Drug|LP-118|novel, oral, selective treatment for hematological malignancies tested through ascending dose levels
46082342|NCT02721186|Drug|MDA with DHAp and SLD Primaquine|
46082343|NCT02803424|Other|Volume controlled ventilation|During anesthesia and surgical procedure, volume-controlled ventilation will be applied with an inspiration:expiration ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg) without ventilatory mode change.
45671552|NCT02819960|Drug|Probio-Tec® BG-VCap-6.5|Each capsule contents: 2 lyophilized probiotic strains, total amount of minimum 2,7x10 9 CFU/cps, ratio LGG®: BB-12® = 50% : 50% (Culture percentages are based on cell concentration and are approximate) Lactobacillus rhamnosus GG® (ATCC 53103) Bifidobacterium animalis subsp. lactis BB-12® (DSM 15954) Additives: maltodextrin, microcrystalline cellulose, silicium dioxide, magnesium stearate
46082344|NCT02803424|Other|Autoflow-volume controlled ventilation|After tracheal intubation, volume-controlled ventilation will be initiated with an I:E ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg). Immediately after CO2 pneumoperitoneum with steep Trendelenburg positioning, Autoflow-volume controlled ventilation will be applied instead of volume-controlled ventilation. Immediately after CO2 desufflation and supine positioning, volume-controlled ventilation will be applied again.
45456187|NCT04770870|Device|Hintermann Series H3 Total Ankle Replacement System|Intervention will include receiving the FDA approved Hintermann Series H3 Total Ankle Replacement System, to include a tibial component, a polyethylene inlay, and a talar component.
45458646|NCT01235533|Dietary Supplement|N-3 polyunsaturated fatty acids|Three capsules per day. Each capsule included 600mg eicosapentanoic acid (20:5n-3), 400 mg of docosahexanoic acid (22:6n-3), tertiary-butylhydroquinone 0.2 mg/g and tocopherols 2 mg/g.
46082345|NCT02726334|Drug|BNC101 Solution for Infusion|Administration: Administered via IV infusion once a week over 60 minutes (1 hour).
46082346|NCT02726334|Drug|BNC101 in combination with FOLFIRI|"BNC101 - Starting dose as determined by Arm A portion (one dose level below recommended Phase 2 dose).~BNC101 Administration: Administered via IV Infusion once a week over 60 minutes (1 hour).~FOLFIRI components:~Irinotecan (IRI) - Starting dose 180 mg/m2 (over 90 minutes on Day 1) Leucovorin (LV) - Starting dose 400 mg/m2 (administered over 120 minutes on Day 1 concurrently with IRI) 5-FU bolus - Starting dose 400 mg/m2 (administered after LV on Day 1, then) 5-FU infusion - Starting dose 2400 mg/m2 (administered over 48 hours starting on Day 1)~FOLFIRI Cycles are repeated every 14 days."
46082347|NCT02803736|Device|acupuncture|Acupuncture involves the insertion of extremely thin needles through skin at strategic points on human body. Many Western practitioners view the acupuncture as a device to stimulate nerves, muscles and connective tissue, and believe that it can increases blood flow.
46082348|NCT02716428|Drug|Faldaprevir|
46082349|NCT02716428|Drug|TD-6450|
46082350|NCT02716428|Drug|Ribavirin|
46082351|NCT02803346|Other|Circulating blood (leukocytes)|mHLA-DR measurement (in vitro)
46082352|NCT05511428|Drug|Daratumumab and Hyaluronidase-fihj|Given SC
45458647|NCT03499366|Diagnostic Test|HFMS, MRC, ACTIVLIM, PedsQl-4.0|Clinical performance tests, quality of life, activity of daily life form.
45458648|NCT04158583|Drug|RO7296682|RO7296682 will be administered as per the schedules specified in the respective arms.
45671553|NCT02819960|Drug|Placebo|Maltodextrin
45671554|NCT04552912|Behavioral|Build Stamina Program|Build StaMINA intervention is a self-management intervention that provides information, motivation, behavioral skills to engage in PA, and ultimately a tailored PA program for adults with AL who are receiving consolidation/maintenance chemotherapy.
45671555|NCT02188459|Drug|Bupropion|A total of 360 participants will be randomly assigned to one of two treatment conditions: Bupropion 300 mg/day (n = 180) or placebo (n = 180). We will use small-block randomization by site (Penn). A PHQ-9 score of 10 or greater will be used to identify major depression and stratify the randomization on it. Study site (Penn) will be the second of the two stratification variables.
45671556|NCT04793282|Behavioral|Telephone Follow-up|Telephone Follow-up within 72 hours to discuss psycho education, discharge planning and clarify any questions they may have.
45671557|NCT04759183|Other|Survey Administration|Ancillary studies
46082353|NCT05511428|Other|Questionnaire Administration|Ancillary studies
45671558|NCT04759183|Procedure|Virtual Reality Game|"Participate in VR Game Angry Birds"
45671559|NCT04759183|Procedure|Virtual Reality Meditation|"Participate in VR Meditation TRIPP"
45456188|NCT04757233|Behavioral|GlucoType|GlucoType is an mobile Health intervention for facilitating self-management in T2DM built for iPhone and Android smartphones. GlucoType includes a custom-built interface for low-burden capture of diet and blood glucose (BG) levels and relies on a commercial activity tracker, FitBit, for capture of sleep and physical activity. It then applies computational phenotyping techniques to identify patterns of associations between daily activities and changes in BG levels. GlucoType uses an expert system developed by our research team to translate identified phenotypes into automatically-generated personalized behavioral goals for improving glycemic control formulated in natural language.
45671560|NCT02743364|Other|Laboratory Biomarker Analysis|Correlative studies
45671561|NCT02743364|Other|Placebo Administration|Given PO
45831083|NCT01433172|Biological|Phase II - GM.CD40L cells Vaccinations|Patients randomized to Arm A will receive vaccinations on 3 occasions, at 2 week intervals. 7.5 X 10^6 irradiated H1944 tumor cells, 7.5 X 10^6 irradiated H2122 cells, and containing 15 X 10^6 GM.CD40L cells (1.1 mL) will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2 weeks after vaccine 3. If patients show no sign of disease progression, patients will then be vaccinated at 4-week intervals.
46082354|NCT05511428|Other|Quality-of-Life Assessment|Ancillary studies
46082355|NCT05511428|Other|Interview|Ancillary studies
45671562|NCT02743364|Other|Quality-of-Life Assessment|Ancillary studies
46082356|NCT00931463|Drug|raltegravir|400 mg raltegravir tablet taken every 12 hours
45671563|NCT02743364|Other|Questionnaire Administration|Ancillary studies
45671564|NCT02743364|Drug|Simvastatin|Given PO
45671565|NCT04192136|Dietary Supplement|Nicotinamide Riboside|"Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."
45671566|NCT04192136|Dietary Supplement|Placebo|The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule).
46082357|NCT00931463|Drug|2N(t)RTI|2N(t)RTIs as prescribed
46082358|NCT00931463|Drug|Ritonavir-boosted lopinavir|2 heat-stable tablets of ritonavir-boosted lopinavir taken every 12 hours
45456189|NCT04749771|Behavioral|Filming Interactions to Nurture Development|FIND is a brief video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction collected in the home.
45671567|NCT04192136|Other|Exercise Intervention|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands.~On aerobic training days, subjects will be given instruction on a recumbent Catrike trainer, titrated such that they spend 20 minutes at their target heart rate as determined by baseline Exercise Stress Test (EST) (60-80% of their heart rate at peak VO2) and as measured by their wearable device.~On resistance training days, subjects will be given instructions to complete circuits of resistance exercises. Resistance training intensity (as determined by graded resistance bands) will be maintained at 60% of pre-training maximal voluntary contraction for each muscle group."
45831084|NCT01433172|Biological|Phase II - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase II: Participants are randomized to one of the 2 arms (ratio 1:1): GM.CD40L versus GM.CD40L.CCL21. Patients in Arm B will receive vaccines at the same dose and schedule as described for patients in Arm A. In addition, their vaccine will include H1944 cells expressing CCL21. Note for patients on Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period."
45831085|NCT01432938|Biological|dulaglutide|Administered subcutaneously
45831086|NCT01432938|Drug|Warfarin|Administered orally
45831087|NCT03025230|Other|Dry needling and electric stimulation|Dry needling technique and the application of electric stimulation of levator scapulae PG
45831088|NCT03025230|Other|Dry needling|Treatment of PG with a filiform needle in levator scapulae muscle
45831089|NCT01392300|Drug|IncobotulinumtoxinA (400 Units)|Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection
45831090|NCT01392300|Drug|Placebo Comparator|Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
45831091|NCT04767204|Behavioral|peer co-delivered vocational rehabilitation service|The services provided by the trained peers in the work training or problem-solving group, which integrates into a supported employment services
45831092|NCT01432626|Drug|I-123 radiolabeled metaiodobenzylguanidine cardiac imaging|All subjects will receive an intravenous injection of 10 mCi (370 MBq) of 123I-mIBG. A ±10% tolerance of the nominal dose will be allowed, thus yielding an acceptable dose range of 9 to 11 mCi (333 to 407 MBq). The investigational medicinal product will be administered in a volume of 5 mL (diluted using 0.9% sodium chloride as needed) and injected over 1 to 2 minutes. The patient will have planar and SPECT imaging performed after the dose is administered. This dosing and imaging procedure will be performed during the acute phase and after the patient has recovered cardiac function, approximately 6 weeks later. This means that each study subject will receive a total of 2 doses of I123-mIBG at 2 different time points.
45831093|NCT02985294|Other|Multiple Excitability Measures of peripheral nerves|The technique of threshold tracking can be used to obtain several measures of peripheral nerve excitability (Multiple Excitability Measures or MEM), such as refractoriness, supernormality, strength-duration time constant and 'threshold electrotonus' (i.e. the changes in threshold produced by long-lasting depolarizing or hyperpolarizing current pulses). Each of these measurements depends on membrane potential and on other biophysical properties of the axons. Many of these excitability parameters are very constant among different subjects, while other, such as the current/threshold parameters and the super/sub-excitability parameters, appear to be characteristic of an individual
45831094|NCT03025776|Behavioral|Reaching|sitting reaching under various task conditions (size, speed, location)
46082359|NCT02694432|Behavioral|GOALS|16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support.
45671568|NCT02214121|Drug|Ticagrelor Dose 1a + Dose 2a|Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week ticagrelor repeated dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
45458649|NCT04089085|Behavioral|STRONGer Together|STRONGer (Successes/Strengths, Triggers, Remember your medications, Ongoing communication, Never give up!, Gratitude) Together is an asthma educational and cognitive behavioral skills intervention for children between 8 - 12 years of age. The intervention is implemented in small groups in 30-minute sessions.
45831095|NCT03025776|Behavioral|Kinematic collection while reaching|sitting reaching under various task conditions (size, speed, location), told how many & which hand to use, kinematic data collected
45831096|NCT01391832|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|For the sham rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the sham mode so that all conditions are similar to the active delivery mode except that transcranial magnetic stimulation is not administered to the scalp and does not down modulate the right frontal lobe.
45831097|NCT01391832|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a 12 session evidenced based, trauma-focused treatment for PTSD. CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the combat related trauma.
45831098|NCT01391832|Device|Repetitive Transcranial Magnet Stimulation (rTMS)|For the active rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the active mode. After motor threshold determination, the stimulator coil is positioned over the dorsolateral prefrontal cortex - DLPFC (Brodmann Area 9/46). The right frontal rTMS will safely, reversibly, and temporarily down modulate the right frontal lobe. The conducting coil is placed over the scalp while electrical current pulses pass through the coil. This alternating current turned on and off rapidly produces magnetic pulses (1.5-2.0 Tesla strength) that last for 100 - 300 microseconds. The time-varying magnetic pulses induce an electrical field that will result in current flow in neural tissue, thereby activating or deactivating cortex subjacent to the coil.
45831099|NCT01410474|Biological|Meningococcal ACWY conjugate vaccine|All subjects received a single dose of Meningococcal ACWY conjugate vaccine and had blood draw at day 1 and day 29.
45831100|NCT04037592|Device|Active standardized iTBS-DMPFC|Participants in the standardized dosage(600 pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
45831101|NCT04037592|Device|Active high-dosage iTBS-DMPFC|Participants in the standardized dosage(1800pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
45831102|NCT04037592|Device|Sham standardized iTBS-DMPFC or high-dosage iTBS-DMPFC|Half of the patients in the sham group received 3-week the same standardized iTBS parameter stimulation (standardized sham-iTBS), and the other half received the same high dosage iTBS parameter stimulation using a sham coil (high dosage sham-rTMS), which also improved the blinding process
45831103|NCT01391130|Drug|LY2510924|Administered subcutaneously
45831104|NCT01391130|Drug|Sunitinib|Administered orally
45831105|NCT04046094|Drug|Ascorbic Acid|Ascorbic Acid Intravenous
45831106|NCT01410240|Procedure|Standard of Care|Conventional hemostatic techniques, such as cautery and manual compression, will be used.
45831107|NCT01410240|Drug|FLOSEAL Hemostatic Matrix + Standard of care|"FLOSEAL will be applied topically to areas of the knee where bleeding is observed (e.g. cut bone surfaces, subcutaneous tissue, posterior joint capsule, synovial tissue, medial and lateral gutters, branches of the genicular vessels, and suprapatellar pouch) and will occur intraoperatively. Sufficient amounts of FLOSEAL will be applied quickly using the provided applicators, followed by immediate approximation with a damp gauze, lap pad or sponge for approximately 2 minutes.~+ Standard of care: conventional hemostatic techniques, such as cautery and manual compression, will be used"
45831108|NCT01409928|Device|LAP-BAND (Allergan, Inc.)|Laparoscopic placement of adjustable gastric banding system for the treatment of severe obesity.
45671569|NCT02214121|Drug|Ticagrelor Dose 1b + Dose 2b|Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week ticagrelor repeted dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
45671570|NCT01681186|Drug|LY2940680 Capsule(s) (Reference)|Administered orally as a capsule(s)
45458650|NCT02319616|Drug|Clobetasol 0.05% ointment|Blinded, daily application to one arm for a period of fourteen (14) days
45458651|NCT02319616|Drug|Placebo|Blinded, daily application to one arm for a period of fourteen (14) days
45458652|NCT01142167|Procedure|Standard Colonoscopy|Standard colonoscopy will be used during colonoscopy
45671571|NCT01681186|Drug|LY2940680 Tablet (Test)|Administered orally as a tablet
45671572|NCT01681186|Drug|Lansoprazole|Administered orally as a capsule
45671573|NCT01681186|Drug|Placebo Capsule(s)|Administered orally as a capsule(s)
45671574|NCT03597464|Drug|Voclosporin|Calcineurin inhibitor, oral, 23.7 mg twice daily (BID)
45671575|NCT03597464|Drug|Placebo Oral Capsule|Voclosporin placebo, oral, 3 capsules twice daily (BID)
45671576|NCT01695772|Drug|5-FU based doublet chemotherapy|Standard 5-FU based doublet chemotherapy. Protocol did not specify any particular chemotherapy regimen. The choice of 5-FU based doublet chemotherapy was as per standard of practice and the dosage of 5-FU based doublet chemotherapy was as per product labels.
45671577|NCT01695772|Drug|bevacizumab|5 mg/kg every 2 weeks, up to 12 cycles pre- and postoperatively
45671578|NCT02159521|Device|EkoSonic® Endovascular System|
45671579|NCT02159521|Biological|Alteplase|Recombinant tissue plasminogen activator
45976358|NCT04476823|Other|Activity|The questionnaire had requested information on the biosafety organization, impact of the COVID-19 crisis on the clinical and molecular pathology and the biobanking activity in thoracic pathology, on the research activity associated with the COVID-19, and on the educational and training organization. It requested the different needs planned by the different laboratories following the COVID-19 crisis and finally the consequence of this latter on the health and virological status of the staff members.
45976359|NCT00415259|Device|Laterally wedged shoe insoles|Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
45976360|NCT00415259|Device|Control insole group|Flat control insoles worn inside the shoes daily for 12 months
45976361|NCT00270621|Behavioral|FHP Night time ENuresis Intervention|Urine alarm/evidence-based psychological Intervention
45671580|NCT01636934|Drug|Minocycline|100 mg by mouth two times a day (200 mg/day) every day for 7 weeks, starting on the first week of chemoradiation therapy.
45671581|NCT01636934|Other|Placebo|1 capsule by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy.
45671582|NCT01636934|Behavioral|Questionnaires|Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
45671583|NCT01712854|Drug|Budesonide|budesonide 80 mcg
45671584|NCT01712854|Drug|Symbicort|A combination of budesonide and long acting beta agonist: Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg
45671585|NCT04552522|Other|shrimp allergy with intend to eat shrimp|shrimp allergy with intend to eat shrimp and treat with oral immunotherapy
45671586|NCT01693120|Device|Medtronic Phased RF Ablation System|Phased RF ablation
45671587|NCT02986594|Drug|Aspirin|
45671588|NCT02986594|Drug|Heparin|
45671589|NCT02159365|Drug|Elotuzumab|
45671590|NCT02159365|Drug|Lenalidomide|
45671591|NCT02159365|Drug|Dexamethasone|
45671592|NCT01712074|Drug|PF-05212377 (SAM-760)|30 mg QD of PF-05212377 (SAM-760)
45671593|NCT01712074|Other|Placebo|Placebo QD
45671594|NCT04124692|Device|Sculptra Aesthetic new dilution|Treatment of cheek wrinkles
45976362|NCT01600300|Device|Tesmac|Subjects were treated twice daily for five consecutive days, followed by two days untreated, and then treated twice daily for five more consecutive days.
45976363|NCT01600300|Device|Sham Tesmac device|Treatment with inactivated Tesmac device on the same schedule as the group treated with the active Tesmac device.
45976364|NCT01600339|Drug|CABAZITAXEL|The patients are planned to receive cabazitaxel at a starting dose of 25 mg/m(2) intravenously over 1 h, following premedication as accepted with cabazitaxel. Treatment cycles are every 3 weeks. All patients will receive primary GCSF support.
45976365|NCT00256022|Drug|Lactobacillus Probiotic|
45976366|NCT00256022|Other|Lactose Powder|
45976367|NCT00270660|Behavioral|biopsy, audiometry, ET function test, ear swab culture, DNE|
45976368|NCT01600456|Behavioral|Prolonged exposure (PE)|PE will include 10 weekly sessions of individual cognitive behavioral therapy.
46082360|NCT02694432|Behavioral|Minding GOALS|16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support, coupled with a mind-body-behavior program to further enhance improvements in blood pressure.
46082361|NCT03974594|Drug|Trifluridine and Tipiracil Tablets|Trifluridine and Tipiracil Tablets given 20mg orally once under fasting or postprandial conditions per cycle
46082362|NCT03974594|Drug|TAS-102|TAS-102 given 20mg orally once under fasting or postprandial conditions per cycle
45671595|NCT02072200|Drug|Lodotra®|Single arm will be received below oral 10mg tablet daily and maximum 10mg/d depending on the clinical symptoms and the patient's response
45671596|NCT04767724|Device|Extracorporeal shock wave|Participants received 3 ESWT sessions once per week for 3 consecutive weeks or a single injection of one mL (40 mg) of betamethasone into the region surrounding the median nerve.
45671597|NCT01692730|Behavioral|Enhanced Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and some combination of novel interactive and social network features, including a variety of better-practice features recommended recent literature, and technologically advanced proactive features (e-mails, SMS texting, and social networking).
45671598|NCT01692730|Behavioral|Basic Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and with minimal interactive web-based features.
45671599|NCT01691794|Drug|Atazanavir|
45671600|NCT01691794|Drug|Ritonavir|
45671601|NCT04547686|Behavioral|Smoke-Free Homes Intervention|The adapted smoke-free homes intervention consists of five components, three interactive mailings and two coaching calls, focused on creating home and vehicle(s) smoking bans among smokers. The intervention is based on principles of Social Cognitive Theory and the Transtheoretical Model's stages of change. The rationale underlying the intervention is that creation of additional smoke-free environments will reduce situational and environmental cues to smoke, reduce opportunities and places to smoke, increase self-efficacy for quitting and increase motivation to quit. The intervention uses persuasion, role modeling, behavioral contracting and goal setting to move smokers through behavioral capability, outcome expectations and self-efficacy for strict smoke-free rules, creation of and compliance/enforcement with smoke-free rules, reduced cigarettes smoked per day, increased motivation to quit, increased quit attempts, and successful cessation.
45671602|NCT04547686|Behavioral|Control|The quitline is a phone number that people can call that offers free smoking cessation counseling to all Georgia residents by the state of Georgia.
45671603|NCT01710514|Drug|FE 999913 vaginal tablet|
45831109|NCT04055220|Drug|Treatment by Regorafenib|"Treatment for 13 cycles (12 months) maximum.~During each cycle, patient will take once a day, during 21 days, followed by 7 days without treatment :~3 tablets daily, corresponding to a total of 120 mg of Regorafenib (3 weeks out of 4 weeks) in patients ≥ 16 years old and patients < 16 years old with BSA ≥ 1.70m²;~2 tablets daily corresponding to a total of 80 mg of Regorafenib (3 weeks out of 4 weeks) in patients < 16 years old with 1.30m² ≤ BSA < 1.70m²;"
45831110|NCT04055220|Drug|Treatment by Placebo|"Treatment for 13 cycles (12 months) maximum.~During each cycle, patient will take once a day, during 21 days, followed by 7 days without placebo treatment :~3 placebo tablets (3 weeks out of 4 weeks) in patients ≥ 16 years old and patients < 16 years old with BSA ≥ 1.70m²;~2 placebo tablets (3 weeks out of 4 weeks) in patients < 16 years old with 1.30m² ≤ BSA < 1.70m²;"
45831111|NCT04037124|Procedure|Cervical procedure|simple hysterectomy, radical hysterectomy or fertility sparing surgery
45831112|NCT01431534|Drug|Ridaforolimus|Oral administration of 10 mg enteric-coated tablets at doses of 22 mg/m^2, 28 mg/m^2, or 33 mg/m^2 based on body surface area (BSA), once daily for 5 consecutive days each week in consecutive 28-day cycles.
45458653|NCT01142167|Procedure|Ultra-thin colonoscopy|Ultra-thin colonoscope will be used during colonoscopy
46082363|NCT02694276|Behavioral|Internet-based cognitive behavior therapy|The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that fruitlessly aim to prevent triggering of AF episodes or to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
45976369|NCT01600456|Other|PE plus Sertraline|PE plus sertraline will include 10 weeks of prolonged exposure therapy plus sertraline. The sertraline dose will be up to 200 mg daily for 10 weeks. There will also be frequent meetings with study psychiatrist. PE will be provided 1x weekly for 10 weeks.
45976370|NCT00289809|Drug|combination of TLC D-99 and Ifosfamide|"TLC D-99: 40 mg/m2 Day 1 every 3 weeks;~Ifosfamide: 3000 mg/m2 Day 1, 2, 3 every 3 weeks"
46082364|NCT03964688|Drug|Vitamin C|vitamin C intravenous during hospitalization, after oral, total 6 weeks.
46082365|NCT03964688|Drug|Placebos|placebo intravenous during hospitalization, after oral, total 6 weeks
46082366|NCT02726100|Behavioral|SMARTHealth Diabetes|SMARTHealth Diabetes is an interactive mobile health platform to promote improved self-management for people with T2DM.
46082367|NCT00610337|Drug|Cethrin® (BA-210)|Intraoperative epidural administration during spinal decompression surgery
45671604|NCT01592344|Device|StimRouter - active stimulation|"The stimulation program settings for this arm are as follows:~Stim Settings~Waveform: Symmetric or Asymmetric~Phase Duration: 100-250 µsec~Pulse Rate: 50-100 Hz~Intensity: 0-30mA Time Settings~Constant Stim: On~Total Time: 6 hour"
45671605|NCT01592344|Device|StimRouter - Control|"The stimulation program settings for this arm are as follows:~Stim Settings~Waveform: Symmetric or Asymmetric~Phase Duration: 200 µsec~Pulse Rate: 1 Hz~Intensity: 0 mA Time Settings~Constant Stim: On~Total Time: 6 hour"
45976371|NCT00256100|Drug|Fondaparinux Sodium|The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
45671606|NCT01636778|Drug|SB-497115-GR|TPO receptor agonist to increase platelet count
45976372|NCT01600534|Behavioral|lifestyle counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet-based program or self-directed educational program.
45976373|NCT00289926|Drug|dehydroepiandrosterone|dehydroepiandrosterone capsules 50.0 mg /capsule DHEA 248.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule
45831113|NCT04053582|Behavioral|AMT|The session will be done on an individual basis. AMT group will receive neurofeedback training from the PCC while focusing on the physical sensations of the breath. The session will last one hour, including 3 neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with neurofeedback (70s).
46082368|NCT00610337|Procedure|placebo|Spinal decompression surgery without administration of Cethrin® BA-210
46082369|NCT02803268|Drug|MT-8554 low dose|
46082370|NCT02803268|Drug|MT-8554 middle dose|
46082371|NCT02803268|Drug|MT-8554 high dose|
45976374|NCT00289926|Drug|placebo|Placebo capsules of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule manufactured to mimic the active DHEA capsule
45976375|NCT01609192|Drug|Hydrea® (hydroxyurea )|treatment by hydroxyurea (20-30 mg/kg/day) for 6 months
45976376|NCT01609270|Device|CardioRoot graft|prospective single arm multi-center study to evaluate CardioRoot grafts implanted in a thoracic position.
46082372|NCT02803268|Drug|Placebo|
46082373|NCT02721264|Biological|Fecal Microbiota Transplant|
46082374|NCT02721264|Other|Standard Medical Treatment|
46082375|NCT00929201|Drug|Sitagliptin phosphate/metformin hydrochloride FDC|Single dose sitagliptin/metformin 50/500 mg FDC tablet after consumption of a high-fat meal in one of two treatment periods.
46082376|NCT00929201|Drug|Sitagliptin phosphate|Single dose sitagliptin 50 mg tablet after consumption of a high-fat meal in one of two treatment periods.
45671607|NCT02159053|Biological|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
45671608|NCT02159053|Biological|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in 1:1:1 ratio
45671609|NCT02159053|Biological|Placebo|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
45671610|NCT02158975|Drug|MLN9708|
45671611|NCT02661464|Biological|Ad26.ZEBOV|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to Ad26.ZEBOV vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
46082377|NCT00929201|Drug|Metformin hydrochloride|Single dose metformin 500 mg tablet after consumption of a high-fat meal in one of two treatment periods.
46082378|NCT02795702|Device|tDCS|Transcranial direct current stimulation
46082379|NCT02795702|Behavioral|training|Cognitive training
46082380|NCT02720796|Other|PDX drug sensitivity testing|Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
46082381|NCT02800772|Dietary Supplement|acetic acid|
46082382|NCT02800772|Dietary Supplement|saline|
45671612|NCT02661464|Biological|MVA-BN-Filo|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to MVA-BN-Filo vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
45671613|NCT02158663|Device|Repetitive Transcranial Magnetic Stimulation|TMS Device
45671614|NCT04804982|Other|Questionnaire|The participants will have to fill in a questionnaire about their knowledge and their attitude regarding auditory risk.
45671615|NCT04804124|Behavioral|Regularized Sleep Schedule|Participants may maintain a self-selected 8-hour per night sleep schedule as an optional intervention. Participants from any of the three groups may complete the intervention.
45671616|NCT02158039|Drug|Ethanol|EUS-guided lavage of a pancreatic cystic neoplasm with ethanol solution. Ethanol was diluted to 80% using normal saline.
45976377|NCT00256139|Drug|Raptiva|
45976378|NCT00270699|Biological|rDEN4delta30-200,201|Live attenuated dengue 4 vaccine (one of three doses)
45976379|NCT00270699|Biological|Placebo|Placebo for rDEN4delta30-200,201
45976380|NCT01609387|Dietary Supplement|Fit For me|
45976381|NCT01609387|Dietary Supplement|Davitamon|
45671617|NCT02158039|Drug|Lidocaine|The final solution contained 1% lidocaine except in subjects allergic to local anesthetics.
45671618|NCT02593994|Device|Onyx Drug Eluting Stent group|
45671619|NCT04754581|Other|Maximal ATP Production (ATPmax)|ATPmax will be measured in order to determine in vivo mitochondrial capacity. The magnetic resonance scans to measure mitochondrial energetics will also be performed.
45671620|NCT04754581|Other|Exercise Testing (VO2max)|Aerobic fitness level will be assessed while participant pedals on a stationary bicycle/walk on a treadmill. The volume of oxygen intake and carbon dioxide (CO2) production will be measured.
45671621|NCT04754581|Procedure|Muscle Biopsy|Sample muscle cells from the left leg Vastus Lateralis (thigh) muscle.
45671622|NCT04754581|Procedure|Adipose Tissue Biopsy|Sample fat tissue from the abdomen.
45671623|NCT04754581|Other|Hyperinsulinemic euglycemic clamp|Measurement of insulin sensitivity.
45671624|NCT04754581|Other|PET imaging|After an overnight fast, an intravenous catheter will be placed in each arm (one with arterial line for PET infusion, and the other for infusion of insulin, glucose, and 6,6 D2 glucose tracer. FDG-glucose will be injected followed by 90-minute PET scanning of the thigh.
45831114|NCT04053582|Behavioral|Sham|The session will be done on an individual basis. Sham group will receive artificial neurofeedback while focusing on the physical sensations of the breath. The session will last one hour, including 3 sham neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with artificial neurofeedback (70s).
45831115|NCT01409382|Behavioral|Daily brisk walking plus a carbohydrate-restricted diet|Daily brisk walking at moderate speed (4 km/h) for at least 40 minutes per day, 7 days a week. Patients will be recommended to avoid high-glycemic index meals (such as snacks, candies, fiber-free juices and sugar-sweetened beverages), and to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting when they decided to get pregnant and continuing until delivery. Recommendations will be emphasised at every appointment. Antidepressants will not be discontinued in both groups, but patients on paroxetine and sertraline, will be switched to fluoxetine.
45831116|NCT01408914|Drug|Higher-Dose Rifampin|The intervention phase of this trial will last 8 weeks. During that time, subjects will receive the following companion drugs: isoniazid (INH, 5 mg/kg/day), ethambutol (EMB, 20 mg/kg/day), and pyrazinamide (PZA, 25 mg/kg/day), pyridoxine (50 mg), the standard doses used in treatment. Subjects will also be randomized to receive one of the following weight-based doses of the study drug, rifampin (RIF): 10 mg/kg/day (standard dose, control), 15 mg/kg/day (intervention 1), 20 mg/kg/day (intervention 2). All patients will receive at least standard dose of RIF, the efficacy of which in multidrug-treatment for TB is well established. Placebo will be used to control only the additional RIF capsules provided in the intervention arms.
45671625|NCT05261282|Behavioral|Mindful Hand Hygiene|Physicians and nurses randomized to the intervention arm will receive mindfulness education and tools to prompt mindfulness during hand hygiene.
45671626|NCT03563222|Drug|Smoflipid|"The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy."
45456190|NCT04749771|Behavioral|The Healthy Toddler Program|HTP, the active control intervention, consists of weekly sessions alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction.
45456191|NCT04749368|Drug|BRII-835 (VIR-2218)|BRII-835 (VIR-2218) will be given by subcutaneous injection
45456192|NCT04749368|Biological|BRII-179 (VBI-2601) with IFN-α|BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection
45456193|NCT04749368|Biological|BRII-179 (VBI-2601)|BRII-179 (VBI-2601) will be administered by intramuscular injection
45831117|NCT04034706|Other|DEXA|DEXA Scans will be performed to measure body fat and estimate muscle mass using a General Electric Lunar iDXA whole-body scanner.
45831118|NCT04034706|Other|Magnetic Resonance (MR) Assessment of the Abdomen|Include measures to assess liver lipid content and stiffness and perform volumetric fat quantitation.
45456194|NCT04747847|Drug|Atorvastatin and anakinra|Anakinra up to 8 mg/kg/day and atorvastatin at 0.75 mg/kg/day in children with acute KD at least 1 year old with CAA
45456195|NCT04740398|Drug|CBP-1008|CBP-1008 for injection; IV infusion; Infusion for 90 minutes
45456196|NCT04739696|Behavioral|PEPRR|Briefly presented in the following order, sessions will include: 1) Overview and Introduction to Stress Management 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with work and caregiver stress, 5) Strategies for maintaining energy and stamina with caregiver and work demands, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs to employers and your loved ones, and 8) Getting the support they need including work accommodations and/or legal protections (e.g., Family Medical Leave Act, Americans with Disabilities Act)
45831119|NCT04034706|Other|MR assessment of Whole Body Fat|Volumetric measurement of fat, muscle and bone
45831120|NCT04034706|Procedure|Adipose tissue biopsy|0.5 cm incision of the upper-outer right vastus lateralis, and either a 3-4mm Mercedes Liposuction needle, or a 4-6 mm Bergstrom needle will be inserted to aspirate approximately 7 grams of adipose tissue.
45831121|NCT04034706|Other|Oral glucose tolerance test|Glucose tolerance will be assessed with a 75 g oral glucose tolerance test (OGTT). Subjects will be studied after an overnight fast.
45976382|NCT01609426|Genetic|DNA chip dedicated to the pharmacogenetic of steroids|direct DNA extraction from peripheral blood cells
45976383|NCT00256178|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
45456197|NCT04739696|Behavioral|Pep-Pal|Pep-Pal program consisted of 11 sessions: 1) Introduction to stress management, 2) Stress and the mind body connection, 3) How thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty, 7) Managing changing relationships and communicating needs, 8) Getting the support they need; 9) Employment related challenges and resources for working caregivers; 10) Employment session one; 11) Employment session two
45456198|NCT04732923|Other|Assigned intervention - procedure|"This study is defined in 3 stages :~STEP 1 : during the cardiac rehabilitation program over 4 weeks 6 minute walk test, questionnaires~STEP 2 : monitoring at 6 months after cardiac rehabilitation program Nurse interview, 6 minute walk test, questionnaires~STEP 3 : monitoring at one year after cardiac rehabilitation program Nurse interview, 6 minute walk test, questionnaires"
45458654|NCT01142245|Drug|Oral esomeprazole|• Oral Esomeprazole 40mg on Day 1, 2 and Day 3 q12h
45976384|NCT00256178|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
45671627|NCT03563222|Drug|Intralipid, 20%|"The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy."
45976385|NCT00256178|Drug|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
46082383|NCT04260815|Device|Transcranial direct-current stimulation (tDCS)|Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. Application of tDCS has been found to improve language production in healthy and brain-injured speakers.
45456199|NCT04725708|Procedure|procedure: cerebral oxygenation intervention|During the surgery, cerebral oxygenation will be followed and intervention will be made to pH, PaO2, PaCO2, mean arterial pressure, hematocrit when necessary. In addition perfusion flow was maintained at or close to between 2.2-2.5 L/min/m2 . Perfusion pressure was adjusted using a phenylephrine infusion to maintain a mean arterial pressure of 50 to 70 mm Hg.
45456200|NCT04708288|Device|ARCHIMEDES Biodegradable Biliary and Pancreatic Stent|Pts that will receive ARCHIMEDES Biodegradable Biliary and Pancreatic Stent
45976386|NCT00270738|Procedure|Indirect training of the PFMs via transversus abdominis|Individual visit: twice a month for 4 months. Exercise regimen: diaphragmatic breathing, tonic activation, muscle strengthening, functional expiratory patterns, and impact activities.
45976387|NCT00270738|Procedure|pelvic floor muscle training|Individual visit: twice a month for 4 months. Exercise: intensive pelvic floor muscle training
45976388|NCT00270738|Procedure|home exercise|PFM exercise at home: at least six high-intensity (near-maximum) contractions 3 times per day at home, with an aim at holding each muscle contraction for 10 seconds, with at least a 10-second rest between contractions.
45458655|NCT01142245|Drug|Intravenous Esomeprazole|"Esomeprazole IV 80mg loading bolus~Esomeprazole intravenous infusion 8mg/hr for 72 hours"
45458656|NCT02319772|Drug|BCX4430|
45671628|NCT05239364|Procedure|Catheter ablation|Catheter-based ablation of arrhythmias using radiofrequency.
45671629|NCT04812392|Device|Continuous Glucose Monitoring System|Subjects will wear a continuous glucose monitoring system for 3 days during the 3 day reduced physical activity phase.
45671630|NCT04803734|Drug|Albuterol Sulfate inhalation aerosol 108mcg per actuation|MDI, 2 puffs, single dose, fasting
45671631|NCT04803734|Drug|Proair HFA (albuterol sulfate) Inhalation Aerosol 90 mcg per actuation|MDI, 2 puffs, single dose, fasting
45458657|NCT02319772|Drug|Placebo|
45671632|NCT04802408|Combination Product|Shampoo and saline|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with saline solution
45671633|NCT04802408|Combination Product|Saline and Listerine|Nasal washes with buffered saline solution and oropharyngeal gargles with Listerine Antiseptic® solution
45671634|NCT04802408|Combination Product|Shampoo and Listerine|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with Listerine Antiseptic® solution
45671635|NCT04802408|Combination Product|Saline and Saline|Nasal washes with buffered saline solution and oropharyngeal gargles with saline solution
45671636|NCT02490800|Drug|Oral daily administration of BAL101553|oral administration
45671637|NCT01635764|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
45671638|NCT05628428|Other|Exercise to strengthen neck area.|An exercise protocol will be carried out through educational videos. There will be a total of four videos which will pose exercises for two weeks each. These exercises will be done twice a week. A reminder will be sent by email on the days that they must be carried out.
45671639|NCT05628428|Other|Information|Information will be provided on neck pain and how exercise is able to help prevent it.
45671640|NCT05609162|Procedure|neurosurgical resection|neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT), EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide
45671641|NCT05578430|Drug|Cadonilimab|10mg/kg by intravenous infusions every 3 weeks
45671642|NCT05578430|Procedure|TACE|TACE will be performed per institutional standard of care.
45671643|NCT05578430|Procedure|Surgery|Surgery will be performed per institutional standard of care.
45671644|NCT03492164|Drug|[18F]FluorThanatrace ([18F]FTT)|1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one also known as [18F]FluorThanatrace or [18F]FTT is a positron emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo inhibition of the PARP-1 nuclear enzyme with positron emission tomography (PET/CT).
45671645|NCT03485924|Diagnostic Test|EUS-FNA with ROSE|EUS-FNA with ROSE vs EUS-FNB without ROSE
45671646|NCT03485924|Diagnostic Test|EUS-FNB without ROSE|EUS-FNA with ROSE vs EUS-FNB without ROSE
46082384|NCT02773212|Drug|d-amphetamine|Participants in this group will receive 60 mg of d-amphetamine daily for 4 weeks. There will be a 1 week run up dosing and a 1 week run-down medication period.
45671647|NCT03432260|Drug|DUR-928 30 mg|Lowest dose of 3 dose escalation arms.
46082385|NCT02773212|Behavioral|Contingency management|Contingency management is an established cocaine use disorder treatment in which individuals receive monetary rewards for abstinence.
46082386|NCT02773212|Drug|Placebo (for d-amphetamine)|60 mg of riboflavin and cornstarch as needed.
45671648|NCT03432260|Drug|DUR-928 90 mg|Middle dose of 3 dose escalation arms.
46082387|NCT05506280|Procedure|blood prolactin levels|The extraction technique was performed by venipuncture in 110 veins located in the antecubital area with a 21G butterfly nut with a Vacutainer Safety 111 Lok@ adapter, a 2.5x45cm latex venous compressor and a tube with separating gel 112 (yellow cap)
45671649|NCT03432260|Drug|DUR-928 150 mg|Highest dose of 3 dose escalation arms.
45671650|NCT04790162|Behavioral|Heartfulness Meditation|Heartfulness meditation with a trainer provided virtually
46082388|NCT00610415|Procedure|tumor biopsy|
46082389|NCT05494268|Drug|Carbohydrate|Preoperative Carbohydrate Loading Drink
45976389|NCT01609504|Procedure|ELRR BY TEM|The surgical technique of ELRR was as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT
46082390|NCT03956810|Other|On-demand transportation|On-demand scheduling via telephone, web portal, or the broker's mobile application.
46082391|NCT03956810|Other|Usual transportation|Usual transportation scheduling via call-center.
45671651|NCT03397628|Other|FIFA 11 for health|
45671652|NCT03370718|Drug|Cabozantinib|Given PO
45671653|NCT03370718|Other|Pharmacogenomic Study|Correlative studies
45671654|NCT03370718|Other|Pharmacokinetic Study|Correlative studies
45671655|NCT05474456|Other|SNAGs|Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
45671656|NCT05474456|Other|Manipulation|Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
45976390|NCT01609504|Procedure|LTME|LAPAROSCOPIC TOTAL MESORECTAL EXCISION INCLUDING MESORECTAL (ACCORDING TO HEALD CRITERIA)
46082392|NCT02720640|Device|Implant 'on' vs implant 'off'|Single group assignment
46082393|NCT00610493|Drug|Bevacizumab|5 mg/kg By Vein Over 90 Minutes on Day 1 of Each 21 Day Cycle
45976391|NCT01609621|Device|Retrograde tibiopedal arterial access|Retrograde, percutaneous arterial access of vessels at or below the tibioperoneal trunk, using a 21 gage needle or micropuncture introducer set, to facilitate crossing and treatment (e.g., angioplasty, stenting, atherectomy) of occlusive arterial lesions in the lower limb.
45458658|NCT02319850|Radiation|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
45671657|NCT03342014|Device|Ultrasound|3DPD and UAD acquisitions (10 min)
45458659|NCT01235767|Other|Food|Animal-source food (ASF) supplement rich in iron, zinc, vitamin A, and vitamin B12 taken week-days at mid-morning separate from other food. Length of intervention is either from pre-pregnancy (time of registration to marry) to term or from 16 weeks gestation to term.
45976392|NCT02488408|Drug|Bemcentinib|
45976393|NCT02488408|Drug|Cytarabine|
45671658|NCT03342014|Biological|Blood sample collection|A blood sampling (20 mL) is collected for biomarker analysis (PAPP-A and PlGF) and biological collection.
45831122|NCT04044846|Behavioral|Physical activity program for homebound older adults faciliated by Personal Support Workers|The intervention is an evidence- informed, theory-driven mobility intervention for community-dwelling OAs who are moderately and severely frail according to the clinical frailty scale (Rockwood et al., 2005). The intervention, entitled Promoting Movement in OAs (ProMO), will be implementable with frail OAs in partnership with any care provider in the home. Investigators will focus the study on the two main providers of care- personal support workers (PSWs) and family caregivers. OAs, PSWs, and caregivers will co-create ProMO with us. ProMO will be distinct from existing home-based exercise programs (Johnson et al., 2003) (Giangregorio et al., 2018) because it will optimize natural opportunities for mobilization during care (e.g., bathing and dressing) and will be embedded in facilitated activities of daily living.
45671659|NCT03341078|Drug|Ibudilast|Ibudilast capsules will be orally ingested twice daily for 6 weeks.
45671660|NCT03341078|Drug|Placebo Oral Tablet|Placebo capsules will be orally ingested twice daily for 6 weeks.
45671661|NCT05228444|Behavioral|CircadianCare|enhancing circadian rhythmicity through an assessment of the patient's specific circadian features/needs and an ad hoc, personalized light-dark, meal and activity schedule to cover the whole of the inpatient stay.
45671662|NCT02407028|Drug|Hyperbaric oxygen (1.5 ATA, no NBH)|HBO at 1.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
45831123|NCT04044222|Biological|Sintilimab|IV
45671663|NCT02407028|Drug|Hyperbaric oxygen (2.0 ATA, no NBH)|HBO at 2.0 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
45831124|NCT04044222|Drug|Carboplatin|IV
45831125|NCT04044222|Drug|Etoposide|IV
46082394|NCT00610493|Drug|Temsirolimus|5 mg By Vein Over 30-60 Minutes on Days 1, 8, 15 of Each 21 Day Cycle
46082395|NCT00610493|Procedure|Additional Blood Drawn|2 teaspoons each time: 4xDay Cycle 1 after start of first infusion; at Day 8 of Cycle 1; at Day 15 of Cycle 1; and at end of Cycle 1.
45671664|NCT02407028|Drug|Hyperbaric oxygen (2.5 ATA, no NBH)|HBO at 2.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
45671665|NCT02407028|Drug|Hyperbaric oxygen (1.5 ATA + NBH)|HBO at 1.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
45831126|NCT04044222|Drug|Ifosfamide|IV
45831127|NCT04044222|Drug|Placebo|IV
45831128|NCT04044222|Drug|Carboplatin|IV
45831129|NCT04044222|Drug|Etoposide|IV
45831130|NCT04044222|Drug|Ifosfamide|IV
45831131|NCT01431144|Procedure|connective tissue autograft|A connective tissue autograft is harvested from the palate and grafted at the site of implant placement on the facial surface.
46082396|NCT00610493|Procedure|Biopsy|First tumor biopsy during screening visit and Second at the end of Cycle 1
46082397|NCT00610493|Procedure|DCE-MRI Scan|DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) scan during screening visit, at 24-48 hours after the start of Cycle 1, and at the end of Cycle 1
46082398|NCT02803112|Procedure|Emergent craniotomy for traumatic brain injury|Emergent craniotomy for traumatic brain injury (either for removal of an epidural hematoma, subdural hematoma, intraparenchymal hematoma or decompressive craniectomy).
46082399|NCT02716272|Drug|Nivolumab|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks
45456201|NCT04699253|Device|SanaCoach Heart failure|Patients will be using the SanaCoach heart failure for at least 6 months during the study period. SanaCoach heart failure is a web application that will be guiding the patient through a regular, systematic assessment of patient's health and wellbeing as well as regular education sessions. The assessment frequency ranges from daily to monthly, based on the settings provided by the health care provider. Furthermore, it provides a repository for patient's care plan to give insight into the course and treatment of the disorder and offers the possibility to contact the health care provider through the web application.
45671666|NCT02407028|Drug|Hyperbaric oxygen (2.0 ATA + NBH)|HBO at 2.0 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
45671667|NCT02407028|Drug|Hyperbaric oxygen (2.5 ATA + NBH)|HBO at 2.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
45671668|NCT02407028|Drug|Normobaric Hyperoxia (NBH)|100% fraction of inspired oxygen (FiO2) for 4.5 hours twice a day for five days or until patient following commands or brain dead
45831132|NCT01431144|Procedure|connective tissue allograft|An acellular dermal matrix allograft (Alloderm, BioHorizons, Inc, Birmingham, AL, USA) is grafted at the site of implant placement on the facial surface.
45831133|NCT01430754|Drug|tasimelteon|20 mg tasimelteon capsules, daily
45831134|NCT01430754|Drug|Placebo|Placebo capsules, daily
45831135|NCT01390428|Drug|Grazoprevir|Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days
45831136|NCT01430130|Device|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
45976394|NCT02488408|Drug|Decitabine|
45671669|NCT02407028|Other|Usual Care|Will be treated with usual and customary care for severe traumatic brain injury
45976395|NCT00270777|Drug|adrenaline, promethazine, hydrocortisone|
45976396|NCT00256256|Drug|glucagon-like-peptide-1|Dose: 1.2pmol/kg/min for 6 hours
45671670|NCT01634360|Drug|Perampanel|1mg once daily for two weeks, followed by 2mg once daily for 2 weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
45671671|NCT04810598|Drug|Venetoclax|Oral Tablet
45671672|NCT04627064|Drug|Abemaciclib|Tablet taken orally
45671673|NCT04627064|Drug|MK-6482|Tablet taken orally
45671674|NCT02198690|Other|Mammography decision aid|
45671675|NCT02198690|Other|Home safety pamphlet|
45671676|NCT04570280|Other|Aerobic Exercises|Aerobic exercises with treadmill will be applied 3 times a week for 12 weeks.
45671677|NCT04570280|Other|Resistive Exercises|Resistive exercises with sandbag will be applied 3 times a week for 12 weeks.
45671678|NCT04570280|Other|Range of Motion Exercises|Range of Motion Exercises will be applied 3 times a week for 12 weeks.
45671679|NCT04788758|Other|Educational Intervention|Receive G8 screening tool administration training
45671680|NCT04788758|Other|Screening Questionnaire Administration|Complete G8 screening tool
46082400|NCT02716272|Drug|Nivolumab + Ipilimumab|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks
45671681|NCT04788758|Other|Referral|Receive referral
45671682|NCT04788758|Other|Questionnaire Administration|Ancillary studies
45671683|NCT04511078|Drug|Panitumumab-IRDye800|single dose infusion of panitumumab-IRDye800CW
45671684|NCT04782986|Diagnostic Test|Pan-intestinal capsule endoscopy|Patients with iron deficiency anemia or overt GI bleeding with non-diagnostic upper GI endoscopy will be submitted to same-day pan-intestinal capsule endoscopy using PillCam Crohn's Capsule (Medtronic) followed by conventional colonoscopy under propofol sedation
45671685|NCT02158052|Drug|Tacrolimus|Tacrolimus starting on Day -1
45671686|NCT02158052|Drug|Equine Anti-thymocyte globulin|20 mg/kg IV on Days -3, -1, +1, +3
45671687|NCT02158052|Procedure|Kidney transplant from a related donor|On Day 0 the renal transplant is performed according to standard surgical techniques.
45831137|NCT04052256|Diagnostic Test|Coronary computed tomography angiography|Computational fluid dynamic model information derived from CT
45671688|NCT02158052|Drug|Bone marrow transplant from a related donor|Donor bone marrow (> 2 x 10e8 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed.
45831138|NCT01407354|Device|Lokomat treadmill training|Lokomat treadmill training: 12 wks, 3x/wk, 45 mins@session
45671689|NCT02158052|Radiation|Total body irradiation 400 centigray (200 cGy X 2)|On transplant day -1
45671690|NCT01635218|Drug|Individualized homeopathic treatment|A single dose of the individualized homeopathic remedy in C-potency was dissolved in a 60 ml bottle of 30% alcohol-distilled water:15 drops PO two times per day following agitation plus fluoxetine-dummy loaded PO daily during 6 weeks. The homeopathic remedy could be changed at every follow-up (week 4) according to patient´s symptoms.
45831139|NCT01407354|Other|Aquatic exercise therapy|Aquatic exercise training: 12 wks, 3x/wk, 45 mins@session
45458660|NCT03499210|Device|ReWalk ReStore device|The ReWalk ReStore device is intended to be used to perform ambulatory functions in rehabilitation institutions under the supervision of a trained therapist for people with hemiplegia/hemiparesis due to stroke.
45458661|NCT03499132|Procedure|anesthesia|Different anesthetic procedures
45671691|NCT01635218|Drug|Fluoxetine|20 mg per day PO during 6 weeks plus individualized homeopathic dummy-loaded (60 bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic dummy-loaded was repeated at week 4.
45831140|NCT01407276|Drug|Omarigliptin|Single oral dose of 3 mg (3 x 1-mg capsules)
45831141|NCT01390272|Behavioral|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
45831142|NCT01390272|Behavioral|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
45831143|NCT01390272|Behavioral|Medium/Level 1 resource intensity|Monthly tailored RN delivered calls + home BP monitoring.
45671692|NCT01635218|Drug|Placebo|Fluoxetine placebo (capsules containing sucrose microgranules) PO daily during 6 weeks plus individualized homeopathic placebo (60 ml bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic placebo was repeated at week 4.
45671693|NCT05193500|Behavioral|Addressed Speech|New words are introduced directly to the child by an experimenter.
45831144|NCT01390272|Behavioral|High/Level 2 resource intensity|Pharmacist delivered telephone behavioral self-management support + Home BP monitoring with feedback to pharmacist + Algorithmic medication changes directed by pharmacist (with physician backup).
45831145|NCT01429584|Drug|interscalene nerve block with 0.25% bupivacaine|interscalene nerve block performed with 20 ml of 0.25% bupivacaine
45671694|NCT05193500|Behavioral|Overheard Speech|New words are introduced with the child as a bystander rather directly taught.
45671695|NCT05189600|Device|Mechnical Insufflation:Exsufflation|Cough Augmentation device
45831146|NCT01429584|Drug|interscalene block with 0.125% bupivacaine|interscalene block with 20 ml of 0.125% bupivacaine
45671696|NCT05351684|Drug|Dolutegravir 50 MG|already included in arm/group descriptions.
45831147|NCT01406652|Procedure|Two-stage bursectomy|Debridement, drainage, and secondary closure of septic bursitis during two surgical interventions
45831148|NCT01406574|Drug|OPB-31121|Oral administration, 400 mg/day or 600 mg once daily after breakfast during the treatment period (1 month)
46082401|NCT05484518|Behavioral|Method of Levels Therapy|"Method of Levels (MOL) is a therapy that is the direct application of Perceptual Control Theory (PCT) (Powers, 2008) which proposes that psychological distress results from a person's reduced control over important life goals. A conflict between two or more goals can occur outside of a person's awareness (Carey, Mansell & Tai, 2014) and the achievement of one goal leaves the other incompatible goal unachievable, leading to distress (Mansell, 2012). MOL therapy aims to help people develop awareness of important goals and conflicts between them, to increase their chances of developing potential solutions. Conflict can be resolved through reorganisation; a mechanism through which random change is continuously generated until control is restored (Tai, 2016).~Therapy uses a questioning style to help clients bring their attention to their problems long enough for them to restore control. In practice clients choose the number, frequency and duration of therapy sessions"
46082402|NCT00926003|Behavioral|Full Computerized cognitive training|8 weeks of 3 times weekly intervention for 60 min per session with the full titrating version of Captain's Log program (3 games for attention, 3 games for visual spatial working memory, 3 games for reasoning/planning
46082403|NCT00926003|Behavioral|Limited computerized cognitive training|Locked Captain's Log CCRT that rotates randomly among simplest level of computer cognitive games training. 8 weeks of 3 times weekly intervention for 60 min per session with the non-titrating version of Captain's Log program (3 games for attention, 3 games for visual spatial working memory, 3 games for reasoning/planning).
46082404|NCT05505032|Drug|Oxygen|Determination of FiO2 threshold value as an indicator of hyperoxemia in anesthesia stages.
46082405|NCT05505032|Device|Masimo Root Radical 7|We use it to measure the oxygen reserve index (ORi).
45671697|NCT02049866|Drug|Denosumab|Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months
45671698|NCT02042300|Device|XIENCE Xpedition/Alpine/Sierra|
45671699|NCT05185856|Procedure|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
45831149|NCT01406574|Drug|OPB-31121 phase2|Oral administration, recommended dose from Phase1 once daily after breakfast during the treatment period (6 months)
45831150|NCT01405950|Drug|Zanaflex Capsules|0.025 mg/kg
45831151|NCT01405950|Drug|Zanaflex Capsules|0.05 mg/kg
45831152|NCT01405950|Drug|Zanaflex Capsules|0.075 mg/kg
45831153|NCT01405950|Drug|Zanaflex Capsules|0.1 mg/kg
45671700|NCT05185856|Procedure|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
45671701|NCT04421222|Drug|EPI-7386 (QD)|Once daily oral dose of EPI-7386
45671702|NCT04421222|Drug|EPI-7386 (BID)|Twice daily oral dose of EPI-7386
45671703|NCT04787744|Procedure|PET-directed Local Therapy using Surgery|Surgery will be used to treat metastases.
45458338|NCT02324374|Device|Endocystoscopy During Colonoscopy|Colonoscopies will be performed as per routine practice. When a colorectal lesion is found that would normally require biopsy or polypectomy; the lesion will be evaluated by chromoendoscopy with the application of 10 ml 1% methylene blue followed by the inspection with the endocytoscope at both magnifications (450X and 1100X). The endocytoscopic images of the abnormal area will be recorded prior to biopsy or removal of the suspicious tissue. For each lesion, a matching endocytoscopy image from normal adjacent tissue will also be obtained, at least 5cm away from the suspect site, but within the same segment of intestine (e.g. ascending colon). No biopsy will be obtained from normal tissue, and this will be assumed to be normal. Following image acquisition, the lesion will be biopsied or removed as per standard clinical care.
45671704|NCT04787744|Radiation|PET-directed Local Therapy using Radiation|"Radiation therapy will be used to treat metastases.~Radiation options include:~Stereotactic body radiotherapy (SBRT) using 1-10 fractions~Conventionally fractionated radiotherapy using elective nodal radiotherapy and a simultaneous integrated boost to involved nodes~The selection of the form of metastasis-directed radiotherapy for each metastasis will be determined using shared decision-making between the treating physician and the Veteran."
45671705|NCT04787744|Other|Salvage Local Therapy for locally recurrent disease|For Veterans who have a local recurrence in addition to oligorecurrent metastatic lesions, they will undergo salvage local therapy using brachytherapy, SBRT, surgery, cryotherapy or HIFU. The selection of modality of salvage local therapy will be determined using shared decision-making between the treating physician and Veteran.
45671706|NCT04787744|Drug|Goserelin, Histrelin, Leuprolide & Triptorelin|Androgen deprivation therapy (ADT) using an LHRH agonist
45671707|NCT04787744|Drug|ADT + Nilutamide, Flutamide, & Bicalutamide|ADT adding anti-androgen therapy to an LHRH agonist
45671708|NCT04787744|Drug|Degarelix & Relugolix|ADT using an LHRH Antagonist.
45671709|NCT04787744|Drug|ADT + Docetaxel +/- prednisone|Enhanced SST using chemohormonal therapy
45671710|NCT04787744|Drug|ADT + Abiraterone + Prednisone|Enhanced SST using Abiraterone + Prednisone
45671711|NCT04787744|Drug|ADT + Abiraterone + Methylprednisolone|Enhanced SST using Abiraterone + Methylprednisolone
45671712|NCT04787744|Drug|ADT + Apalutamide|Enhanced SST using ADT + Apalutamide
45671713|NCT04787744|Drug|ADT + Enzalutamide|Enhanced SST using ADT + Enzalutamide
45671714|NCT04307186|Drug|BAY1747846|Solution for IV injection, single dose
45671715|NCT04307186|Drug|Gadobutrol (Gadovist/Gadavist)|Solution for IV injection, single dose
45671716|NCT04297826|Behavioral|Harvest for Health|Please see previous description
45671717|NCT04274894|Drug|AndroGel 1.62%|AndroGel 1.62% was packaged in pump bottles with quantities sufficient to accommodate study design and could have been dose adjusted between a minimum of 20.25 mg of T (1 pump actuation) and a maximum of 81.0 mg of testosterone (4 pump actuations). For the first study drug administration at the Day 1 Visit, and also at Week 2, Week 4, Week 16 ambulatory blood pressure monitoring (ABPM,) and End of Treatment Visits, participants applied the study drug while on site so that the site staff could observe the proper administration of study drug. If participants forgot to apply their AndroGel 1.62% dose at their regularly scheduled dosing time, they were to take the next dose at the next dosing time.
45671718|NCT04786964|Drug|Cosibelimab|IV infusion
45671719|NCT04786964|Drug|Cisplatin|IV infusion
45671720|NCT04786964|Drug|Carboplatin|IV infusion
45671721|NCT04786964|Drug|Pemetrexed|IV infusion
45671722|NCT04786964|Dietary Supplement|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
45671723|NCT04786964|Dietary Supplement|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
45671724|NCT04786964|Drug|Dexamethasone 4mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
45671725|NCT05177120|Diagnostic Test|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
45671726|NCT05177120|Other|Short form-36|Standardized questionnaire to investigate the quality of life in patients
45671727|NCT05177120|Other|Pittsburgh Sleep Quality Index|Standardized questionnaire to investigate the sleep quality and disturbance
45671728|NCT05177120|Other|Health assessment questionnaire|Standardized questionnaire used to detect the presence of disability
45671729|NCT05177120|Other|Hospital anxiety and depression scale|Standardized questionnaire to investigate the depression and anxiety
45458662|NCT03918577|Other|Caloric Vestibular Stimulation|Cold water creates a convection current in the semicircular canal of the vestibular apparatus, leading to brief (<3 min) and typically well tolerated sense of rotational movement. Similar stimulation is routinely used in standard vestibular diagnostic testing.
45671730|NCT05177120|Diagnostic Test|Fibromyalgia rapid screening tool|Standardized questionnaire to determine the presence of fibromyalgia
45671731|NCT05177120|Other|Familial Mediterranean Fever Quality of life scale|Standardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients
45671732|NCT04269200|Drug|olaparib|Olaparib tablets
45671733|NCT04269200|Biological|durvalumab|Durvalumab by intravenous infusion
45671734|NCT04269200|Drug|durvalumab placebo|Matching placebo for intravenous infusion
45671735|NCT04269200|Drug|olaparib placebo|Placebo tablets to match olaparib
45671736|NCT04269200|Drug|Carboplatin|Standard of care chemotherapy
45671737|NCT04269200|Drug|Paclitaxel|Standard of care chemotherapy
45671738|NCT02213263|Biological|PF-05280586|PF-05280586 (rituximab-Pfizer) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
45831154|NCT01405560|Drug|Vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 24 weeks
45671739|NCT02213263|Biological|MabThera®|MabThera® (rituximab-EU) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
45671740|NCT04781036|Drug|4%Chlorhexidine|4%Chlorhexidine was given to participants with foot odor for 1 month.
45671741|NCT05190068|Drug|HMPL-760|HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles.
45671742|NCT04216784|Drug|Furosemide Injection|Patient will receive furosemide intravenously
45671743|NCT04216784|Drug|Albumin Human|Patient will receive albumin (25%) 12.5 gm intravenously
45671744|NCT05173298|Drug|atezolizumab plus bevacizumab|1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
45671745|NCT05168930|Drug|Venetoclax|C4-15
45671746|NCT05168930|Drug|Zanubrutinib|C1-15
45671747|NCT04785092|Procedure|All Autologous Cartilage Regeneration|All patients will undergo firstly to a blood sampling and then to the arthroscopic debridement of the damage cartilage and subsequently will be harvested the surrounding healthy cartilage The harvested and healthy cartilage will shredded directly in situ with a shaver. This cartilage will then mixed with the patient's own Platelet Concentrate and may be injected directly into the cartilage defect. The Platelet Concentrate stimulates the healing of the cartilage most effectively. At the same time, the Platelet Concentrate will also used to produce autologous fibrin glue, which can be used to fix the applied cartilage chip / Platelet Concentrate product quickly and safely in the damaged cartilage.
45831155|NCT01405560|Biological|peg-IFN|Open-label peg-IFN alfa-2b at 1.5 μg/kg once per week, administered subcutaneously (SC) for 24 weeks
45831156|NCT01405560|Drug|ribavirin|Capsules containing 200 mg RBV, orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 weeks
45831157|NCT01428882|Drug|Midazolam|Midazolam (5 mg/5 mL) 2 mg before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
45831158|NCT01428882|Drug|Propofol|Placebo (normal saline 2 ml) before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
45831159|NCT01428258|Other|GMP Diet/GMP Medical Foods|The intervention consists of a low-phenylalanine (Phe) diet in combination with medical foods made with the peptide GMP supplemented with limiting indispensable amino acids, as provided by Cambrooke Therapeutics, LLC. The diet is formulated to replace the protein equivalents provided by AA medical foods with GMP medical foods, keeping other dietary components constant. The GMP dietary treatment period consists of all subjects following the GMP diet for 3-wks at home. The GMP diet intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
45831160|NCT01428258|Other|AA Diet/AA Medical Foods|The intervention consists of a low-Phe diet in combination with commercial AA medical foods as consumed in each subject's usual diet. A total of 15 different commercial AA medical foods were consumed by subjects in the study. The diet is formulated to provide each subject with their typical daily intake of protein equivalents from AA medical foods. The AA dietary treatment period consists of all subjects following the AA diet for 3-wks at home. The AA Diet comparator intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
45831161|NCT01389882|Procedure|neurally adjusted ventilatory assist (NAVA) ventilator mode|Neurally adjusted ventilatory assist (NAVA) utilizes the electrical activity of the diaphragm (EAdi) to trigger and cycle-off breaths, and therefore presents a means of bypassing the ventilator circuit, and the inherent delays with pneumatic triggering. This is a processed signal, which is not artificially influenced by changes in muscle length, chest wall configuration, and/or lung volume. It represents the summation of muscle motor unit recruitment and/or firing rate, and correlates with phrenic nerve activity. In this mode, the amount of support pressure is coupled with the magnitude of the EAdi. The proportion of support pressure to EAdi (NAVA level) is adjustable.
45671748|NCT02211313|Device|Randomization to size 6 French soft vs. size 6 French hydrophobic ureteral stent.|Subjects will be randomized to one of two study arms according to ureteral stent size and degree of firmness (size 6Fr, soft vs. size 6Fr, hydrophobic) with allocation ratio of 1:1.
45671749|NCT05170724|Drug|Remibrutinib|Remibrutinib should be taken in accordance with the recommendations in the treatment plan.
45671750|NCT04801472|Other|Optimisation of dental implant sites protection from irradiation|"Optimal treatment plan validation after two dosimetric computer-tomography scans (with or without radiological guide) and visualisation of virtual dental implants on scanner images.~Evaluation of toxicity, quality of life and dental implant survival rate"
45831162|NCT01442688|Drug|Amoxicillin + MMX placebo|MMX placebo administered once a day (QD) orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX placebo on Day 4.
45831163|NCT01442688|Drug|Amoxicillin + MMX mesalazine/mesalamine|MMX mesalazine/mesalamine (4.8 g) administered QD orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX mesalazine/mesalamine (4.8 g) on Day 4.
45831164|NCT01466166|Biological|Pegloticase|Pegloticase 8 mg intravenous every 2 weeks
45671751|NCT01975064|Drug|Propofol|Propofol will be infused individually for a sufficient level of anesthesia during the entire surgical procedure.
45671752|NCT01975064|Drug|Sevoflurane|Sevoflurane will be administered by vaporizer individually for a sufficient level of anesthesia during the entire surgical procedure.
45671753|NCT05135702|Dietary Supplement|Sodium Propionate|a 500 mg powder dietary supplement that can be mixed into food or drinks. It will be taken twice daily for four weeks.
45671754|NCT05135702|Dietary Supplement|Placebo|a color, size, calorie, and consistency-matched powder dietary supplement that can be mixed into food or drinks. It will be taken twice daily for four weeks.
45831165|NCT03814200|Drug|Saline|Single i.v. infusion of 100 mL saline 0.9% for 30 min
45831166|NCT03814200|Drug|ACT-246475|Single s.c. dose of 4 mg ACT-246475 in the thigh under fasting conditions
45831167|NCT03814200|Drug|Rifampicin|Single i.v. infusion of 600 mg rifampicin (100 mL) for 30 min
45831168|NCT04031742|Biological|IBI306|Administered by subcutaneous injection
45831169|NCT04031742|Biological|IBI306|Administered by subcutaneous injection
45831170|NCT01426854|Drug|Nepafenac Ophthalmic Suspension, 0.1%|Topical ocular administration
45831171|NCT01426854|Other|Nepafenac Vehicle Ophthalmic Solution|Inactive ingredients used as placebo; topical ocular administration
45831172|NCT04051320|Drug|Leuprolide Acetate 3.75 MG/ML|3.75 mg/month leuprolide acetate intramuscular injection
45831173|NCT04051320|Drug|Estradiol 2 Mg tablet|2 mg estradiol tablet
45671755|NCT05134454|Diagnostic Test|Extended ECG investigation|At least two long-term ambulatory ECG recordings with a duration of 14 days each using Philips ePatch (https://www.myheartmonitor.com/device/epatch/). The two recordings should be 2-4 months apart.
45831174|NCT04051320|Drug|Micronized progesterone|200 mg micronized progesterone tablets
45671756|NCT05051696|Drug|H101|Intra-tumor injected oncolytic viruses H101 within 5 consecutive days,3 weeks for a cycle (1-4cycles)
45671757|NCT04062266|Drug|Azacitidine|Given SC or IV
45671758|NCT04062266|Drug|Venetoclax|Given PO
45671759|NCT04025138|Other|Neuromuscular tests in isometric mode|"Protocol for neuromuscular tests in isometric mode will be assessed by the composite of these measures :~Voluntary maximum forces plantar flexors and knee extensors~Electrically evoked forces~ElectroMyoGraphic activity (EMG)~Three-Modality Evoked Potentials (TMEPs)"
45671760|NCT04025138|Device|Transcranial Magnetic Stimulation (TMS)|Measure of supraspinal activation level and cortical excitation by Transcranial Magnetic Stimulation (TMS).
45671761|NCT04025138|Other|Neuromuscular fatigue assessment test|Neuromuscular fatigue assessment test in dynamic mode will be assessed by the Force/Velocity Profile (FVP) measure: 2 sprints of 8 seconds on a cycle ergometer.
45671762|NCT04025138|Other|treadmill|2 sessions of treadmill will be realized: 8 and 10 km.h-1 for level running and 7 km.h-1 with 10% slope for graded running.
45831175|NCT04050774|Device|Balance boards|The unstable surface will be created with a balance board consisting of a wooden board mounted on a section of a cylinder, creating an unstable support in the sagittal plane or in the frontal plane. The participants will stand on three balance boards, varying the height of the surface of the board above the point of contact (15, 17 and 19 cm respectively). The radius of the cylinder will kept constant at 24 cm. The standing surface will be 48cm x 48 cm
45831176|NCT01426386|Drug|FE 999049|
45831177|NCT01426386|Drug|Gonal - F|
45831178|NCT01404234|Drug|AZLI|AZLI 75 mg was administered 3 times daily via the investigational nebulizer.
45458663|NCT03499054|Other|Breathing exercises|During hemodialysis, the participants in the exercise group are asked to keep ttheir muscles relaxed, breathe normally through the nose at a rate of 3-8 times per minute with each breath held over 5 seconds in length. At the same time, the particpants are asked to also perform lower leg lifts for about 8 seconds per lift. The exercise is performed for 15-20 minutes, and after resting, blood pressure, oxygen saturation and HRV are measured.
45671763|NCT04025138|Biological|Blood sample|Blood sample will be realized to measure hemorrheologic and hematologic parameters.
45671764|NCT04025138|Biological|Urinary sample|Urinary sample will be realized to measure hemorrheologic and hematologic parameters.
45671765|NCT02210689|Drug|clindamycin phosphate vaginal cream 2%|
45671766|NCT02210689|Other|placebo|vehicle used as placebo
45671767|NCT04780178|Behavioral|Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults with Alzheimer's Disease and Related Dementias|A telephone-based acceptance and commitment therapy for caregivers
45831179|NCT01403610|Drug|TH-302 preoperative|TH-302 single dose at 575 mg/m2 administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
45831180|NCT01403610|Drug|Placebo|Placebo administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
45458664|NCT01142401|Drug|Bortezomib|Given IV
45831181|NCT01403610|Drug|TH-302 (escalating) with bevacizumab 10mg/kg|Combination of 10mg/m2 of bevacizumab with an escalating dose of TH-302 from 240 to 670 mg/m2
45831182|NCT01403064|Biological|ALD518|IV
45831183|NCT01403064|Drug|0.9% saline|IV Infusion
45831184|NCT04408014|Diagnostic Test|Serological test|IgM and IgG for SARS-CoV-2
45831185|NCT04408014|Diagnostic Test|Nasopharyngeal Swab|PCR for SARS-CoV-2
45831186|NCT04408014|Diagnostic Test|Oropharyngeal Swab|PCR for SARS-CoV-2
45831187|NCT01402986|Other|Placebo Q2W|Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
45831188|NCT01402986|Biological|Tralokinumab 300 mg, Q2W|Participants received tralokinumab 300 mg subcutaneous injection Q2W for a total of 26 doses up to 50 weeks.
45831189|NCT01402986|Other|Placebo, Q2/4W|Participants received matching placebo subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
45831190|NCT01402986|Biological|Tralokinumab 300 mg, Q2/4W|Participants received tralokinumab 300 mg subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
45831191|NCT01402908|Drug|PI-88|Lyophilized powder reconstituted to provide 160 mg of PI-88
45831192|NCT01402908|Other|Placebo|Lactose lyophilized powder
45831193|NCT01389258|Device|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
45831194|NCT01389102|Drug|Estradiol transdermal one 90 μL spray|Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
45831195|NCT01389102|Drug|Estradiol transdermal spray, two 90 μL sprays|Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
45831196|NCT01389102|Drug|Estradiol transdermal three 90 μL sprays|Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
45831197|NCT01389102|Drug|Placebo transdermal two 90 μL sprays|Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
45831198|NCT01389102|Drug|Placebo transdermal three 90 μL sprays|Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
45831199|NCT01389102|Drug|Placebo transdermal one 90 μL spray|Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
45831200|NCT01402284|Drug|Carfilzomib|Cycle 1: 20 mg/m(2) intravenous (IV) infusion over 30 minutes on days 1 and 2, then 36 mg/m(2) IV on days 8, 9, 15, and 16 Cycle 2-8: 36mg/ m(2) IV infusion over 30 minutes on days 1, 2, 8, 9, 15, and 16
45831201|NCT01402284|Drug|Lenalidomide|Cycle 1: 25 mg oral days 2-21 of 28-day cycle; Cycle 2 - 8: 25 mg oral days 1-21 of 28-day cycle; After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles; After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
45831202|NCT01402284|Drug|Dexamethasone|Cycle 1: 20 mg oral or IV on days 2, 8, 9, 15, 16, 22, and 23 Cycle 2-4: 20 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23 Cycle 5-8: 10 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23
45831203|NCT01402284|Drug|Lenalidomide|After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles
45831204|NCT01402284|Drug|Lenalidomide|After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
45831205|NCT04030338|Drug|18F-DCFPyL-iPSMA|Participants will be injected intravenously with a bolus of 7-10 mCi of 18F-DCFPyL.
45831206|NCT04030338|Drug|68Ga-HBED-iPSMA|Participants will be injected intravenously with a bolus of 3-8 mCi of 68Ga-HBED-iPSMA
45671768|NCT04779710|Other|Staff Survey|A mixed mode survey design comprising of a self-administered electronic survey with a secondary option of a postal survey. The survey population was Speech and Language Therapy (SLT) Clinical Leads for Acute Stroke in Hyper/Acute Hospital Stroke Units in England and Wales. The sample frame was Routinely Admitting, and Non-Routinely Admitting Acute Stroke Hospital Teams registered on the Sentinel Stroke National Audit Programme (SSNAP) register. One hundred and sixty-six hospital teams were included after exclusions. Survey participants were asked to respond about assessment and management of dysphagia and other clinical processes during the first seven days of a person's admission to hospital following a stroke. Respondents were asked to respond about practice on behalf of the Stroke Unit rather than as an individual practitioner.
45831207|NCT04030338|Diagnostic Test|PET/CT scan|The baseline PSMA PET scan may be performed externally or at MSKCC, but all follow-up imaging must be performed at MSKCC. Approximately 60-90 minutes after intravenous injection of radiotracer, patients will be scanned from the mid-skull to the mid-thigh. Imaging will start with a low-dose CT for attenuation correction, followed by a PET scan. Upon completion of imaging and at the discretion of the investigator, the patient may be asked to void and get back in the scanner for 1 additional image of the pelvis.This additional image allows investigator's to see an unobstructed view of the prostate/prostate bed
45831208|NCT01388790|Drug|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m^2) will be administered intravenously followed by once weekly subsequent intravenous infusion of cetuximab 250 mg/m^2 in each 5-week treatment cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
45831209|NCT01388790|Drug|Cisplatin|Cisplatin 60 mg/m^2 will administered as intravenous infusion on Day 8 of each 5-week cycle maximum up to 8 cycles until disease progression, unacceptable toxicity, or withdrawal of consent
45671769|NCT02209597|Drug|Bupropion XL 300|"Subjects will be studied in 4 phases for a total of approximately 28 weeks:~Phase 1: an approximately 4-week lead-in phase during which participants remain on their existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6 weeks on each of the four bupropion study drugs (brand and 3 generics)."
46082406|NCT02753790|Radiation|Intensity Modulated Radiotherapy|"Whole brain radiation using IMRT: 60 Gy to gross disease (planning treatment volume [PTV] 60) or 45 Gy to gross disease (PTV 45) and 30 Gy to subclinical sites (PTV 30) over 15 fractions.~Patients will be treated Monday through Friday (5 days per week) for 3 weeks. Patients with either a single metastasis greater than 15 cubic centimeters (cm) or total volume of metastases greater than 26 cubic cm will receive the lower dose of 45 Gy to visible brain metastases. 45 Gy may also be prescribed per physician discretion.~Gross disease which has received prior radiosurgery will receive 30 Gy."
46082407|NCT05330741|Other|Designed Physical Therapy Program|The designed physical therapy program include gentle stretching exercises, static muscle contraction, facilitation of trunk control from different positions, balance training from different positions on tilting board, facilitation of righting, protective and equilibrium reactions from different positions, facilitation of standing from different positions, gait training and, climbing stairs up and down.
45671770|NCT04418492|Behavioral|Skills for Adaptive Functioning through Executive training (SAFE; tentative title)|An intervention program to improve adaptive skills and executive functions in young adults with high-functioning autism spectrum disorder was administered weekly for 10 weeks to the participants. The participants also completed pre-, mid- and post-intervention assessments.
45671771|NCT03965468|Drug|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1. Durvalumab is expected to stimulate the patient's antitumour immune response by binding to PD L1 and shifting the balance toward an antitumour response.
45671772|NCT03965468|Drug|Carboplatin|Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
45671773|NCT03965468|Drug|Paclitaxel|A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).
46082408|NCT05330741|Other|Whole-Body Vibration|"The designed physical therapy program (mentioned before)~+ Whole-body vibration (WBV) training, child will be asked to stand with slightly flexed knees (30 degrees of knee flexion), and both feet will be placed at an equal distance from the center of the platform to achieve an equal distribution of body weight over both feet. The device will set to produce a peak-to-peak sinusoidal vibration with an amplitude of 2 mm and a vibration frequency ranged from 25 to 30 Hz. WBV will applied for (30 sec. of WBV, 1 min rest, 10 repetitions), (45 sec. of WBV, 1 min rest, 10 repetitions), (60 sec. of WBV, 1 min rest, 10 repetitions) in the 1st, 2nd. and 3rd. months respectively."
45671774|NCT03965468|Radiation|Stereotactic body radiation therapy (SBRT)|SBRT of all oligo-metastatic lesions
45671775|NCT03965468|Procedure|Surgical resection - definitive local treatment.|Surgical resection of primary tumour for patients with single station, non-bulky tumours.
45671776|NCT03965468|Radiation|Radical radiotherapy - definitive local treatment.|Conventional or moderately hypo-fractionated radiotherapy to the primary tumour for other tumour stages, or in case of medical inoperability.
45831210|NCT01388790|Drug|S-1|S-1, a combination of tegafur, gimeracil, and oteracil will be administered intravenously at a dose of 40 to 60 mg/m^2 orally twice daily for first three consecutive weeks of 5-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
45976397|NCT01580176|Device|continuous GlucoseMonitor|The blood glucose and blood lactate levels will be taken continuously by the Continuous GlucoseMonitor and will be recorded twelve times.
45458665|NCT01142401|Drug|Fulvestrant|Given IM
45458666|NCT01142401|Other|Laboratory Biomarker Analysis|Correlative studies
45458667|NCT03498976|Procedure|pulsed radiofrequency|Echoguided technic
45976398|NCT01609660|Dietary Supplement|Saccharomyces boulardii|100mg daily for seven days prior to surgery
45671777|NCT03965468|Drug|Tremelimumab|Tremelimumab is a human mAb of the IgG 2 subclass that is directed against CTLA-4 (CD152), a cell surface receptor that is expressed primarily on activated T-cells and acts to inhibit their activation. Tremelimumab completely blocks the interaction of human CTLA-4 with CD80 and CD86, resulting in increased release of cytokines (interleukin-2 and IFN-γ) from human T-cells, peripheral blood mononuclear cells and whole blood.
45671778|NCT01514552|Other|Strawberry gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this strawberry intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
45831211|NCT01388478|Drug|R-pramipexole|R-pramipexole will be taken as a liquid and start at one teaspoon (5 ml) twice a day for a total dose of 100 mg/day. After 4 weeks, the dose will double (two teaspoons twice a day, or a total of 200mg/day). Four weeks later the dose will be increased again to 2 1/2 teaspoons twice a day (total of 300mg/day) where it will remain for the remaining 16 weeks of study treatment. Prior to each increase, participants and their study partners will be interviewed regarding any possible side effects or problems. These findings will be discussed with the physician prior to increasing the study drug dose. The dose will only increase if the participant is not having side effects.
45458668|NCT02319928|Procedure|Colonoscopy|
45671779|NCT01514552|Other|Placebo control gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this a placebo gummy intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
45831212|NCT04029714|Procedure|Active Surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
45831213|NCT01424670|Drug|Delamanid + OBR|The assigned doses of delamanid were administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
45671780|NCT01469156|Drug|ranibizumab 0.5 or 2.0 mg/0.05 cc|ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.
45831214|NCT01424670|Drug|Placebo + OBR|Matching placebo was administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
46082409|NCT05330741|Other|Gravity Force Stimulation|"The designed physical therapy program (mentioned before)~+ Gravity force stimulation child will be asked to maintain his balance on GFS during each of the following positions as a progression (standing and walking on the surface of two beams connecting the two boxes - standing and walking crossly on the surface of one beam connecting the two boxes - standing and walking sideward on the surface of one beam connecting the two boxes - standing and walking on the edge of the two beams - standing and walking on the edge of one beam: most difficult)"
45671781|NCT05008172|Procedure|Splenic Artery Embolization|The decision for proximal or distal (selective) embolization is at the discretion of the Interventional Radiologist. For patients with angiographically evident injury, the choice of embolization site will be left to the discretion of the operator. For patients without angiographically evident injury, proximal splenic embolization will be performed with approved materials (coils or plugs for most patients) within the main splenic artery. The embolization endpoint will be hemostasis in the main splenic artery.
45831215|NCT01424514|Drug|SB-705498|12mg intra nasal
45831216|NCT01424514|Drug|Placebo|Placebo intra nasal
46082410|NCT02802800|Other|Plyometric training|Plyometric exercises
46082411|NCT02720406|Drug|Intravenous ketamine0.5mg/kg|Intravenous ketamine 0.5mg/kg after anesthesia and before surgery.
46082412|NCT02720406|Drug|Nebulized Ketamine 1mg/kg|Nebulized Ketamine 1mg/kg given by nebulizer before anesthesia.
45831217|NCT04028310|Other|Phonological|"Phase 1: intervention without targeted daily training (30 minutes/ week, for 8 weeks)~Phase 2: intervention with targeted daily training~Phonological training (15 minutes/ day, 5 days/week, for 8 weeks)~Visuo-attentional training (15 minutes/ day, 5 days/week, for 8 weeks)~Cross-modal training (15 minutes/ day, 5 days/week, for 8 weeks)~Phase 3: stopping training sessions for 8 weeks"
46082413|NCT02720406|Drug|Nebulized Ketamine 2mg/kg|Nebulized Ketamine 2mg/kg given by nebulizer before anesthesia.
46082414|NCT02720406|Drug|saline placebo|Saline 0.9% given by nebulizer before anesthesia and iv after anesthesia and before surgery.
45671782|NCT04191434|Drug|Flamboyant 125/12|Flamboyant 125/12 capsule
45671783|NCT04191434|Drug|Budesonide/formoterol 200/6|Budesonid/formoterol 200/6 capsule
45671784|NCT04191434|Other|Flamboyant 125/12 Placebo|Flamboyant 125/12 Placebo capsule
45671785|NCT04191434|Other|Budesonide/formoterol 200/6 placebo|Budesonid/formoterol 200/6 Placebo capsule
45671786|NCT03849716|Other|Blood sample|Blood samples obtained for biomarker analyses
45671787|NCT03849716|Other|Cheek swab|Cheek swab obtained for genetic analysis
46082415|NCT05504876|Drug|Midazolam Syrup|Administered Midazolam Syrup 5 mg orally once daily in fed state;
46082416|NCT05504876|Drug|HEC74647PA|Administered HEC74647PA 100 mg orally once daily in fed state;
46082417|NCT05504876|Drug|HEC110114|Administered HEC110114 600 mg orally once daily in fed state;
45671788|NCT03835676|Drug|Treprostinil|"After inclusion and baseline measurements, patients will receive treprostinil in addition to background therapy for 24 months. Follow-up assessment will include:~Clinical, echocardiographic, laboratory assessments will be repeated at 1, 3, 6, 12, 18, and 24 month (or when there is clinical indication)~CMR will be performed at 6 monthly intervals for 2 years.~Peak power output at 6,12, 18 and 24 month~Right-side cardiac catheterization will be performed at 6, 12 , 18 and 24 months (or when there is clinical indication)"
45831218|NCT04028310|Other|Visual-attention|"Phase 1: intervention without targeted daily training (30 minutes/ week, for 8 weeks)~Phase 2: intervention with targeted daily training~Visuo-attentional training (15 minutes/ day, 5 days/week, for 8 weeks)~Phonological training (15 minutes/ day, 5 days/week, for 8 weeks)~Cross-modal training (15 minutes/ day, 5 days/week, for 8 weeks)~Phase 3: stopping training sessions for 8 weeks"
46082418|NCT02725632|Device|CPAP|The patients on CPAP treatment will be followed-up for 1 month.
46082419|NCT04259177|Other|Scale|This test is divided into 3 sections: neurological examination, developmental motor boundary stones and behavioral status, and consists of a total of 37 items. The first part consists of 26 items such as cranial nerve functions, posture, quality, amount of movements, muscle tone, reflex and reactions. The second part evaluates motor development boundary stones consisting of 8 items. The third part refers to the behavioral condition consisting of 3 items. These items can be easily scored. It can be rated as optimal or inadequate. Each item is scored separately (as 0, 1, 2, 3) and the final total score is calculated. The total score ranges from 0-78. The total score shows the global optimal scores.
45456202|NCT04686851|Other|Comprehensive Geriatric Assessment and follow-up|"All patients will receive standardized oncological treatment according to national guidelines. For patients randomized to the intervention arm, a full Comprehensive Geriatric Assessment (CGA) and corresponding interventions on identified health issues will be performed alongside oncologic treatment. The domains are assessed using validated tests based on a Danish version of the Geriatric Core Dataset (G-CODE). The domains are cognition, mood, comorbidity, functional status, physical status, polypharmacy, nutrition, fall risc and social support. The CGA will be performed by the PhD-student (geriatric resident) or a geriatrician together with geriatric nurses at the Department of Geriatric Medicine, OUH. Nutritional status and interventions are assessed by a dietician. A physical therapist will evaluate the physical performance as part of the CGA.~Follow-up on initial treatment plan is scheduled to one month after baseline CGA."
46082420|NCT02802722|Dietary Supplement|Vitamin D3 supplementation|Capsules to be dispensed using an electronic dispenser to allow real time logging of adherence.
46082421|NCT02802722|Biological|Peripheral blood and induced sputum sampling|To attain samples for immunological testing
46082422|NCT02802722|Radiation|Chest computerised tomography (CT) scans|For volumetric quantification of lung abnormalities
46082423|NCT02802722|Other|Symptom questionnaire|Symptom questionnaire for recent symptom history
45456203|NCT04666831|Behavioral|Adapted Motivational Interviewing (AMI) and Cognitive Behavioural Therapy (CBT)|The intervention combines AMI techniques as described by Miller and Rollnick (2013) in the third edition of their Motivational Interviewing book, as well as CBT techniques from the Tele-CBT protocol for bariatric surgery patients by Cassin et al. (2013).
45456204|NCT04665596|Device|Ultrasound treatment|Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacemen
45671789|NCT03762590|Other|Doxy.me genetic education +/- Color Genomics genetic education|"Doxy.me is a HIPAA compliant telemedicine platform that allows clinicians to provide education to remote patients.~Genetic education via Doxy.me will consist of a pre-recorded genetic education video and a live interactive video conferencing session with a GENERATE genetic counselor.~Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website."
45671790|NCT03762590|Other|Color Genomics genetic education|Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website.
45671791|NCT04963400|Diagnostic Test|Analysis of hs-cTnT serum concentration at hospitalization|Analysis of the hs-cTnT serum concentration in the blood drawn at the day of hospitalization
45671792|NCT04963400|Diagnostic Test|Analysis of hs-cTnT serum concentration after discharge|Analysis of the hs-cTnT serum concentration in the blood drawn after discharge (60 days after hospitalization)
45831219|NCT01423812|Drug|Twice-daily Darunavir and ritonavir|Subjects remain on regimens containing Darunavir 600mg plus Ritonavir 100mg twice-daily
46082424|NCT02802722|Other|Placebo|To be dispensed using an electronic dispenser to allow real time logging of adherence.
46082425|NCT02725944|Device|Implantation of ICRM|All patients will be implanted with ICRM in order to detect an occult PAF.
46082426|NCT02802644|Drug|Sitagliptin|Sitagliptin is indicated to control hyperglycemia in type 2 diabetic patients.
46082427|NCT02802644|Drug|Non DPP-4 Inhibitor|This group patients is permitted to take any other oral anti-hyperglycemic agents except sitagliptin.
45456205|NCT04664790|Device|Hyperbaric Oxygen|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
45671793|NCT04192760|Procedure|Stenting|Comparison of two technical approaches in the interventional treatment on de-novo non-left main coronary lesions
45671794|NCT00909740|Drug|MEGF0444A|Intravenous escalating dose
45831220|NCT01423812|Drug|Once-daily Darunavir and ritonavir|Subjects switched from Darunavir 600mg plus Ritonavir 100mg twice-daily at baseline to Darunavir 800mg plus Ritonavir 100mg once-daily for 48 weeks
45831221|NCT01400958|Drug|Nuvigil®|Nuvigil® 150 mg/day x 42 days THEN, No More Drug
45831222|NCT01400958|Drug|Placebo|Placebo x 42 days; THEN, No More Placebo
45831223|NCT01388166|Procedure|Education|Education
45456206|NCT04664790|Behavioral|Cognitive training|Neuropsychologist guided BrainHQ training
46082428|NCT02744976|Drug|Metformin|In order to minimize gastrointestinal discomfort, metformin treatment will be started with a dose of 500 mg p/o once daily, then gradually increased to 2000 mg p/o once daily for 24 months
46082429|NCT02744976|Behavioral|Lifestyle recommendations|Standard lifestyle recommendations
45458669|NCT01235845|Biological|Biological: DC activated CIK combined with DC|"Dendritic cells pulsed With tumor lysate were injected back into the patient intradermally close to a lymph node, DC vaccinations will be given every week for a total of four vaccinations.~DC activated CIK combined with IL-2 were injected intratumorally via an Ommaya reservoir every week for a total of two vaccinations."
45458670|NCT03498898|Other|Chronic use of Beta adrenergic receptor blocker|Chronic use of Beta adrenergic receptor blocker
45671795|NCT04783532|Behavioral|Telehealth Mindfulness Program|Enrolled participants will participate in an individual (one-on-one) Telehealth-delivered (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight sessions lasting 75 minutes each (except the first session which lasts 90 minutes) over a 3-month period.
45671796|NCT04779008|Other|remote ischemic preconditioning （RIPC）|Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
45671797|NCT02188303|Drug|LY2944876|Administered SC
45671798|NCT02188303|Drug|Placebo|Administered SC
45671799|NCT03651128|Biological|bb2121|bb2121
45831224|NCT01400412|Drug|Darunavir|Darunavir was administered orally once a day as two 400 mg tablets with food. When the 800 mg formulation tablet became available, it was substituted for the two 400 mg tablet.
45831225|NCT01400412|Drug|Ritonavir|Ritonavir was administered orally together with darunavir as one 100 mg tablet once daily with food.
45671800|NCT03651128|Drug|Daratumumab|Daratumumab
45671801|NCT03651128|Drug|Pomalidomide|Pomalidomide
45671802|NCT03651128|Drug|Dexamethasone|Dexamethasone
45671803|NCT03651128|Drug|Bortezomib|Bortezomib
45671804|NCT03651128|Drug|Ixazomib|Ixazomib
45831226|NCT01400412|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate was administered orally as one 300 mg tablet once a day.
45831227|NCT01400412|Drug|Emtricitabine|Emtricitabine was administered orally once a day as one 200 mg capsule.
45831228|NCT01400412|Drug|Placebo for Tenofovir disoproxil fumarate|Placebo for tenofovir disoproxil fumarate was administered orally once a day as one tablet.
46082430|NCT00928889|Drug|Nateglinide 120 mg|Nateglinide 120 mg was supplied as tablets.
45458671|NCT03842917|Other|Biological samples|Urine and blood samples
45671805|NCT03651128|Drug|Lenalidomide|Lenalidomide
45671806|NCT03651128|Drug|Carfilzomib|Carfilzomib
45671807|NCT03651128|Drug|Elotuzumab|Elotuzumab
45671808|NCT03597620|Drug|Metaderm|Metaderm cream and spray will be apply to subjects scalp and body.
45671809|NCT00664898|Drug|bortezomib|Escalating intravenous repeating dose
45671810|NCT00664898|Drug|SGN-40|Escalating intravenous repeating dose
45671811|NCT04867382|Behavioral|Online training|This intervention consisted of two different interactive online trainings delivered through an online learning platform at HealthPartners.
45671812|NCT04418336|Procedure|Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique|Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique in sacrococcygeal Pilonidal sinus treatment
45671813|NCT04850300|Procedure|Total knee prosthesis with medial condylar stabilization|Surgery will be done of Total knee prosthesis with medial condylar stabilization
45831229|NCT01400412|Drug|Placebo for Maraviroc|Placebo for maraviroc was administered orally once a day as one tablet.
45831230|NCT01400412|Drug|Maraviroc|Maraviroc was administered orally once a day as one 150 mg tablet.
45831231|NCT01422876|Drug|high dose FDC|once daily
45831232|NCT01422876|Drug|BI 10773 high dose|once daily
45831233|NCT01422876|Drug|high dose FDC placebo|once daily
45831234|NCT01422876|Drug|low dose FDC placebo|once daily
46082431|NCT00928889|Drug|Acarbose 50 mg|Acarbose 50 mg was supplied as tablets.
45831235|NCT01422876|Drug|high dose FDC placebo|once daily
45458672|NCT03842917|Other|Blood pressure measurement|Home blood pressure self-measurement and hospital blood pressure measurement
45671814|NCT04850300|Procedure|Total knee prosthesis with central pivot stabilization|Surgery will be done of Total knee prosthesis with central pivot stabilization
45671815|NCT04827992|Drug|Medical Marijuana|Patients in this group can choose what type, how much, and when to use medical marijuana to use.
45671816|NCT04827992|Behavioral|Prescription Opioid Taper Support (POTS)|Prescription Opioid Taper Support (POTS), a manualized behavioral prescription opioid taper support intervention developed by consultant, will be offered weekly to all participants to support behavioral self-management of pain and structured, voluntary taper of COT dose.
45831236|NCT01422876|Drug|high dose FDC placebo|once daily
45831237|NCT01422876|Drug|low dose FDC placebo|once daily
45831238|NCT01422876|Drug|low dose FDC placebo|once daily
46082432|NCT02803034|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number- SR15-60-Z15-030).
46082433|NCT02725398|Drug|Buscopan|Buscopan is administered by endoscopic nurse in the Buscopan group,and then recording the outcome measures.
45458673|NCT03498820|Device|Analgesia Nociception Index|: Non invasive monitor based on heart rate variability analysis, assessing the parasympathetic nervous activity
45831239|NCT01422876|Drug|high dose BI 10773 placebo|once daily
45831240|NCT01422876|Drug|low dose FDC|once daily
45831241|NCT01422876|Drug|high dose FDC placebo|once daily
45831242|NCT01422876|Drug|BI 10773 low dose|low dose once daily
45671817|NCT04776980|Diagnostic Test|Post Feraheme Infusion MRI|All participants will receive a ferumoxtyol (Feraheme) infusion 20-28 hours prior to a head MRI. In addition, a blood draw for liquid biopsy targeted tissue sampling during surgery and special iron and macrophage staining on the tumor tissue.
45671818|NCT02187055|Drug|Tofacitinib with methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
46082434|NCT02725398|Drug|Scopolamine|Scopolamine is administered by endoscopic nurse in the Scopolamine group,and then recording the outcome measures.
45671819|NCT02187055|Drug|Tofacitinib without methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
45671820|NCT02187055|Biological|Adalimumab with methotrexate|Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months
45671821|NCT00119366|Radiation|iodine I 131 monoclonal antibody BC8|Given IV
45831243|NCT01422876|Drug|high dose BI 10773 placebo|once daily
45831244|NCT01422876|Drug|high dose BI 10773 placebo|once daily
45831245|NCT01422876|Drug|linagliptin|once daily
46082435|NCT02725398|Drug|physiological saline|Physiological saline is administered by endoscopic nurse in the physiological saline group,and then recording the outcome measures.
45671822|NCT00119366|Drug|fludarabine phosphate|Given IV
45671823|NCT00119366|Radiation|total-body irradiation|Undergo TBI
45671824|NCT00119366|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo PBSC transplantation
45671825|NCT00119366|Procedure|peripheral blood stem cell transplantation|Undergo PBSC transplantation
45671826|NCT00119366|Drug|cyclosporine|Given IV or PO
45671827|NCT00119366|Drug|mycophenolate mofetil|Given PO
45671828|NCT00119366|Other|laboratory biomarker analysis|Correlative studies
45671829|NCT05348486|Radiation|Dose escalation|Dose escalation 75,9 - 79,2 Gy in 33 fractions for GTV hypoxic or any hypoxic LN > 2cm
45671830|NCT02246660|Drug|Resveratrol|"The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.~OR~The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative."
45671831|NCT02246660|Drug|Placebo|Placebo will be taken orally for 6 months.
45831246|NCT01422876|Drug|low dose FDC placebo|once daily
45831247|NCT01422876|Drug|linagliptin placebo|once daily
45831248|NCT01422876|Drug|BI 10773 low dose placebo|once daily
45831249|NCT01422876|Drug|linagliptin placebo|once daily
45831250|NCT01422876|Drug|low dose BI 10773 placebo|once daily
45831251|NCT01422876|Drug|linagliptin placebo|once daily
45831252|NCT01422876|Drug|high dose BI 10773 placebo|once daily
45831253|NCT01422876|Drug|BI 10773 low dose placebo|once daily
45831254|NCT01422876|Drug|low dose BI 10773 placebo|once daily
45831255|NCT01422876|Drug|linagliptin placebo|once daily
45831256|NCT01422720|Drug|Eslicarbazepine Acetate|ESL tablets (800 mg) QD
45831257|NCT01387932|Device|HepaSphere/QuadraSphere Microspheres|HepaSphere/QuadraSphere Microspheres loaded with doxorubicin
45831258|NCT01387932|Procedure|PVA, lipiodol, doxorubicin|Conventional TACE procedure using PVA, lipiodol and doxorubicin
45831259|NCT04413786|Drug|oxytocin treatment|intranasal administration of oxytocin (24IU)
45831260|NCT04413786|Drug|placebo treatment|intranasal administration of placebo (24IU)
45831261|NCT01422408|Drug|Fluocinonide Cream|Given topically
45831262|NCT01422408|Procedure|Management of Therapy Complications|Receive fluocinonide cream
45831263|NCT01422408|Other|Questionnaire Administration|Ancillary studies
45831264|NCT01399788|Drug|Myrin P Forte|Tablet containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide, given once daily, single dose
45831265|NCT01399788|Drug|Single drug references|containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide as single agents
45831266|NCT01387542|Drug|Paliperidone extended release (ER)|Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
45831267|NCT01387230|Drug|GSK573719|62.5 mcg
45671832|NCT04750447|Device|XEN 63|The Xen gelatin microstent (Allergan, CA, USA) is a 6mm gelatin tube used in microinvasive glaucoma surgery (MIGS) to create a bleb. A bleb is a fluid filled blister located in the tissue covering the white portion of the eye (the conjunctiva) created after glaucoma surgery. The bleb allows the eye pressure (intraocular pressure - IOP) to be lowered by bypassing the natural pathways by which the fluid called aqueous leaves the eye and redirecting it towards the bleb to be absorbed by other pathways. Amongst the main advantages of this device is the ability to create a bleb without disrupting tissue unlike other methods of glaucoma surgery (e.g., trabeculectomy). This decreases the amount of wound healing and scarring, and potentially limiting bleb failure.
45671833|NCT03475550|Other|Standard of Care|The intervention involves clinician-provided information to patients receiving a new medication as part of their standard medical care. Intervention 1 includes more detailed information compared to Intervention 2.
45671834|NCT03471260|Drug|Azacitidine|Given IV or SC
45671835|NCT03471260|Drug|Ivosidenib|Given PO
45671836|NCT03471260|Drug|Venetoclax|Given PO
45671837|NCT02246582|Device|Enlite 3|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen & arm used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
45671838|NCT02246582|Device|Guardian Mobile App|
45671839|NCT02246582|Device|640G Insulin Pump|
45671840|NCT04741802|Behavioral|TOPS|weight loss program (Take Off Pounds Sensibly, TOPS) for overweight and obese African American breast cancer survivors in the local chapter of a national African American breast cancer support group (Sisters Network Triangle North Carolina, SNTNC).
45831268|NCT01387230|Drug|GSK573719|125mcg
45831269|NCT01387230|Other|Placebo|Placebo
45831270|NCT01387074|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
45831271|NCT01386606|Drug|Androxal (enclomiphene citrate)|"capsule oral~1X a day 6 weeks"
45458674|NCT03498820|Drug|Remifentanil|intravenous short-acting opioid routinely administered during general anesthesia
45671841|NCT02137369|Drug|Selective serotonin re-uptake inhibitor|Escitalopram, 20mg-40mg daily or Sertraline 50-150 mg daily for 12 weeks
45831272|NCT01386606|Drug|Testosterone|"topical gel~1X a day 6 weeks"
45831273|NCT01385748|Drug|Clonidine Lauriad® 50µg|50µg muco-adhesive buccal tablet once day every day up to 8 weeks
45458675|NCT01142479|Drug|Chinese herbal medicine decoction|100 ml /Qd for 6 weeks(42 days)
45458676|NCT05158309|Other|8% Capsaicin patch|Cutaneous pain was induced using a (5x10 cm) 8% topical capsaicin patch (transdermal patch, 'Qutenza', Astellas) on the volar part of the dominant right forearm (5 cm from the wrist) of each participant.
45671842|NCT02137369|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy, standardized, 16 sessions over 12 weeks.
45671843|NCT02137369|Other|Combination treatment (SSRI + CBT)|study participants who do not remit in the first 12 weeks will be offered combination treatment of both treatments for 12 more weeks.
45671844|NCT02155309|Drug|Scopolamine|
45671845|NCT02155309|Drug|Placebo|
45671846|NCT02186821|Drug|Ceritinib|Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally,once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days. There were no breaks between dosing cycles.
45831274|NCT01385748|Drug|Clonidine Lauriad® 100µg|100µg muco-adhesive buccal tablets, once a day, every day up to 8 weeks
45831275|NCT01385748|Drug|Placebo Lauriad®|placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
45831276|NCT01397448|Drug|E3810|E3810 5 mg/day Group: Orally administered E3810 5 mg tablets and E3810 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
45831277|NCT01397448|Drug|E3810|E3810 10 mg Group: Orally administered E3810 5 mg placebo tablets and 10 mg tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
45831278|NCT01397448|Drug|Teprenone|Teprenone 150 mg/day Group: Orally administered E3810 5 mg placebo tablets and 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg capsules three times daily after each meal.
45831279|NCT01385202|Device|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
45671847|NCT01710358|Drug|Adalimumab|Administered SC
45831280|NCT05366010|Device|Oscillation and Lung Expansion (OLE) therapy|Respiratory airway clearance intervention including continuous high-frequency oscillation and continuous positive expiratory pressure
45831281|NCT05365932|Device|Intra auricular device (IAD)|The Intra Auricular Device (IADs) are a pair of inconspicuous, custom fit auricular prosthetic devices.The ear inserts are manufactured using computer-aided design/computer-aided manufacturing (CAD/CAM) technology and are made from a liquid, photo-reactive acrylate (EShell 300), used in hearing aid shells and otoplastics for the last 10 years. They are designed to be placed into the outer third of the ear canals, and they have a small retraction post used to facilitate removal . A red or blue dot, respectively, indicates the right and the left side. The device do not interfere with hearing or speech
45671848|NCT01710358|Drug|Baricitinib|Administered orally
45671849|NCT01710358|Drug|Methotrexate|Administered orally
45671850|NCT01710358|Drug|Adalimumab Placebo|Adalimumab placebo administered SC.
45671851|NCT01710358|Drug|Baricitinib Placebo|Baricitinib placebo administered orally.
45671852|NCT01633112|Drug|fingolimod|capsule
45671853|NCT01633112|Drug|glatiramer acetate|subcutaneous injection
45671854|NCT03455270|Drug|G1T48|oral SERD
45671855|NCT03455270|Drug|Palbociclib|CDK 4/6 Inhibitor
45671856|NCT04776356|Device|QuickFix Small Staple (Arthrex)|The Arthrex QuickFix Small Staple enables the surgeon to perform a wedge osteotomy of the first phalanx (Akin). The device is made of stainless steel and designed with barbed leg tips. The staple sizes are 8 and 10 mm wide with a 1 mm diameter.
45831282|NCT01384734|Drug|BMS-663068 400 mg|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
45831283|NCT01384734|Drug|BMS-663068 800 mg|Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
45831284|NCT01384734|Drug|BMS-663068 600 mg|Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
45831285|NCT01384734|Drug|BMS-663068 1200 mg|Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
45831286|NCT01384734|Drug|Raltegravir 400 mg|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
45831287|NCT01384734|Drug|Tenofovir 300 mg|Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
45831288|NCT01384734|Drug|Ritonavir 100 mg|Tablets, Oral, 100 mg, Once daily, 96 weeks
45831289|NCT01384734|Drug|Atazanavir 300 mg|Capsules, Oral, 300 mg, Once daily, 96 weeks
45831290|NCT01396512|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous
45831291|NCT01396512|Biological|Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)|0.5 mL, Subcutaneous
45831292|NCT01396434|Biological|Prevenar 13|Prevenar 13 vaccine as prescribed by the physician based on approved product indication
45831293|NCT01383954|Drug|Diclofenac Gel|Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
46082436|NCT02802956|Other|Daily Life Promotion Program|Daily Life Promotion Program
46082437|NCT02802956|Other|general rehabilitation treatment|general rehabilitation treatment
46082438|NCT04258865|Drug|CKD-348 F1|QD, PO
46082439|NCT04258865|Drug|CKD-348 F2|QD, PO
46082440|NCT04258865|Drug|CKD-828, D097, D337|QD, PO
45671857|NCT04715750|Drug|[18F]-PI2620|[18F]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of [18F]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose).
45671858|NCT01691482|Drug|Albuterol/salbutamol|Albuterol/salbutamol (daily)
45671859|NCT01691482|Drug|Ipratropium|Ipratropium (daily)
45831294|NCT05365698|Behavioral|Community Health and Nutrition Program|"The Community Health and Nutrition supported by the United States Agency for International Development (USAID) will be implemented by an international NGO, FHI 360. The goal of the Community Health and Nutrition (CHN) program is to improve the nutritional status of pregnant and lactating women (PLW) and children under the age of two years in the target areas of the Hashemite Kingdom of Jordan. The program will fulfill this goal by implementing activities to support improvements in IYCF practices, increase adoption of optimal family planning practices and maternal, infant and young child nutrition (MIYCN) practices, and by improving health care provider support for proper IYCF practices and use of modern contraceptive methods."
45831295|NCT05365464|Drug|Progesterone Pill|Orally active progesterone
45831296|NCT05365464|Drug|hCG|Given by subcutaneous injection
45671860|NCT04776044|Drug|ATR-002|150mg tablets for oral intake
45671861|NCT04776044|Drug|Placebo|matching tablets for oral intake
45671862|NCT02246114|Device|piCO+ Smokerlyzer® monitor|
45671863|NCT02246114|Other|Text messages|
45671864|NCT01710046|Drug|(CP-6890,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
45831297|NCT01383486|Drug|Naproxen sodium ER (BAYH6689)|Naproxen Sodium ER (BAYH6689): oral tablet upon incidence of pain
45831298|NCT01383486|Drug|Advil|Commercially available Advil; oral caplet upon incidence of pain
45671865|NCT01710046|Drug|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
45671866|NCT01710046|Drug|(CP-690,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks
45671867|NCT01710046|Drug|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
45671868|NCT03267758|Dietary Supplement|Goodbelly first|Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This is followed by 6 weeks of placebo.
45671869|NCT03267758|Dietary Supplement|Placebo first|Consumption of 1 serving of probiotic placebo daily for 6 weeks. of 1 serving of Goodbelly probiotic daily for 6 weeks.
45831299|NCT04407780|Other|No interventions are planned|Non applicable
45671870|NCT04633616|Other|Tailored Patient-Provider Communication|Every 1.5 months, patients randomized to the tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be tailored as the mode of weblink delivery will be customized to patient preference. Patients can choose messages to be delivered via e-mail, SMS, WhatsApp, or Facebook. For example, if one patient determines SMS messaging as their preferred communication mode, then this patient will receive a weblink via SMS directing the patient to customized educational videos and questionnaires. Weblinks delivered via tailored patient-provider communication will be enabled by Wecudos.
45456207|NCT04656028|Genetic|Genetic Testing|DNA is extracted using the QIAamp® DNA Blood Mini Kit (Qiagen, Germany). The DNA concentration is measured on a Qubit 4.0 fluorometer (Thermo Fisher Scientific, USA (TFS)). NGS is performed on Nextseq 550 (Illumina, San Diego, CA, USA). The library preparation is performed using the SeqCap EZ Prime Choice Library kit (Roche, Basel, Switzerland). The Roche panel is used, consisting of 244 (CDS + 25 bp padding) genes including LDLR, APOB, and PCSK9. Reads are aligned to the reference genome (GRCh37). Sequencing analysis resultes in fastq files. Data processing is performed with BWA, Picard, bcftools, GATK3 and generally followed the GATK best practices for variant calling. For clinical interpretation, genetic variants with frequencies in the gnomAD database <0.5% are selected. The pathogenicity of variants is assessed according to the ACMG / AMP2015 guidelines. The identified SNPs are validated by Sanger sequencing (3500 DNA Analyzer, TFS).
45458677|NCT05158309|Other|placebo patch|A transparent patch with no formulation or effect but the same size of the capsaicin patch was applied to the same location.
45831300|NCT04766736|Procedure|Quantification of netrin-1 signals by antibody-based approaches|Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.
45831301|NCT01383174|Behavioral|Peer Support Program|"Work with a trained counselor who is a breast cancer survivor~Meet 8 times in-person over the 8 week program with the counselor~Counselor helps participant develop a personalized support program to help her improve her quality of life~Receives information on breast cancer, its treatments, and stress management"
45831302|NCT01396278|Drug|Placebo|Placebo matching fluticasone propionate HFA MDI
45831303|NCT01396278|Drug|Fluticasone propionate|Fluticasone propionate HFA MDI
45831304|NCT01396278|Drug|BI 54903|BI 54903 via Respimat inhaler
45831305|NCT05365152|Dietary Supplement|Meal Replacement|Meal Replacement
45831306|NCT05365074|Drug|Chloroprocaine Injection|Spinal anesthesia with 50 mg of 1% Chloroprocaine
45831307|NCT01383096|Drug|OZ439 mesylate 800mg Powder in Bottle for Oral Suspension|OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration
45831308|NCT01383096|Drug|OZ439 mesylate 400mg Prototype Solution Formula 1|OZ439 400 mg (as free base) as a prototype solution formulation 1
45831309|NCT01383096|Drug|OZ439 mesylate 800mg Prototype Solution Formula 1|OZ439 800 mg (as free base) as a prototype solution formulation 1
45831310|NCT01383096|Drug|OZ439 mesylate 800mg Prototype Solution Formula 2|OZ439 800 mg (as free base) as a prototype solution formulation 2
45458678|NCT03498742|Other|NO Intervention|Routine clinical data; asthma control test and spirometry
45831311|NCT04040244|Other|Exhaled Breath Collection|Exhaled breath condensate (EBC) and exhaled breath volatiles (EBV) samples will be obtained over 5-10 minutes using a one-time use R-tube apparatus.
45831312|NCT04040244|Other|Blood sample|Blood samples collected simultaneously with routine standard of care blood draws.
45831313|NCT01383018|Device|AMS Penile Prosthesis Devices|Non-interventional device registry. Outcomes for patients receiving marketed AMS penile prosthesis devices.
45831314|NCT01382940|Drug|rituximab|1000 mg in 250 mL intravenous infusion
45671871|NCT04633616|Other|Non-Tailored Patient-Provider Communication|Every 1.5 months, patients randomized to the non-tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be non-tailored such that patients will not be able to choose their preferred mode of communication and will receive hardcopy. Patients will receive hardcopy on how to access psoriasis education. Weblinks delivered via non-tailored patient-provider communication will be enabled by Wecudos.
45671872|NCT02154529|Drug|Tesevatinib|
45671873|NCT02154529|Drug|Trastuzumab|
45456208|NCT04656028|Behavioral|Motivational Counseling|"Motivational counseling will be carried out during Visit 2 and in one month after Visit 2 by certified psychologist with taking into account the results of the psychodiagnostic survey conducted at the first and second visits.~The goals of motivational counseling:~Increasing motivation for a healthy lifestyle;~Increasing adherence to treatment;~Increased motivation to invite relatives for cascade screening. Motivational counseling will be carried out using methods of motivational interviewing, transtheoretical model of changes, cognitive-behavioral therapy, extended preventive counseling."
45456209|NCT04656028|Diagnostic Test|Lipid analysis|Assessment of total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, alanine aminotransferase.
45456210|NCT04656028|Other|Consultation with a cardiologist-lipidologist (correction of therapy, lifestyle, diet)|All patients will be prescribed ezetimibe and statins (atorvastatin / rosuvastatin) at the maximum dosage. If somebody has an intolerance to atorvastatin, the drug will be replaced with rosuvastatin and vice versa. In case of intolerance to all drugs from the statin group, the patient will be prescribed ezetimibe with a PCSK9 inhibitor (alirocumab / evolocumab). After receiving the results of the lipid spectrum, ALT, if necessary, the lipid-lowering therapy may be corrected.
45456211|NCT04656028|Other|Visit 1|"Visit 1: initially (on enrollment) - informed consents signing; lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires. After this visit patients are randomized to groups with or without genetic testing and then randomized to groups with or without motivational counseling.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform, a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
45456212|NCT04656028|Other|Visit 2|"Visit 2 (in 2-3 months): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid lowering-therapy and lifestyle; filling all questionnaires. Patients from the group with genetic testing will get the result of this genetic testing. Patients from the group with motivational counseling will get two consultations with a psychologist (motivational counseling on lifestyle modification) during Visit 2 and in one month after Visit 2.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days"
45671874|NCT01954017|Biological|STP206|Live Biotherapeutic
45671875|NCT01954017|Other|Control|Sterile Water
45671876|NCT02154139|Drug|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg for injection
45671877|NCT02245568|Drug|LMTM|The initial LMTM dose was 200 mg/day (one 100-mg tablet twice daily), except in subjects with bvFTD who were taking a reduced dose (i.e., 100 mg/day) upon entering this extension study. The dose could be increased (after at least 13 weeks of treatment) or decreased (at any time at or after 2 weeks of treatment) by the Investigator in 100-mg increments or decrements. The maximum allowable dose was 300 mg/day (or in those countries where limited by a Competent Authority or Ethics Committee, 200 mg/day).
45671878|NCT02154061|Drug|IIV Flu Vaccine|This is an FDA approved and tested Inactivated Flu Vaccine.
45671879|NCT02154061|Drug|Metronidazole|This is a standard antibiotic
45831315|NCT01382940|Drug|methotrexate|10 to 25 mg/week (oral or parenteral)
45831316|NCT01382940|Drug|methylprednisolone|100 mg methylprednisolone administered by slow intravenous infusion at least 30 minutes prior to the start of each study drug infusion
45831317|NCT01382940|Drug|acetaminophen|1 gram acetaminophen administered orally 30 to 60 minutes prior to the start of each study drug infusion
45831318|NCT01382940|Drug|antihistamine|50 mg diphenhydramine hydrochloride or equivalent dose of alternate antihistamine administered orally 30 to 60 minutes prior to the start of each study drug infusion
45831319|NCT01381926|Drug|exenatide|exenatide 5mcg sq twice daily for one month and exenatide 10mcg twice daily for month 2. The 3rd month is a washout period. Month 4 and 5 saline placebo is given as 5mcg and 10mcg respectively.
45831320|NCT01381926|Drug|Saline|Month 1 and 2 saline placebo is given as a low and high dose respectively. The 3rd month is a washout period. Month 4 exenatide 5mcg sq twice daily and for month 5 exenatide 10mcg twice daily is administered.
46082441|NCT04906902|Drug|Acalabrutinib|Capsule taken by mouth twice daily
45976399|NCT01609699|Device|Treatment with Contour I-Y system|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
45671880|NCT02154061|Drug|Neomycin|This is a standard antibiotic.
45671881|NCT02154061|Drug|Vancomycin|This is a standard antibiotic.
45671882|NCT05180695|Drug|Pazopanib|"Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent."
45671883|NCT05180695|Drug|HDM201|"Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent."
45671884|NCT01907217|Device|ECT Mecta 5000M|ECT is administered twice weekly with hand-held electrodes using the Mecta 5000M device following a standard stimulus dosing protocol. Seizure duration is measured by EEG monitoring. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0 mg/kg) as muscle relaxant. Seizure threshold (ST) is established by a method of limits at the first session and subsequent treatments will be given at 1.5 x ST for BT ECT and 6.0 x ST for RUL ECT. To reflect routine clinical practice, number of ECT treatments is determined by referring physicians who will be blind to randomisation. The treatment period varies between patients to allow up to 12 administrations of ECT, i.e. up to 6 weeks.
45831321|NCT01395888|Drug|fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI)|fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI)
45831322|NCT01395888|Drug|Tiotropium|• Tiotropium (18 mcg) administered QD via a HandiHaler
45831323|NCT01395810|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience.
45831324|NCT01395810|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein). Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode.
45831325|NCT01395810|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein) every second week. Patients will receive instruction on how to treat any bleeding episode they may experience.
45976400|NCT01609699|Device|Treatment with Contour I-Y system|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
45976401|NCT00289965|Behavioral|Counselor-administered Brief Motivational Intervention (BMI)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
45831326|NCT05369598|Device|Post-operative ABF followed by fitting according to clinical standard|Cochlear implant will be fitted first with anatomy-based fitting for 6 months and followed by default fitting for 2 months.
45831327|NCT05369598|Device|Fitting according to clinical standard followed by post-operative ABF|Cochlear implant will be fitted first with default fitting for 6 months and followed by anatomy-based fitting for 2 months.
45976402|NCT00289965|Behavioral|Alcohol 101 Plus (interactive CD-ROM)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
45976403|NCT00289965|Behavioral|AlcoholEdu (Internet-based tutorial)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
45976404|NCT01609738|Device|Left ventricular septum pacing lead|A left ventricular septum pacing lead is permanently placed by introducing a custom lead with extended helix transvenously and, after positioning it against the RV septum, driving it through the inter-ventricular septum into the LV endocardial layer.
45976405|NCT00256334|Drug|Resveratrol|Patients were randomly assigned to one of four dose cohorts: plant-derived resveratrol tablets (purchased through the Life Extension Foundation, Scottsdale, AZ) at a dose of 80 mg/day, plant-derived resveratrol tablets at a dose of 20 mg/day, Grape Powder (GP) dissolved in water and taken orally (supplied by the California Table Grape Commission) at a dose of 120 g/day, and GP at a dose of 80 g/day.
45671885|NCT01907217|Drug|Methohexitone|Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia along with suxamethonium (0.5-1.0 mg/kg)for muscle relaxation. Anesthesia is the same for both arms of the trial.
45976406|NCT01609777|Procedure|SBAR|situation, background, assessment, recommendation
45976407|NCT01609855|Drug|Hyoscine Butyl Bromide 20mg/2 ml i.v.|Hyoscine Butyl Bromide 20mg/2 ml i.v.is administered at time of caecal intubation
45976408|NCT01609855|Drug|Saline 2 ml i.v.|Administration of Saline 2 ml at time of caecal intubation
45976409|NCT00256373|Procedure|Mod. functional restoration-Individ. dynamic back-muscle|
45976410|NCT00270816|Drug|Interferon-ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months
45976411|NCT00270816|Drug|Interferon ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day
45976412|NCT01609972|Device|Spinal Cord Stimulator|Non-inferior comparison of implantable spinal cord stimulators
45976413|NCT00256412|Drug|Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day|Placebo and Omega 3 capsules. All participants receive 4 capsules with either 0, 2, or 4 capsules containing omega 3.
45671886|NCT01907217|Drug|Suxamethonium|Suxamethonium (0.5-1.0 mg/kg)is used for muscle relaxation along with Methohexitone (0.75-1.0 mg/kg) for anaesthesia. Anesthesia is the same for both arms of the trial.
45671887|NCT01953783|Drug|IXAZOMIB|"Part A: Ixazomib 4.1 mg containing approximately 500-nCi [14C]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21.~Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity."
45831328|NCT01381692|Drug|Bortezomib|Given IV or SC
45831329|NCT01381692|Drug|Dexamethasone|Given PO
45831330|NCT01381692|Other|Laboratory Biomarker Analysis|Correlative studies
45831331|NCT01381692|Other|Quality-of-Life Assessment|Ancillary studies
45831332|NCT01381692|Biological|Rituximab|Given IV
45831333|NCT01381692|Drug|Temsirolimus|Given IV
45976414|NCT00256412|Drug|Placebo|4 capsules of placebo each day
45671888|NCT04416009|Device|NİCaS|whole body bioimpedence method
45831334|NCT04013256|Other|Cigarette Smoke|Cigarette smoke, generated by a smoking machine and aged is used to reproduce exposure to secondhand and thirdhand cigarette smoke.
45831335|NCT04013256|Other|Clean Air and Clean Clothing/Sham exposure|"Clean air, created by high-efficiency particulate air (HEPA) and charcoal filtration and temperature and humidity control.~Clean cotton clothing."
45831336|NCT01395030|Diagnostic Test|Computed Tomography|Undergo FCH PET/CT
45831337|NCT01395030|Drug|18F-fluoromethylcholine|Undergo FCH PET/CT
45831338|NCT01395030|Diagnostic Test|Positron Emission Tomography|Undergo FCH PET/CT
45831339|NCT01381068|Device|End tidal CO2 monitor|The sensor is placed in the respiratory circuit in both arms of the trial but the display is visible to the resuscitation team in the monitored arm and is covered in the control arm. The end tidal CO2 data is collected in both arms.
45831340|NCT01394952|Drug|Dulaglutide|Administered subcutaneously
45831341|NCT01394952|Drug|Placebo|Administered subcutaneously
45976415|NCT01602367|Drug|BMS-823778|Capsules, Oral, 2 mg, Once daily, 12 weeks
45976416|NCT01602367|Drug|BMS-823778|Capsules, Oral, 6 mg, Once daily, 12 weeks
45976417|NCT01602367|Drug|BMS-823778|Capsules, Oral, 15 mg, Once daily, 12 weeks
45976418|NCT01602367|Drug|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 12 weeks
45976419|NCT00290004|Drug|motexafin gadolinium|
45976420|NCT01606891|Behavioral|multi-component/setting parent-targeted intervention|parents assigned to this group will be asked to participate in a program of home visiting, community parenting classes, and community food and physical activity resource links
45976421|NCT00256490|Procedure|PET/CT 20 days after the first cycle of chemotherapy|
45976422|NCT01609816|Drug|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
45976423|NCT00256529|Procedure|EGD with biopsies|All subjects presenting with dysphagia will undergo an EGD with distal and proximal biopsies of the esophagus.
45976424|NCT00290043|Drug|Insulin glulisine|
45976425|NCT01606930|Behavioral|Patient Primer Tool|"The instrument is completed before the scheduled appointment and is designed to prompt patients to reflect on their specific goals for the medical encounter, prioritize those goals, and to Prime them to engage in a discussion centered on their concerns and expectations. In addition, participants will be encouraged to bring this form into their physician visit and use it to engage their clinician in a discussion about their health needs."
45976426|NCT00256568|Behavioral|reporting system|Nurses and office staff were asked to report all communications with community pharmacists regarding prescription problems
45976427|NCT02270047|Dietary Supplement|Orange nectar|Orange nectar
45976428|NCT02270047|Dietary Supplement|Orange Nectar with fibre|
45976429|NCT02960607|Drug|Icotinib|Icotinib (250mg tid) until disease progression or unacceptable toxicities occurred.
45671889|NCT02134015|Drug|Patritumab|Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks)
45671890|NCT02134015|Drug|Erlotinib|Oral erlotinib 150 mg/day
45671891|NCT02134015|Drug|Placebo|Placebo infusion every 3 weeks
45671892|NCT04411485|Other|Sexual dysfunction|Sexual dysfunction will be determined with separate scales for women and men
45831342|NCT01394718|Drug|Intravenous Acetaminophen|Scheduled doses of 15 mg/kg of IV acetaminophen will be administered to the treatment arm of the study for a total of 8 doses over a 48 hour period post-operatively.
45831343|NCT01394718|Other|Placebo|Saline placebo will be given at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
45831344|NCT04012710|Procedure|Laparoscopy|Conventional abdominal laparoscopy
45831345|NCT04012710|Procedure|vNOTES|Transvaginal natural orifice transluminal endoscopic surgery for salpingo-oophorectomy
45831346|NCT01394250|Device|Buzzy|Cold, Vibrational Device
45831347|NCT01394250|Drug|Topical Lidocaine 4% Cream|Applied to anticipated IV site at least 30 minutes prior to cannulation.
45831348|NCT01380990|Genetic|Infusion of autologous EFS-ADA LV CD34+ cells|Autologous EFS-ADA LV CD34+ cells (OTL-101*) are infused intravenously
45831349|NCT01380990|Other|Haematopoietic Stem Cell Transplantation (HSCT)|Historical data from a database of ADA-SCID patients treated with allogeneic HSCT from GOSH will be collected as comparator group.
45831350|NCT01380990|Drug|Busulfan|Busulfan is used for non-myeloablative conditioning
45831351|NCT01380990|Drug|Peg-Ada|Peg-Ada enzyme replacement therapy is discontinued at Day +3- (-3/+15 days) after successful engraftment
45831352|NCT01380834|Drug|control group|Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
45976430|NCT02270125|Procedure|Mucotomy|Surgical removal of hypertrophic mucosa of the inferior nasal turbinate by cold-steel instruments under endoscopic control, under general anaesthesia
45976431|NCT02270164|Dietary Supplement|Artichoke Leaf Extract|Capsule
45976432|NCT02270164|Other|Placebo|Capsule
45976433|NCT00290082|Drug|loxapine, midazolam|agitated patients received loxapine 1 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 1 ml/ kg body weight ( midazolam 1mg/ml) if patients were still agitated 20 min after the first treatment, they received loxapine 0.5 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 0.5 ml/ kg body weight ( midazolam 1mg/ml)
45976434|NCT00290082|Biological|blood sample|was evaluated in patients sedated, alcohol level, blood sugar
45976435|NCT00290082|Other|patient monitoring|Till his coming out the emergency service, patient had an hemodynamic, respiratory and neurologic monitoring as well as an agitated score monitoring The occurence of a complication during the 15 days after leaving the emergency department was prospected.
45976436|NCT00290082|Drug|Loxapine|Loxapine 1 mL / 10 kg
45671893|NCT04619979|Procedure|patients undergoing gynecological surgery under general anesthesia|patients undergoing gynecological surgery under general anesthesia
45671894|NCT01924845|Drug|BMN 701|BMN 701 20 mg/kg for intravenous administration over approximately 4 hours every 2 weeks over a 24-week Treatment Period (total of 13 doses), and every 2 weeks over a 240-week Extension Period (up to 120 additional doses).
45671895|NCT01630135|Drug|Fluticasone furoate|55 mcg/day, intranasal, 2 weeks
45671896|NCT01630135|Drug|Placebo|Placebo, intranasal, 2 weeks
45831353|NCT01380834|Drug|treatment group|Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
45831354|NCT04407702|Other|Hygiene Instructions|Two weeks prior to the onset of the study, the volunteers will undergo a wash-out period, in which they will only use oral hygiene products donated by the researchers. These products will be used through to the end of the study. The oral hygiene kit will contain a soft-bristle toothbrush (Professional Lab Series, Colgate Palmolive), fluoride toothpaste with no desensitizing agent (Elmex) and dental floss (Colgate). The participants will be extensively trained with regards to all procedures involved in the experiment.
45831355|NCT04407702|Procedure|Sealant application|The teeth to be sealed will be isolated and 35% phosphoric acid will be applied for 20 seconds, followed by rinsing and drying the dental surfaces. A thin layer of PermaSeal will be applied to the tooth surface for 5 seconds and photopolymerized for 20 seconds. The occlusion will then be evaluated.
45831356|NCT04407702|Radiation|Low-level Laser|Irradiation with AsGaAl laser at a wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP, Brazil) with relative isolation. The power will be set to 100 mW; energy density will be 35 J/cm2 (considering a spot size of 0.028 cm2 of the equipment) and the dose will be 1 J per point. Irradiation will be performed on a cervical point, an apical point and a point precisely over the lesion, totaling a dose of 3 J. Treatment will be performed in three sessions with a 72-hour interval between sessions.
45976437|NCT00290082|Drug|Midazolam|Midazolam 1 mL / 10 Kg
45976438|NCT02270203|Radiation|Pelvic CT at 5 years post-op|Pelvic CT at 5 years post-op
45976439|NCT02270320|Behavioral|Physical activity|The training is 24 forms Yang-style Tai Chi Chuan exercise, which will perform a 60-minute exercise program, three times per week for 12 weeks.
45976440|NCT02270398|Behavioral|Dual-task training group|Balance and gait exercises while simultaneously engaging in a secondary cognitive task.
45671897|NCT01691248|Drug|fidaxomicin|"Fidaxomicin 200 mg tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Study drug treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Study drug treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days."
45976441|NCT02270398|Behavioral|Single-task training group|Balance/gait exercises and cognitive exercises done separately.
45976442|NCT02270398|Behavioral|Flexibility and strength training group|Whole-body flexibility exercises, upper limb strengthening exercises.
45976443|NCT00256646|Drug|Rosiglitazone|ROSIGLITAZONE (roe si GLI ta zone) helps to treat type 2 diabetes. It helps to control blood sugar. Treatment is combined with diet and exercise.
45976444|NCT02270437|Drug|ropivacaine, fentanyl, adrenaline|The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
45671898|NCT01691248|Drug|Placebo|"Placebo tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days."
45976445|NCT02270554|Device|Endo GIA Reinforced Reload with Tri-Staple technology|Device:Endo GIA Reinforced Reload with Tri-Staple technology
45976446|NCT00270933|Device|Registry|
45976447|NCT02270749|Drug|Hydroxocobalamin|patients are treated for 6 months with hydroxocobalamin. Patients will be treated with once a dose of 2000ug, after that treatment will be continued with a dose of 1000ug per 2 months. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
45976448|NCT02270749|Drug|FitForMe vitamin B12|patients are treated for 6 months with a daily dose of 1000ug vitamin B12 tablets. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
45976449|NCT00256685|Drug|DVS-233 SR|
45976450|NCT02270788|Drug|Crenolanib|"Day 1 of Course 1: once followed by pharmacokinetic analysis. Days 2-28 of cycle 1: 3 times per day Crenolanib dose will not be adjusted unless the participant experiences side effects.~All subsequent courses: 3 times per day on Days 1-28. At least 50% of participants in each dose level must be ≤ 18 years old."
45976451|NCT02270788|Drug|Sorafenib|"Days 8-28 of course 1: given orally once each day.~All subsequent courses: given orally on days 1-28 once per day~This is a dose-finding study for the use of sorafenib in combination with crenolanib. Different doses will be given to several participants, with the first participants receiving a lower dose than typically used in children as a single agent. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. If side effects occur, the dose will be lowered."
45456213|NCT04656028|Other|Visit 3|"Visit 3 (in 3 months after Visit 2): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
45671899|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
45976452|NCT02270788|Drug|methotrexate, hydrocortisone and cytarabine with leucovorin|Triple IT therapy includes methotrexate, hydrocortisone and cytarabine with leucovorin rescue given on day 8. All participants will receive one IT chemotherapy on Day 8 of the first cycle. If they do not have leukemia cells in their spinal fluid, they will receive only one IT chemotherapy per cycle. If leukemia cells are present in their spinal fluid, they will receive IT chemotherapy weekly during the course. Triple IT therapy will be repeated on Day 1 of Cycle 2 and with each subsequent cycle in all participants.
45976453|NCT02270827|Drug|Aminophylline|intravenous medication
45976454|NCT02270827|Drug|Hydrocortisone|Intravenous medication
45976455|NCT02270866|Device|TNM(trademark) - thermoneuromodulation|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
45671900|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
45671901|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
45671902|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
45671903|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
45976456|NCT00290121|Drug|Olanzapine|
45976457|NCT02270905|Device|dCELL® Meniscus|decellularised porcine xenograft
45671904|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
45671905|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
45671906|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
45671907|NCT01691092|Drug|Ketamine|All subjects will receive ketamine to induce glutamate release in the brain
45976458|NCT04709744|Drug|Vitamin D|Impact of serum vit D level in SLE patients with COVID-19 disease on severity of infection, duration of COVID-19 disease course, fatigue development as a complication for both SLE and COVID-19 and assess impact of prior chloroquine on COVID-19 disease outcomes
45976459|NCT04709744|Diagnostic Test|ELISA|Measure vitamin D level
45976460|NCT02271022|Other|Non-Interventional Study|Non-Interventional Study
45976461|NCT02271100|Device|ultrasound guidance|use of ultrasound for entry position estimation
45976462|NCT02271100|Device|palpation guidance|use of palpation for position estimation
45976463|NCT00270972|Device|Bilayered Cellular Matrix (OrCel)|
45976464|NCT00256802|Device|MR-angiography, GTN|
45976465|NCT02271139|Drug|Alectinib|Alectinib 600 mg administered orally with food.
45976466|NCT02271178|Other|Combined capsule|Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
45976467|NCT02271178|Other|Conventional therapy|Usual therapy
45976468|NCT00256841|Drug|Chemotherapy|
45976469|NCT00256841|Procedure|Radiation Therapy|
45976470|NCT00290160|Behavioral|Protein supplementation|
45976471|NCT02271295|Drug|Enoxaparine|Enoxaparine 4000UI/day during 24 months
45976472|NCT02271373|Behavioral|increasing time spent outdoors|The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
45976473|NCT02271412|Drug|LY03005|LY03005 is a new investigational pro-drug of desvenlafaxine formulated as extended-release oral tablets for the treatment of major depressive disorder.
45976474|NCT02271412|Drug|Placebo|Placebo
45976475|NCT00256880|Drug|GW786034|
45976476|NCT00271050|Other|external beam radiotherapy plus 90-Y ibritumomab tiuxetan|combination of EBRT followed by radioimmunotherapeutic 90-Y ibritumomab tiuxetan
45976477|NCT02271568|Procedure|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
45976478|NCT02271568|Other|Intensive medical therapy|intensive medical therapy according to published guidelines by ADA and EASD
45976479|NCT02271607|Device|moxibustion|The treatment schedule is three times per week for four weeks. Indirect moxa pillars and indirect-container moxibustion will be used.
45976480|NCT00256919|Drug|GW856553|
45976481|NCT02271646|Drug|0.5% marcaine 20ml|3 levels ultrasound guided thoracic paravertebral block at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
45976482|NCT00271089|Procedure|PBSC Collection|
45976483|NCT00271089|Procedure|Bone Marrow Harvest|
45976484|NCT00271089|Device|CliniMacs Cell Selection System|
45976485|NCT02271685|Other|Instructions about Overestimates|Participants are told that overestimating the duration of sounds are associated with low disease risk.
45976486|NCT02271685|Other|Instructions about Parkinson's|Participants are told that the task is about risk of Parkinson's disease.
45976487|NCT02271685|Other|Instructions about Underestimates|Participants are told that underestimating the duration of sounds are associated with low disease risk.
45976488|NCT02271685|Other|Instructions about Alzheimers|Participants are told that the task is about risk of Alzheimers disease.
45976489|NCT02271763|Other|ultrasound|subjects' neck will be scanned using ultrasound
45976490|NCT00256958|Procedure|total knee replacement|
45976491|NCT02271802|Dietary Supplement|Sodium butyrate|Patients recieved an enema containing butyrate or a placebo during upper abdominal surgery.
45976492|NCT02271802|Dietary Supplement|NaCl|
45976493|NCT02271841|Device|PVI|Pleth Variability Index
45976494|NCT02271958|Drug|Mifepristone|
45976495|NCT02271958|Drug|PLACEBO|
45976496|NCT00257036|Drug|levofloxacin|
45456214|NCT04656028|Other|Visit 4|"Visit 4 (in 12 months after Visit 3): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
45976497|NCT02272036|Procedure|Colonoscopy|Colonoscopy is performed in both study arm as standard examination
45976498|NCT02272036|Device|mobile phone|SMS received by mobile phone
45976499|NCT00271167|Drug|INO-1001|
45976500|NCT02272153|Other|Egg refined grain|
45976501|NCT02272153|Other|Egg Whole Grain|
45976502|NCT02272153|Other|Cereal Refined grain|
45976503|NCT00257075|Drug|Risperidone, oral tablets|
45976504|NCT02272192|Behavioral|Early Start Denver Model (ESDM)|The Early Start Denver Model (ESDM) is a comprehensive developmental and behavioral early intervention approach for children with autism, ages 12 to 48 months. The program encompasses a developmental curriculum that defines the skills to be taught at any given time and a set of teaching procedures based in applied behavioral analysis to deliver this content. The teaching format focuses on trained therapists delivering the intervention 1:1 by engaging reciprocally with children in typical toddler activities involving play or daily routines, adding additional structure for children who need it to progress well. Progress data is collected throughout each session and used to make decisions about teaching approaches.
45456215|NCT04646837|Drug|Durvalumab|Durvalumab 1000 mg IV Q3W for 2 cycle + Followed by adjuvant treatment for 1 year with Durvalumab 1000 mg IV Q3W for 4 months and Durvalumab 1500mg Q4W for 8 months
45456216|NCT04646837|Drug|Albumin Paclitaxel|Albumin Paclitaxel 200-260 mg, depending on the patient's physical condition, for 2 cycle
45976505|NCT02272192|Behavioral|Early Intensive Behavioral Intervention (EIBI)|EIBI is a one-to-one instructional approach based in applied behavior analysis used to teach skills in a planned, controlled, and systematic manner. Each trial or teaching opportunity has a definite beginning and end, thus the descriptor discrete trial. Within DTT, the use of antecedents and consequences is carefully planned and implemented. Positive praise and/or tangible rewards are used to reinforce desired skills or behaviors. Trial by trial data collection is an important part of DTT and supports decision making by providing teachers/practitioners with information about beginning skill level, progress and challenges, skill acquisition and maintenance, and generalization of learned skills or behaviors.
45976506|NCT00290277|Biological|HPV-16/18 L1/AS04|
45976507|NCT02272270|Drug|Minocycline with chemoradiation (temozolomide and radiation therapy)|Patients receive minocycline in conjunction with standard chemoradiation and then they receive minocycline with standard chemotherapy.
45976508|NCT02272387|Dietary Supplement|Vitamin D3 (Cholecalciferol)|
45976509|NCT02272387|Other|Placebo|
45976510|NCT00257114|Drug|bortezomib|
45976511|NCT02272426|Behavioral|CARET|Combined Aerobic and Resistance Exercise Training
45976512|NCT02272426|Behavioral|CTI|Cognitive Training Intervention
45976513|NCT02272426|Behavioral|Sham CARET|Sham Combined Aerobic and Resistance Exercise Training
45976514|NCT02272426|Behavioral|Sham CTI|Sham Cognitive Training Intervention
45976515|NCT02272465|Other|No intervention|Observational study
45976516|NCT00257153|Device|Coronary thrombus aspiration catheter|
45976517|NCT00271206|Drug|Progesterone|compared to placebo
45976518|NCT00271206|Drug|sugar pill|Compared to progesterone
45976519|NCT02272543|Dietary Supplement|Fish surimi peptide|
45976520|NCT02272582|Device|SOMVC001 Vascular Conduit Solution|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
45976521|NCT02272582|Other|Standard of care Heparin-dosed saline|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
45976522|NCT02272621|Procedure|Minimally invasive aortic valve replacement|
45976523|NCT02272621|Procedure|Full sternotomy aortic valve replacement|
45976524|NCT00290316|Procedure|Endoscopy ultrasound|
45976525|NCT02272660|Drug|Parecoxib sodium|The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
45671908|NCT02133001|Drug|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25). Dose may be reduced to 56 mg per day based on Investigator's discretion.
45976526|NCT02272660|Drug|Normal saline injection|The patients in the control group received 2 mL normal saline injection 30 minutes before Normal saline injection incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
45976527|NCT02272699|Drug|Nimotuzumab|Nimotuzumab 200mg per week for 6 weeks.
45976528|NCT02272699|Drug|Paclitaxel|Paclitaxel 175mg per square metre on day 1, repeated every 3 weeks for 2 cycles.
45976529|NCT02272699|Drug|Cisplatin|Cisplatin 30mg per square metre on day 1 and day 2, repeated every 3 weeks for 2 cycles.
45671909|NCT02133001|Drug|Placebo|Matching placebo will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25).
45671910|NCT01709578|Drug|Sarilumab|Pharmaceutical form:solution Route of administration: subcutaneous
45671911|NCT01709578|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
45671912|NCT01709578|Drug|hydroxychloroquine|Dispensed according to the local practice.
45976530|NCT02272699|Radiation|Radiation|IMRT of primary tumor and local lymph nodes with 95% PTV of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.
45671913|NCT01709578|Drug|methotrexate|Dispensed according to the local practice.
45976531|NCT02272699|Procedure|Surgery|Esophagectomy
45976532|NCT02272738|Drug|Gemcitabine|Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
45976533|NCT02272738|Drug|Nab-Paclitaxel|Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
45976534|NCT00271245|Dietary Supplement|200 µg selenium as selenate|200 µg selenium as selenate
45456217|NCT04646837|Drug|Carboplatin/Cisplatin|Carboplatin AUC 6 IV Q3W or Cisplatin 80mg/㎡ for 2 cycle
45671914|NCT01709578|Drug|sulfasalazine|Dispensed according to the local practice.
45671915|NCT01709578|Drug|leflunomide|Dispensed according to the local practice.
45671916|NCT02132767|Drug|Amiodarone|"Amiodarone Initial Dose~Oral: 400 mg po TID for 3 days is recommended~For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose~Oral: at least 200 mg/day to be continued until 60 days after randomization~If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started"
45831357|NCT04000776|Diagnostic Test|FDG Positron emission tomography (PET) scan|"Patients will undergo 18F-FDG and whole-body PET/CT (vertex to thighs, or to feet if known lower-limb metastases).~The patient will be measured and weighed before the exam in order to calculate a personalized dose. An intravenous catheter will be put in place in peripheral vein to allow injection of the tracer."
45831358|NCT04000776|Diagnostic Test|PSMA Positron emission tomography (PET) scan|Patients will sequentially undergo 68Ga-PSMA and whole-body PET/CT (vertex to thighs, or to feet if known lower-limb metastases).
45976535|NCT00271245|Dietary Supplement|400 µg selenium as selenate|400 µg selenium as selenate
45976536|NCT00271245|Dietary Supplement|200 µg selenium as selenomethionine|200 µg selenium as selenomethionine
45671917|NCT02132767|Procedure|DC-cardioversion|DC-Cardioversion - frequency and duration determined by medical professional as medically needed
45976537|NCT00271245|Dietary Supplement|Placebo|Placebo
45976538|NCT02272855|Biological|HF10 plus Ipilimumab|Patients will receive the dose of 1 x 10^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) and ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
45976539|NCT02272894|Procedure|Dissection of the Superior Mesenteric Vein Lymph Node|14v lymph node dissection
45976540|NCT00257270|Drug|gabapentin|
45976541|NCT02272933|Device|Smart Slipper|The shoe measures foot pressure and motion allowing gait to be quantified.
45976542|NCT02272933|Device|Belt-Clip Sensor|The sensor measures acceleration of the body allowing falls to be detected.
45976543|NCT00290394|Drug|rosiglitazone(drug), blood pressure lowering effect|
45976544|NCT02273011|Procedure|caesarean section|elective caesarean section under regional anesthesia
45976545|NCT02273089|Device|CPAP (ResMed S9 AutoSet)|nocturnal CPAP for three months
45976546|NCT00416247|Behavioral|Hypnosis|Hypnosis
45976547|NCT00257348|Drug|Capecitabine|
45976548|NCT00257348|Drug|Docetaxel|
45976549|NCT01580215|Device|Zephyr Endobronchial Valve (EBV)|• Implantation of at least one Zephyr EBV following Chartis assessment
45976550|NCT02273128|Genetic|CTR Gene|2ml blood sample collected from patients to extract DNA for Assessment of CTR Gene polymorphism
45671918|NCT02132767|Drug|Rate Control|Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed
45671919|NCT04749667|Other|MSCs|Autologous bone-marrow derived mesenchymal stem cells
45671920|NCT04749667|Drug|Saline|Isotonic saline
45976551|NCT00290550|Drug|MK0457|IV infusion at 10 mg/m2/hour; 5-day continuous infusion every 21 days
45976552|NCT00257387|Drug|Cyclosporine|
45976553|NCT02273245|Radiation|Thoracic aortogram CT|With and without contrast dye
45976554|NCT02273401|Drug|BI 11054 CL|
45976555|NCT02273401|Drug|Placebo|
45976556|NCT00257426|Drug|octreotide acetate|200mcg,3 times per day, 7 days per week, up to 36 weeks
45976557|NCT01601353|Device|Tissue Genesis Cell Isolation System|Liposuction followed by injection of autologous adipose derived cells
45976558|NCT01601392|Procedure|transcranial direct current stimulation (Anodal)|The anodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the affected hemisphere.
45976559|NCT01601392|Procedure|transcranial direct current stimulation (Cathodal)|The Cathodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the unaffected hemisphere.
45976560|NCT01601392|Procedure|transcranial direct current stimulation (Sham)|The sham group will receive sham tDCS for 25 minutes daily for 6 consecutive days on the affected hemisphere.
45671921|NCT02153905|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
45671922|NCT02153905|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
45671923|NCT02153905|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
45671924|NCT02153905|Biological|Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)|Day 0: MAGE-A3-A1 transduced peripheral blood lymphocytes (PBL) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
45671925|NCT02153827|Other|Eccentric Shoulder External Rotator Training|Eccentric training exercise for the external rotators, 3 sets of 15 daily.
45671926|NCT02153827|Other|General Shoulder exercise|general exercise consisting of active shoulder movements
45671927|NCT04752631|Drug|Tenecteplase|The participants received TNK-tPA thrombolytic therapy
45671928|NCT02153359|Device|High Efficiency Particulate Air Cleaner|
45671929|NCT02153359|Device|Sham air cleaner|
45671930|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
45831359|NCT04000776|Diagnostic Test|OCTREOTATE Positron emission tomography (PET) scan|"In the case a patient would present at least one PSMA-negative/FDG-positive lesion, he will be referred to undertake a whole-body 68Ga-OCTREOTATE PET/CT within 10 days of the first PET/CT. The delay between this third PET scan and the last one should be minimal (not least than 18 hours, not more than 10 days).~Images and data will be reviewed centrally within 4 days by the Imaging Corelab, which will produce a final report confirming patient's eligibility to Radioligand therapy (RLT)."
45831360|NCT04000776|Other|Optional Bone or soft-tissue biopsies|Patients presenting FDG-positive/PSMA-negative or Octreotate-positive lesions on imaging will be asked to undergo a biopsy of these lesions (optional) for research purposes. Bone or soft-tissue biopsies will be collected by an interventional radiologist according to site's standard-of-care procedure and sent to the local pathology department for preparation (formalin-fixed and paraffin-embedded); the blocks being sent to the Pathology Corelab.
45831361|NCT04766658|Other|Gargle Phonation|Subjects will gargle water while making sound
45831362|NCT04766658|Other|Water swallow|Subjects will hold water in their mouth for 5 seconds and swallow
45976561|NCT01601509|Drug|Nasal tramazoline with dexamethazone|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described [7], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
46082442|NCT02795624|Procedure|Spirometry|Test is done to assess how well the lungs work by measuring how much air is inhaled, how much is exhaled, and how quickly it is exhaled.
46082443|NCT02795624|Procedure|Pulse Wave Analysis|It is a non-invasive assessment of the pulse character
46082444|NCT02795624|Procedure|Peripheral arterial tonometry|It is a non-invasive method to measure endothelial dysfunction.
46082445|NCT02795546|Drug|Alendronate sodium|400µg of alendronate sodium is combined with beta-tricalcium phosphate bone graft and implanted in periodontal intra-osseous defects as a single, local dose.
45976562|NCT01601509|Drug|Nasal placebo|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described [7], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
45976563|NCT00416325|Dietary Supplement|lycopene|
45976564|NCT00416325|Other|laboratory biomarker analysis|
45976565|NCT00257465|Biological|Autologous, DNP-modified vaccine (M-Vax)|5.0, 2.5, 0.5, or 0 cells
45976566|NCT00257465|Biological|Autologous, DNP-Modified Melanoma Vaccine|5 million cells
45671931|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
45976567|NCT00257465|Biological|Autologous, DNP-Modified Vaccine|2.5 million cells
45976568|NCT00257465|Biological|Autologous, DNP-Modified Vaccine|0.5 million cells
45976569|NCT00257465|Biological|Autologous, DNP-Modified Vaccine|0 cells
45976570|NCT01601548|Behavioral|Mindfulness Based Cancer Recovery|Defined as practices or interventions that focus on the connection and integration of the mind and body and the ability for these connections to effect changes on physical, emotional and spiritual levels for the purpose of promoting health and well being. MBCR is a psycho-educational program developed by Dr. Linda Carlson. It is a step by step mindful-based stress reduction program (MBSR) designed to help cancer patients cope with their cancer diagnosis and treatment
45976571|NCT01601665|Device|SN6AT6 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 3.75 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
45976572|NCT01601665|Device|SN6AT7 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 4.50 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
45976573|NCT01601665|Device|SN6AT8 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 5.25 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
45976574|NCT01601665|Device|SN6AT9 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 6.00 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
45976575|NCT01601665|Device|SN60WF Intraocular Lens|Acrylic aspheric monofocal intraocular lens. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
45976576|NCT01601743|Behavioral|Sitting|Sitting for the same period of time and duration (30 minutes per session, 3 times per week, over 4 consecutive weeks).
45976577|NCT01601743|Behavioral|Running|Exercise (running) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
45976578|NCT01601743|Behavioral|Walking|Exercise (walking) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
45976579|NCT01601899|Drug|Stavudine|30 mg po BD if wt < 60kg, or 40 mg po BD if wt > 60kg
45976580|NCT01601899|Drug|Stavudine|20 mg po BD if wt < 60kg, or 30 mg po BD if wt > 60kg
45976581|NCT01601899|Drug|Tenofovir|300 mg po QD
45976582|NCT01601938|Dietary Supplement|selenium replacement|Selenium 500 mcg (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
46082446|NCT02795546|Biological|beta-tricalcium phosphate bone substitute|beta-tricalcium phosphate bone graft is implanted in periodontal intra-osseous defects.
46082447|NCT05337696|Procedure|Vertebral Implant PEEK Procedure|Vertebral Implant PEEK (VIP) procedure is a minimally invasive/percutaneous vertebral augmentation (PVA), image guided procedure. Two VIP devices are implanted in each to be treated vertebra. A cavity is drilled allowing the introduction of the implant posteriorly through the pedicle and the vertebral body upto the anterior wall. A part of the implant is embedded into the pedicle, thus providing posterior support. The other part of the device, located in the vertebral body, presents a central canula and lateral perforations, which allow acrylic bone cement diffusion, filling of the vertebral body, filling and fixing the implant, and supporting of the upper endplate. The combination of the implant and the cement allows the treatment of vertebral fractures.
45671932|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
45671933|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
45671934|NCT04546672|Drug|Sugammadex|At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg actual body weight through an intravenous line with brisk flow
45976583|NCT01601938|Dietary Supplement|Placebo|placebo (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
45976584|NCT01602055|Drug|Azithromycin|Single dose 500 mg of film coated tablet
45976585|NCT01602055|Drug|Azithromycin|Single dose 500 mg of film coated tablet
45976586|NCT00257543|Procedure|Alternative donor bone marrow and cord blood|bone marrow transplant - alternative donors for bone marrow and cord blood transplants
45976587|NCT01602133|Procedure|peripheral venous puncture|Ultrasound imaging of the arm is performed. If a suitable vein is identified, a percutaneous puncture is performed under ultrasound guidance. Then, an intravenous catheter is inserted according Seldinger method.
45671935|NCT04546672|Drug|Neostigmine|At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg actual body weight to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be coadministered with Neostigmine at a dose of 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered
45976588|NCT00416403|Drug|fluvastatin sodium|Given orally
45976589|NCT00416403|Procedure|Breast Cancer Surgery Only - Arm III|Breast Cancer Surgery
45976590|NCT01602211|Other|Internet-Based Intervention|Receive full access to INSPIRE
45976591|NCT01602211|Other|Internet-Based Intervention|Receive access to an annotated list of existing resources for transplant and cancer survivors and delayed access to INSPIRE site
45976592|NCT01602211|Other|Medical Chart Review|Ancillary studies
45671936|NCT02245412|Biological|ALXN1007 10 mg/kg once weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
45976593|NCT01602211|Other|Quality-of-Life Assessment|Ancillary studies
45976594|NCT01602211|Other|Questionnaire Administration|Ancillary studies
45976595|NCT01602250|Drug|placebo|Levobupivacaine 8 mg/min ropivacaine 8 mg/min
45976596|NCT01602250|Drug|Intralipid®|Levobupivacaine 8 mg/min ropivacaine 8 mg/min Intralipid® 120 ml in one min
45976597|NCT00257582|Drug|Cetirizine Dry Syrup|
45976598|NCT01602289|Biological|LY2875358|Administered IV
45976599|NCT01602289|Drug|Erlotinib|Administered orally
45976600|NCT01602289|Drug|Gefitinib|Administered orally
45976601|NCT00416442|Drug|RSV604|
45976602|NCT01602328|Biological|AC607|AC607 will be a single administration at a target dose of 2 x 10E6 hMSC/kg body weight
45976603|NCT01602328|Biological|Vehicle Only|The dose will be calculated and recorded in the same way as for AC607.
45976604|NCT00257621|Drug|GW640385|
45976605|NCT00257621|Drug|Ritonavir|
45976606|NCT01602406|Drug|LJM716|LJM716
45976607|NCT01602406|Drug|Trastuzumab|Trastuzumab
45976608|NCT00290628|Drug|anti-thymocyte globulin|
45976609|NCT00290628|Drug|busulfan|
45976610|NCT00290628|Drug|cyclophosphamide|
45976611|NCT00290628|Drug|cyclosporine|
45976612|NCT00290628|Drug|filgrastim|
45976613|NCT00290628|Drug|melphalan|
45976614|NCT00290628|Drug|methylprednisolone|
45976615|NCT00290628|Drug|mycophenolate mofetil|
45976616|NCT00290628|Procedure|radiation therapy|
45976617|NCT00290628|Procedure|umbilical cord blood transplantation|
45976618|NCT01602523|Drug|Budesonide/formoterol|Budesonide/formoterol Spray inhaler 160/4.5 mcg daily 28 days
45976619|NCT01602523|Drug|Placebo|Placebo inhaler once daily 28 days
45976620|NCT00415298|Drug|DACH polymer platinate AP5346|
45976621|NCT00415298|Drug|oxaliplatin|
45976622|NCT00415298|Genetic|gene expression analysis|
45976623|NCT00415298|Other|immunohistochemistry staining method|
45976624|NCT00415298|Other|pharmacological study|
45976625|NCT00415298|Procedure|biopsy|
45976626|NCT01602601|Drug|Idursulfase|recombinant version of IDS produced from human fibroblast. idursulfase is approved for every week (EW) intravenous (IV) administration.
45671937|NCT02245412|Biological|ALXN1007 20 mg/kg once weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
45671938|NCT02245412|Biological|ALXN1007 20 mg/kg twice weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
45976627|NCT01602601|Drug|GSK2788723|GSK2788723 is being developed by JCR and GSK for the treatment of Hunter syndrome
45976628|NCT01602640|Drug|Morphine infusion|Conventional dose
45671939|NCT02244944|Drug|EZ-Urso combination therapy|Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day
45671940|NCT04632056|Drug|Beovu|There is no treatment allocation. Patients administered Beovu by prescription that have started before inclusion of the patient into the study will be enrolled.
45831363|NCT05360940|Diagnostic Test|H.pylori stool antigen rapid test and stool parasitological examination|200 stool samples ( 100 positive and 100 negative for H.pylori) after performance of H.pylori stool rapid antigen test then parasitological stool examination will be done
45671941|NCT01689532|Drug|Sirukumab 100 mg|Sirukumab 100 mg subcutaneous (SC) injection, at Weeks 0, 2, and every 2 weeks through Week 52.
45671942|NCT01689532|Drug|Sirukumab 50 mg|Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52.
45671943|NCT01689532|Drug|Placebo|Between sirukumab injections, placebo SC at Weeks 2, 6, and every 4 weeks through Week 52.
45671944|NCT01924689|Biological|Clostridium novyi-NT spores|Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 x 10(4) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(4) spores/kg.
45671945|NCT01591330|Drug|LY2140023 Reference form|80-mg tablet administered orally
45831364|NCT04407468|Procedure|Prone position|Position of the patient in which he is face down, for an improvement in oxygenation
45976629|NCT01602640|Drug|Fentanyl and Midazolam infusion|Conventional dose
45976630|NCT00290667|Biological|pegfilgrastim|
45976631|NCT00290667|Biological|rituximab|
45976632|NCT00290667|Drug|cyclophosphamide|
45976633|NCT00290667|Drug|doxorubicin hydrochloride|
45976634|NCT00290667|Drug|prednisone|
45976635|NCT00290667|Drug|vincristine sulfate|
45976636|NCT00290667|Other|pharmacological study|
45976637|NCT00290667|Radiation|radiation therapy|
45976638|NCT01602757|Drug|Synera|"Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat (no heat patches) and were crossed over during Study Session 3."
45976639|NCT02961101|Drug|Anti-PD-1 antibody|Anti-PD-1 antibody will be given at 1-3mg/kg on day8 by IV every three weeks
45976640|NCT02961101|Drug|Decitabine|Decitabine will be given at 10mg/d on day 1to 5 by IV every three weeks
45976641|NCT02961101|Drug|Chemotherapy|Chemotherapy be given depends on the cancer type and treatment regimen before enrollment.
45976642|NCT01602913|Drug|Pravastatin alone|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease.
45976643|NCT01602913|Drug|Paroxetine alone|Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
46082448|NCT05337696|Device|Vertebral Implant PEEK (VIP) implant|The study device is V-STRUT© Vertebral Implant manufactured by Hyprevention (VIP -Vertebral Implant PEEK), FDA cleared under K191709, indicated for use in the treatment of vertebral fractures in the thoracic and lumbar spine from T9 to L5. It is intended to be used in combination with PMMA bone cement.
46082449|NCT00608855|Other|questionnaire administration|
45671946|NCT01591330|Drug|LY2140023 Test-Low|80-mg tablet administered orally
45831365|NCT04009746|Procedure|Endoscopic retrograde cholangiopancreatography (ERCP) with Spyglass|Endoscopic retrograde cholangiopancreatography (ERCP) with Spyglass
45976644|NCT01602913|Drug|Pravastatin and paroxetine combined|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease. Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
45976645|NCT01602952|Drug|Radotinib|50mg, 100mg or 200mg Capsule BID
45976646|NCT01602991|Procedure|clinic-based nasopharyngoendoscopy|The study intervention is an in-office transnasal esophagoscopy. It is done in clinic, immediately after deciding the patient requires investigation of their upper gastrointestinal tract and the patient signs consent. The nasopharynx and oral pharynx is topically anesthetized. Since flexible scope is much thinner than a standard endoscopy, there is no requirement for intravenous sedation and thus, no requirement for specialized monitoring, nursing or recovery units. The procedure takes approximately 10 minutes. This study will be using the E.G. Scan II System.
45976647|NCT01602991|Procedure|Standard Endoscopy|The control procedure is standard endoscopy. Endoscopy will be performed as per standard clinic practice. It is typically scheduled within 2 weeks of seeing the patient in clinic. The patient will be required to fast for 6 hours prior to the procedure. In most cases, patients will require intravenous sedation. If sedation is used, the patient will be required to take the day off work and have someone drive them home. This is the standard treatment for patients who present with upper gastrointestinal symptoms post-bariatric surgery. Patients who choose not to participate in this study will still undergo endoscopy as per standard clinical practice.
45976648|NCT00257699|Drug|Metronidazole placebo|
45456218|NCT04646174|Behavioral|Unified Protocol adapted for smoking cessation|Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module.
45671947|NCT01591330|Drug|LY2140023 Test-Medium|80-mg tablet administered orally
45671948|NCT01591330|Drug|LY2140023 Test-High|80-mg tablet administered orally
45671949|NCT01591096|Drug|Tissue plasminogen activator (Activase®)|Investigation labeled tPA will be obtained for all sites by the Core Pharmacy as commercially available recombinant tPA (Genentech as Activase®) for IV administration. The Bayesian method of toxicity probability intervals will be used to select one of the following three dose tiers (0.75, 0.9, 1.0 mg/kg) of IV tPA. The dose escalation for the two age groups (2-10, 11-17 years) will be performed independently. The maximum dose for each tier will be reached at a weight of 90 kg.
45976649|NCT00257699|Drug|ciprofloxacin placebo|
45976650|NCT00257699|Drug|ciprofloxacin|500 mg bid po
45976651|NCT00257699|Drug|metronidazole|250 mg bid po / 250 mg tid po / 500 mg bid po depending on body weight
45976652|NCT01603030|Drug|moxifloxacin 0,5% + prednisolone 1%|1 gtt, 4x/day, 15 days
45976653|NCT01603030|Drug|moxifloxacin/prednisolone combination|1 gtt, 4x/day, 15 days
45671950|NCT04867174|Behavioral|Financial incentives|Each of the study arms, including the no message/control arm, will be interacted with different financial incentives (N=5,000)
45671951|NCT04867174|Behavioral|Convenient scheduling link|In addition, study arms will be randomly assigned a convenient link to the county public vaccine appointment scheduling system highlighted for participants (N=5,000).
45671952|NCT04867174|Behavioral|Race concordant|Randomized to a messenger who is race concordant with the participant
45671953|NCT04867174|Behavioral|Gender concordant|Randomized to a messenger who is gender concordant with the participant
45831366|NCT05368740|Device|integrated pulmonary index monitor|Integrated Pulmonary Index (IPI) is a new monitoring method calculated using respiratory rate (RR), end-tidal carbon dioxide (EtCO2), peripheral oxygen saturation (SpO2), and heart rate (HR). It is designed to obtain information about the patients' oxygenation and ventilation in the form of a single value or waveform from 1 to 10 with a mathematical algorithm using fuzzy logic. According to this scoring system; 10= normal, 8-9= within normal range, 7= close to normal range, requires attention, 5-6= requires attention and may require intervention, 3-4= requires intervention, 1-2= requires immediate intervention [2].
45831367|NCT05361330|Drug|Shuganjieyu capsule|2 capsules each time, twice per day. According to the study progress, the intervention can be adjusted to 4 capsules each time, twice per day
45831368|NCT05361330|Drug|Fluoxetine|Medication in basic study period: Fluoxetine (20 mg, once a day) Medication in the expanded study period: After 8 weeks of basic study period, if the reduction rate of HAMD-17 total scores is below 50 %, for the treatment group, the dosage of Fluoxetine will be adjusted to 40 mg / time, once a day.
45831369|NCT05364060|Other|Questionnaires|Different questionnaires detailed in the objectives part
45831370|NCT00214968|Drug|Modafinil|maximum dosage 400 mg/day (4 tablets)
45831371|NCT00210522|Drug|RWJ 333369|Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
45831372|NCT00214422|Radiation|Radiation|Radiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes.
45831373|NCT03592212|Drug|Salbutamol|Measurement of bronchodilator response (BDR)
45976654|NCT01603069|Drug|AZD3241 300 mg BID|The following dose escalation schedule will be used for 300 mg BID: 100 mg BID from Day 1 through Day 7. On Day 8, the patients will start maintenance treatment of 300 mg BID for the duration of the treatment period.
45976655|NCT01603069|Drug|AZD3241 600 mg BID|The following dose escalation schedule will be used for 600 mg BID: 100 mg BID from Day 1 through Day 7 and 300 mg BID from Day 8 through Day 14. On Day 15, the patients will start maintenance treatment of 600 mg BID for the duration of the treatment period.
45976656|NCT01603069|Drug|Placebo|Placebo to AZD3241 BID
45976657|NCT00257738|Biological|MAGE-A3|Three dose levels of MAGE-A3 vaccine will be tested : 500ug, 1000 ug and 1500 ug
45976658|NCT00257738|Biological|HPV-16 vaccine|Three dose levels of HPV- 16 vaccine will be tested : 500ug, 1000 ug and 1500 ug
45976659|NCT01603108|Drug|Rifaximin|Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
45976660|NCT01603108|Drug|Placebo|Rifaximin placebo will be initiated post LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo dosed at 550 mg twice daily for 90 days (+/10 days) post LT.
45671954|NCT01953003|Drug|vinflunine|intravenous administration day 1 once every 3 weeks, 280 mg/m²
45671955|NCT01953003|Drug|Capecitabine|Arm A : 1650 mg/m² Arm B : 2500 mg/m²
45671956|NCT01952691|Device|kinesiotaping|correction method was used to align hallux.
45671957|NCT01709500|Drug|LMT (atorvastatin, simvastatin, or rosuvastatin)|
45671958|NCT01709500|Drug|alirocumab|Alirocumab administered as a subcutaneous (SC) injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
45671959|NCT01709500|Drug|Placebo|Placebo matched to alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
45671960|NCT01599806|Drug|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
45671961|NCT01599806|Drug|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
45976661|NCT00290823|Drug|Albendazole|400 mg tablet taken orally twice daily
45976662|NCT00290823|Drug|Dexamethasone|6mg or 8mg taken daily
45976663|NCT00290823|Drug|Omeprazole|20 mg tablet taken orally daily
45976664|NCT01603186|Drug|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
45671962|NCT01599806|Drug|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
45456219|NCT04646174|Behavioral|American Lung Association self-management strategies for smoking cessation|Treatment components are self-management strategies provided through printed self-help materials from the American Lung Association. The materials consist of the Freedom from Smoking guide, Relaxation Exercises for Better Breathing, and COPD; Exercise and Daily Activity guide that address evidence-based smoking cessation and self-management strategies to aid in a quit attempt.
45671963|NCT01599806|Drug|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
45671964|NCT01599325|Drug|Azacitidine|Subcutaneous administration of azacitidine 75 mg/m^2/day for 7 days every 28 days optimally for at least 6 cycles until disease progression, unacceptable toxicity, or treatment discontinuation for any other reason
45976665|NCT01603186|Drug|Quetiapine Fumarate|25 mg tablet once a day
45976666|NCT02484937|Other|Group 2 (PCP Treatment)|For the PCP group treatment will be performed (pain treatment/medications) by the Primary Care Physician in his/her office/clinic.
45976667|NCT02484937|Other|Group 1 (PMS Treatment)|For the PMS group treatment will be performed (pain treatment/medications) by the Pain Medicine Specialist in his/her office/clinic.
45976668|NCT00257777|Procedure|Myocardial protection techniques|
45976669|NCT00271284|Drug|insulin glulisine / insulin glargine|insulin glargine administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
45976670|NCT00271284|Drug|insulin glulisin / insulin detemir|insulin detemir administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
45976671|NCT02480257|Behavioral|TARA|The intervention consists of four 3-week modules: 1. Autonomic regulation: Learning and practicing the ability to create a calm and safe inner state through breathing exercises and movement/physical activity. 2. Interoceptive awareness: Attention training, targeting external stimuli then sensory stimuli using short body scan exercises and guided meditations. 3.Emotion regulation: Recognizing, labeling, externalizing, and befriending emotions. 4. Metacognition, core-values, and committed action: Understanding social triggers to negative emotions and experiential avoidance strategies and their impact on obtaining desired life-goals. Home practice of TARA skills is encouraged, with breathing instructions and short, guided meditations provided via audio tracks.
45976672|NCT02487043|Behavioral|A telephone-based case-management intervention|Regular Telephone support delivered by Health coaches
45976673|NCT00257816|Drug|Topotecan|"(First stage of accrual, 6 patients)-2 mg/m2 IV on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)~If none or 1 of the 6 patients in the first Stage of accrual finish the prescribed therapy in over 8 weeks, then the second Stage of accrual (an additional 6 patients) will increase the Topotecan dose to 3 mg/m2 on days 1, 8, 15, 22, 29 and once during parametrical boost (6 cycles). If 2 or 3 of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, the dose of the Topotecan will remain the same in the second Phase of accrual. If 4 or more of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, there will be no second phase of accrual."
45976674|NCT00257816|Drug|Cisplatin|40 mg/m2 IV (Maximum total dose of 70 mg) on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)
45976675|NCT01603303|Behavioral|Questionnaires|Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time.
45671965|NCT01924299|Drug|Baricitinib|Administered orally
45671966|NCT01924299|Drug|Ketoconazole|Administered orally
45671967|NCT01924299|Drug|Fluconazole|Administered orally
45671968|NCT02182999|Device|Wound infiltration catheter|Wound catheter with multiple and laterally aligned holes is inserted through the intact skin via an 16G iv catheter 2 cm proximal-laterally from the proximal end of the dorsomedial skin incision and placed subcutaneously through the wound and medially around the first metatarsal so that the tip projects into the interdigital space 1/2.
45976676|NCT01603303|Other|Education Materials|Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes.
45976677|NCT01603303|Other|Luvena|Use vaginally 2 or 3 times a week.
45976678|NCT01603303|Other|Hyalo-Gyn|Use vaginally 2 - 3 times a week.
45976679|NCT01603303|Other|Vaginal Lubricant|Water-based vaginal lubricant used during sexual activity.
46082450|NCT00608855|Procedure|cryosurgery|
46082451|NCT00608855|Procedure|pain therapy|
46082452|NCT00608855|Procedure|quality-of-life assessment|
46082453|NCT02720328|Biological|Blood samples for DOAC measurement|
46082454|NCT02795312|Behavioral|Smoking Cessation Program|Participants will take part in a 9-week Smoking Cessation Program
45976680|NCT01603303|Behavioral|Interactive Internet-Based Website|Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs.
45976681|NCT01603303|Behavioral|Telephone Counseling.|Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
45976682|NCT00271323|Drug|docetaxel and cisplatin|Docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemo-radiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy.
45831374|NCT05367180|Other|MISOLRE prevention program on sun risks|Training of an ambassador class by a field coordinator Dissemination of the information by the ambassador class to the other classes of the school drawn by lot Transmission of an information document to parents on photoprotection to make them aware of the actions to adopt
45976683|NCT00271323|Radiation|radiotherapy|Docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
45976684|NCT01603342|Drug|clopidogrel|Following a baseline punch biopsy, all subjects will then receive oral clopidogrel (Plavix®) over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy (B1) will be performed
45976685|NCT01603342|Drug|placebo|Following a baseline punch biopsy, all subjects will then receive oral placebo over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy will be performed
45976686|NCT01603381|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Behavioral management of insomnia
45976687|NCT00257855|Drug|Lamotrigine|
45976688|NCT00290862|Device|Percutaneous Vertebral Augmentation of compression fractures|Study eligible patients with painful osteoporotic compression fractures will be randomized to percutaneous vertebroplasty with CORTOSS (treatment group) or PMMA (active control group).
45976689|NCT01603498|Drug|Dexamethasone|Dexamethasone 8mg
45976690|NCT01603498|Drug|Methylprednisolone|Methylprednisolone 40mg
45976691|NCT01603576|Device|Prototype wide view suprachoroidal retinal prosthesis|Manufacturer = Bionics Institute, Australia
45976692|NCT01603654|Drug|sodium picosulphate magnesium citrate|Use of the product in colon cleansing before colonoscopy. Two sachets each containing 10 mg of sodium picosulfate, 3.5 g magnesium oxide and 12.0 g citric acid. The 2 doses are taken diluted in a glass water.
45976693|NCT01603654|Drug|low-volume PEG -ascorbic acid|THe product is used as colon cleanser before colonoscopy. It is supplied as a powder for oral use, to be reconstituted with 2 L of water and drunk as a solution. It consists of 100.0 g macrogol 3350 plus electrolytes (7.5 g sodium sulphate, 2.7 g sodium chloride, 1.0 g potassium chloride) and 4.7 g ascorbic acid.
45976694|NCT00257972|Drug|aripiprazole|
45976695|NCT00271362|Behavioral|Amputation rehabilitation exercise program|participants will be physically exercised with a full array of exercise methodologies.
45976696|NCT00271362|Procedure|Osteomyoplasty vs. routine long posterior flap|participants enrolled randomly in one of two surgical procedures.
45671969|NCT02182999|Drug|NaCl 0.9%|The catheter is connected to the perfusor line filled with saline 0.9% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
45671970|NCT02182999|Drug|Ropivacaine 0.2%|The catheter is connected to the perfusor line filled with Ropivacaine 0.2% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
45671971|NCT01598311|Drug|CB-183,315|CB-183,315 250 mg white coated tablet over-encapsulated in a size 00 opaque hard gelatin capsule.
45831375|NCT05367180|Other|"Vivre avec le Soleil prevention program on sun risks"|Program is delivered directly by the teachers through pedagogical books : 10 workshops over a period of 3 months
45831376|NCT05367180|Other|Sun protection equipment|Distribution of sunscreen, caps and sunglasses
45976697|NCT01603693|Device|Bio-Oss (by Geistlich)|Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
45976698|NCT01603693|Device|BondBone (by Augma)|Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
45976699|NCT01603771|Other|Blood Oxygen Level Dependent (BOLD) functional magnetic imaging (fMRI)|All participants complete MRI scans at baseline and at the end of month 6. Scanning sessions last approximately 30 minutes each and consist of two components: (1) High resolution T1-weighted MPRAGE anatomic images to provide detailed anatomy and maximum gray-white matter contrast for images and to allow any estimate of regional or whole-brain volume, and (2) Resting BOLD functional images to allow assessment of the functional connectivity in large scale networks.
45976700|NCT02960685|Procedure|Echocardiography|
45976701|NCT01603810|Other|OCT|Optical coherence tomography of periocular basal cell carcinoma
45976702|NCT00258050|Drug|Midazolam|Subjects will receive midazolam by oral or IV route on Days 1, 3, 9 and 11. Oral midazolam was supplied as 3 mg tablets; IV midazolam was supplied as 1 milligram per milliliter (mg/L) sterile solution.
45976703|NCT00258050|Drug|Lapatinib|Subjects will receive 1500 mg lapatinib by oral route once daily from Day 4.
45976704|NCT01603888|Other|no intervention|
45976705|NCT00271401|Other|Angioplasty|
45976706|NCT00271401|Other|Intracoronary Stent|
45976707|NCT00271401|Drug|Abxicimab|
45976708|NCT00271401|Drug|Heparin|
45976709|NCT00271401|Drug|Placebo|
45976710|NCT01604005|Radiation|Prophylactic Irradiation of Tracts (PIT)|21 Gy in 3 fractions
45671972|NCT01598311|Drug|Vancomycin|Vancomycin hydrochloride 125 mg capsule over-encapsulated in size 00 opaque hard gelatin capsule.
45976711|NCT00258089|Drug|Levofloxacin|
45976712|NCT01604044|Drug|Meropur 150 a day|one subcutaneous injection a day
45976713|NCT01604044|Drug|Gonal-f 150 plus Luveris 150|one subcutaneous injection a day
45671973|NCT01598311|Drug|Placebo|Placebo size 00 opaque hard gelatin capsules.
45976714|NCT01604161|Drug|somatropin|Collection of safety and efficacy data in connection with use of somatropin (Norditropin®) in daily clinical practice.
45976715|NCT00290901|Drug|Tramadol Hydrochloride 50mg|
45976716|NCT00290901|Drug|Celebrex 200mg|
45976717|NCT00258167|Behavioral|"filling the Experience of Caregiving Inventory"|8 weeks of group therapy for family members
45976718|NCT01604200|Behavioral|focus group|key informant review
45976719|NCT01604239|Drug|Shinbaro Capsule|600mg twice a day (b.i.d) oral herbal medicine
45671974|NCT02182843|Biological|Cellentra VCBM|Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
45831377|NCT03024450|Drug|H+CT|All patients were treated with trastuzumab plus chemotherapy as the first-line therapy. There were no protocol-specified chemotherapy regimens. This is a prospective observational study. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data were collected to evaluate the potential prognostic factors on progressive free survival.
45976720|NCT01604356|Procedure|Electro-acupuncture|Ten treatment sessions at our center during a two week period (5 sessions per week). Each session will last approximately 30 minutes. The intervention will involve the placement of acupuncture needles in a standard set of points across all patients, located on the head, around the eyes, on the abdomen, on the hands, feet, arms and legs. An electro-acupuncture device [Transcutaneous electrical nerve stimulator (TENS) unit by Lhasa OMS Inc.; model AWQ-104L] and will be used on four of the acupuncture points (two per session) located on the forehead, and side of the face/temple.
45976721|NCT04708314|Drug|Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]|Vyondys 53
45831378|NCT03997968|Drug|CYT-0851|Part A and B: Daily oral doses of CYT-0851 for 28 day cycles
45976722|NCT00258245|Dietary Supplement|ascorbic acid|Ascorbic Acid (Vit C)- 1000 mg IVPB after Arsenic Trioxide [ATO] days 1, 4, 8, 11
45976723|NCT00258245|Drug|arsenic trioxide|Arsenic Trioxide (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11
45976724|NCT00258245|Drug|bortezomib|Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP days 1, 4, 8, 11
45671975|NCT02208050|Drug|Fampridine|
45671976|NCT02208050|Drug|Placebo|
45831379|NCT03997968|Drug|CYT-0851 in combination with gemcitabine|Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine
45976725|NCT00258245|Drug|dexamethasone|Dexamethasone (Decadron)- 40 mg/days IVPB or PO d 1, 4, 8, 11
45671977|NCT04770350|Device|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
45671978|NCT02978222|Biological|FRα peptide plus Adjuvant (GM-CSF)|Intradermal injection FRα peptides, 500μg each - plus GM-CSF 125 μg
45671979|NCT02978222|Drug|Adjuvant (GM-CSF) Alone|Intradermal injection 125 μg GM-CSF
45671980|NCT02181673|Drug|Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.
45976726|NCT00258245|Drug|thalidomide|Thalidomide (Thalomid) - 50 mg/day by mouth (PO)
45976727|NCT00258245|Drug|Aspirin|Aspirin - 325 mg by mouth (PO) every day
45671981|NCT02181673|Drug|Golimumab|Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment Group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 24, 28 and thereafter every 8 weeks up to Week 52 in treatment Group 1.
45671982|NCT02929004|Device|Vibrasens|Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
45456220|NCT04640636|Drug|Ketamine hydrochloride injection|single IM injection of ketamine hydrochloride 0.5 mg/kg
45671983|NCT02827370|Behavioral|Behavioral Dietary Intervention|Receive dietary counseling
45671984|NCT02131129|Device|rTMS|"The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration"
45831380|NCT03997968|Drug|CYT-0851 in combination with capecitabine|Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine
45831381|NCT03997968|Drug|CYT-0851 in combination with rituximab and bendamustine|Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab and bendamustine
46082455|NCT05224115|Other|[11C]CHDI-00485180-R|Mutant huntingtin aggregate binding PET radioligand.
46082456|NCT05224115|Other|[11C]CHDI-00485626|Mutant huntingtin aggregate binding PET radioligand.
45456221|NCT04640636|Drug|Midazolam injection|single IM injection of midazolam 0.06 mg/kg
45456222|NCT04635072|Drug|Stabilised Whole Rice Bran|Patients with mild Atopic Dermatitis (AD) will be given SWRB in powder form, to be used as a cleanser after adding water to it according to set proportions given as instructions, once a day. Patients with moderate disease will use SWRB as a cleanser. In addition, they will also use SWRB as an emollient.
45976728|NCT01604434|Procedure|Incubator-torso bag|While being placed into an incubator, infant will be placed into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket over the plastic bag and will receive a cloth hat. He/she will remain in the bag for one hour.
45976729|NCT01604434|Procedure|Incubator-no plastic bag|Infant will be placed in the incubator, wrapped in a blanket, with a cloth hat, according to standard protocol.
45976730|NCT01604590|Radiation|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) will be used to compare bevacizumab to the images of vessel and tumor structure.
45671985|NCT02131129|Device|Sham Comparator|"The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration"
45831382|NCT05368194|Dietary Supplement|Isocaloric Unprocessed Diet|Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.
45976731|NCT00271440|Procedure|skin cleansing with chlorhexidine (0.25%, 0.5%, 1%)|
45976732|NCT01604629|Drug|Reduced doses of anti-TNF|Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab
45831383|NCT05368194|Dietary Supplement|Isocaloric Processed Diet|Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.
45831384|NCT05368194|Dietary Supplement|Excess Calorie Unprocessed Diet|Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.
45976733|NCT01604629|Drug|Stable doses of anti-TNF|Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis
45976734|NCT00258284|Drug|capecitabine|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
45976735|NCT00258284|Drug|docetaxel|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
45976736|NCT00290940|Drug|CS-917|
45976737|NCT00290940|Drug|metformin hydrochloride|
45976738|NCT00290940|Drug|pioglitazone|
45976739|NCT01604707|Other|Medical Yoga|Patients were randomly allocated to a control group receiving standard care, or a yoga group treated with Medical yoga for 1 hour, once a week, over a 12-week period in addition to the standard care.
45976740|NCT00258323|Drug|cisplatin|20mg/m2d/IV continuous infusion x days
45456223|NCT04634396|Behavioral|ACT Acceptance and Commitment Therapy|6 weeks of 1 hour sessions with a masters prepared research specialist to deliver validated tools
45456224|NCT04623125|Behavioral|Spaced Retrieval Practice|Online picture-naming training with 60 words which the participant experiences word-retrieval difficulties. Cards are shuffled arranged by the computerized training program.
45976741|NCT00258323|Drug|fluorouracil|1000mg/m2/d IV continuous infusion x 4 days
45976742|NCT00258323|Drug|Iressa|250mg po qd days 1-28 then x 2 years
45456225|NCT04621201|Other|observation and biopsy|biopsy
45456226|NCT04607850|Biological|ChAdOx1-HPV|Trial vaccine
45456227|NCT04607850|Biological|MVA-HPV|Trial vaccine
45976743|NCT00258323|Procedure|conventional surgery|conventional surgery
45976744|NCT00258323|Radiation|radiation therapy|150 cGy bid
45976745|NCT01604746|Biological|Ross River Virus (RRV) Vaccine|Not applicable, no vaccine will be administered in this study. The RRV vaccine was administered in the precursor study.
45976746|NCT01604863|Drug|HGS1036 + Paclitaxel + Carboplatin|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle. Paclitaxel 175 mg/m2 or 200 mg/m2, IV and carboplatin AUC 6.0 mg∙min/mL, IV every 3 weeks on Day 1 of each 21-day cycle.
45456228|NCT04607850|Biological|Placebo|Saline placebo vaccine
45976747|NCT01604863|Drug|HGS1036 + Cisplatin + Etoposide|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and cisplatin 60-80 mg/m2, IV on Day 1 and etoposide 100-120 mg/m2, IV on Days 1, 2, and 3 of each 21 day cycle.
45976748|NCT01604863|Drug|HGS1036 + Docetaxel|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and docetaxel 75 mg/m2, IV on Day 1 of each 21-day cycle.
45671986|NCT02152345|Drug|Belatacept|"Belatacept 10 mg/kg will be administered in the operating room approximately 1 hour prior to kidney allograft reperfusion (Day 0). It will then be administered at 10 mg/kg on the following post-transplantation days: Day 5, 14, 30, 56, and 84.~Belatacept 5 mg/kg will be administered every four weeks thereafter until end of study."
45671987|NCT02152345|Drug|Tacrolimus|"Tacrolimus 0.05 mg/kg by mouth every 12 hours will be on Day 0 after transplantation. It will then be administered at 8-12 ng/mL on the following post-transplantation days: Day 3-90; at 8-10 ng/mL Day 91-180.~Tacrolimus 6 - 8 ng/mL will be administered daily thereafter until end of study.~(standard of care)"
45671988|NCT02152345|Drug|Mycophenolate|"An immunosuppressive agent used with other medicines to lower the body's natural immunity in patients who receive kidney transplants.~720 mg by mouth every 12 hours (Day 0)(1080 mg AA).~(standard of care)"
45671989|NCT02152345|Drug|rATG|"1.5 mg/kg IV daily on Day 0-3.~(standard of care)"
45671990|NCT02152345|Drug|Methylprednisolone|"500 mg (Day 0), 250mg (Day 1), 125mg (Day 2), 75 mg (Day 3) IV administered from Day 0-3.~(standard of care)"
45671991|NCT02152345|Procedure|Renal transplant|Standard organ transplant of a kidney into a patient with end-stage renal disease.
45671992|NCT02180659|Drug|sublingual buprenorphine tablets|
45671993|NCT02180659|Drug|Buprenorphine implant|
45976749|NCT00290979|Drug|insulin glulisine|
45671994|NCT02180659|Drug|placebo implants|
45831385|NCT05368194|Dietary Supplement|Excess Calorie Processed Diet|Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.
45831386|NCT05363280|Drug|AL8326 low dose group|Taken AL3826 at low dose orally
45831387|NCT05363280|Drug|AL8326 middle dose group|Taken AL3826 at middle dose orally
45831388|NCT05363280|Drug|AL8326 high dose group|Taken AL3826 at high dose orally
45831389|NCT05362578|Device|transcutaneous electrical accustimulation at treatment point.|The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
45976750|NCT00258401|Dietary Supplement|dietary intervention|At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.
45976751|NCT00258401|Procedure|management of therapy complications|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
45976752|NCT00258401|Procedure|quality-of-life assessment|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
45671995|NCT02180659|Drug|sublingual placebo tablets|
45671996|NCT02130427|Diagnostic Test|CT scan|Weekly 3D/4D CT scan
45671997|NCT02207816|Procedure|Blood sampling|Annual blood sampling (Year 1, Year 2 and Year 3) during the present study.
45671998|NCT02207816|Biological|Malaria Vaccine 257049 (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
45671999|NCT02207816|Biological|Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
45976753|NCT01604902|Other|4 mm punch biopsies|4 mm punch-biopsies from lesional and non-lesional psoriatic skin at day 0 and up to four times after treatment at the following days: 4, 14, 28 or 84.
45976754|NCT01604980|Dietary Supplement|Protein intake.|protein intakes will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8 and 2.0g/kg/day
45976755|NCT00271479|Biological|A, C, Y, W135 meningococcal polysaccharide vaccine|
46082457|NCT03978091|Drug|AZACTAM|A synthetic monobactam antibiotic originally isolated from Chromobacterium violaceum
45672000|NCT02207816|Biological|Cell-culture rabies vaccine (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
45976756|NCT00258479|Drug|ModafinilNicotine Replacement Therapy|A dose escalation design includes eight dose conditions across a 12-day study (nicotine low-high, modafinil low-high and 4 combinations). After day 1 placebo dose, placebo sessions occur in random order during low dose, high dose, and dose-combination testing. Modafinil and nicotine are tested alone with subjects exposed to low active doses prior to higher doses. Dose interactions will be determined with low doses tested in combination followed by low-high dose combinations then high-high dose combination. Doses are administered under double-blind, double dummy procedures. A nicotine patch (0, 7 or 14 mg doses) is applied at 7 am. Modafinil doses are prepared in size 00 opaque capsules. The modafinil dose (0, 100, 200 mg) is administered at 5 PM.
45976757|NCT00258479|Drug|Modafinil|See Modafinil Intervention Description above.
45976758|NCT01605331|Drug|sustained-release recombinant human GH (SR-rhGH)|
45976759|NCT01605409|Procedure|Emergency cardiopulmonary bypass under ongoing CPR|"Emergency cardiopulmonary bypass under ongoing CPR~Emergency cardiopulmonary bypass (ECMO: lifebridge (Sorin®) or cardiohelp(Maquet®) will be initiated percutaneously ultrasound guided, during CPR efforts at the Emergency department.~Cannulae and tubing in use will be heparin coated. ECMO flow will be set to 70ml/kgBW/min. Anticoagulation will achieved with unfractionated heparin and monitored using ACT."
45831390|NCT05362578|Device|transcutaneous electrical accustimulation at sham point.|The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
45976760|NCT01605409|Procedure|Standard ACLS|"Standard ACLS Standard ACLS provided by EMS personnel according to current guidelines of the European resuscitation council.~Transportation:~Transport will be initiated as soon as the patient achieves ROSC in the field and transportation is feasible. All patients will be admitted to the ED at the Vienna general hospital.~Standard Post resuscitation Management:~After admission to the ED post resuscitation care and standardized intensive care treatment will be provided according to Utstein protocol and current standards for good clinical practice and according to ILCOR recommendations. A crossover to the ECPB group is possible, if indicated by good clinical practice. If so, it will be counted as treatment failure in the standard ACLS group.~If no ROSC can be achieved and the patient dies in the field pathological results will be obtained if feasible."
45976761|NCT00271518|Drug|growth hormone (somatropin)|dosing regimen is weight based.
45831391|NCT03997422|Procedure|Vertical Sleeve Gastrectomy (VSG)|Vertical Sleeve gastrectomy will be performed using five laparoscopic ports using a 40 French Bougie as a template. If a hiatal hernia is identified it will be repaired. This practice has greatly reduced postoperative reflux disease (see human subjects protection). As VSG for patients with a BMI 30.0-34.9 kg/m2 is not covered by insurance the University hospital will cover costs for up to 24 patients.
45976762|NCT01340014|Drug|Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension|
45976763|NCT01340014|Drug|Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution|
45976764|NCT00258518|Procedure|mechanical ventilation/CT Scan|evaluation of pleural effusion and respiratory mechanics, CT scan
45976765|NCT00291057|Drug|MALG|30 minute application
45976766|NCT00258557|Drug|LPV/RTV|400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
45976767|NCT00258557|Drug|TMC-114/RTV|two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
45976768|NCT00271557|Drug|nesiritide|
45976769|NCT01339897|Drug|5 mg/N6022|Intravenous formulation, given at doses of 5 mg once each day over 7 days.
45672001|NCT02207816|Biological|TritanrixHepB/Hib (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
45672002|NCT02207816|Biological|Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)|Administered orally, during the MALARIA-055 study (NCT00866619).
45831392|NCT04263090|Drug|Rigosertib|Rigosertib will be dosed twice a day for 21 consecutive days, followed by 7 days off treatment (each cycle duration: 28 days). Rigosertib escalation will occur with three dose levels (dose D1: 280mg twice daily; dose D2: 560mg qAM, 280mg qPM; dose D3: 560mg twice daily).
45831393|NCT04263090|Drug|Nivolumab|Nivolumab will be dosed once ever 2 weeks (twice per 28-day cycle; standard fixed dose of 240mg).
45831394|NCT03596424|Drug|Ketamine Hydrochloride|Intraoperative bolus and infusion (see arm description)
45976770|NCT01339897|Drug|Placebo|Same administration procedures as active
45976771|NCT01339897|Drug|10mg/N6022|Intravenous formulation given at doses of 10 mg once each day over 7 days.
45976772|NCT01339897|Drug|20mg/N6022|Intravenous formulation given at doses of 20 mg once each day over 7 days.
45976773|NCT00271635|Drug|Placebo|Placebo 4 capsules b.i.d. during 1 year
45976774|NCT00271635|Drug|ascorbic acid|Ascorbic acid 1000 mg (4 capsules of 250 mg) b.i.d. during 1 year
45976775|NCT01339429|Device|simplified negative pressure wound therapy device (Wound Pump device)|A non-powered negative pressure device utilizing a bellows attached to a specialized dressing via drainage tube to promote healing of open wounds.
45976776|NCT00258596|Device|sirolimus-eluting stent|
45831395|NCT03596424|Drug|Dexmedetomidine Hydrochloride|Intraoperative bolus and infusion (see arm description)
45976777|NCT01339390|Behavioral|MOVE OUT|The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
45976778|NCT01339390|Behavioral|MOVE!|"As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the PCP to determine if the person would benefit from a weight loss program, and to refer them to MOVE if they and the patient agree that it would be beneficial. The MOVE program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs."
45976779|NCT01339273|Procedure|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
45976780|NCT01339273|Procedure|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
45976781|NCT00271674|Device|Q-switched YAG laser|
45672003|NCT05156606|Drug|AndroGel|After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.
45831396|NCT03596424|Combination Product|dexmedetomidine Hydrochloride and Ketamine Hydrochloride|Intraoperative bolus and infusion (see arm description)
45831397|NCT03997266|Drug|Ampicillin|Intravenous ampicillin
45831398|NCT03997266|Drug|Gentamycin|Intravenous gentamycin
45831399|NCT03997266|Drug|Normal saline|Intravenous normal saline
45831400|NCT03832764|Device|ANSPEC-PRO|Device monitors for 140 minutes continuously the pain levels in awake patients in PACU/ICU
45831401|NCT05368272|Other|Processed electroencephalography|Acquisition of raw EEG data from processed EEG monitor. Analysis of data acquired for prespecified bandwidth properties
45831402|NCT05368272|Other|Postoperative delirium assessment|Twice daily assessment for the incidence of postoperative delirium using validated tool (questionnaire)
45831403|NCT05630508|Behavioral|interactive Mhealth Lifestyle behavior intervention|Receiving Standard care, LIVEN educational material and interactive LIVEN application, via having a human component which is a health coach for 3 months
45976782|NCT01334866|Procedure|Minimally invasive coronary artery bypass graft surgery|The MICS CABG procedure can bridge the gap between percutaneous coronary intervention (PCI) and standard sternotomy. The key components are direct vision, creating anastomoses with traditional instruments and proximal aortic location.
45831404|NCT05630508|Other|Sham|Receiving standard care, LIVEN educational material and access to the application
45831405|NCT05368818|Other|Secukinumab|Included patients treated with Cosentyx (Secukinumab) in a retrospective analysis of the BADBIR data source
45976783|NCT04709315|Drug|dexemedetomidine and rocuronium|In the DR group, patients received pretreatment with Dex 1 µg / kg in 10 ml 0.9% saline over 10 minutes and rocuronium 0.6 mg/kg was the intubating muscle relaxant
45976784|NCT04709315|Drug|0.9% saline and succinyl choline 1mg/ kg|0.9% saline over 10 minutes, and succinyl choline 1mg/ kg
45976785|NCT01334710|Drug|Sorafenib and OSI-906|Sorafenib - 400 mg twice daily OSI-906 - 150 mg twice daily
45976786|NCT00271713|Drug|ibandronate, calcium and vitamin D|1: 150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily or
45976787|NCT00271713|Drug|placebo,calcium and vitamin D|2: placebo monthly plus 500mg calcium and 800 UI vitamin D daily
45976788|NCT00258713|Drug|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg BID
45976789|NCT01334554|Drug|Sildenafil|20 mg three times a day.
45976790|NCT01334554|Drug|Placebo|No active drug
45976791|NCT00291213|Drug|levetiracetam|
45976792|NCT00291213|Drug|placebo|
45831406|NCT03995082|Other|Patient Reported Outcome Measure Survey result feedback|Patients will receive a graph of their results from the PROM survey each time they complete a survey
45831407|NCT03994770|Diagnostic Test|Balanced Reach Assessment and Training Protocol|Three one-hour training sessions for one week in the Balanced Reach Training Protocol
45831408|NCT05630274|Drug|Selpercatinib|Administered orally
45976793|NCT01332799|Drug|allopurinol or placebo|Daily active drug (allopurinol administered orally) administered orally for 3 years.
45976794|NCT01332799|Other|Placebo|Sugar pill administered orally for 3 years.
45976795|NCT00258752|Behavioral|IPT-AST|IPT-AST is a school based group treatment program that focuses on prevention, psychoeducation, and interpersonal skill building.
45976796|NCT00258752|Other|Enhanced IPT-AST|Enhanced IPT-AST entails IPT-AST plus three parent-adolescent sessions.
45976797|NCT00258752|Other|School counseling|Usual care consists of standard treatments, including individual counseling with guidance counselor.
45976798|NCT00271752|Procedure|Earlier therapeutic changes regarding infection|For every day Procalcitonin levels increase in the intervention group, antibiotics, surgery, diagnostic imaging and microbiologic testing is intensified
45976799|NCT00258791|Drug|Ibuprofen|
45976800|NCT00291369|Drug|Interleukin-2|
45976801|NCT00291369|Drug|Interferon alfa|
45976802|NCT00291369|Drug|medroxyprogesterone acetate|
45976803|NCT00291408|Procedure|Skin Prick Test|
45976804|NCT00291408|Procedure|Impulse Oscillometry|
45976805|NCT00291408|Procedure|Exhaled Nitric Oxide|
45976806|NCT00291408|Procedure|Spirometry|
45976807|NCT00291408|Procedure|Reversibility|
45831409|NCT05630274|Drug|Moxifloxacin|Administered orally
45831410|NCT05630274|Drug|Placebo|Administered orally.
45456229|NCT04600167|Drug|Isoniazid and Rifapentine (INH-RPT)|Oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.
45456230|NCT04600167|Drug|Placebo|Participants in the control group will receive placebo once weekly for 12 weeks
45976808|NCT00291408|Procedure|Exhaled Breath Condensate|
45976809|NCT00291408|Procedure|Sputum Induction|
45976810|NCT00258947|Biological|Smallpox vaccine, LISTER strain, from chick embryo cells|
46082458|NCT03978091|Drug|Ceftazidime-Avibactam|An antibacterial combination product containing ceftazidime and avibactam
46082459|NCT02795468|Procedure|Radial arterial cannulation|Radial arterial cannulation using usual palpation method or ultrasound guided technique according to the group
46082460|NCT01969812|Device|Evie Slow-release Insemination Device|
46082461|NCT01969812|Other|Traditional Intrauterine Insemination|
45976811|NCT00271791|Drug|Prednisone|PO, 1 mg/kg body weight, 5 days Short tapering regimen: daily reductions in the dose, 12 days
45976812|NCT00271791|Drug|Prednisone|PO, Placebo, 17 days
45976813|NCT00258986|Procedure|Living donornephrectomy|
45976814|NCT01332331|Drug|Ambrisentan - low dose|body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
45976815|NCT01332331|Drug|Ambrisentan - high dose|body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
45976816|NCT00259025|Drug|lipid emulsion with a high content of n-3 fatty acids|
45976817|NCT00291564|Device|Cardiac Resynchronization Therapy Device|
45976818|NCT00259064|Drug|Gefitinib|
45976819|NCT00259064|Other|Placebo|
45976820|NCT01332292|Drug|Fluticasone furoate|Novel dry powder inhaler: 100µg per blister One blister strip containing fluticasone furoate micronised drug blended with lactose and a second blister strip containing lactose and magnesium stearate.
45976821|NCT01332292|Drug|Matching placebo|Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.
45976822|NCT00271869|Procedure|Extracorporeal photoimmunotherapy|
45976823|NCT00271908|Behavioral|Community Mobilization|"ATN 040b is the evaluation sub-study for ATN 040, Phase III of C2P. Phase III is a community mobilization intervention aimed at reducing HIV rates among youth via community structural change. ATN 040b involves annual anonymous data collection with two cohorts per participating ATN/C2P site. Both cohorts will represent the site's target population, or population of focus."
45976824|NCT00291603|Device|FX-class of dialyser|
45976825|NCT00259103|Drug|Serelaxin|
45976826|NCT00259103|Drug|Placebo|
45976827|NCT00259142|Drug|Chloroquine, sulphadoxine-pyrimethamine|
45976828|NCT00259181|Procedure|saturation of polymethylmethacrylate with chlorhexidine gluconate to reduce in vivo plaque formation|
45976829|NCT00291720|Drug|Spironolactone|All patients receive a 4 week open labeled run in phase of 25mg spironolactone daily after which they are randomized to continue or receive matched placebo for 8 months.
45976830|NCT00291720|Drug|Placebo|matching placebo
45976831|NCT00259220|Drug|erythomycin|erythomycin
45976832|NCT00259220|Procedure|gastric lavage alone|gastric lavage alone
45976833|NCT00259220|Procedure|erythromycine and gastric lavage|erythromycine and gastric lavage
45976834|NCT00259259|Behavioral|SALATRIM|
45976835|NCT00291759|Drug|Tamoxifen|
45976836|NCT00291759|Drug|Anastrozole|
45976837|NCT00272025|Drug|Escitalopram|10mg to 20mg tablet daily for 6 weeks
45976838|NCT00272025|Drug|placebo|
45672004|NCT02530658|Other|Study Introduction Visit|Within 5±3 weeks following arrival at SJCRH, or at the participant/family's convenience, participants will meet with a genetic counselor and clinician, provide information for a family pedigree, undergo a physical and discuss germline testing options. Study introduction materials will be provided. Families interested in the G4K study will be referred to the study nurse or other G4K member and an Informed consent visit will be scheduled.
45672005|NCT02530658|Other|Informed Consent Visit|Within 1±3 weeks following the Study Introduction Visit, or at the participant/family's convenience, the research nurse or other study team member will consent the family and collect demographic and medical information. Participants will complete assessment questionnaires.
45672006|NCT02530658|Other|Informed Consent Follow-Up Visit|Within 2-4 weeks following the Informed Consent Visit, or at the participant/family's convenience, a subset of participants (30-40) will participate in semi-structured interviews.
45672007|NCT02530658|Other|Return of Results Conversation|Participants will complete the assessment questionnaires.
45672008|NCT02530658|Other|Return of Results Follow-Up Visits|Return of Results Follow-Up Visits will be conducted twice: the first within 8±4 weeks of the Return of Results Conversation, or at the participant/family's convenience, and the second within 32±8 weeks of the Return of Results Conversation or at the participant/family's convenience. At each visit, participants will complete assessment questionnaires. Semi-structured interviews with parents and adolescents will be conducted.
45672009|NCT02530658|Procedure|Blood Sample|For patients who have not previously provided a blood sample, a sample of blood will be obtained as a source of germline DNA.
45672010|NCT02530658|Procedure|Skin Biopsy|After consent, for participants with a diagnosis where peripheral blood is likely to be contaminated by tumor cells, skin biopsies may be done as a source of germline DNA.
45976839|NCT00291798|Procedure|rate of remission|
45831411|NCT04407624|Other|Intermittent Exercise|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. During the loading period, taking into consideration the heart rate, fatigue and shortness of breath, exercises such as walking, squat, limb movements with weights, stepping on the steps, walking on different floors are shown. Stretching exercises are done during the cooling period. Intermittent loading workouts will consist of 3-minute loads and 1-minute rest intervals. Participants are contacted every two weeks via communication methods such as e-mail, message and telephone conversation. Exercise diary is given to all patients and is taken from them at the end of the study.
45831412|NCT04407624|Other|Control|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. In loading period, moderate aerobic exercise is consist of brisk walking to reach 60-85% of the person's maximum heart rate. Stretching exercises are done during the cooling period.
45976840|NCT04709081|Drug|ACH-0145228|ACH-0145228 was dosed as 2 x 60 milligram (mg) (Part 1) or 1 x 40 mg (Part 2) powder in capsules.
45976841|NCT04709081|Drug|Midazolam|Midazolam was dosed at 2 mg (1 milliliter [mL] of a 2 mg/mL syrup).
45831413|NCT05632692|Other|Menthol solution|Menthol application, through oral solutions, stimulates the mandibular and maxillary branches of the trigeminal nerve (which are predominantly responsible for detection of temperature and nociceptive stimuli across the face and within the oral cavity) and has consistently shown to improve thermal comfort and decrease thermal sensation, which are thought to modulate perceived exertion to improve performance in the heat.
45976842|NCT04709081|Drug|Digoxin|Digoxin was dosed as Lanoxin (or generic equivalent) at 1 x 0.25 mg tablet.
45976843|NCT04709081|Drug|Itraconazole|Itraconazole was dosed as Sporanox (or generic equivalent) at 200 mg (20 mL of a 10 mg/mL oral solution).
45976844|NCT00272064|Drug|Insulin glulisine|individualized, once daily, dose aiming at 2h post-prandial plasma glucose goal < 140 mg/dl (7.8 mmol/l) in the optimized treatment phase, since visit 3, subcutaneous
45456231|NCT04596670|Drug|68Ga-ICAM-1pep|68Ga-ICAM-1pep PET/CT: after intravenous injection of 2.96 MBq/kg body weight of quality-controlled 68Ga-ICAM-1pep, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
45976845|NCT00272064|Drug|Insulin glargine|individualized, once daily, dose to reach mean fasting plasma glucose (FPG) <= 126 mg/dl (7.0 mmol/l), since randomization, subcutaneous
45976846|NCT00272064|Drug|Metformin|1000 mg b.i.d, since the qualification phase, oral
45976847|NCT00259337|Biological|Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine|0.5 mL, IM
45976848|NCT00259376|Drug|Dronedarone (SR33589)|oral administration
45976849|NCT00259376|Drug|placebo|oral administration
45976850|NCT00415337|Procedure|endobronchial ultrasound|EBUS
45976851|NCT01332019|Drug|peginterferon beta-1a|Administered as specified in the treatment arm
45976852|NCT00291837|Drug|CT-2106|
45672011|NCT02419976|Other|a breath analysis using the Aeonose|"using the Aeonose per standard acquisition protocol which spans 15 minutes of which the individuals breaths normally through a sterile disposable mouthpiece with sterile disposable air filters for 10 minutes during signal acquisition while wearing a nose plug. This will be completed in the office setting prior to their endoscopic procedure.~Following their scheduled standard of care endoscopic procedure the patient will be allowed to consume a standardized refreshment (such as juice or soda) prior to discharge from the post procedure area. These refreshments are already provided as standard care. The participant will return to the office setting and repeat the same breath analysis acquisition process that was done prior to the procedure."
45672012|NCT02419976|Device|Aeonose|
45831414|NCT05632614|Device|High-intensity IMST|Participants will use the POWERbreathe KHP2 inspiratory muscle training device. All participants will be assigned to perform 30 inspiratory maneuvers (5 sets of 6, 1-minute rest between sets), 6 days per week, for 6 weeks. Participants will be trained at 55% PIMAX during week 1, 65% PIMAX during week 2, and 75% PIMAX during weeks 3 to 6.
45831415|NCT05632614|Device|Low-intensity IMST|Participants will use the POWERbreathe KHP2 inspiratory muscle training device. All participants will be assigned to perform 30 inspiratory maneuvers (5 sets of 6, 1-minute rest between sets), 6 days per week, for 6 weeks. Participants will be trained at 15% PIMAX for 6 weeks.
45831416|NCT03594162|Drug|iC9-CAR19 cells|One of two dose levels will be given: 1 x 10^5 or 5 x 10^5
45976853|NCT02961140|Other|Cardiac Output Maximization|According to Frank-Starling law, the investigator will administer Voluven 6% 250 mL every 5 minute until stroke volume maximized (stabilized for 20 minutes), and maintain cardiac index and stroke volume variation during the whole operation.
45976854|NCT02961140|Other|Cardiac Output Normalization|The investigator will administer intravenous fluids to keep cardiac index (CI) ≥ 2.2, and maintain CI and stroke volume variation during the whole operation.
45976855|NCT00272103|Drug|Itopride (drug)|
46082462|NCT02800616|Other|The Healthy Primary School of the Future|In two out of four intervention schools, a whole-school approach named 'The Healthy Primary School of the Future', is implemented with the aim of improving physical activity and dietary behaviour. For this intervention, pupils are offered an extended curriculum, including a healthy lunch, more physical exercises, and social and educational activities, next to the regular school curriculum.
45976856|NCT04718688|Other|CO-OP rehabilitation|"The intervention was included within the child's conventional rehabilitation program.~In the CO-OP original protocol, the child sets 3 goals. Here, we concentrated on two rather than three goals, as addressing three occupations per session seemed too ambitious given the children's cognitive profile (the third goal served as control goal).~We chose to increase the number of sessions to 14 (two sessions per week for seven weeks, vs ten in the original protocol).~The global strategy was taught to the child at the first session. The following sessions consisted of an iterative process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the children were experiencing when performing the self-selected tasks. In addition, homework was assigned to encourage the application and practice. Parents were invited to attend the sessions if it was possible for them."
45976857|NCT00415376|Drug|levetiracetam|
45976858|NCT00415376|Procedure|quality-of-life assessment|
45976859|NCT00415454|Genetic|Ad5-yCD/mutTKSR39rep-ADP|Single injection on day 1 at one of five dose levels
45976860|NCT00259415|Behavioral|Caregiver support via telephone|
45976861|NCT00272142|Drug|Zinc|
45976862|NCT00272142|Drug|Placebo|
45976863|NCT00259454|Behavioral|In-home intervention|occupational therapy techniques to reduce caregiver stress
45976864|NCT00291915|Drug|Adalimumab|
45976865|NCT00291915|Drug|Methotrexate|
45976866|NCT00259493|Procedure|Off-Pump Coronary Artery Bypass Graft Surgery|
45976867|NCT00272181|Drug|Proxinium|Intratumoral administration of Proxinium directly to target tumors.
45672013|NCT02241512|Drug|Ibuprofen|
45672014|NCT02241512|Drug|placebo|
45672015|NCT02205476|Drug|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 4 administration of PF-06473871.
46082463|NCT02800616|Behavioral|The Physical Activity School|In the two other intervention schools, a physical-activity school approach called 'The Physical Activity School', is implemented, which is essentially similar to the other intervention, except that no lunch is provided.
45672016|NCT02205476|Drug|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 3 administration of PF-06473871.
45672017|NCT01709110|Drug|Teriparatide|Administered SC
45672018|NCT01709110|Drug|Risedronate|Administered orally
45976868|NCT00259532|Procedure|Ultrasound and contrast agent|contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas
45976869|NCT00291954|Biological|HB-AS02V|HB-AS02V (20µg HBsAg) will be administered at Month 0 and 1
45976870|NCT00291954|Biological|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0 and 1
45976871|NCT00259571|Drug|retarded release phosphatidylcholine|2g daily, given orally QTD
45976872|NCT00259688|Device|CPAP therapy for subjects diagnosed with sleep apnea|CPAP therapy is being offered to women who are diagnosed on Polysomnogram with sleep apnea. However, this is not an intervention study and treatment is not part of the study protocol.
45976873|NCT00272220|Behavioral|modified directly observed therapy (mDOT)|Peers individually administered the 6-week mDOT intervention at the Beira Day Clinic to mDOT participants during their morning weekday dose. Evening and weekend doses were not observed. Nighttime and weekend doses were self-administered. As part of the daily interaction with participants, peers provided social support, information about the benefits and side effects of HAART, how to address stigma's effect on adherence, and encouragement to participate in community support groups. The peers also provided an important link between the individual and other members of the HIV clinic team and the community.
45976874|NCT00272259|Procedure|Participants will interact with up to two small robots and a visual display|
45976875|NCT00259766|Drug|Budesonide|
45976876|NCT00259766|Drug|Formoterol|
45976877|NCT00259766|Drug|Terbutaline|
45976878|NCT00292071|Drug|caspofungin acetate|(50 mg/m²/day and 70 mg/m²/day) Caspofungin will be given for a minimum of 4 days (or at least 2 separate days of 7-point plasma sampling). Patients will be administered caspofungin for a maximum of 28 days.
45976879|NCT04709159|Other|Call for Life Uganda|"Call for Life™ Uganda (C4LU) is a web-based mHealth tool that provides treatment support to patients in the form of daily or weekly pill adherence reminders, health messages, clinic appointment reminders and a remote symptom reporting service. The tool interacts with patients by text message (SMS) or using voice and tone input via keypad (Interactive Voice Response - IVR) on both analogue and smart phones.~The tool uses CONNECT FOR LIFE technology, which is on an open source platform developed by Grameen Foundation and the University of Southern Maine with financial support from the Bill and Melinda Gates Foundation. It was supported by Janssen, the Pharmaceutical Companies of Johnson and Johnson and was released under the terms of the MOTECH open source license agreement."
45976880|NCT00292110|Drug|Methadone|100 mg/day orally
45976881|NCT00292110|Behavioral|Contingency Management|Incentives given for cocaine abstinence
45976882|NCT00292110|Drug|Methadone dose|flexible methadone dosing to 190 mg/day daily orally
45976883|NCT00292110|Behavioral|Contingency Management/Noncontingent Incentives|Incentives given independent of drug use
45976884|NCT00259805|Drug|Rituximab|375 mg/m2 given as an IV infusion once weekly for four doses
45672019|NCT01709110|Drug|Placebo|"Teriparatide arm placebo administered orally.~Risedronate arm placebo administered SC."
45976885|NCT00259844|Biological|TroVax|
45976886|NCT00259883|Drug|paroxetine|1 or 2 tablets once a day
45976887|NCT04718376|Drug|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
45976888|NCT02961335|Procedure|Bronchoscopy|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
45976889|NCT02961335|Procedure|Confocal microendoscopy|Confocal microendoscopy will be performed during this initial bronchoscopy
45976890|NCT02961335|Procedure|Biopsy sampling|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
45672020|NCT01709110|Drug|Calcium|Administered orally
45831417|NCT03594162|Drug|AP1903|Subjects who develop grade 4 CRS or grade 3 CRS that is refractory to standard of care interventions will be given AP1903 at .4 mg/kg.
45831418|NCT03594162|Drug|Cyclophosphamide|900 mg/m^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
45831419|NCT03594162|Drug|Fludarabine|25 mg/m^2/day IV over 30 minutes administered for 3 consecutive days.
45831420|NCT04407312|Drug|Cilostazol Tablets|Cilostazol-SR, capsule, 200mg, once daily, 30 days.
45831421|NCT04407312|Drug|placebo|Placebo, tablet, 200mg, once daily, 30 days.
45831422|NCT04407312|Drug|Aspirin|Astrix, capsule,100mg, once daily, 30 days.
45976891|NCT00272415|Drug|INO-1001|Intravenous repeating dose
45976892|NCT00272415|Drug|temozolomide|Oral repeating dose
45976893|NCT00259922|Drug|Placebo|Placebo
45976894|NCT00259922|Drug|Alvimopan|0.5 mg QD
45976895|NCT00259922|Drug|Alviompan|0.5 mg BID
45976896|NCT00272454|Drug|Cilostazol|
45672021|NCT01709110|Drug|Vitamin D|Administered orally
45672022|NCT02240108|Drug|Rifaximin EIR|Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
45672023|NCT02240108|Drug|Placebo|Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
45672024|NCT01590628|Drug|NiCord|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells
45831423|NCT04407312|Drug|Clopidogrel|Plavix, tablet, 75mg, once daily, 30 days.
45831424|NCT03993444|Behavioral|communication and problem solving|a program for supervisors and employees including skills training, validating communication, problem solving
45831425|NCT03993444|Behavioral|psychoeducation|lecture/course for supervisors and employees on risk factors and actions for people experiencing stress and/or pain
45831426|NCT04009668|Drug|adalimumab|Adalimumab will be dosed based on weight
45831427|NCT04326738|Drug|Midazolam|M group received intravenous injection of 0.03mg·kg-1 (1mg·ml-1) midazolam, After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg (injection was completed in 2s)
45831428|NCT04326738|Drug|normal saline|N group received corresponding intravenous normal saline of1ml·kg-1 .
45831429|NCT03597126|Device|Robot-assisted surgery|robot-assisted intersphincteric resection for low location rectal cancer(T=1&2)
45831430|NCT03597126|Device|Laparoscopic surgery|laparoscopic intersphincteric resection for low location rectal cancer(T=1&2)
45831431|NCT04347486|Drug|Sugammadex Injection 2mg/kg|Intravenous injection of 2mg/kg of sugammadex sodium on reappearance of T2
45831432|NCT04347486|Drug|Sugammadex Injection 4mg/kg|Intravenous injection of 4mg/kg of sugammadex sodium on reappearance of T2
45976897|NCT00272454|Drug|Aspirin|
45976898|NCT00272493|Biological|Hepatitis B virus vaccine with GM-CSF adjuvant|Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.
45976899|NCT00272493|Biological|Hepatitis B virus vaccine|Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.
45976900|NCT00259961|Procedure|open fundoplication|
45976901|NCT00259961|Procedure|laparoscopic fundopliaction|
45976902|NCT00292266|Drug|Rebif®|Rebif® injection will be administered subcutaneously at a dose of 44 mcg, three times per week, up to 72 weeks.
45976903|NCT00292266|Drug|Avonex®|Avonex® injection will be administered intramuscularly at a dose of 30 mcg, once weekly, up to 72 weeks.
45976904|NCT00260000|Drug|5,6,7,8-tetrahydrobiopterin|
45976905|NCT00292305|Procedure|Percutaneous coronary intervention|Implantation of coronary stent in bifurcation lesions
45976906|NCT00260039|Biological|Comparator: Gardasil|0.5 mL intramuscular injection administered at Day 1, Month 2 and Month 6
45976907|NCT00260039|Biological|Comparator: octavalent HPV Vaccine - dose formulation 1|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
45976908|NCT00260039|Biological|Comparator: octavalent HPV Vaccine - dose formulation 2|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
45976909|NCT00260039|Biological|Comparator: octavalent HPV Vaccine - dose formulation 3|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
45976910|NCT00292344|Drug|Rifaximin and loperamide|
45976911|NCT00260117|Behavioral|Exercise|Referal to a website
45976912|NCT00272532|Drug|Thiocolchicoside|
45976913|NCT00417768|Drug|Tissue Plasminogen Activator|The dosage of tPA is determined by the volume of drainage obtained when abscess is first drained. The same dose will be repeated on day 1 and 2.
45976914|NCT00417768|Other|Normal Saline|Normal Saline will be used rather than Tissue Plasminogen Activator for the Sham arm.
45976915|NCT00292383|Procedure|Leads to be implanted according randomization on specified sites. Vitatron pacemakers to be implanted: T60 DR, T70 DR, T20 SR, C60 DR|
45976916|NCT00258635|Biological|RagweedMATAMPL|
45976917|NCT00260234|Biological|Allogeneic Cultured Islet Cells (human); Encapsulated|
45976918|NCT00272571|Procedure|External counter pulsation therapy|
45976919|NCT00260273|Behavioral|Cognitive Behaviour Therapy|therapy
45976920|NCT00272610|Drug|0.4% Retinol Cream|
45976921|NCT00260312|Biological|Inactivated Polio Vaccine given at an accelerated schedule|
45976922|NCT00292422|Drug|BG9924|
45976923|NCT00260351|Biological|Purified Verocell Rabies Vaccine|0.1 mL, ID (TRC regimen)
45831433|NCT04347486|Drug|Sugammadex Injection 8mg/kg|Intravenous injection of 8mg/kg of sugammadex sodium on reappearance of T2
45976924|NCT00260351|Biological|Purified Verocell Rabies Vaccine|0.5 mL, IM (ZAGREB regimen)
45976925|NCT00260351|Biological|Purified Verocell Rabies Vaccine|0.5 mL, IM (ESSEN regimen)
46082464|NCT00610571|Drug|Oral Topotecan and Temodar|"Temozolomide is taken by mouth once day, every day for 5 consecutive days at dose of 200 mg/m2/day.~Oral Topotecan will be taken daily for 5 consecutive days beginning 12-24 hrs after 1st dose of Temozolomide. Dose escalation of Oral Topotecan will be carried out in cohorts of 3 new subjects beginning w dose level 1 @ 0.75 mg/m2/dose."
45831434|NCT04347486|Drug|Neuromuscular reversal agent injection|Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
45831435|NCT03025152|Dietary Supplement|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
45831436|NCT03025152|Other|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
45976926|NCT00292500|Device|Automated distal anastomotic device|CABG
45831437|NCT04407234|Drug|Tirzepatide|Tirzepatide administered SC.
45976927|NCT00272688|Drug|Levodopa (drug), intraduodenal administration|
45976928|NCT00260390|Drug|Testoviron|
45976929|NCT00292539|Device|Any pacemaker with right ventricular pacing option|
45976930|NCT00260468|Other|Clinical examination program|Psychiatric/clinical interview MRI scan Blood samples Saliva samples Eye examination
45976931|NCT00292578|Procedure|NAET Testing Modalities|
46082465|NCT02720250|Dietary Supplement|Omega-3 chicken eggs|Intake of 3 omega-3 fatty acids enriched chicken eggs per day for three weeks.
45831438|NCT04407234|Drug|Acetaminophen|Acetaminophen administered orally.
45976932|NCT00260546|Procedure|AV-node ablation|Patients that are randomized to AV node ablation will have their AV-node ablated using a transfemoral approach. Concurrently,a back-up pacing lead will temporarily be placed in the right ventricle.
45976933|NCT00292656|Procedure|NAET|
45976934|NCT00260624|Drug|Escitalopram (Lexapro)|
45976935|NCT00292695|Other|VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT|"IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1~DVIP: (Q4W, POST-RT) X 2 Dexamethosone 20 mg/m2/d iv D1-4 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-4 Ifosfamide 1.2 gm/m2/d ivd 2 hr D1-4 Mesna 240 mg/m2/d iv at 0, 4, 8 hr D1-4 Cisplatin 20 mg/m2 ivd 1 hr D1-4 G-CSF 250ug subcut D 9-12"
45976936|NCT00260663|Procedure|Group hearing aid fittings|
45976937|NCT00260663|Procedure|Group hearing aid follow-up|
45976938|NCT00292734|Drug|Zolpidem|
46082466|NCT02720250|Dietary Supplement|Regular chicken eggs|Intake of 3 regular chicken eggs per day for three weeks.
46082467|NCT02800460|Procedure|fMRI-3T|fMRI-3T will be performed during the visit 1: day of anesthesia consultation (this fMRI-3T will last approximately one hour)
45456232|NCT04592341|Drug|Gantenerumab|Gantenerumab will be administered by SC injection at a dose of 120 mg Q4W for 12 weeks, followed by 255 mg Q4W for 12 weeks, and 255 mg Q2W for another 12 weeks, followed by the target dose 255 mg Q1W for up to Week 103 and an optional dose of 255 mg Q1W for up to Week 207.
45976939|NCT00260702|Drug|Omalizumab (Xolair)|
45976940|NCT00260741|Drug|Smoked Cannabis|
45976941|NCT00260780|Behavioral|The MISTERS Intervention for Post Jail Release Men|
45976942|NCT00260819|Drug|Bosentan|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
45976943|NCT00260819|Drug|Bosentam TRACLEER|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
45672025|NCT02130193|Drug|Danirixin|Danirixin is available as 50 or 75 mg white, film coated immediate release tablet.
45976944|NCT00292773|Procedure|weight reduction minimal access surgery|Patients will be offered laparoscopic gastric bypass surgery by Mr Roger Ackroyd, in line with the current recommendation for gastric surgery according to NICE guidelines i.e. patients with a BMI over 40 or a BMI over 35 with at least one co-morbidity. Patients will be reviewed monthly for six months.
45976945|NCT00260858|Drug|Test Meal: Reference food (glucose or white bread)|
45976946|NCT00260858|Drug|Test Meal: Pirate's Booty|
45976947|NCT00260858|Drug|Test Meal: Ceaprove wafer|
45672026|NCT02130193|Drug|Placebo|Subjects will receive danirixin matching placebo
45672027|NCT01590082|Drug|Doxycycline|"Phase I Starting Dose: 200 mg by mouth twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts)~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
45672028|NCT01590082|Drug|Ipilimumab|Phase I and II: 3 mg by vein on Day 1 of each 21 day cycle for 4 cycles.
45672029|NCT01590082|Drug|Temozolomide|Phase I and II: 200 mg/m2 by mouth on Days 1 - 4 of each 21 day cycle for 4 cycles.
45831439|NCT05632458|Device|Thrombectomy|Thrombectomy using double stent retriever vs thrombectomy using single stent retriever.
45831440|NCT05632224|Drug|Aprepitant|The drug is given 1 hour before the start of the surgery
45831441|NCT05632224|Drug|Granisetron|The drug is given 10 minutes before the patients's extubation
45976948|NCT00260858|Drug|Test Meal: Stretch Island Strawberry Fruit Leather|
45976949|NCT00298311|Behavioral|mci guidance peer support|12 weeks of home visits by peer mentor recovered from PPD and Keys to Caregiving (NCAST, 1990) program
45976950|NCT00292812|Drug|Nutritional supplementation (nucleotides)|
45976951|NCT00415571|Drug|Fispemifene (once daily for 8 weeks)|
45672030|NCT02285582|Other|Registry study|No intervention.
45976952|NCT00298350|Drug|GS-9137 - A Novel HIV-1 Integrase Inhibitor|
45976953|NCT00298428|Procedure|blood samples|blood samples before percutaneous coronary intervention (PCI) and at 4 months
45976954|NCT02960451|Other|PRIME care|Specialist medication, cognitive behavior therapy, family-focused therapy
45831442|NCT05632146|Procedure|Continuous suturing|In continuous closure, each bite will be taken 2 cm from the cut edge of linea alba and successive bites taken 1 cm from each other in continuous fashion followed by gentle approximation of the wound
45976955|NCT02960451|Other|Usual care|Medication and psychotherapy as available form community providers
45976956|NCT00292890|Device|insulin needle|
45976957|NCT00292929|Drug|Intravenous artesunate|
45976958|NCT00298467|Drug|MDX-060|
45976959|NCT00424853|Drug|Docetaxel and cisplatin followed by gemcitabine|docetaxel 75 mg/m2 day 1 + cisplatin 75 mg/m2 day1 repeated every 21 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles
45976960|NCT00424853|Drug|docetaxel and cisplatin followed by gemcitabine|docetaxel 25 mg/m2 day 1,8,15 + cisplatin 25 mg/m2 days1,8,15 repeated every 28 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles.
46082468|NCT00608933|Other|educational intervention|Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
45976961|NCT00298506|Drug|Multitherapy|Tacrolimus,4mg/d, MMF 1.0g/d
45976962|NCT00292968|Behavioral|Computer based care|
45976963|NCT00292968|Behavioral|Telephone counseling|
45976964|NCT00292968|Behavioral|Group visits|
45976965|NCT00292968|Behavioral|Usual care|
45976966|NCT00424892|Drug|Desvenlafaxine Sustained Release|
45976967|NCT01331239|Drug|LCI699|Osilodrostat 1 mg and 5 mg capsules, was prepared by Novartis and supplied to the Investigator. The capsule formulation of osilodrostat was later changed to tablets and this change was implemented in the study with Protocol amendment 6. Osilodrostat was open labeled 1 mg, 5 mg, 10 mg and 20 mg tablets.
45976968|NCT00424931|Drug|JNJ-17216498|50mg one time
46082469|NCT00608933|Other|questionnaire administration|Patients complete questionnaires
46082470|NCT02795390|Drug|Chinese herbal medicine|
46082471|NCT02795390|Drug|Placebo|
45976969|NCT00424931|Drug|JNJ-17216498|10mg one time
45976970|NCT00424931|Drug|Modafinil|200 mg X 2
45976971|NCT00298545|Drug|placebo and Calcitriol|Placebo tablets twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
45672031|NCT01598636|Procedure|Lateral tibial tunnel|To reduce the rehabilitation time after ACL revision surgery due to a better surgical technique
45976972|NCT00298545|Drug|Calcium and Calcitriol|Calcium twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
45672032|NCT01631474|Drug|CB-03-01|Topical cream, applied once a day
45976973|NCT01331161|Biological|ZOSTAVAX|shingles vaccine, one dose
45976974|NCT00424970|Drug|acetazolamide|
45976975|NCT00298584|Procedure|Percutaneous Suprapubic Aspiration|
45976976|NCT00298584|Procedure|Urethral Catheterization|
45976977|NCT01331005|Drug|nepafenac 0.1% drops|One drop three times per day for one year
45976978|NCT01331005|Other|Nepafenac Vehicle|Placebo
45976979|NCT00293046|Biological|ALK Grass tablet - use of compliance device|
45976980|NCT01330459|Drug|Hydrocodone/acetaminophen|Administration of 2 tablets 5/325mg hydrocodone/acetaminophen 45-90 minutes prior to procedure.
45976981|NCT01330459|Drug|Placebo|Administration of 2 tablets methylcellulose (placebo) 45-90 minutes prior to procedure.
45976982|NCT01330459|Drug|Ibuprofen|800 mg oral ibuprofen
45976983|NCT01330459|Drug|Lorazepam|2 mg oral lorazepam
45456233|NCT04592328|Other|Bacterial cultures taken during surgery.|Cultures taken from skin, subcutaneous tissue, surigal materials and surgical gloves at incision and after two hours.
45456234|NCT04591652|Drug|99mTc-MIRC208|99mTc-MIRC208 SPECT/CT: after intravenous injection of 14.8 MBq/kg body weight of quality-controlled 99mTc-MIRC208 2 h, a Siemens Symbia T16 SPECT/CT scan will be performed within 1 h.
45672033|NCT01631474|Drug|Vehicle|Topical cream, applied once or twice a day
45672034|NCT01631474|Drug|CB-03-01|Topical cream, applied twice a day
45672035|NCT02203916|Drug|Azilsartan medoxomil|Azilsartan medoxomil tablets
45672036|NCT02203916|Drug|Azilsartan medoxomil placebo|Azilsartan medoxomil placebo-matching tablets
45831443|NCT05632146|Procedure|Interrupted X suturing|In interrupted X closure, large bite will be taken outside-in, 2 cm from the cut edge of linea alba and the needle emerged on the other side from inside out diagonally 2 cm from the edge and 4 cm below the first bite and this strand will be crossed and continued outside-in, diagonally at 90 degree to the first diagonal. The two ends will be tied just tight enough to approximate the edges of linea alba.
45831444|NCT05631912|Biological|Autologous CD19-STAR-T cell|Phase 1 dose escalation (3+3) : dose 1 (1×10^6 cells/kg) ,dose 2 (3×10^6 cells/kg) ,dose 3 (1×10^7 cells/kg); Phase 2 : Appropriate dose
45831445|NCT05631912|Drug|Fludarabine|Intravenous fludarabine 25-30 mg/m^2/day on days -5, -4, and -3.
45831446|NCT05631912|Drug|Cyclophosphamide|Intravenous cyclophosphamide 300-500 mg/m^2/day on days -5, -4, and -3.
45831447|NCT03024840|Drug|Sevoflurane|Sevoflurane: 1%~2%
45672037|NCT04774328|Drug|CA-008 (vocacapsaicin)|Single administration of CA-008 (vocacapsaicin) versus placebo
45976984|NCT01330459|Drug|Lidocaine|20 ml 1% buffered lidocaine, injected
45672038|NCT04774328|Drug|Placebo|Single administration of CA-008 (vocacapsaicin) versus placebo
45672039|NCT02179177|Drug|Apixaban|Drug is taken by mouth twice a day for 6 months
45672040|NCT02179177|Drug|Placebo|
45672041|NCT02129803|Device|High-Flow, 20 LPM (via Optiflow cannula)|Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.
45672042|NCT02129803|Device|Low FLow, 5 LPM (via Optiflow cannula)|standard humidified wall medical air.
45672043|NCT02239094|Drug|Lurasidone (Latuda)|Antipsychotic medication approved for use with Bipolar disorder
45672044|NCT02129647|Drug|Axitinib|
45976985|NCT00298623|Drug|XP13512 (GSK1838262)|
45976986|NCT00298623|Other|placebo|
45976987|NCT00293085|Drug|Docetaxel|
45976988|NCT00293085|Drug|Docetaxel|"Docetaxel (Taxotere) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.~Premedication:~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.~Hyperhydration Patients will require intravenous hydration according to institutional guidelines."
45976989|NCT00261053|Drug|i.v. recombinant human C1 inhibitor|
45976990|NCT00298662|Drug|Interferon beta-1b and Tacrolimus|
45976991|NCT01330381|Drug|prucalopride|"prucalopride~subjects with weight ≤50kg: 0.04 mg/kg once daily as oral solution of 0.4 mg/ml~subjects with weight >50 kg: prucalopride 2 mg tablet once daily"
45976992|NCT01330381|Drug|Placebo|Matching oral solution or oral tablets given once daily
45976993|NCT01330381|Drug|PEG 4000|
45976994|NCT00261092|Drug|Oxaliplatin|
45976995|NCT01330303|Drug|Reference formulation|SECOTEX® (tamsulosin hydrochloride) 0,4 mg (Boehringer Ingelheim)
45976996|NCT01330303|Drug|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
45976997|NCT00293124|Drug|Glivec|400mg p.o./day in a population of patients with locally advanced (=not amenable to surgery with curative intent) or metastatic malignant GIST. Glivec® may be increased to 600 mg p.o./day and then 800 mg p.o./day (400 mg b.i.d.) if the patient is progressing
45976998|NCT01330108|Drug|ambrisentan|ambrisentan 2.5mg, 5mg, & 10mg. Daily dosage.
45976999|NCT00261131|Drug|Botulinum Toxin A|
45977000|NCT00298701|Biological|ALK Grass tablet|
45977001|NCT00261170|Drug|bupropion|150 mg daily for the first 3 days, then 150 mg twice daily for 7 weeks
45977002|NCT00261170|Other|placebo|1 pill daily for the first 3 days, then one pill twice daily for 7 weeks
45977003|NCT00261209|Drug|Collagenase|Collagenase injection into adhesion restricting tendon gliding
45831448|NCT03024840|Drug|Propofol|Propofol: 9-15 mg/kg/h
45977004|NCT00261209|Drug|Collagenase injection|injection of collagenase into adhesion restricting tendon gliding
45977005|NCT04718298|Device|ProFlor laparoscopic technique|Inguinal hernia repair laparoscopic
45977006|NCT00261248|Biological|Immunization with inactivated bacteria|
45977007|NCT00261287|Drug|Ciclesonide|
45977008|NCT00261326|Drug|simvastatin|80 mg once daily
45977009|NCT00261326|Drug|placebo|calcium tablets once daily
45977010|NCT00293163|Device|Hylaform, Hylaform Plus (hylan B gel)|
45977011|NCT00261365|Drug|Ipilimumab|Solution, Intravenous, 3 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
45977012|NCT00261365|Drug|Ipilimumab|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
45977013|NCT00293280|Drug|lomustine|
45977014|NCT00261404|Drug|TNFerade™|
45977015|NCT00298779|Drug|omeprazole and bortezomib|
45977016|NCT00261482|Drug|norelgestromin + ethinyl estradiol|
45977017|NCT00261521|Drug|epoetin alfa|
45977018|NCT00298857|Drug|Valproic acid|
45977019|NCT00261560|Drug|acetaminophen|
45977020|NCT00261599|Drug|AQUAVAN® (fospropofol disodium) Injection|
45977021|NCT00261599|Drug|Midazolam HCI|
45977022|NCT00293319|Biological|filgrastim|
45672045|NCT02238626|Drug|Placebo (for MN-166)|
45672046|NCT02238626|Drug|MN-166|
45831449|NCT05366088|Behavioral|Mindfulness-Based Cognitive Therapy|"MBCT is an 8-week therapy integrating formal mindfulness meditation (e.g. breath and body awareness) and informal mindfulness (e.g. eating, walking). Participants are taught to attend non-judgmentally to present moment experiences. MBCT includes cognitive therapy techniques to target the ruminative thought processes and identification with negative emotions seen in depression. MBCT teaches participants how to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns that perpetuate depressive symptoms and increase vulnerability to relapse."
45977023|NCT00293319|Radiation|iobenguane I 131|
45977024|NCT00293358|Drug|carboplatin|
45977025|NCT00293358|Drug|cisplatin|
45977026|NCT00293358|Drug|etoposide phosphate|
45977027|NCT00293358|Drug|ifosfamide|
45977028|NCT00293358|Procedure|adjuvant therapy|
45977029|NCT00293358|Procedure|conventional surgery|
45977030|NCT00293358|Procedure|neoadjuvant therapy|
45977031|NCT00293358|Radiation|radiation therapy|
45977032|NCT00261677|Drug|epoetin alfa|
45977033|NCT00298935|Procedure|Osteopathic manipulative treatment (OMT)|
45977034|NCT00298974|Drug|hydrocodone / acetaminophen extended release|2 tablets twice daily
45977035|NCT00298974|Drug|Placebo|2 tablets twice daily
45977036|NCT00261794|Behavioral|computer-assisted cognitive remediation (CACR)|36 individual computer sessions with a staff clinician. computer activities consist of commercially available educational software designed for use in the classroom.
45977037|NCT00261794|Behavioral|manualized computer control condition (RC).|36 sessions of a manualized computer control condition.
45977038|NCT00293436|Drug|celecoxib|
45672047|NCT02238626|Drug|riluzole|Patient is given 50 mg riluzole twice daily.
45672048|NCT02151643|Drug|PT20|Modified ferric oxide adipate tablets
45672049|NCT02151643|Drug|Placebo|Placebo tablets matched to each PT20 dose arm
45977039|NCT00293436|Drug|erlotinib hydrochloride|
45977040|NCT00293436|Procedure|adjuvant therapy|
45977041|NCT00261872|Drug|Methylphenidate|
45977042|NCT00293475|Drug|Carboplatin|Given IA
45977043|NCT00293475|Drug|Mannitol|Given IA
45977044|NCT00293475|Drug|Methotrexate|Given IA
45977045|NCT00293475|Other|Quality-of-Life Assessment|Ancillary studies
45977046|NCT00293475|Biological|Rituximab|Given IV
45977047|NCT00293475|Drug|Sodium Thiosulfate|Given IV
45977048|NCT00261911|Drug|sibutramine|
45977049|NCT00299013|Drug|COLAL-PRED®|COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
45977050|NCT00299013|Drug|Prednisolone|Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
45977051|NCT00293514|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|
45977052|NCT00299052|Device|Grafton DBM|Grafton DBM will be mixed with bone reamings obtained during tibia IMN and place at the fracture site
45977053|NCT00299052|Biological|Reamings|Bone reamings obtained during tibia IMN will be placed at the fracture site
45977054|NCT00293553|Procedure|Electronic Barostat|
45977055|NCT00299091|Drug|Efavirenz capsules 200 mg and 600 mg|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
45977056|NCT00299169|Behavioral|N of 1 Trials|N of 1 Trials of statin therapy
45977057|NCT00299208|Drug|Artesunate|
45977058|NCT00299208|Drug|Azithromycin|
45977059|NCT00299208|Drug|Quinine|
45977060|NCT00262145|Drug|tea extracts|
45977061|NCT00418119|Drug|erythropoietin|
45977062|NCT00293592|Drug|Dexamethasone|1 mg per kg as a single dose before initiation of cardiopulmonary bypass
45977063|NCT00293631|Drug|Lornoxicam 8 mg|
45977064|NCT00293631|Drug|Lornoxicam 16 mg|
45977065|NCT00293631|Drug|Ketorolac 30 mg|
45977066|NCT00293631|Drug|Placebo|
45977067|NCT00262184|Drug|Soy Isoflavone|
45977068|NCT00262262|Drug|Levetiracetam (drug)|The starting dose of levetiracetam was 500 mg/day and the dose was increased with 500 mg every other day to 6 tablets of 500 mg (Keppra, UCB, Belgium), divided into two doses daily corresponding to 3000 mg/day. The dose was kept at this level throughout the remaining treatment period - 4 weeks total. Six placebo tablets with identical appearance were dosed similarly to levetiracetam in the placebo phase.
45977069|NCT00418158|Behavioral|use of Airlife (therapy)|
45977070|NCT00262340|Other|Non invasive measurement of airway inflammation|Airway inflammation will be assessed non-invasively using induced sputum and exhaled nitric oxide. In the active group the results of these tests will be used to determine if asthma treatment should be changed. In the comparator group treatment changes will be based according to conventional symptom based management
45672050|NCT02203838|Drug|RBP-7000|"120-mg RBP-7000 dose delivered by subcutaneous injection every 28 days for a total of 13 injections (for roll-over participants, the first two injections took place under study RB-US-09-0010).~A one-time down-titration to 90 mg RBP-7000 is permitted at the investigator's discretion should the participant have tolerability issues. Participants who received the 90-mg dose of RBP-7000 and exhibited a worsening in psychiatric symptoms could receive a one-time up-titration back to 120 mg RBP-7000 at the discretion of the investigator.~RBP-7000 is a combination of the ATRIGEL Delivery System and risperidone. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner."
45831450|NCT05366088|Behavioral|Health Enhancement Program|HEP teaches health-enhancing techniques and was designed by University of Wisconsin and NIH as a manualized active control group program for mindfulness-based intervention trials (53,54). We have tailored HEP to be structurally equivalent to MBCT. HEP will be delivered by social workers (or equivalent) who have received the official training course from HEP's developers at the University of Wisconsin. Participants will learn about health promotion, healthy diet, music, and gentle exercise, but not about breathing techniques or meditation.
45977071|NCT00293670|Drug|Goserelin (Zoladex)|
45977072|NCT00262379|Drug|epoetin beta (NeoRecormon®)|• Prescription of the epoetin beta : when blood concentration of hemoglobin is lower or equal to 12 g/dL in male or lower or equal to 11 g/dL in female
45977073|NCT00299247|Drug|sulfadoxine/pyrimethamine|
45977074|NCT00262418|Drug|Administration of ivermectin or permethrin|
45977075|NCT00299286|Drug|Lapatinib|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib tablets are dispensed as 250mg tablets. Patients should be advised to take all 6 tablets at once as one dose (total daily dose 1500mg). Tablets should be taken on an empty stomach either one hour before or one hour after a meal at the same time each day and according to the instructions on the bottle."
45977076|NCT00299286|Drug|Lapatinib-Placebo|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib-placebo tablets will be composed of lactose, cellulose, starch, magnesium stearate, and coated with Opadryl orange and look the same as the active treatment. The patients should take all 6 tablets at once as one dose."
45977077|NCT00262457|Device|Implanted gluteal electrical stimulation system|Implanted electrical stimulation system incorporating BION microstimulators
45977078|NCT00262496|Drug|Botox|
46082472|NCT02725242|Drug|Budesonide/formoterol (160/4.5 μg/d)|After the patients who have all criteria, they will be randomization to take Budesonide/formoterol (160/4.5 μg/d)
46082473|NCT02725242|Drug|Budesonide (400μg/d)|After the patients who have all criteria, they will be randomization to take Budesonide (200 ug) twice daily
45831451|NCT03595644|Radiation|SBRT+TKI|Received SBRT after three months after EGFR-TKI treatment
45831452|NCT03595644|Drug|TKI|Received EGFR-TKI treatment
45831453|NCT05631678|Drug|Rifampicin; ASK120067|Take ASK120067 tablets orally once on the first day at 160mg in fast condition;Take rifampicin capsules orally once on the days 8 to 17 at 600mg in fast condition, and a combination of 160mg ASk120067 and 600mg rifampicin were administrated on the 15th day in fast condition.
45831454|NCT05631678|Drug|ASK120067;itraconazole|Take ASK120067 tablets orally once on the first day at 80mg in fast condition;Take itraconazole capsules orally twice on the days 8 to 13 at 200mg in fed condition, and a combination of 80mg ASK120067 and 200mg itraconazole were administrated on the 11th day in fast condition.
45831455|NCT05631600|Biological|Manuka honey|The honey was applied with special designed cannula. The dosage is not exactly define so we inject the amount of honey until until the excess of the material was observed in the sulcus.
45977079|NCT00293787|Drug|Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
45977080|NCT00293787|Other|Timolol Vehicle|Placebo
45977081|NCT00293787|Drug|Latanoprost 0.005% Ophthalmic Solution (XALATAN)|Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
45977082|NCT00293787|Drug|Timolol Maleate Ophthalmic Solution 0.5%|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
46082474|NCT02802332|Behavioral|Footlength Card|The footlength card has an image of a baby's foot. The card is to be held up against the baby's foot after birth; if a baby's foot is smaller than the image, or if the woman/family member is concerned about the health of their baby, they can call the number printed on the card and hear a pre-recorded message about basic care for newborn babies
46082475|NCT00564733|Drug|carboplatin|Given IV
46082476|NCT00564733|Drug|docetaxel|Given IV
46082477|NCT00564733|Drug|gemcitabine hydrochloride|Given IV
46082478|NCT00564733|Drug|paclitaxel|Given IV
46082479|NCT00564733|Procedure|computed tomography|Undergo FDG PET/CT
46082480|NCT00564733|Procedure|positron emission tomography|Undergo FDG PET/CT
46082481|NCT00564733|Radiation|fludeoxyglucose F 18|Given IV
46082482|NCT00564733|Other|imaging biomarker analysis|Correlative studies
45977083|NCT00299364|Drug|Black Cohosh (iCR) or tibolone|
45977084|NCT00415649|Biological|VRC-HIVDNA016-00-VP|
45977085|NCT00415649|Biological|VRC-HIVADV014-00-VP|
45977086|NCT00415649|Biological|Vaccine placebo|Placebo comparator
45977087|NCT00293826|Drug|AMG 108|50mg via SC (subcutaneous) injection every 4 weeks
45977088|NCT00293826|Drug|AMG 108|250mg via SC (subcutaneous) injection every 4 weeks
45977089|NCT00293826|Drug|AMG 108|125mg via SC (subcutaneous) injection every 4 weeks
45977090|NCT00293826|Drug|Placebo|Placebo via SC (subcutaneous) injection every 4 weeks
45977091|NCT00415688|Behavioral|Low carbohydrate, ketogenic diet|
45977092|NCT00415688|Behavioral|Low glycemic index, reduced calorie diet|
45977093|NCT00299403|Procedure|Right prefrontal lowfrequency ( 1 hz) rTMS.|"Right prefrontal low frequency (1 hz) rTMS. 15 sessions with one daily session during 3 weeks (weekends excluded). Each session covering 2 x 60 minutes of stimulation separated with an intertrain interval of 3 minutes~Arms: 2"
45977094|NCT00299403|Procedure|Electroconvulsive therapy (ECT)|9 ECT ( 3 each week) during 3 weeks
45977095|NCT00415727|Device|auto Continuous Positive Airways Pressure (CPAP) with oxygen supplementation|
45977096|NCT00299442|Behavioral|Self-help Triple P Behavioural Family Intervention|10-week self-help workbook and videos
45977097|NCT00262574|Drug|Nesiritide,|PCI
45977098|NCT00293865|Procedure|sentinel node|detection of the sentinel node in breast cancer
45977099|NCT00293865|Procedure|GAS|
45977100|NCT00262613|Drug|sodium pyruvate in 0.9% sodium chloride solution|
45977101|NCT00293904|Biological|CYT005-AllQbG10|
45977102|NCT00262652|Drug|sodium pyruvate|
45977103|NCT00262769|Drug|cisplatin|25 mg/m2 in 1000 mls 0.9% saline given over 1 hour followed by 500 mls 0.9% saline over 90 mins
45977104|NCT00262769|Drug|gemcitabine hydrochloride|1000mg/m2 in 250-500mls 0.9% saline over 30 mins by intravenous infusions on day 1, 8 and 15 (Arm A only) of each 28 (Arm A) or 21 (Arm B) day cycle.
45977105|NCT00299520|Drug|intravenous iclaprim or intravenous linezolid|
45977106|NCT00261755|Procedure|Acupuncture|Based on international experiences and experiences from the pilot project 34 specified acupuncture points could be used.Treatment was individualised according to the woman's mobility and localization of pain. Needles were sterile stainless steel acupuncture needles in three lengths: 0.20 x 15 mm, 0.30 x 30 mm and 0.35 x 50 mm. No electric stimulation was used. The duration of needling could vary from 30 minutes to two hours and could be repeated. The needles were removed if the patient felt uncomfortable or in cases with obstetric pathology.
45977107|NCT00261755|Other|TENS|The Transcutaneous Electric Nerve Stimulation (TENS treatment) was carried out using a B.C - TENS 120Z unit. Two to four electrodes were placed on the skin of the lower back. The units were set in constant mode, initially with a pulse width of 60 micro-seconds and a pulse rate of 100 pulses per second. The treatment lasted from 20 to 45 minutes and could be repeated. The intensity of stimulation could be adjusted by the woman or the midwife.
45977108|NCT00261755|Other|Traditional Group|All analgesic methods available (Sterile water papules, nitro oxygen, bath tub, pethidine and epidural analgesics (EDA)). A specific analgesic was chosen by the woman and the midwife after informed choice.
45977109|NCT00262808|Biological|sargramostim|
45977110|NCT00262808|Drug|fluorouracil|
45977111|NCT00262808|Drug|leucovorin calcium|
45977112|NCT00262808|Drug|oxaliplatin|
45977113|NCT00262808|Procedure|adjuvant therapy|
45977114|NCT00262808|Procedure|conventional surgery|
45977115|NCT00262808|Procedure|neoadjuvant therapy|
45977116|NCT00262886|Biological|anti-thymocyte globulin|
45977117|NCT00262886|Biological|graft-versus-tumor induction therapy|
45977118|NCT00262886|Biological|therapeutic allogeneic lymphocytes|
45977119|NCT00262886|Drug|cyclophosphamide|
45977120|NCT00262886|Drug|fludarabine phosphate|
45977121|NCT00262886|Drug|mycophenolate mofetil|
45977122|NCT00262886|Drug|tacrolimus|
45977123|NCT00262886|Procedure|allogeneic bone marrow transplantation|
45977124|NCT00262886|Procedure|peripheral blood stem cell transplantation|
45977125|NCT00293943|Procedure|Pulmonary vein ablation|
45977126|NCT00263003|Drug|Irbesartan/hydrochlorothiazide|
45977127|NCT00263003|Drug|Irbesartan|
45977128|NCT00299559|Drug|smart textiles containing menthol, camphor, cineol|application to skin
45977129|NCT00263081|Drug|Lapaquistat acetate and current lipid-lowering treatment|"Cohort 1: Weight is less than 50 kg:~Lapaquistat acetate 50 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.~Cohort 2: Weight is more than 50 kg:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks."
45977130|NCT00263081|Drug|Current lipid-lowering treatment|Lapaquistat acetate placebo-matching tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.
45977131|NCT00293982|Behavioral|Physician knowledge of parental expectations for the visit|
45977132|NCT00263120|Behavioral|Pain Questionnaire|
45977133|NCT00299598|Device|alkylated polyethylenimine nanoparticles antibacterial evaluation|
45977134|NCT00263159|Procedure|Pharmaceutical care for asthma patients|
45977135|NCT00263198|Drug|PTK787/ZK222584|
45977136|NCT00263198|Drug|Letrozole|
45977137|NCT00294099|Biological|Aluminum hydroxide|Aluminum hydroxide adjuvant.
45977138|NCT00294099|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated monovalent subvirion influenza H5N1 vaccine. Supplied in 0.5 mL unit dose vials as a sterile solution for IM injection. Dosages: 45 mcg, 15 mcg, 7.5, mcg, or 3.75 mcg administered with or without aluminum hydroxide adjuvant on Days 0 and 28.
45977139|NCT00263237|Drug|STA-5326|
45672051|NCT02178709|Drug|FOLFIRINOX|"FOLFIRINOX consists of the following combination of drugs:~Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle~Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle~Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle 4.5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.~5.5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle."
45672052|NCT02238080|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered according to the usual standard of care and current best practice guidelines and will be observed during the study period.
45977140|NCT00299676|Drug|Galantamine (Reminyl)|Use of Reminyl according to approved NZ data sheet
45977141|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 2.5 mg, Once daily, 12 weeks.
45977142|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 5 mg, Once daily, 12 weeks.
45977143|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 10 mg, Once daily, 12 weeks.
45977144|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 20 mg, Once daily, 12 weeks.
45977145|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 50 mg, Once daily, 12 weeks.
45977146|NCT00263276|Drug|placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks.
45977147|NCT00263276|Drug|metformin|Tablets, Oral, >/= 1500 mg, Once daily, 12 weeks.
45672053|NCT02150863|Device|Ultrapulse Carbon Dioxide Laser|
45977148|NCT00299754|Drug|Misoprostol|
45977149|NCT00263315|Drug|nebulised liposomal amphotericin B|
45977150|NCT00417807|Drug|Imatinib mesilate|
45672054|NCT02150863|Device|Cellutome epidermal harvesting system|
45672055|NCT01445366|Device|High volume post dilution hemodiafiltration|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
45977151|NCT00263354|Drug|Oxaliplatin|
45977152|NCT00299832|Drug|Aliskiren|
45977153|NCT00263393|Drug|ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin|The first intervention was a clinical algorithm designed to enhance the identification and treatment of high-risk individuals compared to continued usual care. The algorithm was designed to be used by either physician or non-physician health care workers.
45977154|NCT00263393|Behavioral|Health Promotion|The second intervention was a health promotion program designed to increase knowledge of cardiovascular risk factors compared to continued usual practices.
45977155|NCT00263471|Drug|7-methylxanthine|
45977156|NCT00299871|Drug|LIXISENATIDE (AVE0010)|
45977157|NCT00263549|Biological|House dust mite Novo Helisen Depot|
45977158|NCT00299910|Drug|Montelukast|
45977159|NCT00263627|Biological|Birch pollen allergoid|Subcutaneous injections were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
45977160|NCT00263627|Other|Placebo|Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
45977161|NCT00294177|Device|atomic force microscopy|
45672056|NCT01445366|Device|high flux hemodialysis|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
45672057|NCT02178553|Drug|Epidural|
45977162|NCT00294177|Device|dual polarisation interferometry|
45672058|NCT02178553|Drug|Intercostal Bupivicaine (Exparel)|
45672059|NCT01627327|Drug|fluticasone furoate/vilanterol 100/25mcg|inhalation powder
45672060|NCT01627327|Drug|tiotropium bromide 18mcg|inhalation powder
45672061|NCT01627249|Drug|2.0 mg intravitreal aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline and up to every 4 weeks using defined retreatment criteria.
45672062|NCT01627249|Drug|1.25 mg intravitreal bevacizumab|Intravitreal injection of 1.25 mg bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.
45977163|NCT00425594|Drug|HalfLytely and Bisacodyl Tablets - Formulation 1|
45977164|NCT00425594|Drug|HalfLytely and Bisacodyl Tablets - Formulation 2|
45977165|NCT00425594|Drug|NuLYTELY|
45977166|NCT00294216|Drug|Omega-3-acid ethyl ester 90 (n-3 PUFA)|
45977167|NCT00294255|Drug|Risperidone|risperidone will be administered 1-3mg pills, each night, for up to 20 weeks
45977168|NCT00263705|Drug|Adjuvant capecitabine|Capecitabine 2000 mg/m² daily six cycles
45977169|NCT00263705|Drug|capecitabine in aduvant setting|capecitabine in aduvant setting in ederly with breast cancer
45977170|NCT00263744|Biological|MEDI 517|Vaccine is supplied in single use vials containing 0.75 mL of MEDI-517 at a concentration of 40 mg/0.5 mL formulated with SBAS4 adjuvant.
45977171|NCT00263744|Other|Aluminum hydroxide|Aluminum hydroxide supplied in single use vials containing 0.75 mL of aluminum hydroxide at a concentration of 0.5 mg of aluminum in the form of aluminum hydroxide per 0.5 mL.
45977172|NCT00294294|Biological|Prevenar|
45977173|NCT00294294|Biological|Infanrix hexa|
45977174|NCT00263783|Drug|MEDI-522|MEDI-522 will be administered at doses of 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 mg/kg. [As a 30 minute IV infusion initially as a single dose (single-dose treatment period) and 2 to 5 weeks later as weekly doses (multiple-dose treatment period) for up to 1 year.]
45977175|NCT00300105|Drug|Tesaglitazar|
45456235|NCT04590690|Other|Special diet|The research clinic will provide subjects with a special diet for six days. After six days of isocaloric sodium, calcium and fluid intake, the study team will analyze three sequential 24-hour urine compositions including supersaturation of calcium oxalate, calcium, and urine volume, as well as stool collections. We will also evaluate components of 24-hour urine composition, specifically supersaturation, and the microbial contributions to urinary composition in 72-hour stool samples simultaneously collected using shot-gun metagenomic sequencing in men and women 1 year after surgery.
45977176|NCT00263822|Drug|erlotinib hydrochloride|
45977177|NCT00294372|Drug|BILR 355 BS|
45977178|NCT00294372|Drug|Placebo|
45977179|NCT00263861|Procedure|management of therapy complications|Patients undergo an interview and clinical evaluation to measure demographic data, cutaneous sensation, gait and balance, vibration, lower extremity muscle strength, orthostatic blood pressure, and glycemic control.
45977180|NCT00294411|Procedure|elective cesarean section|
45977181|NCT00263900|Device|RSV respi-strip and Quick-vue influenza|Assessments of 2 quick diagnostic tests in the emergency unit during children's care
45977182|NCT00300222|Drug|NGX-4010|
45977183|NCT00263939|Behavioral|Homing in on Health|A peer (non-health professional) delivered intervention to enhance patient self-efficacy for chronic disease self-management. Developed as a modification of the Stanford Chronic Disease Self-Management Program.
45977184|NCT00300261|Behavioral|Telehealth monitoring|Experimental group receives telehealth monitoring equipment in their homes for the duration of home care. Equipment includes blood pressure cuff, scale, and pulse oximeter, or glucometer as needed. Two home care nurses provide video visits with subjects on the days when the home care nurse does not visit. Patients use the equipment daily and the results are downloaded to the nurse's computer at the home care agency where they are checked daily. The nurse acts on any abnormal readings by calling the patient, the home care nurse, or the physician.
45977185|NCT00294450|Device|Fistula Pouching System|3 different sizes of fistula pounching system
45977186|NCT00263978|Drug|Defibrotide|
45977187|NCT00300300|Procedure|Computer-assisted surgery|no description
45977188|NCT00264056|Device|hyperthermia|
45977189|NCT00264095|Procedure|Oncological surgery|surgery is primary observed intervention and blood loss is between 500-3000 ml
45977190|NCT00264134|Drug|Docetaxel|
45977191|NCT00264134|Drug|Irinotecan|
45456236|NCT04582734|Behavioral|Cognitive-behavioural therapy|Cognitive-behavioural therapy intervention
45456237|NCT04578769|Procedure|conventional myotomy|"Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 10 cm proximal to the gastroesophageal junction (GEJ).~Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
45672063|NCT01627249|Drug|0.3 mg intravitreal ranibizumab|Intravitreal injection of 0.3 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
45977192|NCT00264134|Drug|Carboplatin|
46082483|NCT02802410|Device|IQ-Tape|RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
45977193|NCT00300339|Drug|SL650472, Clopidogrel|
45977194|NCT00264173|Drug|Valproate sodium|
45977195|NCT00294528|Device|Nexgen LPS-flex and AGC|
45977196|NCT00264212|Drug|irbesartan and irbesartan-hydrochlorothiazide|
45977197|NCT00300378|Drug|desvenlafaxine 50 mg|
45977198|NCT00300378|Drug|desvenlafaxine 100 mg|
45977199|NCT00264251|Behavioral|Weight loss through diet and exercise|
45977200|NCT00264251|Drug|Rosiglitazone insulin sensitizing agent|
45977201|NCT00294567|Drug|Calcium channel blockers (amlodipine, azelnidipine)|Drug: amlodipine Drug: azelnidipine
45977202|NCT00264329|Other|Transitional Case Management Study|In an effort to address problems involved in parole re-entry, the Transitional Case Management (TCM) intervention tested a model of strengths-based case management consisting of (1) completion by the inmate of a strengths and goals assessment as part of discharge planning, (2) a telephone conference call that included the inmate and people central to the inmate's aftercare plan (including the parole officer), and (3) strengths case management for 12 weeks in the community to promote treatment participation and increase the client's access to needed services.
45977203|NCT00300417|Drug|VRC-WNVDNA020-00-VP|
45977204|NCT04708925|Other|conservative versus plasmapharesis therapy|conservative versus plasmapharesis therapy
45977205|NCT00294606|Drug|Comparison of Effects of Phenylephrine and Norepinephrine|
45977206|NCT00300534|Device|Abbott Laboratories Determine test for syphilis|
45977207|NCT00300534|Device|Investigational syphilis immunochromatographic strip test|
45977208|NCT04708964|Drug|Flurbiprofen|Flurbiprofen solution will be administered, through the subglottic intake door of the endotracheal tube.
45977209|NCT04708964|Drug|saline solution|Saline solution will be administered, through the subglottic intake door of the endotracheal tube.
45977210|NCT00294801|Drug|flex-a-new (food supplement)|
45977211|NCT00264368|Drug|intravenous (IV) ganciclovir|
45672064|NCT04758403|Radiation|Navigation Bronchoscopy|Navigation Bronchoscopy procedure will be performed per product instructions and the institution's standard practice.
45672065|NCT04758403|Radiation|Cone beam computed tomography (CBCT)|Per Protocol
45672066|NCT01688830|Drug|Dabigatran|
45977212|NCT00264407|Drug|Hormone Replacement Therapy - HRT|
45672067|NCT01688830|Drug|BI 655075|
45672068|NCT01688830|Drug|Placebo|
45672069|NCT01569022|Device|CPAP|CPAP Treatment for 12 weeks
45672070|NCT01569022|Device|MAD|MAD Treatment for 12 weeks
45672071|NCT01629823|Device|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.
45672072|NCT01688050|Device|Zenith® TX2® Low Profile Endovascular Graft|Treatment of Blunt thoracic aortic injuries (BTAIs)
45672073|NCT01604278|Drug|NVA237 50 µg and indacaterol 150 µg|NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation.
45672074|NCT01604278|Drug|Placebo to NVA237 and indacaterol 150 µg|Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.
45672075|NCT01687270|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
45672076|NCT01687270|Drug|RBV|Ribavirin (RBV) 200-mg tablet(s) administered orally in a divided daily dose starting at 400 mg, subsequently adjusted (range: 200 to 1200 mg in a divided daily dose) based upon a number of factors including hemoglobin value, creatinine clearance, and weight.
45672077|NCT01589770|Other|cardiac Magnetic Resonance imaging|
45672078|NCT01588990|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 milligrams per square meter (mg/m^2) IV infusion on Day 1 of every 2 weeks cycle during alternative Phase A treatment or 130 mg/m^2 on Day 1 of every 3 weeks cycle during Phase A treatment.
45672079|NCT01588990|Drug|Capecitabine|Participants will receive capecitabine 1000 mg/m^2 per oral (PO) twice daily on Days 1-14 of 3 weeks cycle during Phase A treatment.
45672080|NCT01588990|Drug|Bevacizumab|Participants will receive 7.5 mg/kg IV infusion on Day 1 every 3 weeks (Phase A treatment) or 5 mg/kg IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B).
45977213|NCT00300573|Drug|Dexelvucitabine|nucleoside inhibitor of HIV Reverse Transcriptase
45977214|NCT00300612|Biological|HyperAcute-Melanoma Vaccine|Cells will be injected intradermally every two weeks for twelve vaccinations. If the patient completes all twelve vaccinations, dosage will vary from a total of 1.3 x 109 to 3.8 x 109 HyperAcute™-Melanoma Vaccine cells administered.
45977215|NCT00264446|Drug|ADH300004|
45977216|NCT00300651|Behavioral|Cognitive Behavioral Therapy|
45977217|NCT00264485|Drug|E-TRANS Fentanyl hydrochloride; Morphine|
46082484|NCT02802410|Device|Kinesiotape|RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
45977218|NCT00294840|Device|PET-CT|
45977219|NCT00300690|Device|6 mm Uni-graft® (B-Braun)|
45977220|NCT00300690|Device|6 mm Gore-Tex® (WL Gore)|
45977221|NCT00264524|Procedure|venipuncture to withdraw patient's blood|
45977222|NCT00294879|Procedure|pressure support ventilation at 0, 5, and 10% IRT|
45977223|NCT00264563|Behavioral|Increasing the level of awareness to Iatrogenesis|Increasing the level of awareness to Iatrogenesis
45977224|NCT00264563|Behavioral|Increasing awareness .|Increasing awareness to Iatrogenesis and active daily recordings
46082485|NCT02802410|Other|No-Tape|RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
45977225|NCT00294918|Drug|Serostim®|Serostim® will be administered subcutaneously at a dose of 1 mg to subjects who had encountered toxicity during the antecedent protocol (Study 22388) whereas, other subjects will be randomized in 1:1 ratio, to receive either 2 milligram (mg) or 4 mg (on a weight adjusted basis) daily, starting from Day 1 of Week 1 up to Week 12 (Period 1). During Period 1, subjects who encounter toxicity will receive 1 mg Serostim® subcutaneously, daily for Period 2, starting from Day 1 of Week 13, whereas other subjects will be randomized in a 1:1 ratio to receive either 2 mg or 1 mg (on a weight adjusted basis) up to Week 36.
45977226|NCT00264680|Drug|lamotrigine|
45977227|NCT00264680|Drug|valproic acid|
45977228|NCT00300729|Drug|Celecoxib|Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
45977229|NCT00300729|Drug|Placebo|One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
45672081|NCT01588990|Drug|Leucovorin|Participants will receive leucovorin 400 mg/m^2 IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B). Investigators may elect to chose low dose of leucovorin (either 20 mg/m^2 or 50 mg total dose).
45977230|NCT00264719|Drug|Metoclopramide (Maxolon)|Mothers will be given metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10 and once a day from 11th to 12th day
45977231|NCT00264719|Drug|placebo|placebo 10 mg
45977232|NCT00264758|Device|Conventional hemodialysis|Three times per week in-center hemodialysis
45977233|NCT00264758|Device|Frequent hemodialysis|Six times per week in-center hemodialysis
45977234|NCT00264914|Drug|SR121463B|
45977235|NCT00300807|Drug|XTL 6865|
45977236|NCT00264953|Drug|Adriamycin|
45977237|NCT00264953|Drug|Bleomycin|
45977238|NCT00264953|Drug|Vinblastine|
45977239|NCT00264953|Drug|DTIC|
45977240|NCT00264953|Drug|Etoposide|
45977241|NCT00264953|Drug|Procarbazine|
45977242|NCT00264953|Drug|Prednisone|
45977243|NCT00264953|Drug|Vincristine|
46082486|NCT02725164|Drug|oxygen concentration|oxygen concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
46082487|NCT02725164|Drug|nitrous oxide concentration|nitrous oxide concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
45977244|NCT00264953|Radiation|radiation therapy|20 or 30Gy IF-RT
45977245|NCT00300846|Drug|aripiprazole|Tablets, Oral, 5 mg, 10 mg, 15 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional).
45977246|NCT00300846|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional)
45977247|NCT00294996|Drug|Myocet|
45977248|NCT02960945|Drug|CTP-543, 16 mg (2 x 8 mg tablet)|
46082488|NCT02725164|Drug|carbon dioxide concentration|carbon dioxide concentration will be measured from the tracheal tube and in the oropharynx during spontaneous or controlled ventilation
46082489|NCT02725164|Drug|sevoflurane concentration|sevoflurane concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
46082490|NCT02800538|Dietary Supplement|intragastric infusion of nutrient|Intragastric infusion of nutrient that can be widely found in daily food or placebo.
46082491|NCT00935155|Procedure|Acupuncture|Westerns style acupuncture. Twice a week for 12 weeks
45977249|NCT02960945|Drug|Jakafi 15Mg Tablet|
45977250|NCT00265031|Drug|Cyclophosphamide|
45977251|NCT00265031|Drug|Adriamycin|
45977252|NCT00265031|Drug|Etoposide|
45977253|NCT00265031|Drug|Procarbazine|
45977254|NCT00265031|Drug|Prednisone|
45977255|NCT00265031|Drug|Vincristine|
45977256|NCT00265031|Drug|Bleomycin|
45977257|NCT00265031|Procedure|radiation therapy|
45977258|NCT00300924|Drug|Rizatriptan co-administered with Acetaminophen|
45977259|NCT00265070|Drug|Gefitinib|250 mg tablet oral daily dose
45977260|NCT00295035|Drug|CELECOXIB|
45977261|NCT00295035|Drug|CURCUMIN|
45977262|NCT00418197|Device|Total Facet Arthroplasty System® (TFAS®)|
45977263|NCT00295074|Procedure|neuropsychologic testing|
45977264|NCT00265226|Biological|Intra-dermal administration of Mycobacterium w|Mw Vaccine is given as oral suspension. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
45977265|NCT00295113|Procedure|EFR|
45977266|NCT00265265|Drug|Atomoxetine|
45977267|NCT00418275|Genetic|Recombinant Human Plasminogen Activator (HTUPA)|
45977268|NCT00265304|Drug|Ketoprofen|
45977269|NCT00295152|Behavioral|community occupational therapy in dementia|
45977270|NCT00295191|Procedure|high-flux membrane|high-flux dialyser
45977271|NCT00295191|Procedure|low-flux membrane|low-flux dialyser
45977272|NCT00295191|Procedure|conventional dialysate|conventional dialysate
45977273|NCT00295191|Procedure|ultrapure dialysate|ultrapure dialysate
45977274|NCT00265421|Procedure|Suture technique for perineal repair after delivery|
45977275|NCT00265460|Drug|Oliwer Twist smokeless tobacco (tobacco)|
45977276|NCT00300963|Drug|Talnetant|
45977277|NCT00265499|Procedure|Skeletonization of the internal thoracic artery|
45977278|NCT00295230|Procedure|PSV+VG mode versus SIMV+VG mode|fully assisted mechanical ventilation versus assistance on only a select number of breaths
45977279|NCT00301002|Drug|Alefacept|
45977280|NCT00265694|Drug|vinorelbine, gemcitabine and carboplatin|
45977281|NCT00301041|Other|laboratory biomarker analysis|
45977282|NCT00301041|Procedure|adjuvant therapy|
45977283|NCT00301041|Radiation|radiation therapy|
45977284|NCT00265733|Drug|capecitabine|
45977285|NCT00265733|Drug|paclitaxel poliglumex|
45977286|NCT00301158|Behavioral|exercise intervention|
45977287|NCT00301158|Other|counseling intervention|
45977288|NCT00301158|Other|educational intervention|
45977289|NCT00301158|Procedure|complementary or alternative medicine procedure|
45672082|NCT01588990|Drug|5-Fluouracil|Participants will receive 5-fluouracil loading dose of 400 mg/m^2 IV on Day 1 followed by 2400 mg/m^2 continuous IV infusion over 46 hours Day 1 (Alternative Phase A treatment and Phase B).
45977290|NCT00295269|Drug|Mythylprednisolone|
45977291|NCT00265772|Drug|MODULEN IBD (R) (specific Enteral Nutrition)|
45977292|NCT00265772|Drug|prednisolon|
45977293|NCT00301197|Behavioral|Behavioral Skills Maintenance|
45977294|NCT00301197|Behavioral|Social Facilitation Maintenance|
45977295|NCT00265811|Drug|Folfox|
45977296|NCT00265811|Drug|Cetuximab|
45977297|NCT00295308|Drug|Clonidine|clonidine up to 0.3 mg/day oral
46082492|NCT00935155|Procedure|exercises|Coordination, mobilizing, endurance, strength
46082493|NCT02800694|Drug|"bupivacainediluted with 1 ml of normal saline and 25 μg fentanyl "|The intrathecal medication included 1ml of 0.5% heavy bupivacaine (5 mg) diluted with 1 ml of normal saline and 25 μg fentanyl. Then, the parturients were placed in the supine position with left lateral displacement produced by placing a wedge under the right hip to prevent aortocaval compression and hypotension. Supplemental oxygen was applied using nasal cannula (2-4 L/min). Routine monitoring included maternal vital signs, uterine contractions and fetal heart rate tracing. The cardiotocogram was recorded continuously throughout the study period
46082494|NCT00931385|Drug|BI 1744|BI1744 Respimat Med Dose Once Daily
45672083|NCT01588990|Drug|Irinotecan|Participants will receive irinotecan 180 mg/m^2 IV on Day 1 every 2 weeks during Phase B treatment.
45672084|NCT02176525|Drug|BI 207127 NA|
45672085|NCT02176525|Drug|Placebo|
45672086|NCT02127931|Device|Groundskeeper for ADHD group|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
45672087|NCT02127931|Device|Groundskeeper for control group|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
45672088|NCT02126839|Drug|Albuterol MDPI|90 mcg/actuation of the multidose dry powder inhaler (MDPI).
45977298|NCT00295308|Drug|Placebo|oral capsules daily
45977299|NCT00265928|Drug|bortezomib|
45977300|NCT00265928|Drug|rituximab|
45977301|NCT00265928|Procedure|antibody therapy|
45977302|NCT00265928|Procedure|biological therapy|
45977303|NCT00265928|Procedure|enzyme inhibitor therapy|
45977304|NCT00265928|Procedure|monoclonal antibody therapy|
45672089|NCT02126839|Drug|Placebo|Matching Placebo delivered via a multidose dry powder inhaler (MDPI).
45672090|NCT02126839|Drug|ProAir HFA inhaler|Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.
45977305|NCT00295347|Drug|Spironolactone|
46082495|NCT00931385|Drug|bi1744|1744 low dose
46082496|NCT00931385|Drug|Placebo|Placebo Respimat and Foradil Placebo
46082497|NCT00931385|Drug|Foradil|Foradil 12 mcg twice daily and Placebo Respimat
45672091|NCT04747795|Drug|Vitamin C|IV
45672092|NCT04747795|Drug|Normal saline|IV
45672093|NCT02125279|Drug|Calcitriol|
45672094|NCT02124811|Drug|Minocycline|
45977306|NCT00295347|Drug|fludrocortisone|
45977307|NCT00295347|Drug|escitalopram|
45977308|NCT00265967|Drug|Irbesartan|Irbesartan 150-300 mg/d for 8 weeks
45977309|NCT00295386|Behavioral|Cognitive behavior therapy (CBT)|
45977310|NCT00295386|Drug|Zopiclone|
45977311|NCT00266006|Drug|eptacog alfa (activated)|
45977312|NCT00301236|Drug|Dexmethylphenidate HCl extended-release capsules|
45977313|NCT00295425|Drug|Cyclosporine A versus mycophenolate mofetil for psoriasis|
45977314|NCT00266123|Drug|Sirolimus|
45977315|NCT00301314|Procedure|Autologous stem cell transplant|
45977316|NCT00266162|Drug|Bosentan administration|
45977317|NCT00295464|Drug|Betamethasone sodium phos (drug)|
45977318|NCT00415766|Drug|rHCG 250ug|Injection of 250 ug Ovitrelle to trigger final oocyte maturation
45977319|NCT00415766|Drug|uHCG 5000 IU|Injection of 5000 IU Pregnyl to trigger final oocyte maturation
45977320|NCT00415766|Drug|uHCG 7500 IU|Injection of 7500 IU Pregnyl to trigger final oocyte maturation
45977321|NCT00301353|Drug|Isoflavones-enriched foods|
45977322|NCT00415805|Drug|Multihance|0.5 Molar, single injection at 0.2 mL/kg
45977323|NCT00415805|Drug|vasovist|0.25 molar single injection 0.03 ml/kg
45977324|NCT00301392|Other|life-style intervention|As the life-style interventions aiming to reduce the major risks of developing diabetes mellitus, instruct the following four items:(1)set diet right, (2)maintain normal weight,(3)improve physical activity,(4)normalize smoking and alcohol drinking.
45977325|NCT00301392|Drug|Life style interventions plus concomitant use of pitavastatin.|Once-daily dosing of pitavastatin 1 mg(1 tablet of Livalo Tab 1 mg), or 2mg(2 tablets of Livalo Tab 1mg or 1 tablet of Livalo Tab 2mg);Dosing period of pitavastatin should be 60 months.(max.84 months).
45977326|NCT00415844|Drug|ELC200 (carbidopa+levodopa+entacapone)|
45977327|NCT00301431|Drug|DVS-233|
46082498|NCT04859868|Device|Galvanic Vestibular Stimulation|Low electrical currents to the vestibular system.
46082499|NCT00938509|Drug|ibuprofen suppositories|5-10 mg/kg/day-suppositories
45831456|NCT05631522|Other|foot reflexology|"Warm-Up Phase:~Pre-reflexology foot massage and all-over foot squeeze will be performed for two minutes.~Mini-Reflexology Session:~Specific reflexology will be performed with special attention to two important foot reflex areas that include:~Diaphragm and Solar Plexus Reflex Areas are located in the distance between the upper and middle third of the sole.~The Heart and Lung Reflex Areas are located below the chest of the foot. The heart pumps the oxygen-rich blood around the body"
45831457|NCT05631444|Biological|Cell-based therapy|One dose of auto-BM-MNC, one dose of allo-WJ-MSCs, or one dose of placebo solution (saline solution with 2% of autologous serum), were periadventitial arteries administration in CTLI patients.
45672095|NCT02148445|Other|Standard Smoking Cessation|Participants in the standard smoking cessation (SC) arm will receive a standard approach to smoking cessation, including smoking cessation counseling supplemented with 10 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) if they are willing to make a quit attempt.
45672096|NCT02148445|Other|Extended Nicotine Replacement Therapy|Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
45456238|NCT04578769|Procedure|short myotomy|"Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 6 cm proximal to the gastroesophageal junction (GEJ).~Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
45456239|NCT04578769|Procedure|full-thickness myotomy|"Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 10 cm proximal to the gastroesophageal junction (GEJ).~Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 4 cm proximal to the GEJ, and a full-thickness muscle myotomy is continually carried out from 4cm proximal to the GEJ down to 2 cm distal to the GEJ.~Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
45672097|NCT02148445|Drug|Nicotine replacement therapy|
45831458|NCT03599778|Drug|Apatinib|XELOX + apatinib's MTD
45831459|NCT03990012|Procedure|IR Imaging|Subjects will undergo steady steady state and video IR imaging of the breasts.
45831460|NCT03990012|Procedure|3D Scanning|Subjects will undergo 3D scanning of the breasts.
45831461|NCT03980418|Procedure|DaTSCAN SPECT/CT in VERITON-CT camera|the intervention is based on two recordings in camera VERITON-CT ; the first, in focus striatum mode and the second in brain focus mode
45831462|NCT03979404|Device|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
45831463|NCT03599700|Diagnostic Test|myeloproliferative neoplasms|BLOOD SAMPLING
45831464|NCT04008264|Drug|Scopolamine Patch (Transderm V)|During the observational phase, patients will be given a prescription for an 18 day supply of scopolamine, and patients will record the same data as prior to the intervention.
45831465|NCT05631288|Genetic|Sampe collection|Unstimulated crevicular fluid samples are collected using two sized 35 paper cones per subject, both used in the sampling process. The DNA is extracted from the samples through multiplex PCR at the Egas Moniz Applied Microbiology Laboratory (LMAEM).
45831466|NCT03595410|Other|Recurrence laryngeal cancer|Recurrence laryngeal cancer has a wide range of invasion, rapid progression and poor prognosis.
45831467|NCT03595254|Behavioral|Thrive|Computerized Cognitive Behavior Therapy program
45831468|NCT05631210|Other|Privacy agreements with pictograms|The intervention consisted of a modified privacy agreement talking about health data. Instead of presenting all of that information through text, the investigators added pictograms that summarized the key points at the beginning.
45831469|NCT05631132|Procedure|BAL + NIV|May noninvasive mechanical ventilation (NIV) and/or continuous positive airway pressure (CPAP) increase the bronchoalveolar lavage (BAL) salvage in patients with pulmonary diseases?
45831470|NCT03599466|Drug|BF-Lisinopril Tablets 20mg|BF-Lisinopril Tablets 20mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
45831471|NCT03599466|Drug|Zestril Tab 20mg|Zestril Tab 20mg will be used as a reference drug in this study
45831472|NCT03599388|Behavioral|Self- management for adequate sleep intervention (SASI)|Bedtimes and wake times will be prescribed each week for each participant and allow for gradual increases in sleep opportunity. Bedtimes will be set 15 minutes earlier each week provided sleep efficiency remains >90%. Earlier betimes will extend sleep duration by increasing the opportunity for sleep. Wake times will not be changed because wake times are often determined by external demands, such as work schedules
45831473|NCT03599310|Behavioral|Advance care planning|The ACP guide is adapted from the Serious Illness Communication Guide and a culturally-sensitive ACP programme developed in the local context. The trained ACP facilitators will initiate the conversation by introducing the concepts of ACP with the support of the guide and assessing the patient's illness understanding and readiness to think about end-of-life care issues.
45977328|NCT00415883|Drug|Valsartan|
45977329|NCT00301470|Device|MR urography|undergoing both renal scintigraphy and MR within a month
45977330|NCT00266240|Drug|GK Activator (2)|Escalating doses po bid
45977331|NCT00266240|Drug|Placebo|po bid
45977332|NCT00295542|Device|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
45977333|NCT00295542|Procedure|Chronotherapy, timing of antihypertensive medication|Comparison of effects of awakening versus bedtime dosing
45977334|NCT00295542|Drug|ACEI (including spirapril, enalapril, quinapril, lisinopril)|Treatment at awakening versus bedtime
45977335|NCT00295542|Drug|ARB (including valsartan, telmisartan, olmesartan)|Treatment at awakening versus bedtime
45977336|NCT00295542|Drug|beta blockers (including nebivolol, atenolol, carvedilol)|Treatment at awakening versus bedtime
45672098|NCT02148211|Other|Data collection|Initial and follow-up data was collected using questionnaires.
45672099|NCT02147587|Drug|Tofacitinib|5 mg twice daily of tofacitinib with background methotrexate for 12 weeks
45672100|NCT02147587|Drug|Placebo|Placebo tablets twice daily with background methotrexate for 12 weeks
45672101|NCT02147353|Drug|Sinecatechins 15% Ointment|Following cryotherapy, half of the subjects will be randomized to treatment with sinecatechins ointment twice daily starting one week after cryotherapy (Week 1).
45672102|NCT02147353|Drug|Cryotherapy alone|Cryotherapy will be standardized in all subjects and for all treated lesions.
45831474|NCT03599310|Behavioral|Usual care|In the current practice, patients will have to take the initiative themselves if they would like to discuss their end-of-life care or make an advance directive.
45831475|NCT03987672|Dietary Supplement|Assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula|Kate Farm Peptide 1.5 nutritional Formula
45831476|NCT03987360|Other|Observational|Participants who attended different educational and cultural activities either in a community centers or public institutions like arts museums or universities.
46082500|NCT02800226|Device|10Hz|Magventure Cool B70 Coil with X100 Stimulator and ANT Neuronavigation System
45456240|NCT04578769|Procedure|tailored myotomy|"Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 2 cm proximal to the spastic segment within the esophageal body, which is identified based on information gained from high-resolution manometry (HRM).~Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
45672103|NCT02147197|Drug|Ulipristal acetate (UPA)|UPA tablet
46082501|NCT02800226|Device|iTBS|Magventure Cool B70 Coil with X100 Stimulator and ANT Neuronavigation System
46082502|NCT02725086|Drug|Leucostim®|
46082503|NCT02725086|Drug|Neupogen®|
46082504|NCT00939289|Device|Continuous Glucose Monitoring|Real-time continuous glucose monitoring with 2 commercially available Systems (DexCom SEVEN and Abbott Navigator)
46082505|NCT02724852|Biological|0.5 ml of MMR vaccine|Participants in each arm received the same vaccine, a 0.5 ml of MMR vaccine at deltoid region
45672104|NCT02147197|Drug|Placebo|Matching placebo tablet.
45831477|NCT03986970|Drug|Tenofovir|Pre-exposure prophylaxis
46082506|NCT00938665|Device|COGNISION™ System|30 minute ERP test and 3 minute resting EEG data collected from cognitively healthy and AD to validate ERP and qEEG as useful cognitive biomarkers for AD.
46082507|NCT02800070|Biological|Lentivirus Alpha-gal A transduced stem cells|
46082508|NCT02724618|Drug|Curcumin|120mg/d oral nanocurcumin (3 capsules of SinaCurcumin®40 per day) 3 days before and during radiotherapy
46082509|NCT02724618|Radiation|RT|EBRT is delivered as Intensity-Modulated Radiation Therapy (IMRT) or 3D-conformal RT
46082510|NCT02724618|Drug|Placebo|Placebo (3 placebo capsules of SinaCurcumin®40 per day), 3 days before and during radiotherapy
46082511|NCT02801786|Drug|Placebo|The arm will be composed of 03 women who used placebo capsules and gel.
45672105|NCT04751929|Drug|Abemaciclib|Taken orally 2x daily
45672106|NCT04751929|Drug|Atezolizumab|Intravenously Day 1 of 21 day cycle
45672107|NCT02176291|Drug|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)
45672108|NCT02176291|Drug|Placebo|matched placebo
45672109|NCT04769570|Procedure|interscalene brachial plexus block|Single shot ultrasound guided interscalene brachial plexus block will be performed preoperatively to patients.Patient-controlled analgesia (PCA) with morphine will be used for postoperative analgesia.
45672110|NCT04769570|Procedure|suprascapular nerve block|Single shot ultrasound guided interscalene brachial plexus block and Suprascapular nerve block will be performed preoperatively to patients.Patient-controlled analgesia (PCA) with morphine will be used for postoperative analgesia.
45672111|NCT04769570|Procedure|Group Control|consist of the patient group without any procedure.
45672112|NCT02175745|Drug|18F-fluoro-dihydroxyphenylalanine|Administered intravenously (IV)
45672113|NCT02175745|Procedure|Positron emission tomography (PET)|Component of an 18F-FDOPA PET/CT or PET/MRI scan
45672114|NCT02175745|Procedure|Computed tomography (CT)|Component of an 18F-FDOPA PET/CT
45672115|NCT02175745|Procedure|Magnetic resonance imaging|Component of an 18F-FDOPA PET/MRI
45977337|NCT00295542|Drug|diuretics (torasemide, indapamide, HTCZ) and doxazosin|Treatment at awakening versus bedtime
45977338|NCT00295542|Procedure|Combination therapy in essential hypertension|Treatment at awakening versus bedtime
45977339|NCT00266318|Drug|Interferon Alfacon-1 and Ribavirin|
45977340|NCT00295581|Drug|PpPfs25/ISA51 & ScPvs25/ISA51|
45977341|NCT00266357|Drug|MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)|
45977342|NCT00266357|Drug|Placebo / Duration of Treatment: 2 days for screening period|
45977343|NCT04719026|Other|Full-mouth periodontal examination using computerised Florida probe|It is an observational study to investigate the prevalence of periodontitis in cases and controls.
45977344|NCT00301509|Drug|peginterferon and ribavirin|
45672116|NCT02175277|Drug|Darbepoetin Alfa|The first dose of darbepoetin alfa was the same as that administered at the last dosing visit of the active treatment period in Study 20090160. Doses could be increased up to a maximum of 500 μg every two weeks (Q2W).
46082512|NCT02801786|Drug|Lidocaine|The arm 2 will consist of women who used the placebo capsules for 5 days and 4% lidocaine gel 15 minutes before the test.
46082513|NCT02801786|Drug|Tamoxifen|The arm 01 is composed of patients who use tamoxifen 20mg one capsule per day for 05 days before the test and placebo gel 15 minutes before the exam.
46082514|NCT02720172|Behavioral|Early Home Exercise Program|The early home exercise program is a 6-week program of home exercises with weekly phone calls to monitor progression and compliance.
46082515|NCT02720172|Other|Usual Care|Usual care involves standard postoperative management under the direction of the treating surgeon.
45456241|NCT04576585|Behavioral|Lexicon training|Participants will receive training on the lexicon of appetite on up to 3 days during the training week. This will entail reading written definitions, watching an instructional video, eating exercises and completing training exams demonstrating they understand the distinctions between appetitive terms (hunger, desire to eat, fullness, and prospective consumption). The training will require about 30 minutes to complete. To ensure the success of training, participants must verbally describe the definitions of the outcome sensations to a member of the research team and complete a written quiz with at least 90 % correct responses. Failure to satisfactorily convey understanding of the concepts will result in an offer to repeat the training 2 more times or be rejected from the study.
45672117|NCT02124265|Drug|CeraLyte 90|"This is a prospective pilot study of patients with moderate-major burn wounds (20-65% TBSA).~Patients who meet inclusion/exclusion criteria will be enrolled in the study upon admission to the Burn Unit.~Fluid requirements will be calculated according to the Parkland Formula (4 cc/kg/% Total Body Surface Area) administered over 24 hours since time of injury.~5. Patients will be monitored according to standard of care.~a. If gastric residuals are >300cc, ORT will be stopped and only IV fluid resuscitation will be used."
45672118|NCT02146105|Other|Yoga For Knee Osteoarthritis|Yoga program specifically for women with knee osteoarthritis.
45672119|NCT02175199|Device|Lotrafilcon B contact lenses with color printing|
45672120|NCT02175199|Device|Phemfilcon A contact lenses with color printing|
45672121|NCT02175121|Drug|Placebo|Tablet, once daily for 28 days
45672122|NCT02175121|Drug|PF-06291874|Tablet, 15 mg, once daily for 28 days
45672123|NCT02175121|Drug|PF-06291874|Tablet, 35 mg, once daily for 28 days
45831478|NCT03594942|Diagnostic Test|procto sigmoidoscopy and biopsy if required|procto sigmoidoscopy of patients presenting with per rectal bleed will be carried out to locate the source of bleeding and biopsy if required.
45831479|NCT03594864|Procedure|Liver transplantation with hyper-reduced grafts|Live donor liver transplantation using non-anatomical in-situ ultrasound-guided reduction of left lateral segments with preparation of a graft that is larger than a monosegment, but smaller than Segments 2 and 3.
45831480|NCT03985800|Other|TEAM|TEAM incorporates team-based care with traditional in-person clinic visits. The care team includes a gastroenterologist, nurse practitioner, nutritionist, social worker/behavioral health specialist, and a psychologist or psychiatrist.
45831481|NCT03985800|Other|TECH|TECH uses team-based care similar to TEAM, but in-person care is substituted with telemedicine (i.e., video visits and consultations) and digital behavioral health tools.
45831482|NCT03594786|Device|endovascular aneurysm repair (EVAR)|Patient will be enrolled when the decision of an endovascular procedure with supra renal fixation is required. Before the intervention, Duplex scan will be necessary to evaluate renal arteries ostia. This exam will be realised in the month after the intervention and one year later.
45831483|NCT03599232|Other|Formative objective structured clinical examination (OSCE)|
45831484|NCT03978546|Diagnostic Test|Humphrey Visual Field Test|SITA Standard and 24-2 and 10-2 visual field tests
45831485|NCT03978546|Diagnostic Test|Optical Coherence Tomography (OCT) Scan|Circle and Wide Angle Scans
45831486|NCT03978546|Diagnostic Test|Smart Perimetry - Henson 9000|24+10-2 Smart Supra test
45831487|NCT03594396|Drug|Olaparib|Olaparib 300mg bid will be given on days 1-28 days without rest.
45831488|NCT03594396|Drug|Durvalumab|A fixed dose of durvalumab 1500 mg is given via IV infusion on Day 15.
45831489|NCT03599076|Other|HD Wear|Wearable sensor system for monitoring Huntington's chorea during activities of daily living
45831490|NCT05633784|Other|Teleassistance|Support the nursing case manager through a structured teleconsultation program (telephone and videoconference support at least once a week)
46082516|NCT04258553|Diagnostic Test|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry
46082517|NCT04258553|Diagnostic Test|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry
46082518|NCT04258553|Diagnostic Test|Ischemia Modified Albumin(IU/mL)|The serum Ischemia Modified Albumin concentrations were measured as described by Bar-Or et al. (Bar-Or et al. 2000).
45831491|NCT05633784|Other|Teleconsultation|Cardiological and Diabetological teleconsultation at the beginning of the program and in case of need during the program.
45831492|NCT05633784|Other|Telerehabilitation|Support from a physiotherapist (if needed)
45831493|NCT05633784|Other|Telemonitoring|Telemonitoring of patient vital signs (eg single electrocardiographic trace) and delay steps
45977345|NCT00266396|Behavioral|Recommend full weight-bearing|The full weight-bearing group is trained in 4-point gait with crutches and is recommended to put as much weight as tolerated on the leg on which surgery has been performed, immediately after surgery
45977346|NCT00266396|Behavioral|Recommend parital weight-bearing|The partial weight-bearing group is trained in 3-point gait with crutches and is instructed to limit weight-bearing of the affected leg to 20kg for a period of six-weeks. Scales are used to train these participants not to exceed 20kg
45977347|NCT00301548|Drug|perioperative chemotherapy|
45977348|NCT00266474|Other|Assessment of upper and lower airway colonization, sinonasal symptoms, history, rhinoscopy and rhinomanometry.|
45977349|NCT00295698|Drug|Diethylcarbamazine|
45977350|NCT00266552|Drug|risperidone|
45977351|NCT00301587|Drug|Norgestimate-ethinyl estradiol, with or without folic acid|
45977352|NCT00266591|Drug|topiramate|
45977353|NCT00295737|Procedure|bronchoscopy, allergen/endotoxin instillation|
45977354|NCT04719299|Behavioral|Tell-Play-Do|Using smart phone application
45977355|NCT04719299|Behavioral|Tell-Show-Do|Using traditional behavior management technique
45977356|NCT00301626|Behavioral|smoking reduction intervention (including NRT)|
45977357|NCT00301665|Biological|Botulinum toxin type A|
45977358|NCT00295776|Drug|Lamictal in the treatment of Post-Herpetic Neuralgia|
45977359|NCT00266669|Drug|Topical organogel with nitroglycerin|
45672124|NCT02175121|Drug|PF-06291874|Tablet, 75 mg, once daily for 28 days
45831494|NCT05633784|Other|mHealth|The support of an App for recording and monitoring parameters: delay treatment, clinical parameters such as glycemia, blood pressure, HR, symptoms, etc.
45831495|NCT05633784|Other|telepsycology|Psychological support (if necessary)
45831496|NCT05633784|Other|Quality of life|Minnesota LIVING WITH HEART FAILURE® Questionnaire (MLHFQ), Short Form Survey (SF-12) Questionnaire and Diabetes Quality of Life (DQoL) questionnaire
45831497|NCT05633784|Other|Biochemistry evaluation|Glycemia, glycated haemoglobin, total cholesterol, HDL and LDL, triglycerides, creatinine, BUN, creatinine clearance, BNP
45672125|NCT02175121|Drug|PF-06291874|Tablet, 150 mg, once daily for 28 days
45672126|NCT01568866|Drug|Carfilzomib|Carfilzomib is administered over 30 minutes as an infusion.
45672127|NCT01568866|Drug|Bortezomib|Bortezomib is administered as a 3-5 second bolus IV injection or SC injection (in accordance with regulatory approval)
45977360|NCT00417924|Behavioral|Patient education|
45977361|NCT00266747|Drug|SR58611A|
45672128|NCT01568866|Drug|Dexamethasone|Tablet for oral administration; On days when carfilzomib or bortezomib was administered, the dexamethasone was to be given 30 minutes to 4 hours prior to the carfilzomib or bortezomib dose.
45977362|NCT00418002|Drug|AQW051|
45672129|NCT01568320|Device|Endovascular Treatment (Zenith)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
45672130|NCT01567852|Drug|Ketamine|Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect
45672131|NCT01567852|Drug|Methohexital|Methohexital (1.5mg/kg) will be given for induction
45672132|NCT01588366|Drug|Placebo|Administered orally
45672133|NCT01588366|Drug|LY2409021|Administered orally
45672134|NCT01686958|Device|MR-Guided Transurethral US Ablation of Prostate Tissue|The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.
45977363|NCT00266786|Drug|Intranasal Ketorolac Tromethamine|Intranasal at 30mg
45977364|NCT00266786|Drug|Intranasal Placebo|Intranasal Placebo
45977365|NCT00295815|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, 6 week cycles until PD
45831498|NCT05633784|Other|Clinical evaluation|6-minute-walking test, IMC, NYHA class, Ejection fraction
45831499|NCT05633784|Other|State of health of the patient|Severity Index and Comordbidity index
45831500|NCT03598764|Procedure|Classic head extraction during Cesarean section|by putting the fingers of the right inside the lower uterine segment to deliver the head
45977366|NCT00295815|Drug|lomustine|100-130 mg/m2, oral once, every 6 weeks until PD
45977367|NCT00266981|Device|APOS - exercise component|
45977368|NCT00267137|Device|Pacing Algorithms|
45977369|NCT00295971|Biological|anti-thymocyte globulin|
45977370|NCT00295971|Biological|therapeutic allogeneic lymphocytes|
45977371|NCT00295971|Drug|fludarabine phosphate|
45977372|NCT00295971|Drug|thiotepa|
45977373|NCT00295971|Procedure|allogeneic bone marrow transplantation|
45977374|NCT00295971|Procedure|allogeneic hematopoietic stem cell transplantation|
45977375|NCT00295971|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45977376|NCT00295971|Radiation|total-body irradiation|
45977377|NCT00267176|Drug|lumiracoxib|
45977378|NCT00296010|Drug|cyclophosphamide|cyclophosphamide 50 mg/day orally continuously for 16 weeks
45977379|NCT00296010|Drug|methotrexate|methotrexate 2.5 mg twice a day orally on days 1 and 4 of every week for 16 weeks
45977380|NCT00296010|Drug|pegylated liposomal doxorubicin hydrochloride|Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)
45977381|NCT00296010|Procedure|adjuvant therapy|
45977382|NCT00296010|Radiation|radiation therapy|Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.
45977383|NCT00267215|Drug|Lumiracoxib|
45977384|NCT00296049|Drug|daptomycin|
45977385|NCT00296049|Drug|vancomycin|
45977386|NCT00267254|Drug|torcetrapib/atorvastatin|
45977387|NCT00267254|Drug|simvastatin|
45977388|NCT00301782|Biological|bleomycin sulfate|
45977389|NCT00301782|Drug|carboplatin|
45977390|NCT00301782|Drug|cisplatin|
45977391|NCT00301782|Drug|etoposide phosphate|
45831501|NCT03598764|Procedure|External pop out technique|The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not directly on the fetal head.
45977392|NCT00301782|Drug|vincristine sulfate|
45977393|NCT00267332|Drug|Modafinil|
45977394|NCT00267410|Behavioral|Healthy Relationships|"Healthy Relationships, grounded in the social cognitive theory, is a five-session, group-level intervention originally designed for HIV-positive heterosexual individuals seeking skills-building and support around risk reduction, as well as disclosure of status and sexual preference. Through clip media and active role-plays, the intervention promotes the development of decision-making and problem-solving tools, empowering participants to make voluntary and informed decisions around disclosure and safer sex practices. This model was formally disseminated to AIDS Service Organizations as part of CDC's strategic plan - Advancing HIV Prevention, New Strategies for a Changing Epidemic - which focused on innovative strategies to recruit individuals into HIV testing, as well as a movement towards secondary prevention efforts."
45831502|NCT03594240|Drug|Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM)|Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM) once daily
45831503|NCT03594240|Dietary Supplement|Placebo|Patients in placebo group received placebo that were similar in appearance to Vitamin B complex tablets and the administered dose was as the same schedule as Vitamin B complex.
45672135|NCT01686568|Drug|Omega-3|Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
45672136|NCT01686568|Drug|placebo|
45672137|NCT01567462|Device|Monopolar electrocautery loop in Transurethral resection of bladder tumors|Standard monopolar electrocautery loop in transurethral resection of bladder tumors (TURBT)
45672138|NCT01567462|Device|PK Button Vaporization Electrode in transurethral resection of bladder tumors|PlasmaKinetic (PK) Button Vaporization Electrode in transurethral resection of bladder tumors (TURBT)
45672139|NCT01587898|Drug|GSK1278863|Tablet
45672140|NCT01587898|Other|Placebo|Tablet
45831504|NCT03976908|Device|Deep Brain Stimulation|High frequency deep brain stimulation in the medial geniculate body of the thalamus.
45831505|NCT05633238|Behavioral|Visual Search Information Type (target or distractor information)|Participants will have information about targets, distractors, or neither in different blocks of the intervention.
45831506|NCT03594006|Behavioral|CCI; cancer care coordination instrument|Designed to assess cancer patients' perceptions of care coordination
45977395|NCT04718649|Drug|Celebrex with Joins or not|The enrolled patienst will be divided into the group taking celecoxib 200mg with Joins tab together and the group taking celecoxib 200mg with Joins placebo in the same probability of 2:1 according to the randomization table at the first outpatient visit. Among the co-researchers, one researcher who is in charge of patient assignment will create a randomization table through computer generated randomization. And this researcher who is charge of the patient assignment will not intervene in any other process of this study, and only participates in the task of selecting the assigned group using random checks. The evaluation will be evaluated by an researcher who is not aware of the patient allocation according to the randomization table among researchers participating in the clinical study
45977396|NCT00301860|Biological|anti-thymocyte globulin|
45977397|NCT00301860|Biological|filgrastim|
45977398|NCT00301860|Biological|therapeutic allogeneic lymphocytes|
45672141|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
45672142|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
45977399|NCT00301860|Drug|cyclosporine|
45977400|NCT00301860|Drug|fludarabine phosphate|
45977401|NCT00301860|Drug|melphalan|
45977402|NCT00301860|Drug|methotrexate|
45977403|NCT00301860|Procedure|allogeneic hematopoietic stem cell transplantation|
45977404|NCT00301860|Procedure|peripheral blood stem cell transplantation|
45977405|NCT00267449|Device|SoftScan Optical Breast Imaging System|
45977406|NCT00301899|Biological|pertuzumab|
45977407|NCT00301899|Biological|trastuzumab|
45977408|NCT00267527|Drug|CJC 1295|
45977409|NCT00296127|Drug|Celecoxib|
45977410|NCT00267566|Behavioral|Strongest Families (formerly Family Help Program): Anxiety Program|Evidence-based psychological and behavioural distance intervention
45977411|NCT00296166|Procedure|Catheter ablation|
45977412|NCT00296166|Procedure|Thoracoscopic epicardial ablation|
45977413|NCT00267605|Behavioral|FHPADHD|Evidence-based psychological and behavioural distance intervention
45977414|NCT00267605|Behavioral|ADHD Standard Care|
45977415|NCT00296205|Drug|Cyclophosphamide|
45977416|NCT00267683|Drug|insulin aspart|
45977417|NCT00267683|Drug|glibenclamide|
45977418|NCT00296283|Behavioral|integrative behavior couples therapy|
45977419|NCT00267722|Drug|Visilizumab|
45977420|NCT00301938|Drug|7-hydroxystaurosporine|Given IV
45977421|NCT00301938|Drug|perifosine|Given orally
45977422|NCT00301938|Other|pharmacological study|Correlative studies
45977423|NCT04717869|Diagnostic Test|Ultrasound|2D ultrasound image collection
45977424|NCT04717869|Diagnostic Test|Biomarker Analysis|Inflammatory and nutritional biomarker analysis
45977425|NCT04717869|Other|Frailty Index|A Frailty Index Questionnaire be completed by patients or their surrogates to determine the presence of frailty at ICU admission
45977426|NCT00267839|Behavioral|physical exercise, wellness|
45977427|NCT04717947|Procedure|Interval between NAT and surgery|Evaluate three groups according to the interval between the end of neoadjuvant therapy and surgery.
45672143|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 1SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
45672144|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 2 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
45831507|NCT03593850|Behavioral|Music group|The song was composed on a C major scale and a 60 bpm tempo. The song was composed with high consonance using simple melodic progressions on the C major scale, and using natural positions for chords. No percussion or lyrics were used for the song, and the following instruments were used in the composition: electric guitar and keyboards, violin (digital), cello (digital), clarinet (digital), synthesizers (digital), and fretless bass (digital).
45831508|NCT03593850|Behavioral|Silence Group|Audio file that contained no sounds.
45977428|NCT00267917|Device|Berodual Respimat|
45977429|NCT00267917|Device|Berodual HFA-MDI|
45977430|NCT00296361|Drug|Tacrolimus|immunosuppression
45977431|NCT00296439|Behavioral|Behavior|
45977432|NCT00415922|Drug|ELC200 (carbidopa+levodopa+entacapone)|
45831509|NCT03024762|Procedure|targeted Provider-Initiated-Testing and Counseling (tPITC)|The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
45831510|NCT05633082|Device|Lens 1|Lens 1 - first period of 15 minutes
45977433|NCT00302016|Drug|AMN107|
45672145|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 4SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
45672146|NCT01567306|Biological|Placebo|Increasing volumes of placebo. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
45672147|NCT01587274|Drug|Naproxen|Naproxen 500mg twice/ day x 10 days
45672148|NCT01587274|Drug|Cyclobenzaprine|Cyclobenzaprine 5-10mg three times/ day x 10 days
45672149|NCT01587274|Drug|Oxycodone/ acetaminophen|Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days
45831511|NCT05633082|Device|Lens 2|Lens 2 - second period of 15 minutes
45831512|NCT03976362|Biological|Pembrolizumab|IV infusion
45831513|NCT03976362|Drug|Carboplatin|IV infusion
45672150|NCT01587118|Drug|Adjunctive asenapine|participants who are not responding fully to antidepressant therapy for PTSD will receive adjunctive asenapine (flexible dosing beginning with 5 mg sublingual once per day, titrated up to 10 mg twice per day, as tolerated) for a total of 12 weeks.
45672151|NCT01905657|Biological|Pembrolizumab|IV infusion
45831514|NCT03976362|Drug|Paclitaxel|IV infusion
45831515|NCT03976362|Drug|Nab-paclitaxel|IV infusion
45672152|NCT01905657|Drug|Docetaxel|IV infusion
45831516|NCT03976362|Drug|Olaparib|Tablets
45977434|NCT00415961|Device|CoStar Paclitaxel Drug-Eluting Coronary Stent System|CoStar Paclitaxel Drug-Eluting Coronary Stent System
45977435|NCT00416039|Drug|Midazolam|0.2 mg/kg of sublingual midazolam and 0.5 mg/kg of morphine
45977436|NCT00416039|Drug|Placebo|placebo at 0.2 mg/kg and morphine 0.5 mg/kg
45977437|NCT00296478|Drug|Endometrin|Endometrin 100mg BID x 10weeks
45977438|NCT00296478|Drug|Endometrin|Endometrin 100mg TID x 10weeks
45977439|NCT00296478|Drug|Crinone|Crinone QD x 10weeks
45977440|NCT00302172|Drug|ARQ 197|"Patients in this trial will receive ARQ 197 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 20 mg/day (first cohort) and escalate until the RP2D or MTD is determined. Patients enrolled under a previous amendment will continue to receive ARQ 197 twice daily for 14 days followed by 7 days without therapy. Any patient enrolled under Amendment 3 will take ARQ 197 twice daily for 21 days where cycles will be repeated every three-weeks (21 days).~Patients enrolled under Amendment 4 will receive dose of 360 mg bid (720 mg daily) continuously for 21 days, and cycle will be repeated every three weeks.~All patients will remain on study until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment is permitted."
45977441|NCT00268151|Drug|Oxaliplatin|
45977442|NCT00268151|Drug|Capecitabine|
45977443|NCT00418080|Drug|bicalutamide|
45977444|NCT00296556|Drug|Rivenprost (drug)|
45977445|NCT00268229|Drug|cytarabine|300 mg/m2/day
45977446|NCT00268229|Drug|daunorubicin hydrochloride|45 mg/m2/day
45977447|NCT00268229|Drug|imatinib mesylate|dose escalation (300 mg/day to 800 mg/day).
45977448|NCT00302250|Drug|ALT-711 (alagebrium chloride)|
45977449|NCT00268307|Drug|Autologous, Unfractionated Bone Marrow Mononuclear Cells|Intracoronary infusion of Autologous, Unfractionated Bone Marrow Mononuclear Cells. Dose is 100,000,000 cells. One time infusion over 20 minutes.
45977450|NCT00302289|Drug|tyrosine, green tea, caffeine|
45977451|NCT00268502|Other|study of socioeconomic and demographic variables|
45977452|NCT00268502|Procedure|fatigue assessment and management|
45977453|NCT00268502|Procedure|management of therapy complications|
45672153|NCT02202980|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
45831517|NCT03976362|Drug|Placebo|Placebo to olaparib, tablets
45977454|NCT00268502|Procedure|psychosocial assessment and care|
45977455|NCT00268502|Procedure|quality-of-life assessment|
45977456|NCT00296595|Behavioral|Nutrition|
45977457|NCT00268541|Behavioral|Physical activity|
45977458|NCT00296634|Drug|Aluminum hydroxide|Aluminum hydroxide adjuvant at 1200 mcg/mL.
45977459|NCT00296634|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)|Inactivated monovalent subvirion influenza H5N1 vaccine produced with and without Aluminum hydroxide adjuvant. All formulations of the H5N1 vaccine are supplied in a unit dose (0.5 mL) vial as a sterile solution for intramuscular injection. Vaccine with adjuvant is a turbid liquid whitish-grey in color. Vaccine without adjuvant is essentially clear and slightly opalescent in color.
45672154|NCT02202980|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45977460|NCT00268580|Behavioral|Asthma Care Pathway|Asthma care provided using standardized asthma care pathway
45977461|NCT00268619|Drug|Ramipril|
45977462|NCT00296673|Device|Rehabilitation device|
45977463|NCT00268658|Device|SmartStep(tm) biofeedback device|
45831518|NCT05633004|Device|Vivio|Non-invasive estimation of Left-Ventricular End Diastolic Pressure (LVEDP)
45831519|NCT04747782|Other|no interventions performed. Just collecting data, blood samples and post-mortem biopsies.|no interventions performed. Just collecting data, blood samples and post-mortem biopsies.
45831520|NCT03593694|Behavioral|TECH DM-BAT|Multi-component, high intensity intervention, technology delivered, diabetes-modified behavioral activation treatment.
45456242|NCT04574115|Device|Omega Refractive Capsule with an FDA approved Intraocular Lens|Omega refractive capsule in conjunction with an FDA approved Intraocular Lens
45672155|NCT02202980|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
45672156|NCT02202980|Drug|VOX|100 mg tablet administered orally once daily with food
45831521|NCT03593694|Behavioral|TECH DMBAT Active Comparator|Technology delivered diabetes education and home tele monitoring
45831522|NCT03593694|Behavioral|TECH DMBAT Other|Technology delivered diabetes education
45831523|NCT03593616|Procedure|Phacoemulsification|insertion of intra-ocular lens after emulsification of catractous lens
45831524|NCT05632848|Drug|Chidamide combined with Zimberelimab|Chidamide: 30mg each time, orally, biw; Zimberelimab, 240mg, IV, every 3 weeks.
45831525|NCT03598374|Dietary Supplement|Inositol + Folic acid|"Daily oral supplementation of for 6 months or until pregnancy conception:~Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg"
45831526|NCT03598374|Dietary Supplement|Folic acid|"Daily oral supplementation of for 6 months:~Folic acid: 400 mcg"
45977464|NCT00296712|Drug|escitalopram + bupropion|same dosing as for monotherapy arms
45977465|NCT00268697|Drug|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 24 weeks.
45977466|NCT00268697|Drug|Lapaquistat acetate and ezetimibe|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
45977467|NCT00268697|Drug|Ezetimibe|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
45672157|NCT01952145|Drug|insulin degludec/liraglutide|Insulin degludec/liraglutide is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
45831527|NCT03598374|Behavioral|Regular intercourses|Couples are required to have regular intercourses with the aim to achieve a spontaneous conception.
45831528|NCT03598218|Radiation|Hypofraction radiation|"Hypofractionated dose IMRT: GTVnx 60Gy, GTVnd 60Gy, PTV1 50Gy and PTV2 45Gy in 25 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles."
45977468|NCT00296751|Procedure|ECG recording|
45977469|NCT00296751|Procedure|Epidural catheter insertion|
45977470|NCT00296751|Drug|Intravenous meperidine injection|
45977471|NCT00296751|Drug|Epidural Bupivacaine and fentanyl injection|
45977472|NCT00268775|Behavioral|training and follow-up of pharmacists|
45977473|NCT00268775|Behavioral|patient-directed discontinuation letter|
45977474|NCT00302367|Drug|OROS methylphenidate hydrochloride|
45977475|NCT00302367|Drug|immediate release methylphenidate hydrochloride|
45977476|NCT00296790|Drug|zolpidem tartrate|
45977477|NCT02961296|Other|No intervention|No intervention will be needed.
45977478|NCT00302406|Drug|methylphenidate hydrochloride|
45977479|NCT00302406|Drug|OROS methylphenidate hydrochloride (CONCERTA)|
45672158|NCT01952145|Drug|insulin glargine|Insulin glargine is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
45672159|NCT04416087|Other|Exercise|Positron emission tomography (PET) imaging at rest and during supine bicycle exercise Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
45977480|NCT02961023|Other|Exercise therapy|"3-week residential phase and 12-week outpatient phase.~Residential phase~Exercise will be supervised by a physiotherapist and prescribed based on cardiopulmonary exercise testing.~A monitored daily program of exercise involving bicycle ergometry, walking, breathing exercises, dumbbell exercises 5 days per week.~1.5 to 2 hours of exercise will be performed daily, with rest intervals.~At weekends, lower intensity, unsupervised exercise mirroring the outpatient phase~Ongoing exercise prescription will be based on tolerability, progress and HR~Outpatient phase~A training manual will be compiled based on the subjects exercise performance during the residential program and tailored specifically to their needs~Participants will be provided with a cycle ergometer, weights and a HR monitor~Weekly telephone contact will be made by the study doctor or physiotherapist, with adjustments made to training prescription as necessary"
45672160|NCT01923363|Drug|Piperacillin/Tazobactam Standard Dose to High Dose|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Patients will be switched to higher dose after receiving the standard dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
45672161|NCT01905267|Behavioral|Rumination-Focused Cognitive Behavior Therapy|This intervention targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effective coping strategies. Mindfulness is a key component of this intervention as a strategy for disengaging from one's thoughts. Strategies from Dialectical Behavior Therapy (DBT), such as the use of effective interpersonal skills, are also included as methods for regulating strong emotion. Rumination-Focused Cognitive Behavior Therapy is a structured, manual based program designed to be delivered weekly over eight weeks. Sessions are 60-90 minutes in length.
45672162|NCT04627857|Device|Manual toothbrush|Patients in group 1 (''reference procedure'') receive a manual toothbrush with a small compact head to facilitate access to the posterior teeth and soft bristles.
45831529|NCT03598218|Radiation|Standard dose IMRT|"Standard dose IMRT: GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 54.9Gy and PTV2 54Gy in 33 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles."
45977481|NCT00302445|Drug|Efalizumab|
45977482|NCT00302445|Device|Narrow Band Phototherapy|
45456243|NCT04574115|Device|FDA approved Intraocular Lens|FDA approved Intraocular Lens
45977483|NCT00268814|Drug|Diacetylmorphine|Diacetylmorphine (i.v.), daily
45831530|NCT03593460|Drug|Synthetic PreImplantation Factor|peptide
45831531|NCT03024294|Other|Post-operative care pathway for patients undergoing VATS lobectomy or segmentectomy|To place participants on this specific post-operative care pathway upon the completion of their VATS surgery to determine the discharge rate by midnight on post-operative day (POD) three.
45831532|NCT04407078|Drug|Sugammadex Injectable Product|Sugammadex of 2 mg/kg is injected.
45831533|NCT04407078|Drug|Neostigmine Injectable Product|Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
45831534|NCT04003116|Drug|Oxygen gas|Supplementary oxygen during the first 48 hours added to conventional anticoagulant treatment. Patients will receive anticoagulant treatment according to updated guidelines.
45831535|NCT00218634|Behavioral|CBT-AD|Cognitive behavioral therapy for adherence and depression consisting of 1 session focusing on adherence and 8 sessions consisting of cognitive behavioral therapy for medication adherence and depression.
45831536|NCT00218634|Behavioral|ETAU|Enhanced treatment as usual consisting of 1 session focused on adherence (the same session as the CBT-AD intervention) and 8 sessions for participants to complete self-reports and collect adherence data.
45456244|NCT04570943|Combination Product|Gabrinox|"Regimen: GEMBRAX~Other Names:~Albumin bound paclitaxel 125 mg/m² + Gemcitabine 1000 mg/m²~Regimen: FOLFIRINOX~Other Names:~Oxaliplatin 85 mg/m² + Leucovorin 200 mg/m² + Irinotecan 180 mg/m² + 5FU bolus 400mg/m² + 5FU continuous 2400 mg/m²~Gembrax + Folfirinox = GABRINOX"
45456245|NCT04570943|Radiation|MRI-GUIDED STEREOTACTIC RADIOTHERAPY|"Radiotherapy will start between 5 and 6 weeks after the last injection of chemotherapy (FOLFIRINOX regimen) in non-progressive patients after Gabrinox.~Stereotactic adaptive radiotherapy in five fractions: prescription of five fractions of 10 Gy/each on the planning target volume (PTV). At least two sessions/week should be performed. An interval of at least 18 hours between fractions is recommended."
45831537|NCT00217620|Drug|sorafenib|800 mg per day, daily until progression
45831538|NCT00217464|Drug|fulvestrant|intramuscularly
45831539|NCT00214500|Drug|migalastat HCl|
45831540|NCT04002726|Other|Inter-grader agreement (IGA) app|A smartphone-based app with images of conjunctivae for trachoma grading training purposes.
45977484|NCT00268814|Behavioral|Psycho-education and Counselling|Psycho-educational group therapy and individual counselling
45977485|NCT00268814|Drug|Methadone|Methadone (p.o.), daily
45977486|NCT00268814|Behavioral|Case management and Motivational interviewing|Individual Case Management combined with Motivational interviewing
45672163|NCT04627857|Device|Manual toothbrush and water flosser (Philips Sonicare AirFloss)|- Group 2 patients receive a manual toothbrush with a small, compact head for easy access to the posterior teeth and soft bristles. They also receive a Philips brand interdental microjet (Philips Sonicare AirFloss Ultra) which must be filled with water.
45977487|NCT00296829|Biological|Inactivated, split-virion influenza vaccine|
45977488|NCT00268853|Drug|CPOP-R|Cyclophosphamide 750 mg/m2, pixantrone 150 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
45977489|NCT00268853|Drug|CHOP-R|Cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
45977490|NCT00302484|Drug|Zoledronate|
45977491|NCT00296868|Drug|ascorbic acid (vitamin C) versus placebo|
46082519|NCT03743233|Device|Hand file|A crown-down technique will be performed until reaching the provisory WL. The root canals will be initially deobstructed with size #3 and #2 Gates-Glidden burs (Dentsply-Maillefer) at the coronal and middle root thirds. Then, hand stainless steel K-files (Dentsply-Maillefer) with decreasing sizes will be used (#40, #35, #30, #25). The WL will be determined by an electronic apex locator (Novapex; Forum Technologies, Rishon Le-Zion, Israel). A radiograph will be taken to confirm the WL, which should be 1 mm short of the root apex. Apical patency will be reached and maintained with a size #15 K-file (Dentsply-Maillefer). The root canals will be reinstrumented and a size #50 K-file will be standardized as the master apical instrument. A step-back procedure in 1-mm increments followed until merging with the crown-down rotary enlargement (size #70) will be achieved.
46082520|NCT03743233|Device|Reciprocating|Reciproc R25 file will be used for gutta-percha removal, until reaching the WL. The instrument will be introduced into the canal applying slight movements of 3-mm amplitude. Apical patency will be maintained with a size #15 K-file. The root canals will be reinstrumented using the Reciproc R50 file. For both groups, after the root canal filling removal and reinstrumentation protocol, a new radiograph will be taken, without any intracanal instrument, for posterior analysis of the percentage of remaining filling material in the root canal. If the radiograph demonstrates the persistence of filling material, the technique will be repeated with the last instrument used in the chemomechanical preparation (hand or reciprocating file), also using H-files with circumferential movements against the dentinal walls in order to remove these residual material, followed by abundant irrigation with NaOCl.
45672164|NCT04627857|Device|Sonic toothbrush|- Group 3 patients receive a rechargeable sonic electric toothbrush from Philipps with an integrated excess pressure sensor and a compact toothbrush head for easy access to the posterior teeth.
45672165|NCT04627857|Device|Sonic toothbrush (Philips Sonicare) and water flosser (Philips Sonicare AirFloss)|- Group 4 patients receive a Philips Sonicare ProtectiveClean rechargeable sonic electric toothbrush with an integrated excess pressure sensor and 2 compact toothbrush heads for easy access to the posterior teeth. They also receive an interdental microjet from Philips (Philips Sonicare AirFloss Ultra) which must be filled with water.
45672166|NCT01923285|Device|AXIUM Neurostimulator System|
45672167|NCT01923285|Device|Control Spinal Cord Stimulation Device|
45672168|NCT01904721|Drug|Bimatoprost Solution 1|Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
45672169|NCT01904721|Drug|Bimatoprost Solution 2|Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
45831541|NCT03597984|Radiation|Simultaneous Integrated Boost-SIB on macroscopic metastases|"Delivery of a boost on macroscopic secondary lesion with Simultaneous Integrated Boost technique according this schedule:~- 5 Gy x 3 fr (Whole Vertebra) + SIB 10 Gy x 3 fr on the macroscopic disease Gross Tumor Volume - (GTV)"
45831542|NCT03597906|Procedure|topography guided ablation|using the data obtained from the topolyzer for correction of refractive errors specially astigmatism we use 3 different treatment protocols
45831543|NCT03597906|Procedure|manifest refraction|using for ablation the exact manifest refraction
45831544|NCT03597906|Procedure|full topography modified refraction|full topography modified refraction means changing both sphere and cylinder power in the ablation profile
45831545|NCT03597906|Procedure|partial topography modified refraction|partial topography modified refraction means changing only cylinder power and axis in the ablation profile
45831546|NCT03597516|Drug|RP-G28|powder for reconstitution for oral administration
45831547|NCT03597516|Drug|Placebos|powder for reconstitution for oral administration
45977492|NCT00268931|Behavioral|Movement Training|This group of infants underwent specific movement training activities two times per day with their parents.
45977493|NCT00268931|Behavioral|Social Training|This group underwent special social interactions with their parents two times each day.
45831548|NCT03597282|Biological|NEO-PV-01|Personal Cancer Vaccine
45831549|NCT03597282|Biological|Nivolumab|monoclonal antibody against PD-1
45977494|NCT00296907|Behavioral|Brief psychological intervention|Psychoeducation, provision of medical knowledge, coping skills training
45977495|NCT00268970|Drug|Satraplatin in combination with Paclitaxel|Paclitaxel 200 mg/m2 IV over 3 hours on day 1. Satraplatin 60 mg/m2 administered by mouth once daily for 5 consecutive days (days 1-5). Satraplatin will be administered within 2 hours following paclitaxel infusion on day 1. Subsequent doses on days 2-5 will be taken at approximately 24 hour intervals.
45831550|NCT03597282|Other|Adjuvant|immune adjuvant
45831551|NCT03597282|Biological|APX005M|monoclonal agonist antibody against CD40
45831552|NCT03597282|Biological|ipilimumab|monoclonal antibody against CTLA4
45831553|NCT03597204|Diagnostic Test|Fecal immunochemical test (FIT)|Annual fecal immunochemical test (FIT) for selected high risk individuals to undergo CRC screening. And colonoscopy for those with FIT positive result
45977496|NCT00296946|Drug|ipratropium bromide (drug)|
45977497|NCT00269009|Behavioral|CHERL|
45977498|NCT00296985|Device|Fresenius Cellsaver|
45977499|NCT00269048|Drug|SB-480848|SB-480848
45977500|NCT00269048|Drug|placebo|placebo
45977501|NCT00302523|Drug|Tacrolimus|FK506,0.1mg/kg/d
45672170|NCT01904721|Drug|Bimatoprost Vehicle|Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
45977502|NCT02960412|Drug|furosemide|10mg lasix given intraoperatively
45977503|NCT02960412|Drug|Normal Saline|Normal saline given intraoperatively as placebo
45977504|NCT00269126|Drug|fluticasone propionate/salmeterol combination DISKUS|
45977505|NCT00269126|Drug|salmeterol xinafoate|
45977506|NCT00269165|Procedure|Balloon Aortic Valvuloplasty|
45977507|NCT00269165|Procedure|External Beam Radiation|
45977508|NCT00297024|Procedure|MRI|Patients will be scanned while breathing in varying amounts of oxygen and carbon dioxide in varying amounts through a breathing device.
45977509|NCT00269204|Drug|niacin (+) laropiprant|Duration of Treatment - 24 weeks
45977510|NCT00269204|Drug|ER-niacin|Duration of Treatment - 24 weeks
45672171|NCT05122533|Diagnostic Test|EOS|EOS Micro Dose imaging will be done. SterEOS lower limb alignment reconstruction will be performed measuring the lim length.
45977511|NCT00297141|Drug|Capecitabine|chemotherapy oral use
45977512|NCT00297141|Drug|Oxaliplatin|chemotherapy intravenous use
45977513|NCT00269243|Drug|Quinapril|
45977514|NCT04718064|Drug|Fingolimod|fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days
45977515|NCT04718064|Drug|placebo|placebo once daily, for three consecutive days,
45977516|NCT00297180|Drug|GW869682|
45977517|NCT00302601|Procedure|Scintigraphic interpretation|Not relevant
45977518|NCT00269282|Behavioral|Self-Management Training|Asthma education and self-monitoring strategies
45977519|NCT00269282|Behavioral|Motivational Interviewing (MI)|Motivational Interviewing (MI) is a promising interventional approach that uses a client-centered, non-directive approach for enhancing motivation to change health behaviors.
46082521|NCT02719782|Biological|Biological: TCR-T|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
46082522|NCT02801864|Device|Real tDCS|Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.
46082523|NCT02801864|Device|Sham tDCS|Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.
46082524|NCT02801864|Other|Intensive Speech Therapy|Participants will receive one hour of group therapy and two hours of individual therapy that will follow VNeST format. The purpose of therapy will be to have the client generate verbs and nouns in written and verbal form.
45672172|NCT05122533|Diagnostic Test|Clinical limb length measurements|"Clinical measurement of both lower limbs' length, 3 times in 3 different days by 3 observers.~bony markers position (heel contour, patella and medial malleolus) in resupinate and side position also~tape measuring:~Spina iliaca anterior superior - medial malleolus~umbilicus - medial malleolus~greater trochanter - lateral malleolus~in standing, sitting, resupinate and side position"
45672173|NCT01922895|Dietary Supplement|Lactobacillus Rhamnosus GG|Probiotic nutritional supplement; Lactobacillus Rhamnosus GG
45672174|NCT01922895|Drug|Placebo for Probiotic|Capsule manufactured without active ingredients.
45672175|NCT01922739|Drug|Hydrocodone ER|Participants were instructed to take hydrocodone ER tablets orally with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
45977520|NCT00297219|Drug|Low dialysate calcium|1.25 mmol/L dialysate calcium
45977521|NCT00297219|Drug|high dialysate calcium|1.75 mmol/L dialysate calcium
45977522|NCT00269321|Procedure|Chiropractic Manual treatment + home exercise (procedure+behavior)|"The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation, mobilization and flexion-distraction therapy with light soft tissue massage as indicated to facilitate the manual therapy.~Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active."
45977523|NCT00269321|Procedure|Supervised rehabilitative exercise+home exercise|"The rehabilitative exercise program will consist of 20, 1-hour sessions. It is a modification of exercise protocols used in previous studies by the investigators and incorporates recommendations of leading rehabilitative exercise specialists.~Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active."
45977524|NCT00269321|Behavioral|Home exercise|Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
45977525|NCT00302640|Drug|Alinia (nitazoxanide)|
45977526|NCT00269360|Procedure|Chiropractic + Supervised Rehabilitative Exercise|"Chiropractic care will include manual spinal manipulation, with light soft tissue massage as indicated to facilitate the spinal manipulative therapy. The spinal levels treated will be determined by the individual chiropractors by static and/or motion palpation.~Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises."
45977527|NCT00269360|Procedure|Supervised Rehabilitative Exercise|Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises.
45977528|NCT00269360|Behavioral|Self-care education|Self-care education will be provided by the therapist trained in the study protocol. Two, one-hour sessions will be given regarding self-care measures and ergonomics relative to work and activities of daily living. These will include postural instructions and practical demonstrations of proper body mechanics performed with patient participation.
45977529|NCT00297297|Other|No intervention. Applying gene profiling on needle aspirates|
45977530|NCT00269438|Drug|5 ASA, enemas, suppositories, corticosteroids|
45977531|NCT00418353|Drug|Betamethasone(Celestone soluspan) and Dexamethasone|
45977532|NCT00269516|Drug|pardoprunox|fixed dose 6 mg
45977533|NCT00269516|Drug|Pardoprunox|fixed dose 12 mg
45977534|NCT00269516|Drug|Pardoprunox|12-42mg
45977535|NCT00269516|Drug|Placebo|Placebo
45977536|NCT00418392|Procedure|Simple aspiration with minocycline pleurodesis|Intrapleural instillation of 300mg minocycline within 5 min after simple aspiration
45977537|NCT00418392|Procedure|simple aspiration|Simple aspiration for primary spontaneous pneumothorax by pigtail catheter
45977538|NCT00269555|Drug|Genistein Combined Polysaccharide (GCP)|
45977539|NCT00418431|Drug|Intravitreal injection of Bevacizumab|
45977540|NCT00269594|Drug|Lamictal (lamotrigine)|
45977541|NCT00418470|Procedure|regular dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in regular NS volume
45977542|NCT00418470|Procedure|higher dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in larger NS volume
45831554|NCT04002414|Behavioral|Sufficient physical activity|Physical activity at the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
45831555|NCT04002414|Behavioral|Insufficient physical activity|Physical activity less than the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
45831556|NCT03593304|Drug|Injection Mecobalamin|Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
45831557|NCT03593304|Drug|Tablet Pyridoxine hydrochlorid|Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
45977543|NCT00269672|Biological|13-valent Pneumococcal Conjugate Vaccine|
45977544|NCT00302757|Drug|Radioimmunotherapy|
45977545|NCT00302757|Procedure|allogeneic hematopoietic cell transplantation|
45977546|NCT00416117|Procedure|Manual Physical Therapy and Exercise|
45977547|NCT00416117|Procedure|Minimal Intervention|
45977548|NCT00416156|Behavioral|Lifestyle modification|
45977549|NCT00302796|Drug|Bioclavid|500 + 125 mg times 3 or 6
45977550|NCT00302796|Drug|Placebo|
45977551|NCT00425633|Drug|Homeopathic Potassium Dichromate|5 pellets under tongue q12h until extubation
45977552|NCT00302835|Drug|non-phenacetin containing analgesics|
45977553|NCT00302874|Behavioral|Implementation of a protocol for treatment of hyperglycemia|
45977554|NCT00269750|Drug|OROS® oxybutynin or Ditropan®|
45977555|NCT00269789|Drug|Ritalin|
45672176|NCT01922739|Drug|Placebo|During the double-blind titration period used in the original protocol, placebo tablets matching each dose of hydrocodone bitartrate ER tablets (active drug) were used to maintain the blind but not for purposes of comparison.
45977556|NCT00269789|Drug|OROS Methylphenidate HCl|
45977557|NCT00269789|Drug|Placebo|
45977558|NCT00302913|Drug|Adjustment of clopidogrel dose|
45977559|NCT00269828|Drug|paclitaxel|
46082525|NCT00938743|Drug|Atomoxetine|40-80 mg atomoxetine once daily, including titration 10 weeks
46082526|NCT02719392|Dietary Supplement|N-acetylcysteine|NAC is an FDA-approved mucolytic (a type of drug used to relieve respiratory difficulties) and is also used for the treatment of acetaminophen toxicity.
45672177|NCT02236988|Drug|Apremilast Immediate Release|30 mg immediate release tablets
45672178|NCT02236988|Drug|Apremilast Modified Release 1|75 mg oral tablet of prototype modified release (MR) 1
45672179|NCT02236988|Drug|Apremilast Modified Release 2|75 mg oral tablet of prototype MR 2
45672180|NCT02236988|Drug|Apremilast Modified Release 3|75 mg oral capsule of prototype MR 3
45672181|NCT02236988|Drug|Apremilast Modified Release 4|75 mg oral capsule of prototype MR 4
45672182|NCT02236988|Drug|Apremilast Modified Release 5|75 mg oral capsule of prototype MR 5
45977560|NCT00269828|Drug|paclitaxel poliglumex|
45977561|NCT00269867|Drug|Placebo|Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
45977562|NCT00269867|Drug|Infliximab 3 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
45977563|NCT00269867|Drug|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
45977564|NCT00303030|Procedure|1. Anal injection|Submucosal injection just above the linea dentata in the anal canal of 4 x 1 ml of dextranomere.
45977565|NCT00303030|Procedure|2. Biofeedback|Training under the guidance of a physiotherapist with the help of a biofeedback device with an anal probe.
45977566|NCT00269906|Drug|Abciximab|
45977567|NCT00269906|Drug|Placebo|
45977568|NCT02960373|Other|White Bread (Control)|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
45977569|NCT02960373|Other|Dried Fruit - Glycemic Index|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
45977570|NCT02960373|Other|Catalytic Fructose Dose Effect|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
45977571|NCT02960373|Other|High GI Displacement Effect|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
45977572|NCT00269945|Drug|epoetin alfa|
45977573|NCT00303147|Behavioral|Expressive Writing|
45977574|NCT00269984|Drug|Epoetin alfa|
45977575|NCT00297336|Drug|Topiramate|80 patients with diagnosed with migraine
45977576|NCT00270023|Drug|epoetin alfa|
45977577|NCT00297375|Drug|tramadol HCl/acetaminophen|
45977578|NCT02960984|Other|Task Oriented rehabilitation and aerobic training|Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training and 30' of task-oriented training focused on uppper limb rehabilitation for 3 times a week for 20 sessions.
45977579|NCT00297414|Other|No intervention|No study drug was administered to the patients. Data on vital status was obtained for patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
45977580|NCT00270062|Drug|epoetin alfa|
45977581|NCT00297453|Behavioral|Internet-based smoking treatment|All participants have access to an Internet-based self-help intervention that includes social support through message boards. All participants have access to 10 weeks of nicotine replacement treatment.
45977582|NCT00297453|Behavioral|Individual Counseling|Six individual counseling sessions are provided over a 12 week treatment period. Participants also have access to a 10-week nicotine replacement treatment.
45977583|NCT00297453|Behavioral|self-help|Participants receive a self-help manual and have access to a 10 nicotine replacement treatment.
45977584|NCT00270101|Drug|epoetin alfa|
45977585|NCT00297531|Device|PerioWave|
45977586|NCT00297531|Procedure|Scaling and Root Planing|
45977587|NCT00270140|Drug|epoetin alfa|
45977588|NCT00270179|Drug|epoetin alfa|
45977589|NCT00270218|Biological|VRC-HIVADV014-00-VP|HIV-1 recombinant adenoviral vector vaccine given as a 1 mL intramuscular injection in the deltoid
45977590|NCT00270218|Biological|VRC-HIVDNA009-00-VP|HIV-1 DNA plasmid vaccine given as a 1 mL intramuscular injection in the deltoid
45672183|NCT02236988|Drug|Apremilast Modified Release 6|75 mg oral capsule of prototype MR 6
45672184|NCT02236988|Drug|Apremilast Modified Release 8|80 mg oral capsule of prototype MR 8
45672185|NCT02236988|Drug|Apremilast Modified Release 9|80 mg oral capsule of prototype MR 9
45672186|NCT02236988|Drug|Apremilast Modified Release 11|80 mg oral capsule of prototype MR 11
45672187|NCT02236988|Drug|Apremilast Modified Release 12|80 mg oral capsule of prototype MR 12
45672188|NCT02236988|Drug|Apremilast Modified Release 13|80 mg oral capsule of prototype MR 13
45831558|NCT03593304|Drug|Normal saline|Injection Normal saline(1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
45831559|NCT03593304|Drug|Oral Placebo|Placebo Oral Tablet (25 mg) 2 tablets thrice daily for 5 weeks.
45831560|NCT00211536|Drug|Medtronic MiniMed Implantable Pump Human Recombinant Insulin|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
45977591|NCT00270218|Biological|FFB|Adenoviral vector FFB given as a 1 mL intramuscular injection in the deltoid
45977592|NCT00270218|Biological|PBS|phosphate buffered saline
45977593|NCT00297570|Drug|Pegylated Interferon and Imatinib|
45977594|NCT00270335|Drug|Propofol|
45977595|NCT00297687|Biological|MnB rLP2086|
45977596|NCT00270374|Drug|nesiritide|
45977597|NCT00297726|Behavioral|Self-Management Program|
45977598|NCT00270452|Drug|WT1 and PR1 Peptide Vaccine|
45977599|NCT00270491|Drug|Paclitaxel|
45977600|NCT00270491|Drug|Capecitabine|
45977601|NCT00270530|Drug|Sulfadoxine-pyrimethamine (Fansidar)|
45977602|NCT00297765|Drug|Tacrolimus, Prograf®|
45672189|NCT02236988|Drug|Apremilast Modified Release 14|80 mg oral capsule of prototype MR 14
45831561|NCT00211536|Device|Medtronic MiniMed Implantable Pump System|The implantable pump system is intended to provide continuous intraperitoneal delivery of insulin in subjects with diabetes.
45977603|NCT00270569|Drug|PhyxolTM, Cisplatin|
45977604|NCT00297804|Device|TAXUS Express Paclitaxel-Eluting Coronary Stent System|Paclitaxel-Eluting Coronary Stent System
45977605|NCT00297804|Device|Control stent|control stent
45672190|NCT02236598|Drug|K+ supplement|
45672191|NCT02236598|Drug|Placebo|
45672192|NCT01922349|Drug|BI 113608|Medium dose (Multiple dosing)
45672193|NCT01922349|Drug|Placebo|Placebo (Multiple dosing)
45672194|NCT01922349|Drug|BI 113608|Low dose (Multiple dosing)
45977606|NCT00270608|Procedure|Quantitative Computed Tomography of the tibia and spine|a single time 1 minute procedure
45977607|NCT00270608|Procedure|MRI of the spine and the right knee|a single time 45 minutes procedure
45977608|NCT00270608|Procedure|Blood test|A single time procedure to check lipid profile and hemoglobin A1C
45977609|NCT00297843|Procedure|allergen challenge (grass pollen), nasal lavage|
45977610|NCT00270647|Dietary Supplement|Vitamin E|400 IU synthetic alpha-tocopherol or its placebo on alternate days (provided by BASF)
45977611|NCT00270647|Dietary Supplement|Vitamin C|500 mg synthetic ascorbic acid or its placebo daily (provided by BASF)
45977612|NCT00270647|Dietary Supplement|Multivitamin|Centrum Silver or its placebo daily (provided by Pfizer (formerly Wyeth, American Home Products, and Lederle))
45977613|NCT00270647|Dietary Supplement|Beta-carotene|50 mg Lurotin or placebo on alternate days (provided by BASF)
45977614|NCT00297921|Drug|tandutinib|
45977615|NCT00297960|Drug|ziprasidone or olanzapine|
45977616|NCT00297960|Procedure|hyperinsulinaemic euglycaemic clamp|
45977617|NCT00297960|Procedure|microdialysis (skeletal muscle)|
45977618|NCT00270803|Drug|Tetra Hydro Cannabinol (THC)|Oral THC 13mg and 17mg smoked in low nicotine cigarettes
45977619|NCT00270881|Procedure|Cord blood transplantation|unrelated cord blood transplantation
45977620|NCT00270881|Radiation|TBI|Total body irradiation (TBI) 12Gy
45977621|NCT00270881|Drug|cyclophosphamide|cyclophosphamide 120mg/kg
45977622|NCT00270881|Drug|cytarabine|cytarabine 3g/m2x4
45977623|NCT00270920|Behavioral|Lactation counseling|
45977624|NCT00270959|Behavioral|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
45977625|NCT00270959|Behavioral|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
46082527|NCT02719392|Drug|Minocycline|Minocycline is an FDA-approved antibiotic commonly used to treat bacterial infections.
45977626|NCT00270959|Drug|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
45977627|NCT00270959|Behavioral|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors.
45831562|NCT00211536|Drug|Aventis HOE21PH U400|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
45672195|NCT01922349|Drug|Placebo|Placebo (Single dosing)
45977628|NCT00298194|Drug|Z-338|
45977629|NCT00271037|Procedure|Colpocleisis prolapse repair surgery|
45977630|NCT00271037|Procedure|sling or other to treat or prevent stress incontinence|
45977631|NCT00306306|Device|Reprieve Endovascular Temperature Therapy System|
45977632|NCT00271076|Procedure|IVUS|
45977633|NCT00271076|Device|CAS|
45977634|NCT00271076|Procedure|CEA|
45977635|NCT00306345|Behavioral|Outreach|
45977636|NCT00271115|Behavioral|Kangaroo Holding|Mothers will be asked to Kangaroo hold their infants two times during the first week of life.
45977637|NCT00306423|Procedure|Other: Exercise|exercise 3 times per week for 12 weeks
45831563|NCT04001088|Dietary Supplement|Probiotic|Dosing regimen of one capsule daily for a maximum of 48 weeks.
45977638|NCT00271193|Behavioral|Weight loss counseling|A comparison of weight loss advice provided by primary care physicians to advice plus brief weight loss counseling provided by medical assistants. Participants in both groups receive weight loss materials.
45831564|NCT04001088|Other|Placebo|Dosing regimen of one capsule daily for a maximum of 48 weeks.
45977639|NCT02960256|Device|ekocardiogram test|ekocardiogram test
45977640|NCT00271232|Device|Cardiac resynchronization therapy|
45977641|NCT00418548|Drug|Etanercept|
45977642|NCT00416234|Procedure|Laparoendoscopic Rendez vous|intraoperative ERCP for CBD clearance during laparoscopic cholecystectomy
45831565|NCT03976128|Behavioral|Nordic Walking Training|The excursions will take place predominantly in flat pathways, beginning in a local park and progressing to roadside footpaths. Each session will last an hour including a warm up, NW and a cool down with stretching exercises.
45672196|NCT01922349|Drug|BI 113608|High dose (Single dosing)
45672197|NCT01922349|Drug|BI 113608|Medium dose (Single dosing)
45831566|NCT03976128|Behavioral|Conventional endurance training|15 minutes of Treadmill training with progressive increase of velocity followed by 20 minutes of cycloergometer with progressive increase of resistance. Each session will last an hour including a warm up, training with treadmill and cycloergometer and a cool down with stretching exercises.
45672198|NCT01922349|Drug|BI 113608|Low dose (Single dosing)
45672199|NCT01922349|Drug|BI 113608|High dose (Multiple dosing)
45831567|NCT03596970|Drug|TAC withdrawal|Everolimus (RAD001) with MMF and Steroids
45831568|NCT03596970|Drug|Everolimus with reduced TAC|Active comparator arm: Everolimus (RAD001) with reduced TAC and Steroids
45831569|NCT03596892|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
45831570|NCT03596892|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
45977643|NCT00416234|Procedure|preoperative ERCP and CBD clearance|ERCP and CBD clearance followed by laparoscopic cholecystectomy
45977644|NCT00418587|Drug|Cholecalciferol|800 IU oral daily
45977645|NCT00418587|Drug|Cholecalciferol|2000 IU oral daily
45977646|NCT00418587|Drug|Cholecalciferol|4000 IU oral daily
45977647|NCT00416273|Drug|Bortezomib|Bortezomib will be administered as 1.6 mg/m2 per body surface area on the days 1, 8, 15, 22 for the duration of 4 therapy cycles.
45977648|NCT00416273|Drug|No intervention|Participants in the observation group will be observed and will not receive any consolidation therapy.
45977649|NCT00306462|Drug|Magnesium sulfate|Intravenous magnesium sulfate 6g bolus, then increased by 1 g/hour till a maximum of 5g/hour; gradually wean down to 2 g/hour for a total of 48 hours once uterine contractions is < 6/hour.
45977650|NCT00306462|Drug|Oral Nifedipine or placebo|Oral nifedipine or placebo at 20 mg every 30 minutes for the first hour, then 20 mg every 3 to 6 hours not to exceed 180 mg in 24 hours, keep maintenance dose at 20 mg every 3 to 6 hours for a total of 48 hours if uterine contractions is < 6/hour.
45977651|NCT00416390|Dietary Supplement|lycopene|
46082528|NCT02719392|Other|Placebo|The placebo control is an inactive sugar pill that mimics the active comparators in appearance.
46082529|NCT02802098|Drug|Durvalumab|Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1). PD-L1 can be expressed by tumours to evade detection by the immune system through binding to PD-1 on cytotoxic T lymphocytes. Durvalumab blocks the PD-L1 interaction with PD-1, countering the tumour's immune-evading tactics.
45672200|NCT02236520|Drug|Spironolactone|
45672201|NCT02236520|Drug|Chlorthalidone|
45672202|NCT02236520|Dietary Supplement|Diet|
45672203|NCT02236520|Drug|Placebo|
45672204|NCT04769414|Drug|Gemcitabine fluorouracil|"chemotherapy protocol given as:~Gemcitabine 1000mg/m2 IV short infusion~Leucovorin 400 mg/m2 IV short infusion~Flourouracil 400 mg/m2 direct IV shot~Flourouracil 2000 mg/m2 contineous infusion over 46 hours~The whole regimen will be repeated bi-weekly"
45672205|NCT01922271|Drug|NVA237|NVA237 44 µg inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)
45672206|NCT01922271|Drug|Tiotropium|Tiotropium 18 μg once daily delivered via HandiHaler® device.
45672207|NCT01922271|Drug|Placebo to NVA237|Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).
45977652|NCT00416390|Other|laboratory biomarker analysis|
45977653|NCT00416390|Procedure|biopsy|
45977654|NCT00306501|Procedure|Swallowing Training|Swallowing Training with press of button
45977655|NCT00416429|Biological|aldesleukin|
45977656|NCT00416429|Biological|recombinant interferon alpha-2a|
45977657|NCT00416429|Drug|medroxyprogesterone|
45977658|NCT00306540|Drug|Quetiapine Fumarate|oral flexible dose
45977659|NCT00306540|Drug|quetiapine fumarate placebo|oral 0 mg
45977660|NCT00271271|Drug|oxaliplatine / gemcitabine / Vinorelbine|
45977661|NCT00271310|Drug|hypertonic saline|
45977662|NCT00306618|Drug|Panzem Nanocrystal Colloidal Dispersion|Panzem NCD suspension, 100 mg/mL, four times daily continuous dosing
45977663|NCT00271349|Drug|Budesonide|
45831571|NCT03596892|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
45977664|NCT00306657|Procedure|Optic nerve sheath fenestration|
45977665|NCT00271388|Device|Transcutaneous current to the vestibular nerve|Delivery of randomly oscillating low level current
45977666|NCT00306696|Drug|Rosiglitazone|
45977667|NCT00306696|Drug|spironolactone|
45977668|NCT00306696|Drug|hydrochlorothiazide|
45977669|NCT00306696|Drug|frusemide|
45977670|NCT00271427|Drug|L-Selenomethionine|
45977671|NCT00271466|Drug|DuragesicÂ® (fentanyl) Therapeutic Transdermal System (TTS)|
45977672|NCT00306735|Drug|Palonosetron|
45977673|NCT00271583|Drug|CDB-2914|
45977674|NCT00271583|Drug|levonorgestrel|
45977675|NCT00306774|Dietary Supplement|Vitamin D (cholecalciferol)|2,000 IU vitamin D capsule per day for 2 years
45977676|NCT00306774|Dietary Supplement|Placebo|Placebo capsule per day for 2 years
45977677|NCT00271700|Behavioral|Order Set, Education, Feedback|
45977678|NCT00306813|Drug|Revlimid|
45977679|NCT00271778|Procedure|mastoidotympanoplasty and tympanoplasty|
46082530|NCT02802098|Drug|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
45977680|NCT00271934|Biological|Immune ablation and hematopoietic stem cell support.|Autologous hematopoietic stem cell transplant
45977681|NCT04718142|Device|vNEP|Apply vNEP therapy to the anterior surface of the throat with a variable negative pressure ranging from -20 cmH2O up to -35 cmH2O and vNEP devices of varying shapes and sizes.
46082531|NCT00938821|Procedure|Caudal block|Chart review of patients that received very low dose morphine administered caudally (M) and plain caudal block with Ropivacaine or Marcaine (B)from October 2008 to October 2009.
46082532|NCT02719704|Behavioral|"MEXA-SE"|"MEXA-SE (move yourself) was structured into three main components: A) Physical fitness: The first component was to increase time in moderate to vigorous physical activity during Physical Education lessons. There were also prompts to help students to engage in increased physical activity during school recess; B) Eating habits: The second component consisted of six sessions (45 minutes per session) designed to promote reflection and positive changes in eating habits and health care (to improve knowledge and eating habits), conducted by nutritionist; C) Body image: The third component was composed of 3 sessions (45 minutes per session) focused on body image satisfaction (Espelho, espelho meu: School based Intervention) conducted by Physical Education researcher."
45672208|NCT01922271|Drug|Placebo to tiotropium|Placebo to tiotropium once daily delivered via HandiHaler® device
45831572|NCT03596814|Other|No Interventional study|Retrospective data
45977682|NCT00306930|Device|Acetabular cup|Acetabular cup replacement
45672209|NCT01922271|Drug|Salbutamol|Used as resuce medication
45672210|NCT02236130|Procedure|Regional block|Single shot peripheral nerve block
45672211|NCT02236130|Procedure|General Anesthesia|General Anesthesia with O2/N2O/Sevoflurane
45672212|NCT02236130|Drug|Local Anesthetic Ropivacaine|0.5% Ropivacaine
45672213|NCT02236130|Drug|Opioids Morphine|Morphine
45672214|NCT02236130|Drug|Oral pain medication Acetaminophen with Hydrocodone|Acetaminophen with Hydrocodone
45672215|NCT05153564|Drug|Semaglutide 1.34 mg/mL|Semaglutide will be administered at a dose of 0.25, 0.50 or 1.0 mg as indicated on scale drum once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.
45831573|NCT04199286|Procedure|symmetrical and asymmetrical horizontal strabismus surgery|surgery was done on the medial rectus muscle on both eyes, lateral rectus muscle in both eyes or medial and lateral rectus muscle in one eye
45831574|NCT04198896|Other|incidece of cancers|With a continuous surveillance system to track all subsequent incidents of cardiovascular diseases and/or non-cardiovascular diseases via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified
45831575|NCT03592836|Drug|Loop Diuretics|intravenous administration of diuretics
45831576|NCT03596502|Drug|Direct oral anticoagulants (DOACs)|Exposure to DOACs will be defined as a new prescription for apixaban (ATC B01AF02), dabigatran (ATC B01AE07), or rivaroxaban (ATC B01AF01) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
45977683|NCT00271973|Drug|Oxycodone|
45977684|NCT00306969|Drug|bexarotene|
45977685|NCT00306969|Device|photopheresis|
45977686|NCT00272012|Drug|Insulin glulisine|
45977687|NCT00307008|Biological|Pneumovax 23™|Single dose intramuscular injection
45977688|NCT00272051|Drug|SR57746A|
45977689|NCT00307203|Drug|bupropion SR|Participants were randomly assigned to receive bupropion SR 150 mg or placebo, once daily for 7 days, then twice daily for 11 weeks.
45977690|NCT00307203|Behavioral|Cognitive Behavioral Group Therapy|Participants attended a 12-session, 1-hour, weekly smoking cessation group program with 3 to 7 participants led by a psychologist with tobacco treatment specialist training. Subjects set a quit date, and nicotine patches (Habitrol) and nicotine polacrilex gum (Nicorette) were initiated in the fourth week.
45977691|NCT00307203|Drug|nicotine replacement therapy|Nicotine patch was dosed at 21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks, then discontinued. Nicotine gum (2 mg) was distributed for use as needed for craving up to 18 mg/d.
45977692|NCT00272090|Drug|Insulin glargine|
45977693|NCT00307320|Behavioral|Relaxation Training|Relaxation techniques training
45977694|NCT00272207|Drug|Nabilone|Oral nabilone, 0.5 mg x7 days, increased to 0.5 mg t.i.d x 2 weeks if patient tolerates, then increase if patient tolerating to 0.5 in am and 1.0 mg at hs x 1 week, then if patient tolerating, increase to 1.0 mg b.i.d x 1 week.
45977695|NCT00307515|Drug|Fibrin Sealant 2 (FS2)|FS2 Surgical Sealant Kit: Biological Active Component containing Human Fibrinogen 55-85 mg/mL and Thrombin containing Thrombin 800-1200 IU/mL and Calcium Chloride 5.6-6.2 mg/mL
45672216|NCT05153564|Drug|Semaglutide 3.0 mg/mL|Semaglutide will be administered at a dose of 2.0 mg corresponding to the increment of 67 (pen injector units) as indicated on scale drum. once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.
45977696|NCT00307515|Device|Oxidized Regenerated Cellulose (Surgicel)|Commercially available Surgicel used within label.
45977697|NCT00272246|Procedure|deep brain stimulation of the internal globus pallidus|
45672217|NCT05153564|Drug|NNC0480-0389 10 mg/mL|NNC0480-0389 will be administered at a dose of 0.23, 0.45 or 0.90 mL once weekly by s.c. (under the skin) injections for 14 weeks.
45672218|NCT05153564|Drug|NNC0480-0389 30 mg/mL|NNC0480-0389 will be administered at a dose of 0.60 mL once weekly by s.c. (under the skin) injections for 14 weeks.
45977698|NCT00272285|Drug|Ramosetron|IV, concomitant administration with dexamethasone
45977699|NCT00272285|Drug|Granisetron|IV, concomitant administration with dexamethasone
45977700|NCT00307554|Biological|Pneumococcal (vaccine)|
45977701|NCT00272324|Drug|Aspirin|
45977702|NCT00272324|Drug|Folate|
45977703|NCT00307593|Drug|Infliximab|Infliximab
45977704|NCT00307593|Drug|Rituximab|Rituximab
45977705|NCT00272402|Behavioral|Cognitive Behavioral Intervention|Intervention consists of simulated case based learning for physicians.
45831577|NCT03596502|Drug|Warfarin|Exposure to warfarin will be defined as a new prescription for warfarin (ATC B01AA03) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
45977706|NCT00272402|Behavioral|Office System Redesign Intervention|Intervention consists of clinical decision support within the electronic medical record.
45831578|NCT03759522|Drug|DPA-714 PET/MRI|DPA-714 PET/MRI
45831579|NCT03592680|Dietary Supplement|Vitamin C|1 gram Vitamin C will be administrated orally, twice a day from 5 days before until 10 days after surgery.
45977707|NCT00307632|Drug|Norelgestromine (NLGM)/ethinyl estradiol (EE)|Participants will apply a 20 centimeter square (cm^2) contraceptive transdermal patch on the skin for 1 full week, and then apply a fresh patch for Week 2, and a third patch for Week 3. The fourth week will be patch-free. Each patch delivers 150 microgram (mcg) of NLGM and 20 mcg of EE per day. The treatment duration is of 6 cycles (4 weeks each).
45831580|NCT03592680|Other|Placebo|1 gram Placebo will be administrated orally, twice a day, from 5 days before until 10 days after surgery
45831581|NCT04198194|Diagnostic Test|Predictors of events|Apple Heart & Movement Study in Apple Research app
45831582|NCT03592524|Behavioral|Fasting Ramadan|Muslims recipients refrain from eating and drinking anything from dawn until sunset(14-15 hours)
45831583|NCT04198038|Behavioral|Songwriting with licensed music therapist|Song selected by parent-child dyad with recordings of physiologic components (i.e. heartbeat, breathing)
45831584|NCT03968328|Other|Interview|Take part in interview
45672219|NCT05153564|Drug|Microgynon®|Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
45672220|NCT02233946|Behavioral|computer-facilitated brief intervention|Immediate feedback to patient of screening results and risk for substance use problem, followed by 11 pages of science and true-life stories about health risks of adolescent substance use. Screening results then go to provider who reviews them with patient and gives brief counseling, and refers to an online motivational enhancement therapy intervention for patients at moderate/high risk for substance use problems.
45672221|NCT04768634|Diagnostic Test|Provocative electrophysiology study|Provocative electrophysiology testing will be performed at the bedside using the temporary pacing wires placed at the time of surgery.
45672222|NCT02232698|Device|Sensor Based Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time)."
45831585|NCT03968328|Other|Survey Administration|Respond to survey
45831586|NCT03596346|Other|Rapeseed ingredient (RI)|2 snack bars daily containing 10 g of RI each.
45831587|NCT03596346|Other|Control product without added RI|2 snack bars daily containing 0 g of RI.
45977708|NCT00272441|Drug|inhaled corticosteroids|
45977709|NCT00272480|Drug|Zidovudine/lamivudine|
45977710|NCT00272480|Drug|Placebos|
45977711|NCT00307671|Drug|prednisone, methylprednisolone,cyclophosphamides|treatment conventional
45977712|NCT00307671|Drug|Cyclophosphamide, Azathioprine,prednisone,methylprednisolone|reduction dose
45977713|NCT00307671|Drug|Mycophenolate mofetil,methotrexate|in the treatment conventional and in the reduction dose
45977714|NCT00272519|Behavioral|Life Skills Intervention|Developed to promote life skills among young adolescents perinatally infected with HIV
45977715|NCT00307710|Biological|Trivalent Baculovirus-expressed Influenza HA vaccine|Receive either standard inactivated influenza vaccine or one of three doses of the experimental vaccine, vaccine dose 15, 45 or 135 μg HA per virus, intramuscular injection.
45977716|NCT00272558|Drug|Carboplatin and Vinorelbine|
45977717|NCT00272597|Drug|Risperidone|See Detailed Description.
45977718|NCT00307749|Drug|Placebo|once daily for 24 weeks
45977719|NCT00307749|Drug|MCC-257|20mg, once daily for 24 weeks
45977720|NCT00307749|Drug|MCC-257|40mg, once daily for 24 weeks
45977721|NCT00307749|Drug|MCC-257|80mg, once daily for 24 weeks
45977722|NCT00307788|Procedure|acupuncture|acupuncture
45977723|NCT00272636|Procedure|Radiofrequency catheter ablation|
45977724|NCT00272636|Drug|Amiodarone and cardioversion|
45977725|NCT00281970|Drug|cisplatin|
45977726|NCT00281970|Drug|docetaxel|
45977727|NCT00281970|Procedure|adjuvant therapy|
45977728|NCT00272675|Drug|Chlorhexidine gluconate (drug) vs placebo|
45977729|NCT00307827|Drug|Visilizumab|Visilizumab administered intravenously once per day for two days
45977730|NCT00272714|Drug|Afimoxifene (0.057%) in hydroalcoholic gel|
45977731|NCT00282009|Behavioral|Basic Internet|Basic Internet control intervention
45977732|NCT00282009|Behavioral|Enhanced Internet|enhanced Internet cessation intervention
45977733|NCT00282009|Behavioral|Enhanced Internet + phone|enhanced Internet plus proactive telephone counseling
45977734|NCT00272753|Drug|budesonide/formoterol Turbuhaler|
45977735|NCT00272753|Drug|formoterol Turbuhaler|
45977736|NCT00272753|Drug|salbutamol|
45977737|NCT00307866|Procedure|Resovist (BAY86-4884, SH U 555 A)|Single bolus injection, followed by MRI
45977738|NCT00272831|Drug|Cilostazol|Cilostazol 100 mg twice daily
45977739|NCT00272831|Drug|Placebo|1 tablet twice daily
45977740|NCT00417105|Procedure|hemodialysis|group 1: twice weekly, four hours
45977741|NCT00417105|Procedure|hemodialysis|group 2: twice weekly, eight hours
45977742|NCT00417105|Procedure|hemodialysis|group 3: every other day, eight hours
45977743|NCT00417105|Procedure|hemodialysis|group 4: six days a week, eight hours
45977744|NCT00416468|Drug|Aliskiren|
45977745|NCT00416468|Drug|Valsartan|
45977746|NCT00307905|Drug|Traumeel S|homeopathic remedy
45977747|NCT00307905|Drug|Placebo remedy|identical size, shape and taste of treatment medication
45977748|NCT02960828|Procedure|Subthreshold Laser Photocoagulation|Selective Subthreshold Laser Photocoagulation is applied to the periphery of high-risk macular drusen
46082533|NCT02719704|Behavioral|"Espelho, espelho meu"|"Behavioral: Espelho, espelho meu: School based intervention on body image. Body image is worked in four 45 minutes sessions, conducted with a frequency of once a week by a researcher. The topics covered in these sessions refer to: Beauty Standards (media influence and formation of body image), individual qualities (individual and classmates qualities) and selfesteem. These meetings will be held through video, lecture, dynamics, photo sessions and preparation of posters."
46082534|NCT02795078|Drug|conservative treatment|
46082535|NCT02795078|Procedure|Aneurysms clipping|
45831588|NCT03596190|Diagnostic Test|ultrasonographic diaphragmatic assessment|"Diaphragmatic dysfunction will be determined by intercostal diaphragm thickening. The available image will be saved.~Diaphragmatic motion assessments will be conducted on the side to be blocked both at baseline, and then every 5 minutes until patient leaves for operating room or 30 minutes (whatever is earlier)."
45831589|NCT03592446|Device|Transcutaneous electrical vagus nerve stimulation|All subjects receive electrical VNS stimulation at cymba conchae.
45831590|NCT03592446|Device|Sham vagus nerve stimulation|All subjects receive electrical stimulation at earlobe.
45831591|NCT03596112|Other|application of a polyacrylate wound pad|A sterile polyacrylate wound pad with activated carbon cloth treatment will be applied to chronic wounds in an outpatient clinic from a specialist nurse
45831592|NCT03596112|Other|Hydrocellular foam|Active Comparator: hydrocellular foam pad serile hydrocellular standard foam pad will be applied to chronic wounds in an outpatient clinic from a specialist nurse
45831593|NCT04197570|Drug|Opioid Anesthetics|see arm/group description
45831594|NCT04197570|Drug|Non Opioid Analgesics|see arm/group description
45831595|NCT04197882|Biological|OrienX010 Combination with Toripalimab injection|OrienX010 Produced by Oriengene Biotechnology Co.,Ltd. Strength: 1.0 mL/vial. Toripalimab infusion Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package.
45831596|NCT03591978|Diagnostic Test|Isolation of Circulating Pulmonary Cells in peripheral blood|Blood samples from healthy volunteers will be collected in EDTA tubes (Vacutainer, BD Bioscience). CPC will be isolated according to previous patented method (P201730724)
45831597|NCT04197492|Radiation|Hypofractionated Stereotactic Radiotherapy|Hypofractionated stereotactic radiotherapy (CyberKnife, 25Gy/5fx)
45831598|NCT04197492|Drug|Anlotinib|Anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle.
45831599|NCT04197648|Device|Exercise group|24 week supervised exercise program (strength and cardiovascular program).
45977749|NCT02960828|Drug|intravitreal Anti-VEGF injection|To prevent choroidal neovascularization, intravitreal Anti-VEGF injection is done on a 3 month interval up to 1 year.
45977750|NCT02960828|Device|Subthreshold Laser|
45977751|NCT00307944|Drug|Pantoprazole|
45977752|NCT00416507|Drug|fluorouracil|
45977753|NCT00416507|Drug|gemcitabine hydrochloride|
45977754|NCT00416507|Drug|liposomal cisplatin|
45977755|NCT00416546|Drug|AEB071|
45977756|NCT00282126|Dietary Supplement|Potassium citrate|kcitrate
45977757|NCT00272870|Drug|06Benzylguanine|120 mg/m2/day; given Day 1-5 for up to 6 courses in Block 3
45977758|NCT00272870|Genetic|MGMT P140K|Gene manipulated cells, patients are not expected to receive greater than approximately 10 x 10e6 transduced CD34+ cells/kg
45977759|NCT00272870|Device|Meltenyi CliniMacs|Device used for CD34+ cell separation of peripheral collection
45977760|NCT00308022|Device|High Frequency Percussive Ventilation|
45977761|NCT00272909|Drug|piclozotan low dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
45977762|NCT00272909|Drug|placebo|Continuous IV infusion over a period of up to 72 hours of placebo.
45977763|NCT00272909|Drug|piclozotan high dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
45977764|NCT00282165|Drug|naratriptan|four weeks double blind experimental treatment using oral naratriptan
45977765|NCT00282165|Drug|placebo|four weeks double blind placebo treatment
45977766|NCT00272948|Drug|Defibrotide|Defibrotide 25 mg/kg/d
45977767|NCT00272948|Drug|Defibrotide|Defibrotide 25 mg/kg/d iv in 4 doses beginning at day of conditioning until day +30 or until discharge from inpatient care (with a minimum treatment of 14 days) if VOD does not occur.
45977768|NCT00272948|Drug|Defibrotide|Defibrotide 25 mg/kg/d iv therapeutically when patients fulfil modified Seattle criteria
45977769|NCT00308100|Drug|Hydroxyethylstarch 130/0.4|HES 130/0.4, administered intra- and perioperatively, max. daily dose: 33ml/kg BW; if needed, additionally albumin is administered (ratio crystalloid to colloid= 1:1)
45977770|NCT00308100|Drug|5% Albumin|5% albumin, administered intra- and perioperatively
45977771|NCT00273026|Drug|salmeterol xinafoate/fluticasone propionate|
45977772|NCT00282204|Behavioral|antenatal hypnosis + audio compact disc on hypnosis|
45977773|NCT00282204|Behavioral|Audio compact disc on hypnosis|
45977774|NCT00308178|Drug|Abraxane|Following 4 cycles (8 weeks) of adjuvant chemotherapy (adriamycin and cytoxan), abraxane will be give every 2 weeks for 4 cycles(8 weeks)
45977775|NCT00282321|Behavioral|High Protein diet|
45977776|NCT00282321|Behavioral|High carbohydrate diet|
45977777|NCT00282360|Drug|Trimetazidine|
45672223|NCT02232698|Device|Standard Blood Glucose Monitoring|"Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 3 and 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study (Sensor glucose measurements not visible during this time).~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time)."
45831600|NCT04197024|Device|Exercise capacity test|Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm). Heart rate (HR) will be continuously recorded using a monitor Polar H10.
45831601|NCT04197024|Device|Exercise capacity test in virtual reality|Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm).Heart rate (HR) will be continuously recorded using a monitor Polar H10. VR HTC Vive Pro goggles along with VR health care (aerobic exercise) VR Cycling software will be used for stimulation throughout the duration of the test. The HTC Vive Tracker device will be also use to link images in virtual reality with the pedal speed.
45977778|NCT00273065|Drug|Neosaxitoxin|
45977779|NCT00418626|Drug|Nilotinib|
45977780|NCT00418704|Drug|Erlotinib|Tarceva (150 mg) is a pill you take once a day -- every day
45977781|NCT00418704|Drug|taxotere|Taxotere® (docetaxel) is given intravenously (I.V.) into the vein. Taxotere® chemotherapy treatment takes about one hour, and usually people receive treatments every three weeks.
45977782|NCT00313950|Biological|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, intramuscular (IM) (HAV Day 0 and 168); 0.5 mL, IM (MMR Day 28)
45831602|NCT03024060|Drug|ALA|20% ALA applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
45977783|NCT00313950|Biological|Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine|0.5 mL, IM (MMR, Day 0); 0.5 mL, IM (HAV Day 28 and 168)
45977784|NCT00313950|Biological|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, IM (HAV Day 0 and 168); 0.5 mL, IM (MMR, Day 0)
45977785|NCT00273104|Procedure|Bariatric surgery|Bariatric surgery as a part of public health service offered treatment seeking morbidly obese patients.
45977786|NCT00273104|Behavioral|Intensive lifestyle intervention|Intensive lifestyle intervention as a part of public health service offered treatment seeking morbidly obese patients.
45977787|NCT00273221|Procedure|Glaucoma Implant Surgery|
45977788|NCT00273221|Procedure|trabeculectomy|
45672224|NCT01632800|Device|High pulsed magnetic fields|Magnetic fields will escalate in strength
45831603|NCT03024060|Drug|Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
45831604|NCT03024060|Device|IBL 20 mW|10 J/cm2 blue light delivered at 20mW/cm2 for 8 minutes 20 seconds
45831605|NCT03024060|Device|IBL 10 mW|10 J/cm2 blue light delivered at 10mW/cm2 for 16 minutes 40 seconds
45831606|NCT03024138|Radiation|Repeat CT scan|
45977789|NCT00273221|Procedure|phacoemulsification|
45977790|NCT04708691|Other|Aerobic exercise|aerobic exercise
45977791|NCT02960178|Behavioral|Perturbation-based training|Over-ground practice of stepping and balance tasks in standing with perturbations applied by the trainer (pushes and pulls to the safety harness). One hour in duration with 60 perturbations targeted per hour.
45977792|NCT02960178|Behavioral|Conventional walking training|Over-ground practice of stepping and balance tasks in standing. One hour in duration.
45977793|NCT00273260|Behavioral|individualised bone density feedback and education|
45977794|NCT00273299|Drug|valsartan plus hydrochlorothiazide|
45977795|NCT00314028|Behavioral|Focus on the Future|Focus on the Future is an educational program designed to promote proper condom use.
46082536|NCT02795078|Procedure|Interventional embolization forAneurysms|
45977796|NCT00314028|Other|Control standard of care treatment|Standard of care treatment is the normal treatment that someone would receive for the particular sexually transmitted disease or virus.
45977797|NCT00418782|Drug|naproxen|
45977798|NCT00418782|Drug|CE-224535|
45977799|NCT00418782|Drug|placebo|
45977800|NCT00273338|Drug|calcitriol|
45977801|NCT00273338|Drug|docetaxel|
45977802|NCT00314067|Procedure|Online Comprehensive Quality Management System (CQM) of alcohol-related disorders in primary care|
45977803|NCT00314067|Procedure|Physician training|
45977804|NCT00314067|Procedure|Practice team training|
45977805|NCT00273377|Other|Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg)|
45977806|NCT00273377|Other|Supplemental oxygen (80% vs. 30%)|
45977807|NCT00273377|Drug|Dexamethasone|4 mg
45977808|NCT00273377|Drug|Placebo|placebo
45977809|NCT00273416|Drug|PF-00592379|
45977810|NCT00273416|Drug|Sildenafil 100mg|
45977811|NCT00314184|Drug|quetiapine fumarate|
45977812|NCT00273455|Drug|bimatoprost 0.03%|
45977813|NCT00273455|Drug|dorzolamide 2%/timolol maleate 0.5% fixed combination|
45977814|NCT00273455|Drug|placebo|
45977815|NCT00273494|Procedure|Surgery|
45977816|NCT00308256|Behavioral|nurse-counselling|Phone calls performed by nurse 15 days after each monthly visit
45977817|NCT00273533|Drug|Ramipril|
46082537|NCT02795078|Procedure|stenting for stenosis|
45977818|NCT00273572|Other|Moderate Lifestyle Intervention|Two educational group meetings with a dietitian in the first month of intervention; One individual counselling session with a dietitian at baseline, and at 6-month and 12-month follow-up
45977819|NCT00273572|Other|Intensive lifestyle intervention|A monthly individual counselling session with a dietitian; A monthly group session with a dietitian; Bi-monthly group sessions with a physical activity instructor
45977820|NCT00308295|Drug|Fish oil capsules|
46082538|NCT02719860|Dietary Supplement|Green tea|4 cups/day of green tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
46082539|NCT02719860|Dietary Supplement|Black tea|4 cups/day of black tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
46082540|NCT02719860|Dietary Supplement|Placebo tea|4 cups/day of placebo tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
45456246|NCT04566900|Behavioral|Neurofeedback|Neurofeedback is a technique where brain functions are made accessible to the subject in the form of a metaphor. For instance, frontal brain activity may be shown as an airplane flying. Once the activity is made accessible, the subject can modulate it in a pre-specified direction. The parameters used to achieve successful feedback are made difficult over time and hence the brain is taught or conditioned to improve performance.
45456247|NCT04566900|Other|Placebo|Subjects in this arm will undergo all of the same testing as active treatment. Music and video progression will not depend on brain activity. Instead feedback will be random.
45456248|NCT04560725|Drug|11C-Choline|11C-choline (0.05-0.1mCi/kg) was injected intravenously one week before or after the [68Ga]P137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
45456249|NCT04549597|Drug|Tenapanor|Use of tenapanor
45831607|NCT03024216|Drug|Atezolizumab1200 mg IV|Subjects in ARM 1 will receive 2 doses of atezolizumab 1200 mg intravenously (week 1 and week 4). If no dose limiting toxicity continue onto maintenance, week 13 and receive atezolizumab 1200 mg intravenously every 3 weeks until toxicities or lack of clinical benefit. Subjects in ARM 2 will receive 2 doses at approximately 3 weeks each of atezolizumab 1200 mg intravenously (weeks 7 and 10). If no dose limiting toxicity, continue to receive atezolizumab 1200 mg intravenously every 3 weeks, starting week 13, until toxicities or lack of clinical benefit.
45831608|NCT03024216|Drug|Sipuleucel-T|Subjects in ARM 1 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 6, 8, 10). Subjects in ARM 2 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 1, 3 and 5)
45456250|NCT04542863|Other|18F-DX600 PET/CT|DX600, labeled with 18F will be used as a molecular imaging tracer for PET/CT scanning
45977821|NCT00308295|Drug|matched placebo capsules|
45977822|NCT00273611|Behavioral|Pharmacist Education about Vitamin D|
45977823|NCT00314301|Device|loaded sit-to-stand training|
45456254|NCT04522284|Device|CURATE.AI|Efficacy and toxicity measurements at the end of each dosing cycle, together with an information on given drugs and their doses, and other patient data, will be used by CURATE.AI to recommend the dose of capecitabine and Ibrutinib for the next cycle. The clinical investigators will decide whether or not to administer or prescribe the dose recommendation from CURATE.AI.
45458679|NCT02320006|Other|acupuncture|For RN4、CV6 CV3 and EX-CA1, needles will be inserted vertically to the abdominal muscles. The acupuncturist can feel resistance from the tip of the needle when touching the muscles and continues to insert it to a depth of 2-3 mm and stops. For ST36 and SP6, needles will be inserted vertically to a depth of 25 mm. The needles will be manipulated with an even lifting and twisting method three times to achieve the sensation of deqi.
45831609|NCT03596034|Other|JUUL 5%, Virginia Tobacco, ENDS product|Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and CPD throughout the 15 day product use period.
45831610|NCT03595956|Other|Medical gender affirmation|The intervention to be evaluated is medical gender affirmation delivered in primary care (medical gender affirmation: hormones and/or surgery vs none).
45831611|NCT03981744|Drug|Ustekinumab 6 mg/kg|Participants will receive body weight-range based IV dosing of 6 mg/kg of ustekinumab at Week 0 in Group 1 and at Week 24 in Group 2.
45831612|NCT03981744|Drug|Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg SC at Week 8 and every 8 Weeks (q8w) through Week 72 in Group 1 and q8w Week 32 through Week 72 in Group 2.
45831613|NCT03981744|Drug|Placebo IV|Participants will receive IV dosing of placebo at Week 24 in Group 1 and at Week 0 in Group 2.
45831614|NCT03981744|Drug|Placebo SC|Participants will receive SC dosing of placebo at Weeks 8,16 and 24.
45831615|NCT03591900|Device|insulin pump/CGMS|"A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be subjected to~• Insulin pump will be tried in each diabetic thalassemic patient versus conventional insulin therapy(Bruttomesso D et al., 2009)."
45831616|NCT03591744|Drug|Bortezomib|Given SC
45831617|NCT03591744|Biological|Daratumumab|Given IV
45831618|NCT03591744|Drug|Dexamethasone|Given IV and PO
45831619|NCT03591744|Drug|Lenalidomide|Given PO
45977824|NCT00273689|Drug|montelukast vs pretreatment with albuterol|montelukast 5 or 10 mg once daily for 3 days vs albuterol 2 puffs, 15 minutes before exercise
45977825|NCT00273689|Drug|montelukast|Montelukast 5 or 10 mg once daily for 3 days vs Albuterol inhlare 2 puffs, 15 minutes before exercise
45977826|NCT00273728|Drug|hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline|hydroxy-ethyl starch together with ringer's lactate versus physiologic saline together with saline
45977827|NCT00308334|Drug|Domperidone|10 mg po TID X 14 days
45977828|NCT00308334|Drug|Placebo- Sugar pill|placebo po TID x 14 days
45977829|NCT00273767|Drug|epoetin beta|800UI/kg in 60ml of Nacl IV slow 1 to 3 hours before surgery
45977830|NCT00273767|Drug|placebo|60ml of NaCl IV slow
45977831|NCT00314379|Drug|Vitamin E 400IU/day|
45977832|NCT00273806|Behavioral|Intervention for 4 behavioral risks by medical assistants.|
45977833|NCT00273845|Behavioral|Motivational interviewing|One session
46082541|NCT02795234|Other|Blood samples|
45977834|NCT00273845|Behavioral|Strengths-Based Case Management|5 sessions
45977835|NCT00273884|Drug|Amonafide L-Malate|
45977836|NCT00273884|Drug|Cytarabine|
45977837|NCT00308373|Drug|Metformin vs Thiazolidinedione (Pioglitazone)|
45977838|NCT00273962|Drug|ipratropium plus salbutamol UDV|
45456255|NCT04522284|Drug|Capecitabine|Treatment with the selected regimen will take up to a maximum duration of 12 months, in 3-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range. Maximum total cumulative dose per cycle of capecitabine in the predetermined safety range is set at 100% of standard starting dose (i.e. , 1250mg/m2 twice daily for single agent capecitabine regimen). Minimum total cumulative dose per cycle of capecitabine in the predetermined safety range is set at 50% of the standard starting dose (i.e. 625mg/m2 twice daily for single agent capecitabine). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range.
45458680|NCT01238497|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for either transfemoral or transapical access and any of the 3 valve sizes (23, 26 or 29)
45458681|NCT01238497|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for transapical or transaortic access and any of the 3 valve sizes (23mm, 26mm or 29mm)
45831620|NCT03591744|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
45831621|NCT03595800|Procedure|Hematopoietic stem cells transplantation|Allogeneic Hematopoietic stem cells transplantation
45831622|NCT03023670|Procedure|cardiopulmonary bypass|Low flow of mixed oxygen / air (1:1L) will be used during the period of cardiopulmonary bypass
45831623|NCT03023670|Procedure|cardiopulmonary bypass|Low rate (4\min) with low tidal volume ( 2ml/kg ) will be used during the period of cardiopulmonary bypass.
45831624|NCT03023592|Drug|Iguratimod|Iguratimod 25 mg orally twice a day for 24 weeks
45831625|NCT03591666|Drug|Anlotinib|Anlotinib p.o. qd
45831626|NCT04196946|Drug|25 mcg fentanyl|Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group I received 10 mg hyperbaric bupivacaine (2 cc) and 25 mcg fentanyl (0.5 cc).
45831627|NCT04196946|Drug|250 mcg alfentanil|Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group II received 10 mg hyperbaric bupivacaine (2 cc) and 250 mcg alfentanil (0.5 cc) intrathecally.
45831628|NCT04199208|Other|Prehabilitation and Immunonutrition|See study synopsis
45831629|NCT04199208|Other|Standard Care Arm|Standard care as per the daily routines of the Hospital at which the study takes place
45831630|NCT03591588|Other|diet|The study includes 2 types of diets, i.e., high-saturated fat diet and low-fat high-protein diet, which are provided to each participant in a randomized crossover design.
45831631|NCT04194918|Behavioral|Computer-Assisted Smoking Cessation Intervention|Use the Flexiquit+ program
45831632|NCT04194918|Other|Text Message|Receive text messages
45831633|NCT04194918|Other|Handout|Receive handouts via email
45977839|NCT00273962|Drug|salbutamol UDV|
45977840|NCT00314418|Procedure|Colonoscopy in the prone position|
45977841|NCT00274001|Drug|Nevirapine|
45977842|NCT00308412|Biological|rHPIV3cp45|Placebo for rHPIV3cp45 vaccine is 1X L-15.
45977843|NCT00308412|Biological|Placebo|Placebo for rHPIV3cp45 vaccine
45977844|NCT00274040|Drug|Tiotropium|
45977845|NCT00274040|Drug|Ipratropium|
45977846|NCT00314457|Drug|Bupivacaine|Patients receive either normal saline or Bupivacaine in normal saline that infuses intraarticularly for 48 hours.
45977847|NCT00308451|Drug|Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)|
45977848|NCT00274079|Drug|SPIRIVA|
45977849|NCT00274118|Drug|telmisartan|
45977850|NCT00274118|Drug|enalapril|
45977851|NCT00419055|Procedure|Early discharge after percutaneous coronary intervenntion|Eligible patients receive Bivalirudin at the standard dose during PCI and all have to be eligible for femoral access seal.
45977852|NCT00274157|Behavioral|Behavior|
45977853|NCT00274157|Behavioral|diet control, smoking cessation, exercize|
45977854|NCT00308490|Drug|iron sucrose|
45977855|NCT00416585|Drug|isotretinoin (Roaccutane)|
45977856|NCT00274196|Procedure|ultrasound examination|a single time 10 minutes procedure within the first week after the injury
45977857|NCT00274196|Procedure|MRI scan|a single time 30 minutes procedure, performed always after the ultrasound scan
45977858|NCT00308529|Drug|irinotecan|
45977859|NCT00308529|Drug|carboplatin|
45977860|NCT00308529|Drug|bevacizumab|
45977861|NCT00308529|Procedure|Radiation Therapy|
45977862|NCT00274235|Drug|sulfadoxine-pyrimethamine / mefloquine|
45977863|NCT00308568|Behavioral|Mailed educational brochure|
45977864|NCT00274274|Drug|insulin detemir|
45977865|NCT00274274|Drug|insulin aspart|
45977866|NCT00308607|Drug|Bevacizumab (Avastin)|
45831634|NCT04194918|Other|Questionnaire Administration|Ancillary studies
45831635|NCT04194918|Other|Quality-of-Life Assessment|Ancillary studies
45831636|NCT04194918|Other|Survey Administration|Ancillary studies
45831637|NCT04747938|Device|Energy accumulator|All subjects treated with thermal therapy using the Energy Accumulator by acupoint concepts. The course included 8 sessions of treatment, twice every week for 4 weeks. Each session lasted for 30-45 minutes. During heat therapy, the ceramic nozzle of the Energy Accumulator was lightly pressed in contact of the skin, without any contact medium, and moved slowly along the meridians with some circular movements.
45831638|NCT04747938|Behavioral|Home exercise program|Home exercises aimed at providing gentle mobilization at the shoulder and were capable of carrying out at home. Patients were requested to perform the movements on a daily basis within the first 4 weeks of treatment. Four movements were involved: Movement 1 - Pendular Exercise, Movement 2 - Circle Exercise, Movement 3 - Wall Climbing Exercise, and Movement 4 - Lie on bed and move both arms up and down.
45831639|NCT04196556|Behavioral|Active Families|This intervention, based on the methodology of meaningful learning, will have two components: group education aimed at parents (caregivers) and and education directed to children in the reviews in consultation. Group education (caregivers) groups will consist of 6 sessions, which will be given every two weeks, as determined in the program's follow-up annex, in the 3 months after the initial assessment. The content of the sessions is defined in attached annex. Regarding the proposed methodology, it has nuances and tools different from the traditional ones to achieve significant learning in the field of health. It is based on participatory methods and a more profound modification of knowledge, skills, emotions and attitudes than the brief advice that is used in family intervention in scheduled consultations.
45831640|NCT04196556|Other|STANDARD CARTERA DE SERVICIOS|"An anamnesis or functional assessment on the following aspects:~o Family history of obesity up to 2nd degree inbreeding. o Nutritional status - metabolic that includes at least no meals/day and daily consumption of liquids, fruits, vegetables, dairy, fats and sugars. o Activity - exercise that includes at least the type and intensity of exercise and time spent on sedentary activities (television, video games or the like). o Self-concept that includes at least the existence or not of behavioral problems and body image problems. o Role - relationships that include at least the performance of extracurricular activities.~A care plan in relation to identified problems and/or situations reviewed on a biannual basis.~They will be supplemented with the study-specific variables listed in the data collection notebook."
45831641|NCT03023904|Biological|Nivolumab|Given IV
45831642|NCT03023904|Other|Laboratory Biomarker Analysis|Correlative studies
45831643|NCT03967002|Procedure|Test group with corticotomy surgery|"The surgery of corticotomy is performed with a piezo electric device and a personalized surgical guide just before the placement of orthodontic appliance. The initial impressions of the patient's dental arch as well as its three-dimensional radiography (CBCT) are used to create a perfectly adapted guide for minimally invasive corticotomy surgery.~The incisions are made between the roots of:~the second premolars and first premolars,~the first lower premolars and canines,~the canines and lateral incisors,~the lateral incisors and central incisors, and,~the two lower central incisors."
45831644|NCT03966768|Device|Duramesh suturable mesh for laparotomy closure|Patients undergoing laparotomy will be closed with Duramesh suturable mesh
45831645|NCT03966768|Device|Conventional suture for laparotomy closure|Patients undergoing laparotomy will be closed with conventional polydiaxonone suture
45831646|NCT04406922|Procedure|Personalized cooling protocol|As an intervention, a personalized cooling protocol will be used in order to activate BAT and induce non-shivering thermogenesis. During the cooling procedure, subjects will be exposed to mild cold (approx. 14°C) for 150 min. Since the onset temperature of shivering shows a high interindividual variation, we will use a personal cooling protocol to ensure maximum non-shivering EE (and thus an equal maximum activation of BAT). The right temperature will be determined via a subjective method, e.g. to ask the subject if he or she experiences shivering. The time needed to achieve the right temperature is approximately 30-60 minutes. Then, the stable cooling period of 90 min is started. During this time the subject will be asked every 15 minutes whether he is experiencing shivering. If so, temperature will be increased with 2-3°C so that shivering just stops.
45831647|NCT04196010|Drug|Cladribine|Given IV
45831648|NCT04196010|Drug|Cytarabine|Given IV
45831649|NCT04196010|Biological|Recombinant Granulocyte Colony-Stimulating Factor|Given subcutaneously
45831650|NCT04196010|Drug|Mitoxantrone|Given IV
45831651|NCT03591198|Behavioral|Qigong Training|Eight-Section Brocades
45831652|NCT03591198|Behavioral|Cognitive Training|Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
45831653|NCT04196400|Drug|steroid betamethasone|The steroid is injected using insulin needle in the subcutaneous tissue after finishing the repair
45831654|NCT04021758|Behavioral|Peer to peer program intervention|Peer to peer suicide prevention program aimed at reducing suicide in a military population.
45831655|NCT04196322|Other|observational study|observational study
45831656|NCT04196088|Device|Ultivision Artificial Intelligence Software|Screening Colonoscopy
45831657|NCT04196088|Device|No Artificial Intelligence Software enhancement|Screening Colonoscopy
45831658|NCT04196166|Other|preoperative blood tests|
45831659|NCT03591042|Diagnostic Test|cervical length screening|transvaginal ultrasound cervical length
45831660|NCT04027140|Device|M/L Taper with Kinectiv Technology Stems and Necks|Patients that have been implanted with a M/L Taper with Kinectiv Technology Stem and/or neck to repair hip malfunction/disease.
45831661|NCT04195932|Other|Exercise training|
45831662|NCT03590886|Other|total response Group|biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
45831663|NCT03742986|Drug|Nivolumab 360mg|Nivolumab 360 mg IV on Day 1 of every 21 day cycle (Cycle 1-4)
45831664|NCT03742986|Drug|Paclitaxel 80mg/m^2|Paclitaxel 80mg/m^2 IV on Day of 1, 8, 15 of every 21 day cycle (Cycle 1-4)
45831665|NCT03742986|Drug|Doxorubicin 60mg/m^2|Doxorubicin 60 mg/m^2 IV on Day 1 of every 14 day cycle (Cycle 5-8)
45831666|NCT03742986|Drug|Cyclophosphamide 600mg/m^2|Cyclophosphamide 600mg/m^2 on Day 1 of every 14 day cycle (Cycle 5-8)
45977867|NCT00308607|Drug|dacarbazine|
45977868|NCT00308607|Drug|interferon-alfa-2a (Roferon-A)|
45977869|NCT00274313|Drug|552-02|
45977870|NCT00314613|Drug|Antipsychotic/Risperidone Consta|
45977871|NCT00274352|Drug|adalimumab|Adalimumab 40 mg administered subcutaneously once weekly or placebo injection administered once weekly for 12 weeks, followed by open-label adalimumab 40 mg administered subcutaneously weekly for an additional 12 weeks.
45977872|NCT00416663|Procedure|Intracoronary administration of autologous ACPs|Stem cells type:ACPs. At least 1.5 million of ACPs per one time of treatment
45977873|NCT00314652|Drug|Buprenorphine transdermal delivery system|
45977874|NCT00274391|Drug|7% NaCl|
45977875|NCT00274391|Drug|Amiloride HCl|
45977876|NCT00308724|Behavioral|Cognitive Behavior Therapy|8 to 10 in person CBT sessions up to 60 minutes in duration within a 12 week time period
45977877|NCT00308724|Behavioral|Telephone check-in|Biweekly telephone calls to monitor symptom severity, an enhanced Usual Care condition
45672225|NCT01641809|Drug|GSK1265744 10 mg|GSK1265744 10 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
45672226|NCT01641809|Drug|GSK1265744 30 mg|GSK1265744 30 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
45672227|NCT01641809|Drug|GSK1265744 60 mg|GSK1265744 60 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
45672228|NCT01641809|Drug|Efavirenz 600 mg|Efavirenz 600 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase and Maintenance Phase of the study.
45458682|NCT01238497|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for transfemoral access and requiring a 29mm valve.
45458683|NCT02320084|Drug|Nitisinone|Nitisinone according to prescription
45831667|NCT03742986|Drug|Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2|Paclitaxel 80mg/m^2 on Day 1, 8, 15 of every 21 day cycle (Cycle 1-4) OR Docetaxel 75mg/m^2 on Day 1 of every 21 day cycle (Cycle 1-4)
45831668|NCT03742986|Drug|Trastuzumab 8mg/kg and 6 mg/kg|Trastuzumab 8mg/kg IV on Day 1 of Cycle 1 and then 6mg/kg IV on Day 1 of Cycle 2-4
45977878|NCT00274430|Drug|dexamethasone 8 mg bid|
45977879|NCT00274430|Drug|tadalafil 10mg bid|
45977880|NCT00274508|Drug|tiotropium bromide|
45977881|NCT00314691|Genetic|Blood samples|
45977882|NCT00274547|Drug|Tiotropium|
45977883|NCT00308763|Drug|Nicotine Patch|"After determining that it is appropriate to dispense study medication to a participant, the dosing regimen will be determined. Participants who report smoking more than 20 cigarettes each day will be initially placed on the 21 mg patch; participants who report smoking 10 - 19 cigarettes each day will be initially placed on the 14 mg patch; participants who report smoking 5 - 9 cigarettes will be initially placed on the 7 mg patch.~If a participant is initially placed on the 21 mg patch, the following dosing schedule will occur: 21 mg patch for 4 weeks, 14 mg patch for 4 weeks, 7 mg patch for 2 weeks, and then off. If a participant is initially placed on the 14 mg patch, the following dosing schedule will occur: 14 mg patch for 6 weeks, 7 mg patch for 4 weeks, and then off. If a participant is initially placed on the 7 mg patch, the following dosing schedule will occur: 7 mg patch for 10 weeks, and then off."
45458684|NCT02320162|Behavioral|Experiential learning oral health education|
45672229|NCT01641809|Drug|Rilpivirine 25 mg|Rilpivirine 25 mg will be administered orally once daily in combination with GSK1265744 10 mg, 30 mg and 60 mg in the Maintenance Phase of the study.
45672230|NCT01641809|Drug|Placebo|Placebo matching to GSK1265744 will be administered along with GSK1265744 10 mg and 30 mg in the Induction phase and Maintenance phase of the study.
45672231|NCT01641809|Drug|Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)|The background dual NRTI therapy for all arms in the Induction Phase and Efavirenz 600 mg arm in the Maintenance Phase will be either abacavir 600 mg + lamivudine 300 mg (ABC/3TC) or tenofovir 300 mg + emtricitabine 200 mg (TDF/FTC) as selected by the Investigator.
45672232|NCT01632566|Drug|Placebo|Capsules administered orally
45831669|NCT03742986|Drug|Pertuzumab 840mg and 420mg|Pertuzumab 840mg on Day 1 of Cycle 1 and then 420mg IV on Day 1 of Cycle 2-4
45831670|NCT04020978|Diagnostic Test|Parametric PET/CT|Each patient will undergo a dynamic F18-FDG PET/CT scan at baseline and 2-week post therapy.
45831671|NCT03972774|Diagnostic Test|PET Stress Test|Cardiac positron emission tomography (PET)/computed tomography (CT) and test-result dependent management
45831672|NCT03972774|Other|Non-PET Medical Management|Appropriate medical management without cardiac PET stress-imaging
45977884|NCT00308763|Drug|Sustained Release Bupropion|Participants will receive the sustained-release bupropion 150 mg tablet in the morning for four days. If this dose is well-tolerated, then the dose will be increased to a 150 mg tablet twice daily, with at least 8 hours between the two doses. The sustained-release bupropion medication will begin at the randomization visit (RV) which is approximately one week before the quit date. At the RV, the participant should be dispensed enough of the 150 mg tablets of the sustained-release bupropion or placebo to return for the first follow-up visit with instructions on use. Participants will be evaluated by telephone on their quit date approximately one week after the RV to assess safety. We will discontinue the sustained-release bupropion at the second follow-up visit, at which time participants will have received sustained-release bupropion for approximately 11 weeks.
45977885|NCT00314730|Device|handheld Personal Digital Assistant (PDA)|
45977886|NCT00274586|Drug|Aggrenox® modified release capsules|
45977887|NCT00274586|Drug|Aggrenox® modified release capsules matching placebo|
45977888|NCT00308802|Procedure|Kidney transplantation|Participants in this study will have had a kidney transplant
45672233|NCT01632566|Drug|LY3031207|Administered orally
45977889|NCT00274664|Device|6 hours occlusion by patching|
45977890|NCT00274664|Device|12 hours occlusion by patching|
45977891|NCT00274703|Drug|mepolizumab|
45977892|NCT00274820|Dietary Supplement|ascorbic acid|The dose of ascorbic acid will be 1000 mg PO 2-3 hours prior to ATO infusion. The treatment will follow the same schedule as arsenic trioxide.
45977893|NCT00274820|Drug|arsenic trioxide|Treatment consists of a loading period of five 0.25 mg/kg ATO doses in the first week, followed by maintenance dosing with 0.25 mg/kg ATO twice weekly for 11 weeks. Loading is usually done Monday through Friday of the first treatment week. Maintenance should be started either 72 or 96 hours after the last loading dose. Thereafter, dosing is twice weekly, following an alternating pattern of 72 and 96 hours. For example, maintenance dosing may be done on Mondays and Thursdays, Tuesdays and Fridays, etc. The same pattern should be followed for the entire maintenance dosing period.
45977894|NCT00274820|Drug|dexamethasone|Dexamethasone will be given at a dose of 4mg PO daily for five days every four weeks (i.e., days 1-5, 29-33, 57-61, 84-88, etc.).
45977895|NCT00274820|Drug|thalidomide|The dose of thalidomide will be 50 mg PO daily starting day 1. The dose will be increased to 100mg PO daily after two weeks if tolerated and only if patients experience < grade 1 thalidomide-attributed toxicity using CTC criteria.
45977896|NCT00308841|Drug|Lidocaine (drug)|
45977897|NCT00274859|Drug|gemcitabine hydrochloride|
45672234|NCT01632566|Drug|Celecoxib|Administered orally
45672235|NCT01632566|Drug|Simvastatin|Administered orally
45672236|NCT00752804|Procedure|Dialysis during 4 hours|Blood and dialysate sampling
45672237|NCT00752804|Procedure|Dialysis during 6 hours|Blood and dialysate sampling
45672238|NCT00752804|Procedure|Dialysis during 8 hours|Blood and dialysate sampling
45831673|NCT03023436|Procedure|Cytoreductive surgery|"Gastrectomy with D2 lymph node dissection and Metastasectomy for peritoneal metastatic sites only.~A total, distal, or proximal gastrectomy and the type of reconstruction will be selected according to the surgeon's experience.~Metastasectomy is limited to peritoneal metastatic sites only to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible."
45672239|NCT04773158|Behavioral|Clinical Decision Support|The intervention clinic sites will be provided access to a Clinical Decision Support System (CDSS) that incorporates the Rome IV criteria for evidence-based care recommendations for functional gastrointestinal disorders (FGIDs)
45831674|NCT03023436|Procedure|Hyperthermic Intraperitoneal Chemotherapy|Docetaxel 120 mg diluted in 5.0 L of saline is forced into the abdomen through the inflow catheter by a pump and pulled out through the drains as a heated intraperitoneal perfusion.A heat exchanger keeps the intraperitoneal fluid at 43±0.5℃ and duration limited to 70 minutes.24 hours after cytoreductive surgery no less than 2 cycles postoperative chemotherapy will be recommended.
45831675|NCT03023436|Drug|Fluoropyrimidine|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
45977898|NCT00274859|Drug|oxaliplatin|
45977899|NCT00314847|Device|Extra-Corporeal Life Support -Impella 2.5|Percutaneous implantation of Impella pump for a duration of 3 days as a minimum and up to 7 days (recommended)
45977900|NCT00274898|Drug|celecoxib|
45977901|NCT00274898|Drug|docetaxel|
45977902|NCT00274898|Procedure|adjuvant therapy|
45977903|NCT00274898|Radiation|radiation therapy|
45977904|NCT00308880|Drug|Transamin|
45977905|NCT00277160|Drug|Neulasta (pegfilgrastim)|Commercial pegfilgrastim 6mg single subcutaneous fixed-dose
45977906|NCT00314886|Drug|Diet|
45977907|NCT00277199|Drug|Abatacept|
45977908|NCT02960100|Other|Informational Intervention|Receive standard HPV vaccine information (HPV VIS)
45977909|NCT02960100|Other|Media Intervention|Receive targeted HPV vaccine narrative-style video
45977910|NCT02960100|Other|Survey Administration|Ancillary studies
45977911|NCT00277277|Behavioral|Healthium|
45977912|NCT00308919|Drug|WST09|Treatment with WST09 Vascular Photodynamic therapy
45977913|NCT00277316|Drug|XL999|Treatment was administered on an outpatient basis. XL999 was administered at a dose of 2.4 mg/kg given as a 4 hour IV infusion.
45977914|NCT00308958|Device|High frequency chest wall oscillator|
45977915|NCT00314925|Drug|Seneca Valley Virus (biological agent)|Dose escalation (starting at 1 × 10^7 vp/kg), IV (in the vein) over 1 hour in a single administration
45977916|NCT00277433|Other|Buccal Swab|collection of buccal swab
45977917|NCT00314964|Drug|PD-0299685|
45977918|NCT00277472|Drug|Valsartan/Hydrochlorothiazide|160/12.5 mg taken once daily orally
45977919|NCT00277472|Drug|HCTZ|25 mg taken once daily orally
45977920|NCT00277511|Drug|Levofloxacin|
45977921|NCT00315003|Drug|Telithromycin|
45672240|NCT04863521|Other|MHP|MyHealthyPregnancy app (MHP 3.0) is a mHealth app specifically focused on detection and referral for depression and IPV (Intimate Partner Violence) risk, in addition to its other pregnancy risk detection and support features.
45672241|NCT02254304|Drug|Rebif|Rebif will be administered at a dose of 44 microgram (mcg) subcutaneously using RebiSmart auto-injector three times a week for a total duration up to 12 months.
45977922|NCT00315003|Drug|Azithromycin|
45977923|NCT00277550|Drug|Tegaserod and Placebo|
45977924|NCT00309036|Biological|Recombinant grass pollen|
45977925|NCT00277589|Drug|Levothyroxin-Na|1 tablet 30 minutes before breakfast
45977926|NCT00277589|Drug|Levothyroxine-Na + iodide|1 tablet 30 minutes before breakfast
45977927|NCT00277589|Drug|Iodide|1 tablet 30 minutes before breakfast
45977928|NCT00277589|Drug|Placebo|1 tablet 30 minutes before breakfast
45977929|NCT00315042|Drug|Telithromycin (HMR3647)|
45977930|NCT00315042|Drug|Penicillin|
45977931|NCT00277667|Drug|Quetiapine|Oral dosing: 50mg (Day 1), 100mg (Day 2), 150mg (Day 3), 200mg (Day 4), followed by flexible dosing from 50mg to 800mg through day 56.
45977932|NCT00315081|Drug|Bromocriptin|
45977933|NCT00277706|Procedure|Periodontal surgery|
45672242|NCT04863287|Biological|2217LS|Fully Human Monoclonal Antibody
45977934|NCT00277706|Drug|FORTEO|parathyroid hormone; self-administration for 6 weeks
45672243|NCT04863287|Other|0.9% Sodium Chloride (NaCl)|Subcutaneous injection
45672244|NCT05643365|Radiation|Radioactive Iodine therapy|All the patient need to stop ATD and iodine-containing drugs for 5 days prior to RAI treatment, and followed a low-iodine diet for 2 weeks. After fasting and water deprivation for 8 h, all the patients took RAI orally in the morning. After taking RAI, the patients need to continue fasting and water deprivation for extra 2 h to avoid the effects of food on iodine absorption.
45672245|NCT05642897|Behavioral|Mind|The Mind programme is an intervention based on Acceptance, mindfulness and compassion for women with breast cancer.
45831676|NCT03023436|Drug|Cisplatin|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
45831677|NCT04020042|Other|Ultrasound image guidance|Epidural landmarks will be determined with using ultrasound image
45831678|NCT04020042|Other|Landmark palpation|Epidural landmarks will be determined with palpation
45977935|NCT00277706|Drug|Placebo|placebo; self administration for 6 weeks
45977936|NCT00277706|Dietary Supplement|Vitamin D and Calcium|PO, QD, for six weeks
45977937|NCT00309075|Drug|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
45831679|NCT04026594|Other|Mindfulness Based Stress Reduction|"MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 8 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences."
45831680|NCT04026594|Other|Relaxation group|control group
45977938|NCT00277745|Device|miniaturized microfluidic system|Subjects will provide appropriate periodontal treatment as needed.
45977939|NCT00419133|Biological|Killed bivalent whole cell oral cholera vaccine|"Each 1.5 mL dose, given orally, contains:~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed, 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
45977940|NCT00419133|Biological|Heat Killed E. coli Placebo|Heat Killed E.coli in an optical turbidity identical to cholera vaccine, given in a 1.5 mL oral dose.
45977941|NCT00277784|Procedure|Ultrasound examination|one ultrasound examination
45672246|NCT05642897|Behavioral|Support Group|To promote sharing of cancer-related experiences, active listening, and a sense of community between participants.
45672247|NCT04420091|Dietary Supplement|Cartidyss|Oral intake of two tablets of Cartidyss 500 mg, once daily in the morning, preferably during a meal, with water, during 3 months
45977942|NCT00309114|Procedure|bacterial interference|
45977943|NCT00277823|Drug|DVS-SR 50 mg|
45977944|NCT00277823|Drug|DVS-SR 100 mg|
45977945|NCT00277823|Drug|Placebo|
45977946|NCT00277862|Drug|Pegylated IFN- alpha 2b|
45977947|NCT00277862|Drug|Ribavirin|
45977948|NCT00309231|Procedure|Islet Allotransplantation|Clinical islet transplantation using the Edmonton protocol, steroid free immunosuppression using sirolimus and tacrolimus and basilixumab induction therapy
45977949|NCT00315159|Procedure|Sentinel Node Biopsy|Inguinal sentinel node biopsy will be performed.
45977950|NCT04719260|Behavioral|Nutrition Thinking®|In the first session, the nutritionist will carry out the anamnesis through the Empathy Map and assessment of the nutritional status to define the Nutrition Briefing. The steps described by Design Thinking as understanding, observation, and point of view comprise the first phase of this session. The ideation process will proceed from the definition of the Nutrition Challenge. Prototyping is the final stage of the first session, where an initial prototype of the diet will be co-created based on visual thinking tools and the description underlying the creation of diets. Within 24 hours the individual will receive a summary of the material developed by email. The period between sessions will comprise the testing phase and the follow-up sessions the iteration phase where the experience and previous steps are revisited in order to create new insights, anthropometric measurements will be seen as reflections of the experience and not as primary outcomes of the intervention.
45977951|NCT04719260|Behavioral|Standard Nutritional Approach|In the first session the nutritionist will carry out the food and nutritional anamnesis and assessment of the nutritional status. From this information, the nutritionist will generate the diagnostic hypothesis and determine the specific nutritional needs. The professional will be responsible for generating the dietary prescription defining the characteristics of the diet that will be delivered printed to the individual after a period of 15 days, in the second session of the protocol. The follow-up session will be based on adherence to the established conduct and monitoring of anthropometric variations.
45977952|NCT00315198|Device|Eye Patch|2 hours daily patching
45977953|NCT00315198|Procedure|Near activities|near visual activities while patching
45977954|NCT00315198|Procedure|Distance activities|distance visual activities while patching
45458685|NCT02320240|Drug|Duloxetine|Current exposure to Duloxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
45672248|NCT04862195|Device|Attune™|Software as a medical device
45672249|NCT04862195|Device|Cerena™|Software as a medical device
45672250|NCT04861961|Procedure|DS vs. SADI-S vs. OAGBP|Randomizacion of candidates for either conventional DS, SADI-S or OAGBP.
45672251|NCT05650307|Diagnostic Test|MRI|The magnetic field exposure for MRI in this study is similar to standard clinical MR procedures. The powers of all radio frequency fields in this study are at or under FDA guidelines. The CMR techniques performed here have been used in the literature and in our own clinical cardiac MRI service extensively for several years and have an excellent safety profile in our institution.
45672252|NCT04861805|Device|Vienna Aortic Valve SE System|The Vienna Aortic Valve SE System (valve sizes: 23, 26, 29 and 31 mm) is a biological valve system intended to be implanted percutaneously in the aortic valve via the transfemoral route. The device is made of bovine pericardium leaflets and a pericardium fabric skirt sutured on a radiopaque nitinol self-expanding stent system, designed for supra-annular positioning to optimize hemodynamic performance. The Vienna Aortic Valve SE System is repositionable and retrievable allowing a more optimal prosthesis positioning to minimize residual paravalvular regurgitation, atrioventricular conduction block/disturbances, and mitral or coronary compromise. The valve comes already pre-mounted on the delivery system, ready to be used, eliminating the need for assembly and crimping of the device prior to valve implantation.
45672253|NCT05650151|Dietary Supplement|Vitamin D|576 000 IU D 5-7 days prior to the surgery and 144 000 IU daily on post-operative day 1-2
45831681|NCT04025424|Genetic|Genetic tests of the available tumor and plasma samples|Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned
45831682|NCT04023396|Drug|ABX464|"ABX464~All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks."
45831683|NCT04195464|Other|Dry needling|Dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments
45831684|NCT04195464|Other|Sham dry needling|Sham Dry needling use a non-penetrating acupuncture needle
45831685|NCT04195386|Procedure|Dental Restoration with Chemically activated Composite resin Alkasite|Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with chemically activated composite resin Alkasite.
45831686|NCT04195386|Procedure|Dental Restoration with Resin-Modified Glass ionomer Cement|Selective removal of dental caries with manual instruments, under relative isolation, application of polyacrylic acid and restoration with resin-modified glass ionomer cement.
45977955|NCT00315237|Drug|vinflunine and best supportive care|solution for injection, IV, 280/320 mg/m2, every 3 wks variable duration
45977956|NCT00278018|Procedure|Immunotherapy treatment for solid tumors|
45977957|NCT00309270|Drug|Campath-1H|
45977958|NCT00278057|Drug|dialysisis with and without glucose in the dialysis|
45977959|NCT00315276|Drug|Modafinil|
45977960|NCT00278096|Behavioral|occupational therapy|
45977961|NCT00309309|Drug|Rosiglitazone|
45977962|NCT00278135|Dietary Supplement|DHA (nutritional supplement) or placebo|oral 900mg/day
45977963|NCT00315315|Procedure|Nasolacrimal balloon catheter dilation|Balloon catheter nasolacrimal duct dilation consists of punctal dilation of at least one punctum and the passage into the nose of a semi-flexible wire probe with an inflatable balloon on the tip.
45977964|NCT00315315|Procedure|Nasolacrimal intubation|Nasolacrimal duct intubation consists of punctal dilation of at least one punctum with the passage of a flexible lacrimal probe into the nose and the placement of a temporary stent in the nasolacrimal duct.
45977965|NCT00315315|Procedure|Nasolacrimal duct probing|Simple nasolacrimal duct probing consists of punctal dilation of at least one punctum and the passage of a probe into the nose.
45977966|NCT00278174|Biological|recombinant interferon alpha-1b|
45977967|NCT00309348|Other|Weekly measurement of graft flow|
45977968|NCT00416702|Drug|QAB149|
45977969|NCT00278213|Biological|alemtuzumab|
45977970|NCT00278213|Drug|cyclophosphamide|
45977971|NCT00278213|Drug|fludarabine phosphate|
45977972|NCT00278213|Drug|mitoxantrone hydrochloride|
45977973|NCT00315354|Other|Low glycemic index diet|Feeding protocol, all foods prepared in a metabolic kitchen
45977974|NCT00315354|Other|Low fat diet|Feeding protocol, all foods prepared in a metabolic kitchen
45977975|NCT00315354|Other|Very low carbohydrate diet|Feeding protocol, all foods prepared in a metabolic kitchen
45977976|NCT00278252|Drug|etoposide|
45977977|NCT00278252|Procedure|conventional surgery|
45977978|NCT00315432|Drug|Pegylated Interferon and Ribavirin|
45977979|NCT00278330|Drug|alvocidib|Given by infusion
45977980|NCT00278330|Drug|vorinostat|Given orally
45977981|NCT00315510|Drug|Rosuvastatin|
45458686|NCT02320240|Drug|Venlafaxine|Current exposure to Venlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
45458687|NCT02320240|Drug|Desvenlafaxine|Current exposure to Desvenlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
45977982|NCT00278369|Biological|aldesleukin|The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment. IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5). A second 5 day cycle of IL-2 will begin on the 15th day (days 15-19). This is one complete cycle (days 1-19) of IL-2 treatment
45977983|NCT00278369|Biological|denileukin diftitox|Denileukin diftitox will be administered once daily as a 15 to 60 minute infusion for 3 consecutive days.
45977984|NCT00315549|Drug|Telithromycin|
45977985|NCT00315549|Drug|Penicillin|
45672254|NCT05650151|Dietary Supplement|Placebo|An equal volume of medium chain triglyceride (MCT, as placebo) to vitamin D 5-7 days prior to the surgery and on the post-operative day 1-2.
45672255|NCT02174731|Drug|Roxadustat|Roxadustat will be administered orally three times a week (TIW) to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
45672256|NCT02174731|Drug|Epoetin alfa|Epoetin alfa will be administered TIW consistent with approved prescribing information for epoetin alfa to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
45672257|NCT01922037|Drug|Omalizumab|Participants will receive omalizumab for up to 12 months per investigator standard of care and clinical practice.
45672258|NCT02282813|Drug|CTAP101 Capsules|At week 12, eligible subjects will continue to take 1-2 capsules (30 mcg each capsule) CTAP101 daily
45672259|NCT02282813|Drug|Calcitriol|At week 12, eligible subjects will be randomized to also take calcitriol 0.25 mcg dose one capsule daily
45831687|NCT04195152|Other|Observational|No intervention
45831688|NCT04195074|Drug|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
45977986|NCT00278408|Biological|filgrastim|
45977987|NCT00278408|Biological|rituximab|
45977988|NCT00278408|Drug|cyclophosphamide|
45977989|NCT00278408|Drug|doxorubicin hydrochloride|
45977990|NCT00278408|Drug|prednisone|
45977991|NCT00278408|Drug|vincristine sulfate|
45977992|NCT00278408|Radiation|radiation therapy|
46082542|NCT04013581|Drug|TZD group|Pioglitazone 15mg (Acpio®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM(type 2 diabetes mellitus) patients who had inadequate glycemic control (7% <HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of pioglitazone : from 15mg to 30mg
45672260|NCT02282813|Drug|Doxercalciferol|At week 12, eligible subjects will be randomized to also take doxercalciferol 0.5 mcg one capsule daily
45672261|NCT02282813|Drug|Paricalcitol|At week 12, eligible subjects will be randomized to also take paricalcitol 1 mcg one capsule daily
45672262|NCT04188535|Diagnostic Test|MRI IMAGING|Imaging with MRI will be performed as per disease site standards.
45672263|NCT04878029|Drug|Cabozantinib S-malate|Given PO
45672264|NCT04878029|Drug|Enfortumab Vedotin|Given IV
45672265|NCT04878029|Other|Quality-of-Life Assessment|Ancillary studies
45831689|NCT04195074|Drug|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
45831690|NCT04195074|Drug|Tenofovir Alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
45831691|NCT04194762|Other|Non pharmacological therapy|treadmill training and cycling training in equal intensity exercise.
45977993|NCT00315666|Drug|memantine|
45977994|NCT00278447|Behavioral|Chronic Disease Management for substance abuse|Referral to primary medical care & longitudinal, multidisciplinary care for persons with substance dependence.
45977995|NCT00278447|Behavioral|Standard care|Referral to primary medical care for persons with substance dependence.
45977996|NCT00315744|Drug|Salmeterol/fluticasone|Salmeterol/ fluticasone are a type of long acting beta-agonist (LABA). Salmeterol 50 microgram/ fluticasone 100 microgram combination will be administered to eligible subjects via inhalation route.
45977997|NCT00315744|Drug|Fluticasone propionate|Fluticasone propionate is a type of LABA. Fluticasone 100 microgram dose will be administered to eligible subjects via inhalation route.
45977998|NCT00315744|Drug|Salbutamol|Salbutamol metered dose inhaler will be provided to all subjects as a rescue medication.
45977999|NCT00278486|Biological|Hematopoietic stem cell transplantation.|Autologous hematopoietic stem cell transplantation will be performed.
45978000|NCT00278603|Biological|Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Injection
45458688|NCT02320240|Drug|Citalopram|Current exposure to Citalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
45458689|NCT02320240|Drug|Escitalopram|Current exposure to Escitalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
45672266|NCT04878029|Other|Questionnaire Administration|Ancillary studies
45672267|NCT01903863|Biological|Fresh frozen plasma|Fresh frozen plasma is a pooled blood product containing both pro and anticoagulation factors. Patients enrolled in the intervention arm will receive scheduled fresh frozen plasma treatment every 48 hours. Patients in the control arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
45978001|NCT00309543|Drug|Fluorouracil|
45978002|NCT00309543|Drug|Leucovorin|
45978003|NCT00278642|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
45978004|NCT00278681|Drug|Zinc and ORS|"One strip containing 14 dispersible zinc tablets (20 mg each) along with 2 ORS packets were prescribed to all children aged 1 month to 5 years visiting that channel with diarrhea.~Infants aged less than 6 months were advised half a zinc tablet in a teaspoonful of breast milk; older children were advised 1 tablet in breast milk or clean water."
45978005|NCT02960139|Device|Test- Treatment with Sylys Surgical Sealan|Standard closure of stapled anastomosis plus treatment with Sylys Surgical Sealant
45978006|NCT00278759|Procedure|Nasopharyngeal washing for viral antigen detection by immunofluorescence initiated early in ED visit.|See Detailed Description.
45978007|NCT00278837|Behavioral|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
45978008|NCT00315861|Drug|pemetrexed|
45978009|NCT00315861|Drug|topotecan|
45978010|NCT00279032|Drug|GW406381|
45978011|NCT00309660|Drug|Rosiglitazone|
45978012|NCT00279071|Device|Acupuncture og acupressure when diagnosed with dystocia|Acupuncture points: sp6 li4 ki3 ki6 bl60 Acupressure points: bl67
45978013|NCT00315900|Drug|Depakote ER|depakote ER
45978014|NCT00315900|Drug|Seroquel|seroquel
45978015|NCT00279110|Behavioral|Directly administered antiretroviral therapy (DAART)|Participants are observed taking HIV medications on days when they receive opioid agonist therapy.
45978016|NCT00309699|Drug|Placebo|Daily for 3 weeks
45978017|NCT00309699|Drug|Quetiapine|400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
45672268|NCT02123251|Behavioral|Financial Incentives|This intervention will examine the effects of incentives on improving adult diabetic Medicaid beneficiaries' health outcomes and reducing associated costs through healthy behavior changes in their diabetes self-management. Incentives focus on improving self-management of diabetes, compliance with ADA recommended preventive, treatment and management measures, primary biometric measures of diabetes, and eliminating barriers to a healthy lifestyle
45831692|NCT03971838|Behavioral|Positive Outcomes for Women|"Women and their children 10+ can consent to participate in the diabetes prevention programming offered through the research center. We will collect data at three time points, baseline, 4-6 months, and 12 months.~2. Instead of participating in Encourage, women may participate in other diabetes prevention programming/weight management programming offered by other entities. Researchers will consent these women into the study to complete 3 data collection points, baseline, 4-6 months, and 12 months. Additionally, researchers will consent women to obtain data from their chosen program. For instance, if a woman chooses to do a Diabetes Prevention Program through the YMCA, researchers will ask women to self report their weekly attendance and weight."
45672269|NCT04746469|Behavioral|Delayed automated phone call|Cipher provides automated phone calls to patients; in this case the script for Cipher was modified to provide patients a reminder to return FIT kits, allow patients to request a new kit in case they need a replacement, and to allow patients to provide information if they already completed CRC screening
45831693|NCT04029792|Combination Product|Combination of plant extracts (BSL_EP028)|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
45831694|NCT04029792|Combination Product|Placebo|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
45978018|NCT00309699|Drug|Paliperidone ER|3 to 12 mg daily, flexibly dosed, for 12 weeks
45978019|NCT00279149|Procedure|Visio conference system connected to the Tele-stroke network|Visio conference system connected to the Tele-stroke network
45978020|NCT00315978|Device|Heart-to-Heart Decision Aid|
45978021|NCT00279188|Procedure|Guiding therapy by bronchial hyperrsponsiveness|
45978022|NCT00309816|Drug|sildenafil|
45978023|NCT00279266|Drug|Thiamine|
45978024|NCT00316095|Drug|telmisartan|
45978025|NCT00316095|Drug|simvastatin|
45978026|NCT00279344|Drug|Fentanyl (Matrifen)|
45978027|NCT00418860|Drug|Aspirin, Clopidogrel|Aspirin 100mg qd plus clopidogrel 75mg qd for 3 month after index procedure
45978028|NCT00316134|Procedure|Procedure/Surgery|Diagnostic and/or therapeutic procedure to remove pleural fluid.
45978029|NCT00316212|Drug|INS50589 Intravenous Infusion|
45978030|NCT00309855|Drug|Placebo|im and orally
45978031|NCT00309855|Drug|Testosterone|injections
45978032|NCT00309855|Drug|Anastrazole|orally x 21 days
45978033|NCT00309855|Drug|Dutasteride|orally x 21 days
45978034|NCT00279383|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|Intra-operatively treated patients with hemostatic supporting agents/techniques in addition to the standard surgical procedures
45978035|NCT00316251|Device|Vibration Plate Therapy|
45978036|NCT00279422|Drug|visilizumab|
45978037|NCT00279422|Drug|visilizumab|
45978038|NCT00309894|Biological|sargramostim|
45978039|NCT00309894|Drug|ketoconazole|
45978040|NCT00309894|Drug|therapeutic hydrocortisone|
45978041|NCT00279461|Drug|Placebo in arm A and Vitamin D in arm B|Vitamin D3 at 2,000 units daily, all in one capsule, for 6 months and Placebo provided in matching capsule, one capsule daily, for 6 months
45978042|NCT00279461|Drug|vitamin D 3 for arm A ,and matching placebo for arm B|Arm A 2,000 units of Vitamin D3 in one capsule daily for 6 months. Arm B matching placebo capsule, one daily for 6 months
45978043|NCT00316329|Drug|Artesunate + Amodiaquine|
45978044|NCT00279539|Genetic|Vascular Endothelial Growth Factor (VEGF1)|
45978045|NCT00279578|Drug|ReFacto (Recombinant factor VIII) and Tranexamic acid|
45978046|NCT00316368|Device|Ethicon TPW32 60 cm (pacing wires x 2)|
45978047|NCT00279617|Drug|levetiracetam|open label levetricetam
45978048|NCT00309972|Drug|Control arm (SEQ):|Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
45978049|NCT00309972|Drug|Experimental arm (CON):|concurrent chemo-radiotherapy [55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20] followed by two cycles of cisplatinum/vinorelbine.
45978050|NCT00310011|Drug|cisplatin|
45978051|NCT00310011|Drug|gemcitabine hydrochloride|
45672270|NCT05638529|Drug|Pregnyl (1,500) IU|Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of hCG (Pregnyl 1,500 IU) on their assigned trigger day.
45672271|NCT05638529|Drug|1.5 mL of normal saline|Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of normal saline (1.5 mL - sham placebo) on their assigned trigger day.
45672272|NCT01902303|Drug|Matching Placebo|Sublingual micro dosing of placebo for 7 days
45978052|NCT00310011|Drug|paclitaxel|
45978053|NCT00310011|Procedure|conventional surgery|
45978054|NCT00279656|Behavioral|Pharmaceutical care|
45978055|NCT00316407|Drug|lapatinib (GW572016)|1000 mg po qd
45831695|NCT04029948|Procedure|Laser En Bloc Resection Of bladder Tumor|Using laser beam starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
45978056|NCT00316407|Drug|Carboplatin|AUC 2 weekly x 3 of 4 week cycle
45978057|NCT00316407|Drug|Paclitaxel|60 mg/m2 weekly x 3 of 4 week cycle
45672273|NCT01902303|Drug|BTL-TML-HSV|Sublingual micro dosing of BTL-TML-HSV for 7 days
45672274|NCT02122783|Device|ADR™ brace resistance|
45831696|NCT04029948|Procedure|Electro-surgical En Bloc Resection Of bladder Tumor|Using electro-surgical loop starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
45978058|NCT00279695|Procedure|high frequency ultrasound examination|high frequency ultrasound examination of the eye
45978059|NCT00310089|Biological|filgrastim|
45978060|NCT00310089|Biological|pegfilgrastim|
45978061|NCT00310089|Drug|cediranib maleate|
46082543|NCT04013581|Drug|SGLT-2 group|Empagliflozin 10mg (Jardiance®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM patients who had inadequate glycemic control (7% <HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of empagliflozin : from 10mg to 25mg
45672275|NCT02122783|Device|Conventional brace resistance (using hard stops)|Conventional polypropylene custom molded ankle foot orthosis (MAFO) with Lawrence style double channel adjustable joints containing pins/springs
45672276|NCT04859933|Procedure|AV-node isolation|Abaltion performed in the right atrium isolating the AV-node from the atrium
45672277|NCT04859933|Procedure|AV-node ablation|Right sided ablation of the AV-node
45672278|NCT04859465|Drug|Abraxane combined with liposomal doxorubicin|Patients with advanced or unresectable angiogenic sarcoma who met the criteria of treatment failure received abraxane combined with liposomal doxorubicin regimen. Administration regimen: abraxane 220 mg / m2 D1 plus liposomal doxorubicin 35 mg / m2 D1, IV drip, 3 weeks as a cycle, until the disease progression or intolerable toxicity. Up to 8 cycles.
45672279|NCT01921257|Drug|Cat-PAD|
45672280|NCT01921257|Drug|Placebo|
45672281|NCT02121847|Drug|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
45672282|NCT02121847|Drug|carboxymethylcellulose-based lubricant eye drops|Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
45831697|NCT03590262|Drug|Metformin|take the metformin 500mg twice or three times a day
45831698|NCT04029636|Other|Inhaled Hyperpolarized Xenon-129|How hyperpolarized 129Xe MRI measurements of lung structure and function change over time in a population at high risk for LONIPC related to their transplant
45831699|NCT04029402|Other|RNA sequencing|Transcriptomic analysis of kidney biopsy tissue, and linking with slope of eGFR decline
45831700|NCT04029558|Dietary Supplement|Combination of Plant Extracts (BSL_EP025)|Each participant will consume 2 capsules daily at lunch for 8 weeks.
45831701|NCT04029558|Dietary Supplement|Placebo|Each participant will consume 2 capsules daily at lunch for 8 weeks.
45978062|NCT00310089|Drug|cyclophosphamide|
45978063|NCT00310089|Drug|docetaxel|
45978064|NCT00310089|Drug|doxorubicin hydrochloride|
45978065|NCT00310089|Other|laboratory biomarker analysis|
45978066|NCT00310089|Procedure|conventional surgery|
45978067|NCT00310089|Procedure|neoadjuvant therapy|
45978068|NCT00279734|Drug|Tetanus + pnemococcal vaccines alone|0 mg + vaccines, Single dose, 28 days.
45978069|NCT00279734|Drug|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days.
45978070|NCT00279734|Drug|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 56 days.
45978071|NCT00279734|Drug|Abatacept + Vaccines|parenteral, IV, 750 mg abatacept + vaccines, Single dose, 84 days.
45978072|NCT00310128|Drug|cisplatin|
45978073|NCT00310128|Drug|cytarabine|
45978074|NCT00310128|Drug|etoposide|
45978075|NCT00310128|Drug|methylprednisolone|
45978076|NCT00310128|Drug|rituximab|
45978077|NCT00310128|Drug|yttrium Y 90 ibritumomab tiuxetan|
45978078|NCT00310128|Procedure|antibody therapy|
45978079|NCT00310128|Procedure|biological therapy|
45978080|NCT00310128|Procedure|chemotherapy|
45978081|NCT00310128|Procedure|monoclonal antibody therapy|
45978082|NCT00310128|Procedure|radiation therapy|
45978083|NCT00310128|Procedure|radioimmunotherapy|
45978084|NCT00310128|Procedure|radioisotope therapy|
45978085|NCT00279773|Drug|TKI258|
45978086|NCT00418899|Behavioral|Questionnaire|Questionnaire, 30-40 minutes, about gliomas and its risk factors (such as environmental and genetic information).
45978087|NCT00416741|Behavioral|Implementation of guidelines|Attaining targets for LDL cholesterol, arterial blood pressure, fasting [plasma flucose
45978088|NCT00416780|Other|counseling intervention|
45978089|NCT00416780|Other|educational intervention|
45978090|NCT00416780|Procedure|psychosocial assessment and care|
45978091|NCT00310167|Radiation|radiation therapy|
45978092|NCT00316563|Drug|Marinol (Dronabinol)|Intervention description: Marinol (drug) is being used as an appetite stimulant for treatment of cancer-induced anorexia.
45978093|NCT00316563|Other|Placebo|
45672283|NCT05637593|Behavioral|Upper-limb movement training with the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to listen to the RAS sound, use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They should keep their movements consistent with the sound of the RAS, with one RAS sound corresponding to one pick-up movement.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 21 days."
45978094|NCT00416819|Biological|filgrastim|
45672284|NCT05637593|Behavioral|Upper-limb movement training without the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They are asked to execute the task as fast as possible.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 21 days."
45672285|NCT01921179|Behavioral|GOALS (Goal-Oriented Attentional Regulation)|Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
45831702|NCT04194684|Drug|nab-paclitaxel|nab-paclitaxel 125mg / m2, intravenous drip 30min, d1, 8, 21 days as a cycle, until the disease progresses or intolerable toxicity. According to the calculation results, the administered dose can be within ± 10% of the calculated dose.
45831703|NCT03590106|Behavioral|Peer Recovery Support Program|See above
45672286|NCT01921179|Behavioral|EDU (Brain Health Education)|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
45672287|NCT01587040|Drug|SAR245408|Pharmaceutical form: capsule or tablet Route of administration: oral
45672288|NCT01587040|Drug|SAR245409|Pharmaceutical form: capsule or tablet Route of administration: oral
45672289|NCT02144701|Dietary Supplement|Lactobacillus rhamnosus GG|Given PO
45672290|NCT02144701|Other|laboratory biomarker analysis was not performed because of no differences in the clinical outcomes|Correlative studies
45831704|NCT04194294|Drug|Lidocaine|Before induction of anesthesia; children in group LID received an iv bolus dose of LIDOCAINE 1 mg/kg over 5 minutes followed by 1 mg Kg-1 h-1 ivi until the start of skin closure.
45458690|NCT02320240|Drug|Fluoxetine|Current exposure to Fluoxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
45831705|NCT04194294|Other|Na CL 0.9%|Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of LIDOCAINE.
45831706|NCT04029324|Procedure|tooth extraction|Under local anesthesia, tooth will be extracted atraumatically.
45831707|NCT04029324|Procedure|Implant placement|Dental implants will be placed according to the instructions in fresh sockets or alveolar ridge.
45831708|NCT04029324|Procedure|Bone augmentation|Bone substitute will be used to augment or maintain the bone contour.
45831709|NCT04029324|Procedure|Coronally repositioned flap|After periosteal releasing incision, mucoperiosteal flap will be sutured at a more coronally position
45831710|NCT04029090|Drug|MCI-186|A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.
45978095|NCT00416819|Biological|rituximab|
45978096|NCT00416819|Drug|cytarabine|
45978097|NCT00416819|Drug|etoposide phosphate|
45978098|NCT00416819|Drug|leucovorin calcium|
45978099|NCT00416819|Drug|methotrexate|
45978100|NCT00416819|Drug|temozolomide|
45978101|NCT00310206|Biological|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intradermally (ID); doses: 3 or 9 micrograms.
45978102|NCT00310206|Biological|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intramuscularly (IM); doses: 15 or 45 micrograms.
45978103|NCT00279890|Drug|Topical SR-01|
45978104|NCT00316641|Drug|Lipid-lowing Tea|
45978105|NCT00310245|Procedure|STI (structured Treatment Interruption)|
45978106|NCT00279929|Procedure|DHEA Replacement|
45978107|NCT00279968|Device|ICD|
45978108|NCT00280007|Drug|bevacizumab|bevacizumab 5 mg/kg i.v. every 14 days for 52 weeks
45978109|NCT00316680|Biological|Diphtheria, tetanus, pertussis, hepatitis B, Hib vaccine|
45978110|NCT00280046|Drug|biphasic insulin aspart|
45978111|NCT00310284|Behavioral|Computerized delivery of cognitive-behavioral treatment of insomnia|
46082544|NCT02715960|Drug|Acitretin Capsules|During The first treatment stage:10mg per day, 3 days,oral; The second stage: 20mg per day, 3 days,oral; The third stage: 30mg per day, and maintain this dose,oral.
46082545|NCT03983018|Drug|Rituximab|Infusion
45831711|NCT04029090|Drug|MCI-186|A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.
46082546|NCT02715648|Drug|Phenazopyridine|
45831712|NCT04029090|Drug|Placebo|A single dose of 0.9% w/v saline over 60 min will be intravenously administered.
45831713|NCT04194216|Drug|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg."|Treatment Arm A
45831714|NCT04194216|Drug|"Intra-operative single dose (iv) of cephalexin 2 g or clindamycin 900 mg and postoperative oral dose of cephalexin 250mg (every 4 hours) or clindamycin 150mg(every 6 hours) for 3 days"|Treatment Arm B
45831715|NCT04193982|Drug|Saroglitazar|Patient receives Saraglitazar 4mg once daily
45831716|NCT04193982|Drug|Vitamin E|Patient receive Vitamin E 400mg twice daily after food for 6 months
45831717|NCT04193982|Drug|Combination drug|Patient receives Vitamine E 400mg twice daily and Saraglitazar 4 mg once daily for 6 months
45831718|NCT04193982|Behavioral|Lifestyle Changes|Patients receives dietary advise and does exercise in form of aerobic and targets 7 to 10 percent weight loss in 6 months
45831719|NCT04028778|Drug|Gefitinib|Gefitinib 250mg, p.o., qd, D1-D21; 3 weeks one cycle.
45831720|NCT04028778|Drug|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
45831721|NCT04028778|Other|Placebo|Placebo simulating anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
45831722|NCT04028856|Drug|interferon|Chronic hepatitis B patients were treated with interferon for 48 weeks
45831723|NCT03594474|Other|Intravenous lipid emulsion|using higher dose of IV lipids after birth
45831724|NCT04028544|Drug|Qishenyiqi dropping pills|on the basis of standard treatment, adding QSYQ dropping pills 1 bag each time, 3 times a day
45978112|NCT00310284|Behavioral|Self-help manual to improve insomnia symptoms|
45978113|NCT00280085|Procedure|MR imaging|
45978114|NCT00280085|Procedure|Glucose clamp|
45978115|NCT00280085|Drug|Arginine|
45978116|NCT00310323|Drug|Dextromethorphan|0.5 mg/kg (maximum 30 mg)
45978117|NCT00310323|Drug|Caffeine|Administered as 4 ounces of Coca-Cola
45978118|NCT00310479|Device|Magnetic Resonance Spectroscopy (3Tesla)|
45978119|NCT00280280|Drug|intramuscular Botox versus oral baclofen|Each vial of Botox contains 100 units of Clostridium botulinum toxin type A, 0.5 mg albumin (human) and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. Botox placebo is sterile normal saline (without preservatives) for injection. Baclofen is supplied as 10 mg tablets for oral administration. Inactive ingredients include colloidal anhydrous silica, microcrystalline cellulose, magnesium stearate, povidone, wheat starch. Baclofen placebo tablets are composed of microcrystalline cellulose binder (99%), magnesium stearate 0.5%, and silica gel 0.5% and appear similar to commercial Baclofen tablets.
45978120|NCT00316758|Drug|GK Activator (2)|Escalating doses bid
45978121|NCT00316758|Drug|Metformin|As prescribed, in patients who were in study BM18249
45978122|NCT00280319|Behavioral|interpersonal psychotherapy for groups|psychotherapy
45978123|NCT00280319|Behavioral|creative play therapy|consisted of play activities
45978124|NCT00280358|Drug|Fluticasone Propionate|
45978125|NCT00280358|Drug|Formoterol Fumarate|
45978126|NCT00316797|Drug|123-I INER|Serial whole body planar imaging in the anterior and posterior projection will be performed at 1 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, and 18-24h following injection of 5 mCi of 123-I INER. Venous blood data will be acquired at each imaging time point. In addition a 24 hour urine collection will commence following radiotracer injection and urine sampled in five collections every 4 hours collection for first sixteen hours (4 collections), then one collection from 16 to 24 h. Whole body and source organs uptake will be analyzed on anterior and posterior images for calculating the radiation absorbed doses to organs using the MIRD method as described previously (Seibyl, et al, 1993). Plasma and urine metabolites will be characterized and safety assessments obtained.
45978127|NCT00310518|Drug|ARQ 501|
45978128|NCT00280436|Drug|GW679769|
45978129|NCT00280475|Device|Whole brain radiation therapy arm|Whole brain radiation therapy arm
45978130|NCT00280475|Device|Salvage stereotactic radiosurgery arm|Salvage stereotactic radiosurgery arm
46082547|NCT02799914|Device|Sinus-Venous stent (Optimed GmbH)|Stent implantation
46082548|NCT00565747|Device|Test culture|A standard culture medium with added GM-CSF (ready-to-use)
46082549|NCT00565747|Device|Control culture|The same standard culture medium, but without any additions (ready-to-use)
45978131|NCT00316836|Procedure|mammography|
45672291|NCT05556161|Behavioral|General Practitioners and Diabetes Specialists Co-management|"Self-monitoring of blood glucose: Participants will monitor blood glucose with a a free intelligent home blood glucose meter. Then, the intelligent blood glucose meter will upload data to the platform.~Glycosylated hemoglobin check: Participants will receive HbA1c test once every three months.~Cooperative General Practitioner-Specialist Management: Based on the remote monitoring of blood glucose and HbA1c tests, general practitioners and specialists will jointly carry out management measures including health education, medication adjustment, outpatient consultation, referral, case discussion, etc. for participants."
45978132|NCT00280514|Drug|cefpirome and moxifloxacin administration|
45831725|NCT04028544|Drug|Placebo|on the basis of standard treatment, adding placebo 1 bag each time, 3 times a day
45978133|NCT00280553|Drug|bupivicaine|PCA and bupivicaine infusion for up to five days
45978134|NCT00280553|Other|Saline infusion|PCA and pump with saline infusion for up to five days
45978135|NCT00310557|Drug|Gadopentetate dimeglumine (Magnevist)|Approximately 0.1mmol/kg body weight, single intravenous administration on the study day
45978136|NCT00280592|Drug|Cranberry|Dry essence of cranberry presented as 18 mg of proanthocyanidines sachets of powdered cranberry. Cranberry juice is administered twice a day (in the morning and in the evening).
45978137|NCT00280592|Drug|Placebo|Placebo presented as sachets of powder. Placebo juice is administered twice a day (in the morning and in the evening).
45978138|NCT00316875|Drug|lapatinib ditosylate|1500 mg orally daily for as long as patients remain on trial (up to 8 cycles).
45978139|NCT00316875|Drug|Doxil|Administered intravenously (IV) every 4 weeks in a dose-escalating fashion according to a set schedule
45978140|NCT00280631|Drug|Ezatiostat Hydrochlorine|Oral Tablets in 2 Divided Doses, Dose Escalation From 200 mg Per Day to 6000 mg Per Day on Days 1-7 of each 21 Day Cycle.
45978141|NCT00316953|Drug|dasatinib|Given orally
46082550|NCT02799836|Device|Blindfold|Study subjects will be blindfolded to create an environment of complete light deprivation which will be worn for 48 hours.
46082551|NCT00935233|Genetic|DNA analysis|
45458691|NCT02320240|Drug|Fluvoxamine|Current exposure to Fluvoxamine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
45458692|NCT02320240|Drug|Paroxetine|Current exposure to Paroxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
45672292|NCT01921101|Behavioral|intensive medical nutrition|provision of participants energy and protein needs via enteral, parenteral nutrition from hospital admission to discharge
45672293|NCT01921101|Other|control|participants will receive standard care for nutrition received from hospital admission to discharge
45672294|NCT05071859|Other|Whole Genome Sequencing|Saliva collection and request for banked blood and tumor samples for sequencing
45672295|NCT05071859|Other|Questionnaire Administration|Study questionnaire will include modules that collect information on maternal reproductive history, exposure to known teratogens, medical history, and previous genetic testing.
45672296|NCT05071859|Other|Biospecimen collection|Saliva collection and request for banked blood and tumor samples for sequencing and biomarker analysis
45831726|NCT04406220|Other|Small clog size|Participants will be randomized to run in small clogs
45831727|NCT04406220|Other|Large clog size|Participants will be randomized to run in large clogs
45831728|NCT04193592|Drug|Pirfenidone|Pirfenidone will be titrated over 14 days, as tolerated, to the full dose of 2403 mg per day, as follows: Days 1 - 7: one capsule TID; Days 8 - 14: two capsules TID; Days 15 to week 52: three capsules TID. Dose may be reduced to manage an adverse event.
45831729|NCT04193670|Other|Clinical examination|This is a classic dermatological clinical examination during a classic consultation
45978142|NCT00316953|Other|pharmacological study|Correlative studies
45978143|NCT00316953|Other|laboratory biomarker analysis|Correlative studies
45978144|NCT00280670|Behavioral|Cognitive-behavioral therapy|Cognitive behavioral therapy for children with autism and anxiety.
45978145|NCT00419172|Drug|Deferasirox|
45978146|NCT00419172|Drug|Rifampicin|
45978147|NCT00280709|Device|"Nitinella ; SX-ELLA Stent Biliary (biliary metal stent)"|Nitinella covered (arm 1) or uncovered (arm 2) biliary metal stent. Maximum diameter 10 mm, length 52 or 72 mm
45978148|NCT00280787|Drug|Paclitaxel|175 mg/m2 administered on Day 1, of a 21 day cycle. Subjects will receive 2 cycles
45978149|NCT00280787|Drug|Carboplatin|Area Under the Curve(AUC)=5 administered on Day 1 of a 21 day cycle. Subjects will receive 2 cycles.
45978150|NCT00280787|Drug|CPT-11|100 mg/m2 administered on Day 1 of each 21 day cycle. Subjects will receive 2 cycles.
45978151|NCT00280787|Drug|Pegfilgrastim|6 mg administered on Day 2 each each 21 day cylce. Subjects will receive 2 cycles of treatment.
45978152|NCT00280787|Radiation|Conformal radiotherapy|Radiation therapy will be administered with standard daily fractionation of 2.0 Gy per fraction, 5 days per week.The total dose of radiotherapy will be 74 Gy
45978153|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,1mmol/kg at 10 mL/15 sec
45978154|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 1 at bolus rate (2mL/sec)
45978155|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,3mmol/kg at 10 mL/15 sec
45978156|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 3 at bolus rate (2mL/sec)
45978157|NCT00310596|Drug|Moxifloxacin (BAY12-8039)|400 mg at 0,07 mL/sec over 60 min
45978158|NCT00310596|Drug|Placebo|0,9% saline at 0,6mL/kg at bolus rate
45978159|NCT00280865|Drug|Tesaglitazar|
45978160|NCT00280865|Drug|Pioglitazone|
45978161|NCT00280865|Behavioral|Dietary and Lifestyle Modification Counseling|
45978162|NCT00310635|Biological|Meningococcal C conjugate vaccine|
45978163|NCT00316992|Drug|Ramelteon and Placebo|Ramelteon 8 mg, tablets, orally, one night only and Ramelteon placebo-matching tablets, orally, one night only.
45978164|NCT00280943|Behavioral|Long-term care facilities in the intervention arm will receive education and feedback audit on performance|
45978165|NCT00317031|Drug|Acamprosate or Naltrexone|mg&d 90 days
45978166|NCT00280982|Biological|tumor lysate-loaded autologous dendritic cells|50x10e6 cells per vaccination, 3 times, 2 weeks interval
45978167|NCT00310674|Biological|Meningococcal C Conjugate Vaccine|
45978168|NCT00281060|Procedure|primary stenting|
45978169|NCT00317070|Drug|dimethyl sulfoxide|intravesical installation 50 ml
45978170|NCT00317070|Drug|IC Cocktail|"Heparin 10,000 units~Gentamicin 80 mg~Hydrocortisone sodium succinate (Solucortef) 100 mg~Lidocaine hydrochloride 1% 10 ml~Sodium Bicarbonate 8.4% 5 ml"
45978171|NCT00317148|Drug|Placebos|Placebo capsule
45978172|NCT00317148|Drug|DHEA capsule|One capsule of DHEA
45978173|NCT00281177|Behavioral|Asthma Disparity Reduction Strategy|
45978174|NCT00310713|Biological|Meningococcal C conjugate vaccine|Group 1: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 3 post immunization) Group 2: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 5 post immunization) Group 3: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 7 post immunization) Group 4: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 9 post immunization) Group 5: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 10 post immunization)
45978175|NCT00310752|Device|DermaStream(tm) application and Streaming of Saline|
45978176|NCT00281255|Drug|Allopurinol|
45978177|NCT00281255|Drug|Dobutamine|
45672297|NCT05071859|Other|Laboratory Biomarker Analysis|Saliva collection and request for banked blood and tumor samples for biomarker analysis
45672298|NCT01586806|Drug|Bupivacaine Only|This is the control treatment arm. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic).
45672299|NCT01586806|Drug|Bupivacaine with 1 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 1 mg of dexamethasone. Total injection volume will be 15 ml.
45672300|NCT01586806|Drug|Bupivacaine with 4 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 4 mg of dexamethasone. Total injection volume will be 15 ml.
45672301|NCT05631041|Drug|Silymarin|participants in silymarin group will receive silymarin 140 mg once daily.
45672302|NCT02144077|Drug|BF-200 ALA|Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
45831730|NCT04193670|Procedure|Biopsies|"2 skin biopsies on a lesion area selected according to the inclusion criteria (2 punchs of 4 mm) for each experimental group.~The first half of whole cutaneous biopsies (n = 25) will be studied using biphotonic microscopy. This will be performed on whole biopsies in 3-D according to the protocol developed in the laboratory.~The second half of whole skin biopsies (n = 25) will be studied using the technique of single-cell RNA seq.~The skin controls skin-free subjects will be obtained from skin reduction surgery (abdominoplasty) to subjects who have agreed to the use of their skin sample."
45831731|NCT04193670|Other|Blood test|A blood test on a tube (2 tubes of 10 mL).An assay of specific IgE and the serum level of IL-4, IL-13 and IL-5 will be carried out by ELISA (Enzyme Linked ImmunoSorbent Assay) from the blood samples.The blood samples will be obtained through the French blood establishment from different donors who have given their consent.
45831732|NCT03964272|Device|Exablate Bilateral Subthalamotomy|Exablate bilateral treatment for Parkinson's Disease Motor Features
45831733|NCT03963102|Drug|Ameluz|Leaving on the gel for 4 hours rather than the standard 3 hours.
45831734|NCT03933384|Drug|Tenofovir alafenamide|Tenofovir alafenamide 25mg/tab once daily
45831735|NCT03933384|Drug|Entecavir|Entecavir 0.5mg/tab once daily
45831736|NCT03599856|Other|TraceBook|TraceBook offers the user intelligent dynamic clinical checklist that shows patient specific items to a specific user while being context aware.
45831737|NCT04193358|Dietary Supplement|FERTILIS HOMME®|L-carnitine 220 mg, Zinc 20 mg, Selenium 0.03 mg, L-arginine 125 mg, L-glutathione 40 mg, Folic acid (vitamin B-9) 0.4 mg, Coenzyme Q10 7.5 mg, and Vitamin E 60 mg
45978178|NCT00317187|Biological|Tritanrix-HepB/Meningitec conjugate vaccine|The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection
45978179|NCT00317187|Biological|Tritanrix/Hiberix vaccine|The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
45978180|NCT00281294|Drug|Fontolizumab|
45978181|NCT00310869|Behavioral|Individualized Developmental Care in the NICU|Newborn Individualized Developmental Care and Assessment Program (NIDCAP) utilizes close observation of each infant's thresholds of moving from organization to disorganization and stress, as exhibited by the infant's behavior. Care and environment are then continuously and dynamically adjusted to increase the infant's self-regulation and organization and decrease the infant's stress. This individualized model of NICU care provides an opportunity to investigate the modifiability of very early born infants' brain function and structure and the possibility of reducing or altogether eliminating the disruption and disturbance of fetal brain development in the NICU.
45672303|NCT02144077|Drug|methyl-aminolevulinate|Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
46082552|NCT00935233|Genetic|polymorphism analysis|
45831738|NCT04193358|Other|PLACEBO|Sugar pills
45831739|NCT04193436|Drug|PF-06835919 25 mg|PF-06835919 in 25 mg oral tablet will be administered on Day 1
45831740|NCT04193748|Drug|Topical pomegranate seeds and peel extracts|Topical pomegranate seeds and peel extracts in the form of gel
45978182|NCT00281333|Behavioral|"Karate exercises and strengthening exercises"|
45978183|NCT00317265|Procedure|Coronary bypass surgery|
45978184|NCT00310908|Drug|Tramadol Hcl|Active Comparator
45978185|NCT00281411|Procedure|Computed Tomography Angiography|Computed Tomography Angiography
45978186|NCT00281411|Procedure|Magnetic Resonance Angiography|Magnetic Resonance Angiography
46082553|NCT00935233|Genetic|protein analysis|
46082554|NCT00935233|Other|laboratory biomarker analysis|
46082555|NCT00935233|Other|questionnaire administration|
46082556|NCT00935233|Other|survey administration|
45458693|NCT02320240|Drug|Sertraline|Current exposure to Sertraline will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
45458694|NCT02320318|Drug|Ibodutant 10 mg|Oral tablet, once daily.
45458695|NCT02320318|Drug|Placebo|Oral tablet (identical in appearance and weight to ibodutant tablet), once daily.
45672304|NCT05545553|Device|Piezosurgery|Piezosurgery used as an osteotomy device
45672305|NCT05545553|Device|Conventional burs|Conventional burs used as an osteotomy device
45672306|NCT05544071|Device|Transcranial Magnetic Stimulation (TMS)|Compare active coil with sham coil.
45831741|NCT04028466|Drug|Vonoprazan|Patients will be randomized to receiving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
45831742|NCT04028466|Drug|Omeprazole|Patients will be randomized to receving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
45978187|NCT00317304|Behavioral|Mindfulness-based stress reduction|MBSR is an 8-week group-based program of training in mindfulness and its application to the stresses and challenges of everyday life
46082557|NCT02794922|Drug|Neurovit Forte|
46082558|NCT02794922|Drug|Corn Starch|
46082559|NCT00935389|Drug|tripterygium glycosides|The onset dosage should be 30mg/q.d. and can be reduced into 20mg b.i.d if CR obtained in 3 months. Without CR in 3 months, the dosage of 90mg/d will last for another 3 months and then reduced to 60mg/d.
45672307|NCT02985892|Other|SSASG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization active stretching group (SSASG) will perform stretch exercises in four sets of 30 seconds for each muscle. The active stretching exercises will last 15 minutes. The muscles that will be stretched are pectorals, latissimus dorsi, latissimus dorsi, teres major, rectus abdominis, external and internal oblique."
45831743|NCT04028154|Procedure|Erector Spinae Plane (ESP) Block|ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
45978188|NCT00281450|Behavioral|Educational intervention|We developed a set of explicit criteria for pharmacological inappropriateness for Norwegian GPs' prescribing to elderly patients. The main purpose of the criteria was to serve as quality indicators during an educational intervention: the Prescription Peer Academic Detailing (Rx-PAD) Study, aimed at improving GPs' prescribing for elderly patients.
45978189|NCT00281489|Device|BIS Monitor guided algorithm|BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.
45978190|NCT00281489|Behavioral|Volatile anesthetic guided algorithm|Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
45978191|NCT00317343|Drug|Bivalirudin (thrombin specific anticoagulant)|Percutaneous Coronary Intervention
45978192|NCT00416858|Drug|cisplatin|
45978193|NCT00416858|Drug|fluorouracil|
45978194|NCT00416858|Procedure|adjuvant therapy|
45978195|NCT00416858|Procedure|conventional surgery|
45978196|NCT00416858|Procedure|neoadjuvant therapy|
45831744|NCT04028154|Procedure|Thoracolumbar interfacial plane (TLIP) Block|TLIP Block: BilateralTLIP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
45978197|NCT00416858|Radiation|radiation therapy|
45978198|NCT02960061|Drug|Neoadjuvant chemotherapy|Eligible patients receive 4 cycles of mDOF(docetaxel 50 mg/ m2 day 1 + oxaliplatin 85 mg/ m2 day 2 + fluorouracil 400 mg/ m2 bolus iv followed by 600 mg/ m2 22 hours chronic infusion, day 2/3 + leucovorin 200 mg/ m2, day2/3; repeated every 14 days ).
45978199|NCT02960061|Procedure|D2 radical resection|Laparotomy or laparoscopic surgery are chosen according to the preference of the surgeon. Either cases, a throughout peritoneal cavity exploration is required to comfirmed the tumor resectability and peritoneal metastasis. A curative D2 resection is performed if achievable.
45978200|NCT02960061|Drug|Hyperthermic intraperitoneal perfusion chemotherapy|Two cycle of hyperthermic intraperitoneal perfusion chemotherapy is administered to patients who have received neoadjuvant chemotherapy and D2 resection, dosage and the relative parameter setting is described above.
45978201|NCT02960061|Drug|Adjuvant chemotherapy|Adjuvant chemotherapy using SOX or XELOX regimen will be administered as routine within 4-6 weeks.
45831745|NCT04028076|Behavioral|Peers Supporting Health-Literacy, Self Efficacy, Advocacy and Adherence|An 8-week culturally appropriate educational behavioral intervention that consists of structured group diabetes education and follow-up peer support with PAs. There will be 3 separate group education sessions led by a physician, AA pharmacist and AA diabetes educator. All PAs will attend each group session to learn together with their PBs and build social interactions. Weeks 1 and 2 consist of 2-hour group education between the participants and diabetes educator, and participants and pharmacist, respectively. Pre-test intervention data including A1c will be collected in Week 1. In Weeks 3-7, PAs will deliver the intervention content to PBs over the phone as well as help them set a goal towards getting healthy. An existing video/text messaging app, called WhatsApp® will be offered as an option to use to further enhance PA-PB interaction.
45978202|NCT00416897|Drug|chemotherapy|
45978203|NCT00416897|Drug|dexamethasone|
46082560|NCT02715882|Drug|CBLB502|
46082561|NCT02715882|Drug|Placebo|
45831746|NCT04027764|Drug|Toripalimab Combined With S1 and Albumin Paclitaxel|Toripalimab 240 mg ，every 2-3 weeks S1：80-120mg，bid；oral，d1-14； Albumin Paclitaxel：120mg/m2，D 1 \8
45831747|NCT04027842|Device|Prewarming|In the operating theater, participants allocated in Prewarming group received 10 min-prewarming, which is cutaneous warming before induction of anesthesia. For prewarming, forced air warming system (WarmTouch WT 6000 Warming Unit, Medtronic, Minneapolis, MN, USA) was used and the warming temperature of the device was set to 45°C.
45978204|NCT00416897|Procedure|plasmapheresis|
45978205|NCT00317382|Device|Ultrasound|Ultrasound used to visualize spine to determine best location for lumbar puncture.
45978206|NCT00310986|Behavioral|Breathing Meditation|
45978207|NCT00416975|Other|counseling intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
46082562|NCT02801552|Device|PRF|Regenerative Endodontic Procedure with PRF: autologous PRF will be used instead of blood clot in the second vist.
46082563|NCT00935467|Drug|Saxagliptin|Tablets, oral, 2.5 mg, twice daily, 7 days
46082564|NCT02719548|Device|Soft edge oval - Hard oval - Modified PF breast shield|"Treatment order:~soft-edge oval breast shield~Hard oval breast shield~modified PersonalFit breast shield"
46082565|NCT02719548|Device|Modified PF breast shield - Soft edge oval - Hard oval|"modified PersonalFit breast shield~soft-edge oval breast shield~Hard oval breast shield"
46082566|NCT02719548|Device|Hard oval - Soft edge oval - Modified PF breast shield|"Hard oval breast shield~soft-edge oval breast shield~modified PersonalFit breast shield"
46082567|NCT00935545|Biological|Montanide|Montanide is an oil-based immunoadjuvant similar to Incomplete Freund´s Adjuvant, which is commonly used in combination with peptide vaccines. Although its precise mode of action is not known, it acts to enhance the immune response to vaccination. It has a depot effect that depending on the type of emulsion will release the antigen slowly from the injection site.
45458696|NCT03492736|Dietary Supplement|Melatonin|30 days 10mg Melatonin taken nightly 1 hour before bed
45458697|NCT03492736|Other|Placebo|30 days placebo taken nightly 1 hour before bed
45458698|NCT02320474|Drug|Aflibercept|
45672308|NCT02985892|Other|SSPSG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization placebo stretching group (SSPSG) will perform exercises that simulate stretching, but the muscles will not suffer effective stretch. The placebo stretching exercises will last 15 minutes. The muscles that will be stretched are wrist flexors and extensors muscles and fingers flexors and extensors muscles."
45672309|NCT04544956|Drug|GSK3228836|GSK3228836 will be available as a clear colorless to slightly yellow solution for injection in 150 mg/milliliters (mL) vial to be administered SC once weekly.
45672310|NCT04544956|Drug|Nucleos(t)ide therapy|Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleos(t)ide therapy for the duration of the study.
45831748|NCT04192890|Device|Focal irreversible electroporation of the prostate cancer|Irreversible electroporation is a non-thermal tissue ablation technique in which short duration electrical fields are used to permanently permeabilize the cell membrane.
45831749|NCT03592602|Procedure|arm abduction and adduction|All PICC lines will be placed under the guidance of intravascular ECG. Before the PICC placement procedure, basal ECG will be examed. During the procedure, intravascular ECG data will be collected with the punctured arm adduction and abduction while the catheter advances to the cavoatrial junction. After the procedure, chest X-ray radiographs will be taken with arms 90° abducted and adducted (i.e., 0°abducted) in a supine position.
45831750|NCT03884712|Device|CalmiGo|The CalmiGo handheld device is a device of similar size to an inhaler that uses guided breathing, aromatherapy and grounding techniques to regulate breathing to bring users a sense of calm and relaxation. The CalmiGo handheld device is being tested in this study to alleviate participants' anxiety and panic attack symptoms.
45831751|NCT04027530|Drug|Ertugliflozin 15 mg|Once daily treatment with oral ertugliflozin 15mg for 4 consecutive weeks
45831752|NCT04027374|Procedure|Fetal surgery for MMC repair|Fetal surgery for MMC repair
45831753|NCT03023358|Drug|chidamide|30mg po twice a week
45831754|NCT03023358|Drug|cyclophosphamide|750mg/m2 iv on day 1
45831755|NCT03023358|Drug|liposomal doxorubicin|30mg/m2 iv on day 1
45831756|NCT03023358|Drug|vincristine|1.4mg/m2 iv on day 1
45831757|NCT03023358|Drug|prednisone|100mg/d po on day 1-5
45831758|NCT03023280|Procedure|Radiofrequency ablation|
45831759|NCT04192812|Drug|PREOPERATİVE GnRHa THERAPY (LEUPROLIDE ACETATE) BEFORE SURGERY FOR UTERİN FIBROIDS|THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
45831760|NCT04192812|Drug|NO GnRHa|THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
45831761|NCT04192578|Device|remote ischemic conditioning|RIC is induced by short-term insulting blood-flow of nonvital distant organs intermittently.
45831762|NCT04407000|Drug|Test: Favipiravir 200 mg (LOQULAR)|Test Drug
45831763|NCT04407000|Drug|Reference: Favipiravir 200 mg (Avigan)|Reference Drug
45831764|NCT04192422|Other|no intervention|This is a cohort study no intervention
45831765|NCT04192656|Device|non-invasive positive airway pressure|non-invasive positive airway pressure is the first-line treatment for obstructive sleep apnea
45831766|NCT04192656|Drug|Methylprednisolone Hemisuccinate|Methylprednisolone is the first-line treatment of idiopathic sudden sensorineural hearing loss
45831767|NCT04192656|Drug|Ginaton|ginnaton is ginkgo biloba extract
45831768|NCT04191954|Drug|Fasudil eye drops (concentration 0.5 percent)|receive Fasudil eye drops (concentration 0.5 percent) twice daily
45831769|NCT04191954|Drug|receive artificial tears drop|receive artificial tears drop with the same frequency
45831770|NCT04192032|Other|Preferred Juul pod flavor (5% nicotine)|Preferred Juul pod flavor (5% nicotine)
45831771|NCT04192032|Other|Classic Tobacco Juul pod flavor (5% nicotine)|Classic Tobacco Juul pod flavor (5% nicotine)
45831772|NCT04192032|Other|Preferred flavor with HWL|Preferred flavor (5% nicotine) with HWL
45831773|NCT04192032|Other|Preferred flavor, 3% nicotine|Preferred flavor, 3% nicotine
45831774|NCT04192032|Other|Preferred flavor, 0% nicotine|Preferred flavor, 0% nicotine
45831775|NCT04027062|Behavioral|Diabetes Continuing Education Intervention|"The program will follow the International Curriculum for Diabetes Health Professional Education, which developed by the International Diabetes Federation (IFD) The key components of the proposed program content are Diabetes presentation and complications, Lifestyle, Nutrition, and Fitness.~the intervention will be carried out by group of Diabetes educators from a different discipline, such as an Endocrinologist, Family physician, the dietitian will teach the attended physicians."
45831776|NCT04406454|Device|ApolloVue® S100 Image System|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 3 quality OCT images of B-scan (cross-section) and E-scan (en face) with 4 depths for each skin site respectively for each skin site. There is a total of 6 skin sites.
45831777|NCT04026828|Genetic|Periodontitis Group|Periodontitis group consists of both chronic and aggressive periodontitis patients
45831778|NCT04026516|Device|CAVA Device|The CAVA device will be worn continuously for thirty days, during which time it will record eye and head movements
45831779|NCT04191408|Procedure|PEEP increase|PEEP increase +5 to +15 cmH2O. PLR at 30 degrees.
45831780|NCT04191564|Procedure|low perfusion state|reduce SAP below 100 mmHg
45831781|NCT04191564|Procedure|normal perfusion state|maintain SAP above 100 mmHg
46082568|NCT02799992|Procedure|689 nm Laser Treatment of the Macula|
45978208|NCT00416975|Other|educational intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
45978209|NCT00416975|Procedure|evaluation of cancer risk factors|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
45978210|NCT00311025|Procedure|intensive endurance, strength and balance exercises|
45978211|NCT00417014|Drug|chlorambucil|
45978212|NCT00417014|Drug|prednisolone|
45978213|NCT00417014|Drug|procarbazine hydrochloride|
45978214|NCT00417014|Drug|vinblastine sulfate|
45978215|NCT00417014|Radiation|radiation therapy|
45978216|NCT00317421|Drug|Sildenafil citrate|
45978217|NCT00417053|Biological|filgrastim|
45978218|NCT00417053|Drug|busulfan|
45978219|NCT00417053|Drug|carboplatin|
45978220|NCT00417053|Drug|cyclophosphamide|
45978221|NCT00417053|Drug|doxorubicin hydrochloride|
45978222|NCT00417053|Drug|etoposide phosphate|
45672311|NCT02172625|Dietary Supplement|Protandim Dietary Supplement|This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of Protandim for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
45672312|NCT02172625|Other|Placebo Group|This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of corn starch for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
45831782|NCT04195620|Other|High self-disclosure|"The high self-disclosure condition involves individuals asking and answering a series of questions that are more personal in nature and involve sharing or receiving information that is likely to be emotionally laden and information that is not readily shared in typical conversations. An example of a question from this condition includes If you were to die today without the chance to speak with anyone, what would you most regret not having said to someone? Why haven't you said it yet?"
45831783|NCT04195620|Other|Low self-disclosure|"The low self-disclosure condition involves individuals asking and answering a series of questions that are not personal in nature and involve sharing or receiving information that is shared in very casual conversations. An example of a question from this condition includes What did you do to celebrate Halloween last year?"
45831784|NCT04191018|Diagnostic Test|Liver elastography|Liver stiffness measurement
45831785|NCT04191018|Diagnostic Test|Splenic elastography|Splenic stiffness measurement
45831786|NCT04191018|Diagnostic Test|Gastrointestinal endoscopy|Gastrointestinal endoscopy
45831787|NCT03023982|Drug|Bupivacaine Hydrochloride|40 cc 0.25% of Bupivacaine Hydrochloride injection using ultrasound approach will be administered between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib
45831788|NCT03023982|Device|Ultrasound|All blocks will be done under ultrasound
45978223|NCT00417053|Drug|melphalan|
45978224|NCT00417053|Drug|vincristine sulfate|
45978225|NCT00417053|Procedure|autologous bone marrow transplantation|
45978226|NCT00417053|Procedure|bone marrow ablation with stem cell support|
45978227|NCT00417053|Procedure|conventional surgery|
45978228|NCT00417053|Procedure|peripheral blood stem cell transplantation|
45978229|NCT00417053|Radiation|radiation therapy|
45978230|NCT00317460|Other|Physician Management|Standard physician care
45978231|NCT00317460|Behavioral|Counseling|Physician Management and Counseling
45978232|NCT00311064|Behavioral|physical activity|
45978233|NCT00281567|Drug|Tiotropium|
45978234|NCT00281567|Device|Respimat SMI|
45978235|NCT00281567|Device|HandiHaler|
45978236|NCT00317499|Other|Placebo|Placebo
45978237|NCT00317499|Drug|Etanercept|Etanercept
45978238|NCT00281606|Drug|Different formulations of once-daily lopinavir/ritonavir|CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules
46082569|NCT02799992|Procedure|Half Dose Photodynamic Therapy|
46082570|NCT02724306|Behavioral|Active Lifestyle Programme|
45672313|NCT05618171|Diagnostic Test|Evaluation of the patient's pre- and post-treatment risk profile using the peri-implantitis risk diagram|"By using IDRA, a tool specially developed for patients who have had dental implants in our clinic, patients will be evaluated as low-moderate-high risk in terms of the risk of developing peri-implantitis, according to their initial status. Again, these patients will be re-evaluated 1 year after applying Phase I treatment using the IDRA tool. During this whole process, clinical and radiographic evaluations will be carried out simultaneously."
45672314|NCT04410016|Other|Staff Wellbeing Centres|2 Centres (rooms) accessible to staff for rest and relaxation, work breaks, supports advice and signposting. They are manned by support workers called Wellbeing Buddies.
45672315|NCT05425433|Other|Tailored serial casting intercention|Every participant will undergo 1 week of usual care for the affected joint according to the OT's prescription (static progressive, dynamic or serial static) combined with stretching, moisturizers, pressure therapy, or thermal modalities. After the one week of splinting, if the PROM of the targeted joint does not improve, the participant will start serial casting (Monday to Friday). Patients will have a cast applied on Monday morning and worn for 24hrs/day or for 48hrs according to the OTs and treating physician's decision (rationale documented).The OT will decide how many weeks the participant will be wearing casts and the rationale to stop this treatment will be documented. When the treatment is stopped, patients will be encouraged to wear a maintenance splint for the following 2 weeks.
45672316|NCT02985970|Other|questionnaire|The questionnaire will be send to all members of ČSARIM with the selected 4 controversial clinical scenarios in which the RSI should be used
45672317|NCT04115254|Radiation|MR-guided Linac|Radiation will be delivered on an MR-guided Linear Accelerator
45672318|NCT02143843|Drug|Bimatoprost|Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new Bimatoprost Ocular Insert and used continuously for another 6 months.
45672319|NCT05598905|Drug|Pregabalin 150mg|one capsule of 150mg 90 minutes after 10mg of oxycodone
45831789|NCT03023982|Procedure|Thoracotomy|The patient population will include patients that undergo either open thoracotomy or thoracoscopy for anatomic and non-anatomic lung resection. The standard thoracoscopy approach in our institute includes three holes technic. There are two incisions of 1 cm and utility incision of 4 cm. The standard thoracotomy is posterior- lateral thoracotomy which divided the latissimus dorsi muscle but spears the serratus anterior muscle.
45831790|NCT03023982|Drug|Opioids|standard pain control with opioids
45831791|NCT03023982|Drug|NSAID|standard pain control with NSAIDs
45831792|NCT04191252|Diagnostic Test|A multi-gene panel testing|A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis
45831793|NCT03951870|Behavioral|Neuromodulation via fMRI Neurofeedback task|Two active neurofeedback groups will practice to up regulate their designated neural targets via identical experimental protocol (varying only the origin of the feedback).
45831794|NCT03951870|Biological|Hepatitis B vaccination|Subjects will be vaccinated against Hepatitis B
45831795|NCT04026360|Other|no intervention|
45831796|NCT04192110|Drug|Diuretic initiation or augmentation|The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed
45831797|NCT04025736|Drug|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|Tranexamic acid (TXA) is a synthetic analog of the amino acid lysine which acts by competitively blocking the plasminogen lysine-binding site and inhibiting fibrinolysis. Several studies showed that TXA could reduce both blood loss and the amount of blood transfusion after shoulder arthroplasty surgeries.
45831798|NCT04025736|Drug|0.9% Sodium Chloride Injection|Normal saline is a mixture of sodium chloride in water and has a number of uses in medicine. We use the same volume of normal saline as placebo.
45831799|NCT04766112|Other|Group I|Group I will receive yang style Tai chi exercises combined with mental imagery training
45831800|NCT04766112|Other|Group II|Group II will receive yang style Tai chi exercise which consist of 10 positions.
45831801|NCT04190940|Behavioral|Behavioral Assessment|"Patients will be asked to complete the behavioral assessment before and after their HIFU treatment or on and off their DBS treatment."
45831802|NCT04195230|Behavioral|Multi-tasking Training|Participants will undergo training protocol where they will have, concomitantly, to cook different meals and set the table under different instructions, rules and difficulty level.
45831803|NCT04199598|Drug|Abediterol (2.4 μg)|2.4 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
45831804|NCT04199598|Drug|Abediterol (4.8 μg)|4.8 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
45831805|NCT04199598|Drug|Abediterol (2.4 μg)|2.4 μg (delivered dose) abediterol via OMRON NE-C900-E nebuliser
45831806|NCT04199598|Drug|Abediterol (2.5 μg)|2.5 μg (nominal dose) abediterol via DPI, reference
45831807|NCT04190784|Other|Stretching exercises|Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
45831808|NCT04190784|Other|Placebo stretching|The therapist maintains the same manual contact without stretching force.
45831809|NCT03023748|Drug|Intravenous Paricalcitol|Twenty four months of intravenous paricalcitol will be given twice or thrice weekly post-hemodialysis depending on frequency of hemodialysis of the patients
45831810|NCT04190316|Other|Evaluation of fecal RA and environmental contamination of ESBL-PE carrier in ICU|ESBL-PE carriers included in the study will be sampled for evaluation of their fecal RA of ESBL-PE on day 0, 3, 5, 7, 10, 14 and weekly till day 30 or their discharge from ICU. Urine and respiratory samples will be collected on the same day to identify multiple-site colonization with ESBL-PE. Seven samples of patient care environment will be performed 2-times a week till day 30 or discharge of the patient from the ICU.
45831811|NCT04190160|Drug|IDegLira|A single administration of IDegLira, dose depending on glicaemic control, in place of any pre-existing hipoglycaemic therapeutic scheme
45831812|NCT04190004|Drug|Vasopressins|40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
45672320|NCT05598905|Drug|Oxycodone 10mg|one 10mg tablet
45672321|NCT05598905|Drug|Lacosamide 150 mg|one capsule of 150mg 90 minutes after 10mg of oxycodone
45672322|NCT02121535|Drug|T80/A5 mg FDC tablet|
45978239|NCT00311103|Procedure|Specific clinical care program|The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
45978240|NCT02960789|Other|Formalized clinical assessment of hydration status|Undertake and record a standard formalized clinical hydration assessment
45978241|NCT02960789|Other|Take a measurement of body weight on calibrated scales|Standard body weight measurements conducted on calibrated scales
45978242|NCT02960789|Device|"RF wristband hydration status measurement"|"Take measurements with RF wristband radio-frequency non-invasive wrist-based hydration status assessment device"
45978243|NCT02960789|Other|Measure capillary refill time with manual stopwatch|A standard visual assessment of capillary refill time, aided by the use of a stopwatch
45978244|NCT02960789|Device|"CRT device hydration status measurement"|"Take measurements with CRT device for non-invasively quantitatively assessing Capillary Refill Time"
45978245|NCT00317538|Drug|infliximab, etanercept|
45978246|NCT00281645|Drug|Bicifadine|
45978247|NCT00281645|Drug|Standard of Care (pharmacological analgesic treatment)|
45672323|NCT02121535|Drug|T80/A5 mg FDC tablet|A Telmisartan 80 mg/ Amlodipine 5 mg FDC tablet
45672324|NCT02121535|Drug|H12.5 mg tablet|
45672325|NCT02121535|Drug|T80/A5/H12.5 ng FDC tablet|A Telmisartan 80 mg/Amlodipine 5 mg/HCTZ 12.5 mg FDC tablet
45672326|NCT02121535|Drug|H12.5 mf tablet|A HCTZ 12.5 mg tablet
45672327|NCT02121535|Drug|T80/A5/H12.5 mg FDC tablet|
45672328|NCT05535959|Drug|VX-121/TEZ/D-IVA|FDC tablet for oral administration.
45672329|NCT01586338|Drug|Hylan G-F 20|Intra-articular injection (pre-filled glass syringe)
45831813|NCT04190004|Drug|Placebo|40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
45831814|NCT03961620|Device|The SpotOn system that encompasses the registration unit (3M SpotOn Control Unit), disposable sensor (3M SpotOn Control Sensor) along with the cords and electric power unit.|Patients submitted to major surgical procedure will be assessed for core body temperature by employing SpotOn sensor device, before, during and after surgical procedure.
45831815|NCT04406298|Procedure|small quantity paracentesis|Intermittent small quantity paracentesis (upto 3L/day) for upto 5 days
45831816|NCT04406298|Procedure|Large Volume Paracentesis|Large Volume Paracentesis > 5litres
45978248|NCT00281723|Drug|Pro-Pe adhesive tablet|
45978249|NCT00317577|Drug|brimonidine, timolol|
45978250|NCT00417092|Procedure|Postoperative Pacing|
45978251|NCT00281762|Drug|NSAID|
45978252|NCT00317655|Drug|Glucosamine sulphate|
45672330|NCT05528159|Procedure|Intraabdominal CO2 insufllation|Patients will receive intraabdominal CO2 insufflation and will be operated under trendelenburg position
45978253|NCT00317655|Drug|Ginger|
45978254|NCT00317655|Drug|Ginger-Avocado-Soya|
45978255|NCT00317655|Drug|Ginger-ibuprofen|
45978256|NCT00281801|Procedure|psychosocial assessment and care|psychosocial assessment and care
45978257|NCT00281801|Procedure|Quality of Life Assessments|PACT Scale, Brief COPE, POMS Short Form and FACT BMT
45978258|NCT00311220|Drug|tuberculin for skin test|
45978259|NCT00281996|Drug|Gemcitabine|Administered intravenously over 30 minutes on days 1 and 8 of a 21-day cycle starting at a dose of 700 mg/m2 and increasing to 1000mg/m2 by cohorts
45978260|NCT00281996|Drug|Imatinib mesylate|Administered orally once daily with 8 ounces of water at a starting dose of 300 mg/day and increased to 600 mg/day according to cohort.
45978261|NCT00311259|Drug|Melatonin (drug)|
45978262|NCT00311259|Drug|Laktose|
45978263|NCT00282035|Radiation|APBI utilizing 3D-CRT radiation|Accelerated partial breast irradiation utilizing 3D-CRT
45978264|NCT00282035|Radiation|Whole breast irradiation|Whole breast irradiation
45978265|NCT00282074|Procedure|laparoscopic bilateral hernia repair|
45978266|NCT00317733|Drug|Ketoprofen in Transfersome|
46082571|NCT00935623|Biological|Malaria Challenge|Malaria challenge
46082572|NCT02715570|Drug|PC945 - single doses|Safety and tolerability of single doses
46082573|NCT02715570|Drug|Placebo - single doses|Safety and tolerability of single doses
45978267|NCT00311298|Dietary Supplement|Multimicronutrients|Randomised, double-blind trial among pulmonary TB patients, except those who are found to be sputum positive and HIV positive. Both arms received a daily biscuit weighing 30 g (4.5 g protein, 615 kJ). The biscuit given to the No micronutrient-arm contained no additional micronutrients. The biscuit given to the Micronutrient-arm contained the following micronutrients: vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg. The intervention was given for 60 days during initial TB treatment.
45978268|NCT00311298|Dietary Supplement|Energy and proteins|Randomised, single-blind trial among sputum-positive HIV-coinfected pulmonary TB patients. Both arms received a daily for biscuit weighing 30 g (4.5 g protein, 615 kJ), with micronutrients (vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg). The experimental arm received an additional 5 biscuits without additional micronutrients. Thus, both arms received the same amount of micronutrients. However, the intervention arm received 3690 kJ and 27 g protein per day, while the control arm received 615 kJ and 4.5 g protein. The intervention was given for 60 days during initial TB treatment.
45978269|NCT00282230|Drug|FK778|
45978270|NCT00311337|Drug|bortezomib|
45978271|NCT00282269|Procedure|Induced Hypothermia|Induced Hypothermia within 6 hours of injury and maintained for a minimum of 72 hours
45978272|NCT00317811|Dietary Supplement|ascorbic acid|
45978273|NCT00317811|Drug|bortezomib|
45978274|NCT00317811|Drug|melphalan|
45978275|NCT00282386|Drug|MK0966; Rofecoxib / Duration of Treatment: 156 weeks|
45978276|NCT00282386|Drug|Placebo/ Duration of Treatment: 156 weeks|
45978277|NCT00282425|Biological|Hematopoietic stem cell transplantation|Allogeneic Hematopoietic stem cell transplantation
45978278|NCT00317850|Drug|Gabapentin (Neurontin)|
45978279|NCT00282503|Drug|Methoxsalen+ECP, Methylprednisolone|"Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:~Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),~Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days within a week, but there should never be > 4 days between the ECP treatments within a week.)~Methylprednisolone will be started at 2mg/kg daily dose and may be tapered by reducing dose each week at the following reductions:~Daily Dose (mg/kg)~1 1.5 2 1.0 3 0.70 4 0.50 5 0.40 6 0.30 7 0.20 8 0.10"
45672331|NCT02143141|Drug|duramorph|duramorph 150 mcg given with spinal anesthetic, then receipt of placebo capsules postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
45672332|NCT02143141|Drug|placebo|placebo in an equal volume to that of duramorph 150 mcg given with spinal anesthetic, then receipt of oral acetaminophen 1000mg during first 24 hours postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
45672333|NCT04816708|Behavioral|LIFT Mindfulness|Mindfulness is a type of mind-body therapy that promotes a practice of non-judgmental awareness that can alleviate distress by uncoupling emotional reactions and habitual behavior from unpleasant symptoms, thoughts, and emotions. LIFT is a mobile mindfulness app which can assess levels of emotional distress via survey, and subsequently offer mindfulness content that has previously been used in ICU patients, where it was shown to reduce symptoms of depression, anxiety, and PTSD.
45978280|NCT00282503|Procedure|Ecp|ECP or Extra Corporeal Phototherapy will be used with UVADex
45978281|NCT00311415|Biological|Meningococcal C conjugate vaccine|"Meningococcal conjugate vaccine, active comparator.~Groups 1 to 3 were given a booster dose in the second year of life at 12-16 months of age"
45978282|NCT00317889|Procedure|Bone preparation technique: compaction|
45978283|NCT00317889|Procedure|Bone preparation technique: broaching|
46082574|NCT02715570|Drug|PC945 - repeat doses|Safety and tolerability of repeat doses
45672334|NCT05520047|Behavioral|COVID19-severe Patient|Behavioral and social test assessment
45672335|NCT05520047|Behavioral|family of COVID19-severe Patient|Behavioral and social test assessment
45672336|NCT05500469|Device|Paul glaucoma drainage device (GDD)|Implantation of the GDD
45672337|NCT02171065|Device|sham|
45831817|NCT03949764|Drug|Sofosbuvir/velpatasvir (Epclusa®)|The protocol is intended to follow best practices/standard of care for the treatment of HCV, with additional allowances for the investigators to apply rigorous scientific practices for the research aspects of the study. While the treatment of HCV is fairly straightforward, less is known about treating active drug users and RNA-positive individuals in rural areas. We propose eight visits, including intake, four treatment-related visits, and three visits to determine re-infection (6- and 12-months post-SVR). Because determination of medication adherence and long-term reinfection rates are not part of standard clinical practice, the rural protocol developed at the conclusion of KeY Treat will be streamlined based on findings, consisting of five or fewer clinical contacts. The drug used for treatment is Epclusa®, a 12-week, once per day, pan-genotypic DAA with a favorable side effect profile. Vosevi® will also be available in cases where participants are non-responsive or are re-infected.
45978284|NCT00282542|Procedure|Hepatocyte Infusion|
45978285|NCT00311454|Drug|T.R.U.E.Test|
45978286|NCT00282581|Biological|MVA Smallpox Vaccine|0.5mL of MVA3000 Smallpox Vaccine, 2 doses, separated by 28 days.
45978287|NCT00317928|Drug|Metformin|
45978288|NCT00282620|Drug|Magnesium L-lactate|
45978289|NCT00282659|Drug|magnesium L-lactate|
45978290|NCT00311493|Biological|Tick-Borne Encephalitis vaccine|
46082575|NCT02715570|Drug|Placebo - repeat doses|Safety and tolerability of repeat doses
46082576|NCT02801474|Procedure|direct fracture reduction and fixation|In the DR group, the posterior malleolar fracture was reduced and fixed in a direct way via a posterolateral approach with the patients in prone position.
46082577|NCT02801474|Procedure|indirect fracture reduction and fixation|In the IR group, the posterior malleolus was reduced through ligamentotaxis following open reduction and internal fixation of lateral and medial malleolar fractures. Percutaneous cannulated screws were used to fix the posterior malleolar in anterior-to-posterior direction.
45831818|NCT04025892|Behavioral|Daily weighing|Participants will be asked to use the scale to track their body weight daily at home for six weeks. They will receive a weekly email contact with weight change feedback and either a nutrition or physical activity tip for the week. The study procedures represent minimal risks, and participants will be reminded and encouraged to maintain their regular prenatal care contacts with their provider.
45978291|NCT00282698|Drug|Insulin infusion with a goal|
45978292|NCT00317967|Drug|Atorvastatin|80 mg pills daily
45978293|NCT00317967|Drug|Placebo|80 mg pills daily
45978294|NCT00318006|Procedure|saline irrigation|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
45978295|NCT00318006|Procedure|saline spray|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
45978296|NCT00282776|Behavioral|Care Management for Postpartum Depression|Depression Care Manager calls postpartum women and encourages women to seek appropriate depression care. In this context the depression care manager helps the women to identify barriers to appropriate care, her preferred method of care, and resources available. Calls are made initially at 2 calls per month, followed by one call per month and calls every other month for women who are doing well. Women assigned to this group receive research assessments at 3, 6, and 12 months postpartum. They also receive information about community and health plan resources available for women with depression.
45978297|NCT00282776|Behavioral|TAU|Participants receive treatment as usual for postpartum depression. Women assigned to this arm receive research assessments at 3, 6, and 12 months postpartum. At the baseline home visit where diagnostic assessments are completed women are given information about community and health plan resources if they choose to seek care for depression symptoms. Women are also given phone contact numbers for the research program.
45831819|NCT04406376|Drug|Prednisone tablet|Treatment of Bell's Palsy with prednisone, with or without tapering down.
45831820|NCT04025268|Behavioral|Group Prenatal Care (GPNC)|GPNC participants will attend 11 group sessions total: 10 during pregnancy and one postpartum. Each session will be 90-100 minutes long. Groups will collectively identify the preferred time of day for these sessions. Groups of 10 women will be led by a locally trained, Samoan nurse-midwife with the study Project Director as a co-facilitator. At each of the visits participants will engage in self-assessments of weight and blood pressure, including learning to take their blood pressure with a digital cuff, calculating BMI, and plotting their weight gain on a graph), receive short individual clinical examinations from a midwife, and participate in group discussions about prenatal care, childbirth preparation, and their postpartum care. The session at 6-weeks postpartum will allow women to introduce their babies to the group and share childbirth stories.
45831821|NCT04025268|Behavioral|Standard of Care|Standard of prenatal care
45978298|NCT00318045|Device|Eyeglass lenses|
45978299|NCT00311571|Drug|Ethidronate|
45978300|NCT00311571|Behavioral|Physical training|
45672338|NCT02171065|Device|ABSORB BVS|
45672339|NCT05581745|Procedure|Blood group A2 donor to blood group O recipient lung transplant surgery|Suitable blood group A2 donor lung transplant to a consented blood group O recipient who has acceptably low levels of anti-A antibody titres and a negative virtual cross-match at time of transplant
45672340|NCT05036525|Device|HANBIO BarriGel|an anti-adhesive product
45978301|NCT00282893|Procedure|transluminal ballooning|
45978302|NCT00282893|Other|currently existing therapies for the treatment of vasospasm|
45672341|NCT05033561|Biological|nOPV2|Novel Oral Poliomyelitis Type 2 Vaccine
45672342|NCT01566604|Drug|NVA237|Delivered via a single dose dry powder inhaler
45978303|NCT00318084|Drug|Esomeprazole|
45978304|NCT00318084|Procedure|Ambulatory 24-hour esophageal pH-monitoring|
45978305|NCT00282932|Drug|Detrol LA|
45978306|NCT00318123|Drug|Kivexa|abacavir 600mg + lamivudine 300mg in one tablet QD
45672343|NCT01566604|Drug|Placebo|Delivered via a single dose dry powder inhaler
45672344|NCT05497583|Other|Acetone based HEMA -free universal Adhesive|Teeth that meet the inclusion criteria will be selected. the operator will prepare incisal bevel. Rubber dam isolation will be used .apply etchant (phosphoric acid etching gel 37 %) only on enamel for 15 s Rinse, for 10 s Air dry to remove excess water then will apply Universal adhesive to the entire bonding surface according to manufacture instructions. Bioactive composite ( beautifill II ) will be used.
45672345|NCT05497583|Other|Isopropanol based HEMA- free universal Adhesive|Teeth that meet the inclusion criteria will be selected. the operator will prepare incisal bevel. Rubber dam isolation will be used .apply etchant (phosphoric acid etching gel 37 %) only on enamel for 15 s Rinse, for 10 s Air dry to remove excess water then will apply Universal adhesive to the entire bonding surface according to manufacture instructions. resin composite (Neo Spectra™ ST) will be used.
45831822|NCT04025346|Other|Capsimax|1 capsule to be taken before breakfast.
45831823|NCT04025346|Other|Micro Crystalline Cellulose|1 capsule to be taken before breakfast.
45978307|NCT00318162|Drug|low dose naltrexone|
45978308|NCT00283088|Procedure|hypothermia|"Hypothermia with or without tPA for stroke. Hypothermia is induced using the Celsius Control™ System.~Subjects are stratified by time to six groups."
45978309|NCT00283088|Drug|tissue plasminogen activator|tPA is a naturally occurring protein that opens blocked arteries by dissolving blood clots
45978310|NCT00311610|Drug|SN-38 liposome|38 mg/sq m IV infusion over 30 min q 21 days (1 cycle) until progression
45978311|NCT00283127|Procedure|Home sampling (urine test) for uro-genital C.trachomatis.|
45978312|NCT00318201|Drug|Erythromycin|
45978313|NCT00318201|Drug|Diltiazem|
45978314|NCT00283166|Behavioral|Tailored Education and Coaching|A: Patients receive one-on-one counseling and education about pain management and improving doctor-patient communication B: Patients receive booklet on cancer pain control
45978315|NCT00311649|Biological|Inactivated Influenza A Vaccine A/H5N1|
45978316|NCT00283205|Behavioral|Yoga|
45978317|NCT00318240|Device|High Intensity Focused Ultrasound|Treatment of Radiation failure in Prostate Cancer
45978318|NCT04708652|Other|No intervention|No intervention
45978319|NCT00311688|Drug|Interleukin-2|Biological response modifier in liquid form; dosage of drug will vary by study
45978320|NCT02960750|Behavioral|"A workplace sit less and move more web-based program for Spanish office employees"|W@WS encourages office employees to progressively 'sit less and move more' during workdays over 19 weeks. During the first 8 weeks (ramping phase), tips are provided every two weeks to break occupational sitting time through incidental movement during work tasks, introduce short walks (5-10 minutes) during morning/afternoon work breaks and/or commuting time, introduce longer walks at lunchtime and achieve at least 10,000 daily steps as well as increase walking intensity. During weeks 9 to 19, W@WS provides automated guidance with periodic emails encouraging behaviors achieved in the previous phase. Ecological support strategies such as logging daily step counts into a personal account and receiving visual feedback on the achievement of goals are also provided
45978321|NCT02960750|Behavioral|Active Comparison group|The Active Comparison group maintained habitual behavior. The A-CG was given a pedometer and a paper diary to register daily step counts and self-reported sitting time throughout the intervention.
45978322|NCT00283322|Other|blood samples (2)|Two blood samples were obtained from patients and tested for heparin antibodies.
45978323|NCT00318279|Device|Surgical simulator to practice vascular anastomosis|
45978324|NCT00283361|Drug|ZP120|
45978325|NCT00283361|Procedure|I.v. catherization|
45978326|NCT00283361|Procedure|6-minutes walk performance|
45978327|NCT00283361|Behavioral|Dyspnea severity assessment|
45978328|NCT00283361|Procedure|Blood sampling for laboratory tests|
45978329|NCT00283361|Procedure|ECG|
45978330|NCT00283361|Procedure|Physical examination|
45672346|NCT05492513|Behavioral|Grade 1 CI Therapy +Sensory Components|All participants will receive Grade 1 CI Therapy + Sensory Components over a two-week period of time. The treatment intervention will include all CI Therapy treatment strategies including: 1) supervised motor training in the form of shaping with repeated trials and task practice for 3.5 hours per day for 5 weekdays for 2 weeks 2) a behavioral Transfer Package (TP) will be employed to aid carry-over of skills gained by the participant in the laboratory to the life situation 3) each participant will wear a mitt on the less-affected hand for most of their waking hours to encourage use of the more-affected hand 4) participants will be given home assignments to be carried out for at least 30 minutes each day. Sensory component strategies will be added to stimulate sensory input through the more-affected arm and hand as well as to train sensory discrimination skills.
45672347|NCT01684930|Drug|Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
45672348|NCT01684930|Other|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
45831824|NCT03948984|Behavioral|Therapeutic Music Session|The 20 minute therapeutic music session will consist of classical music performed by a pianist with or without flute accompaniment with an individual patient's ICU room.
45831825|NCT04025034|Procedure|Orbital decompression with ultrasonic bone removal|Deep lateral wall partial rim-sparing decompression for thyroid-related orbitopathy using SONOPET® appears to be safe and effective, reducing the complications associated and damage to neurovascular structures.
45831826|NCT04025112|Device|Armeo®Power|Randomized patients will be offered rehabilitation robotic using Armeo®Power from Hocoma, the first robotic arm exoskeleton for integrated arm and hand therapy, during one month, three times a week, totalizing 12 sessions of 45 minutes.
45978331|NCT00311727|Biological|Influenza A/H5N1|232 subjects receive Influenza A/H5N1 vaccine as part of DMID protocols 04-063 and 04-076.
45978332|NCT00283478|Drug|Iscar Quercus|
45978333|NCT00283478|Drug|Gemcitabine|
45978334|NCT00318318|Drug|Premarin|
45978335|NCT00311805|Biological|Autologous Stem Cells (CD34+)|Intramuscular Injections
45978336|NCT00283010|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
45978337|NCT00283010|Other|Educational DVDs|
45978338|NCT00318396|Procedure|Bone preparation technique: compaction|The bone is pressed very hard together before implantation of femoral component.
45978339|NCT00318396|Procedure|Bone preparation technique: conventional technique|Bone is broached before implantation of femoral component.
45978340|NCT00283517|Drug|antipsychotics|as prescribed
45978341|NCT00318435|Device|Stent or stent-graft deployment|
45978342|NCT00311883|Drug|hydroxychloroquine|
45978343|NCT00283556|Drug|Irinotecan (Camptosar, CPT-11)|"Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes Q 3 weeks x 15 patients; Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients; Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
45978344|NCT00283634|Drug|erlotinib and bortezomib|
45978345|NCT00318513|Drug|Bevacizumab|
45978346|NCT00283673|Behavioral|Exercise|
45978347|NCT00318552|Drug|Meropenem|
45978348|NCT00283751|Drug|insulin detemir|
45978349|NCT00283751|Drug|insulin glargine|
45978350|NCT00311922|Behavioral|Literacy/Numeracy oriented educational intervention|Comprehensive educational Intervention
45978351|NCT00311922|Behavioral|Control Group|Receives comprehensive education that is not literacy/numeracy sensitive
45978352|NCT00318630|Drug|Rosiglitazone|Rosiglitazone will be given as immediate release tablet of 4 milligrams administered orally for 28 days.
45978353|NCT00318630|Drug|Placebo|Subjects will also receive placebo oral tablet.
45978354|NCT00283790|Drug|zolpidem tartrate|
45978355|NCT00318669|Drug|Paroxetine hydrochloride hydrate|
45978356|NCT00283829|Drug|docetaxel|chemotherapy
45978357|NCT00283829|Drug|IL2|immunotherapy
45978358|NCT00311961|Drug|Intravenous prednisolone|
45978359|NCT00311961|Drug|Oral prednisolone|
45978360|NCT00419211|Behavioral|Exercise|Tailored exercise program
45978361|NCT00283946|Drug|Zolpidem MR|Oral
45831827|NCT04025112|Other|Conventional rehabilitation protocol|Randomized patients will be offered the conventional rehabilitation protocol from Barretos Cancer Hospital during one month, three times a week, totalizing 12 sessions of 45 minutes.
45978362|NCT00283946|Drug|Zolpidem|Oral
45978363|NCT00312000|Drug|capecitabine-irinotecan|"st line capecitabine 1250 mg/m2 orally b.i.d. on day 1-14~nd line q 3 w irinotecan 350 mg/m2 IV infusion on day 1"
45978364|NCT00312000|Drug|capecitabine+irinotecan (1st line)|q 3 w irinotecan 250 mg/m2 IV infusion in 30 minutes on day 1 2 hours after discontinuation of the infusion followed by capecitabine 1000 mg/m2 orally b.i.d. on day 1-14
45978365|NCT00283985|Drug|Kidrolase|6000 u/ m2 IM at J2, J4 and J6 and J8. 3 to 6 cycles.
45978366|NCT00283985|Drug|Methotrexate|3 gr/m2 at J1
45978367|NCT00283985|Drug|Dexamethasone|40 mg/ per os at J1, J2 and J4.
45978368|NCT00283985|Drug|Erwinase|"In case of allergy to Kidrolase~20000 u/m2 en IM at J2, J4, J6 et J8. 3 to 6 cycles"
45978369|NCT00419250|Drug|lenalidomide|
45672349|NCT01566214|Behavioral|Motivational Interview|For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
45672350|NCT02253992|Biological|Urelumab|
45672351|NCT02253992|Biological|Nivolumab|
45672352|NCT02252588|Drug|Chlorhexidine|Oral Rinse
45672353|NCT02252588|Other|Placebo|Oral Rinse
45672354|NCT05153018|Other|Blood collection|a 4-mL blood sample collected in a dry tube
45672355|NCT01585558|Drug|Ospemifene (Dose 1)|
45831828|NCT04024722|Procedure|In Vitro Fertilization|Patients suitable for research with poor ovarian response will receive treatment including laparoscopic surgery, resection, and transplantation of ovarian tissue in the same operation to improve the chances of success of in vitro fertilization and pregnancy. Participants will be assessed for surgical incisions and fertility assessment up to two weeks after treatment, including general physical examination, US pelvic examination, and blood tests for a hormonal profile to determine the initiation of ovarian stimulation and IVF. Patients will be monitored from 2 weeks to 1 year after treatment (once a week in the first two months and one month for one year after surgery), which will include a general physical examination, a US test, and blood tests for the hormonal profile at the IVF clinic.
45978370|NCT00419250|Drug|lenalidomide|
45978371|NCT00419250|Drug|lenalidomide|
45978372|NCT00419250|Drug|lenalidomide|
45978373|NCT00419250|Drug|lenalidomide|
45978374|NCT00284024|Drug|domperidone|
45978375|NCT00312039|Drug|elvucitabine|Elvucitabine 10 mg QD for 14days
45978376|NCT00312039|Drug|Lamivudine|Lamivudine 300 mg QD for 14 days
45978377|NCT00284102|Procedure|Mechanical ventilation|measurement of gas exchange, dead space, respiratory mechanics 5, 15, 30, 60 minutes from PEEP change (5 and 15 cmH2O)
45978378|NCT00312078|Dietary Supplement|Yogurt Supplementation|
45978379|NCT04718831|Dietary Supplement|Spirulina|Spirulina, as demonstrated in previous researches in vitro and in animals, can regulate immunity, enhance anti-virus activity, lower inflammation response and slower tumor progression. Liver function and liver fibrosis is improved by Spirulina as well. In our recent clinical trial, hepatitis B patients that received anti-virus medicine orally and was supplemented with Spirulina FEM-102 showed lower qHBsAg, reflecting the clearance of cccDNA. It might be related to immune modulation against HBV, which is induced by Spirulina.
45978380|NCT00318747|Drug|Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)|
45672356|NCT01585558|Drug|Ospemifene (Dose 2)|
45672357|NCT01585558|Drug|Placebo|
45672358|NCT01565980|Behavioral|symptom assessment|attention control receives a weekly symptom assessment phone interview for 6 weeks.
45672359|NCT01565980|Behavioral|Mindfulness Intervention|Participants will receive a weekly home-based mindfulness intervention, and symptom assessment phone interviews for 6 weeks.
45672360|NCT01585246|Drug|Saw Palmetto|1 of 3 doses of Saw Palmetto (320, 640, 960mg/day)
45672361|NCT01585246|Drug|soybean oil soft gel|placebo (soybean oil soft gel)
45978381|NCT00284219|Device|Transcranial Magnetic Stimulation 10Hz|3. rTMS subjects will receive 20 trains of rTMS at a rate of 10 Hz for 6 seconds (1200 pulses/session). Pulses will be administered over the left dorsolateral prefrontal cortex, defined as 5 cm anterior and in a parasagital plane to the point of maximum stimulation of the abductor pollicis muscle. Pulse intensity will be set at 100% motor threshold.
45978382|NCT00284219|Device|Magnetic stimulation using a special sham coil|Sham stimulation will be given at the same location as the active, with special sham coil.
45978383|NCT00312117|Drug|Sodium bicarbonate|
45978384|NCT00284258|Drug|CPT-11 and TS-1|TS-1 was administered orally at 40-60 mg twice daily for 14 days with a rest period of 14 days as one course. CPT-11 was administered intravenously 125 mg per square meter at day1 and day14 in 4 weeks as one course.
45672362|NCT01585168|Drug|Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
45672363|NCT01585168|Drug|Placebo|Identically appearing sugar pill, given orally
45672364|NCT02252042|Biological|pembrolizumab|
45672365|NCT02252042|Drug|methotrexate|
45672366|NCT02252042|Drug|docetaxel|
45672367|NCT02252042|Biological|cetuximab|
45672368|NCT02232074|Other|Patient navigation enhanced with legal support|
45672369|NCT02142283|Device|Trevo Thrombectomy Procedure|stent retriever; intended to restore blood flow in the neurovasculature by removing thrombus (clot)
45672370|NCT02142283|Other|Medical Management|Standard of Care not including mechanical thrombectomy, no intra arterial treatment, may include aspirin, therapy etc
45672371|NCT02231918|Drug|MIRAPEX® - low|
45672372|NCT02231918|Drug|MIRAPEX® - medium|
45672373|NCT02231918|Drug|MIRAPEX® - high|
45672374|NCT02199314|Drug|Desflurane|
45831829|NCT04024800|Biological|AE37 Peptide vaccine|"Starting dose: AE37 vaccine 1000 micrograms split into 2 doses given as intradermal injection on day 1 of every 3 week cycle (21 day cycle) for 5 cycles.~Should ≥ grade 3 systemic toxicities (DLT) occur in > 25% (4) of the first 13 patients (4 or more) the study therapy vaccine dose will be de-escalated to 500 micrograms (dose level -1)."
45672375|NCT02199080|Other|D-dimer assay before ablation of atrial fibrillation|Blood sample collection for D-dimers measurement
45831830|NCT04024800|Biological|Pembrolizumab|Pembrolizumab 200 mg IV on day 1 of every 3 week cycle (21 day cycle) for 2 years (35 cycles)
45831831|NCT04195854|Device|P4HB product|Retrospective use of P4HB in various anatomies
45831832|NCT04199520|Combination Product|surgery combined with systemic therapy|surgery combined with systemic therapy
45831833|NCT04199520|Other|systemic therapy|systemic therapy
45831834|NCT04198662|Device|Cryoneurolysis with a Painblocker (Epimed International, Farmers Branch, Texas)|The application of exceptionally low temperatures to reversibly ablate peripheral nerves, resulting in Wallerian degeneration with nerve regrowth at approximately 1-2 mm/day.
45831835|NCT04198662|Drug|Intercostal nerve block ropivacaine with epinephrine|3 mL of ropivacaine 0.5% (with epinephrine) will be injected perineurally to provide the intercostal nerve block(s)
45831836|NCT04406610|Biological|GD2 CAR-T immunotherapy|Antigen-specific T cell therapy
45831837|NCT04024176|Other|Gait analysis|The duration of participation of each subject is equal to the duration of the examination, i.e. approximately 30 minutes for the gait analysis and 30 minutes for the clinical examination (including 10 minutes for completing the questionnaire). The experiments will be carried out in a single measurement session, including several steps.
45831838|NCT04024332|Drug|ACT-541468|ACT-541468 25 mg; administered orally
45831839|NCT04023864|Dietary Supplement|Platycodon Grandiflorus Extract(GCWB107)|Once-daily, once a tablet, after meals, for 12 week
45831840|NCT04023864|Dietary Supplement|Placebo|Placebo for 12 week
46082578|NCT04235816|Drug|Azithromycin|Administration of azithromycin during the first 15 months of life through the Expanded Program on Immunisation
45672376|NCT02251652|Drug|Ingenol Mebutate|Ingenol mebutate 0.05% gel
45672377|NCT02251652|Procedure|Cryotherapy|1-2 sprays, 5 seconds each, with a 5 second interval
45672378|NCT02197520|Drug|Insulin Peglispro|Administered subcutaneously (SC), (U-100 formulation)
45672379|NCT02197520|Drug|Insulin Glargine|Administered subcutaneously (SC), (U-100 formulation)
45672380|NCT02197520|Drug|Insulin Lispro|Administered subcutaneously (SC), (U-100 formulation)
45672381|NCT04772534|Biological|9vHPV vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
45672382|NCT02230904|Drug|Rotigotine (Test product PR 2.3.1)|"Pharmaceutical form: Transdermal patch~Concentration: 8 mg/24 hours~Route of administration: Transdermal"
45672383|NCT02230904|Drug|Rotigotine (Reference product PR 2.1.1)|"Pharmaceutical form: Transdermal patch~Concentration: 8 mg/24 hours~Route of administration: Transdermal"
45672384|NCT02230670|Drug|IDN-6556|25 mg BID
45672385|NCT02230670|Drug|Placebo|
45672386|NCT02197130|Drug|PF-02545920|20 mg twice a day (BID) for 26 weeks. Each 20 mg dose will be taken as 4 tablets of 5 mg. The 20mg dose will be titrated as follow: 5mg BID for 7 days, 10mg BID for 7 days, 15 mg BID for 7 days and 20 mg BID to week 26. Study drug will be provided in weekly blister cards.
45672387|NCT02197130|Drug|PF-02545920|5 mg twice a day (BID) for 26 weeks. Each 5 mg dose will be taken as 4 tablets: one tablet of 5 mg and 3 tablets of matching placebo. The 5mg dose will not be titrated. Study drug will be provided in weekly blister cards.
45672388|NCT02197130|Other|Placebo|Matching Placebo twice a day (BID) for 26 weeks. Each placebo dose will be taken as 4 tablets of matching Placebo. The placebo dose will not be titrated. Matching placebo will be provided in weekly blister cards.
45831841|NCT03022890|Behavioral|hatha yoga|12 weeks of hour-long gentle hatha yoga classes
45831842|NCT03022890|Behavioral|health education|12 weeks of hour-long classes on nutrition, sleep, coping with pain, and other health educaiton topics
45831843|NCT04021056|Other|No intervention|
45831844|NCT04023786|Procedure|PEEP-TEST|The PEEP test will consist of lowering the PEEP level to 5 cmH2O for a maximum of 2 minutes and a minimum of 1 minute. Patients will be included if the physicians who care for them have decided to set a baseline PEEP level ≥10 cmH2O.
45831845|NCT04023630|Drug|Rivaroxaban 15 MG Oral Tablet|One 15 mg tablet once daily for up to twelve months
45831846|NCT04023630|Drug|Clopidogrel 75 Mg Oral Tablet|One 75 mg tablet once daily for up to twelve months
45831847|NCT04023630|Drug|Ticagrelor 90 MG Oral Tablet|One 90 mg tablet twice daily for up to twelve months
45831848|NCT04199754|Drug|Omnipaque 300mg/mL Solution for Injection|Prior to the contrast enhanced Cone Beam CT, 100mL of Omnipaque will be administered by IV at a rate of 2mL per second, followed by administration of 50mL of 0.9% saline.
45831849|NCT04199754|Radiation|Cone Beam CT|60 seconds after contrast administration, a Cone Beam CT will be performed.
45831850|NCT04199754|Radiation|Radiation Therapy|Standard of Care Radiation Therapy will be administered, dosage depends on the type of tumor being treated.
45831851|NCT04199754|Drug|0.9% Saline|50 ML of 0.9% Saline will be administered immediately after Omnipaque administration
45978385|NCT00284258|Drug|CPT-11, 5-FU and l-LV|Patients were administered FOLFIRI every 2 weeks in one course. FOLFIRI:CPT-11 150 mg per square meter on day1 with l-LV 200 mg per square meter administered as a 2-hour infusion before 5-FU 400 mg per square meter administered as an intravenous bolus injection, and 5-FU 2400 mg per square meter as a 46-hour infusion immediately after 5-FU bolus injection on day1 in 2 weeks.
45978386|NCT00318786|Drug|biphasic insulin aspart|
45978387|NCT00284336|Drug|Caelyx|
45978388|NCT00284336|Drug|endoxan|
45978389|NCT00312156|Drug|insulin detemir|
45978390|NCT00312156|Drug|insulin NPH|
45978391|NCT00312156|Drug|insulin aspart|
45978392|NCT00284414|Procedure|Ultrasonography or MRI|
45978393|NCT00284453|Procedure|Peripheral blood sampling|blood samples will be collected within 72 hours of subjects receiving >2, 1-2(low level) or inappropriate therapies, device data and repeat bloodwork in 3 months(+/- 4weeks).
45978394|NCT00318825|Drug|Nitrous oxide|
45978395|NCT04718753|Behavioral|Mindful breathing intervention|Mindful breathing intervention audio, which is used in mindfulness-based interventions, will be sent to the participants once per day.
45978396|NCT02959788|Other|Heart rate variability|All patients have a 10-minute recording analyzed for indices of heart rate variability.
45672389|NCT02196506|Drug|Placebo + ADT|Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)
45672390|NCT02196506|Drug|Brexpiprazole +ADT|Brexpiprazole + ADT Tablet, Oral, 2mg brexpiprazole and FDA Approved Antidepressant (ADT)
45672391|NCT02228720|Device|Propel Nova Sinus Implant|Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
45831852|NCT04023474|Procedure|Platelet Rich Fibrin (PRF) Application|Platelet Rich Fibrin application to flap defect.
45831853|NCT04023006|Device|Removable prostheses|Full dentures created by Additive manufacturing (Carbon Printers)
45831854|NCT04022928|Other|PRP|, For PRP preparation, specialized platelet concentrate separator containing acid citrate dextrose as anticoagulant and a specific separator gel that harvest PR, preventing contamination of red blood cells and leukocytes were used.
45831855|NCT04147104|Device|Low flow ECCO2R|"Treatment with a medical device called ECCO2R. The device consists of a drainage cannula placed in a large central vein, a membrane lung (artificial gas exchanger), and a return cannula into the venous system. Blood is pumped through the membrane lung, and CO2 is removed by diffusion. A flowing gas known as sweep gas containing little or no CO2 runs along the other side of the membrane, ensuring a diffusion gradient from blood to the other side, hence promoting CO2 removal."
45831856|NCT04147104|Device|Invasive mechanical ventilation|Invasive mechanical ventilation deviceto support acute respiratory failure and facilitate exhalation via an endotracheal tube or tracheotomy.
45831857|NCT04147182|Drug|Hypertonic Saline 3%|3% and 5% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, hypertonic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. The pH may have been adjusted with hydrochloric acid. It contains no antimicrobial agents.
45831858|NCT04147260|Drug|BI 730357|Film-coated tablet
45672392|NCT02228564|Procedure|Percutaneous transluminal angioplasty (PTA)|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
45672393|NCT02228564|Device|LIFESTREAM™ covered stent|Implantation of the LIFESTREAM™ covered stent
45672394|NCT01640951|Drug|AIN457 150 mg|(1 injection per dose) and placebo to Secukinumab 150 mg
45831859|NCT04147260|Drug|Placebo to match BI 730357|Film-coated tablet
45831860|NCT04147260|Drug|Ciprofloxacin|Film-coated tablet
45831861|NCT04146792|Behavioral|body acceptance program|Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete
45831862|NCT04146792|Behavioral|writing creatively program|Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete
45978397|NCT00284492|Procedure|Traditional chinese medicine type acupuncture|10 acupuncture sessions
45978398|NCT00284492|Behavioral|Self Care|Lifestyle advice on diet, physical activity
45672395|NCT01640951|Drug|AIN457 300 mg|Secukinumab 150 mg (2 injections per dose)
45831863|NCT04146948|Other|no intervention|no intervention in this study
45978399|NCT00312234|Behavioral|Aerobic exercise|
46082579|NCT04235816|Drug|Placebo|Administration of placebo during the first 15 months of life through the Expanded Program on Immunisation
46082580|NCT01315392|Procedure|delayed closure|wounds packed open with normal saline wet to dry gauze dressings and were returned to the operating room 36 to 72 hours after initial procedure for a second debridement and definitive closure.
46082581|NCT01315392|Procedure|immediate wound closure|traumatic and surgical wounds closed at the initial surgical intervention
46082582|NCT00936013|Drug|oseltamivir|75mg p.o Bid for 5 days
45672396|NCT01640951|Drug|Placebo|
45672397|NCT05490875|Procedure|Carotid ultrasound|Carotid ultrasound will be done to both sides of the neck to look at the carotid arteries.
45978400|NCT00312234|Behavioral|Qigong exercise|
45978401|NCT00284531|Drug|Daclizumab|
45978402|NCT00312273|Drug|Aminophylline (250mg IV +/- a second dose of 250mg IV)|
45978403|NCT00312312|Biological|Specific immunotherapy|
45978404|NCT00284609|Behavioral|Group based non-pharmacological rehabilitation|"6 x 1.5 hours education program in group classes taught by nurse, physiotherapist, dietitian and chiropodist.~24 x 1.5 hours training program (both aerobic and anaerobic exercise) in group classes supervised by a physiotherapist.~3 x 3 hours cooking sessions in group classes supervised by a dietitian.~Intervention period: 6 month"
45978405|NCT00284609|Behavioral|Individual non-pharmacological rehabilitation|"Individual counseling in Outpatient Clinic, including patient education, physical activity and diet instruction.~4 x 1 hour with a diabetes nurse,~3 x 0.5 hour with a dietitian and~1 hour with a chiropodist.~Intervention period: 6 month"
45978406|NCT00318864|Behavioral|Cognitive behavioral therapy|
45978407|NCT00284648|Procedure|Surgical repair Achilles tendon rupture|
45978408|NCT00284648|Procedure|Non-surgical repair Achilles tendon rupture|
45978409|NCT00312351|Drug|Pegaptanib sodium|
45831864|NCT04022304|Biological|Biocon Insulin N|Biocon Insulin N is an intermediate-acting isophane suspension of human insulin produced by recombinant deoxyribonucleic acid(rDNA) technology utilizing Pichia pastoris (yeast).
45831865|NCT04022304|Biological|Humulin® N|Humulin® N (human insulin [recombinant deoxyribonucleic acid origin] isophane suspension) is an intermediate-acting human isophane insulin. Humulin® N is a suspension of crystals produced from combining human insulin and protamine sulphate.
45831866|NCT04022382|Device|Restylane Defyne|Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL.
45831867|NCT04021446|Other|Exercise|personalized exercise prescription
45672398|NCT05490875|Other|Blood draw|This optional blood draw could occur anytime from the time of enrollment on the study until 90 days after the research ultrasound.
45978410|NCT00284687|Drug|Artesunate|PO Artesunate
45978411|NCT00318942|Drug|Crystalloids|Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay
45978412|NCT00318942|Drug|Colloids|Gelatines, Albumine, Starch, or any other colloids, at the necessary dose to restore hemodynamic (starch cumulative daily dose should not exceed 35/40 ml/kg), for all ICU stay
45978413|NCT00318942|Drug|Crystalloids|Any crystalloids given for correction of hypovolemia during all ICU stay
45978414|NCT00318942|Drug|Colloids|Any colloids given for correction of hypovolemia during all ICU stay
46082583|NCT00936013|Drug|oseltamivir and chinese medicinal herbs|oseltamivir: 75mg p.o bid for 5 days chinese medicinal herbs:200ml p.o qid for 5 days
46082584|NCT02801318|Procedure|Polysomnography|
46082585|NCT02724384|Device|MOE Plasma Delivery System A|Plasma treatment
46082586|NCT02724384|Device|MOE Plasma Delivery System B|Plasma treatment
46082587|NCT00939445|Procedure|Online HDF|Online HDF
46082588|NCT00939445|Procedure|Short Daily Hemodialysis|Short Daily Hemodialysis
46082589|NCT05500976|Other|Semi-controlled dietary intervention - Western|Participants will complete a 2-week washout prior to a 16-week randomized, crossover semi-controlled feeding study of mini-MED vs Western diet. Each diet intervention will last four weeks, with 500 kcal/day of target Western diet foods (eg, beef, potatoes, bread, sour cream) provided during each intervention and will be repeated twice.
45672399|NCT05490875|Other|Survey|Participants will complete a 15-minute survey about how acceptable participants find the ultrasound procedure, whether participants would be open to it in the future if a doctor thought it was necessary, whether participants would be open to getting treatment for artery problems, and how participants feel about their own risk of stroke.
45672400|NCT02228096|Biological|CTL019 T-cells|A target dose of CTL019 transduced cells will consist of a single infusion of 2.0 to 5.0 x 10^6 CTL019 transduced cells per kg body weight (for patients ≤ 50 kg) and 1.0 to 2.5 x 10^8 CTL019 transduced viable T cells (for patients > 50 kg). The following cell dose ranges may be infused if all other safety release criteria are met: 0.2 to 5.0 x 10^6 CTL019 transduced viable T cells per kg body weight (for patient ≤ 50 kg) and 0.1 to 2.5 x 10^8 CTL019 transduced viable T cells (for patients > 50 kg).
45831868|NCT04022460|Diagnostic Test|Video clip assessment|Parents will take short video clips of their child sleeping at night. They will be asked to review the video clips and rate whether they think their child has obstructive sleep apnea (OSA), and if so, how severe it is. Two clinicians will review the video clips on a separate night.
45831869|NCT04022460|Diagnostic Test|Polysomnography (sleep study)|Children will undergo a polysomnography as the gold standard test to assess for OSA.
46082590|NCT05500976|Other|Semi-controlled dietary intervention - MiniMed|Participants will complete a 2-week washout prior to a 16-week randomized, crossover semi-controlled feeding study of mini-MED vs Western diet. Each diet intervention will last four weeks, with 500 kcal/day of target Mediterranean foods (eg, oatmeal, salmon, nuts, basil, olive oil, fruits) provided during each intervention and will be repeated twice.
46082591|NCT00936091|Drug|vitamin A supplements|gelatinous and reddish opaque capsules containing 200 000 IU vitamin A
46082592|NCT00936091|Drug|Placebo|125 children received placebo capsules
46082593|NCT02801630|Device|PainShield SAW Patch Device|The PainShield is a self contained Surface Acoustic Wave device, where the waves are delivered locally through a trasnducer embedded into a patch that sits on the affected area.
46082594|NCT05135676|Device|Blinded CGM|A masked CGM sensor will be worn
46082595|NCT05135676|Device|real-time CGM|An unmasked CGM sensor will worn
45831870|NCT04022460|Other|Educational webinar|After evaluating the video clips of their child sleeping, parents will watch an educational webinar on OSA in children with Down syndrome and how to recognize symptoms.
45831871|NCT03930654|Behavioral|iPrEP|"iPrEP transforms the standard emergency department (ED) visit experience through an intervention presented as a standard assessment that is equipped to: 1) increase knowledge of HIV transmission and 2) provide information on how to reduce an individual's risk for HIV.~Women will receive the iPrEP intervention on an iPAD Air tablet device~iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument~iPrEP uses qualitative themes~iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence~Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument~Scales were modified (in some cases) for cultural competency and tailoring to women"
45978415|NCT00284726|Device|Celsior Cold Storage Solution|
45978416|NCT00284765|Procedure|flector|
45978417|NCT00318981|Drug|Concerta|
45978418|NCT00312390|Procedure|Flicker|
45978419|NCT00312390|Procedure|Retinal Vessel Diameter|
45978420|NCT00312390|Procedure|Retinal Blood Flow|
45978421|NCT00312429|Procedure|Stem Cell Transplantation|Allogeneic umbilical cord blood stem cell transplant
45978422|NCT00284921|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
45978423|NCT00319059|Drug|systemic administration of 99mTc-HYNIC-Annexin A5|
45978424|NCT00319059|Behavioral|10 minutes of ischemic handgripping|
45978425|NCT00284999|Drug|Soothe|
45978426|NCT00284999|Drug|Refresh Tears|
45978427|NCT00312507|Drug|Bovine Lipid Extract Surfactant (administered by lavage)|
45978428|NCT00312507|Drug|Bovine Lipid Extract Surfactant (administered by bolus)|
45978429|NCT00312546|Drug|Enfuvirtide|90 mg subcutaneously twice daily
45978430|NCT00312546|Drug|Valproic acid|500 to 750 mg, taken orally twice daily
45978431|NCT00285077|Drug|SR57667B|
45978432|NCT00319137|Drug|GW274150|
46082596|NCT00563797|Drug|Mecamylamine|mecamylamine 10mg/day for 12 weeks
45672401|NCT01640873|Drug|MK-8655|Participants will receive MK-8655 as a single dose on Day 1. Participants will receive MK-8655, once a day (q.d.), for 14 consecutive days (Day 3 through Day 16). MK-8655 doses may be adjusted downward based on the results of ongoing studies.
45672402|NCT01640873|Drug|Placebo|Participants will receive Placebo as a single dose on Day 1. Participants will receive Placebo, q.d., for 14 consecutive days (Day 3 through Day 16).
45672403|NCT04419623|Drug|TL-895|TL-895, administered by mouth
45672404|NCT04844801|Procedure|Risk control strategy|"Magnesium sulfate 2g intravenous bolus over 20 mn (if creatinine clearance >30 mL/min)~Control of the modifiable NOSVA risk factors: hypovolemia, sepsis, metabolic disorders (e.g., hypokalemia, hyponatremia), acidosis, hypoxia, excess cardiac inotropism of vasopressors, central venous catheter malposition, hyperthermia."
46082597|NCT00563797|Drug|Placebo|Placebo pill
45672405|NCT04844801|Procedure|Rate control strategy:|"Risk-control as described above~Low dose amiodarone:~Intravenous bolus (day-1): 4 mg/kg over 1hr (maximum 300 mg i.e. 2 IVL vials over 1 hour )~Enteral dose maintenance (day-1 to day-7): 200mg once a day (150 mg intravenous over 1hr if enteral route is unavailable)"
45672406|NCT04844801|Procedure|Rhythm control strategy:|"Risk control as described above~High dose amiodarone:~Intravenous bolus (day-1): 7 mg/kg over 1hr 1 hour (maximum 600 mg i.e. 4 IVL vials over 1 hour); followed by continuous intravenous maintenance: for a total of 1200 mg over the first 24 hrs (infusion pump)~Enteral dose maintenance Day-2 and day-3: 400 mg three times a day (720 mg continuous intravenous over 24 hrs if enteral route is unavailable).~Day-4 to day-7: 200 mg once a day (150 mg intravenous over 1hr if enteral route is unavailable)~- Electrical cardioversion (only in patients intubated on mechanical ventilation) if:~NOSVA persists after initial bolus of amiodarone AND norepinephrine base (or epinephrine base) doses > 0.3 µg/kg/min;~NOSVA persists more than 6 hrs after initial amiodarone bolus."
45672407|NCT01683994|Drug|Cabozantinib|Assigned dose given daily during each 21 day cycle. Treatment may continue until disease progression or intolerable toxicity.
45672408|NCT01683994|Drug|Docetaxel|75mg/m^2 intravenous (IV) over approximately 60 minutes on cycle 1 day 1 and repeated every 21 days until disease progression or intolerable toxicity.
45672409|NCT01683994|Drug|Prednisone|5 mg by mouth (PO) twice a day during each 21 day cycle until disease progression or intolerable toxicity.
45672410|NCT02247440|Drug|Peg-interferon + ribavirin under HIV physician supervision|Peg-interferon + ribavirin under HIV physician supervision
45672411|NCT05487989|Other|Clinical examen|MRI sequences for research, pupillometry, OCT-angiography, evaluation of visual cognition
45831872|NCT03930654|Behavioral|Usual Care|"Women will receive usual care~Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use~Social worker will offer a list of substance abuse treatment referral agencies"
45831873|NCT04020900|Other|Respiratory management|Data on respiratory management were collected at different time: data regarding the induction period, ventilatory parameters set and measured during a stable period, ventilatory change made during anaesthesia, use of recruitment manoeuvres, data regarding weaning and extubation
45831874|NCT04020666|Drug|Urinary Kallidinogenase|
45831875|NCT04405986|Procedure|Auditory Evoked Potentials (AEP)|Record of electrophysiological responses (Auditory Evoked Potentials or AEP) during auditory stimulations with an electroencephalogram (EEG).
45831876|NCT04405986|Procedure|Blink and Masseter Inhibitory Reflex|Electrophysiological exploration while stimulating trigeminal nerve to record 1) motor response induced (muscle contraction delay (Blink)) of the facial nerve, or 2) the contraction inhibition of masseters (Masseter Inhibitory Reflex (MIR)).
45831877|NCT03929640|Drug|Acetaminophen|Acetaminophen 650 mg tablet every 6 hours
45831878|NCT03929640|Drug|Placebo|Placebo oral tablet every 6 hours
45831879|NCT03929640|Drug|Ibuprofen|Ibuprofen 600 mg tablet every 6 hours
45831880|NCT04021992|Drug|gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab|All patients enrolled in the study will accept gemcitabine, oral vinorelbine and doxorubicin liposome, with or without rituximab as their salvage chemotherapy.
45831881|NCT04022070|Other|Dynamic Tape® (Tape)|To evaluate the evolution of this symptomatology prior to and thereafter the application of Dynamic Tape® bandage affected by plantar fasciitis during a week the Outcome Measure, pain is evaluate with a VAS (visual pain scale).
45831882|NCT03593148|Other|Lifestyle|Lifestyle treatment
45978433|NCT00425009|Drug|Berberine|
46082598|NCT02799524|Other|comparison of screening scales|Concordance degrees Assessment of each of 2 scales ( HADS and GDS ) from the DSM- V , for diagnostic confirmation of major depressive episodes in elderly patients with cancer or haematological malignancies
46082599|NCT01192698|Drug|IV interferon|IV interferon 5MU during anhepatic phase
45978434|NCT00425009|Drug|Metformin|
45978435|NCT00312585|Procedure|Acupuncture|
45978436|NCT00312585|Procedure|Sham comparator|
45978437|NCT00285116|Procedure|Clinical examination and radiological evaluation|
45978438|NCT00312624|Procedure|contrast-enhanced cardiac MRI|MRI of heart with delayed enhancement
45978439|NCT04718402|Drug|Mitoxantrone Hydrochloride Liposome, intravenous injection|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
46082600|NCT04014361|Drug|LY3154885 - Capsule|Administered orally.
46082601|NCT04014361|Drug|Placebo - Capsule|Administered orally.
45978440|NCT00319215|Drug|Ramelteon 8 mg|
45978441|NCT00319215|Drug|Zopiclone 7.5 mg|
45978442|NCT00285155|Drug|Bupropion|
45978443|NCT00285194|Drug|Allogeneic Islets of Langerhans|
46082602|NCT04014361|Drug|Itraconazole|Administered orally.
46082603|NCT04014361|Drug|LY3154885 - Tablet|Administered orally.
46082604|NCT00771927|Drug|Lacosamide|Vimpat was used as per site routine practices, and in-line with the marketing authorization.
45978444|NCT00285194|Drug|hOKT3γ1 (Ala-Ala)|
45978445|NCT00319293|Drug|Metformin|
45978446|NCT00285233|Biological|Allogeneic islets of Langerhans transplant|Allogeneic islets of Langerhans transplant
45978447|NCT00319332|Drug|Ibritumomab Tiuxetan|
45672412|NCT04760054|Behavioral|HUBOD|Participants in the intervention group will attend 5 separate training sessions instructing them in Hubod. The Hubod exercise is a partnered coordination drill involving moves derived from numerous martial arts, most often seen in the Filipino martial art of Kali. Participants will aim to reach a level of comfort and competency in the basic, non-competitive aspects of the Hubod exercise by the end of their participation in this intervention.
45978448|NCT00319332|Drug|Iodine I 131 Tositumomab|
45978449|NCT00285350|Drug|mycophenolate mofetil|
45831883|NCT03022734|Drug|chemotherapy|cetuximab 250mg/m2 or bevacizumab 5mg/kg, FOLFOX (oxaliplatin 85mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2) or FOLFIRI (irinotecan 180mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2)
45831884|NCT03022734|Radiation|radiotherapy|After FOLFOX 4cycle, subject have short course radiotherapy 5Gy for 5 days.
45978450|NCT00312741|Procedure|empirical versus microbiological guided treatment|
45978451|NCT00285389|Drug|Adriblastin|
45978452|NCT00285389|Drug|dexamethasone|
45978453|NCT00285389|Drug|Chlorambucil|
45456256|NCT04522284|Drug|XELOX|Treatment with the selected regimen will take up to a maximum duration of 12 months, in 3-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range. Maximum dose of capecitabine in the predetermined safety range is set at 100% of standard starting dose (i.e. 1000 mg/m2 twice daily for XELOX regimen). Minimum dose of capecitabine in the predetermined safety range is set at 50% of the standard starting dose (i.e. 500 mg/m2 twice daily for XELOX regimen). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range. The doses of other drug in the XELOX regimen (oxaliplatin) will be held constant or adjusted at the clinical investigator's discretion, as per standard of care.
45831885|NCT04406532|Behavioral|PT-Pal|"Participants will be guided through an exercise program in the PT-Pal app. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness."
45978454|NCT00285389|Drug|rituximab|
45978455|NCT00285389|Drug|cyclophosphamide|
45978456|NCT00285389|Drug|alkeran|
45978457|NCT00285389|Procedure|Total body irradiation (8Gy/4fr)|
45978458|NCT00285389|Drug|vincristine|0,4 mg/day day 1 to day 4
45978459|NCT00312780|Drug|XL784|XL784 softgel capsules (100 mg per capsule) orally administered at a dose of 200 mg/day (or placebo softgel capsules)
45978460|NCT00285428|Drug|hA20-humanized anti-CD20 antibody|once weekly iv dosing for 4 weeks
45978461|NCT00312819|Drug|chemotherapy +/- disulfiram|
45978462|NCT00319410|Procedure|vaginoscopic hysteroscopy|
45978463|NCT00312936|Behavioral|Mindfulness-based Stress Reduction (MBSR)|8 week program
45978464|NCT00319488|Drug|Inhaled Corticosteroid (Budesonide)|Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.
45978465|NCT00319488|Drug|Leukotriene Receptor Antagonist (Montelukast Sodium)|Participants will receive leukotriene receptor antagonist for 7 days, at the first sign of RTI-associated symptoms.
45978466|NCT00319488|Drug|Inhaled Albuterol|All participants will receive inhaled albuterol treatments four times a day.
45978467|NCT00285623|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|treatment in surgery for improvement of haemostasis where standard techniques are insufficient
45978468|NCT00285662|Drug|Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo|Children will get 25mg/1.25mg/kg of SP as a single dose, 4 mg/kg for 3 days of Artesunate and 10 mg/kg for 3 days of Amodiaquine in their respective arms
45978469|NCT00319566|Drug|Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily|
45978470|NCT00285701|Drug|hexaminolevulinate|
45978471|NCT00319605|Drug|Levetiracetam|
45978472|NCT00285740|Behavioral|Cognitive Behavioral Therapy (CBT) in a Group Format|
45978473|NCT00313053|Drug|Human mAb 216|Two treatment courses of mAb infusion will be given, with the same dose of antibody administered on Day 0 and on Day 7.
45978474|NCT00313053|Drug|Vincristine|Vincristine 1.5 mg/m2/dose (max dose = 2 mg) IVP on weekly x 4 doses (Days 7, 14, 21, 28)
45978475|NCT00285896|Drug|Glucagon-like-peptide-1 (7-36) amide|Continuous, subcutaneous GLP-1 at a dose of 4.8 pmol/kg/min for 51 hours
45978476|NCT00285896|Drug|Placebo|continuous subcutaneous placebo infusion at a dose of 4.8 pmol/kg/min for 51 hours
45978477|NCT00319683|Drug|ADH300004|
45978478|NCT00286052|Drug|Low Dose Naloxone|
45978479|NCT00319761|Drug|Calcitriol|
45978480|NCT00286130|Drug|Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan|
45978481|NCT00286130|Drug|FOLFOX 6|"FOLFOX 6:~Oxaliplatin 100 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:"
45672413|NCT04760054|Behavioral|Active Comparator|Participants in the active comparator group will attend 5 separate training sessions. Each session will involve a 5 minute warmup of joint mobilization exercises and mild pedaling on the bicycle before the main effort of continuously using the bicycle for approximately 20 minutes. The session finishes with a 5 minute cooldown period and light stretch. Heartrate will be monitored regularly in order to prevent this exercise exceeding the relative intensity of the Martial Arts intervention group. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
45672414|NCT04760054|Behavioral|Control Condition|Participants in this group will attend 5 separate training sessions. Each session will involve watching educational videos on martial arts techniques and training methods from a sedentary position. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
45978482|NCT00286130|Drug|FOLFIRI|"FOLFIRI:~Irinotecan 180 mg/m² day 1 concurrent with~Leucovorin 400 mg/m² followed by~Bolus 5FU 400 mg/m², followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
45978483|NCT00313092|Device|nCPAP treatment|treatment with positive air pressure during night
45978484|NCT00286208|Drug|Mifepristone, misoprostol|
45978485|NCT00319800|Drug|Gefitinib|
45978486|NCT00319800|Drug|Irinotecan|
45978487|NCT00286247|Genetic|INGN 201|
45978488|NCT00313131|Drug|tinidazole+fluconazole vs metronidazole+clotrimazole|
45978489|NCT00425048|Procedure|wearing gloves|
45978490|NCT00286286|Device|Intraperitoneal Aerosolization System, IntraMyst|
45978491|NCT00319878|Drug|Sirolimus|"Oral loading dose followed by a once daily dose:~Cohort 1: Loading Dose - 1.2 mg; Daily Dose - 0.4 mg~Cohort 2: % Dose Increase - 100%; Loading Dose - 2.4 mg; Daily Dose - 0.8 mg~Cohort 3: % Dose Increase - 67%; Loading Dose - 3.9 mg; Daily Dose - 1.3 mg~Cohort 4: % Dose Increase - 50%; Loading Dose - 6.0 mg; Daily Dose - 2.0 mg"
45672415|NCT05421377|Diagnostic Test|clinical assessment|screening of patients at risk for developing unilateral or bilateral lower limb lymphedema
45672416|NCT05011721|Device|Activity tracker|"Participants will receive a Withings Steel HR activity tracker (Withings, Issy-les-Moulineaux, France), which they will be asked to wear 24 hours per day throughout the whole intervention (12 months). At baseline, the Withings Health Mate mobile phone application will be downloaded onto each participant's smartphone or tablet. The clinical research assistant will instruct the participant in the use of the activity tracker. The participant will then accept and activate the sharing of the data collected with the secure server dedicated to the NeoFit study at the Institut Curie. Participants will be asked to synchronize the activity tracker regularly (ideally daily) via Bluetooth with the Withings Health Mate application, for automatic transfer of the data to the secure NeoFit space."
45831886|NCT04406532|Behavioral|Self-guided exercises|"Participants will use the exercise manual to guide the exercise program. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness."
45831887|NCT04021836|Other|3d evaluation of nasolabial change|Evaluation of With vs without ala cinch suture after lefort 1 osteotomy
45831888|NCT03926130|Drug|Mirikizumab|Administered IV
45978492|NCT00319878|Drug|Cyclosporine|Dose of 5 mg/kg divided as a twice daily oral dose
45978493|NCT00286364|Drug|Downregulation and androgen priming by use of GnRH antagonist, aromatase inhibitor and hCG before COH|
45978494|NCT00319917|Drug|tacrolimus|oral
45831889|NCT03926130|Drug|Mirikizumab|Administered SC
45831890|NCT03926130|Drug|Ustekinumab|Administered IV
45831891|NCT03926130|Drug|Ustekinumab|Administered SC
45831892|NCT03926130|Drug|Placebo|Administered IV
45831893|NCT03926130|Drug|Placebo|Administered SC
45831894|NCT04020588|Drug|Celecoxib 200mg|Will be administered for 6 weeks
45831895|NCT04020588|Drug|Placebo oral capsule|Will be administered for 6 weeks
45831896|NCT04020588|Drug|Minocycline 100mg|Will be administered for 6 weeks
45831897|NCT04146402|Drug|SCT-I10A+chemo|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
45978495|NCT00319917|Drug|placebo|oral
45978496|NCT00286403|Drug|Fenoldopam Mesylate and/or MESNA|
45978497|NCT00313287|Drug|clevudine|
45978498|NCT00286481|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
45978499|NCT00286481|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
45978500|NCT00286481|Drug|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
45978501|NCT00425139|Behavioral|Re-Mission|
45978502|NCT00286520|Procedure|Transanal irrigation with Peristeen Anal Irrigation|
45978503|NCT00320034|Drug|R-albuterol, S-albuterol|
45978504|NCT00286559|Drug|SonoVue|
45978505|NCT00286559|Drug|Optison|
45978506|NCT02959710|Drug|AC-1204 mixed in water|40 g AC-1204 (shaken in 240 mL of water) at Hour 0 on Day 1
45978507|NCT02959710|Drug|AC-1202 mixed in water|60 g AC-1202 (shaken in 240 mL of water) at Hour 0 on Day 1
45978508|NCT02959710|Drug|AC-1202 mixed in Ensure®|60 g AC-1202 (shaken in approximately 8 oz [237 mL of Ensure® Original] at Hour 0 on Day 1)
45978509|NCT00286598|Behavioral|Feet First|Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks.
45978510|NCT00425178|Drug|FGF-1|
45978511|NCT00286676|Drug|Nutropin|
45978512|NCT00286676|Procedure|Oral Glucose Tolerance Test|
45978513|NCT00286676|Procedure|Dual Energy X-ray Absorptiometry (DEXA)|
45831898|NCT04146402|Drug|Placebos+chemo|Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
45831899|NCT04146168|Diagnostic Test|Ultrasound|Closure of previously treated veins (with Venaseal) will be assessed via ultrasound.
45831900|NCT04146480|Diagnostic Test|F18-NaF PET/CT|"The scan will be performed on the Discovery 690 Nuclear Medicine Camera. On the day of the scan, the patient will be admitted to the Office of Nuclear Medicine and will be admitted to administrative. Prior to the scan, the subject will undergo a brief interview by a physician or nurse and a 22 G Prefill will be installed on him, through which a 5 millikiric (mCi) of 18 F-NaF will be injected.~4. An hour after the injection, the PET / CT scan, which will last about 10 minutes, during, the patient is required to lie down and breathe normally.~5. Upon completion of the scan, will be released without any restrictions."
45831901|NCT03021798|Other|No Drug and no aspecific intervention|No intervention
45831902|NCT03021876|Drug|L-carnitine|treatment with oral L-carnitine, 1500 mg/body per day
45831903|NCT03021876|Other|usual intake|baseliner
45831904|NCT03948438|Procedure|Endoscopic septotomy|Patients will be placed in left lateral decubitus position, either in conscious sedation or under deep sedation with propofol or endotracheal intubation.The procedure will be performed with a flexible standard endoscope and started with initial endoscopic examination with suction of possible retained material insidethe diverticulum. An incision of the bridge between the ZD and the esophagus will be done (using one endoscopic procedure as POES or FESD or other)
45831905|NCT04020354|Behavioral|HABIT-ILE|Early Hand and arm bimanual intensive therapy including lower extremities
45831906|NCT04020354|Behavioral|Usual Care|Usual customary care
45831907|NCT03907410|Other|Nominal Financial Incentives|The nominal financial incentives will consist of fixed-ratio incentives for each inhaled corticosteroids (ICS) actuation (25 cents for children on 4 daily ICS doses and 50 cents for children on 2 daily doses), with a maximum of $1 per day.
45831908|NCT03907410|Other|Daily Adherence Reminders/Adherence Performance Feedback|Study participants will receive automated daily text message or push notification reminders and automated weekly feedback summarizing their adherence performance through Way to Health, a mobile health, electronic monitoring platform.
45831909|NCT04145544|Device|Implantation of the ArtiFascia®|"Following are the general instructions for use for the ArtiFascia®:~Cut the ArtiFascia® to the required shape under aseptic conditions~Apply ArtiFascia® to the damaged area~Suture the ArtiFascia® in place~Suture bites should be taken 2-3 millimeters from the edges of the implant. Either a running suture or interrupted stitches' technique may be used, depending on clinical conditions or surgeon's decision.~Important Note: If clinically possible, do not use dural adhesive or sealants as it is an uncontrolled variable, that can influence the results."
45831910|NCT04145544|Device|Implantation of other commercial suturable dural substitute|Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use
45831911|NCT04146558|Drug|Individualized internal ayurvedic treatment|"All possible internal preparations will be administered for a period of 12 months.~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration"
45831912|NCT04146558|Other|External ayurvedic treatment|Application of warm external oil (Ayyapala kera tailam) on affected parts twice daily
45831913|NCT03619044|Other|2 FES-PET Imaging will be performed:|"before treatment initiation~before treatment cycle 3 initiation"
45831914|NCT04146246|Diagnostic Test|G6PD assay|A test for G6PD deficiency.
45831915|NCT04020120|Other|questionnaires|answer questionnaires
45831916|NCT04145856|Dietary Supplement|I31 probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
45978514|NCT00286676|Procedure|Computed Tomography (CT) Scan|
45978515|NCT00320073|Drug|erlotinib hydrochloride|75 mg to 150mg
45978516|NCT00320073|Drug|pemetrexed disodium|Pemetrexed is administered intravenously over 10 minutes, every 21 days
45672417|NCT04844099|Drug|Dihydroartemisinin Piperaquine|Administered as dihydroartemisinin (20mg) and piperaquine (160 mg)
45672418|NCT04419077|Behavioral|Virtual reality exposure|"Patients will be exposed to a 10-20 min virtual reality session just before an oncological procedure (invasive act or chemotherapy).~Patients will be able to choose between 4 virtual universes (beach, underwater, forest, space) and seven musical content."
45672419|NCT04857203|Diagnostic Test|Vitamin D|Vitamin D levels will be measured for the patients undergoing neoadjuvant therapy in patients with locally advanced rectal cancer
45672420|NCT05381597|Drug|Combination cream of 5-fluorouracil and calcipotriene|Apply the cream to the size of the lesion extending to the 0.5 cm area of skin surrounding the lesion.twice a day for 7 days and the treatment can be extended to 14 days based on evaluation at 7 days.
45672421|NCT05381597|Drug|5-fluorouracil cream|Apply the cream to the size of their lesion extending to the 0.5 cm area of skin surrounding the lesion twice daily for 28 days.
45672422|NCT01683838|Drug|Fampridine-SR|25mg bid (twice daily)
45978517|NCT00320073|Drug|vinflunine|Vinflunine is administered intravenously over 20 minutes and should be given after pemetrexed, every 21 days
45978518|NCT00286832|Procedure|PET scan|One extra PET scan after 1 cycle of treatment.
45978519|NCT00313326|Procedure|Adaptative Support Ventilation|Adaptive Support Ventilation (ASV) is a new protocol of weaning of the tracheal prosthesis after surgery which maintains a preset ventilation by an operator, and this whatever the activity of the patient
45978520|NCT00286871|Drug|Neoral|
45978521|NCT00286871|Drug|Tacrolimus|
45978522|NCT00417326|Drug|ONO-5046Na|twenty four hour infusion at 0 mg/kg/hr for 14 days
45978523|NCT00417326|Drug|ONO-5046Na|twenty four hour intravenous infusion at 0.2 mg/kg/hr for 14 days
45978524|NCT00320229|Drug|abciximab|
45978525|NCT00313365|Procedure|Surgical Lavage (Arthrotomy)|
45978526|NCT00313365|Procedure|Arthrocentesis (Serial needle aspiration)|
45978527|NCT00417365|Device|WaterWorks Douching Device|
45978528|NCT00320268|Drug|Quetiapine fumarate|
45978529|NCT00417404|Drug|Aquasol A|IM Aquasol A 10,000IU three times weekly
45831917|NCT04145856|Combination Product|I31 probiotic combined to Alverine/Simethicone|"I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)~Antispasmodic/antifoam drug, consisting of Alverine Citrate 60 mg and Simethicone 300 mg, thrice daily (t.i.d)"
45831918|NCT04145856|Other|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
45978530|NCT00417404|Drug|aquasol A|10,000 IU three times weeks, by intramuscular injection
45978531|NCT00417404|Other|sham injection|sham injection
45978532|NCT00313404|Biological|Safety tested norovirus inoculum|This is a safety tested live infectious norovirus inoculum that has been placed in groundwater that meets EPA drinking water standards
45978533|NCT00417443|Drug|Clonidine|
45978534|NCT00313482|Drug|Sargramostim|250 mcg/m2 SC days 2-15 of each cycle
45831919|NCT04145778|Other|non interventionnal study|non interventionnal study
45831920|NCT04146090|Other|Low-pressure pneumoperitoneum|Pneumoperitoneum will be maintained in 10 mmHg
45978535|NCT00313482|Drug|Docetaxel|75 mg/m2 IV over 1 hour on Day 1 of each cycle
45978536|NCT00313482|Drug|Prednisone|5 mg orally BID on Day 1 continuously
45978537|NCT00417521|Behavioral|Family-Based Treatment|
45978538|NCT00286988|Drug|Topiramate|
45978539|NCT00320307|Drug|abacavir|
45978540|NCT00287027|Drug|Risperdal Long Acting Injectable Antipsychotic Medication|
45978541|NCT00320346|Biological|Pandemic Influenza Vaccine|
45978542|NCT02960906|Drug|Nivolumab|"For Arms 1A and 4A:~Nivolumab alone administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~For Arms 1B, 2B, 3B and 4B:~Nivolumab administered IV over 60 minutes at 3 mg/kg combined with ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks for 4 doses followed by nivolumab administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
45978543|NCT02960906|Drug|Ipilimumab|"For Arms 1B, 2B, 3B and 4B:~Ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks combined with Nivolumab administered IV over 60 minutes at 3 mg/kg for 4 doses until disease progression, unacceptable toxicity or other reasons specified in the protocol."
45672423|NCT01683838|Drug|Placebo|Placebo
45831921|NCT04146090|Other|Standard pressure pneumoperitoneum|Pneumoperitoneum will be maintained in 14 mmHg
45978544|NCT02960906|Drug|Pazopanib|"For Arms 2C and 3C (TKI pazopanib or sunitinib):~Pazopanib 800 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol"
45978545|NCT02960906|Drug|Sunitinib|"For Arms 2C and 3C (TKI pazopanib or sunitinib):~Sunitinib 50 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol"
45978546|NCT04717830|Drug|Gamezumab|solution for infusion
45978547|NCT00287066|Drug|Inhaled Human Insulin|
45672424|NCT05474573|Device|Combined ultrasound and fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope and performing sonography
45672425|NCT05474573|Device|Fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope
45672426|NCT05006261|Device|Tele-Tai Chi|12-week simplified TC program using the Tele-TC platform at home, with recommended training sessions at least three times a week, and two or more supplementary live sessions.
45672427|NCT01683604|Other|Observational study|
45672428|NCT05417243|Other|Trauma life support training|Clusters are randomised for their residents to be trained in one of two trauma life support training programs or to continue providing standard care.
45672429|NCT05417165|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given IM
45672430|NCT05417165|Biological|Pneumococcal Polyvalent Vaccine|Given IM
45672431|NCT04843709|Drug|MRG004A|Administrated intravenously
45672432|NCT02196038|Behavioral|multi-domain rehabilitation intervention|Individual, tailored, progressive physical function rehabilitation intervention
45672433|NCT02196038|Behavioral|Attention Control|Usual care with bi-weekly contact from study staff
45672434|NCT04660643|Drug|Tirzepatide|Administered SC
45978548|NCT00287066|Drug|Regular Human Insulin|
45978549|NCT00313521|Drug|thiotepa|
45978550|NCT00313521|Procedure|adjuvant therapy|
45978551|NCT00313521|Radiation|radiation therapy|
45978552|NCT00320463|Biological|DTPa-HBV-IPV/Hib vaccine|
45978553|NCT00419289|Behavioral|follow-up rehabilitation of participants with COPD|
45978554|NCT00287183|Drug|PF-04494700 (TTP488)|60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication
45978555|NCT00287183|Other|Placebo|Placebo
45978556|NCT00419406|Procedure|UVA1 phototherapy|
45978557|NCT00419406|Procedure|NB-UVB phototherapy|
45978558|NCT00287261|Drug|zoledronic acid|4 mg IV every 3 weeks for 36 weeks
45978559|NCT00313599|Drug|lapatinib|
45978560|NCT00313599|Drug|paclitaxel|
45978561|NCT00287300|Drug|Sulfadoxine-Pyrimethamine|
45978562|NCT00287300|Drug|Azithromycin|
45978563|NCT00287300|Drug|Artesunate|
45978564|NCT00313755|Procedure|Narrow Band Imaging|
45978565|NCT00320502|Drug|BXT-51072|
45978566|NCT00287378|Drug|omalizumab|omalizumab as per weight and IgE
45978567|NCT00320580|Drug|norelgestromin/ethinyl estradiol|
45978568|NCT00287417|Device|echography|
45978569|NCT00287417|Other|blood sample|
45978570|NCT00320619|Drug|Epsilon-Aminocaproic Acid (EACA)|Participants will receive EACA intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
45978571|NCT00320619|Drug|Placebo|Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
45978572|NCT00287456|Device|Insulin Pump|
45978573|NCT00287456|Drug|Insulin|0
45978574|NCT00287456|Procedure|Oral Glucose Tolerance Test|0
45672435|NCT04660643|Other|Placebo|Administered SC
45672436|NCT04659317|Drug|Oxycodone 5 mg Oral Tablet|Encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed
45978575|NCT00287456|Procedure|Whole body Protein Turnover|0
45978576|NCT00313833|Drug|Buprenorphine transdermal delivery system|
45978577|NCT00287495|Drug|BAY 43-9006|BAY 43-9006 200 mg once daily with dose escalation up to 400 mg twice daily
45456257|NCT04522284|Drug|XELIRI|"Treatment with the selected regimen will take up to a maximum duration of 12 months, in 3-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range. Maximum dose of capecitabine in the predetermined safety range is set at 100% of standard starting dose (i.e. 1000 mg/m2 twice daily for XELIRI regimen). Minimum dose of capecitabine in the predetermined safety range is set at 50% of the standard starting dose (i.e. 500 mg/m2 twice daily for XELIRI regimen). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range.~The doses of other drug in the XELIRI regimen (irinotecan) will be held constant or adjusted at the clinical investigator's discretion, as per standard of care."
45672437|NCT04659317|Drug|Placebo oral tablet|Encapsulated placebo tablets x24, to take po q6 hours as need for pain
45978578|NCT00320658|Biological|MSP1 42-C1/Alhydrogel|Recombinant MSP1 42-C1/Alhydrogel vaccine (one of two doses)
45672438|NCT05369585|Dietary Supplement|TOTUM-63|5-g per day dose of TOTUM-63 supplement, a mix of 5 plant extracts. Daily dose for 8 weeks followed by a 4 weeks follow-up period without supplementation.
45831922|NCT03925038|Behavioral|Augmented Care: Electronic Media Dashboard|A participant-specific dashboard that highlights patterns of patient electronic communication usage relevant to understanding participants' mental health will be developed and used to augment treatment as usual.
45831923|NCT03925038|Behavioral|Treatment as Usual|Participants will receive psychotherapy as treatment as usual.
45831924|NCT04149600|Procedure|Patients scheduled to undergo aortic valve replacement or aortic surgery at BIDMC will be approached for participation in this study.|Adult patients undergoing aortic valve replacement (AVR) and/or aortic resection will be enrolled.
45978579|NCT00320658|Biological|CPG 7909|Adjuvant
45978580|NCT00287534|Drug|Anastrozole|oral
45978581|NCT00287534|Drug|Tamoxifen|oral
45978582|NCT00313872|Drug|DP|D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr Pre & Post medication Dexamethasone 8mg PO D0 Night (X1) D1 immediately upon waking in the morning, 1 hour before infusion Taxotere, Night (X3) D0 NS 1500 mL IV overnight hydration D1 DNK2 1000 mL IV over 2 hours, pre & post hydration (if Mg <WNL, mix MgSO4 1 amp) 20% Mannitol 70 mL IV full dripping, 30 mins before cisplatin D2-D3 Dexamethasone 8 mg PO bid, D4-D5 Dexamethasone 4 mg PO bid every 3 weeks
45978583|NCT00313872|Drug|FOLFIRI|FOLFIRI regimen D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan
45831925|NCT04149522|Device|Mepitel Film®|As a part of this research study, Mepitel Film® will be placed prior to a participant's first radiation treatment, and will be removed one week following the end of treatment. The Film will be placed by the physician or his/her designee to cover approximately one-half of the breast divided in the cephalo-caudal plane. The film will remain in place until one week following the completion of radiotherapy. Any loss of film applied will be replaced as needed. Application of the Film is done by research personnel clinically trained in its application procedures.
45831926|NCT04140786|Drug|Gentamicin Sulfate, Injectable|10mg/kg prepared from commercially available stock (typically Kabi Pharmaceuticals) by licensed pharmacists.
45831927|NCT04144998|Diagnostic Test|central sensitization inventory (questionnaire)|T.G. Mayer, R. Neblett, H. Cohen, et al. The development and psychometric validation of the central sensitization inventory Pain Pract, 12 (2012), pp. 276-285
45831928|NCT04147650|Drug|0.05% Voclosporin Ophthalmic Solution (VOS)|0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
45831929|NCT04147650|Drug|0.10% VOS|0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
45831930|NCT04147650|Drug|0.20% VOS|0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
45831931|NCT04147650|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks
45978584|NCT00287573|Device|TAXUS Express2|Paclitaxel-Eluting Coronary Stent System
45978585|NCT00287573|Procedure|Brachytherapy (beta source)|Brachytherapy (beta source)
45978586|NCT00320697|Drug|bupropion + nicotine patch + nicotine gum or lozenges|Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
45672439|NCT04855643|Device|home-based active tDCS|Anode and cathode electrodes will be placed over the left and right dorsolateral prefrontal cortexes, respectively, with the use of the Omni-Lateral-Electrode system. Caregivers will set up and administer tDCS for participants with ADRD at home. tDCS will be applied for 30 min at an intensity of 2mA, with 30 s ramping up and down. All sessions will be remotely supervised by trained research staff.
45831932|NCT04023942|Behavioral|Weight maintenance intervention|Weight maintenance intervention (52 weeks): After randomization, participants will follow either a low carb or a low fat diet and get nutritional assistance either by an app or a newsletter, based on the group they got randomized to (low carb/app, low carb/newsletter, low fat/app, low fat/newsletter).
45978587|NCT00320697|Drug|Placebo pill + placebo patch|Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
45978588|NCT00287612|Procedure|Lap. Fundo. with Mobilization of the Esophageal Junction|Complete mobilization of the esophageal junction
45978589|NCT00287612|Procedure|Lap. Fundo. without Mobilization of the Esophageal Junction|phrenoesophageal membrane left intact
45831933|NCT04022226|Drug|Ketamine|Induction agent that suppresses infra-slow waves
45672440|NCT04855643|Device|home-based sham tDCS|For sham stimulation, electric current will be applied only in the first 30s tDCS. All sessions will be remotely supervised by trained research staff.
45672441|NCT05358353|Device|Bare Temporary Spur Stent System|Treatment of qualifying infrapopliteal arteries with the Bare Temporary Spur Stent System, in subjects with critical limb ischemia.
45672442|NCT03602261|Drug|Calcifediol Oral Capsule|Capsule, weekly
45831934|NCT04022226|Drug|Methohexital|Induction agent that does not suppress infra-slow waves
45831935|NCT04029012|Drug|Methoxyflurane|Methoxyflurane inhaler before Rezum procedure
45831936|NCT04025658|Drug|Oxytocin|Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
45831937|NCT05588856|Other|In depth Interview|In depth Interviews
45978590|NCT00287651|Procedure|Pulsatile IV Insulin|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
45978591|NCT00287651|Procedure|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Control Patients are not given pulsatile intravenous insulin therapy during the study.
45978592|NCT00287651|Procedure|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
45978593|NCT00322296|Drug|Bexarotene 1% gel|
45978594|NCT00320736|Drug|galantamine|
45978595|NCT00287768|Drug|docetaxel + S-1|Docetaxel iv on day one and S-1 po days 1 to 14 every 3 weeks
45978596|NCT00287768|Drug|S-1|S-1 po days 1-28 every 6 weeks
45978597|NCT00320775|Drug|VEGF Trap|"Part A: Six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye.~Part B: Up to 30 subjects will be randomly assigned in a 1:1 ratio to receive a single of 2.0 mg/eye VEGF Trap followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later.~Part C: Approximately 30 subjects will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap.~After completion of Visit 8 (Day 57), patients from all parts of the study, may be eligible to continue in Open-label Extension and will receive 4.0 mg of VEGF Trap."
45978598|NCT00287807|Behavioral|Self-monitoring of blood glucose (SMBG)|2 times a week (one in weekend and one during week) self measurement of blood glucose: fasting and three times post prandial
45978599|NCT00320814|Drug|VEGF Trap-Eye|single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
45672443|NCT03602261|Drug|Placebo oral capsule|Capsule, weekly
45672444|NCT02141659|Drug|TAK-385|TAK-385 Tablets.
45672445|NCT01640249|Drug|Placebo|Capsules administered orally
45672446|NCT01640249|Drug|LY3006072|Capsules administered orally
45831938|NCT05588466|Other|CDS Alone|The practices in the 'CDS alone' arm will receive an updated CDS for HTN management.
45831939|NCT05588466|Other|CDS plus practice facilitation|The practices in the 'CDS plus practice facilitation' arm will receive an updated CDS for HTN management plus practice facilitation to support the adoption of the CDS.
45831940|NCT03605706|Drug|SHR-1210|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
45978600|NCT00287846|Drug|imatinib mesylate|
45978601|NCT00322413|Drug|Epoetin|
45978602|NCT00320853|Drug|Vitamin D|
45978603|NCT00287885|Drug|docetaxel|Three patients will be enrolled and dosed at each level; from dose level 1 of 2.9 mg/m^2/day up to dose level 6 of 6.4 mg/m^2/day
45978604|NCT04717713|Drug|steroid injection|steroid injection at surgical location
45978605|NCT04717713|Drug|placebo|saline injection at surgical location
45978606|NCT00287924|Drug|methotrexate|
45978607|NCT00287924|Procedure|adjuvant therapy|
45978608|NCT00322530|Procedure|Renal replacement therapy|ICU patients with acute renal failure were prospectively randomized to either CVVHD or SLED
45978609|NCT00287963|Drug|topotecan hydrochloride|
45456258|NCT04522284|Drug|Ibrutinib|"Treatment with the selected regimen will take up to a maximum duration of 12 months, in 4-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range.~Maximum total cumulative dose per cycle of Ibrutinib in the predetermined safety range is set at 100% of standard starting dose (i.e. 420 mg once daily for 4 weeks, which constitutes the total of 11760 mg per cycle). Minimum total cumulative dose per cycle of Ibrutinib in the predetermined safety range is set at 50% of the standard starting dose (i.e. 280 mg once daily on alternative days with 140 mg once daily, which constitutes the total of 5880 mg per cycle). The dosing range may be altered to suit the specific circumstances of the participant, thus giving the participant-specific safe dosing range."
45672447|NCT02121301|Drug|Low Dose 0.155µg/mL SkQ1 ophthalmic solution|eyedrops
45978610|NCT00287963|Drug|vinorelbine tartrate|
45978611|NCT00320892|Drug|Atropine Sulphate 1% ophthalmic drops|Atropine Sulphate 1% ophthalmic drops will be used, by Fisher Pharmaceutical Labs, at a dose of 2 drops per administration
45978612|NCT00288002|Biological|trastuzumab|
45978613|NCT00288002|Drug|capecitabine|
46082605|NCT02794688|Procedure|Ductal lavage therapy|"Patient lies in supine position, with routine sterilizing and draping procedure.~Local anesthesia with 2ml lidocaine (1%) around the nipple.~Identification of 4-5 openings of the lactiferous ducts from the nipple.~Insertion of all infusion cannula (21-23G ) into the identified openings of the lactiferous ducts.~Start the infusion pump with 15ml irrigation solution (2% Lidocaine 5ml, Triamcinolone acetonide 40mg，0.9% saline 10ml and ceftriaxone 1.0g). If the patients had elevated white blood cell count and fever (>38 celsius degree), oral intake or infusion of antibiotics were allowed, when necessary.~The patient returns to the clinic the next day, with the irrigation solution staying in the lactiferous ducts overnight, and receives breast massage.~Repeat step 1-6 every other day for 2 weeks.~Fine needle aspiration is allowed. Oral intake of corticosteroids, excisional drainage or surgery are not allowed."
45456259|NCT04512976|Other|Cooing Modalities|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.~A fan will be a commercially available fan will be directed to the research subject throughout the exercise bout.~Skin wetting will be performed by spraying water onto the well-healed grafted skin throughout the exercise bout.~A combination of a fan and skin wetting will be performed by simultaneously applying both cooling modalities throughout the exercise bout."
45456260|NCT04494386|Biological|Umbilical Cord Lining Stem Cells (ULSC)|IV infusion of allogeneic ULSC (100 million cells per dose) in sterile saline for injection
45456261|NCT04494386|Other|Placebo (carrier control)|IV infusion of carrier control consisting of sterile saline for injection
45456262|NCT04492891|Drug|Cyclosporine|2.5 mg/kg PO BID 7 days
45672448|NCT02121301|Drug|High Dose 1.55µg/mL SkQ1 ophthalmic solution|eyedrops
45831941|NCT03605706|Drug|FOLFOX4|Subjects receive FOLFOX4 treatment on D1-D2 of every 2 weeks
45831942|NCT03605706|Drug|Placebo|Subjects receive placebo of SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
45456263|NCT04492891|Other|Standard of Care Treatment|Standard of Care Treatment, N= 25 Patients, 7 days
45831943|NCT03924180|Dietary Supplement|Dietary Supplement for PKU patients|For both treatment groups, the objective in total protein will be 1g / kg / day of ideal weight, in 3-6 doses / day, including natural proteins and supplemented by the products under study.
45831944|NCT05581680|Other|dental impressions|dental impressions
45978614|NCT00288002|Drug|cyclophosphamide|
45672449|NCT02121301|Drug|Placebo (Vehicle) opthalmic solution|eyedrops
45672450|NCT05422703|Device|Kinesio tape|Skin-colored Kinesiology Tape (ARES tape,5 cm×5 m) is waterproof tape is made of 100% cotton,applied in the shape of a fan strip, waterproof. The width is 5 cm and thickness of 0.5 mm (5 cm×5 m ).This tape is sticking with a small stretch (about 15%).
45672451|NCT05422703|Other|Gauze pack|Place gauze pack over surgical site for one hour after surgery.
45672452|NCT05422703|Device|ice pack|Ice packs will be applied for 6 hours after surgery in all patients
45831945|NCT05581680|Other|Simultaneous MoCap and EMG acquisition|Simultaneous MoCap and EMG acquisition
45831946|NCT05581680|Other|Eye-tracking acquisition for pathological subjects|Eye-tracking acquisition for pathological subjects
45831947|NCT05581680|Other|Follow-up visit for pathological subjects|Follow-up visit for pathological subjects
45831948|NCT04023240|Drug|68Ga-FAPI|"68Ga-FAPI is quinoline based PET radiopharmaceutical.~68Ga-FAPI is administered intravenously (IV)"
45831949|NCT04023240|Procedure|Computed Tomography (CT) scan|Participants will have a CT scan for attenuation correction and anatomic localization of PET data.
45831950|NCT04023240|Procedure|Positron Emission Tomography (PET) scan|PET images will be acquired.
45978615|NCT00288002|Drug|docetaxel|
45978616|NCT00288002|Drug|epirubicin hydrochloride|
45978617|NCT00288002|Procedure|adjuvant therapy|
45978618|NCT00288002|Procedure|conventional surgery|
45978619|NCT00288002|Procedure|neoadjuvant therapy|
45978620|NCT00322569|Device|Corio™ Pimecrolimus-Eluting Coronary Stent System|Drug-eluting stent
45978621|NCT00322569|Device|SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System|Drug-eluting stent
45978622|NCT00322569|Device|Costar ™ Paclitaxel-Eluting Coronary Stent System|Drug-eluting Stent
45978623|NCT00288041|Drug|carboplatin|Given IV
45978624|NCT00288041|Drug|paclitaxel|Given IV
45978625|NCT00288041|Drug|bortezomib|Given IV
45978626|NCT00320970|Drug|Candesartan|
45978627|NCT00322608|Drug|NPI-2358|Treatment on Days 1, 8 and 15 in a 28 day cycle
45978628|NCT00288158|Drug|Allopurinol|
45978629|NCT00288158|Drug|Probenecid|
45978630|NCT00288158|Drug|Placebo|
45978631|NCT04717752|Drug|Ovidrel|recombinant human chorionic gonadotropin for injection
45978632|NCT04717752|Drug|Troprilin|triptorelin acetate injection
45978633|NCT00288197|Drug|voriconazole|
45978634|NCT00288236|Drug|Rimonabant (SR141716)|
45978635|NCT00288236|Drug|Placebo|
45831951|NCT05586438|Drug|Colistin Sulfomethate|The patients receive colistin 150 mg intravenous once daily on non-dialysis day and receive colistin 150 mg intravenous every 12 hours on dialysis day
45978636|NCT00322686|Drug|Oglemilast|Oglemilast, 15mg oral administration, once per day and then dose-matched placebo
45978637|NCT00322686|Drug|Placebo then Oglemilast|Dose-matched placebo and then Oglemilast, 15mg, oral administration, once per day.
45978638|NCT00321087|Drug|T2000|Dose escalation from 600 to 1000 mg
45978639|NCT00321087|Drug|T2000|Placebo followed by T2000 dose escalation from 600 to 1000 mg
45978640|NCT00321087|Drug|T2000|Placebo followed by dose escalation from 600 to 1000
45978641|NCT00288314|Procedure|Magnetic Resonance Imaging, Functional|Structural and functional MRI
45672453|NCT05422703|Procedure|Manual therapy|passive and active range of motion, stretching exercises, resistive mouth exercises, mobilization exercises and coordination exercices.
45456264|NCT04490564|Diagnostic Test|PD-L1 Kit|Clinical performance of PD-L1 kit in CTCs of peripheral blood and tumor tissue samples
45456265|NCT04489888|Drug|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each 21-day cycle
45672454|NCT05422703|Drug|Analgesic|NSAIDs like ibuprofen (600-800 mg) or declophenac sodium (50-150 mg) 3 times a day
45672455|NCT05422703|Drug|Proteolytic enzymes|1-2 ampoules daily IM box of 3 ampoules of 5 mg crystallized and lyophilized chymotrypsin (450 E. A. Units) + 3 ampoules of 3 ml apyrogenic saline for one week.
45672456|NCT05422703|Drug|Mouth wash|use 0.12% chlorhexidine or povidone iodine mouthwash daily
45672457|NCT05422703|Dietary Supplement|Soft cold diet|For the day of surgery
45672458|NCT02227862|Drug|Mylan's insulin glargine|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period, and will continue on this for the complete trial. During the 6 week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
45831952|NCT05581524|Device|VASC|At day 0 the patient will undergo the VASC treatment procedure with VelexTM device. VelexTM venous catheter is inserted in the introducer and pushed in the desired position under echo guidance. At 7 days, 1, 3 and 6 months after the procedure, the patients will undergo a clinical examination and an echo-color doppler assessment.
45831953|NCT04765878|Device|RespirAq Humidification|Humidifier
45831954|NCT04024566|Device|Vivio System|Optical/sensor tonometer applied to the neck over the carotid pulse (bilateral)
45831955|NCT04025814|Device|CaregiverAssist|CaregiverAssist is a proposed dHealth tool to promote parent adherence and sustained strategy use of evidence-based parenting strategies.
45831956|NCT04025814|Behavioral|Behavioral Parent Training (CLS Parent Group)|Collaborative Life Skills (CLS) program is implemented at school sites by school mental health providers who are trained by University of California San Francisco (UCSF) project staff
45456266|NCT04489888|Drug|Carboplatin|Carboplatin AUC 5 mg/mL/minute IV infusion given on Day 1 of each 21-day cycle
45456267|NCT04489888|Drug|Paclitaxel|At investigator's choice, paclitaxel 100 mg/m^2 IV infusion given on Day 1 and Day 8 of each 21-day cycle or paclitaxel 175 mg/m^2 IV infusion given on Day 1 of each 21-day cycle
45456268|NCT04483856|Device|DermoRelizema cream|Fingertip units (FTU) depending from the extent of the affected skin to treat, two times per day for 7 (±3) days prior RT until about 14 (±3) days post RT end. The product can be used for further 2 weeks (from V3 to V4) in case of need, according to the investigator's judgment
45831957|NCT05581446|Diagnostic Test|Visual Analogue Scale|pain type severity determination and quality of life assessment
45831958|NCT03921294|Drug|Emicizumab|bispecific monoclonal antibody binding to activated Factor IX and Factor X
45831959|NCT04145232|Biological|Collection of biopsy (FFPE), blood (PBMC) and stool|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
45978642|NCT00321126|Drug|Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.|
45978643|NCT00288353|Drug|aripiprazole (Abilify)|active drug given daily as per package insert according to standard clinical care for twelve month duration of study. Subject will be switched from current antipsychotic to this drug or other randomized study medication.
45978644|NCT00288353|Drug|ziprasidone (Geodon)|active medication will be given daily as per package insert according to standard clinical care for the twelve month duration of the study. Subject will be switched from current antipsychotic medication to this medication or the other randomized medication.
45978645|NCT00288392|Drug|Soluble beta-1,3/1,6-glucan|
45978646|NCT00322764|Drug|Uridine|
45978647|NCT00288431|Drug|ridaforolimus|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
45978648|NCT00288431|Drug|Doxorubicin|administered at 60 mg/m2 intravenously every 3 weeks
45978649|NCT00321165|Drug|taurolidine|
45978650|NCT04718363|Other|PNF stretching|A contract-relax PNF stretching technique will be applied to hamstring muscle.
45978651|NCT04718363|Other|Non-vibration foam rolling prior to PNF stretching|Prior to PNF stretching, participant will perform unilateral hamstring non-vibration foam rolling.
45978652|NCT04718363|Other|Vibration foam rolling prior to PNF stretching|Prior to PNF stretching, participant will perform unilateral hamstring vibration foam rolling (48 Hz).
45978653|NCT00322803|Drug|ELB139|
45978654|NCT00417560|Biological|inactivated influenza A/H5N1 vaccine|
45978655|NCT00321204|Procedure|TZD reducing the incidence of atrial arrhythmias|
45978656|NCT00417599|Behavioral|Lifestyle Intervention|lifestyle intervention .
45978657|NCT00417599|Other|control group|waiting list control group
45978658|NCT00322920|Drug|Topotecan|
45978659|NCT00322920|Drug|Cisplatin|
45978660|NCT00417638|Device|Endovascular cooling by the Celsius Control System|
45978661|NCT00417638|Other|Standard of care|
45978662|NCT00321009|Drug|Enoxaparin|
45978663|NCT00417677|Drug|Combination of Temsirolimus and Sunitinib|
45978664|NCT00417716|Drug|Intravitreal Bevacizumab|
45978665|NCT00321243|Behavioral|Visual clues|
45978666|NCT00321282|Procedure|Atrial Fibrillation|
45978667|NCT00288470|Device|Hylaform, Hylaform Plus (hylan B gel)|
45978668|NCT00321360|Drug|Propofol|
45978669|NCT00321360|Device|Patient maintained sedation|
45978670|NCT02960594|Biological|INO-1400|
45978671|NCT02960594|Biological|INO-9012|
45978672|NCT02960594|Biological|INO-1401|
45672459|NCT02227862|Drug|Lantus®|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period; and will continue on this for the complete trial. During the 6week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
45672460|NCT05422391|Dietary Supplement|3 day caloric restriction/metabolic reset|Participants will consume ~500 kcal/day, using commercially available products (Plexus(r)), for 3 days, measuring physiological relevant parameters pre-and post-intervention.
45831960|NCT04144764|Other|Workplace-based exercise|Participants will have to perform 10-week of workplace-based exercise programme which consist of 5 sessions of 10 minutes per week. The workplace-based exercise programme will consist of general stretching and strengthening exercise using resistance tubing for both the neck and upper limb. Specific rotator cuff and scapular muscles strengthening exercise were also included to enhance glenohumeral and scapular kinematics (Appendix). Each participant will receive a set of elastic resistance tubing that comprise red (2kg), green (3kg) and blue (4kg). The exercise programme will be taught by physiotherapist during their baseline assessment. They will be asked to train at the workplace during workdays (Monday to Friday), five times a week during the 10-week intervention. The program built on the principle of progressive overload.
45978673|NCT00288548|Drug|Metoprolol|
45978674|NCT00321477|Drug|GW679769 oral tablets|
45978675|NCT00288665|Device|Export catheter (Medtronic)|
45978676|NCT00321516|Drug|aripiprazole|Tablets, Oral, 10, 20, or 30 mg (titrated), once daily, 14 days.
45978677|NCT00288743|Drug|to implement an insulin protocol with target blood glucose levels between 81-110 mg/dL.|
45978678|NCT00321633|Drug|carboplatin|
45978679|NCT00321633|Drug|docetaxel|
45978680|NCT02960633|Device|Corail with collar.|
45978681|NCT02960633|Device|Corail without collar.|
45978682|NCT00288782|Drug|Mirtazapine|
45978683|NCT01059825|Drug|Placebo to Ertugliflozin|Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days
45978684|NCT01059825|Drug|Ertugliflozin 1 mg|Tablet, 1 mg, once daily for 84 days
45978685|NCT01059825|Drug|Ertugliflozin 5 mg|Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days
45978686|NCT01059825|Drug|Ertugliflozin 25 mg|Tablet, 25 mg, once daily for 84 days
45978687|NCT01059825|Drug|Sitagliptin 100 mg|Tablet, 100 mg, once daily for 84 days
45978688|NCT01059825|Drug|Placebo to Sitagliptin|Tablet, matching placebo to 100 mg, once daily for 84 days
45978689|NCT01059825|Drug|Metformin|Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).
45978690|NCT00288899|Other|"Enhanced surgical iMedConsent process (with repeat back)"|"Consent process engages patient in discussion about why they are having procedure, risks, benefits, alternatives. Then provider asks patient to repeat backwhat they understand."
45978691|NCT00288899|Other|standard surgical iMedConsent process|Patients are consented in standard VA consent process, where are not necessarily asked to repeat back and no discussion is necessarily documented.
45978692|NCT00321750|Drug|1% pimecrolimus cream|
45978693|NCT00321867|Procedure|Graft augmented posterior repair|Posterior repair with graft
45978694|NCT00321867|Procedure|Control|Native tissue repair
45978695|NCT00288977|Procedure|Islet Infusion|
45978696|NCT00321945|Procedure|ACE-Inhibitors and Angiotensin Receptor Blockers|Retrospective study - no intervention as part of study.
45978697|NCT00323076|Drug|18F-FAZA PET Imaging|"Phase I: 110-600 MBq per injection. A single injection of 18F-FAZA and PET scan will be permitted per patient.~Phase II: 110-600 MBq per injection. Up to three separate injections of 18F-FAZA and PET scans will be permitted per patient."
45978698|NCT00323154|Drug|Nalbuphine|
45978699|NCT00289055|Device|stent|Cordis SMART™ Nitinol Stent
45978700|NCT00289055|Device|angioplasty|balloon angioplasty
45978701|NCT00323232|Device|2 Versus 4 Hole DHS|See Detailed Description.
45978702|NCT00289172|Biological|Live attenuated human rotavirus vaccine|
45978703|NCT00323349|Procedure|Oral Glucose Tolerance Testing|
45978704|NCT00323349|Behavioral|Education tailored to learning style preferences|
45978705|NCT00289250|Drug|Sulfadoxine-pyrimethamine|
45978706|NCT00289250|Drug|Sulfadoxine-pyrimethamine plus artesunate|
45978707|NCT00289367|Drug|Triiodothyronine|0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
45978708|NCT00289367|Drug|triiodothyronine|IV formulation - Triostat, 0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
45978709|NCT00323505|Drug|Pegylated Interferon|
45978710|NCT00323505|Drug|Interferon-alpha2a|
45978711|NCT00289406|Drug|S-amlodipine gentisate|
45978712|NCT00289406|Drug|Amlodipine besylate|
45978713|NCT00323544|Drug|zidovudine and lamivudine (Combivir®)|
45978714|NCT00323544|Drug|emtricitabine and tenofovir DF|
45978715|NCT00289445|Drug|Mitomycin C|
45978716|NCT00289445|Drug|5-FU|
45978717|NCT00289445|Drug|Folinic acid|
45978718|NCT00323583|Drug|paclitaxel|
45978719|NCT00323583|Drug|oxaliplatin|
45978720|NCT00323583|Drug|leucovorin|
45978721|NCT00323583|Drug|5-fluorouracil|
45672461|NCT02120833|Device|EpiCeram® Skin Barrier Emulsion|Device (including sham) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
45978722|NCT00323583|Drug|glutathione|
45978723|NCT00323583|Drug|calcium and magnesium|
45978724|NCT00323583|Procedure|Chemotherapy|
45978725|NCT00323583|Procedure|Chemoprotection|
45978726|NCT00323583|Procedure|Complementary and alternative therapy|
45978727|NCT00289484|Drug|Omega-3 Polyunsaturated Fatty Acids|
45978728|NCT00323661|Device|Rate-adaptive pacemaker: accelerometer|Accelerometer based pacing rate adaptation
45978729|NCT00323661|Device|Rate-adaptive pacemaker: Closed Loop Stimulation|Closed Loop Stimulation (CLS) is a unique concept in rate-adaptive pacing that uses the natural cardiovascular control loop to determine the appropriate pacing rate. Closed Loop Stimulation is the only rate-adaptive system responding to mental stress and thereby assuring optimal cerebral perfusion in everyday activity.
45978730|NCT00289562|Drug|forodesine hydrochloride (BCX-1777)|
45456269|NCT04483856|Device|Dexeryl|FTUs depending on the extent of the affected skin to treat, two times per day. The treatment will be applied since 7 (±3) days prior to RT start and will continue until 14 days post RT end (98-112 applications in total).
45672462|NCT02120833|Drug|Colloidal Oatmeal Cream|Drug (including placebo) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
45672463|NCT04615949|Drug|Cannabidiol, pharmaceutically produced with < 5 ppm THC|CardiolRx 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
45672464|NCT04615949|Drug|Placebo|Placebo 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
45831961|NCT04144764|Other|Ergonomic advice and education|Participants will receive ergonomic training and education on how to adjust their workstations to reduce the ergonomic risk factors when using computers.
45831962|NCT04029246|Behavioral|Follow up phone call|Telephone call to ask if patient has received letter and whether they would like an appointment
45831963|NCT04029246|Behavioral|Incentive|Offer of a shopping voucher if patient attends for appointment
45831964|NCT04144920|Behavioral|CS: Continuous sitting|Participants were asked to sit continuously throughout the duration of the lab visit.
45978731|NCT00289601|Drug|eptifibatide|
46082606|NCT02719470|Behavioral|MIRT|MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
45672465|NCT04597307|Combination Product|IN.PACT™ Admiral™ Drug Coated Balloon (DCB)|For percutaneous transluminal angioplasty (PTA) in subjects with obstructive disease of the peripheral arteries.
45672466|NCT04591379|Drug|Influenza Vaccines|Intratumoral application of an unattenuated influenza vaccine
45672467|NCT05413265|Other|Written cessation & support materials|Resources and referral information on evidence-based tobacco/nicotine cessation treatment services
45672468|NCT05413265|Other|Financial Incentive|Cash rewards for achieving biochemically verified smoking abstinence at each time point
45831965|NCT04144920|Behavioral|HFLD: HIgh frequency, low duration standing breaks|Participants were asked to interrupt their sitting time every 15 minutes using 2.5-minute standing breaks.
45831966|NCT04144920|Behavioral|LFHD: Low frequency, high duration standing breaks|Participants were asked to interrupt their sitting time every 60 minutes using 10-minute standing breaks.
45978732|NCT00323778|Drug|Hyalgan|
45978733|NCT00289679|Device|Hip prosthesis revision|
45978734|NCT00323817|Drug|Z-338|
45978735|NCT00289796|Biological|DTPa-HBV-IPV/Hib|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b conjugate vaccine
45978736|NCT00323895|Device|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
45978737|NCT00323895|Device|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
45978738|NCT00323895|Device|drug-eluting stent|CYPHER Select ™ Sirolimus-eluting Stent
45978739|NCT00289835|Device|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
45978740|NCT00303225|Drug|Vaccine: SIGA-246|
45978741|NCT00323934|Drug|MGCD0103|Oral dosage 2 times weekly.
45978742|NCT00290030|Drug|Alfuzosin|
45978743|NCT00303264|Drug|dexloxiglumide|
45978744|NCT00303264|Drug|Nexium (esomeprazole)|
45978745|NCT00290069|Drug|Tacrolimus|
45978746|NCT00290069|Drug|Rapamycin|
45978747|NCT04718259|Drug|intrathecal bupivacaine|The use of intrathecal bupivacaine will be compared to the use of intrathecal bupivacaine and midazolam.
45978748|NCT04718259|Drug|midazolam|midazolam
45978749|NCT00290108|Drug|Propofol|
45978750|NCT00323973|Drug|Bisoprolol|10 mg qd
45978751|NCT00290225|Behavioral|Breath Water Sound Course and Traumatic Incident Reduction|
45978752|NCT00324012|Drug|cisplatin, taxotere|cisplatin 75 mg/m2 Taxotere 75 mg/m2
45978753|NCT00290264|Drug|Budesonide/formoterol|
45978754|NCT00303303|Biological|Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; active maintenance therapy with 2 vials administered 6, 12, and 18 hours after initial control is achieved.
45672469|NCT05411627|Device|Shockwave Therapy|Participants will receive shockwave therapy once per week for three weeks.
45978755|NCT00303303|Biological|Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; placebo maintenance therapy administered 6, 12, and 18 hours after initial control is achieved.
45831967|NCT04027452|Behavioral|Traumatic memory reactivation|"125 word long exposure scripts of their traumatic memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course."
45978756|NCT00303303|Biological|Placebo|Placebo therapy in place of initial and maintenance antivenom therapy. Note that open-label rescue therapy is mandated if the envenomation syndrome becomes severe, or if progression of envenomation signs/symptoms has not spontaneously halted by 6 hours.
45978757|NCT00303342|Behavioral|mind body treatment|regulation of attention, respiration and posture
45978758|NCT00303342|Behavioral|desensitization|mentation on insomnia behaviors and cognitive activity
45978759|NCT00290303|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
45978760|NCT00324051|Drug|olanzapine therapy|
45978761|NCT00290381|Drug|Study drug administration|
45978762|NCT00290381|Procedure|Skin prick test|
45978763|NCT00290381|Procedure|12-lead ECG|
45978764|NCT00290381|Procedure|Laboratory safety samples|
45978765|NCT00290381|Procedure|Alcohol breath test|
45978766|NCT00290381|Procedure|Smokerlyzer test|
45672470|NCT02170207|Drug|Lansoprazole|Lansoprazole 30 mg injection
45672471|NCT05399927|Other|Music Intervention|The objective of this study is to observe the effects that music produces on physiological parameters, in patients with Acute Cardiovascular Disease (ACVD), and to determine its influence on the types or doses of drugs administered during initial care. The intervention study is carried out in the ambulance cabin during the time of transfer to the destination Hospital.
45978767|NCT00290381|Procedure|Urine drug test|
45456270|NCT04481334|Other|Collaborative occupational therapy interactive vaulting group|Children will participate in a weekly 60 minute group that focuses on the devilment of social skills by incorporating activities that require team work. Part of the intervention will incorporate the equine to better understand non-verbal body language. It should be noted that each child will have two agreed upon goals developed that are agreed upon by the child and the parent and will be of emphasis during each group.
45978768|NCT00290381|Procedure|Blood test for drug concentrations|
45978769|NCT00290381|Procedure|Nasal allergen challenge|
45978770|NCT00290381|Procedure|Nasal filter paper placement|
45978771|NCT00290381|Procedure|Total nasal symptoms scores|
45978772|NCT00303381|Drug|Interferon-beta-1a, 44 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 44 mcg, three times a week up to Week 8.
45978773|NCT00303381|Drug|Placebo|Matching Placebo will be administered subcutaneously, three times a week up to Week 8.
45978774|NCT00303381|Drug|Interferon-beta-1a, 66 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 66 mcg, three times a week up to Week 8.
45978775|NCT00290420|Drug|Chloroquine profilaxis|"Prevention:~Give a profilaxis with chloroquine once a week to prevent Plasmodium vivax malaria attacks and to prevent harmfull effect on birth outcomes"
45978776|NCT00324090|Behavioral|High and low glycemic index|
45672472|NCT04968275|Behavioral|CHAMPS|CHAMPS provides personalized feedback on participants' cannabis use behaviors and supports strategies to change such behaviors. It comprises six modules measuring the use of cannabis protective behavioural strategies, exploring the possible benefits of changing cannabis practices and setting and monitoring the reach of a SMART cannabis use goal.
45978777|NCT00303420|Drug|"Alteplase push protocol"|alteplase 2 mg / lumen. Instill and wait 10 minutes, instill 0.3 ml normal saline, wait 10 minutes, instill 0.3 ml of normal saline, wait 10 minutes and aspirate.
45978778|NCT00303420|Drug|alteplase dwell arm|alteplase 2 mg / lumen. Instill and let it dwell for 30 minutes. Assess catheter and allow to dwell for a total of 2 hours if necessary
45978779|NCT00324129|Drug|MGCD0103|MGCD0103 given orally three times per week.
45978780|NCT00290576|Dietary Supplement|Probiotics supplementation until weight reaches 1800g (Bifidobacterium Longum and Lactobacillus GG )|
45978781|NCT00303537|Drug|metformin|
45978782|NCT00290849|Drug|Bivalirudin|
45978783|NCT00290927|Drug|insulin glulisine|
45978784|NCT00303576|Drug|dapivirine (TMC120) vaginal gel|
45978785|NCT00290966|Drug|XRP6976|
45978786|NCT00324285|Drug|Amylase resistant starch added ORS|
45978787|NCT00291005|Drug|ARD6562, Docetaxel|
45978788|NCT00303615|Drug|Fluoxymesterone 10 mg|
45978789|NCT00303615|Drug|Anastrozole 1 mg|
45978790|NCT00291044|Other|testing for HSV 1 and 2 IgG type specific antibosy|
45978791|NCT00324324|Drug|moxifloxacin hydrochloride|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
45978792|NCT00324324|Drug|Placebo|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
45978793|NCT00303654|Procedure|biopsy|
45978794|NCT00303654|Procedure|therapeutic conventional surgery|
45978795|NCT00291122|Drug|celecoxib 400 mg BID|
45978796|NCT00324363|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day for 16 weeks
45978797|NCT00324363|Drug|Placebo|subcutaneous injection twice daily in volumes equal to exenatide
45978798|NCT00303732|Drug|RAD001 (everolimus)|
45978799|NCT00303732|Drug|PTK787 (vatalanib)|
45978800|NCT00291239|Behavioral|partial sleep deprivation|
45672473|NCT04746079|Behavioral|Positive Imagery Therapy|Perform procedural sedation with slow push of ketamine, 1.5mg/kg, over thirty seconds while reading the Positive Imagery Therapy.
45831968|NCT04027452|Behavioral|Neutral memory reactivation|"125 word long exposure scripts of a neutral (non-traumatic) memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course."
45978801|NCT00291356|Drug|GSK189075 oral tablets|
45978802|NCT00291356|Drug|GW869682 oral tablets|
45978803|NCT00291395|Drug|PGI2|
45978804|NCT00303771|Drug|fluorouracil|
45978805|NCT00303771|Drug|irinotecan hydrochloride|
45978806|NCT00303771|Drug|leucovorin calcium|
45978807|NCT00291473|Drug|CHP-HER2, CHP-NY-ESO-1|
45978808|NCT00324441|Device|Iratherm® 1000|
45978809|NCT00291512|Behavioral|Theory-based counseling program|
45978810|NCT00303810|Drug|carboplatin|
45978811|NCT00303810|Drug|cisplatin|
45978812|NCT00303810|Drug|cyclophosphamide|
45978813|NCT00303810|Drug|etoposide phosphate|
45978814|NCT00303810|Drug|high-dose chemotherapy|
46082607|NCT02801162|Device|conventional ABG analyser|pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
46082608|NCT02801162|Device|Proxima 3®|pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
45672474|NCT04855097|Diagnostic Test|BVA-100|The BVA-100 is a medical device that calculates human blood volume using the method of tracer dilution. The device utilizes a tracer of human serum albumin tagged with iodine-131 to measure injected intravascularly and a series of timed blood draws. The amount of tracer in each blood draw is used to calculate the unknown blood volume. Data inputs come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and tracer transudation rate are reported, with statistics showing the quality of the results.
46082609|NCT02715492|Drug|LMWH|(Enoxheparin) 1 IU/kg per dose twice daily for 2 weeks from the 1st day of TACE
46082610|NCT02715492|Procedure|TACE|Trans arterial chemoembolization
45456271|NCT04480814|Diagnostic Test|PIK3CA kit|Prospective investigation of clinical samples for evaluation of IVD clinical performance
45672475|NCT02227784|Drug|Evacetrapib|Administered orally
45672476|NCT02227784|Drug|Atorvastatin|Administered orally
45978815|NCT00303810|Drug|lomustine|
45978816|NCT00303810|Drug|methotrexate|
45978817|NCT00303810|Drug|thiotepa|
45978818|NCT00303810|Drug|vincristine sulfate|
45978819|NCT00303810|Radiation|radiation therapy|
45978820|NCT00291590|Behavioral|DHEP|
45978821|NCT00324480|Drug|alvocidib|Given IV
45978822|NCT00324480|Drug|vorinostat|Given orally
45978823|NCT00324480|Other|pharmacological study|Correlative studies
45978824|NCT00291629|Drug|G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
45978825|NCT00291629|Procedure|collection of mobilized peripheral blood stem cells|
45978826|NCT00291629|Procedure|Intracoronary infusion of mobilized cells|
45978827|NCT00303888|Drug|docetaxel|Given IV
45978828|NCT00303888|Drug|idronoxil|Given orally
45978829|NCT00303888|Other|placebo|Given orally
45978830|NCT00291707|Drug|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. The infusion rate of cetuximab must never exceed 5 mL/min.
45978831|NCT00291707|Drug|Pemetrexed|• Pemetrexed 350-500 mg/m2 IV over 10 minutes (see dose escalation design. Dose will be decreased to 200 mg/m2, if the first dose level of 350 mg/m2 is not tolerable) on days 1 and 22, (and 43 if >6000 cGy to be delivered)
45978832|NCT00291707|Procedure|radiation therapy|• Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1. Radiation will be given M-F for 6-7 consecutives weeks
45978833|NCT00324519|Device|Foley bulb|
45978834|NCT00324519|Drug|misoprostol|
45978835|NCT00291746|Drug|Esomeprazole|
45978836|NCT00291746|Procedure|Bravo technique|
45978837|NCT00303927|Drug|capecitabine|
45978838|NCT00419484|Drug|pioglitazone|
45978839|NCT00291785|Drug|CT-2106|CT-2106 as 10 minute infusion on days 1, 15 & 29 of each 42-day cycle
45978840|NCT00291785|Drug|Folinic acid|Folinic acid 200 mg IV 1 hour after CT-2106 infusion on days 1, 2, 15, 16, 29 and 30
45978841|NCT00291785|Drug|5-FU (fluorouracil)|5-FU following CT-2106 and folinic acid infusions @ 400 mg/m² IV bolus then 5-FU 600 mg/m² as a 22 hour IV infusion on Days 1, 2, 15, 16, 29, and 30.
45978842|NCT00304005|Drug|laromustine|
45978843|NCT00291824|Behavioral|Cardiovascular risk factors and willingness to change|
45978844|NCT00324558|Drug|Bemiparin|subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT)
45978845|NCT00291863|Drug|Simvastatin|
45672477|NCT02227784|Drug|Ezetimibe|Administered orally
45978846|NCT00304200|Drug|Temozolomide and SU11248|First Cohort: Temozolomide 100 mg/m2 orally week 1 and week 3 of a 28-day cycle; SU11248, 25 mg/day orally on weeks 2, 3, and 4 or a 28 day cycle.
45978847|NCT00291902|Drug|SB-681323|
45978848|NCT00291941|Biological|Henogen HBV vaccine|20µg, Month 0, 2 and 6
45978849|NCT00291941|Biological|FENDRIX|20 µg,Months 0, 1, 2 and 6
45978850|NCT00304239|Procedure|Photodynamic therapy with methyl aminolevulinate cream|
45978851|NCT00291980|Biological|HB-AS02V vaccine|HB-AS02V (20µg HBsAg) will be administered at Month 0
45978852|NCT00291980|Biological|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0
45978853|NCT00324597|Drug|gemcitabine hydrochloride|
45978854|NCT00324597|Drug|motesanib diphosphate|
46082611|NCT03940196|Device|NovoTTF-100L(O)|Patients receive continuous TTFields treatment using the NovoTTF-100L(O) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen/pelvis. The treatment enables the patient to maintain regular daily routine.
45456272|NCT04445532|Other|Gene expression analysis|Gene expression analysis
45672478|NCT02227784|Drug|Placebo|Administered orally
45672479|NCT04419701|Procedure|periarticular infiltration|"The cocktail will be injected at the following 7 anatomical zones as follows:~Zone 1: medial retinaculum Zone 2: medial collateral ligament and medial meniscus capsular attachment Zone 3: posterior capsule Zone 4: lateral collateral ligament and lateral meniscus capsular attachment Zone 5: lateral retinaculum Zone 6: patellar tendon and fat pad Zone 7: cut ends of quadriceps muscle and tendon Injection at zones 2, 3, and 4 will be administered after making the tibial and femoral cuts and ligament balancing. At zones 1, 5, 6, and 7, the injection will be administered after implant placement."
45831969|NCT04144452|Other|Patient Education Session|The intervention of Patient Education will be designed individually according to the patient's need who have undergone lumbar microdiscectomy procedure through MIS. The basic purpose of the educational session will be to inform the participants about their pre operative and current back condition and discuss methods to care for their back. The session will be given for one hour and face to face interaction will be ensured twice a week. Initially the post operative education plan and instructions will be formulated, reviewed and finalized by the operating surgeon.
45978855|NCT00324597|Other|pharmacological study|
45978856|NCT00292019|Procedure|Laparoscopic|Patients with prostate cancer who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robots.
45456273|NCT04445532|Other|Genomic analysis|Genomic analysis
45456274|NCT04445532|Other|Protein expression analysis|Protein expression analysis
45456275|NCT04445532|Other|Proteomic profiling|Proteomic profiling
45978857|NCT00324714|Drug|risedronate sodium|
45978858|NCT00324714|Other|diagnostic laboratory biomarker analysis|
45978859|NCT00292058|Device|Videoconference equipment (telepsychiatry)|
45978860|NCT00304317|Drug|celecoxib|Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.
45978861|NCT00304317|Other|Placebo|Take two capsules by mouth immediately, then take one capsule by mouth every 12 hours until gone.
45978862|NCT00292097|Procedure|Early tracheostomy|early conversion - less than or equal to 72 hours
45978863|NCT00292097|Procedure|Late tracheostomy|Late conversion (10-14 days)
45456276|NCT04445532|Other|Polymerase chain reaction|Polymerase chain reaction
45456277|NCT04445532|Other|Mass spectrometry|Mass spectrometry
45456278|NCT04445532|Other|Immunohistochemistry|Immunohistochemistry
45456279|NCT04445532|Other|Metabolomics profiling|Metabolomics profiling
45456280|NCT04445532|Other|Methylation and epigenetic analysis|Methylation and epigenetic analysis
45456281|NCT04445532|Other|Liquid biopsy analysis|Liquid biopsy analysis, such as cell-free DNA or circulating tumor cell analysis
45978864|NCT00324792|Drug|intensive insulin therapy|
45978865|NCT00292175|Procedure|Narrow Band Imaging|
45978866|NCT00292175|Procedure|colonoscopy|
45978867|NCT00292214|Drug|Paracetamol (acetaminophen)|
45978868|NCT00324831|Drug|autologous immunoglobulin idiotype-KLH conjugate vaccine|
45978869|NCT00324831|Drug|cyclophosphamide|
45978870|NCT00324831|Drug|doxorubicin hydrochloride|
45978871|NCT00324831|Drug|prednisone|
45978872|NCT00324831|Drug|rituximab|
45978873|NCT00324831|Drug|sargramostim|
45978874|NCT00324831|Drug|vincristine|
45978875|NCT00324831|Procedure|Intervention/procedure|
45978876|NCT00324831|Procedure|antibody therapy|
45978877|NCT00324831|Procedure|biological therapy|
45978878|NCT00324831|Procedure|chemotherapy|
45978879|NCT00324831|Procedure|colony-stimulating factor therapy|
45978880|NCT00324831|Procedure|cytokine therapy|
45978881|NCT00324831|Procedure|monoclonal antibody therapy|
45978882|NCT00324831|Procedure|non-specific immune-modulator therapy|
45978883|NCT00324831|Procedure|therapeutic procedure|
45978884|NCT00324831|Procedure|tumor cell derivative vaccine|
45978885|NCT00324831|Procedure|vaccine therapy|
45978886|NCT00292253|Device|Rebif® via Rebiject™Mini|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with Rebiject™Mini, an auto-injection device for 3 months.
45978887|NCT00292253|Device|Rebif® via manual injections|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with manual injections for 3 months.
45978888|NCT00292331|Procedure|cyanoacrylate injection to treat gastric variceal hemorrhage|
45978889|NCT00304434|Drug|Oseltamivir|
45978890|NCT00304434|Drug|Probenecid|
45978891|NCT00292409|Drug|Aripiprazole|
45978892|NCT00324909|Drug|Hyperbaric Oxygen Therapy|
45978893|NCT00304473|Drug|Quetiapine fumarate|
45978894|NCT00292448|Drug|Ba 679 BR Respimat|
45978895|NCT00292448|Drug|Tiotropium (Spiriva) inhalation capsule 18 ug|
45978896|NCT00324948|Drug|Topical alprostadil (PGE-1)|
45978897|NCT00304551|Drug|peginterferon alfa-2a 180μg|180μg（s.c.）/week for 48 weeks
45978898|NCT00304551|Drug|peginterferon alfa-2a 90μg|90μg(s.c.)/week for 48 weeks
45672480|NCT04419701|Procedure|genicular nerve block|The genicular arteries will be identified near the periosteal areas, which are the junctions of the epicondyle and the shafts of the femur and tibia, and confirmed by color Doppler ultrasound. genicular nerve block target points should be next to each genicular artery because the superior lateral, superior medial, and inferior medial genicular artery traveled along each genicular nerve.After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view.
45978899|NCT00304551|Drug|ribavirin|600, 800, or 1,000 mg X 2(p.o.)/day
45978900|NCT00325026|Drug|Misoprostol|
45978901|NCT00325026|Device|Foley bulb|
45978902|NCT00304590|Drug|XL999|Treatment consisted of 8 weekly infusions of 2.4 mg/kg of XL999 with each infusion given over 4 hours, unless drug-related toxicity required a dosing delay or adjustment. In the absence of progressive disease and unacceptable toxicity, subjects may have received XL999 treatment weekly for up to 1 year on this study.
45978903|NCT00292487|Drug|Iopamidol 370 mgI/mL|
45978904|NCT00325104|Procedure|Parathyroid hormone testing|
45456282|NCT04445532|Other|Laboratory biomarker analysis|Laboratory biomarker analysis (such as AFP, CA19-9, CEA)
45831970|NCT04144452|Other|Therapeutic Exercise plus educational session|Therapeutic exercises include strength and endurance training and mat exercises. Strengthening exercises of the trunk extensors will be initiated first and then endurance exercises will be targeted. Mat exercises will be performed to strengthen the back and lower musculature. Treatment will be given twice a week for almost three months. Individualized educational sessions will be performed in the same way as conducted in the other group. Progression of the exercises and the rest periods will be incorporated according to the status of patient.
45831971|NCT03947190|Biological|R21/Matrix-M|R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
45831972|NCT03947190|Biological|ChAd63/MVA ME-TRAP|ChAd63, chimpanzee adenovirus serotype 63; ME-TRAP, multiple epitope string fused to the thrombospondin-related adhesion protein; MVA, modified vaccinia Ankara.
45978905|NCT00325104|Procedure|Serum calcium testing|
45978906|NCT00292526|Drug|Enalapril|enalapril orally administered
45978907|NCT00418509|Drug|Mometasone furoate|
45978908|NCT00418509|Drug|Formoterol fumarate|
45978909|NCT00292721|Drug|Celecoxib|celecoxib: loading and maintenance for 6 months
45978910|NCT00292760|Drug|Alemtuzumab|
45978911|NCT00292760|Drug|Methyprednisolone|
45978912|NCT00325182|Drug|Levetiracetam|
45978913|NCT00325182|Other|Historical controls|
45978914|NCT00292799|Drug|Orlistat Vs Metformin|
45978915|NCT00304629|Drug|galantamine|
45978916|NCT00292838|Drug|fluticasone 25, 50, 100, 200 mcg|
45978917|NCT00304668|Drug|dapivirine (TMC120) vaginal gel|
45978918|NCT04718324|Other|e-PROMS|Participants randomised to the e-PROMS arm will receive a safe link to the e-PROMS and a unique identification number in the electronic form, so as to preserve anonymity. This is a one-time intervention
45978919|NCT04718324|Other|p-PROMS|Participants randomised to the p-PROMS arm will receive the PROMS and PREMS questionnaires and a unique identification number in paper form.
45978920|NCT00292877|Drug|SB-240563 (Mepolizumab)|
45978921|NCT00292916|Behavioral|whole body vibration|
45978922|NCT00292916|Behavioral|resistance exercise|
45978923|NCT00292916|Behavioral|"wellness"|
45978924|NCT00325221|Device|HM on|Home Monitoring activated after implantation
45978925|NCT00325221|Device|HM Off|Home Monitoring activated 9 months after implantation
45978926|NCT00292955|Drug|Cetuximab|monotherapy (day 1), then weekly thereafter along with radiation. dose is at 200mg/m2.
45978927|NCT00325260|Biological|Influvac; subunit influenza vaccine|
45978928|NCT00292994|Behavioral|Exercise|
45978929|NCT00292994|Behavioral|Weight Loss|
45978930|NCT00293072|Drug|Rituximab|
45978931|NCT00293111|Drug|SDX-101 (R-Etodolac)|
45978932|NCT00304785|Drug|latanoprost 0.005%|
45978933|NCT00304785|Drug|Fotil|
45978934|NCT00304785|Drug|placebo|
45978935|NCT00293150|Drug|Eplerenone|
45978936|NCT00325299|Drug|Magnesium|
45978937|NCT02960334|Device|MyDiagnostick|The MyDiagnostick is a compact hand-held device that registers and stores I-lead ECG strips. In one minute, t analyses the rhythm for the presence of AF. It distinguishes AF from normal cardiac rhythms by measuring RR-irregularity.
45978938|NCT00293228|Drug|Isoniazid|Isoniazid (5mg per kg up to 300 mg daily for 6 months)
45978939|NCT00293228|Drug|isoniazid|isoniazid (5mg per kg up to 300 mg daily for 6 months
45978940|NCT00325338|Biological|Ragweed MATAMPL|
45978941|NCT00293345|Drug|gemcitabine hydrochloride|
45978942|NCT00293345|Drug|triapine|
45978943|NCT00293501|Drug|tinzaparin sodium|
45978944|NCT00325377|Procedure|MME Procedure|
45978945|NCT00293618|Device|Automatic Risk Presentation in the operating room|Automatic calculation and presentation of a patient's individual predicted PONV risk by the anesthesia information management system during the entire procedure
45978946|NCT00293618|Other|Education|Specific information is provided to the intervention group: about PONV, about the prediction model. While the Usual Care group only receives information about the study purposes
45978947|NCT00293618|Other|Feedback|Feedback about the physician's personal performance on prevention of PONV
45978948|NCT00325455|Drug|MK0859|
45978949|NCT00293657|Drug|Lornoxicam 8 mg|
45978950|NCT00293657|Drug|Lornoxicam 16 mg|
45672481|NCT04841213|Procedure|Dental implantation|Traditional 2-stage dental implantation according to surgical protocols of dental implant systems (Straumann (Institut Straumann AG, Switzerland), Astra Tech (Dentsply Implant Manufacturing GmbH, Germany), Xive (FRIADENT GmbH, Germany), Alpha Bio (Alpha Bio Tec Ltd., Israel) for different types of bone tissue
45672482|NCT01565668|Drug|AC220|oral
46082612|NCT03940196|Drug|Paclitaxel|Paclitaxel 80 mg/m^2 intravenous infusion will be administered weekly for 8 weeks and then on Days 1, 8 and 15 of each subsequent 28-day cycle.
45672483|NCT04581551|Procedure|SWE assessor 1|"SWE for 6 shoulder muscles will be performed.~m. supraspinatus~m. infraspinatus~m. rhomboideus major~m. deltoideus~m. pectoralis major~m. pectoralis minor"
45672484|NCT04581551|Procedure|SWE assessor 2|"SWE for 6 shoulder muscles will be performed.~m. supraspinatus~m. infraspinatus~m. rhomboideus major~m. deltoideus~m. pectoralis major~m. pectoralis minor"
45672485|NCT04581551|Procedure|Stretch intervention|Transversal stretch of pectoralis major muscle on the hemiplegic side.
45831973|NCT03947190|Biological|intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge|PfSPZ Challenge: cryopreserved Plasmodium falciparum sporozoites.
46082613|NCT05131230|Device|CytoSorb® treatment|Patients with Acute on Chronic Liver Failure (ACLF) due to Severe Alcoholic Hepatitis in combination with systemic inflammation and ACLF grade ≥2 will be enrolled in this study. Every patient that is screened, fulfills the inclusion/exclusion criteria, and consents to the study, will be allowed to enter the study. Patients will receive Standard of Care treatment for alcoholic hepatitis plus treatment with the CytoSorb® 300 mL device.
45456283|NCT04443309|Drug|Camrelizumab|Camrelizumab 200mg,iv,d1,q2w
45672486|NCT04581551|Procedure|No stretch intervention|Passive mobilisation of the hemiplegic hand.
45672487|NCT04577807|Biological|Lerapolturev|Lerapolturev administered via direct lesion injection
45672488|NCT04577807|Biological|Anti-PD-1 Checkpoint Inhibitor|Anti-PD-1 Checkpoint Inhibitor administered per package insert instructions
45831974|NCT04144374|Drug|Omadacycline|Omadacycline will be administered 200 mg IV once daily on day 1 followed by omadacycline 300 mg by mouth once daily for 2-4 doses.
45672489|NCT04577417|Drug|ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate|Both ADHD and control groups of subjects will participate in 2 sessions (on-med and off-med conditions) conducted on the same day. ADHD group will be asked to come to the laboratory in the morning before taking their morning ADHD stimulant medication. They will be tested before and after taking their ADHD medication (off-med and on-med conditions). The investigators will observe changes between the two conditions.
45672490|NCT01683058|Drug|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg
45672491|NCT04419545|Diagnostic Test|Neural network diagnosis algorithm|we feed neural network with chest x-ray radiography images for teaching the network for automatic diagnosis of interstitial pneumonia
45672492|NCT04574921|Other|Light Therapy System (LTS): Active setting|Exposure for 1 hour á day for consecutive days.
45672493|NCT04574921|Other|Light Therapy System (LTS): Sham setting|Exposure for 1 hour á day for consecutive days.
45672494|NCT05374421|Device|Erchonia® THL™|The Erchonia® THL™ is made up of (2) 405-nanometer violet laser diodes mounted in a portable handheld device. The diodes are positioned approximately 4 inches from the skin and applied in a continuous back and forth sweeping motion from the top of the ear down the side of the neck. The treatments will be self-administered by the subject at his or her's place of residence, once per day for 28 days. Each procedure administration lasts 5 minutes per ear, for a total of 10 minutes.
45831975|NCT04144374|Procedure|Microdialysis Catheter Insertion|A 20 kilodalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
45978951|NCT00293657|Drug|Placebo|
45978952|NCT00325494|Drug|MORAb-009|Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m^2 up to 400 mg/m^2.
45978953|NCT00293696|Drug|bicalutamide (Casodex), goserelin (Zoladex)|
45978954|NCT00304863|Drug|Lactobacillus GG|This arm will receive the additional probiotic of lactobacillus GG
45978955|NCT00293735|Drug|labetalol (seizure prevention)|"20mg IV (can be increased to an escalating dose of maximum of 80 mg (20mg, 40 mg, 80 mg q 20min) Cumulative max of 240 mg.~20mg labetalol PO every 6 hours"
45978956|NCT00293735|Drug|MgSO4 (seizure prevention)|4-6g bolus over 20 minutes; 1-2 grams/hr Discontinued 24 hours after delivery.
45978957|NCT00293852|Procedure|Outpatient clinic follow-up|
45456284|NCT04443309|Drug|Lenvatinib|Lenvatinib 8mg (<60kg) or 12mg (≥60kg),po,d2,qd
45456285|NCT04437433|Drug|Atogepant 60 mg|Tablets containing 60 mg atogepant
45978958|NCT00304980|Drug|ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE|
45978959|NCT00293891|Drug|Tacrolimus Cream|
45978960|NCT00325533|Behavioral|Baseline BP Screening|Barbers in the barbershops in the experimental arm will be trained to accurately measure and interpret blood pressure (BP). Each barber will offer a BP check to customers with each haircut, complete an encounter form after each haircut, discuss the BP reading with the customer, identify customers with elevated BP, and refer customers with elevated BP to a regular physician or other primary provider for long-term BP management. Each time a customer with elevated BP goes to a regular medical provider, he receives a free haircut, and the referring barber receives a monetary bonus.
45978961|NCT00325533|Other|Intensive 10-week Blood Pressure Screening|Intensive 10-week Blood Pressure Screening
45978962|NCT00293930|Drug|Tacrolimus|
45978963|NCT00305019|Drug|clevudine|
45978964|NCT00293969|Drug|Morphine 0.1mg/kg versus morphine 0.15 mg/kg|
45978965|NCT00325611|Behavioral|Multidisciplinary palliative care team met with patient|
45978966|NCT00294008|Drug|Risperdal Consta|flexible dosage for 24 months
45978967|NCT00305097|Dietary Supplement|Decaffeinated coffee|5 cups per day for 8 weeks
45978968|NCT00305097|Dietary Supplement|Caffeinated coffee|5 cups per day for 8 weeks
45978969|NCT00305097|Dietary Supplement|No coffee|
45978970|NCT00294086|Drug|valsartan 160 mg|
45978971|NCT00294086|Drug|valsartan 160 mg BID|
45672495|NCT05374421|Device|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® THL™ but does not emit any therapeutic light. The diodes are positioned approximately 4 inches from the skin and applied in a continuous back and forth sweeping motion from the top of the ear down the side of the neck. The treatments will be self-administered by the subject at his or her's place of residence, once per day for 28 days. Each procedure administration lasts 5 minutes per ear, for a total of 10 minutes.
45672496|NCT01626859|Drug|MP-214 3mg|Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for twelve weeks.
45672497|NCT01626859|Drug|MP-214 6mg|Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for twelve weeks.
45831976|NCT04026282|Procedure|GnRH-ant protocol|Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.
45831977|NCT04026282|Procedure|GnRH-a long protocol|The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.
45831978|NCT04144296|Diagnostic Test|Study procedure|"Measurement of the flow rate of supplemental oxygen~Measurement of the peripheral arterial saturation (SpO2) by pulse oximetry~Taking of an ABG sample (ABG1) from the arterial line~Taking of capillary blood gas analysis from the earlobe and from the finger tip~Taking of an a second ABG (ABG2) from the arterial line"
45831979|NCT04144218|Drug|Lacosamide|The experimental group will be given oral lacosamide supplementation on the basis of the original antiepileptic drugs.
45831980|NCT04144218|Drug|Placebo oral tablet|The control group will be given oral placebo supplementation on the basis of the original antiepileptic drugs.
45831981|NCT05580900|Other|Livestream Modality (treatment)|For this evaluation, the livestream modality is considered the treatment.
45831982|NCT05580900|Other|Live Modality (control)|For this evaluation, the live or in-person modality is considered the control group.
45831983|NCT03905538|Drug|[18F]FLT-PET/CT|Dose of 0.07 mCi/Kg [18F]FLT to max of 5 mCi (± 20%) will be given intravenously.
45978972|NCT00325689|Drug|Quetiapine or Risperidone + Aripiprazole|Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Aripiprazole 2-15 mg/day, Flexible, 16 weeks.
45978973|NCT00325689|Drug|Quetiapine or Risperidone + placebo|Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Placebo, Flexible, 16 weeks.
45978974|NCT00294125|Drug|Flavocoxid|Daily flavocoxid for 12 weeks
45978975|NCT00294125|Drug|Placebo|Daily placebo for 12 weeks
45978976|NCT00294164|Drug|Serostim®|Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.
45978977|NCT00294164|Drug|Placebo|Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.
45978978|NCT00325728|Drug|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 8 weeks.
45978979|NCT00325728|Drug|Placebo|Ramelteon placebo matching tablets, orally, once nightly for up to 8 weeks.
45978980|NCT00417794|Drug|Strattera|escalating dosage: 0.5 mg/kg, 1.0 mg/kg, and 1.4 mg/kg titrated up or down according to adverse effects to therapy
45978981|NCT00417794|Drug|Placebo|0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.
45978982|NCT00417833|Drug|Intravitreal Bevacizumab|
45978983|NCT00305214|Procedure|T Wave Alternans Test|
45978984|NCT00417872|Drug|Nitazoxanide|
45978985|NCT00417872|Drug|Metronidazole|
45978986|NCT00294203|Drug|Epoetin Alfa group|Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
45978987|NCT00294203|Other|Placebo group|Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
45978988|NCT00305292|Drug|Modafinil-Alcohol Interactions|
45978989|NCT00294242|Procedure|membrane sweeping|
45978990|NCT00305331|Drug|Domperidone (drug)|
45978991|NCT00294281|Device|Vagus Nerve Stimulation (VNS) Therapy|The VNS Therapy System Pulse Generator is an implantable, multi-programmable bipolar pulse generator. The pulse generator will deliver electrical signals to the vagus nerve via bipolar leads. A programming wand and software system enable non-invasive programming, functional assessments, interrogation, and data retrieval.
45978992|NCT00325767|Drug|nebulized albuterol (2.5 mg/3ml/dose)|
45978993|NCT00325767|Drug|nebulized levalbuterol (1.25 mg/3ml/dose)|
45978994|NCT00325767|Drug|nebulized placebo (3ml/dose)|
45978995|NCT00294359|Drug|Mitomycin C; Capecitabine; Bevacizumab|
45978996|NCT00294437|Drug|Zometa|Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
45978997|NCT00305370|Drug|Aripiprazole|
45978998|NCT00325806|Drug|Ramipril|
45978999|NCT00294476|Drug|IVIG|
45979000|NCT00294476|Procedure|Biological Therapy|
45979001|NCT00305409|Drug|Synbiotic (Synergy I / B.longum)|
46082614|NCT03988179|Diagnostic Test|The Cholinesterase Inhibitor Prognosticator (ChIP) application for iPad|The first part of this application will be used, consisting of a visual vigilance test based on the Continuous Performance Test (CPT). Stimuli consist of a one digit number presented in the middle of the screen. For each trial the application randomly selects a specific number as the target stimulus. Patients are instructed to keep their dominant trigger finger close to the screen and press a button which is located at the bottom of the screen, whenever the target appears. In case another stimulus appears the patient is instructed to do nothing. Each stimulus is presented until the patient presses the button (maximum 3 sec.). Stimuli are presented in a random fashion with a 1, 2, 3, 4, or 5 second inter-stimuli-interval blank, which randomly varies. After an 8 stimuli practice trial, the test starts and a total of 50 stimuli are presented with a 50% target rate. Full-trial duration is approximately 5 minutes. During the trial, reaction time and accuracy of response are registered.
45979002|NCT00294593|Drug|folinic acid|
45979003|NCT00325845|Procedure|Synvisc viscosupplementation|
45979004|NCT00294710|Drug|Aliskiren|
45979005|NCT00294749|Drug|Ciprofloxacine|
45979006|NCT00325923|Behavioral|Decision aid|
45979007|NCT00294788|Biological|Fluvax|
45979008|NCT00294788|Drug|PCC® (Lactobacillus fermentum VRI 003)|
45979009|NCT00325962|Drug|6R-BH4 (sapropterin dihydrochloride)|
45979010|NCT00294866|Drug|Paricalcitol|Patients randomized to either receive Paricalcitol or have it held. After 4 weeks they are switched to the opposite intervention.
45979011|NCT00305487|Drug|Ciclesonide nasal spray|
45672498|NCT01626859|Drug|MP-214 9mg|Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for twelve weeks.
45979012|NCT00294905|Behavioral|Implementation of a combined smoking cessation strategy|
45979013|NCT00305526|Device|Contak Renewal (CRT-D)|
45979014|NCT00294944|Drug|Idazoxan|
45672499|NCT04413682|Behavioral|Structured Supervised Exercise|Structured Exercise Program under the supervision of Physical Therapist
45672500|NCT04413682|Behavioral|Structured telerehabilitation|Structured Exercise Program checked and controlled through telerehabilitation
45672501|NCT02193776|Drug|PA-824|oral
45979015|NCT00326040|Device|Glaucoma Surgery|
45979016|NCT02960477|Other|Pain Neuroscience education|A PNE session covers the neurobiology, neurophysiology and processing of pain.
45979017|NCT02960477|Other|Biomedical Education|A biomedical session covers the normal course of shoulder pain, anatomy, physiology and biomechanics of the shoulder, the expected course of postoperative shoulder pain, and the importance of self-care.
45979018|NCT00326079|Device|Stent|implantation of 1 Glaukos iStent versus 2 Glaukos iStents
45979019|NCT00326157|Drug|AmBisome|3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment (day 50-8th Week) of AmBisome®, IV administration
45979020|NCT00295100|Drug|Tamoxifen|
45979021|NCT00326235|Drug|Buspirone|
45672502|NCT02193776|Drug|bedaquiline|oral
45672503|NCT02193776|Drug|moxifloxacin|oral
45672504|NCT02193776|Drug|pyrazinamide|oral
45672505|NCT02193776|Drug|isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet|oral
45979022|NCT00295178|Drug|Daptomycin|
45979023|NCT00295178|Drug|Vancomycin|
45979024|NCT00305799|Procedure|management of therapy complications|Patients will complete three self-reported questionnaires including the Peripheral Neuropathy Scale, Hearing Handicap Inventory for Adults, and Dizziness Handicap Inventory. Patients will also be asked a series of questions regarding symptoms or complaints about hearing changes, tinnitus, and dizziness that they may have experienced prior to, during, and after completion of chemotherapy. Patients will also undergo a hearing test.
45979025|NCT00295217|Device|ExAblate 2000|
45979026|NCT00305838|Drug|tamoxifen citrate|
45979027|NCT00305838|Other|diagnostic laboratory biomarker analysis|
45979028|NCT00295256|Behavioral|nurse case manager|
45979029|NCT00295295|Device|High frequency, low magnitude vibration|High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
45979030|NCT00295295|Other|Standing|Standing 10 min/day
45979031|NCT00326274|Drug|Helioblock® SX Cream|
45979032|NCT00305916|Procedure|Multislice spiral computed tomography coronary angiography|
45979033|NCT00305916|Procedure|conventional coronary angiography|
45979034|NCT00295334|Drug|alcohol|
45831984|NCT04021602|Behavioral|Diabetes Prevention Program|Phase 1 (core curriculum) of the Diabetes Prevention Program consists of 16 sessions and will take place during Week 18 of pregnancy through Week 33. Participants will receive the DPP curriculum via virtual pre-recorded sessions to which participants will have access. A research coordinator will follow up with each study participant by phone once weekly. If participants do not make adequate progress, the coordinator will assess how much extra time the participant will need to complete each session and will work with the participant if needed. Phase 2 (post-core curriculum) consists of 6 sessions and will be completed after delivery, between Week 6 and Week 20 postpartum. Participants will re-engage into the DPP with an orientation session at Week 6 postpartum. The same session completion format and procedure for inadequate progress will be followed as during pregnancy.
45831985|NCT04021602|Behavioral|Breastfeeding Education|Participants will receive a 2-hour session on breastfeeding and participate in a professional peer support group. The breastfeeding session is between Week 20 and Week 36 of pregnancy and will be taught by an International Board Certified Lactation Consultant (IBCLC). Participants will be provided with a breastfeeding assessment at Days 3 and 10; Week 3 and 6; and Months 2, 3, and 6 postpartum.
45831986|NCT04021602|Behavioral|Usual Care|Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.
45831987|NCT05580822|Drug|Tenecteplase for Injection|intra-arterial TNK infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
45831988|NCT05580822|Drug|Saline|intra-arterial saline infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
45831989|NCT05580744|Other|Traditional occupational therapy|Motor training targeted to goals that are relevant to the functional needs of the patient
45831990|NCT05580744|Other|Mirror therapy using a mirror box|Mirror therapy using a mirror box
45831991|NCT05580744|Other|Augmented reality-based mirror therapy|Augmented reality-based mirror therapy
45831992|NCT04026126|Behavioral|Heat Therapy Treatment|Subjects will undergo 10 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 14 days. Subjects will be immersed up to the shoulder until rectal temperature reacher 38.5 degrees Celsius (approximately 15-20 minutes). Subjects will then remain in the water bath submerged at waist level to maintain between 38.5 to 39.0 degrees Celsius for another 30 minutes. Following hot water immersion, subjects will be monitored for 10 minutes, or until temperature falls below 38.5 degrees Celsius.
45831993|NCT05580588|Drug|SPH4336|400 mg SPH4336 PO QD
45831994|NCT05580354|Drug|BCG combined with Tislelizumab|Patients will receive 17 cycles of Tislelizumab (200mg per cycle) in combination with BCG (6-week induction course of 120mg followed by maintenance with 3 weekly infusions of 120mg at months 3,6,12).
45831995|NCT04144062|Other|CAD/CAM crowns|CAD/CAM crowns
45831996|NCT04143906|Drug|Vinorelbine|injection
45831997|NCT04143906|Drug|Gemcitabine|injection
45831998|NCT04143906|Drug|Carboplatin|injection
45831999|NCT04143750|Drug|[14C]Vicagrel|Take a suspension of 20 mg vicagrel ,containing about 120 μCi [14C]Vicagrel, in fasting within 5 minutes
45832000|NCT03022110|Device|Endoscopic Ultrasound-guided Drainage|Pancratic pseudocyst drainaged under the guide of Endoscopic Ultrasound
45832001|NCT02708004|Drug|Aprocitentan|Formulated in capsules in 2 different strengths; 2 capsules per day
45832002|NCT02708004|Other|Placebo|Matching active drug
45832003|NCT03021720|Procedure|Arterial access|Location of arterial puncture
45832004|NCT02708706|Drug|hyaluronic acid (hyruan)|2cc hyaluronic acid
45832005|NCT02708706|Other|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
45832006|NCT04143672|Device|Electronic digital pressure algometer|"Evaluation of pain threshold using an algometer is conducted one day before surgery.~The pressure of the plunger of algometer is applied vertically to the patient's right thenar muscle belly at a speed of 10 N/sec by the tester. Then the tester removes the algometer when the patients start to feel pain and record the pressure recorded on the algometer."
45832007|NCT04143672|Diagnostic Test|Pain sensitivity questionnaire|Evaluation of pain threshold using the Korean-version pain sensitivity questionnaire is conducted one day before surgery.
45832008|NCT04143828|Behavioral|mobile mindfulness programme|"The mobile mindfulness programme adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of six modules. Each module consists of a short movie (talking head) explaining the content and two audiofiles to guide experiential mindfulness meditation exercises. Participants can follow the different modules based on their own time-schedule.~Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience."
45832009|NCT05587608|Procedure|combined thoracic segmental spinal epidural anesthesia|ultrasound guided thoracic segmental spinal anesthesia at the level of T10 interlaminar space , patients will be in sitting position, spinal needle is then introduced through the epidural needle not more than 0.5 cm beyond the Dura matter. 2cc of heavy Marcaine plus 25 ug fentanyl are injected through the spinal needle.
45832010|NCT02703714|Drug|Pembrolizumab|200 mg given intravenously (IV)
45832011|NCT02703714|Drug|Sargramostim|250 µg given subcutaneously (SC)
45832012|NCT05583474|Drug|OPC-1085EL|one drop for each eye, once per day
45979035|NCT00295373|Drug|Rosuvastatin|
45979036|NCT00295373|Behavioral|Exercise Training|
45979037|NCT00305955|Device|Spectacles|optimal spectacle correction
45979038|NCT00295412|Drug|quetiapine (drug)|
45979039|NCT00295529|Behavioral|Multifaceted educational intervention|Educational materials available at end of study
45979040|NCT00326352|Drug|Sedation with propofol and remifentanil|
45979041|NCT00419601|Drug|Remifentanyl|Start dose:9 µg/kg/h Maximum dose: 30 µg/kg/h
45456286|NCT04435834|Drug|Propofol or Sevoflurane|Patient's will be randomized to the group receiving propofol, or the group receiving sevoflurane.
45672506|NCT04740697|Other|Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.|"Each included patient will be referred to the health care staff for a blood sample:~for the determination of the residual plasma concentration of tamoxifen and its active metabolites,~for the constitution of a biobank.~Patients will then complete a questionnaire to collect information on tamoxifen intake and adherence (via the GIRERD questionnaire), as well as possible Alternative and Complementary Therapeutics (ACT) intake (reason for use, type of ACT, ...)."
45672507|NCT05373407|Other|aerobic exercise|participants will perform different dosage of the same intervention, one group will perform moderate intensity and the other will perform low intensity aerobic training
45672508|NCT04840979|Drug|11C-ER176|11C-ER176 is a novel TSPO radioligand that was developed because of its relative insensitivity to the rs6971 polymorphism. Increased TSPO signal on PET is associated with activation of microglia in the brain. The radioligand will be administered in tracer doses at activity of up to 20 mCi (740 MBq), IV, total of one injection. A single dose of radioligand will be injected over 1 minute.
45672509|NCT04840979|Drug|18F-florbetaben|Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. Florbetaben measures amyloid in the brain.
45832013|NCT05583474|Drug|0.005% Latanoprost|one drop for each eye, once per day
45832014|NCT03919578|Biological|Recombinant Hepatitis B vaccine|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from Serum Institute of India and then formulated and filled at Bio Farma.
45832015|NCT03919578|Biological|Recombinant Hepatitis B (Bio Farma)|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from The Janssen Vaccine Corp and then formulated and filled at Bio Farma.
45832016|NCT03945864|Device|antimicrobial synthetic bone graft|It will be determined whether the silver ion-doped antimicrobial synthetic bone graft that has the capacity to fill the bone voids also has the capacity to treat the infection in the bone in 12 patients with chronic osteomyelitis
45832017|NCT03945864|Device|parentaral antimicrobials and pure bone grafts|Historical data of the department will be used for comparison of the results
45832018|NCT04143048|Other|DNA extraction of tumer tissue samples and high-throughput sequencing of small panels|DNA extraction of stromal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed
45979042|NCT00419601|Drug|Fentanyl|start dose: 3 µg/kg/h Maximum dose: 10 µg/kg/h
45979043|NCT00306033|Drug|Intravenous ImmuneGlobulin|
45979044|NCT00306072|Drug|nutritional herbal extract from Salacia oblonga|
45979045|NCT00295607|Drug|Tacrolimus|immunosuppression
45979046|NCT00295607|Drug|steroids, monoclonal anti-IL2R antibody|immunosuppression
45979047|NCT00326391|Drug|methylphenidate hydrochloride extended-release tablets|
45979048|NCT00306111|Drug|pegfilgrastim|Single dose (6mg) one day after chemotherapy
45456287|NCT04433234|Drug|DS-5141b|Administered via subcutaneous injection once weekly
45832019|NCT04143048|Other|DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels|DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor
45979049|NCT00295685|Drug|Antacids|
45979050|NCT00306150|Drug|Trasylol (Aprotinin, BAYA0128)|Subjects will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The maximal dose of aprotinin, that can be administered is 7,000,000 KIU, regardless of the duration of the operation. When a total of 7 million has been reached the administration of aprotinin must be discontinued.
45979051|NCT00306150|Drug|Placebo|Placebo is used according to the description of Arm 1
45979052|NCT00295724|Drug|Bicifadine|
45979053|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with no infusion of tirofiban 120 minutes after fibrinolysis
45979054|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with infusion of tirofiban 120 minutes after fibrinolysis
45979055|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with no infusion of tirofiban 120 minutes after fibrinolysis
45979056|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis
45456288|NCT04431258|Drug|ABTL0812|ABTL0812 will be administered daily at its RP2D. ABTL0812 will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, ABTL0812 will be maintained once chemotherapy is discontinued, if ABTL0812 is tolerated and if the patient is in response or stable disease.
45979057|NCT00295763|Drug|Thyrogen (thyrotropin alfa for injection)|"No reference therapy was given. All patients in this follow-up study received Thyrogen. Thyrogen 0.9 mg was administered intramuscularly (IM) in the buttock on 2 consecutive days.~For WBS and static neck imaging, each patient received 4 mCi (148 MBq) ± 0.4 mCi 131I PO."
45672510|NCT02170064|Drug|BIA 2-093 (Eslicarbazepine acetate)|Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route
45979058|NCT00326430|Behavioral|Cognitive Therapy, Interpersonal Therapy|
45979059|NCT00417911|Drug|bortezomib|Bortezomib 1,3 mg/sqm Days 1,4,8,11 for two 3-week cycles and then once a week for three weeks in 4 4-week cycles
45979060|NCT00326469|Drug|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for up to 24 months or until disease progression.
45979061|NCT00417950|Drug|Acarbose|
45979062|NCT00306267|Drug|epoetin alfa|
45979063|NCT04718597|Procedure|Robotic assisted inguinal hernia repair|Robotic assisted inguinal hernia repair with DaVinci Xi system instead of open repair
45979064|NCT04718597|Procedure|Open inguinal hernia repair|Classical approach (open repair)
45979065|NCT00326508|Drug|Daclizumab|
45979066|NCT00295802|Device|Integrated Imaging High Intensity Focused Ultrasound|
45832020|NCT04143048|Other|DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels|DNA extraction and small panel sequencing were conducted for each patient sample. Based on the indicator results of the previous mutant spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutant spectrum, and compared with the real clinical data of patients
45979067|NCT00295802|Device|Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)|Cryotherapy
45979068|NCT00326586|Drug|AR Antagonist (BMS-641988)|Tablets, Oral, 6 Patients will be randomized in a 1:1 ratio and in a double-blinded fashion to achieve a single dose of the study drug or Placebo on C1D1. Once daily, at least 3 cycles until the disease progresses
45832021|NCT03904446|Drug|Methylergonovine|0.2 mg of intramuscular methylergonovine at the time of cesarean section following standard IV oxytocin infusion.
45979069|NCT00295841|Drug|clofarabine|
45979070|NCT00295841|Drug|cytarabine|
45979071|NCT00326664|Drug|Cediranib Maleate|Given orally
45979072|NCT04957173|Other|Lifestyle intervention|"The intervention includes a total of 17 virtual meetings and aims to achieve a weight loss of 0.8 to 1% of the initial weight per week.~This will include 3 successive phases:~A significant calorie restriction (A minimum deficit of 800 kcal / day of their daily energy expenditure) for a period of 4 weeks;~A moderate calorie restriction (minimum deficit of 500 kcal / day of their daily energy expenditure) for a period of 4 weeks;~A maintenance phase of weight loss for 16 weeks.~An optional phase of monthly follow-ups for a period of 3 months (no intervention)"
45672511|NCT04562285|Diagnostic Test|Serologic immunoassays to SARS-CoV-2 antibodies|Detect and characterize antibodies to SARS-CoV-2
45672512|NCT05344625|Drug|Ketamine 100 MG/ML|Ketamine Assisted Psychotherapy
45832022|NCT03904446|Drug|Normal Saline (placebo)|1 ml of normal saline intramuscular at the time of cesarean section following standard IV oxytocin infusion
45832023|NCT04143984|Drug|Induction chemotherapy|Induction chemotherapy with the regimen of gemcitabine plus nedaplatin.
45672513|NCT02169830|Drug|nortriptyline|The nortriptyline will be given in an escalating fashion, starting at 25 mg PO qhs for 2 weeks, followed by 50 mg PO qhs for 2 weeks, and finally 75 mg PO qhs. Patients will be encouraged to use the lowest effective dose and to self-titrate their medication.
45672514|NCT02169830|Drug|Topiramate|Topiramate dosing will be 25 mg PO qhs for 1 week, followed by 25 mg BID for 1 week, followed by 25 mg in the morning and 50 mg qhs for 1 week, and finally 50 mg BID
45832024|NCT04143984|Radiation|Carbon-ion radiotherapy|Accelerated carbon-ion beam with pencil beam scanning technique.
45832025|NCT04143984|Drug|Camrelizumab|An anti-PD-1 antibody.
45832026|NCT05583318|Other|Data collection|Data from hematological malignancy registries
45832027|NCT05583318|Other|Questionnaires|"9 questionnaires were sent out:~QLQ-C30 and SF-12 Quality of Life Questionnaire.~Oral quality of life questionnaire QLQ-OH15~Sexuality questionnaire SHQ-C22~Anxiety and depression questionnaire HADS,~Rosenberg Self-Esteem Questionnaire~RNLI Reintegration to Normal Life Questionnaire~Social Support Questionnaire SSQ6,~Socio-economic status questionnaire EPICES,~Complementary questionnaire collecting data on socio-professional status."
45979073|NCT00295919|Drug|fenretinide lipid matrix|
45979074|NCT00295919|Drug|ketoconazole|
45979075|NCT00295919|Other|laboratory biomarker analysis|
45979076|NCT00295919|Other|pharmacological study|
45979077|NCT04930809|Drug|VER-01|standardised cannabis extract (containing 21 mg THC per gram drug product)
45979078|NCT00295958|Biological|LMB-2 immunotoxin|
45979079|NCT00295958|Biological|MART-1 antigen|
45979080|NCT00295958|Biological|gp100 antigen|
45979081|NCT00295958|Biological|incomplete Freund's adjuvant|
45979082|NCT00295997|Biological|anti-thymocyte globulin|
45979083|NCT00295997|Biological|filgrastim|
45979084|NCT00295997|Biological|graft-versus-tumor induction therapy|
45979085|NCT00295997|Biological|therapeutic allogeneic lymphocytes|
45979086|NCT00295997|Drug|busulfan|
45979087|NCT00295997|Drug|cyclophosphamide|
45979088|NCT00295997|Drug|fludarabine phosphate|
45979089|NCT00295997|Drug|methotrexate|
45979090|NCT00295997|Drug|mycophenolate mofetil|
45979091|NCT00295997|Drug|tacrolimus|
45979092|NCT00295997|Procedure|allogeneic bone marrow transplantation|
45979093|NCT00295997|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
45979094|NCT00295997|Procedure|peripheral blood stem cell transplantation|
45979095|NCT00296114|Procedure|Serum and DNA Samples|To collect serum and DNA samples from subjects
45979096|NCT04887480|Device|Abthera™ Open Abdomen Negative Pressure Therapy Device System|Suction set at -125mmHg
45979097|NCT04887480|Drug|Dianeal PD-2 with 2.5% Dextrose|800mL to 1000mL of Dianeal PD-2 into Abthera™ and dwell for 1 hour.
45979098|NCT00296153|Drug|Omega-3-acid ethyl esters 90|Omacor capsule 1000mg x 4 per day. Duration 12 weeks
45979099|NCT00326703|Procedure|Hypobaric hypoxia|
45672515|NCT02169830|Behavioral|Diet Modification|Emphasis will be given to cessation of known migraine triggers such as caffeine, sodas, chocolates, alcohol (especially red wine) and aged cheeses. Patients who have complete control of their symptoms with diet and behavior modification alone will be followed for a total of 4 months to determine the durability of symptom relief.
45979100|NCT00418067|Device|Endeavor|Zotarolimus-eluting stent
45979101|NCT00418067|Device|Cypher|Sirolimus-eluting stent
45979102|NCT00418067|Device|Taxus Liberte|Paclitaxel-eluting stent
45979103|NCT04869969|Procedure|percutaneous nephrolithotomy (supine position)|percutaneous nephrolithotomy to be done in the supine position
45979104|NCT04869969|Procedure|percutaneous nephrolithotomy ( prone position)|percutaneous nephrolithotomy in the prone position
45979105|NCT00296270|Behavioral|Memory for truth|
45979106|NCT00296309|Drug|Tacrolimus|Immunosuppression
45979107|NCT00296348|Drug|tacrolimus|immunosuppression
45672516|NCT04854551|Drug|Naltrexone|Naltrexone is an opioid antagonist with primary action at the mu opioid receptor.
45672517|NCT04854551|Other|Placebo|Placebo will be used to control for expectancy effects
45672518|NCT04545905|Diagnostic Test|ANC surveillance|Clinic-based testing of all pregnant women during antenatal care visits.
45832028|NCT05582772|Other|GA+M Intervention|Typically 8 domains (cognition, comorbidities, falls risk, functional status, medication use, mood - depression, nutritional status, social support) are examined by a team consisting of a nurse and geriatrician. A GA has multiple benefits and has been recommended for all older adults considering chemotherapy by the American Society of Clinical Oncology (ASCO). For a GA to be most useful it needs to be followed by co-management of identified issues.
45832029|NCT05582772|Other|RSM intervention|Telephone-based, symptom management of patients with cancer
45832030|NCT05582772|Other|GA+RSM intervention|Combining a geriatric assessment and remote symptom control
45832031|NCT03902652|Procedure|Intervention (21% oxygen during CC+SI)|"Infants randomized into the 21% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI.~During CC+SI the clinical team will only use 21% oxygen."
45979108|NCT00296348|Drug|mycophenolate mofetil|oral
45979109|NCT00296348|Drug|daclizumab|oral
45979110|NCT00296348|Drug|steroids|oral
45979111|NCT04835376|Device|Percussion Palm Cup: Safety and Usability of Newly Designed Products in Infants and Children with Cystic Fibrosis|Patients/guardians/caregivers will be given 3 percussor palm cups to use over the course of 6 days. Each cup will be trialed for 2 days, allowing for equal time dedicated to each.
45979112|NCT00296387|Drug|Rosuvastatin|
45979113|NCT00296387|Drug|Atorvastatin|
45672519|NCT02169674|Biological|EngerixB, GlaxoSmithKline Vaccines|
45672520|NCT04536467|Drug|Goserelin|chemotherapy+goserelin
45672521|NCT04536467|Drug|Chemotherapy|standard chemotherapy
45979114|NCT00326742|Behavioral|Trier Social Stress Test|
45979115|NCT00296426|Procedure|New technology - PAML|
45979116|NCT00326820|Drug|ibandronate sodium|
45979117|NCT00326820|Drug|zoledronic acid|
45979118|NCT00326820|Drug|Zolendronic Acid|Zoledronic acid 4 mg by intravenous infusion every 4 weeks.
45979119|NCT00296465|Drug|Pulsatile gonadotropin-releasing hormone (GnRH)|Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
45979120|NCT00296465|Drug|Clomiphene Citrate|Oral clomiphene citrate (over encapsulated) for 5 days
45979121|NCT00296465|Drug|Placebo Pulsatile GnRH|Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
45979122|NCT00296465|Drug|Placebo Clomiphene Citrate|oral placebo clomiphene citrate for 5 days
45979123|NCT00326859|Drug|remifentanil|
45979124|NCT00326976|Drug|FX06|400 mg as intravenous injection in two divided boluses
45979125|NCT00326976|Procedure|Percutaneous coronary intervention|
45979126|NCT00296582|Behavioral|Gastric Motor Function Measurement|
45979127|NCT00296621|Drug|L-Glutamine|L-Glutamine
45979128|NCT00296621|Drug|placebo|placebo
45979129|NCT04717011|Diagnostic Test|PCR test|PCR test in two different semen samples from each patient: first with positive diagnosis for COVID-19 and the second after negative diagnosis for COVID-19.
45979130|NCT04762407|Drug|HGP1910|Take it once per period.
45672522|NCT04532489|Drug|FNP-59|FNP-59, a radiotracer, is administered for PET/CT scans.
45672523|NCT04946981|Dietary Supplement|Turmipure Gold®|TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
45672524|NCT04946981|Dietary Supplement|Placebo|Placebo: colored acacia gum - 1 capsule per day - as prescribed
45979131|NCT04762407|Drug|HGP1909|Take it once per period.
45979132|NCT04762407|Drug|HCP1903|Take it once per period.
45979133|NCT00296699|Drug|Duloxetine|"Day 1-7: 20 mg/d; day 8-24: 30 mg/d; day 15-28: 60 mg/d; day 29-56: 120 mg/d.~* dose raises will occur only if pt. is tolerating the previous dose and not remitting.; dose may be lowered or increased in 30 mg increments if pt. has difficulty tolerating."
45979134|NCT00296738|Device|SPECT/CT|GE INFINIA HAWKEYE
45979135|NCT04581486|Other|Optimal-Massive Intervention|Multimodal intervention based on 3 main measures: a) optimal fluid viscosity adaptation (with Nutilis Clear®), b) optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and c) optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning).
45979136|NCT04581486|Other|Control (standard clinical practice)|Standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®))
45979137|NCT04523220|Drug|BAY1213790 (Osocimab)|Single loading dose as subcutaneous abdominal injection followed by monthly maintenance doses.
45979138|NCT04523220|Drug|Placebo|Subcutaneous administration in the same manner as Osocimab.
45979139|NCT00296777|Drug|Escitalopram|8 weeks: up to 40 mg/day
45979140|NCT00296777|Drug|Bupropion|8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.
45979141|NCT00296777|Drug|Imipramine|"8 weeks: up to 300mg/day~*if patient does not have contraindication."
45979142|NCT00327054|Drug|Nigella sativa seed|
45979143|NCT00296855|Drug|Vasovist (BAY86-5283, MS-325)|All patients receive a single IV bolus injection of Vasovist at a dose of 0,03 mmol/kg BW at a flowrate of 0,5 mL/sec, followed by a saline flush of at least 30 mL
45979144|NCT00296894|Drug|Adalimumab (40 mg sc every other week)|Adalimumab (40 mg sc every other week)
45979145|NCT00296894|Drug|Placebo|Placebo
45979146|NCT00296933|Drug|Escitalopram|
45979147|NCT00296933|Drug|Bupropion XL|
45672525|NCT04942457|Behavioral|Fasting|Prolonged fasting for 7-10 days (caloric intake <500 kcal in liquid form)
45672526|NCT05341349|Biological|Ipilimumab|Given IV
45672527|NCT05341349|Biological|Nivolumab|Given IV
45672528|NCT05341349|Biological|Pembrolizumab|Given IV
45672529|NCT05341349|Radiation|Stereotactic Radiosurgery|Undergo SRS
45979148|NCT04494672|Procedure|Intramedullary nailing with ADAPT system|Stryker ADAPT®system (ADAPT, Stryker Leibinger GmbH & Co. KG, Freiburg, Germany) is a computer navigation system which can reconstruct a 3D model of the femoral head from the positional information oriented by bidirectional fluoroscopic views. ADAPT shows the distance from the tip of the screw to the surface of the femoral head, tip-to-head-surface distance (TSD), and tip-apex distance (TAD) intraoperatively
45979149|NCT04494672|Procedure|Intramedullary nailing without ADAPT system|Intramedullary nailing without ADAPT system
45979150|NCT00296972|Drug|peg interferon plus ribavirin|
45979151|NCT00297011|Drug|valacyclovir+clobetasol gel|
45979152|NCT00327093|Drug|cetuximab|indication : second intention treatment
45979153|NCT00327093|Drug|bevacizumab|Indication: first intention treatment
45672530|NCT05341349|Procedure|Tumor Treating Fields Therapy|Undergo TTFields
45672531|NCT04530149|Drug|Acetaminophen|receive ketamine 0.15 mg/kg IV in 100 mL normal saline over 30 minutes for pain
45979154|NCT00297050|Drug|Peramivir|
45979155|NCT04708587|Drug|dual anti-platelet therapy at least 6 months|Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months after randomization. Clopidogrel or prasugrel should be maintained after 6 months.
45979156|NCT04708587|Drug|dual anti-platelet therapy 3months or less|Patient enrolled in the dual antiplatelet therapy less than 3 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for less than 3 months after randomization. After 3 months clopidogrel or prasugrel should be maintained.
45979157|NCT00297128|Drug|Capecitabine|825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
45979158|NCT00297128|Drug|Cetuximab|400mg/m2 week 1, 250mg/m2 week 2-4
45979159|NCT00327132|Drug|Omeprazole, Amoxicillin, Clarithromycin|
45979160|NCT00297206|Drug|Valaciclovir|Valaciclovir will be administered as an extemporaneously prepared suspension formulation. Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF with dose strength of 25 milligram per milliliter (mg/mL) or 50 mg/mL.
45979161|NCT04485195|Drug|Vernakalant|an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump
45979162|NCT04485195|Drug|Procainamide|15 mg/kg in 500 mL of normal saline given over 60 minutes
45979163|NCT04478019|Drug|10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse|2 swab sticks of 10% povidone-iodine in each nares and 0.12% CHG oral rinse
45979164|NCT00297245|Drug|cognitive function|
45979165|NCT00327210|Behavioral|Blood Glucose Awareness Training|
45979166|NCT00297284|Drug|Modafinil|
45979167|NCT04392531|Drug|Cyclosporine|In the experimental group, cyclosporine will be started according to patient weight, and then increased depending on patient tolerance (monitoring renal function and blood pressure)
45979168|NCT04392531|Drug|Standard treatment|Standard of care according to hospital protocol
45979169|NCT00297323|Drug|Topiramate|75 patients over the age of 2 years old with epilepsy.
45979170|NCT00327249|Drug|imexon|
45979171|NCT00327288|Drug|imexon|IV variable dosages, days 1-5 every 21 days for duration of study
45979172|NCT00327288|Drug|docetaxel|IV once every 21 days for duration of study
45979173|NCT04344600|Drug|Peginterferon lambda alfa-1a subcutaneous injection|Peginterferon lambda-1a 180 micrograms by subcutaneous injection
45979174|NCT04344600|Other|Saline|Saline subcutaneous injection
45979175|NCT04333134|Drug|SHR3162|Fluzoparib, also known as SHR3162, is an inhibitor of human PARP
45979176|NCT00327327|Drug|imexon|30-60 minutes IV, days 1,8,15 every 28 days
45979177|NCT00327327|Drug|gemcitabine|30 minutes IV, days 1,8,15 every 28 days
45979178|NCT00327366|Procedure|Light therapy|
45979179|NCT04303104|Other|GeneXpert Edge|Screening intervention: novel diagnostic for Active Case Finding (GeneXpert MTB/RIF) for TB on sputum collected and performed at point-of-contact in a mobile van
45979180|NCT04303104|Other|GeneXpert Ultra|Screening intervention: novel diagnostic test for Active Case Finding (GeneXpert MTB/RIF) for TB on sputum collected at point-of-contact in a mobile van but sent to laboratory
45672532|NCT04530149|Drug|Bupivacain|The injection of bupivicaine into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle.
45672533|NCT04530149|Drug|Saline|The injection of saline into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle.
45672534|NCT04853225|Other|Prospective observational cohort study|Prospective observational cohort study
45672535|NCT04525547|Drug|Nintedanib|Nintedanib
45672536|NCT02169284|Drug|Erlotinib Hydrochloride|Given PO
45832032|NCT03902652|Procedure|Intervention (100% oxygen during CC+SI)|"Infants randomized into the 100% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI.~During CC+SI the clinical team will only use 100% oxygen."
45832033|NCT03916692|Dietary Supplement|Carbohydrate drink|Meal replacement drink containing 200 kcal
45832034|NCT03916692|Dietary Supplement|Energy smart Carbohydrate blend|Carbohydrate blend drink designed for low glycemic responses containing 200 kcal
45979181|NCT00297362|Drug|Galantamine hydrobromide|247 patients with diagnosed mild to moderate Alzheimer disease.
45979182|NCT00297440|Behavioral|Cognitive-behavioral treatment|
45979183|NCT00297440|Behavioral|Exercise|
45979184|NCT00327483|Behavioral|Internet based education software|
45672537|NCT02169284|Other|Laboratory Biomarker Analysis|Correlative studies
45672538|NCT02169284|Other|Pharmacological Study|Correlative studies
45672539|NCT02169284|Other|Placebo|Given PO
45672540|NCT02169284|Other|Quality-of-Life Assessment|Ancillary studies
45672541|NCT02169284|Procedure|Therapeutic Conventional Surgery|Undergo TURBT or cystectomy
45672542|NCT02119819|Drug|LY2944876|Administered SC
45672543|NCT02119819|Drug|Exenatide extended-release|Administered SC
45672544|NCT02119819|Drug|Placebo|Administered SC
45672545|NCT02119819|Drug|Metformin|Oral
45672546|NCT04766450|Drug|Acetyl cysteine|NAC exhibits potent anti-oxidant activity in the cell through augmentation of intracellular GSH, which is a major component of the pathways by which cells are protected from OTS, and its direct scavenging activity of free radicals by providing sulfhydryl groups. Additionally, NAC treatment exhibits anti-inﬂammatory effects via inhibition of NF-κB activation and reducing subsequent cytokine production . Mitochondria-protective mechanisms of NAC may also be related to its anti-oxidant and anti-inﬂammatory properties
45832035|NCT03916692|Dietary Supplement|Liquid Dextrose|Liquid Dextrose drink of 200 kcal
45979185|NCT05459220|Drug|SHR0410 Injection|SHR0410 Injection（Low Dose）
45979186|NCT05459220|Drug|SHR0410 Injection|SHR0410 Injection（High Dose）
45979187|NCT05459220|Drug|Placebo|Placebo for SHR0410 Injection.
45979188|NCT00297518|Device|PerioWave|
45979189|NCT00297518|Procedure|Scaling and Root Planing|
45979190|NCT04231773|Drug|Nitric Oxide|40 parts per million dosage
45979191|NCT04231773|Drug|Placebo|Inhaled placebo. Device connected to same delivery system, but does not deliver nitric oxide.
45979192|NCT04229316|Device|zLOCK Facet Stabilization System|zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains
45979193|NCT00297635|Device|GlucoDYNAMIX™ intervention system|
45979194|NCT00297635|Device|GlucoMON™ telemetry device|
45979195|NCT04224012|Other|Exercise and respiratory therapy|Three weeks in-Hospital Rehabilitation program with continuation of exercise Training at home
45979196|NCT00297674|Drug|Intravenous Clarithromycin|
45979197|NCT00297713|Drug|ALTU-238|
45979198|NCT04207593|Drug|Oxygen|Study medication will be oxygen (O2) in diverse concentrations, titrated until a SaO2>90% or pO2 >60 mmHg is achieved, for 20 patients vs. no supplemental O2 for 20 patients over 90 ± 7 days. Patients of the control group will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group). After the end of the study it is up to the judgment of the investigator to prescribe oxygen to all patients who might benefit from the treatment.
45979199|NCT00297752|Drug|ceriumnitrate silversulfadiazine (flammacerium)|treatment of patients with facial burns with CE-SSD
45979200|NCT00297752|Drug|silversulfadiazine (flammazine)|treatment of patients with facial burns with SSD
45979201|NCT00297791|Procedure|surgery|randomized to open or laparoscopic technique
45979202|NCT05459142|Drug|Medical Abortion|Medical Abortion
45979203|NCT00297869|Procedure|Computer-Assisted Decision Support|Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
45979204|NCT05459103|Other|Bidirectional remote interaction intervention|Intervention group participants engaged in a 12-week bidirectional remote interaction. All interactions were conducted through the same group on Line. A one-hour interactive online group intervention was held every Monday to Friday from 14:30 to 15:30, for a total of 60 hours. The online interactive interventions were conducted in a structured course format, with a facilitator conducting live classes and alternating between static and dynamic classes.
45979205|NCT05459103|Other|Unidirectional remote interaction intervention|Control group participants engaged in a 12-week unidirectional remote interaction. All interactions were conducted through the same group on Line. Research assistants posted a YouTube video on the Line group at 14:30 every day, Monday through Friday, covering art, music, senior sports, long-term care resources, travel, and food preparation.
45979206|NCT00297947|Drug|quetiapine|Participant will receive 1200 mg/day of quetiapine in twice daily dosing for 8 weeks.
45979207|NCT00297947|Drug|quetiapine|Participant will receive 600 mg/day of quetiapine for 8 weeks.
45979208|NCT05459025|Behavioral|Aromatherapy yoga|The research assistant diluted the Lavandula angustifolia essential oil with distilled water (1:75) 10 min before the yoga session started. The solution was then atomized by three aroma diffusers, placed in the front, middle, and back of the classroom. The distance from each participant was less than 10 m to ensure that the aroma was absorbed com-pletely. The yoga course for the aromatherapy yoga group was the same as that of the yoga only group. The yoga group only took a yoga course, without aromatherapy.
45979209|NCT05459025|Behavioral|Yoga|The design of the yoga lessons was based on a past study and a professional yoga instruction book. Yoga lessons were led by certified yoga tutors.
45979210|NCT04718714|Drug|Midazolam|loading dose intravenous infusion of 0.2 mg/kg over 10 minutes followed by a maintenance dose of 0.02 -0.2 mg /kg/hr. over 24 hours.
45979211|NCT04718714|Drug|Propofol|loading dose intravenous infusion of one mg/kg over 15 minutes followed by a maintenance dose of 20-80 microgram/kg/min. over 24 hours.
45979212|NCT04718714|Drug|Dexmedetomidine|loading dose of dexmedetomidine of one µg/kg over 10 minutes followed by maintenance dose of 0.2 -1.5 µg/kg/hr. over 24 hours.
45979213|NCT04053855|Biological|Urinary sample|Urinary sample (100 ml) will be collected in the urology department to analysis urinary exosomes.
45979214|NCT04009239|Behavioral|Time Restricted Feeding|Consuming energy during a short interval during the day
45979215|NCT00297986|Device|Helmet|Evaluation of different interfaces for NPPV
45979216|NCT05458635|Procedure|Right heart catheter|Right heart catheterization was performed for 4 cases with high probability of pulmonary hypertension using multi-lumen swan ganz catheter.
45672547|NCT04852991|Procedure|Modified Purandare cervicopexy|The modified Purandare's cervicopexy will be performed in low lithotomy position . Pfannenstiel incision was utilized and the abdomen was opened in layers maintaining perfect hemostasis. Uterus will be delivered through the incision and held with uterus holding forceps. The bladder was dissected inferiorly. A 25-30 cm long strip of polypropylene mesh was prepared by soaking. The mesh was fixed anteriorly at the level of isthmus by No.1 polypropylene sutures . The ends of the mesh were brought lateral to rectus muscle retroperitoneally on both sides taking care not to injure the inferior epigastric vessels. After confirming the correct fixation and haemostasis the uterovesical fold of peritoneum was approximated. The ends of the mesh were fixed to the rectus muscle by criss crossing using No. 1 polypropylene sutures. After confirming the haemostasis, the abdomen was closed in layers. Per speculum examination was done to note the reduction of prolapse.
45832036|NCT03916068|Procedure|Hyperbaric Oxygen Therapy|Hyperbaric oxygen therapy at 2.4 atmospheres for 90 minutes for 30 sessions.
45832037|NCT03916068|Drug|Trental Pill|Trental 400 mg three times daily, in combination with Vitamin E 400 IU twice daily
45832038|NCT03916068|Dietary Supplement|Vitamin E|Vitamin E 400 IU twice daily, in combination with Trental 400 mg three times daily
45832039|NCT04142970|Drug|HSK3486|HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
45832040|NCT04765332|Other|DLQI and PSO-TARGET QoL grid|At inclusion visit, and after 3 and 12 months, the patient will fill a patient questionnaire containing DLQI and PSO-TARGET QoL grid
45832041|NCT03022344|Radiation|Cardiac CT|
45672548|NCT04852991|Procedure|Abdominal sacral hysteropexy|After peritoneal entry through pfannenstiel incision was, the bladder is mobilized off the cervix. Windows are made in the broad ligament at the level of the isthmus. Posteriorly, the rectovaginal space is entered at the level of the uterosacral ligaments. Next, a 15x15-cm polypropylene mesh is used to fashion two 4.5- to 5-cm-wide strips of mesh; one is bisected for a distance of 5 cm to produce a Y-configuration for the anterior mesh.The anterior mesh arms are passed through the broad ligament windows and attached to the cervix and pubocervical fascia using interrupted 2-0 PDS. The posterior mesh is attached to the rectovaginal fascia using transverse-interrupted 2-0 PDS sutures. Once the sacral dissection has exposed the anterior longitudinal ligament, the proximal ends of the 2 mesh strips are attached to the sacral promontory using two 2-0 polyester sutures to provide elevation of the uterus without tension. The peritoneum is closed over the mesh using a 3-0 vicryl suture
45979217|NCT00298025|Drug|Cetrotide®|Cetrotide® will be administered subcutaneously as 3 mg injection when the lead follicle is >=14 mm till r-hCG day. If the subject did not achieve follicular maturation and did not receive r-hCG within 4 days, then the Cetrotide® will be administered at dose of 0.25 mg subcutaneously on successive days until r-hCG day.
45979218|NCT00298025|Drug|Antagon ™|Antagon™ will be administered subcutaneously at a dose of 0.25 mg once daily when the lead follicle is >=14 mm until r-hCG day.
45979219|NCT00298025|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered at a starting dose of 225 international unit (IU) subcutaneously once daily from S1 up to Stimulation Day 5 (S5). Beginning on Stimulation Day 6 (S6), the r-hFSH dose will be individualized to the subject. The minimum and maximum daily doses are 75 IU and 450 IU, respectively until r-hCG day.
45979220|NCT00298025|Drug|Human Menopausal Gonadotropin (hMG)|Human menopausal gonadotropin (hMG) will be administered subcutaneously daily at a dose of 75 IU till r-hCG day. The total daily dose of r-hFSH and hMG combined is not to exceed 450 IU (375 IU r-hFSH and 75 IU hMG).
45979221|NCT00298025|Drug|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250 microgram (mcg) subcutaneously when there is at least one follicle of >=18 mm and two additional follicles of >=16 mm with an appropriate plasma estradiol levels for the number and size of the existing follicles. The r-hCG will be administered within 36 hours after the last dose of the r-hFSH/hMG.
45979222|NCT00298064|Genetic|Tissue Repository|
45979223|NCT03923439|Device|Multi-b diffusion sequence MRI|Patients will be explored with the multi-b diffusion sequence on a new 3T research magnet equipped with high gradient system.
45979224|NCT03917745|Behavioral|eHealth mindfulness intervention|The web-based intervention consists of eight sessions including psycho-education about the mechanisms of stress, coping and relaxation, especially related to pregnancy, practicing mindfulness skills (i.e. mindful breathing, mindful moving, observing and letting-go of thoughts and emotions with a non-judgmental attitude), sharing experiences, and doing home assignments. The sessions have been developed specifically for pregnant women and acknowledge pregnancy-related distress. An online coach will review questions and home assignments of the participants. Women will start the training at 16 weeks gestation.
45979225|NCT00298142|Procedure|Usual Care provided by a medical doctor (GP or Neurologist)|
45979226|NCT00298142|Procedure|Usual care plus Physio-/ Manual Therapy|
45979227|NCT00298181|Drug|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion open-label at 0.07, 0.22, 0.7 or 2.2 mg/kg
45979228|NCT05458518|Procedure|Cesarean wound dressing removal|The cesarean wound dressing is to be removed and the surgical wound exposed
45979229|NCT00298220|Behavioral|Feedback about patients at risk|GPTs receive this feedback about their patient population; obtained through premeasurement results
45979230|NCT00298220|Behavioral|Dissemination guideline and patient information letters|
45979231|NCT00298220|Behavioral|Tailored educational training|for GP(T)s
45979232|NCT00298220|Behavioral|Tailored outreach based facilitator support|in the practices of the GPTs
45979233|NCT00298220|Behavioral|Facilitation of co-operation with local addiction services|
45979234|NCT00298220|Behavioral|Patient directed interventions|Like poster for the waiting room, self-help booklets, folders
45979235|NCT00298220|Behavioral|Reminder-card for GP's desk|
45979236|NCT00298220|Behavioral|Personal feedback to patients|Patients receive advise based on their premeasurement answers
45979237|NCT05458089|Diagnostic Test|18F-FDG|18F-FDG intravenous injection
45979238|NCT00298259|Procedure|operative fixation of fractured ribs|ORIFof fractured ribs in flail chest patients
45979239|NCT03826641|Drug|HCP1805|Dapagliflozin/Metformin (Xigduo XR) 10/1000mg
45979240|NCT03826641|Drug|HCP1801|Dapagliflozin/Metformin 10/1000mg
45979241|NCT00298298|Biological|L-Vax: Autologous, DNP-Modified NSCLC Vaccine|autologous, DNP-modified NSCLC cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
45979242|NCT03754140|Drug|Polidocanol Injection|Sclerotic agent
45979243|NCT00298337|Drug|Mixture of probiotic bacteria and prebiotic oligosaccharide|
45979244|NCT00419640|Device|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
45979245|NCT00419640|Device|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
45979246|NCT00419640|Device|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
45979247|NCT00419640|Device|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
45979248|NCT03528486|Behavioral|Music Training I|Participants will be attending group classes, guided by a trainer, with up to 10 other older adults.
45979249|NCT00298415|Drug|Paclitaxel + Carboplatin|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D29, 4 cycles) Carboplatin AUC 6 D1 (D1=D29, 4 cycles)
45979250|NCT00298415|Drug|Monotherapy (gemcitabine or vinorelbine)|Gemcitabine 1150 mg/m² D1 and D8 (D1=D22, 5 cycles) Vinorelbine 30 mg/m² D1 and D8 (D1=22, 5 cycles)
46082615|NCT02719236|Procedure|direct anterior approach|"The procedure begins by positioning the patient supine on a normal table . Both feet are draped separately to assist with dislocating and proximal femural shaft exposure.The surgical incision begins 2-4 cm lateral to the anterior superior iliac spine of the pelvis . It is then carried distally and laterally for about 8-12 cm. After protecting the lateral femoral cutaneous nerve, the fascia overlying the tensor fascia latae (TFL) is incised, and a plane is then developed between the TFL and sartorius. After coagulating the ascending branch of the lateral femoral circumflex artery, a capsulectomy is performed. Placement of the final acetabular component is facilitated by the use of an offset inserter handle.~Femoral preparation begins by placing the operative limb in a position of extension, adduction and external rotation to improve the accessibility of the proximal femur.~Once the final implants are in situ, the hip is reduced and assessed."
45979251|NCT03520101|Procedure|TAVI_ViV procedure with Edwards valve|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. The decision for selecting either a 20 or 23mm Edwards valve will be based on 3D CT measurements of the mean inner diameter of the surgical aortic bioprosthesis. A 23mm Sapien 3 valve will be recommended if the inner diameter is >18 mm, and a 20mm valve will be selected if the mean inner diameter is ≤18 mm.
45979252|NCT03520101|Procedure|TAVI_ViV procedure with CoreValve system|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. A 23mm valve will be recommended in all patients randomized to the self-expanding CoreValve Evolut R system.
45979253|NCT00298454|Drug|Furosemide|
45979254|NCT04708392|Device|Spinal Cord Stimulator|A spinal cord stimulator is a surgically implanted device that delivers an electrical signal to a patient's spinal cord to reduce the perception of pain
45979255|NCT03517956|Drug|Rogaratinib (BAY1163877)|"Dose escalation:~Starting dose is rogaratinib 400 mg twice daily (b.i.d.) in continuous 28-day cycles from Cycle 1 Day 3 onwards.~Dose expansion:~With dose identified in dose escalation part."
45979256|NCT03517956|Drug|Copanlisib (BAY80-6946)|"Dose escalation:~Starting dose is 45 mg on Days 1, 8 and 15 of each 28-day cycle.~Dose expansion:~With dose identified in dose escalation part."
45979257|NCT00298493|Procedure|Sedation management strategy|
45979258|NCT00298532|Procedure|Advanced Life Support|
45979259|NCT03505476|Device|Entac Medical device application|Subjects will wear a 3-inch by 3-inch stethoscope device that adheres to the skin of the abdomen via FDA approved adhesive material. It will be applied either in the operating room at the completion of surgery or in the recovery room. The device will remain on the abdomen until discharge or for 10 days, whichever comes first.
45979260|NCT03505476|Other|Patient Daily Assessment|The research team will ask questions of the subject regarding nausea, vomiting, passage of flatus, return of bowel function, and satisfaction with the device every day that the subject is hospitalized.
45979261|NCT03505476|Other|Patient Discharge Assessment|The research team will ask questions of the subject regarding satisfaction or dissatisfaction with having the device placed and attached to their abdomen.
45979262|NCT00298571|Drug|.5% bupivacaine with epinephrine|
45979263|NCT00419679|Procedure|x-ray diffraction of human hair|
46082616|NCT02719236|Procedure|direct lateral approach|"The procedure begins by positioning the patient in the supine decubitus position.~A longitudinal incision is made extending 3-5 cm proximal and about 5-8 cm distal to the tip of the greater trochanter . The fascia is split at the interval between the TFL and gluteus. The tendon and muscle fibres of the gluteus medius are then visualized and split . The gluteus minimus and joint capsule are split. The surgeon then dislocates the femoral head, and performs a femoral neck osteotomy.~The acetabulum is prepared .Soft tissue landmarks and reamer positioning relative to the floor are used to verify acetabular version and inclination.~When preparing the proximal femur, the hip is adducted and externally rotated, with the knee flexed. The femural stem is then press-fitted. Once the final implants are in situ and the hip is reduced, the stability of the construct is assessed."
45672549|NCT04765982|Diagnostic Test|Checking diabetes development in follow up at 3 month|An outpatient visit will be planned approximately three months after ICU discharge. At the time of this visit, we will obtain age, BMI, waist circumference, diet, exercise, history of hypertension and family and personal history of elevated blood glucose to calculate the Finnish diabetes risk score (FINDRISC) questionnaire. (28) Oral glucose tolerance test (OGTT) will be performed according to the guidelines of the World Health Organization (WHO) with 75-g glucose load. Diabetes will be diagnosed according to the American Diabetes Association guidelines that stat fasting plasma glucose ≥126 mg/dl(7mmol/L) and/or 2-h plasma glucose during the OGTT ≥200 mg/dl (11.1mmol/L) and/or HbA1c ≥6.5 % (48 mmol/L); impaired glucose tolerance is noted when 2-h plasma glucose during the OGTT is between 140-200 mg/dl (7.7-11.1mmol/L). Impaired fasting glucose defined as fasting plasma glucose between 100-126 mg/dl (55.7mmol/L). (29)
45832042|NCT04142346|Behavioral|Sitting + moderate intensity breaks|Participants will be followed in a randomized crossover trial undertaken at Faculty of Human Kinetics between April and August 2019. Participants will attend to the laboratory on twelve separate occasions: visit 1 (day 1), baseline assessments for body composition; visit 2 (day 2), cardiorespiratory fitness assessment; visit 3 (day 3), OGTT and the first randomized experimental protocol; visit 4 (day 4), follow-up OGTT; visit 5 (4-6 days after the first experimental protocol), OGTT and the remaining experimental protocol; visit 6 (day following the previous experimental protocol), follow-up OGTT. An additional 6 visits will be performed following the same rational, after a 2-week period of detraining, where participants will be instructed to refrain from structured exercise. The follow-up assessments for body composition and cardiorespiratory fitness will be accomplished after the protocols.
45832043|NCT04142112|Device|Ohana IVF Sperm Preparation Kit (OHB035)|The Ohana IVF Sperm Preparation Kit (OHB035) contains media for processing sperm through a series of timed steps prior to insemination with oocytes.
45979264|NCT00298649|Behavioral|Lay Health Advisor|
45672550|NCT05322239|Device|Intermittent Theta Burst Stimulation|iTBS parameters. A series of 20, 10 s trains will be presented over the course of the ~3.5 min session. Each train will consist of 2 s of stimulation with an 8 s ITI. During the 2 s of stimulation, 10, 50 Hz bursts will be repeated at intervals of 200 ms (5 Hz).
45979265|NCT00298688|Drug|Gefitinib|
45979266|NCT00298727|Behavioral|SHIPS|Stakeholder-Hosted Interactive Problem-based Seminars
45979267|NCT00298727|Behavioral|ePBL|Online Problem-Based Course
45979268|NCT05457894|Biological|Flu-M, Inactivated split influenza vaccine|solution for intramuscular injection, 0.5 ml
45979269|NCT05457894|Biological|Ultrix®, Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
45979270|NCT03448653|Other|Colonoscopy with NBI|Colonoscopy with NBI
45979271|NCT03439839|Drug|LNP023|LNP023 bid
45979272|NCT05457777|Behavioral|Motivational interview in digital game addiction|Motivational interviewing, which is a technique developed by William Miller that aims to change behavior by revealing the contradiction of problematic behavior with the value judgments of the person and creating motivation by the counselor, will be applied to the individuals with digital game addiction.
45979273|NCT00298883|Drug|Myfortic|Myfortic 360mg PO BID for six weeks
45979274|NCT00298922|Drug|Azithromycin|500 mg tablets orally thrice weekly for 24 weeks
45979275|NCT00298922|Drug|Placebo|tablet orally thrice weekly for 24 weeks
45979276|NCT05457738|Other|E-REVA® app|Use of a smartphone app designed for home-based exercise therapy of patients with intermittent claudication. App's name is E-REVA®.
45979277|NCT05457738|Other|No E-REVA® app|No use smartphone
45979278|NCT00298961|Device|Videoconference equipment FALCON/IP|
45979279|NCT03136965|Biological|PRP|Injection of autologous platelet rich plasma (PRP)
46082617|NCT00936169|Procedure|IVUS optimised DES implantation|Ivus optimised stent implantation
46082618|NCT00936169|Procedure|angiographically guided DES implantation|angiographically guided DES implantation
45672551|NCT05322239|Device|Continuous Theta Burst Stimulation|cTBS parameters. A single 600 pulse cTBS train will be delivered during each stimulation session. The train will consist of 50 Hz bursts, repeated at intervals of 200 ms (5 Hz) for 40 sec.
45672552|NCT02168816|Drug|Intravenous Antibacterial Agent|Individuals in this arm receive an intravenous antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an intravenous antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.
45832044|NCT04142112|Device|Standard IVF Preparation Kit (OHB037)|The Standard IVF Sperm Preparation Kit (OHB037) contains media for processing sperm per the traditional steps prior to insemination with oocytes.
45832045|NCT04143282|Drug|Metformin plus chemotherapy|determine the effect of metformin along with standard chemotherapy
45832046|NCT04143282|Drug|Chemotherapy|standard chemotherapy
45832047|NCT04142190|Drug|ELONVA|Elonva is a solution for injection that contains the active substance corifollitropin alfa. It is available as a pre-filled syringe (100 and 150 micrograms).Elonva is used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries.
45832048|NCT04142190|Drug|PUREGON|Puregon contains the active substance follitropin beta. fertilisation). Puregon is administered to stimulate the ovaries to produce more than one egg at a time
45979280|NCT03136965|Procedure|Dry Needling|This is a therapeutic procedure that involves the same injection procedures under ultrasound guidance as in the PRP group but no PRP will be injected inside the patellar tendon.
45979281|NCT03136965|Procedure|Dry Needling - Sham|This is a sham procedure that involves similar injection procedures under ultrasound guidance as in the PRP and DN groups with no injection of PRP or needle placement inside the patellar tendon.
45979282|NCT00299039|Drug|acetaminophen plus codeine|capsules four times daily until pain free or for a maximum of seven days
45979283|NCT00299039|Drug|acetaminophen plus ibuprofen|capsules four times daily until pain free or for a maximum of seven days
45979284|NCT05457621|Other|Effaclar serum|Effaclar serum has been formulated with an ultra-concentrated tri-acids complex for a synergetic action on skin and reinforced with soothing niacinamide for optimal tolerance. It acts in particular on imperfections and persistent marks due to acne.
45979285|NCT00299117|Behavioral|Brief preoperative smoking intervention|One counseling session of approximately 45 minutes duration 3-4 days preoperatively. The intervention is inspired by the principles of motivational interviewing and The Stages of Change Model.
45979286|NCT00299234|Drug|Atomoxetine|titration schedule: 0.5 to 1.5 mg/kg/day
45979287|NCT00299273|Behavioral|Low calorie high fat/protein diet|6 weeks of caloric restriction (50%) on a high fat/protein diet
45979288|NCT05457543|Diagnostic Test|Adult|Investigational use of a novel liver function diagnostic test that involves a paper-based test device and a smartphone application.
45979289|NCT02870517|Other|Relaxing Music|Relaxing music, will be played through noise-cancelling headphones during induction of anesthesia. All of the songs used in this study will have <60 BPM, be instrumental rather than lyrical, and utilize predictable chord progressions. Music will be divided into several themed playlists which will be focused on the type of instruments involved including guitar, steel drum, and piano. The patient will listen to the music through noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
45979290|NCT02870517|Other|No Music|The patient will wear noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
45979291|NCT00299351|Drug|Depsipeptide|
45979292|NCT00299390|Drug|Sagopilone (BAY86-5302, ZK 219477)|Sagopilone; 16 mg/m2 (maximum 32 mg) as 3 hour i.v. infusion
45979293|NCT00299429|Procedure|Stenting and minimally invasive bypass surgery|
45979294|NCT00299429|Procedure|PCI with DES|PCI with DES
45979295|NCT00299468|Behavioral|Patient Activation Measure Intervention Package|
46082619|NCT02724150|Drug|Omeprazole High dose|High regimen of Proton Pump Inhibitors in treatment of bleeding ulcer 80 mg loading dose then 8 mg/h iv for 3 days
45979296|NCT00299585|Procedure|"using PD VitalOs Cement with dental implants"|supporting dental implants with Vitalos bone cement
45979297|NCT02808585|Drug|PB1046 Injection|Four weekly subcutaneous injections of PB1046.
45832049|NCT05582148|Device|Hearing aids fitting|Fitting hearing aids and evaluating the results at 6 months
45979298|NCT02808585|Drug|Placebo Injection|Four weekly subcutaneous injections of placebo.
45456289|NCT04431258|Drug|Folfirinox|"FOLFIRINOX will be dosed according to the standard following regimen:~oxaliplatin 85 mg/m2, administered as 2-hour iv infusion~leucovorin 400 mg/m2, administered as 2-hour iv infusion~irinotecan 180 mg/m2, administered as 1.5-hour iv infusion~fluorouracil 2400 mg/m2, administered as 46-hour iv infusionevery 2 weeks (=1 cycle) until disease progression or unacceptable toxicities."
45456290|NCT04431258|Drug|Placebo|Placebo will be administered daily at the same regim as ABTL0812. Placebo will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, placebo will be maintained once chemotherapy is discontinued, if the patient is in response or stable disease.
45456291|NCT04412369|Diagnostic Test|Non-invasive cardiac imaging|Cardiac MRI ± CT coronary angiography ± Cardiac PET/MRI (68Ga-DOTATATE or 18F-FDG)
45979299|NCT02751762|Other|Observation Only|No Intervention
46082620|NCT02724150|Drug|Omeprazole Low dose|low regimen of Proton Pump Inhibitors in treatment bleeding ulcer 80 mg loading dose then 40 mg two times per day for 3 days
45456292|NCT04409639|Drug|Cobimetinib|Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.
45456293|NCT04409119|Device|HIS/LBB pacing|3830 lead to HIS or LBB
45456294|NCT04409119|Device|LV pacing|LV lead in a CS branch
45456295|NCT04408612|Diagnostic Test|Scales for assessment of symptoms|"Medical Research Council Dyspnea scale, the visual analogue scale of dyspnea, Borg scale, modified dictionary of dyspnea, G. Rose questionnaire, Seattle Angina Questionnaire, Framingham criteria for chronic heart failure, the SHOCK scale."
45456296|NCT04408430|Device|Transseptal ViMAC|Transseptal TMVR using balloon-expandable aortic transcatheter valves.
45832050|NCT04149678|Drug|Ozanimod|Ozanimod
45832051|NCT04149678|Drug|Cyclosporine|Cyclosporine
45832052|NCT05582070|Other|actigraphy|Actigraphy examination will be performed during 2 periods of 7 days before and after nose nasal desobstruction surgery (septoplasty, septorhinoplasty or total ethmoidectomy). Respectively 2 months before surgery (inclusion) and 4 months after surgery.
45832053|NCT05581992|Drug|AMG 510|Oral Tablet
45832054|NCT05581992|Drug|Omeprazole|Capsule
45832055|NCT03021174|Behavioral|EXCAP Exercise|12 weeks of at-home walking and resistance exercise
45979300|NCT00299780|Drug|Stem cell mobilization|
46082621|NCT00939601|Behavioral|Motivational Enhancement Therapy|
45832056|NCT03021174|Behavioral|Nutrition Education Control|12 weeks of implementing eating tips
45979301|NCT05457348|Procedure|Planned incisions during phacoemulsification|Planned three (one 2.8 mm and two 2.0mm) on the or near to steep meridian will be performed in the experimental group during phacoemulsification
45979302|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
45979303|NCT00299819|Biological|MEDI 545|0.3 mg/kg IV (n=6) at Study Day 0
45979304|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
45979305|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
45979306|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
46082622|NCT00939601|Behavioral|Educational Counseling|
46082623|NCT02800850|Behavioral|Bright Light|
45979307|NCT04716660|Other|Sensory block level check|Patients will have their sensory block level checked multiple times following administration of their epidural bolus for labor analgesia.
45979308|NCT00299858|Drug|Theophylline|"Patients assigned to study group, will receive slow-release theophylline at a dose of 10 mg/kg, titrated to blood levels between 55-110 umol/L, for a period of 4 weeks.~Patients assigned to placebo group will receive identical-appearing placebo tablets for the same period of time."
45979309|NCT00299897|Drug|SP01A|
45979310|NCT05455944|Drug|Pregabalin 150mg|Two capsules of pregabalin is administered orally to patients
45832057|NCT03020940|Drug|Cefuroxime Axetil Dispersible Tablets|"Oral. This product can be taken orally, can also be added to the amount of warm water after mixing evenly.~Adult general 0.25g (one time), 2 times a day, the general course of treatment for 5 to 10 days.~Severe Infection or suspected pneumonia, a 0.5g (once 2), 2 times a day; general urinary tract infection, a Times a 0.125g (one and a half tablets), 2 times a day; for patients with no complications of gonorrhea recommended dose of 1g (4 Tablets), a single taking.~Children generally a dose of 0.125g (one-half tablets), 2 times a day; for less than two years of age in the middle ear Inflammatory patients, a 0.125g (one half tablets), 2 times a day; for greater than two years of otitis media patients, one Times a 0.25g (one time), 2 times a day; more than 12 years of age in children, the same dose for adults"
45832058|NCT03020628|Biological|NBP607-QIV|For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular [* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart]
45979311|NCT05455944|Drug|Placebo|Two identical placebo capsules is administered orally to patients
45979312|NCT00299936|Drug|Ribavirin, PEG-Intron|
45979313|NCT02348112|Device|Altis Sling|Altis is a minimally invasive, adjustable incontinence sling that is placed through a single incision in the vaginal wall and anchored inside the body. The sling has an integrated tensioning system eliminating the need for additional skin exits.
45979314|NCT02348112|Device|Transobturator or Retropubic Sling|Both transobturator and retropubic slings are a hammock-like mesh placed underneath the urethra to provide support. A single incision is made in the vaginal wall and two incisions in the abdomen. Tensioning of the sling is achieved by pulling the sling through the abdominal incisions.
45979315|NCT00300014|Procedure|Intravitreal triamcinolone injection|
45979316|NCT00300014|Procedure|Air-fluid exchange|
45979317|NCT00300092|Drug|Cepahlexin (drug)|Cephalexin 50 mg/kg divided 3 times daily for 7 days
45979318|NCT00300131|Device|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation stent in the treatment of coronary artery disease
45979319|NCT05453409|Other|No intervention|No intervention
45979320|NCT01785459|Drug|0.5% bupivacaine|The injection site will be prepared using common sterile technique with 2% chlorhexidine. 1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine. Location would be approximately 1 cm superior to spinous process of C7 and approximately 2-3 cm laterally. The needle is inserted 1 to 1.5 inches into the paraspinous musculature at this level. A 27-gauge needle would be used to minimize tissue trauma and pain to the patient. Our method of injection is followed quite closely with the technique depicted in multiple retrospective studies. We chose to follow previous reported technique secondary to good clinical efficacy and impressive documented safety profile. Additionally, before injection, aspiration would be performed to lesson chance of intravascular injection.
45979321|NCT01785459|Drug|Standard Care|10 mg Intravenous injection of Prochlorperazine
45979322|NCT04716894|Drug|BI 474121|BI 474121 oral solution
45979323|NCT04716894|Drug|Itraconazole|Itraconazole oral solution
45979324|NCT00300287|Drug|Vildagliptin|
45979325|NCT00300326|Procedure|Computer assist|same implant using a computer-assisted surgical technique.
45979326|NCT05451732|Procedure|Nanofat grafting|Naofat grafting in the urethral stricture. The autologous adipose tissue is transferred by injection and in this way, the access to the urethral stricture is carried out with a minimal incision of the male urethra while in the female urethra is transferred exclusively with injections, without incision of urethral tissue.
45979327|NCT00300404|Drug|daraprim|
45832059|NCT03020628|Biological|NBP607-TIV|For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular [* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart]
45979328|NCT00300404|Drug|pyrimethamine|
45979329|NCT00300404|Drug|folinic acid|
45979330|NCT05451654|Drug|Placebo|The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
45979331|NCT05451654|Drug|Experimental drug|The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
45979332|NCT01539447|Drug|Naproxen|• Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
45979333|NCT01539447|Drug|placebo|• Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
45979334|NCT00300443|Drug|bimatoprost|
45979335|NCT05400564|Behavioral|Family Check-Up|This intervention includes access to the Family Check-Up app and telehealth coaching provided by trained mental health providers. Parents can contact their Coach as often as they like and a minimum of 3 coaching sessions will be scheduled.
45979336|NCT00300521|Genetic|ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy|
45979337|NCT00300560|Drug|Colistin|
45979338|NCT00300638|Procedure|Magnetic Resonance Imaging (MRI)|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
45979339|NCT00300638|Behavioral|Interviews, cognitive tests, and emotional measurements|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
45979340|NCT00327522|Biological|pneumococcal vaccine|
46082624|NCT02800850|Behavioral|Placebo Light|
45979341|NCT04718051|Drug|Shen Pu Yang Gan Wan|Shen Pu Yang Gan Wan is Traditional Chinese Medicine; in addition, it has a high dose.
45979342|NCT04718051|Drug|Placebo|Shen Pu Yang Gan Wan is Traditional Chinese Medicine; however, it has a very low dose.
45979343|NCT00327561|Procedure|Intensive periodontal therapy|
45979344|NCT00327561|Procedure|Community based periodontal therapy|
45979345|NCT00300716|Drug|Memantine|
45979346|NCT04717167|Other|Dry Needling|
45979347|NCT04717167|Other|Sham Needling|
45979348|NCT00300794|Drug|Ketamine|
45979349|NCT05373303|Biological|Recombinant Human Erythropoietin Alpha|This study consisted of a screening period (4 weeks), titration period (4~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection
45672553|NCT02168816|Drug|Oral Antibacterial Agent|Individuals in this arm receive an oral antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an oral antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)
45979350|NCT05373303|Biological|Recombinant Human Erythropoietin Alpha|This study consisted of a screening period (4 weeks), titration period (4~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection
45456297|NCT04407611|Behavioral|Online modality|Return of BRCA results directly online or return of printed BRCA results if participant cannot access online or chooses not to
45672554|NCT05315921|Drug|OsrhAAT 1 mg/kg IV|"Drug: OsrhAAT 1 mg/kg IV A single dose of OsrhAAT 1 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
45979351|NCT00300833|Drug|Tirofiban|pci
45979352|NCT00327600|Drug|imexon|
45456298|NCT04407611|Behavioral|Genetic counselor follow-up|Optional genetic counselor follow-up over the telephone
45456299|NCT04401800|Drug|Lenvatinib|Capsules administered orally once daily
45456300|NCT04401800|Drug|Tislelizumab|200 mg intravenous (IV) infusion administered on Day 1 of each cycle
45456301|NCT04400110|Drug|Amoxicillin and Clavulanic Acid in Oral Dose Form|50 mg/kg three times daily administered orally
45456302|NCT04394689|Biological|Measles Rubella Vaccine (MRV-SC)|One dose as subcutaneous injection of a WHO prequalified MR vaccine
45672555|NCT05315921|Drug|OsrhAAT 3 mg/kg IV|"Drug: OsrhAAT 3 mg/kg IV A single dose of OsrhAAT 3 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
45672556|NCT05315921|Drug|OsrhAAT 10 mg/kg IV|"Drug: : OsrhAAT 10 mg/kg IV A single dose of OsrhAAT 10 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
45672557|NCT05315921|Drug|OsrhAAT 20 mg/kg IV|"Drug: OsrhAAT 20 mg/kg IV A single dose of OsrhAAT 20 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
45979353|NCT00327600|Drug|DTIC|
45979354|NCT00300872|Device|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) - Horizon LT 8001 Continuous positive airway pressure (CPAP) device.
45979355|NCT00300872|Device|Sham Continuous positive airway pressure (CPAP)|Sham Continuous positive airway pressure (CPAP) - Continuous positive airway pressure (CPAP) units set to the lowest pressure (4 cm of water pressure) and 6 extra 4mm holes will be inserted in the collar of the main tubing at the end of the mask to allow air escape and to prevent carbon dioxide rebreathing.
45979356|NCT00300911|Drug|Rosiglitazone(drug), cardiac adverse effects|
45979357|NCT00327678|Drug|Rituximab|
45979358|NCT00327678|Drug|Imatinib Mesylate|
45979359|NCT00300950|Biological|GI-4000|Heat-killed yeast cell transfected with target ras mutation.
45979360|NCT00300950|Drug|Gemcitabine|Chemotherapy
45979361|NCT05372601|Dietary Supplement|Relax+|Prebiotics, daily administered
45979362|NCT05372601|Dietary Supplement|Maltodextrin|Placebo, daily administered
45979363|NCT00300989|Device|Inion OTPS Biodegradable Fixation System|
45979364|NCT00327756|Drug|Coenzyme Q10|
45979365|NCT00301106|Biological|adenovirus-mediated human interleukin-12|"The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC."
45456303|NCT04394689|Biological|MRV-MNP|One standard dose of Measles and Rubella vaccine delivered intradermally as a dissolving microneedle patch
45979366|NCT00301145|Behavioral|smoking cessation intervention|
45979367|NCT00301145|Drug|varenicline|
45979368|NCT00301145|Other|counseling intervention|
45979369|NCT00301145|Other|internet-based intervention|
45979370|NCT05366946|Other|Prevalence study|Prevalence study of chronic pain in COPD vs healthy controls
45456304|NCT04394689|Other|PLA-MNP|One placebo dose of a dissolving microneedle patch
45979371|NCT00301223|Drug|Pregabalin|
45672558|NCT05315921|Drug|OsrhAAT 40 mg/kg IV|"Drug: OsrhAAT 40 mg/kg IV A single dose of OsrhAAT 40 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
45672559|NCT05315921|Drug|OsrhAAT 60 mg/kg IV|"Drug: OsrhAAT 60 mg/kg IV A single dose of OsrhAAT 60 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
45672560|NCT04505813|Biological|NEXI-002 T Cells|The NEXI-001 T cell product will be administered as a single IV infusion to patients within 72 hours after completing LD therapy.
45672561|NCT05307107|Behavioral|SHINE|Intervention group will use a 8-workweeks the digital Smart Break SHINE program with workplace support (encouragement and time-support) including daily 3 minutes break exercises twice a day; 1) physical exercise - break and 2) body/mind breathing exercise - break earning stars for exercise completed. The program includes weekly self-reflective task of individual well-being during working hours with weekly changing theme (avoiding sitting time, nature benefits, relaxation exercises, increasing physical activity in workplace etc.) earning diamonds for every weekly task completed. Participants self-monitors their weekly individual resources levels asked in every Thursday (1-5, 1= very poor. 5= very good). Program includes e-mail remainders set by participant themselves for suitable time frame These individual well-being actions takes approximately 15 minutes/workday. Control group will receive this program after this study (waitlist protocol).
45979372|NCT00301301|Drug|Gemcitabine|
45979373|NCT00301301|Drug|Cisplatinum|
45979374|NCT00301301|Drug|Rituximab|
45979375|NCT05320302|Drug|[11C]-Lu AF88370|PET ligand in a single intravenous bolus injection
45979376|NCT00301340|Drug|5% Lice Asphyxiator lotion - Summers Laboratories, Inc.|
45979377|NCT04717206|Other|Plyomtric training to male badmninton players|"Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills."
45979378|NCT04717206|Other|Plyomtric training to female badmninton players|"Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills."
45979379|NCT00301496|Device|Coban 2 Layer Compression System|
45979380|NCT05318625|Device|Gynaecological laparoscopic surgery (Sirius System)|"The laparoscopic procedures were done in the usual manner. The only difference was for the study participants, the Sirius System was used in place of the usual conventional laparoscope. All other procedures and instruments including the number of ports remained the same.~For every procedure using the Sirius System, a conventional laparoscope was on immediate standby to replace the Sirius System should there be an unanticipated equipment failure so that the procedure could be completed without delay."
45979381|NCT00301535|Drug|HBOC-201 (hemoglobin glutamer-250 bovine)|HBOC-201 is an investigational solution of purified, glutaraldehyde-polymerized bovine hemoglobin with a concentration of hemoglobin of 13 ± 1 g/dL
46082625|NCT00771849|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
46082626|NCT00771849|Biological|Haemophilus Influenzae Type b (Hib) vaccine|0.5 mL, Intramuscular
45456305|NCT04394689|Other|PLA-SC|Placebo saline as subcutaneous injection
45456306|NCT04387227|Drug|Carboplatin|Given IV
45456307|NCT04387227|Biological|Pembrolizumab|Given IV
45979382|NCT00301574|Drug|galantamine|
45979383|NCT00327834|Drug|atomoxetine|
45979384|NCT00301613|Drug|Mycophenolate mofetil|MMF,1.0g/d
45979385|NCT00327873|Other|Oxygen|2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
45979386|NCT00327873|Other|Medical Air|2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
45979387|NCT00301652|Drug|mycophenolate mofetil|MMF,1.0g/d
45979388|NCT00327912|Procedure|Laparoscopic Biliopancreatic diversion with Duodenal switch|
45979389|NCT00327912|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
45979390|NCT00301691|Behavioral|behavioral dietary intervention|
45979391|NCT00301691|Other|educational intervention|
45979392|NCT00301691|Other|preventative dietary intervention|
45979393|NCT05252871|Device|Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating|Subjects will be wearing three different PAL designs with different geometries of the optical progression.
45979394|NCT00301730|Biological|aldesleukin|
45979395|NCT00301730|Biological|therapeutic tumor infiltrating lymphocytes|
45979396|NCT00301730|Biological|trastuzumab|
45979397|NCT00301730|Drug|paclitaxel|
45979398|NCT00301730|Procedure|conventional surgery|
45979399|NCT00301769|Drug|SJG-136|Given IV
45979400|NCT00301847|Drug|sorafenib tosylate|
46082627|NCT00936247|Drug|HES 130/0.42 + electrolyte solution|Tetraspan 6% as colloid component combined with Sterofundin ISO as electrolyte component
45979401|NCT00327990|Drug|Ibandronate|
45979402|NCT00327990|Drug|Alendronate|
45979403|NCT00301886|Drug|ibandronate|
45979404|NCT00301886|Drug|zoledronate|
45979405|NCT00301886|Procedure|quality-of-life assessment|
45979406|NCT05238831|Procedure|Biopsy|Undergo tissue biopsy
45979407|NCT05238831|Procedure|Biospecimen Collection|Undergo collection of blood
45979408|NCT05238831|Biological|Ado-Trastuzumab Emtansine|Given intravenously (IV)
45979409|NCT05238831|Drug|Alectinib|Given orally (PO)
45979410|NCT05238831|Biological|Atezolizumab|Given IV
45979411|NCT05238831|Biological|Bevacizumab|Given IV
45979412|NCT05238831|Drug|Cobimetinib|Given PO
45979413|NCT05238831|Drug|Entrectinib|Given PO
45979414|NCT05238831|Biological|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Given SC
45979415|NCT05238831|Drug|Vemurafenib|Given PO
45979416|NCT05238831|Drug|Vismodegib|Given PO
46082628|NCT00936247|Drug|Albumin + electrolyte solution|Albumin 5% as colloid component and NaCl 0.9% as electrolyte component
46082629|NCT04042740|Drug|Glecaprevir/Pibrentasvir (G/P)|Fixed-dose combination (FDC) tablets containing 100 mg of glecaprevir and 40 mg of pibrentasvir; administered as 3 tablets orally.
46082630|NCT04042740|Drug|Ribavirin (RBV)|Tablets containing 200 mg of ribavirin. RBV dosed according to weight-based and renal dosing tables in study protocol.
46082631|NCT00936403|Drug|NNC126-0083|One single dose administered in four dose levels in an escalating order
45456308|NCT04368078|Drug|Toripalimab plus Lenvatinib|"Toripalimab 240mg, every 3 weeks, intravenous infused, day 1, 6 weeks a cycle. Lenvatinib 8mg (weight<60kg) or 12mg (weight≥60kg), once a day, oral at least 38 days of each 6 weeks cycle, day 2.~Number of cycle: until progression or unacceptable toxicity events develop"
45832060|NCT05581914|Other|MY LIFE treatment|"The MY LIFE is a group treatment consisting of 5 workshops, for adolescents with a low motivation for mental health treatment. It aims to increase self- worth, hope for the future and seeking social support through exercises by using music and lyrics and other creative exercises to engage adolescents. The MY LIFE treatment also uses methods that stem from psychodynamic, cognitive behavioral, and solution focused theories. The therapeutic attitude is based on client-centered therapy of Rogers, which includes a genuine, positive regard and empathic understanding, focusing on the inner strength and growth potential of a person. Adolescents are never forced to participate during the workshops, merely encouraged.~The core of the treatment is: the adolescent decides"
45832061|NCT05581914|Other|Care as Usual|The care as usual the adolescents receives
45456309|NCT04364763|Drug|RBT-9 (90 mg)|Subjects will receive a single dose and study duration will be approximately 60 days per subject.
45672562|NCT01584232|Drug|LY2189265|
45672563|NCT01584232|Drug|Insulin glargine|
45979417|NCT05238831|Drug|Alpelisib|Given PO
45979418|NCT05238831|Drug|Nab-paclitaxel|Given IV
45979419|NCT05238831|Drug|Olaparib|Given PO
45979420|NCT05238831|Drug|Capecitabine|Given PO
45979421|NCT05238831|Drug|Irinotecan|Given IV
45979422|NCT05238831|Drug|Carboplatin|Given IV
45979423|NCT05238831|Drug|Paclitaxel|Given IV
45979424|NCT05238831|Drug|Niraparib|Given PO
45979425|NCT05238831|Drug|Anastrozole|Given PO
45979426|NCT05238831|Drug|Letrozole|Given PO
45979427|NCT05238831|Drug|Vinorelbine|Given IV
45979428|NCT05238831|Drug|Palbociclib|Given IV
45979429|NCT05238831|Drug|Fulvestrant|Given by injection
45979430|NCT05238831|Drug|Eribulin|Given IV
45979431|NCT05238831|Other|Quality-of-Life Assessment|Ancillary studies
45979432|NCT00301925|Biological|pegfilgrastim|
45979433|NCT00301925|Drug|capecitabine|
45979434|NCT00301925|Drug|cyclophosphamide|
45979435|NCT00301925|Drug|epirubicin hydrochloride|
45979436|NCT00301925|Drug|fluorouracil|
45979437|NCT00301925|Drug|methotrexate|
45979438|NCT00301925|Procedure|adjuvant therapy|
45979439|NCT00302120|Procedure|Contrast-enhanced MR mammography|
45979440|NCT00328029|Drug|busulfan|5mg/kg/day (oral route : 4 doses/day for 4 days)
45979441|NCT00328029|Procedure|respiratory function tests|respiratory function tests before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).
45979442|NCT00328029|Procedure|pharmacokinetics, done during the treatment|"12 blood collections :~after 1st Busulfan taken : t0; t0 + 30 mn; t0 + 1h; t0 + 2h ; t0 + 3h ; t0 + 4h ; t0 + 5 h.~3 hours after 2nd taken of Busulfan~3 hours after 3rd taken of Busulfan~3 hours after 4th taken of Busulfan~3 hours after 5th taken of Busulfan~3 hours after 6th taken of Busulfan."
45979443|NCT00302198|Behavioral|ALS Registry|
45979444|NCT00302237|Device|RX ACCULINK, RX ACCUNET Embolic Protection System|1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
45979445|NCT05234775|Drug|lerodalcibep|300 mg of each drug given SC as single dose
45979446|NCT05231889|Device|Silverway guidewire|The Silverway guidewire is a newly developed guidewire to overcome the problems the Radifocus guidewire has
45979447|NCT05231889|Device|Radifocus guidewire|The Radifocus guidewire is a hydrophilic coated guidewire that is used when a standard J-tip guidewire does not cross a vascular anomaly
45979448|NCT00302276|Drug|Metobes-compound|
45979449|NCT05194917|Other|Older Smoker Motivational Intervention|OSMI identified in Aim 2 of the study, motivational interventions will be delivered via multiple routes at both treatment clinics (i.e., mailer, in-clinic poster, and telephone calls from UW-CTRI staff) to ensure maximum saturation.
45979450|NCT05194917|Other|Control Motivational Message|"one control motivational message with a standard health- and EBST access-related content (i.e., Quitting smoking is the best thing you can do for your health. Call 1-800-QUIT-NOW for help.), motivational interventions will be delivered via multiple routes at both treatment clinics (i.e., mailer, in-clinic poster, and telephone calls from UW-CTRI staff) to ensure maximum saturation."
45979451|NCT00302315|Device|transcutaneous electrical nerve stimulation|
45979452|NCT00302354|Drug|OROS methylphenidate HCl|
45979453|NCT00302354|Drug|SODAS methylphenidate HCl|
45979454|NCT00302393|Drug|OROS methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of OROS MPH will be 36 mg which will be supplied as one 36 mg capsules. Study treatments will be administered with water following an overnight fast of at least 8 hours.
45979455|NCT00302393|Drug|methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of IR MPH will be 20 mg which will be supplied as one 20 mg capsule. Study treatments will be administered with water following an overnight fast of at least 8 hours.
45979456|NCT00328107|Biological|Influenza Vaccine, recombinant Hemagglutinin|0.5mL dose for IM injection
45979457|NCT00302432|Behavioral|Behavior therapy, cigarette holders, Flowers Menthol|
45979458|NCT00328146|Other|Observation of sternal reentry|Observation of sternal reentry
45979459|NCT00302471|Drug|Comparator: MK0429|"Part 1 - MK3328 of 1600 mg twice a day for 4 weeks given to men with hormone refractory prostate cancer and metastatic bone.~Disease."
45979460|NCT00302471|Drug|Comparator: MK0429|Part 2- MK3328 of 200 mg twice a day for 4 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
45979461|NCT00302471|Drug|Comparator: MK0429|Part 1- MK3328 of 800mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
45979462|NCT00302471|Drug|Comparator: MK0429|Part 2 - MK3328 of 400 mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
45979463|NCT00302510|Procedure|immunoadsorption|immunoadsorption
46082632|NCT00936403|Drug|somatropin|A daily dose of Norditropin NordiFlex® for seven days. Dose will remain constant
46082633|NCT02794454|Other|HeezOn Ultra-1|
45456310|NCT04364763|Drug|0.9% sodium chloride (normal saline)|Subjects will receive a single dose and study duration will be approximately 60 days per subject.
45672564|NCT01584232|Drug|Sulfonylureas (SU)|
45979464|NCT00419913|Dietary Supplement|Dehydroepiandrosterone|DHEA 25 mg tid
45979465|NCT00302549|Drug|FK506|FK506,0.1mg/kg/d
45979466|NCT04716855|Other|Quality of life and daily living activities assessment tests|
45979467|NCT00419991|Drug|Tigecycline|All patients will receive tigecycline infusions approximately every 12 or 24 hours. The usual regimen of tigecycline is (an initial intravenous (IV) dose of 100 mg followed by 50 mg approximately every 12 hours). Patients with severe hepatic dysfunction may, at the investigator's discretion with CPL Associates approval (call enrollment hotline) may be given a total daily dose of 50 mg (one 50 mg dose or 25 mg approximately every 12 hours). Tigecycline infusions will be administered over approximately 30 minutes in 100 mL of normal saline.
45979468|NCT04718090|Procedure|PENG Block|Pericapsular nerve group block in shoulder surgery.
45979469|NCT04716816|Procedure|Stripping massage|Stripping massage for rhomboid myofascial trigger points
45979470|NCT00302627|Drug|Pamidronate|60mg or 90mg given at baseline, 6,12,18, and 24 months
45979471|NCT00302627|Drug|vitamin D|baseline, 6,12 months
46082634|NCT02794454|Other|HeezOn Ultra-2|
46082635|NCT02794454|Other|Placebo|
45456311|NCT04359472|Device|Application of Autologous Amniotic Fluid|Collection and reapplication of amniotic fluid at wound layers during a cesarean section.
45456312|NCT04350463|Drug|CC-90011|CC-90011
45456313|NCT04350463|Drug|Nivolumab|Nivolumab
45456314|NCT04347616|Biological|UCB-NK cells|Natural killer cells generated from CD34+ hematopoietic progenitor cells derived from an allogeneic umbilical cord blood
45456315|NCT04347616|Drug|IL-2|In vivo cytokine support
45672565|NCT01584232|Drug|Biguanide (BG)|
45672566|NCT01639703|Drug|Xenetix-CT perfusion imaging|Injection of 50 ml of Xenetix
45672567|NCT04840121|Diagnostic Test|AdhesioRT|AdhesioRT, a novel diagnostic genetic assay, developed by ovo R&D scientists, helps to predict the endometrial receptivity and embryo implantation.
45672568|NCT04877483|Procedure|Acupuncture|Acupuncture is a form of treatment that inserting very thin needles through a person's skin at specific points on the body. Group GB20 and Group GB20 plus BL2 will received the acupuncture treatment.
45672569|NCT04877483|Diagnostic Test|Oral microbiota|Group GB20, Group GB20 plus BL2 and Healthy control will take the oral microbiota analysis.
45672570|NCT04877483|Diagnostic Test|Schirmer's test|Group GB20 and Group GB20 plus BL2 will take the Schirmer's test.
45979472|NCT00302627|Drug|Calcium Carbonate|baseline, 6,12 months
45979473|NCT05129943|Device|active distraction|The subject receives the injection of local anesthesia while playing a game on a mobile phone mounted on the VR device using a PS4 controller.
45979474|NCT05129943|Device|passive distraction|The subject receives the injection of local anesthesia while watching a cartoon on a mobile phone mounted on the VR device.
45979475|NCT00302666|Drug|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive extended cycles
45979476|NCT00302666|Drug|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive conventional cycles
45979477|NCT05070741|Behavioral|Heat Therapy|Subjects will undergo 12 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 4 weeks. Subjects will be immersed up to the shoulder in a 40°C hot tub until rectal temperature (Tre) increases by 1°C (~20 minutes). Subjects will then remain in the water bath submerged to waist level to maintain Tre between 38.5 and 39.0°C for another 30 minutes (approx. total time submerged ~50 minutes). Following hot water immersion, subjects will be monitored for another 10 min, or until Tre falls below 38.5°C. Core temperature will be monitored using either 1) a rectal probe with sterile disposable sheaths or 2) a sterile disposable rectal thermistor probe (401 A/C, Advanced Industrial Systems, Inc., Harrods Creek, KY) to be inserted ~1 inch past the anal sphincter (inserted by participant). Heart rate and blood pressure will be monitored throughout the treatment. Subjects will be continually monitored and removed from the hot bath if Tre exceeds 39.5°C.
45979478|NCT00328302|Drug|Candesartan|
45979479|NCT00328302|Drug|Placebo|
45979480|NCT00418340|Drug|probiotic (bacterial/dietary supplement)|
45979481|NCT00418418|Procedure|Coronary bypass operation|Coronary bypass operation is performed via sternotomy during cardiac arrest.
45979482|NCT00418418|Procedure|Bone marrow aspiration (crista iliaca)|The bone marrow is aspirated from the iliac crest (100ml). During the operation the aspirate is transported to the stem cell laboratory, where the sample is centrifugated through Ficoll(Registered Trademark).
45979483|NCT00418418|Biological|Intramyocardial mesenchymal stem cell transplantation|During the cardiac arrest, stem cells are directly injected to myocardium. The amount of the cells varies individually (5-1000 x 10e6 cells), the cells are diluted in autologous serum (5 ml)
45979484|NCT00418418|Biological|Intramyocardial injection of autologous serum|Intramyocardial injection of autologous serum is injected during cardiac arrest
45979485|NCT00328380|Drug|Rifaximin|
45979486|NCT00418496|Drug|Aldesleukin|600,000 IU/kg every 8 hours on days 1-5 (week 1) to a maximum of 12 doses. Another cycle of HD aldesleukin will be started on day 15 (week 3).
45979487|NCT00418496|Drug|Sorafenib|To be initiated at a dose of 200 mg orally. Once it is determined that no further HD aldesleukin therapy will be given, sorafenib may be given daily at the FDA approved dose of 400 mg twice daily until there is lack of clinical benefit or intolerable side effects develop.
45979488|NCT05024721|Drug|HIP2101|Test drug
45979489|NCT05024721|Drug|RLD2101|Reference drug
45979490|NCT05024721|Drug|HPP2101|Placebo drug
45979491|NCT05024721|Drug|HPP2102|Placebo drug
45832062|NCT05580198|Diagnostic Test|Transcranial sonography.|Transcranial sonography examination to determine the brainstem raphe echogenicity.
45979492|NCT00302705|Drug|Valsartan, Enalapril|160 mg valsartan versus 10-20 mg enalapril
45979493|NCT00302705|Device|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
45979494|NCT00302705|Procedure|Missing one dose|Patients skip the dose the second day of monitoring
45979495|NCT00328419|Device|photoprotected bags, tubing, syringes|use of photoprotected parenteral nutrition device
45979496|NCT00328419|Device|standard tubing and bags|Use of standard (transparent) parenteral nutrition device
45979497|NCT00302783|Behavioral|Multi-Source Feedback: including self-assessment & coaching|
45672571|NCT04877483|Diagnostic Test|Tear breakup time|Group GB20 and Group GB20 plus BL2 will take the tear breakup time test.
45979498|NCT05015712|Behavioral|moderate intensity continuous training|Moderate intensity continuous training was scheduled 3 times per week for 3 months. Every sessions included warm-up (<50% target intensity for 2 min then gradually increasing load 1-10 W/min up to 100% target intensity for 5-10 min), exercise phase (100% target intensity (heart rate at anaerobic threshold±5) starting with 20 min and gradually lengthening up to 45 min in the 1 month as well as 45 min in another 2 months), cool down with gradual reduction of load within 3 min. The target intensity will be determined by the heart rate at anaerobic threshold measured by cardiopulmonary exercise test (CPET). The intensity will be adjusted after implementation of CPET and will keep at a minimum intensity, gradually increasing to the maximum intensity every month. Moreover, patients will be instructed to complete 2 supervised sessions and 1 home-based session during the 1 month and then to continue 3 home-based session for a further 2 months.
45979499|NCT00302822|Drug|enfuvirtide|from week 0 to 24
45979500|NCT00302822|Drug|emtricitabine/tenofovir|1 pill/day
45979501|NCT00302822|Drug|lopinavir or efavirenz|investigator choice
45672572|NCT04877483|Diagnostic Test|OSDI(Ocular Surface Disease Index)|Group GB20 and Group GB20 plus BL2 will take the OSDI test.
45672573|NCT04877483|Diagnostic Test|TCM pattern|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine pattern diagnosis.
45832063|NCT04141956|Other|High-Flow Nasal Cannula|Incidence of nasal High Flow Nasal Cannula (HFNC) Oxygen therapy in patients admitted to intensive care.
45832064|NCT03645564|Other|Specialized nurse consultation|The purpose of this consultation is to establish a partnership between the patient and the nursing staff. Tools were set up (notebook, movie) to answer the questions of the patient. In case of specific question, an expert will meet the patient (doctor of the service, psychologist, pharmacist or hematologist).
45832065|NCT03645408|Drug|Exenatide|Subject received an injection of 5 mcg of immediate release exenatide.
45979502|NCT00328458|Drug|EPO906 (epothilone B)|
45979503|NCT00302861|Biological|MyVax|
45979504|NCT04716582|Behavioral|Sitting interrupted by light physical activity|Each 30 minutes will be 25 minutes sitting followed by 5 minutes walking that designed as prescribed walking route outside laboratory corridor.
45979505|NCT04716582|Behavioral|Sitting with cognitive task|Participants will perform online cognitive task during prolonged sitting.
45979506|NCT04716582|Behavioral|uninterrupted sitting|Participants will watch documentary during prolonged sitting.
45979507|NCT00302900|Behavioral|Pre-Donation Water Consumption|Consumption of 500 ml of bottled water 30 minutes prior to donating
45672574|NCT04877483|Diagnostic Test|Traditional Chinese Medicine (TCM) tongue diagnosis|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) tongue diagnosis.
45832066|NCT03645408|Other|Sham injection|Subjects received a sham injection with no study drug.
45832067|NCT04141722|Behavioral|Overnight sleep|Participant sent home to sleep overnight wearing PSG.
45979508|NCT00302900|Behavioral|Muscle Tensing Exercise During Donation|Alternating leg lifts at 10-second intervals during donation
45979509|NCT00302900|Behavioral|Muscle Tensing Exercise Prior to Donation|Alternating leg lifts at 10-second intervals prior to insertion of the donation needle
45979510|NCT04716621|Other|Early intervention|"The Pain Management Support System for Primary Care (PMSS-PC) generated best practice alerts and gave clinicians access to a pain assessment template, measures of psychological distress and substance use, guidelines for drug and non-drug therapies, and facilitated referrals. At implementation, clinicians at the practices were offered in-person and virtual education through six webinars on best practices for pain."
45979511|NCT04716621|Other|Delayed intervention|Delayed wait-list control group. The second arm involved three additional sites receiving the PMSS-PC intervention 6 months after the first arm. Initial outcomes from the PMSS-PC Experimental Intervention arm were compared to those of this Wait-list Control arm.
45672575|NCT04877483|Diagnostic Test|TCM pulse diagnosis|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) pulse diagnosis.
45979512|NCT05008224|Biological|Pembrolizumab|"200 mg IV administered on Day 1 of each 3-week cycle for 3 cycles during pembrolizumab monotherapy.~400 mg IV administered on Day 1 of each 6-week cycle for 4 cycles as pembrolizumab consolidation."
45979513|NCT05008224|Drug|Doxorubicin|"25 mg/m^2 IV administered on Days 1 and 15 of each 4-week cycle for 2 cycles in all participants after PET2 and up to 4 additional cycles after PET3 (participants who are PET3 -ve, or +ve & ≥60 years of age).~35 mg/m^2 IV administered on Day 1 of each 3-week cycle for up to 4 cycles after PET3 (participants who are PET3 +ve, <60 years of age)."
45979514|NCT05008224|Drug|Vinblastine|6 mg/m^2 IV administered on Days 1 and 15 of each 4-week cycle for 2 cycles after PET2 (all participants) and up to 4 additional cycles after PET3 (participants who are PET3 -ve, or +ve & ≥60 years of age).
45979515|NCT05008224|Drug|Dacarbazine|375 mg/m^2 IV on Days 1 and 15 of each 4-week cycle for 2 cycles after PET2 (all participants) and up to 4 additional cycles after PET3 (participants who are PET3 -ve, or +ve & ≥60 years of age).
45979516|NCT05008224|Drug|Bleomycin|10 units/m^2 IV administered on Day 8 of each 3-week cycle for up to 4 cycles after PET3 (participants who are PET3 +ve & <60 years of age).
45979517|NCT05008224|Drug|Etoposide|200 mg/m^2 IV administered on Days 1-3 of each 3-week cycle for up to 4 cycles after PET3 (participants who are PET3 +ve & <60 years of age).
45832068|NCT04141722|Behavioral|Wake|Participant sent to go about normal daily routine, instructed not to nap, drink caffeine, or engage in strenuous exercise.
45979518|NCT05008224|Drug|Cyclophosphamide|1250 mg/m^2 IV administered on Day 1 of each 3-week cycle for up to 4 cycles after PET3 (participants who are PET3 +ve & <60 years of age).
45979519|NCT05008224|Drug|Vincristine|1.4 mg/m^2 IV on Day 8 of each 3-week cycle for up to 4 cycles after PET3 (participants who are PET3 +ve &<60 years of age).
45979520|NCT05008224|Drug|Procarbazine|100 mg/m^2 orally (PO) administered on Days 1-7 of each 3-week cycle for up to 4 cycles after PET3 (participants who are PET3 +ve & <60 years of age).
45979521|NCT05008224|Drug|Prednisone|40 mg/m^2 PO administered on Days 1-14 of each 3-week cycle for up to 4 cycles after PET3 (participants who are PET3 +ve & <60 years of age).
45979522|NCT00302978|Behavioral|Behavior therapy|
45979523|NCT00303017|Dietary Supplement|flavocoxid|flavonoid mixture
46082636|NCT02715336|Drug|Ovulation induction with hCG and Lupron (GnRH agonist)|Patients treated for infertility are categorized as a low-, normal- or high responder according to their estimated ovarian response to hormonal stimulation. This classification dictates the hormonal stimulation regimen that they will receive. In contrast to hCG triggering, GnRHa triggering is characterized by simultaneous LH and FSH surges, similar to natural ovulation. A combination of GnRHa plus hCG for triggering creates simultaneous LH and FSH surges by the GnRHa, which resembles physiologic ovulation triggering, together with sustained LH-like activity from the hCG, stimulating the corpus luteum to excrete sufficient hormonal endometrial support.
45672576|NCT04877483|Diagnostic Test|TCM heart rate variability|Group GB20, Group GB20 plus BL2 and Healthy control will take the TCM Heart rate variability.
45672577|NCT04877483|Diagnostic Test|ESSPRI(EULAR Sjögren's Syndrome Patient Reported Index)|Group GB20 and Group GB20 plus BL2 will take the ESSPRI.
45456316|NCT04338763|Drug|RP72|RP72 is formulated as a sterile lyophilized powder which is reconstituted in sterile water for injection (WFI) prior to administration. IV injection of RP72 will be administered thrice weekly in the first 28-day treatment cycle (Cycle 1). RP72 will continue to be administered thrice weekly for 4 weeks for Cycle 2 and each subsequent 28-day treatment cycle.
45672578|NCT04877483|Diagnostic Test|Whole-genome genotyping(TWBv2.0)|Group GB20, Group GB20 plus BL2 and Healthy control will take the Whole-genome genotyping(TWBv2.0).
45672579|NCT04877483|Diagnostic Test|Cytokine markers|Group GB20, Group GB20 plus BL2 and Healthy control will take the cytokine markers(IL-17、MMP-9、BAFF、BCMA) analysis.
45672580|NCT04877483|Diagnostic Test|Blood biochemical analysis|Group GB20 and Group GB20 plus BL2 will take the Blood biochemical analysis(BUN,Cre,AST,ALT,ESR and CRP).
45672581|NCT04877483|Diagnostic Test|complete blood count (CBC)|Group GB20 and Group GB20 plus BL2 will take the CBC(WBC、RBC、Hb、Platelet) analysis.
45672582|NCT04877483|Diagnostic Test|SF-36(36-Item Short Form Survey )|Group GB20 and Group GB20 plus BL2 will take the SF-36 test.
45672583|NCT02119663|Drug|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
45832069|NCT04141410|Drug|Levosimendan|Use of Levosimendan in cardiogenic shock during sepsis
45832070|NCT04141410|Device|Echocardiography|Use of global longitudinal strain in cardiogenic shock during sepsis
45832071|NCT04141488|Other|experimantal group|Control Group
45832072|NCT04141254|Other|Debriefing and educative components|The patient will receive early debriefing and enhanced educative components added to a standardized visit at one month
45832073|NCT04141254|Other|Without debriefing and educative components|Patient will receive a standardized visit alone (without debriefing and enhanced educative components ) at one month
45979524|NCT00303017|Drug|Naproxen|non-steroidal anti-inflammatory drug
45979525|NCT00303056|Drug|HOE140 Icatibant|
45979526|NCT00328497|Drug|Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)|Panzem NCD 1,000 mg, four times daily for 28 consecutive days bevacizumab 5 mg/kg intravenous bolus on Day 1 and Day 15
45979527|NCT00303134|Drug|Islet Cell Transplantation|Islet Cell Transplantation for patients with type 1 diabetes mellitus
45979528|NCT00303173|Behavioral|Guided Imagery|
45979529|NCT00328536|Drug|Omacor|
45979530|NCT04999917|Diagnostic Test|high-resolution PET-CT specimen imaging.|"A single intravenous injection of 18F-FDG (0.80 MBq/kg) is given between 30 minutes and 3 hours before tumor resection.~Surgical resection of the breast tumor (= main specimen) under general anesthesia.~The main specimen is imaged using the Aura 10 PET-CT Specimen Imager (XEOS Medical, Ghent, Belgium). In case of positive margins, the surgeon will perform oriented cavity shaving. The cavity shaves and lymph nodes (if any) are also imaged using the Aura 10 PET-CT Specimen Imager (for scientific purposes only).~The main specimen and if applicable the cavity shaves and lymph node(s) are processed following standard-of-care routine: from tissue samples to HE-stained and IHC-stained sections. The histopathological margin status shall be reported according to the ASCO-CAP guidelines, and shall be compared to the PET-CT images of the resected specimens."
46082637|NCT02799680|Biological|allogeneic CART-33|allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)
46082638|NCT00936559|Biological|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information
45832074|NCT03914976|Procedure|patient having to undergo a high risk programmed digestive surgery|The objective is to determine if there is an association between the mean intraoperative values and within 24 hours postoperative ΔPCO2 and the occurrence of major post-operative complications at day 28 in high-risk surgery (major hepatectomy, esophagectomy or duodeno- cephalic pancreatectomy)
45456317|NCT04338763|Drug|Gemcitabine|Gemcitabine is an anti-cancer chemotherapy drug. IV infusion of Gemcitabine will be administered once weekly in the first 28-day treatment cycle (Cycle 1). Gemcitabine will continue to be administered once weekly for the first 3 weeks and then one week rest in Cycle 2 and each subsequent 28-day treatment cycle.
45456318|NCT04334109|Behavioral|Family Diabetes Self-Management Education and Support|Family Diabetes Self-Management Education and Support demonstrates the effectiveness of family-centered models of DSME that explicitly address diabetes self-management within a family context by educating both patients and family members and focusing on family motivational interviewing, family goal setting, understanding supportive and nonsupportive behaviors, and family behavioral changes.
45832075|NCT04149756|Other|observation of weight after 6months|"This study is an observational study for 96 people who have completed the previous weight loss program.~We will check the body composition and lipid profile of the participants who voluntarily visit after 6months after the end of the study. ."
45832076|NCT04141098|Device|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.|All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board. Any patient meeting any of the three intraoperative exclusion criteria will receive an alternative standard of care therapy.
45832077|NCT05586204|Behavioral|Eligibility reminder|Patients will receive a reminder of their eligibility for the bivalent COVID-19 booster
45979531|NCT00303212|Other|Telemonitoring|Participants in the intervention group are instructed to make a daily toll-free call to an automated telemonitoring system being provided by Pharos Innovations® (Chicago, IL) for 6 months.On each call patients hear a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians at each practice site.
45979532|NCT00328575|Radiation|Intensity-Modulated Radiotherapy (IMRT)|"The duration of radiation therapy will be total of 3 weeks. During the first week, all patients will be treated initially with whole brain radiation therapy (WBRT) at 2.5Gy per fraction daily 5 days a week to a dose of 12.5Gy. This will be delivered through parallel-opposed fields to cover the entire cranial contents.~For the remaining 2 weeks, patients will be treated using intensity-modulated radiation therapy (IMRT) technology such that a higher dose can be delivered to the tumor. IMRT is capable of generating complex 3-D dose distribution to conform closely to the target volume by modulating the radiation beam. This process is based on the inverse method of treatment planning to optimize radiation dose to tumor target coverage and normal tissue sparing."
45979533|NCT00303290|Drug|Peg Interferon Alpha 2b (Peg Intron)|4.5 micrograms/kg once a week
45979534|NCT00303290|Drug|Ara-C (cytosine arabinoside)|10 mg under the skin daily
45979535|NCT00328692|Drug|rolofylline|rolofylline 30 mg IV QD; 3 days
45979536|NCT00328692|Drug|Comparator: Placebo (unspecified)|rolofyline Pbo 30 mg IV QD; 3 days
45979537|NCT04718246|Other|Dental Implants Placed In hyperlipidemia patients|"A preoperative cone beam CT (CBCT) will be performed for each patient prior to the surgery.~Surgical phase (T0):~After local anesthetics, all osteotomies will be prepared by the same operator, using a drilling speed of 1200 rpm, under copious irrigation with normal saline.~Penetration of cortical bone will be achieved with no. 6 round burs.~The osteotomies will be widened, using a drill 1 mm larger than the final drill provided by the manufacturer. The final size of the control osteotomies were same diameter of the implant.~Periotest® will measure initial implant stability. Implant site exposure will take place 6 months following the implant placement. Insertion of the healing collars in order to obtain adequate soft tissue form for 1-2 weeks"
45979538|NCT00419718|Drug|inhaled human insulin|
45672584|NCT02119663|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth twice daily (BID)
45672585|NCT02119663|Drug|Capecitabine|150 mg or 500 mg tablets to be administered by mouth twice daily (BID)
45979539|NCT00303407|Drug|nadroparin|
45979540|NCT00328731|Procedure|Procedure|
45979541|NCT00303524|Drug|Goserelin acetate|Injection 3.6 mg monthly
45979542|NCT00303524|Drug|Goserelin acetate|injection 10.8 mg every 3 months
45979543|NCT00419796|Drug|Lumiracoxib|
45979544|NCT00303563|Drug|P38 Inhibitor (4)|50mg po qd
45979545|NCT00303563|Drug|P38 Inhibitor (4)|150mg po qd
45979546|NCT00303563|Drug|P38 Inhibitor (4)|300mg po qd
45979547|NCT00303563|Drug|Placebo|po qd
45979548|NCT00419835|Drug|enalapril|
45979549|NCT00419835|Drug|losartan|
45672586|NCT04484441|Other|Blood and placenta specimen collection.|Collection of maternal and paternal blood. Collection of infant cord blood and placenta.
45672587|NCT04481009|Drug|YH003|YH003 will be administered intravenously over 60 minutes every 21-day cycle.
45672588|NCT04481009|Drug|Toripalimab|Toripalimab with fixed dose of 240 mg administered intravenously followed by YH003 administered intravenously every 21-day cycle.
45672589|NCT04481009|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered each 21-day cycle.
45672590|NCT04481009|Drug|Gemcitabine|Gemcitabine will be administrated each 21-day cycle.
45979550|NCT00328809|Drug|spironolactone|spironolactone administered to ESRD patients at low dose
45979551|NCT00303641|Device|Medtronic Resting Heart Bypass System|
45979552|NCT00420030|Drug|Abciximab|Abciximab - IIb/IIIa GP inhibitor, dosage - bolus + continuous infusion
45979553|NCT00303758|Drug|cisplatin|
45979554|NCT00303758|Drug|fluorouracil|
45979555|NCT00303758|Drug|gemcitabine hydrochloride|
45979556|NCT00303758|Drug|leucovorin calcium|
45979557|NCT00332280|Drug|AMT2003|
46082639|NCT00936559|Biological|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information.
45672591|NCT05327231|Drug|IN10018|IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours.
45672592|NCT05327231|Drug|Docetaxel|Docetaxel 75mg/m2 every 21 days a cycle.
45672593|NCT04453085|Drug|JR-171 (lepunafusp alfa)|JR-171 IV infusion
45672594|NCT01639469|Behavioral|Structured exercise|Structured exercise includes stretching, strengthening, and balance exercises.
45832078|NCT05586204|Behavioral|Link to a narrow set of vaccine venues|The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to CVS pharmacy
45832079|NCT05586204|Behavioral|Link to a broad set of vaccine venues|The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to vaccine.gov (where people can find a wide set of local pharmacies that carry the bivalent booster).
45832080|NCT05586204|Behavioral|Doctors' recommendation and value of vaccine|The reminder will contain information about the value of the bivalent booster and doctors' recommendation to get it
45832081|NCT04149834|Procedure|Group A (Test): Patients will receive NIPSA|patients received Non- incised papilla surgical approache
45832082|NCT04149834|Procedure|Group B (Control): Patients will receive M-MIST|patients received Modified Minimally Invasive Surgical Technique
45832083|NCT04140474|Device|Archimedes procedure|All patients will initially have a scanner necessary for planning by the Archimedes system of the tunneling path. each patient will then undergo a general anesthesia as for any bronchoscopy. Then start the Archimedes procedure itself to reach the SPN
45832084|NCT05583864|Device|CONDUIT Porous Titanium Spinal Cage|Already included in arm/group descriptions.
45672595|NCT01639469|Behavioral|Lifestyle exercise|Subjects will be taught lifestyle exercises and advised about mobility strategies
45832085|NCT05583864|Device|PROTI 360 Titanium-Coated PEEK Spinal Cage|Already included in arm/group descriptions.
45832086|NCT04149444|Drug|Trifluridine/Tipiracil|Oral medication
45832087|NCT03020706|Drug|Magnesium Sulfate, Injectable|magnesium sulphate intravenous administration during general anesthesia
45832088|NCT04149366|Device|Retainer|Orthodontic retainer
45979558|NCT00303797|Drug|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|
45979559|NCT00303797|Drug|sorafenib tosylate|
45979560|NCT00420069|Device|MRTX device|device for ventilation
45672596|NCT04855721|Drug|AUR101|Oral ROR-gamma inverse agonist
45672597|NCT04855721|Drug|Placebo|Placebo
45672598|NCT02193074|Drug|nusinersen|Administered by intrathecal (IT) injection as specified in the treatment arm.
45979561|NCT00303836|Drug|cyclophosphamide|Given IV
45672599|NCT02193074|Procedure|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
45832089|NCT04148976|Dietary Supplement|Placebo|A mixture of maltodextrins and calcium caseinate divided into 30g individual packets.
45832090|NCT04148976|Dietary Supplement|Dietary portfolio|A mixture of functional foods divided into 30g individual packets.
45832091|NCT05583084|Other|Investigation|
45832092|NCT04140630|Other|No intervention|No intervention; 1 week observational study
45832093|NCT03900624|Drug|Dexamethasone|Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticus
45979562|NCT00303836|Drug|fludarabine phosphate|Given IV
45979563|NCT00303836|Biological|therapeutic autologous lymphocytes|Given IV
45979564|NCT00303836|Procedure|in vitro-treated peripheral blood stem cell transplantation|Undergo in vitro-treated peripheral blood stem cell transplantation
45979565|NCT00303836|Biological|gp100 antigen|Given SC
45979566|NCT00303836|Biological|MART-1 antigen|Given SC
45979567|NCT00303836|Biological|incomplete Freund's adjuvant|Given SC
45979568|NCT00303836|Biological|filgrastim|Given SC
45979569|NCT00303836|Biological|aldesleukin|Given IV
45979570|NCT00303875|Behavioral|behavioral dietary and exercise intervention|
45979571|NCT00420186|Drug|BMS-690514|Tablets / IV, Oral / IV, 100 to 300 mg / Paclitaxel (200 mg/m2) / Carboplatin dose (mg) = Target AUC (6) x (GFR + 25), Once daily Days 4-19, up to 24 mos
45979572|NCT00420225|Device|Low-weight prolypropylene mesh|
45979573|NCT00303992|Biological|trastuzumab|
45979574|NCT00303992|Drug|irinotecan hydrochloride|
45979575|NCT00304226|Drug|valsartan|
45979576|NCT00304226|Drug|amlodipine|
45979577|NCT00420264|Device|Uterine Ablation|Uterine Ablation in the office setting to see if the procedure is tolerated w/o sedation
45979578|NCT00304304|Behavioral|Asthma education|Research assistant worked with CCC staff on asthma prevention
45979579|NCT00332319|Drug|GW679769|
45979580|NCT00304382|Biological|Prevnar|0.5 ml IM into each deltoid muscle one time (or two in group PCV-PCV)
46082640|NCT00936559|Biological|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information,
45979581|NCT00304382|Biological|Pneumovax|0.5 ml IM one time
45979582|NCT00328848|Behavioral|Behavioral|Group Treatment(patient education, self management support, caregiver support)
45979583|NCT00328848|Behavioral|behavioral|patient education, self management support, caregiver support
45832094|NCT04149132|Device|pulse photoplethysmography (PPG)|PPG and systolic blood pressure recording will be performed every two hours for three consecutive days. PPG reading will last two minutes and peaks of NO productions will be captured. Day 1 is considered the day of signing the informed consent followed by the first recording. On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients
45979584|NCT00304421|Drug|rabeprazole|
45832095|NCT04149132|Diagnostic Test|Measurements of nitric oxide (NO) and malondialdehyde (MDA)|On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients. NO will be measured in serum samples by the Griess reaction. MDA that is considered an index of oxidant status will be measured in serum samples by the thiobarbiturate assay and analysis by high-performance liquid chromatography (HPLC)
45832096|NCT03908892|Drug|zanthoxylum nitidum tincture|Local application with zanthoxylum nitidum tincture soaked blocks for the sick nail(s) for 30 minutes, twice a day.
45979585|NCT00304421|Drug|pantoprazole|
45979586|NCT00332397|Device|Rapamycin-eluting Stent|due to randomization, Cypher stent will be implanted
45979587|NCT00332397|Device|Zotarolimus-eluting Stent|due to randomization, Endeavor stent will be implanted
45979588|NCT00332397|Device|Rapamycin-eluting Stent|due to randomization, rapamycin-eluting stent will be implanted
45979589|NCT00304460|Biological|aldesleukin|
45979590|NCT00304499|Drug|Oxybutynin|
45979591|NCT00328887|Genetic|CD40 Gene Transfer|gene transfer, intratumoral administration
45979592|NCT00304538|Drug|very low dose (VLD) glucagon|
45979593|NCT00420498|Drug|Atomoxetine (Strattera™)|
45979594|NCT00304577|Procedure|Bilateral recession|
45979595|NCT00304577|Procedure|Unilateral recession and resection|
45979596|NCT00328965|Drug|Lacidipine|Lacidipine 2, 4, 6mg
45979597|NCT00304616|Drug|Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone|
45456319|NCT04334109|Behavioral|Standard Diabetes Self-Management Education and Support|Diabetes Self-Management Education and Support demonstrates the effectiveness of individual model DSMES that explicitly address diabetes self-management within an individual context by educating individual patients on individual motivational interviewing, individual goal setting, and individual behavioral changes.
45456320|NCT04329728|Drug|AVM0703|Intravenous infusion over ~1 hours
45456321|NCT04322539|Drug|Fruquintinib|Oral VEGFR inhibitor
45832097|NCT03908892|Drug|tetracycline ointment|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day
45832098|NCT04140318|Drug|sintilimab|Sintilimab 200mg, iv, 30-60min, q3w;
45832099|NCT04140318|Drug|nab-paclitaxel|Nab-paclitaxel: 125 mg/m2 iv d1、d8, q3w
45832100|NCT03021408|Other|MIRT + Treadmill|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill training twice per day, 5 times a week, for 4 weeks.
45456322|NCT04322539|Drug|Placebo|Placebo capsule
45456323|NCT04320264|Procedure|Weight loss surgery|Severely obese women (BMI >40) undergo sleeve gastrectomy
45979598|NCT00332436|Drug|brimonidine/timolol fixed combination|
45979599|NCT00304655|Drug|Aripiprazole|
45979600|NCT00329004|Drug|BMS-690514|Tablets, Oral, up to 300 mg, once daily, up to 24 mos
45979601|NCT00304733|Device|cast vs. shoe|
45979602|NCT00332514|Behavioral|telephone call by a pharmacist|
45979603|NCT00332553|Drug|Raloxifene|
45979604|NCT00332553|Drug|medroxyprogesterone acetate|
45979605|NCT00332553|Drug|estrogen|
45979606|NCT00332553|Drug|17 beta estradiol|
45979607|NCT00329121|Drug|PEP005|
45979608|NCT00332631|Drug|N-acetylcysteine|
45979609|NCT00332631|Drug|Placebo|
45979610|NCT00304772|Drug|Fluconazole|400mg/day
45979611|NCT00304772|Drug|Micafungin|150mg/day
45979612|NCT00332670|Procedure|10.000lux blue 1 hour every day during three weeks|10.000lux during 60 minutes, starting 1 hour after wake-up, during 3 weeks
45979613|NCT00332670|Procedure|50lux dim red 1 hour every day during three weeks|50 lux red light, 60 minutes every morning, starting 1 hour after wake-up, during three weeks
45979614|NCT00304811|Drug|Vancomycin|
45979615|NCT00304811|Drug|Vancomycin plus Gentamicin|
45979616|NCT00304811|Drug|Vancomycin plus Rifampin|
45979617|NCT00304811|Drug|Vancomycin plus Gentamicin plus Rifampin|
45979618|NCT00332787|Drug|Fluoxetine|
45979619|NCT00304850|Behavioral|polyamine-free diet|Polyamine-free diet in the 7 days befor surgery
45979620|NCT00304850|Drug|Ketamine or placebo|Peroperative and post operative (48h) ketamine injection
45979621|NCT00329199|Behavioral|Attachment-Based Family Therapy|
45979622|NCT00329277|Procedure|perimetry|
45979623|NCT00329316|Drug|Crinone Gel 8%|
45979624|NCT00305045|Device|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specified brain structures.
45979625|NCT00332826|Drug|Technosphere Insulin|
45979626|NCT00305201|Drug|pravastatin|
45979627|NCT00332865|Behavioral|Swallowing Exercises|Daily exercises
45979628|NCT00305240|Procedure|T Wave Alternans Test|
45979629|NCT00329355|Drug|sumatriptan succinate/naproxen sodium|
45979630|NCT00305279|Other|Dietary|Dietary
45979631|NCT00305279|Other|Dietary|Dietary
45979632|NCT00305279|Other|Dietary|Dietary
45979633|NCT00332904|Drug|propranolol|tablet 80 mg pr. day in a period of 3 weeks, evt. dose adjustment
45979634|NCT00332904|Drug|spironolactone|tablet 200 mg pr. day in 3 weeks, evt. dose adjustment
45979635|NCT00329394|Drug|ketamine|Evaluate the analgesic effectiveness of the systemic ketamine on the control of pain in the alcohol-dependent patient
45979636|NCT00305396|Drug|Sirolimus|
45979637|NCT00332943|Procedure|MR colonography with fecal tagging|
45979638|NCT00305435|Drug|Romiplostim (AMG-531)|Romiplostim (AMG-531)
45979639|NCT00329472|Drug|gemcitabine, cisplatin|
45979640|NCT02960399|Biological|Zostavax®|Zostavax® immunization
45979641|NCT00332982|Behavioral|Focused knowledge translation strategies|
45979642|NCT00305474|Drug|Risperidone|Risperidone will be given in low dosage to a random sample of family members of Schizophrenic patients
45979643|NCT00329511|Drug|methyldopa vs. clonidine|Comparison of compliance
45979644|NCT00329511|Drug|clonidine patch|methyldopa 250 - 750 mg qid clonidine patch 0.1 - 0.4 mg q week
45979645|NCT00305513|Procedure|The phasic alerting treatment|
45979646|NCT00333021|Drug|Fondaparinux sodium|
45979647|NCT00333021|Drug|GSK576428|
45979648|NCT00305552|Drug|THALIDOMIDE|THALIDOMIDE
45979649|NCT00329589|Drug|Velcade (bortezomib)|
45979650|NCT00305591|Drug|l-ornithine l-aspartate|
45979651|NCT00333060|Drug|OT-551 ophthalmic solution|
45979652|NCT00305630|Drug|Periocular injection of triamcinolone acetonide 40mg|
45979653|NCT00329628|Drug|Rivaroxaban (BAY59-7939)|10 mg OD tablet of rivaroxaban administered for 36 +/- 4 days
45979654|NCT00329628|Drug|Enoxaparin|Syringe of Enoxaparin active substance at a dose of 40 mg administered for 13 +/- 2 days
45979655|NCT00305669|Biological|sargramostim|
45832101|NCT03021408|Other|MIRT + Treadmill Plus|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill-plus training (with visual and auditory cues) twice per day, 5 times a week, for 4 weeks.
45832102|NCT03021408|Other|MIRT + Virtual Reality|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Virtual Reality (VR) group will undergo 10-minutes VR training with enhanced perceptions (visual, auditory, and haptic inputs), twice per day, 5 times a week, for 4 weeks.
45832103|NCT03021330|Drug|Daunomycin and Cytarabine (DA Regimen)|"Cytarabine at a dose of 100mg/㎡/d on day 1-7.~Daunomycin at a dose of 60mg/㎡/d on day 1-3."
45832104|NCT03021330|Drug|Daunomycin and Cytarabine (Intermediate Dose of DA Regimen)|"Cytarabine at a dose of 100mg/㎡/d on day 1-4 and 1g/㎡/d on day 5-7.~Daunomycin at a dose of 60mg/㎡/d on day 1-3."
45979656|NCT00305669|Other|immunohistochemistry staining method|
45456324|NCT04304326|Other|Resistence Exercise|"Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises was 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteus: standing hips extension."
45456325|NCT04294004|Combination Product|TGplPTH1-34 in fibrin|TGplPTH1-34 within a fibrin matrix applied within and around a polyetheretherketone (PEEK) intervertebral cage
45979657|NCT00305669|Other|immunological diagnostic method|
45979658|NCT00305669|Other|laboratory biomarker analysis|
45979659|NCT00305669|Procedure|conventional surgery|
45979660|NCT00305669|Procedure|neoadjuvant therapy|
45979661|NCT00333099|Dietary Supplement|Impact (R) Enteral Nutrition|mucositis frequency, treatment tolerance
45979662|NCT00333099|Other|impact|"1500 calories every day :~-5 days before the begining of the chemoradiotherapy and until the last day of the treatment"
45979663|NCT00305708|Biological|anti-thymocyte globulin|
45979664|NCT00305708|Drug|busulfan|
45979665|NCT00305708|Drug|fludarabine phosphate|
45979666|NCT00305708|Procedure|allogeneic bone marrow transplantation|
45979667|NCT00305708|Procedure|peripheral blood stem cell transplantation|
45979668|NCT00305708|Procedure|umbilical cord blood transplantation|
45979669|NCT00305708|Radiation|radiation therapy|
45979670|NCT04716543|Diagnostic Test|ILI and COVID-19 detection|"All participants presenting with ILI symptoms will have non-invasive exam for SARS-CoV-2 detection (nasal, throat, swab, saliva) and a questionnaire.~All family members more than 6 months living with SARS-CoV-2 positive individuals will have will have non-invasive exam for SARS-CoV-2 detection (nasal, throat, swab, saliva) and a questionnaire."
45979671|NCT00305747|Drug|BR-DIM|75 mg orally (po) twice daily. May continue treatment for 12 months, however patients will be taken off study if their disease progresses, or have intolerable side effects.
45979672|NCT00333255|Drug|Nepafenac Ophthalmic Suspension, 0.1%|
45979673|NCT00305786|Drug|gemcitabine hydrochloride|
45979674|NCT00305786|Drug|oxaliplatin|
45979675|NCT00329667|Device|EPIC|Surgical replacement of a diseased, damaged, or malfunctioning native or prosthetic aortic and/or mitral heart valves
45979676|NCT00305825|Biological|bevacizumab|
45979677|NCT00305825|Drug|letrozole|
45979678|NCT00333294|Drug|Gefitinib|
45979679|NCT00333294|Procedure|Radiation therapy|
45979680|NCT00333294|Drug|Cisplatin|
45979681|NCT00333294|Drug|Vinorelbine|
45979682|NCT00305903|Drug|Rivastigmine, memantine|
45979683|NCT00329706|Procedure|FDG-PET brain scan|The difference in the two arms' interventions is the time at which the FDG-PET brain scan information is available for the subjects' managing physicians. Experimental arms will have an immediate release of the PET report, while the Active Comparator arms will have a delayed release of 2 years.
45979684|NCT00329823|Drug|Etanercept sc 50mg per week for 12 weeks|
45979685|NCT00306020|Drug|topical morphine|
45979686|NCT00329862|Procedure|Laparoscopic Truncal Vagotomy|
45979687|NCT00306137|Drug|Trasylol (Aprotinin, BAYA0128)|"Subjects successfully meeting all screening criteria will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The aprotinin was supplied in infusion vials of 200mL solution containing 2,000,000 KIU (10,000 KIU/mL) in 0.9% sodium chloride.~Subjects will be stratified into one of the 4 following strata:~Stratum 1: complete primary pneumonectomy~Stratum II: decortication or completion pneumonectomy~Stratum III: esophagectomy by transhiatal approach~Stratum IV: esophagectomy by transthoracic approach"
45979688|NCT00306137|Drug|Placebo|Placebo solution was supplied in identical vials and will consist of 200mL of 0.9% sodium chloride.
45979689|NCT00329940|Drug|Letrozole|
45979690|NCT00306176|Drug|Rosiglitazone|
45832105|NCT04140006|Drug|ALN Gel|Flapped surgery for insertion of dental implant with topical application of ALN gel
45832106|NCT04140006|Drug|BMP Gel|Flapped surgery for insertion of dental implant with topical application of BMP gel
45832107|NCT04140006|Drug|Mixed Gel|Flapped surgery for insertion of dental implant with topical application of mixed gel of ALN and BMP
45979691|NCT00333333|Procedure|Cord blood|Cord blood will be obtained at the time of delivery.
45979692|NCT00329979|Behavioral|vascular access site|Randomized vascular access site
45979693|NCT00333372|Drug|Z-338|
45979694|NCT00330018|Drug|Valganciclovir|Valganciclovir
45979695|NCT00330018|Drug|Acyclovir|Acyclovir
45979696|NCT00306215|Drug|CCX282-B|CCX282-B or placebo capsules
45979697|NCT00333450|Biological|Pneumococcal vaccine|
45979698|NCT00306254|Drug|PD 0348292|
45979699|NCT00306254|Drug|Enoxaparin|
45979700|NCT00333489|Drug|valsartan|
45979701|NCT00333528|Drug|Human butyrylcholinesterase (HuBChE) derived from human plasma|Intramuscular administration
45832108|NCT04140006|Drug|Control|Flapped surgery for insertion of dental implant without topical application of any gel
45979702|NCT00333528|Drug|Placebo: Normal saline|Intramuscular administration
45979703|NCT03275753|Other|Visual Function Tests|All subjects will undergo a battery of visual function tests
45979704|NCT00330096|Drug|Hesperidin|
45979705|NCT00330096|Other|Placebo|
45979706|NCT03275714|Device|Smartphone APP|Participants use the BiP-App for 6 months. The app continuously records data on light and motion sensors, as well as Global Positioning System (GPS) and mood surveys.
45979707|NCT00330135|Drug|Sodium hyaluronate|Sodium hyaluronate 2.5 ml - 1 injection
45979708|NCT00330135|Drug|placebo injection|placebo injection - 1 injection
45979709|NCT03275558|Drug|Axitinib 1 MG|"Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.~Subjects take a nasal spray BID at a single dose in each nostril (approximately at the same time of day) for 7 weeks or unacceptable toxicity or other adverse events."
45979710|NCT03275558|Drug|Sunitinib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
45979711|NCT03275558|Drug|Pazopanib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
45979712|NCT00330213|Behavioral|red wine and cognac consumption|
45979713|NCT03275519|Other|Randomization to not receive prophylactic antibiotics after surgery.|No antibiotics were ordered after surgery.
45979714|NCT03275519|Other|Randomization to receive prophylactic antibiotics after surgery|In general, the antibiotic given is a combination sulfamethoxazole/ trimethoprim oral suspension (2-3 mg trimethoprim/kg by mouth once a day); or if indicated, nitrofurantoin (1mg/kg by mouth once daily). All subjects did not receive intraoperative antibiotics.
45979715|NCT00333567|Drug|Lumiracoxib|
45979716|NCT02956694|Behavioral|Professional e-learning program on shared decision making|Clinicians will have access to a, e-learning program on shared decision making (e-TUDE) during one month. They will also receive five Decision Boxes (DB) dealing with difficult decisions often faced by seniors with dementia and their caregivers in primary care. They will receive five DBs by email, at a rate of 1 per week for 5 weeks.
45979717|NCT00330252|Drug|Rituximab|Given intravenously on day 1 of every week for eight weeks (or 16 weeks)
45979718|NCT00330252|Drug|Alemtuzumab|Drug: Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks).
45979719|NCT00333645|Drug|Caspofungin|
45672600|NCT04852601|Other|ToolboxDetect|The clinician or staff member will identify the patient by either scanning a barcode or entering his/her name, age and medical record number on an administrative screen (allowing for proper routing of test results). After completing the test, a 'submit' button will automatically generate a secure HL7 message, sharing 1) a binary classification of the results ('impaired cognition' or 'normal function'), 2) the quantitative ToolboxDetect score, and 3) brief clinical decision support to rule out any reversible causes. These results will be linked to a discrete, queriable, Epic SmartData element. As patients undergo multiple AWVs over time, ToolboxDetect quantitative scores will be displayed in Epic Synopsis Activity, a graphical display that can visualize trend data (e.g. patient vitals) and calculate a percentage change from the prior year. This will allow a clinician to establish a patient's own baseline (instead of using normative data only) for reference.
45979720|NCT04698473|Other|NCPAP|NCPAP infants will be randomized into two different non invasive ventilation groups
45979721|NCT04698473|Other|NIPPV|NIPPV NCPAP infants will be randomized into two different non invasive ventilation groups
45979722|NCT00330291|Drug|Xyrem|
45979723|NCT04698707|Other|Vascularized lymph node flap transfer|Patients who have received VLNT as their primary treatment but with minimal improvement
45979724|NCT04698707|Other|Patients without prior lymphedema surgery|Patients without prior lymphedema surgery
45979725|NCT00451100|Drug|Sugammadex|Subjects received a bolus dose of 0.6 mg/kg rocuronium. After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg Org 25969 was to be administered
45979726|NCT00451100|Drug|neostigmine|Subjects received a bolus dose of 0.15 mg/kg cisatracurium. After the last dose of cisatracurium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered. In accordance to the labeling of neostigmine, a maximum of 5 mg neostigmine was to be administered
46082641|NCT02794610|Drug|Tacrolimus|Topical tacrolimus 0.05% eye drops will be instilled into the eyes of patients every minute for 5 minutes. After 15 minutes, at the time of cataract surgery, aqueous samples will be collected and will be subjected to detection of presence and level of tacrolimus.
46082642|NCT00940225|Drug|XL184|All subjects receive 100 mg XL184 (supplied at 19.7-, 50-, and 60-mg strength capsules) daily for 12 weeks. Subjects with a partial or complete response will continue daily XL184 administration until disease progression. Subjects with stable disease will be randomized to Arm 2 or 3.
45979727|NCT00420537|Drug|cyclosporine|cyclosporine trough levels between 100 and 150
45979728|NCT00420537|Drug|cyclosporine|cyclosporine trough levels between 40 and 90 ng/ml
45979729|NCT00420537|Drug|Mycophenolate mofetil|mycophenolate with low doses
45979730|NCT00420537|Drug|Everolimus|
45979731|NCT00451139|Drug|artemether/lumefantrine|
45979732|NCT00451139|Drug|quinine|
45979733|NCT00451139|Drug|atovaquone/proguanil|
45979734|NCT00333684|Device|BIO-ALCAMID SOFT TISSUE ENDOPROSTHESIS|prosthetic bioalcamid was injected- amounts determined by the plastic surgeon and depended individual needs
45979735|NCT00451256|Drug|AVI-5126|
45979736|NCT00330330|Drug|ISIS 113715|
45979737|NCT00330408|Behavioral|GP training|
45979738|NCT00451295|Drug|MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
45979739|NCT00451295|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
45979740|NCT00330486|Drug|Acamprosate|
45979741|NCT00451373|Device|CVVH and SLED|
45979742|NCT00451373|Drug|Vancomycin|
45979743|NCT00451373|Drug|Daptomycin|
45979744|NCT00451373|Device|FX60, AV600 (dialyzer)|
45979745|NCT00333723|Drug|Rosiglitazone|
45979746|NCT00451412|Drug|Certoparin|3000 U anti XA of certoparin in 0.3 ml solution, once daily
45979747|NCT00451412|Drug|Unfractionated Heparin|solution, 5000 IU of unfractionated heparin in 0.3 ml, 3 times daily
45979748|NCT04717245|Drug|Promestriene Vaginal|Patients used promestriene vaginal cream for 3 months. The use was recommended to be diary fot the first 2 weeks, and then, repeat every 3 days.
45979749|NCT04717245|Other|Fractional CO2 LASER|"LASER treatment with fractional CO2 Laser was performed in 3 sessions with intervals of 4 weeks between them. Before each session, the patients underwent specular examination.~Fractional CO2 LASER was applied following these parameters, fixed in all sessions: vagina wall - power40 W, dwel time 1000 mcs, spacing 1000 mcm and stack 2, vestibule - power 10W, dwel time 500mcs, spacing 300mcg and satck 1"
45979750|NCT04717245|Other|Microablative Fractional radiofrequency|"Microablative fractional radiofrequency was performed with the equipment calibrated in FRAXX mode, 45W, Low Energy program 40 milliseconds in the vaginal and introitus wall. Lidocaine spray was applied to vaginal introitus before the procedure.~The patient was in the gynecological position. The vaginal speculum was placed and, afterwards, the vaginal antisepsis was performed with aqueous chlorhexidine and cleaning with 0.9% saline solution.~All liquid contents were wiped off before beginning the procedure. The fractured tip will be pressed lightly and as perpendicular as possible into the vulvar or vaginal surface, ensuring full contact of all points in the tissue, starting at the lateral vaginal walls and from the proximal to the distal third."
45979751|NCT00451490|Drug|Agomelatine|
45979752|NCT00451490|Drug|Fluoxentine|
45979753|NCT00330525|Drug|sibutramine|
45979754|NCT03275441|Diagnostic Test|Electroretinography|An additional electroretinogram performed after 10 minutes of dark adaptation.
45979755|NCT00333918|Drug|bromfenac ophthalmic solution|
45979756|NCT00333918|Drug|placebo comparator|
45979757|NCT04716738|Diagnostic Test|Blood analyses and coprological|We will take a blood and stool sample
45979758|NCT00451568|Drug|Metformin|500 mg 2 tablets 2 times a day
45979759|NCT00451568|Drug|Desorelle|1 tablet/day in 21 days
45979760|NCT04716465|Other|Dysautonomia|Indicators of dysautonomia
45979761|NCT00330603|Procedure|Serial exhaled breath collections|collect breath for 5 minutes on 8 occasions
45979762|NCT00451646|Drug|SMOF lipid and Intralipid|1-2 g, 5-7 days, 28 days
45979763|NCT00451724|Drug|Intranasal ketamine|
45979764|NCT00451763|Drug|Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml)|
45979765|NCT04716348|Procedure|muscle energy technique|muscle energy technique for suboccipital muscles
45979766|NCT00330720|Device|Emergency Response System (Device)|
45979767|NCT00451841|Device|RTube Exhaled Breath Condensate Collection System|Subjects breath through the device to collect exhaled breath condensate
45979768|NCT00330798|Drug|nepafenac 0.1%|Nepafenac 0.1% randomly assigned to one eye, with ketorolac 0.4% in the fellow eye for contralateral post-surgical use.
45979769|NCT00330798|Other|ketorolac 0.4%|Keterolac 0.4% randomly assigned to one eye, with nepafenac 0.1% in the fellow eye for contralateral post-surgical use.
45979770|NCT00451880|Drug|XL281|Gelatin capsules supplied as 5-, 25-, and 100-mg strengths
45979771|NCT00451880|Drug|famotidine|single dose, supplied as 20-mg or 40-mg tablets
46082643|NCT00940225|Drug|Placebo|After 12 weeks of open-label daily XL184, subjects with stable disease randomized to Arm 3 will receive capsules of placebo that are size- and color-matched to XL184 administered daily until disease progression. Subjects will be unblinded at disease progression and, if found to be receiving placebo, given the option to receive XL184.
46082644|NCT00940225|Drug|XL184|After 12 weeks of open-label daily XL184, subjects with stable disease randomized to Arm 2 will continue to receive XL184 (blinded) administered daily until disease progression.
45979772|NCT00451997|Drug|Gleevec|600 mg (capsules) by mouth once daily
45672601|NCT05269589|Other|Thermoneutral water|Participants will immerse their feet in a foot bath that contains thermoneutral water
45672602|NCT05269589|Other|Hot water|Participants will immerse their feet in a foot bath that contains hot water
45979773|NCT00451997|Drug|Ara-C|10 mg as an injection under the skin daily for 21 days of every 28 day cycle
45979774|NCT00330993|Drug|mifepristone, misoprostol|
45979775|NCT00331032|Drug|3% w/w SPL7013 Gel|Twice-daily vaginal application of 3.5 g of VivaGel™ (Carbopol®-based gel with 3% w/w SPL7013) in single use pre-filled applicators.
45979776|NCT00331032|Drug|Placebo|Placebo gel (Carbopol®-based formulation alone) in single use pre-filled applicators.
46082645|NCT00940225|Drug|XL184|All subjects receive open-label, 100 mg XL184 (supplied at 19.7-, 50-, and 60 mg strength capsules) daily until disease progression.
46082646|NCT02801240|Other|Nutrition support product|Nutrition support product contains macronutrients, micronutrients, phytonutrients, prebiotics, and glutamine. Product is in powder form and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
45672603|NCT04839575|Drug|Latiglutenase|Administered orally (daily)
45672604|NCT04839575|Drug|Placebo|Administered orally (daily)
45979777|NCT00452075|Drug|erlotinib|150mg daily
45979778|NCT00331071|Drug|Monophasic or triphasic Oral contraceptive tablet|fourth week is patch free
45979779|NCT00331071|Drug|Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE|worn for 1 week and replaced for 3 consecutive weeks
45979780|NCT00452153|Procedure|Characterization Legionnella|"Characterisation Legionnella by polymerase chain reaction (PCR)~Characterization strain of Legionnella by sequencing the 23S-5S ribosomal intergenic spacer region"
45979781|NCT00331110|Device|Laterally-Wedged Insole with Ankle Strapping|
45979782|NCT00331110|Device|Laterally-Weged Insole|
45979783|NCT02956889|Drug|Vismodegib|Patients will receive a continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg .
45979784|NCT02956889|Radiation|Radiotherapy|Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.
45979785|NCT00333996|Drug|Dexamethasone|
45979786|NCT00452192|Drug|Telmisartan|telmisartan 80 mg daily over 2 weeks
45979787|NCT00334035|Drug|Quetiapine|
45979788|NCT03275363|Diagnostic Test|Neurocognitive battery|"Cognitive impairment status (SCD, MCI, dementia), HK-MoCA, Clinical Dementia Rating (CDR sum of squares), Geriatric Depression Scale (GDS-15), Neuropsychiatric Index (NPI), Barthel Index, Lawton's IADL, Life-Space Assessment, Mini-Nutrition Assessment (MNA), Quality of Life for Alzheimer's Disease (QoL-AD, patient and carer parts), frailty status (FRAIL scale), handgrip strength, walking speed, exercise status, sleep quality, Charlson comorbidity index (CCI, age-adjusted).~NACC: Story recall, Benson's complex figure copy, colour trail test (black & white), verbal fluency, digit forward and backward span."
45979789|NCT03275363|Diagnostic Test|MRI|MRI: T1, T2, FLAIR, SWI, DTI, fMRI, ASL, MRS, for selected patients
45979790|NCT03275363|Biological|Blood tests|Stored samples (unanalysed): serum, plasma, buffy coat (PBMC); also processed for microvesicles and exosome analysis
45979791|NCT03275363|Diagnostic Test|EEG with event-related potential (ERP)|128-channel EEG with ERP for Go/NoGo and Prospective Memory (PM) tasks for selected patients
45979792|NCT03275363|Diagnostic Test|Amyloid PET CT|F18 Flutametamol PET CT for selected patients
45979793|NCT00334152|Drug|casopitant|
45979794|NCT03275324|Device|Capnostream20p|Observational study of patients connected to the Capnostream20p monitor.
45979795|NCT00334191|Drug|Sodium Bicarbonate|
45979796|NCT00334191|Drug|Placebo|
45979797|NCT04698512|Device|AVFistuloplasty with Sirolimus coated balloon|After an initial fistulogram, the lesion will first be predicated with standard high pressure balloon, followed by MagicTouch™ Sirolimus drug coated balloon
45979798|NCT04698668|Device|fusion imaging|To drain a pancreatic fluid collection through the assitance of the CT-scan image that is superimposed on the radiological field
45979799|NCT00334269|Behavioral|Health messaging at weekly home visits by health counsellor|
45456326|NCT04294004|Other|Autologous Bone Graft|Local autograft collected from decompression which may be supplemented with iliac crest bone graft (ICBG) if local autograft is insufficient.
45979800|NCT00334269|Behavioral|Weekly home delivery of bottled spring water|
45456327|NCT04286165|Other|Brief Peer Supported webSTAIR|The BPS webSTAIR program is an online platform where individuals are taught skills in emotion regulation. In this program they will learn how to recognize the emotions they are feeling by assessing their own body language, being attentive to their thought processes, and attempting to replace negative behaviors with positive. Throughout the platform they will engage in written exercises to help them solidify the lessons with their own life experiencing. They will also have the support of peers throughout the program to help them when they need clarification or having a difficult time applying the lesson(s).
45456328|NCT04269837|Other|Counseling|Receive sexual health counseling
45832109|NCT04140084|Device|Real-life clinical meetings|Study coordinators will identify potentially eligible parent/patient dyads and adult patients based on a chief complaint related to head trauma recorded at the time of ED registration and communication with treating clinicians in realtime. After using the decision aid with their health professional, a cognitive interview session will then be organized with the dyads of participants (parents/patients and clinicians) to address any usability issues. These interviews will be audio recorded and transcribed verbatim for content analysis and future reference. This process will allow to identify any conceptual barriers and unanticipated user needs. Written consent form will be signed by participants.
45456329|NCT04269837|Other|Quality-of-Life Assessment|Ancillary studies
45456330|NCT04269837|Other|Questionnaire Administration|Ancillary studies
45979801|NCT00334269|Behavioral|Weekly afterschool physical activity program for 5-18y.o.|
45456331|NCT04265950|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
45672605|NCT04418102|Dietary Supplement|Palmitic acid rich interesterified fat|Muffins and spread containing the palmitic acid rich IE fat will be consumed daily for a 6-week dietary intervention period
45672606|NCT04418102|Dietary Supplement|Stearic acid rich interesterified fat|Muffins and spread containing the palmitic acid rich IE fat will be consumed daily for a 6-week dietary intervention period.
45672607|NCT04765592|Device|WeFlow-Arch Modeler Embedded Branch Stent Graft System|The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.
45672608|NCT04764968|Drug|Dasiglucagon|Abdominal s.c. administration using a multi-dose reusable pen injector
45672609|NCT02192606|Device|Storz 3D Laparoscopy System|The Storz 3D Laparoscopy System is a new device that allows for laparoscopic surgeons to utilize 3D imaging during surgery with a fraction of the cost of the da Vinci Surgical System, a three-dimensional visual system.
45832110|NCT04140240|Behavioral|intervention group|Parallel Assignment a experimental design with pre test and post test
45979802|NCT00334269|Behavioral|Cooking classes and grocery store tours with dietician|
45979803|NCT00334269|Behavioral|Pedometers to track/increase weekly physical activity|
45979804|NCT04698551|Genetic|Non invasive prenatal diagnosis|Search for the familial mutation involved in DPN requests from phasing of parental haplotypes by 3rd generation long-fragment DNA sequencing techniques coupled with targeted sequencing of free circulating DNA from maternal plasma.
45979805|NCT00334308|Procedure|Barley protein bread or control (casein) bread|
46082647|NCT02799758|Drug|NK-104-CR|NK-104-CR 8 mg for 52 weeks
46082648|NCT02799758|Drug|Livalo® IR|Livalo® IR 4 mg daily for 52 weeks
45456332|NCT04259788|Other|AHEI diet|Main intervention is the consumption of an AHEI diet for 12 weeks.
45456333|NCT04255615|Other|AI to analyze 3 D ultrasound|AI to assess 3 D ultrasound to assess antral follicle count
45456334|NCT04249778|Drug|Dapagliflozin|Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Participants will receive 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.
45456335|NCT04249778|Drug|Placebo|Participants will receive a placebo to match 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.
45456336|NCT04247815|Drug|ATI-450|Oral, small molecule MK2 inhibitor
45456337|NCT04247815|Drug|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
45456338|NCT04247815|Drug|Methotrexate|7.5 mg to 25 mg weekly
45456339|NCT04240561|Device|High level of signal manipulation|Hearing aid will be programmed to a high level of signal manipulation.
45456340|NCT04240561|Device|Low level of signal manipulation|Hearing aid will be programmed to a low level of signal manipulation.
45672610|NCT02192606|Device|2D Laparoscopy|The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy.
45672611|NCT01628107|Biological|Epoetin Hospira|Intravenous (IV) injection
45672612|NCT04764734|Device|NightOwl|The NightOwl is a finger-mounted home sleep apnea testing device
45672613|NCT04740151|Procedure|Best PEEP|In OLV, the investigator will perform a PEEP decremental titration trial, decreasing PEEP from 16 to 4 cmH2O (steps of 2-cmH2O, lasting 1 minute). At the end of every step driving pressure (Pplat-PEEP) will be calculated, and the PEEP corresponding to the lowest driving pressure + 2cmH2O will be set.
45672614|NCT04740151|Procedure|Standard PEEP|In OLV, a PEEP of 5 cm H2O will be set.
45672615|NCT04745377|Diagnostic Test|IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus|IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus
45832111|NCT04149288|Dietary Supplement|High-polyphenol olive oil|High-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
45979806|NCT00334347|Drug|Depakote ER|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
45979807|NCT00334347|Drug|Depakote DR|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
45979808|NCT00334386|Drug|Torasemide Prolonged Release (loop diuretic)|
45979809|NCT00334386|Drug|Torasemide Immediate Release (loop diuretic)|
45979810|NCT00452231|Drug|D-cycloserine|
45979811|NCT00452231|Behavioral|Cognitive-Behavioral Therapy|
46082649|NCT02799758|Drug|Placebo (for NK-104-CR)|NK-104-CR 8 mg placebo for 52 weeks
45979812|NCT00334425|Drug|MENOPUR; GONAL-F|
45979813|NCT03275207|Drug|saline|an equal volume of saline
45979814|NCT03275207|Drug|dexmedetomidine|dexmedetomidine, 0.5ug/kg/h by intravenous infusion, intraoperative
45979815|NCT00334464|Drug|Standard of care or genotyping dosing of warfarin dosing|
45979816|NCT03275012|Drug|Gabapentin + Morphine|"Gabapentin: liquid oral formulation (syrup) - 75 mg/ml-three times daily. The starting dose during the optimization period will be defined according to 2 weight groups (5-15kg and >15kg). Dose will be scaled at Day 1,3,5,14,and 21 according to a specific schedule. Maintenance dosing will be scheduled in accordance to the body weight.~Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period."
45672616|NCT04739683|Device|Foley bulb placement|A 16 F Foley catheter with a 30-mL balloon and stylet is inserted into the endocervical canal under direct visualization by sterile speculum exam or by digital palpation. The Foley catheter is advanced to or past the internal os, and the balloon is filled with 30-40 mL of sterile water. The catheter is then placed on genital traction by taping the end of the catheter to the medial portion of the thigh.
45672617|NCT04739683|Device|DILAPAN-S® placement|A bivalve speculum will be used to visualize and prepare the cervix with an antiseptic solution. The DILAPAN-S® (4 x 65 mm) will be inserted in the cervical canal until it traverses the internal os. As many dilators as needed to achieve the desired effect should be inserted. Specific number of pieces always depends on decision and clinical judgement of physician and indications. A gauze pad moistened with sterile water or saline may be inserted into the vagina to help keep the DILAPAN-S® in place, if needed
45832112|NCT04149288|Dietary Supplement|Low-polyphenol olive oil|Low-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
45832113|NCT04146324|Drug|nivolumab|Administered as adjuvant therapy as per the market authorization in Australia
45979817|NCT03275012|Drug|Placebo + Morphine|Placebo liquid oral formulation. Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period.
45979818|NCT00334503|Drug|Miglitol|
45979819|NCT04698395|Behavioral|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|motor learning-based, intensive therapy for children with cerebral palsy
45832114|NCT03588936|Drug|Nivolumab (.25 mg/kg)|Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
45979820|NCT04698395|Behavioral|Regular care|customary or usual care given to any infant/toddler with cerebral palsy
45979821|NCT00334581|Drug|Irbesartan|Administration throughout the study period
45832115|NCT03588936|Drug|Tocilizumab|Participants will receive 2 doses of tocilizumab
45979822|NCT00334581|Drug|Irbesartan|Administration throughout the study period
45979823|NCT00452270|Drug|Xylometazoline|
45979824|NCT00334620|Procedure|15 radon(+CO2) baths vs 15 CO2 baths; beside rehabilitation|
45979825|NCT00334659|Drug|apricitabine|
45672618|NCT01583530|Biological|Single Dose Group: Belimumab IV 240 mg|Belimumab IV 240 mg administered on Day 0
45832116|NCT03588936|Drug|Nivolumab (.5 mg/kg)|Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
45979826|NCT00452465|Behavioral|ElderCare Plan|Nursing assessment and development of an appropriate care plan.
45979827|NCT00452504|Drug|SRA-444|
46082650|NCT02799758|Drug|Placebo (for Livalo® IR)|Livalo® IR 4 mg placebo for 52 weeks
46082651|NCT00938899|Drug|TMC435350; Placebo|
45832117|NCT03588858|Other|structured interview questionnaires|"Module (1): Socio-demographic characteristics~Module (2) :Occupational history~Module (3): Presence of work related injuries and diseases by history and observation.~Module (4): Food frequency questionnaires (FFQ) during the past week.~Module (5): Mental health screening: Self-reporting questionnaire 20 questions for assessment of mental health status of children."
45979828|NCT00452582|Drug|Sildenafil (Viagra)|Dose escalation (one of the following): 25 mg daily for 2 weeks, 50 mg daily for 2 weeks, 75 mg daily for 2 weeks, 50 mg twice daily for two weeks, 50 mg AM and 75 mg PM for 2 weeks, 75 mg twice daily for 2 weeks, 75 mg in AM and 100 mg in PM for 2 weeks, 100 mg twice daily for 2 weeks.
45979829|NCT00452582|Other|Usual care|Physical therapy, occupational therapy, speech therapy
45979830|NCT00452621|Procedure|blood draw|
45979831|NCT00334698|Drug|Cetirizine|
45979832|NCT00334698|Drug|Pseudoephedrine|
45979833|NCT00334698|Drug|Cetirizine with Pseudoephedrine|
45979834|NCT00334776|Biological|MART-1 antigen|
45979835|NCT00334776|Biological|gp100:209-217(210M) peptide vaccine|
45979836|NCT00334776|Biological|therapeutic autologous dendritic cells|
45979837|NCT00334776|Biological|tyrosinase peptide|
45979838|NCT00452660|Drug|Exjade|
45979839|NCT00452738|Behavioral|Therapy dog|
45979840|NCT00452738|Behavioral|Costumed character|
45979841|NCT00452738|Behavioral|Parents-only|
45979842|NCT00334854|Drug|doxorubicin hydrochloride|
45979843|NCT00334854|Drug|ifosfamide|
45979844|NCT00334854|Procedure|adjuvant therapy|
45979845|NCT00334854|Procedure|conventional surgery|
45979846|NCT00334854|Procedure|neoadjuvant therapy|
45979847|NCT00334854|Radiation|radiation therapy|
45979848|NCT03274973|Drug|Zomacton|Injection
45979849|NCT00334932|Drug|bortezomib|
45979850|NCT00334932|Drug|melphalan|
46082652|NCT03259165|Drug|Nitrates|"For patients randomized to the Nitrate intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~IV furosemide (unless already given) (All patients receive at minimum 20 mg IV furosemide or equivalent)~SL nitroglycerin (400 ucg) will be given every 5 minutes, a total of three times. (May be repeated) (Held if SBP decreases to < 120 mmHg)~Reassessment every 2 hours. If LUS B-lines >15, repeat step 2. If < 15, stop algorithm."
45672619|NCT01583530|Biological|Single Dose Group: Belimumab SC 2 x 120 mg|Belimumab SC 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Day 0
45672620|NCT01583530|Biological|Single Dose Group: Belimumab SC 1 x 240 mg|Belimumab SC 240 mg x 1 injection on Day 0
45672621|NCT01583530|Biological|Single Dose Group: Belimumab SC 1 x 200 mg|Belimumab SC 200 mg x 1 injection on Day 0
45672622|NCT01583530|Biological|Multiple Dose Group: Belimumab SC 2 x 120 mg weekly|Belimumab 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Days 0, 7, 14, and 21
45672623|NCT01583530|Biological|Multiple Dose Group: Belimumab SC 1 x 200 mg weekly|Belimumab 200 mg x 1 injection administered on Days 0, 7, 14, and 21
45672624|NCT01639001|Drug|Crizotinib|250 mg two times daily [BID], oral, on a continuous daily dosing schedule. Cycles are defined in 21 day periods.
45672625|NCT01639001|Drug|Pemetrexed/Cisplatin|Option 1: Pemetrexed/Cisplatin; Pemetrexed, 500 mg/m^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Cisplatin, 75 mg/m^2 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and cisplatin will be repeated every 3 weeks for a maximum of 6 cycles.
45832118|NCT03588624|Device|TearCare|The TearCare procedure includes the delivery of thermal energy to the external surface of the eyelids for 15 minutes, immediately followed by manual expression of each eyelid.
45832119|NCT03585582|Other|Prospective follow-up|This is a prospective follow-up study to assess of outcomes at 1 year following the discharge from the hospitalization during which PARDS was diagnosed
45832120|NCT03020862|Dietary Supplement|Dietary beetroot juice|Consumed as concentrated beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days.
45832121|NCT03586128|Drug|PrEP|PrEP will be introduced into clinics according to Uganda national guidelines using a stepped wedge design. Uganda guidelines recommend any tenofovir disoproxil fumarate (TDF) containing medication be used for PrEP; this includes emtricitabine (FTC)/TDF, lamivudine (3TC)/TDF or TDF alone.
45832122|NCT03586128|Drug|ART|ART medication will be provided according to Uganda national guidelines for persons living with HIV.
45832123|NCT03582462|Drug|IONIS FXI-LRx|Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection
45979851|NCT00334932|Drug|pegylated liposomal doxorubicin hydrochloride|
45979852|NCT00452777|Drug|BVT.115959|
45979853|NCT00452777|Drug|Placebo|
45979854|NCT00334971|Procedure|Follicle Aspiration|Follicles will be aspirated using a transvaginal ultrasound guided needle.
45979855|NCT00452816|Behavioral|Workplace Solutions Consulting approach|"Consulting process includes:~baseline measure of best practices~gap analysis and recommendations reporting~delivery of solution set toolkits for each practice chosen for implementation"
45979856|NCT00452816|Behavioral|Delayed intervention|Abbreviated version of the Workplace Solutions Consulting process applied in the intervention group
45979857|NCT00335010|Drug|Nitroglycerin|
45979858|NCT00452855|Procedure|Sevoflurane-remifentanil anaesthesia|
45979859|NCT00335088|Drug|Moxifloxacin and Povidone Iodine vs Povidone Iodine|
45979860|NCT00452894|Drug|varenicline tartrate|
45979861|NCT00335166|Drug|Pardaprunox|12-42 mg
45979862|NCT00335166|Drug|pramipexole|1.5-4.5 mg
45979863|NCT00335166|Drug|Placebo Comparator|Placebo
45979864|NCT00452972|Drug|Spinal Anesthesia|
45979865|NCT00335205|Drug|ropinirole|
45979866|NCT00453011|Device|posterior chamber intraocular lens|
45979867|NCT00453011|Device|anterior chamber intraocular lens|
45979868|NCT03274934|Behavioral|Experimental: face-to-face and online support group:|5-week intervention according to Acceptance and Commitment Therapy principles with the web-and mobile-based Youth COMPASS program, face-to-face support (2 meetings) and weekly online mobile support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
45979869|NCT03274934|Behavioral|Experimental: only online support group:|5-week intervention according to ACT principles with the web-and mobile-based Youth COMPASS program, no face-to-face support, weekly mobile online support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
45979870|NCT03274934|Behavioral|Control|Control group, no intervention, school counseling as usual. (one third of the participants is randomly assigned to this group)
45979871|NCT00335361|Device|Intra Vas Device (IVD)|
45979872|NCT00453050|Drug|imiquimod|
45979873|NCT00453050|Drug|indocyanine green solution|
45979874|NCT00453050|Other|flow cytometry|
45979875|NCT00453050|Other|immunologic technique|
45979876|NCT00453050|Other|laboratory biomarker analysis|
45979877|NCT00335400|Drug|Anesthetic Dilating Gel|
45979878|NCT00453089|Drug|VG101|
45979879|NCT00420576|Drug|DBT-Danggui Buxue Tang|Herbal Combination of Danggui (Radix Angelicae Sinensis) and Huangqi (Radix Astragali)in granules form, in 3 different dosage 6g/3g/1.5g, once time per day for 3 Months treatment
45979880|NCT00420615|Drug|Patupilone and Omeprazole|
45979881|NCT00420615|Drug|Patupilone + Midalzolam|
45979882|NCT00453167|Drug|Paclitaxel|Paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
45979883|NCT00453167|Drug|Gemcitabine|Gemcitabine 1000mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
45979884|NCT00420654|Drug|Growth Hormone|1.25 mg, 6 months
45979885|NCT00420654|Drug|Placebo|Equivalent to 1.25 mg, 6 months
45979886|NCT00420654|Other|Healthy controls|Healthy controls
45979887|NCT00420693|Drug|sevoflurane|
45979888|NCT03274895|Drug|PHMB 0.08%|16 drops in a day for 5 days,8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
45979889|NCT03274895|Drug|Propamidine 0.1%|16 drops in a day for 5 days,8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
45979890|NCT03274895|Drug|placebo|16 drops in a day for 5 days,8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
45979891|NCT03274895|Drug|PHMB 0.02%|16 drops in a day for 5 days,8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
45979892|NCT00420810|Drug|MK0928 / Duration of Treatment : 8 Weeks|
45672626|NCT01639001|Drug|Pemetrexed/Carboplatin|Option 2: Pemetrexed/Carboplatin. Pemetrexed, 500 mg/m^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Carboplatin, at a dose calculated to produce an AUC of 5 or 6 mg.min/mL will be administered by infusion according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and carboplatin will be repeated every 3 weeks for a maximum of 6 cycles.
45979893|NCT00453323|Drug|Paclitaxel|paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks
45979894|NCT00453323|Drug|Capecitabine|capecitabine 900mg/m2 bid po on day 1~14, 1 weeks rest, until disease progression
45979895|NCT00335439|Drug|ketorolac tromethamine 0.5% (Acular®)|
45979896|NCT00453401|Drug|NB-001|
45979897|NCT00453440|Procedure|Cheek swab & blood test|Cheek swab & blood test
45672627|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 5mg QD
45672628|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 15 mg QD
45672629|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
45672630|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 25 mg QD
45672631|NCT04443959|Behavioral|PUMAS|Treatment consists of 6 weekly telemedicine sessions during pregnancy.
45672632|NCT04433897|Other|Questionnaire|"All women fulfilled 3 questionairres~TANGO~ICIQ -N~Perceived Stress Scale"
45672633|NCT05263193|Drug|Caplacizumab|as in real world practice
45672634|NCT02168270|Dietary Supplement|ascorbic acid|Given IV
45672635|NCT02168270|Drug|temozolomide|Given PO
45672636|NCT02168270|Other|quality-of-life assessment|Ancillary studies
45672637|NCT02168270|Other|laboratory biomarker analysis|Correlative studies
45672638|NCT04416581|Drug|PPI|rabeprazole 20mg + tegoprazan 50 mg placebo, once daily.
45672639|NCT04416581|Drug|P-CAB 50|tegoprazan 50 mg + rabeprazole 20mg placebo, once daily.
45672640|NCT02167256|Drug|AZD0530 100mg daily|All patients in experimental group (50%) will be started on 100mg AZD0530 daily
45979898|NCT04698083|Diagnostic Test|Electrocardiography ,Tomographic imaging|Based on electrocardiographic follow-up analyses,the two main groups were compared in terms of rotation condition (i.e., Cwr, normal transition, or CCwr), electrocardiographic intervals, and laboratory findings In our study,CO-RADS5 was considered an advanced tomographic finding(e.g., multifocal ground glass opacities with consolidation, vascular thickening,crazy paving pattern,mixed pattern),while CO-RADS1,2,3, and 4 were considered non-advanced tomographic findings.
45979899|NCT00335595|Drug|XELOXA|XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks
45979900|NCT00335595|Drug|XELOXA-A|"XELOXA-A Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 during 6 cycles followed by Bevacizumab until disease progression or premature drop out of study.~One cycle every 3 weeks"
45979901|NCT00453518|Device|FiberNet EPS used during SVG intervention.|The FiberNet EPS is indicated for use as a guide wire and embolic protection system to capture and remove embolic material produced while performing percutaneous transluminal interventional procedures in saphenous vein grafts.
45979902|NCT00453557|Drug|rhGH|
45979903|NCT00335673|Drug|Irbesartan (Aprovel)|Aprovel (150 & 300mg) & CoAprovel (300/12.5mg hydrochlorothiazide) one tablet a day per os.
45979904|NCT00335712|Drug|ONO-5129|
45979905|NCT00453635|Drug|Docetaxel|Docetaxel at the dose of 75mg/m^2 IV on day 1 every 3 weeks for 6 consecutive cycles
45979906|NCT00453635|Drug|Carboplatin|Carboplatin at the dose of 5 AUC IV on day 1 every 3 weeks for 6 consecutive cycles
45979907|NCT00453635|Drug|Herceptin|Herceptin 8 mg/Kg on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles, IV, every 3 weeks
45979908|NCT00453635|Drug|Vinorelbine|Vinorelbine at the dose of 60mg/m^2 per os,weekly
45979909|NCT00335751|Procedure|positron emission tomography computed tomography (PET/CT)|The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.
45979910|NCT04698278|Device|PanOptix Trifocal Intraocular Lens|This is a FDA approved trifocal lens that will be placed in patients who have had previous myopic LASIK or PRK.
45979911|NCT00335790|Procedure|Hyperbaric Therapy|
45979912|NCT00335868|Drug|danusertib|
45979913|NCT00335868|Other|laboratory biomarker analysis|
45979914|NCT00335868|Other|pharmacological study|
45979915|NCT04698200|Other|Cold exposure|Whole body resting cold (+10 degrees centigrade) and heat (+40 degrees centigrade) for 60 minutes.
45979916|NCT00335907|Procedure|Fluid and Vasopressor Protocol|A Physician Ordered, Nurse Administered Fluid and Vasopressor Protocol
45979917|NCT00335946|Device|HANS non-needle acupuncture|
45979918|NCT00335946|Procedure|Stimulation of two acupuncture points bi-lateral|
45979919|NCT00335985|Drug|GB-0998|8 mL (400 mg of GB-0998)/kg per day is intravenously administered for five successive days
45979920|NCT00335985|Drug|Placebo of GB-0998|8 mL/kg per day is intravenously administered for five successive days
45979921|NCT00336102|Other|physiologic testing|Markers of thyroid function including thyroid stimulating hormone (TSH), Free thyroxine (free T4) and Thyroid peroxidase antibody (TPO Ab). These will be performed at baseline, in 12 months and again 24 months after enrollment. All thyroid function marker assays will be performed by LabCorp.
45979922|NCT00336102|Procedure|fatigue assessment and management|Fatigue Symptoms Inventory (FSI) survey
45979923|NCT00336102|Procedure|management of therapy complications|If baseline testing results suggest hyperthyroidism or hypothyroidism, the enrolling center will give test results to participants for follow-up with their primary healthcare provider. Participants with hypothyroidism, who are not started on thyroid hormone, will continue on study, given the TSH level is below 10. Those with hypothyroidism who have treatment initiated will not continue on study. Participants who develop hypothyroidism during the study will not continue on-study if replacement therapy is initiated or if the TSH level is 10 or higher. Work up the next control nominated by the patient or contact the patient for the name of another control
45979924|NCT00453791|Drug|GW805858|GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.
45979925|NCT00453791|Drug|Placebo|Placebo MDI will be given to the subjects.
45979926|NCT00336141|Drug|Suberoylanilide hydroxamic acid|400 mg QD (every day) for five days, followed by 9 days of no vorinostat
45979927|NCT00453830|Procedure|laparoscopic sigmoid resection|a laparoscopic 5 trocars approach for left colon mobilization, sigmoid colon transsection and intracorporeal colorectal anastomosis
45979928|NCT00336180|Behavioral|HealthWise South Africa curriculum|18 classroom lessons
45979929|NCT02273648|Device|Drug Eluting Stent (DES)|Percutaneous Coronary Intervention
45979930|NCT00336219|Drug|Pantoprazole|Symptom Assessment after treatment with Pantoprozole 40 mg
45979931|NCT04698239|Device|LASER MILESMAN 445 NM|Laser application
45979932|NCT00453869|Other|liver fibrosis evaluation|Evaluation of liver fibrosis with blood test
45979933|NCT00336297|Procedure|Woman Abuse Screening Tool|
45979934|NCT00336297|Procedure|Partner Violence Screen|
45979935|NCT00336297|Procedure|Computerized screening|
45979936|NCT00336297|Procedure|Face to face screening|
45979937|NCT00336297|Procedure|Written screening on forms|
45979938|NCT00453908|Drug|Alfuzosin|
45979939|NCT00336336|Drug|n-3 PUFA|1 g die per os
45672641|NCT02167256|Drug|AZD0530 125mg daily|Patients with plasma drug level <100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.
45979940|NCT00336336|Drug|Rosuvastatin|10 mg die per os
45672642|NCT02167256|Drug|Placebo|50% of patients will receive placebo treatment for the duration of the study.
45672643|NCT02191046|Device|squeezable bottle|nasal irrigation twice daily for 2 weeks period
45672644|NCT02191046|Device|syringe 20 ml|nasal irrigation twice daily for 2 weeks
45672645|NCT04188236|Device|Hernia Blocking System|Hernia Blocking System device implanted during a lumbar discectomy procedure
45672646|NCT04838795|Biological|To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine|To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine among health care workers (HCW) as compared to the general unvaccinated population in South Africa
45672647|NCT04851899|Dietary Supplement|Phaeosol low dose|1 Phaeosol softgel of 440mg/day and 1 placebo softgel of 500mg/day (look like softgel of Phaeosol product) + 1 capsule of 440mg/day of natural stimulant Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
45832124|NCT03582462|Drug|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
45832125|NCT03580278|Biological|ABY-035/AFO2|Analyze the safety, tolerability, PK, and efficacy of ABY-035/AFO2 that 25 subjects will receive for treatment of their active plaque psoriasis
45979941|NCT00336336|Drug|Placebo|1 gram c. per os
45832126|NCT03589950|Drug|anlotinib plus chemotherapy|Anlotinib (12mg QD PO d1-14, 21 days per cycle), Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
45832127|NCT03589950|Drug|chemotherapy|Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
45979942|NCT00336336|Drug|Placebo|10 mg c. per os
45979943|NCT00336375|Drug|artemether-lumefantrine|All treatment doses given either accompanied or not-accompanied with intake of fatty food.
45979944|NCT00336414|Drug|cyclophosphamide-prednisone-azathioprine|
45979945|NCT00336453|Biological|Influenza Vaccination|0.5mL dose for intramuscular injection
45979946|NCT00336453|Biological|Influenza Vaccination|0.25mL dose for intramuscular injection
45979947|NCT00336531|Drug|itraconazole|2.5 mg/kg twice daily for the first two days --> once daily
45979948|NCT00453947|Device|CPAP and Non Invasive Ventilation|
45979949|NCT00454064|Behavioral|cognitive-behavioral treatment|
45979950|NCT00322062|Drug|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|2L gut lavage solution
45979951|NCT00322062|Drug|Sodium Phosphate Solution|1 x 45ml solution, BID
45979952|NCT00454103|Drug|123I-Iodometomidate|
45979953|NCT00336648|Drug|Avastin (Bevacizumab)|10mg/kg by vein (IV) on Days 1, 2, 15 and 29 the adjuvant therapy every two weeks starting approximately 6 weeks after surgery for three months.
45979954|NCT00336648|Drug|Gemcitabine|400 mg/m2 IV once a week on Days 1, 2, 8,15, 22, 29, 36 +/-2 days (Saturdays)
45979955|NCT00336648|Procedure|Radiation Therapy|Day 3 +/-2 days (Monday) Start Radiation therapy, Mon -Fri x 28 days; 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions)
45979956|NCT03274817|Drug|Escitalopram Pill|Subjects randomized to group A will receive Lexapro (escitalopram), in an initial, baseline dosage of 5 mg daily.
45979957|NCT03274817|Drug|Venlafaxine Pill|Subjects randomized to group B will receive Effexor XR (venlafaxine extended release capsules), in an initial baseline dosage of 37.5 mg daily.
45979958|NCT03274817|Drug|Placebo Oral Tablet|Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
45979959|NCT00322140|Drug|CDDO|
45979960|NCT00230087|Procedure|blood donation|phlebotomy until iron depleted
45979961|NCT00230204|Procedure|Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits|
45979962|NCT00230321|Drug|Darbepoetin alfa|During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously.If patients do not achieve a major erythroid response by 6 weeks, the dose of DARBEPOETIN ALFA will be doubled to 9.0 ug/kg/week.
45979963|NCT02959632|Behavioral|Animal Assisted Therapy|Animal Assisted Therapy is the program where a pet, usually dog will visit and interact with the patients.
45979964|NCT00230399|Drug|Celecoxib|
45979965|NCT00230399|Drug|Capecitabine|
45979966|NCT00230399|Drug|Irinotecan|
45979967|NCT00336765|Drug|XL647|Tablets supplied in 50-mg strength administered orally daily
45979968|NCT00230438|Procedure|External Beam Radiotherapy|
45979969|NCT00336843|Drug|Zevalin-BuCyE|rituximab (IV, 250 mg/m2 on days -21 and -14) single dose of 90Y-ibritumomab (IV, 0.4 mCi/kg on day -14) Busulfan (IV, 0.8 mg/kg every 6 h from day -7 to day -5) Cyclophosphamide (IV, 50 mg/kg on days -3 and -2) Etoposide (IV, 200 mg/m2 every 12 h on days -5 and -4) Autologous stem cells infusion on day 0
45979970|NCT00230477|Drug|Hepsera|
45979971|NCT00230477|Drug|Hepsera and lamivudine|
45979972|NCT00230516|Drug|Nexium|
46082653|NCT03259165|Drug|Loop Diuretics|"For patients randomized to the Diuretic intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~Patients receive 1 inch topical nitropaste~IV Loop diuretic dose = patients total oral dose (max dose of 200 mg IV)~Reassessment every 2 hours. If LUS B-lines >15, repeat step 2. If < 15, stop algorithm."
45672648|NCT04851899|Dietary Supplement|Phaeosol high dose|2 Phaeosol softgels of 440mg/day + 1 capsule of 440mg/day of natural stimulant. Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
45832128|NCT03589872|Diagnostic Test|Fine motor dexterity test, nine hole peg test|The nine hole peg test will be performed under two different task (1)single task, (2)adding a cognitive task
45832129|NCT03589716|Other|Vital Moto Mod|All participants receive vital signs measurement using the Vital Moto Mod device and reference devices. The vital signs measured are blood pressure, heart rate, respiratory rate, oxygen saturation and temperature.
45832130|NCT03589716|Other|Welch Allyn Connex Spot Vital Signs Monitor|This is the FDA approved reference device to measure heart rate, SpO2 and temperature.
45832131|NCT03589716|Other|Capnostream 20 Portable Bedside Capnograph|This is the reference device to be used to obtain etCO2 waveforms for respiratory rate assessment.
45832132|NCT03589716|Other|Welch Allyn 767 Mobile Aneroid Sphygmomanometerand 3M Littmann Master Classic II Teaching Stethoscope|These reference devices will be used together for blood pressure measurements.
45832133|NCT03589716|Other|Scifit 1000R cycle ergometer|This is the device that will be used for exercise testing
45979973|NCT00230516|Drug|Prevacid|
45979974|NCT00336882|Drug|Propofol|Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
45979975|NCT00336882|Drug|Midazolam|Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
45979976|NCT00306332|Procedure|T-cell and B-cell depletion|
45979977|NCT00336921|Drug|Alfuzosin|Once daily
45979978|NCT00336921|Drug|Placebo|Once daily
45979979|NCT00306371|Device|1450nm diode laser|
45979980|NCT00336960|Drug|celecoxib|twice daily beginning 5 days prior to radiotherapy and continuing until completion of radiotherapy
45979981|NCT00336960|Drug|fluorouracil|Patients receive concurrent fluorouracil IV continuously for 5 weeks.
45979982|NCT00336960|Procedure|conventional surgery|4-10 weeks after completion of chemoradiotherapy
45979983|NCT00336960|Radiation|radiation therapy|Patients undergo radiotherapy 5 days a week for 5 weeks
45979984|NCT00336960|Procedure|tumor biopsy|at baseline and then at the time of surgical resection
45979985|NCT00336960|Other|laboratory biomarker analysis|blood and urine collected at baseline, 5 days after initiation of celecoxib, 7 days after initiation of celecoxib in combination with fluorouracil and radiotherapy, and at the time of surgical resection. specimens are evaluated for COX-2 expression, eicosanoid production, and gene and protein expression using immunohistochemistry, microarray, and mass spectrometry.
45979986|NCT00306410|Drug|colecalciferol|
45979987|NCT00340080|Drug|Abacavir|
45979988|NCT00418535|Drug|Concurrent Radiotherapy (RT)/cisplatin, VIPD|
45979989|NCT00337038|Drug|N-acetylcystein(drug)|p.O t.Siran 200mg x1 during one weak
45979990|NCT02960243|Device|Deep Brain Stimulation|"DBS System Medtronic~DBS programming settings will be set to maximally alleviate limb tremor, primary reason for referral~These settings will be used to evaluate effects of voice tremor as well"
45979991|NCT00418613|Drug|MK633|MK0633 100mg capsules qd for a 12-wk treatment period.
45979992|NCT00418613|Drug|Comparator: Placebo (unspecified)|MK0633 100mg Pbo capsules for a 12-wk treatment period
45979993|NCT04715841|Other|gait assessment|gait assessment were done using 3DMA system
45979994|NCT02960711|Drug|Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]|
45979995|NCT02960711|Drug|Ludipress, mg stereate, micronized hydrated silica, talcum|Tablet
45979996|NCT00306449|Behavioral|Small group seminar-based educational intervention|
45979997|NCT00306566|Biological|CYT004-MelQbG10|
45979998|NCT00337116|Drug|iso sorbide dinitrate iv bolus or s/l|
46082654|NCT04013659|Other|Dental Bleaching with 35% hydrogen peroxide gel + Violet LED Irradiation|After gum protection, the bleaching gel (35% hydrogen peroxide) was applied to the surface of the tooth and irradiated with VIOLET LED
45672649|NCT04851899|Dietary Supplement|Placebo|2 placebo softgels of 440mg/day (look like softgel of Phaeosol product) + 1 capsule of 500mg/day containing Microcellulose (look like capsule of natural stimulant). Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
45672650|NCT04838171|Other|White blood cell and blood collection|Mononucleocytes will be collected via apheresis
45672651|NCT02166476|Drug|Meropenem-Vaborbactam|Meropenem-vaborbactam
45672652|NCT02166476|Drug|Piperacillin-Tazobactam|Piperacillin-tazobactam
45672653|NCT02166476|Drug|Levofloxacin|Levofloxacin
45832134|NCT03589638|Device|Direct laryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
45672654|NCT02166476|Drug|Saline|Saline
45672655|NCT05318261|Procedure|Spontaneous breathing trial|A spontaneous breathing trial (SBT) is used to identify patients who are likely to fail liberation from mechanical ventilation. The test can be done according to the usual modalities of the participating centre, following the international recommendations, meaning either by disconnecting the endotracheal tube from the ventilator and connecting it to a source of oxygen through the T-tube or by setting pressure support with low positive end-expiratory pressure (PEEP). The choice of the method will not be determined according to the participation in this study but will be done according to the habits of the participating centre.
45672656|NCT04803305|Drug|PF-06946860|subcutaneous injection
45672657|NCT04803305|Drug|Placebo for PF-06946860|subcutaneous injection
45672658|NCT05237609|Dietary Supplement|rehabilitation with muscle strengthening + Oral Nutritional Supplements|Combination of protein intake and muscle strengthening exercises for the improvement of walking capacities, patients in the experimental group
45832135|NCT03589638|Device|C-MAC videolaryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
45832136|NCT03589638|Device|McGrath videolaryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
45832137|NCT03022500|Drug|durvalumab + tremelimumab|Durvalumab: 1.5g Q4W plus Tremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
45832138|NCT04148742|Drug|DZD9008|Daily dose of DZD9008, except for cycle 0 of Part A, in which a single dose of DZD9008 is administrated. Starting dose of DZD9008 is 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008.
45832139|NCT03589560|Drug|Biodentine|a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
45979999|NCT00306605|Behavioral|Questionnaire|Participants will be asked to complete a questionnaire 3 times throughout the first 5 weeks after their infant's birth / hospitalization
45980000|NCT00337155|Drug|Radium-223 dichloride (BAY88-8223)|3 doses of radium-223 at different dose levels, 25, 50 or 80 kBq/kg b.w.given as injection.
45980001|NCT00340314|Procedure|Circumferential Pulmonary Vein Ablation|
45980002|NCT00340314|Drug|Antiarrhythmic Drug Therapy|
45980003|NCT00306644|Drug|Rosiglitazone|study drug
45980004|NCT00337233|Procedure|yoga therapy|10 week yoga class
46082655|NCT02799368|Drug|CJ Plasma Solution A Injection|Intravenous plasma solution (Chloride 90 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
46082656|NCT02799368|Drug|CJ 0.9% Normal Saline Injection|Intravenous plasma solution (Chloride 154 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
46082657|NCT00938977|Device|CPAP|Before and after effect of treatment with CPAP
46082658|NCT00938977|Device|Bilevel Support Ventilation (Non-Invasive Ventilation)|before/after effect of Bilevel support ventilation
46082659|NCT02790398|Behavioral|Transdiagnostic treatment protocol|Transdiagnostic treatment protocol for emotional disorders whose aims are to learn and practice adaptive ways to regulate emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention. These components are organized in twelve modules.
45672659|NCT05237609|Other|rehabilitation with muscle strengthening|Physical activity with only muscle strengthening
45672660|NCT02224274|Drug|Clopidogrel|
45672661|NCT02224274|Drug|Ticagrelor|
45672662|NCT05236517|Drug|Semaglutide D Dose 1|Tablet given orally
45672663|NCT05236517|Drug|Semaglutide D Dose 2|Tablet given orally
45672664|NCT05236517|Drug|Semaglutide D Dose 3|Tablet given orally
45672665|NCT05236517|Drug|Semaglutide C Dose 4|Tablet given orally
45980005|NCT00306683|Drug|DIAZOXIDE|
45980006|NCT00306722|Drug|AQUAVAN® (fospropofol disodium) Injection|
45980007|NCT00337389|Drug|5- Fluorouracil (5-FU)|
45980008|NCT00337389|Drug|bevacizumab (Avastin)|
45980009|NCT00337389|Drug|Leucovorin|
45980010|NCT00337389|Drug|CoFactor (ANX-510)|
45980011|NCT00306761|Device|Dynamic Wheelchair Seating System|
45980012|NCT00306800|Procedure|Photodynamic therapy with methyl aminolevulinate cream|
45456341|NCT04236102|Diagnostic Test|Biocartis Idylla platform - real time PCR detecting EGFR, KRAS and BRAF mutations in liquid based cytology and blood plasma samples|Automated real time PCR mutation analysis - 1. Can the Idylla platform provide a standardised and effective method for detecting EGFR, KRAS and BRAF mutations in blood and liquid based cytology samples for patients with lung and pancreatic cancer. Mutation detection increases the treatment options for patients.
45980013|NCT00340431|Drug|MSP1(42)-FVO & MSP1(42)-3D7|
45980014|NCT00306839|Procedure|standardized Lichtenstein technique|
45980015|NCT00340470|Behavioral|Driver Education|
45980016|NCT00306878|Drug|Abatacept|
45980017|NCT04715724|Other|Positioning and Attachment video-based simulation (telesimulation)|Participants will teach a standardized patient actor (SP) to position and attach the baby doll at the breast of the Lactation Simulation Model in a video-based simulation (telesimulation)
45980018|NCT00306956|Behavioral|offer a pacifier|To offer a pacifier to normal newborn infants at 15 days of age
45456342|NCT04227522|Drug|Rucaparib|A starting dose of 600 mg Rucaparib is taken twice daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.
45672666|NCT05236517|Drug|Semaglutide C Dose 5 (50 mg)|Tablet given orally
46082660|NCT02790398|Behavioral|Transdiagnostic treatment protocol + PA regulation component|Transdiagnostic treatment protocol for emotional disorders + PA regulation components has the purpose of learning and practicing adaptive ways to regulate emotions from a transdiagnostic perspective. This protocol includes the same components but it also includes 4 additional modules focused specifically on the regulation of positive affectivity.
45456343|NCT04227522|Drug|Placebos|Placebo is taken daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.
45456344|NCT04225845|Behavioral|Phone therapy|Weekly phone calls by lay trained personnel to deliver problem solving therapy.
45456345|NCT04225845|Behavioral|Cash transfer|One-time cash transfer of Rs.1000.
45456346|NCT04216953|Drug|Cobimetinib|"Adults: 20mg film coated tablet~Paediatrics:~i) powder for oral suspension containing 250mg of cobimetinib~ii) for pediatric patients ≥12 years-old and with a BW ≥60kg : 20mg film coated tablet same as adults"
45456347|NCT04216953|Drug|Atezolizumab|20-mL glass vial containing 1200 mg of atezolizumab.
45672667|NCT05236517|Drug|Placebo (Semaglutide C)|Tablet given orally
45672668|NCT05236517|Drug|Placebo ( Semaglutide D)|Tablet given orally
45672669|NCT04764110|Dietary Supplement|Cyplexinol|partially hydrolyzed Collagen and its associated proteins including Bone Morphogenetic Proteins (BMPs)
45832140|NCT03589560|Drug|Mineral Trioxide Aggregate|a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
45832141|NCT03589482|Device|Electrical Impedance Tomography|Electrical impedance tomography (EIT) is a new technique that enables real-time visualization of the distribution of ventilation at the bedside. This technique allows clinicians and investigators to immediately determine how applying higher or lower PEEP levels affect stress and strain in the lung. The investigators propose to apply this new technique to test a strategy for finding the optimal level of PEEP that prevents lung injury and improves outcomes in critically ill patients.
45672670|NCT04764110|Other|Placebo|Maltodextrin
45672671|NCT05219669|Drug|Nalmefene Hydrochloride|3mg nasal spray
45832142|NCT03589482|Other|ExPRESS-derived PEEP level|The ExPRESS algorithm is a traditional approach to selecting PEEP based on respiratory mechanics.
45832143|NCT03588390|Drug|BI 1323495|Low strength tablet
45832144|NCT03588390|Drug|BI 1323495|Middle strength tablet
45832145|NCT03588390|Drug|BI 1323495|High strength tablet
45832146|NCT03588390|Drug|Placebo|Placebo to low strength tablet
45832147|NCT03588390|Drug|Placebo|Placebo to middle strength tablet
45980019|NCT02960165|Behavioral|Virtual interface group|First practice on virtual interface in order to evaluate the improvement and its influence on real interface performance (second practice).
45980020|NCT02960165|Behavioral|Real interface group|First practice on real interface in order to evaluate the improvement and its influence on virtual interface performance (second practice).
45980021|NCT00337506|Drug|Dexamethasone|
45980022|NCT00337506|Drug|velcade|
45980023|NCT00307073|Device|Implantable Pulse Generator|
45832148|NCT03588390|Drug|Placebo|Placebo to high strength tablet
45832149|NCT04148898|Drug|Osimertinib|Treatment of LM With osimertinb
45980024|NCT04717856|Other|screening: HCV RNA test and risk factors questionaire|Screening by using a rapid finger prick test for HCV RNA and a questionnaire to assess risk factors.
45980025|NCT04715607|Diagnostic Test|Sequence of testing.|The participants will be tested in the following sequences of sampling technique: (1) nasopharyngeal swab, oropharyngeal swab, and salvia collection OR (2) oropharyngeal swab, salvia collection, and nasopharyngeal swab OR (3) salvia collection, nasopharyngeal swab, and oropharyngeal swab. Only the sequence is different in the different arm, while the sampling technique for each method is the same in all arms.
45980026|NCT00307229|Biological|adenoviral vector encoding rat Her-2/neu|Group 1 1 x 10'7 pfu (2.5 X 10'6 pfu per injection site)(1.6 x 10'9 particles) Group 2 5 x 10'7 pfu (1.25 X 10'7 pfu per injection site)(8.0 x10'9 particles) Group 3 1 x 10'8 pfu (5 x 10'7 pfu per injection site)(1.6 x10'10 particles)
45980027|NCT00337584|Procedure|Pre-surgical screening|
45980028|NCT00307307|Drug|Niacin/simvastatin compared to simvastatin alone at 2 doses|
45980029|NCT00337623|Drug|Prednisolone|
45980030|NCT00337701|Drug|enfuvirtide [Fuzeon]|90mg sc bid by Biojector 2000 NFID for 8 weeks
45980031|NCT00337701|Drug|enfuvirtide [Fuzeon]|90mg sc bid by standard needle and syringe for 4 weeks, followed by 90mg sc bid by Biojector 2000 NFID for 4 weeks.
45980032|NCT00307424|Device|AutoCPAP|
45980033|NCT00307424|Device|FixCPAP|
45980034|NCT00307463|Procedure|strict volume control policy|strict volume control by UF and dietary salt restriction
45672672|NCT04763798|Other|Straight-leg-raise (SLR)|The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For the SLR, the knee was kept in full extension and then, hip flexion was performed until a marked resistance. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.The stretch lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes
45672673|NCT04763798|Other|Passive Knee extension test (PKE)|"The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For the PKE, the hip was kept in 90º flexion and then, knee extension was performed. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.~The stretches lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes"
46082661|NCT02790554|Device|Moyo strap-on|Continous monitoring
45980035|NCT00307463|Procedure|antihypertensive drugs administration|continue antihypertensive medications
45980036|NCT00421005|Drug|fluvastatin|Fluvastatin 80 mg (Arm 1) vs. Fluvastatin 20 mg (Arm 2) increased according with LDL concentrations
45980037|NCT00337740|Procedure|endoscopic variceal banding|
45980038|NCT00337740|Drug|propranolol|
45980039|NCT00307502|Drug|Nevirapine|tablets 200 mg, 400 mg/day
45980040|NCT00307502|Drug|Efavirenz|tablets 600 mg, 600 mg/day
45980041|NCT00307502|Drug|Indinavir/ritonavir|"Indinavir: capsules 400 mg, 1600 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
45980042|NCT00307502|Drug|Nelfinavir|tablets 250 mg, 2500 mg/day
46082662|NCT02790554|Device|Hand-held Doppler|Intermittent monitoring
46082663|NCT00939133|Drug|tretinoin microsphere 0.04% gel|Applied daily to entire face for six months
46082664|NCT00939133|Drug|vehicle gel|Placebo
45456348|NCT04211168|Drug|Toripalimab plus Lenvatinib|"Toripalimab 240mg, every 3 weeks, intravenous infused, day 1, 6 weeks a cycle.~Lenvatinib 8mg (weight<60kg) or 12mg (weight≥60kg), once a day, orally, day 2, 6 weeks a cycle. Dose reduction to 4mg/d or dose termination is allowed according to adverse events.~Number of cycle: until progression or unacceptable toxicity events develop."
45456349|NCT04209673|Other|Multimodal Pain management including TENS unit|Patient receiving multimodal pain management strategies which includes the use of TENS.
45456350|NCT04209673|Other|Multimodal Pain management not including TENS unit|Patient receiving multimodal pain management strategies which does not includes the use of TENS.
45832150|NCT04148898|Drug|Bevacizumab|Treatment of LM With osimertinb combined with bevacizumab
45832151|NCT04148820|Drug|Aspirin, Atorvastatin, Perindopril|Cardiovascular drugs will be administered all together every day at the same time
45980043|NCT00307502|Drug|Saquinavir/ritonavir|"Saquinavir: tablets 500 mg, 2000 mg/day~Ritonavir: tablets 100 mg, 200 mg/day"
45980044|NCT00307502|Drug|Lopinavir/ritonavir|tablets lopinavir 200 mg + ritonavir 50 mg, 800/200 mg/day
45832152|NCT03588312|Procedure|Aortoplasty using autologous pericardial patch|hypoplastic aortic arch repair using a glutaraldehyde treated, autologous pericardial patch.
45832153|NCT03589404|Device|rso2|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
45980045|NCT00307502|Drug|Atazanavir|capsules 200 mg, 400 mg/day
45832154|NCT04148586|Other|Whole Breast Irradiation|Whole Breast Irradiation after CBS in females with DCIS and early stage breast cancer
45832155|NCT03589248|Diagnostic Test|GIF score|assessment by GIF score
45832156|NCT03589248|Diagnostic Test|US score|assessment by ultrasonography score
45832157|NCT03588156|Drug|Benapenem|Dose-escalation For 11 level dose groups A1 ~ A11(each 62.5mg/kg, 125mg/kg, 250mg/kg, 500mg/kg, 1000mg/kg 60min infusion, 1000mg/kg 30min infusion, 2000mg/kg 60 min infusion, 2000mg/kg 30min infusion, 3000mg/kg, 4000mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group
45832158|NCT03588156|Drug|Placebo|Placebo
45980046|NCT00307502|Drug|Atazanavir/ritonavir|"Atazanavir: capsules 150 mg, 300 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
45980047|NCT00307502|Drug|Fos-amprenavir/ritonavir|"Fos-amprenavir: capsules 700 mg, 1400 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
45980048|NCT00307502|Drug|Tipranavir/ ritonavir|"Tipranavir: tablets 250 mg, 1000 mg/day~Ritonavir: capsules 100 mg, 400 mg/day"
45980049|NCT00307502|Drug|Darunavir/ritonavir|"Darunavir: tablets 300 mg, 1200 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
45980050|NCT00307541|Biological|Pneumococcal (vaccine)|
45980051|NCT00307580|Drug|Cathflo Activase (Alteplase)|
45980052|NCT00307619|Drug|topiramate|
45980053|NCT00340938|Procedure|Blood testing|
45980054|NCT00307658|Drug|Intravenous immunoglobulins (human immunoglobulins G)|
45980055|NCT00337974|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
45980056|NCT00337974|Other|Educational DVDs|
45980057|NCT00307697|Procedure|receipt of copy of psychiatic assessment letter|
45980058|NCT00337545|Drug|RAD001|
46082665|NCT02790476|Other|Letters|"The letters will be factual and nonjudgmental, signed by the County Medical Examiner, and would state that a patient they had treated with controlled substances died of an opioid poisoning. The letter will encourage judicious prescribing, and will provide information developed by an advisory group: how to identify and taper unsafe regimens (high dose, polypharmacy, or use of multiple prescribers); how to identify addiction and compassionately refer patients for medication-assisted treatment; and recommendations to avoid bad outcomes (e.g. do not fire your patient for signs of addiction.) The letter would also encourage use of the CURES system before prescribing, as well as co-prescribing of naloxone."
45980059|NCT00307775|Drug|oestradiol|
46082666|NCT00939679|Procedure|Roux-en-Y gastric bypass surgery|Briefly, RYGB is characterized first by creation of a small stomach pouch. The small intestine is then divided approximately 75 cm distal to the ligament of Treitz, creating a proximal intestinal limb that transports the secretions from the stomach remnant, liver, and pancreas, and a 'Roux' limb, that is attached to the new stomach pouch to drain consumed food. The distal end of the proximal limb is then reattached approximately 100 cm distal to the new stomach drainage site, creating a common channel where digestive enzymes mix with ingested food.
45456351|NCT04206397|Behavioral|affective touch|Various types of touch such as brushing, pressure, and tapping, as well as heat pain
45980060|NCT04715919|Diagnostic Test|Chest Computed Tomography|Evaluation of Lung Structure
45980061|NCT04715919|Diagnostic Test|Pulmonary Function Tests|Respiratory Capacity
45980062|NCT04715919|Other|Six Minutes Walk Test|Exercise Capacity
45980063|NCT04715919|Other|Quality of Life|Physical disability assessment tool
45980064|NCT00307814|Drug|Epoetin Alfa|
45980065|NCT00341055|Drug|Epoetin alfa|
45980066|NCT00307853|Drug|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
45980067|NCT00307853|Other|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
45456352|NCT04205942|Device|Argon Plasma Jet|Cold Plasma (CP) therapy is applied in the first week of treatment on a daily schedule, in the second week CP is applied every second day. In total, 8 applications are performed with a one day schedule variance.
45456353|NCT04205942|Device|Placebo|Sham Cold Plasma (sham-CP) (switched off Electric field, no plasma production, just gas) therapy is applied in the first week of treatment on a daily schedule, in the second week sham-CP is applied every second day. In total, 8 applications are performed with a one day schedule variance.
45456354|NCT04196257|Drug|BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)|Dose escalation of BP1001-A intravenously (IV), twice weekly for 4 weeks (28-day cycle) for 6 cycles.
45456355|NCT04196257|Drug|BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel|Dose expansion of BP1001-A IV twice weekly (Maximum tolerated dose or Maximum admistered dose) plus paclitaxel IV weekly for 4 weeks (28-day cycle) for 6 cycles.
45456356|NCT04195438|Procedure|CO Testing Pre/Post Hepatic Resection|Monitor CO in exhaled air of patients before liver resection, at 4 hours and 24 hours after PH
45672674|NCT04763798|Other|Maximum hip flexion (MHF)|"The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For MHF, a maximal hip flexion was performed and then, knee extension was applied. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.~The stretches lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes"
45832159|NCT03588000|Other|Strengthen self-monitoring of blood glucose|Strengthen self-monitoring of blood glucose by Internet mobile terminal（APP）.
45832160|NCT03941808|Drug|Glisodin tablet|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
45832161|NCT03941808|Drug|Placebo tablet|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
45980068|NCT00307853|Other|Placebo|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
46082667|NCT00939679|Dietary Supplement|low calorie diet (1,000 kcal/day)|"Patients will consume a daily diet composed of:~4 powder diet portions (Cambridge Diets, UK)~plain yogurt (100-125g)~skim milk (1L)~a limited variety of vegetables~The diet will be consumed by both groups for a 10 week period."
46082668|NCT02799446|Drug|Reslizumab|Reslizumab 3mg/kg intravenous (IV)
46082669|NCT02799446|Drug|Placebo|Matching Placebo intravenous (IV)
46082670|NCT05477186|Biological|CV0501 (3 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
45832162|NCT03587610|Biological|Remedial vaccination|"if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination."
45832163|NCT03589092|Genetic|Next generation sequencing (NGS)|NGS Panel, Whole exome/genome sequencing
45980069|NCT00338052|Drug|Norethindrone 1 mg / ethinyl estradiol 20 mcg|
45980070|NCT00307892|Drug|Traumeel S: intra-operative irrigation + oral ingestion|homeopathic remedy
45980071|NCT00307892|Drug|Placebo|placebo remedy
45980072|NCT00338091|Drug|Benazepril|
45980073|NCT00338091|Drug|Losartan|
45980074|NCT00307970|Drug|HFA FP MDI|
45980075|NCT00307970|Device|conventional chamber/mask; anti-static chamber/mask|
46082671|NCT05477186|Biological|CV0501 (6 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
46082672|NCT05477186|Biological|CV0501 (12 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
46082673|NCT05477186|Biological|CV0501 (25 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
45832164|NCT03941730|Procedure|Biopsy|Undergo tissue biopsy
46082674|NCT05477186|Biological|CV0501 (50 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
46082675|NCT05477186|Biological|CV0501 (75 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
45832165|NCT03941730|Procedure|Computed Tomography|Undergo CT
45980076|NCT00308009|Procedure|Vaginal Repair for prolapse, TVT procedure|"TVT at the time of Vaginal Repair~TVT 3 months after Vaginal Repair"
46082676|NCT05477186|Biological|CV0501 (100 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
46082677|NCT05477186|Biological|CV0501 (150 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
46082678|NCT05477186|Biological|CV0501 (200 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
46082679|NCT02794532|Procedure|High-flow nasal cannula|Oxygenation will be done via a high-flow nasal cannula
45456357|NCT04195438|Diagnostic Test|ABG Testing Pre/Post Hepatic Resection|Monitor carboxyhemoglobin(COHb) in the arterial blood gas of patients before liver resection at 4 hours and 24 hours after PH
45456358|NCT04195438|Diagnostic Test|CT Evaluations|Analyze the relationship between CO production and the extent of hepatic resection assessed by computed scans liver volumetric study at one and three months after PH, size and weight of the resected specimen and operative report
45456359|NCT04193553|Drug|Lenvatinib|"Lenvatinib will be administered continuously but patient's follow-up visits will be scheduled monthly.~The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for dose reductions will be respected according to BI Lenvatinib.~If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.~Study treatments will be continued until a treatment discontinuation criteria is met."
45458699|NCT01238887|Dietary Supplement|Microcrystalline Cellulose placebo pill|Participants will be given gelatin capsules containing the placebo (microcrystaline cellulose) and will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. This will equal 3000 mg/day of the placebo contents. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
45672675|NCT04837859|Drug|Tislelizumab|age 18-60: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT if PET positive resudues after the end of Tis or Tis-AVD age 60+: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT for all patients
45672676|NCT04763252|Other|Spectrum Therapeutics cannabis products|"For the purposes of this study, subjects enrolled will have been authorized Spectrum Therapeutics (ST) products that are commercially available in Canada. The full repertoire of Spectrum Therapeutics products are outlined on the website https://www.spectrumtherapeutics.com/canada/en/patients/products. It encompasses six colors (order from Red to Yellow follows the descending THC:CBD ratio), and five types of formulations: soft gels, spray, oil, flowers and vapes). Refer to webpage for the most up to date products available per country https://www.spectrumtherapeutics.com/canada/en/patients/products."
45832166|NCT03941730|Procedure|Magnetic Resonance Imaging|Undergo MRI
45832167|NCT03941730|Procedure|Positron Emission Tomography|Undergo PET
45832168|NCT03941730|Biological|Therapeutic Estradiol|Given PO
45832169|NCT03581448|Behavioral|Sensory Restoration During Prosthesis Control|Human subjects who use a robotic arm/hand interface will experience variable sensations of touch over time.
45980077|NCT00308009|Procedure|TVT and Prolapse surgery|"TVT at the time of Prolapse surgery~TVT 3 months after Prolapse Surgery"
45980078|NCT00308048|Drug|Pegylated Interferon alfa 2b and ribavirin|
45980079|NCT00338130|Drug|AZD6244|Oral liquid or Capsule
45980080|NCT00338130|Drug|Temozolomide|oral
45980081|NCT00308126|Drug|Hydroxyethyl Starch 130/0.4 (Voluven)|
45980082|NCT00308165|Procedure|Convection-Enhanced Delivery|microinfusion pumps to deliver chemotherapy directly into brain tumors
45980083|NCT00308165|Drug|Topotecan|chemotherapeutic drug for the treatment of brain tumors
45980084|NCT00338208|Behavioral|Training in the Use of Low Vision Devices|
45980085|NCT00418652|Device|No TMS intervention|"In the no TMS condition, no simulation was given and no coil placed near participants' heads."
46082680|NCT02794376|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|
46082681|NCT02794376|Behavioral|Waiting Period|
46082682|NCT00564889|Drug|cyclophosphamide|300 mg/m^2 days 1, 8 & 15 of a 28 day cycle taken orally with food
45980086|NCT00418652|Device|TMS over the PO3 EEG site|10Hz TMS over the dorsal stream (PO3 EEG site)
45980087|NCT00418652|Device|TMS over the vertex|10Hz TMS for over vertex.
45980088|NCT00418769|Drug|Nilotinib|
45980089|NCT00308204|Drug|Raptiva|injection
45980090|NCT00425334|Drug|Hemospan (MP4OX)|250 mL or 500 mL Hemospan (MP4OX)
45980091|NCT00425334|Drug|Ringer's lactate|250 mL or 500 mL Ringer's lactate USP
45980092|NCT00308243|Drug|Sodium Pyruvate in 0.9% Sodium Chloride Solution|
45980093|NCT00338247|Drug|lapatinib + capecitabine|Experimental
45980094|NCT00308321|Drug|long term tapering of prednisolone|60mg/m2/day (0-4 weeks); 60mg/m2 alternate days (5-6 weeks); 50mg/m2 alternate days (week 7-8); 40mg/m2 alternate days (week 9-10); 30mg/m2 alternate days (week 11-12); 20mg/m2 alternate days (week 13-14); 10mg/m2 alternate days (week 15-16)
45980095|NCT00308321|Drug|standard prednisolone treatment|60mg/m2/day week 0-4; 40mg/m2 on alternate days week 5-8
45980096|NCT00308360|Drug|Risperidone, divalproex|
46082683|NCT00564889|Drug|dexamethasone|40 mg weekly taken orally
45980097|NCT00308399|Drug|Itopride|
45980098|NCT04715802|Procedure|Immediate breast reconstruction with implant|Because most fillers are under the mammary gland, it is better to place the prosthesis into the opening under the pectoralis major muscle, which avoids contact between the prosthesis and the residual hydrogel to reduce the chance of infection. If postoperative complications disappear and imaging shows no filler remnants after more than 3-month follow-up, secondary breast augmentation can be planned. For placement of the prosthesis, the plane under the pectoralis major is preferred, which avoids prosthesis contact with the residual hydrogel to thus reduce the chance of infection.
45980099|NCT04715802|Procedure|delayed breast reconstruction with implant|The first stage included maximal gel removal and purulent tissue debridement, if necessary. Thereafter, patients were invited for a clinical follow-up and discussion about DBR 3 months later. The latter was offered as a second stage in those opting for it.
45980100|NCT04715802|Procedure|delayed breast reconstruction with autologous fat transplantation|Because fat injection after PAAG removal has a high infection risk, it is recommended to be conducted after 3-6 months of follow-up. The advantage of autologous fat transplantation is its ability to repair a variety of breast shape deformities caused by PAAG removal. Fat injections may need to be repeated several times. The interval between injections should be at least 3 months. Usually, the amount of transplanted fat is 150-200 mL/side. A multilayer and multi-tunnel injection method is commonly used.
45980101|NCT00341250|Drug|AMA1-C1/Alhydrogel Malaria Vaccine|
45832170|NCT03941496|Drug|Azacitidine Injection|"In Phase Ib dose escalation stage, 24 participants will receive AZA subcutaenously once a day for 5 days as follows:~5 mg/m^2~15 mg/m^2~30 mg/m^2~50 mg/m^2~75 mg/m^2~Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 36 subjects will receive AZA treatment in total (Phase Ib/IIa). Subjects in Phase II will receive a dose that induces two of the three following:~a decrease DNA methylation levels in genes previously identified to be persistently hyper-methylated despite successful anti-TB therapy~an increase in TNF and IFN-γ signaling pathways~an increase in ex vivo mycobacterial growth inhibition assay"
45980102|NCT00308438|Drug|Teduglutide (ALX-0600)|0.1 mg/kg injected subcutaneously daily
45980103|NCT00338325|Behavioral|Reading program|Reading of children's story/picture books preoperatively
45980104|NCT00308477|Drug|dexamethasone|
45980105|NCT00308594|Drug|Dexamethasone|
45980106|NCT00341328|Biological|Intradermal injection of Mycobacterium w|Mw Vaccine is given as intradermal administration. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
45980107|NCT00338364|Behavioral|PAT|Coping and Distraction Intervention
45980108|NCT00308789|Procedure|Biphasic Infant flow NCPAP|Biphasic Nasal continuous positive airway pressure
45980109|NCT00308789|Procedure|CPAP|Continuous positive airway pressure
45980110|NCT00308867|Procedure|Photodynamic Therapy|
45980111|NCT00308867|Procedure|Cryosurgery|
45980112|NCT00341445|Behavioral|Effect of Cockroach Allergen|
45980113|NCT00308906|Drug|aminoglycoside|Aminoglycosides will be administered and monitored as part of the routine standard of care for the subject.
46082684|NCT00564889|Drug|lenalidomide|15 mg daily days 1-21 of a 28 day cycle taken orally with food
45832171|NCT03895476|Diagnostic Test|palatal wound will not cover|after harvesting the graft from the palate the wound will be left uncovered with secondary healing intention
45832172|NCT03895476|Diagnostic Test|palatal wound covered with platelet rich fibrin|after harvesting the graft from the palate the platelet rich fibrin will be sutured to covered the harvested site
46082685|NCT02790164|Drug|Esmeron|Neuromuscular Blockade
46082686|NCT02790164|Drug|Saline|Normal Saline
46082687|NCT02791633|Other|Questionnaire|Quality of recovery and quality of recovery follow up questionnaires
46082688|NCT05417750|Drug|TIL therapy|A tumor sample is resected from each participant and cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL followed sintilimab.
45832173|NCT03895476|Diagnostic Test|palatal wound covered with a collagen sponge and cyanoacrylate|after harvesting the graft from the palate a collagen sponge will be sealed with cyanoacrylate in position
45832174|NCT03895476|Diagnostic Test|palatal wound covered with a stent|after harvesting the graft from the palate a stent that will be prepared for the patient, will be placed on to cover the wound
45832175|NCT03940560|Device|Duramesh Suturable Mesh|Use of Duramesh Suturable Mesh for internal load bearing closures
45980114|NCT00338403|Procedure|Continuous positive airway pressure (CPAP) at -5, 0, 5 and 10 cm of water|
45980115|NCT00308945|Drug|travoprost 0.004% (drug)|local drop application
45980116|NCT00308945|Drug|latanoprost 0.005% (drug)|local drop application
46082689|NCT00939757|Drug|mirabegron|oral tablet
46082690|NCT05415644|Drug|hrx0701 tablets、Metformin hydrochloride tablets、Retagliptin phosphate tablets|"High-specification group: subject preparation: HRX0701 (50 mg/1000 mg) 1 tablet (to be taken after a meal); Reference preparation: 1 tablet of retagliptin phosphate (50 mg), 2 tablets of metformin hydrochloride (Glucophage®) (500 mg), taken twice after meals.~Low Specification Group:~Preparation: HRX0701 (50 mg/850 mg) 1 tablet (taken after a meal); Reference: 1 tablet of retagliptin phosphate (50 mg), 1 tablet of metformin hydrochloride (Glucophage®) (850 mg), taken twice after meals."
45672677|NCT04392167|Device|a/LCI-OCT imaging probe|a/LCI and OCT imaging measurements of several locations in the esophagus
45672678|NCT04392167|Procedure|esophageal biopsy|biopsies of esophageal tissue imaged by a/LCI-OCT probe
45672679|NCT05369039|Drug|Roflumilust|A selective phosphodiesterase 4 Inhibitor
45980117|NCT00338442|Drug|VariZIG™|Biological / Vaccine
45980118|NCT00338481|Drug|Morphine p.o.|"Morphine p.o. in red morphine drops calculated as 1/12 of the 24 hours opioid consumption converted to morphine p.o., max. 24 mg morphine p.o.and isotonic sodium chloride s.c."
45980119|NCT00338481|Drug|Morphine s.c.|"False red morphine drops without morphine p.o. and 60% of 1/12 of the 24 hours opioid consumption converted to morphine p.o. but given s.c., max. 14,4 mg"
45980120|NCT00309062|Biological|Recombinant birch pollen|
45980121|NCT00309101|Drug|tacrolimus|Oral
45980122|NCT00309218|Drug|methylprednisolone|withdrawal of methylprednisolone in arm A and continuous Steroid Treatment in arm B
45980123|NCT00309296|Behavioral|smoking cessation|This was a randomized controlled trial to compare long-term smoking cessation outcomes between Longitudinal Care (LC) and Usual Care (UC) treatment groups. The LC group received smoking cessation treatment (combined behavioral and pharmacological therapies) for one-year period. This treatment recommended repeat quit attempts or smoking reduction for those who failed to quit after the initial attempt. The UC group received evidence-based treatment that lasted 8 weeks.
45980124|NCT00338637|Device|APOS shoe kit|
45980125|NCT00309335|Drug|Phentolamine Mesylate (NV-101)|
45980126|NCT00341640|Procedure|Blood testing|
45980127|NCT00309374|Drug|LPS 2ng/kg intravenous bolus|
45980128|NCT00309374|Drug|Simvastatin 80mg; administered daily p.o. over 5 days|
45980129|NCT00309374|Drug|Rosuvastatin 40mg; administered daily p.o. over 5 days|
45980130|NCT00309413|Drug|Placebo/Cannabidiol|600 mg/day, oral, capsules, 2 weeks, than cross-over
45980131|NCT00309413|Drug|Cannabidiol/Placebo|600 mg/day, oral, capsules, 2 weeks, than cross-over
45980132|NCT04715880|Procedure|Paravertebral block/Intercostal Block (PVB/ICB) group|A paravertebral catheter will be placed by surgeon into pleural cavity and will not be loaded with bolus dose. At the end of surgery the (consultant anaesthesiologist) will perform intrathoracic unilateral intercostal nerve block two level above and two level below and at site of incision with 4 ml per level of 0.25 % bupivacaine followed by continuous infusion with 0.25 % bupivacaine at 6-8 ml/hour through catheter placed in paravertebral space.
45832176|NCT04406064|Biological|Viral Specific T-cells (VSTs)|VSTs will be infused into study participants who have evidence of SARS-CoV-2 infection.
45980133|NCT04715880|Procedure|Paravertebral Block (PVB) group|A paravertebral catheter will be placed by the surgeon before closure of thoracotomy wound. The catheter will be introduced percutaneously through 18 gauge needle into the pleural cavity. The tip of catheter will be loaded by anaesthesiologist with 0.25 % isobaric bupivacaine with 20 ml followed by continuous infusion with bupivacaine 0.25 % at 6-8 ml per hour
45980134|NCT00309491|Drug|Tamoxifen alone|2 x 20 mg tamoxifen daily, start of therapy within 4 weeks after surgery; therapy duration 5 years
45980135|NCT00309491|Drug|Tamoxifen + Aminoglutethimide|"2 x 20 mg tamoxifen daily (5 years) plus Aminoglutethimide daily (first 2 years)~1st therapy week:125mg/-/125mg Aminoglutethimide daily~2nd therapy week: 125mg/-/250mg Aminoglutethimid daily~as of 3rd therapy week: 250mg/-/250mg Aminoglutethimid daily"
45980136|NCT02960048|Device|Stabilizing splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks. This area will create the eccentric guidance."
45980137|NCT02960048|Device|Anterior repositioning splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position.~Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe."
45456360|NCT04193553|Drug|Placebo|"Placebo will be administered continuously but patient's follow-up visits will be scheduled monthly.~The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for placebo dose reductions are the same as for Lenvatinib. If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.~Study treatments will be continued until a treatment discontinuation criteria is met.~In case disease progression, patients in control arm could switch in the Lenvatinib + BSC arm."
45672680|NCT05369039|Drug|Prednisolone|Systemic corticosteroid
45672681|NCT04851509|Procedure|Dynamic Rotational Locking|Performed, as per the Synthes technique guide, using the 5mm hex flexible set screwdriver and then loosening the set screw by one-half turn of the screwdriver.
45832177|NCT04405752|Device|12-mm metallic biliary stent|Metallic biliary stent, covered or uncovered,KEBOMED HILZO 12mm in diameter (length 4 or 6 cm).
45832178|NCT04405752|Device|10-mm metallic biliary stent|Biliary, metallic, covered or uncovered stent, COOK EVOLUTION 10mm in diameter (length 4 or 6 cm)
45832179|NCT03894150|Drug|F0002-ADC|Every 21 days for 1 cycle, continue treatment until a maximum 16 cycles. Dose Escalating: 0.3 - 4.8 mg/kg
45980138|NCT00309530|Drug|5-fluorouracil, levamisol, interferon|
45980139|NCT00309569|Drug|Cyclophosphamide|Cyclophosphamide 600mg/m2
45980140|NCT00309569|Drug|Methotrexate|Methotrexate 40mg/m2
45980141|NCT00309569|Drug|Fluorouracil|Fluorouracil 600mg/m2
45980142|NCT00309569|Drug|Epirubicin|Epirubucin 60mg/m2 (only node-positive patients)
45980143|NCT00309569|Other|Surgery|Surgery
45980144|NCT00338715|Device|PVI with Medtronic's Cardioblate BP2 radiofrequency catheter|Ablation of the right and left pulmonary veins
45832180|NCT05702892|Diagnostic Test|ELISA|ELISA(enzyme-linked immunosorbent assay)
45980145|NCT00309647|Biological|Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine|2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
45980146|NCT00309647|Biological|Influenza Monovalent Whole virus (H5N1)|2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
45980147|NCT00309686|Drug|Paliperidone ER|
45980148|NCT00309725|Drug|galantamine|
45980149|NCT00309764|Behavioral|Telemedicine|
45980150|NCT00338754|Drug|Human anti-TNF monoclonal antibody adalimumab/ up to 24 weeks|
45980151|NCT00309803|Device|FiberNet Embolic Protection Device|
45980152|NCT00338793|Drug|prednisolone|
45980153|NCT00418847|Drug|miglustat|Target dose of 320 mg/m^2/day (divided in 3 doses) will be based on the Body Surface Area (BSA). For children with a BSA > 1.3, 200 mg TID will be administered. For children with a BSA of 0.8-1.3, 100 mg TID will be administered.
45980154|NCT00309881|Biological|rituximab|
45980155|NCT00309881|Drug|cyclophosphamide|
45980156|NCT00309881|Drug|doxorubicin hydrochloride|
45980157|NCT00309881|Drug|prednisone|
45980158|NCT00309881|Drug|vincristine sulfate|
45980159|NCT00309920|Biological|darbepoetin alfa|
45980160|NCT00309920|Drug|cyclophosphamide|
45980161|NCT00309920|Drug|docetaxel|
45980162|NCT00309920|Drug|doxorubicin hydrochloride|
45980163|NCT00309920|Drug|epirubicin hydrochloride|
46082691|NCT05415644|Drug|hrx0701 tablets|"High specification group HRX0701 (FDC) tablets (50 mg / 1000 mg) for a total of 2 tablets (take 1 tablet after meals or on an empty stomach).~Low-spec group HRX0701 (FDC) tablets (50 mg / 850 mg) for a total of 2 tablets (take 1 tablet after meals or on an empty stomach)."
46082692|NCT00939835|Drug|Citalopram Hydrobromide|
46082693|NCT02690012|Other|Magnesium Oxide|Magnesium Oxide
45672682|NCT04851509|Procedure|Static Locking|Performed by using the torque-limiting set screwdriver and locking the set screw down onto the helical screw to prevent dynamic sliding of the helical screw within the nail.
45672683|NCT04373369|Drug|Vorolanib|Vorolanib is administered orally at a dose of 200 mg on Days 1 through 21 of each 21-day cycle.
45832181|NCT03255564|Other|feacal calprotectin concentration|"Intervention - To monitor the impact of cardiac surgery and enteral feeding on gut inflammation, biomarkers (faecal Calprotectin) will be measured 24-48hrs after surgery and 24-48hrs after enteral feed commences. Additionally, infants that are diagnosed with NEC will have calprotectin levels measured.~Faecal calprotectin - 50-100mg of faeces will be collected in plastic containers from infant's nappies. Samples will then be homogenised by shaking, and supernatants and then sent to laboratories for immediate analysis."
45832182|NCT04148664|Procedure|Catheter ablation with Standard RF ablation settings|"Standard RF ablation settings (n=30):~Maximum 35W for 20-40 seconds, per operator standard."
45980164|NCT00309920|Drug|fluorouracil|
45980165|NCT00309998|Biological|bevacizumab|
45980166|NCT00309998|Drug|vinorelbine tartrate|
45980167|NCT00338832|Behavioral|Physically Ready for Invigorating Movement Every Day (PRIME)|The PRIME program is a lifestyle intervention focused on increasing physical activity. The intervention is cognitive/behaviorally based, 24-weeks in length, and a lifestyle PA intervention known to be effective in the general population of adults. The program has been modified based on theory and empirical findings about this special subgroup. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks. PRIME sessions will focus on learning about PA, setting PA-related goals, and assessing short- and long-term goals. Goals may include early-stage process-oriented goals, such as reading about PA benefits or finding a walking partner.
45980168|NCT00338832|Behavioral|Program for Activity, Leisure Skills, and Socialization (PALSS)|PALSS sessions will focus on motivating participants to engage in leisure and social activity. Sessions will include interactive, structured activity that will be led by a therapist, as well as unstructured leisure activities, such as board games, cards, general socialization, and viewing a travel video. Social and communication skills will not be explicitly taught or practiced. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks.
45980169|NCT00338871|Procedure|home exercise|
45672684|NCT04373369|Drug|Atezolizumab|Atezolizumab is administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.
45980170|NCT00310115|Behavioral|Smoking Prevention Usual Care|Usual care of self-help materials and advice for staying cigarette free
45980171|NCT00310115|Behavioral|Counseling Intervention|6 x 30 minute counseling sessions over the telephone
45980172|NCT00310115|Behavioral|Counseling Intervention|2 in-person counseling sessions
45672685|NCT05181761|Other|Gel Polish|One hand of a subject with receive nail polish to compare bacterial growth between hands with gel nail polish to those without.
45980173|NCT04715217|Biological|CD19-CD22 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
45980174|NCT00310154|Drug|docetaxel|
45672686|NCT04310189|Procedure|Biopsy|All patients will have a blood sample and 2 skin biopsies (2 mm diameter) in lesional and non lesional area
45672687|NCT04285853|Drug|Oxycodone|5 mg oxycodone pills every 4-6 hrs if pain level 7 or higher on Numeric rating scale 1-10
45672688|NCT04285853|Drug|Placebo oral tablet|"Placebo tablets (both trial and rescue) will be matched to size, shape, color, and texture of oxycodone tablets."
45672689|NCT04791059|Drug|S-ketamine|S-ketamine 50 mg is included in the mixture for patient-controlled analgesia.
45672690|NCT04791059|Drug|Dexmedetomidine|Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.
45672691|NCT04791059|Drug|Sufentanil|Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
45672692|NCT05405855|Behavioral|eLIFEwithIBD|eLIFEwithIBD program is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients.
45672693|NCT02189252|Drug|Epanova|
45672694|NCT02189252|Drug|Lovaza|
45672695|NCT05369117|Behavioral|indocyanine green labeled fluorescent laparoscopy|indocyanine green fluorescence labeling was performed under gastroscope before surgery and internal jugular vein puncture was performed routinely for better fluid replenishment after surgery
45980175|NCT00310154|Drug|gefitinib|
45980176|NCT00310154|Other|laboratory biomarker analysis|
45980177|NCT00310154|Radiation|radiation therapy|
45980178|NCT00338910|Drug|Budesonide 2 single doses, Metronidazole multiple-dose|Budesonide 3 mg single oral dose on Day 1 and Day 9. Metronidazole 750 mg b.i.d. from Day 2 until Day 8, Metronidazole 750 mg once daily (in the morning) on Day 9.
45980179|NCT00310232|Drug|Epoetin Alfa|
46082694|NCT02690012|Other|Magnesium Citrate|Magnesium Citrate
46082695|NCT00939913|Drug|intravenous NAC|intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)
46082696|NCT00939913|Drug|Placebo|Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.
45672696|NCT04766099|Other|Childbirth Educational Video|Educational video describing techniques for pushing
45672697|NCT05399069|Drug|VGR-R01|Gene Replacement Therapy
45980180|NCT00418730|Drug|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days
45980181|NCT00310271|Biological|pPJV7630 with pPJV2012 administered by PMED|
45980182|NCT00310349|Biological|23 valent pneumococcal polysaccharide vaccine|
45980183|NCT00342108|Behavioral|cross-modal sensory stimulation|comparison of participant response to unimodal visual stimulation and to bimodal sensory stimulation
45980184|NCT00310505|Drug|Amphotericin B deoxycholate given as daily administration|
45980185|NCT00310544|Drug|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight
45672698|NCT05398913|Drug|Rimonabant|Rimonabant
45672699|NCT05154305|Behavioral|multidisciplinary intervention|"individually adjusted physical program consisting of strength and endurance training > 3 times a week, 2 times guided by a physical therapist at the University Hospital or at a private practice, and ones a week by themselves at home recorded by an activity tracker. Follow-up is foreseen on monthly basis.~multidisciplinary coaching (discipline depending on personal needs of patient) on a monthly basis. These coaching sessions could be in small groups or individual."
45672700|NCT04260347|Drug|Alteplase|Intravenous injection
45672701|NCT04256837|Device|Transcutaneous electrical auricular vagus nerve stimulation (VNS)|Electrical auricular stimulation is accomplished using a Roscoe Medical TENS 7000 that delivers a programmable electrical current density, frequency, and pulse width. The TENS 7000 will be connected to ear clip (or hand held) electrodes to transcutaneously stimulate the cymba conchae of the ear to activate the auricular branch of the vagus nerve (diagram above), also known as Arnold's nerve, which provides sensory innervation to the skin surrounding the ear canal. Through a neural reflex arc, activation of this sensory nerve sends a neural signal to the brainstem that then activates the efferent vagus nerve through the nucleus of the solitary tract (NTS). This is a well-described and clinically accepted neuromodulatory pathway, as transcutaneous electrical auricular stimulation has been studied to treat seizures, similarly to how invasive electrical vagus nerve stimulation has been approved by the FDA for the past two decades for the same indication.
45832183|NCT04148664|Procedure|Catheter ablation with High Power Short Duration RF ablation settings|"High power short duration RF (n=30):~Maximum 50 Watts for 5-15 seconds, per operator standard."
45980186|NCT00310544|Drug|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period 1: Magnevist 0.2 mmol/kg body weightperiod 2: Magnevist 0.1 mmol/kg body weight
45980187|NCT00339066|Drug|Sertraline|
45980188|NCT00310583|Drug|Pregabalin|
45980189|NCT00310622|Device|HyperQ Signal recording|
45672702|NCT05396729|Device|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 30 minutes, twice a day for 3 days.
45980190|NCT00310661|Drug|Sarizotan|The dose of sariztan HCI for each patient in the drug arm will be given 2mg b.i.d. orally during the first 4 weeks of treatment. If efficacy is inadequate and there are no safety concerns, the option to raise the dose to 5mg b.i.d is given. After 8 weeks of treatment, the option to raise the dose to 7mg bid is given. Dose may remain the same or may be decreased again to the previous dose.
45980191|NCT00310661|Other|Placebo|Placebo for each patient randomized to the placebo arm will be given placebo (oral, twice daily) in a pill form for 12 weeks
45980192|NCT00421044|Drug|Patupilone/EPO906|
45672703|NCT05393219|Other|Cardiac biofeedback|6 minutes of relaxing breathing exercise coupled with heart rate variability biofeedback guided on emWave Pro software on a computer just before entering the examination circuit
45832184|NCT04765410|Diagnostic Test|EUS FNA (endoscopic ultrasound fine needle aspiration)|Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will receive EUS FNA (endoscopic ultrasound fine needle aspiration).
45832185|NCT04765254|Other|no intervention as it is an observational study|both groups will be monitored for the disease progress or deterioration and mortality rate
45832186|NCT03581058|Drug|Cannabis|Participants will be assigned to consume one of the cannabis strains and will complete testing immediately after consumption.
45832187|NCT03580980|Drug|Paracetamol and ketamine|intravenous paracetamol and ketamine followed by ketorolac
45832188|NCT03580980|Procedure|Caudal levobupivacaine|an epidural injection of morphine and levobupivacaine through the caudal space
45832189|NCT03580980|Drug|Morphine|patient controlled analgesia by morphine
45832190|NCT04405440|Behavioral|Behavioral avoidance task|Behavioral task able to measure avoidance actions, US-expectancy, and reward-related indexes in different learning times
45980193|NCT00310700|Biological|Meningococcal C conjugate vaccine|
45980194|NCT04715256|Behavioral|Cognitive assessment of obsessive-compulsive and impulsive behaviours|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (attention, impulsivity) and a clinical assessment (impulsive behaviour, autistic traits,obsessive-compulsive behaviour).
45672704|NCT05393219|Other|Mindfulness|6 minutes of a guided video tape made for the study that inspires mindfulness like meditation associated just before entering the examination circuit.
45672705|NCT05393219|Other|Resources mobilization|6 minutes of a guided video tape that purpose to mobilize inner resources and strength of the student just before entering the examination circuit.
45980195|NCT04715256|Genetic|Genomic analysis|A genome-wide association study (GWAS) will be performed for all subjects to search for associations between KCNQ1 mutations, insulin regulation and psychological features.
45980196|NCT04715256|Diagnostic Test|Glucoregulation assessment|Fasted glycaemia and insulinaemia, glycated haemoglobin (HbA1c) and glycaemia following an oral glucose challenge test will be measured in all study subjects.
45980197|NCT00425217|Drug|Rituximab|
45980198|NCT00310778|Drug|high sodium diet|high sodium diet
45980199|NCT00310778|Drug|low sodium diet|low sodium diet
45980200|NCT00310778|Drug|ramipril 10 mg|ramipril 10 mg
45980201|NCT00310778|Drug|valsartan 160 mg|valsartan 160 mg
45980202|NCT00310778|Drug|candesartan 8 mg|candesartan 8 mg
45980203|NCT00310778|Drug|atenolol 50 mg|atenolol 50 mg
45980204|NCT00421083|Drug|tadalafil|
45980205|NCT00310895|Drug|Imetelstat Sodium (GRN163L)|Dose increase by 25% if tolerated infused over 2 hours
45980206|NCT00425256|Drug|Bremelanotide|
45980207|NCT00310934|Drug|methadone|
45980208|NCT00310934|Drug|buprenorphine / methadone sequence|
45980209|NCT00310934|Behavioral|Relapse prevention|
45980210|NCT00310934|Behavioral|Contingency management|
45672706|NCT05393219|Other|Control|6 minutes of standardized neutral video on general topics that generates no modification of affects just before entering the examination circuit.
45672707|NCT05118503|Behavioral|Customized education|Half of subjects will receive access to a customized app that will include brief educational videos that have been selected for each patient based on their medical history. These videos will address stroke etiology, underlying risk factors, and stroke prevention medications.
45672708|NCT05118503|Behavioral|Standard of care discharge education|Half of subjects will be randomized to receive typical discharge education, per the institutional guidelines for standard of care education for stroke patients.
45672709|NCT04738799|Behavioral|Carbohydrate-Last Meal Sequence|Carbohydrates consumed last during mealtimes for 6 days
45672710|NCT04738799|Behavioral|Carbohydrate-First Meal Sequence|Carbohydrates consumed first during mealtimes for 6 days
45832191|NCT02985060|Device|Arctic Sun|"Induction phase: At a temperature of 4℃, a saline 500 mL or 1 L is intravenously administered.~Arctic sun (surface freezing equipment) Target temperature: 35±0.5℃ Within 12 hours of the onset of symptoms, the therapeutic hypothermia is performed~Maintenance phase:The use of bedside shivering assessment scale (BSAS) The use of Columbia anti-shivering protocol,Maintenance period: 48 hours~Recovery phase:Rewarming velocity: 0.05~0.1℃ (within 30 hours)"
45832192|NCT02985060|Other|Standard treatment|"All the patients receive standard treatment modalities for stroke, which are applicable to the international treatment guidelines.~In all the patients, neurological assessments and NIHSS scoring are performed on a daily basis for 4 days with the help of board-certified nurses or specialists in stroke.~Blood pressure, respiratory rate and heart rate are measured at least once at a 4-hour interval for 4 days.~Using an esophageal thermometer, the central temperature is measured at a 2-hour interval for 5 days."
45832193|NCT02985060|Drug|Saline|
45832194|NCT03587454|Diagnostic Test|Teleglaucoma|Subjects are evaluated through a teleglaucoma protocol then by physical presence in a glaucoma clinic
45832195|NCT03587376|Drug|Atabecestat|Blood samples will be collected from participants previously treated with atabecestat.
45980211|NCT00421122|Drug|budesonide/formoterol (Symbicort)|inhalation therapy
45980212|NCT00421122|Drug|budesonide (Pulmicort)|inhalation
45980213|NCT00421122|Drug|terbutaline sulfate (Bricasol)|inhalation therapy
45980214|NCT00310973|Behavioral|Social Network Intervention|
45980215|NCT00425295|Behavioral|Human Simulation Training|Fellows will undergo Human Simulation Training (HST) composed of one 1 hour session of high-fidelity simulation of crisis scenarios requiring management of critical care skills, including triage, Advanced Cardiac Life Support (ACLS), team management, and difficult airway management.
45980216|NCT00311012|Drug|Aliskiren|
45980217|NCT00421161|Drug|olive oil and omega 3 in a combined cream|
45980218|NCT00311051|Drug|ramatroban|
45980219|NCT00311051|Drug|montelukast|
45980220|NCT00311129|Drug|Fludarabine Phosphate (Fludara)|Injection of rituximab on Day 1 along with 5-consecutive day oral dosing of fludarabine phosphate from Day 1 to Day 5, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
45980221|NCT00311129|Drug|Rituximab|Injection of rituximab on Day 1, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
45672711|NCT04737239|Other|Corticosteroid injections for CTS treatment|Treatment of carpel tunnel syndrome with corticosteroid injections for EMG mild and EMG negative patients
45980222|NCT00311285|Device|Electrogram (EMG), heart rate variability (HRV), salivary cortisol, goniometry, inclinometry|
45980223|NCT04715412|Other|patient counseling and adherence support|"Technical interventions include; identification of possible reasons for non-adherence, adherence support by developing simplified schedules for taking medications that were customized to individualized patient's lifestyle. Reminders for dose as well as tools/strategies the RTR may use to follow the dosing schedules if needed as pillbox were provided as needed~Clinical pharmacists' guided patient training was individualized, repetitive, covered 6 months, and included more aspects and provided practical hints and strategies for medication management.~Initial clinical pharmacist face-to-face session will be up to 60-minute then 30-minute follow-up sessions will be conducted monthly for 6 months during the scheduled post-transplant clinic visits as coordinated with the transplant physician to allow for single office visits for transplant related issues and comorbidities."
45980224|NCT00311324|Behavioral|Special Intervention|
45980225|NCT00311324|Behavioral|Delayed Intervention|
45980226|NCT00311441|Biological|Tick-Borne Encephalitis vaccine|
45980227|NCT00342381|Drug|3,4-diaminopyridine|Single dose 3,4 diaminopyridine
45980228|NCT00342381|Drug|Placebo|Single dose placebo treatment
45980229|NCT00311480|Biological|Influenza vaccine surface antigen adjuvanted with MF59|
45980230|NCT00311519|Drug|Hylenex|
45980231|NCT00311558|Biological|recombinant interferon alfa-2b|SSG x 5 week
46082697|NCT02799056|Device|Thoracic ultrasound|The ultrasound will be performed using the ultrasound system GE Logiq XP equipped with a linear probe of 10 MHz. The diaphragm is visualized as two parallel echogenic lines at the eighth intercostal space in the mid-axillary line. The images will be captured during the inspiratory and expiratory tidal volume to and during maximum inspiration and expiration. Each image will be frozen in B mode and the diaphragm thickness will be measured from the center line pleural half the peritoneal line. The fraction of diaphragmatic thickening it is calculated by the formula: diaphragmatic thickness at the end of inspiration - thickness to diaphragmatic at the end of exhalation / diaphragmatic thickness at the end of exhalation x 100. The number of areas with lines B also will be measured.
46082698|NCT04234958|Other|Osteopathic manipulative treatment|Specific protocol including 4 osteopathic techniques targeting the pericardium
46082699|NCT04234958|Other|Sham therapy|Sham therapy mimicking the osteopathic techniques applied to experimental group
45832196|NCT03587298|Procedure|Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)|"The SWE is carried out intercostally. If possible, the patient should hold the breath for 5-10 seconds. So-called colour charts are used, which indicate the derived liver stiffness in colour-coded form. In addition to the visual assessment of these colour charts, the quantitative ROI-based measurement of the SWE in kPa is performed in the hardest appearing areas. The measurement is performed at 5 different sites of the liver parenchyma and all SWE values are recorded."
46082700|NCT04013425|Procedure|Ice Cream Cone Technique|Guided bone regeneration
46082701|NCT02793986|Drug|propofol|For patients in Group P, the sedation was achieved with a target-controlled infusion (TCI) of propofol, and the effect site concentration was set to 0.8-1.0μg/ml.
45832197|NCT04148196|Other|Progressive muscle relaxation exercise|The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 27-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles. Elderly individuals will receive PMR exercise twice a week under the guidance of an investigator for eight weeks.
45980232|NCT00311558|Drug|sodium stibogluconate|SSG & IFN
45980233|NCT00311558|Drug|SSG & interferon|1 arm study with SSG & interferon
45980234|NCT00418925|Drug|Dronabinol|2.5 mg tablets; titrated over 14 days and 7 days steady dose
45980235|NCT00311597|Procedure|Radiosurgery|single fractionated radiation therapy
45980236|NCT00339417|Drug|Albendazole|
45980237|NCT00339417|Drug|Ivermectin|
45980238|NCT00311636|Drug|cyclophosphamide|
45980239|NCT00311636|Drug|docetaxel|
45980240|NCT00311636|Drug|doxorubicin hydrochloride|
45980241|NCT00311636|Drug|epirubicin hydrochloride|
45980242|NCT00311636|Drug|fluorouracil|
45980243|NCT00311636|Drug|methotrexate|
45980244|NCT00311636|Drug|paclitaxel|
45672712|NCT01583374|Drug|Apremilast tablet 20 mg|Apremilast 20 mg was taken orally twice a day (BID)
45980245|NCT00311636|Drug|triptorelin|
45980246|NCT00311636|Procedure|adjuvant therapy|
45980247|NCT00311675|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in single-dose vials containing 90-mcg/mL A/H5N1 HA. Dosage is two 90 mcg doses administered intramuscularly separated by approximately 28 days.
45980248|NCT00311714|Drug|CS-8958 formulated as dry powder|
45980249|NCT00311714|Other|Placebo|
45980250|NCT00339456|Drug|HAART|
45980251|NCT00311753|Drug|Certoparin|Low-molecular-weight heparin, Certoparin (3000 U anti-Xa once daily) treatment period of 10 ± 2 days
45980252|NCT00311753|Drug|Heparin|7500 IU of unfractionated heparin administered twice daily during the treatment period of 10 ± 2 days
45980253|NCT00311792|Behavioral|LapSimGyn training until expert proficiency level is reached|Two consecutive simulations reaching predefined expert level
45980254|NCT00311792|Behavioral|Traditional clinical education|
45980255|NCT00311831|Behavioral|Standard gastroenteritis education|Subjects in this arm of the study will receive an educational handout on gastroenteritis education.
45980256|NCT00311831|Behavioral|Extensive gastroenteritis education|Subjects in this arm of the study will receive an gastroenteritis educational handout as well a home visitation from a trained counselor.
45980257|NCT00311870|Drug|nisoldipine|
45980258|NCT00311870|Drug|lisinopril|
45980259|NCT00311948|Behavioral|Telephone counseling + interactive website = more abstinence|
45980260|NCT00311948|Behavioral|Behavioral: interactive website|
45980261|NCT00311987|Drug|3,5-Diiodothyropropionic acid (DITPA) therapy|
45980262|NCT00342849|Drug|Succimer|Succimer (2,3-meso-dimercaptosuccinic acid) is an orally active dithiol compound that is a relatively specific chelating agent for heavy metals, especially lead, arsenic and mercury. The drug undergoes limited absorption in the gastrointestinal tract and then is rapidly metabolized to mixed disulfides which are eliminated in the urine. Blood levels decline slowly with an apparent elimination half-life of about 48 hours in adults.
45980263|NCT00342849|Drug|Placebo|
45980264|NCT00312026|Drug|efalizumab|
45980265|NCT00312065|Device|Application of reflective heat shield to thermistor probe|
45980266|NCT00312104|Drug|insulin detemir|
45672713|NCT01583374|Drug|Apremilast tablet 30 mg BID|Apremilast 30 mg was taken orally twice a day
45980267|NCT00312104|Drug|insulin glargine|
46082702|NCT02793986|Drug|dexmedetomidine|For patients in Group D, the sedation was achieved with a bolus of dexmedetomidine at 1.0 μg/kg (over a period of 15 to 20 min) and followed by an infusion of dexmedetomidine at 0.2-0.7 μg/kg/h. The depth of sedation was considered enough when patient was unresponsive to voice.
46082703|NCT04013347|Procedure|Rectal Resection|Low Anterior Resection and Abdominoperineal Resection
45832198|NCT03587220|Drug|Capsaicin Topical|Capsaicin patches (dosage form: patch 8% Qutenza) will be applied on 4x4 cm squared areas on the volar forearm. The patches will be left in place for 24h and 3 hours after which they will be removed.
46082704|NCT02794064|Device|Tri-modal imaging|This tri-modal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified
45832199|NCT03587220|Radiation|Ultraviolet-B (UVB) irradiation|Two circular areas (Ø 2 cm) on the forearm are irradiated with 2 x MED (Minimal Erythema Dose) dose of UVB using a calibrated UVB machine (290-320nm wavelength), Saal Mann Multi Tester (Mann Saal, LT SBC 400 Herford, Germany).
46082705|NCT00940069|Drug|pemetrexed|"'TS high expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks.~'TS low expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks."
46082706|NCT00940303|Drug|5-FU|3200mg/m2 continuous iv infusions, day 1 every 2 weeks
46082707|NCT00940303|Drug|bevacizumab [Avastin]|5mg/kg iv infusion, day 1 every 2 weeks
45672714|NCT01583374|Drug|Placebo|Identically matched placebo tablets were taken orally twice a day during the placebo controlled phase.
45672715|NCT05390567|Behavioral|Participant Choice of HPV Self-Test|Opportunity for participants to complete the HPV self-test in a non-clinical setting to be returned via a mailer or courier servie.
45672716|NCT05390567|Behavioral|Survey: Participant cancer history and cervical cancer prevention/screening knowledge|Asking women to respond to questions about their cancer history and knowledge of cervical cancer prevention and screening.
45832200|NCT03587220|Other|Histamine 1%|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.
45832201|NCT03587220|Drug|Lidocaine|Cutaneous anaesthesia will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine)
45832202|NCT04148274|Other|No intervention|There is no intervention for this study.
45832203|NCT04148040|Procedure|G-POEM|Per-oral pyloromyotomy (POP), also named as gastric per-oral endoscopic myotomy (G-POEM), for treating infantile hypertrophic pyloric stenosis (IHPS) has the following steps: mucosal incision, creation of submucosal tunnel, full-thickness pyloromyotomy, closure of the mucosal entry.
45832204|NCT03587064|Device|Conventional 3-lead CRT defibrillator system implantation|Conventional 3-lead(1 atrial and 2 ventricular leads) system implantation
45832205|NCT03587064|Device|2-lead CRT defibrillator system implantation|2-lead (2 ventricular leads with dipole for atrial sensing) DX system implantation
46082708|NCT00940303|Drug|irinotecan|165mg/m2 iv infusion, day 1 every 2 weeks
46082709|NCT00940303|Drug|leucovorin|200mg/m2 iv infusion, day 1 every 2 weeks
46082710|NCT00940303|Drug|oxaliplatin|85mg/m2 iv infusion, day 1 every 2 weeks
46082711|NCT02794220|Device|CN electronic cigarette 10 mg|Inhalation
46082712|NCT02794220|Device|CN electronic cigarette 15 mg|Inhalation
46082713|NCT02794220|Device|Nicorette Inhalator 15 mg|Inhalation
46082714|NCT02794220|Other|Cigarette|Inhalation
46082715|NCT00941083|Drug|Raltegravir (Use RAL as a simplification strategy)|RAL QD: RAL 800 mg/24 hs
46082716|NCT00941083|Drug|Raltegravir (Use RAL as a simplification strategy)|RAL BID 400 mg/12 hs
46082717|NCT00941083|Drug|Raltegravir (Use RAL as a simplification strategy)|RAL BID to QD
45672717|NCT05390567|Behavioral|Participant Choice of Standard of Care in-clinic Pap-test|Participant choice of cervical cancer screening method with either a SOC in-clinic pap test or HPV self-test
45980268|NCT00312104|Drug|insulin aspart|
45980269|NCT00339690|Other|MITE-T-FASTtest kit|The primary objective of this randomized intervention trial is to determine if the use of an inhome test kit, as an adjunct to education, results in greater reductions in dust mite allergen levels than the use of educational materials alone.
45980270|NCT00312143|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
45980271|NCT00343005|Biological|AMA1-C1|
45980272|NCT00343005|Drug|AMA1-C1/alhydrogel Malaria Vaccine|
45980273|NCT00312182|Drug|Nelfinavir|
45980274|NCT00312260|Drug|Gabapentin|Gabapentin will be prescribed at 900mg/d (300mg tid). A dose escalation schedule will be followed: one pill taken at night (~2000h) for the first 3 days, one pill at night and one pill in the morning (~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (~1400h) for the reminder of the trial.
46082718|NCT02798900|Other|Functional task-training|The functional task-training program includes warming up followed by a functional circuit with muscle strengthening exercises for the major groups of hip oriented to daily life activities and ends with stretching.
45980275|NCT00312260|Drug|Amitriptyline|Amitriptyline will be prescribed at a dose of 10mg (qhs). A dose escalation schedule will be followed: one pill taken at night (~2000h) for the first 3 days, one pill at night and one pill in the morning (~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (~1400h) for the reminder of the trial.
45980276|NCT00343122|Procedure|echocardiography for intrapulmonary vasodilatation|
45980277|NCT00312299|Device|Square edge PMMA IOL|Arm 1 A - Square edge PMMA IOL
45980278|NCT00312299|Device|Round edge PMMA IOL|Round edge PMMA IOL
45980279|NCT00312299|Device|Acrysof IOL|Acrysof IOL
45456361|NCT04193553|Other|Best supportive care|At any time during the study, patients should receive best supportive care. Best Supportive care as medically indicated for the patient's well-being may be prescribed at the investigator's discretion. Based on the patient's condition, it may consist (but not limited) of analgesics, antibiotics, steroids, blood transfusion, antiemetics, antidepressants/anxiolytics, nutritional counselling, psychological support, palliative radiotherapy…
45456362|NCT04188548|Drug|LY3484356|Administered orally
45980280|NCT00312299|Device|square Edge PMMA IOL|Square edge PMMA intra ocular lens
45456363|NCT04188548|Drug|Abemaciclib|Administered orally
45832206|NCT03586908|Drug|PHP-201 0.5% ophthalmic solution (topical eye drop)|D1, D7: PHP-201 0.5% topical eye drop OU QD(AM), D2~D6: PHP-201 0.5% topical eye drop OU TID
45832207|NCT03580746|Procedure|Taping and posteromedial release|
45832208|NCT03580746|Procedure|Ponseti|
45980281|NCT00312299|Device|Square Edge PMMA IOL|Square Edge PMMA IOL lens
45980282|NCT00312416|Drug|Clonidin|
45980283|NCT00312416|Drug|Brimonidine|
46082719|NCT02798900|Device|Therapeutic Ultrasound|Therapeutic pulsed ultrasound will be applied prior to functional task-training with an intensity of 2.2 W/cm2, frequency of 1 MHz and application time of 4 minutes on the anterior, medial and lateral hip area.
46082720|NCT04405999|Drug|Bromhexine Hydrochloride|Medical personnel at risk for COVID-19 infection will receive study medication for 14 days
45456364|NCT04188548|Drug|Everolimus|Administered orally
45832209|NCT05702658|Behavioral|CAPS|Community Autism Peer Support is a one-to-one autistic-delivered peer support, community-based intervention focused on independent living and participation.
45456365|NCT04188548|Drug|Alpelisib|Administered orally
45832210|NCT04147572|Drug|Placebo Tiotropium inhalation powder type A|Placebo inhalation from inhaler A
45832211|NCT04147572|Drug|Placebo Spiriva capsule|Placebo inhalation from HandiHaler
45832212|NCT04147572|Drug|Placebo Tiotropium inhalation powder type B|Placebo inhalation from inhaler B
45832213|NCT04147572|Device|Substudy Placebo Tiotropium Easyhaler|Substudy placebo inhalation
45832214|NCT04147572|Device|Substudy Placebo Spiriva® via HandiHaler|Substudy placebo inhalation
45980284|NCT00339768|Drug|Amoxicillin/omeprazole|To treat Helicobacter pylori infections. 2 week course of amoxicillin 1gm bid, omeprazole 20mg bid. This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.
46082721|NCT02794142|Procedure|renal transplantation|
46082722|NCT02794142|Other|No intervention|
45456366|NCT04188548|Drug|Trastuzumab|Administered intravenously
45832215|NCT05702580|Procedure|Agitated Pleural Fluid Thoracentesis|Using a 16-18 gauge cannula, a standard thoracentesis will be performed then a sample of pleural fluid will be aspirated and rapidly flushed into the pleural space and redrawn again for a few cycles before a sample is finally drawn into the collection syringe
45980285|NCT00312455|Drug|Pro-eicosapentaenoic acid (EPA)|450 mg 5x/day
45980286|NCT00312455|Drug|Pro-docosapentaenoic acid (DPA)|100mg 5x/day
45980287|NCT00312455|Drug|Placebo|5 capsules/day
45980288|NCT00343161|Drug|esomeprazole|
45980289|NCT00343161|Drug|Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)|
45980290|NCT00312533|Drug|Hylan F- 20|
45980291|NCT00312611|Device|Transcend II Implantable Gastric Stimulator (IGS), Model 8848|
45980292|NCT00312650|Drug|liposomal doxorubicin and gemcitabine|
45980293|NCT00343200|Drug|Placebo|Placebo tablet orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 8 weeks (DB phase). In 4-week OL phase, subjects received sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period.
45980294|NCT00343200|Drug|Viagra (sildenafil citrate)|Sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 12 weeks (8-week DB phase and 4-week OL phase).
45980295|NCT00312767|Drug|Fabrazyme (agalsidase beta)|
45980296|NCT00312806|Drug|Pantoprazole|Pantoprazole 40 mg o.d.
45980297|NCT00347685|Drug|tramadol ER|
45980298|NCT00312962|Behavioral|Targeted cognitive training (TCT)|TCT includes cognitive remediation exercises that participants practice 1 hour per day, 5 days per week, for 20 weeks. TCT exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal and visuo-spatial targets.
45980299|NCT00312962|Behavioral|Computer games|The control treatment involves commercially available computer games that participants practice 1 hour per day, 5 days per week, for 20 weeks.
45980300|NCT00343239|Drug|Docetaxel|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2"
45980301|NCT00343239|Drug|Cisplatin|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2"
45980302|NCT00343239|Drug|Fluorouracil|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 750 mg/m2/day for 5 days"
45980303|NCT00313001|Drug|biphasic insulin aspart|
46082723|NCT02794298|Device|Transcranial direct current stimulation (tDCS)|
46082724|NCT02794298|Device|sham-tDCS|
45672718|NCT04251377|Device|Defensive Antiadhesive Coating DAC®, Novagenit SRL|"DAC gel, mixed with topical antibiotics is applied on the surface of the implants before implantation, in a sterile environment in the operating room.~The topical antibiotics will be added to the reconstituted DAC® gel preparation, at the discretion of the physician, on the basis of pre-operative culture."
45672719|NCT04245215|Drug|Ustekinumab|re-induction and dose escalation form every 8 weeks to every 4 weeks only in arm 2
45672720|NCT05387759|Drug|Aticaprant Supratherapeutic Dose|Aticaprant supratherapeutic dose capsule will be administered orally.
45672721|NCT05387759|Drug|Aticaprant Therapeutic Dose|Aticaprant therapeutic dose capsule will be administered orally.
45672722|NCT05387759|Drug|Placebo|Placebo will be administered orally.
45672723|NCT05387759|Drug|Moxifloxacin|Moxifloxacin capsule will be administered orally.
45832216|NCT03580590|Drug|oral Diltiazem|Diltiazem, a calcium channel blocker reduced arteriolar tone and fall in blood pressure
45832217|NCT03580590|Drug|IV Tranexamic Acid|Tranexamic acid inhibits fibrinolysis, which reduces blood loss
45832218|NCT03580590|Drug|Placebo Oral Tablet|Placebo Oral Tablet
45832219|NCT03934944|Device|Phone application|Weekly foot alerts and educational video
45832220|NCT03934944|Other|Usual care|Usual routine of diabetic foot education
45832221|NCT03192462|Biological|multiTAA specific T cells|Each patient will receive 6 infusions of multiTAA T cells at a fixed cell dose (1 x 10^7 cells/m2) at the times specified in the group description. The expected volume of infusion will be 1 to 10 cc.
45980304|NCT00313001|Drug|exenatide|
45980305|NCT00343278|Drug|Valaciclovir Hydrochloride|
45980306|NCT00313040|Behavioral|Brief Consultation with Health Counselor, workbook|
45980307|NCT00313040|Behavioral|Usual Care wait list|
45980308|NCT00343317|Drug|Intrapartum Cefoxitin (2g) vs. placebo|
45980309|NCT00313079|Drug|MAb 216|Dosage: 1.25mg/kg intravenous with dose escalation
45672724|NCT01583296|Behavioral|Music Relaxation Therapy (MRT)|music relaxation therapy and breathing at resting respiration rate
45980310|NCT00313079|Drug|Vincristine|Dosage: 1.5mg/m2 intravenous weekly X 4
45980311|NCT00343356|Drug|Trement|
45980312|NCT00347724|Drug|Tramadol HCl ER|
45980313|NCT00313157|Drug|Metoprolol|
45980314|NCT00313157|Drug|Diltiazem|
45980315|NCT00313157|Drug|Verapamil|
45980316|NCT00313157|Drug|Carvedilol|
45980317|NCT00343395|Drug|AVANDAMET|2/500 mg
45980318|NCT00347763|Procedure|10% permethrin in water applied as low volume spray|
45980319|NCT00313235|Biological|DC Vaccine and Cyclophosphamide|"Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).~Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.~CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure."
45980320|NCT00347802|Drug|Bimatoprost 0.03%, Travoprost 0.004%|
45980321|NCT00313274|Drug|Clevudine|
45980322|NCT00343434|Behavioral|behavioral dietary intervention|
45980323|NCT00343434|Behavioral|exercise intervention|
45980324|NCT00343434|Dietary Supplement|soy isoflavones|
45980325|NCT00343434|Dietary Supplement|soy protein isolate|
45980326|NCT00343434|Other|counseling intervention|
45980327|NCT00343434|Other|educational intervention|
45980328|NCT00343434|Procedure|psychosocial assessment and care|
45980329|NCT00343434|Procedure|quality-of-life assessment|
45980330|NCT00419042|Drug|TARCEVA|Tarceva (150 mg) is a pill you take once a day -- every day -- to help treat non-small cell lung cancer.
46082725|NCT05427890|Behavioral|T2D Risk Communication Tool: Relative Risk|Risk of T2D is presented in comparison to the rest of the Singapore population in a scale 1-10. Suggestions on different lifestyle changes and its potential to reduce the individual's relative risk is presented for user to observe impact of preventative behaviours.
45980331|NCT00419042|Drug|Gemzar|GEMZAR by mixing it into a solution and giving it through a needle into a vein-called intravenous infusion (IV). This will take about 30 minutes
45980332|NCT00347841|Drug|Bimatoprost 0.03%, Latanoprost|
45980333|NCT00425126|Drug|Epoetin Alfa|
45980334|NCT00343551|Drug|Aliskiren|
45980335|NCT04715334|Device|Mollii suit|The Mollii suit is a new technology of electrical stimulation in the form of whole-body garment with multiple electrodes individually programmed to stimulate the selected muscles. Based on preliminary studies, it is suggested that the Mollii suit improves spasticity. Recent studies also proposed that it improves mobility, gait, function and quality of life. However, these studies are based on qualitative and subjective measures.
45980336|NCT00347997|Device|217z Laser|LASIK correction of myopia and myopic astigmatism
45980337|NCT00343590|Device|Whole Body Vibration machine|
45980338|NCT00343629|Drug|sulindac|
45980339|NCT00343629|Other|pharmacological study|
45980340|NCT00343668|Drug|S-1, irinotecan|S-1, 40 mg/m2 PO twice daily, days 1-14 irinotecan, 150 mg/m2 IV, day 1
45980341|NCT00348036|Behavioral|Group Intervention for Interpersonal Trauma|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences. Groups will be comprised of three components at each meeting: psycho-education, current relationship issues, and coping skills. Each group session will focus on a different aspect of education. Next, relationship difficulties typically associated with the symptoms discussed in that module will be addressed, and there will be group discussion about participants' relationship difficulties. Each group will end with the therapist teaching a coping skill that fits with the issues discussed earlier.
45980342|NCT00348036|Other|Information only|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences.
45980343|NCT00343707|Drug|vestipitant|
45980344|NCT00343707|Drug|paroxetine|
45980345|NCT00313391|Drug|Risperdal Consta|
45980346|NCT00348075|Device|Neurovision|
45980347|NCT00348114|Procedure|Transplantation of cultivated limbal epithelium|
45980348|NCT00343902|Drug|Crataegus Special Extract WS 1442|
45980349|NCT00348153|Drug|Adalimumab|
45980350|NCT00313508|Biological|Autologous Dendritic Cells (DC)|Given intranodally
45980351|NCT00313508|Drug|Fludarabine|Fludarabine will be administered intravenously (IV) over 30 minutes, daily for 5 consecutive days.
45980352|NCT00313508|Biological|Autologous Lymphocyte Infusion (ALI)|Infusion
45980353|NCT00343941|Drug|Tucaresol tablets 25 mg|
45980354|NCT00313547|Drug|Quinapril 40 mg|
45980355|NCT00313547|Drug|Quinapril 10 mg and amlodipine 5 mg|
45980356|NCT00348192|Drug|SB-742457|
45980357|NCT00348192|Drug|donepezil|
45980358|NCT00313625|Drug|busulfan|
45672725|NCT01583296|Behavioral|CBT and HRVB|cognitive behavioral therapy and heart rate variability biofeedback
45672726|NCT04724915|Procedure|Conventional Total Knee Arthroplasty|People will undergo surgery to replace the knee joint with a prosthesis in case of osteoarthritis. This will be performed with manual instrumentarium (jig-based).
45980359|NCT00313625|Drug|melphalan|
45980360|NCT00313625|Drug|methotrexate|
45980361|NCT00313625|Drug|tacrolimus|
45980362|NCT00313625|Procedure|allogeneic hematopoietic stem cell transplantation|
45980363|NCT00313625|Procedure|peripheral blood stem cell transplantation|
45980364|NCT00343980|Drug|rosiglitazone|Tablets, 4 mg once or twice a day.
45980365|NCT00343980|Drug|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
45980366|NCT00343980|Drug|glimepiride|Tablets, 4 mg/day.
45980367|NCT00313742|Drug|insulin detemir|
45980368|NCT00313742|Drug|insulin glargine|
45980369|NCT00313742|Drug|insulin NPH|
45980370|NCT00313859|Drug|simvastatin|
45980371|NCT00348231|Drug|dual-action insulin analog|
45980372|NCT00313898|Drug|sildenafil (viagra)|
45980373|NCT00344058|Drug|abbreviation of magnesium sulfate therapy (12 hours versus the traditional 24 hours after delivery)|
45980374|NCT00313937|Drug|Insulin glargine|
45980375|NCT00348270|Device|Tecnis Z9000 intraocular lens|
45980376|NCT00348270|Device|MA60 intraocular lens|
45980377|NCT00313976|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250 micrograms every other day, subcutaneously for 104 weeks
45980378|NCT00313976|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2x250 micrograms every other day, subcutaneously for 104 weeks
45980379|NCT00344097|Procedure|Soy protein|
45980380|NCT00314054|Drug|HCV-796|HCV-796 1000mg single dose
45980381|NCT00348387|Biological|Poliomyelitis Vaccine inactivated|0.5 mL, Intramuscular
45980382|NCT00348387|Biological|Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell)|1g dragee, oral
45980383|NCT00314171|Drug|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop in the study eye(s) twice daily for 12 months
45980384|NCT00314171|Drug|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (COSOPT)|One drop in the study eye(s) twice daily for 12 months
45980385|NCT00348426|Drug|Botulinum AntiToxin|
45980386|NCT00348426|Procedure|neuro-electrophysiologic study, repetitive nerve stimulation|
45980387|NCT00348426|Procedure|: Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
45980388|NCT00314210|Drug|Quetiapine SR|
45980389|NCT00344214|Behavioral|Tri-focal cognitive behavioral therapy - social skills training (CBTSS) counseling program|This condition is a Theory-Based Counseling Program. The program will involve nine 90-minute face-to-face counseling sessions that use CBT and strategies associated with social cognitive theory. The theory addresses three treatment domains, including mood regulation, reduction/cessation of meth use, and reduction of high risk sexual practices.
45980390|NCT00344214|Behavioral|Standard care|Standard care involves nine weekly, face-to-face individual counseling sessions that provide standard care in relation to sexual risk, methamphetamine use, and depression. The sexual risk component is a modified version of Project RESPECT 1 (CDC, Atlanta) that focuses on educational materials and personal risk appraisal. The meth component is a modified version of the 12-step drug abstinence program developed by the National Institute of Alcohol Abuse and Alcoholism (NIAAA) (Project MATCH). The depression component is an educational approach based primarily on materials provided by the National Alliance on Mental Illness (NAMI) and the National Institute of Mental Health (NIMH).
45980391|NCT00314288|Drug|Sarizotan HCl|
45456367|NCT04188548|Drug|Aromatase Inhibitor (AI)|Anastrozole or Exemestane or Letrozole administered orally (physician choice)
46082726|NCT05427890|Behavioral|T2D Risk Communication Tool: Metabolic Age|Risk of T2D is presented as an age, compared to their chronological age as a proxy for their current health status. Suggestions on different lifestyle changes and its potential to reduce the individual's metabolic age is presented for user to observe impact of preventative behaviours.
45456368|NCT04188548|Drug|Pertuzumab|Administered intravenously
45456369|NCT04183101|Drug|Aliskiren|Patients will be randomized to start treatment with aliskiren tablet 150 mg every other day up to 300 mg daily depending on weight. After 6 months switch to enalapril 2.5-20 mg daily and continue with that 2.5 years.
45456370|NCT04183101|Drug|Enalapril|Patients will be randomized to start with enalapril 2.5-20 mg daily depending on weight. After 6 months switch to aliskiren tablet 150 mg every other day up to 300 mg daily depending on weight and continue with this treatment for 2.5 years.
45672727|NCT04724915|Procedure|Robot-Assisted Total Knee Arthroplasty|People will undergo surgery to replace the knee joint with a prosthesis in case of osteoarthritis. This will be performed with the help of a surgical robot.
45672728|NCT05386745|Behavioral|physical activity|A series of 10 weekly psychoeducational modules including information on psychosocial determinants of physical activity engagement, adherence and maintenance, as well as a number of other behaviour change tools, like reflection activities.
45672729|NCT04189835|Diagnostic Test|EBV DNA in whole blood and plasma|Consecutive measurements of EBV DNA in whole blood and plasma
45672730|NCT04823585|Drug|Mepolizumab|Solution. Subcutaneous. Mepolizumab is a biological drug, a humanized monoclonal antibody against interleukin-5.
45832222|NCT03586752|Other|On-line program|18 minutes on-line video at home and 30 minutes CPR skill practice at scene in 3 days after watching on-line video
45832223|NCT03586752|Other|Standard program|60-minute CPR teaching video with practice, 20 minutes of automated electrical defibrillator operation, and a 10-minute discussion with regard to the legal issues associated with bystander CPR in Taiwan
45832224|NCT03891576|Drug|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
45832225|NCT03586674|Drug|Lipanthyl|Tablet
45832226|NCT03586674|Drug|Ursogal|suspension
45832227|NCT03586518|Diagnostic Test|Cardiac MRI scan|"A non-contrast cardiac MRI (CMR) scan at 3-Tesla platform (Skyra, Siemens Medical Imaging, Erlangen, Germany).~This non-contrast CMR scan will principally determine: Left ventricular (LV) mass and volumes/ejection fraction and; fibrosis using T1 mapping."
45832228|NCT03586518|Diagnostic Test|Echocardiogram|Assessments will include: LV size and function as per the American Society of Echocardiography guidelines. In addition specific focus will be paid end-diastolic integrated backscatter measurements.
45980392|NCT00348465|Procedure|Brachytherapy with Iodine-125 seeds|Brachytherapy of the prostate, and measurements of the prostate volume using CT scan and TURS
45980393|NCT00344253|Drug|Interferon beta|
45980394|NCT00344253|Drug|Methotrexate|
45980395|NCT00314405|Drug|Methylene blue (1%)|
45980396|NCT00314405|Drug|Rhenium sulfure|
45980397|NCT00314405|Procedure|Surgical procedure|
45980398|NCT00314405|Procedure|Anatomo-pathologic procedure|
45980399|NCT04715295|Drug|Doxycycline Tablets|Doxycycline 200 mg daily for 7 days
45980400|NCT04715295|Drug|Rivaroxaban 15Mg Tab|Rivaroxaban 15 mg tablets daily from day 1 to day 10
45980401|NCT04715295|Combination Product|Hydroxychloroquine and Azithromycin|Hydroxychloroquine 400mg daily from day 1 to day 5 in combination with Azithromycin 500mg on day 1 and 250 mg daily from day 2 to day 5
45980402|NCT00314483|Drug|Mesenchymal Stem Cell Infusion|
45980403|NCT00348504|Drug|levosimendan|
45980404|NCT00348504|Drug|dobutamine|
45980405|NCT00348543|Procedure|laser treatment|
45980406|NCT00314561|Drug|Pioglitazone, Rosiglitazone|
45980407|NCT00344409|Drug|darbepoetin alfa|
45980408|NCT04717817|Device|Inspiratory muscle training (IMT) using an IMT Threshold device (Philips)|Inspiratory muscle training on a daily basis prior to surgery during 2-3 weeks
45980409|NCT04717817|Other|Standard physiotherapy|Standard instructions and physiotherapy prior to surgery during 2-3 weeks
45980410|NCT00314600|Device|above and below elbow cast|
45980411|NCT00348582|Drug|Ketorolac, Nepafenac|
45980412|NCT00314639|Drug|modafinil|Modafinil OR Placebo 100mg orally (on the morning) from day 0 to day 14 and 200mg orally (on the morning) from day 15 to day 28. AND REVERSE : Modafinil OR Placebo 100mg orally (on the morning) from day 42 to day 56 and 200mg orally (on the morning) from day 57 to day 70.
45980413|NCT00348621|Procedure|Visual impairment intervention program|enhanced access to eye care services
45980414|NCT00314678|Drug|Topotecan|
45980415|NCT00314678|Drug|Cisplatin|
45832229|NCT03586518|Procedure|Cardiac explantation|A limited post-mortem will be performed to retrieve patients' hearts for preparation and storage at St George's University, London where direct comparison will be made between levels of scarring seen directly under the microscope between that on the MRI scans.
45832230|NCT03586518|Diagnostic Test|48-Hour continuous cardiac monitoring|Attach continuous Holter monitor (Schiller, medilog®AR12 plus/AR4 plus/FD5 plus, Baar, Switzerland) that will start before dialysis and terminate just before the subsequent dialysis treatment 48h later.
45832231|NCT03586518|Diagnostic Test|Blood samples|Collect blood samples from the arterial needle before dialysis. Approximately 30 millilitres of blood will be collected and then be pipetted into cryotubes and frozen at -80°C in an electronically monitored freezer for analysis in batches throughout the study. These samples will be used to investigate the relationship between circulating biomarkers of fibrosis, the MRI scans and the histological samples.
45832232|NCT05702346|Behavioral|Enhance Physical Activity (EPA)|EPA is eight weeks with four weekly, hour-long parts: virtual group exercises, virtual group discussions, individual PA participation, and individual phone check-ins.
45832233|NCT03156348|Other|Clinical Pharmacist Care|"During hospitalization and at discharge a clinical pharmacist (CP) will monitor daily pharmacological safety and efficacy of the medication to asses and make appropriate recommendations. CP will explain the use reasons of each of the drugs.~At 30 days post-discharge, the CP will review the updated clinical record of patient and conduct a home visit to enhance and ask about adherence, self-medication, medication use at that time and possible results of laboratory tests performed and clarify doubts regarding the use of current medications. The same activities will be made at 60 days by telephonic way, to reinforce the recommendations."
45832234|NCT03580200|Other|Trigger Point Dry Needling|For the purposes of this study, the term trigger point dry needling will be used to describe deep dry needling of muscle tissue. The goal of trigger point dry needling is to eliminate myofascial trigger points within muscle tissue, thereby reducing pain as well as improving motor control and function (Caramagno et al., 2015; Dommerholt et al., 2006; Shah et al., 2015). Trigger point dry needling utilizes a solid filiform needle and focuses on the penetration of a palpable myofascial trigger point at various depths. The needle is then manipulated within the tissue in an attempt to elicit a localized twitch response. Once the localized twitch response has ended, the needle is removed and another myofascial trigger point is located.
45832235|NCT03580122|Drug|Arginine Aspartate|Asparten
45832236|NCT03346668|Drug|Topical gabapentin|topical gabapentin 6% solution
45832237|NCT03156426|Other|Event of interest: Acute kidney injury|AKI as defined by AKIN staging
45832238|NCT03585738|Dietary Supplement|Inositol + Folic acid|"Daily oral supplementation before spontaneous conception until delivery:~Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg"
45832239|NCT03585738|Dietary Supplement|Folic acid|"Daily oral supplementation before spontaneous conception until delivery:~Folic acid: 400 mcg"
45832240|NCT03583164|Drug|F901318|30mg tablets with a maximum daily dose of 300mg with dose adjustments according to plasma levels of F901318 and concomitant treatment with CYP inducers or inhibitors
45832241|NCT03589326|Drug|Ponatinib|Ponatinib Tablets.
45832242|NCT03589326|Drug|Imatinib|Imatinib Tablets.
45832243|NCT03589326|Drug|Vincristine|Vincristine IV injection.
45832244|NCT03589326|Drug|Dexamethasone|Dexamethasone Tablets.
45832245|NCT03589326|Drug|Cytarabine|Cytarabine IV infusion.
45980416|NCT00314678|Drug|Paclitaxel|
45980417|NCT00314717|Behavioral|Control diet|
45980418|NCT00314717|Behavioral|Low GI diet|
45980419|NCT00344526|Drug|Melphalan|
45980420|NCT00344526|Drug|Dexamethasone|
45980421|NCT00344526|Procedure|Autologous stem cell transplantation|
45980422|NCT00314756|Drug|imiquimod|
45980423|NCT00344565|Drug|Modafinil|During the first lead-in week, participants will attend the clinic 3 times per week, participate in one session of neuropsychological assessment and receive motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP). At the end of the first lead-in week participants will be randomized to modafinil or placebo stratified by the levels of cocaine use, and whether or not abstinence was achieved. Participants will then be followed for 11 weeks with measures of cocaine cravings and withdrawal, and drug use outcome, and will receive CBT-RP.
45980424|NCT00344565|Behavioral|Cognitive Behavioral Therapy--Relapse Prevention|Once weekly individual session of motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP)
45980425|NCT00314834|Drug|Intradialytic parenteral nutrition|
45980426|NCT00348699|Drug|AFP464|Given IV
45980427|NCT00348699|Other|pharmacological study|Correlative studies
45980428|NCT00348699|Other|laboratory biomarker analysis|Correlative studies
45980429|NCT00314873|Drug|Gleevec (imatinib)|Imatinib 600mg po qd X 21 days.
45980430|NCT00348738|Drug|Erythropoietin|Administration of 10.000 I.U Erythropoeitin SQ 3x/week, two weeks prior to radiation therapy until a haemoglobin concentration of >14g/dl, <15g/dl is reached or until the end of the radiation therapy.
45980431|NCT00314912|Drug|Tramiprosate (3APS)|
45980432|NCT00344604|Behavioral|Role of psychosocial and quality of life parameters prior to and following LASIK.|
45980433|NCT00314990|Drug|5 mg folic acid, 50 mg pyridoxine and 0.4 mg cyanocobalamin|
45980434|NCT00344643|Device|Silicone Hydrogel Soft Contact Lenses|
45980435|NCT00315029|Behavioral|evidence based decision aid|evidence based decision aid
45980436|NCT00315029|Behavioral|Possible reimbursement 4th IVF/ICSI cycle when necessary|Potential reimbursement 4th IVF/ICSI cycle when necessary
45980437|NCT00348777|Drug|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
45980438|NCT00348777|Drug|3 days access to watering place at 6 months|access to watering place for movement in swimming pool, sauna and hammam.
45980439|NCT00315107|Drug|Alesse|
45980440|NCT04715490|Other|The Multimedia Symptom Management Program Intervention|"The program is composed of two parts: 1) a face-to-face presentation about the contents of the program, and 2) structured telephone support. The first part of the program will be conducted in the cardiology outpatient department. Participants will be instructed to read a HF handbook.~The second part of the program, structured telephone support, allowed the nurses to maintain contact with the participants in order to follow their progress. The participants will be scheduled to receive eight telephone coaching calls over a 3-month period."
45980441|NCT04715490|Other|Control group|The control group will be provided with the HF handbook at the beginning of the 3-month period, and also will be received usual care, which included medical consultations, and two telephone calls.
45980442|NCT02960126|Drug|Aspirin|
45456371|NCT04180462|Other|Practice Facilitation|Practice facilitation to support quality improvement methods to effect practice change to develop a sustainable HPV vaccine delivery system.
45980443|NCT02960126|Drug|Clopidogrel|
45980444|NCT00348855|Other|Cardiovascular drugs strategies|Implementation of drug strategies according to guidelines to try to reach goals proposed in these guidelines.
45672731|NCT04823585|Drug|Placebo|Solution. Subcutaneous.
45980445|NCT00348855|Behavioral|Compliance|Discussion about compliance and questionnaire to assess compliance at inclusion, Year 1 and Year 2.
45980446|NCT00348855|Behavioral|Exercise|Discussion with the patient on necessity to have regular exercise. Assessment of exercise by questionnaire at inclusion, year 1 and year 2.
45980447|NCT00348855|Behavioral|Stop Smoking|Minimal intervention
45980448|NCT00348855|Behavioral|Diet|Discussion with the patient on his (her) alimentation during each of the six consultations and assessment of daily diet at inclusion, year 1 and year 2.
45980449|NCT00348855|Other|Feed Back|Feed back on results in the intervention group at baseline, Year 1 ans Year 2.
45456372|NCT04180462|Other|Education|An educational video to increase the provider's knowledge about guideline recommendations and patient and practice benefits of vaccination by age 13.
45672732|NCT04165577|Device|rTMS|1-Hz rTMS targeting frontal pole
45672733|NCT04165577|Device|sham rTMS|sham rTMS targeting frontal pole
45672734|NCT02222714|Biological|3K3A-APC|3K3A-APC, diluted in 0.9% sodium chloride in water, given as 100 mL IV infusion
45672735|NCT02222714|Drug|Placebo|Matching placebo, 0.9% sodium chloride in water, given as 100 mL IV infusion
45672736|NCT04836689|Device|nasal intermittent positive pressure ventilation (NIPPV).|"NIPPV will be administered using Leoni (Heinen&Löwenstein, Bad Ems, Germany) and RAM cannula (Neotech, Valencia, CA).~After initial setting and before routine blood gas testing, tcCO2 will be connected and calibrated. We will use SenTec digital monitor (SenTec AG, Therwil, Switzerland). Correlation/agreement between the tcCO2 and PCO2 will be assessed and documented in each infant.~For Each infant we will get 2 set of data: Change in measurements when changing from 30 bpm to 10 bpm, and change in measurements when changing from 10 bpm to 30 bpm At the end of each hour, before rate change, we will document the following measurements:TcCO2, FiO2, saturation, the infant's respiratory rate (as measured in the monitor), number of apneas, bradycardia (heart rate<100 bpm), saturation<90% and>94% episodes (as measured in the monitor), 1-hour saturation histogram clasification."
45672737|NCT04809467|Drug|tafasitamab|tafasitamab will be administered at a protocol defined dose once a week for cycles 1-3 and every other week from cycle 4 until progression.
45832246|NCT03589326|Drug|Methotrexate|Methotrexate IV infusion.
45832247|NCT03589326|Drug|Prednisone|Prednisone Tablets.
45832248|NCT05684640|Drug|Rodatristat Ethyl|Tablets, Oral, 600mg, QD
45832249|NCT05684640|Drug|Placebo|Tablets, Oral, 0mg, BID
45832250|NCT05701956|Drug|Tenecteplase|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds) before endovascular thrombectomy
45980450|NCT00315185|Drug|Cetuximab|
45980451|NCT00344721|Dietary Supplement|Omega-3 fatty acid supplement|Participants receive four oral doses of soft-gel capsules to be taken daily (QD) for 3 months.
45980452|NCT00344721|Dietary Supplement|Placebo|Participants receive four oral doses of soft-gel capsules containing wheat germ oil to be taken daily for 3 months.
45980453|NCT00315224|Behavioral|heart-rate controlled 12 week exercise program|
45456373|NCT04180462|Other|Audit and Feedback|Audit and feedback of vaccine coverage to increase motivation to engage in practice change.
45672738|NCT04809467|Drug|parsaclisib|parsaclisib will be administered at protocol defined dose for cycles 1 through disease progression.
45672739|NCT03324893|Diagnostic Test|[F-18]-FCH PET/MRI|Subjects will undergo the [F-18]-FCH PET/MRI within three months prior to scheduled parathyroidectomy.
45832251|NCT05701956|Procedure|Aspiration thrombectomy|A direct aspiration first pass technique is an aspiration-first approach to performing thrombectomy. This technique uses a large-bore catheter to aspirate the thrombus without initially using a stent retriever.
45832252|NCT05701956|Procedure|stent retriever thrombectomy or combination of contact aspiration and stent retriever|stent retriever thrombectomy or concomitant use of contact aspiration during stent retriever thrombectomy (combination of contact aspiration and stent retriever)
45980454|NCT00344760|Drug|Enfuvirtide|subcutaneously twice a day
45980455|NCT00344760|Drug|Efavirenz, lamivudine, and tenofovir|Efavirenz -600mg once daily, lamivudine- 300mg once daily, and tenofovir 300mg once daily
45980456|NCT00348894|Drug|[S,S]-Reboxetine|[S,S]-reboxetine
45980457|NCT00348894|Drug|Any|Any standard of care treatment for DPN
45980458|NCT00315536|Drug|Administration of remifentanil and glycopyrrolate|2 mg, intravenius use
45980459|NCT00348972|Drug|Lantus® (insulin glargine)|
45980460|NCT00315575|Procedure|BOLD and Perfusion brain MRI|Blood oxygenation and perfusion functional MRI performed twice, two weeks apart; each scan lasts 1 hour
45980461|NCT00349011|Procedure|Personalized risk assessment|
45980462|NCT00349011|Procedure|genetic counseling intervention|
45980463|NCT00315692|Device|Biomarker Assay (CA125 and HE4)|
45980464|NCT00315770|Procedure|weight loss diets for young adults|
45980465|NCT00344838|Device|Comparison of LADAR CustomLasik and VISX Wavefront System custom laser ablation devices|
45980466|NCT00349050|Device|laboratory pain assessment|Participants will record their pain experiences every day for 2 weeks before receiving the first of 5 laboratory pain assessments. The laboratory pain assessment uses a small device, controlled by a computer and attached to the underside of the forearm, to produce different temperature stimulations. As the device reaches a level considered painful to the participant, he/she can push a button to return to a level of comfort.
45980467|NCT00349050|Procedure|transcranial magnetic stimulation|"There will be two, 20-minute, 3-day TMS treatment sessions. Participants will be randomly assigned to one of two groups. Group A will receive real TMS for the first 3-day treatment and sham TMS (which does not involve real stimulation) for the second treatment. Group B will receive sham TMS for the first treatment, and real TMS for the second treatment. Regardless of the group, participants will receive both real and sham TMS."
45980468|NCT00349089|Drug|Pemetrexed|Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22
45980469|NCT00349089|Drug|Cisplatin|"Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22~Comparator:~Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29 Cisplatin 50 mg/m2 d1, 8; q d29"
45980470|NCT00349089|Drug|Vinorelbine|Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29
45980471|NCT00349128|Drug|fenofibrate and metformin combination (drug)|
45980472|NCT00349167|Drug|PR-104|
45980473|NCT00349167|Other|laboratory biomarker analysis|
45980474|NCT00349167|Other|pharmacological study|
45980475|NCT00315848|Drug|Buprenorphine transdermal delivery system|
45980476|NCT00349206|Drug|sorafenib tosylate|Given orally
45672740|NCT04821401|Dietary Supplement|Rejuvant|"Rejuvant tablets are sustained release tablets that release the active ingredients over 8-12 hours. Both product tablets are 0.500 round and 0.290 thick.~AKG and AKG salts are grandfathered as GRAS compounds because these compounds were supplements prior to the Dietary Supplement Health and Education Act of 1994 (DSHEA). AKG and AKG salts are currently sold in the United States as supplements.~The other components of the tablets are Vitamin A for the men's product and Vitamin D3 for the women's product. Vitamin A and Vitamin D are GRAS compounds per the FDA"
45980477|NCT00349206|Drug|temsirolimus|Given IV
45980478|NCT00315887|Drug|Buprenorphine transdermal delivery system|
45456374|NCT04180462|Other|Communication Strategy|A communication strategy to improve the provider's communication skills and their self-efficacy to address parental hesitation.
45980479|NCT00421395|Biological|90Y-hLL2|weekly dosing for either 2 or 3 weeks
45980480|NCT00315926|Drug|Melatonin|Melatonin 50 mg during surgery and 10 mg every night for 3 nights
45980481|NCT00315926|Drug|Placebo|a mixture of ethanol and physiological saline
46082727|NCT05427890|Behavioral|T2D Risk Communication Tool: Traffic Light|Risk of T2D is presented as either High (Red) or Low (Green). Generic tips on how to reduce risk of diabetes are included. This imitates the tool that is currently available for residents of Singapore to use to assess their risk of T2D.
46082728|NCT02793908|Drug|Pleyris|Luteal phase will be supplemented starting by the ovulation day for 14 days
46082729|NCT02793908|Drug|Crinone8|Luteal phase will be supplemented starting by the ovulation day for 14 days
45456375|NCT04171765|Drug|Placebo|Participants will receive subcutaneous (SC) placebo matched to BFKB8488A.
45456376|NCT04171765|Drug|BFKB8488A|Participants will receive subcutaneous (SC) BFKB8488A.
45980482|NCT00421434|Drug|Nitazoxanide|One oral nitazoxanide 500 mg tablet with food twice daily for 48 weeks.
45456377|NCT04167683|Other|No intervention|No intervention
45980483|NCT00421434|Biological|Peginterferon alfa-2a|Weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
45980484|NCT00421434|Biological|Peginterferon alfa-2a|Weekly injections of 180 µg peginterferon alfa-2a for 48 weeks.
45980485|NCT00421434|Drug|Ribavirin|Oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 36 weeks.
45980486|NCT00421434|Drug|Ribavirin|Oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
45980487|NCT00315965|Drug|Nitric oxide, Carbon monoxide, Helium|
45980488|NCT00349245|Drug|Remifentanil|
45980489|NCT00349245|Drug|Dexmedetomidine|
45980490|NCT00316043|Behavioral|Written information for parents|
45980491|NCT00316043|Behavioral|Distance learning package for General Practitioners|
45980492|NCT00316043|Behavioral|Distance learning package for practice assistants|
45980493|NCT00349284|Drug|Combination of 145 mg fenofibrate and 10 mg ezetimibe|
45980494|NCT00316160|Drug|Bupropion Hydrochloride Extended-release|
45980495|NCT00316160|Drug|Extended-release Venlafaxine|
45980496|NCT00349323|Behavioral|Community directed treatment|
45980497|NCT02959931|Other|High Potassium Meal|Breakfast meal that provides ~2400 mg of dietary potassium. Meals are isocaloric.
45980498|NCT02959931|Other|Low Potassium Meal|Breakfast meal that provides ~540 mg of potassium. Meals are isocaloric.
45980499|NCT00349362|Drug|Testosterone|Sustanon- 200mg intramuscular testosterone
45980500|NCT00349362|Drug|0.9% saline|Saline intramuscular injection every two weeks
45980501|NCT00316238|Drug|olanzapine-RAIM|
45980502|NCT00316238|Drug|placebo|
45980503|NCT00349401|Drug|ketorolac|
45980504|NCT00349401|Drug|morphine|
45980505|NCT00316316|Behavioral|Motivational interviewing plus exposure and response prevention (MI plus EX/RP)|Participants will receive 18 sessions of MI plus EX/RP.
45980506|NCT00316316|Behavioral|Exposure and response prevention (EX/RP)|Participants will receive 18 sessions of EX/RP.
45980507|NCT00349440|Drug|Cyclosporine, Refresh Plus|"Cyclosporine 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.~Refresh Plus 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily."
45980508|NCT00316394|Device|Preventive Care Checklist Form|
45832253|NCT03156036|Drug|Capecitabine plus temozolomide VS Capecitabine|"For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will be randomised (ratio 1:1 for each arm) into preoperative CRT with capecitabine or preoperative CRT with temozolomide plus capecitabine arms.~Chemotherapy during preoperative chemoradiotherapy:~Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).~dosage: Capecitabine 825 mg/m2 twice daily, Temozolomide 75 mg/m2/day"
45980509|NCT00349479|Behavioral|Barrier assessment / interactive educational intervention|"Intervention hospitals received a barrier assessment - interactive educational intervention (BA-IEI) which included: on-site barrier assessment, annual stroke champions meetings, stroke center telephone access, quarterly mock stroke codes, and ongoing feedback and education."
45980510|NCT00316433|Drug|Irinotecan (CPT-11)|
45980511|NCT00316433|Drug|Oxaliplatin (Eloxatin)|
45980512|NCT00349518|Drug|Dasatinib|
45980513|NCT00316472|Drug|Niacinamide|
45980514|NCT00316511|Drug|Aroplatin|
45980515|NCT00349557|Drug|bevacizumab, bicalutamide and goserelin|
45980516|NCT00349557|Procedure|intensity modulated radiation therapy (IMRT)|
45980517|NCT00316550|Drug|AV608|
45980518|NCT00349596|Drug|Decitabine|Administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
45980519|NCT00316628|Biological|influenza vaccine|
45980520|NCT00349635|Drug|Metformin and Metformin + Fenofibrate|
45980521|NCT00316745|Drug|Campto, Topotesin|100 mg/m2, IV (in the vein) on day 1,15 of each cycle.
45980522|NCT00316745|Drug|TS-1|S-1 Day1~14, everyday P.O.(Day 15~28 rest)
46082730|NCT02793830|Other|Daily reminders of taking medications|Reminders. Participants will receive medication-taking reminders from the researcher. These reminders are sent through the mobile application-BB Reminder on an unencrypted external device (a phone borrowed from Duke University School of Nursing and is used specifically for this study by the researcher). BB Reminder has the function that after inputting a patient's phone number and prescriptions, participants can receive reminders through text messages of the name, dosage, function, and administration route for every dose of his/her medications. The daily reminders will be sent to participants 15 minutes before every dose of their medications.
45672741|NCT04821401|Dietary Supplement|Placebo|Matching placebo tablets are composed of Cellulose, Carnauba wax and/or rice bran wax (to match the specs), stearic acid, magnesium stearate and silica.
45980523|NCT00316745|Drug|L-Plat|Oxaliplatin (85mg/m2) Day 1, 15
45980524|NCT00316745|Drug|Isovorin|l-leucovorin (200mg/m2) Day 1, 15
45980525|NCT00316745|Drug|5-FU|400 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle. 2400 mg/m2, CIV (in the vein) on day 1~3 (48 hours) of each 28 day cycle.
45980526|NCT00349674|Drug|Azathioprine: 2 mg/kg/day|
46082731|NCT02793830|Other|Educational materials|Educational materials. Participants will receive educational materials from the researcher. These educational materials will be sent through the mobile application-WeChat. The educational materials include short articles (< 500 words) and/or pictures. They will be retrieved from the Chinese Cardiovascular Disease-Prevention Information Website (www.healthyheart-china.com), which is governed by the Chinese Ministry of Health. The validity of information from it is guaranteed. The retrieved educational materials will be screened by the cardiologist, the head nurse, and the researcher, before sending to participants. The educational materials will be sent to participants every other day at any time during 8 am and 10 pm.
46082732|NCT02789930|Other|"Device: Accuracy of a program and the anesthesia tape (Anästhesie-Lineal)"|Computer based comparison of the two devices based on collected patient data
46082733|NCT02789618|Other|A01|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The gel will be applied in the evening of three consecutive days during the study time period
46082734|NCT02789618|Other|B99|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The bonding agent will be professional applied immediately prior to the clinical assessments.
46082735|NCT02789618|Other|M89|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days.
45672742|NCT05226143|Other|Gel Cream|Gel Cream
45672743|NCT04809311|Other|Lifestyle|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
45672744|NCT04809311|Drug|Oral antidiabetetic drugs|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
45672745|NCT04809311|Drug|Basal insulin|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
45832254|NCT03583866|Drug|Candesartan|7 days of Candesartan (16mg/day)
45832255|NCT03583866|Drug|Placebo|7 days of Placebo
45832256|NCT05701878|Behavioral|SMARTest mobile app for COVID-19 self-testing|The mobile app has self-testing features and information with regard to self-testing and COVID-19.
45980527|NCT00349674|Drug|methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week|
45980528|NCT00316784|Drug|IDEA-033 (and rescue medication)|
45980529|NCT00344916|Drug|Ng-monomethyl-L-arginine (drug)|
45980530|NCT00316823|Genetic|gene expression analysis|
45980531|NCT00316823|Genetic|polymerase chain reaction|
45980532|NCT00316823|Genetic|reverse transcriptase-polymerase chain reaction|
45980533|NCT00316823|Other|diagnostic laboratory biomarker analysis|
45980534|NCT00316823|Other|immunohistochemistry staining method|
45980535|NCT00316823|Procedure|needle biopsy|
45980536|NCT00344955|Drug|HMG-CoA reductase inhibition (atorvastatin)|
45980537|NCT00316901|Procedure|computed tomography|
45980538|NCT00316901|Procedure|positron emission tomography|
45980539|NCT00316901|Radiation|fludeoxyglucose F 18|
45980540|NCT00316940|Drug|bortezomib|
45980541|NCT00316940|Radiation|samarium Sm 153 lexidronam pentasodium|
45980542|NCT00344994|Drug|pramipexole|PO, 0.25mg, 0.50mg, or 0.75mg QHS
45980543|NCT00349791|Drug|Testosterone Transdermal System|testosterone (300 mcg/day) patch replaced twice a week for two years
45980544|NCT00349791|Drug|Placebo patch|placebo patch replaced twice a week for two years
45980545|NCT00316979|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
45980546|NCT00317018|Behavioral|Evidence-Based Quality Improvement|The implementation intervention is known as Evidence-Based Quality Improvement (EBQI). EBQI is an adaptation of the Plan-Do-Study-Act cycles of Continuous Quality Improvement that emphasizes empirical evidence and the involvement of clinical and implementation experts (i.e., researchers). In the EBQI implementation intervention, both researchers (clinical and implementation experts) and local staff participate fully in the quality improvement process, with the researchers facilitating rather than dictating implementation efforts. Using EBQI methods, researchers and local staff adapt evidence-based practices for local resources, needs and preferences while maintaining fidelity to the evidence-base. PDSA cycles are used to continuously revise the adapted evidence-based practice based on feedback during pilot tests.
45980547|NCT00345072|Device|Web-based decision aid system|
45980548|NCT00317057|Procedure|Patient education and disease management|
45980549|NCT00317096|Procedure|FCM|Active comparator: Chemotherapy
45980550|NCT00317096|Procedure|R-FCM|experimental: Chemotherapy with additional rituximab
45980551|NCT00317096|Drug|rituximab maintenance|2 courses of rituximab maintenance after completion of salvage therapy
45980552|NCT00317096|Other|observation only|no Intervention after completion of FCM or R-FCM
45980553|NCT00349947|Behavioral|Exercise Program|Participants who live within 15 miles of the Palo Alto VA Hospital will take part in a supervised aerobic exercise program 3 days a week. Participants who live farther than 15 miles from the hospital will receive a detailed exercise plan and will exercise on their own while wearing a heart rate and activity tracking device. They will also attend monthly study visits for review of their progress. All participants assigned to the exercise program will be encouraged to increase their daily exercise. Each day they will wear a pedometer; twice a month they will wear a global positioning system (GPS) and heart rate monitor.
45980554|NCT00317135|Biological|Tritanrix-HepB/Meningitec conjugate vaccine|The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection
45980555|NCT00317135|Biological|Tritanrix/Hiberix vaccine|The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
45980556|NCT00345111|Procedure|Clinical visual outcomes of bilateral implantation of Restore Intra Ocular Lens.|
45980557|NCT00317174|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
45980558|NCT00349986|Drug|Insuline glargine|
45672746|NCT04809311|Drug|Glucagon-like peptide-1 (GLP-1)|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
45672747|NCT04809311|Drug|Premixed insulin|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
45672748|NCT03291743|Device|Capsule endoscopy|PillCam(TM) CROHN'S CAPSULE
45672749|NCT04145219|Biological|Sublingual allergy immunotherapy tablet|For daily administration (1 tablet per day)
45832257|NCT03585192|Other|Skin Group|"If the newborn is vigorous (crying, good respiratory effort, good tone) after vaginal delivery, newborn will be able to go directly to Mother's chest for immediate SSC~A pulse oximeter will be placed on the newborn's right wrist. Saturations will be monitored on a pulse oximeter located next to the Mother's bed for the first hour of life."
45832258|NCT03585192|Other|Warmer Group|"Newborn will go to the radiant warmer, pulse oximeter placed on newborn's right wrist, and saturations will be monitored on the Panda Warmer.~If stable per Baby RN after 20 minutes of observation, the newborn will be placed on Mother's chest for SSC. Vital signs will be monitored for the first hour of life."
45832259|NCT03585426|Drug|Vancomycin|Vancomycin, a novel intravenously administered glycylcycline antibiotic, currently plays a key role in the management of complicated multi-organism infections.
45832260|NCT03585036|Drug|dexketoprofen|"Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure."
45832261|NCT03585036|Drug|Tramadol|"Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
45832262|NCT03585036|Drug|Placebo|"Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
45832263|NCT03584880|Device|Diode laser disinfection|Root canal disinfection using a 940 nm dental laser after the removal of root canal filling of failed endodontic cases.
45832264|NCT03584880|Device|Pseudo diode laser disinfection|Without activating laser energy, same procedure as experimental group was performed (Sham laser application)
45832265|NCT03155568|Procedure|sciatic nerve block|sciatic nerve block at popliteal fossa
45980559|NCT00317213|Drug|LIBERTAL- a phospholipid mixture|
45980560|NCT00345150|Drug|Ng-monomethyl-L-arginine (drug)|
45980561|NCT00317252|Drug|Hold ACEI or ARB|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-96 hours post-catheterization (after creatinine measurement)
45832266|NCT03155568|Procedure|ankle block|block of major nerves supplying the foot at the level of the ankle
45832267|NCT03155568|Drug|Bupivacaine|blocking the lower limb nerve supply at the level of the popliteal fossa and ankle using the local anesthetic bupivacaine
45456378|NCT04165772|Drug|TSR-042 or Dostarlimab|Patients will be given TSR-042/Dostarlimab at a dose of 500mg IV, over 30 minutes Q 3 weeks.
45980562|NCT04714788|Device|RECAP_MyLife mobile app|"The intervention will be the use of a mobile application for collecting data from cohorts participants, envisioning to engage participants and collect continuous unbiased records. Participants in the intervention group will install the mobile application on their smartphones on the beginning of the trial and will be asked to self-report information on mood every day. Simultaneously, physical activity (number of steps) will be passively tracked through real-time information.~Participants will complete baseline and post-intervention measures of mood status based on the Circumplex Mood Model and IPAQ-Short form. Following these measures, participants will be asked to complete questionnaires on usability (SUS scale) and acceptability of the intervention."
45980563|NCT04714788|Other|Usual data collection methods|Participants in this group will provide data through usual types of data collection methods (face-to-face assessments, mailed questionnaires, online questionnaires).
46082736|NCT02718846|Drug|Meniace|6 mg of Meniace tablets were administered 3 times per day after meals
46082737|NCT02718846|Drug|Isobide|an initial dosage of 90 mL of Isobide solution was administered orally 3 times a day after meals
45456379|NCT04165772|Drug|capecitabine or 5-FU|Capecitabine 825mg/m2 BID concurrently with radiation per standard radiation guidelines. If patient is unable to tolerate oral medication, infusional 5-FU is an acceptable alternative.
45672750|NCT04145219|Other|Placebo|For daily administration (1 tablet per day)
45456380|NCT04165772|Radiation|Intensity Modulated Radiation Therapy (IMRT)|The radiation dose is 5400 cGy to the tumor and surrounding nodes 4700 cGy to the pelvis, with an integrated boost to the primary tumor and involved nodes of receiving 5400cGy in 27fx.
45458700|NCT01238887|Dietary Supplement|Garcinia cambogia-derived hydroxycitric acid (2800 mg/day)|The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 2,800 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
45980564|NCT00317291|Procedure|Acupuncture/Moxibustion|Acupuncture/Moxibustion: 16 scheduled sessions
45672751|NCT03259763|Device|Lumen-apposing metal stent|In this technique, the gastric wall and its adjacent small intestine are punctured by a needle to make a connection between the stomach and small intestine. Then a lumen-apposing metal stent is deployed at the puncture site to keep the stomach-small intestine connection open.
45672752|NCT03259763|Device|Self-expandable metal stent|In this technique, under endoscopic visualization, a guidewire will be advanced through the obstructed part of the stomach. Then an enteral self-expandable metal stent will be deployed under direct endoscopic visualization and fluoroscopic guidance.
45832268|NCT03584802|Other|Therapeutic plasma exchanges|The patient will initially receive Methylprednisolone bolus of 1g i.v. day 1, then 20 mg/day (or oral prednisone equivalent) for 21 days; and then he will have nine therapeutic plasma exchanges of 1.5x the estimated plasma volumes using albumin:saline (3:1) or fresh frozen plasma in case of an INR superior to 1.5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100 mg/kg). On days 7 and 15, the patient will receive rituximab 1 g i.v. on days 7 and 15 (after therapeutic plasma exchange and premedication); and intravenous immunoglobulin 0.5 g/kg/d on days 16 to 19.
45832269|NCT03584802|Other|Conventional treatment of AE-IPF|Conventional treatment of AE-IPF
45832270|NCT03584568|Behavioral|Perspective Taking Reappraisal|Interventions involving 1) appreciating relational insights; 2) enhancing self-awareness; 3) empathetic understanding of care-recipient; 4) integrating self-care and caring for others and 5) negotiation.
45832271|NCT03584568|Other|Basic Skill Building|These skill-building exercises are commonly used in psycho-education programs for caregivers:monitoring mood and activities, relaxation techniques and scheduling pleasant events, basic communication with the care recipient, communicating the caregivers' own needs with other family member or related persons including helpers and professional staff.
45832272|NCT03020238|Procedure|BiClamp group|electric energy
45832273|NCT03020238|Procedure|water jet group|water jet energy
45980565|NCT00317291|Other|Sham acupuncture/Placebo moxibustion|Sham acupuncture/Placebo moxibustion: 16 scheduled sessions
46082738|NCT00560833|Drug|esmirtazapine|
46082739|NCT00560833|Drug|Placebo|
46082740|NCT02789696|Other|Diagnosis of acromegaly|Biological analysis of IGF-1
45980566|NCT00345189|Drug|CNF2024|"CNF2024 capsules administered orally following 2 schedules:~starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or~starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).~Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment."
45980567|NCT00317330|Drug|Isoniazid|
45672753|NCT04808921|Diagnostic Test|Xiamen Wiz Biotech Co., Ltd. SARS-CoV-2 Antigen Rapid Test|Rapid Antigen diagnostic device performance comparative to RT-PCR
45456381|NCT04155632|Drug|N-acetylcysteine|N-acetylcysteine (NAC) is a medication that is used to treat paracetamol (acetaminophen) overdose, and to loosen thick mucus in individuals with cystic fibrosis or chronic obstructive pulmonary disease. It has a long-established safety record in adults and children, with FDA approval since 1963. The side effects most commonly noted in people who take NAC by mouth include diarrhea, nausea, vomiting, and headache. These side effects are usually mild and go away even with continued use of NAC by mouth. There is also a risk of a skin reaction, such as flushing, itching, or rash. A meta-analysis of studies evaluating long-term oral treatment with NAC for prevention of chronic bronchitis found that NAC was well tolerated, with generally mild, most commonly gastrointestinal adverse effects that did not require treatment interruption.
45980568|NCT00317330|Drug|Pyrazinamide|
45980569|NCT00317330|Drug|Rifampin|
45980570|NCT00350064|Behavioral|Exercise Training|16 weeks of aerobic exercise training at two different intensities
45980571|NCT00317408|Biological|anti-thymocyte globulin|
45980572|NCT00317408|Drug|busulfan|
45980573|NCT00317408|Drug|carboplatin|
45980574|NCT00317408|Drug|carmustine|
45980575|NCT00317408|Drug|cyclosporine|
45980576|NCT00317408|Drug|cytarabine|
45456382|NCT04155632|Device|Theta-burst stimulation (TBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.
46082741|NCT02715414|Behavioral|Multiple Family Group + Clinic Implementation Team|Clinic Implementation Teams (CIT) include providers at the clinic that aim to enhance uptake and implementation of MFG through modifications of MFG (e.g., format, length of sessions), but no modification to content will occur.
46082742|NCT02715414|Behavioral|MFG|MFG is a 12-week group involving 6-8 families of children with problem behaviors. MFG aims to reduce family-level factors that are associated with the onset and perpetuation of problem behaviors. Eight of the 12 sessions are devoted to rules, responsibilities, respectful communication and relationships. Four additional sessions target family stress and social support.
45456383|NCT04142619|Biological|UCARTCS1A|Allogenic engineered T-cells expressing anti- CS1 Chimeric Antigen Receptor
45456384|NCT04117841|Other|Observational|All groups will undergo observational data collection. No interventions will be made to patient care.
45672754|NCT05652959|Device|Cerviron®|Cerviron® is a medical device manufactured by PFC Pharma Manufacturing SL formulated following the provisions of the European Regulation 2017/745 on Medical Devices. Cerviron® is an invasive medical device of short-term use classified under annex VIII of the European Regulation 2017/745 as class IIb according to Rule 21. Cerviron® has a complex composition consisting of three topical pharmaceutical products - hexylresorcinol, collagen and bismuth subgallate - and four phytotherapeutic extracts - Calendula officinalis, Hydrastis canadensis, Thymus vulgaris extract and Curcuma longa. The Instructions for use specify its field of use as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora and of cervical lesions of mechanical origin.
45832274|NCT04405050|Device|Restrata|Restrata® is a novel synthetic nanofabricated scaffold (Restrata Wound Matrix (RWM), Acera Surgical, St. Louis, Missouri) has been developed which is a sterile, single-use device intended for use in the local management of wounds. The RWM is a soft, white, conformable, non-friable, absorbable matrix that acts as a protective covering for wound defects, providing a moist environment for the body's natural healing process to occur (Figure 2). The RWM is made from synthetic biocompatible materials and was designed to include a fibrous structure with high porosity, similar to native ECM. As a viable wrap for surgical procedures, Restrata conforms to injured tissue, can be sutured, and is arthroscopic and robotic procedure friendly.
45980577|NCT00317408|Drug|dexamethasone|
45980578|NCT00317408|Drug|etoposide phosphate|
45980579|NCT00317408|Drug|idarubicin|
45980580|NCT00317408|Drug|ifosfamide|
45980581|NCT00317408|Drug|leucovorin calcium|
45980582|NCT00317408|Drug|lomustine|
45980583|NCT00317408|Drug|melphalan|
45980584|NCT00317408|Drug|methotrexate|
45980585|NCT00317408|Drug|mitoxantrone hydrochloride|
45980586|NCT00317408|Drug|prednisolone|
45980587|NCT00317408|Drug|thiotepa|
45980588|NCT00317408|Drug|vinblastine sulfate|
45980589|NCT00317408|Drug|vindesine|
45980590|NCT00317408|Procedure|allogeneic hematopoietic stem cell transplantation|
45980591|NCT00317408|Procedure|autologous hematopoietic stem cell transplantation|
45980592|NCT00317408|Procedure|peripheral blood stem cell transplantation|
45980593|NCT00317408|Radiation|total-body irradiation|
45980594|NCT00345267|Device|Integrated Care Pathway|
45980595|NCT00317447|Drug|Oral Prednisone|
45980596|NCT00350103|Drug|SPM 929|
45980597|NCT00317525|Device|Spectacle Lenses|
45980598|NCT02959554|Drug|Nivolumab|240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
45980599|NCT02959554|Drug|Sunitinib|According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
45980600|NCT02959554|Drug|Pazopanib|According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
45980601|NCT00345306|Drug|Comparison between two different progesterone administration|
45980602|NCT00317681|Drug|Tacrolimus ointment|
45980603|NCT00350181|Drug|Sirolimus|Immunosuppressant beginning day -3 with 12 mg oral loading dose, 4 mg/day orally for adults
45980604|NCT00350181|Drug|MMF|Immunosuppressant given through IV on day 0 at 15 mg/kg twice daily ≥ 2hr after the completion for the donor cell infusion
45980605|NCT00350181|Drug|BCNU|15 mg/kg, IV
45980606|NCT00350181|Drug|VP-16|60 mg/kg, IV
45980607|NCT00350181|Drug|CY|For subjects aged 18-60 with lymphoma 100 mg/kg, IV For subjects aged with AML, ALL or CML 18-50 60 mg/kg, IV For subjects aged 51-60 with MDS, AML or ALL or patients age 18-60 with MDS, secondary AML or non-CML myeloproliferative disease 45 mg/kg
45980608|NCT00350181|Drug|FTBI|1320 cGy delivered in 11 120 cGy fractions over 4 day
45980609|NCT00350181|Drug|BU|BU 1 mg/kg every 6hr x 4 doses, IV
45980610|NCT00317759|Biological|therapeutic autologous lymphocytes|
45980611|NCT00317759|Drug|fludarabine phosphate|
45980612|NCT00317798|Biological|anti-thymocyte globulin|Escalating doses of rATG,intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
45980613|NCT00317798|Drug|sirolimus|escalating doses of rATG, intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
45980614|NCT00345462|Biological|Trivalent virosomal influenza vaccine|
45980615|NCT00345501|Drug|Iloprost|Iloprost 1ng/kg/min IV starting 1 hour before the procedure and continuing for 4 hours after its end
45980616|NCT00345501|Drug|Placebo|Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end
45980617|NCT00317837|Procedure|Unipolar Hemiarthroplasty of the hip joint|Unipolar Hemiarthroplasty of the hip joint
45980618|NCT00317837|Procedure|bipolar hemiarthroplasty|bipolar hemiarthroplasty
45980619|NCT00345657|Drug|Niacin Extended Release/Lovastatin|
45980620|NCT00317876|Drug|cyclophosphamide|
45980621|NCT00317876|Drug|cyclosporine|
45980622|NCT00317876|Drug|methotrexate|
45980623|NCT00317876|Procedure|allogeneic bone marrow transplantation|
45980624|NCT00317876|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
45980625|NCT04714827|Biological|CD19-CD22 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and BCMA，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-BCMA CAR-T cells .
45980626|NCT00317915|Drug|Irbesartan treatment|
45980627|NCT00317954|Drug|Spironolactone|
46082743|NCT05408390|Other|LPD+LED|Low physical density (LPD) + low energy density (LED) foods. Participants receive breakfast, lunch and snack items engineered to have LPD and LED.
45980628|NCT00317993|Drug|ezetimibe|
46082744|NCT05408390|Other|HPD+LED|High physical density (HPD) + low energy density (LED) foods. Participants receive breakfast, lunch and snack items engineered to have HPD and LED.
45832275|NCT04405050|Device|Negative Pressure Wound Therapy (NPWT)|Negative Pressure Wound Therapy (NPWT) has dramatically changed the care of complex foot wounds. Compared to standard wound care, patients with diabetic foot wounds that are treated with NPWT are 5.9 times more likely to heal and 4.4 times less likely to require amputation. NPWT involves the delivery of sub-atmospheric pressure through a vacuum pump connected to a specialized dressing to maintain a closed environment. NPWT increases perfusion to the wound, accelerates granulation tissue formation, reduces edema, and reduces bio-burden
45832276|NCT03159702|Drug|Evomela|140 mg/m^2/day IV on Day -6 for patients who are < 60 years of age. 70 mg/m^2/day IV on Day -6 For patients who are ≥60 years or have a HCT-CI score of >3
45832277|NCT03159702|Drug|Fludarabine|40 mg/ m^2/day intravenous on Days: -5 -4, -3, -2
45832278|NCT03159702|Radiation|Total Body Irradiation|200 cGy on Day: -1
45832279|NCT04405128|Diagnostic Test|Transcranial Tissue Doppler (TCTD)|"Doppler ultrasound technique called 'Brain Tissue Velocimetry (Brain TV), to investigate brain tissue motion over the cardiac cycle."
45980629|NCT00317993|Drug|simvastatin|
45980630|NCT00317993|Drug|ezetimibe plus simvastatin|
45980631|NCT00350415|Drug|Mesalamine|"Asacol 400g/day (400 mg tablet), oral, for 6 weeks~OR~Asacol 4,8 g/day (800 mg table), oral, for 6 weeks"
45980632|NCT00318032|Drug|multi-factorial intervention|
45980633|NCT00318071|Device|Merci Retriever|"For patients eligible to participate in the trial, the operating physician initiated treatment with the Merci L5 Retriever to remove large vessel thrombotic occlusion and recanalization of the vessel. Subsequent treatment could be made with Merci X6 or X5 Merci Retrievers.~Large vessel arteries are defined as internal carotid, middle cerebral M1/M2 segments, basilar, and vertebral arteries.~Recanalization was defined as TIMI II or TIMI III per angiography."
45980634|NCT00345696|Drug|Bevacizumab|5 mg/Kg intravenous, 90-60-30 minutes, every 2 weeks.
45980635|NCT00345696|Drug|Capecitabine|600 mg/m2, orally, every 12 hours, continuous.
45980636|NCT00345696|Drug|Oxaliplatine|85 mg/m2, intravenous, 2 hours infusion, every 2 weeks
45980637|NCT00318110|Procedure|NST using MUD for metastatic renal cell carcinoma|"Preparative regimen:~Fludarabine 25 mg/m2 IV once a day x 5 days (-6,-5,-4,-3,-2) Melphalan 70 mg/m2 IV once a day x 2 days (-3,-2) Donor Stem Cell Infusion: Stem cells will be infused on day 0 GVHD prophylaxis: Tacrolimus and methotrexate 5 mg/m2 IV day 1, 3, 6 and 11"
45980638|NCT04708236|Drug|ORTD-1 low dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
45980639|NCT04708236|Drug|ORTD-1 mid dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
45980640|NCT04708236|Drug|ORTD-1 high dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
45980641|NCT04708236|Other|Vehicle control|Vehicle Control will be administered intravenously once daily for 5 consecutive days.
45980642|NCT00318188|Procedure|standardized reeducation and readaptation program|
45980643|NCT00350454|Device|rapamycin-eluting Stent with permanent polymer|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
45980644|NCT00350454|Device|rapamycin-eluting stent with biodegradable polymer|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
46082745|NCT05408390|Other|LPD+HED|Low physical density (LPD) + high energy density (HED) foods. Participants receive breakfast, lunch and snack items engineered to have LPD and HED.
45456385|NCT04113759|Behavioral|Blood Flow Restriction Rehabilitative Therapy|"BFR cuffs placed at the proximal thigh, just inferior to the greater trochanter.~Inflation time not to exceed 20 minutes. One BFR session per treatment. BFR exercise dosage: 4 sets of the following repetitions 30, 15, 15, 15, 30 second rest between sets, 1 min rest between exercises.~Progress exercise if pain <2/10 on VAS and RPE <5 on 0-10 scale. (Heerey et al), and no break down in form."
45456386|NCT04113759|Behavioral|Sham BFR Rehabilitative Therapy|The schedule, type of exercises, repetition ranges, and other physical therapy interventions will be the same as the BFR experimental group - however a non-occlusive pressure will be applied with the cuff in the control group.
45980645|NCT00350454|Device|polymer-free, rapamycin-eluting stent|due to randomization, polymer-free.rapamycin-eluting stent will be implanted
45456387|NCT04104360|Dietary Supplement|Galacto-oligosaccharides|During this period subjects will receive 7.2 grams of Vivinal GOS supplements three times daily for four weeks
45456388|NCT04104360|Dietary Supplement|Maltodextrin|During this period subjects will receive 7.2 grams of maltodextrin supplements three times daily for four weeks
45456389|NCT04088630|Drug|Fingolimod 0.5 mg|A single dose of 0.5 mg oral fingolimod within 24 hours of symptom onset
45456390|NCT04088630|Drug|Placebo|A single oral placebo pill within 24 hours of symptom onset
45832280|NCT04405128|Diagnostic Test|Brain MRI|Brain MRI for investigation of brain tIssue motion in the presence of acute acquired brain injury.
45980646|NCT00318227|Procedure|Blood Transfusion|Blood transfusion will be administered when the transfusion trigger is met.
46082746|NCT05408390|Other|HPD+HED|High physical density (HPD) + high energy density (HED) foods. Participants receive breakfast, lunch and snack items engineered to have HPD and HED.
46082747|NCT04233710|Combination Product|Robot Rehabilitation + tDCS|Robotic therapy with Kinarm Exoskeleton Robot and 1 mA cathodal tDCS applied to contralesional M1 for 20 minutes.
45832281|NCT03584412|Behavioral|ACT OPEN|Participants will access the ACT OPEN treatment through a secure online platform. Each session consists of brief videos and audio recordings that provide information about pain and guide participants through experiential exercises (e.g., mindfulness, values clarification, goal-setting). Participants will respond to questions assessing their experiences during the session and their progress using online messaging and/or brief telephone calls according to their preference. Therapists will provide individualised feedback. ACT OPEN consists of 12 sessions over 6 weeks. Participants will be given two further weeks to finish any uncompleted sessions, or to complete additional sessions (up to four) as agreed with their therapist.
45980647|NCT00318266|Device|Nuclear Matrix Protein 22 Urine sample kit|Urine sample obtained from patient will be tested with the NMP22 sample kit to see if it can detect bladder cancer.
45980648|NCT00345735|Drug|Fentanyl|
45980649|NCT00345774|Drug|PRX-08066|
45980650|NCT00318344|Drug|Atuna Racemosa|
45980651|NCT02959749|Drug|Osimertinib|80 mg oral daily; until disease progression, intolerable toxicities, or patient death.
45456391|NCT04088630|Other|Standard of care|Standard of care protocol for the treatment of spontaneous ICH
45456392|NCT04073134|Biological|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
45456393|NCT04073134|Drug|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
45456394|NCT04069962|Behavioral|CGA coordination by geriatric team including intensive patient coaching and follow-up|In the intervention group, the CGA including geriatric recommendations for interventions will be coordinated by the geriatric team and will be complemented with patient coaching. This intervention aims to support patient empowerment by improving self-efficacy and supporting self-management of existing age-related problems before systemic therapy or occurring during systemic therapy, and includes an individual counselling session at start of systemic therapy to discuss the recommendations with the patient and to determine their priorities.
45980652|NCT02959749|Drug|docetaxel, bevacizumab|Docetaxel and bevacizumab are common used in third line therapy in non-small cell lung cancer if not used before. Docetaxel (75 mg/m2) intravenous infusion on day 1 and bevacizumab (7.5 mg/kg) on day 1 every 21days a cycle, until disease progression, intolerable toxicities, or patient death.
45980653|NCT00318383|Biological|NicVAX conjugate vaccine|200 mcg or 400 mcg IM in 4 doses over 6 months; 200 mcg or 400 mcg IM in 5 doses over 6 months; 200 mcg (formulation 2) IM in 5 doses over 6 months; All are adsorbed onto Alhydrogel
45980654|NCT00318383|Biological|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 4 or 5 doses over 6 months
45980655|NCT00350571|Behavioral|brief (behavioral therapy)|up t 3 sessions of phone or office based counseling sessions to promote re-engagement in treatment.
45980656|NCT00350571|Behavioral|Drop out re-engagement motivational intervention|Up to 3 phone or office based counseling sessions to promote reengagement in treatment
45980657|NCT00350571|Behavioral|standard care follow up|routine counselor phone calls and letters
45980658|NCT00318422|Drug|liraglutide|
45980659|NCT00318422|Drug|rosiglitazone|
45980660|NCT00318422|Drug|glimepiride|
45980661|NCT00345813|Dietary Supplement|soy isoflavones|Given orally
45980662|NCT00345813|Dietary Supplement|soy protein isolate|Given orally
45980663|NCT00345813|Other|placebo|Given orally
45980664|NCT00350610|Other|Treatment as usual (TAU)|Standard treatment as usual in a community based treatment setting
45980665|NCT00350610|Behavioral|CBT for CBT|Standard treatment as usual (TAU) plus computer based therapy using CBT
45980666|NCT00318500|Drug|ERB-041|
45832282|NCT03584412|Other|Waiting list control|Participants will receive their usual treatment for 5 months, after which they will complete ACT OPEN as described. A waiting list control was chosen as there is no clearly credible active psychotherapy to serve as the comparator in this context, particularly in light of high drop-out rates in two previous studies of CBT for pain in HIV. Providing the online treatment without therapist support may appear to be a logical comparison group instead of a waitlist control. However, there is evidence that therapist support is a key component of online CBT and, therefore, without this support it may not represent a credible treatment against which to judge the full treatment. In the context of the feasibility aims of this trial these reasons, the use of a waiting list control is thus justified.
45980667|NCT00345852|Procedure|Fetoscopic Selective Laser Photocoagulation|
45980668|NCT00318539|Drug|Quetiapine|
45980669|NCT00345891|Behavioral|Coping-focused counseling telephone calls|
45980670|NCT00350649|Behavioral|Standard CBT|Manualized delivery of CBT by trained clinicians
45980671|NCT00350649|Behavioral|CBT+CM/adherence|CBT and Clinical Management for attendance and completing homework
45980672|NCT00350649|Behavioral|CM/abstinence|Contingency Management
45980673|NCT00350649|Behavioral|CM/abstinence+CBT|Contingency Management for abstinence in addition to manualized CBT delivered by a trained clinician
45980674|NCT00318617|Drug|GW510516X|
45980675|NCT00350688|Radiation|Helical tomotherapy IMRT|Helical tomotherapy IMRT
45980676|NCT00419198|Procedure|Postconditioning|Postconditioning during angioplasty
45980677|NCT00419198|Procedure|standard angioplasty|standard angioplasty without postconditioning
45980678|NCT00346008|Genetic|mutation analysis|
45980679|NCT00346008|Other|high performance liquid chromatography|
45980680|NCT00346008|Other|laboratory biomarker analysis|
45980681|NCT00346008|Other|questionnaire administration|
45980682|NCT00419237|Drug|GW685698X|GW685698X will be available as dry white powder to be inhaled via DISKUS containing cellobiose octaacetate (COA) blended with lactose.
45980683|NCT00350766|Procedure|Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation|Catheter based stem cells delivery of 100 million cells resuspended in a 10 ml solution of saline with autologous serum. About 100 ml of Bone Marrow aspirate were harvested from iliac crest between the fifth and seventh day after myocardial infarction. ABMMC were isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions for injection, after being filtered through 100 um nylon mesh to remove cell aggregates.
45980684|NCT00318695|Dietary Supplement|Probiotics|Bifidobacterium longum [BL999] and Lactobacillus rhamnosus [LPR]
45980685|NCT00318695|Other|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
45980686|NCT00346047|Drug|Placebo|Corresponding placebo is applied for 12weeks
45980687|NCT00346047|Drug|Buprenorphine Transdermal System|Buprenorphine Transdermal System 5, 10 or 20 mg/patch is applied for 12weeks
45980688|NCT00421200|Drug|Hemospan (MP4OX)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
45980689|NCT00421200|Drug|Voluven (HES 130/0.4)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
45980690|NCT00350805|Procedure|EEG|One 20 minutes session
45980691|NCT00318773|Drug|sertraline|50 - 100 mg daily for 2 weeks before each menses for 4 months or 12 months and then switched to placebo.
45980692|NCT00318851|Device|Carotid Stent with Distal Protection Device|Carotid Stent Placement with Distal Protection
45980693|NCT00350883|Behavioral|Cognitive Therapy|Goal-oriented talk therapy
45980694|NCT00350883|Other|Treatment as Usual|Keep getting usual care
45980695|NCT00318890|Drug|Cisplatin|Cisplatin is given at a dose of 75 mg/m2 intravenously for three cycles on Days 1, 21, and 43.
45980696|NCT00318890|Drug|Docetaxel|Docetaxel is given at a dose of 75 mg/m2 intravenously on Days 1, 21, and 43 and continued at variable doses for 4 weeks with standard radiotherapy.
46082748|NCT04233710|Behavioral|Robotic Rehabilitation + sham tDCS|Robotic therapy with Kinarm Exoskeleton Robot and sham tDCS.
45980697|NCT00318890|Procedure|Radiotherapy|Radiation therapy will be given 5 days each week for 4 weeks plus a concomitant boost in the last 2 weeks of treatment to deliver 54 Gy in 30 fractions. Radiotherapy will follow the induction chemotherapy with docetaxel and cisplatin.
45980698|NCT00318890|Drug|Amifostine|Amifostine will be administered as a subcutaneous injection on a daily basis during radiotherapy.
45980699|NCT00346086|Drug|AIC (Amb a 1 Immunostimulatory Conjugate)|
45980700|NCT00318968|Drug|Esomeprazole|
45980701|NCT00350922|Behavioral|Psychoeducation|
45456395|NCT04050683|Procedure|Study - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Prior to and 1-3 days after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). Subjects with abnormal heart pressures during TIPS will have a right heart catheterization (RHC) to monitor heart function, blood flow, and pressures in and around the heart. The subject will be admitted to the Cardiovascular Intensive Care Unit and have a TTE all of which are standard of care. Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; TTEs; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes. Diagnostic RHC will be done as needed per standard of care.
45980702|NCT00319007|Drug|Sulindac (drug)|
45980703|NCT00319007|Drug|VSL#3 (probiotic)|
45980704|NCT00319007|Drug|Inulin (probiotic)|
46082749|NCT04013113|Drug|Haemoperfusion|"Three sessions of Hemoperfusion, 1 plasma volume/session will be done to the selected patients.~Hemoperfusion will be done through bile acids and ammonia filters to adsorb bile acids and ammonia respectively.~Group specific fresh frozen plasma will be transfused to the patient through a peripheral vein catheter to prevent hypotension if required."
45456396|NCT04050683|Procedure|Control - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|"Subject's with normal heart pressures who are having elective (planned in advance and not due to an emergency) TIPS due to refractory ascites (fluid build up in the belly that does not go away or comes back shortly after being removed). Prior to and 1-3 days after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). The subject will be admitted to the hospital after TIPS for standard of care monitoring.~Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes."
45672755|NCT05164991|Behavioral|Visuo-tactile stimulations of the right hand|Participants lay down in the magnetic resonance (MR) scanner are presented with visual stimuli (videos of the virtual rubber hand - visual stroking) simultaneously in real time with tactile stimuli (robotic stroking of the participant's hand - tactile stroking). An MR-compatible robot systematically provides the tactile stroking on the participant's hand. MR-compatible goggles show the visual stroking. Patterns of long and short robotic movements will be provided.
45672756|NCT05652881|Procedure|Joint Lavage|An arthrotomy will be made at the time of temporary external fixation and 1L normal saline will be used to irrigate the ankle joint.
45832283|NCT03155646|Drug|Dexmedetomidine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%)
45832284|NCT03155646|Drug|Clonidine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%)
45832285|NCT03155646|Drug|Levobupivacaine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
45832286|NCT03584178|Device|Budesonide via MAD device|Delivery through Mucosal Atomization Device
45832287|NCT03584178|Device|Budesonide via intranasals Saline Irrigation|delivery via nasal irrigation bottle
45980705|NCT00350961|Drug|Gemcitabine|
45980706|NCT00350961|Drug|Oxaliplatin|
45980707|NCT00350961|Drug|Capecitabine|
45980708|NCT00319085|Procedure|Total hip replacement (Preheating of femur stem)|Total hybrid hip arthroplasty, cementation of femural component, preheating, radiostereometry, DEXA
45980709|NCT00346242|Drug|Zoledronic Acid|
45980710|NCT00421473|Drug|Atovaquone / Proguanil|
45980711|NCT00319163|Drug|levonorgestrel/ethinyl estradiol|
45980712|NCT00346281|Device|32P BioSilicon|
46082750|NCT04013113|Drug|Standard Medical Treatment|Standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
46082751|NCT04013113|Other|Plasma Exchange|"Fresh frozen plasma will be used as replacement fluid.TPE treatment shall be given on first day and continued on an a dailybasis/alternate day till the desired clinical or biochemical response is achieved.~The procedures of TPE and hemoperfusion will be stopped if any major side effects occur (described below), the patient expires or the patient is transplanted within 30 days (whichever is earlier)."
45980713|NCT00319202|Drug|Candesartan|32 mg/d for 6 months
45980714|NCT00319202|Drug|Placebo|Placebo administration for 6 months
45980715|NCT00346320|Radiation|3-dimensional conformal radiation therapy|3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
45980716|NCT00319241|Behavioral|Parenting Intervention|
46082752|NCT03777098|Device|Strepic® Device|The Strepic® device is a qualitative point-of-care diagnostic test for the detection of GAS pharyngitis. The test uses direct visualization of the pharynx with a light source of specified wavelengths, causing excitation of endogenous fluorophores that emit a characteristic colored light pattern. White light images may give additional diagnostic accuracy through use of an artificial intelligence analysis of a large set of images of GAS and non-GAS pharyngitis.
45980717|NCT00421512|Drug|Bevacizumab and Sunitinib|On Cycle 1, Day 0, patients will begin treatment with bevacizumab. Sunitinib will begin on Day 1. The starting dose for sunitinib will be 25mg orally daily. sunitinib will be given in a four weeks on-two weeks off schedule. Bevacizumab will begin on Day 0 and will be administered every two weeks at 10mg/kg. A cycle of therapy is 6 weeks. The sunitinib dose escalation portion of the trial will be performed to determine the MTD of sunitinib given in combination with bevacizumab. Once the MTD has been determined, 10 additional patients will be treated at the MTD of sunitinib in combination with bevacizumab.
45980718|NCT00319280|Procedure|bonesubstitution (Calcibon, Iliac Crest Bonegraft, control)|Osteotomysite are filled with Calcibon (an injectable calcium phosphate cement) or Minced Iliac Crest Bonegraft og local graft as control
45980719|NCT00351078|Drug|PTC124|4-,4-, and 8-mg/kg PO first 14 days 10-, 10-, and 20-mg/kg TID second 14 days
45980720|NCT00319319|Drug|Mecamylamine hydrochloride (Inversine)|
46082753|NCT02723760|Drug|99mTc-3PRGD2|"SPECT/CT scanning: single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on rheumatoid arthritis patients, whole-body planar and lesions section for determination the accumulation of 99mTc-3PRGD2 in the joints and other parts of the body.~For diagnosis study, each patient will be carried out SPECT/CT scanning once. For efficacy evaluation study, each patient will be carried out SPECT/CT scanning three times (before treatment, the midterm treatment and late stage treatment)."
45980721|NCT00346359|Biological|anti-thymocyte globulin|
45980722|NCT00346359|Drug|busulfan|
45980723|NCT00346359|Drug|fludarabine phosphate|
45980724|NCT00346359|Drug|methotrexate|
45980725|NCT00346359|Drug|tacrolimus|
45832288|NCT04405206|Drug|Oxaliplatin|OXA 130mg/m2
45980726|NCT00346359|Procedure|allogeneic hematopoietic stem cell transplantation|
46082754|NCT02789852|Device|Orthosis|use orthosis
46082755|NCT00941161|Drug|metformin/glimepiride combination|long acting metformin/glimepiride 1g/2mg
46082756|NCT00941161|Drug|metformin|long acting metformin 1g once a day with fasting glucose 130-199mg/dL or long actin metformin 1g twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
45672757|NCT04107935|Behavioral|TREAT-ON|"TREAT-ON is a DE-driven self-management and support program that is delivered primarily through a real-time telemedicine videoconferencing platform. Like the usual care intervention, high risk patients with DM receiving care in underserved practices will be identified by a nurse practice-based manager (PCBM) and referred to a DE for self management services. Participants will complete an initial face-to-face visit with the DE to assess needs and develop a self-management treatment plan and goals. Via telemedicine videoconferencing, follow-up visits will be delivered by the DE to participants in their homes. Follow-up visits will be used to evaluate and support progress towards meeting and sustaining self-management goals and outcomes."
45672758|NCT04107935|Behavioral|Usual Care|"A retrospective control group will be formed from individuals who have previously participated in a program called the Diabetes High Risk Initiative. In this program, patients receiving care in underserved practices are identified by a nurse PBCM to be at high risk for DM complications and/or unplanned care and referred to a DE for self management services delivered through primary care. Patients typically participate in one face-to-face visit with the DE to assess needs and develop self-management goals and then one to two follow-up encounters (generally conducted by telephone) with the PBCM or DE."
45832289|NCT04405206|Drug|Capecitabine|Cape 1000mg/m2
45832290|NCT04405206|Radiation|intensity modulated radiotherapy|IMRT 50.4Gy/22f
45832291|NCT04405206|Procedure|DRE-Endoscopy-MRI-CEA|examination process in follow up
45832292|NCT04405206|Procedure|Nonoperative Management|Watch and Wait
45832293|NCT04405206|Procedure|Local excision|For ymriT1N0 and near-cCR patients，LE is optional.
45980727|NCT00346359|Procedure|peripheral blood stem cell transplantation|
45980728|NCT00319358|Dietary Supplement|Antioxidants|600microgm selenium, 0.54g vitamin C, 9000IU beta-carotene, 270IU vitamin E, 2g methionine per day, daily, in divided doses for 6 months
45980729|NCT00319358|Dietary Supplement|Placebo|placebo
45980730|NCT00319397|Behavioral|Exercise-Training Program|
45980731|NCT00346437|Genetic|Ad5FGF-4 vs. Placebo|Intracoronary infusion
45832294|NCT04405206|Procedure|Total Mesorectal Excision|Standard TME surgery openly or laporoscopically
45832295|NCT04405206|Behavioral|Quality of Life Questionnaires|QLQ C30 and QLQ CR29
45832296|NCT05701644|Drug|C1K 150mg|Subcutaneously administrate C1K 150mg at Day 1, Day 8, Day 15
45832297|NCT05701644|Drug|C1K 300mg|Subcutaneously administrate C1K 300mg at Day 1, Day 8, Day 15
45832298|NCT05701644|Drug|Placebo with the same volume of C1K 300mg|Subcutaneously administrate placebo with the same volume of C1K 300mg at Day 1, Day 8, Day 15
45980732|NCT00319475|Procedure|AAA or AF/IB (end-to-end) in patients with Leriche Syndrome|
45980733|NCT00351117|Drug|St. John's Wort|SJW in capsule form 300 mg PO TID
45980734|NCT00351117|Drug|Lactose|lactose in gelatin capsule that same as St. John's wort
45980735|NCT00319514|Drug|Docetaxel|
45980736|NCT00346515|Device|FiberNet Emboli Protection System|
45980737|NCT00319670|Drug|MiraLax|
45980738|NCT00351195|Drug|Etoposide|
45980739|NCT00351195|Drug|Oxaliplatin|
45980740|NCT00351195|Drug|Capecitabine|
45980741|NCT00319709|Drug|SR58611A|
45980742|NCT00346593|Device|Silicone hydrogel contact lens|
45980743|NCT00351234|Drug|Carnitine (drug)|Oral L-carnitine will be obtained from Sigma Tau Pharmaceuticals. Supplementation will be initiated at 50mg/kg body weight and increased to 100mg/kg body weight after one week.
45980744|NCT00319787|Drug|Iressa|
45980745|NCT00319826|Other|No intervention|This is an observational study with no intervention
45980746|NCT00319865|Drug|Velcade|
45980747|NCT00319865|Drug|Thalidomide|
45980748|NCT00319865|Drug|Adriamycin|
45980749|NCT00319865|Drug|Dexamethasone|
45980750|NCT00319943|Procedure|Computer-based training for Mild Cognitive Impairment (MCI)|
45980751|NCT00320021|Drug|Pyridorin (pyridoxamine dihydrochloride)|
45980752|NCT02959593|Device|VISIOR video goggles|View commercially available content through the VISIOR video goggles continuously for thirty minutes.
45980753|NCT00320060|Drug|Pyridorin (pyridoxamine dihydrochloride)|
45980754|NCT00320099|Drug|recombinant human insulin|intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l
45980755|NCT00320099|Drug|hydrocortisone|50 mg as iv bolus every 6 hours for 7 days
46082757|NCT00941161|Drug|glimepiride|glimepiride 2mg once a day with fasting glucose 130-199mg/dL, or glimepiride 2mg twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
46082758|NCT02798822|Procedure|Rapid maxillary expansion|When rapid maxillary expander was in-situ, patients waited 7 days before starting the screw activation of one quarter turn a day (0.22 mm) until overcorrection. Expansion was considered adequate when the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp. When was achieved, rapid maxillary expander stayed in place for 10 months.
46082759|NCT00944515|Drug|placebo|placebo tablet or syrup 3 days/week
46082760|NCT00944515|Drug|azithromycin|azithromycin 3 days/week
46082761|NCT00771654|Drug|Phentermine|Subjects will receive Phentermine 37.5mg everyday for one year
46082762|NCT00771654|Other|Placebo|daily for one year
45832299|NCT05701644|Drug|C1K 600mg|Subcutaneously administrate C1K 600mg at Day 1, Day 8, Day 15
45832300|NCT05701644|Drug|Placebo with the same volume of C1K 600mg|Subcutaneously administrate placebo with the same volume of C1K 600mg at Day 1, Day 8, Day 15
45980756|NCT00320099|Drug|fludrocortisone|50 µg once a day via a nasogastric tube for seven days
45980757|NCT00320099|Drug|Hydrocortisone|hydrocortisone 50mg q6 for 7 days
45980758|NCT00346671|Other|Rest|30 min supine rest
45980759|NCT00346671|Other|Sham|30 min session with Sham practitioner
45980760|NCT00346671|Other|Reiki|30 min session with Reiki practitioner
45980761|NCT00320138|Procedure|Acupuncture, using Chinese Medicine methodology|4 weeks of 2/week treatments (8 total); 4 standardized and 4 individualized treatments
45980762|NCT00351312|Device|special socks|
45980763|NCT00320294|Drug|irinotecan|
45980764|NCT00320294|Drug|cisplatin|
45980765|NCT00351390|Other|Drug therapy for HF|Titration of HF meds in an aggressive out patient manner following guideline direction
45980766|NCT00351390|Other|NT-proBNP guided HF therapy|Standard of care drug therapy following guideline direction, plus adjustment of medication titrated to achieve NT-proBNP <1000 pg/mL
45980767|NCT00320333|Procedure|pulmonary rehabilitation programme|
45980768|NCT00346749|Drug|Salmeterol|
45980769|NCT00346749|Drug|Fluticasone Propionate/Salmeterol Combination Product|
45980770|NCT00320450|Drug|SB-681323|
45980771|NCT00346788|Procedure|Surgical approach for total knee arthroplasty|total knee arthroplasty surgery using minimally invasive surgery or standard technique.
45980772|NCT00419276|Procedure|Ambulatory continuous femoral nerve block for 100 hours|Treatment group: 100 hours of ropivacaine femoral perineural infusion. Standard-of-care group: overnight ropivacaine femoral perineural infusion followed by a normal saline infusion.
45980773|NCT00351429|Device|Polyglycolic acid suture|PGA suture used in Trabeculectomy surgery
45980774|NCT00351507|Drug|Vildagliptin|
45980775|NCT00320567|Drug|norgestimate/ethinyl estradiol|
45980776|NCT00346827|Drug|Apomorphine Nasal Powder|
45980777|NCT00346866|Drug|anecortave acetate|
45980778|NCT00320723|Drug|bupropion, transdermal nicotine patch|
45980779|NCT00351546|Drug|Vildagliptin|
45980780|NCT00320762|Device|OculusGen Biodegradable Collagen Matrix Implant|
45980781|NCT00346944|Procedure|Removal of dental amalgam restorations|Removal of dental amalgam restorations by patient's own dentist. Fillings will be replaced with e.g. resin based filling material, metalloceramic restorations, and ceramic materials. Rubber dam will be used during removal of amalgam restorations.
45980782|NCT00351585|Drug|Vildagliptin|
45980783|NCT00320879|Drug|irbesartan|
45980784|NCT00346983|Drug|Pegaptanib sodium|0.3mg/0.1ml intravitreal injection, every 6 weeks, up to a total of 3 injections
45980785|NCT00346983|Drug|Control|Sham injection, every 6 weeks, up to a total of 3 sham injections
45980786|NCT00347061|Drug|afuzosin|
45980787|NCT00320957|Device|OculusGen Biodegradable Collagen Matrix Implant|
45980788|NCT00347100|Drug|Insulin Glargine|Throughout study period
45980789|NCT00347100|Drug|Glyburide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
45980790|NCT00347100|Drug|Glyclazide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
45832301|NCT05701644|Drug|C1K 900mg|Subcutaneously administrate C1K 900mg at Day 1, Day 8, Day 15
45832302|NCT05701644|Drug|Placebo with the same volume of C1K 900mg|Subcutaneously administrate placebo with the same volume of C1K 900mg at Day 1, Day 8, Day 15
45832303|NCT05701644|Drug|C1K 1200mg|Subcutaneously administrate C1K 1200mg at Day 1, Day 8, Day 15
45832304|NCT05701644|Drug|Placebo with the same volume of C1K 1200mg|Subcutaneously administrate placebo with the same volume of C1K 1200mg at Day 1, Day 8, Day 15
45832305|NCT03101046|Drug|Cabazitaxel|Experimental treatment arm: patients will be treated with intravenous cabazitaxel 20 mg/m² every 3 weeks up to 10 cycles.
45980791|NCT00347100|Drug|Glimiperide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
45980792|NCT00347100|Drug|Glipizide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
45980793|NCT00347100|Drug|Metformin|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
45980794|NCT00347139|Drug|GW642444 (25, 100 & 400 mcg/day)|25, 100 and 400mcg/dose
45980795|NCT00347139|Drug|Salmeterol 50mcg|Salmeterol 50mcg
45980796|NCT00321035|Device|OculusGen Biodegradable Collagen Matrix Implant|
45980797|NCT00347178|Procedure|Laser Peripheral Iridotomy|
45980798|NCT00321074|Drug|TACROLIMUS|Immunosuppression
45980799|NCT04717544|Behavioral|Intervention Arm|The smoking cessation intervention will include 1) a six-week, 60-75 minute weekly cognitive-behavioral therapy (CBT) smoking cessation counseling group; and 2) smoking cessation medication include varenicline (Chantix), bupropion (Zyban) and nicotine replacement therapy (NRT). Dispensing these medications will include a 15-minute medication management visit with a prescribing clinician. Clients will choose their own preferred treatment. The standard prescription for NRT will include a transdermal patch at a dose that approximates for current average mg of nicotine intake and nicotine gums or lozenges (in either 2 mg or 4 mg strengths). Prescription for varenicline will be 0.5 mg once daily for three days, then 0.5 mg twice daily for the next four days, then 1 mg twice daily thereafter. Absent any contraindications to the drugs listed above, bupropion (Zyban) 150mg will be offered and prescribed once daily for one week, following by bupropion 300 mg once daily thereafter.
45980800|NCT00321113|Drug|tacrolimus|immunosuppression
45980801|NCT00321113|Drug|mycophenolate mofetil|oral
45980802|NCT00321113|Drug|steroids|oral
45980803|NCT00347256|Drug|cisplatin|
45672759|NCT05652803|Behavioral|bibliotherapy-based psychoeducation program|In this study, the researcher aimed to gain awareness, skills and attitudes in order to help the participants reduce the negative consequences of depression and hopelessness. Based on the general purpose, a separate target has been established for each session of both intervention types. For bibliotherapy-based psychoeducation, story texts compatible with the goals were added to each session, and the psychoeducation part was supported by bibliotherapy. Considering the ability of the elderly to attend the training regularly, their attention and coordination, it was decided that the study would consist of 6 sessions and each session would be 60 minutes on average.
45672760|NCT05652803|Behavioral|psychoeducation program|The General Purpose of the Psychoeducation Program for Reducing Depression and Hopelessness: To help the participants gain awareness, skills and attitudes in order to help them reduce their depression and hopelessness levels.
45672761|NCT03184571|Drug|Bemcentinib; pembrolizumab|Bemcentinib is a selective Axl kinase inhibitor; pembrolizumab is a PD-1 inhibitor
45672762|NCT04107857|Behavioral|ELEVATE enhancement to electronic health record (EHR) to improve cessation counseling offer|"Brief advise to quit smoking~Referral to Missouri/Illinois Quitlines, Smokefree.TXT, or smokefree.gov"
45832306|NCT03101046|Drug|Docetaxel|standard treatment arm and cohort: Docetaxel is administered at the dose of 75 mg/m² over 1 hour every 3 weeks for 6 cycles (D1=D22).
45980804|NCT00347256|Procedure|targeted radiation therapy|
45980805|NCT00347256|Procedure|tumor resection|
45832307|NCT03152448|Behavioral|Prolaris|Series of three questionnaires to capture treatment decisions based upon standard clinical-pathological information with the addition of Prolaris genomic testing result
45832308|NCT03159936|Biological|Tofacitinib citrate|10 mg daily by mouth
45832309|NCT03027414|Drug|Transcranial Magnetic Stimulation Sham|TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
45832310|NCT03027414|Device|Transcranial Magnetic Stimulation|TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
45980806|NCT00321152|Other|6(S)-5-MTHF (a Medical Food)|The study consists of 8 visits over a period of 8 weeks or 60 days. Eligible participants will be randomized to double-blind treatment with placebo or Deplin (6(S)-5-MTHF). Participants will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study. At the end of the double-blind phase, both responders and non-responders who have completed the 8 week study will have the option of receiving free, open-label adjunctive treatment with either 7.5 mg or 15 mg of 6(S)-5-MTHF for 12 months. Subjects who agree to receive open-label treatment with 6(S)-5-MTHF for 12 months will be assessed every three (3) months until the end of the follow-up phase.
45980807|NCT00347295|Drug|Brotizolam|
45980808|NCT00347295|Drug|Estazolam|
45980809|NCT00321191|Drug|No nitrous oxide|
45980810|NCT00321191|Drug|Administration of N2O|
45980811|NCT00351624|Behavioral|DHA|
45980812|NCT00351624|Behavioral|placebo|
45980813|NCT00321230|Drug|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|
45980814|NCT00351663|Drug|Enoxaparine|"Patients considered eligible will be divided into 2 groups- those receiving vasopressor support and those not receiving vasopressor support at the time of inclusion. The patients in each group will be randomized to receive enoxaparin in accordance with one of the following DVT prophylaxis protocols:~Intravenous Enoxaparine according to their weight (0.5mg/kg x 1/day)~Subcutaneous Enoxaparine according to their weight (0.5mg/kg x 1/day)~Subcutaneous Enoxaparine 40mg x1/day"
45980815|NCT00321347|Drug|Lidocaine|
45980816|NCT00351702|Drug|Isoniazid with Ethambutol|Isoniazid (300mg) with Ethambutol (800mg) daily for 6 months
45980817|NCT00351780|Device|FFR measurement, side branch angioplasty|
45980818|NCT00321425|Procedure|brachial plexus block|
45980819|NCT00321425|Procedure|ultrasound guidance|
45980820|NCT00321425|Procedure|electrical nerve stimulation|
45832311|NCT03156816|Drug|Colchicine group (experimental arm)|In the experimental group, patients will receive colchicine, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily (b.i.d) for 5 days.
45980821|NCT00351858|Drug|ertumaxomab|
45980822|NCT00351897|Device|pulsed dye (585nm) laser therapy|
45980823|NCT00321542|Other|Imaging study, No intervention|Imaging with coronary computed tomographic angiography
45980824|NCT00351975|Drug|Belinostat|Given IV
45980825|NCT00351975|Drug|Azacitidine|Given SC
45980826|NCT00351975|Other|Laboratory Biomarker Analysis|Correlative studies
45980827|NCT00321581|Drug|Cediranib, AZD2171, RECENTIN|
45980828|NCT00321659|Behavioral|Aerobic|3x/week of walking and cycling
45980829|NCT00321659|Behavioral|Strength training|3x/week of resistance training activities
45980830|NCT00321659|Behavioral|Combination|3x/week of aerobic and strength training activities
45980831|NCT00321659|Behavioral|FSHC|Biweekly group education group meetings
45456397|NCT04038567|Behavioral|Mobile mindfulness-based training|The intervention core is a mobile app-based mindfulness training program designed to be used over a 1-month period. All 8 factorial groups will use the app, though the delivery of the app and response to psychological distress symptoms over time will differ by group.
45456398|NCT04034485|Drug|lerodalcibep|PCSK9 inhibitor
45980832|NCT00352092|Drug|calcineurin inhibitor|
45980833|NCT00352092|Drug|sirolimus|
45980834|NCT00352092|Drug|mycophenolate mofetil|
45980835|NCT00322010|Procedure|early PT OT|"Passive range of motion exercises for all limbs in patients who remain unresponsive despite sedative interruption (ten repetitions in all cardinal directions).~Sessions began with active assisted and active range of motion exercises in the supine position.~If tolerated, treatment is advanced to bed mobility activities, including transferring to upright sitting.~Sitting balance activities are followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.~The session progresses to transfer training, and finally pre-gait exercises and ambulation.~Progression of activities is dependent on patient tolerance and stability.~Therapy intervention continues on a daily basis throughout the patient's hospital stay until he/she returns to prior level of function or is discharged."
45456399|NCT04034485|Drug|evolocumab|PCSK9 inhibitor
45832312|NCT03156816|Drug|Placebo group (control arm)|In the placebo group, patients will receive placebo, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily for 5 days.
45980836|NCT00352131|Drug|HuC242-DM4|Dose escalation study to define maximum tolerated dose. Doses will vary per cohort. Patients will receive an IV infusion once every three weeks.
45980837|NCT00322127|Drug|AMD3100|a 2 mL clear glass vial containing 1.7 mL of a sterile isotonic solution.
45456400|NCT04021680|Other|pre-eclampsia screening program|This screening program included the use of ultrasound, biomarkers and maternal factors in calculating the risk of developing preeclampsia.
45456401|NCT04010071|Drug|axitinib plus toripalimab|"Axitinib 5mg, twice a day, orally, 4 weeks a cycle. Dose reduction from 5mg twice a day to 3mg twice a day should be considered according to adverse events.~Toripalimab 240mg, every 3 weeks, intravenous infused, 6 weeks a cycle. Number of cycle: until disease progression or unacceptable toxicity events."
45832313|NCT03583944|Drug|Eribulin Mesylate|Eribulin mesylate IV infusion.
45832314|NCT02841696|Device|Cardiac echography|The exam is in the left lateral decubitus position. 4 electrodes are applied to the patient's chest for a synchronization with the Electrocardiogram (ECG). The examination is conducted as standard with acquisition loops of records in parasternal long axis parasternal short axis, apical 4-cavities, 2-cavities and aorta 2 cavities.
45832315|NCT04764786|Other|EVOO+POLY|a test meal seasoned with extra virgin olive oil rich in polyphenols
45832316|NCT04764786|Other|OO-POLY|a test meal seasoned with olive oil poor in polyphenols
45980838|NCT00352170|Dietary Supplement|calcium supplementation|calcium carbonate 1500 mg/day
45980839|NCT00352170|Dietary Supplement|calcium and vitamin D3 supplementation|calcium carbonate 1500 mg/day vitamin D3 1000 IU/day
45980840|NCT00352170|Dietary Supplement|Placebo|calcium and vitamin D3 placebo
45980841|NCT00322166|Other|Sunlight|Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week.
45980842|NCT00322166|Other|Sunlight and calcium|Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week. In the calcium and sunlight arm, calcium supplements (Caltrate, 600mg elemental calcium, Whitehall) will be administered to the whole group via the Blister/ Webster packs.
45980843|NCT00322166|Other|control|Subjects in the control group will be provided with a brochure about vitamin D deficiency and how to treat it. They will receive their usual routine care and nutrition.
45980844|NCT02959580|Drug|Hydrocortisone Butyrate|topical use
45980845|NCT02959580|Procedure|extended excision|Lesion extended excision with or without a random breast dermo-glandular flap (BDGF).
45980846|NCT00352248|Procedure|Tongue Acupuncture (Procedure)|
45980847|NCT00322205|Drug|zyban|
45980848|NCT00352287|Drug|Recombinant human growth hormone; pioglitazone|
45980849|NCT00322244|Procedure|Massage Therapy|
45980850|NCT00352326|Device|reprogramming assisted communication device interface|The subjects were required to touch targets on the iPad® screen with the index finger of their preferred (less-affected) arm. The experimental task consisted of 180 targets divided in 4 blocks: 45 targets each block with a 1-minute interval between trials to avoid fatigue. Targets appeared at 1 of 9 different locations on the screen, and subjects moved their finger sequentially from one target to the next.
45980851|NCT00322283|Drug|Oglemilast|Oglemilast, 15mg once per day, oral administration
45672763|NCT04107857|Behavioral|ELEVATE enhancement to electronic health record (EHR) to improve smoking cessation medication offer|-Nicotine replacement therapy, varenicline, bupropion, or combination therapy (not provided by study)
45980852|NCT00322283|Drug|Placebo|Dose-marched placebo, once per day, oral administration
45980853|NCT00352404|Device|Endomicroscope|
45980854|NCT00322322|Drug|L-Carnitine|L-Carnitine
45980855|NCT00352443|Drug|everolimus|part 1: dose assigned by ETx online system PO days 1-28 daily part 2: cohort a: 5 mg PO days 1-28 part 2: cohort a: 1250 mg PO days 8-28 (cycle 1) days 1-28 (subsequent cycles)
45980856|NCT00352443|Drug|lapatinib ditosylate|dose assigned by ETx online system PO days 1-28 daily part 2 cohort a: 1250 mg PO d 8-28 (cycle 1) days 1-28 (subsequent cycles) part 2 cohort b: 120 mg PO days 1-28 daily
45980857|NCT00322361|Biological|Comparator: RECOMBIVAX HB™|RECOMBIVAX HB™ 3 x 5-mcg regimen administered via intramuscular injection.
45980858|NCT00322361|Biological|Comparator: Modified process Hepatitis B Vaccine|Modified Process Hepatitis B 3 x 5-mcg regimen administered via intramuscular injection.
45980859|NCT00352482|Drug|Sildenafil (50 mg)|
45980860|NCT00322400|Drug|Docetaxel|Subjects assigned to Arm B, cohorts will receive 75 or 100 mg/m2 of docetaxel (based on cohort assignment) on Day 1 repeated every 21 days (1 cycle). AMG 706 will be administered concurrently on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond.
45980861|NCT00322400|Drug|Paclitaxel|Subjects assigned to Arm A will receive 90 mg/m2 of paclitaxel on Days 1, 8 and 15 repeated every 28 days (1 cycle). On Arm A, AMG 706 will be concurrently administered on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond.
45980862|NCT00322400|Drug|AMG 706|"Subjects assigned to Arm A will receive AMG 706 at 50, 75, 100 or 125 mg daily (based on cohort assignment) on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond in combination wth paclitaxel 90 mg/m2. Paclitaxel will be administered on Days 1, 8 and 15 every 28 days.~Subjects assigned to Arm B will receive AMG 706 at 50, 75, 100 or 125 mg daily(based on cohort assignment) on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond in combination with docetaxel. Docetaxel will be administered at either 75 mg/m2 or 100 mg/m2 on Day 1 every 21 days."
45980863|NCT00352521|Drug|bevacizumab|
45832317|NCT03159546|Device|Device: FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
45980864|NCT00352521|Drug|irinotecan|
45980865|NCT00352521|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
45980866|NCT00322478|Behavioral|Automated informatics driven education and social networking|The patient uses a self-contained wireless accessory to a standard blood glucose meter. This device manages the meter to ensure accurate time stamps and transmits the data to a centralized data management system. The system is then configured to assess the data and take automated steps to derive relevant diabetes education and/or send reports to a registered and authorized team.
45980867|NCT00322478|Behavioral|Blood Glucose Notifications to Remote Caregivers|When children with type 1 diabetes are at school they will connect their blood glucose meter to the GlucoMON appliance. The data from the meter is then transmitted to the central system followed by the most recent blood sugar being sent to the primary caregiver's email address(es) as a plain text message. The investigator is interested to better understand the behaviors that accompany the expectation of the message and actions taken subsequent to receipt of the message by the patient-centric team.
45980868|NCT00322478|Behavioral|Frequency of Pattern Management|The behavioral intervention being studied involves the assessment of frequency of self-care in relation to the primary and secondary outcomes including overall blood sugar control and patient satisfaction.
45980869|NCT00352599|Drug|Lovastatin|
45456402|NCT03992339|Drug|ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle|Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle.
45980870|NCT00352599|Drug|Lovastatin|Lovastatin capsules daily for 14 weeks (titrated up from 10 mg to 40 mg)
45980871|NCT00352599|Drug|placebo pill|
45980872|NCT00352638|Other|counseling intervention|
45980873|NCT00352638|Other|educational intervention|
45980874|NCT00352638|Other|study of socioeconomic and demographic variables|
45980875|NCT00322595|Drug|Quetiapine fumarate|
45980876|NCT00322595|Drug|Paroxetine|
45980877|NCT00352677|Drug|INNO-406|Oral, twice daily self-administration of 10 mg and/or 50 mg tablets
45980878|NCT00352716|Drug|Smecta (Diosmectite), duration of treatment - 7 days|
45980879|NCT00331149|Drug|Ropinirole prolonged release|
45672764|NCT04107857|Behavioral|Data Driven Feedback reports|-Feedback reports will be based on data
45672765|NCT04102865|Device|Negative Pressure Wound Therapy|Single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 1 week.
45672766|NCT03149861|Procedure|PET/MR-ultrasound guided Fusion biopsy|All focal lesion with PI-RADS >=3 on MR or with DCFPyL uptake on PET will undergo a focal fusion biopsy
45672767|NCT03149861|Procedure|Systemic TRUS guided biopsy|Transrectal ultrasound guided systemic prostate biopsy
45832318|NCT03159858|Device|Fenerated AAA Endovascular Graft with H&L-B One Shot Introduction System|The Compassionate Use Request is for the use of the Cook Zenith Fenestrated Endovascular Graft (4 branches) for the treatment of a 70-year-old male patient considered unfit for open surgical repair of his 6cm paravisceral abdominal aortic aneurism (AAA).
45832319|NCT03583632|Other|visual acuity testing|testing of visual ycuity by ETDRS charts
45832320|NCT03583632|Device|optical coherence tomography|optical coherence tomography generates sectional slides of the retinal tomography with light
45980880|NCT00331149|Drug|ropinirole immediate release|
45980881|NCT00331188|Drug|Sanvar® (vapreotide)|
45980882|NCT00352833|Drug|catumaxomab|
45980883|NCT00322673|Drug|XL999|XL999 was administered at a dose of 2.4 mg/kg given as a 4-hour IV infusion weekly for 4 weeks. In the absence of progressive disease and unacceptable toxicity, subjects were to receive XL999 treatment weekly for up to 1 year on this study
45980884|NCT00331305|Behavioral|Supervised Exercise|
45980885|NCT00331305|Behavioral|Home-Based Exercise|
45980886|NCT00331305|Drug|Sertraline (Zoloft)|
45980887|NCT00331305|Drug|Placebo Pill|
45980888|NCT00322751|Drug|Topotecan|The starting dose for the first cohort will be 2 mg/m2/week. Increment between cohorts will be by 1 mg/m2/week if no toxicity related to topotecan occurs. All members of a dose cohort must have safely completed all radiotherapy and topotecan dosing prior to beginning enrollment in the next higher dose cohort. Increments will be reduced to 0.5 mg/m2 if mild to moderate toxicity occurs (grades 1 or 2). The escalation will continue until the maximum dose of 4 mg/m2/week is reached. Therefore the minimum number of dose levels (cohorts) is 3 to reach the goal of 4 mg/m2/week, and the maximum is 5.
45980889|NCT00352950|Drug|AMG 954/Panitumumab|
45980890|NCT00322907|Drug|Cotrifazid vs mefloquine or quinine+SP|
45980891|NCT00352989|Drug|Smecta (Diosmectite), duration of treatment - 7 days|
45980892|NCT00322946|Biological|rDEN4delta30-4995|Live attenuated rDEN4delta30-4995 vaccine (one of three doses)
45980893|NCT00322946|Biological|Placebo|Placebo for rDEN4delta30-4995
45980894|NCT00331500|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
45980895|NCT00331500|Drug|Olopatadine Hydrochloride Ophthalmic Solution Vehicle|Inactive ingredients used as a placebo comparator
45980896|NCT00322985|Drug|Lenalidomide|25 mg/day, orally for 21 days with 7 days rest (28 day cycle). Dosing will be in the morning at approximately the same time each day.
45980897|NCT00353028|Drug|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
45980898|NCT00353028|Drug|Placebo|Placebo
45832321|NCT03583476|Drug|Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole|Triple or quadruple therapy consist of Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole.
45832322|NCT03583398|Procedure|transcatheter aortic valve implantation, surgical aortic valve replacement|Transcatheter aortic valve implantation using transaortic and transfemoral access and surgical aortic valve replacement.
45980899|NCT00323024|Drug|NX1011|
45980900|NCT00331539|Device|Cochlear Implant|
45980901|NCT00323102|Drug|Multihance|
45980902|NCT00331578|Device|Excel drug-eluting coronary artery stent|
45980903|NCT00353067|Drug|veliflapon (DG-031)|
45980904|NCT00323219|Drug|Cefazolin and Moxifloxacin|See Detailed Description.
45980905|NCT00353106|Behavioral|Interview|30-minute interviews of participating patients and their caregiver(s).
45980906|NCT00353106|Behavioral|Questionnaire|Questionnaires that will take approximately 5 minutes to complete.
45980907|NCT00331656|Device|Non-invasive positive pressure mask ventilators|
45456411|NCT03988920|Drug|Tenapanor|NHE3 Inhibitor
45980908|NCT00331656|Device|Extrathoracic biphasic cuirass ventilator (RTX, Hayek)|
45980909|NCT00323375|Drug|AQ-13|A treatment dose of AQ-13 (1750 mg base) was administered orally to subjects randomized to AQ-13 over 3 days (as two capsules on days 1 and 2, plus one capsule on day 3).
45980910|NCT00323375|Drug|Chloroquine (CQ) Treatment|A treatment dose of CQ (1500 mg CQ base) was administered orally to subjects randomized to CQ over 3 days (as two capsules on days 1 and 2, and one capsule on day 3).
45980911|NCT00331695|Drug|17 alpha-hydroxyprogesterones caproate|17 alpha-hydroxyprogesterones caproate
45980912|NCT00323531|Procedure|Chest tube with tPA infusion for 3 days|fibrinolysis through the chest tube
45980913|NCT00323531|Procedure|VATS decortication|thoracoscopic decortication
45980914|NCT00323570|Drug|activated recombinant human factor VII|
45980915|NCT00353145|Drug|Gemcitabine (Gemox)|1000 mg/m^2, infused at 10 mg/m^2/min on Day 1 repeated every 14 days (one cycle).
45980916|NCT00353145|Drug|Oxaliplatin|100 mg/m^2 by vein infused on Day 2 over two hours, repeated every 14 days (one cycle).
45980917|NCT00353145|Behavioral|Questionnaire|Quality of Life Surveys
45980918|NCT00323648|Drug|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis.
45980919|NCT00353184|Drug|Montelukast 5-mg orally added to standard therapy|
45980920|NCT00323687|Drug|Truvada|300mg / 200 mg QD tenofovir DF and Emtricitabine Fixed Dose Combination (FDC) Tablet (oral)
45980921|NCT02959515|Procedure|Capnothorax|Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.
45980922|NCT02959515|Procedure|Capnothorax and CPAP|"Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.~Continuous positive airway pressure of 10 cmH2O delivered by CF 800 Continuous flow CPAP, Drager."
45456412|NCT03988920|Drug|Sevelamer Carbonate|Phosphate binder
45672768|NCT03132155|Drug|AMG 337|6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
45832323|NCT03583320|Diagnostic Test|Cardiac CT angiogram|To the best of the author's knowledge this study will provide the first prospective and randomised data pertaining to hospital length of stay as a primary outcome in the use of CTCA on this acute chest pain cohort (with an intermediate observational zone category) on initial high sensitivity-cardiac troponin (hs-cTn) results presenting to the emergency department in a tertiary care hospital.
45832324|NCT03583242|Drug|Antiangiogenic Agents|3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
45832325|NCT03583242|Drug|Corticosteroid|1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
45980923|NCT00353223|Behavioral|Interpersonal and behavioral psychotherapy|Participants will receive a combined intervention of interpersonal and behavioral psychotherapy designed for people with heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours. The psychotherapy sessions will allow participants to discuss how they are coping with their illness and loss of functioning. They will also aim to help participants with heart failure to develop new recreational activities in keeping with their new level of functioning.
45980924|NCT00353223|Behavioral|Attention control (AC) condition|The AC group will not receive therapy. Instead, a clinician will ask them questions about their depression and heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours.
45980925|NCT00323804|Biological|Peginterferon alfa-2b|PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36
45980926|NCT00323804|Drug|Ribavirin|Ribavirin in addition to PegIFN alfa 2b, from day 0 to M36
45980927|NCT00323804|Drug|Ribavirin-Placebo|Ribavirin-placebo in addition to PegIFN alfa 2b, from day 0 to M36
45980928|NCT00353340|Drug|n acetylcysteine|
45980929|NCT00353340|Drug|sodium bicarbonate|
45980930|NCT00353340|Drug|sodium chloride|
45980931|NCT00323843|Drug|Isoproterenol|
45456413|NCT03986034|Drug|During Venetoclax|Patients with CLL/SLL will enroll on the study. Subjects will be treated at the NIH Clinical Center for the duration of the ramp-up phase of venetoclax. After the ramp-up phase is complete, subjects will be transitioned to the care of their local hematologist/oncologist and receive venetoclax monotherapy or in combination with other agent(s) at the discretion of the treating oncologist. Subjects will have the option to follow-up at the NIH every 6 months (from initiation of venetoclax) and at (suspected) progression.
45456414|NCT03980717|Device|Goldbal Detachable Balloon and delivery microcatheter|Between 28+0/7 - 31+6/7 weeks gestation for severe CDH placement of the detachable balloon. Balloon retrieval will be planned for no later than 36+6/7 weeks at the discretion of the FETO center.
45672769|NCT03107195|Drug|Imaging Time|Participants will be asked to be imaged at an additional time point.
45672770|NCT02164916|Biological|cetuximab|Given IV
45672771|NCT02164916|Drug|irinotecan hydrochloride|Given IV
45672772|NCT02164916|Drug|vemurafenib|Given PO
45672773|NCT05652569|Other|Genomic Profiling / Sequencing|Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) on metastatic biopsy lesions
45672774|NCT04091867|Drug|sEphB4-HSA with chemotherapy|sEphB4-HSA is a fusion protein combining the soluble extracellular EphB4 domain with albumin that targets the ephrin B2 receptor, which is thought to mediate resistance to EGFR-targeted therapy, and acts as a radiosensitizer by enhancing DNA damage and promoting apoptosis. Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines. These can be administered in tri-weekly or weekly doses during the radiation period. The participant will receive the first infusion on Day 15 (+/- 3 days).
45980932|NCT00331812|Procedure|Mitochondrial functions and oxidative stress|
45980933|NCT00323921|Device|dermatological infrared laser|
45980934|NCT00331851|Drug|liraglutide|
45980935|NCT00331851|Drug|insulin glargine|
45980936|NCT00331851|Drug|metformin|
45980937|NCT00331851|Drug|glimepiride|
45980938|NCT00323999|Procedure|Hysteroscopic resection of fibroids, polyps and endometrium.|
45980939|NCT00331890|Drug|Citicoline|1g/12h iv during 3 days and then orally until complete 6 weeks of treatment
45980940|NCT00331890|Drug|Placebo|As active drug
45980941|NCT01059773|Drug|Ustekinumab|Patients weighting ≤ 100 kg will receive ustekinumab 45 mg at Weeks 0, 4 and 16. Patients who achieve a PASI 75 response at Week 28 and 40 will continue receiving ustekinumab 45 mg at Week 28 and 40. Patients who fail to achieve PASI 75 response at Week 28 will receive ustekinumab 90 mg at Week 28 and 40. Patients who achieve a PASI 75 response at Week 28, but fail to achieve PASI 75 response at Week 40 will receive ustekinumab 90 mg at Week 40. Patients > 100 kg will receive ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40, regardless of achievement of PASI 75 response. Consideration will be given to discontinuing treatment in these patients if they show no response at Week 28.
45980942|NCT01059773|Drug|Methotrexate|Gradual reduction of methotrexate therapy over the 4 week period after Week 0. The methotrexate dose reduction regime will depend on the dose of methotrexate at screening. All patients will stop methotrexate regardless of the final dose after 4 overlapping weeks. The last dose of methotrexate will be given within the 7 day period before the second dose of ustekinumab.
45980943|NCT00353379|Drug|Guanfacine|Participants will take guanfacine for 6 weeks. Guanfacine dosages will not exceed 2 mg per day.
45980944|NCT00353379|Drug|Placebo|Participants will take placebo for 6 weeks.
45980945|NCT00324077|Drug|Dasatinib in combination with imatinib|
45980946|NCT00331929|Device|Minato A 500 AS spirometer|Spirometry at rest
45980947|NCT00324194|Drug|MGCD0103|MGCD0103 oral dose given 2 times per week.
45980948|NCT00324311|Drug|DGD|Lyophilized, sterile mixture of proteolyzed enzymes; mixed with gel,for topical application.
45980949|NCT00353613|Behavioral|Package of targeted interventions to reduce error|Interventions will include changes in administration of antibiotics and the improved monitoring of blood glucose and body temperature peri-operatively.
45980950|NCT00324389|Drug|Interferon alpha|
45980951|NCT00332007|Drug|Tonabersat|two tablets once daily
45980952|NCT00332007|Drug|Placebo|two tablets once daily
45980953|NCT00353691|Drug|glimepiride|
45980954|NCT00353691|Drug|metformin|
45980955|NCT00324428|Procedure|Transcranial Magnetic Stimulation|1Hz repetitive transcranial magnetic stimulation for 10 days 26 minutes each day
45980956|NCT00332046|Drug|GW679769|
45980957|NCT00324467|Drug|Cyclophosphamide|"Dose: 750 mg/m^2 Administration: IV infusion day 1 over 20-60 minutes Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)~* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
45980958|NCT00324467|Drug|Doxorubicin|"Dose: 50 mg/m^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)~* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
45980959|NCT00324467|Drug|Vincristine|"Dose: 1.4 mg/m^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)~* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
45980960|NCT00324467|Drug|Prednisone|"Dose: 45 mg/m^2 Administration: IV infusion day 1 (or day 2) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)~* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
45980961|NCT00324467|Drug|Ondansetron|Premedication for R-CHOP Dose: 8 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
45980962|NCT00324467|Drug|Dexamethasone|Premedication for R-CHOP Dose: 12 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
45980963|NCT00324467|Drug|Diphenhydramine|Premedication for R-CHOP Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
45980964|NCT00324467|Drug|Acetaminophen|Premedication for R-CHOP Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
45980965|NCT00324467|Drug|Ifosfamide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3, over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
45980966|NCT00324467|Drug|Mesna (IV)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3 (with ifosfamide) over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
45980967|NCT00324467|Drug|Mesna (oral)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 2 g Administration: PO 2h and 4h after ifosfamide infusion on days 1,2,3 Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
45980968|NCT00324467|Drug|Carboplatin|"R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5 x (25+CrCl*) (maximum dose 800 mg) Administration: IV infusion day 1 over 1 hour Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)~*Carboplatin is dose via the Calvert formula with an AUC of 5, maximum dose 800 mg per cycle.~Estimate Creatinine Clearance (CrCl)"
45980969|NCT00324467|Drug|Etoposide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 100 mg/m^2 Administration: IV infusion day 1,2,3 over 30 minutes Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
45980970|NCT00324467|Drug|Rituximab|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 375 mg/m^2 Administration: IV infusion day 1 (or day 2 or day 3) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
45980971|NCT00324467|Drug|Ondansetron|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
45980972|NCT00324467|Drug|Dexamethasone|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
45980973|NCT00324467|Drug|Diphenhydramine|Premedication for R-ICE Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
45980974|NCT00324467|Drug|Acetaminophen|Premedication for R-ICE Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
45980975|NCT00324467|Other|PET Scan|Investigations: 18F-FDG-PET scan Timing: After 4 cycles of R-CHOP (days 21-28) and after 4 cycles of R-ICE (days 28-35)
45980976|NCT00332085|Drug|Chromium Picolinate|
45456415|NCT03968133|Dietary Supplement|Probiotic|Oral probiotic delivered in powdered form.
45456416|NCT03968133|Dietary Supplement|Placebo|Oral placebo delivered in powdered form.
45672775|NCT04091867|Drug|Cetuximab|Loading dose 400 mg/m2 on D9 Concurrent dose 250mg/m2 weekly D15± 3 day window
45672776|NCT04091867|Radiation|Radiation Therapy|6930 cGy IMRT starting D15-D18
45832326|NCT03078426|Device|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany). Acquisitions will be obtained in the axial plane using a 12-channel thorax/spine coil. Investigators will use previously published sequence parameters for each MRI sequence. PETRA will be acquired under free-breathing with respiratory gating at functional respiratory capacity.
45832327|NCT03078426|Other|Thoracic HRCT (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
45980977|NCT00324506|Drug|Mycophenolate Mofetil (CellCept)|
45980978|NCT00332124|Drug|Choline|900 mg every day until birth of infant
45980979|NCT00332124|Dietary Supplement|Placebo|Corn oil every day in place of choline
45980980|NCT00419432|Other|Routine Observational Analysis (prior to procedure)|Controls will undergo the standard orthopaedic surgery using the information from the physical examination and observational analysis of the gait alone.
45980981|NCT00419432|Other|Routine Observational analysis supplemented with Gait Lab Information (prior to procedure)|This experimental group will undergo standard orthopaedic surgery using the information from the physical examination, observational AND the gait laboratory analysis data
45980982|NCT04714554|Drug|Relugolix/E2/NETA FDC|Relugolix/E2/NETA (40 mg/1 mg/0.5 mg) FDC tablet; oral administration.
45980983|NCT04714554|Drug|Relugolix|Relugolix 120-mg tablets; oral administration.
45980984|NCT04714554|Drug|Erythromycin|Erythromycin 500-mg tablets; oral administration.
45980985|NCT00419471|Drug|Escitalopram|Study medication will be provided as 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day, and matched placebo. The initial dose of escitalopram was 10mg/day generally, but 5mg/day for those aged 65 or over and with hepatic dysfunction. After the 2nd evaluation, the treatment doses are determined by the investigators' clinical decision considering the severity of depression and tolerability of drug. Drugs are taken once daily per orally within 30 min after the supper meal.
45980986|NCT00419471|Drug|Placebo|Placebo medication will be provided as matched 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day.
45980987|NCT00419510|Behavioral|Culturally Tailored Genetic Counseling|
45980988|NCT00353769|Procedure|Hair Apposition Technique|
45980989|NCT00324545|Behavioral|Medium-intensity Minimally-directive Counseling|
45980990|NCT00426348|Drug|Valsartan|Valsartan (80-160mg/day)
45980991|NCT00426348|Drug|Probucol|Probucol (750mg/day)
45980992|NCT00426348|Drug|Placebo|Placebo
45980993|NCT00324584|Device|Telemonitoring of glucose values using GlucoNet device|
45980994|NCT00353808|Drug|[S,S]-Reboxetine|
45980995|NCT00324623|Biological|Melan-A VLP vaccine, IMP321 adjuvant|
45980996|NCT00324623|Biological|adoptive immunotherapy|
45980997|NCT00324623|Biological|therapeutic autologous lymphocytes|
45980998|NCT00324623|Drug|cyclophosphamide|
45832328|NCT03159312|Behavioral|Physical activity based on a moderate exercise program|Physical exercise program begins with a 2-week adaptation stage, climbs onto the treadmill (HP Cosmos®). The programming of the tape will be done initially with an intensity of 40% of its FCdRes obtained from the formula of Karvonen after performing the 6-minute walk test, you will have to maintain that intensity for 15 min, the patient is evaluated with the Borg scale and oxygen saturation permanently.After two weeks of adaptation, the HRdRes becomes to be calculated, 59% of said frequency will be modified until the exercise program is completed.The training is 30 minutes in the tradmill machine.The work of muscle strengthening of biceps, triceps, deltoids and pectorals, will be progressive in intensity and number of repetitions, determined by the evaluation of 1 Rmax. The start of work with weights is 40% of the Rmax, it will be modified monthly from 40% to 75%. Cycloergometer training (Monark ®) is without load for 15 minutes.
45980999|NCT00324623|Drug|fludarabine phosphate|
45981000|NCT00353847|Device|Acupuncture|
45981001|NCT00324662|Device|Implantable cardioverter-defibrillator|
45981002|NCT00426426|Behavioral|Cognitive-Behavioural Therapy|12 sessions with Cognitive-Behavioural Therapy (CBT), and waiting list will be over 12 weeks, and then allocated into Meta-Cognitive Therapy.
45981003|NCT00426426|Behavioral|Meta-Cognitive Therapy|12 sessions with Meta-Cognitive Therapy (MCT), and waiting list will be over 12 weeks, and then allocated into Cognitive-Behavioural Therapy .
45981004|NCT00426426|Behavioral|Waiting list|
45981005|NCT00324779|Biological|rituximab|
45981006|NCT00353886|Procedure|TONI-3|
45981007|NCT00353886|Procedure|WRAT-3|
45456417|NCT03968029|Procedure|suturing meniscal augmented|meniscal tear sutured + bone marrow injection/collagen membrane
45832329|NCT05701410|Diagnostic Test|DPD scintigraphy|Bone tracer scintigraphy, diagnostic for transthyretin amyloidosis.
45832330|NCT03583008|Behavioral|Anticoagulation (AC) Intervention--Academic Detailing|One hour online web-based academic detailing session to develop an anticoagulant (AC) learning plan.
45981008|NCT00353886|Procedure|Connor's Rating Scales PRS & TRS|
45456418|NCT03968029|Procedure|suturing meniscal|meniscal tear sutured
45832331|NCT03583008|Behavioral|Anticoagulation (AC) Intervention--Prescribing Practices|Education and support related to anticoagulant prescribing practices.
45832332|NCT05703126|Diagnostic Test|History taking|Careful history taking, including using questionnaires, to identify risk factors for the development of cardiovascular diseases using the SCORE scale.
45981009|NCT00353886|Procedure|Peabody Picture Vocabulary Test|
45981010|NCT00353886|Procedure|Children's Memory Scale|
45981011|NCT00353886|Procedure|WISC-3|
45981012|NCT00353886|Procedure|Behavioral Assessment System for Children PRS & TRS|
45981013|NCT00324818|Drug|metronidazole and azithromycin|
45981014|NCT00324974|Drug|Lansoprazole microgranules suspension|"Lansoprazole microgranules 0.2-0.3 mg/kg/day suspension, orally, once daily for up to 28 days for infants less than 10 weeks;~Lansoprazole microgranules 1.0-1.5 mg/kg/day suspension, orally, once daily for up to 28 days for infants greater than 10 weeks."
45981015|NCT00324974|Drug|Placebo|Lansoprazole placebo-matching suspension, orally, once daily for up to 28 days.
45981016|NCT00325013|Drug|Docosahexaenoic Acid (DHA)|800mg twice a day for 1 year
45981017|NCT00353964|Drug|rEV131|
45981018|NCT00353964|Drug|Prenisolone sodium phosphate 1.0%|
45981019|NCT00353964|Drug|rEV131 vehicle|
45981020|NCT00354003|Behavioral|A series of questionnaires|Research participants who previously underwent ß-CIT imaging will be contacted by the staff at IND to enquire whether they would like to receive their ß-CIT scan data. After signing a Research Participant Information and Consent Form, all research participants will be asked to complete a questionnaire prior to receipt of their imaging data. Those research participants requesting imaging data will be sent their data by IND and may review their data with IND (by phone) and/ or with their study investigator. All research participants will be asked to respond to a second questionnaire after receiving their imaging data and to a third study questionnaire approximately six weeks following receipt of their imaging data.
45981021|NCT00325169|Drug|Tiotropium + SERETIDE 50/500|
45981022|NCT00426504|Procedure|Radiotherapy|Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
45981023|NCT00325208|Device|partial-vacuum milk bottle|
45981024|NCT00325208|Device|anti-vacuum milk bottle|
45981025|NCT00426543|Drug|MabThera (rituximab)|1000 mg infusion twice with 14 days interval
45981026|NCT00426543|Drug|Rituximab, Mabthera|1000 mg Rituximab infusion in 500 ml isotonic sodiumchloride twice with 14 days interval
45981027|NCT00325247|Drug|ZINC|
45981028|NCT00325286|Drug|Lithium Plus Extended- Release Carbamazepine|Preliminary phase subjects receive ERC-CBZ starting dose range from 100 to 200 mg b.i.d. and further titration up to a maximum dose of 1600 mg/day done at the discretion of the investigator. Titration phase will not extend beyond 2 weeks.Open label phase subjects stabilized on lithium and ERC-CBZ therapy will enter this phase for 6 months
45981029|NCT00354042|Drug|GW597901X|
45981030|NCT00325325|Drug|everolimus and tacrolimus|
45981031|NCT00325481|Drug|FluMist|
45456419|NCT03965390|Behavioral|Oral education|"Oral therapeutic education aims to improve dietary practices, daily hygiene and care, in an approach adapted to the characteristics and consequences of Parkinson's disease. An oral prevention package will be given to patients.~Initially, dentists expose various oral health problems commonly found in Parkinson's disease, in order to give patients the necessary information for the understanding Secondly, dentists dispenseront practical advice tailored to pathology, to maintain good oral health"
45456420|NCT03957369|Diagnostic Test|HIV-1 plasma RNA Genotyping secuencing by Sanger technique|After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.
45981032|NCT00354081|Drug|folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine)|folic acid 0.8 mg plus vitamin B12 0.4 mg and vitamin B6 40 mg, in a capsule, taken orally once a day
45981033|NCT00354081|Drug|folic acid, vitamin B12 (cyanocobalamin)|folic acid 0.8 mg plus vitamin B12 0.4 mg, in a capsule, taken orally once a day
45981034|NCT00354081|Drug|vitamin B6 (pyridoxine)|vitamin B6 40 mg, in a capsule, taken orally once a day
45981035|NCT00354081|Drug|placebo|placebo, in a capsule, taken orally once a day
45672777|NCT04073225|Device|MindPod Dolphin|"The immersive video game being tested in this study is called Bandit the Dolphin, developed by neurologist Dr. John Krakauer, and engineers in the Brain, Learning, Animation, and Movement Lab at Johns Hopkins. Bandit the Dolphin provides an oceanic environment in which the individual's arm movements control a simulated dolphin. The neuromotor effects of this game have been designed to be used in the clinical setting to rehabilitate arm and hand function following stroke. The game has further been modified to a Microsoft Kinect-based system and piloted for play in non-laboratory settings among community-dwelling adults. The game offers a unique combination of skilled arm movements plus varying levels of cognitive challenge. In this way, the individual's arms are challenged the same way the legs would be when walking in a complex, outdoor environment. Importantly, the participant plays while standing, thus engaging the whole body in this novel multi-sensorial experience."
45981036|NCT00325559|Procedure|Normoinsulinemic eu- or hyperglycemic clamp|
45981037|NCT04705311|Other|Pain neuroscience education|Neurophysiological education of pain allows patients to explore a wider contribution to pain through the knowledge that pain is often an unreliable indicator of the extent or extent of tissue damage. This aims at reconceptualization from biomedical or structural models to actual biological psychosocial pain models.
45981038|NCT04705311|Behavioral|Rotator cuff repair rehabilitation|Postoperative rehabilitation programs include thermal therapy, electrical therapy, manual therapy, and therapeutic exercise.
45981039|NCT00325637|Drug|cilnidipine|Cilnidipine 10~20mg, qd, po for 4 weeks.
45456421|NCT03957369|Diagnostic Test|HIV-1 plasma RNA Genotyping secuencing by Ultra-deep sequencing technique|After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.
45672778|NCT04073225|Device|Hand Bike|The control intervention in this study is a hand bike, a single-component upper-arm aerobic exercise device. This arm is innovative in its own right, by evaluating the benefits of upper arm aerobic activity on cognitive and physical health given that the vast majority of physical interventions focus on lower-extremity walking and biking exercise.
45672779|NCT03104543|Behavioral|Education|30 minute education session; 15 minute booster session at 4 months
45832333|NCT05703126|Diagnostic Test|Anthropometry|Anthropometry: measurement of body weight and height. Calculation of body surface area using the Du Bois formula.
45832334|NCT05703126|Diagnostic Test|Complete blood count|Before and after each course of chemotherapy: Complete blood count with counting the number of erythrocytes, leukocytes, leukocyte formula, platelets, erythrocyte sedimentation rate.
45832335|NCT05703126|Diagnostic Test|Biochemical blood test|Before and after each course of chemotherapy: Biochemical blood test with the determination of the amount of total protein, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, creatinine, urea, AlAT, AsAT, LDH, glucose, C-reactive protein, troponin T, proBNP.
45832336|NCT05703126|Diagnostic Test|Coagulogram|Before and after each course of chemotherapy: Coagulogram parameters (fibrinogen, APTT, INR).
45832337|NCT05703126|Diagnostic Test|Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine|Before the start of the treatment and after each course of chemotherapy: Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine.
45832338|NCT05703126|Diagnostic Test|Stress echocardiography with the definition of global longitudinal deformation of the myocardium|Before the start of the treatment and after each course of chemotherapy: Stress echocardiography with the definition of global longitudinal deformation of the myocardium.
45981040|NCT04714593|Biological|CD19-CD22 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
45981041|NCT00426582|Drug|Patupilone|
45981042|NCT04717583|Procedure|Intense pulsed light (IPL) treatment|"After randomization, one side of the face will be treated with IPL using the M22™ Universal IPL device, once every 4 weeks for 3 consecutive times.~Starting from Week 12 (the time point of the primary endpoint), the control side of face will also be treated by IPL if the IPL-treated side shows satisfactory improvement of erythema or telangiectasia by IPL treatment. If the patient was unsatisfied with the improvement in the IPL-treated side at Week 12 visit, no IPL treatment will be given to either side of the face any more."
45981043|NCT00354198|Drug|pentoxifylline|intravenous pentoxifylline (0.33-0.66 mg/kg/h from days 1 to 7) followed by oral pentoxifylline 400-800 mg/day (from days 8-90). The dose of intravenous pentoxifylline will be determined by estimated GFR, patients whose GFRs are 30-59 ml/min/1.73 m2 will be given 0.66 mg/kg/h, and those below 30 ml/min/1.73 m2 will be given 0.33 mg/kg/h. The oral dose of pentoxifylline will also be determined by estimated GFR. Patients whose estimated GFRs are between 30-59 ml/min/1.73 m2 will be given 800 mg/day, and those below 30 ml/min/1.73 m2 will be given 400 mg/day.
45981044|NCT00354198|Drug|corticosteroids|intravenous methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days] x 3 courses
45981045|NCT00325676|Drug|Pantoprazole|
45981046|NCT00325715|Drug|AGN 201904|
45981047|NCT00325715|Drug|esomeprazole|
45981048|NCT00354237|Other|Conventional antidiabetic treatment|No intensive treatment
45981049|NCT00354237|Other|Intensive insulin treatment|Intensive insulin treatment
45981050|NCT00325793|Drug|Nicardipine|
45981051|NCT00426621|Drug|Diclofenac Sodium Gel|4 grams per knee, 4 times per day, for 12 weeks
45981052|NCT00426621|Drug|Placebo|4 grams per knee, 4 times per day, for 12 weeks
45981053|NCT00325832|Device|BpTRU|
45981054|NCT00325832|Device|Conventional mercury sphygmomanometry|
45456422|NCT03956654|Drug|Ribociclib|combination of ribociclib and letrozole
45981055|NCT04717778|Dietary Supplement|Comparison of salivary pH after consuming milk of origin vegetable vs cow's milk|They were given 5 types of milk, each one was measured on different days (Monday cow's milk, Tuesday coconut milk, Wednesday almond milk, Thursday soy milk, Friday rice milk).
45981056|NCT04714242|Drug|Ranibizumab Injection|Three monthly intravitreal injections of Ranibizumab
45981057|NCT00353535|Procedure|Total Lymphoid irradiation|
45981058|NCT00325871|Procedure|concurrent chemoradiation|
45981059|NCT00354276|Drug|cytarabine|
45981060|NCT00354276|Drug|laromustine|
45981061|NCT00325910|Drug|Metformin|
45981062|NCT00354315|Behavioral|Continuous medical education (CME)|The intervention will be held over a 6 months period. DECISION+ is a multifaceted intervention program that includes: Interactive workshops (3x180 min), reminders of expected behaviours and feedback.
45672780|NCT03104543|Behavioral|Test results only|The control group will receive a copy of test results upfront but not experimental educational materials; those will be available at 1 year
45672781|NCT04060277|Drug|Letermovir|Given as SOC
45981063|NCT00325949|Drug|Extended release hydrocodone and acetaminophen (Vicodin CR)|2 tablets BID
45981064|NCT00325949|Drug|hydrocodone/acetaminophen extended release (Vicodin CR)|1 tablet BID
45981065|NCT00325949|Drug|placebo|2 tablets BID
45981066|NCT04714476|Device|Made-to-measure compression garment|"Subjects will wear one of two made-to-measure compression garments:~(1) JOBST® Confidence leggins (BT) and (2) JOBST® Confidence Bermuda (ET)"
45456423|NCT03925402|Drug|Ertapenem|Ertapenem injection
45981067|NCT00326027|Drug|Pantoprazole|Efficacy of Pantoprazole
45456424|NCT03925402|Drug|Carbapenems|Other carbapenems injection
45672782|NCT04060277|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
45672783|NCT04060277|Other|Placebo Administration|Given IM
45672784|NCT04049981|Device|Superpower Glass|The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents.
45672785|NCT05652179|Drug|Stellate ganglion block|Before anesthesia induction, ultrasound-guided stellate ganglion block is performed, injecting 7 ml of 0.375% ropivacaine.
45832339|NCT05703126|Diagnostic Test|Triplex scanning of neck vessels|Before the start of the treatment and after each course of chemotherapy: Triplex scanning of neck vessels.
45832340|NCT05703126|Diagnostic Test|Electrocardiography|Before and after each course of chemotherapy: Electrocardiography.
45832341|NCT05703126|Diagnostic Test|Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes|Before the start of the treatment and after each course of chemotherapy: Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes.
45981068|NCT01059318|Drug|Everolimus|Everolimus was formulated as tablets in strengths of 2.5mg, 5mg and 10mg.
45981069|NCT00326066|Device|Glaucoma Surgery|Comparing the effect in reducing IOP with two Trabecular Bypass Microstents Versus none in patients undergoing cataract surgery, with early open angle glaucoma or ocular hypertension.
45981070|NCT00326066|Procedure|cataract surgery only|Subjects will undergo routine cataract surgery only (no stent implant).
45981071|NCT04714515|Drug|Montelukast|An FDA approved medicine to treat asthmatic patients
45981072|NCT04714515|Drug|Hydroxychloroquine|An FDA approved antiarthritis drug
45981073|NCT04714515|Drug|Ivermectin|An FDA approved anti-parasitic medicine
45981074|NCT00326105|Drug|Quetiapine fumarate|
45981075|NCT00354354|Drug|Combivent|Nebulized Combivent (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered once only to subjects.
45981076|NCT00326144|Drug|Quetiapine fumarate|
45981077|NCT01058655|Drug|Everolimus|
45981078|NCT01058655|Drug|Tivozanib|
45456425|NCT03897361|Genetic|"CTNS-RD-04 or CTNS-RD-04-LB (where the suffix -LB stands for LentiBOOST)"|Peripheral blood autologous CD34+ enriched cell fraction transduced with lentiviral vector, pCCL-CTNS or pCDY.EFS.CTNS.T260I, that contains the human CTNS complementary deoxyribonucleic acid (cDNA) sequence.
45456426|NCT03897270|Procedure|Photoacoustic Imaging|Undergo photoacoustic imaging of the breast
45456427|NCT03892577|Drug|Precision oncology including targeted therapy and immunotherapy|Therapeutic regimens are based on the clinicopathological features, genomic alterations, advices from multidisciplinary tumor board and willings from patients.
45832342|NCT05703126|Diagnostic Test|Cytogenetic examination of the bone marrow to determine genetic abnormalities.|Before the start of the treatment: Cytogenetic examination of the bone marrow to determine genetic abnormalities.
45981079|NCT00326222|Behavioral|Lifestyle counseling|Self-management group education
45981080|NCT00326261|Procedure|Ultrasound compared to dual-endpoint nerve stimulator guided approach.|
45981081|NCT00326261|Procedure|Ultrasound|
45981082|NCT04714164|Behavioral|Group Cognitive Behavioral Therapy|Therapy will be delivered weekly for 8 weeks by Zoom.
45981083|NCT00326300|Drug|methylphenidate hydrochloride extended-release tablets|
45981084|NCT00426777|Drug|risedronate|risedronate 35mg tablet, weekly for 12 months
45981085|NCT00426777|Drug|risedronate|35mg weekly
45981086|NCT00426777|Drug|Control|risedronate-matched placebo weekly
45981087|NCT00326339|Drug|R788|R788 50 mg, 100 mg, or 150 mg PO bid
45981088|NCT00326339|Drug|Placebo|Placebo PO bid
45981089|NCT01058421|Procedure|intensive physical therapy|four week course of daily intensive physical therapy
45981090|NCT01058421|Procedure|control group|four weeks of routine physical therapy
45981091|NCT00419549|Drug|Glyceryl - trinitrate|Transdermal Patch once only
45981092|NCT00419549|Drug|Valdecoxib|Single parenteral administration
45981093|NCT00354471|Procedure|Uterine Artery Embolization|
45981094|NCT00326378|Drug|consolidation chemotherapy with Docetaxel plus cisplatin|definitive CCRT, and followed by consolidation chemotherapy with three cycles of docetaxel plus cisplatin
45456428|NCT03886025|Other|Anodal transcranial Direct Current Stimulation (tDCS)|Non-invasive brain stimulation
45832343|NCT05703126|Diagnostic Test|Cytological examination of bone marrow cells with cytochemical examination|Before the start of the treatment and after each course of chemotherapy: Cytological examination of bone marrow cells with cytochemical examination.
45832344|NCT05703126|Diagnostic Test|Immunophenotypic examination of the bone marrow by flow cytometry|Before the start of the treatment: Immunophenotypic examination of the bone marrow by flow cytometry.
45832345|NCT05703126|Diagnostic Test|Determination of the presence of a FLT3 mutation using the PCR Method|Before the start of the treatment: Determination of the presence of a FLT3 mutation using the PCR Method.
45832346|NCT05703126|Diagnostic Test|laser Doppler flowmetry|Before the start of the treatment and after each course of chemotherapy: Examination of microcirculation by laser Doppler flowmetry using the LAKK-OP apparatus (NPP Lazma, Moscow, 2011) with respiratory and occlusion tests.
45832347|NCT03155334|Other|PIS User Testing|"PIS User Testing based on an iterative 4-step process in a cohort of participants (the target group):~individual reading of the text;~individual questionnaire for a quantitative and qualitative evaluation;~a brief semi-structured interview to each participant;~a text revision to address any problems identified from participant feedback."
45832348|NCT03582696|Behavioral|CHANGE Study|The CHANGE strategy is designed to improve the dissemination and implementation of CVD EBIs by strengthening clinical-community linkages
45832349|NCT03159390|Other|phenylacetate salt of ornithine|
45832350|NCT03159156|Behavioral|Applied Tension|Described above.
45981095|NCT00326378|Drug|CCRT arm without consolidation chemotherapy|definitive CCRT with weekly Docetaxel/CDDP #6 without consolidation chemotherapy
45981096|NCT00326573|Behavioral|Motivational Interviewing|
45981097|NCT04717232|Other|Blended learning approach to mentoring education for dental health care professionals|The participants in the intervention group are dentists´ and dental hygienists´. The mentoring education for dental health care professionals (3 ECTS credits) will be organized by the program leader in Dentistry at the place-blinded. The aim of the mentoring education is to build understanding of how to support a student's professional development (both basic education and specialization) and transfer skills that are relevant to working as an independent expert in oral health care.
45981098|NCT04717232|Other|The interprofessional online mentoring education|The participants in the intervention group are dentists´ and dental hygienists´. The interprofessional online mentoring education (3 ECTS credits) will be organized in collaboration with the Finnish Dental Association in an online environment. The aim of the intervention is to in-crease mentors' competence in guidance processes and interactions, supporting students´ goal-oriented learning and professional evaluation, and providing constructive feedback.
45981099|NCT00326768|Drug|Telmisartan 40 mg/HCTZ 12.5 mg|
45981100|NCT00326768|Drug|Telmisartan 40 mg|
45981101|NCT00326768|Drug|Telmisartan 80 mg/HCTZ 12.5 mg|
45981102|NCT00326807|Drug|Naltrexone|
45981103|NCT01058304|Other|Group Physical Therapy for Knee OA|The group PT arm will include 6 1 to 1 hour visits (every other week) led by a physical therapist and exercise physiologist or PT Assistant, with 8 participants per group. The group PT sessions will include group instruction in joint care (activity pacing and joint projection), group discussion of exercise successes and barriers, group exercise, and scheduled individual consultations with the physical therapist (2 per participant, 15-20 minutes each) to address specific functional and therapeutic needs. Participants will also be given instructions for a home exercise program.
45981104|NCT01058304|Other|Individual Physical Therapy for Knee OA|The individual PT arm, modeled after typical PT care for knee OA at the Durham VAMC and other health care settings, will include 2 1-hour visits with a physical therapist, 2-3 weeks apart. While the individual PT sessions will differ in structure from the group PT sessions they will include the same informational, assessment, and therapeutic content as the group sessions. Participants in this group will also be given instructions for the same home exercise program.
45981105|NCT00327002|Drug|LY518674|
45981106|NCT01058265|Other|Integrative|Integrative Medicine medical evaluation.
45981107|NCT01058265|Other|Standard|Standard general medical evaluation.
45981108|NCT00354510|Drug|GW842470X cream|
45981109|NCT04717037|Biological|Olive Oil Massage|olive oil massage application.
45981110|NCT00354549|Drug|bevacizumab + erlotinib hydrochloride|Patients receive bevacizumab IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
45981111|NCT00354549|Drug|gemcitabine hydrochloride + cisplatin or carboplatin|Beginning within 3 weeks of documented disease progression, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. They also receive cisplatin IV over 1 hour or carboplatin IV over 30 minutes on day 1. Treatment with gemcitabine hydrochloride with either cisplatin or carboplatin repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
45981112|NCT04716998|Biological|MesenCure|Three administrations of MesenCure in addition to standard care
45981113|NCT01057251|Drug|Nebivolol|5 mg, titrated to 20 mg, once daily oral administration
45981114|NCT01057251|Drug|Placebo|5 mg or 20 mg once daily, oral administration
45981115|NCT04708457|Other|VV-ECMO|Early use of VV-ECMO in SARI patients.
45981116|NCT04708353|Drug|placebo capsule (vitamin c)|the patient will receive one placebo capsule (vitamin c) once one hour before the operation
45981117|NCT04708353|Drug|Group pregabalin 150|the patient will receive one capsule of pregabalin 150 mg once one hour before the operation
45981118|NCT04708353|Drug|Group pregabalin 300|the patient will receive one capsule of pregabalin 300 mg once one hour before the operation
45981119|NCT04708574|Behavioral|Lifestyle intervention|
45981120|NCT04708574|Other|Placebo - Control|
45981121|NCT00425646|Biological|bevacizumab|
45981122|NCT00425646|Drug|imatinib mesylate|
45981123|NCT00327080|Procedure|MRI|
45981124|NCT00327080|Drug|L-NMMA|
45832351|NCT03159156|Behavioral|Respiration Control|Described above.
45832352|NCT03159156|Behavioral|Applied Tension/Respiration Control|Described above.
45832353|NCT03582306|Behavioral|High chlorophyll diet - intervention 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the first 4 week period of the study.
45832354|NCT03582306|Behavioral|High chlorophyll diet - control 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the last 4 week period of the study.
45672786|NCT05652101|Other|collection of medical data|"The data collected concerns:~Sex~Age~Socio-professional category of patients or parents / level of education of the parents~Family history~Neonatal patient data (pregnancy, childbirth)~Clinical data (age of onset of symptoms, evolution of these symptoms over the years, psychomotor development, schooling, learning difficulties, rehabilitation)~Therapeutic data (treatments tried, their dosage and effectiveness, changes in dosage over the years)~Paraclinical examinations (Magnetic Resonance Imaging (MRI), scanner, Electroencephalography (EEG))~Genetic data if available"
45672787|NCT05652101|Other|Vineland Adaptive Behaviour Scales (VABS2) questionnaire|"This is a standardized semi structured interview that measures adaptative skills in 4 areas, in the fields of communication, socialization, daily living, and motricity (for children under 7 years). It can be used for children and adults.~Rating: 2 = yes, usually, 1 = sometimes or partly, 0 = no, never, N = not applicable (when a child is not yet of sufficient age, for example), NS = don't know. The results by domain and by sub-domain are given in raw scores which are then transformed into equivalent ages using a grid provided for this purpose."
45672788|NCT05290259|Other|Ballroom Dance|The Ballroom Basics for Balance Program is a dance focused exercise program developed by a Physical Therapist in the Madison area.
45672789|NCT04818125|Other|Patients with breast cancer (stage I, II III or IV)|"Blood samples will be collected at different times:~at Baseline for all patients with breast cancer: before initiation of treatment (i.e. before initiation of planned treatment for stage I to III patients and before any new line of treatment for stage IV patients);~at the time of disease progression (or at 12 months in absence of progression) for patients with metastatic breast cancer (stage IV)~For each patient a tumor sample from the initial diagnosis of the disease (i.e. primary tumor +/- biopsy of a metastasis) will be collected (archived tumor block) for the study."
45672790|NCT05651789|Drug|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 12.5mg/d. Doses are increased 3 days later. Avoid systolic blood pressure <90 mmHg.
45832355|NCT05629182|Other|No intervention applied - Observational study only|Observational study only. Video footage is used to review all 64 matches in the football tournament.
45832356|NCT03582228|Behavioral|Virtual Envrionment for Social Communication|"Once the Virtual Envrionment for Social Communication intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).~Weekly sessions will follow a standardized format:~15 minutes- Social support group (guided discussion of experiences related to weekly topic)~20 minutes- Didactic instruction~15 minutes- Role playing~10 minutes- Debriefing and group feedback"
45981125|NCT00327080|Drug|Acetylcholine|
45981126|NCT00426816|Drug|SB-649868|Active compound at doses of 10mg, 30mg and 60mg
45981127|NCT00426816|Drug|Placebo|Placebo to match SB-649868
45981128|NCT00327119|Drug|ABX-EGF (panitumumab)|
45981129|NCT00426894|Procedure|samples from nostrils, mouth, axillas, perianal area and postoperative wound|
45981130|NCT00327158|Procedure|Transesophageal transducer|One time use of reamer during surgery
45981131|NCT00327158|Procedure|echocardiography|takes photos of right atrium during the reaming processes
45981132|NCT00426933|Drug|Daptomycin|
45981133|NCT00426933|Drug|Vancomycin|
45981134|NCT00327197|Drug|Prednisolone|Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.
45981135|NCT00327197|Procedure|Bronchoscopy|All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.
45981136|NCT00425724|Drug|Methylprednisolone pulses plus prednisone versus Cyclosporine A|The patients will be randomised to receive either MP pulses i.v. or cyclosporine A p.o. The MP pulses will consist of three doses of methylprednisolone 30 mg/kg i.v. given over a period of one week in hospital. On the intermediate days and for a month after the MP pulses, the patients will be given prednisone 30 mg/m2/day p.o., after which the prednisone medication will be gradually run down over 3 months. The patients randomised into the cyclosporine A group will receive an initial dose of 5 mg/kg/day, after which the dosage will be titrated to an optimal therapeutic level by monitoring the B-Cya concentration. The cyclosporine A treatment will be continued for 12 months.
45981137|NCT00426972|Drug|estradiol (Zesteem)|
45981138|NCT00327275|Behavioral|strength training|
45981139|NCT00327314|Procedure|Transplantation|
45981140|NCT00327314|Procedure|Hematopoietic cell transplantation|
45981141|NCT00425763|Drug|AQAS|AQAS dosed by body weight, on days 0, 1, 2
45981142|NCT00327353|Drug|formoterol (TURBOHALER)|
45981143|NCT00327353|Drug|Salmeterol (DISKUS)|
45981144|NCT00425841|Drug|gemcitabine hydrochloride|
45981145|NCT00425841|Drug|oxaliplatin|
45981146|NCT00425841|Procedure|adjuvant therapy|
45981147|NCT00425841|Procedure|neoadjuvant therapy|
45981148|NCT00425841|Radiation|hypofractionated radiation therapy|
45981149|NCT00425841|Radiation|stereotactic radiosurgery|
45981150|NCT00327431|Genetic|Cheek swab samples for DNA|
45981151|NCT00427050|Drug|PEP005|
45981152|NCT05459168|Other|Calm Meditation Smartphone App Feedback|Advisory committee members will be asked to use the current Calm meditation app platform for a full week and to keep an informal journal prior to participating in focus groups in which they will provide feedback about the app.
45981153|NCT05459168|Other|Cancer-Specific Meditation App Prototype Design|Findings from Aim 1 will inform the development of a cancer-specific meditation app prototype to be tested in Aim 3.
45981154|NCT05459168|Device|Cancer-Specific Meditation App Prototype|Recruited cancer patients/survivors will be asked to beta-test the cancer-specific app prototype for four weeks. The prototype will be developed in Aim 2 and informed by qualitative findings of Aim 1.
45981155|NCT05458934|Other|No intervention|no intervention
45981156|NCT05458895|Other|ECIG lab session 1|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
45981157|NCT05458895|Other|ECIG lab session 2|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
45981158|NCT05458895|Other|ECIG lab session 3|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
45456429|NCT03886025|Behavioral|Cognitive training|Iowa Gambling Task will be used for cognitive training
45981159|NCT05458895|Other|ECIG lab session 4|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
45981160|NCT05458895|Other|ECIG lab session 5|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
45981161|NCT05458895|Other|ECIG lab session 6|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
45981162|NCT05458895|Other|ECIG lab session 7|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
45981163|NCT05458895|Other|ECIG lab session 8|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
45981164|NCT00427089|Drug|Macrogol 3350 Na sulphate NaCl KCl Ascorbic Acid Na Ascorbate|2L gut lavage solution
46082763|NCT04234412|Procedure|umbilical cord blood stem cell implantation for osteoarthritis treatment|"The arthroscopic procedure is performed in the supine position after spinal anesthesia. Once the chondral lesion is identified through a standard anteromedial and lateral portal, meniscectomy, meniscal repair, and lateral retinacular release are performed if necessary. microfracture is performed using a microfracture awl.~Once both the unstable cartilage and subchondral bone are removed in the lesion area and the sclerotic bone is peeled slightly by using a burr, hole(s) are created for implantation by using a drill bit(diameter 4; depth: 4mm). After implantation is performed in the hole by injecting the mixture of sodium hyaluronate and hUCB-MSCs, it is trimmed to the height of the surrounding articular surface."
45456430|NCT03886025|Other|Sham transcranial Direct Current Stimulation (tDCS)|Non-invasive brain stimulation
45456431|NCT03875079|Drug|RO6874281|"Part I Safety Run in:~Cohort 1.1: RO6874281 will be administered by intravenous (IV) infusion; 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (i.e. 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part II of this study.~Cohort 1.2: RO6874281 will be administered by IV infusion via an induction and maintenance phase; 10 mg (QW) every week for 3 weeks followed by 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (6 weeks) to confirm safety of the proposed dose and schedule to be used in Part III of this study.~Part II Expansion: RO6874281 will be administered by IV infusion; 10 mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohort 1.1 outcome).~Part III Expansion: RO6874281 will be administered by IV infusion; 10 mg (QW) every week or 10mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes) in either a Q3W or QW/Q3W schedule."
45832357|NCT03159234|Radiation|fetal lung volume|the best method for measurement of fetal lung volume is by the rotational technique in which each lung is obtained by serial contouring of the pulmonary area after rotating the volumetric image.this is more recent method seems to have advantages allowing finer contouring of the lung and subsequent modification of the contour as well as being better able to estimate the volumes of irregular and small lung as in congenital diaphragmatic hernia
45981165|NCT00427089|Drug|Sodium Phosphate solution (NaP)|45 ml solution; BID
45981166|NCT05458661|Device|Clinical Prototype BioBase (SN 07 and SN 08)|Scheimpflug- or OCT based corneal tomographers with the ability to measure anterior and posterior corneal curvature maps >6mm diameter and corneal pachymetry maps >6mm.
45981167|NCT00427128|Drug|fluoxetine|10mg/day increased over 12 weeks to 20-80 mg/day; 20-80 mg/day maintained from week 13-36.
45981168|NCT00427128|Drug|placebo|Week 13-36.
46082764|NCT00941239|Drug|metformin ER|850mg daily for 30 days
46082765|NCT00941239|Drug|metformin|850 mg daily for 30 days
46082766|NCT00771615|Biological|GSK A/turkey H5N1 Influenza vaccine|One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.
46082767|NCT05472740|Device|TENS 7000|TENS device to be used in both the active and placebo groups
45981169|NCT05458466|Other|Pilates training|Eighteen children with autism did not meet the inclusion criteria, ten children did not want to participate in the study, and five children were not included in the study due to different reasons. A total of 22 children between the age of 7 and 12 years were participated in this study. The inclusion criteria were (i) being diagnosed with autism, (ii) not having physical disabilities or neurological disorders, (iii) having the ability to follow the instructions given during evaluations and training, and (iv) having the ability to perform the requested training. All parents of participants signed an informed consent form for participation. were divided into two groups including Aerobic Training (n=11) and Pilates Training (n=11) groups by simple randomization method (internet-based). Since one child in the experimental group did not continue Pilates Training, the study was completed with the participation of 21 children with autism.
46082768|NCT02723604|Device|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
45981170|NCT00427167|Biological|AMA1-C1/Alhydrogel + CPG 7909 (Saline)|
45981171|NCT00427167|Biological|AMA1-C1/Alhydrogel + CPG 7909 (Phosphate)|
45981172|NCT00427167|Drug|AMA1-C1/Alhydrogel + CPG 7909|
45981173|NCT00427206|Drug|acetaminophen (4g/day)|
46082769|NCT02793596|Other|Obstetrical patients|Epidural waveform analysis as a confirmation of loss of Resistance
46082770|NCT04235426|Drug|30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.|30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.
45456432|NCT03875079|Drug|Pembrolizumab|"Part I Safety Run in (Cohorts 1.1 and 1.2): Pembrolizumab will be administered by IV; 200 mg Q3W and will be observed over 2 administration cycles (i.e. 6 weeks).~Part II Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohort 1.1 outcome)~Part III Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes)"
45456433|NCT03867227|Device|left atrial appendage occluder implantation|all patients will get implantation of LAA occluder
45832358|NCT03159234|Radiation|pulmonary artery resistance index|Women placed in semirecumbent position and an axial plane through the fetal thorax to achieve 4 chamber view of the heart. The main pulmonary artery was followed to the point where it divides into right and left branches by rotating the transducer from the 4 chamber view to the short axis view of the heart. Pulsed and colour Doppler was used. The fetal pulmonary artery flow waveform measurements was taken within the proximal portion of the main pulmonary artery
45832359|NCT03159234|Radiation|Fetal adrenal gland volume:|the adrenal gland has a characteristic sonographic appearance; each limb is seen as a long anechoic structure with a thin, echogenic line within its center . Both limbs can sometimes be seen in the coronal plane, and if so there is a strong echogenic line between limbs (probably fat). On the basis of pathologic and histologic studies , we believe the anechoic bulk of the gland represents the fetal zone of the cortex, while the central echogenic core is the medulla.
45981174|NCT00427206|Drug|placebo|
45981175|NCT00425997|Drug|Valsartan/HCTZ|
45981176|NCT00425997|Drug|amlodipine|
45981177|NCT00425997|Drug|HCTZ|
45981178|NCT05458388|Procedure|Kimura-Takemoto classification|All patients were given two risk scores, the order of which was randomly determined.
45981179|NCT05458388|Procedure|EGGIM|All patients were given two risk scores, the order of which was randomly determined.
45981180|NCT00427245|Drug|cyclophosphamide|
45981181|NCT00427245|Drug|goserelin acetate|
45981182|NCT00427245|Procedure|adjuvant therapy|
45981183|NCT00427245|Procedure|fertility assessment and management|
45981184|NCT00427245|Procedure|neoadjuvant therapy|
45981185|NCT05458349|Device|acellular dermis|
45981186|NCT00426036|Drug|Licarbazepine|
45981187|NCT05458154|Other|questionnaires|Participants were recruited from the Baheya Centre for Early Detection and Treatment of Breast Cancer institution. Patients were eligible if they had a previously post-mastectomy pain syndrome (PMPS), and were presented with pain within the surgical area lasting more than 3 months. They were evaluated by questionnaires and methods of pain assessment then received their physiotherapy program specific for pain relief for six sessions, and so re-evaluation. All women gave informed written consent in Arabic and English forms.
45981188|NCT00427323|Procedure|light exposure|
45981189|NCT05458115|Procedure|Liver resection|Patient underwent hepatic R0 resection within a week
45981190|NCT00426075|Device|Elastic stockings|
45981191|NCT05458076|Drug|QLS1128 A-Dose 1~5 and Ritonavir|"Cohort 1:~QLS1128 A-Dose 1 or Placebo~Cohort 2:~Period 1: QLS1128 A-Dose 2 or Placebo, on day 1. Period 2:QLS1128 A-Dose 2 or Placebo with high fat meal on day 5. Period 3:QLS1128 A-Dose 2 or Placebo plus Ritonavir on day 9~Cohort 3:~QLS1128 A-Dose 3 or Placebo~Cohort 4:~QLS1128 A-Dose 4 or Placebo~Cohort 5:~QLS1128 A-Dose 5 or Placebo"
45981192|NCT05458076|Drug|QLS1128 C-Dose 1~3 and Ritonavir|"Cohort 6:~Period 1: QLS1128 C-Dose 1 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 1 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 7:~Period 1: QLS1128 C-Dose 2 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 2 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 8:~Period 1: QLS1128 C-Dose 3 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 3 or Placebo plus Ritonavir , twice daily for 7 days"
45981193|NCT05458076|Drug|QLS1128 D-Dose 1 and Ritonavir|"Cohort 9:~Group A:QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 1. QLS1128 D-Dose 1 plus Ritonavir under fatty food condition, on day 5~Group B: QLS1128 D-Dose 1 plus Ritonavir under fatty food condition , on day 1. QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 5"
45981194|NCT00427362|Drug|Adalimumab|
45981195|NCT05458037|Procedure|Speed of tenaculum application|Fast or slow closure of the tenaculum for application to the uterine cervix
45981196|NCT00426114|Drug|Administration of an IV glucose-injection|
45981197|NCT00426192|Drug|i.v. mannitol|
45981198|NCT00426192|Procedure|hemofiltration|
45981199|NCT05457920|Behavioral|continuous treatment|The treatment period is 12 weeks as a treatment unit, starting from the first day of baseline, subcutaneous injection of Peg-IFN α-2b 180μg once a week, or every 8 weeks of injection, 4 weeks off, periodically, the total treatment course does not exceed 96 weeks.
45981200|NCT05457920|Behavioral|pulse therapy|pulse therapy
45981201|NCT00427401|Drug|PF-00915275|
45981202|NCT00425919|Drug|PPM-204|
45981203|NCT05457881|Dietary Supplement|Scandi-Shake|Scandi-Shake [any of 4 flavors - vanilla, strawberry, banana cream, and caramel] mixed with almond milk (85 grams Scandi-Shake mix to 240 cc almond milk), calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on ideal body weight. The Mifflin St. Jeor equation will be used to calculate the total 24-hour energy needs based on gender, age, height, weight, and activity factor for the PCR diet. Daily physical activity will be assessed by questionnaire to determine the activity factor for accurate calorie restriction calculations. Nutritionists will use this equation to create a unique shake for each individual patient. The shakes will be separated into 4 equal portions per day, for a total of 16 portions across the 4 pre-operative days. Patients can consume the 4 daily portions at whichever time of day they choose. The shakes are frozen 24 hours before distribution.
45981204|NCT01056822|Drug|1|Continue with same dose of MMF as patient was taking before randomisation
45981205|NCT01056822|Drug|2|Increase MPS by 180mg every 12h based on investigator's judgement up to a maximum of 720 mg of MPS every 12 hours
45981206|NCT05457764|Device|Virtual reality headset|"The VR headset was a Pico G2, Pico Interactive, San Fransisco, USA, offering a choice from 60 erotic videos each of 10-30 minutes duration. The men were allowed to watch any and as many of these video clips as they wished. The No VR arm, donors used the computer monitor available in the donation rooms."
45981207|NCT05457530|Drug|DOR/3TC/TDF|100 mg of doravirine (DOR), 300 mg of lamivudine (3TC), and 300 mg of TDF
45456434|NCT03866252|Drug|LSD|LSD administration per os
45832360|NCT03020316|Behavioral|Peer Mentor|A volunteer with a similar disease as the subject
45832361|NCT03020316|Behavioral|Transcendental Meditation|A meditation technique
45981208|NCT05457530|Combination Product|DOR + FTC/TAF|100 mg of doravirine + 200 mg emtricitabine (FTC) and 25 mg of tenofovir alefenamide fumerate (TAF)
45981209|NCT05457530|Drug|BIC/FTC/TAF|Bictegravir sodium 50 mg, emtricitabine 200mg, tenofovir alefenamide fumerate 25mg
45981210|NCT04705194|Procedure|Hepatectomy|Resection of one or more liver segments as treatment for primary or metastatic liver cancer
45981211|NCT04705194|Procedure|PVE or ALPPS|Embolization of the portal vein feeding the diseased liver segments or surgical liver partition and portal vein ligation of the diseased liver segments in order to induce growth of the future liver remnant ahead of the resection.
45981212|NCT05457452|Device|Knee Brace|Installation of an angle-adjustable knee brace, used after ACL reconstruction performed by an orthopedic specialist or orthopedic PPDS with the first week the angle locked at 00, in the second week the angle 0-900, in the third week the angle 0-1200, and the fourth week the angle of flexion full. Braces are used except for physical therapy according to the rehabilitation protocol in the first week.
45981213|NCT04705857|Combination Product|"Histograft, a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene"|gene-activated bone substitute in granular form, concentration of the plasmid DNA is 100 μg per 1.0 g of the OCP scaffold
45981214|NCT04705506|Drug|Gemigliptin|We collected baseline data from all participants for demographic characteristics,comorbid conditions and biochemistry indexes.The biomarkers for vascular calcification and renal injury were collected.Baseline CAC score and CAVI were done.The patients then were randomized into 2 groups: Group 1 received gemigliptin 50 mg /day for 6 months in addition to standard treatment ,Group 2 will have standard treatment for diabetes mellitus (DM) and chronic kidney disease (CKD).The patients will be followed up every eight weeks.Fasting plasma glucose ,BUN creatinine and 24 hour urine protein were measured at each study visit.Patients were scheduled for follow-up visits at months 2,4,and 6.After 6 months ,all the blood tests,CAC score and CAVI will be done again.
45832362|NCT03158844|Other|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
45832363|NCT05628246|Other|Telemedicine|Telemedicine
45832364|NCT05628246|Other|In-person|In-person
45832365|NCT05701332|Biological|Bacillus Calmette Guerin|effect of local B.C.G and Gemcitabine on semen parametes and testicular volume
45981215|NCT05457374|Procedure|PVE|Portal vein embolization (PVE) mainly embolizes the portal vein of the resected liver lobe, causing the non-tumor lobe to proliferate, and after tumor lobectomy, the volume of the non-tumor lobe proliferates so that patients with hepatocellular carcinoma that could not be directly surgically resected are given the opportunity to be surgically resected
45981216|NCT05457374|Procedure|LVD|Combining PVE and Hepatic Vein Embolization (HVE) in the same procedure
45981217|NCT04704960|Other|Diagnostic Test: liquid biopsy|detection of tumor DNA alteration in cf-DNA
45981218|NCT05457335|Procedure|undergoing PGT|Preimplantation genetic testing for aneuploidy
45981219|NCT00432393|Drug|levodopa-carbidopa|
45981220|NCT05455385|Other|standard 12-week rehabilitation program|The standard program consisted of 1 session in the fitness room and 1 session in the sports hall/week during 12 weeks.
45981221|NCT05455385|Other|extra session hydrotherapy|The hydrotherapy group receives 1.5h additional hydrotherapy/week in addition to the standard program.
45981222|NCT05455385|Other|extra session ground exercises|The ground exercise group, receives 1.5h ground exercises/week in addition to the standard program.
46082771|NCT04235426|Procedure|30 patients went to surgical procedure|30 patients went to surgical RELEASE OF TRANSVERSE VOLAR LIGAMENT.
46082772|NCT04235426|Other|Injection|Thirty patients were injected in the carpal tunnel with a of single ultrasound-guided Platelet Rich Plasma (1-2 ml) injections treatments
46082773|NCT02714946|Device|Percutaneous Laser Ablation|Single session with standardized approach: One or two fibers will be used for treatments including one to three illuminations with a fixed output power of 3 W, using the pullback technique. Energy for each emission will be 1200-1800J based on nodule volume. The treatment is performed under local anesthesia and conscious sedation.
45981223|NCT04705077|Drug|SR419|2 formulations of SR419, SR419 suspension and SR419 capsule will be used in the study.
45981224|NCT05454722|Device|ADEX Gel|Emollient Gel with added anti-inflammatory
45981225|NCT05453045|Drug|Albendazole|tablet administration after a meal contaning approximate 15 g of fat
46082774|NCT02714946|Device|Percutaneous Radiofrequency Ablation|Single session with standardized approach: A radiofrequency generator and a 17-gauge, 15-cm electrode with a 1-cm active tip will be used. A transisthmic approach along the short axis of the nodule will be used and the nodules will be managed with the moving-shot technique. 60 W of radiofrequency outpower will be used for all nodules. The treatment is performed under local anesthesia and conscious sedation
46082775|NCT02793440|Other|cortivazol treatment|
46082776|NCT02793440|Other|lumbar traction|
46082777|NCT02723838|Biological|REOLYSIN®|3 cycles (each cycle = 21 days). Cohort 1: 3x10E10 TCID50 intratumoral via cystoscopy on Day 1 of each cycle. Cohort 2: 3x10E10 TCID50 intratumoral via cystoscopy on Day 2 of each cycle.
45456435|NCT03857477|Genetic|Genetic SNP profiling|Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.
46082778|NCT02723838|Drug|Gemcitabine|3 cycles (each cycle = 21 days). Cohort 1: 1000mg/m2 intravenously on Day 2 and Day 9 of Cycle 2 and Cycle 3. Cohort 2: 1000mg/m2 intravenously on Day 1 and Day 8 of each cycle.
46082779|NCT02723838|Drug|Cisplatin|3 cycles (each cycle = 21 days). Cohort 1: 70 mg/m2 intravenously on Day 2 of Cycle 2 and Cycle 3. Cohort 2: 70 mg/m2 intravenously on Day 1 of each cycle.
46082780|NCT00560755|Biological|ProQuad®|ProQuad® manufactured with recombinant human albumin (rHA) is an investigational combined attenuated live virus vaccine for vaccination against measles, mumps, rubella and varicella viruses.
45832366|NCT03582072|Behavioral|letter from the CMO|informed GPs that: The great majority (80%) of practices in England reduced or stabilised their antibiotic prescribing rates in 2016/17. However, your practice is in the minority that have increased their prescribing by more than 4%.*
45832367|NCT03581994|Diagnostic Test|DDI Test Report|Test results of simulated patients
45832368|NCT03581916|Drug|18F-JNJ-64326067|18F-JNJ-64326067 will be administered intravenously between a dose of 185 Megabecquerel (MBq) to 370 MBq.
45832369|NCT03154866|Dietary Supplement|Lactobacillus kefiri LKF01 DSM32079|Lactobacillus kefiri LKF01 DSM32079 in drop formulation. 5 drop/daily for 21 days
45832370|NCT03154866|Dietary Supplement|Placebo|Placebo in drop formulation. 5 drop/daily for 21 days
45981226|NCT04705272|Other|Questionnaire|Pregnant women will be included in the study at the time of their first or second trimester ultrasound in the Hautepierre and CMCO ultrasound department. The period of inclusion should extend from 1 October 2020 to 31 October 2021 with a duration of participation of each subject of 9 months.
45981227|NCT05451251|Device|Deep brain stimulation|Implantation of deep brain stimulation lead within the pontine demyelinating lesion
45981228|NCT00432432|Drug|Infliximab and MTX|MTX 15mg weekly Infliximab 5mg/kg given at day 0, wk 2, wk6
45981229|NCT02957487|Device|Denture supported by 3 dental implants|Metal-reinforced denture without palatal coverage incorporating nylon rings retained by friction to Locator abutments fitted on top of dental implants
45981230|NCT05421494|Behavioral|written exposure therapy-revised version|WET-R is a manualized exposure-based therapy program consisting of 5-7 sequential individual sessions. The interval between every 2 consecutive sessions is 0-3 days. There will be 5-7 one to one online sessions in total (only one index trauma will be discussed), and 1-3 weeks to complete. Sessions are scheduled to last for 1 hour in the first session and 50 minutes in other sessions.
46082781|NCT05276934|Diagnostic Test|Brain computed tomography|This study will use an established local protocol for DCI and intracranial arterial vasospastic stenosis screening, and follow-up to make sure that all patients have the same protocol and don't lose any chance of improvement and good outcome : CT perfusion at different time intervals
46082782|NCT02789150|Drug|Norepinephrine (Levophed)|Titrate norepinephrine to MAP 65-70
45832371|NCT03581838|Behavioral|Observed eating session|Eating a Jimmy Johns turkey or vegetarian sandwich
45456436|NCT03857477|Other|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.
45456437|NCT03857477|Procedure|MRI Scan|MRI scan will be offered to men identified within the top 10% genetic risk score profile.
45456438|NCT03857477|Procedure|Prostate biopsy|Transperineal prostate biopsy under local anaesthetic will be offered to men identified within the top 10% genetic risk score profile.
45981231|NCT05421494|Behavioral|minimal contact control|Participants assigned to MCC will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 3-week MCC period. They will be video-called once per week by a therapist to monitor their status and to provide support as needed. The calls will be limited to 10-15 minutes. MCC participants will also be given contact information to use in case of worsening symptoms or increasing distress.
45981232|NCT02957526|Behavioral|Prompts to report symptoms via study app|Weekly prompts to report aromatase inhibitor use in the previous 7 days and treatment-related adverse symptoms via the web-enabled study app.
45981233|NCT02957526|Behavioral|Clinical Alerts|: Reported symptoms may trigger an email alert to the participant's care team based on predetermined thresholds. Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
45981234|NCT02957448|Drug|BMS 986141|Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
45981235|NCT02957448|Drug|Rifampin|Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
45981236|NCT05389319|Biological|Prime-2-CoV_Beta|1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1
45981237|NCT00432471|Procedure|Optical Imaging|Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
45981238|NCT04704765|Other|abdominal breathing training|The abdominal breathing training at the outpatient clinic (every day 30 minutes, can include every time during the day). When the subjects were at home, they received self-training using the abdominal breathing training video (once every day and 30 minutes every time).
45981239|NCT00427596|Drug|Solabegron|
45981240|NCT00432510|Drug|C1 esterase inhibitor [human] (C1INH-nf)|
45456439|NCT03845829|Procedure|In situ laser assisted fenestration|In situ laser assisted fenestration for the left subclavian artery during the procedure of TEVAR for type B aortic dissection
45981241|NCT05354258|Drug|Albendazole|Anthelminthic drugs for the treatment of soil-transmitted helminths
45981242|NCT05354258|Drug|Praziquantel|Anthelminthic drugs for the treatment of schistosomiasis
45981243|NCT05354258|Drug|Amodiaquine|SMC partner drug
45981244|NCT05354258|Drug|Sulfadoxine pyrimethamine|SMC partner drug
45981245|NCT05338580|Drug|TJ271 Injection in Combination with Pembrolizumab|TJ271 Injection: 0.9% sodium chloride solution Pembrolizumab: 0.9% sodium chloride solution or 5% glucose solution
45981246|NCT00427674|Drug|[123I] mZINT injection and serial dynamic SPECT imaging|Following bolus intravenous injection of 5 mCi of 123-I mZINT over 15 seconds, serial dynamic SPECT brain acquisitions will be obtained to evaluate the regional brain uptake and washout of activity. Venous blood measures will be obtained with each acquisition and characterization of 123-I mZINT and metabolites will be assessed. Safety assessments will include vital signs, serum chemistries, CBC, urinalysis, and EKG.
45981247|NCT05306366|Drug|[11C]-Lu AF90103|PET ligand administrated as a single intravenous bolus injection
45456440|NCT03842384|Behavioral|iENDURE|The proposed intervention will initially target motivational processes in combination with introductory strategies for managing physical and emotional distress through a single, brief, computer-delivered session followed by eight weeks of theoretically-informed text messages intended to enhance motivation and promote distress tolerance.
45456441|NCT03837158|Procedure|early loading|two TiZr implants on SLA surface
45981248|NCT01588899|Device|MR-HIFU uterine fibroid treatment|A single treatment session for uterine fibroids with the MR-HIFU device.
45981249|NCT02273466|Drug|Desipramine tablet|
45981250|NCT02273466|Drug|Crobenetine infusion|
45981251|NCT02273466|Drug|Placebo infusion|
45981252|NCT05245643|Device|Abbott Infinity Deep Brain Stimulation System|DBS is robot-assisted, with 3D intraoperative imaging control, under general anesthesia. Target is defined thanks to preoperative dedicated MRI with 2 independent experts' assessment.
45981253|NCT00427713|Drug|capecitabine|
45981254|NCT00427713|Drug|oxaliplatin|
45981255|NCT00427713|Procedure|adjuvant therapy|
45981256|NCT00427713|Procedure|standard follow-up care|
45981257|NCT05228171|Behavioral|mCC app|Interviewer use of the mCC app during the 24-hour dietary recall interview.
45981258|NCT02273505|Drug|Asasantin (ER)|
45981259|NCT02273505|Drug|Persantin|
45981260|NCT02273505|Drug|Acetyl salicylic acid (ASA)|
45981261|NCT05210621|Drug|Ocrelizumab|ocrelizumab will be administered as single 600-mg infusions in 500 mL 0.9% sodium chloride every 24 weeks (±14 days) up to Week 192 (Year 4) of this study
45981262|NCT00427752|Procedure|Transgastric endoscopic peritoneoscopy.|Exploration of the abdominal area
45981263|NCT05198960|Drug|Direct Oral Anticoagulants|Patients randomized to receive DOAC, at the choice of the investigator: Apixaban 2.5 mg both in day or Rivaroxaban 10 mg once daily.
45981264|NCT05198960|Drug|Low-dose aspirin|Patients allocated to receive LDA: Aspirin 100 mg OD once daily.
45981265|NCT00427830|Biological|MVA85A|
45981266|NCT05174156|Drug|Combination therapy|SHR-1210 (camrelizumab) + albumin-bound paclitaxel + Carboplatin
45981267|NCT00432549|Drug|Almotriptan|
45981268|NCT00432549|Drug|Topiramate|
45456442|NCT03837158|Procedure|immediate loading|four TiZr implants on SLA surface
45981269|NCT05091632|Procedure|Electroencephalography|Undergo EEG
45981270|NCT05091632|Other|Questionnaire Administration|Complete questionnaires
45981271|NCT00427947|Drug|ropivacaine/placebo|Continuous sciatic nerve bloc
45981272|NCT00432588|Drug|misoprostol|
45981273|NCT00432588|Drug|dinoprostone|
45981274|NCT00427986|Drug|Galactose, intravenous|
45981275|NCT00428025|Drug|diclofenac|100 mg diclofenac rectal suppository
45981276|NCT00428025|Drug|placebo|similar shape and size suppository
45981277|NCT00428064|Drug|Sirolimus|
45981278|NCT00428064|Drug|cyclosporine|
45981279|NCT05011253|Other|Electronic Trigger Microhematuria Alert|To evaluate the effectiveness of an InBasket Results message in prompting providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).
45981280|NCT00432627|Drug|Deferasirox|one dose of 20 mg/kg/day
45981281|NCT00419705|Device|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
45981282|NCT00432705|Procedure|Checking stability of ankle|Flexing and walking
45981283|NCT00419783|Drug|bilastine|20 mg tablets.
45981284|NCT00419783|Drug|Bilastine|100 mg (5 tablets of 20 mg)
45981285|NCT00419783|Drug|Bilastine & Ketoconazole|1 capsule containing bilastine 20 mg tablet + ketoconazole 400 mg tablet
45981286|NCT00419783|Drug|Moxifloxacin|1 capsule containing moxifloxacin 400 mg tablet
45981287|NCT00419783|Drug|Placebo|Placebo tablets
45456443|NCT03830788|Radiation|Radiation by brachytherapy|Brachytherapy by Iodine 125 delivering 144 Gy to the prostate
45456444|NCT03830788|Radiation|Radiation by SBRT|SBRT delivers 7.25 Gy per fraction, in five fractions, corresponding to a total dose of 36.25 Gy to the prostate. Fiducials are implanted in the prostate.
45981288|NCT04704492|Drug|Biological: SM03|Biological: SM03 600 mg or 900 mg intravenous (IV) on week 0,2
45981289|NCT00419822|Procedure|Acupuncture|6 Acupuncture visits
45981290|NCT00419822|Procedure|Sham Acupuncture|6 Acupuncture visits with sham procedure
45981291|NCT00419822|Other|Patient to receive standard care without Acupuncture or Sham Acupuncture.|Standard care
45981292|NCT04703517|Diagnostic Test|Point of care ultrasound|Patients will receive a point of care ultrasound at the bedside in the Emergency Department and compare the impression to the x ray result
45981293|NCT04959305|Drug|HCP1803-3|Take it once daily for 8 weeks orally.
45981294|NCT04959305|Drug|RLD2003|Take it once daily for 8 weeks orally.
45981295|NCT04959305|Drug|RLD2004|Take it once daily for 8 weeks orally.
45456445|NCT03813342|Behavioral|Gait training with visual feedback of joint kinematics|Gait training will be accomplished using a Woodway treadmill. The visual feedback will contain information about the real-time lower-limb joint angles. We will instruct participants to use the feedback to reach a target walking pattern.
45981296|NCT04959305|Drug|RLD2005|Take it once daily for 8 weeks orally.
45981297|NCT04959305|Drug|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
45981298|NCT04959305|Drug|HPP2005|Placebo drug. Take it once daily for 8 weeks orally.
45981299|NCT04704687|Other|Transcranial Direct Current Stimulation|Children will perform two successive interventions composed each by a set of 15 sessions of effective-tDCS combine with cognitive-training exercises.
45981300|NCT00428103|Procedure|3 dimensional echocardiography|Lab tests: BNP, 6 minute walk test Transthoracic 3D echocardiogram
45981301|NCT04906109|Drug|Vemlidy Tab|1T
45981302|NCT04906109|Drug|DA-2803 Tab|1T
45981303|NCT00428142|Biological|rituximab|375mg/m2 day 1
45981304|NCT00428142|Drug|bortezomib|1.3mg/m2 days 1 & 8
45981305|NCT00428142|Drug|cyclophosphamide|750mg/m2 day 1
45981306|NCT00428142|Drug|prednisone|40mg/m2 days 1-5
45981307|NCT00428142|Drug|vincristine sulfate|1.4mg/m2 day 1 (dose capped at 2mg)
45981308|NCT04871438|Device|Flash glucose monitoring|Group A will use FreeStyle Libre for two weeks of FGM-based titration of medications at two time-points: 1) At recruitment and 2) At 6 weeks. Outside of these time points, they will use SMBG (standard care) for monitoring of blood glucose.
46082783|NCT02789150|Drug|Norepinephrine (Levophed)|Titrate norepinephrine to MAP 85 or greater
46082784|NCT00770991|Drug|Black raspberry (BRB) Slurry|20 grams BRB Slurry
46082785|NCT00770991|Drug|Black Raspberry (BRB) Suppositories|Two, 730 mg BRB suppositories QHS
46082786|NCT00770991|Drug|Black Raspberry (BRB) Placebo Slurry|20 grams BRB placebo slurry
46082787|NCT02723526|Other|Blood drawing|
46082788|NCT02798666|Other|High intensity exercise training|Exercise training using sprint interval exercise
45981309|NCT04823897|Drug|CCI-001|"Dose Escalation Phase: CCI-001 will be administered by intravenous infusion starting at 1.2mg per square metre of body surface area in the first cohort. The dose will be escalated sequentially in subsequent cohorts. The degree of dose escalation between subsequent cohorts will depend on tolerability, as judged by NCI-CTCAE grading. Once the maximum tolerated dose is determined this phase will be complete.~Dose Expansion Phase: cohorts of patients with the following tumour types will be enrolled: transitional cell bladder cancer, pancreaticobiliary adenocarcinomas, gynecologic cancers (ovarian, cervical, endometrial), and lung adenocarcinoma. These patients will be treated at the dose determined in the dose escalation phase."
45981310|NCT00428181|Behavioral|Brief alcohol intervention|Brief alcohol intervention
45981311|NCT00428181|Behavioral|Brief alcohol intervention plus booster|Brief alcohol intervention plus booster in a later session
45981312|NCT04703478|Other|Breathing exercise|Participants will carry out a breathing exercise program through the RespiraConNosotros mobile application. They will be asked to carry out the proposed exercises with a frequency of 3 times a week for 3 months.
45981313|NCT00432822|Drug|tetrahydrobiopterin (BH4)|
45981314|NCT00432861|Drug|PANCRECARB® (pancrelipase)|Capsules
45981315|NCT00432861|Drug|Placebo|Capsules
45981316|NCT00432900|Radiation|[(11)C]PBR28|PET Ligand
45981317|NCT04627805|Behavioral|MyPath tool|MyPath is a reproductive decision support tool that utilizes a patient-centered approach to help women frame their reproductive decisions in the context of their goals, preferences, and health needs. This tool was developed by Dr. Lisa Callegari with funding from the Veterans Administration (VA) Health Services Research & Development to be used in primary care settings with women veterans. It is conceptually grounded in Self-Determination Theory, which postulates that health care that meets patients' psychological needs in three key domains - autonomy, competence, and relatedness - will result in improved health behaviors and health outcomes. This is particularly relevant in reproductive health care, given the highly individualized and personal nature of these decisions, and the importance of centering a woman's aspirations and goals in her health care decision making.
45981318|NCT00428337|Biological|EP-1233|DNA-HIV-recombinant vaccine
46082789|NCT02798666|Other|Continuous exercise training|Exercise training using continuous exercise at constant heart rate
46082790|NCT00941317|Device|Pathformer (micro-drilling device)|The micro-drilling device drills the nail with a prespecified diameter drill bit and to a prespecified depth in the nail, using skin impedance (also referred to as equivalent resistivity level) as a feedback mechanism for stopping the drilling intervention at a preset trigger level value.
45456446|NCT03794011|Device|fetoscopy|The fetoscopic arm is described above. Patients who have an appropriate window (posterior placenta) and choose fetoscopic surgery will be offered the two fetoscopic options, (i) laparotomy assisted and, (ii) totally percutaneous expandable port assisted. Patients with an anterior placenta will only be offered the lapartotomy assisted approach. All patients will undergo a fetoscopic repair of the fetal open neural tube defect including a the use of a Durepair patch.
45456447|NCT03780751|Behavioral|Cognitive-behavioral treatment|COPE-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and cognitive-behavioral interventions (e.g., thought diaries, challenging of maladaptive thought patterns, behavioral analysis). Participants are encouraged to practice exercises between sessions.
45456448|NCT03780751|Behavioral|Mindfulness-based treatment|MIND-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and mindfulness-based exercises (e.g., breathing meditation, body scan, sitting meditation).
45672791|NCT05651789|Drug|Propranolol|Propranolol is started at a dose of 20 mg/d and the dose will be increased by 10 mg twice a day steps every 2-3 days until the target (heart rate: 55~60 bpm) or to a maximum dose of 160 mg/d. Systolic arterial pressure is not less than 90 mm Hg and heart rate is not less than 50 bpm.
45672792|NCT05651477|Device|Wearable Device (Smart Watch)|A smart watch refers to an embedded system portable watch equipped with improved functions than a general watch, and is almost always in the form of a wrist watch. The device we are using is the Samsung Galaxy 4 (SM-R860/870).
45672793|NCT05651477|Device|Edge-Box|Edge-Box collects data such as air. The device we are using is the TDS Mfepc-4C2R.
45672794|NCT02999477|Drug|Pembrolizumab|Pembrolizumab will be administered in clinic every three weeks.
45672795|NCT02999477|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered in clinic every week.
45672796|NCT02999477|Procedure|Biopsy|Biopsies for research purposes will be performed at three separate timepoints during treatment.
45832372|NCT03581682|Other|Tele-Clinic Visits Using Parent-Acquired Echos|"Every patient will have a tele-visit and an on-site clinic visit 1 day apart 3-6 months after the training session. Parents will have a 1-hour hands-on training session to acquire basic echo images on their children with the same hand-held device that they will use during the tele-visit. The parents will also have an in-service on how to take weight, height, and blood pressure measurements, and how to use the digital stethoscope.~A tele-visit will be schedule a day prior to the patient's regularly scheduled clinic visit. Tele-visit elements will include interim medical history by the parent and patient, and weight, height, vital signs, digital cardiac auscultation, and home echo, all obtained by the parent. Two MFS physicians, following our routine MFS care protocol, will administer either the tele-visit or on-site clinic visit, masked to the findings of the other."
45832373|NCT05703048|Drug|Esmolol Esterase|35 patients will be received i.v. received a loading dose of esmolol 0.5 mg/kg in 30 mL isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min. infusion stopped immediately upon extubation.
45832374|NCT05703048|Drug|Dexmedetomidine|35 patients will be received dexmedetomidine (Precedex; Abbott Laboratories, North Chicago, Illinois, USA) (vial = 2 ml) 100 mcg/ml at bolus dose of 1 mcg /kg slowly infused over 10 min, then continuous infusion by a rate of 0. 5 mcg /kg/h., infused by a syringe pump. infusion stopped immediately upon extubation.
46082791|NCT02715024|Drug|Tamsulosin|Oral
46082792|NCT02715024|Drug|Solifenacin|Oral
46082793|NCT02793752|Other|Age|Maternal Age
46082794|NCT00941395|Other|Survey Administration|Complete surveys
46082795|NCT02798744|Drug|Empagliflozin|25mg once daily to be taken orally for the duration of the study (24 weeks)
46082796|NCT02798744|Behavioral|Diet|Daily energy restriction diet to be followed for the duration of the study (24 weeks)
46082797|NCT02798744|Drug|Placebo|Placebo once daily for the duration of the study (24 weeks)
46082798|NCT02723682|Other|Collect 24-hour urine specimen|A random half sample of NHANES participants 20-69 examined in the mobile examination center were asked to collect a 24-hour urine specimen.
46082799|NCT00925769|Drug|bevacizumab [Avastin]|Escalating doses of 5/10mg/kg q2w
46082800|NCT00925769|Drug|capecitabine [Xeloda]|Escalating doses of 500/650/750/900mg/m2 bid
46082801|NCT00925769|Drug|erlotinib [Tarceva]|Escalating doses of 100/150mg daily
46082802|NCT00770913|Drug|E3810|20 mg taken orally, once a day for 8 weeks.
46082803|NCT00770913|Drug|E3810|10 mg, taken orally, twice a day for 8 weeks.
45981319|NCT00428337|Biological|MVA-mBN32|HIV-recombinant viral vaccine
45981320|NCT04703400|Other|anonymous survey|anonymous survey with 25 mandatory questions
45981321|NCT00428376|Device|Building Blocks|
45981322|NCT04575233|Procedure|laparoscopic-assisted Transversus Abdominis Plane (TAP) block|"The anterior axillary line is used as landmarks. After insertion of the optic trocar, the peritoneum is visualized. A 14 Gauge needle is inserted 2 cm cranially respect the taken landmark through the skin until the penetration of the internal and external oblique fascias, identified as sudden lowering of resistance. A solution of 15 ml of Ropivacaine (0.2%) is then injected. The procedure is performed then 2 cm caudal to the first landmark on the same side.~The procedure is than repeated identically on the contralateral side."
45981323|NCT04575233|Procedure|ultrasound-assisted Transversus Abdominis Plane (TAP) block|Whilst the patient is in the supine position, a high frequency ultrasound probe is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Then 15 ml of local anaesthetic solution is injected. The needle is than retracted until its tip is positioned in the fascial plane between the internal and the external oblique muscles and a second bolus of 15 ml of local anaesthetic is injected. The procedure is than repeated identically on the contralateral side.
45981324|NCT04575233|Drug|Ropivacaine|a solution of 15 ml of Ropivacaine (0.2%) is injected for the treatment of post-operative pain after minimally invasive surgery (TAP block)
45981325|NCT04565951|Behavioral|PsychArmor S.A.V.E.|The intervention is called PsychArmor S.A.V.E. It is an online video-based training tailored to veterans and their close supports. It is free, brief (24 minutes), and includes three scripted role plays.
45981326|NCT04565951|Behavioral|sham intervention|"A sham training consisting of information unrelated to suicide prevention but relevant to transitioning veterans and their loved ones."
45981327|NCT00428415|Drug|Tesofensine|
45981328|NCT04558073|Behavioral|Body Project (BP)|"The BP intervention offers discussions and exercises to make participants realize the cost of pursuing social ideals valuing thinness. This produces cognitive dissonance, a cognitive discomfort due to a contradiction between speech and beliefs, which motivates to modify one's beliefs. The curriculum includes discussions on techniques of the advertising industry and the unique ideal of beauty promoted worldwide, as well as on the costs of pursuing the thin-ideal. Participants are also challenged to try behaviours they avoid because their appearance bother them. Societal activism actions are also discussed."
45981329|NCT04558073|Behavioral|Healthy Weight Program (HW)|The HW intervention allows participants to make personalized changes in their diet and physical activity each week gradually, to aim for a health-ideal rather than a thin-ideal. The intervention is based on small changes, based on behavioural change techniques. Advice is given on what types of changes introduce to promote health, and how to implement changes sustainably. Difficulties are discussed in the group with a problem-solving approach. The last session introduces a long-term view of lifestyle change.
45981330|NCT04507412|Drug|dexamethasone|perioperatively 9 mg i.v subministration
45981331|NCT00428454|Device|sirolimus-eluting stent, zotarolimus-eluting stent|PCI in chronically occluded coronary artery
45981332|NCT00432978|Drug|Bosentan administration|
45981333|NCT00433056|Other|STI|CD4 guided treatment interruption
45981334|NCT00433056|Drug|stable HAART|continuous therapy
45981335|NCT04460612|Device|Active IR sock|Subjects will be wearing the infrared socks for 60 minutes
45981336|NCT04460612|Other|Placebo socks|Placebo Socks will be placed on participants feet first for 60 minute
45981337|NCT00428532|Drug|Licorice root extract or Pomegranate juice|
45981338|NCT04401332|Other|mobile health app|asthma symptom monitoring via a clinically integrated mobile health (mHealth) app installed on patients' smartphones
45981339|NCT01051791|Drug|Everolimus 10mg daily|RAD001 is a pill that will be taken orally (by mouth), at a dose of 10 mg, once a day for 28 days.
45981340|NCT04378049|Procedure|Total knee arthroplasty|Surgeon will perform a total knee arthroplasty procedure according to local standard of care
45981341|NCT04378049|Procedure|Robot-assisted partial knee arthroplasty|Surgeon will perform a robot-assisted unicompartmental or bicompartmental knee arthroplasty procedure
46082804|NCT00770913|Drug|E3810|20 mg taken orally, twice a day for 8 weeks.
46082805|NCT00562861|Drug|citalopram + mood stabilizer|Citalopram dose will be flexibly designed, beginning at 10 mg/d for at least one week, and the increased by 10 mg per week to a maximum of 50 mg/d. No target dose will be provided but rather clinicians will dose to clinical efficacy. Thus the study will provide clinicians data on the effective dose if it is positive. The dose will not be predetermined at static amounts.
46082806|NCT00562861|Drug|placebo + mood stabilizer|This arm will only receive mood stabilizing medication. All subjects will be required to receive treatment with lithium, lamotrigine, valproate, or carbamazepine for at least one month at therapeutic blood levels or doses before randomization, or they must initiate one of these agents at study entry.
45456449|NCT03779620|Device|Ultrasound treatment of Calcified aortic valve|Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacement
45456450|NCT03769298|Drug|Envarsus XR|The Envarsus XR® drug will be administered to study participants once daily, orally. The dosage can be 0.75 mg, 1 mg or 4 mg. The tacrolimus whole blood trough concentrations will be monitored and titrate Envarsus XR® dosage to achieve target whole blood trough concentration.
45456451|NCT03768986|Behavioral|Standard referral for HIV testing|Participants receive standard referral for HIV testing in the community.
45672797|NCT02222558|Drug|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
45981342|NCT04346537|Device|INGEVITY+™ Pace/Sense Lead|The INGEVITY+ lead is indicated for chronic pacing and sensing in the right atrium and/or right ventricle when used with a compatible pulse generator.
45981343|NCT01056510|Drug|bendamustine|90mg/m2 (first-line) or 70mg/m2 (second-line) iv, days 1 and 2 every 4 weeks, cycles 1-6
45981344|NCT01056510|Drug|chlorambucil|10mg/m2 po days 1-7 every 4 weeks, for up to 12 cycles
45981345|NCT01056510|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv day 1 of cycle 1, followed by 500mg/m2 iv every 4 weeks cycles 2-6
45981346|NCT04329767|Device|IRIS 1.0|Intuitive's IRIS 1.0 system is a software only device and service intended to create and deliver segmented image studies (3D anatomical models) based on patients computed tomography (CT) scans. It is intended as software for preoperative surgical planning, and as software for the intraoperative display of the aforementioned multidimensional digital images.
45981347|NCT01051323|Drug|methoxy polyethylene glycol-ep [Mircera]|As prescribed by physician
45981348|NCT04326257|Drug|Nivolumab+Relatlimab|IV administration of both Nivolumab and Relatlimab
45981349|NCT04326257|Drug|Nivolumab+Ipilimumab|IV administration of both Nivolumab and Ipilimumab
45456452|NCT03768986|Behavioral|Online risk reduction training|Participants are encouraged to use the CDC's website to learn more about their individual risks for HIV and how to reduce them.
45456453|NCT03768986|Behavioral|Reinforcement|Systematic reinforcement of desired behaviors Participants will receive a monetary incentive for getting tested for HIV
45981350|NCT04321811|Other|Observation of patients with known, suspected, or at risk for COVID-19 infection|Participants will receive daily diary surveys to track the symptomatic course of known or suspected COVID-19 patients as well as use of any interventions or treatments.
45981351|NCT01056276|Drug|Bendamustine|Treatment: 80 mg/m2 via intravenous (IV) Days 1 and 2; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.
45832375|NCT03157986|Other|Balance Training on a vibration platform|n=24 patients with severe chronic obstructive pulmonary disease. Exercises will be performed on a side-alternating Vibration platform (Galileo) at frequencies between 15 to 26 Hertz.
45981352|NCT01056276|Drug|Bortezomib|"1.3 mg/m2 IV Days 1, 8, 15; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.~Maintenance: 1.3 mg/m2 IV or SQ Days 1, 15"
45981353|NCT01056276|Drug|Dexamethasone|20 mg orally (PO) Days 1, 2, 8, 9, 15, 16 every 28-days for 8 cycles or 2 cycles beyond confirmed complete response, Maintenance: 20 mg PO Days 1, 15
45981354|NCT01055886|Drug|nicotine patch|Nicotine patch, 7-21 mg.
45981355|NCT01055886|Drug|placebo patch|placebo patch used from weeks 4-6
45981356|NCT00433095|Drug|Navelbine|
45981357|NCT00433095|Drug|Herceptin|
45981358|NCT00433095|Drug|Navelbine (oraly)|
45981359|NCT01055613|Device|Vistakon Investigational Multi-Purpose Solution I|Multi-purpose contact lens care solution.
45981360|NCT01055613|Device|ReNu MultiPlus Multi-Purpose Solution|Multi-purpose contact lens care solution
45981361|NCT00433134|Behavioral|Adherence|
45981362|NCT04301804|Drug|SHR6390|a selective small-molecule CDK4/6 inhibitor
45981363|NCT01055457|Device|Vistakon Investigational Multi-Purpose Solution II|contact lens care solution
45981364|NCT01055457|Device|ReNu MultiPlus Multi-Purpose Solution|contact lens care solution
45981365|NCT04258319|Diagnostic Test|Ultrasound Procedure|Ultrasound technique that uses a compression device integrated with ultrasound imaging to perform in vivo ramp-and-hold uniaxial creep-like test on upper extremity lymphedema (UEL) in vivo.
45981366|NCT04148144|Other|No intervention included|No intervention included
46082807|NCT02723448|Drug|aclarubicin|Aclarubicin (3 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days per 28 day cycle. There is no maximum number of cycles.
46082808|NCT00944593|Dietary Supplement|Jejunal Feed|Liquid nutrient (Ensure 200ml (300kcal) over 60 minutes) will be delivered by naso-jejunal feeding tube (previously placed by endoscopy)
45458701|NCT01238887|Dietary Supplement|Garcinia Cambogia derived Hydroxycitric Acid|The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 5,400 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
45458702|NCT02320552|Other|No intervention|no intervention
45832376|NCT03157986|Other|Conventional Balance training|n=24 patients with COPD, Exercises will be performed on a Balance pad
45832377|NCT03158142|Drug|Atropine Sulfate 1% Oph Soln|Atropine sulphate 1% ophthalmic solution is both a mydriatic and cycloplegic
45832378|NCT05701176|Diagnostic Test|[18F]F-AraG PET scan|[18F]F-AraG PET scans are performed to assess the accumulation of activated T-cells in the tumour and healthy tissue.
45981367|NCT00428571|Procedure|laparoscopic gastric bypass surgery|Laparoscopic Gastric Bypass Surgery
45981368|NCT00428571|Procedure|laparoscopic adjustable gastric banding|laparoscopic adjustable gastric banding
45981369|NCT00428571|Procedure|Intensive Medical Management|lifestyle, diet, medication optimization
45981370|NCT04100291|Other|Faecal microbiota transplantation|FMT by daily enema with donor faeces
45981371|NCT04100291|Other|Placebo|Placebo by daily enema with placebo mixture
45981372|NCT04703556|Device|Devices for deep brain stimulation|Effect of DBS parameters (amplitude, frequency) on gait and balance deficits, and their dynamical evolution over a pre-defined time
45981373|NCT04703283|Behavioral|Lifestyle Medicine|Lifestyle intervention with components including exercise, diet, stress management, and sleep management
45981374|NCT04046120|Other|Heel-free bandage|The bandage is made by leaving the heel uncovered.
45981375|NCT04716647|Other|Ayurveda|Dosage was used in common range (Ashwagandha: Doses range from 250 mg to 5 g; Giloy: range from 500mg to 1g; Tulsi: 500mg-1g) Dosage were altered based on age, weight and severity of symptoms.
45981376|NCT04703049|Other|Blood Viscosity Testing|we calculated WBV using the formula [(0.12 × hematocrit) + (0.17 × (total protein - 2.07)]. We defined CIN as the absolute (≥0.5 mg/dl) or relative increase (≥25%) in serum creatinine 48-72 h after exposure to a contrast agent compared with baseline serum creatinine values.
45981377|NCT00428649|Dietary Supplement|20 µg selenium|20 µg selenium as selenomethionine
45981378|NCT00428649|Dietary Supplement|40 µg selenium|40 µg selenium as selenomethionine
45981379|NCT00428649|Dietary Supplement|60 µg selenium|60 µg selenium as selenomethionine
46082809|NCT00944593|Dietary Supplement|Normal Saline|200ml Normal Saline 0.9%
45981380|NCT00428649|Dietary Supplement|80 µg selenium|80 µg selenium as selenomethionine
45981381|NCT00428649|Dietary Supplement|100 µg selenium|100 µg selenium as selenomethionine
45981382|NCT00428649|Dietary Supplement|120 µg selenium|120 µg selenium as selenomethionine
45981383|NCT00428649|Dietary Supplement|placebo|placebo
45981384|NCT03852992|Drug|Post-Laser Minoxidil 2%|2ml of 20mg/ml sterile solution, applied post-laser procedure
45458703|NCT01145989|Drug|AT9283|Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks
45832379|NCT03154944|Device|Ostomy device 1|This device consists of a known adhesive and a new top film
45832380|NCT03154944|Device|Ostomy device 2|This device consists of a new adhesive and a known top film
45832381|NCT03154944|Device|Ostomy device 3|This device consists of a known adhesive and a new top film
45832382|NCT03028740|Drug|Placebo|Cenicriviroc placebo-matching, tablet, orally, once daily for up to approximately 40 months.
45981385|NCT03852992|Drug|At-Home Minoxidil 5%|2ml of 50mg/ml foam q24 h for duration of study
45981386|NCT03852992|Device|Laser|Fractional ablative, deep mode, 5% fractional coverage
45981387|NCT03852992|Drug|Post-laser 5mg minoxidil|0.25ml of 20mg/ml sterile solution, applied post-laser procedure
45981388|NCT03852992|Drug|Post-laser 10mg minoxidil|0.5ml of 20mg/ml sterile solution, applied post-laser procedure
45981389|NCT03852992|Drug|Post-laser 20mg minoxidil|1ml of 20mg/ml sterile solution, applied post-laser procedure
45981390|NCT03790709|Drug|High dose ANAVEX2-73|Oral capsule
45981391|NCT03790709|Drug|Mid dose ANAVEX2-73|Oral capsule
45981392|NCT03790709|Drug|Placebo oral capsule|Oral capsule
45981393|NCT00419900|Procedure|diagnosis of breast cancer by x-ray diffraction of hair|
45981394|NCT04702854|Diagnostic Test|Ultrasound Biomicroscopy|Measure of cutaneous melanomas by ultrasound Biomicroscopy
45981395|NCT00433173|Procedure|intravenous glucose tolerance test|The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
45981396|NCT00433173|Drug|testosterone|transdermal 7.5 g/per day for 3 months
46082810|NCT02715180|Radiation|low dose chest computed tomography|All participants were evaluated 2 scout films during LDCT screenings. The first scout film was obtained while a participant was holding a comfortable expiration with the arms at down position, and the second scout film was obtained while a full inspiration with the arms at raised position. The axial images of LDCT were taken during participants' full inspiration. The radio-opaque marker was attached to the participants' skin where the lowest part of sternum was palpable, because the sternum moves according to the position of arms and respiration.
46082811|NCT02798510|Radiation|Concurrent Chemoradiotherapy|
46082812|NCT02798510|Drug|capecitabine|
46082813|NCT02798510|Drug|gemcitabine|
46082814|NCT05297175|Device|Trammpolin medial meniscus prosthesis|Implantation of the Trammpolin medial meniscus prosthesis in patients with a severe medial meniscus damage
46082815|NCT00941473|Drug|Triamcinilone (kenalog)|Epidural steroid injection of 80mg of Triamcinilone.
46082816|NCT04258475|Combination Product|Calcium supplementation concurrent to HIV treatment with Raltegravir|PK analysis of different doses of calcium in patients undergoing ART treatment for HIV using Raltegravir.
46082817|NCT03944954|Drug|Marinol|Individuals will receive 0, 10, 30mg of Marinol.
46082818|NCT03944954|Device|Transcranial Magnetic Stimulation|Individuals will receive excitatory or inhibitory TMS
46082819|NCT02723214|Procedure|Brain biopsy|Brain biopsy using either the frame-based stereotactic technique, or a frameless fiducial-less brain biopsy method using an optical based navigation system and a mini frame apparatus - trajectory guide.
45458704|NCT03492580|Drug|Canagliflozin|No intervention or treatment assignment imposed by this study. Participants received canagliflozin as a part of routine clinical practice.
45832383|NCT03028740|Drug|Cenicriviroc|Cenicriviroc, 150 mg, tablet, orally, once daily for up to approximately 40 months.
45981397|NCT00433173|Drug|anastrozole|tablet (per oral) 10.0 mg/ daily 3 months
45981398|NCT00433173|Drug|goserelin acetate implant|single depot injection 10.8 mg 3 months
45981399|NCT00433173|Procedure|aerobic capacity (VO2 Max)|This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
45981400|NCT00433173|Procedure|MRI|1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
45981401|NCT00433173|Procedure|muscle biopsy|Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
45981402|NCT00433173|Procedure|measurement of resting metabolic rate (energy expenditure)|Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
46082820|NCT00941551|Drug|levothyroxine|levothyroxine 75-125 ug/day
46082821|NCT00941551|Drug|no levothyroxine|observation only without prophylactic levothyroxine
46082822|NCT00609011|Drug|MPC-6827 + Temozolomide|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Temozolomide at 85 mg/m2 administered orally daily for 21 days in a 4 week cycle.
46082823|NCT00770679|Drug|lipitor|80 mg everyday (QD) for 3 weeks
45832384|NCT03157596|Other|Oral Health Educational Program for Caregivers of Children with developmental disabilities|Oral Health Education Program for Caregivers of Children with developmental disabilities included information about health issues and obstacles encountered in children with DD & methods of prevention and management. It also emphasized on proper oral hygiene measures for this group. (University of Washington 2010)
45832385|NCT05701020|Other|questionnary|If agreeing to the protocol, ; patients will answered questions about sexual health during the gynecologic consultation
45832386|NCT03154632|Device|Ultrasound Therapy|Ultrasound equipment will be used, choosing a continuous mode, with a frequency of 1MHz and an intensity of 1.0 W/cm2. The technique will be applied during 6 minutes with circular movements and a speed of approximately between 2.5 and 4 centimeters per second.
45981403|NCT00433173|Procedure|Dual energy x-ray absorptiometry|Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
45981404|NCT00433173|Procedure|Fasting oral glucose tolerance test|To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
45981405|NCT03626402|Behavioral|Planning for the Care You Want|25-minute culturally specific educational video informing viewers about advance care planning options, palliative care, and hospice care and meeting with a lay health advisor to discuss content of the video.
45981406|NCT01055028|Drug|Bevacizumab|15 mg/kg, IV every 21 days x 6 cycles.
45981407|NCT01055028|Drug|Paclitaxel|"Regimen A / Treatment 1: 200 mg/m² IV over 3 hours every 21 days.~Regimen B / Treatment 2: 90 mg/m² weekly x 3 of a 28-day cycle"
45981408|NCT00433212|Device|nCPAP|Deliver non-invasive respiratory support via ventilator with nCPAP device
45981409|NCT00433212|Device|NIPPV|Deliver non-invasive respiratory support via ventilator with NIPPV device
45981410|NCT03611816|Biological|Blood taken|Collection of clinical data
45981411|NCT03611816|Genetic|Blood taken|Collection of DNA
45981412|NCT03611816|Genetic|Blood taken|Collection of plasma
45981413|NCT00428727|Drug|Controlled nitric oxide releasing patch|daily application of nitric oxide patch during 90 days
45981414|NCT00428727|Drug|placebo patch|daily application during 90 days
45981415|NCT03474029|Drug|Rifapentine daily for 6 weeks|600 mg of Rifapentine (RPT) given once daily (o.d., omni die) for 6 weeks (6wP).
45981416|NCT03474029|Drug|Rifapentine and Isoniazid weekly for 12 weeks|"Rifapentine (RPT) 900 mg and isoniazid (INH) 900 mg given once-weekly for 12 weeks (3HP).*~*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RPT 900 mg once-weekly for persons weighing > 50 kg. For persons weighing < 50 kg, the following doses will be given: weight > 25-32 kg - RPT 600 mg; weight > 32-50 kg - RPT 750 mg; + INH 15 mg/kg (round up to nearest 50 or 100 mg; 900 mg max)."
45981417|NCT03474029|Drug|Rifampin and Isoniazid daily for 12 weeks|"Rifampin (RIF) 600 mg and Isoniazid (INH) 300 mg given once-daily for 12 weeks (3HR)*.~*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing > 50 kg. For persons weighing < 50 kg, give 10 mg/kg daily; round up to nearest 50 or 100 mg; + INH 5 mg/kg daily (rounded up to nearest 50 or 100 mg; 300 mg max)."
45981418|NCT03474029|Drug|Rifampin daily for 16 weeks|"Rifampin (RIF) 600 mg given once-daily for 16 weeks (4R).*~*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing > 50 kg. For persons weighing < 50 kg, 10 mg/kg daily; round up to nearest 50 or 100 mg."
45981419|NCT03440957|Other|Osteopathic treatment|The patients meeting the inclusions criteria will be informed of the study and an osteopathic treatment holistic ,involving all the body will be applied, three time with 2 days between the treatments .Each meeting with the practitioner will last around 40 minutes. The pain and symptoms assessment will be done before and after the treatment .
45981420|NCT00433368|Drug|L-Ornithine L-Aspartate|
45981421|NCT00428766|Drug|MORAb-003|
45981422|NCT04716569|Drug|intranasal ivermectin spray|usage of ivermectin as intranasal spray for treating early covid patiens
45981423|NCT00428805|Behavioral|classroom curriculum|"classroom curriculum for 3 & 4 year old children includes activities to increase intake of fruits, vegetables, & whole grains; increase physical activity; decrease intake of fats and sugared drinks; and decrease screen time following monthly learning modules.~Teachers are trained to carry out the classroom curriculum."
45981424|NCT00428805|Behavioral|In-service training for Head Start teachers/aides|Teachers and teacher aides are trained quarterly by certified trainers and receive a certificate for participating in the training. Topics include the content as well as developmental concepts.
45981425|NCT00428805|Behavioral|Training for Head Start food service|Food service workers are trained (quarterly) to modify food ordering, food preparation, and food serving to match the aims of the study
45981426|NCT00428805|Behavioral|Family intervention component|Families receive the CHILE intervention quarterly at Family Events. These include family activities to increase intake of fruits, vegetables, whole grains, decrease intake of fats and sugared drinks, increase of physical activity and decrease screen time. Parenting skills are also included.
45981427|NCT00428805|Behavioral|Food source|The grocery store component includes field trips, self labeling, and taste testing of promoted foods.
45981428|NCT00428805|Behavioral|Health care providers|The health care provider component includes the health care providers presenting at the Family Events and reinforcing the CHILE intervention message in the practice setting when talking with families of head start children.
45981429|NCT00428805|Behavioral|CHILE Head Start Intervention|There are six components of this transcommunity social-ecological intervention including a classroom curriculum, health care provider component, family component, training of Head Start teachers/aides, training of food service staff and grocery store component.
45981430|NCT03190577|Genetic|blood sample|two 5 ML EDTA tubes of blood will be collected once by patient
45981431|NCT03114059|Diagnostic Test|Glaucoma diagnostics|Heidelberg Retinal Topography, Visual field, intraocular pressure, medication anamnesis, Retinal Nerve Fibre Layer Thickness, Pachymetry, Sonography, full ophthalmological examination
45981432|NCT04703127|Drug|Tadalafil and Combined Dapoxietine|Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse.
45981433|NCT04703127|Drug|Dapoxietine and Combined Lidocaine 5% Spray|Group 2 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.
45981434|NCT00428883|Drug|N-acetylcysteine (NAC)|
45981435|NCT03082391|Device|Heavy weight Mesh|Patients will undergo ventral hernia repair with heavy weight mesh.
45981436|NCT03082391|Device|Medium weight Mesh|Patients will undergo ventral hernia repair with medium weight mesh.
45981437|NCT04702971|Drug|Flunarizine|The flunarizine will be given per clinical routine
45981438|NCT04702971|Other|healthy control|no intervention for healthy control
45981439|NCT02841644|Procedure|Operatively treated traumatic arthrotomy|operatively treated traumatic arthrotomy.
45981440|NCT02841644|Other|Non-operatively treated traumatic arthrotomy|non-operatively treated traumatic arthrotomy.
45981441|NCT00433407|Biological|trastuzumab|
45981442|NCT02763683|Radiation|PiB and VAT|There is no intervention for this study. The PiB and VAT are used during the PET procedures to help to identify any excessive abnormal proteins in the brain.
45981443|NCT00433485|Drug|sirolimus|
45981444|NCT00433485|Genetic|comparative genomic hybridization|
45981445|NCT00433485|Genetic|gene expression analysis|
45981446|NCT00433485|Genetic|microarray analysis|
45981447|NCT00433485|Genetic|protein expression analysis|
45981448|NCT00433485|Genetic|proteomic profiling|
45981449|NCT00433485|Other|laboratory biomarker analysis|
46082824|NCT03914066|Behavioral|A group-based treatment of overweight and obesity|The intervention is a group treatment of overweight and obesity in primary care inspired by cognitive behavioural therapy. The main goal of the group treatment is for the participants to obtain and maintain healthy lifestyle habits, with emphasis on diet and physical activity. Every group has 8-12 participants and is led by two persons; the main group leader is either a primary care nurse or a physiotherapist with special training. The groups meet six times (2 hours every time) once a month over a 6-8 month period. Every group session has a set agenda with different topics, for example a healthy diet, recommended physical activity or how to deal with setbacks. Between group sessions there are home assignments. The home assignments are followed-up at the next session and participants are encouraged to share experiences with each other in order to inspire, challenge and help fellow group participants. Data is collected prior to the start of group treatment, after 6-8 and 12 months.
45458705|NCT03492580|Drug|Empagliflozin|No intervention or treatment assignment imposed by this study. Participants received empagliflozin as a part of routine clinical practice.
45981450|NCT00433485|Other|mass spectrometry|
45981451|NCT00433485|Procedure|biopsy|
45981452|NCT02676791|Drug|Povidone-Iodine|A standard nasogastric tube will be inserted into all patients after induction of general anesthesia. After surgical dissection, the esophagus / stomach will be cut at the desired level leaving the tip of the nasogastric tube proximal to the esophageal carcinoma. Then, 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) will be introduced into the esophagus via the nasogastric tube and evacuated with a suction device (washout). The nasogastric tube will then be removed for completion of esophageal resection and beginning of reconstruction.
45981453|NCT02244125|Drug|PCD|"STUDY TREATMENT PHASE: All patients~4x 28 days cycles of PCD~[Pomalidomide: 4mg/day oral route on 21 days per cycle]~[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle]~[Dexamethasone: 40mg/day oral route on days 1, 2, 3, 4 and 15, 16, 17, 18 per cycle]~CONSOLIDATION PHASE: depends on previous IFM/DFCI 2009's arm:~Arm A:~Melphalan 200mg/m2 followed by Autologous Transplantation~2x 28 days cycles of PCD, three months post transplantation~Arm B:~5x 28 days cycles of PCD~[Pomalidomide: 4mg/day oral route on 21 days per cycle]~[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle]~[Dexamethasone: 40mg/day oral route on days 1, 8, 15, 22 per cycle]~MAINTENANCE PHASE: All patients~- Until progression/relapse or discontinuation for any other reason~[Pomalidomide: 4mg/day oral route on 21 days per cycle]~[Dexamethasone: 20mg/day oral route on days 1, 8, 15, 22 per cycle]"
45981454|NCT02244125|Procedure|Autologous transplantation (ASCT)|"Arm A:~•Melphalan 200mg/m2 followed by Autologous Transplantation"
45981455|NCT00429000|Device|thermospot|
45981456|NCT01600079|Biological|ZOSTAVAX™|ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use
45981457|NCT00429039|Drug|L-leucyl-L-leucine methyl ester (LLME)|
45981458|NCT01370486|Drug|melatonin|melatonin cp 2 mg 1x/d for 1 month
45981459|NCT01370486|Drug|placebo|placebo cp 1x/d for 1 month
45981460|NCT00429078|Genetic|2nd Generation Designer T Cells|
45981461|NCT00433524|Procedure|computed tomography|
45981462|NCT00429117|Behavioral|Survey|Internet survey lasting 30 to 40 minutes.
45981463|NCT00491309|Behavioral|exercise training|exercise training with specific program (respiratory therapy, dumbbell training, ergometer training, mental training)
45981464|NCT00429156|Device|Home non-invasive ventilation|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home NIV for 1 year.
45981465|NCT00429156|Device|Home non-invasive ventilation (sham)|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home sham NIV (CPAP 5 cm H2O) for 1 year.
45981466|NCT00327548|Behavioral|guided imagery|
45981467|NCT00433602|Other|clinical observation|
45981468|NCT00433602|Procedure|management of therapy complications|
45981469|NCT00433602|Procedure|ultrasound imaging|
45981470|NCT00327587|Drug|Valsartan + amlodipine|
45981471|NCT00327587|Drug|Valsartan + HCTZ|
45981472|NCT00327587|Drug|Amlodipine + HCTZ|
45981473|NCT00327587|Drug|Valsartan + amlodipine + HCTZ|
45981474|NCT00429195|Behavioral|Dietary Fatty Acid Modification|
45981475|NCT00327665|Biological|11-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Each group receiving one of the 3 formulations
45981476|NCT00327665|Biological|Pneumo 23™|Single-dose intramuscular injection.
45981477|NCT00327665|Biological|Placebo|1 intramuscular injection.
45981478|NCT00327665|Biological|10-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection
45981479|NCT00433641|Drug|sibutramine|placebo
45981480|NCT00433641|Drug|sibutramine|oral 15 mg sibutramine once per day
45981481|NCT00433641|Drug|sibutramine|oral sibutramine 10 mg once per day
45981482|NCT00327704|Drug|albumin|albumin 20% 100 ml/8 hours for 3 days
45981483|NCT00327704|Drug|saline|saline 100 ml/8hours for 3 days
45981484|NCT01050816|Procedure|Chondron(autologous chondrocyte) Implantation|"Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)~Directions and dosage:~Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected.~*30 subjects participated in this open clinical trial. Those who agreed to participate voluntarily went through screening to confirm the appropriateness for the clinical trial, and then received Gel type CHONDRON (fibrin mixed autologous chondrocytes) transplantation."
45981485|NCT00327821|Behavioral|calorie controlled diet|
45981486|NCT00429234|Drug|Dasatinib|Starting dose 70 mg by mouth daily for Week 1. Cycle is 28 days, except Cycle 1 which is 8 weeks.
45981487|NCT00429234|Drug|Gemcitabine|Starting dose of 800 mg/m^2 by vein once weekly over 30 minutes beginning Cycle 1 Day 1. All other cycles once weekly for 7 weeks on Days 8, 15, 22, 29, 36, and 43. Cycle is 28 days, except Cycle 1 which is 8 weeks.
45981488|NCT00327938|Device|Measuring of skin conductance|
45981489|NCT00327938|Procedure|Tetanic stimuli|
45981490|NCT00433680|Behavioral|Healthy Weight|4 weekly 1 hour meetings that encourage reductions in fat and sugar intake and increases in physical activity to decrease onset of obesity and body dissatisfaction.
45981491|NCT00433719|Drug|Combivir and efavirenz|Arm 1: Combivir and efavirenz for 12 months Arm 2: Placebo for 2 months then Combivir and efavirenz for 10 months
46082825|NCT02718534|Behavioral|stroke rehabilitation|Physical rehabilitation exercise between 24 and 48 hours and after 48 hours
46082826|NCT05330663|Dietary Supplement|Low protein diet with Fresubin® renal|Low protein diet with Fresubin® renal Dosage: 1 bottle per day as a replacement for one regular meal. All patients will get individualized dietary counseling aimed at achieving a protein intake of 0.6-0.8 g/kg actual body weight/day and an energy intake of 30-35 kcal/kg actual body weight.
46082827|NCT05330663|Other|Low protein diet with normal food|All patients will get individualized dietary counseling aimed at achieving a protein intake of 0.6-0.8 g/kg actual body weight/day and an energy intake of 30-35 kcal/kg actual body weight/day.
46082828|NCT03768284|Other|Saliva or buccal sample|Saliva or buccal sample
45981492|NCT00328055|Behavioral|AD-Easy (Advance Directive-Easy)|
45981493|NCT00328055|Behavioral|AD-Standard (Advance Directive-Standard)|
45981494|NCT04704297|Drug|Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.|We are testing which of the three arms is superior for the treatment of Myofascial Pain Syndrome of the Low Back. Pain will be measured using a 10 cm visual analogue scale (VAS) at baseline and 30-minutes after treatment.
45981495|NCT04704297|Drug|Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.|Evaluation of functional ability using a patient centered functional score known as the MODI. The MODI will be scored at baseline and 30-minutes after treatment.
45981496|NCT04704297|Drug|Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.|60-72 after treatment in the Emergency Department, a member of the study team will follow up with participants to repeat a measurement of pain and functional ability on VAS and MODI respectively. This will be compared to baseline measurements.
46082829|NCT04260503|Other|Monitoring of the gut-microbiome and ultrasound elasticity.|The investigator will investigate the alteration of gut-microbiome and liver stiffness by restoration of bile flow by operation.
45981497|NCT04704414|Device|Exophthalmos measurement|Exophthalmos measurement with iPhone 11 vs Artec Space Spider 3D Scanner vs Hertel Exophthalmometer.
45981498|NCT00328211|Dietary Supplement|Bile Acids (Cholic, Ursodeoxycholic, Chenodeoxycholic)|15 mg/kg/day for 18 days
45981499|NCT00328211|Dietary Supplement|Sphingomyelin|1000mg/day for 19 days
45981500|NCT00328211|Other|C13 Stable isotope of Cholesterol|Food provided for 3 days and one time dose of 113mg of C13 Cholesterol.
45981501|NCT04704180|Behavioral|Facilitation Tuchking Position|The nurse placed the neonate in the facilitated tucking position by rolling up a sizeable sterile towel in a U-shape and covering it with covers available in the unit and then placed the neonate in a supine position. The physiological parameters at admission and in the 15th and 30th minutes of facilitated tucking were recorded. In the 30th minute of facilitated tucking, the researcher and the observer nurse completed the COMFORTneo simultaneously but separately. The neonate was in the facilitated tucking position until delivered to its mother. The researcher and the observer nurse had a full view of the neonate's face and body when completing the COMFORTneo, which took them about two minutes. After the neonate stabilized (within the first half an hour to an hour), it was delivered to its mother for breastfeeding based on specialist consent. The first breastfeeding was performed and completed the LATCH by researcher and the observer nurse.
45981502|NCT00433758|Device|GlucoTrack|GT
45981503|NCT00419978|Procedure|Colectomy|
46082830|NCT04260503|Other|Monitoring of the gut-microbiome|The investigator will investigate the alteration of gut-microbiome before and after operation.
46082831|NCT04260503|Other|Monitoring of the gut-microbiome|The investigator will investigate the alteration of gut-microbiome along with the disease progress.
45981504|NCT01054560|Device|SOLITAIRE™ Device|The SOLITAIRE™ Device is the experimental device that will be used in the interventional procedure
45981505|NCT01054560|Device|MERCI® Device|The MERCI® Device is the control device that will be used in the interventional procedure.
45981506|NCT00328250|Behavioral|Cognitive behavioral treatment (CBT) delivered over the Internet|CBT delivered over the Internet for insomnia targets maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems. Treatment includes through educational, behavioral, and cognitive strategies.
45981507|NCT00328289|Device|transcutaneous muscle stimulation, treadmill|
45981508|NCT00433797|Dietary Supplement|Prostate cancer, phytochemical and PUFA|Patients with localized prostate cancer are supplemented with either tomato or a multi-diet cinsisting of grape juice, pomegranate juice, tomato, green tea, black tea, soy, selenium and PUFAs for 3 weeks.
45981509|NCT00328367|Drug|aripiprazole|aripiprazole augmentation of clozapine
45981510|NCT00328367|Drug|placebo|placebo
45981511|NCT04703088|Drug|Ondansetron 4 MG|2 mL of a solution of Ondansetron containing 2mg/ml in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
45981512|NCT04703088|Drug|0.9% Saline|2 mL of 0,9% Saline in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
45981513|NCT00328445|Behavioral|Positive Action|See publications
45981514|NCT00433875|Drug|AMG 714|
45981515|NCT00328484|Behavioral|Lifestyle Activity Program|The lifestyle activity program will consist of 35 exercise and counseling sessions spaced over 11 months. This program will use cognitive-behavioral strategies to encourage physical activity at home. Participants will receive information on how to deal with COPD symptoms (including shortness of breath), goal-setting, social support, and motivation. Participants will also receive follow-up telephone calls from the program staff for additional support.
45981516|NCT00328484|Behavioral|Exercise Program|The 3-month exercise program will consist of 36 1-hour exercise training sessions, conducted 3 times a week for 12 weeks.
45981517|NCT00429312|Biological|JX-594|Thymidine kinase-deleted vaccinia virus plus GM-CSF
45981518|NCT00328640|Drug|Optimal treatment|
45981519|NCT00328679|Device|in vitro and in vivo allergy testing|Patch Test: food to be tested is suspended in sterile saline, placed on the skin of the back using a Finn Chamber secured with surgical tape and left in place for 48 hours.
45981520|NCT00328718|Drug|montelukast (5mg QD)|
45981521|NCT00328718|Drug|Salmeterol/Fluticasone propionate Inhalation Powder (50/100mcg BID)|
45981522|NCT00328757|Behavioral|Regular diet as the first postoperative meal|
45981523|NCT01054443|Drug|Placebo|Tablet
45981524|NCT01054443|Drug|Lusutrombopag|Tablet
45981525|NCT00328796|Procedure|acupuncture in 6 specific points|
46082832|NCT04260503|Other|Monitoring of the gut-microbiome.|The investigator will investigate the alteration of gut-microbiome according to the normal development.
45672798|NCT02975999|Drug|Vasopressin|Vasopressin at dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
45981526|NCT00328796|Drug|lidocaine 10mg/ml|
45981527|NCT01580319|Other|physical exercise|150 minutes per week
45981528|NCT00420134|Procedure|injection of progenitor of hepatocyte drived from Mesenchymal stem cell|
45981529|NCT00429390|Behavioral|Ramadan Fasting|
46082833|NCT03838640|Device|EPIQ 5|As described in summary Trade name of the device Philips EPIQ 5
46082834|NCT04042116|Drug|Lucitanib|Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.
46082835|NCT04042116|Drug|Lucitanib|Oral lucitanib will be administered once daily (QD). The dose will be 6 mg.
45981530|NCT00420173|Procedure|Laboratory analysis|blood withdrawal
45981531|NCT00429468|Drug|Vicodin® CR (extended-release hydrocodone/acetaminophen)|
45981532|NCT00420251|Drug|Genotropin|
45981533|NCT04702698|Drug|Peposertib|Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions.
45981534|NCT04702698|Drug|Peposertib|Participants will receive oral suspension dose of peposertib tablets under fasted condition (Treatment C) in either period 1, 2 or 3 of part 1.
45981535|NCT00328835|Procedure|Brief Elevation of IOP|
45981536|NCT04702542|Drug|Enteral oxygen therapy|Enteral oxygen therapy during the rehabilitation period of patients with CGDP.
45981537|NCT00328874|Drug|Coenzyme Q10|
45981538|NCT00429546|Behavioral|Teaching, Raising, and Communicating with Kids (TRACK)|TRACK is cognitive-behavioral treatment designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child. The treatment consists of three 75-minute sessions that focus on exploring mothers' concerns, determining children's readiness to receive the news, planning for disclosure, and practicing disclosure.
45981539|NCT00429546|Other|Treatment as usual|Treatment as usual includes standard care for HIV infected mothers.
45981540|NCT00328913|Drug|5-hydroxytryptophan (food supplement)|
45981541|NCT00433953|Drug|Mycophenolate Mofetil (CellCept)|
45981542|NCT00433953|Behavioral|Dietary Monitoring|
45981543|NCT00433953|Behavioral|Drug Diary|
45981544|NCT00433953|Procedure|Blood Sampling|
45981545|NCT02957643|Drug|Iron|oral treatment
45981546|NCT00328991|Device|duct tape occlusion therapy|
45981547|NCT02957604|Drug|evolocumab|Pregnant women exposed to evolocumab. Evolocumab is not administered in this non-interventional study.
45981548|NCT00329069|Drug|atorvastatin (drug)|
45981549|NCT00429624|Procedure|Chiropractic manipulation|
45981550|NCT00429624|Drug|acetaminophen|
45981551|NCT00329147|Drug|desvenlafaxine SR|
45981552|NCT00329147|Drug|desipramine|
46082836|NCT04042116|Drug|Lucitanib|"Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.~Subjects will be allowed to intrapatient dose escalate in increments of 2 mg up to a total dose of 10 mg QD lucitanib if they meet the study specific clinical criteria."
45672799|NCT02975999|Drug|Normal Saline|Normal saline at starting dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
45981553|NCT00329147|Drug|paroxetine|
45981554|NCT04702503|Drug|WP1220|Topical administration 2x daily for 84 consecutive days
45981555|NCT00329186|Drug|desvenlafaxine SR|
45981556|NCT00329186|Drug|venlafaxine ER|
45981557|NCT00434031|Drug|docetaxel|
45981558|NCT00434031|Drug|cyclophosphamide|
45981559|NCT00434031|Drug|trastuzumab|
45981560|NCT00434031|Drug|liposomal doxorubicin|
45981561|NCT00329225|Drug|rosiglitazone|
45981562|NCT01050543|Drug|sugammadex|sugammadex 2.0 mg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
45981563|NCT01050543|Drug|neostigmine|neostigmine 50 mcg/kg (total dose not to exceed 5.0 mg) combined with glycopyrrolate 10 mcg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
45981564|NCT00329264|Drug|Quetiapine fumarate|
45981565|NCT00329342|Behavioral|Occupational ergonomic training|Adequate postural habits in activities of daily living
45981566|NCT04703946|Other|observacional|"Analyze the incidence of short sublingual frenulum in newborns of the Hospital Nostra Senyora de Meritxell of the Principat of Andorra.~Association or not of the AG with auxological parameters (weight, height, cranial perimeter) at birth.~Association or not of the AG with sex.~Association or not of the AG with gestational age.~Association or not of the AG with other minor and major malformations."
45981567|NCT00329381|Drug|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
45981568|NCT00329381|Drug|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
45981569|NCT00429780|Biological|Alum-ALM + BCG|Alum-ALM + BCG 200 ug per injection
45981570|NCT00329459|Drug|sumatriptan succinate/naproxen sodium|
45981571|NCT00329459|Drug|placebo|placebo to match
45981572|NCT00329498|Drug|L-Ascorbic Acid|
45981573|NCT00434187|Drug|ERB-041|
45981574|NCT00329537|Drug|Sargramostim (Leukine)|Self-subcutaneous injection
45981575|NCT00329537|Drug|Placebo|Self-subcutaneous injection
45981576|NCT00429897|Drug|Bendroflumethiazide 2.5mg - 5mg|
45981577|NCT00429897|Drug|Amiloride 20-40mg|
45981578|NCT00429897|Drug|Spironolactone 50-100mg|
45981579|NCT00429897|Drug|Frusemide 20-40mg|
45981580|NCT00429897|Drug|Bendroflumethiazide 1.25-2.5mg/ Amiloride 10-20mg combined|
45981581|NCT00329576|Biological|Hepatitis B vaccine|
45981582|NCT00429936|Drug|Fenretinide|Once daily 30 minutes after the evening meal for 24 months
45981583|NCT00429975|Drug|levofloxacin|
45981584|NCT00429975|Drug|ceftriaxone|
45981585|NCT00329615|Drug|Insulatard, flexpen|
45981586|NCT00430014|Drug|Atiprimod|Starting Dose of 60 mg/day orally for 14 days of 28 day cycle.
45981587|NCT00329654|Procedure|Phototherapy with the Embar® light therapy or sham irradiation|Phototherapy with the Embar® light therapy or sham irradiation is followed.
46082837|NCT04042116|Drug|Nivolumab|IV nivolumab 480 mg will be administered once every 4 weeks.
45981588|NCT00430053|Genetic|gene rearrangement analysis|
45981589|NCT00430053|Genetic|polymerase chain reaction|
45981590|NCT00430053|Genetic|proteomic profiling|
45981591|NCT00430053|Other|flow cytometry|
45981592|NCT00430053|Other|immunohistochemistry staining method|
45981593|NCT00430053|Procedure|biopsy|
45981594|NCT04716686|Drug|Niraparib|Patients received oral niraparib 200/300 mg QD and every cycle (28 days) thereafter until disease progression.
46082838|NCT00941629|Behavioral|Cognitive Processing Therapy (CPT)|Patients with PTSD receive a trauma-focused, cognitive-behavioral intervention in Face-to -Face treatment.
46082839|NCT00941629|Behavioral|Cognitive Processing Therapy (CPT)|Provision of Cognitive Processing Therapy over teleconference network (telemental health; telehealth)
46082840|NCT02798432|Procedure|Total knee arthroplasty|Use of an uncemented femoral component or a cemented femoral component randomly assigned.
45981595|NCT01056393|Drug|ibalizumab 800mg Q2Weeks|Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 800mg every 2 weeks.
45981596|NCT01056393|Drug|ibalizumab 2000mg Q4Weeks|Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 2000mg every 4 weeks.
45981597|NCT04716491|Device|Intervention to decrease disruptive sleep in patients undergoing percutaneous intervention to treat cardiac disorders admitted to the ICU: ear protector and eye mask.|When they meet the inclusion criteria and accept to participate in the study, the interventionist nurse will explain to the patient the objectives and protocol of the study, apply the consent form and the instruments for assessing sleep (pittsburgh), trait and state anxiety (STAI). Then the software will be randomized and after defining the group, the nurse will guide the patient on the use of the devices from 9:00 am until the final awakening in the morning. Control group participants will only complete the assessment instruments. Noise and brightness will be measured at randomization of participants. The following morning, the visual sleep scale and the sleepiness scale will be applied for both groups, in addition to filling in information regarding the length of time the devices stay with patients at night and the clinical data that will be collected until discharge from the hospital. ICU, when independent of the group, the state anxiety instrument will be applied.
45981598|NCT01055106|Drug|GW05|vaginal gel once daily regimen A
45981599|NCT01055106|Drug|GW05|vaginal gel once daily regimen B
45981600|NCT01055106|Drug|GW05|vaginal gel once daily regimen C
45981601|NCT01055106|Drug|Metronidazole|vaginal gel 0.75% once daily for 5 days
45981602|NCT00329693|Drug|Norprolac|Placebo
45981603|NCT00329693|Drug|Norprolac|Quinagolide
45981604|NCT00329693|Drug|Norprolac|Quinagolide
45981605|NCT00329693|Drug|Norprolac|Quinagolide
45981606|NCT00430131|Procedure|Cognitive Orientation to Occupational Performance|
45981607|NCT00430131|Procedure|Contemporary Treatment Approach|
45981608|NCT00329810|Drug|Aripiprazole|Tablets, oral, 15 mg, once daily, 12 weeks.
45981609|NCT01053936|Drug|Bardoxolone methyl (amorphous dispersion)|Oral, once daily
45981610|NCT00329888|Procedure|Endoscopic papillary balloon dilatation|
45981611|NCT00329888|Procedure|Endoscopic sphincterotomy|
45981612|NCT00430170|Drug|Dipyridamole|Dipyridamole 2x200mg 7day per os
45981613|NCT00430170|Drug|caffeine|caffeine 4mg/kg iv
45981614|NCT00329927|Biological|Surface Antigen, Inactivated, (Adjuvanted with MF59C.1), form. 2006-07|
45981615|NCT00329966|Biological|Surface Antigen, Inactivated, Influenza (form.2006-07)|
45981616|NCT00434265|Behavioral|Physical training|
45981617|NCT00330005|Behavioral|Group Psychotherapy|
45981618|NCT04716530|Other|No intervention is associated with the study.|No intervention is associated with the study.
45981619|NCT00330044|Drug|Premetrexed (Alimta)|
45981620|NCT00330044|Drug|Carboplatin|
45981621|NCT00430326|Drug|Avotermin|
45981622|NCT00330083|Biological|ALK Ragweed Tablet|
45981623|NCT00430365|Drug|lenalidomide|oral drug
45981624|NCT00430365|Drug|placebo|oral placebo
45981625|NCT00330122|Procedure|fore locked plate|
45981626|NCT00330122|Procedure|external radiocarpal fixer|
45981627|NCT00330239|Drug|Paroxetine CR|
45981628|NCT01051557|Other|Laboratory Biomarker Analysis|Correlative studies
45981629|NCT01051557|Drug|Perifosine|Given PO
45981630|NCT01051557|Drug|Temsirolimus|Given IV
45981631|NCT01051557|Procedure|Therapeutic Conventional Surgery|Undergo cytoreductive surgery
45981632|NCT00330278|Drug|Cefazolin|
45981633|NCT00430404|Other|Collaborative care (Intervention)|Structured shared care with treatment protocol & support
45981634|NCT00330317|Drug|letrozole|2.5mg letrozole once-daily
45981635|NCT03270384|Device|Urotronic Drug Coated Balloon (DCB)|The Urotronic Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
45981636|NCT00330356|Behavioral|Low Salt Diet versus High salt diet|
45981637|NCT00430443|Drug|Liposomal Annamycin|3-day IV infusion
45981638|NCT00330395|Drug|caspofungin acetate|Duration of Treatment 28 Days
45981639|NCT00330434|Other|Trial Withdrawn 1|Trial Withdrawn 1
45981640|NCT00330434|Other|Trial Withdrawn 2|Trial Withdrawn 2
45981641|NCT00434382|Drug|Sevoflurane|
45981642|NCT00434382|Drug|Isoflurane|
45981643|NCT00434382|Drug|Desflurane|
45458706|NCT03492580|Drug|Dapagliflozin|No intervention or treatment assignment imposed by this study. Participants received dapagliflozin as a part of routine clinical practice.
45981644|NCT00434382|Drug|Propofol|
45981645|NCT00434382|Drug|Fentanyl|
45981646|NCT00434382|Drug|Sufentanil|
45981647|NCT00434382|Drug|Alfentanil|
45981648|NCT00434382|Drug|Remifentanil|
45981649|NCT00434382|Device|Midlatency auditory evoked potentials|
45981650|NCT00430560|Behavioral|cognitive rehabilitation|computer training
45981651|NCT00430560|Procedure|work therapy|opportunity to work in carefully supervised hospital job
45981652|NCT00430560|Behavioral|work therapy|work therapy
45981653|NCT01054170|Drug|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
45981654|NCT01054170|Drug|Placebo|2 x matched placebo to oral tablet twice daily (bid) for 12 weeks
45981655|NCT00330629|Behavioral|Standard Behavioral Treatment|Participants in this condition will receive the standard behavioral treatment (SBT) described above. Food tastings will be held at the sessions and will focus on fat modified food products.
45981656|NCT00330629|Behavioral|SBT+LOV|The focus will be on the elimination of meat products as a means to reduce fat intake.
45981657|NCT00330707|Drug|Bacillus Calmette Guerin and interferon alpha|
45981658|NCT00434460|Behavioral|Education|Implementation of clinical practice guideline for ventilator associated pneumonia through education.
45981659|NCT00330746|Drug|cetuximab|400 mg/m2 first dose then weekly at 250 mg/m2 until disease progression
45981660|NCT00330746|Drug|gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for a maximum of 6 cycles
45981661|NCT00330746|Drug|gemcitabine|1200 mg/m2 IV days 1 and 8 every 3 weeks for a maximum of 6 cycles
45981662|NCT00330746|Drug|cetuximab|400 mg/m2 first dose followed by 250 mg/m2 weekly
45981663|NCT01053741|Biological|Radiolabeled autologous seminal fluid|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in seminal fluid vehicle.
45981664|NCT01053741|Biological|Radiolabeled Normosol-R|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in Normosol-R fluid vehicle.
45981665|NCT04702230|Diagnostic Test|MRI|Baseline and follow-up MRI at 1 and 3 months post-TAE or post-TARE
45981666|NCT00330785|Drug|Amlodipine/Atorvastatin|
45981667|NCT00330824|Drug|antibiotic/steroid combination|1gtt, 4x/d, 15 days
45981668|NCT00330824|Drug|moxifloxacin/dexamethasone|1gtt, 4x/days, 15 days
45981669|NCT00434538|Device|BST-DermOn|
45981670|NCT00330902|Drug|sulfadoxine-pyrimethamine (SP) plus artesunate (AS)|sulfadoxine-pyrimethamine (SP) plus three daily doses of artesunate (AS)
45981671|NCT00330902|Drug|primaquine (PQ) plus SP+AS|single dose of primaquine on day 4
45981672|NCT00434616|Procedure|Autologous bone marrow cell concentrate transplantation|bone marrow aspiration (240 ml), processing and reinjection
45981673|NCT00434616|Biological|saline injection|saline injections
45981674|NCT04703868|Drug|Rabeprazole Sodium 10mg|Part A: 1 tablet administered before the breakfast during 7 days
45981675|NCT04703868|Drug|Rabeprazole Sodium 20mg|Part B: 1 tablet administered before the breakfast during 7 days
45981676|NCT00430794|Drug|Spironolactone|
45981677|NCT00330980|Drug|40 mg Pravastatin (Pravachol)|Participants will receive 40 mg of pravastatin for 6 months.
45981678|NCT00330980|Drug|20 mg Simvastatin|Participants will receive 20 mg of simvastatin for 6 months.
45981679|NCT00330980|Drug|Placebo|Participants will receive placebo for 6 months.
45981680|NCT00430833|Drug|candesartan|
45981681|NCT00434655|Procedure|Laparoscopic restrictive procedure|Morbidly Obese VETERANS will receive one of two laparoscopic bariatric restrictive procedures.
45981682|NCT00331058|Procedure|Bronchoscopsy|Healthy and Asthmatic Volunteers
45981683|NCT00331058|Procedure|Prednisolone|Asthmatic Volunteers
45981684|NCT00430872|Behavioral|Survey|Survey about the severity of certain symptoms lasting 10-15 minutes.
45981685|NCT00331097|Drug|docetaxel|35 mg/m2 intravenously on days 1, 8, and 15 every 28 days
45981686|NCT00331097|Drug|cyclophosphamide|600 mg/m2 intravenously days 1, 8 every 28 days
45981687|NCT00331097|Drug|methotrexate|40 mg/m2 intravenously days 1 and 8 every 28 days
45981688|NCT00331097|Drug|5-fluorouracil|600 mg/m2 intravenously days 1 and 8 every 28 days
45981689|NCT00434694|Procedure|Pulmonary Vein Isolation (Radiofrequency Catheter Ablation)|
45981690|NCT00331175|Drug|Peptide YY3-36|
45981691|NCT00430911|Drug|Radiotherapy|
45981692|NCT00331214|Drug|Testosterone Transdermal System|testosterone patch (300 mcg/day), patch changed twice a week for six months
45981693|NCT00331214|Drug|placebo patch|placebo patch replaced every 3-4 days for 6 months
45981694|NCT04702074|Drug|Traditional Chinese medicine granules|"Bu Fei Jian Pi Hua Tan granule for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule for syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules will be administered twice daily for 2 months."
45981695|NCT04702074|Drug|Traditional Chinese medicine granules placebo|"Bu Fei Jian Pi Hua Tan granule placebo for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule placebo for Syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules placebo will be administered twice daily for 2 months.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The granule placebo consists of dextrin, bitter and 5% of the Traditional Chinese medicine granules ."
45981696|NCT00434733|Biological|Pandemic influenza vaccine|
45981697|NCT00434772|Drug|glucagon|
45981698|NCT04703907|Other|Auricular stimulation|"Auricular acupuncture-like stimulation (percutaneous sensory stimulation of cranial nerves)"
46082841|NCT02798432|Device|NEXGEN LPS total knee arthroplasty|Hybrid (non cemented femoral component, cemented tibial component) NEXGEN LPS total knee arthroplasty versus Cemented NEXGEN LPS total knee arthroplasty (both components are cemented).
46082842|NCT04260581|Drug|Determination of drug effects through amantadine cessation|Patients will discontinue amantadine, which has been taken since beginning of diagnosis.
45981699|NCT00331253|Procedure|Indocyanine Green-Mediated Photothrombosis|
45981700|NCT00431028|Device|slow delivery ciprofloxacin + triamcinolone|2 mg ciprofloxacin + 25mg triamcinolone
45981701|NCT00431106|Drug|Gemcitabine|Gemcitabine at the dose of 1000 mg/m2 intravenously (IV) every 2 weeks for 12 consecutive cycles
45981702|NCT00431106|Drug|Capecitabine|Capecitabine at the dose of 1250 mg/m2 twice daily orally (os), from day 1 to day 14, every 3 weeks for 6 consecutive cycles
45981703|NCT00431106|Drug|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on day 1 every 2 weeks for 12 consecutive cycles
45981704|NCT00331370|Behavioral|GP training and Health Education|
45981705|NCT00431145|Drug|Niacin|
45981706|NCT00431145|Drug|Niacin+Statin|
45981707|NCT00331487|Drug|Pioglitazone|Pioglitazone 30 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to pioglitazone 45 mg, capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks
45981708|NCT00331487|Drug|Rosiglitazone|Rosiglitazone 4 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to rosiglitazone 4 mg, capsules, orally, twice daily for up to 12 weeks
45981709|NCT00431223|Behavioral|Cognitive remediation therapy|36 sessions of computerized cognitive skills training over a 12 week duration. 7 patients were assigned to cognitive remediation therapy or CRT Group.
45981710|NCT00331526|Biological|aldesleukin|
45981711|NCT00331526|Biological|therapeutic autologous lymphocytes|
45981712|NCT00331526|Procedure|adjuvant therapy|
45981713|NCT00331526|Procedure|conventional surgery|
45981714|NCT00435084|Drug|APO866|
45981715|NCT00331565|Procedure|Bariatric surgery|Gastric bypass, duodenal switch and sleeve surgery
45981716|NCT00431262|Drug|antabuse (disulfiram)|
45981717|NCT00331604|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
45981718|NCT00331604|Drug|insulin detemir|Injection s.c., 50% of daily dose.
45981719|NCT00331604|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
45981720|NCT00331604|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c. After 2 years.
45981721|NCT00435123|Dietary Supplement|Nutritional Supplement ProStat 64 twice a day|
45981722|NCT00435123|Dietary Supplement|Placebo supplement|Patients randomly assigned to Placebo for the first 3 months will receive open label Prostat for the last 3 months
45981723|NCT04716764|Other|3-Day Food Intake Record|Collecting clinical and socio-demographic information, nutritional status, food consumption (dietary intake of advanced glycation end products, dietary total antioxidant capacity, dietary inflammatory index), anthropometric measurements (body weight, height, body composition, handgrip strength, upper-middle arm circumference, waist circumference, hip circumference, triceps skinfold thickness), quality of life, biochemical biomarkers (serum carboxymethyl lysine, advanced glycation end products receptor, the soluble receptor of advanced glycation end products, TNF-α, IL-1β, IL-6, malondialdehyde, 2,4-dinitrophenyl hydrazine, 8-hydroxy-2'-deoxyguanosine, total antioxidant capacity)
45981724|NCT00331643|Drug|ixabepilone|Given IV
45981725|NCT00331721|Drug|Enecadin|Dose escalating
45981726|NCT00331721|Drug|Placebo|Placebo comparator
45981727|NCT00431340|Drug|PXD101|
45981728|NCT00431379|Drug|Tenecteplase|
45981729|NCT00331838|Drug|Semuloparin sodium|"0.8 mL solution in Type I amber glass vials~Subcutaneous injection"
45981730|NCT00331838|Drug|Placebo (for Enoxaparin sodium)|"0.4 mL solution in ready-to-use prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
45981731|NCT00331838|Drug|Enoxaparin sodium|"0.4 mL solution in ready-to-use pre-filled syringe~Subcutaneous injection"
45981732|NCT00331838|Drug|Placebo (for Semuloparin sodium)|"0.8 ml solution in type I amber glass vials strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
45981733|NCT03277365|Other|Receive genetic risk information|Risk scores are provided by ResearchKit app.
45981734|NCT00331877|Procedure|family conference with bereavement information leaflet|
45981735|NCT00431418|Drug|Sildenafil|Sildenafil oral solution
45981736|NCT00431418|Drug|Placebo|Placebo solution
45981737|NCT00331916|Drug|quinolone|
45981738|NCT00420368|Dietary Supplement|No food supplement|
45981739|NCT00420368|Dietary Supplement|Food supplement: fortified spread|
45981740|NCT00420368|Dietary Supplement|Food supplement: maize-soy flour|
45981741|NCT00420446|Behavioral|Adjusted diet|
45981742|NCT00331955|Drug|doxorubicin hydrochloride|Given IV
45458707|NCT03492580|Drug|Dipeptidyl Peptidase-4 (DPP-4) Inhibitors|No intervention or treatment assignment imposed by this study. Participants received DPP-4 inhibitor as a part of routine clinical practice. DPP-4 inhibitors includes: alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin.
45981743|NCT00331955|Drug|vorinostat|Given orally
45832387|NCT03154632|Device|Digital Capacitive Diathermy Therapy|"The DCD equipment will be used choosing the musculotendinous injury FAST program which lasts 6 minutes. The applicator will move with a velocity approximately between 2.5 and 4 centimeters per second."
45832388|NCT03157674|Other|Non-Interventional|Non-Interventional
45832389|NCT03027648|Procedure|Placement of levonorgestrel-releasing intrauterine system|All the patients accepted treatment of levonorgestrel-releasing intrauterine system
45832390|NCT05252520|Drug|JNJ-77474462|JNJ-77474462 will be administered subcutaneously.
45981744|NCT00331955|Other|pharmacological study|Correlative studies
45981745|NCT00331955|Other|laboratory biomarker analysis|Correlative studies
45981746|NCT03277482|Drug|Durvalumab|Durvalumab is given by intravenous infusion every 4 weeks for a maximum of 13 doses over 52 weeks. One cycle is defined as every 4 weeks. Each infusion will take approximately 1 hour.
45981747|NCT03277482|Drug|Tremelimumab|Tremelimumab is given by intravenous infusion every 4 weeks for a maximum of 4 doses over 16 weeks. One cycle is defined as every 4 weeks. If receiving both durvalumab and tremelimumab for the first 4 cycles, they will be given on the same day. Each infusion will take approximately 1 hour
45981748|NCT03277482|Radiation|Radiation Therapy|Radiation treatment will begin on the same day as the first immunotherapy infusion or on the following day. The radiation treatment course is either 1 day or 5 days.
45981749|NCT00331994|Drug|Bacillus clausii|3 bacillus clausii vials/day for one month
45981750|NCT00331994|Drug|Metronidazole|3 Metronidazole tablets/day for one week
45832391|NCT03886584|Other|Monitoring source test|Internal- and external-monitoring correct responses and inversions
45832392|NCT01670448|Procedure|PECBLOCK under echoguidance|Performance of block under echography
45832393|NCT01670682|Procedure|ischia spinous fascia fixation|Subjects of this group were submitted to surgical treatment with ischia spinous fascia fixation.
45832394|NCT01670682|Procedure|Modified Pelvic Floor Reconstruction Surgery with Mesh|Subjects of this group were submitted to surgical treatment with Modified Total Pelvic Floor Reconstruction Surgery with Mesh.
45981751|NCT00435240|Behavioral|Paleolithic diet|
45981752|NCT00332033|Drug|Pirfenidone|
45981753|NCT00435279|Drug|Eszopiclone|Eszopiclone 3 mg
45981754|NCT00435279|Drug|Placebo|Placebo
45981755|NCT00435279|Drug|Venlafaxine|Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28
45981756|NCT00332072|Drug|bimatoprost/timolol fixed combination|
45981757|NCT00431574|Procedure|dosing|
45981758|NCT00431613|Drug|Docetaxel|Docetaxel 75 mg/m2 IV on day 8 every 3 weeks for 2 cycles
45981759|NCT00431613|Drug|Gemcitabine|Gemcitabine 1100 mg/m2 on days 1 and 8 every 3 weeks for 2 cycles
45981760|NCT00431613|Drug|Carboplatin|Carboplatin 6AUC IV on day 1 every 3 weeks for 3 cycles
45981761|NCT00431613|Radiation|Chemoradiotherapy|"After 21 days from the 2nd chemotherapy cycle definitive concurrent chemoradiotherapy will be started: daily fractions of 1.8 Gy for 5 days/week, for a total dose of 45 Gy.~During the radiotherapy docetaxel 25 mg/m2, IV, will be administered on days 1, 8, 15, 22, 29 and carboplatin 2AUC, IV , on days 4, 11, 18, 25, 32"
45981762|NCT00431613|Drug|Docetaxel|Docetaxel 75mg/m2 IV on day 1 for 3 cycles
45981763|NCT00435318|Procedure|Iontophoresis|
45981764|NCT00332228|Drug|depot naltrexone|long-acting depot parenteral formulation of naltrexone
45981765|NCT00332228|Behavioral|Compliance enhancement (CE)|Compliance enhancement (CE), simulating standard treatment with oral naltrexone
45832395|NCT01670682|Device|polypropylene mesh(Gynemesh)|Pelvic floor reconstruction will be conducted using surgical mesh made from polypropylene.
45832396|NCT01670994|Biological|ALT-801|Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle
45832397|NCT03157752|Behavioral|Quality of life questionnaire|Quality of life questionnaire
45981766|NCT00332228|Drug|BNT|behavioral therapy with oral naltrexone maintenance for the treatment of heroin addiction
45981767|NCT00431691|Drug|vitamin and mineral supplement|"dose: 4 tablets daily for two weeks~vitamin A 7160 IU, vitamin C 113mg, vitamin E 100IU, zinc 17.4mg, copper 0.4mg"
45981768|NCT00431691|Drug|Escherichia coli Endotoxin (LPS)|dose: 2 ng/kg (corresponding to 20 IU/kg), intravenous bolus over 5 minutes on both study days
45981769|NCT00431691|Drug|100% O2|breathing for 30 minutes, 2 breathing periods on both study days
45981770|NCT00431691|Drug|nitroglycerin|dose: 0,8 mg sublingual, applied during FMD measurements on both study days
45981771|NCT00332267|Procedure|Endotoxin infusion, Normobaric hypoxia|
45981772|NCT00435357|Device|mobile-bearing TKA|
45981773|NCT00435357|Device|fixed- bearing TKA|
46082843|NCT00770601|Drug|Canakinumab|
45981774|NCT00332306|Drug|Didanosine, Lamivudine, Efavirenz|Didanosine 250mg patients <60kg, 400mg patients > 60kg once daily Lamivudine 300 mg once daily Efavirenz 600 mg once daily All drugs will be given for 24 months
45981775|NCT00332306|Drug|Didanosine, Lamivudine, Nevirapine|Didanosine 250 mg once daily for patients < 60kg, 400 mg OD patients > 60kg Lamivudine 300 mg once daily Nevirapine 400 mg once daily All drugs will be given for 24 months
45981776|NCT00431730|Procedure|flicker light stimulation|
45981777|NCT00332345|Drug|brimonidine/timolol fixed combination|
45981778|NCT00435396|Biological|GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A|Intramuscular injection, 3 doses
45981779|NCT00332384|Drug|brimonidine/timolol fixed combination|
45981780|NCT00435435|Drug|Disulfiram|
45981781|NCT00435435|Drug|Acamprosate|
45981782|NCT00435435|Drug|Naltexone|
45981783|NCT00420485|Drug|gimatecan|
45832398|NCT03157908|Device|CareConekta|CareConekta is a smartphone app developed in parallel with a series of focus group discussions that uses global positioning system (GPS) data to identify the user's location to meet two primary functions: (1) to allow the participant to locate ART facilities in South Africa that are near her current location, and (2) to trace mobility prospectively.
45672801|NCT05287529|Behavioral|Yoga Via Telehealth - Immediately|The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
45832399|NCT03028896|Procedure|90° rotational technique|the LMA FlexibleTM was rotated counter-clockwise through 90°
45981784|NCT00435474|Procedure|Wound treatment|wound treatment (silver product, alginate and foam dressing)
45981785|NCT00435474|Procedure|wound treatment|wound treatment (honey product, alginate and foam dressing)
45981786|NCT00435474|Other|psycho-social support|psycho-social support (based on the structure in cognitive therapy)
46082844|NCT00941707|Drug|JNJ 38518168|JNJ-38518168 100 milligram (mg) capsules orally (by mouth) once daily for 12 weeks.
46082845|NCT00941707|Drug|Placebo|Placebo capsules matching to JNJ-38518168 orally once daily for 12 weeks.
45832400|NCT03157440|Diagnostic Test|Ring oxymetry|a new type oxymetry wear on index finger like a ring
45832401|NCT05608902|Other|Dynamic full-field optical coherence tomography analysis of skin biopsy or resection|Dynamic full-field optical coherence tomography analysis of skin biopsy or resection in the dermatology department before conventional histopathological analysis
45981787|NCT00435474|Other|relaxation therapy|relaxation therapy
45981788|NCT00332540|Drug|bimatoprost/timolol fixed combination|
45981789|NCT00332618|Device|OXYGENATED GLYCEROL TRIESTERS|
45981790|NCT04704102|Behavioral|Muscle energy technique (MET)|A manual therapy technique that uses the gentle muscle contractions of the patient to relax and lengthen muscles and normalize joint motion.
45981791|NCT04704102|Behavioral|Strain-counterstrain (SCS)|"It's also called the positional release technique, a manual therapy technique that passively positions the hypertonic (spasmed) muscles and dysfunctional joints in positions of shortened or comfort."
45981792|NCT04704102|Behavioral|sham SCS|SCS intervention that position with opposite site limb and direction, and with modified method as consider the easiness of a practitioner to press the tender points
45981793|NCT00332735|Drug|spinal administration of articaine|
45981794|NCT00332735|Drug|spinal administration of bupivacaine|
45981795|NCT00435552|Procedure|Ease-It Spray|
45981796|NCT00332774|Drug|Nepafenac ophthalmic solution 0.1%|1 drop 4 times daily for 90 days
45981797|NCT00332774|Drug|Ketorolac Tromethamine ophthalmic solution 0.4%|1 drop 4 times daily for 90 days
45981798|NCT00332774|Other|Nepafenac ophthalmic suspension vehicle|
45981799|NCT00431769|Drug|Bortezomib|Bortezomib will be given intravenously (into a vein) twice weekly, on Days 1, 4, 8 and 11 and then a 10-day (Days 12 to 21) rest period, of each 3-week cycle for up to a total of 8 cycles. The initial bortezomib dose is 1.0 or 1.3 milligram per meter square (mg/m^2) depending on the previous bortezomib-based treatment, up to a maximum dose of 1.3 mg/m^2. Participants will receive bortezomib in combination with or without dexamethasone, in accordance with the standard of care. The median total dose of dexamethasone per cycle ranges from 120 mg (Cycle 7) to 160 mg (Cycles 1 to 6 and 8).
45981800|NCT00332813|Behavioral|HIV Risk Behavior Intervention|
45981801|NCT00435630|Other|LapSim training|complete curriculum training on LapSim surgical simulator
45981802|NCT00332852|Drug|Letrozole|2.5 mg/day - oraly
45981803|NCT00435669|Drug|Brivanib|Oral Solution, Oral, 800 mg, X1 on Day 1, 10 D for ADME
45981804|NCT00435669|Drug|Brivanib|Tablet, Oral, Brivanib 800 mg, QD, until progression
45981805|NCT00332891|Drug|SR58611A|
45981806|NCT00435708|Behavioral|5 portions fruit and vegetables/day|Participants consume > = 5 portions fruit and veg per day
45981807|NCT00332930|Biological|recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens|
45981808|NCT00332930|Biological|HIV gag-pol antigens and interferon-gamma (IFN-y)|
45981809|NCT00431808|Biological|Malaria vaccine AMA1 (PfAMA-1-FVO[25-545]|3 doses of AMA 1 vaccine
45981810|NCT00431808|Biological|AMA1|50 micrograms of AMA1
45981811|NCT00332969|Drug|Octreotide|
45981812|NCT00333008|Drug|Doxil|
45981813|NCT00333008|Drug|Cyclophosphamide|
45981814|NCT00333008|Drug|Vincristine|
45981815|NCT00333008|Drug|Prednisone|
45981816|NCT00333008|Drug|Rituximab|
45981817|NCT00333008|Drug|Pegfilgrastim|
45981818|NCT00435747|Drug|PARECOXIB SODIUM|
45981819|NCT00333047|Drug|Letrozole|
45981820|NCT00431886|Procedure|64 multi-detector computed tomography|
45981821|NCT00333086|Drug|Letrozole|
45981822|NCT00333125|Drug|Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)|One drop in the study eye(s) once daily, 9 PM, for 6 weeks
45981823|NCT00333125|Drug|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)|One drop in the study eye(s) twice daily for 6 weeks
45981824|NCT00333125|Other|Timolol Vehicle|One drop in the study eye(s) once daily for 6 weeks
45981825|NCT00333164|Drug|Asprin, Cilostazol|
45981826|NCT00333203|Drug|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
45832402|NCT03157050|Other|Intravenous iron therapy|each patient with iron def anemia received an IV syringe of iron sucrose 100 mg every dialysis session for 10 doses
45981827|NCT00333203|Other|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
45832403|NCT03156972|Procedure|Replacment of mitral valve|Mitral valve replacment by prothsis
45832404|NCT01671072|Biological|TissueGene-C|TissueGene-C at 1.8 x 10^7 cells
45981828|NCT01052493|Drug|PP 1420|Single dose of PP 1420, administered subcutaneously at either 2mg, 4mg or 8mg.
45981829|NCT01052493|Drug|Placebo|0.9% saline
45981830|NCT00333242|Drug|dextromethorphan|dextromethorphan PO titrated to 480 mg/day x 5 weeks
46082846|NCT00609089|Behavioral|CRAFT-T|The Community Reinforcement and Family Training for Treatment Retention and HIV Risk Reduction treatment (CRAFT-T) was be developed in phase 1 and 2 of the current study and consists of twelve manual-guided weekly one-hour individual sessions for the concerned significant other and 2 one hour sessions for the identified patient. The intervention also allows for up to two additional sessions (total of 14 visits) to help arrange re-entry into substance abuse treatment when needed. The identified patient receives this intervention in addition to the usual services at the drug treatment program (Maryhaven).
45981831|NCT04703634|Procedure|erector spinae block (ESP)|Administration of local anesthetic under the erector spinae muscle just below the transverse process of the thoracic 12th vertebra
45981832|NCT00333281|Drug|tadalafil|
45981833|NCT00435864|Procedure|Blood test|The study of KIR and HLA genes will be performed on samples of cord blood or peripheral blood donor and recipient before transplant For grafts from placental cord blood, we do ask any additional samples.
45458708|NCT03492580|Drug|Glucagon-like Peptide-1 (GLP-1) Agonist|No intervention or treatment assignment imposed by this study. Participants received GLP-1 agonist as a part of routine clinical practice. GLP-1 agonists includes: albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide.
45832405|NCT01671072|Drug|Normal Saline|Sodium chloride 0.9%, 3.5ml
45832406|NCT05238324|Biological|Genetic HMI-203|HMI-203 delivered intravenously
45981834|NCT00333320|Procedure|postconditioning|patients were treated by repeated cycles of cycles of reperfusion/ischemia at the end of the procedure within the first minute after reperfusion
45981835|NCT00333320|Procedure|Control group|Percutaneous coronary interventions were performed following international guidelines. No additional intervention was performed in the control group.
45832407|NCT01671150|Drug|endotoxin|Low-dose endotoxin (0.8 ng/kg of body weight): EC.O:113 administered once
45832408|NCT03156738|Drug|MT-2990|Subjects will receive a single IV dose of MT-2990
45832409|NCT03156738|Drug|Placebo|Subjects will receive a single IV dose of placebo
45981836|NCT00333398|Biological|CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free|CSL influenza vaccine-prefilled syringe presentation (thimerosal-free) 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
45981837|NCT00333398|Biological|CSL Trivalent Inactivated Influenza Vaccine with Thimerosal|CSL influenza vaccine-multiple dose vial presentation (thimerosal-containing) containing 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
45981838|NCT00333398|Biological|Placebo with Thimerosal|Phosphate buffered isotonic saline solution containing thimerosal. Single dose of 0.5 mL administered on study day 0.
45981839|NCT00333476|Drug|MSI-1256F (Squalamine Lactate)|
45981840|NCT00435981|Drug|rhGAD65 formulated in Alhydrogel® (Diamyd®)|
45981841|NCT04716452|Drug|Ceramide NanoLiposome (Ceraxa)|Ceramide NanoLiposome will be given by IV twice a week. The dose, which is based on body size, will be increased for the next group of patients if the first group of patients tolerates that dose and it will decrease for the next group if they do not tolerate the dose.
45981842|NCT01052103|Drug|LY2140023|40 milligrams (mg), oral tablets, twice daily: 20 mg in the morning, 20 mg in the evening, for 16 or 17 weeks. The dose may be adjusted to a minimum of 20 mg or a maximum of 80 mg.
45981843|NCT01052103|Drug|Placebo|Placebo oral tablets, twice daily: in the morning and in the evening, for 16 or 17 weeks.
45981844|NCT01052103|Drug|Standard of Care|United States (U.S.) label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)
45981845|NCT00333515|Drug|Human Butyrylcholinesterase (HuBChE) derived from human plasma|Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
45981846|NCT00333515|Drug|Placebo: Normal saline|Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
45981847|NCT00333554|Dietary Supplement|DHA Treatment|DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food) depending on age of child.
45981848|NCT00333554|Dietary Supplement|Placebo for DHA|Study placebo given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
45981849|NCT00436020|Device|TMS|Transcranial Magnetic Stimulation
45981850|NCT00436020|Device|Sham TMS|Sham Transcranial Magnetic Stimulation
45981851|NCT00333593|Device|Large pore dialyser|
45981852|NCT00333593|Device|Standard dialyser|
45981853|NCT00432081|Drug|indomethacin|
45981854|NCT00333632|Drug|Dexmedetomidine|
45981855|NCT00333632|Drug|Propofol|
45981856|NCT00333632|Drug|Midazolam|
45981857|NCT00333632|Drug|Fentanyl|
45981858|NCT00333632|Drug|Isoflurane|
45981859|NCT00436059|Drug|bortezomib|
45981860|NCT00420524|Drug|Patupilone/EPO906|
45981861|NCT03276273|Device|recording of Bispectral Index|recording of Bispectral Index
45672802|NCT05287529|Behavioral|Yoga Via Telehealth - Waitlisted|The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
45672803|NCT02932553|Device|BVS+OMT|bioresorbable vascular scaffold implantation plus optimal medical treatment
45981862|NCT00432120|Drug|clopidogrel|To compare two different clopidogrel regimens on the outcomes of patients undergoing elective coronary angiography ± ad-hoc percutaneous coronary intervention
46082847|NCT00609089|Behavioral|Treatment as usual|Treatment as usual will be the normal course of treatment for concerned significant others (CSOs) in the outpatient department.
46082848|NCT02798276|Procedure|AGTP-treatment|Patients with a myocardial necrosis candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered with the adipose graft and the revascularizable area will be treated with the normal procedure (by-pass).
46082849|NCT02798276|Other|Control|Patients with a myocardial necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
46082850|NCT02718378|Drug|estetrol|
46082851|NCT02718378|Drug|placebo|
45458709|NCT03492580|Drug|Anti-hyperglycemic Agents (AHA)|No intervention or treatment assignment imposed by this study. Participants received other selected AHA as a part of routine clinical practice. Other select AHAs includes: acarbose, bromocriptine, miglitol, nateglinide, repaglinide.
45672804|NCT02188784|Drug|Polysaccharide Iron Complex 150 mg|Oral Iron
45672805|NCT02188784|Drug|Placebo (for Polysaccharide Iron Complex)|Sugar capsule designed to mimic Polysaccharide Iron Complex.
45672806|NCT02900339|Device|Magnetic Resonance Imaging|MRI of the Neurinfo platform is an MRI 3 Tesla Magnetom Verio model, Siemens (Siemens Healthcare, Erlangen, Germany). This imager is marked for European Conformity (CE), ensuring compliance with European Union safety standards.
45672807|NCT02848781|Device|Implantable Cardioverter Defibrillator (ICD)|An ICD is a battery-powered device placed under the skin that keeps track of heart rate. Thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat.
46082852|NCT00770367|Drug|Pioglitazone then Placebo|Subjects will take the pioglitazone 30mg tablet daily for 3 months. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take a placebo.
45832410|NCT01671228|Other|Decision Aid|The Yorkshire Dialysis Decision Aid (YoDDA) resource in web and paper format
45832411|NCT01671228|Other|Decision aid + patient stories|The Yorkshire dialysis decision aid (YoDDA) plus a set of narratives provided by patients on the treatment options (home and hospital haemodialysis; continuous ambulatory and automated peritoneal dialysis
45832412|NCT01671228|Other|Decision Aid + values task|The Yorkshire Dialysis decision aid (YoDDA) plus a set of questions to help patients explore what aspects of their life important to them about this decision (values clarification)
45672808|NCT02848781|Procedure|Catheter Ablation|Catheter ablation is a procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore the heart's regular rhythm.
45981863|NCT00436098|Behavioral|Motorpedagogic exercise|physical training
45981864|NCT00432198|Drug|Zolpidem (Myslee®)|Oral
45981865|NCT00432198|Drug|placebo|Oral
45981866|NCT01051986|Procedure|saphenous vein composite grafting|use saphenous vein as a composite graft connected to the left internal thoracic artery
45981867|NCT01051986|Procedure|right internal thoracic artery composite grafting|right internal thoracic artery is used as a composite graft connected to the left internal thoracic artery
45981868|NCT00420563|Drug|CYCLOPHOSPHAMIDE|50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision
45981869|NCT00420563|Drug|MEGESTROL|320 mg/day, per os, 2 pills of 160 mg one time, nonstop until disease progression or toxicity or patient decision
45981870|NCT00432315|Drug|Docetaxel + CDDP|"3 cycles chemotherapy : docetaxel + CDDP~Surgery (if no histologically proven R0-resection could be achieved,additional adjuvant radiotherapy should be considered)~3 cycles adjuvant chemotherapy docetaxel"
45981871|NCT00432315|Drug|docetaxel + CDDP|"3 cycles chemotherapy: docetaxel + CDDP~Radiochemotherapy~3 cycles adjuvant chemotherapy docetaxel"
45981872|NCT00333671|Drug|Glycerol|
45981873|NCT00333749|Biological|Drinking or rinsing the mouth 2-3 times for 1 day|
45981874|NCT00333749|Biological|Pasturlized cow milk|Drinking or rinsing the mouth 2-3 times for one day.
45981875|NCT00432354|Drug|atorvastatin|
45981876|NCT00333827|Drug|optimal therapy for cardiaca failure|optimal therapy for cardiaca failure
45981877|NCT00333827|Procedure|cell|stem cell
45981878|NCT03278184|Device|tDCS sham motor cortex|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to sham stimulation targeting left motor cortex area using the transcranial direct current stimulation device for 30 seconds then stop for 20 minutes.
45981879|NCT03278184|Device|active prefrontal cortex stimulation|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left dorsolateral prefrontal cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
45832413|NCT01671384|Drug|Valproate, Levocarnitine|"All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo."
45981880|NCT03278184|Device|active motor cortex stimulation|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left motor cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
45981881|NCT00333905|Procedure|Ischemic exercise training|
45981882|NCT00436137|Behavioral|Patient mailing|Patient will receive a mailing recommending colonoscopy, followed by telephone outreach
45981883|NCT04716374|Other|Tumor molecular profiling|Tumor tissue processing and all NGS genotyping were performed at the Laboratory of Molecular Oncology (Hellenic Foundation for Cancer Research / AUTH). Paraffin H&E sections from the retrieved tissue blocks were centrally reviewed for tumor histology and tissue adequacy for DNA extraction and were marked for macrodissection along with tumor DNA content [(former tumor cell content (TCC%)] assessment. DNA was extracted from macrodissected tissue fragments with the QIAamp® DNA mini kit (Qiagen, Hilden, Germany), measured in a Qubit fluorometer (Thermo Fisher Scientific, Paisley, UK), and genotyped with NGS in an Ion Torrent Proton sequencer (Thermo Fisher Scientific) by using a previously published custom panel (Kotoula, Lakis et al. 2019). Following stringent variant quality filtering (Kotoula, Chatzopoulos et al. 2021), 500 tumors
45981884|NCT00438009|Drug|Coxsackievirus A21|Two doses of drug, separated by 48 hours
45981885|NCT00333944|Drug|Pralidoxime(drug)|
45981886|NCT04702347|Diagnostic Test|Urine biomarker|Bladder urine samples (> 10 ml) will be collected for cytology and for the methylation test before cystoscopy. Prior to semirigid and flexible ureteroscopy, urine specimens from the upper urinary tract will be obtained via a ureteral catheter.
45981887|NCT00334022|Drug|enfuvirtide|1ml BID
45981888|NCT04701528|Drug|Voclosporin|Temporarily switching of tacrolimus maintenance immunosuppression to voclosporin maintenance immunosuppression with possible additional anti-viral activity
45981889|NCT04701528|Drug|Tacrolimus|Comparator
45981890|NCT00334100|Behavioral|Exercise|Treadmill exercise
45981891|NCT04701294|Device|Giomer Beautifil flow plusF03 Shofu-Japan|A pair of permanent first molars will be used for each participant homologs The operator will apply in the upper / lower first molars the sealant material in the order assigned according to the previous randomization. For the intervention group, they will be sealed based on a fluid resin with s-prg glass ionomer filling (Giomer F03 Beautiful -Shofu) in association with a bottle of adhesive (Single Bond) . The evaluation and monitoring process; another operator will record the retention of the sealant in a period of 6, 9 and 12 months.
45981892|NCT04701294|Device|Tetric N flow ivoclar vivadent-Germany|And on the contralateral side (control) the first upper / lower molars will be sealed will be sealed with a fluid resin compound (Tetric N-Flow ivoclar vivadent) in association with a bottle of adhesive (Single Bond). Both materials have a similar color. The operator and the child will not be informed about the brand of the material used. The assistant will collect the data in the file. The evaluation and monitoring process; another operator will record the retention of the sealant in a period of 6, 9 and 12 months.
45981893|NCT00334139|Drug|Zoledronic Acid|every 4 weeks for 4 months
45981894|NCT00334178|Drug|Laxymig ER (drug)|
45981895|NCT03279978|Drug|BI 730357|up to 28 days
45672809|NCT02222246|Drug|Hydromorphone (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
45672810|NCT02222246|Drug|Morphine Sulfate (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
45981896|NCT03279978|Drug|Placebo|up to 28 days
45981897|NCT03279978|Drug|Midazolam|Dose groups 4 & 5 only
45981898|NCT00334217|Behavioral|Cognitive Remediation|PSS Cogrehab
46082853|NCT00770367|Drug|Placebo then Pioglitazone|Subjects will take the placebo for the first 12 weeks of the study. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take the pioglitazone 30mg tablet daily for 3 months.
46082854|NCT00931307|Device|Lotrafilcon A contact lens|Silicone hydrogel, spherical, soft contact lens
45458710|NCT03492580|Drug|Thiazolidinediones (TZD)|No intervention or treatment assignment imposed by this study. Participants received TZD as a part of routine clinical practice. TZDs includes: pioglitazone, rosiglitazone, troglitazone.
45672811|NCT02222246|Drug|Hydromorphone (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
45672812|NCT02222246|Drug|Morphine Sulfate (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
45672813|NCT04793633|Combination Product|LINFU™ Technique|Non-focused ultrasound excitation of the pancreas with IV Lumason and IV secretin injected during the ultrasound procedure.
45981899|NCT00438048|Procedure|pilocarpine|or secondary symptomatic SS with clinically significant dry mouth were randomized to receive either 5 mg oral Pilocarpine solution (5ml) or artificial saliva (5 ml) 3 times a day for 12 weeks
45981900|NCT00438048|Drug|Artificial Saliva|5ml 3 times daily
45981901|NCT00334256|Drug|Tenofovir (TDF)|
45981902|NCT00334256|Drug|Emtricitabine (FTC)|
45981903|NCT00438087|Drug|methylprednisolone|methylprednisolone administrated intra and post operatively
45981904|NCT00334334|Biological|Pneumococcal (vaccine)|
45981905|NCT00438126|Behavioral|A lifestyle educational program|
45981906|NCT00334373|Procedure|Post conditioning|4 cycles of balloon inflation /deflation (post-conditioning) within first minute of opening up artery in primary PCI for STEMI vs usual balloon inflation sequence
45981907|NCT03279939|Device|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
45981908|NCT03279939|Device|Color Fundus Photography|Non-contact white light photography.
45981909|NCT03279939|Device|Fluorescein Angiography|An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of retinal vessels in two dimensional images.
45981910|NCT03279939|Device|Indocyaine Green Angiography|An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of choroidal vessels in two dimensional images.
45981911|NCT00334412|Drug|Ambisome|
45981912|NCT00334412|Drug|caspofungin|
45981913|NCT00438165|Behavioral|home visitation|Home visitation by nurses from midway through pregnancy until child age 12
45832414|NCT01671384|Drug|Placebo|"All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo."
45981914|NCT04701879|Other|Spine decompression with core stability exercises|"50 minutes per session~Decompression with core stability on alternate days for 8 visits."
45981915|NCT04701879|Other|Spine decompression|"40 minutes per session~-Decompression therapy on alternate days for 8 visits."
45981916|NCT00334490|Drug|Sildenafil|12.5 mg Sildenafil once with optional second dose
45981917|NCT00334490|Drug|Sildenafil|12.5 mg orally once with optional second dose
45981918|NCT00334490|Drug|Placebo|Oral Placebo in 5 mls distilled water
45981919|NCT00436176|Behavioral|Expanded Chronic Care Model|Intervention clinicians receive monthly performance feedback reports, cultural competency training, and health navigation training.
45981920|NCT00334529|Drug|Oseltamivir|
45981921|NCT04716218|Procedure|back up head elevated position|The patient was then placed in the back-up position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table at the hips to prevent patients from sliding off the table.
45981922|NCT03271281|Drug|One injection of 68Ga-NODAGA-E[c(RGDyK)]2|One injection of 68Ga-NODAGA-E[c(RGDyK)]2
45981923|NCT03271281|Device|PET/CT|Following injection of 68Ga-NODAGA-E[c(RGDyK)]2 the patients will be subjected to whole body PET/CT
45672814|NCT04793555|Other|Monitoring by unobtrusive sensors|During the study the behavior of daily activities will be monitored by unobstructive sensors. Most of the sensors will be mounted on the wall or on furniture with direct sight to the participant and thus will not have any physical contact, except some wearables during the stay in the apartment and at home (e.g. watch, mobile polysomnography).
45832415|NCT03154164|Device|Ultrasonic tissue coagulation dissection|ultrasonic coagulation for dissection during laparoscopic cholecystectomy
45672815|NCT04792697|Other|Increase morning bright light|Participants will wear Re-Timer bright glasses for 30 minutes each morning upon rising
45832416|NCT01671540|Device|intrapulmonary percussive ventilation|
45981924|NCT00334568|Drug|Rosiglitazone XR (extended release) oral tablets|Rosi XR tablets
45981925|NCT00334568|Drug|Placebo|Placebo
45981926|NCT03272451|Procedure|culprit vessel intervention|ECG guided immediate culprit vessel intervention using a single transradial guiding catheter such as MAC or JL 3.5
45981927|NCT03272451|Procedure|traditional approach|single diagnostic catheter for complete coronary angiography and guiding catheter selection for PCI
45981928|NCT02273544|Drug|Asasantin ER (new formulation - low)|
45672816|NCT04792697|Other|Decrease evening blue light|Participants will wear blue light blocker goggles for 2 hours before bed
45672817|NCT04792697|Behavioral|Sleep Scheduling|Participants will advance their bedtime by 1.5 hours and regularize their wake time
45832417|NCT01671540|Other|standard treatment|breathing control exercises
45832418|NCT01671774|Drug|IMAB362|800 mg/m2 on d 1 of cycle 1. 600 mg/m2 on d 1 of every other cycle
45832419|NCT01671774|Drug|Zoledronic acid|4 mg on d 1 of cycle 1 and cycle 3
45981929|NCT02273544|Drug|Asasantin ER (new formulation - medium)|
45981930|NCT02273544|Drug|Asasantin ER (new formulation - high)|
45981931|NCT02273544|Drug|Asasantin ER - commercial formulation|
45981932|NCT00334607|Biological|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
45981933|NCT00436293|Drug|Docetaxel|75 mg/m²
45981934|NCT00436293|Drug|Cisplatin|75 mg/m²
45981935|NCT00334646|Drug|Oral GW679769|150mg oral, once daily on days 1-3
45981936|NCT00334646|Drug|IV Cyclophosphamide 500-700mg/m2|IV Cyclophosphamide 500-700mg/m2 on day 1 of each cycle
45981937|NCT04701606|Drug|Artecom® (pyronaridine-artesunate)|"* Participant body weight (Artecom® dose)~≥ 65kg (Artecom® 4 tablets: Pyronaridine 720mg/ Artesunate 240mg)~≥ 45kg and < 65kg (Artecom® 3 tablets: Pyronaridine 540mg/ Artesunate 180mg)"
45981938|NCT04701606|Drug|Placebo|"* Participant body weight (Placebo dose)~≥ 65kg (Placebo 4 tablets)~≥ 45kg and < 65kg (Placebo 3 tablets)"
45981939|NCT00334685|Drug|[S,S]-Reboxetine + Pregabalin|[S,S]-Reboxetine oral, tablet 2, 4 or 6 mg per day for 10 weeks Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
45981940|NCT00334685|Drug|Pregabalin|Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
45981941|NCT00436371|Drug|Amisulpride|Oral tablets
45981942|NCT00334724|Procedure|Home blood pressure measurement|Blood pressure controlled based on home blood pressure measurement
45981943|NCT00334724|Procedure|Office blood pressure measurement|Blood pressure controlled based on office blood pressure measurement
45981944|NCT00436410|Biological|colloidal gold-bound tumor necrosis factor|
45981945|NCT00436410|Other|electron microscopy|
45981946|NCT00436410|Other|pharmacological study|
45981947|NCT00436410|Procedure|conventional surgery|
45981948|NCT00334763|Biological|bevacizumab|
45981949|NCT00334763|Drug|carboplatin|
45981950|NCT00334763|Drug|chemoprotection|
46082855|NCT04012255|Drug|Semaglutide (administered by DV3396 pen)|Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 21 weeks
46082856|NCT04012255|Drug|Semaglutide (administered by PDS290 pen)|Increasing doses of semaglutide given sc in the stomach for 21 weeks
45981951|NCT00334763|Drug|paclitaxel|
46082857|NCT02789462|Procedure|Laser-assisted percutaneous coronary interventions|Chart review and data collection of patients undergoing laser-assisted percutaneous coronary interventions
46082858|NCT02723370|Behavioral|Staff multi-component implementation strategy|Staff will receive a multi-component implementation strategy for evidence based practices (EBPs) for colonoscopy, including split-dosing of bowel preparation, low literacy education materials for patients, and teach-back procedure. The implementation strategy includes a supply of low-literacy patient education materials for split-dosing the medication of their choice, poster and pocket-card with teach-back prompts, consultation to integrate materials and teach-back into workflow and a website with additional training and patient materials.
46082859|NCT04263545|Behavioral|Group session with smoking cessation counsellor|Group session with smoking cessation counsellor
46082860|NCT04263545|Behavioral|Standard Care|standard care arm will receive very brief advice (VBA) and signposting to local organisations to support a quit.
46082861|NCT00941785|Drug|DHA-PQ|"Three monthly administrations of Duocotexcin (DHA-PQ):~dihydroartemisinin 2.1mg/kg and piperaquine phosphate 16.8 mg/kg once daily for three days"
46082862|NCT00941785|Drug|SP-AQ|"Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine:~One dose of Sulfadoxine 25mg/kg and pyrimethamine 1.25mg/kg Three daily doses of amodiaquine phosphate 10mg/kg"
46082863|NCT02793206|Device|Imaging|
46082864|NCT02714556|Other|Physiologic measures of lung function|"Respiratory function tests:~Nitrogen multiple breath washout (N2MBW) measured with an ultrasonic flowmeter (Exhalyzer D with ICU insert, Eco Medics, Duernten, Switzerland) Forced oscillation technique (FOT) measured with a tremoFlo device (Thorasys, Montreal, Canada)"
46082865|NCT00610805|Other|Preventive Cardiology|Patients will receive those interventions recommended by the Preventive Cardiologist. This may include: exercise, electrocardiogram, specialized blood testing, blood pressure monitoring, nutrition counseling, smoking cessation counseling, and pharmacotherapy for hypercholesterolemia, hypertension, and blood sugar abnormalities.
46082866|NCT00610805|Other|Usual Care|Participants will receive usual care per their primary care physician.
46082867|NCT02798198|Other|T2DM|T2DM without DKD
46082868|NCT00944827|Dietary Supplement|Green Tea Extract - Catechins|Combination treatment with 20 mg atorvastatin and 600mg green tea extract, daily for 12 weeks
46082869|NCT00944827|Dietary Supplement|Placebo|Combination treatment with 20 mg atorvastatin and 600mg placebo, daily for 12 weeks
46082870|NCT02723292|Behavioral|TOP|
46082871|NCT02723292|Behavioral|Control intervention|
46082872|NCT02793518|Behavioral|psychological tests|
46082873|NCT00941941|Procedure|Non-mesh Hernia Repair|Non-mesh method for treatment of inguinal hernia without the use of a foreign material (mesh). It involves reinforcement of the weakened posterior wall of inguinal canal with a small, undetached strip of aponeurotic tissue of external
45981952|NCT00334763|Radiation|radiation therapy|
45981953|NCT00436449|Drug|Avotermin|
45981954|NCT04716062|Procedure|Open or Laparoscopic-assisted Colorectal surgery|Colorectal surgery
45981955|NCT00436722|Drug|ATG (Fresenius Biotech)|ATG-Fresenius 9 mg/kg at induction
45981956|NCT00334880|Drug|NRP104|
45981957|NCT00436761|Biological|anti-thymocyte globulin|
45981958|NCT00436761|Biological|graft-versus-tumor induction therapy|
45981959|NCT00436761|Biological|sargramostim|
45981960|NCT00436761|Drug|busulfan|
45981961|NCT00436761|Drug|cyclosporine|
45981962|NCT00436761|Drug|melphalan|
45981963|NCT00436761|Drug|methylprednisolone|
45981964|NCT00436761|Other|flow cytometry|
45981965|NCT00436761|Other|immunologic technique|
45981966|NCT00436761|Other|laboratory biomarker analysis|
45981967|NCT00436761|Procedure|allogeneic hematopoietic stem cell transplantation|
45981968|NCT00436761|Procedure|umbilical cord blood transplantation|
45981969|NCT00436800|Drug|Gemcitabine|1000mg/m² over 10mg/m²/min
45981970|NCT00436800|Drug|Oxaliplatin|100 mg/m² over 2 hours.
45981971|NCT00334997|Procedure|endoscopic surgery|
45981972|NCT00334997|Procedure|laser surgery|
45981973|NCT00334997|Radiation|radiation therapy|
45981974|NCT00436839|Drug|Docetaxel|75mg/m² intravenously (day 1) every 21 days
45981975|NCT00436839|Drug|Mitoxantrone|12mg/m² intravenously every 21 days
45981976|NCT00436839|Drug|Prednisone|10mg orally given daily
45981977|NCT00335036|Device|ICD lead implant|Randomization of ICD lead type at implant
45981978|NCT00335036|Device|Thin leads|Thin (less than or equal to 7 French introducer) isodiametric ICD leads
45981979|NCT00436878|Behavioral|Food portion size|Each of four experiments involves a 2 x 2 within-subjects factorial design, in which the first factor is the portion size of a food served to children: foods will be served in a reference amount (i.e. 250 g macaroni and cheese) or doubled in size(i.e. 500 g of macaroni and cheese). In the Experiment 1, the second factor of the 2 x 2 design is meal type: whether the food is consumed at a meal or a snack. In experiment #2, the second factor is food type: fruit vs. vegetable. In experiment #3, the second factor is entree energy density: a regular energy density or a 40% greater energy density. In experiment #4, the second factor is plate size: a 6 inch plate vs. a 10 inch plate.
45981980|NCT00335075|Drug|Temozolomide|Temozolomide orally for 5 consecutive days (Day 1 through Day 5) every 28 days, at a dose of 150 mg/m2/day for subjects previously treated with chemotherapy, or 200 mg/m2/day for subjects who have not received previous chemotherapy.
45981981|NCT00335075|Drug|Semustine|Semustine orally once every 28 days at a dose of 150 mg/m2/day.
45981982|NCT00436995|Drug|Darbepoetin Alfa|Administered IV or SC, Q2W at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200 or 300ug. Initial Q2W dose calculated from pre-enrollment QW doses. Doses titrated to achieve target Hb.
45672818|NCT04792697|Behavioral|Monitor sleep, mood, and substance use|Participants will complete smartphone-based sleep, mood, and substance use monitoring
45981983|NCT00437190|Device|ATLANTIS™ Cervical Plate System and allograft|Control treatment is commercially available allograft (without bone matrix paste) used in conjunction with the Medtronic Safamor Danek ATLANTIS™ Cervical Plate System.
46082874|NCT00941941|Procedure|Mesh Hernia Repair|Mesh method for treatment of inguinal hernias by use of an implant (mesh) to reinforce the weakened posterior wall of the inguinal canal. The mesh is made of polypropylene material.
45981984|NCT00437190|Device|BRYAN Cervical Disc Prosthesis|The intent is to treat stable degenerative disc disease by implanting the BRYAN Cervical Disc Prosthesis to provide motion like the normal cervical functional spinal unit.
45981985|NCT04716179|Diagnostic Test|Sperm test|The semen sample will be collected and analyzed within an hour after collection.
45981986|NCT04716179|Diagnostic Test|hormone levels (testosterone, FSH, LH, prolactin)|Hormone levels (testosterone, FSH, LH, prolactin) will be assessed on 5-7 days after symptom onset until the end of hospital stay.
45672819|NCT02188160|Drug|KPI-121|KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
46082875|NCT05502081|Drug|Casirivimab and Imdevimab Drug Combination|antiviral Monoclonal Antibodies
46082876|NCT05502081|Drug|Remdesivir|antiviral drug
46082877|NCT05502081|Drug|Favipiravir|antiviral drug
46082878|NCT02723136|Device|Smartphone Application|Smartphone application developed by internists and engineers. Will be made available on iOS(R) and Android(R) operating systems.
45672820|NCT02188160|Drug|Placebo|Subjects randomized to placebo control arms will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
46082879|NCT02793050|Drug|Trabectedin|Collection of data on the clinical use of Trabectedin
46082880|NCT04263233|Other|Analysis using descriptive statistics of patient clinical outcomes.|"Evaluation of the following:~Laboratory values at admission, week 4, and day 90.~Pre and post blood pressure at week one and week 4.~Intradialytic hypotension at week one and week 4.~Ultrafiltration rates at week one, week 4, day 90, day 180, and day 360.~Target weight defined and achievement in week one and week 4 and changes between week one and week 4.~Dialysis access type at week one and day 90.~Hospitalization and mortality rates."
46082881|NCT04263233|Other|Surveys with participants using validated survey tools.|Surveys will assess participants' Symptom index, Quality of Life, Patient Activation as well as satisfaction with the program.
46082882|NCT04263233|Other|Evaluation of the program process including time, costs, referral rates, admission to the program and length of stay.|Data will be collected using tracking tools throughout the program.
46082883|NCT00944905|Biological|MDX-1203|Assigned Interventions: Single dose of MDX-1203 will be administered every 21 days as an intravenous (i.v.) infusion. Subjects will receive one dose of MDX-1203.
46082884|NCT02722980|Dietary Supplement|Placebo|The intervention consists of capsules containing placebo.
46082885|NCT02722980|Dietary Supplement|: Probiotic capsules|The intervention consists of capsules containing probiotics.
46082886|NCT05191979|Other|Exercise regiment (aerobic exercise on bike)|Subjects participating in the current study will be trained progressively and intensively for 12 months primarily on bike indoors and outdoors
46082887|NCT02789306|Procedure|Epidemiological study on the incidence of peri-implantitis|Clinical and radiographic examination in the routine based protocol
46082888|NCT00942097|Drug|Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos|CH 12 preparation, 6 drops, twice a day, 4 days per week, until the end of pregnancy. One medication per appointment.
46082889|NCT00942097|Drug|Homeopathy and Nutritional oriented diet|Homeopathy 6 drops twice a day 4 days per week, active and placebo and Balanced nutritional oriented diet for both groups.
45672821|NCT02221934|Device|Altius|Electrical signal
45672822|NCT04013555|Drug|N-acetylcysteine (NAC)|Flavored effervescent formulation
45672823|NCT04013555|Drug|Placebo|Flavored effervescent formulation designed to mimic NAC
45672824|NCT04013555|Drug|Tryptophan|Oral slurry form
45672825|NCT04190030|Behavioral|mindfulness training|Participants will listen to 20-minute lessons each day for 14 days plus complete brief (3 to 10 minute) exercises daily via their personal smartphone. Each course will involve mental exercises to reduce stress in daily life, along with direct instruction from the course leader to help in learning and applying the stress reduction techniques.
45981987|NCT04716179|Diagnostic Test|SARS-CoV-2 Ig G levels|SARS-CoV-2 Ig G levels will be assessed on 3 months after discharge
45981988|NCT04716179|Other|Testis pathology samples|Postmortem examination of the testes of patients deceased as a result of COVID-19 infection will be carried out using immunohistochemistry analysis.
45981989|NCT00437229|Drug|Casopitant (GW679769) Oral Tablets|Casopitant (GW679769) tablets will be available as white, film-coated tablets containing 50 mg of GW679769 as the mesylate salt for oral administration.
45981990|NCT00437229|Drug|dexamethasone|Dexamethasone will be available as 4 mg tablets for oral administration and injection for IV administration.
45981991|NCT00437229|Drug|ondansetron|Ondansetron for oral use will be available as 8 mg tablets to be taken with 240 milliliters (mL) of water on an empty stomach. For IV use, ondansetron 32 mg will be infused intravenously over a period of 15 minutes.
45981992|NCT00335192|Drug|Patients in treatment with 3TC + TDF + LPV/rtv, stop tenofovir during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h) + Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
45981993|NCT00335192|Drug|Patients in treatment with ABV + TDF + LPV/rtv, stop tenofovir during 4 weeks|ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
45981994|NCT00335192|Drug|Patients in treatment with 3TC + ABV + TDF+ LPV/rtv, stop TDF during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h)+ ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h).
45981995|NCT00437307|Drug|Topotecan|Topotecan: 0,75 mg/m²/d, day 1-3, and Carboplatin: AUC 5 (after Cockroft and Gault Formula) on day 3 after Topotecan, q 21d
45981996|NCT00335231|Drug|gatifloxacin ophthalmic (ZYMAR)|
45981997|NCT00437346|Procedure|Individualized and comprehensive information|Thorough verbal and written information about results of the tests. Individualized meals recommendation based on the results.
45981998|NCT00437346|Drug|Lanzo Melt|30mg, od, 1/2 h before meal
45981999|NCT00437346|Drug|Lanzo Melt|30mg, od, 1/2 h before meal
45982000|NCT00335270|Drug|fos-amprenavir calcium, ritonavir|
45982001|NCT00335270|Drug|abacavir/lamivudine as Epzicom|
45982002|NCT00437385|Drug|TCAs, SSRIs, NARIs, SNRIs, Lithium|Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)
45982003|NCT00437385|Procedure|Electroconvulsive therapy|ECT treatment is administered three times per week on non-successive weekdays and according to existing standards. Treatment lasts for at least three weeks (nine ECT sessions). Psychopharmacological treatment is continued during ECT treatment. Patients receive ultrabrief pulse (0.3 ms), unilateral treatment at a frequency of 40-100 Hertz. Stimulation is applied to the non-dominant hemisphere, according to the d'Elia electrode positioning paradigm. All patients are initially treated with right unilateral stimulation and in case of non-response switched to bilateral treatment. Stimulus intensity is chosen according to individual seizure threshold and administered at 2.5 to 6-fold intensity. During the ECT session, patients are anesthetized, under the influence of a muscle relaxant, and monitored regarding their vital functions.
45982004|NCT00437385|Behavioral|Cognitive behavioral group therapy|"The continuation-psychotherapy (continuation cognitive behavioral therapy, C-CBT) sample took part in a newly developed cognitive behavioral group therapy program called EffECTive. This therapy program was developed within the EffECT-project (Brakemeier et al. 2005), to fit the specific target group of patients finished with acute ECT-treatment. EffECTive is a group therapy that combines several aspects of existing cognitive-behavioral depression manuals with new elements (e.g., the situational analysis from CBASP, McCullough 2000), to fit the target group. Therapy sessions were held once a week and include approximately 15 sessions until follow-up."
46082890|NCT04233320|Device|silicone cream containing Allium Cepa extract|silicone cream containing Allium Cepa extract contains 10% of Allium cepa bulb extract.
46082891|NCT04233320|Device|Commercial scar gel|Commercial scar gel is a topical silicone gel. It contains cyclic and polymeric siloxanes and Vitamin C ester.
46082892|NCT02797886|Other|FES + VOL|Electrical stimulation is applied in concert with the subject's volitional movement.
45672826|NCT04190030|Behavioral|cognitive reappraisal training|Participants will listen to 20-minute lessons each day for 14 days plus complete brief (3 to 10 minute) exercises daily via their personal smartphone. Each course will involve mental exercises to reduce stress in daily life, along with direct instruction from the course leader to help in learning and applying the stress reduction techniques.
45672827|NCT03991949|Other|Experimental Infant Formula|Formula fed Ad libitum
45672828|NCT02220998|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
45672829|NCT02220998|Drug|SOF|SOF 400 mg tablet administered orally once daily
45672830|NCT02220998|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45672831|NCT02220920|Drug|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 16 weeks
45982005|NCT00335309|Procedure|Maxillary Sinus Irrigation|Twice a day irrigation with 100cc saline for 4 days
45982006|NCT00335309|Drug|IV Amoxicillin and Clavulanate acid|IV Amoxycillin and Clavulanate 1 Gram TID for 4 days.
45982007|NCT00437424|Drug|Brivanib|Tablet, Oral, Brivanib 400 mg, based on Day 1 PK, QD, until progression
45982008|NCT00335348|Drug|Bortezomib|Induction- 1.3mg/m2 IV days 1,4,8,11 every 3 weeks up to 8 cycles Consolidation- 1.3mg/m2 IV days 1,8,15,22 every 5 weeks up to 3 cycles Maintenance- 1.3mg/m2 IV days 1,15 every 4 weeks
45982009|NCT00335348|Drug|Dexamethasone|Induction- 20mg orally days 1,2,4,5,8,9,11,12 every 3 weeks up to 8 cycles Consolidation- 20mg orally days 1,2,8,9,15,16,22,23 every 5 weeks up to 3 cycles Maintenance- 20mg orally days 1,2,15,16 every 4 weeks
45982010|NCT00435903|Device|Palm Pilot|
45982011|NCT00334919|Behavioral|Diet (Anti-Inflammatory or standard diabetic diet)|6 weeks standard ADA diet, then randomized to either ADA or antiinflammatory (AI) diet for 6 weeks
45982012|NCT00437463|Drug|Ramipril|2.5mg and increase to 5mg if patient do not develop symptomatic hypotension
45982013|NCT00420602|Dietary Supplement|Over the counter DHA/EPA dietary supplementation|1000 mg/day DHA/EPA
45982014|NCT00437502|Biological|tumor peptide vaccine|Cohort 1 low dose level of vaccine @ 0.3 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
46082893|NCT02797886|Other|FES|Electrical stimulation is applied to the subject while they are asked to do nothing.
46082894|NCT02797886|Other|VOL|The subject initiates and completes the movement without electrical stimulation.
46082895|NCT04964843|Drug|N-acetylcysteine|N-acetylcysteine is an FDA approved medication that is used to treat acetaminophen overdose.
46082896|NCT04964843|Drug|Placebo|Placebo
45982015|NCT00437502|Biological|tumor peptide vaccine|Cohort 2 high dose vaccine @ 1 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
45982016|NCT00420680|Drug|Sugammadex|Sugammadex, 2.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium
45982017|NCT00420680|Drug|Sugammadex|Sugammadex, 4.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium.
45982018|NCT00420680|Drug|Placebo|Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium
45982019|NCT04701567|Diagnostic Test|Magnetic resonance imaging|Advanced multiparametric MRI techniques to diagnose hepatic and pancreatic disease
45982020|NCT00420719|Device|Intramuscular diaphragm electrodes|Conditioning of the diaphragm
45982021|NCT00437541|Device|Insulation retrofitted into house|
45982022|NCT00420758|Dietary Supplement|Food supplement: fortified spread|Provision of fortified spread
45982023|NCT00420758|Dietary Supplement|Food supplement: maize-soy flour|Provision of corn-soy blend (maize-soy flour)
45982024|NCT00437580|Drug|Lactobacillus casei rhamnosus (strain Lcr 35 LC)|Patients will be blindly randomized to be assigned to a 5 weeks regimen with the probiotic or to a 5 weeks regimen with placebo.
45982025|NCT00420797|Drug|10% Phenylephrine hydrochloride gel|
45982026|NCT00437619|Drug|calcipotriol hydrate [Daivonex]|50 micrograms/g bid for 4 weeks (weeks 5-8) in patients who have shown a >50% response to Daivobet from weeks 0-4.
45982027|NCT00420836|Drug|Tobramycin|
45982028|NCT00437697|Drug|dalteparin|
45982029|NCT00335426|Procedure|Spinal manipulative therapy|
45672832|NCT02220920|Drug|Placebo|The patients will receive Placebo orally for 16 weeks
45982030|NCT00437736|Drug|APO010|APO010 starting at 2.5 µg/m² IV on D1, D15, D22 and D29 followed by a two-week drug rest.
45982031|NCT00335465|Drug|Insulin glargine|once a daily, sc injection, 100IU/ml
45982032|NCT00335543|Drug|cisplatin|
45982033|NCT00335543|Drug|gemcitabine hydrochloride|
45982034|NCT00335543|Procedure|adjuvant therapy|
45982035|NCT00335543|Procedure|conventional surgery|
45982036|NCT00335543|Procedure|neoadjuvant therapy|
45982037|NCT00335543|Radiation|radiation therapy|
46082897|NCT02789072|Other|central aortic pressure (measured in mmHg).|"Blood pressure will only be measured during the 0g (microgravity) phase. Seven 5 ml blood sample will be drawn in the aircraft: before the first parabola (1) and after each block of 5 parabola (6).~On ground after flight, a 9th 5 ml blood sample will be drawn and then the mobil-o-graph, the SOMNOtouch NIBP and the intravenous cannula will be removed."
45672833|NCT02220920|Drug|Insulin|
45672834|NCT03966053|Drug|Trifluoperazine|Trifluoperazine (TFP)1mg, 2mg, 5mg, or 10mg will be given once daily by mouth for 21 days
46082898|NCT02788760|Device|Cervical collar (Miami J collar - Össur)|The two groups of patients will similar in every way and will be treated with the same type of cervical collar - the only difference will be the length of treatment
45672835|NCT05204693|Procedure|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
45672836|NCT05204693|Procedure|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
45672837|NCT03949829|Diagnostic Test|Cardiovascular CT|Cardiac and cardiovascular non-contrast and contrast CT
45672838|NCT03946631|Diagnostic Test|2 hour glucose tolerance test using 75g glucose drink|intervention is a 2 hour glucose tolerance test. Involves oral intake of a 75g glucose drink followed by using point of care testing. Glucose drink is taken after at least 6 hours of fasting. Fingerstick blood glucose testing done at three time points: fasting, one hour post drink and two hours post drink.
45982038|NCT00437814|Drug|Ketamine, effect on intracranial pressure|
45982039|NCT00335582|Drug|clonidine hydrochloride|One hour prior to surgery, patients randomized to the treatment arm will receive clonidine as both a 0.2 mg oral tablet and 0.2 mg/day transdermal patch patch will be removed on postoperative day 4 (or hospital discharge, whichever is earlier)
45982040|NCT00437853|Drug|Anastrozole|
45982041|NCT00335621|Drug|Inhaled Tiotropium|
45982042|NCT00437892|Drug|atorvastatin|tablets, 40 mg day, 3 months
45982043|NCT00437892|Drug|atorvastatin|tablets, 40 mg once daily
45982044|NCT00437892|Behavioral|diet|daily
45982045|NCT00437892|Behavioral|diet|daily diet
45982046|NCT00335660|Drug|AV608|
45982047|NCT00437970|Drug|Pioglitazone|15mg of Pioglitazone taken orally twice a day
45982048|NCT00437970|Drug|Metformin|500 mg of Metformin taken orally twice a day
45982049|NCT00335699|Drug|Rosuvastatin|
45982050|NCT03279003|Device|LED light|An exposure to LED light will be carried out twice a week until improvement, maximum 8 weeks.
45982051|NCT04716140|Procedure|Debridement of the MTP1 cartillage lesion and microfracture|Patients with a MTP1 cartillage lesion > grade I (based on based on the ICRS scale and an MS HoloLens measurement) randomised in the treatment group will be treated with debridement and microfracture
45982052|NCT03277170|Drug|Montelukast Oral Granules|Montelukast granules, 30 mg, mixed with applesauce
45982053|NCT00335855|Device|Auto-injector for IM/SC vaccine administration|
45982054|NCT00335894|Drug|hMG-IBSA|
45982055|NCT00335933|Drug|Gabapentin extended-release tablets|
45982056|NCT00336011|Device|Magnetic resonance imaging|
45982057|NCT03270111|Behavioral|Supervised Exercise|Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
45982058|NCT03270111|Behavioral|Home-based Exercise|Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
45982059|NCT03270111|Behavioral|Reduced Energy Diet|Diet is a nutritionally balanced, reduced energy diet recommended by the Academy of Nutrition and Dietetics.
45982060|NCT03270111|Behavioral|Group Phone Calls|Sessions are weekly months 1-3 and every other week months 4-6. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
45982061|NCT00336089|Behavioral|exercise intervention|
45982062|NCT00336089|Other|educational intervention|
45982063|NCT00336089|Procedure|complementary or alternative medicine procedure|
45982064|NCT00336089|Procedure|fatigue assessment and management|
45982065|NCT00336089|Procedure|management of therapy complications|
45982066|NCT00336089|Procedure|pain therapy|
45982067|NCT00336089|Procedure|quality-of-life assessment|
45982068|NCT00336167|Drug|bezafibrate (drug)|
45982069|NCT00336206|Drug|Alemtuzumab|
45982070|NCT00347334|Behavioral|infant home positioning|
45982071|NCT00336245|Device|Copper T Intrauterine Contraceptive Device|
45982072|NCT00336245|Drug|Hormonal Contraception|
45982073|NCT00336362|Drug|Hydroxyurea|"Hydroxyurea: Subjects will be treated for one month with hydroxyurea at a starting dose of 10 mg/kg orally (closest approximation to 500 mg capsule, alternate day dosing, e.g. 500 alternating with 1000 to achieve 750 mg average daily dose), once daily, with a gradual dose escalation up to 20 mg/kg (in non-splenectomized patients) and up to 25 mg/kg (in splenectomized patients).~G-CSF: G-CSF will be administered subcutaneously. In general, G-CSF will be administered at 10μg/kg/day (5μg/kg on a twice a day schedule) for at least 4-5 days before leukapheresis and for 1-2 additional days during collections. For the splenectomized patients who are not receiving HU pretreatment, and for the splenectomized patients who receive HU pretreatment who have greater than or equal to 12,000 WBCs before G-CSF, G-CSF will start at a lower dose (for example, 1.5 or 2.5 µg/kg); the next doses will be adjusted by the Principal Investigator based on the observed degree of leukocytosis."
45982074|NCT00347373|Drug|Tonalin Conjugated linoleic acid (dietary supplement)|
45982075|NCT00336401|Drug|Sevoflurane or Propofol|
45982076|NCT00336518|Drug|peginterferon alfa-2a|
45982077|NCT00336518|Drug|ribavirin|
45982078|NCT00336557|Procedure|NAbs testing|blood drawn for a Binding Antibody (BAb) and Neutralizing Antibody (NAb) test.
45982079|NCT00336596|Procedure|transcranial ultrasound in patients treated with iv t-PA|
45982080|NCT03277872|Device|Laryngoscopy with GlideScope (GVL) Blade|"st Laryngoscopy with GVL Blade~nd Laryngoscopy with MAC Blade~rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
46082899|NCT00942253|Other|Dopamine Agonist and Exercise|Dialysis patients will receive dopamine agonist or placebo for 24 weeks following a 24 weeks period of combined treatment with dopamine agonist or placebo and aerobic intradialytic exercise.
46082900|NCT02792816|Drug|First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)|Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.
46082901|NCT00930761|Behavioral|Music therapy|Music therapy sessions systematically offered to all mothers in the intervention group, three times a week, not mandatory, conducted by two music therapists in an appropriate room, during 60 minutes.
46082902|NCT00940381|Drug|Sirolimus|Beginning dose 3 mg by mouth on Day 1, and 1 mg on Days 2 - 28 for a 28 day cycle.
45458711|NCT03492580|Drug|Sulfonylureas (SU)|No intervention or treatment assignment imposed by this study. Participants received SU as a part of routine clinical practice. SUs includes: glipizide, glyburide, glimepiride, chlorpropamide, tolazamide, tolbutamide, acetohexamide
45672839|NCT05203133|Dietary Supplement|Energy Balance|Energy balance phase to elicit weight-maintenance
45672840|NCT05203133|Dietary Supplement|Energy Deficit|Energy deficit phase to elicit weight-loss
45672841|NCT05203133|Dietary Supplement|Baseline Assessment|Free-living assessment of energy status
46082903|NCT00940381|Drug|Cetuximab|Beginning dose 100 mg/m^2 by vein over two hours on Day 1, and 65 mg/m^2 on Days 8, 15 and 22 for a 28 day cycle.
45672842|NCT04791293|Other|MELD-Na score|MELD-Na scores will be compared between the groups
45672843|NCT03943901|Drug|Rituximab|Rituximab is a monoclonal antibody
45672844|NCT03943901|Drug|Cyclophosphamide|Chemotherapy drug, alkylating agent
45982081|NCT03277872|Device|Laryngoscopy with MacIntosh (MAC) Blade|"st Laryngoscopy with MAC Blade~nd Laryngoscopy with GVL Blade~rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
45982082|NCT00336635|Biological|cell-culture derived smallpox vaccine|
45982083|NCT00347490|Drug|Enoxaparine|
45982084|NCT00336674|Biological|Intranasal insulin|440IU Insulin
45982085|NCT00336674|Other|Placebo|Placebo insulin carrier solution containing benzalkonium chloride and glycerol
45982086|NCT00444483|Behavioral|Structured diabetes teaching and treatment program|
45982087|NCT00336752|Procedure|non operative treatment|non operative treatment -casting for 6 weeks
45982088|NCT00336752|Procedure|operative treatment of ankle fractures|operative treatment of ankle fractures
45982089|NCT00444522|Drug|Alprazolam thermal aerosol|
45982090|NCT00336791|Drug|5-Fluorouracil|"FEC Chemotherapy: 500 mg/m^2 IV on day 1 of 21 day cycle.~FAC Chemotherapy: 500 mg/m^2 IV on day 1 and day 4 of 21 day cycle."
45982091|NCT00336791|Drug|Cyclophosphamide|"FAC and FEC Chemotherapy:~500 mg/m^2 IV on day 1 of 21 day cycle."
45982092|NCT00336791|Drug|Doxorubicin|FAC Chemotherapy: 50 mg/m^2 IV on day 1 over 72 hour continuous infusion or IV bolus.
45982093|NCT00336791|Drug|Paclitaxel|80 mg/m^2 by vein (IVPB) over 1 hour every week for 12 weeks
45982094|NCT00336791|Drug|Epirubicin|FEC: 100 mg/m^2 IV on day 1 of 21 day cycle.
45982095|NCT00347529|Biological|pPML7789 with and without pPJV2012 administered by PMED|
45982096|NCT00336830|Behavioral|MD-endorsed Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program with signature and strong recommendation from attending physician.
45982097|NCT00336830|Behavioral|Standard Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program without signature or recommendation from attending physician.
45982098|NCT00444561|Drug|pramlintide acetate|Clear, colorless, sterile solution for SC administration
45982099|NCT00347568|Device|TX-plore|PI has terminated at institution and there is no one available to report.
45982100|NCT00336908|Drug|a combination of MCT, LCT , and Fish Oil|
45982101|NCT00444639|Drug|Triptorelin (Decapeptyl®)|Two injections of 11.25mg given every 12 weeks
45982102|NCT00336947|Drug|tegafur-gimeracil-oteracil potassium|
45982103|NCT00336947|Drug|tegafur-uracil|
45982104|NCT00336947|Procedure|adjuvant therapy|
45982105|NCT00347607|Behavioral|community surveillance and re-treatment|
45982106|NCT00444717|Drug|pitavastatin|Pitavastatin (2mg/day) was administered for 12 weeks
45982107|NCT00336986|Drug|recombinant interleukin-21|
45982108|NCT00347646|Drug|Plasmin|27 mg of human-derived plasmin to be reconstituted with of 0.9% Sterile Sodium Chloride for a single intravitreal injection
45982109|NCT00337064|Procedure|Radiation Therapy|
45982110|NCT00421278|Drug|MK0633|Single dose MK0633 100mg po in the fed state administered during a 4-wk study.
45982111|NCT00421317|Drug|Imatinib|800 mg/day until disease progression or toxicity
45982112|NCT00337259|Drug|gemcitabine|D1 and 8, Gemcitabine 1250mg/m2 + NS 100ml MIV over 30min, every 3 weeks
45982113|NCT04699734|Diagnostic Test|Xylocaine 1%|Nerve block
45982114|NCT04699734|Diagnostic Test|NaCl 9mg/ml|Nerve block
45982115|NCT00337298|Drug|Amlodipine|1 (5mg) tablet daily, given 14 days totally before measure of outcome.
45982116|NCT00337298|Drug|Lisinopril|Lisinopril 10 mg given daily for 14 days and then outcome was measured.
45982117|NCT04699851|Behavioral|Tailored recommendations|Tailored informations delivered by email about health prevention behavior in a pandemic based on the answers in the survey.
45672845|NCT03943901|Drug|Doxorubicin|Chemotherapy drug, anthracycline antibiotic
45672846|NCT03943901|Drug|Vincristine|Chemotherapy drug, plant alkaloid
46082904|NCT00637988|Drug|Esomeprazole|40mg twice daily
46082905|NCT00637988|Drug|Aspirin|
45672847|NCT03943901|Drug|Prednisone|Steroid, anti-inflammatory
45672848|NCT03943901|Biological|Pegfilgrastim|Granulocyte stimulating factor, biologic response modifier
45982118|NCT04699851|Behavioral|General recommendation|The control group will receive general recommendations by email about health prevention in a pandemic.
45982119|NCT00337337|Behavioral|Multiple grain|
45982120|NCT00337337|Behavioral|Ordinary Asian- rice|
45982121|NCT00337376|Drug|Rapamune|Dose escalation as follows: 5mg PO, 10mg PO, 20mg PO, 40mg PO
45982122|NCT00337376|Drug|Abraxane|intravenous administration of 100mg/m2 Abraxane over 30 minutes, weekly for three out of four consecutive weeks.
45982123|NCT00337415|Drug|MK0354|
45982124|NCT03275688|Diagnostic Test|Breath Analysis|Breath will be analyzed in all three groups using gas chromatography mass spectrometry.
45982125|NCT00337493|Drug|mycophenolate mofetil [CellCept]|Concentration-controlled
45982126|NCT00337493|Drug|mycophenolate mofetil [CellCept]|1g po bid
45982127|NCT00337493|Drug|Cyclosporine or tacrolimus|Reduced
45982128|NCT00337493|Drug|Cyclosporine or tacrolimus|Standard, as prescribed
45982129|NCT00444756|Procedure|J-tip jet injection of 1% buffered lidocaine|
45982130|NCT03275649|Other|Help-seeking for non-motor symptoms|Brief, self-paced, online individually tailored intervention using LifeGuide software. Includes information, videos and exercises.
45982131|NCT04715789|Behavioral|graded exposure and activity|"Graded exposure: This approach followed a model where the patient was gradually exposed to previously pain provocative, feared and or avoided tasks. These activities are started at a diminished level that elicits minimal amounts of fear and then gradually increased to situations that elicit larger amounts of fear patients are asked to create a hierarchy of feared activities. The exposure starts with the least feared activity, and the therapist helps the patient appraise the exposure and its consequences and then address irrational and counterproductive beliefs, leading to reductions in the anxiety associated with the activity~Graded activity exercises: The new postural and movement behaviors were integrated into each person's nominated pain provocative functional activities linked to their goals in order to generalize learning and build self-efficacy the program focuses on functional activities and progresses in a time contingent manner"
45982132|NCT00444834|Drug|Carvedilol|50 mg
45982133|NCT00337688|Device|isometric joystick|isometric joystick
45982134|NCT04698486|Other|Hyperinsulinemic euglycaemic clamp|"Infusion of constant intravenous insulin to achieve hyperinsulinemia and concomitant infusion of glucose to maintain euglycemia (plasma glucose at 5 mM).~Infusion of palmitate and VLDL-triglyceride tracer. PET/CT scans of heart and liver, both in basal period and during intervention."
45982135|NCT00337766|Drug|Desmopressin (DDAVP)|
45982136|NCT00337766|Drug|Placebo|
45982137|NCT00444873|Drug|lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval|Six deep subcutaneous injections of Lanreotide Autogel, 24-56 week intervals.
45982138|NCT00337805|Other|Pentaspan|When fluids are indicated either pentaspan or saline are given in a double blind randomized assignment
46082906|NCT00637988|Drug|Rofecoxib|25mg once daily
46082907|NCT05301595|Procedure|TAP block|Please see description of TAP block group.
46082908|NCT05301595|Procedure|QL Block|Please see description of QL block group.
45982139|NCT01580397|Drug|INNO-206|INNO-206 at a total dose of 350 mg/m2 (260 mg/m2 doxorubicin equivalent) will be administered as a 30 minute IV infusion every 21 days.
45982140|NCT04715594|Device|1st-generation drug-eluting stent|Implantation of 1st-generation drug-eluting stent
45982141|NCT04715594|Device|2nd-generation drug-eluting stents|Implantation of 2nd-generation drug-eluting stent
45982142|NCT00444990|Device|Magnetic Flex Pad|
45982143|NCT00337883|Drug|Erlotinib HCl (OSI-774)|
45982144|NCT00451113|Drug|Sitagliptin 100 mg|All subjects will receive a single 100 mg dose of sitagliptin and a placebo. Which they are given first is determined randomly.
45982145|NCT00337922|Drug|Lamivudine / Abacavir Sulfate|
45982146|NCT04699578|Diagnostic Test|Covid-19 positive|All pregnant women at any stage of pregnancy afferent to obstetrics services who tested positive in confirmation tests by nasopharyngeal swab for viral RNA detection through real-time reverse transcriptase - polymerase chain reaction (rRT-PCR) will be included.
45982147|NCT00337961|Procedure|Optic Nerve Sheath Fenestration|
45982148|NCT00451230|Drug|cocaine|
45982149|NCT00451230|Drug|hydrocortisone|
45982150|NCT00338000|Drug|Epoetin alfa|
45982151|NCT00451269|Device|Rapid diagnosis test for malaria|Rapid diagnosis test for malaria
45982152|NCT00338078|Device|nocturnal oxygen treatment from oxygen concentrators|
45982153|NCT04699617|Device|Dolphin 2.0|The Dolphin 2.0 is a platform that runs an immersive virtual reality software, based on an oceanic environment, where players control simulated creatures.
45982154|NCT00338117|Drug|Galantamine hydrobromide|
45982155|NCT02956707|Other|No pre-operative steroids|Due to new information provide from previous studies at our center the investigator instituted a clinical practice change remove steroid administration in the pre-operative period for all neonates undergoing surgery with cardiopulmonary bypass. This study is to evaluate this change.
45982156|NCT00338195|Behavioral|Individualized caffeine cessation instructions|Intervention is described in the protocol
45982157|NCT00451308|Procedure|Induction of labor with foley balloon - 60cc of saline|60 cc of fluid
45458712|NCT03492580|Drug|Insulin|No intervention or treatment assignment imposed by this study. Participants received Insulin as a part of routine clinical practice.
45458713|NCT01238965|Drug|panobinostat|Given orally
45458714|NCT01238965|Drug|fluorouracil|Given IV
45982158|NCT00451308|Procedure|Induction of labor with foley balloon with 30cc|30cc of saline in foley
45982159|NCT00451347|Device|Quadriceps strength training|
45982160|NCT00451347|Device|Taping|
45982161|NCT00451347|Device|Home exercise|
45982162|NCT00338273|Drug|Aripiprazole|Tablets, Oral, 5 - 30 mg, Once daily, 8 weeks.
45982163|NCT00338273|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
45982164|NCT03277833|Dietary Supplement|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day)|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day), parallel design
45982165|NCT03277833|Dietary Supplement|Placebo|Placebo, parallel design
45982166|NCT00338312|Drug|Testosterone Transdermal System|testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
45982167|NCT00338312|Drug|Placebo patch|placebo patch changed twice a week for one year
45982168|NCT00451386|Drug|MK0826, ertapenem sodium /Duration of Treatment: 14 Days|
45982169|NCT00451386|Drug|Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days|
45982170|NCT00420875|Device|TOPAZ MicroDebrider|The TOPAZ MicroDebrider will be used for patients that fail conservative care. Under sterile conditions in the operating room, patients will be given intravenous sedation (drugs that make you sleepy and unaware of your surroundings) in a hand vein and local anesthetic (drugs to numb the area where the surgical procedure will be done). Depending on the technique used the study doctor may or may not make an incision (cut) about 1 inch long on the side of your foot to expose your tendon. If the study doctor chooses to use the percutaneous method, an incision will not be made. The study doctor will put the tip of the TOPAZ MicroDebrider device (which is about 1/16th of an inch long) into the tendon. A current of energy will be applied on and around the tendon. Steri strips will be placed on the skin to close the area treated.
45982171|NCT02956824|Other|Standard care|Current care
45982172|NCT00338351|Biological|Pneumococcal (vaccine)|
45982173|NCT00451425|Behavioral|motivational intervention in pregnancy|Motivational program including individualized counseling on diet and physical activity
45982174|NCT00338390|Drug|Abacavir|Change tenofovir to abacavir
45982175|NCT00338390|Drug|Didanosine|Increase didanosine dose to 400 mg/day if weight is > 60 Kg. or to 250mg/day if weight is < 60 kg.
45982176|NCT00338390|Drug|Abacavir+Lamivudine|Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
45982177|NCT00338429|Behavioral|FHP Sleep Program|Cognitive-Behavioral Intervention
45982178|NCT02957214|Behavioral|Pain education|
45982179|NCT00338468|Drug|epoetin alfa|
45982180|NCT00338507|Drug|Erdosteine|
45982181|NCT00445185|Biological|Henogen HB vaccine|Month 12, 24 and 36
45456454|NCT03747601|Device|Temporal Interference (TI) Stimulation|2-4 Temporal Interference stimulation sessions. The device is an experimental non-invasive electrical brain stimulator that functions similar to existing non-significant risk devices for electrical stimulation, including human non-invasive brain stimulation. Briefly, the device produces alternating current electrical stimulation in a kilohertz (kHz) range and results in less net charge applied within the brain. The device is powered by rechargeable 20 volt (V) battery (i.e. there is no connection to building power supply). The current is hardwired and limited to 5 milliamp (mA) via internal resistors. It includes extra safety features such as onboard fuses to limit any abrupt high current, and an emergency stop button which effectively insulates the subject and resets the device. The device was tested and characterized at all the required load conditions.
45982182|NCT00445185|Biological|Fendrix vaccine|Month 12, 24 and 36
45982183|NCT00338546|Drug|Cocaine hydrochloride|
45982184|NCT00338546|Drug|Dexmedetomidine|
45982185|NCT00338546|Procedure|Microneurography|
45982186|NCT00338546|Procedure|Laser doppler velocimetry|
45982187|NCT00338585|Drug|alfimeprase|
45982188|NCT00451503|Device|Middle Ear Implant|surgery
45982189|NCT00338624|Drug|oxybutynin chloride extended release|
45982190|NCT00338663|Device|knee immobilization splint|
45832420|NCT01671774|Drug|Interleukin-2 (1 million IU)|1 million IU on day 1, 2 and 3 of cycles 1 and 3.
45982191|NCT00445419|Biological|PEV2A PEV2B|
45982192|NCT00338702|Procedure|Autologous Platelet Gel|
45982193|NCT00451581|Procedure|Endoscopic papillary balloon dilation-5 minutes|
45982194|NCT00451581|Procedure|Endoscopic papillary balloon dilation-1 minute|
45982195|NCT00338780|Drug|Lamivudine/ Placebo 100mg daily|
45982196|NCT00451620|Drug|glyburide|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
45982197|NCT00451620|Drug|GlucoNorm|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
45982198|NCT00338858|Other|walking and balance performance evaluation|
45982199|NCT00338858|Procedure|muscle strength, walking and balance performance|HHD- muscle strength, Balance performance - TUG, FRT, Walking performance- gaiterite and 2 min walk test
45982200|NCT00451737|Device|Isokinetic test|
45982201|NCT00338897|Drug|SR123781A|
45832421|NCT01671774|Drug|Interleukin-2 (3 million IU)|3 million IU on day 1, 2 and 3 of cycles 1 and 3.
45982202|NCT00445497|Drug|amoxicillin-clavulanate potassium|
45982203|NCT00445497|Drug|ciprofloxacin|
45982204|NCT00445497|Procedure|psychosocial assessment and care|
45982205|NCT00445497|Procedure|quality-of-life assessment|
45982206|NCT00451776|Drug|etomidate|patients who received etomidate
45982207|NCT00451776|Drug|propofol|patients who received propofol
45982208|NCT00338936|Drug|Valsartan + Hydrochlorothiazide|
45982209|NCT00445575|Drug|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
45982210|NCT00445575|Drug|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
45982211|NCT00445575|Drug|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
45982212|NCT00445575|Drug|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
45982213|NCT00338975|Behavioral|Cognitive Behavioral Social Skills Training (CBSST)|There are 36 weekly group sessions, each session is 2 hours in length, with a half-hour break after the first hour. The intervention integrates CBT and SST techniques and neurocognitive compensatory aids. All participants are asked to identify a goal. The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. The CBT components are based on techniques developed for CBT in general and techniques developed specifically for patients with schizophrenia. Cognitive therapy is combined with role-play practice of communication skills and problem-solving training.
45982214|NCT00338975|Behavioral|Goal-focused supportive contact (GFSC)|"There are 36 weekly group sessions, each 2 hours in length, with a half-hour break after the first hour. GFSC has a number of specific goals and interventions, including providing a safe environment where the patient can discuss her/his feelings and concerns; to validate these feelings and concerns; and to provide support and guidance to the client so that she/he can make progress to solving problems or alleviating concerns and worries. Psychotic symptoms and cognition are not directly targeted. Therapists utilize non-specific therapeutic techniques, including providing unconditional positive regard, reflective listening, encouraging, paraphrasing, and summarizing. Therapists do not develop a formulation or teach skills."
45982215|NCT00338975|Behavioral|Social Skills Training|The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. Participants engage in role plays and problem solving.
45982216|NCT00338975|Behavioral|Goal Setting|All participants are asked to identify a personally meaningful goal as soon as possible in therapy. Over the 36 weeks, participants in CBSST learn skills related to goal attainment, while participants in GFSC do not receive skills aimed at goal attainment, but are encouraged to discuss their goals .
45982217|NCT00451815|Drug|active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.|
45982218|NCT00451815|Drug|placebo|
45982219|NCT00339014|Drug|Zonisamide CR and Bupropion SR|Zonisamide SR and Bupropion SR
45982220|NCT00339014|Other|Placebo|Identical placebo
45982221|NCT00451854|Procedure|Random, no advanced notice drug and alcohol testing|
45982222|NCT04715828|Other|Cryopreserved semen|sperm will be frozen in Cryosperm® cryoprotectant medium (Origio). The samples will be packaged in previously identified high security straws (Cryobiosystem). Slow freezing of the straws will be carried out using the Nanodigicool® programmable device (Cryobiosystem).
45982223|NCT04715828|Other|Acute and low irradiation|sperm sample will be placed on the scanner's processing table to be exposed for 1 to 2 seconds. Several dose levels will then be made in order to limit the value of 17 mGy
45982224|NCT04715828|Other|Long and low irradiation|sperm sample will be exposed to gamma radiation by adding a solution of Tc99m for 3 hours.
45982225|NCT04715828|Other|Long and medium irradiation|sperm sample will be exposed to gamma radiation by adding a solution of I131 for 3 hours
45982226|NCT00445614|Behavioral|Effects of trout on CVD risk markers and plasma proteome|
45982227|NCT00339053|Drug|Immunonutrition ( Impact)|
45982228|NCT00339092|Behavioral|Modified Directly Observed Therapy|Treatment includes storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals. Participants in the MDOT program will report to the study site each morning for 3 months, Monday through Friday, to take their HIV medication and any other medications prescribed by their primary care doctors. At the end of 3 months, participants will no longer attend the study site for medication assistance. Participants will then attend Action Point, a county program that helps participants adhere to taking medication, for an additional 3 months.
45982229|NCT00339092|Behavioral|Standard Care|Participants assigned to standard care will report to the study site once a month for 9 months, but will not receive any assistance with taking HIV medications. Information about medication adherence, housing, income, use of health services, drug use, sexual practices, and mental health services will be collected at each visit.
45982230|NCT00445731|Behavioral|exercise intervention|
45982231|NCT00445731|Procedure|management of therapy complications|
45982232|NCT00445731|Procedure|observation|
45982233|NCT00420914|Procedure|low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9)|
45982234|NCT00420953|Drug|Cordarone|
45982235|NCT00425204|Drug|Panitumumab (ABX-EGF)|Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
45982236|NCT00425243|Drug|zolpidem-MR (SL800750)|
45982237|NCT00451893|Procedure|Lichtenstein operation with a heavy-weight mesh|Bard flat mesh, polypropylene, 7,5 x 15 cm, 90 g/m2
45982238|NCT00451893|Procedure|Lichtenstein operation with a light-weight mesh|Johnson&Johnson Ultrapro, polypropylene/poliglecaprone, 10 x 15 cm, 28 g/m2
45982239|NCT00425282|Drug|RWJ-333369|
45982240|NCT00339131|Drug|Ultratrace iobenguane I 131|
45982241|NCT00339170|Behavioral|Computer-Based Cognitive Enhancement Training Program|Participants in the cognitive enhancement training program will receive feedback on their cognitive strengths and weaknesses based on the outcomes of the baseline assessment. The training component will be comprised of 150 computer-based exercises that focus on improving memory, attention, and organizational skills. Participants will attend two weekly meetings: one will focus on providing feedback regarding goal-setting and problem-solving, and the other will focus on improving verbal skills and social information processing.
45982242|NCT00339170|Behavioral|Work Therapy Program|Participants in the work therapy program will attend two non-cognitive discussion groups per week.
45982243|NCT00451932|Drug|FK778|
45982244|NCT00451971|Drug|LEFLUNOMIDE|
45982245|NCT00452010|Device|CEFAR PRIMO TENS Class IIA (active)|Active TENS. 4 sessions per day during 3 months.
45982246|NCT00452010|Device|CEFAR PRIMO TENS Class IIA (no active)|Placebo TENS. 4 sessions per day during 3 months.
45982247|NCT00445926|Device|deep TMS H-coil|
45982248|NCT00339365|Behavioral|Promoting First Relationships Program|Participants assigned to PFR will receive ten weekly home visits that will focus on promoting the development of a secure attachment between foster parents and infants.
45982249|NCT00339365|Behavioral|Early Education Support Program|EES will consist of three monthly home visits, during which infants will be assessed and referred for additional care if necessary. EES participants will not receive any training.
45982250|NCT00452049|Procedure|parathyroidectomy|parathyroidectomy
45982251|NCT00452088|Biological|MSP 3 Long Synthetic Peptide|Lyophilized vaccine given at 15 or 30 microgrammes
45982252|NCT00452088|Biological|Hepatitis B vaccine|Hepatitis vaccine adjuvanted in Aluminium hydroxide
45982253|NCT00452088|Biological|Hepatitis B control vaccince|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
45982254|NCT00452166|Drug|rosiglitazone|
45982255|NCT00446004|Drug|Imatinib Mesylate|Dosage form: tablets Dosage: 400 mg Frequency & duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
45982256|NCT00446004|Drug|Omeprazole|Dosage form: capsules Dosage: 40 mg Frequency: On an 18-day schedule, once daily day 10 through day 16 (for Arm A); or once daily day -4 through day 1 (for Arm B)
45982257|NCT00446043|Drug|Adapalene/Benzoyl Peroxide|
45982258|NCT00446082|Drug|Pasireotide|
45982259|NCT03275376|Drug|Atorvastatin 10mg|Atorvastatin or placebo will be administered according to randomized allocations.
45982260|NCT03275376|Drug|Placebo Oral Tablet|Atorvastatin or placebo will be administered according to randomized allocations.
45982261|NCT03275337|Device|Transcranial Direct Current Stimulation|tDCS is a non-invasive form of neuromodulation in which direct current is administered placed over a brain region of interest to induce physiological changes such as inhibition or excitation over that region.
45982262|NCT03275259|Device|THORK Shock Wave® (Extracorporeal shock waves)|Treatment with extracorporeal shock waves: energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
45982263|NCT00339872|Drug|IMA-638|
45982264|NCT03275220|Diagnostic Test|2D Echocardiography and 3D Echocardiography|Imaging of right ventricle by 2d echocardiography and 3D echocardiography to assess right ventricular function accurately
45982265|NCT04698447|Dietary Supplement|Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_MetS|20 eligible subjects with the metabolic syndrome (MetS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months and as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
45982266|NCT04698447|Dietary Supplement|Placebo (without any active ingredients)|20 eligible subjects with the metabolic syndrome will take placebo in a spray-dried formulation (without any active ingredients) directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
45982267|NCT04698447|Dietary Supplement|Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_HS|20 eligible healthy subjects (HS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months, maintained at fixed doses for the entire study.
45982268|NCT00340106|Behavioral|Counseling|
45982269|NCT00446238|Behavioral|Cognitive Behavioral Therapy|CBT enhanced with physical illness narrative, family education, and social skills components.
45982270|NCT00446238|Behavioral|Standard of Community Care Treatment|Treatment as usual for depression and related symptoms provided within the community.
45982271|NCT00340184|Drug|paclitaxel, carboplatin|
45982272|NCT00446277|Procedure|cataract surgery|
45982273|NCT04698408|Other|high-protein, carbohydrate-reduced diet|the high-protein, carbohydrate-reduced diet will consist of 1.2-1.4 g/kg/d protein, 26-20en% carbohydrates and +/- 50en% fatty acids, with mainly unsaturated fatty acids. This diet consist of mainly unprocessed, fresh nutrient-dense food-products. Ultra-processed foods and alcoholic beverages will be totally avoided. Salt consumption will not exceed 5-6 g/d. The diet is ad libitum and caloric restriction will not be applied. The diet will be followed for 6 weeks.
45982274|NCT04698408|Other|Dutch Nutritional Guidelines|the diet according to the Dutch Nutritional Guidelines will consist of a protein intake of 0.8-1.0 g/kg/d and 50-60en% carbohydrates, and +/-30en% fatty acids, with restriction of saturated fatty acids <10en%. This diet consist of mainly unprocessed, fresh nutrient-dense food-products. Ultra-processed foods and alcoholic beverages will be totally avoided. Salt consumption will not exceed 5-6 g/d. The diet is ad libitum and caloric restriction will not be applied. The diet will be followed for 6 weeks.
46082909|NCT02792894|Behavioral|Family networks program|Intervention, Family networks Program (FaNs), is administered once weekly over 9-10 weeks in a group format over 3 hours per sessions. Family networks Program (FaNs) is based on WHO mhGAP module for developmental disorders and incorporates WHO parent skills training program for children with developmental disorders and delays. Parents Skills Training Program includes modules on communication, play, daily living skills, managing challenging behavior, coping with stress. Intervention is provided by the family volunteers (members of community, mostly women, who have a child affected in their families).
45982275|NCT00446316|Drug|Antacids (Mg-Al-based)|the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).
45456457|NCT03695809|Biological|G9a protein|To assess G9a protein expression on vulvar cancer
45456458|NCT03688451|Drug|Rituximab|Intrathecal administration over 3-5 minutes
45458715|NCT01238965|Drug|leucovorin calcium|Given IV
45982276|NCT00446316|Drug|Imatimib Mesylate (Gleevec®)|Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
45982277|NCT00446394|Behavioral|Resources and Activities for Life Long Independence (RALLI)|Strengthening exercises, encouragement to walk daily, pedometer reading, health promotion information for 1.5 hours weekly for 9 weeks
45982278|NCT00446394|Behavioral|Social Walking program (SW)|Group support for walking, pedometer reading, 1 hour weekly for 9 weeks
45982279|NCT03275181|Diagnostic Test|Transthoracic Echocardiography|Non-invasive assessment of left ventricle structure and function
45982280|NCT03275181|Diagnostic Test|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplethysmography
45982281|NCT03275181|Diagnostic Test|Submaximal Exercise|Incremental exercise test to 85% predicted maximal heart rate on a recumbent cycle ergometer
45982282|NCT00446433|Drug|CC-5013|
45982283|NCT00340574|Drug|AMA1-C1/Alhydrogel + CpG 7909|
45982284|NCT00340613|Drug|glargine insulin|
45982285|NCT03275025|Drug|YRA-1909 low dose|A low dose of YRA-1909; daily oral intake for 12 weeks
45982286|NCT03275025|Drug|YRA-1909 mid dose|A mid dose of YRA-1909; daily oral intake for 12 weeks
45982287|NCT03275025|Drug|YRA-1909 high dose|A high dose of YRA-1909; daily oral intake for 12 weeks
45982288|NCT03275025|Drug|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
45982289|NCT00340691|Drug|Doxycycline|
45982290|NCT00452244|Drug|simvastatin|Simvastatin 40mg/QD po daily every 3 weeks
45982291|NCT00452244|Drug|gefitinib only|gefitinib 250mg/QD po daily every 3 weeks
45982292|NCT00446472|Drug|Regranex®|Regranex gel will be used for a total of 16 weeks
45982293|NCT00446472|Drug|Hydrogel|Placebo hydrogel will be applied for 16 weeks
46082910|NCT05330507|Other|Wellinks|"30-day post-discharge period: virtual respiratory therapist sessions twice per week with synchronous virtual pulmonary rehabilitation and educational materials; at-home use of connected spirometer and pulse oximeter; at-home use of mobile app.~12-week intensive period: virtual health coaching sessions once every two weeks; asynchronous virtual pulmonary rehabilitation program; ongoing access to connected devices (spirometer and pulse oximeter) and mobile app."
45456459|NCT03687528|Radiation|CT-scanner|After a clinical exam, patient have a CT-scanner to check any cerebral haemorrhage.
45456460|NCT03664752|Drug|IDP-120 Gel|IDP-120 Gel, once-daily application
45456461|NCT03664752|Drug|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel, once-daily application
45456462|NCT03664739|Drug|IDP-120 Gel|IDP-120 Gel, once-daily application
45982294|NCT04715711|Other|Forearm coolng|forearm immersion will be performed for active cooling assessment
45982295|NCT04715711|Other|Wet-towel cooling|Wet towels will be wrapped around the participant's arms for active cooling
45982296|NCT04715711|Other|mist-fan|a mist-fan will be placed in front of the participant for active cooling
45982297|NCT04715711|Other|passive cooling|"participants will sit in a chair and passively cool (no active intervention)"
45982298|NCT00446589|Drug|ibandronate|iv 1mg ibandronate monthly for one year
45982299|NCT00446589|Drug|teriparatide|sc injection using a pen like device during every hemodialysis session (thrice a week)
45982300|NCT00446628|Behavioral|behaviors reducing spread of influenza|Non-pharmaceutical interventions for flu prevention
45982301|NCT00452322|Drug|Testosterone Substitution by Testosterone Undecanoate i.m.|
45982302|NCT00452478|Drug|Lanthanum carbonate|2250mg/day starting dose of lanthanum carbonate administered orally, in divided doses, with meals (500mg 750mg and 1000mg strengths)for 2 weeks; dose titration will occur based on serum phosphorus results not to exceed 3000mg/day.
45982303|NCT00452517|Procedure|Percutaneous Coronary Intervention|
45982304|NCT00452556|Drug|Docetaxel|Weekly
45982305|NCT00452556|Drug|Leuprolide Acetate (Eligard®)|2.5 years
45982306|NCT00452556|Radiation|Intensity-Modulated Radiotherapy|Standard sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate, followed by irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)
45982307|NCT00452556|Radiation|Intensity-Modulated Radiotherapy|Experimental sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate last, irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)first
45982308|NCT00446667|Drug|mannitol|400mg BD for 2 days
45982309|NCT03277755|Drug|AL-335 800 mg|Participants will receive AL-335 800 mg (2 tablets of 400 mg AL-335) single oral dose on Day 1 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
45982310|NCT03277755|Drug|ODV 25 mg|Participants will receive ODV 25 mg (1 tablet of 25 mg ODV) single oral dose on Day 8 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
45982311|NCT03277755|Drug|SMV 75 mg|Participants will receive SMV 75 mg in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
45982312|NCT03277677|Drug|Normal saline|for resuscitation in sepsis patients
45982313|NCT03277677|Drug|Ringer's Acetate|for resuscitation in sepsis patients
45982314|NCT00452595|Drug|DVS-233 SR (desvenlafaxine sustained release )|
45982315|NCT02956980|Biological|Blood Plasmacytoid dendritic cells (pDCs) absolute number|Two 7 ml tubes will be necessary to perform the functional assays as well as the quantification of blood pDCs absolute number. Functional assays will be performed on isolated PBMC by Ficoll procedure. Quantification of blood pDCs absolute number will be performed on whole blood. After written parental consent, blood sample will be performed on children participating to the study.
45982316|NCT00341354|Behavioral|Prolonged Mechanical Ventilation|
45982317|NCT01580436|Procedure|Tricuspid Valve Annuloplasty|Concomitant Tricuspid Valve Annuloplasty in patients undergoing mitral valve surgery
45982318|NCT02956668|Other|Blindsight Training associated to tDCS|The patient undergo visual rehabilitation while his brain is electrically stimulated with tDCS.
45982319|NCT02956668|Other|Blindsight Training alone|The patient undergo visual rehabilitation
45982320|NCT00341432|Behavioral|Nicotine Replacement Therapy|
45982321|NCT00452634|Drug|Irinotecan|Irinotecan 65mg/m2/iv over 90min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
45982322|NCT00452634|Drug|Cisplatin|Cisplatin 30mg/m2/iv over 30min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
45982323|NCT00452634|Drug|Simvastatin|simvastatin 40mg/QD, PO, daily, every 3 weeks
45982324|NCT04715555|Device|Electrocardiogram monitoring|Continuous monitoring using a wearable, single-lead electrocardiography (ECG) device affixed to the chest.
45982325|NCT04715555|Device|Electrocardiogram recording|Intermittent electrocardiogram (ECG) recordings taken using a wearable device on the wrist.
45982326|NCT04715555|Device|Photoplethysmogram monitoring|Photoplethysmogram monitoring using a wearable device on the wrist.
45982327|NCT04715555|Other|Feedback questionnaire|A questionnaire to collect feedback on participants' experiences of wearing the devices.
45982328|NCT03277599|Drug|IV patient-controlled analgesia (PCA) tramadol|Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
45982329|NCT03277599|Drug|ultrasound guided superficial cervical plexus block|ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine
45982330|NCT03277599|Drug|ultrasound guided Great Auricular nerve block|ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
45982331|NCT00341471|Procedure|Risk Behavior Prevention Intervention Program|
45982332|NCT00452712|Procedure|All subjects will have their blood pressure measured in supine position (after 5 minute of rest) and after 3 minute of standing.|
45982333|NCT00452751|Procedure|laparoscopy-assisted distal gastrectomy|
45982334|NCT00452751|Procedure|open distal gastrectomy|
45982335|NCT00452829|Drug|Folic Acid and inositol|Folic Acid and inositol
45982336|NCT00452829|Drug|Folic acid and placebo|Folic acid and placebo
45982337|NCT03277560|Other|No Intervention as it is an observational study|No Intervention as it is an observational study
45982338|NCT03277443|Procedure|Computer guided surgery|Preoperative surgical simulation and immediate postoperative evaluation will be carried out using Multi Slice CT scan.Craniofacial images from 3D computerized tomography (3D-CT scan) can be used to create a 3D model, which can in turn be used for 3D Cephalometry measurements and surgical simulation.The process of 3D-model contains mounting of 3D virtual models in a 3D virtual articulator; and repositioning of 3D virtual models according to the STO then Fabrication of a 3D virtual intermediate surgical wafer; and materialization of the surgical wafer using a stereolithographic technique. The 3D model can produce actual movement of surgical cuts and movement of segments accordingly
45982339|NCT03277443|Procedure|Conventional model surgery|preparation for orthognathic surgery which involves diagnosis with 2D cephalometric radiograph, face-bow transfer and model surgery on plaster dental cast, and fabrication of intermediate and final occlusal splint.
46082911|NCT02792972|Other|A. oleracea|The plant extract A. oleracea manipulated with Transcutol® were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.
45456463|NCT03664739|Drug|IDp-120 Vehicle Gel|IDP-120 Vehicle Gel, once-daily application
45456464|NCT03654469|Other|questionnaires and electronic mini-spirometry|prospective screening study based on questionnaires and electronic mini-spirometry (Néo-6(®)) that includes a representative sample of dairy farmers from the departments of Morbihan and Île-et-Vilaine in Brittany
45456465|NCT03651973|Other|Standard follow-up|Patients enrolled into standard group will be followed in a standard way without any additional procedure except randomization that allocates to the standard group
45456466|NCT03651973|Other|Learning workshops|Patients enrolled into experimental arm will participate to educative workshops before and after surgery for breast cancer. The aim of these workshop is to educate patient to self massages and self stretching.
45982340|NCT03277443|Device|2D cephalometric radiograph|2D cephalometric radiograph
45982341|NCT03277443|Device|3D computerized tomography|3D computerized tomography
45982342|NCT00452907|Drug|Artesunate|oad, per os, 3 days of treatment
45982343|NCT00452907|Drug|Artesunate + Sulfadoxine-Pyrimethamine|oad, per os
45982344|NCT00452907|Drug|arthemether + lumefantrine|bid, per os. Duration of treatment: 3 days
45982345|NCT00446784|Drug|CE-224,535|
45982346|NCT00446784|Drug|Methotrexate|
45982347|NCT00452985|Drug|Docetaxel|60-75 mg/m²
45982348|NCT00452985|Drug|Carboplatin|AUC 5
45982349|NCT00453024|Procedure|Pericardial graft & tissue glue|
45982350|NCT00453024|Procedure|scleral flap & sutures|
45982351|NCT03277404|Procedure|Root canal treatment with smear layer removal|Canal were irrigated with Naocl and EDTA to remove smear layer
45982352|NCT03277404|Procedure|Root canal treatment without smear layer removal|only sodium hypochlorite was used for irrigation
45982353|NCT03277326|Procedure|ISB|ISB block with 0.5% ropivicaine 15mls ( 45mg )
45982354|NCT03277326|Procedure|aSSB|aSSB block with 0.5% ropivicaine 15mls ( 45mg )
45982355|NCT03277326|Procedure|pSSB|pSSB block with 0.5% ropivicaine 15mls ( 45mg )
45982356|NCT03277287|Radiation|Fractional CO2 laser|Fractional CO2 laser will be applied in cleft lip scar to assess and evaluate the later appearance of the scar
45982357|NCT03277209|Drug|Plerixafor|Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
45982358|NCT00342134|Procedure|Stem Cell Transplanataion|
45982359|NCT00453141|Drug|dosing of Betamethasone|
45982360|NCT03277092|Device|VeinViewer®|Near-infrared (NIR) technology consists on light-emitting diodes placed underneath the hand, that makes vessels visible by projecting the processed image in a green light directly on to the puncture site
45982361|NCT03277092|Procedure|Usual care|The blood drawing is performed traditionally
45982362|NCT00453219|Procedure|Screening evaluation|A detailed history will be taken and a physical examination performed along with a blood sample to verify ovulatory status in women with regular cycles and determine cause of anovulation in women with irregular or absent menstrual cycles.
45982363|NCT00453219|Procedure|Meal Response|The investigators are interested in how nutrition and metabolism can influence reproduction and they will look at how the body senses hunger and how it responses to food. Blood samples will be collected and questionnaires given to assess responses and feeling about hunger and food.
45982364|NCT00453219|Genetic|Blood Collection|A blood sample will be collected and used to check for genetic markers of stress vulnerability.
45982365|NCT00453219|Procedure|Functional MRI|research participants will have an functional MRI scan of their brain while reviewing word lists associated with body image and emotions. This procedure will last about 1 hour.
45982366|NCT00453219|Procedure|Endocrine Assessment|research participants will have a 30 hour inpatient hospital admission with every 15 minute blood sampling for 24 hours. Hormone measures of stress, reproduction, and appetite will be obtained.
45982367|NCT00421031|Drug|DVS-233 SR|
45982368|NCT03277053|Device|Mobile application|A mobile application designed specifically for colorectal patients treated within an enhanced recovery pathway. Contains information, guidelines, questionnaires and feedback
45982369|NCT03277053|Other|Control.|Patient receive an ipad with no application.
45832422|NCT01671852|Drug|Mometasone furoate nasal spray|"Included patients will be randomized to a sequence of treatments including a medicated nasal spray and a saline nasal spray. The medicated group will receive Mometasone nasal sprays at the dosage outlined below for 8 weeks. The placebo group will receive saline nasal sprays for an equal duration. Informed consent of the parents or legal guardians will be obtained.~For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks."
45982370|NCT00421070|Procedure|Massage therapy|A qualified massage therapist will administer a 20-minute standard massage procedure with the client sitting fully clothed in a special massage chair. The massage therapy session will consist of ; 1) long, broad stroking with light-moderate pressure to the back, compression to the back (parallel to spine) from the shoulders to base of spine, trapezius squeeze, finger pressure on the shoulder; 2) arms dropped to the side with arms kneaded from shoulder to lower arm and pressing down on upper and lower arms; 3) entire hands massaged and pulling of fingers, light kneading to area of cervical vertebrae, pressing down on trapezius with finger pressure and squeezing continuing down the arms.
45982371|NCT03274908|Other|regular medical treatment|regular medical treatment
45982372|NCT00421109|Drug|Bilastine|Encapsulated 20 mg Tablet. Once daily for 28 days
45982373|NCT00421109|Drug|Levocetirizine|Encapsulated 5 mg tablet. Once daily for 28 days
45982374|NCT00421109|Drug|Placebo|Encapsulated tablet. Once daily for 28 days
45982375|NCT00446823|Device|XCell cellulose wound dressing|
45982376|NCT00446823|Device|Impregnated gauze dressing|
45456467|NCT03626064|Behavioral|Smoking Cessation Counselling|One on one smoking cessation counselling with a certified mental health nurse
45832423|NCT01671852|Drug|Placebo|
45982377|NCT02273583|Drug|continuous oral cyclophosphamide and methotrexate|
45982378|NCT00446862|Drug|enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers|10 mg by mouth every day; 25 mg by mouth every day
45982379|NCT00453258|Other|Eye Examination|Subjects receiving eye examination
45982380|NCT00342368|Procedure|CPAP delivered by an Helmet|continuous positive airway pressures delivered through an helmet
45982381|NCT00446901|Dietary Supplement|Selenium|Selenized yeast, 300 ug/day
45982382|NCT00453297|Drug|MF101|
45982383|NCT00453375|Drug|BHT-3021|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
45982384|NCT00453375|Drug|BHT-Placebo|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
45982385|NCT00446940|Drug|rosuvastatin|
45982386|NCT00446940|Drug|atorvastatin|
45458716|NCT01238965|Procedure|biopsy|Correlative studies
45982387|NCT00453414|Drug|Iloprost Inhalation Solution (Ventavis)|
45982388|NCT00342836|Procedure|Akt levels|
45982389|NCT00446979|Drug|Placebo gel|HEC (hydroxyethyl cellulose) Control Gel applied vaginally twice daily for two weeks
45982390|NCT00446979|Drug|UC 781|UC 781 0.1% or UC 781 0.25%, applied vaginally twice daily for two intermenstrual weeks
45982391|NCT00453453|Drug|Nesiritide|Nesiritide given orally in the emergency department
45982392|NCT00447018|Drug|20% mannitol|
45982393|NCT00447018|Drug|7.45% hypertonic saline solution|
45982394|NCT05649033|Other|data collection|Work-related stress evaluation
45982395|NCT00343070|Drug|Oral administration of escitalopram during 8 weeks|
45982396|NCT00453492|Drug|risedronate sodium|
45832424|NCT05564208|Drug|elafibranor|Oral Tablet
45832425|NCT01672086|Device|Stelkast Surpass Acetabular System implant|
45832426|NCT04529070|Behavioral|Nightmare Rescripting and Rehearsal|This study aims to test the efficacy of an abbreviated version of Imagery Rehearsal Therapy ('Nightmare Rescripting and Rehearsal Therapy' (NRRT)) administered by non-mental health professionals in a Primary Care setting.
45982397|NCT00447096|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS).
45982398|NCT00343148|Drug|AVI-4126 Injection (RESTEN-NG®)|
45982399|NCT00343187|Drug|ACZONE (dapsone) Gel, 5%|
45982400|NCT00343187|Drug|Vehicle Control|
45982401|NCT00453570|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
45982402|NCT00453570|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
45982403|NCT00453570|Biological|Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed|0.5 mL, IM
45982404|NCT00343226|Drug|Basiliximab|
45982405|NCT00447174|Behavioral|Dyadic treatment for parental bereavement|
45982406|NCT00343265|Drug|Vaginal progesterone gel|Vaginal gel once daily
45982407|NCT00343265|Drug|Placebo gel|once daily
45982408|NCT00453609|Drug|long-lasting injectable naltrexone|
45982409|NCT00343304|Device|Robot|
45982410|NCT00343304|Device|Ergometer|
45982411|NCT00447213|Drug|Insulin glargine|Patient specific, injected, daily, 24 weeks
45982412|NCT00447213|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,12 weeks
45982413|NCT00447213|Drug|Injectable Insulin|Patient specific dose,injected, before meals, 12 weeks
45982414|NCT00343343|Device|NovoFine® needle 6 mm|
46082912|NCT02792972|Other|70% alcohol|70% alcohol were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.
45456468|NCT03626064|Drug|Nicotine Replacement Therapy|Access to a range of nicotine replacement therapy: nicotine patch, nicotine gum, nicotine lozenge, nicotine inhaler
45456469|NCT03619083|Other|SAE battery|The SAE battery yields 12 variables.
45456470|NCT03619083|Behavioral|Assessments|Assessments of their neurocognitive performance will be assessed longitudinally, at 4 time points: prior to adjuvant treatment (post-surgery); 1 month (with a +4 week window) post-chemotherapy; and again at the 12 and 24 months (with a +4 week window) post-treatment time points. These assessment time points are denoted as T1 though T4, respectively. The assessment schedule for the HC and CT- groups will be yoked against that of the CT+ cohort.
45456471|NCT03613532|Drug|Venetoclax|Part 1: 6-7 total doses depending on dose level assigned
45456472|NCT03613532|Drug|Fludarabine|Given once daily for 4 days
45456473|NCT03613532|Drug|Busulfan|Given twice daily for 4 days
45456474|NCT03613532|Drug|Venetoclax|Part 2 and Part 3: 14 doses for 8-12 cycles depending on dose level assigned
45456475|NCT03613532|Drug|Azacitidine|Part 2: 5 doses for 8-12 cycles depending on dose level assigned
45456476|NCT03613532|Drug|Decitabine/cedazuridine|Part 3: 3 doses for 8 cycles
45456477|NCT03593018|Drug|Oral azacitidine|Azacitidine tablets
45456478|NCT03593018|Drug|Romidepsin|Romidepsin injection
45456479|NCT03593018|Drug|Bendamustine|Bendamustine injection
45456480|NCT03593018|Drug|Gemcitabine|Gemcitabine injection
45982415|NCT00343343|Device|NovoFine® needle 4 mm|
45982416|NCT00453648|Other|White-fleshed sweet potatoes|
45982417|NCT00453648|Other|Orange-fleshed sweet potatoes (boiled)|
45982418|NCT00453648|Other|Orange-fleshed sweet potatoes (fried)|
45982419|NCT00453648|Other|WFSP and capsule of retinyl palmitate|
45982420|NCT00343421|Biological|PEDIACEL® and Prevenar®|0.5 mL each, IM (opposite thigh)
45982421|NCT00343421|Biological|Infanrix®-IPV+Hib and Prevenar®|0.5 mL each, IM (opposite thigh)
45982422|NCT00343499|Drug|valsartan|
45982423|NCT00453687|Drug|GSK233705|investigational drug
45982424|NCT00447291|Drug|Supplement: Omega-3 Fish Oil|
45982425|NCT00447291|Behavioral|Multi-Disciplinary Nutrition & Exercise program|
45982426|NCT04715360|Combination Product|autologous activated platelet-rich plasma|Patient received standard medication for COVID-19 management and autologous activated platelet-rich plasma on day 1, 3 and 5 while patient in ICU. On day 0, 4 and 6, hematology analysis, multicytokines measurement and thorax X-ray were done to each patient
45982427|NCT04715360|Drug|Avigan|Patient received avigan 2x1,600 mg for a day, followed by 2x600 mg for five consecutive days.
45982428|NCT00447369|Drug|Pregabalin|
45982429|NCT00447369|Drug|sodium valproate|
45982430|NCT00343616|Procedure|cognitive assessment|Cognitive function will be assessed using the CogState battery and the Cognitive Failures Questionnaire.
45982431|NCT00343616|Procedure|fatigue assessment and management|Fatigue will be evaluated using the Brief Fatigue Inventory.
45982432|NCT00343616|Procedure|psychologic distress|Psychologic distress will be evaluated using the General Health Questionnaire after cognitive testing.
45982433|NCT00343616|Procedure|quality-of-life assessment|Quality of life will be assessed using global linear analogue self-assessment (LASA) indicators for physical well-being, mood, coping effort (PACIS), perceived social support and subjective health estimation.
45982434|NCT00453726|Procedure|Non invasive mechanical ventilation|
45982435|NCT00343655|Drug|Atorvastatin|
45982436|NCT00453765|Drug|montelukast|montelukast, 8 weeks, once daily, 10 milligrams
45982437|NCT00453765|Drug|placebo|placebo
45982438|NCT00343733|Drug|OraVescent Fentanyl|
45982439|NCT00447408|Behavioral|Standard hemodialysis dietary instruction|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments.
46082913|NCT04258163|Drug|Capecitabine|1000-1250 mg/m 2 PO twice daily days 1-14, cycled every 28 days
46082914|NCT04258163|Drug|Liposomal doxorubicin|50 mg/m 2 IV day 1, cycled every 28 days
46082915|NCT04258163|Drug|Gemcitabine|800-1200 mg/m 2 IV days 1, 8, and 15, cycled every 28 days
45982440|NCT00447408|Behavioral|Behavioral counseling plus PDA-based self-monitoring of diet|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments. In addition they receive behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
45982441|NCT00343811|Drug|Modafinil|
45982442|NCT00453804|Drug|injectable naltrexone|
45982443|NCT00453804|Drug|oral naltrexone|
45832427|NCT04529070|Behavioral|standard of care|standard of care
45832428|NCT03153930|Behavioral|Walking breaks|In-Lab (full sample): participants will be asked to walk on a treadmill for 3 minutes every 30 minutes at a moderate pace during a 3-hour OGTT Free-living (sub-sample; N=12): participants will be prompted via an ActivPAL vtap monitor to walk for 3 minutes every time sedentary behavior lasts longer than 30 continuous minutes
45832429|NCT03153930|Behavioral|Sitting only|In-Lab (full sample): participants will remain seated for 3 hours during an OGTT Free-living (sub-sample; N=12): participants will perform their habitual sedentary behaviors
45832430|NCT05547750|Drug|Vitamin K2|Vitamin K2 is a fat-soluble and one of the body's indispensable vitamins. It is mainly synthesized by gut bacteria in the body and plays a role in the mitochondrial electron transport chain. It boosts calcium metabolism, acts on osteoblasts, and promotes bone tissue calcification. It also inhibits osteoclasts from causing bone resorption, thus increasing bone density, and preventing osteoporosis. Furthermore, it regulates the use of calcium and promotes the inhibition of vascular calcification by matrix Gla protein (MGP) activity. Vitamin K2 supplementation at recommended dosage does not affect vitamin K-dependent coagulation factors' activity. It does not enhance the carboxylation of prothrombin in healthy individuals. Vitamin K2 administration does not alter the hemostatic balance in healthy populations without anticoagulation treatment. Thus, vitamin K2 is deemed to have a good safety profile.
45672849|NCT05641103|Other|Patient with splenomegaly or splenectomy|No interventional study
45832431|NCT05547750|Drug|Placebo|Similar-looking placebo tablets
45832432|NCT04370106|Other|Social leg program|Usual care as described for the CG will also be provided to the IG. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by frequenting a social leg program.
45982444|NCT00343850|Drug|Asacol (mesalamine)|
45672850|NCT02710721|Other|Fasting|Patients realize a 60h-modified fasting (36h before and 24h after chemotherapy) with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al. Between chemotherapy a Mediterranean diet with nutrition training individually and in small groups by trained nutritionists at the Study Centre will be practiced.
45832433|NCT04321200|Diagnostic Test|PANDA Gym|Infants will lie supine on a flat surface and will be placed in the PANDA gym where they either move by themselves or will interact with an instrumented toy. We will collect video, mat, and toy data from PANDA gym under two conditions: 1) infants playing supine without a toy and 2) infants reach, grasp and kick of the new PANDA toy. A test session will proceed as follows: The infant will be placed on his or her back at a predetermined position on the gym mat for the 2-minute no toy condition. Next, the toy will be given to the baby and adjusted for the infant to reach or kick. A caregiver will be seated at the head of the baby (out of a baby's sight) to provide comfort if needed. Testing will be done in NICU or at daycare or the rehabilitation robotics lab at University of Pennsylvania.
45456481|NCT03590028|Other|Early Nephrology Consult (ENC)|The electronic risk prediction algorithm (ESTOP-AKI) will interface with electronic medical data to determine the likelihood for the patient to develop AKI. Early Nephrology Consult (ENC) will be implemented. A nephrologist will assess the subject and consult with their care team to advise a treatment plan during the hospitalization.
45672851|NCT02710721|Other|Control|Participants of the control group will receive an individual nutrition training and in small groups according to the Mediterranean diet.
45672852|NCT03903107|Procedure|Conventional fluoroscopy guided Conduction System Pacing(CSP)|conventional standard approach Conduction System Pacing(CSP) using fluoroscopy
45672853|NCT03903107|Procedure|Electroanatomic Mapping (Fluoroless) guided Conduction System Pacing(CSP)|Conduction System Pacing(CSP) using electroanatomic mapping system with no or minimal fluoroscopy
45982445|NCT00447486|Drug|GW842166|
45982446|NCT00343928|Other|Branched-chain amino acids|Participants will spend approximately 2 weeks in each phase over a 9-week period, during which they will receive an amino acid mixture and the placebo control condition.
45982447|NCT00453843|Device|rehabilitation robotics|sequence of intervention
45982448|NCT00453843|Procedure|Movement therapy|sequence of intervention
45982449|NCT00447525|Biological|REVAXIS®|
45982450|NCT00447525|Biological|DT-Polio®|
45982451|NCT00344006|Drug|chlorproguanil-dapsone-artesunate|
45982452|NCT00344006|Drug|artemether-lumefantrine|
45982453|NCT02273661|Drug|Liposomal amphotericin B (Ambisome®)|An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months
45982454|NCT02273661|Drug|placebo|An aerosol of isotonic saline x 1/ week will be administered during 6 months
45982455|NCT00447642|Drug|LX201|"LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant is 0.08 inch wide and 0.04 inch in height. The implants are flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded."
45982456|NCT00447642|Other|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
45982457|NCT00344123|Drug|Tipranavir/Ritonavir|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r."
45982458|NCT00344123|Drug|Rosuvastatin|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r.."
45982459|NCT00453882|Device|flostat (TM) System|
45982460|NCT00344201|Device|Tisseel fibrin adhesive|Intraoperative application to scleral bed and graft
45672854|NCT02673905|Other|Tissue Engineered Product|Implantation of tissue engineered products
45982461|NCT00453960|Dietary Supplement|Genivis|54 mg/day daily for 6 months
45672855|NCT04805333|Drug|Artemisia annua 450mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
45982462|NCT00453960|Drug|Norethisterone Acetate|tablets 10mg/day from day 16 to 25 of menstruation
45982463|NCT00453960|Other|placebo|tablets daily for 6 months
45982464|NCT00344240|Behavioral|Functional circuit training with lifestyle behavior|
45982465|NCT00447681|Drug|ILV-094|
45982466|NCT00454038|Device|HYPRO SORB F|resorbable, double layered, collagen membrane
45982467|NCT04715282|Procedure|Epley maneuver|Epley maneuver
45982468|NCT00454077|Procedure|radioiodine therapy after rhTSH|
45982469|NCT00447720|Behavioral|PATH|We have chosen to translate two proven prevention programs for delivery to the SMI populations by their case managers. These interventions are the Brief Counseling intervention from the Project Respect program and the Community-Based Outreach Program (CBOM). Together we will translate them into ongoing case management for SMI persons who also abuse substances in the Preventing AIDS through Health Project (PATH). Consistent with other findings regarding HIV infections among the SMI, in our preliminary studies we found that these individuals are at much higher risk within the population of persons being served in Philadelphia.
45982470|NCT00344474|Behavioral|PRE-Venture: Personality Risk Education|Motivational and Cognitive-Behavioural interventions targeting four personality risk factors for substance misuse. Two, 90-minute group sessions conducted at school with personality-matched peers and trained psychologists/councellors and co-facilitators.
45982471|NCT00447759|Drug|Celecoxib|200-400mg daily in divided doses
45982472|NCT00447759|Drug|Diclofenac|prescribed medication taken orally
45982473|NCT00344513|Drug|Beta-blockers including Carvedilol|
45982474|NCT00344513|Drug|ACE inhibitors|
45982475|NCT00454155|Drug|Opebacan|4 mg/kg continuous IV infusion for 30 minutes followed immediately by 6 mg/kg/day continuous IV infusion for 3 days
45832434|NCT04321200|Other|Mobile App|"The parent or legal guardian will be consented first via the virtual rounding mobile app. They will also be asked to fill out general surveys including, a demographic survey, and a case report form, and a user feedback survey that provides relevant information, on both the family's and infant's medical history and experience. (see the flow-chart for the app). Within the caregiver survey, we will request the pediatrician (or primary care physician) name. We believe that with the baby name, caregiver name, zip code, and physician name, we will be able to locate the physician if needed.~Parents or legal guardians or the research will be asked to collect video via the MOBILE app. They will be instructed to ensure that the infant lies supine in no more than one-layer of tight-fitting clothing (i.e. infant onesie) while calm and awake. In all cases, we will have video recordings of the baby. They will be asked to upload the video to the app."
45982476|NCT00344552|Drug|Paclitaxel|Injection solution, IV, 100mg/sqm, once weekly, 7 weeks and over
45456482|NCT03590028|Other|Standard of Care (SOC)|Subjects will receive nephrology consultation at the typical timepoint after symptoms of AKI appear.
45672856|NCT04805333|Drug|Artemisia annua 900mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
45672857|NCT04805333|Drug|Artemisia annua 1350mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
45832435|NCT04317612|Other|Active berry product|Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.
45832436|NCT04317612|Other|Reference product|Subjects should consume a reference product (isocaloric to active product) daily during the 12 week intervention period.
45832437|NCT04296006|Drug|Sustained Release d-amphetamine|Twice daily administration of active or placebo d-amphetamine
45982477|NCT00447798|Behavioral|Prevention Care Advocate|Prevention Care Advocate: 8 Session intervention combining cognitive-behavioral skill building & strengths based case management
45982478|NCT00447837|Drug|SPRC-AB01|90 mg/3 mL BID, 180 mg/3 mL bid, placebo
45982479|NCT00344591|Behavioral|Structured Ecosystems Therapy (SET)|
45982480|NCT00344591|Behavioral|Individually tailored intervention|
46082916|NCT04258163|Drug|Fulvestrant|500mg IH Days 0, 14, 28, then every 28 days
45982481|NCT00447915|Drug|ibandronic acid 0.5mg|0.5mg(i.v.)/month for 35 months
45982482|NCT00447915|Drug|RIS placebo|0 mg(p.o.)/day for 36 months
45982483|NCT00447915|Drug|1.0mg ibandronic acid|1.0mg(i.v.)/month for 35 months
45982484|NCT00447915|Drug|ibandronic acid placebo|0mg(i.v.)/month for 35 months
45982485|NCT00447915|Drug|2.5mg RIS|2.5 mg(p.o.)/day for 36 months
45982486|NCT00447915|Dietary Supplement|Calcium and Vitamine D3|Calcium 305 mg and Vitamine D3 200IU(p.o.)/day for 36 months
45982487|NCT00344630|Device|TAXUS Stent and Cypher Stent|
45982488|NCT03274830|Device|aneXys|150 patients with the aneXys cup
45982489|NCT00344669|Drug|Albendazole 400 mg, given 6 monthly|
45982490|NCT03274791|Diagnostic Test|Analysis of induced sputum|"Induced sputum was collected and analysed in the three arms (Healthy subjects, Never smokers with COPD and smokers with COPD) The volume of the sputum sample, was treated with an equal volume of 0.1% dithiothreitol. The samples were then vortexed and placed in a shaking water bath at 37°C for 15 min to ensure complete homogeneisation. The suspensions were centrifuged at 400× g and the sputum supernatant stored at -80°C until cytokines analysis. The cell pellet was resuspended in 0.5% bovine serum albumin in phosphate buffered saline and cytospin were made by putting 100 µL of the cell suspension in the funnels.~Slides for differential cell counts were stained with May-Grünwald Giemsa."
46082917|NCT04258163|Drug|Anastrozole|1mg PO qd
46082918|NCT04258163|Drug|Letrozole|2.5mg PO qd
46082919|NCT00942487|Drug|Nebilet|Trade-mark: Nebilet® (Berlin-Chemie Menarini) INN: nebivolol Dosage and route of administration: 5 mg tablets, o.d. for oral administration
45456483|NCT03587922|Device|Fantom|Treatment of den ovo coronary lesions
45672858|NCT04805333|Drug|Artemisia annua 1800mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
46082920|NCT00942487|Drug|Corvitol|Trade-mark: Corvitol (Berlin-Chemie Menarini) INN: metoprolol Dosage and route of administration: 50 mg tablets, b.d. (100 mg/day) for oral administration
45982491|NCT03274791|Diagnostic Test|Lung Function test|"All the subjects underwent pulmonary function tests (Healthy subjects, Never smokers with COPD and smokers with COPD).~Pulmonary function parameters were measured using a portable spirometer (Easy One ndd. Medizintechnik; Zurich, Switzerland) according to the ATS criteria (American Thoracic Society). Reversibility test was performed 15 min after inhalation of 400 µg of Salbutamol (Ventolin, GlaxoSmithKline, Middlesex, UK). All spirometry data were graded for quality and only tests that met high quality scores were used for the final analysis."
45982492|NCT03274791|Diagnostic Test|Enzyme-linked Immunosorbent Assay|"IL-8 and TNF-α were measured in the sputum supernatant of all the subjects (Healthy subjects, Never smokers with COPD and smokers with COPD).~Commercially available kits were used to detect IL-8 (Human IL-8 Immuno-Biological Laboratories ELISA Kit) and TNF-α (Human TNF-alpha Sigma-Aldrich ELISA Kit) concentrations in the sputum supernatants. The absorbance was measured at 450 nm. The lower limits detection were 2 pg/mL for IL-8 and 5 pg/mL for TNF-α. The intra assay coefficients of variability were 8.7% for IL-8 and 7.7% for TNF- α."
45982493|NCT00344708|Procedure|Transplantation of Tissue-Cultured Human Amniotic Epithelial Cells|
45982494|NCT03274713|Device|Electro-acupuncture|"Patients in this group will be treated by use of 6-7 local acupuncture points (ST34, ST35, ST36, EX-LE2, EX-LE5, GB33, GB34, SP9, SP10, LR7, LR8 and Ashi) and 2-3 distal points (GB31, GB36, GB39, GB41, ST40, ST41, LR3, BL60, SP6 and KI3). Needles will be stimulated manually for 10 seconds to achieve De Qi sensation and an electrical apparatus (HANS-200A acupoint nerve stimulator, Nanjing Jisheng Medical Co., Ltd. production, wave of 2/100Hz) will be then connected to the needles with alligator clips to stimulate the needles in pairs ST36-SP9/GB34 and ST34-SP10. The stimulus intensity will be increased until the patient reports a strong but comfortable intensity."
45982495|NCT03274713|Device|Manual acupuncture|Participants in the group have the same schedule as the electro-acupuncture group except that the electrical apparatus has working power indicator and sound without actual current output.
45982496|NCT00344747|Behavioral|dietary, behavioral, physical activity|
45672859|NCT04805333|Drug|Artemisia annua - recommended phase II dose|Artemisia annua will be self-administered via a preparation of decaffeinated coffee. The dose for this cohort will be based on analysis of previous cohorts.
45982497|NCT00344786|Drug|CNF2024 (BIIB021)|"Dose starting at 12.5 mg/d, p.o. as a once-daily dose for 21 days followed by a 1-week rest period.~Dose escalation will proceed according to the predetermined scheme until the maximum tolerated dose (MTD) is reached due to dose limiting toxicities (DLT) during the first course of treatment."
45672860|NCT05627219|Behavioral|Training and Education|Undergo training and education
45982498|NCT03274674|Other|I-PRF|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
45982499|NCT04715165|Drug|USG-STAP with bupivacaine and dexmedetomidine|Patients will receive USG-STAP block with bupivacaine and dexmedetomidine in both sides ten minutes before skin incision and intraperitoneal normal saline
45982500|NCT04715165|Drug|IP bupivacaine and dexmedetomidine|Patients will receive bupivacaine and dexmedetomidine through the intraperitoneal route and USG-STAP block with normal saline at the end of surgery
45982501|NCT00454233|Drug|YM543|Oral
45982502|NCT00454233|Drug|Metformin|Oral
45982503|NCT00454233|Drug|Placebo|oral
45982504|NCT04715477|Behavioral|Hospital Anxiety Depression Measure|Hospital Anxiety Depression Measure
45982505|NCT00448032|Drug|PPM-204|
46082921|NCT02792738|Behavioral|hypnosis|
45456484|NCT03570099|Drug|Naloxone Nasal Spray|Naloxone Nasal Spray will be distributed at the addiction centres.
46082922|NCT00611039|Drug|Darunavir 900mg + ritonavir 100 mg once a day|Darunavir 900mg + ritonavir 100 mg once a day
45456485|NCT03570099|Other|Historical control cohort|Historical data will be retrieved from quality registries.
45456486|NCT03550391|Drug|Memantine|20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg per week. Memantine should start at 5 mg, and then increased in 5 mg increments at the following schedule, depending on the patient's response and tolerance:
45456487|NCT03550391|Radiation|Hippocampal-avoidant (HA-WBRT) Radiotherapy|30Gy in 10 fractions
45456488|NCT03550391|Procedure|Stereotactic Radiosurgery (SRS)|18-20 or 22 Gy in single fraction
45456489|NCT03541720|Drug|18F-DA|18F-DA is an investigational PET radiotracer
45456490|NCT03529396|Drug|Chloroquine|Standard chloroquine (three days)
45456491|NCT03529396|Drug|Primaquine|Daily Primaquine (0.5 mg of base/kg/day for seven days) starting only at the fifth day post chloroquine initiation.
45456492|NCT03529396|Drug|Primaquine|Weekly primaquine (0.75 mg of base/kg/week for eight weeks) starting with first dose of chloroquine.
45456493|NCT03529396|Drug|Chloroquine|Weekly, once a week chloroquine (5 mg of base/kg/week for twelve weeks)
45456494|NCT03529396|Drug|Primaquine|Standard primaquine (0.5mg of base/kg/day for seven days) concomitant with chloroquine.
45672861|NCT05627219|Other|Educational Intervention|Receive educational booklet
45672862|NCT05627219|Procedure|Discussion|Attend discussion with peer genetic coach
45672863|NCT04790279|Drug|Amlodipine|Initiation of amlodipine 2.5 mg
45672864|NCT04790279|Drug|NIFEdipine ER|Initiation of nifedipine ER 30 mg
45672865|NCT04418843|Procedure|Standard Endoscopic Mucosal Resection|Use of injected colloidal or saline solution to raise a lesion prior to polypectomy snare closed over a polyp with electrocautery
45672866|NCT04418843|Procedure|Cold Snare Endoscopic Mucosal Resection|Use of injected colloidal or saline solution to raise a lesion prior to polypectomy snare closed over a polyp without electrocautery
46082923|NCT00611039|Drug|Darunavir 600mg + ritonavir 100mg twice day|Darunavir 600mg + ritonavir 100mg twice day
46082924|NCT00942565|Drug|tramadol/acetaminophen|
46082925|NCT00942565|Drug|acetaminophen|
46082926|NCT02792660|Device|Injeq IQ-Needle|Injeq IQ-Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
45982506|NCT04714931|Diagnostic Test|Sentinel lymph node detection|Tracer (Indocyanine green or blue dye) will be injected into the IP and utero-ovarian ligaments, after opening of the pelvic and paraaortic retroperitoneal spaces, sentinel lymph nodes which can be identified with the tracer involvement will be removed. Then, systematic lymphadenectomy will be performed according to the routine practice.
45982507|NCT00454272|Drug|Teicoplanin|
45672867|NCT02610023|Other|Questionnaire Administration|Complete the Willett FFQ, the Fred Hutchinson FFQ, and the CCAT
45982508|NCT00454272|Drug|Vancomycin|
45982509|NCT00448071|Drug|MTR107|
45982510|NCT00344825|Drug|Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864)|"Descriptive statistical methods applied for the whole study cohort and for subgroups according to QoL and the correlation of the following parameters: Age, Sex, Stage of disease, Time from first B-CLL diagnosis, number of previous B-CLL treatments, Reason of starting of the new B-CLL treatment (progression disease, relapse, no-response to the previous treatment, previous treatment toxicity), Therapeutic Regimen (Day Hospital, Hospital Admission, etc.), Type of Centre, B-CLL treatment lasting, Response to B-CLL treatment.~QoL at baseline, Change in QoL over time evaluated using an analysis of Variance."
45982511|NCT00448110|Drug|Intravenous Diclofenac (DIC075V)|Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels
45982512|NCT00448110|Drug|Intravenous Ketorolac|Intravenous Ketorolac
45672868|NCT02610023|Other|Laboratory Biomarker Analysis|Correlative studies
45982513|NCT00448110|Drug|placebo|placebo
45982514|NCT00344864|Device|LADARWave|
45982515|NCT00454311|Procedure|Biopsy of Day 3 Embryo|
45982516|NCT00454311|Procedure|· day embryo biopsy|
45982517|NCT00448149|Drug|RAD001|RAD001 will be administered orally once a day, daily, without interruption per 4 wk cycle for 2 cycles. MTD is established in Phase I portion of trial (2.5, 5 or 10mg). If responding, additional therapy will be given.
45982518|NCT00448149|Drug|Sorafenib|A dose of 400mg of Nexavar® will be administered orally twice a day, daily, without an interruption per 4 week cycle for 2 cycles. If responding, additional therapy will be given.
45672869|NCT02610023|Device|Spectroscopy|Undergo resonance Raman spectroscopy
45982519|NCT00344942|Drug|triamcinolone acetonide|220µg/day or a double spray into each nostril once daily for 12 weeks'treatment
45982520|NCT00344942|Drug|placebo|a double spray into each nostril once daily
45982521|NCT00454350|Drug|Hectorol (doxercalciferol injection)|
45982522|NCT00454350|Drug|Zemplar (Paricalcitol injection)|
45982523|NCT00448188|Procedure|central venous catheter application|
45982524|NCT00454389|Device|Epi-Rad90™ Ophthalmic System|A single procedure using the Epi-Rad90™ Ophthalmic System plus 2 injections of Lucentis administered 1 month apart
45982525|NCT00454389|Drug|ranibizumab|Lucentis injection administered monthly for the first 3 injections followed by quarterly injections
45982526|NCT00344981|Drug|Tenofovir|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir.
45982527|NCT00344981|Drug|Hydroxyurea|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir. Volunteers will continue on this regimen for 48 weeks. Patients will be monitored for immunological and virological parameters as well as the incidence of toxicity and side effects during the study. If a patient's viral load reaches >400 copies/ml on 3 consecutive measurements over a 6 week period, they will be terminated from the study and started back on their HAART.
45982528|NCT00448266|Drug|Intensified Cyclophophamide, Carboplatin and Thiotepa|2 courses of Intensified Cyclophophamide, Carboplatin and Thiotepa with PBPC support
45982529|NCT00448266|Drug|dose dense adriamycine and cyclophosphamide|dose dense adriamycine and cyclophosphamide, Q 2 weeks
45982530|NCT04715048|Drug|PrabotulinumtoxinA|Glabellar line correction
45982531|NCT04715048|Drug|Onabotulinum toxin A|Glabellar line correction
45982532|NCT00454428|Procedure|pulsatile intra-aortic balloon pump|
45982533|NCT00345020|Procedure|Deep Lamellar Endothelial Keratoplasty: Small Incision Technique|
46082927|NCT00942643|Device|CPAP machine|a machine delivers positive airway pressure into the upper airway via a nasal mask
46082928|NCT00945373|Drug|calcium dobesilate|2.5% gel
45456495|NCT03515837|Biological|pembrolizumab|IV infusion
45672870|NCT03877289|Drug|Oxybutynin|Oxybutynin is a tertiary amine anticholinergic. It exerts both antispasmodic and antimuscarinic activity on smooth muscle. It also exerts analgesic and local anaesthetic effects.
45672871|NCT03877289|Other|"Orasweet Liquid Placebo"|A formulated Oxybutynin placebo that is nearly identical in appearance, volume, weight, taste, and smell.
45672872|NCT03877289|Drug|Antibiotics|"All patients in treatment and control arms were treated as a co-intervention with an oral antibioitic, the type of which was chosen by the child's attending physician.~Possible prescribed antibiotics include: trimethoprim and sulfamethoxazole (Septra), Cefalotin, Cephalexin, Cefapirin, Cefdroxil, Cefazolin, Cefradine, Cefacetrile, Cefaloridine, Cefroxadine, Cefatrizine, Cefuroxime, Cefixime, amoxicillin/clavulanic acid (Clavulin), and Nitrofurantoin."
45672873|NCT03877055|Drug|Copanlisib|Treatment will be with intravenous copanlisib on days 1, 8, 15 of 28 day cycles.
45672874|NCT03877055|Drug|Ibrutinib|Oral ibrutinib daily in 28 day cycles. A cycle is defined as 28 days of therapy.
45672875|NCT04194047|Other|Transfusion|RBC transfusion (1 unit)
45672876|NCT04194047|Other|Crystalloids infusion|Infusion of 500 ml of balanced crystalloids
45832438|NCT04296006|Behavioral|Money|Three money values offered as alternatives to cocaine
45832439|NCT04244682|Device|Repetitive transcranial magnetic stimulation (rTMS)|In the rTMS procedure a small plastic coil will be placed next to the participant's head. The position of the coil will be guided by neuro-navigational software utilizing the individual's MRI scan. The coil will be placed over the relevant brain region using the Brainsight TMS-MRI co-registration system for visualizing the coil position with respect to the participant's individual MRI scan. The coil will then generate a series of repetitive magnetic pulses, and stimulation will occur, disrupting typical function of the targeted brain region.
45982534|NCT00454545|Drug|Atorvastatin|
45982535|NCT00345059|Drug|docetaxel|
45982536|NCT00345059|Drug|vinorelbine|
45982537|NCT00345059|Drug|gemcitabine|
45982538|NCT00345059|Drug|capecitabine|
45982539|NCT03274635|Behavioral|Desk-based pedaling device and pedaling incentives provided|Varying types of incentives, equivalent in monetary value, will be randomly assigned across the 6 arms to promote regular desk-based pedaling. A free desk-based pedaling device will be provided. Effects on amount of desk-based pedaling and work productivity will be evaluated.
45672877|NCT04792151|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents|The Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C and UP-A) are transdiagnostic, behavioral interventions for youth with emotional disorders, including anxiety, depression, obsessive-compulsive disorders, and irritability.
45982540|NCT00345098|Drug|SR58611A|
45982541|NCT00448305|Drug|EndoTAG-1 + paclitaxel|EndoTAG-1 22 mg/m² + Paclitaxel 70 mg/m² weekly
45982542|NCT00448305|Drug|EndoTAG-1|EndoTAG-1 44 mg/m² twice weekly
45982543|NCT00448305|Drug|Paclitaxel|Paclitaxel 90 mg/m² weekly
45982544|NCT00345137|Drug|Ng-monomethyl-L-arginine (drug)|
45982545|NCT00448383|Biological|adalimumab|40mg every other week
45982546|NCT00345215|Behavioral|High Sodium Diet|250-350 mmol
45982547|NCT00345215|Behavioral|Low Sodium Diet|25-35 mmol
45982548|NCT00448461|Drug|heparin|comparison between heparin and bivalirudin
45982549|NCT00448461|Drug|bivalirudin|comparison between heparin and bivalirudin
45982550|NCT00345410|Drug|AVE1625 B|
45982551|NCT00454623|Behavioral|drawing serum adiponectin level|
45982552|NCT00345449|Behavioral|Decision Aid|
45982553|NCT00454662|Drug|olmesartan medoxomil / amlodipine or azelnidipine|AT1 subtype angiotensin II receptor antagonist / calcium channel blocker : 5-40mg of olmesartan medoxomil / 2.5-5mg of amlodipine or 8-16mg of azelnidipine
45982554|NCT00454662|Drug|olmesartan medoxomil / low dose thiazide type drug|AT1 subtype angiotensin II receptor antagonist / low dose diuretic : 5-40mg of olmesartan medoxomil / low dose thiazide type drug
45982555|NCT00345527|Behavioral|Emotion and Behaviour Regulation Treatment (EBRT)|
45982556|NCT00345527|Behavioral|Cognitive Behavioural Therapy|
45456496|NCT03515837|Drug|pemetrexed|IV infusion
45456497|NCT03515837|Drug|carboplatin|IV infusion
45672878|NCT05554679|Drug|Metformin|Metformin is an oral insulin-sensitising medication that acts to decrease blood glucose concentrations. It inhibits pathways in the liver that stimulate glucose production and also acts to increase glucose uptake into skeletal muscle and fat cells . Metformin is commonly used in the treatment of type 2 diabetes mellitus and polycystic ovarian syndrome , and is being used increasingly in the treatment of gestational diabetes, having been shown to result in decreased rates of neonatal hypoglycaemia and no increased risk of adverse maternal outcomes when compared with insulin.
45982557|NCT00345566|Procedure|Nutrition composition|
45982558|NCT00345644|Drug|risedronate|risedronate sodium 35 mg tablets (once a week dose)
45982559|NCT00345644|Drug|risedronate placebo|placebo for risedronate tablets (once a week dose)
45982560|NCT00345722|Procedure|strawberry dietary intervention|
45982561|NCT00454701|Drug|Alefacept exposure|Observational
45982562|NCT00345761|Drug|Bevacizumab|7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)
45982563|NCT00345761|Drug|Oxaliplatin|130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)
45982564|NCT00345761|Drug|Capecitabine|2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
45982565|NCT00345800|Drug|Sodium Oxybate (Xyrem)|"Active Substance: Sodium Oxybate~Pharmaceutical form: Oral Solution~Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks~Route of administration: Oral"
45982566|NCT00454740|Drug|solifenacin succinate|Oral
45982567|NCT00345917|Device|Retinal transplantation instrument|
45982568|NCT00345917|Device|Fetal tissue.|
45982569|NCT03276897|Other|Nutriage SPF 30 day cream and Nutriage night cream (Difa Cooper S.p.a, Italy)|A fixed quantity of both cosmetic products was applied for an uninterrupted period of 3 months, on the face included the submental area (day cream at the morning and the night cream at the evening), preferentially always at the same hour, with a mild massage
45982570|NCT00345956|Biological|Human rotavirus liquid vaccine|
45982571|NCT03276858|Drug|CRN00808|Investigational drug
45982572|NCT03276858|Drug|Placebo Oral Solution|Placebo
45982573|NCT03276858|Drug|Midazolam oral solution|Midazolam as part of the drug-drug interaction arm of the study
45982574|NCT03276858|Drug|Placebo oral capsule|Placebo
45456498|NCT03515837|Drug|cisplatin|IV infusion
45456499|NCT03515837|Drug|saline solution|IV infusion
45982575|NCT00421187|Drug|Liposomal amphotericin B (AmBisome®)|
45982576|NCT00421187|Drug|Liposomal amphotericin B (AmBisome®)|
45982577|NCT00454896|Drug|VESIcare®|Oral
45982578|NCT00454896|Drug|placebo|Oral
45982579|NCT00421226|Drug|ACZ885|
45982580|NCT03276624|Procedure|CABG|surgical revascularization of stenosed coranary arteries using arterial and venous grafts.
45982581|NCT00346112|Procedure|psycho-educational|
45982582|NCT00346190|Drug|Alendronate|
45982583|NCT00454974|Device|Wearable artificial kidney|
45982584|NCT00346229|Biological|filgrastim|
45982585|NCT00346229|Biological|pegfilgrastim|
45982586|NCT00346229|Drug|lyso-thermosensitive liposomal doxorubicin(Thermodox)|
45982587|NCT00346229|Procedure|hyperthermia treatment|
45982588|NCT00455052|Drug|XMT-1001|XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD.
45982589|NCT00346385|Drug|BB-10901|dose escalation study, dose will vary per cohort. patients will receive an IV infusion once every three weeks.
45982590|NCT00448578|Drug|Quetiapine Fumarate|
45982591|NCT00448578|Drug|Lithium|
45982592|NCT00346424|Drug|Alfimeprase|
45982593|NCT03276507|Diagnostic Test|Pulmonary function studies|
45982594|NCT03276507|Diagnostic Test|Echocardiogram|
45982595|NCT03276507|Diagnostic Test|Electrocardiogram|
45982596|NCT03276507|Diagnostic Test|Chest radiography|
45982597|NCT03276507|Diagnostic Test|Blood test|
45982598|NCT03276507|Behavioral|Quality of life questionnaire|
45982599|NCT00346463|Drug|Allopurinol|
45982600|NCT00455091|Drug|Adefovir Dipivoxil and Lamivudine|Adefovir Dipivoxil 10mg/day x 36 months,Lamivudine 100 mg/day x 18 months#, when HBV DNA =/> 105 copies/mL and ALT > 2.0 x UNL
45982601|NCT00346502|Drug|20% betulinic acid ointment|
45982602|NCT00346502|Drug|BA|20% Betulinic Acid Ointment
45982603|NCT04699305|Device|ActiGraft|Whole blood clot (WBC) gel
45982604|NCT04699344|Diagnostic Test|The level of CNV|The extracted DNA from morning urine will be analyzed by PROUD to determine the level of CNV.
45982605|NCT00346580|Drug|Nelfinavir|
45982606|NCT00346619|Drug|Nelfinavir|
45982607|NCT00346658|Drug|magnesium|
45982608|NCT02273700|Drug|Rivaroxaban|Patients are observed during their first month of Rivaroxaban (Xarelto®) treatment, which is part of their routine care.
45982609|NCT02273778|Procedure|MRI Scan|
45982610|NCT02273778|Procedure|PET-CT Scan|
45982611|NCT02273778|Other|No intervention|
45982612|NCT00346736|Procedure|Acupuncture (Procedure)|
45982613|NCT00448656|Procedure|ablation of pulmonary veins by video assisted thoracic surgery|epicardial ablation using HIFU
45456500|NCT03479593|Diagnostic Test|CMR and OCT in NSTEMI patients with MVD|Lesions >50% stenosis i patients with NSTEMI are examined by OCT. All patients will have CMR performed prior to angiography
45832440|NCT04200768|Other|Prospective data and sample collection|Performance of measurements of adiposity, extra collection of blood samples
45982614|NCT02959658|Drug|Dimethyl fumarate|
45456501|NCT03462407|Behavioral|DAID|"The DAID intervention group will engage in imitation based dog training, using positive reinforcement training (operant conditioning) to teach their dog to copy the physical actions they demonstrate on the command Do it."
45456502|NCT03462407|Behavioral|Dog walking|Children will participate in dog walking. Trained assistants will teach the children to teach their dog basic commands. Dog walking will occur during the intervention phase and children will be encourage to walk their dogs at home.
45982615|NCT02959658|Drug|Placebo|Manufactured to mimic Dimethyl Fumarate capsules
45982616|NCT04698213|Drug|Axitinib Oral Tablet|"Axitinib is an orally bioavailable tyrosine kinase inhibitor currently approved in EU for treatment of patients affected by metastatic renal cell carcinoma (mRCC) progressed after another anti VEGFR-tyrosine kinase inhibitor (TKI).~Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect."
45982617|NCT04698213|Drug|Avelumab|Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity.
45982618|NCT00346814|Drug|intravitreal injection|
45982619|NCT02273817|Drug|Ciclesonide nasal spray, 50 μg per actuation.|"During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.~During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:~Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days."
45982620|NCT00346853|Drug|4-Methylpyrazole|15 mg/kg dose
45982621|NCT00346853|Other|saline|
45982622|NCT00448695|Procedure|MRI Targeted Focal Thermal Therapy of Prostate Cancer|The Interstitial Laser Thermal Therapy (LTT) procedure is similar to brachytherapy, with fibers and probes inserted trans-perineal using transrectal ultrasound guidance. Patients will be under general anesthetic, and the procedure is expected to last 3 hours. Patients will be able to return home the day of the procedure.
45982623|NCT00346892|Biological|Rotavirus (vaccine)|
45982624|NCT00448734|Drug|Picoplatin|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
45832441|NCT04404816|Drug|heliox|NIV-NAVA with a conventional gas mixture (air-oxygen) at baseline, 3 hours of NIV-NAVA with heliox and return to NIV-NAVA with air-oxygen.
45832442|NCT04077372|Behavioral|Serious Illness Conversation Guide (SICG)|The Serious Illness Conversation Guide (SICG) is a structured communication template designed to provide effective tool in initiating advanced care planning discussion with patients.
45832443|NCT04077372|Behavioral|Quality of Life (QOL) survey|Quality of life survey by questionnaire (FACT-G) given every three months
45832444|NCT04348968|Device|Total hip arthroplasty|"The THA surgical procedure involves replacing the head of the femur and acetabulum or socket with an artificial prosthesis. This system is composed of a femoral stem that is inserted into the femoral canal, a ball that attaches to the femoral stem, and an acetabular component or shell that replaces the acetabulum.~In this study, the acetabular component is the Zimmer Maxera Cup, which is a monoblock construct consisting of a pre-assembled shell and liner. The ceramic liner articulates with a ceramic femoral head for a ceramic-on-ceramic large diameter head articulation. The Maxera Cup is intended for single use only and is designed for reconstruction of the hip joint for conditions described in the inclusion and exclusion section of this protocol."
45982625|NCT00448734|Drug|docetaxel|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
45982626|NCT00346931|Procedure|Phacoemulsification, implantation of intraocular lens|
45982627|NCT00346931|Procedure|Phacoemulsification, Implantation of IOL, trabeculotomy|
45982628|NCT00346970|Drug|Extended-Release Niacin|Extended-Release Niacin tablets week 1-4 500 mg/d week 4-8 1000 mg/d week 9-12 1500 mg/d
45982629|NCT00346970|Drug|Placebo|Placebo tablets
45982630|NCT00455130|Drug|Inhaled mannitol|
45982631|NCT00347048|Drug|tacrolimus|oral
45982632|NCT00347048|Drug|Placebo|oral
45982633|NCT00448773|Behavioral|Online education|
45982634|NCT00455169|Biological|Trivalent Inactivated Influenza Vaccine|Influenza vaccine
45672879|NCT05494619|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight ≥ 40 kilograms (kg) and <100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Day 1, followed by crovalimab 340 mg SC injections on Days 2, 8, 15 and 22 in all participants.
45672880|NCT05494619|Drug|Placebo|Placebo will be administered IV on Day 1 at a dose of 1000 mg for participants with body weight ≥ 40 kg to < 100 kg, or 1500 mg for participants with body weight ≥ 100 kg. It will be administered SC on Days 2, 8, 15, and 22 at a dose 340 mg in all participants.
45982635|NCT00347087|Drug|Irbesartan|up-titration over 4 weeks to target dose 300 mg od
45982636|NCT00347165|Drug|bevacizumab intravitreal injection|
45832445|NCT01672398|Other|Telemonitoring plus self-management support|Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
45982637|NCT00455208|Drug|Cura-100|
45982638|NCT00455247|Drug|Glutamine|
45982639|NCT00347204|Drug|ketorolac (Acular LS)|
45982640|NCT00347204|Drug|Nepafenac (Nevanac)|
45982641|NCT00347243|Procedure|phacoemulsification (cataract surgery)|
46082929|NCT00945373|Procedure|pulsed dye laser|All study patients will be treated with 595 nm PDL (Vbeam, Candela Corp, Wayland, Mass) with an initial test spot using a fluence of 10 J/cm2, 7-mm spot size and 1.5-ms pulse duration. Based on the biologic response of the test area, the fluence will accordingly be adjusted up or down to find a fluence that produces a transient purpuric effect for a few seconds only.
45456503|NCT03449602|Device|Mini-thoracoscopy|Thoracoscopic pleural biopsy with the mini-thoracoscope
45456504|NCT03449602|Device|Conventional rigid thoraoscopy|Thoracoscopic pleural biopsy with the conventional rigid thoraoscope
45832446|NCT01672476|Drug|Placebo|Placebo
45832447|NCT01672476|Drug|Valsartan|Valsartan 80mg
45982642|NCT00448851|Biological|inhaled allergen challenge|Subjects will inhale gradually increasing concentrations of Dermatophagoides farinae until a 15% drop in FEV1 is noted
45982643|NCT00455286|Drug|Methotrexate|
45982644|NCT00455286|Drug|Methylprednisolone|
45982645|NCT00455286|Drug|Temozolomide|
45982646|NCT00455364|Drug|Voriconazole|
45458717|NCT01238965|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
45672881|NCT05494619|Drug|Intravenous immunoglobulin therapy|All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.
45832448|NCT01672476|Drug|Fimasartan|Fimasartan 30mg
45832449|NCT01672554|Drug|Quetiapine XR|Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
45982647|NCT00347321|Procedure|Dilatational Percutaneous tracheostomy|Dilatational Percutaneous tracheostomy
45982648|NCT00448929|Device|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
45982649|NCT00347399|Drug|bevacizumab intravitreal injection|
45982650|NCT00347399|Procedure|verteporfin photodynamic therapy|
45982651|NCT00455442|Drug|Mifepristone|
45982652|NCT00347477|Drug|HyperHAES vs. RA-solution/NaCl|
45982653|NCT00347516|Procedure|IOL calculation formula|
45982654|NCT00449085|Procedure|Electrophysiology|
45982655|NCT00449085|Device|CARTO™ XP EP Navigation System V9|
45982656|NCT00347555|Biological|Aluminum Phosphate|1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant; dosage 500 micrograms.
45982657|NCT00347555|Drug|Placebo|0.5 mL normal saline placebo. Sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride).
45982658|NCT00347555|Biological|EBA-175 RII-NG Malaria Vaccine|White, translucent, cloudy, nonparticulate liquid suspension. Recombinant Plasmodium falciparum erythrocyte-binding antigen 175 kDa Region II-nonglycosylated (EBA-175 RII-NG) absorbed to aluminum phosphate adjuvant; dosage levels 5, 20, 80, and 160 micrograms.
45982659|NCT00455598|Drug|ISIS 113715|doses of 100 and 200 mg per week
45982660|NCT00347594|Device|Next Generation Diagnostic Instrument (NGDI)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
45982661|NCT00347594|Device|Zyoptix Diagnostic Workstation (ZDW)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
45982662|NCT00347672|Biological|H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)|Live, attenuated recombinant H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca) vaccine (one of three doses)
45982663|NCT02956863|Procedure|Osteopathic manipulative treatment|Osteopathic manipulative treatment delivered on pragmatic way.
45672882|NCT03826043|Diagnostic Test|Blood sample analysis|Thrombophilia, blood count and coagulation count
45982664|NCT02956863|Procedure|Exercises|Exercise for stretching and strength for neck muscles
45982665|NCT00347711|Drug|Intravitreal injection|
45982666|NCT00455637|Biological|Botulinum toxin type A|
45982667|NCT00347750|Drug|Lopinavir pharmacokinetic/pharmacodynamic analysis|
45982668|NCT00455676|Procedure|Chevron osteotomy versus Scarf osteotomy|
45982669|NCT00347789|Procedure|Glaucoma surgery- Bleb revision|
45982670|NCT03276312|Device|Lipogems|Lipogems® is an innovative system that, starting from minimum quantities of autologous lipoaspirate, provides, with a minimal manipulation, a micro-fragmented and non-expanded adipose tissue product
45982671|NCT00347828|Drug|Moxifloxacin ophthalmic solution 0.5%|
45982672|NCT00347828|Drug|Gatifloxacin ophthalmic solution 0.3%|
45672883|NCT05474495|Other|Pelvic floor muscle training|Pelvic floor muscle training. Two sessions a week for 6 weeks, each session lasting 45 mins.
45982673|NCT00449124|Drug|Placebo|Injections of 0.5 mL of normal saline solution (0.9% NaCl).
45982674|NCT00449124|Biological|TG4040|Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10^6 PFU, TG4040 10^7 PFU and TG4040 10^8 PFU.
45982675|NCT00347867|Drug|Viagra administration in IUGR/PET pregnancies|
45982676|NCT00347906|Procedure|laser treatment|
45982677|NCT00449202|Drug|oleoyl-estrone (MP 101)|
45982678|NCT00347945|Procedure|Pencil Push-ups|
45672884|NCT05474495|Other|Transverse abdominas strength training|Transverse abdominas strength training will be given 5 days a week and continued for 6 weeks.
46082930|NCT02788994|Device|Endovis BA2 nail|"The EBA2 intramedullary nailing system is designed for the treatment of lateral proximal femoral fractures, and consists of a standard or medium length nail implantable with the same set of instruments.~The system has been designed to allow:~stable fracture synthesis for fast rehabilitation and early mobilization~an efficient set of instruments (only 11) for a swift, reproducible operating technique (just 7 surgical steps)"
45458718|NCT01238965|Genetic|western blotting|Correlative studies
45672885|NCT01583218|Drug|Betrixaban|"Betrixaban 80 mg PO once daily (QD) for 35 day + 7 days.~Enoxaparin Placebo: Once daily, 6-14 days"
45672886|NCT01583218|Drug|Enoxaparin|"Enoxaparin 40 mg subcutaneous (SC) QD for 10 ± 4 days.~Betrixaban Placebo: once daily, 35 days"
45672887|NCT01634555|Biological|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B) 8 milligrams per kilogram (mg/kg), administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle (except Cycle 1)
45672888|NCT01634555|Drug|Irinotecan|180 milligrams per square meter (mg/m²) administered IV on Day 1 of each cycle
45672889|NCT01634555|Drug|Folinic acid|400 mg/m² administered IV on Day 1 of each cycle
45832450|NCT03153696|Behavioral|Cellie Coping Kit Intervention|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support.
45832451|NCT03153540|Device|Active iTBS|Intermittent theta burst transcranial magnetic stimulation
45832452|NCT03153540|Device|Sham iTBS|Sham intervention
45832453|NCT05067582|Drug|L1-79|tyrosine hydroxylase inhibitor
45832454|NCT05033808|Drug|Epirubicin|Epirubicin is given once over 15 Minutes via a central line
45832455|NCT05033808|Drug|Placebo|NaCl is given once over 15 Minutes via a central line
45832456|NCT05027256|Device|Entia Liberty|Home Monitoring solution
45982679|NCT00347945|Procedure|Office-based Vision Therapy|
45982680|NCT00347945|Procedure|Placebo Office-based Vision Therapy|
45982681|NCT00455715|Drug|Sildenafil|1 capsule Sildenafil 50mg or Sildenafil 100mg or placebo taken at the time of study visit.
45982682|NCT00455754|Drug|Esomeprazole|
45982683|NCT00347984|Other|Systane Lubricant eye drops|
45982684|NCT00348023|Drug|Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%|
45832457|NCT01672632|Other|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
45982685|NCT00348062|Drug|Bimatoprost|
45982686|NCT00449241|Device|Acupuncture|
45982687|NCT00348101|Drug|Combined therapy with enoximone and esmolol|
45982688|NCT00455832|Procedure|peginterferon alpha and ribavirin|sperm collection
45982689|NCT00348179|Procedure|Measurement of vascular function per SphymgnoCor equipment|Pressure tonometer will be used on various vessels, non-invasive.
45982690|NCT00455871|Drug|reduced fluence photodynamic therapy with Visudyne|reduced fluence photodynamic therapy with visudyne
45982691|NCT00455871|Drug|Lucentis|Lucentis intravitreal injection
45982692|NCT00348218|Device|NeuroVision|
45982693|NCT00449280|Drug|Sorafenib|400mg BID (200 mg twice daily)
45982694|NCT00449280|Drug|Rapamycin|30mg once weekly
45982695|NCT00449280|Drug|Rapamycin|3mg once daily
45982696|NCT00348257|Device|Hair removal by laser/IPL device|
45982697|NCT00455910|Drug|Thalidomide|
45982698|NCT00348296|Drug|High-dose intravenous immunoglobulin (Venoglobulin-IH)|
45982699|NCT00449319|Procedure|Identification of appropriate therapies according to risks factors|
45982700|NCT00449319|Drug|Daunorubicine|
45672890|NCT01634555|Drug|5-Fluorouracil|400 mg/m² bolus over 2 to 4 minutes administered IV on Day 1 of each cycle, followed by 2400 mg/m² administered IV over 46 to 48 hours on Days 1 and 2 of each cycle
45672891|NCT04789733|Other|Tight pressure management|Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg, delayed resumption of chronic antihypertensive medications, and a target ward MAP ≥80 mmHg (tight pressure management)
45982701|NCT00449319|Procedure|Transplant|
45982702|NCT00348335|Drug|Cyclosporine 0.05%|
45982703|NCT00348335|Drug|Ocular lubricant|
45982704|NCT00449358|Procedure|apply methyl-ALA cream|
45982705|NCT00348413|Drug|Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo|
46082931|NCT02788994|Device|Dynamic Hip Screw (DHS)|"The DHS is designed to provide strong and stable internal fixation of a variety of intertrochanteric, subtrochanteric and basilar neck fractures, with minimal soft tissue irritation.~This Dynamic Hip Screw method is currently used and is a one off surgical fixation."
46082932|NCT00945451|Device|CK|Cyberknife Irradiation
46082933|NCT02797730|Behavioral|art-therapy sessions|
46082934|NCT02788916|Other|No Intervention|
45456505|NCT03436784|Behavioral|Indiana SNAP-Ed|First four Indiana SNAP-Ed nutrition education lessons served as the intervention
45456506|NCT03436563|Biological|Anti-PD-L1/TGFbetaRII Fusion Protein M7824|Given IV
45456507|NCT03432819|Behavioral|Siempre Seguiré|A culturally congruent CBT group intervention for HIV-positive LMSM, to include strategies for ART adherence and retention in HIV care.
45456508|NCT03426254|Biological|Injections Subcutaneously Talazoparib|Patients receive per day single dose of subcutaneous Injection contains 1 mg Talazoparib on days 1-28
45456509|NCT03426254|Drug|Oral capsules Talazoparib|Patients receive 1 mg of Talazoparib PO QD on days 1-28.
45456510|NCT03422536|Biological|Cetuximab|Given IV
45456511|NCT03422536|Drug|Ficlatuzumab|Given IV
45456512|NCT03411031|Drug|Elotuzumab|Elotuzumab according to dosing schedule outlined in treatment arms.
45456513|NCT03411031|Drug|Lenalidomide|Lenalidomide according to dosing schedule outlined in treatment arms.
45456514|NCT03411031|Drug|Dexamethasone|"Dexamethasone is a commercially available drug. The description, how supplied, and storage instructions for dexamethasone product are found in the prescribing information.~During the study, dexamethasone will be administered as premedication for elotuzumab as indicated in the package insert."
45672892|NCT04789733|Other|Routine pressure management|Routine intraoperative blood pressure management and immediate restart of antihypertensive medications.
45672893|NCT03810131|Other|'A Bite of ACT' (BOA)|An online Acceptance and Commitment Therapy transdiagnostic psychoeducational intervention called 'A Bite of ACT' (BOA)
45982706|NCT00348452|Drug|tramadol HCl ER; celecoxib|
45456515|NCT03410121|Device|IPolysite ® Mini série 3108 or Polysite ® Standard, série 4108.|Implantation of intravenous medical device in thoracic location
45456516|NCT03410121|Device|Vital Port®Minititanium|Implantation of intravenous medical device in humeral location
45456517|NCT03358017|Drug|Zoledronate|4 mg i.v. every 3/4 weeks for 6 months
45982707|NCT00449397|Drug|Quetiapine Fumarate|
45672894|NCT05355155|Drug|Bevacizumab Biosimilar IBI305|Patients received bevacizumab and FOLFOX4 every two weeks
45672895|NCT01634243|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
46082935|NCT04100655|Drug|GM-CSF|3ml GM-CSF gel will be irrigated into the uterine cavity immediately when hysteroscopy is complete. Then same dose gel will be given every other day twice
46082936|NCT04100655|Drug|17-ß estradiol|A hormone replace treatment by 17-ß estradiol (6mg per day) follows next cycle to prepare for embryo transfer
46082937|NCT00770289|Other|Cohort|Cohort (Patients diagnosed with MDD who are either changing treatment or have never received treatment).
46082938|NCT02797652|Procedure|Neoadjuvant chemotherapy before surgery|The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.
46082939|NCT02797652|Procedure|Surgery followed by adjuvant chemotherapy|The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
45456518|NCT03358017|Drug|Atorvastatin 80mg|80mg /die os for 6 months
45672896|NCT02402309|Drug|Active topical NS2 1% dermatologic cream|
45672897|NCT02402309|Drug|Vehicle placebo 0.0% NS2 dermatologic cream|
45832458|NCT04026984|Drug|Rifamycin SV-MMX|2 Rifamycin SV-MMX® 50 mg tablets b.i.d. plus ORT
45832459|NCT04026984|Drug|Placebo|Matching Placebo tablets
45982708|NCT00348491|Drug|Lumiracoxib|
45832460|NCT04019340|Other|Education|Usual care as described for the CG will also be provided to the IG. Wound size measurement, wound care, and questionnaires will be provided by the institute's nurses. Usual care will be enhanced by a pluridisciplinary educational program
45832461|NCT03992352|Diagnostic Test|Age 60+ with planned HCT for Hematologic Malignancy|questionnaires, geriatric assessments
45982709|NCT03274323|Device|iStent and travoprost or latanoprost|2 iStents will be inserted and patients will be started on travoprost or latanoprost following the procedure
45982710|NCT03274323|Procedure|Trabeculectomy|Standard trabeculectomy
45982711|NCT00348530|Drug|Verapamil|
45982712|NCT00449436|Drug|TRIZIVIR|TRIZIVIR
45982713|NCT00449436|Drug|Non-nucleoside reverse transcriptase inhibitor|Non-nucleoside reverse transcriptase inhibitor
45982714|NCT00449436|Drug|Boosted Protease Inhibitor|Boosted Protease Inhibitor
45982715|NCT00348569|Device|64 Channel VCT|
45982716|NCT03274284|Combination Product|chemoradiation|chemoradiation in case of T1G3 BC after BCG failure.
45982717|NCT00348608|Drug|iodixanol|
45982718|NCT03274245|Behavioral|Intervention Package|"Community Level:~Palla: songs and skits to increase knowledge of and motivation for latrine use, pit emptying, safe feces disposal;~Transect Walk: village walk to identify and mark feces in community;~Community meetings: sex-segregated meetings with village members to decide on an action plan to increase community cleanliness/reduce open defecation;~Wall painting: village map noting households that use latrines always.~Sub-Community level:~Mothers meeting: For caregivers with children under age 5, to provide knowledge of and hardware for safe child feces disposal.~Household Level:~Household visits: to those with latrines to motivate use;~Latrine repairs: for households with non-functional latrines to make functional."
45982719|NCT03274245|Other|Qualitative Research|"For villages receiving the intervention package, investigators will engage community members through qualitative interviews to gain their perception of the intervention, what they thought of the intervention activities, what information they recall, what aspects they enjoyed or disliked, if they had barriers to attendance or participation.~For the three villages not receiving the intervention, investigators will conduct qualitative interviews to determine additional barriers and determinants of latrine use to identify other potential intervention strategies."
45982720|NCT00348647|Behavioral|physical training program to prevent injuries|
45982721|NCT00456027|Drug|rhGAD65 formulated in Alhydrogel® (Diamyd®)|20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart
45982722|NCT00348725|Drug|fenofibrate and metformin fixed combination (drug)|
45982723|NCT00456066|Device|Export Aspiration System|Patients scheduled for emergency angioplasty
45982724|NCT00348764|Drug|lauromacrogol|
45832462|NCT03945240|Procedure|Group 1 -- using Pinnacle Series Laser Device|"Utilizing the Pinnacle Series Laser by Aspen Laser Systems, investigators will apply 635-780nm, 10 mW cw, ~ 5-105 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~Subgroup 1: 10 minutes at 5 mW~Subgroup 2: 10 minutes at 15 mW~Subgroup 3: 10 minutes at 32 mW~Subgroup 4: 15 minutes at 5 mW~Subgroup 5: 15 minutes at 15 mW~Subgroup 6: 15 minutes at 32 mW"
45982725|NCT00456105|Behavioral|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician|See Detailed Description.
45982726|NCT00456105|Behavioral|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team|See detailed description.
45456519|NCT03358017|Drug|Standard neoadjuvant cht|Standard neoadjuvant cht chosen by the investigator and administered according to clinical practice
45456520|NCT03314805|Drug|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), 3 days via i.v. infusion per chemotherapy cycle
45456521|NCT03314805|Drug|Placebo|500 ml saline, 3 days via i.v. infusion per chemotherapy cycle
45456522|NCT03314805|Procedure|EC Chemotherapy|Epirubicin plus Cyclophosphamide every 21 days
45456523|NCT03289351|Drug|Piperacillin, Tazobactam Drug Combination|Single drug therapy
45982727|NCT00456105|Behavioral|Subjects without diabetes will have their blood glucose levels monitored while in the hospital|See detailed description.
45982728|NCT03276156|Drug|Apatinib plus S-1|Drug:Apatinib (425 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (500 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (675mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (750 mg/d) + S-1 (80mg to 120 mg);
45982729|NCT00348842|Procedure|Newcastle Virus|
45982730|NCT00456144|Drug|Gonadotropin Releasing Hormone Agonist Therapy|Given either for 24 months and 6 months
45982731|NCT00456183|Biological|MVA 85A|
45982732|NCT00348920|Procedure|High Spinal and General Anesthesia|Spinal bupivacaine 0.75% in dextrose, 6 mls (45mg) and preservative free morphine 3 mcg/kg (to a maximum of 300 mcg).
45982733|NCT00348959|Behavioral|'Open Window' Project|"Open Window' is an entirely art based intervention comprising a multimedia system that uses a combination of video projectors, audio speakers and bespoke software to make images appear as a 'virtual window' on the wall of the patients' room. Artists use mobile phone cameras and camcorders to record the images that are sent to the unit over the internet and via mobile phone networks. Original music composed for the project may also accompany the images as they appear.~Artists are commissioned to create work for the 'Open Window' project and are aware of the nature of the viewer and the context in which the art will be shown. The art in 'Open Window' encourages the viewer to think about and engage in what they see from their own personal frame of reference."
45982734|NCT00449514|Drug|tamoxifen|
45982735|NCT00449514|Drug|clomiphene citrate|
45982736|NCT00348998|Biological|bevacizumab|
45672898|NCT04815317|Other|Auditive stimulation|"The auditory stimulation will consist of listening to relaxing pieces of music from MP3 files from the International Center for Music Therapy (Noisy le Grand, France).~Listening will be done through noise-cancelling headphones (PLANTRONICS, Gamecom 780, Santa Cruz, California, USA) for 10 minutes."
45982737|NCT00348998|Drug|bicalutamide|
45982738|NCT00348998|Drug|goserelin acetate|
45982739|NCT00348998|Radiation|radiation therapy|
45982740|NCT00456222|Behavioral|Disrupting or changing the timing or the duration of sleep|Disrupting or changing the timing or the duration of sleep
45982741|NCT00349037|Biological|Trivalent DNA vaccine with and without pPJV2012 administered by PMED|
45982742|NCT00449553|Drug|Pioglitazone and sulphonylurea|Pioglitazone 15 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
45982743|NCT00449553|Drug|Pioglitazone and sulphonylurea|Pioglitazone 30 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
45982744|NCT00449553|Drug|Pioglitazone and metformin|Pioglitazone 15 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
45982745|NCT00449553|Drug|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
46082940|NCT02797496|Other|Asymmetric Motor Strengthening|"In the Asymmetric Motor Strengthening program, the principle is to concomitantly reinforce the body openers and stretch the body closers. One alternates two types of practice during a session. Active exercises consist of fatiguing series of rapid alternating movements against light weights working on movements of extension/abduction/external rotation/supination. Stretch postures consists of short 1-2 minutes bouts of flexor/internal rotator/adductor/pronator stretch. The duration of rehabilitation program is 8 weeks."
46082941|NCT02797496|Other|Conventional therapy|Conventional therapy will include general stretch, strengthening and balance exercises, respiratory exercises and relaxation methods.
46082942|NCT02788448|Device|VIVASURE CLOSURE DEVICE|Large hole closure device
46082943|NCT00556933|Drug|rabbit anti-thymocyte globulin|A single 6 mg/kg dose of rATG administered intravenously over 24 hours, beginning before kidney transplantation. Administration of the drug is begun as early as practical, usually after general anesthesia has been established but before surgery has started. The rATG is therefore administered for about two hours before blood flow is restored to the kidney undergoing transplantation.
45456524|NCT03282396|Drug|Ibrutinib|Given PO
45456525|NCT03280667|Drug|Pembrolizumab plus denosumab|Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D
45456526|NCT03272347|Drug|Islatravir|Islatravir at 0.25 mg, 0.75 mg or 2.25 mg is orally administered QD in capsule form for up to 52 weeks. After Week 60 a selected open label dose may be administered.
45456527|NCT03272347|Drug|Placebo to Islatravir|Placebo to islatravir is orally administered QD in capsule form for up to 52 weeks
45456528|NCT03272347|Drug|Doravirine|Doravirine 100 mg is orally administered QD in tablet form for up to 144 weeks
45672899|NCT04815317|Other|Sensitive stimulation|Sensitive stimulation will consist of administering fresh air to the patient's face by means of a fan without blades (DYSON AM01, Malmesbury, UK) for 10 minutes.
45982746|NCT00449592|Drug|Zinc|Oral Zincol 1 Tab TID from day -6/-7 until discharge
45982747|NCT00449592|Drug|Placebo|Oral placebo 1 Tab TID from day -6/-7 until discharge
45982748|NCT00349076|Drug|5-FU and oxaliplatin|"Preoperative radiochemotherapy:~Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35~Adjuvant Chemotherapy:~Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours repeat day 15, 8 cycles"
45982749|NCT00349076|Drug|5-FU|"Preoperative radiochemotherapy:~5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d~Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles"
45982750|NCT00349115|Drug|Thalidomide|
45982751|NCT00456339|Drug|Prednisolone and amoxicillin/clavulanate|Prednisolone 1mg/kg QD for 5 days Amoxicillin/clavulanate 45mg/Kg/d divided BID for 10 days
45982752|NCT00349193|Drug|laquinimod 0.3|laquinimod 0.3mg
45982753|NCT00349193|Drug|laquinimod 0.6|laquinimod 0.6mg
45982754|NCT00349193|Other|Placebo|Blinded Placebo
45982755|NCT00449709|Drug|GSK221149|
45982756|NCT00421421|Drug|Dutasteride|
45982757|NCT03274206|Biological|BLS-ILB-E710c|BLS-ILB-E710c 250mg/capsule
45982758|NCT03274206|Drug|Placebo|BLS-ILB-E710c-placebo
45982759|NCT00421460|Drug|Testosterone Undecanoate,1000mg|duration for 4 injections
45982760|NCT00349232|Behavioral|lifestyle intervention (diet and physical activity)|
45982761|NCT00449826|Procedure|Computed Tomographic Angiography|CT scan
45982762|NCT00349271|Procedure|Stem cell|Stem cell
45982763|NCT00349271|Drug|Filgrastime (G-CSF)|Filgrastime (G-CSF)
45982764|NCT00349271|Drug|Standart therapy|All drug with clinical evidence of benefical effect in Chagas disease
45982765|NCT00456417|Drug|123-I MNI-187 Injection and Imaging Procedures|
45982766|NCT00349310|Drug|Pramipexole|
45982767|NCT03274167|Drug|Gabapentin 300mg|
45982768|NCT03274167|Drug|Placebo oral capsule|
45982769|NCT00349427|Drug|Rosiglitazone 4 mg|
45982770|NCT00449943|Procedure|Computed Tomographic Angiography|CT scan
45982771|NCT00449943|Procedure|Myocardial Perfusion Imaging Scan|SPECT
45982772|NCT00349505|Procedure|hyper thermic chemo + surgery|
45982773|NCT00349583|Drug|Topical Cyclosporine, Tears|
45982774|NCT00449982|Drug|Polyphenon E Ointment 10%, Polyphenon E Ointment 15%|
45982775|NCT00349661|Drug|impact on VASP test|
45982776|NCT00456651|Device|CPAP (Continuous Positive Airway Pressure)|
45982777|NCT00349700|Procedure|Compression: 2 weeks four layer bandages, then stockings|
45456529|NCT03272347|Drug|Placebo to Doravirine|Placebo to Doravirine is orally administered QD in tablet form for up to 52 weeks
45982778|NCT00349700|Procedure|debridement|
45982779|NCT00349700|Procedure|Actisorb plus (r) + Trionic(r)/ Allevyn (r)|
45982780|NCT00450021|Drug|[(11)C] MePPEP|
45982781|NCT00349739|Drug|Anecortave Acetate|Dosage: 0.5ml of 30mg/ml(15 mg) or 60mg/ml(30mg) Duration of action: 159-180 days
45456530|NCT03272347|Drug|Lamivudine|Lamivudine 300 mg is orally administered QD in tablet form for up to 52 weeks
45982782|NCT00456690|Other|Nutritional recommendations|Nutritional status assessment including complete endocrine and lipid laboratory profile and after one year of nutritional follow up a secondary assessment will be done
45982783|NCT00349817|Behavioral|web-based learning, didactic lecture and role-play|
45982784|NCT00450060|Device|lumbar puncture with Quincke-design needles|
45982785|NCT00450060|Device|lumbar puncture with Sprotte-design needles|
45982786|NCT00349856|Device|Biofinity|Soft contact lens
45456531|NCT03272347|Drug|Placebo to Lamivudine|Placebo to Lamivudine is orally administered QD in tablet form for up to 52 weeks
45456532|NCT03272347|Drug|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|Fixed dose combination of 100 mg doravirine + 300 mg lamivudine + 300 mg tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 144 weeks.
45456533|NCT03272347|Drug|Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|Placebo to doravirine/lamivudine/tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 52 weeks
45456534|NCT03272347|Drug|Doravirine/Islatravir|Fixed dose combination of islatravir 0.75 mg/doravirine 100 mg orally administered QD in tablet form for 48 weeks
45456535|NCT03259568|Device|Repetitive TMS|1-10 Hertz rTMS will be administered
45456536|NCT03251300|Drug|daytime dosing of mirabegron|All OAB female patients will receive daytime dosing (08:00 AM) of mirabegron
45456537|NCT03251300|Drug|nighttime dosing of mirabegron|All OAB female patients will receive nighttime dosing (08:00 PM) of mirabegron
45982787|NCT00456729|Drug|Metronidazole|
45982788|NCT00456729|Procedure|Blood tests|
45982789|NCT00349895|Device|Coronary stent implantation|Percutaneous Coronary Intervention
45982790|NCT00349934|Biological|IMP321|"This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).~Three IMP321 dose levels (250 µg, 1,250 µg and 6,250 µg) will be evaluated in three cohorts of 8 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 24 weeks (12 s.c. injections in total), separated by 13-day intervals free of IMP321 administration.~The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy."
45982791|NCT00450099|Drug|bupivacaine|0.125% bupivacaine in a volume determined according to the biased coin up-down sequential allocation model, starting at 8mL.
45982792|NCT00450138|Drug|ZD6474 (vandetanib)|once daily oral dose
45982793|NCT00450138|Drug|Cisplatin|intravenous infusion
45456538|NCT03239470|Biological|Cohort 1: 1.0 x 10^8 PolyTregs|Each participant will receive a target cell dose of 1.0 x 10^8 polyclonal Tregs.
45982794|NCT00450138|Radiation|Radiation|radiation of head and neck
45982795|NCT00350051|Drug|Sagopilone (ZK 219477) + prednisone|Chemotherapy for hormone refractory prostate cancer; 16mg/m2 (up to 32mg/m2 max) IV on day 1 or each 21 day cycle for 6 cycles or until progression or unacceptable toxicity.
45982796|NCT00350090|Drug|Epoetin Alfa|
45982797|NCT04699110|Drug|Adrenaline|Treatment group will receive adrenaline (100 to 400 mcg) for the treatment of No-reflow
45982798|NCT04699110|Drug|Adenosine|Control group will receive adenosine (100 to 400 mcg)
45982799|NCT04698759|Other|No Intervention|no Intervention
45982800|NCT00350168|Drug|valsartan + amlodipine|
45982801|NCT03274089|Device|Kiosk intervention group|"SEEK automates the management of patients with stable well-controlled chronic disease. SEEK has the following capabilities:~Collects patient information using patient-specific identification~Prompts the user for answers to screening questions for acute conditions~Measures relevant physiological parameters: blood pressure, height, weight; and calculates body mass index~Triages patients based on responses to screening questions, physiological parameters and blood test results~Provides recommendations to the patient on the care plan, self management and lifestyle choices"
45982802|NCT00350246|Procedure|Laser Refractive Surgery|
45982803|NCT00456924|Drug|VA2914|
45982804|NCT00350285|Behavioral|Motivational enhancement therapy|Personal feedback with counselor using motivational interviewing strategies.
45982805|NCT00350285|Behavioral|Marijuana education|Information about health and behavioral effects of marijuana use.
45982806|NCT00105534|Drug|AzaSite|"1.0% AzaSite contains 1.0% azithromycin, sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. AzaSite was prescribed as a single topical drop to the infected~eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days."
45982807|NCT00105534|Other|Vehicle|Vehicle contains sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. Vehicle was prescribed as a single topical drop to the infected eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days.
45982808|NCT00350441|Drug|Sildenafil Citrate|
45982809|NCT00350480|Drug|Provera|
45982810|NCT00350480|Drug|Combination Birth Control pills|
45982811|NCT00456963|Behavioral|Diet|total fat < 5%, saturated fat < 10%, vegetables, fruit
45982812|NCT00456963|Behavioral|Moderate exercise|30 min at least 5 times/week
45982813|NCT00456963|Drug|enalapril tablets|one Enalapril 10mg tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet once daily until the end of the randomized treatment phase
45982814|NCT00456963|Drug|placebo tablets|one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
45982815|NCT00456963|Drug|Losartan Tablets|one Losartan 50mg tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet once daily until the end of the randomized treatment phase.
45982816|NCT00350597|Drug|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|
45982817|NCT00457080|Device|Alaris ETCO2 monitor - cont. resp. rate, & apnea events|
45982818|NCT00350753|Drug|Erlotinib and bevacizumab|Erlotonib 150 mg daily bevacizumab 10 mg/kg every 14 days
45982819|NCT00457119|Drug|RAD001|5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm
45982820|NCT00350831|Drug|XL820|
45982821|NCT00350909|Behavioral|brief intervention (cognitive-behavioral therapy)|Consists of 60 minute individual sessions delivered with a therapist using a motivational interviewing (MI) style. Session 1 focuses on eliciting information about the students' substance use and related consequences based on the assessment, their perception of level of willingness to change, examining the cause and benefits of change using the decisional balance exercise, and discussing what goals for change the student would like to select and pursue. Session 2 reviewed the students' progress with the agreed upon goals, identifying high risk situations associated with clients difficulty in achieving the goals, discussing strategies to address barriers toward goal attainment, reviewing where the client is in the stage of change process, and negotiating either the continuation of goals or advancing to more ambitious goals of substance use reduction. Session 3 involved delivering the same MI interviewing style to the primary parent or guardian (student is not present).
46082944|NCT00556933|Drug|mycophenolate mofetil|Patients are switched approximately 6 months after kidney transplantation from maintenance immunosuppression with tacrolimus and sirolimus to maintenance with mycophenolate mofetil and sirolimus. The drug is administered orally, taken daily, with dose adjusted in proportion to measured blood levels, and is required indefinitely to prevent rejection of the transplanted kidney.
45982822|NCT00350948|Drug|Telcyta|Day 1 of 28 day Cycle.
45982823|NCT00350948|Drug|Liposomal Doxorubicin|Day 1 of 28 Day Cycle. 50 mg/m2
45982824|NCT00450567|Procedure|computed tomography|
45982825|NCT00450567|Procedure|positron emission tomography|
45982826|NCT00450567|Radiation|fludeoxyglucose F 18|
45982827|NCT00457158|Device|ALN optional filter|J1 : ALN optional filter M3 : ALN optional filter removed
45982828|NCT00350987|Behavioral|a strategy based on PCT guided AB therapy|In this study a strategy based on PCT guided AB therapy with enforced guideline implementation will be compared.
45982829|NCT00421499|Drug|dark chocolate|
45982830|NCT00421538|Drug|nadroparine calcium|Once-daily injection of 171 U/Kg/day of nadroparine calcium for 6 weeks.
46082945|NCT00556933|Drug|rabbit anti-thymocyte globulin|6 mg/kg rabbit anti-thymocyte globulin delivered in 4 doses of 1.5 mg/kg each, the first administered at the time of kidney transplantation. Subsequent doses are administered on days 2, 4, and 6.
46082946|NCT00556933|Drug|sirolimus|Oral maintenance immunosuppressant administered daily, dose adjusted according to measured serum trough levels, continued indefinitely to prevent kidney rejection
46082947|NCT00556933|Drug|tacrolimus|Oral maintenance immunosuppressant, taken daily, dose adjusted to maintain target blood trough levels, required indefinitely to prevent kidney rejection.
45456539|NCT03239470|Biological|Cohort 2: 2.5x10^8 PolyTregs|Each participant will receive a target cell dose of 2.5x10^8 polyclonal Tregs.
45982831|NCT00421538|Drug|Placebo|Once-daily injectable placebo (sterilized NaCL 0.9%) for 6 weeks
46082948|NCT04100889|Other|No Intervention|There is no intervention for this study.
45982832|NCT03276039|Diagnostic Test|plasma pentraxin-3|Plasma pentraxin-3 was measured using ELISA
45982833|NCT04714697|Drug|Cabometyx|Cabometyx 60mg once daily, oral , up to Progression disease
45982834|NCT03275961|Behavioral|Stress Management and Resiliency Training|Subjects will undergo an 8 week behavioral program. Treatment will consist of weekly group therapy sessions in small groups with core practices to apply the principles of SMART.
45982835|NCT00351026|Drug|Methadone|short-term methadone maintenance
45982836|NCT00351065|Drug|SK3530|
45982837|NCT00457314|Behavioral|Exercise|Regular exercise training
46082949|NCT02792348|Other|Laboratory biomarker analysis on urine sample|Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance
46082950|NCT03985215|Other|Questionnaires|Pediatric Quality of Life Inventory questionnaire. Self-designed questionnaire.
46082951|NCT02792426|Drug|Research ENDS S-TA-U001|
46082952|NCT02792426|Drug|Nicorette Inhalator|
46082953|NCT02797418|Behavioral|Cognitive remediation program|"Comparison between a cognitive remediation program (Cognitus and Me) (groupe 1) and a training group of fine motor skills (group 2)"
45458719|NCT01238965|Other|laboratory biomarker analysis|Correlative studies
45982838|NCT04714658|Other|Therapeutic Education|"Each patient will participate in 1 to 3 PTE sessions.~st group collective workshop : allow the patient to better understand autoimmune~nd workshop : fatigue and techniques that enable its best management.~rd workshop : improving the management of the emotions generated by myasthenia. It allows patients to express their experiences of the disease in front of a group, to talk about their difficulties in their relationships and mobilize their resources to promote exchanges."
45982839|NCT00457353|Drug|Bacillus Clausii|For 5 days
45982840|NCT00457353|Other|Oral rehydration therapy|For 5 days
45672900|NCT04815317|Other|Auditory control|"The auditory control condition will consist of listening to a pink noise. The pink noise, like the white noise, is a normalized noise. The sound produced on a TV set that is out of adjustment during the snow effect is a representative example of such noise. Pink noise is a random signal whose power spectral density decreases by 3dB per octave. This signal is closer to the sensitivity of the ear than white noise."
45982841|NCT00351104|Drug|Ketoprofen Topical Patch 20%|
45982842|NCT03275922|Drug|Placebo ZNS|Placebo Zolmitriptan Nasal Spray
45982843|NCT03275922|Drug|ZNS|Zolmitriptan Nasal Spray
45982844|NCT00351143|Drug|salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training|Salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training will be provided to intervention group in Period 2.
45982845|NCT00351143|Drug|salmeterol/fluticasone propionate 50/250 µg|Salmeterol/fluticasone propionate 50/250 µg will be administered to control group in Period 2
45982846|NCT00457431|Procedure|Mild therapeutic hypothermia|Mild therapeutic hypothermia will be performed by any methods applicable in the hospitals
45982847|NCT00351221|Drug|rhIGF-1/rhIGFBP-3|
45672901|NCT04815317|Other|Sensitive control|The sensitive control condition will be achieved by administering fresh air on the calf.
45672902|NCT01542034|Drug|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
45672903|NCT01542034|Drug|Placebo|Phosphate buffered saline placebo for injection
45672904|NCT04815083|Drug|Aminolevulinic Acid Hydrochloride|PD G 506 A for oral solution (aminolevulinic acid [ALA] hydrochloride [HCl] granules for oral solution) is administered as a single dose (20 mg/kg body weight) approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.
45672905|NCT04815083|Device|Eagle V1.2 Imaging System|Fluorescence imaging camera and associated accessories used to view and capture fluorescence and white light images and videos of the surgical cavity and excised tissue specimens during the surgical procedure.
45672906|NCT04815083|Drug|Placebo|Oral placebo is administered as a single dose approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.
45832463|NCT03945240|Procedure|Group 2 -- using Pinnacle Series Laser Device|"Utilizing the Pinnacle Series Laser by Aspen Laser Systems, we will apply 830nm, 30- 50mW cw, ~ 1-20 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~Subgroup 1: 10 minutes at 5 mW~Subgroup 2: 10 minutes at 15 mW~Subgroup 3: 10 minutes at 32 mW~Subgroup 4: 15 minutes at 5 mW~Subgroup 5: 15 minutes at 15 mW~Subgroup 6: 15 minutes at 32 mW"
45832464|NCT03945240|Procedure|Group 3 -- using Phoenix Thera-Lase Device|"Utilizing the Phoenix Thera-Lase by Phoenix Thera-Lase Systems, we will apply 904nm, 40mW (pulsed) @10000Hz, ~ 4-18 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~Subgroup 1: 10 minutes at 5 mW~Subgroup 2: 10 minutes at 15 mW~Subgroup 3: 10 minutes at 32 mW~Subgroup 4: 15 minutes at 5 mW~Subgroup 5: 15 minutes at 15 mW~Subgroup 6: 15 minutes at 32 mW"
45832465|NCT03153618|Other|VALIDATE system|Will be invited to interact with VALIDATE to answer questions about Family Cancer history and some personal medical and lifestyle history. Based on responses, VALIDATE will determine if they meet referral indications for cancer predisposition assessment.
45832466|NCT03833934|Diagnostic Test|Plasma Next Generation Sequencing (NGS)|Liquid biospys
45832467|NCT04275882|Diagnostic Test|Electrocardiogram|There will be no new intervention performed for the patients.
45832468|NCT04404348|Behavioral|Cognitive Training|Exercises used will be: Mind Bender, Divided Attention, Freeze Frame, Mixed Signals, Target Tracker, To Do List.
45832469|NCT04404348|Behavioral|Placebo Control|Games are drawn from the set of research control games provided by Posit Science-Brain HQ.
45982848|NCT00457470|Drug|AG-014699|
45982849|NCT00351260|Procedure|Coronary Angioplasty|
45458720|NCT01238965|Genetic|gene expression analysis|Correlative studies
45982850|NCT04698642|Drug|CBL-514|Both sides of the abdominal region will receive CBL-514.
45982851|NCT00450606|Procedure|Balneotherapy and hydrotherapy|
45982852|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
45982853|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
45982854|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
45982855|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
45982856|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
45982857|NCT00351494|Procedure|contrast enhanced ultrasonography|"Three contrast-enhanced ultrasonography : before embolization, after one day and after 6 months.~Abdominal route 2.4 ml sonovue per injection / bolus"
45982858|NCT00351494|Procedure|embolization|Intervention is described in the case report form for each patient
45982859|NCT00450645|Drug|low molecular weight heparin|LMWH were continued for additional 6 months after detection of residual vein thrombosis (6 months after the index deep vein thrombosis) in patients randomized to group A. LMWH are stopped in patients randomized to group B or in those patients without residual vein thrombosis after 6 months from the index DVT. Dosage of LMWH are 75% of the therapeutic dosage (almost 1 mg/Kg every 12 hours)
45982860|NCT04714307|Diagnostic Test|SCA3/MJD molecular diagnosis|Double-blind molecular diagnosis for determination of the presence of the mutation.
45982861|NCT04714307|Diagnostic Test|Cognitive Testing|"Cross-sectional Cognitive evaluation with~CCAS Scale~Trail-Making Test parts A and B~Stroop Color-Word Test"
45982862|NCT04714307|Diagnostic Test|Psychiatric Evaluation|Cross-sectional Psychiatric evaluation with Hamilton-Anxiety and Hamilton-Depression rating scales.
46082954|NCT00770211|Drug|IncobotulinumtoxinA (Xeomin) (20 Units)|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.
46082955|NCT00770211|Drug|Placebo|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
46082956|NCT02792036|Drug|Carboplatin|"Carboplatin will be given intravitreally. Participants are eligible to receive up to 8 injections per eye (once approximately every 14 days) based on lack of toxicity and evidence of tumor response. An injection of consolidation will be given once a complete response is observed. If further regression of stable seeds is noted, additional injections (up to 8 maximum per eye) will be provided at the discretion of the treating team. Injections could be repeated if vitreous recurrence occurs from another source (and patient has not reached 8 max limit per eye)."
46082957|NCT02792036|Drug|Maxitrol®|Maxitrol® contains neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension and is for topical ophthalmic use only. It will be given for continued use for five days following the carboplatin injection to prevent infection.
46082958|NCT02792036|Procedure|Focal Therapy|Simultaneously with intravitreal carboplatin, focal therapy will be applied as needed to eradicate the retinal source of the seeding as well as all epiretinal and subretinal active tumors at the discretion of the treating ocular oncologist.
46082959|NCT02792036|Procedure|Plaque Radiotherapy|Participants who have developed progressive disease despite focal (non-irradiative) therapy will receive brachytherapy determined by consensus between the treating ophthalmologist and radiation oncologist.
45458721|NCT01238965|Genetic|RNA analysis|Correlative studies
45458722|NCT01238965|Genetic|polymorphism analysis|Correlative studies
45672907|NCT01564732|Device|Standard-LAGB|The laparoscopic adjustable gastric banding (LAGB) procedure is a safe, effective, and durable treatment option for refractory morbid obesity and its related health consequences.5 This minimally invasive technique is now a popular approach for bariatric surgery, and it offers obvious advantages such as decreased operating time, shorter hospital stay (often same day surgery), and favorable complication rates as compared with other bariatric procedures.
45982863|NCT04714307|Diagnostic Test|Clinical Neurological Evaluation|Cross-sectional neurological evaluation with standardized clinical scales - SARA, SCAFI and CCFS.
45982864|NCT04714307|Diagnostic Test|Emotional Attribution Evaluation|Cross-sectional emotional attribution evaluation by means of the Reading the Mind in the Eyes Test (RMET).
45982865|NCT04714307|Diagnostic Test|Activities of Daily Living|Cross-sectional evaluation of Activities of Daily Living (ADLs) by means of Friedreich Ataxia Rating Scale Part II.
45982866|NCT00457548|Behavioral|Brief Telephone Counseling for risky aclohol use|Two brief sessions (30-40 minutes) of brief counseling using a motivational interviewing approach. The counseling session are delivered by telephone and focus on the alcohol use of inuured ED patients who randomize into the treatment arm of the study. Patient who randomize into the controla rm of the study receive standard emergency department care only plus study assessments.
45982867|NCT00351572|Procedure|Cell Search Assay|
45982868|NCT00450684|Device|Implantation and testing of CRT|Biventricular pacing for 12 weeks (CRT ON) followed by automatic rhythmicity or the original, conventional biventricular stimulation for 12 weeks (CRT OFF), then returning to biventricular pacing (CRT ON).
45982869|NCT00450684|Device|Implantation and testing of CRT|Automatic rhythmicity or original conventional biventricular stimulation for 12 weeks (CRT OFF) followed by biventricular pacing (CRT ON).
45982870|NCT00351689|Behavioral|dietary supplement|
45982871|NCT04714268|Procedure|Aorto-iliac endovascular procedure|Percutaneous procedure with stent placement
45982872|NCT00457782|Drug|KW-2478|Daily intravenous KW-2478 for 5 days in 14-day cycles, ascending dose cohorts
45982873|NCT00351182|Drug|Telithromycin|
45982874|NCT00351182|Drug|Doxycycline|
45982875|NCT00457860|Drug|Immunotoxin therapy|
45456540|NCT03228693|Procedure|Biopsy and/or triamcinolone injection|Subjects will have their blood drawn during the first study visit. Subsequently, a punch biopsy and/or triamcinolone injection will be given based on group timeline.
45982876|NCT00457860|Drug|CAT-8015 immunotoxin|
45982877|NCT00457860|Procedure|Biological therapy|
45982878|NCT00351806|Drug|Erigeron breviscapus injection|
45982879|NCT00351806|Drug|hua tuo zai zao wan (a herbal medicine pill)|
45982880|NCT00351806|Drug|Compound stroke herbal medicine (8 herbal)|
45982881|NCT00457899|Drug|Quetiapine IR (Immediate Release)|oral
45982882|NCT00457938|Other|low-fat diet ( Still recruiting )|This study will compare 10% fat versus 35% fat diets in terms if effect on liver fat, triglycerides adn other metabolic parameters.
45982883|NCT00457938|Other|Diet|10 % versus 35 % fat in diet
45982884|NCT00351845|Behavioral|Low carbohydrate diet (behavior)|
45982885|NCT00458016|Drug|MB07803|Daily oral administration
45982886|NCT00458016|Drug|Placebo|Daily oral administration
45982887|NCT00351884|Drug|Vildagliptin AM|
45982888|NCT00351884|Drug|vildagliptin pm|
45982889|NCT00351884|Drug|placebo|
45982890|NCT00458055|Drug|Atorvastatin; Fenofibrate; Niacin|Atorvastatin 20 mg; Fenofibrate 200 mg; Niacin 2g used sequentially for 8 weeks, after 4 weeks washout.
45982891|NCT00351923|Biological|MeMuRu-OKA (study vaccine)|
45982892|NCT00450762|Drug|gemcitabine|
45982893|NCT00450762|Drug|carboplatin|
45982894|NCT00351962|Procedure|Fractionated Stereotactic Radiotherapy|
45982895|NCT03275883|Procedure|Aortohepatic Conduit|Placement of an interposition graft between hepatic artery and aorta during liver transplantation
45832470|NCT01672944|Other|TBCCN-developed educational materials|Participants will be asked to view the educational materials developed by TBCCN, in either English or Spanish depending on the RCT in which they are enrolled. These materials include a DVD and a booklet that were developed to enhance community members' understanding and awareness of biospecimen collection and biobanking from healthy individuals.
45832471|NCT01672944|Other|NCI-developed educational materials|"Participants will be asked to view the English biobanking educational Brochure entitled Providing your Tissue for Research: What you need to Know, or Spanish brochure entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica."
45832472|NCT03152994|Other|Checking fasting blood glucose(FBG)|This is an observational study,fasting blood glucose(FBG) of each patient will be checked every six months.
45982896|NCT00352079|Biological|BCG vaccine|"Intravesical BCG:~Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)"
45982897|NCT00352079|Drug|gefitinib|Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)
45982898|NCT00352079|Procedure|quality-of-life assessment|Each cycle and at 3 and 6 months after treatment discontinuation
45982899|NCT04698798|Procedure|Muscle Biopsy|Patients will be treated for SARS-CoV-2 symptoms on the intensive care unit. During this treatment two muscle biopsies will be obtained with an interval of seven days between them.
45982900|NCT00352157|Behavioral|Revival Soy Dietary Supplement|
45982901|NCT00450840|Drug|Simvastatin|
45982902|NCT00352196|Drug|Risperidone|12 weeks of treatment with risperidone 0.25 to 11 mg per day.
45982903|NCT00352196|Other|Magnetic Resonance Spectroscopy|Subjects will receive a standard MRS to assess the concentrations and ratios of brain metabolites N-acetylaspartate, creatine, phosphocreatine, and choline.
45982904|NCT00450879|Drug|Pazopanib Hydrochloride|Given PO
45982905|NCT00450879|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
45982906|NCT00450879|Other|Pharmacological Study|Correlative studies
46082960|NCT00942721|Behavioral|Web-based CBT for PPD|A cognitive behavioral intervention that will provide participants with the following: online interactive tools to clarify their attitudes and reasons for wanting to change, information about some of the symptoms and mechanisms associated with feeling depressed during the postpartum period, and guidance on using behavioral and cognitive strategies proven to help reduce depressive symptoms
46082961|NCT00942799|Drug|Genz-644282 (28-day dosing schedule)|Genz-644282 will be administered as a 60-minute IV infusion. The initial dose of Genz-644282 will be 0.5 mg/m2 and will be administered once weekly for 3 consecutive weeks on Day 1, Day 8, and Day 15 of the 28 day cycle. Each 28-day period will represent one treatment cycle. Study drug will continue to be given until disease progression or unacceptable toxicity is observed.
45982907|NCT00450879|Other|Laboratory Biomarker Analysis|Correlative studies
45982908|NCT00352235|Drug|KRN7000|
45982909|NCT00352313|Drug|ATN-161|Given IV
45982910|NCT00352313|Drug|carboplatin|Given IV
45982911|NCT00352352|Procedure|Tongue Acupuncture (Procedure)|
45982912|NCT00450957|Dietary Supplement|lycopene|Given orally
45982913|NCT00450957|Other|pharmacological study|Correlative studies
45982914|NCT00352391|Other|Assessments|At Months 6, 12, 18, 24, 30, and 36, complete medical history will be recorded, and a physical exam will be performed by either a doctor or a nurse. At each of these visits, blood will be drawn for routine tests (about 3 teaspoons) and for research purposes (about 4 teaspoons). Also, a chest x-ray and a chest CT will be done at these visits.
45982915|NCT03275844|Procedure|Physical activity assessment|Assessment of Moderate-to-vigorous physical activity
45982916|NCT00352430|Drug|Nitric Oxide/INP Pulse Delivery|
45982917|NCT00352430|Drug|Nitric Oxide/INO Pulse Delivery|
45982918|NCT00450996|Drug|Topical Steroids|
45982919|NCT00352469|Drug|Seroquel XR|Day 1 and 2 Seroquel XR 50 mg; Day 3-4 Seroquel XR 150mg;Day 5-42 Seroquel XR 300-400mg
45982920|NCT00451074|Drug|Gentamicin infusions twice a week for six months|Gentamicin infusions twice a week
45982921|NCT00352508|Behavioral|Dietary advice|
45982922|NCT00465621|Drug|Xalatan|
45982923|NCT00465660|Behavioral|Progressive resistance training|
45982924|NCT00465699|Drug|Topical B12 0.07%|
45982925|NCT00352625|Drug|Ketoprofen Topical Patch 20%|
45982926|NCT00465777|Behavioral|Guideline adherence and financial incentive|
45982927|NCT00352703|Drug|Kepivance (Palifermin)|
45982928|NCT00465855|Combination Product|Hyperbaric Oxygen (HBO2) - 3 sessions|"Before patients are offered an opportunity to participate in this study, they will receive a single hyperbaric oxygen session. During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~For the second and third hyperbaric oxygen sessions, the subject will breathe 100% oxygen delivered at 2 atm abs for 90 minutes with two 5-minute air breathing periods."
45982929|NCT00465855|Combination Product|Hyperbaric Oxygen (HBO2) - 1 session|"During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~The second and third chamber sessions are sham sessions: room air delivered at 1.0 atmospheres absolute for 90 minutes with two sham 5-minute air breathing periods."
45982930|NCT00352742|Drug|ATN-224 + bortezomib|ATN-224 and bortezomib dose to be determined in Phase I portion of study
45982931|NCT00465933|Drug|AIDA|
45982932|NCT00352820|Behavioral|Interview|Recorded face-to-face session.
45982933|NCT00352820|Behavioral|Questionnaire|Written survey lasting approximately 30 minutes.
45982934|NCT00352859|Drug|Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon|Continue sorafenib with addition of gemcitabine or interferon
45982935|NCT00352859|Drug|Gemcitabine or Interferon (only)|Discontinue Sorafenib and receive Gemcitabine or Interferon only
45982936|NCT00352898|Biological|MeMuRu-OKA (study vac)|
45982937|NCT00352898|Biological|MMR, Varicella vacc (control)|
45982938|NCT00105183|Biological|Placebo|placebo infusion, single
45982939|NCT00105183|Biological|EZ-2053|single IV infusion, 9 mg/kg
46082962|NCT00942799|Drug|Genz-644282 (21-day dosing schedule)|The starting dose of Genz-644282 for the 21-day schedule will be prescriptive and will be based on review of available safety data from the 28-day dosing schedule by the Investigator and Sponsor. Patients will receive Genz-644282 once-weekly for 2 consecutive weeks on Day 1 and Day 8 of a 21 day cycle. Each 21-day period will represent 1 treatment cycle. Patients enrolled in subsequent cohorts will receive higher doses until the MTD is established.
46082963|NCT02788682|Genetic|WT+ Diplotype|3 or 4 vitamin D binding protein major alleles
46082964|NCT04100265|Device|Panel 1 - High risk for postoperative ileus (VIPUN Gastric Monitoring System)|The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed during surgery.
46082965|NCT04100265|Device|Panel 2 - Postoperative ileus arm with investigational device (VIPUN Gastric Monitoring System)|The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed upon the manifestation of clinical signs of postoperative ileus.
46082966|NCT02788526|Procedure|Adjuvant TACE|1~2 cycles TACE were performed as adjuvant therapy after radical hepatectomy
46082967|NCT02788526|Procedure|Follow-up|Patients received just follow-up to monitor the recurrence of HCC
46082968|NCT02601417|Other|Ignoring result of bile culture|Patients in the trial arm will do bile cultures which will not be considered when choosing antibiotics.
46082969|NCT02797340|Other|Blood draws and urine samples for metformin concentration measurements|
46082970|NCT02797340|Drug|Metformin|
46082971|NCT00928187|Drug|emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)|Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening
46082972|NCT00928187|Drug|abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)|Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight < 60 kg, 400 mg if weight > 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening
45456541|NCT03228693|Procedure|Excisional Biopsy|Complete excision of an earlobe keloid will be taken.
45456542|NCT03201458|Drug|Atezolizumab|Given IV
45456543|NCT03201458|Procedure|Biopsy|Undergo tumor biopsy
45456544|NCT03201458|Procedure|Biospecimen Collection|Undergo collection of blood samples
45832473|NCT01673100|Behavioral|Physical Activity Promotion Intervention|Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. Depending on the subject's responses to the questionnaires at baseline (stages and processes of change) they will be given tips to help them engage in physical activity (such as messages to increase their self-efficacy or confidence, walking with a friend or spouse, breaking up physical activity bouts into 10 minutes bouts, etc.) and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
45456545|NCT03201458|Drug|Cobimetinib|Given PO
45456546|NCT03201458|Procedure|Computed Tomography|Undergo CT
45456547|NCT03201458|Procedure|Magnetic Resonance Imaging|Undergo MRI
45672908|NCT01564732|Device|Plicated-LAGB|"At the time of LAGB placement, plication sutures can be placed along the body & greater curvature of the stomach to tighten and cinch up the stomach in a sleeve-like orientation. It was recently reported that this modified technique of plicated LAGB could result in lower band slippage complication rates and faster, early weight loss."
45672909|NCT04104646|Drug|CHF6563|Sublingual CHF6563 administration at starting dose of 10 µg/Kg q8
45672910|NCT04104646|Drug|Morphine|Oral morphine administration at starting dose of 0.07 mg/Kg q4
45832474|NCT03670524|Other|Greenness as a therapeutic intervention|Greenness to be used as a therapeutic intervention
45456548|NCT03198039|Behavioral|Meditation|Isha Kriya (IK) meditation approximately 12 minutes, twice a day
45458723|NCT02320630|Drug|Entanercept|Both Entanercept and MTX were given to patients for 60weeks (Week0-Week60).
45982940|NCT00105183|Biological|EZ-2053 5mg/kg|single IV infusion, 5mg/kg
45982941|NCT00466089|Drug|Erlotinib (Tarceva®)|Erlotinib (Tarceva®), 150mg/day p.o during 6 months.
45982942|NCT04714346|Other|no interventions|there is no intervention
45982943|NCT00466128|Drug|indomethacin|Indomethacin 50mg PO followed by 25mg PO q6hrs
45832475|NCT02653248|Radiation|Stereotactic Body Radiation Therapy|Patients will receive 5 fractions of SBRT radiation, treated every other day. No more than three fractions per week. Total dose will depend on cohort. Cohort 1: 40Gy, Cohort 2: 45 Gy, Cohort 3: 50 Gy.
45982944|NCT00466245|Drug|MVA Smallpox vaccine|Two 0.5mL subcutaneous injections, separated by 28 days
45982945|NCT00466245|Drug|Placebo|Two 0.5mL subcutaneous injections, separated by 28 days
45982946|NCT00353015|Drug|Cisplatin|Cisplatin 25 mg/m2 IV days 1, 8 of a 21-day cycle
45982947|NCT00353015|Drug|Irinotecan|Irinotecan 65 mg/m2 IV days 1, 8 of a 21-day cycle
45982948|NCT00466284|Drug|Tarceva (erlotinib)|
45982949|NCT00353054|Drug|Caltrate® 600 + D|
45982950|NCT00353054|Behavioral|Weight loss intervention|
45982951|NCT00466362|Behavioral|The Evje Model|
45982952|NCT00353093|Procedure|Ultrasonography of the deep vein system of the legs|
45982953|NCT00466401|Drug|Simvastatin|
45982954|NCT00466401|Drug|Ezetimibe|
45982955|NCT00353249|Behavioral|Adapted cognitive behavioral therapy (CBT)|Adapted CBT is a group treatment for PTSD and will occur two times per week for 4 weeks. The sessions will last 90-minutes and will be led by a therapist and co-therapist.
45982956|NCT00466479|Drug|brimonidine|
45832476|NCT04764240|Procedure|R0 resection with lymphadenectomy|Patients received a surgical R0 resection; patients who received an R1 or R2 resection were excluded.
45832477|NCT03024528|Behavioral|CPOT assessment|Polish version of Critical care pain observation tool validation.
45982957|NCT00466479|Procedure|laser trabeculoplasty|
45982958|NCT03272256|Drug|IM156|Sequential 3+3 design.
45982959|NCT00353288|Biological|MeMuRu-OKA (study vacc)|
45832478|NCT04903314|Drug|Xcopri|Xcopri will be administered orally not to exceed 400mg/day adult equivalent
45832479|NCT03021954|Biological|Platelet Rich Plasma|Platelet rich plasma is produced by obtaining patient's whole blood and processed by centrifugation and activation by CaCl2.
45832480|NCT03153072|Biological|Assess the absorption of oral amiodarone|Evaluate the pharmacokinetics of oral amiodarone solution at 15 mg / mL after oral administration
45832481|NCT01673334|Device|Fine Needle Aspiration (FNA) and Core biopsy (FNB)|
45832482|NCT03609372|Behavioral|The STOP-HPV Trial 6: Maintenance|In this period, study team support will be withdrawn after previous bundled intervention (including HPV vaccine communication, performance feedback and provider prompts) was given to reduce MOs and increase HPV vaccination rates.
45982960|NCT00353288|Biological|MMR, Varicella vacc (control)|
45982961|NCT03272100|Procedure|flap|after flap incision , the sinus cavity was opened and then the membrane raised up
45982962|NCT00353327|Procedure|Plasma infusion|
45982963|NCT00353405|Behavioral|Social Skills Training|Social skills training includes two 8-hour sexual health skills building sessions conducted in the community.
45982964|NCT00353405|Behavioral|Mass media|Mass media provides messages that support sexual health skills.
45982965|NCT00353405|Behavioral|Control|Control group received no social skills training and no media mass media messages.
45982966|NCT00466518|Drug|Administration of sitagliptin|Sitagliptin 100 mg daily for 3 months
45982967|NCT00458094|Behavioral|Physical activity intervention with peer support (PA+PS)|Participants in the PA+PS group will have three exercise sessions each week for 4 months, which will include group exercise classes and open gym hours for supervised individual exercise. They will also meet with a peer educator once a week for 15 minutes. Peer educators will provide emotional, informational, instrumental, and appraisal support that is aimed to motivate participants to partake in the exercise sessions.
45982968|NCT00458094|Behavioral|Physical activity intervention without peer support (PA)|Participants in the PA group will attend the three weekly exercise sessions for 4 months but will not attend meetings with the peer educator.
45982969|NCT04714580|Other|Animal Fun Program|This program permits the operators to propose different activities, by following the needing of the children. As the name of this program suggests, all the activities involve an animal description, and ask the children to move like this animal, in a proper, correct and supervised way.
45982970|NCT00353561|Drug|Boric|Gelatin capsules filled with 600 mg of boric acid
45982971|NCT00353561|Drug|Fluconazole|150 mg oral fluconazole gives once in 14 days
45982972|NCT00466596|Drug|Gamma Tocopherol|14 days of daily high dose (1200mg) Gamma Tocopherol. Subjects will receive a 14 day supply (28 softgel capsules, approximately 600 grams of gT each) dispensed by the University of North Carolina Hospitals Investigational Drug Service and provided by YASOO Medical.
45982973|NCT00458172|Behavioral|Assessment of beliefs and attitudes|
45982974|NCT00466635|Drug|GT267-004 (tolevamer potassium sodium)|
45982975|NCT00353678|Drug|YM150|
45982976|NCT00458250|Procedure|Haploidentical hematopoietic stem cell transplantation|
45982977|NCT00458250|Drug|Busulfan|
45982978|NCT00458250|Drug|Cyclophosphamide|
45982979|NCT00458250|Drug|CAMPATH-1H|
45982980|NCT00458250|Drug|Cyclosporin A|
45982981|NCT00458250|Drug|Methotrexate|
45982982|NCT02959736|Behavioral|MATADOC and CRS-R|Behavioural assessments for Disorders of Consciousness
45982983|NCT00466674|Drug|reduced intensity conditioning|reduced intensity conditioning for allogenic transplant
45982984|NCT00353717|Drug|cetuximab paclitaxel|weekly iv paclitaxel 80 mg/m2 and cetuximab 250 mg /m2
45982985|NCT00466713|Drug|Rosiglitazone therapy|
45982986|NCT00353756|Drug|C326, IL-6 Inhibitory Avimer protein|
45982987|NCT00466791|Drug|Methylphenidate Transdermal System|Placebo
45982988|NCT00353912|Drug|valsartan + amlodipine|
45982989|NCT00458289|Drug|Lanthanum carbonate (chewed vs. crushed)|single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder
45982990|NCT00466830|Other|questionnaire administration|
45982991|NCT00466830|Procedure|management of therapy complications|
45982992|NCT00466830|Procedure|psychosocial assessment and care|
45982993|NCT00466830|Procedure|quality-of-life assessment|
45982994|NCT00353990|Drug|Insulin Aspart|
45982995|NCT00458328|Drug|Z-338|
45982996|NCT00354068|Drug|imatinib mesylate|
45982997|NCT00354068|Drug|temozolomide|
45982998|NCT00354068|Other|pharmacological study|
45982999|NCT00466869|Drug|Betahistine|
45983000|NCT00354146|Drug|tipifarnib (R115777)|
45983001|NCT00458367|Drug|Open label risperidone long acting injectable|intramuscular injections every 2 weeks for 26 weeks, flexible dose 25 to 50 mg
45983002|NCT00466908|Device|Pentacam and IOL Master|Pentacam and IOL Master
45983003|NCT00354185|Drug|tanespimycin|Given IV
45983004|NCT00354185|Drug|belinostat|Given IV
45983005|NCT00354185|Other|laboratory biomarker analysis|Correlative studies
45983006|NCT00354185|Other|pharmacological study|Correlative studies
45983007|NCT00458445|Drug|SPD465|
45983008|NCT00458445|Other|Placebo|Placebo is a material that may look similar to SPD465, however, contains no active drug.
45983009|NCT00354263|Biological|IMP321|This study is a single centre, single blind, placebo (step 1) or reference (step 2) randomised study. Healthy young male volunteers will receive single ascending dose of IMP321 in each step (4 doses tested: 3, 10, 30 and 100 µg). In step 1, IMP321 will be given alone and tested versus placebo (physiological saline). In step 2, the association IMP321 + Agrippal (commercially available flu vaccine) will be tested versus Agrippal alone.
45983010|NCT00354263|Biological|saline|saline injected alone in step 1 or mixed with Aggripal in step 2
45983011|NCT00466986|Drug|Abraxane|Carboplatin day1 every 28days. Abraxane day1,8,15 every 28days
45983012|NCT00354302|Dietary Supplement|calcium carbonate|
46082973|NCT00928187|Drug|emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)|Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food
45983013|NCT00354302|Dietary Supplement|calcium citrate|
45672911|NCT04104646|Drug|CHF6563 matched placebo|Sublingual CHF6563 matched placebo administration
45672912|NCT04104646|Drug|Morphine matched placebo|Oral morphine matched placebo administration
45983014|NCT00354302|Dietary Supplement|cholecalciferol|
45983015|NCT00354302|Drug|alendronate sodium|
45983016|NCT00354302|Drug|calcium gluconate|
45983017|NCT00354302|Drug|risedronate sodium|
45983018|NCT00354302|Other|laboratory biomarker analysis|
45983019|NCT00354302|Procedure|dual x-ray absorptometry|
45983020|NCT04714229|Biological|Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine|0.5mL single intramuscular dose on Day 0
45983021|NCT04714229|Biological|Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine|0.5mL single intramuscular dose on Day 0
45983022|NCT00458523|Biological|alemtuzumab|
45983023|NCT00458523|Genetic|fluorescence in situ hybridization|
45983024|NCT00458523|Genetic|mutation analysis|
45983025|NCT00458523|Other|flow cytometry|
45983026|NCT00467064|Behavioral|Arthritis Quick Start|Two week, lay led, workshop focusing on goal setting, problem solving, and content specific to disease management.
45983027|NCT00467064|Other|Delayed treatment intervention|After four months delay, participants in Control Group receive Experimental workshop.
45983028|NCT00354380|Drug|Methylene blue|
45983029|NCT00354380|Drug|Artesunate|
45983030|NCT00354380|Drug|Amodiaquine|
45983031|NCT00354419|Radiation|total-body irradiation|Undergo radiotherapy
45983032|NCT00354419|Drug|cyclophosphamide|Given IV
45983033|NCT00354419|Biological|anti-thymocyte globulin|Given IV
45983034|NCT00354419|Drug|cyclosporine|Given IV
45983035|NCT00354419|Procedure|umbilical cord blood transplantation|Undergo transplantation
45983036|NCT00354419|Drug|mycophenolate mofetil|Given IV or orally
45983037|NCT00354419|Procedure|bone marrow aspiration|Correlative study
45983038|NCT00354419|Genetic|DNA analysis|Correlative study
45983039|NCT00354419|Biological|filgrastim|Given IV or SC
45983040|NCT00458679|Biological|CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS VACCINE|Patients will receive a fixed dose (2 x 10^7) of IL-2 secreting B-cells together with (2 x 10^7)hCD40L expressing B-cells. They will receive 18 deltoid injections over 52 weeks.
45983041|NCT00354458|Drug|rolofylline|rolofylline 30 mg IV QD; 3 days
45983042|NCT00354458|Drug|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
45983043|NCT00458718|Drug|rimonabant (SR141716)|
45983044|NCT00354497|Other|physiologic testing|
45983045|NCT00354497|Other|study of socioeconomic and demographic variables|
45983046|NCT00354497|Procedure|evaluation of cancer risk factors|
45983047|NCT00354497|Procedure|mutation carrier screening|
45983048|NCT00354497|Procedure|study of high risk factors|
45983049|NCT00467181|Drug|Fenoldopam|
45983050|NCT00354536|Drug|GSK716155 subcutaneous injections|albiglutide subcutaneous injection
45983051|NCT00354536|Biological|placebo injection|placebo injection
45983052|NCT00467220|Behavioral|calorie restriction|"Subjects in the calorie restriction arm and the alternate day fasting arm will be asked to follow a menu plan, for three months, that includes some level of calorie restriction."
45456549|NCT03167723|Device|Chest tube placement|Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
45832483|NCT05394948|Dietary Supplement|Dietary recommendations including experimental nutraceutic.|Volunteers allocated in the control group will receive every day and during 3 consecutive weeks the experimental nutraceutic instead of the breakfast. Nutraceutical intake will be accompanied by nutritional advice to follow for the 3 weeks of intervention.
45832484|NCT05394948|Dietary Supplement|Dietary recommendations including control nutraceutic.|Volunteers allocated in the control group will receive every day and during 3 consecutive weeks the control nutraceutic instead of the breakfast. Nutraceutical intake will be accompanied by nutritional advice to follow for the 3 weeks of intervention.
45832485|NCT03504228|Device|Roadsaver|Dual layer micromesh Roadsaver carotid stent
45832486|NCT04843332|Behavioral|Community Health Worker Support|For those in the experimental group, a community health worker will provide health education and support as described in the Community Health Worker Intervention arm.
45832487|NCT01673412|Other|Psychological tests|social and economical level intellectual quotient (Raven's Progressive Matrices Standard) Coopersmith self-esteem inventory BECK Depression inventory Minimal Mental Status
45832488|NCT03153306|Drug|albumin|"Two groups were formed at random for each fluid. In one group, 10ml/kg of 5% albumin was given over 1 hour (the bolus group), and in the other group, the same volume was given over 6 hrs (thecontinuous group)"
45832489|NCT03152916|Device|3d printing personalized plate|3d printing personalized plate will be used in the subtalar arthrodensis
45832490|NCT01673724|Drug|pramipexole|pramipexole
45832491|NCT01673724|Drug|Bromocriptine|bromocriptine
45832492|NCT04765098|Drug|Tamoxifen|Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID continuously
45832493|NCT04765098|Drug|Etoposide|etoposide 50mg/m2 daily
45832494|NCT01673880|Drug|E2006|2.5 mg, 10 mg, and 25 mg E2006 tablets
45832495|NCT01673958|Other|Exercise|Comparison between stair descending and stair ascending training
45832496|NCT01674036|Drug|Genz-682452|Capsules for oral administration.
45832497|NCT01674036|Drug|Placebo|Placebo to Genz-682452
45832498|NCT04348578|Other|QMix 2in1|In QMix 2in1 group root canals were irrigated with Mix as a final irrigation.
45832499|NCT03378102|Biological|IFN-gamma-secreting HAdV antigen specific T cells|Antigen selected cells will be obtained using the CliniMACS(R) Prodigy System from a compatible donor. Isolated cells will be infused into the donor to treat human adenoviral infection after transplant
45832500|NCT01775046|Device|DTA patients (Valiant)|Valiant Thoracic Stent Graft Implantation
45832501|NCT03032328|Dietary Supplement|vitamin D supplement|Patients will be given a dose of vitamin D for at least 2 months
45832502|NCT03025464|Device|Obstructive Sleep Apnea Screening Device|Assessment of ability of device to detect apneas and hypopneas to screen for OSA
45832503|NCT02998164|Behavioral|augmentative and alternative communication technology|
45832504|NCT02998164|Behavioral|Usual Care|No change to the therapy care received
45832505|NCT02980692|Drug|SUNPG1623 I|injection
45832506|NCT02980692|Drug|SUNPG1623 II|injection
45832507|NCT02980692|Drug|SUNPG1623 III|injection
45832508|NCT02980692|Drug|SUNPG1623 IV|injection
45832509|NCT02980692|Drug|PLACEBO|injection
45832510|NCT04747392|Biological|SAL001|administrated once by subcutaneous injection
45832511|NCT04747392|Biological|FORSTEO|administrated once by subcutaneous injection
45832512|NCT03728712|Diagnostic Test|SPECT/CT|"Technegas-Tc99m is approved by Health Canada for the evaluation of ventilation. Technegas will be prepared with a Technegas Generator (Cyclomedica) according to the manufacturer recommendations with a simmer phase and a burning phase. 95% ethanol will be used to wet the carbon crucible. The crucible will be loaded with 20-30 mCi of Tc99m. Tc99m has a physical half-life of 6 hours.~Technegas will be administered to the patient within 10 minutes of its preparation, in a separate room than the scanning room. The inhalation technique will be rehearsed with the patient prior to the actual inhalation. The patient will be in supine position. A mouth piece and a nose clip will be used. The patient will be instructed to take 3 breaths of Technegas, starting after normal exhalation. A survey meter will be used to monitor the quality of the inhalation."
45983053|NCT00425711|Drug|Acamprosate|Acamprosate 666 mg tid, or 333 tid in renal impairment, for 12 weeks
45456550|NCT03143075|Dietary Supplement|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, added to pre-stabilized antidepressant medication
45456551|NCT03125655|Diagnostic Test|Inflammatory markers|
45456552|NCT03108690|Drug|Continuous infusion of beta-lactam antibiotics .|Beta-lactam antibiotic will be administered as continous infusion.
45456553|NCT03108690|Other|Therapeutic drug monitoring of beta-lactam antibiotics.|Dosage of beta-lactam antibiotics will be adjusted according to serum concentration.
45832513|NCT01674192|Drug|prucalopride|single dose of 2 mg prucalopride
45832514|NCT01674270|Drug|Degarelix|
45832515|NCT01674270|Drug|Casodex|
45832516|NCT01674270|Drug|LHRH Agonist|
45832517|NCT01674348|Drug|P2202|Novel oral drug with potent and selective 11 beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1) inhibitory properties, being developed for the management of type 2 diabetes mellitus
45832518|NCT01674348|Drug|Placebo|Placebo
45832519|NCT01674504|Drug|Montelukast sodium chewable tablets 4 mg and 5 mg|Montelukast sodium chewable tablets 4mg and 5mg
45832520|NCT02431104|Device|532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser|Cutera enlighten dual wavelength 532nm KTP/1064nm Nd:YAG laser
45983054|NCT00467337|Procedure|Medial-Wedge Insole intervention|
45983055|NCT00425789|Procedure|Treatment with Hyperbaric oxygen|
45983056|NCT00425867|Behavioral|PAR1 polymoprhisms and placental invasion|
45983057|NCT03274011|Drug|Apatinib|Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to and strongly inhibits vascular en-dothelial growth factor receptor 2 (VEGFR-2), with a decrease in VEGF-mediated endothelial cell migration, proliferation, and tumor microvascular density. Previous data showed that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy. Our study will observe the efficacy and safety of Apatinib for recurrent or metastatic esophageal squamous cell carcinoma: A phase II, prospective, single-arm, multicenter trial.
45983058|NCT03273972|Other|Written Informed Consent|To be completed prior to conducting any study related procedures
45983059|NCT03273972|Other|Inclusion/Exclusion check|Eligibility check
45983060|NCT03273972|Other|Full Clinical Chemistry and Haematology Bloods|Participant required to fast for at least 6-8 hoursprior to visit. (Clear, non-caffeinated fluids are allowed)
45983061|NCT03273972|Other|Serum sample for systemic markers and lipid sub-fractions|Serum samples may be stored for later analysis.
45983062|NCT03273972|Other|Pregnancy Test|If applicable for women of child bearing potential
45983063|NCT03273972|Other|12 Lead ECG|participant resting supine
45983064|NCT03273972|Other|Blood Pressure and Heart Rate|Measured in the seated position after 5 minutes rest
45983065|NCT03273972|Other|Arterial Stiffness|Measure of functional and structural changes which accompanies cardiovascular disease
45983066|NCT03273972|Other|Central Haemodynamics|Measure of functional and structural changes which accompanies cardiovascular disease
45983067|NCT03273972|Other|Carotid Intima Media Thickness|Measurements will be repeated three times, and the average of the median values will be recorded
45983068|NCT03273972|Other|Forearm blood flow studies|Assess and determine vascular function, which can interrogate endothelium dependent and independent mechanisms of nitric oxide bioavailability
45983069|NCT03273972|Other|Concomitant medication check|Review of medication taken by the participant
45983070|NCT03273972|Other|Medication compliance check (Pill count)|Ensure prescribed statin has been taken
45983071|NCT03273972|Other|Physical examination|Check overall health
45983072|NCT03273972|Other|Medical history|Review of volunteers medial history
45456554|NCT03107533|Other|Video recording of clinical visit|For patients and parents that are considering scoliosis surgery, a video recording of the encounter will be obtained during their routine clinical visit to discuss surgery/options.
45456555|NCT03103152|Drug|High dose Aspirin & Vitamin D|Aspirin 1 x 300mg tablet daily & Vitamin D 4,000IU daily. (8 drops).
45832521|NCT02326116|Other|Trachael Preparation Education|
45832522|NCT01674582|Other|MRI, neuropsychological evaluation, blood sampling|"MRI at timepoints given above, neuropsychological testing after surgery, but before radiotherapy or chemotherapy.~Neuropsychological testing month 3 during treatment. Neuropsychological testing after 1 year. Neuropsychological testing after 2 years."
45832523|NCT05353062|Procedure|Hemostatic therapy|Bipolar hemostatic forceps
45832524|NCT05353062|Procedure|Endoscopic therapy with hemoclip +/- injection of epinephrine solution|Endoscopic therapy with hemoclip +/- injection of epinephrine solution
45832525|NCT03152370|Drug|E7046|oral administration
45832526|NCT03152370|Radiation|Long Course Chemoradiotherapy (LCRT)|pelvic radiotherapy
45832527|NCT03152370|Radiation|Short Course Radiotherapy (SCRT)|pelvic radiotherapy
45832528|NCT03152370|Drug|capecitabine|chemotherapy
45832529|NCT03152370|Drug|folinic acid/5-FU/oxaliplatin (mFOLFOX-6)|chemotherapy
45983073|NCT03273972|Other|AE/SAE review & reporting|Monitor safety from the point of consent
45983074|NCT03273972|Drug|Dosing|To be performed at the end of the visit following completion all other study visits
45983075|NCT00425906|Drug|nicotine|
45456556|NCT03103152|Drug|High dose Aspirin, Vitamin D placebo|Aspirin 1 x 300mg tablet daily & Vitamin D placebo (8 drops).
45456557|NCT03103152|Drug|Low dose Aspirin , Vitamin D|Aspirin 1 x 100mg tablet daily & Vitamin D 4,000IU daily. (8 drops).
45456558|NCT03103152|Drug|Low dose Aspirin, Vitamin D placebo|Aspirin 1 x 100mg tablet daily & Vitamin D placebo 8 drops daily.
45983076|NCT00425906|Other|Placebo|
45983077|NCT00425906|Procedure|Quality of life|
45983078|NCT00425984|Procedure|Adult male circumcision|
45983079|NCT00467376|Drug|Insulin Glulisine|3 times a day before each meal
45983080|NCT00467376|Drug|Lispro|3 times a day before each meal
45983081|NCT00467376|Drug|Insulin Glargine|once daily
45983082|NCT00426023|Drug|Cyclosporine A 0,05% eye drop|Cyclosporine A 0.05% eye drops will be administered 2 times daily for six months in the first year of the study and in the second year of the study in a cross-over manner(from March to September)
45983083|NCT00426023|Drug|ketotifen fumarate 0.025% eye drops|ketotifen fumarate 0.025% eye drops 2 times daily for 6 months in the first year of the study (from March to September) and 6 months in the same period in the second year of the study in cross over manner.
45983084|NCT00467415|Behavioral|Partial body weight support treadmill training|Treadmill ambulation for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
45983085|NCT00467415|Behavioral|Exercise|Functional Strengthening exercise program for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
45983086|NCT00467454|Drug|Naltrexone|daily
45983087|NCT00467454|Drug|Placebo|daily
45983088|NCT00426101|Drug|Dexamethasone|"10 mg/m2 daily wk 1-2 5 mg/m2 daily wk 3-4 2.5 mg/m2 daily wk 5-6 1.25 mg/m2 daily wk 7 Steroids tapered wk 8~If continuation:~Pulses every 2nd wk, 10 mg/m2 for 3 days"
45983089|NCT00426101|Drug|Etoposide|"150 mg/m2 iv twice/wk (wk 1-2) 150 mg/m2 iv once/wk (wk 3-8)~If continuation:~150 mg/m2 iv, every 2nd wk"
45983090|NCT00426101|Drug|Cyclosporin|"WK 1-8:~- Aim at around 200 microgram/L (trough value). Start: 6 mg/kg daily (divided in 2 daily doses) wk 1, if kidney function is normal.~If continuation:~- Aim for around 200 microgram/L. Monitor GFR."
45983091|NCT00426101|Procedure|Intrathecal therapy|"If at 2 wks there are progressive neurological symptoms or if an abnormal CSF (cell count and protein) has not improved, then give 4 wkly intrathecal inj. Be aware that some pat may have increased intracranial pressure.~Methotrexate: <1 yr 6 mg, 1-2 yrs 8 mg, 2-3 yrs 10 mg, >3 yrs 12 mg. Prednisolone: <1 yr 4 mg, 1-2 yrs 6 mg, 2-3 yrs 8 mg, >3 yrs 10 mg."
45983092|NCT00426101|Procedure|Stem cell transplant|The SCT procedure is up to the treating physician. However, a suggested regimen is provided.
45983093|NCT00426140|Drug|Patupilone|
45983094|NCT00467493|Drug|Anastrozole|
45983095|NCT00426179|Drug|Imatinib|
45456559|NCT03103152|Drug|Aspirin Placebo, Vitamin D|Aspirin 1 x 300mg placebo tablet daily & Vitamin D 4,000IU daily. (8 drops).
45672913|NCT05271929|Biological|Current standard of care and COVID-19 convalescent and vaccinated plasma|ABO compatible convalescent plasma infused intravenously on study day 1 (as soon as possible after randomisation) and the second on day 1 or day 2. Plasma obtained by apheresis from donors who have recovered from COVID-19 infection (at least 14 days after recovery) and have been vaccinated (at least 3 weeks after first dose of vaccine). A combination of both a SARS-CoV-infection and a SARS-CoV-2 vaccination of the donor is required - irrespective of the sequence of infection and vaccination. As far as the availability of CCP units allows, the two plasma units should have been donated by two different convalescents.
45672914|NCT05271929|Other|Current standard of care|"Standard of care therapy may include anti-SARS-CoV-2 specific medication such as, but not limited to:~Casirivimab~Casirivimab / Imdevimab (REGN-COV2 or Ronapreve)~Imdevimab~Sotrovimab (Xevudy)~Tixagevimab / Cilgavimab (Evusheld)~Molnupiravir (MK-4482)~Nirmatrevlir / Ritonavir (Paxlovid)~Remdesivir~Centres should ensure that medications used as standard of care are used similarly for patients in both treatment arms."
45672915|NCT01541644|Device|Acupuncture|Participants will receive acupuncture treatment twice weekly for 2 weeks, then once per week for 4 weeks, and then biweekly for 4 weeks.
45672916|NCT05428397|Diagnostic Test|Iopromide (Ultravist, BAY86-4877)|X-Ray/CT Diagnostic Imaging
45672917|NCT04853056|Device|virtual reality|wearing virtual reality glasses
45672918|NCT04853056|Device|Cold vibration|Buzzy
45832530|NCT02187120|Drug|Tranexamic Acid|Tranexamic acid is a synthetic lysine derivative that inhibits fibrinolysis by blocking the lysine binding sites on plasminogen therefore inhibiting the conversion of plasminogen to plasmin. Intravenous injection of 1g Tranexamic Acid will be administered in the pre-hospital setting followed by 1g Tranexamic Acid infused intravenously over 8 hours initiated in the hospital emergency department.
45832531|NCT02187120|Drug|Placebo|
45832532|NCT02335710|Device|Journey II BCS TKA|
45832533|NCT01674738|Drug|Pemetrexed|500 mg/m2 i.v. on day 1 (three-week cycle)
45832534|NCT01674738|Drug|Cisplatin|75 mg/m2 i.v. on day 1 (three-week cycle)
45832535|NCT01674738|Drug|Bevacizumab|7,5 mg/kg i.v. on day 1 (three-week cycle)
45832536|NCT01674972|Other|Oral glucose tolerance test|Oral intake of 75 g glucose after overnight fast
45832537|NCT01675206|Dietary Supplement|Vitamin K2 supplementation|
45983096|NCT00458874|Behavioral|CIMT results|"Both groups will receive a weekly confidential packet of scripted materials (e.g. educational materials, class schedules, feedback from diet/exercise logs). The R-CIMT group will also receive an CIMT report which contains a copy of one of their own ultrasound scans, with a comparison normal scan. This report will also include the CIMT thickness, an interpretation that states their measurements are in the highest quartile for persons of their age and gender, and associated CVD risk. Interpreting Your CIMT Results tutorial will be included in the first weekly packet to educate subjects on the detection of atherosclerosis with carotid ultrasound. The CIMT results are withheld from the W-CIMT group until the end of their study participation along with the CIMT tutorial."
45983097|NCT00426218|Drug|ACZ885|
45983098|NCT00458913|Drug|bortezomib|
45983099|NCT00458913|Drug|cisplatin|
45983100|NCT00458991|Drug|Dextromethorphan and Caffeine|"All subjects received standard medical therapy with rhGH and at specified times low doses of the pharmacologic probes (e.g., caffeine and dextromethorphan) as surrogate markers to determine CYP450 activity. The only direct treatment effect measured was the biological response to rhGH."
45983101|NCT01059617|Biological|GSK Biologicals' FluLaval®|Intramuscular injection
45983102|NCT01059617|Biological|Placebo (saline)|Intramuscular injection
45983103|NCT01059617|Biological|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injections
45983104|NCT01059617|Biological|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A|Intramuscular injections
45983105|NCT03271944|Device|CO2 Laser Treatment|Fractional handpiece with CO2 laser: Fractional Ablative laser Treatment of Vulvovaginal Atrophy
45983106|NCT03273933|Device|DragONE|The DragONE application for iOS and Android, developed in collaboration with the Institute for Educational Technologies of the National Research Council of Palermo, allow children to daily fill electronically the C-ACT questionnaire and the symptom diary card.
45983107|NCT03273933|Device|SmartOne|A little portable spirometer connected to DragONE allows daily PEF monitoring.
45983108|NCT00459030|Other|educational intervention via internet|additional cancer screening information via password protected internet site
45983109|NCT00459030|Other|educational intervention mailed|
45983110|NCT00459030|Other|No additional educational intervention|
45983111|NCT04705337|Drug|Levosimendan|administration of levosimendan as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
45983112|NCT04705337|Other|Placebo|administration of glucose as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
45456560|NCT03103152|Drug|Aspirin placebo, Vitamin D placebo|Aspirin 1 x 100mg placebo tablet daily & Vitamin D 4,000IU daily. (8 drops).
45456561|NCT03084822|Behavioral|FAITH! App digital intervention|The digital app will include 10 education modules addressing the major CVD risk factors to be delivered on-demand through an innovative, interactive video series. The digital app will also support the multi-media education modules, interactive surveys/quizzes, self-monitoring (diet, physical activity), and social networking (discussion board) functionality.
45456562|NCT03064087|Device|Colli-Pee|First, two first-void urine samples will be collected with the Colli-Pee device (Novosanis NV, Wijnegem, Belgium) at home, the day before a visit to the colposcopy centre at a gynecology clinic.
45456563|NCT03064087|Device|Multi-Collect Swab|At the colposcopy clinic, one vaginal self-sample will be collected with the Multi-Collect Swab (Abbott GmbH & Co. KG, Wiesbaden, Germany).
45456564|NCT03064087|Device|Evalyn Brush|Another vaginal self-sample will be collected also at the colposcopy centre either with the Evalyn Brush (Rovers Medical Devices B.V., Oss, Netherlands)
45456565|NCT03064087|Device|Qvintip|or with Qvintip (Aprovix AB, Uppsala, Sweden).
45456566|NCT03064087|Diagnostic Test|Abbott RealTime High Risk HPV|The hrHPV assay used, will be the Abbott PCR (Abbott GmbH & Co. KG, Wiesbaden, Germany), which detects separately DNA of HPV16 and HPV18, as well as the pool of twelve other hrHPV types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The accuracy of this PCR assay for the detection of CIN2+ will be determined on all samples: on the first urine sample and on the vaginal and cervical samples. Furthermore, it is possible that in the future other assays will be validated.
45983113|NCT00459069|Biological|Dendritic Cell Tumor Fusion Vaccine|Vaccine administered on weeks 0, 3 and 6
45983114|NCT00426257|Procedure|Secondary debulking|Secondary debulking
45983115|NCT00426257|Procedure|secondary debulking with intraperitoneal chemotherapy|secondary debulking with intraperitoneal chemotherapy
45983116|NCT00467571|Drug|lansoprazole, clarithromycin, amoxycillin|lansoprazole (15, 30 mg) 1 tab twice daily, clarithromycin 7.5 mg/kg twice daily, amoxycillin 25 mg/kg twice daily; rout: orally; duration 14 days
45672919|NCT04814615|Drug|89Zr-daratumumab PET/CT|CD38-targeting imaging
45672920|NCT03800693|Drug|Fluorouracil|Given IV
45672921|NCT03800693|Drug|Leucovorin|Given IV
45672922|NCT03800693|Drug|Oxaliplatin|Given IV
45672923|NCT03799991|Behavioral|Vestibular physical therapy|Vestibular therapy is a set of exercises delivered by a physical therapist involving head movements. The therapy is delivered over a course of 8 weeks.
45672924|NCT03799991|Behavioral|Active control|Strength and flexibility exercises that do not involve head movements.
45832538|NCT01537458|Procedure|follow-up of isolated tricuspid valve repair|follow-up of patients that underwent TV repair in the past.
45832539|NCT03150576|Drug|Olaparib|Patients will self-administer Olaparib by mouth. Olaparib tablets should be taken twice daily at the same time each day approximately 12 hours apart.
45832540|NCT03150576|Drug|Paclitaxel and Carboplatin|Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 & 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.
45832541|NCT01059786|Drug|Pentostatin|28 patients to pentostatin 4 mg/m2 days 1 and 15 of each cycle.
45832542|NCT01059786|Drug|Rituximab|Rituximab 375 mg/m2 on day 1, 15 for 6 x 28-day cycles (all 72 patients)
45832543|NCT01059786|Drug|Bendamustine|28 patients to bendamustine 90 mg/m2/day, days 1 and 2 each cycle
45832544|NCT04747080|Drug|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14).
45672925|NCT04814537|Drug|Bupivacaine Hydrochloride|Local Anesthetic Agent
45672926|NCT01582282|Dietary Supplement|placebo|fiber-free placebo
45672927|NCT01582282|Dietary Supplement|3.4 g psyllium BID|3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil)
45832545|NCT04747080|Drug|Tacrolimus|Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
45832546|NCT01675284|Biological|AT-301|Inactivated H5N1 Influenza Virion Vaccine
45983117|NCT00467688|Device|Real time access to current glucose values during CGMS|One arm gets real time access to current measured glucose values and hypoglycemic or hyperglycemic alerts are elicited, The second arm get´s a retrospective analysis of glucose values
45983118|NCT00426296|Drug|atazanavir (Reyataz)|
45983119|NCT00426296|Drug|ritonavir (Norvir)|
45983120|NCT03271905|Drug|salbutamol sulfate and ipratropium bromide|Nebulization with salbutamol sulfate and ipratropium bromide during mechanical ventilation.
45983121|NCT03271905|Device|Mesh nebulization|Nebulization with Mesh device.
45983122|NCT00426374|Procedure|echocardiography and blood test|
45983123|NCT00459225|Drug|Iron (ferrous sulfate)|The subjects in the iron treatment arm of the study will receive 3 mg/kg of oral/enteral iron solution once a day beginning at the time of discharge until the pre-Glenn screening which is the endpoint of the study. The iron will be dispensed for the subjects upon discharge from the hospital. The subjects randomized to the no iron treatment arm and the patients in Group II of the study will not receive iron upon discharge. However, they may be started on iron therapy in an intent-to-treat anemia by their primary physician in which case this will serve as the endpoint of the study for these participants.
45983124|NCT00426413|Drug|pioglitazone|Obese AA subjects with DKA or severe hyperglycemia that are able to discontinue insulin at 12 weeks or less will be randomized (blinded fashion) to receive either placebo or pioglitazone qd. The subjects will be followed while in the study arm and beta-cell function will be assessed using OGTT at set intervals.
45983125|NCT00459264|Drug|Folic Acid|Folic acid oral solution 2.5mg/5ml daily for up to 3 years
45983126|NCT00459264|Drug|Placebo|Matching placebo for folic acid oral solution (2.5mg/5ml)
45983127|NCT00426452|Drug|Vatalinib|
45983128|NCT00467727|Other|Phase Contrast Mammography|Standard and magnification views
45983129|NCT00426491|Drug|Misoprostol|400 ug Misoprostol or placebo will be placed in the posterior fornix of the vagina using a speculum under the direct visualization of the provider.
45983130|NCT03273777|Procedure|Drawing of an incision line|Drawing of an incision line prior to skin incision at cesarean section
45983131|NCT00426530|Drug|everolimus (RAD001)|
45983132|NCT00459420|Drug|Caffeine 100-200 mg BID|Caffeine 100 mg BID for three weeks, then 200 mg BID for three weeks, then 100 mg BID for 1 week, then placebo
45983133|NCT00459420|Drug|placebo|placebo
45983134|NCT00467766|Behavioral|Psychosocial information, counseling, and support|
45983135|NCT00467766|Drug|Donepezil (Aricept)|
45456567|NCT03033901|Device|Polysomnography - Level 1 and Level 3|Participants will undergo simultaneous administration of Level 1 and 3 polysomnography on the rehabilitation unit with study funded sleep technologist present to meet Level 1 standards.
45983136|NCT00459459|Procedure|Fine needle aspiration of the thyroid|
45983137|NCT00467805|Procedure|Light therapy|
45983138|NCT04705415|Drug|Niclosamide|Niclosamide is an antihelmintic with in-vitro antiviral activity
45983139|NCT04705415|Drug|Placebo|Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
45983140|NCT00467883|Drug|Liposomal Amphotericin B|high dosage
45983141|NCT00426608|Drug|metyrapone|Metyrapone will be available as 250 mg dose capsule.
45983142|NCT00426608|Drug|alprazolam|Alprazolam capsules will be available with dose strength of 0.25mg
45983143|NCT00426608|Drug|placebo|GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.
45983144|NCT00426608|Drug|GSK561679|GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.
45983145|NCT00467922|Drug|Hextend|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
45983146|NCT00467922|Drug|Lactated Ringers|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
45983147|NCT00426647|Drug|Buprenorphine|
45983148|NCT00426647|Drug|Tramadol|
45983149|NCT00468078|Procedure|PET/CT|10min acquisition, 90min after injection of F-18 FPCIT
45983150|NCT00468078|Drug|F-18 FPCIT|5mCi, intravenous injection
45983151|NCT00468156|Behavioral|written materials only|related to fruit/vegetable servings/day
45983152|NCT00468156|Behavioral|written materials|related to fruit/vegetable servings/day
45983153|NCT00468156|Behavioral|telephone support|related to fruit/vegetable servings/day
45983154|NCT00426725|Device|EasyLabour|According to the trial protocol
45983155|NCT01059344|Drug|Mesalamin|4.8g/day, 800 mg tablets
45983156|NCT01059071|Drug|DFMO|"Escalating doses of DFMO in a 3 +3 cohort design.~DFMO at current cohort Dose Level orally each day for 21 day cycles~Dose level 1: 500 mg/m2 PO BID Dose level 2: 750 mg/m2 PO BID Dose level 3:1000 mg/m2 PO BID Dose level 4:1500 mg/m2 PO BID"
45672928|NCT01582282|Dietary Supplement|6.8g psyllium BID|6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil)
45983157|NCT01059071|Drug|Etoposide|Starting with Cycle 2, etoposide will be given at 50mg/m2/dose PO daily for the first 14 days of each 21 day cycle. Capsules will be rounded to closest 50 mg.
45983158|NCT00468234|Drug|nicotine polacrilex|
46082974|NCT05279911|Radiation|low-level laser therapy (LLLT)|low-level laser therapy (LLLT) with dental implants has been suggested to improve bone quality during osseointegration. Low-level laser (Gallium Aluminum Arsenide Diode [Ga-Al-As]) (wavelength: 808 nm, average power density: 50 mW, circular spot diameter:0.71 cm, spot area: 0.4cm2) in continuous mode was applied in six points in contact with peri-implant soft tissue (1.23 minutes in each point of application; dose per point 11 J) before and immediately after suturing. The application points were divided into two points in the labial region where the implant would be placed (apical and cervical); two points in the lingual region (apical and cervical); and two points in the occlusal direction. After suturing the laser protocol was repeated in the same points following the same protocol, resulting in a total dose of 66 J for each application moment (before and after implant placement).
46082975|NCT04235270|Combination Product|FDC of Macitentan and Tadalafil|Fixed dose combination (FDC) of 1 film-coated tablet containing 10 mg of macitentan and 40 mg of tadalafil will be administered orally.
46082976|NCT04235270|Drug|Macitentan|Macitentan 10 mg tablet will be administered orally as free combination.
46082977|NCT04235270|Drug|Tadalafil|Tadalafil 40 mg tablet will be administered orally as free combination.
46082978|NCT00943033|Behavioral|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy for the prevention of depressive relapse/recurrence
45456568|NCT03033901|Device|Actigraphy monitoring|Participants will undergo actigraphy monitoring to assess habitual sleep duration to determine readiness for polysomnography and examine trajectory and duration of sleep.
45456569|NCT03033901|Other|Sleep Apnea Screening|Participants and their family member or proxy, and clinical staff will be asked to answer questions in order to complete the three standardized sleep apnea screening measures.
45456570|NCT03031912|Biological|V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine|The rVSVΔG-ZEBOV-GP vaccine is a live attenuated recombinant virus consisting of a single recombinant VSV isolate (11481 nt, strain Indiana) with the gene for the Zaire ebolavirus GP (ZEBOV GP), Kikwit strain replacing the gene for the VSV GP, which has been deleted. This results in a VSV backbone with the ZEBOV GP constituting the envelope of the virus.
45672929|NCT01599650|Drug|Ranibizumab|
45672930|NCT01599650|Procedure|Laser|laser photocoagulation
45832547|NCT01675362|Drug|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
45832548|NCT01675362|Drug|Calcium Channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
45832549|NCT01675362|Drug|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
45456571|NCT03031912|Other|Saline|Normal saline (0.9%) has been chosen as an inert substance to serve as placebo control.
45456572|NCT02988297|Drug|RNS60|Nebulized RNS60 will be administered by daily inhalation for 24 weeks.
45672931|NCT01541254|Device|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
45832550|NCT01675362|Drug|Placebo|They will receive placebo
45832551|NCT01675440|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
45832552|NCT01675518|Drug|ASP7991|oral
45832553|NCT01675518|Drug|Placebo|oral
45832554|NCT03158532|Drug|Nitroglycerin I|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
45832555|NCT03158532|Drug|Placebo I|Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
45832556|NCT03158532|Drug|Nitroglycerin II|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
45832557|NCT03158532|Drug|Placebo II|Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
45832558|NCT04404738|Procedure|MicroPort® robot-assisted laparoscopic surgery|In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by Microport® Surgical System
45983159|NCT00468234|Drug|nicotine transdermal system|
45983160|NCT00468234|Drug|nicotine inhaler|
45983161|NCT00459615|Drug|Artesunate for Injection|
45983162|NCT00468351|Procedure|Intravitreal Injection of 1,5 mg of bevacizumab|
45983163|NCT00468351|Procedure|Intravitreal injection of 4 mg of Triamcinolone acetonide|
45983164|NCT00459654|Drug|Radium-223 dichloride (BAY88-8223)|Four Radium-223 injections were given at 4-weekly intervals starting after the first fraction of EBR.
45983165|NCT00459654|Drug|Saline|Four Saline injections were given at 4-weekly intervals starting after the first fraction of EBR.
45983166|NCT00468429|Drug|Subconjunctival Bevacizumab|
45983167|NCT00468468|Behavioral|CHESS (Comprehensive Health Enhancement Support System) and Human Cancer Mentor|computer based education and support
46082979|NCT02792270|Other|Caloric Restriction Diet|"A nutritional supplement called Scandishake (Nutridrinks, Perivale, UK) will be used for 3 days before surgery.~- Scandishake will be mixed with 8 oz of whole fat cow milk, whole fat lactaid milk, almond milk or soy milk. The proposed macronutrient profile for the 3 days of caloric restriction (CR) is: 45% fat, 46% carbohydrate, and 8% protein."
46082980|NCT00945607|Other|GRT (Guided Relaxation Training)|Weekly on-site GRT sessions at the center in combination with twice daily independent GRT sessions at home.
46082981|NCT04256525|Drug|Rivaroxaban 10mg|10mg orally per day
46082982|NCT04256525|Drug|Aspirin 100mg|100mg orally per day
45456573|NCT02988297|Drug|Placebo|Nebulized Placebo will be administered by daily inhalation for 24 weeks.
46082983|NCT04256525|Drug|low molecule heparin|0.4ml per day subcutaneous injection
46082984|NCT02791958|Drug|Cardiovascular Fixed Dose Combination Pill AAR|A once daily oral dose of the Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg) for 4 weeks.
46082985|NCT02791958|Drug|Atorvastatin 40 mg|A once daily oral dose of atorvastatin 40 mg (Lipitor®) for 4 weeks
46082986|NCT02791958|Drug|Ramipril 10 mg|A once daily oral dose of ramipril 10 mg (Altace®) for 4 weeks
46082987|NCT00945685|Device|Endymion Imagine™ System for Skin Tightening|"Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~Pulse energy (J);~RF frequency (1MHz);~Pulse duration (30 sec);~Treatment hand piece (skin tightening);"
46082988|NCT00769119|Drug|AZD9668|2 x 30 mg, oral tablet, twice daily for 28 days
46082989|NCT00769119|Drug|Placebo|2 x Matched placebo, oral tablet, twice daily for 28 days
45456574|NCT02986243|Other|Exercise|6 months worth of exercise regimen
45456575|NCT02986243|Dietary Supplement|Diet Plan|Each subject will receive a personalized diet plan from nutritionist.
45456576|NCT02943746|Dietary Supplement|Standard Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day.
45456577|NCT02943746|Dietary Supplement|High Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 4.2 to 4.5 g/kg/day.
45456578|NCT02937285|Drug|Interferon beta 1a|Subcutaneous injection of 44µg 3 times a week
46082990|NCT00945841|Biological|inactivated split influenza vaccine|1 dose of inactivated split influenza vaccine, using the strain composition 2009/2010
46082991|NCT02797106|Other|Practice survey of health professionals|Survey of the practices and opinions of health care professionals to describe care pathways, assessment and treatment of drooling in children with cerebral palsy
46082992|NCT02601651|Drug|Lidocaine|Lignocaine group will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation.
46082993|NCT02601651|Drug|Normal saline|Normal saline group will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation
45456579|NCT02937285|Drug|Mitoxantrone|10 mg / m² monthly infusion for 6 months
46082994|NCT03865238|Biological|EV71vac|Subjects are to receive a 0.5 mL IM injection of EV71vac. Study drug is administered on Day 1 and Day 57 of the study. Subjects 2 months to < 2 years of age will receive a booster vaccination on Day 366.
46082995|NCT03865238|Biological|Placebo|Subjects are to receive a 0.5 mL IM injection of placebo. Study drug is administered on Day 1 and Day 57 of the study. Subjects 2 months to < 2 years of age will receive a booster vaccination on Day 366.
46082996|NCT00943267|Drug|Drotrecogin alpha|Drotrecogin alpha is given intrabronchially by bronchoscopy at t=0
46082997|NCT00943267|Drug|Saline (NaCl 0.9%)|Normal saline is given intrabronchially by bronchoscopy at t=0
46082998|NCT00943267|Drug|Endotoxin|Endotoxin (4 ng/kg body weight) is given intrabronchially in one subsegment at t=0
45456580|NCT02878785|Drug|Decitabine|DNA methyltransferase inhibitor
45456581|NCT02878785|Drug|talazoparib|poly ADP ribose polymerase (PARP) inhibitor
45832559|NCT04404738|Procedure|da Vinci robot-assisted laparoscopic surgery|In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by da Vinci Surgical System
45832560|NCT03879876|Drug|Human T Lymphoid Progenitor (HTLP) injection|Injection of progenitors derived from HTLP culture at Day 8-Day 12 after partially HLA compatible allogeneic hematopoietic stem cell transplantation in SCID patients (Day7 of culture)
45832561|NCT01675986|Drug|hydroxyzine|75 mg
46082999|NCT00943267|Procedure|Bronchoscopy|Bronchoscopies are performed at t=0 (for instillation of LPS and Drotrecogin alpha) and at t=6 (for performing a bronchoalveolar lavage)
46083000|NCT00943267|Procedure|Blood sampling|Blood sampling is done by venapuncture at t=0 and t=6
45832562|NCT01675986|Drug|Pregabalin|150 mg
45832563|NCT01675986|Drug|Lactose|4 g
45832564|NCT03155490|Behavioral|Leadership training|Subjects randomized to the experimental arm of the study will receive an additional 4 hours of simulation-based trauma team leadership training. This training is in addition to the baseline 2 hours of trauma leader training and orientation all subjects receive.
45983168|NCT00468507|Dietary Supplement|nutritional intervention with Respifor and Diasip|Four nutritional interventions on four separate days per test person
45983169|NCT00426803|Drug|activated recombinant human factor VII|
45983170|NCT00459771|Drug|AT1 blocker candesartan|AT1 blocker candesartan, 32 mg oral QD
45983171|NCT00459771|Drug|Placebo|Placebo, 32 mg, oral QD
45983172|NCT01058369|Drug|Deferasirox (Novartis Pharma)|Treatment period 102 weeks. Starting dose 10mg/kg/day. Up to 30/mg/kg according to dose adjustment table as specified in the protocol
46083001|NCT00945919|Drug|Oxymorphone ER|Rapid Opioid rotation/titration
46083002|NCT00945997|Drug|misoprostol|mifepristone 200 mg followed by 200 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
46083003|NCT00945997|Drug|misoprostol|mifepristone 200 mg followed by 400 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
46083004|NCT00927953|Biological|MGAWN1|Humanized monoclonal to West Nile virus. Dose = 30 mg/kg actual body weight intravenous, one dose at Day 0.
46083005|NCT00927953|Biological|Placebo - normal saline|Normal Saline intravenous, volume same as active comparator, one dose at Day 0
46083006|NCT00943345|Drug|indometacin|"capsule for oral consumption~at 22h00 evening before test day: 75 mg~at 7h30 on the test day: 50 mg This intervention will be applied 4 times (4 arms)."
46083007|NCT02797028|Dietary Supplement|Anthocyanidins capsule|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
46083008|NCT02797028|Dietary Supplement|Placebo capsule|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
46083009|NCT02797028|Drug|Allopurinol|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
46083010|NCT00916461|Drug|Minocycline|Minocycline + treatment as usual. 50 mg twice daily increasing to 200 mgs per day, increments of 50 mgs every 2 weeks.
46083011|NCT00916461|Drug|Placebo|Placebo + treatment as usual.
46083012|NCT04011943|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
46083013|NCT03664466|Dietary Supplement|astaxanthin|astaxanthin capsules 12 mg twice daily
46083014|NCT03664466|Other|Placebo|placebo capsules twice daily
45456582|NCT02849223|Device|Anodal Transcranial Direct Current Stimulation|2 milliamps (mA) of anodal stimulation will be applied to the left dorsal lateral cortex for 20 minutes concurrent with working memory training.
45983173|NCT00459849|Procedure|Intraoperative ultrasonography|Intraoperative ultrasonography will be used to determine plaque placement.
45983174|NCT03271788|Other|Mindfulness, MBSR|Participants (stroke patients and one of their closest relatives) will conduct an MBSR Course in Phase B
45832565|NCT03150186|Other|SHS exposure in homes|The investigators will recruit 20 non-smoking volunteers living in different homes with at least one smoker: 10 participants living in more deprived neighborhoods and 10 participants living in wealthier neighborhoods. Nicotine vapor phase will be measured using passive SHS samplers. The investigators will contact with participants and make an arrangement for measuring levels of nicotine at homes. First, the investigators will hang up a passive sampler in the main room of the house in accordance with the written protocol of sample collection. One week later, the investigators will come back to the house in a second visit to remove the sample. During the second visit the investigators will administer a specific questionnaire about environmental tobacco exposure to the participant.
45983175|NCT01057433|Drug|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
45983176|NCT01057433|Drug|Lopinavir/ritonavir|lopinavir/ritonavir 800 mg/200 mg
45983177|NCT00459888|Device|PolarCath Peripheral Dilatation System (Boston Scientific)|
45983178|NCT01057394|Device|Endoscopically guided PVI Ablation|Endoscopically Guided Ablation using the EAS-AC
45983179|NCT01057394|Device|RF PVI Ablation|Radiofrequency ablation
45983180|NCT00459927|Device|Floseal tonsillectomy|
45983181|NCT00459927|Device|Coblation tonsillectomy|
45983182|NCT00459966|Procedure|Preoperative rehabilitation|
45983183|NCT01058642|Drug|ADL5747|
45983184|NCT01058642|Drug|Placebo|
45983185|NCT01058642|Drug|Pregabalin|
45983186|NCT00426881|Behavioral|Exercise Training|Twice weekly resistance training for 52 weeks.
45983187|NCT00426881|Behavioral|Exercise training|Once weekly resistance training for 52 weeks.
45983188|NCT00426881|Behavioral|Exercise training|Twice weekly resistance training for 52 weeks.
45983189|NCT03271437|Behavioral|PC-based Flash|Progressive counting with Flash technique
45983190|NCT03271437|Behavioral|EMDR-based Flash|Eye movement desensitization and reprocessing with Flash technique
45983191|NCT00426920|Drug|Insulin|
45983192|NCT03271710|Device|peripheral balloon angioplasty|Percutaneous transluminal angioplasty (PTA) of the lower extremities
46083015|NCT04100499|Device|ESAR (Endosutured Aneurysm Repair)|EndoAnchors adjunctive therapy for EVAR and TEVAR
45983193|NCT00426959|Device|Image Guided Dynamic Dosimetry|Image Guided Dynamic Dosimetry
45983194|NCT00468624|Drug|pegvisomant/placebo loading dose 80mg sc, thereafter 20mg daily for 2 weeks|
45983195|NCT00468624|Procedure|GH sampling - every 20 min over 24 hours after each limb (pegvisomant/placebo)|
45983196|NCT00468624|Procedure|blood sampling before and after pegvisomant/placebo|
45983197|NCT00468624|Procedure|arginine stimulation test after each limb|
45983198|NCT00426998|Drug|Verteporfin|
45983199|NCT00426998|Drug|Bevacizumab|
45983200|NCT00427076|Drug|Cotrimoxazole|Cotrimoxazole arm: intravenous cotrimoxazole 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 12 hours. Patients intolerant of volume overload will be given the same dose in 250ml D5W (as in the current recommendations used in the hospital). The dose was selected basing on the existing randomized controlled trial and a pharmacokinetic study . 21 For patients with GFR< 30 the dosage interval will be increased to 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 24 hours. 22 Patients on peritoneal dialysis will be given 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) Q 48 hours. Patients with acute renal failure treated with hemodialysis will be given the 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) after dialysis. Patients on continuous hemofiltration for acute renal failure will be administered the dose for GFR<30.
45983201|NCT00427076|Drug|Vancomycin|intravenous vancomycin 1gr Q 12 hours. Adjustment to creatinine clearance: GFR 10-50 1 gr Q 24-96 hours, GFR <10 1gr Q 4-7 days.
45983202|NCT00427115|Behavioral|Multimodal exercise and psychosocial program|
45983203|NCT00427232|Drug|BQ-123 and BQ-788|
45983204|NCT00468702|Device|CoaguChek S|
45983205|NCT00427271|Drug|aspirin|
45983206|NCT00460083|Drug|Elidel(R) (pimecrolimus 1%)|
45983207|NCT00460083|Device|EpiCeram(R) -ceramide based barrier repair cream|
45983208|NCT00427310|Drug|fluorouracil|
45983209|NCT00427310|Other|Observation|
45983210|NCT00427310|Drug|sodium heparin|
45983211|NCT00468741|Behavioral|CHESS (Comprehensive Health Enhancement Support System)|Full CHESS for subject use
45983212|NCT00468741|Behavioral|CHESS|informational services of CHESS available to subject
45983213|NCT00468741|Behavioral|CHESS|CHESS informational services and social support available to subject
45983214|NCT00427388|Drug|Methylprednisolone|Given by IV in 2 doses (250 mg each dose for a total of 500 mg)
45983215|NCT00427388|Other|Placebo|Given in 2 IV doses (approximately 4 ml of 0.9% normal saline solution in each dose)
45983216|NCT01056653|Behavioral|Standard Dose|Two intevention home visits
45456583|NCT02849223|Device|Sham stimulation|30 seconds of anodal TDCS stimulation will be applied to the left dorsal lateral cortex concurrent with working memory training
45456584|NCT02835313|Behavioral|FAST|Subjects participate in fast walking training 3x/week for 12 weeks.
45456585|NCT02835313|Behavioral|FAST+SAM|Subjects participate in fast walking training plus a step activity monitoring program 3x/week for 12 weeks
45456586|NCT02835313|Behavioral|SAM|Subjects participate in a step activity monitoring program 3x/week for 12 weeks
45456587|NCT02825576|Drug|Sugammadex|Sugammadex 2mg/kg given for reversal agent
45456588|NCT02825576|Drug|Neostigmine/Glycopyrrolate|Neostigmine 50 mcg/kg plus Glycopyrrolate 10 mcg/kg given for reversal agent
45456589|NCT02771990|Device|Sham transcranial direct current stimulation|sham stimulation
45456590|NCT02771990|Device|transcranial direct current stimulation|2 milliamp (mA) 20 minutes
45456591|NCT02738606|Drug|Chemotherapy|
45456592|NCT02738606|Other|Laboratory Biomarker Analysis|Correlative studies
45456593|NCT02738606|Procedure|Metastasectomy|Undergo lung metastasectomy
45456594|NCT02738606|Other|Quality-of-Life Assessment|Ancillary studies
45456595|NCT02738606|Procedure|Therapeutic Conventional Surgery|Undergo hepatectomy
45832566|NCT03150186|Other|SHS exposure in private cars|The investigators will measure levels of nicotine in 30 cars (two samples per car) in 2 European countries with different smoke-free legislation (Spain and UK). A convenience sampling will be performed considering feasibility. The investigators will recruit 30 drivers: 10 daily-smoking volunteers that usually smoke within their car; 10 daily-smoking volunteers that do not smoke within their car; and 10 non-smoking volunteers. To be eligible, participants have to spend a minimum of 30 minutes per day within the car. Nicotine vapor phase will be measured using passive SHS samplers. Two samplers will be hung up in each car during a period of 24 hours. One sampler will be open during the 24-hour sampling period. The other sampler will be only open during travelling time.
45983217|NCT01056653|Behavioral|High Dose|Four intervention home visits
45983218|NCT01056653|Behavioral|Comparison Group|One home visit, information only
45983219|NCT01056536|Behavioral|Structured intervention for the prevention of sexually transmitted infections (STI).|The structured intervention will include information about the number of travelers engaging in new sexual relationships, the different types of STI and their prevalence in different countries and population groups. The intervention will last approximately 5 minutes. At the end of the structured intervention the subjects will be offered free condoms.
45983220|NCT01056536|Device|Free condoms|Subjects will be proposed free condoms at the end of the pre-travel consultation.
45983221|NCT00427427|Drug|Trastuzumab|
45983222|NCT04704947|Drug|nonselective beta blocker|nonselective beta blocker
45983223|NCT04704947|Drug|cardio-selective beta blocker group|cardio-selective beta blocker group
45983224|NCT04704947|Drug|alendronate sodium|alendronate sodium
45983225|NCT04705142|Drug|MgSo4|Before and during administration of MgSO4, B.P, Capillary refill time, Heart rate and respiratory rate will be assessed closely i-e on 10 minutes interval, infusion of MgSO4 will be give over 30 minutes and baby will be monitored every 15 minutes interval after completion of infusion as well for 1 hour.
45983226|NCT04705064|Diagnostic Test|Prediction of postoperative acute kidney injury using an artificial intelligence|The performance of an artificial intelligence model to predict postoperative acute kidney injury will be tested prospectively.
45983227|NCT00460161|Procedure|acupuncture|2 treatments/week for 4 weeks
45983228|NCT00460161|Other|placebo/sham acupuncture|2 treatments/week for 4 weeks
45456596|NCT02719613|Drug|Elotuzumab|Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
45456597|NCT02719613|Drug|Dexamethasone|Patients will continue to receive treatment with non-investigational study drug by oral tablet administration at the last dose and schedule received in the previous study.
45456598|NCT02719613|Drug|Dexamethasone|Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
45456599|NCT02719613|Drug|Lenalidomide|Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
45456600|NCT02719613|Drug|Bortezomib|Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) or subcutaneous injection solution administration at the last dose and schedule received in the previous study.
45458724|NCT02320630|Drug|HCQ|Combination of HCQ+SSZ+MTX were given to patients for 60weeks (Week0-Week60).Entanercept was given to patients for 12 weeks (Week0-Week12).
45983229|NCT00427466|Drug|Pemetrexed|
45983230|NCT00468897|Drug|RSG XR|RSG XR tablets 8 mg enteric-coated tablet formulation consisting of 3mg fast release plus 5mg slow release. Subject will receive one 8mg of RSG XR on each dosing day. The subject will receive a single oral dose of regiment A or B with 240 milliliter (mL) of water.
45983231|NCT00427505|Drug|Deferasirox|
45983232|NCT00427544|Drug|PRA-027|
45983233|NCT00460200|Genetic|polymorphism analysis|
45983234|NCT00460200|Other|laboratory biomarker analysis|
45983235|NCT00460200|Other|physiologic testing|
45983236|NCT00460200|Other|questionnaire administration|
45983237|NCT00460200|Procedure|conventional surgery|
45983238|NCT00460200|Procedure|fatigue assessment and management|
45983239|NCT00460200|Procedure|psychosocial assessment and care|
45983240|NCT00427583|Drug|imatinib mesylate|
45983241|NCT00468936|Drug|Myfortic|enteric coated Cellcept pills in applicable dose for patient
45983242|NCT00427622|Other|physiologic testing|
45983243|NCT00469053|Drug|Buprenorphine|
45983244|NCT00427739|Procedure|Cardiac CT|64 slice spiral computerized tomography
45983245|NCT00460278|Drug|XL418|
45983246|NCT00460356|Other|Laboratory Biomarker Analysis|Correlative studies
45983247|NCT00460356|Procedure|Lymphadenectomy|Undergo lymphadenectomy
45983248|NCT00428012|Behavioral|Quality of Life Therapy|8 weekly individual counseling sessions
45983249|NCT00428012|Behavioral|Supportive Therapy|8 weekly individual counseling sessions
45983250|NCT00469131|Drug|tacrolimus + steroid|
45983251|NCT00469131|Drug|tacrolimus + mycophenolate mofetil|
45983252|NCT00428051|Other|Surveillance|No study drug, only interventions are blood draws and Chest X-rays
45983253|NCT00460395|Procedure|Surgery|
45983254|NCT00460395|Procedure|Stereotactic radiosurgery|
45983255|NCT02956356|Dietary Supplement|Control treatment + oral glucose|Control granulates (maize starch and long-chain fatty acids) with powder; 75g oral glucose load
45983256|NCT02956356|Dietary Supplement|SATIOSTAT treatment + oral glucose|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; 75g oral glucose load
45983257|NCT02956356|Dietary Supplement|Control treatment + meal intake|Control granulates (maize starch and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
45983258|NCT02956356|Dietary Supplement|SATIOSTAT treatment + meal intake|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
45983259|NCT00428129|Drug|microplasmin|20mg with Trellis-8 15cm Treatment length 40mg with Trellis-8 30cm Treatment length
45983260|NCT03271515|Biological|anti-CD19 anti-CD20 Bispecific CAR-T|patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
45983261|NCT00428168|Drug|Betahistine|Betahistine 24mg BID
45983262|NCT00428285|Procedure|Argon Plasma Coagulation|Argon Plasma Coagulation (APC) is a non-contact electrosurgical technique delivering a high-frequency electrical current through ionized argon gas i.e. the argon plasma. This current produces a zone of coagulation, desiccation, and devitalisation 2-3 mm deep. Patients will be offered up to 3 treatments if recurrence occur after the first two.
45983263|NCT00428363|Device|Cataract surgery with implantation of an intraocular lens|
45983264|NCT00428402|Behavioral|Focus Group Discussion|Focus groups meeting for up to 1 hour during the regular school day.
45983265|NCT00469170|Device|intravaginal ring|silicone elastomer intravaginal ring containing no drug product
45983266|NCT00469248|Device|Intra-aortic balloon pump counterpulsation|
45983267|NCT00428480|Behavioral|Daily reinforcement of walking speed (DRS)|Inpatients are encouraged to walk faster and given feedback on their walking speed during a daily 10-meter walk as part of their usual physical therapy.
45456601|NCT02719613|Drug|Pomalidomide|Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
45832567|NCT03150186|Other|SHS exposure in outdoor settings|In three types of outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings), nicotine vapor phase will be measured using active SHS samplers. For each country, a convenience sampling of 60 outdoor settings (20 of each of the above mentioned settings) will be performed. Data collection will be conducted from March to October. The measurements will be able to be taken at any time of day providing that there are at least five adults. The investigators will collect nicotine samples using samplers attached to an air pump. Measurements will last 30 minutes. While measurements are being taken, data collectors will also conduct observations in accordance with the protocol of active sampling collection.
45832568|NCT03875664|Drug|Liposomal bupivacaine|Extended-release local anesthetic
45832569|NCT03875664|Drug|Placebo - injection|Injectable normal saline solution
45832570|NCT01676064|Drug|ringer lactate solution|
45983268|NCT00428480|Behavioral|No reinforcement of walking speed (NRS)|Inpatients complete a 10-meter walk as part of their daily physical therapy but are not given any encouragement to walk faster or feedback on their walking speed.
45983269|NCT00460473|Drug|Dexmedetomidine|
45983270|NCT00460473|Drug|Placebo|
45983271|NCT00428519|Drug|Placebo|Placebo for 14 days
45983272|NCT00428519|Drug|Aprepitant|Aprepitant at a dose of 125 mg daily for 14 days
45983273|NCT00428519|Drug|Aprepitant|Aprepitant at a dose of 250 mg daily for 14 days
45983274|NCT00428558|Drug|Chemotherapy (DAUNORUBICINE-CYTARABINE)|A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
45983275|NCT00428558|Drug|Chemotherapy (DAUNORUBICINE-CYTARABINE)|Chemotherapy induction sequential
45983276|NCT00460512|Drug|Paliperidone ER|Paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day was given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics due to lack of efficacy, lack of tolerability, lack of compliance or other reasons.
45983277|NCT01056380|Drug|Nitazoxanide|Tablet, 500 mg with food twice daily for 5 days
45983278|NCT01056380|Drug|Placebo|Tablet, twice daily with food for 5 days
45983279|NCT00460590|Biological|MVA 85A|ID vaccine
46002567|NCT04646733|Other|High Protein Diet Group|The high protein diet (HPD) group is instructed to follow a low carbohydrate, high protein ketogenic diet. This diet has 4 phases, two of weight loss until reaching the ideal weight (attack and cruise) and two of maintenance (consolidation and stabilization). During the first 2 phases, it allows 100 foods (28 vegetables). The first phase lasts 3-10 days and 72 high-protein, low-fat foods are allowed. In the second phase, there are alternate days between consuming the low glycemic index vegetables plus protein and the next day with just protein. The first two phases are ad libitum. Phase 3 (consolidation) aims to avoid rebound and begins the introduction of complex carbohydrates and legumes in individual servings. In phase 4 (stabilization), the subject returns to a free diet. However, three basic rules are introduced: protein one day a week, the exercise of at least 20 min/day (optional) and consumption of 3 tablespoons of oat bran/day.
45832571|NCT01676064|Other|restrictive fluid regime|
45983280|NCT01055834|Drug|Eszopiclone 3 mg|"Group A Period I, Group B Period II:~Eszopiclone 3 mg tablet taken orally (po) with water as a single administration in the morning after fasting >=10 hours.~Except for the water taken with the drug, participants were not allowed any food/ drink from 10 hours before until 4 hours after administration of drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of drug.~Group B Period III:~Eszopiclone 3 mg tablet taken po with water as a single administration in the morning 30 minutes after the start of breakfast.~Except for the food/ drink at breakfast and the water taken with the study drug, participants were not allowed any food or drink from 10 hours before until 4 hours after administration of the drug. Except for the food/ drink at breakfast & the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration."
45983281|NCT01055834|Drug|Eszopiclone 1 mg|"Group A Period II, Group B Period I:~Eszopiclone three 1 mg tablets (total: 3 mg) taken orally with water as a single administration in the morning after fasting 10 or more hours.~Except for the water taken with the study drug, participants were not allowed any food or drink (except water) from 10 hours before until 4 hours after administration of the study drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of the study drug."
45983282|NCT00469326|Drug|Atorvastatin|two days 80mg atorvastatin pre-treatment before PCI
45983283|NCT01055639|Behavioral|In-Person ACT|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
45983284|NCT01055639|Behavioral|Telehealth ACT|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
45983285|NCT00460629|Procedure|Application of activated donor T cells|Ex-vivo generated donor T cells stimulated by antigen presenting cells loaded with peptides derived from leukemia-associated antigens
45983286|NCT00460668|Behavioral|pulmonary rehabilitation|2 or 3 times a week during 8 weeks
45983287|NCT04704713|Drug|Afamelanotide|
45983288|NCT04704713|Drug|Placebo|
45983289|NCT00469365|Behavioral|pharmacist contact with the patient via telephone|
45983290|NCT00469365|Behavioral|Pharmacist contact with the patient's physician via fax|
45983291|NCT00469365|Behavioral|Usual care|
45983292|NCT02957513|Behavioral|Text Messaging (TM)|As specified in the arm description above
45983293|NCT02957513|Behavioral|Health Coaching (HC)|As specified in the arm description above
45983294|NCT02957513|Behavioral|Enhanced Usual Care (EC)|As specified in the arm description above
45983295|NCT00460707|Drug|Casopitant 150 mg|Casopitant 150 mg will be available as white, film-coated tablets. Casopitant tablets will be taken with 240 milliliters (mL) of water at room temperature on an empty stomach.
45983296|NCT00460707|Drug|Ketoconazole|Ketoconazole will be available as 200 mg tablets which will be taken with 240 mL of water on an empty stomach (after a 2 hour fast on Day 4 of Treatment Period 2 and after a 1 hour fast on all other dosing days).
45983297|NCT00460707|Drug|Casopitant 150 mg matching placebo|Casopitant 150 mg matching placebo will be available as white, film-coated tablets.
45983298|NCT00460707|Drug|Casopitant 50 mg|Casopitant 50 mg will be available as pale orange, film-coated tablets. Casopitant tablets will be taken with 240 mL of water at room temperature on an empty stomach.
45983299|NCT00460707|Drug|Casopitant 50 mg matching placebo|Casopitant 50 mg matching placebo will be available as pale orange, film-coated tablets.
45983300|NCT00428636|Procedure|ileostomy|
45983301|NCT00469404|Drug|Buprenorphine|
45983302|NCT01055132|Device|Etafilcon A toric contact lens|contact lens to correct astigmatism
46083016|NCT04260035|Drug|Vasoactive Intestinal Polypeptide (VIP)|20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.
45832572|NCT01670136|Drug|1 dose of sildenafil|A single IV dose of sildenafil will be administered over 90 minutes with no greater than a 15-minute flush. Final dose to be determined based on at least the first 4 participants enrolled in Cohort 1; final dose expected to be a single dose between 0.25 and 0.5 mg/kg.
45832573|NCT03873714|Device|Pipeline™ Vantage Embolization Device with Shield Technology™|Pipeline™ Vantage Embolization Device with Shield Technology™
45983303|NCT01055132|Device|Nelfilcon A toric contact lens|contact lens to correct astigmatism
45983304|NCT00460785|Drug|Opioid|
45983305|NCT01054976|Drug|Galantamine|Orally administered Galantamine 8 mg/day for the first 4 weeks. Thereafter the dose will be increased to 16 mg/day. If tolerated, the dose of galantamine can be increased up to 24 mg/day.
45983306|NCT00469443|Drug|Irinotecan|Irinotecan 150mg/m2 IV on day 1 every 2 weeks for 10 cycles
45983307|NCT00469443|Drug|5-Fluorouracil|5-Fluorouracil 400 mg/m2 infused over 10 min IV and 5-FU 600 mg/m2 infused over 22 hours IV, on Day 1 and 2 (De Grammont regimen), every 2 weeks for 10 cycles
45983308|NCT00469443|Drug|Leucovorin|Leucovorin 200 mg/m2 infused over 2 hours IV, on day 1 and 2 every 2 weeks for 10 cycles
45983309|NCT00469443|Drug|Capecitabine|Capecitabine 2000mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
45983310|NCT00469443|Drug|Bevacizumab|Bevacizumab 5mg/kg IV on day 1 every 2 weeks for 10 cycles
45983311|NCT00469443|Drug|Bevacizumab|Bevacizumab 7,5mg/kg IV on day 1 every 3 weeks for 6 cycles
45983312|NCT00469443|Drug|Irinotecan|Irinotecan 250mg/m2 IV on day 1 every 3 weeks for 6 cycles
45983313|NCT00460863|Procedure|using cool versus warm dialysate during hemodialysis|
45983314|NCT00428870|Procedure|Arthroscopic acromioplasty or arthroscopy alone (sham) or conservative treatment (rehabilitation)|
45983315|NCT00469482|Other|Sedation,RASS Targeted plus BIS Monitoring|Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring
45983316|NCT00469482|Other|Sedation, RASS Targeted|Patient sedation utilizing standard of care methods (RASS targeted)
45983317|NCT00428909|Drug|Imatinib/Acetaminophen|
45983318|NCT00469521|Drug|Refresh Tears, 9582X|
45983319|NCT00429065|Drug|Rituximab|
46083017|NCT04260035|Drug|Sterile saline|20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.
45983320|NCT02956941|Behavioral|BCC on Essential Nutrition and Hygiene Actions (ENHAs)|The behavioral change communication (BCC) on micronutrient intake messages will be implemented based on Essential Nutrition and Hygiene Actions (ENHAs) on micronutrient deficiencies prevention and control. BCC intervention training workshop will be given to science teachers by principal investigator/ senior health professional in local language. Interventions will be delivered to students by their science teachers under the supervision of principal investigator/ school director for the consecutive three times.
45983321|NCT00429221|Behavioral|Tailored Medication Messages for Parents|
45983322|NCT00460902|Device|Transcranial Magnetic Stimulation (TMS)|
45983323|NCT04704206|Other|Children will perform activities on interactive tablet|"The main difference between the types of interventions is the mode of use and the level of interactivity of the interactive media, where the AIMG actively performs activities, that is, there is user interaction with the equipment through touch or verbal response and the performance of activities like rotating an object, dragging and zooming. PIMG is not the same, the user is just a spectator, having contact with the equipment only when switching on / off, choosing the content, performing activities such as increasing / decreasing the volume and touching certain specific objects such as giving play / pause . Both groups will have a total of 48 intervention sessions."
45983324|NCT00469560|Drug|Deferasirox|
45983325|NCT04704167|Other|fixation of double barrel vascularised fibula|3D titanium miniplate or 3D titanium mesh tray are used as a method of fixation for double barrel vascularized fibula
45672932|NCT04114084|Procedure|Bone Marrow Aspirate and Biopsy|The aspirate sample obtained for research at the time a standard-of-care biopsy is taking place will be approximately 40cc. Bone marrow aspiration removes bone marrow fluid and cells through a needle placed into the bone. Usually this sample is taken from the back of the pelvic bone, but it may also be taken from the sternum or the front of the pelvic bone. A bone marrow biopsy removes bone with the marrow inside and is done prior to the aspirate. Each biopsy and aspirate procedure takes approximately 15 minutes total. Bone marrow aspirate may be collected in a separate tube for research or collected from the standard-of-care specimen with left-over aspirate not otherwise needed for clinical purposes, or from previous procedures.
45672933|NCT02163902|Drug|ATX-101|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
45983326|NCT00469599|Drug|paricalcitol|3 microg 3 times a week. dosage is increased/decreased 50 % every second week according to iPTH, ionised s-calcium and phosphate
45983327|NCT00469599|Drug|alfacalcidol|1 microg 3 times a week, dosage is titrated every second week according to iPTH, phosphate and ionised s-calcium.
45983328|NCT00429260|Drug|Saredutant|
45983329|NCT00460980|Behavioral|Virtual reality laparoscopic simulator training|The aim of this project is to determine whether a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience. We aim to show that with the virtual reality trainer, operative skills will be improved and that overall operative time will be decreased.
45983330|NCT00429338|Procedure|AIR-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with an air-filled endorectal coil (AIR-MRSI).
45983331|NCT00429338|Procedure|PFC-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with a perfluorocarbon compound (PFC)-filled endorectal coil (PFC-MRSI).
45983332|NCT00469638|Procedure|Left atrial catheter ablation guided by introducer using Agilis sheeth|Left atrial catheter ablation guided by introducer using Agilis sheeth
45983333|NCT00469638|Procedure|Left atrial catheter ablation guided by introducer using Non-steerable sheeth|Left atrial catheter ablation guided by introducer using Non-steerable sheeth
45983334|NCT00429377|Drug|tacrolimus|
45983335|NCT00469716|Drug|Hypertonic saline (7.2%) hetastarch (6 %)(200/0.5)|
45983336|NCT00429455|Behavioral|Survey|3-Part Questionnaire
45672934|NCT02163902|Drug|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
45672935|NCT01630616|Drug|Odanacatib|single oral dose, tablets, 10 or 50 mg
45672936|NCT01630616|Drug|Placebo|single oral dose, tablets
45672937|NCT03774875|Drug|Apremilast|Apremilast 30 mg tablets taken orally twice a day.
45983337|NCT00461019|Procedure|Implantation and activation of the vagus nerve stimulator|Implantation of the nerve stimulator, cuff nerve electrode and RV sensing lead
45983338|NCT00429533|Drug|Dapsone|
45983339|NCT00461058|Drug|Actos|Titrated to an individual maximum tolerated dose up to 45mg p.o. daily
45983340|NCT00461058|Drug|aleglitazar|Titrated to an individual maximum tolerated dose up to 0.3mg p.o. daily
45458725|NCT02320630|Drug|MTX|MTX was given to patients for 60weeks (Week0-Week60). Entanercept was given to patients for 12 weeks (Week0-Week12).
45672938|NCT03774875|Drug|Placebo|Placebo tablets taken orally twice a day
45672939|NCT02220764|Device|Teeth abutment|
45983341|NCT00429611|Procedure|Cardiac defibrillation at high energy vs low energy levels|Defibrillation with progressive high-energy biphasic shocks at 200J, 300J and 360J or low-energy biphasic shocks at 150J, 150J and 150J.
45983342|NCT00461136|Drug|Aliskiren|
45672940|NCT02220764|Device|Implant abutments|
45672941|NCT05264324|Procedure|Maximal Exercise Capacity|Maximal Exercise Capacity in incremental ramp exercise tests.
46083018|NCT00943423|Radiation|Involved Field Radiotherapy|IFRT 30Gy delivered in daily fractions of 1.8 - 2.0Gy
46083019|NCT00943423|Other|No further treatment|
46083020|NCT04941209|Device|imPulse™ Una infrasound-to-ultrasound e-stethoscope|The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
46083021|NCT04941209|Diagnostic Test|(PPA >95%) FDA EUA RT-PCR|Real-time RT-PCR that detects amplified SARS-CoV-2 genome in sputum, nasopharyngeal or oropharyngeal swabs, bronchoalveolar lavage fluid, nasal or nasopharyngeal aspirate, and lower respiratory tract aspirates.
45672942|NCT04755920|Drug|SGM-101|Fluorescence-guided surgery
45672943|NCT04758806|Biological|Fecal microbial transplantation|Procured faeces procured from unrelated donor
45983343|NCT02957708|Other|mCIMT + SR|"Each participant wears a customized cotton sling on the unaffected arm for six hours everyday. Participant is engaged in fifteen unimanual tasks during the three-week training that provides them sufficient challenge and opportunities for repetition.~SR is incorporated on the 1-hour structured practice by using video playback to help participants realize their own performance for better learning. Participant first performs a task with videotaping, then identifies steps with problems or difficulties by video playback of participant's performance. Secondly, participant is asked for possible solutions, prompting is given if needed. Lastly, participant performs the activity by adopting the suggested solutions with videotaping again to facilitate participant's evaluation of new performance."
45672944|NCT01563172|Drug|Sodium fluoride / silica and carbopol, 0.5g|Dentifrice containing 1150 parts per million (ppm) fluoride as sodium fluoride / silica and 0.4% carbopol
45672945|NCT01563172|Drug|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 1150 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
45672946|NCT01563172|Drug|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 250 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
45672947|NCT01563172|Other|Fluoride free dentifrice|A non fluoride dentifrice was given to participants of each arm at washout period
45983344|NCT02957708|Other|Control|A combination of training on functional and remedial activities on unimanual tasks and bimanual tasks that based primarily on neurodevelopmental approach are provided. The training aims at increasing control, strength and functional use of their affected arm and hand, and improving bimanual coordination in performing daily activities. Each participant receives 1 to 2 hours of training per week at school. Home exercise including both unimanual and bimanual tasks is prescribed to them as well.
45983345|NCT00469794|Procedure|stress test|
45983346|NCT00429650|Behavioral|increased exercise|Use prescribed number of minutes of exercise 5-6 days per week to maintain weight loss.
45983347|NCT00429650|Behavioral|diet|Use a prescribed diet to maintain weight loss
45983348|NCT00429650|Behavioral|Exercise and Diet|Use a combination of exercise and diet to maintain weight loss.
45983349|NCT00461214|Other|Participation in laparoscopic training curriculum|General Surgery Training Outcome
45983350|NCT00429689|Procedure|Saliva sample|
45983351|NCT00469872|Procedure|Context-focused compared to child-focused interventions|
45983352|NCT00429728|Drug|GW876008|
45983353|NCT03271476|Behavioral|EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient supporting Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care Visit 8 : EMDR psychotherapy care ans questionnaires Visit 9 (one month after) : semi-directive interview and data recovery (questionnaires)
45983354|NCT03273738|Diagnostic Test|folate level measurement|the level of folate measured in plasma with homocysteine
45983355|NCT03273738|Diagnostic Test|B12|B12 measurement in blood
45983356|NCT04704245|Drug|epidermal growth factor (EGF)-containing ointment|The subjects applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
45672948|NCT04755764|Drug|Labetalol|Beta blocker
45983357|NCT04704245|Drug|Vehicle ointment|To compare the effect of epidermal growth factor (EGF) ointment, the control subjects applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
45672949|NCT04755764|Drug|Atenolol|Beta blocker
45672950|NCT04755764|Drug|Nifedipine|Calcium channel blocker
45672951|NCT04113616|Drug|KRT-232|KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth.
45672952|NCT04113616|Drug|Cytarabine|Cytarabine is an anti-cancer chemotherapy drug taken via injection.
45983358|NCT04704245|Procedure|Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening."
45983359|NCT03271671|Other|NAVA during Non invasive ventilation|NIV during respiratory failure
45672953|NCT04113616|Drug|Decitabine|Decitabine is an anti-cancer chemotherapy drug taken via injection.
45983360|NCT03271671|Other|PSV during Non invasive ventilation|PSV during respiratory failure
45672954|NCT05330195|Other|Bicycle Ergometer Training|Bicycle ergometer training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 40 minutes total duration consisting of 5 min warm up and 5 min cool down period to children in treatment group.
45672955|NCT05330195|Other|Home-based exercise group|Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
45672956|NCT03774641|Drug|Lamictal|Blood-serum levels will be checked monthly during pregnancy and reference concentration will be maintained
45672957|NCT02161718|Drug|Samidorphan + olanzapine (ALKS 3831)|Oral tablet, taken once daily
45672958|NCT02161718|Drug|Placebo + olanzapine|Oral tablet, taken once daily
45672959|NCT05292989|Other|Frailty Assessment|Personalised (tailored) approach that includes assessment of frailty and structured information provided to the consumer
45672960|NCT05292989|Other|Standard Care|Standard care practice
45672961|NCT03697343|Radiation|Radiosurgery|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm)
45983361|NCT04703933|Other|EVALUATION OF THE LEVEL OF KNOWLEDGE AND ATTITUDE OF THE OPERATING ROOM NURSES|This descriptive study was conducted with 100 nurses working in the operating room of two university hospitals in Istanbul
45983362|NCT03271632|Biological|CAR T cells|Infusion of multi-CAR T cells
45983363|NCT00429806|Drug|DHEA|DHEA
45983364|NCT00429806|Drug|Placebo|Placebo
45983365|NCT03273660|Device|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|"First treatment was performed during baseline visit, after the basal evaluations planned by the study procedure.~0.5-1.1 ml of Aliaxin (new trademark) for emi-face was injected by needle (25-27 G) and/or cannula (25 G, 40 mm).~A touch-up treatment (0.5-1.1 ml of Aliaxin new trademark for subject) was performed after 3-4 weeks (T1) in order to treat possible asymmetry."
45983366|NCT00429845|Behavioral|Nutritional|
45456602|NCT02719613|Drug|Nivolumab|Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
45672962|NCT03697343|Radiation|Fractionated stereotactic radiotherapy|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm
45672963|NCT05186987|Procedure|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
45672964|NCT05186987|Procedure|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
45672965|NCT02100449|Other|Lung ultrasound and Doppler (Day 0)|In patients presenting a consolidation of suspected atelectatic nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0 only.
45672966|NCT02100449|Other|Lung ultrasound and Doppler (Day 0 and Day 3 to 5)|In patients presenting a consolidation of suspected infectious nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0 and on Day 3 to 5. A bronchoalveolar lavage will also be performed on Day 0.
45672967|NCT02219048|Drug|Placebo|680 micrograms BID, Orally inhaled placebo for 12 weeks
45672968|NCT02219048|Drug|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 12 weeks
45672969|NCT02074631|Drug|Pamidronate|Subjects randomized to pamidronate treatment will receive infusions, 1 mg/kg (to a max dose of 60mg) over 4 hours, every 3 months at approximately 100 days, 180 days, and 270 days after HCT.
45832574|NCT01670214|Procedure|pulsed electromagnetic field|parameters of the pulsed electromagnetic field are frequency:10 Hz, intensity 4-5 mT, 6 sessions( 2 week) for placebo and phase 1 treatment ( 3 sessions in week) and added 6 sessions for phase 2 treatment. the solenoid diameter of instrument is 70 cm is placed around the head.
45832575|NCT04747002|Drug|DSP-7888|Cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize WT1 peptides
45832576|NCT03873480|Procedure|Administration of Marcaine without Epinephrine prior to the start of surgery|The intervention is the timing of administration of marcaine without epinephrine during a trigger thumb surgery.
45983367|NCT03271593|Other|No intervention|No intervention
45983368|NCT00469950|Behavioral|exercise training|Exercise training in groups
45983369|NCT00429962|Drug|intravitreal ranibizumab|intraocular injection
45983370|NCT00429962|Drug|intravitreal ranibizumab & photodynamic therapy|intraocular injection photodynamic treatment (LASER) after intravenous injection
45983371|NCT03273504|Other|Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)|The study product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the right or left leg (tibialis area) according to a randomisation list.
45983372|NCT03273504|Other|Placebo|The placebo product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the controlateral leg (tibialis area) right or left leg according to a randomisation list.
45983373|NCT00430001|Drug|docetaxel|
45983374|NCT00430001|Drug|vinorelbine|
45983375|NCT00430001|Drug|trastuzumab|
45983376|NCT00461370|Drug|SRX251|
45983377|NCT04703894|Dietary Supplement|AYMES 'CARDIFF'|AYMES CARDIFF is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
45983378|NCT00461448|Dietary Supplement|Potassium supplement|Patients were randomly allocated to receive either an EGJ containing 234.5 mmol microcrystalline KCl a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily) or PGJ for 28 days.
45983379|NCT00430079|Drug|etanidazole|Given IV
45983380|NCT00430079|Procedure|conventional surgery|Undergo surgery
45983381|NCT00430079|Other|pharmacological study|Correlative studies
45983382|NCT00430079|Other|laboratory biomarker analysis|Correlative studies
45983383|NCT00469989|Procedure|Infection with hookworm larvae|
45983384|NCT00430118|Drug|asparaginase|
45983385|NCT00430118|Drug|cyclophosphamide|
45983386|NCT00430118|Drug|cytarabine|
45983387|NCT00430118|Drug|daunorubicin hydrochloride|
45983388|NCT00430118|Drug|dexamethasone|
45983389|NCT00430118|Drug|doxorubicin hydrochloride|
45983390|NCT00430118|Drug|etoposide|
45983391|NCT00430118|Drug|ifosfamide|
45983392|NCT00430118|Drug|mercaptopurine|
45983393|NCT00430118|Drug|methotrexate|
45983394|NCT00430118|Drug|prednisone|
45983395|NCT00430118|Drug|thioguanine|
45983396|NCT00430118|Drug|vincristine sulfate|
45983397|NCT00430118|Drug|vindesine|
45983398|NCT00430118|Radiation|radiation therapy|
45983399|NCT00461487|Behavioral|Active control on hygiene and nutrition|The active control group will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. The mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the active control on hygiene and nutrition will be delivered to the mother.
45983400|NCT00461487|Behavioral|Families Talking Together|The intervention will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. A mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. There will be three follow-up booster sessions administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
45983401|NCT00461526|Drug|crofelemer|125 mg crofelemer vs. placebo
45983402|NCT00430157|Drug|GSK256066|
45983403|NCT00461565|Drug|Sildenafil|A1) Two dosis of 200 mg Sildenafil orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
45983404|NCT00461565|Drug|Placebo|A2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
45983405|NCT00461565|Drug|Vardenafil (Levitra, BAY38-9456)|B1) At least 15 dosis of 20 mg Levitra orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
45983406|NCT00461565|Drug|Placebo|B2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
45983407|NCT00430196|Drug|BOTOX®|
45456603|NCT02660645|Drug|Hexaminolevulinate hydrochloride (HCL)|Instillation in bladder
45456604|NCT02660645|Device|Karl Storz D-Light C Photodynamic Diagnostic (PDD) system|Cystoscopy procedure
45456605|NCT02625324|Device|Valiant Evo Thoracic Stent Graft System|Procedure: thoracic endovascular aneurysm repair (TEVAR)
45456606|NCT02603887|Other|Laboratory Biomarker Analysis|Correlative studies
45456607|NCT02603887|Biological|Pembrolizumab|Given IV
45456608|NCT02573779|Other|Observational - no intervention|This study will observe cohorts of infants who are fed primarily either their own mother's milk or donor milk as part of their routine care. No direct intervention is performed as part of the study.
45456609|NCT02512003|Device|Fantom Scaffold|
45672970|NCT02074631|Drug|Calcium and vitamin D|All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.
45672971|NCT03635645|Device|New visual processing unit (VPU) with asymmetric waveforms|A VPU will apply asymmetric and symmetric stimulation pulses.
45672972|NCT03635645|Device|New VPU with bipolar stimulation|A VPU will apply bipolar stimulus pulses.
45672973|NCT05185661|Behavioral|eHealth education|"eHealth education intervention regarding the dietary plan, healthy-lifestyle, and hygiene:~Group-wise eHealth education through online PowerPoint presentation session among study participants with their guardian: Two times (Before starting the intervention and mid-line; end of 4th-month intervention)~eHealth education through phone calls & SMS~1st to 4th month: 4 times in a month~5th to 6th month: 3 times in a month~6th to 8th month: 2 times in a month~Control group will not get care and education"
45456610|NCT02475681|Drug|Acalabrutinib|
45456611|NCT02475681|Drug|Obinutuzumab|
45672974|NCT04192799|Behavioral|Direct admission|Process of pediatric admission is through admission directly into the pediatric hospital medicine unit
45672975|NCT04192799|Behavioral|ED admission|Process of pediatric admission is through the emergency department
45832577|NCT03872310|Device|STARSTIM|Right DLPC was located as F4 according to the international 10-20 EEG system. Anodal tDCS was delivered with the anodal pole on the right DLPFCand the cathodal pole on the left cheek of the participant to avoid contaminating other brain regions during electrical stimulation via a pair of rubber electrodes housed in saline-soaked sponge coverings (5x5 cm^2). The direct current was applied with 1.5 mA for 15 min which can facilitate visual short-term memory and create an excitatory effect for up to 90 min. The anodal tDCS stimulated the right DLPC for 15 min with 1.5 mA in active tDCS condition. The sham tDCS condition followed identical tDCS protocol and same 15-min duration except the stimulation time only lasted for the initial 30s so that the participants felt the same initial tingling sensation (if any, only in some participants) but without the actual stimulation. The investigators will perform assessments of adverse effects after each session by a standardized questionnaire.
45832578|NCT04404426|Dietary Supplement|L-citrulline|Administration of citrulline enterally for 7 days.
45832579|NCT04404426|Other|Placebo|Administration of placebo (water) enterally for 7 days
45832580|NCT04764084|Drug|Niraparib|Niraparib 100mg or 200mg, PO, qd，d1-d21
45832581|NCT04764084|Drug|Anlotinib|Anlotinib 12mg, PO, qd，d1-d14
45983408|NCT00430196|Drug|Zanaflex®|
45983409|NCT00470028|Device|Transcranial Magnetic Stimulation|
45983410|NCT00430235|Drug|BAY 43-9006|BAY 43-9006, 400 mg, PO, BID in a 28-day cycle(morning and evening) Bicalutamide 50 mg po Once daily in a 28-day cycle (morning)
45983411|NCT00470145|Drug|SB-568859|
45983412|NCT04697979|Other|Questionnaire|"Selection of patients for a discharge interview in the stroke unit with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week and then at two months after hospitalization.~Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week and then at two months after discharge. Elements on knowledge of treatment, dietary measures and warning signs and recurrence of stroke will be collected and re-explained if necessary."
45983413|NCT00430391|Other|DVD Consent|Participants are randomized to DVD enhanced consent that is either high risk or low risk.
45983414|NCT00430391|Other|Routine Control|Participants are assigned to the routine, standard consent.
45983415|NCT00470340|Drug|Oxaliplatin, gemcitabine, cisplatin, lipiodol|Oxaliplatin, gemcitabine, cisplatin, lipiodol
45983416|NCT00430430|Procedure|High MUFA dietary portfolio|high monounsaturated fat background diet to dietary portfolio
45983417|NCT00430430|Procedure|Low MUFA dietary portfolio|low monounsaturated fat background diet to dietary portfolio
45983418|NCT00430469|Drug|human lactoferrin (hLF1-11)|intravenous 0.5mg in NaCl-solution
45983419|NCT00461643|Drug|Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins|
45983420|NCT00430547|Drug|Carbimazole, radio-active iodine (I131)|
46083022|NCT04941209|Radiation|HR-CT-scan|High-resolution computer tomography, or CT/CAT, is an X-ray scan that produces images of the chest and is used as a confirmatory test in symptomatic patients that have a negative PCR test.
46083023|NCT00768651|Drug|Pantoprazole|Starting on Day 1, Pantoprazole 80 mg daily (40 mg every morning and 40 mg every evening) administered orally at the same time each day for a period of 6 months.
46083024|NCT00768651|Drug|Sitagliptin|Starting on Day 1, Sitagliptin 100mg once daily administered orally at the same time each day for a period of 6 months.
46083025|NCT05378750|Other|Diuretic algorithm|Implementing diuretic algorithm
45456612|NCT02475681|Drug|Chlorambucil|
45456613|NCT02475434|Dietary Supplement|Cream Supplement group|Infants in the intervention arm will receive the cream supplement in addition to the standard regimen.
45672976|NCT04786145|Procedure|Cryoneurolysis|This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways by freezing it. Small probe is inserted in order to freeze the target nerve, can facilitate complete regeneration of the structure and function of the affected nerve.
45832582|NCT03860922|Device|Magnetic Resonance Imaging|all patient will undergo Magnetic resonance imaging and magnetic imaging arthrography of the ankle joint.
45983421|NCT00430586|Drug|Botulinum neurotoxin type A, free of complexing proteins|Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.
45983422|NCT00430586|Drug|Placebo|Single treatment with Placebo given as intramuscular treatment injections of equal amount to 5 sites on Day 0. A volume of reconstituted 0.6 mL per subject was administered. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL Placebo per injection site.
45983423|NCT00461760|Procedure|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See Detailed Description.
45983424|NCT00461760|Procedure|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See detailed description.
45983425|NCT01053962|Drug|SP-304 0.3 mg|SP-304 0.3 mg
45983426|NCT01053962|Drug|SP-304 1.0 mg|SP-304 1.0 mg
45983427|NCT01053962|Drug|SP-304 3.0 mg|SP-304 3.0 mg
45983428|NCT01053962|Drug|SP-304 9.0 mg|SP-304 9.0 mg
45983429|NCT01053962|Drug|Placebo|Placebo
45983430|NCT00461799|Drug|orlistat|
45983431|NCT00430664|Procedure|Pleurodesis with either talc or iodopovidone|
45983432|NCT00461838|Procedure|multidisciplinary laparoscopy|Multidisciplinary (with active involvement of the colorectal surgeon/urologist) fertility-sparing CO2 laser laparoscopic radical excision of deep infiltrating endometriosis.
45983433|NCT00461838|Other|Questionnaires|Patients (n=56) were asked to complete questionnaires regarding quality of life (QOL), pain, fertility and sexuality to compare their status before and after surgery, and their medical files were analyzed.
45983434|NCT00430703|Behavioral|body weight support treadmill training|Gait training: Gait robot (Lokomat®, Hocoma, Switzerland) is adjusted to the patient/healthy volunteer individually with chest strap, pelvic straps, harness, leg cuffs and foot lifters. Weight is adjusted individually, so there is a minimum weight support (i.e. when one foot is standing on the treadmill the other foot lifts free from the treadmill thereby simulating normal gait). Gait speed is 1,7-2,3 km/hour (speed can be changed and adjusted that the normal step length is achieved).The duration of the training session is 20 minutes.Blood pressure and pulse are monitored.
45983435|NCT00470379|Drug|resiquimod|Escalating the dose of resiquimod applied to a fixed area of skin followed by application of topical NY-ESO-1b.
45983436|NCT00430742|Drug|Taranabant|Taranabant 0.5 mg, 1 mg capsule, 2 mg capsule once daily Treatment for 52 weeks.
45983437|NCT00430742|Drug|Comparator: Placebo|Placebo capsule once daily. Treatment for 52 weeks.
45832583|NCT02984904|Other|survey|survey
45456614|NCT02435316|Other|Case vignette-based teaching of cell recognition|Intervention group members will be taught peripheral blood smears by using power point slides and utilizing additive microskills using the compare/ contrast technique to recognize various cell types. Memory will be reinforced by using cases to help recognize the clinical importance of learning about individual cell types.
45456615|NCT02435316|Other|Compare-contrast basic science teaching of cell recognition|The control group will be given a traditional 60-minute lecture using board review questions with accompanying pictures of peripheral blood smears, without explaining individual cell type.
45983438|NCT00430820|Procedure|per intervention|per intervention
45983439|NCT00470457|Biological|Allergen specific immunotherapy|
45983440|NCT00430859|Drug|Alkaline Phosphatase|Intravenous over a period of 24 hours
45983441|NCT00430859|Drug|Placebo|Saline over a period of 24h
45983442|NCT03271320|Other|appearance scales|appearance scales : AVS; ASWAP; DAS 59
45983443|NCT03271164|Device|FBPM10 System|Application of the FBPM10 membrane followed by illumination with a multi-Light Emitting Diode (LED) lamp.
45983444|NCT03271164|Other|Massages with vitamin E cream|The other breast will be treated with wound massages with vitamin E cream.
45983445|NCT00430898|Drug|Basiliximab|3 doses of 40mg, IV at baseline, week 2, and week 4
45983446|NCT00470613|Genetic|SGT-53|For Phase Ib: SGT-53 (2.4 mg DNA per infusion) will be administered in combination with docetaxel at 40 mg/m2 starting dose, cohort 1, cycle 1. SGT-53 will be administered weekly, on day 1 in weeks 2, 3, 5, and 6, and biweekly on days 1 and 4 in weeks 1, 4, and 7. Docetaxel will be administered every 3 weeks (weeks 1, 4, and 7)on day 3. Patients completing cohort 1, cycle 1 without DLT at 40 mg/m2 docetaxel will be allowed to dose escalate to 60 mg/m2 docetaxel in cycles 2 and 3.Cohort 2 (2.4mg DNA/infusion;75mg/m2 Docetaxel) will open 3 weeks after demonstration of 0/3 or ≤1/6 DLTs at docetaxel 60 mg/m2. Cohort 3 (3.6 mg DNA/infusion; 75 mg/m2 Docetaxel) will open after demonstration of 0/3 or ≤1/6 DLTs at SGT-53 2.4 mg DNA/infusion and docetaxel 75 mg/m2.
45983447|NCT00461916|Drug|Half-Dose Depot Triptorelin|
45983448|NCT00461916|Drug|Reduced-Dose Daily Buserelin|
45983449|NCT00430976|Behavioral|Minds in Motion|
45832584|NCT03871530|Other|Coordinate A|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
45832585|NCT03871530|Other|Coordinate B|"PIEB Next Bolus: 45 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
45832586|NCT03871530|Other|Coordinate C|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
45832587|NCT03871530|Other|Coordinate D|"PIEB Next Bolus: 45 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
45832588|NCT03871530|Other|Coordinate E|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 5 mL"
45983450|NCT03273465|Other|Fecal transplantation|Fecal transplantation administered orally via frozen capsules.
45983451|NCT02957409|Drug|sacubitril/valsartan|This study is designed as an observational, naturalistic, multicenter study in patients being treated with sacubitril/valsartan as per the Canadian product label. Treatment initiation with sacubitril/valsartan must be within the last 3 months. Sacubitril/valsartan will be used as commercially available supplies which are available as Film coated tablets in 3 dosage: 1) 24 mg sacubitril / 26 mg valsartan, 2) 49 mg sacubitril / 51 mg valsartan and 3) 97 mg sacubitril / 103 mg valsartan.
45983452|NCT01053221|Drug|Mycophenolic Acid|Mycophenolate mofetil: 750mg po bid x 36 months OR mycophenolate sodium 540mg po bid x 36 months
45983453|NCT01053221|Drug|Standard of Care: CNI and MPA|Tacrolimus or cyclosporine: dosed according to trough levels per standard of care Mycophenolate mofetil 750mg po bid or mycophenolate sodium 540mg po bid x 36 months
45983454|NCT02956551|Biological|DC vaccine|subcutaneous administration
45983455|NCT00431054|Drug|Perifosine|Loading Dose = 100 mg by mouth (PO) every 6 hours, followed by 50 mg by mouth (PO) daily
45983456|NCT00431054|Drug|Docetaxel|75 mg/m^2 by vein over 1 hour every 4 weeks
45983457|NCT00470652|Device|computer-assisted decision support|at the end of the pre-intervention period, the patient flow software was modified to open popup windows automatically when pain intensity was not documented or pain was not reevaluated within the recommended interval. The popup window also detailed appropriate pain treatment guidelines based on the documented pain intensity. In addition, the patient's icon in the flow software changed from black to red when pain intensity was >4/10. After a 10-day test period, the post-intervention data collection started.
45983458|NCT00431171|Drug|Lithium carbonate|
45983459|NCT02956395|Other|Integrated care intervention|"Integrated care intervention is implemented by a multidisciplinary team from the hospital and from the Primary Care.~The intervention after hospital discharge a) Phone call at 24 hours; b) Home visit at 72 hours after discharge by one member of the transitional care team, if is needed; During this visit, the therapeutic plan for each patient will be customized to their individual frailty factors and shared with the primary care team. Reinforcement of the logistics for treatment of co-morbidities and social support will be done accordingly; c) Accessibility to the point of care available 24 hours/day ; d) Accessibility to the individualized PHF, as self-management tool ; d) appointment at 1m after discharge and after 12 m"
45983460|NCT00431210|Biological|Epstein-Barr virus-specific adoptive T-cells immunotherapy|Given intravenously on Day 1 and Day 14
45456616|NCT02425345|Behavioral|Physical Activity|The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.The intervention is conducted primarily by mail with website support and resources available.
45983461|NCT00470691|Procedure|plaster cast|complete circular plaster cast
45983462|NCT00470691|Procedure|dorsal splint|dorsal plaster splint
45983463|NCT00431249|Drug|Cilostazol|
45983464|NCT00431288|Behavioral|diet high in fruits, vegetables, and dairy|
45672977|NCT04786145|Procedure|Radiofrequency ablation|This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways. Small needle with an active heating tip is inserted, to destroy the functionality of the target nerve using heat from radiofrequency energy.
45983465|NCT00431288|Behavioral|Routine nutrition care|
45983466|NCT00470769|Procedure|Color-Doppler Ultrasound, 99mTc-DTPA scintigraphy|
45983467|NCT00470808|Drug|POMx|
45983468|NCT00461955|Procedure|autologous peripheral blood stem cell transplantation, ex vivo amplified|autologous peripheral blood stem cell transplantation, ex vivo amplified
46083026|NCT00943501|Drug|liraglutide|Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
46083027|NCT00943501|Drug|placebo|Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
46083028|NCT00943501|Drug|liraglutide|Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
46083029|NCT00943501|Drug|placebo|Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
46083030|NCT04234256|Other|Static stretching exercise|Standing quadriceps stretch, Gastrocnemius stretch, Standing split, Adductor stretch, Half kneeling groin stretch, Hamstring stretch on the bench, Prayer squat, Seated adductor and hamstring stretch, Hurdle seat, Seated glute stretch, Lying glute stretch, Seated groin abduction, Soleus stretch, Half kneeling quad stretch, Split hamstring stretch
46083031|NCT04234256|Other|Dynamic stretching exercise|Downward dog to runner's lunge, Dynamic squat stretch, Crescent to hamstring stretch, Half kneeling hamstring stretch, Side to side lunge with reach, Standing calf and hamstring stretch, Hurdles, Side to side lunge with step, IT band stretch, Walking quad stretch, Swing the leg forward and back, Swing the leg cross, Knee pull, Standing quat stretch, Standing gluteus stretch
45983469|NCT00470886|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan
45983470|NCT00431483|Behavioral|pharmaceutical consulting|to measure if information and advice by a pharmacist has an impact on quality and quantity of prescribed antibacterials
45983471|NCT00461994|Behavioral|diet|
45983472|NCT00461994|Behavioral|exercise|
45983473|NCT00461994|Behavioral|diet and exercise|
45983474|NCT00431522|Drug|Valproic acid, sodium salt|
45983475|NCT00462111|Drug|Indometacin|
45983476|NCT00431561|Drug|AP 12009 10 µM|10 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
45983477|NCT00431561|Drug|AP 12009 80 µM|80 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
45983478|NCT00431561|Drug|temozolomide or PCV|temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle; PCV (procarbazine, CCNU, vincristine): standard regimen
45983479|NCT00431561|Device|Drug delivery system for administration of AP 12009|Drug delivery system for Convection Enhanced Delivery consists of a portable pump with drug reservoir and infusion line. Main implanted parts are the port access system and the intratumoral catheter.
45983480|NCT00431561|Procedure|Placement of Drug Delivery System|Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
45983481|NCT00462150|Behavioral|home-based emotional disclosure|
45983482|NCT00462150|Behavioral|time management control condition|
45983483|NCT00462189|Drug|Immunotoxin therapy|
45983484|NCT00462189|Drug|CAT-8015 Immunotoxin|
45983485|NCT00462189|Procedure|Biological therapy|
45983486|NCT00431600|Other|100% Oxygen|100% Oxygen- breathing over 30 minutes
45983487|NCT00431639|Behavioral|Animal Assisted Therapy|Every subject will be exposed to both treatment and comparison conditions.
45983488|NCT00470925|Drug|123-I MZINT injection and SPECT imaging|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI
45983489|NCT00470964|Procedure|Titanium Sapphire laser trabeculoplasty|
45456617|NCT02395003|Other|Palmitate Diet|Subject with high VAT/SAT ratio will be randomized to a high or low palmitate oil diet.
45983490|NCT00431678|Drug|Avelox (Moxifloxacin, BAY12-8039)|Sequential intravenous/oral (400/400 mg once daily for 7 to 14 days) of Avelox (Moxifloxacin, BAY12-8039)
45983491|NCT00431678|Drug|Levofloxacin + Ceftriaxone|Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days).
45983492|NCT00471003|Drug|Pritor (Telmisartan , BAY68-9291)|Primary care hypertensive patients starting the therapy with Telmisartan
45983493|NCT04704128|Other|Salivic sample|Collection of total saliva not stimulated
45983494|NCT00462267|Behavioral|Enriched lifestyle intervention|Multi-component lifestyle intervention
45983495|NCT00471042|Drug|Buprenorphine|Dose is determined according to the participants' individual need.
45983496|NCT00471120|Other|P2x7 assay|compare P2X7 assay to biopsy
45983497|NCT02957669|Behavioral|Practice Self-Regulation|PS-R is an in-person, individual-level, clinic-based intervention implemented by mental health professionals trained in the intervention. It is intended to be implemented in ten structured, individual therapy sessions lasting approximately 50 minutes over the course of 18 weeks.
45983498|NCT02957669|Behavioral|Therapy Practice Group|Therapy Practice Group is the control condition aimed at providing the youth a safe space to work on meeting their mental health goals. It is intended to be at least ten sessions over the course of 18 weeks.
45983499|NCT00462540|Drug|Formoterol Fumurate inhalation solution 20 mcg|
45983500|NCT00462540|Drug|Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg|
45983501|NCT04703972|Behavioral|clinical assessment (mood relapses identification)|clinical assessment via psychometric scales physiological data acquired automatically via the connected device (wristwatch, wristband)
45983502|NCT04703465|Drug|Tenofovir Alafenamide 25 MG|Tenofovir Alafenamide 25mg for 48 weeks will be delivered
45983503|NCT00471159|Drug|docetaxel|
45983504|NCT00471159|Drug|PF-3512676|
45983505|NCT04703582|Diagnostic Test|Activated clotting time|Relationship between elongated baseline activated clotting time and comorbidity
45983506|NCT00462618|Drug|Quetiapine|
45983507|NCT00462618|Behavioral|Cogntive behavioral therapy|
45983508|NCT00431795|Drug|Pegylated liposomal doxorubicin (Caelyx)|Pegylated liposomal Doxorubicin (Caelyx) at the dose of 50mg/m^2 IV every 4 weeks for 6 consecutive cycles
45456618|NCT02346305|Device|Non-invasive ventilation|Home NIV installation
45456619|NCT02315196|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
45983509|NCT00431795|Drug|Epirubicin|Epirubicin (Farmorubicin) at the dose of 90mg/m^2 IV every 3 weeks for 6 consecutive cycles
45983510|NCT03271203|Other|Michigan Hand Outcomes Questionnaire|The MHQ is a self-report measure that assesses the function of the hand(s) and/or wrist(s). The MHQ contains six distinct scales including overall hand function, activities of daily living, pain, work performance, aesthetics and subject satisfaction with hand function. In the pain scale, high scores indicate greater pain, while in the other five scales, high scores denote better hand performance.
46083032|NCT04258241|Procedure|Local infiltration analgesia with local anesthetic|The orthopedic surgeon will perform local infiltration analgesia at the end of the surgery. The knee joint capsule, periarticular and subcutaneous tissues will be infiltrated with 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline.
46083033|NCT04258241|Procedure|Local infiltration analgesia without local anesthetic|The orthopedic surgeon will perform local infiltration analgesia at the end of the surgery. The knee joint capsule, periarticular and subcutaneous tissues will be infiltrated with 0.3 mg of epinephrine and 120 ml of normal saline.
46083034|NCT04258241|Device|Needle|18-gauge 40 mm Sterican needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform local infiltration analgesia.
45456620|NCT02315196|Drug|epirubicin hydrochloride|Given IV
45983511|NCT03271203|Other|Real-time data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms.
45983512|NCT00431912|Drug|APO866|APO866 is administered as 0.126 mg/m²/hr for 4 consecutive days (96 hours), every 3 weeks for a total of 3 cycles
45983513|NCT00462657|Genetic|polymerase chain reaction|
45983514|NCT00462657|Other|bronchoalveolar lavage|
46083035|NCT04258241|Drug|Solution with local anesthetic|Solution of 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline will be used to perform local infiltration analgesia.
45456621|NCT02315196|Drug|carboplatin|Given IV
45456622|NCT02315196|Procedure|therapeutic conventional surgery|Undergo definitive surgery
45456623|NCT02315196|Drug|paclitaxel|Given IV
45456624|NCT02315196|Other|laboratory biomarker analysis|Correlative studies
45456625|NCT02315196|Other|quality-of-life assessment|Ancillary studies
45456626|NCT02310399|Device|Nucleus ABI541 Auditory Brainstem Implant|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant device
45983515|NCT00462657|Other|immunoenzyme technique|
45983516|NCT00462657|Other|laboratory biomarker analysis|
45983517|NCT00462657|Procedure|bronchoscopy|
45983518|NCT00462657|Procedure|management of therapy complications|
45983519|NCT00431990|Drug|depsipeptide|Cohort 1. Dose escalation, IV, Weeklyx3 in a 4week cycle. Cohort 2A. 12mg/m2, IV, Weeklyx3 in a 4week cycle. Cohort 2B. 12mg/m2, IV, Weeklyx2 in a 3week cycle.
45983520|NCT00431990|Drug|bortezomib|Cohort 1 and 2A. 3.5mg/m2, IV, day 1, 4, 8, 11 in 28 day cycle. Cohort 2B. 3.5mg/m2, IV, day 1, 4, 8, 11 in 21 day cycle
45983521|NCT00431990|Drug|dexamethasone|20mg for 2 days with each dose of bortezomib
45983522|NCT00462696|Drug|docetaxel|
45983523|NCT00462696|Drug|epirubicin hydrochloride|
45983524|NCT00462696|Procedure|conventional surgery|
45983525|NCT00462696|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
45983526|NCT00462696|Procedure|neoadjuvant therapy|
45983527|NCT00462696|Procedure|radiomammography|
45983528|NCT00462774|Procedure|Intramyocardial injection of autologous CD133+ marrow cells|
45983529|NCT00462813|Drug|oral microencapsulated diindolylmethane|
46083036|NCT04258241|Drug|Solution without local anesthetic|Solution of 0.3 mg of epinephrine and 120 ml of normal saline will be used to perform local infiltration analgesia.
45456627|NCT02276885|Radiation|PBI Radiotherapy 6 Gy|Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 6 Gy x 5, over 5 consecutive days
46083037|NCT04099953|Diagnostic Test|Hand grip, joint range of motion , functional level of the upper extremity, physical activity levels|Hand grip force with Jamar Hand Dynamometer, joint range of motion with Baseline Digital Goniometer, functional level of the upper extremity with the Shoulder-Arm and Hand Problems Questionnaire(DASH), physical activity levels with International Physical Activity Questionnaire Short Form(IPAQ-short form) and physical functions with Human Activity Profile (HAP) were evaluated.
45983530|NCT00462813|Genetic|polymerase chain reaction|
45983531|NCT00462813|Other|cervical Papanicolaou test|
45983532|NCT00462813|Other|cytology specimen collection procedure|
45983533|NCT00462813|Procedure|colposcopic biopsy|
45983534|NCT01052012|Drug|SABER-Bupivacaine|Injectable Extended Release Solution; SABER-Bupivacaine /Once
45983535|NCT01052012|Drug|Bupivacaine HCl|Injectable Solution; Bupivacaine HCl /Once
45983536|NCT01052012|Drug|SABER-Placebo|Injectable Solution; SABER-Placebo/Once
45983537|NCT00462852|Drug|dalteparin|
45983538|NCT00462852|Drug|gemcitabine hydrochloride|
45983539|NCT00462852|Other|diagnostic laboratory biomarker analysis|
45983540|NCT00471393|Drug|1.5% diclofenac in 45.5% DMSO (topical treatment)|
45983541|NCT00471393|Drug|45.5% DMSO (topical placebo)|
45983542|NCT00432029|Procedure|Forearm blood flow measurement, Flow mediated dilation (FMD)|Forearm blood flow measurement: baseline 1 min, 3 min after inflation of cuff, 4 min after 0.8mg Nitroglycerin
45983543|NCT00432029|Device|Zeiss Retinal Vessel Analyzer (RVA), Stimulation with Flicker-light|Stimulation with Flicker-light: 1 min, measurement without flickering light 4 min after 0.8 mg Nitroglycerin
45983544|NCT03273348|Procedure|Oncoplastic breast surgery|, Skin sparing mastectomy and immediate breast reconstruction will be conducted to all women included in the study, transverse rectus abdominis musculocutaneous flap recostruction and latissimus dorsi myocutaneous pedicle-flap with and without implant
45983545|NCT00432068|Drug|Octreotide pamoate|
45983546|NCT03273309|Other|Vibratory Perineal Stimulus|Vibratory perineal stimulus will be applied in patients randomized to this group through an intravaginal probe which emits vibratory pulses, with the device fixed in the following parameters:on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
45983547|NCT03273309|Other|Transvaginal Electrical Stimulation|The transvaginal electrical stimulation will be applied in patients randomized to this group through an intravaginal probe which emits electrical pulses, with the device fixed in the following parameters: frequency = 50 Hz, pulse width = 300ms,on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
45983548|NCT00432107|Drug|APO866|APO866 is administered as 0.126 mg/m²/hr IV every 4 weeks for 4 consecutive days (96 hours) for a total of 3 cycles
45983549|NCT03273231|Drug|Ketamine|Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
45983550|NCT03273231|Drug|Saline|0.9% saline solution
45983551|NCT00432146|Drug|lugol's solution|
46083038|NCT00943657|Biological|Preflucel [Trivalent seasonal influenza vaccine (split virus, Vero cell-derived)]|Single intramuscular injection of vaccine
45983552|NCT00462891|Other|IT System|
45983553|NCT00432224|Procedure|photodynamic therapy|
45832589|NCT03871530|Other|Coordinate F|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 8 mL"
45983554|NCT00432263|Drug|Genotropin (PN-180,307) Somatropin|
45983555|NCT00462969|Procedure|Sonohysterography|Sonohysterography
46083039|NCT02791724|Behavioral|Desiconnect|Desiconnect is an Internet intervention for persons with epilepsy and elevated depression. Content is continuously adapted to patients' concerns and needs. Techniques to overcome depression (e.g., cognitive restructuring, behavioral activation) and to cope with anxiety symptoms (e.g., exposure, role of avoidance, mindfulness exercises) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Topics covered also include coping with epilepsy symptoms, identifying and coping with seizure auras and triggers, and the role of nutrition and exercise. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 180 days after registration.
46083040|NCT02791724|Other|CAU|Care as Usual
46083041|NCT03984981|Other|Assessment of process required to diagnose brain death in adult patients|Assessment of process required to diagnose brain death in adult patients (demographics, clinical, laboratory, imaging, and treatment data). No questionnaires or study visits will be used.
46083042|NCT02796794|Dietary Supplement|Genistein|Total 30 patients will be included into the study They will be divided into two groups each containing 15 patients. Intervention group will receive supplemental genistein (60 mg/day) to enteral nutrition
46083043|NCT02796794|Other|enteral nutrition only|These are the patients receiving enteral nutrition
46083044|NCT04097691|Drug|GLUCOSE 10%|subcutaneous glucose 0.5 ml per site around subcutaneous nerves
46083045|NCT00943813|Behavioral|video-recording and completing a survey|"Video record MD consult before MD has completed Comskill training. Post-Video Recording Survey (5 minutes): This is a 22-item self-report scale that measures patient satisfaction and patient reports of communication behavior (Roter et al 1977). Items are rated using a five-point Likert-type scale ranging from 1, I disagree completely  to 5, I agree completely ."
46083046|NCT02791178|Procedure|Optical coherence tomography (OCT)|Special camera to study part of your heart that was affected
46083047|NCT02791178|Procedure|Index of microcirculatory resistance (IMR)|Special wire to study part of your heart that was affected
46083048|NCT02791178|Other|Cardiac MRI|Special scanner if the heart to assess the damage of your heart
45983556|NCT00432302|Drug|Sagopilone (BAY 86-5302, ZK 219477)|First infusion only: 28 mg, containing 14 kBq/7.8 mcg [14C]-ZK 219477. Subsequent infusions: 16 mg/m2 ZK 219477 without radioactive label. IV infusion was given over a period of 30 min.
45832590|NCT03871530|Other|Coordinate G|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 8 mL"
45983557|NCT00463008|Drug|methotrexate|
45983558|NCT00463008|Other|pharmacological study|
45983559|NCT00471432|Drug|custirsen sodium|
45832591|NCT03871530|Other|Coordinate H|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 5 mL"
45832592|NCT03871530|Other|Coordinate I|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
45832593|NCT03871530|Other|Coordinate J|"PIEB Next Bolus: 15 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
45832594|NCT03871530|Other|Coordinate K|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
45832595|NCT03871530|Other|Coordinate L|"PIEB Next Bolus: 15 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
45983560|NCT00471432|Drug|docetaxel|
45983561|NCT00471432|Other|pharmacological study|
45983562|NCT00432419|Procedure|autologous peripheral blood cell transplantation|
45983563|NCT00463086|Drug|isoniazid|A self-administered daily dose of 5mg/kg of Isoniazid or placebo for 12months(300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
45983564|NCT00463086|Drug|Placebo|A self-administered dose of 5mg/kg of placebo (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
45983565|NCT02957435|Drug|eplerenone|(Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
45983566|NCT03271359|Behavioral|EMDR|Initial EMDR session of up to three hours; about one week later, follow-up session of up to one hour
45983567|NCT03271359|Behavioral|PC|Initial PC session of up to three hours; about one week later, follow-up session of up to one hour
45983568|NCT02957591|Dietary Supplement|Vivomixx®|Streptococcus thermophilus Bifidobacterium breve Bifidobacterium longum Bifidobacterium infantis Lactobacillus acidophilus Lactobacillus plantarum Lactobacillus paracasei Lactobacillus delbrueckii subsp. bulgaricus
45983569|NCT02957591|Other|Placebo|Subjects in the placebo group will receive a placebo that contains starch but no bacteria. The appearance of the placebo will be indistinguishable in color, shape, size, packaging, smell, and taste from that of the probiotic supplement.
45983570|NCT00432536|Other|Quality improvement intervention|determine the effectiveness of adopting quality improvement strategies to reduce embolization, hypotension and cerebral desaturation
45983571|NCT03271125|Behavioral|Treadmill|Participants in the experimental group received supervised treadmill training, 4-5 sessions per week. The treatment protocol was aimed at improving participants' resistance, walking velocity, balance and cognitive functions during motor and cognitive (dual) tasks. The treadmill training was carried out without body weight support but if needed the participants were attached to a safety harness.
45983572|NCT03271125|Behavioral|Resistance|Participants in the control group were treated with Resistance exercises, 4-5 sessions per week. The treatment protocol was aimed at improving strength in muscles involved in walking (hip abductors, quadriceps, plantar flexors, dorsal flexors) according to current guidelines from the American College of Sports Medicine (2009). Three sets of 10 repetitions were performed bilaterally with appropriate weights for each exercise
45983573|NCT00471471|Biological|Peptide vaccine|Multi-epitope peptide vaccine containing MART-1 (26-35, 27L), gp100 (209-217, 210M) and tyrosinase (368-376, 370D) peptides
45983574|NCT00471471|Biological|GM-CSF|80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
45983575|NCT00471471|Biological|PF3512676|0.6 mg/0.04 mL given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
45983576|NCT02273492|Drug|Asasantin ER|
45983577|NCT02273492|Other|Standardized breakfast|
46083049|NCT04097613|Drug|Povidone-Iodine|Povidone Iodine solution 5% (0.5% available iodine) by 3MTM has been specially formulated as a nasal antiseptic. They have shown topical application to be clinically safe, tolerable and to be rapidly bacteriocidal against aerobic gram positive and gram- negative bacteria including methicillin resistant Staphylococcus aureus, methicillin resistant Staphylococcus epidermidis, vancomycin resistant Enterococcus faecium and Enterococcus faecalis (VRE) and yeast (3M study 05-011100,05-011017, 05-011322).
46083050|NCT04097613|Drug|Budesonide|Budesonide is is provided in nebules (1mg/2cc). Patients will place two nebules of budesonide into the 250mls of saline.
46083051|NCT00946387|Drug|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
46083052|NCT00946387|Drug|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
46083053|NCT02788604|Other|Summary of psychosocial risk factors|The treatment team will receive a psychosocial risk summary shortly following diagnosis based on parent report.
46083054|NCT02788604|Other|Control|The treatment team will NOT receive a psychosocial risk summary shortly following diagnosis based on parent report.
45672978|NCT04786145|Procedure|Placebo|No active treatment is given.
45676655|NCT00018057|Behavioral|Attention Bias Modification Training|The intervention is computer-based. The active and control treatments have two components. In one component of the active intervention, subjects are asked to indicate the identity of a letter that appears behind a neutral face, opposite from an angry face. In another component of the active intervention, subjects are asked to identify numbers that are hidden within a puzzle, in locations distal from angry faces. In both components of the active intervention, subjects implicitly learn to shift their attention away from angry faces. This is because the faces are systematically arranged to be far removed from letters and numbers that need to be identified. The control arm of the intervention involves similar components. However, unlike in the intervention arm, angry faces appear in various locations near letters and numbers. Therefore, attention is not shaped in the control arm. This intervention requires five minutes per session and is administered before weekly psychotherapy sessions.
46083055|NCT00943891|Procedure|Tumor biopsies|
45832596|NCT03871530|Other|Coordinate M|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
45676656|NCT00018057|Drug|Fluoxetine|Randomized assignment.
45832597|NCT03871530|Other|Coordinate N|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
45832598|NCT02984826|Other|Strength training|The specific ST group trained and fulfilled a 10 week training diary. The ST consisted of 4 shoulder exercises. During the training the relative loading was progressively increased from 12 repetitions maximum (RM) (70% of maximal intensity) at the beginning to 8 RM (80 % of the maximal intensity). ST was performed with slow concentric and eccentric muscle contractions with resistance from the elastic bands.
45983578|NCT00471510|Drug|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks
45676657|NCT00018044|Drug|Clofazimine|
45983579|NCT02273531|Drug|Asasantin ER, new formulation|
45983580|NCT02273531|Drug|Asasantin ER, present commercial formulation|
45983581|NCT01580345|Dietary Supplement|Docosa-hexaenoic acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through delivery.
45983582|NCT01580345|Dietary Supplement|Placebo|400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through delivery.
45983583|NCT00463203|Drug|Bevacizumab|10 mg/kg every 2 weeks
45983584|NCT00463203|Drug|Irinotecan|125 mg/m2 non-EIAED or 340 mg/m2 EIAED every 2 weeks
45983585|NCT00471549|Drug|Statin (simvastatin)|
45676658|NCT02034877|Biological|13-valent Pneumococcal conjugate vaccine|1 dose (0.5 mL/ pre-filed syringe) of 13vPnC administered at visit 1
45676659|NCT02034877|Procedure|Blood sample collection|10 mL of blood will be collected just before and approximately 1 month after vaccination.
45676660|NCT02034799|Biological|Bioseal Fibrin Sealant|
45983586|NCT00432575|Drug|surinabant (SR147778)|oral administration
45983587|NCT00432575|Drug|placebo|oral administration
45983588|NCT00432614|Drug|SR58611A|oral administration
45983589|NCT00432614|Drug|escitalopram|oral administration
45983590|NCT00432614|Drug|placebo|oral administration
45983591|NCT00463320|Drug|Pazopanib eye drops and Allergen Refresh Plus eye drops|
45983592|NCT00432653|Drug|rituximab|
45983593|NCT00471588|Drug|Pramipexole, Amisulpride|Study Drug
45983594|NCT00432692|Procedure|Falls Prevention Program|
45983595|NCT00463359|Drug|Imiquimod cream|
45983596|NCT00463359|Procedure|curettage and cautery|
45983597|NCT00432731|Biological|VARIVAX®|
45983598|NCT00432731|Biological|M-M-RTM II|
45456628|NCT02276885|Radiation|PBI Radiotherapy 8 Gy|Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 8 Gy x 3, over 5 days, every other day
45456629|NCT02273375|Drug|MEDI4736|
45832599|NCT02984826|Other|Ergonomic and posture|The control group was instructed in ergonomics and posture correction (EP). They were instructed to pay attention to their sitting posture, and how they used a computer or other working tools. Further they were asked to do a posture correction exercise 3 times a day with 10 repetitions. The EP were seen twice during the 10 week period, and had a phone call every 2 weeks. After 10 weeks they were instructed that they should stop the exercise but continue to be conscious of their ergonomics and sitting position.
45832600|NCT03870048|Device|transcranial direct current stimulation|A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.
45832601|NCT03868020|Procedure|Computed Tomography|Undergo PET/CT
45983599|NCT00432770|Drug|ARC1779|
45983600|NCT00471627|Procedure|Pancreaticojejunostomy without stiches through the pancreas|The pancreas is cut with knife, without electric cautery and without stay sutures. Bleeding is controlled with 2-3 exactly placed stiches. The pancreatic stump is sunk inside the jejunum, which is tightened around the pancreas with a purse string. A biodegradable stent is left into the pancreatic duct to prevent its occlusion when tightning the purse string.
45983601|NCT00432887|Drug|caffeine administration|
45983602|NCT00471744|Drug|Treatment with levetiracetam or sulthiame over a six-month period.|
45983603|NCT01051817|Drug|AIN457|infusion 10 mg/Kg
45983604|NCT01051817|Drug|Placebo|infusion
45983605|NCT00471783|Procedure|Chlorhexidine is the generic name of the mouthwash, Peridex is the brand name.|
45832602|NCT03868020|Radiation|Fluciclovine F18|Given IV
45832603|NCT03868020|Procedure|Positron Emission Tomography|Undergo PET/CT
45832604|NCT03866772|Drug|Misoprostol Oral Tablet|50 mcg oral consumption
45832605|NCT03866772|Device|double balloon device for cervical ripening|insertion for 6 hours and followed by the above mentioned protocol
45832606|NCT03866538|Drug|Withdrawal of Oral Budesonide|The intervention arm will taper and stop budesonide therapy (withdrawal).
45832607|NCT03865992|Dietary Supplement|Curcumin|Given capsules for oral administration
45832608|NCT03865992|Other|Placebo|Given capsules for oral administration
45983606|NCT04703660|Procedure|cervical mobilization|3 types of cervical mobilization at the level of C 5- 6
45983607|NCT01327846|Drug|Canakinumab|
45983608|NCT01327846|Drug|Placebo|
45983609|NCT01327846|Drug|Standard of care|Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate
45983610|NCT00463515|Drug|carboplatin/gemcitabine|
45983611|NCT00463515|Procedure|cisplatin/radiation therapy|
45983612|NCT00432926|Behavioral|EDGE counseling, no maintenance|Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
45983613|NCT00432926|Behavioral|EDGE counseling, plus maintenance|Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
45983614|NCT00432926|Behavioral|Attention control|An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
45832609|NCT03865992|Other|Nanoemulsion|Given nanoemulsion curcumin PO
45983615|NCT00433043|Drug|Beta blocker (carvedilol or metoprolol succinate)|Both groups get CRT. Group 1 is uptitrated to target dose beta blocker after CRT. Group 2 maintains their b-blocker dose from study entry.
45983616|NCT00433043|Procedure|CRT (cardiac resynchronization therapy)|Both arms
45983617|NCT00463554|Device|GYNECARE TVT-SECUR* System|A sub-urethral sling for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency
45983618|NCT00433082|Behavioral|Ramadan Fasting|
45983619|NCT01051739|Procedure|Comparison of four visual field testing strategies|We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.
45983620|NCT03273075|Drug|Cangrelor|The intervention comprises add-on Cangrelor infusion (administration in compliance with manufacturer instructions) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy.
45983621|NCT03273075|Drug|Placebo|The intervention comprises add-on placebo infusion (0.9% NaCl) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy as placebo comparator
45983622|NCT03273075|Drug|Prasugrel|The intervention comprises the standard P2Y12-blocker prasugrel therapy if not contraindicated.
45983623|NCT03273075|Drug|Ticagrelor|The intervention comprises the standard P2Y12-blocker ticagrelor therapy if prasugrel is contraindicated and no contraindication to ticagrelor is present.
45983624|NCT00471900|Drug|dehydroepiandrosterone (DHEA)|
45983625|NCT01051661|Biological|GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)|Intramuscular injection, one or two doses
45983626|NCT01051661|Biological|GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)|Intramuscular injection, two doses
45983627|NCT01051661|Biological|Placebo|Intramuscular injection, one dose
46083056|NCT02601261|Other|At the first day of hospitalization the field investigator will submit to pregnant women in a pathological condition five questionnaires|"Some of these questionnaires will have to be completed every day and others every other day:~The Internet questionnaire is divided in two parts. The first one investigates the use of internet at home and it will be administered only once, the second part will investigate the internet use at the hospital, in the case the women have a personal smartphone, tablet or personal computer (they are the owners) and it will be administered every other days.~The questionnaire is aimed to understand the quality of life (EQ-5D) will be administered only once, at the beginning of the hospitalization.~The STAI questionnaire is divided in to parts, the first part aims to determinate the state anxiety and it will be administered every other day, while the second part will discuss the anxiety itself, and has to completed only once.~The short questionnaire on critical events occurring during the day,~The short questionnaire with obstetric anamnesis."
46083057|NCT00943969|Procedure|gastric bypass|gastric bypass combines restrictive and malabsorptive procedures
45983628|NCT00471939|Drug|I-020502|1 mcg/mL TG-PDGF.AB
45983629|NCT04448548|Other|blood sample taking|For study purposes, blood sample was taken during the first medical examination from patients with suspected infection.
45983630|NCT04448782|Diagnostic Test|Asynchronies detection|Asycnhronies detection
45983631|NCT01051466|Drug|Duloxetine|60 milligrams (mg) administered orally daily for 8 weeks then 60-120 mg if non remitter or 60 mg if remitter for 4 additional weeks
45983632|NCT04448197|Other|Chinese Medicine|Dialectical treatment of traditional Chinese medicine according to different constitution
45832610|NCT03865992|Other|Quality-of-Life Assessment|Ancillary studies
45832611|NCT03865992|Behavioral|Questionnaire|Ancillary studies
45832612|NCT03865212|Drug|Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1|Given IT and IV
45832613|NCT03863730|Dietary Supplement|Profermin Plus, FSMP, probiotics|"Participants will have to supply their normal intake with Profermin Plus, FSMP, Prbiotics product twice every day for 24 weeks.~The product Profermin Plus® has changed its name to ReFerm®. The content of the product is unchanged. The change occurred after the clinical part of the study was completed."
45832614|NCT03863730|Dietary Supplement|Fresubin, dietary supplement|Participants will have to supply their normal intake with the control product, Fresubin, dietary supplement twice every day for 24 weeks.
45983633|NCT04446793|Drug|Onvansertib|15 mg/m^2 will be administered orally on Day 1 to Day 5 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
45983634|NCT04446793|Biological|Bevacizumab|5 mg/kg will be administered intravenously on Day 1 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
45983635|NCT04446793|Drug|FOLFIRI|FOLFIRI (180 mg/m^2 irinotecan, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil [5-FU], and 2400 mg/m^2 continuous intravenous infusion 5-FU over 46 hours) will be administered intravenously on Day 1 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
45983636|NCT04446247|Diagnostic Test|Owlet Smart Sock Sensor 3rd Generation|Pulse Oximetry
45983637|NCT00463125|Drug|Platelet Gel|
46083058|NCT00916695|Device|Xience V Everolimus Eluting Coronary Stent System. Abbott Laboratories. Abbott Park, Illinois, U.S.A.|"Complex PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), and subsequent implanting of the stent in the main vessel, the side branch is approached by implanting a new stent as T technique.~Simple PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), a stent is deployed at main vessel. Side branch is approached by using provisional T stenting technique."
46083059|NCT00946465|Drug|Ramipril 10 Capsule (Sandoz)|
46083060|NCT00946465|Drug|Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)|
45456630|NCT02273375|Drug|Placebo|
45983638|NCT01051349|Biological|BIIB019 (Daclizumab)|Administered as specified in the treatment arm.
45983639|NCT01051349|Biological|trivalent seasonal influenza vaccine|All participants who participate in the 2013-2014 influenza vaccine substudy will receive the vaccine at the study site
45832615|NCT03861624|Procedure|Intramedullary nailing with standard SIGN nail|Patients meeting eligibility requirements are randomized to either study arm. Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures using the standard SIGN nail (SIGN Fracture Care International, Richland, WA). The number of interlocking screws is at the discretion of the treating surgeon, who also has the option to use an external fixator for damage control, and later conversion to IMN when clinically appropriate. The experimental group procedure is less common in the study setting, and thus, viewed as the experimental group.
45832616|NCT03861624|Procedure|External Fixation with uniplanar Dispofix external fixator|Patients meeting eligibility requirements are randomized to either study arm. Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures using the uniplanar Dispofix external fixator with two Shanz screws placed proximally and two Schanz screws placed distally to fracture site with a single stainless steel bar.The active comparator group procedure is more common in the study setting, and thus, viewed as the comparator group.
45983640|NCT04329208|Device|Transcranial doppler|"TCD examination was performed using DWL-EZ-Dop machine Compumedics GmbH, Singen, Germany. TCD utilizes low-frequency pulsed insonation (2 MHz) to measure blood flow velocity within proximal cerebral arteries, obtaining systolic and diastolic peaks and mean flow velocities (MFV). MFV is defined as (systolic + diastolic)/3 + diastolic velocities, according to Alexandrov et al..~Initial TCD examination was done after admission serving as a baseline state for cerebral circulation. Follow-up TCD examinations was done at fixed intervals on the first, third, fifth, seventh and tenth days of the onset of SAH."
45983641|NCT04444336|Behavioral|Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms|Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms
45983642|NCT00472017|Drug|vandetanib|Oral vandetanib administration will start on the same day as RT. Treatment with vandetanib will extend for the entire duration of RT, and then will be continued after completion of RT for a maximum duration of 2 years.
45672979|NCT04813991|Drug|Ibuprofen 600 mg|Ibuprofen 600 mg for breakthrough pain.
45983643|NCT02894203|Behavioral|Mindfulness|
45983644|NCT02894203|Behavioral|Yoga|
45983645|NCT00433121|Drug|Risperidone|
45983646|NCT00433121|Drug|Olanzapine|
45832617|NCT01677390|Drug|SGN-75|1-2 mg/kg IV every 21 days
45832618|NCT01677390|Drug|everolimus|10 mg PO daily
45983647|NCT00433121|Drug|Haloperidole|
45983648|NCT00433121|Drug|Quetiapin|
45983649|NCT00433121|Drug|Escitalopram|
45983650|NCT00433121|Drug|Citalopram|
45983651|NCT00433121|Drug|Sertralin|
45983652|NCT00463671|Drug|N-acetylcysteine|
45983653|NCT04442659|Diagnostic Test|pre hospital triage tool|EMS workers fill in an application containing 10-13 vclinical items
45983654|NCT04442386|Other|Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout|Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout
45983655|NCT04703543|Device|Pilot evaluation study on use PSMA and Cu-PET/CT|This study aims at assessing the detection rate of both PSMA and Cu-PET/CT on tissue relapse, study whether this method is equivalent to mpMR
45983656|NCT00591526|Drug|Arac|Ommit ARAC in the chemotherapy
45983657|NCT04440397|Other|xbp-1 - endometriosis patients group|Patients diagnosed with endometriosis by surgery and ultrasound and whose xbp-1 level was examined
45983658|NCT00463710|Drug|Avonex® monotherapy (6.0 MIU administered i.m. each week)|
45983659|NCT02894008|Drug|ChAd63-KH|ChAd63-KH in adults and adolescents with persistent PKDL.
45672980|NCT04813991|Drug|OxyCODONE 5 Mg Oral Capsule|OxyCODONE 5 Mg Oral Capsule for breakthrough pain.
45672981|NCT03624101|Drug|Trikafta|CFTR modulator
45672982|NCT03624101|Drug|symdeko/Trikafta|CFTR modulator
45672983|NCT03624101|Drug|Ivacaftor/Trikafta|CFTR modulator
45672984|NCT04801901|Procedure|dTRA|Subjects randomized to the experimental arm will undergo left heart catheterization, coronary angiography and/or percutaneous coronary intervention using distal transradial access (dTRA)
45672985|NCT04801901|Procedure|fTRA|Left heart catheterization, coronary angiography and/or percutaneous coronary intervention using the left forearm radial artery.
45672986|NCT02218736|Drug|CERC-501|Oral dosing of 10 mg CERC-501 daily for 8 weeks
45983660|NCT04440124|Other|Incremental shuttle walk test|All patients were reviewed by a physiotherapist during their pre-assessment clinic one week prior to surgery to complete an incremental shuttle walk test (ISWT). The ISWT was completed according to a standardised protocol and involved patients walking around 2 cones set up 9 metres apart. Patients were asked to cover the distance between the cones in time to auditory cues. Oxygen levels and heart rate were recorded during the assessment with the use of a portable pulse oximeter. The test was stopped when patients could no longer keep pace with the auditory cues or were too breathless to continue. The total distance mobilised was recorded.
45983661|NCT02893735|Other|Charisma-Diamond|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Charisma-Diamond in combination Gluma2 Bond etch&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
45672987|NCT02218736|Drug|placebo|oral dosing of 10 mg placebo daily for 8 weeks
45672988|NCT03623243|Drug|Siponimod|Siponimod 2mg tablets taken once daily
46083061|NCT04012021|Diagnostic Test|7T Magnetic Resonance Imaging|"T1-weighted and T2-weighted sequences~quantitative magnetic resonance imaging approach~proton spectrum analyses"
46083062|NCT00756717|Drug|MK-0752|Women who are post menopausal will receive letrozole 2.5 mg by mouth one time per day for 24 days. Women who are pre menopausal, or who have a contraindication to letrozole will receive tamoxifen 20 mg orally one time per day for a period of 24 days. Starting on day 15 of this 24 day period all patients will receive the oral gamma-secretase inhibitor drug MK-0752 at a dose of 350 mg for three days on, then off four days, then three days on, for a total of 6 doses over a period of 10 days.
45672989|NCT04813055|Procedure|Therapeutic EUS|"EUS-guided collection drainage (transgastric or transduodenal, performed by Lumen Apposing Metal Stents or double pigtail stents) and eventual endoscopic necrosectomy~EUS-guided biliary drainage (either of the extrahepatic or intrahepatic biliary tree / transduodenal or transgastric / either as access for subsequent rendez-vous or transpapillary stenting OR for transparietal stenting by metal or plastic stents).~EUS-guided gallbladder drainage via Lumen Apposing Metal Stents and eventual subsequent EUS-based cholecystolithotomy~EUS-guided gastro-jejunostomy through Lumen Apposing Metal Stents~EUS-directed ERCP in post-surgical anatomy (by gastro-gastrostomy or entero-enterostomy performed through Lumen Apposing Metal Stents)~EUS-guided pancreatic duct drainage"
45672990|NCT04813055|Procedure|Percutaneous Procedures|Procedures involving a percutaneous access to a target region (fluid collection, gallbladder, biliary tree)
45672991|NCT04813055|Procedure|Surgical Interventions|Surgical interventions to obtain a drainage (e.g. surgical necrosectomy, pancreatico-gastrostomy) or the bypass of a stricture (hepatico-jejunostomy or gastro-jejunostomy)
45832619|NCT03661086|Device|O2matic|O2matic controls oxygen with the aim of maintaining SpO2 within a predefined target interval, e.g. 88-92 % with the lowest possible supplementation of oxygen by nasal cannula
45832620|NCT03658668|Device|active tDCS|tDCS is a therapeutic treatment that utilizes low amplitude direct currents (<4 mA) to induce changes in cortical excitability.
45832621|NCT03658668|Device|sham tDCS|During a sham session, the device is programmed to ramp up to the desired intensity (target 2.5 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then againat the end of the session. These brief periods of stimulation serveto mimic the effects of a true stimulation session.
46083063|NCT00946543|Radiation|hypofractionated radiation therapy|
46083064|NCT00946543|Radiation|intensity-modulated radiation therapy|
46083065|NCT04097457|Behavioral|"Parent training for disruptive behaviors manual (Bearss, Johnson, Handen, Butter, Lecavalier, Smith & Scahill, 2018)"|"The intervention is a short term parent training program based on behavioral principles, which can be delivered by trained therapist. The manual includes eleven core sessions, home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered individually to parents in an outpatient setting.~The protocol will be administered to groups of 3-4 parents, with a quantitative pretest-post test design evaluated at five time points, including a follow up at one month post intervention. The protocol will be administered in various community and educational locations, such as schools and community centers"
45672992|NCT04813055|Procedure|non-EUS-based endoscopic procedures|Other endoscopic procedures not involving EUS (enteral stenting, Enteroscopy-assisted ERCP)
45672993|NCT04418687|Device|Orthoglide|Knee rehabilitation device.
45672994|NCT04418687|Other|Physiotherapy only|Physiotherapy only.
45672995|NCT05268965|Behavioral|Experimental: group comparison|"Standardized psychiatric interview (Mini International Neuropsychiatric Interview MINI)~State-Trait-Anxiety Inventory (Spielberger, 1993)~Beck Depression Inventory (BDI-II, 1998)~Cognitive Emotional Regulation Questionnaire (Jermann & al., 2006) Participant installation and testing: 2 stages (forecasting on a computer, and exposure in virtual reality)~Task / affective forecasting:~Step 1: forecasting about one's own emotional responses regarding pleasant, neutral and unpleasant scenarios~Step 2: experience of the same scenarios in virtual reality"
45676661|NCT02034799|Other|Standard of Care (SoC)|
45832622|NCT03658668|Other|Physical Activity (PA)|20 minutes of cycling on an ergonomic cross-trainer
45983662|NCT02893735|Other|Filtek-Z550|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Filtek-Z550 in combination with Adper™ Single Bond 2 etch&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
45983663|NCT03271086|Behavioral|The StressEraser|The StressEraser is a handheld biofeedback device that measures heart rate variability (HRV). Heart rate increases during inspiration and decreases during expiration. The HRV, depicted on a miniature screen, essentially represents respirations. The investigator's prior study demonstrated that the device is easily mastered and acceptable to children above 6 years of age.
45983664|NCT03271086|Behavioral|Breathe2Relax|Breathe2Relax is a free mobile app, developed by the Dept. of Defense's National Center for Telehealth and Technology to help veterans with PTSD and others use breathing practice for stress management. This application guides users in relaxation breathing and is available for both android and iOS phones. It is adapted for children 6 years and up. For instance, the cycles can be shortened for children, there is a selection of quiet music and the user can choose backgrounds for personalization.
45983665|NCT03271086|Behavioral|Reminder text messages|Weekly texts will be sent out to parents in the technology-enhanced relaxation breathing group to as reminders to practice the daily relaxation breathing with their child.
45983666|NCT00433238|Behavioral|Participants will be screened for depression and cognitive impairment, then receive screening results.|
45983667|NCT00463749|Drug|Acetylcystein|high-dose N-Acetylcystein during PCI and for 2/day for 2 days
45983668|NCT00463749|Drug|Placebo|NaCl as placebo
45983669|NCT00433277|Drug|twice-daily dosage with 0.5% cyclosporine-A eyedrops|
45983670|NCT00463827|Drug|Atorvastatin|
45983671|NCT00463827|Drug|atorvastatin|atorvastatin 40mg
45672996|NCT05266781|Procedure|Surgical repair|Patients affected by a thoracoabdominal aortic aneurysm who received an open surgical repair (aneurysmectomy and aortic reconstruction with a surgical graft
45672997|NCT05266781|Procedure|Endovascular repair|Patients affected by a thoracoabdominal aortic aneurysm who received endovascular repair (with off-the-shelf or custom-made Fenestrated/Branched-Endovascular Aortic Repair - F/BEVAR)
45672998|NCT04801589|Drug|Dexmedetomidine|For patients in the dexmedetomidine group, dose will range from 0.2-2.0 mcg/kg/hr. For example, a 10 kg patient on an infusion of 1 mcg/kg/hr of dexmedetomidine would receive 10 mcg of study drug per hour. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the mini-MENDS study steering committee.
45672999|NCT04801589|Drug|Midazolam|For patients in the midazolam group, dose will range from 0.025-0.25 mg/kg/hr. For example, a 10 kg patient on an infusion of 0.15 mg/kg/hr of midazolam would receive 1.5 mg of midazolam per hour. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the mini-MENDS study steering committee.
45673000|NCT05179187|Behavioral|Movement task|Computer task with experimental conditions manipulating sensory and motivation cues for movement.
45673001|NCT05084261|Drug|BT051 200 mg|Oral BT051 200 mg once daily for 28 days.
45673002|NCT05084261|Drug|BT051 800 mg|Oral BT051 800 mg once daily for 28 days.
45983672|NCT00463827|Drug|matched placebo|Matched placebo
45983673|NCT00433316|Drug|ropivacaine|1% ropivacaine
45983674|NCT00433316|Device|Aeroneb Pro Nezulizer, Aerogen, Ireland|Aeroneb Pro Nezulizer, Aerogen, Ireland
45983675|NCT00472095|Other|Fotonovela|
45983676|NCT00472095|Other|Placebo Fotonovela|
45983677|NCT00433394|Procedure|cancer prevention intervention|
45983678|NCT00433394|Procedure|educational intervention|
45983679|NCT00472134|Drug|bupivacaine|administered locally, 0.5% Bupivacaine (Marcaine Abbott Laboratories) or saline administered continuously for 48 hours at 2 mL/h.
46083066|NCT02788370|Device|a conical positive expiratory pressure device|The CPEP device will be connected to respiratory transducer for generating positive expiratory pressure with therapeutic rang (5 to 20 cm H2O).
45983680|NCT00472134|Device|On-Q PainBuster pump|local anesthetic (bupivacaine) administered via a pain relief system consisting of a 20 gauge soaker catheter attached to an elastomeric balloon pump that is capable of infusing a set volume of local anesthetic over a wide area of surgical site for 2 to 5 days
45983681|NCT00433433|Drug|ABVD q4 weeks|Doxorubicin 25 mg/m2 i.v. day 1 and 15; Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15; Vinblastine 6 mg/m2 i.v. day 1 and 15; Dacarbazine 375 mg/m2 i.v. day 1 and 15
45983682|NCT00433433|Drug|BEACOPP escalated q3 weeks|Cyclophosphamide 1250 mg/m2 i.v. day 1; Doxorubicin 35 mg/m2 i.v. day 1; Vincristine 1.4 mg/m2 i.v.(max.2mg) day 8; Bleomycin 10 mg/m2 i.v./i.m. day 8; Etoposide 200 mg/m2/ i.v. day 1 to 3; Procarbazine 100 mg/m2 orally day 1 to 7; Prednisone 40 mg/m2 orally day 1 to 14; G-CSF 5 mcg/kg s.c. day 9 to recovery leukocytes>1.0x109/l
45983683|NCT00433433|Radiation|IN-RT 30 Gy (+ boost 6 Gy residual)|
45983684|NCT00433433|Procedure|FDG-PET scan|
45983685|NCT00463905|Procedure|Clinical assessment +/- radiography|Clinical assessment: height loss, history of fracture, Margolis pain score, rib/pelvis distance
45983686|NCT00433472|Device|magnetic resonance imaging (MRI)|MRI scan to be complete to look at RSR13 on measurement of T2 and T2* on MRI
45673003|NCT05084261|Drug|BT051 3200 mg|Oral BT051 3200 mg once daily for 28 days.
45456631|NCT02230072|Device|fetoscopy|The fetoscopic arm is described above. All patients will have a laparotomy, exteriorization of the uterus, and a fetoscopic repair of the fetal open neural tube defect.
45983687|NCT03270969|Drug|Tenofovir Disoproxil Fumarate/Emtricitabine|Participants will receive daily TDF/FTC for 14 days
45983688|NCT00463944|Behavioral|Effect of an electronic voting system|
45456632|NCT02207712|Device|Noctura 400 Eye Mask|The intervention is the wearing of the eye mask
45673004|NCT05084261|Drug|Matching Placebo|Placebo Matching BT051
45673005|NCT05037149|Drug|STP707|Investigational Product
45983689|NCT00433667|Drug|RWJ-333369|
45983690|NCT00463983|Drug|octreotide|
45983691|NCT03270813|Behavioral|Relaxation training plus RAGE-Control|RAGE-Control is a biofeedback videogame in which players shoot at enemies while avoiding allies. The player's baseline heart rate is taken before the game and entered into the computer. During the game, the player wears a heart rate monitor, and if the player's heart rate rises above baseline, they are unable to shoot. The player must use relaxation skills to decrease their heart rate below the baseline before they can resume play. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the RAGE-Control videogame.
45983692|NCT03270813|Behavioral|Relaxation training plus Sham Videogame|The Sham videogame is a videogame in which players shoot at enemies while avoiding allies. The player wears a heart rate monitor during the game, but the heart rate does not affect the functioning of the game in any way. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the Sham videogame.
45983693|NCT00464022|Device|Carbon dioxide|
45983694|NCT01050998|Biological|Mavrilimumab 10 mg|Mavrilimumab (CAM-3001) 10 mg injection subcutaneously every other week for 12 weeks.
45983695|NCT01050998|Biological|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks.
45983696|NCT01050998|Biological|Mavrilimumab 50 mg|Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks.
45983697|NCT01050998|Biological|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks.
45983698|NCT01050998|Other|Placebo|Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks.
45983699|NCT00472173|Drug|Mineral Trioxide Aggregate|Apexification treatment of the tooth with Mineral Trioxide Aggregate
45456633|NCT02207712|Drug|Ranibizumab|Standard ranibizumab treatment only
45456634|NCT02179853|Drug|Anakinra|First two doses IV followed by SQ dosing
45456635|NCT02165670|Device|Coronary stenting with CE-marked stent|
45673006|NCT05037149|Drug|STP707|Investigational Product
45673007|NCT05037149|Drug|STP707|Investigational Product
45673008|NCT05037149|Drug|STP707|Investigational Product
45673009|NCT05037149|Drug|STP707|Investigational Product
45673010|NCT03580421|Procedure|ambulatory surgery|total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
45673011|NCT03580421|Procedure|standard surgery|total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
45673012|NCT01540474|Biological|Group 1: 10 ug FMP012 with 2 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
45983700|NCT00472173|Drug|Calcium hydroxide|Apexification treatment of the tooth with Calcium hydroxide
45983701|NCT00472329|Procedure|Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors|
45983702|NCT00472329|Drug|fludarabine|
45983703|NCT00472329|Procedure|TBI|
45983704|NCT00464139|Procedure|Laparoscopy|Laparoscopy
45983705|NCT00464217|Drug|ARA-C|
45983706|NCT00464217|Drug|Idarubicin|
45983707|NCT00464217|Drug|Leucomax|
46083067|NCT02788370|Other|Constant work load cycling test|"Participants will per form constant work load cycling test until symptom limit with 50 to 60 rpm. The termination criteria include~sever breathlessness (>5 /10 score of modified Borg scale)~leg fatigue (can not maintain speed between 50 to 60 rpm)~Hear rate (HR) >80 % age-predicted maximum HR~Exercise time up to 10 minutes~Other symptom that stated by American thoracic Society(2002)"
45983708|NCT00433706|Procedure|Control position by 3DOBI before the fraction|
45983709|NCT00433706|Procedure|Standard imaging|
45983710|NCT03270852|Device|Enhanced reality|"This prototype is developed by investigators for the first time so that it have no trademark or manufacturer name yet.~The patient sits facing the horizontal desk with the ER therapy device, and then raises the wrist joint to the fixed base. The hand, wrist, and distal forearm to be treated are positioned below the ER medical camera so that the wrist is visible on the screen. Fix the wrist and wrist joint using Velcro. When treating the distal forearm, detach the wrist fixing Velcro."
45983711|NCT03270852|Other|No Enhanced reality|Identical rehabilitation without enhanced reality
45983712|NCT00433784|Drug|Clopidogrel|
46083068|NCT00946621|Drug|Ramipril 10 mg Capsule (Sandoz)|
45673013|NCT01540474|Biological|Group 2: 10 ug FMP012 with 5 ug GLA-SE|E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
45673014|NCT01540474|Biological|50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE|E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
45676662|NCT02057575|Drug|PG324 Ophthalmic Solution 0.01%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
45983713|NCT00433784|Procedure|Blood sampling - platelet aggregation|
45983714|NCT00433784|Procedure|Blood sampling - genotyping|
45983715|NCT00464256|Drug|rimonabant|
45983716|NCT00433823|Drug|Atorvastatin, Ezetimibe|
45983717|NCT00464295|Drug|Capecitabine in HCC|
45983718|NCT03273036|Drug|40 mg Triamcinolone acetate 1 cc|40 mg Triamcinolone acetate 1 cc
45983719|NCT03273036|Drug|Placebos|no injected agent
45983720|NCT00433901|Behavioral|Targeted parental instruction for positive lifestyle change with follow-up calls.|
46083069|NCT00946621|Drug|Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)|
46083070|NCT02600793|Drug|Ceftaroline|Following Ceftaroline single IV dose, 3 blood and cerbrospinal fluid samples will be collected
46083071|NCT00940459|Device|Senofilcon A contact lens (Acuvue Oasys)|Silicone hydrogel contact lens CE-marked for the intended usage.
46083072|NCT00940459|Device|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens CE-marked for the intended usage.
46083073|NCT00940459|Device|Lotrafilcon B contact lens (Air Optix)|Silicone hydrogel contact lens CE-marked for the intended usage.
45983721|NCT03270735|Drug|Snake venom thrombin (Treatment)|Snake venom thrombin
45983722|NCT03270735|Drug|Placebo|No snake venom thrombin
45983723|NCT04702841|Drug|Chimeric antigen receptor modified γδ T cells|Dosage: the total dosage of reinfusion is 0.2-5 × 10^6 / kg, which is determined according to the body weight of the subject and the effective content of cell preparation.
45983724|NCT04703114|Diagnostic Test|Blood count|Blood count at each visit
45983725|NCT04703114|Diagnostic Test|Blood collection|Blood collection to understanding of the immunological profile at each visit
45983726|NCT04703114|Diagnostic Test|Nasopharyngeal swab|Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR at day 8 and day 15
45983727|NCT04703114|Diagnostic Test|Saliva samples|Research of SARS-CoV-2 infection in saliva samples at each visit (excepted inclusion)
45983728|NCT04703114|Diagnostic Test|Faeces samples|Research of SARS-CoV-2 infection in faeces samples at day 3, day 15 and day 90
45983729|NCT04703114|Genetic|Genetic blood collection|Collection to further research at each visit
45983730|NCT04703114|Other|Data collection|Demographics, symptoms, biological constants
45983731|NCT04053153|Device|Exercise equipment (a musical instrument that is based on the Medical Didgeridoo)|exercise equipment (a musical instrument that is based on the Medical Didgeridoo)
45983732|NCT04702685|Drug|Ropivacaine|Local anesthetic for injection
45983733|NCT04702685|Other|Placebo|Bandage will be placed in the presumed injection site while patients in under general anesthesia
45983734|NCT00464373|Drug|Botulinum Toxin Type A|Single intrasphincteric injection at the 3,6,9, and 12 o'clock positions of the external urethral sphincter (1 ml of drug solution each)
45983735|NCT00464373|Drug|Placebo|4ml NaCl 0.9%
45983736|NCT00472368|Drug|LBH589|
45983737|NCT00106028|Drug|risedronate sodium (Actonel)|risedronate tablet once a day for one year followed by risedronate once a day for two years
45983738|NCT00106028|Drug|Placebo|placebo tablet once a day for one year followed by risedronate once a day for two years
45983739|NCT00464412|Behavioral|Education|
45983740|NCT00464451|Drug|Dexmedetomidine|Dexmedetomidine 3 micrograms per kilogram per os; subsequent dose of 1 microgram per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
46083074|NCT00940459|Device|Balafilcon A contact lens (PureVision)|Silicone hydrogel contact lens CE-marked for the intended usage.
46083075|NCT00940459|Device|Etafilcon A contact lens (Acuvue 2)|Hydrogel contact lens CE-marked for the intended usage.
46083076|NCT00940459|Device|Contact lens care system (EasySept)|Contact lens care system CE-marked for the intended usage.
46083077|NCT04235894|Drug|Propofol|Intravenous anesthesia with propofol started with 0.5 mg kg-1, and was titrated until a patient was unresponsive to painful stimuli & maintaining spontaneous breathing during gastrointestinal endoscopy
45673015|NCT01540474|Other|Controlled group-Challenged Only: no vaccination|The control group participated in the primary malaria sporozoite challenge.E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
45983741|NCT00464451|Drug|Chloral hydrate|Chloral hydrate 75 milligrams per kilogram per os; subsequent dose of 25 milligrams per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
45983742|NCT00464529|Device|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
45983743|NCT00433940|Drug|Prednisolone|Oral prednisolone sodium phosphate suspension administered in dosage of 15mg/5mL. Medication administered every morning at a starting daily dose of 2.5mg/kg.
45983744|NCT00433979|Drug|antiretroviral treatment|These antiretroviral drugs are a part of the participant's current drug regimen.
45983745|NCT01050764|Drug|Regulatory T-cells|"To ameliorate the impaired immune recovery and address the significant relapse incidence in the haploidentical setting. Cells will be selected by a tandem selection process and infused on day +14. These are the enriched but naturally-occurring regulatory T cells. Possible dose cohorts and levels are:~Cohort 1~T-reg: 1 x 10e5/kg~T-con: 3 x10e5/kg~Cohort 2~T-reg: 3 x 10e5/kg~T-con: 1 x 10e6/kg~Cohort 3~T-reg: 1 x 10e6/kg~T-con: 3 x 10e6/kg~Cohort 4~T-reg: 3 x 10e6/kg~T-con: 1 x 10e7/kg"
45983746|NCT01050764|Drug|Conventional T-cells|These are conventional (unselected) donor T-cells. Cell dosage of the infusion will be based on the CD3+ cell content and infused on day +16.
45673016|NCT01580488|Drug|B LEO 35299 20 mg/g cream|once daily application, 3 weeks
45983747|NCT01050764|Drug|Melphalan|Anti-cancer chemotherapy drug administered IV at 140 mg/m² on Day -8 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
45983748|NCT01050764|Drug|Thiotepa|Anti-cancer chemotherapy drug administered IV at 10 mg/kg on Day -7 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
45983749|NCT01050764|Device|Fludarabine|Anti-cancer chemotherapy drug administered IV at 160mg/m² on Days -6; -5; -4; and -3 prior to HSCT (a component of the conditioning regiment prior to infusion of cells
45983750|NCT01050764|Drug|Anti-thymocyte globulin, rabbit|Rabbit-derived antibodies against human T-cells used as transplant rejection prophylaxis. Administered at 6 mg/kg IV on Days -6; -5; -4; and -3 prior to HSCT
45983751|NCT01050764|Drug|CliniMACS CD34 Reagent System|An in vitro medical device system that uses antibodies conjugated to magnetic beads to select and enrich for CD34+ blood stem cells from the allogeneic donor apheresis product prior to HSCT, while removing other cells that can cause GvHD. CD34+ cell dosage will be based on the participant's body weight.
45983752|NCT00464607|Drug|hMG-IBSA|
45983753|NCT00464607|Procedure|Ovarian stimulation|
45983754|NCT00472485|Procedure|eye movement therapy|
46083078|NCT04096599|Other|Xylitol toothpaste|At-home preventive measures + xylitol-containing (25%) toothpaste
46083079|NCT04096599|Other|Fluoride toothpaste|At-home preventive measures + fluoride (1000 ppm F) toothpaste
46083080|NCT03648632|Radiation|Stereotactic Radiotherapy|Patients should be treated with 50 Gy in 5 fractions within a total of 7 - 8 days.
45673017|NCT01580488|Drug|C LEO 35299 20 mg/g cream|once daily application, 3 weeks
45673018|NCT01580488|Drug|E LEO 35299 10 mg/g solution|once daily application, 3 weeks
45673019|NCT01580488|Drug|F LEO 35299 10 mg/g solution|once daily application, 3 weeks
45673020|NCT01580488|Drug|Daivonex® ointment|once daily application, 3 weeks
45673021|NCT01580488|Drug|Daivonex® ointment vehicle|once daily application, 3 weeks
45673022|NCT01580020|Biological|RFB002|0.5 mg/0.05 mL solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. Each vial contained ranibizumab in an aqueous solution (pH 5.5) with histidine, trehalose and polysorbate 20.
45673023|NCT01580020|Drug|Dexamethasone|Ozurdex (Dexamethasone): intravitreal implant as per commercial label (700 µg Dexamethasone; Dexamethasone was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only. Dexamethasone had to be stored according to label instructions and it had to be kept in a secure locked facility
45832623|NCT03750864|Behavioral|ACT-LCS Therapy|All participants in Stage 1, and those randomized to the intervention condition in Stage 2, will receive the Acceptance & Commitment Therapy for Lung Cancer Stigma (ACT-LCS) intervention. The ACT-LC intervention is designed to be delivered as 6 sessions of individual psychotherapy with a trained psychotherapist at a weekly or bimonthly rate, delivered either in person or over the phone. The treatment manual is based in Acceptance and Commitment Therapy (ACT). Therapists are instructed to begin treatment with Module 1. Modules 2-5 can then be administered in any order at the discretion of the therapist, based upon what the therapist thinks is most likely to be helpful to the patient. Module 6 is the final session of treatment.
45983755|NCT00434096|Drug|rimonabant (SR141716)|oral administration once daily
45983756|NCT00434096|Drug|placebo|oral administration once daily
45983757|NCT00472524|Procedure|Mydriasis/cycloplegia via different modes of administration|
45983758|NCT01050569|Drug|Nicotine Patch|21 mg
45983759|NCT01050569|Other|VLNC Cigarette|Cigarette where the tobacco contains <0.1 mg of nicotine yield.
45983760|NCT01050569|Other|VLNC Cigarette Plus Nicotine Patch|21 mg nicotine patch plus use of cigarette with tobacco containing <0.1 mg nicotine yield.
45983761|NCT00464724|Procedure|3T Magnetic Resonance Spectroscopic Imaging|Part 1 of Study = One MRSI exam with an air-filled endorectal coil (AIR-MRSI) and one with a PFC-filled endorectal coil (PFC-MRSI); Part 2 of Study = MRSI exam with PFC using an endorectal coil only.
45983762|NCT04702490|Drug|MET409 Active|MET409 Active (50mg)
45983763|NCT04702490|Drug|MET409 Placebo|MET409 Placebo (50mg)
45983764|NCT04702490|Drug|Empagliflozin|Empagliflozin (10mg)
45983765|NCT00464763|Drug|Dexmedetomidine|
45983766|NCT00464763|Drug|Placebo|
45983767|NCT00434135|Drug|gemcitabine plus pemetrexed, paclitaxel plus gemcitabine|gemcitabine 1,250 mg/sqm days 1&8 + pemetrexed 500 mg/sqm day 8 paclitaxel 120 mg/sqm + gemcitabine 1,000 mg/sqm days 1&8
45673024|NCT01579474|Drug|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
45983768|NCT00472563|Drug|Bicarbinate 150 mEq/L|75 cc of sodium bicarbonate (8.4%) mixed in 425 cc of D5W
45983769|NCT01050530|Drug|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
46083081|NCT03962101|Drug|OPC-61815 injection|Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria.
45832624|NCT03749070|Dietary Supplement|Silymarin|It is a randomized, double-blind, controlled clinical trial to be performed at outpatient level. The intervention will last 12 weeks and the invited participants will be patients attended at the outpatient clinic of the Edgard Santos Hospital, which will be randomized into two groups: control and intervention. Data on laboratory and clinical markers, imaging, nutritional and dietary assessment will be collected at the beginning and end of the trial for comparison purposes.
45983770|NCT01050530|Drug|Placebo|Once-daily oral administration of placebo after breakfast for 7 days
45983771|NCT03272880|Behavioral|Arts-Based Programming|This feasibility study includes educational components and an experiential components which are assessed with pre- and post-tests. The topics of these components include: Introduction to the Arts and Health; Music, Well-Being, and Resilience; Movement and Physical Activity; Art and Well-Being; Theater and Socialization; Art Appreciation and a Healthy Brain; and Summary/Integration of the Arts into Daily Lives. The impact of this program will be assessed with qualitative follow-up interviews.
46083082|NCT00923351|Drug|Tumor Purged/CD25 Depleted Lymphocytes|
46083083|NCT00923351|Biological|Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH pulsed dendritic cells (minimum of 1 X 10e6 cells/kg) on Day2.
46083084|NCT00923351|Drug|rhIL-7|rhIL-7 (20 mcg/kg/dose SQ) approx. 48 hours prior to vaccine) Day 0, Day 14, Day 28 and Day 42
46083085|NCT00923351|Biological|Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH Pulsed dendritic cell vaccine (1-5 X 10e7 cells/injection site, given in 3 sites intradermal) on Day 2, Day 16, Day 30, Day 44, Day 56, Day 70.
46083086|NCT02788292|Drug|Acetylcysteine|See arm description
46083087|NCT00755937|Other|Data collection post infusion|
46083088|NCT00944203|Drug|Ipomea pes-caprae ointment|Ipomea pes-caprae ointment will be applied twice a day as an add-on therapy.
46083089|NCT05424302|Behavioral|Standard Vestibular Rehabilitation with Adjunct At Home Virtual Reality Vestibular Rehabilitation|The virtual reality intervention will involve standard vestibular rehabilitation as described above and adjunct at home virtual reality video game. This video game will be projected on an android or apple device accommodated into a VR headset for 20 minutes daily until the vestibular rehabilitation is complete. This video will be congruent to current vestibular rehabilitation program exercises. Point-of-view games compatible with both Android and iOS devices will be evaluated by professionals to determine the game that is most representative of current evidence based exercises.
46083090|NCT05424302|Behavioral|Standard Vestibular Rehabilitation with Adjunct Auditory Intervention|The control intervention will involve standard vestibular rehabilitation as described above and adjunct audio intervention while wearing the VR headset for 20 minutes daily until the vestibular rehabilitation is complete.
46083091|NCT00946699|Biological|MEDI-551|0.1 mg/kg
46083092|NCT00946699|Biological|Placebo|0.3 mg/kg
46083093|NCT00946699|Biological|MEDI-551|1.0 mg/kg
46083094|NCT00946699|Biological|MEDI-551|3.0 mg/kg
45673025|NCT01579474|Drug|BI 201335 low dose|BI 201335 low dose with PegIFN/RBV
45673026|NCT01579474|Drug|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
46083095|NCT00946699|Biological|MEDI-551|10.0 mg/kg
46083096|NCT00946699|Other|Placebo|Placebo
46083097|NCT05423756|Other|Arm 1: Routine Care|Routine Antibiotic Stewardship Arm - Continuation of antibiotic stewardship activities in accordance with national standards.
45673027|NCT01579474|Drug|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
45673028|NCT01579318|Biological|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
45832625|NCT03748602|Procedure|Thoracic outlet decompression|TOD consists out of first rib resection with partial scalenectomy and neurolysis. If there are also complaints below the pectoral minor tendon insertion, a pectoral minor tenotomy is performed.
45456636|NCT02152046|Procedure|ROP exam with spring loaded retractor|
45456637|NCT02152046|Procedure|ROP exam with screw retractor|
45673029|NCT01579318|Device|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulseswere administered to each tumor lesion at the approximate point of tavo injection.
45673030|NCT01562782|Other|Fructose + Glucose Beverage|Consumption of a sweet beverage (Fructose:Glucose 1:1, 3g/kg) over 1/2 hour. Blood sampling will occur before and after consumption of beverage.
45673031|NCT01579006|Drug|Tocilizumab|
45983772|NCT01050257|Drug|Oseltamivir IV|Oseltamivir IV infusions over 2 hours two times a day (every 12 hours) for 5 days for patients with moderate renal impairment. Patients with severe renal impairment received once daily dosing and patients on renal replacement therapy received dose/frequency according to protocol.
46083098|NCT05423756|Other|Arm 2: INSPIRE Stewardship Bundle for Skin and Soft Tissue Infection|Quality improvement intervention that includes (1) computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimates for having a skin/soft tissue infection due to a multidrug-resistant organism (MDRO) and recommends standard spectrum antibiotics for low risk patients in the first 3 days of hospitalization; (2) clinician feedback reports, and (3) activities to support CPOE adoption (including education and alignment of CPOE workflows). Other antibiotic stewardship activities to continue in accordance with national standards.
46083099|NCT04096755|Diagnostic Test|Procedure|serum and urine samples will be taken for analysis
46083100|NCT00944281|Dietary Supplement|LNS-Zn5|Daily consumption of 20 g LNS containing 5 mg of zinc and daily placebo supplement
46083101|NCT00944281|Dietary Supplement|LNS-Zn10|Daily consumption of 20 g LNS containing 10 mg of zinc and daily placebo supplement
46083102|NCT00944281|Dietary Supplement|LNS-Zn0|20 g of LNS containing 0 mg of zinc and a daily placebo supplement
46083103|NCT00944281|Dietary Supplement|Suppl-Zn5|Daily 5 mg zinc supplement ant consumption of 20 g LNS containing 0 mg of zinc
46083104|NCT04096911|Drug|Sintilimab|Sintilimab 200 mg intravenously every 3 weeks
46083105|NCT04096911|Drug|quadrivalent HPV vaccine|The first dose of quadrivalent HPV vaccine intramuscularly at the day before the first dose of Sintilimab ，the second and third doses of quadrivalent HPV vaccine intramuscularly at the 60th and 180th days respectively
46083106|NCT04253405|Device|High Flow Nasal Catheter|"HFNC will be delivered through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.~Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize the patient´s comfort and SpO2"
46083107|NCT04253405|Device|Noninvasive positive pressure ventilation (NIPPV)|NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 according to the protocol.
45673032|NCT01578850|Drug|Etanercept|etanercept 50mg once weekly + methotrexate with or without other DMARDs
45832626|NCT03748134|Biological|Sintilimab|For weight <60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
45832627|NCT03748134|Drug|Placebo|For weight <60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
45832628|NCT03748134|Drug|Cisplatin|75mg/m^2 IV Q3W day 1
45983773|NCT01050257|Drug|Oseltamivir Oral|Oseltamivir (TAMIFLU®) capsules taken orally for 5 days. Twice daily (every 12 hours) for patients with moderate renal impairment, once daily for patients with severe renal impairment and dose frequency according to protocol for patients on renal replacement therapy.
46083108|NCT04096677|Procedure|hysteroscpy|
46083109|NCT00944359|Dietary Supplement|Daily preventive Zn; placebo treatment|7 mg zinc / day and placebo supplement during diarrhea episodes
46083110|NCT00944359|Dietary Supplement|Therapeutic Zn; daily placebo|20 mg zinc / day for 10 days during diarrhea episodes and daily placebo supplement
46083111|NCT00944359|Dietary Supplement|Intermittent Zn; placebo treatment|10 mg zinc for 10 days every 3 months, placebo supplements daily for all other days during 12 months; placebo supplements during diarrhea episodes
45673033|NCT01578850|Drug|placebo|etanercept placebo once weekly + methotrexate with or without other DMARDs
45673034|NCT01539538|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually q 20 minutes as needed for pain for at least 48 hours and up to 72 hours
45673035|NCT01539538|Drug|morphine IV PCA|1 mg morphine administered IV q 6 minutes as needed for pain for at least 48 hours and up to 72 hours
45673036|NCT01562548|Drug|Guaifenesin|high and low dose of Guaifenesin each given twice daily over a 4-day treatment period
45673037|NCT01562548|Drug|Placebo|no active ingredient
45673038|NCT03027934|Drug|Ticagrelor|Ticagrelor, 90mg twice daily
45673039|NCT03027934|Drug|Prasugrel|Prasurgrel, 10mg once daily
45673040|NCT01562314|Drug|GWP42003|1 to 5 50 mg capsules taken BID
45673041|NCT01562314|Drug|Placebo|1 to 5 matching capsules taken BID
45673042|NCT04112368|Drug|Estradiol Transdermal Patch 0.1 mg/24 hrs|Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
45832629|NCT03748134|Drug|Paclitaxel|87.5 mg/m^2 IV Q3W day 1, day 8 for first cycle and 175mg/m^2 IV Q3W day 1 after first cycle
45832630|NCT03748134|Drug|Fluorouracil|800 mg/m^2 IV continuous infusion over 24 hours daily on Days 1-5 Q3W
45832631|NCT01345656|Drug|BAY94-8862|Two 1.25 mg BAY94-8862 and 2 placebo tablets for duration of 4 weeks
45832632|NCT01345656|Drug|BAY94-8862|Four 1.25 mg BAY94-8862 tablets for duration of 4 weeks
45832633|NCT01345656|Drug|BAY94-8862|One 10 mg BAY94-8862 tablet for duration of 4 weeks
45832634|NCT01345656|Drug|BAY94-8862|Part B only: Four 1.25 mg BAY94-8862 tablets in the morning and four tablets in the evening for duration of 4 weeks
45832635|NCT01345656|Drug|Placebo|Placebo tablets for duration of 4 weeks
45832636|NCT01345656|Drug|Spironolactone|Part B only: 25 mg spironolactone once daily with up-titration to 50 mg once daily starting at day 15, if serum potassium is less or equal to 4.8 mmol/L, for duration of 4 weeks
45832637|NCT03744624|Procedure|Laparoscopic liver resection|Laparoscopic liver resection for oncological purposes
45832638|NCT03744624|Device|3D printing model|Use of 3D printed liver model in decision-making: preoperative planning and intraoperative guidance.
45832639|NCT03747120|Drug|Paclitaxel|All subjects will receive Paclitaxel weekly for 12 weeks
45983774|NCT03272802|Drug|Edaravone|Edaravone is a free radical scavenger. this drug showed desirable effects like slowing decline of physical function by 33 percent in previous studies.
45983775|NCT03272802|Drug|Riluzole|Riluzole is a treatment option for amyotrophic lateral sclerosis. The occurrence of ventilator-dependence or tracheostomy is delayed in selected patients who treated with this drug.
45983776|NCT01050218|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
45983777|NCT00472719|Biological|VRC-HIVADV027-00-VP|Adenoviral vector booster vaccine
45458726|NCT01142557|Drug|Interferon beta-1a (Rebif)|A dosage of 44 µg or 22 µg interferon beta-1a (Rebif) as subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase of 4 weeks.
45983778|NCT00472719|Biological|VRC-HIVADV038-00-VP|Adenovirus vector booster vaccine
45673043|NCT04112368|Drug|Oral Micronized Progesterone 200mg|100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation (200mg total per day)
45983779|NCT00472719|Biological|VRC-HIVDNA044-00-VP|Experimental, multiclade, multigene HIV DNA vaccine
45983780|NCT01050062|Drug|Telmisartan 80mg|Combination tablet
45673044|NCT04112368|Drug|Inactive Clear Patch|Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
45673045|NCT04112368|Drug|Placebo capsule|Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
45832640|NCT03747120|Drug|Trastuzumab|All subjects will receive Trastuzumab every 3 weeks
45832641|NCT03747120|Drug|Pertuzumab|Arm A and Arm B subjects will receive Pertuzumab every 3 weeks
45983781|NCT01050062|Drug|Telmisartan 40mg|Combination tablet
45983782|NCT01050062|Drug|Hydrochlorothiazide 12.5mg|Combination tablet
45458727|NCT02506387|Device|mitraclip|The decision to implant mitraclip is not part of this observational study but is made by the heart-team.
45832642|NCT03747120|Drug|Pembrolizumab|Arm B and Arm C subjects will receive Pembrolizumab every 3 weeks
45832643|NCT03744312|Drug|11C-ER176|11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease.
45832644|NCT03744312|Drug|Florbetaben|Florbetaben sticks to amyloid plaques, which are in the brain in Alzheimer's disease.
45832645|NCT03743064|Drug|anamorelin HCl|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
45832646|NCT03743064|Drug|Placebo Oral Tablet|Placebo (administered as matching placebo tablets in the fasted condition)
45983783|NCT00464802|Drug|MOA-728|
45673046|NCT01539226|Combination Product|Placebo Vaginal Ring|Dapivirine Vaginal Ring containing 0.0 mg of dapivirine
45673047|NCT01539226|Combination Product|Dapivirine Vaginal Ring, 25 mg|Dapivirine Vaginal Ring containing 25 mg of dapivirine
45673048|NCT01577758|Drug|MLN0264|MLN0264 30-minute infusion on Day 1 of each treatment cycle
45673049|NCT04769674|Other|Sensory Integration Intervention through the STAR Frame of Reference|The individualized therapy program will be based on the results of the comprehensive evaluation. Intervention aligns with the STAR Frame of Reference fidelity measure and Ayres Fidelity Measure.
45983784|NCT00464841|Procedure|Combined spinal epidural|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
45983785|NCT00464841|Procedure|Tsui Test for intrathecal catheter|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
45983786|NCT00464880|Drug|Aliskiren|
45983787|NCT00464919|Drug|Sorafenib|
45983788|NCT00464919|Drug|tegafur/uracil (UFUR®)|
45983789|NCT00434174|Drug|Everolimus|"RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. All proposed dose levels in this study can be given as a combination of these dose strengths.~Daily doses of 2.5, 5, 7.5 and 10 mg of RAD001 will be given alongside the standard 21-day cycle of pemetrexed."
45673050|NCT01537432|Drug|secukinumab|secukinumab
45673051|NCT01537432|Drug|placebo|placebo comparator
45676663|NCT02057575|Drug|PG324 Ophthalmic Solution 0.02%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
45676664|NCT02057575|Drug|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
45832647|NCT03742050|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation
45832648|NCT01196832|Procedure|blood sample|blood sample for fibrocytes analysis
45832649|NCT01196832|Procedure|Clinical and functional evaluation|Plethysmography, Carbon monoxide capacity of transfer , arterial gaz
45983790|NCT00434174|Drug|Pemetrexed|Pemetrexed was supplied to the sites in 500 mg/m2 was administered on Day 1 of each cycle as a 10-minute continuous i.v. infusion in 100mL normal saline
45983791|NCT00464958|Drug|sublingual tizanidine 12 mg|Single sublingual tizanidine 12 mg tablet, to be administered once nightly, via sublingual administration for 12 months
45983792|NCT01055912|Drug|Lixivaptan|Capsule. Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo. One hundred (100) patients will be randomized to receive lixivaptan 100 mg once daily (QD) for 8 weeks. Fifty (50) placebo patients will receive matching oral placebo for 8 weeks.
45983793|NCT01055912|Drug|Placebo|Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
45456638|NCT02133573|Drug|Progesterone|Crinone is supplied in a single use, disposable, white polypropylene vaginal applicator with a teal twist-off cap. Each applicator delivers 1.125 grams of Crinone gel containing 90 mg (8% gel) of progesterone in a base containing glycerin, mineral oil, polycarbophil, carbomer 934P, hydrogenated palm oil glyceride, sorbic acid, purified water and may contain sodium hydroxide. Crinone 8% is administered vaginally at a dose of 90 mg twice daily. The rounded tip of the applicator is inserted into the vagina. After insertion, the plunger is pushed to release the gel into the vagina. The applicator is removed.
45673052|NCT04409938|Other|Progressive Muscle Relaxation|PMR participants rested for ten minutes between the sessions and then practiced PMR for 15 minutes. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises.
45676665|NCT02057575|Drug|Latanoprost Ophthalmic Solution 0.005%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
45676666|NCT02077465|Drug|Andecaliximab|400 mg andecaliximab administered intravenously
45832650|NCT03737916|Other|5 cc 5% Dextrose solution|Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
45832651|NCT03737916|Other|5 cc salin|Ultrasound-guided perineural injection with salin (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
45983794|NCT00472758|Biological|MEDI 545|IV dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
45983795|NCT00472758|Other|Placebo|IV Placebo dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
45983796|NCT01055444|Drug|Heated lidocaine and tetracaine topical patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.
45983797|NCT01055015|Drug|Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, flexible dose, every 4 to 6 hours
45983798|NCT01055015|Drug|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3 mg/2 mg IR Capsule every 4 to 6 hours following a 6 mg/4 mg loading dose.
45983799|NCT00472875|Drug|Glibenclamide|
45832652|NCT04763460|Device|Programming of CRT device settings|Reprogramming of CRT device to maximize the benefit derived from the electrocardiographic assessment.
45832653|NCT04763616|Drug|Isatuximab|The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
45983800|NCT00434291|Drug|TG-873870(Nemonoxacin)|
45983801|NCT03275051|Other|Safety and Efficacy assessments|Safety and efficacy assessment of OTL-300 in subjects with transfusion dependent beta-thalassemia will be performed.
45983802|NCT00434369|Drug|CoFactor (ANX-510)|
45983803|NCT00472914|Device|portable surface electromyography|
45983804|NCT00434447|Drug|Zoledronic acid|
45983805|NCT00472953|Drug|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
45983806|NCT00472953|Drug|insulin aspart|Treat-to-target dose titration scheme, pre-prandial, injection s.c.
45983807|NCT02957630|Drug|15 mg E4/3 mg DRSP|15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
45983808|NCT02957630|Drug|30 mcg EE/150 mcg LNG|30 mcg EE combined with 150 mcg LNG administered in a 21/7-day regimen (i.e. 21 days of yellow active tablets followed by 7 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
45983809|NCT02957630|Drug|20 mcg EE/3 mg DRSP|20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
45983810|NCT00465036|Dietary Supplement|Whole flaxseeds, flaxseed mucilage, glucomannan|
45983811|NCT04702061|Other|Erector spina plane block before general anaesthesia|After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be directed between the erector spina muscle and the transverse process of the T4 vertebra using the in-plane technique. The location of the needle will be confirmed by hydrodissection with saline after touching the transverse process. After the plan open, 5 ml of 2% lidocaine, 10 ml of 0.5% bupivacaine and 10 ml of saline, including hydrodissection, will be given in a total amount of 25 ml. Then a 20-G epidural catheter will be inserted 3-4 cm and fixed.
45983812|NCT04702061|Other|Thoracic epidural block before general anaesthesia|After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be entered through the T4-5 interspinous space (median or paramedian approach). After reaching the thoracic epidural area by loss of resistance method, the epidural catheter will be advanced and fixed to remain 3-4 cm in the epidural area. Following the test dose (2 ml of 2% lidocaine), 3 ml of 2% lidocaine, 5 ml of 0.5% bupivacaine and 5 ml of saline will be administered intermittently in a total volume of 15 ml.
45983813|NCT00465075|Drug|Bazedoxifene/conjugated estrogens combination|
45983814|NCT00434486|Drug|SKI-606|
45456639|NCT02133573|Drug|Vaginal lubricant|Replens Long-Lasting Moisturizer is supplied in pre-filled, sealed and individually wrapped applicators.Replens Long-Lasting Moisturizer will also be dosed at one applicator intravaginally twice daily.
45983815|NCT00465114|Procedure|Hemodynamic Monitoring|
45983816|NCT00434525|Procedure|Laparoscopic restrictive procedure|Patients will receive laparoscopic sleeve gastrectomy with or without omentectomy
45983817|NCT00434525|Procedure|Sleeve gastrectomy|Sleeve gastrectomy
45983818|NCT00465153|Dietary Supplement|flax oil containing alpha linolenic acid|14g alpha linolenic acid per day
45983819|NCT00465153|Behavioral|Resistance exercise training|Resistance training
45983820|NCT02957552|Biological|Mesenchymal Stem Cells|Donor-specific, bone marrow derived mesenchymal stem (stromal) cells
45983821|NCT00465192|Drug|estradiol, 10 mcg|
45983822|NCT00465192|Drug|estradiol, 25 mcg|
45983823|NCT00465192|Drug|placebo|
45983824|NCT00434564|Procedure|Stress nuclear scan|
45983825|NCT00434603|Behavioral|Expressive Arts--Theatre Skills Training Program|The experimental intervention was an intensive theatre skills training program. The group of adolescent participants recovering from ABI met daily for four hours over a period of 4 weeks. During this 4 hour period, regular breaks were scheduled to provide the participants with a mental and physical break from therapy. Theatre training included voice work, breathing, movement, physical warm-up, character development, script analysis, writing skills, three-dimensional awareness, group dynamics, story development, mask work and clowning among others.
45983826|NCT00434681|Drug|paracetamol 4.8% paediatric oral suspension|
45983827|NCT00473070|Drug|Tobradex AF|
45983828|NCT03272646|Procedure|surgery|gastric resection or total gastrectomy
45983829|NCT00434798|Biological|Campylobacter jejuni strains CG8421 and BH-01-0142|Campylobacter jejuni strains CG8421 and BH-01-0142 at a single dose. Dosing will be based on attack rate, to achieve a 75% attack rate. Anticipate use of 10^6-10^9 CFU
45983830|NCT00473109|Procedure|Dialysis without systemic heparinization|Dialysis without systemic heparinization
45983831|NCT00434915|Drug|DHEA|
45983832|NCT00473148|Procedure|BNP-guided weaning|BNP-guided weaning
45983833|NCT00473148|Procedure|Standard physician-directed weaning|Standard physician-directed weaning
45983834|NCT00435032|Procedure|early appendectomy|Appendectomy within 24 hours of admission
45983835|NCT00435032|Procedure|interval appendectomy|Initial antibiotic treatment followed by appendectomy at 6-8 weeks
45983836|NCT00465231|Drug|bupivacaine, fentanyl|10mL of 0.0625% of bupivacaine plus fentanyl 2 mcg/ml
45983837|NCT00465231|Drug|preservative free saline|10mL saline solution
45983838|NCT00435071|Procedure|Carpal Tunnel Release Surgery|Patient will have large incision size during carpal tunnel release surgery.
45983839|NCT00435071|Procedure|Carpal tunnel release surgery|Patient will have a small incision size during carpal tunnel release surgery.
45983840|NCT00473187|Drug|somatropin|
45983841|NCT00435110|Procedure|standard ventilatory settings|
45983842|NCT00435110|Procedure|PEEP and FiO2|
45983843|NCT00473304|Device|Johnson&Johnson Acuevue daily disposable lenses|
45983844|NCT00435149|Procedure|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will be put in a splint after surgery.
45983845|NCT00435149|Procedure|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will have a bandage placed over the incision site after surgery.
45983846|NCT03272568|Drug|Recombinant FVIII Fc fusion product Eloctate|Subjects will get FVIII activity corrected from the baseline level to 100-150% with Eloctate on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 2 hours, 4 hours, 20 hours after the infusion) will be performed to assist with subsequent dosing. 2 total doses of Eloctate likely to be given on day 1 and 3 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Eloctate (with no less than 21 days interval).
45983847|NCT03272568|Drug|Recombinant FIX Fc fusion product Alprolix|Subjects will get FIX activity corrected from the baseline level to 100-150% with Alprolix on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 4 hours, 48 hours, 72 hours after the infusion) will be performed (by home nursing or local lab) to assist with subsequent dosing. Single dose of Alprolix likely to be given on day 1 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Alprolix (with no less than 21 days interval).
45983848|NCT03272568|Device|Patient-operated diagnostic device for anemia AnemoCheck.|Each AnemoCheck test kit enables patients to check hemoglobin levels by pricking their finger to draw 5 μL of blood into a capillary tube, inserting that tube into a larger tube with a pre-filled chemical solution, mixing, waiting one minute, and assessing the color change of the solution using a reference color scale card included with the kit. The test is able to subjectively differentiate low, medium and high levels of hemoglobin to diagnose anemia at home. Study participants are taught to perform a hemoglobin check every other day using Anemocheck during 2 consecutive menstrual cycles. In addition they will have hemoglobin level obtained locally (LabCorp) drawn within 4-6 hours for comparison and correlation.
45983849|NCT00435227|Biological|Motavizumab|A single IM dose of 30 mg/kg will be administered on Day 0 of the study.
45983850|NCT00435227|Other|Placebo|A single IM dose of placebo matched to motavizumab will be administered on Day 0 of the study.
45983851|NCT02956512|Drug|Dexibuprofen|Dexibuprofen 300mg
46083112|NCT00944359|Other|Surveillance control group|Active weekly morbidity surveillance for 3 months. New surveillance control group will be randomly assigned to intervention groups every 3 months
46083113|NCT04241783|Other|descriptive|correlation
46083114|NCT02791412|Procedure|percutaneous coronary intervention or coronary-artery bypass graft|
46083115|NCT04096287|Biological|PNT001|PNT001 diluted in 5% dextrose
46083116|NCT04096287|Drug|Placebo|5% dextrose
46083117|NCT00946777|Other|Systane® Ultra|Systane® Ultra 1-2 drops, 4 times per day for 30 days
46083118|NCT02791256|Drug|Ribavirin|
45673053|NCT04409938|Other|Nature Sounds|PMR+NS participants practiced PMR accompanied by nature sounds. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises.
46083119|NCT02791256|Drug|peginterferon alfa-2a|
46083120|NCT04096209|Device|autograft mixed with xenograft bone|"Eligible patients will be randomized in equal proportions between control group (immediate implant placement without bone grafts in the jumping gap) and study group (immediate implant placement with a mixture of Xenograft and autogenous bone placed in the jumping gap).~All patients will be evaluated by proper history taking and thorough clinical and radio graphical examination and assessed according to the inclusion and exclusion criteria.~Patients of both groups will be subjected to Cone beam Computed tomography (CBCT).~Primary impression will be taken, a study model will then be poured and then waxing up will be performed.~Patients will be instructed to rinse with chlorhexidine 0.1% mouthwash. Articaine 4% (1:100,000) local anesthesia will be given to the patient. Atraumatic extraction of the tooth or remaining root using No. 15c lancet and periotome"
45673054|NCT01537120|Drug|Vildagliptin|
45673055|NCT01537120|Drug|Placebo|
45673056|NCT01537042|Drug|Rotigotine|"Transdermal patch; Dose: 1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h.~Subjects start with a Rotigotine dose of 1 mg/24 h for 1 week. The dose can be increased weekly during Up-Titration Period until either the optimal or the maximal dose of 3 mg/24 h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1 mg/24 h every other day during Taper Period until complete withdrawal."
45673057|NCT01537042|Drug|Placebo|"Transdermal patch; Patches matching to active treatment patches in size and appearance.~Up to 3 weeks of Titration,~2 weeks of Maintenance,~Up to 4 days of Taper Period."
45673058|NCT04111666|Biological|AL101|Active dose of AL101
45673059|NCT04111666|Other|Placebo|Saline solution administered as a single and multiple infusion as placebo.
45673060|NCT03897712|Device|Custom Samfilcon B Contact Lenses|Contact lens
45673061|NCT03897712|Device|Alden Optical HP Sphere Contact Lens|Hioxifilcon D, 54% water, Alden Optical HP Sphere lens
45673062|NCT03897712|Device|ReNu MultiPlus Lubricating and Rewetting Drops|For use as needed during the study.
45983852|NCT00465309|Procedure|protective ventilation with CO2 removal technique|In ARDS patients, presenting a Pplat ≥ 26 cmH2O, Vt was lowered (reaching a Pplat < 26) with CO2-removal veno-venous pump-driven bypass support for 48 consecutive hours with a pH > 7,30 or at least 72 hours from the beginning of the extracorporeal treatment.
45673063|NCT03897712|Device|Biotrue Multi-Purpose Solution|For daily rinsing, cleaning, disinfecting, and storing their lenses in lens cases during the study.
45673064|NCT01536574|Drug|Requip PR|Eligible patients will be dispensed medication to uptitrate their REQUIP PR dose (2, 4, 6, 8mg respectively) during the first 4 weeks of treatment. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control.
45983853|NCT04702334|Drug|Hyaluronic Acid|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of hyaluronic acid gel for the test group . The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.
45983854|NCT04702334|Drug|Lidocain|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of anesthetic for the control group. The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.
45983855|NCT00473421|Procedure|Barium Sulphate and Zirconium Oxide|
45983856|NCT04702412|Other|The Opal patient portal and smartphone application combined with the I-Score patient-reported outcome measure|HIV patients will complete the I-Score PROM via Opal (patient portal) prior to three consecutive clinic visits with their HIV physician who is expected to access their PROM results in time for the visit. The clinic visits will be held at Time 1, Time 2 (3 months) and Time 3 (6 months).
45983857|NCT00465387|Behavioral|Falls, Fractures & Osteoporosis Risk Assessment & Management|
45983858|NCT00435266|Procedure|Remote ischemic preconditioning|Inflation of blood pressure cuff 4 x 5 minutes during transportation to primary PCI
45983859|NCT00473460|Drug|Avelox (Moxifloxacin, BAY12-8039)|Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks
45983860|NCT00473460|Drug|Placebo|Matching placebo capsules orally once daily for 5 days every 8 weeks.
45983861|NCT00435305|Drug|Meropenem|
45983862|NCT00435305|Drug|Vancomycin|
45983863|NCT00435305|Drug|Linezolid|
45983864|NCT00435305|Drug|Piperacillin/Tazobactam|
45983865|NCT00435305|Drug|Cefepim|
45983866|NCT00435305|Drug|Ceftazidim|
45983867|NCT00435344|Behavioral|Pediatric Practice-Based Smoking Intervention|
45983868|NCT00473499|Device|DEBlue vs Cypher vs BMS|BMS vs DES vs DEB+BMS
45983869|NCT00465465|Biological|MVA 85A|i.d. injection
46083121|NCT04258007|Drug|Reversal Neostigmine|Patients will receive 0.02 mg/ kg atropine and 0.04 mg/ kg neostigmine following observing the second response on stimulating the ulnar nerve on the TOF watch
45673065|NCT01536418|Drug|GSK1605786A|500 milligrams once daily, orally administered for 12 weeks
45673066|NCT01536418|Drug|GSK1605786A|500 milligrams twice daily, orally adminstered for 12 weeks
45673067|NCT04410094|Drug|Lazertinib|Lazertinib tablets will be administered orally.
45832654|NCT04763616|Drug|Cemiplimab|The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
45832655|NCT04747158|Biological|Convalescent plasma|COVID-19 convalescent plasma at admission, after confirmation of eligibility, 200 ml on day 1 and 2
45832656|NCT03652974|Drug|sodium valproate with Clozapine|sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
45832657|NCT03652974|Device|modified electroconvulsive therapy(MECT) with Clozapine|modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
45832658|NCT03652974|Drug|amisulpride with Clozapine|amisulpride may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
45983870|NCT02957825|Device|Continuous wireless monitoring|Continuous wireless monitoring of vital signs
45983871|NCT00465504|Procedure|iontophoresis|See Detailed Description.
45983872|NCT00435422|Procedure|Stroke volume optimization|Stroke volume optimization
45983873|NCT00465543|Other|Mint tea high in rosmarinic acid|Mint tea high in rosmarininc acid contains 150mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
45983874|NCT00465543|Other|Mint tea low in rosmarinic acid|Mint tea low in rosmarininc acid contains 10mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
45983875|NCT00435500|Drug|Fluoride varnish|
45983876|NCT03272412|Diagnostic Test|Analysis of serum Progesterone in blood sample|Levels of progesterone will be determined on the day of embryo transfer in patients undergoing artificial endometrial preparation cycles.
45983877|NCT00435578|Drug|Glufosfamide|
46083122|NCT04258007|Drug|Reversal Sugammadex|Interventional Arm Patients undergoing cardiac catheterization will receive sugammadex 4 mg/ kg when the T2 is observed on the TOF watch
46083123|NCT00944437|Device|Helmet|Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
45673068|NCT04410094|Drug|Itraconazole|Itraconazole capsules will be administered orally.
45983878|NCT00435617|Device|Hand Mentor|Use of the Hand Mentor therapy device at home for 6 weeks. Therapy programs include spasticity reduction, motor control, and emg biofeedback for encouraging activity.
45983879|NCT00435695|Drug|GSK163090|
45983880|NCT00473538|Behavioral|Structured exercise training|
45983881|NCT00473538|Behavioral|Hypocaloric hyperproteic diet|
45983882|NCT00473577|Drug|CRA-24781|
45983883|NCT00473616|Drug|AZD7762|intravenous infusion
45983884|NCT00473616|Drug|Irinotecan|intravenous injection
45983885|NCT00435734|Behavioral|obesity intervention|
45983886|NCT00481221|Procedure|Observation of results from laboratory tests|Laboratory data summary only
45983887|NCT00435773|Procedure|Single Leeching|
45456640|NCT02059005|Behavioral|Specialized Community Disease Management|Specialized Community Disease Management is 90-day program that employs specialized teams including a trained clinical social worker and a peer-specialist community health worker who provide evidence-based telephone continuing care, home visits, and focus on patients' substance use following hospital discharge.
45673069|NCT04410094|Drug|Rifampin|Rifampin capsules will be administered orally.
45673070|NCT01576042|Drug|amiodarone|The dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
45673071|NCT01576042|Drug|sotalol|The choice and dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
45673072|NCT01576042|Device|Biosense Webster's NAVI-STAR Thermo-Cool|The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults.
45456641|NCT02059005|Behavioral|Treatment As Usual|Treatment as Usual is a 90-day, post-discharge program that consists of medical monitoring by nurses and community health workers who have no special training in working with substance use disorder patients, and does not address substance use.
45456642|NCT01917877|Drug|Bevacizumab|Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
45456643|NCT01917877|Drug|Dexamethasone|Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
45456644|NCT01906970|Device|ClampArt|
45456645|NCT01845311|Device|ReZolve2 Scaffold|
45676667|NCT02077465|Drug|Placebo to match Andecaliximab|Placebo to match andecaliximab administered intravenously
45676668|NCT02034565|Drug|Apixaban|
45676669|NCT02075515|Biological|Herpes Zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
45676670|NCT02034409|Device|Pulsed Low Intensity Ultrasound|20 minutes daily for 48 weeks
45676671|NCT02034409|Device|Sham Comparator|20 minutes daily for 48 weeks
45983888|NCT00435773|Procedure|Repeated Leeching after 4 weeks|
45983889|NCT00435773|Procedure|Placebo Leeching|
45983890|NCT00473733|Procedure|GLP receptors expression|
45983891|NCT00473733|Procedure|ESOPHAGOGASTRODUODENOSCOPY|
45983892|NCT00481260|Procedure|Medical history and basic laboratory analysis|Medical history and basic laboratory analysis
45983893|NCT00435851|Drug|Thyrogen, thyroid hormone withdrawal, iode 131|
45983894|NCT00435890|Behavioral|Triage Liaison Physician|triage liaison physician stationed with nurses at the triage desk of the Emergency Department.
45983895|NCT00435968|Drug|CVT E002 (Cold-fX)|
45983896|NCT00481338|Procedure|X-rays|X-rays (hip and knee) every 2 years
45983897|NCT00481338|Biological|biological samples|biological sample (blood and urine) every 2 years
45983898|NCT00481338|Other|medical information about osteoarthritis|several questionnaires about pain and function (WOMAC), physical activity (MAQ), quality of life (generic SF-36 and OA specific OAKHQOL/AMIQUAL), comorbidities (FCI), mental status (MMS), heath status (GHQ 28) and health resource consumption
45983899|NCT00436085|Behavioral|Cognitive behavioral stress management training|
45983900|NCT00473772|Device|DEBlue stent vs. Cypher stent|DES vs. DEB with BMS
45983901|NCT03272165|Drug|MEDI1341|Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.
45983902|NCT03272165|Drug|Placebo|Participants will receive IV infusion of placebo matched to MEDI1341.
45983903|NCT00481377|Procedure|ablation|
45983904|NCT00436124|Drug|oseltamivir [Tamiflu]|
45983905|NCT00473811|Behavioral|Low GI|low-GI education
45983906|NCT00473811|Behavioral|ADA diet|ADA dietary education
45983907|NCT03272828|Device|Nobel Biocare titanium dental implants|
45983908|NCT01240473|Drug|Randomized trial for treatment of kala azar in Bangladesh|dose of SAG 20 mg/kg body weight, with a maximum dose of 850 mg/day, for 28 days
45983909|NCT02957474|Drug|GED-0301|
45983910|NCT02957474|Drug|Omeprazole|
45983911|NCT00481416|Device|PillCam Eso|
45983912|NCT00434720|Device|GlideScope Specific Stylet|
45983913|NCT00436202|Behavioral|Iron supplement|
45983914|NCT00473928|Drug|POT-4|Single intravitreal injection.
45983915|NCT00436241|Drug|Oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
45983916|NCT00436241|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-10 of each 2 week cycle
45983917|NCT00481455|Drug|Panzem NCD|2000 mg q8h, continuous dosing in 28 day cycles
45983918|NCT00481455|Drug|Temozolomide|Fixed dose
45983919|NCT02957396|Drug|Finerenone (BAY94-8862): 20 mg intact tablet|20 mg intact finerenone immediate-release tablet; single dose in the fasting condition
45983920|NCT02957396|Drug|Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet|20 mg crushed and resuspended finerenone immediate-release tablet; single dose in the fasting condition
45983921|NCT02957396|Drug|Finerenone (BAY94-8862): 20 mg suspension|20 mg finerenone suspension; single dose in the fasting condition or in the fed condition
45832659|NCT03652974|Drug|placebo with Clozapine|placebo may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
45983922|NCT00436319|Procedure|Duration of GnRH agonist downregulation|"This is a randomized controlled trial. Patients will be randomized to two groups during the first consultation. GnRH agonist will be administrated according to the long luteal protocol. Down-regulation of the pituitary will be controlled on the first day of the menstrual period.~The purpose of this study is to compare the pregnancy rates between the two groups. In the eventuality that pituitary down-regulation has not been confirmed (down-regulation levels determined as Ε2<80 pg/ml and progesterone <1.6 ng/ml), the patient will be assigned to a third group (group 3) and ovarian stimulation will only be initiated after down-regulation has been confirmed.~The GnRH agonist that will be administrated is Buserelin Acetate. Recombinant FSH will be used for the ovarian stimulation and dose determination will be based on patient characteristics and previous history."
45983923|NCT00481533|Drug|Methyl-Ergonovine-Oxytocin|
45983924|NCT00481533|Drug|Oxytocin|
45983925|NCT00436358|Other|Not applicable: none|Please refer to the detailed description section
45983926|NCT00481572|Drug|Terlipressin|continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs
45983927|NCT00481572|Drug|Vasopressin|continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs
45983928|NCT00481572|Drug|Norepinephrine|titrated norepinephrine over a period of 48 hrs
45983929|NCT00436397|Radiation|radiation therapy|
45983930|NCT00436514|Behavioral|diet and absorption of ColoPEG|4l of PEG during 2 days
45983931|NCT00436514|Procedure|Colonoscopy with colic videocapsule|2x 10mg Motilium, 2 Fleet Phospho soda (one is facultative) and 1 dulcolax (facultative)
45983932|NCT00436514|Procedure|Standard colonoscopy|1l of PEG the morning just before colonoscopy
45983933|NCT00481650|Drug|Leios/Alesse|
45983934|NCT00436592|Device|NeuroFlo™ Catheter|45 minute Treatment
45983935|NCT00473967|Biological|Na-ASP-2 Hookworm Vaccine|Injections of one of three different dose concentrations of the Na-ASP-2 vaccine (10, 50, or 100 mcg) vs. the hepatitis B vaccine, delivered at 0, 2, and 4 months by intramuscular injection.
45676672|NCT04691323|Other|HU-Go app|A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
45832660|NCT03650244|Device|REMEEX implantation|Device implantation
45983936|NCT04701554|Other|Qigong program|The intervention group received sixteen sessions lasting one hour with different techniques of diaphragmatic breathing, concentration techniques and exercises with smooth and coordinated musculoskeletal movements. The Qigong program was performed by a therapist with more than 10 years of experience.
45983937|NCT04701554|Other|Information on healthy lifestyles, physical exercise and dietary recommendations.|The control group received information on healthy lifestyles, physical exercise and dietary recommendations.
45983938|NCT00474006|Drug|arm II|Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 90 mg/m2/d civ x 3 days
45983939|NCT04697745|Drug|Intrathecal dexamethasone|intrathecal adjuvants to bupivacaine
45983940|NCT04697745|Drug|Intrathecal dexmedetomidine|intrathecal adjuvants to bupivacaine
45676673|NCT04682587|Drug|Axitinib|Inlyta, axitinib
45676674|NCT04682587|Drug|Avelumab|Avelumab, Bavencio
45832661|NCT03649152|Drug|Propagermanium|Immediate release capsule
45832662|NCT03649152|Drug|Placebo|Placebo capsule
45832663|NCT02082288|Other|Edessy ICSI Outcome Embryo Score|"EIOS:~Age (ys) >35 (0) 30-35 (1) <30 (2) No of retrived oocyte <5 (0) 5-9 (1) ≥ 10 (2) No of EC embryos <2 (0) 2-4 (1) >4 (2) No of good quality embryos <3 (0) 3-5 (1) >5 (2) No of embryos transferred -------- (0) ≤2 (1) >2 (2)"
45832664|NCT00003468|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a low grade astrocytoma that have not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
45983941|NCT00436631|Behavioral|Dietary management of seizures|Using the high-fat, low carbohydrate modified Atkins diet - 15 grams per day initially. This is a 3-month study of this diet.
45676675|NCT04682587|Drug|Pembrolizumab|Pembrolizumab, Keytruda
45983942|NCT00481689|Drug|Cipro XR (Ciprofloxacin, BAYQ3939)|Active Ciprofloxacin XR ( 1000mg) given for 7 to 14 days
45983943|NCT00436709|Biological|bevacizumab|
45983944|NCT00436709|Biological|pegfilgrastim|
45983945|NCT00436709|Drug|cyclophosphamide|
45983946|NCT00436709|Drug|doxorubicin hydrochloride|
45983947|NCT00436709|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
45983948|NCT00436709|Other|flow cytometry|
45983949|NCT00436709|Other|immunoenzyme technique|
45983950|NCT00436709|Other|immunologic technique|
45983951|NCT00436709|Other|laboratory biomarker analysis|
45983952|NCT00436709|Procedure|adjuvant therapy|
45983953|NCT00436709|Procedure|immunoscintigraphy|
45983954|NCT00474084|Device|Intravascular Coronary Stent|
45983955|NCT00436787|Drug|Fondaparinux Sodium|
45983956|NCT00481728|Drug|Tolterodine|Single dose per patient as determined by protocol.
45983957|NCT00481728|Procedure|Filling cystometry|This is a procedure.
45983958|NCT00481728|Procedure|Intravesical neurostimulation|This is a procedure.
45983959|NCT00436865|Behavioral|Weight loss|
45983960|NCT00436943|Drug|nicotine replacement therapy and bupropion|3-6 months
45983961|NCT00436943|Behavioral|smoking cessation counseling and referrals|Organizational counseling and referrals
45983962|NCT00437060|Procedure|Cognitive Assessment|Ancillary studies
45832665|NCT03736590|Behavioral|Financial coaching and services|The intervention will consist of clinic-based financial coaching that focuses on improving financial stability through longitudinal visits with financial services professionals to address financial goals.
45983963|NCT00437060|Procedure|Diffusion Tensor Imaging|Correlative studies
45983964|NCT00437060|Other|Laboratory Biomarker Analysis|Correlative studies
45832666|NCT03646188|Drug|Placebo-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering a placebo.
45983965|NCT00437060|Other|Pharmacological Study|Correlative studies
45456646|NCT01793662|Procedure|Laparoscopic aortobifemoral bypass|Totally laparoscopic aortobifemoral bypass shall be performed and the patients in this intervention arm shall be compared with the control arm randomized for open aortobifemoral bypass operation.
45832667|NCT03646188|Drug|25 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 25 µg of doxorubicin hydrochloride.
45832668|NCT03646188|Drug|50 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 50 µg of doxorubicin hydrochloride.
45983966|NCT00437060|Procedure|Psychosocial Assessment and Care|Ancillary studies
45983967|NCT00474162|Drug|Pentaspan®|15 ml/kg of starch solution, approximately 1 litre
45673073|NCT01561300|Other|Nutrition intervention study with a black tea extract|"Tea extract: 1800 mg/day standardized Brooke Bond black tea extract equivalent to 400 mg flavonoids dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days tea will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups or tea, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
45676676|NCT04417543|Drug|Memantine Hydrochloride|Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor .Memantine hydrochloride tablet was started at the dose of 5 mg once daily orally, and the same dose was given for 3months and dose is titrated to 10 mg once daily orally for the remaining 3months. Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
45983968|NCT00474162|Drug|Normal Saline|15 ml/kg of either saline solution, approximately 1 litre
45983969|NCT00437099|Drug|Omacor®|arm 1: Omacor 1680 Arm 2: Omacor 3360
45983970|NCT00437099|Drug|Placebo|Placebo
45983971|NCT00481884|Other|RadiaPlexRx Gel|RadiaPlexRx Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply RadiaPlexRx gel topically 3 Times Daily to one half of the irradiated breast skin and the control, Aquaphor gel, to the other half of irradiated breast skin. This is determined through randomization process.
45983972|NCT00481884|Other|Aquaphor Gel|Aquaphor Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply Aquaphor gel topically 3 Times Daily to one half of the irradiated breast skin and the experimental, RadiaPlexRx gel, to the other half of irradiated breast skin. This is determined through randomization process.
45983973|NCT00481923|Drug|rimonabant (SR141716)|
45983974|NCT00437138|Behavioral|Exposure to dilute diesel exhaust (300µg/m3) or filtered air|
45983975|NCT00481962|Drug|Tygacil|Initial dose of 100mg followed by 50mg every 12 hours for 5 to 14 days
45983976|NCT00437177|Drug|apomorphine|Apomorphine 0.05 mg/kg subcutaneously at hospital admission and at discharge. Abstinent participants at 3 months will receive a third dose.
45983977|NCT00437177|Drug|[(123)I] iodobenzamide|[(123)I] iodobenzamide 185 MBq I.V., at discharge.
45983978|NCT00482040|Device|Stephanie (TM), Infant Flow (TM), Infant Flow advance (TM), Bubble CPAP|
45983979|NCT00437333|Drug|Metformin cloridrate|
45983980|NCT00482079|Drug|MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks|
45983981|NCT00482079|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks|
46083124|NCT00944437|Device|Full-face mask|Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
46083125|NCT02787824|Drug|Iron Sucrose Supplement|
45983982|NCT00437372|Drug|Sunitinib|"The use of the FDA approved drug sunitinib, used in an off-label manner with external beam radiation therapy."
45983983|NCT00437372|Radiation|External Beam Radiation Therapy|Radiotherapy will be administered Monday through Friday for a maximum of 8 weeks. Total dose will depend on the patient's disease site.
45983984|NCT00437411|Behavioral|Affective Self-Awareness workshop|Affective Self Awareness intervention: 90 minute face-to-face consultation with the treating physician, then three 2-hour weekly small-group workshops involving education regarding Mind-Body connections, written emotional expression, meditation, and self-affirmation practices.
45983985|NCT00482196|Drug|MK0493|
45983986|NCT00437450|Drug|Epoetin/Atra|
45983987|NCT00482235|Drug|MK0359|
45983988|NCT04701710|Drug|Ivermectin / Iota-Carrageenan|The EG received Ivermectin orally 2 drops of 6 mg = 12 mg every 7 days, and Iota-Carrageenan 6 sprays per day for 4 weeks.
45983989|NCT01240707|Other|Fiberoptic bronchoscopy|Fiberoptic bronchoscopy performed to remove secretions and assess soot in central airways
45983990|NCT00437567|Dietary Supplement|Galacto-oligosaccharide (GOS)|Treatment group to receive 1.3 gm/kg/day GOS from initiation of enteral feeds until 35 weeks post-conceptual age.
45983991|NCT00437567|Other|Placebo|Similar quantity of sterile water to be added to milk
45983992|NCT02274129|Device|Healing cap II|Healing cap II is used instead of the traditional healing cap as part of the surgical dressing after bone anchored hearing aid implant surgery
45983993|NCT00437606|Drug|GK Activator (2)|100mg po
45983994|NCT00437606|Drug|Ethanol|40g po
45983995|NCT00482313|Drug|PR OROS Methylphenidate|PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
45983996|NCT00482313|Drug|Placebo|Sugar pill
45983997|NCT00437684|Drug|LPV/r|200/50 mg 2 cpr bid monotherapy
45983998|NCT00437684|Drug|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week
45983999|NCT00437684|Drug|Ribavirin|Ribavirin 1-1.2 g/day
45984000|NCT00437684|Drug|NUCS|Nucleoside Reverse Transcriptase Inhibitors
45984001|NCT00482352|Other|laboratory biomarker analysis|Correlative studies
45984002|NCT00437723|Drug|epoetin beta [NeoRecormon]|At a dose to achieve and maintain an Hb level of 120-135g/dL.
45984003|NCT00482430|Drug|MK0557|MK0557 10mg tablet qd for a 15-wk treatment period
45984004|NCT00482430|Drug|Comparator: Placebo (unspecified)|MK0557 Pbo tablet qd for a 15-wk treatment period
45984005|NCT00437762|Drug|Botulinum Toxin A Injection|Botulinum Toxin A Injection
45984006|NCT00437762|Drug|Placebo injection|Placebo Injection
45984007|NCT00482508|Drug|Omalizumab|
45984008|NCT00437840|Drug|GSK598809|GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.
45984009|NCT00437840|Drug|Placebo|Subjects will receive single oral dose of matching placebo tablet to GSK598809.
45984010|NCT00482586|Other|medical chart review|Review the medical charts of patients with hepatic neoplasms who undergo Image-guided Therapy.
45984011|NCT00482586|Other|questionnaire administration|Patients with hepatic neoplasms who undergo Image-guided Therapy
45984012|NCT00482586|Procedure|quality-of-life assessment|Patients with hepatic neoplasms who undergo Image-guided Therapy
45984013|NCT00437918|Drug|nateglinide|
45984014|NCT00437918|Drug|acarbose|
45984015|NCT00482742|Device|CiTop(TM) Guidewire|
45984016|NCT00437957|Drug|Temozolomide|75 Mg/m2/day for all Cohorts
45984017|NCT00437957|Drug|Valproic Acid|Cohort 1: 20 mg/kg/day Cohort 2: 30 mg/kg/day Cohort 3: 40 mg/kg/day Cohort 4: 50 mg/kg/day
45984018|NCT00437957|Procedure|Whole Brain Radiation Therapy|Concurrently with Temozolomide and VPA
45984019|NCT00482781|Biological|Infanrix|
45984020|NCT00482781|Biological|Pediatrix|
45984021|NCT03270176|Drug|Debio 1143|Debio 1143 100 to 250 mg, capsule orally for 10 days every 2 weeks.
45984022|NCT03270176|Drug|Avelumab|Avelumab 10 mg/kg intravenous infusion every 2 weeks.
45984023|NCT00474279|Drug|Orally active growth hormone secretagogue (MK-677)|
45984024|NCT03270618|Device|CAD/CAM Surgical Template|The templates were designed based on virtual planning and manufactured using three-dimensional printing technique. The template is designed to assist the surgeon to perform the osteotomy and predrill the screw holes to guide the distractor position.
45984025|NCT03270696|Drug|administration of propofol and rocuronium|compare the tidal volume applied from starting facemask ventilation under 15cmH2O of PCV for 1 minute according to administrating propofol and rocuronium simultaneously, or ordinally
45984026|NCT03278600|Genetic|tissue-of-origin (ORIGIN-PanCA○R) profiling|90-gene assay to predict the primary tumor site
45984027|NCT00437996|Drug|Clonidine|
45984028|NCT00437996|Drug|Levobupivacaine|
45984029|NCT00437996|Drug|Sufentanil|
45984030|NCT03270579|Drug|[18F]JNJ-64511070|An IV injection of 185 MBq [18F]JNJ-64511070 will be administered.
45984031|NCT04701125|Device|selective head-neck cooling using PolarCap system|Players receiving selective head-neck cooling after SRC
45984032|NCT00474357|Behavioral|Brief Structured Psychoeducation Group Therapy|weekly brief structured psychoeducation group therapy for seven weeks for bipolar patients
45984033|NCT00474396|Behavioral|Low fat dairy diet|
45984034|NCT04701242|Drug|Ezetimibe 10mg|comparing upfront use of Ezetimibe (added to high intensity statins) after acute myocardial infarction versus selective Ezetimibe initiation to those failing to achieve LDL-C targets when assessed in follow up visit.
45984035|NCT03270267|Other|Questionnaires|
45984036|NCT03279965|Diagnostic Test|MRI|MRI of lungs, paranasal sinuses and liver in addition to established clinical examinations (lung CT, pulmonary function testing)
45984037|NCT00474435|Drug|Emtricitabine/tenofovir/efavirenz|"Co-formulated in one tablet (taken once daily by oral administration):~emtricitabine 200 mg~tenofovir DF 300 mg~efavirenz 600 mg"
45984038|NCT00438035|Procedure|ECG spectral|
45984039|NCT04701320|Drug|Conventional glass ionomer|Conventional glass ionomer with enhanced mechanical and esthetic proberties
46083126|NCT04096131|Procedure|cataract surgery|phacoemulsification
46083127|NCT02796872|Dietary Supplement|GOS|GOS resource (β-galactosidase from Bacillus circulans) Commercial infant formula containing 4% w/w FOS:GOS (1:3)
46083128|NCT02796872|Dietary Supplement|B-GOS 3%|Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 3% w/w FOS:B -GOS (1:2)
45984040|NCT04701320|Drug|Nano hydroxyapatite reinforced glass ionomer|Nanohydroxyapatite reinforced glass ionomer restorative material with enhanced mechanical proberties and chemical adhesion to tooth structure
45984041|NCT03270423|Device|PathMate2|To improve self-regulation of overweight adolescents and subsequently their weight status, we tested, whether a biofeedback relaxation exercise decreases stress and whether relaxation services as well as sensor data integration implemented in a novel Smartphone App supported intervention have effects on stress, physical activity and weight outcomes. During the intensive phase of 6 months, patients of the intervention group (IG) are equipped with a smartphone and a specially designed chat App with game character, which encourages them through a virtual coach to achieve daily activity, healty lifestyle or relaxation challenges and earn virtual rewards, to increase adherance to the health information system.
45984042|NCT03270423|Device|PathMateS|Overweight or obese adolescents of the treatment as-usual group (CG) have monthly visits on site during the intensive phase. Counseling for physical activity, healthy eating and lifestyle as well as psychosocial wellbeing is provided by a pediatrician.
46083129|NCT02796872|Dietary Supplement|B-GOS 2%|Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 4% w/w FOS:B -GOS (1:3)
46083130|NCT02796872|Dietary Supplement|Mother's breast milk|exclusively breastfed infants for at least 7 days prior to enrollment
46083131|NCT04095819|Procedure|Middle Meningeal Artery procedure|Seal off the blood supply to the middle meningeal artery to prevent growth of the Subdural Hematoma
46083132|NCT04095819|Procedure|Traditional Surgery|Drainage of Subdural Hematoma using Craniotomy or Burr Hole
46083133|NCT00946933|Dietary Supplement|NH4Cl (ammonium chloride)|0.2 g/kg/day of NH4Cl (ammonium chloride)
46083134|NCT00946933|Dietary Supplement|placebo|0.025 g/kg/day of NaCl (sodium chloride)
46083135|NCT02796716|Device|Testing on new technology called Accelerate ID/AST system|
46083136|NCT04095897|Procedure|Pecs II Block|Peripheral nerve block - Regional anesthesia : Pectoral Nerve block type 2
46083137|NCT00947089|Device|oxidized regenerated cellulose (Fibrillar SURGICEL)|one gauze made of ORC
46083138|NCT00947089|Device|iodoform gauze|one iodoform gauze
46083139|NCT02787980|Biological|Additional taking blood|Additional blood collection of 1 ml during the biological workup usually done.
46083140|NCT04095741|Diagnostic Test|Questionnaires|Filling in questionnaires of general functioning and symptomes of anorexia nervosa and autism spectrum disorders will demanded to children and their parents. The children all have a history of anorexia nervosa.
46083141|NCT00950053|Procedure|Achilles decompression & debridement|Surgical intervention
46083142|NCT00950053|Procedure|Achilles decompression and debridement with FHL transfer|surgical intervention
45456647|NCT01698840|Dietary Supplement|Vitamin D|
45832669|NCT03646188|Drug|100 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 100 µg of doxorubicin hydrochloride.
45832670|NCT03646188|Drug|200 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 200 µg of doxorubicin hydrochloride.
45832671|NCT03849456|Drug|GWP42006|Oral solution containing cannabidivarin 50 milligrams per milliliter (mg/mL) in sesame oil with anhydrous ethanol, sucralose, strawberry flavoring, and β-carotene.
46083143|NCT02796950|Drug|Acipimox|P.o. administration of 250 mg acipimox
46083144|NCT00755079|Drug|extended release beta-2 adrenergic agonist|Albuterol extended release belongs to a class of drugs known as bronchodilators. It works in the airways by opening breathing passages and relaxing muscles.
46083145|NCT00755079|Drug|placebo|An ambiguous sheathing capsule will be placed over a lactose placebo pill. The placebo will have no effect on pulmonary function.
46083146|NCT00950131|Other|Presentation of information about drug approval and level of warning|Presentation of information about date of drug approval with no new drug warning, a non-directive drug box warning or a directive drug box warning
46083147|NCT02796638|Device|Adaptive Servo-Ventilation|A positive pressure airway device that increases and decreases inspiration pressure in concordance with the patient's natural breathing cycles.
46083148|NCT05301127|Device|spinal-epidural device|received combined spinal-epidural-general anesthesia.
46083149|NCT05370404|Other|Prescription by surgical team|The surgical team prescribes medications to the patient
46083150|NCT05370404|Other|Recommendation by surgical team|The surgical team recommends the patient to take over-the-counter medications
46083151|NCT04096053|Other|TEACHH|See arm/group description.
45832672|NCT03645720|Device|Plastic cannula|puncture using plastic cannula
45832673|NCT03645096|Drug|Pregnenolone 500 mg|Pregnenolone 500 mg capsule.
45832674|NCT03645096|Drug|Pregnenolone 800 mg|Pregnenolone 800 mg capsule.
45832675|NCT03645096|Drug|Placebo|Placebo capsule manufactured to mimic pregnenolone capsule.
45832676|NCT03734640|Other|Low-intensity monitoring strategy|Post-tpa patients will be monitored in a lower intensity with less vital status and neurological assessment
45832677|NCT03734640|Other|Guideline recommended standard monitoring|Post-tpa patients will be monitored in the usual care monitoring environment
45832678|NCT03734172|Diagnostic Test|Sample collection|Specimen collection
45832679|NCT03732300|Other|ASSIP|Three PSychotherapy Sessions plus after 3/6/9/12 months individualized letters
46083152|NCT00950209|Dietary Supplement|saline infusion|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48"
46083153|NCT00950209|Other|euglycaemic hyperinsulinic clamp|an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l
46083154|NCT00950209|Dietary Supplement|infusion of Endolipide and heparin|an infusion with Endolipide 20 % (12,5 ml/h) and heparin (250 U/h) to prevent the suppressive effect of insulin on plasma free fatty acids
45984043|NCT00438113|Drug|Aggressive Blood Pressure control|Aggressive Blood Pressure therapy, alone or combination therapy, to reach a target BP equal to or less than 120/80 mmHg
45984044|NCT03270228|Other|Nonspecific pleuritis after VATS thoracoscopy|Patients with a pleural effusion with unknown origin after a VATS thoracoscopy is classified as nonspecific pleuritis.
45984045|NCT00474474|Procedure|Virtual patient is NOT introduced|
45984046|NCT00438152|Drug|Saquinavir (Invirase®)|Saquinavir 1000mg + Ritonavir 100mg Bd for 24 weeks
45984047|NCT00438152|Drug|Lopinavir/ritonavir (Kaletra®)|Lopinavir/ritonavir 400/100 mg BD 24 weeks
45984048|NCT03279926|Behavioral|PLAY|Activity trackers + curriculum information
45984049|NCT03279926|Behavioral|PLAY Parents|Enhanced parental engagement
46083155|NCT00950209|Other|hyperglycaemic hyperinsulinic clamp|a hyperglycaemic hyperinsulinic clamp to maintain plasma glucose around 2 g/l to prevent the decreasing effect of insulin on plasma glucose.
46083156|NCT04095585|Genetic|chromosomal microarray analysis (CMA) and whole exome sequencing (WES)|"The investigator evaluated the following hypotheses:~i) atypically large 7q11.23 deletions including additional genes; ii) rare pathogenic variants in genes located within the deletion, in particular GTF2I iii) additional pathogenic copy number variants (CNVs) or rare intragenic pathogenic variants located in other chromosomal regions with various inheritance patterns (autosomal recessive, X-linked, de novo autosomal dominant); given the small number of patients recruited, we focused on rare exonic variants considered to be pathogenic according to the criteria of the American College of Medical Genetics and Genomics (ACMG)"
46083157|NCT05370326|Other|Enhanced Opioid Stewardship Program|The goal of the enhanced opioid stewardship intervention is to manage chronic pain while reducing risk of inappropriate/risky opioid use and preventing harms of opioid use.
45673074|NCT01561300|Other|Nutrition intervention study with a control|"Control: 1800 mg/day of a powder that gives a flavoured beverage with a color similar to black tea dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days control will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups of control, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
45673075|NCT01536262|Drug|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
45673076|NCT01536262|Device|Respimat|Respimat inhaler
45832680|NCT04762524|Other|CVVH vs CVVHD|Patients are initiated on CRRT in either the CVVH or CVVHD modality
45832681|NCT03642678|Dietary Supplement|ONS|High-risk patients identified by prediction model in study group are intervened by pre-defined intervention protocol, which include oral nutrition supply, infection prevention, bp control and improving of dialysis therapy options and so on.
45832682|NCT03642210|Combination Product|Levonorgestrel 52 mg intrauterine system|Levonorgestrel 52 mg intrauterine system
45832683|NCT03844386|Biological|MVA.tHIVconsv3|viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
45832684|NCT03844386|Biological|MVA.tHIVconsv4|viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
45984050|NCT03279926|Behavioral|PLAY Teachers|Enhanced teacher engagement with active living initiates for the teachers
45984051|NCT00474513|Drug|GSK239512|
45984052|NCT00438230|Drug|Warfarin|
45984053|NCT00438269|Drug|Site-specific empiric regimens included: Meropenem|
45984054|NCT00438269|Drug|Piperacillin/tazobactam|
45984055|NCT00438269|Drug|Ciprofloxacin and cefazolin +/- metronidazole|
45984056|NCT00474552|Drug|SAM-315|Multiple Ascending Doses of SAM-315 (treatment duration: 14 days): 0.2 mg; 0.5 mg; 1 mg; 2 mg;
45984057|NCT03279887|Diagnostic Test|Lung Ultrasound|
45984058|NCT00474591|Drug|Fondaparinux|
45984059|NCT03279848|Other||Stroke rehabilitation
45984060|NCT03279809|Drug|Aspirin|Aspirin medication (100mg daily) after biliary stent insertion for malignant obstruction
46083158|NCT00947245|Drug|BMS-791325|Capsules, Oral, 300 mg, Single Dose, One day
45673077|NCT01536262|Drug|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
45673078|NCT01536262|Drug|Olodaterol|Olodaterol once daily inhalation
45673079|NCT01536262|Device|Respimat|Respimat inhaler
45673080|NCT01536262|Device|Respimat|Respimat inhaler
45673081|NCT01560988|Drug|Borage and Echium Seed Oils|4.0 g/day borage seed oil and 7.0 g/day echium seed oil. Pills will be taken three times per day for six weeks.
45673082|NCT01560988|Dietary Supplement|Corn oil pills|Corn oils pills will be taken three times per day for six weeks.
45984061|NCT03279809|Drug|Placebo|Case with placebo medication for 6 months after stenting
45984062|NCT00474825|Drug|Hyperbaric Oxygen Therapy|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
45984063|NCT00474825|Drug|Hyperbaric Oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
45984064|NCT00474825|Drug|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
45984065|NCT00474825|Drug|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
45984066|NCT00438347|Behavioral|Aerobic Exercise|One hour per day three times a week for one year
45984067|NCT00438347|Behavioral|Stretching and toning|One hour per day three times a week for one year
45984068|NCT00474981|Behavioral|IMNCI|Implementation of IMNCI in the intervention sites
45984069|NCT00438386|Drug|Aripiprazole|
45984070|NCT00475059|Drug|cimetidine arrow|patients who received cimétidine
45984071|NCT00438425|Dietary Supplement|Dietary Portfolio - Intensive|Dietitians advised participants to consume the following therapeutic diet components (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 7 visits during a 6-month period with the study dietitian.
45984072|NCT00438425|Dietary Supplement|Dietary Portfolio - Routine|Dietitians advised participants to consume the following therapeutic diet components (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 2 visits during a 6-month period with the study dietitian.
45984073|NCT00438425|Dietary Supplement|Control (low saturated fat therapeutic diet)|Dietitians advised participants to consume the following therapeutic diet components (<7% of energy saturated fat, <200 mg/d cholesterol) with a focus on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
45984074|NCT00475098|Drug|Tinzaparin sodium 100 UI/Kg/OD for 12 weeks|treatment in lung tumours
45984075|NCT00438503|Procedure|Procedure|
45984076|NCT00475137|Drug|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. For subjects in this combination therapy arm, antidepressant dose will remain constant throughout the study.
45984077|NCT00475137|Drug|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. Subjects in this group will discontinue their antidepressants prescribed to them before the study.
45984078|NCT00438581|Drug|Yttrium 90 Ibritumomab Tiuxetan ( Zevalin )|
45984079|NCT00438620|Behavioral|Home-based physical activity program|the role of physical activity as a Quality of Life intervention
45984080|NCT00438698|Other|Low Glycemic Index diet|Diet to emphasize carbohydrate foods low in glycemic index
45984081|NCT00438698|Other|High Cereal Fibre Diets|Diet to emphasize whole wheat carbohydrate cgoices
45984082|NCT00475293|Drug|Panitumumab and CPT-11|"Panitumumab will be administered by IV infusion on day 1 of each cycle just prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg~Irinotecan: 350 or 300 mg/m2. day 1~One treatment cycle is defined as the 21 day period following the commencement of treatment with panitumumab + irinotecan plus additional time, as needed, for the resolution of irinotecan-related toxicities"
46083159|NCT00947245|Drug|BMS-791325|Capsules, Oral, 900 mg, Single Dose, One day
46083160|NCT00947245|Drug|BMS-791325|Capsules, Oral, ≤1200 mg, Single Dose, One day
45832685|NCT03844386|Other|Placebo|The appropriate amount of Sodium Chloride for Injection USP, 0.9% will be drawn into a syringe.
45832686|NCT02082678|Drug|Ondansetron|Ondansetron is a serotonin receptor antagonist that is FDA-approved to treat nausea and vomiting caused by cancer therapy and surgery.
45832687|NCT02082678|Drug|Placebo|Inactive ingredient matching the active medication in appearance
45832688|NCT03843294|Biological|TAA-T cells|The patient will receive two TAA-T cell infusions given 2 weeks apart. TAA-T cell dose: 2 x 107 cells/m2.per infusion.
45832689|NCT03843294|Drug|Nivolumab|Nivolumab: For patients <18 years, 3 mg/kg/dose (maximum 240mg/dose) every 2 weeks. For adult patients ≥18 years, a dose of 240mg every 2 weeks or 480mg every 4 weeks
45984083|NCT00438737|Biological|bevacizumab|
45984084|NCT00438737|Biological|cetuximab|
45984085|NCT00438737|Drug|fluorouracil|
45984086|NCT00438737|Drug|leucovorin calcium|
45984087|NCT00438737|Drug|oxaliplatin|
45456648|NCT01698840|Dietary Supplement|Placebo|
45832690|NCT03836430|Behavioral|Newborn Behavioral Observation-Family Wellness (NBO-FW)|The intervention has been described in the arm description.
45832691|NCT03834948|Drug|AO-176|Humanized monoclonal antibody (mAb) targeting CD47
45984088|NCT00438737|Procedure|adjuvant therapy|
45984089|NCT00438737|Procedure|conventional surgery|
45984090|NCT00438737|Procedure|neoadjuvant therapy|
45984091|NCT00475371|Drug|MKC253 Inhalation Powder|Inhalation powder
45984092|NCT00438776|Drug|olanzapine|2.5mg to 15mg daily
46083161|NCT00947245|Drug|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 14 days
46083162|NCT00947245|Drug|BMS-791325|Capsules, Oral, 900 mg, once daily 14 days
46083163|NCT00947245|Drug|BMS-791325|Capsules, Oral, ≤1200 mg, Every 12 hours or once daily, 14 days
45456649|NCT01693263|Other|brachiocephalic fistula (BCF)|We will collect information from physical exams, blood tests, venogram, doppler, vein and artery tissue samples
45456650|NCT01672463|Drug|OKN-007|"Dose escalation/PK cohort: 20 mg/kg, 40 mg/kg or 60 mg/kg OKN-007 via IV infusion, given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.~Expansion cohort: MTD via IV infusion given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter."
46083164|NCT00947245|Drug|Placebo|Capsules, Oral, Single Dose, One day
46083165|NCT00947245|Drug|Placebo|Capsules, Oral, Every 12 hours, 14 days
46083166|NCT00947245|Drug|Placebo|Capsules, Oral, Once Daily, 14 days
46083167|NCT00947245|Drug|Placebo|Capsules, Oral, Every 12 hours or once daily, 14 days
46083168|NCT04095351|Diagnostic Test|Pulmonary function test|Spirometry or plethysmography, measurement of diffusion capacity
45984093|NCT00438776|Drug|sugar pill|matching placebo to olanzapine
45984094|NCT00475410|Drug|ASCs (Cx401, company code)|"Experimental: ASCs: Subjects will be treated with a dose of 20 million ASCs and evaluated after 12 weeks. If needed a second dose of 40 million ASCs will be applied then.~Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 20 million ASCs plus fibrin glue and evaluated after 12 weeks. If needed a second dose of 40 million ASCs plus fibrin glue will be applied then."
45456651|NCT01570296|Drug|Gefitinib and BKM120|Dose escalation study of gefitinib and BKM120 with expansion cohort
45456652|NCT01487928|Dietary Supplement|Human Milk Cream|If the caloric level of human milk (mother's own or donor) falls below 20 kcal/oz, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. For example, if the human milk is 19 kcal/oz, 2 mL of human milk cream will be added to 100mL of human milk.
45832692|NCT03834948|Drug|AO-176 + Paclitaxel|Humanized monoclonal antibody (mAb) targeting CD47 and paclitaxel
45832693|NCT03834948|Drug|AO-176 + Pembrolizumab|Humanized monoclonal antibody (mAb) targeting CD47 and pembrolizumab
45832694|NCT00816114|Other|Chart Review|Investigator review of MDACC CML patient charts.
45832695|NCT04403958|Procedure|PRC|Total wrist arthrodesis with dorsal plate using proximal row of the wrist as bone graft
45456653|NCT01393821|Drug|menadione topical lotion|Given topically
45456654|NCT01393821|Other|placebo|Given topically
45984095|NCT00475410|Drug|Fibrin adhesive|Experimental: Fibrin glue: Subjects will be treated with a dose fibrin glue and evaluated after 12 weeks. If needed a second dose of fibrin glue will be applied then.
45832696|NCT04403958|Procedure|TWA|Total wrist arthrodesis with dorsal plate using iliac crest as bone graft
45832697|NCT03631056|Biological|Human Acellular Vessel (HAV)|
46083169|NCT04095351|Diagnostic Test|Imaging|Thoracic ultrasound, HRCT as scheduled within routine clinical examinations, echocardiography
45456655|NCT01393821|Other|questionnaire administration|Ancillary studies
45456656|NCT01393821|Procedure|management of therapy complications|Given menadione topical lotion
45456657|NCT01277029|Other|No drug|Psychopathology, personality traits of patients with lower urinary tract symptoms
45456658|NCT01199575|Drug|Revlimid|
45456659|NCT01199575|Drug|Rituximab|
45456660|NCT01087619|Procedure|Parathyroid surgery|Parathyroid Surgery (regardless of surgical strategy; i.e., focused operation, unilateral- or bilateral neck exploration)
45456661|NCT00804713|Drug|BST|0.1 mcg/mL (1 dose) Battey skin test (BST) antigen administered using the Mantoux method.
45456662|NCT00804713|Drug|TST|Administer TB Skin test (TST)
45456663|NCT00804713|Other|QFT|Perform QFT TB test
45832698|NCT04763850|Other|Decline Walking with real-time Feedback|Participants are walking decline with self-paced speed on an instrumented treadmill with virtual reality projection under three conditions: without instruction, with instruction for an internal focus of attention and with real-time feedback of their frontal knee alignment
45984096|NCT00438893|Dietary Supplement|Dietary portfolio of cholesterol-lowering foods|A plant based dietary portfolio providing plant sterols (1.0g/1000 kcal), soy protein (22.5g/1000 kcal, viscous fibers 10 g/1000 kcal and almonds 22.5g/1000 kcal)
45456664|NCT00804713|Other|T-spot|Perform T-Spot TB test
46083170|NCT04095351|Biological|Blood sampling|Standard laboratory test for CTDs as part of routine clinical examination
46083171|NCT02791100|Behavioral|Promotion of chicken eggs|Community is provided with chickens and young children are to receive 2 eggs a day plus egg shell
46083172|NCT02600481|Procedure|low-pressure pneumoperitoneum|Using low-pressure(between 7-10 mm Hg ) pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.
46083173|NCT02600481|Procedure|standard-pressure pneumoperitoneum|Using standard-pressure (between 12-16 mm Hg )pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.
46083174|NCT00947323|Drug|Simvastatin|simvastatin 20 daily for six months.
46083175|NCT00947323|Drug|Placebo|
46083176|NCT02790944|Genetic|Multi-gene Next Generation Sequencing Panel|Participants will have genetic testing
46083177|NCT02791022|Device|SPYDER ECG sensor|
46083178|NCT04236050|Drug|Rocuronium|Rocuronium administered in continuous infusion or multiple bolus doses
45832699|NCT03624660|Radiation|HR-A|"The prostate and proximal seminal vesicles will be treated to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks."
45832700|NCT03624660|Radiation|HR-B|"The prostate, proximal seminal vesicles, and pelvic nodes will be treated to 2 cobalt gray equivalent per fraction for 23 fractions for a total of 46 cobalt gray equivalent.~The prostate and proximal seminal vesicles will be treated to an additional 2 cobalt gray equivalent per fraction for 16 fractions for a total of 32 cobalt gray equivalent.~Electively treat the entire uninvolved seminal vesicle to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent when part of the seminal vesicle is involved with tumor.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks."
45832701|NCT03624114|Procedure|comparison of data from MRI with data from CT compared with intraoperative data from endoscopic pituitary adenoma surgery|A comparison of MRI with CT of the skull base or paranasal sinuses and intraoperative Video documentation of the anatomical site will be used.
45984097|NCT00475449|Procedure|percutaneous coronary intervention|
45984098|NCT00475449|Procedure|coronary artery bypass grafting|
45984099|NCT00439010|Drug|[123I] AV 39|
45984100|NCT00475527|Drug|omeprazole,clarithromycin,amoxicillin (or metronidazole)|
45984101|NCT00439049|Drug|modafinil|400 mg daily
45984102|NCT00439049|Drug|d-amphetamine|60mg daily
45984103|NCT00439049|Drug|L-Dopa|800/200mg daily
45984104|NCT00439049|Drug|Naltrexone|50mg daily
46083179|NCT02790866|Behavioral|LuCaS Decision Aid|Web-based Lung Cancer Screening Decision Aid
46083180|NCT02790866|Behavioral|NCI Website|NCI Website on Lung Cancer Screening
45984105|NCT00475566|Device|Dynalink®-E everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (> 50% stenosis) in the native superficial femoral or proximal popliteal artery
45984106|NCT00475566|Device|Dynalink®-E, everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (> 50% stenosis) in the native superficial femoral or proximal popliteal artery
46083181|NCT02790632|Drug|EG-1962 (nimodipine microparticles)|Single intraventricular administration of EG-1962 via EVD and placebo capsules or tablets administered for up to 21 days
45984107|NCT00439166|Drug|doxycycline|capsule, 100 mg, b.i.d., daily for 1 year
45984108|NCT00439166|Drug|rifampicin|capsule, 300mg, o.d., daily for 11 months (administration starts in 2nd month of trial)
45984109|NCT00439166|Drug|Placebo matched to doxycycline|Doxycycline-matched - blue capsule, b.i.d.,daily for 12 months
45984110|NCT00439166|Drug|Placebo matched to Rifampin|Rifampin-matched - red capsule, o.d., daily for 11 months starting at month 2.
45984111|NCT00439205|Device|FastEEM4 System|The FastEEM4 probe is moved toward the edge of the lesion(s) until it measures what appears to be normal mouth tissue.
45984112|NCT00439205|Device|Multispectral Digital Microscope|The MDM instrument will take pictures of abnormal-appearing and normal-appearing areas in the mouth.
45984113|NCT00475683|Other|Mouth wash|Mouth wash with chlorehexidin, three times a day
45984114|NCT00475683|Dietary Supplement|Curcumol|5 ml in 50 ml water, mouthwash for 30 seconds, three times a day
45984115|NCT00439283|Drug|infliximab|
45984116|NCT00439283|Drug|methotrexate|
45984117|NCT00475800|Drug|Lumiracoxib|
46083182|NCT02790632|Drug|Enteral Nimodipine|Enteral Nimodipine capsules or tablets administered for up to 21 days and single intraventricular administration of saline via EVD
46083183|NCT02787122|Behavioral|CBT-E|Patients receive 25 sessions of individual emotion-focused Cognitive Behavior Therapy based on a manual. Interventions aim on patients' mood by implementing positive activities in their daily routine. Further, patients train to reduce worrying behavior. Social contacts are fostered as well. Later, patients are informed on emotions and train emotion regulation strategies. Finally, the focus of CBT-E is on self-acceptance.Patients receive psychoeducation on self-acceptance and learn strategies in order to reduce negative self-schema and foster positive self-schema.
46083184|NCT02787122|Behavioral|Treatment as Usual|Patients receive standardized treatment. After a waiting period of six month, patients receive CBT-E
45673083|NCT03897556|Dietary Supplement|Guarana herb|The intervention is a functional food bar produced in a licensed commercial kitchen that contains guarana powder as well as dates, raisins, oats, spirulina, walnuts, flour, coconut butter, soybean oil, xanthan gum and chocolate chips.
45456665|NCT00611598|Other|Blood draw and Questionnaires|Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
45673084|NCT03897556|Other|Usual Care|Participant will receive 'usual-care' for cancer survivors. At the end of the study, after completing the Final Visit, they will receive 21 guarana energy bars to thank them for being in the study.
46083185|NCT02689934|Dietary Supplement|Lactoflorene colesterolo|1.8 g + 1.8 g once a day per os
45673085|NCT01535638|Drug|BI 207127|Medium dose film-coated tablet
45984118|NCT00475839|Device|Tension-free Vaginal Tape|
45984119|NCT00475839|Device|Monarc sub-fascial hammock|
45984120|NCT00439361|Drug|Bortezomib|1.0 mg/m^2 by Vein Over 5 Seconds on Days 1 and 4
46083186|NCT02689934|Dietary Supplement|Placebo lactoflorene colesterolo|1.8 g + 1.8 g once a day per os
45984121|NCT00439361|Drug|Carboplatin|5 AUC by Vein Over 1 Hour On Day 1
46083187|NCT00925301|Drug|migalastat hydrochloride|Oral capsule QOD
45673086|NCT01535638|Drug|BI 207127|Medium dose film-coated tablet
45673087|NCT01535638|Drug|BI 207127|Medium dose film-coated tablet
45984122|NCT00439361|Drug|Etoposide|100 mg/m^2 By Vein Over 2 Hours On Days 1-3
45984123|NCT00439361|Drug|Ifosfamide|5 Gm/m^2 By Vein Continuous Infusion Over 24 Hours On Day 1
45984124|NCT00439361|Drug|Mesna|5 mg/m^2 IV continuous Infusion over 24 Hours On Day 1; 2 Gm/m^2 IV continuous infusion over 12 hours starting after completion of Ifosfamide + Mesna 24 hour continuous infusion
45984125|NCT00475917|Drug|XL844|Gelatin capsules supplied as 5-mg, 25-mg, and 100-mg strengths; twice-weekly dosing.
45984126|NCT00475917|Drug|Gemcitabine|once-weekly 30-minute IV infusion
45984127|NCT00474669|Drug|docetaxel|Docetaxel will be administered in normal-saline delivered at an inflow temperature of 42 degreesC for 90 minutes by the technique described in Appendix D of the protocol
45984128|NCT00439400|Drug|doxycycline|
45984129|NCT00439400|Drug|placebo|
45984130|NCT00475956|Drug|AZD2171|oral tablet multiple ascending doses 20, 30 or 45 mg
45984131|NCT00475956|Drug|AZD0530|oral tablet multiple ascending doses 125 mg or 175 mg
45984132|NCT00439439|Radiation|Beamer Ablation (Argon Plasma Coagulation)|APC-Beamerablation of heterotopic gastric mucosa
46083188|NCT00925301|Drug|Placebo|Oral capsule QOD
45673088|NCT03889132|Procedure|Bariatric Surgery|Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery
45673089|NCT01535560|Drug|AL-60371, 0.3% otic suspension|Investigational otic suspension intended for the treatment of acute otitis externa
45673090|NCT01535560|Drug|AL-60371 Vehicle|Inactive ingredients used as placebo
45984133|NCT00476034|Drug|lumiracoxib|
45984134|NCT00439478|Drug|Radioiodine|
45984135|NCT00476073|Drug|FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)|
45984136|NCT00439595|Device|Hemocue 210 meter|Diagnostic device
45984137|NCT00439595|Device|Copack HBCS|
45984138|NCT00476112|Drug|Vernakalant Injection 20 mg/mL|
45984139|NCT00476268|Drug|beclomethasone/formoterol (100/6µg) pMDI|Two puffs b.i.d
45984140|NCT00476268|Drug|Beclometasone dipropionate 250 µg/unit dose pMDI|2 inhalations bid
45984141|NCT00476268|Drug|Formoterol powder 12 µg/unit dose|2 inhalations bid
45984142|NCT00105989|Drug|Duloxetine|
45984143|NCT00105989|Drug|placebo|
45984144|NCT00476307|Biological|Fluarix™/Influsplit SSW® 2007/2008|
45984145|NCT00476346|Dietary Supplement|Calcium & Vitamin D|Calcium 2000mg / daily Vitamin D 800IU / daily
45984146|NCT00476385|Drug|somatropine|subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg
45984147|NCT00476424|Drug|efavirenz|EFV 400 mg OD for 14 days EFV 600 mg OD for 14 days
45984148|NCT00439712|Drug|Levocetirizine|1 tablet of Levocetirizine 5 mg OD in the morning for 29+/-4 days
46083189|NCT03633110|Biological|GEN-009 Adjuvanted Vaccine|GEN-009 Adjuvanted Vaccine consists of GEN-009 Drug Product mixed with Hiltonol (poly-ICLC, adjuvant) and is administered by subcutaneous injection.
45984149|NCT00439712|Drug|Placebo|1 placebo tablet OD in the morning for 29+/-4 days
45984150|NCT00476463|Drug|Emtricitabine|Emtricitabine 200 mg OD + Zidovudine 300 mg BID + EFV OD compared to TDF + FTC + EFV
45984151|NCT00439751|Drug|Goserelin Acetate|Continuous goserelin, 12 week (10.8 mg) depot, will be used as ADT for both study arms. It is supplied as a sterile syringe for subcutaneous use.
45984152|NCT00439790|Procedure|Microneurography|Microneurography
45984153|NCT00438243|Drug|Bromfenac (Xibrom)|1 drop to affected eye twice daily.
46083190|NCT03633110|Drug|Nivolumab|Nivolumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
45984154|NCT00438243|Drug|Refresh Plus|1 drop in the affected eye twice daily
45984155|NCT00439829|Drug|Gonal F|"450 IU Gonal-f (Serono Canada) subcutaneously daily (225 IU BID; injections to be given after bloodwork).~Dosing to begin on day 1 or day 4 (day 1=first day of menses), continuing until administration of human Chorionic Gonadotropin (hCG; see below).~Gonal-f dose may be further reduced, at the discretion of the study physician, to minimize the risk of OHSS."
45984156|NCT00439829|Drug|Luveris|"0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~leading follicle is > 13 mm in diameter~if 6 or more follicles develop to > 10 mm and E2 > 1000 pmol/L~Dosing to continue until administration of hCG (see below)."
45984157|NCT00439829|Drug|Cetrotide|"0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~leading follicle is > 13 mm in diameter~if 6 or more follicles develop to > 10 mm and E2 > 1000 pmol/L~Dosing to continue until administration of hCG (see below)."
45984158|NCT00439829|Drug|hCG|"- 10,000 IU hCG (Pharmaceutical Partners of Canada Inc.) subcutaneously when:~o > 3 follicles are > 17 mm in diameter"
45984159|NCT03278769|Procedure|Lung protective ventilator settings|Positive end-expiratory pressure 12, Tidal volume 6 milliliter/kilogram predicted body weight
45984160|NCT00439868|Drug|WellbutrinXL|WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.
45984161|NCT00439868|Drug|placebo|Matching placebo tablets to WELLBUTRIN XL.
45984162|NCT03279653|Procedure|SleeveGastrectomy|Preoperative enzyme test before and after sleeve gastrectomy. Sleeve Gastrectomy will be performed. Preoperative (in one month) and Postoperative (after 3 months) pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
45984163|NCT03277248|Biological|Ublituximab|Administered as an IV infusion.
45984164|NCT03277248|Drug|Teriflunomide|Film coated tablets administered orally.
46083191|NCT03633110|Drug|Pembrolizumab|Pembrolizumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
46083192|NCT04232930|Other|Music|Four types of music will be provided, including pop, classical, jazz or spa music which are prepared by the study team. They contain instrumental songs only without vocal.
46083193|NCT04955327|Drug|A. Paniculata|Extract from A. Paniculata
46083194|NCT04955327|Drug|A. Chilensis|Extract from A. Chilensis
45984165|NCT03277248|Drug|Oral Placebo|Administered orally.
45984166|NCT03277248|Drug|IV Placebo|Administered as an IV Infusion.
45984167|NCT03279614|Drug|SOX|OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
45984168|NCT00439907|Procedure|End-to-end repair of the external anal sphincter muscle|Surgical procedure: End-to-end repair of the external anal sphincter muscle
46083195|NCT04955327|Drug|A. Paniculata and A. Chilensis|Combination of A. Paniculata and A. Chilensis
46083196|NCT04955327|Drug|Microcrystalline cellulose|Placebo comparator
46083197|NCT04966013|Device|RD-X19|Investigational device that uses safe electromagnetic energy to target the oropharynx.
46083198|NCT04966013|Device|Sham|Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro..
45984169|NCT00439907|Procedure|Overlap repair of the external anal sphincter muscle|Surgical procedure: Overlap repair of the external anal sphincter muscle
45984170|NCT03279822|Other|not any intervention|not any intervention
45984171|NCT00439985|Behavioral|Cognitive Behavioral Therapy|The treatment which incorporates cognitive restructuring and skill training, was designed to help children with diabetes and their families develop particular skills and optimistic/positive thinking style in order to facilitate better coping with the enduring demands and stress of diabetes management. The goal of the intervention was to improve the child's diabetes management both medically and psychologically by promoting optimism (positive outlook), mastery (problem-solving) and child-parent collaboration (team-work).
45984172|NCT03279783|Device|LCI (Linked color imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked color imaging)
45984173|NCT00440024|Drug|Tazorac|Tazarotene 0.1% cream applied to the face once daily before bed
45984174|NCT00440024|Drug|Dove Mild Cleanser|Ultra mild cleanser: Dove Non-foaming cleansing lotion
45984175|NCT00440024|Drug|Dove Facial Moisturizer|Moisturizing cream - Dove facial moisturizer with SPF 15
45984176|NCT00476502|Genetic|identify genetic polymorphism in Thai HIV infected|Gene sequencing of Cyp450 metabolic pathway
45984177|NCT00440063|Drug|epoetin beta [NeoRecormon]|
45984178|NCT00438282|Behavioral|home visitation|Home visitation from midway through pregnancy until child age 2. Group 2 is visitation by Paraprofessionals; group 3 is home visitation by Nurses.
45984179|NCT00440102|Drug|Ketamine|Ketamine
45984180|NCT00440102|Drug|Etomidate|Etomidate
46083199|NCT02788136|Drug|human chorionic gonadotropin|At 08 AM of day 0, all subjects underwent to a single intramuscular injection of hCG of 5000 IU
46083200|NCT02788058|Drug|EGFR-TKI|Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
46083201|NCT02788058|Radiation|Thoracic Hypofractionated Radiotherapy|40-45 Gy/5-15f
46083202|NCT02796404|Device|Homebased cardiac rehabilitation program|homebased cardiac rehabilitation program with monitoring vest Nuubo
45673091|NCT04102618|Biological|Pelareorep|4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 & 9
45673092|NCT04102618|Drug|Letrozole|Oral dose of 2.5 mg/day starting on Day 3 for 13 days
45673093|NCT04102618|Drug|Atezolizumab|1200 mg administered intravenously on Day 3
45673094|NCT04102618|Drug|Trastuzumab|8mg/kg administered intravenously or 600mg subcutaneously on Day 3
45673095|NCT01575028|Drug|Ropivacaine|The TAP block will be delivered with 0.2ml/kg of 0.2% Ropivacaine with 1:200,000 epinephrine bilaterally
45673096|NCT01575028|Drug|Bupivacaine|The local anesthetic at the incision sites will be injected by the surgeon.
45673097|NCT03576131|Biological|GEN1029 (HexaBody®-DR5/DR5)|GEN1029 will be administered intravenously. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
45673098|NCT04783961|Procedure|Cold snare endoscopic resection|Cold snare endoscopic resection
45984181|NCT00476541|Drug|Gemtuzumab ozogamicin|Two courses of Gemtuzumab vs. no further therapy
45984182|NCT00476580|Behavioral|Questionnaire|Questions to collect health information specific to Sri Lankans.
45984183|NCT00440141|Drug|latanoprost 0.005% eye drops and brimonidine 0.1% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months
45984184|NCT00440141|Drug|latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops|latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months
45984185|NCT03279575|Behavioral|Night Shift|Physicians in this arm of the trial will be asked to play Night Shift, an adventure video game, for two hours.
46083203|NCT02796404|Other|Traditional cardiac rehabilitation program|multidisciplinary intervention in cardiac rehabilitation gym
46083204|NCT02796482|Dietary Supplement|EnergieShake 1.5kcal Complete|Participants will be given EnergieShake 1.5 kcal Complete drink twice daily. i.e. 2 bottles of ONS per day during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days, followed by 8 day intervention on EnergieShake 1.5 kcal Complete drink.
46083205|NCT02796326|Device|improved tracheal balloon dilatation|Treatment for laryngotracheal stenosis using a modified tracheal dilatation balloon
46083206|NCT04200092|Combination Product|0.5mg AZ-010|Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo
46083207|NCT04200092|Combination Product|1mg AZ-010|Subject will receive a single inhaled dose (1.0 mg) of AZ-010 or matching Staccato Placebo
46083208|NCT04200092|Combination Product|3mg AZ-010|Subject will receive a single inhaled dose (3.0 mg) of AZ-010 or matching Staccato Placebo
46083209|NCT04200092|Combination Product|AZ-010 1mg|2-period, 2-treatment open-label crossover design
46083210|NCT04200092|Drug|IV Granisetron 1mg|2-period, 2-treatment open-label crossover design
45676677|NCT04417543|Drug|Placebo|Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
45676678|NCT02021318|Drug|Roxadustat|Oral tablet.
45984186|NCT03279575|Behavioral|Graveyard Shift|Physicians in this arm of the trial will be asked to play Graveyard Shift, a puzzle video game, for two hours.
45984187|NCT03279575|Behavioral|Educational program|Physicians in this arm of the trial will be asked to use myATLS, an app designed by the American College of Surgeons to serve as an adjunct to the ATLS course, and Trauma Life Support MCQ Review, an app designed to help students prepare for the ATLS exam. They will be asked to spend at least two hours on the combined tasks.
45984188|NCT03279575|Behavioral|Control|Physicians in this arm will serve as a no-contact control group.
45984189|NCT00438321|Drug|Zoladex|
45984190|NCT00438321|Drug|Testosterone gel|
45984191|NCT00438321|Drug|Anastrozole Pill|
45984192|NCT00438321|Other|Placebo|
45984193|NCT00476619|Drug|erythropoeitin|Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
45984194|NCT03279536|Combination Product|Oral lactoferrin|Oral lactoferrin 120 mg twice /day and it's based on fast dissolving through direct swallowing per oral route with fruits flavor taste.
45984195|NCT03279536|Combination Product|TDI of LMW iron dextran|Total Dose Infusion of LMW iron dextran up to 20mg/kg body weight is infused intravenously
45984196|NCT03279497|Behavioral|Health game|Participants allocated to the Health game intervention group get to use the health game during the four week intervention period and participants are allowed to use it on their free time.
45984197|NCT03279497|Behavioral|Sport and fitness application|Participants allocated to the Sport and fitness application intervention group get to use the sport and fitness application during the four week intervention period and participants are allowed to use it on their free time.
45984198|NCT00438438|Behavioral|forced desynchrony protocol with sleep restriction|Subjects are scheduled to live on a non-24 hour day. This separates the sleep-wake schedule from the near-24 hour circadian rhythm. This allows assessment of how circadian rhythms and the length-of-time awake contribute to sleepiness, alertness, and cognitive performance.
45984199|NCT00476697|Device|German manufactured UVA1 emitting light system|The dose and scheduling of irradiation is as follows: Up to 130J/cm2 from a UVA1 Sellamed irradiation device with irradiations up to 5 times per week.
45984200|NCT00440219|Drug|Oral Prednisone|Prednisone 50 mg once daily for 10 days pre-op
45984201|NCT00440219|Drug|Placebo comparator|Placebo pill identical to Prednisone 10 days once daily pre-op
45984202|NCT00438477|Drug|Isosulfan Blue|At time of surgery, breast injected with 3-5 cc of isosulfan blue in subareolar or peritumoral position.
45984203|NCT00438477|Procedure|Lymphangiography|2 lymphoscintigraphy images performed following peritumoral and subareolar injection of breast
45984204|NCT00438477|Radiation|Technetium Tc 99m sulfur colloid|"At least 2 days before scheduled surgery, receive technetium Tc 99m sulfur colloid by peritumoral injection; and again the day before surgery by subareolar injection.~At the time of surgery, patients receive isosulfan blue by subareolar injection."
45984205|NCT00440258|Drug|Cabergoline|
45984206|NCT00440258|Procedure|MR|
45984207|NCT00440258|Procedure|Ultrasound|
45984208|NCT00440258|Procedure|Blood Analysis|
45984209|NCT00438516|Behavioral|nurse home visitation|Nurse home visits from midway through pregnancy to child age 2
45984210|NCT00440336|Drug|Cosopt|
45984211|NCT00440336|Drug|Xalatan|
45984212|NCT03276780|Behavioral|Counseling|Both groups receive smoking cessation counseling although one is focused on medication adherence and addressing barriers to adherence while the other is focused on standard behavioral strategies to quit smoking
45984213|NCT03276780|Drug|combination NRT|Both groups will receive combination NRT to help with smoking cessation
45984214|NCT00440375|Drug|Rosiglitazone|
45984215|NCT04700930|Other|CBD-Cigarettes|CBD-Cigarettes instead of normal Cigarettes: The participants in this arm receive CBD-Cigarettes which are then inhaled/smoked instead of their normal tobacco cigarettes
45984216|NCT00438555|Behavioral|Parents and children group|3 months workshops of parents and children intervention, guided by dietician and phycologist
45984217|NCT00438555|Behavioral|Parent's group|3 months workshop of parents intervention, guided by dietician and phycologist
45456666|NCT00611598|Other|Blood draw and Questionnaires|Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
45456667|NCT00496873|Drug|Cytoxan|600 mg/m^2 on Day 1 of 21-day cycle.
45456668|NCT00496873|Drug|Nipent|4 mg/m^2 on Day 1 of 21 Day Cycle.
45456669|NCT00496873|Drug|Rituxan|375 mg/m^2 on Day 1 of 21 Day Cycle.
45456670|NCT00492778|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiation therapy
45456671|NCT00492778|Drug|Cisplatin|Given IV
45984218|NCT00440414|Drug|Erlotinib (Tarceva)|Erlotinib at the dose of 150 mg orally once a day continually until progression
45984219|NCT00440414|Drug|Pemetrexed (Alimta)|Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks for 6 consecutive cycles
45984220|NCT00476736|Drug|Effect on small airways (N-Acetylcystein)|
45984221|NCT00440453|Other|Nutritional therapy|Nutritional therapy by dietician
45984222|NCT00438594|Behavioral|home visitation|Home visits from mid-pregnancy until child age 2. Group 2 is visits by a paraprofessional; group 3 is visits by nurses.
45984223|NCT00440492|Drug|PLA-695|
45984224|NCT00476775|Behavioral|after school ethnic dance program - ballet folklorica|
45984225|NCT00476775|Behavioral|culturally-tailored, home-based screen time reduction|
45984226|NCT00476775|Behavioral|culturally-tailored health and nutrition education|
45984227|NCT00440570|Device|Low levels of amplitude-modulated electromagnetic fields|
45984228|NCT00440570|Device|Emitter of low levels of amplitude-modulated electromagnetic fields|
45984229|NCT03270462|Drug|Envarsus XR|Pilot study documenting the neurotoxic side effects including tremors in patients with stable graft who are receiving Tacrolimus (Envarsus XR) following kidney transplantation. Standardized questionnaire will be used to document these symptoms.
45984230|NCT00440609|Drug|ranibizumab|0.5mg or 1.0mg intravitreal injection given monthly for 3 months then every other month if needed, for the first year.Patients may be treated monthly as needed. Patients in Cohort 1(the first 30 patients)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 24. Patients in Cohort 2(the remaining 20)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 12.Patients may receive 2.0mg ranibizumab for a period limited to 24 months following administration of the first 2.0mg dose. Patients completing 36 months will be eligible to be followed for an additional 24 months. Starting at Month 36, patients will be able to receive monthly, the assigned dose that they received/or could have received(if re-treatment criteria was met)at Month 35. 2/1/12 - the 2.0mg dose has been discontinued, all subjects will transition to the 0.5mg dose.
45984231|NCT00440648|Drug|sevelamer carbonate, sevelamer hydrochloride|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
45456672|NCT00492778|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45456673|NCT00492778|Radiation|Internal Radiation Therapy|Given intracavitarily or interstitially
45456674|NCT00430313|Procedure|Electro-Stimulation of Yongquan (K1) Acupoint|Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
45984232|NCT00440648|Drug|sevelamer hydrochloride, sevelamer carbonate|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
46083211|NCT00754065|Drug|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated BAY86-5027 for 28 days per Cycle, for 13 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo
45984233|NCT00440687|Drug|Fluticasone 500mcg BD via accuhaler or identical placebo|
46083212|NCT00754065|Drug|Ortho Tri Cyclen Lo|Dose--Ethinylestradiol (EE) + Norgestimate (NGM) Triphasic 21-day regimen. Daily oral administration of one encapsulated Ortho Tri-Cyclen Lo for 28 days per Cycle, for 13 treatment cycles: Days 1-7, 0.025 mg EE+0.180 NGM; Days 8-14, 0.025 mg EE+0.215 NGM; Days 15-21, 0.025 mg EE+0.250 NGM; Days 27-28, placebo
46083213|NCT02787902|Behavioral|Communication|Behavioral weight management program adapted for mother-daughter dyads with communication skills training
45984234|NCT03271047|Drug|binimetinib|Orally, twice daily.
45984235|NCT03271047|Drug|nivolumab|Intravenously (IV) every 4 weeks (Q4W)
45984236|NCT03271047|Drug|ipilimumab|intravenously (IV) every 8 weeks (Q8W)
45984237|NCT00440765|Drug|bortezomib|dose as determined (observational study) by treating physician
45984238|NCT00440804|Drug|ibuprofen l-lysine iv solution (NeoProfen (R) )|
45984239|NCT03276936|Drug|FMX103 1.5%|FMX103 1.5% minocycline foam
45984240|NCT00440843|Drug|Olanzapine (Zyprexa)|OLZ
45984241|NCT00440843|Drug|Typicals|Stay on typicals regimen
45984242|NCT00438789|Drug|eculizumab|600mg IV every week and 900mg IV every 2 weeks
46083214|NCT02787902|Behavioral|Standard|Behavioral weight management program adapted for mother-daughter dyads without communication skills training
46083215|NCT02796248|Other|cross-sectional survey|This is an observation study. Participants will complete a survey at one occasion. Participants are also invited to do a A1c mail-in capillary test.
46083216|NCT02795936|Procedure|Cardiac rehabilitation|Perform exercise prescription for 12 weeks
46083217|NCT02785640|Behavioral|Hourly prompts to stand delivered by Microsoft Outlook|Prompt group
46083218|NCT02787746|Drug|Donepezil|Eligible patients is treated with Aricept® 10 mg/day for 20 weeks of study period. Aricept® should be taken at night, just prior to sleeping. If patient cannot endure 10mg/d，the patient can reduce to 5mg/d for 4 weeks and then increase back to 10mg/d. Patients who cannot endure the 10mg/d titration of 2nd time and then back to 5mg/d or discontinuance of Aricept® should be regarded as to quit the study. There will be a visting at week 0, the end of week 4 and the end of week 20 ,respectively.
45456675|NCT00430313|Procedure|Electro-Stimulation of Yongquan (K1) Acupoint|"Electro-stimulation at a inactive site on the bottom of the foot (a placebo site)."
45673099|NCT04783727|Diagnostic Test|Individualised treatment duration based on RNA transcriptomic model|Anti-MDR-TB treatment with standard drugs and individual treatment duration guided by the RNA transcriptomic model; may be shorter or longer than standard WHO-recommended treatment duration of 20 months.
45984243|NCT00440921|Drug|Single donor Allogenous Fibrin Sealant|
45676679|NCT02021318|Drug|Darbepoetin alfa|Subcutaneous or intravenous injection.
45984244|NCT00440960|Drug|propofol|
45984245|NCT00440960|Drug|midazolam|
45984246|NCT00440960|Drug|alfentanil|
45984247|NCT00440960|Drug|lidocaine|
45984248|NCT00438828|Drug|dexamethasone|8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
45984249|NCT00441038|Behavioral|The Back Guide|Education on postural hygiene and handout of The Back Guide
45984250|NCT00441038|Behavioral|The Back Book|Education on active management and Handout of The Back Book
45984251|NCT00441038|Behavioral|Cardiovascular and general health|Education on cardiovascular and general health
45984252|NCT00438867|Genetic|Ad5FGF-4|Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer
45984253|NCT00438867|Genetic|Placebo|Control group
45984254|NCT00441077|Behavioral|Education|
45984255|NCT00441155|Drug|Nilotinib, Imatinib|Nilotinib 50 mg and 200 mg gelatin capsules and Imatinib 100 mg and 400 mg film-coated tablets in bottles.. Medication labels for each study drug complied with the legal requirements of each country, were printed in the local language.
45984256|NCT00106002|Drug|pemetrexed|600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression
45984257|NCT00441194|Device|Visual Field (Octopus 311 and the HFA 700 series)|
45984258|NCT00476853|Drug|HAART containing nevirapine|Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.
45984259|NCT00441233|Device|Silicone hydrogel contact lens|
45984260|NCT00438906|Procedure|Biopsy, Fine Needle Aspiration (FNA)|If a pancreatic lesion of concern is identified, a small needle is inserted in the lesion in the pancreas and cells of the lesion are aspirated. Diagnosis of the lesion can typically occur with FNA.
45984261|NCT00438906|Drug|Secretin (human synthetic) - ChiRhoClin|Secretin is a synthetic human hormone that encourages the pancreas to create fluid. This will allow pancreatic juice to be collected via gentle suction in the duodenum where the pancreatic juice naturally flows.
45984262|NCT00441311|Behavioral|Academic Detailing|The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
45984263|NCT00438945|Drug|Eprosartan|
45984264|NCT00476892|Procedure|Pelvic Floor Muscle Training|Women in the intervention group attend 5 physiotherapy sessions. At each appointment a clinical history is taken, pelvic floor muscle assessment carried out, exercises taught and prescribed, and appropriate lifestyle advice given. At the first of these appointments a detailed explanation of the pelvic anatomy and different types of prolapse is given.
45984265|NCT00441428|Drug|solifenacin|
45984266|NCT00438984|Drug|cyclophosphamide|Given IV
46083219|NCT04200170|Device|Rose|Rose is a patient-centric, mobile mental health platform designed for in-between clinical mental health monitoring in form of mood tracking, clinical surveys and daily journaling. Rose is used as a participant-facing mobile app and clinician-facing dashboard. Each day, they complete mood and anxiety scales and update their journals. Biweekly, they are also asked to complete the PHQ-9 and GAD-7 assessments as well. The Rose mobile app sends timely self-help articles and notifications for users. The curated insights are selected based on participant responses to the daily mood and anxiety surveys, as well as a built-in sentiment analysis of the journaling. The clinical dashboard is a secure, web-based portal that has a unique login for each provider. Providers have access to only their patients through the system and are able to see all the health metrics collected with the Rose mobile app and the summarized metrics produced by our models.
45984267|NCT00438984|Biological|therapeutic autologous lymphocytes|Given IV
45984268|NCT00438984|Biological|aldesleukin|Given IV or SC
45984269|NCT00438984|Other|immunohistochemistry staining method|Correlative studies
46083220|NCT03266900|Procedure|re-TURBT|2nd bladder biopsy within 4-6 weeks of initial biopsy
45456676|NCT01226875|Procedure|SWL: Shock Wave Lithotripsy Intervention|Shock wave lithotripsy (SWL) is the most common treatment modality for kidney stones. It is a safe and non-invasive treatment performed on patients under intravenous sedation (light anesthesia) on an out-patient basis, whereby shock waves are generated by a source external to the patient's body and are then propagated into the body and focused on a kidney stone. The unique quality of SWL is in its exploitation of shock wave focusing. The Storz lithotripter is an electromagnetic lithotripter with a unique design that allows for a dual focus system with the option of either a narrow (6x28 mm) or wide (9x50 mm) focal zone, depending on the clinical situation. This is the first lithotripter on the market to allow for two different focal zones for shock wave targeting.
45984270|NCT00438984|Procedure|biopsy|Optional correlative studies
45984271|NCT00438984|Other|laboratory biomarker analysis|Correlative studies
45984272|NCT00438984|Other|immunologic technique|Correlative studies
45984273|NCT00438984|Genetic|polymerase chain reaction|Correlative studies
46083221|NCT03266900|Drug|6 weeks BCG instillation|standard 6 weeks of BCG induction
46083222|NCT04095507|Diagnostic Test|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
46083223|NCT03254654|Drug|Vinorelbine|Experimental: 20 mg/m2, D6, D13, D20 Active Comparator: 25 mg/m2, D1, D8, D15
45984274|NCT00441506|Drug|daily interruption of sedatives|
45984275|NCT04700852|Device|Puressentiel protective nasal spray|provocative nasal test with grass pollen and nasal lavage
45984276|NCT00439023|Procedure|dialysis with glucose in dialysis water|
45984277|NCT00441623|Behavioral|observational|effect of protein-bound uremic retention solutes
45984278|NCT00476970|Behavioral|Patient Navigation|Patient navigators will perform an initial interview with participants to identify and explore barriers, work with patients to overcome barriers, educate patients about CRC screening, motivate and coach patients, and schedule and accompany patients to colonoscopy testing
45984279|NCT00441662|Drug|Sub-Tenon triamcinolone 40mg|
45984280|NCT00439062|Drug|Roxithromycin|
45984281|NCT00477009|Device|Mandibular repositioning appliance, adjustable|Comparison between mandibular repositioning appliance for nightly use and a placebo device regarding effects on sleep apneas and daytime symptoms as well as blood pressure and markers of oxidative stress and sleepiness.
45984282|NCT02957162|Drug|Atorvastatin|
45984283|NCT02957162|Other|Blood samples|3-5 mls of blood is taken at baseline and 3 subsequent timepoints and processed for Endothelial Progenitor Count (EPC).
45984284|NCT00439101|Drug|Megstrol Acetate|Megestrol acetatet 7.5 mg/kg/day orally (lemon-lime suspension) for 90 days.
45984285|NCT00439101|Other|Placebo|Placebo (lemon-lime suspension) taken orally for 90 days.
45984286|NCT00441740|Drug|Vinorelbine|Vinorelbine (oral) 70 mg/m2, on days 1 and 15 every 4 weeks for 6 cycles
45984287|NCT00441740|Drug|Gemcitabine|Gemcitabine 900 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
45984288|NCT00441740|Drug|Docetaxel|Docetaxel 75 mg/m2 intravenous on day 8 every 3 weeks for 6 cycles
45984289|NCT00441740|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 intravenous, on days 1 and 8 every 3 weeks for 6 cycles
45984290|NCT02274012|Drug|Afatinib|Afatinib 40mg/PO daily will be administered in combination to standard of care paclitaxel.
45984291|NCT02274012|Drug|Paclitaxel|On the day of the first dose of afatinib, paclitaxel will be administered at a dose of 80 mg/m2 intravenously over 60 minutes on days 1, 8 and 15 of a 28-day cycle.
45984292|NCT00477048|Drug|Saquinavir|SQV/r 1000/100 BID + NNRTI or SQV/r 1600/100 OD + 2 NRTI
45984293|NCT00441818|Drug|TNX-650|
45984294|NCT00477126|Drug|GPO ritonavir versus Norvir|RTV generic compared to reference drugs (Norvir, Abbott)
45984295|NCT03279419|Diagnostic Test|Thermal imaging|Use of thermal imaging camera to capture images of peripheral vasculature (hands).
45984296|NCT03279380|Other|SNP|Screening 150 endurance, 150 power athletes, and 200 healthy control individuals for genetic variant associated to sport performance.
46002568|NCT04646733|Other|No High Protein Diet Group|No high protein diet (NHPD) group received an oat beverage consisted of 55 g of oats in 250 ml of water. Beverage contained 1.6 g of betaG per portion according to FDA recommendations corresponding to 50 % of betaG required per day. Weekly bags containing oat mixture were provided on day 0 and in the third week of the trial. No additional instructions about diet, exercise program or pharmacological treatment was implemented.
46002569|NCT00545246|Drug|aflibercept (AVE0005)|intravenous infusion
46002570|NCT00545246|Drug|docetaxel|intravenous infusion
46002571|NCT04638114|Procedure|Mini-open DAA|Direct anterior approach hip
45984297|NCT03279380|Other|High Intensity Interval Training (HIIT)|The subgroup (n = 40) of the athletes will participate in the acute exercises (HIIT Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory at least three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
45984298|NCT03279380|Other|Low Intensity Continuous Training|The subgroup (n = 40) of the athletes will participate in the acute exercises (LIT Continuous Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
45984299|NCT03277521|Other|Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is a non-invasive brain stimulation technique that can increase corticomotor excitability.
45984300|NCT03279341|Drug|polyethylene glycol|osmotic laxative
45984301|NCT03279341|Drug|Bisacodyl|stimulant laxative
45984302|NCT03279341|Drug|Prucalopride|prokinetic
45984303|NCT00441857|Behavioral|plant stanol consumption|
45984304|NCT00439452|Other|Telemedicine-Based Collaborative Care|Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
45984305|NCT00439452|Other|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
45984306|NCT03279302|Drug|Glepaglutide|Solution for injection
45984307|NCT03279263|Drug|MLR-1023|MLR-1023 Tablets
45984308|NCT03279263|Other|Placebo|Matching Placebo Tablets
45984309|NCT03276741|Dietary Supplement|gastric soft/bland diet|Patients in the experimental group will have a gastric soft/bland diet available.
45984310|NCT03279146|Drug|Tenofovir exalidex (TXL)|Oral formulations
45984311|NCT00439491|Behavioral|Hypocaloric diet|
46083224|NCT03254654|Drug|Apatinib|250 mg/d, D1-5, D8-12, D15-19. The starting dose will be 250mg/d in the first cycle, if tolerable, 500 mg/d will be administered from the cycle 2.
46083225|NCT02785718|Other|Global Haemostasis assays|
46083226|NCT04094805|Drug|Rocaltrol|Rocaltrol 0.25 μg daily for 1 month; HD-DXM (orally at 40 mg daily for 4d )
46083227|NCT04094805|Drug|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d )
45984312|NCT00441935|Device|Interstim Neuromodulation|Two stage procedure to implant an interstim device for neuromodulation.
45984313|NCT03275571|Behavioral|cCBT intervention|During each 30 minutes sessions, the participants will learn key concepts on depression, then will apply them to the program's main character who suffers from depression, and then will apply those techniques to their own personal challenges.
45984314|NCT00442052|Drug|aspirin|
45984315|NCT00442052|Drug|omeprazole|
45984316|NCT00477243|Behavioral|Questionnaire|8 questionnaires will take about 40 minutes to complete.
45984317|NCT00442091|Drug|dandelion juice|10 ml bid for 20-30 days
45984318|NCT00477282|Drug|Karenitecin|Karenitecin 1.0mg/m2/day administered as a single daily IV infusion over 60 minutes for 5 consecutive days every 3 weeks (21 days)
46083228|NCT02786966|Other|Canadian C-Spine Rule|Paramedic assessment for potential cervical spine injuries using the Canadian C-Spine Rule
45984319|NCT00477282|Drug|Topotecan|Topotecan 1.5 mg/m2/day administered as a single daily IV infusion over 30 minutes for 5 consecutive days every 3 weeks (21 days)
45984320|NCT00442130|Biological|GM-K562 vaccine|The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.
45984321|NCT00442130|Procedure|stem cell transplantation|Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation
45984322|NCT00477321|Drug|CYT 107|3 dose levels: 3, 10 and 20µg/kg/week.3administrations
45984323|NCT03279107|Other|Soluble corn fiber|soluble corn fiber
45984324|NCT03279107|Other|maltodextrin|maltodextrin
45984325|NCT00439530|Drug|oseltamivir|
45984326|NCT00439530|Drug|probenecid|
45984327|NCT00442208|Drug|PN 200|
45984328|NCT00442247|Device|Pelvicol|
45984329|NCT00439686|Drug|ZIO-201|ZIO-201 given for 3 consecutive days to be repeated every 21 days for up to 6 months
45984330|NCT03279029|Biological|blood samples|blood samples
45984331|NCT03279029|Biological|biopsy|biopsy of aortic valve
45984332|NCT00477360|Device|Humeral surface replacement hemiarthroplasty (CAP)|C.A.P hemiarthroplasty
46002572|NCT04638114|Procedure|Hip arthroscopy|arthroscopic treatment of hip pathology
46002573|NCT00545285|Procedure|Total Hip Arthroplasty|Surgical implantation of specific hip replacement components for treatment of osteoarthritis
45984333|NCT03278990|Behavioral|Value Affirmation and Future Selves Combination|Following the questionnaire, participants will complete a 10- to 15-minute writing exercise. In the control condition, they will be given a list of values, select two that are least important to them, then write about why those values might be important to others. Next, they will write a short letter to themselves in 2 weeks. In the treatment condition, they will be given a list of values, select two that are important to them, then write for about why those values are important to them and how they have played a role in their life. They will then write a short letter to themselves twenty years in the future.
45984334|NCT03278990|Behavioral|Control writing exercise|In this sham comparator, participants will also write, however, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
45984335|NCT03279744|Drug|Radion™-pdt|The Radion™-pdt will be applied topically to the lesion. The Radion™-pdt applied dosage is about 0.1 mL/cm^2 and properly cover the entire lesion.
45673100|NCT04963283|Drug|Cabozantinib|Cabozantinib is a multi-targeted inhibitor of RTKs. The targets of cabozantinib include several RTKs known to play important roles in tumor cell proliferation and/or tumor neovascularization, namely MET, VEGFR2 (also known as KDR), AXL, and RET. Other recognized targets of cabozantinib include ROS1, TRKA, TRKB, TIE2, TYRO3, and MER, two additional members of the VEGFR family (VEGFR1, VEGFR3), and the closely related RTKs KIT and FLT-3. The mode of action for cabozantinib is similar to other drugs targeting RTKs: binding in a fully reversible manner to a region of the kinase domain (including the ATP-binding site) which forces the kinase activation loop into a pseudo-inactive conformation, thereby inhibiting subsequent catalytic activity.
45984336|NCT03278951|Behavioral|Video Conferencing Group|
45984337|NCT03278951|Behavioral|In Person Group|
45984338|NCT03279705|Device|Water jet channel|The separate water jet channel was used for infusing water.
45984339|NCT03279705|Device|Accessory channel|The accessory channel was used for infusing and/or suctioning water
45456677|NCT03052634|Drug|RC48-ADC 1.5 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 1.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
45673101|NCT04963283|Drug|Nivolumab|Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab binds specifically to the human PD-1 receptor and inhibits the interaction of PD-1 with its ligands, programmed death ligands-1 (PD-L1) and 2 (PD-L2), which promotes immune responses and antigen-specific T-cell responses to foreign- and self- antigens. Nivolumab is expressed in Chinese hamster ovary (CHO) cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies.
45984340|NCT03278834|Device|Neuromuscular muscle stimulation machine- Strength Setting|Muscle stimulation to strength skeletal muscle
45984341|NCT03278834|Device|Neuromuscular muscle stimulation machine - TENS Setting|Muscle stimulation to mimic the intervention but without the strength gains.
45984342|NCT00477399|Behavioral|The Evje Model|
46083229|NCT04094727|Drug|Presumptive treatment with Artemether-lumefantrine (AL)|All eligible HRPs will be presumptively treated with artemether-lumefantrine (AL) at two timepoints, separated by at least one month. All individuals who have provided informed consent, meet eligibility criteria, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages). AL is currently the first line drug used for uncomplicated malaria in Namibia, and has been used previously in northern Namibia for focal mass drug administration and has no severe adverse effects and is well-tolerated, with high adherence and acceptability in this context. AL requires two daily doses for three consecutive days, for a total of six doses. The first antimalarial dose will be delivered by directly observed therapy (DOT) and subsequent doses will be left with the subject, with instructions to self-administer them.
45673102|NCT04858451|Drug|RESP301|"A single RESP301 dose administered at a study site to assess tolerability.~In patients who experience a flare-up during the study period, self-administered RESP301 treatment for 7 days, 3 times a day."
45673103|NCT05168267|Behavioral|Cognitive Processing Therapy|CPT: a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
45456678|NCT03052634|Drug|RC48-ADC 2.0 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.0mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
45673104|NCT04443569|Drug|Lidocaine patch|Lidocaine patch to be placed in post-operative recovery area and used in addition to routine post-cesarean delivery pain management
45984343|NCT04700813|Diagnostic Test|search for rare pathogenic mutations|search for rare pathogenic mutations causing diabetes type 2
45984344|NCT00477477|Other|Diet|Low glycemic load diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
45984345|NCT00477477|Other|Diet|Low saturated fat diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
45984346|NCT00442325|Drug|Atorvastatin (Lipitor)|
45984347|NCT00439764|Behavioral|General health talk|Routine clinical practice and talk on general health
45984348|NCT00439764|Behavioral|Handout of The Back Book|Talk on health of the back and handout of The Back Book
45984349|NCT00439764|Behavioral|Back exercise|Routine clinical practice, talk on back health, handout of The Back Book and back exercise
45984350|NCT03278756|Behavioral|Cognitive control training|10 sessions of an adaptive paced auditory serial addition task, each lasting 15 minutes, over the course of two weeks.
45984351|NCT03278756|Behavioral|Active control training|10 sessions of an low cognitive load task, each lasting 15 minutes, over the course of two weeks.
46002574|NCT04637997|Device|compression stockings class I|Daily wearing of compression stockings class I for four weeks on the affected extremity.
46002575|NCT04637997|Device|compression stockings class II|Daily wearing of compression stockings class II for four weeks on the affected extremity.
45984352|NCT00477516|Procedure|exposure to a high-calcium dialysate bath|Subjects are exposed to a high calcium (3.5 mEq/L) dialysate bath for 150 minutes (part 1). At defined timepoints (0, 45, 90, and 150 min) blood is sampled for calcium, PTH, phosphorous, and FGF-23. At another (later) dialysis session (part 2), the process is repeated except that the subjects are exposed to a normal calcium bath (2.5 mEq/L). For each subject, results from part 1 are compared to the results from part 2.
45984353|NCT00477555|Device|Aortic implantation of Mosaic Ultra porcine bioprosthesis|All patients get implanted with a Mosaic Ultra tissue valve to evaluate hemodynamic performance at 6 months post implant.
45984354|NCT03278639|Behavioral|Rhythmic Auditory Stimulation|Training will be directed to ameliorate gait and balance
45984355|NCT03278639|Behavioral|Kinesiology|Training will be directed to ameliorate gait and balance
45984356|NCT00477711|Drug|cetuximab, cisplatin, capecitabine|Product 1: Cetuximab(Erbitux®) Dosing schedule: 400mg/m2 initial dose and then 250mg/m2 ,weekly dose Mode of administration: intravenously Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously
45984357|NCT03278561|Procedure|Sputum induction|Sputum induction according to the ERS protocol
45984358|NCT03278561|Procedure|Blood sample|A blood sample of 100ml will be taken.
45984359|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the IM route
45984360|NCT00439803|Biological|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the IM route
45984361|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route
45984362|NCT00439803|Biological|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the SC route
45984363|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route
45984364|NCT00439803|Biological|AVX601|3 doses of placebo given at T=0, 8, 24 weeks via the IM route
45984365|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route
45984366|NCT00439803|Biological|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the SC route
45984367|NCT00442403|Drug|chloroquine|
46083230|NCT04094727|Other|Enhanced vector control|"The mop up indoor residual spraying (IRS) campaign will be targeted to farms and cattle posts/kraals in intervention areas in December 2019 to fill gaps from the routine spray campaign (September to November 2019) and utilize the same insecticides and protocols as the national campaign. The team will spray each unsprayed structure with the recommended solution of dichloro-diphenyl-trichloroethane (DDT) for traditional structures and/or Actellic for modern structures, tarps and tents.~Alternative vector control interventions, including LLINs (long-lasting insecticide treated bed nets), sprayed tents/tarps and topical repellents will be distributed to eligible HRPs between November and January 2020 during one round."
45984368|NCT00442403|Drug|dehydroepiandrosterone sulphate|
45984369|NCT00477789|Drug|allopurinol|
45984370|NCT00442442|Device|mosquito coils|mosquito coil / night mosquito coil & LLIN / night
45984371|NCT00442442|Device|LLIN|Sleep under LLIN every night
45984372|NCT00439842|Behavioral|Heart Failure Group Clinic Appointments|Self Management and Care of Heart Failure with Group Clinics (SMAC-HF)
45984373|NCT00442481|Drug|Escitalopram|
45984374|NCT00442481|Procedure|A baseline overnight polysomnography (oPSG)|
45984375|NCT00439881|Drug|SB-681323|
45984376|NCT03279666|Other|Tenaculum replacement|Tenaculum replacement during colposcopic biopsy
45984377|NCT00442637|Drug|capecitabine + bevacizumab|Ca 1250 mg/m2 daily orally continuously, B 7.5 mg/kg i.v. q 3 w
45984378|NCT00442637|Other|observation|observation after induction treatment
45984379|NCT00477828|Device|Continuous positive airway pressure|
45984380|NCT00442676|Drug|Celecoxib|Capsule, 200 mg/day until 32 weeks of gestation
45984381|NCT00442676|Drug|Placebo|Gelatin capsules of lactose
45984382|NCT00477867|Procedure|quality-of-life assessment|
45984383|NCT00442715|Procedure|Exercise chalenge test|
45984384|NCT00477906|Biological|M-Vax- autologous, hapten-modified melanoma vaccine|Autologous, DNP-modified melanoma cells in suspension Dose: 12+-8 million cells Route: intradermal Frequency: weekly X7 + 6 month booster
45984385|NCT00442754|Biological|Allogeneic Tumour Lysate (MelCancerVac)|subcutaneaus, /once weekly /4 wks then /4 weekly
45984386|NCT00477945|Drug|clofarabine|"Cohort N Clofarabine (mg/m2/day)~3-6 30~3-6 40~3-6 50~3-6 60~6-10 70"
45984387|NCT00442793|Drug|Epoetin beta|As prescribed, 3 times weekly
45984388|NCT00442793|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|0.4 micrograms/kg iv every 2 weeks
45984389|NCT00439920|Drug|High-dose anthracycline|
45984390|NCT00442832|Drug|TD-1792|TD-1792 2 mg/kg/day IV
45984391|NCT00442832|Drug|Vancomycin|Vancomycin 1 Gm IV q 12 hrs
45984392|NCT00477984|Drug|alcohol|alcohol(0.02%, 0.05%, 0.08% and 0.10%) and placebo
45984393|NCT00442871|Drug|eltrombopag|eltrombopag 50 mg oral
45984394|NCT00439959|Drug|GSK625433/placebo|
45984395|NCT00442910|Drug|3% SPL7013 Gel (VivaGel)|3% vaginal gel
45984396|NCT00442910|Drug|Placebo Gel|Placebo for SPL7013 gel
45984397|NCT00442910|Drug|HEC Placebo Gel|HEC Placebo gel intravaginally bd for 14 days
45984398|NCT00478101|Drug|oxycodone fentanyl|
45984399|NCT00442949|Procedure|Catheterization immediate PCI|Catheterization immediate PCI
45984400|NCT00442949|Procedure|delayed PCI|delayed PCI
45984401|NCT00439998|Procedure|Ultrasound|ultrasound scan of the lumbar spine with 2-5 MHz curved array probe
45984402|NCT00443027|Device|Vaginal Heat Wash-Out Device|No drug administered. Device tested three times with each subject.
45984403|NCT00440076|Drug|Velcade|
45984404|NCT00443105|Drug|Tacrolimus 0.03% ointment (Protopic)|
45984405|NCT00443144|Drug|recombinant human growth hormone|
45984406|NCT00440154|Drug|AVE5530|
45984407|NCT00440154|Drug|placebo|
45984408|NCT00440154|Drug|ezetimibe|
45984409|NCT00478374|Drug|Sorafenib|Sorafenib 400mg bid
45984410|NCT00478374|Procedure|Transarterial chemoembolisation with doxorubicin|Transarterial chemoembolisation (TACE)
45984411|NCT00478452|Biological|DC-Ova|
45984412|NCT00478452|Biological|DC Ova with Cyclophosphamide|
45984413|NCT03279549|Procedure|Routine dressing change|Through regular dressing changes to clean the wound, reduce bacterial growth in the wound and protect the wound. In recent years, nano-silver ion gel and dressings are widely used in burns, which effectively reduced the risk of wound infection and beneficial for wound healing. This technique is widely used in clinic.
45984414|NCT03279549|Procedure|Limited debridement & Acellular dermal matrix dressing|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. The xenogeneic acellular dermal matrix dressing has a better protective effect on burn wound after debridement. After covering, the wound will remain alive for about two weeks, providing a good microenvironment for wound repair."
45984415|NCT03279549|Procedure|Limited debridement & Epidermal cell spraying|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. Epidermal cell spraying technology is a brand new method to rapidly collect epidermal cells from patients themselves and then used on their wounds. The recipient site is 40-80 times than the donor site."
45984416|NCT03279549|Procedure|Limited debridement & Basic fibroblast growth factor|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. BFGF is a kind of polypeptide capable of promoting the growth of fibroblasts, and it also promotes the proliferation, differentiation and migration of epidermal cells. Studies have shown that bFGF could significantly improve the healing of burn wounds."
45984417|NCT02957058|Procedure|SCAR technique|Thermal ablation of the EMR margin using ERBE Soft Coagulation (Effect 4, 80 watts) and the operator choice of endoscopic resection snare
45984418|NCT00478530|Procedure|ELECTRORETINOGRAM|Bevacizumab 1.25 mg/0.05 ml unilaterally into the vitreous cavity as part of the standard management for choroidal neovascular AMD. ERG responses form both eyes will be measured at baseline and 1 month after intravitreal injection
45984419|NCT00443183|Behavioral|Brief Negotiation Interview (BNI)|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
45984420|NCT00443183|Behavioral|Discharge Instructions|Used as a placebo comparator, scripted discharge instructions are to be read by emergency practitioner and designed to be less than 1 minute in length.
45984421|NCT03275142|Device|Icare tonometer|Icare tonometry effects of keratometry readings, topography, and corneal staining to demonstrate that the Icare tonometer does not alter subsequent evaluation or testing. This would allow IOP testing to be performed by technical staff at any time during the examination process without affecting subsequent tests. A total of fifteen patients at each of four sites will be evaluated using Icare tonometers provided by Icare USA. The investigator will be masked as to which eye will undergo Icare tonometry. Both the study eye and the control eye will undergo pre-tonometry and post-tonometry testing; Keratometry readings, IOL master, Topography via Pentacam, and corneal staining with fluorescein using the Oxford scoring scale.
45984422|NCT03271983|Drug|Metronidazole gel 1|RLD gel
45984423|NCT03271983|Drug|Metronidazole gel 2|generic gel
45984424|NCT03271983|Drug|Metronidazole cream|generic cream
45984425|NCT04700982|Other|Based on the length of hospital stay|Based on the length of hospital stay, patients were divided into two groups: hospital stays ≤ 3 months (Group 1) and > 3 months (Group 2).Clinical features and functional output will be then compared between the groups.
45984426|NCT00443222|Drug|Infliximab|
45984427|NCT00440349|Drug|Tamoxifen|
45984428|NCT00440349|Drug|Prednisone|
45984429|NCT03270930|Procedure|Emergency laparotomy|All patients in study underwent emergency laparotomy within 24 hours of presentation after adequate resuscitation of minimum 1 hour.
45984430|NCT00443339|Drug|Darbepoetin|
45984431|NCT03272763|Device|F&P Toffee mask|Trial Full-Face mask which comes with three seal sizes and two headgear sizes.
45984432|NCT04700228|Drug|Bupivacaine Hydrochloride|We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
45984433|NCT04700228|Drug|Dexmedetomidine|We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
45984434|NCT00440427|Drug|Desvenlafaxine Sustained Release (DVS SR)|
45984435|NCT00443378|Behavioral|CARE+|CARE+ is a .NET based application on tablet computers that comprises risk assessment, medication monitoring, tailored feedback, stage-based skills-building videos, motivational interviewing counseling, an integrated health promotion plan, and printout with referrals. Evidence-based approaches (pharmacist education, self-efficacy/importance scaling exercises, and consequence-framing) are incorporated.
45984436|NCT00478686|Procedure|Phlebotomy|5 to 7.5 milliliter (mL) Blood Sample
45984437|NCT03278522|Drug|Ramosetron|Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery
45984438|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG naive subjects
45984439|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
45984440|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen in BCG immunized subjects
45984441|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
45984442|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG immunized subjects
45984443|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
45984444|NCT04700306|Behavioral|Sophrology|Patient must make 8 visits with interviews and questionnaires, including 7 visits with a session of sophrology.
45984445|NCT00440583|Drug|chemotherapy followed by Zevalin|6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
45984446|NCT04700384|Behavioral|Virtual Operative Assistant Training|Individuals receive the same basic information, have the same amount of time and perform the same scenarios as the control group. In the 5-minutes between attempts, participant receive the Virtual Operative Assistant assessment of their performance and audiovisual feedback.
45984447|NCT04700384|Behavioral|Remote-Based Expert Instructor Training|Individuals receive the same information, have the same amount of time and perform the same scenarios as the control group. Meanwhile, a trained instructor observes the participant's on-screen performance, that is live-streamed, remotely. Instructors are senior neurosurgery residents with extensive experience in performing and assessing this scenario. During the 5-minute feedback session, they chat with the student, discussing the performance and help in setting goals for the next trial.
45984448|NCT00440622|Drug|Gemcitabine|Gemcitabine at the dose of 1250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
45984449|NCT00440622|Drug|Herceptin|Herceptin 8 mg/Kg (90 min IV) on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles over a 30 min IV
45984450|NCT00440622|Drug|Capecitabine (Xeloda)|Capecitabine at the dose of 1250 mg/m2 b.i.d p.o on day 1-14 every 3 weeks 6 cycles
45984451|NCT00443417|Drug|SK-PC-B70M|dosage, frequency
45984452|NCT00440661|Drug|Diacerhein|
45984453|NCT03278444|Other|Basic drugs therapy of HCC|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
45984454|NCT03278444|Drug|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
45984455|NCT03278444|Drug|Trimetazidine hydrochloride|Trimetazidine hydrochloride tablets 20mg/tablet, 40mg, twice a day.
45984456|NCT00440739|Drug|etoricoxib|etoricoxib 120 mg
45984457|NCT00440739|Drug|flavoxate|flavoxate 200 mg 3 times
45984458|NCT00440739|Drug|etoricoxib, flavoxate|etoricoxib 120 mg once and flavoxate 200 mg 3 times
45984459|NCT00440739|Drug|placebo|placebo once and placebo 3 times
45673105|NCT04443335|Behavioral|continous feeding|At the beginning, all the patients received continuous feeding. After achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d) through continuous feeding, the patients were randomly assigned into the sequential feeding (SF) group or the continuous feeding (CF) group with a random number table. Patients in the CF group received continuous feeding with constant velocity by enteral feeding pump over one day.
45984460|NCT00443495|Drug|Chitin microparticles by nasal route|
45984461|NCT00478725|Drug|GW786034, oral|oral, 800 mg
45984462|NCT00478725|Drug|GW786034, IV|IV, 5 mg
45984463|NCT00478725|Drug|GW786034, radiolabeled oral|oral, 400 mg radiolabeled
45984464|NCT00443573|Drug|recombinant nematode anticoagulant protein c2 (rNAPc2)|escalating dose administered 2x/week sq.
45984465|NCT00478764|Drug|intraocular triamcinolone and gatifloxicin|
45984466|NCT00440778|Drug|Abciximab|100% abciximab bolus dose (0.3 mg/kg) ic or iv vs standard bolus (0.25 mg/kg) ic or iv plus 12-hr infusion
45984467|NCT03278405|Drug|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
45984468|NCT00440817|Other|No intervention|All treatments are prescribed by a physician on the basis of usual clinical practice.
45984469|NCT00443612|Drug|Irbesartan/Hydrochlorothiazide|Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg
45984470|NCT00443612|Drug|Irbesartan|Administration of irbesartan 150 mg/day
45984471|NCT00478803|Procedure|Remodeling procedure associated with a subvalvular aortic ring or double sub and supra-valvular aortic annuloplasty|"Remodeling procedure associated with a subvalvular aortic ring: a) Five U stitches are placed inside out in the subvalvular plane (3 stitches 2 mm below the nadir of insertion of each cusp, 2 stitches below 2 of the 3 commissures at the base of the interleaflet triangles (no suture is placed at the base of the interleaflet triangle situated between the right and noncoronary sinuses to avoid injury of the bundle of His)); b) remodeling of the aortic root by scalloping a bulged graft (Gelweave ValsalvaTM); c) The 5 anchoring U stitches are passed through the inner aspect of the prosthetic aortic ring and tied down externally in the subvalvular position; d) anastomosis of the coronary ostia and to distal ascending aorta."
45984472|NCT00478803|Device|Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots|Expansible Prosthetic Aortic Ring: Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots
45984473|NCT00443690|Drug|rolofylline|rolofylline 30 mg IV QD; 3 days
45984474|NCT00443690|Drug|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
45984475|NCT00440856|Behavioral|Presentation of excised intervertebral disc fragments|
45984476|NCT00443807|Device|On-line EEG monitoring during neurosurgery|Comparison of 2 ways of processing the EEG signal
45984477|NCT00443807|Device|EEGo vs BIS|comparison of two processed EEG monitors.
46002576|NCT03456440|Diagnostic Test|MRI|MRI scan of the patients liver with DWI and acquisition of ADC value.
45984478|NCT00440895|Drug|Abciximab|Abciximab (bolus) i.c. or i.v. or placebo, bolus dose is calculated according to current dosage (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
45984479|NCT04697706|Dietary Supplement|Moonstone|"Participants will take one packet of Moonstone powder reconstituted in 500 ml water, twice a day, to total 1 L per day (66 meq of potential alkali/day) plus ad lib fluids. Moonstone packets will be supplied by Dr. Arnie's, Inc.~Participants will follow their own self-chosen ad lib diets and complete a diet diary (Appendix) for days 6 and 7 in the first study period. On day 7, a 24-hour urine collection will be performed, and a 50-ml aliquot of urine will be sent to Litholink (Chicago, IL) via FedEx for analysis. Participants will then continue to the second study period and will use the diet diary completed in the first study period on days 6 and 7 to reproduce the identical diets for days 6 and 7 of the subsequent collection period."
45984480|NCT04697706|Other|Water|"Participants will take in 1L of tap water per day plus ad lib, self-selected fluids.~Participants will follow their own self-chosen ad lib diets and complete a diet diary (Appendix) for days 6 and 7 in the first study period. On day 7, a 24-hour urine collection will be performed, and a 50-ml aliquot of urine will be sent to Litholink (Chicago, IL) via FedEx for analysis. Participants will then continue to the second study period and will use the diet diary completed in the first study period on days 6 and 7 to reproduce the identical diets for days 6 and 7 of the subsequent collection period."
45984481|NCT00440934|Device|Amplitude-modulated electromagnetic fields|
45984482|NCT00440973|Drug|Bevacizumab|monoclonal antibody with anti-angiogenesis properties used as chemotherapy
45984483|NCT00440973|Drug|Interleukin-2|immunotherapy - cytokine signaling molecule used as an immune system regulator to trigger T & B lymphocyte proliferation
45984484|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for three days
45984485|NCT00443924|Drug|Placebo|One drop of placebo in each eye every 12 hours for three days
45984486|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #2 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
45984487|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #3 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
45984488|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #4 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
45456679|NCT03052634|Drug|RC48-ADC 2.5 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
45456680|NCT03052634|Drug|RC48-ADC 2.0 mg/kg (HER2 Low Expression)|45 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
45456681|NCT03931369|Drug|Tolvaptan 15 MG|Single administration of one pill of 15 MG tolvaptan
45984489|NCT00441051|Drug|Diclofenac sodium 1mg/g|
45984490|NCT00443963|Drug|Esomeprazole Magnesium|PPI compared to H2RA
45984491|NCT00441207|Drug|Ascorbic Acid|Delivered via IV Infusion.
45984492|NCT04701255|Procedure|phacoemulsification with intraocular lens implantation|treatment of cataract by phacoemulsification procedure and implantation of different types of IOLs.
45984493|NCT04701255|Device|ocular aberrometer assesment|evaluate total ocular wavefront, corneal wavefront & internal wavefront (High order aberrations ) post operative by corneal tomography and aberrometer
45984494|NCT00444041|Drug|Bevacizumab|neoadjuvant therapy prior to elective surgery
45984495|NCT00441246|Drug|Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets)|
46083231|NCT02787434|Other|Prostate Cancer Screening Decision Aid|All patients recruited to the study will receive the PCSPrep decision aid. There is only 'study arm.' The Clinical Research Coordinator (CRC) will provide the patient with an iPad to complete the pre-test, PCSPrep and post-test. Individuals will see the survey questions on screen and will hear accompanying audio through headsets. Participants will: (1) be introduced to PCSPrep and the menu of activities/topics; (2) enter information about themselves for personal tailoring (e.g., risk factors); (3) participate in a values-clarification exercise to rate the personal importance of varied courses of action (i.e., pros/cons of PCS); (4) receive a printout with an individualized plan for discussing PCS with their primary care provider.
45456682|NCT02290834|Other|Cognitive, functional and subjective assessments|Cognitive and functional assessments
45456683|NCT02290834|Device|MRI|Magnetic Resonance Imaging (MRI) Scan
45456684|NCT02290834|Radiation|PET Scan|Positron Emission Tomography (PET) Scan
45456685|NCT00359216|Drug|Mometasone furoate nasal spray|MFNS, 50 mcg/spray. Each subject to take 200 mcg (4 sprays) once daily in the morning.
45456686|NCT00359216|Drug|Placebo|Placebo nasal spray. Each subject to take 4 sprays once daily in the morning.
45984496|NCT03278288|Device|WellWe-Intervention group|Participants (families) allocated to the intervention group get to use WellWe-app before entering to health visit to assess the current situation of their wellbeing and utilizing these results during the health visit. The access to WellWe-app is permitted throughout the data collection period. Participants (PHNs) randomized to the intervention group get standardized two hour WellWe-training, WellWe-handbook and full access to the WellWe-app during the data collection period.
45984497|NCT00478842|Device|Deep brain stimulation|Deep brain stimulation
45984498|NCT00478959|Drug|Lenalidomide (Revlimid®)|25mg PO daily for 21 out of 28days per cycle
45984499|NCT00444158|Drug|MOA-728|
45984500|NCT00441324|Procedure|recombinant human LH|
45984501|NCT00444197|Behavioral|Mentoring and violence prevention curriculum with parental monitoring|
45984502|NCT00444236|Drug|Nexium|nexium or placebo 40 mg twice a day for 10-12 weeks. Therapy will then be switched for another 10-12 weeks
45984503|NCT00444236|Drug|Placebo|matching placebo for active drug
45984504|NCT00478998|Drug|Tamsulosin|
45984505|NCT02957279|Drug|Antibiotics|In the sepsis group, antibiotics were used when needed.
45984506|NCT00479076|Drug|aflibercept (AVE0005)|intravenous infusion
45984507|NCT00479076|Drug|S-1|oral administration
45984508|NCT00441519|Drug|aspirin|
45984509|NCT00441519|Drug|omeprazole|
45984510|NCT03278171|Behavioral|Impact Event Scale Revisited|Evaluating the ability of the Impact Event Scale -Revisited within 8 days following the intensive care unit exit to predict a post-traumatic stress disorder at 3 months (Impact Event Scale -Revisited score strictly greater than 34)
45984511|NCT00441597|Drug|atorvastatin|atorvastatine 80mg, during 3 days
45984512|NCT03278132|Biological|EV71 vaccine|Two doses vaccination of EV71vaccine (Intramuscular injection, 0.5ml) with a schedule of 0, 28 days.
45984513|NCT04701372|Behavioral|Exposure and response prevention therapy|Exposures and response prevention therapy (a type of cognitive-behavioral therapy for obsessive-compulsive disorder), delivered in real-time by licensed therapists remotely via video. The treatment was augmented by between-session text messaging and online community support.
45984514|NCT00479193|Drug|bacitracin/xeroform|single layer, change every 3 days
45984515|NCT00479193|Drug|Polymem|single layer of Polymen, change every 3 days
45984516|NCT03278054|Other|Root Canal Treatment with hand instruments|Root canal treatment was performed with K files.
45984517|NCT03278054|Other|Root canal treatment with Protaper instruments|Root canals were enlarged with S1 S2 F1F2 F2 Protaper instruments
45984518|NCT03278054|Other|Root canal treatment with hybrid instrumentation|Root canal were enlarged with combination of a combination of ProTaper Universal instruments to shape the coronal and middle thirds and Hyflex CM to prepare the apical third
45984519|NCT00441636|Device|continuous positive airway pressure (CPAP)|CPAP (Respironics: RemStar plus M-series) machines for treatment of obstructive sleep apnea training for participant required by registered sleep technologist
45984520|NCT03278015|Drug|Nab-paclitaxel plus Gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
45984521|NCT03278015|Drug|Gemcitabine monotherapy|Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
45456687|NCT01226953|Biological|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines
45984522|NCT03278015|Drug|S-1 monotherapy|S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
45984523|NCT00441675|Procedure|Symptom Score|Symptom Score
45984524|NCT00441675|Procedure|Symptom Score and PD20|Symptom Score and PD20
45984525|NCT00444314|Drug|Panzem® NCD|NCD suspension, 1500 mg TID daily for 6 week cycles
45984526|NCT00444314|Drug|Sunitinib Malate|Sunitinib Malate, highest tolerated dose (patient's current dose), daily oral administration for 4 weeks, with 2 week break in 6 week cycle
45984527|NCT00479271|Behavioral|Home based, flexible, stepped care intervention|Home based, flexible, stepped care intervention
45984528|NCT00479271|Behavioral|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
45984529|NCT00444353|Device|DL6049 (injectable poly-L-lactic acid)|
45984530|NCT00444392|Behavioral|Calorie controlled diabetic diet for the control patients|Calorie controlled diabetic diet for the control patients
45984531|NCT00444431|Procedure|Pyeloplasty|
45984532|NCT00441714|Procedure|repetitive short ischemia and reperfusion of non dominant fore arm after 10 minute ischemic exercise|
46083232|NCT04094571|Device|Functional Electrical Stimulation (FES) Control Protocol|To measure the delay, the motor will take the tricycle crank to pre-specified angles and then hold that position while various combinations of the quadriceps femoris and the gluteal muscle groups are stimulated in study participants.
45984533|NCT04700631|Diagnostic Test|urinary extracellular vesicle concentration|urinary extracellular vesicle concentration will be determined in urine samples from CRF and healthy patients
45984534|NCT04700631|Diagnostic Test|blood sample|blood sample in order to determine creatin level
45984535|NCT03277898|Behavioral|Aerobic Exercise|Three weekly moderate-vigorous intensity supervised aerobic exercise training for the duration of adjuvant chemotherapy. Home-based exercise will also be introduced in week 3 of the intervention.
45984536|NCT03277898|Behavioral|Usual Care (Wait-list Control)|Three weekly moderate-vigorous intensity supervised aerobic exercise training starting upon adjuvant chemotherapy completion. Home-based exercise will also be introduced in week 3 of the intervention.
45984537|NCT02274051|Dietary Supplement|Kinetin|Titration of Kinetin to maximum individualized dose, then steady state over a 3 year period once daily dose.
45984538|NCT03277859|Behavioral|SAA-TBI|Yoga twice a week for 75 minutes for 8 weeks
45984539|NCT00444470|Drug|Tranexamic acid|"Eligible patients who have consented to be in the study and have been randomised to be in Arm A will receive 10 mg/kg of tranexamic acid, and then a continuous infusion of 1 mg/kg/hr of tranexamic acid."
45984540|NCT00444470|Drug|Placebo|"Eligible patients who have consented to be in the study and have been randomised to be in Arm B will receive 10 mg/kg of placebo followed by a continuous infusion of 1 mg/kg/hr of placebo."
45984541|NCT00479310|Drug|Summers 5% L.A.|
45984542|NCT00444509|Drug|GW685698X|GW685698X will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
45984543|NCT00444509|Drug|GW685698X containing magnesium stearate|GW685698X containing magnesium stearate will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
45984544|NCT02957175|Other|Immunophenotyping|Multiplex assays for screening pro- and anti-inflammatory markers and RNA will be analysed using a next generation sequencing approach
45984545|NCT00444548|Drug|[S,S]-Reboxetine|
45984546|NCT00444665|Drug|Travatan-Z|
45984547|NCT00479349|Drug|SAM-531|Multiple ascending doses of SAM 531: 1,5; 3 and 5 mg.
45984548|NCT00444704|Drug|PRA-027|
45984549|NCT03279354|Behavioral|Family Move app intervention|All the recruited parent-child pairs will be randomized after baseline assessment by an independent statistician using computer randomization tool to either the FAMILY MOVE app intervention group or the HK FitNuts app control group with a 1:1 allocation ratio. Although both groups receive a stand-alone app, the apps have distinct design features: use of competition and point elements (FAMILY MOVE app) or use of traditional demonstration elements (HK FitNuts app). After both groups have completed the 8-week intervention study and follow up measurements at 1 month, 6 months and 12 months after intervention, the control group will receive the same FAMILY MOVE app. Outcome assessments will be conducted by a trained interviewer blinded to the subject group allocation.
45984550|NCT03279354|Behavioral|"HK FitNuts app intervention"|"The parent-child pairs in the control group will be given a link to download the HK FitNuts app which was developed by Hong Kong Association of Sports Medicine and Sports Science, Department of Orthopaedics & Traumatology of the Chinese University of Hong Kong and Hong Kong Dietitians Association to promote healthy lifestyle in Hong Kong. The app includes short video clips demonstrating basic individual exercise moves and provides other textual information related to PA. However, it does not have push notification function. In order to ensure that the intervention and control group will receive equal attention from our research team, we shall send a text about HK FitNuts and general exercise information to participants in the control group three times per week. Same as participants in the intervention group, the control group will also be asked to provide their weekly app usage and PA pattern by completing an online log at the end of each intervention week."
45984551|NCT02957045|Procedure|Cough pressure measurement|
45984552|NCT02957045|Device|Pcough|
45984553|NCT00479583|Drug|BMS-690514 / FOLFIRI|Tablets / IV, Oral / IV, up to 200 mg / irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
45984554|NCT00479583|Drug|BMS-690514 / FOLFOX|Tablets / IV, Oral / IV, up to 200 mg / oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
45673106|NCT04443335|Behavioral|sequential feeding|At the beginning, all the patients received continuous feeding. After achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d) through continuous feeding, the patients were randomly assigned into the sequential feeding (SF) group or the continuous feeding (CF) group with a random number table. In the SF group, continuous feeding was changed into time-restricted feeding. The total daily dosage of enteral nutrition was equally distributed during three time periods at 7-9:00, 11-13:00 and 17-19:00. Other times of the day were fasting times. Enteral nutritional suspension in each time period was administered at a uniform rate within two hours by an enteral feeding pump.
45984555|NCT04699643|Drug|EVER4010001|Please refer to information in arm/group descriptions.
46083233|NCT04094571|Device|Functional Electrical Stimulation (FES) Angle Protocol|To determine the effect of the crank angle on the FES delay and the muscle control effectiveness, the crank is positioned at a pre-specified angle, with various muscle groups being stimulated while holding this position. The motor then takes the crank to another angle and the process is repeated.
45673107|NCT02014415|Procedure|Liver Biopsy (Biopsy Group Only)|A percutaneous (needle) liver biopsy will be performed on subjects in the Liver Biopsy Group, in Year 1 and Year 5 of the study.
45673108|NCT04801355|Procedure|full-thickness laparo-endoscopic colon adenomas excision|Full-thickness laparo-endoscopic removal of colon adenomas will be performed as follows: an endoscopist during intraoperative colonoscopy visualize the neoplasm, intra-luminary marks the margins of resection and stop at this in some cases. In another one: endoscopist start full-thickness removal of this lesion then the abdominal team during laparoscopy, with using laparoscopic technique, performe full-thickness resection of intestine wall with the tumor. Speciment extracted intralumenary or via minilaparotomy. Defect of the intestinal wall is sutured intracorporeally using laparoscopic technic. Desuflation, suturing of trocar sites.
45984556|NCT04699916|Other|EEG based protocol for deep sedation|Protocol established to guide sedation drug dosification to maintain the patient with a Suppression Rate (SR) less than 1% and a Spectral Edge Frequency 95 over 10 Hz
45984557|NCT02274090|Drug|Placebo gel|Placebo gel consist of drug without the active component.
45984558|NCT02274090|Drug|1% Metformin gel|Metformin gel consist of active component.
46083234|NCT02785562|Other|Assessment of PDL1 expression|Intervention : 2 biopsy slides will be analyzed in central laboratory.
45984559|NCT03278327|Procedure|Complete endoscopic resection at Day 1 and months 2, 4, 6 8 and month 10.|Endoscopic resection treatment
46002577|NCT03456401|Drug|Sorafenib or Sunitinib|After two lines of TKIs, patients received a third line with sunitinib or sorafenib, according to previous treatments
46002578|NCT04638192|Device|tACS|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
46083235|NCT02785796|Other|CV4|
46083236|NCT02785796|Other|SHAM TECHNIQUE|
46083237|NCT02787512|Device|Stent|Endoscopic biliary stent insertion
46083238|NCT02785484|Other|Label with constituent disclosure message|Labels with constituent disclosure messages that include text about chemicals in cigarette smoke and health effects of the chemicals will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 disclosures selected at random; at the week 3 visit, they will get one of the 2 remaining disclosures selected at random, and at the week 4 visit they will get the remaining disclosure. Study investigators developed the text and design of these labels.
45984560|NCT03278327|Device|Endoscopic resection at month 2 and month 4|"System of endoscopic resection of the mucous hurts which can take several forms according to the technical necessities.~The device the most used in this case is the system COOK Medical Duett of Laboratories.~The duration of the treatment will be the same duration as the classic endoscopic resection, that is 30 in 60 minutes.~The resection will be preceded by injection of physiological salt solution tinged with carmine indigo in the sub-mucous membrane."
45984561|NCT04700748|Radiation|Brain metastases radiation|Brain metastases radiation according to clinical practice.
45984562|NCT04699955|Behavioral|Deviance Regulation Theory|In the negative message condition, participants received information on the negative aspects of individuals that did not used protective strategies and were encouraged to report why these individuals were viewed so much more negatively. In the positive message condition, participants received information on the positive aspects of individuals that used protective strategies and were encouraged to report why these individuals were viewed so much more positively.
45984563|NCT03279315|Dietary Supplement|iodized table salt, non-iodized table salt|During the first 3 weeks, the diet was provided with non-iodized salt, while the diet with iodized salt was only offered in the last week.
45984564|NCT00444743|Drug|MM-093|60 mg, administered subcutaneously, weekly
46083239|NCT02785484|Other|Label with litter message|Labels with litter messages that include text about littering cigarette butts will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 litter messages selected at random; at the week 3 visit, they will get one of the 2 remaining litter message selected at random, and at the week 4 visit they will get the remaining litter message. Study investigators developed the text and design of these labels.
46083240|NCT03487640|Procedure|TARMR|Transanal resection of rectal mucosa for at least 5cm in length.
46083241|NCT03487640|Procedure|LARSC|We are going to suspend the rectum and to resect rigmarole hidgut Laparoscopically
45984565|NCT00444743|Other|Placebo|Placebo
45984566|NCT00479622|Drug|TRU-015|Arm 1 = 800 mg Arm 2 = 2000 mg
45984567|NCT00444782|Biological|GV1001|
45984568|NCT03279159|Other|Jaluronius CS cream short term evaluation|Short term evaluation to investigate the hydrating activity of a single application of the study product on the forearms (volar surface) after repeated stripping procedure,measured immediately after stripping execution (T0i), 1,8 and 24 hour/s after product application (T1h, T8h and T24h).
45984569|NCT03279159|Other|Jaluronius CS cream long term evaluation|Long term evaluation to investigate the hydrating activity of the repeated application of the study product on the face (twice a day, for an uninterrupted period of 8 weeks), measured at basal visit (T0) and after 4 and 8 week-treatment (T4, T8)
45984570|NCT00444860|Biological|Zoster Vaccine, Live, (Oka-Merck)|A single dose of 0.65 ml of Zostavax injection was given to each study subject
46083242|NCT03476876|Device|Dermacell|Subject will receive treatment for deep diabetic foot ulcer using Dermacell acellular matrix. Subject will be followed for 16 weeks post treatment.
46083243|NCT03476876|Device|Integra|Subject will receive treatment for deep diabetic foot ulcer using Integra acellular matrix. Subject will be followed for 16 weeks post treatment.
46083244|NCT00638066|Drug|botulinum toxin|500 units of botulinum toxin for the second arm
46083245|NCT00638066|Drug|botulinum toxin A|250 units of botulinum toxin A once
45673109|NCT04801355|Procedure|laparoscopic colon resection|Standard laparoscopic colon resection
45984571|NCT00479661|Drug|Dexmedetomidine|Continuous infusion
45984572|NCT00479661|Drug|Propofol|Continuous infusion
45984573|NCT00444899|Behavioral|Intensive treatment|Subjects will be followed by the dietician in combination with his/her endocrinologist. Diet, physical activity, smoking cessation and drug prescriptions will be used to treat subjects.
45984574|NCT00444899|Other|Normal follow-up|Subject will continue to be followed by their endocrinologist and general practitioner as they already do.
45984575|NCT04700670|Biological|measurement of anti-Xa activities|"The measurement of anti-Xa activities will be carried out on frozen-defrosted plasma citrate and CTAD with 4 reagents~STA-Liquid anti-Xa (STAGO) (not containing dextran)~Biophen Heparin LRT (Hyphen) (reactive containing dextran)~Berichrom (Siemens) with dextran~Berichrom (Siemens) without dextran~The dosage of platelet factor 4 and of the beta-TG will be carried out on frozen-defrosted plasma with the asserachrom PF4 and Asserachrom beta-TG (Diagnostica Stago) kits."
45984576|NCT00444938|Device|H1 -coil TMS device|
45984577|NCT00441870|Drug|EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate)|Dose escalation from a starting dose of 0.38mg IV bolus Monday Wednesday and Friday Weeks 1 and 3 of a 4 Week Cycle to the Maximum Tolerated Dose (MTD)
45673110|NCT01906385|Drug|Rhenium Liposome Treatment|At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
45673111|NCT01823549|Other|questionnaire administration|Ancillary studies
45673112|NCT01792583|Drug|Modafinil/armodafinil|
45673113|NCT03511157|Other|Ischemic Preconditioning|See Ischemic Preconditioning Experimental group description
45673114|NCT03511157|Other|Control Group|See Control group description
45673115|NCT04800965|Behavioral|Patient MyChart Scheduling Link|Text message includes a link for patients to sign on to their patient portal (Epic MyChart) and schedule their COVID-19 vaccine appointment.
45984578|NCT00441870|Drug|99mTC-EC20 (Folic acid-technetium 99m conjugate)|20-25 mCi 99m Tc-EC20 administered IV 1-2 hours prior to imaging
45984579|NCT00444977|Behavioral|Case-management linkage intervention|dental care
45984580|NCT04700592|Other|Gabapentin versus Ketamine|A Comparison of Gabapentin and Ketamine in Acute and Chronic Pain
45984581|NCT04699526|Other|Universal Prevention Curriculum Training for Schools|School administrators and teachers participated in UPC training and formed prevention leadership action teams
45984582|NCT00441909|Drug|UC-781|0.1% UC-781 Vaginal Gel
45984583|NCT00441909|Drug|UC-781 placebo|Vaginal Gel Placebo
45984584|NCT00445016|Procedure|peripheral regional anesthesia|evaluation and description of adverse effects
45984585|NCT00445055|Drug|Droperidol|Intravenous injection
45984586|NCT00479700|Drug|SAM-531|
45984587|NCT02957201|Other|Blood samples|Blood samples at baseline and 3 timepoints for EPC analysis
45984588|NCT00479739|Drug|Salmeterol/fluticasone propionate or formoterol/budesonide|
45984589|NCT03277820|Dietary Supplement|Probactiol Mini|6 droplets of Probactiol Mini contain 1 billion bacteria (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12)
45984590|NCT00441948|Device|Peterio|
45984591|NCT00445094|Drug|MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days|
46083246|NCT02786732|Biological|210mg Brodalumab|Brodalumab 210mg administered subcutaneously
46083247|NCT02786732|Biological|140mg Brodalumab|Brodalumab 140mg administered subcutaneously
46083248|NCT02786732|Biological|Ustekinumab|Ustekinumab 45mg or 90mg adminstered subcutaneously
45984592|NCT00445094|Drug|Comparator: amikacin / Duration of Treatment: 3 Days|
46083249|NCT02786732|Biological|Placebo|Placebo administered subcutaneously
45984593|NCT00445094|Drug|Comparator: tazocin / Duration of Treatment: 3 Days|
45984594|NCT00445094|Drug|Comparator: vancomycin / Duration of Treatment: 3 Days|
45984595|NCT00479778|Drug|Bazedoxifene/conjugated estrogens|
45984596|NCT00445133|Device|Magnetic Sleep Pad|
45984597|NCT00442026|Drug|Docetaxel|Docetaxel at the dose of 30mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
46083250|NCT02785250|Other|DPX-Survivac|SubQ injection
46083251|NCT02785250|Drug|Cyclophosphamide|PO BID
46083252|NCT02785250|Drug|Epacadostat (INCB024360)|PO BID
46083253|NCT05319314|Drug|GCC19CART|Single infusion of Chimeric Antigen Receptor (CAR) transduced autologous T cells administered intravenously (i.v.)
46083254|NCT03110822|Drug|Ruxolitinib Oral Tablet [Jakafi]|Ruxolitinib will be administered on days 1-28 of the treatment cycle.
46083255|NCT03110822|Drug|Lenalidomide|Lenalidomide will be administered on Days 1-21 of the treatment cycle.
46083256|NCT03110822|Drug|Methylprednisolone|Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
46083257|NCT02787356|Drug|TDS Lidocaine 5%; generic|TDS Lidocaine 5%; generic
46083258|NCT02787356|Drug|TDS Lidocaine 5%; RLD|TDS Lidocaine 5%; RLD
45673116|NCT04800965|Behavioral|Patient Educational Video|Text message includes a link to a patient education video that aims to encourage patients to obtain the COVID-19 vaccine.
45984598|NCT00442026|Drug|Gemcitabine|Gemcitabine at the dose of 900mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
45984599|NCT00442026|Drug|Gemcitabine|Gemcitabine at the dose of 1200mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
45984600|NCT00479895|Drug|Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)|Pre-oxygenated HBOC-201
45984601|NCT00445250|Drug|Calcipotriol|
45984602|NCT00442065|Device|Aorfix™ Stent Grafts (AAA endovascular procedure)|Endovascular treatment of AAA using the Aorfix™ Stent Graft and Delivery System
45984603|NCT00445289|Device|SmartCare/PS|
45984604|NCT00442143|Procedure|Stem cell implantation|
45984605|NCT02957006|Device|Loop Recorder|Observation of Loop Recorder implanted for clinical reasons
45984606|NCT03279120|Drug|TFV/LNG IVR|Used for 90 days (Continuous or Interrupted)
45984607|NCT03279120|Drug|Placebo|Used for 90 days (Continuous or Interrupted)
45984608|NCT04699760|Dietary Supplement|Fish Oil|8 weeks, 2.2 G EPA/day
45984609|NCT04699760|Dietary Supplement|Placebo|Placebo
45984610|NCT00479934|Drug|imatinib mesylate|6 month treatment with 400mg/day (per os)
45984611|NCT03274778|Drug|Ruxolitinib 20 MG|tablets
45984612|NCT00442182|Drug|ITF2357|
45984613|NCT03274700|Drug|Tamsulosin.|Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
45984614|NCT03274700|Drug|Placebo.|Patients who will receive as placebo a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
45984615|NCT00442221|Drug|Sumatriptan and Naproxen sodium|
45984616|NCT00479973|Dietary Supplement|Cinnamonforce|"Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.~2 capsules after the two largest meals of the day"
45984617|NCT00479973|Dietary Supplement|Placebo|Placebo. 2 capsules after the two largest meals of the day
45984618|NCT00454259|Drug|Fentanyl/Placebo injection|Ultra low dose intravenous injection
45984619|NCT00454298|Drug|AGG-523 (Aggrecanase Inhibitor)|
45984620|NCT03279042|Procedure|Flapless corticotomy surgical intervention will be conducted|Piezocision will be used to perform the procedure
45984621|NCT03279042|Procedure|Traditional corticotomy|Here the surgery involves elevation of flaps and then conducting the surgical intervention using piezo-surgery cutting saws.
45984622|NCT00454337|Drug|FTC/TDF + EFV or LPV/R +T20|emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day
45984623|NCT00454337|Drug|FTC/TDF + EFV or LPV/R|emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day)
45984624|NCT00480012|Device|rTMS|repetitive transcranial meagnetic stimulation of the brain
45984625|NCT00454376|Other|questionnaire administration|
45673117|NCT04800965|Behavioral|Enhanced Follow through Message|Text message includes information that will use enhanced language aimed at reducing psychological barriers that prevent patients from scheduling their appointment.
45673118|NCT01340261|Behavioral|Questionnaires|Questionnaires are completed at admission, discharge, 1-month, 6 month, and yearly follow-up.
45984626|NCT00454376|Procedure|quality-of-life assessment|
45984627|NCT00480051|Device|Cardiac Resynchronization Pacing|
46083259|NCT02787278|Drug|SP-8203 High dose|High-dose group: 160mg will be intravenously administered as 80mg/dose twice daily (intervals of 12 hours).
45673119|NCT04691375|Drug|PY314|Dose of PY314 as a single agent given in a standard 3+3 design.
45673120|NCT04691375|Drug|Combination Therapy: PY314 + Pembrolizumab|Dose of PY314 alone and given in combination with pembrolizumab
45832702|NCT03623100|Behavioral|Speech Production Treatment.|Speech production treatment will be delivered in two phases: Imitation and Spontaneous Production. Treatment will be provided two times weekly in 1-hour sessions, for up to 19 sessions. Every child's intervention program will target a single phoneme that was excluded from his or her phonemic inventory. Each treatment phoneme will be targeted through the production of five words that will be initially introduced to the child using a storybook reading format. Imitation treatment will continue until a child maintains 75% accurate production of the treated phoneme over two consecutive sessions (i.e. performance-based criterion) or until seven consecutive sessions are completed (i.e. time-based criterion). Spontaneous Production will continue until the child maintains either a performance-based criterion of 90% accurate production of the treated phoneme over 3 consecutive sessions, or a time-based criterion of 12 consecutive sessions.
45673121|NCT04676633|Drug|STP705|Investigational Product
45673122|NCT03508895|Other|Whole hemp seed protein|The intervention was provided in the form of a smoothie.
45673123|NCT03508895|Other|Whole hemp seed protein plus bioactive peptides|The intervention was provided in the form of a smoothie.
45673124|NCT03508895|Other|Casein protein|The intervention was provided in the form of a smoothie.
45673125|NCT03507491|Drug|Gemcitabine|Gemcitabine will be administered intravenously once weekly over 60 minutes every 3 out of four weeks. The dose of gemcitabine will start at 675 mg/m2/dose. If the MTD has been exceeded at the Dose Level 1, then the subsequent cohort of participants will be treated with gemcitabine at a dose of 500 mg/m2/dose (Dose Level 0).
45984628|NCT00454493|Drug|Omacor (omega-3-acid ethyl esters)|
45984629|NCT00454610|Behavioral|FLOW|
45984630|NCT00454610|Behavioral|SelfHelp|
45984631|NCT00454688|Drug|Asimadoline|Asimadoline was provided in coated tablets of three dosages (0.15 mg, 0.5 mg, and 1.0 mg). All asimadoline tablets used in this trial were synthesized from the same batch of drug substance (Batch EF418492). Asimadoline was administered orally, BID for 12 weeks
45984632|NCT00454688|Drug|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets.
45984633|NCT03278808|Drug|Chloroquine-Azithromycin (CQ/AZ)|Chloroquine-Azithromycin (CQ/AZ); Chloroquine (CQ) 300mg and 2g of azithromycin (AZ) given orally
45984634|NCT03278808|Drug|Chloroquine (CQ)|Chloroquine (CQ); 300 mg of CQ only given orally
45984635|NCT03278808|Drug|atovaquone-proguanil (Malarone®)|All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
45984636|NCT00480090|Drug|Cytarabine|Initially given at 1g/m2 bid for 2 days every 3 weeks over 2 hours. The dose will be escalated: level 1 - 1.25g/m2, level 2, 1.5g/m2.
46083260|NCT02787278|Drug|SP-8203 Low dose|Low dose group: 80mg will be intravenously administered as 40mg/dose twice daily (intervals of 12 hours).
46083261|NCT02787278|Drug|Placebo|Same dosage of SP8203. Placebo will be intravenously administered twice daily (intervals of 12 hours)
46083262|NCT02785328|Other|memory evaluation at V1 and V2 (with treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance. The children receive drug treatment (BECTS and Narcolepsy) or surgical (OSA) as part of their routine care.
45984637|NCT00454766|Behavioral|Questionnaire|Survey of two educational brochures with approximately the same information, but which vary in their health literacy (readability) level.
45984638|NCT00480129|Behavioral|Probiotic or placebo yogurt consumed daily|
45984639|NCT00480129|Device|Mini Rhinoconjunctivitis Quality of Life Questionnaire|
45984640|NCT00480129|Procedure|Blood sample|
45984641|NCT00480129|Procedure|Nasal lavage|
45984642|NCT03274622|Behavioral|Impact Parent Training|
45984643|NCT03274622|Behavioral|No Impact|
45984644|NCT00442299|Device|Fractionated Plasma Separation and Adsorption (FPSA)|
45984645|NCT00454883|Drug|ziprasidone|Ziprasidone 40 mg twice daily taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as day 3 of treatment.
45984646|NCT00442377|Procedure|exposure to malaria sporozoites|
45984647|NCT00454922|Behavioral|standard of care|no intervention
45984648|NCT00454922|Other|education|meet with trained glaucoma educator 6 times over life of study
45984649|NCT03278652|Other|Consumption of drugs for analgesic use|"Regular assessment of pain~Drug data will be collected (name, dosage, route of administration, time of delivery)"
45984650|NCT00454961|Drug|artemether-lumefantrine|
45673126|NCT03507491|Drug|Nab-paclitaxel|Nab-Paclitaxel will be administered intravenously over 30 minutes once weekly every 3 out of 4 weeks. Nab-paclitaxel will be administered prior to administration of gemcitabine. The starting dose of nab-paclitaxel will be 180 mg/m2/dose (dose level 1). Dose levels for subsequent groups of subjects are 210 mg/m2/dose (for dose level 2) and 240 mg/m2/dose (for dose level 3).
45673127|NCT01313351|Device|RPS InflammaDry Detector™|A noninvasive immunoassay for detecting MMP-9 levels in tears
45673128|NCT03500315|Other|HIV D+/R+|Kidney from an HIV-infected deceased donor
45673129|NCT03418259|Device|KCS Medical Device|Patient treated 6 times with the Active KCS Medical Device during 2 weeks.
45832703|NCT03623100|Behavioral|Speech Production + Speech Perception Treatment.|This speech treatment condition will be administered in the same way as the Speech Production treatment. The difference in conditions will be that speech treatment in this condition will last for 50 minutes rather than 60 minutes. The remaining 10 minutes of each session will involve the speech perception training. These speech perception tasks will involve previously recorded word-level productions focusing on the same phoneme that is addressed in speech production treatment in word-initial position. A variety of words produced correctly and incorrectly by adults and children will be presented in pairs and the children will have to determine if the words contain the same word-initial phoneme or two different phonemes.
45984651|NCT03278574|Procedure|Mitral valve repair|Mitral valve repair with standard technique: resection of prolapsed leaflet and/or artificial neochordae implantation
45984652|NCT03278574|Device|Ring annuloplasty with posterior band|Mitral valve annuloplasty using Cardiamed (Penza, Russia) flexible posterior annuloplasty band
45984653|NCT03278574|Device|Ring annuloplasty with complete ring|Mitral valve annuloplasty using Cardiamed (Penza, Russia) complete semirigid ring
45984654|NCT00455000|Biological|PF-04360365|Monoclonal antibody
45673130|NCT03418259|Device|KCS Medical Device|Patient treated 6 times with the Inactive KCS Medical Device during 2 weeks.
45673131|NCT04566653|Drug|Calcium Polystyrene Sulphonate 15g/60 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
45673132|NCT04566653|Drug|Lokelma® 5 g/45mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
45673133|NCT04566653|Drug|Lokelma® 10 g/45 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
45832704|NCT03621306|Device|DXA and pQCT precision testing|The participants are only being observed; there is no intervention other than DXA and pQCT testing for the purposes of looking at instrument/technician precision..
45984655|NCT00455000|Drug|Placebo|Placebo
45984656|NCT00455039|Drug|GW572016|Dose: 1500 mg daily
45984657|NCT00455078|Procedure|esophagogastroduodenoscopy|EGD will be done pretransplant then again before 18mos post transplant.
45984658|NCT00455078|Other|Standard GER questionnaire (RDQ)|RDQ questionnaire will be done pretransplant then again before 18mos post transplant.
45984659|NCT00455078|Procedure|Scintigraphic evaluation of solid gastric emptying|Scintigraphic evaluation of solid gastric emptying will be done pretransplant then again before 18mos post transplant.
45984660|NCT00455078|Procedure|Twenty-four hour ambulatory pH testing|Twenty-four hour ambulatory pH testing will be done pretransplant then again before 18mos post transplant.
45984661|NCT00455078|Procedure|Esophageal manometry testing|Esophageal manometry testing will be done pretransplant then again before 18mos post transplant.
45984662|NCT00480207|Dietary Supplement|folic acid|
45984663|NCT00480207|Dietary Supplement|omega-3|
45984664|NCT00480207|Dietary Supplement|vit B12|
45984665|NCT00480207|Other|folic acid placebo|
45984666|NCT00480207|Other|omega-3 placebo|
45984667|NCT03274583|Diagnostic Test|Smartphone seismographic recording|A short recording of heart rhythm using a smartphone.
45984668|NCT00442455|Drug|Erlotinib chlorhydrate|150 mg/day for 7 weeks
45984669|NCT00442455|Drug|Cisplatin|30 mg/m2 i.v. weekly for 7 weeks
45984670|NCT00442455|Procedure|Radiation therapy|63 Gy, five days a week, for 7 weeks
45984671|NCT02956655|Other|Fasting therapy|The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. After intervention, all the accomplished patients undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up.
46002579|NCT03456362|Device|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|theta burst stimulation (TBS) is a novel form of repetitive transcranial magnetic stimulation that mimics protocols inducing long-term potentiation (LTP) or long-term depression (LTD) in animal models. Whereas continuous TBS (cTBS) induces long-lasting inhibition of cortical areas, iTBS exerts the opposite effect, increasing cerebellar excitability
45984672|NCT02956655|Drug|Insulin intensive therapy: Human Insulin (Novolin-R, Novo Nordisk)|"Human Insulin (Novolin-R, Novo Nordisk)~Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland~The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. If the glucose target cannot be achieved within 2 weeks or the subjects are not tolerated with this therapy, these members will be exclude from the study and they will receive other treatment according the standard treatment guidelines. After intervention, all the accomplished patients will undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up."
45984673|NCT02956655|Other|Exercise|Middle intense exercise for at least 2 hours,e.g. brisk walking or jogging
45984674|NCT02956655|Behavioral|Lifestyle guidance|Lifestyle guidance is provided by specific physicians through phone calls
45984675|NCT02956655|Device|H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland|
45984676|NCT00480246|Drug|BL 1020|
45984677|NCT00480246|Drug|Perphenazine|
45984678|NCT00455117|Drug|Intravenous Parecoxib ('Dynastat' Pfizer)|parecoxib or placebo
45984679|NCT00442494|Drug|intravenous hydrocortisone|
45984680|NCT03274427|Device|Basic drugs therapy of HCC by TACE|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
45984681|NCT03274427|Drug|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
45984682|NCT03274427|Drug|Trimetazidine hydrochloride|Trimetazidine hydrochloride, 20mg/tablet, 40mg, twice a day.
46083263|NCT02785328|Other|memory evaluation at V1 (without treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance.
46083264|NCT02785328|Other|memory evaluation at V1 and V2 (without treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance.
45832705|NCT01677468|Procedure|Intermediate embolization|TACE with substasis using gelfoam
45832706|NCT01677468|Procedure|Complete embolization|TACE with complete embolization using gelfoam
45832707|NCT00003816|Biological|anti-thymocyte globulin|Given IV
45832708|NCT00003816|Drug|busulfan|Given IV
45984683|NCT03274388|Procedure|nutritional therapy|protein-rich nutritional therapy and counseling, during study period of 12 weeks
45984684|NCT03274388|Procedure|WB-EMS combined with nutritional therapy|protein-rich nutritional therapy and counseling plus whole body electromyostimulation exercise training, twice a week for 20 min., during study period of 12 weeks
45984685|NCT00480285|Procedure|Laparoscopic Nissen Fundoplication|
45984686|NCT00480285|Procedure|Laparoscopic anterior partial fundoplication|
45984687|NCT03274349|Procedure|whole body electromyostimulation exercise|whole body electromyostimulation exercise training twice a week for 20 min each, bipolar, 85 Hz, intermittent pulse/pause, pulse width 350 µsec
45984688|NCT03274349|Procedure|protein-rich nutrition therapy|protein-rich nutrition therapy with an objective of reaching 1,2 to 1,5 g protein/kg body weight and day
45984689|NCT00442650|Drug|Efalizumab|
45984690|NCT02273687|Device|Vivid S6 GE Ultrasound|"Diaphragmatic ultrasound will be performed by the physician supporting the patient on arrival and also at 4 hours later in the beginning of therapeutic management. The patient will be monitored for 24 hours following inclusion.~The exams will all be done with the same ultrasound system (Vivid S6 GE Ultrasound) and a phased array probe, also called a cardiac probe."
45832709|NCT00003816|Drug|carboplatin|Given IV
45984691|NCT00442728|Device|ELECTRICAL STIMULATION|
45984692|NCT00455234|Drug|Intramuscular Olanzepine 10 mg|
45832710|NCT00003816|Drug|cyclophosphamide|Given IV
45832711|NCT00003816|Drug|etoposide|Given IV
45832712|NCT00003816|Drug|fludarabine phosphate|Given IV
45832713|NCT00003816|Drug|melphalan|Given IV
45832714|NCT00003816|Drug|thiotepa|Given IV
45832715|NCT00003816|Radiation|total-body irradiation|Given twice daily for 3 days
45832716|NCT03618654|Drug|Metformin|Given PO
45832717|NCT03618654|Biological|Durvalumab|Given IV
45832718|NCT03617874|Other|PC4PrEP- Intervention Clinics|PC4PrEP is a comprehensive, multi-level, structural and sustainable intervention designed to address barriers at system, provider, and user levels to increase PrEP uptake.
45832719|NCT03617874|Other|Standard of Care Clinics|The standard of care model is the model approved by the health system for their health care clinics.
45984693|NCT00455234|Drug|Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg|
45984694|NCT00480363|Procedure|Maintenance with lower doses of lenalidomide and dexamethasone|After 9 cycles of lenalidomide and dexamethasone, it follows with lower doses for maintenance
45984695|NCT00442806|Drug|Injection of ADRC's|ADRC's are injected
46083265|NCT04184570|Other|Observational Trial|Observational Trial
46083266|NCT02615522|Device|BPK-S Integration|
45984696|NCT00442806|Other|Injection of Placebo|Placebo is injected
45984697|NCT00455390|Procedure|Post-immediate Psychotherapeutic Intervention|
45673134|NCT04566653|Drug|Veltassa® 8,4 g/80mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
45984698|NCT00442845|Drug|Atorvastatin (Lipitor)|
45984699|NCT00455468|Procedure|Day-care treatment vs. hospital care|
45984700|NCT00455507|Drug|Istradefylline|Two 10 mg KW-6002 tablets orally once daily for 12 weeks
45984701|NCT00455507|Drug|Istradefylline|Two 20 mg tablets orally once a day for 12 weeks
45984702|NCT00455507|Drug|Placebo|Two placebo tablets orally once daily for 12 weeks
45984703|NCT00442884|Behavioral|Trier Social Stress Test (TSST)|
45984704|NCT00455546|Drug|A-002|
45984705|NCT00442923|Drug|Coreg|
45984706|NCT00480402|Drug|200 mg of Progesterone|Administration of 200 mg of Progesterone
45984707|NCT00480402|Drug|400 mg Progesterone|Administration of 400 mg Progesterone
45984708|NCT00480402|Drug|Placebo|Administration of a Placebo
45984709|NCT00455585|Drug|nevirapine, stavudine, lamivudine|
45673135|NCT04566653|Drug|Sodium Polystyrene Sulphonate 15g/60 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
45673136|NCT04521569|Drug|Regadenoson|If the donor lungs are randomized the experimental arm, the administration of Regadenoson will be performed at each study site by a qualified medical professional. The donor lungs will be perfused with Regadenoson at a dosage of 1.44 microgram/kg/min (based on donor's weight) for a minimum of three hours and maximum of four hours, using a pediatric syringe pump into the EVLP circuit (XVIVO Perfusion System). The infusion will begin within 10 minutes of the start of the EVLP procedure. Once the EVLP is complete the lungs are re-flushed with Perfadex solution (removing the Steen™ solution and Regadenoson; standard for EVLP).
45673137|NCT04521569|Drug|Placebo|If the donor lungs are randomized to the Steen solution arm, the donor lungs will be perfused with placebo at a rate equivalent to the dosage of Regadenoson (1.44 microgram/kg/min), for a minimum of three hours and maximum of four hours, using the same pediatric syringe pump. The infusion will begin within 10 minutes of the start of the EVLP procedure.
45673138|NCT01574716|Drug|MORAb-004|IV, Days 1 and 8 of every cycle until disease progression
45832720|NCT03614910|Device|Nanoknife Irreversible Electroporation|Irreversible electroporation will be delivered between electrodes that are placed by intraoperative ultrasound guidance around the tumor
45832721|NCT03718104|Other|Pharmacokinetic analysis|Pharmacokinetic analysis of maternal blood, maternal urine, cord blood, infant blood and urine for dyads in the naltrexone group at various time points in the pregnancy, at delivery, and 4 weeks postpartum.
45984710|NCT03278847|Dietary Supplement|Received enteral (milk) feeds during therapeutic hypothermia|"In the enteral component of nutrition, the health technology to be assessed is the gradual introduction of enteral (milk) feeds during therapeutic hypothermia:~Included in this is any type of milk (e.g. expressed maternal breast milk, expressed donor breast milk and artificial formula)~This health technology includes different routes of administering enteral feeds such as nasogastric tube (gavage feeding) and bottle~This health technology also includes different rates of increasing enteral feeds (for example by 15ml/kg/day, by 30ml/kg/day or faster)"
45984711|NCT03278847|Dietary Supplement|Enteral (milk) feeds withheld during therapeutic hypothermia|Withholding enteral feeds (keeping a baby nil per os) for the duration of hypothermia.
45984712|NCT03278847|Dietary Supplement|Received parenteral nutrition during therapeutic hypothermia|"In the parenteral component, the health technology being assessed is administration of parenteral nutrition during therapeutic hypothermia:~Included in this are different compositions of parenteral nutrition (for example standard, pre-prepared bags of nutrition and individually tailored parenteral nutrition)~This health technology includes different routes of administration of parenteral nutrition such as via a peripheral intravenous cannula, percutaneous central venous catheter ('long line') or umbilical venous catheter.~This health technology also includes different volumes of parenteral nutrition (e.g. 40ml/kg/day, 60ml/kg/day or greater)."
45984713|NCT03278847|Dietary Supplement|Did not receive parenteral nutrition during therapeutic hypothermia|Received standard intravenous fluids (10% dextrose with additional electrolytes added where required) for the duration of hypothermia.
45984714|NCT00455624|Drug|Androgen deprivation therapy|According to standard medical care
45984715|NCT03276546|Behavioral|shared decision-making tool (SHARE-D)|questionnaire
45984716|NCT01240005|Biological|DCIK|Renal cell carcinoma patients were treated with three intravenous infusions of DC activated CIK cells at 1-day intervals. Clinical examinations of these patients were performed.
45984717|NCT00455819|Procedure|home treatment|
45984718|NCT00443157|Biological|Meningococcal B Vaccine NZ|
45984719|NCT00455897|Drug|GM-CSF|Given 11 days before day 1 of cycle 1 for 10 days
45984720|NCT00455897|Drug|CHOP|Administered as part of standard care
45984721|NCT00455897|Drug|Rituximab|Administered as part of standard treatment
45984722|NCT00480480|Behavioral|Trauma and Grief Component Therapy for Adolescents (Group Version)|
45984723|NCT00455936|Drug|Gefitinib|gefitinib 250mg tablet/ QD daily until Progression
45984724|NCT00455936|Procedure|chemotherapy|gemcitabine(1250mg/m2 iv on D1 & 8) plus Cisplatin (80mg/m2 iv on D1) every 3 weeks, maximum 9 cycles
45984725|NCT00443196|Procedure|MiCK Assay|Physician determined treatment
45984726|NCT03274310|Behavioral|Educational text messages|Educational text message about ways to decrease household transmission of influenza and other respiratory infections
45984727|NCT00443235|Drug|Melphalan/Prednisone/Velcade|"One cycle:~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
45984728|NCT00443235|Drug|Thalidomide/Prednisone/Velcade|"One cycle:~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity < grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)~Five cycles:~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
45984729|NCT03274232|Device|SUNEKOS ® 200|micro-injections of the study product were performed by a specialized dermatologist, bilaterally on the face (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) of female volunteers aged 45-65 years, with photoaging of mild/moderate grade
45984730|NCT00456053|Drug|FG2216|
45984731|NCT00456131|Behavioral|Healthy Eating Behaviors Training|The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
45984732|NCT00480519|Procedure|Meatotomy|
45984733|NCT00456170|Procedure|Performing Vaginal hysterectomy with Harmonic Scalpel|
45984734|NCT03278535|Diagnostic Test|CAREN-based gait analysis|subjects only walk at CAREN at different speed
45984735|NCT04700943|Procedure|Regional awake anesthesia|We want to assess the impact of regional anesthesia on diaphragmatic function in patients undergoing Video-assisted thoracoscopic surgery pulmonary biopsy in interstitial lung disease
45984736|NCT00456248|Drug|Infergen and ribavirin|Infergen 15 ug QD plus RBV for 36 weeks and Infergen 15 ug QD plus RBV for 48 weeks
45984737|NCT00480558|Biological|MVA 85A|Modified vaccinia Ankara virus expressing antigen 85A from M. tuberculosis. Dose is 5x10^7
45984738|NCT00456287|Device|CPAP (Continuous Positive Airway Pressure)|
45984739|NCT04700709|Drug|Sirolimus Tab.|Orally, once-daily in the morning - The first dose is administered within maximum 6mg/day according to the investigator's judgement, check the blood concentration of Sirolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3~8ng/ml.
45984740|NCT04700709|Drug|Mycophenolate Mofetil Cap./Tab.|Up to 1g BID(total 2g daily), PO
45984741|NCT04698317|Procedure|open flap debridement|Open flap for removal of diseased periodontal tissues and necrotic cementum
46083267|NCT03093818|Other|Pharmacogenomic testing|"The pharmacogenomic panel to be used incorporates 48 genetic variants for the following 13 pharamacogenes: CYP2B6 (cytochrome P450), CYP2C19, CYP2C9, CYP2D6,CYP3A4, DPYD (dihydropyrimidine dehydrogenase), FVL (factor five Leiden), HLA-B (human leukocyte antigen), NUDT15 (Nudix hydrolase), SLCO1B1 (solute carrier organic anion transporter), TPMT (thiopurine methyltransferase), UGT1A1 (UDP-glucuronosyltransferase), and VKORC1 (vitamin K epoxide reductase complex)."
46083268|NCT03083678|Drug|Afatinib|Afatinib will be given daily in a dose of 40 mg orally in a 4 week cycle until disease progression or patient withdrawal.
46083269|NCT04231916|Device|Thermal imaging device|
46083270|NCT04232150|Drug|single-dose midazolam for sedation under spinal anesthesia.|Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring. Group O received 0.025mg/kg midazolam at skin incision.
46083271|NCT04232150|Drug|Double-dose midazolam for sedation under spinal anesthesia.|Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring. Group M received 0.025mg/kg midazolam at skin incision and repeated 5 minutes before maximum stimulation.
45832722|NCT03718104|Other|Safety and Efficacy|Examination of the safety and efficacy of naltrexone and comparison of outcomes with the buprenorphine/naloxone cohort. Outcomes examined will include: 1) maternal outcomes (relapse, retention in care, preterm labor); 2) fetal outcomes (growth, fetal anomalies, fetal distress, cortisol levels); and 3) infant outcomes (NAS, growth, neurodevelopment via NNNS exam at 4 weeks and Bayley exam at 12 months of age).
45832723|NCT03718104|Genetic|Genetic and epigenetic analysis|Maternal blood and saliva DNA samples will be genotyped for single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) to look for associations with effectiveness of NTX and BPH. In addition, DNA methylation levels in the OPRM1 promoter within maternal and infant saliva and placenta at delivery and 4 weeks postpartum will be examined. Lastly, we will compare genome-wide DNA methylation levels at delivery and 4 weeks postpartum in mother-infant dyads.
45984742|NCT04698317|Other|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate plus concentrated growth factors|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate incorporating Concentrated Growth Factors in Periodontal Defect
45984743|NCT04698317|Other|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate alone|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate alone in the Intrabony Periodontal Defect
45984744|NCT04700475|Device|low level laser|"Laser will be performed with a GaAlAs diode laser at a wavelength of 808 nm, 100-mW output power, laser beam area of 0.03 cm2, and in continuous wave mode, three times a week, on alternate days. Laser therapy will be initiated before the first radiotherapy session and ended after the last session, totaling 21 sessions.~The total energy per session (56 J) will be divided into 14 irradiation points, as marked on the overlying skin (Fig.2). Each irradiation point received a dose of 4 J over an irradiation time of 40 s.~With exclusion of tumor area or area of removed tumor laser will be applied as following:~• Extra oral application: The laser will be used extraorally at eight points in the parotid glands (bilaterally, four points in each gland), at four points in the submandibular glands (bilaterally, two points in each gland~• Intraoral application: The will be used intraorally at two points in the sublingual glands bilaterally, one point in each gland ."
45984745|NCT04700475|Drug|citric acid solution|citric acid solution applied as a mouth rinse
45984746|NCT00456404|Drug|peppermint water|
45984747|NCT04700436|Drug|Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)|"IP~Test drug: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)~Control drug: Suvast tablet 10 mg (Rosuvastatin 10 mg)"
45984748|NCT00456443|Procedure|Historical records|
46083272|NCT04232150|Procedure|spinal anesthesia with no sedation.|Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring.
46083273|NCT04197752|Other|Regional anesthesia/analgesia techniques|Neuroaxial or peripheral block anesthesia/analgesia technique that is appropriate for the patient's surgery
46083274|NCT04230902|Biological|Microfragmented Adipose Tissue Transplant|Autologous Microfragmented Adipose Tissue derived using Lipogems® Kit
46083275|NCT04230902|Drug|Corticosteroid injection|intra-articular knee injection of corticosteroid
46083276|NCT02336750|Drug|Aprepitant|125mg D1, 80mg D2-3
46083277|NCT02336750|Drug|Mirtazapine|15mg D2-4
45984749|NCT00480597|Drug|gemcitabine|
45984750|NCT00480597|Drug|cisplatin|
45984751|NCT00480597|Drug|vinorelbine|
45984752|NCT00480597|Drug|capecitabine|
45984753|NCT00456482|Drug|Fluocinolone Acetonide 0.59mg|Fluocinolone Acetonide Intravitreal Implant 0.59 mg
45984754|NCT00456482|Drug|Fluocinolone Acetonide 2.1mg|Fluocinolone Acetonide Intravitreal Implant 2.1 mg
45984755|NCT00480675|Procedure|trochanteric bursa injection done under fluoroscopy with depomedrol and bupivacaine|Depomedrol 60 mg + bupivacaine 2.5 ml
45984756|NCT00480675|Procedure|Trochanteric bursa injection with depomedrol and bupivacaine|Trochanteric bursa injection done with sham x-ray and 60 mg of depomedroal and 2.5 ml bupivacaine using landmarks for guidance.
45984757|NCT00456560|Drug|AV650|
45984758|NCT00456560|Drug|Fluvoxamine|
45673139|NCT01574716|Drug|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
45984759|NCT00456560|Drug|Paroxetine|
45984760|NCT04700358|Other|Blood sampling|"Screening: Blood sampling of 15 ml whole blood~B cell isolation: Blood sampling of max. 400 ml whole blood or 6% of the total blood volume (♀ 65 ∓ 10 ml/kg; ♂ 77 ∓ 10 ml/kg)"
46083278|NCT02784314|Procedure|Robotic-Assisted Radical Prostatectomy|
46083279|NCT02784314|Procedure|Laparoscopic Radical Prostatectomy|
46083280|NCT02784158|Drug|Brigatinib|Brigatinib will be administered orally to eligible patients with locally advanced or metastatic ALK+ NSCLC who are resistant or intolerant to a prior ALK inhibitor at a dose of 180 mg QD with a 7 day lead-in at 90 mg QD, continuously, with or without food.
46083281|NCT02784392|Drug|Ulimorelin|Active
46083282|NCT02784392|Drug|Metoclopramide|Comparator
46083283|NCT02972996|Other|Blueberry|22 g freeze-dried whole blueberry powder
46083284|NCT02972996|Other|Placebo|22 g placebo blueberry powder
46083285|NCT00634556|Drug|levodopa solution 2mg/ml for i.v. use|2mg/mL in normal saline
46083286|NCT00634556|Drug|placebo|normal saline
46083287|NCT02784080|Other|HLA-alloantibodies exposure|"Following analyzes will be done:~LABScreen® Mixed, One Lambda, CA LABScreen® Single Antigen, One Lambda, CA C1qScren™, One Lambda, CA PE-conjugated IgG3 antibody"
46083288|NCT02784860|Drug|Lidocaine|Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the lidocaine group, lidocaine 2% is administered as a bolus followed by a continuous intravenous infusion after loss of consciousness
46083289|NCT02784860|Drug|normal saline|Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the placebo group, the same volume of normal saline is administered after loss of consciousness
46083290|NCT02783924|Drug|Cholecalciferol|Vitamin D preparation
46083291|NCT02783924|Drug|Placebo|placebo
46083292|NCT05249348|Drug|PC14586|An oral dose of PC14586 will be used in Arms A and B (Part 1) and a different dose will be used for Arms C and D and the Japanese cohort (Part 2).
46083293|NCT02783846|Other|normal saline|receive equal volume of normal saline
46083294|NCT02783846|Drug|dexmedetomidine 0.5 µg/kg|receive dexmedetomidine 0.5 µg/kg
45832724|NCT03718104|Other|Breast milk analysis|Mothers in the naltrexone group will have their breast milk analyzed at 4 weeks post-delivery for naltrexone levels, with corresponding maternal and infant plasma levels.
45673140|NCT01574716|Drug|Docetaxel|IV, Day 8 of every cycle until disease progression
45673141|NCT01574716|Drug|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
45673142|NCT01574716|Drug|Docetaxel|IV, Day 8 of every cycle until disease progression
45673143|NCT01574716|Drug|Placebo|
45673144|NCT02161562|Drug|omalizumab|150mg omalizumab via sub-cutaneous injection once every 4 weeks
45832725|NCT03716544|Device|Amplification with hearing aid|Use of hearing aids
45832726|NCT03716544|Device|Customized music|Customized music delivered via an iPod
45832727|NCT03714750|Procedure|DK crush|revascularization of true coronary bifurcation stenosis in DK crush technique
45832728|NCT03714750|Procedure|Reverse TAP|revascularization of true coronary bifurcation stenosis in Reverse TAP technique
45984761|NCT00456638|Drug|Depodur|Depodur vs. traditional management
45984762|NCT04700085|Device|ReMotion Knee|The ReMotion Knee is a prosthetic knee mostly used in low-income countries. It has been approved according to the ISO 10328 standards and has received the CE Mark.
45984763|NCT00480714|Biological|BCG (SSI Strain)|
45984764|NCT00456677|Drug|minocycline|addition of antibiotic minocycline as antiinflammatory agent in addition to standard of care regimen.
45984765|NCT00456677|Drug|Placebos|Addition of oral placebo capsule in addition to standard of care regimen
45984766|NCT03278496|Behavioral|Recovery Housing plus Counseling|Participants receive 3 months of abstinence-contingent program-supported rent payment in community recovery housing. They also receive intensive outpatient counseling (both individual and group) focused on relapse prevention skills training, goal setting, employment seeking and recreational activities.
45984767|NCT03278496|Behavioral|Usual Care Referral|Participants are referred to an outpatient program of their choosing with an appointment made for them.
45984768|NCT03278496|Behavioral|Recovery Housing Only|Participant may receive up to 3 months of abstinence-contingent rent payment in community recovery housing but is not invited to participate in intensive counseling.
45984769|NCT00456716|Drug|sorafenib|400mg po bid
45984770|NCT04700397|Diagnostic Test|Nitroglycerine|We aim to test the repeatability of NTG-Pd/Pa with different dosages of nitroglycerine injection.
45984771|NCT00456794|Drug|Istradefylline (KW-6002)|
45984772|NCT00456833|Drug|RAD001|
45984773|NCT00456833|Drug|erlotinib|
45984774|NCT04700319|Drug|CD19/CD20 CAR-T cell infusion|CD19/CD20 CAR-T,Infusion,iv,0.2×10^6-5×10^6γδT /kg,once
45984775|NCT00456872|Drug|lidocaine|
45984776|NCT00480753|Drug|Nitroglycerin|
45984777|NCT00456911|Behavioral|Fat and carbohydrate controlled diet|
45984778|NCT03274154|Dietary Supplement|Pre-Hyaluron 465 Innēov|Food supplement consisting og a tablet and a capsule, composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese)
46083295|NCT02783846|Drug|dexmedetomidine 1.0 µg/kg|receive dexmedetomidine 1.0 µg/kg
46083296|NCT02786342|Procedure|blood sample collection|
45984779|NCT03274115|Device|BLI (Blue Laser Imaging)|Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps
45984780|NCT04700241|Dietary Supplement|Potassium nitrate|Acute intervention (5.5 hours)
45984781|NCT04700241|Dietary Supplement|Placebo|Acute intervention (5.5 hours)
46083297|NCT02784938|Behavioral|Vocational Empowerment Photovoice (VEP)|The VEP program is a 10-week manualized, structured, peer-led intervention delivered in 2-hour group sessions. The VEP manual includes a Workbook for the clients and a corresponding Leader's Guide for the group peer-leaders. The VEP program integrates Photovoice methodology, Rehabilitation Readiness technology and elements of the Anti-Stigma Photovoice (ASP) curriculum previously developed and tested by the Boston University Center for Psychiatric Rehabilitation (BU CPR). VEP group sessions combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing employment services and opportunities, all refined with input from individuals with a lived experience.
46083298|NCT02864576|Behavioral|Cognitive Remediation_Aerobic Exercise|"Cognitive Remediation:~The REHACOP program consists of: Attention unit training sustained, selective, alternant and divided attention; Memory unit focusing on visual and verbal learning, recall and recognizing memory; Language unit including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit training cognitive planning, proverbs, analogies; and Social cognition unit exercising theory of mind, social reasoning and moral dilemmas.~Aerobic Exercise:~12 weeks of systematic aerobic exercise program. Patients will walk with a moderate intensity 10 minutes the first week and will increase gradually up to 30 minutes-walk with a moderate intensity. Patients will also perform 5 minutes of warm-up and stretching."
45984782|NCT04700046|Drug|Mexiletine 167 mg|Mexiletine 167 mg (equivalent to mexiletine HCl 200 mg) immediate release, oral capsules.
45984783|NCT04700046|Drug|Placebo|The placebo capsules contain the same ingredients as the active formulation with the exception of mexiletine
45984784|NCT00480792|Biological|GenHevac B Pasteur|Intra-muscular injection 20 microgramme Intramuscular use at M0, M1, M6
45984785|NCT00480792|Biological|GenHevac B Pasteur|Intra-muscular injection 40 microgramme intramuscular use at M0, M1,M2, M6
45984786|NCT00480792|Biological|GenHevac B Pasteur|GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
45984787|NCT00457067|Drug|Ranibizumab|
45984788|NCT00480870|Drug|donepezil|donepezil 5 mg 1 p / day for 1 month and 2p / day for 5 months on.
45984789|NCT00480870|Drug|Placebo|Placebo 1p / day for 1 month and 2 / day for 5 months on
45984790|NCT00457106|Drug|Paroxetine|
45984791|NCT00457106|Drug|Risperidone|
45984792|NCT00480948|Behavioral|Infant formula feeding (InFat™)|Infant formula with InFat™ oil (containing ~49% of C16:0 at sn-2 position), 24 wk
45984793|NCT00480948|Dietary Supplement|Control|Standard vegetable oil based infant formula
45984794|NCT00457145|Drug|Ranibizumab|
45984795|NCT00443469|Device|magnetic stimulation|SMS was delivered with a repetitive magnetic stimulator connected to a figure of eight coil capable of delivering a maximum output of 2 Tesla per pulse. The coil measured 90 mm in each wing and was centered over the surface landmark corresponding to the cauda equina region. SMS was performed with the patient lying comfortably in the prone position and a soft pillow supported the lower abdomen. The coil was placed flat over the back with the handle pointing cranially. Each patient on active treatment received 200 trains of 5 pulses delivered at 10 Hz, at an interval of 5 s between each train. As this was a pilot study, each only received 1000 pulses in a single session.
45984796|NCT00443469|Device|Magnetic Stimulation with tilted coil|The placebo arm consisted of 'sham' SMS delivered with the coil angled vertically and one of the wing edges in contact with the stimulation point. As this coil type allows maximum magnetic flux at the center of the intersection, we believe minimum or no stimulation was effected at the edge of the coil in contact with the patient. Stimulation parameters and duration were unchanged in this arm.
45984797|NCT00457184|Procedure|Blood tests|
45984798|NCT01240044|Procedure|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
45984799|NCT01240044|Procedure|Physical Therapy|In this group the newborns were first submitted to the mechanical vibrator applied over a diaper, on the chest of newborns for 5 min, as follows: 1min 1min right hemithorax and the left hemithorax, both previously, followed 30 seconds in the lateral aspect of each hemithorax; more than 1min in each hemithorax in the posterior region. The mechanical vibrator was performed subsequent to manual chest compression, using light hand pressure on the chest of newborns, respecting the compliance of the chest. The chest compression was applied for 2min 2min in the right hemithorax and left-sided chest, above, and 1 minute on each side, another 2 minutes on the back of each hemithorax, totaling 10 minutes of compression. Next to chest compression, mechanical vibration was applied for 5 min in the same topographical sequence described.
45984800|NCT00457223|Procedure|Amniotic membrane transplantation using fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®) in 16 eyes of 16 patients of FG group and continuous suture with nylon 10-0 in 16 eyes of 16 patients of SU group.
45984801|NCT00443508|Drug|adding Certican to therapy|
45984802|NCT00443508|Drug|reducing Tacrolimus|
45984803|NCT00457262|Procedure|soy consumption|
45984804|NCT03278418|Procedure|Tricuspid Valve Repair|It will be performed according to the surgeon preference
45984805|NCT03278418|Procedure|Left-sided valve surgery|It will be performed according to the surgeon preference
45984806|NCT00457340|Drug|Atorvastatin 80mg|
45984807|NCT03278379|Drug|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
45984808|NCT00457379|Behavioral|physical exercise|
45984809|NCT01240083|Device|Thetaburst Stimulation|Thetaburst stimulation: continuous TBS over the right DLPFC, followed by intermitted TBS over the left DLPFC, each with 50 Hz, together 1200 stimuli (80% motorthreshold)
45984810|NCT01240083|Device|High frequency rTMS|Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC (110% motor threshold)followed by 1000 stimuli of 10 Hz over the left DLPFC (110% motorthreshold)
45984811|NCT01240083|Device|Placebo Stimulation|Sham Stimulation (Sham coil):right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
45984812|NCT02956538|Drug|Thalidomide|
45984813|NCT02956538|Drug|placebo(for thalidomide)|sugar pill manufactured to mimic thalidomide 100mg tablet
45984814|NCT01240161|Drug|FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT|Each patient will have 0-3 or more FLT-PET brain scans.
45984815|NCT00457496|Behavioral|Cognitive, behavioral, exercise|Relaxation exercises once a day, visual feedback, exercises for neck and shoulder
45984816|NCT00443586|Behavioral|Developmental Screening|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at ages 12 and 24 months of age
45832729|NCT03714204|Behavioral|Transcendental Meditation technique|The TM technique is a simple mental procedure that is categorized in the automatic self-transcending category of meditation practices. It is automatic in that it does not involve any concentration or control. It allows the mental activity to settle down in a spontaneous and natural manner during a process called transcending, or going beyond, until it reaches a state beyond conscious thinking. Correspondingly, the body settles down to a deep state of rest which allows stress to dissolve and the nervous system to rejuvenate The effortless nature of the TM practice coupled with the vast research supporting its efficacy, its systematic standardized teaching program and the fact that it does not involve any belief or change in one's lifestyle made it the choice intervention for this research.
45832730|NCT03712878|Radiation|Total-Body Irradiation|Undergo TBI
45832731|NCT03712878|Procedure|Donor Lymphocyte Infusion|Given IV
45832732|NCT03712878|Drug|Cyclophosphamide|Given IV
45832733|NCT03712878|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
45832734|NCT03712878|Drug|Tacrolimus|Given IV
45832735|NCT03712878|Drug|Mycophenolate Mofetil|Given IV
45832736|NCT01677078|Device|Neuronavigation system|Neuronavigation
45832737|NCT01677078|Device|Standard localisation method|Manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')
45832738|NCT04763070|Drug|Ciprofloxacin Oral Product|The first stool sample will be taken before treatment and the second one will be taken in day 5 to 7 after treatment initiation. Treatment includes ciprofloxacin tablet 500mg twice a day for 5 days.
45832739|NCT04763694|Device|Multifocal soft contact lenses|Myopic subjects wore multifocal soft contact lenses for 12 months
45832740|NCT04762914|Other|Prehabilitation|Prehabilitation is a multimodal and multidisciplinary person-centred perioperative approach involving supervised exercise training, nutritional education, management of polypharmacy and psychological advice.
45984817|NCT00443586|Behavioral|Screening plus Transportation|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
45984818|NCT00443586|Behavioral|Screening, Transport, Prenatal Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
45984819|NCT00443586|Behavioral|Screen, Transport, Prenatal/Inf Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
45984820|NCT00457574|Drug|GMX1777|
45984821|NCT00443625|Drug|SK3530|
45984822|NCT00457613|Drug|bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)|
45984823|NCT00481026|Device|transcranial direct current stimulation (tDCS)|tDCS
45984824|NCT00481026|Device|active tDCS|Active tDCS
45984825|NCT00457652|Drug|Rosuvastatin|7 day treatment rosuvastatin 20mg
45984826|NCT00443664|Device|EXTERNAL MICROPULSE DIODE LASER TRANSSCLERAL TRABECULOPLASTY|
45673145|NCT02161562|Drug|omalizumab|300mg omalizumab via sub-cutaneous injection once every 4 weeks
45984827|NCT00457769|Drug|Donepezil and self-generated memory training|Aricept 5 mg PO qd for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
45984828|NCT00457769|Drug|Donepezil and experimenter-administered memory training|Aricept 5 mg PO daily for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
45984829|NCT00481104|Drug|Tesofensine|
46083299|NCT02864576|Behavioral|Cognitive Remediation_Health Promotion|"Cognitive Remediation:~The REHACOP program consists of: Attention unit training sustained, selective, alternant and divided attention; Memory unit focusing on visual and verbal learning, recall and recognizing memory; Language unit including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit training cognitive planning, proverbs, analogies; and Social cognition unit exercising theory of mind, social reasoning and moral dilemmas.~Health Promotion:~12 weeks of health promotion sessions. These sessions will be carried out by a specialized/trained nurse."
45984830|NCT00457808|Drug|Rapamycin, sirolimus|
45673146|NCT01559116|Drug|tiotropium + olodaterol|low dose + one dose only
45984831|NCT00443742|Procedure|Validation|
45984832|NCT03278301|Device|Robotic-assisted PCI|The CorPath GRX is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
45984833|NCT00457925|Drug|GSK221149A|
45984834|NCT00481143|Drug|ICL670/Deferasirox|
45984835|NCT00457964|Drug|RAD001|5 and 10 mg/day or 30, 50, 70mg/week
45984836|NCT01240395|Behavioral|Mindfulness-based Cognitive Therapy (MBCT)|"MBCT is partly based on the mindfulness-based stress reduction program (MBSR), developed by Jon Kabat-Zinn and colleagues, and partly on cognitive therapy for depression, the latter influence particularly expressed through the aspect of decentering, meaning not accepting the content of thoughts as facts and not identifying with the thought. The MBCT programme in this study includes 2½ hours of training once a week for 9 weeks. In addition, participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course."
45984837|NCT00458042|Drug|treprostinil sodium|
45984838|NCT00458081|Drug|Rimonabant|20 mg once per day + slightly reduced calorie diet
45984839|NCT00458081|Drug|Placebo|placebo once per day + slightly reduced calorie diet
45984840|NCT00458120|Biological|rDEN1delta30|Live attenuated 10^3 dose of rDEN1delta30 vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN2/4delta30(ME) vaccines.
45984841|NCT00458120|Biological|rDEN2/4delta30(ME)|Live attenuated 10^3 dose of rDEN2/4delta30(ME) vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN1delta30 vaccines.
45984842|NCT00458120|Biological|Placebo to rDEN1delta30 or rDEN2/4delta30(ME)|Placebo vaccines for rDEN1delta30 and rDEN2/4delta30(ME)
45984843|NCT00481182|Drug|fosamprenavir + ritonavir + methadone|
45673147|NCT01559116|Drug|tiotropium|low dose
45673148|NCT01559116|Drug|olodaterol|one dose only
45673149|NCT01559116|Drug|tiotropium|high dose
45673150|NCT01559116|Drug|tiotropium + olodaterol|low dose + one dose only
45673151|NCT01559116|Drug|Placebo|placebo matching tiotropium+olodaterol FDC
45673152|NCT01559116|Device|Respimat|Respimat inhaler
45673153|NCT01574326|Drug|Placebo|Placebo for 0.8 g sachets of powder for oral suspension or 800 mg tablets
45673154|NCT01574326|Drug|Sevelamer carbonate|0.8 g sachets of powder for oral suspension or 800 mg tablets
45673155|NCT01574248|Drug|icatibant|Subcutaneous at time 0 and 6 hours
45673156|NCT01574248|Other|Placebo|Subcutaneous at time 0 and 6 hours
45673157|NCT04761094|Device|Insulin pump|Treatment with continuous subcutaneous insulin infusion
45984844|NCT00458159|Drug|CC-11006|Doses: 10mg, 15mg, 25mg, 35mg, & 50mg, taken once daily, orally.
45984845|NCT00443937|Drug|enteric-coated mycophenolate sodium|oral
45984846|NCT00443937|Drug|everolimus|oral
45984847|NCT00455780|Behavioral|Weight Loss Phase|Weight loss using CBT and meal replacements
45984848|NCT00455780|Behavioral|Continued CBT|Using CBT during weight loss maintenance
45984849|NCT00455780|Behavioral|reduced energy density education|Additional nutritional learning
45984850|NCT00455780|Behavioral|continued use of meal replacements|continued use of meal replacements during weight loss maintenance
45984851|NCT00458198|Behavioral|Integrated behavioral therapy (BT)|Participants in the BT condition will receive twenty 60-minute sessions over 24 weeks. Sessions will focus on graduated exposure to new speaking situations as the primary agent of anxiety reduction. Behavioral procedures will include systematic desensitization, shaping, and self-modeling procedures. Although a variety of exposure exercises will be routinely conducted in-session, any behavioral assignments will take place outside of session. Behavioral exercises will be implemented, as needed, in a modular fashion. For example, exercises may focus on speaking in-session to therapist, either at school or at home with others present. The therapist will be primarily responsible for developing the exposure parameters, but collaboration of parent, teacher, child will be emphasized increasingly over time. Reinforcement for attempts to complete assignments (contingency management program) will occur throughout treatment.
45984852|NCT00487929|Device|nasal CPAP|Nocturnal
45984853|NCT00487929|Device|Sham CPAP|Nocturnal
45984854|NCT00458315|Drug|Cisplatin|
45984855|NCT00458315|Drug|Paclitaxel|
45984856|NCT00458315|Drug|Gemcitabine|
45984857|NCT00458315|Drug|Avastin (Bevacizumab)|
45984858|NCT00443976|Drug|Aurora kinase inhibitor AT9283|The starting dose of AT9283 will be 1.5 mg/m2 given as a 24 hour IV infusion on Days 1 and 8 every three weeks.
45456688|NCT02290912|Behavioral|Health education program|"The intervention is a health education program including: informational website, experiential classes, custom smart phone or smart table application, wearable activity monitor, and informal coaching by student researchers to provide moral support for lifestyle behavioral change goals. Participants are not placed on any specific behavioral regimen but instead are encouraged to adopt healthier lifestyle behaviors per the evidence-based health education program, and to attend the experiential classes cafeteria style (i.e. based on their individual preferences)."
45673158|NCT01573624|Drug|FF/GSK573719|100/15.6
45673159|NCT01573624|Drug|FF/GSK573719|100/31.25
45832741|NCT03611556|Biological|oleclumab|Subjects will receive oleclumab with or without durvalumab and in combination with chemotherapy viz. gemcitabine and nab-paclitaxel or mFOLFOX (5FU, leucovorin and oxaliplatin) until disease progression
45832742|NCT03611556|Biological|durvalumab|Subjects will receive durvalumab with oleclumab and in combination with chemotherapy viz. gemcitabine and nab-paclitaxel or mFOLFOX (5FU, leucovorin and oxaliplatin) until disease progression
45673160|NCT01573624|Drug|FF/GSK573719|100/62.5
45673161|NCT01573624|Drug|FF/GSK573719|100/125
45673162|NCT01573624|Drug|FF/GSK573719|100/250
45673163|NCT01573624|Drug|FF|100
45832743|NCT03611556|Combination Product|gemcitabine|Subjects will receive gemcitabine in combination with nab-paclitaxel and with or without oleclumab and/or durvalumab until disease progression
45673164|NCT01573624|Drug|FF/VI|100/25
45673165|NCT01557946|Drug|citalopram|citalopram 20-40 mg daily
45832744|NCT03611556|Combination Product|nab-paclitaxel|Subjects will receive nab-paclitaxel in combination with gemcitabine and with or without oleclumab and/or durvalumab until disease progression
45832745|NCT03611556|Combination Product|oxaliplatin|Subjects will receive oxaliplatin (as part of modified FOLFOX) in combination with or without oleclumab and/or durvalumab until disease progression
45832746|NCT03611556|Combination Product|leucovorin|Subjects will receive leucovorin (as part of modified FOLFOX) in combination with or without oleclumab and/or durvalumab until disease progression
45984859|NCT00458354|Device|Spinal Sealant|Spinal Sealant System which will be sprayed over the stitches to close the opening in the dura.
45984860|NCT00458354|Procedure|Standard Methods of Closing of the Dura|Standard methods such as the closing of the dura with stitches.
45984861|NCT00444015|Drug|Erlotinib in combination with Dasatinib|6 Cycles @ 28 Days
45984862|NCT00444054|Behavioral|Very low carbohydrate diet (approximately 20 grams per day)|Very low carbohydrate diet for a duration of four weeks.
45673166|NCT01534078|Drug|Brentuximab Vedotin|2 doses administered 14 days apart; followed by combination therapy with AVD for 4-6 cycles; 1.2 mg/kg
45673167|NCT01534078|Drug|Adriamycin, vinblastine, and dacarbazine|Combination therapy with brentuximab for 4-6 cycles; 25 mg/m2 Adriamycin; 6 mg/m2 Vinblastine; 375 mg/m2 Dacarbazine
45673168|NCT03919942|Other|OxyFlower gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
45984863|NCT00458471|Device|Insertion of a urinary catheter coated with benign E. coli|
45984864|NCT00487968|Drug|eltrombopag|
45984865|NCT00458510|Drug|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|treatment of up to 4 episodes of pain per day
45984866|NCT00488007|Device|Hearing aids used : PHONAK Savia and Valeo|5 hours per day during the first 6 months (active or inactive upon randomization) 5 hours per day during the last 6 months (active)
45673169|NCT03919942|Other|Chlorhexidine gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal.
45673170|NCT03919942|Other|Placebo gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
46002279|NCT04013295|Other|Prize-linked savings|"Participants will be eligible for prizes based on the amount by which their account balance goes up in each period (e.g. for every 100 Ksh by which savings increases, participants get an entry into a lottery for monetary rewards where they have a small probability of winning a larger amount, or a larger probability of winning a smaller amount of money). This type of prize-linked savings intervention has been shown to promote savings in other settings.~Other intervention components may include education materials to explain how the prize-linked savings incentives work and that emphasize the potential benefits of saving money. Participants in the intervention group will be encouraged to have more consideration for their future health and economic status, as this may motivate them to save more money. They will also be encouraged to consider the opportunity and health cost of their expenditures on alcohol and transactional sex and not miss the opportunity to win prizes by saving money."
46002280|NCT04006665|Diagnostic Test|Lung Ultrasonography (Baseline)|Lung Ultrasonography will be performed prior to docking Robotic arms in basal three lung zones on both sides.
46002281|NCT04006665|Diagnostic Test|Lung Ultrasonography ( At the end of surgery)|Lung Ultrasonography will be performed after removal of Robotic arms and before extubation in basal three lung zones on both sides to assess degree of atelectasis.
46002282|NCT04003285|Drug|Placebo|ALLO 0 nM (placebo: loading dose, 4-hour infusion, taper)
45673171|NCT02185040|Drug|CC-220|0.3 mg oral capsules once every other day with or without food
46002283|NCT04003285|Drug|Allopregnanolone|ALLO 50 nM (lower dose ALLO: loading dose, 4 hour infusion, taper)
46002284|NCT04003285|Drug|Allopregnanolone|ALLO 150 nM (higher dose ALLO: loading dose, 4 hour infusion, taper)
46002285|NCT04000555|Drug|Oral Vancomycin|Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics
46083300|NCT04198142|Behavioral|Imagery Rehearsal Therapy|"The Imagery Rehearsal Therapy (IRT) intervention used in this study is a short version of the treatment, consisting of 1-2 sessions.~The protocol starts with a very brief explanation of the treatment. Then the patient will be guided through an imagery exercise. The next step is to choose a nightmare. This nightmare is then rescripted to a new narrative, which is in no way distressing to the patient anymore. Subsequently, the therapist will guide the patient through an imagery exercise with the new narrative. The new narrative is then either written down or recorded. Lastly, the therapist will explain to the patient, that he or she should rehearse the new narrative daily with imagery exercises."
46083301|NCT04198142|Behavioral|Treatment as Usual with dream diaries|Treatment as Usual means that patients in this arm will receive usual inpatient care. Additionally, they will keep a dream diary. It has been shown in previous studies that keeping a dream diary has a positive effect on nightmares.
46083302|NCT01890590|Device|CyberKnife|Stereotactic Body Radiation Therapy. 3 or 4 fractions of radiotherapy delivered by Cyberknife.
45673172|NCT02185040|Drug|CC-220|Subjects will receive 0.3 mg oral capsules every day with or without food
45832747|NCT03611556|Combination Product|5-FU|Subjects will receive a bolus of 5-FU followed by continuous 5-FU infusion (as part of modified FOLFOX) in combination with or without oleclumab and/or durvalumab until disease progression
45832748|NCT03828318|Other|Patient Activation Booklet and nursing support for patients with LARS|The LARS Patient-Centered Program will consist of an educational booklet and nursing support made available only to patients randomized to the intervention group.
45832749|NCT03609060|Drug|Dexamethasone|Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3 concomitant to induction and post remission chemotherapy in elderly patients with AML Induction
45832750|NCT04762992|Drug|subcutaneous Enoxaparin|Enoxaparin subcutaneous injections (40 mg, 4000 IU daily) starting immediately after the diagnosis of FGR, and until 36 weeks of gestation or 12 hours before delivery, whichever comes first.
45832751|NCT04762992|Other|standard of care|Obsteric standard of care.
45832752|NCT03706794|Behavioral|Clinical Decision Support Tool|Tailored education provided via a smartphone application.
45832753|NCT03706794|Behavioral|Headache Education|Non-tailored education provided via a smartphone application.
46083303|NCT05242406|Other|Expiratory muscle trainig|This exercise will be used to strengthen forced expiratory muscles.
46083304|NCT02783612|Other|glucose buddy application|
46083305|NCT02783378|Drug|Gaviscon Syrup|
46083306|NCT02783456|Procedure|Noise|The patient is exposed 30 min to the first sound pattern and during the renal hemodynamics will be measured. The following is a 1-hour break.
46083307|NCT02783456|Procedure|Silence|The patient is exposed 30 min to the second sound pattern and during the renal hemodynamics will be measured.
45832754|NCT03705234|Drug|Inclisiran|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
46002286|NCT04000555|Other|Placebo|Matched placebo twice a day prescribed for the duration of antibiotics
46002287|NCT03994822|Device|Mechanical Thrombectomy using the pRESET Thrombectomy device|Clot removal using the pRESET Thrombectomy device
46002288|NCT03994822|Device|Mechanical Thrombectomy using the Solitaire Revascularization Device|Clot removal using the Solitaire Revascularization Device
46002289|NCT03994393|Drug|Tremelimumab|"During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance."
45984867|NCT00458549|Dietary Supplement|omega-3 fatty acids|omega-3 fatty acids Oral 8g once a day for 21 days prior to (biopsy) surgery
45984868|NCT00458549|Procedure|biopsy|
45984869|NCT00458588|Other|physiologic testing|
45673173|NCT02185040|Drug|CC-220|CC-220 oral capsules 0.6 mg and 0.3 mg on alternating days with or without food
45984870|NCT00458588|Other|questionnaire administration|
45984871|NCT00458588|Procedure|breast imaging study|
45984872|NCT00458588|Procedure|dual x-ray absorptometry|
46083308|NCT02783534|Device|Verum acupuncture|"Participants allocated to VA group will receive traditional acupuncture treatment on the Guanyuan(RN 4), bilateral Sanyinjiao(SP 6), bilateral Zigong(EX-CA1), bilateral Xuehai(SP 10). Additional points will be chosen according to TCM syndrome differentiation constitution of patients. If patients with deficient syndrome, bilateral Zusanli (ST 36) will be included. If patients with sufficiency syndrome, bilateral Diji (SP 8) will be included. The NO.16 special type of acupuncture needle (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
45673174|NCT02185040|Drug|CC-220|CC-220 oral capsule 0.6 mg QD with or without food
45673175|NCT02185040|Drug|Placebo|Matching oral placebo daily
45673176|NCT02161406|Drug|Abatacept|Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks
45673177|NCT02161406|Drug|Placebo|125 mg of Placebo
45832755|NCT03705234|Drug|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
45832756|NCT03704766|Diagnostic Test|Synovial Alpha-defensin assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
45832757|NCT03704766|Diagnostic Test|Synovial Neutrophil elastase assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
45832758|NCT03704766|Diagnostic Test|Synovial lactate assay|Synovial Fluid (joint fluid) will be sent out to CD Diagnostics for this test.
45832759|NCT03704766|Diagnostic Test|Synovial C-reactive Protein (CRP)|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
45832760|NCT03704766|Diagnostic Test|Synovial Staphylococcus spp antigen panel|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
45832761|NCT03704766|Diagnostic Test|Synovial Candida spp antigen panel|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
46083309|NCT02783534|Device|Sham acupuncture|We use a non-insertive sham control produced by Asia-med Company in Germany-the streitberger placebo-needle. Sham points are described as follows: 1) 5 inch lateral to the seventh thoracic spine; 2) 5 inch lateral to the eighth thoracic spine; 3) 5 inch lateral to the ninth thoracic spine; and 4) 5 inch lateral to the tenth thoracic spine.
46083310|NCT02783534|Behavioral|Usual care|Patients in usual care group will not receive acupuncture treatment but enhance usual care by providing them with detailed information via propaganda booklets or the internet in the form of health education.
45673178|NCT02161016|Device|map3|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
45832762|NCT03704766|Diagnostic Test|Synovial Enterococcus faecalis assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
45832763|NCT03704766|Diagnostic Test|Synovial bacterial culture by BacT/Alert|The synovial fluid (joint fluid) sent to CD Diagnostics for testing will also be cultured to see if any organisms grow.
45984873|NCT00458588|Procedure|evaluation of cancer risk factors|
45984874|NCT00458588|Procedure|magnetic resonance imaging|
45984875|NCT00488046|Biological|H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)|Intranasal vaccine
45984876|NCT00444132|Drug|clopidogrel|
45984877|NCT03274037|Diagnostic Test|Device for mechanical excitation by pressure waves|"The IRM elastography technique, proven and patented in 2010 by the IR4M (Orsay, France), consists in characterizing by IRM induced waves in the human body in order to determine the mechanical properties Of the target organ.~The mechanical waves will be induced by pressure waves guided at the mouth of the subject elongated in the MRI and consisting of a function generator at a frequency between 5 Hz and 500 Hz, linear amplifier , An electromechanical transducer, a waveguide whose length is adapted to the chosen excitation frequency, an antibacterial filter and a disposable mouthpiece~The MRI imager Achieva 1.5 T MRI (Philips Healthcare, Best, the Netherlands) and the SIGNA Architect GEM 3.0T (GE medical systems, LLC, USA) system will be used to measure brain tissue displacement fields."
45984878|NCT02956733|Procedure|dermotaxis|In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.
45984879|NCT02956733|Procedure|loop suture technique|The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 & 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
45984880|NCT00458744|Drug|talotrexin|
45984881|NCT00458744|Procedure|chemotherapy|
45984882|NCT00444171|Procedure|insulin infusion rate controled by computer algorithm|
45984883|NCT00444171|Procedure|insulin infusion rate guided by in-house glucose management protocol|
45984884|NCT00458900|Drug|IV and enteral administration of moxifloxacin|IV and enteral administration of moxifloxacin
45984885|NCT00488124|Drug|somatropin (Genotropin® treatment)|0,035 mg /kg bodyweight of Somatropin per day given by subcutaneous injections through an injection device (GenotropinPEN)
45984886|NCT00459017|Device|Portable blood pressure wrist manometer|
45984887|NCT00444210|Device|DL6049 (injectable poly-L-lactic acid)|
45984888|NCT03273959|Other|Exercise protocol|Protocol of exercises performed in hospital admission in children and adolescents with cystic fibrosis in the exacerbation phase.
45984889|NCT00488163|Drug|Atomoxetine|Dose escalation from 40 mg to 50 mg of Atomoxetine active treatment.
45984890|NCT00459173|Drug|rimonabant (SR141716)|
45984891|NCT00444249|Procedure|White Alcon IOL|Implantation of white Alcon IOL
45984892|NCT00444249|Procedure|Yellow Alcon IOL|Implantation of yellow Alcon IOL
45984893|NCT00444249|Procedure|White Hoya IOL|Implantation of white Hoya IOL
46083311|NCT01631084|Other|JADE|"Patients are booked for reviews led by the doctor-nurse-HCA team every 2-4 months, preferably in a setting different from the busy clinics in order to facilitate group education and promote peer support.~Between each follow-up visit, the nurse or HCA will contact the patient by phone or email to remind them of the appointments (e.g. medical FU visit or laboratory tests), adhere to medications and healthy lifestyles, perform self glucose monitoring and provide psychosocial support, as appropriate."
45832764|NCT03704766|Diagnostic Test|Synovial Cell count + differential (CBC)|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
45984894|NCT00444249|Procedure|Yellow Hoya IOL|Implantation of yellow Hoya IOL
45984895|NCT00459212|Drug|GTI-2040|Given IV
45984896|NCT00459212|Procedure|pharmacological study|Correlative study
45984897|NCT00459212|Procedure|laboratory biomarker analysis|Correlative study
45984898|NCT00459329|Behavioral|Program to Encourage Active, Rewarding Lives (PEARL)|"Eight 50-minute in-home sessions over 19 weeks with a masters-level social work counselor using Problem Solving Therapy (PST).~PST is a skills-enhancing behavioral depression treatment based on the assumption that an accumulation of problems in living cause and maintain depressive symptoms, and through systematically identifying and addressing these problems, patients achieve decreased depressive symptoms. Counselors also help participants to increase social and physical activities and to incorporate pleasant activities into patients' lives.~Counselors provide education and monitoring for antidepressant use, and work with the participant's physician and PEARL psychiatrist to recommend initiating or adjusting antidepressant medications. The PHQ-9 is administered at each session to track depression change.~After 19 weeks, counselors will maintain monthly telephone calls with participants, administering the PHQ-9 and assessing PST success."
45984899|NCT00488241|Device|Zarzenda|Topically applied daily for 2 weeks
45984900|NCT00459407|Dietary Supplement|defined green tea catechin extract|Given orally
45984901|NCT00459407|Drug|placebo|Given orally
45984902|NCT00459407|Other|immunohistochemistry staining method|Correlative studies
46083312|NCT01631084|Other|DIAMOND|Patients randomized to the DIAMOND group will receive usual care after the initial baseline comprehensive assessment (CA), with repeat CA at 12 and 24 months.
46083313|NCT02785094|Behavioral|Observation|Observation of Participants' behaviour
45832765|NCT03704766|Diagnostic Test|Synovial Gram Stain|This will be performed by CD Diagnostics if any organisms are present in the synovial fluid.
45832766|NCT03704766|Diagnostic Test|Synovial Leukocyte Esterase Test Strips|These test strips will be tested at the hospital where the patient is being seen, a few drops of synovial fluid will be used on the strip.
45832767|NCT03704766|Diagnostic Test|Synovial PCR for Kingella kingae|In participants < 8 years old, a sample of synovial fluid will be tested for Kingella kingae using PCR.
45832768|NCT03704766|Diagnostic Test|Serum Cell count + differential (CBC)|A blood test performed at the hospital.
45984903|NCT00459407|Other|immunoenzyme technique|Correlative studies
45984904|NCT00459407|Other|laboratory biomarker analysis|Correlative studies
45984905|NCT00459407|Procedure|biopsy|Undergo biopsy
45984906|NCT00459407|Other|mass spectrometry|Correlative studies
45984907|NCT00459407|Other|high performance liquid chromatography|Correlative studies
45984908|NCT03278262|Drug|Aflibercept (Eylea, BAY86-5321)|Treatment-naïve eyes with neovascularization AMD (Age-related Macular Degeneration), with the indication to be treated with Aflibercept. One and/or two eyes per patient.
45984909|NCT03273803|Diagnostic Test|Heart sound recording using smartphone application|Heart sound recording and analysis using android smartphones (Samsung Galaxy S5, Galaxy S6, and LG G3)
45984910|NCT00488280|Behavioral|Locomotor Training|Task-specific practice of walking with assistance from trainers using body weight support and treadmill followed by training over ground, 5x/week, approximately 1.5 hours/day
45984911|NCT00459446|Drug|MS-325 Injection (Gadofosveset Trisodium)|
45984912|NCT04698044|Diagnostic Test|Hospital Anxiety Depression Scale|HADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnessesHADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnesses The 4-point Likert type scale, which consists of 14 items, has 2 subscales. Each of the HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) subscales has 7 items. The score given for each question varies between 0 and 3. A high score indicates a high level of anxiety and depression. The responses given to the questions are given certain scores, and as a result, a score of 0-7 refers to a normal level, 8-10 to a level at the limit and 11 and above to a high level (abnormal level).
45984913|NCT00459485|Dietary Supplement|zinc sulfate|20 or 10 mg zinc per day for 3 weeks
45984914|NCT00459485|Dietary Supplement|Placebo|Daily placebo for 3 weeks
46083314|NCT02785874|Drug|Statin|Divide HCC patients into two groups under randomization, one is with Statin and the other is without Statin to verify whether Statin could prolong disease-free survival
46083315|NCT05338814|Other|scapular corrective exercises|40 minutes each, three times a week for six weeks
45984915|NCT00459524|Behavioral|Questionnaire|Questionnaires taking about 30 minutes to complete.
45984916|NCT00459524|Behavioral|Neurocognitive Testing|Neurocognitive testing lasting 30 minutes. Patients will be asked to complete certain tasks that require the use of their hands, eyes, and ears.
45984917|NCT03278145|Genetic|Genetic analyses|Patients treated at the Institute of Hematology and Pediatric Oncology (IHOPe), a department of Prof. Y. Bertrand, for acute leukemia (LA) at the time of diagnosis initial, or relapse, after obtaining signed parental consent. The same patients will benefit from a new sample at the time of their remission balance. Analyses for this research will be made from bone marrow aspiration samples performed for diagnosis and treatment of these patients. The medical team will investigate whether RDs, in particular DCC, are expressed in acute leukemia cells at the time of diagnosis or relapse and then in these patients at the time of the remission balance. This research will be both qualitative and quantitative. Next, investigators will characterize the existence and then the level of expression of the ligand specific for DCC, Netrin-1, in these same leukemic cells, at the time of diagnosis / relapse and remission.
45984918|NCT00459563|Drug|Vitamin D|200,000 IU once weekly for 3 weeks (600,000 IU total dose)
45984919|NCT00459563|Drug|calcitriol|calcitriol 0.5 mcg twice a day for 1 week
45984920|NCT00459563|Drug|Placebo|Placebo once a week for 3 weeks
45984921|NCT01242384|Device|Device: Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
45984922|NCT00488397|Other|In-vitro testing|This is an in-vitro study thus only one group in the study and there is no intervention treatment nor procedure involved in this study.
45984923|NCT00459641|Drug|I-040302|doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
45984924|NCT00459641|Other|Standard of Care|Bone marrow aspirate or steroids
46083316|NCT05338814|Other|conventional neck exercises|40 minutes each, three times a week for six weeks
46083317|NCT05334524|Other|kinesiotaping with combined chain exercises|"3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension.~Combined chain exercises will apply with 10 secs hold with 10 repetitions which will include quadriceps setting, SLR, full arc extension, cycling in the air, wall slides and step-up and step-down exercises"
46083318|NCT05334524|Other|kinesiotaping|"3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension"
46083319|NCT04231994|Device|TPE|singular Therapeutic Plasma Exchange using fresh frozen Plasma as replacement fluid
46083320|NCT02786030|Behavioral|Outreach education training|Printed copies of the patient management tool (PMT) and outreach education training
46083321|NCT02786030|Behavioral|No outreach education training|Printed copies of the patient management tool (PMT) without outreach education training
46083322|NCT04197206|Other|costotransverse block|patient controlled analgesia devices with tramadol
45984925|NCT00488436|Drug|Antithymocyte globulin|
45984926|NCT00488436|Drug|Cyclosporine|
46083323|NCT02863796|Device|WhiteSwell System|To promote movement of interstitial fluid to the intravascular space to allow for the body to remove it, in conjunction with a diuresis regimen.
46083324|NCT05237726|Drug|Enoxaparin 40 mg q24 hours|Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
45832769|NCT03704766|Diagnostic Test|Serum erythrocyte sedimentation rate (ESR)|A blood test performed at the hospital.
46083325|NCT05237726|Drug|Enoxaparin 30 mg q12 hours|Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
46083326|NCT05237726|Drug|Unfractionated heparin 5000 U q8 hours|Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
46083327|NCT04138056|Biological|RSVPreF3 formulation 3|One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.
46083328|NCT04138056|Biological|RSVPreF3 formulation 2|One dose of RSVPreF3 formulation 2 vaccine administered intramuscularly in the left arm.
46083329|NCT04138056|Biological|Boostrix-ex-US|One dose of the dTpa (Ex-US formulation) vaccine administered intramuscularly in the right arm.
46083330|NCT04138056|Biological|Boostrix-US|One dose of the dTpa vaccine (US formulation) administered intramuscularly in the right arm.
45832770|NCT03704766|Diagnostic Test|Serum C-reactive Protein (CRP)|A blood test performed at the hospital.
45832771|NCT03704766|Diagnostic Test|Serum D-dimer|A blood test performed at the hospital.
45832772|NCT03704766|Diagnostic Test|Serum Procalcitonin|A blood test performed at the hospital.
45832773|NCT03704766|Diagnostic Test|Blood Cultures|Blood will be cultured at the hospital to see if any organisms grow.
45984927|NCT00459680|Device|Laser acupoint treatment|Laser
46083331|NCT04138056|Drug|Placebo|One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.
45832774|NCT03704766|Diagnostic Test|Optional blood testing per standard of care (ASO, anti-strep, ANA, anti-DS-DNA, HLA-B27, RF, Lyme and other inflammatory/ rheumatologic markers )|In patients with suspected inflammation/infection, there are other blood tests which may be standard of care and used for diagnosis.
45984928|NCT00459680|Procedure|Acupuncture|Needle acupuncture on ST36 and LI11.
45984929|NCT03277950|Other|Virtual reality with feedback|Individuals with stroke play game with correction of movement.
45984930|NCT03277950|Other|Virtual reality without feedback|Individuals with stroke play game without correction of movement.
45984931|NCT03277950|Other|Healthy|Healthy do not play game
45984932|NCT00488553|Behavioral|Questionnaire|Questions about cancer risk factors, medical history, and family history of cancer.
45984933|NCT00459719|Drug|Tacrolimus modified-release|oral
46083332|NCT02782988|Other|olfactory tests, otoacoustic emissions (OAE)|Two series of olfactory tests will be performed : 1) the first one with simple odorants and 2) the second one with binary mixtures of odorants. These tests of nasal chemosensory performance are based on pen-like odor dispensing devices (Sniffin' Sticks, Burghardt, Wedel, Germany) and measure odor discrimination ability of young children in less than 15 min.
46083333|NCT02783144|Procedure|TAP Block and Dexamethasone|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and dexamethasone is added to levopubivacaine
46083334|NCT02783144|Other|TAP Block and saline|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and saline is added to levopubivacaine
45673179|NCT01573000|Biological|Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)|Subjects will be randomized to receive tositumomab and iodine-131 tositumomab (Arm A) or unlabeled tositumomab (Arm B). Subjects randomized to receive unlabeled tositumomab may crossover and receive radiolabeled Iodine-131 tositumomab following progression of their lymphoma. Response in both arms will be assessed at 7 weeks, 13 weeks, and then at 3-monthly intervals for up to 2 years.
45832775|NCT03826992|Drug|Vyxeos|Vyxeos Dose: daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered via intravenous infusion over 90 minutes on Days 1, 3, and 5.
45832776|NCT03826992|Drug|Venetoclax|"Venetoclax Dose:~Dose Level 0 - weight based daily dosing for 21 days~Dose Level -1 - weight based daily dosing for 14 days~Dose Level -2- weight based daily dosing for 10 days~Dose Level -3- weight based daily dosing for 7 days"
45673180|NCT01572922|Device|R2*-UTE|Ultra short echo time (UTE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2*-UTE scans will be performed.
45832777|NCT00004092|Biological|filgrastim|Given IV or subcutaneously
45832778|NCT00004092|Drug|carboplatin|Given IV
45832779|NCT00004092|Drug|cyclophosphamide|Given IV
45832780|NCT00004092|Drug|doxorubicin hydrochloride|Given IV
45832781|NCT00004092|Drug|paclitaxel|Given IV
45832782|NCT00004092|Drug|thiotepa|Given IV
45984934|NCT00459719|Drug|Prograf|oral
45984935|NCT00495144|Drug|TH-302|
46083335|NCT02783144|Drug|TAP Block and Dexamethasone i.v.|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and dexamethasone is injected intravenously
46083336|NCT04230044|Drug|Perampanel|Perampanel tablets.
46083337|NCT05219240|Other|20Lighter Program|Visceral Adiposity-Focused Anti-Obesity Telehealth Program
45832783|NCT00004092|Procedure|peripheral blood stem cell transplantation|Patients receive autologous peripheral blood stem cells
45832784|NCT00004146|Radiation|radiation therapy|Undergo radiotherapy
45984936|NCT00459758|Device|Hans unit|
45984937|NCT00495183|Drug|caffeine|caffeine from 300 to 1200 mg/d or 15 mg/kg/d, divided in 3 doses per day.
45984938|NCT00495183|Drug|Biperiden|Biperiden 2-4 mg/d, divided in 2 doses per day.
45984939|NCT00495183|Drug|Placebo|Placebo
45984940|NCT00459797|Device|Conventional (reusable) Glidescope|
45984941|NCT00459797|Device|Single-use Glidescope videolaryngoscope|
45984942|NCT00488670|Drug|Escitalopram|See Detailed Description.
45984943|NCT00459836|Drug|PR-104|
45984944|NCT00459836|Drug|docetaxel|
45984945|NCT00459836|Drug|gemcitabine hydrochloride|
45984946|NCT00459836|Other|laboratory biomarker analysis|
45984947|NCT00459836|Other|pharmacological study|
45984948|NCT00495261|Behavioral|Mindfulness-enhanced cognitive behavioural therapy (MCBT)|a variation of cognitive behavioural therapy (CBT)
45984949|NCT00495261|Behavioral|relaxation-enhanced cognitive behavioural therapy (RCBT)|a variation of cognitive behavioural therapy (CBT)
45984950|NCT00459914|Device|cpap treatment during sleep|CPAP
45984951|NCT00488709|Drug|Topotecan|
45984952|NCT00488709|Drug|Fludarabine|
45984953|NCT00488709|Drug|Cytarabine|
45984954|NCT00459992|Drug|Betahistine Hydrochloride|
45984955|NCT00495339|Drug|Levofloxacin|500-1000 mg once a day daily per os with combination of drugs.
45984956|NCT00460148|Drug|Ropinirole|
45456689|NCT01220635|Behavioral|Positive Thoughts and Actions Program|Students in the skills group will attend a 12-session (50 minutes each), 12-week program with 4-6 other students. The skills group will take place at school during school hours. Parents in the skill group will be asked to participate in two parent group workshops to take place at their child's school or other participating middle school (2-hours each). In addition, the skill group leader will conduct two individual family meetings with the student and parent(50 minutes each).
45984957|NCT01242423|Device|extracorporeal shockwave therapy|ESWT is administered as a one-off treatment on the wound surfaces within 24 hours of a 2nd degree burn trauma and immediately after an intraoperative skin graft excision procedure. A defocused sound head is orthogradely applied to the burn wound or the donor site. 100 impulses/cm² is administered at 20 seconds per cm². The defocused sound head is placed on the wound along with a sterile gel (Lavaseptgel®, Octenidingel®) and a sterile protection foil. The shockwaves deployed are not at an energy density that is painful. This single application of ESWT is followed by routine dressing using Mepitel® in combination with Polyhexanid/Octenidin®.
45984958|NCT00460187|Device|Percutaneous intervention of the carotid artery|
45984959|NCT00460226|Drug|lamotrigine|lamotrigine treatment for 12weeks
45984960|NCT00495378|Drug|epoetin alfa|
45984961|NCT00460304|Drug|pramlintide|
45984962|NCT00460304|Procedure|continuous glucose monitoring|
45984963|NCT01242462|Procedure|Conventional Pressure Controlled SIMV|Initial ventilatory settings per clinical physician's discretion-tcCO2 & Saturation (SAT) monitoring. Adjust vent setting approximately every 15min with a goal of: SAT 88-95%, tcCO2 45-55, pH greater than or equal to 7.25. Once goals reached, ventilatory strategy will crossed over to other intervention.
45984964|NCT01242462|Other|Mid-frequency Ventilation|Ventilatory parameters include: max possible rate between 61-150 breaths/min; Shortest inspiration time (Ti) and expiration time (Te), but completed inspiration and expiration on pulmonary graphics. Stepwise weaning of PIP by 1 cm H20 to maintain tcCO2 at baseline. If measured PEEP - delivered PEEP generated is >/= to 1cm H2O, PEEP is reduced to baseline value. Adjustments will be made to PIP, then rate for pH and CO2 changes; FiO2, then PIP for FiO2 changes. Target goal blood gas parameters (same as baseline) Saturations 88-95%; tcCO2 45-55 mmHG; pH >/= 7.25. Maximum period of 2 hours. When goals met, or 2 hours in period, reverted back to SIMV at baseline settings
45984965|NCT00460343|Other|extensive implementation programme|experimental pharmacists follow an extensive implementation programme. They attend two interactive half a day educational meetings tailored to individual needs: one at start of the intervention, and one in May or September 2007. Special attention is given to multiprofessional cooperation with general practitioners and nurse practitioners. Additionally, guided by their own project planning pharmacists receive three or more telephone calls, both as a reminder, feedback, and in order to investigate whether they need any more help.
45984966|NCT00460343|Other|control|pharmacists only receive a written manual with instructions to implement the patient compliance intervention.
45984967|NCT00495417|Biological|AFFITOPE AD01|s.c. injection
45984968|NCT00495417|Biological|AFFITOPE AD01 adjuvanted|s.c. injection
45984969|NCT00460382|Drug|raltegravir potassium|400 mg twice a day
45984970|NCT00460382|Drug|darunavir/ritonavir|2 pills of 300 mg twice a day
45984971|NCT00460382|Drug|etravirine|2 pills of 100 mg twice a day
45673181|NCT01572922|Device|R2*-GRE|Gradient-echo (GRE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2*-UTE scans will be performed.
45456690|NCT01220635|Behavioral|Individual Support Program|Students will be individually interviewed (60-90 minutes) at school to review areas of stress and support. The health professional conducting the interview will reinforce the student's strengths, and provide connections to sources of help from caring adults at home and at school. Parents will be called following the assessment to help the family locate appropriate resources if needed (e.g., tutoring resources, school counselor).
45832785|NCT00004146|Drug|carboxyamidotriazole|Given orally
45832786|NCT00004146|Other|pharmacological study|Correlative studies
45832787|NCT00004500|Drug|Lucinactant|Lucinactant suspension was administered as 10 mg total phospholipid (TPL)/mL, by bronchoalveolar lavage within 90 minutes of randomization. The dose was determined based on the infant's body weight such that the total dose was 16 mL/kg for each of the 2 lavage procedures and 32 mL/kg overall. Infants received 2 doses of lucinactant. Each dose consisted of separate lavage procedures for each lung within 15 minutes (up to 60 minutes) of each other.
45832788|NCT00004500|Other|Standard Care|The Standard Care (SC) group received therapies including, but not limited to, the use of oxygen, controlled mechanical ventilation (CMV), sedation, paralysis, vasopressors, and/or alkalinization. The use of adjunctive therapies (namely: high frequency oscillatory ventilation, high frequency jet ventilation, bolus surfactant, inhaled nitric oxide, extra-corporeal membrane oxygenation, or systemic corticosteroids) were not included in SC
45832789|NCT03825744|Drug|Hetrombopag Olamine+Standard Therapy|once daily
45832790|NCT03825744|Drug|Placebo+Standard Therapy|once daily
45984972|NCT00460382|Drug|Optimized background regimen|NRTIs and or enfuvirtide (investigator choice)
45984973|NCT01242501|Behavioral|60 Minute HIV/STI risk reduction counseling.Single 60 min Social Cognitive Theory-based counseling.|Single session risk reduction counseling delivered in STI clinic settings in South Africa.
45984974|NCT01242501|Behavioral|20-Min education session|Patients receive a single 20 min education session for STI/HIV informationSingle brief HIV/STI education only session for men and women receiving sexually transmitted infection clinic services in South Africa. Includes only brief educational information on sexual risks for HIV infection in a single face-to-face counseling session.
45984975|NCT00460460|Drug|AZD4877|
45984976|NCT01242579|Drug|Maraviroc/Dapivirine Gel|Vaginal gel containing 2.5g - Maraviroc 0.1%, Dapivirine 0.05%
45984977|NCT01242579|Drug|Dapivirine Vaginal Gel|Dapivirine vaginal gel containing 2.5g
45984978|NCT01242579|Drug|Maraviroc Vaginal Gel|Maraviroc vaginal gel containing 2.5g
45984979|NCT01242579|Drug|Matching Placebo Gel|Matching placebo gel containing 2.5g
45984980|NCT00460499|Drug|A IV Insulin drip|These patients will receive 100units of insulin in 100ml of saline intravenously to keep blood glucose between 120-180mg/dl.
45984981|NCT00460499|Drug|B Low Dose GIK|These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl
45984982|NCT00460499|Drug|C High Dose GIK|This group will receive D20W+160units IV insulin to keep blood sugar between 120-180mg/dl
45984983|NCT00495573|Drug|acyclovir|400 mg acyclovir, orally three times a day for 5 days
45984984|NCT00460538|Dietary Supplement|Lectranal|"Dosage form: capsule~1: Dosage: 2 capsule Frequency and duration: 2 times daily over the 6 weeks"
45456691|NCT04525430|Other|childbirth education|"The 1st Session: General information about labor: Factors affecting labor, early signs of labor, signs of the start of labor, steps of labor, and procedures applied during labor.~The 2nd Session: Methods of coping with birth contractions: Breathing exercises, relaxation exercises, massage, changing position, music, cold/warm application, focus, and walking."
45456692|NCT04525430|Other|childbirth education and was subjected to a birth plan|In the birth plan created by the researchers, the pregnant women considered the process from the start of labor to the end of labor and marked the expectation from and preferences about this process on the birth plan.
45456693|NCT03521752|Other|Specific Exercise Program|4 weeks of exercise classes, 2 to 3 times a week for a total of 10 sessions. Classes last approximately 40 minutes. The sessions included balance training, motor strength, endurance and flexibility. The training sessions were divided into warm-up, main activity and finally relaxation.
45984985|NCT00460538|Dietary Supplement|placebo|Dosage form: capsule 2: Dosage: 2 capsules Frequency and duration: 2 times daily over the 6 weeks
45984986|NCT00488787|Drug|intranasal ketamine|low dose
45984987|NCT00488787|Drug|intranasal ketamine|medium dose
45984988|NCT00488787|Drug|intranasal ketamine|high dose
45984989|NCT00488787|Drug|placebo|placebo
45984990|NCT00460616|Drug|Cabergoline|According with our previous studies, in the patients with microprolactinoma and in those with non-tumoral hyperprolactinemia, cabergoline treatment was administered orally at a starting dose of 0.25 mg twice weekly for the first two weeks and then 0.5 mg twice weekly. After 2 months of treatment, dose adjustment was carried out every 2 months on the basis of serum PRL suppression.
45984991|NCT00495651|Drug|Antiretroviral medications|Antiretroviral medications initiation at any time during the trial if at least one WHO-recommended criterion for starting ART is observed.
45984992|NCT00495651|Drug|Antiretroviral medications+Isoniazid prophylaxis|"Antiretroviral initiation at any time during the trial if at least one 2009 WHO-recommended criterion for starting ART is observed.~Isoniazid prophylaxis:300 mg of INH once a day before breakfast for six months, starting one month after study inclusion"
45984993|NCT00495651|Drug|Antiretroviral medications|Early ART initiation on the day of inclusion, before reaching the current WHO criteria
45984994|NCT00495651|Drug|Antiretroviral medications+Isoniazid prophylaxis|"Early Antiretroviral medications initiation on the day of inclusion, before reaching the current WHO criteria~Isoniazid prophylaxis: 300 mg of INH once a day before breakfast for six months, starting one month after study inclusion"
45456694|NCT03932851|Other|IVF-ET|HBV-infected pregnant women and non-HBV-infected pregnant women underwent IVF operation
45456695|NCT03090282|Procedure|mechanical treatment(mainly scaling and root planing), periodontal surgery(if indicated), implant placement.|The investigators shall follow the regular procedure to these patients.
45832791|NCT03606330|Diagnostic Test|Cardiac imaging tests|"2D transthoracic echocardiography~128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).~Shear stress evaluation via computational fluid dynamics.~Intracoronary imaging techniques: IVUS and OCT."
45832792|NCT03606330|Diagnostic Test|Venous blood sample collection|Venous blood sample collection during the acute coronary event for evaluation of serum levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour necrosis factor, hs-cTnI, NTproBNP
45832793|NCT03605628|Other|measuring tape|measurement of change in abdominal wall length [cm] during neuromuscular block with a measuring tape.
45984995|NCT00460694|Biological|infusion of allogeneic CIK cells|infusion of allogeneic CIK cells at graded doses
45984996|NCT01244841|Procedure|fast post MI care|All post MI investigations, treatment, start of medication, information are performed within 3 days after admittance.
45984997|NCT00460733|Drug|Risedronate sodium|Actonel® 35 mg (risedronate sodium) and 1000 mg of calcium and 400 UI of Vitamine D3
45984998|NCT00460733|Drug|Calcium & Vitamine D3|1000 mg of calcium and 400 UI of Vitamine D3
45984999|NCT00488904|Dietary Supplement|supportan|2 sip feed pr. day
45985000|NCT00488904|Dietary Supplement|supportan placebo|2 sip feed pr. day
45985001|NCT00460850|Drug|peginterferon alfa-2a (40KD) [PEGASYS]|180 micrograms sc weekly for 48 weeks
45985002|NCT00495690|Drug|Oral zinc gluconate (5 mg elemental)|Each infant in the study received placebo or 5 mg of elemental zinc (1 RDA) as zinc acetate syrup once daily from 4 weeks of age till 6 months of age.
45985003|NCT00460889|Procedure|donor nephrectomy|The objective of this protocol is to look at the outcomes of laparoscopic donor nephrectomy performed by using hand assisted (HA)or entirely laparoscopic (LDN) surgical techniques. To define the advantages of each technique, we will use records of patients who underwent laparoscopic live kidney donation with HALDN.
45985004|NCT00495729|Drug|SB-649868|Subjects will receive SB-649868 5 mg, 25 mg tablets orally 1 hour prior to simvastatin administration.
45985005|NCT00495729|Drug|Placebo|Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.
45985006|NCT00495729|Drug|Simvastatin|Subjects will receive Simvastatin 10 mg tablets orally.
45985007|NCT00460928|Drug|intravenous immune globulin (IVIG)|
45985008|NCT00495768|Behavioral|Group Training|Participants will be trained in techniques that are useful to cope with possible side effects of treatment, such as: keeping a journal (expressive writing), breathing exercises, cognitive behavioral therapy, mindfulness meditation, and exercise.
45985009|NCT00460967|Device|Rheopheresis|8 rheopheresis treatments over 10 wks.
45985010|NCT00460967|Device|Rheopheresis|Sham treatment
45985011|NCT00488943|Device|AAA Endovascular Bifurcated Stent-Graft|Treatment of Abdominal Aortic Aneurysm with a Zenith Endovascular Bifurcated Stent-Graft.
45985012|NCT00461084|Drug|BIAXIN (CLARITHROMYCIN)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
45985013|NCT00461084|Drug|Biaxin (clarithromycin)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
45985014|NCT00495807|Behavioral|No Words|Without any words was given during pain management
45985015|NCT00495807|Behavioral|Positive words|Positive words was given to PCA pain management patients at different time point,i.e. 3h, 6h, 12h and 18h.
45985016|NCT00495807|Behavioral|Partially Negative Words|Partially negative words was given during PCA pain management at different time point,i.e. 3h, 6h, 12h and 18h.
45985017|NCT00495807|Behavioral|Totally Negative Words|Totally negative words was given during PCA pain management at different time points, i.e. 3h, 6h, 12h and 18h
45985018|NCT00461162|Behavioral|Internet DSMP|Internet Dyspnea Self-management Program (i-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. I-DSMP participants will receive their accessing the modules through the website and participating in weekly online group chat sessions with the research nurse and other participants.
45832794|NCT03605628|Other|neuromuscular block|Measurement of the time course of the neuromuscular block: neuromuscular transmission is measured by assessment of the post tetanic count and the train of four ratio using acceleromyography (TOF Watch SX™, Essex Pharma GmbH, Munich, Germany) at the right adductor pollicis muscle with transcutaneous Ag/AgCl electrodes (electrocardiogram electrodes; Ambu Inc., MD 21060 USA);
45985019|NCT00461162|Behavioral|Face-to-Face Dyspnea Self-management|Face-to-Face Dyspnea Self-management Program (f-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. F-DMSP participants will attend face-to-face group education sessions. The f-DSMP participants will be provide with a hard copy of the education modules and will participate in six 1-hour group sessions for a period of 6 weeks.
45985020|NCT00461162|Behavioral|Attention Control|6 Monthly general health education classes and biweekly telephone calls from a health educator.
45985021|NCT00495846|Drug|Octreotide-LAR, Lanreotide Autogel|Octreotide-LAR intramuscular, dose of 30 mg every 28 days to increase up to 60 mg; lanreotide autogel 120 mg deep subcutaneous every 28 days for 3 months then uptitrated according with the protocol.
45985022|NCT00495846|Other|Locoregional treatments|
45985023|NCT00461201|Procedure|Nurse practitioner care of patients|
45985024|NCT04697316|Device|Transcranial Direct Current Stimulation|To stimulate the left DLPFC, the anode electrode will be placed over F3 and the cathode will be placed over F4. Each stimulation will be applied for 20 min at 2mA intensity.
45985025|NCT04697316|Device|Sham|For the sham treatment, stimulation will be stopped after 30 seconds. Current will be renewed five times throughout the session for 2 seconds each time, to mimic the tDCS stimulation.
45985026|NCT00495924|Procedure|Pancreatic resection (PD)|PD is a standard therapeutic surgical procedure. No additional interventions are performed.
46083338|NCT05260320|Other|Standardized Anesthetic Course from Premedication to Induction|See information in intervention group description
45673182|NCT01572922|Procedure|Liver biopsy|Indications for liver biopsy include, but are not limited, to the need to quantify liver tissue iron and the need to obtain histopathological information of the liver tissue. Liver biopsies will only be performed if clinically indicated and will be done only once per patient. The technique to be used is coaxial percutaneous (transcapsular) technique; however, a coaxial transjugular technique may be performed in subjects with increased bleeding diathesis, since it is associated with less hemorrhagic risk. Healthy volunteers will not undergo liver biopsy.
45985027|NCT00461279|Behavioral|Cognitive Behavior Therapy|Reframing and understanding cognitions of depression
45985028|NCT00461279|Behavioral|Interpersonal Psychotherapy|Established psychotherapy for depression
46083339|NCT02723058|Behavioral|ICMHM|ICMHM participants receive a collaborative care model adapted to include an engagement interview, attention to co-morbid conditions, and attention to basic needs.
46083340|NCT02783222|Drug|Nab-paclitaxel|comparison of different dosages of drug
46083341|NCT02718456|Behavioral|Expedited CD4 testing|
46083342|NCT02718456|Behavioral|Supplemental peer counseling|
45673183|NCT01572844|Device|Fractionated Carbon Dioxide (FCO2) Laser|At each treatment visit, a 2 X 2 cm (+/- 1 cm) area of the target calcinosis lesions will be treated with one pass of the Candela QuadraLase (TM) FCO2 laser. Patients will receive a total of 8-10 treatments over a 6 month period.
45832795|NCT03605628|Other|Surgical rating score|"assessment of operating conditions by means of a standardized score: surgical rating score:~extremely poor conditions~poor conditions~acceptable conditions~good conditions~optimal conditions"
45985029|NCT04697082|Procedure|Open surgery|Each patient entered the operating room, and after the administration of general anaesthesia, the patient was placed in the prone position. Then, the buttocks were stretched to the lateral sides using adhesive bands to remove the disease area. The sacrococcygeal region was cleaned and disinfected with 10% povidone iodine. After covering the area around the region, the sinus tract was examined by using a thin-steel cane. The length and wealth of the cavity were noted. Then, the sinus tract was removed. The depth of the cavity was noted. Then, 50 cc of 0.9% saline solution (SS) was taken into a syringe and applied to the cavity until it filled the whole space, allowing the cavity volume to be measured accurately. The measurement was performed by subtracting the remaining saline-solution volume in the syringe from the whole syringe volume, which was 50 cc.
45985030|NCT04697082|Procedure|Minimal invasive surgery|In the operating room, after the patient was placed in the prone position, the region was removed by stretching the buttocks with adhesive bands and cleaning the area with 10% povidone iodine. The largest pit was excised, and hairs in the cavity were removed with forceps. Then, the whole cavity was curetted meticulously and irrigated with SS. After haemostasis, the cavity volume was measured
45985031|NCT04697082|Other|Platelet rich plasma administration|Platelet rich plasma (PRP) was administered by filling the whole space from the lateral side of the cavity. After the first implementation of PRP, the second one was applied at 48 hours. Until that time, the dressing was not uncovered. PRP was applied on the 3rd, 4th and 5th days postoperatively.
45985032|NCT00105482|Drug|Naltrexone|Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
45985033|NCT00105482|Drug|Transdermal nicotine replacement|Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
45985034|NCT00105482|Behavioral|Behavioral counseling|Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.
45985035|NCT00495963|Procedure|bronchoaleolar lavage|
45985036|NCT00495963|Procedure|Bronchoscopy|
45985037|NCT00489021|Procedure|sub-acute hospitalization|
46083343|NCT04231604|Behavioral|A Lust for Life|A Lust for Life is a universal school-based multi-component programme whose target is to build well-being and emotional resilience in adolescents. The programme was informed by evidence-based psychological approaches including mindfulness, cognitive behaviour therapy and positive psychology. It is delivered in six weekly lessons by the adolescents' school teacher and involves classroom discussions, videos, classroom activities and homework assignments.
46083344|NCT04231604|Behavioral|Waiting list control|Control group placed on a twelve-week waiting list.
46083345|NCT02718222|Device|Post-partum IUD|The PPIUD intervention aims to address the postpartum contraceptive needs of women by training community midwives, health workers, doctors and delivery unit staff in postpartum IUD counselling and insertion.
46083346|NCT02782910|Device|Smartphone-Based Ambulatory Assessment, Feedback via physician|Participants in the experimental condition SBAA+ will be contacted by their treating physician, once the predefined threshold for Smartphone activity is exceeded.
45832796|NCT03701724|Device|Systematic maintenance rTMS|Same parameters as the initial course (session of 8,5 minutes, at 1 Hz, on the right dorsolateral prefrontal cortex (DLPFC) targeting with either neuronavigation or the Beam). The frequency is : 2 sessions / week during 1 month, then 1 session / week during 2 months and finally 1 session every 2 weeks during 8 months.
45832797|NCT03701724|Device|rTMS course in case of relapse|Same parameters as the initial course. The frequency is the same as the initial course: one daily session on 5 consecutive working days from Monday to Friday for at least 20 to 30 sessions over 4 to 6 weeks.
45832798|NCT03701724|Device|sham rTMS|The sham stimulation consists of the identical rTMS procedure at the identical location using a commercial figure-eight sham coil. However, it does not produce the identical tactile sensation. A local electrical stimulation will be delivered with two disposable Electromyogram (EMG) electrodes using a transcutaneous electrical nerve stimulation (TENS) Stimulator.
45832799|NCT00745992|Other|Blood drawn (lab data)|"Check drug blood level 3-5 days after start of drug, treatment failure, occurence of adverse events, or clinically indicated~Check genetic polymorphism of liver enzyme 3-5 days after start of drug"
45832800|NCT03696030|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given HER2-CAR T cells via intraventricular administration
45985038|NCT00496002|Drug|Clevudine|
45673184|NCT01572844|Drug|Sodium thiosulfate|Following treatment with FCO2 laser, 4 ml of 5% Sodium Thiosulfate solution will be applied to the treatment site only. Subjects will receive a total of 8-10 treatments over a 6 month period.
45673185|NCT01557400|Drug|Ataluren|Oral powder for suspension
45673186|NCT04122118|Other|Medical Chart Review|Review of medical chart
45673187|NCT04122118|Other|Educational Intervention|Receive pharmacist-led education
45673188|NCT04122118|Other|Survey Administration|Ancillary studies
45985039|NCT00496002|Drug|Adefovir|
45985040|NCT03273725|Other|Dental examination including taking a saliva sample.|The main focus of the dental examination is enamel defects and caries. Saliva samples (stimulated) will also be taken.
45985041|NCT03273686|Procedure|Discharge the NG tube during the surgery|Discharge the NG tube during the surgery.
45985042|NCT00489060|Procedure|Cryoablation and External Beam Radiation|
45985043|NCT03273647|Radiation|radiation|"A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes."
45985044|NCT00489099|Biological|V232 Modified Process Hepatitis B Vaccine: Lot A|
45985045|NCT00489099|Biological|V232 Modified Process Hepatitis B Vaccine: Lot B|
45985046|NCT00489099|Biological|V232 Modified Process Hepatitis B Vaccine: Lot C|
45985047|NCT00489099|Biological|V232 Current Process Hepatitis B Vaccine|
45985048|NCT03273569|Procedure|PDI-UC protocol|Preplacental delivery intervention for uterine conservation protocol starts after delivery of the fetus during Cesarean delivery and consists of delayed cord clamping, intramyometrial injection of vasopressin, subdecidual injection of saline, ligation of the uterine arteries, multiple 8 compression sutures, followed by delivery of the placenta, application of pressure and interrupted sutures if needed
45985049|NCT00496158|Drug|Clevudine|
45985050|NCT00496158|Drug|Adefovir|
45985051|NCT03273530|Other|Integrated Supported Employment|vocational assessment followed by job placement and on-going work-related social skills revision and reinforcement
45985052|NCT00489138|Drug|Ertapenem|1g a day by drip of 30 min
45456696|NCT02290990|Behavioral|"Imaginative Distention technique"|ID is an Imaginative relaxation technique which combines physical and mental relaxation. ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning. Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
45832801|NCT03825198|Procedure|Erector spinae plane block|Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle
45832802|NCT03825198|Drug|Levobupivacaine 0,25%|20 ml levobupivacaine 0,25% used for the infiltration between the transverse process and the erector spinal muscle
45832803|NCT03825198|Procedure|spine fusion|fusion of lumbar vertebral body on 1 or two levels
45832804|NCT03825198|Drug|NaCL 0,9%|20 ml solution used for the infiltration between the transverse process and th erector spinal muscle
45832805|NCT03825198|Drug|Sufentanil|opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
45832806|NCT03825198|Drug|propofol|induction agent for general anaesthesia ( 2-3 mg/kg)
45832807|NCT03825198|Drug|Rocuronium Bromide|muscle relaxant used during general anaesthesia ( 0,5 mg/kg)
45832808|NCT03825198|Drug|sevoflurane|inhalation aesthetic used for the maintenance of general anaesthesia
45832809|NCT03825198|Drug|paracetamol|postoperative drug for analgesia ( 1 gram 4/day)
45832810|NCT03825198|Drug|Ketorolac|non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
45832811|NCT03825198|Drug|morphine pca|postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml
45985053|NCT00461396|Drug|Interferon-1beta (Betaseron, BAY86-5046)|Male and females, 18 to 50 years of age, after a first clinical demyelinating event suggestive of multiple sclerosis or with onset of RRMS within the past 12 months
45985054|NCT00489177|Device|A|QuickOpt intra-cardiac electrogram optimization
45985055|NCT00489177|Device|B|Single optimization in initial month post-implant
45985056|NCT00461435|Procedure|hyperbaric oxygen therapy|
45985057|NCT01327651|Drug|Daily dosing|A fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate.
45985058|NCT01327651|Drug|Time-driven dosing|TDF/FTC twice weekly with a post-exposure dose
45985059|NCT01327651|Drug|Event-driven dosing|TDF/FTC as needed with a post exposure dose
45985060|NCT00496236|Drug|TNFerade biologic|
45985061|NCT00461474|Behavioral|Shoulder strengthening exercises|
45985062|NCT00461474|Behavioral|Movement Optimization|
45985063|NCT00496275|Drug|Zactima (ZD6474)|
45985064|NCT00496275|Drug|Vinorelbine plus cisplatin|
45985065|NCT00496275|Drug|Gemcitabine plus cisplatin|
45985066|NCT03273491|Behavioral|daily self-weighing|Participants are provided with a wifi-enabled scale and asked to weigh themselves daily, first thing in the morning.
45985067|NCT03273491|Behavioral|daily temperature-taking|Participants are provided with a wifi-enabled thermometer and asked to take their temperature daily, first thing in the morning.
45985068|NCT04329169|Other|Virtual Implant Planning|According to the virtual implant plan, a CAD/CAM tooth supported surgical guide will be fabricated to place the dental implant with a fully guided surgical protocol.The surgical guide will be manufactured from a photopolymer resin using a 3D printing machine. A hex- shaped metal sleeve will be inserted in the surgical guide with the flat surface located buccally so that it will help in orientation of the implant hex during the implant placement.
45985069|NCT00461669|Procedure|ultrasound examination of the hip|
45985070|NCT00489294|Drug|Syntropin|
45985071|NCT00591604|Drug|Vitamin D|Vitamin D, 50,000IU,once weekly for 8 weeks, then every other week for 4 weeks
45985072|NCT00591643|Procedure|Imaging, Adrenal acans|The patient will be given 5 drops of saturated solution of potassium iodide daily for 2 days prior to the study and will continue for 5 to 7 days later to minimize the radiation dose to the thyroid gland. One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes. Anterior and posterior images of the adrenal area will be obtained 72 and 96 hours later. Additional images will be made if indicated. Each image would require 30 minutes carried out in the nuclear medicine laboratory. To verify the exact location of the adrenal glands, renal scan with 99m Tc DTPA or Mag 3 (routine nuclear medicine radiopharmaceuticals) will also be obtained whenever indicated. In some patients, dexamethasone suppression will be carried out to improve the specificity of NP 59 diagnosis for autonomous hormonal secretions by the adrenal tumors.
45985073|NCT00591643|Radiation|(NP-59)|One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes.
45985074|NCT00461747|Drug|VBMCP/VBAD/Velcade|"VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalan, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20."
45985075|NCT00461747|Drug|Thalidomide/Dexamethasone|"Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity < grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.~Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days"
45985076|NCT00461747|Drug|Velcade/Thalidomide/Dexamethasone|"Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is < grade 2, the dose increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.~Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.~Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days"
45985077|NCT00489333|Drug|ProAlgaZyme|
45985078|NCT04328935|Behavioral|WET|The manual is based on established CBT interventions in trauma such as exposure. In short, the treatment is that the participant should be able to approach their intrusive memories and by doing this repeatedly, the memory will give rise to less discomfort.
45985079|NCT00496314|Device|e2TM Cervical Cell Collector|
45985080|NCT00461825|Drug|Cyclosporin A: C0: 75-125ng/ml-dose adapted in the 3 groups|
45832812|NCT03825198|Drug|Dexamethasone|drug given during general anaesthesia to prevent postoperative nausea
45985081|NCT00461825|Drug|Group A: CsA + Azathioprine(1 to 2 mg/kg/day)|
45985082|NCT00461825|Drug|Group B: CsA + CellCept(500 mg x 2/day)|
45985083|NCT00461825|Drug|Group C: CsAm|
45985084|NCT04433026|Diagnostic Test|N terminal pro B type natriuretic peptide (NTproBNP), D-Dimer, and serum Tropinin - I|Biomarkers detected in the serum of patients
45985085|NCT00489372|Drug|Se-methyl-seleno-L-cysteine|Given orally
45985086|NCT00489372|Other|placebo|Given orally
45985087|NCT00489372|Other|pharmacological study|Correlative studies
45985088|NCT00489372|Other|laboratory biomarker analysis|Correlative studies
45985089|NCT04431739|Device|MRI including conventional MRI, DWI with multiple ADC values|The utility of apparent diffusion coefficient obtained in diffusion-weighted MR imaging for the differentiation between benign and malignant vertebral lesions
45985090|NCT04430686|Other|Questionaires|Any validated functional rating scale, such as the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) or the ALSFRS-Revised (if available)
45456697|NCT01223989|Other|hypocaloric diet balanced + nutrition education + ruled physical activity|
45985091|NCT00461864|Procedure|ultrasound examination of the hip|
45985092|NCT04430023|Other|epidemiological and demographic characteristics|Patients' age, gender, BMI, medical history, symptoms at admission (e.g., cough, fever, myalgia, gastrointestinal symptoms, headache), concomitant diseases (e.g., diabetes mellitus, hypertension, chronic lung disease, cerebrovascular disease, kidney disease, heart disease, cancer, smoking
45985093|NCT00496353|Drug|MK2461|MK2461 treatment, bid, 28-day
45985094|NCT04429477|Device|Cerebral compliance and hemodynamics monitoring|Noninvasive devices are been used to assess cerebral circulation and compliance.
45832813|NCT03825198|Drug|Morphine|loading dose morhine 0,1 mg/kg at the end of surgery
45832814|NCT03824106|Other|Control|Participants randomized to the control arm will not receive any of the Frailty Management Interventions.
45832815|NCT03824106|Behavioral|Group Exercise|A recent meta-analysis suggests 180 min/week of exercise (with a high challenge to balance) is most effective for fall prevention. Combined strength and endurance training performed at a moderate weekly frequency (i.e., two times per week) may promote marked gains on muscle hypertrophy, strength and power gains in frail older adults. Balance training is a key component of successful exercise programs for vulnerable older adults.
45985095|NCT00461318|Procedure|Individual placement and support (vocational rehabilitation)|
45985096|NCT04428229|Other|Optic nerve sheath diameter|Pre and post-trendelenburg optic nerve sheath diameter will be measured
45985097|NCT00461903|Drug|Perindopril|Perindopril 4 mg or matching placebo , 1 tablet administrated once daily for the first 2 weeks. If tolarable, dosage increased to 8mg/day until the end of the study (
45985098|NCT00591682|Drug|MSX-122|"Dosage form = capsule~Starting Dose (First Patient Cohort - Dose Level 1) = 50 mg taken orally once daily, 7 days per week for 4 weeks (total of 28 days), followed immediately by a second course of 28 days with identical dosage form and schedule. (Each patient in each cohort treated for a minimum of 56 days, unless obviated by toxicity.)~If there is no evidence of toxicity at the current dose level, then the dose of MSX-122 will be increased by 100% for the next patient cohort.~If a grade 1-2 toxicity is observed, then the dose will be increased by 50% for the next patient cohort.~If a grade 3 toxicity (non-dose limiting toxicity) is observed then the dose will be increased by 25% for the next patient cohort."
45985099|NCT00496392|Drug|Nasal fentanyl|Breakthrough pain in patients with breast or prostate cancer
45985100|NCT04329013|Other|Left lateral Position during intervention|Left lateral position during EGD
45985101|NCT04329013|Other|Prone Position during intervention|Prone position during EGD
45985102|NCT02893696|Other|Various sitting time|Various sitting time
45985103|NCT00496509|Drug|ZD6474 (Zactima) 100mg|
45985104|NCT00496509|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR)|
45985105|NCT00496509|Procedure|Biomarker Draws|
45985106|NCT00496509|Drug|ZD6474 (Zactima) 300mg|
45985107|NCT04136197|Diagnostic Test|Manual palpation for incidence determination|The patients are positioned in a sitting and prone lying posture. Trigger points are discrete, local, hypersensitive spots located in a taut band of muscles. Palpation of the trigger point will cause elicitation pain over the affected area and radiation of pain toward a zone of reference and a local twitch response.
45985108|NCT00496548|Procedure|Fecal calprotectin|Fecal calprotectin levels obtained and compared to urinary PGE-M and serum C-reactive protein (CRP) levels.
45985109|NCT00496548|Procedure|Urinary PGE-M Level|Urinary PGE-M level obtained and compared to fecal calprotectin and serum CRP levels.
45456698|NCT01239550|Drug|Detemir|"Subjects randomized to insulin detemir treatment group will receive the basal insulin in a 3 mL. Flex Pen® containing 300 units of insulin. insulin detemir once daily administered with the evening meal (dinner) or at bedtime as add-on to their oral antihyperglycemia (see inclusion/exclusion criteria) meds throughout the 24 week treatment period. The goal of insulin therapy is to achieve near normoglycemia with a low rate of hypoglycaemic episodes.~Insulin injections will be given subcutaneously preferably in the thigh or abdomen."
45985110|NCT04135222|Diagnostic Test|Measurements of gingiva thickness|Measurements were performed at upper canines and incisors in thirty periodontally healthy patients. The CBCT/CAD technology along with the PDIP software were used to measure crestal (CGT in mm ), supracrestal (SGT in mm) and free gingival thickness (FGT in mm ) as well as alveolar crest-gingival margin (AC-GM) and cemento-enamel junction (AC-CEJ) distance and the TLPAC localized 2, 4 and 8mm apically than the edge of the AC. Width of keratinized tissue (WKT) were measured using a periodontal probe. For each patient, the periodontal phenotype was evaluated on the basis of coronal width/length (CW/CL in percentages) ratio of both upper central incisors. For each tooth, the gingival phenotype was assessed on the basis of the GT measurement( in mm).
45985111|NCT02893618|Drug|Diazoxide choline controlled-release tablet|QD tablet formulation of choline salt of diazoxide
45985112|NCT03273452|Drug|Chidamide|Chidamide will be given orally 30mg,biw, along with PET regimen (prednisone 100mg,po,qd,d1-5; etoposide 100mg,po,qd,d1-5; thalidomide 100mg,po,qn,d1-14;)
45985113|NCT00496665|Drug|Vandetanib|Taken orally once a day in 28-day cycles (the dose will vary)
45985114|NCT00496665|Drug|Cyclophosphamide|Metronic Chemotherapy: Low dose pills taken every day of each 28-day cycle
45985115|NCT00496665|Drug|Methotrexate|Metronic Chemotherapy: low dose pills taken on days 1 and 2 of each week
45985116|NCT04423003|Procedure|Endoscopic intervention|All endoscopic interventions in COVID-19 positive tested patients were included
45985117|NCT03273374|Device|Intraoperative radiation therapy (IORT)|IORT with 50 kV x-ray will be delivered during surgery as a single dose of 10 Gy at 5 millimeter depths of the tumor bed, followed by gemcitabine chemotherapy (1000 mg/m2) every 4 weeks for a total of 6 cycles
45985118|NCT00496704|Drug|capecitabine|
45985119|NCT00496704|Drug|gemcitabine hydrochloride|
45985120|NCT00496704|Drug|oxaliplatin|
45985121|NCT04420117|Other|Perioperative assessment of physical capacity|Evaluation of physical capacity with the Short Physical Performance Battery (SPPB) questionaire
45985122|NCT04698005|Dietary Supplement|25g Ketone monoester without added salts|oral supplementation of ketone monoester
45985123|NCT04698005|Other|Placebo|The patients will receive a placebo drink (drinking water) of equivalent volume (3x 65ml)
45985124|NCT00496743|Device|Low-dose total skin electron beam therapy (4 Gy)|
45985125|NCT04419064|Diagnostic Test|Point of care ultrasound|Tracheal and lung ultrasonography
45985126|NCT04418050|Procedure|Shoulder arthroplasty|Surgery consisting in replacement of gleno-humeral joint by a shoulder prosthesis
45985127|NCT04417426|Other|Survey|A survey was conducted, which was filled voluntarily and completely anonymously; the demographic data asked were: sex, age, religion, and semester. We included questions about their sexual behavior: if they considered having enough knowledge about STDs, sexual intercourse onset, number of sexual partners in the last year, the total number of sexual partners, sexual orientation, the use of condoms and contraceptives, exclusive or non-exclusive sexual intercourses, frequency of STDs screening, and then if they know the location of STD testing centers.
45985128|NCT02893852|Behavioral|standard CO-OP Approach|The CO-OP protocol originally developed by Mandich and Polatajko (2004) comprises 12 sessions. The therapist teaches the participants a global cognitive strategy: GOAL - PLAN - DO - CHECK. The participants use the global strategy and cooperate to learn specific strategies to solve each task performance breakdown identified through Dynamic Performance Analyses (DPA). The therapist uses DPA at pre-intervention and throughout the sessions and mediational techniques to guide participants to use GOAL-PLAN-DO-CHECK to discover specific strategies to solve performance problems and to support generalization and transfer of skills.
45985129|NCT02893852|Behavioral|standard CO-OP Approach plus coaching parents|CO-OP Approach with parents coaching groups will include an addition of four extra coaching groups sessions for parents to provide additional information to supplement their knowledge on CO-OP (how to use GOAL-PLAN-DO-CHECK at home; how to use dynamic performance analysis to support their children's' performance solutions; to talk about their experiences with their children at home).
45985130|NCT00496821|Drug|ALN-RSV01|
45985131|NCT00461942|Drug|Green Tea Polyphenols (EGCG/ECG)|
45456699|NCT01353326|Device|Cormet|Cementless hip resurfacing system
45456700|NCT01353326|Device|Conserve|Cemented hip resurfacing system
45985132|NCT04416022|Diagnostic Test|Ultrasound examination|Women that are planned for labour induction, will undergo a routine ultrasound examination prior to the initiation of the induction process.
46083347|NCT05081232|Device|MLG (Multi-Layered Perinatal Issue Allograft) Allograft|"MLG allografts contains more than 450 bioactive proteins including growth factors and cytokines known to modulate inflammation and promote tissue healing.~MLG is supplied as sterile sheets having dimensions of 2cm x 2cm and a thickness of approximately 0.8-1.0mm thick.~Participants receiving MLG will have it placed around the neurovascular bundle. Placement of the graft should not take over 5 minutes of time to impact overall surgical time length significantly."
45673189|NCT04121806|Other|UC intervention diet|The treatment diet has been designed based on the literature with the goal of influencing the biodiversity and density of the microbiome. All food through the duration of the 8 week dietary intervention period of the study will be provided to the treatment arm study participants.
45673190|NCT01533922|Drug|Placebo|placebo matching tiotropium + olodaterol FDC
45673191|NCT01533922|Drug|Tiotropium|Tiotropium 5 mcg once daily
46083348|NCT02689856|Drug|Hydrocortisone acetate and lidocaine hydrochloride|Hydrocortisone and lidocaine in combination
46083349|NCT02689856|Drug|Placebo control|Vehicle cream alone
46083350|NCT02689856|Drug|Hydrocortisone acetate|hydrocortisone alone
46083351|NCT02689856|Drug|Lidocaine hydrochloride|lidocaine alone
45673192|NCT01533922|Drug|Olodaterol|Olodaterol 5 mcg once daily
45673193|NCT01533922|Drug|tiotropium + olodaterol|tiotropium + olodaterol 5 mcg once daily
45985133|NCT02893774|Other|quality of life assessment|"All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis.~Those assessment will use standardized quality of life questionnaire :~QLQ-C30~SWLS (Satisfaction with Life Scale)~PTGI (Post-Traumatic Growth Inventory)~HADS (Hospital Anxiety and Depression Scale)~Brief COPE~MHLCS (Multidimensional Health Locus of Control Scale)"
45985134|NCT00462059|Behavioral|Treatment|
45985135|NCT00591877|Procedure|Acupuncture|"Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation.~The acupoints that will be used are:~ST-36: 3 finger breadths inferior to lower edge of patella between tibialis anterior muscle and the tibia, 1 finger breadth lateral to the anterior crest of the tibia.~PC-6: 2 finger breadths proximal to and in the middle of the most distal transverse crease of the wrist, between the tendons of palmaris longus and flexor carpi radialis.~CV-12: 4 finger breadths superior to the umbilicus."
45985136|NCT00591877|Procedure|Sham Acupuncture|"The acupoints for SAC are:~LI-4 : adjacent to and at the middle of the radial side of the 2nd metacarpal bone, at the same level as the end of the crease when the thumb and index fingers approximate.~GB-32: on the lateral aspect of the thigh 5 finger breadths proximal to the popliteal crease, 2 finger breadths inferior to GB31.~UB -15: 1.5 finger breadths lateral to the midline of the spine on a level between the 5 th and the 6 th thoracic vertebrae."
45985137|NCT00591877|Other|Yoga|The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
45985138|NCT00591916|Drug|Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]|Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).
45985139|NCT00591916|Procedure|Blood sample|Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery
45985140|NCT00591916|Procedure|Biopsy|Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.
45985141|NCT00496938|Device|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
45985142|NCT04413916|Diagnostic Test|miRNA expression|Analysis of expression of selected miRNAs (miR-29c, miR-126, miR-146a, miR-150, miR-155, miR-223) by qPCR.
45985143|NCT00462098|Device|hyperbaric oxygen|40 sessions of 100% oxygen at 2 atmospheres of pressure for 2 hours each
45985144|NCT00462098|Device|non-treated control group|no change from routine care, no HBO
45985145|NCT00462137|Procedure|Sleep Studies|
45985146|NCT04413487|Other|Extra echocardiogram|Subjects will receive an extra echocardiogram after 2 cycles of chemotherapy
45985147|NCT04412902|Drug|adjuvant therapy|Adjuvant chemotherapy and/or radiotherapy
45985148|NCT00462176|Procedure|multidisciplinary laparoscopy|Laparoscopic segmental bowel resection for deep infiltrating colorectal endometriosis performed by an experienced colorectal surgeon.
45985149|NCT00462176|Other|Questionnaires|All 45 patients were asked to complete the Oxford Endometriosis Quality of Life questionnaire, a sexual activity questionnaire, visual analogue scales (VAS) for dysmenorroe, chronic pelvic pain and deep dyspareunia, and to answer questions about medication and fertility, to compare their status before surgery and at the moment of the evaluation (December 2008).
45985150|NCT02893969|Behavioral|Physical Activity|After 72 hours of full physical rest patients will gradually reintroduce physical activity into their daily routine.
45985151|NCT02893969|Behavioral|Rest|Complete physical rest until asymptomatic.
45985152|NCT04328896|Other|CGM-Tele-monitoring|"Baseline Visit-Visit 0~Obtain informed consent~Administer questionnaires~Measure A1C~Start study Dexcom CGM device (those already on CGM will change to the study device).~The patient will be signed into Tidepool using a research code name and email.~Visit 1-2 weeks~14 days worth of data will be downloaded from the patient's CGM device.~Systems will be checked to be sure they are functioning~Remote monitoring program will be activated.~Telemedicine procedure will be discussed with patient; emergency contact numbers will be obtained in case patient cannot be reached~Visit 2-14 weeks~Administer questionnaires~Measure A1C.~Collect CGM data and compare to baseline~Testing and Assessments:~Continuous glucose monitoring~Tidepool cloud upload~HbA1c~T1D REDEEM diabetes distress questionnaire~Hypoglycemia Fear Survey~Assessment of Severe Hypoglycemia and Diabetic Ketoacidosis"
45985153|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004
45985154|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004
45456701|NCT01220713|Procedure|Hyperbaric Oxygen Therapy|1.5 atm abs oxygen equivalent of 75% oxygen (balance 25% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
45985155|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005
45985156|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005
45985157|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
45985158|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
45985159|NCT04410640|Other|survey|Members chosen for this study group are general surgery residents. A quintet with stations composed of normal pancreaticobiliary anatomy, common bile duct tumor, stony cholecystitis, pancreatic head cancer and cholelithiasis was assembled for the study. Each station contained CT, 3D-STL images and 1:1 solid models of cases. Each imaging method associated with the scenarios of the quintet is observed by the residents of the study. An explanatory assessment measure is being used as data collection method where the perception of each imaging method is being evaluated based on their effectiveness in problem identification as well as their efficiency in diverse diagnosis and pre-surgery organization. Participants' perception of residency training was evaluated with a multi-entry survey. The focus of the survey, which was applied by our team was by domains, self determined decision-making, diverse diagnosis, academic scholarship, and scientific appraisal.
45985160|NCT00462254|Drug|ROZEREM|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 4-11).
45985161|NCT00462254|Drug|Ramelteon|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 15-22).
45985162|NCT00496977|Procedure|annual CT screening|
45985163|NCT04410172|Diagnostic Test|Mirror and prope|Mirror and probe will be used for each patient. Mirrors for proper visualization especially for maxillary teeth, explorers will be used to aid in tactile sensation.
45456702|NCT01220713|Procedure|Hyperbaric Oxygen Therapy|2.0 atm abs oxygen equivalent of 100% oxygen (no nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
45832816|NCT03824106|Combination Product|Nutrition and Medication review|"Nutrition review: Conduct nutritional screening flow and review any questions, provide some additional counseling/coaching. Protein supplements will be provided to all participants unless contraindicated.~Medication review: Review/update current medication list and forward the list and medical history to the consultant study pharmacist."
45985164|NCT04328545|Device|Anodal tDCS on DLPFC|Participants will receive anodal tDCS on the left DLPFC for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
45985165|NCT04328545|Device|Anodal tDCS on M1|Participants will receive anodal tDCS on the left M1 for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
45985166|NCT04328545|Device|Sham tDCS|Participants will receive sham tDCS. The anode will be placed on the left DLPFC and the cathode on the over the right supra orbital area. The electrodes are 25cm², There will be a ram up and down of 30 seconds each, after the ramp up the current will be turned off.
45985167|NCT00462371|Device|Insulin pump (CSII)|
45985168|NCT00497016|Drug|atorvastatin 80 mg|
45985169|NCT04406701|Other|Ceres|This will be a self-administered survey on eating habits and their relationship to coping strategies and economic level among nurses.
45985170|NCT00462410|Other|counseling intervention|
45985171|NCT00462410|Procedure|psychosocial assessment and care|
45985172|NCT02893891|Procedure|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy involves removing most of the stomach, limiting the amount of food the patient can eat.
45985173|NCT02893891|Procedure|Laparoscopic gastric plication|Laparoscopic gastric plication involves sewing one or more large folds in the stomach. During the laparoscopic gastric plication, the stomach volume is reduced about 70%, which makes the stomach able to hold less and helps the patient eat less.
45985174|NCT02893891|Procedure|Intragastric balloon|The introduction of the balloon is non-invasive as it is inserted endoscopically (down the oesophagus). The balloon is then filled inside the stomach with a dyed physiological solution, which reduces the volume of the stomach.
45456703|NCT01220713|Procedure|Hyperbaric Oxygen Therapy|sham--air equivalent of 10.5% oxygen (balance 89.5% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
45456704|NCT03524014|Other|Only advice for diagnosis and prevention|Only advice for diagnosis and prevention
45456705|NCT01210534|Other|No intervention|No intervention
45673194|NCT01533922|Drug|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + Olodaterol 5 mcg once daily
45673195|NCT01533922|Device|Respimat|Respimat inhaler
45832817|NCT03824106|Dietary Supplement|Protein Supplement|Protein supplementation will be provided.
45832818|NCT03824106|Dietary Supplement|Vitamin D|1000 IU of oral vitamin D
45832819|NCT03598998|Biological|Pembrolizumab|Given IV
45832820|NCT03598998|Drug|Pralatrexate|Given IV
45985175|NCT02893891|Device|Intragastric balloon implantation|Intragastric balloons (End-Ball, Medsil) will be implanted in the patients with morbid obesity.
45985176|NCT04405414|Other|Form|Data regarding the use of CBD will be collected: the form, the route of administration, the effects sought and felt, the method of obtaining, the impact on other drugs and/or substances use and the drug liking of CBD
45985177|NCT00462566|Device|motor cortex stimulation|
45985178|NCT00497094|Device|carotid artery stenting|Using retrograde transfemoral access an overview aortic angiogram is established. A stiff wire is then placed in the external carotid or distal common carotid artery to introduce a long hydrophilic sheath into the common carotid artery. The stenosis is then crossed with a Filter wire. For stent implantation Monorail Carotid Wallstents or the Monorail Nitinol Stent of Boston Scientific are used. Road map or overlay technique with a magnification of 20 to 28 inch is used to localize the stenosis during the procedure. Finally a control angiogram is performed to ensure correct placement of the stent. After successful completion of the procedure, the arterial access site is closed using a standard closure device.
45985179|NCT00222872|Drug|Parathyroid Hormone-related Protein|PTHrP(1-36) starting at 500 micrograms, then increasing by 125 micrograms up to a maximum of 1,500 micrograms.
45985180|NCT00222872|Drug|Placebo|Placebo drug via subcutaneous injection in single blinded fashion daily for 3 weeks
45985181|NCT00497172|Device|CYPHER Sirolimus-eluting stent|drug-eluting stent
45456706|NCT02291068|Behavioral|psychotherapy treatment|3 months long (12 sessions) dynamic psychotherapy. The dynamic psychotherapeutic technique which will be applied in the current research is derived from Malan's focused, brief psychodynamic psychotherapy (Malan 1976) and from the literature specifying psychodynamic psychotherapies distinctive techniques (Shedler 2010). The principle of this treatment is a time limited intervention in which the primary objective is to enhance the patient's insights regarding repetitive conflicts. As psychodynamic psychotherapy is suitable for all kinds of adjustment disorders, no special adjustment in the course of therapy was made for the different subtypes (Cabaniss et al. 2011).
45985182|NCT00497172|Device|Bx SONIC bare metal stent|bare-metal stent
45985183|NCT03273296|Drug|Amoxicillin|Amoxicillin (po) 500 mg x 3 per day for 3 days.
45456707|NCT03721328|Combination Product|vancomycin hydrochloride and tobramycin sulfate|vancomycin hydrochloride and tobramycin sulfate via local irrigation
45985184|NCT03273296|Drug|Azithromycin|Azithromycin (po) 500 mg x 1 on day 1, 250 mg x 1 on day 2, and 250 mg x 1 on day 3.
45985185|NCT03273296|Drug|Vancomycin|Vancomycin (po) 125 mg x 4 per day for 3 days.
45985186|NCT00497211|Procedure|Intracoronary mononuclear cell infusion|
45985187|NCT00497250|Drug|Gefitinib|gefitinib 250 mg/day,PO concurrent with RT and 250 mg/day,PO for 60 days after the completion of RT.
45985188|NCT00497250|Device|Radiation Therapy|group 1.54Gy/27Fx concurrent with gefitinib group 2.56Gy/28Fx concurrent with gefitinib group 3.58Gy/29Fx concurrent with gefitinib group 4.60Gy/30Fx concurrent with gefitinib
45985189|NCT00462878|Drug|Meropenem|antibiotic
45985190|NCT00462878|Drug|Vancomycin|Antibiotic
45985191|NCT00462878|Drug|Teicoplanin|Antibiotic
45985192|NCT01242618|Biological|engineered nasal cartilage graft|implantation of engineered nasal cartilage grafts in the alar lobule
45456708|NCT03042416|Drug|18F-DOPA|18F-DOPA intravenous injection single dose
45985193|NCT00222911|Device|dorsiflexion night splint|
45985194|NCT00222911|Device|medial arch support|
45985195|NCT01242696|Procedure|Coronary artery stenting|Coronary artery stenting with drug eluting stents
45985196|NCT00462956|Drug|Tykerb|lapatinib 1500mg daily
45985197|NCT01242735|Behavioral|Aerobic exercise|12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals.
45985198|NCT01242735|Behavioral|Health and Wellness|12-week health and wellness education control. Weekly sessions about 12 different topics related to OCD, led by an OCD expert.
45985199|NCT00462995|Drug|Erlotinib|150mg once a day for 28 days
45985200|NCT00462995|Drug|Erlotinib|28 days of Erlotinib before surgery in patients with stage I-IIb NSCLC
45985201|NCT00489450|Drug|SK3530|
45985202|NCT00489528|Drug|Somatropin; Recombinant human growth hormone (r hGH)|
45985203|NCT00463034|Genetic|microarray analysis|
45985204|NCT00463034|Genetic|polymerase chain reaction|
45985205|NCT00463034|Genetic|polymorphism analysis|
45985206|NCT00463034|Other|high performance liquid chromatography|
45985207|NCT00463034|Other|immunohistochemistry staining method|
46083352|NCT02718144|Drug|Estetrol|Estetrol formulated in tablets, in escalating doses, will be investigated in patients with estrogen receptor positive (ER+) locally advanced or metastatic breast cancer.
46083353|NCT02500316|Drug|MOD-4023|Once weekly injection of long acting r-hGH (MOD-4023) provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a single patient use, multi-dose, disposable pre-filled pen (PEN).
45985208|NCT00463034|Other|laboratory biomarker analysis|
45985209|NCT00463034|Other|questionnaire administration|
45985210|NCT01242852|Procedure|Office hysteroscopy (in combination with a 'Saline Infusion Sonography'(SIS))|Routine fertility work-up, added up with diagnostic tests. In 5 research centers the extra tests consist of SIS & hysteroscopy (HY). In the other research hospitals it consists of only a HY. The HY examination will be scheduled on Day 3-12 of a cycle. It will be performed in an outpatient setting with a vaginoscopic approach. A 5-mm diameter continuous flow hysteroscope and a 30º direction of view will be used. The uterus will be inspected methodically a endometrial biopsy obtained and the findings recorded into a standardized form. Intrauterine pathology is defined as septum, endometrial polyp, submucous myoma, adhesions & endometritis. These will be treated, using scissors, Versapoint, grasping forceps, polyp snare or antibiotics. In 5 of the research hospitals, 1 week prior to the HY, also a SIS will be performed. Via a catheter saline solution will be infused into the uterine cavity as distention media. The findings at the following sonography will be standardized recorded.
45985211|NCT03273140|Device|Gamification Diabetes Education Program (GDEP)|"Diabetic application focuses on diabetes management and consists of two gamelets and consist of story-telling, case scenarios with the integration of problem-based decision-making and solving skills in diabetes management. These scenarios created are familiar to the patients and nurses - to make the games more interactive and realistic to the players (participants). Immediate feedback will be given after they select their decision. The visual reward will appear after attaining one score for each correct question. Participants can easily access and play the games several times till contents are reinforced and knowledge is retained or at their own comfort level. This game mechanics aim to motivate and assist patients to achieve their desired result and self-efficacy behaviors. It addresses the deficits from the current literature review, by aiming to be up-to-date, reliable with new updated scenarios and platform."
45985212|NCT01242891|Device|EXCOR® Pediatric Ventricular Assist Device|Extracorporeal Ventricular Assist Device
45985213|NCT00463073|Drug|Cetuximab|
45985214|NCT00463073|Drug|Bevacizumab|
45985215|NCT00463073|Drug|Irinotecan|
45985216|NCT00222989|Drug|PPI|
45985217|NCT00489567|Procedure|Blood sample collection|
45985218|NCT00463112|Drug|Sibutramine|
45985219|NCT00489606|Drug|SK3530|
45985220|NCT00223028|Drug|sirolimus, mycophenolat mofetil, fluvastatin|
45985221|NCT00489645|Drug|placebo|placebo SC during euglycemia
45985222|NCT00489645|Drug|pramlintide|pramlintide SC during eglycemia
45985223|NCT00489645|Drug|placebo|placebo during hyperglycemia
46083354|NCT02722902|Drug|Carnitor|"CARNITOR® (levocarnitine) is a carrier molecule in the transport of long-chain fatty acids L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes.~across the inner mitochondrial membrane."
46083355|NCT02722902|Dietary Supplement|IntraLipid|Lipid emulsion for infusion
46083356|NCT02722902|Dietary Supplement|Placebo|Saline will be used as placebo
46083357|NCT05206448|Drug|Letrozole|Letrozole tablet
46083358|NCT05206448|Drug|Clomiphene Citrate|Clomiphene Citrate tablet
46083359|NCT02722824|Device|Electro-stimulation|
46083360|NCT02722824|Other|Placebo|
46083361|NCT05257278|Device|MonoPlus®|MonoPlus® is indicated for use in general soft tissue approximation, specially in cases where extended wound support of more than 4 weeks is desirable
46083362|NCT02784782|Device|Orthesis|
46083363|NCT02784782|Behavioral|No orthesis|
46083364|NCT02722746|Drug|Ropivacaine|Epidural block infusion with Ropivacaine 0.2% will be provided as the anesthesia per standard of care during the procedure.
45985224|NCT00489645|Drug|pramlintide|pramlintide SC during hyperglycemia
45985225|NCT00465686|Device|ergonomic chair and desk (Q-Learn Classic Chair and Q-Learn Desk)|ergonomic school chair and desk adjusted to fit the child user as per the manufacturer's instructions
45985226|NCT00465686|Device|ergonomic desk and chair (Q-Learn Desk)|child sits on chair and desk for 5 minutes, then provides handwriting sample at one desk, then repeats this for the other desk
45985227|NCT01243008|Drug|Application of SHB001|"Cohort 1: Application of SHB001 on the skin of right thigh~Cohort 2:~Application of SHB001 on the skin of right thigh~punch biopsies of treated skin areas"
45985228|NCT04697199|Drug|Lactobacillus Reuteri Oral Drops|Subgingival delivery of probiotic suspension
45985229|NCT04697199|Procedure|Scaling and root planing|Scaling and root planing using hand and ultrasonic instruments
46083365|NCT02722746|Drug|Epinephrine|Participants will receive epinephrine in their epidural block infusion during the procedure. The amount of epinephrine provided during the procedure will be based on the group assignment.
46083366|NCT02784626|Drug|Dexmedetomidine|Intraoperative sedation using dexmedetomidine
46083367|NCT02784626|Drug|Propofol|Intraoperative sedation using propofol
46083368|NCT02717988|Drug|SKI-O-703 capsule|SKI-O-703 25 mg capsule or 200 mg capsule without excipient
46083369|NCT02717988|Drug|Placebo capsule|Placebo 180 mg capsule filled with microcrystalline cellulose
46083370|NCT02782754|Drug|Carboplatin|
46083371|NCT02782754|Drug|Etoposide|
45985230|NCT00463190|Drug|Biothree|
45985231|NCT00463268|Drug|alendronate|alendronate 70 mg every 2 weeks
45985232|NCT00463268|Dietary Supplement|Calcium/Vitamin D|Calcium 500 mg and vitamin D supplementation according to serum level
45985233|NCT00463268|Drug|placebo|identical placebo every 2 weeks
45985234|NCT00489723|Drug|tamsulosin 0.4mg|
45985235|NCT00463424|Device|NeuFlex metacarpophalangeal implant|
45985236|NCT00463424|Device|Swanson metacarpophalangeal implant|
46083372|NCT02782754|Drug|Cyclophosphamide|
46083373|NCT02782754|Drug|Bleomycin|
46083374|NCT02782754|Radiation|Reduced dose of radiotherapy|
46083375|NCT04799340|Behavioral|cognitive training|training to improve encoding and recognition of faces
46083376|NCT02717910|Behavioral|Health game|Health game intervention consists of 20 minutes guided training session with the health game at school and 2 weeks free usage of the health game via own smart phone or tablet computer during free time. The health game includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized content is presented in a format of a game including tasks, rules, goals, rewards and opponents. There are also sound effects and background music included in the game.
45456709|NCT03927469|Other|age, sex, hemiplegic side, stroke duration, First hospitalisation duration (day)|This is a retrospiective descriptive study
45456710|NCT03523936|Dietary Supplement|Prebiotic product|Prebiotic product used during the course of antibiotic treatment
45456711|NCT03523936|Dietary Supplement|Placebo|Placebo
45456712|NCT01353404|Drug|Sequence 1|fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral
45985237|NCT04697433|Device|Myotonometry|The examiner should exert a slight pressure on the determined point to the necessary depth, which will be indicated by changing the color from red to green light on the device. The device has an automatically controlled preload (0.18 Newton (N)) that will be applied to the contact area by an automatic mechanical pulse, with a duration of 15 milliseconds (ms) and a constant force of 0.4 N , these oscillations will be registered by an accelerometer next to the measurement mechanism inside the device. For each evaluation, a series of 10 consecutive pulses (multiscan mode) will be used with an interval of one second between each pulse. In each shot, the tone, stiffness, elasticity, relaxation time and creep will be calculated.
45985238|NCT00489762|Procedure|Installation of an energy efficient heater|
45985239|NCT00105443|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid); 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment.
45985240|NCT00105443|Drug|Placebo|Sorafenib-matching placebo tablets were orally administered twice daily (bid).
45985241|NCT00489801|Other|Exercise|Exercise intervention and lifestyle counseling at centre or exercise intervention at home
46083377|NCT02717910|Behavioral|Web page|Web page intervention consists of 20 minutes guided training session with the web page at school and 2 weeks free usage of the web page via own smart phone or tablet computer during free time. The web page includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized elements are presented with pictures and video clips. These visualized elements do NOT contain game elements (NO activating tasks, rules, goals, rewards or opponents). The video clips contain sound effects, but no background music.
45673196|NCT01533688|Drug|Golytely (polyethylene glycol electrolyte lavage solution) and placebo|4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely))+ placebo given the evening prior to the colonoscopy
45832821|NCT03596658|Drug|SHR9549|If initial dosing of SHR9549 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose(MTD) is defined
45832822|NCT03596268|Diagnostic Test|Imaging|3T Prisma MRI
45832823|NCT03596268|Diagnostic Test|Serum Laboratory Tests|Blood (plasma and cellular) will be collected.
45832824|NCT03596268|Diagnostic Test|Lumbar Puncture|CSF will be collected
45832825|NCT03690648|Other|Quality of life survey|Administration of scales: SF-12v2, EQ-5D, QCD, DN4, EIMIR, MFIS-5 et EHAD
45832826|NCT03690648|Genetic|Saliva collection|Collection of 20 ml of saliva with a kit of saliva collection
45985242|NCT01243047|Drug|Chemotherapy|Erlotinib, Oxaliplatin, Capecitabine
45985243|NCT00489840|Drug|Anecortave Acetate Sterile suspension 15 mg|anecortave acetate sterile suspension 15 mg., juxtascleral injection, every 6 months. for 24 months
45985244|NCT00489840|Drug|Anecortave Acetate|anecortave acetate suspension 15 mg. juxtascleral injection every 6 months for 24 months.
45985245|NCT00463463|Drug|90Yttrium Ibritumomab Tiuxetan (Zevalin)|
45985246|NCT00489879|Device|Mobile Health Care System (DrUB)|
45456713|NCT01353404|Drug|Sequence 2|fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
45985247|NCT00465725|Drug|Picoplatin|The IV dose will be 120 mg/m2. Three oral dose levels will be studied sequentially (6 subjects per dose level) in the absence of dose limiting toxicity 200 mg, 300 mg, or 400 mg total dose.
45985248|NCT00463502|Drug|Metformin|
45985249|NCT00489996|Drug|gemcitabine|
45985250|NCT00489996|Drug|cisplatin|
45985251|NCT00465764|Other|Alternate protein infant formula|Feed as per HCP directions
45985252|NCT00465764|Other|Standard infant formula|Feed as per HCP directions
45985253|NCT00490074|Biological|DNA-C|1.0mg per ml of DNA HIV-C vaccine 2x2 ml IM
45985254|NCT00490074|Biological|NYVAC-C|NYVAC-C 1 ml IM
45985255|NCT04696926|Other|Edwards Intuity TM Valve implantation|aortic valve replacement with an Edwards Intuity TM bioprosthesis
45985256|NCT00463541|Drug|solifenacin succinate|oral
45985257|NCT00490113|Drug|Pyridoxamine|Two 250 mg capsules, or placebo, given twice a day for four, 4 week periods. Subjects with primary hyperoxaluria will aslo receive escalated doses up to 3500 mg/day for up to 6 1/2 days.
45985258|NCT00463619|Drug|Retarded release phosphatidylcholine|2g phosphatidylcholine, given QTD
45985259|NCT01243164|Other|Wheelchair Skills Training Program|The Wheelchair Skills Training Program will be administered in 2, 1 hour sessions.
45673197|NCT01533688|Drug|split dose of Golytely (polyethylene glycol electrolyte lavage solution) + placebo|split dose (2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters Golytely + placebo
45673198|NCT01533688|Drug|split dose of Golytely (polyethylene glycol electrolyte lavage solution) and bisacodyl|split dose ( 2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters of Golytely + bisacodyl 10 mg
45673199|NCT01532986|Other|Coordinated care management for Parkinson's disease|Nurse care managers will use standardized assessment tools and care coordination protocols to address unmet needs of Veterans with PD, and collaborate with these Veterans and their families, providers, and community partners to manage PD care.
45832827|NCT03690648|Genetic|Blood collection|Collection of 20 ml of blood with kit of blood collection
45832828|NCT03689634|Device|Move For Surgery Preconditioning Program using a Wearable Activity Tracker (Fitbit) Intervention Group|Participants randomized to this group will be be provided with a wearable activity tracker (Fitbit) for the duration of the study and asked to reach daily step goals.
45832829|NCT01677156|Diagnostic Test|CORUS CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
45832830|NCT03689166|Dietary Supplement|Probiotic|Reduce preterm birth with this dietary supplement
45832831|NCT03689166|Other|Placebo|Placebo
45832832|NCT03684408|Device|RFID Localization|The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
45832833|NCT03684408|Device|Wire Localization|The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
45985260|NCT00465881|Device|CGM System for Type 1 and Type 2 Diabetes Mellitus|
45985261|NCT01243203|Drug|Champix|Days 1 - 3: 0.5 mg once daily (1 table each day) Days 4 - 7: 0.5 mg twice daily (1 in the morning and 1 in the evening) Days 8 - 12 weeks 1.0 mg twice daily (1 in the morning and 1 in the evening)
45985262|NCT03273101|Device|Mechanical assisted sit-to-stand training group|Mechanical assisted sit-to-stand training 100 repetitions or 10 mins / session 10 sessions
45985263|NCT03273101|Other|Manual assisted sit-to-stand training group|Manual assisted sit-to-stand training 100 repetitions or 10 mins / session 10 sessions
45985264|NCT00490152|Behavioral|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
45985265|NCT00490152|Behavioral|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
45985266|NCT00490152|Behavioral|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
45985267|NCT00465920|Behavioral|modified cognitive behavioural therapy (mCBT)|
46083378|NCT02694354|Drug|BI 685509|
46083379|NCT02694354|Drug|Placebo|
45832834|NCT03684408|Device|RFID and Wire Localization|Both RFID and the standard of care wire localization will be performed for physician training.
46083380|NCT05341076|Procedure|Amniotomy|Amniotomy, artificial rupture of membranes, is done with an initial delay of labor (in partograph: extension beyond the alert line, in labor scale: when progress reaches the membrane line)
45456714|NCT01353404|Drug|Seqeunce 3|fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral
45456715|NCT01353404|Drug|Sequence 4|fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral
45832835|NCT03817320|Drug|Ixazomib|"Days 1, 4, 8, and 11. Note: at least 72 hours must have elapsed between doses~Dose Phase 1 - Assigned upon study entry.~Phase 2 - PO formulation at RP2D"
45832836|NCT03817320|Drug|Vincristine|"IV push over 1 minute or infusion via minibag as per institutional policy~Days 1, 8, 15 and 22~Dose: ≥ 1 year: 1.5mg/m2/dose (maximum dose 2mg)~≥ 6 months and < 1 year: 1.2mg/m2/dose~< 6 months: 1mg/m2/dose"
45832837|NCT03817320|Drug|Dexamethasone|"Days 1-14~Dose: ≥ 1 year: 10mg/m2/day, divided BID (i.e., 5mg/m2/dose, BID)~≥ 6 months and < 1 year: 8mg/m2/day, divided BID (i.e., 4 mg/m2/dose, BID)~< 6 months: 7mg/m2/day, divided BID (i.e., 3.5 mg/m2/dose, BID)"
45985268|NCT01245036|Drug|Antituberculous therapy along with steroids|INH (300 mg/day) plus Rifampicin (450 mg/day if wt.<50 kg and 600 mg/day if wt. >50 kg) for six months Prednisolone 1 mg/kg/day for 6 weeks (maximum 80 mg) Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 3 months (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 3 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
45985269|NCT00466037|Biological|Influenza vaccine|
45985270|NCT00490191|Drug|Somatropin|
45985271|NCT00463658|Other|Falls Prevention|Subjects in the interdisciplinary group will receive home care services from a team of professional service providers (CCAC Case Manager, Public Health Nurse (Registered Nurse), Occupational Therapist, Physiotherapist, Nutritionist) with experience and training in falls prevention. The team will provide a comprehensive, coordinated and evidence based approach to falls prevention through weekly case conferencing, a written interdisciplinary care plan, and joint client visits.
45985272|NCT00497328|Drug|N-acetylcysteine|
45985273|NCT00497328|Drug|Sodium Bicarbonate|
45985274|NCT00466076|Drug|Copaxone (Glatiramer acetate)|
45985275|NCT01245075|Other|Deep brain stimulation|Deep brain stimulation on
45985276|NCT01245075|Other|Placebo|deep brain stimulation off
45985277|NCT00463697|Drug|GW642444H (100mcg)|H salt
45985278|NCT00463697|Drug|placebo|placebo
45985279|NCT00463697|Drug|GW642444M (25, 100 & 400 mcg)|M salt
45985280|NCT00490230|Drug|WR 279396|
45985281|NCT00466154|Drug|Aspirin|
45985282|NCT00490308|Drug|Treatment with estradiol valerate|
45985283|NCT00463736|Drug|Magnesium sulfate|
45985284|NCT00490347|Device|VentrAssist Left Ventricular Assist Device|
45985285|NCT00490425|Drug|Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)|
45985286|NCT00497367|Device|Percutaneous Coronary Intervention (PCI) TAXUS Petal|TAXUS Petal, paclitaxel eluting stent
45985287|NCT00497406|Procedure|Salivary gland transfer|Retrograde flow method
45985288|NCT00497406|Procedure|Helical Tomotherapy treatment|total of 30 fractions
45985289|NCT00497445|Procedure|angioplasty / surgery|Percutaneous vascular intervention or surgery for peripheral arterial disease
45985290|NCT00497445|Procedure|Angioplasty / surgery and exercise therapy|Percutaneous vascular intervention or surgery for peripheral arterial disease followed by supervised exercise therapy
45985291|NCT00497484|Drug|recombinant human somatotropin|
45985292|NCT00490464|Drug|Nicardipine and Nipride|
45985293|NCT00497523|Drug|Beclomethasone dipropionate|
45985294|NCT00497523|Drug|Beclomethasone dipropionate/Salbutamol combination|
45985295|NCT00497523|Drug|Salbutamol|
45985296|NCT00463775|Drug|Topiramate|SSRI plus topiramate SSRI plus placebo
45985297|NCT00463853|Procedure|Autologous stem cell therapy|
45985298|NCT00463853|Procedure|CABG|
45985299|NCT00463853|Radiation|CMRI|
45985300|NCT00490620|Drug|Combination antiviral therapy|Zidovudine 300mg and lamivudine 150mg BID for 6 months
45985301|NCT00490620|Drug|Placebo|placebo BID for 6 months
45985302|NCT00466232|Drug|Topotecan|4 mg/m2 IV on day 1, 8, 15. Repeat every 28 days.
45985303|NCT00466232|Drug|Sorafenib|Dose escalation study at 3 dose levels: 200 mg po daily, 200 mg po bid, 400 mg po bid.
45985304|NCT00490659|Drug|gemcitabine|
45985305|NCT00490659|Drug|cisplatin|
45985306|NCT00490659|Procedure|radical surgery|
45985307|NCT00490659|Procedure|chemoradiotherapy|
45985308|NCT00463892|Procedure|High-resolution contrast-enhanced MRI scan|High-resolution contrast-enhanced MRI scan of regional lymph nodes every 6 months on study
45985309|NCT00490737|Drug|daptomycin|6mg/kg, i.v. infusion over 30 minutes; every 48 hours for a total of 3 doses
45985310|NCT00497562|Drug|sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group)|
45985311|NCT00497562|Drug|amitriptyline, fluoxetine and tramadol alone (control group)|
45985312|NCT00497601|Drug|Amphotericin B fat emulsion in visceral leishmaniasis|Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 & 3 in group A Amphotericin B in fat emulsion (Amphomul) 10 & 5 mg/kg on day 1 & 3 in group B Amphotericin B in fat emulsion (Amphomul) 12.5 & 2.5 mg/kg on day 1 & 3 in group C Amphotericin B in fat emulsion (Amphomul) 15 mg/kg on day 1 in group D
45985313|NCT00497601|Drug|Amphotericin B fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
46083381|NCT05341076|Drug|Oxytocin|oxytocin augmentation: given with further delay of labor (according to the point of intervention of the partograph or the scale)
46083382|NCT05341076|Procedure|Cesarean Section|Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
45985314|NCT00497601|Drug|Amphotericin B in fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
45985315|NCT00466388|Drug|Cevimeline|
45985316|NCT00497640|Procedure|Artificial Neural Network|Use of a predicted optimal CPAP
46083383|NCT02722512|Biological|Heat Shock Protein Peptide Complex-96 (HSPPC-96)|The vaccine is patient specific, created from the patient's own brain tumor resected at a clinically necessary surgery. The vaccine is administered intradermally on a weekly basis.
45673200|NCT01532986|Other|Educational handout|"To minimize potential bias from participants' awareness of randomization arm assignment, the investigators will provide to all study participants (intervention arm and usual care arm) on enrollment a brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook (page 273). This information includes a definition of PD, its symptoms, and several suggestions for managing PD such as medications and regular exercise."
45673201|NCT01532908|Biological|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous, up to 15 infusions over 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
45673202|NCT01532908|Drug|Telaprevir (Part 1)|Two 375 mg tablets, 3 times a day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
45832838|NCT03817320|Drug|Asparaginase|"Days 2, 15~Dose ≥ 1 year: 2,500 International units (IU)/m2/dose~≥ 6 months and < 1 year: 2,000 IU/m2/dose~< 6 months: 1,750 IU/m2/dose~Patient with allergic reaction to Pegaspargase can be given Erwinase IM/IV on Mon/Wed/Fri (or every other day per institutional standard) x 6 doses for each dose of Pegaspargase.~Dosing guideline for Erwinase:~1 year: 25,000 IU/m2/dose~6 months and < 1 year: 20,000 IU/m2/dose~< 6 months: 17,500 IU/m2/dose"
45832839|NCT03817320|Drug|Doxorubicin|"Day 1~Dose ≥ 1 year: 60mg/m2/dose~≥ 6 months and < 1 year: 48 mg/m2/dose~< 6 months: 42mg/m2/dose"
45832840|NCT03817320|Drug|Methotrexate (IT)|For patients with CNS 1 or CNS 2, on Days 1, 15, and 29
45832841|NCT03817320|Drug|Triple IT (Methotrexate, Hydrocortisone, Cytarabine)|For patients with CNS 3, on Days 1, 8, 15, 22, and 29
45832842|NCT03817320|Drug|Leucovorin|For patients with Down syndrome only, on Days 2, 9, 16, 23, and 30 (based on dates when IT Methotrexate or Triple IT is given)
45832843|NCT03684018|Biological|IgPro10|Normal human immunoglobulin G administered intravenously
45985317|NCT00497679|Drug|AZD1152|7-day continuous intravenous infusion
45985318|NCT00466466|Drug|Everolimus|RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. The drug will be packaged in blisters containing 10 tablets per blister. Blisters and packaging will be compliant with local regulations and be printed in local language.
45985319|NCT00490854|Drug|Human Insulin Inhalation Powder|patient specific, inhaled, at meals, 76 weeks
45985320|NCT00490854|Drug|Neutral protamine hagedorn insulin|patient specific dose, injected, daily, 76 weeks
45985321|NCT00463970|Behavioral|Brief Intervention|Physical examination, education and follow up by a physiotherapist
45985322|NCT00463970|Behavioral|Cognitive Behavioural Therapy|7 sessions of CBT over a period of 2 months, included a booster session after 3 months
45985323|NCT00463970|Dietary Supplement|Seal oil|20 capsules per day for 3 months
45985324|NCT00463970|Dietary Supplement|Soy oil|20 capsules per day for 3 months
45985325|NCT00497718|Procedure|Chiropractic Manipulation|
45985326|NCT00464009|Behavioral|Continuing medical education|"Group A practices took part in a 90 minute lecture with slides, case-based presentations and discussions of the clinical interventions, instruction in children's dental development, common dental diseases and prevention, screening, referral, counseling and fluoride varnish application. Group B practices received the same as group A and additionally were offered support through telephone conference calls using learning collaborative methods where staff receive ongoing support from CME instructors and learn from one another as they begin to implement systems for preventive care in their practices. The conference calls were moderated by research staff with clinical expertise in primary health care who had assisted in other interventions among NC pediatric and family medicine offices. Group C received the same intervention as Group B and were offered additional in-office support for implementation of preventive dental procedures provided by a dental hygienist."
45985327|NCT00464048|Procedure|controlled physical exercise|
45985328|NCT00490893|Drug|Detemir|
45985329|NCT00464126|Other|5% albumin|5% albumin in 10cc/kg aliquots for postoperative volume resuscitation
45985330|NCT00464126|Other|crystalloid|saline in 10cc/kg aliquots for postoperative volume resuscitation
46083384|NCT02722512|Procedure|Tumor Resection|Clinically-indicated removal of the tumor
46083385|NCT02722512|Radiation|Radiation|Focal Radiation Therapy
46083386|NCT05133518|Drug|MELT-300|Sublingual tablet
45985331|NCT00490932|Drug|Hypo-osmolar ORS|
45985332|NCT03272399|Other|Diet/nutrition intervention|The intervention will be administered through food products rather than dietary supplements
45985333|NCT00491010|Procedure|radiofrequency catheter ablation|
45985334|NCT03272126|Drug|Vitamin D|vitamin D given as bolus versus daily dosing
45985335|NCT03272126|Drug|Placebo|identical looking as vitamin D
45985336|NCT00491049|Drug|0.5% levofloxacin eye drops|
45985337|NCT00464165|Drug|rimonabant|
45673203|NCT01532908|Drug|Sofosbuvir (Part 2)|One 400 mg tablet, 1 time per day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
45673204|NCT02160782|Drug|LUM001 (Maralixibat)|LUM001, also known as Maralixibat (MRX) will be administered orally Once Daily (OD). To be administered Twice Daily (BID) for patients who are eligible.
45673205|NCT02160782|Drug|Placebo|Placebo will be administered orally once daily during randomized withdrawal period
45673206|NCT02160626|Drug|A-101 Vehicle|Placebo control
45673207|NCT02160626|Drug|A-101 (40) Topical Solution|A-101 (40) Topical Solution - high dose
45832844|NCT03681366|Device|DISC3.5 plus|The Defocus Incorporated Soft 3.5 Plus Contact Lens (DISC3.5 Plus) is a soft contact lens that comprises of simultaneous distance optical prescription and myopic defocus areas.
45832845|NCT03680586|Drug|Radiation Therapy|Undergo ultra low-dose radiation
45832846|NCT03593226|Drug|AGI-134|AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
45832847|NCT03591354|Device|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Participants will use the Tandem t:slim X2 insulin pump with Control-IQ Technology & Dexcom G6 CGM for 3 months.
45832848|NCT03591354|Device|t:slim X2 with Basal-IQ & Dexcom G6 CGM|Participants will use a Tandem t:slim X2 insulin pump with Basal-IQ and a study CGM (Dexcom G6) for 3 months.
45832849|NCT03589794|Other|AP10-602|Glucopyranosyl Lipid A -liposome-Quillaja Saponaria 21 (GLA-LSQ).
45832850|NCT03589794|Other|Malaria challenge|Exposure to mosquitoes infected with P. falciparum.
45832851|NCT03589794|Biological|rCSP|The rCSP malaria vaccine is a recombinant full-length P. falciparum circumsporozoite protein comprised of an amino terminus that binds heparin-sulfate proteoglycans, a four-amino-acid repeat region and a carboxy-terminus that contains a thrombospondin-like Type I region domain.
45985338|NCT00497913|Drug|NaCl 0.9%|
45985339|NCT00497913|Drug|Botulinum Toxin A|
45985340|NCT00497991|Drug|AZD1152|
45985341|NCT03272321|Drug|Oxytocin|Syntocinon nasal spray
45985342|NCT03272321|Drug|Placebo|Placebo nasal spray
45985343|NCT00491088|Device|CPAP|CPAP for 12 weeks
45985344|NCT00466544|Device|Plasmaknife|
45985345|NCT00466544|Device|Monopolar|
45985346|NCT00491127|Drug|gemcitabine|
45985347|NCT00491127|Drug|cisplatin|
45985348|NCT00491127|Drug|dexamethasone|
45985349|NCT00491166|Drug|Bromfenac ophthalmic solution|
45985350|NCT00491283|Device|Swab Specimen Collection (QuickVue)|
45985351|NCT00498069|Device|Harvest Smartprep2 BMAC System|injection of 40cc bmac
45985352|NCT00498069|Device|SmartPReP2 BMAC System|Injection of autologous bone marrow concentrate prepared with the SmartPReP2 BMAC System
45985353|NCT00498069|Biological|placebo|injection of placebo into ischemic tissue of the lower extremity
45985354|NCT03273062|Drug|Tolcapone 200 MG|Tolcapone 200 MG TID
45985355|NCT03273062|Other|Placebo|Placebo, TID Placebo will be in capsules that are identical in appearance to intervention drug, Tolcapone.
45985356|NCT00498108|Drug|Rotigotine|
45985357|NCT00464321|Biological|GC1008|1 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
45985358|NCT00464321|Biological|GC1008|2 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
45985359|NCT00464321|Biological|GC1008|4 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
45985360|NCT00464321|Biological|GC1008|0.3 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
45985361|NCT03272984|Procedure|ERAS group|ERAS is the name of a procedure. Patients in this group need receive the ERAS procedure instead of one drug.
45985362|NCT03272984|Procedure|SC group|Patients were managed in accordance with SC programs during the perioperative period. SC programs were used daily in our center and were still routinely used in most of the other hospitals in China.
45985363|NCT00498147|Other|ADEC Program|Interventions (managed diabetes care) employed by the ADEC Program include: diabetes education, nutrition care, individual and group counseling sessions, foot care, and insulin and oral diabetes medication adjustments with a signed medical directive. ADEC Diabetes Educators (Registered Dietitians and Registered Nurses) will use adult education principles throughout the education process and promote self-care by encouraging responsibility and promoting a positive attitude towards acceptance of diabetes. All patients will be encouraged to self-monitor their blood glucose at home. Team member collaboration and with other agencies to promote a total client care approach to diabetes management will be employed.
45985364|NCT00466583|Drug|Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN)|IV infusion of EZN 2968 given in 6 week cycles for (3 weeks on 3 weeks off) until recommended phase 2 dose identified. Up to 3 intensification cohorts will receive the recommended Phase 2 dose of EZN-2968.
45985365|NCT00498225|Drug|Gemcitabine plus TS-1|Gemcitabine plus TS-1:Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8 followed by 2 week rest as 1 course. TS-1 was co-administered orally at 40 mg/m2 twice daily for 14 days with a rest period of 1 week as one course.
45985366|NCT00498225|Drug|TS-1|TS-1 was administered orally at 40 mg/m2 twice daily for 28 days with a rest period of 2week as one course.
45985367|NCT00498225|Drug|Gemcitabine|Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8, 15 followed by 2 week rest as 1 course.
45985368|NCT00466622|Drug|Metformin|1000 mg x 2 daily. Orally. First tablet taken after the first Doppler examination and 3 hours before the next Doppler examination.
45985369|NCT00466622|Drug|Placebo|Placebo 2 tablets x 2 daily. Orally from Weifa
45985370|NCT00498264|Behavioral|walking program, resistance muscular exercise|
45673208|NCT02160626|Drug|A-101 (32.5) Topical Solution|A-101 (32.5) Topical Solution - low dose
45985371|NCT01327612|Drug|Modified FOLFOX6|The mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m² administered as a 2-hour intravenous (IV) infusion on day 1 and leucovorin 400 mg/m² racemate or 200 mg/m² levo-leucovorin administered as a 2-hour infusion on day 1, followed by a loading dose of 5-fluorouracil (5-FU) 400 mg/m² IV bolus administered on day 1, then 5-FU 2400 mg/m² via ambulatory pump administered for a period of 46 to 48 hours every 14 days.
45985372|NCT01327612|Biological|Conatumumab|Administered by intravenous infusion Q2W or Q3W.
45985373|NCT01327612|Biological|Ganitumab|Administered by intravenous infusion Q3W or Q4W.
45985374|NCT01327612|Biological|Bevacizumab|Administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle.
45985375|NCT01243281|Drug|PEG-IFN and entecavir|The patients will be randomized in approximately 1:1 ratio into one of 2 treatment regimens; to receive PEG-IFN alpha-2b (1.5 microgram/kg/week) plus entecavir (0.5 mg/day) or PEG-IFN alpha-2b (1.5 microgram/kg/week) alone for 48 weeks by using pre-generated randomization schedule.
45985376|NCT00464399|Drug|everolimus|
45673209|NCT02160314|Device|pessary|disposable, single-use pessary
45985377|NCT04132882|Drug|Sodium Thiosulfate (STS)|
45985378|NCT01243359|Drug|sunitinib malate|Given PO
45456716|NCT01353404|Drug|Sequence 5|fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
45456717|NCT01353404|Drug|Sequence 6|fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral
45673210|NCT02160314|Device|Absorbent pad|
45673211|NCT02160002|Procedure|Weaning from an incubator at a lower weight (1600 grams)|Infants will be weaned from an incubator at a lower weight (1600 grams)
45673212|NCT02160002|Procedure|Weaning from an incubator at a higher weight (1800 grams)|Infants will be weaned from an incubator at a higher weight (1800 grams)
45673213|NCT02218268|Drug|Pre-meal bolus|Long acting insulin as scheduled per usual routine PLUS rapid/ short acting (bolus) prior to Boost
45832852|NCT03583086|Drug|VEGFR/PDGFR Dual Kinase Inhibitor X-82|Given by mouth
45832853|NCT03583086|Biological|Nivolumab|Given by IV
45832854|NCT03582852|Procedure|Surgical treatment of genital prolapse|Laparoscopy performed according to the usual technique of the participating center with pneumoperitoneum between 12 and 15 mmHg. Placement of the 5 mm trocar operator left and right iliac fossa and 5 mm pubic addition.
45832855|NCT03581136|Device|Dose Fractionation|Patients will receive 5 fractions of radiation. These should not be on consecutive days. At least 40 hours between each fraction and a maximum of 21 days to complete, i.e.: Tuesday, Thursday, Monday, Wednesday, Friday.
45832856|NCT00006156|Other|Control|No injection of FSH
45832857|NCT00006156|Drug|Drug: FSH|FSH Stimulation Test
45832858|NCT03677778|Procedure|Normal saline injected via interscalene nerve catheter|With the catheter covered, treatment group patients will receive a normal saline (NS) bolus regimen (30cc 0.9% NS) via their interscalene nerve block catheter.
45832859|NCT03677778|Other|Placebo|With the catheter covered, placebo group patients will go through the same steps as the treatment group, but no solution will be injected into the interscalene nerve block catheter.
45832860|NCT03675126|Drug|SRP-5051|SRP-5051 administered as an IV infusion.
45985379|NCT01243359|Biological|bevacizumab|Given IV
45985380|NCT01243359|Other|pharmacological study|Correlative studies
45985381|NCT01243359|Other|laboratory biomarker analysis|Correlative studies
45985382|NCT01243359|Other|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
45985383|NCT01243359|Procedure|positron emission tomography|Undergo FLT PET/CT
45985384|NCT01243359|Procedure|computed tomography|Undergo FLT PET/CT
45985385|NCT04403581|Other|Questionnaire|Questionnaire for assessing stresses, knowledge and attitudes of doctors in COVID-19 pandemic
45985386|NCT02893579|Behavioral|Early SR intervention|Self-directed stress reduction program delivered through a smart-phone application
45985387|NCT02893579|Behavioral|Delayed SR intervention|Activity tracking only for the first month
45985388|NCT00498303|Biological|trivalent split influenza vaccine|
45985389|NCT04402567|Other|No Intervention|Not Apply
45985390|NCT01243398|Procedure|quality-of-life assessment|
45456718|NCT01220791|Other|In vitro fertilization treatment for infertility|IVF treatment
45456719|NCT03521284|Other|Parental educational program|Behavior: psychotherapy, life hygiene advice
45673214|NCT02218268|Drug|No meal bolus|Long Acting insulin as scheduled per usual routine (given once daily)
45673215|NCT02217878|Drug|Morphine|IV bolus injection
45673216|NCT02217878|Drug|Placebo|IV bolus injection
45673217|NCT02217878|Drug|Ticagrelor|180 mg loading dose
45985391|NCT04400812|Other|questionnaire|Arabic questionnaire focused on knowledge, perception and attitude
45985392|NCT04400461|Other|Data collection and clinical testing of subjects|"Clinical Testing: muscle strength. Muscle strength, as a component of physical function, will be assessed with the Medical Research Council sum score (MRC- SS) at discharge from the ICU and at discharge from the hospital.~Clinical testing: physical function. The Functional Status Score for the ICU (FSS-ICU) will be used to evaluate 5 functional tasks at discharge from hospital."
45985393|NCT00498342|Drug|N-acetylcysteine|
45985394|NCT04399174|Device|US|
45985395|NCT00466856|Drug|octreotide acetate|"Lung/liver Ratio Dose of SIR-Spheres~<10% Administer full dose of SIR-Spheres~10% to 15% Reduce dose of SIR-Spheres by 20%~16% to 20% Reduce dose of SIR-Spheres by 40%~>20% Do not give SIR-Spheres"
45985396|NCT00466856|Radiation|yttrium Y 90 resin microspheres|radiation
46083387|NCT05133518|Drug|Midazolam alone|Sublingual tablet
46083388|NCT05133518|Drug|Ketamine alone|Sublingual tablet
46083389|NCT05133518|Drug|Placebo|Sublingual tablet
45985397|NCT04398979|Procedure|Thoracoscopic Atrial fibrillation Ablation|After blunt dissection of the oblique and transverse sinus, an AtriCure Lumitip Dissector was introduced around the pulmonary veins. Pulmonary vein isolation was achieved with an AtriCure Isolator Synergy ablation clamp around the pulmonary vein antrum at least six times for each side. Ganglionated plexus identification and ablation were performed using an AtriCure Synergy ablation pen. The additional superior and inferior ablation lines connecting the bilateral pulmonary vein isolations were created by applying the AtriCure Synergy ablation pen. Following completion of the ablation on the right side, ablation on the left side was accomplished in a similar manner. The ligament of Marshall was dissected by electrical cautery. Conduction block was confirmed upon completion of the ablation procedure on the left side.
45673218|NCT04189640|Drug|Postoperative analgesia management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure. If the VAS score will be ≥ 4, 0.5 mg/ kg tramadol IV will be administered.
45832861|NCT03674346|Other|Hypnoanalgesia group|"The running of a hypnosis session is protocolized and is based on three times:~The hypnotic induction time that allows to move from the state of consciousness to a modified state of consciousness: it will be adapted according to the patient as specified by the procedure of Ericksonian hypnosis. It varies from a few seconds to 10 minutes. Induction time depends on the patient's level of stress, apprehension, subsequent experiences of hospitalization, history, and level of hypnotizability.~The dissociation time. It is the state of modified consciousness obtained at the end of the induction which is prolonged,~The time of return. It is time that allows the patient to regain his classic state of consciousness."
45985398|NCT02893189|Genetic|Infusion of modified CAR19 T-cells (4G7-CARD T-cells)|The original stem cells donor (or if not available the patient) will undergo unstimulated leucapheresis for generation of the Advanced Therapy Interventional Medicinal Product (ATIMP) 4G7-CARD T-cells. Escalating doses of the ATIMP will then be infused to the patient depending on outcome and any experienced side effects.
45985399|NCT00498381|Device|CPAP|
45985400|NCT00464516|Drug|placebo|once daily for 14 days orally
45985401|NCT00464516|Drug|Estetrol|once daily for 14 days orally
45832862|NCT03674346|Other|Meopa Group|"The pain management will be done exclusively by a mask delivering the equimolecular mixture of oxygen and nitrous oxide (MEOPA) throughout the procedure.~For optimal use, the beginning of its administration by the radiological technologist is performed 3 minutes before the sclerosant injection (at the end of the locating ultrasound). The end of administration will correspond to the end of the injections of the sclerosing product. These sclerosing products are not considered experimental or ancillary products in this study."
45985402|NCT01243437|Drug|ciprofloxacin|"For adults and children aged > 15 years: 500 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~For children aged 8-15 years: 15 mg/kg (maximum 500 mg per dose) orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
45985403|NCT01243437|Drug|doxyxcycline|"For adults and children weighing 45 kg or more: 200 mg orally one time as an initial loading dose, followed by 100 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~For children weighing less than 45 kg: 4.4 mg/kg orally one time as an initial loading dose, followed by 2.2 mg/kg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
45985404|NCT00591994|Drug|piribedil|50 mg once a day, after lunch 3 month therapy
45985405|NCT00464594|Behavioral|Standard lifestyle guidance|
45985406|NCT00464594|Drug|Lifestyle guidance and monotherapy with acarbose|
45456720|NCT03521284|Other|Questionnaires|knowledge questionnaire + parental anxiety questionnaire
45456721|NCT04499456|Other|Personalised Normative Feedback|The Personalised Normative Feedback provides information on 1) alcohol consumption (the number of drinks consumed, alcohol-pattern use, binge drinking); 2) normative comparisons; 3) alcohol-related consequences; 4) practical costs of alcohol consumption (money spent and calories consumed); 5) strategies to avoid or risks associated with alcohol use.
45456722|NCT03930667|Procedure|clips|
45832863|NCT03580824|Biological|R21 in Matrix- M adjuvant vaccine|R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
45985407|NCT00464594|Drug|Lifestyle guidance and monotherapy with metformin|
45985408|NCT00464594|Drug|Lifestyle guidance and monotherapy with gliclazide|
45985409|NCT00592033|Other|oxygen from a portable concentrator|2 l/minute during exercise
45985410|NCT02893345|Behavioral|Safe@Home Intervention Group|For the 8 training visits, participants may select to work on skills in 2 of 5 activity modules: Improving mobility, balance and strength; Managing health and wellness; Staying On Your Own at Home; Maintaining the home; Getting out in the community. Participants may seek single service rehabilitation, medical, and psychological care as usual.
45456723|NCT03930667|Procedure|knotting|
45456724|NCT02291146|Behavioral|LA Sprouts intervention|see arm 1 description
45456725|NCT01126411|Procedure|immunoadsorption / immunglobulin substitution|Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
45985411|NCT02893345|Other|Usual Care Group|Persons can set goals and work on activities with or without a family member as they so choose. Participants may seek single service rehabilitation, medical, and psychological care as usual.
45985412|NCT04328233|Behavioral|Time-Restricted Eating|Participants will reduce the amount of time they eat to 10 hours per day over a 12-week monitored intervention followed by a 12-week self-directed intervention and will log their dietary intake using a smartphone application (mCC app). The participants will select a 10-h eating window that best suits their lifestyle. All food/beverages except water must be consumed within the time-interval. No further dietary restrictions will be applied. The participants will be provided with behavioral nutritional counseling by a dietician.
45985413|NCT04397302|Diagnostic Test|Role of Sacubitril/Valsartan in Hemodynamic and Echocardiographic Improvement of Heart Failure With Reduced Ejection Fraction|Reverse Remodeling is Associated With Hemodynamic Improvement and Stabilization in Outpatients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan: an Echocardiographic Study
45985414|NCT03272945|Procedure|Linked-color imaging|Linked-color imaging colonoscopy
45985415|NCT04396210|Other|Questionnaire|Eligible patients will be selected electronically from our database and digital agenda. After selection, patients will be contacted via email to participate. Two reminders will be send in case the questionnaire is not filled out: a first reminder after one week, a second reminder after two weeks.
45985416|NCT04395898|Procedure|pancreaticoduodenectomy|Whipple's procedure
45985417|NCT00466895|Drug|lenalidomide|Dose level -1: 2.5 mg daily for days 1-7, 2.5 mg daily for days 8-21. Dose level 1: 2.5 mg daily for days 1-7, 5 mg daily for days 8-21. Dose level 2: 2.5 mg daily for days 1-7, 7.5 mg daily for days 8-21. Dose level 3: 2.5 mg daily for days 1-7, 10 mg daily for days 8-21. Dose level 4: 2.5 mg daily for days 1-7, 15 mg daily for days 8-21
45673219|NCT02217566|Drug|Abiraterone acetate|Participants will receive abiraterone acetate 1000 mg (4*250 mg tablets) orally once daily until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
45985418|NCT04395664|Device|C3+ Holter Monitor|ECG monitoring
45985419|NCT04395391|Diagnostic Test|SARS-CoV-2|Determine usability of study materials and kit
45985420|NCT04395313|Other|no intervention carried out|no intervention was done
45985421|NCT00498459|Behavioral|Physical activity|Physical promotion according to socio-ecological model Limitation of sedentary behaviour
45985422|NCT04132258|Other|survey|(presence of certain antecedents, weight, height, current or past existence of inflammatory rhinitis) and a second by the specialist doctor (pathology at the origin of the start of biotherapy, year of beginning of treatment, previous biotherapies over the last 3 years).
45985423|NCT03272087|Device|Thoracoscopy|50 % of patients will have performed af medical thoracoscopy (pleuroscopy)
45985424|NCT03272087|Device|VATS (thoracoscopy)|50 % of patients will have performed a VATS (video-assisted thoracic surgery) thoracoscopy
45985425|NCT02893306|Biological|MSCs|origin: bone marrow of healthy donor; manipulation: ex vivo expanded; via: intravenous; vehicle: 5% human recombinant albumin in physiological serum; dose: 2-3 millions/Kg; dosage: single
45985426|NCT02893540|Drug|Capecitabine|we are going to compare two maintenance treatment models with capecitabine in this study
45985427|NCT04393090|Other|eHealth platform CANKADO|The patients were asked to use the open eHealth platform CANKADO as a digital supporting tool.
45985428|NCT01327573|Drug|eculizumab|"Eculizumab Induction 600mg IV every 7 days for 4 doses~Eculizumab 900mg IV 7 days later~Eculizumab Maintenance 900mg IV every 14 days for total of 26 weeks"
45985429|NCT04328428|Other|acupuncture|Use one acupuncture needle insert in a acupoint.
45985430|NCT02893384|Drug|Local Anesthetic Injection above the serratus anterior|This is a quantitative pilot study assessing whether a new technique of local anesthesia injection during mastectomy surgery gives better pain outcomes than the standard methods. Patients who meet inclusion criteria will be invited to partake and all patients will have the injection technique. These patients will then be monitored for pain outcomes up to 7 days following the surgery and the results compared with historical results from patients who have already had the surgery.
45673220|NCT02217566|Drug|Prednisone|Participants will prednisone 5 mg orally once daily from Day 1 of Cycle 1 and continues until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
45673221|NCT02217566|Drug|Androgen deprivation therapy (ADT)|Participants will remain on a stable regimen of ADT, that is, luteinizing hormone-releasing hormone (LHRH) agonists including leuprolide acetate and goserelin acetate as per Investigator's discretion.
45673222|NCT02217410|Biological|CFZ533|
45673223|NCT02217410|Drug|Tacrolimus (Tac)|
45673224|NCT02217410|Drug|Mycophenolate mofetil (MMF)|
45673225|NCT02217410|Drug|Corticosteroids (CS)|
45985431|NCT02893228|Procedure|Saline|At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected.
45985432|NCT02893228|Drug|Levobupivacaine|the needle tip will then be positioned between C5 and C6 nerve roots. At this location, 20 ml of 0.25% levobupivacaine will be injected in 5 ml increments with intermittent aspiration. The needle tip will not be repositioned unless the patient complaints of paraesthesia
45985433|NCT00466973|Device|Dry bipolar radiofrequency (RF) clamp|Specified device used for ablation during standard surgical procedure
45985434|NCT00466973|Device|Unipolar microwave antenna|Specified device used for ablation during standard surgical procedure
45985435|NCT00466973|Device|Unipolar cryothermic probe|Specified device used for ablation during standard surgical procedure
45985436|NCT00466973|Device|Irrigated unipolar RF antenna|Specified device used for ablation during standard surgical procedure
45985437|NCT00466973|Device|Irrigated bipolar RF clamp|Specified device used for ablation during standard surgical procedure
45985438|NCT00466973|Device|Hi-intensity focused ultrasound wand|Specified device used for ablation during standard surgical procedure
45985439|NCT00498537|Drug|spironolactone|
45985440|NCT04387747|Other|SARCOPENIA IN STROKE PATIENTS|Demographic characteristics, duration of stroke, sarcopenia presence,thigh circumference , Hand grip strength , TANITA BIA analysis
45985441|NCT04387513|Procedure|Cardiac surgery|Cardiac surgery, if indicated, delayed or not by neurological complications
45985442|NCT00464750|Device|Pulmonary artery catheter|Four series of cardiac output measurements, each series consists of eight measurements using cold and eight measurements using tepid injectate. Randomized order of temperature at first series and crossover design.
45985443|NCT00491478|Drug|sertraline|
45985444|NCT03272204|Behavioral|No pubic hair|Natural pubic hair to fully removed pubic hair
45456726|NCT04495166|Behavioral|Motherly 1.0|A mobile app designed to promote life habits that have been shown to improve physical and mental health in pregnant women. The app consists of a package of specific and customized interventions defined by eight different modules: 1) Mental Health; 2) Sleep; 3) Nutrition; 4) Physical activity; 5) Social support; 6) Prenatal support; 7) Postnatal support, and 8) Library of pre and postnatal content. The app relies on extensive psychoeducational content delivered as tutorials, brief messages, and available as a library that can be read at the users' discretion; behavior monitoring using schedules, checklists, and notifications to help participants keep track of their health care visits, and schedule behavior activation activities; and gaming elements such as changes in background appearance to reflect participant's mood assessment and ratings of activities, and graphical and easy-to-use questionnaires for obtaining information (mood, nutrition habits).
45673226|NCT02217410|Biological|anti-IL2 Induction|
45985445|NCT03272204|Behavioral|Pubic Hair|Removed pubic hair to natural pubic hair
45985446|NCT00491517|Drug|Sirolimus|Patients will be given Sirolimus starting at the oral daily dose of 3 mg with periodically whole blood level measurements. The daily dose will be adjusted to keep sirolimus concentration within 10-15 ng/ml.
45985447|NCT00491517|Drug|conventional therapy|Antihypertensive drugs for patients with high blood pressure.
45985448|NCT00464789|Drug|Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet|
45985449|NCT00491595|Drug|High Dose Soy isoflavones|
45985450|NCT00467012|Drug|bevacizumab|10mg/kg，Day1, 15 of 1 cycle(4 weeks)
45985451|NCT00467012|Drug|Paclitaxel|90mg/ m2，Day1, 8, 15 of 1 cycle(4 weeks)
45985452|NCT03272867|Dietary Supplement|ProManna|
45985453|NCT00498654|Biological|Ty800 (Salmonella typhi) Oral Vaccine|
45985454|NCT01327495|Other|placebo acyline|Placebo acyline subcutaneous injection every 2 weeks
45985455|NCT01327495|Other|placebo gel|daily placebo testosterone gel applied transdermally x 12 weeks
45985456|NCT01327495|Drug|Testosterone 1% gel 1.25 g|testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
45673227|NCT02217332|Drug|dexpramipexole|Dexpramipexole capsule-shaped film-coated tablets at the dose strength of 150 mg administered orally as 1 tablet twice daily (300 mg/day)
45985457|NCT01327495|Drug|Testosterone 1% gel 2.5 g|Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
45985458|NCT01327495|Drug|Testosterone 1% gel 5.0 g|Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
45985459|NCT01327495|Drug|testosterone 1% gel 10 g|Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
45985460|NCT01327495|Drug|testosterone 1% gel 15 g|Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
45985461|NCT01327495|Drug|Acyline|300 ug/kg subcutaneous injection every 2 weeks
45985462|NCT00491634|Drug|treosulfan|12 g/m2 x 3 days
45985463|NCT00491634|Drug|Treosulfan|12 g/m2 x 3
45985464|NCT04328155|Procedure|Hotpack Group|Hotpack Group received 20 minutes hotpack to hamstring muscles region at prone position and participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
45985465|NCT04328155|Procedure|Infrared Group|Infrared Group received 20 minutes infrared to hamstring muscles region at prone position and participants stretchted the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15. seconds .
45985466|NCT04328155|Procedure|Ultrasound Group|Ultrasound Group received 5 minutes 1 M-Hz, 1,5 watt/cm2 ultrasound therapy to hamstring muscles region at prone position and participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
45985467|NCT04328155|Procedure|Control|Control Group participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
45985468|NCT01327339|Drug|Ropinirole|Basically there is no treatment allocation. Subjects who would be administered of ropinirole at their physician's direction will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
45985469|NCT01243515|Device|Non-Invasive Central Venous Pressure monitor|An adhesive patch (connected to the Mespere NICVP monitor) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with CVP values obtained by physical examination (standard clinical practice)
45985470|NCT01243515|Procedure|Physical examination of jugular vein|Physicians assess CVP using the jugular vein of the subject
45985471|NCT03272789|Other|Interviews with coach|For Interviews : done at Day 0 and at 1, 2, 3, 6 and 12 months. Questionnaires : given at Day 0, and at 3, 6 and 12 months.
46083390|NCT02714712|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180μg plus daily oral weight-based ribavirin (1,000 mg for body weight 75 kg or less, 1,200 mg for body weight greater than 75 kg) for 24 or 48 weeks
45985472|NCT01327300|Drug|Mesalamine|Apriso is a 5-ASA drug with Intellicor ™ extended-release delivery technology. A 1.5 gram dosage of Apriso (equaling four 375 mg capsules) once a day will be administered orally for a period of 12 weeks followed by a 3 week wash out prior to crossing over to the placebo arm.
45985473|NCT01327300|Other|Placebo|4 capsules (.375 gm sugar pill capsules) administered orally once a day. This group will receive the placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
45985474|NCT00491673|Procedure|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
45985475|NCT00491673|Procedure|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
45985476|NCT00467129|Genetic|microarray analysis|
45985477|NCT00467129|Genetic|mutation analysis|
45985478|NCT00467129|Genetic|polymerase chain reaction|
45985479|NCT00467129|Genetic|polymorphism analysis|
45985480|NCT00467129|Other|laboratory biomarker analysis|
45985481|NCT00467129|Other|questionnaire administration|
45985482|NCT04381273|Other|No intervention|questionnaire-based assessment
45985483|NCT00464828|Procedure|Internal jugular vein cannulation|
45985484|NCT00464828|Device|ultrasound|
45985485|NCT00467168|Behavioral|Diet|
45985486|NCT04379245|Other|Data research, database analysis|"Extraction of virological data at the virology laboratory (date, SARS-COV2 PCR result, identification number, sex, date of birth) (Excel file)~Extraction of demographic and viro-immunological data from patients infected with HIV and on PrEP followed at the Hospices Civils de Lyon, France, over the period concerned (Access extraction)~Data crossing (Excel / Access) and statistical analysis~Calculation of the positivity rate per calendar period (= number of diagnosed cases / number of patients tested) and the attack rate per calendar period (number of diagnosed cases / number of people exposed (= active file of patients followed reduced by the number already known to be positive))."
45985487|NCT04328389|Behavioral|electric toothbrush|Participants will be instructed to use their electric toothbrushes twice a day for controlling oral plaque
45985488|NCT04328389|Procedure|Professional oral hygiene|Professional oral hygiene using ultrosound scaling and root planing
45673228|NCT04758650|Drug|68GaNOTA-Anti-MMR-VHH2|"All subjects will receive at least one single intravenous injection of the IMP followed by a total body PET/CT prior to receiving standard-of-care therapy.~For patients in cohorts 1 and 2 : an optional injection of the IMP during or after therapy can be administered if a patient is treated with non-surgical modalities. Patients in cohort 6 who receive standard-of-care treatment can receive an optional injection of the IMP."
45673229|NCT02184572|Biological|Priorix|1 dose administered subcutaneously in the triceps region of left arm at Day 0
45985489|NCT00467207|Drug|Botulinum Toxin A|
45985490|NCT00467207|Behavioral|Resistance training|
45985491|NCT04378855|Other|Questionnaire|Quality of life assessment
45985492|NCT00592111|Drug|COPP/ABV|4 courses of COPP/ABV hybrid
45985493|NCT00592111|Drug|COPP/ABV|6 courses of COPP/ABV hybrid
45985494|NCT00592111|Drug|intensive chemo with concurrent growth factor|6 cycles (2 courses) of intensive chemotherapy with concurrent growth factor
45985495|NCT00592150|Drug|fenoldopam|The fenoldopam infusion rate will be 0.05 μg/kg/min for 3 hours
45985496|NCT00592150|Drug|Placebo|Placebo infusion for 3 hours
45985497|NCT00464867|Biological|Whole cell killed cholera vaccine & probiotic|The oral cholera vaccine Dukoral will be administered to all study participants in two doses,two weeks between doses.Each dose of the formalin inactivated whole cell vaccine contains one mg of recombinant B subunit of cholera toxin(rCTB).The vaccine will be administered in bicarbonate-tartaric acid buffer to counteract the effect of low pH in the stomach.
45985498|NCT00592189|Procedure|blood draw|blood collection
45985499|NCT00592228|Device|Cypher, Taxus or Endeavor|"percutaneous drug-eluting stent implantation,~FFR group: if FFR<0.75~Routine DES group"
45985500|NCT00592306|Drug|thymoglobulin (intraoperative)|"All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm I will receive thymoglobulin intraoperatively followed by a postoperative placebo dose and two subsequent thymoglobulin doses."
45985501|NCT00592306|Drug|thymoglobulin (postoperative)|"All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm II will receive placebo intraoperatively followed by 3 postoperative doses of thymoglobulin."
45985502|NCT00467246|Drug|Levemir|
45673230|NCT02184572|Biological|M-M-R II|1 dose administered subcutaneously in the triceps region of left arm at Day 0
45673231|NCT02184572|Biological|Varivax|1 dose administered subcutaneously in the triceps region of right arm at Day 0
45673232|NCT02184572|Biological|Havrix|1 dose administered intramuscularly in the anterolateral region of the right thigh at Day 0
45673233|NCT02184572|Biological|Prevnar 13|1 dose administered intramuscularly in the anterolateral region of the left thigh at Day 0 to subjects recruited in US
45673234|NCT04755218|Other|Vaginal Misoprostol|"Although labeled experimental for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States"
45673235|NCT04755218|Other|Oral Misoprostol|Patients will receive standard oral misoprostol 100mcg according to current labor induction protocol
45985503|NCT00592345|Radiation|Proton Beam Radiation|Administered over a period of 12 weeks.
45985504|NCT00592345|Radiation|Photon Beam Radiation|Administered over a period of 12 weeks.
45985505|NCT00592345|Radiation|Interoperative radiation|Radioactive plaque applied at the time of surgical removal of the tumor.
45985506|NCT00498732|Device|CPAP|CPAP treatment for 4 weeks
45985507|NCT04377295|Drug|Ranibizumab 0.5Mg/0.05Ml Oph Inj|All patients received one monthly intravitreal injection of Ranibizumab (0.5 mg/0.05 ml) through the pars plana under aseptic conditions until maximum visual acuity was achieved and there was no sign of macular edema at optical coherence tomography
45985508|NCT00491712|Procedure|Glaucoma drainage implant with/without triamcinolone|
46083391|NCT05329610|Dietary Supplement|Beta-alanine|Slow-release beta-alanine.
45985509|NCT00467324|Device|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
45985510|NCT02893111|Drug|Bortezomib|Bortezomib will be subcutaneously applicated in 4 treatment cycles with 4 injections of 1 mg Bortezomib /m2 body surface per cycle
45985511|NCT00498771|Behavioral|Aquatic Exercise arm|Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference & volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
45985512|NCT00464984|Behavioral|Lifestyle intervention|Intensive lifestyle intervention at a rehabilitation centre 3 times a week the first 3 months of study
45985513|NCT04328272|Drug|Hydroxychloroquine 200 Mg Oral Tablet|Hydroxychloroquine administered orally with water
45985514|NCT04328272|Drug|Azithromycin 500Mg Oral Tablet|Azithromycin administered orally with water
45985515|NCT04328272|Dietary Supplement|Glucose tablets|administered orally with water
45985516|NCT04328194|Diagnostic Test|Serum Autotaxin|Marker
45985517|NCT04328194|Radiation|chest x-ray|chest x- ray will be done for the study group
45985518|NCT04328194|Diagnostic Test|Breast ultrasound or mammography|Breast ultrasound or mammography will be done for the study group to diagnosis of breast cancer
45985519|NCT04328194|Diagnostic Test|Histopathological examination of breast mass specimens|by True cut or fine needle aspiration cytology
45985520|NCT04328194|Radiation|Magnetic Resonance Imaging ( MRI) and Bone scan|will be done for the study group
45985521|NCT04328194|Diagnostic Test|Peripheral haemogram|blood sample will be taken from the patients
45985522|NCT04328194|Diagnostic Test|Renal and liver functions|to exclude any other morbidity
45985523|NCT04328194|Diagnostic Test|Prothrombin time and concentration|blood sample will be taken from the patients
45985524|NCT04328194|Diagnostic Test|Cancer Antigen 15-3 (CA15-3).|will be done for the 2 groups
45985525|NCT04328194|Other|Full medical history|full medical history will be taken from all patients
45985526|NCT04328194|Other|Full clinical examination|full clinical examination will be done for the patients
45985527|NCT03272750|Dietary Supplement|Bioscalin® new formulation with Galeopsis Segetum|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of study product at lunch for the first 3 months of the trial.
45673236|NCT02181842|Drug|Pioglitazone|Pioglitazone tablets
45985528|NCT03272750|Dietary Supplement|Reference product|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of reference product at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
45985529|NCT03272750|Dietary Supplement|Placebo|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
45673237|NCT04754594|Biological|BNT162b2|Intramuscular Injection
45673238|NCT04754594|Other|Placebo|Intramuscular Injection
45673239|NCT04761770|Other|Geriatric assessment (GA) pre-transplant|Assessment of comorbidities, polypharmacy, and functional, nutritional, and psychosocial impairment.
45673240|NCT04761770|Drug|conditioning regimen|"Based on the Geriatric assessment.~HCT-CI/Age ≤4 AND no IADL impairment (less vulnerable/fit) -> Myeloablative (MA) regimen~HCT-CI/Age >4 AND/OR any IADL impairment (more vulnerable) -> Reduced-intensity (RIC)/Nonmyeloablative (NMA) regimen"
45985530|NCT00498810|Procedure|complete repair|
45985531|NCT00498810|Procedure|partial repair of the abdominal wall|
45985532|NCT04374682|Other|exercises|stretching exercises - physiotherapy modalities - self care instructions
45985533|NCT04374370|Biological|SARSCoV2 Convalescent Plasma|Provide expanded access to SARSCoV2 convalescent plasma (EAP) collected from matched donors as described to patients with severe or life-threatening illness owing to COVID-19.
45985534|NCT00465023|Procedure|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday) for 3 weeks.
45985535|NCT00491790|Drug|Montelukast|Montelukast 4 mg rapid dissolving granules in sterile water given orally once
45985536|NCT00491790|Other|Sterile water|Sterile water
45985537|NCT02892994|Other|ultrasound|
45985538|NCT04371328|Other|RECOP unit patient|"All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.~30 days after inclusion, virological status and mortality will be collect"
45985539|NCT04371211|Behavioral|Telemedicine Brain Injury Coping Skills|"BICS is a 12 session (one session per week), manualized, cognitive-behavioral treatment group designed to provide support, coping skills, and psychoeducation aimed to improve perceived self-efficacy (PSE) and emotional functioning. PSE has been found to be strongly linked to social participation, increased positive regard toward the caregiving role, and was found to be the greatest contributing factor to predicting life satisfaction.~For this study, the Brain Injury Coping Skills (BICS) group intervention will be administered electronically in a web-based group telemedicine platform, BICS-T. The purpose of this phase is to test the feasibility, participant training protocol, and ease of use of equipment and technology."
45985540|NCT00498849|Device|CPAP|
45985541|NCT04369261|Drug|Synovian®|Synovian® Inj.
45985542|NCT03272009|Drug|EYP001a|Capsules administered orally. Number of morning and evening capsules depending on treatment arm
45985543|NCT03272009|Drug|Placebo|Placebo capsules for oral administration, identical in appearance to the EYP001a capsules
45985544|NCT03272009|Drug|Entecavir|Tablets administered orally
45985545|NCT03272009|Drug|peg-interferon alfa-2a|Ready-to-Use pre-filled syringes for subcutaneous injection
45985546|NCT04327882|Diagnostic Test|Point-of-care ultrasound|performance of a POCUS: lung and cardiac ultrasound mainly
45985547|NCT00498888|Procedure|tolterodine|Detrusitol SR 4 mg, 1 capsule for a day, 3 months.
45985548|NCT00498888|Procedure|bladder training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
45985549|NCT00498888|Procedure|pelvic floor muscle training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
45985550|NCT00498888|Procedure|pelvic floor rehabilitation|The Pelvic floor rehabilitation protocol based on bladder training protocol and PFMT and lifestyle advice and information about good bladder and bowel habits. Four visits in 3 months was made with pelvic floor physical therapist, who is trained in the procedure.
45985551|NCT02893072|Behavioral|Individualized medical nutrition therapy|The intervention group involves dietary and exercise advice and monitoring.
45985552|NCT04369105|Other|Prone position|The patients will be put in prone position while receiving invasive mechanical ventilation and the investigators will monitor changes in mechanical power applied to the respiratory system and compare with supine position
45985553|NCT04368754|Other|Questionnaire|Patients evaluated with different questionnaire.
45985554|NCT00491868|Drug|R744|100μg/4week for 8 weeks, then 50~250μg/4week for 16 weeks
45985555|NCT00491868|Drug|R744|150μg/4week for 8 weeks, then 50~250μg/4week for 16 weeks
45985556|NCT00491868|Drug|rHuEPO|2250IU or 3000IU(i.v.) 2 or 3 times/week for 8 weeks, then 750~9000IU(i.v.)/1~3week for 16 weeks
45985557|NCT00491868|Drug|rHuEPO|4500IU or 6000IU(i.v.) 2 or 3times/week for 8 weeks, then 750~9000IU(i.v.)/1~3week for 16 weeks
45985558|NCT00491868|Drug|R744 placebo|0 μg/4week for 24 weeks
45985559|NCT00491868|Drug|rHuEPO placebo|0 IU 2 or 3 times/week for 8 weeks, then 1~3 times/week for 16 weeks
45985560|NCT04367896|Other|Survey Group|"The survey sought to elucidate equity principles that are influencing transplant decision making. The group of respondents included solid organ transplant doctors (surgeons, referring doctors, transplant physicians, transplant coordinators, ICU transplant doctors), COVID-doctors (ICU doctors, Infectious Disease Doctors, Pulmonologists, Internists), and Ethicists with experience of transplant related issues.~Respondent identification:~A. The e-mail addresses of corresponding authors from Scopus January 1, 2017 and march 20, 2020:~All (surgery) AND subj (medi) and key (transplantation), All (critical care) AND subj (medi) and key (transplantation), All (ethics) AND subj (medi) and key (transplantation). B. Emailing through the mailing list of scientific societies. C. The link to the survey published online. D. The link to the survey circulated through personal contacts and via social media sites."
45985561|NCT02893033|Device|repetitive transcranial magnetic stimulation|rTMS
45985562|NCT00491907|Drug|folic acid 5mg/day|
45985563|NCT03271931|Behavioral|Active choice|EHR alert prompting cardiologists to make an active choice to prescribe a statin or not.
45985564|NCT03271931|Behavioral|Passive choice|EHR passive alert to cardiologists about prescribing a statin
45985565|NCT00467441|Drug|VSF-173|
45985566|NCT00499005|Drug|Syntommetrine and Carbetocin|Syntommetrine 1ml and Carbetocin 100microgram
45985567|NCT00499005|Drug|Syntommetrine and Carbetocin|Syntommetrine 1ml and Carbetocin 100micgrams
45985568|NCT00465140|Drug|creatine supplementation|
45985569|NCT00465140|Behavioral|aerobic exercise training|
45985570|NCT04327765|Combination Product|0.5mg AZ-010|Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo
45985571|NCT04327765|Combination Product|1mg AZ-010|Subject will receive a single inhaled dose (1mg) of AZ-010 or matching Staccato Placebo
45985572|NCT04327765|Combination Product|3mg AZ-010|Subject will receive a single inhaled dose (3mg) of AZ-010 or matching Staccato Placebo
45985573|NCT04362163|Device|Snorkel-based improvised personal protective equipment|An improvised PPE design based on a full face snorkel mask mated to a heat-and-moisture exchange filter via a 3D printed adaptor.
45985574|NCT00491946|Drug|Actinomycin-D|
45985575|NCT00491946|Drug|Vincristine|
45985576|NCT03272048|Behavioral|Lethal Means Counseling|Lethal means counseling is broadly defined as clinician-initiated discussions that encourage an individual at risk for suicide to safely store his or her firearms. Examples in this domain include applying a gun lock, separating the gun from its ammunition, dismantling the firearm and keeping its components locked and/or separated, or safely transferring the firearm to a trusted loved one, friend, or police station until risk abates (Bryan, Stone, & Rudd, 2011; Jin, Khazem, & Anestis, 2016). Further, given that recent purchasers of firearms are at markedly increased risk of death by suicide (Wintemute, Parham, Beaumont, Wright, & Drake, 1999), anticipatory counseling on firearm safety should also be considered for at-risk individuals who do not report currently owning or having access to a firearm, but who report prior firearm ownership/access or intentions of obtaining a firearm in the future (Harvard T.H. Chan School of Public Health, 2017).
45985577|NCT04361344|Biological|blood samples|Clinical examination and blood samples will be done at inclusion (day 0), at day 7 (between day 4 and exit from intensive care) and at day 60.
45985578|NCT04358848|Device|X-PLO2R|Portable Oxygen Concentrator (POC)
45985579|NCT01245231|Genetic|protein expression analysis|
45985580|NCT01245231|Genetic|western blotting|
45985581|NCT01245231|Other|flow cytometry|
45985582|NCT01245231|Other|laboratory biomarker analysis|
45985583|NCT01245231|Other|medical chart review|
45985584|NCT03272672|Other|Össür Unloading Knee Brace|"During the braced walking condition, a valgus unloader brace (Össür Unloader One®, Össur Americas, Orange County, CA) will be fitted by a certified athletic trainer per manufacturer instructions to the dominant limb while the participant is seated with knee flexed to approximately 80°.~The brace will be maximally adjusted to unload the medial compartment."
45985585|NCT00592423|Other|Continuous Positive Airway Pressure during MRI|10 cm H20 pressure for CPAP while lateral neck positioning is done for MRI - each side should take 5 minutes.
45985586|NCT00592462|Procedure|Whole Body MRI|The whole body MRI will include T1-weighted and T2-weighted phase-sensitive MR imaging as well as diffusion weighted imaging of the whole body in multiple patient table stations.
45985587|NCT00592540|Procedure|Unrelated Donor BMT|Unrelated donor bone marrow transplantation has not been performed with these patients in the past
45985588|NCT00491985|Biological|A/H5N1 Inactivated, split-virion pandemic influenza vaccine|0.5 mL, Intramuscular
45985589|NCT00491985|Biological|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.5 mL, Intramuscular
45985590|NCT00491985|Biological|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.25 mL, Intramuscular
46083392|NCT05329610|Dietary Supplement|Placebo|Taste and appearance-matched placebo (tapioca starch).
45985591|NCT04355884|Diagnostic Test|Standard 12-lead ECG, NT-proBNP, echocardiography|Cardiac assessment
45985592|NCT03272594|Other|Breastfeeding|Infants will be placed in skin-to-skin contact with their mother at least five minutes prior to heel lance to allow time to settle and initiate breastfeeding. Breastfeeding position will be determined based on individual maternal preference in order to optimize feeding as well as to facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Active breastfeeding will be facilitated to ensure it takes place for a minimum of two minutes prior to heel lance, and will continue until the procedure is completed.
46083393|NCT04096716|Drug|Tc-99m tilmanocept|Tc-99m tilmanocept is a radioactive diagnostic agent.
46083394|NCT02782598|Device|CRT+NAVH|Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
46083395|NCT04095234|Procedure|Acupuncture|Acupuncture, a therapy of traditional Chinese medicine (TCM), involves penetrating the skin with thin, solid, metallic needles that are manipulated by hand or electrical stimulation. If the patient has an electronically charged device, they will not receive TENS stimulation.
45985593|NCT03272594|Drug|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance. Non-nutritive sucking will be offered using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose.
45985594|NCT02892916|Drug|Ketamine|A bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
45985595|NCT02892916|Drug|Placebo|A bolus of an intravenous normal saline solution following induction of anaesthesia.
45985596|NCT01245309|Procedure|scratching|endometrial scratching before COH in IVF
45985597|NCT01245309|Procedure|A PLACEBO PROCEDURE|A PLACEBO PROCEDURE
45985598|NCT04354792|Diagnostic Test|Serum SARs COV 2 IGg screening in health care workers|Blood samples will be collected from the enrolled HCWs. Sample collection, processing, and laboratory testing will follow guidance from the World Health Organization
46083396|NCT04095234|Procedure|Massage|Massage, which involves the manual manipulation of muscles and other soft tissue areas of the body, is one of the earliest known forms of pain relief.
46083397|NCT02784470|Device|gastroduodenal stent placement|
46083398|NCT02784470|Procedure|gastrojejunostomy|
45985599|NCT04354285|Other|Observational|Observational
45985600|NCT02956304|Other|PMv stimulation (iTBS)|PMv stimulation (iTBS)
45985601|NCT02956304|Other|PMv inhibition (cTBS)|PMv inhibition (cTBS)
45985602|NCT02956304|Other|Control (SHAM)|Control (SHAM)
45985603|NCT04354753|Other|No Intervention|No intervention
45985604|NCT00492102|Drug|Montelukast|One oral dose of Montelukast 0.15mg (infants weighing 500-1000gm) or 0.2mg (infants weighing >1000gm). Two blood samples will be obtained from each infant within 24 hours of the drug administration and plasma Montelukast levels will be determined.
45985605|NCT00465218|Procedure|Prophylaxis of Thrombosis after aortic valve replacement|Two standard prophylactic treatments of thrombosis within the first 3 months postsurgery currently used in our institution: a) daily dose of aspirin (325 mgs; b) daily dose of aspirin (81 mg) plus Warfarin for target INR 2.0-2.5
45985606|NCT00499044|Other|CDR Computerized Cognitive Assessment System|Cognitive Drug Research Computerized Cognitive Assessment System consists of performance tasks that measure reaction time, numeric and spatial working memory, word and picture recall and recognition, and episodic secondary memory. CDR is a single, unified battery that can be stored and administered using a laptop computer.
45985607|NCT00499044|Other|MATRICS Consensus Cognitive Battery|The MATRICS Consensus Cognitive Battery measures functioning across various cognitive domains, such as attention, working memory (verbal and nonverbal), learning (verbal and visual), reasoning and problem solving, and social cognition. Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes.
45985608|NCT02892838|Device|mobile bearing knee system for total knee arthroplasty|
46083399|NCT04182230|Other|No intervention. This study was an evalution with no intervention.|Not an interventional study
46083400|NCT02717676|Procedure|Episiotomy|episiotomy will be done after crowning of the fetal head
46083401|NCT02782520|Drug|Ringer Lactate (10ml/kg) fluid expansion|
46083402|NCT02782520|Drug|Hypertonic saline (3ml/kg) fluid expansion|
46083403|NCT02714166|Other|Sunscreen lotion SPF (Sun Protection Factor) 50 (BAY987521)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
46083404|NCT02714166|Other|Ophthalmic Ointment|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
46083405|NCT04094064|Device|Continuous Glucose Monitor|Use of a continuous glucose monitor during study period.
45985609|NCT02892838|Device|fixed bearing total knee prosthesis|
45985610|NCT00467636|Procedure|Blood glucose monitoring|Regular pre and post meal blood glucose monitoring.
45985611|NCT00467636|Drug|Insulin Glulisine|Sub cutaneous injection given twice daily for 3 days. Dosage titrated to body mass index and body weight (BMI < 30 = 0.1 unit/kg. BMI > 30 = 0.2 unit/kg)
45985612|NCT00492141|Drug|Temozolomide|Cycle 2, Dose Level 1 = 100 mg/m^2 by mouth (PO) Daily, Days 1-5 Prior to L9-NC; Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, advance to 100 mg/m^2 PO Every 12 Hours, Days 1-5 Prior to L9-NC. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2; Cycle 4 and beyond = Patients will continue on dose level 1 or 2 as given in cycle 3.
45673241|NCT04761770|Procedure|Allogeneic CD34+ selected stem cells|Stem cells are collected as per institutional guidelines. CD34+ enriched stem cells will be obtained using the FDA approved reagents from Miltenyi, according to the instruction manual.
45832864|NCT03810534|Behavioral|Connect-Home|Connect-Home will introduce organizational structure to support delivery of transitional care processes. New elements of structure include:electronic health record (EHR) template, Connect-Home Toolkit, and Staff Training. After structural elements are added, SNF staff will use Connect-Home care processes to deliver the 2-step transitional care intervention.In Step 1, SNF nurses, therapists, and social workers will develop a Transition Plan of Care and prepare the patient and caregiver to manage the patient's serious illness and functional needs. In Step 2, the Connect-Home Activation RN will visit the patient's home within 24 hours of discharge; the nurse will activate the Transition Plan of Care at home. Both intervention steps focus on 6 key care needs to optimize patient and caregiver outcomes: 1) home safety and level of assistance; 2) advance care planning; 3) symptom management; 4) medication reconciliation; 5) function and activity; and 6) coordination of follow-up medical care.
45832865|NCT05347914|Behavioral|Mindfulness|Participants will be taught a mindfulness exercise and will be instructed to use this exercise (following a mobile app) whenever they experience a food craving to eat for non-homeostatic reasons.
45832866|NCT05347836|Diagnostic Test|ELISA|Determination of serum levels of sCD14 and sCD163 using ELISA
45832867|NCT05347758|Drug|HRS-7535|Drug: HRS-7535
45832868|NCT05347758|Drug|Placebo|Drug: Placebo
45832869|NCT05347680|Device|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction
45832870|NCT05347680|Device|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
45832871|NCT03673644|Other|Questionnaires|Two questionnaires will be administered, one focusing on life space and the other focusing on low luminance.
45832872|NCT03809598|Behavioral|Mindfulness Based Cognitive Therapy|"See Mindfulness Based Cognitive Therapy (MBCT) Arm description"
45832873|NCT03580434|Device|V-STRUT|Minimally invasive implantation of V-STRUT
45985613|NCT00492141|Drug|L9-NC|"Cycle 1 = Administered by aerosol 5 consecutive days per week for 2 weeks. A total of 10 ml of 0.4 mg/ml in an aerosol reservoir delivered over approximately 30 minutes per day given once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 2, Dose Level 1 = Week 1, doses 1-5 preceded by temozolomide. Continue L9-NC once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, due to drug, during cycle 2, L9-NC may be increased to twice daily, approximately 12 hours apart. Week 1, the morning dose on days 1-5 preceded by temozolomide. L9-NC will be given twice a day, 5 days a week, for 2 weeks, followed by 2 weeks off. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2.~Cycle 4 and beyond, patients will continue on dose level 1 or 2 as given in cycle 3."
45985614|NCT04350112|Other|Clinical assessment|Clinical assessment (history, examination) is gold standard for diagnosing constipation - gold standard will be compared with simple question about constipation, Rome IV diagnostic criteria for OIC, and common definitions of constipation for constipation / OIC
45985615|NCT00467675|Device|CGM System for Type 1 and Type 2 Diabetes Mellitus|
45985616|NCT04350151|Behavioral|no intervention|no intervention
45985617|NCT04327726|Drug|Dexmedetomidine Nebulization|ultrasonic nebulization of 1 µg/kg dexmedetomidine for PDPH treatment
45985618|NCT04327726|Other|0.9% Saline Nebulization|nebulization of 4mL 0.9% saline
45985619|NCT00499161|Behavioral|New model of nursing care|
45985620|NCT04349254|Device|Corneal treatment by a low vision aid device|Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The change of modulus produces a change of corneal stiffness and shape that modifies the distribution of light onto the retina. Light rays are redirected from dysfunctional areas of the retina that have been damaged by age-related macular degeneration (AMD) to functional areas of the retina, thereby improving patient vision.
45673242|NCT01632020|Drug|Placebo|2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
45673243|NCT01632020|Drug|Metformin|850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
45673244|NCT02181296|Drug|ropivacaine|
45673245|NCT04761692|Behavioral|Full VEPMP Intervention|Delivery of intrapersonal/interpersonal (i.e., motivational interviewing, vaccine educators, personal testimony, etc.), AND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)
45673246|NCT04761692|Behavioral|Partial VEPMP Intervention|Delivery of iAND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)
45673247|NCT04761692|Behavioral|Delayed VEPMP Intervention|Delayed implementation of delivery of intrapersonal/interpersonal AND organizational after 1 year of study start
45832874|NCT03580356|Biological|Ligelizumab|Liquid in vial
45832875|NCT03580356|Biological|Omalizumab|Lyophilized powder for solution in vial
45832876|NCT03580356|Other|Placebo|Liquid in vial
45832877|NCT03670680|Device|Use of the Lina LibrataTM|Use of the Lina LibrataTM
45832878|NCT03807414|Device|oXiris|Every center will prescribe EBPT with oXiris in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
45985621|NCT00492219|Device|Vanguard M fixed-bearing or Oxford mobile-bearing prostheses|Patients that are appropriate for partial knee replacement will be randomized to receive one of these two FDA-approved implant systems.
45985622|NCT00492219|Device|Total Knee Replacement|Patients undergoing total knee replacement with the Vanguard Complete Knee implant system
45985623|NCT00465257|Drug|artesunate + amodiaquine|
45832879|NCT03578796|Diagnostic Test|ECAS-N|assessing ALS-specific cognitive impairment
45985624|NCT04131127|Device|Sentinel Device|Sentinel Device used during TAVI in a Low Risk Patient
45985625|NCT01245465|Other|Profermin|Medical Food (food for special medical purposes)
45832880|NCT03578796|Diagnostic Test|MoCA|assessing cognitive impairment
45832881|NCT03578796|Diagnostic Test|CDR|assessing global cognitive impairment, as well as possible diagnosis- and Level of dementia
45832882|NCT03578796|Other|Questionnaire|Questions related to work situation and car driving
45832883|NCT03668106|Procedure|sperm processing method|different sperm processing method for selcting most proper sperm for ICSI
45832884|NCT03575832|Other|Counseling|Complete nutrition counseling sessions
45832885|NCT03575832|Other|Informational Intervention|Receive an exercise plan and printed materials
45832886|NCT03575832|Other|Quality-of-Life Assessment|Ancillary studies
45832887|NCT03575832|Other|Questionnaire Administration|Ancillary studies
45832888|NCT03575832|Behavioral|Telephone-Based Intervention|Receive telephone coaching calls
45832889|NCT03807336|Behavioral|Emotion-Focused Skills Training for Parents - Experiential|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
45832890|NCT03807336|Behavioral|Emotion-Focused Skills Training for Parents - Psychoeducational|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
45832891|NCT03806244|Other|Intraoperative acquisition (robotic c-Arm) of images|"Conventional laparoscopic colorectal oncologic resection is performed. During the procedure, the operator will identify previously defined anatomical landmarks, point them with an instrument tracked by the navigation system and the accuracy of the stereotactic navigation system will be calculated by comparing the surgical anatomical point and its correspondent on the images of the navigation platform."
45832892|NCT03575052|Drug|Pimavanserin|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)
45832893|NCT03575052|Drug|Placebo|Placebo, tablets, once daily by mouth (provided as two placebo tablets)
45832894|NCT03804606|Other|Referral to MTM Pharmacist|Patients will be referred for an encounter with a medication therapy management pharmacist.
45832895|NCT03574896|Other|Computer model predictions of acute kidney injury|Comparison of the performances of AKIpredictor and physicians in predicting AKI stage 2 or 3 in the 7 days following ICU admission
45832896|NCT04762056|Other|Chelsea Critical Care Physical Assessment Tool|Chelsea Critical Care Physical Assessment Tool is a bedside assessment tool firstly reported in 2013 to measure physical morbidity in the critical care population, consisting of 10 items (respiratory function, cough, moving within the bed, supine to sitting on the edge of bed, dynamic sitting, standing balance, sit to stand, transferring from bed to chair, stepping, and grip strength) rated on a 6-point scale from complete dependency (level=0) to independency (level=5). Therefore, the CPAx sum score ranges from 0 (worst condition) to 50 (best functioning/independence)
45832897|NCT04761900|Diagnostic Test|the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases|
45832898|NCT03804528|Behavioral|Aerobic Exercise|Participants will be fitted with a heart rate monitor and will be instructed to walk (or trot) to maintain 55-64% of maximal heart rate (determined by exercise test) for the first 4-weeks of exercise or to maintain 65-90% of maximal heart rate (determined by exercise test) for the second 4-weeks of exercise during each session.
45832899|NCT03556020|Drug|Pemziviptadil (PB1046)|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
45832900|NCT03570918|Biological|MGD014|HIV-1 x CD3 bispecific DART molecule
45985626|NCT04130776|Diagnostic Test|Measurement of four prostate-specific kallikreins for the 4Kscore Test when serum stored uncentrifuged|The 4Kscore Test helps clarify the biopsy decision-making process by determining a patient specific probability for finding aggressive, Gleason score 7 or higher prostate cancer upon biopsy. These are the aggressive prostate cancers that always require medical treatment or intervention. The 4Kscore Test relies on the measurement of four prostate-specific kallikreins in the blood: Total PSA, Free PSA, Intact PSA, and Human Kallikrein 2 (hK2). The blood test results are combined in an algorithm with patient age, digital rectal exam (nodules, no nodules), and prior negative biopsy (yes, no) to give physicians a personal score for each patient. The 4Kscore Test predicts the risk percent score from <1% to >95% of a man having aggressive cancer in a prospective biopsy.
45673248|NCT02215616|Drug|Laquinimod|Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.
45673249|NCT02215616|Drug|Placebo|Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.
45673250|NCT02213666|Device|Intracardiac Imaging|Imaging of the RAA and LAA with ICE and assessment of thrombus.
45673251|NCT02213510|Device|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
45673252|NCT02213510|Device|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
45985627|NCT00492258|Drug|sorafenib tosylate|
45985628|NCT00492258|Procedure|adjuvant therapy|
45985629|NCT04327648|Device|Social interaction treatment|Children in social interaction treatment group will have 30min social interaction each day for 3 months.
45832901|NCT03570372|Behavioral|Internet-based treatment for adults with autism spectrum|Internet-based CBT. The intervention includes 18 modules focusing on: Psychoeducation, individual goal setting, behavioral change, management strategies and stress management
45985630|NCT04327648|Device|Neuronal cognition treatment|Children in neuronal cognition treatment group will experienced neural cognition training 30min each day for 3 months.
45985631|NCT04327648|Other|Routine treatment|Children in routine treatment group will keep the same initial treatment.
45985632|NCT00467714|Procedure|rhinoplasty|COLUMELLA STRUT PLACEMENT
45832902|NCT03570372|Behavioral|Psychoeducation about autism spectum disorder|"Self-studies by reading the book What does the disability mean ?: Living with autism / Asperger syndrome. Project Empowerment (2004), by Norrö & Swing Åström, as well as a book of biographical stories of people who have ASD. The first book will be read during the first half of the project, and the second will be in the second half."
45985633|NCT03272438|Device|Accelerometer|Participants use an accelerometer to monitor their steps activity
45985634|NCT03272438|Behavioral|Step goal|Participants are given a daily step goal to aim for
45985635|NCT03272438|Behavioral|Consistent contexts|Participants plan to take steps in contexts that are similar from day to day
45985636|NCT03272438|Behavioral|Inconsistent contexts|Participants plan to take steps in contexts that vary from day to day
45985637|NCT02955810|Drug|Daratumumab|
45985638|NCT02955810|Drug|Cyclophosphamide|
45985639|NCT02955810|Drug|Bortezomib|
45985640|NCT02955810|Drug|Dexamethasone|
45985641|NCT04342468|Other|non-interventional|No intervention
45985642|NCT04339855|Other|CAD with LCI for colorectal polyp detection|Polyps within fully recorded endoscopy videos with LCI mode, covering the whole spectrum of adenomatous histology, are used to evaluate the efficacy of CAD with LCI for polyp detection.
45985643|NCT00465296|Drug|rosiglitazone|
45985644|NCT00492414|Drug|Paroxetine CR|
45985645|NCT04337983|Device|Transpulmonary thermodilution|Obtained by averaging the results of three thermodilution measurements. Each thermodilution is performed by injecting a bolus (15 mL) of cold saline (less than 10°C)
45985646|NCT04337983|Device|Echocardiography|Daily echocardiography evaluation
45985647|NCT04337320|Other|newborns from covid 19 positive mothers|Evaluation of apgar, hemogram and developmental status of babies born from covid 19 positive mothers
45985648|NCT03272555|Other|WILD 5 Wellness Interventions|Students enrolled in the study will be asked to complete activities in five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition for 30 days.
45673253|NCT02158442|Procedure|Percutaneous Isolated Limb Perfusion (PILP) delivery|The Percutaneous Isolated Limb Perfusion (PILP) delivery intervention procedure enables the use of existing antibiotic therapies in a more targeted and aggressive fashion; it addresses limitations associated with the use of conventional antibiotic drug delivery. As part of the procedure, the circulation of the limb is isolated separately from the general circulatory system enabling the delivery of antibiotic at high therapeutic doses that are not achievable when standard doses are administered intravenously.
45673254|NCT02158442|Drug|Timentin|The Control Group will receive standard dosings of intravenous Timentin plus other standard care.
45832903|NCT05347524|Other|Baseline blood draw and blood-based biomarkers analyses|Baseline blood draw and blood-based biomarkers analyses
45832904|NCT01677546|Device|CSII+BC+CL|Insulin pump bolus calculator wirelessly communicated with blood glucose meter (Contour Link)
45832905|NCT01677546|Device|CSII+BC|Insulin pump bolus calculator without wireless communication with blood glucose meter (Contour Link)
45832906|NCT04403724|Drug|Bupivacaine-fentanyl-Morphine.|2.4 ml Bupivacaine 0.5%, 20 µg Fentanyl and, 100 µg preservative free morphine
45832907|NCT04403646|Dietary Supplement|ARBOX|dry extract of polyphenols (tannins) form quebracho and chestnut 240 mg, B12 vitamin 0.72 µg
45832908|NCT04403646|Other|PLACEBO|Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for ARBOX
45832909|NCT03567876|Drug|Venetoclax|Consolidation and maintenance phases with Venetoclax (for a total of 2 years) after an induction phase R-BAC (up to 6 cycles for law risk patients and up to 4 cycles for high risk patients)
45832910|NCT04403568|Drug|Ursolic Acid|Ursolic Acid 150mg
45832911|NCT04403568|Drug|Curcumin|Curcumin 600mg
45832912|NCT03552822|Other|ERAS Protocol Implementation|Implementation of ERAS Protocol Implementation
45985649|NCT00499200|Drug|SRA-444|
45985650|NCT04327492|Diagnostic Test|Biomarker - FGF 23; troponin I; PCR - high sensitivity; BNP|peak wave velocity; gray weale plaque classification
45985651|NCT00499278|Behavioral|Rehabilitation after joint replacement surgery|
45985652|NCT04334395|Procedure|primary tumor resection group|resection of cancer at colon
45985653|NCT04333186|Other|Data from ultrasound measurements|Data from ultrasound measurements and from the electronic patient record will be obtained / analyzed. One additional blood sample will be obtained within 24 hours after inclusion, during planned blood collection (from arterial line or venous puncture).
45985654|NCT01243632|Drug|Prolonged 6-hr infusion of gemcitabine|Gemcitabine 250 mg/m2 in prolonged 6 hr infusion on day 1 and 8, and cisplatin at 75 mg/m2 on day 2 of 3 week cycle, for 4-6 cycles
45985655|NCT00467909|Behavioral|micronutrients|
45985656|NCT04327375|Other|Observational|Observational
45985657|NCT00499356|Device|pressure reducing insole|
45985658|NCT00499356|Device|GlideSoft®|
45985659|NCT04327453|Device|double antibiotic paste with XP-endo Finisher file|XP-endo Finisher files (FKG Dentaire, La Chaux-de-Fonds, Switzerland). file will be used with an endodontic motor X-Smart (Dentsply Sirona, Ballaigues, Switzerland) in removal of double antibiotic paste
45985660|NCT04327453|Device|double antibiotic paste with Irrisafe Ultrasonic tip|passive ultrasonic irrigation (PUI) with an IrriSafe Ultrasonic tips (Acteon,France), which will be driven by an ultrasonic device (Newtron P5, Satelec, Acteongroup, Merignac, France) in removal of double antibiotic paste
45985661|NCT04327453|Device|double antibiotic paste with side vented needle|conventional syringe irrigation with side vented needle (prime Dent, India) in removal of double antibiotic paste
45985662|NCT04330105|Device|ECG, HolterECG ,Echocardiography|ECG, HolterECG ,Echocardiography to determine any type of arrythmia,ischaemic heart disease,valvular heart disease,systolic and diastolic dysfunction
45985663|NCT00467948|Drug|cefazolin|
45673255|NCT02158364|Drug|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
45673256|NCT02180672|Drug|Nasal Fluticasone|One spray per nostril, per day.
45985664|NCT01245504|Other|Assessed for socket fit|Subjects are clinically assessed during standing to see how well computer manufactured sockets fit
45985665|NCT00592579|Drug|2-methoxyestradiol|800 mg of 2ME2 (capsules) administered orally every 12 hours for a total daily dose of 1600 mg.
45985666|NCT04327414|Behavioral|Intervention group|Standing desks
45985667|NCT00592618|Drug|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks|
45985668|NCT00465374|Procedure|Change ventilatory parameters with stress index monitoring|
45985669|NCT01243710|Device|Taurolidine with heparin (500 units/ ml)|Central venous catheter will be locked (the designated volume required to fill the dead space) with taurolidine with heparin after each dialysis session. The control arm will be locked with heparin as is current practice.
45985670|NCT00622843|Biological|pneumococcal conjugate vaccine|"Prevnar is manufactured as a liquid preparation. Each 0.5 mL dose is formulated to contain:~2 μg of each saccharide for serotypes 4, 9V, 14, 18C, 19F, and 23F, and 4 μg of serotype 6B per dose (16 μg total saccharide); approximately 20 μg of CRM197 carrier protein; and 0.125 mg of aluminum per 0.5 mL dose as aluminum phosphate adjuvant. After shaking, the vaccine is a homogeneous, white suspension."
45985671|NCT00622843|Biological|pneumococcal polysaccharide vaccine|PNEUMOVAX 23 is manufactured according to methods developed by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25 μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.
45985672|NCT03271736|Behavioral|Stepping-in-place exercise with external auditory cues|The stepping-in-place exercise includes 10-session training. In each session, subjects are asked for stepping for 50 steps. In auditory cued condition, the cued frequency is set at 110% of the usual walking cadence. While in non-cued condition, we ask the subjects to step according to their own internal rhythm.
45985673|NCT03271736|Device|Transcranial magnetic stimulation (TMS)|TMS is used to assess the cortical excitability of the motor cortex. The stimulation intensity is set at 130% of the motor threshold in single-pulse condition. In paired-pulse condition, the first stimulus is set at 80% of the motor threshold and the second stimulus is set at 130% of the motor threshold.
45985674|NCT00592735|Procedure|laparoscopic gastric banding|standard surgical procedure
45985675|NCT00592813|Behavioral|Enhanced Strong for Life|"The program contains 5 minutes of warm-up, 25 minutes of strengthening, and 5 minutes of cool-down exercises. The SFL program is contained on a 35 minute videotape. Subjects are instructed to increase resistance when they can perform 10 repetitions of a movement pattern without significant fatigue or loss of proper execution. Subjects are instructed to move within a comfortable range of motion.~Participants will be taught the SFL program during two home visits conducted by a physical therapist. On the first visit, the exercise techniques will be taught, modified as needed based on individual needs and practiced as necessary until proper technique is attained. Each participant will be given written guidelines for how to progress resistance of the program, how to modify the exercises and how to complete bimonthly exercise calendars."
45985676|NCT00592813|Behavioral|cardiovascular nutrition education|administered as an attention control intervention using home visits, phone calls and mail-outs of information
45985677|NCT01245543|Drug|AC480IV|AC480IV will be administered as an infusion using a dose escalation design.
45985678|NCT01245543|Drug|Docetaxel|Docetaxel will be administered intravenously, initially as monotherapy and subsequently in combination with docetaxel immediately following AC480IV administration.
46083406|NCT03251144|Drug|Switch to E/C/FTC/TAF daily|"If the participant is on an antiretroviral regimen other than Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)] (E/C/FTC/TDF) then the participant will be asked to switch to E/C/FTC/TDF for up to 6 months. This will allow for future switch (after these 6 months) from E/C/FTC/TDF 1 tablet once daily to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/FTC/TAF) 1 tablet once daily for a period of 12 months.~b) If the participant is on E/C/FTC/TDF 1 tablet once daily then the participant will be asked to switch from /C/FTC/TDF 1 tablet once daily to /C/FTC/TAF 1 tablet once daily for a period of 12 months."
45673257|NCT02180672|Drug|Placebo|One spray per nostril, per day.
45673258|NCT02213198|Behavioral|Engagement focused care|Engagement focused care includes a group intake appointment called Access group with flexible scheduling allowing ease of rescheduling and access as soon as the same day, as well as Shared Decision Making coaching. For Shared Decision Making, a coach meets with the person prior to or following appointments with the prescriber to assist the person regarding what to ask, what to tell, to review options, and to foster choice.
45673259|NCT02213198|Behavioral|Standard Care|Standard treatment provided by a university based transitional care clinic, with individual intakes and follow-ups for medication/therapy scheduled as soon as possible from intake but at least 1 week away-no prioritization of cases
45673260|NCT02157506|Drug|CXL-1427|
45673261|NCT02157506|Drug|Placebo|
45673262|NCT01920711|Drug|LCZ696|LCZ696 50mg, 100mg and 200 mg dosage strengths will be available for dose adjustments.
45985679|NCT00592891|Drug|Hyperbaric oxygen therapy|Total body pressurized oxygen
45985680|NCT00592930|Drug|olanzapine|flexibly dosed oral olanzapine 2.5 to 15 mg/day
45985681|NCT00592930|Drug|placebo|
45985682|NCT00468026|Device|ProstaPlant Stent|
45985683|NCT00592969|Drug|metformin|
45985684|NCT00592969|Drug|biphasic insulin aspart|
45985685|NCT01245582|Drug|oxaliplatin (SR96669)|"Pharmaceutical form:injection~Route of administration: intravenous"
45985686|NCT01245582|Drug|capecitabine|"Pharmaceutical form:tablet~Route of administration: oral"
45985687|NCT01245582|Drug|sorafenib|"Pharmaceutical form:tablet~Route of administration: oral"
45985688|NCT00593008|Drug|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 8, 15 and 22). Participants may continue to receive study treatment as long as their tumor is responding and they don't experience any serious side effects.
45985689|NCT00593008|Drug|Gemcitabine|Given intravenously every other week of each 28-day cycle.
45985690|NCT00593047|Drug|KB2115|tablet formulation given once daily for 12 weeks
45985691|NCT00465413|Device|Small volume spacer and/or Rinsing the mouth with water|
45985692|NCT00593086|Procedure|Pain management|Pain mamagement for burn care procedures.
45985693|NCT00593086|Other|Standard of care/no virtual reality game|no intervention for standard of care
45985694|NCT02956200|Drug|Fingolimod|Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
45985695|NCT00593125|Drug|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will not be blind to the subject's medication administration. The medication will be discontinued over a two-week period
45985696|NCT00593164|Device|Cooling with ThermoSuit with Magnesium Sulfate Infusion|Cooling with LRS ThermoSuit within 15 minutes of intravenous Magnesium Sulfate infusion (30 mg/kg, added to 100 ml normal NaCl solution, given over 15 min).
45985697|NCT00593164|Device|Cooling with ThermoSuit with Normal Saline Infusion|Cooling with LRS ThermoSuit within 15 minutes of normal saline infusion (100 ml of normal NaCl solution, given over 15 min).
45985698|NCT01316107|Drug|ipragliflozin|oral
45985699|NCT01316107|Drug|nateglinide|oral
45985700|NCT00492453|Procedure|laparoscopic cholecystectomy|elective laparoscopic cholecystectomy using CO2 pneumoperitoneum under different methods of anesthesia
45985701|NCT01316185|Drug|EBP921|Patients randomized to receive low or high dose. All dosing of EBP921 should be taken with food.
45985702|NCT05654194|Drug|Azacitidine Combined With Venetoclax and ATRA group|AZA 75mg/m² per day for days 1-7 and venetoclax 100mg orally for day 2 , 200mg orally for day 3, 300mg orally for day4-6, 400mg orally for day7-10,ATRA 45mg/m² for day 12-28,every 28 days for up to 2 cycles as the inductive therapy.ATRA 45mg/m2 per day for d1-21 ,AZA 70mg/m² per day for days 1-7, every 28 days for up to 4 cycles for consolidate therapy.ATRA 45mg/m2 for d1-21 every 28 days,AZA 70mg/m² per day for days 1-7, every 3 month for Maintenance therapy
45985703|NCT05654155|Other|auricular acupressure|Auricular acupressure therapy is a well-established treatment strategy whose foundations lie in Traditional Chinese Medicine and is a therapy that is increasingly used in Western medicine.
45673263|NCT01920711|Drug|Valsartan|Valsartan 40mg, 80mg and 160mg dosage strengths will be available for dose adjustments.
45832913|NCT03551028|Device|HPV self collection|The proposed community based participatory study aims to determine whether offering self-collection for HPV testing through the mobile mammography unit is an acceptable and feasible method to increase access to cervical cancer screening for under-screened women in Southwest Virginia.
45832914|NCT03549858|Other|Quality of life measure (survey)|The QoL tool is a questionnaire
45832915|NCT03547986|Diagnostic Test|Duplex Ultrasound (DUS)|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Duplex Ultrasound
45832916|NCT03547986|Diagnostic Test|IVUS with Intraarterial pressure measurement (IAP) if needed|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Intra-vascular ultrasound associated to Intraarterial pressure measurement if needed
45832917|NCT03546972|Other|Behavioral, Psychological or Informational Intervention|Take part in DDP
45832918|NCT03546972|Other|Behavioral, Psychological or Informational Intervention|Take part in HT
45673264|NCT02180438|Drug|Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks|
45673265|NCT02179190|Device|BARREL VRD|The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
45832919|NCT03546972|Other|Questionnaire Administration|Ancillary studies
45985704|NCT00468065|Device|VeinViewer|Veinveiwer is used to view veins subQ
45985705|NCT00468065|Device|Veinviewer|near infrared light reveals veins subcutaneously
45985706|NCT05654116|Behavioral|Caregiver Interaction Profile (CIP) training|The CIP training aims to boost six interactive skills in daycare providers: sensitive responsiveness, respect for children's autonomy, structuring and limit setting, verbal communication, developmental stimulation, and fostering positive peer interactions. The training takes place with 1 or 2 daycare providers at a time, and consists of 5 or 6 weekly sessions, respectively. In individual trainings, sessions 1-3 focus on two skills each, session 4 is a recap of two skills the daycare provider chooses, and the final session is shared with a colleague. In pairwise sessions, session 1 focuses on the first two skills, sessions 2-5 each focus on one skill, and the last session serves as a recap of two skills the daycare providers choose. The training uses a video-feedback method: daycare providers are filmed in interactions with children in daycare, the CIP trainer preselects relevant fragments of video recordings to discuss with the daycare provider(s) during the training sessions.
45673266|NCT02157116|Drug|cisplatin|
45673267|NCT02157116|Drug|Docetaxel|
45673268|NCT02157116|Drug|Pegfilgrastim|
45673269|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 0.1 mg/kg - one single infusion
45673270|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 0.2 mg/kg - one single infusion
45985707|NCT00492492|Procedure|trans-styloid and intrafocal pinning on the one side|
45985708|NCT00492492|Procedure|volar fixed-angle plating on the other side|
45985709|NCT05653453|Device|Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel|"Device: Tumor treating fields Subjects will use tumor treating fields until disease progression or for a maximum of 30 months.~Drug: Gemcitabine hydrochloride and albumin binding paclitaxel Subjects will receive Gemcitabine hydrochloride and albumin binding paclitaxel until disease progression or for a maximum of 30 months."
45985710|NCT05653453|Drug|Gemcitabine hydrochloride and albumin binding paclitaxel|Drug: Gemcitabine hydrochloride and albumin binding paclitaxel Subjects will receive Gemcitabine hydrochloride and albumin binding paclitaxel until disease progression or for a maximum of 30 months.
45985711|NCT00468182|Drug|Interferon-beta 1b (Betaseron)|Treatment of patients with FDA-approved Rx
45985712|NCT05653375|Other|Mindfulness-based psychoeducation program|In this study, a mindfulness-based psychoeducation program was applied to the experimental group, 2 times a week for 4 weeks, with a total of 8 sessions, including methods such as meditation, body scanning, mindful eating, and breathing work. Measurement tools were applied to the experimental and control groups before and after the program.
45985713|NCT05653375|Other|ongoing life|The control group continued with their lives without any intervention. Only pre-test and post-test were applied. While the program was applied to the experimental group, no intervention was made to the control group.
45985714|NCT05653297|Device|Vacuum-Assisted Closure|NPWT (MEDWAY GROUP VAC) will be applied on post traumatic raw areas until the wound is ready for reconstruction, Then it will be applied over skin graft after coverage
45985715|NCT05649163|Drug|Disitamab Vedotin|Cohort 1: received a regimen containing Disitamab Vedotin. Cohort 2: received an investigator-selected regimen in addition to Disitamab Vedotin; Treatment options selected by the investigator: no treatment containing Disitamab Vedotin was given, and other systemic antitumor agents (including chemotherapy, such as paclitaxel, docetaxel, irinotecan, and fluorouracil) were selected by the investigator in line with clinical practice. Targeted therapy: such as apatinib, ramucirumab; Combination therapy: ramucirumab + paclitaxel; Immune checkpoint inhibitors such as PD1/PD-L1); Cohort 3: receiving a regimen containing Disitamab Vedotin.
46083407|NCT02717520|Device|EQUIA Forte and Tetric EvoCeram|"GC cavity conditioner (20% polyacrylic acid) will be applied for 10 sec, rinsed and the cavity will be dried with a cotton pellet. EQUIA Forte will be prepared according to the manufacturer instructions, applied in bulk and compacted with a condenser. The self-curing restoration will be finished after hardening, approximately 2 min 30 sec after the start of the capsule mixing, using Arkansas stones under water cooling. EQUIA Forte Coat will be applied to the surfaces and light cured with D-light for 20 sec.~Enamel will be etched with 37% orthophosphoric acid for 10 sec. After the acid gel removal, the cavity will be carefully dried. The adhesive (Adhese 2, Ivoclar Vivadent) will be applied and light cured with D-light (1200 mW/cm2, slow mode) for 10 sec. The composite resin will be placed with an incremental technique (2 mm layers), and light-cured with D-light (20 sec). Restorations will be finished with fine diamond and carbide burs in slow and high-speed hand-piece and polished."
45985716|NCT00499395|Procedure|positron emission tomography|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. When evaluating patients with liver metastases, we routinely obtain a dedicated liver PET study (Liver View) after the whole body PET. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
45985717|NCT00499395|Procedure|radiofrequency ablation|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
45673271|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 0.5 mg/kg - one single infusion
45673272|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 1.0 mg/kg - one single infusion
45673273|NCT01920555|Drug|Placebo Midazolam|Dose of Midazolam (active placebo) will be 0.045 mg/kg - one single infusion
45673274|NCT02156804|Drug|Nivolumab (BMS-936558)|
45832920|NCT03546738|Procedure|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
45832921|NCT03546738|Procedure|Sham spinal cord stimulation|No spinal cord stimulation is provided
45832922|NCT03546738|Device|SCS implant|"a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Boston Scientific will be implanted: Precision NoviTM implantable pulse generator and InfinionTM CX 16-contact lead or LinearTM ST 8-contact lead."
45832923|NCT03564756|Dietary Supplement|Vitamin C|1000mg Vitamin C per day
45673275|NCT02156492|Drug|Evacetrapib|Administered orally.
45673276|NCT02156492|Drug|Simvastatin|Administered orally.
45832924|NCT03561246|Other|Incline treadmill walking|Those with a Pp 0.47 will undergo INCLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
45673277|NCT02156492|Drug|Atorvastatin|Administered orally.
45673278|NCT04753970|Drug|Cilostazol|Cilostazol 100mg BID
45673279|NCT04753892|Other|3SM2-G-CRM197 with squalene adjuvant|Immune challenge agent
45673280|NCT04187690|Drug|Jin-shui Huan-xian granule|Jin-shui Huan-xian granule will be administered 5days on and 2 days off for 52 weeks.
45832925|NCT03561246|Other|Decline treadmill walking|Those with a Pp 0.53 will undergo DECLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
45985718|NCT00465452|Drug|Continuous Release Dopamine Agonists|Continuous Release Dopamine Agonists
45985719|NCT05652010|Device|Iris - new coupling|"SenSura Mio Click maxi bag (open, wide outlet), 50mm Ø with new coupling and lock ring~Baseplate flat: SenSura Mio, click base plate with belt ears, 50 mm, 10-45 mm with improved weld-ing bead~Baseplate Concave: Item 18510 SenSura Mio Concave, click base plate with ears size Ø50, 10-45 mm"
45985720|NCT05652010|Device|Sensura Mio Click|"SenSura Mio Click 2p bag, item #11472. Open, wide outlet, maxi, neutral grey. 50mm with inspection window and circle filter 430~Baseplate flat: Item #10512 SenSura Mio Click Base Plate with belt ears, 50 mm, 10-45 mm~Baseplate concave: Item #18510 SenSura Mio Concave, click base plate with ears size Ø50, 10-45 mm"
45985721|NCT05650684|Other|data collection|continuation of exclusive breastfeeding until the post-natal visit (6 to 8 weeks after birth)
45985722|NCT00465491|Drug|picoplatin|IV picoplatin 150mg/m2 q3wk
45985723|NCT00465491|Other|best supportive care|best supportive care
45985724|NCT00499512|Behavioral|Questionnaire|Questionnaires that ask questions about religion, spirituality, and decisions about treatment at three points (at time of diagnosis, end of primary chemotherapy, and one year later).
45985725|NCT00468221|Drug|Ozone Exposure|Low dose ozone exposure in chamber
45985726|NCT01379521|Drug|everolimus|
45832926|NCT03557502|Other|Heat Therapy Group|30 sessions of immersion in 40.5 degree celsius water for 45 minutes per session
45985727|NCT01379521|Drug|everolimus placebo|
45985728|NCT00499551|Device|Iontophoresis second generation Eyegate II device|
45985729|NCT00468260|Drug|Patupilone|
45985730|NCT01371994|Drug|solifenacin succinate|oral
45985731|NCT01371994|Drug|Placebo|oral
45985732|NCT00465608|Drug|propranolol|propranolol by mouth (per os)
45985733|NCT01245777|Drug|ferric carboxymaltose|20 women with Restless Legs Syndrome (RLS) and iron deficiency and/ or anaemia in the third trimester of pregnancy will receive intravenous Ferric carboxymaltose in one or two single doses.
45985734|NCT00468338|Device|BIS monitor|BIS monitor measures the depth of anesthesia and was used in the entire group
45985735|NCT01371877|Drug|Vitamin D3|Vitamin D 4000 IU per day for 3 months
45985736|NCT01371877|Drug|Vitamin D3|Vitamin D 600 IU per day
45985737|NCT00468416|Device|Compression Anastomosis Ring (CAR)|
45985738|NCT01245816|Drug|Eflornithine plus Sulindac|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Sulindac, 150 mg tablet, one tablet orally once a day
45985739|NCT01245816|Drug|Eflornithine plus Placebo|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Placebo, one tablet orally once a day
45673281|NCT04187690|Drug|Jin-shui Huan-xian granule placebo|Jin-shui Huan-xian granule placebo will also be administered 5days on and 2 days off for 52 weeks. The placebo consists 5% of the same components as Jin-shui Huan-xian granule besides dextrin and bitter. The There is no obvious difference in appearance, weight and odor between Jin-shui Huan-xian granule and placebo.
45673282|NCT01920477|Biological|Ofatumumab|Ofatumumab (human monoclonal antibody) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product
45673283|NCT01920477|Biological|Placebo|Placebo to match the active doses will consist of prefilled glass syringes filled with normal saline.
45673284|NCT04641741|Drug|Mepolizumab 100 MG|Discovery of predictive/prognostic biomarkers of response to mepolizumab using flow cytometry, transcriptomic, and proteomic technologies.
45673285|NCT04641195|Dietary Supplement|Vitamin D3 (cholecalciferol)|180,000 international units (IU) of vitamin D3 at enrollment, followed by 2000 IU once per day from enrollment to 8 weeks
45832927|NCT03557502|Other|Aerobic Exercise Group|30 sessions of aerobic exercise training for 45 minutes at 60% of VO2peak
45832928|NCT03462966|Drug|Rifaximin|Rifaximin will be administered to patients diagnosed with IBS-D or IBS-M to evaluate whether the medication is effective in decreasing rectal hypersensitivity. The secondary objective of the study is to assess the role of SIBO in rectal sensitivity.
45985740|NCT01245816|Drug|Sulindac plus Placebo|Sulindac, 150 mg tablet, one tablet orally once a day; Placebo, two tablets orally once a day
45985741|NCT00468455|Procedure|Laparoscopic or open colorectal surgery|Application of a post-operative diary to be completed by subjects. The intervention is standard of care laparoscopic or open surgery.
45985742|NCT00492687|Drug|carboplatin|
45985743|NCT00492687|Drug|tamoxifen citrate|
45985744|NCT00492687|Drug|temozolomide|
45985745|NCT00492687|Procedure|adjuvant therapy|
45985746|NCT00492687|Radiation|radiation therapy|
45985747|NCT01371838|Drug|Ceftaroline|Two consecutive infusions q12h for 5 to 7 days
45985748|NCT01371838|Drug|Ceftriaxone|One dose infusion followed by IV saline placebo infused q24h for 5 to 7 days plus two consecutive saline placebo infusion q24h.
45985749|NCT01245855|Drug|lipo-PGE1|those in the PGE1 group received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
45985750|NCT00473603|Drug|lipid/heparin infusion|to perform an i.v. lipid heparin infusion infusion for 4 h
45985751|NCT00492765|Drug|Interferon-beta-1a|dosage and frequency as per label
45985752|NCT00492765|Drug|Simvastatin|dosage and frequency as per Biogen Idec protocol
45985753|NCT00492765|Drug|Placebo|dosage and frequency the same as simvastatin as per Biogen Idec Protocol
45985754|NCT00468533|Drug|Aripiprazole|
45985755|NCT00473681|Behavioral|Self-Help Intervention Program-High Blood Pressure|
45985756|NCT00499629|Drug|FXR 450|capsule, single oral doses from 10 mg to 450 mg
45985757|NCT00499629|Drug|placebo|capsule similar to active drug
45985758|NCT01371721|Drug|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.
45985759|NCT00473720|Drug|Satraplatin|Dose escalation of 40, 60 and 80 mg/m²/day on days 1-5
45985760|NCT00473720|Drug|Abraxane|Dose escalation of 80 and 100 mg/mm²/day on days 1,8,15,22 every 28 days
45985761|NCT00492804|Procedure|Lichtenstein hernia repair|Lichtenstein hernia repair with tension free mesh
45985762|NCT00492804|Procedure|Neurectomy|Neurectomy
45985763|NCT01605448|Behavioral|Mindfulness Based Stress Reduction (MBSR)|8 weekly classes of meditation/yoga
45985764|NCT00468572|Behavioral|Affectionate Writing|Participants assigned to the experimental group will spend 20 minutes writing an affectionate letter to a loved one. Levels of cortisol will be measured using saliva samples from each participant during the writing session. Levels of oxytocin, a hormone known to transmit signals within the brain and often associated with bonding and building trusting relationships, will be measured from blood samples taken during the writing session as well.
45985765|NCT00468572|Behavioral|Meaningless Writing|Participants assigned to the control group will spend 20 minutes writing about meaningless topics. Participants will undergo the same testing during the writing session as the experimental group.
45985766|NCT00499668|Drug|aprepitant|125 mg orally for 7 days
45985767|NCT00499668|Drug|ondansetron hydrochloride|24 mg orally for 7 days
45985768|NCT00499707|Drug|rosiglitazone maleate/metformin hydrochloride|rosiglitazone maleate/metformin hydrochloride
45985769|NCT00468611|Drug|MBP8298|500mg MBP8298 IV every six months for a period of two years
45985770|NCT03270995|Behavioral|Cognitive Existential Therapy Group 1|Six group sessions of two hour each using a cognitive-existential group approach
45985771|NCT03270995|Behavioral|Supportive Therapy Group 2|Six group session of two hour each using a supportive group approach.
45985772|NCT01366534|Biological|Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01)|One dose will be administered intramuscularly at Study Day 0.
45985773|NCT01366534|Biological|GSK Biologicals' malaria vaccine 257049 (2 doses)|Two doses will be administered intramuscularly at monthly intervals
45985774|NCT01366534|Biological|GSK Biologicals' malaria vaccine 257049 (3 doses)|Three doses will be administered intramuscularly at monthly intervals
45985775|NCT01366534|Other|Sporozoite challenge|Subjects were challenged with sporozoite-infected mosquitoes to determine whether immune protective response had been induced by vaccination.
45985776|NCT00492843|Drug|Ibandronate (Bondronat)|Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.
45985777|NCT01605487|Drug|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
45985778|NCT01605487|Drug|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days
46083408|NCT05340920|Diagnostic Test|Oral Food Challenge|diagnostic values of skin prick test and specific IgE for allergy confirmed by oral food challenge (routine, not an intervention)
46083409|NCT04231682|Drug|Denosumab Injection|Use of denosumab in post liver transplant patient for prevention and management of osteoporosis and bone loss.
46083410|NCT04231682|Drug|Placebos|Use of placebo in post liver transplant patient for prevention and management of osteoporosis and bone loss.
45673286|NCT04641195|Dietary Supplement|Zinc (zinc gluconate)|40mg of zinc gluconate taken once per day from enrollment to 8 weeks
45673287|NCT04641195|Dietary Supplement|Zinc (zinc gluconate) & Vitamin D (cholecalciferol)|180,000 IU of vitamin D3 at enrollment, followed by 2000 IU of vitamin D3 and 40mg of zinc gluconate once per day from enrollment to 8 weeks
45673288|NCT04641195|Other|Placebo|Placebo vitamin D bolus at enrollment followed by placebo daily vitamin D maintenance doses and placebo daily zinc supplements.
45985779|NCT01605487|Drug|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
46083411|NCT05224674|Device|Extracorporeal Shock Wave Therapy (ESWT)|The ESWT device is product of Elettronica Pagani, Italy.
46083412|NCT05340842|Other|simulation training group|In this study, applied breastfeeding training with Lactation Simulation Model was given to pregnant women in the intervention group (simulation training group, n=64) during antenatal period
45985780|NCT01605487|Drug|Rupatadine|Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
45985781|NCT01605487|Drug|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
45985782|NCT01605487|Drug|Rupatadine|Rupatadine in Tab. 10mg: 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days
45985783|NCT03271775|Other|physical therapy program (group)|Exercises group transmitted by physical therapist (Up to four participant in each group).
45985784|NCT03271775|Other|physical therapy program (computerized exercises)|Remote exercises program accompanied by a physical therapist guidance
46083413|NCT02722356|Drug|Oxytocin|Oxytocin administered per oxytocin group or standard practice group (see above)
46083414|NCT00753675|Drug|ZD6474, Vandetanib|300 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
46083415|NCT00753675|Drug|ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
46083416|NCT00753675|Drug|Gemcitabine|administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles or until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
45985785|NCT00499824|Behavioral|Education of general practitioners on the IDF-WPR guidelines|"The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). This will involve:~an initial educational symposium and a follow-up continuing medical education symposium at 3 months; paper or electronic reminders of the guidelines sent to GPs every 3 months; desktop reminder cards with guideline algorithms; insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse; provision of each patient with a diabetes passport to be held by the patient."
45985786|NCT01365910|Drug|linifanib|Given PO
45985787|NCT00473798|Behavioral|Questionnaire|Questionnaire
45832929|NCT03462654|Behavioral|iLiFE|In the individual LiFE (iLiFE), the program is taught in seven visits in the individuals' homes within eleven weeks. Participants are supervised in a face to face situation by one qualified trainer (physiotherapist or sports scientist). Each home visit takes between 1 and 1.5 hours. A total of five balance exercises, seven strength exercises for the lower extremities, and two exercises to increase physical activity are taught. In addition to the home visits, all participants receive two 'booster telephone calls' within the remaining weeks until the 6-month follow-up assessments.
45985788|NCT01605526|Drug|RO5045337|Multiple escalating oral doses, Days 1-5 (1-3) of each 28-day cycle, up to 6 cycles
45832930|NCT03462654|Behavioral|gLiFE|The group-based LiFE (gLiFE) program consists of seven group sessions (n = 8-12 participants) which are held over the course of eleven weeks, with a maximum duration of 2 hours per session. Each session is led by two qualified trainers (physio therapists or sports scientists), i.e., one main and one co-trainer. In all group sessions, trainers will teach the participants how to perform and integrate the LiFE program, i.e., LiFE balance and strength activities into their daily routines. After the group sessions have ended, participants will receive two 'booster telephone calls' within the remaining weeks until the 6-month follow-up assessments.
45985789|NCT01605526|Drug|doxorubicin|60 mg/m2 (75 mg/m2, 50 mg/m2) iv on Day 1 of each 28-day cycle, up to 6 cycles
45985790|NCT00492882|Drug|usual administration of exogenous recombinant FSH|
45985791|NCT00468689|Drug|SB-751689 oral tablets (100 and 400 ng)|
45985792|NCT00468689|Drug|Ketoconazole (NIZORAL) oral tablets (200 mg)|
45985793|NCT02274480|Device|cardiac MRI with DWI|
45832931|NCT01678872|Drug|RetinoStat|Long Term Follow up of patients who received RetinoStat in a previous study
45985794|NCT00473915|Drug|fluticasone furoate|corticosteroid nasal spray
45985795|NCT00499902|Drug|alfimeprase|Alfimeprase will be given as a single bolus of 1mg/2mL, or a split bolus of 5mg/2mL or 10mg/2mL in a three-tier dose escalation format. The 5mg and 10mg doses will be administered as split doses with 1/2 of the total dose given initially and 1/2 of the total dose given 30 minutes after the initial dose.
45985796|NCT00473954|Genetic|EGEN-001 (phIL-12-005/PPC)|"In stage 1, patients will receive standard doses of IV carboplatin and docetaxel for 2 treatment cycles with a 3 week interval. Patients will also receive 4 IP infusions of EGEN-001 at 12mg/m2 EGEN-001, 18mg/m2, or 24mg/m2, 10-11 days apart.~Stage 2 of the study will involve cycle escalation at the highest EGEN-001 dose identified from Stage 1. All patients will receive up to 8 doses of EGEN-001, 10-11 days apart plus up to 4 IV carboplatin and docetaxel cycles with 3 week intervals. After receiving the assigned number of treatments of EGEN-001, carboplatin, and docetaxel, patients may continue to receive up to 4 additional infusions of EGEN-001 and 2 IV carboplatin and docetaxel cycles with 3 week intervals."
45985797|NCT00468767|Drug|Vernakalant Injection 20 mg/mL|
45985798|NCT00493077|Drug|low immunogenic interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
45985799|NCT00474071|Drug|Remifentanil|See Detailed Description.
45985800|NCT00468884|Drug|Increasing doses of GLP-1|
45985801|NCT00468884|Drug|PYY3-36|
45832932|NCT03535818|Procedure|Radiofrequency ablation|RF application to achieve complete pulmonary vein isolation +/- ganglionated plexus ablation
45832933|NCT03794700|Other|Hospice Decision Aids|Paper and video hospice decision aid
45832934|NCT04403412|Procedure|Left atrial appendage closure group|Left atrial appendage closure Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
45985802|NCT00474110|Drug|Ketamine & hydromorphone|See Detailed Description
45985803|NCT00500058|Drug|SB-485232|SB-485232 for injection, 7 mg/vial, will be available as a lyophilized cake. It will be reconstituted with 1.4 mL of water for injection. Each vial of this drug product is a clear, colorless solution containing 5 mg/mL of SB-485232.
45985804|NCT00500058|Drug|Rituximab|Rituximab 375 mg/m^2 will be administered by IV infusion.
45985805|NCT00468923|Drug|Candesartan/HCT|Candesartan 16 mg/HCT 12.5 once daily
45985806|NCT00468923|Drug|Rosuvastatin|Rosuvastatin 10 mg once daily
45985807|NCT00500097|Device|Digital retina image|
45985808|NCT00500097|Device|direct ophthalmoscopy|
45985809|NCT00500097|Procedure|comprehensive eye exam|
45985810|NCT01365481|Drug|Valsartan|week 1: 40/80/160 week 2-78: 80/160/320mg, oral, by mouth, once daily
45985811|NCT01365481|Drug|amlodipine|added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
45985812|NCT01365481|Drug|Hydrochlorothiazide|added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
45985813|NCT03271619|Other|Surface current measurement|Measurement of surface current between electrodes placed on the chest wall during defibrillation
45985814|NCT01605604|Behavioral|buddhist mind fullness|there are two group one group recieve Buddhist mindfulness group intervention 8 times second group recieve nothing
45985815|NCT00493116|Drug|Interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
45985816|NCT00493116|Drug|methylprednisolone|dosage and frequency as per Biogen Idec protocol
45673289|NCT02213042|Drug|Lapatinib|Lapatinib is available as 250-mg orange tablets. Subjects randomized to the Lapatinib plus Trastuzumab arm received 1000 mg per day of Lapatinib, so wre instructed to take 4 x 250 mg tablets per day. Lapatinib was to be taken either 1 hour (or more) before a meal or 1 hour (or more) after a meal
45985817|NCT00468962|Drug|FACOS (functional food)|
45985818|NCT01605682|Dietary Supplement|Fresh berry extract.|Fresh berry extract containing 500mg, 250mg, 125mg per 60 kilos of body weight. Or placebo.
45985819|NCT00493155|Drug|RG1530|Administered po at escalating doses (10 cohorts)
45985820|NCT01357915|Procedure|Blood sampling|"Blood samples will be collected at 2 time points:~At the long-term follow-up at approximately Month 48 of study (= ± 42 months post dose 3) from all subjects in the vaccine group.~At the long-term follow-up at approximately Month 60 of study (= ± 54 months post dose 3) from all subjects."
45985821|NCT01357915|Biological|GSK149203A|GSK Biologicals' Recombinant CMV glycoprotein B Vaccine, Intramuscular injection, 3 doses
45985822|NCT00474227|Behavioral|group therapy, physical exercise, nutrition lectures|weekly group therapy, physical exercize, nutrition guidance
45985823|NCT00493194|Drug|sirolimus|
45985824|NCT00493194|Drug|cyclosporine|
45985825|NCT00493194|Drug|daclizumab|
45985826|NCT01350973|Drug|Omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
45985827|NCT01350973|Drug|Eicosapentaenoic acid-ethyl (EPA-E)|EPA-E, 0.6 g, orally, three-times daily for up to 12 weeks.
45985828|NCT00500136|Procedure|mortality salience|
45832935|NCT04403412|Procedure|Radiofrequency ablation group|Radiofrequency ablation Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
45832936|NCT04403412|Procedure|LAAC combined with radiofrequency ablation group|LAAC combined with radiofrequency ablation group Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
45832937|NCT03532542|Drug|Casimersen|Casimersen solution for IV infusion
45832938|NCT03532542|Drug|Golodirsen|Golodirsen solution for IV infusion
45832939|NCT03531762|Drug|Tepotinib|Participants will receive single oral dose of Tepotinib in Treatment Period A, B and C.
45832940|NCT03531762|Drug|Omeprazole|Participants will receive omeprazole alone on Day 1 to 4 and co-administration of omeprazole with Tepotinib on Day 5 in Treatment Period B and C.
45985829|NCT03270722|Device|FLIP topography|During upper endoscopy, the FLIP topography balloon will be advanced into the esophagus and inflated, providing additional information about the distensibility of the esophagus. This generally takes about 5 extra minutes and no complications have been reported. Theoretical complications include bleeding, infection, risk with extra anesthesia time, and putting a hole in the esophagus.
45985830|NCT03270722|Procedure|Upper Endoscopy|A standard upper endoscopy will also be done in all patients. A small scope will be passed via the mouth to examine the esophagus, stomach, and first part of the small intestine. The risks of this procedure include the risks associated with anesthesia, a small risk of bleeding, infection, and a very small risk of putting a hole in the gastrointestinal tract.
45985831|NCT01350544|Behavioral|Treatment Advocacy|Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with APLA's social service programs, as necessary.
45985832|NCT01350505|Behavioral|White light exposure|~200 lux of broad spectrum white light
45985833|NCT01350505|Behavioral|Dim white light exposure|~28 lux of broad spectrum white light
45985834|NCT01350505|Behavioral|Very dim white light exposure|<0.5 lux of broad spectrum white light
45985835|NCT01350505|Behavioral|Dim orange light exposure|~28 lux of orange light
45985836|NCT00500175|Device|TempTouchRM|
45985837|NCT00500175|Device|Offloading|
45985838|NCT00469001|Procedure|Treatment according NT Pro BNP level|
45985839|NCT01605721|Device|XIENCE PRIMETM everolimus-eluting coronary stent|"Active prospective registration of patients receiving the following stent~: XIENCE PRIMETM"
45985840|NCT01605760|Drug|immunotherapy Staloral|Staloral (R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy. During a 16 day incrementally increasing dose period, patients took daily increasing doses period, patients took 1-8 drops of the 100 IR/ml extract during the first 8 days. Then, on days 9-16, patients took 1-8 drops of the 300 IR/ml extract. Next, patients received maintenance treatment consisting of five applications of eight drops (equivalent to 0.5 mL) of 300 IR/mL extract five times a week. The mean duration of the treatment was 28.2 months (range: 3-36 months).
45985841|NCT00469040|Drug|GW642444M for 14 days|M salt
45832941|NCT03458676|Procedure|Advanced Magnetic Resonance Imaging Scan|"AMRI scan performed within 2 weeks before standard of care brain biopsy and tumor removal surgery.~AMRI scan should take less than 1 hour to complete"
45673290|NCT02213042|Biological|Trastuzumab|Trastuzumab is a sterile, white to pale yellow, preservative-free lyophilized powder for IV administration. Trastuzumab was administered on Day 1 of the start of Lapatinib or in conjunction with the first cycle of chemotherapy, as an 8 mg/kg loading dose. Subsequently, Trastuzumab was administered q3weekly as a 6 mg/kg maintenance dose. At the discretion of the investigator, weekly Trastuzumab could be given in either of the three treatment arms (loading dose 4mg/kg followed by weekly administration of 2mg/kg).
45985842|NCT01350271|Drug|Mebendazole polymorph A and C 500 mg|Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C
45985843|NCT01350271|Drug|Mebendazole polymorph C|Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone
45985844|NCT01350271|Drug|Placebo|Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
45985845|NCT00469118|Device|DRX9000™|Nonsurgical spinal decompression
45985846|NCT00474305|Behavioral|Virtual Reality Treatment for PTSD|12 session protocol for Prolonged Exposure with Virtual Reality. All sessions 90 minutes.
45985847|NCT00493233|Drug|2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine)|"Primary antipsychotic medication (olanzapine, oral risperidone, seroquel, clozapine, haldol, perphenazine) will be determined by the treating physician and participants will continue taking the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician. The dose of the second antipsychotic drug will remain fixed throughout the study period."
45985848|NCT00493233|Drug|main antipsychotic medication and placebo|"The main antipsychotic drug will be determined by the treating physician. Participants will be allocated to placebo in place of the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician."
45832942|NCT03458676|Procedure|Standard of Care Brain Biopsy and Tumor Removal|"During the surgery, the neurosurgeon(s) uses the information collected from the AMRI to decide what area of the brain tumor will be biopsied.~Biopsies from up to 5 locations taken before the tumor is surgically removed."
45832943|NCT03458598|Procedure|Rectus sheath block|Rectus sheath block under ultrasound
45832944|NCT03458598|Procedure|Bilateral rectus sheath catheter|A nerve block catheter known as a continuous rectus sheath block is inserted by the surgeon at the end of the operation. An infusion of 0.2% ropivacaine is delivered through this for up to 48 hours post-operatively.
45832945|NCT03458598|Drug|Patient controlled opioid analgesia (PCA)|Patients in both groups will have PCA dilaudid or morphine prescribed for the post-operative period.
45985849|NCT00469157|Drug|Optive|Optive 30ml- (in the eye) Instill one in each eye twice daily starting one week after surgery
45985850|NCT00500214|Procedure|elective ilioinguinal nerve excision|
45985851|NCT03270410|Other|Data collection|"After parental information and collection of their non-opposition, the data of the daily cardio-respiratory recordings of the newborns hospitalized in the units of Neonatology are collected and analyzed.~At the same time, a video recording is set up. This video recording does not modify the care provided for the child, the organization of the day with nursing and parental care."
45985852|NCT00493272|Drug|Fibrinogen|Fibrinogen behandling
45985853|NCT00500253|Device|exhaled nitric oxide measurement|exhaled nitric oxide measurement
45985854|NCT00500253|Procedure|bronchial hyperresponsiveness with methacholine (PC20M)|bronchial hyperresponsiveness with methacholine (PC20M)
45985855|NCT00500253|Procedure|symptom score diary (according to 2007 GINA guidelines)|symptom score diary (according to 2007 GINA guidelines)
45985856|NCT00469196|Procedure|Tomotherapy|40 Gy in 15 fractions, at one fraction per day. Dose will be prescribed to the 95% isodose line.
45985857|NCT03270566|Device|Domestic ion-exchange water softener|Ion-exchange water softeners exchange calcium and magnesium, amongst other divalent cations, for monovalent sodium cations using a polystyrene resin. The sodium ions come from sodium chloride (common salt). The salt needs to be topped up every 3-4 weeks and sufficient quantities of block salt will be supplied to participants. The water softener used in this study does not require electricity and has two cylinders of resin which are used alternately. A control valve alternates the flow between the two cylinders and ensures a constant supply of regenerated resin. Ion-exchange water softeners typically reduce downstream water hardness to close to zero.
45985858|NCT00469235|Drug|Avotermin|"10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.~10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure."
45985859|NCT01243788|Drug|Salmeterol/Fluticasone Propionate|Salmeterol/Fluticasone 50/500ug twice daily Duration:12 weeks
45985860|NCT03270605|Procedure|Myomectomy|Surgical removal of uterine fibroid
45985861|NCT01243827|Drug|carvedilol|carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP <140/90 mmHg.
45985862|NCT01243827|Drug|bisoprolol|bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP <140/90 mmHg.
45985863|NCT00500409|Drug|Osteoform|Administer Osteoform 20 µg daily subcutaneously and 1000 mg calcium and 500 IU vitamin D orally for 180 days
45985864|NCT00500409|Drug|SHELCAL|Administer calcium and vitamin D (1000 mg calcium and 500 IU vitamin D) orally for 180 days
45985865|NCT00469352|Drug|Ranibizumab|Ranibizumab as needed
45985866|NCT01243866|Other|comprehensive dental treatment|Early treatment children were scheduled for comprehensive dental treatment over a 2-month period (from May to June 2007). All test children had their last dental treatment visit within the last 2 weeks of the second treatment month. The follow-up survey was scheduled for each child to be approximately 6-month after their dental last visit. This step was very important to make sure that all children were examined at exactly the same interval between end of treatment and when re-examined at the follow-up examination.
45985867|NCT01243866|Other|Only emergency dental treatment|Regular treatment did not receive any dental treatment in the period when the early children were treated unless they had toothache or dental infection. In that case they were treated for the pain but did not have comprehensive dental treatment
45985868|NCT00469430|Drug|cefotaxim and metronidazol|iv administration for at least 24 h
46083417|NCT00753675|Drug|Placebo matching ZD6474|Placebo to match ZD6474 100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
46083418|NCT04229186|Dietary Supplement|EVOO-C|Each patient will consume 10 mg total daily amount EVOO-C
46083419|NCT04229186|Dietary Supplement|ROO|Each patient will consume 10 mg total daily amount ROO
46083420|NCT05131178|Device|ON-Q Pump® with continuous infusion of bupivacaine|270 ml of 0.5 % bupivacaine. The device being used is a fixed flow pump meaning the rate of 2 mL/hour. The pump is connected to the catheter and left in place for up to 4 post-operative days or until the completion of the infusion.
45673291|NCT02213042|Drug|Aromatase Inhibitors (AIs)|Subjects who were hormone receptor-positive were required to receive an aromatase inhibitor as combination treatment; however the choice of the aromatase inhibitor selected for each patient was determined by the patients' investigator. The AIs the Investigator could choose from were anastrozole, exemestane, and letrozole and dosing was per product information.
45832946|NCT03458598|Procedure|Subcutaneous injection saline placebo|Subcutaneous injection of 1ml of normal saline under ultrasound guidance at the same site bilaterally as rectus sheath blockade is performed
45832947|NCT01674816|Device|Repeated Measurements of Knee Alignment and Kinematics|Repeated Measurements of Knee Alignment and Kinematics using tools developed by Eiffel Medtech Inc.
45832948|NCT01674816|Device|Computer Guidance of Surgical Actions|Computer Guidance of Surgical Actions using tools developed by Eiffel Medtech Inc.
45832949|NCT01672242|Device|HFNC|Graded high flow nasal cannula oxygen at 10, 20 , 30, and 40 liters per minute (LPM) to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
45985869|NCT00500487|Behavioral|Affect Management|12-session group intervention including affect management training as well as sexual health skills training.
45985870|NCT00500487|Behavioral|HIV Prevention Skills|12-session group intervention including sexual health skills training.
45985871|NCT00500487|Behavioral|General Health Promotion|12-session group intervention including health information on a variety of health topics.
45985872|NCT00474422|Behavioral|Proactive assignment to attend a breastfeeding clinic|
45985873|NCT01243905|Other|Family psychoeducational therapy plus TAU|Group psychoeducation every two weeks for eight weeks in addition to treatment as usual administered by physicians
45985874|NCT01243905|Other|Treatment as usual|Treatment as usual administered by physicians
45985875|NCT00474461|Biological|Treatment group|Intracoronary injection of cardiac stem cells
45985876|NCT00500526|Other|Singing practice|
45985877|NCT00500526|Other|Singing classes|
45985878|NCT00500526|Other|Hand craft classes|
45985879|NCT03270488|Other|Laser|Laser (power of 3.0w).
45985880|NCT03270488|Other|Placebo|Laser (power 0,0w)
45985881|NCT00493350|Procedure|Blood Sample|1x4 ml (Serum Tube); 2x10 ml (CellSave Tube); 1x10 ml EDTA (Selected Centers)
45985882|NCT00469469|Drug|Bevacizumab|
45985883|NCT00500565|Drug|Saline|On-Q Pain Pump filled with Saline. The On-Q pump will be connected to the catheter to deliver a constant flow of saline for up to 5 days.
45832950|NCT01672242|Device|CPAP|Graded contiuous positive airway pressure at 5, 10 , 15, and 20 cm H2O applied to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
45985884|NCT00500565|Drug|Bupivicaine|On-Q Pain Pump filled with 0.375% Bupivicaine through two catheters at a total rate of 4 cc/hr over 111 hours. The On-Q pump will be connected to the catheter to deliver a constant flow of Bupivicaine for up to 5 days.
45985885|NCT03270293|Device|Profhilo|
45985886|NCT01243983|Drug|LX211|"Subjects will be sequentially assigned to one of the following treatment arms in a 1:1 ratio:~Treatment Arm A: voclosporin 0.4 mg/kg p.o. b.i.d., not to exceed 40 mg p.o. b.i.d.~Treatment Arm B: placebo p.o. b.i.d.~Dosage Form:~• Soft gelatin capsule~Duration of treatment:~• 24 weeks"
45985887|NCT00469547|Other|62% ethanol in emollient gel|62% ethanol in emollient gel used as a topical male microbicide
45985888|NCT00469547|Drug|Placebo|15% ethanol in emollient gel used as a topical male microbicide
45985889|NCT00469547|Other|15% ethanol in emollient gel|15% ethanol in emollient gel used as a topical male microbicide
45985890|NCT00500604|Drug|Irbesartan/hydrochlorothiazide|150/12.5mg tablet and 300/12.5mg tablet
45985891|NCT00500604|Drug|Valsartan/hydrochlorothiazide|80/12.5mg tablet and 160/12.5mg tablet
45832951|NCT03791736|Procedure|Injection of sandostatine|Intramuscular injection of sandostatin 30 mg 3 days before surgery
45832952|NCT01672008|Drug|NOX-100|
45832953|NCT01676376|Device|eSVS Mesh treated saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be treated with eSVS Mesh and implanted in the right or left coronary system.
45832954|NCT01676376|Other|Control saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be the control (no eSVS Mesh) and implanted in the right or left coronary system.
45985892|NCT00500604|Drug|Hydrochlorothiazide|12.5 mg administered orally, once daily in the morning
45985893|NCT03270215|Procedure|Computed tomography|The diagnostic power to discriminate malignant from nonmalignant causes of e pleural effusion
45985894|NCT01348828|Device|Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System)|Endovascular repair of juxtarenal or pararenal aortic aneurysm using the Endologix Fenestrated Stent Graft System
46083421|NCT05131178|Device|ON-Q Pump® with continuous infusion of saline|270 mL of normal saline. The device being used is a fixed flow pump meaning the rate of 2 mL/hour. The pump is connected to the catheter and left in place for up to 4 post-operative days or until the completion of the infusion.
45673292|NCT04721314|Device|Adjustment of lower rate limit|Patients with preserved ejection fraction (EF >50%) and implanted pacemakers will have the lower rate limit adjusted to a personalized heart rate based on a heart rate algorithm.
45673293|NCT04721314|Device|Maintenance of lower rate limit|Lower rate limit will be maintained at 60 beats-per-minute
45673294|NCT04418180|Drug|Fenofibrate|Patients were randomly assigned to receive oral fenofibrate 10 mg/kg/hr
45673295|NCT04418180|Drug|Placebo|oral distilled water
45673296|NCT02212730|Drug|Pembrolizumab Pre-Resection|200 mg administered by IV, once every 3-week cycle for a maximum of 2 cycles
45673297|NCT02212730|Procedure|Surgical Resection|Standard of care surgical resection of RCC tumor
45832955|NCT03458520|Diagnostic Test|PET/MR imaging|undergo PET/MR imaging
45832956|NCT03458520|Diagnostic Test|MR imaging|Undergo MR imaging
45832957|NCT03458520|Diagnostic Test|PET/CT imaging|Undergo PET/CT imaging
45985895|NCT00493389|Drug|Adrenocorticotrophic hormone|
45673298|NCT02212730|Drug|Pembrolizumab Post-Resection|200 mg administered by IV, once every 3-week cycle for a maximum of 17 cycles
45673299|NCT02178956|Drug|BBI608|BBI608 480 mg orally two times daily (960 mg total daily dose)
45673300|NCT02178956|Drug|Paclitaxel|Paclitaxel 80 mg/m2 I.V. infusion on Days 1, 8, and 15 of every 4-week cycle
45985896|NCT03270254|Device|light activated dye photodynamic therapy (PDT)|light activated dye photodynamic therapy-PDT to periodontal pockets
45985897|NCT01348789|Device|Hair2Go (Mē)|Treatment with Hair2Go (Mē) three times every 2-4 days
45985898|NCT01605994|Drug|BMS-933043|
45985899|NCT01605994|Drug|Placebo matching with BMS-933043|
45985900|NCT01605994|Drug|Antacid Buffer Predose Solution|
45985901|NCT01606033|Other|questionnaires|Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction survey
45985902|NCT01606033|Other|questionnaire|understanding of the implications of participating in a clinical trial
45985903|NCT00500721|Drug|HCV-796|HCV-796 500mg BID x 14 days
45985904|NCT00500721|Drug|Desipramine|"Period 1: Single oral dose of desipramine (50 mg) on day 1. No test article administration on days 2 to 6.~Period 2: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 1 to 9.~Period 3: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 10 to 14 and a single oral dose of desipramine (50 mg) on day 10."
45985905|NCT00469586|Drug|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
45985906|NCT00469586|Drug|metformin|Tablets, 2000 mg/day.
45985907|NCT00469586|Drug|glimepiride|Tablets, 4 mg/day.
45985908|NCT00469586|Drug|inhaled human insulin|Treat-to-target dose titration scheme, post-prandial, inhalation.
45985909|NCT01606111|Drug|Cerebrolysin|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
45985910|NCT01606111|Drug|0.9% NaCl, saline|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
45985911|NCT01606267|Other|health systems intervention: HEP+ICCM|In the HEP+ICCM intervention areas, HEWs will assess and treat childhood pneumonia with cotrimoxazole. The program will strengthen the capacity of HEWs to assess, classify and treat malaria (with ACTs), diarrhea (with ORS) and undernutrition (with therapeutic feeding) through refresher trainings and strengthening supervision, logistical support and the ICCM system overall.
45985912|NCT00493428|Drug|Baclofen|Patients will receive an initial dose of: 5 mg tid to be increased as tolerated to a maximum dose of 20 mg qid. This dose range and schedule reflects that suggested for the drug's muscle relaxant properties in human.
45985913|NCT01342510|Drug|Magnesium Sulfate|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
45985914|NCT01342510|Drug|Lidocaine|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
45985915|NCT01342510|Drug|Control|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
45985916|NCT01342510|Drug|Lidocaine/Magnesium|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
46083422|NCT04094649|Device|Ultrasound Vagus Nerve Stimulation (DECIMA)|This is a single-site, double-blind, randomized, prospective, sham-controlled, crossover early feasibility study to determine whether ultrasound Vagus Nerve Stimulation (uVNS) inhibits postprandial hyperglycemia in humans.
45832958|NCT03525288|Radiation|PSMA -PET/CT simulation|"PET/CT simulation.~If no additional lesions detected: RT as planned per standard care.~If PSMA-PET/CT imaging consistent with oligometastases (1-5 lesions): all lesions must be treated with definitive RT.~If PSMA-PET/CT imaging consistent with widely metastatic disease (>5 lesions): treatment of all detected disease with RT is not recommended, but treatment of the primary site as initially planned is encouraged."
45832959|NCT03525288|Radiation|Standard-care simulation|No PSMA-PET/CT as part of RT treatment planning.
45832960|NCT01679964|Drug|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
45832961|NCT03787134|Behavioral|working memory and attention|Behavioral tests of working memory and attention
45832962|NCT02404818|Procedure|Cardiac Magnetic Resonance Imaging|A cardiac MRI will be performed.
45832963|NCT02404818|Procedure|Echocardiogram|An echocardiogram will be performed for the following information: M-mode, two-dimensional, Doppler blood flow measurements, and longitudinal strain and strain rate imaging
45985917|NCT01606345|Drug|Valrubicin|Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days following nephrostomy placement and within 6 weeks of tumor treatment/resection.
45985918|NCT01244022|Procedure|colorectal cancer resection|Open radical resection of colorectal cancer, according to oncological principals, depending on the tumor site
45985919|NCT00474500|Drug|Coca, Cola, Diet Coke|
46083423|NCT02714244|Other|Volume expansion|Volume expansion with rapid administration of 500 ml of crystalloid
46083424|NCT04197284|Device|Biofeedback, Myomed 632|"Biofeedback is a mind-body technique that involves using visual or auditory feedback to gain control over involuntary bodily functions.~Electrical stimulation is a technique used to elicit a muscle contraction using electrical impulses."
45673301|NCT02178956|Other|Placebo|Orally two times daily
45673302|NCT02211638|Drug|Candesartan Cilexetil|Candesartan Cilexetil tablet
45673303|NCT02178566|Drug|Inhaled Treprostinil|A dose of inhaled treprostinil or placebo will be administered to all study participants prior to each of their Pulmonary Rehab sessions. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
45673304|NCT02211014|Drug|acalabrutinib|
45673305|NCT01631864|Drug|LCZ696|LCZ696 was provided as 400 mg tablets.
45673306|NCT01631864|Drug|amlodipine|amlodipine was provided as 5 mg tablets.
45673307|NCT01631864|Drug|Placebo|Matching placebo to LCZ696 and amlodipine.
45673308|NCT02210780|Drug|Dupilumab|Administered via subcutaneous injection.
45985920|NCT01245894|Drug|Low-dose Rosuvastatin|Rosuvastatin 5mg/day for one year
45985921|NCT01245894|Drug|High-dose Rosuvastatin|Rosuvastatin 40mg/day for one year
45985922|NCT00469625|Drug|paricalcitol (initial dose 1 mcg orally per day)|
45985923|NCT01316367|Behavioral|PRECEDE HPE model|"The model considers the influence of the following three factors on health-related behavior:~Predisposing: factors influencing the patient's motivation to undertake the behavior to be analyzed or encouraged.~Facilitators: factors influencing the level of easiness or difficulty the patient and his/her family have in undertaking a given behavior.~Reinforcing: factors arising after the patient has undertaken the behavior, and which reward or punish it."
45985924|NCT01316367|Behavioral|CHPE|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
45985925|NCT00469664|Drug|Guanfacine/Tenex|
45985926|NCT00469703|Drug|Thalidomide|
45985927|NCT01244100|Drug|PL2200 fasted|Fasted state
45985928|NCT01244100|Drug|PL2200 fed|Fed state
45985929|NCT04697888|Drug|Omegaven|Expanded Access Therapy with Omegaven will be initiated at a starting dose of 0.5 gm/kg/day to be infused over 24 hrs. After two days of infusion the dose will be increased to 1gm/kg/day.
45985930|NCT01340872|Drug|ST10-021|30 mg capsules to be taken orally twice a day for 12 weeks
45832964|NCT05346822|Procedure|integrated rehabilitation (the collaborative patient education)|Pre-operative education and rehabilitation. During hospitalization: group rehabilitation education program. Discharge: post-operative care navigation for total knee arthroplasty
45832965|NCT03524898|Drug|Nab-Paclitaxel|150 mg/m2 / 125 mg/m2
45832966|NCT03524898|Drug|gemcitabine|1000 mg/m2
45832967|NCT03524820|Drug|Cetuximab|Administration of drug
45832968|NCT03524508|Drug|Onivyde|The recommended dose and regimen of Onivyde is 70 mg/m2 intravenously over 90 minutes, followed by dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks.
45832969|NCT03524508|Drug|5-FU/LV|The recommended dose and regimen of dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks
45832970|NCT03524118|Drug|Clesrovimab|Single ascending doses of clesrovimab will be administered via IM injection.
45832971|NCT03524118|Drug|Placebo|Placebo (0.9% sodium chloride [NaCl]) will be administered via IM injection.
45985931|NCT01340872|Drug|Placebo Comparator|Matching sugar pill to be taken orally twice a day for 12 weeks
45985932|NCT00474656|Device|High-frequency oscillation|
45985933|NCT00474656|Device|Conventional lung-open mechanical ventilation|
45985934|NCT00469781|Drug|2. Xibrom (Bromfenac)|Group 1 and 2: 1 drop(Instill one drop in the eye that was operated on twice daily)3 days prior to surgery and 4 doses during dilation immediately before the procedure. Use for 4 weeks after surgery.
45985935|NCT00469781|Drug|1. Pred Forte|"Group 1 Instill one drop in the eye that was operated on four times a day starting on day of surgery and use for four weeks.~Group 2 Instill one drop in the eye that was operated on twice a day starting on day of surgery and use for four weeks."
45985936|NCT01244139|Drug|BIIB033|IV infusion of 0.3, 1, 3, 10, 30, 60 or 100 mg/kg
45985937|NCT01244139|Drug|Placebo|IV infusion dummy drug
45985938|NCT01340794|Other|Laboratory Biomarker Analysis|Correlative studies
45985939|NCT01340794|Drug|Pazopanib Hydrochloride|Given PO
45985940|NCT00469820|Biological|autologous tumor cell vaccine|
45985941|NCT00469820|Biological|peripheral blood lymphocyte therapy|
45985942|NCT00500838|Device|Transthoracic Impedance|Impedance measures will be automatically collected via the device
45985943|NCT00474695|Drug|Lucentis|0.05 mg intravitreal injection
45985944|NCT00500877|Behavioral|Mood Management Phone Counseling for Smoking Cessation|Phone counseling addressed mood management and smoking cessation
45985945|NCT00474734|Device|Intravascular ultrasound of the liver|
45985946|NCT00500916|Device|ProSeal LMA|GEB vs digital vs introducer tool
45985947|NCT03271502|Procedure|Total intravenous anesthesia|Total intravenous anesthesia with propofol and remifentanil
45985948|NCT03271502|Procedure|Inhalation anesthesia|Inhalation anesthesia with sevoflurane and remifentanil
45985949|NCT00500955|Drug|Rosiglitazone|
45985950|NCT00474773|Drug|Celecoxib|
45985951|NCT00474890|Drug|cetericine and pseudoephedrine|
45985952|NCT00501033|Device|Mechanical induction of labor|
45985953|NCT00501033|Device|Double Balloon|
45985954|NCT00501033|Device|Foley Catheter|
45985955|NCT03271463|Behavioral|Selective Control Assessment of Lower Extremity (SCALE)|Inter- and intra-rater reliability Validity: correlation analysis with Fugl-Meyer Assessment - Lower Extremity Component (FMA-LE) and 10 meter walk test (see below)
45985956|NCT00501072|Device|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
45985957|NCT01340482|Drug|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injections every 28-days (up to 4 doses) based on a dosing algorithm and discretion of the investigator and sponsor.
46083425|NCT04197284|Device|device for electrical stimulation, BTL 4000 Smart|Electrical stimulation is a technique used to elicit a muscle contraction using electrical impulses. Electrodes, controlled by a unit, are placed on the skin over a predetermined area. Electrical current is then sent from the unit to the electrodes and delivered into the muscle causing a contraction.
46083426|NCT04197284|Other|kinesitherapy|isometric exercise of the quadriceps muscle
45673309|NCT02210780|Drug|Placebo|An inactive substance containing no medicine administered via subcutaneous injection.
45673310|NCT01557244|Drug|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 24 weeks
45673311|NCT01557244|Drug|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
45673312|NCT01557244|Drug|Fesoterodine PR 8 mg|Fesoterodine 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
45673313|NCT01557244|Drug|Oxybutynin|Oxybutynin extended release tablets according to approved pediatric labeling for 12 weeks with dose titration phase for first 4 weeks to achieve dose optimisation.
45673314|NCT01557244|Drug|Fesoterodine PR|Fesoterodine 4 mg or 8 mg tablets once daily for 12 weeks after 12 weeks of oxybutinin. Those assigned to 8 mg will take 4 mg for the first week.
45673315|NCT01557244|Drug|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 24 weeks.
45673316|NCT01557244|Drug|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 24 weeks, with the first week being 2 mg.
45673317|NCT02155712|Device|Triathlon Tritanium Knee|Cementless
45673318|NCT02155712|Device|Triathlon Knee|Cemented
45832972|NCT03523338|Drug|Apalutamide|Participants will receive apalutamide 240 mg orally once daily.
45832973|NCT03523338|Drug|ADT (Standard of Care)|Participants who did not undergo surgical castration, should receive and remain on a stable regimen of ADT according to local standard of care.
45832974|NCT03522168|Drug|Risperidone|Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
45832975|NCT03522168|Drug|Aripiprazole|Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
45832976|NCT03521856|Behavioral|shoulder exercise|Exercises performed 3 times a week for 12 weeks
45832977|NCT03521856|Behavioral|education|
45832978|NCT03457818|Drug|Denosumab 60 mg/ml [Prolia]|Denosumab 60 mg will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
45832979|NCT03457818|Other|Placebo|Placebo will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
45673319|NCT02177942|Other|Test beverage powder (High Proteins and added micronutrients)|High protein and added Micronutrients at recommended dietary allowance levels
45985958|NCT03271697|Drug|Astragalus Membranaceus|This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.
45985959|NCT03271697|Drug|Placebo|as a comparator comparing with AM group
45985960|NCT00501111|Drug|AZD3480|3 oral doses
45985961|NCT00501111|Drug|Donepezil|
45985962|NCT00475007|Device|IBV® Valve System|The IBV Valve is a small, umbrella shaped device designed to redirect airflow to healthier areas of the lungs. It is implanted without incisions using a bronchoscope.
45985963|NCT00501150|Drug|linezolid|
45985964|NCT03271541|Drug|Bitopertin|Bitopertin will be administered orally once daily at doses up to 120 milligrams (mg).
45985965|NCT00501189|Biological|human papillomavirus vaccine L1, type 6,11,16,18|Subjects are those getting gradasil vaccination already. This is really not an intervention
45985966|NCT01340209|Drug|Tiotropium Respimat|Tiotropium high dose once daily delivered with Respimat inhaler
45985967|NCT01340209|Drug|Placebo Respimat|Tiotropium placebo once daily delivered with Respimat inhaler
45985968|NCT01340209|Drug|Tiotropium Respimat|Tiotropium low dose once daily delivered with Respimat inhaler
45985969|NCT00475046|Behavioral|Motivational Interviewing|
45985970|NCT01246089|Drug|ranibizumab injection|Ranibizumab intravitreal injection of 0,5 mg ( 0.05mL)
45985971|NCT00598897|Drug|clarithromycin, rifabutin|Clarithromycin three times per week (variable dosage) in combination with multiple drugs including rifabutin or rifampin three times per week (variable dosage). Dosage dependent on age, weight and other patient-specific health factors.
45832980|NCT03456804|Drug|ESK981|Treatment with ESK981 for patients with metastatic castrate resistant prostate cancer
45985972|NCT04697732|Other|General anesthesia|Following emergence from general anesthesia, patients will be evaluated at 4 different timepoints; (a) One hour after emergence, (b) Twenty four hour after emergence (c) One week after emergence (d) One month after emergence. The first interview will be made face-to-face in the recovery unit, and other interviews will be made by phone.
46083427|NCT05456997|Procedure|Muscle biopsy|Patients will have muscle biopsies taken at time of surgery under general anaesthetic. Open biopsies from the operation field (abdominal wall) will be taken by the surgical team without extending or making new skin incisions. Briefly, muscle samples (approximately 0.5cm3) are excised and haemostasis secured. The muscle biopsies will be snap frozen and stored at -80°C for the analysis of pathways relevant to muscle homeostasis using biochemical and molecular techniques.
46083428|NCT02546934|Drug|ABX, cisplatin|ABX 125 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
45985973|NCT00501267|Drug|solabegron and oxybutynin|
45985974|NCT00598936|Device|CDI 1000 COM and INVOS 5100|CDI 1000 and INVOS 5100 sensors were attached to subject's forehead for a 12 hour period, digital photographs were taken before and after sensor placement.
45985975|NCT04326244|Diagnostic Test|blood test|High-density lipoprotein- cholesterol, Low-density lipoprotein- cholesterol, Total cholesterol, Triglyceride, Leptin, Glucose AC, Hemoglobin A1C, Insulin
45985976|NCT04326244|Diagnostic Test|genetic test|FTO、MC4R、BDNF、PPARG、ADRB3、UCP1
45985977|NCT04326244|Diagnostic Test|Constitution in Chinese Medicine Questionnaire|Constitution in Chinese Medicine Questionnaire
45832981|NCT01676844|Drug|Oral thin film therapy (Potassium acid phosphate oral thin films)|"Orally dissolving thin film. White, square oral thin film. 15 mm x 15 mm surface area. 1-2 mm film thickness. No markings.~Place a single OTF on the tongue, inside cheek or palate and allow to dissolve."
45985978|NCT04326244|Diagnostic Test|Epworth Sleepiness Scale|Epworth Sleepiness Scale
45985979|NCT04326244|Diagnostic Test|cephalometry|Evaluation of craniofacial morphology in OSA patients
45985980|NCT04326244|Diagnostic Test|polysomnography|to evaluate Apnea-Hypopnea Index (AHI) for the severity of sleep apnea
45985981|NCT00599209|Other|clinical decision support|CDS is provided to prescribers on intervention units upon ordering medication which offers advice on prescribing and monitoring practices
45985982|NCT01326910|Drug|Colloidal Oatmeal|Topical cream applied twice daily (or as needed)
45985983|NCT01326910|Device|Topical Cream|Topical cream applied twice daily (or as needed)
46083429|NCT02546934|Drug|Gemcitabine, Cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
46083430|NCT05123066|Other|Aquatic Exercises|"These 3 sets were the following:~Set 1: warming up exercise as floating exercise 24 Set 2: Standing education/training Set 3: Walking education/training~The exercises will be conducted taking in consideration safety measures as:~Each participant will use Noodles to ensure safety.~Each participant will train individually to ensure safety and avoid distraction.~Each participant will use special swimming suit in case of lack of bowel and/or bladder control."
46083431|NCT05123066|Other|Land Exercises|All participants were physical therapy intervention according to their level of functional impairment :
45832982|NCT01676844|Drug|Standard therapy (Potassium acid phosphate oral solution)|Each millilitre contains approximately 136mg Monobasic Potassium Phosphate Ph.Eur. (KH2PO4) equivalent to 1mmol Potassium (39mg) and 1mmol Phosphate (31mg Phosphorus). Manufacturer: Specials Products Ltd., Surrey, UK.
45832983|NCT04270266|Other|Educational Intervention|Attend educational sessions
45832984|NCT04270266|Other|Meditation Therapy|Attend meditation sessions
45985984|NCT00469937|Drug|lithium carbonate|Dose levels Neoadjuvant lithium Concurrent lithium Dose level -1 300mg po QD 300mg po QD Dose level (starting dose) 300mg po BID 300mg po BID Dose level 2 300mg po TID 300mg po TID Dose level 3 300mg po QID 300mg po QID
45985985|NCT00469937|Procedure|cognitive assessment|cognitive assessment
45985986|NCT00469937|Procedure|quality-of-life assessment|quality-of-life assessment
45985987|NCT00469937|Radiation|radiation therapy|Protocol radiotherapy must begin within seven days following initiation of Lithium therapy if day seven falls on a holiday or weekend; it is acceptable to begin treatment the next business day. One treatment of 3Gy will be given daily with the exception of weekends and holidays for a total of (10 fractions) for a total of 30 Gy over 2 to 3 weeks.
45985988|NCT00599287|Drug|Haloperidol|Haloperidol 2,5 mg. 2 dd 1, oral. (if patient is 69 years or younger) Haloperidol 1 mg. 2 dd 1, oral (if patient is 70 years or older)
45985989|NCT00599287|Drug|Methylphenidate|Methylphenidate 5 mg. 2 dd 1, oral, increased every day with 10 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 30 mg./day
45985990|NCT00599287|Drug|Rivastigmine|Rivastigmine 1,5 mg. 2 dd 1, oral, increased every third day with 3 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 12 mg./day
45985991|NCT00599365|Other|Pharmacy care arm|"The pharmacist will take all your medication bottles, and give you medication boxes filled with your medications in the order you should take them in.~You will need to give a complete list of medications to the pharmacist.~You will need to describe how you take these medications.~The pharmacist will teach you about the medications. This includes side effects, drug interactions, and directions.~The pharmacist will give you a medication schedule, and other papers about your medications."
45985992|NCT00599404|Drug|PN400|500 mg esomeprazole/20 mg naproxen, once daily on Days 1-10 and twice daily on Days 2-9
45985993|NCT00475124|Device|Home Monitoring of pacemaker|Daily Home Monitoring data transmission from the implanted pacemaker to Home Monitoring service center.
45985994|NCT00475124|Device|Home Monitoring of pacemaker deactivated|No Home Monitoring data transmission.
45985995|NCT04326166|Drug|Evogliptin|Evogliptin
45985996|NCT04326166|Drug|Evogliptin|Evogliptin
45985997|NCT04326166|Drug|Metformin and Evogliptin|Metformin and Evogliptin
45985998|NCT00599443|Biological|Seasonal cell-derived influenza vaccine|0.5 mL im, single dose
45985999|NCT00599443|Biological|Placebo Comparator|0.5 mL im, single dose
45986000|NCT00501384|Drug|satavaptan (SR121463B)|
45986001|NCT00599482|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far infrared radiation for 30 to 40 minutes during each session.
45986002|NCT00599560|Genetic|vasopressin, V2 receptor and cyclic AMP|plasma vasopressin, V2 receptor, cyclic AMP
45986003|NCT00599599|Behavioral|Prolonged Exposure Therapy|Participants will meet with a therapist twice a week for 5 weeks to complete the therapy. If the therapist and participant feel more sessions are needed, an additional 8 sessions will be provided.
45986004|NCT02891668|Drug|Levothyroxine treatment|Eltroxin/Euthyrox is part of the normal treatment for hypothyroidism, and the patient is treated equally, whether he/she participates or not.
45986005|NCT02956343|Device|Five minutes pulse wave recording|Patients will wear a smart watch and a wristband each at one arm. A standard egg (lead I) and pig signals from the wearables will be recorded for five minutes.
45986006|NCT00599677|Other|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
45986007|NCT00599677|Drug|Itopride|Each pill weighs 50mg, once a pill, three times a day. The pills are taken half an hour before meals, and be taken 4 weeks continuously.
45986008|NCT00599716|Drug|sodium hyaluronate|a sterile, unpreserved eye drop containing sodium hyaluronate in a proprietary formulation to be administered by ocular instillation
45986009|NCT00599716|Drug|vehicle|identical to proprietary formulation of active eye drop but without active ingredient, sodium hyaluronate
45986010|NCT01246284|Drug|Triamcinolone acetonide|Injections will be given within a 3 cm2 area of alopecia which will be divided into 4 quadrants. Three different concentrations of triamcinolone acetonide will be used: 2.5, 5, and 10 mg/ml. Each quadrant will receive injections with either triamcinolone acetonide 2.5 mg/ml, triamcinolone acetonide 5 mg/ml, triamcinolone acetonide 10 mg/ml, or normal saline as a control. Injection of 0.1 ml will be given intradermally using a 30 gauge half inch long needle attached to a 3 ml syringe. Each quadrant will receive approximately 7 injections per treatment session so the total dose of triamcinolone acetonide will be around 13 mg. Injections will be given vertically, with the beveled side of the needle directed to the opposite side and 2 mm away from the margin of the adjacent quadrant to avoid a diffusion effect. The treatment will be repeated every 4 to 6 weeks for a total of 6 treatment sessions.
45986011|NCT01246284|Other|Normal saline|
45986012|NCT00599833|Biological|cetuximab|
45986013|NCT00599833|Radiation|3-dimensional conformal radiation therapy|
45986014|NCT00469976|Drug|bevacizumab|
45986015|NCT00469976|Drug|carboplatin|
45986016|NCT00469976|Drug|enzastaurin hydrochloride|
45986017|NCT00469976|Drug|gemcitabine hydrochloride|
45986018|NCT00599911|Drug|Lu AA24530|per oral, once daily for 6 weeks
45673320|NCT02177942|Other|Control beverage powder (Low protein and no added micronutrients)|Low protein and no added micronutrients
45673321|NCT02155322|Biological|Pegylated Interferon Alfa-2b|6 μg/kg, weekly dosing, subcutaneous administration, Induction Phase - first 8 weeks
45673322|NCT02155322|Biological|Pegylated Interferon Alfa-2b|3 μg/kg SC once weekly for a 42-week maintenance phase (for a total treatment of up to approximately 1 year)
45986019|NCT00599911|Drug|Duloxetine|per oral, once daily for 6 weeks
45673323|NCT02210000|Drug|Placebo|Camicinal matching placebo is available as tablet to be taken orally with 100mL of water in the morning
45673324|NCT02210000|Drug|Camicinal|Camicinal is available as 25 mg tablet to be taken orally with 100mL of water in the morning
45673325|NCT01531894|Drug|GSK2110183 (afuresertib)|Afuresertib is an oral, low nanomolar pan-AKT kinase inhibitor immediate release (IR) 50 mg or 75 mg tablets was to be taken orally with at least 200 mL of water, with or without food, in the morning.
45673326|NCT02209766|Drug|D5884|1st cohort: Dose 1(2g) D5884(n=6) in Japanese 2nd cohort: Dose 2(4g) D5884(n=6) in Japanese 3rd cohort: Dose 2(4g) D5884(n=6) in Caucasian
45986020|NCT00599911|Drug|Placebo|per oral, once daily for 6 weeks
45986021|NCT00501462|Drug|GSK189075|single 250 mg dose of drug
45986022|NCT00599950|Drug|Mitomycin C and Photorefractive keratectomy (PRK)|Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
45986023|NCT00475163|Behavioral|Behavior modification|
45986024|NCT00600145|Drug|Mirtazapine|15 mg Mirtazapine is administered followed 2 hours later by 20 mg of methamphetamine / placebo (administered at each testing visit)
45986025|NCT00600145|Other|Placebo|Placebo
45986026|NCT00501501|Procedure|Cesarean section|
45986027|NCT00501501|Procedure|Vaginal delivery|
45986028|NCT00600223|Behavioral|questionnaires and standardized, digital voice recording|Patient will be asked to complete four sets of forms. Upon completion of these forms, the study subject and the investigator will proceed to a quiet room for the standardized, digital voice recording. Recording will be made on digital audiotape using a standardized portable, digital audio recorder.
45986029|NCT00470015|Biological|MART-1 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
45986030|NCT00470015|Biological|IL-2|0.5x10^6/m^2
45986031|NCT00470015|Biological|gp100 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
45986032|NCT00470015|Biological|GM-CSF|300mcg
45986033|NCT00470015|Biological|MART-1a peptide|1000 mcg; Day 1 of a 21 day cycle x 4
45986034|NCT00600262|Drug|intravitreal bevacizumab|
45986035|NCT00600301|Drug|Triamcinolone Acetonide and Bevacizumab|
45986036|NCT04325971|Other|Neuroimaging|MR, EEG recordings
45986037|NCT04326127|Device|Intervention is the validation of a sleep monitoring device (i.e. Somfit) against the gold-standard polysomnograph with electroencephalograph (i.e. the Greal system)|Data were recorded overnight by both devices simultaneously
45986038|NCT00501579|Drug|Difluprednate|
45986039|NCT00501579|Drug|Prednisolone Acetate|
45986040|NCT00600379|Device|Virtual reality system (CAREN™ Integrated Reality System; MOTEK BV, Netherlands).|Training 2/w for 9 weeks (total 18 sessions).
45832985|NCT04270266|Other|Questionnaire Administration|Ancillary studies
45986041|NCT05661448|Behavioral|Cognitive remediation|The goal of this program is to improve performance on cognitive domains known to hinder functioning. It aims to promote positive attitudes towards learning and facilitate the development of independent learning skills to foster competence and confidence. Another aim is to increase patients' awareness of their cognitive strengths and weaknesses and their own problem solving strategies.
45986042|NCT05661448|Behavioral|MetaCognitive Training|The metacognitive training (MCT) program is based on the theoretical foundations of cognitive models of schizophrenia but employs a slightly different focus in its therapeutic approach targeting the specific cognitive biases underlying delusions. The modules aim to raise awareness of these biases and prompts participants to critically reflect on and update their problem-solving repertoire.
46083432|NCT02717598|Procedure|cold snare polypectomy|CSP was performed by using a disposable oval snare with a diameter of 10 mm under gentle suction to reduce colon wall tension. The tip of the endoscope was deflected toward the polyp base to ensnare 1 to 2 mm of normal mucosa surrounding the polyp. Afterward, additional EMR was performed at the polypectomy site to evaluate for the presence of residual polyp tissue,including an additional 1 to 2 mm clear margin, was resected by the snare and Endocut current after submucosal injection of a mixed solution.In the event that no tissue could be removed or if EMR failed to get in situ mucosal specimens. At least four cold biopsies using forceps on the remaining margins were obtained.After each procedure, the polypectomy site was observed for 30 seconds to confirm the absence of immediate bleeding.Cross-sections of the EMR specimens were collected at 1-mm intervals.
45673327|NCT02209766|Drug|Placebo|"st cohort: Dose 1(2g) D5884(n=3) in Japanese~nd cohort: Dose 2(4g) D5884(n=3) in Japanese"
45832986|NCT04403334|Drug|Levofloxacin Ophthalmic|0.1 ml of unpreserved 0.5% levofloxacin
45986043|NCT02891707|Device|Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD)|"The study will use a novel piece of technology, the ReLOAD, which is a data collector system that uses instrumented insoles, custom, miniature (1x1) microcontroller with accelerometer, gyroscopes, and geomagnetic sensors connected to a Bluetooth transceiver to collect and transmit gait kinematic data to mobile devices, such as an iPad and iPod. When a person walks or performs a specific activity, the ReLOAD system captures the movement, which can then be stored locally within the mobile device and/or encrypted and sent to a secured central server. This allows the patient or provider to access clinically relevant biomechanical data to help guide rehabilitation."
45986044|NCT00501618|Drug|Fazaclo|single-arm
45986045|NCT00600457|Device|Polyurethane Film|The modified polyurethane film is combined with a secondary absorbent dressing and remained intact until the 10th postoperative day
45986046|NCT02891434|Device|Acquisition on TouchScreen|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
45986047|NCT02891434|Device|Acquisition on Kinect|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
45986048|NCT02891434|Device|Acquisition on LeapMotion|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
45673328|NCT02209454|Drug|Enantyum® oral solution|One dose of 25 mg DKP oral solution
45673329|NCT02209454|Drug|Keral® tablet|One dose of 25 mg DKP tablet
45673330|NCT01571596|Drug|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor.
45673331|NCT01557166|Drug|liraglutide|3.0 mg liraglutide administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
45832987|NCT04403334|Drug|Moxifloxacin Ophthalmic|0.1 ml of unpreserved 0.5% moxifloxacin
45673332|NCT01557166|Drug|placebo|Placebo administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
45673333|NCT01556932|Drug|ABH gel|Given topically
45986049|NCT00600535|Drug|Stage 1 Group 1: abiraterone acetate|1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.
45986050|NCT00600535|Drug|Stage 1 Group 2: abiraterone acetate|1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.
45986051|NCT00600535|Drug|Stage 2: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.
45673334|NCT01556932|Other|placebo|Given topically
45986052|NCT00600535|Drug|Stage 3: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle).
45986053|NCT00600535|Drug|Stage 3: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).
45986054|NCT00600535|Drug|Stage 4: abiraterone acetate|1000 mg tablets/day orally for up to 24 cycles (28 days/cycle).
45986055|NCT00600535|Drug|Stage 4: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for up to 24 cycles (28 days/cycle).
45986056|NCT00600574|Other|physical therapy|weekly pool physiotherapy with muscle stretching
45986057|NCT00600574|Other|physical therapy|weekly pool physiotherapy with Ai Chi movements during a 6 months period
45986058|NCT00470171|Drug|Ursodesoxycholic acid|
45986059|NCT00600691|Drug|Finasteride|one tablet (5mg) of finasteride
45986060|NCT00623077|Biological|filgrastim|"Beginning 24 hours after chemotherapy end: 10 microgram/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophile count (ANC) > 1,000/mm^2.~Starting that day, increase dose to 15 microgram/kg/day SQ or IV given as a single injection for 3 doses."
45986061|NCT00623077|Drug|busulfan|Part of pre-transplant conditioning chemotherapy: Administered as Busulfan 9.6 mg/kg IV (>4 yrs of age) or 13.2 mg/kg IV (< 4 years of age),every 6 hours on Days -8 through -6.
45986062|NCT00623077|Drug|etoposide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 100 mg/m^2/day intravenous (IV) over 1 hour for 5 days.
45456727|NCT04495166|Behavioral|Brief Psychotherapy|Brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation (BA). Participants will be guided by psychotherapists to plan, schedule, and engage in positively reinforcing activities, and will be aided to develop problem-solving strategies for circumventing barriers to completing scheduled activities. Implementation of these techniques will be conducted with the aid of the Motherly 1.0 for participants in the experimental arm; for participants in the control arm, BA will be implemented without the aid of Motherly 1.0. Throughout the four sessions, psychotherapists will monitor participants' adherence, answering questions about the strategies and providing support for solving problems or CBT techniques, such as cognitive restructuring, relaxation techniques, sleep hygiene, stress and anxiety management, among other evidence-based techniques might be used if appropriate to the case.
45673335|NCT02985736|Drug|Topicort Topical Spray|
45673336|NCT02985658|Drug|Veliparib|"Patients will start veliparib at 300 mg po BID days 1 through 21 of the first 21 day cycle, then increase to 400 mg po BID days 1 through 21 of each subsequent cycle, as tolerated by the patient.~At the treating investigator's discretion, and with principal investigator approval, veliparib may be used in combination with cisplatin and/or vinorelbine. Veliparib (300mg) will be dosed po BID on Days 1 through 14 of each 21-day cycle.~The patient will receive therapy as long as there is therapeutic benefit"
45673337|NCT02985658|Drug|Cisplatin|Cisplatin will be administered intravenously (75 mg/m2) on Day 1 of each cycle
45673338|NCT02985658|Drug|Vinorelbine|Vinorelbine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle
45673339|NCT02177786|Drug|Selonsertib|Tablets administered orally once daily
45986063|NCT00623077|Drug|ifosfamide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m^2/day intravenous (IV) over 1 hour on for 5 days.
45986064|NCT00623077|Drug|melphalan|Part of pre-transplant conditioning chemotherapy: Administered as 100 mg/m^2 intravenous (IV) over 30 min on Days -5 through -4.
45986065|NCT00623077|Drug|thiotepa|Part of pre-transplant conditioning chemotherapy: Administered as 500 mg/m^2 intravenously (IV) over 2 hrs on Days -3 through -2.
45986066|NCT00623077|Procedure|stem cell transplantation|Regardless of whether the patient will be receiving peripheral cells or bone marrow, infusion will be intravenous on day 0, immediately after thawing.
45986067|NCT00623077|Radiation|tomotherapy|"We plan to deliver the total marrow irradiation (TMI) to the upper half of the body using Tomotherapy TMI as explained in this protocol. However the lower part of the body will be treated with Anterior/Posterior linac based radiation treatment. Tomotherapy will then be delivered at a dose rate so as to keep the total treatment time to no more than 30 minutes. We anticipate that the dose rate will be around 400 cGy~/minute (instantaneous dose rate)."
45986068|NCT00623077|Radiation|total marrow irradiation|"TMI will be delivered to all bony sites as part of the conditioning. Additional spot therapy to PET positive lesions, primary disease (if not previously irradiated to maximum tolerated dose), and lungs will be performed on Day +60. Cohorts of 3 patients will be treated at a total dose of 600 cGy, 900 cGy or 1200 cGy on Days -11 through -9."
45986069|NCT00623077|Drug|Mesna|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m^2/day divided in every 6 hrs dosing for 5 days.
45986070|NCT00623077|Radiation|Whole lung radiation|At Day 60, patients with prior lung metastasis should receive whole lung irradiation (1500cGy in 10 fractions).
45986071|NCT00475358|Drug|Duloxetine|
45986072|NCT00475358|Drug|Placebo|
46002290|NCT03994393|Drug|Durvalumab|"During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance."
45986073|NCT00623116|Drug|Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below)|clinical examination, biochemical profile, and genetic characterization. Possibility to stop hormone therapy with drugs containing testosterone (Atmos®, Testim®, Testogel®, Nebido®, Panteston®, Sustanon®), FSH (Gonal-F®, Puregon®), hCG (Pregnyl®), estrogenic compounds (such as Estrofem®, Divigel®, Estrena®, Climara®, Estradot®, Evorel®, Femseven®: Merimono®, Progynova®, Ovestin®, Zumenon®, Estrogel®, Femoston®, Femoston combi®, Divina®, Divitren®, Indivina®, Estalis sekvens®, Evorel sequi®, Novofem®, Trisekvens®, Activelle®, Estalis®, Evorel conti®, Kliogest®, Mericomb®, Mericomb Mite®, Merigest®: Angeliq®) for 3 mo to assess reversibility of GnRH-deficiency will be offered.
45986074|NCT00623155|Drug|Seasonal IPT in children - Sulfadoxine-pyrimethamine|Subjecs randomized to receive two intermittent preventive treatments with standard recommended treatment doses of Sulfadoxine-pyrimethamine at 8 weeks interval during the peak malaria transmission season.
45986075|NCT00600730|Procedure|Hyperinsulinemic euglycemic clamp with fMRi|Hyperinsulinemic euglycemic clamp on day 1 with morning fMRi
45986076|NCT00600730|Procedure|Hyperinsulinemic hypoglycemic clamp study with fMRi|Hyperinsulinemic hypoglycemic clamp on day1 with fMRi in morning
45986077|NCT00600769|Drug|Clarithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
45986078|NCT00600808|Drug|BPLG-003|
45986079|NCT00470210|Drug|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week
45986080|NCT00470210|Drug|Ribavirin (Copegus®) 1600 mg/day|Ribavirin (Copegus®) 1600 mg/day
45986081|NCT00470210|Drug|Epoetin β (450 UI/kg/week)|Epoetin β (450 UI/kg/week)
45986082|NCT00600847|Drug|desloratadine|single dose for 7 days, oral, 20mg
45986083|NCT00600847|Drug|desloratadine|single dose for 7 days, oral, 5 mg
45986084|NCT00600847|Drug|placebo|single dose for 7 days, oral
45986085|NCT04325932|Drug|Urinary Kallikrein|
45986086|NCT00501657|Drug|Sitagliptin|100mg mane for 2 days
45673340|NCT02177786|Drug|Placebo to match selonsertib|Tablets administered orally once daily
45986087|NCT00501657|Drug|Placebo|100mg mane for 2 days
45986088|NCT00600964|Drug|GX15-070MS|A 60-minute or 3-hour IV infusion every 2-3 weeks.
45986089|NCT00600964|Drug|GX15-070MS|GX15-070MS at various doses and schedules
45986090|NCT00475397|Drug|Duloxetine|
45673341|NCT02153918|Biological|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.
45986091|NCT00475397|Drug|Placebo|
45986092|NCT02891512|Other|ELF|Very low frequency magnetic fields (ELF) at intensity of 100 mT and a frequency of 1-80 Hz. Protocol (antiedema-antinflammatory): 12 sessions, 3 times a week for 4 consecutive weeks, each session lasted 30 minutes.
45986093|NCT02891512|Other|Xinepa®|2 tablets of Xinepa daily (morning and evening) for 1 month.
45986094|NCT02891512|Other|Placebo Xinepa®|2 tablets of Xinepa placebo daily (morning and evening) for 1 month.
45986095|NCT00601042|Other|Swedish snus (smokeless tobacco)|Snus in sachets 1.0 g or 0.5 g, 2 flavors. Usage ad libitum.
45986096|NCT00601042|Other|Onico|Tobacco-free, nicotine-free placebo snus, 2 sachet sizes (1.0 g, 0.5 g), 2 flavors (same as in the experimental arm). Usage ad libitum.
45986097|NCT00501696|Drug|4.5 mg Naltrexone|low dose naltrexone 4,5mg on the multiple sclerosis quality of life inventory (MSQLI54)
45986098|NCT00501696|Drug|Naltrexone|4,5mg low dose naltrexone on the multiple sclerosis quality of life inventory (MSQLI54)
45986099|NCT00601120|Procedure|Radiofrequency Ablation|Needles are inserted into the tumor(s) under guidance by a CT scan or ultrasound. The electrodes in the needles will be heated up to 202 degrees Fahrenheit and will remain heated for up to 12 minutes.
45986100|NCT00475436|Drug|GSK573719|
45673342|NCT02153918|Biological|PROSTVAC-F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
45673343|NCT04753346|Other|Physical Activity Level|International Physical Activity Questionnaire
45673344|NCT04753346|Other|Anxiety and Depression Assessment|Hospital Anxiety and Depression Scale
45986101|NCT04326322|Dietary Supplement|Methionine Intake|Intakes will be randomly chosen from a list of 7 doses of methionine. Each intake will will be repeated approximately 5 times.
45986102|NCT04326088|Other|Reconstruction group|Patients with primary tumor which underwent free flap reconstruction group.
45986103|NCT04326088|Other|Recurrent group|Patients with recurrent tumor which underwent free flap reconstruction group.
45986104|NCT00601198|Drug|Amifostine|Patients should be treated with oxaliplatin-based chemotherapy in combination with amifostine for 12 cycles, or until unacceptable toxicity is observed or disease progression
45986105|NCT00601237|Behavioral|HIV-related text messaging|Participants will receive up to 90 text messages related to abstinence, monogamy, and condom use over 3 months.
45986106|NCT00601237|Behavioral|Nutrition-related text messaging|Participants will receive up to 30 text messages about nutrition and healthy eating over 3 months.
45986107|NCT00475475|Behavioral|Fructose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
45986108|NCT00475475|Behavioral|glucose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
45986109|NCT00475475|Behavioral|non-caloric sweetener|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
45986110|NCT00601276|Drug|leuprorelin|Subcutaneous injection, 3.75 mg every 4 weeks
45986111|NCT00601276|Drug|Cyproterone acetate|2.0 mg/kg/day, tablet, per os
45986112|NCT00601315|Drug|Clarithromycin|
45986113|NCT02274714|Other|Questionnaire Only|Subjects will have an interview with a study coordinator to fill out questionnaires for the study
45986114|NCT00601393|Behavioral|Cognitive behavioral therapy (CBT)|CBT treatment is delivered via the Internet. Adaptations to the CBT program will include the addition of content of particular relevance to mothers of young children and the incorporation of instructional design principles to promote self-learning. The treatment program will take advantage of the unique properties of the Internet, including multimedia presentations and interactive components with professional and moderated peer social support.
45986115|NCT00601393|Other|Treatment as usual (TAU)|Participants receiving TAU will be offered the CBT treatment after a wait-list period. During the wait-list period, participants will be offered facilitated referrals to treatment provided in the community.
45986116|NCT00470249|Drug|Carboplatin|At a dose equivalent to an area under the concentration-time curve of 4.5 mg/ml.min on day 1 of every 2-week cycle
45986117|NCT00470249|Drug|Gemcitabine Hydrochloride|1500 mg/m2 on day 2 of every 2-week cycle
45986118|NCT04325893|Drug|Hydroxychloroquine|First dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
45986119|NCT04325893|Drug|Placebo|TFirst dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
45986120|NCT00601432|Drug|levofloxacin oral solution|
45986121|NCT00501813|Procedure|Hepatectomy|irregular Hepatectomy
45986122|NCT00501813|Procedure|TACE combined with local regional therapies without hepatectomy|TACE combined with RFA, MCT, PEI, and so on.
45986123|NCT00475514|Drug|Frovatriptan 2.5mg QD|
45986124|NCT00475514|Drug|Frovatriptan 2.5 mg BID|
45986125|NCT00475514|Drug|placebo|
45986126|NCT00601471|Other|proximal tibiofibular manipulation|proximal tibiofibular manipulation
45986127|NCT00601471|Other|distal tibiofibular manipulation|distal tibiofibular manipulation
45986128|NCT00601471|Other|no intervention|no intervention / control
45673345|NCT04753346|Diagnostic Test|Exercise Capacity|6 Minute Walk Test
45673346|NCT04753346|Diagnostic Test|Pulmonary Function Test|Spirometry
45673347|NCT04753346|Diagnostic Test|Cardiopulmonary Fitness Level|Cardiopulmonary Exercise Test
45832988|NCT03779646|Drug|Bisoprolol Fumarate|Bisoprolol was initiated at a dose of 1.25 mg every 24hr. At subsequent biweekly visits, the bisoprolol dose was increased 1.25mg progressively until a daily dose of 0.2mg/kg or the maximum tolerated dose (The rest heart rate <75bpm and systolic blood pressure <90mmHg) is achieved. If the participant feel dizziness or the rest heart rate below 60 bpm or systolic blood pressure below 85mmHg or there is any new onset contraindication to bisoprolol, the doctor will decide to return back to the previous dose or stop bisoprolol. Each time the dose is increased, the medication is administered in an outpatient clinic setting, with assessment of the participant's heart rate, blood pressure, symptoms and ECG. Once reach the target dose, the patients will be followed up every 8 weeks in an face-to-face or video visit. After 12 months , the participants will repeat cardiac MR besides heart rate, blood pressure, symptoms, ECG and brain natriuretic peptide(BNP), echocardiography records.
45986129|NCT00601510|Drug|capecitabine|
45673348|NCT03028090|Device|SHERLOCK 3CG™ Tip Confirmation System with MODUS Software|The SHERLOCK 3CG™ Tip Confirmation System (TCS) is a fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology. It was cleared by the FDA on March 19, 2012 and is indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients. In order to further develop the SHERLOCK 3CG™ platform and simplify the PICC placement for the clinician, Bard Access Systems, Inc. is developing MODUS, a software package.
45673349|NCT02176928|Device|AutoPAP|"PAP will be delivered by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.~AutoPAP treatment 7 nights a week for four months (16 weeks)."
45986130|NCT00601510|Drug|cisplatin|
45986131|NCT00601510|Drug|imatinib mesylate|
45986132|NCT00501930|Drug|GSK189075|
45986133|NCT00470288|Procedure|bladder flap during cesarean section|
45986134|NCT00601549|Procedure|Laparoscopic surgery|Laparoscopic surgery
45986135|NCT00601549|Procedure|Traditional open surgery|Open surgery
45986136|NCT00601588|Drug|Sertraline|
45986137|NCT00601666|Drug|Zolpidem|
45986138|NCT00601744|Behavioral|Audio-Taped Interview|"Meeting with a research staff member either in person or by phone, lasting 2 to 2 1/2 hours~Arm 1: Questions about emotional well-being, appearance, coping ability with the cancer, and the types of social relations and support available (such as relationships with friends and family)~Arm 2: Questions regarding if and how social relations may have been affected by his/her cancer experiences after the orbital exenteration."
45986139|NCT00601744|Behavioral|Questionnaire|5-10 minute questionnaire to be completed after the interview.
45986140|NCT01246362|Drug|Control|Given placebo
45986141|NCT01246362|Drug|Etoricoxib|Given etoricoxib 120mg 24 hours preoperatively and 120mg 2 hours preoperatively
45986142|NCT04325854|Procedure|I and II level ART procedure|I level: Intrauterine insemination II level: Invitro fertilization technique; Intracytoplasmic sperm injection; Embryo transfer
45986143|NCT00470405|Drug|oxaliplatin|75-100 mg/m2 iv infusion Approximately 2 hours beginning approximately 30 minutes after the end of ALIMTA infusion on Day 1 of a 14-days cycle
45986144|NCT00470405|Drug|pemetrexed disodium|a novel antifolate with multiple targets.
45456728|NCT04495166|Behavioral|Educational app|A simplified version of the Motherly 1.0 app consisting of psychoeducational content about various aspects of pregnancy, maternal physical and mental health, and child development. Active intervention functionalities, such as behavioral activation, activity scheduling, sleep hygiene, among others, are NOT present in this simplified version of the app.
45832989|NCT03774732|Radiation|Radiotherapy|Irradiation technique (3D-CRT or SABR) will be at physician discretion.
45832990|NCT03774732|Drug|Pembrolizumab|pembrolizumab will be administered as per standard of care every 3 weeks until progression or toxicity
45832991|NCT03774732|Drug|Chemotherapy|for squamous NSCLC carboplatin AUC6, paclitaxel 200 mg/m² every 3 weeks for 4 cycles; for non-squamous NSCLC carboplatin AUC5 or cisplatin 75 mg/m² every 3 weeks for 4 cycles, and pemetrexed 500 mg/m² every 3 weeks until progression or toxicity
45832992|NCT03500016|Other|High intensity interval training|See under arm description.
45986145|NCT04207372|Dietary Supplement|whey protein isolate|whey protein isolate
45986146|NCT04207372|Dietary Supplement|Zein|zein protein
45986147|NCT04207372|Other|protein-free|protein free
45986148|NCT00601822|Behavioral|Cognitive remediation therapy (CRT)|CRT includes eight sessions over 6 months that aim to improve cognitive flexibility and strengthen thinking skills.
45986149|NCT00601822|Behavioral|Cognitive behavioral therapy (CBT)|CBT includes 20 to 28 weekly psychotherapy sessions over 6 months, depending on treatment group assignment. CBT sessions aim to change participants' beliefs and behaviors toward eating disorders and to teach ways to handle the daily struggles of an eating disorder.
45986150|NCT00502008|Drug|Coccinia Cordifolia (herbal extract)|
45986151|NCT00601861|Drug|recombinant interleukin-21|Fixed and equal dose for s.c. injection, 3 times weekly
45986152|NCT00470444|Procedure|Transfusion with Red Blood Cells|Units of donated Red blood cells
45986153|NCT00470444|Biological|1 unit of donated red blood cells|Units of red blood cells
45986154|NCT00470444|Biological|1 unit of donated red blood cells|Units of donated red blood cells
45986155|NCT00601978|Drug|carbidopa/levodopa|
45986156|NCT00601978|Drug|Carbidopa/Levodopa/Entacapone|
45986157|NCT00601159|Drug|gemcitabine and cisplatin|Cispaltin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 repeat every 3 weeks
45986158|NCT00502047|Drug|Plantago ovata husk|
45986159|NCT00602017|Drug|Amlodipine|
45986160|NCT00470483|Drug|Placebo treatment during 8 weeks|comparator
45986161|NCT00470483|Drug|Paroxetine treatment during 8 weeks|treatment drug
45986162|NCT00602056|Other|Redesigned immunization card|A low cost nad simplified redesigned immunization card
45986163|NCT00602056|Other|Center based education to mothers/caregivers|A 2-3 minute center based education to mothers/caregivers
45986164|NCT00602056|Other|Redesigned immunization card with center based education to mother/caregivers|Redesigned immunization card with center based education to mother/caregivers
45986165|NCT00602095|Drug|misoprostol|0.025mg tablet vaginally every 4 hour until progress
45986166|NCT00602095|Drug|dinoprostone|2mg vaginal gel every 6 hours until progress
45986167|NCT00602095|Device|Bard Catheter (balloon catheter)|Intracervical balloon catheter positioned above internal cervical os and filled with sterile water. Removed when cervix was dilated
45986168|NCT00502086|Dietary Supplement|Viusid (nutritional supplement)|Viusid three sachets daily during 96 weeks
45986169|NCT00502086|Other|Placebo|Placebo three sachets daily during 96 weeks
45986170|NCT00475553|Other|remove ring if bleeding or spotting occurs more than 5 days|Both groups of women will be using the nuvaring continuously, ie if the ring is placed on 3rd of January, on the 3rd of February the ring would be removed and a new one inserted. On the 3rd of March the same thing would happen and so forth. Group 2 if bleeding or spotting occurs for more than 5 days then on the 6th day the ring is removed and will keep it out for three more days and reinsert the same ring on the 4th day.
45986171|NCT00475553|Other|If bleeding does not remove ring|Subject is using the nuvaring continuously. For example she puts the ring in on 3rd of January then the 3rd of February is when that ring is removed and another one is inserted. The 3rd of March the same thing occurs.
45986172|NCT01326481|Drug|TRC105|IV
45986173|NCT01326481|Drug|Capecitabine|oral
45986174|NCT00502125|Procedure|Reflectance Confocal Imaging|A photograph will be taken of any abnormal areas inside the mouth. A small probe will expose the oral lining to a small amount of light. Some of this light will be reflected back into the probe, and be picked up by a computer. Pictures will be made of the tissue.
45986175|NCT03271346|Behavioral|intensive trauma-focused therapy|
45986176|NCT00502164|Drug|AZD2171|
45986177|NCT00475592|Device|Esophageal Capsule Endoscopy|
45986178|NCT00475592|Device|Upper Gastrointestinal Endoscopy|
45986179|NCT00502281|Drug|highly purified urinary FSH|
45986180|NCT00502281|Behavioral|timed intercourses, intrauterine insemination|
45986181|NCT00470522|Drug|Methotrexate and folic acid|
45986182|NCT00502359|Device|capillary blood glucose measurement|
45986183|NCT00475748|Procedure|Early and late surgery for traumatic central cord syndrome|Surgical decompression of the spinal cord, either front, back or combined
45986184|NCT01244178|Drug|Insulin|Intravenous Hyperinsulinemic therapy
45986185|NCT01244178|Drug|Insulin|Standard Intravenous Insulin Therapy
45986186|NCT00470561|Drug|Aspirin|Two 325 mg doses of aspirin per day for 6 months
45986187|NCT00470561|Drug|Placebo|Two placebo pills per day for 6 months
45986188|NCT00502398|Procedure|Blood test|
45986189|NCT00475826|Drug|Statins and Ezetimibe|
45986190|NCT00493506|Drug|ProAlgaZyme|
45986191|NCT00502437|Drug|GRANISETRON|
45986192|NCT00470678|Drug|ranibizumab|
45986193|NCT00502476|Procedure|Bathing with Chlorhexidine Impregnated Washcloths|
45986194|NCT00470756|Other|mechanical triggering of peroneal activity|mechanical triggering of peroneal activity
45986195|NCT00470795|Other|Acupuncture|acupuncture treatment (or placebo), 20 minute treatment each; twice weekly for four weeks (total of eight treatments). repeat treatment schedule following crossover (placebo-treatment)
45673350|NCT02176928|Device|Sham PAP|"Sham PAP treatment will be delivered by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events. The pressure is too low to eliminate respiratory events and serves as sham or sub-therapeutic PAP.~Sham PAP treatment 7 nights a week for four months (16 weeks)./"
45986196|NCT00470795|Procedure|placebo/sham acupuncture|acupuncture at sham points without skin penetration
45986197|NCT00493545|Biological|HspE7 and Poly-ICLC|3 injections of HspE7 and Poly ICLC given every 28 days for 3 injections
45673351|NCT04752566|Biological|Eculizumab|Eculizumab will be administered via IV infusion once a week for 4 weeks.
45673352|NCT04752566|Drug|Placebo|Placebo will be administered via IV infusion once a week for 4 weeks.
45673353|NCT01628510|Device|Dandle Roo/Dandle Wrap|Infant remains in the Dandle Roo/Dandle Wrap throughout the NICU stay when the infant is lying in the isolette or crib, but is taken out for hands on care times or when held.
45832993|NCT03499080|Behavioral|Medication free treatment|Inpatient unit dedicated to medication free treatment. This is an inpatient treatment unit for voluntary, planned treatment. The unit is staffed for a patient group that can be managed within a regime of open doors, voluntary treatment and low supervision. This means that high suicidal risk, severe acting out, active drug abuse etc. is excluded. They have an 8 week treatment program including Illness managment an recovery (IMR), Feedback informed treatment (FIT) and Affect consciousness treatment (ABT).
45832994|NCT03499080|Behavioral|Treatment as usual Myrvegen|Inpatient unit on a different location from the others. Same Level of care. Different treatment program. Intermediate treatment duration (mainly 4-6 weeks).
45986198|NCT00470873|Drug|Levitra (Vardenafil, BAY38-9456)|Primary care erectile dysfunction patients for whom physician decided to start the treatment with vardenafil
45986199|NCT00493584|Procedure|Primary Percutaneous Coronary Intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
45986200|NCT00493584|Procedure|Coronary angiography / Percutaneous coronary intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
45986201|NCT00493623|Drug|Placebo|Placebo i.v. single dose
45986202|NCT00493623|Drug|ibandronate [Bonviva/Boniva]|3mg i.v. single dose
45986203|NCT02955849|Device|SLT laser|Patients will be offered initial SLT laser by doctors
45986204|NCT00476099|Drug|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
45986205|NCT00476099|Drug|Budesonide 200 µg plus formoterol 6 µg DPI|two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.
45986206|NCT00476099|Drug|Formoterol 12 µg DPI|one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
45986207|NCT00493662|Drug|Polyethylene Glycol 400 0.4%|
45986208|NCT00493662|Drug|Propylene Glycol 0.3%|
45986209|NCT00493662|Drug|0.15% sodium Hyaluronate|
45986210|NCT00493662|Drug|sodium chloride|
45986211|NCT00493662|Drug|sodium phosphate monobasic|
45986212|NCT00470912|Drug|sunscreen RV 2547C|
45986213|NCT02274519|Other|Tai Chi|Arm 1
45986214|NCT02274519|Other|Education|Arm 2
45986215|NCT00476138|Drug|Epigallocatechin-gallate|
45986216|NCT02955888|Drug|PBI4050|Investigational Medicinal Product
46083433|NCT02717598|Procedure|hot snare polypectomy|HSP, which is using electrocoagulation on the basis of using cold snare.After HSP, another independent endoscopic surgeon judged whether the endoscopic eradication was successful. Afterward, additional EMR was performed at the polypectomy site to evaluate for the presence of residual polyp tissue,including an additional 1 to 2 mm clear margin, was resected by the snare and Endocut current after submucosal injection of a mixed solution.In the event that no tissue could be removed or if EMR failed to get in situ mucosal specimens. At least four cold biopsies using forceps on the remaining margins were obtained.After each procedure, the polypectomy site was observed for 30 seconds to confirm the absence of immediate bleeding, the specimens were retrieved and stored in formalin. Cross-sections of the EMR specimens were collected at 1-mm intervals; accurate tissue section of the marked site was ensured.
46083434|NCT00586521|Drug|Kogenate (BAY14-2222)|One group two treatment schedules, first on-demand then switch to prophylaxis
45986217|NCT02955888|Drug|Placebo|Comparator
45986218|NCT00470951|Procedure|open rectal resection|open rectal resection
45986219|NCT00470951|Procedure|laparoscopic rectal resection|laparoscopic assisted rectal resection
45986220|NCT02956083|Other|Systane Balance eye drops|Propylene Glycol 0.6% Over the counter lipid based artificial tears.
45986221|NCT02956083|Other|Systane Contacts eye drops|Hydroxypropyl methycellulose over the counter non-lipid based artificial tears
45986222|NCT02956083|Other|saline|Saline - no brand name
45986223|NCT00470990|Drug|GnRH antagonist (Acyline)|3 Subcutaneous injections (300 mcg/kg) over 36 days
45986224|NCT01246440|Drug|Catumaxomab|Catumaxomab: 4 intraperitoneal infusions of catumaxomab over 11 days administered in a period of 3 hours through an intraperitoneal catheter with the following dosage: 1) 10 µg on Day 0. 2) 20 µg on Day 3. 3) 50 µg on Day 7. 4) 200 µg on Day 10.
45986225|NCT03271112|Other|Exercise program|Measurement of physical performance before and after the 12 wks-exercice program
45986226|NCT00493740|Procedure|chocolate cake|
45986227|NCT00471029|Drug|esomeprazole|
45986228|NCT00476177|Biological|Infusion of donor dendritic cells|Given in the outpatient setting
45986229|NCT00476177|Biological|Infusion of donor lymphocytes|Given in outpatient setting
45986230|NCT00493818|Drug|GSK690693|
46083435|NCT02782286|Drug|Ketorolac|The patients randomised to this arm will receive 30 mg intravenous ketorolac.
45673354|NCT01628510|Other|Traditional NICU Positioning|These methods aim at providing containment and flexion and may consist of interventions such as swaddling, use of boundaries around the infant, rolled blankets, Snuggly®, or Bendy Bumper®
45673355|NCT01571362|Drug|ALO-02|20 to 160mg total daily dose of oxycodone, divided into symmetric doses and administered twice daily
46083436|NCT02782286|Drug|Morphine|The patients randomised to this arm will receive 0,1 mg/kg intravenous morphine.
45673356|NCT01571362|Drug|Placebo|oral placebo, divided into symmetric doses and administered twice daily
45673357|NCT01571284|Drug|AFLIBERCEPT AVE0005|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
45673358|NCT01571284|Drug|FOLFIRI|irinotecan, 5-FU and leucovorin
45673359|NCT04825756|Behavioral|Manualized equine assisted therapy|This equine assisted therapy (EAT), which is delivered in a group setting, combines therapeutic horseback riding with cognitive behavioral strategies for anxiety. Each 45 minute session is delivered in a group format with up to four children between 6 and 17 years of age. Each session follows the same structure: (1) weekly review; (2) groom and connect; (3) warm-up period; (4) session activity; (5) cool down; (6) parent/caregiver psychoeducation, during which the instructor facilitates psychoeducation; and (7) homework instruction.
45673360|NCT02137772|Drug|Letermovir|Letermovir 240 mg / 480 mg tablets, or 240 mg / 480 mg intravenous solution in 250 mL to be infused over 60 minutes.
45673361|NCT02137772|Drug|Placebo|Placebo tablets, or intravenous solution in 250 mL to be infused over 60 minutes.
45986231|NCT00476216|Drug|Combination of Arixtra with chemotherapy|"Single arm, 2 cohort feasibility study:~Carboplatin will be administered intravenously over approximately 30 minutes after paclitaxel infusion is completed and the dose will be calculated on basis of an area under the curve (AUC) of 6, according to the formula administered every 21 days. Paclitaxel will be administered 200 mg/m2 over 3 hours every 21 days.~Patients in both cohorts 1 & 2 will receive standard chemotherapy alone during cycle 1.~Cohort 1:During subsequent cycles (2-4) patients will receive a daily prophylactic dose (day 1 through 21) of Arixtra and continue 21 days after the last course of chemotherapy.~Cohort 2: Patients in cohort 2 will receive standard chemotherapy alone during cycle 1. During subsequent cycles, the patient will receive a therapeutic weight based dose of Arixtra for the first 2 days of each chemotherapy cycle followed by a daily prophylactic dose of Arixtra (day 3 through 21) until the next course of chemotherapy."
45986232|NCT00502632|Drug|Urokinase and Dornase alfa|"Intrapleural administration of:~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days"
45986233|NCT00502632|Drug|Urokinase|"Intrapleural administration of:~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~25ml normal saline, twice daily for 4 days"
45986234|NCT00471185|Drug|Acyline|10, 20 and 40 mg of Oral acyline, given on 3 occasions, separated by 1 week.
45986235|NCT01325701|Drug|ibrutinib|ibrutinib is an inhibitor of BTK
45986236|NCT00493857|Drug|Nimotuzumab Humanized Monoclonal Antibody|Nimotuzumab 400mg every week
45986237|NCT00493857|Drug|Nimotuzumab|Nimotuzumab 400mg every 2 weeks
45986238|NCT00476255|Behavioral|Enhanced Standard Care (ESC)|Reading material
45986239|NCT00476255|Behavioral|Brief Motivational Intervention (BMI)|Motivational interview with trained therapist
45986240|NCT00476294|Other|Telephone Questionnaire|Follow-Up Telephone Calls Every 6 Months for 5 Years.
46002291|NCT03991624|Diagnostic Test|cognitive assessment|"MMSE : Mini-Mental State Examination~5 words of Dubois~Direct Assessment of Functional Status~Trail Making Test~BREF : Fast Front End Efficiency Battery~short battery of praxies~Quality of Life in Alzheimer's Disease"
46083437|NCT04231448|Drug|R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)|R-CHOP : rituximab 375 mg/m2 IV, cyclophosphamide 750 mg/m2 IV, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 IV [maximum total 2 mg], and prednisone [or equivalent] 100 mg orally as the background therapy for 6 cycles (21 days/cycle).
45986241|NCT01325623|Device|Model 106 VNS Therapy System|The VNS Therapy System is an adjunctive therapy for the treatment of epilepsy. VNS Therapy is available as a scheduled stimulation, this is cyclic stimulation between programmable On- and Off- times (e.g., a 30-second burst every 5 minutes). VNS Therapy is also available as on-demand stimulation, that is, when a magnet is introduced briefly over the implanted device (Magnet Mode). The AspireSR VNS Therapy System includes a new feature, Automatic Magnet Mode or AutoStim. In addition to Normal Mode and Magnet Mode, AspireSR uses a Seizure Detection Algorithm to identify a potential seizure onset based on associated heart rate increases known as ictal tachycardia. The purpose is to deliver stimulation at or near the onset of a seizure.
45986242|NCT00494052|Behavioral|Heart to Heart (Web-Based Decision Aid)|Participants in the intervention group will access Heart to Heart, a Web site designed to educate them about their overall CHD risk, specific risk factors, and strategies and preferences for risk reduction.
45986243|NCT00494052|Behavioral|Physician Education Session|A physician education session will be included in the program.
45986244|NCT00476333|Device|APOS biomechanical gait system|
45986245|NCT01246518|Drug|MOB015|Arm 1; MOB015 once a day for 3 months. Arm 2; MOB015 once a day for 9 months.
45986246|NCT01325584|Drug|Omegaven|initial dose of 0.1 g/kg body weight (1ml/kg) and increased to 0.2 g/kg body weight (2ml/kg) on day 2 or 3 of treatment. The infusion rate will not exceed 0.5mL Omegaven/kg body weight/hr (corresponding to 0.05g fish oil/kg/hr). Patients will receive the initial infusion of PN containing Omegaven at Midwestern Regional Medical Center (MRMC) in the infusion center to observe for adverse reactions. Patients will continue to receive infusions at MRMC for the first 2 to 3 days of dosing. After tolerance is established, patients will receive treatment at home. All study patients will have a Screening Visit; Day 1, Day 2 and Day 3 visits; and weekly visits for one month.
45986247|NCT04207294|Other|Pork arm|The effect of 1 portion of vitamin D-enriched pork on 25(OH)D concentration in comparison to a vitamin D supplement and control pork.
45986248|NCT04207294|Other|Chicken arm|The effect of 1 portion of vitamin D-enriched chicken on 25(OH)D concentration in comparison to control chicken.
45986249|NCT00502749|Behavioral|Exercise program|Daily group or personal exercise programs designed to promote flexibility, endurance, and strength.
45986250|NCT00502749|Behavioral|Questionnaires|Questionnaires taking 15 minutes to complete.
45986251|NCT02891473|Other|Mézières Method|10 sessions of rehabilitative treatment according to the Mézières Method, 2 sessions per week for 5 weeks, each lasting 1 hour.
45986252|NCT02891473|Other|Home based exercise program|1 single training session lasting 1 hour for the explication of the rehabilitation program that the patient has to perform independently at home followed by 2 sessions of home based exercises per week for 5 weeks, each lasting 1 hour.
45986253|NCT04126915|Genetic|Whole Exome Sequencing|Whole Exome Sequencing of the patient's primary tumor, metastases
45986254|NCT00502788|Drug|Peginterferon Alfa-2a and Ribavirin|"Patients will be treated with alfa-2a and ribavirin as follows:~Peginterferon alfa-2a will be started as a dose of 180 ug subcutaneously once weekly."
46083438|NCT04231448|Drug|Tucidinostat|Tucidinostat ：30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle，for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of Tucidinostat on day 1, day 4, day 8, day 11 in a 21-day cycle.
46083439|NCT04231448|Drug|Placebo|Placebo：30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle，for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of placebo on day 1, day 4, day 8, day 11 in a 21-day cycle.
46083440|NCT04094493|Drug|vit D|preoperative intra muscular vit D injection
45673362|NCT04410250|Behavioral|oral hygiene|Mothers will be instructed on the oral hygiene of the newborn
45673363|NCT04418024|Drug|AG10|TTR stabilizer administered orally twice daily (BID)
45673364|NCT04418024|Drug|Placebo|Non-active control
45673365|NCT03027856|Device|Magmaris|Implantation of a sirolimus eluting bioresorbable magnesium stent
45673366|NCT01555138|Drug|Indacaterol|Indacaterol is delivered via a SDDPI.
45673367|NCT01555138|Drug|Salmeterol|Salmeterol/fluticasone is delivered via a MDDPI
45673368|NCT02137226|Drug|BI 695501|BI 695501, every two weeks for 48 weeks (25 injections in total)
45673369|NCT02137226|Drug|US-licensed Humira®|one injection every 2 weeks for 48 weeks (25 injections in total)
45673370|NCT01530334|Drug|Gefitinib 250mg|Gefitinib 250mg once daily
45673371|NCT01570192|Drug|IV meropenem|Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
45673372|NCT01570192|Drug|I.V. Meropenem|"Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage"
45673373|NCT01570192|Drug|Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h|a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
45673374|NCT01570192|Drug|Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.|Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.
46083441|NCT02694042|Behavioral|Mission is Remission®|A web-based teaching a support program for adolescents living with inflammatory bowel disease (IBD).
46083442|NCT02780960|Device|HPV self-testing|Patients will perform HPV testing themselves at home.
45673375|NCT01570192|Device|tobramycin nebulization|tobramycin nebulization 600mg/day
45673376|NCT02136914|Drug|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 25 weeks
45986255|NCT00502788|Drug|Ribavirin|Ribavirin will be started at a dose of 800mg daily for those weighing less than or equal to 50 kg, 1000 mg daily for those with body weight 51 to 75 kg and 1200 mg daily for those with body weight > 75 kg. Ribavirin will be given orally in two divided doses. The lower dose has been included because potentially-eligible patients in the TCRN registry have a mean weight of 57 kg.
45986256|NCT00602134|Drug|6-Mercaptopurine|
45986257|NCT00471224|Other|Observational Trial|No intervention is being used in this study.
45986258|NCT02891590|Drug|DTRMWXHS-12|
45986259|NCT00502827|Behavioral|Cell Phone Intervention|Study participants called on a cell phone 11 times over course of a 12 - 13 week period, during 10 minute calls questions asked about smoking and quitting smoking.
45986260|NCT00502827|Other|Recommended Standard of Care|Advice from your physician to stop smoking and written materials designed to help you quit smoking.
45986261|NCT00471263|Drug|Casigold|
45986262|NCT00471263|Drug|Casimax|
45986263|NCT00471263|Drug|Placebo|
45986264|NCT00494208|Drug|Testosterone|Testosterone ester
45986265|NCT00471341|Drug|Celecoxib|
45986266|NCT00471341|Drug|placebo|
45986267|NCT01325428|Drug|Afatinib once daily (OD)|Patient to receive afatinib monotherapy until progression of their disease
45986268|NCT01325428|Drug|Vinorelbine Weekly|Patients additionally receive vinorelbine weekly on disease progression on afatinib monotherapy
45986269|NCT00502983|Behavioral|Interview|Interview lasting approximately 50 minutes.
45986270|NCT00476411|Biological|HBV vaccine|HBV vaccine 3 doses at month 0, 1, and 6
45986271|NCT00494247|Device|coronary stent (Genous, OrbusNeich) with immobilised anti-CD34 antibody to capture circulating endothelial progenitor cells|coronary stent covered with anti-CD34 antobody, (Genous, R-stent, produced by OrbusNeich). 30 patients will undergo PCI with implantation of Genous stent and 30 patients will receive bare metal stent (BMS)
45986272|NCT00471419|Drug|Rimexolone|
45986273|NCT01325350|Drug|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
45986274|NCT01325350|Drug|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
46083443|NCT02600247|Drug|Duloxetine|"Experimental: Duloxetine group~Phase I (preemptive): 1day before operation (30mg for 1 day)~Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)~Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon~Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
45832995|NCT03499080|Behavioral|Treatment as usual Åråsen|Unit colocated with the medication free unit. Similar treatment program. Short treatment duration (average 3 weeks).
45832996|NCT05347134|Drug|SKB264|"SKB264 ：5 mg/m2, IV (in the vein) on day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Eribulin:1.4mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Capecitabine:1000-1250mg/m2, po,bid, from day 1 to Day 15 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Gemcitabine:800-1000 mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Vinorelbine:25 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."
45986275|NCT01325350|Drug|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
45986276|NCT01325350|Drug|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
45986277|NCT01325350|Drug|minoxidil 2% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
45986278|NCT01324999|Drug|Tadalafil|20mg/day for one month then 40mg/day for additional 4 months
45986279|NCT00503022|Drug|ACZ885|
45986280|NCT02891356|Device|DEXA|The Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
45986281|NCT03273335|Device|Millipore biomarker assay plate|Millipore biomarker assay plate CSF cytokine assays as well as CSF flow cytometry
45986282|NCT00494286|Behavioral|Abused-focused cognitive behavioral therapy (AF-CBT)|Practitioners will be randomly assigned to provide the AF-CBT treatment for 3 to 6 months. Patient participants will continue to see their regular practitioner, but will receive AF-CBT at treatment visits. Practitioners who are assigned to AF-CBT will first receive training in the treatment method. The training curriculum will include a published treatment book, intensive training sessions, which will occur weekly for 8 hours over 4 weeks, handouts that illustrate key therapeutic information and exercises, and ongoing case consultation reviews for 5 months.
45986283|NCT00494286|Behavioral|Treatment as usual (TAU)|This condition consists of those practitioners in each agency who will not receive study training in AF-CBT. These practitioners will simply provide services as available within their agencies.
45986284|NCT03271385|Diagnostic Test|evaluated by the predetermined differentiating formula|After recruiting patients, collecting the baseline data, a CMR scan will be carried out and post-processed, a predetermined differentiating formula (including left ventricular morphology, ejection fraction, presence of late gadolinium enhancement, T1 value and strain data) will be used to produce a cardiac values, which is to be input into our differentiating flow.
45986285|NCT01324570|Drug|Buprenorphine transdermal system|Buprenorphine transdermal system 2.5 mcg/h, 5 mcg/h, 10 mcg/h or 20 mcg/h applied transdermally for 7-day wear.
45986286|NCT05645653|Behavioral|Motivational tteaching|A comprehensive assessment of adherence problems will be firstly conducted to identify the factors that affect adherence, including how and why these factors contribute to poor adherence. Medication-related knowledge and skills will be provided based on individual treatments and barriers to adherence. Motivational interviewing techniques will be used for a better understanding of patients' cognitive factors of adherence behavior.
45986287|NCT05645458|Other|mobile application ( PEG Assist )|The mobile application is used for PEG care. İt gives some information to caregivers related to PEG, PEG care, etc. Also, the researcher can monitor all feeding times with this application.
45986288|NCT03271229|Biological|Concentrated Bone Marrow Aspirate (BMAC)|Participants will have a knee injected with BMAC stem cells harvested from the iliac crest
45986289|NCT03271229|Biological|Platelet-Rich Plasma (PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the antecubital vein.
45986290|NCT04325698|Drug|PF-06439535 (CN)|15 mg/kg, IV on day 1 of each 21 day cycle for up to 2 years, or until progression or unacceptable toxicity develops.
45986291|NCT04325698|Drug|Bevacizumab-EU|15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 weeks. At Week 25, the participants with clinical benefit will received PF-06439535 (CN) monotherapy for up to 2 years from randomization in this study
45986292|NCT04325698|Drug|Paclitaxel|175 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
45986293|NCT04325698|Drug|Carboplatin|AUC 5 (max=750mg) via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
45986294|NCT00503100|Device|Thermal stimulation|Cerebral SEP response (P300, Medoc Ltd., Israel) to thermal stimulation (550C). Warm-sensation threshold (WST), heat-pain threshold (HPT), Cold sensation threshold (CST) and cold pain threshold (CPT) by using Thermal sensory analyzer (TSA-2001,Medoc Ltd., Israel). Pain threshold to tactile stimulation will be measured by using Von-Frey hairs.
45986295|NCT01324141|Drug|Tempol|Tempol gel will be applied to the bilateral groins and the gluteal cleft, avoiding a 3 cm radius from the anal verge, immediately prior to each fraction of radiation therapy (RT).
46083444|NCT02600247|Drug|celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone|"Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
46083445|NCT04229108|Device|Medopad|Timed up and go module of Medopad application. About page explains how to perform test and conditions, subsequent page contains timer, once completed test, commence on final page which has a number of short questions to complete
46083446|NCT05453253|Biological|Delayed second dose of oral cholera vaccine, Euvichol-Plus|The intervention arms (6 and 12 months) will modify the recommended interval for administration of the second vaccine dose, which will be extended to 6 and 12 months according to the intervention arm.
45456729|NCT02291224|Behavioral|Interactive multimedia platform|An interactive platform that includes video vignettes of young women who are choosing dual protection strategies (based on a synthesis of focus group data from members of the TSC patient population), as well as true/false questions to build knowledge about dual protection and dispel common myths about contraceptive strategies. There will also be reflection questions that encourage participants to consider values and priorities in their own lives that may influence their dual protection strategy selection.
45456730|NCT02291224|Behavioral|Intervention arm counseling|Counseling for the intervention group will follow carefully developed guides and incorporate the participants' answers to the reflection questions in the interactive multi-media component. This counseling has a set structure (set forth in separate counseling guides for health care providers and nurse educators), incorporates motivational interviewing techniques, includes multiple opportunities for role play, and is designed to be patient-centered.
45986296|NCT01324141|Drug|5-Fluorouracil|5-FU will be delivered as 1000mg/m(2)/day as 96 hour continuous infusion beginning on day 1 and 29.
45673377|NCT02136914|Other|Placebo|Oral capsules to be administered once nightly at bedtime, for 25 weeks
45673378|NCT01530256|Biological|ALD518|160 mg IV q 4 weeks for 4 doses
45832997|NCT05346744|Other|Chairside CAD/CAM ceramic materials for dental restoration|"6 crowns made from 6 chairside ceramic materials were milled by CEREC MCXL-EF mode for mandibular first molar of each participant.~The six materials are as follows:~ZIR: InCoris TZI (Dentsply Sirona, York, PA)， CD: Celtra Duo (Dentsply Sirona, York, PA), EMA: e.max CAD (ivoclar, Vivadent AG), LC: LiCi (UPCERA, China), ENA: Vita Enamic (Vita Zahnfabrik, Bad Sackingen, Germany) RC: RunCi (UPCERA, China)"
45832998|NCT00089778|Drug|117-126:Fibroblast growth factor 5 (FGF-5)|Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
45832999|NCT00089778|Drug|Fibroblast growth factor 5 (FGF-5):172-176/217-220|Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
45986297|NCT01324141|Drug|Mitomycin-C|Mitomycin-C (MMC) will be delivered at a dose of 10mg/m(2) on days 1 and 29
45986298|NCT01324141|Procedure|Radiation Therapy|Radiation therapy (RT) will be delivered to a total dose of 50-54 Gray (Gy) based on tumor characteristics.
46083447|NCT05453253|Biological|Oral cholera vaccine, Euvichol-Plus, according to manufacturer notice|"Euvichol-Plus, a WHO prequalified oral cholera vaccine, contains modified killed whole cell vaccine of formalin killed Vibrio cholerae strains of O1 Inaba, O1 Ogawa and O139.~In the control arm, participants will receive the Euvichol-Plus following the manufacturer recommendations: two doses administered orally 14 days apart for individuals aged ≥1 year."
45673379|NCT01530256|Biological|ALD518|320 mg IV q 4 weeks for 4 doses
45673380|NCT01530256|Biological|ALD518|640 mg IV q 4 weeks for 2 doses
45673381|NCT01554904|Device|Facial-Flex|Oral exercise device
45673382|NCT01529632|Drug|QVA149|QVA149 110/50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
45673383|NCT01529632|Drug|NVA237|NVA237 50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
45673384|NCT01529632|Drug|QAB149|QAB149 150 ug supplied as capsules in blister packs for inhalation via SDDPI , once daily
45673385|NCT01529632|Drug|Placebo|Placebo capsules provided in blister packs for inhalation via SDDPI, once daily
45673386|NCT01554514|Biological|rituximab|rituximab intravenously 100 mg every week for four doses
45986299|NCT00471575|Procedure|ultra sound examination|
45986300|NCT00503217|Drug|Tryptorelin|
45986301|NCT01324102|Behavioral|Yoga therapy|For the second aim of the study, individuals will complete an 8 week yoga intervention in a non-randomized trial to establish safe procedures for yoga for an older post colorectal cancer veteran population.
45986302|NCT00503256|Behavioral|Questionnaire|Questionnaires each taking 60 minutes to complete.
45986303|NCT01324024|Drug|Lisdexamfetamine|In a counterbalanced fashion, participants would receive titrated doses of LDX 20 to 60 mg/d for 4 weeks followed by a 2-week washout and then crossed over to the placebo tablets for another 4 weeks. All women will start with LDX 20 mg/d and then be titrated to 40 mg/d after 1 week and 60 mg/d after 2 weeks (as tolerated).
45986304|NCT01324024|Drug|Placebo|In a counterbalanced fashion, participants would receive placebo tablets for 4 weeks followed by a 2 week washout, then will receive titrated doses of LDX 20 to 60 mg/d for 4 weeks.
45986305|NCT00476528|Behavioral|Reality Orientation|Two matched groups of patients diagnosed with TBI are selected from two university hospitals. In addition to conventional treatment, patients in one group are introduced to a reality- orientation programme consisting of systematic orientation, information, and systematic cooperation with the patient´s relatives.Patients in the other group receive conventional treatment only. All patients are tested on a daily basis in accordance with the RLAS and the GOAT test.
45986306|NCT00476528|Behavioral|Reality Orientation|A quasiexperimental study
45986307|NCT00494520|Procedure|Errorful training condition|"Errorful training condition: Participant saw a picture and named it without any cues. If an error was produced, the cue with the least amount of information was provided (e.g. for pumpkin, pu). Cues with increasing information were provided until the picture was correctly named (e.g. for pumpkin: pump, pumpki, then pumpkin). Once the correct name was provided, the trial ended."
45986308|NCT00494520|Procedure|Errorless training condition|"Errorless learning (EL) condition: Participant saw a picture with its name, and repeated the word. The participant continued to name the picture as the auditory cues provided less and less of the word (e.g. for banana she would hear banan, bana then ba and finally no cue). If an error was produced at any stage, the whole word was presented, the participant repeated it, and the trial ended."
45986309|NCT00476567|Other|standard|standard antenatal care
46083448|NCT04229498|Drug|Monotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)|In carbapenem heteroresistant Klebsiella pneumoniae group, carbapenem monotherapy (ertapenem, imipenem, meropenem) vs other treatment groups will also be compared
45673387|NCT01553188|Drug|AMG 386|AMG 386 dose will be calculated using the subjects actual body weight (Kg). Supplied in 240 mg v will be administered as an intravenous (IV) infusion using an intravenous infusion pump given over a 60-minute period.
45986310|NCT00476567|Behavioral|specific training program|a specific training program 12 weeks between pregnancy week 20 and 36. regular exercise 45-60 minutes minimum three times per week.
45986311|NCT00502554|Procedure|photopheresis|2-day cycles of photopheresis every 3 weeks for 3 months
45986312|NCT00503295|Biological|REOLYSIN®|REOLYSIN® is given intravenously at a dose of 3x10E10 TCID50 over 60 minutes on Days 1-5 of a 28 day cycle.
46083449|NCT04005066|Drug|Elunate®|The recommended dose is 5 mg once daily (1 capsule, each capsule contains 5 mg of fruquintinib); three weeks of continuous drug administration followed by one week of drug free period (4 weeks as one treatment cycle).
46083450|NCT05448651|Drug|UPB-101|Subcutaneous injection
46083451|NCT05448651|Drug|Placebo|Subcutaneous injection
46083452|NCT04229342|Procedure|Per-oral endoscopic myotomy|"Per-oral endoscopic myotomy (POEM) is an endoscopic modality for the management of achalasia cardia. In this study, we will evaluate the impact of two different techniques of posterior POEM on the incidence of gastroesophageal reflux disease (GERD).~Posterior POEM will be performed using the standard technique. The myotomy beyond the GEJ will be different in the two groups. In one group, the sling fibers will not be spared from dissection and in the second group, the sling fibers will be selectively spared from myotomy."
46083453|NCT02717052|Drug|(S)-ketamine (Main study)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)"
45673388|NCT01553188|Drug|Abiraterone|A 1,000 mg dose of abiraterone should be taken orally once daily
45673389|NCT01553188|Drug|Prednisone|Prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day a patients preference.
45673390|NCT02175758|Drug|SOF|SOF administered orally once daily
45986313|NCT00471614|Drug|NucleomaxX (contains uridine)|Escalated doses of NucleomaxX tid
45986314|NCT01244217|Drug|fexofenadine/Allegra (M016455)|"Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral"
45986315|NCT00471653|Drug|temozolomide|
45986316|NCT00471653|Genetic|comparative genomic hybridization|
45986317|NCT00471653|Genetic|polymorphism analysis|
45986318|NCT00471653|Other|laboratory biomarker analysis|
45986319|NCT00471653|Other|pharmacological study|
45986320|NCT00471653|Radiation|radiation therapy|
45986321|NCT00471692|Drug|Ropivicaine|
46083454|NCT02717052|Drug|(S)-ketamine (Pilot II)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.10mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight i.v. applied over the course of 130 minutes."
45673391|NCT02175758|Drug|RBV|RBV oral solution or capsules will be administered orally in a divided daily dose based on weight
45986322|NCT01244295|Behavioral|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided weekly.
45986323|NCT01244295|Behavioral|Interpersonal Therapy|Standard form of interpersonal psychotherapy delivered for 16 sessions weekly.
45986324|NCT00476684|Procedure|radiofrequency treatment|Radiofrequency-neurotomy of the medial branch at 80 degr. C needle temperature for 70 seconds, after diagnostic blocks
45986325|NCT00476684|Procedure|sham neurotomy|Radiofrequency-neurotomy of the medial branch at 37 degr. C needle temperature for 70 seconds, after diagnostic blocks
45986326|NCT00494559|Drug|Pioglitazone|Actos 15mg once a day before breakfast
45986327|NCT00494559|Drug|Placebo|Placebo drug with the same appearance as actos
45986328|NCT00503334|Dietary Supplement|preOP booster (oral nutritional supplement, food for special medical purposes)|3x1 dosage pre-operatively
46083455|NCT02717052|Drug|(R,S)-ketamine (Pilot II)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.20mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied i.v. over the course of 130 minutes."
46083456|NCT02717052|Drug|Placebo|0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)
45456731|NCT02291224|Behavioral|Standard of care counseling|Standard of care counseling is provided by health care providers and health educators at TSC. It incorporates extensive counseling on methods to prevent both unintended pregnancy and sexually transmitted infections, however the structure of the counseling and techniques used are dependent on the standard practice of each provider or educator. This counseling does not incorporate answers to reflection questions from the multi-media platform because control arm participants will not view this content.
45456732|NCT03775681|Procedure|Endoscopic Retrograde Cholangiopancreatography|Undergo standard of care ERCP
45456733|NCT03775681|Other|Interview|Ancillary studies
45456734|NCT03775681|Device|Laryngeal Mask Airway|Wear LMA
45456735|NCT01353482|Drug|Cisplatin|Cisplatin (75mg/m2 iv) wil be administered on day one of a 21 day cycle for up to 6 cycles
45456736|NCT01353482|Drug|Pemetrexed|Patients will be given Pemetrexed (500mg/m2 iv) on day one of a 21 day cycle for up to 6 cycles
45456737|NCT01353482|Drug|Vorinostat|The dose and frequency of vorinostat will be determined in the Phase I study. Vorinostat will be given concurrently with Cisplatin/Pemetrexed.
45673392|NCT01529008|Drug|Core decompression/PREOB® implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
45673393|NCT01529008|Drug|Core decompression/placebo implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of placebo into the necrotic lesion (single administration).
45673394|NCT01599104|Drug|LCZ696|200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily
45673395|NCT01599104|Drug|Olmesartan|Olmesartan 20 mg capsule one daily
45673396|NCT01599104|Drug|Placebo|Placebo to LCZ696 or Olmesartan
45673397|NCT01569568|Other|MRI scanning|1H MRS, DTI, FMRI
45673398|NCT01569568|Behavioral|Cognitive testing|Behavioral testing
45833000|NCT00089778|Other|IL-2|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours beginning on the day after immunization and continuing for up to 4 days (a maximum of 12 doses).
45833001|NCT00089544|Drug|Dacarbazine|Given IV
45833002|NCT00089544|Drug|Doxorubicin Hydrochloride|Given IV
45673399|NCT05255432|Other|nil intervention|Users observation using medical device on manakin, different scenarios per group
45833003|NCT00089544|Biological|Filgrastim|Given subcutaneously
45833004|NCT00089544|Drug|Ifosfamide|Given IV
45833005|NCT00089544|Other|Laboratory Biomarker Analysis|Correlative studies
45833006|NCT00089544|Radiation|Radiation Therapy|Undergo radiotherapy
45833007|NCT00089544|Drug|Thalidomide|Given orally
45833008|NCT00089544|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
45986329|NCT00494598|Drug|Sufentanil|200 mcg intra-arterial one time bolus
45986330|NCT00503412|Drug|AZD2171|oral 14C
45986331|NCT00503451|Drug|LBH589|
46083457|NCT02717052|Other|PILOT Study II: PET1|[11C]DASB PET
46083458|NCT02717052|Other|PILOT Study II: PET2|[11C]DASB PET
46083459|NCT02717052|Other|Main Study: PET1|[11C]DASB PET
46083460|NCT02717052|Other|Main Study: PET2|[11C]DASB PET
46083461|NCT02717052|Other|PILOT Study I: PET1|[11C]DASB PET
45986332|NCT00471809|Drug|Budesonide + Salmeterol + Azithromycin|
45986333|NCT00471809|Drug|Budesonide + Salmeterol + Montelukast|
46083462|NCT02717052|Other|PILOT Study I: PET2|[11C]DASB PET
46083463|NCT02717052|Drug|(R,S)-ketamine (Pilot I)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.50mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)"
45986334|NCT00471809|Drug|Budesonide + Salmeterol + Placebo|
45986335|NCT00503490|Drug|MP-376 (Levofloxacin solution for Inhalation)|40, 80, 120mg RDD
45986336|NCT00503490|Drug|placebo|BID
45986337|NCT00476801|Device|German manufactured UVA1 light emitting device|The UVA1 dose will be up to 130 J/cm2.
45986338|NCT04696965|Other|Correct/recheck strategy|One month after recruitment and every 3 months. 1. Check the inhaler step errors of patients by research assistant; 2.Demonstrate the right way by research assistant; 3. give the inhaler check list with marks of the wrong step(s) patients made to patients and 4. confirm the patients do the right way of the previous wrong step(s).
45986339|NCT04696965|Other|Usual verbal instruction|One month after recruitment and every 3 months.1. Check the inhaler step errors of patients by research assistant; 2. Verbal instruction with a physical demonstration will be given by educational nurse in usual care.
45986340|NCT00494637|Drug|sodium bicarbonate|isotonic sodium bicarbonate at 3 cc/kg for one hour followed by 2 cc kg/hr for 4 hours
45986341|NCT00471965|Drug|Oxaliplatin + 5-Fluorouracil/Leucovorin|"Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
45986342|NCT00471965|Drug|Doxorubicin|Day 1: Doxorubicin 50mg/m² iv infusion. Repeated every 3 weeks.
45986343|NCT00472004|Drug|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle)|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined, 1 Daily, 1 year duration
45986344|NCT00472004|Drug|Tibolone (Livial)|Tibolone 2.5 mg 1 daily, 1 year duration
45986345|NCT00494715|Drug|Benazepril|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
45986346|NCT00494715|Drug|Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
45986347|NCT00494715|Drug|Benazepril/Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
45986348|NCT00472043|Procedure|PDT with Metvix 160 mg/g cream and Placebo cream|
46083464|NCT02717052|Drug|(R,S)-ketamine (Pilot III)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.80mg/kg bodyweight i.v. over 50"
46083465|NCT02717052|Other|PILOT Study III: PET1|[11C]DASB PET
45673400|NCT02136680|Other|CASA Education|Basic palliative care competencies for outpatient use.
45986349|NCT00503529|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Vaccination by intramuscular injection into the right or left upper arm (musculus deltoideus)
45986350|NCT02273999|Device|RecoveryRx™|Appliance of the device after surgery
45986351|NCT01323946|Biological|GSK Biologicals' investigational vaccine GSK1562902A|Three intramuscular injections
45986352|NCT03271073|Drug|Apatinib|Apatinib,500mg,qd,po,d1-21;S1,40mg,bid,d1-14;every 21days a cycle
46083466|NCT02717052|Other|PILOT Study III: PET2|[11C]DASB PET
45833009|NCT00089076|Biological|ipilimumab|Given IV
45833010|NCT00089076|Other|laboratory biomarker analysis|Correlative studies
45833011|NCT03774654|Genetic|CD19.CAR-aNKT cells|"Patients will be given the T-cell product by intravenous injection (into the vein through an IV line) at the assigned dose.~Dose Level 1: 1 x 10^7/m2. Dose Level 2: 3 x 10^7/m2. Dose Level 3: 1 x 10^8/m2."
45833012|NCT03773562|Drug|Erenumab|Erenumab will be used per label instructions.
45833013|NCT00088374|Drug|17 allylamino-17-demethoxygeldanamycin|17 allylamino-17-demethoxygeldanamycin (17 AAG) given intravenously at a dose of 300 mg/m2 on days 1,8 and 15 of 28 day cycles.
45986353|NCT01246557|Drug|Lenalidomide|"Lenalidomide - Revlimid®: an analogue of thalidomide, is an immunomodulator agent with anti-angiogenic properties. The chemical name is 3-(4 ́-aminoisoindoline-1 ́ona)-1- piperidine-2,6-dione.~REVLIMID® (lenalidomide) is available in capsules of 5 mg, 10 mg and 15 mg p.o.. Each capsule contains lenalidomide as active ingredient and the following non active ingredients: anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate."
45986354|NCT01246557|Drug|Dexamethasone|Dexamethasone will be administered as 20 mg/day (on days 1 to 4) for oral administration.
45986355|NCT00476879|Drug|Somatropin and pegvisomant|Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml
45986356|NCT01246596|Procedure|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus,[1] thus helping to establish a periodontium that is free of disease.[2]
45986357|NCT01246596|Procedure|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
45986358|NCT01246596|Procedure|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
45986359|NCT00472121|Device|TOF-Watch SX (neuromuscular monitor)|The variation between arms (dominant or non-dominant) when monitored with the same method on both arms
45986360|NCT00494793|Procedure|VAWC and mesh mediated fascial traction|"The first period of 2-5 days only the abdominal VAWC dressing is applied. On day 3-10 a polypropylene mesh is sutured to the fascial edges, between the two layers of the VAWC system, and tightened.~The VAWC dressing is changed and the mesh tightened every 2-3 days, resulting in gradual approximation of the fascial edges.~Finally the mesh is removed and the fascia is closed"
45986361|NCT00476918|Drug|Intravitreal injection (triamcinolone acetonide)|
45986362|NCT01246635|Device|Trufit CB (Cartilage Bone) Implant|Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.
45986363|NCT01246635|Procedure|Microfracture if the knee|Creation of small holes through subchondral bone with the goal of stimulating cartilage growth
45986364|NCT00472160|Procedure|Non Invasive Ventilation|Non Invasive Ventilation
45986365|NCT00472238|Behavioral|endurance training|control group.
45986366|NCT00472238|Behavioral|exercise training|Treadmill exercise training to optimize physical endurance
45986367|NCT01323790|Drug|NKTR-118|12.5 mg oral tablet once daily
45986368|NCT01323790|Drug|NKTR-118|25 mg oral tablet once daily
45986369|NCT01323790|Drug|Placebo|Placebo to NKTR-118
45986370|NCT00477035|Drug|CIK cells|2x10e8 cells/kg
45456738|NCT01353482|Drug|Placebo|Patients randomised into the placebo arm of the trial will receive Cisplatin and Pemetrexed as standard as well as placebo.
45986371|NCT00477035|Drug|etoposide|60 mg/kg
45986372|NCT00477035|Drug|bcnu|15 mg/kg
45986373|NCT00477035|Drug|cyclophosphamide|100 mg/kg
45986374|NCT00477035|Drug|gemcitabine|1250 mg/m2
45986375|NCT00477035|Drug|vinorelbine|30 mg/m2
45986376|NCT00477035|Drug|melphalan|200 mg/m2
45456739|NCT03774823|Device|RF and PEMF|RF and PEMF treatment is deployed using either a small or large handpick applied to the skin and moved slow random patterns homogeneously over the area of treatment
45986377|NCT00494832|Drug|Dexmedetomidine|"10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour"
45986378|NCT00494832|Drug|Normal Saline|"10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour"
45986379|NCT00477074|Procedure|bronchoalveolar lavage, blood analysis|
45986380|NCT01323673|Drug|clobetasol propionate 0.05%|2 times a day, 14 total days study treatment
45986381|NCT01323673|Drug|Vehicle / Placebo|2 times a day, 14 total days of study treatment
45986382|NCT00494949|Drug|Hemospan (MP4OX)|200, 400, 600, 750, or 1000 mL of Hemospan (MP4OX)
45986383|NCT00494949|Drug|Ringer's lactate|200, 400, 600, 750, or 1000 mL of Ringer's lactate solution
45986384|NCT00472316|Behavioral|Active Case Finding for Tuberculosis|Active case finding of TB in the community using community health workers
45986385|NCT01246752|Biological|Human Stem Cell Transplantation|Human allogenic stem cells
45986386|NCT01246752|Drug|Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)|Consolidation chemotherapy, recommended regimen: HiDAC = 3 x 2g/sqm BID on days 1,3,5
45986387|NCT01323634|Drug|Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg|inhalation powder
45986388|NCT01323634|Drug|Fluticasone Propionate 250mcg/ salmeterol 50mcg|inhalation powder
45986389|NCT05645302|Drug|Lidocaine Cataplasms|The main ingredient of this product is lidocaine, the cream surface is white or almost white, the cream is evenly spread on the back, and the cream surface is covered with film.
45986390|NCT00494988|Drug|insulin aspart|
45986391|NCT00494988|Drug|insulin NPH|
45986392|NCT01323478|Drug|Vortioxetine (Lu AA21004)|15 or 20 mg/day; tablets; orally
45986393|NCT00472355|Drug|apomorphine|
45986394|NCT04325581|Drug|Liraglutide 6 MG/ML|Liraglutide in incremental dose upto maximum of 1.8 mg per day SC daily
45986395|NCT04325581|Drug|Placebos|Normal Saline SC daily
45456740|NCT03774823|Device|Ultrasound|Ultrasound is applied to the subject by placing a probe on the treatment area and moving it rapidly and homogeneously over the treatment area
45456741|NCT01346462|Behavioral|Patient-Centered Transition Intervention|Community Health Workers will act as PaCT Partners for uninsured/Medicaid patients who are being discharged from the Hospital of the University of Pennsylvania and Presbyterian Hospital. PaCT Partners will help patients to overcome the challenges of transition, including arranging primary care provider (PCP) follow-up, filling medication prescriptions and obtaining referrals to community-based social services.
45986396|NCT02956161|Device|Stimulation of up-phase of sleep slow oscillation|
45986397|NCT02956161|Device|Random stimulation of up phase of sleep slow oscillation|
45986398|NCT02956161|Device|No stimulation|
45986399|NCT05645263|Other|dieting Coca-cola|The patients all dieted Coco-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coco-cola period of group A is 3 days, group B is 5 days and group C is 7 days.
45986400|NCT00623272|Other|compare measurements of left ventricular volumes and LVEF (by Cardiac Magnetic Resonance and Echocardiography)|To compare measurements of left ventricular volumes and LVEF obtained by 2DE, 3DE, and CMR after a ST elevation myocardial infarction (STEMI) complicated by systolic left ventricular dysfunction.
45456742|NCT01348178|Procedure|Follow-up|Follow-up
45986401|NCT04325776|Drug|AL2846|AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met.
45986402|NCT04325776|Drug|Zoledronic Acid Injection|Zoledronic acid is a bisphosphonate drug that has a strong inhibition of bone resorption and a potential to promote bone formation, and can be used for bone metastasis caused by malignant tumors.
45986403|NCT03276845|Diagnostic Test|Ultrasound of the breast|Multiparametric ultrasound of the breast including elastography, color/power Doppler, contrast agent application and 3D sonography.
45986404|NCT01322386|Drug|Vancomycin|Oral 50mg/Kg per day up to maximum of 1500 mg a day for three months.
45986405|NCT00495027|Behavioral|Internet-delivered Stress Innoculation Training|
45986406|NCT03275909|Behavioral|Integrated Psychological Therapy|The psychological treatment includes 50 sessions of integrated psychological therapy focused on attentional skills, social perception skills, verbal communication skills, social skills and interpersonal problems solving skills and 10 sessions of specific emotional management therapy , designed for this research. and based on the contents developed by Hodel, Kern and Brenner
45986407|NCT00495066|Drug|Ipilimumab|Intravenous Solution, Intravenous, Ipilimumab 3 mg/kg, Ipilimumab - one dose every 3 wks for a total of 4 doses. Subjects who are eligible may receive another 4 doses given every 3 wks; Until disease progression, unacceptable toxicity or withdrawal of consent
45986408|NCT00477308|Procedure|salvage therapy|
45456743|NCT01129843|Drug|Directly observed home based daily iron therapy|Directly Observed Home based Daily Iron( ferrous sulphate) therapy (DOHBIT) will be provided to the anemic women by the local village volunteers. Dose of elemental iron therapy will be 100 mg once daily for mild to moderate anemia and twice daily for severe anemia for a cumulative duration of 90 days
45986409|NCT01246908|Drug|Placebo|Placebo administered twice per day for six weeks.
45986410|NCT01246908|Drug|CX157 (TriRima)|One tablet administered twice per day (total daily dose of 250 mg) for six weeks.
45986411|NCT00472433|Drug|Alemtuzumab|
45986412|NCT00495105|Behavioral|Two Servings of Dairy Snacks|2 servings of dairy products as snacks at school to third, fourth, and fifth grade students each day for 24 weeks. The serving size of each dairy snack is based on its calcium content with the goal of adding an extra 300 mg of calcium to the intervention group's daily intake.
45986413|NCT00472472|Device|paclitaxel coated balloon catheter (device with drug)|PTA vs Paccocath
45986414|NCT01247025|Other|No intervention|This study will not contain a specific intervention
46083467|NCT04020861|Device|Active PBM|To active photobiomodulation therapy (PBMT) the patient will be oriented to lie preferably in prone. The treatment area will be defined according to painful area. In the active group will be used the followings parameters: low-level laser therapy, 808 nm, 4 infrared diodes, 180 mW, 9 J. In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
46083468|NCT04020861|Device|Active TENS|To active transcutaneous electrical nerve stimulation (TENS) the patient will be oriented to lie preferably in prone. Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. It will be used the following parameters: frequency of 100 Hz, pulse duration of 125 µs (positive phase), 30 minutes of current stimulation and the pulse amplitude will be increased until the patient reports a strong but comfortable paresthesia (including motor level stimulation but no painful TENS). The amplitude will be adjusted (if necessary) each 5 minutes to keep a strong but comfortable paresthesia.
46083469|NCT04020861|Device|Placebo PBM|In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
45986415|NCT00477347|Device|Closed loop administration|intraoperative closed loop administration of propofol and remifentanil
45986416|NCT00477347|Device|Manual administration|intraoperative manual administration of propofol and remifentanil
45986417|NCT01244568|Behavioral|Prostate cancer treatment DESI|DESI is a 50 minute program on treatment choices for prostate cancer that will be given out to the experimental group. The program explains several treatment options including surgery (radical prostatectomy), radiation therapy (external beam and/or brachytherapy), hormone therapy, and active surveillance and watchful waiting. The program's intended audience is men with early state prostate cancer who are trying to make a treatment decision.
45986418|NCT00503568|Biological|Ad100-gp96Ig-HLA A1|Dose Schedule 1 (DS-1): 4x10^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10^7 cells twice weekly, maximum 36 vaccines/patient
45986419|NCT00472550|Drug|esomeprazole 20 mg|
45986420|NCT01244607|Drug|Placebo|single i.v. administration
45986421|NCT01244607|Drug|NI-0801|single i.v. administration
45833014|NCT00088374|Drug|18 FDG (Fludeoxyglucose 18F)|18FDG PET performed at baseline and 12 weeks after treatment. At each timepoint participants can receive 250mCi 0-15 water and 15 mCi F18-FDG.
45986422|NCT00503607|Drug|BLI-800|
45986423|NCT00503607|Drug|Polyethylene glycol 3350 based bowel preparation|
45986424|NCT00477503|Drug|Gallium-67 Citrate (Ga-67)|"Group A: Ga-67 citrate injection alone, in the baseline study.~Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study."
46083470|NCT04020861|Device|Placebo TENS|To placebo transcutaneous electrical nerve stimulation (TENS) Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. This device was customized to deliver a current for 30 seconds (both channels) and then ramp off over the next 15 seconds so that it will be active for a total of 45 seconds. This will permit the patient to fell the TENS sensation while applying the settings.
45986425|NCT00477503|Drug|In-111 DTPA (In-111 pentetate)|"Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study."
45986426|NCT00472628|Procedure|Blood samples collected|
45456744|NCT01129999|Behavioral|Cognitive-Behavioral Therapy|a cognitive-behavioral smoking cessation program; 6, weekly-held, group sessions (90 min each)
45833015|NCT00088374|Drug|[15-O] H2O|[15-0] H20 performed at baseline and 12 weeks after treatment. At each time point participants can receive 250mCi 0-15 water and 15 mCi F18-FDG. The water scans were done as several intravenous injections for several scans but not over a total of 250 mCi.
45986427|NCT00503646|Other|communication intervention|
45986428|NCT00503646|Other|counseling intervention|
45986429|NCT00503646|Other|questionnaire administration|
45986430|NCT00503646|Procedure|psychosocial assessment and care|
45986431|NCT01244334|Drug|Difluprednate ophthalmic emulsion 0.05%|Difluprednate ophthalmic emulsion 0.05%: 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
45986432|NCT01244334|Drug|Prednisolone acetate 1%|Prednisolone acetate 1% : 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
45986433|NCT00477542|Drug|clofarabine|"Cohort- n- Clofarabine (mg/m2/day)~-1 3-10 20~3-6 30~3-6 40~3-6 50~3-6 60~6-10 70"
45986434|NCT00503724|Drug|enzastaurin hydrochloride|Participants receive 200, 260, 340, or 440 mg/m2/day of enzastaurin orally once daily for 28 days (one course) during the dose escalation phase of the study. To study the toxicity profile of the MTD or phase II recommended dose established during the dose escalation phase, participants receive twice daily doses of enzastaurin orally at the phase II recommended dose for 28 days (one course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 13 courses (approximately one year).
45456745|NCT01129999|Behavioral|Hypnotherapy|hypnotherapeutic smoking cessation program; 6, weekly-held, group sessions (90 min each)
45456746|NCT01348256|Drug|Dendritic cells vaccine|Vaccination with autologous dendritic cells loaded with autologous tumor antigens
45986435|NCT00472667|Procedure|Procalcitonin guided strategy|Procalcitonin guided strategy
45986436|NCT00503763|Drug|Simvastatin|
45986437|NCT00477581|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
45986438|NCT00477581|Drug|sitagliptin|oral administration (100mg), once a day in the morning
45986439|NCT00503802|Procedure|Radiofrequency Turbinate Reduction|Radiofrequency Turbinate Reduction
45456747|NCT03930589|Procedure|Remote Ischemic conditioning|BP cuff inflation for 5 min and deflation for 5 mins with 4 cycles
45456748|NCT03930589|Other|Standard of care|Standard of care
45986440|NCT00503802|Procedure|Sham RF|The steps of the procedure are as follows: 1) application of topical anesthetic to the turbinate mucosa bilaterally; 2) injection of 1.0 ml of lidocaine 1% with epinephrine 1:100,000 with a 30-gauge needle into each inferior turbinate anteriorly; 3) delay five minutes for local anesthetic to take full effect; 4) re-insertion of the anesthetic needle to check for complete anesthesia on one side, and injection of another 1.0 ml of lidocaine 1% with epinephrine 1:100,000 5) placement of the radiofrequency electrode (23-gauge, 1 cm long) into the inferior turbinate; 6) delivery of 300 Joules of radiofrequency energy to the turbinate over 29 seconds (no energy will be delivered in sham procedure)7) placement of a cotton pledget (soaked in oxymetazoline solution 0.05%) against the treatment site 8) repeat steps 3 - 8 for the contra-lateral inferior turbinate; 9) removal of the cotton pledgets after several minutes; and 11) observation of hemostasis.
45986441|NCT00477620|Behavioral|Wearing of reading glasses during prolonged near work|
45986442|NCT00477737|Drug|Sevoflurane|
45986443|NCT00477737|Drug|propofol|
45986444|NCT01247103|Drug|AZD4316|Single oral doses of AZD4316 suspension in the fasted state. In one group in Part A, subjects will receive a second dose of AZD4316 in the fed state (within 30 min after receiving a high fat breakfast)
46083471|NCT05342558|Drug|Fluticasone Furoate/Vilanterol 100/25 mcgs|Dry powder inhaler with 30 blisters. 100/25mcgs a day for 24 weeks.
46083472|NCT05342558|Drug|Umeclidinium/Vilanterol 62.5/25 mcgs|Dry powder inhaler with 30 blisters. 62.5/25mcgs a day for 24 weeks
45986445|NCT01247103|Drug|AZD4316|Multiple oral doses of AZD4316 suspension. It's planned that doses will be administered in the fasted state, however, if in Part A it's shown that food increases absorption of AZD4316, then doses will be administered after a meal.
45986446|NCT01247103|Other|Placebo|Placebo to match AZD4316
45986447|NCT00477776|Drug|Metoclopramide (Maxolon)|Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, once a day for day 11 and 12
45986448|NCT00477776|Drug|Placebo|Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10, once a day from day 11 to 12
45986449|NCT00504699|Procedure|Ovarian stimulation in vitro fertilization cryopreservation|Letrozole 5 mg/day during ovarian stimulation
45986450|NCT00477815|Biological|rituximab|375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22)
45986451|NCT00477815|Drug|melphalan|100/m2 in 1000 ml 0.9% NaCI IV infusion over 1 hour daily x 2 days.
45986452|NCT00477815|Biological|Stem Cell|greater than or equal to 2 x 106 CD34+/kg by IV
45986453|NCT00477815|Biological|Sargramostim (GM-CSF)|500 mcg by Subcutaneous QD
45986454|NCT00477815|Radiation|90Y-Zevalin|Dose escalation scheme. The dose of Zevalin will be based on the calculated radiation to the liver.
45986455|NCT00477815|Biological|111In Zevalin|5.0 mCi by IV
45986456|NCT01247181|Other|Mobile phone text message|Weekly message with motivational content
45986457|NCT01247181|Other|Usual care|Usual care provided at clinic
45986458|NCT01244685|Device|Deltex CardioQ Probe|Deltex CardioQ probe will be placed nasally in the operating room by the anesthesia team and fluid management will be administered via anesthesia protocol.
46083473|NCT00923273|Drug|FDG-PET|PET CT will be performed at baseline and after two cycles of treatment.
46083474|NCT00923273|Drug|Pemetrexed|
45986459|NCT00477854|Drug|Chromium Picolinate|Test whether Chromium Picolinate supplementation affects food intake at both a test lunch meal and at a test dinner meal presented 4.5 hours later among healthy, overweight and/or obese, adult women who are determined to be carbohydrate creavers.
45673401|NCT05218694|Diagnostic Test|CCTA guided focused coronary angiography examination.|Focused examination based on Images from CCTA, by choice of optimal catheter used and projection.
45986460|NCT01247259|Drug|Pangramin®|During a 4-week increasing-dose phase, the patients increased the daily dose from 1 to 5 drops of 1.6 STU/mL solution from day 1 to 10, 1 to 5 drops of 8 STU/mL solution from day 11 to 15, 1 to 5 drops of 40 STU/mL solution from day 16 to 20, 1 to 5 drops of 200 STU/mL solution from day 21 to 25, and 1 to 5 drops of 1000 STU/mL solution from day 26 to 30. After reaching the maintenance dose, 5 drops of 1000 STU/mL solution, the patients took the allergen three times per week during the maintenance phase.
45986461|NCT00477893|Drug|Adalimumab|sc. injection Humira 40 mg every other week, from week 0 or 12 to the end of study
45986462|NCT00477893|Drug|Placebo|sc. inj. placebo every other week, week 0, 2, 4, 6, 8, and 10.
45986463|NCT01245426|Drug|GW870086 2mg|oral inhalation
45986464|NCT01245426|Drug|GW870086 4mg|oral inhalation
45833016|NCT00088374|Drug|EPL diluent|17AAG is formulated with this diluent. Supplied in a 50 mL flint vial containing 48 mL of 2% egg phospholipids, and 5% dextrose in Water for Injection, USP. Patients with a history of serious allergic reactions to eggs should not receive this agent.
45833017|NCT03773250|Behavioral|Behavioral intervention|The intervention has an intensive phase and a maintenance phase.
45833018|NCT03493620|Procedure|Device arm|Make a gastric tube (endoscopic sleeve gastroplasty) using the Apollo Overstitch suturing device through endoscopy.
45986465|NCT01245426|Drug|GW870086 Placebo|oral inhalation
46083475|NCT00923273|Drug|Sirolimus|
46083476|NCT00923273|Dietary Supplement|Vitamin B12|1000 micrograms intramuscularly every 63 days administered the preceding first dose of pemetrexed
46083477|NCT00923273|Dietary Supplement|Folic acid tablets|1 mg dose every 63 days administered during the week preceding first dose of pemetrexed and will be continued for 21 days following last dose of pemetrexed.
45833019|NCT03493620|Procedure|Sham arm|Group II will be conducted identically to Group I except for the procedure itself, and only the endoscopist, that is the researcher, will be aware of which group each patient belongs to.
45986466|NCT01245426|Drug|GW870086 1mg|oral inhalation
45986467|NCT01245426|Drug|GW870086 3mg|oral inhalation
46083478|NCT00923273|Drug|Dexamethasone tablets|4 mg dose twice daily the day before, the day of, and the day after pemetrexed.
46083479|NCT02714478|Device|equistasi|3 devices will be placed in each patient: 1 at the spinosus process of L5; 1 at the insertion of transverse abdominis; 1 at the insertion of the gluteus medius to the femur. The devices will be kept for 55 minutes, during standard Physiotherapy
46083480|NCT02714478|Device|placebo|3 devices will be placed in each patient: 1 at the spinosus process of L5; 1 at the insertion of transverse abdominis; 1 at the insertion of the gluteus medius to the femur. The devices will be kept for 55 minutes, during standard Physiotherapy
46083481|NCT04019925|Device|ADM/MDM hip|Dual Mobility Hip prosthesis manufactured by Stryker Orthopaedics: ADM/MDM
46083482|NCT04231370|Drug|Sintilimab|Sintilimab, 200mg, iv day1
46083483|NCT04231370|Drug|Lenalidomide|25mg/d oral d1-14
45833020|NCT03772548|Diagnostic Test|MRI|We will examine acute (<4 weeks post SCI) to chronic (>6 months post SCI) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
45986468|NCT00478010|Other|counseling intervention|
45986469|NCT00478010|Other|study of socioeconomic and demographic variables|
45986470|NCT00478010|Procedure|psychosocial assessment and care|
45986471|NCT00478010|Procedure|quality-of-life assessment|
45986472|NCT01247337|Drug|Oxaliplatin, capecitabine, gemcitabine, cetuximab|Intrahepatic oxaliplatin
45986473|NCT01247337|Drug|Oxaliplatin, capecitabine, gemcitabine cetuximab|Oxaliplatin given intravenous
45986474|NCT00478049|Drug|Gefitinib|250 mg oral tablet
45986475|NCT00478049|Drug|Docetaxel|intravenous infusion
45986476|NCT01248975|Drug|FP/SAL 250/50mcg BID|FP/SAL 250/50mcg BID
45986477|NCT01248975|Drug|GSK2190915 200mg QD (AM)|GSK2190915 200mg QD (AM)
45986478|NCT01248975|Drug|GSK2190915 100mg QD (AM)|GSK2190915 100mg QD (AM)
45986479|NCT01248975|Drug|Montelukast 10mg QD (PM)|Montelukast 10mg QD (PM)
45986480|NCT01248975|Drug|Placebo tablets (2) (AM)|Placebo tablets (2) (AM)
45456749|NCT01353638|Drug|Dipeptiven (Alanyl-glutamine-dipeptide)|Two arms (A and B) and two treatment periods (1 and 2) are scheduled for this study. Each arm includes 14 patients. Schedule arm A: Treatment period 1 with one single peritoneal dialysis exchange (standard PD solution) with Alanyl-Glutamine-Dipeptide as add-on. 17,4 ml Dipeptiven (=3,48g N(2)-L Alanyl-L-Glutamin) will be dissolved at a final concentration of 0,174 %(= 8 mmol/l) in 2 liters of Dianeal®PD4 (at PH:5,5; Glucose-Concentration 3,86 %). After a wash out period (28 days + max 7 days), arm A undergoes treatment period 2, that is one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide. Schedule Arm B: Treatment period 1 with one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide followed by wash-out. Treatment period 2 for arm B includes one single peritoneal dialysis exchange with standard PD solution with Alanyl-Glutamine-Dipeptide as add-on. Dosages remain exactly the same.
46083484|NCT02717286|Procedure|restorative|It was performed direct restoration using two kinds of adhesive system (total-etching adhesive and self-etching adhesive)
45833021|NCT03772548|Diagnostic Test|MRI|We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
45673402|NCT01552954|Behavioral|Intensive education of low salt diet|For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks.
46083485|NCT04094025|Drug|dATS|d-Amphetamine Transdermal System
45833022|NCT00087594|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)
45673403|NCT02175368|Device|Adhese One F Upgrade|
45986481|NCT01248975|Drug|Placebo capsule (PM)|Placebo capsule (PM)
45986482|NCT02955927|Drug|0.01% atropine eye drops|
45986483|NCT02955927|Device|ortho-k|
45986484|NCT00478283|Other|survey administration|
45986485|NCT01247454|Behavioral|academic detailing|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is turned off. Providers receive academic detailing.
45986486|NCT01247454|Behavioral|Electronic Health Record (EHR) prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease.
45986487|NCT01247454|Behavioral|EHR prompt and patient prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease. And a brief information sheet is distributed to patients prior to their visit asking them to discuss ASA therapy for primary prevention with their provider.
45986488|NCT00478322|Drug|Placebo|Matching placebo of 100 mg BID
45986489|NCT00478322|Drug|INCB013739|INCB013739 100 mg BID
45986490|NCT01322347|Drug|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
45986491|NCT01322347|Device|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
45986492|NCT01247493|Drug|induction chemotherapy (fludarabine, cytarabine, idarubicin)|fludarabine, cytarabine, idarubicin
46083486|NCT04231292|Drug|RD01|RD01 is a PEGylated recombinant human erythropoietin with the same biological effects as natural erythropoietin
46083487|NCT04231292|Drug|Recombinant Human Erythropoiesis Injection (CHO cell)|rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
46083488|NCT04231292|Drug|placebo|placebo
45986493|NCT00478439|Dietary Supplement|ZeaVision EyePromise Restore|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, Zeaxanthin 8mg,mixed tocopherols 6mg, lutein 4mg,
45986494|NCT00478439|Dietary Supplement|Multivitamin|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, mixed tocopherols 6mg, lutein 4mg,
45986495|NCT04325425|Drug|FOLFOXIRI Protocol|Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
45986496|NCT04325425|Drug|Cisplatin injection|"Cisplatin 100 mg/m2, IV infusion over 3 hours or Carboplatin AUC 5, IV infusion over 30 minutes on day 1 [the dose of carboplatin will be determined for each cycle using the Calvert's formula (carboplatin dose (mg) = target AUC 5 x estimated glomerular filtration rate (eGFR, mL/min) + 25)];~• Etoposide 100 mg/m² IV infusion over 1 hour on day 1,2 and 3"
46083489|NCT02717208|Biological|HL036|
46083490|NCT02717208|Biological|Vehicle|
46083491|NCT02600169|Drug|Pemprolizumab|All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma.
46083492|NCT04231136|Drug|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
46083493|NCT04231136|Drug|EAPA115|EAPA115
46083494|NCT04231136|Drug|RAPA115|RAPA115
45673404|NCT01518244|Drug|Brinzolamide/timolol maleate fixed combination|
45673405|NCT01552408|Drug|0.3 mg ranibizumab|Cohort 1: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity.
45833023|NCT00087594|Drug|ribavirin|1000/1200mg (< or >= 75 kg, respectively), po in two doses daily for 48 weeks (G 1) or 800 mg po in two doses daily for 24 weeks (G 2/3)
45833024|NCT03770286|Device|5% Fluoride Varnish|Topical varnish
45833025|NCT03770286|Device|38% Silver diamine fluoride|Topical varnish
46083495|NCT02722122|Drug|AIR DNase™|
46083496|NCT00916773|Device|continuous positive airway pressure (CPAP)|CPAP of optimal pressure used during sleep for 3 months
45833026|NCT03770286|Device|Floss|Floss will be used as a delivery agent of SDF to target interproximal carious lesion.
45833027|NCT03492528|Biological|blood samples|blood samples
45986497|NCT02891395|Drug|Imatinib Mesylate and Nilotinib|"For patients under Imatinib Mesylate: the total length of follow up period for those patients will be for 52 weeks following IM treatment, with a follow up at weeks IM4, IM8, IM12, IM26, IM38 and IM52.~For patients requiring a salvage phase: after the switch for nilotinib, the total length of follow up period for this phase will be for 52 weeks following nilotinib treatment, with a follow up at weeks nilo4, nilo8, nilo12, nilo26, nilo38 and nilo52."
45986498|NCT00478478|Procedure|Mechanical Thrombectomy|Thrombectomy performed with the Merci Retriever in the setting of acute ischemic stroke.
45986499|NCT05645185|Diagnostic Test|Diagnosis test|Tests can be used: immunofluorescence, immunodot, western blot, tests CBA on sera or CSF.
45673406|NCT01552408|Procedure|Targeted Pan Retinal Photocoagulation|Cohort 2: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at V3 (Day 7) they will receive targeted pan retinal photocoagulation (PRP) based on ultra wide 200º field angiography. After the first session of PRP, subject's will have ultra wide 200º field angiography performed every 3 months to indicate areas of peripheral ischemia, which will be selectively treated at V9 (Month 6), V21 (Month 18), and V28 (Month 25), preserving areas of more perfused retina. This will minimize any visual field loss secondary to nonselective pan-retinal photocoagulation.
45833028|NCT03769350|Device|Smartphone-delivered CBT for MDD|8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
45833029|NCT03492372|Other|Waste tissues are collected at the time of spinal surgery.|This is a single visit study. Waste tissues are collected at the time of spinal surgery.
45986500|NCT01247532|Behavioral|Mindfulness-Based Stress Reduction - Cancer-Related Fatigue|7 week 2 hour class
45986501|NCT00478517|Drug|Erythropoetin (rHuEPO, EPREX®)|
45673407|NCT04099888|Drug|Fimaporfin and Gemcitabine|PCI treatment consists of IV administration of Amphinex solution for injection (investigational product) at 0.22 mg/kg dose of fimaporfin, followed 4 days later by a standard dose of gemcitabine infusion (1000 mg/m²) and intraluminal laser light application. Up to 2 PCI treatments will be given.
45986502|NCT03273218|Device|Tiger catheter|
45986503|NCT03273218|Device|Judkins catheter|
45986504|NCT01321879|Drug|Telavancin|10 mg/kg by vein once daily for patients with a creatinine clearance of more than 50 ml/min, and a dose of 7.5 mg/kg once daily for patients with a creatinine clearance of 30-50 ml/min.
45986505|NCT03271853|Device|Sentinel BreastScan II|The SBS II will automate the recording of thermal data used in the Therma-Scan manual thermology protocol by utilizing a thermal camera sensitive to changes in breast temperature. The SBS II system uses a very sensitive thermography camera that detects and visually displays heat patterns that naturally emanate from the breast. SBS II captures this data digitally for subsequent analysis by Therma-Scan.
45986506|NCT01321723|Drug|PTH analog|A recombinant 1-31 amino acid fragment of PTH.
45673408|NCT04099888|Drug|Gemcitabine/Cisplatin chemotherapy|Up to 8 cycles of gemcitabine/cisplatin combination chemotherapy will be administered.
45833030|NCT05347056|Diagnostic Test|Lumbar Spine Magnetic Resonance|Metal artifact reduction sequence (mars), axial t2 sequence
45833031|NCT05347056|Diagnostic Test|Isokinetic trunk flexion-extension trunk muscle strength and endurance test|To evaluate for trunk muscle strength and endurance angular velocity of 60 and 120°/s
45986507|NCT01321723|Drug|Placebo|
45986508|NCT01321723|Drug|Forsteo (Teriparatide)|A recombinant 1-34 amino acid fragment of PTH.
45986509|NCT01247649|Device|Physical Logic Continuous Glucose Monitoring System|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
45986510|NCT00478634|Drug|RAD001, Cetuximab, Irinotecan|
46083497|NCT02786108|Procedure|left gastric artery embolization|
46083498|NCT02786108|Behavioral|healthy diet and exercise|
46083499|NCT05175404|Diagnostic Test|PET/CT scan F18-PSMA-11|PET/CT scan with F18-PSMA-11
46083500|NCT05205408|Biological|Oncolytic Virus Injection(RT-01)|Administered by intratumoral injection as single agent.
46083501|NCT05340530|Drug|The injectable TQD3606|TQD3606 is a fixed-dose combination of meropenem and avibatam.
46083502|NCT05340530|Drug|meropenem|Meropenem is a carbapenem antibiotic
46083503|NCT05340530|Drug|Avibactam Sodium|Avibactam is beta-lactamase inhibitor.
45833032|NCT05347056|Diagnostic Test|Lomber Region Range of motion assessment|To evaluate for lomber region ROM with digital inclinometer
45833033|NCT05347056|Diagnostic Test|Radiograph|spinal radiograph AP/Lateral
45986511|NCT01247688|Drug|Cytoxan|50 mg/kg/dose will be given IV on day -5,-4, -3, -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.
45986512|NCT01247688|Drug|Fludarabine|40mg/m2/day will be given IV over 1 hour on day -4, -3, -2
46083504|NCT05340530|Drug|Placebo|It is a placebo.
45986513|NCT01247688|Radiation|Total Body Irradiation (TBI)|1.75Gy/fraction will be given on day -9, -8, -7, -6
45986514|NCT01247688|Procedure|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on day 0
45986515|NCT01321606|Dietary Supplement|Lactobacillus rhamnosus HN001|Subjects will be given a pill formulation of a probiotic L. rhamnosus HN001 to be taken once a day, at a dose of 1 x 10^10 organisms
45986516|NCT01321606|Dietary Supplement|sugar pill (placebo)|Placebo identical to the active product will be given
45986517|NCT00503919|Procedure|Multi-spectral Digital Colposcopy (MDC)|Use of a digital camera and a special light to take pictures of the cervix and vagina.
45986518|NCT00478790|Device|ologen™ Collagen matrix implantation in glaucoma filtering surgery|ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
45673409|NCT01528696|Device|Silverlon|"Patients will be randomized to either receive a silver dressing. Patients who receive a silver dressing will have that dressing replaced on postoperative day number 2. This will be left in place until the patient is seen for follow up by the visiting nurse.~All patient will be evaluated by the visiting nurse on postoperative day 4 or 5 and have their wounds photographed. All patients will be contacted for a brief survey 6 weeks postpartum."
45986519|NCT02956187|Behavioral|Biofeedback|Functional outlet obstruction will be treated by biofeedback: sessions of biofeedback guided by anorectal manometry combined with instructions for daily exercizing for 4 weeks.
45986520|NCT02956187|Dietary Supplement|Fiber supplement|3.5 g plantago ovata per day will be administered for 4 weeks.
45986521|NCT04517682|Diagnostic Test|RT-PCR|The RT-PCR assay will be performed on paired nasopharyngeal and saliva samples
45673410|NCT01528696|Device|Standard Dressing|Standard island dressing. Patients who receive a standard dressing will have that dressing removed on postoperative day 2. This will be left in place until the patient is seen for follow up by the visiting nurse.
45673411|NCT02174276|Drug|Tenofovir disoproxil fumarate|TDF 300 mg tablet administered orally once daily
45833034|NCT05347056|Behavioral|SRS 22|SRS-22 Patient Questionnaire
45986522|NCT01320943|Drug|TDF|Tenofovir disoproxil fumarate (TDF) 300 mg tablet administered orally once daily
45986523|NCT01320943|Other|Stop TDF|Participants will stop TDF therapy
45986524|NCT04519008|Device|Mobile app|Medical device for improving emotion dysregulation
46083505|NCT02600091|Behavioral|Mindfulness-Based Cognitive Therapy|The MBCT intervention is manualised and delivered to groups. The aim of the MBCT intervention is to increase mindfulness skills and to facilitate their use in relation to emotional wellbeing and diabetes self-management. Participants will attend on 8 occasions, once per week, for 2 hours. These meetings will have a standard structure. First, participants will describe their efforts to practice mindfulness at home over the previous week, followed by discussion of an educational topic relevant to the aims of the course. Finally, the group will do a mindfulness practice together, and the home practice for the following week will be set. In-between meetings, participants are asked to practice mindfulness by listening to an audio file or CD for about 30 minutes per day.
45673412|NCT02174276|Biological|GS-4774|GS-4774 subcutaneous injection administered every 4 weeks for a total of 6 doses
45673413|NCT01528072|Device|Dynesys Spinal System|Dynesys Spinal System will be used for all subjects
45673414|NCT01527682|Drug|Latanoprost, Dorzolamide|"Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)~Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost"
45673415|NCT01527370|Biological|Zoster Vaccine Live|One approximately 0.65 mL injection subcutaneously on Day 1
45833035|NCT00087516|Drug|Sitagliptin (MK0431)|Phase A: Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
45833036|NCT00087516|Drug|Sitagliptin|Phase A: Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
45986525|NCT04519008|Combination Product|Treatment as usual|Bimonthly individual psychotherapy and psychostimulant medications
45986526|NCT04325347|Other|Virtual Reality application|Virtual Reality application with a VR goggle
45986527|NCT00472706|Procedure|excision|excision 3 mm margin
46083506|NCT02714088|Other|Novel high-intensity interval training|
45673416|NCT01527292|Radiation|Stereotactic Radiation Therapy|SRT only
45833037|NCT00087516|Drug|Placebo|Phase A: Placebo matching Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
45833038|NCT00087516|Drug|Placebo|Phase A: Placebo matching Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
45986528|NCT00472706|Procedure|Photodynamic therapy|Photodynamic therapy
45986529|NCT02955459|Drug|VNRX-5133|
45986530|NCT02955459|Drug|Placebo|
45986531|NCT00478907|Drug|KETAMINE, PROPOFOL, THIOPENTAL|
45986532|NCT02275377|Other|Inspiratory muscle training (IMT)|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 40% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 40% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
45986533|NCT02275377|Other|Sham IMT|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
45986534|NCT00478946|Drug|(FOLPI) Picoplatin with 5-FU and Leucovorin|Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
46083507|NCT00634712|Drug|Candesartan|
46083508|NCT00634712|Drug|Placebo|
46083509|NCT00636714|Behavioral|Nursing judgement|Based on the nursing judgement, titrate insulin infusion and determine glucose check frequency to achieve a target glucose of 5-8 mmol/L
45673417|NCT01527292|Radiation|SRT with Vertebral Augmentation Procedure|SRT with VAP
45986535|NCT00478946|Drug|FOLPI|Picoplatin, 150 mg/m2 to be administered with every alternate cycle of 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W, will be administered as a 2-hour infusion, either alone or, if the patient is to receive picoplatin that cycle, at the same time as picoplatin, in separate bags using a Y-line. The leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
45986536|NCT00478946|Drug|FOLFOX|Oxaliplatin 85 mg/m. Leucovorin (400 mg/m2 in D5W). Oxaliplatin and leucovorin Leucovorin + oxaliplatin 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
45986537|NCT01247844|Device|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. The man must return to the clinic for device removal. To remove the device, the outer ring locking mechanism is broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
45833039|NCT00087516|Drug|Metformin - Rescue|Phase A: Patients not meeting specific glycemic goals will receive open-label metformin as 500 mg, 850 mg, and 1000 mg oral tablets titrated at the discretion of the investigator. Phase B: These patients will not initiate Phase B double-blind medication.
45986538|NCT01247961|Drug|Dexamethasone acetate|10 mg intravenous given as single administration with optional repeat dose after 36 hours.
45986539|NCT01247961|Other|Placebo|Normal saline
45986540|NCT00478985|Behavioral|Imatinib ending|Interruption of the treatment by Imatinib
45986541|NCT01248000|Procedure|FDG-PET|PET interpretation is based on a site-to-site comparison of FDG uptake both before and after chemotherapy (qualitative approach), according to the criteria defined by Cheson (2008)
45986542|NCT01248078|Drug|Keflex|2g of i.v. cefazolin singleshot administered before skin incision
45986543|NCT01248078|Drug|Keflex|2g of i.v. cefazolin singleshot administered after umbilical cord clamping
45986544|NCT01248078|Drug|saline solution|100cc administered before skin incision
45986545|NCT00472823|Dietary Supplement|Vitamin D3|Orally for one year
45833040|NCT03768960|Drug|Daratumumab|Participants will receive 16 mg/kg of daratumumab as IV infusion QW in Cycles 1 and 2 (Days 1, 8, 15 and 22) and Q2W in Cycle 3 to 6 (Days 1 and 15).
45986546|NCT00472823|Dietary Supplement|Calcium Citrate (Citracal)|Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
45986547|NCT02275416|Drug|Ipilimumab|
45986548|NCT02275416|Biological|UV1 vaccine|
45986549|NCT02275416|Biological|GM-CSF|
45986550|NCT00472862|Behavioral|Cognitive training|Cognitive training for 16 weeks integrated in OPUS psychosocial treatment
45986551|NCT00472901|Drug|Afamelanotide (CUV1647)|16mg implant
45833041|NCT00087126|Drug|topotecan hydrochloride|
45833042|NCT03490968|Behavioral|Supervised Exercise|Subjects will have 3 visits per week for 12 weeks.
45833043|NCT03490968|Behavioral|Vascular Assessment|"Screen: Subjects will undergo a H&P, ankle brachial index, ECG, CBC, CMP, lipid panel, HgA1C, and urinalysis. A urine pregnancy test will be performed on women of childbearing age.~Testing Visit 1: MRI, IV in common femoral vein with phlebotomy (60 cc total) before and after sphygmomanometric cuff occlusion of lower limb, 6-minute walk test, 4-meter walk speed test, walking impairment questionnaire, and muscle biopsy.~Supervised exercise and leg revascularization patients will return in 12 weeks and have the same study procedures as testing visit 1, plus an ankle brachial index, repeated."
45833044|NCT03767946|Diagnostic Test|Quantiferon Gold Plus Test|Small volume of whole blood incubated with specific TB antigen and then dosage of Interferon gamma production.
45986552|NCT02483247|Drug|BBI503|Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.
45986553|NCT02483247|Drug|Capecitabine|Capecitabine 1000 mg/m^2 body surface area is administered orally, twice daily, on days 1-14 of each 21 day cycle.
45986554|NCT02483247|Drug|Doxorubicin|Doxorubicin 60 mg/m^2 body surface area is administered intravenously once every three weeks (21-days).
45986555|NCT02483247|Drug|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes on day 1 and day 15 of each 28 day cycle.
45986556|NCT02483247|Drug|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every three weeks (21-days).
45986557|NCT02483247|Drug|Paclitaxel|Paclitaxel 80 mg/m^2 body surface area is administered intravenously once weekly on day 1, day 8, and day 15 of each 28 day cycle.
45986558|NCT02483247|Drug|Sunitinib|Sunitinib 37.5 mg is administered once daily.
45986559|NCT00479024|Drug|iodinated contrast agent|iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque
45986560|NCT02482233|Behavioral|ENDD (NJOY)|As described above.
45986561|NCT02482233|Drug|NRT (NicoDerm CQ)|As described above.
45986562|NCT02482233|Behavioral|telephone counseling|Referral to the California Smokers' Helpline. California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.
45986563|NCT02482233|Behavioral|brief advice|"Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider. The advice will be similar to the following statement (customized as needed to the patient): The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery. Quitting smoking before surgery may improve your chances of healing quickly. There's evidence that the longer you quit before your surgery, the fewer complications you'll have. I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible."
45986564|NCT02482233|Behavioral|brochure|"A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery.~Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure_%20For%20Posting.pdf"
45986565|NCT02489526|Drug|VVZ-149 Injections|Experimental group will receive a loading dose of 1.8 mg/kg VVZ-149 intravenous infusion for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h VVZ-149 intravenous infusion for 7.5 hours.
45986566|NCT02489526|Drug|Placebo|Placebo group will receive the corresponding amount of placebo.
45986567|NCT00473018|Behavioral|standard versus enhanced risk reduction counseling|
45986568|NCT00479102|Drug|Ferripel-3 - iron polysaccharide complex for prevention|
45986569|NCT01248117|Drug|ranibizumab 2.0mg|Monthly, intravitreal injection 0.05ml
45986570|NCT00479141|Behavioral|HIV skills training|Eight 2-hour group skills training sessions will occur during Weeks 1 through 8 and booster sessions will occur every two months during Months 3 through 15
45986571|NCT00479141|Behavioral|Popular Opinion Leaders training|Two-hour training sessions about anti-stigma and anti-discrimination will occur for 4 weeks, followed by support meetings every 2 months during Months 2 through 13.
45986572|NCT00479180|Biological|Vascugel|One time implant on the day of surgery
45986573|NCT00479180|Biological|Placebo Comparator|One time implant on the day of surgery
45986574|NCT01248234|Drug|propofol|Propofol 1mg/kg will be given once to put the patient to sleep for surgery.
45986575|NCT01248234|Drug|Etomidate|Etomidate 0.3mg/kg will be given once to put the patient to sleep for surgery.
45986576|NCT01248234|Drug|Propofol and Etomidate|Etomidate 0.2mg/kg plus Propofol 0.5mg/kg will be given once to put the patient to sleep for surgery.
45986577|NCT00479219|Drug|GSI-953|
45986578|NCT00479219|Other|Placebo|
45986579|NCT00479297|Drug|SAM-531|
45673418|NCT04748692|Procedure|Local exercise therapy|The local exercise therapy group will focus on strengthening knee and hip muscles three times a week for 6 weeks. Once a week, patients will train with the support of a physiotherapist. The physiotherapist gradually increases the intensity of the exercises improving muscle endurance. The exercises will be supplemented with mobilisations of the patellofemoral joint. Twice a week, patients train at home following a prescribed exercise program writing down their work-out in an exercise journal.
45986580|NCT00503958|Genetic|DNA methylation analysis|
45986581|NCT00503958|Genetic|DNA stability analysis|
45986582|NCT00503958|Genetic|gene expression analysis|
45986583|NCT00503958|Other|epidemiologic study|
45986584|NCT00503958|Other|study of socioeconomic and demographic variables|
45676680|NCT02041286|Device|Karajishi Contour Investigational BG Monitoring System|Subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi Contour Investigational BG Monitoring System with no training. All BG results are compared to reference method results obtained from subject capillary plasma. Also, study staff test subject venous blood and BG results are compared to reference method results obtained from subject venous plasma.
45986585|NCT00503958|Procedure|biopsy|
45986586|NCT00503958|Procedure|evaluation of cancer risk factors|
45986587|NCT00503958|Procedure|study of high risk factors|
45986588|NCT00473057|Other|Autologous cell transplantation|Intra-arterial or intravenous delivery of autologous bone marrow cells
45986589|NCT00473096|Behavioral|Informed breast cancer surgical treatment|
45986590|NCT04517487|Biological|Vaginal Microbiome Transplantation (VMT)|Healthy donors vaginal fluid is introduced into recipients' vagina to replace their indigenous disease-associated microbiome
45986591|NCT04517487|Biological|Placebo|Placebo
45986592|NCT00473135|Biological|rDEN1delta30|Live attenuated rDEN1delta30 vaccine at a dose of 10^3 PFU
45986593|NCT00473135|Biological|Placebo|Placebo for rDEN1delta30
45986594|NCT01248273|Biological|Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21|The injection will be administered subcutaneously during weeks 1, 2, 3, 7 and 19, totaling five injections over the course of the study. Three dose levels are planned: 25 mcg, 50 mcg and 100 mcg. We plan to vaccinate six patients at each dose level unless 2 dose limiting toxicities are observed, and an expansion cohort of 6 patients will be enrolled at the highest dose level achieved.
45986595|NCT00479375|Procedure|Adding Human Papillomavirus testing to organised cervical screening|
45986596|NCT01248312|Device|Sentec monitoring device|Sentec monitor applied transcutaneously to forehead
45986597|NCT01248312|Device|sentec monitor|transcutaneous monitoring
45986598|NCT01248351|Other|autologous stored platelets|Administration of autologous stored platelets
45986599|NCT01248351|Other|administration of autologous stored platelets|administration of autologous stored platelets
45986600|NCT01248351|Biological|autologous stored platelets|transfusion of autologous stored platelets
45986601|NCT00473174|Drug|Ramipril|Dosing on awakening versus bedtime
45986602|NCT00473174|Device|ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
46083510|NCT00636714|Behavioral|Nomogram|A preprinted order outlining a nomogram with instructions for how insulin infusion should be changed based on measured glucose values and how frequent the glucose checks should be
45986603|NCT01248390|Behavioral|Interactive metronome|A randomized, controlled investigation into the effects of IM training on a sample of boys with attention deficit disorder showed positive results. Compared to an active control treatment, IM training improved performance on a host of measures, including attention, motor control, language processing, reading, and parental reports of improvements in the regulation of aggressive behavior.16 It should be noted that these cognitive and behavioral functions are common symptom areas in individuals surviving TBI and are likely to be especially affected in cases of blast injury
45986604|NCT00473213|Drug|Interferon Beta 1|
45986605|NCT02274831|Other|Email Reminder of need to follow up with primary physician|
45986606|NCT01320202|Drug|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
45986607|NCT01320202|Device|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
45986608|NCT00479531|Device|AirCast Sequential Compression Device|
45986609|NCT00479570|Drug|PF-00446687|Single 200mg dose
45986610|NCT00479570|Drug|Placebo|
45833045|NCT03490734|Dietary Supplement|Black Cherry and Orange Flavored Beverage with added sugar|10 oz daily for three weeks
45986611|NCT01319383|Drug|Vorinostat|Vorinostat (VOR) 400mg will be given as single doses by mouth. Participants eligible to advance in study will have opportunity to receive more than one dose of VOR. Each participant will only take one dose of VOR in a 24 hour period. Repeat doses will be administered at least 24 hours apart, with option for dosing at intervals up to 96 hour
45986612|NCT05645029|Other|glass ionomer-chlorhexidine|chlorhexidine will be added to glass ionomer
45986613|NCT05645029|Other|glass ionomer-titanium dioxide powder|titanium dioxide will be added to glass ionomer
45986614|NCT05645029|Other|glass ionomer|glass ionomer will be used without any additives
45986615|NCT00479609|Drug|Transdermal testosterone therapy|testosterone 1% hydroalcohol gel
45986616|NCT00479609|Drug|Placebo|Placebo gel
45833046|NCT03490734|Dietary Supplement|Strawberry Kiwi &Lemonade Flavored Beverage with added sugar|10 oz daily for three weeks
45986617|NCT04325113|Drug|levobupivacaine|Patient satisfaction and pain score using a visual anagogic scale (VAS)
45986618|NCT02275104|Device|Contrast-enhanced ECG-gated multi-detector computed tomography|Depending on potential contra-indications to iodine-enhanced computed tomography. It will be performed using the usual method on a 64-slice dual energy scanner. Data will be acquired after the injection of 120 mL iodine contrast media. Contrast will be injected at the rate of 4 mL/s without additional saline flush in order to obtain homogeneous enhancement of the 4 cardiac chambers, there by simplifying subsequent segmentation. The objective will be to obtain a 3-dimensional imaging of cardiac structures
45986619|NCT02275104|Device|Magnetic resonance imaging|Depending on potential contra-indications to gadolinium-enhanced magnetic resonance. It will be performed on the 1.5 Tesla clinical device associated to MUSIC equipment (Magnetom Avanto, Siemens, Erlangen, Germany). Myocardial fibrosis will be imaged using a free-breathing delayed-enhancement method initially developed for atrial imaging. The method uses a 3-dimensional, inversion recovery-prepared, ECG-gated and respiratory-navigated Turbo Fast Low Angle Shot sequence with fat saturation. Acquisition will be initiated 15 minutes after the injection of a double-dose of gadolinium-based contrast media.
45986620|NCT02275104|Device|Positron emission tomography|Only in patients with a contra-indication to magnetic resonance imaging. It will be performed on a PET/CT 600 device. Acquisition will be preceded by a standard metabolic preparation for 18 fluoro-deoxy-glucose viability imaging. The objective will be to obtain a 3-dimensional imaging of ventricular scar.
45986621|NCT02275104|Device|Body surface mapping|It will be obtained using a 252-electrode vest. The position of each electrode with respect to epicardium will be assessed at multi-detector computed tomography prior to mapping. In patients referred for ventricular arrhythmia, body surface mapping will aim at recording the clinical arrhythmia whenever possible. In patients referred for atrial arrhythmia, body surface mapping will aim at recording atrial fibrillation.
46083511|NCT00923195|Drug|MART-1: 26-35(27L) Peptide|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
46083512|NCT00923195|Drug|Montanide ISA 51 VG|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
45673419|NCT04748692|Procedure|Spinal manual therapy|The spinal manual therapy group will be treated one a week for 6 weeks. Before the first intervention an experienced manual therapist performed a clinical examination of the lower back, SIJ, hip and knee. Anatomical maps showing innervation areas of spinal nerve roots will be used to explain the regional interdependence model in the treatment of anterior knee pain. Manual therapy treatment will include manipulations of the thoracolumbar (T12-L3) region or SIJ as well as hip joint. Manipulation will be conducted if a restriction of range of motion will be found in any of the regions. Patients will also be asked to do home exercises focusing on mobilizing the thoracolumbar region and to write down their performance in an exercise journal.
45673420|NCT01516216|Drug|FOLFOX + bevacizumab|
45673421|NCT01516216|Dietary Supplement|Vitamin D|
45833047|NCT03490734|Dietary Supplement|Black Cherry and Orange Flavored Beverage no added sugar|10 oz daily for three weeks
45833048|NCT03490734|Dietary Supplement|Strawberry Kiwi & Lemonade Flavored Beverage no added sugar|10 oz daily for three weeks
45833049|NCT03490734|Other|Water|Three mL administered per associated logo presentation only during MRI procedure.
45833050|NCT04763382|Other|experimental group: Training of caregivers|Pre-test, post-test, retention test, education, guide booklet delivery, android application installation and urinalysis
45833051|NCT04763382|Other|Control gruop|Pre-test, post-test and urinalysis
45986622|NCT02275104|Procedure|Cardiac ablation procedure|Ventricular procedures will be performed endocardially using trans-septal or retro-aortic approach, potentially combined with sub-xiphoid epicardial access. Atrial procedures will be performed endocardially using trans-septal approach to access the left atrium. Bi-atrial bipolar contact mapping will be performed at high density during atrial fibrillation prior to ablation.
45986623|NCT05644717|Drug|Ertugliflozin 5 mg, 15mg|Ertugliflozin 5/15mg once daily in addition to standard of care
45986624|NCT01248429|Biological|CPK dosage|CPK dosage during a blood sample realized at least one week after the begining of the treatment
45986625|NCT01248429|Other|Clinical exam|Examination of the patient for myalgia, cramps, medical history and concomitant medication
45986626|NCT01316614|Device|FNA with and without a stylet|If the patient agrees to enrollment in the study, the initial stage of the EUS exam will be performed in the usual manner. If a solid lesion that requires FNA is identified, an envelope will be opened which contains a computer generated randomization sequence for all passes. These sequences will be generated by a web-based program at http://www.randomizer.org/form.htm. Passes will be made based on the randomization, either with or without a stylet. Six passes (three with a stylet and three without a stylet) will be performed on solid lesions and four passes (two with and two without a stylet) will be performed on lymph nodes. Additional passes will be made at the discretion of the endosonographer as clinically indicated but will not be included in the data.
45833052|NCT03489564|Behavioral|Active|No behavioral intervention included but the exposure is level of physical activity. Individuals in the Active group will be categorized by their own routine physical activity levels.
45986627|NCT00479648|Biological|CSL412|
45986628|NCT00479648|Biological|Inactivated trivalent influenza vaccine|
45986629|NCT01316575|Device|nCPAP|The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.
45986630|NCT01316575|Device|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
45986631|NCT02955771|Combination Product|PDT-Deuteporfin（6 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China） followed by the illumination of the tumor. 6 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China） will be applied to the tumor.The second courses of PDT may be given at 3-month intervals.
45986632|NCT02955771|Combination Product|PDT-Deuteporfin（9 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China) followed by the illumination of the tumor.9 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China) will be applied to the tumor. The second courses of PDT may be given at 3-month intervals.
45986633|NCT02955771|Device|stenting|The stenting procedure consists in the placement of plastic stents （Boston Scientific Corporation, MA,USA；or Cook Medical, Bloomington,USA）above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC).
45986634|NCT00473408|Device|Functional MRI (DCE-MRI)|MRI examination with i.v. gadolinium contrast to assess blood perfusion in remaining tumor tissue.
45986635|NCT00473408|Procedure|Blood sample|See protocol.
45833053|NCT03489564|Behavioral|Sedentary|No behavioral intervention included but the exposure is level of physical activity. Individuals in the Sedentary group will be categorized by their own routine physical activity levels.
45986636|NCT00473408|Procedure|Tumor sample|See protocol.
45986637|NCT02891161|Drug|durvalumab|1500 mg Q4 weekly
45986638|NCT02891161|Radiation|Radiation Therapy|64.8 Gy, 36 daily fractions on weekdays over about 7 weeks
45986639|NCT02955732|Device|Dexmedetomidine|A 2-4 µg/kg dose of the study drug, 2 µg/kg of intranasal dexmedetomidine, will be administered using a LMA MAD Nasal™ -device approximately 20 min prior to planned sedation/anesthesia.
45986640|NCT00473447|Behavioral|Modified Constraint-induced movement therapy|
45986641|NCT01315678|Drug|Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~Administration time is approximately 13 minutes.~liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
45986642|NCT01315678|Drug|Tobramycin inhalation solution using a PARI LC® Plus nebulizer.|"300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.~Nebulization time is approximately 20 minutes for each administration.~Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment"
45986643|NCT02955693|Drug|LAS41008 120 mg / Fumaderm® 120 mg|Single dose of LAS41008 120 mg or Fumaderm® 120 mg in each Period
45986644|NCT00479726|Drug|duloxetine hydrochloride|
45676681|NCT02020616|Drug|LY3053102|Administered SC
45986645|NCT04697121|Dietary Supplement|Combined Bergamot phytosome and Artichoke leaf dry extract|600 mg of Bergamot Phytosome and 100 mg of Artichoke leaf standardized dry extract. Supplementation regimen was 2 daily tablets, one before lunch and one before dinner, for 8 continuous weeks.
45986646|NCT04697121|Combination Product|Placebo|Supplementation regimen was 2 daily tablets, one before lunch and one before dinner, for 8 continuous weeks.
45986647|NCT03270761|Other||
45986648|NCT01315249|Drug|indacaterol and glycopyrronium (QVA149)|QVA149 capsules delivered via dry powder inhaler (SDDPI), once daily.
45986649|NCT01315249|Drug|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol delivered via Accuhaler® device, twice daily.
45676682|NCT02020616|Drug|Exenatide ER|Administered SC
45676683|NCT02020616|Drug|Placebo|Administered SC
45676684|NCT02020616|Drug|Metformin|Administered orally (PO)
45986650|NCT01315249|Drug|fluticasone/salmeterol|Fluticasone/salmeterol dry inhalation powder delivered via Accuhaler® device, twice daily.
45986651|NCT01315249|Drug|Placebo to indacaterol and glycopyrronium (QVA149)|Placebo to QVA149 delivered via dry powder inhaler (SDDPI), once daily
45986652|NCT03270800|Biological|CTA control|Sublingual and intradernal application of a mucosal adjuvance, drug product is not yet on the market.
45986653|NCT03270800|Biological|IMX101 vaccine|Sublingual and intradermal application of a vaccine, drug product is not yet on the market.
45986654|NCT04325035|Drug|Istaroxime|Reconstituted istaroxime and lactose lyophilized powder delivered via IV infusion
45986655|NCT04325035|Drug|Placebo|Reconstituted placebo (lactose lyophilized powder) delivered via IV infusion
45986656|NCT04207411|Drug|Bupivacaine|Injection of anesthetics blocks once a week during 4 weeks.
45986657|NCT04207411|Drug|Lidocaine|Injection of anesthetics blocks once a week during 4 weeks.
45986658|NCT01248663|Procedure|antecolic reconstruction|see study arm description
45986659|NCT01248663|Procedure|retrocolic reconstruction|see study arm description
45986660|NCT00473486|Drug|pemetrexed, carboplatin, sorafenib|"Ph. 1: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; Sorafenib 200mg po bid days 2-19; 400mg po bid days 2-19~Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1;sorafenib depending on results of Ph 1"
45986661|NCT00473486|Drug|pemetrexed, carboplatin, placebo|Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; placebo day 2-19
45986662|NCT05644483|Drug|Remimazolam|Remimazolam: loading (6mg/kg/hr) + continuous infusion (1-2mg/kg/hr)
45986663|NCT05644483|Drug|Propofol|Propofol: target controlled infusion: 2-3mcg/mL
45986664|NCT01315132|Device|Matched Sibling Allogeneic Transplantation|Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization
45986665|NCT00479804|Device|inertgas rebreathing|determination of cardiac output by inertgas rebreathing
45986666|NCT00479804|Device|spirometry|spirometry for testing the ventilatory function
46083513|NCT00923195|Drug|gp100:154-162 Peptide|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
46083514|NCT00923195|Procedure|Radiation|2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute
46083515|NCT00923195|Drug|Aldesleukin|Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).
45986667|NCT00479804|Device|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
45986668|NCT00504036|Device|inflatable intra-gastric balloon|inflatable intra-gastric balloon
45986669|NCT01248702|Other|Use of the ICD Critical Pathway|The critical pathway is a series of predetermined processes designed to assess a patient's eligibility for an ICD. The critical pathway will incorporate current evidence-based practice guidelines.
45986670|NCT00479843|Behavioral|Nutritional programme|
45986671|NCT01248819|Drug|Ropivacaine 60 mg|Nebulization grou received intraperitoneal instillation of saline 20 ml on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum (total of 60 mg). The first ropivacaine nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
45986672|NCT01248819|Drug|Ropivacaine 100 mg|Instillation group received intraperitoneal instillation of ropivacaine 0.5%, 20 ml (100 mg) on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus and intraperitoneal nebulization of normal saline 3 ml before the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum. The first saline nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
45673422|NCT01950819|Biological|Induction therapy|All subjects received induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.
45673423|NCT01950819|Drug|Corticosteroids|All subjects received maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.
45673424|NCT01950819|Drug|EVR+rCNI|Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
45673425|NCT01950819|Drug|MPA+sCNI|Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
45673426|NCT04097860|Behavioral|Text message including biomarker of breast pumping adequacy|The intervention group will be sent one message that includes general information pertinent to all mothers expressing BM for their infants and one personalized real-time biomarker based message which will include the sodium level contained in the BM since the previous message, the number of times pumped on those days and will either congratulate the participant on how well the participant is pumping BM for the infant or how many more times per day the participant needs to pump to decrease the BM sodium level and increase BM production
45673427|NCT04742608|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
45673428|NCT04742608|Other|Electronic Health Record Review|Medical charts are reviewed
45673429|NCT04767490|Procedure|Standard Duodenal Switch|
45673430|NCT04767490|Procedure|Single Anastomosis Duodenal Switch|
45986673|NCT01313767|Drug|Botulinum toxin type A|Botulinum toxin type A
45986674|NCT01313767|Drug|Botulinum Toxin type A|Botulinum Toxin type A
45986675|NCT00479921|Biological|Trivalent influenza subunit vaccine|
45986676|NCT01248858|Drug|GSK2126458 and GSK1120212|GSK2126458 and GSK1120212 are experimental treatments for patients with cancer.
45986677|NCT00481286|Behavioral|Improving outcomes using group clinics for older patients|Collaborative group clinics to empower older patients to adopt goal-setting behaviors with their health care providers and improve their diabetes-related outcomes.
45986678|NCT00481286|Behavioral|Standard of Care|Standard of care for diabetes patients
45986679|NCT01313728|Drug|Dapsone plus Tretinoin Gel|Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks
45986680|NCT01313728|Drug|Tretinoin Gel|Tretinoin gel applied once daily to the assigned side of the face for 2 weeks
45986681|NCT05661370|Other|Dermloop Learn|Educational Mobile Application with a library of digital patient-cases and written learning modules the user can access on 36 common skin lesions, both benign and malignant.
45986682|NCT01248897|Other|This study is non-interventional study, so this section is not applicable.|This study is non-interventional study, so this section is not applicable.
45986683|NCT00481364|Drug|atorvastatin|atorvastatin 40 mg/day
46083516|NCT00923195|Drug|Fludarabine|Day -6 to -2: Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days
45986684|NCT00481364|Drug|placebo|1 tb/day
45986685|NCT05661331|Device|Transjugular intrahepatic portosystemic shunt|The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is indicated for use in the treatment of portal hypertension and its complications such as variceal bleeding and refractory ascites. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is a current generation of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion was designed to build on the success of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion allows for intraoperative diameter control to reach a targeted portal pressure gradient.
46083517|NCT00923195|Drug|Cyclophosphamide|Day -6 to -5: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna15 mg/kg/day over 1 hr X 2 days.
45986686|NCT00479960|Behavioral|commercially available omega-3 fatty acids supplementation|
45986687|NCT01249014|Other|Warmed fluids|IV fluids warmed by a Belmont fluid warmer
45986688|NCT01249014|Other|Fluid warmer and warming blanket|Warm are blown into a Bair hugger warming blanket covering the patient
45986689|NCT01249014|Device|Belmont fluid warmer|Belmont fluid warmer used to warm fluids
46083518|NCT00923195|Genetic|Anti-gp 100:154 TCR PBL|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14"
46083519|NCT00923195|Genetic|Anti-MART-1 F5 TCR PBL|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14"
45833054|NCT04763304|Other|Gown personal protective equipment (PPE-G) suit|Placement of PPE-G under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
45833055|NCT04763304|Other|Coverall personal protective equipment (PPE-C) suit|Placement of PPE-C under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
45833056|NCT00086346|Drug|Sirolimus (Rapamune)|
45833057|NCT00086346|Drug|Cyclosporine or Tacrolimus|
45833058|NCT03763032|Behavioral|Counseling|The patient navigator will provide educational materials, assessments, and counseling to the patients
45833059|NCT00085566|Drug|everolimus|
45833060|NCT00085566|Drug|gefitinib|
45986690|NCT01249014|Device|Bair hugger warming blanket|Bair hugger warming blanket laid on body
45986691|NCT01240460|Drug|XL765 (SAR245409)|Supplied as 10-mg and/or 50-mg capsules
45986692|NCT01240460|Drug|XL147 (SAR245408)|Supplied as 100-mg, 150-mg and/or 200-mg tablets
45986693|NCT01249170|Behavioral|First year program|Information on group that underwent new educational program
45986694|NCT01249170|Other|Control comparison|Information from group that did not undergo new first year program
45986695|NCT00479999|Drug|VRC-HIVADV027-00-VP|
45986696|NCT00479999|Drug|VRC-HIVADV038-00-VP|
45986697|NCT01249209|Device|lifestyle advice|
45986698|NCT00481442|Drug|Phenylephrine|
45986699|NCT01249248|Device|PD2i Analyzer|Analysis of heart rate variability from a standard digital ECG for 6-12 minutes
45986700|NCT00480038|Other|WHODAS II|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
45986701|NCT04697537|Drug|Ultrasound guided regional anesthesia|Applied perineurally preoperatively ultrasound guided regional anesthesia
45833061|NCT00085098|Biological|filgrastim|Given by infusion or injection
45833062|NCT00085098|Drug|carboplatin|Given IV over 1 hour
45986702|NCT04697537|Drug|Local infiltration analgesia|Applied in the wound intraoperatively from the orthopedics
45986703|NCT01249326|Other|bariatric surgery|This is a prospective longitudinal study of the effect of bariatric surgery on protein requirements and protein metabolism, and protein supplementation interest, appropriate to the digestive tract changes, for the mass and muscle function
45986704|NCT01313650|Drug|62.5/25mcg|GSK573719/GW64244
45986705|NCT01313650|Drug|62.5mcg|GSK573719
46083520|NCT04093791|Behavioral|"Collective Intervention G"|"The steps are:~Listening/establishing relationship. This step is characterized by listening and understanding the critical points from the new mothers. The operator maintains a nonjudgmental approach encouraging the women to describe the need for behavioral change.~Analysis. The situation must be carefully evaluated, considering the discomfort and emotional distress. The stress situation will be described in a subjective way and they will assign a grade of discomfort for each problem.~Assessment. The operator will carry out a multidimensional evaluation of the mothers within the dyad. The operator will evaluate the strategies implemented by the mothers to face problems and the reasons of the failures.~Summary and goal of the intervention. The problems detected by the operator will be explained and summarized to the participants. The operator explores ways to implement change."
45986706|NCT01313650|Drug|25mcg|GW642444
46083521|NCT04093791|Behavioral|"Individual Intervention I"|"The steps are:~Listening/establishing relationship. This step is characterized by listening and understanding the critical points from the new mother. The operator maintains a nonjudgmental approach encouraging the woman to describe the need for behavioral change.~Analysis. The situation have be carefully evaluated, considering the discomfort and emotional distress. The stress situation will be described in a subjective way, and she will assign a grade of discomfort for each problem.~Assessment. The operator will carry out a multidimensional evaluation of the mothers within the dyad. The operator will evaluate the strategies implemented by the mother to face problems and the reasons of the failures.~Summary and goal of the intervention. The problems detected by the operator will be explained and summarized to the participants. The operator explores ways to implement change."
46083522|NCT05117996|Other|capsule endoscopy|capsule endoscopy
46083523|NCT05117996|Other|standard small bowel preparation|2 L of polyethylene glycol and free residue diet the day before the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
45986707|NCT01313650|Drug|Placebo|Placebo
46083524|NCT05117996|Other|Simplified small bowel preparation|Liquid diet the evening before and water on the morning of the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
46083525|NCT02713932|Device|Transcatheter aortic valve implantation|
45986708|NCT02274909|Other|TRAINING PROGRAM|Sixty healthy elderly women were randomly divided into 3 groups: Pilates group (PG), PNF group (PNFG) and Control group (CG). Pilates and PNF groups underwent one-month training program with Pilates and PNF methods, respectively. CG received no intervention along the one month.
45986709|NCT04697615|Device|Algometry|The evaluation with the algometer was carried out in the same way by the two examiners, who held the instrument with the dominant hand, in order to adjust and coordinate the movements, while the non-dominant hand was used to stabilize the participant's skin, providing more security, avoiding thus small deviations. The pressure was applied at an angle of 90 ° (between the tool surface and the evaluated point), the rate of pressure increase was approximately 2 kg / cm² / s (kilogram per centimeter squared per second), up to the level that the participant reported a change in the sensation of pressure to a sensation of discomfort and immediately the examiner removed the device from the positioned location.
45986710|NCT00504114|Procedure|ACL Reconstruction Surgery|
45986711|NCT00504114|Procedure|Cartilage Resurfacing Surgery|
45986712|NCT00504114|Procedure|Total Knee Replacement|
46083526|NCT05342480|Other|EMDR and PE combined treatment|Daily program monday to friday with daily PE and EMDR sessions, physical activity between sessions, in vivo exposure treament and psychoeducational groups. Daily rotation of both EMDR and PE therapists. Multidisiplinary team attached to each pati
46083527|NCT04965857|Diagnostic Test|Hologic's Genius Digital Diagnostics System|Genius Digital Diagnostics is a digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
46083528|NCT02721888|Drug|Liraglutide|
46083529|NCT02721888|Drug|MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)|
46083530|NCT02721888|Biological|Blood sample|
46083531|NCT02721888|Other|Kinetic substudy (10 patients)|
46083532|NCT02784236|Device|telemedicine|The study population corresponds to patients> 18 and <65 years with DM1 of> 1 year of evolution, and treated with MDI HbA1c> 7%. It is changing one group of subjects between two observation times due to any intervention in this case the addition of a tele
45986713|NCT00481481|Drug|tacrolimus|immunosuppression
45986714|NCT04516317|Other|None (Observational study Group intravenous artesunate)|Retrospective descriptive study of Group intravenous artesunate
45986715|NCT04516317|Other|None (Observational study Group intravenous quinine)|Retrospective descriptive study of Group intravenous quinine
45986716|NCT02891239|Device|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wavelength of 785 nm that was added to the system
45986717|NCT02891083|Drug|Adjuvant chemotherapy (Paclitaxel and Cisplatin)|Adjuvant chemotherapy group: three cycles: (Paclitaxel: 175mg/m2 ivgtt, 3h, d1 4week × 3 and cisplatin: 75mg/m2 ivgtt, d1 4 week × 3)
45986718|NCT02891083|Radiation|Adjuvant radiotherapy|"Target: the upper mediastinum and bilateral supraclavicular region (Upper bound: thyrocricoid, lower bound: carina of 3cm)~Dose: 50Gy~Technology: strong tone~Segmentation: conventional segmentation 2Gy/d"
45986719|NCT02891083|Other|Control group (Surgery alone)|
45986720|NCT02890966|Drug|SHR4640|Day1~Day7:oral administration
45986721|NCT02890966|Drug|placebo|Day1~Day7:oral administration
45986722|NCT04515147|Biological|CVnCoV 6 μg|Participants will receive an intramuscular injection by needle in the deltoid area.
45986723|NCT04515147|Biological|CVnCoV 12 μg|Participants will receive an intramuscular injection by needle in the deltoid area.
46083533|NCT00753519|Device|Real iTBS|Real iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
46083534|NCT00753519|Device|Sham iTBS|Sham iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
46083535|NCT04256057|Drug|Magnesium Sulfate|After the induction of anesthesia, a loading dose of magnesium sulfate 50mg/kg in 100mL of isotonic saline as within 5 to 10 minutes(23) followed by a maintenance dose of 10 mg/kg/hr up to the end of surgery
45986724|NCT04515147|Biological|Hepatitis A vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
45986725|NCT04515147|Biological|Pneumococcal vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
45986726|NCT04515147|Biological|CVnCoV 12μg|Participants will receive an intramuscular injection by needle in the deltoid area.
45986727|NCT02890927|Other|Cardio-geriatric co-management|"A comprehensive geriatric assessment on admission will stratify patients in groups:~Low risk patients are expected to do well and will not receive co-management.~Medium risk patients are expected to develop complications. A geriatric nurse will visit the cardiology wards daily to co-manage these patients aiming to prevent complications by coordinating interdisciplinary care, implementing protocols, perform assessments and bedside education. The geriatric nurse will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning.~High risk patients have an acute geriatric syndrome. The geriatric nurse will visit the cardiology wards (see above), and a geriatrician will co-manage the acute geriatric syndrome(s). The geriatrician will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning."
45986728|NCT05644405|Diagnostic Test|FloTrac Vigileo|A dedicated transducer (FloTrac TM, Edwards Lifesciences, LLC, Irvine, CA, USA) was connected to the radial arterial line on one side and to the Vigileo System (Vigileo TM Edwards Lifesciences, LLC, Irvine, CA, USA) on the other side
45986729|NCT05661253|Drug|25 ml of bupivacaine 0.25% via serratus anterior block|patients will receive conventional serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia,
45986730|NCT05661253|Drug|25 ml of bupivacaine 0.25% via modified serratus anterior palne block|patients will receive modified serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia.
45986731|NCT02891005|Device|paclitaxel controlled release balloon catheter (VasoguardTM)|paclitaxel controlled release balloon catheter implantation for small vessel lesion
45986732|NCT02891005|Device|common balloon catheter (Maverick2)|common balloon catheter implantation for small vessel lesion
45986733|NCT02891044|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z44-040)
45986734|NCT00481559|Drug|Voraxaze (glucarpidase)|50 Units/kg in a bolus intravenous injection over 5 minutes
45986735|NCT00504816|Drug|GSK189075|Given with Brevicon to determine any effects of GSK189075 on Brevicon PK.
45986736|NCT00504816|Drug|Brevicon|Given with GSK189075 to determine if GSK189075 exerts an effect on GSK189075 PK.
45986737|NCT00623350|Other|Telephone|Acute Stroke consult by Telephone for the decision of tPA within 3 hours of symptom onset.
45986738|NCT00623350|Other|Two way audio/video telemedicine consult|Acute Stroke consult by two way audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
46083536|NCT05342324|Diagnostic Test|Optical coherence tomography angiography|To evaluate the vessel density in choriocapillary vascular networks, using optical coherence tomography angiography
46083537|NCT02721810|Behavioral|Consideration of 3-month functional prognosis|
46083538|NCT02598765|Procedure|Standard Trabeculectomy|Fornix-based trabeculectomy with a 3x4 mm scleral flap.
46083539|NCT02598765|Procedure|Microtrabeculectomy|Fornix-based trabeculectomy with a 2x2 mm scleral flap.
46083540|NCT05340218|Other|Speech analysis|Speech analysis to detect and monitor mild cognitive impairment
46083541|NCT04189302|Procedure|connective tissue graft harvest using KPM blade|after local anesthesia is injected, the surgical procedure is initiated with 15 C blade and the connective tissue graft is detached from epithelium and underlying periosteum. then the connective tissue is harvested with the help of 2 vertical and 1 horizontal incisions using KPM blade.
46083542|NCT04189302|Procedure|connective tissue graft harvest using 15 C blade|after local anesthesia is injected, the surgical procedure is initiated with 15 C blade and the connective tissue graft is detached from epithelium and underlying periosteum. then the connective tissue is harvested with the help of 2 vertical and 1 horizontal incisions using 15C blade.
45986739|NCT00480116|Biological|Adjuvanted Hepatitis B vaccine Lot 1|20 µg, IM, month 0 and 1
45986740|NCT00480116|Biological|Adjuvanted Hepatitis B vaccine Lot 2|20µg, IM, month 0 and 1
45986741|NCT00480116|Biological|Adjuvanted Hep B vaccine Lot 3|20µg, IM, month 0 and 1
45986742|NCT00504855|Other|Casting using Gortex (waterproof) cast padding materials|
45986743|NCT00504855|Other|Casting using cotton/cotton-poly cast padding materials|
45986744|NCT00481598|Procedure|magnet resonance spectroscopy|magnet resonance spectroscopy
45986745|NCT00504933|Drug|bilastine|20 mg (encapsulated) tablets QD/14days
45986746|NCT00504933|Drug|Cetirizine|10 mg (encapsulated) tablets. QD/14 days
45986747|NCT00504933|Drug|Placebo|(encapsulated) Tablets QD/14 days
45986748|NCT01313299|Biological|Botulinum toxin type A|500 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
45986749|NCT01313299|Biological|Botulinum toxin type A|1000 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
45986750|NCT01313299|Drug|Placebo|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
46083543|NCT02780726|Drug|roxadustat|Oral
46083544|NCT02598921|Radiation|three dimensional ultrasound|
46083545|NCT02598921|Device|Office hysteroscopy|
45986751|NCT00480155|Biological|Frozen FluMist®|Monovalent vaccine is supplied in intranasal sprayers containing 0.5 mL.
45986752|NCT00480155|Other|Placebo|
45986753|NCT00504972|Drug|hLL1|hLL1 administered intravenously once daily Monday through Friday for 2 consecutive weeks (10 total doses) at one of 4 planned dose levels: 1.5, 4, 6 or 8 mg/kg.
45986754|NCT01313221|Biological|etanercept|Administered by subcutaneous injection
45986755|NCT01313221|Drug|Topical agents|"Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following:~hydrocortisone 2.5%~betamethasone valerate 0.1%~betamethasone dipropionate 0.05%~clobetasol 0.05%~calcitriol~calcipotriol plus betamethsone dipropionate 0.05%"
45986756|NCT01313182|Drug|mupirocin calcium ointment, 2%|"Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.~After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares."
45986757|NCT01313182|Drug|3M Skin and Nasal Antiseptic|The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds.
45986758|NCT04516512|Biological|Blood draw|For each participants to the research a peripherical blood draw will be performed
45986759|NCT04512495|Other|Blood samples will be collected at two times :|"at Baseline,~after surgery or at the time of post-chemotherapy evaluation."
45986760|NCT00505050|Other|Disease Program Management|"This DMP inclused intervention content with education for out patients and caregivers; medication management with optimized therapy based on guidelines, and remote monitoring; delivery personnel with nurses, cardiologists, pharmacists, social workers, dietitians, physical therapists, psychologists; face-to-face individual/group communication, and telephone in-person; the intensity/complexity was long-term follow-up with 6 months interval repetitive education; the environment was hospital out-patient; and the outcomes measured were clinical, quality of life, and adherence.~After randomization patients undergone our multidisciplinary education sessions 60-minute long that covered the basic principles related to heart failure. Telephone calls were used to reinforce the contents of the sessions of the ambulatory education activity, and monitoring of the compliance/adherence, symptoms/signs of worsening heart failure, and self-control mechanisms."
45986761|NCT00480194|Drug|xylometazoline hydrochloride and ipratropium bromide (ZyComb)|Common cold in a real-life OTC setting
45986762|NCT00505089|Drug|ACZ885|
45986763|NCT00505089|Drug|ACZ885|
45986764|NCT00505089|Drug|ACZ885|
45986765|NCT00505089|Drug|ACZ885|
46083546|NCT02714010|Drug|EGFR-TKI|Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid
46083547|NCT02714010|Radiation|whole brain radiotherapy|30Gy/10F
46083548|NCT05340140|Diagnostic Test|deep learning model|deep learning model developed by computer science expert and based on convolution neural network , and trained by our datasets.
46083549|NCT00917241|Drug|MMI combined with IID|MMI titration regimen for 18 months,initial dosage of MMI was 20 mg/d,which combined with IID for 3 months.Dexamethasone was injected into the two side of thyroid, the dose of dexamethasone was 5 mg by every side, twice a week. The treatment strategy was changed to once a week at the second month and twice a month at the third month, the dose of dexamethasone was the same as the first month.
46083550|NCT00917241|Drug|MMI|MMI treatment with titration regimen for 18 months, initial dosage was 20 mg/d.
45833063|NCT00085098|Drug|cisplatin|Given IV over 6 hours
45833064|NCT00085098|Drug|cyclophosphamide|Given IV over 1 hour
45833065|NCT00085098|Drug|etoposide|Given IV over 2 hours
45833066|NCT00085098|Radiation|radiation therapy|Patients undergo radiotherapy 5 days a week
45833067|NCT00084864|Dietary Supplement|calcitriol|Given orally
46083551|NCT00919061|Drug|Gemcitabine|Gemcitabine: 800 mg/m^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
46083552|NCT00919061|Drug|Cisplatin|20 mg /m^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
46083553|NCT00919061|Drug|Sorafenib|400 mg PO once a day continuously.
46083554|NCT02716662|Dietary Supplement|Axona|medical powder, supplement food
46083555|NCT05106296|Drug|Ibrutinib|Ibrutinib will be taken by mouth once daily, on days 1-21 of each treatment cycle.
46083556|NCT05106296|Drug|Indoximod|Indoximod will be taken by mouth twice daily, throughout each treatment cycle.
45833068|NCT00084864|Drug|dexamethasone|Given orally
45833069|NCT00084864|Other|clinical observation|No intervention before surgery
45833070|NCT03487302|Other|Brain MRI|Acquisition of 3D T1-weighted, 3D FLAIR and GRE brain MRI scans
45986766|NCT00481715|Behavioral|Web-Based Weight Loss Program|Participants will take part in a Web-based weight loss program.
45986767|NCT00481715|Behavioral|Cash Incentive Weight Loss Program|Participants will take part in a cash incentive weight loss program.
45986768|NCT00505128|Procedure|Endoscopic sphincterotomy|procedure
45986769|NCT00505167|Drug|Memantine|Patients randomized to receive either memantine or donepezil
45986770|NCT00505167|Drug|Donepezil|Patients randomized to receive either memantine or donepezil
45986771|NCT00480272|Drug|adalimumab, plus prednisone|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo or prednisone 50 mg/po day then reduced to 6.25/po day
45986772|NCT00480272|Drug|adalimumab plus placebo|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo daily for 6 months
45986773|NCT04513041|Procedure|Pinhole surgical technique and tunnel technique in a split mouth design|Each subject will have the each surgical procedure which are both considered routine minimally invasive clinical care for gingival recession. Gum recession on one side will receive Pinhole surgical technique (test procedure). The other side will receive Tunnel technique (control procedure), Research component involved is the capture of digital impression using intra-oral scanner in the baseline (preoperative) and the final visit (6 months postoperative).
45986774|NCT04517058|Other|psychology therapy|If the symptoms are mild, patients will get the psychology therapy. If it's necessary according to patients' willings, patients will be given SSRIs antidepressant therapy.
45986775|NCT00480311|Other|WHODAS II (World Health Organization Disability Assessment Schedule II)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
45986776|NCT04519788|Drug|AT-301B|Nasal Spray
45986777|NCT04519788|Drug|AT-301A|Nasal Spray
45986778|NCT00480350|Behavioral|rice based food supplement|
45986779|NCT04519593|Procedure|Laparoscopic myomectomy with prior temporary uterine blood supply occlusion|Visualization and temporary bilateral clipping of uterine/internal iliac arteries and suspensory ligaments of ovaries.
45986780|NCT04519593|Procedure|Conventional laparoscopic myomectomy|Laparoscopic myomectomy without prior temporary uterine blood supply occlusion
45986781|NCT00480389|Drug|Sorafenib|Starting dose: 400 mg (2x200mg tablets) BID (total= 800mg/day) taken orally. The dose can be adjusted as per investigator if required due to toxicity (ex. 200mg BID, 200mg QD). Study drug is taken for 12 weeks preoperatively. Patients restart on study drug 6 weeks postoperatively and continue until progression or unacceptable toxicity occurs.
46083557|NCT05106296|Drug|Cyclophosphamide|Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
45986782|NCT04519554|Device|Endometrial sampling|Endometrial sampling with 2 different forceps
45986783|NCT04519710|Biological|o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B|to receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
45986784|NCT00482027|Biological|tgAAC09|one or 2 doses of AAV-2 HIV vaccine (tgAAC09) at 3 dosage levels, dose escalation and dose optimization
45986785|NCT02275455|Behavioral|real life situations|Four phases will be carried out on autism participants and aged-marched controls: 1) 24-hour baseline pre-experiment (physical activity, sleep), 2) 2-hour in real life situation, 3) 30-minute in a quiet environment, interrupted by a few seconds stressful sound, 4) an interview to get comments and feelings about events that triggered anxiety. Autism and control participants will be together for phases 2 and 3, revealing different physiological responses to the same situations, and thus identifying potentially problematic events.
45986786|NCT03272243|Procedure|short segment posterior spine fixation|
45986787|NCT03272243|Procedure|long segment posterior spine fixation|
45986788|NCT03270137|Device|repetitive transcranial magnetic stimulation- IDLPFC|Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC). Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC) compared to six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex [rDLPFC]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
45986789|NCT03270137|Device|repetitive transcranial magnetic stimulation - Six regions|Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered on six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex [rDLPFC]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
45986790|NCT04519398|Genetic|Complete thrombophilic profile testing by multiplex PCR|"Complete thrombophilic profile testing by multiplex PCR and reverse hybridization of DNA to assess the presence of prothrombotic genotypes:~Factor V Leiden~Factor V 4070 A>G (Hr2)~Factor II G20210A~Methylenetetrahydrofolate reductase (MTHFR) C677T~MTHFR A1298C~Cystathionine β-synthase (CBS) 844ins68~PAI-1 4G/5G~Glycoprotein IIIa T1565C (HPA-1a/b)~ACE-DEL/INS~Apolipoprotein E (ApoE)~AGT M235T~Angiotensin II type 1 receptor (ATR-1) A1166C~Fibrinogen - 455 G>A~Factor XIII Val34Leu"
45986791|NCT00482066|Drug|Abatacept (Orencia)|"500mg for patients under 60kg 750mg for patients 60-100kg~1g for patients>100kg given as i.v. infusion over 30 minutes at day 0, 14, 28 and then monthly for a further 11 months 914 infusions in total) placebo groups receive saline only I.v."
45986792|NCT04519047|Biological|PRP|Beginning on treatment period, subjects will receive either Rejoint Gel or normal saline with PRP intra-articular injection twice for one month (Visit 3 and 4).
45986793|NCT00482105|Other|EGIR Tape|Tape stripping is a non-invasive method that allows the recovery of cells
46083558|NCT05106296|Drug|Etoposide|Etoposide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
46083559|NCT02598687|Drug|TH-302|TH-302 day 4 (pre-treatment) and weekly during chemo-radiotherapy (CRT)
45673431|NCT01514422|Drug|Minocycline|Minocycline 100 to 300mg per day for 8 weeks
45833071|NCT03487302|Other|Neuropsychological test battery|"Mini Mental State Examination (MMSE), Measso et al. (1993);~Frontal Assessment Battery (FAB), Appollonio et al. (2005);~Symbol Digit Test, Amodio et al. (2002);~Digit Cancellation Test, Della Sala et al. (1992);~Trial Making Test (TMT A-B), Giovagnoli et al. (1996);~Weigl's Sorting Test, Laicona et al. (2000) and Inzaghi (2010);~Digit Span, Orsini et al (1987);~Corsi block-tapping test, Orsini et al. (1987);~Babcock story recall test, Carlesimo et al. (2002);~Phonemic verbal fluency in MDB, Caltagirone and Carlesimo (2010);~Semantic verbal fluency, Novelli (1986);~Imitating gestures, De Renzi et al. (1980);~Coloured Progressive Matrices (CPM47), Measso et al. (1993)."
45833072|NCT01677702|Dietary Supplement|Yili Lactoferrin ShuHua Milk (Lactoferrin 5mg/100ml)|Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
45833073|NCT01677702|Dietary Supplement|Yili Lactoferrin ShuHua Milk (Lactoferrin 10mg/100ml)|Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
45833074|NCT01677702|Dietary Supplement|Recombined low protein milk|Total 250ml of placebo milk will be taken once a day at 10am daily during the 84 day intervention.
46083560|NCT02598687|Other|HX4 scan|HX 4 scan day 1 and day 8
46083561|NCT02598687|Drug|Carboplatin|2mg/ml/min
46083562|NCT02598687|Drug|Paclitaxel|50 mg/m2
46083563|NCT02598687|Radiation|Radiotherapy|23 x 1.8 Gy
46083564|NCT02598687|Procedure|surgery|minimally invasive transhiatal approach including a one-field node dissection or transthoracic approach with a two-field lymph node dissection
46083565|NCT04880447|Biological|BNT162b2|COMIRNATY is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each). It is recommended to administer the second dose 3 weeks after the first dose.
45986794|NCT04519242|Procedure|Surgery|"ORIF will be done by using bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS). For fixation TMT4 and/or TMT5 K-wires (1.6 or 2.0mm) can be used instead.~PA will be done by removal of articular surface and subsequent stabilization with bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS).~Type and sequence of fixation of the involved rays as needed, partial or complete fixation as needed, judgement by treating surgeon."
45986795|NCT00482144|Procedure|PDL 450 microseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
45986796|NCT00482144|Procedure|PDL 1.5 milliseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
45986797|NCT04519359|Other|Stop NAs therapy|Stop NAs therapy
45673432|NCT03027700|Device|MRI|MRI scan performed on 1.5T Philips Ingenia MRI scanner.
45673433|NCT01513330|Device|SenSura Mio|Ostomy product - 1 piece closed bag
45673434|NCT01513330|Device|Standard Care|Ostomy product 1 piece closed bags. Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima.
45673435|NCT04415775|Other|Game based treadmill Program|Participants will be expected to play several cognitive computer games while standing on a sponge pad (10-min warm-up and while walking on the treadmill at your self-selected comfortable speed. (Dual-task treadmill training). This would be done in intervals of 2-4 min with rest periods for a total time of 35 minutes Treadmill speed and the difficulty level of the cognitive games will progress depending on participant performance and comfort level.
45986798|NCT00482183|Drug|Pioglitazone|
45986799|NCT04518774|Biological|Ex-vivo expanded allogeneic γδT cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
45986800|NCT01312909|Drug|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
45673436|NCT04415775|Other|Conventional Gait Rehabilitation|Participants will undergo a mixture of current gait training programs available for people with Parkinson's Disease. The protocol will be a Warm-up exercise consisting of rhythmical large movements (10 minutes), as well as video game practice while standing (i.e., single-task; 10 minutes). Treadmill walking in intervals of 2-4 minutes with rest periods. Walking over the ground while negotiating through obstacles. (10 minutes) The speed of the treadmill will be progressed gradually and as tolerated.
46083566|NCT04229810|Procedure|STD-02|Conventional standardized ventilatory approach.
46083567|NCT04229810|Procedure|iOLA-iHFNC|Indivudualized perioperative open lung ventilatory approach.
46083568|NCT04090281|Genetic|CYP2C19 genotyping|Upon hospital discharge, patients will undergo CYP2C19 genotyping to guide initial P2Y12 inhibitor selection. At 14 days, post discharge, patients will undergo on treatment platelet reactivity phenotyping to further guide deescalation of P2Y12 inhibitor therapy
46083569|NCT02713620|Biological|recombinant HBV vaccine (Hepavax-Gene® Berna, Korea)|Different HBV vaccine regimen in each group
45673437|NCT05110911|Biological|Influenza vaccination: Fluarix Tetra, Vaxigrip Tetra, Fluquadri, Fluad Quad, Afluia Quad, Flucelvax Quad|Influenza vaccine made available to healthcare workers at the participating healthcare sites, as part of their free vaccination campaigns for healthcare workers.
46083570|NCT05338190|Drug|Combination of Rituximab with subcutaneous belimumab|Belimumab 200 mg subcutaneous weekly (i.e., every 7 days ±1 day) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
46083571|NCT05338190|Drug|Combination of Rituximab with subcutaneous placebo|Placebo subcutaneous weekly (i.e., every 7 days ±1 day starting from day 0) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
45673438|NCT05110911|Biological|SARS-CoV-2 vaccination: Comirnaty or Vaxzevria|SARS-CoV-2 vaccine made available to healthcare workers at the participating healthcare sites, as part of their free vaccination campaigns for healthcare workers.
45673439|NCT01524796|Other|No intervention. Non-interventional study|No intervention. Non-interventional study
45673440|NCT01547728|Drug|Recombinant antithrombin (rhAT)|Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
45673441|NCT01523392|Drug|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
45673442|NCT01523392|Drug|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
45833075|NCT01677780|Drug|RO5045337|Participants will receive RO5045337 orally in doses ranging from 20 milligram per square meter (mg/m^2) to 1800 mg/m^2 daily, and up to 1500 mg dose twice daily on a variety of schedules including daily for up to 20 days and weekly dosing for 3 weeks in 28 day cycles until disease progression or unacceptable toxicity with maximum treatment duration of 24 months.
45833076|NCT05346978|Dietary Supplement|Nasturtium (Tropaeolum majus)|Freeze dried nasturtium (Edible flower)
45833077|NCT05346978|Dietary Supplement|Placebo|collagen colored with green pigment used in the food industry
45833078|NCT03485196|Other|Microsatellite instability|The microsatellite instability status are definite to three type:MSI-H, MSI-L,and MSS. The gastric cancer patients who received D2 resection were included in 3 groups：MSI-H group， MSI-L group，and MSS group. All patient must be accept fluorouracil(5-FU) based adjuvant chemotherapy. We will analyze the relationship between MSI status and efficacy of 5-FU based adjuvant chemotherapy by observing the survival period of patients with different MSI status.
46083572|NCT02598609|Behavioral|Education program for NICU caregivers|"standardized educational program : learning how to retrospectively analyze causes of a medical error in the NICU in order to prevent it (compulsory)~implementation of a central line maintenance bundle and checklist, of a central line insertion bundle and checklist and of a daily goals bundle and checklist. (compulsory)~poster for prevention of extravasation injuries"
45986801|NCT01312909|Drug|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
45986802|NCT01312909|Drug|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
45986803|NCT00482222|Biological|cetuximab|
45673443|NCT01512160|Drug|PF-04531083|2000 mg oral solution
45986804|NCT00482222|Drug|capecitabine|
45986805|NCT00482222|Drug|fluorouracil|
45986806|NCT00482222|Drug|leucovorin calcium|
45673444|NCT01512160|Other|Placebo|Placebo tablets for Ibuprofen
45673445|NCT01512160|Drug|PF-04531083|1000 mg oral solution
45986807|NCT00482222|Drug|oxaliplatin|
45986808|NCT00482222|Other|study of socioeconomic and demographic variables|
45986809|NCT00482222|Procedure|adjuvant therapy|
45986810|NCT00482222|Procedure|neoadjuvant therapy|
45986811|NCT00482222|Procedure|quality-of-life assessment|
46083573|NCT04908605|Drug|Mirtazapine|Every patient will be given mirtazapine 30 mg tablet
46083574|NCT04908605|Drug|Melatonin|Every patient will be given melatonin 5 mg tablet
46083575|NCT04908605|Drug|Placebo|Every patient will be given a matching placebo tablet
45673446|NCT01512160|Other|Placebo|Placebo tablets for Ibuprofen
45673447|NCT01512160|Drug|Ibuprofen|2 x 200 mg tablets
45833079|NCT01473108|Drug|Finerenone (BAY 94-8862) PEG solution|2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862
45833080|NCT01473108|Drug|Finerenone (BAY 94-8862) immediate release tablet|20 mg BAY 94-8862 administered as 2 x 10 mg IR tablets
45986812|NCT04518813|Device|Prototype 0.5|Investigational Medical Device collecting Raman data from tissue
45986813|NCT01312129|Drug|Sulfasalazine|500mg capsules of Sulfasalazine x 3 doses 12 hours apart.
45986814|NCT01312129|Drug|Placebo|Placebo capsule x 3 doses 12 hours apart
45986815|NCT00480467|Drug|SAM-315|
45986816|NCT04518852|Combination Product|TACE combined with sorafenib and PD-1 mAb|the combination of local therapy (TACE), anti-angiogenic therapy (sorafenib), and immunotherapy (PD-1 monoclonal antibody)
46083576|NCT04229732|Device|ClearMateTM|Passive isocapnic hyperventilation breathing circuit.
45986817|NCT02955615|Drug|ILT-101|"Induction phase followed by weekly administrations of ILT-101 on top of SLE background therapy.~SLE background therapy includes ..."
46083577|NCT02716740|Dietary Supplement|Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week|After 3 months of obesity-surgery, if patients lost more than 15% of muscular weight, they will take a leucine-enriched amino acid supplementation during 3 months added with a regular physical training (30 minutes, 3 times/week). Arm A will take 2.46g/day of leucine-enriched amino acid supplementation and arm B 4g/day.
45673448|NCT01512160|Other|Placebo|Placebo solution for PF-04531083
45673449|NCT01512160|Other|Placebo|Placebo solution for PF-04531083
45673450|NCT01512160|Other|Placebo|Placebo tablets for Ibuprofen
45673451|NCT01546168|Device|esophageal deviation with IDE device|esophageal deviation during AF ablation
45673452|NCT01901289|Device|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
45673453|NCT01950741|Drug|aflibercept|Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.
45673454|NCT01950273|Drug|BI 695500|BI695500, once a week for 4 weeks (4 administrations in total)
45673455|NCT01950273|Drug|MabThera|MabThera, once a week for 4 weeks (4 administrations in total)
45676685|NCT02048072|Drug|Gilenya|Autonomic testing during first dose administration of Gilenya.
45676686|NCT02047604|Drug|SAN-300 0.5 mg/kg QW|
45676687|NCT02047604|Drug|SAN-300 1.0 mg/kg QW|
45676688|NCT02047604|Drug|SAN-300 2.0 mg/kg QOW|
45676689|NCT02047604|Drug|SAN-300 4.0 mg/kg QOW|
45676690|NCT02047604|Drug|SAN-300 4.0 mg/kg QW|
45676691|NCT02047604|Drug|Placebo|
45833081|NCT01473108|Drug|Eplerenone (Inspra®)|Single oral dose of 50 mg eplerenone
45833082|NCT01473108|Drug|Placebo|Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step
45833083|NCT03541512|Behavioral|Mindfulness + Education|"Women in the mindfulness + education group will be asked to meditate daily, 10 minutes a day for the first 4 weeks with the option to increase their time to 20 minutes daily during the second 4 weeks. Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health."
45986818|NCT02955615|Drug|Placebo|"Induction phase followed by weekly administrations of placebo on top of SLE background therapy.~SLE background therapy includes ..."
45986819|NCT01311661|Drug|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
45986820|NCT01311661|Drug|Olodaterol low daily dose twice daily|Inhaled Olodaterol medium daily dose administered as low dose twice daily
45986821|NCT01311661|Drug|Olodaterol medium daily dose twice daily|Inhaled Olodaterol high daily dose administered as medium dose twice daily
45986822|NCT01311661|Drug|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
45986823|NCT01311661|Drug|Olodaterol high daily dose once daily and placebo|Inhaled Olodaterol high daily dose administered as one full dose once daily and placebo once daily
45986824|NCT01311661|Drug|Olodaterol medium daily dose once daily and placebo|Inhaled Olodaterol medium daily dose administered as one full dose once daily and placebo once daily
45986825|NCT04518735|Other|Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19|Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy
45986826|NCT00482261|Drug|Lenalidomide|15mg daily, days 1-21 of a 28 day cycle for 4 cycles. Patients who get stable disease or better will then receive 15mg on days 1-21 from cycle 5 onwards
45986827|NCT00482261|Drug|dexamethasone|20mg day 1-4, 9-12, 17-20 for 4 cycles. Patients who get stable disease or better will then get dexamethasone 20mg on days 1-4 of a 28 day cycle, from cycle 5 onwards
45986828|NCT00482261|Drug|aspirin|100mg/day
45986829|NCT04518618|Drug|Fentanyl|Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and 25 ugs fentanyl (0.5 ml)
45986830|NCT04518618|Drug|Naloxone|Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and fentanyl 25 ug combined with 20 ugs naloxone in 0.5 ml
45986831|NCT00480584|Drug|gemcitabine|Levels 1 through 4: 1000 mg/m^2
45986832|NCT00480584|Drug|capecitabine|Level 1: 500 mg/m^2; Level 2: 825 mg/m^2; Level 3: 1000 mg/m^2; Level 4: 1250 mg/m^2
45986833|NCT00480584|Drug|erlotinib|Levels 1 through 4: 100 mg
45986834|NCT01311505|Drug|Myrin© 2 (Rifampicin + Isoniazid)|Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg
45986835|NCT01311505|Drug|Rimactane® (Rifampicin)|One (1) capsule of Rifampicin 300 mg
45986836|NCT05644366|Other|Postural Control Balance Assessment|Postural Stability Testing Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks.
45986837|NCT05644327|Behavioral|Cardiovascular training (CT)|12 weeks of CT
45986838|NCT05644327|Behavioral|Resistance training (RT)|12 weeks of RT
45986839|NCT05644327|Behavioral|Multimodal training (MT)|12 weeks of MT
46083578|NCT05330117|Procedure|TENS|"This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (procedure typically will take from 5-15 minutes). The TENS units have pre-program settings improving convenience, reproducibility and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject."
45833084|NCT03541512|Behavioral|Education|"Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health."
45833085|NCT00084318|Biological|cetuximab|400 mg/m^2 intravenously over 120 minutes on day 1 (week 1) followed by 250 mg/m^2 intravenously over 60 minutes in weeks 2 through 7.
45833086|NCT00084318|Drug|cisplatin|30 mg/m^2 intravenously infused over over 60 minutes in weeks 2 through 7.
45833087|NCT00084318|Drug|docetaxel|15 mg/m^2 intravenously infused over 30 minutes in weeks 2 through 7.
45833088|NCT00084318|Radiation|radiation therapy|60 Gy (2 Gy once a day, 5 times a week)
45986840|NCT01240538|Biological|wild-type reovirus|Given IV
45986841|NCT01240538|Drug|cyclophosphamide|Given PO
45986842|NCT01240538|Other|laboratory biomarker analysis|Correlative studies
45986843|NCT01240538|Other|pharmacological study|Correlative studies
45986844|NCT04518579|Procedure|thoracic epidural|undergo insertion of an epidural catheter, between T9 and T11 in patients undergoing left-sided resections and between T8 and T10 in patients undergoing right-sided resections
45986845|NCT01310803|Drug|VALSTAR - Maintenance Therapy|Treatment phase - 10 monthly intravesical installations starting 10 to 12 weeks after the beginning of induction. Follow-up phase
45986846|NCT01310803|Other|No Maintenance treatment ( Standard of Care)|Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
45986847|NCT01240577|Drug|IPdR|
45986848|NCT04518540|Drug|lipoic acid group|"The patients will take lipoic acid for 6 course, the first course of treatment is 14 days with 14 days of rest, and the following course is the first for 10 days, with 14 days interval.The patients will use 600mg domestic lipoic acid in 250ml normal saline by intravenous, once a day.~At the same time, the patients will take domestic riluzole tablets 50mg orally, twice a day."
45833089|NCT00084084|Drug|Agalsidase alfa|0.2 mg/kg agalsidase alfa administered by IV infusion over 40 (+/- 10) minutes every other week for 52 weeks, with periodic reassessments for study continuation beyond 52 weeks
45833090|NCT00083616|Biological|Panitumumab|Panitumumab 6 mg/kg every once 2 weeks weeks administered by intravenous (IV) infusion.
45833091|NCT04402710|Behavioral|Self-compassion|Six week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes
45986849|NCT04518540|Drug|control group|The patients will take domestic riluzole tablets 50mg orally, twice a day.
45986850|NCT00480623|Drug|Satraplatin plus radiation therapy|
45986851|NCT00505323|Device|Implantation of neurostimulators and their auxiliary components|"Implantation neurostimulators and their auxiliary components :~Stimulateur KINETRA TM modèle 7428, Electrode Resume II modèle 3587A, Extension kit DBS 7482"
45986852|NCT01240655|Drug|LCL161|
45986853|NCT01240655|Drug|Paclitaxel|
45986854|NCT01240031|Other|Individualised nutritional therapy|"Nutritional therapy as based on previous results of the project on patient meal experiences and preferences (note citations below) and comprising of:~Thorough sensory and nutrition assessment (questionnaire).~Nutrition plan adjusted daily according to the assessment.~Serving appetising, energy- and protein-dense meals, snacks and drinks."
45986855|NCT01240031|Other|Usual nutrition care|Nutritional therapy according to current practice and general nutrition advice.
45986856|NCT04518189|Drug|lidocaine patch|lidocaine patch applied 3 hours before the procedure
45986857|NCT04518189|Drug|Sham patch|Sham patch applied 3 hours before the procedure
45986858|NCT00482300|Procedure|Systematic pelvic lymphadenectomy|
45986859|NCT00505401|Biological|recombinant HIV-1 Tat protein|
45986860|NCT00505440|Behavioral|Telephone case management and motivational interviewing|'Telephone case management and motivational interviewing': Immediate screening results are given to the physician during the patient's visit. Telephone case management and motivational interviewing (MI) at 1, 6, and 9 weeks to enhance engagement and commitment to change
45986861|NCT00505440|Behavioral|Usual care|Usual care with mailed screening results
45986862|NCT00482378|Drug|Pamidronate|90 mg by IV monthly.
45986863|NCT00482378|Drug|Zoledronic acid|4 mg by IV monthly.
45986864|NCT00482378|Radiation|Sm 153 lexidronam|0.5 mCi/kg or 1 mCi/kg by IV.
45986865|NCT04517955|Device|Transcatheter Aortic Valve Implantation (TAVI)|Transcatheter Aortic Valve Implantation with Evolut R or Evolut Pro
45986866|NCT00480818|Drug|SAM-531|
45986867|NCT01310413|Biological|Influenza A (H5N1) Virus monovalent vaccine|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
45986868|NCT01310413|Biological|Saline placebo|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
45986869|NCT02275572|Procedure|Pharmacist Intervention|
45986870|NCT00482417|Drug|MK0359|
45986871|NCT02275689|Procedure|Arthroscopic acromioplasty|Surgical intervention With arthroscopic acromion resection
46083579|NCT05330117|Procedure|Control TENS|"This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (procedure typically will take from 5-15 minutes). The TENS units have pre-program settings improving convenience, reproducibility and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject."
45833092|NCT04402710|Behavioral|Control Group|Six week behavioural change program aimed to increase physical activity plus information on general health topics.
45833093|NCT00083226|Drug|doxorubicin|Given IV
45833094|NCT00083226|Drug|bortezomib|Given IV
45833095|NCT05346510|Procedure|ALND Group|ALND is performed in patients with positive axillary lymph nodes on CT scan and on AAUS. pALND is performed in patients with negative axillary lymph nodes on CT scan but positive on AAUS.SLNB will be performed for those with negative axillary lymph nodes on CT scan and on AAUS.
45833096|NCT00082758|Biological|hu14.18-Interleukin-2 fusion protein|Given IV
45986872|NCT02275689|Procedure|Microtenotomy|Arthroscopic radiofrequency microtenotomy of rotator cuff tendon
45986873|NCT00482456|Drug|Nitrous oxide|
45986874|NCT00480896|Drug|tacrolimus ointment|Topical application
45986875|NCT00480896|Drug|Placebo ointment|Topical application
45986876|NCT01309828|Drug|Azilsartan medoxomil and chlorthalidone|Fixed-dose combination tablets.
45986877|NCT01309828|Drug|Olmesartan medoxomil and hydrochlorothiazide|Fixed-dose combination tablets.
45986878|NCT00482820|Behavioral|attention-bias training|one group recive an attention training away from threat. The second group, the controll group, recive a placebo training
45986879|NCT00482495|Biological|bevacizumab|
45986880|NCT00482495|Genetic|gene expression analysis|
45986881|NCT00482495|Genetic|protein expression analysis|
45986882|NCT00482495|Other|laboratory biomarker analysis|
45986883|NCT00480935|Drug|Sunitinib Malate (Sutent)|Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 1 week washout period. The dosage may change during the cycle due to possible drug toxicities. The nephrectomy will then take place following a one-week washout period.
45986884|NCT02955264|Dietary Supplement|D-Galactose|D-Galactose is an oral powdered dietary supplement to be taken by mouth.
45986885|NCT00480974|Other|Clinical follow up and laboratory analysis|Clinical follow up and laboratory analysis
45986886|NCT04518150|Device|Bakri balloon|the Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
45986887|NCT04518150|Procedure|Bilateral Uterine Artery Ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
45986888|NCT00482573|Procedure|Dental local anesthesia|"2% lidocaine solution with epinephrine 1:100,000~infusion of 1,8 mL (one cartridge)~Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)"
45986889|NCT00482573|Procedure|Dental local anesthesia|"2% lidocaine solution without vasoconstrictor~infusion of 1,8 mL (one cartridge)~Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)"
45986890|NCT00482898|Drug|MK0359|
45986891|NCT00482937|Drug|CD-NP|
45986892|NCT00482651|Radiation|Multidetector computed tomography scanning|contrast Multidetector CT-scanning
45986893|NCT00482651|Procedure|Coronary angiography (CAG)|CAG and if necessary PCI. Included patients are already assigned for CAG
45986894|NCT00482651|Procedure|Intravascular ultrasound|During CAG Intravascular Ultrasound will be performed in the three coronary arteries
45986895|NCT00482651|Procedure|Blood sample|a blood sample at baseline after 3 months and at the end of the follow up (after 12 months)
45986896|NCT00482976|Drug|Ruboxistaurin|
45986897|NCT00482976|Drug|Placebo|
45986898|NCT00481013|Drug|Valproic Acid (VPA)|Drug: Valproic Acid and Levocarnitine; capsules
45986899|NCT00481013|Drug|Placebo|For six months, pts are randomized into placebo or treatment. After 6 months, all pts are on treatment
45986900|NCT00483015|Behavioral|smoking|
45986901|NCT00482768|Behavioral|Practice Facilitation|Clinics in the experimental arm will meet with a trained facilitator to work on change strategies that will improve risk factors for diabetes complications.
45986902|NCT01309243|Drug|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen administered orally once daily with a meal
45673456|NCT01919307|Other|Auricular acupuncture|The NADA Protocol for auricular acupuncture will be performed by the PI, a certified NADA protocol practitioner, using sterile, single-use, Seiren 0.22mm, one cm disposable detox needles. Both ears will be sterilized with alcohol swabs. There will be no electrical or other stimulation performed. Needles will be placed subcutaneously with one half twirl upon insertion to the following 5 points (in order per ear): Sympathetic, Shen Men, Kidney, Liver, Lung. Needles will remain in place for 40 minutes and will then be removed in the same order as they were inserted. Needles that become dislodged will be replaced per typical NADA protocol.
45986903|NCT01309243|Drug|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/FTC 200 mg/TDF 300 mg single-tablet regimen administered orally once daily on an empty stomach, preferably at bedtime
45986904|NCT01240070|Other|Intensive care|Intensive multi-factorial treat-to-target intervention program designed according to international guidelines
45986905|NCT04517409|Procedure|Goal-directed hemodynamic therapy|Eligible patients were equally randomized into two study groups: 1) Standard perioperative (Control group ) and 2) hemodinamic management based using radial artery pulse contour analysis (GDHT group). Randomization was performed the day before surgery by the study member responsable for anesthesia delivery using sealed opaque envelope technique stored in non-transparent containers with group allocation in a 1:1 ratio. Only patients were blinded to group allocation. Care providers and investigators could not be blinded due to the presence of the cardiac index trending monitor
45986906|NCT04517409|Procedure|Control|"Before hepatic resection (Static phase) all patiens received continuous infusion of balanced crystalloid with the goal of CVP of 5 mmHg.~After hepatic resection (Dynamic phase), the patiens received colloid solution, vasopressors, and inotropes at the discretion of the anaesthetist, acording to CVP, MAP and orine output. In this group, CO monitoring was not performed. Intraoperative treatment goals in the control arm were flexible to avoid both extremes of clinical practice and practice misalignment."
45986907|NCT01240109|Drug|Remifentanil|"propofol group : propofol effect site-TCI 2-4mcg/ml + remifentanil effect site-TCI 2-4ng/ml~sevoflurane group: sevoflurane end-tidal concentration 0.5-1.0 MAC + remifentanil effect site-TCI 2-4ng/ml"
45986908|NCT04517526|Drug|pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT|pemetrexed (500 mg/m2/d1) + cisplatin/carboplatin (20-25 mg/m2 × 3 days/AUC 5) + bevacizumab (7.5 mg/kg) + durvalumab (10 mg/kg) every 3 weeks for 4 to 6 cycles after informed consent, followed by bevacizumab and/or durvalumab anti-maintenance therapy until the emergence of what the investigator considers to be treatment-related toxicity or disease progression in the patient, followed by stereotactic radiotherapy to appropriate oligometastatic or oligoprogressive sites.
45673457|NCT01919229|Drug|LEE011 (ribociclib)|Ribociclib was supplied in 200 mg hard gelatin capsules for oral use.
45833097|NCT01678014|Procedure|Deep Brain Stimulation(DBS)|Deep Brain Stimulation(DBS)is a neurosurgical procedure which include the implantation of deep brain electrodes and the connect to an implantable pulse generator (IPG) that is implanted below the collarbone.
45833098|NCT01678014|Procedure|Capsulotomy|
45833099|NCT04403178|Diagnostic Test|Radiographic examination with a Migration of > 40 %|Radiographic examination
45986909|NCT01309204|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension|
45986910|NCT01309204|Drug|Vehicle|Inactive ingredients used as a placebo for masking purposes
45986911|NCT01309204|Drug|Brinzolamide 1% ophthalmic suspension|
45986912|NCT01309204|Drug|Brimonidine tartrate 0.2% ophthalmic solution|
45673458|NCT01919229|Drug|letrozole|Letrozole was supplied in 2.5mg tablets for oral use.
45673459|NCT04626375|Drug|Bioarginine|In the Bioarginine group the partecipants take bioarginine (2 vials per os of 1.66 g every 12 hours) for 4 week
45986913|NCT01309165|Behavioral|CO-OP|CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10-session intervention format. The client and the therapist work together, using the Canadian Occupational Performance Measure (COPM), to select 3 skills and establish baseline skill performance. In the second meeting, when CO-OP actually begins, the approach is introduced to the client and the global cognitive strategy (GOAL-PLAN-DO-CHECK) is learned. In all subsequent sessions this strategy is used as the main problem-solving framework to facilitate skill acquisition.
45986914|NCT01309165|Behavioral|Standard Occupational Therapy|Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
45986915|NCT00482807|Drug|bicalutamide|
45986916|NCT00482807|Drug|docetaxel|
45986917|NCT00482807|Drug|goserelin|
45986918|NCT00482807|Radiation|intensity-modulated radiation therapy|
45986919|NCT01308853|Device|Macrolane|Device: Macrolane Treatment: Initial injection (incl touch-up) of a maximum of 120 ml/breast.
45986920|NCT02890888|Other|hyperbaric oxygen treatment|Patients are treated in a hyperbaric oxygen chamber for 1 hour at 2ATA, 10 times over 2 consecutive weeks, 5 times per week
45986921|NCT04517331|Procedure|Thoracic paravertebral block-single injection|The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
45986922|NCT04517331|Procedure|Thoracic paravertebral block-double injection|The blocks were performed at both T2-T3 and T4-T5 levels bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
45986923|NCT01240148|Drug|AZD3161|Single dose, intradermal injection
45986924|NCT01240148|Drug|Lidocaine|Single dose, intradermal injection
45986925|NCT01240148|Drug|AZD3161 Placebo|
45673460|NCT04626375|Drug|Placebo oral tablet|In the Placebo group the participants take bio-arginine (2 vials per os of 1.66 g every 12 hours) for 4 week
45673461|NCT01901055|Device|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
45986926|NCT04325191|Dietary Supplement|Melatonin|Daily consumption of a high sodium diet and melatonin for 10 days
45986927|NCT04325191|Other|Placebo|aily consumption of a high sodium diet and placebo for 10 days
45986928|NCT04324879|Drug|TQ-B3525|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
45986929|NCT04517292|Drug|Eribulin,cisplatin|Eribulin 1.4mg/m2, IV , D1, D8；Cisplatin 75 mg/m2, IV，D1
45986930|NCT04517292|Drug|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV , D1, D8； Cisplatin 75 mg/m2, IV, D1
46083580|NCT02782208|Drug|Acipimox|Acipimox is administered 4 times previous to and during the investigation day. Acipimox is used to suppress the lipolytic effect of GH.
46083581|NCT02782208|Drug|Placebo|Placebo is administered 4 times previous to and during the investigation day.
46083582|NCT02782208|Drug|GH substitution|GH substitution as usually
46083583|NCT02782208|Other|GH pause|GH substitution pause two days prior to the experimental day
45673462|NCT01901055|Device|Sham-CPAP|Sham-CPAP is a device that has a mask worn over the nose that is attached to a device that looks and sounds like CPAP however it does not provide positive airway pressure. Sham-CPAP is worn while sleeping, it does not splint open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
45986931|NCT02890849|Other|Liquid biopsy|
46083584|NCT02598453|Drug|Ibandronate|Either 150 mg oral tablet once monthly or 3 mg IV injection once every 3 months
45986932|NCT00482846|Biological|Palifermin|Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is >40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3
45986933|NCT00482846|Drug|melphalan|"Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:~Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;~Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. <60)adm. via I.V.:~Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;"
46083585|NCT00611286|Drug|clopidogrel treatment after bare metal stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of bare metal stent
46083586|NCT00611286|Drug|clopidogrel treatment after bare metal stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 1 month after BMS implantation.
46083587|NCT00611286|Drug|clopidogrel after zotarolimus-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of zotarolimus-eluting stent coronary implantation
45833100|NCT03424512|Behavioral|Group Metacognitive Therapy|Group MCT is based on a manualised protocol and is structured in the following way. In session 1, idiosyncratic case formulations based on the generic metacognitive model are developed for each participant. Socialization helps patients to understand that worry/rumination and unhelpful coping strategies are maintaining emotional distress. Patients are then introduced to, and practice well established treatment techniques to modify negative beliefs about uncontrollability of rumination/worry. Later sessions address relapse prevention and involves modifying remaining use of the 'cognitive attentional syndrome', reviewing residual conviction in positive and negative beliefs and consolidating and strengthening alternative ways of responding to negative thoughts.
45986934|NCT00482846|Other|questionnaire administration|Day -5 to Day +28
45986935|NCT00482846|Procedure|autologous peripheral blood stem cell transplantation|Day 0
45986936|NCT00482846|Other|quality-of-life assessment|Day -5 to Day +28
46083588|NCT00611286|Drug|clopidogrel after paclitaxel-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of paclitaxel-eluting stent
46083589|NCT00611286|Drug|clopidogrel after everolimus-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of Everolimus-eluting stent
46083590|NCT00611286|Drug|clopidogrel after zotarolimus-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
45986937|NCT01308736|Drug|Varenicline|Participants randomized to receive varenicline will follow the Pfizer recommended dosing schedule (0.5 mg QD on days 1-3, 0.5 mg BID on days 4-7, and 1 mg BID thereafter.
45986938|NCT01308736|Drug|Placebo pill|Participants randomized to receive placebo pill will follow the same dosing schedule as those randomized to receive varenicline (1 pill labelled 0.5 mg on days 1-3, pills labelled 0.5 mg BID on days 4-7, and pills labelled 1 mg BID thereafter.
45986939|NCT04517214|Drug|Toripalimab|PD-1 inhibitor
45986940|NCT04517214|Radiation|IMRT to the nasopharynx and neck|IMRT to the nasopharynx and neck
46083591|NCT00611286|Drug|clopidogrel after paclitaxel-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
45986941|NCT04517214|Drug|Gemcitabine and Cisplatin Chemotherapy|Systemic chemotherapy
45986942|NCT04517214|Drug|Adjuvant chemotherapy with Capecitabine|Adjuvant chemotherapy after radiation
45986943|NCT01240187|Drug|perampanel|Single dose of 6 tablets 2 mg orally
45986944|NCT01240187|Drug|perampanel|Single dose of 1 tablet 12 mg orally
45833101|NCT03424200|Behavioral|Routine care|Participants will receive routine care
45986945|NCT00483054|Drug|efavirenz|efavirenz 600 mg/day + stavudine + lamivudine
45986946|NCT00483054|Drug|nevirapine|nevirapine 400 mg/day + stavudine +lamivudine
45986947|NCT01240226|Drug|GDC-0941|Oral repeating dose
45986948|NCT01240226|Drug|GDC-0941|Oral repeating dose
45986949|NCT01240226|Drug|ketoconazole|Oral repeating dose
45986950|NCT01240824|Drug|aminophylline|One of three escalating doses of aminophylline (3 mg/kg, 6 mg/kg and 9 mg/kg) administered intravesically
45986951|NCT00482924|Other|Lifestyle intervention|Regular sports and dietary advices. Controlled by analysis of laboratory parameters, BMI change and performance diagnostics. No drugs included so far.
45986952|NCT01240941|Drug|MK-2206|dose to be determined on the Phase 1b trial (listed under a separate NCT number)
45986953|NCT01240941|Drug|Exemestane|25 mg orally daily
45986954|NCT01240941|Drug|Goserelin|3.6 mg orally monthly
46083592|NCT00611286|Drug|clopidogrel after everolimus-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
45833102|NCT03424200|Other|Coaching plus routine care|Participants will receive coaching plus routine care
45833103|NCT03438318|Drug|CMP-001|CMP-001 will be administered as per the dose and schedule specified in the respective arms.
46083593|NCT04257851|Drug|Theophylline Anhydrous Oral Tablet|Theophylline tablet (150 mg/12h)
46083594|NCT04257851|Drug|Sumatriptan Succinate Oral Tablet|Sumatriptan tablet (25 mg/12h)
46083595|NCT05342246|Procedure|Endodontic retreatment|retreatment of the patent root canal only without attempt to retrieve the separated instrument
45673463|NCT01901055|Behavioral|Diabetes Education|Diabetes Education will be delivered to participants in both the CPAP group and the Sham-CPAP group. The education will be based on ADA and AADE guidelines and consist of 2 in-person sessions (90 minutes and 60 minutes) and 3 follow-up phone calls 9about 15 minutes each)
45673464|NCT04615377|Behavioral|Kaia hip and knee pain application|The Kaia Knee and Hip pain app software, when loaded onto a smartphone, recommends to the participant specific exercises for the lower extremity. Using the camera on a smartphone, the software then tracks the participant's movements as the participant performs the exercises, analyzes those movements using machine learning, and provides audio-visual feedback to the participant. The exercise therapy is augmented by educational content and cognitive behavioral therapy to provide a multidisciplinary approach to self-management of osteoarthritis. Behavioral Health Coaches ensure participant motivation throughout the program based on a predefined curriculum.
45833104|NCT03438318|Drug|Atezolizumab|Atezolizumab will be administered as per the approved label and according to the schedule specified in the respective arms.
45986955|NCT04517097|Biological|blood sample|one blood sample and one questionnaire to each patient and salaried staff included
45986956|NCT00482963|Drug|levonorgestrel, efavirenz|
45986957|NCT01240980|Drug|BMS-903452|Solution, Oral, 0.1 mg, once daily, 1 day
45986958|NCT01240980|Drug|BMS-903452|Solution, Oral, 0.6 mg, once daily, 1 day
45986959|NCT01240980|Drug|BMS-903452|Suspension, Oral, 3.0 mg, once daily, 1 day
45986960|NCT01240980|Drug|BMS-903452|Suspension, Oral, 10 mg, once daily, 1 day
45986961|NCT01240980|Drug|BMS-903452|Suspension, Oral, 30 mg, once daily, 1 day
45986962|NCT01240980|Drug|BMS-903452|Suspension, Oral, 60 mg, once daily, 1 day
45986963|NCT01240980|Drug|BMS-903452|Suspension, Oral, 120 mg, once daily, 1 day
45986964|NCT01240980|Drug|Placebo|Solution, Oral, 0 mg, once daily, 1 day
45986965|NCT01240980|Drug|Placebo|Suspension, Oral, 0 mg, once daily, 1 day
45986966|NCT01240980|Drug|BMS-903452|Suspension using crystalline form, Oral, 10 mg, once daily, 1 day
45986967|NCT01240980|Drug|BMS-903452|Suspension using crystalline form, Oral, 60 mg, once daily, 1 day
45986968|NCT01240980|Drug|Placebo|Suspension using crystalline form, Oral, 0 mg, once daily, 1 day
45986969|NCT01240980|Drug|BMS-903452|Solution, Oral, 0.6 mg, once daily, 1 day
45986970|NCT01240980|Drug|BMS-903452|Suspension, Oral, 10 mg, once daily, 1 day
45986971|NCT01240980|Drug|BMS-903452|Suspension, Oral, 120 mg, once daily, 1 day
45986972|NCT01240772|Device|doppler-guided arterial ligation with mucopexy|doppler-guided arterial ligation with mucopexy
45986973|NCT01240772|Device|stapled haemorrhoidopexy according to Longo|stapled haemorrhoidopexy according to Longo
45986974|NCT01241019|Drug|Topiramate in newborns with hypoxic ischemic encephalopathy treated with therapeutic hypothermia|TPM 10 mg/kg once a day will be administered with an orogastric tube as enteric-coated granules mixed with water on arrival in the NICU, when the cooling will be begun (T0), once a day for the first 3 days of life, for a total of 3 doses per patient.
45986975|NCT01240928|Drug|MSK-2206|Level 1: MK-2206 135mg weekly
45986976|NCT01240928|Drug|Exemestane|Level 1: Exemestane - 25mg daily
45986977|NCT01240928|Drug|Goserelin|Level 1: Goserelin- 3.6mg monthly for pre-menopausal subjects only
45986978|NCT04517175|Diagnostic Test|Flow cytometry|Flow cytometric immunophenotyping and determination of proliferative activity by means of Ki-67.
45986979|NCT00481169|Drug|Bazedoxifene Acetate (TSE-424)|
45986980|NCT04516980|Other|Questionnaires administration|"Administration of Identification of Functional Ankle Instability (IdFAI) and the following assessment scales: Self-reported question assess the ankle instability as functional/stable or not functional/unstable, Foot and Ankle ability Measure Italian Version - Activity Daily Living (FAAM-I/ADL), Short-form 36-item Health Survey Italian Version (SF-36), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (VAS ankle instability).~After a week the participants will fill in the following questionnaires: Identification of Functional Ankle Instability (IdFAI), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (Vas ankle instability) with the additional question to measure the change in complaints."
45986981|NCT01240421|Drug|Eribulin Mesylate|At a dose of 1.4 mg/m2 as a 2 to 5 minute intravenous bolus on Days 1 and 8 of a 21-day cycle.
45986982|NCT04516863|Diagnostic Test|German Autobiographical Memory Interview short-form|Diagnostic Test
45986983|NCT01240967|Drug|TC-5214|Oral tablets, single dose
45986984|NCT04517019|Device|"Fitness tracker based activity training for Arm A and B. Booklet physical training, exercise and cancer and an introduction about physical activity during cancer therapy for Arm A, B, C"|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing about physical activity during cancer therapy. With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer. A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps. The setting will be to maintain to this daily activity of 6000 steps during radiotherapy."
45986985|NCT00483093|Drug|NGR-hTNF|iv q3W escalating dose NGR-hTNF up to 1.6 mcg/sqm
45986986|NCT00483093|Drug|Cisplatin|iv q3W 80 mg/sqm 30 minutes after NGR-hTNF infusion for a maximum of six cycles
45986987|NCT00487916|Drug|AMA1-C1/ISA 720|
45986988|NCT00483132|Drug|interferon alpha 2a|
46083596|NCT04708860|Behavioral|Prolonged Nightly Fasting|Restriction of consumption of calorie-containing food/drinks after 8pm
45986989|NCT00483080|Drug|NGR-hTNF|iv q3W or q1W NGR-hTNF 0.8 μg/m²
45673465|NCT04615377|Other|Treatment as usual|Participants allocated to the control arm will be advised to continue receiving treatment as usual ( standard care) without restrictions, except participation in other investigational trials, and will likewise be followed up for 90 days. Apart from that, they are encouraged to seek care, as they would do normally.
45833105|NCT03438318|Radiation|Radiation Therapy|Radiation therapy will be administered using either 3-dimensional (3D) conformal radiotherapy or intensity-modulated radiation therapy (IMRT) to non-target node or metastatic lesion as per the dose and schedule specified in the respective arms.
46083597|NCT04708860|Behavioral|Exercise|Personalized moderate-intensity, aerobic exercise and strength training
46083598|NCT02780492|Other|Set of assessment tools|
46083599|NCT04255979|Drug|HY209|6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
46083600|NCT00611364|Other|Physical Therapy and education meetings|Physical therapy was realized three two times per week and education meeting every fifteen days
46083601|NCT00611364|Other|education meetings|This group only participed of education meeting (every fifteen days)
46083602|NCT02780102|Other|Cognitive-Motor Rehabilitation|Cognitive-Motor Rehabilitation (CMR) group received 20 sixty-minute sessions of cognitive-motor exercises
46083603|NCT02780102|Drug|Ritalin|2 or 3 doses of 10 mg tablets of immediate-release Methylphenidate (Ritalin) per day for 8 week.
45673466|NCT01511536|Drug|Cabazitaxel XRP6258|Pharmaceutical form:solution Route of administration: injection
45673467|NCT01511536|Drug|Abiraterone acetate|Pharmaceutical form:tablets Route of administration: oral
45673468|NCT01511536|Drug|Prednisone 5 mg|Route of administration: oral
45833106|NCT03087942|Drug|QAW039|450 mg
45833107|NCT03087942|Drug|QAW39A|450 mg
45833108|NCT03087942|Drug|QAW39A2107|450 mg
45833109|NCT03087942|Drug|QAW39A2107|450 mg
45833110|NCT01678092|Biological|omalizumab|
45833111|NCT03088098|Device|LAAO|Left atrial appendage occlusion for stroke prevention
45986990|NCT00483210|Drug|Fenofibrate|
45673469|NCT01890759|Biological|Meningococcal Diphtheria Toxoid Vaccine|0.5 mL, Intramuscular
45673470|NCT01900899|Procedure|Blood Sampling|At 2, 3, 4, 5, 6 years after booster vaccination.
45673471|NCT01510912|Drug|Diclofenac|35 mg bid or tid Capsules
45673472|NCT04615221|Other|Specimens|Specimens (blood, biopsy, cervical smear, vaginal swab)
45986991|NCT00487955|Procedure|Resting Energy Expenditure examination|
45986992|NCT00483288|Other|educational intervention|
45986993|NCT00483288|Other|questionnaire administration|
46083604|NCT02780102|Other|Active Control|Active Control group simultaneously received 20 sixty-minute sessions of low dose cognitive-motor exercises
46083605|NCT00747435|Device|Electric Acoustic System|Combination of a cochlear implant and a hearing aid
46083606|NCT04252781|Other|Exhaustive exploration|"clinical investigations~imagery~blood assessment~functional respiratory investigations~muscle function / skeletal muscle index"
45986994|NCT00483288|Other|study of socioeconomic and demographic variables|
45833112|NCT04402320|Drug|Midazolam|reconnected to mechanical ventilation before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use
45986995|NCT00483288|Other|survey administration|
45986996|NCT00487994|Drug|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin placebo-matching capsules, orally, once daily for up to 96 weeks.
45986997|NCT00487994|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
45986998|NCT00487994|Drug|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
45986999|NCT04516824|Procedure|Orthopaedic Surgical Procedures|Intramedullary nails, Dynamic Compression Plate, Dynamic Hip Screw, Manipulation Under Anaesthesia POP, Ilizarov, Cannulated Screw Fixators, Bipolar Hemiarthroplasty, Locking Compression Plate, AO External fixators, Tension Band Wiring Patella, Pelvis and Acetabulum Fixations, Elbow Reconstructions, K wiring, Disc Excision, Spine Fracture i-e TPSF, Posterior Cervical Decompression and LMS, Dura repair, AD cage,Bilateral Total Hip Replacement, Unilateral Total Hip Replacement, Bilateral Total Knee Replacement, Unilateral Total Knee Replacement, Knee Arthroscopy for Mensicectomy, Arthroscopic Anterior Cruciate Ligament reconstruction,Removal of Implant, Amputations, VAC dressings,Wound wash, Arthrotomy for Septic Arthritis, Biopsy
45987000|NCT02955342|Other|no intervention|no intervention
45987001|NCT00483158|Drug|Finafloxacin hydrochloride|Tablets, oral single dose and multiple dose once daily for 7d
45987002|NCT00483366|Drug|capecitabine|"Dose level Capecitabine~-1 400 mg/m2 bid~0 500 mg/m2 bid~500 mg/m2 bid~600 mg/m2 bid~600 mg/m2 bid~725 mg/m2 bid~725 mg/m2 bid~850 mg/m2 bid~850 mg/m2 bid"
45987003|NCT00483366|Drug|gemcitabine hydrochloride|"Dose level Gemcitabine~-1 400 mg/m2 0 450 mg/m2~550 mg/m2~550 mg/m2~675 mg/m2~675 mg/m2~825 mg/m2~825 mg/m2~1000 mg/m2"
45987004|NCT00483366|Drug|imatinib mesylate|"Dose level Imatinib~-1 400 mg/d 0 400 mg/d~400 mg/d~400 mg/d~400 mg/d~400 mg/d~400 mg/d~400 mg/d~400 mg/d"
45987005|NCT00483366|Genetic|mutation analysis|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
45987006|NCT00483366|Genetic|nucleic acid sequencing|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
45987007|NCT00483366|Genetic|polymerase chain reaction|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
45987008|NCT00488111|Other|Ringer's Lactate|Ringer's Lactate was used 15min before operation
45987009|NCT00488111|Other|6% Starch|6% Starch was used 15min before operation
45987010|NCT02955381|Device|Restylane Silk, 1.0 ml|Restylane® Silk was approved in 2014 submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
45987011|NCT02955381|Device|Saline, 1.0 ml|Simple saline solution. To be used as placebo (control). No active ingredients.
45833113|NCT04402320|Device|ventilator|reconnected to mechanical ventilation before extubation for one hour with sedation
45833114|NCT03436056|Radiation|Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)|Stereotactic Body Radiotherapy (SBRT) dosed at 30 Gy in 3 fractions (#) in week 3
45987012|NCT00483197|Device|VentrAssistTM Left Ventricular Assist Device|
45987013|NCT02955420|Drug|BC 007|
45987014|NCT02955420|Drug|NaCl 0.9 %|
45987015|NCT02955303|Other|TECH: Tablet Enhancement of Cognition and Health|cognitive training using touchscreen tablet gaming applications
45673473|NCT01510756|Drug|Sorafenib|Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Subjects without significant toxicity or progressive disease may elect to continue treatment for a total of twelve cycles.
45673474|NCT01522456|Drug|Epiduo Gel|Once-daily application of fixed dose of adapalene 0.1% and benzoyl peroxide 2.5% in an aqueous based gel.
45673475|NCT01522456|Drug|Retin-A Micro Microsphere 0.1%|Once-daily application of tretinoin gel, 0.1% by weight, in a formulation of porous microspheres in an aqueous gel.
45987016|NCT01308580|Drug|Cabazitaxel (XRP6258)|"Pharmaceutical form: Concentrate and solvent for solution for infusion~Route of administration: Intravenous"
45987017|NCT01308580|Drug|Prednisone (or Prednisolone)|"Pharmaceutical form: Tablet~Route of administration: Oral"
45987018|NCT00483275|Drug|Alfacalcidol|
45987019|NCT00483275|Behavioral|Balance, gait and strength training|
45987020|NCT00483275|Behavioral|Patient education|
45833115|NCT03436056|Radiation|Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#)|Stereotactic Body Radiotherapy (SBRT) dosed at 54 Gy in 3 fractions (#) in week 3
45987021|NCT00483444|Behavioral|Scheduled telephone follow-up|Persons in the experimental group (group 1) received scheduled telephone counseling calls focused on symptom management and self-management skills.
45987022|NCT04325152|Device|FCSEMS plus Clip|After successful cannulation, a 10mm FCSEMS with the length of 6cm or 8cm were inserted into CBD. Then a metal clip was used to fix the distal end of FCSEMS with the duodenal mucosa adjacent to papilla.
45987023|NCT04325152|Device|FCSEMS|FCSEMS was released as the same as mentioned above. No fixating method was used.
45987024|NCT02890810|Other|Real Acupuncture with Electrical Stimulation|Acupuncture is a therapy commonly used in East Asian countries, where the practitioner insert thin needles at specific body sites in order to relieve pain and illnesses. Recent studies found low frequency electricity applied through acupuncture needles can lead to profound pain relief by increasing endorphin levels in the central nervous system. Electroacupuncture will thus be used as the active intervention to treat chronic low back pain in this clinical study.
45987025|NCT02890810|Other|Simulated Acupuncture with Electrical Stimulation|This intervention serves as the placebo control of the active intervention. Sterile acupuncture needles and the ITO electrical stimulators will be used in this intervention. But special care will be taken to have this intervention mimic the real treatment yet remaining as physiologically inert as possible.
45987026|NCT00483314|Drug|N-acetylcysteine|2 g p.o. BID x 60 days
45987027|NCT04516629|Diagnostic Test|heart rate variability, pulse diagnosis device|check heart rate and pulse rate
45987028|NCT01308463|Device|Discovery elbow minimally constrained|patient participating in the Discovery Elbow Multi-center study
45833116|NCT03436056|Radiation|Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose|Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose (MTD) determined in Part A in week 3
45833117|NCT03436056|Drug|Pembrolizumab|Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
45833118|NCT03088176|Drug|Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil|Up to 4mL administered on C1D1 intratumorally
45833119|NCT03088176|Drug|Talimogene Laherparep 100 Mil Pfu/Ml 1Ml|Up to 4 ML administered on Week 4 Day 1 and every 2 weeks thereafter
45833120|NCT03088176|Drug|Dabrafenib|150mg PO qday
45987029|NCT04324918|Drug|HCP1102|The participants will receive tretment of HCP1102(combination of Montelukast + Levocetrizine), orally, once daily for 4weeks.
45987030|NCT04324918|Drug|HGP1408|The participants will receive tretment of HGP1408(Levocetrizine), orally, once daily for 4weeks.
45987031|NCT00483353|Procedure|Intra-nasal allergen challenge with Phleum pratense.|
46083607|NCT04197128|Device|Resorbable Collagen membrane with bone graft for augmentation|"Local anaesthesia Lignocaine and Adrenaline 1:80000 Injection (Lignox® 2% A, Indoco remedies Ltd, Mumbai) will be administered and midcrestal incison will be made and full thickness flap would be raised buccally. To obtain tension free adaptation of flap margins, the buccal flap advancement will be done using periosteal releasing incision. Implant osteotomies will be performed with sequential drilling and with standardised drills. All the subjects will receive the same implant system. (Norris medical ltd. Hatasia street, Nesher, Israel) For augmentation of deficient ridge, bovine bone graft will be place with overlying resorbable collagen membrane. Stabilisation would be achieved with internal resorbable horizontal mattress suture.~The tension free flap margins will be adapted around the healing abutment with simple interrupted Vicryl 4.0, 3/8, reverse cutting resorbable sutures (Ethicon, Hamburg, Germany)"
45833121|NCT03088176|Drug|Trametinib|2mg PO qday
45833122|NCT00087984|Biological|MB-002|Dendritic Cell Immunotherapy
45833123|NCT03477942|Biological|Autologous Mesenchymal Stem Cells|Bone marrow will be harvested from each individual patient's iliac crest, followed by stem cell isolation, expansion and preparation. Stem cell will be injected approximately 3-4 weeks after bone marrow harvest, injecting 50x10^6 MSCs in the knee via a medial parapatellar approach under sterile technique in 8 patients with generalized knee OA or focal chondral defects.
45987032|NCT00483353|Procedure|Collection of nasal effluent using filter paper.|
45833124|NCT01678404|Drug|131I-rituximab|
45833125|NCT03087864|Drug|Atezolizumab|Atezolizumab 1200 mg i.v. day 1-22-43-64-85
45833126|NCT03087864|Drug|Carboplatin|Chemotherapy
45833127|NCT03087864|Drug|Paclitaxel|Chemotherapy
45833128|NCT03087864|Radiation|Radiotherapy 23 x 1.8 Gy|Radiotherapy
45833129|NCT03087630|Behavioral|Reasoned-Based Intervention|Receives personalized feedback based on the reasoned pathway of the Prototype Willingness Model.
45987033|NCT00483353|Procedure|Measurement of nasal congestion using acoustic rhinometry.|
45833130|NCT03087630|Behavioral|Social-Based Intervention|Receives personalized feedback based on the social pathway of the Prototype Willingness Model.
45833131|NCT03087630|Behavioral|Integrated Intervention|Receives personalized feedback based on both the reasoned and social pathways of the Prototype Willingness Model.
45987034|NCT00483483|Behavioral|Individual and group HIV risk behavior counseling sessions|Healthy Relationships Intervention (HRI) culturally adapted and modified to address substance use and associated risk behaviors; subjects will attend three 2-hour structured group sessions in addition to two 1-hour individualized sessions over the course of 10 days.
45987035|NCT00483483|Behavioral|health education and support group|general health information (nutrition, stress reduction) in 2 individual sessions and 3 group sessions.
45987036|NCT01308424|Drug|BTL TML HSV|Sublingual micro-dosing for 7 days
45987037|NCT01308424|Drug|Matching placebo|sublingual dosing for 7 days
45987038|NCT05644288|Other|Help eNursing|"The proposed intervention is a telephonic telenursing program aimed at managing social isolation in the elderly, the HELPeN (Help eNursing) program.~The operational part of the intervention will be carried out by volunteers nursing students from the University of Murcia enrolled in the academic years 2020-2023. To ensure homogeneity in the intervention carried out by the volunteers they will receive a 15-hour training oriented to ensure the acquisition of essential communication skills for the implementation of the intervention and to know the specific interventions of support and counseling for the elderly in social isolation.~Over the 36 weeks of the HELPeN Program, each volunteer is expected to provide intervention to 2 seniors, making 1 call per week to each subject lasting approximately 30 minutes. Students will perform physical and psychosocial assessments of the elders and create individualized care plans based on each subject's needs."
45987039|NCT00483522|Behavioral|Self-management telephone counseling|Subjects are contacted 7 times in year 1 after discharge from hospital rehabilitation unit and 4 times in year 2. Telephone counseling based on a self-management/problem-solving model is conducted by a research care manager.
45987040|NCT00483392|Drug|metformin, rosiglitazone|
45987041|NCT00483431|Dietary Supplement|Placebo|
45987042|NCT00483431|Dietary Supplement|MK7|
45987043|NCT00483600|Drug|fondaparinux|injections of 2.5mg every other day for 4 weeks
45987044|NCT00488189|Drug|Tazocin (pipercillin/tazobactam)|over 50% third generation cephalosporin should be replaced by Pip/Taz
45987045|NCT04516551|Biological|anti-CD19 allo-CAR-T cells|The T cells collected from haploidentical donors have been manufactured to express CAR to binding CD19 on B-cell leukemia.
45456750|NCT02291380|Drug|Botulinum Toxin Type A for Injection|In these studies ,patients received a minimum intramuscular (IM) dose of 155 U of Botulinum Toxin Type A（HengLi®）administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 5 U in 0.1 mL). In addition, up to 40 U Botulinum Toxin Type A,administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. Thus, the minimum dose was 155 U and the maximum dose was 195 U. In the core phase, two doses of HengLi® will be injected.In the extension phase, three doses of HengLi® will be injected.
45833132|NCT03087630|Behavioral|Attention Control|Receives personalized feedback related to nutrition and exercise, unrelated to drinking behavior.
45833133|NCT01678482|Device|light based device for treatment of acne|
45833134|NCT01678716|Behavioral|EHC + BCC|This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
45833135|NCT01678716|Dietary Supplement|Micronutrient powders|"In this intervention arm, frontline health workers will visit households and promote and sell micronutrient powders to them. The micronutrient powder is sold by the brand name Pushtikona in Bangladesh and contains 15 micronutrients including iron, zinc, vitamin A, vitamin C, and others."
45833136|NCT01678716|Behavioral|Mass media|A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
45833137|NCT00081510|Drug|Lonafarnib|
45833138|NCT00081510|Drug|Placebo|
45833139|NCT00081510|Drug|anastrozole|
45833140|NCT00088452|Drug|Ethosuximide|Ethosuximide is a common treatment for childhood absence epilepsy.
45833141|NCT00088452|Drug|Lamotrigine|Lamotrigine is a common treatment for childhood absence epilepsy.
45833142|NCT00088452|Drug|Valproic acid|Valproic acid is a common treatment for childhood absence epilepsy.
45833143|NCT04278534|Other|Educational Intervention|Complete radiation therapist-led education module using virtual reality
45987046|NCT00488228|Behavioral|self-regulation|The current study involves a behavioral weight loss intervention tailored specifically to young adults. All participants receive calorie and activity prescriptions as well as training in behavior modification. In addition, one group receives training in self-regulation techniques using daily weighing.
45987047|NCT00483639|Other|Medical chart review|medical chart review
45987048|NCT00483639|Other|Liebowitz Social Anxiety Scale and the Social Phobia and Anxiety Inventory|survey administration
45987049|NCT00483639|Procedure|management of therapy complications|management of therapy complications
45987050|NCT00483639|Procedure|Structured Clinical Interview for the Diagnostic and Statistical Manual-IV SCID|psychosocial assessment
45987051|NCT00483639|Other|Functional Assessment of Cancer Therapy-General (FACT-G)|survey administration
45987052|NCT02956421|Biological|RABIPUR®|Biological rabies vaccine
45987053|NCT02956421|Biological|PIKA rabies vaccine|Biological rabies vaccine
45987054|NCT04516239|Device|THA|Three surgeons performed the surgeries through a posterior surgical approach in both groups. The fascia lata was opened and the gluteus maximus was split in line with its muscle fibers. The short external rotators were released from the greater trochanter. A posterior capsulotomy was performed and the hip dislocated. For the THA, the standard techniques proposed by the manufacturer for insertion of the stem were followed. Neck sleeve adapters and three different prosthetic neck-shaft angles (125, 135, and 145) were available to adjust leg length and femoral offset with the large-diameter head THA system.
45833144|NCT04278534|Other|Educational Intervention|Receive the usual verbal and written education materials
45987055|NCT04516239|Device|HR|Three surgeons performed the surgeries through a posterior surgical approach in both groups. The fascia lata was opened and the gluteus maximus was split in line with its muscle fibers. The short external rotators were released from the greater trochanter. A posterior capsulotomy was performed and the hip dislocated. In the HR group, the capsulotomy was completed circumferentially, and the gluteus tendinous insertion on the femur was released in all men, but only when needed in women, to improve femur mobilization.
45987056|NCT00483470|Biological|Hepatitis A vaccine AVAXIM 80U|0.5 mL, Intramuscular
45987057|NCT00483470|Biological|Hepatitis A vaccine (HAVRIX 720)|0.5 mL, Intramuscular
45456751|NCT02291380|Drug|Placebo|In these studies, patients received placebo administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 0.1 mL). In addition, up to 0.8 mL placebo, administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. In the core phase, two doses of placebo will be injected.
45456752|NCT01353716|Drug|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class of HIV medications. There will be a one single dose of 50 mg.
45673476|NCT04409626|Other|Plasma sodium level (continuous variables)|Observational study, so the exposures of interest (5-year mean and minimum plasma sodium) are not administered to the patients. Ultimately, our interest is in hyponatraemia.
45987058|NCT00483678|Other|counseling intervention|
45987059|NCT00483678|Other|questionnaire administration|
45987060|NCT00483678|Procedure|psychosocial assessment and care|
45987061|NCT00483587|Drug|Heme arginate|1-3 x heme arginate infusion, in 30 minutes iv. Heme arginate is dissolved in 250 ml NACl.
45456753|NCT03927625|Drug|Ascorbate-Meglumine|Ascorbate, meglumine and sodium salt made by combining 375 mM sodium ascorbate, 125 mM ascorbic acid and 125 mM meglumine in sterile water for injection.
45673477|NCT01545934|Behavioral|Lifestyle intervention|The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
45673478|NCT03027544|Radiation|tomotherapy|"Tomotherapy: The regular fraction modes were as follows: a. lesions≥3 cm:52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions<2cm:36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm: 40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem:50-60Gy/2.5-3Gy/20f; 3. multiple lesions with large lesion: whole brain radiation (WBRT) with 40Gy/2Gy/20f and concurrent boost of 60Gy/3Gy/20f of the lesions.~TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2*5d, q28d, up to 6cycles."
45673479|NCT01521364|Drug|Addition of different doses of clarithromycin.|"At week 1, 250mg clarithromycin once a day will be added to linezolid therapy during two weeks.~At week 3, 500mg clarithromycin once a day will be added to linezolid therapy during to weeks."
45673480|NCT01545388|Drug|Sitagliptin|Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)
45673481|NCT01545388|Drug|Metformin|Metformin, orally, 500 mg daily (single dose; two 250 mg tablets) for 24 weeks
45673482|NCT01545388|Drug|Metformin|Metformin, orally, 500 mg daily (divided dose; 250 mg tablet b.i.d.) for 24 weeks
45673483|NCT01545388|Drug|Placebo|Placebo to match metformin 250 mg tablets, orally, for 24 weeks
45833145|NCT04278534|Other|Educational Intervention|Complete radiation therapist-led face-to-face education module
45833146|NCT04278534|Other|Survey Administration|Ancillary studies
45833147|NCT03417570|Procedure|Esophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI)|-The second endoscopist will be blinded to the results of the initial exam.
45833148|NCT03417570|Device|Olympus Disposable Distal Attachment Cap|-The second endoscopist will be blinded to the results of the initial exam.
45833149|NCT03087552|Procedure|Transradial balloon aortic valvuloplasty|Mini-invasive balloon aortic valvuloplasty consisting in transradial access
45833150|NCT03087552|Procedure|Transradial balloon aortic valvuloplasty|Rapid pacing using the 0.035-in. retrograde left ventricular support wire
45833151|NCT03087474|Other|Non-Interventional|Non-Interventional
45833152|NCT01679106|Other|TAP catheter with Ropivicaine|Patients will receive TAP catheter with continuous infusion of Ropivicaine.
45833153|NCT01679106|Other|Fentanyl IV PCA and placebo TAP catheter|Patients will receive placebo TAP catheter with Fentanyl IV PCA.
45987062|NCT04516590|Other||There was no intervention in this observational study
45987063|NCT00488306|Drug|tigecycline|
45987064|NCT01307800|Drug|LY2140023|Administered orally
45987065|NCT01307800|Drug|Placebo|Administered orally
45987066|NCT04516044|Behavioral|Video games|See arm description
45987067|NCT00483626|Drug|oral sildenafil|
45456754|NCT04481672|Drug|Magnesium Sulfate|Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.
45456755|NCT01126567|Other|Sampling Rate|Both cohorts will have a lumbar catheter placed and CSF samples will be obtained. The only difference between the two arms will be the sampling rate of CSF. One arm will have a high sampling rate and the other will have a low sampling rate.
45673484|NCT03027232|Other|No intervention (drugs) will be given. Purpose: collecting blood for in vitro studies|No drugs or interventions are given. Single purpose is to draw blood from healthy subjects to study immune cell biology in vitro. No records about subjects to be kept.
45673485|NCT01545076|Biological|IgPro20 (low dose)|"20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.2 g/kg body weight (low dose arm)"
45673486|NCT01545076|Biological|Placebo|2% human albumin administered by weekly SC infusions during the SC treatment period of the study.
45673487|NCT01545076|Biological|IgPro10|10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue Therapy during SC Treatment Period for subjects with a CIDP relapse.
45673488|NCT01545076|Biological|IgPro20 (high dose)|"20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.4 g/kg body weight (high dose arm)"
45673489|NCT01544920|Biological|peg-Interferon alfa-2a|peg-IFN (180 ug) was taken once weekly via subcutaneous injection.
45833154|NCT04403100|Drug|Hydroxychloroquine Sulfate Tablets|Tablets of 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days
45833155|NCT04403100|Drug|Lopinavir/ Ritonavir Oral Tablet|tablets of 200/ 50 mg; Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days
45833156|NCT04403100|Drug|Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets|"Hydroxychloroquine Oral Tablet 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days~plus~Lopinavir/ Ritonavir Oral Tablet of 200/ 50 mg: Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days"
45833157|NCT04403100|Drug|Placebo|Placebo tablets - 01 tablet twice daily from day 01 through day 10.
45987068|NCT00483795|Drug|sodium citrate, sodium chloride, sodium borate, propylene glycol. citrate, tetronic 1304, AMP 95|
45987069|NCT05644210|Drug|Telitacicept|160mg once a week for 24 weeks
45987070|NCT05644210|Drug|Rituximab|Patients received 200mg of rituximab intravenously at week 0 and week 2.
45987071|NCT05644210|Drug|Aspirin|50-100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
45987072|NCT05644210|Drug|Warfarin|Warfarin should be used in patients with arterial thrombosis, and rivaroxaban should be replaced if the patient cannot reach the standard or cannot tolerate it
45987073|NCT05644210|Drug|Hydroxychloroquine|200mg, po, twice per day (Bid) prescribed，if tolerated by the patient， the dose should remain constant during the observation period
45987074|NCT05644210|Drug|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
45987075|NCT00488384|Drug|Chemopreventive application (Acitretin)|Chemopreventive application (Acitretin)
45987076|NCT04325074|Other|Mental practice|During each of the 12 treatment sessions, the patient was asked to select two tasks from a list of MP activities, graded by level. Once the task was selected, patients received the specific visual or audio instructions and subsequently performed the task. The recording was viewed three times and the audio instructions were repeated two times. To listen to the audio instructions, the participants were requested to close their eyes in order to aid concentration. After listening to the recordings, the patient was asked to perform the task once again, practicing what had been learnt. After the process was completed, the participant completed a questionnaire and scored each task.
45987077|NCT04325074|Other|Mental practice + skill training|In this option, six sessions of MP were alternated with six sessions of skills training (ST). The MP protocol was the same as in group A: selecting, performing, visualizing, listening to and scoring the selected tasks. The activities performed in the skills training were based on the Kamm et al. (2015) protocol and bimanual tasks. After the performance of each task, the patients were allowed to rest for 1 or 2 minutes to avoid the appearance of fatigue.
45987078|NCT04325074|Other|Control group|The control group only received their usual physical therapy and occupational therapy treatments provided by their association. The treatment mainly consisted of the application of the Bobath concept and the Vojta method, dry needling, myofascial induction therapy, passive mobilizations, training of gross and fine motor coordination of the upper limbs, resistance training and static and dynamic balance training.
45987079|NCT00483834|Drug|Bevacizumab|7.5mg/kg, IV, day 1 of each cycle
45987080|NCT00483834|Drug|Irinotecan|200mg/m^2, IV, day 1 each cycle
45987081|NCT00483834|Drug|Capecitabine|1000mg/m^2 or 750mg/m^2 for patients over 65yrs old PO BID, day 1-14 each cycle
45987082|NCT04324801|Other|Homeostatic plasticity induction using transcranial direct current stimulation|Homeostatic plasticity will be induced in the left primary motor cortex using tDCS applied for 7 minutes followed by an interval of 3 minutes and another block of 5 minutes of stimulation
45987083|NCT01307449|Biological|PNEUMOVAX|1 dose of PNEUMOVAX
45987084|NCT01307449|Biological|Prevnar|1 dose of Prevnar
45987085|NCT00483665|Procedure|Computed tomography angiography|Computed tomography angiography
45987086|NCT00483665|Procedure|Magnetic resonance imaging|Magnetic resonance imaging after injection of Vasovist
45987087|NCT00483912|Device|Molecular adsorbent recirculating system|
45987088|NCT00488423|Procedure|Mixed Meal Tolerance test, Hyperglycemic clamp|Subjects undergo a standard mixed meal tolerance test & hyperglycemic clamp to assess insulin secretion & sensitivity (whole body glucose disposal) pre-op. Following surgery, at 1week, 1 month, 6 months and 12 months subjects will undergo hyperglycemic clamp & mixed meal tolerance test. During these tests, measurements will include plasma levels of glucose, insulin, C-peptide, free fatty acid levels and adipocyte hormone profile (adiponectin, leptin, resistin). A gut hormone profile (ghrelin, glucagons-like-peptide 1 GLP-1, glucose-dependent insulinotropic polypeptide GIP, PYY) will be performed at fasting & specific postprandial times. Results will be compared between two groups: patients undergoing laparoscopic Roux-en-Y gastric bypass & gastric banding.
45987089|NCT04516122|Procedure|Biospecimen Collection|Undergo collection of blood samples
45987090|NCT04516122|Procedure|Dual X-ray Absorptiometry|Undergo DXA scan
45987091|NCT01307020|Drug|Dexketoprofen Trometamol|Dexketoprofen Trometamol low dose, oral film-coated table, once
45987092|NCT01307020|Drug|Dexketoprofen Trometamol|Dexketoprofen Trometamol high dose, oral film-coated table, once
45987093|NCT01307020|Drug|Tramadol Hydrochloride|Tramadol Hydrochloride low dose, oral film-coated table, once
45987094|NCT01307020|Drug|Tramadol Hydrochloride|Tramadol Hydrochloride high dose, oral film-coated table, once
45987095|NCT01307020|Drug|Ibuprofen|Ibuprofen 400 mg, oral film-coated table, once
45987096|NCT01307020|Drug|Placebo|Placebo, oral film-coated table, once
45987097|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl low dose, oral film-coated table, once
45673490|NCT01544920|Drug|Ribavirin|RBV 200 mg tablets taken by mouth at a total daily dose of 1,000 mg (body weight <75 kilograms [kg]) or 1,200 mg (body weight ≥75 kg) with total daily dose divided into 2 dosings.
45673491|NCT01544920|Drug|Boceprevir|Four 200 mg BOC capsules taken three times a day by mouth for a total daily dose of 2,400 mg.
45673492|NCT04105036|Other|Data Collection|Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
45673493|NCT01509664|Behavioral|Discount intervention|50% discount on selected fruits and vegetables at participating supermarket
45673494|NCT04409704|Device|Repetitive Transcranial Magnetic Stimulation|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week, 20-30 sessions.
45673495|NCT01543828|Drug|indacaterol|delivered via single-dose dry-powder inhaler
45673496|NCT01543828|Drug|placebo|delivered via single-dose dry-powder inhaler
45673497|NCT03027622|Behavioral|quality of life in the patients with mild pericoronitis|active surviallence by OHIP-14 TR after treatment
45987098|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl high dose, oral film-coated table, once
45987099|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl low dose, oral film-coated tablet, once
45987100|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl high dose, oral film-coated tablet, once
45987101|NCT00483743|Drug|TPI 1020|250 mcg/caps 2 caps BID x 42 days
45987102|NCT00483743|Drug|Budesonide|400mcg mcg capsules- 2 capsules BID
45987103|NCT00483743|Drug|Placebo|2 caps BID x42 days
45987104|NCT05644132|Device|InDx Implant for the carpometacarpal joint|Treatment of thumb base joint arthritis with the InDx Implant
45987105|NCT04515654|Other|IDEAS (Identity Evolution and Sharing) Performance|60 minute webinar depicting first-hand stories of transgender and gender non-conforming individuals followed by expert panel/talk-back
45987106|NCT04324996|Biological|NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells|The CAR-NK cells are universal off the shelf NK cells enriched from umbilical cord blood and engineered genetically.
45987107|NCT00483782|Biological|bevacizumab|
45987108|NCT00483782|Drug|carboplatin|
45987109|NCT00483782|Drug|paclitaxel|
45987110|NCT00483782|Other|questionnaire administration|
45987111|NCT00483782|Other|study of socioeconomic and demographic variables|
45987112|NCT00483782|Procedure|quality-of-life assessment|
45987113|NCT00483951|Device|Toshiba Aquilion ONE CT|The Toshiba Aquilion ONE CT system has the ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy.
45987114|NCT00483951|Device|SWiemens MRI scanner|Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.
45987115|NCT00488462|Device|non-pneumatic anti-shock garment|In the intervention arm, half of the study clinics will use the NASG when a patient meets the study criteria.
45987116|NCT04516005|Procedure|foot reflexology|Acupressure was applied at the plantar side of the right foot at the first metatarsal bone, around 1-1.5 centimeters proximal to the first metatarsophalangeal joint. (Figure 2) Approximately 3-kilogram pressure was applied by using a knuckle of the right index finger (dorsal part of the proximal interphalangeal joint in flexing position) in a perpendicular manner and held for 15 seconds (sec) then released for 5 sec. This hold-release cycle was done 5 times over the course of 2 min. This method was recommended by the Department of Thai Traditional and Alternative Medicine in accordance with the Zone theory and the Meridian theory.
45987117|NCT02890732|Device|Appet HEART|smartphone application prototype of personalized care of patients after hospitalization for coronary artery disease
45987118|NCT02890771|Procedure|Tooth Brushing with Dentifrice|Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
45987119|NCT02890771|Procedure|Turmeric Massaging|:-Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with whole Turmeric Powder.
45987120|NCT02890771|Procedure|SRP with turmeric massaging|on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with whole Turmeric Powder shall be carried out by the patients/subjects
45987121|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose
45987122|NCT01306162|Drug|Dabigatran etexilate|150 mg as single dose
45987123|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose (staggered administration)
45987124|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid
45987125|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid (staggered administration)
45987126|NCT04327960|Diagnostic Test|Cardiac troponin (cTn)|Cardiac troponin (cTn) will be measured with the Dimension RxL-HM analyzer .The one-step enzyme immunoassay is based on cTn specific monoclonal antibodies, performed on a separate module of the analyzer, assay-time is 17 minutes.
45987127|NCT00483821|Other|medical chart review|medical chart review
45987128|NCT04515732|Drug|Apremilast Oral Tablet|As in description
45987129|NCT01305577|Drug|Deoxycholic acid injection|
45987130|NCT01305577|Drug|Placebo|Phosphate buffered saline placebo for injection
45987131|NCT00483990|Drug|PSD502|
45987132|NCT05644054|Drug|Cannabis oil|The participants will receive 0.15 mg/kg of the drug
45987133|NCT01304329|Drug|BI 10773|Medium dose oral administration
45987134|NCT01304329|Drug|simvastatin|Medium dose oral administration
45987135|NCT01304329|Drug|simvastatin|Medium dose oral administration
45987136|NCT01304329|Drug|BI 10773|Medium dose oral administration
45987137|NCT04515420|Drug|noradrenaline|noradrenaline infusion
45987138|NCT00488540|Drug|Paracetamol|Suppository
45456756|NCT01224067|Drug|Quetiapine|Adjunctive quetiapine -Participant will receive up to 300 mg/day of quetiapine for 8 weeks.
45456757|NCT04465942|Drug|(chemo)immunotherapy|Patients are receiving immunotherapy or chemoimmunotherapy as a standard of care
45456758|NCT02529085|Other|blood samples|blood samples for the bank
45833158|NCT03087318|Behavioral|Physical activity|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal heart rate measured during the exercise stress testing (from the screening)~during 3 months."
45833159|NCT03086538|Drug|Pemetrexed|Pemetrexed is a multitarget antifolate (MTA) whose mechanism of action relies mainly on the inhibition of TS, with weaker secondary effects on glycinamide ribonucleotide formyltransferase (GARFT) and dihydrofolate reductase (DHFR), leading to impairment of DNA synthesis and repair.
45833160|NCT03086538|Drug|Tarceva 100Mg Tablet|Erlotinib (tarceva) is oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
45987139|NCT00488540|Drug|Placebos|Suppository
45987140|NCT00484068|Drug|enalapril|
45987141|NCT00484068|Procedure|chicken diet|
45987142|NCT00483860|Drug|Topotecan|once a day
45987143|NCT01241097|Drug|simvastatin, combined with simvastatin ezetimibe, placebo|simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
45987144|NCT00483899|Drug|GW870086X|Subjects will inhale 0.25 or 1.5 mg/inhalation GW870086X for four times
45987145|NCT00483899|Drug|Placebo|Placebo matching GW870086X will be administered by subjects
45987146|NCT01303861|Drug|Varenicline|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
45987147|NCT01303861|Drug|Bupropion|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive bupropion at a dose of 150mg once per day. Subsequently, the dose will be 150mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
45987148|NCT01303861|Drug|Nicotine patches|"Nicotine Replacement Therapy Groups:~For smokers with high baseline carbon monoxide (CO): 42 mg/24 h for 2 weeks before the quit date and 3 weeks after the quit date, 21 mg/24 h for 4 weeks, 14 mg/24 h for 2 weeks, and 7 mg/24 h for 2 weeks; or~For smokers with low baseline CO: 21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.~Varenicline and varenicline in combination with bupropion groups:~For smokers with high baseline CO: 42 mg/24 h for 1 week~For smokers with low baseline CO: 21 mg/24 h for 1 week"
45987149|NCT01303861|Drug|Nicotine Inhaler|Nicotine inhaler to use as needed after quit date
45987150|NCT05661136|Device|Warm air blower|Lower body blanket with warm air blower set at 44 deg c started after spinal anesthesia when patient placed in supine/left lat position
45987151|NCT05661136|Other|Control: Lower body blanket not attached to warm air blower|Control: Lower body blanket placed, not attached to warm air blower
45987152|NCT01241136|Procedure|open wide-excision pilonidal cystectomy|traditional open wide-excisional pilonidal cystectomy
45833161|NCT04761276|Device|Surgical implantation of intra ocular lens|Cataract surgery may be indicated when the cataract reduces visual function to a level that interferes with everyday activities of the patient leading the patient to desire a surgical intervention to improve its vision.
45673498|NCT01520506|Device|Covidien OneShot™ System|Placed percutaneously, the OneShot™ balloon catheter is advanced into the renal artery using a routine femoral approach in a cardiac catheterization laboratory setting. RF is applied with pre-programmed time and intensity in each of the renal arteries.
45673499|NCT01519960|Drug|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, Weeks 1- 48
45673500|NCT01519960|Drug|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, after Week 48 for Group B patients who have not experienced HBeAg seroconversion
45673501|NCT01543204|Drug|Etanercept|Administered by subcutaneous injection
45673502|NCT01488994|Biological|BAX326|All participants underwent a pharmacokinetic evaluation with BAX326 (recombinant Factor IX) followed by twice weekly prophylactic treatment for 6 months or for at least 50 exposure days, whichever occurred last.
45673503|NCT01508650|Behavioral|Usual care|Usual care control group
45673504|NCT01508650|Behavioral|Rehabilitation intervention|Multi-domain rehabilitation intervention
45673505|NCT03027154|Biological|ESAT6-CFP10 in left arm and TB-PPD in right arm|All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
45833162|NCT03473730|Procedure|Biopsy|Undergo biopsy
45833163|NCT03473730|Biological|Daratumumab|Given IV
45833164|NCT03473730|Other|Laboratory Biomarker Analysis|Correlative studies
45833165|NCT03473730|Procedure|Metastasectomy|Undergo metastasectomy
45833166|NCT03473730|Procedure|Nephrectomy|Undergo nephrectomy
45833167|NCT01679262|Device|Guedel type color-coded OPAs|The OPAs was used four different sizes as No. 8 (80 mm, green), 9 (90 mm, yellow), 10 (100 mm, red), and 11 (110 mm, orange) in regular sequence. The curvilinear distance from the incisors to the tip of the epiglottis was measured by FOB (Olympus LF-GP; Olympus Optical Co., Tokyo, Japan) with tape marking via each size of OPAs. The distance from the distal end of OPA to the tip of the epiglottis was calculated by the difference between measured distance from the incisors to the tip of the epiglottis via each OPA by FOB and typical distance from the flange to distal end of each OPA via inside tube of OPA. When the size of OPAs was longer than distance from the incisors to the tip of the epiglottis, OPAs were partly withdrawn and repositioned the distal end of OPAs is placed just above the tip of epiglottis. Then, the length from the incisors to the flange of OPAs was measured. .
45833168|NCT02984748|Device|Cochlear implant|
45833169|NCT03081858|Drug|TSD-001|Administered via intravesical instillation.
45833170|NCT03082560|Diagnostic Test|Boston Grade of Activity in Lichen Planopilaris|A clinical assessment tool to objectively and accurately measure activity and severity in lichen planopilaris over time.
45833171|NCT01679340|Drug|S-1|Mode of administration: orally (capsules) Dosing schedule:80mg/m2, Bid,D1-14,every 3 week,for 8-10cycles
45987153|NCT01241136|Procedure|minimal invasive pilonidal cystotomy|unroofing the cyst cavity and curettage the cyst
45987154|NCT00488579|Drug|Two policies of iron prophylaxis|60mg ferrous sulphate daily (+folic acid); Screening and therapy: Hb measurement on each visit, Hb>9g/dl only folic acid, Hb<9g/dl 60-120 of ferrous sulphate daily (+folic acid).
45987155|NCT01303627|Drug|remifentanil|1-4 ng/mL i.v. infusion during the surgery, maintenance dosage till LMA removal is 1.5 ng/mL.
45987156|NCT01303510|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2008-2009 season, containing per 0.5 mL dose:~15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~15 µg HA antigen of B/Florida/4/2006-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
45987157|NCT00505557|Procedure|Transaxillary dual plane technique|
45987158|NCT00488657|Device|SpeechEasy Model ITC|The delayed auditory feedback ranging from 50 to 220 ms, and the altered frequency feedback ranging from 500 to 2,000 Hz.
45987159|NCT02890654|Other|First time measure|"Initial Interview~Initial Survey,~Quality of life Scale~Kinesitherapy Review~Anxiety Scale"
45987160|NCT02890654|Other|Second time measure|"Kinesitherapy review~Second survey including numeric scale of pain~Anxiety scale~Scoliosis Research Society 22 quality of life scale"
45987161|NCT02890654|Other|Third time measure|"Scoliosis Research Society 22 quality of life Scale~Anxiety scale~Numeric scale of pain~Kinesitherapy review"
45987162|NCT02890576|Other|telemedicine|Monitoring of patients with cochlear implant with sessions of telemedicine
45987163|NCT01241175|Drug|Magnesium Sulfate|
45987164|NCT01241175|Drug|normal saline|
45987165|NCT02890615|Behavioral|Depression self-care|Toolkit and coaching
45987166|NCT05644015|Other|escape room game|Escape room game is a live action team based game where players discover clues, solve puzzles and complete tasks in one or more rooms to accomplish a specific goal (usually by escaping the room) in limited time.
45987167|NCT04324723|Behavioral|WhatsApp message|"The experimentally evaluated part of the intervention is a WhatsApp message.~The message translated from Arabic to English appears below. Dear [First name], Your BP reading during Beirut Marathon was [reading]. This indicates that you have elevated blood pressure. You should seek medical attention at your earliest convenience. Your wellbeing matters to us. Nudge Lebanon team"
45987168|NCT05643937|Behavioral|Routine health education|The control group received routine health education after catheterization, including introducing the purpose, method, advantages and complications of PICC insertion to patients before catheterization and signing informed consent. During catheterization, PICC assistant explained relevant matters needing attention and cooperative actions to the patient. After catheterization, patients were instructed to carry out grip training and limb activities.
45987169|NCT05643937|Behavioral|Routine health education + precise health education|On the basis of routine health education in the control group, the experimental group screened the high-risk behaviors of patients through the questionnaire of daily life behavior habits, and formulated the precise and concrete health education program for their high-risk behaviors
45987170|NCT02955498|Drug|Sevikar tab. 10/40mg|Reference drug: Sevikar tab. 10/40mg, 1T, single oral administration in the fasted state
45987171|NCT02955498|Drug|Lodivikar tab. 5/40mg|Test drug: Lodivikar tab 5/40mg, 1T, single oral administration in the fasted state
45987172|NCT05643898|Behavioral|Mamá, te entiendo (Mom, I get you)|"Mamá, te entiendo is a guided 8-week cognitive-behavioral app-based intervention that targets postpartum women with minor and major depression. The development of the intervention followed the CeHRes Roadmap. It includes some elements from attachment and mentalization theories.~The intervention consists of six main sequential modules and three optional modules. All modules except the two psychoeducational ones include homework. Participants will receive feedback from an e-coach. They also can contact the e-coach to solve doubts about the app content and exercises. Other sections of the app include infographics about other relevant topics (for example, How to strengthen the couple relationship), a shareable document with reading about how to support a loved one struggling with depression and a resources section with links to websites and documents of interest."
45987173|NCT01303159|Device|Endoscopic bipolar radiofrequency probe (ENDOHPB)|EndoHPB (EMcision Ltd, UK) is a single use sterile device for use at ERCP or PTC. It is a 8F (2.6mm) catheter with a 1.8m working length, that is designed to be inserted into the target duct of the hepatic, biliary or pancreatic system over a guide wire. The device is compatible with endoscopes that have a working channel of 3.2mm or greater. It comprises of a coaxial over the wire (OTW) catheter with 2 ring electrodes spaced 8mm apart at its distal end. The distal electrode is 5mm from the leading edge of the catheter. The two electrodes at the distal end of EndoHPB are designed to produce a heating zone length of approximately 25 mm.
45987174|NCT00484107|Drug|Conjugated Estrogen Cream (Premarin®)|
45987175|NCT00488696|Device|Endovascular Bifurcated Stent-Graft|Treatment of Aneurysm involving the proximal aortic arch with endovascular bifurcated stent-graft.
45987176|NCT00505596|Behavioral|Informed free choice|Women will be instructed to view an updated prenatal testing decision aid and will be told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study
45987177|NCT00488735|Behavioral|Cognitive-behavioral rehabilitation|
45673506|NCT03027154|Biological|ESAT6-CFP10 in right arm and TB-PPD in left arm|All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
45673507|NCT01488448|Drug|3% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
45673508|NCT01488448|Drug|0.9% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
45673509|NCT01518946|Drug|Midodrine HCl|dose at the subject's current dose level
45673510|NCT01518946|Drug|Placebo|single dose of matching placebo
45987178|NCT00488735|Behavioral|Traditional primary care|
45987179|NCT01302964|Drug|Placebo|Subjects randomized to placebo will receive placebo for duration of the study
45987180|NCT01302964|Drug|Mirtazapine|Subjects will receive 7.5 mg daily at the start of the trial. The dose will be increased by 7.5 mg per week for subjects weighing less than 50 kg and up to 15 mg per week for subjects weighing more than 50 kg depending on efficacy and tolerability.
45987181|NCT04515381|Other|Therapeutic Touch|Therapeutic Touch
45987182|NCT04515381|Other|Control group|Making measurements at the beginning of the research and 4 weeks
45987183|NCT04515381|Other|Sham Therapeutic Touch|Sham Therapeutic Touch
45987184|NCT00484055|Drug|Local application of collagen-gentamicin|Application of 2 sponges (5 x 20 cm) of collagen-gentamicin between the sternal halves immediately before sternal closure
45987185|NCT00484055|Procedure|Fixation of the sternotomy with more than six wires|At least 7 (or more) sternal fixation wires (preferaby put as separate single wires) used for fixation of the sternum at wound closure
45987186|NCT01302691|Drug|losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)|One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
45987187|NCT01302691|Drug|Losartan potassium|One tablet, containing 50 mg losartan potassium, orally, once daily, for 8 weeks.
45987188|NCT01302691|Drug|Amlodipine besylate|One capsule, containing 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
45987189|NCT01302691|Drug|Placebo to MK-0954E|One tablet, containing placebo, orally, once daily, for 8 weeks.
45987190|NCT01302691|Drug|Placebo to losartan potassium|One tablet, containing placebo, orally, once daily, for 8 weeks.
45987191|NCT01302691|Drug|Placebo to amlodipine besylate|One capsule, containing placebo, orally, once daily, for 8 weeks.
45987192|NCT01241084|Dietary Supplement|Antileukotrienes + Lactobacillus reuteri|Montelukast (5mg/die) + 1000000000 CFU per day (5 drops) for 2 months
45987193|NCT01241084|Dietary Supplement|Antileukotrienes + Placebo|Montelukast (5mg/die) + 5 drops of placebo daily for 2 months
45456759|NCT04465552|Other|Patients received standard of care treatment during hospitalization|All patients admitted with covid-19 will be enrolled and followed for the duration of their hospitalization as well as during outpatient follow for up to 6 months, in those recovered, to assess clinical outcomes.
45673511|NCT01488370|Device|Endotracheal intubation|Endotracheal intubation
45673512|NCT01518322|Device|NIOX MINO®|Fractional Exhaled Nitric Oxide (FeNO) will be measured with the NIOX MINO®
45673513|NCT03026998|Procedure|MRI|MRI will be performed each year during 10 years.
45673514|NCT01507246|Drug|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via PCA pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the PACU or immediately upon transfer to the floor if the stay in the PACU is less than one hour.
45833172|NCT01679340|Drug|oxaliplatin|Mode of administration: intravenously Doseing schedule: 65 mg/m2 D1,D8,every 3 week, for 6 cycles
45833173|NCT01679340|Drug|cisplatin|Mode of administration: intravenously Dosing schedule: 75mg/m2 D1,every 3 week,for 6 cycle
45833174|NCT03087084|Device|Cardiac Pacing and Impedance Measurement system|Subjects indicated for Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy Defibrillator device implant will be requested to perform some respiratory manoeuvres while impedance and electrogram signals are recorded by the system
45833175|NCT03089814|Procedure|ischemic conditioning|Four cycles of 5-min inflation of pneumatic cuff on upper extremity up to 200 mmHg, followed by 5-min deflation with no pressure.
45833176|NCT03089970|Diagnostic Test|Exhaled breath condensate collection|Breath from humans is cooled, condensed, and collected
45833177|NCT03087006|Other|Automatic Self Transcending Meditation (ASTM)|Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
45833178|NCT03087006|Other|Treatment as Usual|Usual Care includes usual care of the participants including dry eye disease medications
45833179|NCT01679574|Drug|Letrozole|•Drug: Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days
45833180|NCT01679574|Drug|Clomiphene|•Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation
45987194|NCT05643820|Drug|Permethrin 5% topical lotion|patients in group A prescribed with 5% topical permethrin lotion two overnight applications seven days apart
45987195|NCT05643820|Drug|Ivermectin|patients in group B and weighing more than 15 kgs were given oral ivermectin 200 microgram/kg two doses seven days apart
45987196|NCT01302418|Device|artus Influenza A/B RT-PCR Test|The investigational assay, used for detecting the presence of Influenza A/B.
45987197|NCT01241123|Procedure|Ambulation regimen|Assistance and encouragement for at least ambulation 3 times a day
45987198|NCT01241123|Drug|Sitz-Markers|radiopaque markers to subjectively follow the return of bowel function
45987199|NCT01241123|Radiation|Daily abdominal x-rays|daily abdominal x-rays for 7 days - to follow the radiopaque markers
45987200|NCT01241123|Device|pedometers|to record the amount of ambulation
45987201|NCT00484263|Drug|Hypertonic saline 6% -|Hypertonic saline (6%) - 5mls twice a day via a nebuliser for 12 months
45987202|NCT01242449|Drug|Trastuzumab|Initial dose 8 mg/kg i.v. Subsequently, 6 mg/kg i.v. at intervals of 3 weeks
45987203|NCT01242449|Drug|Vinorelbine|Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsule on day 1 to be taken at the hospital, and on day 8 at home.
45987204|NCT00484302|Behavioral|Cognitive behavioral therapy with motivational interviewing|Individual and group therapy, education of family and case-manager.
45987205|NCT00484302|Behavioral|Non-manualized standard treatment|Treatment by case-manager
45987206|NCT01241162|Biological|Autologous dendritic cell vaccine with adjuvant|"Week 1:~Decitabine (DAC): 10 mg/m2/day IV (Mon-Fri)~Weeks 2 and 3:~Vaccine: 3-5 E6 peptide pulsed DC (Mon)~Hiltonol applied topically to vaccine site before and after vaccination"
45987207|NCT04515303|Other|Diverse Intervention Participation in DASH|A qualitative examination of barriers and facilitators of the DASH dietary pattern, and quantitative investigation of the types of recruitment methods effective for black adults entering a digital DASH-promoting intervention.
45987208|NCT00484133|Drug|Dopamine|
45987209|NCT00484133|Drug|dobutamine|
45987210|NCT00484133|Drug|enoximone|
45987211|NCT00484133|Drug|nitroglycerine|
45987212|NCT00484133|Drug|noradrenaline|
45987213|NCT00484341|Drug|low-dose NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
45987214|NCT00484341|Drug|high-dose NGR-hTNF|NGR-hTNF: 45 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
45987215|NCT00484341|Drug|Doxorubicin|Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²
45987216|NCT01242566|Drug|Temozolomide|orally 150-200 mg/m2/day for 5 consecutive days every 4 week
45987217|NCT04515225|Other|Blood Sample|Blood Sample
45987218|NCT00484172|Procedure|blood draws|
45987219|NCT04514835|Drug|Cisplatin+Capecitabine+Sintilimab|"The first stage:concurrent chemoradiotherapy，cisplatin，25-30mg/m2 ivgtt d1;capecitabine,800mg/m2, bid d1-5，qw，5weeks;concurrent radiotherapy,1.8-2Gy/d，5d/W，50-50.4Gy.~second stage:Sintilimab, 200mg,q3w, a total of 3 times，Each infusion lasted for 30-60 min until disease progression or intolerable toxicity, with a maximum duration of no more than 12 months."
45833181|NCT01679574|Drug|Metformin|•Drug: metformin HCl (Cidophage®; CID,Cairo, Egypt) metformin HCl 1500 daily for 3 months
45833182|NCT01679652|Drug|Nebivolol|Tablet i blinded in capsula
45833183|NCT01679652|Drug|placebo|
45833184|NCT05346198|Drug|CART-BCMA|The CART-BCMA (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.
45833185|NCT03086928|Other|lava ultimate|resin nano ceramic material
45833186|NCT03086928|Other|E.max cad|Lithium disilicate glass ceramic
45833187|NCT03464760|Dietary Supplement|3.5g of spirulina per day in 1% silicone|5 tablets of 700mg per day
45833188|NCT03464760|Dietary Supplement|placebo|5 tablets per day of potato-based placebo
45833189|NCT04761744|Drug|Nivolumab|Study treatment consists of nivolumab 3mg/kg, and will be repeated every 2 weeks.
45833190|NCT01679886|Radiation|Rubidium PET|Rubidium PET
45833191|NCT04402476|Device|Powder Free Polychloroprene Surgical Gloves, Sterile. Low Dermatitis Potential, tested for use with Chemotherapy drugs.|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
45987220|NCT00484211|Drug|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
45987221|NCT00488813|Drug|Third generation cephalosporins|
45987222|NCT00484380|Procedure|Coronary scanner|multislice spiral computed tomography coronary angiography
45987223|NCT00484250|Drug|metronidazole,doxycycline|
45987224|NCT00484458|Device|Interspinous process and dynamic stabilization (Wallis System)|Interspinous stabilization
45987225|NCT00484458|Device|Total Disc Replacement|Total disc
45987226|NCT00488891|Drug|Paliperidone ER|Route = oral. Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
45987227|NCT00488891|Drug|Atypical antipsychotics (AAP)|Route = oral. AAP including quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
45987228|NCT00484497|Drug|cyclamax|
45987229|NCT00484328|Drug|Ribavirin|different dosing regimes of Ribavirin
45987230|NCT04514640|Behavioral|The Calm app|"All participants (n=100) will be asked to download the Calm app to their phone. Participants will then receive an email containing 4-weeks of free access to Calm. All participants be asked to use Calm once per day for at least 10 minutes based on their group assignment (i.e., general meditation during daytime, sleep meditation before bed, or sleep stories before bed). Participants will be asked to turn on the take a moment feature in the Oura app in order for the Oura ring to collect neurophysiological measures before, during, and after meditations. Additionally, participants will be asked to complete sleep diaries every day throughout the intervention."
45987231|NCT00488930|Other|Observational|data collection ONLY
45987232|NCT00484575|Drug|Sevoflurane|given by infusion via AnaConDa for sedation with target MAAS 2-3
45987233|NCT00484575|Drug|propofol|propofol given intravenously for sedation in control group
45987234|NCT04697342|Behavioral|strategy of education|"one of the strategies is microvideo with nursing information system(NIS); another of the strategies is workshop with NIS.~NIS of PI education is the routine education"
45987235|NCT04514796|Drug|Adalimumab|SB5 (adalimumab), 40 mg, single-dose
45987236|NCT00484367|Behavioral|Adolescent group therapy|Adolescent group therapy
45987237|NCT00484367|Behavioral|Transitional family therapy|Transitional family therapy
45987238|NCT00484614|Procedure|Positron Emission Mammography|Molecular Imaging Device
45987239|NCT00484614|Procedure|Magnetic Resonance Imaging|Imaging Device
45833192|NCT03089736|Behavioral|Education|Six education areas was offered: pain and pain physiology, pain medication, side effects and prevention of side effects, abuse of medications, sleep advice and advice on anxiety.
45987240|NCT00488969|Drug|Modified-release morphine|During the first three weeks of each treatment (drug or placebo), the dose will be escalated toward a maximally tolerated dose or a dose sufficient to eliminate pain (up to a ceiling dose of 120 mg), whichever is reached first. During the entire fourth and fifth week of each period, subjects will receive their maximally tolerated dose of study medication. During the sixth and seventh weeks, they will undergo a seven-day dose tapering and a seven-day complete washout of the study drug.
45673515|NCT01507246|Drug|EXPAREL (bupivacaine liposome injectable suspension)|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
45987241|NCT00488969|Drug|Placebo|
45987242|NCT00484653|Procedure|cervical smear|biological analysis
45987243|NCT04697108|Other|Shoulder reproduction teste assisted by laser pointer|In the step (1) of Familiarization in which the SRTLP was applied through a single evaluator with the aim of knowledge and understanding of the test. After five minutes, step (2) test started. In this step, the test was applied twice, by different evaluators, with an interval of five minutes between applications (inter-rater reliability). Ten minutes after the end of the tests, step (3) retest (intra-rater reliability) was started, following the same procedures as in step 2. The order of the evaluators was randomized through a draw in Excel, the order of randomization of the steps (2) and (3) was the same in order not to influence intra-rater reliability
45987244|NCT00484692|Drug|sustained-release bupropion (Zyban(R))|
45987245|NCT00484692|Behavioral|Psychodynamic Model Training (R) = PDM(R)|
45987246|NCT00489008|Procedure|Stereotactic Body Radiation Therapy (SBRT)|"Cohorts 1 & 2: 50 gray (GY) with 12.5 GY per Fraction for 4 treatments~Cohort 3: 40 GY with 10 GY per Fraction for 4 treatments"
45987247|NCT00484731|Procedure|Infiltration with Saline|Infiltration with Bupivacaine according to protocol
45987248|NCT00484731|Procedure|Infiltration with Bupivacaine|
45987249|NCT04515069|Procedure|traditional technique of tooth preparation|"Depth cutter wheels of predetermined depths (Komet, Germany) were used to perform the preparation directly on the tooth structure.~Depth cuts were performed on the labial surface using depth cutter wheels (Komet, Germany) with radius of 0.3 mm and 0.5 mm which is directly related to the thickness of the laminate veneers in the cervical and incisal one thirds respectively. Then islands of tooth structure between depth orientation grooves were removed.~Proximal reduction:~The interproximal reduction was completed just labial to the contact areas using a round end tapered diamond stone (Mani, Japan), and polishing was performed using polishing strips (Sof-Lex, 3M ESPE, Seefeld, Germany).~Incisal reduction:~Vertical depth grooves were created. Then, the round end tapered diamond stone (Mani, Japan)was used to create 1.5 mm incisal butt joint preparation.~Then, finishing and polishing of tooth preparation was performed."
45987250|NCT04515069|Procedure|aesthetic preevaluative temporary technique for tooth preparation|"The data obtained from digital smile design was used for construction of the diagnostic wax-up. The wax-up was then be transferred to the mouth using a silicone index, creating the aesthetic pre-evaluative temporary (APT). The APT was tested esthetically and functionally. Once approved by the operator and the patient, tooth preparation was performed through the APT. Depth cuts were performed similar to those performed in the traditional preparation with the difference of being prepared on the aesthetic pre-evaluative temporary instead of directly on the dental structure. Using tapered stone with round end (Mani, Japan), islands of tooth structure between depth orientation grooves were removed.~Proximal reduction, Incisal reduction Finishing and polishing of tooth preparation were carried out using the same technique as in the Group T with the difference of being performed through the APT, resulting in minimal tooth preparation"
45987251|NCT00484484|Drug|Ketamine|Ketamine
45833193|NCT03089736|Behavioral|Self Care|The following instructions on self-care for pain relief: apply ice or crushed ice in the oral cavity, lubricating and antiseptic mouth rinses, pain relieving gel, tongue movements and gaps exercises. Prevention of dryness in the mouth and throat; saliva stimulants and saliva substitute agents in different preparations, increased measures of good oral hygiene. Physical activities and regular rest once to several times per day. Sleep restriction and measures to treat sleep disorders.
45673516|NCT01507090|Device|Mercy TAPE|2D Mercy TAPE and 3D Mercy TAPE
45833194|NCT03089736|Other|Treatment as usual (TAU)|pharmacological treatment + advices
45987252|NCT00484523|Procedure|SPET, PET and MRI|60 healthy subjects after a a consultation with a neurologist for wich 4 examinations will be programmed in two days ( 1 cerebral MRI, 1pet scan, 1 spet, 1 datascan
45987253|NCT04514601|Other|Standard Operating Protocol|This was a written protocol on how the handover process should be conducted.
45987254|NCT00484562|Device|Standard oxygen delivery system|Standard oxygen tank with pulse dose regulator
45987255|NCT00484562|Device|Homefill oxygen delivery system|Homefill oxygen delivery system, pre-filled from a larger oxygen concentrator base unit.
45673517|NCT03870022|Device|Pivot Breath Sensor System|Collect breath sample from the Pivot Breath Sensor to measure the carbon monoxide in the participant's exhaled breath, along with recording responses to user documentation questions and rating scales.
45833195|NCT03432000|Other|Performances of patients and controls on temporal task|To carry out this work, we will rely on an experimental paradigm (derived from Michotte's paradigm) which makes it possible to explore the links between temporal sequencing and perception of causality, validated in the normal subject. subjective consequences of these alterations will be explored using a phenomenological-inspired clinical scale (EAWE time-scale items)
45987256|NCT00484562|Device|Helios oxygen delivery system|Liquid oxygen portable system pre-filled from a larger liquid oxygen tank
45987257|NCT00484562|Device|FreeStyle oxygen system|portable battery-powered oxygen concentrator delivery system
45987258|NCT00484601|Drug|Ifosfamide|
45987259|NCT00484601|Drug|Doxorubicin|
45987260|NCT00484770|Device|Brain Natriuretic Peptide Levels -- Diagnostic testing|
45987261|NCT00484770|Other|clinical assessment|
45987262|NCT00484640|Drug|Coumadin|
45987263|NCT04514718|Device|Holmium laser|low energy holmium laser
45987264|NCT00489125|Other|physiologic testing|physical testing of range of motion, grip strength etc.
45987265|NCT00484757|Drug|Orexine A|
45987266|NCT04514406|Device|APERTO OTW DCB|Drug Coated Balloon Angioplasty
45987267|NCT00489164|Device|Sirolimus-Eluting BX Velocity Balloon-Expandable Stent|
45987268|NCT00484809|Drug|Enbrel (Etanercept)|
45987269|NCT00489242|Procedure|Procedure / Percutaneous angioplasty|
45987270|NCT04514094|Drug|SDF|SDF promotes enamel and dentin remineralization, as well as inhibit the growth of cariogenic bacteria. the Food and Drug Administration (FDA) approved SDF as a device for reducing tooth sensitivity in the USA.
45987271|NCT04514094|Procedure|ART|The ART technique involves caries excavation by hand instruments only with care to avoid pulp exposure. Such excavation is mainly from the periphery of the lesion to achieve a good seal of the restoration and minimize leakage. The tooth is then restored by glass ionomer cement.
45987272|NCT00489320|Device|Cypher Stent|
45987273|NCT00484848|Device|Vortex port and Celsite port|
45987274|NCT00484796|Procedure|MED-SEP|intraoperative neurophysiological monitoring
45987275|NCT00484796|Procedure|TRI-SEP|intraoperative neurophysiologic monitoring
45987276|NCT00484796|Procedure|neuropsychological tests|neurological short- and longterm outcome
45987277|NCT04514289|Drug|Indocyanine green solution|Indocyanine green (ICG) is a cyanine dye used in medical diagnostics.ICG is a fluorescent dye that is used in medicine as an indicator substance.
45987278|NCT00484835|Procedure|Performing abdominal hysterectomy using gyrus electrocoagulation forceps|
45987279|NCT00484913|Procedure|abdominal hot compress|
45987280|NCT00484926|Drug|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
45987281|NCT00484926|Drug|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
45987282|NCT01242683|Behavioral|Vivamos Activos Fair Oaks Program|"Comparison of Case-management vs. Case-management plus Home Visits vs. Usual Primary Care.~Case-management: Five 60 minute individual and 15 90 minute group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator.~Home-visits: Seven home visits provided by a community health worker to provide life-style/environmental support for behavior change to facilitate weight loss.~Usual primary care: Usual care provided at health center that is available to participants in all three study arms."
45987283|NCT01242722|Device|CRT-D|Cardiac pacing via a pulse generator and implanted intracardiac leads
45987284|NCT00484965|Procedure|Coronary stenting|
45987285|NCT02275806|Drug|Irinotecan|
45987286|NCT02275806|Drug|Cisplatin|
45987287|NCT01241409|Drug|Rabeprazole sodium: Treatment A|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
45987288|NCT01241409|Drug|Rabeprazole sodium: Treatment B|One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
45987289|NCT01241409|Drug|Rabeprazole sodium: Treatment C|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered after consumption of a standardized high-fat high-caloric breakfast. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
45987290|NCT01242839|Device|CACICOL20|CACICOL20 is a solution of dextran & poly(carboxymethylglucose sulphate)in physiological salt serum. CACICOL20 is presented in 0.33 mL strip. One drop is instilled at each application to impregnate cornea.
45987291|NCT01242839|Device|Placebo|It is the placebo of CACICOL20, containing dextran in physiological serum salt. It is presented, like CACICOL20, in a 0.33 mL strip. One drop is delivered at each application.
45987292|NCT02275845|Drug|Metformin|Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg (from 14 weeks pregnancy untill delivery)
45987293|NCT02275845|Other|control diet|2000 calories/day diet, with an adequate distribution of carbohydrates during the day
45987294|NCT01241201|Dietary Supplement|Priobiotic supplement VSL#3|four weeks, twice daily two sachets of VSL#3, a priobitics mixture
45987295|NCT02275884|Dietary Supplement|Dark chocolate (85% cocoa)|
45987296|NCT02275884|Dietary Supplement|White chocolate (0% cocoa)|
45987297|NCT00489398|Drug|epinastine HCL and olopatadine HCL|
45987298|NCT04514445|Other|Observational|
45987299|NCT01241357|Device|Hepatic biomagnetic susceptibility measurement|Subjects will first have an ultrasound study to determine the location of the liver and measure the distance from skin surface to the liver. Subjects will then be examined with the high Tc susceptometer to determine the amount of iron in the liver. The entire procedure will usually take one-half hour or less.
45987300|NCT00485004|Device|Cutting balloon|Cutting balloon
45987301|NCT00485004|Device|Sirolimus-eluting stent|Sirolimus-eluting stent
45987302|NCT01241396|Other|Any MMY treatment|Any line of treatment for MMY
45987303|NCT00485043|Behavioral|Modified T'ai Chi: T'ai Chi for Arthritis|
45987304|NCT00484991|Drug|Sapropterin dihydrochloride|20mg/kg/day orally, physicians may adjust the dose within a range of 5-20mg/kg/day as warranted by their clinical judgment.
45987305|NCT00485121|Drug|Ezetimibe|
45987306|NCT00489437|Device|ID-PaGIA Heparin/PF4 antibody test|All patients have a 4T's Score completed, a same-day PaGIA performed and a Serotonin Release Assay performed.
45987307|NCT00489437|Procedure|Clinical Prediction Score-HIT Score Card|"clinical prediction rule~rapid immunoassay"
45987308|NCT00485160|Drug|Continuous indomethacin|
45987309|NCT00485160|Drug|ibuprofen|
45987310|NCT00485030|Device|Cypher|sirolimus-eluting stent
45673518|NCT03870022|Device|Similar Carbon Monoxide breath sensor system|Collect breath sample from a similar breath sensor to measure the carbon monoxide in the participant's exhaled breath.
45987311|NCT00485030|Device|Xience-V|everolimus-eluting stent
45987312|NCT00485199|Procedure|Pneumatic Retinopexy|
45987313|NCT00485199|Procedure|Vitrectomy with Gas|
45987314|NCT04514172|Device|Passive industrial exoskeleton for back support|The goal is to compare the human response to the simulated industrial tasks
45987315|NCT04514172|Other|The protocol will be performed without exoskeleton|The protocol will be performed without exoskeleton
45987316|NCT04513821|Drug|Mino-Lok Therapy (MLT)|Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter. Mino-Lok is made available through this expanded access protocol to patients who otherwise do not qualify for the phase 3 clinical trial (NCT02901717) Other Name: Standard of care antibiotics + Mino-Lok
45987317|NCT00485108|Drug|prednisolone 1%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
45987318|NCT00485108|Drug|ketorolac 0.5%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
45987319|NCT00485108|Drug|Artificial Tears (Methyl cellulose drops)|eye drop once in each eye treated, 4 times / day for 5 days post-laser
45987320|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu two times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity
45987321|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
45987322|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 3 x 10e11 cfu i.w. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
45987323|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 4 x 10e 11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
45987324|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 2 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
45987325|NCT01242917|Drug|CCX-354-C|200mg film-coated tablets once daily for 12 weeks + Methotrexate
45987326|NCT01242917|Drug|Placebo|Placebo film-coated tablets twice daily for 12 weeks + methotrexate
45987327|NCT01242917|Drug|CCX354-C|100mg film-coated tablets twice daily for 12 weeks + methotrexate
45673519|NCT01464346|Device|Enlite Sensor|This is the Enlite sensor (all subjects)
45673520|NCT02073448|Drug|GK530G|
45673521|NCT02073448|Drug|CD0271|
45673522|NCT02073448|Drug|CD1579|
45987328|NCT04513704|Drug|Oral Semaglutide|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days).
45673523|NCT01487200|Drug|FX006 10 mg|single 3 mL IA injection
45673524|NCT01487200|Drug|FX006 40 mg|single 3 mL IA injection
45673525|NCT01487200|Drug|FX006 60 mg|single 3 mL IA injection
45673526|NCT01487200|Drug|TCA IR 40|single 1 mL IA injection
45673527|NCT01463878|Dietary Supplement|Glycerna|Diabetes specific formula
45673528|NCT01463878|Dietary Supplement|Jevity - Control Diet|Control Diet
45987329|NCT01241474|Dietary Supplement|EPAX 6000 (marine omega 3 EPA/DHA fatty acid concentrates|6 x 1g capsules per day of marine oil (contains 3g/d docosahexaenoic acid plus eicosapentaenoic acid) for a 9 month period
45987330|NCT01241474|Dietary Supplement|Maize (corn) oil|6 x 1g capsules per day for 9 months
45987331|NCT00485238|Procedure|Argon laser Iridoplasty|
45987332|NCT00485238|Drug|Intravenous acetazolamide|
45987333|NCT00485277|Biological|MVA-BN-HER2|Experimental vaccine, subcutaneous injection q3weeks x 3
45987334|NCT01242956|Behavioral|verum group|video-based training after stroke
45987335|NCT01242956|Behavioral|Placebo group|non-video group
45987336|NCT00485316|Procedure|Laparoscopic assisted resection of colorectal carcinoma|
45987337|NCT00485147|Procedure|Recording of GPS during a free walking in a public park|Analyse the clinical change after surgery from GPS measurements and compare it with laboratory measurement.
45987338|NCT00485355|Procedure|conventional laparoscopic hysterectomy|Total laparoscopic hysterectomy
45987339|NCT00485355|Procedure|robotic assisted laparoscopic hysterectomy|Robotic assisted laparoscopic hysterectomy with DaVinci robot
45987340|NCT04513509|Drug|Atenolol, Bisoprolol, Metoprolol, Nebivolol, Propranolol, Diltiazem, Verapamil, digoxin|Start with empirical lower dose for 3 months, and then titrate up
45833196|NCT03089502|Other|Exercise Rehabilitation|The intervention will consist of a walking or biking program performed at an intensity of 60-80% of VO2peak, progressing to a minimum of 150 minutes/week. Each session will include a warm up and cool down. One weekly exercise session will be supervised and participants will be expected to complete four additional aerobic training sessions at home or in the community each week. Resistance training will be introduced during the 4th week of the program and will consist of 10 exercises targeting all major muscle groups. One weekly resistance training session will be supervised following the aerobic training, and participants will be expected to complete one to two additional sessions at home or in the community each week. Weekly education sessions will follow the supervised exercise session.
45987341|NCT00485342|Drug|Peg-interferon alpha 2a and ribavin|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (1000 mg/day if weight < 75 kg and 1200 mg/day if weight ≥ 75 kg).~Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
45987342|NCT00485342|Drug|ribavirin with adaptation dose|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (dose adaptation) Dose adaptation : Day 7, dependant of result of AUC Ribavirin dose increments : 200 mg, 400 mg or 600 mg with a maximum of 50% of the initial dose (600 mg) applied every 4 days up to the adjusted dose proposed in order to reach the targeted AUC.~The maximum daily dose will not exceed 3600 mg Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
45987343|NCT00485394|Drug|OT-551|OT-551 0.3% ophthalmic solution, 2 drops 4 times daily
45987344|NCT00485394|Drug|OT-551|OT-551 0.45% ophthalmic solution, 2 drops 4 times daily
45987345|NCT00485394|Drug|vehicle placebo|OT-551 0% ophthalmic solution, 2 drops 4 times daily
45987346|NCT01242995|Procedure|Endoscopic Retrograde Cholangiopancreatography (ERCP)with Cholangiopancreatoscopy using the thin scope|Endoscopic Retrograde Cholangiopancreatography (ERCP) with cholangiopancreatoscopy using the thin scope system.
45987347|NCT04513587|Behavioral|CBT-based weight loss model|Methods of cognitive behavioral psychotherapy
45987348|NCT04513587|Behavioral|Control|Treatment as usual
45987349|NCT00489593|Drug|Olanzapine|2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
45987350|NCT01241487|Drug|valsartan/amlodipine|160/10 mg
45987351|NCT00489632|Behavioral|Questionnaire|Questionnaires administered to pediatric patients and their parent(s) or caregiver(s).
45987352|NCT00505791|Drug|Nesiritide|Study drug will be administered for 24 hours. Study drug will be initiated with a 2-µg/kg loading bolus followed by .01-µg/kg/min infusion. This may be increased at a rate of .005-µg/kg/min. every 3 hours until maximum dose of .03-µg/kg/min. Any increase in the infusion rate will be preceded by a 1-µg/kg bolus and increases in infusion rates will be permitted only in patients who have a systolic blood pressure > 100 mmHg.
45987353|NCT00485420|Other|Internet based disease management program|Usual Care is augmented with internet-based education, self-monitoring and clinician monitoring
45987354|NCT02955108|Procedure|Distractive Auditory Stimuli|"Participants will self-select 1 music piece from a list of choices to keep the rhythm and tempo consistent throughout the 6MWT. The instructions to participants for selecting the music will be standardized. TThe music volume will be standardized to be moderately loud as rated by participants for the music condition. Participants will not be specifically instructed to synchronize their walking movements with the music tempo. The music is based on a cognitive therapy (distraction) strategy conceptual framework. Music will be played during the 6MWT (in-task) only."
45987355|NCT02955108|Procedure|No Distractive Auditory Stimuli|Participants will wear headphones with no music playing
45987356|NCT04513626|Drug|DORAVIRINE 100 MG [Pifeltro]|Immediate switch
45987357|NCT04697303|Other|anorectal function test|anorectal function test
45987358|NCT02274207|Device|NPWT application|NPWT mode is cyclic mode : -125~-50 mmHg
45987359|NCT00485459|Drug|Atomoxetine Hydrochloride|
45987360|NCT00485459|Drug|Placebo|
45987361|NCT04513431|Biological|Anti-CEA-CAR T|T cells modified with CEA targeted chimeric antigen receptor.
45987362|NCT00489710|Drug|talabostat mesylate|
45987363|NCT00489710|Procedure|diagnostic procedure|
45987364|NCT00489710|Procedure|enzyme inhibitor therapy|
45987365|NCT00489710|Procedure|flow cytometry|
45987366|NCT00489710|Procedure|laboratory biomarker analysis|
45987367|NCT00489710|Procedure|non-specific immune-modulator therapy|
45987368|NCT02274246|Drug|gadobutrol|Gadobutrol administration in healthy volunteers
45987369|NCT01241630|Procedure|Somatosensory reflex arch (Xiao Procedure)|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
45987370|NCT00489749|Procedure|Protected early weightbearing/Achilles tendon surgery|
45987371|NCT04513275|Drug|non-medicine intervention|rating by MCCB only one time
45987372|NCT02274194|Device|Nasal CPAP|use of nasal mask to titrate CPAP during a manual full night: if nasal mask is the best interface during titration compared with oronasal mask - patients will go 30-day period of treatment
45987373|NCT02274194|Device|Oronasal CPAP|use of oronasal mask to titrate CPAP during a manual full night: if oronasal mask is the best interface during titration compared with nasal mask - patients will go 30-day period of treatment
45987374|NCT00505830|Other|questionnaires|"Primary outcome:~Autism Spectrum Quotient (AQ)~Secondary outcome measure:~Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score"
45987375|NCT02274233|Drug|SP-420|
45987376|NCT04697511|Drug|Midazolam|Participants will receive single oral dose of midazolam on Days 1, 3 and 13 under fed conditions.
45987377|NCT04697511|Drug|M2951|Participants will receive multiple oral doses (twice daily) of M2951 on Day 3 to Day 13 under fed conditions.
45987378|NCT00485511|Drug|Hydroxyurea|
45987379|NCT02274272|Other|ADR-1|two ADR-1 capsules, once daily, QD
45987380|NCT02274272|Other|GMNL-263|two GMNL-263 capsules, once daily, QD
45987381|NCT02274272|Other|placebo|two placebo capsules, once daily, QD
45987382|NCT04512963|Drug|Progerinin|100 mg/g nano-suspension for oral use
45987383|NCT04512963|Drug|Placebo|A substance that has no therapeutic effect, used as a control in testing Progerinin
45987384|NCT00485498|Drug|Olanzapine Hydrochloride|
45673529|NCT04080544|Drug|[18F]AV-1451|The subject will receive up to a target dose of 370 megabecquerel (MBq) as a single IV bolus of [18F]AV-1451.
45673530|NCT04080544|Procedure|Positron Emission Tomography|Approximately 80 minutes after injection subjects will be placed in the UTSW PET/CT scanner for a 20-minute brain scan.
45673531|NCT01505608|Drug|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.
45833197|NCT03089658|Drug|Avelumab|Avelumab should be administered intravenously as per the recommended dose. Administration of Avelumab should continue according to the recommended schedule until disease progression or unacceptable toxicity.
45833198|NCT03089190|Dietary Supplement|DC7-2|Effects on appetite
45833199|NCT03089190|Dietary Supplement|DC7-2 + potato protein isolate|Effects on appetite
45833200|NCT03089190|Dietary Supplement|Potato protein isolate|Effects on appetite
45833201|NCT03089190|Dietary Supplement|Placebo|Inactive whey protein, not expected to affect appetite.
45833202|NCT03089268|Procedure|Colonoscopy|A colonoscopy will be performed to all individuals.
45987385|NCT00485498|Drug|Risperidone|
45987386|NCT01302067|Drug|Fesoterodine 8mg|Oral, 1 tablet per day, 12 weeks duration, 8mg/day
45987387|NCT01302067|Drug|Fesoterodine 4mg|Oral, 1 tablet per day, 12 weeks duration, 4mg/day
45987388|NCT01302067|Drug|Placebo|Oral, 1 tablet per day, 12 weeks duration
45987389|NCT00485550|Drug|Atomoxetine Hydrochloride|
45987390|NCT00485550|Drug|Methylphenidate Hydrochloride|
45987391|NCT00485550|Drug|Placebo|
45987392|NCT04697147|Behavioral|Conscious Discipline-Based Environmental Enrichment Intervention|Conscious Discipline, a social-emotional skills-based learning program that draws on current brain research and fosters enhanced connections between parents and their children.
45987393|NCT00485537|Procedure|oocyte retrieval and ICSI procedure|
45987394|NCT00485628|Drug|Atomoxetine Hydrochloride|
45987395|NCT00485576|Drug|eculizumab|eculizumab 600 mg or matching placebo iv infusion.
45987396|NCT00485667|Drug|SKY0402|Subects received either 300mg or 450mg
45987397|NCT00485667|Drug|Moxifloxacin 400mg|
45987398|NCT00485667|Drug|Placebo injection|
45987399|NCT00485667|Drug|Placebo tablet|
45987400|NCT01301950|Other|Custom Patient Instrumentation|TruMatch® Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation (CPI). TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon
45987401|NCT01301950|Other|Conventional Instruments|Total Knee Arthroplasty implanted using conventional instruments (non-CPI) and surgical technique.
45987402|NCT00489905|Drug|Zolderonic acid (Zometa)|
45987403|NCT00485615|Drug|Omega 3 Joy enteric coated concentrated fish oil|1500-3000mg; one per day
45987404|NCT00489944|Drug|cisplatin|
45673532|NCT01505608|Drug|Temozolomide|Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle
45673533|NCT01505608|Drug|Irinotecan|Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.
45673534|NCT01486966|Drug|insulin detemir|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
45987405|NCT00489944|Drug|sunitinib malate|
45987406|NCT00489944|Drug|tamoxifen citrate|
45987407|NCT00489944|Procedure|adjuvant therapy|
45987408|NCT00485706|Procedure|high calcium dialysate|
45987409|NCT00505869|Behavioral|Health & Wellness Intervention|Counseling focusing on health concerns related to pregnancy, information about smoking and pregnancy, tips for quitting, and problem-solving skills to manage situations that might be triggers for smoking.
45987410|NCT00505869|Behavioral|Questionnaire|Questionnaires about mood, confidence in quitting, smoking behavior, and social support.
45987411|NCT00505869|Behavioral|Mood Management Intervention|Counseling focusing on learning to manage negative moods (depressed mood, tension, anxiety), as well as providing tips for quitting smoking, problem-solving skills, and information about smoking and pregnancy.
45987412|NCT00505947|Drug|infliximab|infliximab 5 mg/Kg body weight by intravenous infusion
45987413|NCT00505947|Drug|placebo|placebo 5 mg/Kg body weight by intravenous infusion
45987414|NCT00489983|Drug|pemetrexed|
45987415|NCT00489983|Drug|gemcitabine|
45987416|NCT01241682|Biological|DC + CTX|3x 50x10e6 DC + cyclophosphamide
45987417|NCT01241669|Drug|E5555|Drug: Oral E5555 400 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV.
45987418|NCT01241669|Drug|E5555|Drug: Oral E5555 100 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV bolus.
45987419|NCT00505986|Procedure|endometrial biopsy|
45987420|NCT01241825|Other|Trident sugarless chewing gum.|Patients will be randomly divided into 2 groups, one subject group (these chew gum) and one control group (these do not chew gum). The subjects will have to chew Trident sugarless chewing gum for 20-30 minutes every 2 hours, all together 4 times at t=0 h, t=2, t=4 and t=6 h.
45987421|NCT01241825|Other|One control group (these do not chew gum).|The control group will not chew chewing gum while undergoing capsule endoscopy
45987422|NCT01241721|Device|Positron Emission Mammography (PEM)|Phase 1 of the study will involve imaging the breast with cancer up to 3 times over 2 hours using one half (1/2) of the standard dose of the radioactive tracer, F18FDG, for PEM imaging. If this reduced dose is equivalent to the standard dose then one quarter (1/4) dose will be tested to find the lowest effective radiation dose of tracer to see breast cancer. Phase 2 of the study will involve imaging of both breasts several times over a shorter duration using the lowest effective dose of tracer identified in the first part of the study. This will allow us to examine the reliability of PEM to identify a second unsuspected abnormality in either breast. Patients will be offered biopsy by ultrasound, MRI or PEM as clinically appropriate of lesions suspected of being cancer prior to final surgical planning.
45673535|NCT01486966|Drug|insulin aspart|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
45673536|NCT01486966|Drug|insulin NPH|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
45673537|NCT01486966|Drug|human soluble insulin|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
45673538|NCT01486966|Drug|metformin|For subjects previously treated with metformin, the dosage and frequency will be kept unchanged
45673539|NCT04080076|Drug|Acthar 80 UNT/ML Injectable Solution|ACTHar 80 Units SQ 1042 x Week
45833203|NCT03089268|Procedure|Polypectomy or biopsy|All lesions will be removed or biopsied during the procedure
45833204|NCT03089268|Genetic|Molecular analysis|"Molecular analysis will be performed in all colorectal cancers and in those polyps diagnosed with serrated lesion"
45833205|NCT03089424|Device|Placebo PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 0 J. At the end of the 12 treatment sessions, patients will receive a total dose of 0 J.
45673540|NCT04080076|Drug|Oral Tab Tacrolimus|Oral Tab Tacrolimus (1.0 mg PO BID) in combination with ACTHar 80 Units SQ 2 X week
45673541|NCT01900665|Drug|Solanezumab|Administered Intravenously (IV)
45673542|NCT01900665|Drug|Placebo|Administered IV
45673543|NCT01900431|Drug|Sarilumab|Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
45987423|NCT01241942|Device|Steen Solution™|This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs. After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™ and taken to UNC Hospitals (UNCH) where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNCH based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP with Steen Solution™ will be transplanted into recipients as per current clinical practice.
45987424|NCT01241942|Other|Conventional Lung Transplant|No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.
45987425|NCT00490178|Drug|Fenofibrate 80 mg and metformin 1000 mg (fixed combination)|
45987426|NCT01241799|Procedure|Endoscopic ultrasound guided fine needle aspiration biopsy|22 gauge fine needle aspiration biopsy of the pancreatic mass with the stylet in. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the style out is then used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle masses done.
45987427|NCT01241799|Procedure|Stylet out FNA first, Stylet in FNA second|22 gauge FNA biopsy of pancreatic mass with the stylet out. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the stylet in is used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle passes done.
45987428|NCT01241838|Device|Pacemaker|Routine postoperative temporary pacemaker Rate change of 65-80-95-110-125 beats/second in random order at day 3-4 after operation
45987429|NCT00485771|Drug|Olanzapine|
45987430|NCT00485771|Drug|Fluoxetine|
45987431|NCT00485771|Drug|Lamotrigine|
45987432|NCT01241877|Dietary Supplement|astaxanthin|astaxanthin
45987433|NCT01241877|Dietary Supplement|placebo|placebo
45987434|NCT04512729|Diagnostic Test|Colonoscopy|"For all patients, either moderate sedation with intravenous midazolam or conscious sedation with intravenous propofol will be administered in a standard fashion prior to undergoing colonoscopy.~The colonoscope will be inserted and cecum will be intubated. Photo documentation of the cecum will be performed. The colonic mucosa will be carefully visualized upon withdrawal of the colonoscope.~The time spent in inspecting the mucosa during withdrawal of the colonoscope will be documented as the withdrawal time. Meticulous technique will be employed during the withdrawal phase with special efforts to visualize portions of colonic mucosa on the proximal aspects of haustral folds, flexures and valves.All polyps detected will be documented: size, location, and morphology. Photo documentation of the polyps will be performed."
45987435|NCT00485784|Other|Blood test|Blood test
45987436|NCT00485810|Drug|Olanzapine Hydrochloride|
45987437|NCT04512651|Other|Tibiotarsal Thrust Manipulation|The dancers were positioned in dorsal decubitus position with the heel outside the stretcher. The osteopath positioned in a lateral feint, inflected knees and forearms in the same plane as the participant's leg. With the internal hand slipped the pinky finger on the medial edge of the foot to the talus neck, the other fingers on the dorsum of the foot and the thumbs controlling the first metatarsus. The position of the talus in relation to the tibia was corrected, initially by placing the foot in eversion and then in dorsal flexion. The osteopath left the body weight behind, causing a traction in the joint. The thrust consisted of a impulse of high speed and low amplitude impulse in a caudal direction, closing the elbows20. The technique was performed until the obtainment (achieved) the joint noise only in the restricted foot, and only one service was performed. After one week, a reassessment of the painful sensation after the dance was performed.
45987438|NCT04512651|Other|Simulation Tibiotarsal Thrust Manipulation|Simulation of the technique Tibiotarsal Thrust Manipulation, with the participants and the osteopath positioned in the same way as the IG, however there was no reproduction of joint noise.
45987439|NCT00490373|Drug|pemetrexed|
45987440|NCT00485823|Drug|Olanzapine Hydrochloride|
45987441|NCT00485823|Procedure|Weight Management Program|
45987442|NCT00485849|Drug|Atomoxetine Hydrochloride|
45987443|NCT04512417|Drug|Camrelizumab+Radiotherapy|The combined treatment group received radiotherapy for recurring or metastatic lesions: at least one or more lesions were irradiated, stereotactic body radiotherapy (SBRT, 8Gy/time, 3-5 times) or conventional radiotherapy (parts not suitable for SBRT, total Dose 30Gy or more); start immunotherapy within 8 weeks after radiotherapy.Until PD or toxicity is intolerable or up to 24 months.
45987444|NCT04512417|Drug|Camrelizumab|Camrelizumab,200mg,Q3W,Until PD or toxicity is intolerable or up to 24 months.
45987445|NCT00485888|Drug|Cipralex|10-20mg; one per day
45987446|NCT00485888|Drug|Placebo|Matched to Cipralex
45987447|NCT00485862|Drug|Atomoxetine Hydrochloride|
45987448|NCT00485862|Drug|Sertraline|
45987449|NCT00485862|Drug|Placebo|
45987450|NCT00485927|Behavioral|stress|
45987451|NCT00485901|Drug|Olanzapine Hydrochloride|
45987452|NCT00485901|Drug|Haloperidol|
45673544|NCT01900431|Drug|Prednisone|Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
45673545|NCT01900431|Drug|Methotrexate|Pharmaceutical form: Tablet or Capsule or Suspension; Route of administration: Orally or intravenously or intramuscular
45673546|NCT01900431|Drug|Folic/folinic acid|Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
45673547|NCT01900431|Other|Placebo (for Sarilumab)|Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
45833206|NCT03089424|Device|PBMT active|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 220.05 J. At the end of the 12 treatment sessions, patients will receive a total dose of 2640.60 J.
45987453|NCT00490412|Dietary Supplement|Vitamin D supplement|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Groups A and C once every four weeks during study visits.
45987454|NCT00490412|Other|Placebo|A placebo will be administered orally to subjects in Groups B and D once every four weeks during study visits.
45987455|NCT01241955|Behavioral|video decision aid|video of CPR
45987456|NCT00485966|Drug|CX-3543|360 mg/m2 daily x 5 q 21 days
45987457|NCT00485940|Drug|Prucalopride|2 mg o.d.
45987458|NCT00485940|Other|Placebo|Placebo o.d.
45987459|NCT00485940|Drug|Prucalopride|4 mg o.d.
45987460|NCT00486005|Drug|Olanzapine Hydrochloride|
45987461|NCT00486005|Drug|Nizatidine|
45987462|NCT00486005|Drug|Placebo|
45987463|NCT00485979|Drug|larotaxel (XRP9881)|intravenous administration
45987464|NCT00485979|Drug|docetaxel|intravenous administration
45987465|NCT00485979|Drug|trastuzumab|intravenous administration
45987466|NCT00486083|Drug|Atomoxetine Hydrochloride|
45987467|NCT00486083|Drug|Methylphenidate Hydrochloride|
45987468|NCT04512027|Other|Prolectin-M; a (1-6)-alpha-D-Mannopyranose class|A treatment to decrease viral load, detected through digital droplet PCR, in mild to moderate cases of RT-PCR positive COVID-19
45987469|NCT04512027|Other|Standard of Care|Currently approved standard of care for patients without symptoms requiring hospitalisation will be provided to all.
45987470|NCT00490685|Drug|Sorafenib (BAY-43-9006)|
45987471|NCT00486122|Drug|Atomoxetine Hydrochloride|
45987472|NCT00486122|Drug|Placebo|
45987473|NCT04511715|Drug|Intravitreal Bevacizumab IVB|Intravitreal Bevacizumab IVB group (50 eyes) that receive 6 bimonthly IVBs within a period of 10 months following the enrollment
45987474|NCT04511715|Other|Follow-up with regular examination for determination of DR progression|regular examination for determination of DR progression
45987475|NCT00486135|Drug|XL147 (SAR245408)|Gelatin capsules supplied in 25-mg and 100-mg dosage strengths
45987476|NCT00486135|Drug|XL147 (SAR245408)|Tablets supplied as 100-mg, 150-mg, and 200-mg dosage strengths
45987477|NCT00486317|Drug|Oral salmon calcitonin, salmon calcitonin nasal spray|
45987478|NCT04511910|Procedure|Early Laparoscopic Cholecystectomy|
45987479|NCT00490880|Drug|gemcitabine|
45987480|NCT00490880|Drug|cisplatin|
45987481|NCT00490880|Procedure|radical cystectomy|
45833207|NCT03089346|Diagnostic Test|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE)|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE) pulse sequences on a 1.5T magnet (Avanto dot, Siemens) with 3D reconstruction of the bronchial tree using Neko-MR software in asthma in order to assess bronchial thickness.
45833208|NCT03089346|Diagnostic Test|Computed tomography (CT)|Computed tomography (CT) on a Definition 64 (Siemens) with 3D reconstruction of the bronchial tree using Neko-3D software in asthma in order to assess bronchial thickness.
45833209|NCT03081234|Drug|Ribociclib|Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Ribociclib will be supplied in the form of 200 mg tablets.
45987482|NCT00490880|Procedure|radiotherapy|
45987483|NCT01241994|Other|AASD dialysis technique|
45987484|NCT01242033|Dietary Supplement|red raspberries|single serving of one, two or four cups red raspberries
45987485|NCT01242033|Dietary Supplement|bread controls|two slices white bread alone or with 200 mg vitamin C supplement
45987486|NCT00486174|Drug|methylene blue|2.0 mg/kg of Methylene Blue administered every 6 hours (as required) for up to 48 hours.
45987487|NCT00486356|Drug|capecitabine|
45987488|NCT00486356|Drug|carboplatin|
45987489|NCT00486356|Drug|epirubicin hydrochloride|
45987490|NCT00486356|Genetic|microarray analysis|
45987491|NCT00486356|Genetic|polymorphism analysis|
45987492|NCT00486356|Other|pharmacological study|
45987493|NCT04511793|Device|Medtronic Synchromed II pump|The pump will be placed during surgery and the pump will be filled with a combination of floxuridine (FUDR), dexamethasone, heparin, and saline.
45987494|NCT00490958|Drug|telmisartan|
45987495|NCT00486213|Dietary Supplement|pyridoxine hydrochloride|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
45987496|NCT00486213|Other|Placebo|
45987497|NCT00486395|Device|CPAP|"CPAP administered via Bubble method or Infant Flow Driver"
45987498|NCT00486395|Device|Mechanical ventilation|Volume guarantee strategy
45987499|NCT00486369|Drug|Oral salmon calcitonin|
45987500|NCT00490997|Drug|Ketamine only|"Ketamine 1.0 mg/kg IV and placebo intralipid as initial sedation agents (double blinded).~Ketamine .25 mg/kg IV and placebo intralipid q2 minutes prn for additional sedation"
45987501|NCT00490997|Drug|Ketamine - Propofol|"Ketamine .5 mg/kg and Propofol 1 mg/kg as initial sedation agents (double-blinded).~Saline Placebo and Propofol .5 mg/kg q 2minutes for additional sedation"
45987502|NCT04511949|Diagnostic Test|COVID-19 IgG / IgM rapid test (whole blood, serum, plasma)|"The rapid test is performed using a drop of blood obtained at the fingertip (10 microliters) using a lancet.~The dropper pipette, held vertically, collects the drop of whole blood up to the sample line~Place 1 drop of whole blood (10 μL in the sample well (S) of the cassette.~Immediately add 2 drops (80μL) of buffer to the well (B) of the cassette.~Avoid air bubbles; if there is an air bubble, add a 3rd drop of buffer.~The reading is taken after 10 minutes at most by the healthcare professional under medical supervision.~In case of sepositivity of the rapid test, it may be offered to index cases and adult contacts, a blood sample of 5 ml of blood for a serothèque allowing a characterization of the antibodies and in particular of the neutralizing antibodies."
45987503|NCT00486473|Drug|Multihance|0.5 Molar at a single dose injection
45987504|NCT00486473|Drug|Magnevist|0.5M at a single dose injection
45987505|NCT00486408|Biological|MRKAd5 HIV-1 gag/pol/nef|1.5x10^10 Ad vg
45987506|NCT00486590|Procedure|Prolact-Plus Human Milk Fortifier|
45987507|NCT04511637|Drug|Rivaroxaban (BAY 59-7939, Xarelto) in ODT form|15 mg as 1 x 15 mg orally disintegrating tablet (ODT)
45987508|NCT04511637|Drug|Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form|15 mg as 1 x 15 mg film-coated tablet
45987509|NCT00491036|Device|Intraaortic balloon pump|intraaortic balloon pump from Datascope/Maquet or Arrow/Teleflex will be used
45987510|NCT00486486|Drug|Drug: bimatoprost/timolol fixed combination AM|3-month chronic dosing in the morning
45987511|NCT00486486|Drug|Bimatoprost/timolol fixed combination dosed PM|Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months
45987512|NCT04511481|Other|Radiomic Algorithm|Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction
45987513|NCT00491114|Drug|Gemcitabine|
45987514|NCT00486564|Drug|Nifurtimox|Escalating dose by cohort starting at 20mg/kg/day. PO drug taken TID.
45987515|NCT00486668|Drug|doxorubicin|60 mg/m2 IV every 21 days for cycles 1-4
45987516|NCT00486668|Drug|cyclophosphamide|600 mg/m2 IV every 21 days for cycles 1-4
45987517|NCT00486668|Drug|paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days for cycles 5-8
45987518|NCT00486668|Drug|trastuzumab|First dose: 4 mg/kg IV, subsequent doses: 2 mg/kg IV weekly beginning on day 1 of the first paclitaxel cycle until 1-7 days before surgery
45987519|NCT00486668|Drug|lapatinib|Group 2: 1250 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery. Group 3: 750 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery.
45987520|NCT04511598|Device|"Bellus 3D Face Camera"|The depth sensor uses infrared structured light scanning technology to capture depth and the camera on the phone or tablet to capture color texture of the face.
45987521|NCT04511598|Device|"Planmeca ProMax 3D Proface"|The lasers scan the facial geometry and the digital cameras capture the color texture of the face.
45987522|NCT00486681|Device|Accu Chek Inform and Cobas IT 1000|period II (warning activated)
45987523|NCT00486707|Behavioral|Questionnaire|A questionnaire will be completed.
45987524|NCT04510935|Procedure|general anesthesia|the patient will receive general anesthesia during surgery in this group.
45987525|NCT04510935|Procedure|local anesthesia|the patient will receive local anesthesia during surgery in this group.
45987526|NCT00491192|Drug|Diclofenac|
45987527|NCT04510974|Other|Spinal Cord Injury|Spinal Cord Injury
45833210|NCT03081234|Drug|Placebo|Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Placebo will be supplied in the form of 200 mg tablets.
45833211|NCT03081234|Drug|Adjuvant endocrine therapy|Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total duration of at least 60 months. In premenopausal women, adjuvant endocrine therapy may include GnRH agonist administered every 28 days.
45987528|NCT00486746|Behavioral|Lifestyle intervention (physical activity and dietary counseling)|One-year intervention
45673548|NCT01948791|Drug|ENA713|The following strengths of Rivastigmine capsules were provided: Rivastigmine capsule strengths: 1.5mg, 3mg, 4.5mg. The 6mg dose was administered as one 1.5mg capsule and one 4.5mg capsule, and when necessary, the 3mg dose could also be administered as two 1.5mg capsules. Rivastigmine was administered from 3mg/d at baseline. Then dose escalation was made in 3mg/d increments, at a minimun of 4 weeks between dose increases to a maximum dose of 12mg/d or the individual's best tolerated dose.
45673549|NCT01899729|Drug|IMO-8400 Regimen 1|IMO-8400 0.075 mg/kg q wk x 12 wk by subcutaneous injection
45987529|NCT00486746|Behavioral|General information on healthy lifestyle habits|A single session
45987530|NCT04510896|Other|InheRET|Primary Appropriate Referral Rates 6-months pre-intervention vs post-intervention Compare appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the pre-intervention vs post- intervention period. Only referrals to Michigan Medicine genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
45987531|NCT04510896|Other|Patient Acceptance|Acceptance by Patients Over the course of the study Acceptance measures will include completion rates and levels of ease of use of InheRET by the patient. Impact measures will include uptake of advised risk management interventions. We will qualitatively describe why patients do not follow up with their referral. We will explore patterns of acceptance and impact levels by demographic and clinical data using correlation, t- tests, ANOVA, or their non-parametric equivalents.
45987532|NCT04510896|Other|Physician Acceptance Survey|Secondary Acceptance by Physicians Over the course of the study Acceptance by physicians will measure the physician effort required to deploy and use InheRET in their respective clinics, and overall satisfaction. Impact measures will include appropriate referral rates and rates of genetic testing. We will qualitatively describe why patients are not referred for genetic counseling if indicated. We will explore patterns in acceptance and impact levels by demographic and clinical data using correlations, t-tests, ANOVA, or their non-parametric equivalents.
45987533|NCT00486798|Drug|Quetiapine|
45987534|NCT00486798|Procedure|Rating Scales|
45673550|NCT01899729|Drug|IMO-8400 Regimen 2|IMO-8400 0.15 mg/kg q wk x 12 wk by subcutaneous injection
45673551|NCT01899729|Drug|IMO-8400 Regimen 3|IMO-8400 0.3 mg/kg q wk x 12 wk by subcutaneous injection
45673552|NCT01899729|Drug|Saline Placebo|Saline q wk x 12 wk by subcutaneous injection
45673553|NCT01899729|Drug|IMO-8400 Regimen 4|IMO-8400 0.6 mg/kg q wk x 12 wk by subcutaneous injection
45987535|NCT00486798|Procedure|Self Assessment Form|
45987536|NCT00486798|Procedure|Blood and urine samples|
45987537|NCT00486798|Procedure|Sleeping pattern|
45987538|NCT01301833|Drug|teneligliptin|
45987539|NCT01301833|Drug|glinide|
45987540|NCT01301833|Drug|biguanide|
45987541|NCT01301833|Drug|alpha-glucosidase inhibitor|
45987542|NCT00486785|Drug|Alfuzosin|Alfuzosin 10mg Once Daily for 24 weeks
45987543|NCT04324411|Drug|sirolimus and ATRA|sirolimus (serum concentration 4-10ng/ml) and ATRA 20mg bid
45987544|NCT04324489|Drug|DAS181|Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.
45987545|NCT00486876|Drug|Dextofisopam|capsules, 0 (placebo), 100, 200, and 300 mg BID for 12 weeks
45987546|NCT05643703|Procedure|Suture method|One-layered Suture: Single layer intermittent suture; Two-layered Suture:Single layer intermittent suture plus U type reinforcement stitching
45987547|NCT00491270|Device|VS Sense|An applicator to diagnose pH increase above 5.2
45987548|NCT05643586|Drug|Ticagrelor|Patient treated with 180 mg ticagrelor 12 hours before the procedure
45833212|NCT03417492|Drug|Sildenafil Citrate|Three 20 mg capsules for the single dose studies. For the 5-week treatment phase, subjects will be assigned to a titration of doses for the 5 week duration of the study. Subjects will be instructed to take 20mg twice per day for 3 days, then 40mg twice per day for 3 days, and then 80mg twice per day for 4 weeks.
45833213|NCT03080922|Biological|hematopoietic stem cell|high dose of donor G-CSF mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
45833214|NCT04402164|Device|Herbst appliance|telescopic appliance for mandibular advancement
45833215|NCT03395184|Drug|PF-06651600 Placebo|12 weeks, followed by PF-06651600, 50 mg once daily (QD) for 52 weeks
45987549|NCT05643586|Drug|Prasugrel|Patient treated with 60 mg prasugrel 12 hours before the procedure
45987550|NCT05643430|Device|BioFreedom Ultra|The BioFreedom Ultra CoCr DCS is a combination product consisting of two key components: the cobalt chromium stent platform coated abluminally with the active ingredient BA9TM (polymer and carrier free) and the delivery system.
45987551|NCT01242059|Dietary Supplement|yellow pea protein|Served in a tomato soup
45987552|NCT01242059|Other|yellow pea fiber|Served in a tomato soup
45987553|NCT01242059|Dietary Supplement|Control|Served in a tomato soup
45987554|NCT05643391|Radiation|Radioembolization using Holmium-166|This technic consists of the intra-arterial infusion of smaller beads that are loaded with a radioactive isotope (yttrium-90), and it relies on the beta radiation emitted by the isotope to induce tumor necrosis, with a minor contribution from microembolization and without risk of ischemia of the remaining liver.
45987555|NCT01242072|Drug|palifosfamide-tris|Intravenous on days 1, 2 and 3 of each 21-day cycle for up to 4 cycles
45987556|NCT05643352|Procedure|Barbed reposition pharyngoplasty|Barbed reposition pharyngoplasty was performed in all patients
45987557|NCT05643235|Device|Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)|Patients initiating BTK inhibitors will be offered the option of monitoring using the Medtronic Insertable Cardiac Monitor (ILR). The device will be implanted by a certified and credentialed electrophysiologist to enable monitoring to begin at least 24 hours prior to the first administration of the BTK inhibitor. Monitoring data will be collected prospectively until the patient withdraws consent, the device is removed, or up to 60 months
45987558|NCT00491348|Drug|duloxetine hydrochloride|duloxetine 30 mg QD, may titrate to 30 mg BID, and maintain the dosage for 6 weeks
45987559|NCT01242098|Drug|Fixed dose combination salmeterol / fluticasone|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
45987560|NCT01242098|Drug|Fixed-dose combination beclometasone dipropionate / formoterol|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
45987561|NCT01301092|Biological|LY2189265|administered intravenous, subcutaneous or intramuscular
45987562|NCT01242150|Device|NCPAP by helmet|The infant helmet (Castar Starmed© Mirandola, Italy) is secured to a soft collar that adheres to the child's neck and is connected to a high flow NCPAP circuit (high fresh gas flow >40 L/min to avoid carbon dioxide rebreathing). To facilitate tolerance up to a maximum of 2 boluses of midazolam 0.1 mg/kg i.v. can be administered eventually followed by an i.v. continuous infusion rate according to OPS scale. Once the interface is positioned, a baseline Continuous Positive Airway Pressure (CPAP) level is set at 4 cm H2O and then raised in increments of 2 cm H2O every 20 min up to a maximum of 10 cm H2O. FiO2 is set to achieve a SpO2 ≥ 92%. If intolerance persisted despite sedative administration, the alternate interface can be used before considering tracheal intubation. All patients are kept in semirecumbent position.
45987563|NCT01242150|Device|NCPAP by facial mask|The size of NCPAP full face or nasal masks are chosen to be more comfortable for the infants (Respironics, Murrysville). The masks are secured by head straps while avoiding a tight fit and air leaks. A protective hydrocolloid sheet was applied over the nasal bridge (DuoDERM, ConvaTec, Deeside, UK). After a short adaptation period, it is firmly applied on the face by a pediatric head cap (Respironics, Murrysville ) to minimize air leaks. The mask is then connected to the same circuit previously described for helmet NCPAP.
45987564|NCT05643157|Device|Adaptive optics imaging|adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
45987565|NCT04510623|Other|ARBs and/or ACE inhibitors|This is an observational study only.
45987566|NCT04510623|Other|Usual Care|This is an observational study only.
45987567|NCT05643040|Other|femoral nerve block|To evaluate the intraoperative analgesia effectiveness of femoral block in patients who will have knee surgery.
45987568|NCT05643040|Other|adductor canal block|To evaluate the intraoperative analgesia effectiveness of adductor canal block in patients who will have knee surgery.
45987569|NCT05643040|Other|4in1 block|To evaluate the intraoperative analgesia effectiveness of 4in1 block in patients who will have knee surgery.
45987570|NCT05367622|Behavioral|Self-regulation health education|"Insert the continuous blood glucose monitor~Give self-regulation model of health education to assist patients in making a judgmental decision on how to modify health promotion behaviors to reach a good glucose control~Use Telecommunications on the modifications of health promotion behaviors for 7 days"
45987571|NCT05367622|Behavioral|Usual diabetes health education|"Practice self-monitoring of blood glucose~Give usual diabetes health education"
45987572|NCT02274350|Radiation|radiation therapy|Radiation therapy either in the form of external beam radiation or radioactive gold seeds planted directly in the prostate.
45987573|NCT04510818|Drug|Capecitabine, Camrelizumab|This is a single-arm study with all patients receiving these two drugs.
45987574|NCT00623584|Procedure|Corneal transplantation|Full thickness penetrating keratoplasty
45987575|NCT00623584|Procedure|Corneal transplantation|Full thickness penetrating keratoplasty
45987576|NCT01243307|Drug|CT327 (or placebo) followed by placebo (or CT327)|"During treatment/testing period 1, subjects will apply 0.25 g CT327 (or placebo) to 4 test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.~During treatment/testing period 2, subjects will apply 0.25 g placebo (or CT327) to 4 different test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications."
45833216|NCT03395184|Drug|PF-06651600|200 mg QD for 8 weeks, followed by 50 mg QD up to 56 weeks
45987577|NCT05642845|Drug|Atorvastatin film-coated tablet 40 mg / Liprimar® film-coated tablet 40 mg|"Atorvastatin is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of atorvastatin.~Liprimar® is manufactured by Pfizer Pharmaceuticals LLC, Puerto Rico, LLC Polysan Scientific and Technological Pharmaceutical Firm; RU holder: Pfizer Inc, USA. Each tablet contains 40 mg of atorvastatin."
45987578|NCT04510662|Drug|Telmisartan|Patients in this group will receive telmisartan 40 mg daily plus standard care.
45987579|NCT05642806|Biological|Mepolizumab|Mepolizumab will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
45987580|NCT05642806|Other|Placebo|Placebo will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
45987581|NCT00486941|Behavioral|Exercise and diet - based on DPS and DPP|
45987582|NCT05642689|Other|Iron fortified milk with iron salt labelled with 58Fe and 57Fe|Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
45987583|NCT05642689|Other|Iron fortified milk with iron salt labelled with 58Fe and 57Fe|Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
45987584|NCT00486915|Procedure|Left Atrial Appendage Ligation|
45987585|NCT01243502|Drug|0.01% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 1000 μg/dm2.
45987586|NCT01243502|Drug|0.001% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 100 μg/dm2.
45673554|NCT01898091|Drug|Neem Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
45833217|NCT03395184|Drug|Placebo PF-06700841|12 weeks, followed by PF-06700841, 30 mg QD for 52 weeks
45833218|NCT03395184|Drug|PF-06700841|60 mg QD for 12 weeks followed by 30 mg QD for up to 52 weeks
45987587|NCT01300819|Other|Placebo|"Placebo patches of 2, 4, 6 & 8 mg / 24 hours Daily application of Placebo patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose was 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
45987588|NCT01300819|Drug|Rotigotine|"Rotigotine patches of 2, 4, 6, and 8 mg / 24 hours~Once daily application of Rotigotine patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose is 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
45673555|NCT01898091|Drug|Placebo Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
45673556|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin low dose
45987589|NCT00486980|Drug|Peramivir 150mg|
45987590|NCT00486980|Drug|Peramivir 300mg|
45987591|NCT00486993|Behavioral|Dietary and nutritional modification|
45987592|NCT00486993|Behavioral|Stop smoking|
45987593|NCT00486993|Behavioral|Regular physical activities|
45987594|NCT00486993|Behavioral|Weight reduction to normal ranges|
45987595|NCT00486993|Behavioral|Regular intake of polyphenols, esp. from Ilex paraguayensis|
45987596|NCT01300741|Device|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
45673557|NCT01947855|Drug|Empagliflozin|Empagliflozin low dose
45673558|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin high dose
45673559|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin low dose
45673560|NCT01947855|Drug|Empagliflozin|Empagliflozin high dose tablet once daily
45673561|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin high dose
45673562|NCT01888965|Drug|Dovitinib|"All patients in the study will receive Dovitinib, 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years.~If 500 mg is intolerable, 400 mg will be dosed. If 400 mg is intolerable, 300 mg will be dosed"
45673563|NCT01888497|Drug|Gabapentin|250 mg, oral, prior to bedtime on the night before performance testing
45673564|NCT01888497|Drug|Diphenhydramine citrate|76 mg, oral, prior to bedtime on the night before performance testing
45833219|NCT03080532|Other|dietary habits|
45833220|NCT03080766|Drug|Decitabine|Decitabine (trade name Dacogen®) is a cytidine deoxynucleoside analogue, which selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation that can result in reactivation of tumor suppressor genes, induction of cellular differentiation or cellular senescence followed by programmed cell death.
45833221|NCT03080688|Device|Prizma Oxygen Saturation Measurement|"A radial arterial cannula was placed in either the left or right wrist of each subject.~Blood gas analysis to determine oxyhemoglobin saturation was performed on an OSM-3® multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). No subject was anemic (Hemoglobin ≤ 10gm•dl-1)."
45833222|NCT03080298|Drug|BP101|
45987597|NCT01300741|Device|Galyfilcon A contact lens (ACUVUE® ADVANCE® Plus)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
45987598|NCT01300741|Device|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
45987599|NCT02275962|Drug|K-877|
45987600|NCT02275962|Drug|Rifampin|
45987601|NCT05642494|Device|SDF|Silver Diamine Fluoride 38% (Applied bianually)
45987602|NCT05642494|Device|NaF|Sodium Fluoride Varnish (5%) (Applied at baseline and after 3 months)
45987603|NCT00487058|Drug|Gimatecan|
45987604|NCT05642455|Genetic|Afamitresgene autoleucel|Single infusion of afamitresgene autoleucel Dose: For subjects ≥10 kg to <40 kg: starting dose of 0.025 - 0.200 x 10'9 transduced cells/kg. For subjects ≥40 kg 1.0x109 to 10x109 transduced by a single intravenous infusion
45987605|NCT00487032|Drug|Oxymetazoline 0.05% w/v|2 squirts in each nostril thrice daily
45987606|NCT00487032|Drug|Fluticasone propionate 50 micrograms per actuation|2 Squirts in each nostril twice daily
45987607|NCT00487032|Drug|Prazosin hydrochloride|Prazosin 1mg one dose only
45987608|NCT00487032|Drug|Placebo to Prazosin|Placebo 1 tablet one dose only
45987609|NCT05642377|Drug|HGR4113|Once-daily oral administration
45987610|NCT05642377|Drug|Placebo|Once-daily oral administration
45987611|NCT00491426|Drug|Ampicillin|Drug prescribed per routine medical care.
45987612|NCT00491426|Drug|Metronidazole|Drug prescribed per routine medical care.
45987613|NCT00491426|Drug|Piperacillin/Tazobactam|Drug prescribed per routine medical care.
45987614|NCT00491426|Drug|Acyclovir|Drug prescribed per routine medical care.
45987615|NCT00491426|Drug|Amphotericin B|Drug prescribed per routine medical care.
45987616|NCT00491426|Drug|Ambisome|Drug prescribed per routine medical care.
45987617|NCT00491426|Drug|Anidulafungin|Drug prescribed per routine medical care.
45673565|NCT01888497|Drug|Triazolam|0.5 mg, oral, prior to bedtime on the night before performance testing
45673566|NCT01888497|Drug|Placebo|Oral, prior to bedtime on the night before performance testing
45833223|NCT03080298|Drug|Placebo|
45833224|NCT04401618|Other|Retrospective evaluation of RMGI and GIC Class V Restorations|Retrospective evaluation of RMGI and GIC Class V Restorations that were placed by dental students over the last three years were evaluated using the modified USPHS criteria using mirrors and probes.
45833225|NCT03080376|Other|Web-based intervention with support|Web-based combined aerobics and muscular strength exercises.
45833226|NCT03080376|Other|Web-based intervention without support|Web-based combined aerobics and muscular strength exercises.
45987618|NCT00491426|Drug|Caspofungin|Drug prescribed per routine medical care.
45987619|NCT05642338|Diagnostic Test|WATS3D|the WATS3D brush samples the esophagus by abresing the tissue. the brush is directed through the workingchanel of endoscope into the oesophagus
45987620|NCT05642299|Device|MBCI-SR|Participants will be asked to wear and EEG+NIRS cap and a soft robotic glove on their stroke-impaired hand. The participant will be instructed to ask to imagine to picture moving the stroke-imparied hand in the mind. The brain signal (EEG and NIRS data) will be recorded as a reference. When the participant pictures this move again, upon detection of such imagined move by MBCI-SR system, the glove will be activated and assists the participants to perform a specific upper limb task based on individual ability. There are six different activities of daily living (ADL)-oriented tasks enacted through a virtual arm and virtual objects, which formed the visual feedback for the participants. These tasks include scanning goods, moving an object upward to a cabinet, using two hands to move a towel, pouring of water into a cup, eating action and fine motor movement of picking up a small block using two fingers. Training intensity is 1.5 hours for 3 times a week for 6 weeks, a total of 18 sessions.
45987621|NCT05642260|Other|fall prevention programe|Patients in the experimental group will receive a comprehensive fall prevention program (guided by the post-TKR protocol followed at Al-Razi Orthopedic Hospital) into the conventional physiotherapy treatment
45987622|NCT02274363|Other|No Intervention|Participants will not receive any intervention in this study. Participants with chronic plaque type psoriasis will be assessed at a single time point, primarily for severity of plaque-type psoriasis Participants will not be followed over time. Data will be collected from the medical consultation notes, medical records and during interviews.
45673567|NCT01505530|Drug|LY2495655|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
45673568|NCT01505530|Drug|Placebo|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
45833227|NCT03080376|Other|Traditional intervention|3 months of Printed-based combined aerobics and muscular strength exercise intervention.
45987623|NCT00487097|Dietary Supplement|Eicosapentanoic acid, docosahexaenoic acid|Enteral nutrition formula enriched with Eicosapentanoic acid, docosahexaenoic acid
45987624|NCT01300546|Drug|Sumatriptan/Naproxen Sodium|Each tablet of Treximet for oral administration contains Sumatriptan 85mg / Naproxen Sodium 500mg. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
45987625|NCT01300546|Drug|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
45987626|NCT00487071|Device|Anal fistula plug|
45987627|NCT05642104|Drug|Neoadjuvant therapy|all procedures is in accordance with international guidelines and domestic expert consensus on breast cancer.
45833228|NCT03080844|Behavioral|Delay time to first cigarette|Participants asked to delay time until they smoke first cigarette of the day.
45833229|NCT03080844|Behavioral|Therapy|Participants receive tips on how to resist the urge to smoke and control cravings to smoke.
45833230|NCT03392064|Biological|AMG 119|Investigational, adoptive cellular immunotherapy for the treatment of small cell lung cancer
45833231|NCT03080064|Behavioral|Health Coach Intervention|Please see arm description.
45833232|NCT04761354|Procedure|Unilateral adrenalectomy|
45987628|NCT00487110|Drug|Tropisetron|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
45987629|NCT00487110|Drug|paracetamol|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
45987630|NCT00487136|Drug|Warfarin|Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.
45987631|NCT00487136|Drug|warfarin plus ABT-335 plus rosuvastatin 5 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
45987632|NCT00487136|Drug|warfarin plus ABT-335 plus rosuvastatin 20 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
45987633|NCT02276001|Drug|K-877|
45987634|NCT02276001|Drug|Cyclosporine|
45987635|NCT00491543|Drug|ALT-2074|
45833233|NCT03089112|Drug|HGP1607|Take it once per period
45987636|NCT02276118|Device|device: e.motion PS Pro|patients will undergo total knee arthroplasty with e.motion PS Pro implant
45987637|NCT02276118|Device|device : Genesis II|patients will undergo total knee arthroplasty with Genesis II implant
45987638|NCT00491582|Drug|Growth hormone replacement therapy in growth hormone deficient patients only.|Genotropin once/daily sc., titration scheme according to the consensus guidelines of the GH and IGF-research society Duration: 6 months
45987639|NCT00491621|Procedure|surgery or biopsy of the kidney tumor|surgery or biopsy of the kidney tumor
45987640|NCT04510155|Behavioral|Overnight fasting duration|Subjects will adhere to overnight fasting protocol for 1 day
45833234|NCT03089112|Drug|HGP1501|Take it once per period
45833235|NCT03089112|Drug|HGP1607+HGP1501|Take it once per period
45833236|NCT03083886|Other|Identify, Coordinated, Enhanced (ICE) Decision Making + PCP led care|Subjects seeking care at a clinic assigned to this arm will receive the ICE care model through referral by their primary care provider. The ICE care model was developed by the Clinical Excellence Research Center at Stanford University based on a review of the peer-reviewed literature for adult subjects with incident neck or back pain less than six weeks in duration who are not using high-dose opioid medications or receiving spine-related long-term disability payments.
45987641|NCT00487175|Drug|Tramadol|to compare of the analgesic of tramadol versus placebo in a pain model using evoked potentials
45987642|NCT00487227|Drug|caffeine|
45458339|NCT02324374|Device|Endocytoscope|The endocytoscopes, prototype I and prototype II will be used during the study along with the standard colonoscopes. The endocytoscope is a soft catheter type endoscope, with an outside diameter of 3.4 mm at the distal end and 3.2 at the shaft, and total length of 380 cm (working length of 250 cm) which uses a lens system for magnification. The Prototype 1 endocytoscope (low resolution type) has a magnification capability of x 450, depth of field of 50 um, field of view of 300X 300 um with a spatial resolution of 1.7 um. The Prototype 2 (high resolution) has a magnification capability of x1125, depth of field of 5um, field of view of 120X 120 um, and a spatial resolution of 4.2 um, The ECS system can be passed through the working channel of a standard colonoscope.
45987643|NCT00487227|Drug|Placebo|
45987644|NCT00487266|Other|Acupuncture|Acupuncture of low back and legs.
45987645|NCT00491660|Behavioral|supine positioning|
45987646|NCT00491660|Behavioral|lateral positioning|
45987647|NCT00487344|Procedure|Non-Personalized Meal Planning|
45987648|NCT00487344|Procedure|Personalized Meal Planning and Dietetic Consultation|
45987649|NCT01300351|Drug|Fulvestrant|Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
45987650|NCT01300351|Drug|Placebo|Matching placebo was supplied as a castor oil based solution in clear neutral glass prefilled syringes. Each syringe will contain 5 ml.
45987651|NCT00487253|Drug|Miltefosine|Oral Miltefosine, dosage 1,5mg -2,5mg/kg/day, during 28 days.
45987652|NCT00487253|Drug|Meglumine antimoniate|Parenteral meglumine antimoniate Amp of 5ml (83mg/ml). Dosage: 20mg/kg/day one doses IM, during 20 days.
45987653|NCT05641987|Behavioral|Healthy Workplace Participatory Program|The Center for the Promotion of Health in the New England Workplace's (CPH-NEW's) Healthy Workplace Participatory Program (HWPP) is a participatory process in which end-users design TWH interventions that simultaneously change organizational and individual behavior to improve the health, safety and well-being of their workforce. The HWPP uses a process to empower workers to identify the root causes of health and safety concerns and then design, implement and evaluate interventions to address those problems.
45987654|NCT04510233|Drug|Ivermectin nasal|Ivermectin nasal spray one ml in each nostril two times daily
45987655|NCT04510233|Drug|Ivermectin oral|Ivermectin oral (one tablet 6 mg three times daily)
45987656|NCT04510233|Other|standard care|oxygen via masks or ventilators
45987657|NCT00487292|Behavioral|naps and pulses of bright light|
45987658|NCT05641909|Drug|Remifentanil|Remifentanil
45833237|NCT03083886|Other|Individualized Postural Therapy (IPT) + PCP led care|IPT involves the evaluation of a subject's posture to identify postural and alignment deviations and, based on this, a personalized corrective exercise program is prescribed. This method does involve the use of prescription medications, surgery, or manipulation. A treatment course typically lasts eight sessions over eight weeks. In order to allow for the consistent delivery of this arm of the study at multiple study-sites across the country, IPT will be delivered by The Egoscue Method. Egoscue was founded in 1971 and has 25 clinics worldwide.
45987659|NCT05641909|Drug|Fentanyl|Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
45987660|NCT05641753|Drug|Evolocumab Cartridge|Injectable PCSK9 inhibitor.
45987661|NCT05641753|Drug|Atorvastatin Calcium Tablets|HMG-CoA reductase inhibitor for oral use.
45987662|NCT05641753|Drug|Ezetimibe Tablets|Will only be distributed to patients with statin intolerance; replacement for both Atorvastatin and Evolocumab. Inhibitor of intestinal cholesterol for oral use.
45987663|NCT05641753|Drug|18F-FDG|Optional procedure. Positron emission tomography (PET) and computed tomography (CT) imaging to assess vascular inflammation and related anatomy requires injection of the PET tracer 18F-FDG. 18F-FDG is an FDA-approved analogue of sugar, routinely used to evaluate elevated metabolism in tissues, including increased metabolism due to inflammatory cells. A standard dose of 7.0 mSv will be administered.
45987664|NCT05641753|Device|Angiocatheter 20IV|Optional procedure (endothelial cell harvesting). An angiocatheter ≤ 21 gauge will be inserted into a peripheral vein on the upper extremity using aseptic technique. A 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be then advanced into the angiocatheter, to a distance of 4cm beyond the end of the angiocatheter.
45987665|NCT05641753|Device|J-Wire|Optional procedure (endothelial cell harvesting). Either a 0.021in. diameter J-shaped wire (Daig, Minnetonka, MN) or a 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be used.
45833238|NCT03083886|Other|Usual PCP led care|Primary care provider will direct patients' care pathway.
45833239|NCT04279626|Procedure|LETS-M|A 1.5-centimeter skin incision was made over the umbilicus, and the abdominal wall was opened layer by layer with an open method. A wound retractor (Alexis, 2-4 centimeter; Applied Medical Resources Corp., Rancho Santa Margarita, CA) was placed, and the glove port was set up, with a 10-millimeter trocar in the thumb over patient's right side, and a 5-millimeter trocar in the little finger over the left side. The pneumoperitoneum was established. A 10-millimeter rigid laparoscope was inserted via the 10-millimeter trocar and controlled by the assistant. The ancillary 5-millimeter port was made over the left lower abdomen under laparoscope inspection. The surgeon performed the surgery via the two 5-millimeter trocars.
45833240|NCT03088956|Other|Assessments|Cognitive, Behavioral and Functional as described in the Outcome Measures
45987666|NCT05641753|Device|GlycoCheck Glycocalyx Measurement Software|Optional procedure (assessment of vascular function). Video microscope developed by GlycoCheck.
45987667|NCT00487331|Other|Acupuncture|Acupuncture sessions 1-3 times per week.
45987668|NCT00487331|Behavioral|Survey|2 pain questionnaires + satisfaction survey completed at beginning and end of treatment
45458340|NCT01350908|Other|Blood sampling|30mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
45987669|NCT05639452|Other|Data collection for developing an algorithm for an Early Warning Score|Data collection of patient parameters (heart rate, respiratory rate, clinical outcomes (death, transfer to intensive care unit, adverse events like sepsis, infection, heart attack))
46002580|NCT04646538|Other|Regenerative Endodontics Procedures (REPs)|REPs was done for 10 mature maxillary necrotic teeth with periapical lesions. Instrumentation was done using Protaper Next system till size X3. Irrigation with 1.5 % NaOCl was done in the first visit. in the second visit, bleeding was induced in the canal by irritating the periapical area followed by the application of Biodentine as cervical plug then completion of the coronal restoration.
45987670|NCT05639179|Biological|UCAR-T Cells|"UCAR-T Cellswill be administered by vein. The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set:Dose level one:1×10^6 cells/kg;Dose level two:2×10^6 cells/kg;Dose level three:5×10^6 cells/kg. Each dose group requires at least three subjects. The trial will start from dose level one. The second portion includes a dosage extended cohort and will start after the finish of the3+3dose escalation study. Twelve subjects will get infusion of UCAR-T Cells at the best dose verified in the first portion."
45987671|NCT04510077|Behavioral|SmartQuit Smoking and Tobacco Cessation Program|Use SmartQuit program
45987672|NCT04510077|Other|Survey Administration|Ancillary studies
45987673|NCT05637892|Other|No intervention|This is a prospective observational study with no intervention
45987674|NCT02274389|Drug|No Intervention|This is an observational study and participants did not receive any intervention in this study. Participants initiating bedaquiline (BDQ) treatment as decided by healthcare provider, will be prospectively observed.
45987675|NCT05637619|Device|Monolithic Zirconia|Maxillary or/and mandibular screw retained zirconia monolithic prostheses supported by at least 4 implants
45987676|NCT05637619|Device|Hybrid-Acrylic|Maxillary or/and mandibular screw retained hybrid prostheses supported by at least 4 implants;
45987677|NCT05637619|Behavioral|Dentate Patients|Dentate Patients with natural dentition or tooth supported crowns
45673569|NCT01505530|Drug|Standard of Care Chemotherapy|Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan). The choice of gemcitabine-based regimen or FOLFIRINOX will be determined by the investigator (based on the standard of care used at the treating institution or as directed by local regulatory authorities).
45673570|NCT01485796|Biological|Immune Globulin Infusion (Human), 10%|Subcutaneous administration will be used in Study Epochs 1 and 2.
45673571|NCT01485796|Biological|Recombinant human hyaluronidase|rHuPH20 will be administered subcutaneously (SC) immediately before each SC IGI, 10% infusion, through the same needle, at a rate of 1 to 2 mL/min.
45833241|NCT03088722|Other|Training CHEWs to provide contraceptive implants|Training CHEWs to provide contraceptive implants
45987678|NCT02276196|Drug|Lixisenatide|GLP-1 receptor agonist
45987679|NCT02276196|Drug|Insulin glulisine|Insulin analogue
45833242|NCT03088644|Drug|JNJ-54175446|JNJ-54175446 up to 600 mg suspension for oral dose administration.
45673572|NCT01505374|Procedure|Study Technique|One leg will receive the saphenous nerve block, at the level of the adductor canal (study technique). The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
45833243|NCT03088644|Drug|18F-JNJ-64413739|18F-JNJ-64413739 fluid for injection administered intravenously.
45833244|NCT03088254|Drug|Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)|Twinstar(80/10 mg) and Rosuvastatin 20 mg for 8 weeks
45987680|NCT05635123|Other|No intervention|This is a prospective observational study with no intervention.
45987681|NCT00487370|Procedure|Implantation of gold beads around a knee through needles|
45833245|NCT03088254|Drug|Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)|Twinstar(80/10 mg) and Rosuvastatin placebo for 8 weeks
45833246|NCT03088254|Drug|Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)|Twinstar placebo, Amlodipine 10 mg and Rosuvastatin 20 mg for 8 weeks
45833247|NCT03088488|Diagnostic Test|fasting venous blood samples|
45833248|NCT05685420|Drug|Herombopag|Thrombopoietin receptor agonist
45833249|NCT05685342|Drug|Acetaminophen/Ibuprofen fixed-dose combination|Intravenous administration of Acetaminophen (1000 mg)/Ibuprofen (300 mg) fixed-dose combination (total 100 ml)
45833250|NCT04279080|Other|low anterior resection syndrome evaluation|evaluation of postoperative functional bowel outcome
45987682|NCT00487370|Procedure|Sham implantation: Insertion of needles around a knee|
45987683|NCT00487422|Drug|prucalopride|2 mg o.d.
45987684|NCT00487422|Drug|Prucalopride|4 mg o.d.
45987685|NCT00487422|Other|Placebo|o.d.
45987686|NCT00491699|Drug|XL999|XL999 will be administered as a once-weekly 4 hour IV infusion as a single agent. The first cohort will be dosed at 0.4 mg/kg IV once weekly. The maximum dose cohort will not exceed 1.6 mg/kg IV once weekly. Ten subjects are planned for each dosing cohort, with dose escalation dependent on safety and available PK data from prior cohorts
45987687|NCT05620615|Other|Intensive Drug Therapy|Observational only and no predesigned interventions in this study
45987688|NCT00506181|Drug|probiotic mixture|"Jarro-Dophilus probiotic mixture (4,400,000,000 bacteria in each capsule). One capsule X2/day."
45987689|NCT00506181|Drug|Placebo|
45987690|NCT00487409|Procedure|Bipolar electrosurgical generator and instruments|laparoscopic colectomy using the Ligasure device
45987691|NCT00487409|Procedure|Disposable stapling instruments|laparoscopic colectomy using clips, cautery and stapler
45987692|NCT00623662|Other|Preoperative glucose infusion|Glucose infusion from 15:00 on the day before the operation until beginning of surgery.
45987693|NCT00623662|Other|Preoperative normal saline infusion|Normal saline infusion from 15:00 on the day before surgery until beginning of the operation.
45987694|NCT05609812|Drug|Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
45987695|NCT05609812|Drug|Placebo|placebo
45987696|NCT02274402|Biological|blood sampling|Blood sample of 4 ml at enrolment and then at two following visits
45987697|NCT00491777|Device|Noninvasive Hemodynamic Patient Monitor|
45987698|NCT04327531|Behavioral|turkish physicians|turkish physicians, who work active in pandemic hospital.
45987699|NCT04697355|Dietary Supplement|naringenin and beta carotene|Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day for eight weeks
45987700|NCT00491816|Drug|Erlotinib with neoadjuvant chemotherapy|150 mg orally (PO) once daily on days 3 to 14, given with cycle 1 to 6 or 3 to 6 of neoadjuvant chemotherapy
45987701|NCT00487500|Device|Electroconvulsive Therapy (ECT)|Electroconvulsive therapy involves applying a small electrical charge to the scalp while the patient is anesthetized and provoking a short-lasting generalized seizure
45987702|NCT00491855|Drug|Bevacizumab|Starting dose level 2.5 mg/kg given intravenously on day 1.
45987703|NCT00491855|Drug|Oxaliplatin|Starting dose level 25 mg/m^2 given intraperitoneally on day 2.
45987704|NCT00491855|Drug|Paclitaxel|Starting dose level 110 mg/m^2 given continuous infusion on day 1 and 30 mg/m^2 given intraperitoneally on day 8.
45673573|NCT01505374|Procedure|Control Technique|The other leg will receive the femoral nerve block (control technique). The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
45673574|NCT04613674|Drug|Camrelizumab Plus Chemotherapy|camrelizumab+chemotherapy
45833251|NCT05684718|Drug|BV100 (300 mg)|Intravenous solution
45833252|NCT05684718|Drug|Itraconazole 200 mg|Oral solution
45673575|NCT04613674|Drug|placebo+chemotherapy|placebo+chemotherapy
45833253|NCT05689086|Other|Virtual Heart Failure Optimization Program|"Participants referred to the Virtual Heart Failure Optimization Program will be seen for initial consultation by a HF program nurse and cardiologist within 1 week. Patients will be offered the opportunity to participate in virtual cardiac rehabilitation.~Following this, patients will be assessed virtually every two weeks by a HF program nurse for addition and up-titration of medical therapy. All medication changes will be performed algorithmically and reviewed with the overseeing cardiologist. Following all medication changes, appropriate monitoring will be performed algorithmically as well.~All participants will be asked if they would like to participate in cardiac rehabilitation and an automatic referral will be sent by the overseeing cardiologist. Virtual cardiac rehabilitation will be conducted weekly with phone follow-up appointments with a program kinesiologist and virtual education programming."
45987705|NCT04697277|Drug|Antibiotic prophylaxis timing (before skin incision and after cord clamping) for caesarean section|
45987706|NCT00487448|Drug|Fludarabine|
45987707|NCT00487448|Drug|Cytarabine|
45987708|NCT00487448|Drug|G-CSF|
45987709|NCT00487448|Drug|Idarubicin|
45987710|NCT00487448|Procedure|Peripheral blood stem cell transplantation|
45987711|NCT00487448|Procedure|Bone marrow transplantation|
45987712|NCT00506259|Drug|dTR Melatonin (NIH CC PDS)|
45987713|NCT00506259|Device|Phototherapy (Bright Light)|
45987714|NCT00506259|Drug|Melatonin CR|
45987715|NCT00506298|Drug|bezafibrate + diflunisal|bezafibrate + diflunisal
45987716|NCT00506298|Drug|bezafibrate + placebo|bezafibrate + placebo
45987717|NCT01242215|Device|ipragliflozin|oral
45987718|NCT01242215|Drug|Placebo|oral
45987719|NCT01242215|Drug|Sulfonylurea|oral
45987720|NCT00487617|Procedure|Fruit juice or placebo absorption|absorption of 300 ml of fruit juice ; 24 hours later, absorption of 300 ml of placebo.
45987721|NCT00491933|Procedure|Quantiferon-TB Gold assay|
45987722|NCT00491933|Procedure|Tuberculin skin test|
45987723|NCT01242228|Drug|ipragliflozin|oral
45987724|NCT01242228|Drug|DPP-4 inhibitor|oral
45987725|NCT02274428|Drug|pneumostem|human umbilical cord blood derived mesenchymal stem cells
45987726|NCT00506337|Drug|Qingyi granules|"Control group: The therapeutic methods accord to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis introduced by the Pancreatic Surgery Group of Surgical Chapter of Chinese Medical Association.~Treatment group: In addition to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis, during the first stage of the disease herbal Qingyi granules 1-B 4 bags dissolved in water 200ml were administered through the gastric tube q6h. Then the gastric tube was closed for 1h, and Qingyi granules 1-B another 4 bags dissolved in water 400ml were given through enema q6h. During the second stage (from the 2nd week to the 4th week after onset) Qingyi granules 2-B 2bags dissolved in water 200ml were added QD."
45987727|NCT01316354|Other|Bread types|Bread with 50 g available carbohydrate
45987728|NCT00487526|Procedure|duodenal jejunal bypass|
45987729|NCT00491465|Behavioral|Intensive Physical activity|
45673576|NCT01897233|Drug|Lumacaftor|
45673577|NCT01897233|Drug|Ivacaftor|
45673578|NCT01887717|Device|TheraSphere®|Intrahepatic treatment of advanced hepatocellular carcinoma
45673579|NCT01887717|Drug|Sorafenib|Standard of care therapy for treatment of advanced hepatocellular carcinoma
45987730|NCT00491465|Behavioral|Control- regular physical activity|
45987731|NCT01242306|Drug|intracoronary infusion of acetylcholine|Acetylcholine will be infused at a concentration of 140 microg/minute, over a period of 2 minutes, yielding estimated intracoronary concentrations of 10(-5)mol/L, with the assumption of a flow rate of 80mL/min). All infusions will be delivered at a constant rate using an infusion pump. Subsequently, in order to evaluate the endothelium-independent vasomotor response, 2mg of isosorbide dinitrate or bolus 250microg of nitroglycerine will be infused by intracoronary bolus in all subjects. The response to nitrate will be recorded 1 minute after the bolus. A 3-min period will be allowed to elapse between each drug infusion.
45987732|NCT01242345|Device|Capnography|Monitoring of the capnography curve for early detection of apnea
45987733|NCT04511364|Other|Clinical imaging is performed during the 24 and 60 month follow-up visits|X-ray and DXA scan
45987734|NCT00492011|Drug|Ramelteon|Ramelteon 1 mg, tablets, orally, once nightly for 4 nights.
45987735|NCT00492011|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once nightly for 4 nights.
45673580|NCT04618653|Other|assessment only|Three assessment will include computerized assessments, interviews, and subset will provide daily reports of prescribed AA behaviors and practices
45987736|NCT00492011|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for 4 nights.
45987737|NCT00492011|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for 4 nights.
45987738|NCT04518072|Other|Blood sample (1 EDTA tube, 1 SST tube, 1 Streck tube) and urine sample (100 ml)|assessed biomarker in clinical samples
45987739|NCT01242254|Biological|Intravitreal injection of KH902|0.5 mg 2.0 mg once per 4 weeks during fixed dosing phase once as needed during extended treatment phase
45987740|NCT04513353|Device|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to total knee arthroplasty post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 3 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 3 to 12 weeks post surgery."
45987741|NCT04513353|Other|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
45987742|NCT00492128|Drug|Losartan/amlodipine or losartan/hydrochlorothiazide|Losartan 50mg/amlodipine 5mg and the fixed dose combination drug of losartan 50mg/hydrochlorothiazide 12.5mg once a day during 12 months.
45987743|NCT00487734|Radiation|Testosterone gel|testosterone gel, applied daily. Dosed to achieve testosterone level <500 ng/dL. Possible doses include 2.5g, 5g, 7.5g or 10g gel packets.
45987744|NCT00487734|Drug|Placebo for testosterone gel|Placebo gel, 2.5g for each gel packet
45987745|NCT01242293|Other|0.9% Saline with glucose 5%|intravenous hydration at a rate of 125 ml per hour during labor
45987746|NCT01242293|Other|Ringer lactate|intravenous hydration at a rate of 250 ml per hour during labor
45987747|NCT01242293|Other|Ringer lactate - Controls|intravenous hydration at a rate of 125 ml per hour during labor
45987748|NCT01300234|Drug|Tenofovir disoproxil fumarate (TDF) tablets|white, almond-shaped, film-coated tablets containing 300mg of TDF
45987749|NCT01300234|Drug|Adefovir dipivoxil (ADV) tablets|white to off-white, round, biconvex tablets containing 10mg of ADV
45987750|NCT04510701|Other|videoscope|a videoscope will be used to evaluate the integrity of the membrane while doing lateral maxillary sinus elevation surgery
45833254|NCT03086772|Behavioral|Tai Chi|Individuals in the Tai Chi intervention group will participate in a 12-week Tai Chi program (one hour per class, two classes per week, plus home practice for 12 weeks) led by an experienced Tai Chi Instructor, assisted by an undergraduate research assistant.
45673581|NCT01886781|Drug|Lactobacillus plantarum 299v|two capsules of 5 X 10 ^9 c.f.u each
45833255|NCT03086772|Behavioral|Light Exercise|Individuals in the exercise control group will meet for a twice weekly class involving walking, weight training, stretching and health education (one hour per class, two classes per week for 12 weeks, taught by a trained graduate research assistant, assisted by an undergraduate research assistant.
45833256|NCT05689008|Biological|UC-MSCs treatment|Participants will receive two doses of UC-MSCs treatment, each dose will contain 1*10^6 cells/kg suspended in 100 ml albumin solution.
45987751|NCT01242332|Drug|Pregabalin|75 mg po 2 hrs before surgery
45987752|NCT00487773|Drug|budesonide|budesonide
45987753|NCT00487773|Drug|D3 vitamin|D3 vitamin
45987754|NCT00487773|Drug|montelukast sodium|montelukast sodium
45673582|NCT01886781|Drug|Placebo comparator|Micro-crystalline cellulose powder, identical taste, texture and appearance
45673583|NCT01886781|Other|Run in period|Run -in period of one to two weeks. No treatment. Treatment started at baseline following randomization to either L.plantarum 299v or placebo
45673584|NCT01886781|Other|Wash - out period|Wash - out period following treatment phase of eight weeks
45987755|NCT00487773|Drug|salbutamol|salbutamol
45987756|NCT01299961|Drug|abatacept|125 mg once a week up to 12 months.
45987757|NCT00487643|Procedure|Tear Collection|The tear sample will be collected from the left eye of each subject. Subjects wearing contact lenses will be instructed to remove their lenses and wait at least 5 minutes before proceeding with the tear collection procedure. The patient will then be instructed to sit with eyes gently closed for two minutes after instilling one (1) drop of 0.5% proparacaine on the cornea and conjunctiva. Tear collection was accomplished by using a polyester fiber rod wick. This wick will be placed in contact with the tear fluid at the lower cul-de-sac for a minimum time to obtain fluid without irritating the subject's eye approx. for 3 to 5 minutes.
45987758|NCT04327297|Dietary Supplement|Amino acid-based formula|Amino acid based formula is formula which is used as dietary supplement instead of dairy products in cow's milk allergic infants
45987759|NCT00492245|Procedure|PTK with mitomycin in Adenoviral Opacities|
45987760|NCT00487812|Procedure|Low-dose dobutamine Tc-99-m-mibi gated SPECT imaging|All patients will be evaluated by ce-MRI during the initial hospital stay (5th - 6th day)
45987761|NCT01299805|Drug|Vortioxetine|Encapsulated tablet
45987762|NCT01299805|Drug|Placebo|Vortioxetine placebo-matching capsules.
45987763|NCT00487682|Drug|ASP2151|oral
45987764|NCT00487682|Drug|Valacyclovir hydrochloride|oral
45673585|NCT01946529|Drug|vincristine|Dosage and route of administration: Infants < 12 months of age: 0.05 mg/kg IV day 1; participants ≥ 12 months of age: 1.5 mg/m^2 IV day 1 (max. dose 2 mg).
45833257|NCT05688930|Other|PENMT (Experimental Group)|The neuromuscular injury prevention intervention protocol contains field work activities that involve proprioceptive exercises, flexibility, and specific and general muscle strength of the MMII and trunk soccer players.
45833258|NCT05688930|Other|FIFA 11+ (Control Group)|Treatment or experimental condition. 1: FIFA 11+ Program
45673586|NCT01946529|Drug|doxorubicin|Dosage and route of administration: Infants < 1 year 2.5 mg/kg continuous infusion (CI) over 48 hours, days 1-2; participants > 1 year of age 75 mg/m^2 CI over 48 hours, days 1-2.
45673587|NCT01946529|Drug|cyclophosphamide|Dosage and route of administration: The dose and route are different in neo-adjuvant/adjuvant chemotherapy and maintenance therapy. Please see the Detailed Description for further information.
45673588|NCT01946529|Drug|ifosfamide|Dosage and route of administration: Infants < 1 year of age 60 mg/kg/day IV over 60 minutes days 1-5; participants > 12 months of age 1800 mg/m^2 IV over 60 minutes x 5 days, days 1-5.
45833259|NCT05684484|Drug|Roflumilast 500 Ug ORAL TABLET [Daliresp]|Roflumilast has been approved by U.S. Food and Drug Administration (FDA) for attenuating bronchial and dermatological disorders
45833260|NCT05684484|Drug|corticosteroids +immune suppressive +amino salicylic acid|conventional treatment
45987765|NCT00487851|Procedure|surgery|hepaticojejunostomy and gastroenterostomy
45673589|NCT01946529|Drug|etoposide|Dosage and route of administration: Infants < 1 year of age 3.3 mg/kg/day IV over 60 minutes days 1-5; children > 1 year 100 mg/m^2 daily IV over 60 minutes days 1-5.
45673590|NCT01946529|Drug|temozolomide|Dosage and route of administration: Temozolomide 100 mg/m^2 PO once daily, days 1-5.
45673591|NCT01946529|Drug|temsirolimus|Dosage and route of administration: Temsirolimus 35 mg/m^2 IV once day 1 and day 8.
45673592|NCT01946529|Drug|bevacizumab|Dosage and route of administration: Bevacizumab 15 mg/kg IV on day 1 every 3 weeks.
45987766|NCT00487851|Procedure|endoscopic strategy|Stent insertion
45987767|NCT01299766|Behavioral|Behavioral Activation (BA)|BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
45987768|NCT01299766|Behavioral|Supportive Therapy (ST)|ST is a person-centered psychotherapy in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.
45987769|NCT04512261|Drug|Tucatinib|Initial dosage of trial treatment for tucatinib will be given as 300 mg (dispensed as 2 x 150 mg tablets) orally twice a day for Days 1 - 21 of each 3-week cycle during the treatment period.
45987770|NCT04512261|Drug|Pembrolizumab|Initial dosage of trial treatment for pembrolizumab will be given as 200 mg by intravenous infusion every 3 weeks on Day 1 of each 3-week cycle during the treatment period. Pembrolizumab will be administered for a maximum of 35 doses.
45987771|NCT04512261|Drug|Trastuzumab|Initial dosage of trial treatment for trastuzumab will be given as 8 mg/kg by intravenous (IV) infusion once on Day 1 of Cycle 1, and 6 mg/kg by IV every 3 weeks on Day 1 of each 3-week cycle starting on Cycle 2 during the treatment period.
45987772|NCT00492362|Behavioral|ergometer exercise during hemodialysis|
45987773|NCT00492362|Behavioral|pedometer activity outside of hemodialysis|
45987774|NCT04519515|Device|Allergan Vollure|Injection of Allergan Vollure into Atrophic Scars
45987775|NCT00487799|Drug|Ularitide|
45987776|NCT04516785|Diagnostic Test|FIT and VOC|Stool sample (FIT) analysed for blood in faeces and urine sample (VOC) analysed for the presence of volatile organic compounds
45987777|NCT05149248|Biological|Gardasil® [Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant vaccine]|HPV vaccination in an alternative schedule for MSM of 1 dose (M0).
45987778|NCT05149248|Biological|Two dose|HPV vaccination in an alternative schedule for MSM of 2 doses over a 6-month period (M0,6)
45987779|NCT05149248|Other|Control group|HPV vaccination at 12 months
45987780|NCT05149248|Biological|2 dose vaccination over 6 month|2-dose HPV vaccination regimen over a 6-month period (M0,6)
45987781|NCT01243541|Procedure|cryotherapy|Patients wear an Elasto-Gel cold glove and sock
45987782|NCT01243541|Other|questionnaire administration|Ancillary studies
45987783|NCT01243541|Procedure|quality-of-life assessment|Ancillary studies
45673593|NCT01946529|Drug|sorafenib|Dosage and route of administration: 90 mg/m^2/dose PO BID
45987784|NCT01243541|Procedure|management of therapy complications|In this therapeutic study, cold therapy is administered with an Elasto-Gel cold glove and sock (study device) that will be worn on your right hand and foot or your left hand and foot. The study device is a glycerine-based gel cold pack shaped like a mitten or sock with a cloth-like fabric kept at a constant temperature. The study device is not known to cause any major adverse affects and it is considered of non-significant risk. If you choose to participate in this study, you will be asked to wear a glove and sock at each paclitaxel infusion (4 treatments total). We hope the use of this study device will prevent or significantly reduce the onset and potential severity of paclitaxel-induced peripheral neuropathy and nail problems.
45987785|NCT01243541|Procedure|assessment of therapy complications|Study Treatment Assessment You will be asked permission for pictures to be taken of only your hands and feet. This is to have a visual documentation of symptom development during your treatment. This will be done at all six time points before you begin chemotherapy that day.
45987786|NCT04518033|Device|Various commercially available face coverings|Various commercially available face coverings
45987787|NCT05149209|Procedure|cervical restoration|A class v cavity will be prepared after local anesthesia has been given as required. Rubber dam isolation will be done. Selective enamel etching and a universal adhesive agent (Beautibond, Shofu, Japan) will be applied over all the cavity surfaces. Followed by, placement of restorative material according to the randomization sequence. Finally, restoration finishing and polishing will be done.
45987788|NCT00487877|Device|SenseWear Pro3 Armband|
45987789|NCT00487877|Device|i-button DS2191 H|
45987790|NCT00495209|Other|Qigong|EQT daily for 5 consecutive days prior to surgery.
45987791|NCT05149170|Drug|Anti-PD-1 monoclonal antibody|inductive Anti-PD-1 antibody + concurrent Anti-PD-1 antibody with RT
45987792|NCT02956226|Drug|Cannabinoids - 99% pure cannabinoids mix|99% pure cannabidiol (CBD) and 99% pure Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
45987793|NCT02956226|Drug|Placebo|Olive oil and flavors solution.
45987794|NCT02956226|Drug|Cannabinoids - whole plant extract|Whole plant extract enriched with cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to achieve 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
45987795|NCT04516473|Procedure|Abdominal Body Contouring|These are surgeries that correct for excess skin and its adverse consequences. The surgeries that focus on central area to remove a large hanging pannus is usually called panniculectomies or abdominoplasties; the former is focused on the excision of excess tissue to relieve impairment while the latter is generally considered a cosmetic surgery. The form of the surgery is case dependent and can range from removing apron of skin to complete contouring of the abdomen with tightening of the abdominal muscle and moving the belly button.
45673594|NCT01946529|Procedure|surgery|If participant meets the criteria, they will have surgical resection of their tumor.
45987796|NCT05149092|Dietary Supplement|Chicken protein hydrolysate supplement|Daily oral self-administration of 18 g of supplement dissolved in water/mineral water, spread over 2-3 occasions
45673595|NCT01946529|Radiation|radiation|If the participant meets the criteria, participants will receive radiation therapy. Chemotherapy will continue during radiation.
45987797|NCT05149092|Dietary Supplement|Placebo|Daily oral self-administration of 18 g of supplement dissolved in water/mineral water, spread over 2-3 occasions
45833261|NCT03391908|Diagnostic Test|cardiac imaging tests|Patients will undergo non-invasive Cardiac Computed Tomography for assessment of coronary plaques and myocardial perfusion, and invasive intracoronary imaging tests (coronary angiography, Intravascular ultrasound, optical coherence tomography and FFR). If imaging will reveal existence of a significant coronary plaque, a percutaneous coronary intervention (PCI - stenting) will be performed.
45833262|NCT03086382|Drug|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
45833263|NCT03086382|Drug|Lacosamide (LCM) syrup|Treatment B: Single dose of Lacosamide (LCM) 200 mg given as syrup
45987798|NCT00492440|Biological|recombinant interleukin-7|
45673596|NCT01463098|Drug|E2006 1.0 mg|E2006 1.0 mg capsule.
45673597|NCT01463098|Drug|E2006 2.5 mg|E2006 2.5 mg capsule.
45673598|NCT01463098|Drug|E2006 5.0 mg|E2006 5.0 mg (2 capsules of 2.5 mg each).
45673599|NCT01463098|Drug|E2006 10.0 mg|E2006 10.0 mg capsule.
45673600|NCT01463098|Drug|E2006 25.0 mg|E2006 25.0 mg (2 capsules of 10 mg each and 2 capsules of 2.5 mg each).
45673601|NCT01463098|Drug|E2006 50.0 mg|E2006 50.0 mg capsule.
45987799|NCT00492440|Genetic|gene expression analysis|
45987800|NCT00492440|Genetic|polymerase chain reaction|
45987801|NCT00492440|Genetic|protein expression analysis|
45987802|NCT00492440|Other|flow cytometry|
45987803|NCT00492440|Other|immunoenzyme technique|
45987804|NCT00492440|Other|immunologic technique|
45987805|NCT00492440|Other|laboratory biomarker analysis|
45987806|NCT00492440|Other|pharmacological study|
45987807|NCT04518501|Drug|Arsenic trioxide Tablet +Fuzuloparib Capsules|Arsenic trioxide Tablet : 0.27*9 tid po consecutive 21 days with 1 week rest． Fuzuloparib Capsules: 150 mg bid po
45987808|NCT00495248|Behavioral|Group intervention inspired by Lifestyle Redesign|Group intervention inspired by Lifestyle Redesign
45987809|NCT00495248|Behavioral|Group intervention inspired by Lifestyle redesign|Lifestyle programme once a week for two hours over an intervention period of 9 months
45987810|NCT05149053|Dietary Supplement|Hydrolyzed Collagen|Active product was composed of Hydrolyzed Collagen, lemon flavoring, anhydrous citric acid (acidifier), calcium ascorbate (vitamin C), sucralose (sweetener) and stevia (sweetener). One 10.728 g dose provides 10 g of HC and 80 mg of vitamin C.
45987811|NCT05149053|Other|Placebo|Placebo packet contained sucralose (sweetener) and stevia (sweetener) in identical proportions to the active preparation.
45987812|NCT00495287|Drug|cytosine arabinoside|"Arm A: use of standard-dose cytosine arabinoside (100 mg/m2/bd iv. on days 1-7) in association with idarubicin and etoposide.~Arm B: use of high-dose cytosine arabinoside (1000-2000 mg/m2/bd according to age +/-65 years iv. on days 1-2 and 8-9) in association with idarubicin."
45987813|NCT04696185|Drug|Dapagliflozin 10 MG|Dapagliflozin 10 mg (daily oral dose)
45987814|NCT00495326|Drug|Nevirapine based therapy|"Patients below 60 kg: 1 tablet twice a day of Triomune30®, including NVP 200 mg, 3TC 150 mg and D4T 30mg~Patients above 60kg: 1 tablet twice a day of Triomune40®, including NVP 200 mg, 3TC 150 mg and D4T 40 mg)"
45987815|NCT00495326|Drug|Efavirenz based therapy|Efavirenz EFV 200 mg (3 tablets/d) Lamivudine 3TC 300mg (2 tablets of 150mg/d) D4T generic 30mg or 40mg (2 tablets/d)
45673602|NCT01463098|Drug|E2006 100 mg|E2006 100 mg (2 capsules of 50 mg each).
45673603|NCT01463098|Drug|E2006 200 mg|E2006 200 mg (4 capsules of 50 mg each).
45673604|NCT01463098|Drug|Zolpidem 10 mg|Zolpidem 10 mg immediate release tablet.
45673605|NCT01463098|Drug|E2006 Matched Placebo or Zolpidem Matched Placebo|E2006-matched placebo capsules or zolpidem-matched placebo tablets.
45673606|NCT01463098|Drug|E2006 Matched Placebo|E2006-matched placebo capsule.
45673607|NCT01626079|Device|MitraClip System|Percutaneous mitral valve repair using MitraClip System
45833264|NCT04401696|Device|Bubble CPAP|"The bCPAP will be delivered using an oxygen flow meter as the oxygen source. This inspiratory limb containing oxygen from the flow meter will be connected to humidifier and tubing from humidifier will be connected to short binasal prongs, which would be applied to neonate with the help of adhesive bandage on both cheeks. It will be ensured that binasal prongs make appropriate seal. An orogastric tube will be placed for gastric decompression. A 1000 ml/500ml bottle filled with sterile water be used and marks will be made on it at 1cm distance, with '10' marked at base and '0' mark at the water interface.~The expiratory limb from the nasal prongs was connected to tubing that will be dipped in water up to the desired level to provide positive end expiratory pressure. Pressure is varied by varying the depth of the dipped end of tubing."
45833265|NCT04401696|Other|Nasal Oxygen|The oxygen will be delivered from a wall oxygen source, delivered between 1 to 6 L/min and the rate varied via a flow regulator.
45833266|NCT05680428|Other|early feeding|oral feeding within 12hours after stoma reversal
45833267|NCT05680428|Procedure|conventional feeding|oral feeding after 48hours of NBM after stoma reversal
45833268|NCT05688618|Dietary Supplement|Enteroccocus Facieum and Agave Inulin|A pack of symbiotic powder with 1 gram of e. facieum and 8g of agave inulin will be administered daily for 8 weeks
45833269|NCT05688618|Other|Placebo|A pack of unsweetened almond powder milk will be administered daily for 8 weeks
45833270|NCT03086304|Device|transcutaneous acupoint electrical stimulation|Transcutaneous acupoint electrical stimulation is same to the traditional Chinese medicine acupuncture treatment,treat diseases by stimulate different acupuncture points.
45833271|NCT03086304|Device|no transcutaneous acupoint electrical stimulation|the choice of acupoints are same with TEAS group,tape over the electrode but don't give electroacupuncture stimulation.
45833272|NCT03415308|Other|Focus Groups|Investigators will use qualitative methods to gather data on the elements associated with the patient perception of implicit bias (e.g. communication, respect, patient-centeredness) to ensure that our selected outcomes reflect the breadth of patients' concerns.
45833273|NCT03415308|Other|Cognitive Interviews|To gather insights from stakeholders regarding how to best refine the design of our existing implicit bias intervention to ensure that we have addressed potential facilitators and barriers to uptake, use, and sustainability
45833274|NCT03415308|Other|Pilot Testing of Implicit Bias Training|Determine the feasibility of delivering the refined implicit bias reduction intervention and assessing patient centered outcomes by giving providers a refined implicit bias training.
45458341|NCT01359722|Drug|N-acetylcysteine|N-acetylcysteine is administered at a dose of 150mg/kg in 500mL of saline EV in 1 hour followed by a dose of 50mg/kg in 500 mL of saline IV within 6 hours, beginning the infusion together to surgery.
45458342|NCT01359722|Drug|Control|The control group will receive only the infusion of saline in the same doses and infusion rate.
45673608|NCT01462942|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol Fixed Dose Combination (FDC) low dose (400/6 μg), twice per day
45458343|NCT01238185|Drug|acetylsalicylic acid|
45458344|NCT01238185|Genetic|gene expression analysis|
45673609|NCT01462942|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC high dose (400/12 μg), twice per day
45673610|NCT01462942|Drug|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
45673611|NCT01462942|Drug|Placebo|Inhaled dose-matched placebo, twice per day
45673612|NCT01462942|Drug|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
45987816|NCT00495326|Drug|Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)|"Intensive phase: 2 months daily E(RMP)HZ. PTB smear positive patients at month 2 will receive 1 more month intensive phase.~Continuation phase: 4 months daily H(RMP).~Patients with meningitis will receive Streptomycin instead of E during intensive phase."
45987817|NCT00492479|Drug|Kinerase Pro+Therapy Line day repair, serum, night repair|
45987818|NCT00492479|Drug|Kinerase Pro+Therapy Line Ultra rich day repair|
45987819|NCT00492479|Drug|LubriDerm|
45987820|NCT00506766|Behavioral|Bladder Health Class consisting of 6 weekly group sessions|1 time
45987821|NCT00506766|Behavioral|Practice PFMT and BT|As needed for 4 years
45987822|NCT00506766|Behavioral|Clinic examination for pelvic muscle function|1/year for 4 years
45987823|NCT00506766|Behavioral|Record keeping in 3-day voiding diary|Every 6 months for 4 years
45987824|NCT00495365|Drug|Epoetin alfa|
45987825|NCT04515927|Drug|JS002|Biological: JS002 Administered by subcutaneous injection
45987826|NCT00492518|Drug|Acetylcysteine|
45987827|NCT00492518|Drug|Theophylline|
45987828|NCT00492518|Drug|Placebo|
45458345|NCT01238185|Genetic|protein expression analysis|
45673613|NCT01462630|Drug|pazopanib hydrochloride|Given PO
45673614|NCT01462630|Other|laboratory biomarker analysis|Correlative studies
45673615|NCT01462630|Procedure|positron emission tomography|Correlative studies
45673616|NCT01462630|Procedure|computed tomography|Correlative studies
45673617|NCT01462630|Radiation|fludeoxyglucose F 18|Correlative studies
45833275|NCT04279002|Other|Brief 15-question questionnaire|Questionnaire is mailed retrospectively to the respiratory rehabilitation program and aimed at targeting 17 psycho-social traits. Response time is estimated at 10 minutes
45833276|NCT03414996|Other|Exercise training|Patients will undergo two weekly exercise training sessions with high-intensity interval training or moderate-intensity continuous exercise training for a period of 12 weeks.
45833277|NCT03086226|Drug|Fosravuconazole|Fosravuconazole will be given in two arms either as 300mg or 200mg. The drop-the loser design adaptive clinical trial design will allow two stages of the trial separated by a data based decision. In the first stage a decision will be taken on which arm to drop either the Fosravuconazole 200 or the Fosravuconazole 300 arm. The best treatment will be compared against the standard of care, itraconazole. At the end the focus will be comparing the best treatment against standard of care.
45987829|NCT05148936|Other|COVID-19 Testing Home-based (Aim 1)|Implementation of Antigen and PCR testing at participant homes
45987830|NCT05148936|Other|COVID-19 Testing Mobile (Aim 1)|Implementation of Antigen and PCR testing at mobile test sites
45458346|NCT01238185|Other|laboratory biomarker analysis|
45673618|NCT01504204|Drug|Adapalene + benzoyl peroxide samples|A sample size tube of the study medication, combination adapalene 0.1% plus benzoyl peroxide 2.5% gel, will be provided with instruction on proper application, including demonstration, at the first visit.
45673619|NCT01504204|Drug|Adapalene + benzoyl peroxide from standard tube|Subjects are instructed to apply the combination adapalene 0.1% plus benzoyl peroxide 2.5% gel once daily to all affected areas.
45987831|NCT05148936|Other|COVID-19 Testing Mobile Approach 1 (Aim 2)|Implementation of Antigen and PCR testing at mobile test sites - active outreach
45987832|NCT05148936|Other|COVID-19 Testing Mobile Approach 2 (Aim 2)|Implementation of Antigen and PCR testing at mobile test sites - baseline outreach
45987833|NCT00495404|Behavioral|Physician Treatment Guidelines|
45987834|NCT04513860|Drug|YKP3089|Capsule, dose to be titrated Tablet, dose to be titrated
45987835|NCT00495443|Device|Peterio|
45987836|NCT04510545|Diagnostic Test|Endobrain, Computer Aided Diagnosis (CAD)|Artificial intelligence
45987837|NCT00506805|Drug|SNX-5422|dose escalated, tablets every other day; undetermined duration until disease progression
45987838|NCT00495560|Drug|Addition of misoprostol 25 mcg 12 hours before induction|Misoprostol given buccally the night before induction
45987839|NCT00506376|Behavioral|Interview|Interview that will take about 20 minutes to complete.
45987840|NCT00495599|Procedure|Cytokines assessed from fat tissue|Cytokines assessed from fat tissue
45987841|NCT00506844|Drug|Cetuximab, Irinotecan, Capecitabine|
45987842|NCT04515693|Other|6 Minutes Walking Test|A walkway of 12 meters will be marked with one cone at each end. The patient will be instructed to walk back and forth as many times as possible in six minutes.
45987843|NCT00495833|Behavioral|Personalized brochure|either photo personalization, blood pressure personalization, both, or no personalization
45987844|NCT00495833|Behavioral|Promotional gift|half of participants who go to a fire station will receive a gift card.
45987845|NCT00506961|Drug|Rosuvastatin|10 mg rosuvastatin for 4 weeks followed by rosuvastatin or another 12 weeks
45987846|NCT00506961|Drug|Simvastatin|20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
45987847|NCT00492635|Drug|Levitra (Vardenafil, BAY38-9456)|9 months DAILY dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
45987848|NCT00492635|Drug|Levitra (Vardenafil, BAY38-9456)|9 months PRN dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
45987849|NCT00492635|Drug|Placebo|9 months placebo (double blind)2 months single-blind placebo wash-out period (subject only is blinded)2 months open-label PRN treatment with active medication
45987850|NCT00492674|Device|APOS biomechanical gait system|
45987851|NCT00492674|Procedure|Physical Therapy|
45987852|NCT00507000|Drug|Cholecalciferol|Drug: Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months Arms: A, Cholecalciferol
45987853|NCT00507000|Drug|Lactose granules|Drug: Lactose placebo Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
45987854|NCT00495872|Drug|Dasatinib|50 mg by mouth (PO) Twice Daily for 28 Days Every 28 Days
45987855|NCT00495872|Drug|Erlotinib|100 mg PO Daily for 28 Days Every 28 Days
45987856|NCT00495872|Drug|Lapatinib|1000 mg PO Daily for 28 Days Every 28 Days
45833278|NCT03086226|Drug|Itraconazole|This will be the active comparator
45987857|NCT00495872|Drug|Lenalidomide|15 mg PO Daily for 28 Days Every 28 Days
45987858|NCT00495872|Drug|Sorafenib|400 mg PO Daily for 21 Days Every 28 Days
45987859|NCT00495872|Drug|Sunitinib|25 mg PO Daily for 21 Days Every 28 Days
45987860|NCT00495872|Drug|Valproic Acid|40 mg/kg PO Daily for 7 Days, then 7 Days Off
45987861|NCT00507039|Procedure|inhalative grass-pollen provocation|Subjects undergo allergen challenges with incremental doses of grass pollen allergen. In subjects, who develop a fall in FEV1 of more than 20%, this will be followed by two single-step challenges.
45987862|NCT00507078|Procedure|Surgical treatment for OSA|
45987863|NCT00492713|Other|dark chocolate|dark chocolate
45987864|NCT00492713|Other|Milk chocolate 1|Milk chocolate 1
45987865|NCT00492713|Other|Milk chocolate 2|Milk chocolate 2
45987866|NCT00507117|Drug|Lunesta|Lunesta 3mg prior to PSG
45987867|NCT00507117|Drug|Placebo control|matching placebo
45987868|NCT00492791|Device|wireless endoscopy capsule|Firslty patency ingestion then wireless endoscopy capsule exam done
45987869|NCT00492830|Drug|TRC093 recombinant humanized IgG1k monoclonal antibody|TRC093 is a humanized monoclonal antibody to cleaved collagen administered i.v. on days 1 and 15 of each 28 day cycle until pregression or unacceptable toxicity develops.
45987870|NCT01299727|Biological|rhHNS-10 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
45673620|NCT01485640|Drug|Lurasidone|Lurasidone flexibly dosed; doses of 20, 40, 60 or 80 mg/day will be taken orally with food
45833279|NCT03085992|Drug|FOLFOXIRI plus Bevacizumab|"BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~IRINOTECAN 165 mg/sqm IV over 1-h, day 1~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1 administered every two weeks for 6 cycles (3 months)."
45833280|NCT03085992|Other|Chemoradiotherapy plus Bevacizumab|"FLUOROURACIL 225 mg/sqm/day by protracted IV continuous infusion or -CAPECITABINE 825 mg/sqm/bid p.o. continuously without interruption for all the duration of radiation treatment;~EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 daily fractions over 5.5 weeks;~BEVACIZUMAB 5 mg/kg over 30 minutes, starting on day 1 of radiation treatment day 1 and then every two weeks (for 3 cycles)."
45987871|NCT01299727|Biological|rhHNS-45 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
45987872|NCT01299727|Biological|rhHNS-90 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
45987873|NCT00492908|Device|Helistent Titan2 (Titanium coated stent)|Titan2
45987874|NCT00492908|Device|EndeavorTM (Zotarolimus-Eluting Stent)|Endeavor
45987875|NCT01299571|Drug|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
46083608|NCT04197128|Device|Ribose cross linked collagen matrix for augmentation|"Local anaesthesia Lignocaine and Adrenaline 1:80000 Injection (Lignox® 2% A, Indoco remedies Ltd, Mumbai) will be administered and midcrestal incison will be made and full thickness flap would be raised buccally. To obtain tension free adaptation of flap margins, the buccal flap advancement will be done using periosteal releasing incision.~Implant osteotomies will be performed with sequential drilling and with standardised drills. All the subjects will receive the same implant system. (Norris medical ltd. Hatasia street, Nesher, Israel) For augmentation of deficient ridge, ribose cross linked collagen matrix will be cut and adapted to the buccal wall and ridge around the buccal aspect of healing abutment. Stabilisation would be achieved with internal resorbable horizontal mattress suture.~The tension free flap margins will be adapted around the healing abutment with simple interrupted 4.0, 3/8, reverse cutting resorbable sutures (Ethicon, Hamburg, Germany)."
45673621|NCT04745065|Behavioral|Connect2BWell|Please see the description provided for arm 1.
45673622|NCT04744207|Drug|GS-248|120 mg, capsule, once daily for 4 weeks
45987876|NCT01243736|Drug|Combination Prep|"combination bowel preparation, which consists of:~drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;~drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;~drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;~lying on your right side for 30 minutes following the swallowing of the capsule endoscope."
45987877|NCT02274467|Device|Trans-catheter electric stimulation test|
45987878|NCT01299376|Drug|L50/H12.5/A5|
45987879|NCT01299376|Drug|L50/H12.5|
45987880|NCT01299376|Drug|Placebo to L50/H12.5/A5|
45673623|NCT04744207|Drug|Placebo|capsule, once daily for 4 weeks
45673624|NCT02118961|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)|0.5 mL, subcutaneous injection
45833281|NCT03362424|Biological|Mesenchymal stem cell|Mesenchymal stem cells applies at the end of rotator cuff repair in de active group
45833282|NCT03362424|Procedure|Rotator cuff repair|Rotator cuff repair
45833283|NCT04401462|Procedure|Tension band wiring or plate fixation|Operative fixation of olecranon fracture with either of the methods mentioned in the intervention name
45987881|NCT01299376|Drug|Placebo to L50/H12.5|
45987882|NCT04324450|Device|MRI|"The MRI protocol is composed of:~T1-weighted anatomical sequences~DTI sequences~resting functional MRI~3D MR spectroscopic imaging"
45987883|NCT04324450|Behavioral|Cognitive assessment|Battery of neuropsychological tests
45987884|NCT02890537|Drug|Core decompression/PREOB® implantation|All subjects received a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
45987885|NCT02890537|Drug|Core decompression/BMC implantation|All subjects received a core decompression under general anesthesia combined with the implantation of BMC into the necrotic lesion (single administration).
45987886|NCT00492947|Biological|dendritic cell vaccine|3 vaccinations total: Day 10, Day 20, Day 30
45987887|NCT02890225|Procedure|3 days after|in 3 days after RIRS.
45987888|NCT02890225|Procedure|10days after|in10 days after RIRS.
45987889|NCT02890225|Procedure|EPVL performed in30days after RIRS|Patients in Group C undergo EPVL in630days after RIRS.
45987890|NCT01299025|Other|Training using Nintendo Wii Fit|Training 2 times per week, 30 minutes, for 6 weeks.
45987891|NCT00492986|Drug|Nexavar (Sorafenib, BAY43-9006)|Multikinase inhibitor: Sorafenib mono therapy 400 mg bid
45987892|NCT04324528|Device|vv-ECMO + cytokine adsorption (Cytosorb adsorber)|in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)
45987893|NCT04324528|Device|vv-ECMO only (no cytokine adsorption)|COVID-19-diseased treated with vv-ECMO
45987894|NCT05608018|Other|Intervention|Participants will receive the app with all features turned on.
45673625|NCT02118961|Biological|Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)|0.1 mL, subcutaneous injection
45673626|NCT02140645|Drug|linagliptin|non-randomized
45987895|NCT05608018|Other|Control|Participants will receive the app with some features turned off.
45673627|NCT02140411|Drug|Ranibizumab Intravitreal injections|Ranibizumab intravitreal injections 3 months 1 per month and after PRN treatment.
45673628|NCT02139943|Drug|Canagliflozin 100 mg|Canagliflozin capsule of 100 mg dose will be taken orally, before the first meal of the day.
45673629|NCT02139943|Drug|Canagliflozin 300 mg|Canagliflozin capsule of 300 mg dose will be taken orally, before the first meal of the day.
45833284|NCT04401462|Behavioral|Sling or a long-arm plaster|Non-operative treatment and progressive range of motion as tolerated. A long-arm plaster will be used, if necessary, for pain relief.
45833285|NCT05688540|Other|e book|e book
45833286|NCT05688540|Other|traditional education booklet|traditional education booklet
45987896|NCT01298596|Procedure|Loop Electrosurgical Excision Procedure (LEEP)|LEEP procedure uses a low-voltage electrified wire loop to cut out diseased part of cervix
45987897|NCT01298596|Procedure|Cryotherapy|Cryotherapy procedure involves using a cryoprobe and carbon dioxide or nitrous oxide gas to freeze the diseased part of the cervix
45987898|NCT02890108|Dietary Supplement|Sugar sweetened beverages|350 cc (1 can) of sugar sweetened beverage
46083609|NCT02693886|Other|doctor experience|
45673630|NCT02139943|Drug|Placebo|Matching placebo capsule will be taken orally, before the first meal of the day.
45673631|NCT01485172|Drug|ropinirole monotherapy|ropinirole as monotherapy in Parkinson's disease
45673632|NCT01485172|Drug|placebo monotherapy|placebo as monotherapy in Parkinson's disease
45673633|NCT02105701|Drug|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.
45673634|NCT02105701|Drug|Ribavirin|200 mg capsule
45673635|NCT04418011|Device|Repetitive Transcranial Magnetic Stimulation|"The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)"
45676692|NCT01622660|Drug|Gemcitabine|Patients will receive gemcitabine 1200 mg/m2 intravenously on day 1 and day 8 and. Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
45833287|NCT03086070|Drug|Omeprazole 20mg|omeprazole 20 mg capsules were administered per os half an hour before breakfast for 8 weeks
45833288|NCT03086070|Drug|Placebo oral capsule|Matching placebo oral capsules were administered per os half an hour before breakfast for 8 weeks
45833289|NCT05688306|Drug|Recombinant Human Interleukin-11 for Injection|received rhIL-11 injection for at least 5 consecutive days
45833290|NCT03086148|Drug|Ketamine|Ketamine will be administrated intravenously at dural opening, with the total dose of 0.5 mg/kg and continual infusion for 40 minutes.
45987899|NCT02890108|Dietary Supplement|Artificially sweetened beverages|350 cc (1 can) of artificially sweetened beverage
45987900|NCT00493259|Behavioral|Health-Related Quality of Life instrument|Adolescents will fill out questionnaires regarding quality of life and dealing with diagnosis of Insulin Resistance Syndrome
45987901|NCT00493259|Behavioral|Depression Scale for Children (CES-DC)|questionnaire
45987902|NCT04324138|Drug|Jianpi Qinghua granules|3 times a day and 1 hour after a meal, for 4 weeks
45987903|NCT04324138|Drug|Jianpi Qinghua placebo granules|3 times a day and 1 hour after a meal, for 4 weeks
45987904|NCT00493337|Behavioral|advanced adherence counseling+reminder|
45987905|NCT00493337|Device|Compliance Card|
45987906|NCT01243814|Device|hyaluronate intra-articular injection|joint injection in ankle with hyaluronate
45987907|NCT01243814|Device|placebo injection|joint injection with saline solution for placebo
45987908|NCT01243853|Dietary Supplement|Alpha-galactosidase|3 months intervention, daily 3 x 3 capsules alpha-galactosidase enzyme (400 GalU/capsule) or 3 x 3 capsules placebo
45987909|NCT01298518|Drug|PF-04620110|5 mg of PF-04620110 given once daily
45987910|NCT01298518|Drug|PF-04620110|2.5 mg of PF-04620110 given twice daily
45987911|NCT01298518|Drug|Placebo|Matching placebo giving for 4 weeks
45987912|NCT01243970|Drug|Phenylephrine|"Infusion dose 50 mcg / minute. On/off regimen in response to blood pressure (BP) readings every minute. Approximative 30 minutes treatment duration. Total dose 50 mcg - 1500 mcg *~* We will start the infusion after the spinal anaesthetic (see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 1500 mcg."
45987913|NCT01243970|Drug|Ephedrine|"Infusion dose 4mg / minute. On/off regimen in response to blood pressure readings every minute. Approximative 30 minutes treatment duration. Total dose 4 mg - 120 mg. *~* We will start the infusion after the spinal anaesthetic(see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 120mg."
45987914|NCT04515576|Drug|LY3493269|Administered SC
45987915|NCT04515576|Drug|Dulaglutide|Administered SC
45987916|NCT04515576|Drug|Placebo|Administered SC
45987917|NCT01298362|Drug|Aromatase Inhibitors|
45987918|NCT01298362|Drug|Chemotherapy|
45987919|NCT00493376|Procedure|Cervical tissue biopsy analysis: Comet assay|Cervical tissue biopsy analysis: Comet assay
45987920|NCT00493376|Procedure|Biopsy: Measurement of histone gamma H2AX phosphorylation|Biopsy: Measurement of histone gamma H2AX phosphorylation
45987921|NCT00493376|Procedure|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha
45987922|NCT00493376|Procedure|Measurement of vascular perfusion: contrast enhanced MRI|contrast enhanced MRI
45987923|NCT00493415|Drug|nitroglycerin iv|loading dose of 4mg/h iv in the first 30 minutes, 2 mg/h iv in the next 23 hours and 30 minutes
45987924|NCT00493415|Drug|placebo = nacl 0.9%|4 ml/h iv in the first 30 minutes, 2 ml /h iv in the next 23 hours and 30 minutes
45987925|NCT01244009|Drug|MK-4827|MK-4827 will be administered daily as an oral formulation in continuous 21-day cycles.
45987926|NCT04511832|Drug|Diclofenac|Patients who were diagnosed as breast cancer and met the inclusion criteria will be recruited and randomly assigned to acupuncture group or drug (NSAIDs) group. After each subgroup completing the 4 weeks intervention, all the participants were enter washout period lasting 2 weeks to eliminate the effect of the previous treatment. Crossover was held after washout period and made the patients to have the other treatment in the following 4 weeks. After receiving the case, the third group recorded the pain indicators for the first month, followed by a one-month trial- combination of acupuncture and NSAID treatment, and then followed up for another month after stopping.
45987927|NCT04513782|Diagnostic Test|Audiological Assessments|Participants will all undergo routine audiological assessments. The results from these assessments will be evaluated in order to advance understanding of central hearing loss.
45987928|NCT01298323|Behavioral|Patient outreach|Patients will be contacted at week 1 and then every 2 weeks until completion of 52 weeks to detect/treat AEs sooner
45987929|NCT01298323|Drug|Vandetanib|Treatment 300mg vandetanib opel label.
45987930|NCT00495950|Behavioral|Questionnaire|Questionnaires relating to symptoms experienced during and following standard cancer treatment.
45987931|NCT05148507|Device|PROKERA|Amniotic membrane is the sac that encloses the baby during pregnancy. Amniotic membrane has been used to treat many ocular (eye) diseases and repair ocular surface damage. PROKERA contains amniotic membrane fastened between a ring system and can be worn in the eye like a contact lens. PROKERA is a medical device that was cleared by the United States food and drug administration (FDA) in 2001. PROKERA is considering it investigational for the study
45987932|NCT00495989|Procedure|saliva sampling + dental calculus collection|
45987933|NCT05148273|Behavioral|telenursing|7-24 counseling and daily treatment protocol reminders will be given to the intervention group.
45673636|NCT04418011|Device|Repetitive Transcranial Magnetic Stimulation (Intermittent Theta Burst Stimulation)|"The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)"
45987934|NCT01244204|Dietary Supplement|Vitamin D|Daily dose of 800IU of vitamin D
45673637|NCT04418011|Device|Repetitive Transcranial Magnetic Stimulation (Sham)|Other Name: MagPro X100 or R30(Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)
45673638|NCT04411225|Drug|Cannabidiol oral solution|Both the active drug (cannabidiol) and placebo will be in oral solution.
45673639|NCT04743349|Procedure|Steam inhalations|Exposure of airway mucosae to humidified steam through steam inhalation for at least 20 min (4 cycles of 5 min) daily, for 10 days.
45987935|NCT01244204|Dietary Supplement|Placebo|Identically appearing capsules
45987936|NCT00496028|Drug|AZD0530|oral tablet
45987937|NCT00496028|Drug|Carboplatin|intravenous infusion
45987938|NCT00496028|Drug|Paclitaxel|intravenous infusion
45987939|NCT00493493|Procedure|surgery (Pore Excision, Curettage, and Injection of Cymetra)|
45987940|NCT00496067|Device|Doppler-Guided Uterine Artery Occlusion Device|For bilateral occlusion of the uterine arteries
45987941|NCT04516278|Biological|bevacizumab|1.25 mg, intravitreal injection
45987942|NCT04516200|Device|transcranial direct current stimulation and traditional physical therapy program|Transcranial stimulation will be applied only for the study group.
45987943|NCT04516200|Other|designed physical therapy program|sensory training and balance training
45987944|NCT00493532|Drug|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
45987945|NCT01297465|Drug|Gonal-f®|Gonal-f® (follitropin alfa) 300 International Unit (IU) will be administered subcutaneously once daily from stimulation day 1 (S1) to stimulation day 5 (S5).
45673640|NCT05132491|Other|TECH-Prep Intervention|Participants in the treatment program will be asked to complete 10 online training modules (1 hour each), attend 5 online motivational speaker forums (1 hour each), and view 5 coding workshops. The activities will be completed over an 8 week period.
45673641|NCT01502956|Device|InterStim® device|Eligible subjects will complete baseline assessments, be randomized and scheduled for first stage lead placement (FSLP) InterStim®. The criterion for an initial clinical response to InterStim® therapy will be defined as a ≥50% improvement in the mean number of UUIE/day on a minimum 3 day bladder diary, completed during the 7-14 days following the first stage lead placement (FSLP). Subjects with a ≥ 50% improvement mean number of UUIE/day will be eligible to proceed with implantation of the implantable pulse generator (IPG). Subjects will then be followed monthly to determine the response to therapy.
45987946|NCT01297465|Drug|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously starting from S6 until recombinant human chorionic gonadotropin (r-hCG) administration day (at least 1 follicles >= 18 mm). The dose of Pergoveris® was adjusted based upon the participant's ovarian response and according to the site's standard practice.
45987947|NCT01297465|Drug|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously once daily from S1 until r-hCG administration day (at least 1 follicles >= 18 mm). The dose of Pergoveris® was adjusted starting from S6 based upon the participant's ovarian response and according to the site's standard practice.
45987948|NCT01297465|Drug|Recombinant human chorionic gonadotropin (r-hCG)|250 microgram of r-hCG will be administered once subcutaneously on r-hCG day (at least 1 follicles >= 18 mm).
45987949|NCT02276508|Drug|E. coli Nissle 1917|Participants will all take E. coli Nissle 1917 orally administered medication for 30 days
45987950|NCT00496106|Behavioral|Telephone counseling|6 telephone counseling sessions
45987951|NCT00496106|Behavioral|Telephone interview|telephone interview
45987952|NCT04511286|Behavioral|Exposure|Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
45987953|NCT00493571|Drug|Gimatecan|Starting dose: 0.6 mg capsules administered orally once daily.
45987954|NCT02276586|Procedure|Horizontal Tooth preparation|Round parallel chamfer diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
45987955|NCT02276586|Procedure|Vertical Tooth preparation|Long flame diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
45987956|NCT00496145|Behavioral|Spanish Diabetes Self-Management Program|small-group self management education program
45987957|NCT01297309|Drug|NPSP558|All patients will inject NPSP558 individual titration of 25, 50, 75 or 100 μg SC QD into alternating thighs in the morning via a multidose injection pen device.
45987958|NCT04518462|Drug|Exparel|EXPAREL (bupivacaine liposome injectable suspension)
45987959|NCT04518462|Drug|Bupivacaine Hydrochloride|0.25% bupivacaine
45987960|NCT00496184|Drug|Nifedipine cream topical application|
45987961|NCT00493610|Drug|N-acetylcysteine(Mucomyst)|
45987962|NCT05146908|Biological|2 Blood samples from arterial and/or central venous catheters|5 mL blood sample taken at the same time as a blood sample scheduled in regular patient management before the introduction of enteral nutrition and 24H after
45673642|NCT01502956|Drug|Botox® injection|Eligible subjects will complete baseline assessments, be randomized and scheduled for Botox A® injection visit. Subjects who received a Botox A® injection will be assessed for a clinical response, at 1 month from injection, using the same clinical criterion (≥50% improvement in the mean number of UUIE/day on a 3 day bladder diary completed prior to the 1 month visit). Those subjects that experience a clinical response, at one month, will be eligible for a repeat Botox A® injection after 6 months, if they experience degradation of clinical effect, using the PGSC.
45673643|NCT01502644|Drug|Oxycodone|Daily dosage up to 120 mg
45987963|NCT05146908|Other|Echography|"In 3 steps:~before initiation of enteral nutrition~4h after initiation of enteral nutrition~After 24 hours of enteral nutrition"
45987964|NCT05146908|Other|Data collection|"At inclusion:~Calculation of severity scores; collection of reason for admission and demographic data; main comorbidities and treatments administered; the time between admission and nutritional recovery; risk factors for gastroparesis; current organ failure and supplements. Presence of parenteral nutrition, ongoing carbohydrate intake. Caloric objective.~Within the first 24 hours, collection of:~echographic parameters at H0, H4 and H24~venous congestion parameters~biological parameters within 24 hours Constitution of a biobank (at H0 and H24)~Within the first 7 days, collection of:~the occurrence or not of the primary endpoint (and time to occurrence).~symptoms of gastrointestinal dysfunction~Within 30 days, collection of:~organ failure and replacement over the period, and mortality.~the occurrence or not of ventilator-associated lung disease (VAPD). Each patient is followed for 30 days. Survival will be assessed at 30 days before discharge from the study."
45987965|NCT02274506|Drug|Cyclophosphamide|60 mg/kg by vein on Days -8 and -7.
45673644|NCT01502644|Drug|Morphine|Daily dosage up to 90 mg immediate release or 180 mg extended release
45673645|NCT01502644|Drug|Placebo|Placebo-matching oxycodone, placebo-matching morphine
45987966|NCT02274506|Drug|Fludarabine|25 mg/m2 by vein on Days -6 to -2.
45987967|NCT02274506|Procedure|T-Cell Infusion|T-cells infused no sooner than 48 hours and no later than 1 week post completion of chemotherapy on Day 0.
45987968|NCT04519632|Other|Qualitative study|Qualitative interviews
45987969|NCT00496223|Drug|Sunitinib|Sunitinib will be given PO once daily on days 1-14 of each 21 day cycle. The exact dose of sunitinib will be determined during the Phase I part of the trial.
45987970|NCT00496223|Drug|Dacarbazine|Dacarbazine will be given at 1000 mg/m2 on day 1 of every 21 day cycle.
45987971|NCT02593422|Behavioral|Expressive Writing|Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer
46083610|NCT02693964|Other|Bone density and carotid ultrasound|All participants will be asked for relevant medical, personal, family and diabetes history, treatment and complications, and history of falls and fractures and will undergo measurement of bone density, carotid ultrasound and a blood draw.
45987972|NCT02593422|Behavioral|Fact Writing (Control)|Participants will be asked to write about the facts of their experience with ovarian cancer
45987973|NCT00496301|Drug|Gemcitabine, Capecitabine and Sorafenib (6 cycles)|Gemcitabine: 1000 mg/m2 i.v. days 1 and 8. Capecitabine: 650 mg/m2 i.v. day 1 to 14. (change to 500mg/m2 after amendment nº2 (dated on 10/10/2007) Sorafenib:400 mg/12h v.o. day 1 to 21
45987974|NCT00493688|Other|Cardiopulmonary Exercise Testing (CPET)|Pedaling on a Stationary Bicycle at 60 Revolutions Per Minute as the Resistance to Pedaling Gradually Increases.
45987975|NCT02597985|Other|Prehabilitation|Supervised exercise training intervention will include three sessions per week for four weeks at a Mayo Clinic system cardiac rehabilitation facility. The Rochester, Minnesota Cardiac Rehabilitation Program will provide guidance and oversight. Modes of aerobic exercise will include treadmill walking (the primary mode of training) supplemented with non-weight-bearing activities such as stationary cycling and combination arm/leg recumbent exercise (NuStep device), as needed. Intensity will be set using Borg Perceived Exertion Scale (RPE) ratings of 12-14 (somewhat hard), keeping patients below the threshold for more than mild angina.
45987976|NCT02597985|Other|Usual Care|
45987977|NCT00496418|Device|Mesh in permanent colostomy|
45987978|NCT05141838|Drug|Vitamin D|Adding vitamin D preparations to the therapy in the individual required dosage to correct the deficient state
45987979|NCT05141838|Dietary Supplement|Oral nutritional supplement|Adding оral nutritional supplement to the therapy depending on the degree of protein-energy malnutrition
45987980|NCT00493727|Drug|N-acetylcysteine(Mucomyst)|
45987981|NCT05143788|Procedure|Awake craniotomy|The awake neurosurgical procedure performed on the brain is to provide a real-time neurological functions monitoring in order to preserve the functions of brain to the greatest extent.
45987982|NCT00493766|Drug|LBH589|
45987983|NCT05140005|Diagnostic Test|GlowTest COVID-19 Antigen Home Test|diagnostic testing for Covid 19
45987984|NCT00496457|Drug|Experimental|Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks
45987985|NCT00496457|Drug|Placebo comparator|4 Capsules of PBO per day before noon meal
45987986|NCT02598648|Other|FXR|FXR could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. FXR were measured in neonate with ALI、ARDS and control
45987987|NCT02598648|Other|RIPK3|FXR(farnesoid-X-receptor) could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. RIPK3 were measured in neonate with ALI、ARDS and control.
45987988|NCT00493844|Other|Exercise testing|Exercise testing
45987989|NCT00493844|Other|Clinical evaluation + NTproBNP|Clinical evaluation + NTproBNP levels
45987990|NCT05146479|Procedure|Fluoride varnish and pit and fissure sealants onto first permanent molars|Quarterly application of fluoride varnish. Application of pit and fissure sealant, and replacements if necessary.
45987991|NCT01297270|Drug|BI201335|QD BI 201335
45458347|NCT01238185|Other|questionnaire administration|
45673646|NCT04408378|Other|observation of covid 19 pneumonia|We try to reveal the fact,covid-19 pneumonia prognosis can be estimated by using MPV/PLT ratio
45673647|NCT01462318|Drug|Midazolam|5 mg
45673648|NCT01462318|Other|Caffeine|200 mg
45673649|NCT01462318|Drug|S-warfarin|10 mg
45673650|NCT01462318|Other|Vitamin K|10 mg
45673651|NCT01462318|Drug|Omeprazole|40 mg
45673652|NCT01462318|Drug|Dextromethorphan|30 mg
45673653|NCT01462318|Biological|BIIB019 (Daclizumab)|150 mg in 1 ml PFS
45673654|NCT01485094|Drug|GRT6010|Oral solution given once daily.
45673655|NCT01485094|Drug|Pregabalin|Over-encapsulated pregabalin capsules 75mg twice daily on Days 1 to 3, and 150mg twice daily on Days 4 to 7.
45673656|NCT01485094|Drug|Matching Placebo|"Matching Placebo capsules to the over-encapsulated Pregabalin capsules and Matching Placebo oral solution to the GRT6010 solution.~Capsules twice daily on Days 1 to 7. Solution once daily."
45673657|NCT04079686|Drug|Cephazolin|Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and postoperatively every 6 hours, for 24 hours.
45673658|NCT04079686|Other|Sterile saline|Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and intravenous sterile saline postoperatively, every 6 hours, for 24 hours.
45673659|NCT01484938|Device|OPTI-FREE PureMoist|Commercially marketed multi-purpose contact lens solution for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses
45987992|NCT01297270|Drug|PegIFN/RBV|
45987993|NCT01297270|Drug|BI201335|QD (once daily) BI 201335
45987994|NCT01297270|Drug|Placebo|
45987995|NCT00496535|Drug|TNFerade biologic|
45987996|NCT05145621|Drug|Fingolimod 0.5 mg capsules- Test drug|An oral dose of the assigned formulation (3 capsules) will be administered in the morning to subjects with about 240 mL of water at ambient temperature according to the randomization scheme.
45987997|NCT00493883|Device|yttrium Y 90 microspheres (TheraSphere®)|Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver
45987998|NCT01296568|Drug|LY2603618|Administered intravenously
45987999|NCT01296568|Drug|Pemetrexed|Administered intravenously
45988000|NCT01296568|Drug|Gemcitabine|Administered intravenously
45988001|NCT05140668|Device|Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization|Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization
45988002|NCT00496574|Biological|Novo Helisen Depot, Phostal|subcutaneous immunotherapy
45988003|NCT02598999|Drug|ALX-009|Solution for inhalation administered through nebulization
45988004|NCT02598999|Drug|OSCN-|Solution for inhalation administered through nebulization
45988005|NCT02598999|Drug|bLF|Solution for inhalation administered through nebulization
45988006|NCT02598999|Drug|Placebo|Solution for inhalation administered through nebulization, Sodium Chloride 0.9%
45988007|NCT00493922|Procedure|Rapid diagnostic test|Introduction of rapid diagnostic test for malaria
45988008|NCT00493922|Procedure|Microscopy|Microscopy for diagnosis of malaria
45988009|NCT00493922|Procedure|Clinical diagnosis for malaria|The use of Clinical diagnosis for the diagnosis of malaria
45988010|NCT01296412|Drug|sitagliptin|100 mg tablet, orally, once daily.
45988011|NCT01296412|Drug|liraglutide|0.6 mg by subcutaneous (pen) injection, once daily, on Days 1-7; up-titrated on Day 8 to 1.2 mg daily. At Week 12, dose may be increased to 1.8 mg once daily for participants who did not meet protocol-specified glycemic goals.
45988012|NCT01296412|Drug|glimepiride|starting dose of 1 mg tablet (up-titrated as needed), once daily, as needed, after Week 12.
45988013|NCT01296412|Drug|metformin|metformin tablets at a dose of ≥1500 mg per day
45988014|NCT05605561|Other|Digital Story|It is the standard of care given according to the hospital's policies and procedures.
45988015|NCT05146128|Other|Strengthening exercises|The participants had to perform specific exercices 3 times a week during 8 weeks
45988016|NCT00496652|Radiation|Radiotherapy|Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4)
45988017|NCT00496652|Drug|Zalutumumab|Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
45988018|NCT01295905|Device|delefilcon A contact lens|Investigational silicone hydrogel, single vision soft contact lens
45988019|NCT01295905|Device|narafilcon B contact lens|Commercially marketed silicone hydrogel, single vision soft contact lens
45988020|NCT02956148|Radiation|Radioligand [18F]MNI-659|The effective radiation dose for the injection of [18F]MNI-659 is approximately 5.6 mSv (approximately 2 years of background radiation in Sweden) for an average person weighing 70 kg.
45988021|NCT02597634|Drug|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
45988022|NCT02597634|Drug|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
45988023|NCT00494039|Procedure|Radioactive seed implant to prostate|
45988024|NCT05148429|Other|Ultrasound exam|Ultrasound exam
45988025|NCT05148429|Other|Fetal MRI|Fetal MRI
45988026|NCT05148429|Other|Postnatal abdominal ultrasound|Postnatal abdominal ultrasound
45988027|NCT05148429|Other|Pediatric Follow up|Pediatric Follow up
45988028|NCT00496691|Behavioral|Family-based HIV prevention program|comparison between parent-child intervention targeting parent-teen sexual communication, condom use skills, and assertiveness training to an adolescent-only intervention that targets similar constructs minus parent-teen sexual communication and a general health promotion intervention
45988029|NCT05145972|Other|Ultrasound Guided Superior Hypogastric Plexus|The division of abdominal aorta into common iliac arteries will be identified by using longitudinal sonography , and the body of the fifth (5th) Lumbar vertebra will be identified by placing the transducer transversely. A skin wheal will be raised with subcutaneous infiltration with 2% lidocaine solution nearly 3-4 cm below the umbilicus. A 15-cm Long 22-G Chiba needle will be used with out of plane technique, and the needle will be advanced under USG-guidance to reach the anterior- most point of the fifth Lumber vertebral body avoiding the vascular structures. The needle will be withdrawn nearly 1-2 mm after hitting the vertebral body to avoid injecting the drug into the periosteum. After confirming a negative aspiration of blood, known amount of neurolytic agent according to the grouping will be injected for the neurolysis of superior hypogastric plexus. The uniform spread of the drug will be confirmed under real-time sonography.
45988030|NCT00496847|Drug|PERIOGEN|Implantation of rhPDGF-BB (0.3 mg/ml) + β-TCP (0.5 g)
45988031|NCT00496847|Drug|Beta TCP alone|Implantation of β-TCP (0.5 g) alone
45988032|NCT02591199|Drug|URG101|
45988033|NCT02591199|Drug|Placebo|
45673660|NCT01502410|Drug|sorafenib tosylate|Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28
45833291|NCT03086148|Drug|Normal saline|Normal saline will be administrated intravenously at dural opening, with the total dose of 0.5 ml/kg and continual infusion for 40 minutes.
45833292|NCT03359538|Drug|Rapamycin|tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
45833293|NCT03359538|Drug|Placebo Oral Tablet|tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
45988034|NCT02591199|Drug|Lidocaine|
45988035|NCT02591199|Drug|Heparin|
45988036|NCT00494078|Device|Real-time glucose monitoring system (Guardian, Medtronic)|Patients randomised to the intervention arm are treated with intensive insulin therapy guided by the real time glucose monitoring system.
45988037|NCT00494078|Drug|intensive insulin therapy|intensive insulin therapy according to an algorithm
45988038|NCT02596035|Drug|Nivolumab|
45988039|NCT00494117|Device|ApneaLink|A two channel sleep screening device for the assessment of Sleep Disordered Breathing.
45458348|NCT01238185|Procedure|biopsy|
45458349|NCT03501472|Behavioral|text-only PWL|
45988040|NCT05147883|Behavioral|Exercise|Patients will be given an aerobic exercise program for 1 hour, 3 days a week for 12 weeks
45988041|NCT00494156|Drug|heparin|
45988042|NCT00494156|Drug|aspirin and clopidogrel|
45988043|NCT02595489|Dietary Supplement|vitamin D3|Daily oral supplement provided by study investigators
46083611|NCT04197050|Drug|Sacubitril / Valsartan Oral Tablet|After recruiting participants and collecting the baseline information, sacubitril/valsartan group will receive sacubitril/valsartan and optimal pharmaceutical treatment (OPT). The control group will receive valsartan and OPT. A CMR scan and a post-processed imaging procedure will later be carried on in order to detect the cardiac impairment.
45458350|NCT03501472|Behavioral|low-emot PWL|
45673661|NCT01502410|Other|pharmacological study|Optional correlative studies
45673662|NCT01502410|Other|laboratory biomarker analysis|Optional correlative studies
45673663|NCT01462162|Drug|Tocilizumab|
45673664|NCT01483924|Drug|Apo805K1|Sequential parallel dose escalation.
45673665|NCT01462084|Device|Adaptive servo-ventilation (ASV)|Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual.
45673666|NCT01462084|Device|Bi-Level PAP|Bi-Level PAP delivers therapy at 2 pressures IPAP and EPAP that are fixed.
45673667|NCT02134028|Drug|Dupilumab|Pharmaceutical form: Solution for injection Routes of administration: Subcutaneous
45988044|NCT00494195|Genetic|rAAV1.tMCK.human-alpha-sarcoglycan- First cohort|"The first cohort of subjects with LGMD2D (alpha-sarcoglycan deficiency) and proven mutations will undergo gene transfer with a minimum of three subjects enrolled into this cohort and will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml.~In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo."
45988045|NCT00494195|Genetic|Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort|The second cohort will receive the same dosis of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
45988046|NCT00497003|Drug|Treatment with either metoprolol or carvedilol|
45988047|NCT00494273|Behavioral|Cognitive Behavioral and Standard Care with Healthy Living|
45988048|NCT00494312|Drug|Pioglitazone|Pioglitazone 15 mg or 30 mg titrated to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 156 weeks.
45988049|NCT00494312|Drug|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 5 mg or 10 mg titrated to 15 mg, capsules, orally, once daily for up to 156 weeks.
45988050|NCT05145348|Biological|Immune response to Sars-CoV-2 vaccinations; including COVID-19 vaccin Moderna, Comirnaty (Pfizer) and Vaxzevria (AstraZeneca)|The vaccination is not part of the study, but part of the national immunization programme of the Netherlands. Blood will be drawn at 4 time points: baseline (t=1, <2 months prior to first vaccination); t=2: 21-28 days after first vaccination and prior to second vaccination; t=3: 28 (21-42) days after second vaccination; t=4: 12 months (+/- 1 month) after second vaccination. Mucosal Lining Fluid (MLF) samples will be collected at 28 days (3-6 weeks) (t=3) and 12 (+/- 1) months (t=4) after the second vaccination.
45988051|NCT00494351|Procedure|Long-pulsed Nd:YAG laser 1064 nm|Laser once monthly
45988052|NCT02595372|Drug|Omeprazole|
45988053|NCT00497042|Device|Self Adjusting File|
45988054|NCT05142969|Other|2% Chlorhexidine bathing|Eight chlorhexidine-impregnated cloths are used in sequential order to wipe the body surfaces from neck to toe to avoid exposure of chlorhexidine to the mucous membranes of the eyes, ears and mouth.
45988055|NCT01244867|Biological|20 micrograms dose H5 VLP|2 doses given 21 days apart of 20 micrograms of H5 VLP vaccine mixed with Alhydrogel
45988056|NCT01244867|Biological|30 micrograms dose H5 VLP|2 doses given 21 days apart of 30 micrograms of H5 VLP vaccine mixed with Alhydrogel
45833294|NCT04272138|Behavioral|Calm Meditation|"The intervention will run for 4-weeks. Participants will complete the 30 day, How to Meditate meditation series that provides daily 10-minute meditations. Throughout the intervention, participants will be sent reminder emails via REDCap to participate in their assigned practice sessions participants and will complete online weekly participation logs via REDCap. Additionally, they will answer one, multiple-choice ecological momentary assessment question, randomly, 3x per day via test message assessing how one currently feels. Participants will complete baseline and post-intervention measures of the Perceived Stress Scale, Hospital Anxiety and Depression Scale, Mindfulness Attention Awareness Scale, International Physical Activity Questionnaire, Salzberg Stress Eating Scale, Brief Cope, and Brief Resilience Scale. Following these measures, participants will be asked to complete a satisfaction questionnaire (week 5) and have the opportunity to volunteer for a short phone interview."
45988057|NCT01244867|Biological|45 micrograms dose H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine mixed with Alhydrogel
45988058|NCT01244867|Biological|45 micrograms non-adjuvanted H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine
45988059|NCT01244867|Biological|Placebo|2 doses given 21 days apart of the placebo
45988060|NCT05141604|Other|Field expansion view|Overlaid small window on HMD to show the part of the scene in the blind field into portions of the participants' remaining, seeing, field of vision
45988061|NCT02596503|Drug|Eribulin|Intravenous eribulin administered on days 1 and 8 of a 21-day cycle.
45988062|NCT02596503|Drug|Irinotecan|Irinotecan will be administered orally at a fixed dose of 90 mg/m2/day on days 1 -5 of a 21-day cycle.
45988063|NCT02596503|Other|Cefixime|Cefixime will be given to all patients to reduce irinotecan-associated diarrhea. It will be administered Day -1 through Day 8 of each cycle.
45988064|NCT00494429|Drug|Morphine|Gestational Age< 29 weeks: A loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/h.
45988065|NCT00494429|Drug|Morphine|Gestational Age>= 29 weeks: A loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
45988066|NCT01245023|Procedure|Laparoscopic adhesiolysis|Laparoscopic adhesiolysis and Sprayshield
45988067|NCT01245023|Procedure|Placebo-surgery|skin incisions without laparoscopy or related procedures
45988068|NCT05147103|Device|Low-Intensity Focused Ultrasound|LIFU application using various durations, responses of neuromodulation recorded using TMS and EMG.
45988069|NCT00497120|Drug|acetazolamide|
45988070|NCT00497120|Drug|placebo|
45458351|NCT03501472|Behavioral|high-emot PWL|
45988071|NCT00497120|Procedure|uvulopalatopharygoplasty|
45988072|NCT02276352|Drug|Treatment 1|
45988073|NCT02276352|Drug|Treatment 2|
45988074|NCT02276352|Drug|Treatment 3|
45988075|NCT00494468|Drug|Zolpidem|
45988076|NCT00497237|Drug|Beclomethasone plus formoterol fixed combination|100+6 pMDI
45988077|NCT00497237|Drug|Fluticasone plus salmeterol fixed combination|diskus 250/50
45988078|NCT05144061|Drug|HRS2398 Tablets|Take 5mg to 320mg once or twice a day ; Oral administration , 21 days as a cycle.
45988079|NCT01244282|Procedure|fMRI with sensory stimulation|BOLD fMRI study with sensory stimulation followed by fMRI in the presence of increasing concentrations of ferumoxytol (Feraheme™)
45988080|NCT00494546|Procedure|Pd-103 with 20 vs 44 Gy supplemental beam XRT|
46083612|NCT00917319|Other|Bundling Infection Control Interventions|identify risk factors for developing HAIs, receive general infection control measures as well as infection control measures appropriate for the identified risk factor (s)
45988081|NCT05146440|Drug|PM14|"Pharmaceutical form: PM14 drug product is provided as a sterile lyophilized powder for concentrate for solution for infusion with a strength of 5.0 mg of the active moiety.~Route of administration: PM14 drug product was developed for administration by the i.v. route. Before use, the vials are reconstituted with 10 mL of sodium chloride 9 mg/mL (0.9%) solution for infusion to give a solution containing 0.5 mg/mL of PM14. Prior to administration, the reconstituted DP solution should be further diluted with sodium chloride 9 mg/mL (0.9%) solution for infusion. Each vial of PM14 5.0 mg is a single use vial."
45988082|NCT00497276|Procedure|placement of popliteal catheter|Bolus naropin 7,5 mg/ml 30 ml; infusion bupivacaine 2,5 mg/ml 5-10 ml/h
45988083|NCT00497315|Drug|combination chemotherapy (pemetrexed + cisplatin)|pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 (q 3 weeks for 3 cycles)
45988084|NCT00497315|Radiation|thoracic irradiation + pemetrexed|pemetrexed 500 mg/m2 (q 3weeks for 2 cycles), 60 GY (30 fractions of 2 GY)
45988085|NCT05142072|Drug|Vitamin D3|intranasal film
45673668|NCT04752488|Other|Telerehabilitation (TR)|The home exercise program will be educated to the patient on the first day. Exercises for isometric and isotonic strengthening, stretching, and stabilization of the neck muscles will be given. Exercises will be presented to the patients in audio-video format and detailed instructions with explanations. The exercise protocol will also be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
45673669|NCT04752488|Other|Conventional Rehabilitation (CR)|The home exercise program will be educated to the patient on the first day. Isometric and isotonic strengthening, stretching and stabilization exercises for the neck muscles will be given. Exercise information form including explanation and picture of the exercises will be given to the patients. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
45673670|NCT02172950|Biological|rVIII-SingleChain|Recombinant single-chain coagulation factor VIII
45988086|NCT00497354|Drug|Variation in volume of local anesthetic|
45988087|NCT00497354|Procedure|Ultrasound-guided interscalene brachial plexus block|
45988088|NCT00497393|Behavioral|Clinical Decision Unit|a dedicated 2-bed area to see patients and then rotate them back into the waiting room area for labs and diagnostic imaging.
45988089|NCT05140785|Diagnostic Test|Advanced MRI sequences|Advanced MRI sequences which look to a) determine structure of a primary brain tumour and b) metabolism within a primary brain tumour
45988090|NCT00494624|Drug|prednisolone|
45988091|NCT00507156|Procedure|Standard primary PCI|Acute re-opening of the occluded coronary artery
45988092|NCT00507156|Procedure|Mechanical postconditioning|Mechanical postconditioning with 4 cycles 30/30 sek balloon inflations
45988093|NCT00494663|Drug|DIO-902|150mg tablet once per day for 16 weeks
45988094|NCT00494663|Drug|DIO-902|300mg tablet once per day for 16 weeks
45673671|NCT04757636|Biological|2.0 mg OPT-302|intravitreal injection
45673672|NCT04757636|Biological|2.0 aflibercept|intravitreal injection
45673673|NCT04757636|Procedure|Sham|intravitreal injection
45673674|NCT02151266|Behavioral|Exercise and Cognitive retraining|Walking 5 times per week at moderate intensity; cognitive retraining one-hour 2 times per week.
45673675|NCT02151266|Behavioral|Exercise Only|
45833295|NCT04272138|Behavioral|Educational Podcast Control|The intervention will run for 4-weeks. Control group participants will listen to daily 10-minute health education podcasts. Throughout the intervention, participants will be sent reminder emails via REDCap to participate in their assigned practice sessions and participants will complete online weekly participation logs via REDCap. Additionally, they will answer one, multiple-choice EMA (ecological momentary assessment) question, randomly, 3x per day via test message assessing how one currently feels. Participants will complete baseline and post-intervention measures of the Perceived Stress Scale, Hospital Anxiety and Depression Scale, Mindfulness Attention Awareness Scale, International Physical Activity Questionnaire, Salzberg Stress Eating Scale, Brief Cope, and Brief Resilience Scale. Following these measures, participants will be asked to complete a satisfaction questionnaire (week 5) and have the opportunity to volunteer for a short phone interview.
45833296|NCT05345808|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide formulated with chondroitin sulfate and sodium hyaluronate
45988095|NCT00494663|Drug|DIO-902|450mg DIO-902 tablet once daily for 16 weeks
45988096|NCT00494663|Drug|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
45988097|NCT00494663|Drug|DIO-902|150mg tablet of DIO-902 once daily for 16 weeks
45988098|NCT00494663|Drug|DIO-902|300mg DIO-902 tablet daily for 16 weeks
45988099|NCT00494663|Drug|DIO-902|450mg DIO-902 tablet for 16 weeks
45988100|NCT00494663|Drug|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
45988101|NCT05147766|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
45988102|NCT05146674|Drug|Tadalafil 5mg|"Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group)."
45988103|NCT00494702|Procedure|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-88%
45988104|NCT00494702|Procedure|Resuscitation|Oxygen inspiratory fraction needed to keep oxygen saturation in the preset limits of 90-93%
45988105|NCT00507195|Drug|Hypnotics: propofol, sevoflurane, desflurane,desflurane,midazolam|
45988106|NCT00497471|Drug|Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone)|
45988107|NCT00497471|Drug|iron (2 mg/kg/daily)|
45988108|NCT05146635|Drug|Intravesical Bcg|Patients will receive induction and maintenance BCG after complete TURBT.
45988109|NCT05146635|Drug|Intravesical chemotherapy (epirubicin)|Patients will receive induction and maintenance epirubicin after complete TURBT.
45673676|NCT02151266|Behavioral|Stretching and Flexibility|
45988110|NCT00494741|Drug|mycophenolate mofetil|Patients randomized in this group will receive 750 mg of MMF per os twice a day starting on the day of transplant. MMF dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
45988111|NCT00494741|Drug|azathioprine|Patients randomized in this group will receive 75 mg of AZA per os (or 125 mg if body weight > 75 kg) once a day starting on the day of transplant. AZA dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
45988112|NCT00507234|Drug|formoterol fumarate inhalation solution|
45988113|NCT00507273|Other|GIST Registry|Internet based data registry about how different physicians treat and manage patients with gastrointestinal stromal tumors.
45988114|NCT00497510|Procedure|Chiropractic manipulation|
45988115|NCT00507312|Device|HD medical device (ViScope)|Device
45988116|NCT00507312|Device|CSIRO device|device
45988117|NCT00497549|Procedure|side-to-side stapled|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
46083613|NCT02712918|Behavioral|Brief Behavioral Activation Treatment for Depression|Behavioral treatment of depression which focuses on increasing the Level of positive reinforcement through systematic and goal directed activation of behavior. Goal and values are assessed and used to determine target behaviors.
46083614|NCT02712918|Other|Standard Care|Treatment as usual at the ward
45456760|NCT01126645|Procedure|RFA|"A max.of 2 percutaneous RFA sessions is permitted per patient with a max.of 2 liver lesions treated in each RFA session. Randomization to sorafenib or placebo is performed after completion of RFA. Percutaneous RFA is to be performed according to the manufacturer's instructions and following as far as possible routine procedures of the participating hospital. Typically, RFA will be performed under conscious sedation, general anesthesia is permitted. After local anesthesia of the site of puncture, the applicator is positioned in the center of the lesion using ultrasound-, CT- or MR-guidance. The success of ablation is to be controlled directly after RFA using ultrasound, contrast-enhanced CT, or MR imaging. If for any reason RFA is deemed incomplete within the immediate follow-up (up to 2 weeks after the initial ablation), RFA is to be repeated once (in this case, the total (max.) number of RFA sessions will be three).~The study procedure guide will contain further instructions for RFA."
45458352|NCT03501472|Behavioral|immed posttest|
45458353|NCT03501472|Behavioral|delay posttest|
45458354|NCT01143805|Drug|Tasocitinib 10 mg oral tablet|Treatment A: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of an oral tablet
45673677|NCT02151110|Biological|MEDI4920 3 mg|Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
45673678|NCT02151110|Biological|MEDI4920 10 mg|Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
45673679|NCT02151110|Biological|MEDI4920 30 mg|Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
45673680|NCT02151110|Biological|MEDI4920 100 mg|Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
45673681|NCT02151110|Biological|MEDI4920 300 mg|Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
45833297|NCT04401228|Other|predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables?|"patients were questioned about their usual medication (Sartan, angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory drug, immunosuppressive drugs), their health condition (diabetes, hypertension, tobacco use, mental status). The Body mass index was computed.~Age, gender, caucasian/african, weight, body mass index, number of days with symptoms before hospitalization, asthenia, pyrexia, dyspnea, chest pain, digestive sign, anosmia, ageusia, confusion, Travel or contact < one month, cigarette consumption ,hypertension, diabetes, mental status, angiotensin-converting-enzyme inhibitors, Sartan, non-steroidal anti-inflammatory drugs, immunosuppressive drugs, SpO2,Thoracic Computerized Tomography : % of lung injury, Thoracic Computerized Tomography : density of lung injury, blood type, white blood cells, neutrophils, lymphocytes, blood platelets, fibrinogen, ferritin, triglycerides, LDH, troponin, CRP. The dates of admission to ICU and death were recorded"
45833298|NCT02336958|Drug|intermediate cervical plexus block ropivacaine|20ml ultrasound guided intermediate cervical plexus block.
45833299|NCT02336958|Drug|pericarotidal infiltration (active comparator) ropivacaine|5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.
46083615|NCT05342168|Diagnostic Test|Using a swallowed expanding sponge (Cytosponge TM) to obtain sampling of the esophageal musosa|A gelatin capsule containing the collapsed mesh sponge is swallowed with an attached string fixed to the cheek. After 8 minutes the gelatin capsule will have dissolved and the expanded soft mesh sponge can be with drawn sampling the surface of the esophagus on the way out. The sponge then will be spun and the supernant fixed, processed and stained.
46083616|NCT02598375|Other|Feeding intolerance|In this study ; it is aimed to show the value of IFABP regarding the identifying the feeding intolerance and early detection of enteral feeding intolerance
45673682|NCT02151110|Biological|MEDI4920 1000 mg|Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
45988118|NCT00497549|Procedure|hand sewn|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
45988119|NCT05148546|Drug|Neoadjuvant nivolumab|Patients will receive 2 cycles of nivolumab 360mg (arm A and C) or 3mg/kg (arm B) every 3 weeks followed by a nephrectomy.
45988120|NCT05148546|Drug|Neoadjuvant ipilimumab|Patients will receive 2 cycles of ipilimumab 1mg/kg every 3 weeks followed by a nephrectomy.
45988121|NCT05148546|Drug|Neoadjuvant relatlimab|Patients will receive 2 cycles of relatlimab 360mg every 3 weeks followed by a nephrectomy.
45988122|NCT00507351|Behavioral|Questionnaire|3 questionnaires that will take 20 minutes total to complete.
45988123|NCT00497588|Procedure|surgery|
45988124|NCT00497588|Radiation|radiotherapy|
45988125|NCT00506532|Drug|Surfactant (calfactant)|
45988126|NCT00494858|Behavioral|Cognitive behavioral therapy - focused (CBT-EF)|Focused CBT concentrates only on BN symptoms. There will be 20 sessions over the course of 5 months.
45988127|NCT00494858|Behavioral|Cognitive behavioral therapy - broad (EB)|Broad CBT addresses symptoms of BN, as well as those of the personality disorder. CBT-EB incorporates ED interventions from CBT-EF but also has modules focused on addressing mood intolerance and interpersonal difficulties. There will be 20 sessions over 5 months.
45988128|NCT05143983|Behavioral|Positive valence music|Subjects will have to listen to 3 minutes of unfamiliar musical excerpts, with positive valence characteristics (fast tempo, major key). They will be told to listen carefully in order to then answer a short questionnaire. The listening will be followed by an liking scale (from 1 : not liked at all, to 5 : liked a lot) and a familiarity scale (from 1 : not familiar at all, to 5 : very familiar).
45988129|NCT05143983|Behavioral|Neutral valence music|Subjects will have to listen to 3 minutes of unfamiliar musical excepts with neutral valence. They will be told to listen carefully in order to then answer to a short questionnaire. The listening will be followed by a liking scale (from 1 : not liked at all, to 5 : liked a lot) and a familiarity scale (from 1 : not familiar at all, to 5 : very familiar).
45988130|NCT05149560|Drug|Ticagrelor 90mg|All patients will be prescribed ticagrelor as monotherapy
45988131|NCT00494897|Drug|Asparaginase|
45988132|NCT00494897|Drug|Cyclophosphamide|
45988133|NCT00494897|Drug|Cytarabine|
45988134|NCT00494897|Drug|Daunorubicin|
45988135|NCT00494897|Drug|Mercaptopurine|
45988136|NCT00494897|Drug|Prednisone|
45988137|NCT00494897|Drug|Vincristine|
45988138|NCT00494897|Drug|Methotrexate|
45988139|NCT00494897|Procedure|Intrathecally treatment|
45988140|NCT05148624|Procedure|embryo transfer|immediate ambulation after embryo transfer
45988141|NCT05145153|Procedure|Thoracic surgery application|The chronic pain findings of the patients who underwent thoracic surgery will be questioned at the postoperative 3rd and 6th months.
46083617|NCT03995472|Drug|SHR-1501|Administered subcutaneously
46083618|NCT03995472|Drug|SHR-1316|Administered intravenously
46083619|NCT04229030|Drug|RZL-012|small synthetic molecule for the treatment of Dercum's Disease lipomas
46083620|NCT04229030|Drug|Vehicle|Vehicle of RZL-012 drug product
45988142|NCT00497666|Drug|Rosiglitasone (retrospective observation)|
45988143|NCT05144919|Behavioral|Promotion of a biodiverse diet|"Component 1 - Participatory Identification of Intervention Approach (PIIA) Component 2. Local stakeholder consultation Component 3. Sensitisation of community Diversity club will receive capacity building from a Village health worker based on the prioritised species selected in component 2.~The following topics will be covered for each species selected for promotion:~Where to locally source inputs and expected price~How/when to prepare plots using organic inputs~Planting and best-practice management practices~Seed saving and storage~Possible intercropping combinations OR ecosystem services provided Component 4. Active Cooking demonstrations and Nutrition Education and counselling: Diversified cooking practices"
45988144|NCT05144568|Other|Nutrition education|Nutrition education will be given to improve PMS
45988145|NCT05144217|Drug|Placebo|1 capsule per day of placebo
45988146|NCT05144217|Drug|2x 140 mg per day|2 capsule per day of silimarit
45988147|NCT05144217|Drug|3x 280 mg per day|3 capsule per day of silimarit
45988148|NCT05144217|Drug|1x 1120 mg|8 capsule per day of silimarit
45988149|NCT00497744|Drug|Intraperitoneal Cefepime|
45988150|NCT00495053|Drug|hMaxi-K|Two dose levels (5000 µg/90 mL intravesical instillation and 10000 µg/90 mL intravesical instillation)
45988151|NCT00495053|Other|Placebo|Matching placebo (PBS-20% sucrose)
45988152|NCT05143554|Device|Auricular percutaneous neurostimulation|Percutaneous neurostimulation
45988153|NCT05143554|Device|Sham percutaneous neurostimulation|Sham percutaneous neurostimulation
45988154|NCT00497783|Drug|Lactoserum|
46083621|NCT02781974|Other|Exercise|Strength and balance exercise in Groups, focusing on lower limb strength, back strength and static and dynamic balance
45988155|NCT05143515|Behavioral|PACE label|There were 34 food and drinks choices available for consumption in the pop up café. The labels were displayed next to the food/drink item in the pop up café. The food items were kept in the same position for each participant kitchen to simulate the café environment. Then researchers changed the labels on the display according to the randomisation allocation of each participant. After randomsation participants were informed that they have £10 to spend in the pop-up café and that they could eat the food they selected in a private social eating room.
45988156|NCT00495092|Drug|Caffeine|Caffeine from 300 mg/d to 1200 mg/d or 15 mg/kg/d
45988157|NCT00495092|Drug|Biperiden|Biperiden 2-4 mg/d p.o.
45988158|NCT00495092|Drug|Placebo|Placebo + Placebo
45988159|NCT05143359|Diagnostic Test|Wharfe and Pederson difficulty index|Efficiency of Wharfe and Pederson Difficulty index in extraction of third molars.
45988160|NCT05143359|Diagnostic Test|Winters difficulty index|Efficiency of Winters Difficulty index in extraction of third molars.
45988161|NCT00497822|Procedure|Aerobic exercise training|
45988162|NCT00497861|Procedure|Activator Methods Chiropractic Technique|
45988163|NCT01244360|Dietary Supplement|resveratrol|Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
45988164|NCT01244360|Other|Placebo Comparator: Sugar Pill|Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
45833300|NCT02336958|Drug|jugular infiltration prilocaine|5ml prilocaine 1% jugular infiltration for wound drainage.
45988165|NCT00506571|Drug|S-1, irinotecan, oxaliplatin|
45988166|NCT00497900|Drug|Vitamin D|Daily vitamin D (cholecalciferol) tablets and rocaltrol
45988167|NCT05143125|Biological|Decitabine combined with NK cell infusion|Decitabine combined with NK cell infusion
45988168|NCT01244555|Other|ultrasound|Twice weekly ultrasound sessions for 6 weeks
45988169|NCT01244555|Other|massage|Twice weekly massage sessions for 6 weeks
45988170|NCT05143008|Behavioral|SMART Intervention|Counseling sessions will be conducted by research project staff that has, at least, masters level or equivalent degrees. Sessions will occur up to 10 times at their regularly scheduled obstetric appointments and also weekly by phone and text messages. In person sessions will last approximately 20-30 minutes.
45988171|NCT00497939|Drug|Saw palmetto and sanmiaoshan capsule|
45988172|NCT05142930|Other|Intermittent ultrasound|Intermittent ultrasound treatment will be applied to the muscles of the bilateral coccyx region
45988173|NCT05142930|Other|Continuous ultrasound|Continuous ultrasound treatment will be applied to the muscles of the bilateral coccyx region
45988174|NCT01244594|Other|Cycling with functional electrical stimulation|Subjects will cycle with functional electrical stimulation for one hour, 3 times per week at Magee Rehab's outpatient center. Subjects will cycle for a total of 26 weeks (6 months).
45988175|NCT00497978|Dietary Supplement|taurine|6 grams of taurine will be given each day in capsules, starting the day of admission till the sixth postoperative day
45988176|NCT00497978|Dietary Supplement|placebo|a similar amount of placebo will be given each day in capsules, starting the day of admission till the sixth postoperative day
45988177|NCT00506610|Drug|T-62|
45988178|NCT01244672|Procedure|Ferguson|This is a modification of the Milligan-Morgan technique, whereby the incisions are totally or partially closed with absorbable running suture. A retractor is used to expose the hemorrhoidal tissue, which is then removed surgically. The remaining tissue is either sutured or is sealed through the coagulation effects of a surgical device.
45458355|NCT01143805|Drug|Tasocitinib 10 mg IV Infusion|Treatment B: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of a 30 minute intravenous infusion
45833301|NCT02336958|Drug|pericarotidal infiltration (placebo comparator) saline|5ml saline 0.9% (placebo comparator): pericarotidal infiltration.
45833302|NCT03409926|Dietary Supplement|Acacia Gum|dietary supplement will be added to the participant's usual diet
45833303|NCT04760886|Other|Type of hospital (rural DGH vs Urban MTC)|In this small cohort study, the hospital in which the patients were treated was the intervention. One was in a rural area and was a district general, whereas one was in an urban enviroment and was a major trauma centre.
45988179|NCT01244672|Procedure|THD|Transanal hemorrhoidal dearterialization will be performed using an endoscopic ultrasonic probe. Approximately 7-8 hemorrhoidal arteries will be ligated at 1, 3, 5, 7, 9, 11 o'clock position as previously described in the literature. The ligation will be performed using a vicryl suture. The ultrasonic probe locates the arterial signal.
45988180|NCT05142852|Device|Extracorporeal shock wave therapy|The participants in the experiment group received 5 consecutive sessions of ESWT for 5 minutes. Treatment parameters for the shock wave therapy group were set similar to a previous study (Devrimsel et al., 2013) 2000 shock waves with 1.6 bar intensity and 16 Hz frequency were applied for five sessions using the Swiss DolorClast Master (EMS, Nyon, Switzerland). All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
45988181|NCT05142852|Other|Conventional physiotherapy|The participants in the control group received 5 sessions of conventional physical therapy intervention for 5 minutes. The control group intervention consists of a 1-minute friction massage over the common extensor tendon of the elbow, followed by 3 minutes therapeutic ultrasound with a frequency of 1.5 Hz, and a 1-minute ice massage over the common extensor tendon of the elbow. All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
45988182|NCT00498056|Biological|VRC-HIVDNA016-00-VP|DNA vaccine administered intramuscularly
45988183|NCT00498056|Biological|VRC-HIVADV014-00-VP|Adenovirus vaccine administered intramuscularly
45988184|NCT00498056|Biological|VRC-HIVDNA016-00-VP placebo|DNA vaccine placebo administered intramuscularly
45988185|NCT00498056|Biological|VRC-HIVADV014-00-VP placebo|Adenovirus vaccine placebo administered intramuscularly
45988186|NCT00498095|Procedure|Renal biopsy|
45988187|NCT05141331|Device|piezoelectric|Comparing Piezoelectric split-crest technique versus expansion using Hand Driven Ridge Expanders in treatment of Maxillary Narrow Ridges
45988188|NCT00498134|Drug|Triple therapy for H. pylori infection|
45988189|NCT00498134|Drug|Cox-2 inhibitor|
45988190|NCT05146557|Other|Dental examination|In this cross sectional observational study only Dental examination and a self response survey was applied.
45988191|NCT00502580|Behavioral|Interview|Interview taking about 10 minutes to complete.
45988192|NCT05146518|Behavioral|Supportive and Dignified Maternity Care|"The core components of intervention would include: capacity-building of a typical maternity team comprising clinical staff (gynaecologists, doctors, nurses) and support staff (ward boys/porters and maids); collaborative care, a team-driven approach, led by gynaecologists (ward in-charge), attempts to integrate care and behaviour practices of staff according to the principles of measurement-guided care-plans, quality improvement and accountability, with a focus on meeting SDMC needs; staff and patient feedback: a complaints register will be maintained by designated staff; and brief exit interviews will elicit, and record, the degree to which care has been supportive and respectful; Accountability and governance (performance review): reports of non-respectful care will be discussed, and remedial actions decided, in periodic meetings.~Note: Since it is a behavioural intervention being administered at health system level so LSHTM has exempted this study to have a sponsor."
45988193|NCT00498251|Drug|inhalation of salbutamol (5 mg)|
45988194|NCT00498251|Drug|ipratropium|
45988195|NCT05146401|Other|Plasma fatty acid concentration|Plasma concentrations of fatty acids were measured by gas chromatography - mass spectrometry (Agilent 7890B gas chromatography coupled with an Agilent 5977A Series mass spectrometry). Individual fatty acids with relative concentrations ≥ 0.05% were used to derive fatty acid patterns through principle components analysis.
45988196|NCT00502619|Procedure|Acupuncture|A specific regimen of acupuncture sites will be needled twice weekly for eight weeks and once weekly for a subsequent eight weeks.
45988197|NCT00502619|Other|Treadmill Exercise|After the first four weeks of acupuncture treatments, subjects will initiate a three times per week treadmill program, which will continue for a total of 12 weeks in conjunction with the acupuncture treatments.
45988198|NCT00498290|Procedure|enhanced recovery after surgery (ERAS) protocol|An integrated protocol aims to allow patients to recover more quickly from major surgery, avoid medium-term sequelae of conventional postoperative care (e.g. decline in nutritional status and fatigue) and reduce health care costs by reducing hospital stay
45988199|NCT00498290|Procedure|control|normal recovery protocol as usually
45988200|NCT00502658|Behavioral|Dietary supplement containing vitamins, minerals, and herbs|
45988201|NCT00502658|Behavioral|Shakes with nutrients and herbs|
45988202|NCT00502658|Behavioral|Control dietary supplement|
45988203|NCT00502658|Behavioral|Isocaloric, isonitrogenous control shakes without herbs|
45988204|NCT00502658|Behavioral|Personal energy tracking tool|
45988205|NCT02954562|Other|fMRI|Participants will undergo two to three fMRI scans
45988206|NCT00502736|Drug|ibandronate [Bondronat]|6mg iv on days 1-3
45988207|NCT02954679|Other|Online self-administrated and anonymous survey questionnaire|The study will be conducted during a period of 3 years, between September 2016 and September 2019, according to a standardized methodology identical in every school involved and a procedure based on an online self-administrated and anonymous survey questionnaire. The questionnaire, elaborated on Limesurvey®, will be available for two successive academic years for all students aged more than 18 years old.
45988208|NCT01246505|Device|CTO Crossing and Percutaneous transluminal angioplasty|Crossing of the CTO with the BridgePoint Medical System and subsequent treatment of the CTO via PTA (specific devices to be used for PTA at investigators' discretion)
45988209|NCT05146245|Other|Therapeutic Drug Monitoring|Physician receives dosing advice based on risperidone plasma level.
45988210|NCT05146245|Other|Risperidone plasma level|Plasma levels of risperidone and 9-OH risperidone are measured in a Dried Blood Spot.
45988211|NCT05146089|Other|Hypoxic exposure|30 minutes of intermittent hypoxia achieved using breaths of low oxygen air (5% oxygen) followed by room air through a mask.
45988212|NCT05146089|Other|modified Oxford test|An intravenous bolus of sodium nitroprusside (100 μg) will be given to decrease blood pressure, followed 1 minute later by a bolus of phenylephrine (150 μg) to increase blood pressure, occurring before and after intermittent hypoxia exposure.
45988213|NCT05146089|Drug|Oral Bosentan 62.5 mg|Prior to completion of visit 2, male subjects will consume 62.5 mg twice daily for 3 days as well as the morning of the study visit (7 pills) at home and experimental sessions will be performed 3 hours after oral intake of the final dose.
45988214|NCT05146089|Other|Hypoxic ventilatory response test|Hypoxia will be achieved using breaths of low oxygen air (5% oxygen) followed by room air through a mask. This will be repeated 4-5 times per test, occurring before and after intermittent hypoxia exposure.
45988215|NCT02955030|Biological|NSV0001|sublingual
45988216|NCT02955030|Biological|"Influenza HA vaccine Biken HA"|subcutaneous
45988217|NCT02955030|Biological|Placebo|sublingual
45988218|NCT00498407|Drug|CP-4055|CP-4055 5 mg/mL for infusion, dose: 200 mg/m2/day, schedule: d1-5 q4, 30 minutes IV infusion
45988219|NCT02954913|Procedure|Simultaneous Resection|Resections of 3 or more segments of the liver will be considered a major liver resection.(Reddy) The anesthetic technique and the order of liver resection or rectal resection will be determined by each surgeon's standards. It is recommended that a low central venous pressure be maintained in order to decrease intraoperative blood loss (Chen; Hughes) and that liver resection be performed prior to colorectal resection in order to keep a low central venous pressure during that part of the case.
46083622|NCT02712840|Procedure|Freeze-All Protocol|All good morphologic quality blastocysts are vitrified on day 5 or 6. The best quality vitrified blastocyst frozen on day 5 will be warmed and transferred in a subsequent cycle.
45458356|NCT01362764|Drug|Abiraterone acetate suspension Formulation 1|Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL
45458357|NCT01362764|Drug|Abiraterone acetate suspension Formulation 2|Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL
45458358|NCT01362764|Drug|Abiraterone acetate tablets|Type=exact, unit=mg, number= 250, form=tablet, route=oral use, as a single dose
45988220|NCT00498524|Device|ICD|Received an ICD
45988221|NCT00498524|Device|ICD|Have not received an ICD
45988222|NCT02954757|Procedure|HIFU treatment|High intensity focused ultrasound
45456761|NCT01126645|Procedure|Radioembolization (SIRT)|"One SIRT prescription consists of the pre-treatment assessment followed by one or 2 treatment sessions The aim of pre-treatment assessment is to ensure delivery of the microspheres to the target. Evaluation includes a determination of the arterial location and any consequent necessity for coil-embolization of the gastroduodenal artery, right gastric artery and any other accessory arteries to prevent inadvertent administration of microspheres into the gastrointestinal tract or pancreas. In addition, parasitic extrahepatic supply should be coil-embolized.~Patients in whom the shunt fraction indicates potential exposure to the lung to an absorbed radiation dose of more than 30 Gy should be excluded from treatment with SIR-Spheres. Patients who are randomized to receive SIRT but who are not regarded as eligible for SIRT after the pre-treatment assessment will be switched to the sorafenib only group within the palliative treatment arm."
45988223|NCT00502814|Procedure|3-D Optical Surface Scan|3-D digitized images of the breasts and chest will be taken over a period of five minutes.
45988224|NCT00502814|Procedure|Mechanical Testing|A small device with a mild suction will be used to measure how the skin tends to stretch.
45988225|NCT00502814|Procedure|Cutaneous Ultrasound|Cutaneous ultrasound using a 20 MHz machine and the skin thickness will be recorded.
45988226|NCT00502814|Procedure|Breast MRI and/or CT|Imaging of the breasts and chest using an MRI and/or CT scan over about one hour.
45988227|NCT02954640|Biological|Blood sampling|Additional blood sampling for the realization of the test on the gene panel
45988228|NCT00498563|Procedure|altitude exposure in hypobaric chamber|
45988229|NCT02954796|Drug|SGN-CD352A|On the first day of each 28-day cycle, SGN-CD352A will be given IV. The dose of SGN-CD352A is different in each cohort of the study, with the lowest dose in Cohort -1 (4 mcg/kg) and the highest in Cohort 6 (65 mcg/kg). Patients can only be enrolled into a higher dose level arm if lower doses have proven safe.
45988230|NCT00502892|Drug|Topotecan|0.5 mg/m^2 IV Daily x 3 Days
45988231|NCT00502892|Drug|Ifosfamide|1.8 grams/m^2 IV Over 1 Hour x 5 Days
45988232|NCT00502892|Drug|Carboplatin|AUC = 3 mg/ml/min IV Over 1 Hour x 3 Days [for patients > 22 yrs of age, 3 mg/mL/min IV Over 1 Hour x 2 Days]
45988233|NCT02954835|Device|Prevena|Prevena is a sterile silver dressing. On top of the silver dressing is an adhesive plastic, which is connected to a therapy unit through a short length suction tube.
45988234|NCT02954835|Device|Traditional Dressing|Sterile gauze dressing secured by tape.
45988235|NCT00502970|Drug|16 weeks Interferon Tiw with Ribavirin|16 weeks Interferon Tiw
45988236|NCT00502970|Drug|24 weeks Interferon|24 weeks Interferon Tiw with Ribavirin
45988237|NCT00506649|Other|protocol|management protocols of non-pharmacological strategies and individualized titration of analgesics, sedatives, and anti-psychotics based on observed scores to manage sedation, analgesia and delirium.
45988238|NCT00498641|Procedure|computer program and patching|
45988239|NCT05149287|Drug|Ceftriaxone|single intravenous dose of 1 g of ceftriaxone
45988240|NCT05149287|Other|Placebo|1% lidocaine and saline
45988241|NCT05140980|Other|Data collection|evaluation of women's knowledge concerning sexuality
45988242|NCT00498680|Drug|Sildenafil, Vardenafil|Sildenafil 100mg, vardenafil 20mg, combination of both half dosage.
45988243|NCT00498680|Drug|Sildenafil|100mg
45988244|NCT00498680|Drug|Vardenafil|20mg
45988245|NCT00498680|Drug|Sildenafil & Vardenafil|50mg & 10 mg
45988246|NCT05146011|Procedure|Gatsric balloon insertion|Insertion of Gastric balloon prior to laparoscopic gastric bypass surgery
45988247|NCT00498719|Behavioral|Cognitive Training Program|Cognitive training sessions over a 4 to 6 month training period, each lasting about 2 hours.
45988248|NCT00498719|Other|Control Group|Standard educational support.
45988249|NCT00498758|Device|APOS System - biomechanical wedge shoe|
45988250|NCT00507390|Dietary Supplement|n-3 polyunsaturated fatty acids (PUFAs)|2g n-3 PUFAs once daily for 8 weeks
45988251|NCT00507390|Dietary Supplement|olive oil|1 capsule day
45988252|NCT00503087|Procedure|Saline Injection|
45988253|NCT00503087|Device|Pneumatic Skin Flattening (PSF)|
45988254|NCT05145387|Behavioral|Transitioning Emotionally and Academically to Middle School Successfully (TEAMSS)|Students randomized to TEAMSS will receive reading materials on transitioning to middle school and a a school tour with the middle school clinician (in 5th grade) and the TEAMSS group sessions (in 6th grade) delivered over 10 weeks. During the 10 weeks of TEAMSS, parents of students will attend two group meetings and clinicians will consult with at least one teacher (usually the advisory/homeroom teacher).
45988255|NCT00498953|Drug|carboplatin|
45988256|NCT00498953|Drug|cisplatin|
45988257|NCT00498953|Drug|docetaxel|
45988258|NCT00498953|Drug|fluorouracil|
45988259|NCT00498953|Drug|lapatinib ditosylate|
45988260|NCT00498953|Genetic|cytogenetic analysis|
45988261|NCT00498953|Genetic|fluorescence in situ hybridization|
45988262|NCT00498953|Genetic|in situ hybridization|
45988263|NCT00498953|Genetic|polymerase chain reaction|
45988264|NCT00498953|Genetic|reverse transcriptase-polymerase chain reaction|
45988265|NCT00498953|Other|immunohistochemistry staining method|
45988266|NCT00498953|Other|laboratory biomarker analysis|
45988267|NCT00498953|Procedure|conventional surgery|
45988268|NCT00498953|Procedure|neoadjuvant therapy|
45988269|NCT00498953|Radiation|fludeoxyglucose F 18|
45988270|NCT00498953|Radiation|radiation therapy|
45988271|NCT00506688|Drug|reduced glutathione sodium salt|646 mg GSH-Na powder per vial to prepare a 4ml solution, twice daily for 24 weeks.
45988272|NCT00506688|Drug|0.9% normal saline (control)|4 ml of a 0.9% normal saline solution (9mg/ml NaCl), twice daily for 24 weeks.
45988273|NCT00503126|Drug|bivalirudin|anticoagulation
45988274|NCT05145894|Device|Lung auscultation with LungPass device (electronic auscultation)|Lung auscultation with electronic stethoscope
45988275|NCT00503165|Biological|Menitorix (MenC and Hib conjugate)|
45988276|NCT05145543|Drug|Saline 0.9%|0.9 NaCl % (Saline) (5 ml) will be applied
45988277|NCT05145543|Drug|Levobupivacaine Hydrochloride|0.25 % levobupivacaine (5 ml) will be applied.
46083623|NCT02712840|Procedure|Fresh Protocol|Participants receive fresh embryo transfer of best morphologic quality blastocyst on day 5 and vitrification of all good quality supernumerary blastocysts.
46083624|NCT03976479|Other|Body composition, questionnaires, biochemistry and blood pressure results|Body composition status, nutritional status, cardiovasculat status, health status, lifestyle factors
45458359|NCT01236781|Device|Screening Tomosynthesis|Tomosynthesis imaging sets (limited tomosynthesis set and then a sequential read with the low-dose CC view added for the tomosynthesis plus set).
45988278|NCT05145543|Drug|Fentanyl|fentanyl plus 0.25 % levobupivacaine (5 ml) will be applied.
45988279|NCT05145543|Drug|Dexamethasone|Dexamethasone plus levobupivacaine (5 ml) will be applied.
45988280|NCT00503204|Drug|Cediranib|oral tablet
45988281|NCT00503204|Drug|Lomustine|oral capsule
45988282|NCT05145504|Diagnostic Test|Evaluation of IL-6 biomarkers in synovial fluid|Evaluation of IL-6 biomarkers in synovial fluid in obese and normal weight patients with gonarthrosis
45988283|NCT00503243|Drug|Delayed and extended release mesalazine|
45988284|NCT05145465|Other|Telerehabilitation group|"All the subjects in the telerehabilitation group will measure their heart rate and SpO2 with a pulse oximeter and blood pressure with digital sphygmomanometer themselves before ,during and after the end of each session for safety after they had been taught by physiotherapist. The patients will also oversee their blood sugar level before and after each session in order to prevent hypoglucemia events.~The target heart rate for each patient will set at 60-80% of heart rate reserve plus the heart rate rest and wiil be calculated by the physiotherapist for each patient based on if they receive beta blockers medication or not."
45988285|NCT00498992|Dietary Supplement|collagen/aloe vera/vitamin E/lidocaine topical hydrogel|
45988286|NCT04696107|Behavioral|Psychoeducative intervention|"This workshop is centred in psychoeducational and training action in emotional self-regulation in a group modality and participatory character, aimed at patients with mCNCP to acquire basic knowledge in:~Neurology and psychoneuroimmunology.~The role of beliefs in our manifestation of the disease.~Body language and modulation of pain perception.~Relaxation body-mind techniques.~Creative visualization for pain management.~Mirror feed-back.~The workshop will take place at the Hospital San Juan de Dios del Aljarafe, in four weeks, once a week, three hours each. Until now, the attendance was 24 patients per workshop. After the pandemic, we will reduce to 15 to increase safety distance. We will also conduct a telephone survey of each patient on symptoms of Covid infection in the 24 hours prior to the workshop."
45988287|NCT02276391|Drug|Telmisartan/HCTZ combination|
45988288|NCT02276391|Drug|Telmisartan|
45988289|NCT05145270|Dietary Supplement|Escitalopram+Sulforaphane|Escitalopram(No-specified) 10-20mg/d, once per day; Sulforaphane(ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.). 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day .
45988290|NCT05145270|Device|Escitalopram+rTMS|Escitalopram(No-specified) 10-20mg/d, once per day; rTMS: rTMS is delivered to the left dorsolateral prefrontal lobe position. Stimulation parameters are set to be 80 stimulation strings of 10Hz with an interval of 12 seconds. Each stimulation string includes 30 stimulations lasting for 3 seconds. One session includes 2400 stimulation strings lasting for 19 minutes and 40 seconds. The course of rTMS treatment includes 20 sessions, once a day or twice a day.
45988291|NCT05145270|Drug|Escitalopram|Escitalopram(No-specified) 10-20mg/d, once per day.
45988292|NCT05149443|Behavioral|theory-based mHealth-intervention (app)|Measuring the effect of the buddy and gamification components separately. During the A1 phase (baseline) and the A2 phase (reversal), participants will be asked not to use the 'Move it, Move ID' intervention: the app will be blocked. After an A phase, the app will be unblocked. During the B1 and B2 intervention phase, participants use the 'Move My it, Move ID' intervention only consisting of the buddycomponent. During the intervention period, adolescents and buddies are asked to wear an accelerometer. During the first AB pair we examine whether the buddy component has an effect on PA compared to no intervention. In the A2 reversal phase possible carryover effects can be measured. It will be informative to investigate whether some parts of the intervention are automatized or internalized and will still have some effect even when participants have no access to the intervention anymore (i.e. A2 phase). The study duration is 32 days; each phase will have a duration of minimum 5 days.
45988293|NCT05149443|Behavioral|theory-based mHealth-intervention (app)|"After the first study, other participants will be recruited. In a second study, the set-up remains the same, but the A1 and A2 phase this time consist of the buddy component (i.e. control phase) and in the B1 and B2 phase the gamification component will be added. This way, we can determine whether the gamification component has an effect on PA compared to the baseline buddy component intervention.~The study duration is 32 days for all participants. The duration of the 4 different phases of the design will vary between participants, but each phase will have a duration of minimum 5 days."
45988294|NCT01245179|Drug|panobinostat|"Panobinostat oral capsules taken THRICE WEEKLY (Monday, Wednesday, and Friday) for 12 weeks, exploring the following dosing regimens:~15 mg MWF 3 weeks on, 1 week off (if needed)~15 mg MWF every week (starting dose)~20 mg MWF 3 weeks on, 1 week off~20 mg MWF every week"
45988295|NCT02276625|Biological|rabies vaccine|Compare ID administration to IM administration. 1 visit schedule.
45988296|NCT02276664|Behavioral|Self-Help (SHI)|The newly revised Stop Smoking for Good booklets.
45988297|NCT02276664|Behavioral|Usual Care (UC)|The existing Clearing the Air smoking-cessation manual published by the National Cancer Institute (NCI).
45988298|NCT01245296|Procedure|Timing of clamping the umbilical cord|The time passed after delivery until that the midwife stops circulation in the umbilical cord with a clamp.
45988299|NCT04695990|Drug|Wenyang Huoxue Decoction|Wenyang Huoxue granules
45988300|NCT04695990|Drug|Wenyang Huoxue placebo|Wenyang Huoxue placebo have an identical appearance and scent as the active treatment granules.
45988301|NCT00503321|Drug|Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)|S-1 80mg/m2 4weeks on 2 weeks off, PSK 3g/day
45988302|NCT00503321|Drug|Tegafur/gimeracil/oteracil potassium (S-1)|S-1 80mg/m2, 4weeks on followed by 2 weks off
45988303|NCT02276703|Device|Skin Conductance Monitor|monitors skin conductance values
45988304|NCT00499070|Genetic|polymerase chain reaction|
45988305|NCT00499070|Other|flow cytometry|For analyzing GPI deficient clones full blood will be analyzed by phenotyping using flowcytometry. For that purpose CD14, CD16 and CD24 expression will be evaluated in CD45 positive cells. Erythroid cells will be evaluated for CD55 and CD59 expression searching for clear populations with a lack of GPI-linked molecules. In addition, immunophenotyping using flowcytometry will be performed to evaluate which differentiation stages of the major hematopoietic lineages in BM and PB are associated with TCRVβ repertoire skewing. Comparison between BM and PB will identify which is the optimal compartment to analyze the responsible hematopoietic clones.
45988306|NCT00499070|Other|immunologic technique|
45988307|NCT00499070|Procedure|biopsy|
45988308|NCT00503360|Drug|SAD448|
45988309|NCT05147844|Drug|Toripalimab|"Toripalimab: 240mg, iv. Q3W for 1 year or until disease progression/intolerable toxicity~Radiotherapy:~Newly diagnosed patients: IMRT for nasopharynx lesions and cervical lymph nodes, pGTVnx 70 Gy, pGTVnd 99Gy, pCTV1, 60 Gy, pCTV2, 54 Gy, 33 times, completed in 7 weeks.~Relapsed patients: IMRT for nasopharynx lesions and cervical lymph nodes, pGTVnx 60Gy, pGTVnd 60Gy, 20-25 times, completed in 4-5 weeks.~Newly diagnosed and relapsed patients: SBRT for oligometastatic lesions, pGTV 25-40 Gy, 3-5 times, completed in 1-2 weeks."
45833304|NCT03085602|Behavioral|Cognitive behavioral therapy|Therapy focused on explaining the physiological and psychological effects of nicotine. Training is focused on adherence to smoking instructions, physiological and psychological effects of nicotine, reviewing reasons for quitting, and coping with smoking urges. Smokers will be asked to begin smoking on a set schedule leading up to their quit day.
45833305|NCT03085602|Behavioral|Health education|Therapy that provides health education on the importance of healthy eating. Participants will be instructed to smoke as usual.
45988310|NCT00503477|Drug|AZD2171|oral tablet
45988311|NCT05147961|Other|Digital Health|Automated behavioral intervention via e-mail, web, and mobile phone
45988312|NCT05147961|Other|Standard care|Conventional recommendations on diet and exercise
46083625|NCT02781896|Device|pacing catheter|Rapid pacing during TAVI is required to ensure transient cardiac standstill while predilatation is performed and the valve is being positioned and deployed. In the right ventricular pacing arm, rapid pacing is provided by a standard right ventricular pacing catheter.
45988313|NCT00499148|Other|herbal extract; root of woody shrub grown in India/Sri-Lanka|
45988314|NCT05144295|Drug|Lubiprostone Pill|Oral pills for constipation (Lubiprostone) will be given in a dose range from 24 mcg once daily to 24 mcg twice daily according to the participant weight.
45988315|NCT05144295|Drug|Lactulose Oral Liquid Product|"Lactulose  Lactulose, or Duphalac syrup at a dose of 1 ml/kg once or twice daily (maximum 60 mL/day)"
45988316|NCT05144295|Drug|Bisacodyl 5 MG|Bisacodyl tablet (5 mg/tablet) in a dose of 2 tab/day for < 12 years or 3 tab/day for > 12 years
45988317|NCT05144295|Drug|Sodium Picosulfate|Sodium Picosulfate 0.75% drops in a daily dose of 2.5-20 mg/day
45988318|NCT05141487|Device|UroMonitor|The UroMonitor is small wireless sensor that is temporarily inserted into the bladder. While in the bladder it transmits bladder pressure measurements to an external radio. After a short period of use it is removed using an extraction string and discarded.
45988319|NCT05141487|Device|ASCU|The ASCU is a wearable nerve stimulator containing a radio and computer processor. It receives pressure information from the bladder and determines when to turn on sacral nerve stimulation. It is only used temporarily during research visits.
45988320|NCT01245452|Drug|Tocilizumab|Tocilizumab (8 mg/kg monthly from week 0 to 20)
45988321|NCT01245452|Drug|Methotrexate|MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
45988322|NCT00503516|Drug|Megestrol acetate|1 sachet of powder containing 160 mg of megestrol acetate b.i.d. during 24 weeks
45988323|NCT00503516|Drug|Placebo|1 sachet of 160 mg of placebo b.i.d.
45988324|NCT05148195|Drug|Envofolimab|300mg，Q3W (arm A,B and C)or 200mg, Q2W(arm D)
45988325|NCT05148195|Drug|BD0801|2mg/kg，Q3W(armA, B and C) or 2mg/kg，Q2W
45988326|NCT05148195|Drug|Docetaxel|75mg/m2，Q3W
45988327|NCT05148195|Drug|Irinotecan|180 mg/m2，Q2W
45988328|NCT05148195|Drug|Leucovorin calcium|400mg/m2，Q2W
45988329|NCT05148195|Drug|5-Fluorouridine|2400 mg/m2，Q2W
45988330|NCT04696991|Behavioral|The postpartum discharge education with PechaKucha Method.|The postpartum discharge training in which the PechaKucha method was applied via the smartphones was offered to the mothers in the experimental group whereas the mothers in the control group had solely the routine discharge training. The postpartum training was offered as per the Postpartum Care Management Guideline of the Ministry of Health of Turkey. The discharge training was offered to the experimental group by using the PechaKucha presentation technique.
45988331|NCT05146869|Drug|DBPR108 tablets|DBPR108 tablets, oral, once daily on Day 1 and Day 3-9 for a total of 8 doses.
45988332|NCT01245491|Other|Vibration|Whole-body vibration, 17 Hz, 1.1ms-2
45988333|NCT05143827|Other|Pasta manufactured with traditional wheat varieties (Senatore Cappelli, Korasan)|A single meal composed of a portion of pasta (with standardized dressing) manufactured with different wheat varieties
45988334|NCT05143827|Other|Pasta manufactured with current wheat varieties (Claudio)|A single meal composed of a portion of pasta (with standardized dressing) manufactured with different wheat varieties
45988335|NCT00499187|Procedure|Blood Draws|A single whole blood sample was collected for genomic analysis.
45988336|NCT05143749|Other|video tutorial|get video tutorial
45988337|NCT05147259|Drug|HR011408 injection|Drug: HR011408 injection (formulation A), administered subcutaneously. Drug: HR011408 injection (formulation B), administered subcutaneously.
45988338|NCT00499265|Drug|gemcitabine hydrochloride|1000 mg/m2 as 30 min i.v. infusion once weekly for 7/8 weeks and then every 3/4 weeks
45988339|NCT00499265|Drug|Serine Proteinase Inhibitor WX-671|oral, daily
45988340|NCT00499265|Drug|Serine Proteinase Inhibitor WX-671|oral, daily
45988341|NCT05147064|Procedure|minimally invasive surgery|using (tubular dilators, surgical microscope, and/ or endoscope). the other group will be operated by conventional inter laminar decompression.
45988342|NCT05147064|Procedure|conventional open surgery|open interlaminar lumbar decompression
45988343|NCT01246622|Drug|cytarabine|Given IV
45988344|NCT01246622|Drug|lenalidomide|Given PO
45988345|NCT01245530|Drug|Aricept|Aricept Comparator Intervention: Drug: Aricept 5~10 mg orally every day for 24weeks
45988346|NCT01245530|Drug|INM-176|INM-176: Experimental Intervention: Drug:INM-176 600~1200 mg orally every day for 24weeks
45988347|NCT00499382|Procedure|Nuclear Medicine Cardiac Scan|Scan lasting 30 minutes while being hooked up to a heart monitor that takes pictures every time your heart beats.
45988348|NCT00499382|Procedure|PET/CT Cardiac Scan|Scan lasting 10-15 minutes and performed after the normally scheduled PET/CT scan.
46083626|NCT02781896|Device|valve delivery guidewire|Rapid pacing during TAVI is required to ensure transient cardiac standstill while predilatation is performed and the valve is being positioned and deployed. In the Left ventricular pacing arm, rapid pacing is provided via the valve-delivery guidewire inserted into the left ventricle. The cathode of an external pacemaker is placed on the external end of the guidewire using an alligator clamp. The TAVI catheter provides the necessary insulation. The anode is attached directly to the subcutaneous tissue at the femoral entry site (also using an alligator clamp).
45988349|NCT05148312|Drug|Budesonide Inhalant Product|Single-dose of budesonide solution administered by nebulization.
45988350|NCT01246700|Other|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group A received SAFEx for 12 weeks then received no treatment for 12 weeks."
45988351|NCT01246700|Other|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group B received no treatment for 12 weeks, then received SAFEx for 12 weeks."
45988352|NCT05142306|Biological|COVID-HIG|Anti-SARS-CoV-2 Immunoglobulin (Human) [COVID-HIG] is a purified liquid immunoglobulin G (IgG) preparation
45988353|NCT05143437|Behavioral|Love Together Parent Together|A brief, low-intensity writing intervention adapted for parents of young children, designed to reduce conflict-related distress, prevent relationship deterioration and encourage the use of conflict reappraisal strategies designed to reduce conflict-related distress, etc.
45833306|NCT04401306|Other|Home-based self-regulated simulation training (SRST)|Participants allocated to the SRST arm train basic laparoscopic skills at home. Participants train by themselves using a portable box training model (BT). Training is conducted and structured through an online application-based training platform. Training is instructed by online instructional videos and texts. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
45988354|NCT00499499|Drug|E7107|E7107 will be administered as an intravenous infusion over 30 minutes at a starting dose of 0.6 mg/m^2 to the first cohort of patients. The same dose will be given on Days 1 and 8 of a 21-day cycle. Dose escalation will not occur until the maximum tolerated dose is reached. The selection of subsequent dose levels will be performed according to an accelerated design.
45988355|NCT05148663|Diagnostic Test|CCM Hemorrhagic Panel|Biomarker
45833307|NCT04401306|Other|Centralized instructor-regulated simulation training (IRST)|Participants allocated to the IRST arm train basic laparoscopic skills at the simulation centre. Participants train on a portable box training model (BT). Training is structured through an online application-based training platform and facilitated and instructed by surgical specialists. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
45988356|NCT01246817|Drug|Temsirolimus|temsirolimus (standard schedule: 25 mg weekly, by 1-hour i.v. infusion)
45988357|NCT04696341|Procedure|Matrix Rhythm Therapy|Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.Five sessions of MRT (2., 5., 6., 8., 10. sessions of combined physiotherapy programme) was added at combined physiotherapy to Matrix Rhythm Group. Matrix Rhythm Therapy was applied to cervical and thoracic regions using 10 Hz frequency for 30 min (15 min for right and left sides each) according to the instructions of the technique developer.
45988358|NCT04696341|Procedure|Control|Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.
45988359|NCT05147025|Other|Revascularization|Regain pulp vascularity for young permenant teeth
45988360|NCT00499538|Drug|SKI-606|
45988361|NCT01245803|Drug|additional rosuvastatin loading|additional rosuvastatin (10mg p.o.)is given at 18 hours and 4-6 hours before PCI
45988362|NCT01245803|Drug|placebo control|sugar pill is given 18-24hr and 4-6hr before PCI as control
45988363|NCT05148975|Diagnostic Test|Bronchoalveolar lavage fluid diagnostics|Bronchoalveolar lavage fluid diagnostics for superinfection in patients with COVID-19 pneumonia.
45988364|NCT01246934|Other|ASR METHOD|
45988365|NCT05146947|Device|near infrared spectroscopy|near infrared spectroscopy monitoring on kidney after reperfusion
45988366|NCT01247012|Dietary Supplement|Omegaven|Omegaven 1g/kg/day until infant receiving full enteral feeds
45988367|NCT01247012|Dietary Supplement|Lipid minimization|"1g/kg/day daily until infant receiving full enteral feeds~IF conjugated bili rises above 100, crossover to Omegaven (1gram/kg/day)"
45988368|NCT03454191|Procedure|Erector spinae plane block|Injection of local anaesthetics below the erector spinae muscle after induction of anaesthesia
45988369|NCT03454191|Procedure|No injection|No injection
45988370|NCT00499577|Biological|CMV pp65 peptide|Given intramuscularly
45988371|NCT00499577|Biological|hTERT I540/R572Y/D988Y multipeptide vaccine|Given subcutaneously
45988372|NCT00499577|Biological|pneumococcal polyvalent vaccine|Given intramuscularly
45988373|NCT00499577|Biological|survivin Sur1M2 peptide vaccine|Given subcutaneously
45988374|NCT03450096|Other|LPB|A bolus injection for LPB of 0.5 ml/kg ropivacaine 3.75 mg/ml (max 40 ml will be performed and the catheter will be placed before surgical interventions. A continuous perineural infusion of 0.2 ml/kg/h ropivacaine 0.2%, starting immediately after initial bolus injection will be then administered
45988375|NCT02274740|Drug|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
45988376|NCT02274740|Drug|metformin|Pharmaceutical form:tablet Route of administration: oral
45673683|NCT02151110|Biological|MEDI4920 3000 mg|Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
45673684|NCT02151110|Other|Placebo|Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
45673685|NCT04749680|Device|PD cycler Silencia|Treatment for 2 weeks either with PD-Night or Homechoice PD cycler (Comparators) depending on the previous Treatment ((clinical phase I). At the end of these 2 treatment weeks and a subsequent training phase which up to 3 weeks, treatment with the Silencia PD cycler for 2 further weeks (clinical phase II).
45673686|NCT02132312|Drug|OMS302|
45673687|NCT02132312|Drug|Phenylephrine HCl|
45988377|NCT05146830|Other|Safety and Efficacy Assessments|Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention.
45988378|NCT00499733|Drug|cyclophosphamide|500 mg/m^2 of cyclophosphamide is infused via intravenous route three days post cryoablation surgery.
45988379|NCT00499733|Device|Cryoablation|Per treating physician's discretion, largest and most accessible lesion will be treated with cryoablation surgery on day 0 of the study.
45988380|NCT03452202|Device|Soterix 1x1 line tDCS low-intensity stimulator|Introduction of the independent variable (treatment) across three different points in time. Participants will be randomly assigned to have each treatment phase begin after 3, 4, or 6 baseline sessions. This current stimulates the cortex, with anodal stimulation leading to a depolarized state in which neurons are more likely to fire.
45988381|NCT03452202|Device|Sham|Patients will have two electrodes applied (one anode, one cathode) administering no stimulation
45988382|NCT00503594|Drug|Methotrexate and temozolomide|Methotrexate and temozolomide
45988383|NCT00503594|Drug|Methotrexate , procarbazine ,vincristine ,cytarabine|Methotrexate , procarbazine ,vincristine ,cytarabine
45988384|NCT04696302|Behavioral|Focus of attention|Individuals were asked to laterally weight shift while seated with either internal focus or external focus instructions.
45988385|NCT05146791|Procedure|Inlay Bristow|A modified Bristow procedure
45988386|NCT05146791|Procedure|Bristow|Traditional Bristow procedure
45988387|NCT00499811|Drug|vorinostat|Given orally
45988388|NCT00499811|Other|pharmacological study|Correlative studies
45988389|NCT05146752|Device|extremely low frequency electromagnetic fields|extremely low frequency electromagnetic fields
45988390|NCT05146752|Other|routine care|routine care
45988391|NCT03451422|Drug|Efavaleukin Alfa|Efavaleukin Alfa will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
45988392|NCT03451422|Drug|Placebo|The placebo will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
45988393|NCT00503711|Drug|Vandetanib|100 mg every other day, 100mg once daily
45673688|NCT02131766|Device|DiAs|DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
45673689|NCT02131766|Other|Sensor Augmented Pump Therapy|Insulin pump plus CGM.
45988394|NCT00503711|Drug|Vandetanib 300 mg|300mg once daily
45988395|NCT03451188|Device|Cerecare compression garments|all Cerecare compression garments
45988396|NCT00499850|Drug|ZD6474 (vandetanib)|once daily oral dose
45988397|NCT00499850|Drug|5-Fluorouracil|intravenous infusion
45673690|NCT02150954|Drug|pitocin|
45673691|NCT04757012|Device|calinange|calinange
45673692|NCT02131532|Behavioral|A brief psychological intervention|This intervention is based on the principle of cognitive-behavioral therapy
45673693|NCT04188392|Drug|Pimavanserin|pimavanserin tablet
45673694|NCT02170688|Drug|Isovue 370|All contrast media doses administered for this study are within the FDA approved dose range in the package insert.
45673695|NCT02170688|Other|Weight calculation|
45673696|NCT04749524|Diagnostic Test|Measurement of Otoacoustic Emissions with and without suppression noise|Otoacoustic emissions will be recorded using an ear probe with and without a suppression noise.
45673697|NCT02170298|Drug|Lisdexamfetamine|Participants will be given either the study drug or placebo in tablet form. All participants will start with a 20 mg dose and will be titrated up to a 70 mg daily dose over 9 weeks. Participants between 12-18 years of age will be titrated in 10 mg increments and participants between 18-25 years of age in 10-20 mg increments.
45988398|NCT00499850|Drug|Leucovorin|intravenous infusion
45988399|NCT00499850|Drug|Oxaliplatin|intravenous infusion
45988400|NCT05146713|Dietary Supplement|Propolis nanoparticles extract solution|20 mg/ml propolis nanoparticles in the form of solution prepared from honeybee from various plants.
45988401|NCT05146713|Drug|sodium hypochlorite|2.5% sodium hypochlorite (household bleaching agent)
45988402|NCT00503789|Procedure|fecal bacteria analysis|ad lib feeding
45988403|NCT05149989|Device|Proning Pillow System|Participants will be asked to lie on the proning pillows in prone position for no more than 5 minutes. Each participant will then be asked to lie on standard hospital pillows for no more than 5 minutes.
45988404|NCT00499928|Drug|SB-751689|
45988405|NCT00503828|Drug|Derris scandens Benth extracts|Derris scandens Benth extracts (oral) 400 mg twice per day for 4 weeks
45988406|NCT00503828|Drug|naproxen|Naproxen 500 mg/day for 4 weeks
45988407|NCT05149677|Behavioral|Music therapy|Music therapy intervention + Standard of Care for labor pain
45988408|NCT03455478|Device|spectacles|dispending spectacles for uncorrected refractive error
45988409|NCT00499967|Drug|GS-9191 ointment|GS-9191 ointment (0.01%, 0.03%, or 0.1%) or placebo applied topically to anogenital warts for one or three cycles, each cycle lasting 5 consecutive nights of ointment application followed by 9 nights off-ointment. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
45988410|NCT00499967|Drug|GS-9191|GS-9191 ointment (0.3% or 1.0%) or placebo applied topically to anogenital warts for one or three cycles; each cycle consists of dosing occuring over a 5-night period with ointment application on nights 1, 3 and 5 followed by a 9-day off-ointment period. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
45988411|NCT00499967|Drug|Placebo|Placebo matching GS-9191 ointment
45988412|NCT03457077|Behavioral|Brief intervention|A brief motivational intervention with feedback about drinking levels compared to norms
45988413|NCT00500006|Drug|MK0457|"Schedule A: 5-day continuous IV infusion every 28 days MK0457 (dose determined by height and weight). Starting dose = 20 mg/m2/hour titrating up to 33 mg/m2/hour.~Schedule B: 6-hr IV infusion every 14 days MK0457 (dose determined by height and weight). Starting dose = 64 mg/m2/hour titrating up to 216 mg/m2/hour."
45988414|NCT00500006|Drug|dasatinib|Oral dasatinib 70 mg b.i.d. tablets twice daily.
45988415|NCT03459534|Drug|Radotinib HCl|"Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.~Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)~Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder~Storage conditions: Store in an airtight light proof container at room temperature."
45988416|NCT00500123|Procedure|Alpha-1 Antitrypsin Genotype|Home fingerstick testing for alpha-1 antitrypsin genotype
45988417|NCT01247051|Procedure|Precoating|preoperative filling of heart lung machine with patients blood
45988418|NCT01247051|Procedure|Standard priming|preoperative filling of heart lung machine with colloids
45988419|NCT00506727|Drug|Mixed amphetamine salts (ADDERALL XR)|
45988420|NCT00506727|Drug|Atomoxetine hydrochloride|
45988421|NCT01247168|Drug|AZD2461|oral capsules, continuous dosing and intermittent dosing
45988422|NCT03455517|Drug|Venetoclax|Venetoclax and rituximab association
45988423|NCT03455517|Drug|Rituximab|Venetoclax and rituximab association
45988424|NCT00500162|Behavioral|Tri-Luma Maintenance regimen|
45988425|NCT03453567|Procedure|Valve Replacement|Aortic valve replacement
45988426|NCT00500201|Drug|SB- 773812 60 mg|SB- 773812 will be available dose strength of 60 mg and administered orally by subjects.
45988427|NCT00500201|Drug|SB- 773812 120 mg|SB- 773812 will be available dose strength of 120 mg and administered orally by subjects.
45673698|NCT05152316|Other|Observational study|This is an observational study and no additional interventions will be done except for those that are standard care. Blood and tracheal aspirates will be taken to assess the surfactant protein levels and inflammatory markers including cell counts and cytokine levels.
45833308|NCT03356496|Device|AirLife 4000 cc incentive spirometry device|Incentive spirometry device provides improved lung expansion and respiratory muscle strength
45673699|NCT02131064|Drug|Carboplatin|Carboplatin IV infusion at a dose to achieve an AUC of 6 mg*min/mL q3w
45673700|NCT02131064|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV infusion q3w
45673701|NCT02131064|Drug|Pertuzumab|Pertuzumab 840 mg (loading dose); and 420 mg (maintenance dose) IV infusion q3w
45673702|NCT02131064|Drug|Trastuzumab|Trastuzumab 8 mg/kg (loading dose); and 6 mg/kg (maintenance dose) IV infusion q3w
45673703|NCT02131064|Drug|Trastuzumab Emtansine|Trastuzumab Emtansine 3.6 mg/kg IV infusion q3w
45833309|NCT03085446|Behavioral|PDM nutritional intervention|personalized, diet-induced alterations in microbiota (PDM) for six months. (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3).
45833310|NCT03085446|Behavioral|General information on nutrition and health|General information on nutrition and health for six months: (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3),
45833311|NCT03085368|Drug|lapatinib/herceptin|Lapatinib produced by glaxosmithkline. Oral small molecule epidermal growth factor tyrosine kinase inhibitor. Mainly used for combined with capecitabine in the treatment of ErbB-2 over expression, including received prior anthracycline, paclitaxel and trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer. Our clinical trial want to see its benefit in early breast cancer
45988428|NCT00500201|Drug|Placebo|Placebo tablets will be administered orally by subjects.
45988429|NCT01247246|Drug|SCV-07|clinical trial material; (placebo or SCV 07) at doses of 0 (placebo), 0.1, 0.3, and 1.0 mg/kg will be administered sc
45988430|NCT01247246|Drug|Placebo|Placebo
45988431|NCT04696536|Other|Colgate Cavity Protection Toothpaste|Participants will use Colgate cavity protection toothpaste for brushing teeth twice daily.
45988432|NCT04696536|Other|American Dental Association (ADA) Referenced Toothbrush|Participants will brush teeth at least one minute with provided toothbrush twice daily.
45988433|NCT04696536|Other|5% Hydroalcohol Mouth Rinse|Participants use 20 mL of 5% Hydroalcohol mouth rinse as negative control for 30 sec twice a day after brushing.
45988434|NCT04696536|Other|REACH Dental Floss|Participants after brushing, rinse mouth with water and floss using Reach dental floss once a day.
45988435|NCT04696536|Other|Alcohol-containing Essential Oil (AEO) Mouth Rinse (Listerine Cool Mint, marketed)|Participants after brushing, rinse with 20mL of the AEO mouth rinse for 30 seconds twice a day.
45988436|NCT00500279|Drug|Celecoxib|
45988437|NCT03459651|Behavioral|ANS training|In-home computer-based ANS training
45988438|NCT00500396|Procedure|Open-Sky Vitrectomy|Open-Sky vitrectomy with removal of the Tunica vasculosa lentis and retinal reattachment
45988439|NCT00507468|Procedure|Transendocaridal Transplantation of Autologous Bone Marrow|Single treatment, harvest and transplant of patients own bone marrow. Cells are delivered to the myocardium via transendocardial delivery catheter.
45988440|NCT01245881|Device|Non-ablative fractional photothermolysis laser|"Wavelength: 1,550 nm;~Energy: 15 mJ/MTZ;~Total coverage: 20%;~Total density: 1,048 MTZs/cm2;~Density per pass: 131 MTZ/cm2;~Number of passes: 8."
45988441|NCT01245881|Other|broad-spectrum sunblock (SPF 50+)|
45988442|NCT00500435|Procedure|Extraperitoneal Laparoscopic Lymphadenectomy|Laparoscope used to find and remove para aortic lymph nodes in abdomen.
45988443|NCT01247402|Device|drug eluting balloon angioplasty|3 microgram Paclitaxel/mm2 on balloon, 60s application
45988444|NCT01247402|Device|standard balloon angioplasty|standard balloon angioplasty
45988445|NCT01247441|Other|Clinical data|
45988446|NCT00508170|Behavioral|Questionnaire|The questionnaire contains 23 questions and is estimated to take approximately 10 minutes to complete.
45988447|NCT00500474|Procedure|endolymphatic sac drainage with steroids|
45988448|NCT03458247|Drug|Abiraterone acetate standard dose|1000 mg/day
45988449|NCT03458247|Drug|Abiraterone acetate escalated dose|2000 mg/day
45988450|NCT01247519|Other|Post-hospitalization care|Post-hospitalization care included telephone call contact for caring after discharge, for opening for question, and for health education.
45988451|NCT03453216|Behavioral|neuropsychological tests|"Part 1: to determine the cognitive capacity, the subjects undergo different neuropsychological tests To determine individual characteristics children, adolescents and adults complete self-assessment questionnaires .~Adults spend a semi-directive interview. Part 2: while the subject 1 (S1) is installed in the MRI, he perform behavioral tasks with the subject 2 (S2) (familiar peer of the same age ± 2 years) installed in an adjacent room, alternating periods when S1 is observed by S2 (condition Social) and periods when S1 is not observed by S2 (condition Alone)."
45988452|NCT00500513|Procedure|CT Scans|CT scan performed weekly to measure how much the tumor moves + additional pulmonary function measurements.
45988453|NCT00500513|Procedure|Implanted markers|Implanted radio-opaque fiducial markers, diameter of 1.0 - 2.0 mm, inserted through a catheter at several chest locations using a flexible bronchoscope
45988454|NCT00500513|Radiation|Radiation Treatment (RT)|Radiotherapy incorporating respiratory treatment delivery
45988455|NCT02954718|Other|activity training|
45988456|NCT01247558|Other|Metanx® (a medical food)|Patient cohort compliant on Metanx® BID therapy for >120 days
45833312|NCT05638932|Drug|Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)|Real world use of either IL6Ri (TCZ or SAR) or JAKi (BAR or TOF)
45988457|NCT01247558|Other|Not treated with Metanx®|Non-treated comparative cohort
45988458|NCT02954445|Biological|Anti-BCMA-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived BCMA-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
45988459|NCT00500552|Drug|Perhexiline/Placebo|
45988460|NCT02954250|Behavioral|Mindfulness Based Cognitive Therapy|The 8-week MMBCT protocol combines the practice of specific meditation techniques with cognitive therapy principles applicable to anxiety and depression. Each session will cover a meditation practice, as well as a relevant topic for discussion. The initial sessions will introduce general concepts of mindfulness (non-judgemental awareness, being in the moment, fostering curiosity, etc.), which will be expanded to more elaborate notions that are particularly relevant to anxiety, depression and suicidal ideations (recognizing thoughts are not facts, cultivating loving kindness for oneself, improving communication with others, etc.) Participants will be encouraged to practice the mindfulness techniques between sessions, a process that will be reviewed during groups in an ongoing fashion.
45988461|NCT00500591|Behavioral|Questionnaire|Questionnaire regarding weight history, gynecologic, and medical history, lasting about 30 minutes.
45988462|NCT02954289|Behavioral|Dietary intervention|"Session 1:The Breakfast Club: ways to increase the healthiness of breakfast and all meals.~Session 2: Calcium and Vitamin D -Keys to Bone Health~Session 3: Fruits and Veggies -Your New Best Friends~Session 4: Let's Talk About Fat~Session 5: Shopping Therapy~Session 6: Celebrity Chefs Share Their Secrets"
45988463|NCT00500630|Device|Body fixed 3D sensors|
45988464|NCT00508209|Drug|bortezomib|1.3 mg/sqm days -5 and -2 in connection with high-dose melphalan (200mg/sqm day -2) and autologous stem cell support
45988465|NCT04696913|Diagnostic Test|Exposure: Positive COVID-19 infection|Exposure: Positive COVID-19 infection as determined by RT-PCR
45988466|NCT04696913|Diagnostic Test|Exposure: Negative COVID-19 infection|Exposure: Negative COVID-19 infection as determined by RT-PCR
45988467|NCT02954016|Device|ePass|Subject is implanted with the device for up to 3 years.
45988468|NCT00500669|Drug|Betadine|Topically
45988469|NCT00507585|Drug|Fluorouracil|300 mg/m^2 IV over 10 Minutes, then 600 mg/m^2 IV over 22 Hours repeated every 3 weeks (1 Cycle).
45988470|NCT00507585|Drug|Avastin|10 mg/m^2 IV Over 90 Minutes repeated every 3 weeks (1 Cycle).
46083627|NCT02712684|Procedure|multiparametric MRI. Multi-parametric ultrasound|The investigators aim to test the hypothesis that multiparametric ultrasound is able to detect clinically significant prostate cancer with an accuracy that is similar to multiparametric MRI. Multi-parametric ultrasound uses different types of ultrasound images to visualise different aspects of the tissue. In other words, the standard grey-scale images shows the gross anatomy, Power Doppler and Contrast enhanced Ultrasound image blood supply (cancers have more blood supply), and Real-Time Elastography images the density of tissue (cancers are more dense).
45833313|NCT03085290|Other|Autologous serum eye drops|Autologous serum eye drop doses will be 6 times daily in each eye
45833314|NCT03085290|Other|Allogeneic serum eye drops|Allogeneic serum eye drop doses will be 6 times daily in each eye
45833315|NCT03409770|Other|Therapeutic hypothermia|Whole body cooling using a servo controlled device
45833316|NCT05687760|Biological|bromelain|is a proteolytic enzyme derived from the stem part and fruit of pineapples (Ananas comosus).used as intracanal medication
45833317|NCT05687760|Drug|Calcium hydroxide|calcium hydroxide
45988471|NCT00507585|Drug|Leucovorin|200 mg/m^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
45988472|NCT00507585|Drug|Oxaliplatin|60 mg/m^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
45988473|NCT01247636|Other|Balance- training and home-exercise|Balance-training admitted at the geriatric hospital Home-exercise or advice to be generally active
45988474|NCT01247636|Other|Balance-training and home-exercise|The aim of the intervention was to enhance health-related quality of life, self-efficacy and physical function through education and exercise. The education program consisted of information given both oral and in writing regarding the benefits of physical activity. The aim was to increase the participants knowledge about the benefits of physical activity and to stimulate them to integrate physical activity into their immediate environment during daily routines. They were given an exercise-log and were advised to write down all their daily activities and exercise. The exercise program were conducted 2 times per week for 45 min per session. The content of these sessions were balance training with main focus on balance-exercises considered essential for daily living.
45988475|NCT00508248|Dietary Supplement|omega 3 fatty acids|1g daily
45988476|NCT00508248|Dietary Supplement|placebo|olive oil capsule
45988477|NCT01247714|Dietary Supplement|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
45988478|NCT01247714|Dietary Supplement|T-Diet plus Diabet NP|T-Diet plus Diabet NP is a complete balanced oral nutrition supplement, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
45988479|NCT01247714|Dietary Supplement|Glucerna|GLUCERNA 1.0 CAL is a reduced-carbohydrate, modified-fat, fiber-containing formula clinically shown to blunt blood-glucose response in patients with abnormal glucose tolerance.
45988480|NCT01247714|Dietary Supplement|Novasource|Complete high protein diet for diabetic patients and hyperglycemic
46083628|NCT04090047|Drug|PF-06700841|PF-06700841 oral tablets in 5mg and 25mg provided for a 30mg dose
45988481|NCT00507663|Drug|Atenolol|Patients with a standing prescription for β-blockers will be continued on that medication. Pts not currently receiving a beta blocker will be given 50mg of atenolol on the morning of surgery, 50-100mg, twice per day, on the first postoperative day until postoperative day 7.
45988482|NCT00508287|Drug|BMS-686117|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
46083629|NCT04090047|Drug|Itraconazole|200 mg oral solution administered as 20 milliliters(mL) (10 mg/mL)
45988483|NCT00508287|Drug|Byetta|Injection solution, Subcutaneous, 5 mcg, Once daily, Single dose.
45988484|NCT00508287|Drug|Placebo|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
45988485|NCT00507702|Procedure|phlebotomy|Standard of care
45988486|NCT00500747|Biological|HCV E1E2/MF59|The investigational vaccine contains envelope glycoproteins gpE1 and gpE2 and the adjuvant, MF59. MF59 is a sterile oil-in-water emulsion in a citrate buffer, which comprises 50 percent of the vaccine. The antigen and adjuvant are combined prior to the injection. The volume to be administered is 0.5 mL for all vaccine dose levels. The vaccine has a milky white opacity. Vaccine dosages: 4 mcg, 20 mcg and 100 mcg.
46083630|NCT02708550|Behavioral|Participatory Organizational Intervention|
46083631|NCT02782052|Drug|Nebulized ipratropium bromide|"Administration at V3 or V4 or V5 in a random order:~Placebo (P; sterile 0.9% sodium chloride solution)~Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
46083632|NCT02782052|Drug|Nebulized combination ipratropium bromide with salbutamol|"Administration at V3 or V4 or V5 in a random order:~Placebo (P; sterile 0.9% sodium chloride solution)~Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
45833318|NCT03409380|Dietary Supplement|Arginine Drink|10 g of arginine in a formulated drink
46083633|NCT02782052|Drug|Nebulized Placebo|"Administration at V3 or V4 or V5 in a random order:~Placebo (P; sterile 0.9% sodium chloride solution)~Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
46083634|NCT00918749|Drug|150 mg|150 mg immediate release (IRBB) risedronate tablet administered orally at least 30 minutes before breakfast.
45833319|NCT03409380|Dietary Supplement|Plain Drink|formulated drink
45833320|NCT05687604|Behavioral|multiple behavior change therapy|goals related to their physical activity, smoking, and/or obesity, and will be asked to meet those goals weekly/daily. Participants will also be asked to record their weight, activity, and/or cigarette smoking daily, and will complete 16 telehealth sessions with study staff across the 12 months of the study. Will have physical measures taken or extracted from the medical record at baseline, 3 months, 6 months, and 12 months.
45833321|NCT03085134|Other|Test infant formula with HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) with HMOs intended for management of CMPA.
45833322|NCT03085134|Other|Control infant formula without HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) intended for management of CMPA.
45833323|NCT05687526|Biological|Telitacicept 2.5 mg/kg|Subjects will be given Telitacicept 2.5 mg/kg (with a maximum dose of 160 mg) subcutaneously once a week plus SOC for 12 weeks.
45988487|NCT00500747|Drug|Placebo|Four doses sterile saline (0.5 mL total volume) at 0, 4, 24, and 28 weeks.
45833324|NCT03084978|Procedure|General Anesthesia|General anesthesia by standard endotracheal intubation.
45833325|NCT03084978|Procedure|Conscious Sedation|Conscious sedation
45833326|NCT03084744|Behavioral|Schema therapy|Schema therapy for chronic depression, a face-to-face psychological intervention by clinical psychologists.
45833327|NCT03084744|Behavioral|Active monitoring|Active tele-monitoring by clinical psychologists.
45988488|NCT00508326|Drug|Paclitaxel|Starting dose 150 mg/m^2 HAI once every 4 weeks
46083635|NCT00918749|Drug|75 mg|75 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
45988489|NCT01247753|Behavioral|Walking group|Internet-mediated pedometer-based walking program with gradually increasing step count goals and feedback on step counts. Also includes nutritional coaching course consisting of 1 individual session with a dietician, 4 group sessions, and monthly follow-up. Oral glucose tolerance tests pre and post-intervention.
45988490|NCT00507780|Drug|GnRH antagonist|
45988491|NCT00500786|Biological|CYT006-AngQb|
45988492|NCT00507858|Drug|Pemetrexed|Starting dose of 500 mg/m^2 IV Once Over 10 Minutes Every 3 Weeks
45988493|NCT00507858|Drug|Dexamethasone|Arm 2 = 20 mg IV On Day 1; Arm 3 = 4 mg oral (PO) Twice Daily for 3 Days
45988494|NCT01245920|Biological|DFDBA + Bio-Gide Membrane|For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.
45988495|NCT01245920|Other|Non-FDBA|Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
45988496|NCT00500825|Procedure|Measurement of Resting Energy Expenditure|Non-invasive measurement of Resting Energy Expenditure
45988497|NCT00508365|Drug|Carvedilol CR capsules|The carvedilol micropump (COREG) CR cpsules will be available with doses of 20 milligrams and 40 milligrams administered orally once daily.
45988498|NCT00508365|Drug|Placebo|Placebo capsules to match each dose level will be provided.
45988499|NCT00508365|Drug|Lisinopril|Lisinopril will be available as 10 milligrams tablets administered orally once daily.
45988500|NCT01316393|Other|XER2020|mucoprotective product
46083636|NCT00918749|Drug|100 mg|100 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
46083637|NCT02708628|Drug|extract of allium cepae, allantoin and heparin|prophylactic use of a topical gel containing extract of allium cepae, allantoin and heparin two times in a day after second c-section
46083638|NCT02708628|Procedure|Scar excision|Scar excision in second c-section
45673704|NCT02130986|Other|Procalcitonin level|A procalcitonin (PCT) will be drawn level within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion.
45673705|NCT02130986|Other|Results of procalcitonin (PCT) level to treating clinician|In the ED, we will quickly (<1 hour goal) provide clinicians the procalcitonin result.
45833328|NCT05619432|Device|HMD: Immersive VR|"The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~STIMULATION:~One or more of the spheres is temporarily cued (target). Then all spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using a laser pointer, the initially cued target(s) among the eight spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)"
45833329|NCT03084588|Drug|methadone|Patients will be given methadone at induction of anesthesia
45833330|NCT03084588|Procedure|Interscalene block|Patients will be given an interscalene block prior to induction of anesthesia
45833331|NCT03408366|Procedure|Laparotomy|Laparotomy via vertical midline incision and after the planned surgical procedure is complete.
45833332|NCT03408366|Other|ICG|ICG will be injected intravenously ICG is a fluorescent iodide dye.
45833333|NCT03408366|Other|Spectrum NIR imaging system|The Spectrum NIR imaging system uses a handheld camera that emits light in the NIR range.
45833334|NCT05613660|Dietary Supplement|Veg Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
45833335|NCT05613660|Dietary Supplement|Bovine Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
45833336|NCT05613660|Dietary Supplement|"Fish | Marine Collagen Peptide"|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
45833337|NCT05613660|Dietary Supplement|Chicken Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
45833338|NCT03084276|Other|High-fat meal|High-fat meal
45833339|NCT03084276|Other|Low-fat meal|Low-fat meal with the same physical and organoleptic characteristics as the high-calorie meal.
45833340|NCT03084432|Diagnostic Test|Dual Energy X-ray Absorptiometry|Dual Energy X-ray Absorptiometry done for both studied groups
45833341|NCT05345652|Procedure|deep anterior lamellar keratoplasty|DALK is a partial-thickness corneal transplant which involves only the donor stroma, leaving the recipient's own Descemet's membrane and endothelium
45988501|NCT00500864|Drug|Magnesium Sulfate 2 grams|
45988502|NCT00508560|Behavioral|Contingency Management|"Participants draw from a fishbowl to obtain tokens when they attend a smoking cessation treatment session. The number of draws will be based upon attendance at consecutive sessions. Tokens include messages of encouragement (Good job!) or VA canteen vouchers of varying monetary value."
46083639|NCT05339906|Device|ZOV.ai digital therapy candidate|ZOV.ai is a novel auditory neuro modulating technology that leverages euphonic music tracks with broad-spectrum binaural beats to induce selective EEG spectral power changes to improve stuttering symptoms
45988503|NCT00508560|Behavioral|Reward|Participants receive set reward (VA canteen voucher) for each week of smoking cessation treatment they attend. The value of the reward will not change regardless of attendance at consecutive sessions.
45988504|NCT01247831|Procedure|Selective Laser Trabeculoplasty|100 spots with an energy of 0,8 mJ are applied over 360° of the trabecular meshwork of glaucoma patients with a Q-switched 532 nm frequency doubled neodymium YAG Laser.
45833342|NCT05345574|Drug|dexmedetomidine infusion|dexmedetomidine as anaesthetic adjuvant
45988505|NCT00507975|Drug|nicotine versus placebo|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
45988506|NCT01247909|Drug|Ceftriaxone v penicillin and gentamicin|Ceftriaxone v the standard treatment of infant meningitis (penicillin and gentamicin). Ceftriaxone will be given at a dose of 80mg/kg once a day for at least 14 days.
45988507|NCT02954328|Device|tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
45988508|NCT01247948|Procedure|navigation assisted spine surgery|navigation assisted pedicle screw placement of spine surgery
45988509|NCT01247948|Procedure|traditional spine surgery|traditional spine surgery without navigation assist
45988510|NCT02954211|Device|repetitive transcranial magnetic stimulation (rTMS)|"rTMS can be given to either the stroke or nonstroke hemisphere. For the nonstroke hemisphere, priming rTMS will be given to the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by 25-s OFF period. The ON-OFF cycling continues for 10 min. Principal rTMS follows priming and is applied at the same intensity at 1 Hz continuously for 10 minutes. The rationale for 6-Hz priming is to make the 1-Hz principal rTMS more effective. The after-effects of the principal rTMS are inhibition of the underlying neurons in the nonstroke hemisphere, which has a facilitating effect on the stroke hemisphere.~For the stroke hemisphere, rTMS will involve 6-Hz stimulation at the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by a 25-s OFF period. The ON-Off cycling continues for 10 minutes. With either form of rTMS, the desired effects of the rTMS are facilitation of the neurons in the stroke hemisphere."
45988511|NCT02954211|Behavioral|Physical therapy|Following the total rTMS treatment and a 3-minute break, physical therapy treatment will commence. The physical therapy treatment will consist of 15 minutes of finger movement tracking training followed by 15 minutes of virtual hand exercises. The tracking involves placing an small device on the weak hand that records finger motion and moving the index finger into finger extension and flexion to track a computer screen cursor as accurately as possible along a target track. The virtual hand exercises involve placing the weak hand in front of a computer with a program that will show a virtual hand and some blocks on a computer screen. The patient will attempt to stack the blocks by doing active hand movements that control the virtual hand. Another virtual hand exercise involves using the thumb and index finger to pluck petals from a virtual flower shown on the screen. There are further exercises like this.
45988512|NCT01245998|Drug|Dalteparin|dalteparin 5000 I.U./24 h s.c. for 6 weeks
45988513|NCT01245998|Drug|Dalteparin|dalteparin 15000 I.U./24 h s.c. for 6 weeks
45988514|NCT02954484|Drug|pregabalin|see arm/group description. Lyrica manufacture site: Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany.
45988515|NCT02954484|Drug|Placebo|Placebo capsule containing lactose and MCC (no active ingredients).
45988516|NCT02954484|Drug|Etoricoxib|Etoricoxib 120mg per oral once daily on postoperative days 1,2,3. 'Arcoxia' manufacture site: MSD International GMBH, Singapore
45988517|NCT02954484|Drug|paracetamol|Paracetamol 1g per oral 6hourly on postoperative days 1,2,3. Manufacture site: SM Pharmaceuticals, Malaysia
45988518|NCT02954484|Drug|Morphine|"patient-controlled analgesia intravenous morphine sulphate on postoperative days 1,2,3.~Manufacture site: Hameln Pharma Plus GMBH, Hameln, Germany"
45988519|NCT02954484|Drug|Ropivacaine|Femoral block with ropivacaine 0.5% 30mls. Ropivacaine manufacture site: AstraZeneva AB, Sweden
45988520|NCT01247987|Procedure|Blastocyst cryopreservation|Embryos cryopreserved at the blastocyst stage
45988521|NCT01247987|Procedure|Bipronuclear oocyte cryopreservation|Bipronuclear oocyte cryopreservation.
45988522|NCT02954367|Dietary Supplement|PROTEIN|Immediately (<10 min) after completing each training session (resistance training) participants will consume a beverage containing 20g of meat protein (10g) plus whey (10g) mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
45988523|NCT02954367|Dietary Supplement|CARBOHYDRATE|Immediately (<10 min) after completing each training session (resistance training), participants will consume a beverage containing about 20g of maltodextrin mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
45988524|NCT01248026|Other|Buttermilk|"Consumption of the 2 experimental periods~buttermilk (45 g/d)~placebo (45 g/d,)"
45988525|NCT02954133|Device|Invisalign (7 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 7 days.
45988526|NCT02954133|Device|Invisalign (5 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 5 days.
45833343|NCT05345574|Drug|remifentanil infusion|remifentanil as anaesthetic adjuvant
45833344|NCT03084198|Procedure|hiHep Bioartificial Liver Support System|Continuous treatment with the hiHep bioartificial liver support system for a minimum of 3 days to a maximum of 14 days. The subject's ultrafiltrated blood is circulated through 4 cartridges. The parameter is set to Circuit 1：120-200ml/min；Circuit 2：30-50ml/min；Circuit 3：200 ml/min.
45833345|NCT03084198|Procedure|Standard care for ALF|A standard of care for subjects with acute liver failure.
45833346|NCT03083964|Behavioral|Usual Care|Usual care is not considered an intervention. This arm of the study involves a lifestyle coaching intervention delivered in primary care sites to the subjects.
45988527|NCT02954133|Device|OrthoPulse|Daily 10 minute (5 minutes per arch) OrthoPulse treatments are administered at home.
45988528|NCT02954133|Device|Invisalign (3.5 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 3.5 days.
45988529|NCT00500942|Behavioral|Questionnaire|Questionnaires about the pain level experienced during and after standard procedures are performed in the IR.
45988530|NCT00500981|Procedure|Volume challenge|
45988531|NCT00500981|Procedure|Ultrasound evaluation of internal jugular vein|
45988532|NCT00501020|Drug|Rosiglitazone|
45988533|NCT00508014|Other|Usual Care|Usual Care with primary care provider during time period
45988534|NCT00508014|Behavioral|Concurrent Peer Review visit|Participants are offered an office visit with a peer of their clinician primary clinician. This office visit is structured and focused on blood pressure, diabetic, and/or lipid control with decision support available at point of care
45988535|NCT00501098|Drug|Caspofungin|"Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.~No stratification is planned."
45988536|NCT00508053|Procedure|Small stitches|
45988537|NCT00508053|Procedure|Mass closure|
45988538|NCT00501137|Biological|HPV (Human Papillomavirus) Vaccine|HPV (Human Papillomavirus) Vaccine received by all participants in groups 1, 2 and 3 according to the arm
45988539|NCT00508131|Other|Whole Cows Milk|400 mL, administered as two 200 mL drinking episodes per day of either fortified or not fortified milk for 12 months.
45988540|NCT01248260|Dietary Supplement|Folic Acid|4mg of higher strength folic acid once a day until delivery
45988541|NCT00508950|Procedure|Large volume blood draw|Large volume blood draw
45673706|NCT02130986|Other|Provide procalcitonin guideline to treating clinician|"Procalcitonin antibiotic guideline --~Procalcitonin level (ug/L) -- Bacterial etiology -- Recommendation~< 0.1 -- Very unlikely -- Antibiotics strongly discouraged(1)~0.1 - 0.25 -- Unlikely -- Antibiotics discouraged(1)~> 0.25 - 0.5 -- Likely -- Antibiotics recommended(2)~> 0.5 -- Very likely -- Antibiotics strongly recommended(2)~Initial antibiotics can be considered for critical illness, Legionella pneumophilia. Procalcitonin should be evaluated in context with all findings and the total clinical status; clinical judgment always necessary.~For outpatients, antibiotic duration based on level (> 0.25-0.5 ug/L:3 days; > 0.5-1.0 ug/L:5 days; >1.0 ug/L:7 days). Physician follow-up is recommended."
45988542|NCT00503945|Device|Nasal continuous positive airway pressure (nCPAP)|
45988543|NCT01246037|Drug|Bisoprolol|In the first 4 months of study, the dose of the drug will be gradually increased; the titration scheme is based on the 'farmacotherapeutisch kompas' and monitored according to the ACC/AHA/ESC guidelines. Up titration will be performed under the responsibilities of an experienced heart failure cardiologist and pulmonologist.
45988544|NCT00501215|Procedure|Parathyroid Surgery|Parathyroid surgery 1-3 weeks after the first PSG.
45988545|NCT00501215|Behavioral|Telephone Interview|Interview about sleep quality lasting 15-20 minutes.
45988546|NCT00501215|Procedure|Parathyroid Surgery|Parathyroid surgery after completing the second PSG and after the study participation ends.
45988547|NCT00501215|Behavioral|Polysomnography (PSG)|"2 overnight sleep tests~Group 1: First PSG 1-3 weeks before surgery + Second PSG 6-8 weeks after surgery~Group 2: First PSG 1-3 weeks before phone interview + Second PSG 6-8 weeks after phone interview"
45988548|NCT00509184|Drug|Rituximab|375 mg/m^2, weekly (4 weeks), repeated after 4 weeks gap
45988549|NCT00508599|Other|Study 2 (48 hours of complete bed rest)|Effects of 48 hours of bed rest on insulin resistance in type 2 diabetic subjects.
45988550|NCT00501254|Drug|Slow release acetyl salicylic acid|
45988551|NCT00501254|Behavioral|Antithrombotic effect|
45988552|NCT00509301|Drug|131-I-chTNT-1/B MAB|The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.
45988553|NCT01248338|Drug|metoprolol succinate|once daily 50 or 100 mg for one year
45988554|NCT01248338|Drug|Nebivolol|once daily 5 mg capsule for one year
45988555|NCT01248377|Procedure|Skin tests and ELISPOT assay|Patch test and/or intradermal test will be performed in patients as well as cytokine secretions from PBMCs will be analyzed by ELISPOT assay
45988556|NCT01246154|Other|EXERCISE TRAINING|EXERCISE TRAINING
45988557|NCT02953743|Drug|Lenvatinib|Lenvatinib 4 mg capsules will be administered orally, once daily continuously 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
45988558|NCT01246193|Drug|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
45988559|NCT01246193|Drug|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
45988560|NCT00509340|Behavioral|Cognitive behavioral therapy (CBT)|Participants in this group will receive individual sessions of cognitive-behavioral training for improvement of medication adherence and reduction of depression.
45988561|NCT02274935|Other|Exercise|Balance and gait exercise twice a week for an hour
45988562|NCT00509379|Drug|Rituximab|Rituximab 375 mg/m2 as slow iv infusion day 1-8-15-22.Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
45988563|NCT00509379|Drug|VELCADE|VELCADE 1,6 mg/m2 iv bolus days 1-8-15-22 (Velcade will be administrated prior of Rituximab infusion).Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
45988564|NCT00509418|Dietary Supplement|Viusid|Viusid, a nutritional supplement. Three oral sachets Daily 24 weeks
45988565|NCT00509418|Other|Hypocaloric Diet with controlled exercise|Modified ADA diet in combination with controlled exercise daily 24 weeks
45988566|NCT02274974|Drug|Lidocaine|•The wound of C.Swill be infiltrated before closure of the skin, with 20 ml of 2% lidocaine.
45988567|NCT02274974|Drug|lidocaine and Epinephrine|The wound of C.S will be infiltrated before closure of the skin, with 20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000.
45988568|NCT00509457|Biological|GV 1001 Telomerase peptide|
45988569|NCT02274545|Biological|H7N9 Anhui 2013/AA ca|10^7.0 fluorescent focus units (FFU); 0.5 mL of vaccine will be delivered as a nasal spray by an Accuspray device (0.25 mL per nostril)
45988570|NCT02274545|Biological|Inactivated subvirion H7N9 vaccine|30 mcg
45673707|NCT02130986|Other|Telephone Visit|We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30
45833347|NCT03083964|Behavioral|Priming|The intervention is a just in time eating or physical activity reminder. Each individual participant reports physical activity goals as well as times that they most often eat. This information is used to select for that individual the best time to send an eating or physical activity reminder. The reminders come to the participant's smartphone or a study provided smartphone. Participants will receive reminder 2 to 4 times per day depending on their goals and behavior pattern.
45988571|NCT02953470|Behavioral|Individual tailored functional exercise|Receive individual tailored exercise to increase ability to perform everyday activities through increased physical function and self-efficacy in relation to be able to exercise and decreased pain-related beliefs such as fear of falling, catastrophizing thoughts and fear of movement.
45988572|NCT02953470|Behavioral|Standard care|Receives written and oral advice about physical Activity and the benefits of being physically active by one visits from a physiotherapist. Than will the participants receive Telephone reminder about following the advice once a week during intervention week 1-8 and 10.
45988573|NCT02275013|Drug|Levosimendan|
45988574|NCT00509535|Drug|vitreoscilla filiformis cream|
45988575|NCT02274584|Genetic|Anti-CD30 CAR T cells|Autologous 4th generation withdrawal lentiviral-transduced anti-CD30 CAR T cells
45988576|NCT02274623|Drug|CTAP101 Capsules|escalating doses
45988577|NCT00509613|Drug|Sorafenib|
45988578|NCT00509613|Drug|Sirolimus|
45988579|NCT02953626|Behavioral|Mother Matters Online Postpartum Support Group|"Mother Matters is a 10-week online support group for women with postpartum depression. It involves: 1) A private, online forum that can be accessed by participants 24-hours per day. During regular business hours (9:00 am to 5:00 pm on weekdays) it is moderated by a psychotherapist, and there is a weekly moderated live chat hour; 2) Weekly topics with readings are provided with questions to prompt discussion on the online forum. Topics incorporate symptom management (i.e. Interpersonal Therapy, Cognitive Behavioural Therapy) and affect regulation strategies (i.e. Mindfulness, DBT) with a supportive counselling approach. External resources related to each week's topic, are also shared."
45673708|NCT04739306|Biological|CT-P42|2mg/0.05 mL by Intravitreal injection
45673709|NCT04739306|Biological|Eylea|2mg/0.05 mL by Intravitreal injection
45673710|NCT02130284|Device|Predictive Low Glucose Management Feature in Insulin pump|All subjects will undergo hypoglycemic induction at Visit 2 with target set to 65 mg/dL using the rate of change basal increase algorithm. Low Limit setting when PLGM ON is 65 mg/dL.
45988580|NCT00501332|Biological|Maxy-G34|Maxy-G34 will be administered by subcutaneous injection during each of 6 TAC chemotherapy cycles.
45988581|NCT02953353|Device|Active transcranial direct current stimulation (tDCS)|Participants will receive 10 daily sessions (phase 2) and 3 times a week (phase 3) of tDCS (2mA, 30 min per session). The tDCS montage will target the left dorsolateral prefrontal cortex (DLPFC) (anode: F3 based on the 10:20 system; cathode over the right supraorbital area). For stimulation the investigators will use 5x5cm sponge pads that will be soaked in 0.9% saline during the sessions.
45988582|NCT02953353|Other|Hypocaloric diet|During phase 3, participants will undergo a supervised hypocaloric diet intervention for 2 weeks based on a low-calorie diet (LCD) providing a hypocaloric diet based in 20% reduction from total energy expenditure (TEE). The diet will be individualized on the basis of physical activity levels, age for each participant. This intervention will be be conducted at an inpatient, well-controlled setting to guarantee adherence to the diet. Here the diet intervention will be administered in combination with tDCS. tDCS will be applied every other day (Monday, Wednesday, Friday) over the course of these two weeks.
45988583|NCT02953353|Other|Sham transcranial direct current stimulation (tDCS)|Subjects in the control group will receive sham stimulation (placebo) (similar procedure and duration as real tDCS, but here electric current flows for 30 s only, to mimic the subjective sensations that occur with active tDCS).
45988584|NCT00501371|Drug|MCS|soft-gel capsule, 15 mg/cap., Qd, 12 weeks
45988585|NCT00501371|Drug|Placebo|soft-gel capsule, Qd, 12 weeks
45988586|NCT00509652|Procedure|Arm 1: Erythrocyte apheresis|Erythrocyte apheresis
45833348|NCT05598606|Drug|Denosumab Injection|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection plus intravenous placebo every 6 months (Q6M)
45833349|NCT05598606|Drug|Zoledronate|Intravenous zoledronic acid 5 mg plus subcutaneous placebo every 12 months
45833350|NCT03350880|Other|Flexibility training|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
45988587|NCT00509652|Procedure|Arm 2: Whole blood phlebotomy|Traditional whole blood phlebotomy
45988588|NCT00501410|Drug|5-FU|2400 mg/m^2 by vein over 46 Hours On Days 1 & 2.
45988589|NCT00501410|Drug|Cetuximab|Initial Dose = 400 mg/m^2 by vein, then 250 mg/m^2 Weekly On Days 1 & 8
45988590|NCT00501410|Drug|Dasatinib|Starting dose level: 100 mg by mouth daily on days 1-14.
45988591|NCT00501410|Drug|Leucovorin|400 mg/m^2 by vein on day 1.
45988592|NCT00501410|Drug|Oxaliplatin|85 mg/m^2 by vein on day 1.
45988593|NCT02953392|Device|Anorganic Bovine Bone Graft Material|Anorganic bovine bone graft material is intended for augmentation or reconstructive treatment of the alveolar ridge, filling periodontal defects, filling defects after root resection, apicoectomy, and cystectomy, filling extraction sockets to enhance preservation of the alveolar ridge, and elevation of maxillary sinus floor.
45988594|NCT02953392|Device|Collagen Membrane|Collagen dental wound dressing is intended for the management of oral wounds and sores, including; dental sores, oral ulcers, periodontal surgical wounds, suture sites, burns, extraction sites, surgical wounds, and traumatic wounds.
45988595|NCT02953392|Device|Shelta Platform Switching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and/or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
45988596|NCT02953392|Device|Shelta Platform Matching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and /or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
45988597|NCT00501449|Behavioral|Questionnaire|Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.
45988598|NCT00508833|Biological|287615 containing HBsAg with adjuvants|
45988599|NCT02955953|Drug|LY2963016|Administered SC
45988600|NCT02953275|Drug|vedolizumab|standard of care
45988601|NCT02953275|Drug|Pentoxifylline|added to vedolizumab
45988602|NCT02953275|Drug|placebo|added to vedolizumab
45988603|NCT00501488|Drug|rosiglitazone|
45988604|NCT02953119|Other|Prehabilitation|
45988605|NCT02955563|Other|CSDM Web-Based Tool Intervention|The web and tablet-based tool is designed to help family members become familiar with ICU environment, routines, and clinicians, prepare for family meetings, and learn how to make values-based decisions for their loved one. The tool contains short videos, interactive exercises, and links to other resources. Family members work through the tool shortly after admission to the ICU, before each family meeting, and any other time they wish to during the ICU admission.
45988606|NCT00508911|Drug|GW876008|GW876008 tablets will be available as white to off-white coated tablets. Each subject will receive a single oral dose of GW876008, daily for up to 35 days in Session 2. GW876008 will be administered in the morning with a light breakfast.
45988607|NCT00508911|Drug|COC|COC containing ethinylestradiol 30 microgram and levonorgestrel 150 microgram will be administered in the morning with a light breakfast.
45988608|NCT02955719|Drug|Sertraline|
45988609|NCT02955719|Drug|Venlafaxine|
46083640|NCT02713464|Behavioral|maternal education|Antenatal and/or postpartum Instruction on risks of neonatal jaundice, dangerous practices, technique to evaluate jaundice, early signs of ABE, when to seek care.
45988610|NCT02955719|Other|CBT/Psychological Therapy|
45988611|NCT02955719|Other|Psychiatric Consultation|
45988612|NCT02955719|Other|Lifestyle Intervention Resources|
45988613|NCT00509691|Biological|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
45988614|NCT00509691|Genetic|polymerase chain reaction|
45988615|NCT00509691|Other|diagnostic laboratory biomarker analysis|
45988616|NCT00509691|Other|flow cytometry|
45988617|NCT00509691|Other|immunologic technique|
45988618|NCT00501527|Biological|Immunotherapy with modified extract of P. pratense pollen|Sublingual (2 drops daily)
45988619|NCT00501527|Other|Placebo|Placebo 2 drops daily
45988620|NCT00509730|Procedure|Urodynamics|
45988621|NCT02955524|Drug|Tetracaine 0.5%|One drop of 0.5% Proparacaine to nasolacrimal Duct to numb the ethmoidal nerve in the nasal passage on the side of the eye to be treated.
45988622|NCT02955524|Drug|Lidocaine hydrochloride ophthalmic gel 3.5%|1ml of lidocaine gel is placed over the conjunctivae of the eye to be treated after the patient is under general anesthesia and before the procedure
45988623|NCT02953041|Drug|Glycopyrronium|long-acting muscarinic antagonist
45988624|NCT02953041|Drug|Indacaterol|ultra long-acting beta agonist
45988625|NCT00501566|Drug|satavaptan (SR121463B)|
45988626|NCT00509808|Device|Electrostimulation|"1st month GN wearing (activated or sham mode)~2nd month wearing (opposite mode)~3rd - 5th month: activated GN wearing for 1, 5 or 10 minutes~6th - 8th month: activated GN wearing for 1, 5 or 10 minutes~9th - 11th month: activated GN wearing for 1, 5 or 10 minutes"
45988627|NCT00501605|Drug|AZD2171|
45988628|NCT00509847|Drug|human lactoferrin peptide 1-11|(A) hLF1-11 (once-daily 0.5mg IV for 10 days): Group #1, n=10; OR (B) Placebo (to match hLF1-11): Group #2, n=10
45988629|NCT01248494|Drug|BEZ235|"Dose level 1: 400mg PO BID~Dose level -1: 400mg PO in AM and 200mg PO in PM~Dose level -2: 200mg PO BID"
45988630|NCT01248494|Drug|BKM 120|"Dose Level 1: BKM120, 100 mg PO daily~Dose level -1: BKM120, 80 mg PO daily~Dose Level -2: BKM120, 60 mg PO daily"
45988631|NCT01248494|Drug|Letrozole|All levels: 2.5mg/day PO
45988632|NCT01248494|Drug|BKM120|"Dose Level 1: BKM120, 100 mg PO from Mondays through Fridays, weekly~Dose level -1: BKM120, 80 mg PO from Mondays through Fridays, weekly~Dose Level -2: BKM120, 60 mg PO from Mondays through Fridays, weekly"
45988633|NCT00509886|Drug|Drysol|20% aluminum chloride hexahydrate
45988634|NCT00509886|Drug|Drioff|1% aluminum acetate
45988635|NCT00501683|Drug|Radiolabelled GSK189075|
45988636|NCT02952573|Drug|JNJ-42756493|Once daily dosing
45988637|NCT02952573|Drug|Dexamethasone|Cycle 1 and 2: OD dosing on days 1-4, 9-12, and 17-20;Cycle 3: OD dosing on days 1, 8, 15, 22
45988638|NCT03459963|Device|indwelling urinary catheter|85 women undergoing first elective CS will be catheterized immediately preoperatively using Foley's catheter by applying catheterization precautions.
45988639|NCT01248572|Device|Softec HD IOL|Posterior chamber intraocular lens intended for the replacement of the human crystalline lens following phacoemulsification cataract removal in adults over the age of 21.
45988640|NCT02953080|Other|Call for life mHealth adherence support|Daily/ weekly pill reminder support Health Info-tips Appointment visit reminders Self-reported symptom support
45988641|NCT00501722|Drug|satavaptan (SR121463B)|
45988642|NCT02952768|Behavioral|ultrasound training|Through the ultrasound-circulation-airway-breathing training curriculum to integrate the ultrasound into clinical practice.
45988643|NCT01248611|Drug|fentanyl|nasally, dose titrated to effect
45988644|NCT00509964|Drug|irinotecan|Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.
45988645|NCT00509964|Drug|ILF|Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and 5-fluorouracil, on day 1 every 2 weeks.
45988646|NCT04696874|Procedure||All testes were fixed to the ipsilateral sub-dartos pouch. All epididymides and vasa deferentia were carefully examined, and any observed anomalies were recorded.
45833351|NCT03347292|Drug|Regorafenib(Stivarga, BAY73-4506)|Regorafenib 80mg/120mg/160mg q.d., 3 weeks on / 1 week off + pembrolizumab 200mg i.v. every 3 weeks
45988647|NCT02952729|Drug|XMT-1522|one intravenous dose administered in-clinic every 21 days
45988648|NCT00501761|Behavioral|Personalized Exercise Program|Walking up to thirty minutes on most days of the week.
45988649|NCT00501761|Behavioral|Questionnaire|Questionnaires regarding physical activity, exercise, and quality of life.
45988650|NCT00501761|Behavioral|Suggested Exercise Program|Exercise program performed over 7 days.
45988651|NCT01248650|Drug|nalfurafine hydrochloride|
45988652|NCT00510471|Drug|autologous immunoglobulin idiotype-KLH conjugate vaccine|
45988653|NCT00501839|Drug|clomiphene citrate|
45988654|NCT00510003|Drug|Pimecrolimus|Pimecrolimus cream 1 %
45988655|NCT00501878|Drug|2.5% or 10% phenylephrine|
45988656|NCT00510549|Procedure|Modality: Peritoneal Dialysis|Peritoneal Dialysis: CAPD; Hemodialysis: 3 times/week
45988657|NCT00501917|Drug|G-CSF with/without darbepoetin, peripheral blood stem cell infusion|
45833352|NCT03347292|Drug|Pembrolizumab|200 mg i.v.(Intravenous(ly)) every 3 weeks (Q3W). This dose will not be escalated or deescalated and the dosing schedule will not be changed
45833353|NCT05597358|Radiation|High Intensity Laser Therapy (HILT)|Nd:Yag 1064 nm pulsed high intensity laser will be applied to the vulvar area.
45833354|NCT05597358|Radiation|Sham High Intensity Laser Therapy|Nd:Yag 1064 pulsed high intensity laser deactivated probe will be applied to the vulvar area.
45833355|NCT03084120|Other|Collection of bloods samples for the mother|-During pregnancy, childbirth and after delivery
45833356|NCT03084120|Other|Retrieval of umbilical cord blood.|-During childbirth
45833357|NCT03084120|Other|Retrieval of placenta.|-During childbirth
45988658|NCT00510588|Other|training|regular physical exercise training for 6 months
45988659|NCT00510588|Other|training + metformin|regular physical exercise training in combination with metformin for 6 months
45988660|NCT00510588|Other|training + glitazon|regular physical exercise training in combination with a glitazon for 6 months
45988661|NCT00501956|Drug|Intradialytic Parenteral Nutrition (IDPN)|compounded IDPN, 3 x/week, 16 weeks intervention
45988662|NCT00510627|Device|Radiofrequency Ablation (RFA)|The RF3000 radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue.
45988663|NCT00510627|Drug|Chemotherapy|Standard of care chemotherapy regimen
45988664|NCT02953236|Procedure|Instrumented massage|The first group will receive a 20 min session of instrumented massage on back and neck areas. Subjects will be in prone position and physical therapist will applied instrumental massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
45988665|NCT02953236|Procedure|Manual massage|The second group will receive a 20 min session of manual massage on back and neck areas. Subjects will be in prone position and physical therapist will applied manual massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
45988666|NCT00502034|Drug|Interferon Alfa-2a|Interferon Alfa-2a in combination with Interleukin
45988667|NCT00502034|Drug|Interleukin-2|Interferon Alfa-2a in combination with Interleukin
45988668|NCT00510666|Drug|Saline|Saline infusion adjunct to morphine PCA pump
45988669|NCT00510666|Drug|Butorphanol tartrate|Butorphanol was delivered at a continuous infusion manner adjunct to morphine PCA pump
45988670|NCT00510666|Drug|Tramadol Hydrochloride|100mg tramadol was used preemptively to morphine PCA pump
45988671|NCT00510666|Drug|Saline|Preemptive saline as a control group to tramadol one
45988672|NCT00508092|Procedure|local anesthetic administration|"Pre incision skin infiltration with local anesthetic 0.5% bupivacaine by weight~OR~Pre incision skin infiltration and deeper field infiltration (deep to external oblique) with local anesthetic 0.5% bupivavcaine by weight"
45988673|NCT01248845|Other|Titration of various level of assistance|Exploration of the effects on diaphragmatic electrical activity (EMG) and on respiratory pattern of various level of assistance delivered by the ventilator in intubated spontaneously breathing patients in pressure support (PS) and in Neurally Adjusted Ventilatory Assist (NAVA) by step by step increasing of the level of assistance. Flow, airway pressure, transesophageal EMG signal and transcutaneous EMG signal will be recorded.
45988674|NCT00510705|Other|exercise training|physical exercise training on a bicycle ergometer daily for 4 weeks
45988675|NCT00510705|Other|exercise training + metformin|physical exercise training on a bicycle ergometer + metformin (2 x 850 mg) daily for 4 weeks
45988676|NCT00510705|Other|exercise training + glitazone|physical exercise training on a bicycle ergometer + glitazone daily for 4 weeks
45988677|NCT00502073|Drug|cyclosporine|
45988678|NCT01248923|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
45988679|NCT01248923|Drug|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care; Part 2: standard of care determined in Part 1.
45988680|NCT01248923|Drug|Dexamethasone, steroid; oral|Part 1: standard of care; Part 2: standard of care determined in Part 1.
45988681|NCT01248923|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
45988682|NCT01248923|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating
45988683|NCT01248923|Drug|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care
45988684|NCT01248923|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care
45988685|NCT01249001|Drug|Oral Aprepitant|Subject will receive an oral suspension containing 125mg of Aprepitant
45988686|NCT01249001|Drug|Aprepitant|Subjects will receive a 125 mg Aprepitant capsule
45988687|NCT01249040|Procedure|Physical therapy|
45988688|NCT01249040|Procedure|steroid intraarticular injection|
45988689|NCT00502112|Drug|lintuzumab|4 or 8 mg/kg IV (in the vein) on Days 1, 8 and 15 for the first 21-day cycle; 4 or 8 mg/kg IV (in the vein) on Days 1 and 8 for the second through the eighth 21-day cycle
45988690|NCT00502112|Drug|lenalidomide|10 or 15 mg per day, taken orally on Days 1-14 of each 21-day cycle
45988691|NCT04695912|Device|The SENS motion® sensor|"The sensor is a wearable physical tracker giving investigators feedback about daily activity~The SENS motion® system consists of:~The sensor 'SENS Motion Patch' A smart-phone application 'SENS motion´~SENS motion cloud storage database, a web-based visualization of data for the healthcare team~The iSpine app shows activity-information recorded by the sensor to the patient and gives nudges to activity."
45988692|NCT03459495|Device|therapeutic ultrasound|Patients in the ultrasound group will be administered to the posterior neck region for 5 minutes in pulsed mode (pulse rate 1: 1) at 1 MHz, 1.5 W / cm2. The treatment will be done 5 days a week for a total of 10 days
45988693|NCT03459495|Device|placebo ultrasound|When the ultrasonic device is in the closed position, the ultrasonic probe will be applied for 5 minutes in the posterior neck region of the patients. The treatment will be done 5 days a week for a total of 10 days.
45988694|NCT00502190|Device|Silicon ring positioned in the vagina, around the cervix|Silicon ring positioned in the vagina, around the cervix
45988695|NCT01249079|Other|No intervention would be provided in this research|No intervention would be provided in this research,but need to draw blood
45988696|NCT00510822|Drug|Cimicoxib|50 mg per tablet, bid (total daily dose 100 mg)
45988697|NCT00510822|Drug|Placebo|tablet
45988698|NCT00502229|Drug|Clomiphene citrate, metformin, highly purified urinary FSH|
45988699|NCT02953158|Other|Haas Avocado|Hypocaloric weight loss diet
45988700|NCT02953158|Behavioral|Dietary Counseling|Dietary Counseling
45988701|NCT00502268|Drug|Doxercalciferol administration|Doxercalciferol administration
45988702|NCT00502268|Drug|Doxercalciferol administered by 1-84-7-84|Doxercalciferol administered by 1-84-7-84
45988703|NCT02953197|Radiation|FDG-PET guided radiation dose escalation|Selective dose escalation
46083641|NCT02780570|Procedure|Small Volume Plasma Exchange|Six sessions will be done daily for consecutive 8 days (total 48 sessions). 7 ml/body weight blood will be drawn at each session and will be separated into plasma and blood cells. Blood cells will be infused back to the patients and plasma will replaced by equal volume of fresh frozen plasma and colloid solution. At the end of each day 1200 ml plasma (total 9600 ml in 48 sessions) will be removed.
45988704|NCT00502346|Drug|PM10|
45988705|NCT01249196|Drug|SK-PC-B70M|for dosage
45988706|NCT00510081|Device|Calcium Hydroxylapatite injection|filler injection
46083642|NCT00746733|Drug|Lisdexamfetamine Dimesylate|50mg capsule
46083643|NCT00746733|Drug|Adderall XR (mixed salts amphetamine)|20mg capsule
46083644|NCT04860323|Other|Analytical Treatment Interruption|"Participants will stop taking their HIV medication and will stay off HIV medication unless and until the HIV levels in their blood show that their immune system is not controlling their HIV or they meet other ART re-start criteria as noted in section Detailed Description."
46083645|NCT05098184|Biological|Tumor Infiltrating Lymphocyte|Adoptive transfer of 1x10^9-5x10^10 autologous TILs to patients i.v. in 30-120 minutes.
46083646|NCT00636870|Drug|Fexofenadine|
45833358|NCT03084120|Other|Collection of newborn's and mother's lock of hair.|-During childbirth
45833359|NCT03084120|Other|Dietetic Patient Outcomes Questionnaires for the mother.|-During pregnancy and after delivery
45833360|NCT03084120|Other|Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire).|-At 2 years of age
45833361|NCT03084042|Device|fMRI|
45833362|NCT03406884|Biological|c-kit+ cells|The autologous c-kit+ cells will be harvested from participant's right atrial tissue obtained from participant's SOC Norwood Operation. The harvested c-kit+ cells containing up to a total of 12,500 cells/kg will be delivered through 6-10 intramyocardial injections of approximately 100uL per injection for a total volume of approximately 0.6 mL.
45833363|NCT04400916|Drug|Tranexamic acid|A single drop administered topically
45988707|NCT00502385|Drug|AZD2171|
45988708|NCT02952651|Procedure|Pulse oximeter|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, POP waveforms are obtained from each index finger, which pulse oximeter sensor is applied by increasing contact force (from 0 to 1.4N, being increased by 0.2-0.3N). Then intravenous crystalloid 10 mL/kg is infused for 15 min.
45988709|NCT01249235|Procedure|Patch or bandage contact lens|Patients will be given a patch or a bandage contact lens at the conclusion of pterygium excision surgery.
45988710|NCT00510120|Behavioral|Parent management training (PMT)|PMT primarily involves teaching parents strategies to respond consistently and correctly to their child's behavior. Parents assigned to the PMT group will be taught how to respond consistently and appropriately to their child's positive and negative behaviors. Participants will attend a 1-hour treatment session each week for 10 weeks.
45988711|NCT00510120|Behavioral|Collaborative problem solving (CPS)|CPS is a treatment approach that involves both the parent and child by teaching parents to help their child control their emotions and to problem solve as a family. Parents assigned to the CPS group will be taught strategies to help their child identify and regulate emotions and to solve behavior problems together as a family. Participants will attend a 1-hour treatment session each week for 10 weeks.
45988712|NCT00510120|Behavioral|Waitlist control|Participants assigned to the waitlist control condition group will wait 10 weeks before beginning treatment one of the two treatment options.
45988713|NCT00502424|Device|Splint|
45988714|NCT00510159|Drug|Artesunate+Sulfamethoxypyrazine/pyrimethamin|
45988715|NCT00510159|Drug|Praziquantel|
45988716|NCT00502463|Procedure|radio-immunotherapy|
46083647|NCT00634790|Drug|alprazolam XR|Alprazolam XR oral tablet 1 mg daily for 7 days; thereafter the daily dose will be titrated at a maximum rate of 1 mg every 7 days up to a maximum dose of 6 mg; dose adjustments up or down may be made, at a rate not to exceed 1 mg every 7 days; alprazolam XR will be administered for a total of 6 months followed by a gradual taper at a rate of 1 mg every 7 days.
45673711|NCT04749212|Diagnostic Test|serum high-sensitivity Troponin I (TnI) and NT-Pro-Brain Natriuretic Peptide (NT-proBNP)|Both biomarkers will be determined in each patient preoperatively and at postoperative day 1 and day 2.Measurements will not necessarily be taken independently of other measurements, meaning that the addition of the biomarker could be included in routine pre or postoperative day-1 and day 2 blood tests.
45673712|NCT04748822|Other|questionnaires|The Alcohol Quality of Life Scale (AQoLS) will be completed at baseline and at 6-month follow-up. Alcohol status (relapse/abstinence) will be assessed at 6 months.
45673713|NCT02147288|Device|Renasys*GO Negative Pressure Wound Therapy System|Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).
45673714|NCT04752020|Drug|Netarsudil Ophthalmic|Use of netarsudil after Descemetorhexis without endothelial keratoplasty
45833364|NCT04400916|Other|Balanced Salt Solution|A single drop administered topically
45833365|NCT05582538|Drug|Ceralasertib|240mg orally BD (dose level 0) on days -6 to 0 prior to day 1 cycle 1 and then on days 22 to 28 of cycle 1 and every subsequent cycle
45833366|NCT05582538|Drug|Durvalumab|1500 mg i.v. day 1 (q28)
45833367|NCT05582538|Drug|Nab-paclitaxel|100mg/m2 i.v. day 1,8,15 (q28)
45833368|NCT03406650|Drug|Neoadjuvant and adjuvant durvalumab|Neoadjuvant durvalumab 1500 mg q3w for 4 cycles Adjuvant durvalumab 1500 mg q4w for 10 cycles
45833369|NCT03406104|Genetic|GS010|Lenadogene nolparvovec Intravitreal occular unilateral Injection
46083648|NCT04831151|Drug|Yasmin|Yasmin: 0,03 mg ethinylestradiol + 3 mg drospirenone
46083649|NCT04831151|Drug|Diane-35|Diane 35: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate
46083650|NCT00917397|Drug|Sertraline|varies
46083651|NCT00917397|Behavioral|trauma-focused cognitive behavioural therapy|once a week
45458360|NCT01236781|Device|Diagnostic Tomosynthesis|Tomosynthesis imaging sets (limited tomosynthesis set and then a sequential read with the low-dose CC view added for the tomosynthesis plus set).
45458361|NCT04457960|Drug|JNJ-66525433|Participants will receive JNJ-66525433 oral capsules.
45458362|NCT04457960|Drug|Placebo|Participants will receive matching placebo oral capsules.
45833370|NCT03406104|Other|Sham|Lenadogene nolparvovec Intravitreal occular unilateral Injection
45833371|NCT05571072|Other|Opioid calculator|Our research group previously created an Opioid calculator that can be used to predict the number of opioids needed post-operatively based on patient health history and characteristics.
45833372|NCT05571072|Other|Standard opioid prescription|Patients will receive prescription for post-operative opioids based on what the attending surgeon usually provides.
45833373|NCT04761042|Other|WAYA-Wilderness|"The wilderness intervention includes challenging tasks in order to help participants' overcome and master new physical and psychological challenges in an unknown environment, with the idea to support self-efficacy, self-esteem, and ability to recover from adversity. The program is designed to encourage participants to connect with nature as to experience gratitude for the richness of the natural world, a sense of calmness and trust upon spending time in nature, and to be more physically active in nature.~Elements previously described Participants will continue in a three-month program at home (on-line supported) after the initial 8-days in order to empower participants to incorporate elements of the onsite wilderness program into their daily life. An individualized a plan for activities will be developed together with the participant.~After three months, there will be a re-visit with follow up on outcome measures and reconnection."
45833374|NCT04761042|Other|WAYA-Holiday|"An attention control group (information in Detailed description)"
45988717|NCT00502502|Behavioral|Questionnaire|Weekly questionnaires lasting about 30 minutes.
45988718|NCT01249391|Device|Splinting|Gutter thermoplastic custom-made splint for nominated joint, to be worn at night-time for consecutive nights for 3 months
45988719|NCT02952807|Drug|Misoprostol|vaginal Misoprostol Plus Foley Catheter
45988720|NCT02952807|Device|Foley Catheter|
45988721|NCT02275130|Procedure|Calcium Hydroxyapatite|Surgical augmentation of the vocal cords with injection of calcium hydroxyapatite
45988722|NCT02275130|Device|Radiesse Voice (Calcium Hydroxyapatite)|
45988723|NCT03459417|Procedure|intrathecal morphine+LA|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage. patients will receive intrathecal LA 15 mg (3 mL) (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.
45988724|NCT03459417|Procedure|intrathecal morphine+LA+ Mg sulp. 50|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal +0.5 mg preservative free morphine + magnesium sulphate 50 mg.
45988725|NCT03459417|Procedure|intrathecal morphine+LA+ Mg sulp. 100|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal with 0.5 mg preservative free morphine + magnesium sulphate 100 mg.
45988726|NCT00502541|Drug|fluocinolone acetonide|fluocinolone acetonide 0.59 mg intravitreal implant
45988727|NCT00502541|Procedure|Standard of Care|Repeat macular grid laser or observation
45988728|NCT03459378|Other|no intervention - retrospective analyses|retrospective data examination, there are no study related interventions
45988729|NCT01249430|Drug|Azacitidine|Given IV
45988730|NCT01249430|Drug|Cytarabine|Given IV
45988731|NCT01249430|Drug|Etoposide Phosphate|Given IV
45988732|NCT01249430|Other|Laboratory Biomarker Analysis|Correlative studies
45458363|NCT03498118|Drug|20 mL of bupivacaine 0.25%|"In the infiltration group, at the end of surgery, 30 mL of bupivacaine 0.25% was injected subcutaneously in the surgical wound (15 mL in each of the upper and lower sides) by the obstetrician before skin closure. Sam procedure was performed by the primary investigator after completion of surgery by pressing a covered spinal needle on both sides of the patient's abdomen.~In the TAP group, after completion of surgery, 20 mL of bupivacaine 0.25% was injected under direct visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side."
45988733|NCT01249430|Drug|Mitoxantrone Hydrochloride|Given IV
45988734|NCT01249430|Other|Pharmacological Study|Correlative studies
45988735|NCT02952963|Drug|Chenodeoxycholic Acid|
45988736|NCT02952963|Drug|Colesevelam|
45988737|NCT00510939|Drug|Tipifarnib plus Bortezomib|
45988738|NCT00504062|Drug|budesonide|
46083652|NCT02708472|Device|synchronized Transcranial Magnetic Stimulation (sTMS)|"Subjects who qualify will receive daily active sTMS treatments with the NeoSync, Inc sTMS device. The device includes an EEG recording module and the device uses a proprietary algorithm to determine the individualized alpha frequency (IAF). The IAF obtained during this baseline recording is used throughout the study.~The device contains three magnets in the sagittal line above the subject's scalp, which rotate along a transverse axis. sTMS stimulation is delivered broadly over the prefrontal and frontal regions of the brain. These magnets rotate to generate a sinusoidal magnetic field set at precisely the average individualized alpha frequency (IAF). Each therapy session lasts 30 minutes."
46083653|NCT02708160|Drug|Fluoride Free toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
45458364|NCT01145131|Other|Intact or minced beef meat|135 gram piece of intact or minced beef meat, beef steak or minced beef resp.
45988739|NCT00504062|Drug|fluticasone|
45988740|NCT03459339|Device|Tethered Capsule Endomicroscopy (TCE)|Tethered Capsule Endomicroscopy will be used to detect Barrett's Esophagus
45988741|NCT00504101|Drug|Arsenic trioxide|Arsenic Trioxide will be given on day -6, -5, -4,-3,-2 (total of 5 doses). The dose of Arsenic trioxide (ATO) is 0.25 mg/m2.
45988742|NCT00504101|Drug|Bortezomib|Bortezomib will be given on day -6, -4, -2 (total 3 doses) beginning at a dose of 0.8 mg/m2 each day of therapy.
45988743|NCT00504101|Drug|Melphalan|Melphalan will be given at 200 mg/m2 on day -2 (1 dose only)
45988744|NCT00504101|Biological|Autologous hematopoietic stem cell transplantation|On day 0 a minimal of 2 x 106 CD 34 cells/kg will be infused by central catheter according to institutional standards.
45988745|NCT00510978|Biological|Bifidobacterium infantis 35624|1 sachet/day for one year
45988746|NCT00510978|Biological|Lactobacillus salivarius UCC118|1 sachet per day for 1 year
45988747|NCT00510978|Biological|Placebo|1 sachet per day for 1 year
45988748|NCT02952690|Device|Glidescope® with tip manipulated stylet|The intubating style is curved in accordance with the curve of GVL blade and the distal tip of style is additionally bended to the left (15-20 degree)
45988749|NCT02952690|Device|Glidescope® with standard-curved tip|The style is curved in accordance with the curve of GVL blade
45988750|NCT00510237|Behavioral|"Adolescents Coping, Connecting, Empowering, and Protecting Together (Project ACCEPT)"|The intervention will consist of a combination of individual and group-based sessions in which the youth will participate. This combination allows for more intensive individualized attention as well as supportive group sessions. Youth will first participate in two individual sessions, followed by nine group sessions, and end with one additional individual session.
45988751|NCT00504140|Drug|Etoposide|100 mg/m^2 Intravenous Daily for 5 days, beginning one hour after IFN-alpha treatment.
45988752|NCT00504140|Drug|Interferon Alpha|5x10^6 mu/m^2 Subcutaneously Daily for 5 Days
45988753|NCT00510315|Other|Questionnaires, Laboratory tests, Abdominal MRI|Height, weight, waist and hip circumference; systolic and diastolic blood pressure; questionnaires; fasting blood tests: insulin, glucose, lipids (low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, LDL pattern, HDL and LDL subspecies), cardiac inflammatory markers (hsCRP, IL-1B, IL-6, IL-10, TNFa), leptin, adiponectin, IGF-1, and IGFBP3; abdominal MRI for visceral and subcutaneous fat measurement
45988754|NCT02955992|Behavioral|Improving communication during the end-of-life process|
45988755|NCT00511017|Drug|Doxercalciferol|.05 mcg/kg by mouth daily x 28 Days
45988756|NCT00504179|Procedure|Osteopathic Manipulative Treatment|
45988757|NCT02955875|Behavioral|Pharmaceutical care|Outpatient drug history management, drug regimen review, patient counseling and education before and/or after physician evaluation on the day of facility visit
45988758|NCT00511212|Drug|intravenous immunoglobulin|
45988759|NCT00510354|Drug|Imatinib mesylate|
45988760|NCT01241006|Drug|Dexamethasone|Dexamethasone 12mg PO single dose x 1 Placebo 1 capsule PO for 4 days
45988761|NCT01241006|Drug|Prednisone|Prednisone 60mg PO q day for 5 days
45988762|NCT04695951|Dietary Supplement|Renalof|A total of 120 patients treated with the study product Renalof® at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
45988763|NCT04695951|Other|Placebo|A total of 35 patients treated with Placebo at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
45988764|NCT01249508|Other|nutrition label|
45988765|NCT00510393|Device|XIENCE V everolimus eluting coronary stent system|
45988766|NCT00510393|Device|MULTILINK VISION coronary stent system|
45988767|NCT01249547|Drug|axitinib|starting dose of 5 mg twice daily for 4 consecutive weeks without interruption.
45988768|NCT02952339|Biological|RSV LID ΔM2-2 1030s vaccine|10^5.0 PFU; administered as nose drops
45833375|NCT04400526|Behavioral|A video competition|Each Individual/group will be required to produce a maximum of 2-minute video on one of the following themes: (1) the hazardous effects of drug especially less psychotropic drugs such as Cannabis, (2) encouraging messages to drug abusers, and (3) existing anti-drug services.
45833376|NCT04400526|Behavioral|A training workshop|The workshop will last for 6 hours, and will be delivered by an experienced counsellor from C.H.O.I.C.E. The content of the workshop will include (1) hazardous effects of drug abuse especially less psychotropic drugs such as Cannabis, (2) signs and symptoms of drug abuse particularly less psychotropic drugs like Cannabis, (3) alternatives to drug abuse, (4) community resources available, and (5) how to refer drug abusers. Besides, all children will be taught to use the AWARD model for referrals in the workshop.
45988769|NCT02952339|Biological|Placebo|Administered as nose drops
45988770|NCT00504608|Drug|Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)|
45988771|NCT00504647|Device|Biventricular Pacemaker|
45988772|NCT02952495|Behavioral|Online alcohol educational class|"Participants will be asked to review an online alcohol education class. This is a web-based patient educational program designed to prevent hazardous and harmful drinking in older adults. The project's specific objectives are to 1) provide reliable information on the extent to which A Toast to Health in Later Life! reduces alcohol-related risks and problems among older patients who drink and 2) evaluate the extent to which these reductions are associated with increases in health-related quality of life, patient knowledge and self-efficacy and decreases in the use of health services and the costs of care."
45988773|NCT01249586|Other|E-learning|A traditional class of blindness prevention plus an additional e-learning material. The e-learning material included a PDF article about blindness prevention. This material was e-mailed one week before the traditional class.
45988774|NCT00511719|Drug|Technosphere Insulin|48U
45988775|NCT00511719|Drug|Actrapid|24IU
45988776|NCT00504686|Other|manual therapy|manual therapy - thoracic spine thrust manipulation
45988777|NCT00504686|Other|exercise|therapeutic exercise
45988778|NCT00511758|Procedure|Digital Imaging|Images of the cervix will be taken using different types of light and compared with the colposcopy procedure.
45988779|NCT01245335|Device|BMAC injection|Injection of 40 ml of autologous bone marrow aspirate concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
45988780|NCT01245335|Device|Placebo injection|Injection of placebo into ischemic tissue of the lower extremity
45988781|NCT00511290|Other|no generic names|
45988782|NCT00511368|Drug|matching placebo|
45988783|NCT00511368|Drug|Bevirimat|
45988784|NCT01246232|Drug|Amisulpride|Clozapine augmentation with another second-generation antipsychotic, amisulpride (400mg amisulpride for the first 4 weeks, then the option of titrating up to 800mg amisulpride for the remaining 8 weeks).
45988785|NCT01246232|Drug|placebo|Clozapine augmentation with 1 capsule placebo for the first 4 weeks, then the option of titrating up to 2 capsules placebo for the remaining 8 weeks).
45988786|NCT00511407|Device|Renal tubule assist device|Standard hemofiltration cartridge containing nonautologous human renal tubule cells, connected to conventional continuous venovenous hemodialysis circuit.
45988787|NCT01248962|Drug|carboplatin|Carboplatin Standard 30-minute infusion. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg (or famotidine 20mg IV)IV and diphenhydramine 50mg IV before carboplatin infusion.
45988788|NCT01248962|Drug|carboplatin|Extended 3-hour infusion carboplatin. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg IV (or famotidine 20mg IV) and diphenhydramine 50mg IV before carboplatin infusion.
45988789|NCT02952183|Device|PAMS I|"After general anesthesia, pressure sensor of PAMS I is placed into bladder, vagina and rectum. Then pressure change is monitored during performing pelvic autonomic nerve dissection.~Both PAMS I and IOM will be used for monitoring."
45673715|NCT05209178|Diagnostic Test|Collection of nasal and oropharyngeal specimen for COVID19 antigen test|Regarding two independent sampling procedures from the anterior part of the nose and the oropharynx, participants are randomized to either perform the sampling by themselves with written instructions or having the procedure performed by trained personnel. The specimen is meant for a rapid antigen test for COVID-19 infection.
45988790|NCT01249742|Behavioral|Internet intervention|Our intervention, Sugarsquare, is a secured treatment environment only accessible by patients of the KDCN and members of the treatment team. Sugarsquare consists of two main sections. The first section is a semi-public setting on which adolescents can exchange experiences with their diabetes (care) through a forum and a real time chat-application. All patients and treatment team members can see all messages posted here. The second section consists of patients' individual pages with treatment overview and an application for private interaction with the treatment team. Patients can only access their own individual page; treatment team members can access pages of all patients. Sugarsquare is a secured webpage, accessible only through computers equipped with the right certificate (access device) and by using the appointed username-password combination.
45988791|NCT00511446|Drug|docetaxel, oxaliplatin, capecitabine|"Docetaxel: 35 mg/m2, IV day 1, 8 of each 21 day cycle; Oxaliplatin: 70 mg/m2, IV day 1, 8 of each 21 day cycle; Capecitabine: 2x800 mg/m2 PO IV day 1 evening till morning of day 15 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
45988792|NCT02956109|Drug|Finerenone (BAY94-8862): 1 0mg tablet|10 mg finerenone immediate-release tablet; single dose in the fasting condition
45988793|NCT02956109|Drug|Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets|5 x 0.25 mg (1.25 mg) oro-dispersible tablets; single dose in the fasting condition
45988794|NCT02956109|Drug|Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet|1.25 mg finerenone oro-dispersible tablets; single dose in the fasting condition or in the fed condition
45988795|NCT02952300|Procedure|neolix|single rotation file
45988796|NCT02952300|Procedure|wave one|single reciprocation file
45988797|NCT02955446|Drug|PF-03084014|Two patients enrolled in this study will continue receiving 80mg BID doses of PF-03084014, which was the same dose/schedule of their latest cycle on protocol A8641014. PF-03084014 will be administered twice a day in the morning and evening divided by approximately 12 hours. PF-03084014 should be administered in cycles of 21 days continuously.
45988798|NCT00511524|Drug|GW842166X|GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X.
45988799|NCT00511524|Drug|[carbonyl-^11C]GW842166|[carbonyl-^11C]GW842166 will b available as Intravenous solution.
45988800|NCT00511563|Drug|GW876008 and GSK561679|GW876008 and GSK561679
45988801|NCT02955368|Drug|DP-R212|DP-R212 + C1-R212 placebo + C2-R212 placebo
45988802|NCT02955368|Drug|C1-R212|DP-R212 placebo + C1-R212 + C2-R212 placebo
45988803|NCT02955368|Drug|C2-R212|DP-R212 placebo + C1-R212 placebo + C2-R212
45988804|NCT00511602|Drug|Technosphere Insulin|Technosphere Insulin Inhalation Powder
45833377|NCT04400526|Behavioral|A mass promotional campaign|Children who complete the training workshop in phase 2 will be invited to join phase 3. They are encouraged to design their own promotional activities for community members in the targeted districts. The activities can be delivered by a group (a maximum of 5 ADAs per group) or by an individual. Types of activities can include but not limited to health talks, booths, outreaching activities, games, posters, leaflets and websites. Likewise, if the ADAs encounter any drug abuser in their social circles, the ADAs will be asked to deliver a brief advice based on the AWARD model.
45988805|NCT00511602|Drug|Technosphere Placebo|Technosphere Inhalation Powder
45673716|NCT04739150|Drug|nintedanib|nintedanib
45673717|NCT04737356|Behavioral|Cognitive behavior therapy|Internet-based CBT intervention based on CBT theory as well as self-determination therapy for low self-esteem among adolescents.
45833378|NCT03405480|Other|Rehabilitation|Rehabilitation
45833379|NCT05686746|Drug|Baricitinib 4 MG|4 mg oral daily
45988806|NCT00511641|Behavioral|Questionnaire|Questionnaires lasting up to 30 minutes.
45988807|NCT01248455|Drug|(Anti-KIR)|Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
45988808|NCT00511680|Behavioral|Behavioral Based In-Home Intervention|The 10 session intervention delivered by a social worker in the home includes five treatment components (education, referral, care management, stress reduction, behavioral activation). Each component has been shown to be effective in treating depression in previous research.
45988809|NCT00511953|Drug|Gabapentin Extended Release tablets|1800mg
45988810|NCT00511953|Drug|Gabapentin|1800mg
45988811|NCT01249820|Drug|anidulafungin 200 mg q48h|Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)
45833380|NCT05686746|Drug|Baricitinib 2 MG|2 mg oral daily
45833381|NCT05686746|Drug|MMF|1000 mg oral daily
45988812|NCT01249820|Drug|anidulafungin 300 mg q72h|Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
46083654|NCT02708160|Drug|1.1% Fluoride toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
45988813|NCT02952378|Drug|Albumins|Infusion of 3ml/kg bodyweight of hyperoncotic albumin 20% during 30 minutes.
45988814|NCT01247090|Drug|Vasopressin - Very Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.15 mU * 70 kg, or 10.5 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
45988815|NCT01247090|Drug|Vasopressin - Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.30 mU * 70 kg, or 21 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
45988816|NCT01247090|Drug|Placebo Comparator|Participants in Group 3 will receive an equal volume of normal saline (placebo) infusion during their standard thrice-weekly dialysis treatments.
45988817|NCT02952417|Other|Excess mortality|Relative survival was defined as the observed survival among patients with STEMI and NSTEMI divided by the expected survival in the age, sex and year matched populace of Sweden.
45988818|NCT00504764|Drug|Arsenic Trioxide|"Induction ATO 0.15 mg/kg/day IV until CR or a maximum of 60 days In isolated molecular relapse ATO will be administered at same dose, 5 days a week, during 6 weeks.~Consolidation ATO 0.15 mg/kg/day IV 5 days week, during 5 weeks"
45988819|NCT00504764|Procedure|Autologous Transplantation|Autologous Transplantation
45988820|NCT00504764|Procedure|Allogenic Transplantation|Allogenic Transplantation
45988821|NCT00504764|Drug|ATRA|Consolidation: ATRA 45 mg/m²/day oral during 5 weeks
45988822|NCT04519073|Biological|V-306 candidate vaccine|"Each V-306 monomer consists of the following elements:~A Lipopeptide Building Block that contains an optimized, artificially designed coiled-coil domain, which self-assembles into highly stable trimers.~A 'universal' T-helper epitope fused at the C-terminus of the coiled-coil domain.~A lipid component di-palmitoyl-S-glyceryl cysteine (Pam2C), fused at the N-terminus.~A mimetic of the Palivizumab epitope, referred to RSV F-protein site II antigen mimetic (FsIIm), which is coupled near the C-terminus of the Lipopeptide Building Block via a short maleimide-PEG-oxime linker."
45988823|NCT02952144|Device|Lixelle® treatment|The treatment will be performed with the Lixelle® column connected to upstream of the dialyzer in series on the routine HD circuit according to the description in the IFU. The dialyzer and the Kt/V urea in the conventional HD for each patient will be kept equal in Lixelle®-treatment. Since the maximum blood flow rate for Lixelle® is 250 ml/min, the dialysis time will be extended to achieve the target Kt/V urea. The study will not restrict the type of hemodialyzer and other conditions of HD as specified by the physician. However, any changes to the HD procedure should be recorded properly, and the Kt/V urea should be kept equal to that at the enrollment.
45988824|NCT00504296|Drug|HDAC inhibitor SB939|SB939 will be administered initially for 3 consecutive days every other week at the first dose level and then for 5 consecutive days every other week at escalating doses.
45988825|NCT00504296|Other|immunoenzyme technique|
45988826|NCT00504296|Other|immunohistochemistry staining method|
45988827|NCT00504296|Other|immunologic technique|
45988828|NCT00504296|Other|laboratory biomarker analysis|
45988829|NCT00504296|Other|liquid chromatography|
45988830|NCT00504296|Other|mass spectrometry|
45988831|NCT00504296|Other|pharmacological study|
45988832|NCT02952027|Behavioral|Use-recording, patient-reminder alarm for incentive spirometry|
45988833|NCT00504335|Drug|BIO 300 Capsules|
45988834|NCT02951910|Device|Ophylosa tear supplement|Tear film dynamics is assessed by non-invasive tear film breakup time (NI-BUT) in parallel with continuous recordings of ocular sensations during forced blinking. Corneal sensitivity thresholds to selective stimulation of corneal mechanonociceptors, thermal receptors and chemical nociceptors are assessed using the Belmonte gas esthesiometer. All baseline measurements are repeated after one month of tear supplementation with zinc-hyaluronate (Ophylosa eye drop) 4x/day
45988835|NCT04516577|Other|Assesssing the severity of pulmonary alveolar proteinosis|Three severity scores will be used to assess the severity of patients with pulmonary alveolar proteinosis.
45988836|NCT02951754|Drug|Immediate-release Methylphenidate|Standard initial dose of 10 mg, twice or three times daily with doses increasing weekly until symptom control or occurrence of limiting adverse effects
45988837|NCT00504374|Behavioral|Questionnaire|Symptoms questionnaire lasting about 5 to 10 minutes.
45988838|NCT02952066|Procedure|Bronchial biopsy|Bronchial tissue taken during biopsy
45988839|NCT00504413|Drug|midazolam(drug), digoxin (drug)|Midazolam (2mg po) and digoxin (0.5mg po) will be administered one time, an hour apart. Blood concentration will be collected at various points in an 8 hour period.
45988840|NCT00504413|Drug|Bupropion (drug)|Bupropion (150mg po) will be administered one time on a separate visit. Blood concentrations will be collected at various points in a 72 hour period.
45988841|NCT00504413|Drug|Methadone (drug)|Methadone (10mg po) will be administered at a separate visit 2 weeks after the bupropion visit. The dose is given once. Blood concentrations will be measured at various points in a 72 hour period. Pupil constriction will be measured and urine will be collected during this period as well.
45988842|NCT00513045|Behavioral|IRT|Cognitive behavior intervention
45988843|NCT00513045|Behavioral|Exposure|Exposure intervention
45988844|NCT00513084|Behavioral|SDT and Motivational Interviewing in Obesity Treatment|Thirty group sessions, designed to follow SDT, covering PA, eating/nutrition, body image, and other cognitive-behavioral contents. Central to the intervention are improving autonomy, intrinsic motivation, and self-regulation of behavior change. Accepting ambivalence for change, rolling with resistance, and developing discrepancy were used throughout the program, with an emphasis on promoting intrinsic, self-regulated motivation for exercise and weight control.
45988845|NCT02275325|Other|Preoperative vestibular rehabilitation|12 one-hour sessions with exercises of balance on unstable conditions (foam, tilt of the platform, biofeedback)
45988846|NCT00513123|Procedure|Colposcopy|As part of routine colposcopic evaluation, patients will undergo routine colposcopy with the digital colposcope (DC) will then be used to take an image of the vagina and cervix.
45988847|NCT02275403|Procedure|Acupuncture|10 x weekly sessions (40 minutes per session) of acupuncture by a trained therapist.
45988848|NCT02275403|Other|Medication taken to manage the symptom burden of CIPN|Standard of care medication to manage CIPN symptoms, as determined by a clinician in accordance with local trust policy. The standard care for CIPN includes a variety of oral medications to manage the altered sensations caused by damage to the peripheral nerves. These oral medications include, but are not limited to; Gabapentin, Amitriptyline and Pregabalin. In addition, medicated creams and gels may be used.
45988849|NCT04517825|Diagnostic Test|Cepheid Xpert HIV-1 Viral Load Assay|Rapid, on-site molecular HIV-1 viral load testing used in accordance with cleared/approved labeling
45988850|NCT01249976|Other|blood culture|blood culture
45988851|NCT01244438|Drug|FP-1039|FP-1039 will be administered at a dose up to 16 mg/kg intravenously over 30 minutes once a week.
45988852|NCT02951793|Other|AUDIT-C|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including AUDIT-C about his/her alcohol behavior during last year and will be categorized into two groups: Those with AUDIT-C>4 versus AUDIT-C of 4 or below.
45988853|NCT02951793|Other|Smoking history|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including smoking history during last year and will be categorized into two groups: Current smoker versus ex- or never smoker (we also recorded smoking pack-years to distinguish heavy smokers)
45988854|NCT02951793|Other|Prior psychotropic medication use|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including psychotropic medication use prior admission to ICU and will be categorized into two groups: Those who use psychotropic medication versus those who do not use psychotropic medication.
45988855|NCT00512187|Other|low calorie diet|Low calorie diet was designed to achieve a loss of 5-10% of initial weight. All enrolled patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range 1200-1500 Kcal/day for women, 1300-1600 Kcal/day for men). Calorie intake consisted approximately of 60% carbohydrates, 25% fat, 15% protein
45988856|NCT01241864|Biological|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression varies but may include prograf, cellcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
45988857|NCT01241864|Procedure|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
45988858|NCT02951715|Drug|zinc gluconate|2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day)
45833382|NCT03403686|Biological|blood draw|Blood sample will be obtained and CD34+ cells will be isolated for functional testing.
45988859|NCT01243658|Drug|Oxytocin|Oxytocin
45833383|NCT04400760|Drug|DAPA Tx|The intervention, dapagliflozin will be administered 10mg per oral daily for two weeks.
45833384|NCT03083574|Device|Photopheresis Theraflex ECP™|The Macopharma (Theraflex ECP™) approach is based on a multistep procedure involving (1) standard mononuclear cell apheresis, (2) injection of the 8-Mop in the apheresis bag, (3) UVA exposure of the bag in the Macogenic illumination device, and (4) reinfusion of the cells into the patients.
45833385|NCT05686668|Other|assessment by scales|Assessment from many scales: AASP, HARS, HDRS, CORE, EES, CISS, SHAPS at V1 Assessment from many scales: AASP, HARS, HDRS, CORE, EES, SHAPS at V2
45833386|NCT05686512|Behavioral|Step-by-Step|"The Step-by-Step follows a stepped care approach, were all children (and caregivers) complete the first step (a brief group intervention followed by an individual session). Those with more needs are offered to continue to step 2 where individual CBT is given. See Figure 1 for a schematic representation of the stepped care approach, and Table 2 for an overview of session content.~Step 1 Session 1-4: Group sessions including psychoeducation, parenting skills and mapping stress and vulnerability factors, exposure and coping skills (90 minutes) Session 5: Individual session - If ending after step 1 a maintenance plan is completed. If continuing to step 2 continued exposure and selection of optional focus areas such as emotion regulation, social skills, stress- and vulnerability factors, child worry or parental worry. (45 minutes)~Step 2 Session 6-8: Individual sessions - Exposure and selected focus areas. (45 minutes)"
45988860|NCT01243658|Other|placebo|placebo
45988861|NCT02951676|Procedure|Extraction|Extraction of impacted third molar teeth
45988862|NCT01249664|Biological|VEGF Trap-Eye (BAY86-5321)|1 intravitreal injection of the experimental drug, followed by monthly re-injections if needed
45988863|NCT01249664|Procedure|No Drug|Sham procedure NOT involving injection of any substance; patient´s eye is anesthetized and a syringe without needle gently pressed on the cornea
45988864|NCT00513162|Drug|Valproate|Starting Dose of 10 mg/kg By Mouth Daily
45988865|NCT00513162|Drug|Etoposide|25 - 50 mg/m^2 By Mouth Daily
45988866|NCT00512226|Other|Cardiac and Liver T2* MRI|Laboratory examinations that are routinely used in follow up of those patients and T2* MRI analysis.
45988867|NCT04513418|Dietary Supplement|Preoperative immunonutrition|Preoperative immunonutrition includes an omega-3 fatty-acid enriched enteral nutritional emulsion given by oral intake, nasogastric feeding tube or jejunostomy 600ml per day, lasting for the whole period of neoadjuvant chemoradiation. Meanwhile, oral intake is encouraged to reach 25-30kcal/kg through regular food.
45988868|NCT00513201|Drug|lyspro|
45988869|NCT00513201|Drug|regular insulin|
45988870|NCT00513279|Drug|GSK618334|GSK618334 will be available as white to off-white coated tablets. GSK618334 will be swallowed with 250 milliliters (mL) of water.
45988871|NCT00513279|Drug|GSK618334 matching placebo tablets|GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient. GSK618334 matching placebo will be swallowed with 250 mL of water.
45988872|NCT00512265|Drug|n-acetylcysteine|150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3
45988873|NCT00512265|Drug|250mL glucose 5%|placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
45988874|NCT00504803|Procedure|Mesenchymal stem cell infusion|Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.
45988875|NCT00513396|Drug|Isoniazid|"High-dose isoniazid (16-18 mg/kg/day) in addition to standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)~Regular dose isoniazid (5 mg/kg/day) in addition to standard regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)"
45988876|NCT00513396|Drug|Placebo|Similar appearing and similarly packaged placebo tablets in addition to the standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
45988877|NCT01249274|Drug|Progesterone|100mgs progesterone twice daily
45988878|NCT01249274|Other|Placebo|Matched placebo pills to be taken twice daily
45988879|NCT00512304|Procedure|association chemotherapy and radiochemotherapy|
45988880|NCT04695834|Procedure|Neurolysis peroneal nerve|The surgical approach for entrapment at the fibular head is usually through a curvilinear incision just distal to the fibular head. The subcutaneous tissue is bluntly dissected, and the common peroneal nerve is identified proximal to the peroneus longus muscle. The peroneal nerve is then released from the surrounding fibrous tissue and fascia. The nerve is decompressed distally as it dives under the peroneus longus muscle. The decompression at this site is essential. Certain authors state that an adequate decompression should extend beyond the bifurcation in the deep and superficial peroneal nerve and should involve cutting the intermuscular septa
45988881|NCT04695834|Other|Maximal physiotherapy|Mobilization of ankle and foot, stretching of the calf muscles (prevention of contractures) Tonification of the dorsiflexion- and eversion muscles of the ankle Proprioceptive training Gait rehabilitation Home exercise schedule
45988882|NCT04695756|Other|COVID-19 pandemic|The exposure of this observational study is the COVID-19 pandemic
45988883|NCT00512382|Device|WEEM - Wheezy Monitoring|loudspeaker recording (WEEM) is attached externally to the chest simultaneously with PH-Impedance.
45988884|NCT00512421|Procedure|computer-assisted surgery|
45988885|NCT00504842|Drug|MRX-801|
45833387|NCT05686512|Behavioral|Cool Kids|"The Cool Kids Program is an Australian manualized group CBT treatment of child anxiety, which has been broadly implemented in Sweden. Several studies have found evidence of its efficacy.~Session 1-10: Group sessions including psychoeducation, cognitive restructuring (gather evidence to reevaluate anxiety related thoughts), parent skills, exposure, social skills, coping skills (cognitive and behavioral strategies to handle anxiety reactions, learning problem-solving skills). (120 minutes)"
45988886|NCT00504842|Drug|Placebo|
45988887|NCT00512460|Drug|RTA 744|4.8 mg/m^2 by vein Over 2 Hours On Days 1-3.
45988888|NCT01249157|Device|Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)|An additional 5 women will be enrolled at the beginning of the study for training purposes only and will not be included in the assessment of this study. Once the patient has had both breast MRI and PEM, the location of each site of potential breast cancer will be listed for each modality. The location of each abnormality on each imaging examination will be documented. Once the histopathologic evaluation has been performed, the pathology results will be compared to the imaging results for each modality. Furthermore, comparison of the performance of MRI and PEM will then be made with the pathological results as the truth. Comparison of the histology and biomarkers in each lesion detected by each modality will be done in order to determine if these factors affect detection by each modality.
46083655|NCT02708160|Drug|0.243% Fluoride toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
45833388|NCT03832452|Drug|Lucerastat (Treatment A)|2000 and 4000 mg; hard capsules for oral administration
45833389|NCT03832452|Other|Placebo|hard capsules for oral administration
45833390|NCT03832452|Drug|Moxifloxacin|400 mg; film-coated tablets for oral administration
45833391|NCT03832452|Drug|Lucerastat (Treatment B)|1000 mg; hard capsules for oral administration
45833392|NCT03832452|Drug|Lucerastat (Treatment C)|4000 mg; hard capsules for oral administration
45833393|NCT03343860|Procedure|AT case 1.1|"In the case of AT at the time of ablation :~In the case of sinus rhythm restoration, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
45833394|NCT03343860|Procedure|AT case 2.1|"In the case of AT at the time of ablation :~In the case of sinus rhythm restoration, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
45988889|NCT00512499|Behavioral|Control group|Informing patient that fracture probably of fragility origin and suggesting to consult primary care practitioner. After 8 months, if not treated, Intensive intervention will be offered
45988890|NCT00512499|Behavioral|Minimal Intervention|Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
45988891|NCT00512499|Behavioral|Intensive Intervention|"INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.~Sequential serum will be stored frozen in order to measure levels of blood markers of bone metabolism (at a later date)"
45988892|NCT00504452|Drug|KP-1461|Oral dosage, 1600 mg bid for 124 days
45988893|NCT00512538|Device|Bi-layered cell therapy (Apligraf)|
45988894|NCT00504920|Behavioral|Questionnaire|Questionnaires (30 minutes each) + instruction on telephone survey system for measuring symptoms. Questionnaires 2 times a week while in the hospital or until able to use the telephone survey system.
45988895|NCT00513513|Drug|TMC114 (darunavir) / ritonavir|
45988896|NCT00504959|Drug|ranibizumab|
45988897|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu 2 times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
45988898|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
45988899|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 2 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
45673718|NCT04751708|Procedure|endovascular treatment|For patients randomized to endovascular treatment arm, EVT has to be initiated within 12 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. The endovascular procedures allowed by the steering committee include mechanical thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation, or any combination of above procedures. We recommend applying ADAPT as the first choice of treatment. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
45988900|NCT00504998|Genetic|Rexin-G|Dose Schedule: 3 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has less than Grade 1 or less toxicity.
45988901|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 4 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
45988902|NCT04695561|Other|Self Myofascial Relaxation|Total of 12 times for 6 weeks
45988903|NCT04695561|Other|Instrument Assisted Soft Tissue Mobilization|Total of 12 times for 6 weeks
45988904|NCT04695561|Other|Only Exercise (Control)|Every day for 6 weeks
45988905|NCT04512794|Device|AcQMap High Resolution Imaging and Mapping System|Evaluate the safety and effectiveness of the AcQMap System in mapping atrial arrhythmias when a specific procedure work flow is followed.
45673719|NCT04751708|Other|best medical management|best medical management
45673720|NCT02147132|Drug|Nicotine Nasal Spray|7 days. 1 mg/dose, up to 40x/day.
45988906|NCT00512616|Drug|Ceftriaxone|
45988907|NCT01249118|Drug|GDC-0973 IV Infusion|IV infusion.
45988908|NCT01249118|Drug|GDC-0973 Oral Capsules|Oral dose.
45988909|NCT00512655|Behavioral|Fall prevention course|Duration: 5 weeks, 2 sessions of 2 hours per week: 10 sessions in total.
45988910|NCT00505037|Drug|ASP1585|Oral
45988911|NCT00505037|Drug|Placebo|Oral
45988912|NCT00505037|Drug|Sevelamer hydrochloride|Oral
45988913|NCT00513552|Drug|Rifabutin, Clarithromycin, and Clofazimine|Rifabutin 150 mg by mouth twice daily, Clarithromycin 250 mg by mouth twice a day, and Clofazimine 100 mg by mouth each morning
45988914|NCT02275169|Drug|Urofollitropin|Urofollitropin 75 IU 2 ampoules three times a week for three months
45988915|NCT02275169|Other|Placebo|Placebo ampoules administered three times a week for three months
45988916|NCT02275208|Procedure|SIPS the stomach, intestinal, pylorus, sparing procedure|Bariatric Procedure
45988917|NCT00513630|Drug|Glipizide|
45988918|NCT00513630|Drug|Metformin|
46083656|NCT00634868|Other|Qray light therapy device|The light is filtered from harmful UV and InfraRed light and only light at wavelight of 405nm until 1000nm is delivered.
45988919|NCT02275247|Drug|Stellate Ganglion Block|stellate ganglion block will be administered using either 6-8mL saline (Group 1) or 0.25% ropivacaine 6-8mL (Group 2)
45988920|NCT00513669|Biological|PEV 301& 302 in virosomes|PEV 301 50 µg plus PEV 302 10 µg formulated in virosomes and injected at day 0 and 90
45988921|NCT00513669|Biological|Inflexal V (active comparator)|Inflexal V is a marketed influenza vaccine that will be given at day 0 and 90
45988922|NCT04696679|Other|Patient Quality of life assessment|Other: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France
45988923|NCT04696679|Other|Control group Quality of life assessment|Other: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France relationships with teachers, schoolwork, and self-esteem)
45673721|NCT02147132|Drug|Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
45988924|NCT04515719|Biological|Belimumab|Belimumab 2mg/kg intravenously
45988925|NCT04515719|Biological|Placebo|Placebo intravenously
45988926|NCT00513786|Drug|Carboplatin|AUC (area under curve) 5 Intervenous (IV) over 30 minutes given every 21 days for a maximum of 6 cycles.
45988927|NCT00513786|Drug|Paclitaxel|175 mg/m2 over 3 hours given every 21 days for a maximum of 6 cycles.
45988928|NCT00513786|Drug|bevacizumab|15 mg/kg intervenous (IV) given every 21 days for a maximum of 6 cycles.
45988929|NCT00504491|Drug|Rituximab-CHOP-Alemtuzumab|Four Rituximab - CHOP courses will be given The courses will be given every 21 days
45988930|NCT00512811|Drug|furosemide|
45988931|NCT04516070|Other|Questionnaire Administration|Ancillary studies
45673722|NCT02147132|Drug|Placebo Nasal Spray|7 days. 1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day. This will appear similar to the Nicotine Nasal Spray, but will be a placebo.
45673723|NCT02147132|Drug|Placebo Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.
45673724|NCT02146430|Drug|DS-5565|DS-5565 15 mg tablet for oral administration
45673725|NCT02146430|Drug|Pregabalin|Pregabalin 150 mg capsule for oral administration
45833395|NCT03343860|Procedure|AT case 1.2|"In the case of AT at the time of ablation :~In the case of termination to another AT, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
45833396|NCT03343860|Procedure|AT case 1.3|"In the case of AT at the time of ablation :~In the case of AF deterioration, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps"
45673726|NCT02146430|Drug|Placebo tablet|Placebo tablet (matching DS-5565) for oral administration
45673727|NCT02146430|Drug|Placebo capsule|Placebo capsule (matching pregabalin) for oral administration
45988932|NCT04516070|Radiation|Stereotactic Radiosurgery|Undergo SRS
45988933|NCT00513825|Drug|Sodium Bicarbonate|IV solution of NaCl 0.45% (Arm 1) or IV 75 cc of sodium bicarbonate 8.4% solved in 1 liter of NaCl 0.45% (Arm 2) . Each fluid is infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
45673728|NCT02129192|Drug|Amlodipine 5mg capsule|Amlodipine 5mg capsule
45673729|NCT02129192|Drug|T80/H12.5 mg FDC tablet|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg FDC tablet
45673730|NCT02129192|Drug|T80/A5/H12.5 mg FDC tablet|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg FDC tablet
45988934|NCT04518254|Biological|Blood collection|A blood sample will be collected before and after treatment administration
45988935|NCT04518254|Drug|L-Tyrosine 500 Mg|The participants will be administered 4 capsules of L-Tyrosine 500 mg per oral route
45988936|NCT04518254|Drug|Placebo|The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route
45988937|NCT04518254|Behavioral|Cognitive tasks|The participants will perform cognitive decision-making tasks: Simon task and masking task after treatment administration
45988938|NCT04518254|Other|Stress exposure|Unpleasant but not painful skin stimulations will be administered to the participants at variable intervals on the left leg during the cognitive tasks
45988939|NCT04518254|Behavioral|Anxiety scale|Spielberger's State Trait Anxiety Inventory (STAI) will be filled by the participants before and after cognitive tasks
45988940|NCT04518254|Device|Electromyography (EMG)|Electromyography measurements will be performed during cognitive tasks.
45988941|NCT04518254|Device|Electroencephalography (EEG)|Electroencephalography measurements will be performed during cognitive tasks.
45988942|NCT00513864|Drug|Dextromethorphan|one time dose - 0.3mg/kg PO
45988943|NCT00513864|Drug|Codeine|one time dose - 2mg/kg PO
46083657|NCT00634868|Device|Qray light therapy device-Sham|non curative light- the device emits the same broad light, but with very low intensity
46083658|NCT02708082|Device|OCT scanning and HFA perimetry|Imaging of the optic nerve and nerve fiber layer / measurement of visual field
45673731|NCT02105948|Drug|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
45988944|NCT00513864|Drug|Morphine|one time dose - 0.15mg/kg IV
45988945|NCT01248884|Biological|Infanrix hexa™|3 doses, intramuscular into left thigh
45988946|NCT01248884|Biological|Prevenar 13®|3 co-administered doses, intramuscular into right thigh
45988947|NCT01248884|Biological|GSK217744|3 doses, intramuscular into left thigh
45988948|NCT00512850|Dietary Supplement|Folic acid|Intervention group 1g folic acid per day
45988949|NCT00512850|Other|Placebo|One placebo pill per day
45673732|NCT02105948|Drug|Placebo|Sterile 0.9% sodium chloride solution
45988950|NCT04695522|Biological|ADR-002K administration|ADR-002K administration
45988951|NCT00512889|Biological|therapeutic autologous lymphocytes|Autologous CTL generated from peripheral blood following culture with MART1/Melan-A peptide pulsed aAPC.
45988952|NCT00512889|Genetic|Use of an artificial antigen presenting cell (aAPC) to generate CTL|A genetically modified artificial antigen presenting cell (aAPC) is used in the generation of anti-tumor CTL.
45988953|NCT00512889|Drug|GM-CSF|GM-CSF will be used as an immune activator and combined with the infusion of MART1/Melan-A specific CTL.
45988954|NCT00512889|Radiation|Irradiation of cutaneous tumor lesion|Irradiation of cutaneous melanoma lesion will be combined with the infusion of MART1/Melan-A specific CTL.
45988955|NCT01248728|Dietary Supplement|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of Nutra Sea HP (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
45988956|NCT01248728|Dietary Supplement|Placebo|Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
45988957|NCT00512928|Drug|acenocoumarol|max 5 mg per day during 10 weeks
45988958|NCT00512928|Dietary Supplement|menaquinone-7|In successive weeks (6 weeks) the dosage is increased over the range 10 µg to 20 µg increasing to 45 µg MK-7 for the final week.
45988959|NCT04695405|Genetic|Saliva Genetic Samples|Patients will provide two saliva swabs containing genetic materials.
45988960|NCT02951442|Biological|Biological sample|
45988961|NCT02951442|Procedure|Non invasive Arterial investigations|
45988962|NCT02951442|Procedure|Abdominal tomodensitometry|
45673733|NCT02128724|Drug|BKM120|Buparlisib is a highly specific inhibitor of phosphatidylinositol 3-kinase (PI3K). Buparlisib is supplied as 10mg and 50mg hard gelatin capsules.
45673734|NCT02128490|Drug|Febuxostat IR|Febuxostat IR over-encapsulated tablets
45673735|NCT02128490|Drug|Febuxostat XR|Febuxostat over-encapsulated capsules
45988963|NCT02951247|Device|Hearing Aid|Successor of Phonak Virto V90-10 NW O
45988964|NCT00505154|Drug|Rosuvastatin|Rosuvastatin 10 mg tablets od for 6 months
45988965|NCT00505154|Drug|placebo|placebo
45988966|NCT00513903|Behavioral|Minimal intervention|Minimal intervention patients will be seen by a clinical pharmacist during the hospitalization period to improve continuity of pharmacy care following hospital discharge.
45673736|NCT02128490|Drug|Febuxostat placebo|Febuxostat IR and XR placebo-matching capsules
45673737|NCT02128490|Drug|Colchicine|Colchicine tablets
45673738|NCT02128490|Drug|Naproxen|Naproxen tablets
45673739|NCT02128490|Drug|Lansoprazole|Lansoprazole capsules
45673740|NCT02146352|Device|AXIOS Stent with Electrocautery Enhanced Delivery System|Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.
45673741|NCT02105636|Drug|Nivolumab|
45673742|NCT02105636|Drug|Cetuximab|
45673743|NCT02105636|Drug|Methotrexate|
45673744|NCT02105636|Drug|Docetaxel|
45988967|NCT00513903|Behavioral|Enhanced Intervention|Enhanced intervention patients will be visited in the hospital and will also be called by the clinical pharmacist following discharge to follow-up on any problems that might have developed after discharge.
45988968|NCT00513942|Other|Fetal Movement Counting|Women in the intervention group will receive an information pamphlet. The main items will be basic information and interpretation of fetal activity and instructions when to contact health professionals if experiencing DFM.
45988969|NCT01246973|Drug|Curcumin|4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
45988970|NCT01246973|Drug|Placebo|4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
45988971|NCT00514605|Other|Behavioral counseling|Standard-of-Care counseling at the Point-of-Care.
45988972|NCT00514605|Device|HIV-1 Antibody Test Kit|Assay to detect HIV antibodies
45988973|NCT01246466|Device|Hybrid: AtriCure Bipolar System & EP ablation procedure|AtriCure Bipolar System plus a catheter ablation
45988974|NCT00513981|Drug|leucovorin calcium|
45988975|NCT00513981|Drug|methotrexate|
45988976|NCT00513981|Other|mass spectrometry|
45988977|NCT00513981|Other|pharmacological study|
45988978|NCT00505232|Drug|Y-90 Ibritumomab tiuxetan|"Study Design~The present study will be split into two cohorts:~Patients younger than 60 years who will receive 8 chemotherapy cycles~Patients older than 60 years who will receive 6 chemotherapy cycles~The induction schema summarises as follows :~Anti-CD20/Hyper -CVAD chemotherapy will be alternated with anti-CD20 +MTX/Ara-C chemotherapy twice. Afterward, response will be evaluated, followed by, either, four cycles further patients younger than 60 years who will obtain a CR or PR, or 2 cycles patients older than 60 y. (see figure 1 and flow chart).~Consolidation treatment will consist in a single dose of Y90-Ibritumomab -Tiuxetan (Zevalin) [0.4 mCi/Kg b.w or 0.3 mCi/kg if platelets < 100,000/µl] will be administered 8 to 12 weeks after last chemotherapy."
45988979|NCT00514644|Other|Carotid ultrasound examination|Ultrasonographic examination of the carotid arteries to determine the grade of carotid stenosis.
45988980|NCT00514644|Other|Panorama examination|"Examination with the odontological radiological method Panorama, including a frontal verification image"
45988981|NCT02275442|Other|EPICES scale|
45988982|NCT00514722|Other|umbilical cord stem cells|umbilical cord stem cell allogeneic transplantation
45988983|NCT01245764|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)|
45988984|NCT01245764|Biological|Placebo|
45988985|NCT00514059|Drug|Boostrix polio|1 dose (0.5 ml) i.m.
45988986|NCT00514761|Drug|AZD6244|oral vial
45988987|NCT00514761|Drug|Capecitabine|oral tablet
45988988|NCT04514315|Procedure|Minimally invasive cardiac valvular surgery|Minimally invasive valve surgery via right mini-thoracotomy.
45988989|NCT04514315|Procedure|Conventional cardiac valvular surgery|Conventional valve surgery via full median sternotomy
45988990|NCT03459261|Diagnostic Test|blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4)|Laboratory analyses of peripheral venous blood on admission (blood sample ADD), 24 hours after surgery (blood sample POD1) and fourth-day after surgery (blood sample POD4) included biochemical analysis, complete blood count, C-reactive protein (CPR), procalcitonin (PCT), albumin/protein level, prothrombin time and international normalized ratio (INR) (only on admission) and for determination of cytokines: tumor necrosis factor alpha (TFN-α), interleukin-6 (IL-6), interleukin-10 (IL-10).
45988991|NCT04695600|Drug|Botulinum Toxin Type A Injection [Botox]|100 units of Botulinum toxin A (Botox, Allergan, CA) under endoscopic guidance will be injected in the cricopharyngeus muscle
45833397|NCT03343860|Procedure|AT case 1.4|"In the case of AT at the time of ablation :~In the case of no AT termination, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
45833398|NCT03343860|Procedure|AT case 2.2|"In the case of AT at the time of ablation :~In the case of termination to another AT, ablation of the subsequent AT will be performed until sinus rhythm restoration. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
45988992|NCT01245140|Drug|alitretinoin|to receive verum (20 patients)
45988993|NCT01245140|Drug|Placebo|to receive placebo (10 patients)
45988994|NCT00514800|Behavioral|Intervention - a validated home BP monitor and support from the specialist nurse|
45988995|NCT00514800|Behavioral|Control - usual care (BP monitoring by their practice)|"Patients will not receive a blood pressure monitor and will continue with usual GP care for hypertension management.~GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings."
45988996|NCT02951637|Drug|Pemetrexed plus carboplatin combined with gefitinib|Pemetrexed (500mg/m(2) d1) plus carboplatin (AUC5 d1) combined with gefitinib (250mg d4-28) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with gefitinib every four weeks.
45988997|NCT02951637|Drug|Gefitinib|Gefitinib (250mg daily)
45988998|NCT01245101|Drug|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
45988999|NCT01245101|Drug|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
45989000|NCT00514839|Behavioral|Motivational Interviewing|Two sessions of Motivational Interviewing (after baseline assessment and 4 weeks later) plus one individualized feedback based on the Transtheoretical Model of Behavior Change (8 weeks after baseline assessment)
45673745|NCT04748042|Drug|Abiraterone|Abiraterone 1000 mg by mouth per day for approximately 6 months.
45673746|NCT04748042|Drug|Prednisone|Prednisone 5 mg by mouth per day for approximately 6 months.
45673747|NCT04748042|Radiation|External Beam Radiotherapy|External beam radiotherapy, dose will depend on lesion location. Completed within 40 days of study start.
45673748|NCT04748042|Biological|Androgen Deprivation Therapy (ADT)|ADT by luteinizing hormone-releasing hormone (LHRH) agonist or antagonist for 6 months.
45673749|NCT04748042|Drug|Olaparib|Olaparib tablets 300 mg by mouth twice a day for approximately 5 months.
45833399|NCT03343860|Procedure|AT case 2.3|"In the case of AT at the time of ablation :~In the case of AF deterioration, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
45833400|NCT03343860|Procedure|AT case 2.4|"In the case of AT at the time of ablation :~In the case of no AT termination, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
45989001|NCT02951520|Procedure|new technique for lower limb nerve blocks using a single skin puncture (SOFT block)|The patients will be in supine position. The block needle will be inserted at the inguinal crease (medial to the femoral vein) and advanced towards the femoral nerve, then redirected towards the obturator nerve (deep to the pectineus muscle). Lastly, it will be redirected posteriorly towards the sciatic nerve (deep to the quadratus femoris muscle). A ropivacaine-lidocaine-epinephrine mixture will be used to block these nerves. The block success rate (painless surgery), performance time and patient discomfort will be recorded.
45989002|NCT01245062|Drug|GSK1120212|MEK inhibitor
45673750|NCT01626872|Drug|MP-214 3mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
45989003|NCT01245062|Drug|Chemotherapy|Investigator Choice of DTIC or paclitaxel
45989004|NCT04695717|Biological|IVACFLU-S|"The Seasonal Inactivated, Split Virion, Trivalent Influenza Vaccine (TIV) were purified by the method of super centrifugation to create gradient segments in sucrose sugar produced by IVAC, or placebo produced by IVAC. Vaccines are produced on eggs, inactivated with formaldehyde. The dose of the vaccine tested was 15 mcg of HA for each antigen component in 0.5 ml.~The influenza virus strains used to produce the 2020-2021 seasonal vaccine will also be provided by the NIBSC, which will be used according to WHO's recommendation, which is expected to include the following Southern Hemisphere strains:~Influenza A / H1N1 strain: Recombinant strain IVR-190 44250 E12 of the strain (A / Brisbane / 02/2018).~Influenza strain A / H3N2: strain IVR-197 (H3N2) 44850 E14 recombinant strain (A / South Australia / 34/2019).~Flu strain B (B / Washington / February 2019)."
45989005|NCT02951286|Device|high pull headgear + OBA|a modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied in compination with a high pull headgear.
45989006|NCT02951286|Device|OBA (control group)|A modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied alone (Control group)
45989007|NCT01244984|Drug|Fluticasone Furoate/GW642444 Inhalation Powder|Fluticasone Furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
45989008|NCT01244984|Drug|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate inhalation powder inhaled orally once daily for 52 weeks
45989009|NCT04695483|Drug|Corifollitropin alfa|Controlled ovarian stimulation long-acting protocol
45989010|NCT04695483|Drug|Follitropin Beta|Daily controlled ovarian stimulation protocol
45989011|NCT02951403|Procedure|Elbow arthroscopy|Arthroscopic debridement, osteophyte excision, loose body extirpation is carried on to patients.
45989012|NCT02951403|Other|Conservative treatment|Physiotherapy protocol is introduced to patients.
45989013|NCT01244516|Device|galyfilcon A, BC 8.30|galyfilcon A, BC 8.30 soft contact lens
45989014|NCT01244516|Device|lotrafilcon B, BC 8.60|lotrafilcon B, BC 8.60 soft contact lens
45989015|NCT01244516|Device|comfilcon A, BC 8.60|comfilcon A, BC 8.60 soft contact lens
45673751|NCT01626872|Drug|MP-214 6mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
45673752|NCT01626872|Drug|MP-214 9mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
45989016|NCT02951208|Device|Active tDCS|Active anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.
45989017|NCT02951208|Behavioral|Active VR Motivation Training|Active computerized treatment with a virtual reality-based motivation training program, administered for 60 minutes, three times per week for four weeks.
45989018|NCT02951208|Device|Sham tDCS|Sham anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.
45989019|NCT02951208|Behavioral|Sham VR Motivation Training|Sham computerized training in a virtual reality-based environment, administered for 60 minutes, three times per week for four weeks.
45989020|NCT02951325|Other|Adjuvant RT|"Radiation therapy:~All patients will be offered conformal technique with IMRT +/- image guidance. The adjuvant RT will start within 8 weeks from the date of surgery if chemotherapy not planned or 4 weeks from the date of last adjuvant chemo cycle.~Dose:~•50.4 Gray (Gy) in 28 fractions (1.8Gy/#) for the nodal PTV. For R1 and/or R2 resection increased to 54-56 Gy in 28 fractions based on the constraints achieved during planning.~Patient assessments:~Clinical:~Toxicity:~Weekly RT with toxicity scoring.~RTOG toxicity criteria at baseline, 6-8 weeks post RT and f/b 3 monthly x 2 years and 6 monthly x 5 years.~QOL will be assessed at baseline f/b 3-6 monthly.~Disease evaluation:~i. first f/u all patients will be at 6-8 week to assess toxicity. ii. Clinical evaluation of the disease will be done at each f/u visit. iii. CT scan (abdomen and pelvis) 6 monthly from visit 2 onwards up to 2 years f/b 12 monthly or as clinically indicated."
45989021|NCT02955680|Procedure|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath.  At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
45989022|NCT02955680|Procedure|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath. "
45989023|NCT02951169|Other|No intervention|No intervention. Treatment are accordance with clinical practice.
45989024|NCT01244126|Drug|Intranasal fentanyl|2mcg/kg fentanyl IN
45673753|NCT01626872|Drug|Risperidone 4mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4. In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
45989025|NCT01244126|Drug|morphine IM|0.1 mg/kg morphine IM for postop pain
45989026|NCT01244126|Drug|IV morphine|0.1 mg/kg morphine IV
45989027|NCT04695639|Other|Test of Arm Selective Control|It will be used to assess selective voluntary motor control. It is a reliable and valid evaluation tool used to quantify and describe selective voluntary motor control in children with spastic cerebral palsy. The goal of the assessment is to systematically evaluate a person's ability to move the upper extremity with selective voluntary motor control by observing movement control, coordination, fluency, mirroring, and speed at each joint, and then assigning a grade, all in 'real time. Clinically this measure may guide the selection of medical, surgical, or therapy interventions and may improve outcome prognosis after brief training. Raters demonstrated excellent reliability in assessing upper extremity SVMC in a group of children with hemiplegic, diplegic, and quadriplegic CP using the Ttest of arm selective control
45989028|NCT04695639|Other|Hand Held Dynamometer|Hand held dynamometer (Camry Digital Hand Dynamometer Grip Strength, Model EH101-37, China) will be used to assess hand grip strength of the affected upper extremity. It is generally small, portable and relatively cheap reliable measurement instruments to measure muscle strength of the arm and hand in children with spastic cerebral pasly. It is used to measure strength; maximal voluntary isometric contraction; objectively in kilograms, pounds or newtons. Such devices have been proven to have good to excellent reliability in different populations. It represents an easily accessible way to assess muscle weakness in children with cerebral palsy and the overall reliability is considered to be good.
45989029|NCT04695639|Other|Quality of Upper Extremity Skill Test|It will be used to assess function of the affected upper extremity. It is a reliable and valid outcome measure designed to evaluate movement patterns and hand function in children with cerebral palsy. It is designed to be used with children who have neuromotor dysfunction with spasticity and has been validated with children from 18 months to 8 years of age.
45989030|NCT01243892|Device|NuSpin|Device for administration of doses of somatropin.
45989031|NCT01243892|Drug|Somatropin|Somatropin using either NuSpin or Nutropin AQ Pen, as per standard dosing.
45989032|NCT01243775|Drug|Belotaxel|60 mg/m2 3 weekly (day 1)
45989033|NCT01243775|Drug|Belloxa|70 mg/m2 3 weekly (day 2)
45989034|NCT00514293|Drug|bexarotene|
45989035|NCT00514293|Drug|capecitabine|
45673754|NCT01598090|Biological|Peginterferon Lambda-1a|Syringes, subcutaneous (SC), 180μg, Once weekly, 24 or 48 weeks depending on response
45673755|NCT01598090|Biological|Peginterferon Alfa-2a|Syringes, SC, 180μg, Once weekly, 24 or 48 weeks depending on response
45673756|NCT01598090|Drug|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 24 or 48 weeks depending on response
45673757|NCT01598090|Drug|Telaprevir|Tablets, Oral, 750 mg, three times a day, 12 weeks only
45673758|NCT02105012|Drug|BD MDI 320 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
45673759|NCT02105012|Drug|BD MDI 160 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
45673760|NCT02105012|Drug|BD MDI 80 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
45989036|NCT00514293|Drug|carboplatin|
45989037|NCT00514293|Drug|cisplatin|
45673761|NCT02105012|Drug|BD MDI 40 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
45673762|NCT02105012|Drug|Placebo MDI|Placebo MDI administered as 2 inhalations BID
45673763|NCT02145182|Drug|Eculizumab|Eculizumab is a complement component 5 inhibitor.
45673764|NCT02145182|Drug|Placebo|0.9% sodium chloride
45673765|NCT02145026|Drug|Epoetin beta|Epoetin beta 30,000 or 60,000 IU per week SC injection
45673766|NCT02144012|Drug|Trastuzumab|For the first three-week cycle, trastuzumab was administered IV at 8 mg/kg. For subsequent cycles, trastuzumab was administered IV at 6 mg/kg Q3W.
45673767|NCT02144012|Drug|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 milligrams/kilogram (mg/kg) was administered intravenously (IV) over 30-90 minutes Q3W.
45673768|NCT02144012|Drug|Docetaxel|Docetaxel was administered IV at either 75 milligrams/square meter (mg/m^2) or 100 mg/m^2 Q3W.
45989038|NCT00514293|Drug|docetaxel|
45989039|NCT00514293|Drug|tretinoin|
45989040|NCT02955641|Drug|Dexamethasone Disodium Phosphate 0.1%|four drops a day for four days after LPI treatment
45989041|NCT02955641|Drug|Nepafenac 0.1%|four drops a day for four days after LPI treatment
45989042|NCT02955641|Drug|Hydroxyethylcellulose 0.19%|four drops a day for four days after LPI treatment
45989043|NCT00514956|Behavioral|Emotional Freedom Techniques (EFT)|
45989044|NCT01243268|Drug|Twynsta tablet|Telmisartan and Amlodipine T40/A5, T80/A5 and T40/A10
45989045|NCT00504530|Drug|Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)|
45673769|NCT02103062|Drug|ABI-007|
45673770|NCT04751552|Procedure|Erector Spinae Plane Block (for postoperative pain relief)|A ultrasound guided single bolus injection of 20 ml of levobupivacaine or placebo between the erector spinae muscle and process transversus of vertebra T5.
45673771|NCT02141672|Drug|Voclosporin High Dose|
45673772|NCT02141672|Drug|Voclosporin Low Dose|
45673773|NCT02141672|Drug|Placebo|
45673774|NCT02141516|Biological|rMenB+OMV|2 doses of vaccine 2 months apart
45673775|NCT02141516|Biological|rMenB+OMV|2 doses of vaccine 2 months apart
45673776|NCT02141516|Biological|rMenB+OMV|2 doses of vaccine 2 months apart
45673777|NCT02141360|Device|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
45673778|NCT01628198|Device|Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter|"Saline-Irrigated Radiofrequency Ablation Catheter will be placed in the renal arteries in a circumferential manner and energy will be delivered to create 4 burn lesions.~There are 2 devices that can be used---this is optional, based on physician preference:~Celcius Thermacool Catheter Biosense Webster, Inc Diamond Bar, California~or~Chilli II Cooled Ablation Catheter Boston Scientific Corporation San Jose, California"
45673779|NCT01628120|Biological|Epoetin Hospira|Subcutaneous(SC) injection
45673780|NCT01627340|Biological|Engerix™-B vaccine|3 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
45673781|NCT02125838|Device|Laryngeal Mask Airway-Supreme|Group LM-S (Laryngeal Mask Airway-Supreme)Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.
45673782|NCT02125838|Device|Endotracheal Tube|ETT
45673783|NCT02125604|Drug|dimethyl fumarate|capsules administered according to the prevailing product label
45673784|NCT02124746|Drug|Momelotinib|Momelotinib tablets administered orally once daily
45673785|NCT02123966|Drug|Sirolimus|
45673786|NCT02123576|Drug|Pentoxyfylline|
45673787|NCT02123576|Drug|Placebo|
45673788|NCT02123576|Drug|AMO Therapy|Albumin, midodrine and octreotide therapy (standard of care for HRS)
45673789|NCT01177397|Drug|CC-223|Part A: (closed to enrollment) Dose level starts with 7.5mg daily taken by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose level is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity). Part B: (closed to enrollment) Optimal dose is administered in 28 day cycles until disease progression.
45673790|NCT01160861|Drug|MEMP1972A|Repeating ascending dose
45673791|NCT01160861|Drug|placebo|Repeating ascending dose
45673792|NCT01158677|Procedure|Meniscectomy|patients undergoing meniscectomy will be asked to complete the KOOS-scale,Vas-scale, Tegner questionnaire, SF-36 questionnaire pre-operatively and at 3, 6 and 12 months post-operatively
45673793|NCT05235347|Biological|Sotrovimab|500mg IV
45673794|NCT03368729|Drug|Niraparib|Niraparib is an oral PARP-1 and -2 inhibitor with high potency.
45673795|NCT03368729|Drug|Trastuzumab|Trastuzumab is a commercially available agent administered by intravenous infusion. A loading dose of 8 mg/kg will be given as the first dose followed with all subsequent doses of 6 mg/kg every 3 weeks.
45989046|NCT00514995|Drug|Sodium Oxybate|4.5 g/night - 9 g/night, liquid taken twice per night
45989047|NCT01242371|Dietary Supplement|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
45989048|NCT01242371|Dietary Supplement|Identical-appearing Placebo|Probiotic identical placebo 1 tablet by mouth daily
45989049|NCT01242176|Drug|BI 10773 XX (Trial Formulation 2)|one single dose tablet in the morning
45989050|NCT01242176|Drug|BI 10773 (Final Formulation)|one single film-coated tablet in the morning
45989051|NCT00515151|Drug|0.1% Octenidine with 30% 1-propanol and 45% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of >200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
45989052|NCT00515151|Drug|74% Ethanol with 10% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of >200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
45989053|NCT01242020|Drug|Perflutren Lipid Microsphere Injectable Suspension|1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used
45989054|NCT00514332|Procedure|stent|stent placement for colorectal cancer obstruction
45989055|NCT01241786|Drug|Revlimid|Lenalidomide PO daily Day 1-21. For patients with baseline calculated creatinine clearance ≥ 30 ml/min and < 60 ml/min the starting dose is 5 mg every other day (odd numbered days during Days 1-21). For patients with baseline calculated creatinine clearance ≥ 60 ml/min the starting dose is 5 mg daily on Days 1-21).
45989056|NCT01241786|Drug|Azacitidine|Azacitidine 75 mg/m2 IV or SC D 1-5
45989057|NCT00514410|Drug|Folic Acid|Folic acid 5 mg once a day for three months as a supplement to their antidepressant treatment
45989058|NCT00514410|Drug|Placebo|Matching placebo taken once a day for three months
45989059|NCT01241318|Drug|Chlorhexidine gluconate (4%)|Chlorhexidine is a topical antiseptic that has long been tested for safety and widely used in developed country hospitals, pre-surgical antiseptic technique, wound cleaning and disinfection. Mothers will be instructed to apply 10 ml of 4% chlorhexidine once a day following the infants bath every day from birth until three days after the cord completely separates from the infant's body.
45989060|NCT01241318|Procedure|Dry cord care|Mothers will be instructed to keep their infants' umbilical cord stumps clean and dry and to not apply any foreign substances to the cord stump.
45989061|NCT00514488|Drug|STI571 (400 mg/day; or 800 mg/day)|
45989062|NCT00514527|Drug|oritavancin|Oritavancin as a single, infrequent or daily dose.
45989063|NCT01241279|Device|Crystalens AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the Crystalens AO intraocular lens.
45989064|NCT01241279|Device|SoftPort LI61AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the SoftPort LI61AO intraocular lens.
45833401|NCT03343860|Procedure|SR Case 1|"In the case of SR at the time of ablation:~PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. The CTI line will be performed in all patients with a ECG showing a typical counterclockwise flutter. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
45989065|NCT00514566|Device|Suture for midline abdominal closure|closure with Polyamide or Polydioxanone
45989066|NCT01241240|Drug|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
45989067|NCT01241240|Drug|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
45989068|NCT02950623|Other|titanium dioxide denture|patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover design
45989069|NCT02950623|Other|rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) according to the principle of crossover design
45989070|NCT00515970|Procedure|Curettage|"Curettage without subcutaneous tissue using a 7 mm ring curette and the fountain-pen technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The curette is held between the thumb, index and middle finger. This method of holding enables precise guiding of the instrument, so that the piece of tissue can be removed in one well-targeted incision. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining. Measurement of tumor thickness in mm."
45989071|NCT00515970|Procedure|Deep excision|12 o'clock mark. Excision with a scalpel down to the subcutaneous level. Plastic reconstruction. Three vertical, parallel bread loaf sections for histology. Preparation with paraffin. Staining with hematoxylin-eosin. Histologic diagnosis including report of tumor thickness in mm. Comment on complete removal (R0 versus R1). In case of R1 excision directed reoperations are performed until R0 is achieved.
45989072|NCT00515970|Procedure|Shave excision|Shave excision with a safety margin, using a scalpel. Wound healing by secondary intention. Preparation with paraffin. Parallel vertical bread loaf sections for histology. Staining with hematoxylin-eosin. Histologic diagnosis. Comment on complete removal (R0 versus R1). In case of R1 excision a reoperation is performed until R0 is achieved.
45989073|NCT00515970|Procedure|Curettage|"Curettage with a 7 mm ring curette with the potato-peeler technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The handle of the curette is held in the distal inter-digital fold of the index finger, and supported by the other fingers of the curetting hand. The thumbs serve to provide a stable base. This technique makes it possible to guide the instrument, applying greater pressure, but accuracy is reduced. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining."
45989074|NCT04695249|Behavioral|Exposure intervention using 360 degree videos|The intervention consists of eleven sessions. The first five sessions are dedicated to functional assessment and psychoeducation. The second five sessions are dedicated to exposure in 360-degree videos. The last session is provided for relapse prevention.
45673796|NCT03338933|Behavioral|magnetic resonance imaging (MRI)|All subjects will undergo a baseline MRI and subjects in both alcohol groups (alcohol use disorder and combined alcohol and nicotine use disorder) will undergo a followup MRI 3 months after baseline.
45673797|NCT00864227|Biological|Hematopoietic Umbilical Cord Blood Stem Cell Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~Fludarabine: 40 mg/m^2 intravenously (IV) on Days -6, -5, -4, -3, and -2~Cyclophosphamide: 50 mg/kg IV on Day -6~Total body irradiation: 200 centigray (cGy) on Day -1"
45989075|NCT00516009|Drug|DEXAMETHASONE|
45989076|NCT00516009|Other|PLACEBO|
45989077|NCT02950584|Other|Titanium dioxide denture|Patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles) for 1 month in the initial phase then in the second phase after one month they will receive (rapid heat cured acrylic resin)denture according to the principle of crossover design
45989078|NCT02950584|Other|Rapid heat denture|Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) according to the principle of crossover design
45989079|NCT01240811|Drug|IUD placement|Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).
45989080|NCT01240811|Drug|Levonorgestrel IUD|
45989081|NCT01240811|Drug|Copper T380A IUD|
45989082|NCT03459144|Drug|verteporfin|Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab(0.05mg) will be given to the participants when necessary（every three months）.
45989083|NCT03459144|Drug|verteporfin and ranibizumab|Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary.
45989084|NCT03459105|Procedure|Ultrasound-assisted paramedian spinal anesthesia|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
45989085|NCT03459105|Procedure|Landmark-guided spinal anesthesia|Spinal anesthesia will be done using conventional landmark-guided technique.
45989086|NCT03459105|Drug|0.5% heavy bupivacaine|0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
45989087|NCT01240382|Drug|3% DE-089 ophthalmic solution|
45989088|NCT01240382|Drug|0.1% sodium hyaluronate ophthalmic solution|
45989089|NCT00516087|Biological|Genetically modified CTLs|"LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Three different dosing schedules will be evaluated. Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10^7 cells/m2 Day 14 2x10^7 cells/m2~Group Two Day 0 2x10^7 cells/m2 Day 14 1x10^8 cells/m2~Group Three Day 0 1x10^8 cells/m2 Day 14 2x10^8 cells/m2"
45989090|NCT01244828|Drug|Asenapine|5 mg or 10 mg fast-dissolving sublingual tablets BID for up to 52 weeks
45989091|NCT00504192|Drug|Gemcitabine and Oxaliplatin|gemcitabine 1000mg/m2 IV on day 1 and oxaliplatin 85mg/m2 on day 2 every 2weeks
45989092|NCT01243346|Drug|Crenolanib besylate (CP-868,596-26), Dose: 140mg BID|Highly potent inhibitor of both PDGFR receptors alpha and beta
45989093|NCT01249443|Drug|vorinostat|Given PO
45989094|NCT01249443|Other|diagnostic laboratory biomarker analysis|Correlative studies
45989095|NCT01249443|Other|pharmacological study|Correlative studies
45989096|NCT01249443|Drug|carboplatin|Given IV
45989097|NCT01249443|Drug|paclitaxel|Given IV
45989098|NCT01243073|Drug|Imetelstat|
45989099|NCT01242488|Biological|CDP6038|60 mg subcutaneously (sc) at Weeks 0, 2, 4 6, 8, and 10
45989100|NCT01242488|Biological|CDP6038|120 mg sc at Weeks 0, 2, 4 6, 8, and 10
45989101|NCT01242488|Biological|CDP6038|240 mg sc at Weeks 0, 2, 4 6, 8, and 10
45989102|NCT01242488|Biological|Tocilizumab (Actemra or RoActemra)|8 mg/kg intravenously (iv) at Weeks 0, 4 and 8
45989103|NCT01242488|Biological|CDP6038|60 mg sc at Weeks 0, 4 and 8
45989104|NCT01242488|Biological|CDP6038|240 mg sc at Weeks 0, 4 and 8
45989105|NCT01242488|Biological|CDP6038|120 mg sc at Weeks 0, 4 and 8
45989106|NCT01242488|Other|Placebo sc|0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10
45989107|NCT01242488|Other|Placebo sc|0.9% Sodium chloride for injection at Weeks 2, 6 and 10
45989108|NCT01242488|Other|Placebo iv|0.9% Sodium chloride for injection at Weeks 0, 4 and 8
45989109|NCT00516243|Other|placebo|Given PO
45989110|NCT00516243|Other|quality-of-life assessment|Ancillary studies
45989111|NCT00516243|Procedure|questionnaire administration|Ancillary studies
45989112|NCT00516243|Procedure|laboratory biomarker analysis|Correlative studies
45989113|NCT00516243|Drug|defined green tea catechin extract|Given PO
45989114|NCT01240889|Drug|Fluticasone|nasal spray
45989115|NCT01240889|Drug|Fluticason|2 sprays per day in each nostril
45989116|NCT00516282|Drug|CLORETAZINE|CLORETAZINE will be administered intravenously on day 7. The starting dose of CLORETAZINE will be 100 mg/m2 given within 3 hours after the last dose of Temodar on day 7. CLORETAZINE will be given as an IV infusion over 15-30 minutes via a freely flowing peripheral or central intravenous line. CLORETAZINE will be escalated by 50 mg/m2 for the second cohort then by 25 mg/m2 increments in the following cohorts of 3-6 patients using a standard phase I trial design until a MTD is determined. If dose level 2 has two DLTs then patients will be accrued to a new dose level of 125 mg/m2. Prior to receiving Cloretazine, blood will be drawn for gene methylation studies.
45989117|NCT00516282|Drug|temozolomide|Temozolomide will be given orally at a dose of 75mg/m2 daily on day 1 through 7. There will be no dose modification for this agent. Prior to receiving Temozolomide, blood will be drawn for gene methylation studies.
45989118|NCT04512131|Procedure|dialysis mode|intermittent hemodialysis or continuous renal replacement therapy
45989119|NCT02950389|Device|PMMA filter|
45989120|NCT02950389|Device|HFR17 filter|
45989121|NCT02950389|Device|F7 filter|
45989122|NCT04511117|Other|Control group|ProTaper Next rotary system and iRoot SP sealer with composite restorations.
45989123|NCT04511117|Other|Endocrown group|ProTaper Next rotary system and iRoot SP sealer with endocrown restorations.
45989124|NCT04512092|Behavioral|Compassionate Mind Training for Caregivers|CMT-C is a 12-session group program, each lasting about 2,5 hours, which run on a weekly basis. The program is organized across 3 modules: 1) Our mind according to a compassion-based approach (to provide insight into the evolved and socially shaped mind and the affect regulation systems); 2) Compassionate mind training (understanding and cultivating the attributes and competencies of compassion in its three flows, and addressing its fears); and 3) final session (revising key information and practices and its application to the RCH practices/routines). Its sessions have the following structure: 1) Check-in (grounding exercise, reviewing the previous session, sharing the weekly practice); 2) Exploration of the session theme (psychoeducation and experiential practices followed by group opportunities for share experiences and discussion); 3) Check-out (session summary and application to the self, youths and RCH practices, weekly practice challenge, session evaluation, session take-off).
45989125|NCT01249521|Drug|AMG386 and bevacizumab|AMG386 10mg/kg qw iv Bevacizumab 7.5mg/kg q3w iv
45989126|NCT04513301|Drug|Sintilimab|Sintilimab (200 mg q3w ×2 cycle)
45989127|NCT04513301|Radiation|Radiotherapy|RT 50-60Gy/25-30f
46083659|NCT02782130|Behavioral|Epic Allies App Intervention|"The Epic Allies app addresses barriers to ART adherence through:~Users track health progress through an interactive dashboard, logging daily adherence for those on ART and, optionally, exercise, smoking, alcohol and drug use, and mood. Those not on ART will rate how close they are to getting on it.~Users pick medication reminder timing. The app sends weekly messages to users based on adherence progress and other tracked behaviors.~A key part of the app is contact between users to foster a setting that supports norms for medication-taking, reducing stigma related to HIV status and ART use. Users send and receive encouragement to spur behavior change, recognize positive behaviors, and inspire others to reach an adherence goal.~Users progress through Epic Allies' virtual world, creating allies with other users.~The Daily Dose newspaper has content to improve HIV/ART knowledge, promote disease management and increase drive and self-efficacy."
45673798|NCT00864227|Biological|GVHD prophylaxis|"GVHD prophylaxis regimen will consist of:~Cyclosporine: beginning on Day -3 with the dose adjusted to maintain a level of 200-400 mg/mL~MMF: 1 gram IV three times a day (TID) if greater than 50 kg, or 15 mg/kg IV TID if less than 50 kg beginning on Day -3; continued until Day 30 or 7 days after engraftment, whichever day is later~Day 0 is the day of the infusion of the umbilical cord blood graft units, which will be obtained from partially HLA-matched unrelated donors.~Beginning on Day 1, participants will receive G-CSF 5 mcg/kg/day until absolute neutrophil count (ANC) is greater than or equal to 2,000/mm^3 for three consecutive measurements, each on different days."
45673799|NCT00769223|Other|medical chart review|
45673800|NCT00769223|Other|questionnaire administration|
45673801|NCT00769223|Procedure|quality-of-life assessment|
45673802|NCT00769223|Radiation|brachytherapy|
45673803|NCT00769223|Radiation|radiation therapy|
45989128|NCT04516421|Dietary Supplement|Protein supplementation|The experimental group contained 14g protein, 0.6g fat, 7g carbohydrate, 4.4 g BCAA , 2.4g glutamate, 0.5g arginine and 0.4g taurine with 90 kcal/pack (Affix Health, Taiwan Branch).
45989129|NCT04516421|Dietary Supplement|Placebo oat drink|placebo oat drink contained 1.5g protein, 0.5g fat, 0.1g carbohydrate with 8.3kcal/pack (Zhan Xuan, Co. Ltd., Taiwan).
45989130|NCT01249599|Procedure|blood sample analysis|The aim of this prospective single-center study is to evaluate endothelial function, vascular compliance, oxidative stress parameters, quality of life and platelet adhesion in patients with apical ballooning syndrome and age-matched controls.
45989131|NCT04512014|Diagnostic Test|serum lactate|perioperative measurement of lactate levels
45989132|NCT01249677|Drug|insulin glargine|14 patients with type 2 diabetes on previous metformin therapy were treated with insulin glargine, aimed to normalize fasting glycaemia.
45989133|NCT04519970|Behavioral|Case Management|Each tier will have a different level of case management and support, all with the goal of increasing adherence to Biktarvy for HIV management.
45989134|NCT04697043|Procedure|Systemic therapy followed by surgery if the disease is not progressive|Primary systemic therapy (PST) or neoadjuvant therapy is used in nonmetastatic breast cancer to treat systemic disease earlier, decrease tumor bulk ideally to a complete pathological response (pCR), and reduce the extent of surgery. The systemic therapy followed by surgery if the disease is not progressive.
45989135|NCT04511975|Drug|IBI188|IBI188: 100 mg/mL, intravenous infusion once a week
45989136|NCT04511975|Drug|Azacitidine|Azacitidine (VIDAZA) for Injection:100 mg per vial, subcutaneous injection will be administered for 7 days in each 28 day cycle
45989137|NCT04511663|Combination Product|Assertive community treatment|The intervention team consisted of psychiatrists, nurses, clinical psychologists, social workers, rehabilitation teachers. The specific services provided by the team include individual service plan. Each patient got a comprehensive evaluation within one month to establish treatment goals and individual intervention plan, rehabilitation training, family intervention peer support group, individual psychological counseling and crisis intervention.
45989138|NCT04511663|Combination Product|Basic public health services.|The control group received regular medical follow-up including symptom and medication evaluation, social function evaluation and physical examination after hospital discharge. The frequency was once a quarter.
45989139|NCT04519931|Other|Stress ball|The stress ball is a toy, usually no larger than 7 cm. It is used to relieve stress and muscle tension. Stress ball is one of the cognitive and behavioral therapy methods used in pain control. Stress ball is used as a method of diverting attention during painful procedures. It appears to reduce pain and anxiety.
45989140|NCT02950194|Procedure|PPAWI|One-step procedure of a panniculectomy performed by a plastic surgeon together with a mesh augmentation of the abdominal wall by a general surgeon.
45989141|NCT04511936|Device|i-Lumen AMD|Microcurrent stimulator
45989142|NCT04511936|Device|i-Lumen AMD Sham|Sham microcurrent stimulator
45989143|NCT01249794|Procedure|non invasive ventilation|continuous positive airways pressure
45989144|NCT04519736|Device|Single Band vs. Dual Band Pulsed Light Technology for the Treatment of Photodamage|
45989145|NCT02950116|Device|Perform three multiple breath nitrogen washout tests (N2-MBW-test)|"Patient is sitting in upright position, nose clip in place and breathing through a mouth piece with filter (neither sitting forward with back bent, nor supporting arms such that shoulders are raised)~Patient's breathing pattern is stable for a minimum of 5 breaths~Start of washout by inhaling 100% oxygen (initiated by lab technician)~Continuous stable breathing pattern until end of washout test~End target = 1/40th of start N2 concentration~To ensure end of washout is achieved, patients should breathe 5 more breaths below the target concentration before the trial is terminated~Three N2-MBW-tests are performed consecutively. Time between each test is [duration of the previous test*1.5] (e.g. test duration = 6 min., time to next test = 6*1.5 = 9 min.)"
45989146|NCT04511897|Drug|An'ningpai|An'ningpai Enteric Soft Capsules was a kind of expectorant, comprised with Eucalyptol, Limonene and Pinene. 300 mg, oral, three times daily for 12 months.
46083660|NCT02782130|Behavioral|Epic Allies - Control Branch|Subjects will receive weekly phone-based notifications to encourage the subjects to view educational information presented in the app.
46083661|NCT03974919|Other|NO intervention required|NO intervention required
46083662|NCT03929016|Drug|DNDI-0690|capsules of 10, 100 and 200 mg
45989147|NCT04695093|Other|Ultra Low Emission Zone (ULEZ)|"The ULEZ comprises a Central London zone, implemented on 8th April 2019, within which polluting vehicles are subject to a charge. Using number plate recognition technology, a daily penalty charge notice is issued for vehicles entering this central zone not meeting the standard of Euro 4 for petrol, Euro 6/VI for diesel, and Euro for motorcycles.~The ULEZ will subsequently be extended to include:~In 2020, a London-wide ULEZ for heavy duty vehicles (HDV) within the LEZ boundary (green zone). HDVs not meeting Euro 6 standard will be charged daily.~In 2021, an Inner London ULEZ area for all light duty vehicles (LDV) within the boundary of the North and South Circular Roads (yellow zone). Vehicles not meeting the above criteria will be charged daily as for the Central London area."
45989148|NCT04519463|Drug|Xylocaine Mucosal Product|Xylocaine 10% Nasal Spray
45989149|NCT04519463|Drug|Placebo|Sodium Chloride 0.9%
45989150|NCT02950311|Drug|Intranasal xylitol spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
45989151|NCT02950311|Other|Intranasal saline spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
45456762|NCT01348334|Procedure|Synthetic sling surgery|An incision of inverted A shape was inflicted on the anterior vaginal wall(AVW)of the vagina.The upper part of A shaped incision was formed into an island belonging to the vaginal wall.This patch was 3×4cm in most of the patients.Proximal AVWwas dissected as a flap.Synthetics mesh materials were first sutured onto the upper part of the A on the vaginal island with absorbable vicrly sutures.Then,with 2polypropilen sutures,these meshes were fixed on both the right and left sides of this island in a helical manner to form a suspension and using curved Kishner needles,the prolene sutures were transferred to suprapubic area.These sutures were ligated on the rectus fascia in a crosswise manner.The mobile lower wing was advanced onto the island and was sutured onto the vaginal skin with intermittent sutures using 3-0 monocryl sutures.After cystoscopy,the prolene sutures were ligated crosswise in the suprapubic region.Special attention was paid notto create much tension on the mesh material.
45456763|NCT03133078|Other|Step-Down Test (2 min)|The 2-minute single limb lateral-step down test will be used to induce lower extremity muscle fatigue. Participants will be instructed to perform a single limb lateral step-down test on a 31 cm box (12-inches), touching their heel to the floor each time as many times as possible in 2 minutes. The number of lateral step-downs will be recorded.
45989152|NCT04519424|Biological|CSL324|Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
45989153|NCT04519424|Drug|Placebo|Normal saline (0.9% sodium chloride)
45989154|NCT04696770|Behavioral|Mindfulness|Mindfulness techniques will be taught to the participants
45989155|NCT04511780|Other|questionnaire filling|assessment of post-traumatic stress, anxiety and burn out
46083663|NCT03929016|Drug|Placebo of DNDI-0690|capsules of matching placebo
46083664|NCT04164186|Other|Automatic detection and segmentation of NSCLC tumors|an automated deep learning detection and segmentation software for non-small cell lung cancer (NSCLC) that can automatically detect and segment tumors on CT scans and thus reduce the human variation.
46083665|NCT04257461|Drug|Fluoropyrimidine|Monotherapy: 12 cycles of 5FU or 8 cycles of Capecitabine. The choice of fluoropyrimidine must be specified prior to randomisation.
46083666|NCT04257461|Drug|Oxaliplatin|Bichemotherapy: Oxaliplatine combined with Fluoropyrimidine.
45989156|NCT04696848|Drug|CKD-516 plus Durvalumab|"Stage 1 : dose escalation durvalumab (1500 mg Q4W) in combination with CKD-516 at 1 of 3 planned dose levels (9, 11, or 13 mg/m2 twice a week for 3 weeks in each cycle, Q4W).~Stage 2 : durvalumab (1500 mg Q4W) in combination with CKD-516 at recommended phase 2 dose (twice a week for 3 weeks in each cycle, Q4W)."
45989157|NCT04511585|Behavioral|Great Live and Move Challenge|Physical activity program for children
45989158|NCT04519346|Other|intradermal injection|Mesotherapy was performed by an experienced and trained physician using disposable 4 mm and 6 mm long 30 Gauge needles (Meso-relle, Biotekne SRL, Italy)to the pericarotid region, glabella, and the area between the eyes and ears, and to the area of the head where pain occurred (such as frontal, parietal, occipital region) for each patient
45989159|NCT02950077|Behavioral|mindfulness based stress reduction|The intervention will be delivered in a group setting and the group will meet for 2 hours once per week for 8 weeks. The intervention is based on new neuroscience of stress and resilient adaptive behaviors, mindfulness based stress reduction, therapeutic breath and synchronized yogic movement with a focus on the lower abdomen, integrated with cognitive and behavioral strategies for self-control and healthy decision making.
45989160|NCT04519112|Procedure|Catheter Ablation|Catheter Ablation with RMN and MCN
45989161|NCT01249950|Other|feasibility|feasibility
45989162|NCT00505271|Genetic|Rexin-G|"Three patients will receive Rexin-G at Dose Level I. If 1 of 3 patients at Dose Level I develops a grade 3 or 4 adverse event (CTCAE Version 3.0) which appears to be related or possibly related to Rexin-G, then 3 additional patients will be enrolled at the same dose level. If at least 2 of the first 3, or 3 of 6 patients at Dose Level I develop a grade 3 to 4 adverse event which appears to be related or possibly related to Rexin-G, accrual into the study will be held.~At any dose level, up to six patients may be enrolled if there is evidence of biological activity in the first three patients. Dose escalation may stop if there is impressive evidence of biological activity. An amendment would be submitted to allow further expansion of dose level based on impressive biological activity."
45989163|NCT01249989|Behavioral|Sequential MBC Condition|Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.
45989164|NCT01249989|Behavioral|Simultaneous MBC Condition|Simultaneous MBC condition will target FV+, Sed- and PA+ simultaneously. Participants in the simultaneous condition will wear their accelerometers and enter diet and sedentary activity 5 days/week. All 3 goal thermometers will be activated from the outset of prescription. The goal will be to close 1/3 of the gap between their FV, Sed, and PA statuses and the targets in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain target level behavior changes for FV, Sed and PA through week 12.
45989165|NCT01249989|Behavioral|Stress Management|Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
45989166|NCT04511351|Drug|Chidamide|chidamide administration during radiation and chemotherapy phase in the study group
45989167|NCT04519268|Diagnostic Test|Adult patients scheduled for an elective general surgical operation.|"The anesthesiologist, who is in charge of preoperative assessment at each hospital unit, will assess patients who are scheduled for elective surgery; and will inform senior anesthesiologists (with a minimum 3 years of experience) & consultant anesthesiologists, about the patients' data.~Patients data with all requested preoperative investigations & required preparations, peri-operative course and post-operative outcome will be collected."
45989168|NCT01244256|Drug|Clotrimazole + Gentamicin + Beclomethasone|Treatment with Clotrimazole + Gentamicin + Beclomethasone
45989169|NCT01244256|Drug|Clotrimazole + Gentamicin|Treatment with Clotrimazole + Gentamicin
45989170|NCT04511507|Procedure|hemoadsorption|three consecutive sessions of hemoadsorption in patients with liver failure
45456764|NCT03133078|Other|Side hop test (30 s)|The 30 second side hop test will be used to induce lower extremity muscle fatigue. Participants will be instructed to jump as many times as possible over two parallel strips of tape placed 40 cm apart, but must initiate approximately 30 degrees of knee flexion each jump. The number of successful jumps performed within 30 seconds will be recorded and used for data analysis. An unsuccessful jump will be defined as touching the tape or the area inside the tape. We will record the number of successful trials.
45989171|NCT01249833|Drug|Oseltamivir|Oseltamivir 75mg BID for 5 days
46083667|NCT03974841|Procedure|laparoscopic cornual resection|patients undergoing laparoscopic cornual resection due to cornual ectopic pregnancy
46083668|NCT05328830|Other|Instrument assisted soft tissue mobilization|Myofascial release technique will be applied to the Quadriceps, Hamstring and Gastrocnemius muscles of the participant's dominant lower extremity with the Graston technique®. The application will be at 450 angles for each muscle, 2 minutes, for a total of 6 minutes. The IASTM application will include sweep-fan-sweep strokes and cycle through each muscle for the specified time.
45456765|NCT01343186|Drug|Peginterferon alfa|s,c, 45mcg of Ypeginterferon alfa-2a
45456766|NCT01343186|Drug|Peginterferon alfa 2a|s,c, 90mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
45456767|NCT01343186|Drug|Peginterferon alfa-2a|s,c, 180mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
45989172|NCT04511546|Device|BPET Prototype Scan|Scan on the BPET Prototype PET system and qualitative comparison with a PET image acquired on a conventional clinical PET system.
45989173|NCT02275143|Radiation|CT TAP Scan|Modification of chest CT protocol in the routine CT TAP: The Research CT of Thorax will be acquired as per the routinely performed CTCA with inclusion of the lung apices. Therefore the study will be acquired axially with prospective gating.
45989174|NCT04511390|Device|Transparent, reusable respirator|A novel respirator with dual N95 filter cartridges
45989175|NCT02950233|Drug|NMDA active|NMDA active group will involve ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10 mg BID [following three weeks]).
45989176|NCT02950233|Drug|Steroid active|Steroid active group will involve two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.
45989177|NCT02950233|Drug|NMDA placebo|NMDA active group will involve normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (1 capsule BID [first week]; 1 capsule BID [following three weeks]).
45989178|NCT02950233|Drug|Steroid placebo|Steroid placebo group will involve two doses of normal saline; one dose given prior to starting surgery and one dose given on the morning of second postoperative day.
45989179|NCT01249404|Biological|Botulinum toxin type A|I.M. injection on day 1 (single treatment cycle)
45989180|NCT01249404|Drug|Placebo|I.M. injection on day 1 (single treatment cycle)
45989181|NCT04511000|Drug|Lipilou®(generic atorvastatin drug) 20 mg|Patients assigned to experimental group are treated with Lipilou® 20 mg
45989182|NCT04511000|Drug|Lipilou®(generic atorvastatin drug) 10 mg|Patients assigned to comparator group are treated with Lipilou® 10 mg
45989183|NCT04519385|Drug|Tocilizumab|Tocilizumab therapy
45989184|NCT04519385|Drug|Dexamethasone|dexamethsone pulse therapy
45989185|NCT01249365|Biological|GSK580299 (Cervarix)|3-dose schedule intramuscularly vaccination
45989186|NCT00506051|Drug|ZD6474 (vandetanib) 100mg|once daily oral tablet
45989187|NCT00506051|Drug|pemetrexed|intravenous infusion
45989188|NCT00506051|Drug|ZD6474 (vandetanib) 300mg|
45989189|NCT00504465|Drug|dinoprostone|
45989190|NCT04518800|Drug|Jin Youli(PEG-rhG-CSF)|Jin Youli(PEG-rhG-CSF) was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight <45 kg. Inject once every chemotherapy cycle
45989191|NCT00516360|Device|3.15% chlorhexidine as daily antiseptic on needleless access port|3.15% chlorhexidine as daily antiseptic on needleless access port. 1 wipe used to cleanse port each time the port is accessed
45989192|NCT04510883|Behavioral|PACO|The intervention is a fully-automated web-based eHealth application in which two embodied conversational agents engage in dialogue with older adults in order to motivate them towards dietary behavior change and decrease loneliness. The application consists of five different modules, each one applying different behavior change techniques.
45989193|NCT04510883|Behavioral|Waiting list + PACO|Waiting list + PACO
45989194|NCT01249131|Drug|Cobimetinib|Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.
45989195|NCT04510961|Other|Paraffin baths therapy|Patients in treatment group will receive paraffin wax baths for five days per week for 12 weeks. Prepare the paraffin device and blocks of paraffin wax. Put the paraffin wax blocks inside the tank and set the thermostat 35 to 40◦C. Melting paraffin was taken from 90 to 120 minutes. Adjust the suitable temperature for each patient before immersion of patient's hand. Submerge patient's hand completely for three to four seconds then withdraw it
45989196|NCT04510649|Drug|Part A|in Part A, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 11 and receive Rabeprazole 30 mg single dose on study days 5 through 11
45989197|NCT04510649|Drug|Part B|in Part B, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 12 and receive Rifampin 600 mg single dose on study days 5 through 16
45989198|NCT01249092|Drug|Pentoxifylline|Patients will take 400mg of pentoxifylline three times daily for a total duration of 6 months.
45989199|NCT02275182|Drug|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
45989200|NCT02275182|Drug|Saline|0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
45989201|NCT05653947|Procedure|Root canal instrumentation, 2.5% NaOCl irrigation|Root canal instrumentation, 2.5% NaOCl irrigation
45989202|NCT01248936|Drug|RO5185426|
45989203|NCT01248780|Drug|Golimumab|50 mg subcutaneous (SC) injection every 4 weeks for up to 48 weeks
45989204|NCT01248780|Drug|Placebo|Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter up to Week 48.
45989205|NCT01248780|Drug|Methotrexate (MTX)|A stable dose of MTX (oral or injectable) will be administered to participants according to the local prescribing guidelines for up to 48 weeks.
45989206|NCT01248468|Drug|Aspirin, acetaminophen and caffeine|2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)
45989207|NCT01248468|Drug|Sumatriptan|100 mg Sumatriptan
45989208|NCT01248468|Drug|Placebo|placebo
45456768|NCT01343186|Drug|Peginterferon alfa-2a|s,c, 270mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
45989209|NCT02275299|Drug|Iguratimod|Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
45989210|NCT02275299|Drug|Leflunomide|Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
45989211|NCT02275299|Drug|Methotrexate|Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks
45989212|NCT02955576|Device|Microneedle HA patch|"The microneedle HA patch were made of hyaluronic acid with microneedles which can enhance the drug permeation. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with microneedle HA patches.~Microneedle HA patch (Therapass®, RMD-6.5A) was prepared at Raphas Co., Ltd. (Cheonan, South Korea).~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied."
45989213|NCT02955576|Device|Patch|"The patch were made of hyaluronic acid with no microneedles to rule out the occlusion effect of microneedle HA patch. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with patches.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied.~The hyaluronic acid patch was prepared at Raphas Co., Ltd. (Cheonan, South Korea) for this clinical trial, not for sale."
46083669|NCT05328830|Other|Foam Roller|Will be applied to the Quadriceps, Hamstring and Gastrocnemius muscles of the participant's dominant lower extremity using rigid Foam Roller. A total of 6 minutes will be applied to a person, 2 minutes for each muscle. Pressure intensity; According to the Visual Analog Scale, which is the point where pain will not be felt but moderate to severe discomfort will be felt, it will be done at a severity of 7/10.
45673804|NCT05230511|Drug|Lactobacillus RhamnosusGG|LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
46083670|NCT02712528|Drug|remifentanil-based|
46083671|NCT02712528|Drug|sevoflurane-sufentanil balanced|
46083672|NCT04089657|Drug|Apatinib Mesylate|Apatinib 500mg qd, oral, taken half an hour after a meal
46083673|NCT04089657|Drug|Sintilimab|Sintilimab 200mg intravenously on day 1
45989214|NCT02955576|Other|Control|"All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment only.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied."
45456769|NCT02291458|Drug|L-arginine|9 gram L-arginine / day for 6 weeks
45456770|NCT02291458|Drug|Placebo|9 gram placebo / day for 6 weeks
45456771|NCT01329289|Drug|SOM230|60 mg intramuscularly (IM) on day 1 of each 28 day cycle
45456772|NCT01329289|Drug|Bortezomib|1.3 mg/m2 intravenously (IV) on days 1, 4, 8, and 11 of each cycle. Bortezomib will be infused by IV push.
45833402|NCT03343860|Procedure|SR Case 2|"In the case of SR at the time of ablation:~PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. The CTI line will be performed in all patients with a ECG showing a typical counterclockwise flutter. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 10 consecutive AT)"
45833403|NCT03083496|Drug|Potassium Oxalate 5%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
45833404|NCT03083496|Drug|Potassium Oxalate 10%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
45833405|NCT03083418|Device|control group|No EDP treatment
45833406|NCT03083418|Device|EDP|Turn on the device, and clean the skin where the patch will be located according to the screen tip. Paste the two groups of small electrodes to the inferior 1/3 of the outer edge of bilateral sternocleidomastoid, and the large electrodes are pasted to the corresponding 2nd intercostal skin surface of pectoralis major at midclavicular line.Adjusting the stimulus intensity according to the daily maximum tolerance (patients with no pain and tension).30 minutes continuous stimulation each time, twice a day, a total of one weeks of treatment .
45989215|NCT01247922|Drug|Erlotinib|continuous oral Erlotinib 85 mg/m^2 per day
46083674|NCT04257539|Behavioral|Intervention to Reduce Sedentary Time|Chronic low back pain participants in the intervention group will be provided with a wrist-worn activity device that vibrates after prolonged sedentariness and meet with a health coach trained in motivational interviewing to discuss individual sedentary levels and provide education surrounding sitting habits and strategies for new habit development. Participants will meet with the health coach initially and at 4 weeks during the 8 week intervention period.
46083675|NCT05339750|Device|AI-based smartphone application|AI-based smartphone application to record and interpret the patch test results
46083676|NCT05339750|Diagnostic Test|Allergen patch|Allergens applied to a patch which is placed on the skin on the forearm region. The patch contains 10 dime-sized disks which contain a different allergen.
45456773|NCT01329289|Drug|Dexamethasone|20 mg orally on day of and day after bortezomib (Days 1, 2, 4, 5, 8, 9, 11, 12).
45456774|NCT01317914|Other|Dietary instruction|Subjects subsequently diagnosed with celiac disease will have gluten-free diet instructions given by registered dietitian experienced in the gluten-free diet. Subjects will have follow-up in 3 months time from initial instruction to verify compliance.
45456775|NCT02291536|Drug|tetrahydrocannabinol|
45673805|NCT05230511|Drug|Saline bladder wash|Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
45673806|NCT04810715|Other|Patients with Ankylosing Spondylitis|Observational study, not applicable
45989216|NCT04518956|Procedure|inter maxillary fixation with shockwave therapy|Shockwave therapy device which give 1500-4000 pulses per session with or without anesthesia, and the treatment session takes approximately 5-10 minutes at the day after surgery.
45989217|NCT04518956|Procedure|Inter maxillary fixation and exposure to low intensity pulsed|Low-intensity pulsed ultra sound was applied three times weekly for six weeks from the second day after surgery.
45989218|NCT04518956|Procedure|Inter maxillary fixation|Closed reduction will be done. Intermaxillary fixation (IMF) will be secured after proper reduction of the fractured segments to assure proper occlusion using upper and lower arch bars or eyelet wires for six weeks.
45989219|NCT01246206|Drug|Tacrolimus and Thymoglobulin|"Intravenous Tacrolimus 0.03 mg/kg/d, beginning day -3, where day 0 is the day of stem cell infusion or transplant. Intravenous tacrolimus will be discontinued once the participant starts eating, and the drug will then be given orally at a dose of approximately 4 times the intravenous dose. Tacrolimus will be discontinued starting 100 days after transplant unless signs of acute and chronic GVHD develop or if severe toxicity occurs. Thymoglobulin will be given 0.5 mg/kg day-3, Thymoglobulin 1.5 mg/kg day -2, Thymoglobulin 2.5 mg/kg day -1. Thymoglobulin will be given intravenously over 6 hours."
45989220|NCT04510610|Drug|Camrelizumab and Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function. Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
45989221|NCT01246011|Drug|Argatroban and warfarin|Subjects with the presence of heparin PF4 antibodies without signs or symptoms of HIT post CABG will be randomized to receive argatroban and warfarin or no drug for one month.
45989222|NCT04518878|Drug|Eltrombopag|Fixed dose of eltrombopag oral 25mg daily
45989223|NCT04518878|Drug|rhTPO|Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
45989224|NCT04518371|Other|Reinforced composite for the fabrication of permanent, indirect restorations using a CAD/CAM grinding process.|Shock-absorbing effect due to the dentine-like modulus of elasticity makes BRILLIANT Crios extremely well suited for implant restorations.it is composed of dental glass (barium glass ˂ 1.0 μm), amorphous silica (Sio2 ˂ 20 nm), resin matrix (cross-linked methacrylates) and pigments
45989225|NCT01244490|Drug|Extended-release Guanfacine Hydrochloride|Tablet, once daily, optimised dose (1mg to 7mg based on age and weight), 6-week maintenance duration on optimised dose.
45989226|NCT01244490|Drug|Atomoxetine Hydrochloride|Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose
45989227|NCT01244490|Drug|Placebo Comparator|Placebo
45989228|NCT00506090|Procedure|pulsed dye laser therapy|Treatment will begin on the day of suture removal. Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device at 3 weeks intervals for 6 sessions. Another part will be treated with pulsed dye laser and dynamic cooling device at 6 weeks intervals for 6 sessions. Only dynamic cooling device will be used for remaining part serving as control.
45989229|NCT04510376|Device|Test Article|Omeza Collagen Matrix
45989230|NCT04510376|Other|Positive Control|1.0 mg/mL Histamine Base
45989231|NCT04510376|Other|Negative Control|Aqueous Negative Control
45673807|NCT02102204|Drug|Etelcalcetide|Etelcalcetide was supplied as a sterile, preservative-free, ready-to-administer aqueous solution.
45673808|NCT02141204|Biological|HRV Liquid|Two doses administered orally according to a 0, 1-month schedule.
45673809|NCT02141204|Biological|HRV Lyophilized|Two doses administered orally according to a 0, 1-month schedule.
45673810|NCT02140970|Drug|Ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
45833407|NCT05548920|Other|Ultrasound guided Superior Vena Cava Collapsibility Index|Preoperative Ultrasound guided Superior Vena Cava Collapsibility Index will be measured
45989232|NCT01243944|Drug|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
46083677|NCT02713074|Drug|povidone-iodine|The patients will be subjected to povidone-iodine (Betadine7.5%) for vaginal cleaning before office hysteroscopy
45673811|NCT02140970|Drug|Placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
45673812|NCT04736342|Other|PALI questionaire|Survey comprised of a series of multiple choice questions
45673813|NCT02101112|Drug|Apixaban|
45833408|NCT05548920|Other|Inferior Vena Cava Collapsibility Index|Preoperative Inferior Vena Cava Collapsibility Index will be measured.
45833409|NCT03083340|Behavioral|Deprexis|Participants will complete an 8 week self-help computerized treatments through a web-based online Deprexis program.
45833410|NCT05547984|Device|Dual Mobility Cup|Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the Dual Mobility cup
46083678|NCT02713074|Drug|normal saline|The patients will be subjected to normal saline (Sod. Chloride 0.9%, Nile) for vaginal cleaning
46083679|NCT05089292|Behavioral|Narrative breast health education|Health education program utilizing narrative messages to promote breast cancer screening in Chinese immigrant women will be delivered in a group format in the community
45833411|NCT05547984|Device|Standard Acetabular component|Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the standard device with polyethylene + vitamin E inlay and metal head
45989233|NCT01243944|Other|Best Available Therapy (BAT)|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
45989234|NCT04518488|Other|Exercises|Personalized and individualized exercises for lower limb soft-tissue sarcoma of each participant in this group.
45989235|NCT04518488|Other|Informational Support Group (Control group)|The focus for participants in the Informational Support Group will be on needs for information and psychosocial support during the pre-operative period.
45989236|NCT04510571|Other|Evaluating Postoperative Pain After Root Canal Treatment with Protaper Next|Patients were randomly separated into two groups and root canal treatments were completed with Protaper Next file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
45989237|NCT04510571|Other|Evaluating Postoperative Pain After Root Canal Treatment with Reciproc Blue Files|Patients were randomly separated into two groups and root canal treatments were completed with Reciproc Blue file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
45989238|NCT00516399|Drug|povidone-iodine 1.25% ophthalmic solution|
45989239|NCT00516399|Drug|natamycin ophthalmic suspension, USP 5%|
45989240|NCT04518527|Device|Tape|The tape is an elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability
45989241|NCT00516438|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
45989242|NCT00516438|Drug|Topotecan|intravenous infusion
45989243|NCT02275949|Device|acupuncture|Acupuncture needles are inserted at the acupoints Zusanli(ST 36), Neiguan(PC 6), Gongsun(SP 4), and Xiangu(ST 43) bilaterally.
45989244|NCT02275949|Device|Electroacupuncture|The electric stimulator will be connected to the handles of each needles on the ST 36 and PC 6 bilaterally with 5Hz.
45989245|NCT02275949|Device|Intradermal acupuncture|Intradermal acupuncture needles with tape are inserted on the ST36, PC6, SP4, ST43 bilaterally and maintained until the next session.
45989246|NCT02275949|Device|Mock transcutaneous electrical nerve stimulation|Electrical insulator are attached on the ST36 and PC6 bilaterally, the same electric stimulator will be connected on the points with the same parameters as the study group, but without current intensity.
45989247|NCT02275949|Device|sham intradermal acupuncture|Intradermal acupuncture needles are put over the tape not penetrating the skin.
45989248|NCT00516477|Biological|voretigene neparvovec-rzyl|Subjects will be dosed unilaterally (one eye) beginning with the lowest dose. Subjects will be injected with AAV2-hRPE65v2 by means of a subretinal injection. Dose escalation to the next cohort will be dependent on assessment of the safety data by the DSMB out to at least 4 weeks following the injection. Because there is a delay between time of delivery of AAV2 and the peak transgene expression there will be a delay of six weeks between all subjects.
45989249|NCT00516516|Dietary Supplement|L-Carnitine|L-Carnitine, 1g orally, twice daily
45989250|NCT00516516|Dietary Supplement|Placebo|Placebo, similar in appearance to study tablets, given orally, twice daily.
45989251|NCT00505349|Behavioral|Computer-based cognitive training|The experimental cognitive training program consists of interactive training exercises in which the participant responds to visual patterns and stimuli. The program is designed upon the principles of brain-plasticity, and, for the purposes of this study, is intended to be used for an 8-10 week period (40 total hours of training.)
45833412|NCT04279938|Drug|Tinostamustinein|Tinostamustine80-120mg IV Q3W (dose to be determined in part 1) for 6 cycles
45833413|NCT04279938|Drug|Pembrolizumab|Pembrolizumab 200mg IV Q3W until disease progression or unacceptable toxicities (max. 2 years)
45833414|NCT04279938|Drug|Rituximab|Rituximab 375 mg/m2 IV Q3W for 6 cycles
45833415|NCT03083262|Other|no intervention|None, there is no intervention
45833416|NCT05534256|Behavioral|Sit Less Program|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention
45833417|NCT05686434|Drug|Osimertinib|This is a prospective, open, single-center, single-arm phase II clinical study with EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory，to evaluate the efficacy and safety of adjuvant Osimertinib therapy in completely resected stage I non-squamous non-small cell lung cancer (NSCLC) with high-risk factors (solid and/or micropapillary component ≥10%, and/or airway spread).
45833418|NCT05686356|Drug|Sutezolid|Sutezolid will be given at a dose of 1200mg QD in arm 1 and at a dose of 1600mg QD in arms 2 and 3.
45833419|NCT05686356|Drug|N-acetyl cysteine|NAC will be given at a dose of 1800 mg BID in arm 3
45833420|NCT05686356|Drug|Pretomanid|Pretomanid will be given at its approved dose
45989252|NCT02275988|Drug|K-877|
45989253|NCT02275988|Drug|Clarithromycin|
45989254|NCT00516594|Procedure|Diet with polyfructans and viscous fibers or soy protein|
45989255|NCT02950155|Drug|Rituximab|A single infusion at a dose of 500 mg Mabthera/Rituximab.
45989256|NCT02950155|Drug|Sodium Chloride solution|A single infusion of Placebo/Sham.
45989257|NCT00516633|Behavioral|Extra information and support|Four group discussions with parents in close connection to diagnosing the children
45989258|NCT00516672|Drug|pazopanib|Pazopanib oral tablet
45989259|NCT00516672|Drug|Lapatinib|Lapatinib oral tablet
45989260|NCT00516711|Drug|Sevoflurane|
45989261|NCT00516750|Drug|cisplatin|
46083680|NCT02712372|Drug|AZD4831|AZD4831 1-50 mg/g oral suspension
45989262|NCT00516750|Drug|doxorubicin hydrochloride|
45989263|NCT00516750|Drug|methotrexate|
45989264|NCT00516750|Drug|vinblastine|
45989265|NCT00516750|Genetic|gene expression profiling|
45989266|NCT00516750|Procedure|neoadjuvant therapy|
45989267|NCT02276105|Other|Questionnaires|On three time-points (Baseline, Retest, Follow-Up), each participant has to fill out the questionnaires: Michigan Hand Questionnaire, EuroQol EQ-5D-5L and the Short Form SF-12 Health Survey
45989268|NCT04694625|Other|Structured Rehabilitation Program|Early Function Phase (Protective phase) week 1 Progressive Function Phase (Recovery Phase) 2nd and 3rd week Advance Function Phase (Activity Phase) 4th week
46083681|NCT02712372|Drug|AZD4831 placebo|AZD4831 placebo oral suspension
46083682|NCT00637793|Drug|NGX267|2 capsules in the am of each treatment period
45989269|NCT04694625|Other|Conventional Physical Therapy|• Rapid post-operative mobilization • Range of motion exercises started • Passive extension by placing pillow under foot • Flexion-by dangling the leg over the side of bed • Muscle strengthening exercises • Weight bearing is allowed on 1st post-operative
45989270|NCT00505427|Dietary Supplement|Alpha Lipoic Acid|
45989271|NCT00506168|Drug|Irinotecan, Capecitabine|
45989272|NCT02950038|Drug|Ibrutinib|560 mg given by mouth daily in a 28 day cycle.
45989273|NCT02950038|Drug|Nivolumab|3 mg/kg by vein beginning with Cycle 2 on Days 1 and 15 of every 28 day cycle.
45989274|NCT02276144|Other|Liver ultrasound|For evaluate whether fatty liver is exist or not
45989275|NCT02949960|Drug|DMT210 Topical Gel|DMT210 Topical Aqueous Gel 5% applied twice daily
45989276|NCT02949960|Drug|Vehicle Control|Topical Vehicle Gel applied twice daily
45989277|NCT02276183|Dietary Supplement|Nutrition intervention, test formula|
45989278|NCT02276183|Behavioral|progressive physical activity|Tai Chi; dynamic strength training (knee extension, knee flexion, hip extension, side leg raise, plantar flexion); flexibility warm up and cool down (shoulder and upper arm stretch, hamstrings stretch, calf stretch, ankle stretch); aerobic fitness training(walking on even flat ground); balance training(standing on one foot; heel-to-toe walk; toe stand)
45989279|NCT02949999|Drug|Voclosporin|
45989280|NCT04510415|Drug|Olmutinib|"600 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria."
45673814|NCT02139644|Drug|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100/12.5 mcg Fp/Sx or 50/12.5 mcg Fp/Sx in the morning and evening for a total daily dose of 200/25 mcg or 100/25 mcg Fp/Sx.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
45989281|NCT02949882|Dietary Supplement|Yakult|Containing at least 6,5*10^9 colony forming units (cfu) of Lactobacillus casei Shirota (LcS)
45989282|NCT02949882|Dietary Supplement|Dairy Peach Drink (AH Basic)|Commercially available dairy drink with peach flavour.
45989283|NCT04517942|Behavioral|EVERYbody Project|Brief behavioral intervention (4 hours across two meetings)
45989284|NCT04517942|Other|Video + Expressive Writing|Brief video-based intervention (4 hours across two meetings)
45989285|NCT02949609|Other|Mirror Therapy|Mirror therapy will consist in placing a large mirror in the sagittal plane of the subject so as to reflect his healthy arm while hiding the paretic one, and then asking him to perform movements of his healthy arm while looking at its reflection in the mirror.
45989286|NCT02949609|Other|Control Therapy|Performance of the same movements as the experimental group without the mirror or instructions as to where to look, 5 days/week, for 4 weeks.
46083683|NCT00637793|Drug|NGX267|2 capsules in the am of each treatment period
46083684|NCT00637793|Drug|NGX267|2 capsules in the am of each treatment period
46083685|NCT00637793|Drug|NGX267|2 capsules in the am of each treatment period
45456776|NCT02291536|Drug|cannabidiol|
45673815|NCT02139644|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100 mcg or 50 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 100 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
45833421|NCT05686356|Drug|Bedaquiline|Bedaquiline will be given at its approved dose
45833422|NCT05686356|Combination Product|Rifafour|Fixed dose combination tablets for TB treatment will be given at approved doses
45833423|NCT03083184|Drug|Ethanol|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
45833424|NCT03083184|Drug|enoxaparin|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
45833425|NCT05686278|Device|Bipolar i and cemented stem (Océane+ or Meije)|Hip hemiarthroplasty is a surgical procedure that involves replacing half of the hip joint
45833426|NCT03083106|Device|Elevoplasty|The Elevo™ Kit Snoring Intervention Device is designed to facilitate deployment of the Elevo™ suture implant into the submucosal tissue of the soft palate via a minimally invasive, outpatient procedure performed by an otolaryngologist in a medical office setting.
45833427|NCT03338244|Drug|Azithromycin|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months
45833428|NCT03338244|Drug|Placebo|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo suspension every 6 months
45989287|NCT04510220|Drug|Ofatumumab|Ofatumumab (OMB157) is a fully human anti-CD20 monoclonal antibody (mAb) self-administered by a once-monthly subcutaneous injection that is in development for MS. Ofatumumab drug product (also referred as OMB157) is formulated as 20 mg/0.4 mL (50 mg/mL) solution for injection, provided in autoinjectors, for subcutaneous administration. The autoinjectors contain a small overfill to allow for a complete withdrawal of the labeled amount (20 mg) of ofatumumab.
45989288|NCT04510220|Drug|[F-18]PBR06|PET radiopharmaceutical. Subjects will undergo [F-18]PBR06-PET (microglial activation).
45989289|NCT02949648|Device|Electronic cigarette|Electronic cigarettes are devices that do not burn or use tobacco leaves but instead vaporize a solution the user then inhales. The device contains an electronic vaporization system, rechargeable batteries, electronic controls and cartridges of the liquid is vaporized.
45989290|NCT04510337|Drug|standard rocuronium dose|0.6 mg/kg rocuronium during induction of anesthesia
45989291|NCT04510337|Drug|Magnesium sulfate|50 mg/kg magnesium sulphate added to 0.40 mg/kg rocuronium
46083686|NCT04228640|Other|NMN|Investigational Product
46083687|NCT04228640|Other|Placebo|Starch Powder
46083688|NCT00745875|Drug|ZD4054|10mg oral tablet, once daily
46083689|NCT00745875|Drug|Pemetrexed|500mg2/m IV infusion
45989292|NCT02949687|Procedure|ileal interposition with sleeve and sympathectomy|laparoscopic ileal interposition with sleeve and sympathectomy
45989293|NCT04510259|Procedure|Selective Brachial plexus Block|It is one type of peripheral nerve blocks for upper extremity surgery. In this study, the block will be done under the ultrasound guidance and the local anesthetic agent (a mixture of 2% Xylocaine with 1: 200,000 adrenaline and 0.5% Chirocaine in a total of 25ml) will be injected at the trunks of the brachial plexus in order to produce the surgical anesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries.
45989294|NCT04694898|Behavioral|Standard programme|The control arm will receive national standard programme for women and children under the age of 2 years. This includes 1) national nutrition and health care including iron & folic acid (IFA) supplementation in pregnancy; 2) early initiation and exclusive breastfeeding until 6 months of age; 3) timely introduction of liquid and semi-solid complementary foods; and 4) diversified complementary foods.
45673816|NCT02139644|Drug|Placebo MDPI|Placebo administered via a multidose dry powder inhaler (MDPI) one puff in the morning and one puff in the evening for 12 weeks.
45989295|NCT04694898|Behavioral|SURE intervention|"The SURE package includes: 1) promoting diversified agriculture; 2) promoting infant and young child feeding practices; 3) women empowerment in decision making related to agriculture, food and health; and 4) enhanced food security and Water, Sanitation and Hygiene (WASH) practices."
45989296|NCT00516828|Drug|cytarabine|subcutaneously twice daily from Day 1 to 10
45989297|NCT00516867|Radiation|UV radiation|UV radiation with 99.5% UVA and 0.5%UVB
45989298|NCT00516867|Radiation|UV radiation|UVB 1.4 % and UVA 98.6
45989299|NCT02949765|Drug|Iron sulfate 105 mg|Daily supplementation with iron sulfate 105 mg 1 pill/day
45989300|NCT02949765|Dietary Supplement|Iron-rich diet|
45989301|NCT04694664|Other|This is an online survey with no intervention.|As this is an online survey about health and wellbeing, there is no intervention.
45989302|NCT04518176|Procedure|bilateral uterine artery ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally
45989303|NCT04518176|Drug|Oxytocin|20 units by slow intravenous drip injection
45989304|NCT04694859|Device|Transcatheter Aortic Valve Implantation|Transfemoral or transapical Transcatheter Aortic Valve Implantation
45989305|NCT04510064|Drug|Camrelizumab plus mFLOT regimen|Patients were treated with domestic PD-1 antibody (Camrelizumab for injection) commbined with mFLOT regimen immunotherapy every three weeks, and HER-2 positive patients were added with Herceptin therapy. Camrelizumab 200mg on day 1, albumin bound paclitaxol 125mg/m² on day 1,oxaliplatin 85 mg/m² on day 1, leucovorin 200 mg/m² on day 1, and 5-FU 2600 mg/m² as 24-h infusion on day 1.Herceptin 6mg/Kg at the first time, followed by 4mg/Kg if needed.
45989306|NCT04510064|Procedure|R0 surgery|The efficacy of therapy was evaluated every 3 treatment cycles. If the tumor can be R0 resected after 6-9 cycles, then proceeded to surgery. After the operation, patients continued to receive the prior immunotherapy totally to 12 cycles or to the disease progressed or intolerable toxicity.
45989307|NCT02275520|Device|NIO Adult device|IO access-1
45989308|NCT02275520|Device|Bone Iniection Gun|IO access-2
45989309|NCT02275520|Device|EZ-IO|IO access-3
45989310|NCT02275520|Device|Jamshidi Intraosseous Needle|IO access-4
45989311|NCT02275520|Device|Cook Intraosseous Needle|IO access-5
45456777|NCT02291536|Other|placebo|
45673817|NCT02139644|Drug|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
45673818|NCT02139644|Drug|Beclomethasone dipropionate|QVAR (beclomethasone dipropionate) 40 mcg inhalation aerosol is a pressurized MDI that contains a Food and Drug Administration (FDA)-approved formulation of beclomethasone dipropionate. Patients took 1 puff twice a day from open-label QVAR 40 mcg hydrofluoroalkane (specifically, HFA-134a) metered-dose inhaler (MDI) for the duration of the Run-in Period (14-21 days) and prior to randomization. A clinically equivalent dose of inhaled corticosteroid (ICS) was substituted in countries where QVAR 40 mcg was not available.
45673819|NCT04733768|Diagnostic Test|18F-PSMA-1007|18f-PSMA-1007 PET/CT scan
45833429|NCT03083028|Procedure|Non Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
45989312|NCT04694703|Drug|Covid-19 group|Routine COVID-19 treatment
45989313|NCT04694742|Other|data collecting|"Within 24h from ICU admission, the ventilatory efficiency will be assessed by the following Ventilatory Ratio equation:~Ventilatory Ratio = [minute ventilation (ml/min) × PaCO2 (mm Hg)]/(predicted body weight × 100 × 37.5).~Where PaCO2 is the partial pressure of carbon dioxide in mmHg in the arterial blood.~Tha quasi-static compliance will be calculated according to the equation:~C=Tidal Volume/(Paw plateau - PEEP total)~where Paw plateau is the airway pressure measured during 4 seconds of inspiratory pause, PEEP total is the airway pressure measured during 4 seconds of expiratory pause.~In the same time frame, complete blood count, d-dimer, sequential organ failure assessment score, blood gas analysis, haemodynamic and ventilatory parameters will be collected."
45989314|NCT04510181|Dietary Supplement|amino acid-based blend|blended (listed in descending order) L-lysine, L-arginine, oxo-proline, N-acetyl-l-cysteine, L-glutamine, and Schizonepeta tenuifolia
45989315|NCT00516945|Drug|Lamivudine|
45989316|NCT04510103|Drug|Moisturizer A, F#9155-005|OTC Monograph Drug. Used twice daily on left or right lower leg per randomization schedule.
45989317|NCT04510103|Other|Moisturizer B, F#E1387-004|Cosmetic Moisturizer. Used twice daily on left or right lower leg per randomization schedule.
45989318|NCT04510103|Procedure|Regression|2 week regression period after 6 weeks of moisturizer use.
45989319|NCT04510103|Procedure|Non-Regression|Physical insult (tape stripping) on the lower leg after 6 weeks of moisturizer use.
45989320|NCT00516984|Procedure|Placebo|No-touch control condition applied while subject was at a 50-degree head-up tilt.
45989321|NCT00516984|Procedure|Sham|Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
46083690|NCT00745875|Drug|Placebo|10mg oral tablet, once daily
45989322|NCT00516984|Procedure|OMT|Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
45673820|NCT02100644|Drug|Lamotrigine tablets 25/100 mg|Lamotrigine (LTG) is administered according to the package insert: that is, 25 mg of LTG will be orally administered once every other day for the first 2 weeks and then once daily for the next 2 weeks. Thereafter, the dose will be gradually escalated by 25-50 mg every 1-2 week for once or twice daily administration. During the VPA reduction phase and LTG&amp;VPA maintenance phase, as specified in the information of package insert, maintenance dose of LTG will be administered twice daily.
45989323|NCT02275598|Drug|Brentuximab vedotin|1.8 mg/kg, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 2
45989324|NCT02275598|Drug|ABVD|Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle. Number of Cycles: 3 or 6 according to initial disease stage.
45989325|NCT00517023|Device|Sleuth Implantable Loop Recorder|ILR insertion under aseptic conditions in left pectoral region (local anaesthetic procedure only)
45989326|NCT00517023|Other|Other|Routine care and tests usually offered for syncope patients.
45989327|NCT04510025|Diagnostic Test|Magnetic Resonance Imaging|We will undertake multi-organ MRI to assess the health of vital organs including the brain, heart, lung, kidneys and liver. We will additionally examine the burden of ongoing respiratory limitations, mental health problems and quality of life in survivors of COVID-19 at 3, 6 and 12 months.
45989328|NCT00517062|Drug|Growth hormone (Genotropin)|Growth hormone 0.1 mg self-injected once a day subcutaneously at bedtime.
45456778|NCT01317992|Drug|Ibudilast|Ibudilast 4 x 10 mg capsules, orally, twice daily for 8 weeks.
45673821|NCT04798469|Drug|Testosterone Undecanoate 250 MG/ML|Intramuscular administration at a dose of 750 mg at baseline, weeks 4, and week 14.
45673822|NCT04798469|Drug|Placebo|Intramuscular administration of placebo at baseline, weeks 4, and week 14.
46083691|NCT02712294|Other|Neuromuscular Electrical Stimulation|
45456779|NCT01317992|Drug|Placebo|Placebo 4 capsules, orally, twice daily for 8 weeks.
46083692|NCT04203563|Behavioral|Strong People Strength Training|A community-based progressive strength training program
46083693|NCT02712216|Procedure|Laparoscopy|Determine best port sites to insert bariatric trocars
46083694|NCT05082740|Other|Notification of a revised breast cancer risk estimate|These women will be given the opportunity to learn of their revised breast cancer risk estimate which has been re-calculated with the inclusion of new strong independent risk factors. These women will be offered a clinical consultation to discuss their risk and will a subset will be asked to take part in a qualitative interview about their experiences.
45456780|NCT03927547|Device|Inclined Sleep|Study participants randomized to the interventional arm will be instructed to sleep on inclined wedge mattress.
45833430|NCT03083028|Procedure|Open reduction internal fixation of the ankl|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
45456781|NCT03635788|Drug|Standard of Care (SOC) Oral ART|SOC oral ART regimen must include at least 3 drugs with 2 or more drugs predicted to be fully active, including a boosted protease inhibitor (PI) and/or an integrase strand transfer inhibitor (INSTI)
45833431|NCT03082950|Diagnostic Test|polymerase chain reaction|PCR is performed with all patients. The result (hpv positive or negative) will define the patiens Group Affiliation.
45989329|NCT00517062|Drug|Placebo|Placebo self-injected once a day subcutaneously at bedtime.
45989330|NCT00517140|Procedure|Repeat Caesaen section|
45989331|NCT00517140|Procedure|vaginal delivery|
45989332|NCT02275676|Other|bioelectrical impedance analysis|
45989333|NCT02275676|Other|indirect calorimetry|
45989334|NCT00517179|Drug|Vardenafil 10mg|
45989335|NCT04517981|Behavioral|Psychological intervention|Choose according to the wishes of the enrolled subjects and the results of the evaluation
45989336|NCT04517981|Other|Comprehensive intervention|Choose according to the wishes of the enrolled subjects and the results of the evaluation
45989337|NCT00517218|Drug|Genasense® (, oblimersen sodium G3139)|
45989338|NCT00506207|Drug|S-1, Irinotecan, Oxaliplatin|
45989339|NCT00517257|Drug|Atorvastatin|80 mg orally once daily for 24 weeks
45989340|NCT00517257|Drug|Placebo|Placebo tablet orally once daily for 24 weeks
45989341|NCT00506246|Drug|Propofol|"intravenous (total intravenous anaesthesia)~induction and maintenance"
45989342|NCT00517335|Procedure|Functional magnetic resonance imaging (fMRI) scan|Healthy control women, recovered bulimia women, and also recovered anorexia women will complete specific tasks in an fMRI scanner that will take up to 60 minutes.
45989343|NCT04517708|Other|Nutritional counseling|Each patient was assigned a specific menu which were prepared by research members during the time of staying at the hospital. Before discharge, patients were instructed on preparing their diets at home with the recommended amount of energy and protein and given formula milk within two months
45673823|NCT04782323|Drug|aQII-1|Biological/Vaccine: Investigational aQII-1 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
45673824|NCT04782323|Drug|aQII-3 Investigational|Biological/Vaccine: Investigational aQII-3 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
45456782|NCT03635788|Drug|Oral RPV|RPV 25 mg tablets
45833432|NCT03082794|Dietary Supplement|NCD|Negative Calorie Diet
45833433|NCT03082794|Dietary Supplement|LCD|Low Calorie Diet
45989344|NCT04517240|Other|endoscopy|upper and lower endoscopy and fecal calprotectin test
45456783|NCT03635788|Drug|Oral CAB|CAB 30 mg tablets
45456784|NCT03635788|Drug|RPV-LA Loading Dose|900 mg administered as one 3 mL (900 mg) intramuscular injection in the gluteal muscle
45833434|NCT05685888|Other|Medication history|The study was retrospective and did not involve the application of interventions
45456785|NCT03635788|Drug|CAB-LA Loading Dose|600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
45833435|NCT05525676|Behavioral|Brief Relationship Checkup (BRC)|"The investigators are using the three 30-minute session protocol developed for Air Force Primary Care (Cigrang et al., 2016). Although it is simply referred to as the Marriage Checkup in that manuscript, the investigators use the name BRC to distinguish it from many other versions of Dr. James Cordova's Marriage Checkup (Cordova, 2014) adapted for different settings. Sessions in this version are briefer than other versions (30 mins vs. 60-90 mins) and this trial does not have any eligibility restrictions based on marital status."
45989345|NCT01243242|Drug|Metadoxine (MG01CI)|MG01CI 1400 mg, that will be taken daily by the patients for a duration of 6 weeks.
45989346|NCT01242813|Drug|ACZ885|
45989347|NCT00517491|Drug|lanreotide (Autogel formulation)|120 mg administered every 28 days via deep subcutaneous injection. A total of 4 injections will be administered during the study.
45989348|NCT00517569|Genetic|GX-12|a mixed plasma DNA (HIV-1 antigen genes and human IL-12 mutant) 4, 8, 16mg, i.m., once every other weeks for 22 weeks (total 12 times)
45989349|NCT00517569|Drug|HAART|Highly active antiretroviral therapy; Discontinuation at 24 weeks; NB: The patients should be treated with 2 NRTIs+1 NNRTI or 2 NRTIs + 1 PI, according to the guidelines published by DHHS in the USA.
45989350|NCT00506363|Procedure|pulsed dye laser therapy|Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device on the day of suture removal. Another part will be treated with pulsed dye laser and dynamic cooling device 2 months after suture removal. Only dynamic cooling device will be used for remaining part serving as control. Treatment will repeat for 6 sessions at 3 weeks intervals.
45989351|NCT01242111|Drug|BMN 110|Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of approximately 4 hours per infusion, for up to 240 weeks.
46002292|NCT03991624|Other|Inhibition evaluation|"Stroop Victoria : This test consists of 3 sheets of 24 items, organized in 6 lines of 4 (points, neutral words or names of colours), from which the subject must identify the ink of the stimuli as quickly and precisely as possible.~Stop Signal task on the computer to give a response to the presentation of a target stimulus (Go signal) (e.g. pressing a button when a red circle appears on the screen, but doing nothing when a blue triangle appears), and prevent this response when the stimulus is followed or preceded by a beep (stop signal) (e.g. the appearance of a red circle is immediately preceded or followed by a beep, the subject should not press the button)."
45989352|NCT04517591|Behavioral|The Take a STAND for health|A 4-month parallel-group randomised controlled trial will be performed, in which patients post-bariatric surgery will be assessed at baseline pre-surgery (PRE-BAR), 3 months after surgery and pre-intervention (PRE-INT) and 4 months after intervention (POST). Moreover, a sub-sample of patients will perform a randomised crossover trial at baseline (PRE). Patients will complete three experimental sessions in a random manner, as follows: Prolonged sitting (SIT), in which participants engaged in prolonged sitting throughout an 5-h period and were instructed to minimize excessive movement; Exercise followed by prolonged sitting (EX), in which participants performed a 30-min moderate-to-vigorous exercise bout on a treadmill, subsequently, participants engaged in prolonged sitting as described for SIT; Light-intensity breaks (BR), in which participants completed a 3-min bout of light-intensity walking every 30 min of sitting throughout the experimental period.
45989353|NCT04517630|Diagnostic Test|urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic|Determine the evolution of NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic at basal, and the 3 , 5 and 7 days after recruitment
45989354|NCT00517608|Device|Laparoscopic colectomy|
45989355|NCT04517201|Drug|iNCDSS based insulin regime|Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).
45989356|NCT04517201|Drug|Physician based insulin regime|Patients of this group will receive the insulin regime recommended by professional endocrinologists.
45989357|NCT01241604|Device|BiPAP S/T|Mechanical Non-invasive Ventilation
45989358|NCT01241604|Device|BiPAP Auto SV3|Auto Servo Ventilation Device
45989359|NCT04515524|Other|Non-Interventional|No study treatment will be administered in this study
45989360|NCT00517647|Drug|ATMX|Medication phase: After screening assessments are completed, the child will enter the medication phase of the study. The child will be started on atomoxetine at 0.5 mg/kg/day, with the dosage increased to a maximum dose of 1.8 mg/kg/day. The dose will be determined by how well the child responds to and tolerates the drug. The dose will be given twice a day to minimize side effects. After the optimum dose is determined, the child will be kept at this stable dose for 4 weeks.
45989361|NCT04519775|Behavioral|Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
45989362|NCT01241292|Biological|BMS-901608 (Elotuzumab) 10 mg|Injection, Intravenous, 10 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
45989363|NCT01241292|Biological|BMS-901608 (Elotuzumab) 20 mg|Injection, Intravenous, 20 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
45989364|NCT04696406|Device|RESPINOR DXT|Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
45989365|NCT00517686|Other|Information feedback intervention|This study will evaluate an information feedback intervention: measuring, reporting and feeding back information to primary care teams on the need for treatment intensification in patients at high risk for cardiovascular disease (CVD).
45989366|NCT00517725|Drug|carvedilol|
45989367|NCT00517725|Drug|bisoprolol|
45989368|NCT00517725|Drug|Nebivolol|
45989369|NCT04512248|Behavioral|Quit and Stay Quit Monday Model|Participants randomized to the study intervention will receive: (1) 2 telephone smoking cessation coaching calls; (2) enrollment into SmokefreeTXT; and (3) enrollment in the iquitmonday.org weekly email newsletter. The telephone coaches will ask these participants to identify a future Monday as their quit date and provide coaching to achieve a Monday quit. The coaches will also enter the selected Monday as the patient's quit day when enrolling the patient into SmokefreeTXT.
45456786|NCT03635788|Drug|RPV-LA Maintenance Dose|600 mg administered as one 2 mL (600 mg) intramuscular injection in the gluteal muscle
45456787|NCT03635788|Drug|CAB-LA Maintenance Dose|400 mg administered as one 2 mL (400 mg) intramuscular injection in the gluteal muscle
45456788|NCT01348412|Drug|oxaliplatin|130 mg/m²Every 21 days
45456789|NCT01348412|Drug|raltitrexed|3 mg/m² with a maximum of 6 mg every 21 days
45456790|NCT01348412|Drug|other intravenous chemotherapy drugs|
45833436|NCT05525676|Behavioral|Co-Located Collaborative Care (CCC)|"The investigators are using the Co-Located Collaborative Care model developed by the VA Center for Integrated Healthcare to deliver at all VAs. Although the CCC model is flexible and can range from 1-6 sessions, in this study the investigators standardize the model to three sessions for a clear comparison with BRC. Session 1 uses the CCC Functional Assessment/Initial Assessment protocol. Sessions 2 & 3 use the CCC Follow-up protocol.~Session 1 (25-30 min)- Veteran completes a functional assessment of concerns (15 mins) and then develops a personalized action plan (10 minutes) Session 2 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan (20 minutes) Session 3 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan, including receiving referrals (20 minutes)"
45833437|NCT03335670|Drug|[68Ga]Pentixafor|68Ga Pentixafor is a radiolabeled cyclic pentapeptide with high affinity for CXCR4 receptor
45989370|NCT04516889|Procedure|Doubled sutured SFIOL|Recruited subjects would undergo implantation of SFIOL with the modified technique under either local or general anesthesia. The surgeon would mark the sclerotomies as per routine sutured SFIOL at 2mm behind the nasal and temporal limbus, followed by passage of 2 pairs of prolene sutures. The intraocular lens with islets would be implanted into the posterior chamber and sutured to the sclera as per single suture SFIOL.
45989371|NCT02276261|Procedure|Vaginal cuff closure - vertical|Vaginal cuff is closed vertically.
45989372|NCT02276261|Procedure|Vaginal cuff closure - horizontal|Vaginal cuff is closed horizontally.
45989373|NCT01240863|Drug|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
45989374|NCT01240863|Drug|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
45989375|NCT02275715|Behavioral|Parent Training Program|An 11-session manualized behavioral parent training program for the treatment of feeding problems teaching parents to use a range of behavioral procedures to address a variety of common feeding problems.
45989376|NCT04517045|Drug|Dachengqi decoction|Raw rhubarb 30g, Glauber's salt 30g, Citrus aurantium 20g, Magnolia officinalis 20g. The decoction was decocted uniformly in the decoction room of Xinhua Hospital, Shanghai Jiaotong University School of Medicine, and decocted 200 mL thickly, fed via nasogastric tube/nasal intestine tube and enema, 1 dose/d, and continued treatment until the end of the trial
45989377|NCT04517045|Drug|probiotic L9|L92 2 tablets/time, tid, oral or nasal feeding
45989378|NCT04517045|Other|Conventional treatment|Conventional treatment
45989379|NCT02955485|Other|Patients do not undergo any type of interventions, but standard care if offered and accepted.|
45673825|NCT04782323|Drug|aQII-6 Investigational|Biological/Vaccine: Investigational aQII-6 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
45673826|NCT04782323|Other|aQII-7 Investigational|Biological/Vaccine: Investigational aQII-7 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
45833438|NCT03400410|Behavioral|Education Arm|The educational video will be an overview with brief pros and cons of all types of available hormonal contraception. There will be emphasis on the importance of condom use as part of dual method protection.
45833439|NCT04348188|Behavioral|Education program on healthy habits|6-week supervised educational program with 12-month follow-up compared to the same unsupervised intervention
45833440|NCT03082404|Other|Inspiratory muscle training|Inspiratory muscle training will be performed during the first hour of hemodialysis treatment and the protocol will consist of five series with 10 repetitions, each series with a two-minute interval of according to patient tolerance. The overload will be adjusted weekly, beginning with 50% of the maximum inspiratory pressure, during the first week, 60% of maximum inspiratory pressure in the second and third week and 70% of maximum inspiratory pressure in the fourth and fifth weeks. Maximum inspiratory pressure will be evaluated before the protocol period and adjusted weekly by manovacuometry.
45989380|NCT01240746|Biological|Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to <9 years), Intramuscular
45833441|NCT03334344|Device|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
45989381|NCT01240746|Biological|Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to <9 years), Intramuscular
45989382|NCT01240746|Biological|Quadrivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months), or 0.5 mL(3 to <9 years), Intramuscular
45989383|NCT04513028|Dietary Supplement|Beta-Glucan|500mg (1 capsule) by mouth twice a day for 21 days.
45989384|NCT04516382|Drug|PTG-300|Active drug
45989385|NCT04517123|Other|Prone Positioning|Prone Positioning
45989386|NCT01240590|Drug|Crolibulin|Phase I:Dose Level (DL) 1 - 13 mg/m(2) intravenous (IV),DL 2 - 13 mg/m(2) IV, DL 3 - 20 mg/m(2) IV. Phase II: 20 mg/m(2)
45989387|NCT01240590|Drug|Cisplatin|Phase I:Dose Level (DL) 1- 75 mg/m(2) intravenous (IV),DL 2 - 100 mg/m(2),DL 3 - 100 mg/m(2). Phase II: 100 mg/m(2)
45989388|NCT04516187|Diagnostic Test|signs and symptoms, blood tests|signs and symptoms as observed by the treating GP, blood tests (CRP, Procalcitonin, White blood cell count)
45989389|NCT02949804|Behavioral|Comparison between two groups|Comparison will be made between smokers and non smokers regarding vasovagal tendency
45989390|NCT01240200|Drug|Glargine|oral antidiabetic agents plus once daily insulin glargine via an insulin syringe
45989391|NCT01240200|Device|glargine via insulin pen|oral antidiabetic agents plus insulin glargine in a pre-filled pen
45989392|NCT04516460|Device|Interventional arm: endoscopic resection plus PuraStat®|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to prevent bleeding after endoscopic resection of colorectal neoplastic lesions
45989393|NCT00504543|Drug|AEB071|oral, twice daily
45673827|NCT04782323|Drug|aQII-9 Investigational|Biological/Vaccine: Investigational aQII-9 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
45673828|NCT04782323|Drug|aQII-10 Investigational|Biological/Vaccine: Investigational aQII-10 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
45989394|NCT00504543|Drug|Certican|twice daily
45989395|NCT00504543|Drug|Neoral|twice daily
45989396|NCT02949570|Drug|Inecalcitol|Prospective open label, non-comparative, multicentre exploratory study. Divided in 2 parts Part1: Inecalcitol treatment will be added to imatinib for 12 months. Part 2: Follow-up after discontinuation of inecalcitol. Imatinib will be maintained for 2 years and then will be stopped for those still in MR4.5. These patients will then be followed for 2 additional years after discontinuation of imatinib.
45989397|NCT02949843|Drug|Chemotherapy|Receive other treatment
45989398|NCT02949843|Biological|Immunotherapy|Receive other treatment
45673829|NCT04782323|Drug|aQII-11 Investigational|Biological/Vaccine: Investigational aQII-11 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
45673830|NCT04782323|Drug|QII Active Comparator|Biological/Vaccine: Investigational QII Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
45989399|NCT02949843|Other|Laboratory Biomarker Analysis|Correlative studies
45989400|NCT02949843|Biological|Nivolumab|Given IV
45989401|NCT02949843|Biological|Pembrolizumab|Given IV
45989402|NCT02949843|Drug|Targeted Molecular Therapy|Receive drug targeting secondary mutation
45989403|NCT02949843|Drug|Tyrosine Kinase Inhibitor|Given PO
45989404|NCT04516343|Device|Robotic Ankle Assist Device (RAAD)|The RAAD (Robotic Ankle Assist Device) is an intelligent, powered ankle device designed to increase independence, mobility, and deliver gait training to children with movement disorders, such as CP
45989405|NCT00517764|Drug|escitalopram|Patients started on 20mg of escitalopram and this dose was increased based on tolerability and therapeutic response to a maximum dose of 40mg by week 12. The trial was 16 weeks. The treatment trial has completed and is no longer accepting patients.
45989406|NCT04516265|Procedure|neurodevelopmental treatment|A personally designed treatment program will be applied in line with the principles of neurodevelopmental treatment.
45989407|NCT04516265|Procedure|video-based trunk training|Games developed for the use of children with cerebral palsy will be used for trunk training.
45989408|NCT04516265|Procedure|Video-based trunk training will apply with Theratogs|Video-based trunk training will apply with Theratogs
45989409|NCT00517803|Dietary Supplement|Probiotic Yogurt B: with various micronutrients|175g probiotic yogurt / day 25% RDA for each nutrient
45989410|NCT00517803|Dietary Supplement|Probiotic Yogurt A: Kaiser micronutrients|175g probiotic yogurt/ day 25% RDA for each nutrient
45989411|NCT00517803|Dietary Supplement|Probiotic yogurt C: with basic micronutrients|175g yogurt/ day 25% RDA for each nutrient
45989412|NCT00517803|Dietary Supplement|Probiotic Yogurt D: Placebo -- no added micronutrients|175g/day probiotic yogurt
45989413|NCT01243125|Drug|NVC-422, 0.2%|0.2% NVC-422 (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
45989414|NCT01243125|Drug|Sterile normal saline, 0.9%|Saline (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
45673831|NCT04239521|Other|Exposure of interest (studies 2 & 3).|Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder Atopic conditions consist of Atopic dermatitis, allergic rhinitis, asthma Autoimmune conditions consist of Crohn's disease, ulcerative colitis, Coeliac disease, Pernicious anaemia, Type 1 diabetes, Hashimoto's thyroiditis, Grave's disease, Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Systemic lupus erythematosus, polymyalgia rheumatica, Sjögren's syndrome, Psoriasis, vitiligo, Multiple sclerosis
45673832|NCT04219007|Drug|Vosoritide|After enrollment, subjects will be followed for a 6 month observation only period to establish a baseline height velocity as well as safety profile and quality of life assessment. Vosoritide will then be administered daily via subcutaneous injection at a dose of 15 µg/kg/day for 12 months.
45673833|NCT04168073|Other|High-sodium diet 300 mmol sodium/day|Day 7 or day 21 high-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
45989415|NCT04516304|Dietary Supplement|Placebo|4 tablets/d (2 in the morning and 2 in the evening)
45989416|NCT04516304|Dietary Supplement|S-equol|4 tablets/d (2 in the morning and 2 in the evening), providing 10 mg S-equol total a day Other Names: •Equelle®
45989417|NCT01242930|Drug|Imetelstat (7.5 mg/kg)|Imetelstat 7.5 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
45989418|NCT01242930|Drug|lenalidomide standard of care|Patients who are receiving lenalidomide as maintenance therapy upon enrollment as part of their treatment regimen may remain on this therapy during trial participation, provided that they have received this treatment for a minimum of 3 months and demonstrate evidence of stabilization of their response.
45989419|NCT01242930|Drug|Imetelstat (9.4 mg/kg)|Imetelstat 9.4 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
45989420|NCT01241331|Drug|BLI1100|BLI110 topical cream
45989421|NCT01241331|Drug|Vehicle cream|Vehicle topical cream
45989422|NCT04516031|Procedure|Posterior Component Separation with Transversus Abdominis Muscle Release|The posterior component separation technique with transversus abdominis muscle release was done as prescribed in Novitsky et al in 2012.
45989423|NCT04516031|Procedure|Mesh-only repair|The prosthetic mesh only repair was done as described by Wantz in 1991.
45989424|NCT04515758|Other|Exercise and Cognitive Training|Exercise: 12-week, twice-weekly 60-minute program. Each session includes a brief 5 minute educational lesson on a health-related topic (i.e. healthy eating, good posture, etc.). Each participant receives individualized and progressive exercise program from qualified exercise providers (YMCA instructors). The programs include whole body exercises including squats, rows, chest press, bicep/tricep exercises, shoulder exercises, and core exercises. A 5 warm-up is done (individually or in a group) and a 5 minute group cool-down (stretching) is done each class. Cognitive training: focuses on dual-task training (provided by an Android tablet). Each cognitive task requires the participant to choose and execute the response appropriate for the stimuli presented. Participants must prioritize their response and perform tasks as fast as possible while maintaining accuracy. The difficulty of the training is individualized and progressive based on their ongoing performance.
45989425|NCT04515758|Other|Exercise Training Only|Exercise: 12-week, twice-weekly 60-minute program. Each session includes a brief 5 minute educational lesson on a health-related topic (i.e. healthy eating, good posture, etc.). Each participant receives individualized and progressive exercise program from qualified exercise providers (YMCA instructors). The programs include whole body exercises including squats, rows, chest press, bicep/tricep exercises, shoulder exercises, and core exercises. A 5 warm-up is done (individually or in a group) and a 5 minute group cool-down (stretching) is done each class.
45989426|NCT01241214|Drug|ACT-129968|ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily
45989427|NCT01241214|Drug|ACT-129968|ACT-129968 (Dose 4) & matching placebo administered orally once daily
45989428|NCT01241214|Drug|Cetirizine|Ceterizine administered once daily
45989429|NCT01241214|Drug|Placebo|Matching placebo administered twice daily.
45989430|NCT01240512|Drug|Cholecalciferol|Vitamin D3 (cholecalciferol) 200 IU and 2000 IU drops will be supplied by D Drops. It is supplied as a liquid containing 400 drops/bottle with a potency of 200 IU/drop or 2000 IU/drop. The contents of the label will be in accordance with all applicable regulatory requirements. The droppers are gravity-metered to deliver a consistent drop size (dosage). Two drops (either 200 IU or 2000 IU) of Vitamin D (cholecalciferol) is to be taken orally once-daily.
45989431|NCT04513769|Behavioral|Vegan diet|Participants will receive a behavioral intervention on a vegan diet in partnership with a local vegan soul food restaurant
45989432|NCT00517842|Drug|ViNeuro|
45989433|NCT04515368|Biological|Immunization|Immunisation with one of four licensed vaccines
45989434|NCT01240629|Other|laboratory biomarker analysis|Correlative study
45989435|NCT01240629|Other|questionnaire administration|Correlative study
45989436|NCT01240629|Drug|doxorubicin-GnRH agonist conjugate AEZS-108|Given IV
45989437|NCT04515446|Diagnostic Test|Rapid test for diagnosis orientation|Rapid tests screen for influenza viruses in less than 30 minutes. They detect internal viral nucleoproteins by immunochromatography using specific antibodies attached to one or more strips.
45989438|NCT04515446|Diagnostic Test|quantitative PCR|Molecular biology method of gene amplification in vitro. It allows a large number of known DNA or RNA sequences to be duplicated
45989439|NCT03459066|Diagnostic Test|Institution-Group|"The study includes three measurement times:~Time 1 (T1): corresponds to the first measurement, which will take place between the 3rd and 10th day of hospitalization.~Time 2 (T2): corresponds to the second measurement, which will be carried out 3 months after the first measurement.~Time 3 (T3): corresponds to the third measurement, which will be carried out 12 months after the first measurement.~The evaluations will be tone, functionality and quality of life."
45989440|NCT00506402|Drug|MKC-1|Capsule, 30 mg and 100 mg, BID, continuous dosing
45989441|NCT02949531|Drug|oxygen|
45989442|NCT04515641|Drug|Islatravir|Two ISL 30 mg capsules taken by mouth.
45989443|NCT00517959|Radiation|Stereotactic Conformal radiotherapy|SCRT
45989444|NCT00517959|Radiation|Conventional radiotherapy|
45989445|NCT04515992|Behavioral|High Intensity Body-weight Circuit Training (HIBC)|HIBC Exercise Protocol- The HIBC circuit repetition and order is as follows: modified squats (10 repetitions), modified rows (5 repetitions), crunches (10 repetitions), and modified push-ups (5 repetitions). The exercise sessions involved repeating a series of repetitions of each movement in sequence, and completing as many sequences as possible in good form in the time allotted for the exercise (initially, 5 minutes). Participants were instructed to complete three sessions per week and documented the number of cycles completed. After 3 weeks of consistent training, participants were asked to add a 4th session each week as tolerated. Initially, the HIBC sessions were 5 minutes long, and the duration of the sessions were increased by one minute each week as tolerated beginning in week four, peaking at 10-minutes per session as early as the eighth week of training. Session duration was capped at 10 minutes.
45989446|NCT00518232|Drug|OROS-methylphenidate|
45989447|NCT04515602|Procedure|Primary debulking surgery|Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
45673834|NCT04168073|Other|Low-sodium diet 10 mmol sodium/day|Day 7 or day 21 low-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
45676693|NCT01622660|Drug|Pazopanib|pazopanib 800 mg orally daily day 1 through day 21 (1 cycle = 21 days) Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
45989448|NCT04515602|Procedure|Neoadjuvant chemotherapy|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
45989449|NCT04515602|Drug|PARPi|For patients with gBRCA/sBRCA mutation and CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors.
45989450|NCT00517998|Drug|Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel|10 mL Hydrogel
45989451|NCT00505505|Drug|Insulin (Actrapid)|50 UI Actrapid diluted in 50 ml of saline
45989452|NCT00505583|Drug|MOA-728|
45989453|NCT00518271|Drug|Rapamune® (Sirolimus)|
45989454|NCT00518271|Drug|Tacrolimus|
45989455|NCT00518271|Drug|Corticosteroids|Perioperative
45989456|NCT04518605|Dietary Supplement|Low protein breakfast|Low protein yoghurt containing approx. 2 g protein per 100 g. Participants will be asked to consume ~60 g bread, 20 g jam and 250 ml juice for breakfast.
45989457|NCT04518605|Dietary Supplement|High protein breakfast|High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) yoghurt with 40 g oats for breakfast.
45989458|NCT04518605|Other|Exercise training|Participants will be asked to participate in organized exercise training 3 times per week.
45989459|NCT00518310|Drug|Placebo|
45989460|NCT00518310|Drug|AZAPRED|The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks. The dose will continue to decrease at a rate of 5 to 10 mg per week, to a dose of 0.25 or 0.125 mg/kg/day. Azathioprine will be given at a dose of 2-3 mg/kg/day (max 100 mg).
45989461|NCT00518388|Behavioral|Focus Group|Focus groups each lasting about 2 hours.
45989462|NCT00518388|Behavioral|Questionnaire|Questionnaire relating to your health practices and knowledge about cervical cancer and HPV.
45989463|NCT02955407|Other|no intervention|observational case-control study
45989464|NCT00518193|Drug|ERBITUX|400 mg/m² 2h injection at week 1, then 250 mg/m² in one hour injection the following weeks
45989465|NCT04519814|Procedure|selective laser trabeculoplasty (SLT)|Treatment will be performed on Day 0 using the VISULAS green with Option CSLT for SLT treatment and a mirror goniolens to visualize the trabecular meshwork. The initial energy level is set according to the grade of angle pigmentation and bubble formation. Approximately one hundred non-overlapping lesions will be applied in a single session to 360° of the trabecular meshwork.
45989466|NCT00518427|Drug|Insulin Glargine|"Lantus (insulin glargine [rDNA origin] injection), individual dosing , subcutaneous injection, 100 IU/ml.~Duration of treatment will be judge by the investigator. Last QoL assessed in the study will be 9 months after start of glargine treatment."
45989467|NCT04515173|Diagnostic Test|Artificial intelligence diagnosis and treatment assistance system|An artificial intelligence robot that can assist psychiatrists in disease screening, diagnosis, treatment, and follow-up.
45989468|NCT00518466|Drug|topiramate|25 mg modified-release capsules
45989469|NCT00518466|Drug|phentermine|7.5 mg immediate-release capsules
45989470|NCT00518466|Drug|topiramate|100 and 25 mg immediate-release tablets
45989471|NCT00518466|Drug|phentermine|37.5 and 7.5 mg immediate-release tablets
45989472|NCT04518020|Procedure|40 patients will be randomly allocated to short implants and standard implants in conjunction with MSFA|40 patients will be randomly allocated to short implants (group 1) and standard implants in conjunction with MSFA using 50% particulated autogenous mandibular bone graft mixed with 50% Bio-Oss (group 2).
45989473|NCT00518505|Other|Symptom questionnaire|This questionnaire will assess patient outcomes before and after surgery for gastroesophageal reflux disorder.
45989474|NCT04518761|Procedure|Elective surgery|Any patient who needs to undergo an elective surgery.
45989475|NCT00519714|Dietary Supplement|1-Methylnicotinamide (1-MNA)|Following a 6-8-week placebo and dietary-controlled baseline period, 195 men and women will be randomized to receive placebo, 30 mg MNA or 90 mg MNA three times daily for twelve weeks.
45989476|NCT00519714|Dietary Supplement|Placebo|Placebo
45989477|NCT00518544|Drug|administration of hydroxyehtyl starch|colloid is administered during operation according to blood loss.
45458365|NCT03498040|Other|Study of the occurrence of Carcinoid Heart Disease|"Patient at high risk of Carcinoid Heart Disease (metastatic ileum or bronchial well-differentiated neuroendocrine tumors, patients with high level of urinary 5HIAA or with carcinoid syndrome) are followed with annual echocardiography to detect the occurrence of carcinoid heart disease.~In case of documented Carcinoid Heart Disease, a six or three months' cardiac follow-up is necessary to evaluate the progression and the severity of the disease.~Investigators collect the data of clinical parameters (flushes, diarrhea, …) biological parameters (urinary 5HIAA, NT-ProBNP …) and cardiac parameters that may influence the occurrence, severity and progression of Carcinoid Heart Disease."
45989478|NCT00506480|Procedure|endometrial sampling|Endometrial biopsy is a procedure in which a tissue sample is obtained from the endometrium. This procedure is performed without anesthesia during pelvic examination. The cervix is cleaned with an antiseptic solution and then grasped with an instrument (tenaculum) to steady the uterus. A small, hollow plastic tube is gently passed into the uterine cavity. Gentle suction removes a sample of the lining. The tissue sample and instruments are removed, and the sample is examined by pathology, immunohistochemistry, PCR and western blotting.
45989479|NCT04694508|Device|Headphones (Disok, Alicante, España)|A pair of non-reusable headphones (Disok, Alicante, Spain)
45989480|NCT04515056|Drug|Papain 10 µg|The area will be exposed to 10 µg of papain.
45989481|NCT04515056|Drug|Papain 50 µg|The area will be exposed to 50 µg of papain.
45989482|NCT04515056|Drug|Papain 100 µg|The area will be exposed to 100 µg of papain.
45989483|NCT04515056|Other|Vehicle|The area will be exposed to vehicle
45989484|NCT04515056|Drug|Papain 1 SPT|Papain will be applied by 1 SPT prick thought the skin
45989485|NCT04515056|Drug|Papain 5 SPT|Papain will be applied by 5 SPT pricks thought the skin
45989486|NCT04515056|Drug|Papain 25 SPT|Papain will be applied by 25 SPT pricks thought the skin
45989487|NCT04515056|Other|Cowhage|The last area will be exposed to cowage spicules (made chemically inert by autoclaving) soaked in 5 mg/ml papain solution.
45989488|NCT00518583|Drug|Pegylated Liposomal Doxorubicin (Doxil)|Doxorubicin administered once every three weeks Taxol administered weekly Herceptin administered weekly
45989489|NCT04514900|Behavioral|Video Chat +Personalized Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via video chat and weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A group facilitator will monitor digital food diaries and provide detailed weekly feedback on diet and exercise.
45989490|NCT04514900|Behavioral|Video Chat + Basic Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via video chat and weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A group facilitator will monitor digital food diaries and provide basic weekly feedback on diet and exercise.
45989491|NCT04514900|Behavioral|Discussion Board for Social Support +Basic Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. They also are provided with a study discussion board for social support from fellow participants. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A weight loss counselor will monitor digital food diaries and provide basic weekly feedback on diet and exercise.
45989492|NCT04514900|Behavioral|Discussion Board for Social Support+Personalized Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. They also are provided with a study discussion board for social support from fellow participants. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A weight loss counselor will monitor digital food diaries and provide personalized, detailed weekly feedback on diet and exercise.
45989493|NCT00519753|Drug|Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)|One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
45989494|NCT00519792|Drug|Omega DUROS device|Omega DUROS device 25mcg inserted SC for 48 weeks Omega DUROS device 50mcg inserted SC for 48 weeks
45989495|NCT00519870|Drug|nifedipine, losartan|I: nifedipine 30 mg/d II: losartan 50 mg/d
45989496|NCT00519870|Drug|losartan|II: losartan
45989497|NCT00519870|Drug|Nifedipine, losartan|I: nifedipine II: losartan
45989498|NCT00518700|Other|new MPS|
45989499|NCT00518700|Other|RepleniSH|
45989500|NCT00519909|Other|Dairy calcium|Diets with different content of calcium and fat
45989501|NCT04694937|Device|heart rate variabilty measured by pulse oximetry|"Resting HRV will be measured by Pulse Oximeter BM2000A/Shanghai Berry Electronic Tech Co., Ltd. that is validated for this purpose and is approved by FDA. The measurement, at the patient's fingertip, takes 5 minutes. The measurement will be performed twice - at two consecutive visits at the clinic, as part as the routine follow up of the patient every 3 months.~HRV will be correlated to demographic and metabolic parameters between patients. In order to reveal whether HRV can serve as a predictor to metabolic disease progression or improvement, HRV will be correlated to metabolic parametrers in the same patient at two time-points."
45989502|NCT04514978|Procedure|Blood donation and blood transfusion|24 subjects (12 female, 12 male) is phlebotomized and four weeks later ~130 mL packed red blood cells are re-infused in the same subjects.
45989503|NCT02949492|Drug|IL-2 (interleukin 2)|Low-dose IL-2 will be initiated while study participants remain on a calcineurin inhibitor immunosuppressant. Following 4 weeks of treatment, participants showing at least a 2-fold increase in peripheral blood absolute Treg numbers, stable liver function and no adverse effects will undergo a liver biopsy to exclude sub-clinical graft damage, and subsequently will initiate immunosuppression withdrawal. Low-dose IL-2 will be maintained for a total of 6 months.
45833442|NCT04348344|Behavioral|pulmonary rehabilitation|"Patients receive health education of pulmonary rehabilitation, using the home-based rehabilitation exercise prescription, taking home exercise as the main form, using the sports bracelet and special respiratory rehabilitation app software, the home management system integrating home rehabilitation training, detection and feedback is mainly adopted, which is a combination of aerobic endurance training: walking, intermittent strength training: elastic band and inspiratory muscle training:apparatus, abdominal breathing training."
45989504|NCT04512599|Other|Prebiotic Bar|The prebiotic bar is a proprietary formula created by the study co-investigators, who will not be involved in participant recruitment, selection or outcome measures.The prebiotic bars will be shipped and stored at room temperature prior to consumption.
45989505|NCT00518739|Drug|MK2461|Patients will be administered oral MK2461 twice daily and will be treated for 28 day cycles. Patients will be enrolled in cohorts and will be treated at sequentially rising dose levels of MK2461. 60 mg dry filled capsules, escalating to 240 mg ( for dosing in Cohort 4 & beyond).
45989506|NCT04514861|Device|Wireless Lumee Oxygen Platform|The Lumee Oxygen Platform is designed to monitor oxygen dynamics with a hydrogel placed in subcutaneous tissue
45989507|NCT00519948|Drug|new MPS, opti-free express no rub MPS|
45989508|NCT04514666|Other|Breath analysis|The breath of patients undergoing liver or kidney transplant will be sampled and volatile organic compounds will be identified
45989509|NCT02949102|Dietary Supplement|Crave Crush|Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
45989510|NCT02949102|Dietary Supplement|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
45989511|NCT04511234|Device|MagicTouch PTA sirolimus drug coated balloon (DCB)|For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion, (defined as <30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch PTA sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
45989512|NCT04511234|Device|POBA standard balloon|For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
45989513|NCT04514822|Diagnostic Test|Dynamic PET|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FDG intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained.And then underwent whole body static PET scan.
45989514|NCT04514588|Dietary Supplement|caffeine consumption|In this trial we are going to study the results of the consumption of 5mgr/kgr body weight of caffeine on appetite, food consumption and hormones ghrelin, asprosin, leptin and pancreatic polypeptide in relation to gene polymorphisms that affect caffeine metabolism and body weight
45989515|NCT02276300|Drug|Cyclophosphamide|Treatment of mild Endoxan application three days before Her2 vaccination
45989516|NCT02276300|Drug|Sargramostim|Sargramostim is part of Her2 vaccination
45989517|NCT02276300|Drug|HER2-Peptid-Vakzine|Her2 vaccination is supplemented by Sargramostim and Aldara Creme application
45989518|NCT02276300|Drug|Imiquimod|Imiquimod is part of Her2 vaccination
45458366|NCT03497962|Procedure|Venepuncture|Taken from established arterial or central lines in critical care setting or by experienced clinicians if no line available and in healthy volunteers.
45673835|NCT04167527|Device|Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device|"Treatment initiation is defined as the date and time of arterial puncture. Femoral artery puncture will occur within 45 minutes of randomization and no longer than 90 minutes after the completion of the qualifying imaging. It must occur before 8 hours since the subject was last known well.The initial procedure will be performed using only the EmboTrap II Retriever for the first two passes, and a third pass is encouraged. Date and time of arterial puncture, revascularization, and procedure end will be recorded. It is expected that the interventional procedure will be completed within two hours of arterial access.~All subjects, regardless of randomization arm, will receive best medical management based on current American Heart Association, Canadian, or European guidelines according to their geographic location."
45833443|NCT05512962|Drug|Triamcinolone Acetonide|Single suprachoroidal Administration of Triamcinolone acetonide
45833444|NCT05512962|Device|Semi-automated Suprachoroidal Microcatheter|Ophthalmic Adminstration Device
45833445|NCT05505864|Behavioral|Health Action Process Approach (HAPA)|Health Action Process Approach (HAPA) using action planning and coping strategies to create health behaviour change
45989519|NCT02949453|Behavioral|Semi-directed interview performed by a social sciences researcher|"Two semi-directed interviews performed by social sciences researcher:~first interview performed 6 weeks after the suicide attempt, in an suicide prevention unit, duration 1 to 1.5 hour~second interview performed 3 month after the suicide attempt, in a suicide prevention unit, duration 1 to 1.5 hour"
45989520|NCT04514939|Other|Elevation of the legs during bed rest|Patients of Group A will will lie in their hospital bed with a moderate leg elevation (between 15 and 30 degrees)
45989521|NCT02949414|Procedure|Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells|The tracheal graft will be manufactured from cadaveric tracheal scaffold and bone marrow derived mesenchymal cells.
45989522|NCT02955173|Procedure|Surgery|Laparoscopic or open surgery for resection of gastric or rectal cancer
46083695|NCT04196660|Behavioral|Labor Dance|The pregnant women and their spouses were trained about the labor dance in the prenatal training without disclosing any information regarding the delivery and labor pain. The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music (on a YouTube channel named Ohgertam Jugrefem) in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing. During the active phase of labor, the pregnant women in the DPMG danced with the midwives who were attendant in the delivery room and who were monitoring the pregnant women's status.
46083696|NCT04252937|Drug|Adrecizumab|HAM8101 (Adrecizumab) is a humanized IgG1 monoclonal antibody (mAb).
46083697|NCT04089813|Drug|Metformin|Patients use metformin to control blood sugar
45989523|NCT00520026|Drug|lithium|
45989524|NCT00520026|Drug|placebo|
45458367|NCT03497962|Procedure|Bronchoscopy|Broncho-alveolar lavage to obtain alveolar macrophages
45673836|NCT04167527|Combination Product|Initial medical management (iMM)|"Patients will receive standard medical therapy based on current AHA guidelines. For patients who are treated with intravenous tissue plasminogen activator (rtPA), the sites' post-rtPA protocol will be followed. Rescue mechanical thrombectomy (rMT) is allowed for patients initially assigned to iMM if they suffer major neurological worsening that clearly requires an intra-arterial intervention in the judgment of the treating team.~All subjects, regardless of randomization arm, will receive best medical management based on current American Heart Association, Canadian, or European guidelines according to their geographic location."
45673837|NCT02074982|Drug|AIN457 300 mg|
45989525|NCT00518856|Other|Neonatal resuscitation protocol|training in neonatal resuscitation and sepsis identification early treatment
46083698|NCT05321225|Diagnostic Test|the level of biomarker in bood|Elisa is used to test the level of biomarker in blood.
45673838|NCT02074982|Drug|ustekinumab 45/90 mg|
45673839|NCT02074982|Drug|placebo secukinumab|Placebo
45673840|NCT04150913|Drug|Anakinra|Subcutaneous, dosage per protocol. Day 0 through Day 6.
45673841|NCT04150913|Drug|Axicabtagene Ciloleucel|Once, intravenous infusion, dosage per protocol
45833446|NCT03832218|Diagnostic Test|Psychiatric assessment|"Psychiatric assessment and neuropsychological tests~Test : Wechsler Intelligence Scale for Children (WISC-V)~Test :Behavior Rating Inventory of Executive Function (BRIEF) : BRIEF-Parents, BRIEF-Teacher~Global Assessment of Functioning Scale~Scale : Brief Psychiatric Rating Scale (BPRS)~Test : Children Depression Inventory (CDI)~Scale : Revised-Children's Manifest Anxiety Scale (R-CMAS)~Survey : Pediatric Quality of Life Inventory Version 4.0 (PedsQL™ 4.0)~Scale : Conners' scale (parents and teachers)"
45833447|NCT03082248|Other|Physical Therapy|Patients allocated to the conservative treatment group will receive physical therapy according to the treatment-based classification approach and also educational leaflets and folders.
45989526|NCT00518856|Other|Standard of care|continued with current standard of care for birth attendants
45989527|NCT02955251|Drug|ABBV-428|ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.
45989528|NCT02955251|Drug|Nivolumab|Nivolumab will be administered by intravenous infusion according to approved dose and dosing schedules.
45989529|NCT00518895|Drug|dacarbazine plus Genasense|Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus Genasense group will receive Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the Genasense infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
45989530|NCT00518895|Drug|dacarbazine plus placebo|Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus placebo group will receive placebo (that is, locally available commercial 0.9% Sodium Chloride Injection) by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the placebo infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
46083699|NCT02708316|Genetic|sequencing faecal metagenome|sequencing faecal metagenome is not the intervention measure.It is the observational method for investigators to detect the component of faecal microorganism.
46083700|NCT05071430|Drug|HB-01|HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
46083701|NCT05071430|Drug|Placebo|HB-1 matched placebo
46083702|NCT02598141|Biological|Biological sampling grinding|One half of the biological material collected during the intervetion (according to standard procedures) will be ground using the Ultra Turrax technique before proceeding with culturing.
46083703|NCT02598141|Biological|Biological sampling with standard procedures|One half of the biological material collected during the intervetion (according to standard procedures) will be treated according to standard techniques before proceeding with culturing.
46083704|NCT04255667|Procedure|Eyelid margin crush|after marking eyelid , hemostat is used for eyelid margin incision crush . Then eyelid surgery is done
45673842|NCT04798001|Biological|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
45989531|NCT02275754|Behavioral|PN+LCNC|Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
45989532|NCT02275754|Behavioral|PN Only|Participants will be navigated by PN on request
45989533|NCT02954978|Drug|Placebo Oral Capsule|"25 patients in group 1 will receive Placebo (sugar pill) one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up."
45989534|NCT02954978|Drug|Nilotinib 150mg oral capsule [Tasigna]|25 patients in group 2 will receive 150mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
45989535|NCT02954978|Drug|Nilotinib 300mg oral capsule [Tasigna]|25 patients in group 3 will receive 300mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
45989536|NCT00520065|Other|enteral nutritional formula|Meal glucose tolerance test
45989537|NCT00520065|Other|Diabetes specific enteral product|Meal Glucose tolerance test
45989538|NCT00518934|Other|Study for safety and efficiency of therapeutic angiogenesis for patients with limb ischemia by transplantation of human cord blood mononuclear cell|
45989539|NCT00520104|Drug|intranasal ketamine|drug interaction
45989540|NCT00519012|Drug|Sertraline to Paroxetine|For subjects enrolled in this arm, sertraline will be initiated at 25mg, increased to 50mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, sertraline will be continued and titrated at 50 - 100mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, sertraline will be continued and titrated at 50 - 100mg, whereas in the other group sertraline will be switched to paroxetine. In this switching group, paroxetine will be started at 10mg on days 15 and 16, increased to 20mg on day 17, and further increased to 40mg by a weekly 10mg increase, while sertraline will be dosed at 25mg on day 15 and terminated on day 16.
45673843|NCT04798001|Biological|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
46002293|NCT03991624|Other|Assessment of mental flexibility|"a letter-number pair task. The subject sees 4 blocks of 48 letter-number pairs appear successively on a screen. When the pair appears at the top, the subject must make a parity judgment but when the pair appears at the bottom, the subject must make a consonant / vowel judgment.~a category change task, which consists in classifying a word according to one category or another according to a visual clue that appears. The task consists of 4 blocks of 48 stimuli."
46083705|NCT00611988|Behavioral|Self-managed walking|The intervention includes individual therapy, group reinforcement, and follow-up phone contact
46083706|NCT00611988|Other|Control group|Attention control group will receive routine follow-up phone calls
46083707|NCT05070728|Drug|Sham Injector|Sham injection
45458368|NCT01141777|Dietary Supplement|Spirulina platensis|Subjects received 19g daily of supplement averagely.This was supplied as powder daily, in packs that lasted for 2weeks each. Each subject was therefore seen every two week to obtain new stock of supplements and evaluate compliance
46083708|NCT05070728|Drug|FAI Insert|FAI insert
46083709|NCT04252469|Other|Oral care|oral care using 20mL of 0.12% CHX and gargling with 30 seconds.
46083710|NCT05068388|Drug|Z-Endoxifen|Z-Endoxifen
46083711|NCT05068388|Drug|Placebo|Placebo
46083712|NCT05320679|Other|Implementation of Questionnaire|Compartment of results of questionnaires which already been used in literature and results of developing Pain Related Avoidance of Movement Questionnaire
46083713|NCT02712060|Other|No intervention|
45833448|NCT03082248|Procedure|Spinal Surgery|Patients allocated to the surgical procedure group will undergo spinal surgery procedures and techniques specific for the low back region.
45833449|NCT05454228|Behavioral|postoperative delirium|Postoperative delirium (POD) occurs within 1 week after surgery in patients, with obvious time characteristics, mainly occurring within 1-3 days after surgery. Postoperative delirium has adverse effects on the short and long term prognosis of patients. Patients with delirium have an increased risk of postoperative complications, perioperative death, longer hospital stay and increased medical costs during hospitalization.
45833450|NCT03082092|Drug|Methylprednisolone Sodium Succinate|single intravenous dose of 125mg methylprednisolone diluted in 2.1ml of diluent given on induction of total knee replacement
45833451|NCT03082092|Drug|Placebos|0.9% intravenous saline (2.1ml) intravenously on induction of total knee replacement
45833452|NCT04401852|Drug|MgSo4|a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose.
45833453|NCT04401852|Drug|Isotonic saline|equal volume of isotonic 0.9% saline over 15-20 minutes
45833454|NCT03332238|Device|Autologous Stomal Vascular Fraction Material|Autologous Stomal Vascular Fraction Material Prepared from the Tissue Genesis® Icellator Cell Isolation System™
45833455|NCT03332238|Device|Ringer's solution|Ringer's solution
46083714|NCT02780258|Device|Restylane Silk|
46083715|NCT04252547|Other|Kangaroo Care|The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before the first feeding hour when they are included in the study and then they will be held on their mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother. A chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. The infant's heart rate and oxygen saturation will also continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weight is measured without a diaper change and his/her weight will be recorded. Then he/she will be taken back in the incubator to sleep.
46083716|NCT04252547|Other|Control|The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before feeding when they are included in the study and then they will be breastfed by their mothers. The chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. Also, the infant's heart rate and oxygen saturation will continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weighed without a diaper change and his/her weight will be recorded. When the care process is over, it will be taken back in the incubator to sleep.
46083717|NCT00611208|Biological|A-dmDT390-bisFv(UCHT1)|A-dmDT390-bisFv(UCHT1) will be administered as 60 μg/kg total given as 7.5 μg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes
46083718|NCT05339204|Procedure|allo-HSCT|allo-HSCT from any type of donor
46083719|NCT00555217|Drug|losartan|50 or 100mg/day
45989541|NCT00519012|Drug|Paroxetine to Sertraline|Paroxetine will be initiated at 10mg, increased to 20mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, paroxetine will be continued and titrated at 20 - 40mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, paroxetine will be continued and titrated at 20 - 40mg, whereas in the other group paroxetine will be switched to sertraline. In this switching group, sertraline will be started at 25mg on days 15 and 16, increased to 50mg on day 17, and further increased to 100mg by a weekly 25mg increase, while paroxetine will be dosed at 10mg on day 15 and terminated on day 16.
45989542|NCT00520143|Biological|alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])|IV infusion: 20mg/kg qow
45989543|NCT03459027|Dietary Supplement|Super Beets|Nitrate rich beetroot powder (10g) acutely
45989544|NCT03459027|Dietary Supplement|Beetroot powder|Nitrate devoid beetroot powder (10g) acutely
45989545|NCT00520182|Behavioral|MUFA diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). MUFA diet included only low glycemic index carbohydrates. The diet consisted of 35% carbohydrates and 45% fat (50% of them were mono-unsaturated fatty acids [MUFA]). Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
45989546|NCT00520182|Behavioral|ADA 2003|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). The carbohydrates are with mixed glycemic index. The diet contains 50-55% carbohydrates, 30% fat and 15-20% protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
45989547|NCT00520182|Behavioral|Low Glycemic index (LGI) diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). LGI diet included only low glycemic index carbohydrates. The diet consisted of 50-55% carbohydrates, 30% fat and 20%. protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
45989548|NCT02954900|Other|RealRisks|RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
46083720|NCT00555217|Drug|lisinopril|10, 20 or 40 mg/day
46083721|NCT02711904|Drug|Extubation U|"Dose of remifentanil according to the randomization; the infusions that were used to reach the PC target were:~20 years old - 6.0 mcg/Kg/h~30 years old - 5.7 mcg/Kg/h~40 years old - 5.3 mcg/kg/h~50 years old - 5.0 mcg/kg/h~60 years old - 4.6 mcg/kg/h~70 years old - 4.3 mcg/kg/h~80 years old - 4.0 mcg kg/h."
45673844|NCT04798001|Biological|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
45673845|NCT04798001|Biological|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops|Intranasal dose on Day 1 by intranasal drops. Followed by a second, identical dose on Day 36 by intranasal drops
45673846|NCT04798001|Biological|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray|Single intranasal dose on Day 1, by intranasal spray
45673847|NCT04797845|Other|teleconsultation|Patients will benefit from a quarterly teleconsultation to assess the study criteria through different questionnaires during 12 months.
45673848|NCT02074514|Drug|Sofosbuvir|400 mg tablet administered orally once daily
45673849|NCT02074514|Drug|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45673850|NCT04191161|Device|Wearing the rigid brace|Custom braces are made from 4mm thick polyethylene with Velcro® fastening. They are Computer Aided Designed and are made by the same manufacturer (LAGARRIGUE). A thermal sensor chip will placed in the brace to assess observance.
45673851|NCT04081493|Other|Low-load blood flow restricted exercise|"Leg press and knee extension exercise 3 times per week for 8 weeks. Repetition scheme: 30-15-15-until exhaustion interspaced by 30 sec rest. 5 min free-flow rest between exercises"
45989549|NCT02954900|Other|BNAV|Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
45989550|NCT02949336|Radiation|Observational use of fluoroscopy|Minimal radiation exposure (0.17 mSv) for observational purpose
45989551|NCT04514237|Drug|BOS172767 enantiomer E1 or E2|Oral tablets
45673852|NCT04073303|Biological|Botulinum Toxin Type A|Day 1 Administration of bilateral intramuscular injections into the masseter
45989552|NCT04514237|Drug|Placebo|Oral tablets
45989553|NCT00520260|Drug|bromfenac|0.09%, BID, 6 weeks
45989554|NCT00520260|Drug|ketorolac|0.4%, BID, 6 weeks
45989555|NCT04514354|Behavioral|GEST|On either Visit 3 or 4, subjects performed a maximal cardiopulmonary GEST following the Balke protocol. Immediately prior to the GEST, the study physician or his designee performed a brief physical examination, in which BP was assessed and all relevant medical information (i.e. medical history, medications, family history) were reviewed. The physician who completed the physical examination remained present during the GEST to monitor the subjects' electrocardiogram (ECG) and other physical signs. After the GEST was completed, the study physician reviewed the ECG for signs of ischemia. Breath-by-breath analysis of expired gases (i.e. oxygen and carbon dioxide) (ParvoMedicsTruneOne® 2400 Metabolic Measurement System, ParvoMedics Inc., Sandy, UT) determined maximal oxygen uptake (VO2max). Heart rate was measured continuously with a 12-lead ECG system and BP was measured by auscultation every 3 minutes during the GEST.
45989556|NCT00520338|Drug|celecoxib|"placebo~celecoxib 400 mg oral single dose"
45989557|NCT02594072|Radiation|stereotactic ablative radiotherapy|Linac-based prostate stereotactic radiotherapy, using Volumetric Modulated Arc Therapy planning and delivery, with fiducial marker and cone-beam CT based image guidance.
45989558|NCT02594072|Radiation|external beam radiation therapy|Conventional intensity modulated radiotherapy, with fiducial marker or cone-beam CT based image guidance.
45989559|NCT02594072|Drug|Zoladex ®|The preferred agent for the protocol is goserelin acetate (Zoladex ®) 3-month depot, but other LHRH agonists are permitted. The total duration of ADT will be 6 months for men with intermediate risk disease, and 18 months for those with high risk disease. ADT is to be initiated prior to the start of RT.
45989560|NCT04694391|Genetic|whole exome sequence|To seek genomic characteristics of relapsed esophageal cancer with whole exome sequence.
45673853|NCT04073303|Other|Placebo|Day 1 Administration of bilateral intramuscular injections of placebo (normal saline) into the masseter
45673854|NCT04070573|Drug|acetylsalicylic acid|High risk pregnant women will be treated with daily aspirin during pregnancy.
45673855|NCT02099708|Drug|Lansoprazole|Lansoprazole Capsules 15 mg/ Orally Disintegrating (OD) Tablets 15 mg
45673856|NCT02073656|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
45673857|NCT02073656|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45673858|NCT02242643|Biological|FluLaval™ Quadrivalent|1 or 2 doses administered intramusculary (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
45673859|NCT02242643|Biological|Fluzone® Quadrivalent|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
45989561|NCT00520377|Drug|MD05|recombinant human GDF-5 coated onto beta-tricalcium phosphate
45989562|NCT00520377|Device|Beta-TCP and autologous bone|beta-tricalcium phosphate and autologous bone
45989563|NCT00519051|Other|monitorized pharmacotherapy with antidepressants drugs (Fluoxetine)|Fluoxetine oral,20-60 mg/day for 6 months with telephone monitorization
45989564|NCT02948946|Procedure|NETest|5 mL of blood will be drawn from participants for testing.
45989565|NCT00520416|Procedure|Carbon dioxide angiogram|see description of procedure
45989566|NCT02948673|Dietary Supplement|Glutathione|4 oral GSH tablets/day (1000mg/day) for 4 weeks
45989567|NCT02948673|Other|Placebo|4 oral placebo tablets for 4 weeks
45989568|NCT02597075|Other|standard therapy + physical activity program|
45989569|NCT02597075|Other|standard therapy|
45989570|NCT04694118|Other|rebound therapy|3 days a week in 12 weeks
45989571|NCT02597738|Other|Fresh tissue biopsy|Fresh tissue biopsy will be collected.
45989572|NCT02597738|Other|Blood/Urine Sample Collection|A one time blood sample will be collected.
45989573|NCT00519129|Device|3D-imager|3D-imager vs fluoroscopy during coloscopy
45989574|NCT00519168|Procedure|Urine sample|Standard of care
45989575|NCT00519168|Device|Electrode sleep recorder|Standard of care
45989576|NCT00519168|Procedure|phlebotomy|Standard of care
45989577|NCT02275832|Drug|3 % Minoxidil lotion|
45989578|NCT02275832|Drug|Placebo|
45989579|NCT00519207|Drug|Lidocaine|1g of liposomal lidocaine will be administered 30-40 minutes prior to venipuncture and occluded by a dressing.
45673860|NCT02097290|Device|CRT-D|For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
45989580|NCT00519207|Drug|24% Sucrose Solution|2ml of 24% sucrose will be administered 2 minutes prior to venipuncture
45989581|NCT02590094|Drug|Intravitreal bevacizumab or intravitreal ziv-aflibercept|Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.
45989582|NCT00520455|Drug|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and condoms|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B). Study subjects to take medication after unprotected vaginal intercourse
45989583|NCT02275871|Other|MRI|High risk screening MRI will be performed as part of the patient's routine care.
45989584|NCT02275871|Other|CESM|After the MRI is complete, the patient will be brought to the mammography department for the contrast enhanced mammogram. The contrast enhanced mammogram will be independently interpreted by two study radiologists (randomly assigned) who are blinded to the MRI. They will then compare to the MRI to determine clinical follow-up. Any finding seen on MRI will be followed according to the MR protocol. Any finding seen on CESM only, will have a diagnostic work-up with mammography and ultrasound. If this work-up is negative, then follow-up CESM exams will be performed. Each patient will be followed for 2 years to determine sensitivity and specificity for both modalities.
45989585|NCT02948439|Other|Aerobic exercise|Brisk walking 3-4 times per week for up to 40 minutes of activity.
45989586|NCT02590757|Device|NIV-NAVA|Non-invasive neurally adjusted ventilatory assist
45989587|NCT02590757|Device|N-CPAP|Nasal-continuous positive airway pressure
45833456|NCT04761510|Behavioral|Mindfulness-SOS for Refugees|Mindfulness-SOS for Refugees is a brief internet-based mobile-supported intervention program which is a mobile-health adaptation of MBTR-R - a mindfulness- and compassion-based, trauma-sensitive, and socio-culturally adapted group intervention program designed for FDPs. Mindfulness-SOS for Refugees entails 8 brief sessions and 9 mindfulness meditation practice exercises - delivered via audio recordings using participants' smartphones. The intervention program is specifically designed to mitigate acute stress and related mental health symptoms among FDPs. During participation in the Mindfulness-SOS for Refugees intervention program, participants will be encouraged to complete 2 sessions per week and practice each day for 4 weeks but can choose to extend this up to 8 weeks. Delivery of Mindfulness-SOS for Refugees entails administrative guidance as well as adherence-focused guidance.
45989588|NCT02949375|Drug|Placebo Comparator|Placebo gel capsule to be taken daily for 28 days
45673861|NCT04061213|Diagnostic Test|Tc-99m-DPD scintigraphy|Myocardial scintigraphy
45673862|NCT02072174|Drug|Anaferon for Children|Anaferon for children: For oral use.
45673863|NCT02209181|Drug|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
45673864|NCT02209181|Drug|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
45833457|NCT03328104|Drug|Everolimus|Given once daily orally via mouth or NG tube beginning at Dose Level (DL) 1 (4 mg/m2/day). Depending on safety and tolerability, dose levels will be escalated to DL2 (5 mg/m2/day). There is also a dose level de-escalation to DL0 (3 mg/m2/day) if toxicity is noted at DL1. Begins at Day 1 through 28.
45833458|NCT03328104|Drug|Nelarabine|650 mg/m2 IV daily x Day 1-5
45989589|NCT02949375|Drug|Active Comparator:4.5mg GRI-0621|4.5mg GRI-0621 gel capsule to be taken daily for 28 days
45989590|NCT02949375|Drug|Active Comparator: 6.0mg GRI-0621|6.0mg GRI-0621 gel capsule to be taken daily for 28 days
45989591|NCT04514432|Other|Music|If patients experienced agitation, they were able to request to listen to music for 30 minutes. They listened to genre playlists generated by the music application Spotify.
45989592|NCT02949180|Device|Five minutes puls wave recording|iPhone will be positioned on the index finger for five minutes to record a pulse wave
45989593|NCT02598947|Other|Manual therapy|Exercise, behaviour change interventions and manual therapy
45989594|NCT02949258|Drug|oxaliplatin|oxaliplatin 150 mg will be administered from the celiac artery on day 1 of every cycle in all cases
45673865|NCT02209181|Drug|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
45673866|NCT02209181|Drug|acetaminophen / Tylenol|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
45989595|NCT02949258|Drug|etoposide|etoposide 100 mg will be administered from the celiac artery on day 1 of every cycle in all cases
45989596|NCT02949258|Drug|epirubicin|epirubicin 30 mg will be administered from the celiac artery on day 1 of every cycle in all cases
45989597|NCT02949258|Drug|S1|Oral S-1 120 mg per day will be administered on days 1-14 of every cycle in all cases
45989598|NCT04514081|Drug|Chidamide; Decitabine; Camrelizumab|"Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.~Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.~Camrelizumab is a humanized anti-PD-1 monoclonal antibody."
45989599|NCT04514081|Drug|Decitabine+Camrelizumab|Decitabine+Camrelizumab
45989600|NCT02948517|Other|Time restricted feeding|Time restricted feeding
45989601|NCT04514120|Other|AJESS scoring process|We will collecto endoscopic pictures from stable and non stable participants. Pictures will be taken for each sinus, olfactory cleft, and middle meatus in private clinical exam rooms. For each anatomic site [left middle meatus (LMM), left ethmoid sinus (LES), left frontal sinus (LFS), left maxillary sinus (LMS), left olfactory cleft (LOC), left sphenoid sinus (LSS), right middle meatus (RMM), right ethmoid sinus (RES), right frontal sinus (RFS), right maxillary sinus (RMS), right olfactory cleft (ROC), right sphenoid sinus (RSS)], numerical scores describe edema or polyposis while alphabetical scores, in lower case or upper case corresponding to severity, describe CRS features: crusting, synechiae, purulence, mucus, recirculation, and ostial narrowness.
45989602|NCT00520611|Behavioral|Financial Incentives|Participants call in their weight on daily basis. Participants must report under their daily targets to qualify for entry into lottery. Call-in weights are verified at monthly weigh-ins.
45989603|NCT00520611|Behavioral|Financial Incentives|Participants call in their weight on daily basis. Participants must report under their daily targets to qualify to receive daily incentive. Call-in weights are verified at monthly weigh-ins.
45989604|NCT04514042|Procedure|Peroral endoscopic myotomy|Patients will be hospitalized for 24 hours before procedure or at the day of procedure (depending on preference of each center). Procedures will be performed always using carbon dioxide insufflation and whenever possible under general anesthesia with endotracheal intubation by anesthesiologist recommendations. The procedure will begin after general endoscopic evaluation of the Zenker's diverticulum and esophagus. An incision of the bridge between the Zenker's diverticulum and the esophagus will be done using procedure as peroral endoscopic myotomy. All the procedures will be documented with photographs or videorecordings.
45989605|NCT04514042|Procedure|Flexible endoscopic septotomy|Patients will be hospitalized for 24 hours before procedure or at the day of procedure (depending on preference of each center). Procedures will be performed always using carbon dioxide insufflation and whenever possible under general anesthesia with endotracheal intubation by anesthesiologist recommendations. The procedure will begin after general endoscopic evaluation of the Zenker's diverticulum and esophagus. An incision of the bridge between the Zenker's diverticulum and the esophagus will be done using procedure as flexible endoscopy septotomy. All the procedures will be documented with photographs or videorecordings.
45989606|NCT00519246|Drug|Saline|Saline 5 ml administrated intravenously
45989607|NCT00519246|Drug|Opioid|Butorphanol tartrate 1 mg i.v.
45989608|NCT00519246|Drug|Opioid|Butorphanol Tartrate 2 mg i.v.
45989609|NCT00519246|Drug|NSAID|Flurbiprofen Axetil 50 mg i.v.
46083722|NCT02711904|Drug|Extubation T|"Dose of infusion of remifentanil to reach a PC 3 - 4 ng/ml, in the following manner:~The assistant placed the infusion balloon in such a way that it could not be seen by the treating anesthesiologist, he proceeded to open the corresponding wrapping according to the consecutive which corresponds to the patient.~The remifentanil dose was adjusted according to the randomization:~20 years old - 9.0 mcg/Kg/h~30 years old - 8.5 mcg/Kg/h~40 years old - 8.0 mcg/kg/h~50 years old - 7.5 mcg/kg/h~60 years old - 7.0 mcg/kg/h~70 years old - 6.5 mcg/kg/h~80 years old - 6.0 mcg kg/h."
45989610|NCT00519246|Drug|NSAID|Flurbiprofen Axetil 100 mg i.v.
45989611|NCT00519246|Drug|Opioid|Tramadol Hydrochloride 10 mg i.v.
45989612|NCT00519246|Drug|Opioid|Tramadol Hydrochloride 20 mg i.v.
45989613|NCT00519987|Drug|intranasal ketamine|intranasal ketamine
45989614|NCT02596490|Behavioral|Questionnaires|"Phase 1: At end of second meditation and discussion session, couples complete complete a written review about the program in general and a questionnaire about their general health and well-being.~Phase 2: Couples complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, their relationship, and quality of life. Same questionnaires completed 1 week after mediation sessions.~Phase 3: Participant complete 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. AC group completes same questionnaires with no intervention."
45989615|NCT02596490|Behavioral|Meditation and Discussion Sessions|"Phase 1: Participant and partner attend 2 meditation sessions with a mediation trained instructor. Each session will last about 60-90 minutes.~Phase 2 and 3: Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped."
45989616|NCT02596490|Behavioral|Cancer-Related Discussion Program|Phase 3: Participant and partner attend 1 discussion session each week for 4 weeks with a trained interventionist. During the discussion sessions, participants discuss issues for couples coping with cancer. Each session will last about 60 minutes.
45989617|NCT00519324|Drug|Everolimus|10 mg/day (2 tablets of 5 mg each)
45833459|NCT03328104|Drug|Cyclophosphamide|440 mg/m2 IV x Day 1-5
45989618|NCT04514471|Other|Unventilated filter cigarettes|Currently marketed unventilated cigarettes
45989619|NCT04514471|Other|Ventilated filter cigarettes|Currently marketed ventilated cigarettes
45989620|NCT00520650|Drug|Aripiprazole|
46083723|NCT05326490|Drug|PB-201|PB-201: 100 mg each time, orally in the morning and evening respectively
45833460|NCT03328104|Drug|Etoposide|100 mg/m2 IV x Day 1-5
45833461|NCT03081936|Dietary Supplement|Oral consumption of Nutricia Aptamil Stage 1 formula|Daily oral consumption of Nutricia Aptamil Stage 1 formula
45833462|NCT03081936|Dietary Supplement|Oral consumption of a2® Platinum Stage 1 formula|Daily oral consumption of a2® Platinum Stage 1 formula
45833463|NCT03081936|Dietary Supplement|Oral consumption of breast milk|Daily oral consumption of breast milk
45989621|NCT04513535|Other|Thoracic Manipulation|A supine thoracic manipulation will be utilized. Participants will be lying supine on the plinth with their arms crossed over their chest, making sure the forearms are not crossed. An experienced clinician will place their hand on the inferior segment (T4); the superior segment (T3) will be placed in the midrange of thoracic flexion and extension. The clinician will apply a high velocity, end range, anterior to posterior thrust by using their body weight to deliver the thrust through the participants crossed elbows, thus creating a bilateral gapping of the facet joints. If a cavitation is achieved after the first thrust, the thoracic manipulation intervention is complete. If not, one more attempt will be made to achieve a cavitation. Regardless of if there was a cavitation or not, after the second attempt the intervention is complete.
45989622|NCT04513535|Other|Cervical Manipulation|Participants will be lying supine on the plinth on the table. A high velocity low amplitude manipulation will be performed to the cervical spine by an experienced clinician.The clinician will place the right proximal phalanx of the index finger over the posterolateral aspect of the articular pillar at the right C4/C5 segment to maximally influence the C5 myotomal distribution. The clinician's left hand will be cradling the participants head. The participant will be brought into midrange flexion-extension, ipsilateral side bend, and contralateral rotation of C4/5. Once a firm end feel is felt the manipulation will be administered into left rotation in an arc toward the left eye. If a cavitation is achieved after the first thrust, the intervention is complete. If not, one more attempt will be made to achieve a cavitation;after the second attempt the intervention is complete.
45989623|NCT04513535|Other|glenohumeral posterior glide mobilization|Participants will be instructed to lay supine on the plinth and a plastic orthopedic wedge will be placed under their scapula for stabilization on the side that is receiving the mobilization. The experienced clinician will stand on the same side being mobilized and held the participant's arm proximal to the medial and lateral humeral epicondyles. The clinician will hold the participant's arm in the scapular plane, approximately 55 degrees of abduction and slight ER with a grade one long axis distraction applied and sustained throughout the entire mobilization. A grade three oscillatory mobilization will be applied for three sets of 30 seconds with a 30 second rest in between.
45989624|NCT04513535|Other|Sleeper stretch|Participants will be positioned in a side lying position with the arm to be stretched on the table. The arm to be tested will then be positioned at a 90-90 shoulder abduction and elbow flexion position. A support will be positioned behind the patient to ensure there is no compensatory trunk movement during the stretch, and an examiner verified the arm is in a 90-90 position. A sleeper stretch will be subsequently completed, in which the participant will internally rotate the arm to stretch the posterior shoulder musculature. Three, thirty second stretches will be completed
45989625|NCT00519363|Drug|atorvastatin|atorvastatin 40mg, given orally daily for 3 months.
45989626|NCT02595710|Other|skin punch biopsy collection|Four-mm skin biopsies from non-lesional skin will be acquired from the patients, processed using our published techniques with Bartonella biomarkers, and imaged using confocal microscopy.
45989627|NCT02595710|Other|Blood collection|Blood will be tested for presence of Bartonella DNA and Bartonella antibodies using the Alpha Proteobacterium Growth Medium (BAPGM) multi-platform testing, including liquid culture, enriched agar plating and molecular techniques.Blood smears will be analyzed for presence of intra-erythrocytic Bartonella spp. by immunostaining.
45989628|NCT02595710|Other|Urine sample collection|Urine samples will be collected and analyzed for Bartonella spp specific microRNAs.
45989629|NCT00519402|Other|tonsillar examination and questionnaire completion|
45989630|NCT02591030|Drug|GEMCIS|"At D1 and D8 of each cycle, i.e. every 21 days for 6 months:~Cisplatin 25 mg/m² over 1 hour at D1 and D8~Gemcitabine 1000 mg/m² over 30 minutes at D1 and D8."
45989631|NCT02591030|Drug|mFolfirinox|"At D1 of each cycle, i.e. every 15 days for 6 months:~Oxiplatin: 85 mg/m² (IP/120 minutes)~Irinotecan: 180 mg/m² (IV/90 minutes)~Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine [calcium levofolinate]) (IV/2 hours), via a Y connector at the same time as irinotecan~5-FU: 2400 mg/m² (IV over 46 hours) without 5FU bolus at D1"
45989632|NCT00519441|Other|pH study|All patients will have 48 hour pH study
45989633|NCT02955017|Behavioral|traditional follow_up|"Multidisciplinary support with educational face to face family based intervention at 6, 9 and 12 months after inclusion.~Two days of a complete medical check at 9 and 15 months"
45989634|NCT02955017|Behavioral|"distance follow-up new technologies"|"Multidisciplinary support with long distance monitoring Mobile apps.~Two days of a complete medical check at 9 and 15 months"
45989635|NCT00519480|Drug|GSK189075|GSK189075 will be available as an oral tablet with dosing strengths of 500 milligrams and 250 milligrams.
45989636|NCT00519480|Drug|Metformin|Metformin will be available as an immediate release oral tablet with dosing strengths of 500 milligrams and 850 milligrams.
45989637|NCT00519480|Drug|Placebo|Placebo will be available as an oral tablets.
45673867|NCT02208089|Procedure|Transepithelial Photorefractive Keratectomy (TransPRK)|Aberrometry or topography guided transepithelial photorefractive keratectomy (TransPRK) using the Schwind Amaris 750s excimer laser (www.eye-tech-solutions.com), an 8mm treatment diameter, and a tissue saving algorithm targeting selected higher order aberrations only. TransPRK will be followed immediately by corneal collagen cross-linking (CXL).
45989638|NCT04696211|Other|Music-with-movement exercise|A music-with-movement exercise programme to reduce chronic pain in older adults.
45989639|NCT00520689|Device|Silicone Hydrogel Contact Lens|use of lens over 2 days
45989640|NCT02955056|Drug|Forsteo|20 micrograms/80 microlitres solution for injection in pre-filled pen
45989641|NCT00520728|Behavioral|Occupational Time Use Intervention|12 week behavioral intervention administered by Occupational Therapists.
46083724|NCT05326490|Drug|PB-201 matched placebo|PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively
46083725|NCT05326490|Drug|Metformin hydrochloride|The dosage and administration of metformin hydrochloride remain unchanged before screening
45989642|NCT02954939|Drug|MMF-MMF|Class III/IV+/-V lupus nephritis patients to receive PRED+MMF
45989643|NCT02954939|Drug|CTX-AZA|Class III/IV+/-V lupus nephritis patients to receive PRED+CTX followed by AZA
45989644|NCT00519519|Drug|Omeprazole|intravenous 80mg bolus followed by 8mg / hr for 3 days
45989645|NCT02598557|Drug|Exemestane|Given PO
46083726|NCT04245995|Diagnostic Test|Feature Extraction Technology|The study´s aim was evaluation of the clinical applicability of the Feature Extraction Technology (FET) during a simulated blood loss scenario in comparison to visual estimation.
45989646|NCT02598557|Other|Laboratory Biomarker Analysis|Correlative studies
46083727|NCT05339048|Genetic|Genetic risk variants|Exposure: Genetic predisposition to complex diseases.
46083728|NCT05339048|Other|Diet|Exposure: dietary intake of unhealthy foods known to be associated with higher prevalence of respiratory and cardiovascular diseases.
45673868|NCT02208089|Procedure|Corneal Collagen Cross-Linking (CXL)|"Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure.~UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source)"
45673869|NCT02242487|Drug|CVT-301|
46083729|NCT05339048|Behavioral|Physical activity|Exposure: frequency of moderated or intense physical activity, and daily exposure to sedentary behavior.
45673870|NCT02241785|Drug|natalizumab|Administered as specified in the treatment arm
46083730|NCT05339048|Other|Socio-economic conditions|Exposure: socio-economic vulnerability indexes associated with higher prevalence of respiratory and cardiovascular diseases (including household conditions, accessibility to health care services, among others).
45989647|NCT02598557|Other|Pharmacological Study|Correlative studies
45833464|NCT03318120|Behavioral|Progressive Resistance Training|Participants will perform required resistance training exercises at regular intervals for a period of up to 3 years. They will be tested at a baseline visit, then every 6 months for a total of at least 5 visits. During these visits, they will be asked to complete the following: questionnaires about quality of life and depression, tests to measure strength and motor function, tests to measure cognition, an orientation session to learn a precision griping task, structural and functional MRI scans of the brain, measurement of brain waves using a non-invasive technique called electroencephalography (EEG) and muscle activity using electromyography (EMG), measurement of brain function with TMS, pregnancy test (if applicable).
45833465|NCT03399318|Drug|Acetaminophen|30 mg/kg load then 15mg/kg
45833466|NCT03399318|Drug|Ibuprofen|10 mg/kg
45989648|NCT02598557|Other|Placebo Administration|Given PO
45989649|NCT02598557|Other|Quality-of-Life Assessment|Ancillary studies
45458369|NCT01141777|Dietary Supplement|Soya bean|Each subject received 19g of supplement on average daily. Subjects were seen every two weeks to evaluate compliance and obtain a new stock.
45673871|NCT02241551|Drug|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
45833467|NCT03399318|Drug|placebo for acetaminophen|placebo for acetaminophen
45833468|NCT03399318|Drug|placebo for ibuprofen|placebo for ibuprofen
45833469|NCT03398538|Other|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
45989650|NCT02598557|Other|Questionnaire Administration|Ancillary studies
45989651|NCT02598557|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45989652|NCT00520806|Drug|Relaxin|Intravenous infusion for 48 h at 30 ug/kg/day
46083731|NCT00745251|Drug|VI-0521|15 mg Phentermine and 92 mg Topiramate
46083732|NCT00745251|Drug|placebo|placebo
46083733|NCT04252157|Other|Kinesiotaping|Kinesiotape will be applied to the group. During the orbicularis oris muscle, I tape will be applied around the lip with a mechanical correction technique with 50-75% tension. I tape will be applied just below the Hyoid with a 50-75% tension mechanical correlation technique.
46083734|NCT04252157|Other|Plesebo Taping|An approximately 5 cm I tape will be applied to the group without applying any tension to the temporomandibular attachment for placebo taping.
46083735|NCT04252157|Other|Control|no kinesio or tape will be applied
46083736|NCT02693808|Procedure|Autologous fat injection|Injection in one side with autologous fat and the other side with hyaluronic acid.
46083737|NCT02693808|Procedure|Hyaluronic acid injection|Injection in one side with autologous fat and the other side with hyaluronic acid.
46083738|NCT02779868|Dietary Supplement|Omega-3|patients included in this group will take 2g (4 capsules) per day of eicosapentaenoic acid.
46083739|NCT02779868|Dietary Supplement|Olive oil|patients included in this group will take 4 capsules per day of olive oil.
45673872|NCT02241551|Drug|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
45833470|NCT03398538|Other|Additional (outer) Dressing Application|Application of outer a moisture retentive dressing, and a multi-layer compression dressing.
45989653|NCT00520806|Drug|Placebo|Intravenous infusion for 48 h
45989654|NCT00505739|Drug|Mifepristone|200 mg by mouth (PO) Daily x 4 Weeks
45989655|NCT00519597|Device|ResMed S8 (Auto-CPAP)|AutoCPAP during sleep
45989656|NCT05142800|Device|Perometer|The perometer uses light sensors to calculate the length and volume of your arms
45989657|NCT05142800|Device|SOZO device|The machine measures the amount of fluid on the arm(s)
45989658|NCT00519558|Drug|somatropin|
45989659|NCT05149820|Other|Electronic Point of Care Randomisation tool|Two designs of electronic point of care randomisation tool will be evaluated.
45989660|NCT05149820|Drug|Magnesium|Liberal Strategy: magnesium supplementation at serum level < 0.75 mmol/L Restrictive Strategy: magnesium supplementation at serum level < 1.0 mmol/L
45989661|NCT02948985|Other|treated with FOLFIRI±cetuximab|Peripheral blood samples of 10 mL were collected from the patients for CTCs analysis and tumor marker in every cycle D0 and D8. Tumor response evaluation will be performed after four cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastatic organ, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.The correlation of the RAS status on CTCs and the mutant gene in ctDNA to the therapeutic response will be evaluated.
46083740|NCT05319977|Behavioral|Mobile incentive-based intervention|a technology-based behavioral intervention to address maternal alcohol use with mobile breathalyzer technology or/and urinalysis for biochemical verification of alcohol use, contingent financial incentives on alcohol abstinence, and text-based health promotion.
46083741|NCT00950287|Device|No intervention|The recordings will be performed in neonatal units with the preterm infant remaining in usual condition with limitations of external stimulation during the study period. The usual monitor will remain in function. The intervention of the nurses in case of apnea will not be modified during the study period. The recording will be obtained from derivation of the signal usually recorded by the monitor in use completed in one centre by a polysomnographic recording (Medtronics France SA), in order to test a possible influence of the sleep status on the detection.
45989662|NCT04513457|Other|Liver resection and Neoadjuvant chemotherapy|
45989663|NCT04513457|Other|Liver resection and Adjuvant chemotherapy|
45989664|NCT04513457|Other|Liver resection, Neoadjuvant chemotherapy and Adjuvant chemotherapy|
45989665|NCT04513457|Procedure|Liver resection|
45989666|NCT02276339|Other|Exercise|The exercise intervention will consist of an individual home-based progressive eccentric-concentric strengthening programme. Patients will be reviewed every two weeks during their rehabilitation; exercises will be progressed accordingly by their physiotherapist.
45989667|NCT00521040|Drug|Levocetirizine dihydrochloride|
45989668|NCT04696601|Diagnostic Test|Olfactory test|The olfactory test (Olfascan) is in the form of a paper stick, previously impregnated with an odorant (non-liquid). It is placed a few centimetres from the participant's nose at the time of the test. It is a single-use test, without contact with the participant.
45989669|NCT04513730|Other|Rehabilitation|A device originally designed with the function of keeping the user in a comfortable position of pelvic suspension, in dorsal decubitus, with fixation in the popliteal region and ankles was built to promote lumbar traction. The device is designed in autoCAD software with 2d technical representations and 3d electronic model. It consists of a structure of pipes and fittings and padded material at the support points.
45989670|NCT00521118|Other|Laboratory Biomarker Analysis|Correlative studies
45989671|NCT00521118|Procedure|Therapeutic Conventional Surgery|Undergo second curettage
45989672|NCT04694235|Dietary Supplement|Egg intervention|Eggs are boiled until the white and yolk are firm (ca. 8 minutes) to maintain quality and safety and ensure the eggs are safe for consumption.
45989673|NCT04513340|Drug|WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS|CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG
45989674|NCT05144945|Biological|Quadrivalent Recombinant Influenza Vaccine (RIV4)|Solution for intramuscular injection
45673873|NCT04769687|Biological|probiotic Vivomixx®|Vivomixx® is in powder form packaged in sachets of 4.5.1011 bacteria. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days). For the study, the symbiotics will be packaged in the same sachet at the same doses as mentioned above.
45673874|NCT04769687|Biological|prebiotic Orafti®Synergy1|Orafti®Synergy1 is a slightly sweet white powder packaged in 5 g sachets. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).
45989675|NCT05144945|Biological|Quadrivalent inactivated influenza vaccine (IIV4)|Suspension for intramuscular injection
45989676|NCT02949063|Behavioral|Comfortable Cafeteria Program|6-week program integrated into the cafeteria lunchtime to build capacity of supervisors and students to create a positive social and emotional atmosphere so that students can enjoy eating their lunch and socializing with peers.
45989677|NCT04513379|Drug|Efavirenz 600mg|EFV 600 mg per day given orally
45989678|NCT04513379|Drug|Efavirenz 400mg|2 tablets of EFV 200 mg per day given orally
45989679|NCT05142839|Procedure|EUS-CD|EUS-guided choledochoduodenostomy
45989680|NCT05142839|Procedure|EUS-GEA|EUS-guided gastroenterostomy
45989681|NCT00521157|Drug|Go Medical Naltrexone implants|Naltrexone implants 3.2 g (double of 1,6 g)
45989682|NCT04694352|Other|Jumping Exercises|Jumping in place Jump and clap Jump and reach Jump and twist Jump and turn Half jumping jack Jumping side to side Each exercise done for 1 minute, 5 repetitions is session of 1 hour 15minutes
45989683|NCT04694352|Other|Conventional Physical therapy|"Drop and catch a ball Squeeze ball between legs, jump up and catch the ball Walking on a straight line Stand on one leg try to pick object from floor without using hands (do this on both legs) Drop the ball and catch it with both hands Jump up stair with both limbs off the floor simultaneously while holding railing.~Skipping. At least 5 repetitions for each exercise in session of total 1 hour"
45989684|NCT00505817|Drug|Cetrorelix and Leuprolide|
45989685|NCT02948595|Other|Video feedback followed by structured verbal feedback|Video feedback followed by structured verbal feedback
45989686|NCT02948595|Other|Structured verbal feedback followed by video feedback|Structured verbal feedback followed by video feedback
45989687|NCT04513262|Procedure|mechanical ventilation during video-assisted surgery|observed variation of ventilatory parameters during video-assisted surgery
45989688|NCT00521391|Other|Allez Hop|a tailored physical activity intervention involving moderate-intensity exercise
45989689|NCT05144633|Device|Auscultation|This study will be to determine if the addition of Eko AI-assisted lung auscultation examination to a standard of care Pulmonary POCUS + assists with acute respiratory failure diagnosis.
45989690|NCT00521430|Biological|anti-thymocyte globulin|
45989691|NCT00521430|Drug|busulfan|
45989692|NCT00521430|Drug|cyclosporine|
45989693|NCT00521430|Drug|fludarabine phosphate|
45989694|NCT00521430|Drug|methotrexate|
45989695|NCT00521430|Drug|methylprednisolone|
45989696|NCT00521430|Procedure|allogeneic hematopoietic stem cell transplantation|
45989697|NCT00521430|Procedure|peripheral blood stem cell transplantation|
45989698|NCT00521196|Device|DC Stimulator (Transcranial Direct Current Stimulator)|Subjects will receive a total of 10 sessions of either active tDCS or sham tDCS over a four-week period (administered every other day during weekdays over the course of one month). During each tDCS session, two electrodes are placed over selected areas of the brain. The anode is placed on the motor cortex contralateral to the side where migraines predominant; the cathode is placed near the supraorbital area, opposite the anode. A small battery powered device drives 2 mA of direct current through the two electrodes. The direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.
45989699|NCT00521469|Device|Pro Adjuster|
45989700|NCT00505973|Drug|SCA-136|
45989701|NCT00521274|Biological|MVA 5T4|Docetaxel will be administered at the completion of the first three TroVax® injections. Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients will receive up to 10 total Docetaxel infusions over the course of the study. Subsequent TroVax® injections will be delivered on Day 1 of each Docetaxel cycle, 2 hours prior to the chemotherapy administration.
46083742|NCT05186688|Behavioral|Braining|"Braining is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training session and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan."
45989702|NCT00521274|Drug|Docetaxel|Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over). Patients will receive up to 10 total Docetaxel infusions over the course of the study. If patients cross-over, TroVax® will be administered 2 hours prior to the chemotherapy administration.
45989703|NCT05146778|Procedure|Opioid-free anesthesia|OFA group will be sedated using dexmedetomidine and lidocaine.
45989704|NCT05146778|Procedure|Conventional opioid-based anesthesia|Conventional opioid-based anesthesia group will be sedated using remi-fentanyl
45989705|NCT04694430|Procedure|Blood sample|2 ml venous blood was collected and separated into serum.
45989706|NCT04694430|Other|Data collection|"Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination;~Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;~Assess COPD using ABCD assessment tool."
45989707|NCT04694430|Procedure|Throat swab|"Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue.~Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth.~Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time."
46002294|NCT03991624|Other|Evaluation of the update|"an update span task for which letters appear on a screen sequentially, and subjects must memorize the last three, without knowing the length of the list. The task will consist of 3 tests of training and then 20 tests. After three errors consecutive, the task ends.~an n-back task that consists of a sequential presentation of letters, during which the subject must indicate when the stimulus. The task consists of 3 levels, with n = 1, n= 2 or n = 3. For level 1 (with n = 1), the subject must press a button when the same letter appears twice in a row on the screen. This task consists of 75 letters."
45456791|NCT01128127|Behavioral|Group education, audit-feedback and computer support|"Psycho-educational group workshop: two theory-practice sessions on both evidence-based guidelines on PPI-NSAID prescription and communication and negotiation skills to deal with patients. All participants will fill out an initial questionnaire concerning prescribing patterns and barriers to appropriate prescription. All attendees will be given a reminder printed material designed to give the necessary information in a brief fashion and for maximal visual impact.~Audit-Feedback: participants will receive, monthly and by e-mail, an individualized report with data of their own appropriate/inappropriate PPI prescriptions and avoidable costs.~CCDSS: interactive computer program designed to assist physicians with decision making when prescribing PPI associated to NSAID. It consists in pop-up alert screens that aim to influence prescription choice according to each patient characteristics and evidence-based clinical guidelines."
45673875|NCT04769687|Other|Placebo|Placebo
45673876|NCT02207621|Drug|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
45673877|NCT02207621|Drug|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
45673878|NCT02207621|Other|Placebo|1 drop QD, AM, OU
45673879|NCT02207621|Drug|AR-13324 Ophthalmic Solution 0.02% BID|1 drop BID, AM/PM, OU
45989708|NCT05143385|Other|Virtual reality|"Those patients who are randomly assigned as the intervention group will be given an explanatory session on the use of the video game console, controllers and game accessories.~The intervention will begin 15 calendar days after admission.~The intervention will be carried out once a week with a duration of 20 minutes with one of the games chosen by the patient together with the physiotherapist.~The end of the intervention will be until the patient is discharged from hospital, with a minimum of four sessions completed in order to participate in the study.~The intervention will be carried out with an average of six sessions in each patient, including in the study those who perform a minimum of four sessions. However, the interventions will continue until hospital discharge.~After completion of the clinical trial, a registry table will be drawn up quantifying the number of sessions for each patient and the type of session:"
45989709|NCT00505700|Drug|velcade|
45989710|NCT00505700|Drug|Idarubicin|
45989711|NCT00505700|Drug|Cytarabine|
45989712|NCT04694274|Device|stabilization splint|The device made of a hard acrylic on stone cast of the upper jaw in the centric relation position. It has a thickness of 1.5 mm at the level of the first molar.
45989713|NCT04694274|Procedure|physical therapy|Home-exercise program included exercises for passive and active stretching, joint mobilization, passive extension, and translational movements to the right, left, and forward.
45989714|NCT04694274|Device|placebo splint|The placebo splint was made of thin heat-treatable foil (0.5 mm). The foil was heated and printed over a plaster model of the upper jaw resulting in a very thin film over the occlusal surfaces of all teeth.
45989715|NCT02948283|Other|Laboratory Biomarker Analysis|Correlative studies
45989716|NCT02948283|Drug|Metformin Hydrochloride|Given PO
45989717|NCT02948283|Other|Pharmacological Study|Correlative studies
46083743|NCT02780336|Other|No intervention.|Participants will complete questionnaires and interviews as well as have a neurological exam that will be video recorded. For this exam they will do simple movements (like looking at the camera, squeezing your eyes closed, moving your head, and writing).
45673880|NCT02240693|Drug|BI 409306|
45989718|NCT02948283|Drug|Ritonavir|Given PO
46083744|NCT04252079|Procedure|Endovascular Repair of Juxtarenal Aortic Aneurysm|"History taking and clinical examination.~Preoperative Imaging~CTA is the cross-sectional imaging modality of choice.~Preoperative evaluation~a-Renal evaluation~b_ cardiac evaluation C-Pulmonary evaluation~Surgical techniques~Anesthesia The use of general anesthesia due to the duration of the procedures and the necessity to control patient breathing to allow precise imaging and accurate device deployment.~Intra operative imaging A hybrid operating room with high-quality fixed imaging is needed for the performance of FEVAR.~C-Device delivery and deployment all FEVAR procedures begin with access of the femoral arteries by either open or percutaneous technique."
45989719|NCT02948283|Other|Quality-of-Life|Ancillary studies
45989720|NCT02948283|Other|Questionnaire|Ancillary studies
45989721|NCT02275910|Drug|E7090|
45989722|NCT00521508|Procedure|gene transcription and cytometry|samply of 30 ml of blood
45989723|NCT00523146|Drug|Kanion Capsule|
46083745|NCT02711982|Procedure|Optic canal and optic nerve sheath decompression|within 5 days from trauma
45989724|NCT00506012|Drug|T2000|T2000 at doses of 200 mg a day to 1000 mg a day
45989725|NCT04693728|Behavioral|Resilient Intrinsic Self-Regulation Strategies in Extremes|The manualized intervention covered resilience strategies organized into four modules: (1) engagement, (2) social relatedness, (3) transformation of pain and (4) building a good life. The modules were delivered in 8 weekly sessions of 90 minutes each.
45989726|NCT04512872|Biological|CT-P41|60 mg/mL single dose, Solution for injection in PFS
45673881|NCT02240693|Drug|Placebo|
45833471|NCT03398538|Other|Mirragen Wound Matrix Dressing|Application of Mirragen to wound site along with standard of care treatment
45833472|NCT03398538|Other|Fibracol Wound Dressing|Application of Fibracol Alginate along with standard of care treatment
45833473|NCT03314922|Drug|Parsaclisib|Parsaclisib administered orally once daily for 8 weeks at the protocol-defined dose, followed by a once-weekly regimen at the same dose.
46083746|NCT02711982|Drug|methylprednisolone|within 5 days from trauma
46083747|NCT00745095|Drug|Neostigmine|Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established
46083748|NCT05036096|Device|CBBCT Imaging|Both breasts will be scanned by CBBCT. Only one breast will be scanned if the patient had mastectomy.
46083749|NCT05036096|Device|Digital Mammography|Both breasts will take digital mammography standard views (CC, MLO) Only one breast will take digital mammography standard views if the patient had mastectomy.
45673882|NCT02240693|Drug|BI 409306|
45673883|NCT02240693|Drug|Placebo|
45673884|NCT02240693|Drug|Placebo|
45673885|NCT02240693|Drug|BI 409306|
45673886|NCT02240693|Drug|BI 409306|
45673887|NCT02240693|Drug|Placebo|
45673888|NCT02240693|Drug|Placebo|
45673889|NCT02239679|Drug|Aminolevulinic Acid|20% ALA applied to face for one hour prior to 10 J/cm2 blue light
45673890|NCT02239679|Drug|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face one hour prior to 10 J/cm2 blue light
45833474|NCT03081780|Biological|FATE-NK100|"Preparative regimen:~Fludarabine 25 mg/m2 x 5 days start Day -6~Cyclophosphamide 60 mg/kg x 2 days on Day -5 and -4~Apheresis cell collection (collected from the Donor Day - 8) will be enriched for FATE-NK100 per CMC. IL-2 at 6 million IU subcutaneously (SC) every other day (EOD) for 6 doses with Dose 1 on Day 0 (no sooner than 4 hours post NK cells) and last dose no later than Day +12."
45989727|NCT04512872|Biological|EU-approved Prolia|60 mg/mL single dose, Solution for injection in PFS
45989728|NCT00521547|Procedure|Electroacupuncture|
45989729|NCT05144867|Radiation|Stereotactic Radiosurgery|All patients to undergo planning CT simulation with 1mm slice thickness. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging. A Planning Target Volume (PTV) margin of 2-5 mm will be added. Organs at risk visible in the planning CT scan will be contoured. The doses will be prescribed to approximately 100% isodose level and 95% of the PTV should receive 95% of the prescription dose. Metastases with a maximum diameter of up to 2 cm will be treated with doses of 22 to 25 Gy and those larger than 2 cm will be treated with doses of 18 to 20 Gy.
45989730|NCT05144672|Diagnostic Test|Laboratory tests|"Fasting blood glucose (FBG), postprandial blood glucose, total cholesterol (CHO), triglycerides (TG), high-density lipoprotein cholesterol and low-density lipoprotein cholesterol (LDL-C), urea, creatinine, and uric acid by point colorimetric assay.~Serum irisin."
45989731|NCT05144672|Other|Anthropometric measurements|Height, weight, waist circumference, and hip circumference were taken as a way of assessing the nutritional status and BMI
45989732|NCT05144672|Procedure|Electrocardiogram and Fundus examination|Fundus examination by direct ophthalmoscope
45989733|NCT05144672|Other|Estimated glomerular filtration rate (eGFR)|Estimated glomerular filtration rate (eGFR) was calculated by EPI equation.
45673891|NCT02239679|Device|BLU-U|10 J/cm2 blue light delivered at 10 mW/cm2
45989734|NCT05144672|Other|Brachial index|The ankle-brachial index test compares the blood pressure measured at your ankle with the blood pressure measured at your arm
45833475|NCT04278612|Other|Quality improvement intervention to strengthen health service provision|Quality improvement intervention comprising of regular improvement meetings based at clinics.
45989735|NCT05144672|Diagnostic Test|Laboratory tests|Glycosylated haemoglobin. ACR,urinary albumin (mg) and creatinine (g).
45989736|NCT05144672|Radiation|Abdominal ultrasound.|It will be performed for patients only.
45989737|NCT02948166|Procedure|Angioplasty with stenting of the femoral artery|A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon expandable or self-expanding) of all the extension is mounted.
45989738|NCT02948166|Procedure|Open surgery|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
45989739|NCT04694040|Device|Modjaw® device|Analysis of mandibular kinematics with Modjaw® device
46083750|NCT00950443|Device|Acoustic reflection method|Acoustic reflection gives the longitudinal cross-sectional area profile along airway.Based on planar acoustic wave propagating in a rigid duct connected to airway.
46083751|NCT00950443|Device|Acoustic method and breathing/endoscopic evaluation|Endoscopic evaluation done under general anaesthesia.
46083752|NCT02711748|Device|electrostimulation|Electrostimulation using manual defibrillator
45989740|NCT04694469|Procedure|Closed reduction and percutaneous pinning (CRPP)|Operated for supracondylar humeral fractures
45673892|NCT02239679|Procedure|Cryotherapy|Liquid nitrogen cryotherapy by standard of care method to all visible/palpable actinic keratosis (AK) lesions at screening.
45673893|NCT02072096|Drug|Glimepiride|Administered orally
45673894|NCT02072096|Drug|Metformin|Administered orally
45673895|NCT02072096|Drug|Pioglitazone|Administered orally
45673896|NCT02072096|Drug|Acarbose|Administered orally
45673897|NCT02072096|Drug|Linagliptin|Administered orally
45673898|NCT02072096|Drug|Sitagliptin|Administered orally
45673899|NCT02072096|Drug|Liraglutide|Administered subcutaneously (SC)
45833476|NCT05430282|Other|Only vestibular rehabilitation|Vestibular adaptation exercises, static and dynamic balance exercises, proprioceptive and conditioning exercises.
45833477|NCT05430282|Other|Cervical exercises in addition to vestibular rehabilitation|Cervical range of motion exercises, stretching exercises for the trapezius muscle, isometric and isotonic strengthening exercises in addition to conventional vestibular rehabilitation exercises.
45833478|NCT03082482|Behavioral|Self-help materials|Self-help smoking cessation materials
45833479|NCT03082482|Drug|nicotine patch|Participants who smoke >10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches. Participants who smoke <10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
45989741|NCT04693923|Procedure|Fluid challenge|Fluid challenge according to the assigned group
45989742|NCT00523185|Drug|Lorazepam|Lorazepam 1 to 2 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
45989743|NCT00523185|Drug|Diazepam|Diazepam 20 mg by mouth every two hours x 3 doses, or for parenteral treatment, diazepam 10 mg intravenously every one hour x 6 doses. Give additional diazepam 10 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
45989744|NCT04512443|Drug|Daflon|All consecutive patients were randomly allocated into 2 groups to receive Daflon (Detralex) at a dose of 1000 mg once daily (study group) or placebo (control group).
45673900|NCT02072096|Drug|Insulin Glargine|Administered SC
45673901|NCT02072096|Drug|Exenatide once weekly (QW)|Administered SC
45673902|NCT02072096|Drug|Exenatide twice daily (BID)|Administered SC
45673903|NCT02071706|Device|PET/MRI system|Enrolled subject undergoes PET/MR scan
45673904|NCT05107700|Procedure|Stay at altitude 2500 m above sea level (high altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.
45673905|NCT05107700|Procedure|Stay at altitude 470 m above sea level (low altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m.
45673906|NCT01631825|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
45673907|NCT02071082|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
45673908|NCT03836105|Drug|cemiplimab|No investigational agents will be provided to enrolled patients by the sponsor as part of this study. Patients will have recently initiated or be planning to initiate treatment with commercially available cemiplimab for advanced CSCC or advanced BCC in a real-world setting according to respective label indications. In addition to cemiplimab, patients may receive other therapies as deemed necessary by their physicians for the treatment of CSCC or BCC or comorbid conditions.
45673909|NCT02123108|Drug|Basiliximab|Peri-operative 40 mg IV dose within 4 hours of OLT Postoperative 20mg IV dose Day 4
45989745|NCT04512404|Drug|HMG-CoA Reductase Inhibitor|
45989746|NCT04693962|Diagnostic Test|Plasmatic Fibroblast Growth Factor-23 by means of ELISA|Plasma levels of FGF-23 will be measured by ELISA
45989747|NCT05149118|Procedure|Polydeoxyribonucleotide (PDRN)|A total 1mL of PDRN was injected along the suture line at distance of 1cm in one day and two days after the surgery.
45989748|NCT00521664|Biological|Prophylactic platelet transfusion|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
45989749|NCT00521664|Biological|Therapeutic platelet transfusion|In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
45989750|NCT05144399|Other|Accelerated antibiotic treatment|"E. faecalis uncomplicated: 4 weeks.~E. faecalis complicated: 4 weeks.~S. aureus uncomplicated: 2 weeks.~S. aureus complicated: 4 weeks.~Streptococci spp. NVE: 2 weeks.~Streptococci spp. PVE or abscess: 3 weeks.~Subsequent to cardiac surgery with a negative valve culture (organism NOT grown in laboratory from valve): Minimum 1 week after surgery regardless of previous antibiotic treatment received.~Subsequent to cardiac surgery with a positive valve culture (organism grown in laboratory from valve): treatment will continue with the start date of antibiotics changed to the date of surgery.~Complicated IE defined as patients with abscess, embolic event, surgically treated IE, and/or PVE.~NVE: native valve endocarditis, PVE: prosthetic valve endocarditis."
45989751|NCT05144399|Other|Standard treatment length|"E. faecalis uncomplicated: 6 weeks.~E. faecalis complicated: 6 weeks.~S. aureus uncomplicated: 4 weeks.~S. aureus complicated: 6 weeks.~Streptococci spp. NVE: 4 weeks.~Streptococci spp. PVE or abscess: 6 weeks.~Subsequent to cardiac surgery with a negative valve culture (organism NOT grown in laboratory from valve): Minimum 2 weeks after surgery regardless of previous antibiotic treatment received.~Subsequent to cardiac surgery with a positive valve culture (organism grown in laboratory from valve): treatment will continue with the start date of antibiotics changed to the date of surgery.~Complicated IE defined as patients with abscess, embolic event, surgically treated IE, and/or PVE.~NVE: native valve endocarditis, PVE: prosthetic valve endocarditis."
45989752|NCT00521703|Drug|Lidocaine|oral cavity and throat were sprayed with lidocaine 10% two to three puffs before propofol infusing
45989753|NCT00521703|Drug|Tannic acid|oral cavity and throat were sprayed with placebo (tannic acid 0.5%) two to three puffs before propofol infusing
45989754|NCT05144321|Other|Impact of environment upon obstetrical|Impact of environment upon obstetrical
45989755|NCT05144321|Other|neonatal and maternal adverse outcome|neonatal and maternal adverse outcome
45989756|NCT00523224|Procedure|Angiogenic Cell Precursors(ACPs) or Vescell TM|at least 1.5 million of ACPs per one time of treatment
45989757|NCT00523224|Biological|Angiogenic Cell Precusors|Stem cells type Angiogenic Cell Precusors(ACPs) at least 1.5 million ACPs per each treatment
45989758|NCT00521742|Drug|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 52 weeks.
45989759|NCT00521742|Drug|Glyburide|Glyburide 2.5 mg to 15 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
45989760|NCT00521742|Drug|Pioglitazone|Pioglitazone 15 mg or 30 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally once daily for up to 52 weeks.
45989761|NCT00521742|Drug|Glyburide|Glyburide 5 mg or 10 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally once daily for up to 52 weeks.
45989762|NCT05144204|Behavioral|Low FODMAP diet|Low FODMAP diet instruction to irritable bowel syndrome patients.
45989763|NCT05144165|Other|Experts consensus|Consensus opinion using Delphi Methodology
45989764|NCT00521781|Drug|Abraxane|100 mg/m2 IVPB Day 1, 8, 15, 22, 29,36,43,50 of each cycle for 4 nine-week cycles (Each cycle of Abraxane/hormonal therapy will consist of 8 weeks of Abraxane therapy and 1 week of rest.)
45989765|NCT00521781|Drug|Leuprolide|7.5 mg monthly or 22.5 mg quarterly, can begin within 3 months of initiating Abraxane for 2 years
45833480|NCT03082482|Behavioral|Counseling|Proactive phone counseling with a Certified Tobacco Treatment Counselor
45833481|NCT03082482|Other|Smartphone-delivered automated treatment|Tailored video clips, text and graphical messages delivered automatically each week to the participant.
45833482|NCT03082170|Device|FEES|FEES test. During this test the investigators look at the pharynx and larynx of the participant while he eats and drinks Economy using number of textures aim to identify swallowing pathology.
45833483|NCT03082170|Diagnostic Test|SDQ|The participant will fill a questionnaire containing 14 questions.These Questions rigorously test all aspects of the swallowing. High score in this test is consistent with swallowing disorder.
45833484|NCT03082170|Behavioral|data review|Reviewing the data from the test summary of participants who have already undergone post operative swallowing assessment.
45833485|NCT03310632|Drug|Antroquinonol|Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
45989766|NCT00521781|Drug|Bicalutamide|50 mg p.o. daily starts week 36 of initiating Abraxane.
45989767|NCT05144126|Other|CT radioraphic assessment|CT radioraphic assessment
45989768|NCT00521820|Drug|Pioglitazone|Pioglitazone 30 mg (titrated to 45mg with tolerance), tablets, orally once daily and glyburide placebo-matching tablets, orally, once daily for up to 24 weeks.
45989769|NCT00521820|Drug|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 10 mg (titrated to 15mg with tolerance), capsules, orally, once daily for up to 24 weeks.
45989770|NCT00523263|Device|heparin-bonded and collagen coated polyster|femoro-popliteal bypass
45989771|NCT00523263|Device|Human umbilical vein femoro-popliteal bypass|
45989772|NCT04696328|Biological|Human (allogeneic) iPS cell derived-cardiomyocyte sheet|Transplantation
45989773|NCT00521859|Drug|Cloretazine|800 mg/m^2 by vein daily
45989774|NCT00521859|Drug|Fludarabine|25 mg/m^2 by vein daily x 5 Days
45989775|NCT02954861|Other|No intervention|No intervention
45989776|NCT00521898|Procedure|Descemet Membrane Endothelial Keratoplasty (DMEK)|
46083753|NCT02711748|Device|cardiopulmonary resuscitation|CPR according to guidelines of European Resuscitation Council. Cardiopulmonary resuscitation using manual defibrillator
46083754|NCT02780180|Drug|QGC001|
45989777|NCT02954666|Device|radio-frequency ablation|"Patients will undergo a tailored 'radio-frequency ablation' of the ARGP with the Smart Touch™ catheter or with the nMARQ™ catheter. Radiofrequency applications will be interrupted if no significant P-P interval shortening is observed after 30 seconds or if P-P interval is ≤ 550 ms during ablation.~The ablation procedure is considered complete when one of the following conditions is fulfilled:~P-P interval < 70% baseline procedural P-P interval after 5minute of waiting time; P-P interval < 600 ms after 5 minute of waiting time; 5 radiofrequency applications > 30 seconds have been delivered with the nMARQ™ catheter or 10 applications with the Smart Touch catheter."
45989778|NCT00521937|Other|Dermagen®|Weekly topical applications
45989779|NCT02954705|Other|Non interventional study|This is a non interventional study because all levies are performed during visit planned for the care of patients.
45456792|NCT01128127|Behavioral|Audit-feedback and computer support|"Audit-Feedback: participants will receive, monthly and by e-mail, an individualized report with data of their own appropriate/inappropriate PPI prescriptions and avoidable costs~CCDSS: interactive computer program designed to assist physicians with decision making when prescribing PPI associated to NSAID. It consists in pop-up alert screens that aim to influence prescription choice according to each patient characteristics and evidence-based clinical guidelines."
45673910|NCT02123108|Drug|Tacrolimus|Day #7 post-transplant or when serum creatinine (SCr) < 1.8 mg/dl 6 months to 1 year: 0.03-0.1 mg.kg q12h po to maintain whole blood trough concentration of 3-5ng/mL
45833486|NCT05422638|Behavioral|RBSTE|8-week health promotion group focused on supporting coping with racism and empowerment
45989780|NCT04693611|Behavioral|Individual cognitive stimulation therapy (iCST)|The intervention group will receive 24 individual CS sessions per participant. Each session will last approximately 45 minutes and will have the following structure: session introduction (5 minutes); reality orientation (10 minutes); stimulation of cognitive domain (25 minutes); session closure (5 minutes). The sessions will be led by a previously trained therapist. The intervention program will include several activities based on the principles of CS and adjusted for participants without any neurocognitive disorder.
45989781|NCT04693611|Procedure|Functional near-infrared spectroscopy (fNIRS)|The acquisition by fNIRS will be performed in each CS session in four regions of interest (ROIs) in the prefrontal cortex: left dorsolateral prefrontal cortex (LDLPFC); left medial prefrontal cortex (LMPFC); right medial prefrontal cortex (RMPFC); right dorsolateral prefrontal cortex (RDLPFC).
45989782|NCT02954822|Drug|Evogliptin→Evogliptin+Glimepiride→Glimepiride|"Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days. After the washout period for 10 days, Glimepiride 4mg will be administered for 2 days.~Glimepiride : Glimepiride 4mg QD~Evogliptin + Glimepiride : Evogliptin 5mg QD + Glimepiride 4mg QD"
46083755|NCT02780180|Drug|Placebo|Lactose capsule manufactured to mimic QGC001 50 mg and 250 mg
46083756|NCT00947479|Other|continuous positive airway pressure (CPAP)|After being qualified into the study according to the aforementioned inclusion criteria and after giving an informed consent the polysomnography will be performed in all patients during night rest.In all patients eligible to sleep apnea treatment according to apnea/hypopnea index (AHI, number of apneic/hypopneic episodes per 1 h of effective sleep) from diagnostic polysomnography, CPAP treatment will be introduced under polysomnographic surveillance and the same panel of clinical and biochemical parameters will be evaluated.
46083757|NCT02707848|Other|No intervention|
46083758|NCT02623010|Drug|Imbruvica|Bruton's Tyrosine Kinase Inhibitor Ibrutinib as maintenance treatment in elderly patients with primary CNS lymphoma following first line chemotherapy treatment
45673911|NCT02123108|Drug|Tacrolimus|Day #1 post-transplant to 6 months: 0.03-0.1mg/kg q12h po to maintain whole blood trough concentration of 7-10 ng/mL + 6 months to 1 year: maintain whole blood trough concentration of 5-8ng/mL
45673912|NCT02123108|Drug|Mycophenolic Acid|Enteric coated mycophenolic acid 360-720 mg po bid
45673913|NCT02121392|Device|Adductor Canal Nerve Block Catheter|ACNB catheter will be placed by anesthesia residents under the supervision of board-certified anesthesiologists familiar with regional anesthesia techniques, who are part of the anesthesia pain service. They will be performed at the bedside, aseptically, with the patient's vital signs monitored throughout the procedure. 1% lidocaine will be infiltrated in the skin and subcutaneous tissues overlying the adductor canal as visualized on ultrasound. Via a 17 gauge touhy needle a closed tip non-stimulating, epidural catheter will be placed after 1% lidocaine is used to hydrodissect the space lateral to the superficial femoral artery within the adductor canal. The catheter will be secured to the skin. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The functional ACNB pumps will run 8cc/h.
45833487|NCT05422638|Behavioral|PCT|8-week health promotion group focused on providing support and facilitating problem solving
45833488|NCT05096598|Drug|ZP8396|Participants will receive 1 single dose of ZP8396 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.
45833489|NCT05096598|Drug|Placebo (ZP8396)|Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm).
45833490|NCT03308916|Diagnostic Test|transient elastography|Ultrasound elastography using shear-wave elastography to measure liver stiffness as a marker of liver fibrosis. Patients with transient elastography above 8.0 kPa selected for liver biopsy to detect advanced liver fibrosis
45989783|NCT02954822|Drug|Glimepiride→Evogliptin→Evogliptin+Glimepiride|After 2 days of administration of Glimepiride 4mg follows the 10-day washout period. Afterwards Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days.
45989784|NCT00522015|Drug|rivastigmine|rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day
45989785|NCT02954744|Procedure|HIFU treatment|High intensity focused ultrasound
45989786|NCT00523380|Drug|recombinant interleukin-21|Administered i.v. in treatment cycles of 28 days.
45989787|NCT00523380|Drug|caelyx (pegylated liposomal doxorubicin)|Administered i.v. in treatment cycles of 28 days.
46083759|NCT00950521|Procedure|Intercerebral implantation of Autulogous Stem Cells|2-8 millions Stem cell per patients plus convention therapy
45989788|NCT00506870|Device|INRatio / Coaguchek XS|INR measured by patient himself using INRation or Coaguchek device. And one follow-up of INR per month, measured in laboratory.
45989789|NCT00506870|Device|Conventional follow-up of anti-coagulation|At least, one follow-up of INR per month. Measured in laboratory.
45989790|NCT02948322|Device|CMRI|Myocardial Imaging (CMRI) will be performed in patients (at baseline and 6 month after treatment) and healthy volunteers (baseline)
45989791|NCT02948322|Drug|Gadolinium|gadolinium injection will be performed during CMRI in patients and healthy volunteers.
45989792|NCT02948322|Procedure|OGTT|Growth Hormon (GH) secretion and metabolic status of the acromegalic will be evaluated by an measure of plasma glucose, insulin and GH (OGTT), and insulin-like growth factor-1 (IGF-I) will be measured in patients and healthy volunteers.
45989793|NCT05143580|Behavioral|Cognitive therapy|"The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~Provide a manual for disease health education.~Provide post-operative care and environmental imaging materials, explain the importance of intensive care unit routines and related equipment, indwelling pipelines, related nursing staff, post-operative care methods, and provide imaging and health education manuals for explanation.~Use gamification to evaluate: pain relief skills, lung expansion skills."
45989794|NCT05143580|Behavioral|Routine care|"The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~Provide a manual for disease health education."
45989795|NCT00522054|Other|Physical exercise|Tai Chi exercise, twice a week during 12 weeks
45989796|NCT00506987|Drug|SCH 486757|SCH 486757 2 x 50-mg capsule twice daily orally for 2 weeks followed by a 2-week washout period and 2 weeks of crossover treatment
45989797|NCT00506987|Drug|Placebo Dose 1|Matching placebo capsules twice daily orally for 2 weeks followed by a 2 week washout period and 2 weeks of crossover treatment
45989798|NCT02276820|Biological|Viralym-A|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-A infusion. If a patient has multiple Viralym-A infusions the schedule resets again at the beginning so follow up relates to the last Viralym-A infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
45989799|NCT00522093|Drug|TJ-100|TJ-100 2.5g three times per day for 6 weeks
45989800|NCT00506558|Procedure|Ventral Surgical Decompression with Instrumented Fusion|Multi-level discectomy or Corpectomy are performed at surgeon's discretion. After decompression an instrumented fusion is performed.
45989801|NCT00506558|Procedure|Dorsal Decompression With or Without Fusion|Dorsal decompressive laminectomy, laminoplasty, or laminectomy with lateral mass instrumented fusion
45989802|NCT00523458|Drug|efavirenz or nevirapine|"Patients co-infected with HIV and TB will receive either standard doses of nevirapine (200 mg 2x daily) or efavirenz (600 mg daily) or high doses of nevirapine (400 mg and 200 mg daily) or efavirenz (800 mg daily) that are chosen to compensate for the change in pharmacokinetics shown to occur when co-infected patients are treated with the antituberculous drug, rifampin."
45989803|NCT00507065|Drug|Mixed salts of a single-entity amphetamine (ADDERALL XR)|
45989804|NCT00507065|Drug|Placebo|
45989805|NCT00522132|Drug|Artesunate|intravenous application
45989806|NCT00523497|Device|Non invasive mechanical ventilation|
45989807|NCT00522210|Drug|Detemir|Patients will discontinue their usual bedtime dose of intermediate acting insulin and replace this with the same unit dose of detemir at supper time. The detemir will not be mixed with the rapid acting insulin and will be given as a separate injection. The patient's morning dose of intermediate acting insulin will be decreased by 20% to adjust for the longer duration of action of detemir. Doses of rapid acting insulin will remain the same at breakfast and at supper.
46083760|NCT00950521|Drug|convention therapy|antiplatelet
46083761|NCT05181462|Drug|Carboplatin|Carboplatin Area Under the Curve (AUC) 2 mg/mL/min intravenous (IV) on days 1 and 8, every 3-week cycles
46083762|NCT05181462|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV on days 1 and 8, every 3-week cycles
46083763|NCT05181462|Drug|Nadunolimab|Nadunolimab escalation (DL -1: 0.5 mg/Kg, DL 1: 1 mg/kg, DL 2: 2.5 mg/kg), DL 3: 5 mg/kg IV on days 1 and 8, every 3-week cycles.
46083764|NCT02781662|Behavioral|Pharmacist Home-Visit|
46083765|NCT00947635|Dietary Supplement|Dietary intervention - supplements|Supplement bar & spread formulated with key nutrients (fish oil, phytosterols, almonds, soy protein) shown to help in reducing blood lipid levels
45989808|NCT00522210|Other|Novolin NPH or Humulin N|Patients will continue on their usual insulin regimen of insulin three times per day. Intermediate and rapid acting insulin at breakfast, rapid acting insulin at supper, and intermediate acting insulin at bedtime.
45989809|NCT05143151|Biological|CD276 CAR-T cells|CD276 CAR-T cells infusion
45989810|NCT00523536|Behavioral|Patient Navigator - Nurse Team Intervention|The patient navigator-nurse disease management intervention for treating hypertension and its associated cardiovascular risk factors will use information obtained in earlier phases of the LUCHAR grant: i.e., algorithms, risk factor profiles, and qualitative data from focus groups and interviews. The study will test the effect of this intervention on blood pressure control and utilization of hospital services in adult patients with hypertension.
45989811|NCT00523575|Dietary Supplement|Cubitan|400 ml/d
45989812|NCT05143112|Biological|Allogeneic CD19 CR-T cell|Allogeneic CD19 CR-T cell infusion
45989813|NCT00523653|Other|blood test|looking at DNA
45989814|NCT05142995|Diagnostic Test|sleep study|Assessment of sleep disorders using either sleep study or a set of sleep questionnaires (Epworth sleepiness scale, SF36, Pittsburgh sleep quality index)
45989815|NCT00522249|Drug|Pegylated Alfa Interferon|Each patient will receive PEG-Intron administered subcutaneously one day per week of each 6 week cycle. The dose of PEG-Intron is determined based on the patient's weight and the dose level.
45989816|NCT00522249|Drug|sunitinib|Patients will receive sunitinib orally as a single daily dose on Days 1-28 of each 42-day cycle. The dose will depend on the dose level.
45989817|NCT00522249|Drug|erlotinib|Tarceva will be administered orally, 1-42 of each 42 day cycle. Dose will depend on dose level. Supplied as 150-mg, 100-mg and 25-mg strengths, white film-coated tablets for administration.
45989818|NCT05148767|Drug|Neoadjuvant chemoradiotherapy based on irinotecan|"Patients with locally advanced rectal cancer treated with irinotecan-based chemoradiotherapy were enrolled in this study. The dose of irinotecan is determined by the genotype of UGT1A1.Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 and *6: 6/6+GG) or 65mg/m2 (UGT1A1*28 and *6 ：6/7+GG or 6/6+GA) or 50mg/m2 （UGT1A1*28 and *6 ：7/7+GG or 6/6+AA or 6/7+GA）."
45989819|NCT00522288|Device|Soft contact lenses|Daily wear soft contact lenses disposed of daily or biweekly
45989820|NCT00522288|Device|Spectacle|Spectacles for the treatment of myopia
45989821|NCT00522327|Other|remote simultaneous medical interpreting|remote simultaneous medical interpretation
45989822|NCT00522327|Other|usual and customary|usual and customary interpreting
45989823|NCT00522327|Other|ENglish speaking|English speakers
45989824|NCT05148728|Procedure|Endoscopic fulguration|already included. WE will use Storz monopolar device for fulguration
45989825|NCT00523692|Drug|Etanercept, methotrexate and depomedrone|Etanercept (50mg weekly; subcutaneous) Methotrexate (7.5-25mg weekly; oral) Depomedrone (up to 120mg; intraarticular / intramuscular)
45989826|NCT00523692|Drug|depemedrone|depomedrone (up to 120mg im/ia) methotrexate (added after symptoms have been present for 12 weeks)
45989827|NCT03458949|Other|awareness campaign|awareness campaign for colorectal cancer screening in the workplace
45989828|NCT05148689|Drug|Oxymetazoline hydrochloride Cream, 1%|Cream
45989829|NCT05148689|Drug|Rhofade™ (oxymetazoline) cream, 1%|cream
45989830|NCT05148689|Drug|Placebo|cream
45989831|NCT03458910|Behavioral|HRV training|Participants will be asked to undergo daily practice to regulate (either increase or decrease) HRV for 5 weeks.
45989832|NCT05148650|Diagnostic Test|Standard laboratory coagulation tests and rotational thromboelastometry measurements|"Blood for coagulation tests (thromboelastometry, aPTT, PT, INR, fibrinogen concentration, D dimers) and blood morphology was collected just before and immediately after the fluid infusion. With the use of a vacuum system, 20 ml of blood was collected through an IV cannula. The first 5 ml of blood were disposed of due to the possible interference with vascular stasis and fluid infusion on the measurements results.~Functional tests of coagulation were analysed through ROTEM. ROTEM coagulation analysis was carried out using a ROTEM delta analyzer (Tem Innovations GmbH, Munich, Germany), and assays were allowed to run for 60 minutes. Assays were run immediately after blood sampling to minimize a preanalytical error. Three ROTEM assays were run simultaneously, INTEM, EXTEM, and FIBTEM."
45989833|NCT00523731|Procedure|Angiogenic Cell Precursors (ACPs) or Vescell TM|
45989834|NCT00523770|Procedure|Urine sample collection|Urine samples will be collected and tested for the presence of S. pneumoniae
46002295|NCT03991624|Other|working memory|"the empan baba task, which mainly involves maintaining information, and which consists in retaining a series of letters, appearing sequentially on a screen, and whose latency time between two word presentations is required for a secondary task: the repetition of baba syllables.~the task of reading operations which consists in recalling operations series of letters whose presentation is interspersed with the reading aloud of simple operations and of their results.~the ongoing operational task of recalling a list of letters, the presentation of which is interspersed with operations that are simple to read aloud and to to solve head-on."
46002296|NCT03991624|Other|episodic memory|- A recognition task with a Remember/Know paradigm
45673914|NCT02121392|Device|Adductor Canal Nerve Block Sham Catheter|Patients randomized to the sham catheter will have a chlorhexidine prep of the skin and ultrasound examination of the adductor canal on postoperative day #1. To minimize patient risk, a wooden applicator will be used to apply 10 seconds of pressure to the leg followed by catheter securing to the skin with the same tegaderm and paper tape dressing used on functional catheters. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The sham catheter pumps will not be turned on.
46002297|NCT03970733|Biological|VLA15|a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
46083766|NCT00612612|Drug|obatoclax mesylate|Given IV
46083767|NCT00612612|Drug|fludarabine phosphate|Given IV
46083768|NCT00612612|Biological|rituximab|Given IV
46083769|NCT00612612|Other|laboratory biomarker analysis|Correlative study
45989835|NCT00522405|Procedure|TACE|"Under local anesthesia, the Femoral artery would be punctured~A catheter would be introduced and a flush aortogram, superior mesenteric arterioportography and the celiac artery run would be undertaken to define the size and location of the tumors, feeding vessels and to assess the portal vein patency~Superselective catheterization of the hepatic artery feeding the tumor would be done~By placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~Stable drug mixture would be prepared by using Doxorubicin 50mg, Cisplatin 100mg in combination with 10-15ml of ionic contrast media and 10-20ml of lipiodol by continuously agitating the mixture.~The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-luer locks syringes connected across a three way.~Gelfoam particles would be injected following this for embolization"
45673915|NCT02121392|Drug|Bupivacaine|In the functioning continuous adductor canal block, 0.125% bupivacaine will be infused at a rate of 8cc/hr.
45673916|NCT02097056|Drug|Donepezil HCL|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
45989836|NCT00522444|Drug|Nebulized Magnesium Sulfate|6.3% solution of magnesium heptahydrate, which is equivalent to 3.18% anhydrous magnesium sulfate
45989837|NCT00522444|Other|Nebulized normal saline|standard of care
45989838|NCT05148143|Drug|Raltitrexed combined with oxaplatin|Raltitrexed combined with oxaplatin as second line treatment of cholangiocarcinoma
45989839|NCT00523887|Drug|Fentanyl transdermal therapeutic system|
45989840|NCT02276534|Behavioral|SENSE Theatre|A peer-mediated, theatre-based intervention.
45989841|NCT02276534|Behavioral|Delayed Intervention|
45989842|NCT00506636|Behavioral|Tissue engineering for hair follicle regeneration|
45989843|NCT00522561|Other|energetic and non invasive limb mechanical measurements|Force velocity stiffness running
45989844|NCT02276573|Biological|buccal cavity sample|
45989845|NCT05145218|Drug|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
45989846|NCT05145218|Drug|Paclitaxel injection|Paclitaxel is a novel anti-microtubule agent.
45989847|NCT05145218|Drug|TQB2450 injection|TQB2450 is a programmed cell death protein 1 (PD-1) humanized monoclonal antibody.
45989848|NCT00523926|Drug|TMC207|
45989849|NCT05146271|Procedure|Complete mouth rehabilitation under general anesthesia in a group of Egyptian children with Down syndrome|Complete mouth rehabilitation under general anesthesia in a group of Egyptian children with Down syndrome
45989850|NCT00522639|Other|18F-deoxyglucose (FDG)|contrast medium
45989851|NCT00522678|Drug|GW685698X|Subject will receive GW685698X containing magnesium stearate with unit dose strength of 400, 600 and 800 mcg inhaled via DISKUS
45989852|NCT00522678|Drug|Placebo|Subject will receive Placebo matching GW685698X via DISKUS.
45989853|NCT05140850|Biological|neuroimaging examination,neuro-cognitive test,blood pressure,blood sample|neuroimaging will be perform,neuro-cognitive will be tested,blood pressure will be monitored,blood samples will be tested
45989854|NCT00522717|Behavioral|Cognitive Behavioral Therapy (CBT)|Subjects receive CBT in the home for 8 weeks with blood draws every other week during therapy.
45989855|NCT00522717|Behavioral|Usual Care|Subjects receive Usual Care for 8 weeks followed by CBT
45989856|NCT05142098|Drug|Dexamethasone|Intramuscular
45989857|NCT05142098|Drug|Etoricoxib 60 mg|Orally
45673917|NCT02121002|Drug|Diclofenac Sodium Topical Gel, 1%|Opaque, white gel
45673918|NCT02121002|Drug|Voltaren Topical Gel, 1%|Opaque, white gel
45673919|NCT02121002|Drug|Vehicle Diclofenac Sodium Topical Gel|Opaque, white gel
45673920|NCT02096900|Drug|zolpidem|Zolpidem will be given one time at 0.25 mg/kg pre-operatively
45673921|NCT02096900|Drug|Midazolam|
45673922|NCT02120924|Drug|Azelaic acid|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
45673923|NCT02120924|Drug|Vehicle|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
45673924|NCT02120924|Drug|Finacea|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
45833491|NCT03308916|Diagnostic Test|Enhanced liver fibrosis test|Patented, commercially available algorithm of hyaluronic acid (HA), N-terminal propeptide of collagen type 3 (P3NP) and tissue inhibitor of metalloproteinase 1 (TIMP-1)
45673925|NCT02096744|Drug|Catapres-TTS-1|Catapres-TTS-1 Oppanol
45833492|NCT03308916|Diagnostic Test|Indirect serum markers of liver fibrosis|Diagnostic markers using combination of routine liver biochemistry: age, AST, ALT, platelet count, cholesterol, GGT
45989858|NCT00523965|Drug|amphotericin B deoxycholate|Amphotericin B deoxycholate 1 mg/kg on alternate days for 15 infusions
45989859|NCT00523965|Drug|Liposomal Amphotericin B with Miltefosine|Liposomal Amphotericin B 5 mg Miltefosine 50 mg twice daily if patient weighs equal to or > 25 kg Miltefosine 50 mg once daily if patient weighs <25 mg
46083770|NCT02781740|Device|Continous Positive Air Pressure Device|
45833493|NCT03308916|Diagnostic Test|Direct serum markers of liver fibrosis|Serum markers that reflect liver extracellular matrix turnover and -accumulation
45989860|NCT00523965|Drug|Liposomal Amphotericin B and Paromomycin Sulfate|AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
45989861|NCT00523965|Drug|miltefosine + Paromomycin sulfate|oral miltefosine 50mg once daily (< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
45989862|NCT05141669|Drug|Fingolimod|Participants who initiated fingolimod to treat multiple sclerosis (MS)
45989863|NCT00522756|Drug|Sodium bicarbonate|Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
45989864|NCT00522756|Drug|Sodium chloride|0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
45989865|NCT02954783|Behavioral|High Intensity Interval Training|"Supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes. Patients will perform a test of maximum cardio-respiratory (VO2 peak test). Using the patient's individual wattmax, a personalized exercise program will be prescribed.~After a light warm-up, patients will perform 25 min of aerobic high intensity interval training on a stationary bicycle, intervals will consist of cycles of HI intervals with 120% of wattmax for 1 min followed by recovery for 3 min at 30% of wattmax. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load."
45989866|NCT02954783|Behavioral|Usual Care Observational Control|The reference group will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.This includes information regarding smoking cessation and alcohol reduction and a physiotherapist consultation regarding pelvic floor exercises. This group is allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise program. This will be monitored by self-report.
45989867|NCT04693845|Behavioral|Collaborative Assessment and Management of Suicidality|"CAMS is a suicide-focused intervention that stabilizes the suicidal patient and identifies, targets, and treats patient-defined suicidal drivers-the problems (e.g., trauma, financial issues, relationship loss) that compel a patient to consider suicide. CAMS is theoretically agnostic, patient-centered, and can be used across different suicidal populations and clinical settings."
45989868|NCT04693845|Behavioral|Treatment as Usual|Treatment as Usual was based on the staff, policies, and procedures of the community mental health center Next Day Appointment clinic (CMHC) affiliated with our university. Research therapists and the research psychiatrist were hired from the CMHC staff who followed standard CMHC policies and procedures.
45989869|NCT05141240|Drug|Ribiciclib|Participants who initiated CDK4/6i therapy
45989870|NCT05141240|Drug|Palbociclib|Participants who initiated CDK4/6i therapy
45989871|NCT05141240|Drug|Abemaciclib|Participants who initiated CDK4/6i therapy
45989872|NCT00522912|Procedure|Trichiasis surgery|Posterior lamella tarsal rotation
45989873|NCT00522912|Procedure|Epilation|Epilation of lashes by another well sighted person using quality epilating forceps
45989874|NCT02954627|Dietary Supplement|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
45456793|NCT01128127|Behavioral|Control|"Usual intervention includes:~Compulsory attendance both to courses (10-12 hours) and to short sessions (around 30 min.) on the rational use of drugs held in groups and during working hours. Each primary care physician attends to 1-2 courses and 3-4 short sessions per year.~Every three months, physicians receive a feedback paper with information on his/her own prescribing overall costs comparing to his/her primary care center average cost.~Distribution of a printed booklet of recommendations, delivered personally or through mass mailings, on the prescribing of PPI-NSAID."
45673926|NCT02096744|Drug|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
45673927|NCT02096744|Drug|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
45456794|NCT01353794|Drug|Sorafenib (Nexavar, BAY43-9006)|The treatment with Sorafenib 200mg tablets should comply with the recommendations written in the local product information. The decision about the duration of treatment is solely at the discretion of the attending physician
45673928|NCT02096744|Drug|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
45673929|NCT02096744|Drug|Catapres-TTS-1|Catapres-TTS-1 Vistanex
45673930|NCT02096744|Drug|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
45833494|NCT03308916|Diagnostic Test|LiverTRAIL|Software that contain 199 diagnostic algorithms, containing combinations of routine tests: age, AST, albumin, alkaline phosphatase, bilirubin, GGT, INR, platelet count, cholesterol and sodium, and specialist tests: transient elastography and direct serum markers of fibrosis.
45833495|NCT03308916|Diagnostic Test|Cytokeratin 18|Cytokeratin 18 from liver cell cytoskeleton; when cells undergo apoptosis, caspase-cleaved CK18 is released (M30), whereas full-length CK18 is realised during necrosis (M65)
45833496|NCT03308916|Diagnostic Test|Omics markers|Markers combining signatures of liver fibrosis and hepatic inflammation from many 'omics technologies
45833497|NCT03081702|Drug|Hydroxychloroquine|Hydroxychloroquine is approved/used for the treatment of rheumatoid arthritis, and discoid and systemic lupus erythematosus, as well as suppressive treatment and treatment of acute attacks of malaria.
45833498|NCT03081702|Drug|Itraconazole|Itraconazole is approved and used for the treatment of certain systemic fungal infections.
45833499|NCT05345964|Drug|GST-HG151|Subjects will take GST-HG151 orally(once daily) on Day 1
45833500|NCT05345964|Drug|Placebo|Subjects will take Placebo orally(once daily) on Day 1
45833501|NCT05345964|Drug|GST-HG151|Subjects will take GST-HG151 orally (once daily) from Day 1 to Day 7
45833502|NCT05345964|Drug|Placebo|Subjects will take Placebo orally (once daily) from day 1 to day 7
45989875|NCT00524004|Biological|Anti-CsbD Bovine IgG|Three times a day for seven days
45989876|NCT00524004|Other|Placebo|Three times a day for seven days
45989877|NCT00524004|Biological|Anti-CS17 Bovin IgG|Three times a day for seven days
45989878|NCT05145803|Device|Polyvinylalcohol strip [diagnostic]|The investigators will measure SARS-CoV-2 in exhaled breath of asymptomatic and symptomatic persons using PVA test strips embedded in face masks (FMS) - an innovative, non-invasive method for detection of SARS-CoV-2 in exhaled air. Utilizing this approach, the study aims to utilize the test results extracted from the masks to identify risk factors for SARS-CoV-2 transmission and timing of infectious period in exposed people (pre-symptomatic, asymptomatic, and symptomatic).
45989879|NCT04694079|Procedure|Group 1, CMR-guided/aided VT ablation|"Ablation of the anatomical channels of heterogeneous tissue within the scar"
45989880|NCT04694079|Procedure|Group 2, CMR-aided VT ablation|"Ablation of the electrical conduction channels within the scar"
45989881|NCT04694079|Procedure|Group 3, Electroanatomical guided ablation|Ablation guided by an electro-anatomical system without the aid of CMR
45989882|NCT05146076|Other|home-based physical training|home-based physical training minimum 150 min./week with telemonitoring
45989883|NCT05146076|Other|institutional physical training|institutional physical training supervised by physiotherapist 2-3 times 60 min./week
45989884|NCT04696367|Procedure|Emergency laparotomy|Midline laparotomy for acute intra-abdominal pathology
45989885|NCT05147168|Other|Questionnaire|Psychometric Validation of Chinese Version of the EORTC QLQ-PAN26 and EORTC QLQ-C30 in Taiwan
45989886|NCT02948127|Biological|RSV LID cp ΔM2-2 Vaccine|10^5 plaque-forming units (PFUs); administered as nose drops
45456795|NCT01224301|Behavioral|School based flu vaccine: Low intensity|Interventions: Parents of children in Low Intensity Notification schools got less than 3 communications from schools describing influenza vaccine and the clinics, and consent forms sent home one.
46083771|NCT05018156|Behavioral|Default Genetics Referral Process|Patients and their oncology providers will be notified of their eligibility for a cancer genetics referral, with an option to opt out if they are not interested in proceeding. Everyone else will be automatically referred to their local hospital's cancer genetics program for contact and scheduling. Standard genetic counseling, testing, and results disclosure will take place, including usual methods of payment and insurance coverage for testing.
45989887|NCT02948127|Biological|Placebo|Administered as nose drops
46083772|NCT00744939|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients will be followed for 2 years after the administration of Magnevist at the approved dose to see if symptoms consistent with NSF develop
45989888|NCT05146583|Procedure|Autologous bone marrow aspirate injected intradiscal after microdiscectomy|Harvested from SI-joint, 2-5ml BMA is injected in the discectomy defect.
45456796|NCT01224301|Behavioral|School based flu vaccine: High intensity|Interventions: Parents in high intensity schools have 3 or more communications from schools about influenza illness, influenza vaccine, and school based clinics.
45989889|NCT05146583|Procedure|Discectomy only|Transflaval discectomy with or without the use of a microtube (according to surgeons' preference).
45989890|NCT02948010|Device|Auto CPAP + comfort feature A|Auto CPAP + comfort feature A using Fisher & Paykel Healthcare CPAP Device
45989891|NCT02948010|Device|Auto CPAP with comfort feature B|Auto CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
45456797|NCT01353872|Dietary Supplement|Nutrattente / Nutraperf / Nutrarecup|500 mL of Nutrattente before each match 500 mL/h of Nutraperf during each match 250 mL of Nutrarecup after each match
45989892|NCT02948010|Device|Auto CPAP with no comfort feature|Auto CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
45989893|NCT02948010|Device|Auto CPAP with comfort feature A+B|Auto CPAP with comfort feature A+B using Fisher & Paykel Healthcare CPAP Device
45989894|NCT02948010|Device|CPAP with comfort feature A|CPAP with comfort feature A using Fisher & Paykel Healthcare CPAP Device
45989895|NCT02948010|Device|CPAP with comfort feature B|CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
45989896|NCT02948010|Device|CPAP with no comfort feature|CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
45989897|NCT02948010|Device|CPAP with comfort feature A + B|CPAP with comfort feature A + B using Fisher & Paykel Healthcare CPAP Device
45989898|NCT02948010|Device|CPAP at Sub therapeutic level|CPAP at Sub therapeutic level using Fisher & Paykel Healthcare CPAP Device
45989899|NCT05145998|Dietary Supplement|Glucola|50 grams of Glucola sugar beverage
45989900|NCT05145998|Dietary Supplement|Whole pea meal|Whole cooked peas with spaghetti sauce and a slice of bread.
45989901|NCT05145998|Dietary Supplement|Pea flour meal|Pea flour with spaghetti sauce and a slice of bread.
45989902|NCT05145998|Dietary Supplement|Whole lentils|Whole cooked lentils with spaghetti sauce and a slice of bread.
45989903|NCT05145998|Dietary Supplement|Lentil flour|Lentil flour with spaghetti sauce and a slice of bread.
45989904|NCT05145959|Device|Maskin Probe|The eyelids are examined using meibography to evaluate which eyelids are more severe (right or left). A drop of proparacaine 0.5% solution is added and a bandage contact lens is placed. To avoid patient discomfort, anesthetic ointment is instilled using a sterile cotton-tipped applicator. In some cases, 4% lidocaine can be directly applied to the lid margin. The Maskin probe will be passed through the gland orifice perpendicular to the lid margin. After first using a 1-mm probe, a 2- or 4-mm probes may be used in cases of persistent resistance. The BCL is removed and the eyes are rinsed with sterile preservative-free saline. The patient is given preservative-free artificial tears to use every hour. A brief slit lamp exam will performed in order to ensure that there is no unanticipated damage to the lid or cornea. The probing device will be properly disposed of in the sharps containers.
45989905|NCT02948205|Procedure|3D group|infertility patient get TU-LESS by 3D Laparoscopy
45989906|NCT02948205|Procedure|normal group|infertility patient get normal laparoscopic surgery
45989907|NCT05148377|Drug|Liquaemin|The standardized dose for the study was 150UI / kg heparin. It was administered directly through the dialysis equipment.
45989908|NCT05148377|Drug|Heptar|The standardized dose for the study was 150UI / kg heparin. It was administered directly through the dialysis equipment.
45456798|NCT01353872|Dietary Supplement|Nutrattente placebo / Nutraperf placebo / Nutrarecup placebo|500 mL of Nutrattente placebo before each match 500 mL/h of Nutraperf placebo during each match 250 mL of Nutrarecup placebo after each match
45989909|NCT00524160|Drug|Fentanyl transdermal patch|
45989910|NCT00523029|Behavioral|Chronic Disease Self-Management Program|Chronic disease self-management is a 6-week group program that teaches participants how to manage their chronic medical illness. Group leaders, also suffering from a chronic medical condition, will lead discussions based on the following topics: nutrition; exercise; appropriate use of medications; ways to communicate effectively with family, friends, and health care professionals; and how to make informed treatment decisions.
45456799|NCT01221025|Drug|Parecoxib|The study group will receive first dose of intravenous (IV) injection of parecoxib sodium 40 mg (in a volume of 2 ml) 60 min before the anticipated end of surgery, followed 2 ml IV injection of parecoxib 40 mg will be occurred at 12, 24 and 36 h after the first dose of parecoxib.
45456800|NCT01224379|Device|Topping off system|"The intervention group will receive a topping off system (PLIF -posterior intervertebral fusion- connected with a flexible pedicle screw system above the fusion)."
45456801|NCT01224379|Device|monosegmental PLIF|The control group receives a monosegmental PLIF. This is the current standard therapy for many pathologies in the lumbar spine (e.g. Spondylolisthesis)
45833503|NCT05345964|Drug|GST-HG151|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
45456802|NCT03149042|Diagnostic Test|CCTA|Diagnostic Test
45456803|NCT03523390|Drug|Avelumab|Subjects will receive an intravenous infusion of avelumab once every 2 weeks (q2w) or every week for the first 12 weeks and then q2w from Week 13 until progressive disease.
45833504|NCT05345964|Drug|GST-HG151|Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
45833505|NCT04399824|Radiation|High-Dose Rate Brachytherapy|Undergo HDR brachytherapy
45833506|NCT04399824|Other|Quality-of-Life Assessment|Ancillary studies
45989911|NCT00524199|Drug|Mesna|12 mg/kg IV infusion over five minutes at the beginning of dialysis thrice weekly.
45989912|NCT00524199|Other|Saline|Saline IV infusion over five minutes at the beginning of dialysis thrice weekly.
45989913|NCT00523068|Drug|Tolterodine|
45989914|NCT00523068|Procedure|tension free vaginal tape|
45989915|NCT00524238|Drug|L-thyroxine|The hypothyroid patients receive usual treatment with L-thyroxine in our out patient clinic. The doctors there subscribe the medication, this study has no protocol regarding this, we observe the patients again after having been biochemically euthyroid for at least two months.
45989916|NCT02276378|Drug|Telmisartan low|
45989917|NCT02276378|Drug|Telmisartan high|
45989918|NCT02276378|Drug|Hydrochlorothiazide (HCTZ)|
45989919|NCT02276378|Other|Japanese meal|
45989920|NCT00525954|Drug|A-002|
45989921|NCT04696250|Drug|Antineoplastic and Immunomodulating Agents|Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
45989922|NCT05145842|Procedure|floroscopy|After proper antiseptic dressing and draping, sacral hiatus was identified. the position of the needle was confirmed by lateral and anteroposterior fluoroscopic images. The needle was introduced up to S3 level for proper spread of the drug.
45989923|NCT05145842|Procedure|ultrasound+fluoroscopy|After proper antiseptic dressing and draping, the caudal region will be shown in the longitudinal section using sterile probe cover and gel. Under ultrasonographic imaging, the sacrococcygeal ligament will be crossed and the needle will not be advanced any further once the sacral canal is entered. The fluoroscopy phase of the combined imaging will be started and the needle position will be checked by taking an anteroposterior view. The needle tip will be positioned at the sacral 3 level. The needle will be repositioned until the proper position is achieved. The research will be terminated at this point and the time to this stage and the radiation exposure dose will be obtained.
45989924|NCT00524433|Drug|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4 mL/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
45989925|NCT00524433|Drug|placebo|
45989926|NCT03458832|Diagnostic Test|FSHD-specific functional rating scale|The FSHD-COM is composed of disease-relevant functional tasks such as leg function; shoulder and arm function; trunk function, hand function, and balance.
45989927|NCT03458832|Device|Electrical Impedance Myography|EIM is a non-invasive, painless, and fast technique for obtaining information on how a patient's muscle structure is changing. EIM uses a small electrical current to measure the health of the underlying muscle. The patient will be asked to lie down and a trained clinical evaluator will perform testing on 16 total muscles (8 on each side) on your arms and legs.
45989928|NCT05142878|Device|Ultracore Repose® mattress|Residents will be placed on the Ultracore Repose® mattress during 14 days
45989929|NCT00524550|Dietary Supplement|moderate alcohol consumption|drinking commercially available alcohol-free beer or beer (26 grams of alcohol per day), for three weeks
45989930|NCT05145647|Radiation|Add-on Brachytherapy|Brachytherapy protocol starts within 2 weeks after consolidative EBRT, subjects who are enrolled will receive brachytherapy with specified balloon applicator. High-dose-rate (HDR) brachytherapy system will be used in the treatment, 5-Gy per fraction is delivered to the pre-treatment esophageal length of primary tumor(s), second treatment will be finished within 2 weeks after the first one, a total of 10Gy in 2 fractions will be delivered.
45989931|NCT05145647|Device|"BRAXX Esophageal Brachytherapy Applicator"|The device is intended for use with commercially available afterloader during brachytherapy. The purpose of the device is for delivery of radioactive source to the esophagus. This device is sterile, disposable and single-use.
45989932|NCT05148416|Radiation|High intensity laser treatment|20 patients received high power laser therapy . Zimmer High power laser applied by laser probe perpendicular to and in slight contact with the skin around knee joint , the total energy was delivered to the patient during one session was 1060 j in 3 phases of treatment.
45989933|NCT05148416|Device|sham HILT.|"20 patients received placebo laser  sham laser . The same treatment protocol of HILT was given to the sham group, but the laser instrument was switched off during applications. All laser applications were performed by the same physiotherapist."
45989934|NCT05148416|Other|knee osteoarthritis conventional exercises program|"knee osteoarthritis conventional exercises program in form of stretching exercises for both vastus medialis and gastrocnemius muscles , ROM exercises for knee flexion and extension , and isometric strengthening exercise of previously mentioned muscles .~all interventions were done under the supervision of physiotherapist for 30 minutes once a day for 3 days per week during a period of 4 weeks."
45989935|NCT02947932|Drug|Resveratrol|pre-ERCP intervention
45989936|NCT02947932|Drug|Indomethacin|post-ERCP intervention in high risk patients
45989937|NCT02947893|Drug|Placebo Capsule(s) Once a Day by Mouth|1 capsule of Placebo once a day for 6 months followed by 2 capsules of Placebo for another 6 months
45989938|NCT02947893|Drug|Nilotinib Capsule(s) Once a Day by Mouth|1 capsule of Nilotinib 150 mg once a day for 6 months followed by 2 capsules of Nilotinib (150 mg each capsule = 300 mb total) for the subsequent 6 months
45989939|NCT05141747|Drug|MRG002|Administrated intravenously
45989940|NCT02946528|Device|urgent-start peritoneal dialysis catheter|Patients initiated peritoneal dialysis as urgent-start dialysis modality with a peritoneal dialysis catheter.
45989941|NCT02946528|Device|central venous catheter|Patients initiated hemodialysis as urgent-start dialysis modality with a central venous catheter.
45989942|NCT05146154|Drug|Imipenem/Cilastatin/Relebactam 1.25g|Imipenem/cilastatin/relebactam is a combination beta-lactam/beta-lactamase inhibitor antimicrobial marketed under the brand name Recarbrio and the approved dose is 1.25g Q6h in patients with normal renal function. The individual components of this agent must be administered together and cannot be separated. Therefore, this constitutes only one intervention. Each subject will receive at least 2 doses of study drug.
45673931|NCT02096042|Drug|Brentuximab Vedotin|"Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle."
45989943|NCT00524667|Drug|Valproic acid & fludarabine|valproic acid (VPA) starting dose of 15 mg/day p.o. in divided doses, increased weekly by 5 mg/kg/day until >1mM Fludarabine 40 mg/m2/day orally will be added after completing 28 days of VPA if participant has been identified as having stable or progressive disease.
45989944|NCT05145686|Diagnostic Test|Matris metalloproteinase -2, -8, -9 expressions|. The aims of this in vivo study was to compare the expression levels of MMP-2, -8 and -9 in primary molars with reversible and irreversible pulpitis and to compare the clinically and radiographically success of MTA and Biodentine materials at the end of 18 months.
45989945|NCT00524706|Drug|S-1, oral Leucovorin, Oxaliplatin|
45989946|NCT05145179|Drug|SSGJ-705|0.1, 1, 3, 6, 10, 15 or 20mg/kg, IV, Day 1, 8, 15 of each treatment cycle, up to disease progression or intolerable toxicity, death, early withdrawal from the study or loss to follow-up, withdrawal of consent, or the end of the treatment period, whichever occurs first. Every 4 weeks a treatment cycle.
45989947|NCT04692987|Other|Decision-aid video|Decision-aid video will be developed to disseminate knowledge and to raise awareness on colorectal cancer screening
45989948|NCT05147870|Procedure|Peritoneal irrigation|For patients allocated to the irrigation group, peritoneal lavage was performed at the surgeon's discretion based on surgical findings and preference.
45673932|NCT02096042|Drug|5-Azacytidine|Phase I Dose-Escalation Phase and Phase II Dose-Expansion Phase: 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.
45673933|NCT02120456|Drug|LEO 43204|
46002298|NCT03970733|Biological|Placebo|PBS (Phosphate Buffered Saline)
45673934|NCT02120456|Drug|Placebo|
45673935|NCT02120300|Drug|LDV/SOF|90/400 mg FDC tablet administered orally
45673936|NCT02120300|Drug|SOF|400 mg tablet administered orally once daily
45989949|NCT05147870|Procedure|Suction only|In the suction only group, one surgical gauze each was placed in the splenophrenic space and Morison's pouch to soak up any remaining purulent fluid followed by turning the patient into the Trendelenburg position for inspection of the lower abdominal cavity. Any interloop adhesions were carefully divided and the gauze-wiping maneuver was used to soak up the residual peritoneal fluid, and all bowel loops were investigated to the root of the mesentery.
45989950|NCT05142644|Procedure|ultrasound|An extra ultrasound performed during pregnancy
45989951|NCT02947542|Device|One-catheter concept|Coronary angiography will be performed using the one-catheter concept.
45989952|NCT02947542|Device|Standard catheter|Coronary angiography will be performed using a standard catheter.
45989953|NCT05144360|Drug|Atenas|ATENAS 1 coated tablet, once a day EMPAGLIFLOZIN PLACEBO Empagliflozin placebo 1 coated tablet, once a day TELMISARTAN + AMLODIPINE PLACEBO Telmisartan + amlodipine 1 coated tablet, once a day
45989954|NCT05144360|Drug|Atenas placebo|Drug: EMPAGLIFLOZIN Empagliflozin 25 mg 1 coated tablet, once a day. Drug: TELMISARTAN Telmisartan + Amlodipine 40 + 5/80 +5 mg 1 coated tablet, once a day ATENAS PLACEBO Atenas placebo 1 coated tablet, once a day
45989955|NCT02946762|Other|Test and treat|All incarcerated individuals found to have HIV infection will be offered universal voluntary HIV counseling and testing (HCV) through routine care provided at the correctional facility followed by referral to the study for immediate (routine, non-study prescribed) ART, regardless of CD4 cell count. The ART regimen prescribed will be the standard first-line, fixed-dose combination efavirenz plus lamivudine/emtricitabine and tenofovir per Zambian national guidelines.
45989956|NCT00507143|Drug|irinotecan|
45989957|NCT00507182|Procedure|Fluorescence Spectroscopy|1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
45989958|NCT00525993|Drug|etoricoxib 90mg 14 days|each patient in this group will receive 90mg once daily, for the 14 days treatment.
45989959|NCT00525993|Drug|etoricoxib 60mg daily for 14 days|Patients in this group will receive 60mg of the drug, daily
45989960|NCT00526032|Procedure|OIR Imaging|Images from 4 different positions will be taken per lesion. The entire imaging procedure will take about 5 minutes per lesion.
45989961|NCT05147714|Device|Surgical Pleth Index (SPI)|SPI data were recorded at one-minute intervals during the last five minutes (6 times in total) until the entropy value reached 60
45989962|NCT02947854|Drug|Fimaporfin (Photosensitizer)|
46083773|NCT00940615|Other|aerobic exercise|, participants assigned to the exercise treatment group of the proposed study will participate in an aerobic exercise regimen of brisk walking on a treadmill for a 60 minute interval, three times a week
45456804|NCT01221103|Drug|Combination of dexamethasone, ofatumumab and bendamustine|"Ofatumumab (liquid concentrate for infusion in glass vials) infused iv on day 1 at 300 mg during the first cycle, followed by infusions of 1000 mg on day 1 of each subsequent cycle~Bendamustine (powder dissolved in sterile water) infused iv over 30-60 minutes at the dose of 120 mg/m2 (days 2,3 every 21 days) or 120 mg/m2(days 2,3 every 28) or 90 mg/m2 (days 2,3 every 28 days) depending on toxicity~Dexamethasone administered i.v. at 40 mg (days 1,2,3,4)"
45456805|NCT03521206|Behavioral|ACP+ programme|Training program for nursing home staff.
45456806|NCT03706898|Drug|Elpida®|Elpida® capsules, 20mg
45456807|NCT03706898|Drug|Dolutegravir|Dolutegravir, film-coated tablets, 50mg
45456808|NCT03706898|Drug|Sofosbuvir|Sofosbuvir, film-coated tablets, 400mg
45456809|NCT03706898|Drug|Daclatasvir|Daclatasvir, film-coated tablets, 60mg
45456810|NCT03927313|Drug|Linezolid|For both experimental arms: 1.2g linezolid 28 days, followed by 600mg linezolid for 28 days
45456811|NCT03927313|Drug|High dose rifampicin|For both experimental arms: additional 25mg/kg (making a total of 35mg/kg) rifampicin, for the first 56 days of treatment
45456812|NCT03927313|Drug|Aspirin|For only one of the experimental arms: 1000mg of aspirin daily for 56 days.
46083774|NCT00940615|Other|stretching/toning|Individuals in the control group will participate in a low intensity stretching and toning session for 60 minutes, three times a week
45456813|NCT03927313|Drug|Standard of Care anti-tuberculous therapy|10mg/kg oral rifampicin, 5mg/kg oral isoniazid, 15mg/kg oral ethambutol, 25mg/kg oral pyrazinamide daily for 56 days.
45456814|NCT03927313|Drug|Dexamethasone|Dexamethasone according to doses of Thwaites criteria for the first 8 weeks of anti-tuberculous treatment. Doses differ according to participants Medical Research Council (MRC) grade. Given orally if participant can swallow and intravenously if they cannot.
45456815|NCT03523234|Drug|neoadjuvant chemotherapy|etoposide with cisplatin/carboplatin, undergoing in prior to the surgery
45456816|NCT03523234|Procedure|radical surgery for stage II and IIIA small cell lung cancer (SCLC)|Lobectomy/total lung resection plus mediastinal lymph node dissection.
45456817|NCT03523234|Procedure|prophylactic cranial irradiation|prophylactic cranial irradiation (PCI) undergoing with adjuvant chemotherapy simultaneously
45456818|NCT03523234|Drug|Chemotherapy|etoposide with cisplatin/carboplatin
45989963|NCT02947854|Biological|Hiltonol (Poly-ICLC)|
45989964|NCT02947854|Biological|HPV E7 (Human Papilloma Virus E7) peptides|
45989965|NCT02947854|Biological|KLH (Keyhole Limpet Hemocyanin)|
45989966|NCT02947815|Drug|Clostridium Botulinum Toxin Type A|
45989967|NCT02947815|Drug|Clostridium Botulinum Toxin Type A|
45989968|NCT05147363|Device|Shockwave Intravenous lithotripsy with a Supera stent|Pre-dilation with the option of using a 2-3mm balloon to cross a lesion for lithotripsy with the shockwave device followed by placement of supera stent.
45989969|NCT00526149|Drug|BI 2536|
45989970|NCT00526149|Other|high performance liquid chromatography|
45989971|NCT00526149|Other|mass spectrometry|
45989972|NCT00526149|Other|pharmacological study|
45989973|NCT05147285|Other|stabilization exercises|Patients will be applied only online supervised stabilization exercises three times a week for 8 weeks.
45989974|NCT05147285|Other|combined exercises|Patients will be applied online supervised aerobic exercise training and stabilization exercises.Aerobic exercises will be performed for 8 weeks, for 30-45 minutes, at 65-75% of the maximum heart rate, 3 days a week, on the days when stabilization exercises are not performed.
46083775|NCT00947713|Drug|low dose human chorionic gonadotropin|patients will receive low dose human chorionic gonadotropin (HCG) in combination with clomiphen citrate
45989975|NCT05147285|Other|Physical activity recommendations|The importance of physical activity will be explained to the patients and appropriate physical activity recommendations will be made.
45989976|NCT00507221|Drug|Albendazole|"Every 3 months for 24 months (enrollment 3, 6, 9, 12, 15, 18, 21, and 24 months):~400mg/day X 3 days"
45989977|NCT00507221|Drug|Praziquantel|At enrollment and 12 months: 25mg/kg X 1
45673937|NCT02120300|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45989978|NCT00507221|Drug|Current standard of care in Kenya|Current standard of care for HIV patients in Kenya based on WHO guidelines.
45989979|NCT04693299|Diagnostic Test|colonoscopy|A colonoscopy scheduled within the normal pathway of care will be performed. No interventions will be performed.
45989980|NCT00507260|Behavioral|Food Record|A record of the amount and kind of food and drink you intake will be completed.
45989981|NCT00507260|Other|Nutritional Consults|Meeting with a dietician consultant regarding issues related to food intake. Participants will also receive the results from the food records.
45989982|NCT03458793|Behavioral|Group walking and group educational workshops|"The experimental group will take part in 12 week intervention consisting of group walking and group educational workshops.~Group walking sessions will run once weekly for up to 45 minutes each in small groups (up to 8-9 people per group) and will be delivered by a trained walk leader once weekly for duration up to 45 minutes per session.~Group educational workshops will be delivered in the form of a group presentation once weekly for up to 45 minutes by the research team (i.e. the PhD student) on a variety of topics focused on the healthy ageing, such as eye hygiene, mental health and well-being, preventing falls, social support, nutritional guides, physical activity recommendations for older adults and other topics"
45989983|NCT00507338|Procedure|PCI|early PCI for NSTEMI; primary PCI for STEMI
45456819|NCT01343420|Biological|Dog Hair Extract, ALK-Abelló, Inc.|ALK-Abelló dog epithelial 1:10w/v glycerin
45456820|NCT01224457|Drug|Phenobarbital|phenobarbital 20mg/kg iv infusion, after 24hours of loading, 2.5mg/kg bid daily
45456821|NCT03133312|Drug|Chlorhexidine Gluconate|Pre-operative vaginal preparation with 4% Chlorhexidine Gluconate Intervention
45456822|NCT03133312|Drug|Povidone-Iodine Scrub and Paint|Pre-operative vaginal preparation with 10% Povidone-Iodine Scrub and Paint Intervention
45673938|NCT02070380|Drug|MultiHance 0.1 mmol/kg|MultiHance administered at 0.1 mmol/kg
45673939|NCT02070380|Drug|Dotarem|Dotarem administered at 0.1 mmol/kg
45673940|NCT02070380|Drug|MultiHance 0.05 mmol/kg|MultiHance administered at 0.05 mmol/kg
45673941|NCT02069366|Drug|Dronabinol|Dronabinol (7.5mg) is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants in each diagnostic group [HC = 20; PTSD = 20; TEC = 20] will receive dronabinol.
45673942|NCT02069366|Drug|Placebo|Placebo is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules. Half of the participants in each diagnostic group [HC = 20; PTSD = 20; TEC = 20] will receive placebo.
45673943|NCT04732208|Diagnostic Test|Colour fundus photography|Fundus images will be captured before and after administration of mydriatic agent
45673944|NCT02068508|Drug|Pioglitazone|Pioglitazone Tablets
45833507|NCT04399824|Other|Questionnaire Administration|Ancillary studies
45833508|NCT04399824|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45456823|NCT01354184|Drug|CRD007|
45456824|NCT01354184|Drug|CRD007 matching placebo|
45456825|NCT02291692|Procedure|paravertebral blockade|ultrasound guided thoracic paravertebral block with 0.5 ml/kg bupivacaine %0.5
45673945|NCT02068352|Drug|OPA-15406|OPA-15406 topical ointment
45833509|NCT05410392|Behavioral|Physical exercise intervention|Home-based physical exercise with the use of a stationary recumbent style bike.
45989984|NCT02946723|Procedure|ultrasound|Lead implantation surgery for SNM using ultrasound guided technique
45989985|NCT02946723|Procedure|X-ray|Lead implantation surgery for SNM using X-ray technique
45989986|NCT05140031|Other|PNE4Adults|"It is a clear and concise program, that consists of a manual for the physiotherapist delivering the education and a board game to enhance engagement and participant involvement. It not only provides the physiotherapist with a clear how-to manual but also provides an easy and accessible way for the patient to grasp the difficult and complex concept of pain."
45989987|NCT02947737|Other|Amniotic membrane dressing|We will place an amniotic membrane dressing on the donor site
45989988|NCT02947737|Other|Gentamicin and xeroform dressing|We will place xeroform, gentamicin and telfa on the donor site
46002299|NCT03961438|Biological|ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes|Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg and will be admixed with 500 μg MPLA formulated in liposomes.
46083776|NCT00947713|Drug|Clomiphen citrate plus HMG|patients will receive Clomiphen Citrate plus HMG
45673946|NCT02068352|Drug|Vehicle ointment|OPA-15406 1%-matching placebo topical ointment
45673947|NCT02207231|Drug|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 252 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 252 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 252 (Group III).
45833510|NCT05410392|Behavioral|Cognitive exercise intervention|Home-based cognitive exercise with the use of smartphone to complete cognitive activities.
45833511|NCT05410392|Behavioral|Health education|Provision of general information about a variety of topics
45833512|NCT04279782|Other|Comprehensive treatment|Comprehensive treatment includes antiviral therapy, antibiotics therapy, symptomatic treatment, supportive therapy.
45833513|NCT05397210|Device|Infinity-Lock Button System|Infinity-Lock Button System
45833514|NCT05393076|Drug|Linerixibat|Linerixibat dose and administration as per study intervention.
45833515|NCT05385510|Biological|R21/Matrix-M™|Adjuvanted malaria vaccine
45833516|NCT05381220|Other|early mobilization|Received early activities provided by the Institute 24 hours after stroke
45989989|NCT05147012|Other|Data collected|"The variable of the characteristic of the patients (i.e.: age, sex, hypertension, diabetes, atrial fibrillation, coronary arteries diseases, body mass index (BMI), surgery, medications) were retrieved from the anesthesia consultation file (Easily, Hospices Civiles de Lyon, France).~We retrieved the mean arterial pressure from our local anesthesia software for each patient ( Diane®, Bow medical, Amiens France). We also performed an automatic extraction of data from our anesthesia software (Diane, Bow Medical, France) with a rate of 1 value / minute for some continuous arterial pressure.~All data was extracted from our institutional database and collected by a physician who was not involved in the care of the study patients."
45989990|NCT04693104|Device|PVA Hydrogel|PVA Hydrogel will be supplied in 2 mL sterile and endotoxins-free pre-filled syringes containing a biocompatible polyvinyl alcohol crosslinked (PVA CL, main component) and buffered water for injections.
45989991|NCT04693104|Device|Synvisk-One®|Synvisc One® (comparator) will be supplied in a 6 mL sterile and non-pyrogenic syringe containing containing Hylan polymers (hylan A + hylan B) (main component), sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate monohydrate and water for injections.
45989992|NCT05146934|Radiation|high resolution CT|Ground glass，honeycomb，reticulation, consolidation
45989993|NCT05146895|Drug|Imiquimod treatment|As an control arm, for patients with flat warts
45989994|NCT05146895|Device|Local Hyperthermia at 44℃|As an experimental arm, for patients with flat warts
45989995|NCT02947776|Behavioral|PEER|The experimental group will receive usual care + peer befriending. Peer befriending aims to utilise the skills and 'lived experience' of people with longer-term aphasia to offer support to others with aphasia, starting at a time of transition (discharge from hospital and withdrawal of intensive therapeutic input) and increased need. It aims to help people develop their own strategies for adjusting to life post-stroke. Peer-befrienders will visit participants 6 times over a period of 3 months (+2 times within the next 6 months). The schedule, nature of visits, and goals (e.g. discuss concerns; pursue activities) will be agreed between the pair. Visits may include: conversation, problem solving, trips out, joint activities.
45673948|NCT02207231|Drug|Placebo for guselkumab|Subcutaneous injections to maintain the blind.
45673949|NCT02207231|Drug|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 47.
45989996|NCT02947776|Behavioral|USUAL|The control group will receive usual care, i.e. all health, social care and voluntary services available to them in their borough. It is not known what exactly usual care comprises for people with aphasia who are discharged in the community with low levels of psychological problems, and this project will help to document this.
45989997|NCT05143073|Behavioral|Alcohol use disorder and strategies to reduce risk educational material|Participants will be directed to educational information (~5 minutes) regarding alcohol use disorder and strategies to reduce risk which they will read.
45989998|NCT05143073|Behavioral|Complex polygenic risk scores, alcohol use disorder, and strategies to reduce risk educational material|Participants will be directed to educational information (~10 minutes) regarding complex polygenic risk scores, alcohol use disorder and strategies to reduce risk which they will read.
45989999|NCT02946372|Procedure|internal limiting membrane transplantation (ILMT)|internal limiting membrane autologous transplantation (ILMT)
45990000|NCT02946567|Other|Noisy City information about hearing health care|Participants will play the game Noisy City, which contains information about hearing health care.
45990001|NCT02946567|Other|Generic Game|Participants will play a generic game without any particular information about hearing health care.
46002300|NCT03961438|Biological|ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes|Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg at months 0 and 2, and 20 μg at month 6. All immunogen dosages will be admixed with 500 μg MPLA formulated in liposomes.
45673950|NCT02207231|Drug|Placebo for adalimumab|Subcutaneous injections to maintain the blind.
45673951|NCT02239601|Other|Physical Therapy|Physical therapy assessment and treatment for any positive signs of nerve entrapment prior to chemotherapy including nerve gliding exercises, education and splinting. A home program was provided and continued throughout chemotherapy treatment
45673952|NCT02236559|Device|Noninvasive positive pressure ventilation (NIPPV)|"Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 > 88%."
45673953|NCT02236559|Device|Vapotherm|Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance. FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 > 88%.
45673954|NCT02206685|Drug|Methadone|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes
45673955|NCT02206685|Drug|Normal Saline|the control group will receive a 20 ml normal saline placebo infusion over 10 minutes
46002301|NCT03955146|Drug|Pamrevlumab|Pamrevlumab will be administered per dose and schedule specified in the arm description.
45456826|NCT01318148|Drug|caspofungin|Intermittent intravenous application of caspofungin
45990002|NCT05148338|Other|Comprehensive risk factor treatment|"Apnea screening with Home Sleep Apnea Test. Referral to sleep physician if apnea-hypopnea index (AHI) is greater than 5~Weight management counseling by dietician if body mass index (BMI) is above 27 kg/m2~Physical activity program under supervision of physiotherapist at a specialized cardiac rehabilitation centre if BMI is over 27 or if there are complaints during exercise~Smoking cessation at specialized outpatient clinic~Blood pressure control, lipid management, glycaemic control, alcohol intake reduction by specialized AF nurse~Motivation and education through a digital health platform"
45990003|NCT05148338|Other|Standard of care|Standard usual care: Treatment by cardiologist conform existing guidelines
45990004|NCT00524784|Biological|ApoCell|Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses starting at a single dose of 35 million apoptotic cells/kg in the first cohort of three subjects. Unless a DLT is experienced by subjects in a given cohort, the dose in the subsequent cohort will be increased by two-fold. The second cohort will receive 70 millions cells/kg, and the third cohort 140 millions cells/kg. The final fourth cohort will receive 210 millions cells/kg.
45990005|NCT00524862|Drug|Optimized medical therapy|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
45990006|NCT00524862|Device|Implantable Cardioverter Defibrillator|an implanted device, called a defibrillator, which monitors heart rhythm and treats life-threatening rhythms accordingly
45990007|NCT05146817|Other|Oral care|Treatment group - original protocol of oral care: special device for tooth brushing 3 times a day with chlorhexidine . Control group - traditional protocol of oral care ( traditional tooth brushing 1 time a day + chlorhexidine rinsing
45990008|NCT02946450|Drug|Other: Not applicable-observational study|
45990009|NCT05149703|Other|Mezieres Postural Treatment|Implementation of 12 weeks suitable postures of Mezieres method
46083777|NCT05341934|Other|Evaluative Conditionning Task|A word will appear in one of the four quadrants on the computer screen. They will have to answer the word as quickly as possible by pressing the space bar. They will also be told that an image will be displayed briefly (400 ms) in the same quadrant by pressing the answer key. This procedure will be repeated for 120 trials: 30 trials with alcohol-related Conditional Stimulus (CS), 30 trials with CS related to non-alcoholic beverages and 60 trials with the CS of filling. The CS referring to alcohol will be the words Beer, Wine …; The CS referring to soft drinks will be the words Coca-Cola, Fanta… and Filling CS referring to vegetables and fruits will be: Apple, Banana…In experimental conditions, alcohol-related CS will be followed by negative Unconditional Stimuli (US) (images from the International Affective Picture System (Lang, Bradley, & Cuthbert, 1997)), CS referring to soft drinks linked to positive images and CS referring to fruits and vegetables will be linked to neutral US.
45990010|NCT00524901|Drug|Epoetin alpha|A single dose of epoetin alpha during CABG for three vessel disease, 60.000 IU intravenously.
45990011|NCT00524901|Drug|NaCl 0.9%|A single dose of NaCl 0.9% during CABG for three vessel disease, 1 ml intravenously.
46083778|NCT00940693|Drug|duloxetine|60 mg capsule once per day for 6 weeks
45990012|NCT02954588|Dietary Supplement|Pyridoxamine|
46083779|NCT00940693|Drug|placebo|one capsule of placebo taken one a day for 6 weeks
46083780|NCT02598063|Drug|Adefovir dipivoxil|ADV will be administered orally at a dose of 10 mg QD for 72 weeks.
46083781|NCT02598063|Drug|Lamivudine|Lamivudine tablets will be administered orally at a dose of 10 mg QD for 12 weeks.
46083782|NCT02598063|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a injection will be administered at a dose of 180 mcg QW for 48 weeks.
46083783|NCT05165654|Device|Transcranial Electrical Stimulation|Transcranial electrical stimulation
45456827|NCT03740347|Behavioral|Questionnaires|"Response to questionnaires evaluating chronic pain and its repercussion :~anxiety questionnaire (Revised Children's Manifest Anxiety Scale),~depression questionnaire (Children's Depression Inventory score),~sleepiness questionnaire (Pediatric Daytime Sleepiness Scale),~quality of life questionnaire (Pediatric Quality of Life inventory score)."
45990013|NCT02954588|Dietary Supplement|Placebo|
45990014|NCT04692792|Dietary Supplement|Placebo drink|consume 1 bottle (50 mL) per day for 8 weeks
45990015|NCT04692792|Dietary Supplement|Dai Dai flower drink|consume 1 bottle (50 mL) per day for 8 weeks
45990016|NCT02954549|Dietary Supplement|Vitamin D3|As in Arms
45990017|NCT02946411|Procedure|Cardiac surgery|Glucose level will be measured after cardiac surgery.
45990018|NCT05145608|Drug|Lamotrigine ER tablet 50mg|In each study period, a single 50 mg dose of lamotrigine will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.
45990019|NCT05143034|Dietary Supplement|TCI66207 Essence|Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
45990020|NCT05143034|Dietary Supplement|Placebo Essence|Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
46083784|NCT02707458|Drug|Probucol|"Probucol was used with good effect for more than a decade in Canada and the US to reduce plasma cholesterol. Although withdrawn from the Canadian and US markets by its manufacturer for commercial reasons, it is still widely used for this purpose in Japan and Korea. Over the past decade, long-term follow-up studies in Asian populations at high risk of cardiovascular events have shown that the drug reduces the incidence of these events in a manner not unlike statin drugs used widely in Canada and the US."
45990021|NCT02946294|Drug|Bupivacaine 0.25% with epinephrine|
45990022|NCT02946294|Drug|Bupivacaine 0.25% with epinephrine|
45990023|NCT05146349|Other|Minnesota RETAIN|RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and an control group that is not.
45990024|NCT00525018|Device|contact heat evoked potential stimulator|
45990025|NCT05146232|Other|induction of anesthesia|induction of anesthesia during gastric sleeve surgery
45990026|NCT05146232|Other|maintainance of anesthesia|maintainance of anesthesia during gastric sleeve surgery either opioid free or opioid based
45990027|NCT05146232|Other|monitoring|electrocardiogram, noninvasive blood pressure, SpO2, rSO2 (Masimo oximeter), and neuromuscular monitoring (TOF-Watch SX; Organon, Dublin, Ireland) were performed on the patients.
45990028|NCT05146232|Other|First postoperative analgesia|IV acetaminophen will be administered every 6 h
45990029|NCT05146232|Other|Second postoperative analgesia|50 mg IV dexketoprofen every 8 h for the first 48 h.
45990030|NCT00525096|Drug|placebo|2 tablets twice a day per os
45990031|NCT00525096|Drug|Celecoxib|2*200 mg tablets twice a day per os
45990032|NCT00525096|Drug|Exemestane|Exemestane 25 mg per day per os
45990033|NCT05142176|Other|Erector spinae catheters insertion|Ultrasound-Guided ESPB The ESPB will be performed with the child in a right lateral decubitus position under aseptic precautions by a high frequency (6-13 MHz) linear ultrasound transducer
46083785|NCT00950677|Drug|Byetta (exenatide)|exenatide 5 mcg subcutaneously
45990034|NCT05142176|Drug|Postoperative pain management|IV acetaminophen 15 mg/kg every 8 hours as a component of multimodal analgesia.
45990035|NCT00525213|Drug|Rob 803|two capsules per day during 12 weeks
45990036|NCT00525213|Drug|Placebo|two capsules per day during 12 weeks
45990037|NCT04693026|Drug|Remdesivir|Remdesivir 100 IV Infusion as a lyophilized powder
46083786|NCT00950677|Drug|Symlin (pramlintide)|pramlintide 60 mcg subcutaneously
45673956|NCT02206607|Drug|PF-04937319 IR MST|Immediate release material sparing tablet (IR MST) administered as 150 mg with morning meal and 100 mg with lunch
45990038|NCT04693026|Drug|Baricitinib|Baricitinib oral tablet form
45990039|NCT04693026|Drug|Tocilizumab|Tocilizumab IV Infusion
45673957|NCT02206607|Drug|PF-04937319 MR 1|Modified release formulation #1 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
45673958|NCT02206607|Drug|PF-04937319 MR 2|Modified release formulation #2 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
45990040|NCT02276859|Drug|insulin aspart|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
45990041|NCT02276859|Drug|insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
45990042|NCT02276859|Drug|insulin glulisine|A kind of study bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial
45990043|NCT05143970|Drug|IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB|"Part I-Dose escalation Patients will receive IPH5301 alone on day 1 (Week 1). Treatment will be administered every 2 weeks until progression or unacceptable toxicity or other reasons requiring treatment discon-tinuation, for a maximum duration of 12 months.~Part II- Expansion cohort Patients will receive IPH5301 at a recommended dose (RP2D) or a next lower dose (RP2D-1)in combination with trastuzumab and paclitaxel, at day 1 and every 2 weeks up to 6 cycles of paclitaxel. The RP2D dose will not exceed the designated maximum tolerated dose (MTD)."
45990044|NCT00526266|Behavioral|Emotional Freedom Techniques (EFT)|A half hour treatment with EFT following a standardized protocol. Both Range of Motion (ROM) physical issues are treated with EFT, as well as any possible emotional issues underlying limited ROM.
45990045|NCT00526266|Behavioral|Diaphragmatic Breathing (DB)|"Diaphragmatic Breathing (DB) instead of EFT tapping, but with all the Setup Statements and components of the Experimental Group, with the exception of tapping. DB is substituted for tapping."
45990046|NCT05149547|Diagnostic Test|blood culture versus mNGS detection|peripheral 4ml for mNGS detection
45990047|NCT04692753|Other|Training and education|Training and education of health care workers in the form of online seminars and bed side demonstration of care and maintenance of venous access devices
45990048|NCT05146115|Other|Realization of the Athletic Shoulder Test and the Modified Athletic Shoulder Test|The participants will have to perform both tests two times, with a 7-10 days rest period between the two sessions
45990049|NCT02946606|Drug|GX-H9|Human growth hormone
45990050|NCT02946606|Drug|Genotropin|Human growth hormone
45990051|NCT05147090|Drug|Empagliflozin 10 MG|Empagliflozin 10mg daily
45990052|NCT05147090|Drug|Placebo pills|Identical in appearance to empagliflozin 10mg daily
45990053|NCT00525252|Drug|Baclofen|Baclofen orally administered for 12 consecutive weeks. For the first 3 days, baclofen administered at a dose of 5 milligrams 3 times per day; subsequently, the daily dose of baclofen will be increased to 10 milligrams 3 times per day.
45990054|NCT00525252|Drug|placebo|Placebo will be orally administered for 12 consecutive weeks
46083787|NCT02689622|Other|research of disease-related factors|included in IPSS and IPSS-R, lactate dehydrogenase, ferritin level, transfusion- dependence, molecular markers as genes mutations
45673959|NCT02206607|Drug|PF-04937319 MR 3|Modified release formulation #3 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
45990055|NCT05149391|Biological|CD19/CD20-directed Chimeric Antigen Receptor T Cells|Autologous 2nd generation CD19/CD20-directed Chimeric Antigen Receptor T Cells, single infusion intravenously
45990056|NCT02947191|Biological|Collagen membrane + HUC-MSCs|After separating bilateral nasal septum mucosas via septum reconstruction incision under endoscopy, the clinical grade HUC-MSCs combined with collagen membrane will be transplanted between the bilateral nasal septum mucosas and fixed. The patients will be treated with antibiotics for 1 week, and with naristillae menthae compositae, mucus promoting agent and other drugs for improving microcirculation for 1 month.
45990057|NCT05146193|Other|Nude back photo|Nude back photo at baseline and at follow-ups for each patient and visual severity and curve type classifications
45990058|NCT02947113|Drug|Cisplatin|Cisplatin will be administrated in a 3-weekly scheme for 2 courses combined with pemetrexed (non-squamous cell lung cancer) or etoposide (squamous cell lung cancer)
45990059|NCT02947113|Radiation|hypofractionated radiotherapy|Hypofractionated radiotherapy of 24 x 2.75 Gy will be given combined with a 3-weekly scheme of cisplatin and pemetrexed/etoposide
45990060|NCT02947113|Drug|Pemetrexed|Pemetrexed will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for non-squamous cell lung cancer)
45990061|NCT02947113|Drug|Etoposide|etoposide will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for squamous cell lung cancer)
45990062|NCT05149274|Drug|DWP14012 Tablet A|DWP14012 10mg
45990063|NCT05149274|Drug|DWP14012 Tablet B|DWP14012 40mg
46083788|NCT02689622|Other|research of comorbidities|HCT-Comorbidity Index, MDS-Comorbidity Index, Adult Comorbidity Evaluation-27, Cumulative Illness Rating Scale-G
45990064|NCT02947464|Procedure|Standard clinical practice|Control weight will be started in obese children to decrease upper airway resistance and airway collapsibility. Close follow-up in order to detect comorbidities.
45990065|NCT02947464|Device|Standard clinical practice + Rapid Maxillary Expansion|Mid-palatal suture osteogenic distraction delivered through a self-activated acrylic intraoral device custom-fit into the children´s palate and maxillary posterior teeth providing a transverse expansion of the dentofacial skeleton.
45990066|NCT00525291|Device|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
45673960|NCT02119676|Drug|Ruxolitinib|"5 mg tablets to be administered by mouth~Ruxolitinib 20 mg twice a day (BID) (Part 1) (NOTE: The starting dose for the randomized portion of study (Part 2) was 15 mg BID based on results from Part 1.)"
45673961|NCT02119676|Drug|Regorafenib|Regorafenib 160mg once daily for the first 21 days of each 28-day cycle. (NOTE: Dose interruptions and modifications for regorafenib are expected when toxicities occur in which dose interruptions or modifications are appropriate.)
45673962|NCT02119676|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
45990067|NCT00525291|Device|EMG-biofeedback alone|In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
45673963|NCT02206061|Behavioral|School-Based Asthma Care for Teens (SB-ACT)|
45673964|NCT02206061|Behavioral|Directly Observed Therapy|
45673965|NCT02206061|Behavioral|Asthma Education|
45673966|NCT02095106|Device|Waterproof Cast|
46083789|NCT02689622|Other|physical performance|Activities of Daily Living and physical performance
45990068|NCT02276690|Biological|hepcidin|"In order to assess iron deficiency by innovative method (dosage of Hepcidin), an additional collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to hepcidin levels"
45990069|NCT02276690|Biological|ferritin and transferrin saturation|"In order to assess iron deficiency by using usual biomarkers (ferritin and transferrin saturation), collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to ferritin levels."
45990070|NCT02947269|Drug|Prucalopride|Prucalopride 2mg capsule
45673967|NCT02095106|Device|Traditional cast|
45833517|NCT05378958|Other|Individual interview|"Individual semi-directed explication interview with phenomenological questioning centered on lived experience.~The individual interview aims to collect data by questioning the participants using interview communication techniques, essentially on the reformulation technique. The interview is structured using an interview guide containing the list of open questions with prompts to be answered during the discussion."
45990071|NCT02947269|Drug|Placebo Oral Capsule|Placebo capsule
45990072|NCT00526305|Drug|Vincristine|1,5 mg/m2 i.v., days 1 and 8
45990073|NCT00526305|Drug|Daunorubicin|60 mg/m2, i.v., days 1 and 8
45990074|NCT00526305|Drug|Prednisone|60 mg/m2 day, i.v. or oral, days 1 to 14
45990075|NCT00526305|Drug|L-Asparaginase|10.000 UI/m2, i.v., days 5-7 and 11-13. Total: 6 doses.
45990076|NCT00526305|Drug|Mitoxantrone|12 mg/m2 i.v days 15, 16 and 17
46083790|NCT05174598|Drug|Calcipotriol/AKVANO, 50 μg/g cutaneous solution|Topical spray formulation containing Calcipotriol 50 μg/g. Twice daily treatment by spraying on a psoriasis affected area for 8 weeks.
45833518|NCT04347876|Diagnostic Test|Tuberculin test|Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination
45990077|NCT00526305|Drug|Cytosine Arabinoside|1.500 mg/m2 /12 hours, days 16, 17 and 18 (total: 6 doses) If slow response to treatment: 3.000 mg/m2/12 hours, days 18, 19, 20 and 21 (8 doses)
45990078|NCT00526305|Drug|Hydrocortisone|10 mg ,15 mg or 20 mg depending of age
45990079|NCT00526305|Drug|Mercaptopurine|50 mg/m2, oral, days 1 to 7, 28-35 and 56-63 in consolidation
45990080|NCT00526305|Drug|Cyclophosphamide|600 mg/m2 day, i.v., days 1 to 15 in consolidation
45990081|NCT00526305|Drug|Dexamethasone|10 mg/m2 day, oral or i.v. days 1-14 5 mg/m2 day, oral. or i.v., days 15-21
45990082|NCT04696016|Procedure|Skin conductance guided antinociception|The value of skin conductance guides the titration of sufentanil
45990083|NCT04696016|Procedure|Standard care antinociception|The intensive care team titrates antinociception based on their standard approach (using a clinical approach by assessing blood pressure, heart rate, and ventilator dyssynchrony).
45990084|NCT02276768|Drug|GIC-1001 375 mg TID|GIC-1001 375 mg TID mid-dose, oral tablet, white-coated, to be taken with water
45990085|NCT02276768|Drug|GIC-1001 500 mg TID|GIC-1001 500 mg TID high-dose, oral tablet, white-coated, to be taken with water
45673968|NCT01631747|Behavioral|Lifestyle Intervention Group|Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet & activity and use of pedometer
45673969|NCT01631747|Behavioral|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
45673970|NCT02068118|Device|Telecardiology program|"The telecardiology program is a combination of a scale, a device asking the patients questions about the symptoms associated with their heart failure, and regular phone calls made by nurses.~Automatic algorithms have been built-up in order to detect early the need for a hospitalization due to heart failure."
45990086|NCT02276768|Drug|GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)|GIC-1002 345 mg TID mid-dose, oral tablet, white-coated, to be taken with water
45990087|NCT02276768|Drug|GIC-1002 460 mg (equimolar to GIC-1001 500 mg)|GIC-1002 460 mg TID high-dose, oral tablet, white-coated, to be taken with water
45990088|NCT02276768|Other|Placebo|Placebo identical and matching active drugs GIC-1001 and GIC-1001
45990089|NCT02946255|Behavioral|Welcome Basket (WB)|"Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions."
46002302|NCT03955146|Drug|Placebo|Placebo matching to pamrevlumab will be administered per schedule specified in the arm description.
46083791|NCT05174598|Drug|Calcipotriol Ointment 50 micrograms/g|Topical Ointment formulation containing Calcipotriol 50 micrograms/g. Twice daily treatment by applying on a psoriasis affected area for 8 weeks.
46083792|NCT05174598|Other|Placebo|Topical spray formulation containing Vehicle of test formulation. Twice daily treatment by spraying on a psoriasis affected area for 8 weeks.
45673971|NCT03736889|Drug|Tislelizumab (BGB-A317)|Anti-PD-1 Antibody
45673972|NCT01623830|Behavioral|Virtual Reality Exposure Therapy|Treatment will consist of 8 weekly sessions. Session 1: information gathering, treatment procedures and rationale. Session 2: Cognitive restructuring. Session 3: Breathing retraining and thought stopping. Session 4: Review cognitive restructuring and hyperventilation exposure. Sessions 5-8 Fear of flying exposure in the Virtual environment.
45673973|NCT04731896|Procedure|Amniotomy|artificial rupture of the amniotic sac
46083793|NCT04229420|Device|Ultrasound guided Rectus sheath block vs Erector spinae plane block|Ultrasound guided Rectus sheath block vs Erector spinae plane block
46083794|NCT02329808|Procedure|blood drawing|The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
46083795|NCT04344054|Biological|RV3-BB|1.0 mL of the thawed rotavirus vaccine to be administered orally at birth, 6 weeks and 10 weeks of age
46083796|NCT04344054|Biological|Trivalent P2-VP8|0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at approximately 6, 10 and 14 weeks of age
45673974|NCT01634165|Drug|LY2963016|Administered subcutaneously
45673975|NCT01634165|Drug|Lantus|Administered subcutaneously
45673976|NCT03575897|Diagnostic Test|Assessment of infant body composition|Serial assessments of infant body composition with air displacement plethysmography in very preterm infants will occur in the first 14 days after birth (baseline measure), at 32 weeks postmenstrual age (PMA), and at 36 weeks PMA or hospital discharge (whichever occurs first)
45673977|NCT02235311|Drug|Pantoprazole|Pantoprazole 40mg orally daily x 8 weeks after acute management of UGIB
45673978|NCT04778579|Drug|ARI-0001 cells|Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z
45833519|NCT05059704|Other|Circuit Class Training|Station 1 will include tasks for warm-up specific for upper extremity, station 2 will include shoulder exercises, station 3 will include elbow exercises, station 4 will include wrist exercises and station 5 will include hand activities and functional training. Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
45833520|NCT05059704|Other|Individual Task specific training|Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
45833521|NCT05034042|Drug|Fezolinetant|oral
45833522|NCT05034042|Drug|Placebo|oral
45833523|NCT03244722|Dietary Supplement|Very-low energy Diet (VLED)|Structured, intensive dietary intervention using liquid meal replacements aimed at providing 800 kcal/day with a weight loss goal of 15% from baseline
45833524|NCT03244722|Other|Standard of care (SOC)|Standard consultation with registered dietitian to determine appropriate caloric deficit for a low calorie diet, education and advice to achieve weight loss in obese women. Standard of care for normal weight women
45833525|NCT05026710|Device|Silicone (Coloplast Imajin Hydro) ureteral stent|During the end of the standard of care ureteroscopy the silicone stent will be placed.
45833526|NCT05026710|Device|Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer)|During the end of the standard of care ureteroscopy the Non-silicone (Polyurethane/Percuflex) stent will be placed.
45833527|NCT05019144|Procedure|Face-to-face burn care|If the participants are assigned to FTF care, they will receive standard burn care including a return follow-up in the burn clinic on a routine basis as prescribed by the clinical burn team (at least once per week) until the burn has healed.
45990090|NCT02946255|Behavioral|Welcome Basket Brief (WBbr)|The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
45990091|NCT02946255|Behavioral|Treatment As Usual|Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
45990092|NCT05148221|Other|Questionnaires|Once each participant signs an informed consent form upon agreeing to participate in the study, they will be asked to complete a simple demographic questionnaire including year in program, work schedule, self-reported height and weight, age, and sex. They will also be interviewed by a faculty of university of Wisconsin-Eau Claire (UWEC) regarding their current and past exercise habits, exercise preferences, and perceived exercise barriers. Two questionnaires listed above (Occupational Fatigue Exhaustion Recovery (OFER 15) and Maslach Burnout Inventory (MBI)) will also be completed by each participant on Qualtrics online platform.
45990093|NCT05148221|Other|Actigraph and activPAL devices|Actigraph and activPAL devices will be set up based on the demographic information and will be provided to each participant to wear for 7 consecutive days during all waking hours and sleep, except when bathing or swimming. If the first 7-day monitoring period was an overnight inpatient week, the second 7-day monitoring period will be scheduled during a non-overnight week. A day before the first day of the second monitoring period, a new set of Actigraph and activPAL devices will be delivered to each participant. Once the second monitoring period ends, devices will be retrieved from each participant, and data will be downloaded from devices.
45990094|NCT00526383|Drug|Tricyclic antidepressants|antidepressant version medical dispositive
45990095|NCT05145257|Dietary Supplement|Elix Cycle Balance|Each day in the morning and at night in the week prior to the menstruation, the participants will take 6 full droppers of Elix Cycle Balance
45833528|NCT05019144|Procedure|Telemedicine enhanced burn care|Participants assigned to TOBI will be given instructions how to download and use TOBI on a smartphone, including how to interface with burn clinicians using text-messaging, videoconferencing, and sending photos of the child's burn(s). The participants will have scheduled video visits with the care provider at least weekly until the burn has healed. The participants will be able to use other features of the app, such as text-messaging and sending photos of the burn(s), as needed. The participants will be able to use standard FTF burn care as well. They will be given instructions how to contact the burn team through the hospital paging operator if TOBI is unavailable or there is an emergency.
45833529|NCT05012202|Device|Hemi device|A sample of vaginal blood will be collected following delivery and analyzed by the device to provide a hematocrit level, which will be masked to the clinical team.
45990096|NCT05147753|Drug|Moxonidine|0.6 mg moxonidine daily
45990097|NCT00525408|Biological|Mycobacterium w.|Immunomodulator
45990098|NCT00525408|Drug|Docetaxel|Chemotherapeutic agent
45990099|NCT00508235|Behavioral|Questionnaire|Questionnaire about the patient's relationship with their best friend.
45990100|NCT00525447|Drug|SGN-40|2-12 mg/kg IV (in the vein) on Days 1, 4, 8, 15, and 22 of Cycle 1; 4-12 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 of Cycles 2-4; 4-12 mg/kg IV (in the vein) on Days 1, 8, and 15 of Cycles 5-8.
45990101|NCT00525447|Drug|lenalidomide|Up to 25 mg daily of a 21-day cycle.
45833530|NCT03244644|Drug|RBX2660|RBX2660 is a microbiota suspension administered as an enema
45833531|NCT03244644|Drug|Placebo|Placebo is normal saline solution administered as an enema
45833532|NCT03243396|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|Eight small-group sessions, including eight children and one guardian for each child, will meet separately, with joint activities in the final three sessions. TF-CBT will be delivered via community health volunteers in the community setting, and via selected teachers in the school setting--with two lay counselors leading the child group, and one leading the guardian group. Most TF-CBT components (psychoeducation, parenting, relaxation, cognitive coping, grief specific skills) will be delivered in groups, but 2-3 individual sessions mid-group will be used for imaginal exposure (i.e., talking about/processing traumatic events).
45990102|NCT00525447|Drug|dexamethasone|40 mg administered weekly.
45990103|NCT00525486|Drug|Nifedipine extended release|Nifedipine extended release PO 30 mg X2/d until 34 weeks' gestation
45990104|NCT05145101|Biological|Prevnar13|Patients receive one dose of Prevenar13 followed by one dose of Pneumovax23 2 months later
45990105|NCT02946060|Other|Audiobooks|iPods with audiobooks
45990106|NCT02946060|Other|Tempo-pace synchronized playlists|Playlists with or without RAS
45990107|NCT02946060|Other|Usual Care|iPods containing either a silent track or white noise
45990108|NCT00525564|Drug|Placebo|Placebo diskus inhalation powder
45990109|NCT00525564|Drug|Salmeterol diskus inhalation powder|50 micrograms twice a day
45990110|NCT04693143|Other|A randomized controlled open-label clinical trial.|This was a single-center; open-label randomized controlled trial performed at a Pediatric Intensive Care Unit (PICU) in tertiary care hospital
45673979|NCT04777955|Other|core stabilization exercises|"Core is at the center of almost all kinetic chains in the body. Core force, balance, and motion control maximize all kinetic chains of upper and lower limb function. A stable and strong core can contribute to more efficient use of the lower extremities. Core stability is defined as the ability of the lumbo-pelvic hip complex to prevent bending of the vertebral column and return to balance after perturbation.~Neuromuscular electrical stimulation (NMES) is a technique in which muscle contraction is electrically stimulated in the area where the surface electrodes are connected. It improves secondary muscle atrophy and weakness in immobilization by preventing a decrease in muscle protein synthesis.~Kinesiological banding (CT) is a treatment method used in the treatment of various musculoskeletal and neuromuscular deficits. The mechanism of action of CT is to facilitate muscle activation, increase blood and lymph circulation and reduce pain due to neurological suppression."
45673980|NCT02204579|Drug|NPSP795|
45673981|NCT02235077|Drug|Spironolactone|"Patients receiving no MRA at home will receive spironolactone 100 mg (4x25 mg capsules) once daily for 96 hours.~Patients already receiving low-dose MRA at home will be randomized to receive spironolactone 25 mg (1x25 mg capsules) or 100 mg (4x25 mg capsules) in hospital for 96 hours. The patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding."
45990111|NCT03453125|Behavioral|Spanish modified Story Memory Technique (mSMT)|
45990112|NCT04692909|Device|dTMS with mPFC stimulation|dTMS with Brainsway's H7 device, stimulating the mPFC.
45990113|NCT02953964|Other|Behavioral: perceptual-based memory encoding training|Participants are trained in the use of perceptual-based memory encoding strategies, inclusive of visual imagery and the method of loci. Visual imagery involves the creation and encoding of mental images, while the method of loci refers to linking these images with specific places to facilitate memory (Simon et al., 2012). Participants are taught to visualise performing each step of a task in a familiar environment, such as in their home (Liu et al., 2009). After participants can correctly visualise the entire task, they then progress to actually performing the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
45990114|NCT02953964|Other|Behavioral: semantic-based memory encoding training|Participants are asked to encode the steps of a task by forming an association of the steps and sequence. Participants are trained in the use of the chunking association method and honeycomb concept and perform different tasks each week, implementing this encoding strategy (Lim et al., 2012). The chunking association method breaks down information into smaller parts and helps with the encoding and retrieval of information. The honeycomb concept allows the steps to form a story in relation to place, time, characters, problem and solution and the story is verbalised. Participants then complete the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
46002303|NCT03943017|Other|Inspection and safety evaluation by 3 longstanding experience physicians of early clinical researches|Adjudicate each ARC's observations according to the 3 physicians perceived medical importance regarding safety; first, adjudications are performed separately. Then disagreements are settled during a final adjudication meeting between them.
46083797|NCT04344054|Biological|Rotarix|1.5 mL of the liquid vaccine containing the RIX4414 strain of human rotavirus vaccine to be administered orally at 6 weeks and 10 weeks of age.
46083798|NCT04344054|Biological|RV3-BB birth dose|1.0 mL of the thawed rotavirus vaccine to be administered orally at birth.
46083799|NCT04344054|Biological|Trivalent P2-VP8 Booster dose|0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at 14 weeks of age
45833533|NCT03303612|Device|Pacemaker implant|Patient will be in the electrophysiology laboratory. The doctor will freeze the groin area and a medication may be given to help the patient relax. A catheter will be inserted into the groin up to the heart and the heart's electrical system will be recorded.
45833534|NCT03303612|Device|Transcutaneous cardiac monitor|"Transcutaneous cardiac patches will allow continuous electrocardiographic monitoring for a 30-day period. For the first randomized patients at the Montreal Heart Institute, Icentia was used and then was changed to a m-Health® device which allows continuous cardiac monitoring. The PocketECG from m-Health® is attached to 3 electrodes on the chest and contains a SIM card that transmits to a server located in Burlington, Ontario .The COME-TAVI coordinating center and the associated site will be informed rapidly of any events that occur . These events include:~Ventricular fibrillation; Sustained ventricular tachycardia Any RR interval >5 sec; Third-degree AV block or Mobitz 2 AV block;"
45833535|NCT05006352|Drug|DNL343|Oral repeating dose
45833536|NCT05006352|Drug|Placebo|Oral repeating dose
45990115|NCT02953964|Other|Behavioral: Cognitive stimulation group (control group)|Participants receiving cognitive stimulation intervention. It consists of eight sessions that train participants' visual attention and memory, auditory attention and memory and their application in daily activities. Two sessions are also given which allow for participants to apply the training practically in their daily lives. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
45990116|NCT02954003|Device|Endo Bypass System|Subject is implanted with the device for up to 3 years.
45990117|NCT00525642|Drug|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 six cycles
45990118|NCT00525642|Drug|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 100mg/m2 four cycles; Doxorubicin 60mg/m2 or epirubicin 75mg/m2 ,cyclophosphamide 600mg/m2) four cycles
45990119|NCT02954042|Device|Pelvital probe|Pelvital probe
45990120|NCT02954042|Device|Placebo Probe|Placebo Probe
45990121|NCT00526422|Procedure|Dental Preventive|
45990122|NCT03459365|Device|Euflexxa|Aspirations performed before each injection and at six weeks.
45990123|NCT00525681|Drug|cyclosporine A|Cyclosporine is dosed twice daily and is individualized as per center practice and kept stable during the study.
45990124|NCT00525681|Drug|tacrolimus|Dosing of tacrolimus is given twice daily and individualized as per center practice.
45990125|NCT03455387|Diagnostic Test|sampling of the serum marker sFlt1 and PlGF|sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery
45990126|NCT03456635|Other|guided antimicrobial prophylaxis|During the intervention period, antimicrobial prophylaxis decisions will be guided by a computerized program
45990127|NCT04692636|Diagnostic Test|Measure: BP measurements, inter-dialysis BP variability, intra-dialysis hypotension|BP will be measured at the beginning and end of each dialysis session in a seated position by a trained dialysis nurse in accordance with the routine unit practice and entered into an electronic database. BP was measured using validated oscillometric BP monitor equipped in hemodialysis machines (Fresenius 4008S or Nikisso DBB-05), which were maintained as per dialysis unit protocols.
45990128|NCT02955095|Device|Quit Smoking Phone Application|The app will be downloaded on participants' phones, and used by the participant for 30 days to make a quit attempt. Participants will be encouraged to use the app every day and to utilize all of its features, including features such as setting a quit date, taking the assessment section, and entering cigarette use and reasons for cravings
45990129|NCT02276898|Drug|Hypertonic Saline 7%|PARI Hyper-Sal™ Sodium Chloride Solution - 7%
45990130|NCT02276898|Drug|Isotonic Saline 0.9% (Placebo)|
46083800|NCT05338346|Drug|ATG-018|"Dose Escalation Phase:~For both dose escalation groups, subjects will receive a single dose of ATG-018 monotherapy on Cycle 1 Day 1 (C1D1) for single dose PK samples' collection. From the morning dose on Cycle 1 Day 2, twice daily dosing (except Dose Level 1: 5 mg QD) will be initiated. Subject(s) will receive intermittent dosing in a 3 days on/4 days off schedule in 21-day cycles until disease progression or unacceptable toxicity.~Dose Expansion Phase :~Dose Expansion Phase will begin at the defined MTD/RP2D for solid tumors and hematological malignancies groups, to further evaluate the safety, tolerability, and PDx profile of ATG-018. Subjects with solid tumors and hematological malignancies will be enrolled."
46083801|NCT02707380|Other|Resistance Training|7 muscle-strengthening exercises using body weight resistance and elastic resistance bands
46083802|NCT02707380|Other|Standard of Care|3 exercises that do not include these 7 muscle-strengthening exercises
46083803|NCT04978376|Behavioral|Time restricted eating|We will compare the effects of time restricted eating alone and combined with resistance exercise of endurance exercise versus a no intervention control group.
46083804|NCT02707536|Procedure|Socket grafting with PRF|Extraction with socket grafting using PRF.
46083805|NCT02707536|Procedure|Socket grafting with bone graft|Extraction with socket grafting using bone graft.
46083806|NCT00951067|Other|Exercise, Elevation, and Compression Garment|"Patients will be asked to daily:~exercise~elevate arm~wear an arm compression garment"
46083807|NCT00951067|Device|E0650 PCD with non-sequential waveform|Use of an E0650 PCD with non-sequential waveform for two hours every day.
46083808|NCT00951067|Device|E0651 PCD with sequential, non-gradient waveform|Use of an E0651 PCD with sequential, non-gradient waveform for two hours every day
46083809|NCT00951067|Device|E0652 PCD with sequential, gradient waveform|Use of an E0652 PCD with sequential, gradient waveform for two hours every day.
45990131|NCT00508313|Procedure|Thermal Imaging|Thermal imaging sessions, each taking approximately 10 minutes.
45990132|NCT02945982|Drug|Entecavir+Carvedilol|The subjects will be taking half a Carvedilol per day at first week and one Carvedilol per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day for 96 weeks.
45990133|NCT02945982|Drug|Entecavir+Carvedilol+ Fuzheng Huayu|The subjects will be taking half a Carvedilol tablet per day at first week and one Carvedilol tablets per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
46083810|NCT00951067|Device|E0652 PCD with peristaltic pulse waveform|Use the E0652 PCD with peristaltic pulse waveform for two hours every day.
46083811|NCT05016284|Other|JW-100|Cosmetic CBD cream (JW-100)
46083812|NCT05016284|Drug|Eucrisa|Topical EUCRISA®, Pfizer
46083813|NCT02707614|Procedure|Robotic vs open prostastectomy|robotic minimal invasive surgery
46083814|NCT02779322|Procedure|Minigastric bypass|The patient will be submitted to a minigastric bypass at the time of the operation
46083815|NCT02779322|Procedure|Gastric bypass|In this case a simplified conventional gastric bypass will be performed
46083816|NCT02711436|Device|Computed Tomography Scan|
46083817|NCT02711436|Device|Fast Magnetic Resonance Imaging|
46083818|NCT05341856|Drug|isosorbide mononitrate|insert vaginal tablet of isosorbide mononitrate in cases of unexplained recurrent pregnancy loss
45990134|NCT00508352|Procedure|Helical tomotherapy IMRT|Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
45990135|NCT02947230|Other|Tailored Knowledge Translation|Tailored knowledge translation strategies specific to maintaining and increasing physical mobility with age.
45990136|NCT02954393|Procedure|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
45990137|NCT02954393|Drug|Metronidazole active phase|Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
45990138|NCT02954393|Drug|Metronidazole healing phase|Metronidazole 400 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
45990139|NCT02954393|Drug|Amoxicillin active phase|Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
45990140|NCT02954393|Drug|Amoxicillin healing phase|Amoxicillin 500 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
45990141|NCT02954393|Drug|Placebos active phase|Amoxicillin and metronidazole placebos thrice a day for 14 days in the active phase (beginning with the first SRP session).
45990142|NCT02954393|Drug|Placebos healing phase|Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (3 months after active phase).
46083819|NCT05341856|Drug|Placebo|insert vaginal tablet of placebo in cases of unexplained recurrent pregnancy loss
46083820|NCT05143710|Diagnostic Test|PRES in PE or E|patients diagnosed with posterior reversible encephalopathy syndrome with preeclampsia or eclampsia
45990143|NCT00526461|Drug|HPPH|IV
45990144|NCT02947152|Drug|HKT288|Cadherin-6-targeting antibody-drug conjugate for intravenous administration
45990145|NCT02954276|Drug|Omexa Sublingual Sumatriptan tablet|75 mg
45673982|NCT02235077|Drug|Placebo|"Patients receiving no MRA at home will receive 100 mg placebo (4x25 mg capsules) once daily for 96 hours.~Patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding."
45673983|NCT02234141|Drug|Placebo|Tablet administered orally once daily
45673984|NCT02234141|Drug|Selonsertib|Tablets administered orally once daily
45673985|NCT02234063|Other|Immediate Genetic Testing|Participants will receive the APOL1 genetic test. Trained research staff will meet with participants to communicate results and lifetime ESRD risk attributable to variations in the APOL1 gene. Primary care providers will receive APOL1 genetic risk information via a best practice alert in the participant's EMR upon commencement of a patient encounter and through results filed in the participant's genetics results section of their EMR.
45673986|NCT02232893|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
45990146|NCT02954276|Drug|Imitrex Oral Product|100 mg
45990147|NCT02947074|Behavioral|Yoga Meditation|Briefly, subjects will be taught to progressively drive their attention to their inner-self, and keep a calm, nonjudgmental and observational approach towards their own thoughts for 30 minutes.
45990148|NCT00507494|Drug|pioglitazone|Pioglitazone 30 mg o.d. tablet for 12 weeks or placebo o.d. tablet for 12 weeks in random order. After 12 wk treatment there is a 4 wk washout out which is followed by switch of study medication in a cross over fashion and a further 12 wk treatment.
45990149|NCT00526500|Behavioral|Tilt Table With Integrated Stepping System|Passive Gait Training: one session, 20 minutes, table tilted to 70-80 degrees, speed 60 steps per minute.
46083821|NCT00947947|Behavioral|Tailored Information Program for Safer Sex|Health communication intervention delivered on a laptop computer to increase positive perceptions of condoms and increase skills to use condoms.
45673987|NCT02232893|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
46083822|NCT03817866|Diagnostic Test|BRAHMS CgA II KRYPTOR|"The BRAHMS CgA II KRYPTOR kit is an automated immunofluorescent assay for the quantitative determination of the concentration of CgA in human serum.~The assay is to be used as an aid in monitoring disease progression during the course of disease and treatment in patients with GEP-NETs (grade 1 and grade 2).~Serial testing for patient BRAHMS CgA II KRYPTOR assay values should be used in conjunction with other clinical methods for monitoring GEP-NETs (grade 1 and grade 2)."
46083823|NCT00951223|Drug|Infergen® (Interferon alfacon-1)|Infergen at either the 15 mcg or 9 mcg dose given per Providers instructions, with or without weight based ribavirin
46083824|NCT02711592|Genetic|Genetic Panel for Analgesics|All patients will receive genetic test panel to determine individualized optimal pain management following Total Knee Arthroplasty.
46083825|NCT00948103|Drug|Nitrous Oxide|nitrous oxide inhalation during intravesical injection. Dose depends on gender and pain
46083826|NCT00948103|Drug|Oxygen|oxygen
46083827|NCT02012114|Other|Cysteamine bitartrate|No intervention
45673988|NCT02203721|Device|TECNIS Symfony Extended Range of Vision IOL, Model ZXR00|
45673989|NCT02203721|Device|TECNIS Monofocal IOL, Model ZCB00|
45990150|NCT00507533|Procedure|Continuous positive airway pressure|
45990151|NCT00526539|Other|Total hip replacement, Spectron and Taperloc|
45990152|NCT00507572|Other|Medical Chart Review|Medical records are reviewed
45990153|NCT00507611|Procedure|Sentinel node mapping|Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
45990154|NCT00507650|Dietary Supplement|Fluid intervention|Volume of fluid prescribed by physician or provider/day X 5 days.
45990155|NCT00507650|Dietary Supplement|Fluid intervention plus 10 ml/kg/day|Fluid volume and type prescribed by physician or provider plus 10 ml/kg/day X 5 days.
45990156|NCT02946957|Behavioral|Cognitive Behavior Therapy for Insomnia|Six telephone sessions that last 20-30 minutes presenting cognitive behavioral therapy for insomnia.
46083828|NCT00951301|Drug|mangosteen juice|6 ounces of juice containing mangosteen taken twice daily, AM and PM, for 6 months duration of study participation.
46083829|NCT00951301|Drug|placebo juice|6 ounces of specially prepared juice not containing mangosteen taken twice daily, AM and PM, for 6 months duration of the study participation.
45676694|NCT04697498|Procedure|Bilateral bi-level Erector spine plane block|After intubation of the trachea and rotation on the abdomen before the skin incision will be performed bilateral bi-level Erector spine plane block. Before surgery, the level of screw placement will be discussed with the surgeon, and the blockade will be performed at two levels of the spine bilaterally as close as possible to the screw placement site. For blockade a solution for prolonged blockade of peripheral nerve plexuses with bupivacaine 0.375%, dexamethasone 0.02% and epinephrine 0.00018% will be used.
46083830|NCT02579317|Behavioral|Resonance Breathing|Breathing is paced with a pre-installed iPhone app that includes a visual pacer.
46083831|NCT02579317|Behavioral|Non-Resonance Breathing|Breathing is paced with a pre-installed iPhone app that includes a visual pacer.
45990157|NCT02946957|Behavioral|Education Only Control|Six telephone sessions that last 20-30 minutes presenting sleep and osteoarthritis education.
45990158|NCT00507806|Drug|perflutren lipid microsphere|
45990159|NCT00526578|Behavioral|Questionnaire|Questionnaire taking about 30-40 minutes to complete.
46083832|NCT02711046|Procedure|single stage nasolabial flap|The versatility of this flap has been attributed to the fact that there is often abundant non-hair-bearing skin in this well-vascularized region. The facial and infraorbital arteries are frequently cited in anatomic descriptions of the nasolabial flap. The venous drainage is believed to be via the angular and facial veins.
46083833|NCT05012462|Device|CM-1500|The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors five (5) parameters of a patient's body. A combination of these parameters is represented by a single number known as the Relative Index value. This value is indicative of relative changes in fluid volume.
46083834|NCT02707302|Device|Iodophor-impregnated adhesive drapes group|Odd-numbered patients are randomized to the iodophor-impregnated adhesive drapes group.3M™ loban™2 iodophor-impregnated adhesive drape(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-impregnated adhesive drapes group.
46083835|NCT02707302|Procedure|Iodophor-free adhesive drapes group|Even-numbered patients are randomized to the iodophor-free adhesive drapes group. Iodophor-free aseptic adhesive drapes(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-free adhesive drapes group.
46083836|NCT00948259|Drug|NP031112|unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
46083837|NCT00948259|Drug|Placebo|unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
45833537|NCT05418192|Other|Enriched Environment|Enriched Environment (EE) consisted of motor and sensory enriched play environment to promote participant's self-generated movements, exploration and task success. EE also included positioning in a graded manner. Visual stimulus and level appropriate vestibular stimulus was also given. Dosing of positioning and sensory inputs was done throughout the therapy. Primary Intervention will be given for 20 to 25 minutes intermittently for period of 4-5 hours a day, 5 days a week for 24 weeks.
45990160|NCT00508430|Drug|ASP8825|oral
45990161|NCT00508430|Drug|Placebo|oral
45990162|NCT00526617|Drug|ABT-888|Oral capsules
45990163|NCT00526617|Drug|Temozolomide|Oral capsules
45990164|NCT00507845|Drug|Ramipril-Felodipine|Ramipril + felodipine 2.5/2.5mg per tablet. One tablet to be taken Od for 8 weeks (this dose could be increased at week 2 to 4 to 5 mg daily because of uncontrolled hypertension).
45990165|NCT04693065|Other|ponseti|Standard of care, treatment by ponseti method
45990166|NCT02946177|Biological|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
45990167|NCT02946177|Other|Sterile Saline|0.5 mL of sterile Saline administered im
45990168|NCT04693455|Drug|ZD03|ZD03 capsule
45990169|NCT04693455|Other|Placebo|placebo capsule
45990170|NCT02946138|Radiation|carbon-ion radiotherapy|Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gy RBE in 5 fractions
45676695|NCT04697498|Procedure|General anaesthesia|The control group - will include patients who will undergo surgery under general anaesthesia
45676696|NCT04680182|Procedure|Suction drain|Suction drain either kept for three weeks or gradually pulled out.
45990171|NCT00507884|Procedure|3 Tesla MRI Scan|MRI of the kidneys and abdomen to be done within 15 days following the routine CT and lasting 1 - 2 hours.
45990172|NCT00525759|Drug|5-FU, Epirubicin, Cyclophosphamide, Docetaxel|3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days
45990173|NCT00525759|Drug|5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid|3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days Zoledronic acid: 4mg intravenous infusion Day 2, AFTER FIRST CYCLE CHEMOTHERAPY ONLY
45990174|NCT00507962|Drug|Cisplatin|100 mg/m^2 Intraarterial On Day 1 Every 4 Weeks
45990175|NCT00507962|Drug|Liposomal Doxorubicin|Starting dose 20 mg/m^2 IV On Day 1 Every 4 Weeks
45673990|NCT01618695|Drug|Perampanel|"Core study: 4 milligram (mg) group- Week 0 Once daily 2 milligram per day (mg/day), Week 1 to Week 18 Once daily 4 mg/day; 8 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 to Week 18 Once daily 8 mg/day; 12 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 Once daily 8 mg/day, Week 4 Once daily 10 mg/day, Week 5 to Week 18 Once daily 12 mg/day.~Extension study: 4 mg group- Week 19 to Week 22 Once daily 4 mg/day, Week 23 Once daily 6 mg/day, Week 24 Once daily 8 mg/day, Week 25 Once daily 10 mg/day, Week 26 to Week 75 or more Once daily 12 mg/day; 8 mg group- Week 19 to Week 22 Once daily 8 mg/day, Week 23 Once daily 10 mg/day, Week 24 to Week 75 or more Once daily 12 mg/day; 12 mg group- Week 19 to Week 75 or more Once daily 12 mg/day."
45673991|NCT01618695|Drug|Placebo|"Core study: Week 0 to Week 18 Once daily placebo.~Extension study:~Week 19 to Week 22 Once daily placebo, Week 23 Once daily perampanel 2 mg/day, Week 24 Once daily perampanel 4 mg/day, Week 25 Once daily perampanel 6 mg/day, Week 26 Once daily perampanel 8 mg/day, Week 27 Once daily perampanel 10 mg/day, Week 28 to Week 75 or more Once daily perampanel 12 mg/day."
45833538|NCT05418192|Other|Traditional Physcial Therapy|Participants of this group received traditional physical therapy based NDT. No additional dosing guidance was given to this group. No home program was specifically assigned to this group. No specific environmental modifications were made for this group.
45990176|NCT02946099|Procedure|Reciproc files in reciprocating motion|An endodontic file that works through a reciprocating motion
45990177|NCT02946099|Procedure|ProTaper Next files in continuous rotary motion|An endodontic file that works through a continuous rotary motion
45990178|NCT02954315|Other|Almonds|
45990179|NCT04692948|Other|Chimeric antigen receptor T cells (car-t)|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
45990180|NCT00508508|Behavioral|Interactive Voice Response System|Participants using IVR will receive training in peer communication techniques and participate in an initial nurse-led interactive group visit. They will then be asked to communicate at least weekly with their partner using the IVR system. The IVR system will also automatically send reminder calls to participants and allow them to leave voice mail messages for their partner and their care manager.
45990181|NCT00508508|Behavioral|Nurse-Led Group Clinic Visits|At Months 1, 3, and 6, participants will take part in group visits led by nurses to discuss HF self-management strategies.
45990182|NCT02485938|Drug|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|Intracoronary delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002)
45990183|NCT00508586|Drug|PTC299|PTC299 orally administered twice per day given in combination with anastrozole (Arimidex®), letrazole (Femara®), or exemestane (Aromasin®)
45990184|NCT02946216|Genetic|ctDNA analysis|
45990185|NCT00508040|Drug|interferon alpha 2a|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
45833539|NCT04399434|Other|test gut microbiota, SCFAs and glucolipid metabolism and insulin sensitivity|test gut microbiota and SCFAs in mothers and their newborns and glucolipid metabolism and insulin sensitivity in mothers
45833540|NCT04760574|Diagnostic Test|Testosterone|Serum total testosterone and free testosterone level
45833541|NCT03237390|Drug|Gemcitabine Hydrochloride|Given IV
45833542|NCT03237390|Other|Laboratory Biomarker Analysis|Correlative studies
45833543|NCT03237390|Other|Pharmacological Study|Correlative studies
45990186|NCT00508040|Drug|prednisone|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
45990187|NCT02946840|Device|FNA with 25 G Beacon needle|
45990188|NCT00508664|Radiation|Radiation|Radiation start in week 11
45990189|NCT00508664|Drug|Cetuximab|Day 1 400mg/m2 i.v. than weekly 250 mg/m2 i.v. for 16 weeks
45990190|NCT00508664|Drug|Docetaxel|75 mg/m2 i.v. day 1 3 times
45990191|NCT00508664|Drug|Cisplatin (TP)|75 mg/m2 i.v. day 1 3 times
45990192|NCT00508664|Drug|5-Fluorouracil (TPF) (only until Feb 2009)|Only patients recruited until Feb 2009: 750 mg/m2 i.v. day 1-5, 3 times
45990193|NCT02946684|Drug|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
45990194|NCT02946684|Drug|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
45990195|NCT02953379|Drug|EMS Mometasone gel|The patient should administer 2 spray in each nostril, once daily.
45673992|NCT01896531|Drug|5-Fluorouracil|Participants will receive bolus and infusional 5-fluorouracil on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity. The infusion times for infusional 5-fluorouracil may be determined per local and/or institutional standards and product labeling.
45673993|NCT01896531|Drug|Ipatasertib|Participants will receive ipatasertib, 600 milligrams (mg) orally once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
45673994|NCT01896531|Drug|Leucovorin|Participants will receive leucovorin or equivalent substitute orally, on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity.
45673995|NCT01896531|Drug|Oxaliplatin|Participants will receive oxaliplatin via intravenous (IV) infusion on Day 1 of each 14-day cycle (part of mFOLFOX6 therapy). Oxaliplatin will be discontinued after completion of 8 cycles
45673996|NCT01896531|Drug|Placebo|Participants will receive matching oral placebo capsules once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
45833544|NCT03237390|Drug|Ribociclib|Given PO
45833545|NCT03302910|Other|Short Stay Unit|Subjects will be treated for acute heart failure in the SSU and observed for improvement then, if appropriate, discharged. If not appropriate for discharge they will be admitted to inpatient.
45833546|NCT03302910|Other|Standard of Care|Subjects who come to the ER with acute heart failure who are randomized to inpatient stay.
45833547|NCT03302910|Drug|Loop Diuretics|IV loop diuretics are commonly used in AHF management
45833548|NCT03302910|Drug|Nitroglycerin|Nitroglycerin or nitrovasodilators are commonly used in AHF management
45833549|NCT05328804|Drug|rhTPO|subcutaneous injection
45833550|NCT05328804|Drug|Herombopag|Orally by mouth
45833551|NCT05348850|Device|Tensiomayography (TMG)|Quadriceps muscle contractile properties will be assessed using tensiomayography
45833552|NCT03300258|Device|Robotic therapy|"The Robotic group will use a robotic training protocol to incentivize recovery of motor control by changing task demands throughout the training period. One or more target tasks will be chosen to mimic different sub-functions of gait, including some which are not normally excited in typical cycling behavior. Also, tasks may be designed to target non-gait motions such as hip ab/adduction. The required task may be changed periodically. This therapy protocol will occupy 30 minutes of each training session. Prior to testing, EMG electrodes will be placed on the major muscles of both legs, a procedure that takes roughly 15 minutes. Another 15 minutes is for changing clothes, briefing the subject, and other ancillary study activities. The total time per training session is 1 hour."
45990196|NCT02953379|Drug|Mometasone spray nasal|The patient should administer 2 spray in each nostril, once daily.
45990197|NCT02946645|Device|Neuromuscular Bite (orthotic/sub-lingual)|Bite is a device which simulates a set of properly positioned teeth
45990198|NCT02946645|Procedure|Mandibular Physiotherapy|"Mandibular Stabilisation Exercises~Place knuckle of index finger between top and bottom teeth.~Remove it, keeping the teeth separated one-knuckle apart.~Apply gentle pressure to the to the jaw using your index finger/thumb as demonstrated in the pictures above."
45990199|NCT02946645|Other|Placebo|No interventions.
45990200|NCT02954120|Other|no intervention provided|
45990201|NCT02946801|Drug|Essential oils|
45990202|NCT02946801|Drug|Essential oils without alcohol|
45990203|NCT02946801|Drug|Sterile water|
45990204|NCT02953808|Drug|Placebo|0.9% weight by volume (w/v) saline solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2).
45990205|NCT02953808|Drug|GSK2315698|200 mg/mL stock solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2). The stock solution will be diluted to obtain dosage levels of 10 mg/hr, 20 mg/hr, or 40 mg/hr.
45990206|NCT02953847|Drug|Rimactane|150 mg capsules, Sandoz MCC registration # A/20.2.3/784
45990207|NCT02953847|Drug|Rifafour e-275|Rifampicin/isoniazid/pyrazinamide/ethambutol 150/75/400/275 mg This 4-drug FDC is the most widely used 4-drug FDC in South Africa with an estimated 100% of the SA DOH tender.
45990208|NCT02953847|Drug|Rimactazid 150/75|Rifampicin/isoniazid 150/75 mg This 2-drug FDC is one of 2 widely used 2-drug FDCs in South Africa, with an estimated 30% of the SA DOH tender. Rifinah® made by Sanofi-Aventis holds about 70% of the tender, however as the Sanofi-Aventis 4-drug FDC will also be evaluated.
45990209|NCT00526695|Drug|Sevoflurane (Preconditioning)|Inhalation of sub-anesthetic doses of sevoflurane
45990210|NCT02953730|Drug|PEG-rhG-CSF|
45990211|NCT00526929|Drug|darbepoetin alfa|10 mcg NESP administered SC every other week 15 mcg NESP administered SC every other week 20 mcg NESP administered SC every other week 30 mcg NESP administered SC every other week 40 mcg NESP administered SC every other week 50 mcg NESP administered SC every other week 60 mcg NESP administered SC every other week 80 mcg NESP administered SC every other week 100 mcg NESP administered SC every other week
45990212|NCT02953691|Drug|Galacto-Oligosaccharide|Mixture produced from lactose utilizing the transgalactosidic activity of Bifidobacterium bifidum NCIMB 41171 beta-galactosidase
45990213|NCT02953691|Drug|Maltodextrin (Placebo)|Maltodextrin is a polysaccharide commonly used as a food additive. It is produced from starch by partial hydrolysis.
45990214|NCT02953535|Drug|Magicbuvir|1 tablet contains 400 mg sofosbuvir
45990215|NCT02953535|Drug|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
45990216|NCT02953535|Drug|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
45990217|NCT02953613|Device|NIRS/IVUS|Cardiac catheterization using infraredx
45990218|NCT02953574|Procedure|daily sleep enhancement nursing protocol|
45990219|NCT00526734|Biological|filgrastim|
45990220|NCT00526734|Biological|pegfilgrastim|
45990221|NCT00526734|Drug|melphalan|
45990222|NCT00526734|Procedure|autologous hematopoietic stem cell transplantation|
45990223|NCT00508703|Radiation|Intensity Modulated Radiotherapy (IMRT)|Dose of 45Gy
45990224|NCT00508703|Procedure|CT Scan|CT Scans: Twice a week during the 5 weeks of radiation treatment.
45990225|NCT00526773|Other|telephone management plus a motivational intervention|heart failure intervention
45990226|NCT00526773|Other|telephone management with standard patient education|heart failure intervention
45990227|NCT02953496|Drug|vonapanitase|Vonapanitase will be administered to the target lesion of the SFA or PA via percutaneous needle injection under ultrasound guidance.
45990228|NCT00508781|Behavioral|Multiphoton laser image in cutaneous pathology|
45990229|NCT00526812|Drug|RTA 744|Aqueous solution added to 10%D/W and infused over 2 hours on three consecutive days. 5 mg vials contain 1 mg/ml.
45456828|NCT03521128|Procedure|radiological tubal blockage|In radiological tubal blockage group, under the fluoroscopy of X-ray, after confirming HX by HSG, selective catheterization will be done for the affected tube and micro spring coils will be put in to the interstitial tube and isthmus through micro catheter. The micro spring coil will be placed into the proximal end of the Fallopian tube (unilateral or bilateral depending on whether one or two HX were present) through micro catheter under the fluoroscopy of X-ray. Then HSG will be carried out to check the position of the micro spring coil and confirm complete blockage. Four weeks after the radiological procedure, a HSG will be performed to recheck the position of the micro spring coil and complete blockage of the tubes. FET is proceeded in the next menstrual cycle after HSG examination.
45676697|NCT04708730|Device|Delipid Extracorporeal Lipoprotein filter from Plasma|As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke
45990230|NCT00526812|Drug|RTA 744 injection|Aqueous solution in 1mg/ml. Doses are escalated. Drug is infused intravenously over 2 hours one day a week for four consecutive weeks.
45990231|NCT00508859|Drug|Sertraline|maintenance treatment with sertraline
45990232|NCT00508859|Drug|placebo|placebo
45990233|NCT00526851|Other|survey administration|Nursing home dentists practicing in Ohio are contacted through a recruitment letter and are asked to respond to questions regarding oral cancer screening practices, knowledge of oral cancer detection, and opinions about oral cancer screening using a newly developed survey, which is based on parts of an existing, pre-tested instrument (Oral Cancer Prevention and Early Detection Survey).
45990234|NCT00508898|Drug|Calcitriol|Patients will receive calcitriol (oral capsule) at a fixed dose of 1 mcg twice weekly.
45990235|NCT00508898|Drug|Multivitamin|Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
45990236|NCT02944890|Device|Drug Eluting Balloon Catheters(RESTORE DEB）|
45990237|NCT02944890|Device|Drug Eluting Balloon Catheters(SeQuent® Please）|
45990238|NCT00508937|Other|Diet|15% protein, 55% carbohydrate, 30% fat (7% saturated, 7% polyunsaturated)
45990239|NCT00508937|Other|Diet|20% protein, 35% carbohydrate, 45% fat (7% saturated, 7% polyunsaturated)
45990240|NCT00508937|Other|Diet|20% protein, 35% carbohydrate, 45% fat (15% saturated, 7% polyunsaturated)
45990241|NCT00508937|Other|Diet|30% protein, 35% carbohydrate, 35% fat (7% saturated, 7% polyunsaturated)
45990242|NCT00508937|Other|Diet|30% protein, 35% carbohydrate, 35% fat (15% saturated, 7% polyunsaturated)
45990243|NCT04692558|Biological|HYALURONIC ACID|Hyaluronic acid will be applied on denuded root surface after reflection of isolated gingival recession.
45990244|NCT04692558|Procedure|coronally advanved flap with connective tissue harvesting|Coronally advanced flap surgery with connective tissue harvesting from palate
45990245|NCT02952599|Drug|Edoxaban|Prescribed according to approved label
45990246|NCT00526968|Drug|EVT 101|8 mg capsule, single oral dose
45990247|NCT00526968|Drug|EVT 101|15 mg capsule, single oral dose
45990248|NCT00526968|Drug|placebo|Placebo capsule, single oral dose
45990249|NCT00510419|Drug|"InvestigationalAuto-injector (sumatriptan succinate)"|
45990250|NCT00527007|Other|External cooling|External cooling
45990251|NCT00510536|Drug|Acetaminophen|dose to be determined by investigator
45990252|NCT00510536|Drug|NSAID|dose to be determined by investigator
45990253|NCT03458715|Drug|SGLT2 inhibitor (Empagliflozin 25 MG)|We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
45990254|NCT03458715|Drug|DPP4 inhibitor (Linagliptin 5 MG)|We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
45990255|NCT00510575|Device|Spinal rod|Posterior spinal fusion using a 5.5 or 6.35 size rod
45990256|NCT02944812|Drug|Chidamide|Chidamide is given to the patients as described, and drug concentration is measured in patients' serum and CSF, also, parameters concerning efficacy and safety are also obtained.
45990257|NCT00510614|Drug|tinidazole|1 gram twice weekly for 12 weeks
45990258|NCT00510614|Drug|Placebo|one pill twice weekly for 12 weeks
45990259|NCT00508976|Drug|Injected bupivacaine post-operatively|Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation, and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
45990260|NCT00508976|Drug|Streamed bupivacaine versus streamed normal saline|Patients will receive 30ml of 0.9% normal saline divided equally and injected prior to port site incisions, then 10ml of 0.5% bupivacaine streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
45990261|NCT00508976|Drug|Aerosolized bupivacaine versus aerosolized saline|Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.5% bupivacaine aerosolized into coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
45990262|NCT00508976|Drug|Injected lidocaine pre-incision vs saline pre-incision|Patients will receive 30ml of 1% lidocaine divided equally and injected prior to port site incisions, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
45990263|NCT04692285|Drug|Zolpidem|Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single 5 mg dose of Zolpidem.
45990264|NCT04692285|Drug|Placebo|Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single dose of placebo.
45990265|NCT00509015|Drug|Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg)|500mg S&25mg P/20 kg, 1 day, single dose
45990266|NCT00509015|Drug|Artesunate (day 1,2,3: 4 mg/kg)|4 mg/kg, daily single dose over three days
45833553|NCT03300258|Device|Aerobic therapy|The Control group protocol is identical to that of the Robotic group, except the robotically-incentivized exercise is replaced with an aerobic exercise. This intervention emulates a commercial motorized exercise bike to improve cardiovascular unfitness contributions to gait impairment. This therapy implements assist-as-needed and constant-velocity control. The patient's target pedaling speed (e.g. 20 rev/min (to be finalized through pilot tests) and power level (set by heart rate to require approximately 50-70% of maximal oxygen uptake) are set at the beginning of each session and a motor provides assistance or resistance to compensate for the performance of the patient. The exercise will be performed in this mode for 30 minutes per training session.
45833554|NCT05340348|Other|Blood samples (36 mL) + fecal samples + hair sample|Blood samples at inclusion, 2 years later and/or if relapse, fecal samples at inclusion and every years for 5 years, hair sample at inclusion
45990267|NCT00509015|Drug|Primaquine-base (day 3: 0.75 mg/kg)|single dose at 0.75 mg/kg on day 3
45990268|NCT00509015|Drug|placebo tablets|3 days of lactose tablets (160mg) albochin
45990269|NCT04692246|Other|Plant-based oral rinse|Oral rinse enriched with plant-based essential oils.
45990270|NCT04692246|Other|Placebo oral rinse|Oral rinse with the exact characteristics in terms of colour and odour of the plant-based one, but without the essential oils aimed to test in this study
45990271|NCT00509054|Procedure|Prophylactic mesh|A low weigth partly absorbable mesh in a subaly posistion
45990272|NCT00509132|Drug|trodusquemine|
45990273|NCT02945202|Device|Biometry|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
45990274|NCT02945202|Device|Refraction|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
45990275|NCT02945202|Device|Corneal Topography|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
45990276|NCT00509210|Drug|telaprevir (VX-950)|
46083838|NCT02707068|Behavioral|Quality Of LIfe Tool for IBD (QOLITI)|The cognitive-behavioural therapy (CBT)-inspired manual will contain several chapters each of which addresses a different topic with information, guidance in setting goals for behaviour change and accompanying tasks to aid implementation which will be completed at home in the participant's own time. Key themes are likely to include symptom management, dealing with social implications of the disease and interacting effectively with healthcare professionals among others. Each chapter will address a theme providing information, sign posting to appropriate organisations, step-by-step tasks and quotes from pwIBD among others, drawing on relevant therapeutic approaches for self-management including CBT and certain elements of Acceptance and Commitment Therapy.
45990277|NCT00528060|Drug|Atazanavir|2pills/day
45990278|NCT00528060|Drug|Ritonavir|1 pill/day
45990279|NCT00528060|Drug|Tenofovir/emtricitabine|1 pill/day
45990280|NCT03459560|Drug|PolyPill|After the baseline enrollment and excluding non-eligible participants, we randomized villages to Polypill and control arms. Follow-ups are scheduled for 1, 3, and 6 months after the initial enrollment in the Polypill arm and every six months thereafter. For the minimal care arm, the follow-ups are arranged every six months.
45990281|NCT00527085|Drug|AMG 073|30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
45990282|NCT00527085|Drug|Placebo|30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
45990283|NCT00509327|Drug|bisacodyl|10mg capsule twice daily from one day preoperatively to day three postoperatively
46083839|NCT02779400|Device|Self testing INR device|the procedure involves a series of repeated measurements of INR with the studied device
45676698|NCT02019602|Procedure|Blood sampling from mother|A blood sample from the mother will be taken within 24 hours before/after the delivery.
45990284|NCT00509327|Drug|glucosemonohydricum|10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
45990285|NCT02945007|Drug|JNJ-53718678|Participants will receive JNJ-53718678 under fed or fasted conditions.
45990286|NCT00509405|Drug|potassium citrate|6 times 10 mEq per day, oral for 24 months
45990287|NCT00528099|Drug|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
45990288|NCT00509444|Behavioral|Educational materials|
45990289|NCT00509444|Behavioral|educational materials, plus patient navigation|
45990290|NCT00528138|Other|Laboratory Test|CRP, white blood cell count, hepatic function tests
45990291|NCT00509483|Radiation|Radioactive iodine|Radioactive iodine preceded by rhTSH
45990292|NCT02945865|Other|Pain assessment|Pain assessment with assessment tools
45990293|NCT00510770|Device|CPAP application|
45990294|NCT02945709|Behavioral|Personalized Attention control training (ACT)|In this intervention, participants will be trained with a personalized Dot-Probe task. Each participant will perform the task with the set of words that he or she ranked as the most threatening according to a Word Ranking Task.
45990295|NCT02945709|Behavioral|Non-personalized Attention control training (ACT)|"In this intervention, participants will be trained with the same Dot-Probe task as in the personalized condition, except that the word stimuli will be randomly fit for each participant. It should be noted that 25% out of the words in this condition will be high ranked words according to each patient's word ranking. The aim of this is to enhance similarity to a generic ACT intervention (see Badura-Brack et al., 2015), where there is some degree of exposure to what one may consider personalized stimuli (i.e., threat words that were randomly included by the researchers), although it is not deliberately set to idiosyncratic preferences."
45990296|NCT02945709|Behavioral|Control training.|In this intervention, participants will perform a computerized task, similar to the Dot-Probe task. In each trial, one neutral word will be presented at the center of the screen and participants will respond to a probe ('E' or 'f') presented following the removal of the words display. This version does not include the essential ingredients thought to reduce PTSD symptoms in the other dot-probe tasks: exposure to threat content and competition on attentional resources. Thus, this control version provides a control condition for the ACT interventions.
45990297|NCT00509561|Biological|cetuximab|
45990298|NCT00509561|Drug|capecitabine|
45990299|NCT00509561|Drug|cisplatin|
45990300|NCT00509561|Radiation|radiation therapy|
45990301|NCT02945943|Other|High Velocity Low Amplitude mobilization|Mobilizations were performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
45990302|NCT02945943|Other|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
45990303|NCT00509639|Drug|10% Metronidazole Ointment|Metronidazole 10% ointment applied perianally three times daily for four weeks. Placebo ointment applied perianally three times daily for four weeks
45990304|NCT02945904|Procedure|adrenalectomy|Unilateral adrenalectomy for Conn's adenoma
45990305|NCT02952716|Biological|Human cord blood mononuclear cell|The patients were treated by human cord blood mononuclear cell through subarachnoid space
45990306|NCT02952716|Other|hyperbaric oxygen|The patients were treated by hyperbaric oxygen
45990307|NCT00528177|Drug|Morphine and oxycodone|"At the end of surgery, group 1 will receive intravenous morphine 0.07 mg/kg and intravenous PCA morphine 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours. Group 2 will receive intravenous oxycodone 0.07 mg/kg and intravenous PCA oxycodone 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours.~The patients will use the PCA until the next morning."
45990308|NCT00509678|Drug|Rituximab|1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15). The first infusion of rituximab should be administered IV at an initial rate of 50 mg/hr. If a hypersensitivity or infusion related reaction does not occur, escalate the infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
45990309|NCT00528216|Drug|Capsaicin Dermal Liquid|
45990310|NCT00528255|Drug|Misoprostol Vaginal Insert (MVI 100)|The MVI 100 is misoprostol 100 mcg, formulated in a sustained release, nonbiodegradeable hydrogel polymer, with a polyester knit retrieval tape; IV oxytocin is permitted ad lib 30 minutes following removal of the MVI assuming no contraindications.
45990311|NCT02953106|Drug|Azelastine-Fluticasone Nasal|137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate
46083840|NCT02781350|Other|HFHC meal|900 Cal high fat high carbohydrate fast food meal (HFHC). meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).
45990312|NCT02953106|Drug|Placebos|Placebo nasal spray
46083841|NCT02781350|Dietary Supplement|HFHC MEAL plus Fiber|900 Cal high fat high carbohydrate fast food meal containing egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).with FiberOne Original cereal 14 grams (half cup) each before and after the HFHC meal
45990313|NCT02944773|Procedure|Facilitated tucking device|20 newborns are using a facilitated tucking device weight during the procedure to assess the level of stress
45990314|NCT02952833|Drug|Saline|Sodium chloride solution.
45990315|NCT02952833|Biological|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
46083842|NCT05071560|Other|Combined exercise training|"Before the intervention, these women will undergo an evaluation of cardiorespiratory fitness, functional fitness, psychological status and a physiatry assessment. A consent form is signed before the start.~The physical exercise intervention was planned based on the recommendations of the American College of Sports Medicine for cancer survivors (ACSM 2019), with two supervised combined training sessions (mobility, aerobic training, strength and flexibility training) planned, and one unsupervised aerobic training session per week, interspersed with at least one rest day in between, for 8 weeks. The intensity will be individualized and defined based on the initial assessment. The structure of the training plan was based on the FITT-VP principles (frequency, intensity, time, type, volume and progression) recommended by the ACSM (2019)."
46083843|NCT05301205|Drug|oral gabapentin|will be received oral gabapentin capsule 2 HOURS pre-operatively.
45990316|NCT02952989|Drug|SGN-2FF|SGN-2FF oral daily dosing.
45990317|NCT02952989|Drug|pembrolizumab|200 mg every 3 weeks by IV infusion
45990318|NCT00509717|Other|intensive implementation programme|educational manual; interactive educational meeting tailored to individual needs; reminders and feedback by 3 newsletters and at least 3 telephone calls.
45990319|NCT00509717|Other|control|educational manual
45990320|NCT02952794|Procedure|endoscopic submucosal dissection (ESD) and endoscopic mucosal band ligation (EMBL) for early cancer|
45990321|NCT00509756|Drug|FXR-450|capsule, single oral doses from 10 mg to 450 mg
45990322|NCT00509756|Drug|Placebo|capsule similar to active drug
45990323|NCT00510926|Drug|Imatinib Mesilate (Glivec)|
45990324|NCT00509834|Drug|hLF1-11|"The study treatment consists of IV administration of:~(A) hLF1-11 (0.5mg IV bolus daily for 14 days) + fluconazole (up to 1g IV four times daily; 14 days): Group #1, n=10; OR (B) Fluconazole (up to 1g IV four times daily; 14 days) + matching placebo for hLF1-11: Group #2, n=10"
45990325|NCT00509834|Drug|hLF1-11|0.5mg hLF1-11 iv per day for 14 consecutive days
45990326|NCT00509834|Drug|Placebo|Placebo
45990327|NCT02952560|Other|Ultrasound scan|Ultrasound scanning examinations will be performed twice (pre-CT scan and post CT-scan). Each examination will be performed by two observers who are blinded to each other's measured values.Patients will be asked to place a small sip of water (20 mL)in their mouth and keep the mouth open during the imaging. A second ultrasound examination of each patient by the two observers will be performed after the CT-scan.
46083844|NCT02707224|Drug|DP-R208|Investigational product is prescribed to all of randomized subjects
45990328|NCT03459404|Combination Product|Sufentanil NanoTab PCA System|15 mcg Sufentanil NanoTab self-administered sublingually up to every 20 minutes as needed for pain for at least 48 hours and up to 72 hours
45990329|NCT00527202|Drug|botulinum toxin A|Botulinum toxin A versus saline in parallel groups
45990330|NCT03459989|Diagnostic Test|Ultrasound|Samsung H60 Ultrasound
45990331|NCT00527241|Behavioral|Raices nuevas|8 90-minute sessions (once a week) of problem-posing and facilitated discussion on respect, anger, support, trust, negotiating, partnership with your intimate partner.
45990332|NCT00527280|Procedure|Feasibility ot face transplantation|Feasibility ot face transplantation
45990333|NCT02952521|Procedure|Blood Draw|CA125 and ctDNA
45990334|NCT02952521|Procedure|Tumor Tissue Biopsy|Only collected at time of surgery if patient undergoes surgical debulking
45990335|NCT00527358|Behavioral|SAFER (Seguridad, Apoyo, Familia, Educacion, y Recursos)|"community lay workers will do family outreach and assist families in networking with other families and accessing community services, facilitating parent-youth and family-school communication and homework help for children, and help with translation of school or government/official notices;~youth leaders will provide a supportive presence, help youth navigate the system at school so that they can get help if needed, disseminate information about job training and possibilities, provide education about avoiding violence;~school support services will offer academic support, acculturation orientation, language, conflict resolution skills training, advocacy and referrals;~Youth drop-in center will provide youth with an adult supervised place to hang out, do homework, or participate in sports and job training."
45990336|NCT00509951|Behavioral|One-session exposure treatment|Participants receiving OST will attend one extended treatment session, lasting up to 3 hours in duration. During this session, the child will be taught a number of cognitive and behavioral skills to deal effectively with the feared situation or object. The child will also be exposed to the feared situation or object in a highly structured, safe, and controlled manner.
45990337|NCT00509951|Behavioral|Augmented one-session exposure treatment|Family-enhanced OST (augmented OST) involves the parents of affected children and provides the parents with strategies to assist their children in overcoming phobias. Participants receiving augmented OST will attend the same type of extended treatment session, but, in addition, their parent or guardian will attend a 3-hour session.
45990338|NCT02945670|Behavioral|Focus Group|We had recruited 64 women and completed 7 focus group sessions
45990339|NCT00510965|Drug|Intravitreal injection ranibizumab|Monthly intravitreal injection of 0.5mg ranibizumab in one eye over one year
45990340|NCT02945826|Drug|One injection of 68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE105
45990341|NCT02945826|Device|PET/MRI|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/MRI of the brain
45990342|NCT00509990|Drug|Pimecrolimus|Pimecrolimus cream 1 %
45990343|NCT02945358|Procedure|adult cardiac surgery with cardiopulmonary pump|Open-heart surgery both coronary artery bypass graft (CABG) and valve surgery
45990344|NCT02952209|Device|Xenograft|
45990345|NCT02945397|Behavioral|Group-based activity|Regular follow-up from welfare authority as well as a 3 month group activity with weekly gatherings, focusing on coping, goal-setting and relevant information regarding available public services.
45990346|NCT02945397|Behavioral|Individual activity|Regular follow-up from welfare authority as well as a 3 month membership card at a given gym.
45990347|NCT02952287|Device|4D PC MRI acquisition|Flow-sensitive 4D-MRI acquisitions will be synchronized to the heart rate and breathing using prospective ECG-gating and adaptive diaphragm navigator gating41. The MRI sequence will consist of a segmented k-space spoiled gradient echo sequence with interleaved 3D velocity encoding. Data will be acquired in a sagittal oblique 3D data volume individually adapted to include the heart and the thoracic and upper abdominal vessels of interest like ascending, transverse and descending aorta, main and branch pulmonary arteries, pulmonary veins, superior and inferior vena cava, celiac and superior mesenteric vessels. Velocity encoding (VENC) will be set at 150-500 cm/sec to encompass flow in various vessels.
45990348|NCT04695782|Radiation|Pencil beam proton radiotherapy|Doseescalated pencil beam proton Therapy
45990349|NCT00527436|Dietary Supplement|fish oil|Fish oil pills will be taken daily for 12 weeks
45990350|NCT00527436|Dietary Supplement|Placebo|Placebo (corn oil) will be taken daily for 12 weeks
45990351|NCT03459911|Drug|Cozaar 100mg Tablet|Cozaar® ( Losartan potassium) 100 mg Tablets(Merck Sharpe & Dohme B.V. , Haarlem, the Netherlands)
45990352|NCT03459911|Drug|Losartan potassium 100mg|Losartan potassium 100 mg Tablets ( Pharmtechnology LLC, Republic of Belarus)
45990353|NCT02945592|Behavioral|Cueing|
45990354|NCT03459872|Procedure|Acupuncture|Alternative medicine therapeutic intervention
45990355|NCT03459872|Device|RU-Fit|FDA approved medical device for the measurement of fine motor control
45990356|NCT02945514|Other|DayTwo machine learning algorithm|Personally tailored nutrition insights based on DayTwo machine learning algorithm when combining facets of your postprandial glycemic response to food consumed during collection week and your individual gut microbiome composition
45990357|NCT03459833|Drug|Hyaluronic Acid|Glans penis augmentation using multiple puncture technique as described by Abdallah et al. (2012) with minor modifications. HA is injected at two circular levels: one at the level of corona of glans penis and a second circular level is mid-way between the corona and urethral meatus. Six injections are injected at coronal level and four are injected in the second level, each injection is of 0.2 ml and is injected into deep dermis.
46002304|NCT03933163|Drug|Resveratrol|Drug name: Micronised resveratrol. Dosage form: 500mg capsules. Alternate name: 1,3-Benzenediol, 5-[2-(4-hydroxyphenyl)ethenyl]-, (E). Ingredients: 99.50% pure trans-resveratrol. Placebo capsules will be identical in terms of taste, smell, and appearance.
46002305|NCT03921411|Biological|Nemolizumab|Participants received subcutaneous (SC) injection of 30 milligram (mg) of Nemolizumab every 4 weeks (Q4W) over a 16-week treatment period, with a loading dose of 60 mg on Day 1.
45833555|NCT03293238|Procedure|Joint line ultrasound|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will be aided by real time visualization utilizing ultrasound guidance.
45833556|NCT03293238|Procedure|Joint line landmark|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will not be aided by ultrasound guidance, but completed based strictly on tactile feedback from the injecting physician.
46002306|NCT03906851|Behavioral|Activity and diet|Physical activity: use of physical activity in theoretical subjects (3 x 30 min/week), physically active breaks (5 x 5 min/week), physical education (2 x 45 min/week) Nutrition: focus on school meals
46083845|NCT02707224|Drug|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
46083846|NCT02707224|Drug|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
46083847|NCT00951613|Drug|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m^2 (or 18 mg/m^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
45990358|NCT05648487|Drug|HIPEC,anti-PD-1 antibody Sintilimab (Tyvyt®), Chemotherapy,Surgery|"HIPEC: HIPEC is performed after laparoscopic exploration, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgical exploration.~Chemotherapy(SOX) and anti-PD-1 antibody Sintilimab (Tyvyt®) treatment followed (4 cycles): SOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid, po, day 1-14, every 3 weeks for a total of 4 cycles; Sintilimab (Tyvyt®) 200mg fixed dose every 3 weeks, for a total of 4 cycles.~Surgery: Imaging and secondary surgical exploration, assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases). For patients undergoing surgery, HIPEC for three cycles followed, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgery; For inoperable patients, continue to use standard chemotherapy of guidelines recommend.~After the surgery, continue to use standard adjuvant chemotherapy."
45990359|NCT04695665|Other|Cervical pain|Exercise program for cervical spine according to McGill's approach.
45990360|NCT04695665|Other|Thoracic pain|Exercise program for thoracic spine according to McGill's approach.
45990361|NCT04695665|Other|Lumbar pain|Exercise program for lumbar spine according to McGill's approach.
45673997|NCT01618305|Drug|Lamivudine/zidovudine|"Participants received one lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet twice a day from entry through delivery*.~* Participants may have received a locally supplied nucleoside reverse transcriptase inhibitor (NRTI) backbone in place of lamivudine/zidovudine with permission of the protocol team obtained prior to randomization."
45673998|NCT01618305|Drug|Efavirenz|Participants received one 600 mg tablet of efavirenz each night from entry through delivery.
45990362|NCT00527553|Dietary Supplement|not enriched egg|daily consumption of a regular egg, not enriched with either lutien nor zeaxanthin
45990363|NCT00527553|Dietary Supplement|lutein|daily lutein enriched egg
45990364|NCT00527553|Dietary Supplement|zeaxanthin|daily zeaxanthin enriched egg
45990365|NCT00527553|Dietary Supplement|egg product from enriched eggs|daily egg product from lutein enriched eggs
45990366|NCT00511082|Drug|OPB-31121|Patients will receive OPB-31121 administered orally, once daily for 4 weeks.
45990367|NCT00527631|Radiation|whole abdomen irradiation using IMRT|Whole abdomen irradiation as consolidation therapy using intensity modulated radiation therapy (IMRT) to a total dose of 30 Gy in 1.5 Gy fractions
45990368|NCT00511121|Drug|STI571 and PEG INTRON|
45990369|NCT00527670|Procedure|Normal Controls|The control group will have small slivers of tissue removed from the skin and abdomen during surgery to compare genomic information.
46083848|NCT04996628|Diagnostic Test|Quantitative Sensory Test 1|Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.
46083849|NCT04996628|Diagnostic Test|Quantitative Sensory Test 2|Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.
46083850|NCT04996628|Diagnostic Test|Quantitative Sensory Test 3|Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
46083851|NCT00744861|Device|Exospine sham|Inactive Exospine LIPUS device (dual transducers)
46083852|NCT00744861|Device|Exospine|Active Exospine LIPUS device (dual transducers)
46083853|NCT00744861|Device|Exogen 4000+|Active Exogen LIPUS device (single transducer)
45833557|NCT03293238|Procedure|Suprapatellar ultrasound guided|Patients will be lying supine on exam table. Ultrasound will be used to capture a longitudinal view of the proximal patella and the plane between the prefemoral fat pad and suprapatellar fat pad. After the desired visualization is achieved, injection of Euflexxa will be made within the suprapatellar pouch.
45833558|NCT03293238|Procedure|Suprapatellar Landmark|Patients will be lying supine on exam table. Injecting physician will insert needle lateral to the vastus lateralis toward the suprapatellar pouch, and will inject of Euflexxa once it is believed that the needle tip is in the pouch.
46083854|NCT00744861|Device|Exogen 4000+ sham|Inactive Exogen 4000+ LIPUS device (single transducer)
45833559|NCT03292926|Drug|Bupivacaine|Bupivacaine will help treat pain and sensation after ACL repair
45990370|NCT00527670|Procedure|Recurrent Hernia|This group will have small slivers of tissue removed from the skin and abdomen during hernia repair surgery to find genetic proof of hernias being inherited.
45833560|NCT03292926|Device|Ultrasound|Ultrasound will guide anesthesiologist in performing the different nerve blocks
45833561|NCT03292926|Drug|Dexamethasone|Dexamethasone will be used to prolong block duration
45990371|NCT00511160|Procedure|Myocardial biopsies with TRU CUT 14 Gauge needle|Myocardial needle biopsy and right atrial appendectomy
46002307|NCT03896724|Biological|R21 adjuvanted with 25mcg Matrix-M|Vaccine
46002308|NCT03896724|Biological|Rabies Vaccine|Vaccine
45673999|NCT01618305|Drug|Raltegravir|Participants received one 400 mg raltegravir tablet twice a day from entry through delivery.
45674000|NCT01886313|Drug|Civamide Nasal Spray|
45674001|NCT01886313|Drug|Placebo|
45674002|NCT01896297|Drug|Pradaxa, dabigatran etexilate|75mg BID by oral
45674003|NCT04618263|Drug|GATE-101|GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist
45833562|NCT03292068|Combination Product|Acupuncture, acupressure|"Intervention group will receive usual care in combination with Pyonex-needles and Kulplåster. The control group will only receive usual care."
45674004|NCT01884675|Drug|Ambrisentan 5 mg|White, film-coated, immediate-release tablets, containing 5 mg ambrisentan for single dose oral.
45674005|NCT01884675|Drug|Placebo|White, film-coated, ambrisentan-matching placebo tablet for single oral dose
45833563|NCT03292068|Dietary Supplement|Timbal diet|Intervention group will receive usual care in combination Timbal diet including Protein-enriched ice cream, made with egg yolks and Cream. The control group will only receive usual care.
45833564|NCT03292068|Other|Extended telephone counseling|Intervention group will receive usual care in combination with Extended telephone counseling. The control group will only receive usual care.
45833565|NCT03268668|Other|Collection of thrombus that is responsible for stroke and blood sample|"A blood sample (venous or arterial) of 10 ml will be made, on ethylene Diamine Tetra-Acetic (EDTA) tube (5 ml) and citrate (5 ml).Thrombus resulting from thrombectomy will be collected at the end of the procedure. The samples will be transferred to a biobank. Treatment efficacy, etiology and prognosis of patients will be assessed using the following criteria :~A) TOAST score (etiology) B) TICI score (status of final recanalization) C) Extravasation of contrast agent on post-intervention CT (rupture of the blood-brain barrier :yes/no) D) Symptomatic haemorrhagic transformation corresponding to an increase > 4 of the NIHSS score due to a haemorrhagic transformation identified on brain imaging 24 hours after stroke E) Decreased NIHSS score by 8 points or NIHSS score = 0 24 hours after stroke (improved neurological status: yes/no) F) Modified RANKIN score (mRS) measured at 3 months evaluating neurological prognosis"
45990372|NCT00511160|Procedure|Endomyocardial biopsies|The control arm C consists of routine-workup of patients with suspected myocarditis, independent of the study arm C, but with analogous screening methods and comparable biopsy sampling
45990373|NCT02953223|Other|Free amino acid infant formula|Patients who will be fed a free amino acid based infant formula
45990374|NCT00528489|Biological|PennVax B|DNA vaccine containing the HIV genes Gag, Pol, and Env
45990375|NCT00528489|Biological|IL-12|Cytokine injection
45990376|NCT00528489|Biological|IL-15|Cytokine injection
45990377|NCT02953067|Procedure|Open reduction and internal fixation|Stratum 1: Conservative treatment versus open reduction and internal fixation Stratum 2: Open reduction and internal fixation versus arthrodesis
45990378|NCT02953067|Procedure|Primary arthrodesis|Primary arthrodesis versus ORIF
45990379|NCT02953067|Procedure|Conservative treatment|Conservative treatment versus open reduction and internal fixation
45990380|NCT00528684|Biological|REOLYSIN®|REOLYSIN® is administered as a single intratumoral infusion over 72 hours. Dose levels in Phase 1 will be 1x10E8, 3x10E8, 1x10E9, 3x10E9, 1x10E10 TCID50. The dose level for Phase 2 will be the top dose reached in Phase 1.
45990381|NCT02953028|Device|CPAP|Auto-CPAP-machine for treating Obstructive Sleep Apnea With positive airway pressure
46083855|NCT00951691|Behavioral|Enhanced acute medical rehabilitation|"Daily up to 3-hour sessions of enhanced physical and occupational therapies (see Lenze et al, Enhanced Medical Rehabilitation Increases Therapy Intensity and Engagement and Improves Functional Outcomes in Postacute Rehabilitation of Older Adults: A Randomized-Controlled Trial. J American Medical Director's Association, 2012 for details and outcome data."
46083856|NCT00951691|Behavioral|Treatment as usual|Standard treatment with physical and occupational therapies
46083857|NCT02706990|Device|Physica KR|Kinematic retaining total knee implant
46083858|NCT02706990|Device|Physica PS|Posterior stabilized total knee implant
46083859|NCT04229264|Drug|Apixaban|Oral Apixaban 2.5 mg twice daily for one year
46083860|NCT04229264|Drug|ASA|Acetil Salicilic Acid 100mg once daily for one year
45674006|NCT01884597|Drug|high-dose ranibizumab|20mg ranibizumab vials, 0.05ml injected intravitreally, monthly
46083861|NCT04229264|Drug|Clopidogrel 75mg|Clopidogrel 75mg once daily for 3 months
45990382|NCT02953028|Device|Mandibular Advancing Splint|Oral Appliance for providing an open upper airway as a mean of treating Obstructive Sleep Apnea
45990383|NCT04692051|Drug|Nab-paclitaxel + Cisplatin|Nab-paclitaxel 125mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
45990384|NCT04692051|Drug|Gemcitabine + Cisplatin|Gemcitabine1000mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
45990385|NCT00510029|Drug|GAP-134|atrial fibrillation 24-hr IV infusion; 1-minute IV bolus; PO
45990386|NCT00528723|Drug|salbutamol 100 mcg|To be used as needed for symptom relief
45674007|NCT01884597|Drug|ranibizumab|3 mg ranibizumab, liquid, vials, 0.1ml injected intravitreally monthly
45674008|NCT01895361|Drug|SelG1|
45674009|NCT01895361|Drug|Placebo|
45676699|NCT02019602|Procedure|Blood sampling from infant|Blood samples from the infant will be taken within 24 hours after birth, at Week 4 and at Week 8.
45676700|NCT02019602|Procedure|Blood sampling from umbilical cord|A blood sample from the umbilical cord will be taken directly (within 1 hour ) after delivery.
45990387|NCT00528723|Drug|BDP/salbutamol HFA pMDI|Patients assigned to BDP/salbutamol HFA pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative CFC placebo
45990388|NCT00528723|Drug|BDP/salbutamol CFC pMDI|Patients assigned to BDP/salbutamol CFC pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative HFA placebo
45990389|NCT00510107|Drug|oxaliplatin|oxaliplatin 120 mg/m2 will be given on day 1.
45990390|NCT00510107|Drug|Cisplatin|Cisplatin 60 mg/m2 will be given on day 1.
45990391|NCT00528762|Behavioral|Focus Group|Focus group discussion about puberty and body image lasting 1 1/2 hours.
45990392|NCT03459326|Other|IIEF (International Index of Erectile Function questionnaire )|"The questionnaire is presented and answered without help. Answers to the IIEF Questionnaire will be collected in order to obtain the following scores (the total score is of no interest):~Erectile function (score 1 to 30)~Orgasmic function (score 0 to 10)~Desire (score 2 to 10)~Sexual satisfaction (score 0 to 15)~Overall satisfaction (score 2 to 10)"
45456829|NCT03521128|Procedure|laparoscopic salpingectomy|In the laparoscopic salpingectomy group, after confirming HX, a unilateral or bilateral salpingectomy will be performed in a standard manner, depending on whether unilateral or bilateral HX are present. In women with extensive pelvic adhesions during laparoscopy, proximal tubal ligation will be performed as an alternative procedure to salpingectomy. FET is proceeded in the next menstrual cycle after the laparoscopic operation.
45990393|NCT01580514|Drug|exenatide BYETTA® (Amylin-Lilly)|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to exenatide were treated with 10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
45990394|NCT01580514|Drug|Saline|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to saline were treated with 10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
45990395|NCT00528918|Drug|Glulisine (Apidra)|An algorithm to determine the initial doses of insulin and dose adjustments is as follows: Lean subjects (BMI less than 25 kg/m2) will initially receive a total of 0.4 units/kg/day, overweight subjects (BMI 25-30 kg/m2) 0.5 units/kg/day and obese subjects (BMI greater than 30 kg/m2) 0.6 units/kg/day. Fifty percent of the total amount of insulin will be given as Glargine and 50% as regular insulin or Apidra. Supplemental short-acting insulin will be given for hyperglycemia before meals. Automated order sets shall be generated to minimize errors in order entries. Glucose concentrations will be measured before each meal and at bedtime, and if symptomatic. In addition, eight-point blood glucose profiles will be obtained every three days starting on day 2. Dose adjustments will be made to keep blood glucose concentrations between 80 and 120 mg/dl pre-prandially and less than180 mg/dl after meals.
45456830|NCT01354262|Dietary Supplement|Vitamin D|600 IU daily oral supplementation
45990396|NCT00510185|Other|systematic coronary intervention|Coronary angiography within 72 hrs
45990397|NCT00510185|Other|coronary intervention only for cases refractory to medical therapy|Initially conservative treatment with coronary angiography only for recurrent ischemia
45990398|NCT00515190|Drug|S-1,oxaliplatin|"Arm A (continuous arm): S-1 80mg/m2/d p.o. twice daily(q 12-h)on D1(evening)-D15(morning)plus oxaliplatin 130mg/m2 IV(in the vein)on D1 every 3 weeks, until disease progression, unacceptable toxicity, or consent withdrawal.~Arm B (intermittent arm):Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles."
45990399|NCT00511277|Drug|Seroquel®|dosage form: oral, dosage: 300-800mg/d, frequency: twice daily
45990400|NCT00529074|Device|Epidural Catheter for Analgesia|Patients enrolled will be placed into one of two groups of 30 patients. The decision to place the patients in either one of the two groups will be randomized as above. The Epidural group will have a thoracic epidural catheter placed pre-operatively at the T6-T7 level before general anesthesia is given. (using a .1% Marcaine and .1% Meperidine solution) A dose of Ketorolac will be given 15 minutes before the patient will be awakened from anesthesia (provided that there is good renal function and the patient is not hypovolemic) The catheter will be used preoperatively as an adjunct for general anesthesia as well as used postoperatively for continuous epidural analgesia(CEA). The control group will be given general anesthesia alone and post-operative PCA along with NSAIDS before leaving for the recovery room (as above).
45990401|NCT02953184|Drug|Pegylated Liposomal Doxorubicin|35mg/m2 iv drop during the first 4 cycles every three week
45456831|NCT01354262|Dietary Supplement|Vitamin D|50,000 IU supplementation bi-monthly
45833566|NCT04400136|Drug|Lansoprazole oral tablets 30 mg|Post operative prescription
45456832|NCT03932617|Device|end tidal carbon dioxide by capnography|"Moreover, since PETCO2 is mainly determined by tissue CO2 production (VCO2), alveolar ventilation and CO, when stable metabolic conditions are assumed and minute ventilation is kept constant, acute changes in PETCO2 have been shown to correlate strongly with changes in CO.~Thus, PETCO2 has been suggested as a simple economic and noninvasive alternative for continuous assessment of CO in different shock states."
45833567|NCT04983654|Diagnostic Test|patients with limb ulcers|"For patients with limb ulcers : at inclusion visit and after healing or at 6 months if ulcer does not heal:~Microvascular analysis (laser doppler, TcPO2),~Neurological analysis ( sensitivity testing with thermal and mechanical test),~Analysis of physical characteristics of red blood cells and inflammatory marks,~Analysis of cytokine and metalloproteases in the wound fluid,~Assessment of healing according usual treatment"
45990402|NCT02953184|Drug|Cyclophosphamide|600mg/m2 IV drop during the first 4 cycles every three week
45990403|NCT02953184|Drug|Taxotere|100mg/m2 IV drop during the last 4 cycles every three week
45990404|NCT02953184|Drug|Dexrazoxane (DZR)|DZR will be administrated for protecting Cardiac toxicity in the group of Active comparator.
45990405|NCT02953184|Drug|vitamin B|Vitamin B will be administrated for protecting HFS in PLD group
45990406|NCT02953184|Drug|Doxorubicin|60mg/m2 Doxorubicin IV drop during the first 4 cycles every three week
45990407|NCT02953184|Procedure|Breast Conserved Surgery|Patients will undergo Breast Conserved Surgery if the tumor/breast ratio is proper and she demands to conserve the breast after 8 cycles of chemotherapy
45990408|NCT02953184|Procedure|Modified Radical Mastectomy|Patients will undergo Modified Radical Mastectomy if she does not keep her breast after 8 cycles of chemotherapy
45990409|NCT02953184|Procedure|Sentinel Lymph Node Biopsy（SLNB）|Patients will undergo Sentinel Lymph Node Biopsy（SLNB） if the evaluation of lymph node are negative after 8 cycles of chemotherapy
45990410|NCT00515229|Drug|amitriptyline|"Each individual capsule has a filling volume of 25 mg, 50 mg und 75 mg Amitriptyline.~Placebo: 25 mg corn starch"
45990411|NCT00511316|Drug|Montelukast/ Singulair|20 mg daily for six months
45990412|NCT00511316|Drug|Placebo|Placebo 20 mg daily for 6 months
45990413|NCT02944695|Other|audit|Practice adherence to guidelines
45990414|NCT02952950|Other|Oralstimulation|The intervention group granted in total 1 hour instructions in a program of oral stimulation by one of two occupational therapists with experience in oral stimulation of preterm infants. The first guidance for parents has duration of approximately half an hour and then follow-up once or twice, depending on the needs of the family. To maintain consistent intervention over time is the program of oral stimulation written in a script, where the family also must record the following variables: date and time of oral stimulation. In occupational therapy the guidance and in the script examines the signs that the infant exhibits when it is ready / not ready for stimulation. The family also sees a movie where these signs and the program of oral stimulation review auditory and visual.
45990415|NCT02951091|Other|biomarker screening|immunohistochemistry and in situ hybridization
45990416|NCT00511394|Drug|20% Human Albumin|Infusion of 100 mL of 20% Albumin over 3 hours
45990417|NCT00511394|Drug|Normal Saline|Infusion of 100 mL of Normal Saline
45990418|NCT00529230|Behavioral|Questionnaire|A set of questionnaires regarding sexual function, physical and psychological symptoms.
45990419|NCT00529230|Other|Blood draws to assess gonadal function|Testosterone, FSH, and LH levels at study onset.
45990420|NCT02952443|Behavioral|Exercise|Participants will be randomized, using a table of random numbers, to either an Exercise (EX) or a Control (CON) group. The EX group will participate in a 16-week multi-component training intervention (3x per week, 45 to 60 minutes/session, at moderate to vigorous intensity) that will include primarily resistance exercises, an aerobic warm-up and cool down, and include both flexibility and balance exercises throughout the session (Bray et al., 2016).
45456833|NCT03521674|Device|pregnancy termination|Second trimester pregnancy termination for fetal anomali or in utero mord fetus will be done
45990421|NCT02952443|Behavioral|Control|The CON group will be asked to maintain their normal daily living habits for the same duration (16 weeks). At the conclusion of the 16-weeks the exercise program will be made available to the CON group.
45990422|NCT00529269|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
45456834|NCT01343498|Drug|BEZ235|BEZ235 will be given on a dose-escalation design, beginning at 200 mg BID (SDS sachet) in 3 patients and progressing to 400 mg, 600 mg, and 800 mg respectively based on tolerability.
45456835|NCT01221259|Drug|E2212|single ascending doses ranging from 10mg to 250mg
45456836|NCT01221259|Drug|placebo|a single dose of matching placebo
45456837|NCT03521050|Device|defibrillator lead|observation of long-term performance of defibrillator leads
45990423|NCT02952911|Device|Smartphone and Smartwatch|Multiple sclerosis participants and healthy controls are required to wear the smartwatch; and to carry smartphone preferably in a median position in a belt bag, or alternatively in their pocket as they go about their daily routine.
45990424|NCT00515268|Drug|GSK256066|GSK256066 will be available as dry powder inhaler with dosing strengths of 12.5, 37.5, 50 micrograms per inhalation.
45990425|NCT00515268|Drug|Placebo|Subjects will receive placebo inhaler.
45990426|NCT00515307|Procedure|Cellular transplantation|600 million to 1 billion cells will be infused through the portal vein over 30 minutes. Infusion will be done one time.
45990427|NCT01356966|Drug|Tetrahydrobiopterin|Tetrahydrobiopterin (BH4) 200 mg PO BID for 12 weeks
45990428|NCT01356966|Drug|Placebo|2 placebo pills PO BID for12 weeks
45990429|NCT01356966|Dietary Supplement|Folate|Folate 1 mg daily for 12 weeks
45990430|NCT02952677|Behavioral|Remind-to-move|Participants were required to wear sensory cueing wristwatch devices with vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
46002309|NCT03896724|Biological|R21 adjuvanted with 50mcg Matrix-M|vaccine
45990431|NCT02952677|Behavioral|Sham|Participants were required to wear sensory cueing wristwatch devices without vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
45990432|NCT02952677|Other|Control|Participants received usual care
45990433|NCT02944734|Drug|Candesartan Cilexetil 8mg|Candesartan Cilexetil 8mg Daily oral administration for 8 weeks
45990434|NCT02944734|Drug|Candesartan Cilexetil 16mg|Candesartan Cilexetil 16mg Daily oral administration for 8 weeks
45990435|NCT02944734|Drug|Amlodipine 5mg|Amlodipine 5mg Daily oral administration for 8 weeks
45990436|NCT02944734|Drug|Amlodipine 10mg|Amlodipine 10mg Daily oral administration for 8 weeks
45990437|NCT00510263|Drug|Prednisolone + placebo|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
45990438|NCT00510263|Drug|Valaciclovir + placebo|Valaciclovir 500 mg 2 tablets 3 times daily for 7 days. Placebo tablets 12 per day for 5 days, tapering 2 tablets per day until day 10.
45990439|NCT00510263|Drug|Prednisolone + valaciclovir|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Valaciclovir 500 mg 2 tablets 3 times daily for 7 days.
45990440|NCT00510263|Drug|Placebo + placebo|Placebo 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
45990441|NCT00515346|Device|Xpert(TM) Self-expanding Transhepatic Biliary Stent System feasibility in treating chronic critical limb ischemia|
45990442|NCT00511589|Other|chagas disease diagnostic|
45990443|NCT00515385|Drug|MGAWN1|"Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg"
45990444|NCT00515385|Drug|MGAWN1|Single IV dose
45990445|NCT00515385|Other|Placebo|Single IV dose
45990446|NCT00515424|Drug|RKI983|
45990447|NCT00511628|Drug|Risperidone|As prescribed
45990448|NCT00529347|Device|neurally adjusted ventilatory assist (NAVA)|assessment of breathing pattern at various ventilator settings
45990449|NCT00510302|Behavioral|Questionnaire|Questionnaire regarding melanoma risk-reduction.
45990450|NCT00510302|Behavioral|Interview|Interview via telephone about topics related to melanoma risk-reduction.
45990451|NCT00529425|Drug|Ropivacaine|
45990452|NCT03459755|Behavioral|Physical Activity|"Patients will have a baseline assessment by undergoing a maximal exercise testing protocol.~For 12 weeks, patients will participate in an exercise session 3 days per week~The patient will then enter a 12 week Step Down program in which the number of sessions is decreased to every week, then every 3 weeks.~After the second 12-week period, the patient will enter a 28-week follow up period of unsupervised exercise."
45990453|NCT00515580|Procedure|Tongue Sutures for Obstructive Sleep Apnea|Mandibular osteotomy with placement of Silhouette sutures for genioglossus advancement and hyoid suspension.
45833568|NCT04983654|Diagnostic Test|For patients without limb ulcers|"For patients without limb ulcers : at inclusion visit only~Microvascular analysis (laser doppler, TcPO2),~Neurological analysis (sensitivity testing with thermal and mechanical test),~Analysis of physical characteristics of red blood cells and inflammatory marks"
45990454|NCT00510341|Behavioral|Collaborative Management in Pediatrics (CMP) Program|Pediatric residents will receive two 4.5 hour training sessions on the CMP Program.
45990455|NCT02950974|Drug|Sterofundin|Fluid loading
45990456|NCT02950974|Drug|NSS|Fluid loading
45990457|NCT03459716|Other|No intervention|No intervention
45990458|NCT00529581|Drug|C105|
45990459|NCT02952755|Drug|Co-administration of DWC20155/DWC20156|
45990460|NCT02952755|Drug|DWC20162|
45990461|NCT02950935|Drug|Progesterone|subcutaneous injection of progesterone solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
45990462|NCT02950935|Drug|Placebo|subcutaneous injection of placebo solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
45990463|NCT02952404|Procedure|Educational workshop|The educational workshop for improved perineal support during vaginal delivery
45990464|NCT00515658|Device|theta-burst rTMS|
45833569|NCT04962126|Drug|Obinutuzumab 25 MG/1 ML Intravenous Solution|"For intravenous infusion during:~Induction phase: Day 1, 8 and 15 of cycle 1 & Day 1 of cycle 2-6 (q3/52); Maintenance phase: Day 1 of each cycle (q8/52) for up to 12 cycles."
45833570|NCT04962126|Drug|Atezolizumab 1200 MG/40mL Intravenous Solution|For intravenous infusion during induction phase only day 1 of each cycle q3/52 for up to 6 cycles.
45990465|NCT00529620|Drug|sulfalene-pyrimethamine plus amodiaquine|Monthly treatments during the malaria transmission season
45990466|NCT00529620|Drug|dihydroartemisinin plus piperaquine|Monthly treatments during the transmission season
45990467|NCT00529620|Drug|sulfadoxine pyrimethamine plus piperaquine|Monthly treatments during the malaria transmission season
45990468|NCT00529698|Biological|Biologically active recombinant Tat protein|
45990469|NCT02952014|Dietary Supplement|C4 Extreme|Pre-Workout Dietary Supplement
45990470|NCT02952014|Dietary Supplement|C4 Extreme (without Advantra Z|Pre-Workout Dietary Supplement
45990471|NCT02952014|Dietary Supplement|Placebo|Pre-Workout Dietary Supplement
45990472|NCT00529737|Procedure|Breast Biopsy|Stereotactic-guided breast biopsy via standard practice of care
45990473|NCT00529737|Procedure|Post Procedure Mammogram|View of post-procedure mammogram same projection as used in the biopsy procedure (View A), and mammographic view orthogonal projection to the first view (View B).
45990474|NCT00512993|Drug|Zoledronic acid|Infusion of zoledronic acid (4 mg) every 4 weeks for six doses, followed by every 3 months for 8 doses, followed by every 6 months for 5 doses
45990475|NCT00529776|Procedure|Continuous lateral rotation therapy|
45990476|NCT00513032|Drug|methylene blue|5mg.kg-1 methylene blue in 250 ml 5% glucose-saline, administered intravenously approximately 60 min before anaesthesia induction
46002310|NCT03873818|Biological|Ipilimumab|Given IV
45990477|NCT00529815|Device|Continuous Glucose Monitor|The intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
45990478|NCT00529815|Device|Glucometer|The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
45990479|NCT00513110|Genetic|AMPD1 polymorphism|Endotoxin 2ng/kg to subjects with a AMPD1 polymorphism
45990480|NCT00513110|Drug|Caffeine infusion|Endotoxin 2ng/kg combined with caffeine. Caffeine (4mg/kg) is used as an adenosine receptor antagonist.
45990481|NCT00513110|Drug|placebo|Endotoxin 2ng/kg combined with saline infusion (0.9%)
45990482|NCT00529854|Other|SIC-IR Billing Module|Medical informatic application designed to help with billing and documentation within the surgical and trauma intensive care unit
45990483|NCT00511745|Drug|Rabeprazol|As prescribed
45990484|NCT02951897|Procedure|lobectomy|
45990485|NCT02951897|Procedure|segmentecomy|
45990486|NCT02951897|Drug|chemotherapy（pemetrexed+CISPLATIN）|
45456838|NCT01348568|Dietary Supplement|low glycemic index diet with canola oil bread|
45833571|NCT04962126|Radiation|4 Gy in 2 fractions|Involved site radiotherapy will only be administered to participants to achieve a PR/SD after at restaging after cycle 2, treatment will be between cycle 3 and 4 of induction treatment.
45990487|NCT02951897|Procedure|Lymphadenectomy|Lymphadenectomy or lymph node dissection is the surgical removal of one or more groups of lymph nodes. It is almost always performed as part of the surgical management of cancer. In a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; in a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed.
45456839|NCT01348568|Dietary Supplement|High fiber diet|
45456840|NCT01221337|Other|heparin free haemodialysis|"Comparison of two haemodialyzers VIE 2,1 versus EVODIAL 2,2 in a strategy of heparin-free haemodialysis (HFH)."
45990488|NCT02951897|Other|CanPatrolTM to detect CTCs|CanPatrol TM was used to detect CTCs, which is a newly established technology to detect CTCs, containing the following steps: (1) To remove erythrocytes by red blood cell lysis and deplete CD45+ leukocytes in 10ml blood sample using a magnetic bead separation method; (2) To enrich CTCs by 8-μm-diameter-pore calibrated membrane filters; and (3) To identify and characterize CTCs by using RNA-in situ hybridization (ISH), based on the branched DNA (bDNA) signal amplification technology, to detect EMT markers, e.g., cytokeratins(CK) 8, 18 and 19, epithelial cell adhesion molecule (EpCAM), vimentin and twist. The details of classification of CTCs by using CanPatrol TM was depicted in the recently published protocol. Finally, the CTCs were clustered into three subtypes, as per the EMT markers, i.e., epithelial (E-) CTCs, mesenchymal (M-) CTCs and epithelial- mesenchymal (E&M-) CTCs.
45990489|NCT02945124|Other|K tape|Applying K tape to children to the lower limb muscles during motor activities.
45990490|NCT02944929|Other|Self-rehabilitation program|The self-rehabilitation program will be based on muscle stretching, strengthening and task oriented exercises. For each patient, two exercises will be selected by the therapist for each of these 3 domains (total of 6 exercises) from a list of 50 exercises.
45990491|NCT00511823|Drug|casopitant|The doses of casopitant will be comprised of 150 mg (one 150 mg tablet) and 50 mg (one 50 mg tablet). Casopitant will be taken with 240 milliliters (mL) of water on an empty stomach following at least 2 hour fast.
45990492|NCT00511823|Drug|dolasetron|The dose of oral dolasetron will be comprised of 100 mg (one 100 mg tablet or two 50 mg tablets). Dolasetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
45990493|NCT00511823|Drug|granisetron|The dose of oral granisetron will be comprised of 2 mg (two 1 mg tablets). Granisetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
45456841|NCT01354340|Dietary Supplement|Limicol|3 tablets (Limicol) + 3 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
45833572|NCT04941066|Behavioral|Active neurofeedback|The session will be done on an individual basis. The active group will receive neurofeedback training from the rumination-related brain functional connectivity.
45833573|NCT04941066|Behavioral|Sham neurofeedback|The session will be done on an individual basis. The sham group will receive neurofeedback training from an artificially generated random feedback signal.
45833574|NCT04938336|Behavioral|Delphi Procedure and interviews|Delphi procedure with expert healthcare professionals and interviews with patients, healthcare professionals and informal carers
45990494|NCT00511823|Drug|rosiglitazone|The dose of oral rosiglitazone will be comprised of 4 mg (two 2 mg tablets or one 4 mg tablet). Rosiglitazone will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
45990495|NCT00515736|Drug|Selenium (Se), Zinc (Zn), Vitamin C, Vitamin B1, Vitamin E|Se 270mcg, Zn 30mg, C 1.1g, B1 100mg, E 300mg
45990496|NCT00515736|Drug|Placebo|vehicle
45990497|NCT02952482|Procedure|newborns testing for ALD|Routine newborn screening dried blood spots sample is used to test if elevation of C26:0-lyso-PC
45990498|NCT00511940|Drug|acamprosate|999 mg/day - 2997 mg/day, oral
45990499|NCT00511940|Other|placebo|oral, placebo
45990500|NCT02950857|Drug|EPEG|(Pegylated erythropoeitin)
45990501|NCT00513149|Drug|Clopidogrel|Clopidogrel 600 mg loading
45990502|NCT00515814|Device|Retina implant is surgically placed into subretinal position|Subretinal implant is either in ON or in OFF condition during test periods, such as FrACT, BaLM, grating, orientation & mobility.
45990503|NCT02944344|Behavioral|Four Conversations|The online Four Conversations program consists of tutorial videos, printable documents, and live sessions with a counselor to educate subjects on shared decision making and care planning for those with advanced disease.
45990504|NCT02952326|Procedure|XP Endo Finsher as final step of the irrigation protocol|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument. XP Endo finisher is used after the last instrument in preparation
45990505|NCT02952326|Procedure|Conventional needle irrigation only|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument.
45990506|NCT02944227|Drug|Lucentis|Lucentis fixed-treatment arm
46083862|NCT02706912|Behavioral|VOTA Therapy|During sessions of approximately one hour in duration, participants practice performing virtual activities of daily living (ADLs) using the VOTA system. During this practice, the participant's real-world motion is replicated by an avatar's motion in the virtual world. To complete the activities, participant's must perform a wide range of functional arm movements while interacting with virtual objects. Individuals are asked to perform three such one-hour virtual ADL practice sessions per week over a participation period of approximately eight weeks.
46083863|NCT02597829|Drug|Certolizumab Pegol|Subcutaneous Injection
46083864|NCT04012879|Combination Product|CD19 CART|CD19 CART
45456842|NCT01354340|Dietary Supplement|Limicol|6 tablets (Limicol) / day during 1 month and follow-up 1 month without treatment
45456843|NCT01354340|Other|Placebo|6 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
45456844|NCT03523546|Other|Cancer Episode Payment Model (CEM)|Oncologists will be paid for an episode of care with the opportunity to receive a value based payment based on 6 quality metrics.
45456845|NCT01130233|Procedure|robotic assisted rectal resection|robotic assisted rectal resection
45456846|NCT01130233|Procedure|laparoscopic rectal resection|laparoscopic rectal resection
45833575|NCT04932252|Drug|A4368 or placebo tablet|orally administered
45833576|NCT03233646|Device|Retinal Imaging|Non-invasive OCTA scan of retina
45833577|NCT04278300|Biological|blood sampling|dosage of omega 3 polyunsaturated fatty acids, search for age-related macular degeneration susceptibility genese
45833578|NCT04278300|Biological|faecal sampling (optional)|analysis of the microbiota by DNA sequencing
45833579|NCT02984436|Procedure|Blood Sample|Blood samples will be collected from study participants for hs-cTnT analysis. Results of hs-cTnT will be used for research purposes only. Providers and participants will be blinded to results and participants will be treated by their healthcare providers per the standard of care.
45833580|NCT02984436|Behavioral|HEART Score|The HEART Score is a prospectively studied scoring system to help emergency departments risk-stratify chest pain patients. Patients score on a scale of 0-10.
45833581|NCT05266014|Drug|tinlarebant|"Phase 1b Portion: tinlarebant will be self-administered orally once daily for 2 cycles, 14 days per cycle.~Phase 2 portion: tinlarebant will be self-administered orally once daily for 24 months."
45833582|NCT05338086|Drug|MB09 (denosumab biosimilar)|PFS 60 mg/mL solution,
45833583|NCT05338086|Drug|EU-Prolia|PFS 60 mg/mL solution, administered as subcutaneous injection
45833584|NCT05338086|Dietary Supplement|Elemental Calcium|at least 1000 mg daily
45833585|NCT05338086|Dietary Supplement|Vitamin D|at least 400 IU daily
45833586|NCT03287544|Other|Combined rehabilitation|Linguistic training as well as communication training.
45990507|NCT04695938|Diagnostic Test|MRI|MRI examination with Black Bone, and ultrashort/zero echo time MRI techniques
45990508|NCT04691778|Procedure|CTO PCI with the first-choice Gladius guidewire|CTO PCI using antegrade wiring strategy with the first-choice Gladius guidewire
45990509|NCT04691778|Procedure|CTO PCI without the first-choice Gladius guidewire|CTO PCI using standard antegrade wire escalation strategy
45990510|NCT00513188|Biological|denileukin diftitox|
45990511|NCT00513188|Drug|cyclophosphamide|
45990512|NCT00513188|Drug|cytarabine|
45990513|NCT00513188|Drug|doxorubicin hydrochloride|
45990514|NCT00513188|Drug|leucovorin calcium|
45990515|NCT00513188|Drug|methotrexate|
45990516|NCT00513188|Drug|prednisone|
45990517|NCT00513188|Drug|vincristine sulfate|
45990518|NCT00513188|Genetic|protein expression analysis|
45990519|NCT00513188|Other|flow cytometry|
45990520|NCT00513188|Other|laboratory biomarker analysis|
45990521|NCT02950779|Other|Handgrip Strength Measurement|
45990522|NCT00513266|Biological|bevacizumab|
45990523|NCT00513266|Biological|cetuximab|
45990524|NCT00513266|Drug|fluorouracil|
45990525|NCT00513266|Drug|irinotecan hydrochloride|
45990526|NCT00513266|Drug|leucovorin calcium|
45990527|NCT00513266|Drug|oxaliplatin|
45990528|NCT00513266|Other|laboratory biomarker analysis|
46083865|NCT02711202|Drug|MabCampath,|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
45990529|NCT00513266|Procedure|adjuvant therapy|
45990530|NCT00513266|Procedure|biopsy|
45990531|NCT00513266|Procedure|conventional surgery|
45990532|NCT00513266|Procedure|neoadjuvant therapy|
45990533|NCT00513383|Drug|Panitumumab|Part A: Intravenously once a week for 7 weeks Part B (Induction Chemotherapy): Intravenously on Day 1 of a 21-day cycle for 3 cycles Part B (After Induction chemotherapy): Intravenously once a week for 7 weeks at the dosing level established during Part A
45990534|NCT00513383|Drug|Carboplatin|Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
45990535|NCT00513383|Drug|Paclitaxel|Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
45990536|NCT00513383|Radiation|Intensity Modulated Radiation Therapy|Part A: Daily five days a week for 7 weeks Part B (After Induction therapy): Daily five days a week for 7 weeks
46083866|NCT02711202|Drug|Remicade|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
45833587|NCT03287544|Other|Linguistic rehabilitation|Rehabilitation only focused on linguistic processes.
46083867|NCT02711202|Drug|Sirolimus|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
45833588|NCT03693144|Other|Full LIITA3H App|This is the full version of the LIITA3H mobile app that will use the Enhanced Location Identification (ELI) technology to identify when a user is in an eating venue and then deliver culturally and individually tailored point of purchase prompts (POP) to encourage healthy choices and will allow participants to take pictures of the food they purchase using the Self-report of Nutrients with Annotated Photos (SNAP) function.
45833589|NCT03693144|Other|Partial LIITA3H App|This is a version of the LIITA3H mobile app that will track participants' location and allow them to submit photos of their food.
45833590|NCT03693144|Other|LIITA3H Location only|This is a version of the LIITA3H mobile app that will only track participants' location.
45833591|NCT04902768|Other|This is an observational study, there is no intervention|This is an observational study, there is no intervention. Hence, this is not applicable.
45833592|NCT02984670|Behavioral|Cognitive Therapy|Cognitive Therapy involves challenging negative automatic thoughts about sleep and the use of behavioral experiments to challenge and test five cognitive processes (i.e., worry, dysfunctional thoughts, monitoring, safety behaviours, misperception) proposed to perpetuate insomnia.
45990537|NCT00513383|Drug|5-Fluorouracil|Intravenously at one of two dose levels on days 1-4 of a 21-day cycle for three cycles
45990538|NCT00513383|Drug|Docetaxel|Intravenously on day 1 of a 21-day cycle for 3 cycles
45990539|NCT00513383|Drug|Cisplatin|Intravenously on day 1 of a 21-day cycle for 3 cycles
45990540|NCT00513422|Dietary Supplement|Glucosamine sulphate and chondroitin|"Glucosamine: Two 750mg capsules once daily for two years;~Chondroitin: Two 400mg capsules once daily for two years."
45990541|NCT00513422|Dietary Supplement|Glucosamine sulphate|"Glucosamine: Two 750mg capsules once daily for two years;~Placebo Chondroitin: Two capsules once daily for two years."
45990542|NCT00513422|Dietary Supplement|Chondroitin sulphate|"Chondroitin sulphate: Two 400mg capsules once daily for two years;~Placebo glucosamine: Two capsules once daily for two years."
46002311|NCT03873818|Biological|Pembrolizumab|Given IV
45990543|NCT00513422|Dietary Supplement|Placebo capsules for glucosamine and chondroitin|"Two placebo glucosamine capsules once daily for two years;~Two placebo chondroitin capsules once daily for two years."
45990544|NCT02944305|Procedure|Endotracheal intubation|Endotracheal intubation under direct laryngoscopy using McIntosh blade
45990545|NCT04695821|Device|Senti V1.0 Device|"This device class I, CE marked garment, with a similar form to a T-Shirt, embedded with ten sensor modules encased in silicone; the device comes with a charging stand in the form of a clothes hanger. Depending on the outcome of this feasibility study, the device may, in the future, form part of a class IIb medical device system, when accompanied by cloud-based software to listen to both current and historically recorded breath sounds for each Senti patient. The Senti Version One device will be labelled clearly to indicate the device version, on the inside of the garment, conforming to the MDR.~The garment itself will be made from textile composite, including cotton, elastase, micromodel, spandex, and polyester. All other components (including electronic and other plastic components) will be entirely encased in medical-grade silicone."
45990546|NCT00515892|Drug|Immunotoxin therapy|
45990547|NCT00515892|Drug|CAT-8015 Immunotoxin|
45990548|NCT00515892|Procedure|Biological therapy|
45990549|NCT00515892|Procedure|Antibody Therapy|
45990550|NCT00515892|Procedure|Monoclonal Antibody Therapy|
45990551|NCT00513539|Drug|porfimer sodium|
45990552|NCT00513539|Procedure|biliary stenting|
45990553|NCT00515931|Radiation|Radiation therapy (external beam photons)|A cumulative radiation dose of 30 to 40 Gy is administered in 1.8 to 2.0 Gy fractions, 5 fractions per week, to the target lesion(s).
45990554|NCT04695470|Drug|Fruquintinib and Sintilimab|"fruquintinib 5mg qd for 2 weeks on and 1 week off, Q3w~Sintilimab 200mg iv, Q3w"
45990555|NCT04691973|Behavioral|Health and lifestyle tool|Health and lifestyle tool used online
45990556|NCT04691973|Other|Usual care|Usual care at ordinary healthcare provider
45990557|NCT00511979|Drug|Technosphere Insulin|
45990558|NCT00511979|Drug|Technosphere insulin|
45990559|NCT00511979|Drug|Technosphere insulin|
45990560|NCT00511979|Drug|Regular human insulin|
45990561|NCT02950701|Device|Observational data collection.|
46083868|NCT02711202|Drug|Tacrolimus|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
45990562|NCT00513578|Biological|PR1 leukemia peptide vaccine|
45674010|NCT01883895|Device|Forgionei-Barber pressure-pain stimulator|Pain testing will be conducted using a Forgioni-Barber pressure-pain stimulator to deliver 3000-gm force to the middle digit of the non-dominant middle finger for up to 120 seconds. During stimulation, subjects will press a button attached to a timer when the pressure stimulus first becomes painful (pain threshold) and will also rate their perceived pain intensity using a 0-100 numeric pain rating scale at 20 second intervals during the 2 minute exposure to the pressure stimulus. This validated protocol has been used in previous research by investigators in this study. This will be used for both exercise sessions and the control session. Forgionei-Barber pressure-pain stimulator will be used.
45674011|NCT01883895|Other|Concentric Exercise|Concentric testing will utilize a dumbbell with elbow flexion exercise. Subjects will perform 5 sets of 20 reps at 30% MVC. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
45674012|NCT01883895|Other|isometric exercise|When undergoing isometric exercise, subjects will perform 5 sets of sustained muscle contraction for 65 seconds using a hand-grip dynamometer. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
45674013|NCT01864005|Drug|Ticagrelor|90mg tablets. loading dose of 180mg ticagrelor tablets (two 90mg tablets) taken orally, followed by 90mg of ticagrelor 12 hours after the first dose. Duration of treatment: 6 weeks.
45674014|NCT01864005|Drug|Clopidogrel|75mg capsule. loading dose of 600mg clopidogrel capsules (eight 75mg capsules) taken orally, follow by 75mg of clopidogrel capsules orally od. Duration of treatment: 6 weeks.
45674015|NCT01863849|Biological|Vaccination with Fluval AB suspension for injection|Single intramuscular injection with Fluval AB suspension for injection in both age groups
45833593|NCT02984670|Behavioral|Behavior Therapy|Behavior Therapy involves the use of stimulus control and sleep restriction in order to reverse maladaptive sleep habits (time in bed, napping, bedtime variability, rise time variability) proposed to maintain insomnia. It also involves the practice of sleep hygiene principles.
45833594|NCT02984670|Behavioral|Waitlist.|The waitlist serves as a passive control which will receive the same measures administered to the cognitive and behaviour therapy groups.
45833595|NCT04592406|Other|CVP screening|An appropriate dual screening process including both renal and cardiac parameters to minimize the risks of post-contrast renal adverse outcomes and of prophylactic hydration in eGFR<30mL/min/1.73m2 patients.
45833596|NCT02984592|Behavioral|physical exercise|regular exercise programs in the previous 6 months.
45833597|NCT03262974|Diagnostic Test|PCR|PCR
45833598|NCT03262974|Diagnostic Test|HPLC-UV|HPLC-UV
45833599|NCT04746144|Procedure|Total knee arthroplasty|
45990563|NCT00513578|Biological|incomplete Freund's adjuvant|
45990564|NCT00513578|Biological|sargramostim|
45990565|NCT02950662|Other|Overdenture|Active comparator will be metal housing and peek housing
45990566|NCT02952053|Device|MTrP Group|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle. 10 fast in and fast out needle insertions."
45990567|NCT02952053|Device|TB Group|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle. 10 fast in and fast out needle insertions."
45990568|NCT00513656|Drug|Oxycodone|
45990569|NCT00513656|Drug|Oxycodone/Naloxone|
45990570|NCT00529932|Other|CD133+ infusion|Subjects will be infused with all available autologous CD133+ cells after processing during one infusion session (during angiography).
45990571|NCT00529932|Other|placebo infusion|Buffered normal saline will be infused in the coronary artery during an angiography.
45990572|NCT00513734|Other|Hydrogel dressing|3x3cm hydrogel dressing over closed eye
45990573|NCT00513734|Other|Lacrilube ointment|lubricant put into eye (inferior formix)
45990574|NCT00531102|Other|continuous positive airway pressure|Infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes
45990575|NCT00531102|Other|Free flow oxygen|Infants will receive 50% oxygen delivered by a modified neonatal T-piece resuscitator circuit that does not generate pressure for at least 5 minutes.
45990576|NCT02951858|Behavioral|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.
45990577|NCT02951858|Behavioral|Control Group|The participants only receive the materials about the harm of substance use.
45990578|NCT00529971|Behavioral|MBSR group|8-week MBSR group, 3 hours per week plus one all day retreat
45990579|NCT00529971|Other|Control|Treatment as usual, which could include medications or psychotherapy
45990580|NCT02951741|Other|RTHRA group|hematologic variables measurement in patients undergoing revision total hip replacement
45990581|NCT00530127|Drug|placebo|Same dose and frequency as treatment
45990582|NCT00530127|Drug|deferiprone|100 mg/mL
45990583|NCT00530127|Drug|deferiprone|100 mg/mL
45990584|NCT00530127|Drug|placebo|Same dosage and frequency as study drug
45990585|NCT00530127|Drug|deferiprone|100 mg/mL
45990586|NCT02951936|Device|NiCAS treated|"Measure each patient with the NiCAS once a day If Cardiac Index < 2.9 +Total Peripheral resistance Index >3000+Mean arterial pressure >70mmHG then add vasodilators.~If Heart Rate<60 consider to reduce beta blockers dose If Cardiac Index>4.2 and Mean arterial pressure 70-100mmHG and HR >100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics"
45990587|NCT02951936|Device|Non NiCAS treated|Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment For treatment we will use the standard care
45990588|NCT00513851|Drug|OSI-930|Oral OSI-930 administered once daily at increasing doses until disease progression or unacceptable toxicity
45990589|NCT00513851|Drug|OSI-930|Oral OSI-930 administered twice daily at increasing doses until disease progression or unacceptable toxicity
45456847|NCT03496012|Genetic|BIIB111|Administered as specified in the treatment arm.
45833600|NCT05323110|Drug|CBS001|Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.
45833601|NCT05323110|Drug|Placebo|CBS001 matched placebo
45833602|NCT04857840|Drug|Firibastat (QGC001) Period 1|1000 mg (2 x 500 mg) tablets QD per Os
45833603|NCT04582968|Other|Pyrotinib Plus Capecitabine combined with brain radiotherapy|Drug combined with radiation
45990590|NCT04691934|Procedure|Anesthesia management|Patients who underwent cesarean section and had positive PCR nasopharyngeal swabs for COVID-19 were included in the study. Patients who tested negative and were clinically suspicious were excluded from the study. PCR test was not performed on all elective and emergency pregnant women to be taken for cesarean section in our hospital. It was only applied to patients with symptoms or patients who were suspected. All patient demographics and information about anesthesia were analyzed retrospectively from the patient files.
45990591|NCT00513890|Device|Infantflow [EME, Brighton, England]|
45990592|NCT02944266|Other|Pre operative Focus assessed Transthoracic echocardiographic assessment.|
45990593|NCT00512018|Device|NMES|"In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES limbs).For the NMES, a symmetric double-phase sine-wave was used. Bearing wave frequency was of 2500 Hz, modulated in 50 bursts/s, with pulse duration of 200 µs, interburst interval of 10 ms. This configuration is known as Russian current."
45990594|NCT00512018|Other|Isokinetic exercise|Subjects realized training sessions twice a week with a 2-day minimum interval between the sessions, for 4 weeks. Each session included 5 min period of warm-up in a stationary bicycle, followed by 3 series of quadriceps stretching, as previously described. After being positioned at the isokinetic dynamometer, just as in the evaluation sessions, subjects firstly performed 3 sets of 10 maximum isokinetic concentric repetitions at the speed of 30º/s with one limb (EX limb), respecting the rest interval of 3 minutes between the sets.
45990595|NCT00530205|Other|physiologic testing|
45990596|NCT00530205|Other|questionnaire administration|
45990597|NCT00530205|Procedure|management of therapy complications|
45990598|NCT00530205|Radiation|radiation therapy|
46083869|NCT00948337|Behavioral|Brochure of Secondary Cancer Screening|One kind of printed educational material
45833604|NCT04563468|Procedure|Strength inspiratory muscle training|Two training sessions per day consisting of 30 breaths (against external load of ~50% Pi,max; 4-5 minutes per session), 7 days/week (once/month supervised at the research center), for 6 months will be performed using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH1, HaB International Ltd., Southam, UK) according to an established method. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain external load at ~50% of Pi,max values. Ratings of perceived inspiratory effort on a modified Borg scale (4-5 out of 10) will also be used to support decisions on increasing training load.
45833605|NCT04563468|Procedure|Endurance inspiratory muscle training|Two daily sessions of 30 breaths using TFRL device (POWERbreathe®KH1, HaB International Ltd., Southam, UK) and will train at an inspiratory load of no more than 10% of their initial Pi,max. This training load will not be changed during the entire study period. Participants in the control group will be offered the active treatment upon completion of the study.
45990599|NCT00512057|Drug|allopurinol|allopurinol 300mg twice a day
45990600|NCT00512057|Drug|placebo|placebo
45990601|NCT00531141|Other|examination only|OCT performed twice
45990602|NCT00513929|Dietary Supplement|Zinc sulphate|Arm X : Zinc sulphate 10 mg will be given orally twice a day since admission to resolution of pneumonia episode in addition to standard antibiotic treatment.
45990603|NCT00531180|Procedure|4D CT scans|Three 4D CT scans will be performed. After you are out of the CT scanner, ventilation images will be calculated from the 4D CT images and will be compared with the standard ventilation imaging method.
45990604|NCT00531180|Procedure|Lung Function Imaging|Lung function imaging performed to provide information on how well the lungs work, how air moves into the lungs with breathing, and blood circulation into the lungs.
45990605|NCT00512174|Other|BladderScan BVI 3000|
45990606|NCT00531219|Procedure|Transgastric Appendectomy|The appendix will be removed through an incision in the stomach and pulled out through the mouth
45990607|NCT00531219|Procedure|Transgastric Cholecystectomy|The gallbladder will be removed through an incision in the stomach and pulled out through the mouth.
45674016|NCT01863771|Drug|Golimumab|Participants will receive 200 mg golimumab at Week 0 and 100 mg golimumab at Week 2 as a subcutaneous (SC) (under the skin) injection in the induction phase. Participants who have a clinical response in the induction phase and are randomly allocated to golimumab in the maintenance phase will receive 100 mg SC every 4 weeks through Week 52. Participants who do not have a clinical response in the induction phase will receive 100 mg of golimumab SC at Week 4 and will continue with 100 mg of golimumab SC every 4 weeks through Week 52 only if a response is obtained by Week 8.
45674017|NCT01863771|Other|Placebo|Participants who have a clinical response to golimumab in the induction phase and are randomly allocated to placebo in the maintenance phase will receive SC placebo every 4 weeks through Week 52. However, participants receiving placebo and who will lose clinical response any time during the study will be eligible to receive 100 mg golimumab SC every 4 weeks through Week 52.
45990608|NCT00513968|Genetic|a mixed plasmid DNA (HB-110)|HB-110 2mg (or 4mg or 8mg), im, every other week, from week 0 to week 22 (total 12 injections) and Adefovir(Adefovir dipivoxil 10mg), od, from week -10 to from week 48.
45990609|NCT00513968|Drug|Adefovir|Adefovir(Adefovir dipivoxil)10mg, od, from week -10 to week 48.
45990610|NCT00530244|Dietary Supplement|Docosahexaenoic acid (DHA)|Infant formula with 0.96% of fatty acids as DHA
45990611|NCT00530244|Dietary Supplement|Standard formula (Enfamil)|This is a standard, commercially available infant formula.
45990612|NCT00514007|Drug|OSI-906|OSI-906 administered orally
45456848|NCT01348646|Behavioral|Brief intervention|The adolescents were shown a series of photographs of discoloured teeth caused by smoking. Then a mirror was given to the adolescent to let him/her see if similar stains could be seen on his/her teeth. Non-smoking adolescents also received positive feedback for being non-smokers. Duration of a single brief intervention was 2-3 minutes.
45990613|NCT00530283|Other|PET-CT|
46083870|NCT02597751|Behavioral|Cognitive Orientation to Occupational Performance (CO-OP)|"CO-OP is a cognitive approach to solving functional motor problems (Polatajko et al., 2001b). Therapists teach children a global problem solving strategy (Goal-Plan-Do-Check) as a framework for developing specific strategies for overcoming motor problems; these strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists will see children once weekly for one hour over 10 weeks as per published protocol (Polatajko et al., 2001b), plus two assessment sessions. Children will select three functional motor goals to be addressed over the course of treatment, rating their performance and satisfaction of these goals pre- and post-intervention."
46083871|NCT04227938|Drug|ALPN-101|A single dose of ALPN-101 will be administered via intravenous infusion.
46083872|NCT02711358|Drug|indomethacin suppositories|The patients will be instructed to self-administer a single rectal dose of 50 mg indomethacin 30 min before the scheduled time of the procedure
46083873|NCT02711358|Drug|placebo|The patient swill be instructed to self-administer a single rectal dose of placebo 30 min before the scheduled time of the procedure
45456849|NCT01354418|Drug|Phenylephrine HCl Extended Release|One phenylephrine HCl 30 mg extended release tablet orally
45456850|NCT01354418|Drug|Phenylephrine HCl Immediate Release|One phenylephrine HCl 10 mg immediate release tablet every 4 hours for three doses
45456851|NCT03520972|Drug|PB-119 75ug|60 eligible patients will be included in this group
45456852|NCT03520972|Drug|PB-119 150ug|60 eligible patients will be included in this group
45456853|NCT03520972|Drug|PB-119 200ug|60 eligible patients will be included in this group
45990614|NCT00512213|Dietary Supplement|Immunonutrition for 5 days preoperative|Impact vs Meritene
45990615|NCT00512213|Dietary Supplement|Standard enteral nutrition for 5 days preoperative|Impact vs Meritene
45990616|NCT00514085|Biological|recombinant human interleukin-21|"Patients enrolled in Part A will receive treatment daily x 5 on weeks 1, 3, and 5 of an 8 week cycle.~Patients enrolled in Part B will receive treatment daily x 5 on weeks 1, and 3 of a 6 week cycle"
45990617|NCT00514085|Other|immunohistochemistry staining method|Cycle 1 Day 1 and Cycle 1 Day 29
45990618|NCT00514085|Other|laboratory biomarker analysis|slides will be blocked for 15 minutes in 20% normal goat serum and then incubated in primary antibody
45990619|NCT00514085|Other|pharmacological study|Starting dose of 50μg/kg/day as an IV push
46083874|NCT00948415|Behavioral|Evaluation of the Shape Up RI Campaign|The SURI enhanced group will receive the standard Shape Up RI program. In addition, participants will be asked to record and report their daily calorie intake, body weight, minutes of physical activity, and pedometer steps. Participants will receive automated feedback on progress as well as a behavioral lesson delivered online during each week of the program. Participants assigned to the SURI Standard arm will receive the standard Shape Up RI program. The intervention will take place during the 12-week Shape Up RI campaign.
45990620|NCT02951585|Device|KARTILAGE CROSS|Intra-articular injection of Kartilage Cross
45990621|NCT02951585|Device|PLACEBO|Intra-articular injection of physiological serum (saline solution)
45990622|NCT04691349|Drug|CAR-T|The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region.
45456854|NCT03520972|Drug|placebo|60 eligible patients will be included in this group
45456855|NCT02818868|Drug|apixisaban|
45990623|NCT02951624|Behavioral|Control|Control intervention
45990624|NCT02951624|Behavioral|Breaker|Short breaks of physical activity
45990625|NCT02951624|Behavioral|Prolonger|longer breaks of physical activity
45990626|NCT02951624|Behavioral|Intermediate|Intermediate breaks of physical activity
45990627|NCT00531258|Device|rTMS|Bilateral rTMS
45990628|NCT00531258|Device|Sham rTMS|sham rTMS
45990629|NCT02951468|Procedure|LCP plus iliac crest autograft|After exposure of the non- or malunion a complex multidimensional osteotomy of the clavicle with medial and lateral axial correction up to vital bone was performed [14]. Vital bone was verified by local blood extravasation resulting from drilling the previously osteotomized bone segments. The tricortical iliac crest bone graft was harvested according to the size assessed in the preoperative CT scan, consecutively adapted to the intraoperative measured size of the bony defect. After implantation of the bone graft the LCP was centered onto the clavicular shaft.
45990630|NCT02944500|Drug|liraglutide|
45990631|NCT02944500|Other|Placebo|
45833606|NCT03261570|Drug|Pyridostigmine|60mg by mouth
45990632|NCT03459248|Other|Dual therapy|combination of 10 mg metoclopramide with 4 mg ondansetron
45990633|NCT03459248|Other|Monotherapy|10 mg metoclopramide
45990634|NCT03459248|Other|General anesthesia|Induction of general anesthesia will be performed followed by endotracheal intubation.
45990635|NCT00531297|Procedure|endoscopic posterior mesorectal resection|6 weeks after local excision of a T1 rectal cancer a rectum sparing endoscopic removal of the dorsal part of the mesorectum by EPMR is performed.
45990636|NCT00512291|Drug|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses. Each injection should take about 1 to 2 minutes.
45990637|NCT02944032|Other|CogmedRM|Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. Difficulty of the tasks is automatically adjusted on a trial-by-trial basis throughout each training session to match a child's current working memory span, such that as the child becomes more proficient, the exercises become more difficult. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.
45990638|NCT02944032|Other|Mobymax|"MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period."
45990639|NCT00514163|Drug|gemcitabine + S-1|gemcitabine on day one and 8th S-1 po days 1 to14 every 3 weeks
45990640|NCT00514163|Drug|gemcitabine|gemcitabine DIV on day one , 8th and 15th
45990641|NCT04691466|Procedure|Joint replacement|Routinely performed hip- or knee replacement
45990642|NCT04695548|Other|Concentric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
45456856|NCT03774433|Behavioral|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
45833607|NCT03261570|Drug|Digoxin|0.5 (500mcg) by mouth
45833608|NCT03261570|Drug|Placebo|Lactulose 50mg by mouth
45833609|NCT05296902|Device|Mucosal Closure|mucosal closure in oral surgery (mucosal sutures)
45990643|NCT04695548|Other|Isometric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder and maintaining the tension of the elastic band for 5 seconds
45990644|NCT04695548|Other|Eccentric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of asking the participant to lower their shoulder, against the resistance of the elastic band, in a slow and controlled manner for 5 seconds.
46083875|NCT04962152|Drug|Nalbuphine Sebacate or Sesame oil (placebo)|ultrasound-guided intramuscular injection after the induction of anesthesia immediately
46083876|NCT02597595|Other|spirulina|oral spirulina (tablet=500mg) will be given to patients for 3 months in a dose of 250 mg/kg/day (maximum 4 gm)
46083877|NCT04012645|Procedure|application of near infrared-indocyanine green imaging system|Underwent laparoscopic TME and colon-rectum or colon-anal anastomosis. near infrared-indocyanine green imaging system was used to evaluate the anastomotic flood perfusion during the operation; The operator may decide whether to change the surgical programme based on the outcome of the evaluation.
45833610|NCT05292612|Behavioral|iCBT(C&W) for SAD|iCBT(C&W) for SAD implements all the key procedures of the face-to-face treatment. Patients are guided through the treatment by using secure messaging and regular telephone or webcam calls. The treatment comprises a series of online modules, each of which includes educational texts, patient testimonies, video illustrations, case examples, questionand- answer boxes, monitoring sheets, behavioural experiments and other homework assignments.
45990645|NCT04695548|Other|Analytic passive stretching|The patient remains supine position. The analytical passive stretch of the upper trapezius will be performed only once, bringing the muscle to the limit of elastic tension perceived by the subject. The passive stretching technique will be held for 30 seconds.
45456857|NCT02289040|Procedure|cardiac surgery|cardiac surgery with extracorporeal circulation for congenital heart disease
46083878|NCT04012645|Procedure|Non-application of near infrared-indocyanine green imaging system|Underwent laparoscopic TME operation, and the operator judged anastomotic blood supply with naked eyes and performed the surgical intervention based on the experience
46083879|NCT02779946|Device|Fibro Scan|
45456858|NCT02289118|Drug|[18F]-T807 imaging tracer|Tau Imaging tracer
45456859|NCT01224535|Dietary Supplement|Maize and Amaranth|80g porridge per day, 5 days a week, for 16 weeks (4 months)
45456860|NCT02291770|Biological|Mesenchymal Stromal Cells|Mesenchymal stem cell(MSC). Patients with newly diagnosed cGvHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).
45456861|NCT03927235|Procedure|Transbronchial Cryobiopsy|Transbronchial Cryobiopsy in the Diagnosis of Diffuse Parenchymal Lung Diseases
45456862|NCT02289196|Drug|Vx-006: 0,5mg|
45456863|NCT02289196|Drug|Vx-006: 1mg|
45990646|NCT04691388|Drug|Amlotinib+Sindili|All patients will receive Sindelizumab combined with Antinib Hydrochloride capsule every 3 weeks
45456864|NCT02289196|Drug|Vx-006: 5mg|
45456865|NCT02289196|Drug|Vx-006: 10mg|
45456866|NCT02291926|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intra-articular injection, and repeated every month for four times.
45456867|NCT01221493|Procedure|Cryo biopsy|Cryoprobe, Erbe Company
46002312|NCT03855475|Behavioral|Aerobic exercise|Participants will complete 12 weeks of supervised aerobic exercise, 3 times per week, on a treadmill or stationary bicycle
46002313|NCT03855475|Behavioral|Stretching|Participants will complete 12 weeks of supervised stretching, 3 times per week
46083880|NCT02779946|Genetic|PNPLA3|
46083881|NCT03969589|Behavioral|Reproductive Life Planning-Mental Health (RLP-MH) Intervention|RLP-MH intervention is comprised of two parts: 1) an in-person interactive session in which the participant works with an RLP-MH facilitator to explore pregnancy intentions and RLP goals, consider important factors that impact those goals (e.g. mental health and physical health conditions, psychosocial and lifestyle factors, values, preferences), and identify personal action steps to address RLP goals and 2) a 15-20 minute follow-up session in person or by phone one month later to discuss progress in addressing RLP goals.
46002314|NCT03829501|Drug|KY1044|A human anti-ICOS monoclonal antibody
46083882|NCT03969589|Other|Written Materials on Reproductive Life Planning|Participants will receive written materials on reproductive life planning, contraception, and VA resources. Participants will be given the materials and study staff will briefly discuss the content with the participant.
45990647|NCT04695626|Procedure|The combination of bone marrow stimulation and modified suture bridge(Greenhouse tec)|According to the anteroposterior diameter of the injury, single or double high braided thread were used to suture the tendon in a modified Mason Allen way without knotting. Bone marrow stimulation was carried out in the footprint area of rotator cuff. A 2.0 mm diameter cone was created with a depth of 1 cm and a spacing of 5 mm. Six to eight holes were made due to the diameter of the tear of rotator cuff until blood and fat droplets exudate. Then the threads were passed through the locking eyelet of the lateral row anchor. After tightening the threads, the anchor was screwed in at the distal part of the gteater tuberosity. With this new technique, the rotator cuff was repaired by one lateral row anchor without medial row knotting.
45990648|NCT00530322|Procedure|Laparoscopy|"A second-look laparoscopy, in patients who require further surgery (for example a liver resection or closure of ileostomy)."
45990649|NCT04695743|Other|Online Cognitive Stimulation Therapy|Participants will attend 14 x 1 hour online CST sessions that involve a variety of activities to stimulate the brain and focus on cognitive strengths based on a variety of themes i.e. childhood, using money, etc. This will aim to be multisensory and give choice and empowerment to participants. Benefits of face to face CST are shown to slow cognitive decline and improve quality of life. Adapting it for online use will investigate whether participants can still benefit in this way.
45990650|NCT02943486|Other|dac-MSCs|Cell-free therapy
45990651|NCT02943486|Other|MSCs|Cell-based therapy
45990652|NCT02943486|Drug|Fitostimoline|Triticum vulgare
45833611|NCT03227562|Drug|RisperiDONE 0.5 MG|To be prescribed a 0.5mg risperidone treatment for anxiety is required to be enrolled.
45833612|NCT04277364|Dietary Supplement|phosphatidic acid supplementation|The total daily doses will be distributed in 3 individual doses: in the group that will ingest 750mg per day, the individual doses will be 250mg, while in the group that will ingest 375mg per day, the individual doses will be 125mg. The capsules should be consumed at breakfast, 30 minutes before each training session (or at lunch, on days when there is no training) and at dinner.
45833613|NCT04277364|Other|Placebo (corn starch supplementation)|Three individual doses of corn starch will be consumed per day. The capsules should be consumed at breakfast, 30 minutes before each training session (or at lunch, on days when there is no training) and at dinner.
45456868|NCT02289274|Drug|NVP-1203|NVP-1203(eperisone SR + aceclofenac)
45674018|NCT01894581|Dietary Supplement|LOVAZA|Subjects will be instructed to take 2 grams twice daily of oral omega-3-acid ethyl esters (Lovaza) starting with day 1 to 3 of their menstrual period. Each capsule contains 60mg of other omega-3 FA. On day 1 of their subsequent menstrual period, subjects will be instructed to discontinue.
45674019|NCT01894581|Drug|GnRH|An intravenous bolus of exogenous GnRH (75 ng/kg dosing based on total body weight) will be administered at 6 hours.
45833614|NCT04277364|Other|Strength training|All participants will be submitted to a 8-week strength training program, with 3 training sessions per week, totaling 24 training sessions.
45833615|NCT05277168|Drug|SHR-A1904|Single Arm ：It is a dose-escalation and dose-expansion study of SHR-A1904 in subjects with advanced solid tumors
45833616|NCT05276778|Diagnostic Test|Diabetic Retinopathy Screening|Screenings are performed in the diabetes consultation in general practice
45833617|NCT04557228|Dietary Supplement|Placebo|4 weeks of placebo supplements
45990653|NCT00514202|Drug|Placebo|matched placebo
45990654|NCT00514202|Drug|Dextroamphetamine SR|60 mg/day
45990655|NCT00530361|Drug|Nesiritide|
45990656|NCT00512408|Drug|testosterone|
45990657|NCT00530400|Drug|cefuroxime|preoperative intravenous 1.5g cefuroxime
45456869|NCT02289274|Drug|Eperisone SR tab. + and Airtal tab.|Eperisone SR and aceclofenac
45674020|NCT02203331|Drug|Placebo|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
45674021|NCT02203331|Drug|Levonorgestrel|Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
45990658|NCT00530400|Drug|placebo|preoperative intravenous placebo
45990659|NCT00531336|Drug|intravitreal injection of Bevacizumab (Avastin)|1.25 mg Avastin intravitreally applied once in arm 1 every 6 weeks in arm 2
45990660|NCT00531336|Drug|Pegaptanib (Macugen)|0.3 mg intravitreally applied every 6 weeks as long as required
45990661|NCT00530478|Drug|Donepezil|
45990662|NCT00531375|Device|Silicone hydrogel contact lens|
45990663|NCT00530556|Drug|zolpidem|
45990664|NCT00512486|Biological|MEDI-563|"BIW-8405/MEDI-563 administered at one of five dose levels:~0.03 mg/kg intravenous injection~0.1 mg/kg intravenous injection~0.3 mg/kg intravenous injection~1.0 mg/kg intravenous injection~3.0 mg/kg intravenous injection~Following the -3.0 mg/kg dose level,~BIW-8405/MEDI-563 administered at one of two lower dose levels:~0.003 mg/kg intravenous injection 0.0003 mg/kg intravenous injection"
45990665|NCT00530595|Drug|candesartan or valsartan or losartan|
45990666|NCT02951507|Other|O T unilateral attachment|O T unilateral attachment system
45990667|NCT02951507|Other|New design of extracoronal attachment system|O T unilateral attachment
45990668|NCT00512525|Drug|Ghrelin and saline (as placebo)|Intravenous infusion
45990669|NCT00531492|Behavioral|TK as soon as possible within 24 hours after birth|Start TK as soon as possible within 24 hours after birth
45990670|NCT00531492|Other|Conventional care|Start conventional care (At first use incubator, and start TK when the infants and mother are completely settled and ready)
45990671|NCT00512564|Other|Laboratory analyses of iron overload|Summary of clinical status related to iron overload and laboratory analysis of Iron overload including Total serum Iron, Transferrin, Ferritin and Non transferrin Binding Iron and Labile Plasma Iron
45990672|NCT02943759|Drug|Neem leaf extract|A natural irrigant solution act as anti-inflammatory and anti bacterial
45990673|NCT02943759|Drug|Chlorhexidine gluconate|2%chlorhexidine gluconate , anti bacterial root canal irrigant solution
45990674|NCT00514241|Device|The GPS™ II Platelet Concentrate Separation Kit|The GPS™ II Platelet Concentrate Separation Kit system is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of blood at the patient's point of care. The PRP can be mixed with autograft and allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements.
45990675|NCT02943915|Device|Ekso GT Rehabilitation Therapy|Walking Improvement for Spinal Cord Injuries with Exoskeleton
45990676|NCT02943915|Device|Body Weight Supported (BWS) Treadmill Training|Standard gait training using BWS PT and overground training
45990677|NCT02944110|Drug|Glucagon receptor antagonist LY2409021|single oral dose of 300mg
45456870|NCT01224613|Biological|Intanza|0.1 mL of Intanza intradermally at visit # 1
45833618|NCT04557228|Dietary Supplement|Phosphatidylserine|4 weeks of 900mg phosphatidylserine supplements
45990678|NCT02944110|Drug|Placebo|Oral dose of placebo tablets
45990679|NCT03459209|Other|tube feeding|The obtained milk aliquots undergo in vitro administration through three different tube feeding techniques.
45456871|NCT01224613|Biological|Intanza|0.1 mL of Intanza intradermally at visit #1
45833619|NCT04278378|Dietary Supplement|Riboflavin|1.6 mg riboflavin / day for 24 weeks
45833620|NCT04278378|Dietary Supplement|Folic acid|0.4 mg folic acid / day for 24 weeks
45990680|NCT02943837|Procedure|Device: 22G FNA needle|
45456872|NCT03523078|Procedure|Breast reconstructive surgery|All sorts of breast reconstructive surgery are allowed in this study in terms of timing, autologous/prosthetic and so forth.
45456873|NCT03932695|Dietary Supplement|Low dose milk peptide|what is the effect of milk peptides 1400mg on postprandial glycemia after a meal rich in carbohydrates (75g)
45456874|NCT03932695|Dietary Supplement|High Dose milk peptide|what is the effect of milk peptides 2800mg on postprandial glycemia after a meal rich in carbohydrates (75g)
45456875|NCT03932695|Dietary Supplement|Placebo|what is the effect of placebo on postprandial glycemia after a meal rich in carbohydrates (75g)
45456876|NCT03110146|Device|EnSite Precision|Ablation procedure
45990681|NCT02943837|Procedure|Device: 20G FNB needle|
45990682|NCT00530751|Other|counseling intervention|Participants undergo a 45-60 minute interview to assess their attitudes and concerns about providing family medical history online for genetic risk assessment or research. Participants' feelings about whether or not to use an online genetic assessment tool (i.e., Genetic Risk Easy Assessment Tool [GREAT]) are explored.
45990683|NCT02951975|Drug|dexamethasone intravitreal implant|Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
45990684|NCT00514397|Drug|motexafin gadolinium|
45990685|NCT00514397|Drug|temozolomide|
45990686|NCT00514397|Procedure|adjuvant therapy|
45990687|NCT00514397|Procedure|quality-of-life assessment|
45990688|NCT00514397|Radiation|radiation therapy|
45990689|NCT02943603|Drug|mFLOFOX6 + pembrolizumab|the combination of mFOLFOX6 + pembrolizumab is the single intervention even though the is dosed differently.
45990690|NCT00514436|Behavioral|Asthma coaching|Inperson contact followed by telephone with approach by issues raised by family
45990691|NCT00531687|Drug|Paclitaxel|"Paclitaxel 175 mg/m2 day 1 (3 hour infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
45990692|NCT00531687|Drug|Cisplatin|"cisplatin 50 mg/m2 day 1 and 2~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
45833621|NCT04278378|Dietary Supplement|Placebo|
45833622|NCT04399512|Procedure|Nonsurgical root canal treatment|Nonsurgical root canal treatment will be given
45990693|NCT00531687|Drug|Gemcitabine|"gemcitabine 1000mg/m2 days 1 and 8 (in a 30 minute infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered"
46002315|NCT03829501|Drug|KY1044 and atezolizumab|A human anti-ICOS monoclonal antibody in combination with anti-PD-L1 monoclonal antibody (atezolizumab)
45990694|NCT00514475|Drug|90Y-ibritumomab tiuxetan (Zevalin)|90Y-ibritumomab tiuxetan (Zevalin) at 0.4 mCi/kg is administered one week prior to start high-dose chemotherapy (BEAM/BEAC) in patients who have not achieved CR after induction therapy. Predosing with rituximab 250 mg/m2 one weeks prior to radioimmunotherapy and the same day.
45990695|NCT00530829|Drug|zinc|10 day blister pack of 20 mg zinc disperable tablets, 1 tablet qd for children 6 months to 4 years, 1/2 tablet qd for children 2-5 months
45990696|NCT00512681|Drug|Irinotecan, Oxaliplatin, TS-1|"S-1 40 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)~Irinotecan 150 mg/m2 mixed in d5w 500 ml iv over 90-min on days 1~Oxaliplatin 85 mg/m2 mixed in d5w 250 ml iv over 2-h on days 1"
45990697|NCT00530868|Other|Letrozole (Femara)|Letrozole 2.5 mg PO a day for 24 weeks
45990698|NCT00530868|Drug|Letrozole; Avastin|Letrozole 2.5 mg PO a day and Avastin 15 mg/kg IV every 3 weeks
45990699|NCT00530907|Drug|Valproic Acid|5.3 mg/kg by mouth daily x 28 days
45990700|NCT00530907|Drug|Bevacizumab|2.5 mg/kg by vein over 90 minutes every 2 weeks
45990701|NCT02951663|Dietary Supplement|Protein|
46083883|NCT02706600|Behavioral|myCOPD|"myCOPD is a system that can be accessed by patients using any device that can connect to the internet and can operate in any internet browser. It contains: Educational information, Inhaler technique videos explaining the correct technique required to use different inhaler devices licensed for use in people with COPD.~Medication and symptom diaries. Appointment diary Bitesize pulmonary rehabilitation videos designed to promote and support exercises that can be done in a home setting.~Oxygen Alert Card - Users can create their own oxygen alert card online A 5 Day local weather and pollution reports - Feed for reports come from the met office and DEFRA.~A Self management plan, which consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate. The action plan is populated automatically with the information input by the patients."
46083884|NCT02706600|Behavioral|Written Self management plan|The HealthQuest written self management plan was produced in 2013. It is a one page document which contains a written self management plan which can be individualised for the patient. It consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate.
46083885|NCT02778854|Genetic|detection of driver mutation|participants are received gene detection via the liquid biopsy
46083886|NCT05031702|Dietary Supplement|Camellia Sinensis leaf extract|2 tablets per day of 150 mg (1 before lunch and 1 before dinner)
46083887|NCT05031702|Combination Product|Placebo|2 tablets per day of 150 mg (1 before lunch and 1 before dinner)
46083888|NCT04945928|Procedure|Surgery|Participants having been evaluated as operable after receiving first-line treatment (first-line chemotherapy, targeted therapy, immunotherapy, chemotherapy combined with immunotherapy, etc.) will receive surgery.
46083889|NCT04011865|Procedure|Radical prostatectomy|The patients diagnosed with prostate cancer (local or locally advanced stages) will be allocated to the study for performing radical prostatectomy surgery.
46083890|NCT00744627|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets.
46083891|NCT00744627|Drug|Placebo|Vortioxetine placebo-matching capsules
46083892|NCT04942886|Drug|Entecavir|The intervention group take entecavir 0.5mg everyday by oral administration for 3 years after hematopoietic stem cell transplantation.
46083893|NCT00951847|Drug|oxcarbazepine 300 mg/5 mL oral suspension|
46083894|NCT04227782|Diagnostic Test|Magnetic Resonance Imaging|Magnetic Resonance Imaging
45990702|NCT00530985|Behavioral|Benefits Counseling|Help deciding whether to work
45990703|NCT00530985|Behavioral|VA Orientation|Orientation to services available at VA
45990704|NCT00531024|Drug|Bevacizumab|3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
46083895|NCT04227782|Other|Stable Isotope Study|Stable Isotope study
46083896|NCT02711280|Drug|Sevoflurane|
46083897|NCT02711280|Drug|Propofol|
46083898|NCT03959137|Other|None - Common practice|None - Common practice
46083899|NCT05341388|Diagnostic Test|MOCA cognitive evaluation test|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
46083900|NCT05341388|Diagnostic Test|BDNF levels|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
46083901|NCT05341388|Other|SF-36 test|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
45990705|NCT00531024|Drug|Sodium Chloride|3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
45990706|NCT00512759|Drug|Goal-directed preload and afterload decrement|Early goal-directed preload and afterload decrement with a target systolic blood pressure (RR) of 90-110 mmHg for the entire hospitalization using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).
45990707|NCT00531726|Device|DBS of Cg25|
45990708|NCT00514670|Other|Alcohol-based hand sanitizer & quaternary ammonium wipes|
45990709|NCT00531063|Drug|Everolimus (RAD001)|
45990710|NCT00512837|Behavioral|Mobile phone technology|
45456877|NCT03522922|Device|Dermaroller|The derma roller used (dermaroller MF8, MT dermaroller Beverly Hills, California USA) is a plastic device with a 12-cm handle that holds a drum-shaped cylinder at the end, similar to a small paint roller, 2 cm in diameter and 2 cm in width. The surface of the cylinder holds 192 titanium needles in eight rows. Each 0.25 mm in diameter and 1.5 mm length sterilized by UV/ Gamma rays.
45456878|NCT03522922|Drug|Topical Vitamin C|The used vitamin C product was in the form of 17% concentration of L- Ascorbic Acid serum that was encapsulated in gelatinous capsules each contain 1 mg of the serum. The patient instructed to open one capsule and apply its serum content on the treatment area daily at night. This capsule form for topical application help to insure stability of the product and also insure use of equal dose in each application
45456879|NCT03930433|Drug|Nebivolol|Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
45456880|NCT03930433|Drug|Diltiazem|Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
45456881|NCT03930433|Drug|Nebivolol+Diltiazem|Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
45674022|NCT02203331|Drug|Anastrozole|Participants received Anastrozole 300 µg/d or 600 µg/d or 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
45990711|NCT02943798|Drug|etoposide plus carboplatin|etoposide is administered by venus with a dose of 100mg/m2 from day 1 to3, and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
45990712|NCT02943798|Drug|Paclitaxel plus carboplatin|Paclitaxel is administered by venus with a dose of 175 mg/m2 from day 1 and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
45990713|NCT00512915|Device|pacemaker implantation|St. Jude Medical Dual Chamber Pacemaker model Identity (ADx) DR, Victory DR, or newer
45456882|NCT03520894|Radiation|Neoadjuvant radiotherapy|single 21 Gy fraction of Radiotherapy before surgery
45674023|NCT02203331|Drug|Lupron / Leuprolide acetate|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
45674024|NCT04776629|Drug|Orticumab|A human recombinant monoclonal antibody against a specific oxidized low-density lipoprotein (oxLDL) epitope
45674025|NCT04776629|Drug|Placebo|Placebo for orticumab, containing all components of formulation except the active ingredient
46083902|NCT05341388|Diagnostic Test|Geriatric depression test|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
46083903|NCT02706756|Other|Manual therapy|Hip joint and spine manual therapy techniques applied toward the impairments of the subject.
46083904|NCT02706756|Other|Exercise|Prescriptive exercise program of self-mobilization and/or strengthening program to address impairments of the subject.
45456883|NCT01585519|Dietary Supplement|High/ Low Epicatechin Apples/ Apple Extract/ Granules|"(Group 1) Low Apple Diet (i.e. <1 portion per day) + 2 placebo capsules daily.~(Group 2) 2 x High Epicatechin Apples daily + 2 placebo capsules daily.~(Group 3) 2 x Low Epicatechin Apples daily + 2 placebo capsules daily.~(Group 4) Low apple diet + 2 x 4.4g of apple granules daily + 2 placebo capsules daily.~(Group 5) Low apple diet + 2 x Apple Extract Capsules daily."
45456884|NCT01221571|Drug|AFM 13|Cohort escalation then expansion phase design. Starting dose 0.01 mg/kg. 4 weekly drug administrations.
45456885|NCT01224769|Drug|bendamustine +/- rituximab|
45456886|NCT02289430|Drug|Crestor+Ezetrol|rosuvastatin+ezetimibe
45833623|NCT04399278|Diagnostic Test|Diagnostic Test: end-expiratory occlusion (EEO) test|"A set of respiratory and hemodynamic measurements (including cardiac output) will be recorded at each stage:~T0: baseline.~T1: At the end of the first EEO (15 sec or 30 sec)~T2: 1 minute after completion of the first EEO. Return to baseline.~T3: At the end of the second EEO (15 sec or 30 sec)~T4: 1 minute after completion of the second EEO. Return to baseline.~T5: Before the fluid challenge test (4 ml/kg of 0.9% saline over 5 min)~T6: 1 minute after the end of the fluid challenge~A first set of measurements will be performed after intubation (before the surgical incision) and will be repeated, if necessary, in case of further decrease in stroke volume during surgery or in case of any clinical indication of volume expansion (i.e., arterial persistent hypotension, major hemorrhage, etc.)."
45833624|NCT04551144|Drug|testosterone cypionate|intramuscular injection every 2 weeks. Dose will be titrated based on blood levels
46083905|NCT02706756|Other|Education and advice|All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care).
46083906|NCT02706756|Other|Supervised neglect|Monitoring of group without formal intervention.
46083907|NCT00951925|Other|Bone Marrow Aspirate Draw|5cc of Bone Marrow Aspirate will be drawn
46083908|NCT04089501|Diagnostic Test|Stool collection|Stool will be collected from subjects who have been diagnosed with IBD or whom small intestinal, colonic or ileocolonic and have signed consent for the control group. Stool will be self-collected or through routine colonoscopy procedure.
46083909|NCT04089501|Diagnostic Test|Biopsy collection|3 additional biopsies (for research purposes) will be taken from patients who undergo colonoscopy as per standard of care
46083910|NCT02781194|Device|3M™ Bair Hugger™|forced-air warming blanket
46083911|NCT02781194|Device|F&P HumiGard™ Surgical Humidification System|warmed, humidified insufflation
45456887|NCT02289430|Drug|Ezetrol|ezetimibe
45456888|NCT02289430|Drug|Crestor|rosuvastatin
45456889|NCT03930511|Procedure|Pulmonary Rehabilitation|According to patients' needs and physician referral, individually tailored treatments of respiratory physiotherapy, functional training, exercise training and patient education
45674026|NCT01893411|Drug|IncobotulinumtoxinA (16 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 400 units; Mode of administration: intramuscular injection into spastic muscles.
45674027|NCT01893411|Drug|IncobotulinumtoxinA (12 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 300 units; Mode of administration: intramuscular injection into spastic muscles.
45674028|NCT01893411|Drug|IncobotulinumtoxinA (4 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 100 units; Mode of administration: intramuscular injection into spastic muscles.
45674029|NCT02232425|Drug|IX-01|
45674030|NCT02232425|Drug|Placebo|
45990714|NCT02943369|Drug|Ticagrelor 180 mg loading dose|Ticagrelor 180 mg
45990715|NCT02943369|Drug|Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min|Intravenous Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min for 2 hours
45990716|NCT02943330|Other|Questionnaire|Questionnaires such as Hospital Anxiety and Depression Scale (HADS) and Montgomery Asberg Depression Rating Scale (MADRS), Short-form Health-related Quality of Life (SF-36), as well as psychiatric diagnostic interview with the Mini-International Neuropsychiatric Interview (MINI) and the Family Interview for Genetic Study (FIGS).
45990717|NCT00514748|Procedure|DIEP|flap survival, operation time, flap complications, donor site morbidity.
45990718|NCT00514748|Procedure|Interconnected DIEP|flap survival, operation time, flap complications, donor site morbidity.
45990719|NCT02943876|Other|personalized depression risk information|The personalized depression risk information is determined by sex-specific risk prediction algorithms based on one's family history of depression, current health status, childhood traumatic experience and ongoing life stressors. The information is in the form of probability of having a major depressive episode in the next 4 years.
45990720|NCT00515957|Genetic|genetically modified CTLs in combo with CD45 antibodies|"LMP1- and LMP2- specific cytotoxic T-lymphocytes (CTL) in combination with CD45 monoclonal antibody (MAb).~--Infusions of CD45 MAbs: A fixed dose of CD45 MAbs will be used determined from our previous and ongoing studies in stem cell transplant recipients will be used43, 400ug/kg over 6 to 8 hrs daily x 4 given as 4 daily intravenous infusions that will be completed 48-72 hours prior to CTL infusion.~Day 1 YTH 24/54 400ug/kg over 6 to 8 hr 2 YTH 24/54 400ug/kg over 6 to 8 hr 3 YTH 24/54 400ug/kg over 6 to 8 hr 4 YTH 24/54 400ug/kg over 6 to 8 hr 5 Rest 6-8 CTL Infusion (provided CD45 MAb level <100 ng/ml)~--LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~2x 10^7 cells/m2~1x 10^8 cells/m2 3 x 10^8 cells/m2~1 x 10^9 cells/m2"
45990721|NCT02943681|Biological|Measles vaccine|
45990722|NCT00514826|Other|altitude exposure|sojourn at moderate altitude (1860m and 2590m) during 2 days/nights each
45990723|NCT02943642|Biological|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
45833625|NCT04551144|Drug|Estradiol Valerate|intramuscular injection every week. Dose will be titrated based on blood levels
45990724|NCT02943642|Drug|Vorinostat|ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.
45990725|NCT02943720|Drug|AllerT|Bet v 1 contiguous overlapping peptides mixed with aluminium hydroxide solution
45990726|NCT02943720|Drug|placebo|placebo
45990727|NCT04695353|Procedure|Telemedicine: Virtual visits (videoconferences, texts)|Patients will receive clinical care by using telemedicine (virtual visits)
45833626|NCT04523376|Device|CliniMACS|Peripheral blood stem cells from closely matched unrelated donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
45833627|NCT04797468|Drug|HLX23|administered IV.
45833628|NCT04785924|Drug|Imipenem+Relebactam|Antibiotic treatment for KPC producing CRE-containing gram-negative infections
45833629|NCT04765176|Device|Endovascular Repair|Endovascular repair of the infrarenal aorta using a AAA stent graft.
45833630|NCT04514562|Device|NeVa Stent Retrievers|mechanical neurothrombectomy
45990728|NCT02944149|Procedure|tubal ligation by minilaparotomy|Tubal ligation will be performed by minilaparotomy as per the Tanzanian government standards, with the standard family planning counseling and minilaparotomy surgical protocols used by the government being followed during the study.
46002316|NCT03798639|Biological|Ipilimumab|Given IV
46002317|NCT03798639|Biological|Nivolumab|Given IV
46002318|NCT03798639|Radiation|Radiation Therapy|Receive radiation therapy
46083912|NCT04011553|Other|Virtual Reality based Rehabilitation Program|"Virtual reality-based rehabilitation was implemented via MarVAJED system. At first the sensors of MarVAJED® were placed under and above the knee joint and then it was calibrated. The content of the game programs included in the MarVAJED system and how to perform these games with the exercises were explained to the participants. We used games called Crazy Wings and Blasting Ball included in the MarVAJED®.There was a bird figure in Crazy Wings game and represented knee joint of participants. Although the bird figure moved upwards during knee flexion, it moved downward in knee extension, there were some obstacles on the way of the bird went. The subjects were asked to follow the bird figure visually and to pass through the obstacles by flexing or extending their knees when they encountered obstacles."
46083913|NCT02706522|Dietary Supplement|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
46083914|NCT02706522|Dietary Supplement|Allocated to Placebo group|Patients received 400 mL of oral flavored water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before
46083915|NCT00948493|Drug|Buccal insulin spray|Oral insulin spray absorbed in buccal mucosa
46083916|NCT00952003|Drug|Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel|
46002319|NCT03774901|Drug|Avelumab|intravenous 10 mg/kg every 2 weeks
46002320|NCT03762018|Drug|Carboplatin|Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
46002321|NCT03762018|Drug|Pemetrexed|Pemetrexed is a type of drug known as an anti metabolite. It stops cells making and repairing DNA so they can't grow and multiply.
45990729|NCT04695509|Drug|"moderate propofol sedation (Bispectral index monitoring 70-90; The Richmond Agitation and Sedation scale (RASS) -2 - -3"|Two peripheral venous blood catheters are placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, noninvasive blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol light-moderate sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C*. After 26 patients are recruited, the blood plasma is analyzed by conducting the enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
46002322|NCT03762018|Drug|Bevacizumab|Bevacizumab is an angiogenesis inhibitor. It works by targeting a protein called vascular endothelial growth factor (VEGF) that helps cancers form new blood vessels. By stopping this process, bevacizumab 'suffocates' the blood supply to the cancer, shrinking it and stopping it from growing.
45674031|NCT01631435|Other|Pillcam colon capsule and PillCam™ Prep Procedure|PillCam® Crhon capsule preparation will include a clear liquid diet and administration of a purgative sulfate-free polyethylene glycol electrolyte lavage (SF-ELS) solution (e.g. Nulytely) divided into two doses: the first dose on the evening before the exam and the 2nd dose on the morning of the exam day.
45674032|NCT01631435|Device|Ileocolonoscopy|"Conventional ileocolonoscopy Examination (same day or within 24 hours)of CE procedure~• Ileocolonoscopy with intubation of terminal ileum"
45674033|NCT02230085|Other|Administration of the questionnaire and monitoring of CPAP adherence|
45674034|NCT01882803|Drug|Duvelisib|PI3K Inhibitor
45674035|NCT02202785|Drug|MLN0264|MLN0264 IV infusion
45674036|NCT01882647|Drug|000-0551 Lotion|
45833631|NCT04509180|Procedure|Catheter ablation|Endovascular approach
45674037|NCT01882647|Drug|Vehicle Lotion|
45674038|NCT01882257|Device|BiPAP|BiPAP-auto (Phillips Respironics)is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is used to treat obstructive sleep apnea.
45674039|NCT01882257|Device|BiPAP/AVAPS (Phillips Respironics)|BiPAP/AVAPS (Phillips Respironics) is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is specifically designed to treat nocturnal hypoventilation due to an underlying neuromuscular disorder.
45674040|NCT04612413|Drug|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.
45833632|NCT04509180|Procedure|Convergent procedure|Surgical and endovascular approach
45674041|NCT04612413|Other|Placebo|Solution containing all excipients except for the Allocetra-OTS cells
45674042|NCT01862991|Other|Hygroscopic cervical dilators|Dilapan-S osmotic cervical dilators inserted through the internal os.
45674043|NCT01862991|Drug|Misoprostol|400 mcg buccal misoprostol 90 pre-op
45833633|NCT04509024|Behavioral|Incidental training|Nonspeech perceptual building block categories are established, which may be used to scaffold language learning.
45833634|NCT04509024|Behavioral|Explicit training|Traditional explicit language training, which involves establishing sound to meaning.
45833635|NCT04348110|Dietary Supplement|Placebo tablets|consume 2 tablets per day for 8 weeks
45833636|NCT04348110|Dietary Supplement|Blueberry Chewable Tablets|consume 2 tablets per day for 8 weeks
45990730|NCT04695509|Drug|"deep propofol sedation (BIS 60-70, The Richmond Agitation and Sedation scale (RASS) -4)"|Two peripheral venous blood catheter is placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol deep sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C*. After 26 patients are recruited, the blood plasma is analyzed by conducting enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
45990731|NCT02943135|Drug|lidocaine in-situ gel|lidocaine in-situ gel
45990732|NCT02943135|Drug|placebo in-situ gel|placebo in-situ gel
45990733|NCT02951234|Other|IVIG only|All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin.
45990734|NCT02951234|Other|IVIG and Aspirin|All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside.
45990735|NCT00531765|Other|sodium bicarbonate infusion|short infusion of sodium bicarbonate
45990736|NCT00531804|Drug|gantenerumab|Administered iv at escalating doses (7 cohorts)
45990737|NCT02951390|Other|High-definition white-light endoscopy|The intervention is do not perform chromoendoscopy
45990738|NCT02950610|Device|"Breath analysis - electronic signature Breath-print"|Patients and Healthy volunteers ( as defined in 3 cohorts) will breath into disposable, once-use only bacterial filter channeled into electronic device comprising on sensors capable to reacting to organic compounds. Breathing manoeuvre will be simple, non-exertional and relaxed. 2 breathing manoeuvres will be performed and sensor responses will be captured.
45990739|NCT02943252|Drug|Apatinib|apatinib 500 mg in tablet once daily
45990740|NCT02943252|Drug|S1|S-1 40-60mg bid, days 1-14 , every 3 weeks
45990741|NCT00514982|Drug|Mesalamine|5-Aminosalicylic Acid Derivative used to treat mild to moderate Ulcerative Colitis
45990742|NCT00514982|Drug|Infliximab|Antirheumatic, Disease Modifying Gastrointestinal Agent, Miscellaneous, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat gastrointestinal disorders.
45990743|NCT00514982|Drug|Corticosteroids|Systemic Corticosteroid used to treat inflammatory conditions.
45456890|NCT02289508|Device|Ultrasonic cardiac output monitor|An Ultrasonic Cardiac Output Monitor, a non-invasive Doppler ultrasonography, is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD). It has been compared favorably with a wide range of standard techniques, including PATD, with good interobserver reliability. USCOM may help on monitoring HF and suggesting proper treatment in order to reduce the mortality of adHF.
45456891|NCT02289508|Device|Echocardiography|2D-echo is a conventional standard-of-care tool for non-invasive hemodynamic assessments in adults. The use of 2D-echo requires highly trained personnel, and assessments may take anywhere between 30-45 minutes. It is used to find out the ejection fraction and to compare the haemodynamic parameters with USCOM in this study.
45833637|NCT04506294|Behavioral|eScreen system|The eScreen system is composed of a child screening component and a parent information component. The child screening component is delivered via a game-like interface and includes assessment of current pain, PTSS, and functional recovery. Children are asked to play the game at least 3x/week. The parent information component consists of text / email messages sent to parents at least weekly that summarize child ratings and include a link to an online dashboard with additional personalized information for parents.
45833638|NCT05251818|Other|acupressure|A suitable environment will be prepared for postpartum women where privacy can be protected. Application points will be determined by choosing the most comfortable position of the mother. LI4 and TH were selected as the most preferred points among the points reported to be effective on intestinal functions by scanning the literature on the determined points. Acupressure will be applied to the LI4 and TH6 points for a total of 12 minutes in the first hour after the surgery. Light pressure will be applied with the thumb of the practitioner's hand. After applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is done without interruption
45833639|NCT05251818|Other|Control|No application will be made to puerperant women in this group. Only hourly follow-up will be done until the first bowel sound is heard. In addition, defecation and gas extraction will be questioned every 12 hours.
45833640|NCT04498806|Other|Fitbit|The Fitbit device monitors daily activity as a measure of physical function.
45990744|NCT00514982|Drug|6-Mercaptopurine|Antineoplastic Agent, Antimetabolite, Immunosuppressant Agent used traditionally to treat Acute lymphoblastic leukemia. Unlabeled use as steroid-sparing agent for corticosteroid-dependent Crohn's disease (CD) and ulcerative colitis (UC); maintenance of remission in CD; fistulizing Crohn's disease.
45990745|NCT00514982|Drug|Tacrolimus|Immunosuppressant Agent used to treat Liver, Heart, Kidney transplant, prevent host vs graft disease, severe atopic dermatitis.
45456892|NCT01224847|Drug|Tetracaine|1 gtt
45456893|NCT01224847|Drug|Cocaine|1 gtt
45833641|NCT04498026|Device|Adherus Dural Sealant System|Adherus Dural Sealant, In situ polymerizing sealant
45833642|NCT04498026|Device|DuraSeal Exact Dural Sealant System|DuraSeal Exact (P080013b)
45990746|NCT00514982|Drug|Adalimumab|Antirheumatic, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat Rheumatoid arthritis and Crohn's disease.
45990747|NCT02950532|Other|Retrospective radiological evaluation|Radiological evaluation will be performed in already existing imaging exams. Superior-inferior end plate angle (SIEA), vertebral body height (BH), local kyphosis (LK), inter-spinous distance (ISD) and inter-pedicular distance (IPD) will be measured in CT scans and radiographs (if available). PLC injury will be determinated with the gold standard method (MRI).
45990748|NCT02950337|Radiation|Group 1: Peripherally Located Tumors|Group 1: For peripherally located tumors patients will receive SBRT(Stereotactic Body Radiation Therapy) , 3 fractions of 18 Gy to a total dose of 54 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
45990749|NCT02950337|Radiation|Group 2: Peripherally Located Chest Wall Adjacent Tumors|Group 2: For chest wall adjacent tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 12 Gy to a total dose of 60 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
45990750|NCT02950337|Radiation|Group 3: Centrally Located Tumors|Group 3: For central tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 10 Gy to a total dose of 50 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
45674044|NCT01862991|Drug|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation
45674045|NCT01862991|Drug|Mifepristone|200 mcg Mifepristone orally
45990751|NCT00531999|Drug|Raltegravir then lopinavir/ritonavir|raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study
45990752|NCT00531999|Drug|Lopinavir/ritonavir then raltegravir|lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study
45990753|NCT00516035|Biological|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine given by nasal spray
45990754|NCT05318118|Procedure|Medial Meniscus Arthroscopic Reconstruction Using the Fast Fix|Arthroscopic reconstruction of damaged Medial Meniscus using Fast-Fix (Smith & Nephew) implant.
45990755|NCT05318118|Procedure|Medial Meniscus Arthroscopic Reconstruction Using the Fiber Stitch|Arthroscopic reconstruction of damaged Medial Meniscus using Fiber-Stitch (Arthrex) implant
45990756|NCT00515060|Other|Sensory Tests|Tests to find the threshold at which perceive stimuli.
45990757|NCT05319912|Drug|ALXN1840 Enteric-coated Tablet|ALXN1840 (60 milligrams) was administered orally as EC tablets at Hour 0 on Day 1.
45990758|NCT05319912|Drug|ALXN1840 Non-coated Capsule|ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
45990759|NCT05319912|Drug|Omeprazole|Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
45990760|NCT00515138|Drug|Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib|Bortezomib starting at 1 mg/m(2), and escalating to 1.3, 1.5, 1.7. Bortezomib will be given on Days 1 (prior to rituximab) and 4, rituximab at 375 mg/m(2) on day 1, carboplatin AUC 5 and ifosfamide with mesna, each 5 mg/m(2), on day 3 and etoposide 100 mg/m(2)/day on days 2, 3, and 4 of a 21-day cycle. They will also receive filgrastim on days 6-13 or pegfilgrastim on day 6
45990761|NCT05319834|Drug|Aspirin tablet|group1: oral aspirin at a dose of 100mg once daily at the same time with progesterone
45990762|NCT05319834|Drug|Placebo|group 2: oral placebo once daily at the same time with progesterone
45990763|NCT04695587|Diagnostic Test|123 MIBG scintigraphy testing|123 MIBG scintigraphy testing in subacute phase and 12 months after the acute episode in a subgroup of patients according to individualized needs.
45990764|NCT04695587|Diagnostic Test|MSNA|MSNA in subacute phase and 12 months after the acute episode
45674046|NCT04415697|Diagnostic Test|Gene expression test using nanostring technology.|Evaluation of gene expression profile of a panel with 770 genes related to disease progression using nanostring technology
45674047|NCT02202551|Drug|ADS-5102|
45674048|NCT02202317|Device|PET/CT Scan|Subjects will receive a PET/CT Scan in addition to SPECT imaging, from the level of the lower chest to the lower pelvis, typical of an abdominal CT, usually within 1-3 hours after Yttrium-90 treatment.
45674049|NCT02118337|Biological|MEDI0680|Participants will receive IV infusion of MEDI0680 0.1 or 0.5 or 2.5 or 10 or 20 mg/kg Q2W in dose-escalation phase and 20 mg/kg Q2W in dose-expansion phase.
45833643|NCT04398810|Procedure|robotic single port cholecystectomy|"Local anesthetic administration during wound incision In the experimental group and the control group, a local anesthetic was administered to the wound surface when a glove port was installed on the navel at the start of surgery. (bupivacaine 0.5% 14ml subcutaneous injection)~Residual gas aspiration~Pulmonary recruitment maneuver In both the experimental group and the control group, before the operation was completed and the wound was closed, the patient was taken to the Trenedelenburg position, and then the pressure of 60 cm H2o in the abdomen was applied, and manual inflation was performed twice, 5 seconds at a time, and pulmonary recruitment was performed.~Warming of the washing solution in the abdominal cavity"
45833644|NCT04722666|Drug|MIJ821 Intravenous Injection|MIJ821 supplied in vials to be prepared on a mg/kg basis and to be administered for 40 minutes IV infusion on Day 1, Day 15 and Day 29
45833645|NCT04722666|Drug|Placebo Intravenous Injection|40 minutes IV infusion of 0.9% sodium chloride solution on Day1, Day 15 and Day 29
45833646|NCT02084628|Drug|Gadoxetate disodium (Eovist/Primovist, BAY86-4873)|Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole [mmol]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent [%] solution) manually.
45833647|NCT04760418|Behavioral|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)|A 12-session integrated cognitive behavioral therapy for posttraumatic stress disorder and substance use
45833648|NCT04277520|Procedure|Root canal therapy|Different types of instrumentation motions during root canal therapy
45833649|NCT04466358|Procedure|Modified CLOSE protocol|Modified CLOSE protocol guided isolation of pulmonary veins.
45833650|NCT04466358|Procedure|High density mapping guided pulmonary vein isolation|Modified CLOSE protocol guided isolation of pulmonary veins with additional ablations at sites of gaps or dormant conduction as evidenced by high density mapping of pulmonary vein antra.
45990765|NCT04695587|Diagnostic Test|ABPM|ABPM in subacute phase and 12 months after the acute episode
45833651|NCT04399902|Device|Thermal Blanket|Ready-Heat 6-Panel Blanket (Military style, manufactured by Techtrade LLC). The 6-panel military-style blanket (86cm x 152 cm, 1.13kg) warms to 40˚C in approximately 15-20 minutes and maintains this temperature for 10 hours.
45990766|NCT04695587|Diagnostic Test|ECHO|ECHO in subacute phase and 12 months after the acute episode
45990767|NCT04695587|Diagnostic Test|24hour ECG|24hour ECG in subacute phase and 12 months after the acute episode
45990768|NCT04695587|Diagnostic Test|CMR|CMR in 12 months after the acute episode
45990769|NCT00515255|Drug|Minocycline|Capsules
45990770|NCT02943018|Other|anovaginal distance variation|Kappa calculation
45990771|NCT00516113|Drug|paroxetine|Capsules containing either placebo or paroxetine 20 mg. The treatment start after ovulation and when the subject has experienced premenstrual irritability for 2 days. The dosage is one capsule daily at 8 AM
45990772|NCT02942940|Device|mobile app|The mobile app follow-up group will have no planned in-person follow-up, however these visits will be replaced with surgical site examination via submitted photos, Visual Analogue Scale (VAS), and Quality of Recovery - 9 questionnaire (QoR-9) and limb specific recovery monitoring. All information is submitted with the mobile app (QoC Health Inc, Toronto).
45833652|NCT04277754|Other|Observational|To Observe and describe motor and visual development
45833653|NCT04451772|Drug|Elsubrutinib|Oral; Capsule
45990773|NCT02942940|Other|conventional in-person|Patients in the conventional follow-up group will have a planned clinic follow-up at 2 and 6 weeks post-operatively, which is the schedule currently used by our surgeons. At these scheduled follow-up visits, patients will be asked to complete the VAS to assess pain and the QoR-9 in addition to recovery questions about their operated extremity.
45990774|NCT04695197|Drug|Artemether-lumefantrine (AL)|Current first line treatment of malaria. Dose: Bodyweight (kg) Dose (mg) of artemether + lumefantrine given twice daily for 3 days (total, six doses) 5 to < 15 20 + 120 15 to < 25 40 + 240 25 to < 35 60 + 360 >=35 80 + 480; Twice daily for 3 days (total, six doses)
45990775|NCT04695197|Drug|Pyronaridine-artesunate (PA)|Antimalarial; Dose: Body weight (kg) Dose (mg) of pyronaridine + aresunate given once daily for 3 days (total, three doses) 5 to < 8 60 + 20 8 to <15 120 + 40 15 to <20 180 + 60 20 to <24 kg 180 + 60 24 to <45 360 + 120 45 to <65 540 + 180 >=65 720 + 240; Once-daily for 3 days (total, three doses).
45990776|NCT05317962|Diagnostic Test|Transthoracic echocardiogram|Abbreviated transthoracic echocardiogram
45833654|NCT04451772|Drug|Placebo for Elsubrutinib|Oral; Capsule
45833655|NCT04451772|Drug|Upadacitinib|Oral; Tablet
45833656|NCT04451772|Drug|Placebo for Upadacitinib|Oral; Tablet
45833657|NCT03831984|Drug|0,09% Bromfenac|topical 0,09% Bromfenac, one drop twice daily 3 days before surgery
45833658|NCT03831984|Drug|0,1% sodium hyaluronate|topical 0,1% sodium hyaluronate, one drop twice daily 3 days before surgery
45833659|NCT02084706|Procedure|Triamcinolone (20 g) and 2% Lidocaine injection over the A1 pulley|
45833660|NCT02084706|Drug|2% Lidocaine|
45833661|NCT02084706|Drug|Triamcinolone (20 g)|
45833662|NCT02084706|Procedure|J-tip lidocaine administration|
45990777|NCT00516152|Drug|Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF|"Day Preparative Regimen for GVHD Prophylaxis~7 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~6 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~5 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~4 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~3 Fludarabine 30 mg/m(2)IV~2 REST Tacrolimus 0.01 mg/kg CIVI~1 REST 0 Unrelated Stem Cell/Bone Marrow Infusion~1 Methotrexate 5mg/m(2)IV~3 Methotrexate 5mg/m(2)IV~6 Methotrexate 5mg/m(2)IV~7 G-CSF 5mcg/kg SQ daily~11 Methotrexate 5mg/m(2)IV~90 Evaluate Response"
45990778|NCT05319678|Other|evaluation with Meludia music software|"Measurement instruments:~- MuMu Questionnaire~MuRQoL Questionnaire~Questionnaire for subjects aged 6-17 years~Music tool Meludia (www.meludia.com)~Acoustic analysis of the voice: the Praat programme~Audiological tests"
45990779|NCT00516191|Drug|Liposomal Doxorubicin/Melphalan/Bortezomib|"Day 1 Bortezomib 0.7 mg/m(2)IV + Doxil 10-20 mg/m(2)IV+Melphalan 5-10mg/m(2)IV Day 4 Bortezomib 0.7 mg/m(2)IV Day 8 Bortezomib 0.7 mg/m(2)IV Day 11 Bortezomib 0.7 mg/m(2)IV~The treatment cycles will be repeated every 28 days. Dose Level 1: Doxil 10mg/m(2), Melphalan 5 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 2: Doxil 10mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 3: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 4: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 1.0mg/m(2)"
45990780|NCT05319483|Other|No intervention|No intervention.
45990781|NCT00516308|Device|NightHawk|
45990782|NCT00515333|Drug|TRx0014|Hard capsule; 60 milligrams; t.i.d.
45833663|NCT02084706|Procedure|Triamcinolone (20 g) Injection over the A1 pulley.|
45833664|NCT04704024|Drug|Tenofovir Disoproxil Fumarate|oral TDF medication 300 mg daily
45833665|NCT04704024|Drug|Lamivudine Oral Solution|Oral lamivudine with weight-based dosing BID from birth until 6 months of age
45990783|NCT00515333|Drug|TRx0014|Hard capsule; 30 milligrams; t.i.d.
45990784|NCT00515333|Drug|Placebo|Hard capsule; 0 milligrams; t.i.d.
45990785|NCT00515333|Drug|TRx0014|Hard capsule, 100 milligrams, t.i.d.
45990786|NCT02943174|Behavioral|MIND programme for cancer patients|Psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for cancer patients Other: Cancer Treatment as Usual
45990787|NCT02943174|Other|Treatment as Usual (TAU)|Standard personalized treatment of cancer
45990788|NCT02941887|Behavioral|Behavior Analysis|One examiner observed global behavior of patients during a dental care session, guided by a behavioral scale.
45833666|NCT04439994|Other|hypertonic saline|The participant will be given i.d. in 0.1 mL volumes of a hypertonic saline solution
45833667|NCT04439994|Other|Saline injection|The participant will be given i.d. in 0.1 mL volumes of a saline solution
45833668|NCT04439994|Procedure|Blood sampling|Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected
45833669|NCT03256656|Other|electrical stimulation (non painful) of the lower urinary tract to determine the current perception threshold and record sensory evoked potentials|
45833670|NCT04686084|Device|Dual-energy computed tomography scan|Diagnostic CT scan
45990789|NCT00515450|Biological|GB-0998 (Intravenous immunoglobulin)|
45990790|NCT00515450|Procedure|Plasmapheresis|
45990791|NCT00516347|Genetic|comparative genomic hybridization|
45990792|NCT00516347|Genetic|genetic linkage analysis|
45990793|NCT00516347|Other|laboratory biomarker analysis|
45990794|NCT00516347|Other|questionnaire administration|
45990795|NCT00516347|Procedure|study of high risk factors|
45990796|NCT02941848|Drug|HGP0816|
45990797|NCT02941848|Drug|HGP1404|
45990798|NCT02941848|Drug|HCP1306|
45456894|NCT01224847|Drug|Lidocaine|Lidocaine soaked pledget
45674050|NCT02118337|Biological|Durvalumab|Participants will receive IV infusion of durvalumab 3 and 10 mg Q2W in dose-escalation phase and 750 mg Q2W in dose-expansion phase.
45674051|NCT02118337|Biological|Nivolumab|Participants will receive IV infusion of nivolumab 240 mg Q2W in dose-expansion phase.
45990799|NCT00515489|Drug|Risperidone|as prescribed
45674052|NCT05131555|Drug|Placebo: Placebo + exercise training.|Oral placebo Exercise training: Interval-based cycling exercise
45990800|NCT02941653|Device|Potassium nitrate 2% gel|"Teeth will be cleaned using rubber cups associated to pumice and water;~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the potassium nitrate 2% desensitivity gel application on vestibular surface, for 10 minutes.~Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil)~A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
45990801|NCT02941653|Device|Potassium oxalate 5% gel|"Teeth will be cleaned using rubber cups associated to pumice and water~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
45990802|NCT02941575|Other|Crystal Ultra|Crystal Ultra: is a resin nano-ceramic material, that combines both advantages of ceramics and composites.
45990803|NCT02941575|Other|All ceramic|IPS Emax: is an all ceramic crown that has proven superior aesthetics and strength properties.
45990804|NCT00515606|Drug|helium:oxygen|
45990805|NCT02941731|Drug|HIP1403|Oseltamivir 6mg/mL
45456895|NCT02289586|Procedure|invasive ventilation|
45456896|NCT02289586|Procedure|interventional bronchoscopy|
45674053|NCT05131555|Drug|H1 blockade: H1 receptor antagonist + exercise training|H1 blockade: oral blockade Exercise training: Interval-based cycling exercise
45674054|NCT05131555|Drug|H2 Blockade: H2 receptor antagonist + exercise training|H2 blockade: oral blockade Exercise training: Interval-based cycling exercise
45990806|NCT02941731|Drug|HGP0919|Oseltamivir phosphate 6mg/mL
45990807|NCT05319210|Procedure|Venous catheter application|To examine the effect of virtual reality glasses and buzzy application on pain management during venous catheter insertion in children.
45990808|NCT02951039|Drug|Edoxaban|Prescribed according to approved label
45990809|NCT02951117|Drug|Venetoclax|Tablet
45990810|NCT02951117|Drug|ABBV-838|Intravenous infusion
45456897|NCT02289586|Device|noninvasive ventilation|
45456898|NCT02289586|Drug|sedation(dezocine and midazolam)|
45456899|NCT02289586|Drug|general anesthesia(midazolam, fentanyl，rocuronium，propofol and Remifentanil）|
45990811|NCT02951117|Drug|Dexamethasone|Tablet or intravenous infusion
45990812|NCT02941809|Behavioral|Open-Label Placebo (OLP)|We are designating this as a behavioral intervention for two reasons: (1) the placebo pill is physiologically inert and is not classified under FDA regulations; and (2) other studies have demonstrated that the efficacy of the placebo pill is strongly dependent on the participants' anticipation of an effect. We are presenting the pill's efficacy in an open and transparent way to the participants, but using a positive frame. We feel that this qualifies the placebo pill use as a behavioral intervention, in the same general category as exercise or relaxation.
45990813|NCT02951000|Procedure|platysma suture|
45990814|NCT02951000|Procedure|no platysma suture|
45990815|NCT02941770|Behavioral|Physical activity behavior change|Physical activity consultation will consist in a patient-centered, one-to-one session based on the transtheoretical model and will use motivational interview in order to strengthen individual's intrinsic motivation to achieve a positive PA behavior change. In these sessions the following topics will be explored: (i) explore and resolve ambivalence; (ii) identify difficulties/barriers, and benefits of behavior change; (iii) find their own means and their own solutions for step over the identified barriers; (iv) enhancement of autonomy and self-efficacy.
45990816|NCT02941770|Other|Exercise|Experimental group II will participate accordingly with their availability in two exercise sessions per week (≈60 min/session) directed by one exercise physiologist. The ability to exercise will be assessed in order to customize the exercise plan. All the sessions will include: 10 minutes of warm-up, 5 minutes of agility exercises, 15 minutes of resistance training (including the major upper and lower muscles, 12-15 sets of 15 repetitions), 20 minutes of aerobic exercise, and 10 minutes of cool-down (50-80% heart rate reserve - Polar Vantage NV, Polar Electro Oy, Kempele, Finland). All the participants will have to attend at least 80% of the scheduled sessions.
45990817|NCT02950181|Device|NIRS|Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
45990818|NCT02941536|Diagnostic Test|Circulating tumor cells evaluation|Sample collection of circulating tumor cells (CTC) before and 4-5 weeks after focal stereotactic radiotherapy in single (SRS) or fractionated (SFRT) dose.
45990819|NCT02951078|Procedure|Thulium Laser en Bloc Resection of bladder tumor|
45990820|NCT02951078|Procedure|Electrical transurethral resection of bladder tumor|
45990821|NCT05319171|Device|TAVR|TAVR
45990822|NCT02950376|Other|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the beginning of withdrawl、3 months later、 6 months later and 1 year later and record the information synchronously.
45990823|NCT02950376|Other|Virtual reality-based addiction assessment system|The healthy controls will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the baseline and 1 month later and record the information synchronously.
45990824|NCT02950376|Other|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.In this group which is designed to construct the norm of assessment system, the test will record the information synchronously and proceed after baseline assessment.
45990825|NCT02942901|Procedure|PET-CT|
45990826|NCT00515645|Other|Head-down tilt and immersion|Head-down tilt -6° at inclusion, head-down tilt -15° at week one and Water Immersion at week two
45990827|NCT02950220|Drug|Ibrutinib|Given PO
45990828|NCT02950220|Other|Laboratory Biomarker Analysis|Correlative studies
45990829|NCT02950220|Biological|Pembrolizumab|Given IV
45990830|NCT00515684|Drug|bevacizumab (Avastin)|
46083917|NCT02597517|Device|Digital chromoendoscopy and magnification|After the gastric body mucosal evaluation with white light endoscopy, the Optical Enhancement chromoendoscopy and magnification will be used for a more detailed evaluation of the subepithelial capillary network, the collecting venules and mucosal pits
46002323|NCT03762018|Drug|Atezolizumab|Atezolizumab is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain protein in cancer cells. This helps the immune system to fight against the cancer cells, and helps to slow tumor growth.
46002324|NCT03750825|Device|NIDA Standard Research E-cigarette (SREC)|Smokers will switch to NIDA Standard Research E-cigarette (SREC).
46083918|NCT00612144|Drug|Glimepiride/metformin fixed combination|"Amaryl M 1/250mg~4/1000mg bid for 12~26 weeks~Maintenance dose for 10 weeks after 2~14 weeks of dose titration~Dose titration according to titration algorithm based on daily mean SMBG"
46083919|NCT00612144|Drug|Metformin HCl|"Metformin HCl 500mg~1250mg bid for 12~26 weeks~Maintenance dose for 10 weeks after 2~14 weeks of dose titration~Dose titration according to titration algorithm based on daily mean SMBG"
46083920|NCT04227548|Diagnostic Test|needle electromyography|Direct muscle stimulation was performed to deltoid and tibialis anterior muscles with a monopolar needle electrode. Recording was made with a concentric needle electrode.
46083921|NCT02597361|Drug|Irbesartan|Irbesartan: 150 or 300 mg o.d. The up-titration of irbesartan from 150 mg to 300 mg o.d. occur during the first 8 weeks following randomization
46083922|NCT02597361|Drug|Placebo|Placebo o.d. to match 150mg or 300mg irbesartan tablets
45456900|NCT01221649|Device|ICD/CRT-D|BIOTRONIK ICD family Lumax 540 and its successors
45674055|NCT02117713|Drug|LUM001 (Maralixibat)|Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 280 micrograms per kilogram (mcg/kg).
45990831|NCT02941497|Behavioral|Social marketing and health promotion campaign|Students in the intensive intervention group developed a nine-month social marketing health campaign. The campaign included five costumed characters who interacted with students on campus in residence halls, dining halls, and other highly-trafficked public areas on campus. Photos and videos of interactions were put on social media. Student participants from the general population (the diffuse intervention group) were asked to set weekly healthy goals related to diet, physical activity, and stress management throughout the campaign and received email and text messages with goal-specific written and video health-promotion messages. Faculty partnered with the students throughout the intervention process to educate and give advice on the content of health promotion messages.
45990832|NCT02950883|Drug|Active Treatment Group 7% Hypertonic Saline|"Drug: 7% Hypertonic Saline (HS) 4 mL of HS will be administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI compressor (PARI Vios® Pro in USA, PARI BOY SX in Australia and Europe).~Other Names:~Hyper-Sal™, inhaled saline"
45990833|NCT02950883|Drug|Control Group 0.9% Isotonic Saline|"Drug: 0.9% Isotonic Saline (IS) 4 mL of IS will be administered via inhalation twice daily for 48 weeks The delivery system is the same as that for the test product.~Other Names: Normal saline"
45990834|NCT05317767|Biological|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
45990835|NCT05317767|Biological|Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
45990836|NCT02950454|Other|High intensity interval training|1.5 min intervals at 80-95% heart rate max on cycle ergometer 1.5 min intervals at nominal resistance on cycle ergometer
45674056|NCT02105467|Drug|Grazoprevir 100mg / Elbasvir 50 mg FDC|
45990837|NCT02950454|Other|Continuous moderate exercise|20 min at 60-70% heart rate max on cycle ergometer
45990838|NCT02942862|Drug|Orcein staining|Prognostic value of venous emboli detected by orcein staining
45674057|NCT02105467|Drug|Placebo to Grazoprevir / Elbasvir 50 mg FDC|
45990839|NCT04695158|Drug|COVID-19 group (Group I)|Routine COVID-19 treatment
45990840|NCT04695158|Drug|Type II Diabetes Mellitus and COVID-19 group (Group II)|Routine Type II Diabetes Mellitus and COVID-19 treatments
45990841|NCT05317650|Other|Multi-gravitational suspension-based therapy (M-Gravity)|Multi-gravitational suspension-based therapy (M-Gravity) is a comprehensive discipline based on the principles of non-gravity, which serves to increase the quality of life and holistic health of the individual with the rehabilitation content of non-pressure inversion therapy.
45990842|NCT02950142|Other|CPOE with order sets for lab testing|CPOE including series of recommended tests ordered per indication
45674058|NCT02202161|Drug|GSK2330672|GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
45990843|NCT02950142|Other|CPOE without order sets for lab testing|CPOE only
45674059|NCT02202161|Drug|Placebo|Matching placebo will be available as oral solution to be administered for 14 days, BID. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
45990844|NCT04691310|Device|Kinesio Tex Gold|The Kinesio Tex Gold is a kinesio tape that had been certified and patented.
45990845|NCT00515762|Device|elasto-gel cap|scalp cooling cap
45990846|NCT02941341|Drug|r-hFSH|As per standard practice
45674060|NCT02202161|Drug|Sitagliptin|Sitagliptin will be available as film-coated tablets Tablet of 50 mg to be administered orally, BID, for 14 days
45674061|NCT02202161|Drug|Metformin|Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
45990847|NCT00515801|Drug|glibenclamide|glibenclamide 15 mg single dose
45990848|NCT00515801|Drug|placebo|placebo capsules, single dose
45990849|NCT03458364|Device|High flow nasal cannula|High-flow nasal cannula (HFNC) oxygen therapy is a recent technique delivering a high flow of heated and humidified gas. HFNC is simpler to use and apply than noninvasive ventilation (NIV) and appears to be a good alternative treatment for hypoxemic acute respiratory failure (ARF). HFNC is better tolerated than NIV, delivers high fraction of inspired oxygen (FiO2), generates a low level of positive pressure and provides washout of dead space in the upper airways, thereby improving mechanical pulmonary properties and unloading inspiratory muscles during ARF.
45990850|NCT03458364|Device|Noninvasive ventilation|Non-invasive ventilation (NIV) is the use of airway support administered through a face (nasal) mask instead of an endotracheal tube. Inhaled gases are given with positive end-expiratory pressure often with pressure support or with assist control ventilation at a set tidal volume and rate. Numerous studies have shown this technique to be as effective as, and better tolerated than, intubation and mechanical ventilation in patients with exacerbations of COPD
45990851|NCT00515840|Other|Physiotherapist|Physiotherapist administered breathing retraining programme
45990852|NCT05317611|Drug|Intraperitoneal instillation of ondansetron and bupivacaine|The aim is to detect the effect of intraperitoneal instillation of ondansetron for prevention of postoperative nausea and vomiting
45990853|NCT05317611|Drug|Intravenous ondansetron and intraperitoneal instillation of bupivacaine|The aim is to detect effect of intravenous ondansetron for prevention of postoperative nausea and vomiting
45990854|NCT05317611|Drug|Intraperitoneal instillation of bupivacaine|The aim is to detect effect of intraperitoneal instillation of bupivacaine
45990855|NCT04695314|Device|Massage|Foot reflexology board (JAPAN TSUBO HH-700) with massage focused at the base of the second and third toes
45990856|NCT04695314|Procedure|Experimental insert|Raised shoe insert, insert used for massage
45990857|NCT04695314|Procedure|Sham insert|Flat shoe insert, insert used for massage
45990858|NCT05317572|Drug|80 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 80 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
45990859|NCT05317572|Drug|120 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 120 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
46083923|NCT02706444|Device|Conventional Balloon angioplasty|After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
46083924|NCT02706444|Device|Drug-coated Balloon angioplasty|After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
45674062|NCT03267563|Behavioral|EIAU|Enhanced implementation as usual consists of initial training and problem-solving plus planning for sustainment,
45674063|NCT03267563|Behavioral|LICF|"Enhanced implementation plus low intensity will have received initial training and problem-solving plus planning for sustainment and after that every 3 months will receive one clinical and one operational telephone booster meeting."
45674064|NCT03267563|Behavioral|HICF|Enhanced implementation plus high intensity will receive will receive everything that the clinics in LICF receive, but at a higher intensity.
46083925|NCT04228406|Drug|GST-HG161|There are 7 dose cohorts, including60mg, 150mg, 300mg, 450mg, 600mg, 750mg, 900mg QD in the dose escalation stage and GST-HG161 will be administered orally to patients once daily for each dose cohort. Recommended dose in the dose expansion stage will be determined by the results in the dose escalation stage .
46083926|NCT00562627|Drug|ropivacaine|intraoperative and 1. postoperative day
46083927|NCT00562627|Drug|adrenaline|intraoperative LIA (IV and IA) and continuous EDA
45833671|NCT05156112|Device|Positive Airway Pressure Device|Each PAP treatment initiation meeting will include 1) mask fitting; 2) psycho-education to what to expect and reviewing PAP machine problem solving; and 3) setting up correct PAP treatment (e.g., auto PAP or in rare conditions, bi-level PAP).
45456901|NCT02292004|Device|ACL Repair with MIACH Scaffold|Surgical insertion of the MIACH scaffold to promote ACL healing/repair
45674065|NCT03109847|Drug|Metformin Hydrochloride|Given Orally
45674066|NCT03109847|Other|Radioactive Iodine|Undergo radioactive iodine treatment
45674067|NCT03109847|Other|Placebo|Given orally
45833672|NCT04434066|Procedure|Total Laparoscopic Hysterectomy|Participants will be randomized into either abdominal or vaginal morcellation at time of total laparoscopic hysterectomy
45833673|NCT04433988|Drug|Pentoxifylline|Pentoxifylline 400 mg SR tablet
45833674|NCT04433988|Drug|Placebo|Placebo tablet
45833675|NCT04425408|Device|Consecutive trial of two different devices for the treatment of positional sleep apnoea, for 3 nights with each device (positional pillow and vibrating belt).|Patients will be randomly allocated to use either a positional pillow or a vibrating belt for three consecutive nights at home followed by three nights with the other device.
45833676|NCT04685538|Drug|Chloroprocaine 3%|"Administration: three IMP drops instillation as follow:~1st Drop instillation, then wait for 5 minutes~Eye Disinfection, then wait for 2 minutes~2nd Drop instillation, then wait for 1 minute~3rdDrop instillation, then wait for 1 minute~Start of Surgery."
45833677|NCT04685538|Drug|Tetracaine 0.5%|"Administration: three IMP drops instillation as follow:~1st Drop instillation, then wait for 5 minutes~Eye Disinfection, then wait for 2 minutes~2nd Drop instillation, then wait for 1 minute~3rdDrop instillation, then wait for 1 minute~Start of Surgery."
45833678|NCT03255798|Device|G2 and G3|Two iStent inject devices and one iStent supra device
46083928|NCT00562627|Drug|ketorolac|intraoperative and 1. postoperative day
46083929|NCT00562627|Drug|morphine|intraoperative
45833679|NCT04673760|Behavioral|Specialized palliative home care|"Specialist palliative home care teams will initiate care as usual, including managing a systematic and collaborative process of advance care planning with patients, family caregivers, GPs and SPITEX nurses using the Betreuungsplan, information packages and regular case meetings. The GP was additionally provided with educational palliative care information by the study team."
45990860|NCT05317572|Drug|160 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 160 mcg of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
45990861|NCT02950805|Drug|Placebo|Subjects will receive a placebo in either period 1 or period 2 by inhalation.
45990862|NCT02950805|Drug|AZD5634|Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.
45990863|NCT02950727|Device|3 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the first group the osteotomy will be fixed using 3 bicortical screws
45990864|NCT02950727|Device|adjustable plate and 2 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the second group the osteotomy will be fixed using adjustable plate and 2 bicortical screws
45990865|NCT02950571|Behavioral|Digital Picture Frame|The intervention is the provision of digital picture frames in long stay inpatient rooms in a ward at CAMH.
45990866|NCT02950571|Behavioral|Standard Care|High level of support from an interdisciplinary team.
46002325|NCT03747146|Device|Continuous Adductor Canal Catheter (ACC)|At the end of the case or in the PACU, a pseudo sham catheter will be affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
46083930|NCT00562627|Drug|fentanyl|continuous postoperatively
46083931|NCT00562627|Drug|bupivacaine|continuous postoperatively
46083932|NCT04159428|Diagnostic Test|HHIE-S survey score|"First, the patient will fill in the French translation of the HHIE-S questionnaire in the observation book.~Secondly, he will perform the audiometry in silence test: for the tonal test in silence, we will test the frequencies 500, 1000, 2000 and 4000 hertz in each ear with pure tone sound. For the vocal in silence test, we will use the dissyllabic lists of words (Fournier's lists) at the intensities of 20, 30, 40, 50 and 60 decibels. This test will be in free-field conditions testing both ears.~Thirdly, he will perform the speech in noise audiometry test that consists in repeating sentences pronounced at an equal intensity (60 decibels) while the intensity of the noise is increasing. This test will be in free-field conditions testing both ears."
46083933|NCT04227626|Device|GlucoSTAT|Closed-loop blood glucose control using intravenous insulin and dextrose
46083934|NCT02597283|Device|Biguard sirolimus-eluting bifurcation stent system|PCI with Biguard sirolimus-eluting bifurcation stent system
46083935|NCT02597283|Device|Sirolimus-eluting stent system|PCI with sirolimus-eluting stent system
46083936|NCT02779010|Behavioral|Hand washing with soap and Health education|Health education on key environmental variables and hand washing with soap
45833680|NCT04746222|Biological|Oral capsule faecal microbiota transplantation|Single dose of 30 oral capsules containing healthy donor stool from a stool bank
45833681|NCT04746222|Other|Placebo|Single dose of 30 oral placebo capsules
45833682|NCT04746768|Combination Product|exercise and nutritional support|exercise and nutritional support program during an active support phase (0 to 6 months) followed by an empowerment phase (from 6 to 12 months)
45833683|NCT05122962|Diagnostic Test|Remote Heart Rhythm Monitoring|We will be looking to see if remote heart rhythm monitoring for 3 months at baseline, 12, and 24 months, helps for early identification of adverse cardiac events.
46083937|NCT00948649|Drug|Placebo|Participants will take placebo pills for 21-days using the same regimen as the varenicline study period.
46083938|NCT00948649|Drug|Varenicline|Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - End of Treatment 1.0mg twice daily
46083939|NCT04920006|Behavioral|Enhancing Active Caregiver Training|The intervention has three components within each session. Step 1, View, involves group viewing of a caregiving scenario, developed during previous research, which portrays a situation in which a caregiver is dealing with a challenging behavioral symptom. Step 2, Practice, involves small-group rehearsal activities that facilitate understanding, making choices, and examining possible responses. Step 3, Reflect, involves self-reflection and group processing surrounding choices and observations.
46083940|NCT04195490|Procedure|feminizing genitoplasty|feminizing genitoplasty including vaginoplasty,clitroplasty, labioplasty and urethroplasty
45833684|NCT05121246|Drug|MB05 (Proposed palivizumab biosimilar)|Single IM dose of 3 mg/kg
45990867|NCT02942745|Behavioral|Betel Nut Cessation Social Support|The cessation sessions will be led by trained facilitators over 22-day period. Session 1 (Day 1) includes a discussion of health risks associated with betel nut chewing, and introduction to self-monitoring and triggers logs. Session 2 (Day 8) includes a review of their logs, and discussions of lifestyle changes to assist cessation of betel nut chewing. Session 3 (Day 15) will be the quit day for chewers. Coping mechanisms and plans to maximize social support will be discussed. Session 4 (Day 18) will focus on quitting experiences. Facilitators will also review the negative health effects when wanting to chew again. Discussion on quitting experiences will continue in Session 5 (Day 22). Facilitators will also address those who have experienced relapse, and how to manage relapse.
45990868|NCT02942745|Behavioral|Betel Nut Cessation Booklet|Participants will receive minimal intervention via a single booklet that contains all the information offered in the experimental group, minus the social support sessions. The participants will meet with study staff individually at a designated office in Guam or Saipan to receive the betel nut cessation booklet, complete three assessments (baseline, 22 days, 6 months), and provide saliva samples.
45990869|NCT00515918|Dietary Supplement|iron|
45990870|NCT02950688|Biological|Seasonal LAIV|10^7.0 fluorescent focus units (FFU); administered by intranasal spray
45990871|NCT02950688|Biological|Placebo|Administered by intranasal spray
45990872|NCT02950688|Biological|Wild-type A/California/2009-like Influenza Virus|Approximately 3.5 x 10^6 TCID50; administered intranasally
45990873|NCT05317533|Procedure|cardiac catheterization via distal radial artery|cardiac catheterization via distal radial artery
45990874|NCT00516425|Biological|pegfilgrastim|
45990875|NCT00516425|Drug|cyclophosphamide|
45990876|NCT00516425|Drug|doxorubicin hydrochloride|
45990877|NCT00516425|Drug|epirubicin hydrochloride|
45990878|NCT00516425|Genetic|proteomic profiling|
45990879|NCT00516425|Other|diagnostic laboratory biomarker analysis|
45990880|NCT00516425|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
45990881|NCT00516425|Other|pharmacological study|
45990882|NCT00516425|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
45990883|NCT00516425|Procedure|adjuvant therapy|
46083941|NCT00952159|Biological|Monitoring seric concentrations of O-demethyl-tramadol and tramadol|The first aim of this study is the validation of monitoring seric concentrations of O-demethyl-tramadol and tramadol to make the ratio in order to detect CYP2D6 poor metabolizers in therapeutic situation, comparing the result with genotyping. The finding of a poor metabolizer status in a patient will make the choice of analgesic drugs easier, avoiding tramadol and codeine. The final objective of this research is to be able to determine the CYP2D6 phenotype in a patient treated by tramadol without a good analgesia. By a single take of blood and a rapid response, this method should be liked to improve pain management. Furthermore, CYP2D6 phenotyping is interesting for the patient because many other drugs depend on this way of metabolism.
45990884|NCT02942706|Drug|Cetuximab|anti-EGFR monoclonal antibody
45990885|NCT02942706|Drug|mFOLFOX6|Oxaliplatin+LV5FU2
46083942|NCT05265234|Drug|Dupilumab|IL-4 antagonist to improve moderate-severe atopic dermatitis
45990886|NCT02942706|Drug|FOLFIRI|Irinotecan+LV5FU2
45990887|NCT00516464|Drug|Lucentis (ranibizumab)|
46083943|NCT05265234|Device|Optical Coherence Tomography|OCT is a noninvasive imaging device that can be used to monitor inflammatory skin disorders.
45990888|NCT02942628|Other|Vegetarian diet followed by meat diet or vice versa|Half the patients will follow either a vegetarian diet for 6 weeks and the other half will adhere to or a meat-based diet for six weekd. This is followed by a 4 week period where patients eat their usual diet. Thereafter patients initially randomized to a vegetarian diet will follow a meat-based diet for six weeks while the patients initially randomized to meat will follow a vegetarian diet for six weeks.
45990889|NCT04694690|Other|Self adhesive resin cement|Self adhesive resin cement
45990890|NCT04694690|Other|Resin cement|Resin Cement system used after surface treatment
45456902|NCT02292004|Procedure|Standard ACL Reconstruction|Standard surgical reconstruction of the ACL with autograft hamstring tendon
45456903|NCT03740581|Drug|Insulin|Basal Bolus regimen (Participant to receive, Insulin >= 3 times per day)
45990891|NCT00516542|Drug|letrozole|A daily dose of 2.5 mg will be used throughout the study.
45990892|NCT00516542|Drug|DHEA|Will be dispensed in either 500mg or 1000mg tablets. Subjects will start at a dose of 500 mg and may increase up to 5000mg depending on the cohort.
45990893|NCT00516542|Other|pharmacological study|PK draws will happen on day 1 and day 14, then every 2 weeks.
45990894|NCT05305170|Diagnostic Test|Levels of EETs, DHETs and HETEs|The plasmatic concentration of EETs, DHETs, and HETEs.
45990895|NCT05302947|Drug|Baricitinib Oral Tablet|Baricitinib was administered at a dose of 4 mg once or twice per day for 3-8 days (5 days on average) depending on the individual patients' condition
45990896|NCT05302947|Drug|Tocilizumab Injection|Tocilizumab was administered by a single intravenous dose of 400 mg
45990897|NCT05302947|Drug|Netakimab|Netakimab was administered by a single subcutaneous injection of 120 mg
45990898|NCT05302947|Other|Standard of care therapy|SOC treatment included hydroxychloroquine (400 mg twice on day 1, followed by 200 mg twice per day on days 5-10), azithromycin (500 mg once per day for 5 days), lopinavir-ritonavir (400/100 mg twice per day for 14 days), and low molecular-weight heparin according to personal indicators
45990899|NCT02941419|Biological|Platelet lysate|Autologous intramuscular platelet lysate injection for patients with peripheral arterial disease
45990900|NCT04694768|Behavioral|Rehabilitation|Rehabilitation program
45990901|NCT03458481|Drug|SOF|400 mg tablet administered orally once daily
45990902|NCT03458481|Drug|DAG181|Capsule administered orally once daily
45990903|NCT02950103|Drug|Phosphoethanolamine|Phosphoethanolamine PO daily
45990904|NCT02942394|Device|sinus-Obliquus Stent System|
45990905|NCT00516620|Behavioral|No further instruction|Participants receive Health Canada's Food Guide and Physical Activity Guide and no other intervention for the 6 months of the intervention period.
45990906|NCT00516620|Behavioral|Food Delivery|Participants receive Canada's Food Guide and Physical Activity guide, in addition to a a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products.
45990907|NCT00516620|Behavioral|Fruits (F), vegetables (V), and whole grain (WG) counseling|Participants receive Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
45990908|NCT00516620|Behavioral|Counseling to reduce soft drink intake.|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
45990909|NCT00516620|Behavioral|Food Delivery & F, V & WG counseling.|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
45990910|NCT00516620|Behavioral|Food delivery & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
45990911|NCT00516620|Behavioral|F, V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counseling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
45990912|NCT00516620|Behavioral|Food delivery and F,V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, receive a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
45990913|NCT02949752|Drug|Aripiprazole|Aripiprazole 5 mg every morning will be prescribed for 12 weeks
45990914|NCT05299983|Other|MyMenoPlan|Participants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.
46083944|NCT05265234|Device|Reflectance confocal microscopy|RCM is a noninvasive imaging device, with resolution approaching that of histology, which can monitor structural changes in the epidermis and superficial dermis, monitor inflammatory cells, and can overcome the limitations of a traditional biopsy.
46083945|NCT00948727|Behavioral|Dose adaptation according to CN activity monitoring|The protocol of the CALCICLO trial consisted in a CsA dose adaptation during the first 100 days following transplantation. This dose adaptation was performed according to both residual CsA blood and CN activity levels only if the safety of vital functions - especially renal, liver, and neurological - was preserved as assessed by clinical evaluations and laboratory analyses such as creatinine clearance higher than 40 ml/min, serum bilirubin lower than 40 µM and absence of neurological signs. According to the protocol, CsA blood levels and CN activity were measured concomitantly at least once a week from day 0 to day 15, twice a week from day 16 to day 35 and then once a week until day 100.
46083946|NCT00948727|Drug|Cyclosporine (CsA)|Cyclosporine (CsA)
46083947|NCT04195334|Device|internal fixation by IMN|using retrograde or antegrade IMN for femooral fractures fixation using a fit nail to the femoral intramedullary canaland follow up for union
45674068|NCT01461928|Drug|Chemotherapy (Induction Period)|Participants will receive standard combination chemotherapy every 3-4 weeks for 6 to 8 months. The chemotherapy regimen will be selected at Investigator's discretion, for individual participant. Study protocol does not enforce any particular chemotherapy regimen.
46083948|NCT05264766|Device|Cooling helmet on|Cooling helmet with circulating cold water
46083949|NCT05264766|Device|Cooling helmet off|Cooling helmet without circulating cold water
46083950|NCT00952237|Drug|GM-CSF|"GM-CSF (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor) The dose and duration of GM-CSF (7.5 mcg/kg/day) was selected. If used alone, this dose and duration would result in effective mobilization. GM-CSF will be started on Day #7 and will continue until completion of leukapheresis.~G-CSF will be started (5mcg/kg/d) on Day #7 and will be given each morning. G-CSF will continue until completion of leukapheresis."
45456904|NCT02289664|Device|MAC|Direct-Laryngoscopy
45456905|NCT02289664|Device|Coopdech|Video-Laryngoscopy -1
45674069|NCT01461928|Drug|Rituximab|Participants will receive rituximab according to the regimen specified in individual arm.
45833685|NCT05121246|Drug|EU-Synagis®|Single IM dose of 3 mg/kg
45833686|NCT05121246|Drug|US-Synagis®|Single IM dose of 3 mg/kg
45833687|NCT03278340|Behavioral|Sun Safe Workplaces - Technology|After randomization, program staff will contact managers at the recruited employer and schedule the initial web-enabled visit in the first 6 months. Follow-up meetings will be scheduled as needed to discuss policy adoption, and managers will schedule employee education using the SSW-T online training. Staff will follow-up with managers through Month 34 (Wave 1) or Month 46 (Wave 2). Electronic materials will be published on KB's state-of-the-art web server for employers to access and use.
45990915|NCT05299983|Other|Control|"Participants are asked to spend at least 20 minutes on at least one of the following websites:~North American Menopause Society: https://www.menopause.org/for-women~National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause~The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause"
45990916|NCT04694963|Procedure|Blood sample|2 ml venous blood was collected and separated into serum.
45990917|NCT04694963|Procedure|Data collection|"Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination;~Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;"
45990918|NCT04694963|Procedure|Throat swab|"Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue.~Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth.~Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time."
45990919|NCT02942550|Drug|Methylnaltrexone bromide (Relistor®).|
45990920|NCT02942550|Drug|Sodium Chloride 9mg/mL|
45990921|NCT02949986|Behavioral|Tablet-based Fall Prevention|The focus of the Otago Exercise Program is on improving strength and balance with a home-based balance exercise program. The program will be self-administered via tablet-based version of the Otago fall prevention program. Participants will complete 2 months of the home-based balance exercise program using the Health in Motion app. Participants will be asked to perform the exercises for 30 minutes 3x/week. Participants will be asked to perform the exercise program for 2 months.
45674070|NCT03097991|Behavioral|Focused Coparenting Consultation|Six 90-minute sessions completed within 10 weeks address importance of coparenting for child development; overcoming challenges to coparenting collaboratively; anger and conflict management and communication skills. Parents develop a coparenting plan to support one another's involvement as parents to the baby. A 90-minute booster session one month after the baby's birth reinforces lessons learned in the 6-session intervention.
45674071|NCT02892305|Procedure|Hepatic Resection or Ablation with Pancreaticoduodenectomy|"Patients will undergo pancreaticoduodenectomy, or the Whipple procedure, which involves removal of the head of the pancreas, the duodenum, and a portion of the stomach, as well as the gallbladder and a portion of the bile duct.~The patient will also undergo a Hepatectomy, the surgical resection or removal of all or part of the liver or Microwave Ablation (MWA) if determined by the surgeon to be the best course of care."
45674072|NCT04775069|Biological|BNT162b2|Intramuscular injection
45990922|NCT02942589|Other|Meal portion size|
45990923|NCT02949596|Behavioral|Quality of life and quality of sexual life questionnaires|
45990924|NCT02941302|Procedure|Detecting of Biological Borders of Gliomas|Neural navigation combined with Intraoperative ultrasound detecting the borders of gliomas, In accordance with established plan to collect multiple targets undergo pathological examination and contrast with imaging boundary to determine the biological boundaries.
45990925|NCT00516698|Genetic|polymorphism analysis|
45990926|NCT00516698|Other|high performance liquid chromatography|
45990927|NCT00516698|Other|laboratory biomarker analysis|
45990928|NCT00516698|Procedure|radiomammography|
45990929|NCT02949557|Procedure|Decortication + bone grafts|
45990930|NCT02942433|Behavioral|Behavior Change Communication|9-month weekly episode behavior change radio drama with interactive voice response (IVR)/short message service (SMS) listener engagement
45990931|NCT02942433|Behavioral|Community Mobilization|Listening and discussions groups, 2 male and 2 female groups per study site meet weekly for 39 weeks and will receive training on gender equity, intimate partner violence (IPV), life skills, community mobilization, non-violent conflict resolution for listening and discussion group (LDG) facilitators to support knowledge and skill set acquisition of LDG members. There will be a joint couple's session every month to foster mutual learning and understanding in addition to community mobilization incentives led by LDGs and encouragement of family members of LGD members to listen to the radio and attend LDG sessions once every 3 months. Participants will also receive awareness raising and street theater to engage families and community members.
45990932|NCT02942433|Behavioral|Advocacy|Training and 6-month follow up of religious/community leaders and religious leaders support community mobilization activity of local listening and discussion group (LGD).
45990933|NCT02942316|Device|Pupil dilation reflex measurement|"Pupillometry (PDR) at four standardized times perioperatively~after induction, before opioid administration~after opioid administration, steady state~surgical incision~end of procedure"
45990934|NCT04694612|Drug|Favipiravir|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
45990935|NCT04694612|Drug|Placebo|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
45990936|NCT04694612|Drug|Remdesivir|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to Remdesivir Injection in the patients with moderate COVID-19
45990937|NCT02942238|Procedure|CME|"the group underwent laparoscopic right hemicolectomy with CME. In CME group, in addition to D2 dissection, the whole mesocolon, from ascending colon to right half transverse colon, as well as the central lymph nodes should be entirely removed.~Intervention: Procedure: Complete mesocolic excision (CME)"
45990938|NCT02942238|Procedure|D3|"the group underwent laparoscopic right hemicolectomy with D3 lymph node dissection. In D3 group, the mesocolon should be removed and the dissection involves the paracolon and intermediate lymph nodes,including No.6 lymph node, which along the feeding vessels.~Intervention: Procedure: D3 radical operation"
45990939|NCT02950064|Drug|BTP-114|"Part 1 (Escalation) IV treatment of BTP-114 in 21-day cycles. Doses will be increased in sequential cohorts until the maximum tolerated dose is determined which will lead to the recommended phase 2 dose~Part 2 (Expansion) 5 cohorts of patients will be treated at the RP2D of IV BTP-114 in 21-day cycles for the tumor types pancreatic cancer, castration-resistant prostate cancer, ovarian cancer, triple-negative breast cancer and deoxyribonucleic acid (DNA) repair mutation-positive advanced solid tumors."
45990940|NCT02941224|Device|SELUTION DCB (sirolimus coated balloon)|
46083951|NCT00952237|Drug|IL-2|"IL-2 dose escalation: IL-2 will be administered as a single daily subcutaneous injection each evening until completion of leukapheresis.~Escalation of the dose of IL-2 will be performed using the below schema with the following levels. Patients will be started on Level 1. (Level 0 is included since, if toxicity is meet in Level 1, the dose will be decreased to Level 0).~Level 0 - 3 x 105 i.u./m2/day for 11 days Level 1 - 6 x 105 i.u./m2/day for 11 days Level 2 - 1 x 106 i.u. /m2/day for 11 days as above Level 3 - 1.5 x 106 i.u. /m2/day for 11 days as above Level 4 - 2 x 106 i.u. /m2/day for 11 days as above"
46083952|NCT02778776|Drug|Metformin|Metfomin in tablet presentation of 500 mg
46083953|NCT02778776|Dietary Supplement|Agave inulin|Oligofructan in powder obtained from agave plant, it was given to each patient a full 10 mg container.
46083954|NCT02778776|Other|Placebo of agave inulin|Calcinated magnesia powder
46083955|NCT02778776|Other|Metformin placebo|Calcinated magnesia tablet
46083956|NCT05264610|Other|Data collection (Laboratory tests, Radiologic diagnostics, Patient data taken from existing medical charts)|Data collection: Bone turnover laboratory parameters: alkaline phosphatase (AP), calcium (corrected for albumin), PTH, Calcidiol (25-OH-D3), N-terminales Kollagen Typ 1 -. Propeptid (P1NP), glomerular filtration rate (GFR), calcium/creatinine (in urine); Radiologic diagnostics: Bone densitometry (DEXA), X-rays, computer tomograms, MRI for analysis of time of the bone healing (or a non-union); Patient data taken from existing medical charts: side effects, tolerability of PTH, patient compliance, presence of previous illnesses as risk factors for the formation of pseudoarthrosis, indication for therapy, time at which therapy started and length of therapy with PTH, precise characterization of the operation (type and whether it is a revision or first operation).
46083957|NCT00948805|Drug|GnRH agonist|3,6mg of goserelin acetate, 250mg of hCG, FSH variable dose according to the number of days required for appropriate ovarian stimulation
46083958|NCT00948805|Drug|Control|250mg of hCG, Zoladex, FSH variable dose according to the number of days required for appropriate ovarian stimulation
45674073|NCT04775069|Biological|CoronaVac|Intramuscular injection
46083959|NCT05264532|Other|Informational Intervention|Receive information-graphic video
46083960|NCT05264532|Other|Informational Intervention|Receive family letter
46083961|NCT05264532|Other|Survey Administration|Ancillary studies
46083962|NCT04194632|Procedure|Temporary right ventricular pacing|As described previously. Patients will undergo temporary pacing at the site of latest endocardial activation with measurement of hemodynamic effects.
46083963|NCT02710812|Procedure|Local Excision or Wait-and-See|"Local excision can be done both with traditional technique and with endoscopic technique (TEM, TAMIS, etc.).~The following principles should be respected:~A gross margin of at least 0.5 cm;~full-thickness excision including mucosa, submucosa, muscle and peri-rectal fat;~determination of the specimen on the support by pins at the edges in order to facilitate the interpretation of histological pathologist."
45456906|NCT02289664|Device|CoPilot|Video-Laryngoscopy -2
45456907|NCT02289664|Device|Intubrite|Video-Laryngoscopy -3
46083964|NCT04227236|Other|E-based virtual facilitator training for Making Proud Choices|Participants complete the Making Proud Choices (MPC) facilitator training using an e-based virtual trainer on a computer. Making Proud Choices! (MPC) is an evidence-based pregnancy and HIV/STI risk-reduction program for youth. The facilitator training prepares educators to effectively deliver the MPC curriculum.
45674074|NCT04775069|Biological|AZD1222|Intramuscular injection
45990941|NCT02949791|Procedure|Cytoreductive surgery|Maximal surgical effort to obtain a minimal residual disease of less than 2.5 mm
45990942|NCT02949791|Other|Low Intra abdominal pressure HIPEC|Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 8-12 mmHg
45990943|NCT02949791|Other|High Intra abdominal pressure HIPEC|Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 18-22 mmHg
45990944|NCT02941107|Drug|Rotarix (RV1)|ROTARIX™ (RV1) is a live-attenuated human monovalent oral vaccine containing attenuated G1P[8] human rotavirus strain sponsored and distributed in Australia by GlaxoSmithKline Biologicals where it is licensed for the prevention of rotavirus gastroenteritis.
45990945|NCT02941107|Drug|Placebo|The placebo for this trial will be Viscosweet, a clear and flavoured solution used as a pharmaceutical excipient repackaged into a labelled syringe identical to the active and firmly sealed with an end cap.
45990946|NCT02949713|Behavioral|Text messaging-motivational interviewing|Interactive weekly mobile phone text messaging plus prospective motivational interviews
45990947|NCT00518219|Drug|TW|TW,120mg/d
45990948|NCT00516854|Drug|chlordiazepoxide 5 mg, clidinium 2.5 mg, twice daily|
45990949|NCT04694729|Other|videoconference-based|Exercises will be done 3 days a week for 6 weeks, with the help of a physiotherapist via video conference.
45990950|NCT04694729|Other|video-based|The exercise video will be sent to the patients and they will do it 3 days a week for 6 weeks. The subjects will be asked to keep an exercise diary and the status of the diaries will be followed by calling once a week.
45990951|NCT05318742|Procedure|laser|Endolaser photocoagulation during PPV
45674075|NCT02623205|Drug|Escitalopram|Participants randomized to the escitalopram group will be given the medication for 8 weeks, after which they will be given the option to continue for 4 more weeks if they are close to remission. This additional 4-week treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
45674076|NCT02623205|Drug|Placebo|To reduce the burden of the patients on placebo, the placebo trial will have a target of 8 weeks. To provide an opportunity for placebo non-responders to receive active drug and to aid in recruitment, we will provide 8-12 weeks of SSRI treatment to placebo non-responders. This treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
45674077|NCT01500694|Drug|Extended-release Guanfacine HCl (Intuniv, SPD503)|Subjects will be dosed orally once-daily in the AM at 1, 2, 3, 4, 5, 6, or 7 mg according to subjects weight and age
45990952|NCT02949869|Other|Spinal Sonography|As described previously
45990953|NCT02940990|Radiation|SBRT concurrent with GM-CSF|SBRT and GM-CSF 125ug/m2 for 14 days
45990954|NCT02940990|Drug|two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel|two-drug regimen
46083965|NCT04227236|Other|In-person facilitator training for Making Proud Choices|Participants complete the Making Proud Choices (MPC) facilitator training using the standard in-person training method. Making Proud Choices! (MPC) is an evidence-based pregnancy and HIV/STI risk-reduction program for youth. The facilitator training prepares educators to effectively deliver the MPC curriculum.
45674078|NCT04188977|Other|Usual Practice|OTP Directors are able to ask their state health officials permission to use interim methadone treatment. The state officials are in turn able to ask officials from the Center of Substance Abuse Treatment for permission to provide interim methadone treatment.
45990955|NCT00518297|Drug|Raltegravir|Tablet, Oral, 400 mg, twice daily for 5 Days
45990956|NCT00518297|Drug|Atazanavir|Capsule, Oral, 300 mg, twice daily for 7 Days
45990957|NCT00518297|Drug|Atazanavir + Raltegravir|Capsule/Tablet, Oral, 300/400, twice daily for 14 Days
45990958|NCT05240742|Other|no intervention, the CORFU study conducts analyses based on data which has been prospectively collected (and aggregated when possible) in 7 existing cohorts|(Clinical) baseline and follow-up data will be collected in the 7 existing cohorts. These data will be aggregated (when possible). The CORFU analyses will be conducted based on the aggregated data.
45990959|NCT00518375|Drug|Rapamune® (Sirolimus)|
45990960|NCT00518375|Drug|Neoral® (Cyclosporine)|
45990961|NCT00518375|Drug|Corticosteroids|Left up to local practice but steroids are typically used perioperatively
45990962|NCT04691583|Other|Fast diet|"Fast diet of High control ：From May 24, 2018, the method of fast diet was adopted on alternate days. According to the dietary records of normal diet, the normal caloric intake of each subject was calculated. Fast diet was carried out according to 2/3, 1/2, 1/3 and 1/4 of the original normal caloric intake.Each caloric stage last for 4 days, and the total cycle of fast diet was 31 days.~Fast diet of Low control ：After the intervention of fast diet of high control, the subjects were allowed to continue the diet fast diet every other day. It was suggested that the daily caloric intake was 600kal/ day for males and 500kal/ day for females."
45990963|NCT00518414|Other|Marketed infant formula with DHA and ARA|
45990964|NCT00518414|Other|Milk-based infant formula with DHA and ARA|
45990965|NCT00518414|Other|Milk-based formula with DHA, ARA, prebiotics|
45990966|NCT02277015|Device|Miller Laryngoscope|Direct Laryngoscopy
45990967|NCT02277015|Device|The Berci-Kaplan DCI|Videolaryngoscope-1
45990968|NCT02277015|Device|The AirTraq|Videolaryngoscope-2
45990969|NCT02277015|Device|GlideScope GVL|Videolaryngoscope-3
45990970|NCT02277015|Device|The Pentax AWS|Videolaryngoscope-4
45990971|NCT02942199|Other|MySafeRx|The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser (i.e., MedicaSafe 3000), and a standardized protocol for supervising self-administration of medication via videoconferencing.
45990972|NCT00518453|Biological|Surface antigen inactivated influenza vaccine|1 dose of Fluvirin 2007/2008 Northern Hemisphere vaccine composition
45990973|NCT05318664|Other|Cryotherapy|20 minutes of cryotherapy on the dominant shoulder with ice bags
45990974|NCT02942121|Other|LifeScience Technologies application|Application for mobile devices. The app enables users to review educational videos about a surgery and recovery from a surgery from home. It also enables the user to track different metrics specific to the user's health.
45990975|NCT02941185|Drug|Devit-3 Oral Drop|
45990976|NCT00518492|Procedure|Blood Sampling|Blood draws at 6 and 12 months following end of 6108A1-500 trial.
45990977|NCT02942043|Drug|Bevacizumab|"Group A (low dose group) Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group B (medium dose group) Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group C (high dose group) Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard."
45990978|NCT00516971|Drug|Esomeprazole 20mg once daily|
45990979|NCT02942082|Other|ACP oral care gel|a desensitizing agent will be applied on tooth before and/or after bleaching
45990980|NCT02942082|Other|glycrin|glycrin will be applied on tooth surface before and/or after bleaching
45990981|NCT00517088|Drug|IPAQ|
45674079|NCT04188977|Other|Implementation Facilitation|Implementation Facilitation (IF) will consist of educational outreach to OTP staff, identification of local champions, training, performance feedback, and learning collaborative for OTP staff and state health department officials.
45990982|NCT02939664|Device|Banded (with polypropylene mesh) gastric bypass|The patient will be submitted to a Laparoscopic Roux-en-Y banded gastric bypass at the time of the operation, with a polypropylene mesh around the gastric pouch.
45990983|NCT02939664|Procedure|Gastric bypass|In this case a simplified conventional gastric bypass will be performed
46083966|NCT00949039|Drug|Isolated pelvis perfusion|injection of TNF-α 0.3 mg followed 5 minutes later by melphalan 1,5mg/kg
46083967|NCT00949039|Radiation|radiotherapy|chemotherapy and/or radiotherapy and/or surgery
46083968|NCT00949039|Procedure|Surgery|
46083969|NCT02710656|Device|Legflow® balloon|Percutaneous angioplasty performed with a Drug coated balloon (DCB) with Paclitaxel
46083970|NCT02710656|Device|Standard PTA|Percutaneous angioplasty performed with a standard balloon
46083971|NCT00952471|Other|Evidence Based Intervention to order set|The order set was altered to include evidence based care items
45674080|NCT01500382|Drug|Vibegron|Tablet, 50 or 100 mg, once daily, for up to 10 days based on treatment assignments and treatment period.
45674081|NCT01500382|Drug|Tolterodine ER|Capsule, 4 mg, once daily, for up to 10 days based on treatment assignment and treatment period.
45674082|NCT01500382|Other|Placebo (vibegron)|Inactive agent in tablet form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
46083972|NCT02778698|Dietary Supplement|Omegaven|
46083973|NCT04227392|Device|vaginal radiofrequency|2 sessions of vaginal radiofrequency therapy with 3 week interval. A session last 20 minutes.
46083974|NCT00952549|Procedure|Facial Yoga Toning Program|Patients will be instructed on 18 exercises which are intended to strengthen and tone the muscles of facial expression. DVD is provided.
46083975|NCT02710500|Drug|rAAVrh74.MHCK7.DYSF.DV|Biological/Vaccine: rAAVrh74.MHCK7.DYSF.DV Recombinant adeno-associated virus carrying a dysferlin transgene under control of a muscle specific MHCK7 promoter.
46083976|NCT02781038|Behavioral|Teaching intervention|Subjects will receive a pamphlet which describes the relationship between smoking and negative outcomes in fracture healing.
45674083|NCT01500382|Other|Placebo (tolterodine ER)|Inactive agent in capsule form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
45990984|NCT00518570|Drug|Levetiracetam|Levetiracetam was started at 250 mg qhs at the end of the first week of the follicular phase. Dose was gradually increased up to 1500 mg bid as tolerated or clinically effective. The treatment phase lasted 4 months.
45990985|NCT05190588|Other|Mesotherapy|Mesotherapy (MT) Sterile and disposable (0.26mm × 4mm and 0.3mm × 13 mm, Terumo) will be used. Patients will receive 2 ml of 2% lidocaine, 2 ml of pentoxifylline and will be used. Injection techniques (IDP=2-4 MM) AND (IDS=1-2 MM) will be used.
45990986|NCT02939586|Procedure|Haemodiafiltration post-dilution model|Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months, 1 month wash-out (HD) and cross-over to the other dialysis model- eg. HDF (2months) and switch to HD for 2 months, with 1 month washout period (using standard HD). Haemodialysis post-dilution model will be delivered using fresenius 5008 machine. Prescription for HDF post-dilution will be comparable to HD.
45990987|NCT02939586|Procedure|Haemodialysis|Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months and cross-over to the other dialysis model- eg. HD (2months) and switch to HDF for 2 months, with 1 month washout period (using standard HD). Haemodialysis treatment will be delivered using fresenius 5008 machine. treatment time/parameters may vary depends on individual prescription.
45990988|NCT00517127|Drug|Lactated Ringer's Solution|Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
45990989|NCT00517127|Drug|Hydroxyethylstarch 6% 130/0.4|Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
45990990|NCT05174130|Device|RESPIRA device.com® Advanced|Ventilation of patients with continuous monitoring of the patient's clinical parameters and the parameters that the investigational medical device shows.
45990991|NCT00518648|Other|Multifactorial fall prevention program|Individualised multifactorial fall prevention program containing PD-specific elements as well as generic elements
45990992|NCT00518648|Other|Usual care|Usual care
46083977|NCT02781038|Behavioral|Control|Subjects in this group will not receive the pamphlet
45990993|NCT03458208|Drug|Metformin|"First aIntervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition"
45990994|NCT03458208|Drug|Glucophage®|"Second Intervention Period:~Single administered dose of Glucophage® (1 000 mg tablet immediate release) in a fasting condition"
45990995|NCT03458208|Drug|Metformin|"Third Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
45990996|NCT03458208|Drug|Glucophage®|"Fourth Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
45990997|NCT00517166|Device|CAT (Combat Arms Tourniquet)|device
45990998|NCT02939625|Device|muscle training|
45990999|NCT02939625|Device|Continue Positive Airway Pressure|
45991000|NCT02939625|Device|bilevel positive airway pressure|
45991001|NCT00517205|Procedure|Non-contrast helical computerized tomogram (NCHCT)|
45991002|NCT00517283|Drug|exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 3 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
45991003|NCT00517283|Drug|Exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 2 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
46083978|NCT02710578|Drug|Alcohol|A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol (Vodka) to tonic water to obtain a target BAC of 0.08mg%
46083979|NCT02710578|Drug|Placebo|A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
46083980|NCT00940849|Dietary Supplement|Plant sterol containing drink|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
45991004|NCT00517283|Drug|Exenatide and placebo|Period 1 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
46083981|NCT00940849|Dietary Supplement|Standard macaroni meal|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
45456908|NCT03874897|Drug|CAR-CLDN18.2 T-Cells|"Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~• Chimeric Antigen Receptor T Cells Targeting Claudin18.2"
45456909|NCT03874897|Drug|PD-1 Monoclonal Antibody|Chimeric Antigen Receptor T Cells Targeting Claudin18.2 with PD-1
45456910|NCT03874897|Drug|Chemotherapy|First-line systemic therapy according to physician's choice
46083982|NCT02780882|Drug|Pasireotide|
46083983|NCT02710266|Drug|Preoperative Gabexate Mesilate group|Gabexate Mesilate is administered from the preoperative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.
45456911|NCT02294188|Device|Spatial Repellent product with active ingredient (SHIELD)|Spatial Repellent Product
45456912|NCT02294188|Device|Active ingredient|Transfluthrin (Active ingredient)
45456913|NCT02294188|Device|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
45991005|NCT02940912|Drug|Apomorphine|cross-over with start with Apokinon in the 1st phase- in the 2nd phase of continuous treatment with Physiologic Serum.
45991006|NCT02940912|Drug|Placebo|cross-over with start with.Physiologic Serum in the 1st phase- in the 2nd phase of continuous treatment with Apokinon.
45991007|NCT00518726|Biological|Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008|seasonal influenza vaccine 15ug
45991008|NCT02941029|Other|Plasma Blood collection|Plasma blood collection is collected at specific intervals prior to and during radiation treatment.
45991009|NCT03459053|Behavioral|CBART|Cognitive Behavioral protocol that uses art-making for stress reduction and cognitive interventions
45991010|NCT02940795|Other|Coke|Patients were given a 20 ounce bottle of Coke Cola.
45991011|NCT02940795|Other|Diet Rite|Patients were given a 12 ounce can of Diet Rite.
45991012|NCT00517322|Drug|ramipril|ramipril 2.5- 5 mg once daily
45991013|NCT00517322|Drug|irbesartan|irbesartan 150-300 mg once daily
45991014|NCT02939430|Drug|Sugammadex intravenous|Intravenous Injection of sugammadex (2 mg/kg) for reversal of rocuronium induced muscle relaxation
45456914|NCT01127035|Biological|sublingual immunotherapy|
45456915|NCT01127035|Biological|placebo|
45456916|NCT03520816|Other|Burn Physiotherapy Protocol|It consisted of parameters such as early mobilisation and ambulatory training, chest physiotherapy, and both active and passive normal joint movement exercises.
45991015|NCT02939430|Drug|Intravenous neostigmine and atropine|
46083984|NCT02710266|Drug|Intraoperative Gabexate Mesilate group|Gabexate Mesilate is administered from the operative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.
46083985|NCT02710266|Drug|hepatectomy with dextrose water|Gabexate Mesilate is not administered. As placebo, 500cc of 5% dextrose water is administered at 40cc/hr for 12 hours
45456917|NCT01127113|Other|Infusion of investigational product|The investigational product will be delivered via intravenous infusion
45456918|NCT01127113|Other|Cardiac magnetic resonance imaging|Cardiac MRI will be performed prior to infusion of investigational product and 1, 2, 7 and 30 days after.
45991016|NCT00517400|Device|Deep repetitive Transcranial Magnetic Stimulation (rTMS) real or sham|
45991017|NCT02940717|Other|Vita suprinity|New glass ceramic material
45991018|NCT02940717|Other|Emax CAD|standard etchable glass ceramic used for laminate venneers
45991019|NCT00518765|Drug|Aliskiren|
45456919|NCT02294266|Drug|Mephedrone and alcohol|"Single oral dose mephedrone~Single oral dose alcohol"
45991020|NCT00518765|Drug|Aliskiren plus placebo|
45991021|NCT00518765|Drug|Aliskiren|
45674084|NCT01500382|Drug|Prophylactic Antibiotic|A pre-procedural prophylactic antibiotic (ie, levofloxacin 250 mg, cephalexin) administered orally, 30 minutes prior to each scheduled urodynamic study intervention. It is up to the discretion of the Investigator, based on study protocol recommendations, as to which type of antibiotic may be administered.
45991022|NCT00518765|Drug|Aliskiren plus placebo|
45991023|NCT02939469|Other|Physiologic maneuvers|"Subjects will perform~Valsalva maneuver Hand Grip Post exercise cuff occlusion Loud Noise and Skin pinch"
45991024|NCT00517478|Procedure|Blood Sample|
45991025|NCT02939391|Drug|KW-6356|Oral administration
45991026|NCT02939391|Drug|KW-6356|Oral administration
45991027|NCT02939391|Drug|Placebo|Oral administration
45991028|NCT00518804|Behavioral|Functional Behavioural Skills Group and Parent Training|
45991029|NCT02940873|Behavioral|HARPdoc courses|A six week group education package including hypoglycaemia-focussed cognitive behavioural therapy
45991030|NCT02940873|Behavioral|BGAT courses|A structured psycho-education programme focussing on better prediction and recognition of high and low blood glucose values
45991031|NCT00517517|Biological|Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation|Subjects will be randomized 1:1 to receive two intramuscular injections of the whole virion, Vero cell-derived influenza vaccine containing either 3.75 mg or 7.5 mg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation on Day 0 and Day 21.
45991032|NCT02939352|Device|Real continuous Theta Burst Stimulation|Continuous Theta Burst stimulation delivered
45991033|NCT02939352|Device|Sham continuous Theta Burst Stimulation|active sham Continuous Theta Burst stimulation delivered
45674085|NCT02137837|Drug|Fulvestrant|
45991034|NCT00517673|Drug|GSK945237|
45674086|NCT02137837|Drug|Anastrozole|
45674087|NCT02137837|Drug|Everolimus|
45991035|NCT00517673|Drug|Sugar Pill|Placebo
45991036|NCT02940756|Drug|artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
45991037|NCT02940756|Drug|artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to <15 kg, two tablets twice daily for those weighing 15 to <25 kg and three tablets twice daily for those weighing 25 to < 35 kg, for three days."
45991038|NCT02940756|Drug|Dihydroartemisinine-piperaquine|Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine. Half a tablet once daily for children weighing 5 to <7 kg, one tablet once daily for those weighing 7 to <13 kg, and two tablets once daily for those weighing 13 to <24 kg, for three days.
45991039|NCT02949245|Procedure|Interventions|"Procedure/Surgery: Routinely performed surgical correction of spinal deformity~Routinely performed surgical correction of spinal deformity"
46083986|NCT04229576|Device|TENs|Assessing the efficacy of TENs in pain relieve during office hysteroscopy .
45456920|NCT02294266|Drug|Mephedrone|Single oral dose mephedrone
45456921|NCT02294266|Drug|Alcohol|Single oral dose alcohol
45456922|NCT02294266|Drug|Placebo|Single oral dose placebo
45456923|NCT01227733|Other|Breast Tumor Blocks|
45674088|NCT02137837|Drug|Placebo - Anastrozole|
45674089|NCT02137837|Drug|Placebo - Everolimus|
45991040|NCT02939547|Drug|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick Disease C1 ( NPC1)
45991041|NCT02949167|Behavioral|MyHealth|The MyHealth intervention is a nurse-led individually tailored symptom management program, focused on patient education and regularly collection of Patient Reported Outcomes (PRO) subsequently evaluated by specialist nurses and navigation to health care service. The nurse will meet with the patient on three-five planned appointments focused on adjustment of life after breast cancer treatment including information on symptoms of relapse or late effects and how to react on these. Close relatives are invited if patients accept. Patients will report PRO´s on symptoms of recurrence and late effects every three months during the first year and thereafter every six months.The appointments with the nurse are finalized within 3-6 month and patients will be followed with PRO for three years.
45991042|NCT02941068|Drug|fluconazole and caspofungin|
45991043|NCT00517712|Drug|Single agent arsenic trioxide|duration of maintenance therapy, 6 months versus 12 months
45991044|NCT00518843|Behavioral|FBT-BN|Mobilizing parents to curtail binge eating and purging
45991045|NCT00518843|Behavioral|SPT|Supportive the individual patient to explore factors that might underlie the eating disorder
45991046|NCT00517907|Drug|Preimplantation factor (PIF-1)|"The study will include 6 patients and will last for at least six months. The first three patients will receive PIF-1 (0.5 mg/kg/day for 14 days) by subcutaneous injection. The dosage in the next three patients may be increased to 1 mg/kg/day for 14 days.~Patients will be treated serially: each patient will be followed for 2 weeks after cessation of PIF-1 administration before the next patient begins PIF-1 administration."
45991047|NCT02939274|Drug|Verteporfin|
45991048|NCT02939274|Device|Continuous Low-Irradiance Photodynamic Therapy (CLIPT)|
45991049|NCT00518921|Drug|Capadenoson (BAY 68-4986)|1mg Capadenoson, double dummy
45991050|NCT00518921|Drug|Capadenoson (BAY 68-4986)|2mg Capadenoson, double dummy
45991051|NCT00518921|Drug|Capadenoson (BAY 68-4986)|4mg Capadenoson, double dummy
45991052|NCT00518921|Drug|Placebo|Placebo, double dummy
45991053|NCT02940678|Other|No intervention|
46083987|NCT00612846|Procedure|Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy|Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy
45991054|NCT04694183|Drug|Paclitaxel + S-1 + anti-PD-1 antibody (Peritoneal metastasis)|"Drug：Paclitaxel~50mg/m², intravenous drip administration, d1, d8, q3w.~Drug：Paclitaxel~20mg/m², intraperitoneal administration, d1, d8, q3w.~Drug:S-1~Oral, d1-14, q3w.~Drug:Camrelizumab~200mg，Intravenous drip administration, d1, q3w."
45991055|NCT04694183|Drug|SOX regimen + anti-PD-1 antibody (Liver metastasis, para-aortic lymph node metastasis )|"Drug:Oxaliplatin~Injection: 130mg/m² intravenous drip administration, d1, q3w.~Drug:S-1~Oral, d1-14, q3w.~Drug:Camrelizumab~200mg，Intravenous drip administration, d1, q3w."
45991056|NCT00516659|Biological|Heat-Labile Enterotoxin of Escherichia coli (LT)|Subjects in Group 1 will receive two vaccinations of a patch containing 37.5µg LT 2 to 3 weeks apart.
45991057|NCT00516659|Biological|Placebo|The placebo patch contains all of the components of the active patch, but with no LT included in the formulation.
45991058|NCT00518960|Drug|ProAlgaZyme|
45833688|NCT03278340|Behavioral|Sun Safe Workplaces -In Person|After randomization, program staff will contact managers the recruited employer and schedule the initial in-person visit in the first 6 months. Follow-up meetings will be scheduled as needed to discuss policy adoption; managers will schedule employee education with SSW-IP project staff. Printed materials will be sent to SSW-IP employers 3 times during the intervention. Staff will follow-up with managers through Month 34 (Wave 1) or Month 46 (Wave 2).
45991059|NCT02940600|Device|Normothermic machine perfusion|Patients undergoing liver transplant with the use of grafts preserved with normothermic perfusion machine
45991060|NCT02940600|Procedure|Static cold storage|Patients undergoing liver transplant using statically cold preserved grafts
45991061|NCT02949401|Behavioral|Use of Virtual Reality App|The VR app will consist of relaxation techniques as well as a virtual tour of the hospital (pre-op area, IV placement, cath lab, and post-op area).
45991062|NCT03458091|Device|THRIVE|Oxygenation during apnea using transversal humidified oxygen
45991063|NCT03458091|Device|Endotracheal intubation|Ventilation during the procedure is governed by an endotracheal tube in the trachea and mechanical ventilation
45833689|NCT04344678|Drug|Sildenafil Citrate|Esitalopram 20 mg tablet plus Sildenafil Citrate 50 mg tablet once daily
45833690|NCT04344678|Drug|Placebo oral tablet|Esitalopram 20 mg tablet plus placebo tablet once daily
45991064|NCT04694144|Device|telescoping intramedullary nail|All osteogenesis imperfecta patients with lower limb skeletal deformities corrected with multiple corrective osteotomies and insertion of two parts male and female segments of intramedullary telescoping nail
46083988|NCT00612846|Procedure|Laparoscopic bile duct exploration during cholecystectomy|Laparoscopic bile duct exploration during cholecystectomy
46083989|NCT04181450|Other|Determination of the Cut-off Scores of Biodex Balance System|Based on the findings of the Sherafat et al. (Sherafat, S., Salavati, M., Takamjani, I. E., Akhbari, B., Mohammadirad, S., Mazaheri, M., & Negahban, H. (2013). Intrasession and intersession reliability of postural control in participants with and without nonspecific low back pain using the Biodex Balance System. Journal of manipulative and physiological therapeutics, 36(2), 111-118.) related to intrasession and intersession reliability of BBS in patients with NSLBP12, in the present study, one stability level (Level 5; ICC ≥0.70) and two conditions (eyes-open and eyes-closed) will be selected as testing procedure. All postural assessments will be performed during bilateral stance for a period of 30 seconds.
46083990|NCT04104126|Other|Standard of Care Physical Therapy|Will receive standard of care physical therapy
45991065|NCT00517946|Drug|pseudoephedrine hydrochloride|
45991066|NCT00517946|Drug|cetirizine hydrochloride|
45991067|NCT04988685|Device|Sirolimus Eluting Balloon|PTCA with either a Sirolimus eluting balloon or Paclitaxel eluting balloon
45991068|NCT00517985|Drug|Duloxetine|During the current study, for a short period of time participants will receive a placebo (a pill that looks like the study drug but which does not contain any medication), although during the majority of the study, participants will be receiving the actual study medication (Duloxetine). The initial dose of Duloxetine to be given will be a 30 mg dose with the dosage increased over time to 60 mg per day. This study will be blinded, meaning that participants will not know whether they are taking placebo or the study drug. However, all subjects will receive duloxetine for the majority of the time they are enrolled in the trial. Investigators will know when subjects are receiving the placebo but in order to maintain the blinding of this study, the study staff will not be able to tell participants when they are taking placebo and when they are taking Duloxetine.
45991069|NCT04690920|Drug|Tocilizumab|Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls
45833691|NCT03212118|Behavioral|Treatment as usual (TAU-0)|"The standard NAV procedure, which consists of a telephone call within 8 weeks to an employer who have employees on 100% sick leave, in addition to regular NAV conversations on-demand (not fixed intervals) between the NAV caseworkers and the employees."
45833692|NCT03212118|Behavioral|Structured talks (TAU-2)|Two structured talks (not including elements from motivational interviewing)
45833693|NCT03212118|Behavioral|motivational interviewing (MI)|Two structured talks (must have a valid motivational interviewing content).
45833694|NCT04056312|Behavioral|Group Memory retraining exercises|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
45833695|NCT04056312|Behavioral|Placebo controlled group memory exercise training|Placebo group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
45991070|NCT00519038|Other|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period with the aim to enhance the quality of care by improving patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources. They are also developed by multi-professional teams
45991071|NCT00519038|Other|Usual Care|Usual care is the current practice actually performed in the hospital
45991072|NCT04691895|Other|SARS-CoV2 infection|Confirmed COVID19 cases The definitions of COVID19 state are according to the WHO document released in March 2020. A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.
45991073|NCT00518024|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|Bilateral Theta Burst Stimulation
45991074|NCT02939508|Other|Colon originated: Neostigmin, Colonoscopy decompression, Surgery|
45991075|NCT02939508|Other|Non-colon originated: Neostigmin, Colonoscopy decompression|
45991076|NCT00518102|Drug|REGRANEX (becaplermin)|A cohort of REGRANEX (becaplermin) users (ie, patients treated with REGRANEX (becaplermin), a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).
45991077|NCT00518102|Other|REGRANEX (becaplermin) comparators|A cohort of REGRANEX (becaplermin) nonusers (ie, patients who are not treated with REGRANEX [becaplermin]) but are similar in characteristics to patients in the REGRANEX [becaplermin] user cohort)
45991078|NCT02939235|Drug|Crushed ticagrelor followed by morphine|Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
45991079|NCT02939235|Drug|Crushed ticagrelor, morphine,metoclopramide|Crushed ticagrelor (180 mg) orally followed by morphine 5 mg and metoclopramide 10 mg intravenously
45991080|NCT00518141|Drug|Acetyl Salicylic Acid and Terbutalin|ASA 75 mg, Terbutalin 5mg
46083991|NCT04104126|Other|Blood flow restriction|Blood flow restriction therapy is a blood pressure cuff placed around the desired limb with a handheld device that controls the pressure exerted by the cuff. The cuff is placed around the desired limb before a specific exercise, the physical therapist determines the appropriate pressure and time, and the patient completes the exercise as they normally would. The monitor determines the limb occlusion pressure and has an automatic timer that will deflate after the specified time has elapsed.
45674090|NCT01483690|Drug|Decitabine|10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.
45674091|NCT01483690|Drug|Vorinostat|180 mg/m2/day (Max dose=400mg daily) given orally on days 2 through 7 and days 16 through 21.
45674092|NCT01483690|Drug|Vincristine|1.5 mg/m2/day (Max dose 2 mg) given IV push on days 10, 17, 24 and 31.
45674093|NCT01483690|Drug|Dexamethasone|20 mg/m2/day divided BID given orally on days 8 through 12 and 22 through 26.
45833696|NCT03250026|Behavioral|Workplace convergence dialogue|Work place contact as a convergence dialogue between the employer and employee with the Rehab Coordinator as a guide
45833697|NCT03250026|Behavioral|Care Manager|Regular contact Care Manager during around 12 weeks
45833698|NCT03249558|Drug|Morphine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
45991081|NCT02938962|Drug|Tranexamic Acid|
45991082|NCT00519701|Drug|hydroxyurea|
45991083|NCT02939040|Behavioral|Positive Activities|"The PPB intervention involves noting at least one positive event each day, writing it down on a slip of paper and then depositing this piece of paper in a piggy bank. This practice is to take place at the end of the day, every day over a circumscribed period of time. At the end of the deposit period the participant closes the account and makes a full withdrawal by taking all of the slips out of the piggy bank and reading each one the night before surgery."
45991084|NCT00519116|Drug|Rapamune® (Sirolimus)|
45991085|NCT00519116|Drug|Tacrolimus|
45991086|NCT00519116|Drug|Perioperative Corticosteroids|The corticosteroids use was left up to the investigators decision.
45674094|NCT01483690|Drug|Mitoxantrone|10 mg/m2/day given on days 8 and 9 as a short IV infusion over 5-15 minutes; do not infuse over less than 3 minutes
45674095|NCT01483690|Drug|Pegaspargase|2500 international units/m2/day IM or IV on days 10 and 24.
45674096|NCT01483690|Drug|Methotrexate|"Given intrathecally to all patients the dose defined by age below.~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age~CNS 1 or 2 patients get doses on day 8, 22 and 35 and CNS 3 patients should get doses on day 8, 15, 22, 29 and 35"
45674097|NCT02104765|Drug|LY2951742|Administered subcutaneously.
45833699|NCT03249558|Drug|Duloxetine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
45833700|NCT03249558|Drug|Placebo|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
45833701|NCT03220776|Drug|N-Acetylcysteine|5 day trial of N-acetylcysteine with titration to 2,400mg
45991087|NCT02939157|Other|Cardiac diagnostic ultrasound|Point-of-care ultrasound for diagnosing heart failure in primary care patients
45991088|NCT00519155|Drug|MD05 and open flap debridement|recombinant human GDF-5 coated onto ß-tricalcium phosphate
45991089|NCT00519155|Procedure|Open flap debridement|Open flap debridement alone
45991090|NCT02939196|Procedure|office hysteroscopy 3.7|office hysteroscopy with a 3.7 -mm outer sheath
45991091|NCT02939196|Procedure|office hysteroscopy 4|office hysteroscopy with a4-mm outer sheath
45991092|NCT00519740|Other|inhalative specific bronchial provocation with grass-pollen|
45991093|NCT04691076|Drug|Propofol|Propofol is administered by target-controlled infusion
45991094|NCT04691076|Drug|Esketamine|Esketamine is intravenously administrated
45991095|NCT04691076|Drug|Fentanyl|Fentanyl is intravenously administrated
45991096|NCT00519935|Behavioral|Multisystemic Therapy|MST is an individualized approach that begins with a comprehensive, multi-informant assessment that allows for the development of treatment goals and interventions that are individually tailored for each family. Therapists draw upon a menu of evidenced-based interventions that include cognitive-behavioral therapy, parent training and behavioral family systems therapy.
45991097|NCT04690842|Diagnostic Test|PTH measurements post-thyroidectomy (at 5 and 60 min post thyroid removal)|We implement an algorithm employing PTH levels post-thyroidectomy to stratify patients according to their postsurgical risk for hypoparathyroidism, and to distinctively manage them in the immediate postsurgical period. High risk patients are quickly supplemented with Calcium iv and activated 25OH vitamin D. Low risk patients are clinically controlled and calcium level were checked at 24 and 48 hs post thyroidectomy.
45991098|NCT02949323|Other|urinary stone|patients of group one have urinary stones
45991099|NCT04690959|Other|neural mobilization|Neural mobilization, or neurodynamics, is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
45991100|NCT04690959|Other|Sham intervention|it is faked neural mobilization that mimic the neural mobilization treatment but believed not to stress the neural tissues in the upper extremity.
45991101|NCT02949206|Drug|JNJ-64179375|During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.
45991102|NCT02949206|Drug|Placebo|Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).
45833702|NCT03220776|Drug|Gabapentin|5 day trial of gabapentin with titration to 1,200mg
45833703|NCT03220776|Drug|Placebo Oral Tablet|5 day trial of matched placebo
45833704|NCT04054596|Behavioral|SME|The treatment group (TX) will complete 8 sessions of SME (2 sessions per week for 4 weeks), de-signed to teach the concepts of SG, SL and RP and the application of these techniques in daily life. Sessions are approximately 30-45 minutes long.
45991103|NCT02949206|Drug|4 Factor Prothrombin Complex Concentrate (PCC)|Following a single dose of JNJ-64179375, participants will receive a single IV dose of 4 factor-PCC.
46083992|NCT00562159|Drug|Placebo|Placebo sublingual tablet
46083993|NCT00562159|Biological|SCH 697243|SCH 697243 (2800 Bioequivalent Allergen Units [BAU] of Phleum pratense extract, containing approximately 15 mcg Phl p 5), administered sublingually once daily.
45674098|NCT02104765|Drug|Placebo|Administered subcutaneously.
45674099|NCT01483144|Drug|Eflornithine|Eflornithine [250 mg tablet, three tablets (750 mg) orally once a day]
45674100|NCT01483144|Drug|Eflornithine Placebo|Eflornithine placebo [three tablets orally once a day]
45674101|NCT01483144|Drug|Sulindac 150 MG|Sulindac [one tablet orally once a day]
45674102|NCT01483144|Drug|Sulindac placebo|Sulindac placebo [one tablet orally once a day]
45833705|NCT03246828|Other|Omission of gliclazide|Participants will stop taking gliclazide for 3 days. Data from the OGTT will be compared with that prior to stopping the medication.
45991104|NCT02939001|Device|iris recognition scanner|
46083994|NCT00562159|Drug|Loratadine 10 mg Rescue Treatment|Loratadine 10 mg RediTabs tablets were dosed orally once daily as rescue medication among participants with a total symptom score ≥ 4 during the GPS.
46083995|NCT00562159|Drug|Olopatadine 0.1% Rescue Treatment|Olopatadine hydrochloride 0.1% ophthalmic solution was administered intraocularly at a dose of 1 drop in each affected eye twice daily as rescue medication for rhinoconjunctivitis, as needed.
46083996|NCT00562159|Drug|Mometasone 50 mcg Rescue Treatment|Mometasone furoate monohydrate nasal spray 50 mcg was admininstered intranasally at a dose of 2 sprays in each nostril once daily as rescue medication for rhinoconjunctivitis, as needed.
46083997|NCT00562159|Drug|Prednisone 5 mg Rescue Treatment|"Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day~(maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for rhinoconjunctivitis among participants with a total symptom score of ≥ 4 despite treatment with loratadine and mometasone furoate nasal spray."
46083998|NCT00562159|Drug|Albuterol sulfate 108 mcg|Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administed via inhalation at a dose of 2 inhalations every 4 to 6 hours, as needed, as rescue medication for asthma.
45991105|NCT02949440|Procedure|the caudal-to-cranial approach|Cutting the peritoneum along the line between the right mesocolon and retroperitoneum, enter the Toldt's space to dissect the posterior of Superior mesenteric vein and Superior mesenteric artery and their branches, and then finished the D3 dissection from caudal to cranial on both sides of the mesentery along the Superior mesenteric vein. In the end, cut the lateral ligament to mobilize the posterior space of ascending colon. This approach is called the caudal-to-cranial approach.
45991106|NCT02949440|Procedure|the medial-to-lateral approach|First, the pedicle of ileocolic vessels is identified and the mesocolon is dissected between the pedicle and the periphery of the Superior mesenteric vein to expose the second portion of the duodenum. The ileocolic vessels are then cut at their roots. The ascending mesocolon is separated from the retroperitoneal tissues, duodenum, and pancreatic head up to the hepatocolic ligament cranially. The important detail in this procedure is the wide separation between the pancreatic head and the transverse mesocolon.This approach is the medial-to-lateral(MtL) approach
45991107|NCT02938884|Device|HidrateSpark Water Bottle|HidrateSpark water bottle is a smart water bottle that glow when its time to drink water. It is run through an app on a smart phone
45991108|NCT05135052|Device|Rhenium-SCT|Rhenium-SCT irradiation device
45991109|NCT02948972|Procedure|complete surgery|complete surgery of colorectal deep infiltrating endometriosis
45991110|NCT02948972|Procedure|In vitro fertilization without surgery|IVF without endometriosis surgery
45991111|NCT05108454|Drug|Multiple micronutrient supplementation|Multiple Micronutrient Supplements (MMS) is a nutritional supplement for use during pregnancy based on United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) formulation following WHO specification. It contains 15 micronutrients including Iron and Folic Acid (IFA) at dosages that approximate the recommended dietary allowances for pregnancy.
46083999|NCT00562159|Drug|Fluticasone propionate 44 mcg|Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of two inhalations twice daily, to a maximum dose of 10 inhalations twice daily, as rescue medication for asthma among participants utilizing four or more albuterol sulfate inhalations/day for 2 days for nocturnal asthma or shortness of breath.
46084000|NCT00562159|Drug|Prednisone 5 mg|Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day (maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for asthma at the discretion of the investigator for the treatment of asthma exacerbation.
46084001|NCT02710344|Behavioral|Telehealth Program|Psychiatric telehealth program, content assigned based on diagnosis, entry to study requires psychiatric instability defined as use of emergency/high cost psychiatric services.
46084002|NCT02710110|Device|PowerLung trainer|PowerLung trainer will be utilized which has both an inspiratory and expiratory loading capacity for training. A single daily training session will consist of three sets of 10 repetitions for a total of 30 inspiratory repetitions and 30 expiratory repetitions (i.e. 60 repetitions) for 5 days a week, for 3 months.
46084003|NCT02710110|Device|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flange rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest Maximum Inspiratory Pressures (MIP) and Maximal Expiratory Pressure (MEP) used.
46084004|NCT02710110|Procedure|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
45674103|NCT01881789|Drug|Oprozomib|Extended release (ER) tablets administered orally
45674104|NCT01881789|Drug|Lenalidomide|Administered orally at a dose of 25 mg on days 1 through 21 of each 28-day cycle for a maximum of 24 cycles.
45674105|NCT01881789|Drug|Dexamethasone|Administered at 20 mg, orally, on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. After the first cycle the dose may be decreased to 10 mg/day in participants > 75 years of age, at the discretion of the investigator.
45674106|NCT01881789|Drug|Cyclophosphamide|Administered orally at 300 mg/m² (up to a maximum of 600 mg) on days 1, 8, and 15 of each 28-day cycle for a maximum of 8 cycles of therapy (approximately 8 months).
45833706|NCT04336644|Device|BodyGuardian Heart|The BodyGuardian Heart attaches to the upper chest of the patient through the use of an adhesive patch. ECG tracings are recorded continuously and sent to the linked smartphone and subsequently to a cloud server.
45991112|NCT04694222|Device|Nd:YAG laser|For LANAP, the fiber optic tip of the Nd:YAG laser (1064 nm) (Fotona Fidelis AT, USA) was used. For LLLT R24 biostimulation handpiece tip (950-μm) Nd:YAG laser (1064 nm) was used.
45676701|NCT02019602|Biological|Certolizumab Pegol|"Mothers who decided to continue on, or to start treatment with, CZP for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.~Active Substance: Certolizumab Pegol~Pharmaceutical Form: Solution for injection~Concentration: 200 mg/ml~Route of Administration: Subcutaneous Use"
45833707|NCT04746300|Procedure|Biopsy|A biopsy will be taken from metastatic tissue, which will be used for DNA sequencing
45833708|NCT04746300|Procedure|Blood sample|Blood samples will be taken for additional translational research
45676702|NCT01994876|Device|Coloplast Test 1|Coloplast Test 1 is a newly developed 1-piece convex ostomy appliance
45833709|NCT02476812|Behavioral|Positive Piggy Bank|Already noted.
45833710|NCT04316442|Biological|STI-6129|Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
45991113|NCT04690881|Behavioral|Psychodrama group psychotherapy|In order to reduce the fear of cihildbirth, pregnant women are given 90 minutes right after the training in addition to the routine pregnancy training. In the psychodrama-based pregnancy education program, fear of childbirth were assesment by sociometric measurement in order to increase the awareness of pregnant women about birth fear levels in the first week. Afterwards, they were given the opportunity to express themselves about the factors that may cause fear in pregnant women (their previous traumatic experiences, negative prejudices about childbirth, etc). The group members shared about their process in the first session and the session was ended. The session was evaluated with other researchers. In the following sessions, in order to strengthen their coping with the fear of childbirth, besides psychodrama warm-up games, the basic techniques of psychodrama, role switching, matching and mirror were used in protogonist works.
45991114|NCT00519233|Drug|AGS-1C4D4|IV
45991115|NCT02940561|Drug|Methotrexate - Amneal|"Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate, USP and are round, biconvex, yellow tablets, scored in half on one side, engraved with A above the score and 1 below"
45991116|NCT02940561|Drug|Methotrexate - DAVA|Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, yellow tablets, scored in half on one side, engraved with M above the score, and 1 below
45991117|NCT00519974|Other|counseling intervention|
46084005|NCT02710110|Procedure|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
46084006|NCT02710110|Other|Swallowing Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
46084007|NCT02710110|Device|Iowa Oral Pressure Instrument|The IOPI is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
46084008|NCT02710110|Drug|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
45674107|NCT02075203|Biological|AERAS-404|The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK & a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 & saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.
45674108|NCT02075203|Drug|Placebo|Saline
45991118|NCT00519974|Other|study of socioeconomic and demographic variables|
45991119|NCT00519974|Procedure|management of therapy complications|
45991120|NCT00519974|Procedure|psychosocial assessment and care|
45991121|NCT02940366|Drug|Pitavastatin 4 mg orally daily|Pitavastatin 4 mg orally daily for 24months
45991122|NCT02940366|Drug|Atorvastatin 20 mg orally daily|Atorvastatin 20 mg orally daily for 24months
45991123|NCT00519272|Behavioral|Questionnaire|Series of surveys to be completed at the time of diagnosis and within one month after completion of treatment, taking approximately 45 minutes each time.
46084009|NCT05284292|Device|GUARDIAN platform|The enrolled elderly subjects and their caregivers will use at home the GUARDIAN platform consists of the Senior App, the Caregiver App and the Misty II robot.
46084010|NCT00949195|Other|Measure pulmonary artery pressure change during exercise|Semi-supine echocardiography test
46084011|NCT00949195|Other|Pulmonary pressure response during exercise|Semi-supine echocardiography test
46084012|NCT05264454|Device|high flow nasal cannulae|The plan is to examine the effects of the size of the IVC size based upon varrying levels of high flow nasal cannulae flow
46084013|NCT04936646|Device|RepetitiveTranscranial Magnetic Stimulation (rTMS)|The rTMS protocol consist of one session per day for five days during the first week, then three sessions the second week and then one session the third week, followed by two monthly sessions.
46084014|NCT00952627|Dietary Supplement|Pycnogenol|50 mg tablet, 200 mg/day, 4 tablets/day
46084015|NCT00952627|Dietary Supplement|Placebo|
46084016|NCT02710188|Drug|HTL0009936 modified release|HTL0009936 modified release
46084017|NCT02710188|Drug|HTL0009936 immediate release|HTL0009936 immediate release
45676703|NCT01994876|Device|Coloplast Test 2|Coloplast Test 2 is a newly developed 1-piece convex ostomy appliance
45676704|NCT04696718|Dietary Supplement|daily supplementation|the patients will consume 1 pill of probiotic each day for 28 days per treatments each treatment is separated by a wash out period of 21 days
45991124|NCT02940405|Drug|Ketorolac Tromethamine|A 10 mg tablet of the medication will be given one hour before starting the root canal treatment
45991125|NCT02940405|Drug|Placebo|The placebo given as a tablet one hour before staring the root canal treatment
45991126|NCT02940444|Drug|Heparin|
46084018|NCT04011709|Combination Product|VR647 Inhalation System + VR647 Smart Card 3 Secs|3 attempts of 19 inhalations, 3 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
46084019|NCT04011709|Combination Product|VR647 Inhalation System + VR647 Smart Card 2 Secs|3 attempts of 28 inhalations, 2 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
46084020|NCT04011709|Combination Product|VR647 Inhalation System + VR647 Smart Card 4 Secs|3 attempts of 14 inhalations, 4 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
45674109|NCT02075203|Biological|Bacillus Calmette-Guérin (BCG)|BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).
46084021|NCT04862832|Other|Music intervention|"The cold pressor test will consist in the immersion of the participants' arm in 10 degrees circulating water for two minutes.~The music sequences will be all 20 minutes, instrumental, professionally recorded in the studio and composed specifically for the Music Care application and are thus unfamiliar to participants. There will be two music conditions: the most-liked-music (MLM) and least-liked-music (LLM) conditions."
45456924|NCT03521440|Behavioral|Psychomotor Massage|Sessions will be conducted by a graduated therapist, experienced in Psychomotor Massage and weekly supervised by a specialist in this therapeutic approach. The Psychomotor Massage involves smoothly touching the head, upper and lower limbs, followed by micro-stretching and slow mobilisations of upper and lower limbs.
45456925|NCT03521440|Behavioral|Progressive Muscle Relaxation|Sessions will be conducted by a graduated therapist, experienced in Progressive Muscle Relaxation, and weekly supervised by a specialist in this therapeutic approach. The Progressive Muscle Relaxation protocol consists in tensing and releasing 16 muscle groups for several seconds, following a specific order.
45456926|NCT03926767|Other|Pain Neuroscience Education (PNE)|A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 30 minutes each. The intervention program will be divided into 17 thematic topics according to Explain Pain.
45456927|NCT03926767|Other|Orofacial Manual Therapy|A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. The manual therapy techniques will be: Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.
45456928|NCT03926767|Other|Orofacial Exercises|Two mandibular exercises: Mandibular body-condylar cross-pressure chewing technique and Post-isometric relaxation stretches-laterotrusion and opening. Each exercise will be executed 10 times per session for 10 seconds.
45674110|NCT01892163|Device|Ozurdex|Dexamethasone implant (Ozurdex)
45991127|NCT00520052|Drug|zoledronic acid|5 doses of 4mg iv given 3 monthly over one year (as infusion over 15 mins in 100 mls normal saline)
45991128|NCT04690647|Other|Opioid and non opioid postoperative analgesia.|Postoperative analgesia will be based on opioid and non opioid analgesics according to standardised protocol.
45991129|NCT04690647|Other|Fascia iliaca compartment block|Ultrasound guided suprainguinal fascia iliaca compartment block will be performed using 0.375% ropivacaine and 5ug/ml adrenaline according to standardised protocol.
45991130|NCT04690647|Drug|Dexamethasone|Dexamethasone will be administered preoperatively in a dose of 0,1 mg/kg.
45991131|NCT00519311|Behavioral|Health Intervention Package|CHAP and Ask Diary
46084022|NCT00952783|Drug|Lesion count|Lesion count in area treated by study drug in a prior study over a 12 month period No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
45674111|NCT01881009|Device|Hybrid Closed-loop System|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter, PID-IFB (proportional-integral-derivative based with insulin feedback) algorithm on an Android platform with remote monitoring.
45674112|NCT01881009|Device|Sensor-augmented pump|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter.
45674113|NCT01500226|Drug|Rolapitant|(4 X 50 mg capsule) 200 mg PO
45674114|NCT01500226|Drug|Granisetron|2 mg PO
45674115|NCT01500226|Drug|Dexamethasone|20 mg PO
45674116|NCT01500226|Drug|Placebo|(4 X 0 mg capsules) 0 mg PO
45676705|NCT02040428|Biological|EVARREST™ Fibrin Sealant Patch|
45676706|NCT02040428|Biological|Topical hemostat|
45991132|NCT02938845|Behavioral|Spielberger's State-Trait Anxiety Inventory(STAI )|State anxiety (STAI-S) refers to a temporary emotional state related to a specific situation, whereas trait anxiety (STAI-T) represents anxiety as a relatively stable personality character. Each scale has values ranging from 20 to 80, with higher scores representing more severe anxiety. The STAI has no established categories, but a cutoff score of 40 has been used to identify patients with high/very high anxiety. The validity and reliability of the Turkish versions of these instruments have been validated.
45991133|NCT02938845|Procedure|total laparoscopic hysterectomy(TLH)|
45991134|NCT02938845|Procedure|total abdominal hysterectomy(TAH)|
45991135|NCT00519350|Procedure|Blood collection|In arterial or venous lines already present, small amounts of blood will be collected at certain timepoints following operation
46084023|NCT02779712|Procedure|Remote ischaemic conditioning|1 dose (=4 cycles) of intermittent upper limb ischaemia (1 cycle = 5minutes inflation to 20mmHg above systolic BP, 5 minutes deflation). Dose escalation: (i) Recruits 1-20 receive this cycle once (ii) Recruits 21-40 receive a second dose of 4-cycles one hour after the first. (iii) Recruits 41-60 receive further dosing, twice daily until day 4.
46084024|NCT02779712|Procedure|Sham|4 cycles of intermittent sham procedure (1 cycle = 5 minutes inflation to 30 mmHg, 5 minutes deflation), matching the dose escalation described in the intervention
46084025|NCT00611676|Drug|Venlafaxine|Weeks 0-2: placebo. Weeks 2-3: 75 mg Venlafaxine. Weeks 3-4: 150 mg Venlafaxine. Weeks 4-12: 150-225 mg Venlafaxine.
45676707|NCT02018822|Device|urethane dimethacrylate|Experimental urethane dimethacrylate resin based composite resin for teeth used with prime and Bond Elect bonding agent
45676708|NCT02018822|Device|TPH3|light-cured resin composite for teeth
45833711|NCT02295306|Device|Respiratory Volume Monitor (RVM, ExSpiron)|Connecting patient to the ExSpiron monitor and continuous ExSpiron data collection during the patient's polysomnography (PSG)
45833712|NCT03175302|Behavioral|digital cognitive testing|The digital testing is hypothesized to identify latent features for differentiating cognitively impaired presurgical patient subgroups
45833713|NCT03175224|Drug|APL-101 Oral Capsules|"Phase 1 Subjects will be assigned to a dose level of APL-101 in the order of study entry. Treatment includes 28-day cycles at four planned dose levels (100mg, 200mg, 300mg and 400mg). Each treatment cycle is administered by daily oral capsules taken every 12 hours.~Phase 2 Subjects will be given 400mg daily dose (200mg BID) of APL-101 capsules."
45991136|NCT00519467|Drug|Chlorproguanil-dapsone-artesunate (CDA)|
45991137|NCT02940483|Drug|5-Azacytidine|5-Azacytidine 10 mg into the fourth ventricle of the brain via the Ommaya reservoir 1 day a week for 12 weeks.
45991138|NCT04974684|Device|HeartMate 3|Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.
45991139|NCT04974684|Drug|Apixaban|Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.
45991140|NCT00520091|Drug|CPT- 11|65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
45991141|NCT00520091|Drug|Cisplatin|Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
45991142|NCT00520091|Drug|Celecoxib|400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin
45991143|NCT00520091|Radiation|Radiation|4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
45991144|NCT00520091|Procedure|Surgery|Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
45991145|NCT05095623|Other|Natural History Observation|This is a natural history study.
45991146|NCT00520169|Drug|intranasal ketamine|A randomized, open label, single center, single-dose study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30mg in healthy adult volunteers. The Pilot Phase will be conducted as a parallel study, while the Test Phase will be conducted as a crossover study.
45991147|NCT00519506|Other|ThromboView|Radiopharmaceutical, single dose, of the diagnosis of venous thromboembolism
45991148|NCT02938533|Behavioral|Intervention|The intervention includes a clinic-based component and a take-home component. All components include the priming image of a Baobab tree. The clinic-based component is an interactive poster that rewarded appointment attendance. Patients who attend three consecutive on-time visits are congratulated and given a colored sticker to place on a poster that is publicly displayed at the clinic. In one clinic, the take-home component is a 2015 calendar in Kiswahili that contained the priming Baobab image. In the other clinic, the take-home component is a small plastic pillbox featuring the Baobab logo.
46002326|NCT03747146|Device|Adductor Canal block with sham catheter|Adductor canal block (ACB) will be administered. At the end of the case or in the PACU, a catheter will be inserted and affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
45991149|NCT00520208|Drug|Tamibarotene|For induction therapy, tamibarotene will be self-administered via tablets on an outpatient basis at a dose of 6 mg/m2 per day, taken orally, in two divided doses approximately one hour after breakfast and dinner. Induction therapy will continue for a maximum of 56 days until either a morphologic leukemia-free state or complete response (CR) has been achieved. For patients who achieve a CR with induction therapy, consolidation therapy will commence 4 to 8 weeks after the end of induction therapy. For patients who have a morphologic leukemia-free state after induction therapy but who fail to achieve a CR, consolidation therapy will commence 8 weeks after the end of induction therapy.
46084026|NCT05279378|Radiation|lung ultrasonography versus CT|"chest CT will be done before admission and LUS within first 24 h from admission into the quarantine sector. In addition to 2 weeks after admission.~CT images will be reviewed by chest radiologist expert, who will calculate a CT severity score based on extension and distribution of GGOs and consolidations.~All CT scans will be performed in supine position at end inspiration without intravenous administration of contrast media.~Within 24 h from admission and CT scanning, bedside LUS will be performed by clinician who will be blind to chest CT findings.~Examinations will be performed with the patient in the sitting position, systematically scanning the front and the back side of each hemithorax.~Blood sample will be collected into 4 mL Vacuette containing EDTA. Samples will be stored on ice, processed within 30 min and plasma will be isolated by centrifugation at 2000g for 20 min at 4 °C. Plasma will be immediately frozen at - 80 °C in several aliquots."
46084027|NCT00949273|Procedure|cylindrical abdominoperineal resection|Extended abdominoperineal resection with human acellular dermal matrix reconstruction of the pelvic floor for rectal cancer
45991150|NCT00520247|Drug|enalapril plus folic acid|enalapril 10.0 mg daily for 8 weeks (the control group); enalapril 10.0 mg plus folic acid 0.4 mg daily for 8 weeks (Low-dose group); enalapril 10.0 mg plus folic acid 0.8 mg daily for 8 weeks (High-dose group)
45991151|NCT00519545|Behavioral|Prayer|Data collection on physiological biomarkers
45991152|NCT02949050|Biological|subcutaneous allergen immunotherapy (SCIT)|20 patients who (prior to study enrollment and initiation) completed more than 1 year of timothy grass SCIT vs. 20 control patients who underwent corn pollen exposure for for greater than one year during the same prestudy time interval. Efficacy will be assessed by analyses of symptom score surveys and quality of life surveys.
45991153|NCT02949050|Biological|SCIT|Treatment group consists of patients who completed > 1 year of SCIT while control group patients did not undergo SCIT
45991154|NCT02940132|Drug|SC10914|SC10914 will be administered orally.
46084028|NCT04848714|Drug|ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab)2] lyophilized powder for solution 10 mL|Antivenin latrodectus (black widow) equine immune F(ab)2] lyophilized powder for solution 10 mL for intravenous use [parenteral formulation]; hence, a single-dose fasting pharmacokinetic study is planned.
45991155|NCT00519662|Drug|SNS-314|"Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15~Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1"
45991156|NCT05044065|Other|Physical exercise|The intervention group will receive an exercise program consisting of a combination of supervised and home-based exercise with a focus to induce metabolic stress during both a pre- and postoperative period consisting of a total of 5-6 weeks. Protein supplementation will be given to exclude insufficient intake.
45991157|NCT00520325|Drug|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
46084029|NCT02710032|Behavioral|Social Network-Based Adherence Intervention|Participants in clusters randomized to the intervention arm will be asked to attend a series of weekly group workshops emphasizing a collective approach to HIV prevention and mutual support for PrEP adherence.
46084030|NCT02710032|Behavioral|Social Media Platform|ii) Social Media Platform: The social media component of the intervention will include structured internet platforms designed to educate, motivate, and promote discussions of PrEP adherence within the participant network, unstructured participant-generated interactions to articulate and reinforce newly developed social norms within the network, and practical tools to support daily PrEP adherence.
45991158|NCT00520325|Drug|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
45991159|NCT04925466|Device|CPAP at pressure of 10 cmH2O|Patients used CPAP with the pressure of 10 cmH2O during overnight polysomnography
46002327|NCT03737643|Drug|Bevacizumab|Bevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice.
46084031|NCT05300581|Other|OPAT for PWID|Observational: Patients with a history of injection opioid use will receive home OPAT while also receiving substance use disorder care including medications for opioid use disorder and multidisciplinary health coach and case management support.
46084032|NCT00952861|Drug|Doxycycline|200 mg QD in 5 days
46084033|NCT00952861|Drug|Placebo (matching)|Placebo QD i 5 days
45674117|NCT02075047|Drug|placebo oral capsules|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects <45 kg having a target dose range of 60-80 mg/day and subjects >/= 45 kg having a target dose range of 120-180 mg/day.
45991160|NCT04925466|Device|CPAP at minimal effective pressure|Patients with OSA will be treated with CPAP at minimal effective pressure derived from manual titration during sleep.
45991161|NCT00520364|Other|Observation of IVF outcomes in relation to chemo history and AMH|Women undergoing IVF with or without history of chemotherapy, AMH levels compared
45991162|NCT02949089|Drug|ACH04|The subjects will receive the study medication in each group
45991163|NCT02940210|Device|Mediclore® (adhesion barrier)|
45991164|NCT02948816|Behavioral|Facebook|Participants will spend 30 minutes on a Facebook page that is primarily non-food related posts.
45991165|NCT02948816|Behavioral|Facebook + Food|Participants will spend 30 minutes on a Facebook page that is food related posts.
45991166|NCT02948816|Behavioral|Colouring|Participants will spend 30 minutes colouring quietly.
45991167|NCT04880694|Drug|STC3141|"To receive continuous infusion of STC3141 at rate 58.3mg/hr up to 3 days (72hours).~Also to receive appropriate standard of care."
45991168|NCT04880694|Drug|STC3141|"To receive continuous infusion of STC3141 at rate 87.5mg/hr up to 3 days (72hours).~Also to receive appropriate standard of care."
45991169|NCT00520442|Drug|ibuprofen|
45991170|NCT00520442|Drug|acetamin w codeine|
45991171|NCT02948894|Device|Mandibular advancement device|an oral appliance (a dental device) for obstructive sleep apnea
45991172|NCT04870320|Behavioral|Endeavor: Computer-Based Cognitive Stimulation Intervention|Endeavor application will be utilized by participant on iPad
45991173|NCT04870320|Behavioral|Words!: Computer-Based Cognitive Stimulation Intervention|Words! application will be utilized by participant on iPad
45991174|NCT04870320|Other|Quality of Life (QOL) Questionnaires|Standardized QOL questionnaire will be administered at each study visit
45991175|NCT03458013|Behavioral|Mindfulness Meditation|Guided using an mp3 player and noise cancelling headphones, participants will be led through a series of mindfulness meditations lasting approximately 20 minutes each.
45991176|NCT02948738|Behavioral|Interactive Asthma Education|Active participation to develop asthma action plan and teach back cycles for asthma inhaler teaching/training
45991177|NCT02948738|Behavioral|Standard Asthma Education|Basic review of asthma action plan and inhaler use
45991178|NCT02938572|Drug|NNC0143-0406|Administered subcutaneously (s.c. under the skin)
45991179|NCT02938572|Drug|Insulin Aspart|Administered subcutaneously (s.c. under the skin)
45991180|NCT02940054|Other|Red-flags questionnaire|A questionnaire composed by 8 items will be administered by GPs to those patients and they will be referred to a gastroenterologist with expertise in CD. All those patients will be evaluated, as per usual practice, to confirm or exclude Crohn's disease.
45991181|NCT02940093|Other|Stem cell transplantation|Intervention is not conducted as part of the study but patients at Tübingen University Hospital undergoing this intervention as part of their standard care are being monitored in this observational study.
45991182|NCT02948699|Dietary Supplement|Nutrison|Nutrison(400-600ml/d) will be given to Arm 1 patient between regular diet. When the daily ration was cut down to 50%,100ml/h Nutrison was added. When grade Ⅲ-Ⅳ oral mucositis appeared, total Nutrison was applied to patients by NG or PEG.
45991183|NCT00521417|Behavioral|short-term dynamic therapy|
45991184|NCT00521417|Behavioral|long-term dynamic therapy|
45991185|NCT02938728|Other|Biopsies|
45991186|NCT02938650|Drug|Nitrosomonas eutropha|Subjects will get nitrosomonas eutropha to apply for one week. There is only one arm to this study. Subjects will apply the medication twice a day for one week.
45991187|NCT04866303|Diagnostic Test|Home-based SARS-CoV-2 test kit|A two-arm pragmatic randomized trial of SARS-CoV-2 home-based testing kit completion using active kit assistance by community health educators vs. passive kit delivery. Will be done with two partner communities, Yakima Valley Latino community in WA and Flathead Reservation, American Indian community in MT. N = 200 participants in each community.
45991188|NCT04694417|Other|Compression stocking|Please see the description of the intervention in another section
45991189|NCT04694417|Dietary Supplement|Magnesium tablet|Please see the description of the intervention in another section
45991190|NCT04694417|Other|Placebo tablet|Please see the description of the intervention in another section
45991191|NCT02948621|Procedure|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device (Overstitch, Apollo Endosurgery, Austin, Tx. USA). Continuous stitches are placed to create a sleeve-shaped gastric path of 2 cm diameter to reduce stomach volume from the proximal antrum to the oeso-gastric junction.
45991192|NCT00520598|Biological|Comparator: V505 formulation 1|0.5 ml injection of V505 formulation 1 as 3 dose regimen at Day 1, Month 2 and Month 6.
45991193|NCT00520598|Drug|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 3 dose regimen at Day 1, Month 2 and Month 6.
45991194|NCT00520598|Drug|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 2 dose regimen at Day 1 and Month 6.
45991195|NCT00520598|Biological|Comparator: V505 formulation 3|0.5 ml injection of V505 formulation 3 as 2 dose regimen at Day 1 and Month 6.
45991196|NCT00520598|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant|0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen at Day 1, Month 2 and Month 6.
45991197|NCT00520598|Biological|Comparator: Placebo (unspecified)|0.5 ml injection of placebo to V505 as a 1 dose regimen at Month 2.
46084034|NCT04844346|Dietary Supplement|Plant stanol mini drinks|Oat milk based mini drinks (100 mL) containing 2g plant stanols each (delivered as plant stanol esters).
45833714|NCT02090712|Procedure|PCI|Balloon dilatation of the culprit artery followed by stent implantation will be made immediately for patients not receiving thrombolysis or after 3 to 24 hours after thrombolysis, under clinical indication and current practice patterns, in the setting of acute myocardial infarction
45991198|NCT02939898|Drug|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
45991199|NCT02939898|Drug|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
45991200|NCT00520637|Drug|EZN-2208|
45991201|NCT02938338|Procedure|Bariatric surgery|Bariatric surgery, with an anticipated mean weight loss of 30 kg
45991202|NCT00521495|Device|neodymium permanent magnet|"3/4 diameter by 1/8 thick permanent magnet"
45991203|NCT00521495|Device|neodymium magnet|A. 450 Gauss static magnetic field at target B. 150 Gauss static magnetic field at target C. 0 Gauss static magnetic field at target
45991204|NCT00521495|Device|magnet|0 Gauss magnets are worn every night during hours of sleep for 6 weeks.
45991205|NCT02939703|Other|Diet|Participants will consume either a Control Western Diet or a Microbiome Enhancer Diet.
45991206|NCT02938221|Device|Telemedical video-oculography system|Telemedical video-oculography setup consisting of video goggles (EyeSeeCam, Interacoustics GmbH, Germany), a mobile telemedical workstation and an extended conferencing and remote control system (MEYTEC GmbH, Germany)
45991207|NCT00520754|Drug|levocetirizine dihydrochloride|
46084035|NCT04844346|Dietary Supplement|Placebo mini drinks|Oat milk based mini drinks (100 mL) without added plant stanols (delivered as plant stanol esters).
46084036|NCT04844346|Biological|COVID-19 vaccine|First dose of one of the COVID-19 vaccines. Participants have to wait until they are invited to receive the vaccine by the government; this study does not interfere with national planning of the vaccines.
46084037|NCT04179422|Other|anthropometric measurement|weight, height, BMI
45833715|NCT03987126|Dietary Supplement|Human Milk Oligosaccharides (HMO)|Sachet containing 10 grams of HMO
46084038|NCT04179422|Other|nutritional questionnaire|24hs food recall, presence of feeding disorders
45833716|NCT03987126|Other|Placebo|Sachet manufactured to mimic 10g of HMO
45833717|NCT03206190|Other|SPRS Score and clinical signs|Patients will clinically characterized by using the SPRS Score and the inventory V3
45833718|NCT03206190|Behavioral|Cognition Testing using CANTAB|Patients will be tested using the CANTAB
45833719|NCT03206190|Diagnostic Test|Lumbar Puncture and blood draw|Biomaterial will be collected (not obligate) to compare e.g. Nfl levels in serum and CSF
45833720|NCT03206190|Diagnostic Test|MRI|MRI will be used to reveal presymptomatic brain morphology changes (not obligate)
45991208|NCT04811196|Drug|Selinexor|Selinexor
45991209|NCT00520832|Device|Microcurrent|20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
45991210|NCT00520832|Device|Microcurrent|Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
45991211|NCT02939859|Procedure|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
45991212|NCT02939859|Device|Centricyte 1000|Use of Centricyte 1000 closed system digestion adipose tissue stromal vascular fraction to create a AD-cSVF
45991213|NCT02939859|Procedure|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
45991214|NCT00521534|Device|CRT with atrial overdrive pacing|Both groups receive CRT, one group receives atrial overdrive pacing
45833721|NCT03206190|Diagnostic Test|Electrophysiology|Electrophysiological tests will be used to characterize patients better.
45991215|NCT02277132|Drug|Sildenafil|Sildenafil 25 mg three times daily orally from randomization until delivery
45991216|NCT02277132|Drug|Placebo|Placebo tablets three times daily orally from randomization until delivery
45991217|NCT00520871|Drug|Blueberry juice|
45991218|NCT00520949|Drug|Augmentin (Amoxicillin-clavulanic)|Amoxicillin-clavulanic acid 1 gram b.i.d
45991219|NCT00520949|Drug|Furoxone (furazolidone)|furazolidone 200 mg b.i.d
45991220|NCT00520949|Drug|Cebes (colloidal bismuth subcitrate)|colloidal bismuth subcitrate 240 mg b.i.d
45991221|NCT00520949|Drug|Esso (esomeprazole)|esomeprazole 40 mg b.i.d for 14 days
45991222|NCT02938104|Dietary Supplement|Whey Protein Isolate Powder|"Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Posder (Immunocal) is provided.~Immunocal (1.5g/kg PO (by mouth) per day in daily doses"
46084039|NCT00949351|Drug|Aliskiren 300mg/d|Aliskiren 300mg/d v.s. placebo for 12wk
46084040|NCT02779790|Other|Liquid Meal Replacements|An intervention that contains a mixture of protein, carbohydrate, and fat, along with added vitamins and minerals in liquid ready-to-drink or powder formulas that require mixing.
46084041|NCT00952939|Genetic|fluorescence in situ hybridization|At time of surgery
46084042|NCT00952939|Other|laboratory biomarker analysis|At time of surgery
46084043|NCT00952939|Procedure|fine-needle aspiration|At time of surgery
46084044|NCT00952939|Procedure|therapeutic conventional surgery|At time of surgery
46084045|NCT00952939|Other|Questionnaires|The MINI (a structured psychiatric interview) will be administered to all patients that had a pre or post-operative HADS score for suggestive or probable depression or anxiety. A semi-structured interview would be administered to those patients who had some or full decision regret pre-operatively. After completion of the interview, the MINI, a structured psychiatric interview, will be administered.
45991223|NCT02938104|Behavioral|Physical Exercise Program|Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
45991224|NCT02938104|Behavioral|Relaxation Techniques|Relaxation techniques consisting of breathing exercises and using a relaxation CD
45991225|NCT02948504|Procedure|Coiling or Clipping|All patients are treated under general anesthesia and systemic heparinization. A bolus of 50-75 IU/kg of heparin is given after femoral sheath placement, and intermittent boluses of 1250 IU per hour are given during the procedure. Activated clotting time is maintained at 2-3 times baseline level. Balloon-assisted coiling or stent-assisted coiling are considered in aneurysms with an unfavorable morphology (aneurysm neck≥ 4.0 mm or dome/neck ≤2.0). All anterior circulation aneurysms are clipped through a standard pterional or frontal temporal approach. The posterior circulation aneurysms are treated using far lateral approach depending on the aneurysm location.
45991226|NCT02938260|Drug|Metoprolol vs Diltiazem|
45991227|NCT00520988|Behavioral|Use of telephone-based Interactive Voice Recognition system|Use of telephone-based Interactive Voice Recognition system, for reporting of health information and blood pressure measurements
45991228|NCT04781244|Device|EndWarts® FREEZE|EndWarts® FREEZE is an alternative home cryotherapy device. Patients don't have to go to the hospital to receive treatment for their wart.
45991229|NCT04781244|Device|Liquid nitrogen|Liquid nitrogen is a conventional cryotherapy treatment for cutaneous wart performed by physician at the hospital.
45991230|NCT00521027|Device|Versajet Hydrosurgery System|Debridement with Versajet Hydrosurgery System
46084046|NCT05140070|Dietary Supplement|Vegetable and fruit mousse enriched with a fiber preparation from potato starch with prebiotic properties|All children in the intervention group will consume on daily basis vegetable and fruit mousse enriched with a fiber preparation from potato starch with prebiotic properties for six months
46084047|NCT05140070|Dietary Supplement|Vegetable and fruit mousse|All children in the control group will consume on daily basis vegetable and fruit mousse for six months
46084048|NCT05140070|Behavioral|Dietary and physical activity counselling|All children in the study will obtain 4 dietary and physical activity advice during the course of the study
46084049|NCT00953095|Behavioral|Joint Attention Intervention|Intervention in both conditions occurs once a week for 2 hours. Participants will be randomized to 1 of 2 interventions : (1) Caregiver Mediated Model (CMM):focuses on joint attention/engagement and involves individual meetings with the parents and children at their homes. Parents will be specifically taught techniques for altering the home environment and ways to enhance children's language, social, and play development. Parents will given guided practice (input/ coaching from the interventionist) as they implement these techniques with their child. (2) Caregiver Education Model (CEM): focuses on teaching parents information about autism, behavior modification, and community services. Parents will receive information on child development each week, and will be able to ask questions and discuss the information. Parents meet in a group (without their children) in a community-based setting to receive the intervention.
45833722|NCT03206190|Diagnostic Test|Testing functional performance|By using the 3 minute walk, 5 stair-climb test, and 10m walking test we will try to identify and measure subclinical progression prior to disease onset
46084050|NCT05137730|Drug|rhPTH(1-84)|Participants in both part I and part II of the study will receive a single SC injection of rhPTH(1-84) depending upon the treatment sequence allocation on Day 1 of each treatment period.
46084051|NCT04228562|Other|non-modifiable factor|the presence of an uncontrollable / unremovable risk factor for a disease
45833723|NCT03206190|Diagnostic Test|Non motor symptoms|By using a number of different tests we try to identify other non-motor symptoms which might manifest prior to disease onset.
45833724|NCT04277052|Device|Determination muscles sections by Ultrasonography|Determination muscles sections by Ultrasonography
45991231|NCT00521027|Procedure|Conventional surgical debridement techniques|Conventional surgical debridement with scalpel and pulse lavage
45991232|NCT02938182|Drug|clopidogrel|clopidogrel troche 75 mg daily for three months
45991233|NCT00521066|Device|GYNECARE PROSIMA* Pelvic Floor Repair System|procedure for pelvic organ prolapse
45991234|NCT02931552|Behavioral|Nuevo Amancer-II Stress Management Program|Participant meets weekly with a trained interventionist called a Compañera (a peer who has had breast cancer) to complete a structured 10-week program designed to develop cognitive and behavioral skills to manage stress and distress, improve communication with family and clinicians, and increase knowledge of self-management after breast cancer.
45991235|NCT00521105|Other|Virtual visit|Participants will alternate between a multidisciplinary visit (MD, RN and RD) and a phone contact with the diabetes nurse educator (the phone contact will replace the physician-only visit). Prior to the phone contact, transmission of information from the participant will be sent through either fax or a web browser.
45991236|NCT02938065|Procedure|Ultrasound|Baseline ultrasound is performed upon arrival. Ultrasound is performed when beverage is consumed and then every 30 minutes thereafter until stomach is empty.
45991237|NCT02938065|Other|2% milk|16 participants will drink 10 ounces of 2% milk
45991238|NCT02938065|Other|apple juice|16 participants will drink 10 ounces of apple juice
45833725|NCT03918798|Drug|Chloroprocaine 1% Injectable Solution|All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
45833726|NCT03918798|Drug|Chloroprocaine 2% Injectable Solution|All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
45833727|NCT03909282|Procedure|Lumpectomy|Standard of Care surgery for DCIS (either lumpectomy or mastectomy)
45991239|NCT02938065|Other|ensure clear|16 participants will drink 10 ounces of ensure clear
46002328|NCT03737643|Drug|Durvalumab|Durvalumab by intravenous infusion
46002329|NCT03737643|Drug|Olaparib|Olaparib tablets
46002330|NCT03737643|Drug|Placebo olaparib|Placebo tablets to match olaparib
46084052|NCT04228562|Other|induction of anticipated regret|higher level of elaboration on potential regret
45833728|NCT03909282|Radiation|Partial breast irradiation prior to surgery|Partial breast irradiation (PBI) will be delivered once aday for 5 days. The planned daily dose is 6 Gy prior to surgery (neo adjuvant)
45991240|NCT00521183|Drug|Cytochlor|The study's starting dose of CldC is 50 mg/m2/day. The dose of CldC will be escalated / de-escalated for patients. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
45991241|NCT00521183|Drug|Tetrahydrouridine|A fixed dose of H4U at 720 mg/m2/day will be used, regardless of the dose of CldC administered. H4U will be delivered by an IV bolus infusion over a period of 5 minutes, followed 5 minutes later by an IV bolus infusion of CldC. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
45991242|NCT00521183|Radiation|Radiation Therapy|One treatment of 3 Gy will be given daily 5 days per week (10 fractions) for a total of 30 Gy over two weeks.
45991243|NCT02938026|Procedure|Bariatric surgery|
45991244|NCT02938026|Behavioral|Telephone Intensive Lifestyle Counselling|
45991245|NCT00521573|Other|Dark chocolate|
46084053|NCT04922294|Other|Clinical decision support system|To develop a clinical decision support system based on a published cardiometabolic disease staging system.
45991246|NCT02937714|Other|School Mental Health training|School based intervention (Teacher training intervention) is the teachers training program based on World Health Organization, Eastern Mediterranean Region (WHO-EMRO) School mental health manual draft (December 2014). Topics to be covered in training workshop include normal childhood development, behaviour management strategies for schools, life skills training, essential components for healthy schools, recognizing warning signs for common psychiatric and developmental disorders common to children and adolescents & school based interventions for various psychiatric problems
45991247|NCT00521612|Drug|sevoflurane|Volatile anaesthetic sevoflurane 1 MAC (2,0 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic sevoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic sevoflurane. Change will be +10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
45991248|NCT00521612|Drug|isoflurane|Volatile anaesthetic isoflurane 1 MAC (1,2 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic isoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic isoflurane. Change will be +10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
45674118|NCT02075047|Drug|ziprasidone oral capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects <45 kg having a target dose range of 60-80 mg/day and subjects >/= 45 kg having a target dose range of 120-180 mg/day.
45991249|NCT02937909|Other|Use of wound care products from a single manufacturer|The participating Healthcare Professionals will be asked to use BSN medical wound care products for the study duration
45991250|NCT00521261|Biological|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|
45991251|NCT02931591|Drug|Metformin|Metformin is administered as an oral solution
46084054|NCT04889066|Radiation|Stereotactic Radiation Therapy|"24-27 Gy in 3 fractions- one plan, given once every other day with first cycle of Durvalumab for comparator arm. 24-27 Gy in 3 pulses- each pulse of radiation re-planned, given once every 4 weeks with each Durvalumab for experimental arm."
45674119|NCT01859949|Drug|Genotropin (somatropin)|Genotropin(somatoropin) 12 mg, Genotropin(somatropin) will be given at a dose of 0.067 mg/kg/day or 0.033 mg/kg/day to all participating patients
45674120|NCT05108181|Other|Muscle typology + exercise training|Exercise training: Participants perform 9 weeks of strength training at 60% of their 1RM.
45674121|NCT05108181|Other|Muscle typology + training frequency|Training frequency: leg A and arm A of the participants train 3 times per week, leg B and arm B train 2 times per week.
45674122|NCT01859793|Drug|sitagliptin|100 mg pill, administered once/day orally
45833729|NCT03204786|Drug|Vasopressin (USP) Injectable Solution [Vasostrict]|Nasal Spray
45833730|NCT03204786|Drug|Placebo|Placebo Nasal Spray
45833731|NCT03204396|Drug|Dulaglutide|Application of Dulaglutide (Trulicity®) 1.5 mg s.c. once weekly for 12 weeks.
45833732|NCT03204396|Drug|0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])|Application of 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl]) once weekly for 12 weeks
45991252|NCT02931591|Drug|Growth Hormone|Growth Hormone- no specific band
45991253|NCT02931591|Drug|Placebo|
45991254|NCT00521300|Drug|Octreotide|First week: Octreotide 50 micrograms subcutaneously three times daily. Second week: Octreotide 100 micrograms subcutaneously three times daily. From the third week on: Octreotide LAR 20 mg intramuscularly every 28th day for 6 months
45991255|NCT00521300|Procedure|Direct surgery for acromegaly|Direct transsphenoidal surgery
45991256|NCT02931435|Procedure|Nerve Block with Radiofrequency Ablation|Ablation of the genicular nerves of the knee by radiofrequency
46084055|NCT04889066|Drug|Durvalumab|Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
45991257|NCT02931435|Procedure|Nerve Block with Sham Radiofrequency Ablation|Genicular radiofrequency of the knee without neurotomy
45991258|NCT00521690|Drug|insulin detemir|
45991259|NCT02931825|Behavioral|Reminder letter|"The letter will consist in several parts:~Reminder of : -the need of individual follow-up for high risk people for colorectal cancer AND - the general recommendations (one colonoscopy every 5 years)~Recommendation to consult their general practitioner or gastroenterologist if they haven't done their follow up~Request information if they've done their follow-up or if we have incorrect information~Indication that the letter is sent as part of a surveillance program specific for high risk people for colorectal Cancer"
45991260|NCT00523133|Drug|naltrexone|50 mg naltrexone daily for 3 months
45991261|NCT00523133|Drug|naltrexone|50 mg of naltrexone daily for 6 months
45991262|NCT00523133|Behavioral|Broad Spectrum Treatment|8-14, one hour sessions over 6 months
45991263|NCT00523133|Behavioral|Motivational Enhancement Treatment|4, 20 minute sessions over 3 months
45991264|NCT02937792|Drug|intrathecal 15 mg bupivacaine|spinal anesthesia with a large dose of bupivacaine 0.5% in elective caesarean section
45991265|NCT00521729|Procedure|Exposure to Cold Temperature|
45991266|NCT02931474|Drug|Tesamorelin|Growth Hormone-Releasing
45991267|NCT02931474|Other|Placebo|
45991268|NCT02931357|Device|Hyaluronic Acid 0.54%|Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day
45991269|NCT02931357|Drug|Calgel®|Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
45991270|NCT00521768|Behavioral|Prolonged exposure|
45674123|NCT01859793|Drug|Placebo|Matching placebo in appearance given once/day orally
45674124|NCT01859715|Drug|Oxycodone|Subjects given oxycodone 5mg by ED provider decision or by triage nurse randomization.
45991271|NCT02937597|Behavioral|ePBP: eProficiency Based Progression|National e-learning programme plus Proficiency-based progression through 4 scenarios in an online learning course and facilitator when requested
45991272|NCT02937597|Behavioral|eS: eScenarios|National e-learning programme plus access to 4 scenarios in an online learning course and facilitator when requested
45991273|NCT02937597|Behavioral|HSE|National HSE e-learning programme only
45991274|NCT04694027|Drug|Omega 3 fatty acid|omega 3 1000 mg
45991275|NCT04694027|Drug|VitaE|vitamin e 400 mg
45991276|NCT00521807|Procedure|Hypnosis|a standardized hypnosis treatment with ten consecutive therapeutic sessions once a week,
45991277|NCT04577274|Dietary Supplement|smoothie with regular formulas (SM)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
45991278|NCT04577274|Dietary Supplement|smoothie with low carbohydrate formulas (SMLS)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
45991279|NCT04577274|Dietary Supplement|conventional diabetic enteral drinks (Glucerna)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
45991280|NCT04693988|Behavioral|Case Management|a case manager is available by phone to assist patient with attending cardiac rehabilitation sessions as well as provide advice about cardiac symptoms and behavioral life style changes
45991281|NCT02937675|Drug|Tomivosertib (eFT-508)|eFT508
45991282|NCT00523172|Procedure|manual or manipulative therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the hip (HVLA hip manipulations per protocol 1) with pre-manipulative static and post manipulative active-assisted stretch of hip muscles after each manipulation.
45991283|NCT00523172|Procedure|Manual / Manipulative Therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the lumbosacral, sacroiliac, hip and knee, ankle and foot joints (HVLA and Grades I-IV mobilization per protocol 2) stretching and exercise.)
45991284|NCT00523172|Procedure|Supportive Care|"Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.~Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed."
45991285|NCT02937519|Device|Chrono-chemotherapy pump:Melodie|
45991286|NCT02937519|Device|Routine intravenous drip|
46084056|NCT04223778|Drug|DOR/ISL|A FDC of 100 mg DOR/ 0.75 mg ISL taken in tablet form, orally, once daily
45991287|NCT02937519|Drug|induction Chrono-chemotherapy|
45991288|NCT02937519|Drug|induction Routine-chemotherapy|
45991289|NCT02937519|Drug|cisplatin chrono-chemotherapy|
46084057|NCT04223778|Drug|ART|Baseline background ART regimen will be administered as per approved label. ART medication will not be provided by the Sponsor; participants will provide their own ART medications. Allowed drug classes include nucleoside analog reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transferase inhibitors (InSTIs), fusion inhibitors, chemokine receptor 5 (CCR5) antagonists, post-attachment inhibitor, and pharmacokinetic (PK) boosters.
46084058|NCT05109416|Drug|Bupivacaine Hydrochloride 0.5% Injection Solution|Local anesthetic
46084059|NCT05109416|Drug|Saline 0.9%|Isotonic crystaloid
46084060|NCT05100290|Diagnostic Test|Hyperventilation Provocation Test (HPTest)|"During the HPTest, the subject is comfortably seated in a chair with armrests and breathes in a mouthpiece with a salivary collector and a nasal clamp. Parameters of ventilation and gas exchange are analyzed via an Oxycon ProTM (SN808008) with TripleV-Volume Sensor digital(Jaeger).~The HPTest begins with a 3-minutes adaptation phase during which the patient is asked to breathe normally. During the 3-minutes of voluntary hyperventilation phase, the patient is asked to increase his tidal volume and support a breath rate of at least 30/min in order to reduce his PETCO2 by at least 50%. During the recovery phase of the HPTest, the patient is invited to regain a natural breathing for 5 minutes, without guidance on tidal volume or breath rate."
46084061|NCT04226924|Drug|Trehalose|90 mg/ml trehalose solution for IV infusion
46084062|NCT02778386|Drug|N-Methanocarbathymidine|Patients will receive 200 mg, 400 mg, 800 mg or 1200 mg of N-Methanocarbathymidine administered orally on day 1 after subject's full screen for each cohort. Each dose will be completely evaluated for safety and pharmacokinetics. The doses of each cohort will be given after complete evaluation of the preceding cohort for any sign of toxicity. In the absence of no observed toxicity, the next cohort will be started in the normal subjects.
46084063|NCT02778386|Other|Placebo Capsule|Two patients in Cohort 3 & 4 will receive placebo capsules which is mannitol filled into size 0 capsules.
46084064|NCT02779088|Other|exercise and nutrition|Exercise:muscle strengthening exercise Nutrition: 7.2 g branched chain amino acid every day and 1200 mg Ca+800 IU Vitamin D3
46084065|NCT05264064|Other|The motor assessment to establish validation of the Polish version of the AIMS|The translation, cultural adaptation, and validation were conducted according to existing recommendations. The motor development of infants was assessed with the Polish scoresheet of the AlMS and the PDMS v.2. The examination was conducted by two peadiatric physiotherapists with a minimum 7 years of experience.The examination methodology was concordant with the recommendation of the authors of AIMS and PDMS-2.The intrarater reliability test included two assessments (with one-month interval) performed by one researcher (Rater A). For the second assessment, the videos of spontaneous motor performance of infants were recorded during the examination. The interrater reliability involved assessments by two researchers (Rater A, Rater B). The Gross Motor Scales of the PDMS v.2 was administered to estimate concurrent validity (participants at the age of 0-12 months).
46084066|NCT04074564|Combination Product|MASCT-I,PD1 Antibody,Apatinib|"Multi-antigen autoimmune cell injection (MASCT-I) is an adoptive cellular immunotherapeutic product being developed by Heng Ruiyuan.~PD1 antibody is a blocking antibody of human programmed death receptor-1 (PD-1). It can bind to PD-1 receptor, block its interaction with PD-L 1 and PD-L2, release PD-1 pathway mediated inhibition of immune response, including anti-tumor immune response.~Apatinib is a small molecule targeted anti-angiogenesis drug. It can highly selectively compete for ATP binding sites of endothelial growth factor R-2, block downstream signal transduction and inhibit neovascularization in tumor tissues."
46084067|NCT02778542|Behavioral|Electronic Pill Bottle|Patients receive electronic pill bottle for their blood pressure medication. Study team can monitor pill bottle openings. Patients also receive daily text reminders to take their blood pressure medication.
46084068|NCT02778542|Behavioral|Bidirectional Text Messaging|Patients receive daily text reminders to take their blood pressure medication. Patients are asked to text their adherence daily.
46084069|NCT00612300|Behavioral|Lokomat - Physical therapy|A: Lokomat training, 30 minutes per day for 3 weeks, 5 days per week. B: Categorized gait training by physical therapist, 30 minutes per day for 3 weeks, 5 days per week
46084070|NCT00612300|Behavioral|Physical therapy - Lokomat|"B: Daily 30 minutes of gait training with a physical therapist, 5 days per week for 3 weeks.~A: Daily 30 minutes of Lokomat training, 5 days per week for 3 weeks."
46084071|NCT02778308|Drug|Gemcitabine + Cisplatin|Day 1 and day 8 Gemcitabine Day 1 cisplatin
45676709|NCT02018822|Device|Esthet-X HD|light cured resin composite for teeth made by Dentsply Caulk
45991290|NCT02937519|Drug|cisplatin routine-chemotherapy|
45991291|NCT02937519|Radiation|intensity-modulated radiation therapy|
45991292|NCT03457974|Other|saliva|salivary secretion rate, salivary buffering capacity, pH, protein levels, superoxide dismutase (SOD), ferric reducing antioxidant power (FRAP), the thiobarbituric acid reactive substances (TBARS), protein carbonyl, protein thiols, total sialic acid.
45991293|NCT00521963|Biological|Intraarticular injection of infliximab|A single injection of 100 mg of infliximab
45991294|NCT02937402|Procedure|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with bronchoalveolar lavage
45991295|NCT02937402|Other|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
45991296|NCT02937363|Dietary Supplement|Alpha-lipoic acid|A trial of exercise before and after 4 weeks of alpha-lipoic acid supplementation.
45991297|NCT02937363|Other|Placebo|A trial of exercise before and after 4 weeks of placebo administration.
45991298|NCT04693871|Device|Transesophageal ultrasound|Patients with nonvalvular atrial fibrillation underwent radiofrequency ablation combined with left atrial appendage closure and recovered to sinus rhythm after the operation. To study the changes of left atrial organization and function of two groups of patients with different left atrial appendage emptying speeds.
45991299|NCT02948348|Drug|Nivolumab|Capecitabine:Dose of 1650mg/m2,14days, Radiation:45Gy/25 fractions, Nivolumab :240mg on day1 of each cycle, Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR).
45991300|NCT02948348|Drug|Ipilimumab|For only Cohort D,1 mg/kg at six-week intervals
45991301|NCT02937480|Other|Task-specific training|The task-specific training will be composed by 30 minutes for upper limb and 30 minutes for lower limb tasks. Subjects will performed five minutes of exercise in each station of the circuit and only the last station will last 10 minutes and will involve a walking training with auditory stimulation. Individuals will be encouraged to work as hard as possible at each station and verbal feedback and instructions aimed at improving performance will be taken. Between each task, the participants will be allowed to rest for at least 1-2 minutes, and individual adjustments will be carried out for better adaptations to the training.
45991302|NCT02937480|Other|Global stretching, memory exercises, health care orientation|The control intervention will be composed by 40 minutes for global stretching, 20 minutes of memory exercises and health care orientation
45991303|NCT04693910|Other|Multimedia-Based Hormone Therapy Information Program|The multimedia hormone therapy information program lasted 6 weeks and covered 6 topics, namely the recognition of hormone therapy and multimedia information programs, mindfulness, exercise, stress relief, positive thinking, and prevention or reduction of fatigue.
45991304|NCT02937441|Other|Ultrasonic Measurement|"How we measure;~First measurement shall be taken in 4 hours.~Second measurement shall be taken at 12 hours in mild and 12-18 hours measurement shall be taken for severe diabetic ketoacidosis,~Third measurement shall be taken after fluid treatment.~Fourth measurement shall be taken at patients polyclinic control."
45991305|NCT00523211|Drug|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
45991306|NCT00523211|Drug|Placebo|One tablet of placebo once daily.
45991307|NCT02931318|Behavioral|Nevsehir|The data of the study were collected with the questionnaire
46084072|NCT00612378|Device|GFX System|The GFX system employs minimally invasive technique utilizing bi-polar radio frequency (RF) technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
46084073|NCT02709876|Biological|Stem Cell Transplantation|Bone marrow-derived CD34+, CD133+, CD271+ stem cells in 1.0 ml normal saline will be injected into the vitreous cavity.
46084074|NCT02709798|Drug|Shenfu Injection|
46084075|NCT02709798|Drug|5% Glucose Injection|
46084076|NCT02776202|Drug|Fludarabine monophosphate|"The HSCT preparative regimen will consist of~Thymoglobulin: 2.5 mg /kg/day intravenously (IV) on Days -8 through -5~Fludarabine: 35 mg/m2/day IV on Days -8 through -4~Melphalan: 140 mg/m2 IV on Day -3~Rest on Day -2 and -1~Day 0 is the day of transplant~GVHD prophylaxis: sirolimus beginning on Day -1 for at least one year and mycophenolate mofetil (MMF) from Day -3 to +45 or to 7 days after neutrophil engraftment, whichever is later."
46084077|NCT00921557|Drug|Alendronate|Oral tablet taken once weekly: 70 mg if participant greater than 30 kg or 35 mg if participant less than or equal to 30 kg
46084078|NCT00921557|Drug|Placebo|Oral tablet taken once weekly
46084079|NCT00921557|Dietary Supplement|Calcium carbonate/vitamin D|Tablet taken once or twice daily: calcium carbonate (600 mg) and vitamin D (400 IU) once daily for participants with 25-OH-vitamin D levels greater than or equal to 20 ng/mL or twice daily for those with 25-OH-vitamin D levels less than 20 ng/mL
45991308|NCT02931279|Device|PASS OCT® Spinal System|Posterior osteosynthesis of the cervical and upper thoracic spine
46084080|NCT00611754|Drug|Oxaliplatin, 5-FU|Oxaliplatin: 130 mg/m² in 500 mL of 5% glucose solution as a 2-hour intravenous (IV) infusion on Day 1 and repeated every 3 weeks; 5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 toDay 4, every 3 weeks.Dose adjustments were made if the patient experienced AEs.
46084081|NCT04711278|Device|Mask-wearing hypnosis|"Virtual mask will be worn by patients before and during surgery of Hallux valgus to realize hypnosis.~Virtual mask with 2 types of voice: female voice and male voice. Several types of image or music to choice by patient."
46084082|NCT04711278|Other|Without hypnosis|No hypnosis during surgery of Hallux valgus.
46084083|NCT00550615|Drug|Dasatinib|"Dasatinib will be orally administered once daily for 28 day cycles.~There will be three dose cohorts for the Dasatinib in the Phase I portion of this trial. A minimum of three patients will be enrolled into each of the following dose cohorts:~Dose cohort # 1 will be 100 mg per day Dose cohort # 2 will be 150 mg per day Dose cohort # 3 will be 200 mg per day~The MTD will be determined in the Phase I portion of this trial."
45674125|NCT01859715|Drug|Hydrocodone|Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
45674126|NCT01859715|Drug|Ondansetron|Subjects given ondansetron 4mg for reported nausea or vomiting. Treatment determined either by triage nursing protocol or by provider discretion. Observational intervention only.
45991309|NCT03458897|Diagnostic Test|serial functional magnetic resonance imaging (MRI)|All subjects with sickle cell disease undergoing bone marrow transplantation will undergo up to 4 functional MRI scans.
45991310|NCT02937246|Device|SEMS(self-expandable metallic stent)|Find the obstruction site by ERCP(endoscopic retrograde cholangiopancreatography) and insertion the SEMS(self-expandable metallic stent) through duodenal endoscopy. Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
45991311|NCT02937246|Device|Stenting by ERCP (endoscopic retrograde cholangiopancreatography)|
45991312|NCT00522158|Drug|simvastatin|
45991313|NCT00522158|Drug|atorvastatin|
45991314|NCT02937324|Device|CloudUPDRS smartphone software assessment|Smartphone software consisting of a series of tapping and tremor-measurement tests designed to measure a subset of the UPDRS.
45674127|NCT01890915|Other|Heat Exposure|Heat exposure of 95 degrees F for up to 2 hours.
45676710|NCT02055157|Drug|BMN 111|BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.
45676711|NCT02022007|Drug|Metformin XR|"Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks~Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study"
45676712|NCT02022007|Drug|Saxagliptin|"Start 1 pill (5 mg)) for 3 weeks~Remain at 1 pill (5mg dose) for remainder of study"
45676713|NCT02022007|Drug|Saxagliptin-Metformin XR|"Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks~Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study"
45676714|NCT04716595|Drug|K-877 ER 0.2 mg/day morning administration (once daily)|K-877 ER 0.2 mg tablet
45991315|NCT02937324|Other|Clinical assessment|A clinician will assess the motor signs of the participant using the Unified Parkinson's Disease Rating Scale. The examination will be videoed and rated by 3 blinded examiners.
45991316|NCT00522197|Dietary Supplement|multi-herbal agent ACAPHA|
45991317|NCT00522197|Dietary Supplement|Sugar Pill|
45676715|NCT04716595|Drug|K-877 ER 0.2 mg/day evening administration (once daily)|K-877 ER 0.2 mg tablet
45991318|NCT00522236|Biological|Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008|"A single 0.5mL dose of Novartis adjuvanted subunit influenza vaccine, Fluad contained 45μg of viral hemagglutinin, composed of 15μg of the three influenza antigens:~A(H1N1) strain: IVR-145 (Solomon Island/3/2006 - like strain)~A(H3N2) strain: NYMC X-161B (A/Wisconsin/67/2005-like strain)~B strain: (B/Malaysia/2506/2004-like strain) in accordance with the recommendations of the World Health Organization, the EU and the national Regulatory Agencies for the 2007/2008 season.~The vaccine is a milky liquid, and was packaged in ready to use, single dose syringes.~A single dose of FLUAD vaccine was administered intramuscularly, preferably in the deltoid muscle of the non dominant arm."
46084084|NCT00550615|Drug|Dasatinib Maximum Tolerated Dose|An additional 29 patients using the Two-Stage Simon design will be enrolled into Phase II using the MTD determined in Phase I.
45991319|NCT02931123|Drug|lattulose and rifaximine|
45991320|NCT02948114|Other|Control: Cow milk-based infant formula|
45991321|NCT02948114|Other|Experimental 1: Cow milk-based infant formula|Experimental 1: Cow milk-based infant formula with prebiotics
45991322|NCT02948114|Other|Experimental 2: Cow milk-based infant formula|Experimental 2: Cow milk-based infant formula with probiotics
45991323|NCT02948114|Other|Experimental 3: Cow milk-based infant formula|Experimental 3: Cow milk-based infant formula with prebiotics and probiotics
45991324|NCT02937207|Drug|Ke Chuan Liu Wei Mixture|Experience formula of famous traditional Chinese professor Yingen Wu
45991325|NCT02937207|Drug|Chuan Xiong Ping Chuan Mixture|Experience formula of famous traditional Chinese professor Changrong Shao
45991326|NCT02937207|Drug|Xie Wu Capsule|Experience formula of famous traditional Chinese professor Jianhua Hu
45991327|NCT02937207|Drug|Dan Ma Jia Tablet|Experience formula of famous traditional Chinese professor Xiaopu Xu
45991328|NCT02937207|Drug|Zhi Chuan Capsule|Experience formula of famous traditional Chinese professor Yingen Wu
46084085|NCT04226378|Device|Omnipod|Switch from MDI therapy to an Omnipod as part of usual clinical practice. An Omnipod is a patch pump that consists of a handheld controller and a disposable pod that delivers insulin.
45676716|NCT04715035|Other|Physical therapy interventions|mobilization, stretch, education, eccentric exercises
45676717|NCT04689919|Drug|Rivaroxaban 20 MG Oral Tablet|The subjects randomly received single oral dose of Rivaroxaban 20 MG Tablet.
45676718|NCT04689685|Other|Wearing smartwatch and continous glucose sensor|Patients will be wearing a smartwatch and a continuous glucose meter (CGM) over a maximum duration of 3 months in an outpatient setting.
45833733|NCT04398498|Diagnostic Test|Diagnostic Test: TruGraf® Testing|5 mL collection PAXgene blood sample
45833734|NCT02008656|Drug|Oxaliplatin (OXAL)|
45833735|NCT02008656|Drug|5-Fluorouracil (5-FU)|
45833736|NCT02008656|Drug|Leucovorin|
45833737|NCT02008656|Drug|Capecitabine (Xeloda®)|
45833738|NCT02008656|Radiation|intensity modulated radiotherapy (IMRT)|
45833739|NCT02008656|Behavioral|Quality of Life Questionnaires|
45833740|NCT02008656|Procedure|DRE-Endoscopy|
45833741|NCT04300140|Drug|Batiraxcept|Batiraxcept is experimental drug
45991329|NCT02937207|Drug|Bu Shen Na Qi Granule|Experience formula of famous traditional Chinese professor Changrong Shao
45991330|NCT02937207|Drug|Ke Chuan Liu Wei Mixture placebo|Low dose combination for treating prescription of Ke Chuan Liu Wei Mixture
45991331|NCT02937207|Drug|Chuan Xiong Ping Chuan Mixture placebo|Low dose combination for treating prescription of Chuan Xiong Ping Chuan Mixture
46084086|NCT04226378|Other|MDI|Continued use of MDI therapy (traditional basal/bolus insulin regimen).
45991332|NCT02937207|Drug|Xie Wu Capsule placebo|Low dose combination for treating prescription of Xie Wu Capsule
45991333|NCT02937207|Drug|Dan Ma Jia Tablet placebo|Low dose combination for treating prescription of Dan Ma Jia Tablet
45991334|NCT02937207|Drug|Zhi Chuan Capsule placebo|Low dose combination for treating prescription of Zhi Chuan Capsule
45991335|NCT02937207|Drug|Bu Shen Na Qi Granule placebo|Low dose combination for treating prescription of Bu Shen Na Qi Granule
45991336|NCT00522314|Device|NIV and ACBT|
45991337|NCT00522314|Other|Active Cycle of Breathing Techniques|
45991338|NCT04690062|Drug|Brolucizumab-Dbll|intravitreal injection of Brolucizumab (BEOVU)
45991339|NCT04694495|Diagnostic Test|16S rRNA gene sequencing of cervical secretions|"16S rRNA gene sequencing of vaginal secretions: using NGS technology to assess the microbiota of the vaginal secretions~Microecology assessment of vaginal secretions: morphology test, functional assessment and Nugent score assessment of the vaginal secretions are included.~Genotyping of HPV and detection of sexually transmitted diseases pathogens based on the cervical exfoliated cells~Thinprep cytologic test of cervical exfoliated cells: to evaluate the grade of cervical intraepithelial neoplasia"
45991340|NCT02936934|Drug|Morphine|"Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~200μg / kg of morphine + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration:24hours"
45991341|NCT02936934|Drug|Oxycodone|"Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~150μg / kg of oxycodone + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration: 24hours."
45991342|NCT02936973|Device|Real catgut implantation at acupoints|"Absorbable surgical suture will be embedded in acupoints as below. Group A ：Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40). Each group will be used alternatively and treated once every 2 weeks.~lifestyle intervention :Experienced nutritionists calculated every participant's basal metabolic rate,then designed a proper diet and exercise treatment for them. During the treatment, a diet and exercise diary will be distributed to the patients, and detailed guidance concerning their diet and exercise will be provided according to the diary. The patients should be encouraged to maintain the diet and exercise diary for at least 4 days per week ."
45991343|NCT02936973|Device|sham catgut implantation at acupoints|"Empty needles without catgut will be pushed into the chosen position as below :Group A ：1 cun lateral from the Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：1 cun lateral from the Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40).Those two groups of acupoints will ultimately be selected for alternative treatment. Each group will be used alternatively and treated once every 2 weeks.~lifestyle intervention :It will be performed as the same as the real catgut implantation at acupoints group."
45991344|NCT00522353|Dietary Supplement|Oligofructose|21 grams per day in distributed over 3 doses per day for 3 months
45991345|NCT00522353|Dietary Supplement|Placebo|7.89 grams of placebo maltodextrin divided into 3 equal doses per day for 3 months
45991346|NCT04690296|Device|cathetherization approach|real time ultrasound guidance versus anatomical landmarks subcalvain vein catheterization
45991347|NCT00522470|Drug|rosiglitazone|
45991348|NCT04689789|Diagnostic Test|optical coherence tomography angiography|optical coherence tomography aniography is a non-invasive, fast, diagnostic imaging technique that evaluates the retinal vascular network
45991349|NCT00522509|Drug|Floxuridine FUDR|
45991350|NCT02937090|Other|Blood Draw|Blood sample will be drawn from participants at study entry.
45991351|NCT02937090|Other|Stool collection|Stool will be collected from participants at study entry.
45991352|NCT00522587|Drug|Fixed sevoflurane dose 1|Dose 1 of sevoflurane
45991353|NCT00522587|Drug|Fixed sevoflurane dose 2|Dose 2 of sevoflurane
45991354|NCT00522587|Drug|Fixed sevoflurane dose 3|Dose 3 of sevoflurane
45991355|NCT00522587|Drug|Fixed sevoflurane dose 4|Dose 4 of sevoflurane
45991356|NCT00522587|Drug|Fixed sevoflurane dose 5|Dose 5 of sevoflurane
45991357|NCT00522587|Drug|Fixed sevoflurane dose 6|Dose 6 of sevoflurane
45991358|NCT00522587|Drug|Fixed remifentanil dose 1|Dose 1 of remifentanil
45991359|NCT00522587|Drug|Fixed remifentanil dose 2|Dose 2 of remifentanil
45991360|NCT00522587|Drug|Fixed remifentanil dose 3|Dose 3 of remifentanil
46084087|NCT02709720|Drug|Vinorelbine|Cycle 1 and 2 50 mg/day, (Monday, Wednesday and Friday)
46084088|NCT02709720|Drug|Cisplatin|Cycle 1 and 2 day 1, 80 mg/m2
45991361|NCT00522587|Drug|Fixed remifentanil dose 4|Dose 4 of remifentanil
45991362|NCT00522587|Drug|Fixed remifentanil dose 5|Dose 5 of remifentanil
45991363|NCT00522587|Drug|Fixed remifentanil dose 6|Dose 6 of remifentanil
45991364|NCT04689633|Procedure|nerve block|bilateral ultrasound-guided posterior quadratus lumborum block was done in the lateral decubitus and linear or curvilinear probe was used according to the depth and placed in the midaxillary line in the transverse plane above the iliac crest
45991365|NCT00522665|Drug|Irinotecan|Irinotecan 125 mg/m2 IV days 1 and 8
45991366|NCT00522665|Biological|Cetuximab|Cetuximab 250mg/m2 IV days 1, 8 and 15
46084089|NCT02709720|Drug|Vinorelbine|Cycle 3 and 4 30 mg/day, (Monday, Wednesday and Friday)
45991367|NCT00522665|Biological|RAD001|Patients on Arm A will crossover and receive RAD001 at disease progression
45991368|NCT02931084|Other|Rehabilitation|In line with current treatment guidelines, patients will undergo rehabilitation for at least the first three months, before a decision regarding ACL reconstruction is taken
45991369|NCT02931084|Procedure|ACL reconstruction|Approximately half of the patients will have ACL-reconstruction after an initial time of rehabilitation
45991370|NCT00522704|Other|Dynamic Arterial line Pressure (DALP)|eEBF will be record with dynamic arterial line pressure of -60 mmHg (eEBF-60 mmHg), -100 mmHg (eEBF-100 mmHg), -160 mmHg (eEBF-160 mmHg), -200 mmHg (eEBF-200 mmHg) and -260 mmHg (eEBF-260 mmHg) during the first one half hour of the dialysis session. Access Blood flow will be performed with blood thermal monitor.
45991371|NCT00522743|Drug|growth hormone and gonadotropin-releasing hormone agonist|GH & GNRHa treatment
45991372|NCT00522743|Drug|growth hormone|GH treatment
45991373|NCT02937012|Drug|Bezafibrate|Bezafibrate 200 mg manufactured in a pill/capsule presentation
45991374|NCT02937012|Drug|Ursodeoxycholic Acid|The patients will continue with the administration of ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day throughout the study
45991375|NCT02937012|Drug|Placebo (for Bezafibrate)|Starch pill/capsule manufactured to mimic bezafibrate 200 mg tablet
45991376|NCT04694456|Other|cytokines dosage|Mesure of cytokines concentration in serum
45991377|NCT04694456|Procedure|test of walk|patient must walk during 6 minutes on a flat surface
45991378|NCT04694456|Procedure|Manual muscular test|test performed to evaluate the patient muscular weakness
45991379|NCT04694456|Procedure|Motrice fonction mesurement|scale allowing the evaluation of patient posture and upper body movements
45991380|NCT00522782|Drug|Nebulized Budesonide|Pulmicort Respules 0.5mg/2cc
45991381|NCT00522782|Device|Nitric Oxide Analyzer|Niox NO analyzer
45991382|NCT00522821|Drug|intravenous immunoglobulins|"Adults: 600 mg/kg bodyweight every 3 weeks~Children: 800 mg/kg bodyweight every 3 week"
45991383|NCT00522821|Drug|antibiotics|"Children ≥5-12: If well tolerated, 4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily, every day of the week (max160/800mg/day), combined with 5 mg folic acid.~Adults and children ≥12 years or ≥40 kg: If well tolerated, 160 mg trimethoprim and 800 mg sulfamethoxazole once daily, every day of the week combined with 5 mg folic acid."
45991384|NCT02937051|Other|Tobacco product administration and assessment|two bouts of 10 puffs of a tobacco product with a 30-second interpuff interval separated by 60 minutes; preceded and followed by physiological, subjective and topography assessment
45991385|NCT02930928|Other|Accuracy of weight estimation|Computer based comparison
45991386|NCT00522860|Procedure|Trichiasis surgery with absorbable sutures|Posterior lamellar tarsal rotation. Vicryl sutures, 5/0, 3/8 curved needle, cutting. Three everting sutures.
45991387|NCT00522860|Procedure|Trichiasis surgery with non-absorbable sutures|Posterior lamellar tarsal rotation. Silk sutures. 4/0. 3/8 curved cutting needle. Three sets of everting sutures.
46084090|NCT02709720|Drug|Cisplatin|Cycle 3 and 4 day 1, 80 mg/m2
46084091|NCT02709720|Radiation|Radiotherapy|concomitant therapy during cycles 3 and 4. Total dose: 66Gy
46084092|NCT04226066|Biological|T601|"Part1: T601 is injected once (Day1). Dose range: 1E+7, 3E+7, 1E+8, 3E+8, 1E+9pfu.Trial cycle: Day1-21.~For part1, 3+3 dose-escalation. After all patients of one dosage finished DLT evaluation, investigator judged that patients can benefit from treatment and no intolerable toxicity occurred, patients could receive maintenance treatment, and treatment plan is same as Cycle 1."
46084093|NCT04226066|Combination Product|T601+5-FC|"Part2: T601 is injected once (Day1). Dose range: MTD-2, MTD-1 and MTD of Part1. 5-FC is taken on Day5-18 for 14 consecutive days. Trial cycle: Day1-28.~Part3: T601 is injected 3 times (Day1, 8, 15). Dose range: MTD-1 and MTD, or MTD-2 and MTD-1 of Part2. 5-FC is taken on Day5-7, Day12-14 and Day19-32. Trial cycle: Day1-46.~Part4: Protocol revised based on results of Part1-Part3. Preliminary plan: 30 patients with gastric cancer, pancreatic cancer and hepatocellular cancer who have failed standard therapeutic options are enrolled (10 patients for each indication). Treatment plan is same as Part3.~For part2 and part3, 3+3 dose-escalation. After all patients of one dosage finished DLT evaluation, investigator judged that patients can benefit from treatment and no intolerable toxicity occurred, patients could receive maintenance treatment, and treatment plan is same as Cycle 1."
46084094|NCT02709642|Behavioral|Deposit Contract|"A deposit contract (DC) is an agreement in which study participants puts their own money at risk, with the goal of earning it back by achieving a goal, in this case maintaining prior weight loss. If DC participants successfully maintain their weight, they get their money back. If they are not successful, they lose their money. For each 10 week period for one year, DC participants will make a deposit of at least $100 but will be allowed to increase their contribution if they would prefer."
46084095|NCT04252391|Procedure|Perineural electrical dry needling|Standard care plus use of perineural electrical dry needling involving use of a monofilament needle of 15 or 30 mm length, 0.25 mm diameter will be placed utilizing the therapist's dominant hand following palpation of correct needle location. An electrical stimulation unit will be used to conduct an electrical impulse. The unit used will be an ES-130 by ITO (Japan) using a DC 9V battery producing an asymmetrical biphasic waveform. The unit has 6 available leads with alligator clamps, connecting to needle shafts. Parameters of PNED will include intensity set at a strong yet comfortable setting according to patient feedback. Treatment duration will be 15 minutes. Treatment frequency will be set to Medium at level 8 (80 Hz). Parameters will be set to elicit a sensory response.
46084096|NCT04252391|Procedure|Standard Care|cervical or thoracic manipulation or mobilization, muscle stretching, muscle strengthening, electrical trigger point dry needling , soft tissue release and prescribed therapeutic exercises .
45991388|NCT02936895|Drug|Vitamin D3|vitamin D at a dose of 50,000 IU per day for 2 days
45991389|NCT02936895|Drug|Placebo|Placebo for 2 days
45991390|NCT00522899|Behavioral|Group 1|Aerobic exercise plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
45991391|NCT00522899|Behavioral|Group 2|Aerobic exercise plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
45991392|NCT00522899|Behavioral|Group 3|Stretching/toning exercise group plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
45991393|NCT00522899|Behavioral|Group 4|Stretching/toning exercise group plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
46084097|NCT02776124|Dietary Supplement|Healing Elements,Methuselah Medical Technology|ONS group will receive Healing Elements ONS everyday during CRT
45674128|NCT04617327|Radiation|Hypofractionation|"Shorter radiation therapy means that a higher dose will be given on a daily basis. The goal is to target microscopic disease and decrease the chances of local recurrence.~Organs at risk (OAR) will receive doses following the constraints from the Timmerman tables used for reference when using 5 or more fractions of EBRT.~Treatment will be delivered every 2nd day, for a maximum of 3 fractions per week. Daily pretreatment Image Guided Radiotherapy Images (IGRT) (Cone-Beam CT - CBCT) will be co-registered with the CT simulation dataset to adjust patient position before each treatment by matching the bone adjacent to the planned tumour volume (PTV). Treatment will be administered if there is <3 mm in any dimension, or rotation is <3 degrees. If the isocentre set-up exceeds 3 mm at any given treatment session, the treatment couch will be translated to restore its planned position."
45674129|NCT04599465|Drug|ELX/TEZ/IVA|Fixed dose combination (FDC) tablet for oral administration.
45674130|NCT04599465|Drug|IVA|Tablet for oral administration.
45674131|NCT04616235|Drug|Tocilizumab Injectable Product|The intervention group will undergo intense aerobic exercise with prior IL-6R infusion for 1h prior to the exercise bout.
45991394|NCT02931006|Other|water|
46084098|NCT05263752|Device|ERCP with NvisionVLE® Imaging Low Profile System|Endoscopic Retrograde Cholangio-Pancreatography (ERCP) with NvisionVLE® Imaging Low Profile System
46084099|NCT02779634|Drug|ubiquinol|Ubiquinol three times daily
46084100|NCT02779634|Drug|Placebo|Sugar pill three times daily
45674132|NCT04616235|Other|Saline 0.9% 100 ml NaCl 0.9% will be infused over 1 hour|The control group will undergo intense aerobic exercise with saline infusion for 1h prior to the exercise bout
45991395|NCT02931006|Other|bovine milk|
46084101|NCT04255589|Drug|CKD-495 75mg|CKD-495 75mg Tab.
46084102|NCT04255589|Drug|Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
45674133|NCT01615263|Device|Lung isolation device|Lung isolation for one-lung ventilation with a left double lumen tube
45674134|NCT01615263|Device|Lung isolation device|Lung isolation for one-lung ventilation with a bronchial blocker inserted through a 8.0 mm simple lumen endotracheal tube
45676719|NCT04681963|Other|Clinical Assessment within 4 hours of admission|Demographics, Symptoms, Severity scores (Triage at admission, confusion, urea, respiration, blood pressure, age (CURB 65) and pneumonia severity score (PSI), clinical parameters, blood testing, chest x-rays, comorbidities, electro-cardiogram
45676720|NCT04680949|Drug|Anakinra|Standard-of-care and anakinra. Anakinra is injected subcutaneously as 100 mg once daily for 10 days
45676721|NCT04680949|Drug|Placebo|Standard-of-care and placebo. Placebo is injected subcutaneously once daily for 10 days
45991396|NCT00522938|Drug|CHR-2797 (tosedostat)|Once daily, oral ingestion of CHR-2797 capsules(PhaseI: 120mg, 160mg or 200mg depending on cohort or Phase II: recommended dose) capsules until progressive disease or withdrawal from the study
45991397|NCT00522938|Drug|erlotinib|Once daily, oral ingestion of erlotinib tablets 150mg tablets until progressive disease or withdrawal from the study. Per protocol, the Investigator may reduce the dose of erlotinib or cease treatment with erlotinib(per label) with Sponsor approval.
45991398|NCT02936856|Device|Hepatic Arteriography|
45991399|NCT04694105|Drug|Dexmedetomidine injection|perineural injection of Bupivacaine 30 ml 0.25% combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline
45991400|NCT04694105|Drug|Dexamethasone|perineural injection of Bupivacaine 30 ml 0.25% combined with 4 mg peri neural dexamethasone (2 ml)
45991401|NCT04694105|Drug|saline|perineural injection of Bupivacaine 30 ml 0.25% combined with 2 ml normal saline
45991402|NCT02930694|Drug|JNJ-54175446 (capsule)|Participants will receive JNJ-54175446 capsule at a dose of 50 mg or 100 mg, orally.
46084103|NCT04255589|Drug|Placebo of the CKD-495 75mg|Placebo of the CKD-495 75mg Tab.
46084104|NCT04255589|Drug|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
46084105|NCT05261256|Diagnostic Test|Exercise stress echocardiography|Study participants perform an exercise stress echocardiography on a semi-supine bicycle ergometer using using a continuous incremental bicycle protocol with a work rate increment every 3 minutes according to gender and weight.
46084106|NCT02776280|Other|Meal|Typical Brazilian meal consisting of rice, beans and meat with vegetables
46084107|NCT04225910|Drug|225Ac-PSMA|all the patients will receive 225Ac-PSMA RLT for 2 cycles. The dosage will be calculated according to 100KBq/kg body weight. The drug will be administered by vein injection.
46084108|NCT04211922|Drug|Alkotinib Capsules|Alkotinib 400mg QD
45991403|NCT02930694|Drug|JNJ-54175446 (suspension)|Participants will receive JNJ-54175446 suspension at a dose of 50 mg or 100 mg, orally.
45991404|NCT00523016|Procedure|Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP)|LCCNPAP: acupuncture needle insertion at acupuncture points on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks.
45991405|NCT00523016|Procedure|Sham acupuncture|Sham acupuncture: Simulated acupuncture that includes insertion of acupuncture needles on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
45991406|NCT02936739|Device|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
45991407|NCT02936739|Device|Anterior cervical discectomy with prosthetic disc replacement / Rotaio.|Anterior cervical discectomy, with the use of the Rotaio prosthesis (Manufacturer: Signus Med, Alzenau, Germany) for the disc replacement.
45991408|NCT02948153|Other|clinical study|It is a comprehensive study in a large sample using multiple techniques to assess various aspects of the disease. All patients underwent the following : Induced Sputum, spirometry, fractional exhaled nitric oxide (FeNO), prick test, total IgE and blood albumin. Analysis of mucins and TLRs
45991409|NCT02930733|Drug|Bupivacaine|30 ml %0,25 bupivacaine bilaterally
45991410|NCT02930733|Drug|Saline|2 ml saline subcutaneously bilaterally
45991411|NCT02931162|Other|Herb-partitioned moxibustion|Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
45991412|NCT02931162|Other|Sham herb-partitioned moxibustion|Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
45991413|NCT00523055|Drug|Lidocaine|Lidocaine, 5 mg/kg, via needle placed adjacent to brachial plexus with ultrasound, dosing separated by 1 week, 2 doses in total, one block will contain 5 mcg/kg of adrenaline
45991414|NCT02930967|Biological|autologous CSR T|Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, a prescribed dose of CSR T cells will be intravenously infused to patient in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
45991415|NCT02947958|Other|Teleconsultation|Teleconsultation - the teleconsultation usage in chronic diseases, such as benign hyperplasia, seems to be a promising scenario. Once the patient symptoms are evaluated and diagnosed as a stable disease he is able to keep his treatment annually. In a way to do not overload de tertiary system, such monitoring could be done under a teleconsultation with a urological supervision in the primary care.
45676722|NCT02031679|Drug|AZD1981|AZD1981 is an oral, potent, selective, reversible antagonist of CRTh2 (Chemoattractant Receptor Homologous Molecule expressed on Th2 cells).
45991416|NCT02947958|Other|Hospital (control)|The patient will keep his usual care at the tertiary care.
45991417|NCT04761081|Behavioral|Habitual physical activity assessment|7 days habitual physical activity via accelerometry (ActiGraph GT3x). Specifically steps per day, light physical activity (minutes per day), and moderate to vigorous physical activity (minutes per day).
45991418|NCT00523289|Drug|Bupivacaine|Dosage: 150mg at once for anesthesia induction
45991419|NCT00523289|Drug|Ropivacaine|Single dose of ropivacaine, 150mg
46084109|NCT04252313|Other|Music|Studies have been conducted to assess the effects of sound and noise on neonatal stress. Recently, music is being used in neonatal units to improve physiological and behavioral outcomes (Harling et al, 2009). Of the few studies done on the effectiveness of music during circumcision is a randomized double-blinded controlled trial conducted by Joyce et al (2001): it found that some physiologic outcomes were significantly lower among the music group in comparison to the EMLA group. They concluded that there is preliminary evidence to support the efficacy of EMLA and music in pain management of newborn circumcision; however, more rigorous studies are warranted for conclusive results.
46084110|NCT02776358|Other|High Fidelity Simulation|"A HFS session for an asthma attack require:~a 5 minutes briefing session: case and equipments presentation and choice of participants~15 minutes of actual simulation~40 minutes of debriefing~A pre and a post test will be taken by the students before and after the session and a satisfaction questionnaire at the end of the course.~Also, another test will be done after 7 days of the course."
45676723|NCT02031679|Drug|Placebo|Sugar pill manufactured to mimic AZD1981 10 mg tablet
45676724|NCT04689139|Diagnostic Test|blood sample tests for determination of biomarkers levels|Using of proadrenomedullin, presepsin, NT-proBNP, Troponin I to determine the correlation of perioperative complications.
45991420|NCT03457857|Other|Cleanser|Cosmetic Baby Cleanser/Shampoo
45991421|NCT03457857|Other|Cleanser and Lotion|Cosmetic Baby Cleanser/Shampoo and Baby Lotion
45991422|NCT04506216|Other|cohort|"During a regular follow-up visit, the following data will be collected:~questionnaires on lifestyle, eating custom (SCOFF-F, 5th question of the m-SCOFF) and physical activity (IPAQ)~bio-electric impedance analysis~insulin pump and sensor data collection"
45991423|NCT00524381|Drug|Etanercept (Enbrel)|TNF-alpha antagonist, subcutaneous injection, 25 mg twice/week, 14 days.
45991424|NCT00524381|Drug|Sodium chloride (placebo)|NaCl, isotonic saline, subcutaneous injection, 1 ml twice/week, 14 days.
45991425|NCT03457779|Dietary Supplement|Glucose|"The first 4 patients enrolled on trial will undergo the research core biopsies of their TNBC without the 13C glucose infusion; these samples will serve as control tissue that will be processed identically to the tissues obtained from patients who received the glucose isotope.~The following 12 patients will receive 6 grams (g) of [1,2-13C] glucose as an IV"
45676725|NCT02053753|Drug|Denosumab CP4|Denosumab produced by a process referred to as CP4, administered subcutaneously.
45991426|NCT03458858|Other|Mixed Berry Diet|Mixed Berry Treatment
45991427|NCT03458858|Other|Carbohydrate Control Jello|Carbohydrate Control
45991428|NCT03458858|Other|Fiber Enriched Jello|Fiber Control
45991429|NCT03458858|Other|Low Fiber Mixed Berry Juice|Anthocyanin Control
45991430|NCT03457740|Dietary Supplement|Formula 1|Dietary supplement for strength, testosterone, sexual function, quality of life
45991431|NCT03457740|Dietary Supplement|Formula 2|Dietary supplement for strength, testosterone, sexual function, quality of life
45991432|NCT03457740|Dietary Supplement|Placebo|Placebo comparison
45991433|NCT04502667|Drug|Cholecalciferol|1000U or 2000U every 24 hours orally
45991434|NCT00524498|Drug|OPC-18|OPC-18: 500IU * 3 times a week, sc 5-FU : 500mg infusion for 5days into hepatic artery
45991435|NCT00524498|Drug|cisplatin|infusion into hepatic artery with cisplatin 10mg and 5-FU 250mg a day
45991436|NCT04492917|Other|CV4|The osteopath was sitting at the head of the examination table, with the subject lying supine. The osteopath approximated with the hands the lateral angles of the occipital squama, taking the cranium into sustained extension. The technique ended when the osteopath perceived the still point, a condition in which the balanced membranous or ligamentous tension is achieved.
45991437|NCT04492917|Other|ST|The subject was lying in the supine position, while the osteopath positioned the index and middle fingers of the caudal hand on either side of the subject's sacrum. Then establishes a point of balance between the coccyx and the vertex facilitating the sacral extension until the achievement of the still point
45991438|NCT04492917|Other|Sham CV4|the sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch
45991439|NCT04492917|Other|Sham ST|The sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch
45991440|NCT00523406|Procedure|Photodynamic therapy and intravitreal triamcinolone|combination of photodynamic therapy and intravitreal triamcinolone combination to treat neovascular AMD
45991441|NCT03457662|Combination Product|OMC and pseudo-SDT|OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
45991442|NCT03457662|Combination Product|OMC and SDT|OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml.DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site of each lesion.
45991443|NCT00524615|Drug|spironolactone|25 mg of spironolactone once daily or placebo for 2 months
46084111|NCT02776358|Other|Video case|"a video case (or video box) session in which students will attend a video-projection of a real case of an asthma attack and discuss with the trainer the different steps of the assessement and management of an asthma attack.~A pre and a post test will be taken by the students before and after the session and a satisfaction questionnaire at the end of the course.~Also, another test will be done after 7 days of the course."
45674135|NCT04590495|Drug|300 mg Cannabidiol (CBD) oil|Participant will either be given a 300mg dosage of CBD oil. After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
45676726|NCT02053753|Drug|Denosumab CP2|Denosumab produced by a process referred to as CP2, administered subcutaneously.
45991444|NCT00524654|Procedure|HVLA chiropractic manipulation|
45676727|NCT02019979|Drug|metformin|Addition of metformin 1000 mg po bid to standard of care platinum based chemotherapy
45676728|NCT02019979|Behavioral|carbohydrate restricted diet|addition of dietary counseling and metformin 1000 mg po bid to platinum based chemotherapy
45676729|NCT04713007|Behavioral|Quality of Life Ted Talks|There will be 9 training modules released weekly on the tablet. A survey will be required at baseline, each of the 9 weeks and at 3 months.
45991445|NCT03458819|Diagnostic Test|Isolation of peritoneal mesothelial cells|HPMCs will be isolated and stored at -80 degrees until analysis. Changes in the protein expression of EMT markers such as E-cadherin, a- SMA, Snail, and fibronectin in the HPMCs will be evaluated by Western blot analysis.
45991446|NCT04689750|Diagnostic Test|Next generation sequencing|"Genetic profile of donors will be collected at the time of PBSC or BM stem cell donation. Genetic profile of recipients will be collected at 1-month, 6-month, 12-month post-HSCT and at time of relapse or occurrence of leukaemia.~Gene mutations and pathogenic gene fusion will be determined in the peripheral blood and/or marrow samples by next-generation sequencing (NGS) using a myeloid-gene panel and nanopore long-read sequencing."
45991447|NCT02948192|Other|Survey, Sample collection|Survey is collected on the dietary intake of both cohorts. Sample collection is done from patients in both cohorts at multiple time points.
45991448|NCT02936817|Device|Aerobika® Device|For a period of 15 +/- 3 days subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily).
45991449|NCT02936817|Radiation|HRCT scans|A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, and visit 3. An upper airway (UA) scan will be taken on visit 1.
46002331|NCT03737643|Drug|Durvalumab placebo|Matching placebo for intravenous infusion
45991450|NCT00523445|Drug|Varenicline(Chantix)|The dose of antipsychotic drug will remain fixed throughout the study and the titration of varenicline will be as follows: varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice per day for days 4 to 7, then 1 mg twice per day through week 8.
45991451|NCT00523445|Drug|Placebo|The dose of antipsychotic and concomitant medications remained fixed throughout the study and the titration of varenicline was as follows: Placebo will be supplied twice daily through week 8.
45991452|NCT02936661|Drug|Tranexamic Acid|
45991453|NCT02936661|Drug|Placebo|
45991454|NCT02948075|Drug|Quisinostat|
45991455|NCT02948075|Drug|Paclitaxel|
45991456|NCT02948075|Drug|Carboplatin|
45991457|NCT04690725|Drug|TQB3525|TQB3525 is an orally bioavailable, potent, class I kinase inhibitors of PI3Ka and PI3Kd.
45991458|NCT02930811|Drug|Sildenafil 100 mg oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
45991459|NCT02930811|Drug|Placebo oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
45991460|NCT02947919|Behavioral|Music|A previously defined list of songs will be administered by headphones to these patients with an MP3 device with headphones.
45991461|NCT04690569|Diagnostic Test|MeMed BV|The MeMed BV™ Test is an immunoassay that measures three non-microbial (host) proteins (TRAIL, IP-10, and CRP) in adult and pediatric serum samples. The test is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection. The test is indicated for use in patients presenting to the ED, urgent care center and inpatients with suspected acute bacterial or viral infection. The MeMed BV™ Test generates a numeric score that falls within discrete interpretation bins based on the increasing likelihood of bacterial infection. The MeMed BV™ test is intended for in vitro diagnostic use only.
45991462|NCT00523523|Behavioral|Constraint-Induced Movement Therapy + auditory rhythm cues|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. Participants in the experimental group will perform this practice to the beat of a metronome. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
45991463|NCT00523523|Behavioral|Constraint-Induced Movement Therapy|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
45991464|NCT02947880|Drug|Bumetanide|For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
45991465|NCT02947880|Drug|Placebo|For the patient of 25kg and more the placebo is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
46084112|NCT04252001|Device|YESS! game|"The YESS! game is a real-life game for smartphone or tablet in which the player has to solve a mystery. The adolescent plays an active role in the course of the story. This results in an interactive experience. During the game, the adolescent is challenged with regard to self-management and responsible behaviour in general life, with parallels to medical selfmanagement and responsible behaviour.~The adolescent has to decide at several different moments whether to take action or not, whether to accept help or not and whether to share (fictive) confidential information or not. Other aspects that are covered are 'taking responsibility' and 'being on time'. The choices the adolescent makes throughout the game are registered in a coded manner, for later analysis. The game is available in Dutch, English and Spanish."
46084113|NCT04252001|Device|Snake '97|Snake '97 is a game for smartphone or tablet which is free and can be downloaded in the App Store. The game is a remake of the original snake on the mobile phone in 1997 in which the player moves the snake around and makes the snake 'consume food' (little dots) which causes the snake to grow longer. The goal is to make the snake as large as possible. The game has 12 difficulty levels.
46084114|NCT04252001|Other|Transition-toolkit|The transition toolkit consists of paper cards with assignments, ideas and tips regarding medical self-management.
45991466|NCT04690491|Other|follicular cyclus|Days of cyclus 6-12
45991467|NCT04690491|Other|luteal cyclus|Days of cyclus 20-24
45991468|NCT00523562|Other|diet intervention|controlled hypercaloric high fructose, high fat, or high fat/high protein diet
45991469|NCT02930655|Drug|Lucerastat|Hard gelatin capsules for oral administration formulated at a strength of 250 mg, and administered as 4 capsules in the morning and 4 capsules in the evening.
45991470|NCT02930655|Drug|Enzyme replacement therapy (ERT)|All the subjects received an ERT as background therapy for at least 24 months prior to the screening visit and they had to continue receiving this treatment during the conduct of the study.
45991471|NCT04690803|Drug|air cooling|intervention is adding air-cooling to treatment
45991472|NCT00523757|Drug|Spironolactone|
45991473|NCT00523757|Drug|Placebo|
46084115|NCT00744471|Biological|tanezumab|Tanezumab 10 mg IV every 8 weeks
45676730|NCT04713007|Behavioral|Quality of Life Supportive Resources|The tablet will be preloaded with cancer information and supportive care resources from the National Cancer Institute. A survey will be required at baseline, each of the 9 weeks and at 3 months.
45676731|NCT04687501|Device|Virtual Reality|Virtual reality in gynaecological surgery in the pre- and postoperative setting
45991474|NCT00524693|Drug|Montelukast|4mg sachets
45991475|NCT00524693|Drug|Placebo granules|
46002332|NCT03737643|Drug|Carboplatin+Paclitaxel|Standard of care chemotherapy
46002333|NCT03728582|Device|Active tDCS plus Speech-Language Therapy|1-2 milliamps (mA) of Anodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge is placed on the left inferior frontal gyrus (IFG). The stimulation will be delivered at an intensity of 1-2 mA in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be verb naming therapy in a sentence context.
45991476|NCT02931201|Device|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post-injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
45991477|NCT00524732|Biological|Tetanus and diphtheria toxoids and acellular pertussis|0.5 mL, Intramuscular
45991478|NCT02930772|Drug|BAY987516|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code: Z46-100)"
45991479|NCT02936700|Behavioral|Relaxation|relaxation program consists of 7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants.
45991480|NCT02936700|Behavioral|ACT therapy|"7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants. The ACT program aims at~decreasing the tendency to try to escape unpleasant mental experiences~increasing psychological flexibility~developing acceptance of psychological events and engagement in valued actions"
45991481|NCT04693481|Other|nature exposure|Nature exposure has different ways, such as walk in the real nature environment; viewing nature photos. Two main reasons make this study will not use the real nature environment: (1) the limitation of time before or amid the soccer competition; (2) the pandemic situation does not allow people go outside as frequently as before. Therefore, the current study will select some nature photos, which are restorative environments and can restore directed attention to counteract mental fatigue.
45991482|NCT02930382|Other|Baroreflex assessment|
45991483|NCT02947724|Drug|SURGICEL®|Insertion of 4 pieces of SURGICEL® inside the cyst cavity. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
45991484|NCT02936583|Drug|BAY987521|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code:Z09-067)"
45991485|NCT02936544|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code:Z09-054)
45991486|NCT02936427|Drug|Dexamethasone|perineural infiltration of dexamethasone
45991487|NCT00523913|Drug|rosiglitazone|
45991488|NCT02930499|Device|Hyalomatrix extra-cellular matrix|An exta-cellular matrix made from hyaluronic acid
45991489|NCT02930499|Device|Mepilex wound dressing|A siliconized non-adhesive foam wound dressing
45991490|NCT02947763|Drug|mixture of metronidazole, ciprofloxacin, and minocycline|placement of intracanal medication
45991491|NCT02947841|Other|Alternating stimulation|Two different, but equally efficacious, settings will be determined for each subject. The settings will differ by a minimum of two of the following parameters: electrode configuration, voltage, frequency and pulse width. The different settings will be named Setting A and Setting B. The treatment cohort will receive both Setting A and Setting B that will differ by the parameters listed above.
45991492|NCT02947841|Other|Placebo|The control cohort will receive Setting A but Setting B will be identical to Setting A.
45676732|NCT02019667|Drug|SGS-742|
45676733|NCT02019667|Drug|Placebo|
45676734|NCT02030821|Drug|Amicar|Subjects randomized to receive Amicar will receive this during surgical intervention
45991493|NCT02930421|Other|Exercise training|30 min of exercise on a cycle ergometer at 80% of HRmax, 30 min of strength training of upper and lower limbs
45991494|NCT00523952|Drug|tacrolimus ointment|tacrolimus, single arm, 0.1 ointment
46084116|NCT00744471|Biological|tanezumab|Tanezumab 5mg IV every 8 weeks
46084117|NCT00744471|Biological|tanezumab|Tanezumab 2.5 mg IV every 8 weeks.
46084118|NCT00744471|Biological|Placebo|Placebo to match tanezumab IV every 8 weeks
46084119|NCT02776436|Drug|Dexamethasone|Dose of prophylactic dexamethasone will be reduced for all patients
45676735|NCT02030821|Drug|TXA|Subjects randomized to receive TXA will receive this during surgical intervention
45991495|NCT02936349|Other|Transthoracic Contrast Echocardiogram|A transthoracic contrast echocardiogram (TTCE) is a still or moving image of the internal parts of the heart using ultrasound following the injection of microbubble contrast (agitated saline) into a vein in the arm, which then travels to the heart.
45991496|NCT00524069|Biological|bevacizumab|
45991497|NCT00524069|Drug|capecitabine|
45991498|NCT00524069|Drug|gemcitabine hydrochloride|
45991499|NCT00524069|Other|flow cytometry|
45991500|NCT00524069|Other|laboratory biomarker analysis|
45991501|NCT00524069|Procedure|adjuvant therapy|
45991502|NCT00524069|Procedure|computed tomography|
45991503|NCT00524069|Procedure|neoadjuvant therapy|
45991504|NCT02936193|Procedure|Pylorus preservation|Patients undergo Laparoscopic Gastrectomy featuring pylorus-preservation
45991505|NCT02936193|Procedure|Distal gastrectomy|Patients undergo laparoscopic gastrectomy in distal gastric resection with D2 lymphadenectomy
45991506|NCT00524810|Drug|Pegylated liposomal doxorubicin|Caelyx 30 mg/m² day 1 every 3 weeks
46084120|NCT02776436|Drug|Prednisone|standard prednisone 5 mg bid for patients with prostate cancer
46084121|NCT04251923|Device|Retro pubic sling|patient after hysterectomy will undergo retropubic sling surgery in the same setting. Retropubic sling will be inserted vaginally in the retropubic area following standard protocol.
46084122|NCT02773004|Other|EPClin genomic test|
46084123|NCT02775968|Drug|Cephalosporins and Macrolide Antibiotics|The intervention drugs are prescribed by treating caregiver.
45991507|NCT00524810|Drug|Docetaxel|Taxotere 75 mg/m² day 2 every 3 weeks
45991508|NCT00524849|Biological|Zoledronic acid|Zometa 1 mg weekly (intravenous)
45991509|NCT00524849|Drug|Zoledronic acid|Zometa 4 mg every four weeks (intravenous)
45991510|NCT02936154|Drug|PF-06650833|
45991511|NCT02936154|Drug|placebo|
45991512|NCT00524888|Procedure|suturing laceration|suturing simple lacerations of the hand
45991513|NCT00524888|Procedure|bioadhesive|using bioadhesive on simple lacerations of the hand
45991514|NCT02936115|Other|TruSkin®|
45991515|NCT02936115|Other|Wound Cover|
45991516|NCT00524927|Drug|Methoxyflurane|
45991517|NCT00524927|Drug|Normal Saline|
45991518|NCT02936310|Behavioral|Mindful Living With Stress|The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.
45991519|NCT00524966|Procedure|Bipolar Versus Ultrasonic Hemostasis Techniques|OUTLINE: Patients undergoing thyroidectomy for thyroid cancer, thyroid nodules, hyperthyroidism and goiter will be randomized to either bipolar energy sealing system or ultrasonic coagulation.
45991520|NCT02935920|Behavioral|Individualized, tailored follow-up program|Individualized follow-up in the context of shared decision making, with the use of PRO-data to evaluate the patient needs of consultations.
45991521|NCT02276846|Device|Paclitaxel-Eluting Balloon|
46084124|NCT02776046|Drug|High FiO2|High FiO2 with a perioperative open lung strategy
45676736|NCT02052739|Drug|SAGE-547|Solution for injection for IV infusion
45676737|NCT02019277|Drug|Docetaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
45676738|NCT02019277|Drug|Nab-paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
45676739|NCT02019277|Drug|Paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
45991522|NCT02935725|Drug|Low dose AUT00206 800mg|
45991523|NCT02935725|Drug|High dose AUT00206 2000 mg|
45991524|NCT02935725|Drug|Placebo|
45991525|NCT02935725|Drug|Ketamine|
45991526|NCT02935725|Other|Saline|
45991527|NCT04693442|Other|taking of blood, urine and blood samples and objective scar assessment|blood, urine and skin tissue sampling & scar assessment questionnaires
45991528|NCT02935764|Drug|Irinotecan|180 mg/m2 iv gtt, d1
45991529|NCT02935764|Drug|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
45991530|NCT02935764|Drug|Leucovorin|400mg/m2 iv gtt,d1
45991531|NCT02935998|Drug|Ziprasidone|During the study, at least 1 injection is needed per day. Whether the second, third or fourth one is needed according to patients' symptoms. If the BARS score>=5, clinicians are supposed to give 10mg or 20mg.If lower than 5, clinicians could choose to give 10mg or not according to patients' symptoms and doctor's experience. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.It is not recommended to combine with other oral antipsychotic drugs. But if the patients' daily dose of injection has reached 40mg and agitation occurred 4 hours later after the last injection, with the BARS score higher than 5.The clinicians can determine whether or not to combine oral antipsychotic drug, and the dosage.
45991532|NCT04693208|Device|Laser therapy|Laser treatment parameters will be two combined wavelength (660 and 970 nm), 3.2 Watt peak power, 320 milliWatt/cm2, 36.8 Joule/cm2 fluency, and 50% frequency, for a total time of 3 minutes for each site
45991533|NCT02930616|Device|Patients in Group 1 will receive pCLE at first and WLE 2 months later|
45991534|NCT02930616|Device|patients in Group 2 will receive WLE at first and pCLE 2 months later.|
45991535|NCT02930304|Other|first physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions
45991536|NCT02930304|Other|second physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Kinesio taping will be applied two times per week total six times in addition to conventional physiotherapy
45991537|NCT02930304|Other|third physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Extracorporeal shockwave therapy (ESWT) will be applied one times per week total three session.
45991538|NCT00524147|Procedure|Pigtail drainage|
45991539|NCT02930109|Drug|PTX-200|During the Phase I study, increasing dose levels of PTX-200 will be administered as an intravenous infusion on Day 1 each cycle. Triciribine will be infused over 1 hour on Day 1 of each 21 day cycle. The initial dose level will be 25 mg/m2 and each dose level will be increased by 10 mg/m2 to a maximum dose of 55 mg/m2
46084125|NCT02776046|Drug|Conventional FiO2|Conventional FiO2 with a perioperative open lung strategy
46084126|NCT02775734|Drug|N-acetyl-cysteine|N-acetyl-cysteine + Clomiphene citrate + Laparoscopic ovarian drilling
46084127|NCT02775734|Drug|Clomiphene citrate|Clomiphene citrate + Laparoscopic ovarian drilling
45991540|NCT02930109|Drug|Cytarabine|Cytarabine will be given at a dose of 400 mg/m2 as a continuous IV infusion on days 3-7 of each cycle.
45991541|NCT00524186|Drug|fluorouracil|Given IV
45991542|NCT00524186|Drug|irinotecan hydrochloride|Given IV
45991543|NCT00524186|Drug|leucovorin calcium|Given IV
45991544|NCT00524186|Drug|sunitinib malate|Taken Orally
45991545|NCT00524186|Other|flow cytometry|Correlative Study
45991546|NCT00524186|Other|pharmacological study|Correlative Study
45991547|NCT04442178|Drug|CYT107|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
45991548|NCT04442178|Drug|Placebo|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
45991549|NCT00525005|Drug|DOS (Docetaxel, Oxaliplatin and S-1)|Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
45991550|NCT00525200|Drug|5-Fluoruracil, Cisplatinum|"5 FU 1000mg/m2; days 1-5; 3 cycles: q21~Cisplatin 80mg/m2; day 1; 3 cycles: q21"
45991551|NCT00525200|Drug|Docetaxel|Docetaxel 75mg/m2, day 1; 3 cycles; q21
45991552|NCT02929992|Other|ART initiation in the home|Participants initiate ART use in the home without visiting a clinic
45991553|NCT02929992|Other|Mobile Van Refill and Monitoring|Participants will pick up their medication refills from the mobile van and have all clinical monitoring conducted in the mobile van.
45991554|NCT02929992|Other|Clinic ART Initiation|Participants are referred to the clinic to initiate ART use
45991555|NCT02929992|Other|Clinic ART Refill and Monitoring|Participants will return to the clinic for ART refill and clinical monitoring.
45991556|NCT03458780|Drug|Yellow Fever Vaccine|Yellow Fever Vaccine .5 ml
45991557|NCT02930148|Other|PEGASO System (ICT based system/mHealth solution)|"Participants will be provided with a smart phone with the PEGASO system and will be asked to join the PEGASO community through the PEGASO Portal. Two smart garments, and two sensors will be provided at month 2 (to minimise the burden on the schools and participants allocating time and resources). The PEGASO System allows empowering the participants toward healthy habits, recording what he or she eats, monitor physical activity variables. The serious game is a central motivational component of PEGASO: it has an energy bar, used up by the player's actions, and replenished when achieving their behavioural goals, and it implements research mechanics that require the player to apply and develop their nutritional knowledge. The Bridge allows the connection between the PEGASO ecosystem and the personal health folder by creating a report to be shared with physicians"
46084128|NCT02778230|Dietary Supplement|Pea Fiber|Snacks (2 baked goods) fortified with 5 g pea hull fiber
46084129|NCT02778230|Dietary Supplement|Control|Snacks (2 baked goods) without fiber fortification.
46084130|NCT02772926|Dietary Supplement|Benfotiamine|Benfotiamine (S-Benzoylthiamine O-monophosphate) 900 mg per day
46084131|NCT02772926|Dietary Supplement|Placebo|Placebo 900 mg per day
46084132|NCT02709564|Drug|Misoprostol 400 sublingual|patients will take 2 tablets of sublingual misoprostol 400 microgram 3 hours and 1 hour before the surgery
45676740|NCT02019277|Drug|Pertuzumab|Pertuzumab will be administered on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg as an IV infusion every 3 weeks.
45991558|NCT03458741|Other|Glycogen Supercompensation|The subjects arrived in the morning in the overnight fasted state at day 1, day 2 and day 5. Upon arrival in the morning the subjects were given a meal corresponding to 5% of their daily energy intake (~600-800 kJ). During the 5 day supercompensation regime the subjects were provided a predefined isocaloric diet containing 80% carbohydrates, 10% fat and 10% proteins. All food items were handle out to the subjects and compliance of the diet regime was ensured by survey.
45991559|NCT02947802|Other|Effectiveness of Labels in Reducing Purchasing of Sugar Sweetened Beverages|In one of our parallel assigned conditions participants will receive additional information (e.g., an intervention) of effectiveness information. These consumers will learn how effective these labels were in reducing the purchasing of sugar sweetened beverages in a recent study.
45991560|NCT02947802|Other|Control condition|In one of our parallel assigned conditions participants will receive no additional information and be asked to rate their support for the label.
45991561|NCT02947568|Other|non-interventional study|
45991562|NCT02930265|Drug|Liraglutide|Liraglutide intervention group will accept liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
45991563|NCT02947490|Other|Self BP measurement|BP home measurement by patient, results to GP and GP alters treatment as per usual practice
46084133|NCT02709564|Drug|placebo 400 sublingual|patients will take 2 tablets of sublingual placebo 400 microgram 1 hour before the surgery
46084134|NCT02773082|Device|Reclaim™ DBS Therapy|The Medtronic Reclaim DBS Therapy is indicated for bilateral stimulation of the anterior limb of the internal capsule, AIC, as an adjunct to medications and as an alternative to anterior capsulotomy for treatment of chronic, severe, treatment-resistant obsessive compulsive disorder (OCD) in adult patients who have failed at least three selective serotonin reuptake inhibitors (SSRIs). Medtronic received humanitarian device exemption (HDE) approval for Reclaim DBS Therapy for the management of OCD on February 19, 2009.
46084135|NCT00611832|Behavioral|"Triple P Media Series -- Standard Information-Only version"|10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors.
45991564|NCT02947490|Other|Standard Care|Self BP measurement and patient management of anti-hypertensive treatment altering their own medication under supervision depending on home BP measurements
45991565|NCT02947490|Other|Standard BP management|GP to measure BP and manage BP control
45991566|NCT02947490|Other|Treatment|Contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels.
45991567|NCT02929953|Other|chart review|data from charts and from registries will be compared
46084136|NCT00611832|Behavioral|"Triple P Media Series -- Enhanced Behavior Activation version"|10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors; includes specific content elements designed to promote parents' adoption of the targeted parenting skills
45991568|NCT02947178|Procedure|Fascial iliac regional soft tissue infiltration blockade|Fascial iliac regional soft tissue infiltration blockade: Pain relief procedure (offered to all patients undergoing hip arthroscopy)
45991569|NCT02947178|Behavioral|Pain Score Survey|Utilizing: Defense and Veterans Pain Rating Scale (DVPRS)
45991570|NCT02947178|Behavioral|Pill Count|Patient reported as needed (prn) pain medication usage
45456929|NCT03926767|Other|Neck Motor Control Exercises|A protocol of neck motor control protocol will be adopted in our study. The exercises included bracing exercises (six hierarchical levels) in neurodevelopment stages for the cervical spine. Extremity range of motion exercises will be conducted while maintaining a stable spine at the specific positions. Also, cervical isometric exercises (five hierarchical levels) will be carried out directly forward, obliquely, toward right and left, and directly backward by maintaining a stable spine with elastic resistive bands. Finally, exercises also included functional training with elastic resistance and exercise balls on unstable surfaces (eight hierarchical levels). The criteria to progress in each exercise domain (bracing, isometric exercises or functional training) will be sustain the contraction for 10 seconds, 10 times.
45456930|NCT02294344|Other|DFPP&CTX|"First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~Then double volume of plasma was processed during each DFPP session every two day. A fraction plasma separator(Asahi Kasei Medical, surface area 2.0 m2,pore size 0.03 mm)and another fraction plasma separator (Asahi Kasei Medical, surface area 2.0 m2, pore size 0.01 mm)were used as first and second filter for plasma fractionation, respectively. 1.5 volume of plasma was processed, and 35~45g human albumin and blood plasma was supplemented during each session. The patients were treated with DFPP every two days for at least 3 times. After DFPP, 300-500ml blood plasma was supplemented."
45674136|NCT04590495|Drug|Placebo|Participant will either be given a placebo . After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
45991571|NCT02947178|Drug|Bupivacaine|
45991572|NCT02947178|Drug|Liposomal Bupivacaine|
45991573|NCT02929797|Biological|CD8+NKG2D+ AKT Cell|AKT: CD8+NKG2D+ AKT cell
45991574|NCT02929797|Drug|Gemcitabine|gemcitabine
45991575|NCT00525239|Drug|ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz|100 mg, twice daily, for four weeks
45991576|NCT02929758|Behavioral|Speed of processing training (SOPT)|This is a game-like program designed based on the UFOV. It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour). The duration of training will be 3 months. Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.
45991577|NCT02947139|Drug|Co-administration of DWC20155/DWC20156|
45991578|NCT02947139|Drug|DWC20161|
45991579|NCT02929836|Procedure|PVI|PVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.
45991580|NCT02929836|Procedure|LA linear ablation|LA linear ablation include mitral isthmus ablation and roof line ablation. Mitral isthmus ablation (from the mitral annulus to the left inferior PV) was performed first, followed by roof line ablation (between the right and left superior PVs).
45991581|NCT02929836|Procedure|CFAE ablation|Ablation catheter was maintained in a stable position when the electrograms were being recorded for at least 5 s to avoid artifacts.The procedural endpoint of CFAEs was the complete elimination of fragmented atrial activity in local electrograms.
45991582|NCT02929836|Procedure|linear ablation|Right atrial CTI ablation was performed during SR.
45991583|NCT02929836|Device|CARTO|3 dimensional mapping system
45991584|NCT04693052|Other|No interventions|This is a self-reported survey study about receiving mental health care during the COVID-19 pandemic
45991585|NCT02929914|Procedure|Local anesthesia and rubber dam isolation|Local anesthesia was performed. Tooth was isolated using a rubber dam isolation in order to collect the dentin samples.
45991586|NCT02929914|Procedure|Incomplete caries removal and microbiological samples collection|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a spoon (1#) was performed.
45991587|NCT02929914|Procedure|Dentin washed with sodium 0.9% saline|The remaining dentin was dipped in sodium 0.9% saline for 2min.
45991588|NCT02929914|Procedure|Antimicrobial Photodynamic Therapy|The remaining dentin was disinfected with aPDT for 2 min.
45991589|NCT02929914|Procedure|Microbiological samples collection and Indirect pulp treatment|A new dentin collection was performed after this treatment at another site of the cavity. Then teeth were conventionally restored using the following materials: calcium hydroxide lining material and resin (Z350,3M).
45991590|NCT02947334|Biological|Bococizumab|Bococizumab PFS
45991591|NCT02947334|Drug|Placebo|Placebo
45674137|NCT01859403|Genetic|Personalized Genomics|A set of single nucleotide polymorphisms in genes important for obesity, eating behaviors and exercise
45991592|NCT00525278|Drug|Levocetirizine dihydrochloride|
45991593|NCT00525317|Drug|"Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)"|120 mg x 3 or placebo
45991594|NCT02929719|Drug|Test.|gel
45991595|NCT02929719|Drug|Aczone Gel 5%|gel
45991596|NCT02929719|Drug|Placebo|gel
45991597|NCT00525980|Behavioral|Computer Program|"Participants will be given a program to learn about breast cancer risk and genetic testing.~Arm 3 Only = Participants will use the program with the assistance of a promotora (female promoter, community health worker, sometimes known as a lay health advisor)."
46084137|NCT02777996|Device|Low Dose Computed Tomography|Assessment protocol were adopted from the ELCAP study (modified) for Non Calcific Nodule with a diameter of less- equal than 5 mm at baseline and 3mm at repeated.
45674138|NCT01859403|Genetic|Usual Care|Patients receive the same dietary recommendation regardless of their genetic information
45674139|NCT01858701|Device|Lotrafilcon B toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
45674140|NCT01858701|Device|Comfilcon A toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
45674141|NCT01461538|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
45674142|NCT01461538|Drug|brentuximab vedotin|2.4 mg/kg every 3 weeks by intravenous (IV) infusion
45991598|NCT00525980|Behavioral|Focus Group|Focus group discussion lasting about 60 to 90 minutes.
45991599|NCT00525980|Other|Written Materials|Printed materials will be given. The CD-ROM will be offered at the end of the study.
45991600|NCT00525980|Behavioral|Questionnaires|Occasional questionnaire, written or verbal phone survey, about knowledge and attitudes toward cancer and genetic testing.
45991601|NCT02929875|Behavioral|Education based on TPB|Three Training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions.
45991602|NCT00525356|Device|Medtronic Talent Stent-Graft-System|
45991603|NCT04689672|Diagnostic Test|Lung ultrasound|Bedside lung ultrasound
45991604|NCT00525395|Genetic|Sequential phototherapy|Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment
45991605|NCT00525395|Procedure|Continuous phototherapy|Group B: 6 months non-stop treatment.
45991606|NCT04325685|Drug|Control|Oropharyngeal decontamination with saline will be performing three time a day every 8 hours during mechanical ventilation
46084138|NCT02693340|Biological|sampling|"• Sampling period(s):~Blood: W0, W6, W14, W30 and W52 and relapse.~Biopsies and fecal: W0, W14 and M52 and relapse."
46084139|NCT02777840|Device|face mask oxygen|oxygen given by face mask as per routine practice
46084140|NCT02777840|Device|High flow oxygen|High flow oxygen given via optiflo machine / device
46084141|NCT04688814|Procedure|Single puncture combined lumbar erector spinae plane block and quadrates lumborum block|"Patients will lay laterally with the fracture side independent, a curvilinear transducer will be placed in a parasagittal plane 3-4 cm lateral to the lumbar spinous process of L4.The probe is shifted slowly to the lateral side till the transverse processes disappear. After subcutaneous local infiltration with lidocaine 1% at the cephalic end of the probe, the block needle is advanced through the erector spinae and QL muscles, until it pierces the epimysium of the QL muscle. LA is injected anterior to the QL, between the QL and psoas muscles.~Then the caudal end of the probe is rotated slowly medially towards lumbar spine till the transverse process of L4 appears in the ultrasound image. The needle is withdrawn to subcutaneous tissue, then advanced in plane towards transverse process of L4. After contacting it, LA is deposited between transverse process and overlying ESM."
45991607|NCT04325685|Drug|Antiseptic Solution|Oropharyngeal decontamination with antiseptic solution will be performing three time a day every 8 hours during mechanical ventilation
45991608|NCT04325685|Drug|Bacteriophage|Oropharyngeal decontamination with bacteriophage will be performing three time a day every 8 hours during mechanical ventilation
45991609|NCT04693559|Procedure|secondary alveolar bone graft|Under general anaesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will made on both the sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will dissected. Next, the bone particles will implanted into the bone defect. The cleft site will closed without tension by advancement of the gingival flaps
45991610|NCT04693559|Procedure|harvesting of the autogenous bone graft|osteotome and then cut into small bone granules. The bone granules will then carefully placed into a syringe and pressed to its densest state by pushing the plunger
45991611|NCT04693559|Procedure|Nanocrystalline Hydroxyapatite|Nanocrystalline Hydroxyapatite will be used to fill the alveolar defect
45991612|NCT04323150|Device|Closed suction systems|Closed suction systems are using for prevention of the ventilator-associated pneumoniae
45991613|NCT04323150|Device|Conventional suction system|The using of open (conventional) suctioning
45991614|NCT00525434|Device|Seraffix LTB|wounds closure by using laser and albumin
45991615|NCT02929524|Drug|Ketamine|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
45991616|NCT02929524|Drug|Placebo|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
45991617|NCT00525473|Drug|Azathioprine|azathioprine usual dosage 100mg per day
45991618|NCT04310475|Other|Virtual reality assisted CBT|This study uses virtual reality technology to assist cognitive behavioural therapy for social difficulties in people with first episode psychosis.
45991619|NCT00526136|Drug|Placebo|
45991620|NCT00526136|Drug|Vernakalant (oral)|Vernakalant (oral), 150 mg (b.i.d.) Vernakalant (oral), 300 mg (b.i.d.) Vernakalant (oral), 500 mg (b.i.d.)
45991621|NCT02929446|Procedure|Mobilisation|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible
45991622|NCT02929446|Procedure|Mobilisation and breathing exercises|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible and breathing exercises with PEP
45991623|NCT00526175|Drug|Prednisone|60 mg/m2 day, i.v. or oral, dyas 1 to 27 30 mg/m2 day, i.v. or oral, days 28 to 35
45991624|NCT00526175|Drug|Vincristine|1,5 mg/m2 i.v., days 8, 15, 22 and 28
45991625|NCT00526175|Drug|Daunorubicin|30 mg/m2, i.v., days 8 and 15
45674143|NCT01461538|Drug|brentuximab vedotin|1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion
45991626|NCT00526175|Drug|L-Asparaginase|10.000 UI/m2, i.m. or i.v., days 9 to 11, 16 to 18 and 23 to 25. Total: 9 doses.
45991627|NCT00526175|Drug|Cyclophosphamide|1000 mg/m2, i.v., day 22.
45991628|NCT00526175|Drug|Methotrexate|Age <1 year 1-2 years 2-3 years > 3 years MTX 5 mg 8 mg 10 mg 12 mg
46084142|NCT04688814|Drug|Morphine Sulfate|Patients will receive GA and analgesia will be based on opioids mainly intravenous morphine
46084143|NCT02775890|Behavioral|Eating wild game shot with lead bullets|Participants will eat meat harvested with lead bullets, prepare mince meat and eat at least a standard serving (>85 grams).
45991629|NCT00526175|Drug|Cytosine Arabinoside|Edad <1 year 1-2 years 2-3 years > 3 years ARA-C 16 mg 16 mg 20 mg 30 mg
45991630|NCT00526175|Drug|Mercaptopurine|50 mg/m2,oral, days 1 to 7, 28-35 and 56-63
45991631|NCT00526175|Drug|VP-16|150 mg/m2 i.v., days 14-15 and 42-43
45991632|NCT02930031|Dietary Supplement|n-acetylcysteine|20 mg//kg/day, orally, daily for eight days following exercise
45991633|NCT02930031|Dietary Supplement|Placebo|500 mL orally, daily for eight days following exercise
45991634|NCT02929563|Drug|Pantoprazole|
45991635|NCT02929563|Drug|Placebo (for pantoprazole)|
45674144|NCT02117479|Drug|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
45674145|NCT02117479|Drug|Placebo|5 mg tablets to be administered by mouth twice daily (BID)
45674146|NCT02117479|Drug|Capecitabine|150 and 500 mg tablets to be administered by mouth twice daily (BID)
45674147|NCT02229851|Drug|somapacitan|Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.
45674148|NCT02229851|Drug|somatropin|Administered subcutaneously (s.c., under the skin) once daily for 26 weeks following 8 weeks of titration. Re-randomisation to extension of 44 weeks' treatment following 8 weeks of titration.
45674149|NCT02229851|Drug|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration.
45991636|NCT00525551|Drug|Acetylcysteine|150 mg / kg body weight. Drug is dissolved in NaCl to a final volume of 300 mL. This volume is infused starting one hour prior to surgery, and continued 1 hour after the end of surgery.
45991637|NCT00525551|Drug|Placebo (NaCl)|300 mL 0.9% NaCl
45991638|NCT04689399|Diagnostic Test|Standard Q COVID-19 Ag - test, produced by SD Biosensor INC.|Alle Danish citizens tested for infection with SARS-CoV-2 by swabs in the oropharynx, and subsequently analysis of the specimens by RT-PCR test at Testcenter Danmark's test centers will be included in the study. Participants will, in addition to the oropharyngeal swab they are already schedule for, be examined by a rapid antigen test.
45991639|NCT04288323|Drug|Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid|This study involves an on-label use of Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid for the ....
45991640|NCT02946359|Drug|Crizotinib, bevacizumab|Eligible patients with ALK translocation or ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID and bevacizumab at the dose of 7.5mg/kg every three weeks. The dose of crizotinib and bevacizumab may be adjusted depending on the type and severity of toxicity encountered
45991641|NCT02929173|Other|Allceram|Pressed E-max coping veneered with E-max veneering system
45991642|NCT02929173|Other|hybrid crown|pressed Bio HPP coping veneered with visolign veneering system
45991643|NCT02946437|Drug|Sevoflurane|Postconditioning with sevoflurane (0.5-1.5vol%) for 4 hours after coiling or clipping of cerebral aneurysm in patients with severe SAH
45991644|NCT02946437|Drug|Propofol|Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
45991645|NCT02946437|Drug|Midazolam|Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
45991646|NCT02946437|Device|MIRUS™System|The MIRUS™System is the normally used standard equipment for the administration of volatile anaesthetics to patients.
45991647|NCT02946632|Drug|triple combination therapy|Xigduo (metformin 1000mg + dapagliflozin 10mg) saxagliptin 5mg
45991648|NCT02946632|Drug|Stepwise add-on therapy|metformin -> glimepirde -> sitagliptin
45991649|NCT02929134|Drug|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg)
45991650|NCT02929134|Drug|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
46084144|NCT02709252|Device|PVI and deltaPP after trendelenburg position change|Comparison of hemodynamic parameters during surgery after position change
45833742|NCT04300140|Drug|Cabozantinib (Cabo)|Cabozantinib is standard of care as monotherapy and in combination with nivolumab in ccRCC
45833743|NCT04300140|Drug|Nivolumab|Nivolumab is standard of care in the first line treatment of ccRCC
45833744|NCT03631680|Procedure|Bilateral Oophorectomy Surgery|Women undergoing elective, laparoscopic bilateral oophorectomy surgery will be enrolled.
46084145|NCT04826042|Other|thoracic epidural catheterization|thoracic epidural catheterization
46084146|NCT04160442|Behavioral|Carevive CarePlanning System|Subject will complete brief survey prior to seeing provider in clinic. Utilizing the CarePlanning System, the provider will review the subject's responses directing the conversation and treatment decision will be made. A treatment careplan will be developed and given to the subject.
46084147|NCT02772692|Behavioral|Squatting pan|Using squatting pans to replace standard-sized toilets in one group of the included constipation patients
46084148|NCT04653480|Drug|Surufatinib|250mg per oral, once daily
46084149|NCT04653480|Drug|Toripalimab|3mg/kg IV, once every 2 weeks
45991651|NCT04693091|Device|Senti V1.0 Device|"This device class I, CE marked garment, with a similar form to a T-Shirt, embedded with ten sensor modules encased in silicone; the device comes with a charging stand in the form of a clothes hanger. Depending on the outcome of this feasibility study, the device may, in the future, form part of a class IIb medical device system, when accompanied by cloud-based software to listen to both current and historically recorded breath sounds for each Senti patient. The Senti Version One device will be labelled clearly to indicate the device version, on the inside of the garment, conforming to the MDR.~The garment itself will be made from textile composite, including cotton, elastase, micromodel, spandex, and polyester. All other components (including electronic and other plastic components) will be entirely encased in medical-grade silicone."
45991652|NCT02929212|Other|Solid Meal|Subjects will receive solid meals during meal study
45991653|NCT02929212|Other|Liquid Meal|Subjects will receive liquid meals, during meal study
45991654|NCT02929212|Drug|Acetaminophen|All subjects given acetaminophen to measure gastric emptying
45991655|NCT02929212|Other|Single, 600 kcal meal|Subjects will receive a single, 600 kcal meal during meal study
45991656|NCT02929212|Other|Multiple, 200 kcal meals|Subjects will receive three, 200 kcal meals, during meal study
45991657|NCT02947373|Drug|Hyperpolarized Pyruvate|Hyperpolarized Pyruvate
45991658|NCT02929251|Drug|Anakinra|Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks
45991659|NCT02929251|Drug|Tocilizumab|Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.
46084150|NCT04653480|Drug|chemotherapy|oxaliplatin or irinotecan based regimens, according to the first line treatment
45833745|NCT03174132|Device|Restylane Perlane Lidocaine|Intradermal injection
45833746|NCT03174132|Device|Restylane Perlane|Intradermal injection
45833747|NCT03173976|Drug|Zoledronic Acid|Zoledronic acid, a member of bisphosphonate class, inhibits bone resorption.
45833748|NCT03592368|Device|IBT|Interpretation bias training
45991660|NCT02929251|Drug|Adalimumab|Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
45991661|NCT02929368|Device|PICC implantation under fluoroscopy|PICC Catheter implantation
45991662|NCT02929368|Device|PICC Implantation under Sherlock System|PICC Catheter implantation
45991663|NCT02946281|Behavioral|Do CHANGE|The intervention aims to increase behavioral flexibility and change patients' (unhealthy) lifestyle. At the same time the intervention should increase patient self-management and improve the patient reported outcomes (e.g. quality of life, anxiety, depression).
45991664|NCT02929290|Drug|BPI-9016M|"Part I：Four dose cohorts will be evaluated, including 300mg, 450mg, 600mg, 800mg. BPI-9016M Tablet will be administered orally to patients once daily for each dose cohort.~Part II：400mg BPI-9016M Tablet will be administered orally to patients twice a day."
45991665|NCT02947451|Other|Manual Therapy|"In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee.~Stretching, myofascial release and mobilizations will be held for 30 seconds, with three repetitions of each. The intervention will be applied only once."
45991666|NCT02947451|Other|TENS|In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application. The intensity will be defined by the patient, should the stimulus be considered intense, but pleasant to it.
45991667|NCT02929095|Drug|dexmedetomidine|
45674150|NCT01482910|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants in the VEGF Trap-Eye group received intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks for an overall treatment period of 48 weeks. Additionally, sham PDT treatments was administered as needed.
45674151|NCT01482910|Drug|Visudyne|Participants in the PDT group (Visudyne group) received Visudyne as needed. Additionally, sham IVT injections was administered until week 28. Thereafter, subjects in the PDT group received active (= no sham) VEGF Trap-Eye treatment until week 48.
45674152|NCT04077190|Device|Adipose-derived stem cells|5cc adipose derived stem cells.
45991668|NCT02929095|Drug|midazolam|
45991669|NCT02929095|Drug|remifentanil|- remifentanil will be administered to both dexmedetomidine and midazolam group as a routine part of procedure and it is no of interest of the protocol
45991670|NCT02946554|Biological|HepaStem|
45991671|NCT02928861|Device|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post- injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
45991672|NCT02946476|Other|prognostic impact of non cardiac comorbidities|
45991673|NCT02928900|Behavioral|Clinician training intervention|This intervention is a clinician training using SP actors to improve communication and empathy skills of HIV care providers who serve HIV-positive adolescents and youth in Kenya.
45991674|NCT00525668|Drug|epigallocatechin-gallate (Sunphenon)|200 mg twice daily, after 3 months 400 mg twice daily
45991675|NCT00525668|Drug|placebo|2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily
45674153|NCT04077190|Device|cortisone injection|cortisone injection
45991676|NCT02928783|Behavioral|Home-based cardiac rehabilitation|
46002334|NCT03728582|Device|Sham tDCS plus Speech-Language Therapy|Sham tDCS stimulation is provided to the left inferior frontal gyrus (IFG) using a tDCS device. Speech-language therapy will be verb naming therapy in a sentence context.
46002335|NCT03644186|Drug|Paclitaxel|Chemotherapy plus HER2 Blockade
46002336|NCT03644186|Drug|Trastuzumab|Chemotherapy plus HER2 Blockade
45674154|NCT04595422|Other|Educational Intervention|Undergo training consisting of a 60-minute educational session
45674155|NCT04595422|Other|Educational Intervention|Receive lung cancer screening educational materials
45674156|NCT04595422|Other|Questionnaire Administration|Complete questionnaire
45674157|NCT04595422|Other|Survey Administration|Ancillary studies
45833749|NCT04271904|Other|Placebo Diet|"The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). Occasional cheat foods are built into the placebo diet but with more pro-inflammatory options (e.g. two glasses of wine per week)."
46002337|NCT03644186|Drug|Pertuzumab|Chemotherapy plus HER2 Blockade
46002338|NCT03644186|Drug|Palbociclib|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
46002339|NCT03644186|Drug|Letrozole|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
45674158|NCT01626391|Drug|TRx0237|TRx0237 tablets 250 mg/day (given as 125 mg bid) for 4 weeks
45674159|NCT01626391|Drug|Placebo|Placebo tablets will be administered twice daily (b.i.d.) for 4 weeks. The placebo tablets include 4 mg of TRx0237 as a urinary and faecal colourant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
45674160|NCT04742257|Device|MyoRegulator® device|Trans-spinal DCS paired with peripheral DCS
45674161|NCT02103439|Drug|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
45674162|NCT02103439|Drug|PegIntron|1.5 µg/kg of body weight subcutaneously, once a week
46002340|NCT03644186|Drug|Trastuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
45991677|NCT02946593|Behavioral|Stroll Safe outdoor fall prevention program|The structure of the program will model the evidenced-based Lifestyle Re-Design program (Clark et al., 2012). Session 1, 2, 4 & 5 will include a brief didactic presentation about outdoor fall risks and strategy use from the group leader. This will be followed by group discussion/problem solving related to addressing risks. Identified strategies will be recorded on a wipe board and transcribed for group members in order to create handouts. Each 90 minute session will end with action planning, where participants will write down behavioral changes they will implement in the coming week. Session 3 and 6, also 90 minutes, will include outdoor mobility training and practice using strategies discussed in previous sessions. Training sessions will be led by the PI and an assistant. The final session will be a review of risks, strategy use, and reinforcement of behavioral changes in participant's action plans.
45991678|NCT02946593|Behavioral|Outdoor fall prevention brochure|The control group participants will be given a written brochure on tips for preventing outdoor falls.
45991679|NCT02928822|Behavioral|VR-based sensorimotor aphasia therapy|VR-based sensorimotor aphasia therapy. 8 weeks, 1 session a week, 30min-1h per session of language and motor therapy using using VR rehabilitation gaming system. The patients will play in pairs.
45991680|NCT02928822|Behavioral|Control Group (conventional aphasia rehabilitation)|8 weeks, 1 session a week, 30min-1h per session of conventional aphasia rehabilitation training the same vocabulary as the experimental group.
45991681|NCT00525707|Drug|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
45991682|NCT02929017|Other|SUPPORT|Members of this group will receive personal, enhanced printed materials, as well as face-to-face support, and digital information provided by the interventionist.
45991683|NCT02929017|Other|Currently Available Printed Material|Subjects will receive their usual standard of care, including currently available printed patient material.
45991684|NCT00526214|Drug|celecoxib medication|In the celecoxib group, patients will take celecoxib 400mg twice (per day), orally for 14 days.
45991685|NCT02928744|Other|COPD|Plethysmography
45991686|NCT02928744|Other|COPD|Forced oscillations
46084151|NCT00744237|Drug|Nebivolol|"Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration~Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration~Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration~Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration"
46084152|NCT00744237|Drug|Metoprolol ER|"Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration~Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration~Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration~Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration"
45991687|NCT02928705|Procedure|physician operated telemedical prehospital analgesia|Ambulances in the EMS of the city of Aachen are equipped with a portable telemedicine system. In emergencies requiring intravenous analgesia paramedics can use this system to contact the tele-EMS physician with an audio-connection. Vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) can be transferred in real-time. The transmission of still pictures - taken with an official smartphone - and video streaming from the inside of the ambulance are also possible. The tele-EMS physician supports the paramedics and can delegate the application of morphine and other analgesics based on two predefined algorithms for trauma and non-trauma cases that are displayed on a context-sensitive telemedical documentation system in the teleconsultation center.
45991688|NCT02928705|Procedure|prehospital analgesia by on-scene EMS physicians|This (control) group represents the conventional treatment in German emergency medical service (EMS). In addition to an ambulance manned with paramedics, a prehospital EMS physician is deployed to conduct analgesic treatment on-scene. Treatment data for this group are selected from the time period before implementing teleconsultation in routine and therefore represent a historical control group.
46084153|NCT00744237|Drug|HCTZ|"HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration~HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration"
46084154|NCT04821284|Drug|Gemcitabine Hydrochloride|Given IV
46084155|NCT04821284|Drug|Nab-paclitaxel|Given IV
45674163|NCT02229539|Drug|doxepin hydrochloride oral solution|2.5 mL (25 mg) doxepin and 2.5 mL water administered orally
45674164|NCT02229539|Drug|DLA (diphenhydramine, lidocaine and antacids) rinse|5.0 mL administered orally
45991689|NCT00526253|Biological|MyoCell|Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 400 million cells.
46084156|NCT04821284|Drug|Fluorouracil|Given IV
46084157|NCT04821284|Drug|Irinotecan Hydrochloride|Given IV
46084158|NCT04821284|Drug|Leucovorin Calcium|Given IV
46084159|NCT04821284|Drug|Oxaliplatin|Given IV
46084160|NCT04821284|Other|Perflubutane Microbubble|Oxaliplatin
45674165|NCT02229539|Other|Placebo|2.5 mL placebo and 2.5 mL water administered orally
45674166|NCT01835223|Drug|Tivozanib (1mg)|Given PO
45674167|NCT01835223|Drug|Tivozanib (1.5mg)|Given PO
45991690|NCT00526253|Biological|MyoCell|Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 800 million cells.
46084161|NCT04821284|Procedure|Contrast-Enhanced Ultrasound|Undergo CEUS
46084162|NCT04821284|Other|Quality-of-Life Assessment|Ancillary studies
46084163|NCT05260554|Drug|Fosfomycin|In this group with urinary tract inflammation; Fosfomycin was prescribed for 7 days (3 doses, 2 days apart). There are 80 patients in total.
46084164|NCT05260554|Dietary Supplement|Cranberry|In this group with urinary tract inflammation; 7 days (used every day) cranberry tablet was given. There are 80 patients in total.
45674168|NCT01482598|Device|Remote Care Follow up|Patient device is checked daily through remote transmitter (Merlin@Home) and every 6 month a complete transmission with all device data is performed
45674169|NCT01460446|Device|Aviva Expert blood glucose meter|
45674170|NCT01460446|Device|Aviva Nano blood glucose meter|
45674171|NCT02229383|Drug|Exenatide|2 mg weekly suspension injection
45674172|NCT02229383|Drug|Exenatide matching placebo|Once weekly Placebo injection
45991691|NCT00526253|Procedure|Hypothermosol|After the cell culture period of time has passed, patient's myocardium will be injected with the transport media alone. Patient will not receive any cultured myoblasts during these injections.
45991692|NCT02928939|Other|drug-drug or drug-disease interaction|
45991693|NCT03457584|Procedure|air arm|epiretinal membranes are excised during membrane peeling and air-tamponade is left in the eye
45991694|NCT03457584|Procedure|BSS arm|epiretinal membranes are excised during membrane Peeling and BSS is left in the eye
45991695|NCT04693013|Device|Virtual Reality for Anxiety Reduction|Virtual Reality for Anxiety Reduction during suturing of perineum
45991696|NCT02928666|Other|DSS for mitigating interactions between recommendations|DSS that detects and mitigates interactions between recommendations, proposing a set of non-conflicting guideline recommendations
45991697|NCT02947256|Procedure|standard laparoscopic cholecystectomy|which included the classic dissection of Calot's triangle to achieve the CVS, with separate clipping and division of cystic duct and artery
45991698|NCT02947256|Procedure|RI approach|which included separation of the lower third of GB from its bed down to its pedicle (artery and duct) with mass ligation of both.
45991699|NCT02928510|Procedure|Biospecimen Collection|Undergo biospecimen collection
45991700|NCT02928510|Procedure|Colonoscopy|Undergo colonoscopy
45991701|NCT02928510|Procedure|Colposcopic Biopsy|Undergo colposcopic biopsy
45991702|NCT02928510|Drug|Idelalisib|Given PO
45991703|NCT02928510|Other|Laboratory Biomarker Analysis|Correlative studies
45991704|NCT02928510|Other|Pharmacological Study|Correlative studies
45991705|NCT02928510|Procedure|Physical Examination|Undergo physical examination
45991706|NCT02928510|Procedure|Sigmoidoscopy|Undergo sigmoidoscopy
45991707|NCT04692974|Device|Mobile phone application and smart watch|Mobile phone application prompts
45991708|NCT02928393|Drug|Basmisanil|Basmisanil immediate-release granules at a dose of 240 mg will be given orally twice daily for 90 days.
45991709|NCT02928393|Drug|Placebo|Placebo matched to basmisanil immediate-release granules will be given orally twice daily for 90 days.
45991710|NCT02947412|Other|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
45674173|NCT01499368|Drug|Lafutidine|Lafutidine 20mg/day
45674174|NCT01499368|Drug|Famotidine|Famotidine 40mg/day
45674175|NCT01499368|Drug|Omeprazole|Omeprazole 20mg/day
45674176|NCT01835145|Drug|Cabozantinib S-malate|Given PO
45674177|NCT01835145|Drug|Dacarbazine|Given IV
45674178|NCT01835145|Other|Laboratory Biomarker Analysis|Correlative studies
45991711|NCT02928354|Drug|Treatment A - AZD7594|Particle size Large as a single inhaled dose of 440 µg (nominal dose), administered via DPI
45991712|NCT02928354|Drug|Treatment B - AZD7594|Particle size Medium as a single inhaled dose of 440 µg (nominal dose), administered via DPI
45991713|NCT02928354|Drug|Treatment C - AZD7594|Particle size Small as a single inhaled dose of 440 µg (nominal dose), administered via DPI
45991714|NCT02946944|Drug|Sildenafil/apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups. Dual drug therapy is going to be administered to this group (experimental): sildenafil 30mg 3p \ g + 10 mg apixaban 2p \ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
45674179|NCT01835145|Drug|Temozolomide|Given PO
45674180|NCT02229227|Drug|Albiglutide|Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
46002341|NCT03644186|Drug|Pertuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
46002342|NCT03626662|Drug|AMG 890|Ascending Single Doses of AMG 890
46002343|NCT03626662|Drug|Placebo|Calculated volume to match experimental drug.
46002344|NCT03614234|Drug|pegunigalsidase alfa|Recombinant human alpha galactosidase A
46002345|NCT03613077|Procedure|surgical placement of an endosteal implant|Subjects, male or female at least 18 years old, with the need of dental implant therapy and restoration according to the cleared indications for the implant
46002346|NCT03593395|Other|Peer Mentoring [PM]|Virtual Peer Mentoring
46002347|NCT03593395|Other|Structured Education Based Transition Program STE|Education-based program
45991715|NCT02946944|Drug|apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups.Mono drug therapy is going to be administered to this group (active comparator): apixaban 10 mg 2p \ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
45991716|NCT02928471|Dietary Supplement|Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
45991717|NCT02946983|Other|Fructose|Intragastric administration of fructose (25g dissolved in 250ml distilled water)
45991718|NCT02946983|Other|Control|Intragastric administration of distilled water
45991719|NCT02928432|Drug|Steroids switch|Change of prednisone 5mg/12h to dexamethasone 0.5mg/24h
46084165|NCT02693652|Biological|CVI-HBV-002|"Investigational product: CVI-HBV-002~Dose: 20ug or 40ug~Frequency: 3 or 6 times~Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months~Administration route: Intramuscular injection"
45991720|NCT02928549|Behavioral|semi-structured interviews|
45991721|NCT02947061|Drug|S1 plus Docetaxel|S1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
45991722|NCT02947061|Drug|Capecitabine plus Docetaxel|Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
45991723|NCT02928276|Other|RheumaKit: Prediction of the response to anti-TNFs DMARDs|
45991724|NCT02946320|Device|Predilatation with non-compliant balloon|Coronary artery stenosis is dilated before BVS implantation with the use of non-compliant balloon (standard procedure). Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
45991725|NCT02946320|Device|Predilatation with scoring balloon (Scoroflex)|Coronary artery stenosis is dilated before BVS implantation with the use of scoring balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
45991726|NCT02946320|Device|Predilatation with cutting balloon (Flextome)|Coronary artery stenosis is dilated before BVS implantation with the use of cutting balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
45991727|NCT02928627|Other|Analysis of microRNA expression|sample analysis
46084166|NCT04089345|Drug|Ustekinumab|All patients will receive intravenously (IV) ustekinumab ~6mg/kg at baseline and subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48.
45833750|NCT01825278|Device|ExSpiron Respiratory Volume Monitor (RVM, ExSpiron™, Respiratory Motion, Inc.; Waltham, MA|Monitoring sensors will be applied to patient's right chest and the monitoring device will collect breathing parameters such as breathing rate and volumes before, during and after the procedure until patient is ready to leave the recovery room. At the beginning and at the end of the study investigator will perform a one-time measurement of patient's respiratory parameters using a standard handheld spirometer. This is a non-invasive device that is commonly used in clinical care not related to research.
45833751|NCT01812252|Drug|Azacitidine|Given IV or SC
45991728|NCT02928315|Drug|Magnesium Sulfate|The patients in the study group will receive 10 mmol of magnesium sulphate (2.47 gm). Five ampoules of 500 mg of magnesium sulphate will be dissolved in 100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
45991729|NCT02928315|Other|control|100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
45991730|NCT00525746|Behavioral|Interview|Interview lasting about 50 minutes.
45991731|NCT04692090|Other|Yoga|"Each class started with a check-in period during which any questions or concerns could be raised, after which the patients were given 5 minutes for seated meditation and 10 minutes for Shavasana (lying down in a restorative position).~The following poses were instructed during the course: standing poses with mountain pose (tadasana), chair pose (utkatasana), extended triangle pose (utthita trikonasana), extended side angle pose (utthita parshvakonasana), warrior 1 (virabhadrasana 1), warrior 2 (virabhadrasana 2) and tree pose (vrikshasana). The intervention was applied twice a week for 10 weeks."
45991732|NCT00526409|Drug|Prednisolone|Induction: 60 mg/m2/day, oral or i.v x 21 days and 30 mg/m2/day oral or iv x 7 days Reinduction-Intensification Treatment: 60 mg/m2/d x 14 days and 30 mg/m2/day oral x 7 days
45991733|NCT00526409|Drug|Daunorubicin|Induction: 30 mg/m2, i.v, days 1, 8, 15, 22 Consolidation (Bloc II)30 mg/m2, i.v, day 1
46084167|NCT02772536|Other|Visual Stimulus Condition Set|"In this single arm study, all participants are subject to a set of three visual stimulus conditions.~Low ambient light for 10 mins: Self selected tinted light (20 Mins); White light (20 mins).~VAS/CGI scores for each stimulus condition in the above set are reported at five minute intervals."
46084168|NCT02693574|Drug|Clarithromycin|
45833752|NCT01812252|Drug|Decitabine|Given IV or SC
46084169|NCT02693574|Drug|Levofloxacin|
46084170|NCT02597205|Behavioral|physician-facing app and patient-facing messages|A physician-facing app was designed to help physicians with recruiting and managing patients and with evidence-based medications prescription. Messages were also developed to send to patients to improve their medical adherence and modify lifestyle.
46084171|NCT02709174|Procedure|blood draw|blood draw
45833753|NCT01812252|Other|Quality-of-Life Assessment|Ancillary studies
45833754|NCT05005806|Drug|Omega 3 fatty acid|omega 3 fatty acid soft gel
45833755|NCT05005806|Drug|Placebo|placebo soft gel
45991734|NCT00526409|Drug|Vincristine|Induction: 1,5 mg/m2 iv, days 1, 8, 15, 22 Consolidation (Bloc I):1,5 mg/m2 iv, days 1, 8 Consolidation (Bloc II):1,5 mg/m2 iv, days 1, 8 Reinduction: 1,5 mg/m2 iv, days 1, 8 Maintenance:1,5 mg/m2 iv, day 22
45991735|NCT00526409|Drug|L-Asparaginase|Induction: 10.000 U/m2 im or iv, days 9,11,13,16,18,20,23,25,27 Consolidation (Bloc II): 20.000 U/m2 im or iv, day 7 Maintenance: 20.000 U/m2 im or iv, day 22
45991736|NCT00526409|Drug|Cyclophosphamide|Induction: 500 mg/m2 iv, days 1, 2, 29 Consolidation (Bloc I): 500 mg/m2 iv, day 8 Reinduction:500 mg/m2 iv, day 15
45674181|NCT02229227|Drug|Insulin Glargine and Insulin Lispro|Insulin glargine and insulin lispro will be provided as injection pens for SC injection
45991737|NCT00526409|Drug|Methotrexate|Consolidation (Bloc I): 5 g/m2 24 hours infusion Consolidation (Bloc II): 5 g/m2 24 hours infusion Reinduction: 3 g/m2 24 hours infusion Maintenance: 20 mg/m2/d, IM/week x 3 (1, 7, 14)
45991738|NCT00526409|Drug|Cytosine Arabinoside|Consolidation (Bloc I): 1 g/m2/12 h iv, days 5, 6 Consolidation (Bloc II): 1 g/m2/12 h iv, days 5, 6 Reinduction: 1 g/m2/12 h iv, days 43, 44
45991739|NCT02928237|Device|transcranial direct current stimulation tDCS|A battery driven DC stimulator (neuroConn Gmbh,98693 llmenau, Germany)
45991740|NCT00526448|Drug|ribavirin|2000 mg/day
45991741|NCT00526448|Drug|ribavirin|1000-1200 mg/day
45991742|NCT00526448|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180 mcg/week
45991743|NCT00526448|Drug|epoetin beta|epoetin beta 450 UI/week
45991744|NCT02928159|Device|Mecta spectrum 5000Q device|LAP-ST and Right Unilateral (RUL) electrode placement.
45991745|NCT05647629|Procedure|Total hip arthroplasty|hip prosthesis surgery
45991746|NCT00525863|Drug|oxygen|Patients will be treated with oxygen for 1 month and then for 1 month with regular air with the same flow rate and procedure or randomly in the opposite order. We propose to enrich the inspired oxygen partial pressure from 21 kPA to ~40 kPa in a double blind cross-over design. Ninety percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours/day, throughout the night.
45991747|NCT02928198|Device|ABSORB BVS|
45991748|NCT04692545|Dietary Supplement|Immunonutrition|nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
45991749|NCT04692506|Other|Probiotic|The study product is probiotic
45991750|NCT00527865|Drug|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.
45991751|NCT00527865|Drug|Placebo|Capsules containing 10.5 mg of lactose will be supplied as placebo.
45991752|NCT00526487|Device|Zenith® Dissection Endovascular System|The Zenith® Thoracic Dissection Study is a clinical trial to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of dissections (length-wise tear) of the descending thoracic aorta. The Zenith® Dissection Endovascular System is comprised of the Zenith TX2® TAA Endovascular Graft and the Zenith® Dissection Endovascular Stent. Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the graft and the dissection stent into place in the aorta.
45991753|NCT00526487|Device|Endovascular Repair|Endovascular Repair
45991754|NCT02928081|Procedure|Extended lymphadenectomy|Extended lymphadenectomy with nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1)
45991755|NCT02928081|Procedure|Standard lymphadenectomy|Lymph node dissection includes(LN5, LN6),(LN8a, 8b),(LN12b1, 12b2, 12c),(LN13a, 13b),(LN14a, 14b),(LN17a, 17b)
45991756|NCT00526565|Behavioral|Tapas Acupressure Technique|Practice of the TAT technique involves application of pressure to select acupoints combined with specific mental focus. The TAT pose involves lightly touching the tips of the left thumb and 4th finger to the area 1/8 inch above the inner corner of each eye and the 3rd finger to the point midway between the eyes, about ½ inch above eyebrow level. The right hand is on the back of the head, with the palm cradling the occiput and the thumb just above the hairline. Once in this position, the process is to 1) focus attention on the identified problem or behavior to be changed (e.g., over-eating); 2) focus on a positive thought related to the problem; 3) focus on the thought of healing or clearing the origins of the problem; and 4) focus on an awareness of healing or clearing any storage of the problem, at a cellular, mental, emotional, or energetic level.
45991757|NCT00526565|Behavioral|Social support|The LIFE SS maintenance intervention will consist of a series of professionally facilitated social support groups where the session content is directed by the participants. The contact hours for SS will match those of the TAT intervention. The initial SS group session will orient participants to the basics of weight maintenance, and subsequent sessions will provide opportunities for participants to share experiences and ask questions. Participants may choose to use behavioral tools as desired. In addition to the basic materials about weight loss maintenance used in both maintenance interventions, will we use the materials already used in the weight loss program for the SS group as needed. We will measure adherence by taking attendance at the SS group sessions.
45991758|NCT02928003|Procedure|Lung surgery|Genetic analysis and questionnaires
45991759|NCT02946827|Dietary Supplement|Balanced low FODMAPs /gluten free diet|
45991760|NCT02946827|Dietary Supplement|Balanced gluten free diet|
45991761|NCT02928042|Other|Lactobacillus bacteria|Antimicrobial effects of Lactobacillus bacteria (LAB) and nisin bacteriocin on pathogen bacteria and commercial strains of the same bacteria's growth rate will be investigated.
46084172|NCT04179266|Drug|Ketamine|One Cluster headache attack is treated with intranasal ketamine
46084173|NCT00743145|Drug|Inactive Marijuana (0% THC)|Marijuana cigarette containing 0% THC
46084174|NCT00743145|Drug|Active Marijuana (5.5% THC)|Marijuana cigarette containing 5.5% THC
45674182|NCT01499290|Drug|CAZ-AVI|Ceftazidime 2000 mg and 500 mg of avibactam
45674183|NCT01499290|Drug|Metronidazole|500 mg of Metronidazole
46084175|NCT00743145|Drug|Active Marijuana (6.2% THC)|Marijuana cigarette containing 6.2% THC
46084176|NCT00743145|Drug|Naltrexone|Naltrexone (12mg/70kg)
45674184|NCT01499290|Drug|Meropenem|1 gram of Meropenem
45676741|NCT02019277|Drug|Trastuzumab|Trastuzumab will be administered at a fixed dose of 600 mg SC every 3 weeks.
45676742|NCT04712773|Device|PMD-200 monitor|Patient is connected to non-invasive PMD-200 monitor, measuring Nociception Level
45991762|NCT02946671|Biological|Mogamulizumab|Mogamulizumab (0.1, 0.3 or 1.0 mg/kg) is administered.
45991763|NCT02946671|Biological|Nivolumab|Nivolumab (3.0 mg/kg) is administered.
45991764|NCT02927886|Procedure|Per-oral endoscopy pyloromyotomy|
45991765|NCT02927886|Procedure|Intrapyloric injection of Botulinum toxin|
45991766|NCT00526604|Behavioral|work related rehabilitation|"The workplace intervention includes two steps:~Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.~Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks."
45991767|NCT02945280|Drug|apixaban|12 weeks of apixaban treatment to monitor for efficacy in the prevention of VTE-related mortality
45991768|NCT02946164|Behavioral|Stick To It|The intervention is a prize system linked to points earned through online and real-world activities designed to incentivize young MSM to test for HIV and STIs every three months. Participants receive points for pre-determined activities, such as: answering online quizzes, inviting friends to participate, and getting tested for HIV/STIs. Points are redeemable in person at two AIDS Healthcare Foundation Men's Wellness Centers, where participants will be able to exchange their points for gumballs from a gumball machine; different color combinations of gumballs correspond to prizes of different values. Participants are reminded to get tested regularly via SMS messages; in addition, they can check when their next test is due by checking their testing timer on the stick2it.org website.
45991769|NCT02946710|Biological|cerebrospinal fluid|Biological analysis on cerebrospinal fluid
45991770|NCT02927730|Other|no interventions|no interventions
45991771|NCT04692402|Device|Solitaire™ thrombus retrieval device|After consent has been obtained, interventional cardiologist selects the proper solitaire device size per device-specific instructions for use. Adjunctive intervention with Solitaire will be done with a maximum of 2 device deployments. Do not perform more than three recovery attempts in the same vessel using the devices (Maximum of 2 attempts per device per subject). Do not reposition each device more than two times. TIMI flow, thrombus grade and myocardial blush grade will be assessed immediately upon completion of procedure. If recanalization is deemed inadequate by the interventional cardiologist, rescue treatment will follow as per current clinical practice. All other procedures followed will be as clinically indicated.
45991772|NCT02927808|Behavioral|Motivational Interview|Informational leaflet about the risks of high LDL-C and the importance of adherence to lipid-lowering medication in patients with coronary artery disease. Follow-up motivational interviewing at 1 and 6 months after discharge.
46084177|NCT00743145|Drug|Placebo naltrexone|Naltrexone (0mg)
46084178|NCT04875728|Drug|Cefazolin|Given IV
46084179|NCT04875728|Procedure|Resection|Undergo standard of care surgical resection
46084180|NCT02772614|Drug|BIA 3-202 (200 mg)|200 mg powder for oral use of unlabelled BIA 3-202
46084181|NCT00917631|Procedure|Co-bedding (caring for twins in the same incubator)|"Twin infants will be placed together in a Incubator or crib lying side-by-side. Twins will be diaper clad and nested together in boundaries consistent with neonatal care practices. All infants will have cardio-respiratory monitoring while co-bedding.~Infants in the co-bedding group be co-bedded for no less than 24 hours prior to heelstick to allow for stabilization following transfer. The heelstick being studied will occur no greater than 10 days following initiation of co-bedding. Duration of co-bedding will be recorded and controlled for in the analysis if necessary.~Monitoring and video-tape recording will take approximately 20-30 minutes per participant - a baseline period (5-10 minutes prior to heel stick), warming (3 minutes), heel stick (2-5 minutes), and recovery phase (approximately 10 minutes)."
46084182|NCT00611910|Device|sirolimus-eluting stent|due to randomization Cypher stent will be implanted
46084183|NCT00611910|Device|paclitaxel-eluting stent|due to randomization Taxus stent will be implanted
46084184|NCT00611910|Device|biodegradable-polymer-based sirolimus-eluting stent|due to randomization a rapamycin-eluting stent with biodegradable polymer will be implanted
46084185|NCT00611910|Device|bare metal stents|Due to randomization one bare-metal stent will be implanted. The decision about the stent type will be up to the interventionalist
45674185|NCT01833897|Drug|Standard of Care|Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression. Quetiapine dosing will follow the product label(Anon), and will be titrated over the first 4 days to the target dose of 300 mg. Olanzapine-fluoxetine dosing will also follow standard guidelines. Lurasidone will be started at 20 mg, and titrated up to 60 mg daily as clinically indicated. Study physicians will use clinical judgment to choose between standard-of care treatments, and have the option to titrate standard-of-care within approved ranges, and to prescribe adjunctive benztropine and benzodiazepines if clinically indicated.
45833756|NCT04233528|Diagnostic Test|Evaluation of systemic skin microvascular endothelial function|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
46084186|NCT04089189|Drug|IMP4297|IMP4297 100mg PO QD
45676743|NCT04712773|Device|Surgical Pleth Index monitor|Patient is connected to non-invasive monitor measuring Surgical Pleth Index
45833757|NCT01680510|Dietary Supplement|Alga Dunaliella Bardawil|
45833758|NCT01680510|Other|Placebo (starch)|
45833759|NCT04398186|Diagnostic Test|Anogenital distance measurement|Measurements of AGD and perineal muscle strength
45833760|NCT04217694|Behavioral|Cogstate Assessment Battery|Complete CogState testing
45833761|NCT04217694|Drug|Memantine|Given PO
45833762|NCT04217694|Drug|Memantine Hydrochloride|Given PO
45833763|NCT03818802|Dietary Supplement|Nicotinamide Riboside|It will be administered a total of 1000 mg/day of NR in a regimen of 500mg every 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of 1000mg/day (500mg every 12 hours) for 6 weeks more, completing total of 6 months.
45833764|NCT03818802|Dietary Supplement|Placebo|It will be administered a correspondent placebo with the same shape and color as the active pill 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of correspondent placebo every 12 hours for 6 weeks more, completing total of 6 months.
45991773|NCT02927652|Other|Questionnaires|"New patients at the Duke Clinic 1F and Duke Raleigh Otolaryngology will be asked to complete the Brief Symptom Inventory-18 (BSI-18), patient control scale, and CG-CAHPS.~If a patients answers a 1, 2, 3, or 4 to question #17 (Thoughts of ending your life) on the BSI-18, the nurse will immediately contact the investigator, who will refer for further assessment and/or treatment. The Duke Social Work office is available to provide support, and the Duke Emergency Department has certified social workers and a psychiatric team to do full evaluations if needed."
45991774|NCT02946086|Behavioral|HABIT-ILE with prismatic adaptation|Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation
45991775|NCT02946086|Behavioral|HABIT-ILE without prismatic adaptation|Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation wearing sham goggles.
45991776|NCT02945241|Drug|Vancomycin|Intravenous
45991777|NCT02945241|Other|Cystatin C dosing algorithm|Expressed in milliliters per minute
45991778|NCT02945241|Other|Creatine clearance dosing algorithm|Vancomycin dosing algorithm based on creatinine clearance, expressed in milliliters per minute
45991779|NCT00526643|Drug|gemcitabine|1200 mg/m2 intravenous infusion on days 1 and 8, every 3 weeks for a maximum of 4 cycles
45991780|NCT00526643|Drug|cisplatin|cisplatin 60 mg/m2 on day 1 for 4 cycles
45991781|NCT02945163|Drug|Tenofovir|Tenofovir Disoproxil Fumarate
45991782|NCT02945163|Drug|Lamivudine|Lamivudine
45991783|NCT02945163|Drug|Efavirenz|Efavirenz
45991784|NCT00526682|Dietary Supplement|Irvingia/cissus combo|
45991785|NCT02927574|Device|DCB|
45991786|NCT02927574|Device|POBA|
45991787|NCT02927418|Behavioral|Strength & Conditioning|
45991788|NCT02927418|Behavioral|Control|
45991789|NCT00526760|Drug|Dexmedetomidine|
45991790|NCT00526838|Drug|XL228|1-hour IV infusion
45991791|NCT02927379|Drug|Dexmedetomidine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus dexmetedomidine in two divided doses i.e. 20 ml is administered on each side of incision
45991792|NCT02927379|Drug|Ketamine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus ketamine in two divided doses i.e. 20 ml is administered on each side of incision
46084187|NCT02708940|Other|Participatory technology development|Creating mobile support tools by patients and their therapists
46084188|NCT02708940|Other|Usual Care|Usual care as part of the UCLA PHP and IOP programs
46084189|NCT05388903|Drug|DS-2325a|Subcutaneous injection (starting dose 30 mg)
46084190|NCT05388903|Drug|DS-2325a|Intravenous infusion (starting dose 100 mg)
46084191|NCT05388903|Drug|Placebo|Subcutaneous injection
46084192|NCT05388903|Drug|Placebo|Intravenous infusion
46084193|NCT04089267|Drug|TPO|
46084194|NCT04788524|Behavioral|Computer Task Manipulation|Participants will complete computer tasks.
46084195|NCT00635180|Behavioral|isometric exercise|
46084196|NCT03967236|Other|Collection of stool and blood samples|"For each visit, stool and blood samples will be collected during a pediatric gastroenterology day hospital stay.~This collection of stool and blood specific IVOIRE study is carried out in the context of examination already planned for the usual care of the patient."
45676744|NCT02030119|Behavioral|Financial Incentives|
45676745|NCT02030119|Behavioral|Daily feedback|
45991793|NCT02927379|Drug|Bupivacaine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline only in two divided doses i.e. 20 ml is administered on each side of incision
45991794|NCT00526877|Drug|Risperidone|Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
45991795|NCT02927496|Drug|Doxycycline|"Once daily tablet for 6 weeks:~Active comparator: Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg)"
45991796|NCT02927496|Drug|Placebo|Once daily tablet for 6 weeks. Placebo comparator: matching tablets containing no active ingredients
45991797|NCT00526916|Drug|[C-11]PBR28|
45991798|NCT02927535|Drug|TNF blockers monotherapy|
45991799|NCT00527969|Drug|HT1001 extract of Panax quinquefolius L|
45991800|NCT00527033|Drug|YM178|Oral
45991801|NCT00527033|Drug|Placebo|Oral
45991802|NCT02945891|Device|HPV testing of Evalyn®Brush, FloqSwab and Colli-Pee specimens|Each woman use the self-sampling devices in an advised order the day before they go to the hospital. There will be change of sampling order with every patient so that 50% of women will use Evalyn®Brush (Rovers Medical Devices, Oss, The Netherlands) first and 50% a FloqSwab (Coban Flock Technologies, Italy) first. In addition women are asked to provide a first void urine sample using a Colli-PeeTM (Novosanis, Belgium) on the same morning as the hospital visit. At the hospital clinician will take an additional specimen for which the performance of different self-sampling devices will be compared to.
45991803|NCT02945072|Procedure|TIVA|TIVA is use to anesthesia maintenance after anesthesia induction (Propofol 10mg/kg/h, Remifentanil 0.2mcg/kg/min, dose adaptation as required for sufficient anesthesia)
45991804|NCT02945072|Procedure|Sevoflurane|Sevoflurane is use to anesthesia maintenance after anesthesia induction (target et 2 Vol% in 50-70% N2O, dose adaptation as required)
45991805|NCT02924922|Procedure|Laparoscopic partial nephrectomy|The renal hilus is identified and both vein and artery are dissected. A laparoscopic ultrasound probe is introduced through a 12 mm port to define the tumor resection margins. A laparoscopic Satinsky clamp is used to induce total kidney ischemia, clamping both vein and artery. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Ischemia is interrupted once renorrhaphy is completed
46002348|NCT03579680|Behavioral|ADT ORDER CHECK ATTESTATION (OR)|Order restrictions (Or) operate as an organizational constraint, widely perceived as a forcing function giving providers little leeway to exercise judgment but have a strong evidence-base for changing provider behavior.
46002349|NCT03579680|Behavioral|PROVIDER SCRIPT (SC)|The provider script (Sc) is a communication aid to be used and documented as an accountable justification in the electronic medical record. This strategy also has a strong evidence-base for changing provider behavior.
45991806|NCT02924922|Procedure|Robot assisted partial nephrectomy|The renal hilus is carefully dissected, so that the arterial segmental branches are reached. Tumor resection margins are identified through ultrasound. Drop-in bulldog clamps are used to clamp segmental arterial branches and induce selective ischemia. Indocyanine green 0.2-0.3mg/KG is infused intravenously a few seconds after the selective ischemia is induced. The Firefly near infra-red fluorescence system is used to determine the extent of the ischemic area. The ischemic zone can now be tailored to the tumor by adding or removing bulldog clamps according to the vascular anatomical conditions. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The resection defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Selective ischemia will be interrupted once renorrhaphy is completed
45991807|NCT02924922|Device|Conventional laparoscopic instruments|Endoscope, Scissor, Needleholder, Forceps, Suction unit, Ports, Tissel, CO2, Sutures, Needles, Scalpel, Ultrasound-Probe, Monitors
45991808|NCT02924922|Device|Da- Vinci Robot and conventional laparoscopic instruments|Da Vinci Robot, Console, Ports and Instruments; Suction unit, Forceps, Tisseel, Ultrasound Probe, Monitors
45991809|NCT02924922|Drug|Mannitol|
45991810|NCT04692896|Drug|lidocaine|different concentrations of lidocaine with same concentration of adrenaline
45991811|NCT02927340|Drug|Lorlatinib|
45991812|NCT00528008|Other|povidone-iodine solution|Abdominal surgical field cleaned with 5% povidone-iodine detergent scrub, detergent cleaned from surgical area with sterile water, and then painted with 1% povidone-iodine solution.
45991813|NCT00528008|Other|chlorhexidine gluconate|Abdominal surgical field painted once using 2% chlorhexidine in 70% alcohol.
45991814|NCT02925039|Other|Rehab with computer feedback|Sit to stand training with addition of computerised feedback (speed, symmetry and trunk tilt)
45991815|NCT02925039|Other|Treatment as usual|Treatment as usual
45991816|NCT02946203|Other|Barium Sulfate|Barium Sulfate Oral Contrast-VoLumen
45991817|NCT02946203|Other|Flavored beverage Oral Contrast|Flavored beverage for neutral abdominal/pelvic imaging
45833765|NCT03817632|Device|Computer assisted primary total knee replacement with OrthoPilot FS101 navigation system and Software 5.1|Computer Assisted Total Knee Replacement with the OrthoPilot FS101 and the software TKA 5.1
45991818|NCT02924961|Device|Triathlon PS total knee system with mobile-bearing|
45991819|NCT02924961|Device|Triathlon PS total knee system with fixed-bearing|
45991820|NCT04692740|Drug|Chlorambucil, Oral, 2 Mg|Eligible patients will be treated with Chlorambucil 6 mg/m2 daily p.o. for 42 consecutive days (weeks 1-6). After restaging, responder patients (complete or partial response) and those with stable disease will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days every 28 days until disease progression or unbearable toxicity, patient refusal or medical decision. Patients' clinical data will be collected pseudo-anonymously and a sequential identification code number will be assigned to each patient enrolled in the study.
45991821|NCT02925000|Drug|TLC178|TLC178
45991822|NCT04692857|Procedure|supra inguinal fascia iliaca block|injection of 30,40 or 50 ml of 0.2 ropivacaine .
45991823|NCT00528047|Drug|PRLX 93936|PRLX 93936 will be administered intravenously over one hour daily for 5 days.
45991824|NCT01580462|Other|Observational study|"Study plan - data collecting:~Patients will attend diabetes clinic as usual, with one additional visit in the middle of the 3-months period. During those visits - V0, V1 and V2, data from glucometers and insulin pumps will be downloaded."
45991825|NCT02927028|Other|Chewing|"On the first visit, the random nut treatments will include chewing walnuts, almonds and pistachios. The chewing conditions will include: 1) 5 g nuts alone, 2) 5 g nuts with 5 ml water, 3) 5 g nuts with 5 ml apple juice, 4) 5 g nuts with 5 g plain yogurt, 5) 5 g nuts with 5 g sweet yogurt.~On visits 2 and 3 the treatments of either 28 g of walnuts or walnut butter will be presented."
45991826|NCT02926989|Drug|Plasmalyte Glucos 50 mg/mL|Solution contains potassium chloride 5 mmol/L and sodium chloride 140 mmol/L.
45991827|NCT02926989|Drug|0.45% saline in 5% dextrose|Solution contains potassium chloride 20 mmol/L and sodium chloride 80 mmol/L.
45991828|NCT04692272|Behavioral|Exercise in the XBOX kinect|"The XBOX group performed exercise for 60 min, three times/week, for 6 weeks, using the Xbox Kinect game Your Shape Fitness evolved. This game was chosen because it simulates an environment with a variety of physical activities, in which the majority can be practiced by older adults. The activities were carried out individually. The game activities selected for the physical activity sessions were: 1) Zen-Develop it (stretching, balance and flexibility activities, similar to Yoga); 2) Pump it (to fill balls until they burst); 3) Wall Breaker (to break blocks, similar to boxing); 4) Kick it (soccer activity); 5) Hurricane (to lift the balls off the floor and not let them fall); 6) Stack in Up (balance activity)."
45833766|NCT03817632|Device|Computer assisted primary total knee replacement with OrthoPilot Elite navigation system and Software 6.0|Computer Assisted Total Knee Replacement with the with the OrthoPilot Elite and the software TKA 6.0
45833767|NCT04398108|Drug|Margetuximab Margetuximab-IV|Drug: Chosen Chemotherapy (Capecitabine) -Oral Capecitabine tablet Drug: Chosen Chemotherapy (Vinorelbine) Vinorelbine -IV Drug: Chosen Chemotherapy (Gemcitabine) Gemcitabine -IV
45991829|NCT02924805|Other|Telemedical care|Telemedically guided care based on a standard operating procedure
45991830|NCT02924649|Procedure|Early Intensive mobilisation|The intervention will be performed using a tilt table with integrated stepping movements of the lower extremity (ERIGO, HOCOMA, Switzerland). The goal of the intervention session is that the patient stands upright for 20 minutes. If orthostatic intolerance or increase in intracranial pressure occurs the session will be paused. When the patient is stable mobilization is continued.
45991831|NCT00528125|Procedure|active laser acupuncture|low level laser acupuncture, 830 nm, 30 mW, 0,3 J per acupoint, 2 points per neonate (Hegu and Shen Men). Overall 30 seconds of treatment
45991832|NCT00528125|Procedure|placebo laser acupuncture|placebo laser acupuncture at two acupoints (Hegu, Shen Men). Overall treatment time 30 seconds.
45991833|NCT02945696|Procedure|laparoscopic guided nerve blocks|It is common to use ultrasound to define the correct plane for abdominal wall nerve blocks, however, the utilization of laparoscopy to identify this plane is a new intervention that is previously undescribed in children.
45991834|NCT02945696|Drug|Ropivacaine|Ropivacaine is a local anesthetic used to prevent pain during and after procedures. In this study, ropivacaine will be injected either directly at the port sites, or for a regional abdominal wall nerve block, either under ultrasound or laparoscopic guidance.
45991835|NCT02926872|Other|There is no intervention in the study|
45991836|NCT02926794|Behavioral|SA and II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
45991837|NCT02926794|Behavioral|SA and No II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
45991838|NCT02926794|Behavioral|No SA and II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
45991839|NCT02926794|Behavioral|No SA and No II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
45991840|NCT00528164|Behavioral|Team PLAY|Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
45991841|NCT02924766|Drug|Niraparib|Participants will start with niraparib 200 mg once daily.
45991842|NCT02924766|Drug|Apalutamide|Participants will receive apalutamide 240 mg (4*60 mg) once daily orally.
45991843|NCT02924766|Drug|Abiraterone Acetate|Participants will receive 1000 mg (4*250mg) once daily.
45991844|NCT02924766|Drug|Prednisone|Participants will receive 10 mg (1*5 mg twice daily).
45991845|NCT02926755|Procedure|Coronary Angiography|Coronary angiography which includes fractional flow reserve (FFR),that allows precise measurement of blood flow in the arteries to the heart; the Near Infra-Red Spectroscopy-Intravascular Ultrasound (NIRS IVUS) provides information about the amount of lipid and cholesterol in the plaque, and plaque volume;the Optical Coherence Tomography (OCT) allows physicians to assess tears in the surface of plaque and plaque thickness; and Coronary CT Angiography (CCTA) to evaluate plaque characteristics, and correlate with the invasive findings. The research portion of the study requires all imaging studies be performed (NIRS, IVUS, OCT, FFR) during coronary angiography, rather than just one or two of these imaging studies, and the CCTA.
45991846|NCT00528281|Drug|Lapatinib|Lapatinib was administered once daily orally. Patients will begin treatment at Dose Level 0, using a lower dose of pemetrexed, 400mg (approved dose is 500mg). Absent a DLT or need for treatment delay in cycle 1, Dose level 0 or 1, patients may be dose escalated to dose level 1 or 2, respectively in cycle 2.
45991847|NCT00528281|Drug|Pemetrexed|Pemetrexed is administered intravenously on a 21 day schedule. Two dose levels are used in the dose escalation: 400 and 500 mg.
45991848|NCT00528320|Device|Ovatio CRT|
45833768|NCT01625286|Drug|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 2 days on-treatment, 5 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
45991849|NCT02926599|Behavioral|Personal Optimization Training|
45991850|NCT01580501|Drug|Tadalafil and Sildenafil|PDE-5 Inhibitor; Low dosages will be 0.5mg/kg and high dosages will be 1.0mg/kg
45991851|NCT02924532|Biological|immediate post operative bioassay of Parathyroid Hormone|
45991852|NCT00528359|Drug|quetiapine or olanzapine or risperidone or aripiprazole|
45991853|NCT02946008|Radiation|Stereotactic Body Radiation Therapy|Delivered over 5 treatment sessions for approximately 1.5 weeks total.
45991854|NCT02946008|Procedure|Radical Prostatectomy|Open, laparoscopic, or robotic radical prostatectomy and pelvic lymph node dissection to remove the prostate, seminal vesicles, and pelvic lymph nodes.
45991855|NCT02944721|Genetic|Genetical analyses|
45991856|NCT02944721|Other|Chronic pain identification questionnaires|
45991857|NCT02944721|Other|Neurophysiological and psychophysical evaluations|
45991858|NCT02944721|Other|Quality of life questionnaires|
45833769|NCT01625286|Drug|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 4 days on-treatment, 3 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
45833770|NCT01625286|Drug|AZD5363when combined with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
45991859|NCT02924493|Other|Diet low in fermentable carbohydrates (low FODMAP diet)|The participants follow the diet in 4 weeks. They have been provided with some foods (bread, pasta, cereal products), but will by the rest themselves. They have been provided with lists of foods to include and foods to avoid. They have also been provided with suggestions to a 4 week meal plan, based in their individual need for energy.
45991860|NCT00527150|Drug|Varenicline Tartrate|Varenicline 1.8 mg AMT-8 controlled release tablets administered twice a day for 14 days.
45991861|NCT00527150|Drug|Varenicline Tartrate|Planned dose is Varenicline 2.4 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
45991862|NCT00527150|Drug|Varenicline Tartrate|Planned dose is Varenicline 3 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
45991863|NCT00527150|Drug|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
45991864|NCT00527150|Drug|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
45833771|NCT01625286|Drug|A placebo in combination with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of placebo matched to AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. placebo and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
45991865|NCT00527189|Behavioral|Balance Exercises|Home based balance exercises based on Otago Exercise programme
45991866|NCT00527228|Drug|deflazacort|In the first 12 months, patients will receive no treatment to assess the natural history of the disease. Afterwards, patients will be treated with deflazacort 1mg/kg/day or placebo for the first month on treatment, from the second month on deflazacort or placebo will be administered on an alternate day regimen). Patients will be randomized to six months verum or placebo each, after a 3-months wash-out patients cross over to the alternate treatment for six months. In a 2-years follow-up phase after the double-blind treatment phase, long-term development of the disorder will be documented.
45991867|NCT00527228|Drug|placebo|
45991868|NCT02926482|Behavioral|Prescriber Recruitment Bundle (PRB)|The Prescriber Recruitment Bundle (PRB) is a bundle pharmacotherapy capacity building practices. The PRB to be implemented contains the following elements, a) candidate identification strategies, b) prescriber education forums, c) prescriber-friendly workflow and risk-reduction strategies, d) academic detailing to recruit OUD prescribers, e) telemedicine, and f) organizational leadership and culture to support building OUD pharmacotherapy capacity.
45991869|NCT00527267|Drug|Placebo|30 mg placebo once daily orally 60 mg placebo once daily orally 90 mg placebo once daily orally 120 mg placebo once daily orally 180 mg placebo once daily orally
45991870|NCT00527267|Drug|AMG 073|30 mg AMG 073 once daily 60 mg AMG 073 once daily 90 mg AMG 073 once daily 120 mg AMG 073 once daily 180 mg AMG 073 once daily
45991871|NCT02924298|Behavioral|SLIMM|Participants will perform 5 minutes of light activity for every 25 minutes spent seated for 12 weeks. Following the week 12 visit, participants will increase light activity to 10 minutes for every 20 minutes spent seated.
45991872|NCT02924415|Behavioral|Tele-care support|Psychoeducation treatment based on telemedicine
45991873|NCT02924415|Other|Control group|Standard care
45991874|NCT02944994|Other|Unified protocol|This is a transdiagnostic cognitive behavioral therapy
45991875|NCT02944994|Other|Routine Care|This arm will reflect typical care received in routine mental health care
45991876|NCT02924181|Device|SmartTouch Catheter|Pulmonary vein (PV) isolation guided by CF information
45991877|NCT00527306|Dietary Supplement|multivitamin|Subject will be asked to take a multivitamin capsule or a placebo (inactive pill) once a day for one year. There will be an equal chance of getting the multivitamin or the placebo.
45991878|NCT02926287|Other|Ambulatory surgery|All patients who accepting participation to the study and operated for prolapse surgery, Patient eligible for Ambulatory surgery and return home on the same day if delivery criteria are satisfied ( Chung criteria+tsuccessful trial of void) Patient not eligible for Ambulatory surgery are included as control group
45991879|NCT02924259|Device|The GRID foam roll|Commercial rigid foam roll with an outer foam covering
45674186|NCT01833897|Drug|Ketamine|Ketamine administration will be carried out according to the methods as described by previous studies. Subjects will receive ketamine hydrochloride (0.5 mg/kg) intravenously during 40 minutes. This dosage was selected based on previous trials of ketamine for the treatment of refractory depression and bipolar depression. Vital signs (blood pressure, heart rate) will be closely monitored throughout the time of infusion. Subjects will be evaluated for 2 consecutive days during this phase; i.e. treatment days (day 1) and rating days (day 2). Non-responders to ketamine will not proceed into the DCS phase. Response will be a 25% improvement on the Hamilton Depression Rating Scale (HDRS).
45674187|NCT01833897|Drug|D-cycloserine|Immediately after the ketamine infusion, subjects will begin an eight-week treatment of DCS adjunctive to standard of care. DCS dosing will begin at 250 mg for three days→500mg (2 capsules)/day for 1 week → 750 mg (3 capsules)/day for 1 week → and 1000 mg (4 capsules)/day for the remainder of the study.
45674188|NCT01481896|Device|Metal-on-metal primary total hip arthroplasty (DePuy )|Replacement of a patient's native hip with an artificial implant featuring a metal-on-metal articulation
45674189|NCT02226653|Drug|Evacetrapib|Administered orally
45674190|NCT02201771|Drug|Aspirin|
45674191|NCT02201771|Drug|Ticagrelor|
45674192|NCT01460368|Drug|LY2409021|Administered orally
45991880|NCT02944916|Device|IryPump R Set|
45991881|NCT02924454|Drug|metoprolol|One hundred and twenty ml, 0.5 mg metoprolol/ml (as metoprolol tartrate) is administered as an intravenous bolus injection followed by a continuous infusion. Infusion is halted if heart rate drops below 35 bpm or systolic blood pressure drops below 80 mm Hg, or the participant experiences subjective side effects. Infusion stops at T=30 minutes.
46084197|NCT00920855|Drug|bendamustine|"Bendamustine was administered to 3 cohorts of patients at escalating doses of 50 (cohort 1), 70 (cohort 2) and 90 mg/m^2/dose (cohort 3). Doses were administered by intravenous (iv) infusion once daily on days 1 and 4 of each 28-day cycle. Each iv was administered over 60 minutes and followed the injection of bortezomib.~Bortezomib will be administered to patients at a dose of 1.0 mg/m2/dose as an iv push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered to patients on days 1, 4, 8 and 11 of the 28-day cycle."
46084198|NCT00920855|Drug|bortezomib|Bortezomib was administered at a dose of 1.0 mg/m^2/dose as an intravenous (iv) push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered on days 1, 4, 8 and 11 of each 28-day cycle.
46084199|NCT04247256|Drug|FOLFIRI Protocol|FOLFIRI standard treatment on day 5 to 7 (both days included) of a 14 day period. repeated bi-weekly
45674193|NCT01460368|Drug|Placebo|Administered orally
45674194|NCT01460368|Drug|Moxifloxacin|Administered orally
45674195|NCT02135705|Drug|Lomitapide|As prescribed by Physician.
45674196|NCT01460290|Drug|Asenapine|Asenapine will be administered open-label in pill form. Asenapine will be initiated at 5 mg twice a day and increased as tolerated to a maximum of 20 mg/day. It is anticipated that maximum stable dosing will be achieved by 4 weeks of treatment, although dosage may be reduced due to tolerability concerns at the discretion of the treating research psychiatrist.
45674197|NCT01911533|Procedure|extracorporeal removal of CO2 (ECCO2-R)|To promote a better gas-exchange, the patient with ARDS will be mechanically ventilated. This can be aggressive and harmful for the lungs. With the use of an extra-corporeal CO2-remover, CO2 can be removed so that the mechanical ventilation setting will be less aggressive and will decrease lesions in the lung. The veno-venous extracorporeal CO2-remover pumps blood from a vein via a catheter through an oxygenator (gas exchanger that adds oxygen to the blood and extracts carbon dioxide from the blood) and back into a vein.
45674198|NCT01911533|Procedure|No extracorporeal CO2-removal|Patients are their own control group.
45674199|NCT04408456|Drug|HCQ|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)
45674200|NCT04408456|Other|Standard therapy|Home quarantine for 2 weeks plus social distancing plus personal hygiene
45674201|NCT03026608|Behavioral|Veggie Van Program|This includes 1.) Weekly delivery of fresh local produce; 2.) Cooking and nutrition demonstrations; 3.) Weekly newsletters about cooking, nutrition and local produce mailed to all study participants and distributed at Veggie Van
45674202|NCT02200211|Device|iPad®|Binocular therapy on iPad®
45674203|NCT02200211|Other|Patching 2 hours per day, 7 days per week|
45991882|NCT02924454|Drug|intravenous lipid emulsion|Intravenous lipid emulsion 20 % is administered as an intravenous bolus infusion (1.5 ml/kg) followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Lipid emulsion infusion is stopped at T = 30 minutes.
45991883|NCT02924454|Drug|Sodium chloride 0.9% solution - lipid emulsion dummy|Isotonic 0.9 % sodium chloride solution is administered as an intravenous bolus infusion (1.5 ml/kg), followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Infusion is stopped at T = 30 minutes.
45991884|NCT02924454|Drug|Sodium chloride 0.9% solution - metoprolol dummy|Saline solution is administered as an intravenous bolus injection followed by a continuous infusion to T=30 minutes.
45991885|NCT04692038|Device|Forceps biopsy combined with puncture biopsy under the guidance of Augmented Reality Navigation and Radial EBUS|During the operation, under the guidance of Augmented Reality Navigation, the bronchoscope will reach the location of the target pulmonary nodules, and the EBUS probe will be inserted through the bronchoscope working channel, and gradually approach the target nodules to obtain EBUS images. After typical EBUS images are observed and the location is confirmed, the EBUS probe will be withdrawn and biopsy forceps and puncture biopsy needle will be used to obtain samples at the target locations respectively.
45991886|NCT02924337|Drug|Placebo|
45991887|NCT02924337|Drug|Imeglimin|
45991888|NCT02924337|Drug|Moxifloxacin|
45991889|NCT00528515|Drug|Diprivan (propofol), Astra-Zeneca|continuous intravenous infusion with a dose of 3-5 mg/kg/h
45991890|NCT00528515|Drug|Suprane (desflurane), Baxter|a vapor concentration of 3-7 vol% is maintained with use of vaporizer and under control of arterial blood pressure, heart rate, and BIS index.
46084200|NCT04247256|Drug|SCO-101|Investigational Medicinal Product, oral tablet administered on day 1 to 6 (both days included) of a 14 day period. repeated bi-weekly
46084201|NCT04088877|Behavioral|Exercise|The participants will attend the exercise facility at Wellspring two times a week. Sessions are completed under the supervision of an exercise physiologist and the duration of each session ranges from 1.0 - 1.5 hours. Each session includes a warm up on an aerobic exercise machine, a full body progressive RET program followed by balance and stretching exercises.
46084202|NCT04088877|Behavioral|Art Sculpting Class|The sculpting program will take place once a week for 2 hours over an 8-week period. Sessions will be themed around body image and facilitated by an artist and registered psychologist who will lead the group in art techniques and self-reflection, respectively. Each group session will focus on a theme related to body image, and the participants will have the opportunity to reflect through their art and social interactions with one another.
46084203|NCT02772458|Other|Dodecanoate acid and saline|Test drink
45991891|NCT02923986|Drug|BP1001 (varying dose)|BP1001 (varying dose)
45991892|NCT02923986|Drug|BP1001 (fixed dose)|BP1001 (fixed dose)
45991893|NCT02923986|Drug|Dasatinib|Dasatinib
45991894|NCT00528554|Procedure|laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, energy dosage 1J/point, average of 8 points to be treated, once daily during chemotherapy course
45991895|NCT00528554|Procedure|placebo laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, average of 8 points to be treated, once daily during chemotherapy course
46084204|NCT02596815|Procedure|Median Nerve Neural Mobilization|Nonsurgical noninvasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
46084205|NCT02596815|Device|Goniometer|
45991896|NCT02926248|Drug|Colchicine|Colchicine is an anti-fibrotic and anti-inflammatory drug
45991897|NCT02926248|Other|Placebo|
45991898|NCT02945735|Behavioral|Attention Modification|Feedback according to participants' viewing patterns, in order to modify their attention.
45674204|NCT01459666|Drug|Dysport (abobotulinumtoxinA)|Intramuscular injection effects lasting up to 3 months
46084206|NCT02775422|Biological|Serological Test s for the Virus Chicken Pox Virus|
46084207|NCT04251767|Other|washed microbiota transplantation|"Washed microbiota suspension (5u) delivered through nasogastric tube, nasojejunal tube or oral.~Dose and frequency: 5u, once."
45674205|NCT01459666|Drug|Bacteriostatic 0.9% Sodium Chloride (vehicle)|Intramuscular injection
45674206|NCT01858389|Drug|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter. The dose of dacomitinib for patients in Cohort A may be further escalated in increments of 15 mg.
46084208|NCT04251767|Other|placebo|"Placebo (edible suspension of the same color as the washed microbiota suspension，5u) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.~Dose and frequency: 5u, once."
45674207|NCT01858389|Drug|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter.
45674208|NCT01645475|Drug|Desmopressin lyophilisate (Melt)|Patient receives Desmopressin lyophilisate (Melt).
45674209|NCT04767113|Drug|Heparin sodium|"For infants without thrombosis at enrollment, heparin 1 U/kg/h/line for term infants was used and 0.5 U/kg/h/line for preterm infants. The speed of infusion was 0.5ml/h.~For infants with thrombosis at enrollment, heparin 10-15 U/kg/h for term infants was used with a target activated partial thromboplastin time 60-70s. Other interventions were at the clinical team's discretion under the local protocol."
45991899|NCT02924025|Behavioral|Motivational interview|Motivational interview is an interview form based on the patients own thoughts of motivation. It will be conducted by a nurse who is specially trained in this interview type.
45991900|NCT00528593|Drug|epoetin alfa|Group 1 will receive Procrit once every three weeks, and group 2 will receive Procrit every week.
45991901|NCT02926404|Device|UNiD Rods|Spinal osteosynthesis
45991902|NCT00528632|Other|Specimen biopsy and serum laboratory tests|"Biopsy of the surgical specimens (gallbladder) submitted after cholecystectomy~Laboratory tests measuring levels of plasma total cholesterol and triglycerides"
45991903|NCT02926326|Drug|BCT197|A single dose of BCT197
45991904|NCT02926326|Drug|Azithromycin|3 daily doses of Azithromycin
45991905|NCT00528671|Drug|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.8 - 2.8 for aortic valve recipients and 2.5 - 3.5 for mitral or double valve recipients, INR-self management once a week
45991906|NCT00528671|Drug|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management once a week
45991907|NCT00528671|Drug|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management twice a week
45991908|NCT02924103|Device|Contamination free bacterial swab|"A comparison of the bacteriology in bacterial swabs (Eswab 481CE, Copan Diagnostics, Italy) from the middle meatus. On the RIGHT side using the Contamination free bacterial swab introduction device that facilitates the introduction of a bacterial swab into the nose without direct or indirect contact with the nasal vestibule."
45991909|NCT00528710|Dietary Supplement|SAM-e (S-Adenosyl-L-Methionine)|One 400 mg tablet daily in the morning.
45991910|NCT02926443|Other|Upper Extremity Neuromuscular Training Program|Neuromuscular and strengthening shoulder exercises in a group setting.
45991911|NCT02926443|Other|Usual Physiotherapy Care|One-on-one physiotherapy care in a clinical setting.
45991912|NCT00528749|Other|Patient will wear ARES device while undergoing sleep study|Device is worn on forehead
45991913|NCT02924142|Device|OT Cap attachment|The RHEIN 83 OT CAP attachment system is an extra-coronal castable attachment positioned on the distal of the abutment crowns as an extension allowing a lot of vertical space for optimal esthetics.
45991914|NCT02945462|Biological|autologous mesenchymal stem cells|Patients will be injected with autologous mesenchymal stem cells, intracavernously
45991915|NCT00528827|Drug|Cardene® I.V.|"5 mcg/kg/min Cardene I.V.~2.5 mcg/kg/min Cardene I.V.~0.5 mcg/kg/min Cardene I.V."
45991916|NCT02926170|Drug|Rivaroxaban|Rivaroxaban will be started at 20 mg/day. Dose will be adjusted according to Cr Clearance. Cr Clearance 30-49 ml/min will receive 15 mg/day.
45991917|NCT02926170|Drug|acenocumarol|Doses will be adjusted according to INR
45991918|NCT04691765|Drug|Kineret|escalating doses of drug will be administered to 3 groups of 4 patients for 7 months
45991919|NCT04689204|Drug|CTA30X|CTA30X cell injection by intravenous infusion
45991920|NCT04691687|Drug|Furosemide|IV loop diuretic therapy
45991921|NCT04691687|Drug|IV Solution|IV Placebo comparator
45991922|NCT02923908|Other|Noldus Facereader 7|A video recording of a subject's facial expressions while tasting a sweet, bitter, and neutral flavored liquid will be analyzed using Noldus Facereader 7 software.
45991923|NCT02923908|Other|Voice Recording|A voice recording will be made for the duration of the tasting period.
45991924|NCT02923908|Other|5-Point Facial Hedonic Scale|A 5-point facial hedonic scale will be given to the participant to complete prior to the administration of any test substances and about 5, 10, and 30 minutes after the administration of each test substance.
45674210|NCT04767113|Drug|Normal saline|For infants enrolled, normal saline was infused at the corresponding speed.
45991925|NCT02923908|Other|Follow-Up Questionnaire|Participants will be asked a few questions about each test agent after tastings.
45674211|NCT04774991|Drug|Azithromycin for Oral Suspension|"Azithromycin will be administered as a single dose in oral suspension form for children as follows:~Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~For children 1 to <12 months of age, weight-based dosing will be used~For children 12 to 59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program."
45674212|NCT02199509|Drug|Levetiracetam|Anticonvulsant
45674213|NCT01458574|Drug|Placebo|Placebo 10 mg orally (PO) twice a day (BID)
45674214|NCT01458574|Drug|CP690,550|CP-690,550 5 mg orally (PO) twice a day (BID)
45674215|NCT01458574|Drug|CP-690,550|CP-690,550 10 mg orally (PO) twice a day (BID)
45991926|NCT04110327|Device|MicroStent|Treatment of arterial stenosis or occlusion with the MicroStent Perihperal Vascular Stent System
45991927|NCT04107675|Drug|Liposomal Cyclosporine A|Liposomal Cyclosporine A is administered with the PARI L-CsA eFlow Nebulizer. This latter is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
45991928|NCT04107675|Drug|Liposomal Placebo|Liposomal Placebo is administered with the PARI L-CsA eFlow Nebulizer. This latter is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
46084209|NCT02693028|Drug|Probiotic lozenges|The women participating in the study will take two probiotic lozenges per day (morning and evening) after meals.Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
45674216|NCT02224703|Drug|GWP42003-P|
45674217|NCT02224703|Drug|Placebo Control|
45674218|NCT02198963|Drug|Hypochlorous acid solution 106 mg/L|test product
45674219|NCT02198963|Drug|0.1% (w/v) Sodium Lauryl Sulfate|positive control
45674220|NCT02198963|Drug|0.9% Physiological Saline, USP|negative control
45991929|NCT04049175|Drug|Treatment A|Tablet of CHF 6532
45991930|NCT04049175|Drug|Treatment B|Tablet of CHF 6532
45991931|NCT04049175|Drug|Treatment C|Tablet of CHF 6532
45991932|NCT04049175|Drug|Treatment D|Tablet of CHF 6532 placebo
45991933|NCT02926131|Other|Blood sampling|"One full capillary tube (50µl blood) will be used to measure the Hct level and the routine SBR using the BR-501 bilirubin meter machine (non-study procedure).~An additional half- filled capillary tube (25µl blood) will be used for the SBR measurement with the Bilistick system"
45991934|NCT04692311|Device|an intelligent client-centred task-oriented training|3 x 45min of training with i-ACT system
45991935|NCT04692311|Other|Semi-structured interview|Participants, patients and therapists, were invited to a semi-structured interview after training period.
45991936|NCT02923869|Drug|Levobupivacaine|Children will receive 0.15 ml/kg of 0.2% Levobupivacaine through bilateral suprazygomatic MNB.
45991937|NCT02923869|Drug|Bupivacaine|Children will receive 0.15 ml/kg of 0.2% Bupivacaine through bilateral suprazygomatic MNB.
45991938|NCT00528905|Drug|AZD3480|oral capsule
45991939|NCT02923791|Biological|Filgrastim Hospira|5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
45991940|NCT02923791|Biological|US-Approved Neupogen|5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
45991941|NCT02926092|Diagnostic Test|Observation|Observation of progression of disease over time
45991942|NCT00527462|Procedure|Bronchoscopy|bronchoscopy with segmental allergen challenge
45991943|NCT00527462|Other|Exposure to ultrafine carbon black particles|Exposure to ultrafine carbon black particles for 2 hours
45991944|NCT04689243|Procedure|ALA-PDT|Low concentration ALA-PDT, 3 times a week.
45991945|NCT04689243|Procedure|red light|red light, 3 times a week.
45991946|NCT00527540|Drug|Pegylated Interferon alpha 2a + Ribavirin|Pegaferon: Ampule, 180 microgram per week Ribaverin: Tablet, 10-15 mg/kg per day
45991947|NCT02926053|Procedure|Surgical removal of tumor tissue for T cell production|Surgical removal of > 1 cm3 tumor tissue chosen with regards to high rate of success and to minimize the general risks involved in a surgical procedure.
45991948|NCT02926053|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
45991949|NCT02926053|Drug|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1. Maximum dose of 50 mg per administration.
45991950|NCT02926053|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
46084210|NCT02693028|Drug|Placebo lozenges|The women participating in the study will take two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
46084211|NCT02693028|Drug|Probiotic capsules|The women participating in the study will take two probiotic capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
45674221|NCT02074384|Device|Continuous Glucose Monitor|CGM device for measurement of interstitial glucose on a 24/7 continuous cycle.
45674222|NCT02074384|Device|Self Monitoring Blood Glucose|Participants will use their own SMBG device.
45991951|NCT02926053|Drug|Interleukin-2|Interleukin-2 is administered as high-dose bolus infusions (600.000 IU/kg) over a 15 minute period every 8 hours and continuing for up to 5 days (maximum of 15 doses).
45991952|NCT00527579|Drug|[F-18]FBR|
45991953|NCT00527657|Drug|Lomustine|Starting dose 30 mg/m^2 by mouth daily on Day 1 and 29.
45991954|NCT00527657|Drug|Temozolomide|75 mg/m^2 by mouth daily on Days 1 to 42.
46084212|NCT02693028|Drug|Placebo capsules|The women participating in the study will take two placebo capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
45674223|NCT02074384|Other|Clinician|Survey of clinicians after study visits
45674224|NCT01458106|Drug|BIIB031 (rFVIIIFc)|Vials of rFVIIIFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
45991955|NCT00527657|Drug|Thalidomide|200 mg/m^2 by mouth daily.
45991956|NCT02925897|Behavioral|Behaviour change and motivational interviewing|nurses will help patients to identify health behaviours that they would like to change and to explore their motivation and strengths to achieve this.
45991957|NCT00528983|Drug|Subcutaneous (SC) Azacitidine|75 mg/day for first 7 days of 28 day cycle for 1 cycle only.
45991958|NCT00528983|Drug|Oral Azacitidine|Cycle 2 and beyond starting dose of 120 mg/day for first 7 days of 28 day cycle. Dose will escalate in increments of 60 mg. Following evaluation dose escalation will occur in 120 mg increments until maximum tolerated dose (MTD) is reached.
45991959|NCT00528983|Drug|Oral Azacitidine|Starting dose for 14 day-QD treatment schedule will be 300 mg/day. Starting dose for 14 day-BID, 21 day-QD, 21 day-BID treatment schedules will be 100 mg, 200mg, 300mg. Dose will escalate in increments of 100 mg until MTD is reached.
45991960|NCT02923752|Device|MRI|Contrast-enhanced MRI
45991961|NCT00529022|Drug|Azacitidine|75 mg/m^2 Subcutaneous Injection or by vein Daily for 5 Days.
45991962|NCT00529022|Drug|Valproic Acid|40 mg/kg by mouth Daily for 7 days.
45991963|NCT00529022|Drug|Carboplatin|AUC 2 by vein on Days 3 and 10 over 60 Minutes.
45991964|NCT02923596|Procedure|History of prior Surgery|History of prior Surgery will be reviewed
45991965|NCT02923596|Radiation|History of Radiation Therapy|History of prior radiation therapy will be reviewed
45991966|NCT00527696|Procedure|transvaginal obturator tape|
45991967|NCT02923557|Drug|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of nephroureterectomy.
45991968|NCT02923635|Procedure|Standard wide local excision.|Excision of breast cancer without integration of plastic technique
45991969|NCT02923635|Procedure|oncoplastic breast surgery.|Integration of plastic techniques with oncological surgery for resection of breast cancer.
45991970|NCT00529139|Device|Standard extended dialysis|Standard extended dialysis dosed to maintain plasma urea levels between 120-150 mg/dL (20 -25 mmol/L)
45991971|NCT00529139|Device|Intensified extended dialysis|Intensified extended dialysis dosed to maintain near-normal plasma urea levels, i.e. <90 mg/dL (<15 mmol/L)
45991972|NCT02925975|Drug|Carvedilol|Carvedilol starts from 6.25mg daily and increase to 12.5mg once daily in next week if being tolerated.
45991973|NCT02925975|Device|3D-vHPS|This 3D model of HPS is rebuilt by a software combining the anatomic information of vessels from CTA (computed tomographic angiography) and the blood stream speed of targeted vessel from Doppler Ultrasound.
45991974|NCT02925975|Procedure|Routine endoscopic procedures|These include esophageal band ligation and tissue glue injection in the fundus of stomach by upper GI endoscopy if there are visible varies in cirrhotic patients. There routine procedures are done to prevent potential varies associated bleeding.
45991975|NCT00527813|Procedure|prone position|prone position for at least 16 hours per day
45674225|NCT01458106|Drug|FVIII (PK subgroup only)|Baseline prestudy FVIII dosing in participants who enter the PK subgroup. Vials of prestudy FVIII were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
45991976|NCT02925936|Other|Thyroid facing the anode end of xray machine|Thyroid position: facing the anode end of xray machine
45991977|NCT02925936|Other|Thyroid facing the cathode end of xray machine|Thyroid position: facing the cathode end of xray machine
45991978|NCT00527852|Device|Flocked swab|
45991979|NCT04692428|Procedure|Locoregional analgesia|the supra-inguinal fascia iliaca block versus the femoral nerve block
45991980|NCT04259892|Biological|2019-nCoV PCR|Nasopharyngeal swabs
45991981|NCT02945033|Drug|aspirin intake|Patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years
45991982|NCT02945033|Drug|placebo intake|Patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years
45991983|NCT02945033|Procedure|Surgical resection of colonic adenocarcinoma stage III or II high risk|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines
45991984|NCT02945033|Biological|Molecular analysis of exon 9 and 20 of PI3K|Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece
45991985|NCT02945033|Biological|blood intake|Blood intake will be done every 6 months to evaluate patient compliance to treatment
46084213|NCT02693028|Drug|Probiotic chewing gum|The women participating in the study will take two probiotic chewing gums per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
45674226|NCT01457950|Drug|denosumab|double-blind phase: 60mg subcutaneous injection, single dose
45674227|NCT01457950|Drug|placebo|double-blind phase: placebo subcutaneous injection, single dose
45674228|NCT01457950|Drug|open-label denosumab|open-label phase: 60mg subcutaneous injection, single dose
45674229|NCT01499134|Drug|nebivolol|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at the study visits. Nebivolol is approved for hypertension treatment at a dose of 5-40 mg daily. Based on the study titration schedule, the maximum doses used will be 20 mg of nebivolol (each maximum dose being contained in 4 capsules for daily dosing).
45674230|NCT01499134|Drug|Metoprolol succinate|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at study visits. Metoprolol succinate at 25-400 mg daily. Based on the study titration schedule, the maximum dose used will be 200 mg of metoprolol succinate (each maximum dose being contained in 4 capsules for daily dosing).
45674231|NCT02198651|Biological|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
45674232|NCT02198651|Other|Placebo|Pre-filled syringe, administered by subcutaneous injection in the Double-blind period
45991986|NCT02945111|Behavioral|Real-time view|
45991987|NCT02945111|Behavioral|No visual support|
45991988|NCT04256967|Other|Body and health focused study environment|Students are exposed to lectures, literature, co-students, contexts that provide body and lifestyle awareness beyond the existing exposure of the society in general
45991989|NCT02944760|Other|Low-Level Light Therapy|The application of laser therapy will take place 30 minutes before the start of dialysis. The application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. It is irradiated 6 points in quadriceps and 4 points in gastrocnemius, bilaterally by 30 seconds. The patient will be supine on a stretcher to the implementation of the intervention.
45991990|NCT02923518|Other|Questionnaire|Observational study without any intervention described under intervention type
45991991|NCT02923479|Device|Specific ankle rehabilitation by ARBOT device|ARBOT is a programmable robotic device consisting in a two-degree-of-freedom electromechanical platform developed by Italian Institute of Technology - Advanced Robotics and Rehab Technologies. It is composed of a fixed base, a central strut, a moving platform supporting patient's foot and three actuated limbs with a universal-prismatic-spherical kinematic chain. A six-axis force/torque sensor mounted between the moving platform and the footplate senses the human-robot interaction force and torque. The device is interfaced to a standard all-in-one touch screen Personal Computer with graphic applications to give patients visual feedback in real time.
45991992|NCT02923479|Other|General Rehabilitation|All patients underwent general rehabilitation (gait training, aerobic conditioning), including - if necessary - an initial weight training phase before the functional full weight-bearing program.
45991993|NCT02923479|Other|Specific ankle rehabilitation performed by physiotherapist|Subjects in the control group underwent manually assisted range of motion exercises.
46084214|NCT04816019|Biological|ChAdOx1 nCov-19|A single dose of ChAdOx1 nCov-19 delivered intranasally (IN)
46084215|NCT04251845|Dietary Supplement|topical melatonin|Topical melatonin at 3% concentration with dosage of 15 mg once daily will be applied on the lesion for 6 weeks followed by a follow up of 3 months
46084216|NCT04251845|Other|PLACEBO|Topical application of placebo once daily for 6 weeks with a follow up for 3 months
46084217|NCT02775578|Procedure|Coronary Artery Bypass Grafting|Using coronary artery bypass grafting surgery as the coronary revascularization therapy for patients enrolled.
45674233|NCT03026920|Procedure|less invasive method|The less invasive surgical method was conducted in this study. Then, the clinical results were compared with the patients treated using traditional methods to assess the less invasive method.
45991994|NCT02923479|Device|Specific ankle rehabilitation by Biodex System 3 dynamometer|Subjects in the control group performed non-robotic resistive training using a Biodex System 3 dynamometer
45991995|NCT02923479|Device|Specific ankle rehabilitation by ProKin PK254 platform|Subjects in the control group performed non-robotic proprioceptive training using a ProKin PK254 mobile electronic platform.
45991996|NCT02944838|Behavioral|Senior Change Makers Advocacy Program|see description
45991997|NCT02944838|Behavioral|Senior Change Makers Physical Activity Program|see description
45991998|NCT00529256|Behavioral|Feeback group|The intervention practices received a quarterly comparative feedback performance report based on the Achievable Benchmarks of Care (ABC) research conducted by Kieffe (YEAR).
45991999|NCT04231968|Drug|AK0529|AK0529 capsule will be orally administered at the twice-daily dosing levels of 10 mg, 20 mg, or 40 mg for five days according to the weight of patients.
45992000|NCT04231968|Drug|Matching placebo of AK0529|The placebo capsule was made with the same smell and appearance as AK0529 but without the active ingredients and will be orally administered per the same treatment schedule as those in the experimental arm.
45992001|NCT00529295|Drug|misoprostol|Titrated oral misoprostol: one tablet of 200 microgram was dissolved in water 200 ml, and 20 ml P.O. per one hour for 4 doses, then titrated against uterine response; Vaginal misoprostol: 25 microgram per vagina
45992002|NCT00529334|Radiation|CyberKnife Partial Breast Irradiation|Body radiosurgery will be delivered to the lumpectomy cavity with specified margin. Radiation dose will be 600 cGy x 5 stages = 3000 cGy over five to ten total days.
46084218|NCT02775578|Procedure|Percutaneous Coronary Intervention|Using percutaneous coronary intervention as the coronary revascularization therapy for patients enrolled.
45992003|NCT04218903|Behavioral|Combined training performed four times per week (CT4)|CT4 will perform four combined training sessions per week throughout 12 weeks. Each session will be composed 10-15 minutes of resistance exercise (1-4 sets of 10-15 repetitions, using an intensity corresponding to 50-70%1RM in 3 exercises) followed by 20-25 minutes of aerobic exercise (walking or running at an intensity corresponding to 60-70% of VO2peak).
45992004|NCT04218903|Behavioral|Combined training performed two times per week (CT2)|CT2 will perform two combined training sessions per week throughout 12 weeks. Each session will be composed 20-30 minutes of resistance exercise (1-4 sets of 10-15 repetitions, using an intensity corresponding to 50-70%1RM in 6 exercises) followed by 40-50 minutes of aerobic exercise (walking or running at an intensity corresponding to 60-70% of VO2peak).
46084219|NCT02775578|Procedure|Hybrid Coronary Revascularization|Patients enrolled will take coronary artery bypass grafting surgery at first, then treated with percutaneous coronary intervention.
45674234|NCT03026842|Drug|Decitabine|20 mg/m2/day for 5 days
45674235|NCT03026842|Drug|Daunorubicin, Cytarabine|Daunorubicin: 45 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
45992005|NCT02945306|Procedure|Adenotonsillectomy|
45456931|NCT02294344|Drug|CTX|"First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~After three months therapy, if the renal function was not recover, the patient would be withdrawn from the study. The other patients after CTX pulse therapy for 6 months and achieve remission to receive oral maintenance therapy with azathioprine (AZA).~The dosage of AZA was 1.0-2.0mg/kg/d(more than 50mg/d) and adjusted by white cell count and liver enzyme. If white cell count <3×109/L or an increase in liver enzyme to more than twice the normal upper limit, the dosage of AZA should be reduced. If white cell count <3×109/L or liver enzyme increased repeatedly, the patient would be withdrawn from the study."
45992006|NCT02945306|Drug|Watchful waiting with supportive care|Use of widely prescribed medicines to treat associated conditions
45992007|NCT04210206|Other|PHE-diet|phenylalanine-restricted diet with phenylalanine free supplements for 8 weeks
45992008|NCT02945618|Device|Neurocryostimulation|"CRYOFOS will be applied on the ankle at the end of each of the 8 sessions (in accordance to the protocol established). The treatment time with the CRYOFOS will take between 1 and 2 minutes, and will be pain-free.~Both groups will also receive the same conventional program consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing."
46084220|NCT05207358|Drug|Rituximab|2 doses of Rituximab 1 g and Methylprednisolone 500 mg on days 1 and 15.
46084221|NCT05207358|Drug|Mycophenolate Mofetil|Patients will receive Mycophenolate Mofetil, initially 500 mg twice daily, titrated to a maximum of 1.5 g twice daily, depending on leukocyte count and digestive tolerance, which will be maintained 24 months.
46084222|NCT05207358|Drug|Cyclophosphamide|All patients will receive Cyclophosphamide intravenously starting day 1, 6 pulses at a fixed dose of 500 mg given at 2 weeks. After 3 months, Azathioprine (2 mg / kg / day) is initiated 2 weeks after the last administration of Cyclophosphamide and maintained for the next 21 months.
45456932|NCT03926455|Biological|Typhax (investigational typhoid fever candidate vaccine)|
45674236|NCT03026842|Drug|Mitoxantrone, Cytarabine|Mitoxantrone: 8 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
45674237|NCT03026842|Drug|Aclacinomycin, Cytarabine|Aclacinomycin: 20 mg/day for 5 days; Cytarabine: 100 mg/m2/day for 5 days
45674238|NCT01498822|Drug|Levetiracetam|250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks
45674239|NCT01498822|Drug|Oxcarbazepine|150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)
45674240|NCT04774211|Diagnostic Test|SOS-PD|Validation of SOS-PD bedside assessments comparing the Danish SOS-PD scale with a Child Psychiatrist using DSM-V as the reference standard
45674241|NCT04773587|Drug|ARQ-151 Active|ARQ-151 Cream 0.15% - Active
45674242|NCT04773587|Drug|ARQ-151 Vehicle|ARQ-151 Cream - Vehicle
45992009|NCT02945618|Other|Ice|The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
45992010|NCT02922933|Drug|entinostat|HDAC (histone deacetylase inhibitor)
45992011|NCT02922933|Dietary Supplement|Omeprazole|Proton pump inhibitor
45992012|NCT02922933|Dietary Supplement|Famotidine|Histamine-2 blocker
45992013|NCT00529412|Other|Seprafilm|two sheets per body
45992014|NCT00529490|Drug|Hypertonic lactate|Parenteral solution administered to a maximal volume of 10 ml/kg BW over the first 12 hours post-CABG
45992015|NCT00529490|Drug|Ringer's lactate|Parenteral solution administered to a maximal dose of 30 ml/kg BW over the first 12 hours post-CABG
45992016|NCT02923089|Other|Muffin: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
45992017|NCT02923089|Other|Muffin: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
45992018|NCT02923089|Other|Wheat muffin|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
45992019|NCT02923089|Other|Soup: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
45992020|NCT02923089|Other|Soup: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
45992021|NCT02923089|Other|Potato soup|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
46084223|NCT05207358|Drug|Corticosteroids|3 daily pulses of 750 mg of intravenous Methylprednisolone, followed by oral corticosteroid therapy starting with a dose of 0.5 mg / kg / day for 4 weeks, then decreased by 2.5 mg of Prednisolone / day each 2 weeks. A low dose of glucocorticoid (5-7.5 mg / day) is maintained until 24 months after enrollment.
45992022|NCT02923089|Other|Chili: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
45992023|NCT02923089|Other|Chili: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
45992024|NCT02923089|Other|Rice chili|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
45992025|NCT00527891|Procedure|Signa Excite 3.0 T MRI Scan|Signa Excite 3.0 T MRI scan within a two week period from the date of receiving standard 1.5 T MR of the liver area.
45992026|NCT02923050|Behavioral|Simple Suppers|Theory-based 10-week family meals program
45992027|NCT02945267|Drug|Nimotuzumab plus S1|Nimotuzumab Injection: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area<1.5 m2) or 60 mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
45992028|NCT02945267|Drug|Placebo plus S1|Placebo: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area<1.5 m2) or 60 mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
45992029|NCT02926014|Device|Videolaryngoscopy|A rigid 70 degree laryngoscope is inserted into the subject's oropharynx, which allows to visualize the lingual tonsils. The size of the lingual tonsils is evaluated using DelGaudio and Friedman grading systems.
46084224|NCT02596737|Behavioral|wittyFit concept|
46084225|NCT04251299|Behavioral|home-based, mentored vegetable gardening program|The mentored vegetable gardening program pairs each participant with a certified Master Gardener. The participant/Master Gardener dyads work together to plan, plant and tend to a vegetable garden at the participant's home throughout the year. Gardening supplies, plants and seeds are provided.
46084226|NCT02772380|Device|Defibrillation following induction of VT/VF|Up to 10 attempts to induce two VF/VT episodes for defibrillation testing
46084227|NCT04186884|Other|Quality-of-Life Assessment|Ancillary studies
46084228|NCT04186884|Other|Questionnaire Administration|Complete questionnaires
46084229|NCT04256993|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Follow the physician's prescription in routine clinical practice. This study does not involve prescription of the drugs.
46084230|NCT04256993|Drug|Other standard care|Docetaxel, cabazitaxel, enzalutamide, abiraterone and others standard of care following the physician's prescription in routine clinical practice.
46084231|NCT02596581|Other|non-surgical periodontal treatment|scaling and root planing were performed
46084232|NCT02777684|Other|Qualitative study|
45992030|NCT02926014|Other|Reflux Symptom Index Questionnaire|A validated clinical tool for suspecting laryngopharyngeal reflux (LPR). The questionnaire was proposed by Belafsky et al. (2002) and consists of 9 most common gastroesophageal reflux disease (GERD) and LPR symptoms: hoarseness or a problem with your voice; clearing your throat; excess throat mucus or postnasal drip; difficulty swallowing food, liquids, or pills; coughing after you ate or after lying down; breathing difficulties or choking episodes; troublesome or annoying cough; sensation of something sticking in your throat or a lump in your throat; heartburn, chest pain, indigestion, or stomach acid coming up. Each symptom is evaluated on a scale from 0 to 5 (0 - no complaint, 5 - severe symptom). The sum of all symptom evaluations ranges from 0 to 45.
45992031|NCT02926014|Other|Dysphagia Screening Questionnaire|"A validated questionnaire, proposed by Ohkuma et al. (2002). Lithuanian version of the questionnaire consists of 16 questions: choking during swallowing meals / liquids; difficulty eating solid foods; difficult swallowing; feeling of food getting stuck in the throat; longer than before eating time; feeling of food remaining in the mouth; feeling that food or liquid is going up into the throat from the stomach; feeling of food being stuck in the esophagus; weight loss; food getting stuck in the throat; food falling from the mouth; difficulty coughing during or after meals; occurrence of pneumonia; hoarseness; coughing during the night. Interpretation of dysphagia screening questionnaire:~Advanced symptom - 2 points; Moderate intensity symptom - 1 point; No symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points."
45992032|NCT00529607|Drug|contrast echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
45992033|NCT00529607|Procedure|2D and 3D echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
45992034|NCT00529607|Procedure|cardiac MRI|before discharge and after 6 months
45992035|NCT00529607|Procedure|blood sampling|"routine lab work plus infarction and inflammation biomarkers~1: before PCI, after PCI, at 34 hours, at discharge, at 6 months 2 and 3: one blood sample in total before PCI in 2 and at any time in 3"
45992036|NCT02922972|Device|Autologous Platelet Rich Plasma obtained with RegenKit®-BCT|After complete resection of the keloid scar, the first injection was administered before closure into the lesion resection bed and edges. Three additional injections were administered with a one-month interval.
45992037|NCT00529646|Drug|APD791|
46084233|NCT04257149|Diagnostic Test|Hemorrhagic stroke group (group A)|Group A: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
46084234|NCT04257149|Diagnostic Test|Ischemic stroke group (group B)|Group B: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
46084235|NCT04257149|Diagnostic Test|Stroke mimic group (group C)|Group C: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
46084236|NCT02596425|Procedure|40 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 40 cmH2O at the end of surgery.
46084237|NCT02596425|Procedure|60 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 60 cmH2O at the end of surgery.
46084238|NCT02596425|Procedure|Passive deflation|In the controls, CO2 was removed by the traditional passive deflation of abdominal cavity.
46084239|NCT02772146|Device|CLS UF|One single ultrafiltration session of 10 hours.
46084240|NCT04593810|Procedure|INTELLiVENT-ASV|INTELLiVENT-ASV is activated as soon possible. The sensors for ETCO2 and SpO2 are connected and activated. Patient's gender and height are set on the ventilator and patient condition is chosen if applicable.
46084241|NCT04593810|Procedure|CONVENTIONAL VENTILATION|Conventional ventilation consists of VCV or PCV and PSV, depending on patient's activity. None of the semi or fully automated modes of ventilation is allowed at any time.
45992038|NCT02922855|Behavioral|0 dollars group|Those assigned to the $0 group will not receive an incentive for visiting their PCP.
45992039|NCT02922855|Behavioral|50 dollars group|Those assigned to the $50 group will receive $50 if they visit their PCP within 6 months of study enrollment.
45992040|NCT02922855|Behavioral|25 dollars group|Those assigned to the $25 group will receive $25 if they visit their PCP within 6 months of study enrollment.
45992041|NCT04689321|Other|No intervention|This is not an interventional study.
45992042|NCT00527930|Drug|TS-1 and Eloxatin|"S-1 80 mg/m2/day on day 1-14 Oxaliplatin 130 mg/m2 IV for 2 hour on day 1 Every 3 week~Number of Cycles: until progression or unacceptable toxicity"
45992043|NCT00529841|Drug|Hydrocortisone sodium acetate|Subcutaneous administration of medication via insulin pump
45992044|NCT00529880|Drug|Fludarabine , cytarabine|
45992045|NCT02922504|Behavioral|Music intervention group|
45992046|NCT02922504|Behavioral|Controlled group|
45992047|NCT02944643|Other|Mindfulness and Support Groups|
45992048|NCT02925702|Drug|Radium 223 55mBq/Kg every 4 weeks intravenously|Radium-223 55kBq/kg infusion IV every 4 weeks
45992049|NCT00531089|Drug|Rituximab|Rituximab will be administered on weeks 1, 2, 3, and 4 at a dose of 375 mg/m2 per infusion. Premedications (prednisone 50 mg, diphenhydramine 50 mg, acetaminophen) will be administered prior to study infusion. Patients will also be treated with plasma exchange as per institution/apheresis centre.
45992050|NCT02922699|Drug|OMEZ 40|Omez 40 given to patients for 58days along with Amoxicilin and Clarithromycin
45992051|NCT02922699|Drug|OMEZ 80|Omez 80 patients for 58days along with Amoxicilin and Clarithromycin
45992052|NCT02944604|Drug|PEG-rhG-CSF|
45992053|NCT02922660|Drug|desflurane|method of anesthesia maintenance with desflurane ranged from 0.5~1.5 MAC during the procedure
45992054|NCT02922660|Procedure|total intravenous anesthesia|method of anesthesia in group TIVA is total intravenous anesthesia(TIVA) during the procedure
45992055|NCT02922660|Procedure|inhalation anesthesia|method of anesthesia in group DES is inhalation anesthesia with desflurane during the procedure
45992056|NCT02922660|Drug|Propofol|using propofol as sedative during the procedure of anesthesia and maintaining with propofol Cp 2-4 μg/ml in TCI
45674243|NCT01421849|Procedure|Denture implantation|"In a preliminary phase, a new denture is made according to standardized prosthodontic protocol or the old denture is adapted to provide a well-fitting denture.~Eight weeks after insertion of the new denture an implant is placed under local anaesthetics in the centre of the mandibula.If primary stability is good, the implant is immediately loaded by the denture. If not, the implant is loaded after 6 to 12 weeks. Before, during and after the treatment patient satisfaction is evaluated by a 20 item questionnaire. Afterwards questionnaires are compared. After the insertion of the implant clinical evaluations take place at several moments.~The total duration of the study will be 12 to 18 months."
45674244|NCT01498120|Drug|Rotigotine|"Optimal dose after titration period~0.5 mg/24 h (2.5 cm^2)- 1 mg/24 h (5 cm^2)- 2 mg/24 h (10 cm^2)- 3 mg/24 h (15 cm^2)~1 patch /day"
45674245|NCT01381211|Drug|TACE-DEB|Transcatheter arterial chemoembolization (TACE) is performed with drug eluting beads (DEB), polyvinyl alcohol-based microspheres loaded with the chemotherapeutic agent doxorubicin.
45674246|NCT01381211|Drug|90Y-RE|Glass Yttrium-90 microspheres (TheraSphere®; MDS Nordion Inc.) will be used
45833772|NCT04277130|Behavioral|Intervention with active video games|Participants in intervention group were paired up by their teachers. Each participant had a classmate playing with him/her, and the waiting time is minimal because Xbox 360 Kinect allowed double play mode. The intervention group was provided with an AVG, the Xbox 360 Kinect technology (Kinect Sports Seasons I & II, including bowling, soccer, boxing, track and field, table tennis, beach volleyball, golf, tennis). The AVG intervention consisted of two 30-min sessions per week, for a total of 12 weeks. Participants either played in PE classes and/or recess. They had no other specific routing of activities but straight played the AVG during the intervention. They could free to choose games they like in the Xbox 360. The AVGs of Xbox 360 chosen was of moderate to vigorous intensity (3-6 METs) and no matter what games they chose, their PA level would be between moderate and vigorous intensity.
45833773|NCT01583322|Drug|vargatef|"400 mg (200 mg twice daily) Route of administration= oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment are met, no intake of Vargatef® (Nintedanib) on days of paclitaxel and carboplatin administration. The maximum time on monotherapy is 2 years."
45992057|NCT02922660|Drug|Remifentanil|using remifentanil as analgesics during the procedure of anesthesia and maintaining with remifentanil 2-4 ng/ml in TCI
45992058|NCT02276924|Device|Laser confocal microscopy|Patients undergoing a reno-ureteroscopy for diagnosis or treatment indication will receive an intra-vesical instillation of fluorescein (0.1%) for 5 minutes, followed by the laser confocal microscopy procedure.
45992059|NCT02922465|Drug|K-877|
45992060|NCT02922465|Drug|Clopidogrel|
45992061|NCT02944292|Procedure|Deepening of sedation|Deepening of sedation will be achieved with a bolus and subsequent continuous infusion of propofol.
45992062|NCT02944292|Drug|Propofol|"Propofol will be dosed according to lean body weight (LBW) for bolus administration and according to total body weight (TBW) for continuous infusion.~All patients will receive a bolus of propofol 1 mg/kg LBW as a rapid infusion during one minute. Measurements will be made one minute after the ending of bolus infusion. Continuous infusion of propofol at a rate of 3 mg/kg/h will be started immediately following completion of measurements, not later than 5 minutes after bolus administration. The propofol infusion rate is decreased in case of hemodynamic instability by 1 mg/kg/h and until a minimum of 1 mg/kg/h, if needed. Maximum total dose of infusion of 5 mg/kg/h will not be exceeded (bolus not considered)."
45992063|NCT02922426|Drug|ALKS 3831|Daily dosing for 21 consecutive days
45992064|NCT02922426|Drug|Olanzapine|Daily dosing for 21 consecutive days
45992065|NCT02922426|Drug|Placebo|Daily dosing for 21 consecutive days
46084242|NCT04255355|Other|Pelvic alignment and forceful expiration|"The participant will be in supine with feet flat on a wall and the knees and hips flexed to 90 degrees. A standard 5 ball will be placed between the knees. The participant will hold a standard 9-inch balloon in the mouth with one hand. The subject will be instructed to isometrically contract the hamstrings to lift the ischium off the table while maintaining a posterior pelvic tilt. In this position, subject will be instructed to perform isometric hip adduction by squeezing the ball placed between the knees. The subject will then be instructed to breathe in through the nose and blow the air out into the balloon with full exhalation to activate the transverse and oblique abdominals. The participant will hold the breath for 3 seconds while maintaining hamstring contraction, adductor contraction, and transverse and oblique abdominal contraction. This process will be repeated four times. This exercise will be performed once daily under the supervision of the therapist for 5 days."
45674247|NCT01497262|Drug|Fingolimod|Fingolimod will be supplied as 0.5mg capsules in bottles of 35.
45674248|NCT02224625|Drug|2% CHG Cloth solution|Investigational CHG
45456933|NCT03926455|Biological|Placebo|Placebo is administered to the control group on Day 0 and 28
45456934|NCT03926455|Biological|Active Comparator Typhim Vi|A single dose of commercial typhoid fever vaccine Typhim Vi is administered on Day 0, followed by placebo control on Day 28
45456935|NCT03520738|Other|Blood samples|Blood samples on an empty stomach
45674249|NCT02224625|Device|Vehicle Cloth|Excipients from CHG cloth only
45674250|NCT02224625|Drug|Active Comparator|Active comparator
45674251|NCT02224625|Other|Saline|Negative control
45674252|NCT02224625|Other|SLS|Provides a slight irritation for a positive control
45674253|NCT01195493|Other|Essential Oils solution|(Essential oils solution, Listerine®, Johnson & Johnson) to use twice a day (2 x 20 ml) following daily mechanical oral hygiene practices
45674254|NCT01195493|Other|negative control solution|this solution would be used twice per day (2 x 20 ml) following daily home care.
45674255|NCT04094038|Drug|Olimel N12|A mixture of glucose, lipids, amino acids.
45674256|NCT04094038|Drug|Glucose IV|Glucose 5%
45992066|NCT04691921|Behavioral|Current clinical practices of participating physicians|Current clinical practice of participating physicians on choice of pharmacological agents for clinical management of Severe COVID-19
45992067|NCT00529919|Dietary Supplement|Weight loss|Weight loss study including consumption of either 22-25 g of medium chain triglyceride oil or olive oil
45992068|NCT02922114|Other|Ultrasonography|B-mode and power Doppler ultrasonography examination.Ultrasonography assessments includes wrists, metacarpophalangeal, proximal interphalangeal, elbows, shoulders, knees, ankles, metatarsophalangeal and twenty six tendons (wrist extensors, finger flectors and tendons of the ankles).
45992069|NCT02925663|Behavioral|EFI-E|This is 10 web-based modules addressing foundational EF skills. Each online module will be accompanied by a videoconference with a therapist to review the skills and problem solve around adolescent-identified goals.
45992070|NCT02943629|Device|Apneic oxygenation: Eight minute|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
45992071|NCT02943629|Device|Without apneic oxygenation|A Pentax AWSTM video laryngoscope with attached P blade will be placed for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
45992072|NCT02943629|Device|Apneic oxygenation: five minutes|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for five minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
45992073|NCT02925624|Procedure|Pulmonary vein isolation|
45992074|NCT00531128|Behavioral|High/Low Sitosterol|
45992075|NCT02925351|Procedure|Computed Tomography|Undergo PET/CT scan
45992076|NCT02925351|Radiation|Fluorine F 18 Clofarabine|Given IV
45992077|NCT02925351|Procedure|Positron Emission Tomography|Undergo PET/CT scan
45456936|NCT03520738|Other|Urinary samples|first urinary in the morning
45456937|NCT01127191|Other|military equipment|Military exercise of 24 hours
45674257|NCT00913679|Procedure|Surgical approach (ReCap Hip Resurfacing System)|two different surgical approaches in hip resurfacing arthroplasty
45674258|NCT00752453|Procedure|Dialysis during 4 hours|Blood and dialysate sampling
45674259|NCT00752453|Procedure|Dialysis during 6 hours|Blood and dialysate sampling
45674260|NCT00752453|Procedure|Dialysis during 8 hours|Blood and dialysate sampling
45674261|NCT02197247|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
45674262|NCT02197247|Drug|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 29 to Day 49 (Part A)
45992078|NCT02944409|Device|total knee prothesis VEGA System|total knee replacement
45992079|NCT00531167|Drug|combination of lamivudine+adefovir vs entecavir|Lamivudine 100 mg/day, Adefovir 10 mg/day, Entecavir 0.5 mg/day
45992080|NCT02922192|Drug|TNF-α antagonists, non-TNFs, DMARD non-biologics|Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.
45992081|NCT02944214|Drug|Febuxostat|It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
45992082|NCT02944214|Drug|Benzbromarone|It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
45992083|NCT02925546|Drug|GSK2798745 Micronized API without SLS and hypermellose (Tablet A)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions
45992084|NCT02925546|Drug|GSK2798745 Micronized API with SLS and hypermellose (Tablet B)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions with 240 mL of water
45992085|NCT02925546|Drug|GSK2798745 milled API without SLS and hypermellose (Tablet C)|This is an immediate release tablet containing 2.4 mg of milled GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions, with 240 mL of water
45992086|NCT02944331|Procedure|Endovenous steam ablation|
45674263|NCT02197247|Drug|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken daily from Days 1 to 77. Part B: AZD9291 80mg tablet taken daily for 12 months.
45674264|NCT02197247|Procedure|Pharmacokinetic sampling - rifampicin|Blood sampling to measure rifampicin levels
45992087|NCT02922075|Biological|Connective tissue graft|A 1.5 mm thick soft tissue graft removed from the palate with determined dimensions. The recipient site was prepared by performing laterally a delicate elevation of the facial tissue avoiding the mesial and distal papilla. The soft tissue graft length was equal to the horizontal distance between the two papillas and its length was set at 6 mm. Soft tissue grafts were placed at the level of the gingival margin and stabilized with simple interrupted sutures.
45992088|NCT02922075|Biological|Collagen matrix graft|A 15x20 mm collagen matrix trimmed according to determined dimensions. The recipient site was prepared by performing laterally a delicate elevation of the facial tissue avoiding the mesial and distal papilla. The soft tissue graft length was equal to the horizontal distance between the two papillas and its length was set at 6 mm. Soft tissue grafts were placed at the level of the gingival margin and stabilized with simple interrupted sutures.
45992089|NCT02922075|Device|Immediate implant|A conical implant with a morse-taper connection with moderate roughness implant surface was properly installed in the ideal tridimensional position with its platform placed 4 mm below the facial gingival margin. After tooth extraction and dental implant installation with a torque > 32 Ncm patients were randomized into three groups (8 patients per group): 1- No soft tissue graft, Control group (CTL); 2- Collagen Matrix group (CM); 3- Connective tissue graft group (CTG).
45992090|NCT02922075|Procedure|Tooth extraction|Compromised tooth was gently removed and the socket was debrided thoroughly, cleansed and inspected. The socket's palatal and apical bone was sequentially drilled. All surgeries were performed by the same surgeon and were individually planned according to the clinical and tomographic evaluation. Implant diameter was set as 3.5 mm and its length was selected according to the quantity of bone available apically to the fresh alveolar socket.
45992091|NCT02922075|Device|Immediate restoration|A titanium abutment was installed in the dental implant with manual torque and a prefabricated tooth shell was relined with resin material to fabricate cement or screw retained interim restoration. All interim restorations were installed in infra-occlusion matching the adjacent teeth color and form, with light proximal contacts and presented a subgingival concave contour.
45992092|NCT02922075|Biological|Bone regeneration|All sites received a non-cross linked collagen membrane and deproteinized bovine bone mineral containing 10% of porcine collagen.
45992093|NCT02922075|Drug|Post operative medication|Postoperative instructions were given, antibiotics were prescribed for 7 days (amoxicillin 500 mg t.i.d), analgesics to relieve from pain (Paracetamol 750 mg) and chlorhexidine 0.12% rinse twice a day for 15 days. Complementary, the patients were instructed to avoid chewing in the anterior region and to follow a soft diet.
45992094|NCT02922075|Device|Definitive prosthesis|Definitive implant-supported restorations were performed 6 months after dental implant placement.
45992095|NCT02922075|Other|No soft tissue graft|No soft tissue graft was used
46084243|NCT04255355|Other|Pelvic repositioning exercise|The participant will be positioned supine with their feet flat on a wall and the knees and hips flexed to 90 degrees. The subject will be instructed to isometrically contract the hamstrings to allow the ischial tuberosities to lift off the table while also maintaining a posterior pelvic tilt. The tailbone should be slightly lifted off the table, the abdominal muscles should be relaxed, and the low back should be flat on the table. While maintaining the posterior pelvic tilt, the subject will be instructed to perform isometric hip adduction by squeezing the ball that is placed between the knees. The subject will hold for 3 seconds and then relax. This process will be repeated four times. This exercise will be performed daily under the supervision of the therapist for 5 days.
46084244|NCT04255355|Other|Diaphragmatic breathing exercise|For diaphragmatic breathing exercise, the subject will be in supine position. The investigator places both hands around the participant's lower ribs and abdominal area. The investigator applies slight manual resistance to the chest and abdominal wall during inhalation phase of breathing.The participant is instructed to apply outward pressure against the investigator resistance and to raise the chest and abdominal wall simultaneously with inhalation. Then participants performs a full exhalation and hold his/her breath for 3 seconds before breathing in again. This process is repeated for 4 breathing cycles. Participants will perform this exercise once a day under investigator supervision.
46084245|NCT05387031|Drug|Ustekinumab|The initial intravenous (IV) infusion with ustekinumab at baseline was weight-adjusted (260 mg ≤55 kg, 390 mg between 55 and 85 kg, 520 mg ≥85 kg). According to the label, the first subcutaneous (SC) 90 mg induction dose was administered at week 8 followed by a maintenance dose of 90 mg SC every 8 or 12 weeks, at the discretion of the physician. This study evaluated the CD disease activity, obstructive symptoms, and radiographic or endoscopic remission in patients at different follow-up time points, and comprehensively evaluated the efficacy of ustekinumab in relieving stenotic CD and its related factors.
46084246|NCT02777606|Drug|Si-Ni-Tang|Treatment adheres to the International guidelines for management of severe sepsis and septic shock( 2012) and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015 for both the treatment group and the control group. In addition, 150ml of Si-Ni-Tang will be given by p.o. or by a nasogastric tube once a day for 3 days in the treatment group.
46084247|NCT04251455|Procedure|Arthroscopy or discectomy with sampling of synovial fluid and synovial tissue|"Arthroscopic lysis and lavage: performed under general anaesthesia. Before initiation of arthroscopy synovial fluid was sampled with a push-and-pull method. The TMJ was investigated with an arthroscope during irrigation with sterile saline solution. Adhesions were addressed with a coblator. Synovial tissue biopsies were taken from the posterior attachment of the disc.~Discectomy without replacement: performed under general anaesthesia. Before initiation of surgery, synovial fluid was sampled as above described. During surgery synovial tissue biopsies were taken as described above."
45833774|NCT01583322|Drug|placebo|"Contains 0 mg of Vargatef® (Nintedanib) in capsules matching 100 mg and 150 mg of Vargatef® (Nintedanib) Route of administration: oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment is met, no intake of placebo on days of paclitaxel and carboplatin administration.~The maximum time on monotherapy is 2 years."
45992096|NCT02944487|Drug|Lucerastat|Hard gelatin capsule for oral administration containing lucerastat
45992097|NCT02944487|Drug|Placebo|Matching placebo capsules
45992098|NCT00531245|Drug|TS-1, oxaliplatin|Oxaliplatin(130 mg/m2) day 1, intravenously TS-1 at a dose of 60, 70, 80, 90, 100, 110, 120 mg/m2 given orally starting day 1 until day 14(2 weeks ON, 1 weeks OFF), every 3 weeks
45992099|NCT00529997|Device|Stabilimax NZ® Dynamic Spine Stabilization System|Surgical Implantation
45992100|NCT03458585|Other|Self-administered questionnaire|Self-administered questionnaire
45992101|NCT02943395|Other|E.Max CAD Laminate Veneers cemented with dual cure amine free adhesive resin cement|
45992102|NCT02943395|Other|E.Max CAD Laminate Veneers cemented with light cured adhesive resin cement|
45992103|NCT02922348|Drug|Hormone Replacement Therapy|Hormone replacement therapy as indicated in Arm 1
46084248|NCT02596659|Procedure|Radial extracorporeal shock wave therapy (rESWT)|Each participant in the experimental group received rESWT for 3 sessions, consisting of 2000 impulses for each session, and one session per week over 3 weeks (a total of 6000 shock waves were given). The pneumatic pressure was set at the maximum level tolerable for each patient. The frequency of pulses was set at 10 Hz.
45456938|NCT02289976|Procedure|core decompression|Drilling of the avascular necrosis of the talus by 10mm drill under x-ray control
45456939|NCT01130311|Drug|Cholecalciferol|Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
45674265|NCT02197247|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
45833775|NCT03801174|Behavioral|Partner-assisted intervention|All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Partners will attend some patient group sessions and be informed of patients' goals and relapse plans. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
45833776|NCT03801174|Behavioral|Patient-only intervention|All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
45833777|NCT03796962|Drug|XEN1101|Oral dose
45833778|NCT04204122|Drug|Vigamox|-FDA approved medication
45992104|NCT02922348|Drug|Combined Oral Contraceptives|Combined oral contraceptives as indicated in Arm 2
45992105|NCT02922270|Other|Peritoneal dialysis patients at the Istanbul Medical Faculty|The aims of this study were to evaluate patient and technique survival rates, investigate peritonitis rates and evaluate factors affecting mortality in peritoneal dialysis (PD) patients over a period of 20 years at Istanbul Faculty of Medicine Peritoneal Dialysis Unit.
45992106|NCT00527501|Drug|Travoprost/brinzolamide|
45992107|NCT02943512|Other|Discharge day of procedure|Subjects will be discharged the day of the procedure if safe
45992108|NCT02925468|Device|Bite turbo|In this study the nature and speed of adaptation of the occlusal changes following insertion of an anterior bite plane (bite turbos) for the reduction of a deep overbite in growing patients will be investigated.
45992109|NCT02922387|Drug|Varenicline|Varenicline was given for 12 weeks to all patients in group A. The initial dose was 0.5 mg/day for days 1-3, and was then up-titrated to 0.5mg on days 4-7, and finally to 1 mg twice daily from day 8 until the end of treatment
45992110|NCT02922387|Behavioral|Behavioral support|An initial private consultation session and motivational interview while still in the hospital that lasted for at least 60 minutes. Follow-up phone calls with a minimum duration of 10 minutes were scheduled in weeks 1, 2, 4, and months 3,6 and 9 following smoking cessation.
45992111|NCT00530153|Behavioral|dietary counseling|Various activities and materials for teachers, students, parents and school catering personnel aiming at increasing their awareness and knowledge of good nutrition.
45992112|NCT00530153|Dietary Supplement|xylitol|Delivery of xylitol lozenges (about 1 g xylitol/student/school day) and guidance on tooth brushing.
45992113|NCT02922309|Behavioral|Vocal Training Via Telepractice|Vocal Training Via Telepractice, delivered by integrated communication service
45992114|NCT02922309|Behavioral|Vocal Training Via face-to face practice|Vocal Training Via face-to face practice at medical facilities
45992115|NCT00530192|Other|Treatment based on Molecular Profiling|Treatment with commercially available treatments (per package insert instructions)
45992116|NCT02922231|Biological|RIXUBIS|Recombinant Factor IX (rFIX) for intravenous use
45992117|NCT02921724|Device|TreC-Onco|"TreC-Onco is composed of two tools aimed at supporting patient self-care and health professional monitoring and intervention:~Mobile diary app. This is an Android app (for Android version 2.2 and higher) that allows patients to record parameters related to their health state (e.g. medications; blood pressure, weight, fever; side-effects or other symptoms) through a mobile device. Data are stored in a central database and are made available in real time to health professionals through a web dashboard on the TreC server or through a tablet app.~Web dashboard. Through this, oncologists can check patient data, monitoring their side-effects and adherence to prescriptions. The Dashboard is optimized for the Firefox browser in version 7 or higher."
45992118|NCT04691882|Behavioral|Diaphragmatic contraction|Sequential periods (30 s) of voluntary diaphragmatic contraction after meal ingestion
45992119|NCT04691882|Behavioral|Diaphagmatic relaxation|Sequential periods (30 s) of voluntary diaphragmatic relaxation after meal ingestion
45992120|NCT02925507|Other|Swallowing Screen|Patient will be ask to undergo a swallowing screen by study staff
45992121|NCT00531323|Drug|TMC125 once daily|Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
45992122|NCT00531323|Drug|TMC125 twice daily|Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
45992123|NCT02921880|Other|Cardiac Rehabilitation|
45992124|NCT02944253|Other|Low energy diet 70 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 70 gram carbohydrates
46084249|NCT02596659|Procedure|sham shockwave therapy|Sham shockwave therapy were given by the same physiatrist using the same machine as the experimental group, with the same rESWT protocol (3 sessions, 2000 impulses for each session, one session per week over 3 weeks) and the same frequency (10 Hz) of impulses, but the pneumatic pressure was set at 0.1 bar, with a similar sound to the regular rESWT but without actual energy conduction.
45833779|NCT04204122|Drug|Placebo|-The placebo is artificial tear drops
46084250|NCT02596659|Procedure|Physical therapy|The physical therapy program was performed 3 times a week over the same 3 weeks as rESWT, and consisted of 5 minutes of ultrasound diathermy, 15 minutes of transcutaneous electrical nerve stimulation (TENS), and 10 minutes of therapeutic exercise, including wrist common extensor stretching and self-massage.
46084251|NCT02777450|Procedure|lumbar facet block|injection of Levobupivacaine 0,25% and corticosteroids
46084252|NCT04805411|Biological|CM310|IL-4Rα monoclonal antibody
46084253|NCT04805411|Biological|Placebo|Placebo
46084254|NCT04570644|Drug|ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)|"Drug : ALZT-OP1a~Mast cell stabilizer~Neuroinflammatory microglial modulator~ALZT-OP1b anti-inflammatory~Device: Dry Powder Inhaler The inhaler will be used to deliver ALZT-OP1a via oral inhalation for dosing on study."
46084255|NCT02596347|Procedure|Blood draw|We will draw 4 heparin tubes for peripheral blood mononuclear cells (PBMC)
45833780|NCT05158062|Biological|pembrolizumab|pembrolizumab 200 mg every three weeks (Q3W)
45833781|NCT05158062|Drug|olaparib|olaparib 300 mg twice daily (BID) during maintenance period
45833782|NCT05158062|Biological|bevacizumab|bevacizumab 15 mg/kg Q3W
45992125|NCT02944253|Other|Low energy diet 100 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women
45992126|NCT02944253|Other|Low energy diet 130 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 130 gram carbohydrates
46084256|NCT02596347|Procedure|bronchoscopy|CBD subjects will undergo a bronchoscopy with lavage. This is the passage of a think flexible tube through the nose into the windpipe then into the bronchial tubes. Sterile saltwater solution is through the flexible tube then immediately removed.
46084257|NCT05016596|Dietary Supplement|turmeric|Turmeric supplement
45833783|NCT05158062|Drug|carboplatin|carboplatin AUC=5 or 6 Q3W during treatment period
45992127|NCT02921958|Behavioral|occupational therapy|Family-centered occupational therapy services
46084258|NCT05016596|Dietary Supplement|placebo|Placebo
46084259|NCT05192070|Other|Percussive Massage Group|Quadriceps, hamstring and gastrocnemius muscles of the participants will done massage for 3 minutes with a hypervolt massage device.
46084260|NCT05192070|Other|Dynamic stretching group|Dynamic stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
46084261|NCT05192070|Other|Static stretching group|Static stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
46084262|NCT04019847|Device|STAK Tool|Medical stretching device
45833784|NCT05158062|Drug|paclitaxel|paclitaxel 175 mg/m2 Q3W during treatment period
45833785|NCT05158062|Drug|docetaxel|docetaxel 60 ~ 70 mg/m2 Q3W during treatment period
45992128|NCT04689126|Procedure|surgical or nonsurgical endodontic treatment|Change in diagnosis and treatment plans between the two imaging - periapical radiography and cone beam computed tomography
45992129|NCT00531362|Drug|Plain aspirin|Plain aspirin 75 mg or 150 mg
45992130|NCT02925585|Other|Pre/post imaging|
45992131|NCT00531401|Drug|Salirasib|600mg BID until disease progression or unacceptable toxicity occurs.
45992132|NCT02925273|Other|palmar grasp without dorsal stimulation|"The patient will then be asked to keep the arms at 90 degrees and the researcher will slightly stroke palm and fingers of both hands of the patient simultaneously. After completion of each technique, the presence or absence of the response will be noted. In addition, the prominence of the response on the rating scale will be obtained as explained below.~The scaling of the grasp response is as followed:~Flexion at the distal interphalangeal joint of the hand~Flexion at the proximal interphalangeal joint of the hand~Flexion at the metacarpal-phalangeal joint of the hand"
45992133|NCT02925273|Other|standard palmar grasp test with dorsal stimulation|The patient will be asked to put their arms at 90 degrees and the researcher will hold one hand at the wrist and dorsum of the palm and lightly stroke the palm and fingers. The patient will be instructed to relax hands and not hold on while doing the grasp and see if the response persists. The same technique will be repeated for the patient's other hand.
45992134|NCT00531440|Drug|Everolimus (RAD001)|
45992135|NCT04015011|Combination Product|LCD Intervention|composed of approximately 1,080 kcal/day, which includes 3 New Direction Meal Replacements containing 200 kcal (27g protein, 12g carbhydrate, 2g fiber), 1 protein bar containing 160 kcal (5 g protein, 18g carbohydrate, 5g fiber, 2g sugar alcohol), and a 350-calorie controlled meal of protein and vegetables that the patient will make on his/ her own.
45992136|NCT02944526|Drug|Ropivacaine Monohydrochloride|Suprascapular nerve block under ultrasound control: injection of 5ml Ropivacaine HCL 2mg /ml
45992137|NCT02944526|Drug|Placebo - Concentrate|Placebo suprascapular nerve block under ultrasound control: injection of 5ml physiological / isotonic saline
45992138|NCT04013763|Other|wheat containing skin care products|stop or continue using wheat containing skin care products
45992139|NCT00530309|Drug|GSK716155 for injection|GSK716155 will be available with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks.
45992140|NCT00530309|Drug|Placebo|Subjects will also receive placebo.
45992141|NCT02917785|Device|Karman curettage|
45992142|NCT04000854|Drug|Calcium hydroxide (Calacept)|Long-term follow up of pulp regenerative treatment using two different root canal dressings: calcium hydroxide and chlorhexidin digluconate in immature necrotic traumatized incisiors
45992143|NCT03994614|Other|TEAS|Patients in the experimental group will be given TEAS treatment for 12 weeks prior to COS. The patients will be given three times acupuncture every week except menstruation. The acupuncture acupoint locations are as follows: head acupoint Baihui(DU20), abdominal acupoint Zhongji (RN3), Guanyuan (RN4), Zigong(EX-CA1), leg acupoint Sanyinjiao(SP6), waist acupoint Shenyu (BL23) and Guanyuanyu(BL26).
45992144|NCT00530387|Drug|19 organic sunscreen filters and 5 topical NSAIDs|
45992145|NCT04689165|Biological|Experimental Group A meningococcal polysaccharide vaccine|Two doses of Experimental Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
45992146|NCT04689165|Biological|Control Group A meningococcal polysaccharide vaccine|Two doses of Control Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
45992147|NCT04689087|Combination Product|TTFields|For patients with relapsed GBM, before receiving electric field treatment, the patient can be re-operated, and TTFields+BPC chemotherapy is used after surgery
46084263|NCT04019847|Other|Standard treatment|Physiotherapists tailor treatment of arthrofibrosis to meet their patients' individual needs. Treatment may comprise the following: education, advice and a range of stretching exercises/techniques to change the length and density of the adhesions and shortened tissue. These include active range of movement (AROM), passive range of movement (PROM), strengthening exercises, hands-on high intensity passive physiological stretches, joint mobilisations and a home exercise programme involving full weight bearing exercises with the aim of enabling the patient to regain AROM and function
46084264|NCT02775110|Other|Natalizumab discontinuation|Patients will be randomized to one of two groups: The Immediate Discontinuation Group (stop natalizumab immediately and continue with new DMT 1 month afterward) and the Taper-off Group (two additional infusions of natalizumab, one at 6 weeks and the next at 8 weeks following discontinuation. A new DMT will be initiated within 2 months of final natalizumab infusion).
45833786|NCT01176474|Biological|NY-ESO-1 157-165 (165V)|"The vaccine contains two peptides from two different proteins (peptides are pieces that make up proteins) called gpl00 and NY-ES0-1.~Route of Administration: When prepared as a vaccine emulsion with Montanide ISA 51 VG, the vaccine is given by deep subcutaneous injection.~Method of Administration: The 0.5 mg vaccine emulsion dose is administered as a 1 mL injection (0.5 mg/1 mL) as a deep subcutaneous injection in the anterior thigh of the same extremity. Injections should be separated by at least 3 cm to avoid the formation of coalescent granulomas. All 4 peptides (total of 6 injections) will be administered in the same thigh and alternating thighs will be used for each subsequent treatment."
45992148|NCT00530543|Procedure|Robot-assisted gait training|
46084265|NCT02775188|Device|interACTION|
46084266|NCT02775188|Other|Standard of Care Physical Therapy|
46084267|NCT04250909|Device|Passeo-18|POBA
46084268|NCT04250909|Device|Passeo-18 Lux|DCB
45674266|NCT02224157|Drug|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
45992149|NCT00530582|Drug|progesterone|300mg progesterone /placebo each for 21 days
45992150|NCT00530660|Biological|H5N1 influenza vaccine (whole virion, Vero cell-derived), 7.5 µg HA antigen, non-adjuvanted|All subjects who have completed the Day 42 visit at the Austrian study site in Study 810501 will be invited to receive a booster vaccination, 12 to 17 months after the first vaccination with the A/Vietnam/1203/2004 influenza vaccine administered in Study 810501, with a heterologous whole virion, Vero cell-derived influenza vaccine containing 7.5 mg A/H5N1/Indonesia/05/2005 hemagglutinin (HA) antigen in a non-adjuvanted formulation.
45992151|NCT02917863|Drug|L-Thyroxine (tablet, per os)|
45992152|NCT02917863|Drug|L-Thyroxine (oral drops, solution)|
45992153|NCT00530699|Drug|AZD1152|intravenous
45992154|NCT02917824|Device|High-intensity IMT|30 breaths at 50% of the maximal inspiratory pressure, twice daily for 6 weeks
45992155|NCT02917824|Device|Low-intensity IMT|30 breaths at 15% of the maximal inspiratory pressure, twice daily for 6 weeks
45992156|NCT00530738|Drug|Lipoplus|i.v. fat emulsion for parenteral nutrition
45456940|NCT01130311|Drug|Saline injection|normal saline, intramuscular preperation,given in 2 doses at week 0 and week 4 of trial
45992157|NCT00530738|Drug|Lipofundin MCT|i.V. fat emulsion for parenteral nutrition
45674267|NCT02224157|Drug|budesonode bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
45992158|NCT02921685|Drug|Monalizumab|Four dose levels will be tested.
45992159|NCT02944175|Drug|Sugammadex|At the end of surgery and when 2 responses were achieved on the TOF stimulation, Sugammadex 2 mg·kg-1 was administered intravenously in Group S
46084269|NCT02775266|Other|Alpha lipoic acid|Scaling and root planing will be done at baseline and systemic antioxidant Alpha lipoic acid 1800mg/day in 3 divided doses for a period of 3 months.
46084270|NCT02775266|Procedure|Scaling and Root planing|Scaling and root planing will be done at baseline.
45674268|NCT02196701|Drug|Adalimumab|Administered by subcutaneous injection every other week.
46084271|NCT04770311|Behavioral|Microbiome friendly diet|Families in the intervention group will have a microbiome-friendly nutrition assessment and will also receive groceries one time per week for four weeks to help achieve a more microbiome-friendly diet.
46084272|NCT02692638|Procedure|Early laparoscopic enterolysis|The surgeon will make about 3-4 small incisions in the participant's abdomen. A port (nozzle) is inserted into one of the slits, and carbon dioxide gas inflates the abdomen. A laparoscope is inserted through another port. The laparoscope looks like a telescope with a light and camera on the end so the surgeon can see inside the abdomen. Surgical instruments are placed in the other small openings and used to cut the scar tissue in order to relieve the obstruction. After all this has been accomplished, the carbon dioxide is released out of the abdomen through the slits, and then these sites are closed with sutures or staples, or covered with glue-like bandage and steri-strips.
46084273|NCT02692638|Procedure|nonoperative management|Sometimes a bowel obstruction can be treated by suctioning out the contents of the stomach, giving IV fluids, and not letting the patient eat for a few days.
46084274|NCT04254887|Procedure|EPBD|Small incision of the duodenal nipple + EPBD
46084275|NCT04254887|Procedure|EST|Large incision of the duodenal nipple + EPBD
45992160|NCT02944175|Drug|Neostigmine|At the end of surgery and when 2 responses were achieved on the TOF stimulation neostigmine 0.05 mg·kg-1 + atropine 0.02 mg·kg-1 was administered intravenously
45992161|NCT02917746|Drug|Imiquimod|Patients in this group are treated with vaginal imiquimod cream during 16 weeks. A control colposcopy with diagnostic biopsies will be performed after 10 weeks to rule out disease progression. A final colposcopy with diagnostic biopsies will be performed after 20 weeks to evaluate disease efficacy.
46084276|NCT01524926|Drug|Crizotinib (PF-02341066)|For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of 500, 400 or 250 mg/day depending on toxicitie; for patients younger than 15yo, 280 mg/m²/dose BID, with reductions allowed to 80% as first reduction and to 60% as second reduction respectively of the initial dose.
45674269|NCT02196701|Drug|Methotrexate|Methotrexate was provided as 2.5 mg tablets for oral administration.
45833787|NCT01176474|Drug|Nivolumab|"Nivolumab (BMS-936558) is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1).~Nivolumab will be given at the following dosages: 1, 3, or 10 mg/kg.~Nivolumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate."
45992162|NCT02917746|Procedure|Large Loop Excision of the Transformation Zone|Patients in this group are treated with LLETZ.
45992163|NCT04688892|Device|Cupping|dynamic cupping
45992164|NCT02944370|Behavioral|PlayFit - modified exercise games|Play modified games with other adults three times a week for 12 weeks. Complete a brief survey on the games played and program satisfaction.
46084277|NCT05342766|Dietary Supplement|Nutrigenetic|"Each grup will receive two interventions (Nutrigenetic and Standard), in a cross-over design (3 months each), spaced by a wash-out period (3 months)."
45992165|NCT00531557|Drug|Darunavir ritonavir|
45992166|NCT02921568|Device|P200TE|Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
45456941|NCT03520582|Device|Tube placement|Placement of enteral feeding tubes
45456942|NCT03926377|Procedure|bone densitometry|Patients with bullous pemphigoid will benefit from bone densitometry at the initiation of treatment, at 3 months (theoretical end of the treatment of attack) and at 6 months (theoretical end of the treatment).
45456943|NCT03926377|Biological|blood test|Blood test of serum calcium, phosphoremia, albumin, 25 OH vitamin D and cortisol at 8 hours to highlight possible correlations between changes in bone mineral density and phosphocalcic parameters and 8 hours cortisolemia.
45674270|NCT04763291|Dietary Supplement|Juice Plus+ Fruit, Vegetable and Berry blends|Encapsulated juice powder concentrate derived from 36 dried fruits, vegetables and berries.
45674271|NCT04763291|Dietary Supplement|Juice Plus+ Omega blend|Encapsulated plant-based fatty acid supplement.
45674272|NCT04773119|Procedure|PVI only|Patients in this group receive PVI only
45992167|NCT02921568|Device|Spectral OCT/SLO|Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
45992168|NCT02944097|Dietary Supplement|Vineatrol 30 native powder|
45992169|NCT02944097|Dietary Supplement|Vineatrol 30 micelles|
46084278|NCT04747925|Other|Mulligan two leg rotation core muscle strengthning exercises|Group A :is receiving moist heat for the hamstrings muscles prior the Mulligan Two leg rotation technique for 10mins.Hold the position for 30 seconds, relax for 1 minute. Reps are given 3 repetitions. And 3 Sets at each session .core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, is being performed. Position is being held for about 10 seconds and each exercise are performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
45992170|NCT02917902|Other|Food boxes|Box of approximately 50 pounds of nutritious foods provided by food pantry, including fresh fruits and vegetables as well as shelf-stable items selected for diabetic patients, along with brief education provided by food pantry staff.
45674273|NCT04773119|Procedure|PVI with substrate ablation|Patients in this group receive PVI as well as substrate ablation
45992171|NCT00531596|Drug|EMSAM (Selegiline Transdermal System) 6mg/24Hr|EMSAM 6mg/24HR
45992172|NCT00531596|Drug|EMSAM (Selegiline Transdermal System) 9mg/24Hr|EMSAM 9mg/24Hr
45992173|NCT00531596|Drug|EMSAM (Selegiline Transdermal System) 12mg/24hr|EMSAM 12mg/24Hr
45992174|NCT02921646|Other|Measure of resting energetic expenditure|measure of resting energetic expenditure
45992175|NCT02943707|Procedure|Autologous bone marrow stem cells infusion|Autologous bone marrow stem cells are infused into proper hepatic artery
45992176|NCT02943707|Drug|drugs such as Ursodeoxycholic Acid tablets|Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
45992177|NCT00531635|Drug|Mycophenolate Mofetil|Induction of Mixed Hemopoietic Chimerism in Patients Using Mycophenolate Mofetil
45992178|NCT02917551|Other|7 days of adequate antibiotic treatment|
45992179|NCT02917551|Other|14 days of adequate antibiotic treatment|
45992180|NCT00531674|Dietary Supplement|fortified milk-based beverage|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
45992181|NCT00531674|Dietary Supplement|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
45992182|NCT00531674|Dietary Supplement|tablets|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
46084279|NCT04747925|Other|mulligan bent leg raise technique, core muscle strengthning exercises|Group B is receiving moist heat for the hamstrings muscles prior the Mulligan Bent leg raise technique for 10 minutes. Hold the position for 30 seconds, relax for 1 minute. Reps are 3 repetitions. And 3 Sets at each session .Subject is being receive 2 weeks protocol. core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, are being performed. Position is held for about 10 seconds and each exercise is performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
46084280|NCT02775032|Behavioral|Advance care planning conversations between patients and their GP|
46084281|NCT05342688|Behavioral|Task-specific practice of upper extremity functions|The intervention will consist of training of items from the Wolf motor function test.
46084282|NCT05329805|Behavioral|job crafting intervention|the participated nurses will receive session about job crafting followed by activity related to job crafting
45674274|NCT01481116|Drug|TAK-875|TAK-875 25 mg, tablets, orally, once daily and metformin ≥1500 mg or Maximum Tolerated Dose (MTD) for up to 104 weeks.
45674275|NCT01481116|Drug|TAK-875|TAK-875 50 mg, tablets, orally, once daily and metformin ≥1500 mg or MTD for up to 104 weeks.
45674276|NCT01481116|Drug|Glimepiride|Glimepiride 1 mg, tablets, orally, once daily (up-titrated to 2 mg after 1 week of treatment. Up-titrated to a maximum of 6 mg in 2 mg increments/down titrated if recurrent (or severe) hypoglycemia occurs) and metformin ≥1500 mg or MTD for up to 104 weeks.
45674277|NCT02222207|Drug|Regorafenib, ophthalmic oily suspension (BAY73-4506)|Subjects receive Regorafenib as eye drops
45674278|NCT02222207|Procedure|Sham IVT|Sham injections
45674279|NCT02222207|Drug|Ranibizumab|Subjects receive Ranibizumab as intravitreal injection
45674280|NCT02222207|Drug|Placebo|Placebo eye drops
45674281|NCT01457014|Device|servo ventilation auto|Expiratory pressure automatically adjusted to stabilize the upper airway. Inspiratory pressure automatically adjusted to deliver consistent peak flow.
45674282|NCT01457014|Device|Continuous positive airway pressure|continuous positive airway pressure
45992183|NCT00531674|Dietary Supplement|Fortified milk-based pap|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for children.
45992184|NCT00531674|Dietary Supplement|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
45992185|NCT00531674|Dietary Supplement|Syrup|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
45992186|NCT02921529|Other|TEAS|Electric stimulation was given through electrode attached to specific acupoints
45992187|NCT02921529|Other|false stimulation|Electrodes were attached to specific acupoints without electric current
45992188|NCT02943824|Other|Machine Learning Planning|The intervention being tested is a novel approach to planning LDR treatment plans using a machine learning computer algorithm.
45992189|NCT02943824|Other|Radiation Therapist Planning|The intervention being compared to the experimental arm is conventional manual planning by a human expert LDR brachytherapy planner.
45992190|NCT02921607|Other|Observational group|Participants will be asked to complete a questionnaire prior to discharge and 3 months later to follow up
45992191|NCT00530933|Procedure|Percutaneous posterior tibial nerve stimulation|Once weekly for 30 minutes
45992192|NCT00530933|Procedure|Transcutaneous tibial nerve stimulation|30 minutes once weekly
45992193|NCT00530933|Procedure|Sham transcutaneous tibial nerve stimulation|Once weekly for 30 minutes
45992194|NCT02917668|Other|FreeO2|Oxygen delivery automatically titrated by a closed-loop system that adjusts the oxygen flow based on the patient's real-time SpO2 and a programed SpO2 target of 90 %
45992195|NCT02917668|Other|Usual care|Oxygen delivery manually titrated by the nursing staff for a SpO2 target of > or = 95 %
45992196|NCT00531713|Drug|Triiodothyronine|50 microgram of the usual T4 is withdrawn and the patients is given 20 microgram of T3
45992197|NCT02921334|Procedure|switching between invasive and noninvasive ventilation|As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
45992198|NCT00530972|Drug|Peginterferon alfa-2a plus ribavirin adjusted to body weight|PegInterferon 180 mcg/week, Adjusted body weight Ribavirin (1000 mg <75 kg, 1200 mg >75 kg)
46084283|NCT04763174|Behavioral|mHealth Coping Skills Training for Symptom Management (mCOPE)|mCOPE participants will complete 5 videoconferencing sessions (within 5-9 weeks) with a psychologist, each lasting 45-60 minutes, from a location convenient to the patient (e.g., home, work). Sessions will include cognitive behavioral coping skills designed to target pain, fatigue and psychological distress symptoms unique to colorectal cancer patients. mCOPE will include a mobile app for: 1) coping skills content (e.g., audio, video), 2) daily symptoms assessment and coping skills use tracking transmitting in real-time to study staff, and 4) push notifications for reminders, encouragement, and personalized feedback.
46084284|NCT03761706|Behavioral|Engagement in Physical Activity|Study participants will be asked to wear a FitBit provided by the research team and agree to FitBit data downloads during regularly scheduled chemotherapy clinic visits. Participants will also complete a daily exercise log to record the total number of minutes walked and the total number of steps from the FitBit.
45992199|NCT02943863|Device|HFNC followed by conventional nasal cannula|
45992200|NCT02943863|Device|Conventional nasal cannula followed by HFNC|
45674283|NCT01457014|Device|servo ventilation manual|servo ventilation titrated in manual mode
45674284|NCT02254421|Drug|Presatovir|Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
45674285|NCT02254421|Drug|Placebo|Placebo to match presatovir administered orally or via nasogastric tube
45674286|NCT04773041|Procedure|Infinitome|All patients will have rs-FMRI images analyzed with the Infinitome cloud-based software processing program.
45833788|NCT01176474|Biological|gp100:280-288 (288V)|"The vaccine contains two peptides from two different proteins (peptides are pieces that make up proteins) called gpl00 and NY-ES0-1.~Route of Administration: When prepared as a vaccine emulsion with Montanide ISA 51 VG, the vaccine is given by deep subcutaneous injection.~Method of Administration: The 0.5 mg vaccine emulsion dose is administered as a 1 mL injection (0.5 mg/1 mL) as a deep subcutaneous injection in the anterior thigh of the same extremity."
45833789|NCT01176474|Drug|Montanide ISA 51 vegetable grade (VG)|"Route of Administration: Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.~Method of Administration: Divide peptide vaccine emulsion dose volumes of greater than 1.5 mL into 2 or more injections. Administer injections typically into the anterior thigh deep subcutaneous tissue. Perform subsequent injections in rotating sites. Use a 20 or 21 gauge needle for deep subcutaneous injection of the peptide vaccine emulsion."
45833790|NCT01176474|Drug|Ipilimumab|"Ipilimumab will be given at the following dosage: 3 mg/kg.~Ipilimumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate."
45674287|NCT02252939|Radiation|X-Ray|X-ray as part of standard care
45674288|NCT02196077|Drug|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
45833791|NCT01176474|Procedure|Apheresis Procedure|"Some blood will be removed from the participant's veins and processed by a machine to remove a small portion of the white cells. The rest of the blood will be returned into their veins. This procedure is called apheresis. Apheresis is done to collect cells to allow the investigators to understand how their immune system is functioning before and after receiving nivolumab and vaccine. This will be done for research purposes only. The red cells and blood clotting cells will not be permanently removed during this procedure. White blood cells will need to be removed by apheresis before participants receive the study drug."
45833792|NCT01076868|Drug|Primaquine|Primaquine x 14 days
45833793|NCT03193866|Drug|Rituximab|Comparisons of efficacy and safety between rituximab and all other frequently used immunomodulating drugs against multiple sclerosis
45992201|NCT02943278|Behavioral|Intensive Sleep Retraining|Participants in this group you will spend just over 1 day at our sleep lab, starting around their usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake participants up after a few minutes if they fall asleep.
45992202|NCT02943278|Behavioral|Sleep Hygiene|Participants in this group will complete one session with a clinician focused on psychoeducation regarding sleep positive practices.
45674289|NCT02196077|Drug|BFF MDI 160/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
45674290|NCT02196077|Drug|BFF MDI 80/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
45992203|NCT02943434|Other|Processed food|This is examining the effects of processed foods on diet-induced thermogenesis.
45992204|NCT02917707|Other|normal colorectal tissues|The investigators will extract total protein, DNA and RNA from these groups.
45992205|NCT02921451|Device|Restorelle Smartmesh|Patients will have surgery using the device, Restorelle Smartmesh, for treatment of uterine prolapse.
45992206|NCT02943317|Drug|Part A - VS-6063|Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
45992207|NCT02943317|Drug|Part A - Avelumab|Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
45992208|NCT02917590|Other|Dual-task obstacle crossing training|Obstacle crossing simultaneously a color word stroop task training
46084285|NCT03761706|Other|Questionnaires|Study participants will complete the following questionnaires: Health Behavior Questionnaire (HBQ), Short Physical Performance Battery (SPPB), Functional Assessment of Cancer Therapy-General (FACT-G), 4.4.5 Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), PROMIS Cognitive Function (Short Form 8a), Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12) Version 4, Nutrition Survey, Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM),
46084286|NCT05007236|Drug|RP7214 + Standard of care (SOC)|RP7214 tablets will be administered orally twice a day for 14 days
45456944|NCT03926377|Procedure|radiographs of the thoracic and lumbar spine|standard radiographs of the thoracic and lumbar spine will be done at the initiation of treatment and at 6 months.
45456945|NCT03926377|Procedure|Clobetasol propionate|Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.
45456946|NCT03132688|Drug|Propofol|Intravenous administration with dose of 100-200mcg/kg/min
45674291|NCT02196077|Drug|BD MDI 320 μg|Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
45674292|NCT02196077|Drug|FF MDI 9.6 μg|Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
46084287|NCT05007236|Drug|Placebo + Standard of care (SOC)|Placebo will be administered orally twice a for 14 days
46084288|NCT02772224|Device|Drug eluting balloon angioplasty|In the DEB group, the guide wire will be passed through the occluded or stenosed lumen and the predilatation of the target lesion with standard balloon(s) will be performed before dilatation with a paclitaxel-eluting balloon of the diameter, at least about that of the pre-dilatation balloon (Arteryguard, Rientech, Dezhou, China). The drug eluting balloons will then be inflated according to the manufacturer recommendations. The patients will then be followed every six months for a year to compare its treatment efficacy and safety with that of conventional balloon angioplasty group.
45992209|NCT02917590|Other|Single-task obstacle crossing training|Obstacle crossing training
45992210|NCT02943356|Drug|Tadalafil|Patients will be treated with Tadalafil for 8 weeks
45456947|NCT01227811|Drug|Darifenacin|Single oral dose Darisec(R) 15.0 mg
45456948|NCT01227811|Drug|Darifenacin|Single oral dose Enablex(R) 15 mg
45456949|NCT01225081|Drug|ipragliflozin|oral
45456950|NCT01225081|Drug|Placebo|oral
45456951|NCT01225081|Drug|Pioglitazone|oral
45456952|NCT02294422|Device|PBP|the pilot balloon is continuously palpated o felt for adequate pressure as its being inflated.
45456953|NCT02294422|Device|LOR|
45674293|NCT02195687|Biological|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) injected into bilateral crow's feet line areas.
45674294|NCT02195687|Drug|Normal Saline|Normal Saline (placebo) injected into bilateral Crow's Feet Line areas.
45992211|NCT02921373|Biological|19F Cell Sense-labeled PBMC|"Peripheral blood mononuclear cells (PBMC) will be isolated from patient whole blood samples and labeled in a GMP facility with GMP grade 19F Cell Sense imaging agent.~These cells will be re-administered to the patient prior to imaging."
45992212|NCT02921373|Device|MRI|Participants will undergo Magnetic Resonance Imaging (MRI) at 1 hour and 24 hours following PBMC administration
45992213|NCT02943239|Drug|REGN1033|REGN1033
45992214|NCT02943239|Drug|REGN2477|REGN2477
45992215|NCT02943239|Other|Placebo|Placebo
45992216|NCT02917512|Drug|HU00701|Cyclosporine 0.01% + 3% trehalose
45992217|NCT02917512|Drug|HU007|Cyclosporine 0.02% + 3% trehalose
45992218|NCT02917512|Drug|Restasis|Cyclosporine 0.05%
45992219|NCT02917512|Drug|Placebo|Vehicle
45992220|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 6 weeks|PCV10 1+1, 6 weeks & 9 months
45992221|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 14 weeks|PCV10 1+1, 14 weeks & 9 months
45992222|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV10 ) 2+1|PCV10 2+1, 6&14 weeks & 9 months
45992223|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 6 weeks|PCV13 1+1, 6 weeks & 9 months
45992224|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 14 weeks|PCV13 1+1, 14 weeks & 9 months
45992225|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV13 ) 2+1|PCV13 2+1, 6&14 weeks & 9 months
45992226|NCT03800823|Behavioral|Parent group|In group sessions parents will learn how to use positive parenting practices (e.g., encouragement and limit setting) instead of ineffective practices (e.g., coercive behaviour, negative reciprocity). Using a parent group approach, each of the 10 sessions consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments.
45992227|NCT03800823|Behavioral|mHealth component|After the group sessions, parents will receive a 6-month mHealth program (MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet/physical activity behaviours. The program includes information, advice, and strategies to change unhealthy behaviours and the possibility to register the child's intake of fruit, vegetables, candy, sweetened beverages, and sedentary time.
45992228|NCT03800823|Behavioral|Standard care|Standard care for overweight and obesity.
45992229|NCT00531908|Drug|furosemide|furosemide
45992230|NCT03403569|Drug|Triptolide Wilfordii|In addition to appropriate ART, Triptolide Wilfordii will be given to patients in the experimental group at a dosage of 20mg three times a day per os for 12 months.
45992231|NCT03403569|Drug|Placebo Oral Tablet|In addition to appropriate ART, placebo oral tablets will be given to patients in the experimental group at a dosage of 2 pills three times a day per os for 12 months.
45992232|NCT00531791|Drug|prednisone group|Patients in the prednisone group will receive prednisone 40 mg per day with concomitant placebo diskus 2 inhalations twice a day for 10 days. All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
45992233|NCT00531791|Drug|Advair group|Patients in the second group will receive Advair® 50/500 ug 2 inhalations twice daily with placebo pills once a day for 10 days (twice the regular dosage). All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
46084289|NCT02772224|Device|Conventional balloon angioplasty|The guide wire will be passed through the occluded or stenosed lumen and the conventional balloons will be inflated as recommended by the manufacturer. The primary and secondary outcome will then be assessed and compared with DEB group, on follow up at six and 12 months.
46084290|NCT03738228|Drug|Atezolizumab|Given IV
46084291|NCT03738228|Radiation|Brachytherapy|Undergo standard of care image guided brachytherapy
46084292|NCT03738228|Drug|Cisplatin|Given IV
46084293|NCT03738228|Radiation|Radiation Therapy|Undergo standard of care radiation therapy
46084294|NCT04756232|Drug|Mecamylamine Challenge|Mecamylamine 20 mg oral pill administered once
46084295|NCT04756232|Other|Placebo Comparator Challenge|Matching placebo oral pill administered once
46084296|NCT02774876|Device|Patient's insulin pump|The patient's insulin pump will be used to regulate glucose levels.
46084297|NCT02774876|Drug|Insulin|Patient's usual fast-acting insulin analog will be used.
46084298|NCT02774876|Device|Dexcom G4 Platinum glucose sensor|The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
46084299|NCT02774876|Other|Single-hormone closed-loop|Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at IRCM at 6:30 am in a fasting state. At 7:00, single-hormone closed-loop will be initiated. At 8:00, if glucose levels are between 3.5 and 12.5 mmol/L, the meal will be served. Patients will have 20 minutes to consume the meal. If glucose levels are not in this target range, the meal will be delayed for a maximum of 45 minutes. If after 45 minutes, glucoses levels are still not between 3.5 and 12.5 mmol/L, the test will be cancelled and rescheduled. The test meals will be: 1) 75g of CHO; 2) 75g of CHO + 35g of protein; 3) 75g of CHO + 35g of fat; or 4) 75g of CHO + 35g of protein + 35g of fat. The intervention day will end at 13:00.
46084300|NCT00614016|Drug|Sodium ST20|single administration of oral dosage form
46084301|NCT04225364|Drug|camrelizumab|Participants will receive camrelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
45456954|NCT02294422|Device|Aneroid manometer|The pilot balloon is attached onto the manometer and cuff pressures are raed off from the gauge.
45456955|NCT02298166|Drug|chemotherapy (Mitoxantrone, Cytarabine)|"Induction therapy:~Mitoxantrone 10 mg/m² IV, push (8 mg/m² for patients > 60 years of age and/or previous allogeneic HCT) d 1-3~Cytarabine 1000 mg/m² IV (500 mg/m² for patients > 60 years of age and/or previous allogeneic HCT), over 3 hours, d 1-6~Consolidation therapy:~Younger adult patients (18 to 60 yrs):~Cytarabine 1500 mg/m² by i.v infusion over 3 hours BID on days 1-3 (total dose 9000 mg/m²).~Older patients (> 60 yrs) and or previous allogeneic HCT:~Cytarabine 1000 mg/m² by i.v. infusion over 3 hours BID on days 1-3 (total dose 6000 mg/m²)."
46084302|NCT04225364|Drug|Paclitaxel for injection (albumin-bound)|Paclitaxel for injection (albumin-bound): 260mg/m2(in total), ivgtt d1, d8, q3w，for 2 cycle
46084303|NCT04225364|Drug|Cisplatin|75mg/m2(in total), ivgtt d1-d3, q3w, for 2 cycles
46084304|NCT04510350|Other|Biomarkers analysis|Genetic analysis of regions of interest
46084305|NCT00742209|Drug|GSK1838262|Flexible dosing: 1200 mg/day, 1800 mg/day, 2400 mg/day and 3000 mg/day
46084306|NCT00742209|Drug|Placebo|Placebo-control
46084307|NCT02774720|Behavioral|Centre-based exercise|Participants will come to a centre (University of Waterloo or Toronto Rehabilitation Institute) for a one-hour, small group exercise class each week. The classes will include progressive aerobic and resistance exercise. They will be prescribed additional exercise to be performed independently (either at home or in the community).
45992234|NCT02943551|Other|Online Tutorial|For each group of practices, during the first month of intervention participation, study staff at Seattle Children's Research Institute will send each participating provider within a group/wedge, via email, a password to access the online tutorial. Participants will be asked to view the 40-minute tutorial at a time that is convenient for them but prior to the first webinar. Investigators will be able to track whether and how often participants access the online tutorial as a measure of engagement in the intervention. PROS will follow up, via email or phone, with providers who have not completed the tutorial within a three week timeframe.
45674295|NCT02195531|Behavioral|Education and feedback|The education leaflets are information concerning Obstructive Sleep Apna (OSA) and CPAP treatment. The feedback reports are CPAP usage patterns.
45992235|NCT02943551|Other|Webinars|"The first webinar, focused on making appropriate antibiotic choices for bacterial ARTIs, will be held at the beginning of month 2 of intervention participation, and the second webinar, focused on recommended communication practices during visits for ARTIs, will be held at the beginning of month 3 of intervention participation. Due to webinar faculty time constraints, we will establish dates/times for the webinar prior to recruitment. Providers will be given information on webinar dates in both the randomization email, as well as include the dates in the study box letter.~The webinars will be recorded to facilitate attendance for those who are unable to make the scheduled date/time. Included in the recording will be the presentation and any questions and answers from participants."
45992236|NCT02943551|Other|Booster Sessions|"An online link to the first booster video vignette will be sent to practice participants via email at the beginning of month 5 of intervention participation for each group/wedge. The link will lead to a website in which the provider will need to create a user name and password to access the booster videos. Two additional booster vignettes will be made available for viewing at the beginning of months 7 and 9 of intervention participation.~For each of the three booster sessions, up to three reminders to complete viewing the video vignette will be sent over a 2-week period. The study team will be able to monitor whether participants access and complete the questions at the end of each vignette."
45992237|NCT02943551|Other|Feedback Reports|"During the intervention phase, providers will also receive 6 audit and feedback reports given by parents.~The first report will have two parts:~The first part will focus on the provider's overall antibiotic prescribing rates for all ARTIs (viral and bacterial) and rates of using second-line antibiotics for bacterial ARTIs.~The second part will report the rates at which the provider uses the targeted communication practices as well as their average satisfaction scores."
45992238|NCT02943551|Other|Parent Survey|Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit.
45992239|NCT02921178|Other|Omalizumab|comparision of using Omalizumab and non-Omalizumab treatment
45992240|NCT03279276|Procedure|Total Hip Arthroplasty|"The usual procedures of the department: Moore incision and insertion of uncemented joints (exceed with vitamin E enriched polyethylene liner and 32 or 36 mm head). Cyclokaprone is administered peroperatively (bleeding-reducing), antibiotics and thrombosis prophylaxis. Follow the usual rehabilitation regimes, fast track, incl. Use of crutches and must support within the pain limit, possibly with crutches the first 4 weeks after surgery, then full load.~By default, postoperative X-ray and RSA recordings will be performed on the 1st or 2nd postoperative day. The surgery will be performed by specialist physicians in orthopedic surgery associated with the hip arthroplasty sector."
45992241|NCT02943044|Device|No intervention, this is an observational study|Non interventional, non-invasive measurements of tissue samples suspected of squamous cell carcinoma using an optical probe.
45992242|NCT02921217|Dietary Supplement|Active Probiotic|Product 1: 200 mg maltodextrin and 100 mg of active Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) (1011 CFU/g),
45674296|NCT02252081|Drug|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR > 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =< 45 ml/min
45992243|NCT02921217|Dietary Supplement|Inactivated probiotic|Product 1: 200 mg maltodextrin and 100 mg of Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) inactivated by heat (1011 CFU/g),
45992244|NCT02921217|Dietary Supplement|Control|Placebo: 300 mg maltodextrin.
45992245|NCT02943122|Device|Ambulatory blood pressure monitor|
45992246|NCT00531986|Drug|Lopinavir-Monotherapy|Patients on triple HAART will be switched to LPV/r-monotherapy
45992247|NCT00531986|Drug|HAART|Patients will continued their current HAART
45992248|NCT03792282|Behavioral|Time Restricted Feeding|Participants will receive a diet of 1200-1500kcal/d and be instructed to eat only during a window of 8 hours (Finishing the last meal before 4pm).
45992249|NCT03792282|Behavioral|Usual care|Participants receive a general lifestyle counseling.
45992250|NCT00531869|Behavioral|biases towards products|
45674297|NCT02252081|Drug|Placebo|placebo pill(s) orally per day for 16 weeks
45674298|NCT01623752|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
45674299|NCT01623752|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
45674300|NCT01623596|Drug|Fingolimod|
45674301|NCT01623596|Drug|Disease Modifying therapy|
45674302|NCT02219477|Drug|ombitasvir/paritaprevir/ritonavir|tablet; paritaprevir co-formulated with ritonavir and ombitasvir
45674303|NCT02219477|Drug|dasabuvir|tablet
45674304|NCT02219477|Drug|ribavirin|tablet
45674305|NCT02119286|Drug|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
45992251|NCT02917434|Dietary Supplement|Very Low Energy Diet (VLED)|Very Low Energy Diet (VLED), divided into 4 daily doses, gives any intake of 640 calories per day together with the recommended doses of vitamins and minerals. During an initial period of 12 weeks the patients only consume VLED. After the strict period food is successively reintroduced during a period of 18 weeks.
45992252|NCT05319899|Drug|ALXN1840|ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
45992253|NCT05319899|Drug|Omeprazole|Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
45992254|NCT02920827|Combination Product|Dapivirine Vaginal Ring|A platinum-catalysed silicone elastomer matrix vaginal ring containing 25mg of dapivirine used over 28 days
45992255|NCT02920827|Combination Product|Placebo vaginal ring|Placebo vaginal ring containing no dapivirine
45992256|NCT05319743|Other|Medicaid Expansion|Expansion of Medicaid, 01/01/2014
45674306|NCT02119286|Drug|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
45992257|NCT02921100|Procedure|cytology|The conventional cytology was interpreted independently by two cytopathologists, both of whom are blinded to the DIA results. The conventional cytologic diagnosis were classified as no abnormal cells, atypical cells, suspicious malignant cells and malignant cells.
46084308|NCT02774720|Behavioral|Home-based exercise|Participants will be prescribed aerobic and resistance exercise to be performed independently (either at home or in the community). They will receive monthly phone calls to discuss achievements and barriers and to tje adjust exercise prescription.
45992258|NCT02921100|Procedure|DNA ploidy|DIA is a form of cytologic analysis that quantifies cellular constituents by using spectro photometric principles and a sister technique to flow cytometry.Quantification of DNA content, chromatin distribution, and nuclear morphology can be determined and suggest features of malignancy
45992259|NCT02921100|Procedure|EUS-FNA|All the enrolled participants underwent an operation of EUS-guided fine needle aspiration. Histological and cytological samples were obtained following this step.
45992260|NCT02921100|Device|EUS-guided fine needle|
45992261|NCT02943005|Procedure|Rotator cuff repair|
45992262|NCT02943161|Dietary Supplement|L-Citrulline|The purpose of this study is to see if citrulline supplementation will restore NO levels and lung function in subjects with asthma.
45992263|NCT02921139|Radiation|Stereotactic ablative radiotherapy (SABR)|Patients with HCC after incomplete TACE are randomized to stereotactic ablative radiotherapy (SABR). SABR will be delivered in 5 fractions.The preferred inter-fraction time interval is 48 hours. The entire treatment with 10 days is preferred.
45992264|NCT02921139|Procedure|Re-Transcatheter arterial chemoembolization (re-TACE)|Patients with HCC after incomplete TACE are randomized to further re-TACE.
45674307|NCT02119286|Drug|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
45674308|NCT02119286|Drug|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
45674309|NCT02250443|Drug|BYM338 (Bimagrumab)|
45674310|NCT02093390|Drug|TAK-385|TAK-385 tablets
45674311|NCT02093390|Drug|Fluconazole|Fluconazole tablets
45674312|NCT02093390|Drug|Atorvastatin|Atorvastatin tablets
45992265|NCT05319704|Other|Test of effort on cycle on concentric or excentric mode|participants may receive 4 interventions sequentially during the protocol
45992266|NCT05319704|Other|Kinetics on concentric or excentric mode during test of effort|participants may receive 4 interventions sequentially during the protocol
45992267|NCT05318456|Dietary Supplement|MoodElite T-4003-1|Participants will be instructed to take two capsules of MoodElite T-4003-1 once daily with water, after dinner without food for 42 days.
45992268|NCT05318456|Dietary Supplement|Comparator|Participants will be instructed to take two capsules of comparator once daily with water, after dinner without food for 42 days.
45992269|NCT05318456|Other|Placebo|Participants will be instructed to take two capsules of placebo once daily with water, after dinner without food for 42 days.
45992270|NCT05319665|Device|Head-mounted display|The intervention is a visual and auditory contact via a head-mounted display (HMD) worn by the mother airing a live video of her newborn filmed by a 2D 360° camera during and after a caesarean section. The HMD will be worn by the new mother from the moment that her newborn is moved to an adjacent room to receive the initial care until the moment when they can be reunited again. The camera will be placed in the adjacent room where the newborn, the mother's partner and a midwife will be. The camera will film the newborn and transmit the live images and the sound to the HMD worn by the mother. The mother will be able to see and hear what happens in the next room and change her angle of view by moving her head from one side to another.
45992271|NCT02920905|Drug|Lidocaine|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
46084309|NCT02771834|Other|Biomechanical analysis|
46084310|NCT02771834|Other|Kiphosis analysis|
46084311|NCT02771834|Other|Vitamin D level|
46084312|NCT02774564|Drug|BIA 3-202|Nebicapone tablets 50 mg, oral administration
46084313|NCT02774564|Drug|Placebo|Nebicapone matching placebo tablets
45992272|NCT02920905|Drug|atracurium|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
45992273|NCT02920905|Drug|Mg sulphate|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse . The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
45992274|NCT05319470|Diagnostic Test|Intraocular pressure (IOP)|Measurement of intraocular pressure in both eyes of the study population using the Goldman applanation tonometer.
45992275|NCT05319470|Diagnostic Test|Tear Break-up Time (TBUT)|TBUT will be calculated after instillation of a drop of fluorescein dye, by slit lamp biomicroscopy.
45992276|NCT05319470|Diagnostic Test|Conjuctival Hyperemia|Conjunctival hyperemia will be assessed by slit lamp biomicroscopy using a validated grading system.
45992277|NCT05319470|Diagnostic Test|Schirmer Test|Schirmer test will be performed on both eyes to asses tear production.
45674313|NCT02194985|Drug|migalastat HCl 150 mg|Migalastat HCl 150 mg (equivalent to 123 mg migalastat) was provided as capsules in blister packs. One capsule was taken orally every other day.
45674314|NCT02219087|Drug|Liposomal bupivacaine|
45674315|NCT02219087|Drug|Standard of Care|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
45674316|NCT02248961|Drug|Fimasartan|"Starting dose of Kanarb (Fimasartan) is 60 mg, orally, once a day in the morning. The subjects will visit the clinical site every 4 weeks to measure Arterial blood pressure (ABP). The dose will be doubled in case if SBP ≥140 mmHg or DBP ≥90 mmHg at Visit 3 (Day 28) or at Visit 4 (Day 56).~If necessary, the dose of the study drug may be increased based on the assessment of patient's condition performed at the phone contact (Day14±3). Patient may be called for an unscheduled visit for treatment adjustment (decided individually, with possibility of dose titration as per investigator's judgment, indicated in source documents).~When possibilities are, the patient should be administrated by the study medication at the same time in the morning."
45674317|NCT02248961|Drug|Losartan|Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, tablets 50/100 mg
45992278|NCT05319470|Diagnostic Test|Visual Fields and OCT RNFL|Visual field examination using a Humphrey perimeter and measurement of peripapillary retinal nerve fiber layer thickness with optical coherence tomography.
45992279|NCT02920944|Device|EUS-FNB with 20 gauge ProCore needle|EUS-FNB with 20-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
45992280|NCT02920944|Device|EUS-FNB with 22 gauge ProCore needle|EUS-FNB with 22-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
45992281|NCT02917395|Device|echocardiography|Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.
45992282|NCT05319392|Diagnostic Test|Observational study|Exploration of transcriptomic signatures related to tumor microenvironment having a significant role in prognosis of gastric adenocarcinoma patients
45992283|NCT02917200|Drug|Moxifloxacin|Oral route
45992284|NCT02917200|Device|DAV132|Oral route
45674318|NCT02219009|Device|MIND1 System|Subjects will receive aripiprazole tablets embedded with an IEM. They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole + IEM tablets (eg, at the previously prescribed dose) during the 8-week treatment period for this study. Aripiprazole + IEM tablets must be taken on a once-daily dosing schedule.
45674319|NCT02248649|Behavioral|Structured physical activity|Walking instruction and encouragement
45674320|NCT02248649|Behavioral|Health education|Provision of general information about a variety of health topics
45674321|NCT02218541|Device|abutment margin 0.5 mm subgingival|
45674322|NCT02218541|Device|abutment margin 1.5 mm subgingival|
45674323|NCT02217527|Drug|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.
45992285|NCT02917200|Other|Negative control|Oral route
45992286|NCT05318144|Other||
45992287|NCT05319275|Drug|Acetyllevocarnitine Hydrochloride Tablets|500 mg (2×250 mg/tablet) after meal, 3 times per day
45992288|NCT05319275|Drug|Placebo|500 mg (2×250 mg/tablet) after meal, 3 times per day
45992289|NCT02920515|Drug|Triptorlin or Leuprorelin|Gonadotrophin releasing hormone agonists (GnRHa)
45992290|NCT02920515|Drug|Zhibo dihuang pills|Traditional Chinese Medicine
45992291|NCT02920515|Drug|Dabu ying pills|Traditional Chinese Medicine
45992292|NCT02942069|Behavioral|Blood glucose measured using CGM during standardized physical activity|Standardized exercise on bicycle at 70% of the participants work capacity for ½ hour.
46084314|NCT02774564|Drug|Sinemet®|Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg) tablets
46084315|NCT02777294|Behavioral|Online intervention|Therapist-facilitated, multimedia, cognitive-behavioral online intervention targeting rape-related PTSD
45992293|NCT02917356|Other|Spiritual laying on of hands (SP)|"The SP will be applied after physical therapy (kinesiotherapy). Spiritual healers from Spiritism will perform the SP. In order to produce a culturally acceptable environment, the Spiritist therapists will 'prepare' the environment by praying for 5 minutes. The Spiritist therapists will hold both hands 10-15 cm above the patients' head. Then, they will longitudinally lower their hands starting from the patients' head towards their legs, for four times. Subsequently, the therapists shall lay their hands on patients' head and on their knees. The therapists will remain silent during these procedures and try to 'heal' the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
45992294|NCT02917356|Other|Non-spiritual Laying on of Hands|"The non-spiritual laying on of hands will be applied after physical therapy (kinesiotherapy), for 5 minutes, without touching the patients and without 'preparing' the environment. They will hold their hands 10-15 cm above patient's head and will focus on healing the patients. They will visualize the following sentence: I want you to heal; without saying prayers or invocations. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
45992295|NCT02917356|Other|Control group|"The patients will be subjected to physical therapy (kinesiotherapy), only. However, they will be accompanied by people who will stay in the room and move slowly and randomly in order to sham the presence of someone performing the laying on of hands. However, they will not perform the laying on of hands. These people will not focus on healing the patients and they will be asked to mentally count 5 minutes while they are with the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
45992296|NCT02920554|Procedure|wedge resection|The extent of hepatic resection is wedge resection of liver including gallbladder fossa
45992297|NCT02920554|Procedure|bisegmentectomy|The extent of hepatic resection is 4b/5 bisegmentectomy of liver
45992298|NCT02942849|Drug|r-hFSH|As per standard clinical practice
45992299|NCT02917005|Drug|Palbociclib|CDK 4/6 inhibitor
45992300|NCT02917005|Drug|Exemestane|Aromatase inhibitor
45674324|NCT02217527|Drug|Placebo pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.
45992301|NCT02917005|Drug|Goserelin|LHRH agonist
45992302|NCT02920632|Behavioral|Online cognitive training 1|Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.
45992303|NCT02920632|Behavioral|Online cognitive training 2|Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
45992304|NCT02942810|Drug|WCK 5222|IV infusion over a period of 60 minutes
45674325|NCT01456936|Drug|Placebo|Triple dummy placebo for each treatment arm
45674326|NCT01456936|Drug|varenicline tartrate|Subjects will be titrated to the full dose during the first week in the following manner: 0.5 mg (tablet form) once a day for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 11 weeks
45992305|NCT02920710|Drug|Repository Corticotropin Injection|"Initial treatment with 80 units daily for ten days (induction phase)~Maintenance treatment with 80 units twice weekly (maintenance phase)"
45992306|NCT02941913|Drug|palonosetron|receive a fix dose of 75 μg of palonosetron (group I - GI) and another forty patients will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron (group II - GII).
45674327|NCT01456936|Drug|bupropion hydrochloride|Subjects will receive 150 mg (tablet form) once a day for 3 days and then will take 150 mg twice a day for the remainder of the treatment period (11 weeks and 4 days).
45674328|NCT01456936|Drug|Nicotine Replacement Therapy Patch|Subjects will start active dosing the morning of the Week 1 visit and will receive a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment.
46084316|NCT02777294|Behavioral|Psycho-educational website|Psycho-educational self-help website about rape-related PTSD
45674329|NCT01456780|Drug|Loteprednol/tobramycin|Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.
45674330|NCT01456780|Drug|Loteprednol|Eye drops, 1 drop twice a day for 4 weeks
46084317|NCT00613470|Drug|citalopram and escitalopram|"escitalopram tablets starting at 10 mg, increase to 20 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 < 5.~citalopram tablet or solution starting at 2o mg, increase to 40 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 < 5."
46084318|NCT02771912|Drug|Propofol|Propofol and excipients
46084319|NCT02771912|Drug|Placebo|Qualitative composition of Propofol lipuro 2% excipients
46084320|NCT00741819|Drug|Inhaled treprostinil|
46084321|NCT04482270|Drug|fezolinetant|Oral
45674331|NCT01456780|Drug|B+L Advanced Eye Relief Lubricant Drop|Bausch + Lomb (B+L) Advanced Eye Relief Lubricant Drop (Artificial Tears), 1 drop twice a day for 4 weeks.
45674332|NCT01480258|Biological|PR5I|DTaP-HB-IPV-Hib (Diphtheria, tetanus, pertussis [acellular, component], hepatitis B [recombinant DNA], polio virus [inactivated], and Haemophilus influenza type b conjugate vaccine [adsorbed]) Vaccine 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. PR5I is a liquid suspension hexavalent vaccine.
45674333|NCT01480258|Biological|Rotavirus vaccine|Rotarix™ 1.5 mL oral dose at 2 and 4 months of age (subset 1, Italy and Sweden) or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age (subset 2, Finland)
45674334|NCT01480258|Biological|Prevenar 13™|Prevenar 13™ 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine.
45674335|NCT01480258|Biological|INFANRIX™ hexa|Combined Diphtheria-Tetanus-acellular Pertussis [DTaP], Hepatitis B [HepB], Poliovirus [IPV] and Haemophilus influenzae type b [Hib] Vaccine 0.5 mL intramuscular injection at 2, 4 and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. INFANRIX™ hexa is provided as 2 components (lyophilized Hib and liquid DTaP, IPV, and HepB). Prior to administration, the vaccine must be reconstituted by adding the liquid DTaP-HepB-IPV component to the vial containing the Hib pellet.
45674336|NCT01479868|Drug|TMC435|TMC435 150 mg will be administered once daily for 12 weeks along with peginterferon alpha-2a and ribavirin.
45992307|NCT05319002|Behavioral|Group EMDR|The eight phases of the adapted group EMDR protocol was administered during each session: 1. Meeting: Explaining the nature of trauma, group rules, name tags, filling in the scales. 2. Preparation: Exploring children's support system, explaining EMDR, safe place, resource exercise, and installation with bilateral stimulation (BLS, butterfly hug or knee tapping). 3. Assessment: Drawing the worst image on a small separate sheet of paper, SUD level, (negative cognition, emotions, body sensations - if possible). 4. Desensitization: It is done with drawing on 4 separate papers with BLS (butterfly hug or knee tapping). 5. Installation: With the healing story written according to the adaptive information processing (AIP) model, the installation is accompanied BLS. 6. Body scan: A positive body state is installed with the relaxation technique. 7. Closure & future template: Strong closure with artwork. 8. Re-evaluation: if possible.
45992308|NCT02917161|Device|Prostatic Artery Embolization (PAE)|PAE is performed 6 weeks before radical prostatectomy
45992309|NCT02941952|Device|Cardiac output and stroke ejection volume monitoring with both ClearSight® and PICCO® in major abdominal surgery.|
45992310|NCT02917044|Procedure|Atrial Fibrillation Ablation|Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by assessing electrograms circumferentially around the PV using the Orion catheter.
45992311|NCT02917044|Device|Catheters used to isolate pulmonary veins|Catheters transiently inserted into body via femoral veins in order to produce pulmonary vein isolation. These catheters are the same in each arm and comprise the Orion catheter (Boston Scientific) and the Tacticath (St Jude) which are used to produce pulmonary vein isolation and which are approved for use in standard EP procedures by the relevant authorities (CE marked). It is merely the protocol by which they are used that iffers in the two arms.
45992312|NCT02917044|Procedure|Atrial Fibrillation Ablation with HD mapping to isolate PVs|Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by use of electroanatomical mapping with the Orion catheter around the sites ablation in order to target points of breakthrough.
45992313|NCT02917044|Device|Rhythmia HD mapping|Mapping activation patterns using the Rhythmia system in conjunction with the Orion catheter
45992314|NCT02942693|Drug|Apatinib|Apatinib will be used as induction therapy in experimental arm.
45992315|NCT02942693|Radiation|Particle Therapy|Same total dose and fractionation will be used in both arms.
46084322|NCT02774408|Device|Saturation sensitive backup ventilation|
46084323|NCT04088721|Biological|AD17002|LTh(αK) as immunomodulator
46084324|NCT04088721|Other|Formulation Buffer|Formulation buffer
45992316|NCT02916888|Other|Care provided by general pediatrician|Standard of care management of atopic dermatitis by a general pediatrician.
45992317|NCT02916888|Other|Care provided by pediatric dermatologist|Standard of care management of atopic dermatitis by a pediatric dermatologist.
45992318|NCT02941874|Other|Blood sample collection during an OGTT to assess IRAP blood concentration|Blood sample collection during an OGTT to assess IRAP blood concentration. Blood samples will be collected every 15 minutes during 3 hours
45992319|NCT02941835|Radiation|pre-operative irradiation|pre-operative whole breast irradiation of 21 fx of 2.2Gy and boost of 2.66Gy
45674337|NCT01479868|Drug|Pegylated interferon alpha-2a|Pegylated interferon alpha-2a 180 microgram will be administered as subcutaneous injection of 0.5 mL until 24 to 48 weeks.
45992320|NCT02920593|Drug|Vitamin D3|Vitamin D prophylaxis
45992321|NCT02942732|Dietary Supplement|cholecalciferol (Euro-Pharm International, Canada)|All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
46084325|NCT04175756|Device|Caiman 5 articulating Maryland|Laparoscopic colorectal surgery
46084326|NCT04457466|Drug|Nerve Growth Factor|Induction of experimental muscle soreness using intramuscular injections of Nerve Growth Factor.
46084327|NCT00917709|Other|Imaging with IBVM|in vivo molecular imaging of presynaptic molecular target of cholinergic systems with [123I]-iodobenzovesamicol
46084328|NCT00917709|Other|Imaging with DATSCAN|in vivo molecular imaging of presynaptic molecular target of dopaminergic systems (DAT) with DATSCAN
46084329|NCT00917709|Behavioral|neuropsychological evaluation|neuropsychological evaluation using neuropsychological tests
46084330|NCT02774330|Other|Policy|This local policy change (i.e., the Minneapolis Staple Foods Ordinance) establishes minimum stocking criteria for a wide array of healthy foods as a requirement of food store licensing. To our knowledge, it is the first and only policy of its kind in the U.S. This Staple Foods Ordinance requires stores to stock specific types of foods in minimum quantities and varieties, including fruits and vegetables, low-fat dairy, and whole grains. A full list of all requirements can be found online through the City of Minneapolis: http://www.minneapolismn.gov/health/living/eating/staple-foods.
46084331|NCT05197335|Device|Chimaera short nail (length = 180 mm) in combination with one or two telescopic cephalic screws|The enrolled patients will proceed by undergoing the surgery necessary for the application of the medical device under observation (Chimaera), which coincides with the start of the treatment period.
46084332|NCT04225208|Drug|[14C]-AZD4205, single 50 mg oral dose administrated on day 1|Each subject will receive 50 mg AZD4205 oral solution (free base equivalent) containing a nominal dose of 15 µCi [14C]- radiolabelled AZD4205 as a single administration .
45674338|NCT01479868|Drug|Ribavirin|Ribavirin 1000 or 1200 mg twice daily will be administered each day until 24 to 48 weeks.
46084333|NCT02771444|Device|Tomo Assessment|A four-view tomosynthesis examination
46084334|NCT02678013|Procedure|RFA|Radiofrequency ablation(RFA)for small recurrent HCC
46084335|NCT02678013|Procedure|RFA+highly-purified CTL|Radiofrequency ablation(RFA) plus highly-purified CTL for small recurrent HCC
46084336|NCT02774486|Device|IQP-AK-102|IQP-AK-102 has been qualified as a medical device (CE certificate has been ob- tained), class IIb, according to MDD 93/42/EEC, annex IX, rule 5.
46084337|NCT02678169|Device|Penumbra Aspiration System|Penumbra Aspiration System using the ADAPT technique for recanalization of an occlusion large vessel in the brain
46084338|NCT04790318|Procedure|Trans-incisional Quadratus lumborum block|patients will receive combined general anesthesia and quadratus lumborum block (trans-incisional) with 0.5 mL/kg of bupivacaine 0.2 %. with maximum volume was limited to 20 ml
46084339|NCT04790318|Procedure|Caudal block|patients will receive combined general anesthesia and caudal analgesia (just after wound closure) with 1.25 mL/kg of bupivacaine 0.2 % (three parts 0.25 % bupivacaine to one part saline.
45992322|NCT02942459|Other|Music therapy|25 Weekly Hours of Music Therapy by an Educated Music Therapist
45992323|NCT02942459|Other|Music Listening|25 weekly Hours of Being Together with an unknown Care Staff Member
45992324|NCT02920437|Behavioral|Four-week weekly intervention to reduce salt intake|The intervention group will receive a four-week weekly intervention, about 15 minutes each. Two sessions will be face-to-face and two sessions will be on the phone. The participants will be informed of their 24-hour urinary sodium excretion at each measurement time once available.
45992325|NCT02920437|Other|Usual government pamphlets|The control group will receive usual government pamphlets when they know their 24-hour urinary sodium excretion at baseline. However, they will not be informed of their follow-up urinary sodium excretion results immediately.
45992326|NCT02942420|Drug|Bucillamine|Thiol donor which results in a cysteine-bucillamine complex for removing excess cysteine from the urine
45992327|NCT02920359|Drug|LEUPRORELIN ACETATE|
45992328|NCT02916849|Other|Safe Step|Strength and balance exercise-digital version
45992329|NCT02916849|Other|OEP|Strength and balance exercise -paper version
45992330|NCT02941796|Drug|HCP1105|
45992331|NCT02941796|Drug|HCP0918|
46084340|NCT02677935|Other|Community education programs|
46084341|NCT02677857|Behavioral|Common intervention components for Lifestyle|Participants in these conditions will receive standard care and one of the Lifestyle conditions. There are several components that will be identical for both Lifestyle conditions. These components include treatment structure, dietary goals, and cognitive behavioral strategies.
46084342|NCT04954742|Drug|Riociguat|Treatment will be initiated and individually adjusted according to systolic blood pressure and tolerability. During the titration phase, each patient will be asked to measure their peripheral systolic blood pressure and the heart rate at home three times per day and document the values in the patient diary. The results will be examined by the investigator during each visit/phone call-visit. Provided that the systolic blood pressure is ≥ 95 mmHg measured at trough before intake of each dose and the patient has no signs or symptoms of hypotension, the dose of study medication will be titrated by +0.5 mg tid every 2 weeks until maximal tolerated dosage (maximal permitted dose: of 2.5 mg tid). After the titration period, blood pressure should be measured upon signs or symptoms of hypotension. Maintenance dose: The established individual dose should be maintained unless signs and symptoms of hypotension occur.
46084343|NCT05662995|Diagnostic Test|Lung ultrasound|Lung ultrasound will be performed with the patient in supine position (with or without left uterine displacement, depending on clinical circumstances). A phased-array transducer will be used for lung ultrasound and will be used for the assessment of B-lines, which arise from the pleural line and extend to the bottom of the screen and move with the sliding lung
46084344|NCT04193696|Drug|Radiation therapy and systemic anti-PD-1 immunotherapy for patients with advanced hepatocellular carcinoma|The treatment will be started within 1 week after being admitted into the trial. IMRT or SBRT are adopted , and dose of radiation: Dt-PGTV=40Gy/10fractions,Dt-PGTV=30Gy/10fractions,Dt-PGTV=20Gy/10fractions ,and so on.200mg/ of Carelizumab for injection will be given intravenously every 3 weeks for 5 times since the first day of radiotherapy until disease progression, or intolerable toxicity.
46084345|NCT00642447|Drug|helium:oxygen mixture|
45674339|NCT01478620|Drug|Canephron® N|3x 2 coated tablets/day for 7 days p.o.
45674340|NCT01455220|Drug|Tysabri ® (Natalizumab)|IV, monthly
45992332|NCT02941796|Drug|HCP0816|
45992333|NCT05318963|Biological|LCAR-AIO cells product|before treatment with LCAR-AIO cells, subjects will receive a conditioning regimen (IV infusion of cyclophosphamide 300 mg/m^2 and fludarabine 30mg/m^2 once daily (QD) for 3 days.
45992334|NCT02916654|Dietary Supplement|sucrosomial iron|administration of sucrosomial iron
45992335|NCT02916654|Drug|Sulphate iron|administration of sulphate iron
45992336|NCT02916576|Device|Blood-Glucose Monitoring Systems for self-testing|"This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices."
45992337|NCT02941562|Radiation|Short-course radiotherapy|Preoperative Radiation doses: 25 Gy in 5 fractions to the pelvis
45992338|NCT02941562|Drug|FOLFOX4 chemotherapy,preoperative|"FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks"
45992339|NCT02941562|Radiation|Radiotherapy of neo-adjuvant therapy|Preoperative Radiation doses: 45 Gy in 25 fractions to the pelvis, 5.4 Gy in 3 fractions to the pelvis
45992340|NCT02941562|Drug|Concurrent chemotherapy of neo-adjuvant therapy|Capecitabine 825mg/m2 twice daily 5 days/week
45992341|NCT02941562|Procedure|Radical rectal cancer resection|Radical rectal cancer resection
46084346|NCT04181541|Procedure|Provider type: Physicians|In this cohort, women will receive second trimester medical abortion care from physicians
45992342|NCT02941562|Drug|FOLFOX4 chemotherapy,post-operative|"FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks"
45992343|NCT02942888|Dietary Supplement|Nicotinamide riboside|Oral administration of Niagen ramp up 250mg to 1g/day as tolerated
45992344|NCT02942888|Dietary Supplement|Sugar Pill|This is a placebo compounded by ChromaDex, Inc.
45992345|NCT02916420|Drug|Pomalidomide|4mg/day, d1-d21, 28 days per cycle
45992346|NCT02916420|Drug|Dexamethasone|≤70 years,40mg/day; >70 years,20mg/day, d1、d8、d15、d22, 28 days per cycle
45992347|NCT05318924|Drug|Ghrelin|Participants will receive an infusion that is intended to raise ghrelin level up to a steady plateau.
45992348|NCT05318924|Other|Placebo|Participants will receive a saline infusion as the placebo control condition.
45992349|NCT02920398|Drug|turoctocog alfa pegol|Administered as intravenous injections at a dose of 50 U/kg. Patients will receive each product in a randomised cross-over design for comparison of the pharmacokinetics between turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process.
45992350|NCT05318885|Other|A Randomized Controlled Study|For forward-leaning position, the child is first placed on a suitable chair with a soft pillow on their knees. The child will remain in the same position for the duration of the nebulization, and the pillow provides support, ensuring the child does not get tired. The child leans forward at an angle of 45°, places their arms on the pillow as shown in the figure and holds their head upright with their eyes facing forward (slight hyperextension). The upright head position of the child prevents spillage of the liquid medicine from the nebulizer chamber.
45992351|NCT02916342|Procedure|Interscalene brachial plexus block|Patients will receive an ultrasound-guided interscalene brachial plexus block before general anaesthesia.
45992352|NCT02916342|Procedure|Supraclavicular-axillary nerve blocks|Patients will receive ultrasound-guided supraclavicular and axillary nerve blocks before general anaesthesia.
45992353|NCT05318846|Drug|HRS4800 tablets|Dosing frequency: single dose; Route of administration: oral
45992354|NCT05318846|Drug|Placebo tablets|Dosing frequency: single dose; Route of administration: oral
45992355|NCT02920203|Genetic|Heart and spleen tissue|genetic sequencing
45992356|NCT02942381|Drug|Hydroxychloroquine Sulfate|200mg Bid (eGFR>60 ml/min/1.73m2 ), 100mg Tid(eGFR45-59 ml/min/1.73m2 ), 100mg Bid(eGFR 30-44 ml/min/1.73m2 )
45992357|NCT02942381|Drug|Placebo|
45992358|NCT02920281|Other|Polysomnography|
45992359|NCT02941718|Behavioral|Sleep Advancement Counseling|Participants will receive cognitive behavioral counseling on achieving adequate sleep duration.
45992360|NCT02941718|Behavioral|General Health Information|Participants will receive educational information on general health topics including diet, physical activity, skin protection, oral health and cancer screenings.
45992361|NCT02920320|Other|Internet-based self-help program|
45992362|NCT03458468|Drug|Tranexamic Acid|1g Tranexamic acid prior to skin incision
45992363|NCT03458468|Drug|Saline|Equivalent volume of saline prior to skin incision
45992364|NCT02919891|Other|Questionnaire|Questionnaires
45992365|NCT02941679|Drug|HCP1202|Hanmi Pharmaceutical. Co., Ltd.
45992366|NCT02941679|Drug|HGP1011|Boehringer Ingelheim
45992367|NCT02941679|Drug|HCP0910|GlaxoSmithKline
45992368|NCT02919930|Device|Switch from oronasal to nasal mask during ASV treatment|One night of ASV treatment with oronasal mask followed by one night of ASV treatment with nasal mask.
45992369|NCT02919930|Device|Switch from nasal to oronasal mask during ASV treatment|One night of ASV treatment with nasal mask followed by one night of ASV treatment with oronasal mask.
45992370|NCT02942537|Device|Microwave treatment|Percutaneous or vaginal application of microwave antenna with microwave treatment of fibroma
45992371|NCT02942537|Procedure|uterine artery embolization|Percutaneous applicaiton of a catheter into the femoral artery and embolization of uterine artery or branches thereof
45992372|NCT02916537|Drug|CTT1057|Single IV dose (370 MBq, or 10 mCi) of CTT1057 followed by combined PET/MR imaging (prostate + whole body).
45992373|NCT02916537|Procedure|Prostatectomy|Radical prostatectomy with lymph node dissection
45992374|NCT02916615|Other|High nitrate vegetables|vegetables naturally high in nitrate
45992375|NCT02916615|Dietary Supplement|Low nitrate vegetables + nitrate|pill containing KNO3
45992376|NCT02916615|Other|Low nitrate vegetables|vegetables naturally low in nitrate
45992377|NCT02942342|Procedure|Computed Tomography (CT) Scan|CT Scans will be used as a diagnostic tool for asymptomatic CAD.
45992378|NCT02916459|Device|21G EBUS-TBNA needle|
45992379|NCT02916459|Device|Flexible 19G EBUS-TBNA needle|
45992380|NCT02942303|Drug|Dysport|
45992381|NCT02942303|Procedure|lateral orbicularis injection|
45992382|NCT02942303|Procedure|Lateral orbicularis + corrugator injection|
45992383|NCT02920086|Behavioral|Nutrition Education Program|"The OPTimal nutrition by Informing and Capacitating family members of best practices (OPTICS) intervention~Nutritional education will be provided to ICU patents' families by a dietitian~Tracking of nutritional information by family~Encouragement for families to advocate for two or more Oral Nutritional Supplements per day for the patients (approximately 400 kcal/day)"
45992384|NCT02920086|Other|Decision Support Program|"Families will be provided with a web-based decision support tool (My ICU Guide)~Families will meet with the ICU medical team early in ICU stay to review goals of care"
45992385|NCT02942147|Device|TENS|Group 2 patients were administered TENS therapy 30 minutes a day for 15 days at the outpatient physiotherapy unit of the Physiotherapy and Rehabilitation Department. The TENS therapy was applied in the form of conventional TENS subtype with 80-100 Hz frequency by placing four electrodes on the region where the pain was most intense.
45992386|NCT02942147|Procedure|Conventional or Pulse Radiofrequency|In the radiofrequency method applied to Group 1 and Group 3 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position. During this marking, the fluoroscope was directed towards cephal or caudal so that at whatever level the median ramus block was to be involved the endplate of that vertebra would become a straight line. The connection point of the superior articular protrusion was marked on the fluoroscope using the transverse process and the intervention was applied with a 22G, 10-cm radiofrequency cannula with 0.5 cm active tip in a way that bone contact was established through the tunneled vision technique. The intervention was completed after the radiofrequency procedure was applied at four levels.
45992387|NCT02916381|Procedure|PEC block + General anaesthesia|Patients will receive an ultrasound-guided PEC block after the induction of general anaesthesia.
45992388|NCT02916381|Procedure|General anaesthesia|
45992389|NCT02920047|Drug|Fimasartan/Amlodipine|Treatment B
45992390|NCT02920047|Drug|Fimasartan + Amlodipine|Treatment A
45992391|NCT02920125|Drug|SUVED|Ayurvedic formulation in ghana (concentrated) in capsules; 500 mg each
45992392|NCT02920125|Combination Product|REIMMUGEN|Whole Cow colostrum in powder put in capsules; 300mg each
45992393|NCT02920125|Other|Grain flour placebo|Grain flour in capsules. Jowari flour in dummy Reimmugen and Ragi flour in dummy Suved placebos
45992394|NCT02942030|Other|Computerized assesment battery|All participants will do a computerized assessment battery to identify specific attentional profile
45992395|NCT02916264|Procedure|a scalp block|Bilateral blocks of six nerves: ie. supraorbital and supraorbital nerves (V1), zygomaticotemporal nerves (V2) , auriculotemporal nerves , greater occipital nerves, and lesser occipital nerves will be performed by a well trained anesthesiologist with 0.5% bupivacaine not exceeding 3 mg/kg
45992396|NCT02941991|Biological|hESC-RPE|sub-retinal injection
45992397|NCT02915952|Device|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure Device will be used for surgical wound closure in C-Section Surgery
45992398|NCT02915952|Other|Conventional Sutures|Conventional Sutures will be used for surgical wound closure in C-Section Surgery
45992399|NCT05318495|Device|Standard Colonoscopy|The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).
45992400|NCT05318495|Device|CAD-EYE|CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.
45992401|NCT05318495|Device|G-EYE|The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning.
45992402|NCT02920164|Device|Auricular acupuncture|Auricular acupuncture with indwelling permanent needles
45992403|NCT02920164|Device|Placebo acupuncture|Placebo acupuncture with placebo needles
45992404|NCT02940938|Other|Applying pulse oximeter sensor|During general anesthesia, pulse oximeter sensor is applied with gradually increased contact force, from 0 to 1.5N (increase by about 0.2N), at an index finger and POP waveform is obtained for 60 seconds.
45992405|NCT02941055|Other|Fiber diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
45992406|NCT02941055|Other|Protein diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
45992407|NCT02919852|Procedure|laparoscopic retrovesical colpopectinopexia|Laparoscopic correction of pelvic organ prolapse using a mesh in retrovesical space with pectineal ligament fixation.
45992408|NCT02941094|Device|needle PLT-805AT|comparing success rate and complications using different needle to US probe angles.
45992409|NCT02941094|Device|Ultrasound|Xario, Toshiba Tokyo Japan
45992410|NCT02916030|Dietary Supplement|Vit D|It is to examine the relationship between serum 25 (OH) D levels and Stroke either ischemic or hemorrhagic types
45992411|NCT02941133|Other|Neural Mobilization|Neural mobilization techniques aimed at the lumbar root that is affected
45992412|NCT02941133|Other|Standard Care|Ultrasound - Transcutaneous electrical nerve stimulation (TENS) - Massage therapy - Strengthening exercises
45992413|NCT02916069|Device|Nearinfrared Spectroscopy (NIRS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
46084347|NCT04181541|Procedure|Provider type: Midlevel Providers|In this cohort, women will receive second trimester medical abortion care from midlevel providers.
45992414|NCT02916069|Device|Transcranial Doppler (TCD)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
45992415|NCT02916069|Device|Bispectral index (BIS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
46084348|NCT04941638|Procedure|Distal radial access|Vascular access for primary PCI in patients with STEMI
46084349|NCT04181697|Device|PA measurement with Fitbit Charge 3|Measurement of PA with Fitbit for all participants and controls.
46084350|NCT04181697|Device|PA measurement with Fitbit and ActiGraph GT3X|Measurement of PA with ActiGraph for a subgroup of 20 participants.
46084351|NCT02774252|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation number - Y49-103)
45456956|NCT02298166|Drug|Placebo|"Induction therapy:~Placebo to be given as p.o. TID starting d 7+, given continuously thereafter until 48 hours prior to the next chemotherapy.~Consolidation therapy:~Placebo will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy with placebo is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.~Maintenance with placebo will be given at the same dose tolerated during induction therapy."
45456957|NCT02298166|Drug|Crenolanib|"Induction therapy:~Crenolanib to be given as p.o. TID starting d 7+, given continuously until 48 hours prior to the next chemotherapy.~Consolidation therapy:~Crenolanib will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy with Crenolanib is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.~Maintenance with Crenolanib will be given at the same dose tolerated during induction therapy."
45674341|NCT01454830|Behavioral|Tailored|Individualized on critical indicator (Self-efficacy measure in Sleep Apnea) measured at each intervention delivery period (pre-diagnosis, immediately post-diagnosis, post-CPAP titration, and during week 1 of home CPAP treatment. Intervention components include patient education, preparatory skills training, modification of inaccurate/unrealistic cognitive perceptions of risk, outcome expectations, and treatment self-efficacy
45674342|NCT01454830|Other|Usual care|Usual care comparison group will proceed from initial clinical evaluation for OSA, diagnosis by polysomnography, CPAP titration polysomnography, and home CPAP treatment initiation as per current standard of care
45674343|NCT01454596|Biological|Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL|Day 0: Cells will be infused intravenously over 20-30 minutes. Patients will receive two cell doses, 2 hours apart.
45674344|NCT01454596|Drug|Aldesleukin|Aldeskeukin 72,000 IU /kg intravenous (IV) or 720,000 IU /kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
45674345|NCT01454596|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
45833794|NCT05151432|Device|Pulsed Ultrasound|Active US therapy will be administered using a device 4cm², 1- MHz US with a sound-head area of effective 4cm, radiating area of 3.5 to a beam non-uniformity ratio of cm². 5:1, and a therapeutic dose of approximately 112.5J/ That is, the pulsed US will be delivered for 9.5 minutes with a peak intensity of 1W/cm² at a 20% duty cycle, to achieve a spatial-temporal average intensity of 0.2W
45992416|NCT02941016|Drug|Evolocumab or Alirocumab|All patients are treated with PCSK-9 inhibitors (Evolocumab or Alirocumab) to lower cholesterol
45674346|NCT01454596|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hr.
45833795|NCT05151432|Device|Pulsed Electromagnetic field|The patient's knee will be placed between 2 plates coil applicator generating a magnetic field intensity of 1.5 mT and a frequency of 75Hz.
45833796|NCT05151432|Other|Traditional exercise program|Stretching exercises, Isometric quadriceps exercise, Straight leg raising (SLR) exercise, Isometric hip adduction exercise, Hip abductor strengthening, Hip extensor strengthening, Hip external rotator strengthening
45833797|NCT05151432|Device|Sham Pulsed US & Electromagnetic field|The patients will receive Sham Pulsed US & Electromagnetic field.
45992417|NCT02941172|Other|Cold exposure|Controlled cold exposure is performed before and during PET scan
45992418|NCT02941172|Other|[18F]FMPEP-d2|PET radiotracer used in imaging
45992419|NCT02941172|Other|[18F]FDG|PET radiotracer used in imaging
45992420|NCT02916225|Behavioral|High Intensity Interval Training|The HIIT group will warm up for 10 minutes at 60% to 70% of peak heart rate(50% to 60% of V̇O2peak) before walking four 4-minute intervals at 85% to 95% of peak heart rate. Each interval will be separated by 3-minute active pauses, walking at 60% to 70% of peak heart rate. The training session will be terminated by a 3-minute cool-down at 60% to 70% of peak heart rate. Total exercise time will be 38 minutes for the HIIT group. Patients will perform 3 training sessions per week for 12 consecutive weeks.
45992421|NCT02916225|Behavioral|Moderate Continuous Training|The moderate continuous training (MCT) group will undergo treadmill walking continuously at 60% to 70% of peak heart rate for 47 minutes each session to make sure the training protocols will be isocaloric. Patients will perform 3 training sessions per week for 12 consecutive weeks.
45992422|NCT02916186|Biological|Acellular Dermal Matrix|Puros Dermis is a collagenous membrane derived from solvent preserved,human dermis, works as biological scaffold for the new formation of vasculated connective tissue.
45992423|NCT02916186|Procedure|Tunnel technique with the subepithelial connective tissue graft|Tunnel prepared with the placement of subepithelial connective tissue graft harvested from the palate
45992424|NCT03200379|Other|directly acting antivirals (DAAs)|Eligible subjects would be those CHC patients who receive approved DAA in the daily practice in Taiwan. No clinical developing medications will be allocated patients.
45992425|NCT02941484|Procedure|early oral intake|early oral intake is started within 24 hours after pancreaticoduodenectomies following to the ERAS guideline
45992426|NCT02941484|Procedure|jejunostomy tube feeding (JTF)|The jejunostomy tube was placed using the Flocare CH-10 tube with the longitudinal Witzel jejunostomy technique.nutrition is supplemented via JTF rather than early oral intake.Velocity is progressively increased by 20ml/hr until full nutritional goal (25Kcal/Kg)
45992427|NCT02915913|Behavioral|Experimental: High Intensity Interval|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 500 kcal
45992428|NCT02915913|Behavioral|Resistance training|Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 500 kcal
45992429|NCT02915913|Behavioral|Plus: High Intensity Interval + Resistance Training|Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached
45992430|NCT02915913|Other|Non-exercise|This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
45992431|NCT02277002|Device|Cabin Air Filtration|
45992432|NCT02277002|Other|Placebo|No Cabin Air Filtration
45992433|NCT04688619|Behavioral|"Prevention Program young In Favor of Myself, active parents"|"Prevention program: young In Favor of Myself, with parent participation"
45992434|NCT04688619|Behavioral|"Prevention Program young In Favor of Myself, no parental involvement"|"Prevention program: young In Favor of Myself, without parent participation"
46084352|NCT02677467|Biological|Blood-pressure variability|Day to Night Blood pressure variability
46084353|NCT02774096|Drug|xenon|
46084354|NCT02677389|Other|Educational Intervention|Receive educational material regarding physical activity and standardized emails with wellness tips and information on stress management
45992435|NCT02919735|Drug|CG 428 cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
45992436|NCT02919735|Drug|Placebo cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
45992437|NCT02941250|Device|ISSD emulator|induced tachy-arrhythmia to be terminated by ISSD emulator
45992438|NCT02919774|Drug|POMA|"Pomaglumetad (POMA) is a mGluR 2/3 partial agonist"
45992439|NCT02919774|Drug|placebo|matching placebo tablets
46084355|NCT02677389|Other|Internet-Based Intervention|Receive email and technical or how-to support from study coordinator
46084356|NCT02677389|Device|Monitoring Device|Wear a Fitbit web-integrated physical activity tracker
46084357|NCT02677389|Other|Quality-of-Life Assessment|Ancillary studies
46084358|NCT02677389|Other|Questionnaire Administration|Ancillary studies
46084359|NCT04181385|Drug|Olanzapine 10 milligram|Oral olanzapine capsule
45992440|NCT02941445|Drug|sitagliptin and metformin|
46084360|NCT04181385|Drug|Bromocriptine 5 milligram|Oral bromocriptine capsule
45992441|NCT02941445|Drug|Metformin|
45992442|NCT02941757|Behavioral|Mediterranean diet Intervention|"Educational materials (online learning) will be provided via the study website; group educational sessions and written materials (brochure with Mediterranean Diet recommendations, shopping list recommendations and sample recipes, specific Mediterranean Diet Pyramid; videos; educational sessions; in-person chef-led, Mediterranean cooking demonstrations.~Peer-education and support~Discounted food access: The investigators have partnered with Kroger supermarkets, a large national chain with numerous stores in the Indianapolis area, to provide discounted access to key Mediterranean foods for both participating firefighters and their families.~Email or text message encouragement and reminders during the intervention."
45992443|NCT02919501|Drug|Vortioxetine (IV)|17 mg, solution for infusion, administered, over 2 hours as single dose
45992444|NCT02919501|Other|Placebo (IV)|Saline: isotonic sodium chloride, administered, over 2 hours as single dose
45992445|NCT02919501|Drug|Vortioxetine (tablet)|10 mg, tablets, oral administration once daily for 15 days (open labelled)
45992446|NCT02940782|Procedure|Reciproc single file system|A reciprocating Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
46084361|NCT04181385|Drug|Placebo oral tablet|oral placebo capsules
46084362|NCT02774018|Behavioral|Mindfulness-Based Stress Reduction (MBSR) program|
46084363|NCT00924443|Drug|clofarabine|
45992447|NCT02940782|Procedure|One Shape single file system|A rotary Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
45992448|NCT02940782|Device|X-smart Plus, Dentsply Maillefer, Ballaigues, Switzerland|It is a micro-motor designed for performing root canal treatments with the reciprocating, single file technique or traditional continuous rotation file system.
45992449|NCT02919579|Drug|Placebo (Intranasal)|Participants will receive intranasal placebo in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
45674347|NCT04542850|Dietary Supplement|5-ALA-Phosphate + SFC (5-ALA + SFC)|"Moderately ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) two times daily (resulting in 500 mg 5-ALA-Phosphate and 286.8 mg SFC (30.4 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days~Severely ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) three times daily (resulting in 750 mg 5-ALA-Phosphate and 430.2 mg SFC (45.6 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days"
45992450|NCT02919579|Drug|Esketamine|Participants will receive intranasal esketamine in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
45992451|NCT02919579|Other|Alcohol|Participants will receive oral alcohol in Part A (as per the treatment sequence in period 1,2 and 3).
46084364|NCT05662917|Behavioral|Individual semi-structured interviews|After information and written consent, the investigator will interview the participants through a semi-structured individual interview (conducted by an interview guide). The interview is expected to last 45 minutes (variable depending on the subject). It will be recorded by dictaphone, respecting the anonymity of the participant throughout the interview. The subject's participation will end after the interview.
46084365|NCT02677155|Radiation|Radiotherapy|Radiotherapy 8 Gy single dose
46084366|NCT02677155|Biological|Rituximab|Intranodal injection 5 mg
46084367|NCT02677155|Biological|Autologous dendritic cells|Intranodal injection of 1 x 10 e8 cells
46084368|NCT02677155|Biological|GM-CSF|Subcutaneous injection of 50 ug
46084369|NCT02677155|Biological|Pembrolizumab|Intravenous infusion of 200 mg
46084370|NCT02773940|Device|ClariCore System|Biopsy tissue and correlative spectral data will be acquired using the ClariCore System during a patient's already scheduled radical retropubic prostatectomy (RRP) surgery.
46084371|NCT04256447|Diagnostic Test|Urinary sodium concentrations|The urinary sodium excretion was measured using an immunochemical methodology
46084372|NCT02771756|Dietary Supplement|zhen qishen capsule and Oral Supplement of Yuyikang|
45674348|NCT02247479|Drug|Lampalizumab|Participants will receive 10 mg dose of lampalizumab administered intravitreally.
45674349|NCT02247479|Other|Sham|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
46084373|NCT02771756|Dietary Supplement|zhen qishen capsule placebo and Oral Supplement of Yuyikang placebo|
46084374|NCT02771756|Radiation|chemotherapy|
46084375|NCT02771756|Other|nutrition education|
46084376|NCT04254965|Other|Music therapy|Treatment including instrument playing, singing, lyrics modification/music organized play, listening to music and discussing each treatment process.
46084377|NCT04254965|Device|Biosignal analysis|Measurement of facial expression emotion recognition, electrodermal activity, heart rate variability, sleep pattern, blood pressure, and electromyogram.
46084378|NCT02537691|Drug|FP|ICS consisting of FP will be administered by DPI (or equivalent) as per investigator discretion.
45674350|NCT01454284|Drug|Glargine|
45674351|NCT01454284|Drug|LY2605541|
45674352|NCT01454284|Drug|Insulin Lispro|
45674353|NCT04541290|Drug|Protopic 0.1 % Topical Ointment|Applied in a thin layer covering all of the arm including the armpit and hand once a day for six months
45992452|NCT02919579|Drug|Placebo (Oral)|Participants will receive oral placebo in Part A (as per the treatment sequence in period 1,2 and 3).
45992453|NCT04688697|Procedure|prepectoral implant-based reconstruction|In this group, patients receive breast reconstruction with prosthesis placed to anterior pectoralis major, synthetic mesh is used to enclose the prosthesis and place it to anterior pectoralis major.
45992454|NCT04688697|Procedure|subpectoral implant-based reconstruction|In this group, patients receive breast reconstruction with placed to posterior pectoralis major, part of the mesh is placed under the pectoralis major during the operation, and the mesh is used to cover the suture of the prosthesis on the inferior plica, or to directly enclose the lower part of the implant.
45674354|NCT02247401|Drug|2 DAA|ABT-450/r/ABT-267 tablets
45674355|NCT02247401|Drug|RBV|Ribavirin tablets
45992455|NCT02940821|Other|Toothbrushing|Mechanical plaque removal
45992456|NCT02940821|Other|Fluoridated Dentifrice (.15% sodium monofluorophosphate)|Fluoridated dentifrice application
45992457|NCT02940821|Other|Fluoridated Dentifrice Whitening System (.454% stannous fluoride with 2% hydrogen peroxide)|Application of Tooth Whitening Agent in Dentifrice
45992458|NCT02940821|Other|Whitening (4.5% hydrogen peroxide)|Application of Whitening Agent
45992459|NCT02940821|Other|Other Fluoridated Dentifrice (.454% stannous fluoride)|Fluoridated dentifrice application
45992460|NCT03654807|Behavioral|High Intensity Walking|70-80% HRmax
45992461|NCT03654807|Behavioral|Casual Speed Walking|Self selected pace
45992462|NCT02941601|Drug|Necitumumab|Administered IV
45992463|NCT02941601|Drug|Gemcitabine|Administered IV
45992464|NCT02941601|Drug|Carboplatin|Administered IV
45992465|NCT02940899|Other|Intervention: Syracuse University Fir Families Program (SUFFP)|The SUFFP (Syracuse University Fit Families Program) is a randomized clinical trial, were 40 children with autism spectrum disorders ages 5-11 and at least one parent were randomly assigned to one of two group-based conditions; interventions or a control wait list group.
45992466|NCT03631719|Biological|Wolbachia-carrying Ae.aegypti mosquitoes|Wolbachia-infected Ae. aegypti mosquito eggs and adults sequentially deployed into Medellin and Bello, Colombia. Deployments cease once Wolbachia prevalence has reached a predetermined frequency (usually ≥60%).
45992467|NCT04691453|Procedure|QM-C Hysterectomy|This operation corresponds to the classical radical hysterectomy. The lateral border is defined as the medial aspect of the internal iliac artery and vein. Transection of the rectovaginal and rectouterine ligaments is performed at the rectum. Transection of the ventral parametrium ligament is performed at the bladder. Both the vesicouterine and vesicovaginal ligaments are resected. The ureter is completely mobilized and lateralized. The length of the vaginal cuff is adjusted to the vaginal extent of the tumor.
45992468|NCT04691453|Procedure|QM-B Hysterectomy|Type B is the modified radical hysterectomy. The ureter is unroofed and mobilized laterally, permitting transection of the paracervix at the level of the ureteral tunnel. Partial resection of the uterosacral peritoneal fold of the rectouterine ligament (dorsal parametrium) and the vesicouterine (ventral parametrium) ligament also is a standard component of this resection. Approximately 10 mm of the vagina from the caudal edge of the cervix or tumor is resected, without intent to radically resect the paravaginal tissues.
45992469|NCT02940743|Behavioral|Education (Edu)|This intervention will take place during weeks 1-4 at the dialysis center. Each week, study staff will present participants with a brief educational video on: phosphorus binder adherence (week 1), meeting dietary protein needs (week 2), restricting dietary sources of phosphorus (week 3), and eliminating phosphorus-based food additives (week 4). These videos will be loaded onto tablet (Personal Computers) PCs so that participants can easily view them during regular dialysis treatment.
45992470|NCT02940743|Behavioral|SM intervention|During the first 12 weeks of the intervention, a study dietitian will review the participants' records, and provide individualized feedback via a password-protected NYULMC email address. Feedback will be provided twice per week during weeks 1-4, once per week during weeks 5-8, and once every two weeks during weeks 9-12. The email messages will focus on both the importance of self-monitoring and the behavioral targets of the intervention. Feedback will use standardized language rather than specific dietary examples to avoid providing individualized counseling to participants (which is not the purpose of the SM intervention).
45992471|NCT02940743|Behavioral|Social Cognitive Therapy (SCT)|This intervention will be delivered remotely online using the same tablet PCs provided for the SM intervention component of this treatment condition. The behavioral training program will focus on building a sense of self-efficacy with emphasis on mastery experiences that will include emphasizing past successes; setting incremental, easily achievable goals; self-monitoring to stay on track; identifying modifiable barriers to healthy behavior; positive feedback in goal achievement; and developing participant expertise in both the regimen and in problem solving around barriers to adherence.
45992472|NCT03458390|Device|HyGIeaCare colon irrigation|PillCam COLON for visualization of bowel lining
45992473|NCT03160638|Drug|Azithromycin 250 mg|Patients will be treated with azithromycin 250 mg once daily for 28 days. An azithromycin loading dose of 500 mg (two tablets of 250 mg) will be administered on day 1
45992474|NCT02940704|Procedure|Reciproc|"Canals will be instrumented using Reciproc reciprocating system set on an electric motor, with adjusted torque and speed according to the manufacturer's instructions.~There is no need for coronal preflaring with a Gates Glidden drill or an orifice opener since the design of the Reciproc instrument allows any obstructions in the coronal third to be removed, as claimed by the manufacturer.~Reciproc file selection: R40 (40/0.06) is to be used."
45992475|NCT02940704|Procedure|One Shape|"Coronal preflaring will be performed using Gates Glidden drill.~Canals will be instrumented using One Shape single-file (25/0.06) set on an electric motor with adjusted torque and speed according to the manufacturer's instructions.~For wide canals, One Shape Apical (30/0.06, 37/0.06) will be used."
45992476|NCT02940587|Device|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
45992477|NCT02919540|Other|Kangaroo care approach|skin to skin contact between stable preterm infants and their naked mother's chest
45992478|NCT02919462|Drug|Oral vinorelbine|Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) every 3 weeks, for 4 cycles
45992479|NCT02919462|Drug|Cisplatin|Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles
45992480|NCT02919462|Drug|Maintenance with Metronomic Oral Vinorelbine|Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks).
45992481|NCT02919462|Drug|Pemetrexed|Pemetrexed, 500 mg/m2, day 1 every 3 weeks, for 4 cycles
45992482|NCT02919462|Drug|Cisplatin|Cisplatin 75 mg/m2, day 1 every 3 weeks, for 4 cycles
45992483|NCT02919462|Drug|Maintenance with Pemetrexed|Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks)
45992484|NCT02941367|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
45992485|NCT02941367|Drug|Sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
45992486|NCT02941367|Drug|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
45674356|NCT02247011|Other|Questionaire survey|We used a questionnaireto collect clinical data of the subjects. The questionnaire includes basic data, menstruation and pregnancy, habits and customs, daily activity, common healthy situation, history of drugs and history of factures.
45992487|NCT02941367|Drug|basal insulin|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
45992488|NCT03153150|Drug|Apixaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
45992489|NCT03153150|Drug|Rivaroxaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
45992490|NCT03153150|Drug|Edoxaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
46084379|NCT02537691|Drug|LABA|LABA will be administered as per investigator discretion.
46084380|NCT02537691|Drug|LTRA|LTRA will be administered as per investigator discretion.
45674357|NCT02247011|Radiation|Bone mineral density examination|We use dual energy X-ray absorptiometry (DXA) to exam the BMD at lumbar spine (L2-4, LS) and hip.
45992491|NCT03153150|Drug|Dabigatran|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
45992492|NCT03153150|Drug|Acenocoumarol|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
45674358|NCT02247011|Radiation|Vertebral fracture assessment|X-ray of thoracic and lumbar spine was taken, and the pictures were read by radiological specialists. The diagnosis of vertebral fracture was executed according to Genant's semiquantitative technique.
45992493|NCT03153150|Drug|Phenindione|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
45992494|NCT03153150|Drug|Warfarin|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
45992495|NCT02940431|Other|High Autonomy|Children will be given two active video games (AVGs) of their choice. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will be allowed to select their next game.
45992496|NCT02940431|Other|Low Autonomy|Children will be given their most-liked active video game (AVG) from the baseline relative reinforcing value assessment. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will receive a pre-determined game.
45992497|NCT05317598|Other|Kindness and honesty psychoeducation based on positive psychotherapy: The Key Model Of Courtesy And Integrity (KMCI)|It is an application that investigates the effect of kindness and honesty psychoeducation based on positive psychotherapy on effective communication skills of nursing students.
45992498|NCT02916147|Drug|Sevoflurane|
45992499|NCT02916147|Drug|Propofol|
45674359|NCT02247011|Other|Biochemical markers analysis|Fasting blood sample was collected for each subject. Common biochemical maerkers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP), alanine aminotransferase(ALT) were analyzed. Besides, we also detect bone speficific markers including 25-hydroxyl Vitamin D(25OHD), parathyroid hormone(PTH), β-isomerized C-terminal telopeptide of type I collagen(β-CTX), N-terminal procollagen of type 1 collagen(P1NP) and osteocalcin(OC).
45674360|NCT02246777|Device|Ex-PRESS® Glaucoma Filtration Device, Model P50PL|
45992500|NCT04688970|Other|no intervention|no intervention
45992501|NCT05317559|Behavioral|room light|The room light condition (n=10) included one night of sleep in dim light (< 3 lux) followed by one night of sleep with overhead room lighting (100 lux). The dim light condition (n=10) included two consecutive nights of sleep in dim light.
45992502|NCT02915562|Other|exercise|
45992503|NCT05316194|Other|Digital treatment for hip and knee osteoarthritis|"The program is an app-based version of the Swedish face-to-face management program for OA Better management of patients with OsteoArthrits and includes weekly educational sessions, individualized exercises and a possibility to chat asynchronously with a physical therapist during the entire duration of the program."
46084381|NCT02537691|Drug|LAMA|LAMA will be administered as per investigator discretion.
46084382|NCT02537691|Drug|Theophylline|Theophylline will be administered as per investigator discretion.
46084383|NCT02537691|Drug|Oral Corticosteroids|Oral corticosteroids will be administered as per investigator discretion.
46084384|NCT04836884|Procedure|Percutaneous Vascular Anomaly/Malformation Biopsy|US-guided percutaneous vascular anomaly core needle biopsy of up to 10 cores using an 18-gauge co-axial core needle biopsy device at the time of clinically indicated sclerotherapy, embolization or ablation treatment.
46084385|NCT04881383|Diagnostic Test|OGTT and HbA1c|An investigation form will be given to the patient to attend an approved private laboratory for blood pressure, weight, height, waist and hip circumferences, and a blood test on OGTT, HbA1c, complete blood count (CBC) and lipid profile within three months
45992504|NCT02915718|Procedure|protein A immunoadsorption|protein-A immunoadsorption for 5 days and i.v. IgG（0.5g/kg Body weight）substitution
45992505|NCT03458351|Device|Remote ischemic preconditioning|Four cycles of 5 min of ischemia, which is induced by a blood pressure cuff in the upper arm inflated to 200 mmHg, followed by 5 min of reperfusion, during which the cuff is deflated.
45992506|NCT03458351|Device|Sham control|The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10 mm Hg and ischemic preconditioning is not induced.
45992507|NCT02915757|Device|EDOR test|"The ElectroDermal Orienting Reactivity (EDOR) specifically is optimized for the detection of electrodermal hyporeactivity.~The EDOR investigation last about 30 min. The EDOR Test Data is sent immediately after each EDOR Test for each Test Person to a Company named EMOTRA for blind analyses. The EDOR Test Report may change the basis for the assessment and a new risk assessment may be needed to be done.~Blood sample and clinical assessment"
45992508|NCT05302388|Drug|SIBP-R002|SIBP-R002: injection; strength: 1, 2, 4, 8 or 12 mg; dose escalation and the first group is 1mg (intravenous infusion, 5 groups, the first group consisted of four people, and the other groups consisted of eight).
45992509|NCT05302388|Drug|Dexamethasone or Methyl prednisolone|Intravenous infusion, 5mg or 1~2mg/kg. These were administered within 30 minutes prior to infusion of the experimental drug.
45992510|NCT05302388|Drug|Diphenhydramine|10mg, intramuscular injection.These were administered within 30 minutes prior to infusion of the experimental drug.
46084386|NCT02773862|Device|HS-1000|
46084387|NCT04256135|Other|Mulligan mobilization|Mobilization will be performed while the patient actively performs knee flexion and/or extension depending on the patient's painful or limited movements. Three series of ten repetitions will be performed.
45674361|NCT01495702|Drug|NNRTI|NNRTI agents administered according to prescribing information; allowed NNRTIs include efavirenz (EFV), nevirapine, or rilpivirine.
45674362|NCT01495702|Drug|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
45674363|NCT01495702|Drug|Stribild|Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
45674364|NCT01630889|Drug|Roxadustat|Oral capsule
45674365|NCT01495000|Drug|denosumab|60mg subcutaneous injection, single dose
45674366|NCT01495000|Drug|placebo|placebo subcutaneous injection, single dose
45992511|NCT05302388|Drug|Placebo|The same volume of placebo as SIBP-R002: injection; strength: the same volume of placebo as SIBP-R002 of 1, 2, 4, 8 or 12 mg (intravenous infusion, 5 groups, the first group consisted of one people, and the other groups consisted of two). The rule and dose of placebo were the same as SIBP-R002.
45992512|NCT02919384|Other|2% oxygen concentration in the incubator|"At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6."
45992513|NCT05296616|Behavioral|Mindfulness Based Stress Reduction Intervention|Mindfulness Based Stress Reduction intervention is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 90 minute sessions, once per week for eight weeks.
45992514|NCT02915640|Other|Remote technology|Utilization of remote technology versus not using remote technology when triaging and managing pediatric patients in remote settings prior to pediatric specialized inter-facility transportation.
45992515|NCT05291078|Device|A transcutaneous trigeminal nerve stimulator: High Frequency|30min/day, at least 5 to 7 times a week
45992516|NCT05291078|Device|A transcutaneous trigeminal nerve stimulator: Low Frequency|30min/day, at least 5 to 7 times a week
45992517|NCT05291078|Device|A transcutaneous trigeminal nerve stimulator: Sham|30min/day, at least 5 to 7 times a week
45992518|NCT05291078|Device|Sound Therapy|Notch Therapy at least 30min/day, at least 5 to 7 times a week
45992519|NCT02919072|Drug|Chloroprocaine|The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.
45992520|NCT02919072|Drug|Ropivacaine|The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.
45992521|NCT02941328|Drug|Pyridostigmine|Pyridostigmine, administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
45992522|NCT02941328|Drug|Placebo|Placebo administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
45992523|NCT02915796|Biological|G-CSF + CD133(+) cells|Patients in the G-CSF + CD133(+) cells + PTA group, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize CD 133 cells from bone marrow to peripheral blood. After 72-120 hrs, 100 ml suspension of peripheral arterial blood were collected and send to Good Products Manufacturing (GPM) certified laboratory (Shanghai Chen Chuan Biological Material Co. Ltd.) within 24 hrs of obtaining sample to isolate CD 133(+) endothelial progenitor cells (EPC) using magnetic cell separator. Subjects in this group, after vascular PTA treatment, received transarterial infusion of 50 ml suspension of isolated autologous CD 133(+) cells over 30 min via catheter opened into popliteal artery. The infusion of CD 133 cells was repeated after 24 hours.
45992524|NCT02915796|Biological|G-CSF|Subjects in this group, after vascular PTA treatment, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize EPCs from bone marrow to peripheral blood. But the C133 (+) cells were not isolated from the peripheral blood to infuse transarterially as in G-CSF + CD133(+) + PTA.
45992525|NCT02915796|Procedure|percutaneous transluminal angioplasty (PTA)|Subjects in this group only underwent below the knee percutaneous transluminal angioplasty .
45992526|NCT02915796|Biological|Placebo infusion|Neither G-CSF was injected nor CD133(+) cells. Instead, subjects received placebo infusion (50 ml of 0.9% sodium chloride injection ) over 30 min.
46084388|NCT04256135|Other|AP Maitland mobilization|The joint mobilization, will be carried out in the knee with both hands, with displacement of the tibia from the front to the back of the femur in an oscillatory way without pain, will be carried out in blocks of 2 minutes with rests of 30 seconds with a duration of about 6 minutes.
45674367|NCT04762277|Drug|Spesolimab|Spesolimab
45674368|NCT04762277|Drug|Placebo|Placebo
45674369|NCT01494922|Drug|EXC 001 (currently called PF-06473871)|Single dose administered by injection at four different times
45992527|NCT02941289|Procedure|visual search performance of everyday objects in realistic scenes|
45992528|NCT02919228|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
45674370|NCT02192099|Drug|Rapastinel (225 mg/450 mg IV administration)|Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel
45992529|NCT02941211|Device|Aqueduct -100|
45992530|NCT02915484|Device|Transcranial Direct Current Stimulation|TDCS involves sending a weak electrical current to the brain to modulate brain functions.
45992531|NCT02940977|Other|Blood draws|Blood draws, from peripheral veins, each time 2 tubes, each 5 ml.
45992532|NCT02915211|Dietary Supplement|Keyo|Keyo is a Food for Special Medical Purposes (FSMP) and is intended for use in the KD. It has a fat to protein and carbohydrate ratio of 3 to 1. This makes it appropriate for inclusion in all versions of the KD - classical, MCT, MAD and LGI. Keyo has been designed as a nutritionally complete, ready to use, pleasant tasting and versatile medical food for use in a KD.
45992533|NCT05268731|Procedure|External plastic endoprosthesis|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of an external plastic endoprosthesis if the duodenum or jejunum cannot be accessed by a guide wire
45992534|NCT05268731|Procedure|Combined external internal plastic endoprosthesis|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of an external/internal plastic endoprosthesis if the duodenum or jejunum can be accessed by a guide wire. No definitive drainage intended in initial procedure.
45992535|NCT05268731|Procedure|Primary metal stent|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of a self-expanding metal stent if the duodenum or jejunum can be accessed by a guide wire. A definitive drainage is intended in the initial procedure, for example in patients with malign bile duct obstruction
45992536|NCT02915328|Device|Filterwire EZ™|
45992537|NCT02915328|Device|MO.MA Ultra|
45992538|NCT02915328|Device|Stent Roadsaver®|
45992539|NCT02915328|Device|Carotid Wallstent|
45992540|NCT05238545|Other|gluten-free diet|Diet excluding foods containing gluten.
45992541|NCT02915133|Procedure|macular buckling surgery|Participants with high myopia foveoschisis are scheduled to macular buckling (MB) surgery.
45674371|NCT01494610|Drug|SERETIDE Rotacaps|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods and a placebo delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
45992542|NCT04691336|Behavioral|Educational and Training with counselling|The nurse conducts a structured interview that covers the following areas: information on respiratory attraction and the symptom of dyspnea, expectations and beliefs about oxygen therapy, use of oxygen therapy, healthy habits, social support. It also evaluates the patient's perception of oxygen therapy, and the level of dyspnea using the mMRC scale. After this, the nurse evaluates the current level of adherence, and if she considers that the patient needs a reinforcement session, she schedules a workshop with 3 other patients and their main caregivers. This workshop takes place 30 days after this interview. In other patients, depending on the level of adherence, a support call is made, and all patients are visited again at the center at 90 days, performing the same evaluation with a structured interview and the scales that were made on day 1
45992543|NCT02915250|Drug|BioChaperone® Combo|Injection of BioChaperone® Combo
45992544|NCT02915250|Drug|Humalog® Mix25|Injection of Humalog® Mix25
45992545|NCT02915250|Drug|Humalog®|Injection of Humalog®
45992546|NCT02915250|Drug|Lantus®|Injection of Lantus®
45992547|NCT02915250|Drug|Placebo|Injection of 0.9% NaCl
45992548|NCT02277041|Drug|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute
46084389|NCT04225052|Drug|YHP1903|YHP1903 Tab. 1mg
45992549|NCT02277041|Drug|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
45992550|NCT02915289|Procedure|Povidone Iodine|Vaginal preparation with 10% povidone iodine prior to non-emergent cesarean section.
45992551|NCT02915289|Procedure|Chlorhexidine gluconate|Vaginal preparation with 4% chlorhexidine gluconate prior to non-emergent cesarean section.
45992552|NCT02939378|Dietary Supplement|Ketogenic diet|Ketogenic diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
45992553|NCT02939378|Dietary Supplement|Standard diet|Standard diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
45992554|NCT02915406|Device|CliniMACs|
45992555|NCT02939339|Device|continuous theta burst stimulation (real)|a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
45992556|NCT02939339|Device|continuous theta burst stimulation (sham)|a sham version of a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
45992557|NCT02918916|Other|Phototherapy|The dosage applied will be 30 Joules per site (180 Joules per muscle). Parameters are described in the attached document.
45992558|NCT02918916|Other|Placebo|The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled.
45992559|NCT02939417|Other|Grape seed extract|Grape seed extract - collagen cross-linking agent
45992560|NCT02919033|Other|Usual care|The hypertension care of this arm complies with the national guideline and includes designated follow-ups by PCPs once every 1-3 months for stage-1 (≥ 140/90 mm Hg) hypertension patients, once every 1 month for stage-2 (≥ 160/100 mm Hg) and once every 2 weeks for stage-3 (≥ 180/110 mm Hg) patients.
46084390|NCT04225052|Drug|Champix|Comparator Champix Tab. 1mg
46084391|NCT02777138|Other|Maintaining a normal daily living lifestyle|participants will undertake a normal lifestyle with no alterations to daily living in order to access the differences in tissue (muscle and adipose) and systemic inflammation between the two age cohorts
46084392|NCT00642525|Procedure|Contrast swallow radiography, endoscopy|Contrast swallow radiography is performed using water soluble contrast medium Esophagoscopy is performed according to standard safety guidelines
45992561|NCT02919033|Device|Self-management|"Usual care~Patients receive a BP telemedicine system developed by CareLinker Inc. (Shanghai, China) to facilitate BP self-management in addition to all the usual care components. The system consists of: 1) a BP tele-monitor with embedded GSM module that can upload BP readings; 2) a mobile App that allows patients to manually input healthcare data, display history BP measurements and lab test results, receive personalized lifestyle coaching contents and medication reminders, and communicate with PCPs through text-messaging.~All patients receive proficiency training in using the BP tele-monitor, and mobile App."
45992562|NCT02919033|Other|PCTM intervention|"Usual care~Self-management~PCPs and cardiologists use the secure CareLinker website to review patient data including BP measurements, lab test results and medications in use and comorbidities. The auto analytics tools of the website reveal BP average, BP trend, and risk score of each patient. Text alerts of abnormal BP variability will be pushed to PCPs' App when they occur and proactive interventions including phone consultation and medication dosage adjustment will be offered. A case review session will be set once every 1-2 months for PCPs and cardiologists to exam patients' disease progresses. The proprietary web-based analytic module also produces automated individualized medication recommendations to PCPs.~PCPs and cardiologists receive training of the CareLinker website."
45992563|NCT02939456|Other|Magnetic Resonance Imaging|Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) and Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
45992564|NCT02918799|Behavioral|Mpowerment|MP is a multi-level intervention that reaches out to all YMSM in a community by mobilizing men to encourage their friends to reduce risk behavior and join the program (informal outreach), along with holding social activities that promote safe sex (formal outreach). MP provides YMSM with skills, support and confidence to find solutions within themselves for sexual health, and seeks to affirm the validity and rights of same-sex behavior and identities.
45992565|NCT02939261|Behavioral|Intervention - 4 Home Visits|4 home visits from a health educator, weekly e-mails, and monthly mailed behavioural supports.
45992566|NCT02939261|Behavioral|Control|monthly emails with general health information
45992567|NCT02918682|Other|Exercise - FIRST PHASE|the participants do not need to perform the first phase or can advance to the second phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8 m/s and walking 30 meters without stopping; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO stance for 30 seconds and the Tandem EO stance for more than 5 seconds; 4. Having sitting stability limits with eyes open; 5. In upright position, able to bend the trunk forward, standing parallel to a wall, between 16.5 - 32 cm but stable. For the muscle strength: being able to perform hip flexion with 50% of 1 repetition maximum (RM) for 8 repetitions; hip extension with 50% of 1RM for 8 repetitions; hip abduction without load but at least for 8 repetitions; knee extension with 50% of 1RM for 8 repetitions; knee flexion with 50 % of 1RM for 8 repetitions;
45992568|NCT02918682|Other|Exercise - SECOND PHASE|the participants do not need to perform the second phase or can advance to the third phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8-1 m/s and ability to walk 60 meters; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO and FFEC stance for more than 5 seconds and the Tandem EO stance for 10-20 seconds; 4. Having sitting stability limits with eyes closed; 5. Being able to bend the trunk forward, standing parallel to a wall, between 20-32 cm ad being stable. For muscle strength: being able to perform hip flexion with 60% of 1 RM for 8 repetitions; hip extension with 60% of 1RM for 8 repetitions; hip abduction without load but between 8-12 repetitions; knee extension with 60% of 1RM for 8 repetitions; knee flexion with 60% of 1RM for 8 repetitions;
45992569|NCT02918682|Other|Exercise - FOURTH PHASE|at the end of the exercise protocol, the participants who have reached the fourth phase must be able to achieve: 1. Gait speed of 0.8-1 m/s and able to walk 90 meters; 2. Stand up and sit down five times from the chair properly within less than 15 seconds; 3. TUG performance less than 14 seconds; 4. Maintenance of 30 seconds in FFEO and FFEC stance, maintenance of 30 seconds in Tandem EO and Tandem EC stance, maintenance of the single-leg stance for more than 21 seconds; 5. Normal sitting stability limits with eyes closed; 6. Bending the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For muscle strength: able to perform hip flexion with 70% of 1 RM for 6-10 repetitions; hip extension with 70% of 1RM for 6-10 repetitions; hip abduction with 40-60% of 1RM for 8-12 repetitions; knee extension with 70% of 1RM for 6-10 repetitions; knee flexion with 70% of 1RM for 6-10 repetitions.
45992570|NCT02918682|Other|Exercise - THIRD PHASE|participants do not need to perform the third phase or can advance to the fourth phase if they have obtained: 1 Gait speed of 0.8-1 m/s and walk 90 meters; 2 perform the stand up and sit down five times from the chair properly within less than 15 seconds; 3 Performing the TUG test within less than 14 seconds; 4 Maintaining the FFEO and FFEC stance for 30 seconds, maintaining the Tandem EO and Tandem EC stance for 30 seconds and maintaining the single-leg stance for more than 20 seconds; 5 Having sitting stability limits with eyes closed; 6 In the upright position, to bend the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For the muscle strength test, perform hip flexion with 60 % of 1 RM for 8-12 repetitions; hip extension with 60 % of 1RM for 8-12 repetitions; hip abduction without load or 5% of 1RM for hip abductor and between 8-12 repetitions; knee extension with 60 % of 1RM for 8-12 repetitions; knee flexion with 60 % of 1RM for 8-12 repetitions;
46084393|NCT04255121|Drug|2% adrenaline lidocaine associated with 4.2% sodium bicarbonate|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an alkalinization of adrenaline lidocaine solution
45674372|NCT01494610|Drug|SERETIDE Diskus|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods and a placebo delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
45992571|NCT05034536|Drug|Pembrolizumab|Intravenous infusion
45992572|NCT05034536|Drug|Infliximab|Intravenous infusion
45992573|NCT05034536|Drug|Placebo|Intravenous infusion
45992574|NCT05018351|Behavioral|Integrated Care|Participants receive integrated physical and mental health care from their usual provider.
45992575|NCT05018351|Behavioral|Peer Navigation|Peer navigators will meet individually and face-to-face with participants to address their health and weight goals (i.e. working on health-related goals, attending health care appointments. and facilitating follow-up activities related to healthcare appointments).
45992576|NCT02915094|Drug|Anakinra|
45992577|NCT02918643|Other|Use of an application to for mobile devices like decision-making support for prescription drugs to elderly patients|
45992578|NCT05012891|Other|OneStep Smartphone Application|"OneStep technology is a smartphone application (app) utilizing smartphone sensors to provide ongoing gait diagnostics. The eligible study participants will be asked to download and install the app on their own smartphones and carry the smartphone in their front pants pocket at all times.~The app will collect the required gait parameters but, will not present them (or any summary thereof) to the study participants or their physiotherapists, in order not to influence the rehabilitation plan."
45992579|NCT02939027|Device|Electronic Brachytherapy (6,1 Gy)|A total dose of 36.6 Gy is planned over 6 fractions of 6.1 Gy, given 2 days/week, during 3 weeks or lees, at least 2 days apart each fraction.
45992580|NCT02939027|Device|Electronic Brachytherapy (7 Gy)|A total a dose of 42 Gy is planned over 6 fractions of 7 Gy, given 2 days/week during 3 weeks or lees, at least 2 days apart each fraction.
45992581|NCT02915172|Drug|Lenvatinib|"Phase 1 Dose Escalation: Starting dose of Lenvatinib 10 mg by mouth once daily of a 21 day cycle.~Phase 2 Dose Expansion: Starting dose of Lenvatinib is maximum tolerated dose from Phase 1."
45992582|NCT02915172|Drug|Capecitabine|Phase 1 Dose Escalation and Phase 2 Dose Expansion: Capecitabine 1000 mg/m2 twice daily by mouth on Days 1 - 14 of a 21 day cycle.
45992583|NCT02938988|Procedure|Antimicrobial photodynamic therapy|Described in arm/group
45992584|NCT02938988|Procedure|Scaling and root planning|Described in arm/group
45992585|NCT02938988|Device|red laser|658nm; 0.1W; 2229J/cm², 10s per point
45992586|NCT02938988|Drug|methylene blue dye|
45833798|NCT04199052|Behavioral|LinkPositively|LinkPositively is a culturally tailored, trauma-informed smartphone app for Black women living with HIV/AIDS affected by interpersonal violence. Core components of LinkPositively include: a) Virtual Peer Navigation that includes phone and text check-ins and 4 weekly one-on-one video sessions to build skills to cope with barriers and navigate care; b) Social Networking platform to receive peer support; c) Educational and Self-care database with healthy living and self-care tips; d) GPS-enabled Resource Locator for HIV care and ancillary support service agencies; and e) ART self-monitoring and reminder system.
45992587|NCT02918994|Behavioral|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
45992588|NCT02939144|Dietary Supplement|Liquorice|Liquorice ingestion will mimic the inherited condition of 'Apparent mineralocorticoid excess (AME)by showing the effects of the reduced activity of 11ßHSD-2 (which leads to an accumulation of cortisol which binds MR and hence has the effect of aldosterone).
45992589|NCT02915055|Drug|Ibuprofen 600 mg|Ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN
45992590|NCT02915055|Drug|standard oxycodone/acetaminophen|
45674373|NCT02116777|Other|Laboratory Biomarker Analysis|Correlative studies
45833799|NCT04195776|Drug|Tenofovir Douche|660 mg TFV in 125 mL hypo-osmolar solution
45833800|NCT04193826|Device|Left Atrial Appendage Closure|Closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the LAAC device will be performed according to device specific instructions for use based on both TEE guidance, ICE and angiography, femoral access and inter-atrial septum crossing
45992591|NCT02939222|Device|Implant placement|Routine implant placement in the ideal three dimensional implant position
45992592|NCT02938910|Other|non interventional study|Non invasive imaging study without interventional procedures
45992593|NCT04690790|Procedure|Thoracoscopy|Patients who are indicated for thoracoscopic nodulectomy.
45992594|NCT01295827|Biological|Pembrolizumab|IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.
46084394|NCT04255121|Drug|2% adrenaline lidocaine|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an adrenaline lidocaine solution
46084395|NCT05662839|Device|Cytological Brushing|All participants will undergo cytological brushing to collect cell samples for analysis
45992595|NCT02918838|Behavioral|Own Adherence Group|Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
45992596|NCT02918838|Behavioral|Fixed Adherence Group|Participant is told to meet a pre-determined target of 90%. If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
45992597|NCT02918838|Behavioral|Control Group|
45992598|NCT02918760|Drug|Gabapentin|This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.
45992599|NCT02918760|Other|Placebo|Group B (controls):This group will include (32) women according to inclusion and exclusion criteria and will receive a card of placebo.
45992600|NCT02914743|Behavioral|Motivational Interviewing|This intervention will involve a discussion intended to explore subjects' motivations to pursue dental care and empower them to visit a dentist upon release from the hospital.
45992601|NCT02914743|Procedure|Dental cleaning|This procedure will involve the removal of plaque and supragingival and subgingival calculus from the surfaces of the teeth.
45992602|NCT04983368|Drug|Xanamem® 5 mg|"Oral Xanamem® (UE2343) capsules 5 mg, administered orally once daily."
45992603|NCT04983368|Drug|Placebo|Matching placebo which is identical in appearance to the test product (5 mg, 10 mg Xanamem® QD) except that it contains no active ingredient.
45992604|NCT04983368|Drug|Xanamem® 10 mg|"Oral Xanamem® (UE2343) capsules 10 mg, administered orally once daily."
45674374|NCT02116777|Other|Pharmacological Study|Correlative studies
45833801|NCT03737214|Drug|Lucerastat|Administered in hard gelatin capsules containing 250 mg of lucerastat.
45992605|NCT02918604|Device|infrared technology: Veinsite|peripheral vein access performed with Veinsite support by expert paediatric anaesthesiologists and intensivists
45674375|NCT02116777|Drug|Talazoparib|Given PO
45833802|NCT03708588|Drug|Ticagrelor|Chewed
45833803|NCT03708588|Drug|Ticagrelor|Integral
45833804|NCT03706170|Behavioral|Physiological recording in response to different types of stimuli|In order to answer these questions, the study is designed to record in a single session: (i) physiological vegetative reactions (electrodermal, pupillary responses and heart rate) to emotional stimuli ; (ii) a neurophysiological marker of consciousness; and (iii) physiological parameters during a trace conditioning experiment using auditory stimuli with and without emotional valence.
45992606|NCT01295671|Behavioral|Provision of beverages|Home delivery of specified beverage type
45992607|NCT02918526|Device|airway management|airway management with Laryngeal Mask or Oro Tracheal Intubation
45992608|NCT02938871|Dietary Supplement|Synbiotic|The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
45992609|NCT02938871|Dietary Supplement|Control|The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
45992610|NCT01295320|Procedure|Blood sample|Blood sample will be collected at Month 48, Month 60 and Month 72
45992611|NCT02918448|Other|Training group|The investigation was carried out over a period of 18 weeks, with 12 weeks dedicated to the RT program and 6 weeks allocated for measurements. Anthropometric, one repetition maximum tests (1RM), body composition, blood pressure (BP), dietary intake and blood sample measurements were performed in weeks 1-3, and 16-18. A supervised progressive RT program was performed between weeks 4-15 by the training group.
46084396|NCT02777060|Procedure|Exergame|Subjects will perform progressive and computerized foot and ankle exercises which include weight shifting, ankle reaching task while standing, and virtual obstacle crossing task (i.e. balancing on single leg) using wearable sensors technology (Exergaming) equipment). Subjects will perform these exercises for 4-6 weeks, twice per week. The duration of exercise per session is anticipated to be 30-45 minutes.
46084397|NCT02777060|Procedure|Home based balance training|Subjects in the control group will ask to perform a standard home based balance program for 4-6 weeks. The home based program includes similar exercise components as proposed in the experimental group, however without computerized feedback and Exergaming equipment.
45674376|NCT02116777|Drug|Temozolomide|Given PO
45674377|NCT01494532|Drug|ropinirole/L-dopa|Ropinirole as adjunctive therapy with L-dopa
45674378|NCT01494532|Drug|placebo/L-dopa|Placebo as adjunctive therapy with L-dopa
45674379|NCT02191397|Drug|Bupropion|Bupropion is an extended-release plain creamy white colored tablet which contains bupropion hydrochloride equivalent to 150 mg of bupropion.
45674380|NCT02191397|Drug|Bupropion Matching Placebo|Bupropion hydrochloride matching placebo tablets will be supplied to maintain blinding
45674381|NCT02191397|Drug|Escitalopram|Escitalopram is available as a Swedish orange capsule containing escitalopram oxalate equivalent to 10 mg of escitalopram.
45674382|NCT02191397|Drug|Escitalopram Matching Placebo|Escitalopram oxalate matching placebo tablets will be supplied to maintain blinding
45992612|NCT04690517|Procedure|tracheal ultrasound|When checking tracheal ultrasound, several signs are used in judgements. Direct signs include reverberation artifact and double ring sign. Indirect sign means checking the bilateral lung sliding.
45992613|NCT01295281|Device|LoFric POBE 2.0|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
46084398|NCT02773784|Other|immunohistochemistry and/or FISH|Patients with invasive breast cancer diagnosed by core needle biopsy (CNB) and not to receive neoadjuvant system therapy are eligible for this study. ER, PR, Her-2 and Ki67 are determined by immunohistochemistry (IHC) in CNB and surgical specimen. FISH analysis will be carried out in all HER2 2+ samples.
46084399|NCT03521232|Drug|Niclosamide|enema given twice daily for 6 weeks
46084400|NCT02677311|Procedure|Blood draw|Blood draws will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
46084401|NCT02677311|Procedure|Pelvic Ultrasound|Pelvic ultrasound will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
46084402|NCT00924287|Drug|in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses
46084403|NCT00924287|Drug|Cyclophosphamide|60 mg/kg/day x 2 days intravenously (IV) in 250 ml 5% dextrose in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour
46084404|NCT00924287|Drug|Fludarabine|25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
46084405|NCT00924287|Drug|Mesna|3 mg/kg/hour intravenously diluted in a suitable diluent over 23 hours after each cyclophosphamide dose.
46084406|NCT02696954|Drug|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
46084407|NCT02696954|Drug|Amodiaquine|Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
46084408|NCT02696954|Drug|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
46084409|NCT02696954|Drug|Artemether-lumefantrine + Amodiaquine|Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
46084410|NCT02696954|Drug|Primaquine|Primaquine on Day 0 Washout period: more than 1 week
46084411|NCT02696954|Drug|Artemether-lumefantrine + Primaquine|Artemether-lumefantrine on Day 0, 1 and 2 + Primaquine on Day 0 Washout period: more than 6 weeks
45833805|NCT03706170|Behavioral|EEG recording in response to different types of stimuli|In order to answer these questions, the study is designed to record in a single session: (i) physiological vegetative reactions (electrodermal, pupillary responses and heart rate) to emotional stimuli ; (ii) a neurophysiological marker of consciousness; and (iii) physiological parameters during a trace conditioning experiment using auditory stimuli with and without emotional valence.
45833806|NCT03681054|Other|Carbohydrate restricted diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: <10 E%; fatty acids: saturated fatty acids < 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
45833807|NCT03681054|Other|Plant-protein based diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 50 E%; fat 30 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: <10 E%; fatty acids: saturated fatty acids < 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
45833808|NCT03667404|Dietary Supplement|Resistant maltodextrin|Resistant maltodextrin powder
45833809|NCT03667404|Dietary Supplement|maltodextrin|maltodextrin powder
45833810|NCT04276662|Drug|DS-3201b|1 dose of 50 mg DS-3201b
45833811|NCT04130802|Drug|OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL|OCS-01 eye drops
45833812|NCT04130802|Drug|Placebo|Vehicle eye drops
45992614|NCT01295281|Device|LoFric PVC|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
45992615|NCT02914821|Behavioral|Simulated tax via 3 cent per ounce price increase|For each of the 3 experimental conditions, investigators will increase the price of sugar-sweetened beverages by 3 cents per ounce. This price increase will be reflected in the price tag and described as a surcharge. In two of the arms (Pre-K and Childhood Healthy Eating), the beneficiary of the surcharge will be named.
45992616|NCT04690712|Behavioral|Health Education|"All students who attended the school were provided training by the researchers to improve oral and dental health and general hygiene. These trainings were made using slide shows and various entertaining materials. In addition, education was transformed into a drama with a theater show, and the importance of hand washing, hair and toilet hygiene was explained.~In addition to hygiene, students were given training on correct eating patterns for a day so that they could develop healthy."
45992617|NCT01294696|Drug|Standard of care for treatment of osteoarthritis (OA) of knee(s)|All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
45992618|NCT02914704|Device|MRI-HIFU|Treatment of uterine fibroids with MRI-HIFU
45992619|NCT04324255|Procedure|LT|Liver transplantation
45992620|NCT04690751|Drug|Cenobamate|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
45992621|NCT04326361|Procedure|Neonatal surgeries|Current practices of neonatal surgeries in India
45992622|NCT02918487|Drug|Polyherbal|Each capsule contains four herbs: Inula racemosa, Ocimum sanctum, Terminalia Belerica and Piperum longum
45992623|NCT02918487|Drug|Placebo|Inactive compound that is similar looking as the intervention
45992624|NCT04207606|Behavioral|Post Epidural Steroid Injection Follow-up|All enrolled patients will undergo epidural steroid injection with fluoroscopy per the Spine Intervention Society guidelines as part of their normal care. Patients will then be contacted for survey responses every 3 days for a maximum of 23 days, to assess pain intensity and change.
45992625|NCT03458078|Drug|Saline Solution|Spinal injection of 10 mg hyperbaric bupivacaine 0.5% (2 ml) + 100γ morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 1 ml physiological saline.
45992626|NCT03458078|Drug|Magnesium Sulfate|Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 100 mg MgSO4 (1 ml).
45992627|NCT03458078|Drug|Midazolam 5 MG/ML Injection|Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ Sufentanil (0.5ml) + 2mg Midazolam (0.4 + 0.6cc physiological saline (1 ml)).
45992628|NCT02914860|Device|Cardiac CT|"Cardiac CT - contract enhanced cardiac CT according to standard protocol~D-SPECT SUMO study - standard SUMO protocol (suggested reduction in mIBG dose and increase in scan time to minimize overall radiation burden)~Merge CT and D-SPECT image data to generate SUMO map."
46084412|NCT02696954|Drug|Artemether-lumefantrine + Amodiaquine + Primaquine|Artemether-lumefantrine Day 0, 1 and 2 + Amodiaquine on Day 0, 1 and 2 + Primaquine on Day 0 Washout period: more than 6 weeks
46084413|NCT02696954|Drug|Artemether-lumefantrine + Primaquine|Artemether-lumefantrine on Day 0, 1 and 2 + Primaquine on Day 0
46084414|NCT02773628|Device|Acar'up system|
46084415|NCT02773628|Device|Acar'up placebo system|
46084416|NCT02677077|Drug|natalizumab|Participants with RRMS receiving commercial natalizumab in Belgium and Czech Republic
46084417|NCT03523416|Device|Transcatheter Atrial Shunt System|Transcatheter treatment of symptomatic left heart failure patients
46084418|NCT00923975|Device|DIDGET World Web Community Reports|During the study subjects performed specific tasks, such as uploading meter results to a secure website and displaying reports.
45833813|NCT04276350|Procedure|Acupuncture|Acupuncture sessions - 2-3 times/week, each session lasting 1 hour, over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling)
45833814|NCT04276350|Procedure|Best Medical Therapy|Best Medical Therapy - 3 biofeedback sessions over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling), where subjects learn and practice the exercises daily
46084419|NCT02676999|Procedure|Implantation of a Scheker total distal radioulnar joint prosthesis|
46084420|NCT02771600|Device|Buzzy|See arm description
45833815|NCT03613740|Drug|Fucoxanthin|Intervention will be administered 30 minutes before breakfast.
46084421|NCT02771600|Drug|Topical anaesthetic cream|See arm description
46084422|NCT04203407|Behavioral|ACP game|Participants in the intervention group will be divided into groups of 4 participants to play a 1-hour culturally-sensitive theory-driven ACP board game with 15-minute debriefing delivered by facilitators. The ACP board game is developed by the principle investigator in a previous project.
45833816|NCT03613740|Drug|Placebo|Intervention will be administered 30 minutes before breakfast.
45992629|NCT02914860|Procedure|Ablation Procedure|"CARTO-reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO.~High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline).~RF ablation only at points where there is an HFS positive response to SUMO DUA (in sinus rhythm if AF converts)~Target a region of 1.0 - 1.5 cm diameter around the SUMO mIBG DUA~Control HFS~At operator discretion, conventional PVI by circumferential antral ablation according to standard procedures.~Exit and entrance block confirmation~Attempt to induce sustained atrial tachycardia; optional mapping and ablation of post-ablation atrial tachycardia."
45992630|NCT02914860|Device|D-SPECT|
46084423|NCT04203407|Behavioral|Usual care|Participants in the control group will receive a 1-hour board game about health lifestyle.
45992631|NCT04690556|Drug|Lucentis (ranibizumab)|Lucentis® 0.5 mg via intravitreal injection once monthly
45992632|NCT04690556|Drug|LUBT010 (proposed ranibizumab biosimilar)|LUBT010 (proposed ranibizumab biosimilar) 0.5 mg via intravitreal injection once monthly
45992633|NCT01294579|Biological|Ofatumumab|"1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase~1000 mg IV every 2 months for 2 years"
45992634|NCT01294579|Drug|Bendamustine|90 mg/m2 on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)
45992635|NCT03554655|Device|Momentum app|The Momentum system consists of a smartphone app (for the patient) and a web portal (for the provider). Information entered in the app by the patient will automatically be transferred to the web portal for the provider to see. While one goal of the system is to support SDM, the Momentum app is not a classic decision aid focusing on finding a choice to a one-off treatment decision. Instead, the Momentum app is an aid to support some of the underlying elements behind SDM such as collaboration with one's provider, awareness and eliciting of one's needs, preferences and values.
45992636|NCT02938559|Behavioral|Cognitive Therapy (CT) for depression|There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.
45992637|NCT02938559|Behavioral|Cognitive Therapy (CT) for depression + Memory Support|The Memory Support Intervention will be delivered interwoven with CT. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. It is comprised of eight memory promoting strategies: attention recruitment, categorization, evaluation, application, repetition, practice remembering, cued-based reminder and praise recall. These strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
45992638|NCT04972331|Procedure|Arthroscopic Partial Meniscectomy|"Arthroscopic partial meniscectomy was performed by three senior surgeons using two standard portals, no outflow cannula, a 5.5-mm 30° arthroscope, and a pressure-controlled irrigation system.~A standard surgical protocol was used to document possible findings in the cartilage, ligaments, synovium, and medial and lateral meniscus. In each case, surgery was limited to resection with limited debridement of the articular surface lesion, preserving as much of the meniscus as possible. Patients who underwent additional procedures, such as removal of loose bodies or subchondral drilling for any articular lesions, were excluded from this study (Figure 1). No patients underwent total meniscectomy or meniscal repair."
45992639|NCT04972331|Procedure|Platet- Rich-Plasma|Peripheral venous blood was collected from all patients, which was then centrifuged to isolate red blood cells from the upper plasma layer. We used the Arthrex® kit APC®. The upper plasma layer was carefully collected with a serological pipette and placed in a new centrifuge tube or set aside for injection. The 5 mL remaining upper plasma layer was centrifuged again to separate platelet-poor plasma from PRP for 7 min. We activated the PRP sample by adding calcium chloride through ultraviolet irradiation, and then a 4- to 8-mL sample was used for two injections. One injection was performed intra-articularly with a supero-lateral approach. One ultrasound-guided injection was performed at the meniscal wall. Our protocol allowed us to have < 1% blood cells and <1% white cells in the injection.
46084424|NCT04180839|Behavioral|gaming-related retrieval-extinction|"During one training session,participants will first view a 5-min retrieval video containing gaming content and then, 10 minutes later, receive 1-hour of extinction training in which they will be administered four sequences of video, picture and in vivo gaming cues.~The whole training includes 2 training sessions. Participants will receive one training session once a day for two consectutive days."
46084425|NCT04180839|Behavioral|nongaming-related retrieval-extinction|"During one session,participants will first view a 5-min neutral video and then, 10 minutes later, receive 1-hour of extinction training in which they will be administered four sequences of video, picture and in vivo gaming cues.~The whole procedure includes 2 sessions. Participants will receive one session once a day for two consectutive days."
46084426|NCT05249010|Procedure|acupuncture and moxibustion|Participants receive acupuncture and then measure the VAS and electric characteristic by the semiconductor analyzer Agilent B1500A first. The investigators add the burned moxa on the acupuncture as a method for moxibustion, and then measure the VAS and electric characteristic again.
46084427|NCT02773316|Drug|MR902|
45674383|NCT01630811|Drug|Nuedexta|Nuedexta (Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg) will be given once daily for 7 days. If well-tolerated, it will be given every 12 hours for the next 7 weeks.
46084428|NCT02773316|Drug|IR morphine sulphate|
46084429|NCT00642681|Drug|Technosphere Insulin|Technosphere® Insulin (TI) Inhalation Powder, prandial
46084430|NCT04188444|Biological|Blood test|20 ml of blood, three times
45674384|NCT01630811|Other|Placebo|Placebo will be given once daily for 7 days.
45674385|NCT03027076|Procedure|Genitourinary Specimen Collection|Collect urethral swab, urine before prostatic massage (pre-M), urine after prostatic massage (post-M) and Expressed Prostatic Secretion (EPS)
45674386|NCT03027076|Procedure|Collect midstream urine samples|Collect midstream urine samples
45992640|NCT04972331|Other|Post-intervention|All patients were discharged the day after surgery with no limitation of mobility but with restrictions on sports for four weeks. Interruption of work was given for 10-45 days. The same analgesics and NSAIDs were administered in both groups for two weeks. All patients then received a rehabilitation program conducted by a physiotherapist, using the same protocol as in the PRP group for four weeks.
45992641|NCT02914665|Drug|elamipretide|20 mg elamipretide administered intravenously once daily for 7 consecutive days
45992642|NCT02914665|Drug|Placebo|Placebo administered intravenously once daily for 7 consecutive days
45992643|NCT04927169|Drug|Interleukin-7|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
45992644|NCT04927169|Drug|PLACEBO|IM administration of a volume of saline identical to 10μg/kg CYT107, twice a week for three weeks and up to 7 administrations according to Hospital length of stay
45992645|NCT02914626|Drug|Intravitreal ranibizumab|Intravitreal ranibizumab injection
45992646|NCT02918331|Drug|Daratumumab (16 mg/kg)|Daratumumab (16 mg/kg) will be administered by IV infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.
45992647|NCT02918331|Drug|Lenalidomide|Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle. Participants with creatinine clearance (CrCl) between 30 and 60 milliLitre (mL)/minute (min) will receive lenalidomide 10 mg every 24 hours.
45992648|NCT02918331|Drug|Dexamethasone|Participants will receive dexamethasone 40 mg weekly, at day 1, 8, 15, 22 of each cycle.
45992649|NCT02918058|Other|MedSafer|MedSafer is an electronic tool for the treating team (physician and pharmacists) to facilitate medication deprescription. MedSafer can identify potentially inappropriate medication use and communicate the risk of adverse drug events to the treating team.
45992650|NCT03457961|Drug|Perampanel|This study collects clinical information during the first 16 weeks after the first dose of AMPA/NMDA receptor antagonist. Subjects or caregivers shall provide seizure diary which documents seizure type and seizure frequency as per usual medical care. The final visit will be based on the week-16 visit.
45992651|NCT02914587|Device|ARTAS System|
45992652|NCT02914587|Other|Manual Implantation|
45992653|NCT02938715|Other|teledermatology feedback|subject provided feedback to continue or discontinue their cream (based on actinic keratoses grading and lesion counting)
45992654|NCT02914431|Device|3D Printing Personalized Titanium Plate|The cutting guides were placed onto the planned position. The cutting guides also worked as the drilling guide. Several screw holes were drilled using the predetermined screw holes on the guides. The osteotomy / ostectomy then start. Next, the 3D printing personalized maxillary fixation plates were adapted to reposition the Le Fort I segment to the planned position. The screw holes on the bones prepared by the cutting guides were used as the bony reference. The personalized plate was first firmly installed on the maxilla above the osteotomy line by aligning the corresponding screw holes on the plate to the bone. Afterwards, the position of the osteotomized Le Fort I segment was adjusted till all the remaining corresponding screw holes on bone and plate were aligned.
45992655|NCT02918136|Biological|Adipose derived regenerative cells|
46084431|NCT04853381|Other|dietary treatment (low FODMAP)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
46084432|NCT04853381|Other|dietary treatment (gluten free)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
45992656|NCT02918136|Drug|Cortisone Injectable|
45992657|NCT01294462|Drug|Ticagrelor|90 mg, oral dose twice daily
45992658|NCT01294462|Drug|Clopidogrel|75 mg, oral dose once daily
45992659|NCT01294462|Drug|Acetylsalicylic acid ASA|Low Dose ASA
45992660|NCT01294423|Drug|Dapagliflozin|Dapagliflozin 5mg/matching placebo for Dapagliflozin 10mg oral dose
45992661|NCT01294423|Drug|Dapagliflozin|Dapagliflozin 10mg/matching placebo for Dapagliflozin 5mg oral dose
45992662|NCT01294423|Drug|Placebo|Matching placebo for Dapagliflozin 5mg/10mg oral dose
45992663|NCT02918175|Behavioral|mHealth|Personalized step count feedback and medication teaching tool.
45992664|NCT04841798|Other|[11C]SL25.1188 PET radiotracer|Monoamine oxidase B (MAO-B) occupancy before and after medication treatment using [11C]SL25.1188 PET
45992665|NCT02914353|Drug|EP=7041|Factor X!a Inhibitor
45992666|NCT02914353|Drug|Placebo|Normal Saline
45992667|NCT02938598|Behavioral|Maternal Depression Education and Care-Seeking Motivation|Multicomponent behavioral and educational intervention. The investigators are only testing 3 components: Engagement, Problem-Solving, and Follow-Up Motivation
45992668|NCT02914197|Other|Full information|Patients will be randomized to receive full information or standard information at the study start. The second wave will follow the same randomization process 6 months following the study start.
45992669|NCT02938832|Behavioral|Advice on what food to choose and eat|Dietary advice
45992670|NCT02910570|Drug|Liraglutide 3 mg (Saxenda)|Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks
45992671|NCT02910570|Drug|Liraglutide 3 mg placebo|Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks.
45992672|NCT02910453|Procedure|Pulmonary lobectomy|
45992673|NCT02938754|Behavioral|VR-based motor training|Subjects will perform 3 different training protocols in Virtual Reality that imply performing tasks of vertical and planar reaching and hitting spheres, or hockey pucks, spaced at different time, speed and color.
45992674|NCT02938754|Behavioral|Conventional Therapy|Subjects will perform conventional rehabilitation tasks for the upper-extremities that imply vertical and planar reaching movements.
45992675|NCT02938364|Other|Earplugs|Plastic earplugs on both ears
45992676|NCT02938364|Other|Acupressure|Sea Bands put on the wrists of the participant to apply pressure on P6 points
45992677|NCT02938364|Other|Placebo|Non pressure bands put on the wrists of the participant
45674387|NCT04091464|Behavioral|Backward Walking Training|Training will consist of BW training on both a treadmill and overground. All participants will receive 1x/week training with a trained member of the research team, who will progress the participant week-to-week and ensure safety. Treadmill speed will be determined by baseline BW walking speed and incrementally increased with each training week to subject tolerance. Participants will follow a home exercise program for the remainder of the week that includes BW, backward stepping, and functional exercises that incorporate BW movements.
45674388|NCT04091464|Behavioral|Forward Walking Training|Training will consist of FW training on both treadmill and overground. All participants will receive 1x/week training with a trained member of the research team, who will progress the participant week-to-week and ensure safety. Treadmill speed will be determined by baseline FW walking speed and incrementally increased with each training week to subject tolerance. Participants will follow a home exercise program for the remainder of the week that includes FW, forward stepping, and functional exercises that incorporate FW movements.
45674389|NCT02170025|Drug|Riociguat (Adempas, BAY63-2521)|Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.
45674390|NCT02170025|Drug|Placebo|Participants received matching placebo tid.
45674391|NCT02169791|Drug|MLN9708|MLN9708 will be given weekly x 3 weeks every 28 day cycles, for up to 12 cycles starting at D+5 post-transplant.
45674392|NCT02216591|Device|Active Cognitive Training (ACT)|
45674393|NCT02216591|Device|Control (CON)|
45674394|NCT02216357|Drug|Ifetroban, Oral Capsule|
45992678|NCT01294150|Device|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the United States, European Union, and several other countries (see www.urolift.com). It was developed for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
45992679|NCT01294150|Other|Cystoscopy|The Control Group will undergo cystoscopy.
45992680|NCT01294150|Device|Crossover|Subjects crossed over and received the UroLift System from the Control Group.
45992681|NCT03077685|Drug|NanoPac®|Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.
45992682|NCT04324216|Other|3D virtual reality and hands-on aromatherapy|Participants will receive 8-session 3DVR aroma therapy activities. Each session was delivered over 2 hours once a week, and at each session, the participant received hands-on guidance for preparing an aromatherapy product that they could use for the next seven days.
45992683|NCT02938208|Device|Jupiter Full Face Mask|Full Face Mask for the treatment of obstructive sleep apnea (OSA) using CPAP therapy.
45992684|NCT04832516|Other|Performing following WHO (World Health Organization)|The CLA group will perform exercises following WHO (World Health Organization) prescription
45992685|NCT04832516|Other|Performing on their needs|The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
45992686|NCT02910141|Device|Continuous subcutaneous insulin infusion|Infusion of short-acting insulin from a portable pump
45992687|NCT04817072|Other|Blood sample|Blood sample (20mL) for pro-inflammatory cytokines assay
45992688|NCT02910336|Other|Quantitative Sensory Testing|sensory testing profile
45992689|NCT04817033|Procedure|Spinal anesthesia with intraoperative dexmedetomidine sedation|Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
45992690|NCT04817033|Procedure|Spinal anesthesia with intraoperative midazolam sedation|Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
45992691|NCT04817033|Drug|Dexmedetomidine|Dexmedetomidine 0.5 ug/kg during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
45992692|NCT04817033|Drug|Midazolam|Midazolam 0.25 mg/kg ideal body weight during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
45992693|NCT01292473|Drug|Placebo|Placebo was supplied lyophilized in vials.
45992694|NCT01292473|Drug|Omalizumab|Omalizumab was supplied lyophilized in vials.
45992695|NCT03026049|Device|deep venous stenting|Deep venous stent
45992696|NCT03457883|Device|herniamesh|Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
45992697|NCT03457883|Device|biological graft|Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
45992698|NCT02938247|Dietary Supplement|High caloric, high protein ONS|
45992699|NCT02914002|Behavioral|Psychoeducational intervention|A mobile kitchen visits the 16 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned as well as the importance of cooking at home and having family meals . A printed version of the recipe is given to every participant. Every session participants are encouraged to prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
45992700|NCT02938286|Device|Fractional CO2 laser, 2.5 mJ, 5% density|Pretreatment at 2.5 mJ/microbeam and 5% density. Pain stimulus at 50 mJ/microbeam and 5% density
45992701|NCT02938286|Device|Fractional CO2 laser, 2.5 mJ, 15% density|Pretreatment at 2.5 mJ/microbeam and 15% density. Pain stimulus at 50 mJ/microbeam and 5% density
45992702|NCT02938286|Device|Fractional Er:YAG laser, 9 mJ, 5% density|Pretreatment at 9 mJ and 5% density.
45992703|NCT02938286|Device|Fractional Er:YAG laser, 9 mJ, 15% density|Pretreatment at 9 mJ and 15% density.
45992704|NCT02938286|Device|Fractional CO2 laser, 50 mJ, 5% density|Pain stimulus at 50 mJ/microbeam and 5% density
45992705|NCT02938286|Drug|AHES|Topical application at test region I-IV under occlusion for 15 minutes
45992706|NCT02913963|Device|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
45992707|NCT02913963|Device|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
45992708|NCT01292239|Drug|Placebo|Placebo capsule taken by mouth once daily for 12 weeks
45992709|NCT01292239|Drug|TMC435|100-mg capsule taken by mouth once daily for 12 weeks
45992710|NCT01292239|Drug|Peginterferon alfa-2a (pegIFN alfa-2a)|PegIFN alfa-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks for patients randomized to TMC435 and for up to 48 weeks for patients randomized to placebo.
45992711|NCT01292239|Drug|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is > 60 kg to <=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is <=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
45992712|NCT02938091|Other|High-fat diet|Typical Western diet
45992713|NCT02938091|Other|Low-fat diet|Traditional Caribbean Hispanic diet
45992714|NCT01291225|Other|Playground renovation and development|Playgrounds in Chillicothe will be renovated based on priorities determined by audits.
45992715|NCT01291225|Behavioral|Educational campaign|Educational materials will be developed and distributed in Ross County.
45674395|NCT02216357|Drug|Placebo, Oral Capsule|
45674396|NCT01492426|Drug|Daclatasvir|Film-coated tablet, oral, 60 mg, once daily, 24 weeks
45674397|NCT01492426|Drug|Telaprevir|Film-coated tablet, oral, 750 mg, 3 times daily
46084433|NCT04853381|Other|dietary treatment (low FODMAP+gluten free)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
45674398|NCT01492426|Drug|Peginterferon alfa-2a|Solution for injection, subcutaneous injection, 180 μg, weekly
45992716|NCT02909985|Other|Tungsten halogen light with narrow bandpass filters|As intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band tungsten halogen light source that passes through narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see.
45992717|NCT02909985|Other|ERG|Participants will undergo electroretinography using both normal settings and infrared as the stimuli.
45992718|NCT02909985|Other|VEP|Participants will undergo visual evoke potential tests using both normal settings and infrared as the stimuli.
45992719|NCT02937974|Drug|Xuebijing|Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
45992720|NCT02937974|Drug|Placebo|Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
45992721|NCT05600179|Drug|Dexamethasone intravitreal implant|Dexamethasone intravitreal implant
45992722|NCT05599945|Drug|NNC0581-0001|Participants will receive up to four single dose levels of subcutaneous NNC0581-0001 in a sequential manner with the dose increasing between cohorts.
45992723|NCT05599945|Drug|Placebo|Participants will receive single dose of subcutaneous injection of placebo matched to NNC0581-0001.
45992724|NCT01290796|Device|Ajust Adjustable Single-Incision Sling|The Ajust™ Adjustable Single-Incision Sling is a minimally invasive suburethral sling indicated for the treatment of female SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency (ISD). The system consists of a unique adjustable polypropylene mesh sling with permanent, self-fixating, polypropylene anchors, an introducer, and a flexible stylet for securing the mesh sling after adjustment.
45992725|NCT02937662|Drug|Idarubicin|Idarubicin at a dose of 10 mg/㎡/d on days 1-3.
45992726|NCT02937662|Drug|Cytarabine|Cytarabine at a dose of 100mg/㎡/d on days 1-7.
45992727|NCT02937662|Drug|Cyclophosphamide|Cyclophosphamide at a dose of 350mg/㎡/d on the second day and the fifth day.
45992728|NCT02937662|Drug|Physician-Directed Regimens without Cyclophosphamide|Regimen without cyclophosphamide including FLA±G regimen, DA regimen, AAG regimen, decitabine with AA regimen.
46084434|NCT04853381|Other|dietary treatment (Traditional diet recommendations)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
46084435|NCT02771288|Device|Bioresorbable Vascular Scaffold|
45456958|NCT02298166|Other|Allogeneic stem cell transplantation|"In patients achieving a CR or CRi after salvage-reinduction chemotherapy allogeneic HCT from a matched related or unrelated donor is the preferred form of consolidation. Preferred source of allogeneic HSC are mobilized peripheral blood stem cells. Other forms of allogeneic transplantation (haploidentical donor; cord blood) are allowed.~Allogeneic HCT should be conducted at the earliest time point after the start of the last chemotherapy but no later than after 56 days. A delay of transplant beyond this time window need to be discussed with the Coordinating Investigator. Patients can receive allogeneic HCT directly after salvage re-induction chemotherapy with MC, but also later on following consolidation with IDAC."
45674399|NCT01492426|Drug|Ribavirin|Film-coated tablet, oral, in a body weight stratified dose range of 1000-1200 mg per day
45674400|NCT01453348|Biological|MenACWY-CRM|Novartis meningococcal ACWY conjugate vaccine will be administered intramuscularly (IM) on day 1.
45992729|NCT02909946|Behavioral|Multi-modal Infection Control Program|"Standard precautions and hand hygiene for care of all residents. Enhanced barrier precautions including hand hygiene, glove use, and gown use for HCW when providing ADL assistance for residents at highest-risk (caregiver intervention).~Hand hygiene education to residents and families (resident-level intervention).~Standardized bathing practices including using chlorhexidine-based cloths to reduce resident MDRO colonization (resident-level intervention).~Standardized environmental protocol and education to reduce contamination on inanimate objects and surfaces (environmental intervention).~Feedback monthly of facility-level microbial data and new MDRO acquisition rates to infection control practitioners, HCWs, and facility leadership (facility intervention)."
45992730|NCT01290757|Drug|Dabigatran etexilate|150 mg Capsugel (T)
45992731|NCT01290757|Drug|Dabigatran etexilate|150 mg Qualicaps (R)
45992732|NCT04687956|Procedure|LYMPHA|Axillary reverse mapping is performed before surgery, axillary lymph node resection is performed, and 'LYMPHA' (Lymphatic microsurgical preventing healing approach) is performed, and the surgery is terminated. Subsequently, the occurrence of lymphedema is followed up.
45992733|NCT04687956|Procedure|control|In the control group, axillary lymph node resection is performed and the surgery is terminated without additional procedures. Subsequently, the occurrence of lymphedema is followed up.
45992734|NCT02937857|Drug|Standard treatment only|standard treatment， such as antiasthmatic,expectorant,antipyretic
45992735|NCT02937857|Drug|Standard treatment+Xiyanping injection|standard treatment+Xiyanping injection:standard treatment， such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection,0.2-0.4mL/kg/day,qd for 5 days.
45992736|NCT04324060|Drug|Danazol + rhTPO (recombinant human thrombopoietin injection)|subcutaneous injection, 300U/kg/d×14d every month，stop if the PLT≥100×10e9/L or increased >50×10e9/L, total course is 6 months
45992737|NCT04324060|Drug|Danazol + sodium chloride|Danazol 0.2g tid po+ control (sodium chloride)
45992738|NCT01290718|Drug|capecitabine [Xeloda]|900mg/m2 bid po on days 1-14 of each 3-week cycle
45992739|NCT01290718|Drug|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg iv every 3 weeks
45992740|NCT04324294|Drug|EUS enhanced with contrast to evaluate pancreas|Patients will receive intravenous contrast during EUS to assess whether it improves the evaluation of pancreas.
45992741|NCT02937935|Biological|Protocol Guided Renal Replacement Therapy|In the on-demand group patients would get dialysis only when patient fulfills absolute criteria requiring dialysis such as metabolic acidosis with ph<7.2, hyperkalemia, refractory fluid overload (non-responsive to diuretics) or oliguria with urine output of less than 0.5ml/kg for more than 24-48 hours from the time of randomization.
45992742|NCT02937935|Biological|On Demand Renal Replacement Therapy|Patients to be randomized to the intervention as per standard of care
45992743|NCT04688424|Device|FES|FES will be applied via surface electrodes placed over bilateral quadriceps muscles. FES-stimulation will be ramped from sensory level (the level at which the individual feels a cutaneous sensation from the stimulation) to the maximum-tolerated level using a closed loop system controlled by computer software Subjects will exercise at home, three times per week, with FES on for 8 weeks with a goal of attaining 30 minutes of continuous cycling per session. If the individuals are unable to cycle for 30 continuous minutes, rest breaks will be provided with a goal of cycling for a total of 30 minutes. The length of each session will be approximately 45 minutes, with 15 minutes of set-up and 30 minutes of cycling.
45992744|NCT04688424|Other|Cycling|Subjects will exercise at home, three times per week, without FES for 8 weeks with a goal of attaining 30 minutes of continuous cycling per session. If the individuals are unable to cycle for 30 continuous minutes, rest breaks will be provided with a goal of cycling for a total of 30 minutes. The length of each session will be approximately 45 minutes, with 15 minutes of set-up and 30 minutes of cycling.
45992745|NCT02937896|Drug|Desmopressin|40 micrograms Nasal Desmopressin.
46084436|NCT04791449|Other|Structured exercise program|Medically-supervised participation in 2-3 exercise sessions per week over 12-wk study period. Exercise conducted in the cardiac rehabilitation program.
46084437|NCT02676687|Procedure|total resection|Removing the parenchyma until signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
46084438|NCT02676687|Procedure|supratotal resection|Extended removing the parenchyma at least 1cm beyond signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
45674401|NCT01453348|Biological|Combined inactivated hepatitis A & recombinant hepatitis B|Combined inactivated hepatitis A and recombinant hepatitis B vaccine will be administered by IM on days 1, 8 & 29 for subjects unprimed with hepatitis A and B; and a single booster injection on day 1 for primed subjects.
45674402|NCT01453348|Biological|Recombinant hepatitis B vaccine|Recombinant hepatitis B vaccine will be administered intramuscularly on days 8 and 29
45674403|NCT01453348|Biological|Inactivated hepatitis A vaccine|Inactivated hepatitis A will be administered intramuscularly on days 8 and 29.
45674404|NCT04076410|Device|Z1 lens|CE marked device
45674405|NCT04076410|Device|Experimental Lens 1|CE marked device
45992746|NCT02937896|Drug|Ketorolac|30mg intravenous Ketorolac.
45992747|NCT02937896|Drug|Normal Saline|1cc intravenous Normal Saline.
45992748|NCT02937896|Drug|Normal Saline|4 puffs nasal Normal Saline.
45992749|NCT04688151|Drug|Rituximab|Dose level 1:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO once every day Durvalumab 1500mg infusion once every 4 weeks Dose level 2:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO twice every day Durvalumab 1500mg infusion once every 4 weeks Expansion:Determined by the result of the dose escalation phase
45674406|NCT04076410|Device|Experimental Lens 2|CE marked device
45992750|NCT02937779|Drug|Tenofovir disoproxil fumarate|tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for HBe Ag positive women only.
45992751|NCT02937779|Device|Rapid tests HBe Ag|For all HBs Ag positive women
46084439|NCT02773550|Drug|Bortezomib|Low dose of bortezomib
46084440|NCT02773550|Drug|Melphalan|
46084441|NCT02773550|Drug|Prednisone|
46084442|NCT05230680|Drug|ACHOP|"Phase I Azacitidine D-2~D1, starting from dose level 1. Based on the BOIN design described above, if no DLT is identified in level 1, the dose will be escalated stepwise to levels 2, 3, and then 4.~Azacitidine combined with CHOP regimen every 3 weeks as below:~Level 1 - Azacitidine 50mg/m2 D-2, -1, 1~Level 2 - Azacitidine 75mg/m2 D-2, -1, 1~Level 3 - Azacitidine 100mg/m2 D-2, -1, 1~Level 4 - Azacitidine 125mg/m2 D-2, -1, 1~Azacitidine at each level will be combined with the corresponding CHOP regimen as follows:~Cyclophosphamide 750mg/m2 d1~Doxorubicin 50 mg/m2 d1~Vincristine 1.4 mg/m2 (Max: 2 mg) d1~Prednisolone 100mg PO d1-5~Phase II~Azacitidine determined dose daily for D-2, -1, 1~CHOP (Cyclophosphamide 750mg/m2 d1, Doxorubicin 50 mg/m2 d1, Vincristine 1.4 mg/m2 (Max: 2 mg) d1, Prednisolone 100mg PO d1-5), 6 cycles in total"
46084443|NCT04181073|Device|Jet Nebuliser|Jet Nebuliser
46084444|NCT04181073|Device|Vibrating Mesh Nebuliser|Aerogen Device
46084445|NCT02770976|Device|Increasing and decreasing NAVA levels with 10-min intervals|
45674407|NCT04076410|Device|Experimental Lens 3|CE marked device
45674408|NCT04076410|Device|Experimental Lens 4|CE marked device
45674409|NCT01453036|Procedure|23S rRNA point mutation test of Helicobacter pylori|mutation test group>> Helicobacter pylori polymerase chain reaction kit by dual-priming oligonucleotide-based multiplex polymerase chain reaction system before eradication of Helicobacter pylori at mutation test groupConventional Conventional AOC group, Conventional AOM group >> no intervention
45674410|NCT01453036|Procedure|UBT test & Gastroenterology with biopsy c silver stain|UBT test & Gastroenterology with biopsy c silver stain due to indentify H. pylori infection Conventional AOM group, Conventional AOC group, Mutation test group >> intervention
45674411|NCT01475734|Biological|albiglutide|subcutaneous injection
45674412|NCT01475734|Biological|placebo|subcutaneous injection
45992752|NCT04688229|Device|Hummingbird hand training device plus standard of care rehabilitation|The Hummingbird is a comprehensive hardware and software platform that isolates the hand, wrist, and forearm in a neutral and comfortable position, allowing linear force and angular torque to be measured at the finger-tips between 0-10 Newtons at milli-newton resolution at 100 Hz per digit, in 5 degrees of freedom simultaneously, in real-time, for all 5 digits. The platform allows isolating and characterizing fine resolution forces with sufficient sensitivity and resolution to record data in severe paralysis. The platform also comprises therapeutic software to train exploratory, individuated, and inter-digit complex finger movements by coupling force and torque output to NeuroAnimation physics-based virtual interface in engaging therapeutic experiences.
45992753|NCT04688229|Other|Comparison (sham) intervention|During each hour of sham therapy the therapist will select cognitive tasks (e.g. puzzles and games) targeted to a level of difficulty based on the subjects ability. No grasping or object manipulation using the target upper limb will be included in this intervention. Rather, the participant will use either the unaffected limb (or non-targeted limb for SCI subjects) as needed for any particular puzzle or game.
45992754|NCT04688073|Behavioral|Exercise|Running
45992755|NCT04688073|Behavioral|Rest|sit and rest
45992756|NCT02937428|Behavioral|Look away from the needle|Participant looks away from the needle during vaccination
45992757|NCT02937428|Behavioral|Look at the needle|Participant looks at the needle during vaccination
45674413|NCT01452412|Drug|Sodium bicarbonate|0.4 mEq/kg/day ideal body weight to be taken once a day
45992758|NCT02909790|Device|Curve Low Level Laser Therapy|"Subjects assigned to the treatment group will be treated with 4 multi-paddle low-level diode laser consisting of 8 independent diode laser heads per treatment paddle, each emitting 630-680nm (red) laser light with each diode generating 40mW output (CURVE Laser - manufactured by YOLO Medical Inc.)."
45992759|NCT01290679|Drug|Placebo|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 48 weeks
45992760|NCT01290679|Drug|TMC435|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 24 or 48 weeks
45992761|NCT01290679|Drug|Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)|One subcutaneous (under the skin) injection of PegIFNα-2a (containing 0.5 mL solution with 180 mcg PegIFNα-2a) OR PegIFNα-2b (0.5 mL from a pre-filled pen) once weekly for up to 48 weeks.
45992762|NCT01290679|Drug|Ribavirin (RBV)|200-mg tablets of ribavirin (Copegus or Rebetol) (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
45992763|NCT03457389|Drug|Cabergoline|Cabergoline tablet
45992764|NCT02937467|Device|SWE|a novel ultrasound-based elastographic method, a new real-time, quantitative, operator-independent, and reproducible technique
45992765|NCT02937311|Other|NMES|Participants received NMES using a portable, page-sized battery-powered stimulation device, which delivered current-regulated, charge-balanced, asymmetrical biphasic pulses. The implementation was done on the deltoid and supraspinatus muscles
45992766|NCT02937311|Other|Kinesiotape|The deltoid and supraspinatus muscles were taped in this study to align the shoulder in correct position to facilitate the function and achieve preferred body alignment. For supraspinatus application, Y strip tape was applied from the muscle insertion at the greater tuberosity of the humerus to its origin at the supraspinatus fossa of the scapula while the muscle was in an overstretched position. No tension was applied to the tape. For deltoid application, Y-shaped tape was used by placing the anchor acromion process. The front tail was implemented in the extended arm position, while the back tail was implemented in the horizontal abducted arm position. Both tails ended below the deltoid tubercule of the humerus. No tension was applied during application.
45674414|NCT01452412|Drug|Placebo|To be taken on the same schedule as the active arm
45674415|NCT04409392|Other|Prothestic joint infection due to Staphylococcus lugdunensis|description of prosthetic joint infection with Staphylococcus lugdunensis
45674416|NCT01491802|Drug|LAMA/LABA|GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks.
45674417|NCT01491802|Drug|LAMA|GSK573719 (125mcg) inhalation powder is a long-acting muscarinic antagonist that will be taken once daily for 4 weeks
45674418|NCT02168777|Drug|Refametinib (BAY86-9766)|"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
45992767|NCT02937311|Other|Standardized Physiotherapy|All participants received rehabilitation including Bobath neurophysiological approach. Bobath approach and other exercise programs were implemented early after the onset of the stroke to prevent immobility and soft tissue contracture and to alter the muscle tone to gain mobility. Through the exercise program and use of weight-bearing techniques, the therapist attempted to maintain and improve trunk and shoulder alignment to allow the functional use of the upper extremity.
46084446|NCT04614935|Behavioral|Action Plan|See arm description.
46084447|NCT04436016|Drug|Ivabradine|Ivabradine pills will be crushed and encapsulated for adequate dosing (0, 2.5mg, 5mg or 7.5 mg) and blinding.
45992768|NCT02890186|Device|Narcotrend|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.
45992769|NCT02890186|Other|experience|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
45992770|NCT02909673|Behavioral|Fourth R|Fourth R integrates the promotion of healthy relationship skills and prevention of teen dating violence into existing school curricula so that students receive regular course credit in health. Fourth R is grounded in social cognitive theory in which youth learn to formulate and choose behavior strategies, which translate into knowledge and practice in decision-making, non-aggressive conflict resolution skills, and self-efficacy..
45992771|NCT02937233|Biological|Zika Virus Purified Inactivated Vaccine|
45992772|NCT02937233|Other|Placebo|
45992773|NCT02909751|Drug|Epirubicin 90 mg/m2 iv|Max. 3 months
45992774|NCT02909751|Drug|Cyclophosphamide 600 mg/m2 iv|Max. 3 months
45992775|NCT02909751|Drug|Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv|Max. 3 months
45992776|NCT02909751|Drug|Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)|Max. 3 months.
45992777|NCT02909751|Drug|Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)|Max. 3 months
45992778|NCT02909751|Dietary Supplement|Tocotrienol 300 mg x 3 daily|Max. 6 months
45992779|NCT02909829|Device|Closed Loop Delivery|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm.
45992780|NCT02909829|Device|Closed Loop Delivery with Meal Detection Module|Closed Loop Delivery with Meal Detection Module Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm with an overlying meal detection module which detects missed meals and will increase insulin infusion rates based on a predictive meal detection algorithm
45992781|NCT02909829|Device|Conventional Pump Therapy|Insulin will be delivered by subcutaneous insulin infusion pump with participants usual infusion rate
45992782|NCT02909712|Drug|sulfadoxine-pyrimethamine (SP)|"Women in Groups 1 and 2 will be provided the following SP regimen as directly observed therapy:~3 tablets total of 500 mg sulphadoxine and 25 mg pyrimethamine; 1 day of dosing."
45992783|NCT02909712|Drug|dihydroartemisinin-piperaquine (DHA-PQP)|Women in Groups 3 and 4 will be provided the following DHA-PQP regimen as directly observed therapy 3 tablets of 40 mg dihydroartemisinin and 320 mg piperaquine daily; 9 tablets total; 3 days of dosing.
45456959|NCT02298244|Procedure|PV isolation + GP Ablation|In real time builds the 3D card LA using nonfluoroscopic navigation system.Left and right PVs encircle in 1 lesion line by circumferential PV isolation.Radiofrequency energy delivered at 43◦C,35 W,0.5 cm away from the PV ostia at the anterior wall,and reduced to 43◦C,30 W,1 cm away from the PV ostia at the posterior wall,with a saline irrigation speed of 17 ml/min.Each lesion of ablation continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 seconds.The endpoint of circumferential PV isolation is PV isolation;this confirm when Lasso mapping show the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.To accomplish ganglionated plexi ablation,LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter HFS.Rectangular electrical stimuli were delivered at a frequency of 50 Hz,output amplitude 15V and pulse duration of 10 ms,for 5 sec
45674419|NCT02168777|Drug|Regorafenib (Stivarga, BAY73-4506)|"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 1b dose escalation, regorafenib will be administered in a 3-weeks-on / 1-week-off schedule except in one cohort, that uses regorafenib 2 weeks on / 2 weeks off regimen (dose level -2). In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
45674420|NCT01491178|Drug|Prazaxa|Dabigatran etexilate
45674421|NCT02189837|Biological|Evolocumab|Administered by subcutaneous injection
45992784|NCT02913885|Drug|Curodont Repair|composed of biomimetic regeneration scaffold self-assembling peptides (P11-4) used for remineralization
45992785|NCT02913885|Drug|fluoride varnish|fluoride inhibit the progression of white spot lesion
46084448|NCT04436016|Drug|Placebo|Mannitol will be encapsulated for adequate blinding.
46084449|NCT02676531|Other|Exercise|Walking meditation exercise program
45674422|NCT02189837|Drug|Atorvastatin|Administered by mouth
45674423|NCT02189837|Drug|Placebo to Evolocumab|Administered by subcutaneous injection
45674424|NCT02189837|Drug|Placebo to Atorvastatin|Administered by mouth
45992786|NCT01290601|Drug|Tafenoquine|Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.
45992787|NCT01290601|Drug|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.
45992788|NCT01290601|Drug|tafenoquine|Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.
45992789|NCT01290601|Drug|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
45992790|NCT02978391|Device|UI-EWD Hemostatic system|Adhesive endoscopic hemostats, powder type
45992791|NCT02978391|Drug|epinephrine endoscopic injection (conventional therapy)|endoscopic submucosal injection of epinephrine (1: 10,000)
45992792|NCT01290523|Device|Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere)|Administration of Yttrium-90 TheraSphere glass microspheres into the hepatic artery
45992793|NCT02936882|Procedure|Preoperative gastric ultrasonography|Before surgical emergency procedure, a preoperative antral ultrasonography is performed to assess gastric content.
46084450|NCT02773472|Device|electroacupuncture|The acupoints that will be stimulated are: daheng, tianshu, zhongwan, xiawan, qihai, guanuian, hegu, guchi, zusanli, sanyinjiao, gongsun. An alternating fast-slow frequency of 20Hz/6Hz will be used with an interval of 250msec. The intensity (mA) will be adjusted to a level tolerated by each individual patient.
46084451|NCT02773472|Drug|morphine|Patient will not receive electroacupuncture. Patient will use morphine for analgesia.
45674425|NCT02216123|Drug|Tafenoquine|Tafenoquine will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides. Each tablet will contain 150mg TQ.
45674426|NCT02216123|Drug|Tafenoquine Placebo|Placebo TQ tablets will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides, with common excipients of appropriate quality.
46084452|NCT00637871|Drug|Casodex|150mg once daily
46084453|NCT00637871|Drug|Tamoxifen|
46084454|NCT00635258|Drug|triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain)|0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state.
46084455|NCT00635258|Drug|GnRH antagonist (Orgalutran®)|GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.
46084456|NCT04777019|Other|Not applicable as standard of care Colonoscopy|Not applicable since not an intervention
46084457|NCT00642837|Drug|Tramadol/acetaminophen|Osteoarthritis, flexible dose depending on patients' pain relief
46084458|NCT00642837|Drug|Tramadol/acetaminophen|Post surgical neurophatic pain, flexible dose depending on patients' pain relief
45674427|NCT02216123|Drug|Chloroquine|"One of two formulations of commercially available generic chloroquine may be utilized in this study:~tablets containing 500 mg chloroquine phosphate (equivalent to 300 mg chloroquine free base); or,~tablets containing 250 mg chloroquine phosphate (equivalent to 155 mg chloroquine free base)."
45992794|NCT01290094|Drug|ibandronate [Bonviva/Boniva]|3 mg intravenously every 3 months
45992795|NCT04324957|Other|Neonatal cardio-pulmonary outcome measure used to assess cardio-pulmonary status|Neonatal cardio-pulmonary outcome measure will be used to assess overall status of pulmonaryand cardio-vascular system
45992796|NCT04688346|Drug|HemeRX epinephrine pellets|Racemic Epinephrine Pellet
45992797|NCT02936765|Device|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
45992798|NCT02936765|Device|Anterior cervical discectomy with prosthetic disc replacement / Squale.|Anterior cervical discectomy, with the use of the Squale spacer (Manufacturer: OSD, Avignon, France) for the disc replacement.
45992799|NCT04324333|Behavioral|Digital wearable system|Owlytics Healthcare's system is dedicated to improving the lives of all seniors by using the predictive power of data analytics.
45992800|NCT04688268|Drug|deep neuromuscular blockade|Train of Four=0/4, Post tetanic count 1-2
45992801|NCT02936726|Behavioral|Exercise, Health Coaching and Meditation|Comparing Exercise, Health Coaching and Meditation In Combination
45992802|NCT02936726|Behavioral|Exercise and Health Coaching|Comparing Exercise and Health Coaching Alone
45992803|NCT02913846|Other|Nutritional evaluation|A first nutritional evaluation will be performed within 48h of patient admission. Weight and BMI will be measured once a week.
45992804|NCT02913846|Other|Muscular assessment|An assessment of muscular force will be performed once a week.
45992805|NCT02913846|Other|Pre-albumine dosage|Dosage performed once a month.
45992806|NCT04762589|Drug|RT001|RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 5 months
45992807|NCT04762589|Drug|Placebo|Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
45992808|NCT01289821|Drug|Regorafenib (Stivarga, BAY73-4506)|Subjects will receive regorafenib 160 mg od on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets. In case of administration as a single agent during the study, regorafenib will be administered 160 mg od for 3 weeks on/1 week off. Each cycle consists of 28 days.
45992809|NCT01289821|Drug|Oxaliplatin|On day 1 and day 15 of each cycle, participants will receive 85 mg/m^2 oxaliplatin as a 2 hour i.v. infusion.
45992810|NCT01289821|Drug|Folinic acid|On day 1 and day 15 of each cycle, participants will receive folinic acid (either 400 mg/m^2 D/L-folinic acid or 200 mg/m^2 L-folinic acid) as a 2 hour i.v. infusion.
45674428|NCT02216123|Drug|Primaquine|Commercially available primaquine containing primaquine phosphate united states pharmacopeia (USP), 26.3 mg (equivalent to primaquine base 15 mg) will be utilized in this study. Primaquine, a pink film-coated tablet imprinted W on one side and P97 on the other side. The PQ tablets for this study have been over-encapsulated in a Swedish orange size B supro capsule.
45992811|NCT01289821|Drug|5-FU (mFOLFOX6)|Participants will receive a 400 mg/m^2 5 FU i.v. bolus injection immediately followed by a 2400 mg/m^2 5 FU 46 hour i.v. infusion.
45992812|NCT02913768|Drug|Ondansetron|
45992813|NCT02913768|Drug|Normal saline|
45674429|NCT02216123|Drug|Primaquine Placebo|Placebo to match PQ will be supplied as Swedish orange size B supro capsules with common excipients of appropriate quality.
45992814|NCT03457844|Drug|Anlotinib|Anlotinib is followed Day 1 to day 14 by 7 days off treatment in a 21-day cycle） and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
45992815|NCT03457805|Device|Prostatic Artery Embolization|PAE is performed under local anesthesia using commercially available and approved microspheres (study is not limited to a specific manufacturer or product).
45992816|NCT04690283|Drug|Mimetic granules of Yiqi-Wenjing prescriptions|The intervention relates to a multiple granules, which contains 2.5% concentrated Huangqi-Guizhi-Wuwu decoction (a classical traditional Chinese prescription consists of astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube), 2.5% concentrated Danggui-Sini decoction (a classical traditional Chinese prescription consists of angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root), bitter principle, food colouring and starch.
45992817|NCT04690283|Drug|Huangqi-Guizhi-Wuwu granules|The intervention relates to a traditional Chinese prescription granules, which contains astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube.
45992818|NCT04690283|Drug|Danggui-Sini granules|The intervention relates to a traditional Chinese prescription granules, which contains angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root.
45992819|NCT04747418|Procedure|Diagnostic Hysteroscopy|Collection of first 5 cc of normal saline from the output port during diagnostic hysteroscopy
45992820|NCT04747418|Procedure|Trans-vaginal ultrasound|Trans vaginal ultrasound performed immediately following the diagnostic hysteroscopy ( as sonohysterography)
45992821|NCT02913534|Radiation|whole brain radiotherapy|
45992822|NCT02936804|Device|Low Dose Computed Tomography|LDCT was performed at baseline and 2 rounds of biennial repeated LDCT. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm. The management of abnormal nodules including precision diagnosis by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), electromagnetic navigation bronchoscope (ENB) and peripheral biomarkers, and precision therapy by intraoperative frozen section guided lung resection and ENB radiofrequency ablation.
45992823|NCT02913807|Procedure|Customized Jigs and Plates|The titanium locking reconstruction plates will be prefabricated based on the preoperative CT scans. Prior to procedure, customized planning for osteotomies will generate the prefabricated jigs.
45992824|NCT02913807|Procedure|Hand Contoured Osteotomies and Reconstruction Bars|This will be the traditional method of hand-conjuring the bar and bony sites.
45992825|NCT02936570|Drug|BAY987521|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code:Z09-067)"
45992826|NCT01289782|Drug|Placebo|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 48 weeks
45992827|NCT01289782|Drug|TMC435|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 24 or 48 weeks
46084459|NCT00642837|Drug|Tramadol/acetaminophen|Post traumatic neuropathic pain, flexible dose depending on patient pain relief
45992828|NCT01289782|Drug|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
45992829|NCT01289782|Drug|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
45992830|NCT02913417|Device|SIR-Spheres® Yttrium 90|Patient treatment will consist of three parts: first, selective internal radiation with SIR-Spheres Yttrium-90 microspheres with dosage per package insert , reduced to give 35cGymax to normal liver; second, concurrent ipilimumab 1mg/kg and nivolumab 1mg/kg every 3 weeks for 4 doses (immunotherapy part 1); then maintenance nivolumab at 480 every 2 weeks (immunotherapy part 2) until progression or 3 years
46084460|NCT00642837|Drug|Tramadol/acetaminophen|Spinal Cord Injury, flexible dose depending on patients' pain relief
46084461|NCT00642837|Drug|Tramadol/acetaminophen|Failed Back Surgery Syndrome,flexible dose depending on patients' pain relief
46084462|NCT00642837|Drug|Tramadol/acetaminophen|Diabetic Neuropathy, flexible dose depending on patients' pain relief
45992831|NCT02913417|Drug|ipilimumab|ipilimumab 1mg/kg every 3 weeks x 4
45992832|NCT02913417|Drug|nivolumab|nivolumab 3mg/kg every 3 weeks x 4 then 480mg q 4 weeks
45992833|NCT02936492|Drug|BAY1003803 0.01% lipophilic cream|Topical administration for 22 h per day
45992834|NCT02936492|Drug|BAY1003803 0.1% lipophilic cream|Topical administration for 22 h per day
45992835|NCT02936492|Drug|BAY1003803 0.01% ointment|Topical administration for 22 h per day
45992836|NCT02936492|Drug|BAY1003803 0.1% ointment|Topical administration for 22 h per day
45992837|NCT02936492|Drug|Lipophilic cream vehicle|Topical administration for 22 h per day
45992838|NCT02936492|Drug|Ointment vehicle|Topical administration for 22 h per day
45992839|NCT02936492|Drug|Clobetasol propionate|Topical administration for 22 h per day
45992840|NCT02913573|Device|Ultrasound|Pectoral nerve block is a regional block administered under ultrasound guidance which blocks the nerves of the thorax and chest areas.
45992841|NCT02913573|Drug|0.25% bupivacaine|Pectoral nerve block is a regional block administered under ultrasound guidance where 15 mL of 0.25% bupivacaine is instilled between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
45992842|NCT01289353|Drug|Carboplatin|IV, weekly for 6 weeks, AUC of 2.0
45992843|NCT01289353|Radiation|3D-RT or IMRT|"From week 2 to week 4 in the 6-week Carboplatin treatment:~Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy"
45992844|NCT02913651|Device|Polysomnography|The polysomnography, for both groups, was performed accordance with standard practice
45992845|NCT02936414|Drug|Berberine|Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.
45992846|NCT02936414|Drug|Placebo|Accept placebo(300 mg/tid)+SGAs monotherapy.
45992847|NCT02913300|Drug|Lignocaine 1% concentration solution|
45992848|NCT02913300|Drug|Lignocaine 2% concentration solution|
45992849|NCT02936375|Drug|Iguratimod|25mg twice a day, orally administrated
45992850|NCT02936375|Drug|Cyclophosphamide|1g/m², every 4 weeks, intravenous
45992851|NCT02936375|Drug|Azathioprine|2mg/kg·d, once a day, orally administrated
45992852|NCT02936375|Drug|Steroids|Prednisone, methylprednisolone or prednisonlone, once a day, orally administrated. Steroids should be 1mg/kg·d in the beginning four weeks, then tapered 5-10mg/d every two weeks till 30mg/d, then tapered 2.5-5mg/d every two weeks. After 24 weeks of follow-up, a patient should receive steroids no more than 10mg/d. Patients may receive temporal high dose of steroids (1mg/kg·d) because of symptoms outside of kidney, for no more than two weeks. All the dosage of steroids above is calculated by prednisone.
45992853|NCT02913690|Dietary Supplement|Placebo|2 x 150mg capsules daily
45992854|NCT02913690|Dietary Supplement|TRF|2 x 150mg capsules daily
45992855|NCT01289119|Drug|Alogliptin|Alogliptin tablets
45992856|NCT01289119|Drug|Placebo to alogliptin|Alogliptin placebo-matching tablets.
45992857|NCT01289119|Drug|Metformin|Stable metformin dose
45992858|NCT01289119|Drug|Pioglitazone|Stable pioglitazone dose
45992859|NCT02936336|Other|exercise|circuit exercise, aerobic dance and Tai Chi exercise
45992860|NCT02913378|Procedure|Osteosynthesis with locking plate|Open reduction and osteosynthesis with locking plate
45992861|NCT02913378|Procedure|Sling|Conservative treatment with sling and rehabilitation
45992862|NCT02936141|Behavioral|Group psychotherapy|Includes a group (up to 10 participants) weekly session with a duration of 90 minutes where it is stimulated communication, adaptative behaviour and social living
45992863|NCT02913339|Other|mHealth Risk Assessment|Using mobile phone application to calculate CVD risk and to schedule interviews at local government clinics.
45992864|NCT02936180|Biological|HD-TIV|
45992865|NCT02936180|Biological|SD-QIV|
45992866|NCT01289041|Drug|BKM120|
45992867|NCT02913183|Drug|young Fresh Frozen Plasma|Blood plasma from healthy male donors aged 18-30 years old.
45992868|NCT02913183|Drug|old Fresh Frozen Plasma|Blood plasma from healthy male donors aged 40-55 years old.
45992869|NCT01288729|Device|Sure-T Steel Infusion Set Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
45992870|NCT01288729|Device|Quick-Set Teflon Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
45992871|NCT02936258|Procedure|Standard of Care|Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).
45992872|NCT02936258|Procedure|MRI|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
45992873|NCT02936258|Procedure|MRI Targeted Biopsy|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
45992874|NCT01288612|Device|Sedated Endoscopy|The sedated esophagogastroduodenoscopy procedures were performed using a conventional high-definition endoscope (GIF-180, Olympus America, Center Valley, Pennsylvania) under conscious sedation with intravenous midazolam and fentanyl.
45992875|NCT01288612|Device|Transnasal Endoscopy|Unsedated transnasal endoscopy performed using the EndoSheath transnasal esophagoscope (TNL-5000, Vision Sciences). Topical anesthetic aerosol spray was applied to the posterior pharynx and nasal spray mixture was applied to the patients nares 10-15 minutes before the endoscopy procedure.
45992876|NCT02913027|Other|External Exam|"The pelvic exam will be completed in the following order: external, speculum, bimanual exam in the Standard group. In the Experimental group the pelvic exam will be done with external exam, bimanual exam, then speculum exam."
45992877|NCT02913027|Other|Bimanual Exam|
46084463|NCT00642837|Drug|Tramadol/acetaminophen|Post stroke pain, flexible dose depending on patients' pain relief
46084464|NCT00642837|Drug|Tramadol/acetaminophen|Low back pain, flexible dose depending on patients' pain relief
46084465|NCT00642837|Drug|Tramadol/acetaminophen|Post Herpetic Neuralgia, flexible dose depending on patients' pain relief
45992878|NCT02913027|Other|Speculum Exam|
45992879|NCT04323982|Procedure|new surgical procedure|（ACCC + I / A + PCCC + TA+ A-vit) or （ACCC + I / A + PCCC + IOL + TA + A-vit）
45992880|NCT04323982|Procedure|traditional surgical procedure|（ACCC + I / A + PCCC + A-vit) or （ACCC + I / A + PCCC + IOL + A-vit）
45992881|NCT02936297|Dietary Supplement|High dose Gluten|
45992882|NCT02936297|Dietary Supplement|Low dose Gluten|
45992883|NCT02936297|Dietary Supplement|Lactose free placebo|
45992884|NCT01287832|Drug|Vancomycin|Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
45992885|NCT01287832|Drug|Daptomycin|
45992886|NCT02913066|Other|S-1 concurrent radiotherapy|Radiotherapy 60~66 Gray/28~33 times (50.4~60 Gray /28~33 planning target volume times, 60~66 Gray/28~33 Gross tumor volume of primary tumor), synchronous chemotherapy S-1 70 mg/m2 5 to 1 per week, to the end of radiotherapy. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1, 70 mg/m2, 1~ 14 days, 21 days for a cycle.
45992887|NCT02913066|Other|S-1 plus Cisplatin concurrent radiotherapy|Radiotherapy 60~66 Gray/28~33 times (50.4~60 Gray /28~30 planning target volume times, Gross tumor volume of primary tumor60~66 Gray/28~33), synchronous chemotherapy S-1 70 mg/m2 1~ 14 days and 29 to 42 days, plus cisplatin 25mg/m2 1~ 4 days and 29 to 33 days. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1 70 mg/m2 1~ 14 days, plus cisplatin 25mg/m2 1~ 4 days, 21 days for a cycle.
45992888|NCT00623701|Biological|Allerslit forte|sublingual placebo preparation, daily
45992889|NCT00623701|Biological|Allerslit forte|Sublingual preparation, 40 micro grams Phl p 5 maintenance dose,daily
45992890|NCT02936063|Procedure|Surgical staples|Closure of surgical wound at skin level with surgical staples
45992891|NCT02936063|Procedure|Subcuticular sutures|Closure of surgical wound at skin level with subcuticular sutures
45992892|NCT01287754|Drug|erlotinib [Tarceva]|150 mg daily orally
45992893|NCT02912832|Device|TBDx|The TBDx is an automated platform is based on an Olympus BX41 microscope with a 40 x objective lens, fitted with an Olympus XC 10 colour camera and a movable slide stage, with an attached computer that receives high-quality digital images acquired from the camera. The computer then operates detection algorithms that segment, evaluate, and classify objects of interest in these images which can be stored for subsequent review. The platform is able to integrate an optional 200-slide automated slide loader for high volume settings. The application can capture 100, 300 or more digital fields-of-view and can provide results for positive or negative smears in 5 minutes or less.
45992894|NCT02912793|Drug|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick C1
45992895|NCT02935751|Other|Lab tests for plasma levels of apixaban and anti-10a factor|All patients will have a blood draw at 48 hours prior to elective surgical procedure and then a second blood draw on the morning of the procedure to test apixaban plasma and anti-Xa levels.
45992896|NCT02912871|Other|MRIgHIFU unilateral subthalamotomy|High Intensity focused ultrasound unilateral subthalamotomy: Unilateral thermolesion in the Subthalamic nucleus performed by High Intensity Focused ultrasound
45992897|NCT02935790|Drug|ACY-241|tablet
46084466|NCT00642837|Drug|Tramadol/acetaminophen|Complex Regional Pain Syndrome, flexible dose depending on patients' pain relief
46084467|NCT02777216|Device|ConfidenHT system|ConfidenHT Medical system
46084468|NCT05282849|Procedure|ultrasound guided fascia iliaca block|ultrasound guided fascia iliaca block anesthetizes variable combinations of the femoral nerve , lateral femoral cutaneous nerve , and obturator nerve, and is effective for many painful hip surgeries making it potentially useful for analgesia following Developmental Dysplasia of Hip (DDH) surgery.
46084469|NCT05282849|Procedure|ultrasound guided quadratus lumborum block|ultrasound-guided quadratus lumborum (QL) block provides perioperative somatic, even visceral analgesia for patients including pediatrics, undergoing abdominal or hip surgery. The local anesthetic injected adjacently into the quadrates lumborum muscle spreads in a medial and cranial direction under the crura and arcuate ligaments of the diaphragm, then into the thoracic paravertebral space anesthetizing the hip region
46084470|NCT00613548|Procedure|CABG alone|CABG alone
45833817|NCT03595098|Behavioral|Family Based Cognitive Behavioural Therapy|Family Based Cognitive Behavioural Therapy (FCBT) focuses on the interrelation between thought, emotion, and behaviour, Exposure and Response Prevention, family involvement, homework assignments, and formulating of specific goals for the child. The important, active components is Exposure and Response Prevention. It involves exposing the child to a feared object, situation or thought, and preventing the child from carrying out compulsions to show the child that distress/anxiety can decrease or disappear without performing rituals.
46084471|NCT00613548|Procedure|CABG + Mitral repair|CABG + Mitral repair
45992898|NCT02935790|Drug|nivolumab|infusion
45992899|NCT02935790|Drug|ipilimumab|infusion
45992900|NCT02912637|Other|Hyperpolarized Xenon MRI|MRI & MRS of lung using inhaled hyperpolarized Xenon as a contrast agent
45992901|NCT02912910|Other|Nifedipine|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
45992902|NCT02912910|Other|Labetalol|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
45992903|NCT02935829|Other|Glucose as reference food|Ten subjects (male: 6, female: 4) consumed 25g glucose diluted in 250ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
45992904|NCT02935829|Other|White bread as reference food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from white bread along with 250ml water, two times, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
45992905|NCT02935829|Other|Carob snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from carob snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
45992906|NCT02935829|Other|Chocolate cookie snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from chocolate cookie snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
46084472|NCT04226534|Other|Maximal effort test|Performing a maximal effort test on the treadmill
45992907|NCT02935829|Other|Carob preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g carob snack). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
45992908|NCT02935829|Other|Chocolate cookie preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g chocolate cookie). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
45992909|NCT02912598|Device|Mallinckrodt™ Endobronchial Tube|
45992910|NCT02912598|Device|Fuji Uniblocker™|
45992911|NCT02912598|Device|ETView VivaSight™-SL+EB|
45992912|NCT02912598|Device|COOK© Arndt Endobronchial Blocker|
45992913|NCT02935712|Drug|AZD8601+Placebo (SAD)|"Six subjects are randomized to receive one treatment of AZD8601 and one treatment of Placebo.~Single ascending dose (SAD) with a sequential cohort design and three dose levels of AZD8601 are planned to be investigated. Subjects will receive 0.004 mg per injection of AZD8601/placebo with a total proposed dose of 0.024 mg."
45992914|NCT02935712|Drug|AZD8601+Placebo|Subjects will receive dose with sufficient vascular endothelial growth factor (VEGF)-A protein production and a good safety profile as determined in Part A and the total dose per patient will not exceed the maximum dose given in Part A.
45992915|NCT02935712|Drug|Placebo+Placebo|Subjects are randomized to receive 2 placebo treatments.
45992916|NCT02912754|Drug|ruxolitinib|ruxolitinib will be added to ibrutinib or 3 out of 5 weeks per cycle
45992917|NCT02912754|Drug|ibrutinib|patients will be taking ibrutinib for at least 6 months and will continue to take it at the same dose and schedule while taking ruxolitinib
45992918|NCT02912676|Drug|Thioguanine (oral)|Addition of incremental doses of oral Thioguanine to oral daily 6-mercaptopurine and oral weekly methotrexate maintenance therapy of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Oral 6-thioguanine is added at a starting dose of 2.5 mg/m.sq. with dose increments of 2.5 mg/m.sq. at two weeks intervals until a maximum dose of 12.5 mg/m.sq. of 6-thioguanine is given or dose-limiting toxicity occurs.
45992919|NCT02912481|Procedure|posterior tibial artery|
45992920|NCT02912481|Procedure|radial artery|
45833818|NCT03595098|Behavioral|Family Based Psychoeducation/Relaxation Training|Family-based Psychoeducation/Relaxation Training (FPRT) as an active control matches the experimental intervention as closely as possible, many elements of the control intervention are similar to FCBT. The main and intended difference between the two approaches is the absence of the Exposure and Response Prevention component, which is deemed the most effective treatment for OCD.
45992921|NCT02912481|Procedure|dorsalis pedis artery|
45992922|NCT02935985|Other|Point-of-care bio-markers (cTnI, hsCRP, D-Dimer) and biological parameters (CBC, glucose, cholesterol, LDL cholesterol, triglycerides, fibrinogen)|"Clinical evaluations will be performed, along with collecting venous blood samples for determining point-of-care bio-markers and biological parameters.~Participants will be assessed (clinically or by telephone) over a period of 180 days."
45992923|NCT02935439|Other|Cell Phone|Participants responded to questions about their heart failure symptoms using a cell phone.
45833819|NCT03216486|Drug|BPS804|IV administration of BPS804 in 5% Dextrose solution
45992924|NCT02912169|Procedure|Liposuction under local anesthesia|Procedure will be performed via liposuction to harvest Adipose-derived stromal vascular fraction cells.
45992925|NCT02912169|Biological|Infusion of AD-SVF via IV and Intranasal|IV and Intranasal Infusion of isolated AD-SVF
46084473|NCT05252273|Other|Observational, No intervention|Open-label observational study that will evaluate the reliability and responsiveness of patient-reported symptoms and endoscopic and histologic items for assessing pouchitis disease activity in 43 patients undergoing standard of care (SOC) antibiotic therapy.
46084474|NCT05608863|Other|Lifestyle - group sessions|The Combined Lifestyle Intervention Program consists of a total of 7 individual coaching sessions and 16 group sessions in a 2 year program. The individual coaching sessions will be done in a virtual setting.
45992926|NCT02912520|Drug|Anti-Bacterial Agents|administration of any antibiotic substance(s) over the course of 2 weeks
45992927|NCT02935166|Other|Respiratory muscle training|General high-intensity training consists in maximum effort intervals of 30 seconds duration against an equivalent resistance 0.075 kg / kg of body mass followed by a recovery period of 4 minutes cycle ergometer; the total duration was 3 weeks. They were made in this regard, five weekly sessions of 30 minutes per session, Additionally, randomly, the patients were divided into one of 3 possible groups of respiratory training, which consisted of 5 sets of 10 full breaths (inspiration and expiration) in the morning and afternoon during 3 weeks.
45992928|NCT02935959|Drug|nebulized ketamine|Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of 100% oxygen at 6 L/min for 10 to 15 minutes (30 minutes before GA). Treatment will be stopped when the nebulizer began to sputter.
45992929|NCT02935959|Drug|nebulized Dexmedetomidine|
45992930|NCT02935959|Drug|nebulized midazolam|
45992931|NCT02935127|Procedure|Absorbable suture|Vascular anastomoses will be performed with absorbable materials
45992932|NCT02935127|Procedure|Non-Absorbable suture|Vascular anastomoses will be performed with non-absorbable materials
45992933|NCT02912286|Device|conventional needle irrigation|conventional side-vented syringe used to deliver irrigant in root canal treatment
45992934|NCT02912286|Device|passive ultrasonic irrigation|ultrasonic tip (IrriSafe) activate the irrigant after mechanical preparation in root canal treatment
45992935|NCT02912286|Device|sonic irrigation|vibringe system is a sonic device that deliver and agitate the irrigant
45992936|NCT02912325|Dietary Supplement|Daily administration: 2 tablets FaseMETS a day|Treatment with FaseMETS for 6 consecutive months in lowering serum lipids and glucose in subjects with Metabolic Syndrome
45992937|NCT02935322|Drug|0.12 % chlorhexidine + 0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
45992938|NCT02935322|Drug|0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
45992939|NCT02935322|Drug|0.12% chlorhexidine|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
45992940|NCT02935322|Other|Placebo|"Contained all basic ingredients as the other three mouthrinses but no chlorhexidine and no NaF. In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned solution twice daily after tooth brushing during a 6-week period."
45674430|NCT02189759|Other|Continuous Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
45674431|NCT02189759|Other|Standard Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
45992941|NCT02912130|Dietary Supplement|Protein Supplementation|1.2-1.5g/kg/body weight per day
45992942|NCT02912130|Other|Aerobic Exercise|30-60 minutes per week of moderate intensity exercise
45992943|NCT02912130|Other|Resistance Exercise|60 minutes per week of progressive resistance training
45992944|NCT02935049|Procedure|Endoscopic resection|Endoscopic resection with technique EMR piecemeal or hybrid technique EMR/ESD
45992945|NCT02934893|Other|Medication Management Clinic|referral to medication management clinic from primary care
45992946|NCT02934893|Other|Diabetes+Me plus connected glucometer|Use of software and medication modeling tool as add on to medication management standard of care
45992947|NCT02935647|Drug|Diprivan|
45992948|NCT02934815|Other|Supportive-expressive group therapy|The supportive-expressive group therapy (SEGT) is an intervention for women with BC that is designed to build bonds and to facilitate changes in emotional expression and regulation taking into account the role that emotions play in physiologic function, intimately related to the progression of the disease. It is based on seven main themes: building bonds, expressing feelings, detoxifying dying, reordering life priorities, improve support from and communication with family and friends, fortifying families, dealing with doctors, and control pain and anxiety. Although originally developed according to an existential perspective, recently the supportive-expressive group therapy has been used according to an attachment framework.
45992949|NCT02912247|Drug|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, 40mg,subcutaneous injection,once
45992950|NCT02912247|Drug|adalimumab|adalimumab, 40mg,subcutaneous injection,once
45992951|NCT02935491|Device|Transcatheter Aortic Valve Implantation (TAVI)|"TAVI is a well-accepted method for aortic valve replacement without surgery. It is currently proposed to patients at high surgical risk or contraindicated to surgery. It consists of introducing a valve inserted inside a stent by the femoral artery in most cases.~Aortic calcifications will be determined by the analysis of the CT-scan performed systematically before the procedure. A semi-automated software (CreaTools) will be used"
45992952|NCT02935010|Drug|Esomeprazole|proton pump inhibitor
45992953|NCT02935010|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
45992954|NCT02935010|Drug|Amoxicillin|antibiotic for H. pylori eradication
45992955|NCT02935010|Drug|Clarithromycin|antibiotic for H. pylori eradication
45992956|NCT02935010|Drug|Metronidazole|antibiotic for H. pylori eradication
45992957|NCT02935010|Drug|Levofloxacin|antibiotic for H. pylori eradication
45992958|NCT02912013|Device|Me Mini|Home use hair removal device
45992959|NCT02934776|Device|MRI machine|The Philips Ingenia 3.0T is an MRI machine intended to be used by specialist radiologists in the hospital. It is able to acquire high quality images of wide variety of organs. For imaging the prostate, T2-weighted turbo spin-echo images are normally obtained in three orthogonal planes (axial, sagittal and coronal). This device is been clinically used in the MRI department in Belinson hospital.
45992960|NCT02911974|Device|Acquire EUS Biopsy Device|1. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
45992961|NCT02911974|Device|Expect EUS Aspiration Needle|1. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
45992962|NCT04690244|Other|Tai Chi Chuan trainings|10 weeks of Tai Chi Chuan practice by 6-year experienced training teacher, 2 times per week, 60 min per session.
45992963|NCT02935569|Device|Compression HeadBand|"commercially available office rubber bands (Alliance® Sterling Rubber Bands, Size 105) OR commercially available medical non-latex bands (Allegience® 1 x 18 x .025) with Velcro adhesion~Plastics disks, hollow (3.5 cm diameter, by 1 cm height)~Two bands will be placed just behind the ears laterally, and over the occipital protuberance posteriorly. The plastic inserts will be placed in the temporal fossae bilaterally, under the band to provide adequate tension on the temporal artery."
45833820|NCT04110522|Other|Direct to patient PsA Screening Questionnaire|Patients randomized to an intervention group will be asked to complete and score the 5-item Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Those patients with an elevated score (PEST ≥3 out of 5) will be advised to complete a rheumatologic evaluation for PsA.
45992964|NCT04690166|Other|The speech records related to the reading document|"The document consists bit, bet, but words and Diyet passage. Volunteers will read the document in front of the microphone and also the speech will recorded by a computer."
45992965|NCT02935530|Drug|s-LMWH|2125KU, subcutaneous injection of 5-10 days
45992966|NCT02935530|Drug|LMWH|4250KU, subcutaneous injection of 5-10 days
45992967|NCT02935530|Drug|Argatroban|20mg, injection for 5-10 days
45992968|NCT02934737|Other|Progression of diabetes|
45992969|NCT02935608|Drug|BIIB074|Administered as specified in the treatment arm
45992970|NCT02935608|Drug|Placebo|Matched placebo
45992971|NCT02935803|Procedure|Trans-vaginal Mesh operation|Modified the transobturator TVM operation reported by Sergent et al. by inserting a stabilizing suture, which fixing the anterior edge of the mesh to the paraurethral tissues at the level of the mid-urethra with two non-resolvable anchoring stitches thereby promoting the proper elevation and closure of the urethra
45992972|NCT02934386|Device|WinMedical WinPack device|
45833821|NCT03189420|Procedure|Tumor resection|The tumors will be resected in routine therapeutic surgeries
45833822|NCT03166098|Diagnostic Test|Cognitive Function Assessments|The NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) is a consensus battery that is considered state-of-the art in the evaluation of cognitive skills for schizophrenia research.(Burton et al., 2013, Harvey, 2014) The complete cognitive battery takes about one hour to administer, and is comprised of 10 subtests measuring seven essential domains of function, with very good reliability and validity.(Nuechterlein 2008, August et al., 2012) The MATRICS subtests have been incorporated into the cognitive battery described below, with supplementary subtests included where indicated within each domain.
45833823|NCT03087162|Drug|Dexlansoprazole 60 mg once daily|Once daily dose dexlansoprazole(Dexlansoprazole(60) OD) in experimental arm and Twice daily dose dexlansoprazole(Dexlansoprazole(60) 1 BID) in active arm
45833824|NCT03165942|Other|Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
45833825|NCT03165942|Other|Non-Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
45833826|NCT03165942|Drug|Ethanol|
45992973|NCT02912052|Drug|Peri-operative chemotherapy|Patients receive 2 cycles of chemotherapy before surgery,and contniue to receive another 4 cycles of chemotherapy 21-28 days later after surgery.The chemotherapy regime is XELOX(oxaliplatin130mg/m2 ivd d1 + Capecitabine1000mg/m2 po bid d1-14, 21d/cycle)
45833827|NCT03164460|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT/IMPT
45833828|NCT03164460|Radiation|Proton Radiation|Undergo IMRT/IMPT
45833829|NCT03164460|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45992974|NCT02912052|Drug|postoperative chemotherapy|Patients receive 6 cycles of chemotherapy 21-28 days later after surgery.The chemotherapy regime is XELOX(oxaliplatin130mg/m2 ivd d1 + Capecitabine1000mg/m2 po bid d1-14, 21d/cycle)
45992975|NCT02934620|Device|CSD500 Condom|CSD500 is a commercial condom that complies fully with the requirements of ISO 4074, the international standard for male latex condoms. The product is designed to increase sexual pleasure.
45992976|NCT02934620|Device|Standard Condom|The standard condom is a standard condom in Vietnam at the time of the study. It is provided for pregnancy and disease prevention.
45992977|NCT02934620|Behavioral|Condom Counseling|The intervention arm will receive counseling that briefly addresses condom's dual protection against pregnancy and HIV/STI but that otherwise emphasizes the potential for increased sexual pleasure with CSD500 use. Counseling to this arm also will include CSD500-specific instructions, such as the need to briefly massage the gel inside the condom teat onto the penis head after donning the condom and to not use multiple condoms within a 24-hour period. The control arm will receive standard counseling to use condoms for pregnancy and disease prevention without receiving any messages about the use of condoms for sexual pleasure.
45992978|NCT02935881|Device|Radio Frequency Ablation (RFA) (Stretta Procedure)|Radio Frequency Ablation (RFA) for the treatment of refractory gastroesophageal reflux disease.
45992979|NCT02935881|Procedure|Sham Procedure|Stretta device will be used but Radio Frequency Ablation (RFA) will not be generated.
45833830|NCT04103892|Drug|CLE-100|1 tablet of CLE-100 administered once daily
45992980|NCT02934464|Drug|RAMUCIRUMAB|
45992981|NCT02934464|Drug|Paclitaxel|Paclitaxel
45992982|NCT02934464|Drug|FOLFOX 4|
45992983|NCT02934464|Drug|mFOLFOX 6|
45992984|NCT02934464|Drug|XELOX|
45992985|NCT02946879|Biological|AAV OPTIRPE65|comparison of different doses of AAV RPE65
45992986|NCT02934542|Device|AutoLap system|
45992987|NCT02935413|Device|tDCS|Device: verum tDCS real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes Behavioral: VRT Vision restoration training, 10 sessions, 20 minutes
45992988|NCT02935413|Behavioral|Standard rehabilitation|Standard rehabilitation procedures involving PC-based training of saccades and visual exploration
45992989|NCT02934425|Other|Refined carbohydrate-rich breakfast|Refined carbohydrate-rich breakfast containing approximately 8/66/26% kcal from protein/carbohydrate/fat, respectively
45992990|NCT02934425|Other|High pork protein breakfast|High pork protein breakfast containing approximately 35/39/26% kcal from protein/carbohydrate/fat, respectively
45992991|NCT02935218|Behavioral|Parenting Skills for Mothers with BPD|The cognitive-behavioral Group Training for mothers with BPD consists of 12 weekly sessions promoting parenting skills including primary needs of children, stress and stress management, dealing with conflicts, mindfulness, emotion regulation, routine and flexibility, the role of the body in parenting, basic assumptions about parenting, and self-care.
45833831|NCT04103892|Drug|placebo|1 tablet of placebo administered once daily
45992992|NCT02934308|Device|Skin Conductance Monitor|
45992993|NCT02934269|Drug|Placebo|
45674432|NCT02189759|Other|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
45992994|NCT02934269|Drug|CC-90006|
45992995|NCT02788461|Radiation|Chemoradiotherapy|Patients will receive radiotherapy of 60Gy in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
45992996|NCT02788461|Radiation|Chemoradiotherapy with Integrated Boost Dose|Patients will receive an RT integrated boost to tumor subvolumes (max boost dose of 85Gy) in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
45992997|NCT02934035|Drug|Antidepressant|
45992998|NCT02911740|Other|Urine LAM Ag test|TB diagnostic assay
45992999|NCT02934152|Drug|H pylori eradication|H pylori eradication
45993000|NCT02934152|Other|H pylori eradication timing|Early or late eradication
45833832|NCT03163992|Drug|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
45833833|NCT04397328|Drug|Hydroxychloroquine|Hydroxychloroquine vs placebo (1:1 design) double blind intervention
45833834|NCT04397328|Drug|Placebo|Hydroxychloroquine vs placebo (1:1 design) double blind intervention
45993001|NCT02935296|Behavioral|Integrated Intervention|systems navigation, psychosocial counseling
45833835|NCT04101630|Behavioral|Activity Monitoring|Monitoring with FitBit
45993002|NCT02934074|Other|No intervention|
45993003|NCT02911779|Procedure|change of medilateral angle line during crowning of the head|change of medilateral angle line during crowning of the head
45993004|NCT02934113|Behavioral|iOTA|The Individual Obesity Treatment Approach (iOTA) will assess individual behavior risks, collaborative goal-setting with a health coach, and the use of an interactive text system to provide ongoing support and self-monitoring of behavior change goals.
45993005|NCT02934113|Behavioral|HWPP|Work groups will participate in the Healthy Workplace Participatory Program (HWPP) to adapt and deploy interventions that change their work environments to support healthy eating and physical activity.
45993006|NCT02935335|Drug|Menotrophin|
45833836|NCT04100538|Behavioral|health coach|"The health-coaching program includes (1) my file, (2) lesson, (3) self-assessment, and (4) interaction modules. My file allows participants recording their disease history. The lesson includes knowledge of fibromyalgia, stress and relaxation, emotion and positive thinking, sleep hygiene, communication skills, and exercise. The self-assessments includes symptom diary, exercise and general diary. The interaction encourages participants interacting with peers and the health coach. Participants can share practical advices, strategies, real-life examples or questions via texts or photos in share garden. Participants can connect to the health coach via contact with health coach. The coach will provide comments or responses approximately 10-30 min for each time. The coach will monitor each participant's lesson list and attendance for each lesson. The health coach will also guide the participants to create their own tailored programs according to participants' predominant symptom subtypes."
45993007|NCT02933996|Device|TEAS+GA group|The acupoints including Zusanli and Shenshu, were identified before electrical stimulation with surface electrodes. Selection of these acupoints was based on a consensus between the acupuncturists of the study.
45993008|NCT02933996|Device|Sham TEAS+GA group|No electrical stimulation sensation is performed in the Sham TEAS group. In the Sham TEAS group, pseudo-stimulation is provided by deliberately connecting the electrodes to the incorrect output socket of the electroacupuncture device, and thus there is no flow of electric current. Patients could see the output light flashing but no current was transmitted throughout the procedure. Patients would be told that the stimulation frequency selected was not perceivable by human beings.
45993009|NCT02934230|Behavioral|Prehabilitation Program|"Strength training: This component consists of 1 set of 10 repetitions of each exercise: a. push-ups (modified to the individual's level of function as either wall push-ups, knee push-ups, or full push-ups); b. seated row (performed with an elastic resistance band); c. chest fly (performed with an elastic resistance band); d. deltoid lift (performed with an elastic resistance band); e. biceps curls (performed with an elastic resistance band); f. triceps extensions (performed with an elastic resistance band); g. chair squats; h. hamstring curls; i. standing calf raises; j. abdominal crunches (modified to be performed seated in a chair)~Aerobics: Walking for 20 minutes at moderate intensity.~Flexibility: Chest, arm, leg and truck stretches, with each stretch to be held for 20 seconds, done for 2 repetitions."
45993010|NCT02933918|Other|Probiotics|Safety of nasal irrigation with probiotics in healthy volunteers
45456960|NCT02298244|Procedure|PV isolation + GP ablation + Pulmonary GP ablation|"The procedure of AF ablation is the same like in the circumferential PV isolation + GP Ablation.~8-Fr sheath is carried through the right heart into the pulmonary artery trunk. Using ablation electrode constructed 3D map of the pulmonary artery trunk and the right and left main branches. Further HFS performed with the tip ablation electrode at the bifurcation of the pulmonary artery and in the ostium of the left and right pulmonary arteries (less than 2 mm distal to the bifurcation) 20 Hz, duration of each stimulus 10 ms. A positive response would be considered an increase in the RR interval of more than 50% of baseline within 10 seconds. In areas with a positive response to HFS, will be performed RFA Efficiency criterion: no previously described responses to HFS in the ablation area. Parameters RFA: 8-10 watts for 60 seconds duration at one point, the irrigation speed of 5 ml / min."
45456961|NCT03932149|Device|Intermittent Theta Burst Stimulation (iTBS)|The target is left DLPFC and the iTBS protocol is: 70% of RMT; triplet 50 Hz bursts, repeated at 5 Hz; 2s on and 8s off; 600 pulses a session.
45456962|NCT03932149|Device|Sham stimulation|The target is right DLPFC and the sham stimulation protocol is: triplet 50 Hz bursts, repeated at 5 Hz; 2s on and 8s off; 600 pulses a session.
45456963|NCT03520426|Device|Votiva RF|The Votiva system is approved by the U.S. Food and Drug Administration for treatment of sexual dysfunction as well as in combination with Kegel exercises for tightening of the muscles of the pelvic floor to increase muscle tone. One part of the system, the fractora handpiece, is approved for tissue coagulation for the purpose of skin rejuvenation. The Votiva has two hand pieces, Forma and Fractora, which have been cleared by the United States Food and Drug Administration (FDA) and are used during dermatological procedures.
45833837|NCT03163602|Drug|Control group|Access flap and debridement
45833838|NCT03163602|Device|Test group|Regenerative treatment
45993011|NCT02933840|Device|AlertWatch|AlertWatch holds 510(k) FDA clearance K15335. It is a software program that takes data present in the medical record, including vital signs and laboratory results, and determines whether it meets predetermined thresholds for alerting a clinician. These thresholds are intended to correlate with signs of acute clinical deterioration in the patient being monitored.
45993012|NCT02911662|Drug|Cephalexin|Cephalexin will be prescribed for women with a positive urine culture but no symptoms of urinary tract infection.
45993013|NCT02911662|Drug|Nitrofurantoin|Macrobid will be prescribed for women allergic to penicillin with a positive urine culture but no symptoms of urinary tract infection.
45993014|NCT02933723|Procedure|Blood Draw|Sampling 3 blood draws Day 0 for humoral and CMI 30 ml prior to vaccination (up to 2 week prior to vaccination) Day 7 for CMI 20 ml (+/- 1 day) Day 28 for humoral 10 ml (+/- 3 days)
46084475|NCT05608863|Other|Lifestyle - individual coaching|The Individual Intervention consists of a total of 7 individual coaching sessions in a 2 year program and additional written information. These will be done in a virtual setting.
45833839|NCT03162432|Drug|Vitamin D3|Oral Vitamin D3 therapy.
45993015|NCT02911623|Device|Shockwave Lithoplasty® System|The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
45993016|NCT02935101|Drug|Prednisolone|formulated for oral administration. encapsulated.
45993017|NCT02935101|Drug|Placebo (for Prednisolone)|Sugar pill manufactured to mimic Prednisolon 10mg capsules
45993018|NCT04689971|Drug|Standard therapy|Gabapentin, pregabalin, or amitriptyline
45993019|NCT04689971|Drug|Vitamin B combination|Vitamin B combination (B1 100 mg, B2 200 mg and B12 200 mcg) tablet once daily
45993020|NCT02934945|Drug|budesonide 160μg/formoterol 4.5μg|SMART regimen
45993021|NCT02933762|Drug|JNJ-54175446|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
45993022|NCT02933762|Drug|Placebo|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
45993023|NCT02933645|Drug|Actrapid|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays or 160 IU of fast-acting human insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray.
45993024|NCT02933645|Drug|Placebo|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.
45993025|NCT02933645|Radiation|[18F]-FDG PET-CT|All subjects will undergo two positron emission tomography (PET) studies. On both visits they are injected with 185 MBq [18F]-fluorodeoxyglucose and scanned with a combined PET and computed tomography scanner.
45993026|NCT02933645|Drug|Hyperinsulinemic euglycemic clamp|All subjects will undergo two hyperinsulinemic euglycemic clamp studies. The insulin infusion will be administered intravenously at a steady rate of 0.25 mU/kg/min for approximately 170 minutes. Glucose will be administered intravenously as a 200 mg/ml fluid to at varying rate to maintain euglycemia.
45993027|NCT02911701|Drug|Acetaminophen|
45993028|NCT02911701|Drug|Ibuprofen|
45993029|NCT02933567|Other|CSC OnDemand|CSC OnDemand is a multifaceted online learning product that includes four levels: 1) an online readiness tool and CSC Learning Hub; 2) dynamic multimedia core curriculum on first episode psychosis and CSC; 3) live faculty-led online courses; and 4) ongoing support, including an online community of practice to support peer-to-peer learning.
45993030|NCT02933684|Drug|Seromycin|Seromycin (aka D-cycloserine) is an analogue of D-alanine and a partial agonist at the NMDA receptor, which facilitates the process of fear extinction.
45993031|NCT02933684|Behavioral|Virtual Reality Exposure Therapy|Allows for delivery of exposure therapy on an iPad. Participants read a speech to a virtual audience. Exposures become increasingly more difficult as the audience becomes more hostile and speeches increase in length and complexity.
45993032|NCT02933684|Drug|Placebo|Administered in pill form.
45993033|NCT02934867|Other|Protocol phone advice|Protocol phone advice
45993034|NCT02934867|Other|Usual phone advice|Usual phone advice
45993035|NCT02933333|Biological|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils.
45993036|NCT02933333|Biological|G-CSF|Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. G-CSF is a relatively specific stimulator of the growth and differentiation of hematopoietic progenitor cells committed to the neutrophil lineage.
45993037|NCT02933333|Biological|GM-CSF and G-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF and G-CSF share a number of biologic activities, GM-CSF seems to be more potent against fungi.
46084476|NCT02776748|Drug|FTC/TDF PrEP|Daily oral directly observed FTC/TDF PrEP administered to breastfeeding HIV-uninfected women
45993038|NCT02911584|Procedure|Laparoscopic procedure|
45993039|NCT02933294|Procedure|Triportal pulmonary resection surgery|Uniportal video-assisted thoracoscopic surgery
45993040|NCT02933294|Procedure|Uniportal pulmonary resection surgery|Triportal video-assisted thoracoscopic surgery
45993041|NCT02934828|Drug|Neoadjuvant Chemotherapy|Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year.
45993042|NCT02934828|Drug|postoperative chemotherapy|postoperative chemotherapy: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
45993043|NCT02670252|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
46084477|NCT02676609|Device|Automated carbohydrate and meal insulin dose computing|Use of smart phone application will compute carbohydrate amount and meal insulin dose according to individual meal insulin/carbohydrate ratio.
46084478|NCT02693496|Other|Installation or registration of smartphone application|Completed the installation and registration of mobile terminal software online
45456964|NCT01127269|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
46084479|NCT02771054|Drug|TAF/FTC|Change of nucleoside backbone
46084480|NCT00642915|Drug|Lantus, Amaryl|
46084481|NCT02676297|Drug|tiotropium|four inhalations
45993044|NCT02670252|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
45993045|NCT02670252|Radiation|Total Body Irradiation (TBI)|Total Body Irradiation was given 4.5 Gy TBI/day on days -5 and -4.
45993046|NCT02933177|Behavioral|2 months control condition - 4 months chariot-flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~Boards of known photographs to recall autobiographical memories~Newspapers to read, talk, associate memories around an article~Massage Oil, refreshing wipes, cream to reconnect with the body~Clay, cookie pieces, washable felt and paper to create shapes, draw.~Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~Listening to music~Relaxation-Breathing~Cushion, foam balls to vent his energy on secure hardware.~Plush doll or to invest a vector object of affection and empathy~Sensory flash balls that the patient can squeeze, throw, roll.~Games with which the patient can play according to its possibilities."
45993047|NCT02933177|Behavioral|4 months control condition-2 months chariot flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~Boards of known photographs to recall autobiographical memories~Newspapers to read, talk, associate memories around an article~Massage Oil, refreshing wipes, cream to reconnect with the body~Clay, cookie pieces, washable felt and paper to create shapes, draw.~Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~Listening to music~Relaxation-Breathing~Cushion, foam balls to vent his energy on secure hardware.~Plush doll or to invest a vector object of affection and empathy~Sensory flash balls that the patient can squeeze, throw, roll.~Games with which the patient can play according to its possibilities."
45993048|NCT02911467|Drug|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
45993049|NCT02911467|Device|MRI|MRI scan following the Pyruvate injection
45993050|NCT02934789|Procedure|Hysteroscopic myomectomy with Truclear|Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).
45993051|NCT02934789|Drug|Medical therapy|Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids.
45993052|NCT02933099|Drug|Aprepitant+palonosetron+dexamethasone|Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus palonosetron 0.25 mg IV and dexamethasone (20 mg orally on day 1 and 8 mg orally on days 2 and 3)
45993053|NCT02933099|Drug|palonosetron+dexamethasone|Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: palonosetron 0.25 mg IV and dexamethasone (12 mg orally on day 1 and 8 mg orally on days 2 and 3)
45993054|NCT02935023|Radiation|CIRT with systemic therapy arm|carbon ion radiotherapy to the prostate(59.2GyE/16Fx to prostate and seminal vesicle) Systemic therapy:Hormonal therapy (LHRH agonist and/or antiandrogens) or chemotherapy
45993055|NCT02911506|Other|Polysomnography|
45993056|NCT02934906|Procedure|Standard clinical treatment, including intravenous immunoglobulin and/or platelet transfusion|Observational study.
45993057|NCT02911350|Drug|Hormone Suppressors|
45833840|NCT03084354|Other|Semi-structured interviews|Semi-structure interviews to gain a deep understanding of women's experiences of maternity bladder care. Interviews will last between thirty minutes to a couple of hours and they will be digitally recorded and transcribed verbatim.
45833841|NCT04398576|Behavioral|Training and support|GP's receive the tools to make early identification of harmful and hazardous alcohol use possible. They are given guidelines to apply a brief intervention. At the start of the study, the T&S-group receives two face-to-face educational trainings of two hours each. Another two face-to-face booster sessions will follow at 6 and at 12 months.
45833842|NCT04398576|Behavioral|Community actions|There will be embedded community-based actions within a local strategy.
45993058|NCT02911350|Drug|Paclitaxel|
45993059|NCT02911350|Radiation|Radiation Therapy|
45456965|NCT03932227|Device|Cardioskin|Subjects will have a 24h recording with Cardioskin, next will be unequipped.
45833843|NCT03081468|Device|Binocular OCT prototype|Participants in the study will undergo pupil measurement using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA). For the binocular OCT imaging system, testing will be performed twice in the same session, by the same examiner, to allow assessment of repeatability (test-retest variability).
45833844|NCT03081468|Device|Konan RAPDx|Participants in the study will undergo pupil measurement using a validated, commercially available pupilometer (RAPDx; Konan Medical USA, Inc., Irvine, CA).
45993060|NCT04623983|Device|bonding tray|Orthodontic bonding tray
45993061|NCT02911428|Procedure|blood sampling collection|It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
46084482|NCT02537535|Other|survey|This is a cross-sectional study without specific intervention
46084483|NCT02776592|Other|Cow's milk-based formula with added nutrients|
46084484|NCT02776592|Other|Cow's milk-based formula|
46084485|NCT04180761|Drug|intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC)|single dose application of hyperthermic intraperitoneal chemotherapy (HIPEC) at 42.5°C for 60 minutes after the gastrectomy
45833845|NCT03392376|Drug|Haloperidol Injection|ICU patients with diagnosed delirium are treated with 2,5mg haloperidol x 3 daily intravenously with additional as needed doses to a maximum of 20mg/daily.
45456966|NCT03932227|Device|Holter|Subjects will have a 24h recording with Holter, next will be unequipped.
45456967|NCT02298400|Device|Acuvue® Oasys® Lenses (senofilcon A)|Contact lenses placed in each eye during the day for about 8 hours
45456968|NCT02298400|Device|30-Day Bausch + Lomb PureVision (balafilcon A)|Contact lenses placed in each eye during the day for about 8 hours
45993062|NCT04690049|Other|Neuromuscular resistance exercise program|This neuromuscular resistance exercise program will be organized in 5 stages, distributing the different phases in 2, 4, 4, 2 and 2 weeks respectively, with a frequency of 3 sessions/week. In addition, 2 weekly sessions of aerobic work with cycloergometer will be developed. The duration of each session will last 30 minutes. The parameters of load and execution speed will be modified as the exercise program progresses along the phases, with the goal of have an impact on the different aspects of the neuromuscular system.
45993063|NCT04690049|Other|Control exercise program with elastic band|"This program is based on previous literature so that it remains comparable to the experimental program.~The parameters will consist in 3 sets of 10 repetitions, 2 times/day, 3 times/week, for a total of 6 weeks."
45993064|NCT02911389|Other|Home PT via web-based platform|
45993065|NCT02911389|Other|Home PT via paper manual|
45993066|NCT02911389|Other|outpatient PT|
45993067|NCT02933021|Other|Blood sample taken|
45993068|NCT02933021|Other|Answering a lifestyle questionnaire|
45993069|NCT02933021|Other|Follow-up phone call from researcher (two years after first visit)|To enquire about status of participants monoclonal gammopathy of unknown significance, and whether there has been progression to multiple myeloma.
45993070|NCT02934750|Behavioral|Pursed lip breathing|"Pursed lip breathing will be taught to the participants following the chronic obstructive pulmonary disease (COPD) Foundation recommendations:~Breathe in through your nose (as if you are smelling something) for about 2 seconds.~Pucker your lips like you're getting ready to blow out candles on a birthday cake.~Breathe out very slowly through pursed-lips, two to three times as long as you breathed in.~Repeat."
45993071|NCT02932709|Behavioral|suicide attempt|suicide attempt : We evaluated the effectiveness of telephone follow-up of patients who had referred to an emergency psychiatric unit for attempted suicide on any further attempt/s over the following year.
45993072|NCT02911233|Biological|Thromboelastograpgy|
45993073|NCT02932748|Dietary Supplement|Portion Controlled Meals (PCM)|Portion controlled meals provide conveniently packaged, low-energy, high-nutritional content food.
45993074|NCT02932748|Behavioral|Group Phone (GP)|Weight management program delivered via group conference call.
45993075|NCT02932748|Dietary Supplement|Conventional Diet|Conventional diet (CD) will consist of a nutritionally balanced, reduced energy, high volume, lower fat (fat= 20-30% energy) diet based on USDA's MyPlate recommendations.
45993076|NCT02932748|Behavioral|Individual Phone (IP)|Weight management program delivered via individual phone call.
45456969|NCT02298400|Device|Clariti® 1-Day (Somofilcon A)|Contact lenses placed in each eye during the day for about 8 hours
45993077|NCT02932748|Behavioral|Enhanced Usual Care (EUC)|Weight management topics delivered face-to-face at clinic office every 6 months.
45993078|NCT02932514|Device|Eversense (Senseonics) Continuous Glucose Monitoring System|"Evaluate accuracy of Eversense CGM System to SMBG Meter.~Compare performance between abdomen and arm insertion sites.~Determine the usability of the Eversense System in a home-use setting for 180 days."
45993079|NCT02911311|Drug|intravitreal injection of conbercept|conbercept is an anti-VEGF agent and is approved by the Food and Drug Administration for wet age-related macular degeneration
45993080|NCT02911311|Device|PRP|panretinal photocoagulation (PPR) is the standard treatment for proliferative diabetic retinopathy (PDR) and is applied to the peripheral retinal tissue to ablate areas of the peripheral retina and thereby reduce retinal oxygen consumption
46084486|NCT02773160|Other|Sensor-based postural feedback|Motion tracking sensors will provide feedback to subjects during the learning phase of a motor control task
46084487|NCT02773160|Other|Mirror feedback|Subjects will receive feedback from a mirror during the learning phase of a motor control task
45833846|NCT03392376|Other|Saline (0,9%)|ICU patients with diagnosed delirium are treated with 0,5ml isotonic saline x 3 daily and as needed doses to a maximum of 4ml/daily, corresponding to the algorithm in the experimental arm.
45456970|NCT03930355|Other|Blood transfusion|Patients who received blood transfusion in the perioperative period
45456971|NCT03930355|Other|Control|Patients who did not receive blood transfusion in the perioperative period
45456972|NCT03514654|Procedure|Mastectomy|Removal of the whole breast.
45456973|NCT03514654|Procedure|Therapeutic Mammoplasty|Excision via lumpectomy of multifocal or multicentric cancers with breast volume displacement techniques to maximise cosmetic outcomes.
45833847|NCT04083612|Procedure|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of ixekizumab
45833848|NCT04083612|Other|Patient questionnaires|The study participant will complete the Dermatology Quality of Life Index (DLQI) and EQ5D5L questionnaires at each study visit.
45833849|NCT05243628|Biological|Afrezza (insulin human) Inhalation Powder|"Pharmaceutical form: powder~Route of administration: inhalation"
45993081|NCT02932631|Other|THERAPY CONTROL AND MOVEMENT OF INDUCTION|"Volunteers conventional physiotherapy group will stretching, strengthening and / or mobilization and functional training of the affected muscles with 3 sets of 10 repetitions for 60 minutes.~The restriction therapy group and induction motion the volunteers will wear a brace on the top healthy member to be restricted in each session during the exercises for this group for a period of 60 minutes, encouraging tasks involving activities of daily living and / or daily. In group practice mental, the volunteers listen to a CD that in the first two minutes, will promote progressive relaxation where imaginary in a calm and quiet place followed by 13 minutes of listening to the restriction therapy exercise protocol and motion induction. The association group practices and mental restriction therapy, volunteer listens to the CD for 15 minutes following the same procedures mentioned in group practice mental, followed by exercises functional activities for 45 minutes in the paretic limb."
45674433|NCT02189759|Other|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
45993082|NCT04690101|Other|none, this is an observational study|none, this is an observational study
45456974|NCT03929965|Drug|Anlotinib|Anlotinib
45993083|NCT02932358|Other|Flexible Family Visitation Model (FFVM)|Visitation to ICU patients allowed during the period of 12 consecutive hours per day.
45993084|NCT02932358|Other|Restrictive Family Visitation Model (RFVM)|Visitation to ICU patients allowed during intermittent periods according local ICU regulation.
45993085|NCT04689906|Other|surgery|This is a retrospective study that includes patients operated for suspicion of acute appendicitis
45993086|NCT04690257|Other|Trace Image and Coloring for Kids-Book (TICK-B)|A collection of pictures designed as a book contains and given to children during the procedure and they take a picture as they favored.
45993087|NCT02932397|Drug|Intravenous dose of 0.5 mg/kg of propofol|
45993088|NCT02932397|Drug|Intravenous dose of 0.05 mL/kg of saline solution|
45993089|NCT02932319|Device|Foley catheter|The Foley cathter will be inserted at term + 4 days for 24 hours.
45833850|NCT05243628|Biological|insulin degludec|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
45833851|NCT05243628|Device|Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)|Acceptable AID systems in this study are Medtronic 670G/770G and Tandem Control IQ
45833852|NCT05249478|Procedure|bupivacaine and fentanyl|bupivacaine and fentanyl will be infused through the catheter
45833853|NCT04083222|Drug|Placebo|ISIS 757456-matching placebo solution administered as SC injection.
45833854|NCT04083222|Drug|ISIS 757456|ISIS 757456 administered as SC injection.
45456975|NCT02298478|Behavioral|NO-FEAR Airlines|"NO-FEAR Airlines is a computer program that allows people who are afraid to fly to be exposed to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.~NO-FEAR Airlines divides the flight process into six sequential stages: (1) flight preparation, (2) a series of activities immediately prior to flying on the day of the flight, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway and landing, (6) sequence with images and auditory stimuli related to plane crashes."
45456976|NCT01127425|Procedure|laparoscopic colonic resection|Conventional surgery compared to laparoscopic sigmoid resection
45456977|NCT01127425|Procedure|laparoscopic sigmoid resection|sigmoid resection by laparoscopic surgery
45993090|NCT02932319|Other|expectative|expectative until the next day befor starting the induction
45993091|NCT02911272|Device|2-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 2-hour from the alert line
45993092|NCT02911272|Drug|Oxytocin|Oxytocin augmentation of slow labour progress at the respective action line location on the WHO modified partograph
45993093|NCT02911272|Procedure|Forewater amniotomy|Forewater amniotomy at the vaginal examination confirming active phase labour
45993094|NCT02911272|Device|4-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 4-hour from the alert line
45993095|NCT02932241|Behavioral|Computerized Dialectical Behavior Therapy Skills Training|8, 50 minute skill training sessions made available to participants each week
45993096|NCT02911194|Dietary Supplement|a2 milk|replace all milk with a2 milk
45993097|NCT02911194|Dietary Supplement|a1 containing milk|use a1 containing milk
45993098|NCT02932436|Drug|Empagliflozin|10 mg per os daily for 12 weeks
45993099|NCT02932436|Drug|Placebo|amount of Placebo corresponding to empagliflozin 10 mg per os daily for 12 weeks
45993100|NCT04694820|Other|Text Message-Based Navigation Intervention|Receive txt4TKI
45993101|NCT04694820|Other|Survey Administration|Ancillary studies
45993102|NCT02932670|Other|costoclavicular nerve block|ultrasound-guided costoclavicular nerve block
45993103|NCT02910960|Device|Acquire EUS Biopsy Device|At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
46084488|NCT02773160|Other|Control group|Subjects will receive no feedback during the learning phase of a motor control task
46084489|NCT02676219|Other|RS01|Oral Care product containing sodium monofluorophosphate and sodium fluoride
46084490|NCT02676219|Other|Water|
46084491|NCT02696720|Drug|Lidocaine|
46084492|NCT02696720|Other|Sham|
45456978|NCT03929809|Device|Cochlear Implant|adults with unilateral hearing loss who wish to regain bilateral hearing will be implanted with a cochlear implant on their deafened ear.
45993104|NCT02910960|Device|SharkCore Biopsy System|At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
45993105|NCT02932124|Device|mechanical chest compression device|
45993106|NCT02932007|Drug|Chloroquine Phosphate|Two tablets of study drug are to be taken on the day of study drug initiation and the next day, followed by one tablet each day for the next 12 days. Study drug to be orally administered and taken with food.
45993107|NCT02932085|Device|Neurostar TMS Therapy System, NeuroStar XPLOR System|Repetitive transcranial magnetic stimulation
45993108|NCT02934399|Other|27 hour subcutaneous fluid sampling|"One hour prior to the microdialysis catheter insertion the participants will be asked to receive a local anaesthetic on the injection site for the microdialysis catheter. Lignocaine 1% will be injected subcutaneously at a localised site on the abdomen covering a horizontal area of about 5cm after a brief acclimatisation period at the hospital.~A sterile linear catheter will be inserted using aseptic precautions at the anaesthetised site on the abdomen. The catheter is connected at one end to the microdialysis pump, and at the other end to the automated collection device. Subcutaneous tissue microdialysis samples will be collected regularly for the duration of the sampling period (27 hours)."
46084493|NCT04180683|Other|Battery of screening tests with semi-structured interview|First, participants will be administered the Mini-Mental State Examination to assess if they meet the inclusion criteria and an ID will be assigned to the participants that meet the criteria. Posteriorly, a clinical psychologist will administer the GDS-30, GDS-15, GDS-10 and GDS-5, the BDI-II and a semi-structured interview about depressive disorders according to the DSM-5 criteria. Participants with even ID's from each institution will be answer the instruments according to the order GDS-30, GDS-10, BDI-II, GDS-5 e GDS-15 and participants with odd ID's will answer the battery in the reverse order. The assessment session will take place in a single moment in time. After the assessment, the clinical psychologist will answer a questionnaire about which version was more easily understandable by the participants and the participants' preference regarding the GDS versions.
46084494|NCT04180683|Other|Battery of screening tests without semi-structured interview|First, participants will be administered the Mini-Mental State Examination to assess if they meet the inclusion criteria an ID will be assigned to the participants that meet the criteria. Posteriorly, a psychologist will administer the GDS-30, GDS-15 and the BDI-II. Participants with even ID's from each institution will answer the instruments according to the order GDS-30, BDI-II and GDS-15 and participants with odd ID's the administration order will answer the battery in the reverse order. The assessment session will take place in a single moment in time.
46084495|NCT02767700|Genetic|NGS|Next generation sequencing
46084496|NCT02767778|Device|REAL Pulsed ELF-MF stimulation|Within 48 hours from the onset of the stroke, the enrolled patients will undergo to 120 min, daily, pulsed ELF-MF treatment for 5 consecutive days, during their hospital stay.Pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy) producing a single-pulsed signal at 75±2 Hz, with a pulse duration of 1.3 ms and a peak intensity of the magnetic field of 1.8±0.2 mT.
45456979|NCT01221883|Drug|Diazepam|Single dose 10mg Diazepam tablet
45674434|NCT01490866|Drug|Axitinib|5-mg tablets PO BID
45993109|NCT04603547|Device|Transcutaneous Carbon Dioxide Monitoring|Once an infant is identified as being eligible for TH treatment and hypothermia was initiated according to the department clinical practice guidelines, and written informed consent was obtained from one of the parents, tcPCO2 monitoring can be started. Transcutaneous CO2 will be measured by SenTec Digital Monitor (software version SW-V07.00; MPB SW-V05.00.12) with V-Sign™ Sensor (SenTec AG, Thervil, Switzerland). Also, we will use small blood samples (0.2 ml) from clinical blood draws up to 4 times following starting transcutaneous CO2 monitoring for measuring blood gas for research purposes.
45993110|NCT02910882|Drug|PEGylated Recombinant Human Hyaluronidase (PEGPH20)|"PEGPH20 Dosing (Cohort I, Dose Escalation, First 3 patients): Administered as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute:~Dose level 1 - 1 mcg/kg; Dose level 2 - 1.6 mcg/kg; Dose level 3 - 3 mcg/kg.~PEGPH20 Dosing (Cohort II, Patients 4-10): Administered at a dose of 3 mcg/kg as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute.~Dosing Schedule: Twice per week beginning Day #1 for 8 doses, then weekly until end of radiotherapy."
45993111|NCT02910882|Drug|Gemcitabine|"Gemcitabine Dosing: Administered at a dose of 600 mg/m2 as an IV infusion over 30 - 60 minutes with standard antiemetic pre-medication. If administered on PEGPH20 day, Gemcitabine will be infused 2-4 Hours after PEGPH20 infusion is completed.~Dosing Schedule: Weekly, beginning Day #2, per standard regimen."
45993112|NCT02910882|Radiation|Radiation|Radiotherapy, beginning Day #2, delivered at 1.8 Gy per fraction, 5 fractions per week (Monday - Friday), until a total dose of 50.4 to 54 Gy for up to 6 Weeks.
45993113|NCT02931968|Device|Monolithic zirconia prosthesis|Edentulous arch subjects treated with a monolithic zirconia implant supported fixed dental prosthesis.
45993114|NCT02934438|Dietary Supplement|Neo40|
45993115|NCT02934438|Dietary Supplement|Placebo|
45993116|NCT02932046|Dietary Supplement|Standardized noon meal|"The meal is treatment as usual in the specialized somatic stabilization ward for patients with severe anorexia nervosa."
45993117|NCT02934516|Procedure|Cesarean section|"Abdominal disimpaction with lower uterine segment support: the edge of the lower uterine segment is grasped by 3-4 modified Allies forceps (with broader jaws) applied along the lower edge of the incision until it is completely supported. These forceps are handled by the assistant, and gentle traction is applied upward, perpendicular to the uterine surface and away from the fetal head without excessive force. Accordingly, the hand of the surgeon could be inserted into the uterine cavity, and adequate space for manipulations is available without applying pressure on the lower segment. The fetal head is eventually grasped and delivered.~Classic push method: delivering the head with assistance by pushing the fetal head vaginally"
45993118|NCT02932202|Other|Longitudinal Nutritional Counseling|
45993119|NCT02932202|Other|Standard Care|
45993120|NCT02934594|Other|Palliative Decompression|palliative decompression to MSCC patients: before motor deficit (Group A), within 48 hours after motor deficit (Group B1), 48 hours after motor deficit (Group B2)
45993121|NCT02931929|Drug|68Ga-NeoBOMB1, 2-vial kit|intravenous application of a radiopharmaceutical for Positron Emission tomography (PET)
45993122|NCT02910804|Drug|68Ga-BBN-IRDye800CW|
45993123|NCT02910804|Device|PET/NIRF|
45993124|NCT02910804|Procedure|PET/NIR fluorescent imaging-guided surgery|
45993125|NCT02931734|Drug|Resin modified glass ionomer|Prophylaxis, washing and removing water excess , apply the Clinpro forming a uniform layer of 0.5mm, lightcure for 20 seconds
46084497|NCT02767778|Device|SHAM Pulsed ELF-MF stimulation|SHAM pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy). The device for SHAM stimulation is identical and produces the same auditory sensation of the device for REAL stimulation but the SHAM device has no stimulating effect on the brain.
46084498|NCT04180293|Behavioral|Pilot psychoeducation program|Canadian Armed Forces veterans and their family members will be recruited to participate in this pilot virtual psychoeducation program and its evaluation. Two six-week sessions will be implemented over a virtual care platform (Zoom for healthcare) based out of OSI Clinic in Atlantic Canada - the first in January/February of 2021 and the second in the spring of 2021. A maximum of 10-15 participants (including both veterans and their family members) will be recruited for each group. Family members are defined as spouses/partners, siblings, parents, and adult children. Each of the weekly sessions will take place virtually and will be led by at least two trained facilitators (one from the research team, and one member of the OSI clinical staff team). Each of these sessions will focus on providing education of different topics relevant to those accessing services at the clinic (e.g., types of treatments available, tools to support families, self care, etc.).
46084499|NCT04180293|Other|Program evaluation|At the end of each six-week session, program outcomes will be assessed qualitatively by a member of the research team. Participants will take part in semi-structured interviews guided by questions informed by the ecological family systems theory.
45674435|NCT01490866|Drug|Bevacizumab|5 mg/kg Days 1 and 15; IV
46084500|NCT02767622|Procedure|Liver transplantation|
46084501|NCT02767544|Procedure|Vaginal wound local analgesia after laparoscopic hysterectomy|
46084502|NCT00643071|Drug|Tacrolimus|Oral
45674436|NCT01490866|Drug|5-Fluorouracil|400 mg/m2 Days 1 and 15; IV
45833855|NCT04080648|Procedure|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of guselkumab.
45833856|NCT04080648|Other|Patient questionnaires|The study participant will complete the dermatology quality of life index (DLQI) and EQ-5D-5L questionnaire at each study visit
45993126|NCT02931734|Drug|Potassium Nitrate 2%|Prophylaxis, apply uniformly on the teeth, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
45993127|NCT02931734|Procedure|Low level laser therapy|Prophylaxis, applying infrared laser at low power in points: mesial, buccal, distal and in the apical point in the foyer of fornix with power of 110MW for 11 seconds at each point.
45993128|NCT02934672|Other|Survey|Internet panelists, who self-reported that they or another adult in their household has osteoarthritis, were sent an email invitation to the survey site.
45993129|NCT02931656|Other|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
45993130|NCT02910765|Drug|methylene blue|
45993131|NCT02910765|Drug|ozone|
45993132|NCT02910765|Other|saline infusion|
45993133|NCT02910765|Other|oxygen|
45993134|NCT02931773|Device|Task Force® Monitor|A head up tilt test carried out with a Task Force monitoring system
45993135|NCT02934633|Behavioral|Keeping Baby Safe 2-DVD package|Keeping Baby Safe is a 2-DVD package that teaches childhood injury prevention skills to parents of children from birth to 24 months of age. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
45993136|NCT02934633|Behavioral|The Injury Prevention Program (TIPP) sheets|American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets parents would typically receive from their pediatrician or general practitioner at well-baby visits.
45993137|NCT02931617|Other|Chest Physiotherapy|
45993138|NCT02931617|Device|Post-therapy lung volume measurements|In both intervention groups.
45993139|NCT02925026|Dietary Supplement|Lactoferrin|
45993140|NCT02925026|Dietary Supplement|Lysozyme|
45993141|NCT02925026|Dietary Supplement|Placebo|
46084503|NCT03728634|Drug|ION-682884|ION-682884 administered SC
46084504|NCT03728634|Drug|Placebo|Placebo comparator calculated volume to match ION-682884 administered SC
46084505|NCT03728634|Dietary Supplement|Vitamin A|Oral supplement
46084506|NCT02767466|Procedure|Physical therapy and robotic assisted gait training|
46084507|NCT02767310|Drug|Rosuvastatin 20 mg film-coated tablets|Single oral dose of 20 mg
45833857|NCT05249946|Other|FoodStep - a sustainable health-promoting model for food services and early childhood education and care|The investigators create a sustainable food system model that reduces the climate impact of the food system in early childhood education and care. In practice, the investigators i) promote plant-rich recipes, sustainable food purchases and consumption through municipality food services, ii) renew food education, and iii) reduce food waste in early education and care. To ensure the feasibility and long-term commitment, the investigators bring together municipal stakeholders and key actors within the food system and education sectors to co-create the content of a sustainable food system intervention. The randomized controlled intervention will be carried out at 26 daycare centers within four municipalities in Finland. The impact of the changes at a food system level on children's dietary intake and nutritional status, costs of the whole food system, the climate impact of the menus and children's diets as well as food waste in the daycare centers will be examined.
45833858|NCT04276506|Other|music group|to reduce anxiety, some selected music pieces will have patients listened by headset.
45833859|NCT04276506|Other|information group|A visual information booklet which is prepared by the researchers will be used
45833860|NCT03148080|Procedure|Cognitive Assessment|Complete CogState
46084508|NCT02767310|Drug|Crestor 20 mg film-coated tablets|Single oral dose of 20 mg
46084509|NCT04180605|Other|Additional support for preoperative planning of LAA closure procedures|"The results of the computational simulations provided by FEops HEARTguideTM will be used in the computational simulation arm as an additional preoperative planning tool and their potential added value will be assessed by comparison to the standard of care arm."
46084510|NCT04180605|Procedure|Left atrial appendage closure|Transcatheter device insertion to exclude the LAA from the cardiac circulation
46084511|NCT02771132|Behavioral|"12-hr IMPower empowerment self defense course"|"The purpose of the 12-hr IMPower empowerment self defense course intervention for girls is to empower then to avoid risky situations, advocate for themselves, and, if needed, defend themselves against an attack."
46084512|NCT02771132|Behavioral|12-hr Source of Strength for boys|The 12-hr Source of Strength for boys curriculum is specifically designed for 10-13 year-old boys and focused on promoting gender equality, developing positive masculinity, and teaching safe and effective bystander intervention techniques.
46084513|NCT02771132|Behavioral|Life-skills course|A 1.5-2 hour life skills class that is based on the Kenyan Ministry of Education life skills course and includes a wide range of topics, including sexual assault but also sanitation, food safety, and personal rights. All school-aged children who attend school typically receive this type of curriculum.
45833861|NCT03148080|Other|Questionnaire Administration|Complete Self-Report Questionnaire
45833862|NCT03567330|Behavioral|Family-based attachment-focused intervention|5 2-hour biweekly sessions involving parent and/or adolescent(s).
45993142|NCT02925065|Other|Non-traditional group guitar instruction|A 6-week curriculum for non-traditional training in finger-style guitar has been developed with rhythmic and goal oriented upper extremity and finger movements. Guitar group intervention will be implemented at the Towson campus of the Peabody Preparatory. Intervention approaches will include rhythmic digital grip with finger isolation, goal directed rhythmic reach on the fret-board and rhythmic alternating tap-like digit and hand movements on the guitar. Participants will be provided with the instruments in the group setting without expectation of practice at home.
45993143|NCT02925182|Device|Er,Cr:YSGG Laser|
45993144|NCT02924987|Drug|Aflibercept Injection|Intravitreal injections of 0.05 mL (2mg) of Aflibercept will be injected. The intravitreal between the first 5 treatments sessions is 4 weeks, and the interval for the following treatment sessions up to week 52 is 8 weeks.
45993145|NCT04687995|Procedure|Endoscopic myringoplasty|Endoscopic myringoplasty by using two different grafts one each time
45993146|NCT02925104|Drug|INC280|
45993147|NCT02910687|Other|This is an observational study|
45993148|NCT02924909|Drug|carboplatin paclitaxel|induction carboplatin paclitaxel for 2 cycles
45833863|NCT03567330|Behavioral|Psychoeducation|Provides equivalent number of American Cancer Society psychoeducational sessions involving only parents.
45993149|NCT02934360|Device|TR(ACE) Assay Testing|Serial plasma testing with TR(ACE) Assay
45993150|NCT02924948|Procedure|Balloon inflation|EUS balloon inflation will be done before insertion through the subjects throat
45993151|NCT02934321|Dietary Supplement|Erythritol|Erythritol is a well tolerated, low calorie sugar alcohol that is becoming more widely used as a sugar substitute.
45993152|NCT02934321|Dietary Supplement|Aspartame|Aspartame is a well tolerated, commonly used artificial sweetener.
45993153|NCT02924831|Other|Acupuncture|Stimulating acupoints by using stainless steel needles with manual manipulation.
45993154|NCT02924831|Other|moxibustion|Stimulating acupoints by using burned moxa
45993155|NCT02924831|Other|placebo|Stimulating acupoints by using stainless steel needles without manual manipulation.
45993156|NCT02934126|Other|breast cancer patients|semi structured face to face interviews
45456980|NCT02294656|Drug|Ranibizumab,|Intravitreal injection of Ranibizumab as treatment for acute pseudophakic cystoid macular edema. Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.
45833864|NCT05246124|Other|Zumba dance exercise|The intervention was Zumba dance done 3 times a week during the 2-week self-isolation period, with each session lasting for 50 minutes. The participants did exercise by following instructions from Zumba video shown
45833865|NCT05244252|Drug|dexmeditomidine and bupivacaine|Transversus abdominis plane block will be given bilaterally
45833866|NCT05244252|Drug|Bupivacaine|bupivacaine
45993157|NCT02924753|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
45993158|NCT02924753|Drug|Fludarabine|Fludarabine 25mg/m2/day IV for 3 days (Day-5 to day-3).
45993159|NCT02924753|Biological|CART-19 cells|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
45993160|NCT04673136|Device|GI-GENIUS Medtronic|Colonoscopy assisted by GI-GENIUS device
45993161|NCT04673136|Other|Colonoscopy|Standard colonoscopy
45993162|NCT02924792|Device|Reinfusion - Sternal IO needle|
45993163|NCT02924792|Device|Reinfusion - Intravenous needle|
45993164|NCT02910375|Other|Cohort A|Venous sampling (n=13) will be performed in the hospital at D0 (prior to first golimumab injection), D3, D7, D14 (prior to second injection), D28, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D3, M1D7, M2D0 (8 weeks after M0D0, week 14), M3D0 (12 weeks after M0D0, week 18) Dried blood spot sampling (n=39) will be performed at D0 (prior to first golimumab injection), D1, D2, D3, D4, D5, D6, D7, D10, D14, D15, D16, D17, D18, D19, D20, D21, D28, D35, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, rig week 14), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, week 18)
45993165|NCT02910375|Other|Cohort B|Venous sampling (n=8) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D3, M1D7, M2D0 (8 weeks after M0D0, right before next injection), M3D0 (12 weeks after M0D0, right before next injection) Dried blood spot sampling (n=20) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, right before next injection), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, right before next injection)
45993166|NCT02924675|Drug|Pregabalin|150mg daily in three doses during three weeks
45993167|NCT02924675|Drug|Placebo|Three doses daily with lactose
45993168|NCT02910609|Device|Echocardiography|Echocardiography is a kind of ultrasound test that shows the inner structure and functions of the heart in both groups.
45993169|NCT02924597|Procedure|zero ischemia robot-assisted laparoscopic RFA assisted TE|
45993170|NCT02924597|Procedure|zero ischemia robot-assisted laparoscopic partial nephrectomy|
45993171|NCT02910492|Device|enLighten Laser|Nd:YAG dual-pulse duration laser for the treatment of skin rejuvenation
45993172|NCT02924558|Other|Egg protein/unsaturated fatty acid|Study test foods (yogurt, muffins, waffles, and cookies) containing 8% higher protein energy (egg protein) and 8% higher fat energy (unsaturated fatty acids) than Control
45993173|NCT02924558|Other|Control|Study test foods (yogurt, muffins, waffles, and cookies) containing 16% higher carbohydrate energy than Egg protein/unsaturated fatty acid
45993174|NCT03847545|Drug|Fampridine|sustained-release tablet 10 mg morning and evening.
45993175|NCT02924285|Procedure|Procedure (Radiofrequency catheter ablation)|Radiofrequency catheter ablation
45993176|NCT02924285|Drug|Amiodarone|"Amiodarone, Verification of superiority of catheter ablation over amiodarone for treatment of PVCs in patients with structural heart disease as:~Antiarrhythmic Drug Amiodarone"
45993177|NCT02924363|Diagnostic Test|Cardiac MRI with or without contrast dye|MRI scans of the heart are performed before and after the MitraClip clinical procedure with an FDA cleared device with or without an FDA approved contrast dye.
45993178|NCT02924363|Diagnostic Test|Blood sample|Blood samples collected to calculate hematocrit for measurements of the CMR extracellular matrix.
45993179|NCT02934048|Other|7-day triple regimen guided by AST|Patients in this group will receive a 7-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
45993180|NCT02934048|Other|10-day triple regimen guided by AST|Patients in this group will receive a 10-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
45993181|NCT02934048|Other|14-day triple regimen guided by AST|Patients in this group will receive a 14-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
46084514|NCT04353414|Procedure|Transmuscular Quadratus Lumborum Block|Transmuscular Quadratus Lumborum Block (TQLB) is a relatively new block that targets thoracic and lumbar nerves. The decrease in sensation means a decrease in pain. The TQL block will be preformed in addition to an incision-site injection (on hip), called pericapsular injection. The potential risks associated with the Transmuscular Quadratus Lumborum Block (TQLB) include nerve damage and infection at injection site. In addition, there can be temporary sensory and motor loss, depending on the dosage, site of injection and duration of the nerve block. However, the amount (30mL) used in this study meets FDA dosage-regulations for this medication.
46084515|NCT04353414|Procedure|Pericapsular injection|Pericapsular injection (PCI) of 20 mL of 0.25% Bupivacaine HCL (numbing medication) into the incision-site (hip portal sites) to decrease sensation. The potential risks associated with the pericapsular injection include bleeding, infection at injection site and local anesthetic toxicity however, the likelihood is low due to the expertise of the surgeon preforming the injection and the sterile environment and good clinical practice from clinicians, which reduces the likelihood of infection.
45674437|NCT01490866|Drug|5-Fluorouracil|2400 mg/m2 over 46-48 hours Days 1 and 15; Continuous Intravenous
45674438|NCT01490866|Drug|Leucovorin|400 mg/m2 Days 1 and 15; IV
45674439|NCT01490866|Drug|Oxaliplatin|85 mg/m2 Days 1 and 15; IV
45674440|NCT02215967|Drug|Cyclophosphamide|300 mg/m^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
45674441|NCT02215967|Drug|Fludarabine|30 mg/m^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
45674442|NCT02215967|Biological|Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells|0.3x10^6- 15.0x10^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
45674443|NCT02168387|Device|continuous high frequency oscillator (CHFO)|
45674444|NCT02168387|Drug|Acetylcysteine|
45993182|NCT02924207|Other|PATH electronic decision support tool|PATH, a clinical decision support tool for Type 2 Diabetes, was developed based on patient impact of efficacy, cost, implementation difficulty, comorbidities, side effects, and evidence based pleiotropic benefit. Drug efficacy was estimated using published clinical data for agents, both in terms of placebo controlled trials and head-to-head studies. Additional information regarding interventions was added with regard to FDA package inserts as well as large post marketing studies. Cost impact of intervention was described in terms of patient's estimated copay drawn from insurance plan as well as average retail price.
45993183|NCT02934087|Procedure|Endovascular Aneurysm Repair|Endovascular aneurysm repair (or endovascular aortic repair) (EVAR) is a type of endovascular surgery used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm (AAA)
45993184|NCT01287520|Drug|LY2090314|Administered intravenously
45993185|NCT01287520|Drug|pemetrexed|Administered intravenously
45993186|NCT01287520|Drug|Carboplatin|Administered intravenously
45993187|NCT01287520|Other|ranitidine|Per I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine given as pretreatment to LY2090314 for stomach pain.
45993188|NCT02924246|Biological|cholera vaccination|Oral cholera vaccination on day 0 and day 14
45993189|NCT02924246|Other|raw milk|raw milk
45993190|NCT02924246|Other|pasteurized milk|pasteurized milk
45993191|NCT02924246|Other|UHT milk|UHT milk
45993192|NCT04323865|Diagnostic Test|fetal heart rate variability|No direct intervention, as the study is observational.
45993193|NCT00623740|Drug|hydrocortisone|Intravenous slow of hemisuccinate hydrocortisone 0.5 mg/kg/12 hours during 7 days then 0.5mg/kg/24 hours during 3 days.
45993194|NCT00623740|Drug|placebo|intravenous slow of placebo 0.5mg/kg/12 hours during 7 days then 0.5 mg/kg/24 hours during 3 days
45993195|NCT01287403|Other|Refined wheat flour|A treated cereal flour mixed with milk.
45993196|NCT01287403|Other|Esterase wholegrain wheat flour|A treated cereal flour mixed with milk.
46084516|NCT04353414|Drug|Bupivacaine Hydrochloride|Bupivacaine used for this study is the standard of care for both TQLB and PCI. Pericapsular injection (PCI) contains 10 mL of 0.25% Bupivacaine HCL which will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.
45993197|NCT01287403|Other|Wholegrain wheat flour|A treated cereal flour mixed with milk.
45993198|NCT01287403|Other|Liquid whole grain wheat flour|A treated cereal flour mixed with milk.
45993199|NCT01287403|Other|Wholegrain barley flour|A treated cereal flour mixed with milk.
45993200|NCT01287403|Other|Liquid wholegrain barley flour|A treated cereal flour mixed with milk.
45993201|NCT02924168|Device|Active Radial Shockwave|Four weekly sessions of active radial shockwave treatment.
45993202|NCT02924168|Device|Sham Radial Shockwave|Four weekly sessions of sham radial shockwave treatment.
45993203|NCT02889913|Other|No intervention only description|No intervention only description
45993204|NCT02923934|Drug|Ipilimumab|CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.
45993205|NCT02923934|Drug|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
46084517|NCT04226300|Procedure|Laparoscopic|A transversus abdominis nerve block will be placed laparoscopically.
46084518|NCT04226300|Procedure|Ultrasound|A transversus abdominis nerve block will be place by ultrasound
46084519|NCT03492606|Procedure|Samples|lumbar puncture, blood and CSF samples, SNPs analysis
46084520|NCT02676453|Other|Intervention|Dental hygienist support
45456981|NCT02294656|Drug|Triamcinolone acetonide|Intravitreal injection of Triamcinolone acetonide as treatment for acute pseudophakic cystoid macular edema. Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.
45993206|NCT01287364|Drug|ciclesonide hydrofluoroalkane (HFA) nasal aerosol|ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily for one week.
45993207|NCT01287364|Drug|mometasone nasal inhalation|mometasone nasal inhalation 200 μg once daily for one week
45993208|NCT02924012|Other|video game active|The session lasted 40 minutes. The participants held an active video game session. At the end they were monitored for 60 minutes at rest.
45993209|NCT02924012|Other|sedentary video game|The session lasted 40 minutes. The participants held an sedentary video game session, using the traditional joystick. At the end they were monitored for 60 minutes at rest.
45993210|NCT02924012|Other|walking|The session lasted 40 minutes. The participants held a walk using the treadmill. At the end they were monitored for 60 minutes at rest.
45993211|NCT02889757|Drug|Acteylcysteine|randomized into three arms
45993212|NCT02889952|Device|Near infrared camera (NIR)|"Surgical field was examined with NIR, during a few minutes (<5') with room lights switched off, to avoid parasite lights, then conventional open thyroidectomy was resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, were checked visually.~NIR consisted of a 750 nm class 1 laser excitation, with a power <20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international norm IEC 60601-2-41). It was provided by the Fluobeam® camera, which was inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 1 device)."
45993213|NCT02889835|Device|Supreme Universal Restorative|
45993214|NCT02889835|Device|Supreme Flowable Restorative|
45993215|NCT02889835|Device|Bulk Fill Flowable Restorative|
45993216|NCT02923973|Other|Transvaginal ultrasound cervical length screening|Serial transvaginal ultrasound cervical length scan every week from 16 to 24 weeks
45993217|NCT01287013|Device|Cone-beam computed tomography (CT)|Imaging
45993218|NCT01287013|Device|Conventional Computed Tomography (CT)|Imaging
45993219|NCT02934243|Device|laryngeal mask insertion|airway management with laryngeal mask
45993220|NCT02924090|Drug|Etomidate|Etomidate will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.3 mg/kg
45993221|NCT02924090|Drug|Ketamine|Ketamine will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.5 to 1.0 mg/kg.
45993222|NCT02924090|Procedure|Hyperventilation|Hyperventilation will be performed in patients after full pre-oxygenation and induction of anesthesia, by administering 20 breaths in 30 seconds using a well-fitting face mask immediately before application of the ECT electrical stimulus.
45993223|NCT02924090|Procedure|Electroconvulsive therapy (ECT)|Bilateral, bitemporal electrode placement will be utilized to elicit a seizure via a SpECTrun 5000Q (MECTA Inc.). The electrical dose required will be determined in advance by the patient's attending psychiatrist.
45993224|NCT01286779|Biological|BAX 326 (Recombinant factor IX)|The treatment with BAX 326 will be at the discretion of the investigator and will consist of either twice weekly prophylactic treatment with 50 IU/kg, modified prophylaxis, or on-demand treatment.
45993225|NCT02934165|Behavioral|Family Safety 123|Theoretically-based injury prevention videos for families
45993226|NCT02934165|Behavioral|AAP TIPP sheets|American Academy of Pediatrics The Injury Prevent Program materials converted to web-based materials.
45993227|NCT04137770|Other|Ice pack and ketorolac|Scheduled IV ketorolac will be administered and ice packs will be applied to the surgical site
45993228|NCT05594797|Drug|Human BCMA Targeted T Cells Injection|A single dose of predetermined level CAR-positive T cells will be infused.
45993229|NCT01286740|Drug|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily
45993230|NCT02934009|Device|Dermal nuclear magnetic resonance (NMR)-profile measurement|Nuclear magnetic resonance (NMR)-profile measurement of the dermis
45993231|NCT01286311|Behavioral|Direct-to-patient tailored cardiovascular risk message system|Patient informational mailings
45993232|NCT02923856|Device|The results of clarithromycin susceptibility test of H. pylori isolates|According to the results of antibiotic susceptible testing, patients who were resistant to clarithromycin were belonged into clarithromycin resistance group.Patients who were sensitive to clarithromycin were belonged into the 7days/10days/14days treatment groups.
45993233|NCT02923856|Device|Computer generated random number, randomly assigned into groups|The patients with clarithromycin sensitive. Computer generated random number,randomly assigned into 7days/10days/14days treatment groups.
46084521|NCT00643149|Drug|amoxicillin|10 day regimen, 45 mg/kg/day, given in divided doses every 12 hours
46084522|NCT00643149|Drug|azithromycin SR|60 mg/kg dose of azithromycin SR was as safe and effective as a 10-day regimen of amoxicillin when used to treat children with strep throat
46084523|NCT02770898|Behavioral|Family Holistic Health|Interventions for probationers will aim to promote physical and psychosocial health, family relationships and Family 3H (happiness, harmony and health).
46084524|NCT05141682|Drug|Oral Azacitidine|Given PO
46084525|NCT02770664|Drug|Placebo|Placebo
46084526|NCT02770664|Drug|LC28-0126 Dose A|LC28-0126 Dose A
46084527|NCT02770664|Drug|LC28-0126 Dose B|LC28-0126 Dose B
45993234|NCT02923856|Device|The result of 13C-urea breath test of patient in 7days/10days/14days treatment groups|The intervention focused on the results from the result of 13C-urea breath test at 8 weeks after treatment in patients. All patients were taking 75mg 13C-urea and analysis with a modified isotope ratio mass spectrometer to determine the 13CO2 content.The successful treatment groups were patients with negative in 13C-urea breath tests.The failed treatment of H. pylori groups were patients with positive in 13C-urea breath tests after the standardized triple therapy treatment.
45993235|NCT02934204|Drug|methotrexate|
45993236|NCT02934204|Drug|temozolomide|
46084528|NCT02770664|Drug|LC28-0126 Dose C|LC28-0126 Dose C
46084529|NCT02676141|Other|Manual Therapy|The treatment the patients receive is not specifically set up for the study. Participants will already be seeing a practitioner before the participants are included in the study.
46084530|NCT04333680|Diagnostic Test|Focused Assessment of Sonography for Trauma Exam|Speed and image quality of ultrasound exams performed with either transducer specified in the arms.
46084531|NCT00643227|Drug|clarithromycin extended release (ER)|7 days of clarithromycin extended release (ER), 1.0 g by mouth once daily
46084532|NCT00643227|Drug|azithromycin SR|Single, 2.0 g oral dose of azithromycin sustained release (SR) by mouth once daily
46084533|NCT00613392|Dietary Supplement|powdered antioxidant|one vial mixed with water every day orally or through enteral tube
46084534|NCT00613392|Dietary Supplement|powdered cornstarch placebo|one vial mix with water and administer orally or via enteral tube
46084535|NCT02776514|Drug|Triamcort|Fluoroscopic guided injection in the knee joint
46084536|NCT02776514|Drug|Platelet-rich-plasma|
46084537|NCT02776514|Drug|Suplasyn1|
46084538|NCT02776514|Drug|Placebo|
46084539|NCT04113278|Genetic|FGL2 immunohisyochemistry|Correlation between FLG2 expression and progression free survival and overall surviv
45993237|NCT01286077|Drug|bortezomib|Each cycle will consist of 5 weeks treatment. Subjects in the treatment group will receive: Velcade® 1.6 mg/m2 as an intravenous bolus injection on Days 1, 8, 15, and 22 of each cycle followed by a 13-day rest period (Days 23 to 35) Cycle will be repeated on Day 36. Subjects in the treatment group will receive up to 4 treatment cycles, unless they experience either unacceptable toxicity or if the subject requests to withdraw from the study.
45993238|NCT04689152|Biological|Cellgram-LC|Patients will receive single injection of Cellgram-LC(mesenchymal stem cell) hepatic artery.
45993239|NCT03749655|Behavioral|Physical Activity Promotion|The physical activity (PA) promotion intervention will be provided only to the intervention group, and will include: 1) a step-counter with a digital display, 2) an interview discussing motivational issues, favourite daily activities and strategies to become more physically active; and 3) a tailored physical activity coaching plan including an Individualised activity goal (in steps/day) revised twice weekly through consultation sessions (16 sessions in total). Patients' targets will be revised twice weekly during the consultation sessions which will be incorporated into the Pulmonary rehabilitation sessions. The aim is to increase physical activity by 10% each week. The goal can be altered if required.
45993240|NCT05590936|Drug|Dimenhydrinate Tablets|2 hours preoperative per os administration of 50 mg dimenhydrinate
45993241|NCT05590936|Drug|Ondansetron iv|Intraoperative intravenous administration of 4 mg ondansetron
45993242|NCT01285960|Device|ExAblate Treatment UF V2|Treatment with the ExAblate UF V2 system. Patients may have up to two ExAblate treatments within a two-week period.
45993243|NCT02933814|Drug|Liposomal Bupivicaine|Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
45993244|NCT04323826|Other|olive oil-water mixture|50% olive oil in water, processed with high shear mixer at 8000 rpm power without adding emulsifier, well shaked before consumption.
45993245|NCT04323826|Other|olive oil-water emulsion|50% olive oil in water (4% whey protein isolate), stirred for 5 mins using a high shear mixer at 8000 rpm power and was further processed with high pressure homogenizer at 100 MPa.
45993246|NCT04323826|Other|coconut oil-water mixture|50% coconut oil in water, processed with high shear mixer at 8000 rpm power without adding emulsifier, well shaked before consumption.
45993247|NCT04323826|Other|coconut oil-water emulsion|50% coconut oil in water (4% whey protein isolate), stirred for 5 mins using a high shear mixer at 8000 rpm power and was further processed with high pressure homogenizer at 100 MPa.
45993248|NCT04690140|Procedure|Epithelialized free gingival graft|The Epithelialized free gingival graft placed on the prepared bed.
45993249|NCT04690140|Procedure|Modified coronally advanced tunnel technique|Connective tissue graft placed under the prepared tunnel
45993250|NCT05578183|Device|theta burst stimulation|expect for the TBS, all patients get cognitive training alike on a training system in medical center.
45993251|NCT05578183|Device|sham stimulation|expect for the TBS, all patients get cognitive training alike on a training system in medical center.
45993252|NCT05575609|Other|children with Diabetes Mellitus, Type 1|assessment of Relation between anthropometric measurements and balance in children with type 1 diabetes
45993253|NCT02923817|Biological|Transplantation of autologous bone marrow-derived mononuclear cells by lumbar injection|
45993254|NCT02933775|Genetic|CAR-CD19 T cells|Initial dose: A total of 1 - 10×10^7 CAR-CD19 T cells/kg will be administered by 1 - 3 infusions. Subsequent dose will be based on the subject's response to initial dose.
45993255|NCT02933775|Drug|Fludarabine|30 mg/m^2/day×4 days
45993256|NCT02933775|Drug|Cyclophosphamide|500 mg/m^2/day×2 days
45993257|NCT02923700|Biological|Leukocyte-rich PRP intra-articular injections|
45993258|NCT02923700|Biological|Leukocyte-poor PRP intra-articular injections|
45993259|NCT03441477|Device|Nidek Tonoref III|The auto ref/kerato/tono/pachymeter TONOREF III is a medical device which measures objective refractive errors, corneal curvature radius, intraocular pressure and corneal thickness of the patient's eye.
45993260|NCT03441477|Device|Haag-Streit Goldmann Manual Tonometer|Haag-Streit Goldmann Manual Tonometer measures intraocular pressure to aid in the screening and diagnosis of glaucoma
45993261|NCT03441477|Device|NIDEK CEM-530|Nidek CEM-530 is a non-contact ophthalmic microscope, optical pachymeter, and camera used for examination of the corneal endothelium and for measurement of the thickness of the cornea.
45993262|NCT02923622|Other|Traditional Chinese medicine herbals|TCM herbal treatment based on TCM syndrome differentiation，without any anti tumor therapy in Western Medicine
45993263|NCT02923622|Other|Integrated traditional Chinese and Western medicine|TCM herbal treatment combine with anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
45993264|NCT02923622|Other|Western medicine|Anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
45993265|NCT02923583|Biological|M834|
45993266|NCT02923583|Biological|US-Sourced Orencia®|
45993267|NCT02923583|Biological|EU-Sourced Orencia®|
45993268|NCT02933580|Drug|JNJ-56136379|Participants will receive a single oral dose (tablets) of JNJ-56136379 on Day 1.
45993269|NCT02933580|Other|Placebo|Participants will receive matching placebo tablets on Day 1.
45993270|NCT02923388|Drug|Injection Mecobalamin,|Injection Mecobalamin (500mcg) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.
45993271|NCT02923388|Drug|Tablet Pyridoxine hydrochloride|Tab. Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks
45993272|NCT02923388|Drug|Intravenous normal saline 1 ml|Normal saline 1 ml three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks
45993273|NCT02923388|Drug|Placebo pill|Placebo pill orally thrice daily for 5 weeks
45993274|NCT02933658|Drug|Telmisartan|
45993275|NCT02933658|Drug|Amlodipine|
45993276|NCT02933658|Drug|Rosuvastatin|
45993277|NCT02923661|Device|CM LOC|
45993278|NCT02923661|Device|ball attachment|
45993279|NCT02933853|Drug|Faster-acting insulin aspart|A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
46084540|NCT05018676|Drug|ARX788|1.5 mgkg IV infusion on Day 1 of each 21-day treatment cycle.
45993280|NCT02933853|Drug|Insulin Aspart|A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
45993281|NCT02923505|Procedure|polygraphy or polysomnography|
45993282|NCT02923310|Biological|Platelets Rich Plasma|
45993283|NCT02923310|Biological|Leucocyte - Platelets Rich Plasma|
45993284|NCT02923310|Drug|Hialuronic Acid|
45993285|NCT00532194|Drug|cediranib|Once-daily oral tablet starting dose 20mg
45993286|NCT02933268|Dietary Supplement|High water intake|High water intake aimed at achieving an urine osmolality < 270mOsmo/kg. Individualised prescription for each participant based on the free water clearance formula calculation.
45993287|NCT02933268|Other|Ad libitum water intake|Water intake guided by thirst
45993288|NCT02923154|Drug|MT-3995|
45993289|NCT02923154|Drug|Placebo|
45993290|NCT02665143|Drug|Nintedanib and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. In the phase I part, all patients will receive the combination with Nintedanib 200mg bid begun at day 8 and continued until end of cycle. If a significant incidence of dose limiting toxicities is demonstrated, Nintedanib will be given at a lower dose level (150mg bid).
45993291|NCT00532272|Drug|Letrozole ,Goserelin|Letrozole 2.5mg qd. Goserlin 3.6mg monthly(premenopausal)
45993292|NCT02922920|Other|Tart cherry juice|16 fl. oz of tart cherry juice
45993293|NCT02922920|Other|Placebo|16 fl. oz of placebo
45993294|NCT03292419|Procedure|Topography-guided LASIK|LASIK surgery
45993295|NCT02933385|Behavioral|Health Risks assessement|Home made questionnaire questioning about the participant's lifestyle habits, risk factors and other.
45993296|NCT02933385|Behavioral|Web-based health discussions|Create interactions between the employees.
45993297|NCT02933385|Behavioral|SOScuisine website|Site that is personalized to the employee. It provides menus, grocery shopping list and other.
45993298|NCT02933385|Behavioral|Health screening|Screen for diabetes, cholesterol, blood pressure and body weight.
45993299|NCT02933385|Behavioral|Closing events|these aim to motivate the employees to continue into the program.
46084541|NCT02537457|Drug|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule15mg for one day
45993300|NCT02933385|Behavioral|Coaching|The first year participant will be coached by a nurse, second year by a nutritionist, and third year by a kinesiologist.
45993301|NCT02933385|Behavioral|Social Health platform|
45993302|NCT02933385|Behavioral|Accelerometer provided|Social Health Platform: employees can challenge themselves or each other.
45993303|NCT02922842|Device|Transcutaneous Electrical Nerve Stimulation|
45993304|NCT02933190|Procedure|transvaginal surgery；UAE and D&C|For cesarean scar pregnancy treatment
45993305|NCT02923076|Other|CCR5 delta32/delta32 cord blood transplantation|
45993306|NCT02923037|Procedure|Yoga|Complete guided and home yoga sessions
45993307|NCT02923037|Other|tape measurement of arm|Ancillary studies
45456982|NCT01225237|Drug|Ramosetron|oral
45456983|NCT01225237|Drug|Placebo|oral
45993308|NCT02923037|Other|Quality-of-Life Assessment|Ancillary studies
45993309|NCT02923037|Other|ldex measurement of arms|
45456984|NCT03517930|Drug|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
45993310|NCT02933229|Device|biopsy|patients enrolled in the study will receive gastroscopy and biopsies in order to evaluate status of pathology.
45993311|NCT02933229|Drug|H. pylori eradication|"H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.~If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication."
45993312|NCT02922803|Drug|1 combination tablet of Vitamin D3/calcium per day|Combination tablet of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
46084542|NCT02537457|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet15mg for one day
45456985|NCT03517930|Drug|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
45456986|NCT01221961|Device|Masimo Radical-7|The Masimo device will be placed on one finger of the patient. To see whether or not the hemoglobin values recorded at the same time matches between the standard clinical practice (CSMC Lab and outside Lab) and the Masimo device
45674445|NCT02168387|Drug|dornase alfa|
45674446|NCT04418219|Drug|Cyclophosphamide|alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.
45674447|NCT04418219|Biological|Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM|Breast Cancer Vaccine SV-BR-1-GM, Bria-IMT, GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM, SV-BR-1 Breast Cancer Cell Line Vaccine, SV-BR-1-GM, SV-BR-1-GM Vaccine
45674448|NCT04418219|Biological|Pembrolizumab|1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218'')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'''':229-229'''')-bisdisulfide, Keytruda, Lambrolizumab, MK-3475, PEMBROLIZUMAB, SCH 900475
45993313|NCT02922803|Drug|2 combination tablets of Vitamin D3/calcium per day|Combination tablets of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
45993314|NCT02933424|Dietary Supplement|Protein Powder|
45993315|NCT03194568|Device|Anterior Vertebral Tether|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
45993316|NCT02922569|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets processing speed, memory and attention.
45993317|NCT02922569|Other|Commercially available computerized training|Thirty minutes of training on computerized, casual video games.
45456987|NCT02292316|Behavioral|gait and cognitive assessments|several tests are given in each domain
45456988|NCT02292316|Biological|blood sample|routine analyses in rheumatology such blood count and 25OH-D
45993318|NCT02922569|Other|Mindfulness Training|Ten minutes of using an online training course that teaches skills to help overcome ongoing life stressors.
46084543|NCT02762864|Other|platelet (P2Y12) reaction units|VerifyNow P2Y12 assay point-of-care testing
45993319|NCT02922569|Other|Traumatic Brain Injury Information Session|Ten minutes of viewing traumatic brain injury related news, information, and programs.
45993320|NCT02834559|Drug|5-fluorouracil and low molecular weight heparin|Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV).
45674449|NCT04418219|Biological|Recombinant Interferon Alpha 2b-like Protein|Novaferon, Recombinant IFN Alfa-2b-like Protein
45993321|NCT02834559|Drug|Placebo|Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV).
45993322|NCT02922608|Other|simulation practice|simulation session
45993323|NCT02933307|Device|HealthPatch|The HealthPatch (Vital Connect) is a wireless patch and continuously measures single-lead ECG, heart rate, respiratory rate, stress, skin temperature, body posture and steps
45993324|NCT02933307|Device|ViSi Mobile|ViSi Mobile (Sotera Wireless) is wireless device that is able to continuously measure all important vital parameters: ECG, heart rate, oxygen saturation, blood pressure, respiratory rate and skin temperature.
45993325|NCT02922686|Drug|Flucloxacillin|One flucloxacillin capsule of 500mg strength taken four times daily for 7 days
45993326|NCT02922686|Drug|Phenoxymethylpenicillin|One capsule of phenoxymethylpenicillin of 500 mg strength taken four times daily for 7 days
45993327|NCT02922686|Drug|Placebo (for phenoxymethylpenicillin)|Over-encapsulation of phenoxymethylpenicillin will be performed by the manufacturer of the investigational medicinal products such that placebo and active phenoxymethylpenicillin are identical in size, shape, colour and smell, and are packaged in identical bottles
45993328|NCT02922530|Other|Computerized Plasticity-based Adaptive Cognitive Training|
45993329|NCT02922530|Other|Commercially available computerized training|
45993330|NCT02922452|Drug|BMS-986141|Single dose BMS-986141 and Multiple doses of Dilitazem
45993331|NCT02922452|Drug|Dilitazem|Single dose BMS-986141 and Multiple doses of Dilitazem
45456989|NCT02292316|Other|osteodensitometry|Looking for osteoporosis
45674450|NCT04418219|Other|Questionnaire Administration|Ancillary studies
45993332|NCT02677974|Device|On-X Aortic Heart Valve replacement|Aortic valve replacement with low dose warfarin
45993333|NCT02922374|Drug|corticosteroids|Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
45993334|NCT02933151|Dietary Supplement|Nutritional Supplement|Selection of which supplement to give to the patients will be left to the dialysis unit's governing body as this study is not interested in a specific supplement's effect on nutrient restoration and subsequent outcomes but rather on oral replacement of amino acids regardless of the agent used.
45993335|NCT02922491|Dietary Supplement|vitamin E|daily intake of vitamin E
45993336|NCT02922491|Dietary Supplement|starch|daily intake of starch (control)
45993337|NCT02637024|Radiation|APBI: 30 Gy|30 Gy in 5 fractions of 6 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
45993338|NCT02637024|Radiation|APBI: 27.5 Gy|27.5 Gy in 5 fractions of 5.5 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
45993339|NCT04687722|Other|High Intensity Aerobic Training.|Participants will perform 2-5 minutes of low to moderate intensity warm up exercises and then 20 minutes of high intensity aerobic training at 80-90% of heart rate maximum increased gradually on treadmill and elliptical trainer and then 2-5 minutes of low to moderate intensity cool down exercises.
45993340|NCT04687722|Other|Low intensity Aerobic Training|Participants will perform 2-5 minutes of low to moderate intensity warm up exercises and then 20 minutes of low intensity aerobic training at 40-60% of heart rate maximum increased gradually on elliptical trainer and jogging and then 2-5 minutes of low to moderate intensity cool down exercises.
45993341|NCT03457454|Other|Primary Care Provider/Staff Participants Interview|-Approximately a 30 minute interview
45993342|NCT03457454|Other|Patient Participant Interview|-Approximately 45-60 minute interview
45993343|NCT03457454|Other|Patient Participant Anonymous Survey|-Survey completion will take approximately 15 minutes
45993344|NCT03457454|Other|Colonoscopy Provider/Staff Participants Interviews|-Approximately a 30 minute interview
45456990|NCT03932383|Device|Custom CPAP mask|Modified CPAP mask based on 3D image capture
45674451|NCT04418219|Other|Quality of Life Assessment|Ancillary studies
45674452|NCT02188589|Device|INEX nasal implant|Treatment group may receive unilateral or bilateral INEX nasal implants (maximum of 4, 2 per side)
45674453|NCT02167451|Drug|Maraviroc|
45674454|NCT02167139|Drug|Humira (adalimumab)|
45674455|NCT02167139|Drug|SB5 (proposed biosimilar to adalimumab)|
45993345|NCT02933112|Device|Auto-titrating mandibular positioner test|Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
45993346|NCT02922140|Behavioral|pharmaceutical care service|
45993347|NCT02932917|Device|MapMySmoke|Each patient in the study arm will download and install the MapMySmoke app to record all of their smoking and craving events. The app will generate a quantitative summary of their smoking behavior during a pre-quit phase, and will provide dynamic text support messages during the post-quit phase. The app will also capture spatial details of any relapse events during the post-quit phase.
45993348|NCT02922179|Drug|Long- and intermediate- acting insulins|alone or in combination with metformin, short-acting insulin, or second-generation sulfonylurea
45993349|NCT05467644|Procedure|Treatment of Fracture Related Infection|Observational Retrospective Study. Only one group. Patients diagnosed with fracture-related infection and submitted to surgical treatment
45993350|NCT02922062|Other|Canola Oil|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be canola oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
46084544|NCT02762864|Drug|ticagrelor|Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
45993351|NCT02922062|Other|Palm Oil|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be palm oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
45993352|NCT02922062|Other|Butter|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oils used in food preparation will be butter. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
45993353|NCT02922101|Behavioral|Audit and Feedback|An online dashboard that provides insight into clinical performance on pain management quality indicators. It also incorporates an empty action plan, in which participating intensive care units can define potential bottlenecks in the care process and what actions they intend to undertake to improve.
45993354|NCT02922101|Behavioral|Toolbox|A quality improvement toolbox, incorporated within the action plan, that comprises for each pain management quality indicator (e.g., percentage of patients per shift whose pain is measured) a list of potential bottlenecks in the care process (e.g., staff is unaware of the prevailing guidelines for measuring pain every shift), associated recommendations for actions to solve mentioned bottlenecks (e.g., organize an educational training session), and supporting materials to facilitate implementation of the actions (e.g., a slide show presentation discussing the importance and relevance of measuring pain every shift).
45993355|NCT02932839|Device|NeuroPort micro-electrode array|Implantation of the Blackrock NeuroPort micro-electrode array for up to 29 days in patients who are undergoing evaluation with intracranial EEG electrodes
45993356|NCT02932800|Procedure|"Fixation with ballerina technique and flip"|
45993357|NCT02932800|Procedure|Habitual Fixation|Evaluation on the third and fift days, filogisticos and infectious signs, fixing loss, and culture
45993358|NCT02932800|Other|Evaluation on the third and fift days, filogisticos and infectious signs, fixing loss, and culture|
45993359|NCT02921984|Drug|Docetaxel|Docetaxel only: 80 mg/m2 on day one, every 21 days if
45993360|NCT02921984|Radiation|Intensity-modulated radiotherapy|a total dose of 60-66Gy in 30-32 fractions over 6-7 weeks
45993361|NCT02921984|Drug|Pemetrexed|Pemetrexed only: 500 mg/m2 on day one, every 21 days
45993362|NCT02921984|Drug|Cisplatin|Cisplatin only: 70 mg/m2 on day one to day three, every 21 days
45993363|NCT02921867|Other|Simulation-based training|The simulation-based training will consist of nine modules that can be trained in random order and training periods within the eight weeks before clinical training starts.
45993364|NCT05467566|Device|Transcranial direct current stimulation|Exercise protocol + application of active direct current stimulation for 30 minutes.
45993365|NCT05467566|Device|Sham Transcranial direct current stimulation|Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
45993366|NCT02921945|Biological|SCT800|recombinant human coagulation factor VIII
45993367|NCT05467527|Behavioral|Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice|The PACT group will receive a combination of 6 online modules and 4 group-based video conferencing sessions of Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice via a mobile app across 12 weeks. The modules will cover real-life scenarios of daily parenting challenges in caring for a child with SHCN, followed by age-appropriate positive parenting advice based on the Centers for Disease Control and Prevention guidelines. After going through the scenarios, parents will be audio/visually guided to participate in ACT activities, including mindfulness exercises, ACT metaphors and experiential exercises, which will be used to increase psychological flexibility.
45993368|NCT05467527|Behavioral|Positive parenting advice|The Control Group will receive a total of 6 online modules and 4 group-based video conferencing sessions in a closed group of 6-8, 60 minutes per session guided by a trained facilitator via the mobile app across 12 weeks. The online modules will provide identical contents to those in the PACT group, but no guided ACT metaphors or experiential exercises. The interaction sessions serve to review and discuss the contents of online modules, but without the contents related to ACT/prosociality.
45993369|NCT04689230|Procedure|upper eyelid blepharoplasty|upper eyelid blepharoplasty
45993370|NCT04647825|Other|Collection of data from non-invasive epilepsy monitoring|Creation of a large long-term EEG database for seizure detection/prediction
45993371|NCT04689269|Other|"The simulated easy airway"|A high-fidelity simulator (Airway Management Trainer, model AA-3100, Laerdal Medical Ltd., Orpington, England, UK) will be equipped to create an easy airway situation by adjusting the manikin until it becomes in a neutral position
45993372|NCT04689269|Other|"The simulated difficult airway"|"A high-fidelity simulator (Airway Management Trainer, model AA-3100, Laerdal Medical Ltd., Orpington, England, UK) will be equipped to create a difficult airway scenario will be established by placing the occiput on an Oasis Elite™ Prone Head Rest, Adult (140 mm in height) (Covidien, Mansfield, MA, USA), and inhibiting head and neck movement by securing the head with an adhesive tape, simulating the effect produced by a cervical-collar."
45993373|NCT04689269|Device|King Vision Laryngoscope|Using a King Vision Laryngoscope for placement of the DLT
46084545|NCT02762864|Drug|Comparator|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patient followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period.
45993374|NCT04689269|Device|MacGrath Laryngoscope|Using a MacGrath Laryngoscope for placement of the DLT
45674460|NCT02116621|Behavioral|Trialist Intervention|Clinician and patient set up N-of-1 trial and patient uses Trialist smartphone app to answer daily questions about pain and associated side effects.
45993375|NCT05467488|Procedure|photofunctionalization|UVA and UVC photofunctionalization of dental implants
45993376|NCT01285609|Drug|Ipilimumab|
45993377|NCT01285609|Drug|Placebo|
45993378|NCT01285609|Drug|Paclitaxel|
45993379|NCT01285609|Drug|Carboplatin|
45674461|NCT02116621|Device|smartphone|
45674462|NCT02116309|Drug|Rectal Indomethacin|
45674463|NCT02116309|Drug|Epinephrine|
45674464|NCT02115607|Drug|Definity infusion|3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min
45674465|NCT01490632|Drug|Placebo|Administered orally
45993380|NCT02921672|Other|Mediterranean Diet|Diet consisting of fruits, vegetables, grains, dairy, olive oils, seafood, and nuts. It is low in red meat and solid fats.
45993381|NCT04689984|Drug|Standard therapy|Gabapentin, pregabalin, or amitriptyline
45993382|NCT04689984|Drug|Astaxanthin|Astaxanthin 6 mg tablet once daily
45993383|NCT02921711|Device|LVIS®|Low-profile Visualized Intraluminal Support device
45993384|NCT05467254|Biological|CLL1+CD33 CAR-T|CLL1+CD33 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
45993385|NCT03981341|Drug|Duavive (0.45 estrogens mg and 20 mg bazedoxifene)|Drug given for 3 months in each participant
45993386|NCT04620057|Dietary Supplement|butyrate|sodium butyrate (20 mg/kg body weight/day)
45993387|NCT04620057|Other|placebo|cornstarch
45993388|NCT03924440|Diagnostic Test|Proov (Ovulation Double Check) Test|Rapid response urine progesterone test strips, Proov (formerly named Ovulation Double Check
45993389|NCT01285492|Drug|QVA149|QVA149 (110 μg indacaterol / 50 μg glycopyrronium o.d.), delivered via Concept1
45993390|NCT01285492|Drug|Tiotropium|Tiotropium (18 μg o.d.), delivered via Handihaler®
45993391|NCT02889991|Other|High Intensity Dry Needling|"This technique follows the criteria established by Dr Hong C-Z. This technique is known as fast in and fast out technique and uses repeated insertion of the acupuncture needle in the myofascial trigger point, with the aim to get multiple local twitch responses. The technique ends when the local twitch responses disappear."
45993392|NCT02889991|Other|Low intensity Dry Needling|Technique proposed by the main investigator and based on the studies of Professor Dr. Jay P. Shah and the mechanisms of neuromodulation that transmits us the acupuncture scientific evidence.
46084546|NCT05556915|Other|Ultrasound-guided AVF cannulation method|For ultrasound-guided cannulation, the same ultrasound device will be used for all patients (TE5-POC ultrasound MINDRAY® system). The ultrasound device will identify the AVF aspect , the location including the depth (distance from the skin surface) , the vessel diameter and guide the cannulation in real-time. The device will be disinfected between uses and covered with a transparent adhesive film to avoid any direct contact with the patient. Sterile gel will be used for the cannulation.
46084547|NCT05556915|Other|Conventional AVF cannulation method|The AVF cannulation is carried out by palpation. This technique consists of manually evaluating the position, direction and depth of the fistula in order to determine the puncture site where the 2-dialysis catheters will be inserted. After local asepsis, the AVF is therefore needled at 2 points 5 cm apart.
45674466|NCT01490632|Drug|Baricitinib|Administered orally
45993393|NCT02889991|Other|Fascial Mechanotransduction Dry Needling|"The Fascial Mechanotransduction Dry Needling Technique, strikes with the acupuncture needle until it reaches and pierces the myofascial trigger point. Then the acupuncture needle is rolled in the connective tissue, which causes an intense coupler that we define as needle grasp. Finally, the acupuncture needling is pulled-out twice.~The screwing and the two pull-out of the acupuncture needle is performed in the infraspinatus and supraspinatus muscles and we describe it as mechanotransduction cycle. Each cycle lasts 30 seconds and the whole technique lasts 3 minutes per session."
45993394|NCT02889991|Other|Technique Placebo of Dry Needling|"Technique with a total duration of 3 minutes per session:~To locate the myofascial trigger points of infraspinatus and supraspinatus muscles and put each bridle on them.~Monitor longitudinally taut band, with index and middle fingers.~Percuss with tube and needle placebo (Sham needle) on Infraspinatus.~Remove the tube and needle placebo from the device. Reintroducing the placebo needle into the tube and strike on the supraspinatus. Repeat this sequence without interruption for 3 minutes.~Remove the bridles and perform hemostasis with cotton.~We will give end to the technique placebo of dry needling."
46084548|NCT02767154|Device|A colloid Dextran 40 solution for extracorporeal circulation|The oncotic pressure of the PrimECC solution is higher than that of a crystalloid Ringer-acetate/mannitol solution. It should maintain the plasma oncotic pressure during and after cardiopulmonary bypass (CPB). Subsequently, the leakage of fluids from the systemic circulation to the interstitial compartment during CPB can be reduced, and a higher plasma volume and a better fluid balance can be achieved.
45674467|NCT04726111|Other|Specimens specific for the study|Specimens (blood, umbilical cord, umbilical cord blood, placenta)
45993395|NCT04615143|Drug|Tislelizumab|Patients receive Tislelizumab on week 1 and week 4 (200mg, iv, q3w). After 2 cycles of Tislelizumab and evaluation of resectability, patients will receive surgery in 6 weeks after enrollment. Patients will receive Tislelizumab for 1 year (200mg, iv, q3w, 17 cycles) in 4-6 weeks after surgery.
46084549|NCT02767154|Device|Ringer-Acetate and Mannitol|Currently clinic standard for priming the CPB circuit.
46084550|NCT04178499|Diagnostic Test|cytokine analysis|analysis of intraocular cytokines
45674468|NCT01451554|Behavioral|portion control plate|Individuals are provided with a portion control plate to use while eating and dietary counseling by dietician
45674469|NCT01451554|Behavioral|Usual Care|self-help booklets
45674470|NCT01474486|Drug|Micronutrients|Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
45993396|NCT04615143|Drug|Tislelizumab combined with Levatinib|Patients receive Tislelizumab on week 1 and week 4 (200mg, iv, q3w); Lenvatinib from Day1 to Day 28 (8/12mg qd). After neoadjuvant treatment and evaluation of resectability, patients will receive surgery in 6weeks after enrollment. Patients will receive Tislelizumab combined with Lenvatinib for 1 year in 4-6 weeks after surgery.
45993397|NCT02921594|Device|Total knee arthroplasty with Vanguard XP|
45993398|NCT02921594|Device|Total knee arthroplasty with Vanguard CR|
45993399|NCT05467137|Device|MSOT|MSOT imaging (after ICG injection)
45993400|NCT02933463|Other|Embrace Wetbond|not require an additional bonding agent hydrophilic, fluoride releasing
45993401|NCT02933463|Other|Clinpro sealant|
45993402|NCT04689035|Drug|AVLX-144|Test drug
45993403|NCT04689035|Drug|Placebo|Placebo
45993404|NCT02921633|Other|Intervention letter|
45993405|NCT01284634|Drug|GWP42003 200 mg/day Dose|GWP42003 was presented as Licaps® size double zero (Size 00) hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
45993406|NCT01284634|Drug|GWP42003 400 mg/day Dose|GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
45993407|NCT01284634|Drug|GWP42003 800 mg/day Dose|GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
45993408|NCT01284634|Drug|Placebo|Placebo was presented as Licaps® Size 00 hard gelatin capsules containing excipients (Gelucire 44/14).
45993409|NCT02932722|Other|Control|Patients in the control groups do not receive any anesthetic during remote ischemic preconditioning.
45993410|NCT02932722|Drug|Propofol|Patients in the propofol group receive propofol anesthesia during remote ischemic preconditioning.
45993411|NCT02932722|Drug|Sevoflurane|Patients in the sevoflurane group receive sevoflurane anesthesia during remote ischemic preconditioning.
45993412|NCT02921516|Behavioral|N'ap Grandi|Eight 90-minute adolescent cognitive behavioral modules and four 90-minute caregiver cognitive behavioral modules, delivered in weekend workshops over a 1 month period, with the last two modules for joint participation of adolescents and caregivers.
45993413|NCT02921516|Behavioral|N'ap Grandi - A|Eight 90-minute adolescent cognitive behavioral modules delivered in weekend workshops over a 1 month period.
45993414|NCT02921516|Behavioral|Health Promotion - A|Eight 90-minute adolescent health promotion modules delivered in weekend workshops over a 1 month period.
45993415|NCT01284361|Device|30 cm Intermittent Catheter|Randomized cross-over
45993416|NCT01284361|Device|40 cm Intermittent Catheter|randomized cross-over
45993417|NCT02921438|Device|VitalScan Magnetocardiograph|A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
45993418|NCT02932761|Drug|GnRHa|Two doses of GnRHa were administered by subcutaneous injection. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure.
45993419|NCT02932761|Procedure|Vaginal repair of CSD|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
46084551|NCT02767232|Drug|Recombinant tissue plasminogen activator (rt-PA)|Catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
46084552|NCT02767232|Drug|Standard Anticoagulation Therapy|Standard anticoagulation determined by physician for a period of 3-6 months
46084553|NCT00614172|Radiation|Proton radiation therapy|Proton radiotherapy will start 2-4 weeks following surgical excision. The treatment area will include the lumpectomy site with an additional margin. Daily proton therapy will be given as an out-patient over a two week coarse.
46084554|NCT02673645|Other|SAGA Innovations|An intensive math tutoring program.
45833867|NCT05249790|Drug|Recommended treatment schedule|Non-steroidal anti-inflammatory drugs (NSAiDs), Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
45833868|NCT05249790|Drug|Usual care|Treatment regimens different from the recommended one according to family physician personal practice
45833869|NCT03370224|Behavioral|Memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
45833870|NCT03370224|Behavioral|Placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
46084555|NCT02767076|Procedure|conventional paramedian spinal anesthesia|land mark guided paramedian spinal anesthesia
45833871|NCT03304314|Diagnostic Test|objective chromatic multifocal pupillometer|objective chromatic multifocal pupillometer (OCMP) enables objective and accurate measurement of pupillary responses to chromatic light at different wavelengths and light intensities and at different visual field locations.
45833872|NCT03286842|Drug|Olaparib|Patients will be administered olaparib orally, twice daily at 300 mg. Two (2) 150 mg olaparib tablets should be taken at the same time each morning and evening of every day, approximately 12 hours apart.
45833873|NCT05243784|Behavioral|MOVI-HIIT intervention|"Each HIIT break will last approximately 5 minutes and will not require any specific materials. The structure of the HIIT-Rest will be as follows: 1' to describe the work to be done; 3' of work following the HIIT protocol: 6 repetitions of a functional movement such as squats, Jumping Jack or running on site for 20 at high intensity (85-90% of HR -heart rate- max) followed by 10 of recovery (65-75% of HR max); and 1' to perform a return to calm in order to lower the activation and prepare the student body to return to class activities."
45833874|NCT05247060|Other|no experimental intervention|There will not be any experimental intervention. The study will be conducted according with normal clinical practice
45833875|NCT05245188|Other|Chocolate milk shakes - Product 1|11.3 glucose
45833876|NCT05245188|Other|Chocolate milk shakes - Product 2|8.84 glucose
45833877|NCT05245188|Other|Chocolate milk shakes - Product 3|4.24 glucose
45993420|NCT01283971|Drug|tocilizumab [RoActemra/Actemra]|Tocilizumab 8 mg/kg IV every 4 weeks for 24 weeks.
45993421|NCT01283971|Drug|adalimumab|Adalimumab 40 mg SC every 2 weeks.
45993422|NCT01283971|Drug|placebo to tocilizumab|Placebo to tocilizumab IV every 4 weeks for 24 weeks.
45993423|NCT01283971|Drug|placebo to adalimumab|Placebo to adalimumab SC every 2 weeks for 24 weeks.
45993424|NCT01283971|Drug|methotrexate|Methotrexate 10-25 mg weekly.
45993425|NCT01283971|Drug|folate|Folate at least 5 mg weekly.
45993426|NCT05466981|Behavioral|Cognitive Behavioral Counseling|The intervention consisted of 12 weeks of HCV treatment combined with smoking cessation pharmacotherapy and brief behavioral counseling conducted by a LMSW. The brief behavioral counseling consisted of cognitive behaioral components and was provided by phone and in-person. The intervention followed these 5 phases: increase motivation to quit smoking, quit attempt, maintain short-term abstinence, and lapse and relapse prevention.
45993427|NCT02921282|Genetic|Genotype dopamine|Laboratory investigations of nicotine reinforcement
45993428|NCT02921282|Genetic|Genotype cannabinoids|Laboratory investigations of nicotine reinforcement
45993429|NCT02921360|Drug|acetylsalicylic acid|
45993430|NCT02932605|Drug|Placebo|Placebo
45993431|NCT02932605|Drug|Cannabidiol|Cannabidiol
45993432|NCT02921204|Other|Vitamin D status|There is no intervention in this study
45993433|NCT01283581|Drug|Delafloxacin|300mg IV every 12 hours for 5-14 days
45993434|NCT01283581|Drug|Linezolid|600mg IV every 12 hours for 5-14 days
45993435|NCT01283581|Drug|Vancomycin|15mg/kg, up to 1250 mg, IV every 12 hours for 5-14 days
45993436|NCT05466903|Dietary Supplement|Early diet opening|Effects of early dietary recovery after colon polypectomy and colonoscopic mucosal resection on postoperative hemorrhage in patients
45993437|NCT01283542|Drug|Pasireotide LAR|20 and 40 mg of powder in vials and 2 mL of vehicle in ampoules (for reconstitution) administered as a depot intragluteal IM (intramuscular) injection
45993438|NCT05466864|Device|Belun Sleep platform|BSP(Belun Technology Company Limited) is a novel wearable system using a neural network algorithm that consists of a patented wearable device (Belun Ring), a charging cradle, and cloud-based software. The Belun Ring, an FDA-cleared pulse oximeter, acquires signals from the radialis indicis artery of the proximal index finger. The Belun Ring total sleep time can be derived from features extracted from accelerometer, SpO2, and PPG signals, whereas Belun Ring AHI can be derived from Ring-TST and features extracted from HRV and SpO2 changes. The BSP proprietary OSA detection algorithm was using neural network. BSP performance can be improved by training the algorithm through continual data collection. To our knowledge, BSP is the only validated sleep platform using a medical-grade wearable pulse oximeter, actigraphy, and artificial intelligence algorithm that has the capability to identify sleep stages, detect OSA events, and monitor autonomic nervous system activity changes during sleep.
45993439|NCT02921048|Dietary Supplement|omega-3 fatty acids|
45993440|NCT02932488|Drug|Sumatriptan|Sumatriptan is a 5-HT1B receptor agonist used for treatment of migraine attacks
45993441|NCT02921165|Drug|analgesic mouth rinses (dissolved Aspirin)|Group 1 and Group 2 patients will be prescribed analgesic mouth rinses (dissolved Aspirin) twice daily along with the standard prescription of analgesics and antibiotics.
45993442|NCT02921165|Drug|Normal saline rinses.|Non Hypertensive patients will be prescribed normal saline rinses twice daily along with the standard prescription of analgesics and antibiotics.
45993443|NCT01283386|Drug|Chlorambucil|10 mg/m^2 orally on Days 1-7 of each 28-day cycle for 6 cycles
45993444|NCT01283386|Drug|Cyclophosphamide|150 mg/m^2 IV or orally on Days 1-3 of each 28-day cycle for 6 cycles
45993445|NCT01283386|Drug|Fludarabine|20 mg/m^2 IV or 32 mg/m2 orally Days 1-3 of each 28-day cycle for 6 cycles
45993446|NCT01283386|Drug|Rituximab|375 mg/m2 IV on Day 1 of Cycle 1; 500 mg/m2 IV on Day 1 of Cycles 2-6 (28-day cycles)
45993447|NCT05466786|Other|Standard Management|Standard Management
45993448|NCT02920931|Drug|Tenofovir disoproxil|
45993449|NCT01283152|Drug|Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)|If randomized to this arm, subjects will receive a 1 time dose of 1 gallon
45993450|NCT01283152|Drug|Lactulose|If randomized to this arm, subjects will receive 10-30 grams per standard of care
45993451|NCT02932527|Behavioral|Questionnaire about cannabis consumption|Questionnaire about cannabis consumption will be assessed to infertile male exposed to cannabis and infertile male not exposed to cannabis.
45993452|NCT02932527|Procedure|blood intake|blood intake is done for infertile male exposed and infertile male not exposed.
45993453|NCT02932527|Procedure|Semen samples collection|Semen samples are collected for infertile male exposed and infertile male not exposed.
45456991|NCT02294812|Behavioral|Cognitive training|"Participants will engage in eight weeks of training that focuses on improving various cognitive abilities. For example, short term memory.~Cognitive training will take place 30 minutes per day, five days per week, for eight weeks. Training will be done in the participant's own home using web-based software. Participants will be randomly assigned to either the active control group, the control cognitive training group, or the experimental cognitive training group following the second study visit.~After eight weeks, participants will no longer partake in training."
45993454|NCT01283035|Drug|Akt Inhibitor MK2206|Given PO
45993455|NCT01283035|Other|Laboratory Biomarker Analysis|Correlative studies
46084556|NCT02767076|Device|ultrasound guided paramedian spinal anesthesia|real time ultrasound guided paramedian spinal anesthesia
45993456|NCT02920853|Behavioral|Biofeedback Training (BT-CPR)|Participants will receive biofeedback training (which will include electric stimulations) to reduce arousal and pain
46084557|NCT04178733|Drug|LY3493269 - SC|Administered SC
45456992|NCT01130467|Drug|methylphenidate|IR-MPH were started on a dose of 5 mg tid po, and this was increased to 10 mg tid and then to 15 mg tid as necessary. OROS-MPH was started on a dose of 18 mg qd, and this was increased to 36 mg qd and then to 54 mg qd as necessary.
45833878|NCT05245188|Other|Chocolate milk shakes - Product 4|4.36 glucose
45833879|NCT05240274|Drug|Metformin|metformin 500mg OD for 3 months to start within 10 days post-renal transplant
45833880|NCT05240274|Drug|Placebo|placebo 500mg OD for 3 months to start within 10 days post-renal transplant
45833881|NCT05240196|Other|music|playing binaural or non-binaural music
45833882|NCT05240586|Procedure|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
45833883|NCT05240586|Procedure|acupuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and number of acupuncture therapy according to participants' conditions.
45993457|NCT02920853|Behavioral|Biofeedback Training|Participants will receive biofeedback training to reduce arousal and pain
45993458|NCT02932371|Device|ECOM™.|
45993459|NCT02932371|Device|Trans-esophageal echography|
45993460|NCT01283464|Drug|Retinol|1.0% cream
45993461|NCT01283464|Drug|Tretinoin|0.02% cream
45993462|NCT01282801|Drug|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
45993463|NCT01282801|Drug|Effexor® XR|150 mg Extended-Release Capsule
45993464|NCT02920814|Other|Cognitive Behavioural Therapy|Time intensive CBT over 8 weeks, including 6 weekly sessions and two intensive days of 4 hours each.
45993465|NCT00532350|Drug|QAT370|
46084558|NCT04178733|Drug|Placebo - SC|Administered SC
46084559|NCT04178733|Drug|LY3493269 - IV|Administered IV
46084560|NCT02766764|Drug|DHEA|Women will receive oral DHEA 25 mg t.d.s. for 12 weeks before ICSI.
45993466|NCT00532350|Drug|Placebo|
45993467|NCT00532350|Drug|Tiotropium|
45993468|NCT02920775|Other|Non-interventional study - retrospective database review|
45833884|NCT05240586|Procedure|physical therapy, medication(prn)|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions. According to clinical judgment, clinicians can prescribe analgesics and muscle relaxants if necessary.
45833885|NCT05244018|Drug|Vitamin D3 tablets|Vitamin D3 tablets 50,000 IU units
45993469|NCT02932566|Drug|Pirfenidone|Pirfenidone is an orally bioavailable, small molecule antifibrotic agent.
45993470|NCT02932566|Drug|Placebo|Placebo capsule, manufactured with the exact components of the Pirfenidone capsules, without the active ingredient / investigational medicinal product
45993471|NCT00532389|Drug|LBH589|
45993472|NCT02920580|Procedure|Extubation|This is an extubation by removal of endotracheal tube which must be done on the day of randomization or the following day. Any decision to subsequently reintubate the patient will be left to the discretion of the clinical team. Similarly, if a tracheostomy is deemed necessary in a patient who fails the extubation attempt, this will be managed at the discretion of the treating team. If for any reason the patient is not extubated according to the randomized schedule, the reason(s) will be recorded on a protocol violation form and the site investigator will be notified. If a patient receives a tracheostomy instead of being extubated we will again record reasons for this, but the patient will be analysed in the extubation group according to the intention-to-treat principle.
45456993|NCT01130467|Drug|Atomoxetine|Atomexetine was started (weight of 70 kg or less) 0.5 mg/kg/day orally and increased after a minimum of 3 days to a target dose of 1.2 mg/kg/day. The maximum dosage is 1.4 mg/kg/day or 100 mg/day (whichever is less).
45993473|NCT02920580|Procedure|Usual Care|Patients in this group will be treated according to usual care, which may include extubation (removal of endotracheal tube) or insertion of a tracheostomy, timed according to physicians' discretion. The inclusion of this arm will allow prompt extubation to be compared to usual practice, which often involves further observation and delayed decision-making due to clinician uncertainty about the optimal airway management strategy. Incorporation of usual care arms has been promoted as a design feature to improve the safety and interpretability of critical care clinical trials.
45993474|NCT02932644|Other|Baseline serum vitamin D level below 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
45993475|NCT02932644|Other|Baseline serum vitamin D level at or above 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
45993476|NCT02920697|Drug|S 55746|S 55746, per os administration, from 50 to 1500 mg, once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
45993477|NCT05466708|Drug|Esketamine combined with dexmedetomidine|"Asic ketamine, injection, 50mg/ bottle, source: hospital pharmacy, production unit: Jiangsu Hengrui Pharmaceutical Co., LTD., validity: 2 years, storage condition: airtight shading, room temperature.~Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature."
45993478|NCT05466708|Drug|Dexmedetomidine|Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature.
45456994|NCT01130467|Behavioral|behavioral modification|Parenting and teaching skill education
45456995|NCT02294890|Procedure|Total knee arthroplasty|
45674471|NCT04075552|Behavioral|Pre Meal Presentation|Pre-Meal Presentation. In the Pre-Meal Presentation (PMP) condition, school staff delivered the plate of vegetable pieces prior to students regularly scheduled lunchtime (about 5 min). Like baseline, no programmed consequences were provided for student interaction or consumption of the vegetables.
45674472|NCT04075552|Behavioral|Pre Meal Presentation + Modeling|"Similar to the prior condition, each participant will be offered a plate containing target foods for 4 min. Once the plate has been delivered to each participant, a staff person will model eating the food. The model will have an identical plate of food. Within six feet of students oriented towards the model (i.e., the students will be facing the model), the model will pick up one piece of food, say Yum, this looks good in a loud and excited tone, eat it, and then deliver a soft prompt to the participants to try it (e.g., You should try this!). Staff will avoid giving a firm/hard demand (e.g., Eat the food). Repeat this for four pieces of food, alternating between the two target foods, with about 10-20 sec between each bite. Repeat the model as necessary based on the room arrangement, such that each students contacts the model within six feet while oriented towards the model."
45833886|NCT05244018|Drug|Vitamin D tablets|Vitamin D tablets 5000 units as daily requirements
45833887|NCT03190200|Device|MRI|No intervention - observational trial using MRI
45833888|NCT03103932|Other|Biomarker guided discharge algorithm|participants randomized to the biomarker guided discharge algorithm will follow a pre-determined care pathway for treatment of heart failure symptoms based on admission NTproBNP levels
45993479|NCT02920541|Drug|S 055746|S 055746, per os administration, from 50 to 2000 mg once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
45993480|NCT01282294|Device|ETN PROtect|Expert Tibial Nail PROtect with Gentamicin coating
45993481|NCT02932293|Drug|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
45993482|NCT02920502|Dietary Supplement|Arm 2: cholecalciferol 50,000 IU|One time dose of cholecalciferol 50,000 IU
45993483|NCT02920502|Dietary Supplement|Arm 3: cholecalciferol 100,000 IU|One time dose of cholecalciferol 100,000 IU
45993484|NCT02920502|Dietary Supplement|Arm 4: cholecalciferol 200,000 IU|One time dose of cholecalciferol 200,000 IU
45993485|NCT02920502|Other|Arm 1: Placebo|One time dose of Placebo
45993486|NCT01282216|Biological|Havrix|1440 ELISA units, or 1 mL, IM
45993487|NCT01282216|Biological|PCV13|0.5 mL IM
45993488|NCT04323709|Other|Data collection|Clinical data are collected from the medical record of the institution. At admission, date were collected on age, gender, body mass index, Simplified Acute Physiology Score II, Sequential Organ Failure Assessment, hypertension, diabetes, hypercholesterolemia, smoking, history of stroke or congestive heart failure, coronary or peripheral artery disease, renal failure with dialysis, Left Ventricular Ejection Fraction(LVEF), Tricuspid Annular Plane Systolic Excursion, mean arterial pressure, heart rate, central venous pressure, ScvO2, presence of an intra-aortic balloon pump and biochemical parameters. During hospitalization data were collected on reason for initiation of VA-ECMO and its characteristics (duration, type, flow L/min, RPM, FiO2), length of stay in ICU, catecholamines and inotropes maximal dose and length of administration, patients with heart transplantation or LVAD. In patients with levosimendan treatment, timing of administration regarding ECMO canulation was collected
45993489|NCT04323709|Other|Data analysis|Continuous variables were presented as mean ± standard deviation and compared using Student's t-test or Mann-Whitney U-test depending on their normality. Categorical variables were presented as counts and percentages and compared using Pearson's chi-squared test or Fisher's exact test, as appropriate. Survival at day 28 was estimated using the Kaplan-Meier method and compared using the log rank test. Investigators conducted a multivariable logistic regression with propensity score matching, which was defined as the probability of exposure to levosimendan. Results were reported as odd ratios (ORs) together its 95%CI assuming a 5% level of statistical significance. All analyses were carried out using STATA 15.0 (Stata Corp, College Station, Texas 77845 USA).
45993490|NCT01281865|Other|diagnostic laboratory biomarker analysis|Correlative studies
45993491|NCT01281865|Drug|everolimus|Given PO
45993492|NCT01281865|Drug|imatinib mesylate|Given PO
46084561|NCT02766764|Drug|Growth hormone|Women will receive GH subcutaneous injections daily from day 6 of hMG administration until the day of hCG administration.
45993493|NCT02932683|Device|MedNav|MedNav is a tablet based platform that uses auditory and visual cues to prompt people to perform the correct steps in neonatal resuscitation.
46084562|NCT02766764|Drug|Placebo 1|Women will receive an oral placebo similar to DHEA t.d.s for 12 weeks before ICSI
46084563|NCT02766764|Drug|Placebo 2|Women will receive subcutaneous placebo injections similar to GH daily starting from day 6 of hMG injections until the day of hCG injection
46084564|NCT02673411|Device|ultrasound shear wave elastography|ultrasound shear wave elastography is performed in GE ultrasound scanner according to guidelines of ultrasound elastography.
46084565|NCT04658654|Drug|Roflumilast|chronic intervention (24 weeks): roflumilast capsule
46084566|NCT04658654|Drug|Placebo oral tablet|Pill with inactive ingredients to mimic same appearance of roflumilast capsule
46084567|NCT04178343|Radiation|tomotherapy|"the prescription of tomotherapy: whole brain radiation (WBRT) with 40Gy in 20 fractions and concurrent boost of 60Gy of the leptomeningeal metastases;~WBRT of 50Gy in 25 fractions, with dose limitation of hippocampus and brain stem; c.TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2*5d, q28d, up to 6cycles.~d. Some patients received intrathecal chemotherapy (MTX+AraC+Dex) based on the cytology of cerebrospinal fluid (CSF)."
45833889|NCT04396314|Behavioral|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), a health oriented, multi-perspective and person-centred approach with a focus on the patient's resources. It is a movement awareness training approach in physiotherapy, aiming to promote movement quality in daily life through self-exploration and self-experience enabling the learning of new movement habits
45993494|NCT02920658|Drug|NAVS Naphthalan|
45993495|NCT02920658|Drug|0.05% Betamethasone dipropionate|
45993496|NCT02889679|Procedure|Underwater resection|Underwater resection of eligible lesions will be performed with air exclusion (air will be suctioned and completely removed) without submucosal injection in a partially collapsed colon lumen filled with water. Water will be infused with the foot pedal to facilitate visualization during UR and there will be no limit to the amount of water infused. Hot and cold resection techniques will be utilized.
46084568|NCT02673801|Other|Orthopedic assessment in the outpatient clinic|Orthopedic assessment based on clinic evaluation, patient symptoms and radiographic evaluation
46084569|NCT02766842|Procedure|EUS-FNB with ProCore needle|The use of the standard ProCore needle to acquire diagnostic tissue
46084570|NCT02766842|Procedure|EUS-FNB with SharkCore needle|The use of new SharkCore needle to acquire diagnostic tissue
45833890|NCT04396314|Behavioral|Psychological treatment|Cognitive-behavioural therapy, cognitive processing therapy, cognitive therapy and prolonged exposure therapy
45833891|NCT04276818|Procedure|PRP group|Demonstrating the effectiveness of dressing with PRP in the treatment of second-degree burns
46084571|NCT02766842|Device|ProCore needle|This is the standard needle used currently to procure tissue from lesions under endoscopic ultrasound guidance
46084572|NCT02766842|Device|SharkCore needle|This is the new FDA approved needle for tissue procurement under endoscopic ultrasound guidance.
46084573|NCT02673177|Procedure|robot-assisted total mesorectal excision|The Da Vinci Surgical System may help to protect subtle anatomical structure and provide more functional protection when compared to laparoscopic surgery. This study aimed to compare RTME and laparoscopic total mesorectal excision (LTME) for rectal cancer with regard to Urinary, sexual function and sphincter- preservation outcomes.
45993497|NCT02889679|Procedure|Conventional (gas distended colon) resection|Conventional polypectomy of eligible lesions will be performed in a gas distended colon. Hot and cold resection techniques will be utilized. Submucosal fluid injection with a solution containing hydroxyethyl starch, dilute epinephrine and a contrast agent may be used with conventional techniques for large (≥1cm) and/or flat lesions. There will be no limit to the amount of submucosal injection used.
45993498|NCT02889679|Procedure|Standard polypectomy|Standard polypectomy will be performed for diminutive (<6mm), pedunculated and semi-pedunculated lesions that do not fall under the inclusion criteria for the study. These lesions will be removed in a gas distended colon with a 9mm firm, thin wire cold snare or snare electrocautery for large (≥1cm) lesions.
45993499|NCT02890030|Behavioral|Questionnaire|"Neurotoxicity~Medications of interest~General health~Family history"
45993500|NCT02920619|Device|Ultrasound|Imaging of the rectus femoris, lower-trapezius, brachioradialis, tibialis anterior, middle deltoid, and pectoralis major will be conducted in Veteran participants during a single visit to the Washington D.C. Veterans Affairs Medical Center. Imaging will be conducted by investigators experienced with quantitative ultrasound using diagnostic musculoskeletal B-mode ultrasound with a 10 Mhz linear transducer.
45993501|NCT01281202|Drug|Vigabatrin|Tablets
45993502|NCT01281202|Drug|Matching Placebo|Tablets
45993503|NCT02889718|Device|CONCERT-CL® station|"During cancer surgery (surgery > 1 hour), CONCERT-CL® station will be used in accordance with its CE marking to administer anesthetic agents:~Port B = open loop: Analgesic~Port A = closed loop: Hypnotic~Port C = closed loop: Curare"
45993504|NCT02889718|Other|Surgery|Regardless of the type of surgery the patient receives for his cancer, this surgery must be greater than 1 hour.
45674473|NCT04075552|Behavioral|Pre Meal Presentation + Token Economy|Similar to prior condition, expect each participant can earn tokens for eating food items. Tokens can be exchanged for small prizes (e.g., pencil or sticker) at the end of a session.
45993505|NCT02932215|Drug|lorcaserin|Open label
45993506|NCT02932215|Other|Fitbit Charge HR|This is actually not an intervention- it is a tool to measure activity and sleep; all participants will be receiving one to collect data
45993507|NCT01281124|Drug|Azacitidine|Given subcutaneously
45993508|NCT01281124|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
45993509|NCT01281124|Other|Pharmacological Study|Correlative studies
45993510|NCT00623857|Dietary Supplement|Zinc|Daily oral supplementation with zinc, 10 mg, for an average of 60 weeks
45993511|NCT00623857|Dietary Supplement|Vitamins and minerals other than zinc|Daily supplementation with vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
45993512|NCT00623857|Dietary Supplement|Vitamins plus zinc and other minerals|Daily oral supplementation with zinc, vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
46084574|NCT02673177|Procedure|laparoscopic total mesorectal excision|Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer.
45993513|NCT00623857|Dietary Supplement|Placebo|Daily oral supplementation with placebo for vitamins and all minerals; for an average of 60 weeks
45674474|NCT01451398|Drug|Technosphere® Insulin|Technosphere® Insulin Inhalation Powder
45993514|NCT05466435|Other|Heavy Slow Resistance|Heavy slow resistance exercise will be given twice a week for 12 weeks along with traditional physical therapy program
45993515|NCT05466435|Other|Control group|Traditional physical therapy program only will be given twice a week for 12 weeks
45993516|NCT02920424|Drug|JNJ-56022473|Subjects will be administered with JNJ-56022473 SC depending upon on the dose levels.
45993517|NCT02920424|Drug|Placebo|Subjects will receive matching placebo.
45993518|NCT01280968|Biological|NIC002 in Aluminum hydroxide (Alum)|Fifty-five subjects will receive 4 subcutaneous injections of 0.1 mg Nicotine-QB (NIC002) in Alum vaccine with a 4-week interval between injections.
45993519|NCT01280968|Biological|Placebo Vaccine - Aluminum hydroxide|Ten subjects will receive 4 subcutaneous injections of indistinguishable placebo (Alum alone) with a 4-week interval between injections.
45993520|NCT02889445|Drug|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
46084575|NCT00644241|Biological|stem cell harvest|stem cells will be harvested from the iliac crest of the patients
46084576|NCT00644241|Procedure|angiographic transplantation of stem cells|autologous bone marrow derived stem cells will be transplanted in the gastroduodenal artery of the patient angiographically
45674475|NCT01451398|Drug|Technosphere Powder|Placebo Comparator
45993521|NCT02920385|Drug|Semaglutide|Oral administration once daily alone or together with levothyroxine or Placebo
45993522|NCT02920385|Drug|SNAC|Oral administration once daily alone or together with levothyroxine or semaglutide
45993523|NCT02920385|Drug|Levothyroxine|Oral administration alone or together with SNAC or oral semaglutide
45993524|NCT02920385|Drug|Placebo|Oral administration once daily together with semaglutide
46084577|NCT02770508|Drug|darunavir/ritonavir|
46084578|NCT02770508|Drug|Lamivudine|
46084579|NCT02770508|Drug|emtricitabine-tenofovir(FTC/TDF)|
46084580|NCT04178421|Other|Computerized training program|Eye-gaze fixation computer based training program
46084581|NCT04178421|Other|Placebo|Pac-Man, Zookeeper, Tetris
45993525|NCT01280812|Behavioral|Mobile phone based physical activity intervention with maintenance plus|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer and a mobile phone physical activity diary.
45993526|NCT01280812|Behavioral|Mobile phone based physical activity intervention with maintenance regular|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer.
45993527|NCT01280812|Behavioral|Control (pedometer only)|This group will receive a pedometer. Over a 9-month period, participants in this group will be asked to wear a pedometer.
45993528|NCT02932020|Drug|AlloGen-LI|interlaminar epidural injection of 2mL 0.5% marcaine and one 2-ml dose of AlloGen-LI
45993529|NCT02932020|Drug|depomedrol|interlaminar epidural injection of 2mL 0.5% marcaine and 1mL steroid (depomedrol 80mg/ml)
45993530|NCT02932020|Device|MRI|contrast enhanced MRI of the lumbar spine performed at Visit 1 and Visit 6 weeks (+7 days)
45993531|NCT02932020|Drug|0.5% marcaine|epidural injection of 2mL 0.5% marcaine
45993532|NCT02932098|Behavioral|Discharge instructions reminders|"Week 1, Day 1: Click through each discharge instruction; Week 1, Days 2-7: Click through single list of all discharge instructions.~Participants will receive a reminder of discharge instructions everyday for the first week post-discharge."
45993533|NCT02932098|Behavioral|Prompts to report symptoms via the web-enabled app|Group will receive reminders to enter new symptoms or changes in symptoms (based on a Likert scale or Y/N) on the following schedule: Week 1 (daily), Week 2 (every other day), Weeks 3-4 (once per week)
45993534|NCT02932098|Behavioral|Clinical Alerts|Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
45993535|NCT05466396|Behavioral|smoking|Smoking history and spirometry are used to define groups
45993536|NCT05466279|Drug|remazolam|Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil.
45993537|NCT05466279|Drug|Propofol|Propofol (2,6-diisopropylphenol) is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus
45993538|NCT05466279|Drug|Midazolam|Midazolam, like diazepam, is a benzodiazepine anxiolytic drug, which is used to treat anxiety, but its t ½ is much shorter or only about 2 h compared with 43 h for diazepam
45993539|NCT02920307|Procedure|TEP without fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
46084582|NCT02762786|Behavioral|musical training|The subjects in the experimental group will receive weekly one-hour lessons on musical training for 12 weeks, conducted by the Music Children Foundation.
46084583|NCT02537301|Other|joining in the platform|The activities (contents, chatting frequency etc.) of ERCP doctors on the chatting group were retrospectively extracted. The data related to the performance of ERCP (such as case volume, cannulation success rate and PEP etc.) by ERCP doctors were collected by a questionaire.
45993540|NCT02920307|Procedure|TEP with fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
46084584|NCT02762942|Drug|Misoprostol|Administration of 25 mcg of vaginal misoprostol every 4 hours up to 5 doses
46084585|NCT02762942|Device|Foley catheter|Insertion of a Foley catheter (16French) through the internal os for a maximum of 12 hours
46084586|NCT02673099|Procedure|HDF online|Hemodialysis by the HDF online method
46084587|NCT02770430|Biological|mesenchymal stem cells|MSCs derived from bone marrow (BM) will be isolated and expanded in the laboratory under conditions of Good Manufacturing Practice. The quality control involves immunophenotyping, differentiation, microbiological control, mycoplasma and endotoxin tests. Patients will receive five infusions of MSC. Dosage: 2x10E6 cells/Kg
45456996|NCT03517774|Device|3D Printed Socket|Twenty participants will be fitted with a 3D Printed socket created using 3DPrintAbility hardware and software. To do this, a 3D model of the participants residual limb will be generated which will be used to create the 3D printed sockets. These 20 participants will also receive standard care for prosthetic fitting at SJR. The fittings will be done by one prosthetist. Our team will compare the feasibility, function, quality and stability of the prosthetics through quantitative, economic and qualitative analyses. All fittings will be done under the supervision of a qualified Sunnybrook prosthetist who has previous experience with using 3D printed technologies for creation of prosthetics.
45993541|NCT02920307|Procedure|TAPP without fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair without mesh fixation
45993542|NCT02920307|Procedure|TAPP with fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair
45993543|NCT01280656|Drug|Conventional Interferon|Conventional interferon according to the standard of care and aligned with the local prescription instructions
45993544|NCT01280656|Drug|Peginterferon Alfa-2a|Peginterferon alfa-2a according to the standard of care and aligned with the local prescription instructions
45993545|NCT01280656|Drug|Peginterferon Alfa-2b|Peginterferon alfa-2b according to the standard of care and aligned with the local prescription instructions
45993546|NCT01280656|Drug|Ribavirin|Ribavirin according to the standard of care and aligned with the local prescription instructions
45993547|NCT05466162|Other|Soft tissue mobilization|"Soft tissue massage therapy includes Madenci hand massage technique initiate with 30-second (sec) effleurage, followed by 60- sec friction, 30-sec petrissage, 30-sec shaking, and ends with 30-sec effleurage. It takes totally of 3 min Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~. Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs"
45993548|NCT05466162|Other|Joint and nerve mobilization|"Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs."
45993549|NCT03741530|Drug|Glibenclamide Tablets|Giving glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
45993550|NCT03741530|Other|Standard management for ICH|Usual care and drug in hospital
45993551|NCT01280617|Drug|Thymoglobulin|Thymoglobulin 1.25mg/kg dose
45993552|NCT01280617|Drug|Thymoglobulin 0.75mg/kg dose|Thymoglobulin
45993553|NCT02920268|Other|Dance and yoga intervention|
45993554|NCT02932137|Drug|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2）
45674476|NCT02073565|Device|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
45993555|NCT02889484|Procedure|Lumbar disc hernia surgery|
46084588|NCT02770430|Drug|conventional treatment|"Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.~If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR."
45993556|NCT02889328|Drug|Regorafenib|Regorafenib 100mg continuous dosing arm
46084589|NCT05355987|Other|Early oncological supportive care|Several appointments (at diagnosis, 3 months, 6 months and 9 months) with nursing coordinator to define the needs in oncological supportive care. Different appointments will be planned according to patient's needs, with several possibilities: oncological supportive care nurse, social worker, psychologist, physiotherapist, adapted physical activity, medication reconciliation, oncologic geriatric medicine, dietician, nutritionist, smoking cessation advisor, sexologist, sophrologist, pain management nursing and palliative care, socio-aesthetician and religious cult coordinator.
46084590|NCT05355987|Other|Delayed oncological supportive care|Two appointments (6 months and 9 months) with nursing coordinator to define the needs in oncological supportive care. Different appointments will be planned according to patient's needs, with several possibilities: oncological supportive care nurse, social worker, psychologist, physiotherapist, adapted physical activity, medication reconciliation, oncologic geriatric medicine, dietician, nutritionist, smoking cessation advisor, sexologist, sophrologist, pain management nursing and palliative care, socio-aesthetician and religious cult coordinator.
46084591|NCT02762630|Device|Carestream Health Inc. weight bearing cone beam CT scanner|
46084592|NCT02673255|Biological|Tetanus and Diphtheria (Td) Vaccine|
46084593|NCT02672787|Behavioral|ED-based behavioral intervention|Data collection, antihypertensive adherence assay, antihypertensive interview and EHR review, barrier identification, personalized goal setting, communication with PCP, and reminder messages/engagement messages.
46084594|NCT02672787|Behavioral|ED usual care plus education|Data collection, antihypertensive adherence assay, antihypertensive interview, EHR review, and usual care education.
46084595|NCT00918203|Biological|Olaratumab|15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered intravenously (IV) at 25 milligram/minute (mg/min), with a minimum infusion time of 30 minutes.
45833892|NCT04276818|Procedure|conventional treatment group|The effectiveness of conventional dressing containing silver sulfadiazine in the treatment of burns will be compared with the method of dressing with PRP.
45833893|NCT04396392|Behavioral|VR-based training|"All interventions will be home-based and self-guided. The participants will work on the interventions after school hours at home.~All participants will be randomized into four groups (see Figure 1). All participants will receive an introduction module, with information tailored to their study group. Parents will receive an introduction module with information about the study group their adolescents belong to."
45833894|NCT02395224|Other|cancer treatment and follow-up according to current regional and national guidelines|
45993557|NCT02932059|Behavioral|Metamemory|Metamemory evaluation using a sentence construction strategy
45993558|NCT01280266|Drug|Udenafil or Amlodipine|Amlodipine 10mg daily then Udenafil 100 mg daily OR Udenafil 100 mg daily then Amlodipine 10mg daily
45993559|NCT01279447|Drug|0.25% Bupivacaine|10cc, single dose, US guided injection
45993560|NCT01279447|Drug|Normal Saline|10cc, single dose, US guided injection
45993561|NCT05466045|Other|Olive oil application in hemodialysis patients with pruritus|Experimental group: In addition to routine care, a brown glass bottle containing extra virgin olive oil was applied on the itchy skin every 12 hours by rubbing (after washing the patient's face in the morning and after dinner). The intervention duration was 28 days.
45993562|NCT05466045|Other|Normal saline application in hemodialysis patients with pruritus|Control group: In addition to routine care, a brown glass bottle containing normal saline was applied on the itchy skin every 12 hours by rubbing (after washing the patient's face in the morning and after dinner). The intervention duration was 28 days.
45674477|NCT02073565|Device|Everolimus Eluting Stent (EES)|Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
45993563|NCT02920034|Device|Radiofrequency denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Spyral™ Catheter (Medtronic, MN, USA)
45993564|NCT02920034|Device|Radiofrequency denervation of renal arteries and branches|Catheter based renal sympathetic denervation of the main renal arteries and its branches using the Spyral™ Catheter (Medtronic, MN, USA)
45993565|NCT02920034|Device|Ultrasound denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Paradise™ Catheter (ReCor Medical, CA, USA)
46084596|NCT00918203|Drug|Paclitaxel|200 mg/m2 is then administered IV over 3 hours
46084597|NCT00918203|Drug|Carboplatin|AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.
45993566|NCT02931981|Procedure|surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result
45993567|NCT02920151|Other|balance exercises circuit|Thirteen workstations were organized in a circuit format on involved multidirectional gait in different bases of support, unstable surfaces, functional reach, exercise with balls, and single-leg stance
45993568|NCT02932254|Drug|Magnesium Sulfate|After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution).
45993569|NCT02932254|Drug|Saline|After 90% of baseline T4 / T1, are injected intravenously saline solution over 10 minutes (100 mL solution).
45993570|NCT02920112|Behavioral|Telephone based Cognitive Behavioral Therapy|6 sessions of Telephone based Cognitive Behavioral Therapy over the telephone, lasting approximately 60 minutes each.
45993571|NCT05466006|Procedure|Soft tissue augmentation with subepithelial connective tissue graft (SCTG)|After the assessment of the vestibular bone dehiscence at implant site from the most apical extension of the trans-mucosal implant collar (≤3 mm evaluated in a vertical direction), SCTG will be harvested from the palate and sutured to the flap. Simple interdental sutures will be performed in order to stabilize the flap in close contact with the healing screw.
46084598|NCT02766452|Behavioral|"You and your child in the recovery room DVD"|
45993572|NCT05466006|Procedure|Soft tissue augmentation with xenogenic volume stable collagen matrix (VCXM)|After the assessment of the vestibular bone dehiscence at implant site from the most apical extension of the trans-mucosal implant collar (≤3 mm evaluated in a vertical direction), VCMX will be sutured to the flap and simple interdental sutures will be performed in order to stabilize the flap in close contact with the healing screw.
46084599|NCT02766452|Behavioral|Standard pre-operative preparation|Attendance to the Pre-anesthetic assessment clinic to meet with registered practical nurse and anesthesiologist (physical assessment and medical history). Completion of the Surgery Virtual Tour.
46084600|NCT02673021|Procedure|Microwave ablation|Microwave tumor ablation is a procedure that uses heat made by an electric current to destroy a tumor (ablation). With imaging equipment, such as ultrasound or CT (computed tomography), and a small incision made in the skin, the tumor is located and treated with radiofrequency energy. The cells that are killed by the microwave ablation are typically not removed but are eventually replaced by fibrosis and scar tissue.
45456997|NCT01128439|Other|No intervention|No intervention
45456998|NCT03517696|Procedure|Membrane sweeping|Participants assigned to membrane sweeping will have an additional exam during their initial evaluation in which the membranes will be separated from the cervix and lower part of the uterus with a finger inserted into the cervical os. This would be done with at least one rotation counterclockwise and one rotation clockwise.
45456999|NCT03930043|Diagnostic Test|Metagenomic shotgun sequencing|preforming metagenomic shotgun sequencing on patients' or volunteers' feces specimen
45833895|NCT02391402|Behavioral|Cognitively Augmented Behavioral Activation|CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
45993573|NCT02920190|Drug|Liraglutide|1.8 mg Liraglutide administered subcutaneously once daily for 12 consecutive months
45993574|NCT05465850|Diagnostic Test|Modified USPHS criteria|It assess the restorations with visual inspection using a mirror and explorer. It includes Marginal integrity, shade matching, retention, marginal discoloration, gingival inflammation, and recurrent caries.
45993575|NCT02919878|Drug|Gemcitabine|Nucleoside analog- Chemotherapy
45993576|NCT02919878|Radiation|XRT|pre-operative radiotherapy given concurrently with Gemcitabine chemotherapy
46084601|NCT00644319|Drug|ibuprofen|
46084602|NCT00644319|Drug|morphine sulfate|
46084603|NCT00644319|Procedure|management of therapy complications|
46084604|NCT00644319|Procedure|pleurodesis|
45993577|NCT02919878|Drug|capecitabine|Capecitabine is given post operatively as adjuvant chemotherapy for 6 cycles. Each cycle consist of 2500 mg/m2 per day given orally from D1-14
45993578|NCT02931786|Drug|propofol|propofol, midazolam and atropine administration via intravenous cannula.
45993579|NCT02931786|Drug|Ketamine propofol mixture|Administration of ketamine propofol mixture, midazolam and atropine via intravenous cannula
45993580|NCT02931747|Dietary Supplement|Placebo|Subjects are received Placebo once daily for 16 weeks.
45993581|NCT02931747|Dietary Supplement|Bacopa Monnieri 300 mg/day|Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.
45993582|NCT02931747|Dietary Supplement|Bacopa Monnieri 600 mg/day|Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.
45993583|NCT02919605|Drug|Single dose of Pentamidine|The patients will come to the hospital to take a single dose of the Pentamidine.
45993584|NCT02919605|Drug|Two doses of Pentamidine|The patients will come to the hospital to take two doses of the Pentamidine, in interval of one week between them.
45993585|NCT02919605|Drug|Three doses of Pentamidine|The patients will come to the hospital to take three doses of the Pentamidine, in interval of one week between them.
45993586|NCT02931708|Other|Diaphragm functional electrical stimulation|Functional electrical stimulation: 80 Hz frequency, 0.4 ms pulse, rise 1s, 1s time on, decay 2s, 1s time off, intensity as patient tolerance
46084605|NCT04754438|Behavioral|e-CBT|Electronically delivered cognitive behavioural therapy
46084606|NCT04754438|Behavioral|Mental Health Coaching|Electronically delivered mental health coaching
46084607|NCT02672865|Drug|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
46084608|NCT04224116|Drug|Tranexamic acid injection|to receive tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.
46084609|NCT04224116|Drug|SSI|Serum Salin isotonic injected
45674478|NCT02072941|Behavioral|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning (ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
45674479|NCT02100631|Biological|PXVX0200|
45674480|NCT02100631|Biological|Placebo|
45674481|NCT01451164|Drug|OPC-34712|orally administered once daily
45674482|NCT01451164|Drug|OPC-34712|orally administered once daily
45674483|NCT01451164|Drug|OPC-34712|orally administered once daily
45674484|NCT01451164|Drug|Placebo|orally administered once daily
45674485|NCT02071849|Device|HAART 200 Aortic Valve Annuloplasty Device|Surgical repair of bicuspid aortic valve using the HAART 200 Aortic Valve Annuloplasty Device .
45674486|NCT02071771|Device|Nelfilcon A toric contact lenses|
45674487|NCT02071771|Device|Etafilcon A toric contact lenses|
45833896|NCT02391402|Behavioral|Treatment as Usual|"TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to process his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need."
45993587|NCT02919800|Biological|MOD-5014|MOD-5014, a long-acting modified recombinant Factor VIIa
45993588|NCT02919800|Other|MOD-5014 Placebo|Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes
45993589|NCT04687605|Procedure|Temporary hypercapnia|Temporary daily hypercapnia for 2 hours between day 4 and 14 after SAH
45993590|NCT02931630|Other|Whey protein powder|60 g of whey protein powder
45993591|NCT02931630|Other|Maltodextrin powder|60 g of Maltodextrin powder
45993592|NCT02931630|Other|High fiber bread|Wheat bread with high content of dietary fibers (approximately 30 g fibers/day)
45993593|NCT02931630|Other|Low fiber bread|Wheat bread with low content of dietary fibers (approximately 10 g fibers/day)
45993594|NCT03718091|Drug|M6620|M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.
45993595|NCT02931669|Other|Qualitative Descriptive Study|
45993596|NCT02919722|Behavioral|Music Therapy|The majority of each study session will be spent engaging in music therapy: playing live music with a music therapist with the help of an occupational therapist. At the beginning and end of each session subjects will complete 2 assessments.
45993597|NCT02931864|Other|Online mindfulness training|5 weekly sessions of online self-administered mindfulness training programme in which they will receive audio-recorded and video-recorded instructions, pictorial or text-based instructions for various mindfulness exercises such as body scan meditation, mindful breathing and walking meditation.
45993598|NCT02931864|Other|Online symptom management|5 weekly online education module in which they will receive video-recorded, audio-recorded, pictorial or text-based instructions for various self-management strategies. Topics include fatigue, pain, numbness/tingling, lymphedema, anxiety/depression, and problems with sleeping.
45993599|NCT00532428|Drug|Raloxifene|60 mg QD
45993600|NCT00532428|Drug|Raloxifene|120 mg QD
45993601|NCT00532428|Drug|Placebo|Placebo
45993602|NCT02919839|Other|non-Interventional|
45993603|NCT00532467|Drug|SRX251|
45993604|NCT02919527|Other|Self-Myofascial-Release|Self-Myofascial-Release performed at the anterior thigh
45674488|NCT02071225|Drug|bendamustine|70 milligrams per square meter (mg/m^2) given by intravenous (IV) infusion on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of subsequent cycles.
45993605|NCT02919527|Other|Stretching|Static Stretching performed at the anterior thigh
45993606|NCT00532506|Drug|SK-0403|
45993607|NCT02919644|Biological|autologous dendritic cells loaded with autologous tumour homogenate|Each vaccine dose consists of 10_7 autologous dendritic cells loaded with autologous tumor homogenate
45457000|NCT02295046|Drug|Amlodipine besylate/Atorvastatin calcium|Amlodipine besylate/Atorvastatin calcium 10/80 mg
45674489|NCT02071225|Drug|obinutuzumab|1000 mg given by IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of subsequent cycles.
45993608|NCT02919644|Drug|IL2|Each vaccine dose is followed, after two days, by IL-2 as adjuvant, at a dose of 3 MU daily for five consecutive days
45993609|NCT05465733|Drug|Envafolimab;Pemetrexed|single agent, 300mg Q3W IH until disease progressed,The duration of treatment with Envafolimab should not exceed 2 years.
45993610|NCT02919488|Other|Exercise Condition|A bout of exercise in the evening followed by high-sugar meal consumption the following morning
45993611|NCT02919488|Other|Control Condition|Rest in the evening followed by high-sugar meal consumption the following morning
45993612|NCT00533286|Drug|benzodiacepine|diazepam (2 x 5 mg/ die)
45993613|NCT03680456|Drug|Ferric carboxymaltose|maximum of 750mg in U.S. is given, maximum of 1000mg in EU
45993614|NCT03680456|Drug|Crystalloid|an equivalent volume dose of Natriumchlorid is administered
45993615|NCT03673787|Drug|ipatasertib|Ipatasertib will be supplied as film-coated tablets in two strengths (100 and 200 mg) differentiated by size, shape, and weight of tablets. Ipatasertib tablets are packaged in high-density polyethylene bottles with desiccant.
45993616|NCT03673787|Drug|Atezolizumab|Atezolizumab will be supplied as a single-use 20 mL USP/Ph. Eur Type 1 glass vial as a colourless-to-slightly-yellow, sterile, preservative-free clear liquid solution intended for intravenous (IV) administration.
45993617|NCT05465694|Procedure|2-minute-time interval of per oral 24% sucrose|Experiment began with a five-minute observation period of all outcome measures while infant was resting in an incubator. Later, attendant nurse gave 1 ml of 24% sucrose solution on neonate's tongue. In the 2-two minute-time interval prior to heel lance intervention, following two minutes of waiting period, heel lance procedure was applied to infant's foot. In no time interval of sucrose given immediately prior to heel lance intervention, attendant nurse performed heel lance procedure immediately after giving 1 ml of 24% sucrose solution sucrose on tongue. Infant's facial actions and heart rate, and oxygen saturation were recorded by using two video cameras. Recording was carried out by a nurse during whole procedure. After collecting data, researcher watched videos separately and scored them by using PIPP-R. Measurement of study outcome relied on data collection strategies: Neonatal close-up video recording of infant facial actions, pulse oximeter, observation for adverse events.
45993618|NCT05465694|Procedure|no time interval of per oral 24% sucrose|no time interval of per oral 24% sucrose
45993619|NCT04830228|Device|Ballon expandable stent and PTA|Endovascular treatment for the peripheral artery disease of the Iliac artery
45993620|NCT03615248|Device|BreatheSuite|"BreatheSuite (patent pending) is a device and mobile application developed by Mr. Brett Vokey, an engineering student at Memorial University of Newfoundland. BreatheSuite has been recognized by numerous provincial competitions, featured at the Eastern Health Innovation Showcase, and was recently selected as a finalist for the New York Health Innovation Challenge.~This device attaches to metered dose inhalers and it can determine if:~the dose was given,~the metered dose inhaler was properly shaken,~the metered dose inhaler is properly aligned,~the flow of medication is appropriate and~there is no accidental exhalation into the inhaler."
45993621|NCT04805112|Behavioral|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits to distribute to their sexual partners for partner testing or couple testing. Phone interviews will be conducted with the participants to assess whether they provided a HIV self-test to their partner, if the test was used, how it was used (partner testing or couple testing), if the partner disclosed his results, the partner's reaction to the results, and if the partner went for confirmatory testing
45993622|NCT03571802|Drug|Simvastatin|"The subject will take simvastatin 20mg at 0 h (after stopping simvastatin for 5 days). 5 mL of blood will be sampled at 0 h, 1 h, 2 h, 3 h, 5 h, 7 h.~There will be 2 blood sampling sessions: 1 before and the other 3 months after surgery."
45993623|NCT04799652|Other|Survey|Survey of 21 questions. The questions were divided into sections, evaluating demographics, COVID-19 test status and symptoms, the surgeon's opinion on the COVID-19 vaccination and their main concerns. The questionnaire was completed anonymously between 15/01/2021 and 24/01/2021, before the start of vaccination of health care professionals in a Belgian hospital.
45993624|NCT02919332|Procedure|Computed Tomography|Undergo 18F-FDG PET/CT
45993625|NCT02919332|Radiation|Fludeoxyglucose F-18|Given IV
45993626|NCT02919332|Procedure|Positron Emission Tomography|Undergo 18F-FDG PET/CT
45993627|NCT05465577|Other|CC Links|The CC Links intervention is built on a platform of interdisciplinary team-based science, which ensured that the financial navigator worked closely with other members of the healthcare team including oncologists, nurses, transplant coordinators, social workers, and case managers, to help enhance financial hardship screening and connect survivors and caregivers with financial assistance services.
45993628|NCT02919254|Dietary Supplement|Beet It Sport Shot|Commercially available concentrated beetroot juice supplement intended for athletes.
45993629|NCT02919254|Other|Placebo|Fruit juice cordial containing negligible nitrate
45993630|NCT02919293|Biological|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)|30μg /dose, Intramuscular
45993631|NCT02919293|Biological|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant)|0.5ml /dose, Intramuscular
45993632|NCT05463315|Device|Moziak Device|Applying Moziak Device Compared to Standard Manual Compression
45993633|NCT02919371|Drug|Sunitinib|Oral therapy ( Anti-vascular endothelial growth factor Tyrosin Kinase Inhibitor): given as 50 mg daily from day 1 to day 28- cycle repeated every 42 days
45993634|NCT02919371|Drug|Bevacizumab|Monoclonal antibody against vascular endothelial growth factor: given intravenously on day 29 of each sunitinib cycle
45993635|NCT05460819|Other|Acupuncture treatment|"Acupoint selection: Hegu-Yinxi acupoint group (clearing heat and relieving sweat), Sanyinjiao-Fuliu acupoint group (nourishing yin and tonifying kidney), Tianshu-uteri acupoint group (special effect points) (12 acupoints on both sides).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: Use a one-time sterile acupuncture needle (0.30×40mm, Huatuo brand), insert the needle 0.5 inch along the anatomical position, level up and relieve the qi, and keep the needle for 20 minutes."
46084610|NCT05252975|Other|Setup and Imaging for at CT radiation planning|Patients will undergo an additional CT scan acquisition at CT radiotherapy planning in order that all participating patients have a prone and supine CT scan available to compare radiation therapy plans.
45993636|NCT05460819|Other|Sham Acupuncture treatment|"Selecting acupoints: Select the side opening positions of the 6 acupuncture points in the real acupuncture group, and select non-meridian and non-points (points with less nerve distribution, sparseness, and rich muscles).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: ① Shallow needling scheme: use a disposable sterile acupuncture needle, insert the needle 0.2 inch, without twisting, and keep the needle for 20 minutes. ②Non-invasive acupuncture plan: choose a special comfort needle with no needle tip at the top of the needle, paste a disposable sterile foam pad on the non-acupoint, and use a disposable sterile flat head The acupuncture needles were pierced into the foam pad, lightly touching but not piercing the skin, and not breathing; the needles were kept for 20 minutes."
45993637|NCT02919410|Device|iodophor-impregnated adhesive drapes|
45674490|NCT01450696|Drug|Capecitabine|Capecitabine will be administered at a dose of 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
45993638|NCT02919410|Other|No adhesive drapes|
45993639|NCT05458830|Behavioral|Brief Barrier Reduction Intervention|After selecting a barrier in the barrier survey, participants receive tailored information with the purpose of addressing common concerns and misconceptions about the helpline.
45993640|NCT05458830|Behavioral|Plain advisory text|Care as usual
45993641|NCT02919215|Behavioral|Teacher Help Intervention|The intervention will be provided to collaborating psychologists and their teachers to access. Teachers will work through the intervention, and psychologists will act as the online support for teachers. Teachers will work with one student in their classroom with ADHD, ASD, or LD throughout the intervention phase. Each session in the program will provide factual information to teachers, strategies for implementation of best practices to address the specific mental health disorder in the classroom setting (i.e., ADHD, ASD, or LD), and access to additional help and advice.
45993642|NCT04748016|Other|3D printed (3DP) bone models + CT imaging|In addition to CT-MPR and CT-3DR, 3DP models will be used for surgical planning and intraoperative visualization.
45993643|NCT04748016|Other|CT imaging|CT-MPR and CT-3DR used for surgical planning and intraoperative visualization.
45993644|NCT02919449|Biological|MV-NIS|This is an open label single ascending dose phase I study designed to determine the safety profile and MTD after IT administration of a single dose of MV-NIS in combination with Atezolizumab in patients with metastatic NSCLC
45993645|NCT02919449|Biological|Atezolizumab|Atezolizumab will be administered every 3 weeks
45993646|NCT04736901|Drug|Enoxaparin|0.5 mg/kg every 12 hours
45993647|NCT04736901|Drug|Enoxaparin|40 mg/day
45993648|NCT04736901|Drug|Rivaroxaban|10 mg once daily
46084611|NCT02672943|Behavioral|Rehabilitation treatment|The walking exercise will be aerobic with a Borg rating perceived exertion around 11-14 scales. Before and after the 12 weeks rehabilitation training, should accept MRI and Clinical assessments.
45674491|NCT01450696|Drug|Cisplatin|Cisplatin will be administered at a dose of 80 mg/m^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
45674492|NCT01450696|Drug|Herceptin|Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
45674493|NCT02070991|Drug|Macitentan|oral tablet, 10 mg once daily
45674494|NCT02070991|Drug|Placebo|matching placebo
45993649|NCT04736901|Drug|Rivaroxaban|20 mg once daily
45993650|NCT04736901|Drug|Apixaban|2.5 mg twice daily
45993651|NCT04736901|Drug|Apixaban|5 mg twice daily
45993652|NCT02919176|Drug|Mirabegron|Mirabegron 50 mg/day
45993653|NCT02919176|Drug|Pioglitazone|Pioglitazone 30 mg/day
45993654|NCT02919176|Drug|Mirabegron and Pioglitazone|Mirabegron 50 mg/day and Pioglitazone 30 mg/day
45993655|NCT04734678|Drug|Tocilizumab|400 mg IV only once
45993656|NCT04734678|Drug|Infliximab|5 mg/kg/day IV for 2 doses 12-24 hours
45993657|NCT02919059|Drug|Dapagliflozin 10 mg|"Dagliflozin will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
45993658|NCT02919059|Drug|Glimepiride 4 mg|"Glimepiride will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
46002350|NCT03574974|Device|Experimental Feedback|"Feedback is presented in the form of a line graph that is updated every 2 seconds throughout the scan to indicate activity in the target area. A red diamond will indicate periods of symptom provocation, during which participants are exposed to symptom-provoking auditory stimuli in the form of personalized trauma scripts and sound clips. A blue arrow will indicate periods of down-regulation, where participants will try to bring the feedback line down as much as possible (by trying to decrease their fear/anxiety). The investigators believe that this feedback may help participants learn to control their PTSD symptoms.~Participants will attend a total of 18 feedback scans over the course of 3 sessions."
45993659|NCT05421507|Radiation|Radioactive Iodine-125 Seeds Implantation|Radioactive Iodine-125 Seeds Implantation(RISI) belongs to permanent inter-tissue brachytherapy. Guided by CT or ultrasound,radioactive I-125 seeds are implanted into tumor tissue, and radioactive I-125 continuously releases radiation to kill tumor cells.Radioactive I-125 seeds can reach a higher dose in the tumor, and the dose of the normal tissue around the tumor is lower, and the damage to the normal tissue is less while reaching the radical dose. The NCCN guidelines recommend RISI as the standard treatment for early prostate cancer. For early prostate cancer, RISI can achieve comparable efficacy as surgery, complications and side effects are lower than surgery, therefore patients can obtain better quality of life. RISI is also recommended by NCCN as one of the treatments for locally recurrent rectal cancer. Several studies have confirmed that RISI is safe and effective in the treatment of locally advanced or recurrent head and neck, chest, abdominal and retroperitoneal tumors.
45993660|NCT00533364|Drug|SBG (Soluble beta-glucan)|Oral administration, three dose levels, administered day 1-8 in each 3-weeks treatment cycle, 4 treatments cycles.
45993661|NCT02918786|Device|Nasal high-flow|After extubation, the patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set until maximal level of 60 LPM.
45993662|NCT02918786|Device|CPAP|After extubation, patients will receive CPAP at 5 cmH2O delivered by the variable generator WhisperFlow System. The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
46084612|NCT02672943|Other|non-rehabilitation treatment|The walking exercise will be aerobic with a Borg rating perceived exertion around 11-14 scales. Before and after the 12 weeks non-rehabilitation training, should accept MRI and Clinical assessments.
46084613|NCT02696408|Device|Laser treatment|"Patients randomized to the experimental arm receive in addition to mouthwash, preventive treatment of mucositis by LLLT performed by nurses consisting of daily scanning the entire oral cavity for 2 minutes with a power of 250 mW, starting with conditioning and ongoing until the onset of mucositis of grade 1.~If the mucositis is localised, preventive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), preventive laser is stopped for curative laser only."
45457001|NCT03926221|Behavioral|Parent Behavior Change Intervention (PBC-I) and Transdiagnostic Sleep and Circadian Intervention (TranS-C)|PBC-I will be administered to the parent and TranS-C will be administered to the teenager. Both interventions are cognitive-behavioral and comprised of six weekly sessions. Parent and teenager sessions will be held in parallel.
45993663|NCT04731753|Device|mechanical debridement|The mechanical debridement is performed using the debridement pad Cutimed DebriClean. After the pad is moistened with wound-cleansing solution, the wound is cleaned using circular movements while applying gentle pressure.
45993664|NCT02918981|Behavioral|Resistance Exercise|Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage
45993665|NCT02918981|Dietary Supplement|14 g Whey protein|
45993666|NCT02918981|Dietary Supplement|6.6 g Whey protein + 1.25 g leucine|
45993667|NCT02918981|Dietary Supplement|4 g Whey protein + 1.25 g leucine + 2.6 g Whey peptides|
45993668|NCT02918981|Dietary Supplement|6.6 g Whey protein + 1.25 g leucine + 0.8 g Citrulline|
45993669|NCT02918981|Other|Water control|
45993670|NCT04727775|Drug|Favipiravir|Antiviral drugs
45993671|NCT04727775|Drug|Remdesivir|Antiviral drugs
45993672|NCT02918825|Drug|Olanzapine|Olanzapine
45993673|NCT02918825|Drug|Paliperidone|Paliperidone
45457002|NCT03517618|Drug|S-1+leucovorin|"Eligible patients will receive TS-1 orally 40-60 mg (depending on patient's body surface area (BSA)) in combination with calcium folinate 30 mg twice a day for 7 days in a 2-week cycle.~The treatment will be administered until disease progression, intolerable toxicity, or consent withdrawal during any time of the study."
45457003|NCT03929887|Other|Kidney Biopsy|Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core and various patient-derived samples.
45993674|NCT05420376|Procedure|Split Mesh|TEP repair of inguinal hernias using either split or whole mesh
45993675|NCT02919020|Other|Proprioceptive neuromuscular facilitation (PNF)|Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members
45993676|NCT02919020|Other|Resistance exercise|resistance exercise to strengthen lower limbs
45993677|NCT04724070|Genetic|NGS, PDO/PDX establishment|Patients' tumor specimens will be collected for next generation sequencing, PDO/PDX establishment and tissue banking.
45993678|NCT02918903|Procedure|Minimal caries removal|the experimental group will be treated by minimal caries removal where only caries at lateral walls of cavity will be removed then stainless steel crown will be placed as final restoration.
45993679|NCT02918903|Procedure|Complete caries removal|the control group will be treated by complete caries removal where all caries along lateral and pulpal walls of cavity will be removed, a base of resin modified glass ionomer will be placed then stainless steel crown will be placed as final restoration.
45993680|NCT05407935|Behavioral|ACTivity|Acceptance and Commitment Therapy for physical activity promotion plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
45993681|NCT05407935|Behavioral|Relaxercise|Relaxation training plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
46084614|NCT02696408|Device|Placebo|"Patients randomized to the Placebo arm receive in addition to mouthwash fictive laser treatment performed by nurses until the onset of mucositis of grade 1.~If the mucositis is localised, fictive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), fictive laser is stopped for curative laser only."
46084615|NCT05269901|Genetic|SLC7A11, GPX4, P53|Obtained patients or healthy controls peripheral blood , used Western blot and Rt-qPCR to investigate the possible difference between two groups
46084616|NCT02672709|Drug|apixaban|
45457004|NCT01130623|Drug|Pazopanib (GW786034)|
45457005|NCT02295124|Drug|Oxycodone|Patients will receive oxycodone 10mg (5mg if > 65) every 2 hours based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
45993682|NCT02918747|Drug|pegaspargase|"P-Gemoxd Arm: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: four.~P-CHOP Arm: 2000U/m2 im on day 2 of each 21 day cycle. Number of Cycles: four."
45993683|NCT02918747|Drug|Gemcitabine|800mg/m2, ivd on day 1 and 5 of each 21 day cycle. Number of Cycles: four.
45993684|NCT02918747|Drug|Oxaliplatin|85 mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: four
45993685|NCT02918747|Drug|Dexamethasone|15 mg, Ivd on day 1 to day 5 of each 21 day cycle. Number of Cycles: four.
45993686|NCT02918747|Drug|Cyclophosphamide|750 mg/m2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
45993687|NCT02918747|Drug|Doxorubicin|50mg/m 2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
45993688|NCT02918747|Drug|Vincristine|1.4 mg/m 2(≤2mg），ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
45993689|NCT02918747|Drug|Prednisone|60 mg/m 2 /day orally on days1- 5 of each 21 day cycle. Number of Cycles: four.
45993690|NCT02918747|Radiation|IMRT|After chemotherapy, if the patients get CR, PR or SD, IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions.
45993691|NCT02918708|Biological|Synflorix|10-valent pneumococcal conjugate vaccine
45993692|NCT02918708|Biological|Prevenar13|13-valent pneumococcal conjugate vaccine
45993693|NCT04707651|Dietary Supplement|Formula diet|Formula diet for 12 weeks
45993694|NCT02918591|Drug|Empagliflozine|All 6type 2 diabetic participant will receive treatment with Empagliflozine during 2 month
45993695|NCT04702113|Diagnostic Test|Cipherome Lighthouse Pilot|Preemptive pharmacogenomic testing
45993696|NCT02918513|Behavioral|Wellness Element 1 - Exercise|1. Daily wellness element focusing on Exercise; adherence documented online daily
45993697|NCT02918513|Behavioral|Wellness Element 2 - Mindfulness|2. Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
45993698|NCT02918513|Behavioral|Wellness Element 3 - Sleep Hygiene|3. Daily wellness element focusing on sleep hygiene; adherence documented online daily
45993699|NCT02918513|Behavioral|Wellness Element 4 - Social Connectedness|4. Daily wellness element focusing on Social Connectedness; adherence documented online daily
45457006|NCT02295124|Drug|Hydromorphone|Patients will receive an initial dose of hydromorphone 2mg (1mg if > 65) every 2 hours as needed based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
45457007|NCT03925051|Drug|Prolia®|mAb targeting RANKL. human monoclonal antibody targeting RANKL.
45457008|NCT03925051|Drug|CMAB807|human monoclonal antibody targeting RANKL.
45993700|NCT02918513|Behavioral|Wellness Element 5 - Nutrition|5. Daily wellness element focusing on Nutrition; adherence documented online daily
45993701|NCT02918513|Behavioral|Wellness Element 6 - Wellness Exercises|6. Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
45993702|NCT02918513|Behavioral|Wellness Element 7 - Motivational Messages|7. Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
45993703|NCT02918240|Procedure|Appointment intervals|
45993704|NCT02918240|Device|fixed orthodontic braces|
45993705|NCT04680039|Device|Continuous monitoring|Identifying intradialytic hypotension using a PPG-based wearable monitor
45993706|NCT02918045|Device|HemCon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
45993707|NCT02918045|Device|Oxidized Cellulose Gauze|A common hemostatic measure after dental extractions placed into the extraction socket.
45993708|NCT05405673|Diagnostic Test|Fecal immunochemical test (FIT)|A kind of stool test
45993709|NCT02918123|Biological|FURESTEM-CD Inj.|Patients will be treated FURESTEM-CD Inj. Subcutaneous injection
45993710|NCT05400096|Other|Psychological therapy|The protocol for the group will be developed collaboratively between the chief researcher and the supervisor based in the weight management service. The protocol will contain Compassion Focused Therapy (CFT) based therapeutic approaches, but the group will integrate some Acceptance and Commitment Therapy (ACT) concepts.
45993711|NCT02917850|Procedure|Isokinetic hip flexors strengthening|Isokinetic excentric strengthening of paretic hip flexors, 3/w during 6 weeks, in addition to conventional rehabilitation 7/w.
45993712|NCT02917850|Procedure|Conventional rehabilitation|Conventional rehabilitation 10/w during 6 weeks
46002351|NCT03574974|Device|Control Feedback|"Feedback is presented in the form of a line graph that is updated every 2 seconds throughout the scan to indicate activity in the target area. A red diamond will indicate periods of symptom provocation, during which participants are exposed to symptom-provoking auditory stimuli in the form of personalized trauma scripts and sound clips. A blue arrow will indicate periods of down-regulation, where participants will try to bring the feedback line down as much as possible (by trying to decrease their fear/anxiety). The investigators do not believe this feedback can help participants' PTSD symptoms.~Participants will attend a total of 18 feedback scans over the course of 3 sessions."
45993713|NCT05394987|Device|Spectacles|"Prescription of refractive error correction in spectacles.~Refractive error will be determined as part of a standard optometric eye exam (performed by a registered optometrist).~Guidelines for optical correction for the prescription of the study spectacles (based on Pediatric Eye Disease Investigator Group [PEDIG] amblyopia clinical trial protocols): Hypermetropia - not under-corrected by more than +1.50D spherical equivalent and the reduction in plus sphere must be identical between the two eyes. Anisometropia - full correction of the anisometropic difference. Astigmatism - full cylinder power prescribed.~Appropriate refractive error correction will be prescribed. Participants will be instructed to wear the optical correction full-time (i.e., more than 50% of waking hours) for the duration of the study."
45993714|NCT03825575|Device|Low level laser therapy (LLLT)|A 3 week treatment period with a total of 8 treatments of 1 hour over the sacral spinal cord
45993715|NCT04678167|Diagnostic Test|Caloric test|Lying, patientwill be placed so that he can introduce water (hot then cold) into his external ear canal. It is the reaction of the vestibular system (sensory organ responsible for balance) which is then measured with a helmet placed over his eyes and which measures the nystagmus (movement of the eye) which reflects vestibular activity.
45993716|NCT04678167|Diagnostic Test|Measurement of the speed of Nystagmus|A helmet with an infrared camera will be placed in front of patient eyes. This will allow visualizing on screen and measuring eye movements spontaneous or induced in the dark by various tests.
45993717|NCT04678167|Diagnostic Test|Angle of deviation at Fukuda|The patient will be asked to trample on the spot (30 steps) with the indexes pointed forward. In the event of vestibular asymmetry, the patient turns at a varying angle to the right or to the left. This will then measure what is called the angle of deflection of the fukuda.
45457009|NCT03514576|Drug|Pasireotide 0.3 MG/ML|See arm description
45674495|NCT02114515|Behavioral|Hospital usual care|Written discharge instructions provided to patients prior to hospital discharge.
45993718|NCT04678167|Diagnostic Test|Alexander's degree of nystagmus|"there are 3 degrees:~Degree I: nystagmus that exists only when the eyes are turned to the right.~Degree II: also exists when the eyes are to the right or to the front.~Degree Ill: exists when the eyes are on the right, front, or left"
45993719|NCT04678167|Other|EHTEV questionnaire|Handicap Scale for Balance Disorders and Vertigo
45993720|NCT04678167|Other|EEV questionnaire|European Vertigo Assessment Questionnaire
45993721|NCT04678167|Other|anxiety VAS|visual analog scale of anxiety
45993722|NCT00532545|Drug|Teriparatide|Teriparatide 20 micrograms/daily subcutaneously
45993723|NCT03819062|Device|Low Level Laser Therapy|A 3 week treatment period with 8 treatment sessions in total.
45993724|NCT04674111|Device|Temporary Percutaneous Transvalvular Circulatory Support System (Vortex System)|The Vortex System is indicated to provide temporary circulatory support in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).
45993725|NCT03792737|Device|Spiral PDS Plus|The Spiral PDS Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral PDS Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
45993726|NCT03792737|Device|Spiral MONOCRYL Plus|The Spiral MONOCRYL Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral MONOCRYL Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
45993727|NCT03792737|Device|PDS Plus|PDS Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
45993728|NCT03792737|Device|MONOCRYL Plus|MONOCRYL Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
46084617|NCT02770274|Drug|Cilostazol|Dual therapy with Cilostazol 100 mg twice daily
45674496|NCT02114515|Behavioral|Navigator intervention|A Patient Navigator will provide social support, literacy appropriate education, and act as a conduit between the patient and the patient's medical team
46084618|NCT02770274|Drug|Aspirin|Monotherapy with aspirin 100 mg once daily
46084619|NCT00910221|Drug|Atorvastatin|Atorvastatin tablet
46084620|NCT00910221|Drug|Placebo|Placebo tablet
45674497|NCT02114515|Behavioral|Peer-led telephone support line|The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team.
45674498|NCT01490086|Drug|RP5063|daily
45993729|NCT03792737|Device|VICRYL Plus|VICRYL Plus antibacterial suture is a non-barbed synthetic absorbable sterile, surgical suture. The suture contains triclosan, a broad spectrum antibacterial agent.
45833897|NCT04397640|Diagnostic Test|Sonovue|Contrast myocardial echocardiography with sulphur hexafluoride microbubbles Sonovue (Bracco, Milan, Italy) injection and using the time-intensity curves profile to evaluate the myocardial microcirculation.
45993730|NCT04686942|Diagnostic Test|After sonazoid|0.015ml/mg sonazoid enhanced US to detection of liver metastases.
45993731|NCT03782519|Other|Dialysis frequency reduction|At initiation, frequency of dialysis will be reduced to 2 weekly sessions (incremental HD)
45993732|NCT03782519|Other|Frailty diagnosis|Before randomization, we will determine whether patients are frail. We will define frailty as the presence of at least three of the following five conditions: malnourished according to dietitian assessment and/or short form of Mini Nutritional Assessment (MNA), grip strength and gait speed using participants' scores on the SF-36 Physical Functioning (PF) scale, exhaustion using in the quality of life questionnaire SF-36 vitality (VT) scale and physical activity according to patient assessment (one single question)
45993733|NCT00533403|Drug|MK0686|
45993734|NCT05381883|Other|Questionnaire|"Participants will answer socio-demographic questions, questions about the lifetime experience of potentially traumatic events, the presence of a known psychological or medical disorder and the taking of medication, and a series of psychological assessment questionnaires.~The questionnaires, performed outside routine care, are as follows :~Posttraumatic stress disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders-5 Beck Depression Inventory-Fast Screen General Anxiety Disorder-7 Coping Inventory for Stressful Situations Maslach Burnout Inventory Medical Outcomes Study Short-Form~The total time for completing the questionnaires is estimated at 20 minutes"
45993735|NCT03771989|Biological|autologous, micro-fragmented adipose tissue|"The active treatment is an intra-articular injection with autologous, microfragmented adipose tissue prepared using the Lipogems system.~Implantation of the graft is performed with the patient supine using two injections sites in order to reduce the risk of extra-articular injection."
45993736|NCT03771989|Other|Saline|The placebo is an injection with saline
45993737|NCT00533481|Drug|MK0557|
45993738|NCT03763136|Biological|hPSC-CM Therapy|Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 200 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
45993739|NCT03756155|Procedure|isometric intervention|The research participants will perform isometric repetitions against the hand held dynamometer
45993740|NCT00533520|Drug|ranibizumab|Arm A: 0.5 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Arm B: 1.0 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Third Arm 2.0mg Arm with retreatment based on defined criteria not to occur sooner than every 28 days
45993741|NCT03694262|Drug|Rucaparib|Rucaparib 600mg orally twice daily by continuous dosing
45993742|NCT03694262|Drug|Bevacizumab|15mg/kg IV on day 1 of every cycle
45993743|NCT03694262|Drug|Atezolizumab|1,200mg IV on day 1 of every cycle
45993744|NCT05356104|Drug|Exenatide extended release|2mg once weekly via subcutaneous injection
45993745|NCT00533559|Drug|sodium phenylbutyrate|buphenyl, 7.5 gm/day for two weeks for two studies, one with saline and one admission with intralipid and heparin
45993746|NCT00533559|Drug|Placebo|Placebo comparator
46084621|NCT00918281|Drug|Fluciclatide Injection|Fluciclatide Injection (AH111585 (18F) Injection)
45674499|NCT01490086|Drug|placebo|daily
45833898|NCT02398500|Biological|LMG324|IVT injection
45993747|NCT03685253|Drug|Niagen|Niagen® (3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride - NR) will be the experimental treatment, at a dose of 1000 mg/day taken as two 250 mg capsules twice daily for 6 months.
45993748|NCT03685253|Drug|Placebo|Placebo capsules matched to the experimental drug and taken orally as 2 capsules twice daily for 6 months.
45993749|NCT04673604|Diagnostic Test|Assessment of ocular surface staining (Oxford score 0-15 scale)|Corneal and conjunctiva staining will be recorded according to the Oxford grading scheme for ocular staining (0-15 score).
45993750|NCT04673604|Drug|mean diurnal intraocular pressure-lowering|At the end of each 6-month period patients will undergo diurnal intraocular pressure assessment with both therapies.
45993751|NCT03663608|Procedure|WALANT Technique|pure local anaesthesia and without use of a tourniquet (WALANT Technique) for trigger finger release surger
45993752|NCT05349513|Other|ESSME questionnaire|The experimental ecological questionnaire ESSME is administered 7 to 14 days after the inclusion visit and 7 to 14 days after the 6 months follow-up visit to the patient at their home.
46084622|NCT02766530|Other|PETMR study|Use of PETMR study to evaluate the treatment response of breast cancer women
46084623|NCT00644397|Device|95-degree Angled Blade Plate|
46084624|NCT00644397|Device|4.5mm Condylar Locking Plate|
46084625|NCT04657562|Drug|Tacrolimus|Prevention of rejection in kidney or liver transplant: a standard immunosuppressive therapy according to international protocols.
46084626|NCT04657562|Diagnostic Test|Unbound tacrolimus measurement|Unbound tacrolimus measurement in plasma ultrafiltrate.
45457010|NCT03514576|Diagnostic Test|Meal tolerance test (MTT)|Subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
45833899|NCT02398500|Biological|Ranibizumab 0.5 mg|IVT injection
45833900|NCT02398500|Biological|Sham|Fake injection used for masking purposes
45833901|NCT03042858|Other|Infants with PPV|Data will be collected for up to 18 years to monitor for inguinal hernia.
45833902|NCT03042858|Other|Infants without PPV|Basic data will be collected regarding the surgery and the subject's study participation will be complete.
45833903|NCT03039660|Behavioral|RefreshMD|Online Sleep Improvement Course
45993753|NCT03640754|Biological|G-CSF|G-CSF injected subcutaneously 3 times (Days 0, 28, 56)
45993754|NCT03640754|Other|Placebo/Saline|Placebo/saline injected subcutaneously 3 times (Days 0, 28, 56)
45993755|NCT04602819|Device|PicoSure 755nm picosecond alexandrite laser with diffractive lens|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography and other noninvasive methods.
45993756|NCT04602819|Device|ApolloVue® S100 Image System|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography.
45993757|NCT04602819|Device|Cutometer® dual MPA 580|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the Cutometer® dual MPA 580.
46084627|NCT04657562|Diagnostic Test|CYP3A4 and CYP3A5 genotyping|DNA purification and genotyping
46084628|NCT05252117|Drug|Articaine Hydrochloride 40 MG/ML|Analysis of uterovaginal plexus block with articain for intrauterine device placement
46084629|NCT05252117|Drug|Mepivacaine|Analysis of uterovaginal plexus block with mepivacaine for intrauterine device placement
46084630|NCT02672397|Behavioral|Additional Epidural Education|All women allocated to receive additional epidural educational will be given a language appropriate pamphlet and video on neuraxial anesthesia. The video and pamphlet will be in the subject's primary language. After the subject watches the educational video they will be given an opportunity to go through the pamphlet with the research assistant and ask any questions they may have. For Spanish-speaking subjects this will occur through a telephone interpreter. The obstetric anesthesia providers and obstetricians caring for the subject will be absent for the educational video and post-video conversation.
45457011|NCT03929731|Diagnostic Test|Indocyanine Green Angiography|Intravenous injection of dye-indocyanine green
45457012|NCT02298790|Behavioral|Meal schedule|
45674500|NCT01490086|Drug|RP5063|daily
45674501|NCT01490086|Drug|RP5063|daily
45674502|NCT01490086|Drug|aripiprazole|daily
45674503|NCT02114203|Drug|PDE9i|oral dose, every 12 hours for 28 days
45674504|NCT02114203|Drug|PDE9i|oral dose, every 12 hours for 28 days
45993758|NCT04602819|Device|VISIA®|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the VISIA®.
45993759|NCT05348109|Other|Well finished cases|To decide whether extraction or non-extraction decision will be made for each case
45993760|NCT03429218|Drug|TP-0184|Oral dose once weekly for 4 weeks
45993761|NCT00532181|Behavioral|Savings Behavior and Consumer's Approach to Risk|
45993762|NCT00532220|Drug|Ibandronate IV|Ibandronate IV (Bonviva® IV), 10.5 mg divided in 4 single infusions within 2 weeks(1x1.5 mg, 3x3 mg), followed by a fifth infusion after 3 months (V4)
45993763|NCT00532220|Drug|Placebo|Placebo IV, divided in 4 single infusions within 2 weeks, followed by a fifth infusion after 3 months (V4)
45993764|NCT00532584|Drug|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
45993765|NCT03457259|Device|PVC and/or PICCline|Pt. will receive PVC and/or PICCline
45993766|NCT03457259|Device|Midline|Pt. will receive midline
45993767|NCT04687332|Other|Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany)|One group was treated with IA and the single use tryptophan adsorber, the other group was treated with PE and the Plasmaflow (see above). In total, all patients receive 5 treatments.
45993768|NCT05467709|Drug|Midazolam|2 mg Day 1 and Day 16
45993769|NCT05467709|Drug|CTP-543|12 mg q12 hour for 14 consecutive days starting on Day 3
45993770|NCT00532623|Drug|Gemcitabine plus Vinorelbine|Gemcitabine, 1,000mg/m2 and Vinorelbine, 25mg/m2, on day 1 and day 8, every 3 week cycles
45993771|NCT00532623|Drug|Sequential|"Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles."
45993772|NCT05467670|Drug|Pembrolizumab|A type of immunotherapy that stimulates the body's immune system to fight cancer cells by targeting and blocking PD-1 proteins on the surface of certain immune T-cells, thus triggering the T-cells to find and kill cancer cells.
45993773|NCT05467670|Drug|ALX148|A fusion protein comprised of a high affinity CD47 blocker linked to an inactive immunoglobulin Fc region, enhancing innate and adaptive immune responses against cancer.
45993774|NCT05467670|Drug|Doxorubicin|An anthracycline that slows/stops the growth of cancer cells by blocking an enzyme called topo isomerase 2, used as second line non-platinum chemotherapy in patients with platinum-resistant ovarian cancer.
46084631|NCT00631397|Device|Ultrasound machine|Weekly Bone Density measurements using the Sonometer
46084632|NCT04178265|Other|Electroacupuncture|needles were inserted to Kunlun(BL60), Yanglingquan (GB34), Sanyinjiao(SP6), Taixi (KI 3) contralateral to the operated leg and deqi sensation elicited at acupoints.
45674505|NCT02114203|Drug|placebo for PDE9i|oral dose, every 12 hours for 28 days
45993775|NCT04687488|Other|Fluorescein|For droplet visualization, we will use fluorescein, which has been used for many years in medicine for diagnostic purposes and is safe upon topical administration, as a tracer. There are no local or systemic side effects of topical sodium fluorescein (5). Fluorescein is routinely used in the mouth to stain dental plaque (6). Through the lacrimal duct, the nasal cavity is exposed to fluorescein when it is used for ophthalmological purposes (7). Allergic reactions have been described to intravenous injection, which is not part of our trial. In the setting of head-and-neck and otolaryngological surgeries, coating the mouth with fluorescein has been used to quantify droplet spread, to assess for risk of transmission of COVID-19 (8). Hence, fluorescein can be safely applied to nasal and oropharyngeal cavities. We will use a similar approach, coating the nasal cavity, to study droplet spread from the nose during naso-gastric intubation for motility or reflux testing.
45993776|NCT04687488|Other|Particle measurement|Quantification of aerosol will be done using a medical particle counter, as used for hospital safety measurements.
45993777|NCT05467631|Other|Topical oil application|Topical Comparison
45993778|NCT00533598|Drug|MK0557|
46084633|NCT04224350|Drug|TacroBell SR cap.|"Orally, once-daily in the morning~After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3~12ng/ml for 0 to 3months and then at 3~8ng/ml for 3 to 6months of study treatment."
46084634|NCT04224350|Drug|Tacrolimus cap.|"Orally, twice a day in the morning and night~After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment."
45993779|NCT05467592|Other|Standard Physical Therapy care|All therapy will be given as it would have routinely been administered in the clinic. Standard care for all patients includes physical therapy and chiropractic treatment at each visit. There is a nurse practitioner on site. If necessary, patients can receive trigger point injections to the musculature around the back and neck, platelet rich plasma, or headache injections by the nurse practitioner. These interventions vary on a case by case basis. Involvement in the study will not impact the patients plan of care. We will collect this information as confounders and factor into statistical analysis.
45993780|NCT00532662|Drug|S(+)-ketamine|epidural or intravenous 1 mg kg-1 once concurrent with caudal anesthesia
45993781|NCT00532337|Drug|ONO-5334|Placebo - 24/mos.
45993782|NCT00532337|Drug|ONO-5334|100mg QD /24 months
45993783|NCT00532337|Drug|ONO-5334|50mg BID /24 mos.
45993784|NCT00532337|Drug|ONO-5334|300mg QD /24 mos.
45993785|NCT00532337|Drug|ONO-5334|Alendronate 70mg once weekly / 24 mos
45993786|NCT05341167|Device|HPI algorithm using Edwards device https://www.edwards.com/gb/devices/decision-software/hpi|The HPI algorithm will be used in order to prevent hypotensive episodes. When the HPI is greater than 85%, the anesthesiologist will have to intervene within the next 2 minutes taking the hemodynamic parameters available into consideration, as well as the treatment protocol that has been designed according to current literature
45993787|NCT05341167|Drug|Vasoactive Agent|Hypotensive episodes will be treated with vasoactive agents and fluids. The HPI algorithm recordings will be blinded and will not be available to the anesthesiologist for the duration of the operation.
45993788|NCT05467436|Drug|Local anesthetics, IV sedation drugs and analgesics.|Personalized prescription for local anesthetics, IV sedation drugs and analgesics, based on pharmacogenomic assesment, social, dietary and medication history
45993789|NCT00533637|Drug|Cetirizine dihydrochloride (10 mg/ml) liposomal formulation|2x110μL in each nostril twice daily for 7 days
46084635|NCT02672631|Other|physical examination|Investigators will apply for evaluate clinical median nerve function to all of groups. (Adductor pollicis power (x/5), sense exam(normal/hipoestesia/anestesia) of hand, tinnel test(+/-), DASH score, DN4 neuropathic pain score)
45674506|NCT02114203|Drug|PDE9i|oral dose, every 12 hours for 28 days
45674507|NCT02113579|Device|Experimental Mouth Rinse 12027-033|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
45833904|NCT03039660|Behavioral|Bond Between Us|Online Educational Course
45833905|NCT03037476|Behavioral|Web-based PFI|A web-based 5 component Personalized Feedback Tool covering content on: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol.
45833906|NCT03037476|Behavioral|Assessment Only|The Assessment Only condition receives assessment on substance use, health behaviors, and academic behaviors at baseline, 6 month follow-up, and 12 month follow-up.
45833907|NCT04276896|Biological|Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs|Patients will receive approximately 5x10^6 LV-DC vaccine and 1x10^8 CTLs via sub-cutaneous injections and iv infusions, respectively.
45993790|NCT00533637|Drug|Cetirizine dihydrochloride (10 mg/ml) buffer solution|2x110μL in each nostril, as a single dose
45674508|NCT02113579|Other|Placebo Mouth Rinse|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
45993791|NCT00533637|Drug|Placebo|Citrate buffer with preservatives
46084636|NCT02672631|Other|DTI|Investigators will apply for evaluate median nerve healing countable results to all of groups (apparent diffusion coefficient for avarage diffusion (ADC) and fractional anisotropy diffusion orientation(FA) - FA :0 means diffusion is homogenic FA:1 means tissue has heterogenic diffusion
46084637|NCT02672631|Other|ENMG|Investigators will apply for evaluate median nerve healing countable results to all of groups. And they will evaluate motor nerve transmission speed, sensitive nerve transmission speed and united muscle action potential
45993792|NCT00533676|Drug|MK0524A, /Duration of Treatment : 8 Weeks|
45674509|NCT01474018|Drug|QR-bromocriptine|The study drug is added-on to patients on existing type 2 diabetes treatment with insulin +metformin+exercise/nutritional counseling. The study drug is titrated up starting at one 0.8mg tab daily for 1 week, then 2 (0.8mg) tablets for week 2, then 3 tablets for week 3, then 4 tablets for week 4, then 5 tablets for week 5, then six tablets for week 6 (total 4.8). The limiting factor is nausea at which point the patients will back down the highest tolerated dose and continue on that dose for the remainder of the 6 months of the study.
45674510|NCT02100475|Drug|insulin degludec/liraglutide|"Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.~Dose individually adjusted."
45674511|NCT02100475|Drug|insulin aspart|Dose titration of insulin aspart will be based on the respective pre-meal(s) and bedtime SMPG measured daily.
45993793|NCT00533676|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks|
45993794|NCT05467319|Drug|Ferric Derisomaltose Injection|1000mg of ferric derisomaltose in 100mL of normal saline by intravenous infusion
45833908|NCT02984514|Radiation|Positron emission tomography with tracer 18F-deoxy glucose|Assessment of activity of brown adipose tissue with positron emission tomography using the tracer 18F-deoxy glucose
45833909|NCT04276428|Drug|LY3209590|Administered SC.
45993795|NCT05467319|Drug|Normal saline|100 mL of 0.9% normal saline (w/v) by intravenous infusion
45993796|NCT04590300|Other|QUESTIONNAIRES|"1 questionnaire at the beginning of the study, before FTE program~1 questionnaire at the end of FTE"
45833910|NCT04276428|Drug|Insulin Degludec|Administered SC.
45833911|NCT05248932|Drug|Norepinephrine bolus|5 microgram bolus therapy
45833912|NCT05248932|Device|cardiometry|cardiac output, stroke volume and fluid responsiveness monitoring
45993797|NCT05467241|Behavioral|Self-induced therapeutic tremor (SITT) combined with mindfulness|"SITT is a way to reduce stress by turning on a natural shaking response. This can calm the participant's body. It involves doing simple exercises. The muscles will gently shake, and release built up stress. This shaking of the muscles lets the participant's body physically let go of tension and stress.~Mindfulness is the ability to be fully present in a moment. This allows focus on what the participant is sensing and feeling in the moment. It involves the acceptance of thoughts and feelings without judging them.~Practicing mindfulness involves breathing methods, guided imagery, and other practices to relax the body and mind, help reduce stress, and not be overwhelmed by what's going on around the participant."
45993798|NCT05467202|Drug|CLL1 CAR-T|A single infusion of autologous CLL1 CAR-T cells administered intravenously
45993799|NCT05338788|Other|neck pain and dual task|"The Neck Disability Index (NDI) was used to assess neck pain related disability. The Biodex Balance System was used to assess postural control.Clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task.In order to avoid the order bias of postural control measurements during Single-task and Dual-task for each case, the order of the measurements was determined by randomization on the first day by using sealed envelope method. After single/double task randomization was made, the order of tests was also randomized by using sealed envelopes containing two different orders (1-mCTSIB, 2-ASLT, 3-Fall test, 4-LOS and 1- LOS, 2- Fall test, 3- ASLT, 4-mCTSIB)."
45674512|NCT04741087|Drug|AMT-101 (oral)-Dose A|AMT-101 is an orally administered biologic therapeutic, taken once daily.
45674513|NCT04741087|Drug|AMT-101 (oral)-Dose B|AMT-101 is an orally administered biologic therapeutic, taken once daily.
45674514|NCT02113189|Other|Walking program with ankle brace|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with the bilateral ankle braces on.
45674515|NCT02113189|Other|Individualized walking program|Walking program will include instructions on walking activities at home such as time of walking
45833913|NCT05248932|Drug|Norepinephrine infusion|2.5 microgram/min infusion
45833914|NCT05246826|Other|Clinical Pilates Exercises|Pilates exercises; warm-up and cool-down exercises will be performed for 5 repetitions, while other exercises will be performed by the same physiotherapist as 10 repetitions depending on the patient's pain and fatigue. The exercises will be advanced at the end of the 3rd week.
45993800|NCT05325840|Other|music terapy|The aim of this study was to examine the effects of the music concert applied during the nonstress test procedure on the health of the fetus, the anxiety level of the pregnant woman and blood pressure.
45993801|NCT05466968|Drug|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
45993802|NCT05466968|Drug|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
45993803|NCT04562805|Device|DynamX Bioadaptor|DynamX Bioadaptor Treatment
45993804|NCT04562805|Device|Resolute Onyx|Resolute Onyx Treatment
45993805|NCT05466812|Drug|Sr-89|"strontium-89 chloride treatment~periodical evaluation and follow-up"
45993806|NCT00533754|Procedure|drawing blood|
45993807|NCT05466773|Behavioral|Hemodialysis eating index (HDEI) base education intervention|The investigators have developed the educational materials for patients, in order to improve the dialysis outcomes. The interventions will be delivered to patients and nurses in hospital based hemodialysis centers.
45993808|NCT00533793|Procedure|open fracture reduction|internal fracture fixation: osteosynthesis plates or intra-medullary nails
45993809|NCT05466695|Drug|Tadalafil 5mg/sildenafil 25 mg|patients will use daily tadalafil or daily sildenafil for 2 months blood sample will be obtained before and after 2 months and also IIEF-5 score for clinical response
45993810|NCT00533832|Device|vagus nerve stimulation (VNS)|"intermittent vagus nerve stimulation~Placebo group were implanted, but did not receive vagus nerve stimulation during the acute phase."
46084638|NCT02770716|Drug|Terlipressin|Terlipressin solution for injection
45993811|NCT05466617|Behavioral|Mobile Health for Physical Activity Behavior Change|All participants received visualized step-by-step instructions (eg, search and download on Google Play or App Store, user registration, goal setting, and PA behavior tracking) on the assigned PA app (PuzzleWalk or Google Fit) and used it from the beginning of the intervention start (fourth week) until the end of the intervention (eighth week). Both the PuzzleWalk and Google Fit groups received reminders regarding the use of the PA app during the first week of the intervention period and autonomously continued to use the app until the intervention ended.
45993812|NCT04484610|Drug|Pharmacist Practice Change to Dispense Appropriate Opioid Quantities for Acute Pain|Pharmacist eLearning modules, support tools and resources to promote assessing and dispensing appropriate opioid quantities for acute pain.
45993813|NCT04687670|Diagnostic Test|ERA|Before the randomization, Endometrial Fluid (EF) and Endometrial Biopsy (EB) samples will be collected from all participants. EF will be obtained by aspiration immediately prior to the EB after around 120 hours of progesterone (P) impregnation following the standard HRT cycle. The results of the ERA test will be provided to participants and their gynecologists for the personalized embryo transfer.
45993814|NCT04687670|Diagnostic Test|ERA|Before the randomization, Endometrial Fluid (EF) and Endometrial Biopsy (EB) samples will be collected from all participants. EF will be obtained by aspiration immediately prior to the EB after around 120 hours of progesterone (P) impregnation following the standard HRT cycle. The results of the diagnosis will not be disclosed with the patients randomized into this arm nor with their gynecologists.
45993815|NCT05321316|Drug|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
45993816|NCT05466266|Device|ICE|All patients received ICE examination.
46084639|NCT02770716|Other|Placebo|Matching placebo solution for injection
45993817|NCT05466266|Device|TEE|All patients received TEE examination.
45993818|NCT05307354|Other|Tibial Nerve Mobilization|The person performing tibial nerve mobilization will start mobilization by keeping the lower extremity in a horizontal position, with the patient's hip and knee in 45° flexion and ankle in neutral position. Then, in order to mobilize the tibial nerve better, the patient will bring the patient's toes to the extension position, the ankle to the dorsiflexion and eversion position, and the knee joint to the extension to provide appropriate stabilization. Finally, while the patient is in this position, mobilization will be completed by plantar flexion of the distal ankle and flexion of the toes to allow the nerve to slide further distally. This mobilization technique will be performed by an experienced physician/physiotherapist twice a week for 4 weeks, and the patients will be given 5 sets of 10 cycles with a 1-minute rest period in each set.
45674516|NCT02113189|Other|Walking program with custom braces.|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with custom-fabricated ankle braces on.
45674517|NCT01440946|Drug|rFIXFc|Vials of rFIXFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
45674518|NCT01440946|Drug|FIX|Vials of prestudy FIX (provided by the participants) were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
46084640|NCT04224896|Diagnostic Test|UPPER ENDOSCOPY|UPPER ENDOSCOPY
46084641|NCT04846829|Drug|Placebo|saline PBO will be administered intravenously using established clinical procedures. A single dose if saline PBO will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
46084642|NCT04846829|Device|intermittent theta burst stimulation|"10 sessions of treatment with cTBS to right DLPFC TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~iTBS paradigm of a 2 s train repeated every 10 seconds"
46084643|NCT04846829|Drug|intravenous citalopram hydrochloride (CIT)|CIT will be administered intravenously using established clinical procedures. A single 40 mg dose of CIT diluted in 60 cc normal saline will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
46084644|NCT04846829|Device|continuous theta burst stimulation|"10 sessions of treatment with iTBS to left or cTBS to right DLPFC TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~1800 pulses of cTBS will be delivered"
46084645|NCT02672319|Procedure|EUS-guided glue injection|Experimental: EUS-guided glue injection Gastroesophageal varices > 3mm in diameter will be treated with EUS guided cyanoacrylate injection for variceal obturation in standard fashion. A conventional 19G needle (19G-Echotip needle, Cook Medical, USA) will be advanced into the target varix under real-time EUS guidance. Cyanoacrylate injection (Histoacryl, B. Braun Surgical, Germany) will be performed according to established protocol. Each aliquot of cyanoacrylate injection will consist of 0.5ml of Histoacryl + 0.7ml of lipiodol. 1 - 3 aliquots of cyanoacrylate injection may be given depending on the number of varices needed to be treated. EUS with colour Doppler will be used to monitor obliteration of blood flow in varices during and after cyanoacrylate injection.
45674519|NCT01450540|Device|REMstar Auto A-Flex|Standard CPAP
45674520|NCT01450540|Device|modified REMstar Auto A-Flex with AGPAP|Modified device -Software upgrade to GP 12
45674521|NCT04075240|Drug|Rivaroxaban 10 MG and acetylsalicylic acid 81 mg|Starting post op, rivaroxaban (5 days) followed by aspirin (9 days for TKA; 30 days for THA)
45674522|NCT04075240|Drug|acetylsalicylic acid 81 mg|Starting post op, aspirin for 9 days for TKA and 30 days for THA
45674523|NCT02070757|Drug|Ceftolozane/tazobactam|Ceftolozane/tazobactam is an antibacterial consisting of a co-formulation of ceftolozane, a novel antipseudomonal cephalosporin and tazobactam, a well-established beta (β)-lactamase inhibitor (BLI) being developed for the treatment of serious bacterial infections.
45674524|NCT02070757|Drug|Meropenem|Meropenem is a broad spectrum injectable antibiotic widely used to treat serious infections such as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.
45674525|NCT04417933|Device|Tumor Electric Fields Treatment System|Patients wear two pairs of electrodes on the head for 19-22 hours a day. Each patient is required to wear the device as long as possible and not less than 6 months. The treatment has a two-day break for every four weeks.
45993819|NCT05307354|Other|Foot-ankle range of motion exercises|In exercise program, foot-ankle joint range of motion exercises will be given. In our study, all exercises will be explained and performed once under the supervision of a physiotherapist, and then the participants will be asked to do all exercises with 10 repetitions, 3 times a day, for four weeks, without the supervision of a physiotherapist.
45993820|NCT05466227|Other|Implementation of Modified Valsalva maneuvre|"Modified Valsalva maneuvre:~Patient is attached to 12-lead ECG monitoring~The patient sits in an upright position and performs forced expiration for 15 seconds by blowing on a 10 mL syringe~Patient's legs are elevated (45°) for 15 seconds~Afterwards, the patient is placed back in an upright position~If not efficient, this maneuver can be repeated up to two times"
45993821|NCT04472793|Diagnostic Test|SARS-CoV-2|"Testing weekly samples from nasal swabs to promptly diagnose acute COVID-19 infection.~Testing monthly serum samples to document post-viral infection."
45993822|NCT05466149|Drug|Furmonertinib|240mg QD on a continuous dosing schedule.
45993823|NCT00532701|Drug|Peg-IFN + WB RBV for 16 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4~Rapid virologic response (RVR) at week 4 of therapy: achieved~Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 5-16"
45993824|NCT00532701|Drug|Peg-IFN + LD RBV for 16 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-6~Rapid virologic response (RVR) at week 4 of therapy: achieved~Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 6-16"
45993825|NCT00532701|Drug|Peg-IFN + WB RBV for 24 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4~Rapid virologic response (RVR) at week 4 of therapy: not achieved~Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-24"
45993826|NCT00532701|Drug|Peg-IFN + WB RBV for 48 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4~Rapid virologic response (RVR) at week 4 of therapy: not achieved~Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-48"
45993827|NCT00532701|Drug|Peg-IFN + LD RBV for 24 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 1-24~Rapid virologic response (RVR) at week 4 of therapy: both achieved and not achieved"
45993828|NCT01276639|Drug|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
45993829|NCT01276639|Drug|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
45993830|NCT01276639|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
45993831|NCT01276639|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
45993832|NCT05465915|Device|Electroconvulsive therapy|Patients are treated with ECT.
45993833|NCT05465837|Procedure|Tracheostomy|Early and Late Tracheostomy (</= 10 days: Early and >10 days: Late)
45993834|NCT05465759|Other|disease|Frequency of SARS COV-2 infection among malignant patients at south Egypt Cancer institute.
45993835|NCT04452357|Radiation|PLDR|"PLDR radiation will be delivered as 10 fractions of 20 cGy, initiated once every 3 minutes. Dose levels will be selected as follows:~Dose level 1: 56 Gy; Dose level 2: 66 Gy Drug: Gemcitabine"
45993836|NCT04449198|Drug|Resveratrol|500 mg of oral trans-resveratrol twice daily (in the morning and evening) for 12-weeks
45674526|NCT04417855|Diagnostic Test|G-Walk|"Every individual will be examined with a non-invasive G-Walk device which is a sensor mounted on a belt and fasten on individuals' lumbar spine region during two test activities: Timed up and go and 6-meter walk tests. Data collection will include kinematic parameters. Oswestry Disability Index (ODI) score will also be collected."
45674527|NCT02100319|Drug|Azilsartan|Azilsartan tablets
45674528|NCT01625845|Drug|Pentoxifylline|Pentoxifylline 400 mg p.o. t.i.d. for 12 weeks
45993837|NCT04449198|Other|Placebo|placebo for 12 weeks
45993838|NCT00532415|Drug|Triamcinolone Acetonide Injectable Suspension|Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
45993839|NCT00532454|Drug|Tamoxifen|tamoxifen 20mg, PO, QD until disease progression
45993840|NCT01275625|Drug|HIV therapy|Combivir one tablet BD with maraviroc 300mg BD for 48 weeks
46084646|NCT02766296|Behavioral|Active Emotional Working Memory Training|This training regimen has adapted the existing n-back paradigm, which has been widely used in the field. Training requires participants to shift between visual and auditory information while continually updating their working memory.
46084647|NCT02766296|Behavioral|Control Working Memory Training|This training utilized a fixed dual 1-back training paradigm.
46084648|NCT04254029|Dietary Supplement|MOROLSTEVER1|The intervention consisted of a daily consummation of 425 ml of drink containing the extracts of 1,38mg of leaves extracts of moringa oleifera and 23,46 mg of stevia rebaudiana Bertoni leaves extracts lasting 45 days.
45993841|NCT05465720|Behavioral|falls-prevention programs|Each group will receive 10-minute warm up, followed by 20-minute exercises in the ICF body function level, 20-minute exercises in the ICF activity level, and finally 10-minute cool down. The 10-minute war up include dynamic mobility exercises of the upper extremity and trunk (ribbons dancing on a chair) and of the lower extremity (marching in place). The 10-minute cool down include flexibility exercises of multiple muscles especially focusing on neck, hamstring, and calf muscles.
45993842|NCT05463458|Other|nutrition|Standard of nutrition Care plus adjusted and calculated dose of omega-3 polyunsaturated fatty acids (PUFA) anti-oxidants.
45993843|NCT05459792|Procedure|median nerve block|It will be given by one researcher using 5 ml 0.25% bupivacaine with 1% lidocaine for each nerve block after negative aspiration for blood so as to cover the nerve circumferentially
45993844|NCT05459792|Procedure|radial nerve block|It will be given by one researcher using 5 ml 0.25% bupivacaine with 1% lidocaine for each nerve block after negative aspiration for blood so as to cover the nerve circumferentially
45993845|NCT05459792|Procedure|local infiltration|intradermal infiltration followed by a subcutaneous injection with a total of 3 mL of 0.25% bupivacaine with1% lidocaine with a27- G needle
45993846|NCT04686825|Drug|DA-8010 2.5mg (Fasting)|Test drug l : DA-8010 2.5mg (Fasting)
45993847|NCT04686825|Drug|DA-8010 2.5mg (Fed)|Test drug ll : DA-8010 2.5mg (Fed)
45993848|NCT04686825|Drug|DA-8010 5mg (Fasting)|Test drug llI : DA-8010 5mg (Fasting)
45993849|NCT04686825|Drug|DA-8010 5mg (Fed)|Test drug lV : DA-8010 5mg (Fed)
45993850|NCT05455892|Other|Clinical data collection during hospitalization in short geriatric units.|Retrospective clinical data collection, at time of infection and 10 days later. Correlation between mortality and gravity. Identification of predictive mortality factors such as frailty, preexisting comorbidities, complications and treatments. Description of medical prescription evolutions.
45993851|NCT05454800|Other|Scoliosis Specific Corrective Exercises and Physical Activity Counseling|Scoliosis specific corrective exercises and physical activity counseling
45993852|NCT05454800|Other|Scoliosis Specific Corrective Exercises|Only scoliosis specific corrective exercises
45993853|NCT04686552|Dietary Supplement|cinnamon|6 g of ground cinnamon
45674529|NCT01625845|Other|Placebo|Placebo pills will match the study drug for color, taste, texture, size, and smell. Participants will receive the same instructions as those randomized to pentoxifylline.
45674530|NCT01625845|Behavioral|Standard Treatment|BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
45674531|NCT01473940|Biological|ipilimumab|Given IV
45674532|NCT01473940|Drug|gemcitabine hydrochloride|Given IV
45674533|NCT01473940|Other|laboratory biomarker analysis|Correlative studies
45674534|NCT04408846|Device|Lumbar fusion|Patients will receive a single level instrumented fusion using a minimally invasive or open traditional surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either minimally invasive or open.
45833915|NCT05246826|Other|Clinical Pilates Exercises and Conventional Treatment|In addition to pilates exercises, a conventional treatment program will be applied. As part of the conventional treatment program, 20 minutes of Hotpack to the cervical area, 20 minutes of conventional Transcutaneous Electrical Nerve Stimulation (TENS) to the painful area (80 Hertz (Hz), 100 microseconds (μs), until tingling is felt, asymmetrical biphasic rectangular waveform), 8 minutes to the cervical area Ultrasound (US) (4 minutes + 4 minutes, 1.5 watts/cm2, 1 MHz, continuous) will be applied.
45833916|NCT05247528|Drug|MANP|Novel designer peptide to represent a pGC-A/cGMP therapeutic
45993854|NCT05453630|Behavioral|Patient Navigation|Patients will receive navigation from a trained lay navigator at the community-based Washington Association for Community Health. The patient navigator will work with patients to schedule their colonoscopy and identify, explore, and overcome barriers. They will educate patients about the colonoscopy procedure and preparation, provide resources, and coach and motivate patients.
45993855|NCT05453630|Behavioral|Usual Care Control|Educational brochure about colonoscopy
45993856|NCT00533988|Device|Antimicrobial impregnated catheter (5593)|Comparison of 14-day placement of a standard triple lumen (ARROW Standard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US) versus an antimicrobial impregnated catheter (Chlorhexidine-silver sulfadiazine)(ARROWgard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US)
45993857|NCT05285748|Behavioral|Self-Paced Intensity Physical Activity|Participants are given a prescription to engage in 150-300 minutes per week of structured exercise with an emphasis on walking. For this study arm, participants are given the explicit recommendation to engage in self-selected intensity PA.
45993858|NCT05285748|Behavioral|Prescribed Moderate Intensity Physical Activity|Participants are given a prescription to engage in 150-300 minutes per week of structured exercise with an emphasis on walking. For this study arm, participants are given the explicit recommendation to engage in moderate intensity PA consistent with national guidelines.
45993859|NCT05424887|Drug|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
46084649|NCT02672241|Drug|Nimotuzumab|Nimotuzumab given during radiotherapy, is administered via intravenous drip with a dosage of 150mg/m2, weekly, for 6 consecutive weeks. After radiotherapy and evaluation, disease progression-free patients will continue to receive Nimotuzumab treatment biweekly until disease relapse or progression.
45993860|NCT05424887|Drug|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
45833917|NCT05247528|Drug|Placebo|Placebo Comparator
45833918|NCT02392026|Drug|Metronidazole Gel|Metronidazole Vaginal Gel 1.3% administered via applicator
45993861|NCT05284500|Procedure|Pediatric cardiac surgery with cardiopulmonary bypass|All patients undergoing pediatric cardiac surgery with cardiopulmonary bypass will be extracted from our database
45993862|NCT05423639|Device|palodent|innovative sectional matrix system with Nickel-Titanium rings, anatomically shaped matrix bands and adaptive self-guiding wedges that provides predictable, tight contacts and restorations that accurately replicate the natural tooth anatomy.
45993863|NCT05423639|Device|optracontact|The instrument is used to achieve large and tight proximal contacts in posterior teeth.
45993864|NCT05281185|Drug|Extended half-life FVIII concentrates with PK-guided dosing|Extended half-life FVIII concentrates with PK-guided dosing as low-dose factor replacement prophylaxis (10-20u/kg, 2-3 times/week) for 6 months in severe haemophilia A patients that previously receive weight-based factor replacement prophylaxis
45993865|NCT05281185|Drug|standard half-life FVIII concentrates with weight-based dosing|standard half-life FVIII concentrates with weight-based dosing, that current patients' regimen before enrolling in this study
45674535|NCT03026374|Behavioral|Be Resilient to Breast Cancer|This is a supportive-expressive group therapy.
45993866|NCT00532532|Drug|tolperisone HCl|Low dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
45993867|NCT00532532|Drug|tolperisone HCl|High dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
45674536|NCT01832727|Drug|Oprozomib|Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib. Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib. Both formulations were administered in a single dose on dosing days. The tablet formulation required multiple tablets to reach each dose on dosing days.
45993868|NCT00532532|Drug|tolperisone HCl|Placebo three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
45993869|NCT04393935|Behavioral|Pharmacy delivered PrEP Intervention|Men who are eligible and agree to the clinical screener will be provided with a pre-packaged kit of self-administered tests for HIV, rectal chlamydia, syphilis and gonorrhea and creatinine and directed back to the private area of the pharmacy to perform their screenings. Participants will be asked to return the screening tests to the pharmacy technician. The pharmacy technician will process/ interpret the results of the rapid HIV test first in case a treatment referral needs to be set up. Then s/he will process/interpret the results of a rapid rectal chlamydia, syphilis, gonorrhea and rapid finger prick creatinine test. HIV negative customers will be provided with their results and be given a 7-day prescription for PrEP, culturally appropriate PrEP counseling and a follow-up appointment with a PrEP prescribing physician. Participants will be contacted after 3 months to determine whether they continued PrEP use.
45993870|NCT05405036|Other|simulated patient|In the last month of the Measurement and Evaluation course in Physiotherapy, a simulated patient session will be held four times (with disease in the cervical-lumbar-shoulder and knee region). Students will be evaluated by the methods they learned about patients. 10 days before and after the simulated patient sessions, the questionnaire will be applied in Turkish for validity and reliability, and then the questionnaire will be repeated after the simulated patient sessions are over, and the effect of the smile patient sessions on the perceived communication skills of the patient will be examined.
45993871|NCT04390308|Procedure|Ovarian puncture|Egg collection
45993872|NCT04390308|Other|Hormonal blood Test|AMH (ng/ml), FSH (IU/mL), E2(pg/mL), P4(ng/mL), LH (IU/mL)
45993873|NCT04390308|Diagnostic Test|Transvaginal ultrasound|Doppler of arteria ovarica. Resistance index
45993874|NCT05381480|Behavioral|In-home Preventive Health Visits by Advanced Practice Nurse|Elements of Comprehensive Geriatric Assessment used as a preventive, health risk assessment, with recommendations tailored for health risks identified and offered to building tenants
45993875|NCT05381480|Behavioral|On-site Evidence-based Physical Activity, Health and Wellness Classes|Weekly calendar of health promotion and injury/illness prevention classes offered to building tenants.
46084650|NCT02672241|Drug|Temozolomide|Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
46084651|NCT02672007|Device|SensiumVitals|The patients will have their respiratory rates, heart rates and temperature (axilla) measured continuously by the SensiumVitals patch.
46084652|NCT02671929|Behavioral|self-help program|Access to the internet-based self-help program
46084653|NCT02671929|Behavioral|therapeutic feedback|Therapeutic feedback on the written information sent to the online therapist
46084654|NCT03794310|Drug|NPF-08 （1-day treatment）|NPF-08 will be administered on the day of colonoscopy.
46084655|NCT03794310|Drug|NPF-08 （2-day split dose）|NPF-08 will be administered at 2 days divided into the day before and on the day of colonoscopy.
46084656|NCT03794310|Drug|Moviprep（1-day treatment）|Moviprep will be administered on the day of colonoscopy.
46084657|NCT04177875|Drug|Teripalimab|Teripalimab Injection 240mg/6ml fixed dose (3mg/kg for patients weighing less than 40kg) ,injection on day 1, each infusion for 30min (no less than 60 minutes for the first injection); every 3 weeks. docetaxel dose was 75mg/m2, injection on day 1;Albumin-bound Paclitaxel (no anti-allergic treatment required), 260mg/m2, injection on day 1; Cisplatin was 75mg/m2, injected on day 1.A total of two treatment cycles.
46084658|NCT02770118|Behavioral|Partial Sleep Restriction|4 hour time in bed (TIB), participants will go to bed 4 hours later than during the HS condition. Wake-up times will be the same. During the in-lab portion of the PSR, meals, fulfilling weight-maintenance energy requirements, will be supplied by the research staff as BOOST shakes.
46084659|NCT02770118|Behavioral|Total Sleep Deprivation|0 hour time in bed (TIB), participants will remain awake throughout the night. Meals will be provided as BOOST shakes at the same meal.
45674537|NCT01832727|Drug|Dexamethasone|Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally. If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
45993876|NCT04330482|Behavioral|CARE-Well App|Participants randomized into this group will be instructed to use the CARE-Well App at least 4 times per week.
45993877|NCT04330482|Behavioral|Internet Links|Participants randomized into this group will be instructed to use a computer tablet pre-loaded with a list of internet links relevant to dementia caregiving at least 4 times per week.
45993878|NCT05354297|Device|Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Expert guidance via coaching
45993879|NCT05354297|Device|Fitbit plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Fitness and wellness guidance
45993880|NCT05354297|Device|Noom plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Behavioral weight loss program
45993881|NCT05354297|Device|Welldoc plus OneTouch Verio Reflect® BGM and Welldoc app|Multi condition support
45993882|NCT05276544|Behavioral|Dietary intervention|Dietary intervention: Preparation and follow-up of diet program.
45993883|NCT00532571|Drug|CoQ10|
45993884|NCT05346614|Behavioral|Lifestyle intervention|Lifestyle coaching will be given on a digital app-based platform. Individuals will receive real-time feedback via a smart scale, activity monitor, and continuous glucose monitor (first 4 weeks, longer if required). Coaching will be focused on gradual behavior change, assisted by digital nudges, one-on-one, and small group coaching sessions. Coaching will include education regarding lifestyle to improve health literacy with respect to diet and diabetes management. Additionally, coaches will guide participants in the implementation of individualized diet and exercise program with varying levels of carbohydrate restriction and caloric deficit.
45993885|NCT00532610|Drug|GSK189075|
45993886|NCT04322565|Drug|Colchicine|Cochicine 1mg/day
45993887|NCT04687826|Other|Goal directed fluid therapy|Patients in 2015 got intraoperative fluid therapy in goal directed fluid therapy technique.
46084660|NCT02770118|Behavioral|Habitual Sleep|8 hours time in bed (TIB), for 3 nights, with fixed bed and wake times, while at home. During the 3-d HS phase, participants will be provided will BOOST meal replacement shakes in amounts required to achieve weight maintenance.
46084661|NCT00917579|Drug|Atorvastatin|A single 10 mg dose of marketed 10 mg atorvastatin tablets
46084662|NCT00917579|Drug|Atorvastatin|A single 10 mg dose of new formulation of 10 mg atorvastatin
46084663|NCT03808740|Drug|Atomoxetine|atomoxetine 0.5 mg/kg/day.
46084664|NCT03808740|Drug|Placebo|sugar pill
45674538|NCT03026296|Behavioral|Healthy Life Center|Depending on what behavior participants aim to change, they get individual counselling using elements from motivational interviewing, group-based exercise twice a week, diet courses and tobacco secession courses during three months
46084665|NCT02762552|Device|Transcranial-holter monitoring|Transcranial holter with an 4 hour-recording
46084666|NCT04277286|Behavioral|survey|"Behavioral study of patients who are in the Transend Program (compliance in follow-up visits after transfert from pediatric to adult care in the 24 months)"
46084667|NCT02766140|Drug|SHR1020 plus Docetaxel|SHR1020 20mg qd 2-21days, Docetaxel 60 mg/m^2 IV Day1/3weeks
45674539|NCT04647058|Procedure|Cubital tunnel release|The control group will undergo cubital tunnel release in situ. In cases of preoperative or intraoperative ulnar nerve instability, anterior transposition of the ulnar nerve will be performed.
45833919|NCT03025386|Other|logatoms test|A forced choice test will evaluate the discrimination of the most confusing logatoms in the cochlear implant users, and representative of the French language.
45833920|NCT03025386|Other|Electroencephalography|Mesure of the mismatch negativity wave
45833921|NCT03140514|Drug|Rejection treatment according to clinical standard-of-care|Standard-of-care treatment is based on the severity and phenotype of biopsy-proven rejection
45993888|NCT04687826|Other|Liberal fluid therapy|Patients in 2017 got liberal intraoperative fluid therapy influenced by their anaesthesiologist.
45993889|NCT05267691|Procedure|Excision|Surgical excision of the lesion and histopathology evaluation using Hematoxylin and Eosin stains
45993890|NCT05342285|Diagnostic Test|Flow mediated dilation|flow mediated dilation in brachial artery
45993891|NCT05259189|Drug|NBL-012 Injection|a single subcutaneous injection
45993892|NCT05259189|Drug|Placebo|a single subcutaneous injection
45993893|NCT05333354|Other|education strategy|The educational course of the experimental group will last for 6 weeks, including classroom teaching and simulated situational teaching. The classroom teaching will be divided into 3 times, a course of about 2 hours at a time; after the class, simulated situational teaching is also arranged for 4 hours at a time/ Caring for many patients with delirium, and performing related research. The simulated scenario lesson plan plans to design 3 major themes (delirium assessment, delirium risk factors, delirium prevention, each major theme will have 2 scenarios, each The simulation teaching exercise starts with pre-briefing, and after the end, debriefing reflection and discussion with the students.
45993894|NCT05227638|Other|exercise|participants were between ages 10-18, volunteered for the study, were diagnosed with adolescent idiopathic scoliosis, were Cobb angle between 10-30 degrees, were 0-3 Risser sign, and were Lenke curve type 1.
45993895|NCT00532688|Drug|N-acetylcysteine|28 days of oral n-acetylcysteine (500mg bd)(in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
45993896|NCT00534144|Drug|iron sucrose injection, USP|iron sucrose injection, USP, 100 mg intravenously (IV) per week, for 5 weeks
45993897|NCT00534144|Drug|sodium ferric gluconate complex in sucrose injection|sodium ferric gluconate complex in sucrose injection, 100 mg intravenously (IV) per week, for 5 weeks
45993898|NCT00534183|Drug|Olanzapine|Olanzapine in dose range of 10-20mg
45993899|NCT00534183|Drug|Risperidone|Risperidone 1-6mg
45993900|NCT00534183|Drug|Haloperidol|Haloperidol 10-20mg
46084668|NCT02766140|Drug|Placebo plus Docetaxel|Placebo matching SHR1020 qd 2-21days, Docetaxel 60 mg/m^2 IV Day1/3weeks
46084669|NCT04177641|Diagnostic Test|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
45993901|NCT05303714|Combination Product|FOLFOX and PIPAC|"A minilaparotomy is performed in the midline. A 5 mm balloon trocar is inserted under finger protection in the right side and the fascia of the minilaparotomy is closed. The abdomen is insufflated with CO2 and a second 10-12mm trocar is introduced under videoscope control in upper left side. Ascites volume is documented and removed sending a sample for cytological examination, an accurate exploratory laparoscopy is performed, possibly placing an additional 5 or 10-12 mmHg trocar, the Peritoneal Cancer Index is calculated. Multiple biopsies are performed in different abdominal quadrants. A nebulizer CAPNOPEN© is inserted into the upper left side trocar and fixed with a 45° angle. The drugs (Cisplatin 10.5 mg/m2 body surface in 150 mL; Doxorubicin 2.1 mg/m2 body surface in 50 mL) are then injected through remote control with a flow rate of 0.7 mL/sec with a pressure of 200 psi. After an aerosol exposure phase of 30min, the aerosol is evacuated via a closed waste system."
45457013|NCT01128517|Behavioral|Maternal education on complementary feeding|"CF education to the mothers in intervention arm.~Ten important key messages developed based on recommended practices (WHO/UNICEF, 2000 & 2006).~First session --> cover the importance of breast feeding, its continuation for whole two years, hand washing, hygiene and importance of CF initiation at 6 months of age.~Second session -->breastfeeding promotion, complementary food consistency, initial complementary food selection and age related complementary food education.~Third session --> previous sessions recall. protein based and iron rich food encouragement.~The control arm continue to be benefited from the lady health workers program, while breastfeeding promotion would be provided to control arm"
45457014|NCT01128517|Behavioral|Education|Maternal education on complementary food
45993902|NCT04269408|Drug|Nicardipine|10 NicaPlant® implants releasing 4 mg nicardipine each.
45993903|NCT04269408|Other|Standard of care|Both arms receive the usual standard of care.
45993904|NCT05298605|Behavioral|Faith in Action! Church-based Navigation Model|Cancer screening education and navigation by identified trained navigators in faith based settings + American Cancer Society Screening Guidelines pamphlet
45993905|NCT05298605|Other|Control|Presentation on healthy behaviors (physical activity, nutrition) + American Cancer Society Screening Guidelines pamphlet
45993906|NCT05296928|Procedure|laparoscopic incision|laparoscopic umbilical trocar entry pathways
45993907|NCT05226195|Other|Sterile Kinesio Taping|The standard post-surgical protocol and sterile EDF kinesio-taping will be applied to this group in the operating room at the end of the surgery in a sterile manner according to the epidermis-dermis-fascia (EDF) technique previously described in the literature (without tension). Original KinesioTex® Tape will be used in the study. The day of taping will be considered as Day 0 and the tapes will be changed on the 4th day, the 7th day.
45993908|NCT05223387|Device|Axiom TL REG|"Anthogyr AXIOM TL Reg will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis"
45993909|NCT05223387|Device|Axiom BL REG|"Axiom BL Reg implants will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis"
45993910|NCT00532727|Drug|Carboplatin|AUC 6 every 3 weeks for six cycles (18 weeks)
45993911|NCT00532727|Drug|Docetaxel|100mg/m2 every 3 weeks for six cycles (18 weeks)
46084670|NCT04177641|Diagnostic Test|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
45457015|NCT02299024|Behavioral|Additional Opioid Information|Patients receiving this intervention are given additional information about the opioid pain medication that they are receiving in the form of a one page handout. The hand out was written in a health-literacy appropriate manner. A research assistant read the handout to them out loud, and they were given a copy to take home with them.
45457016|NCT03929419|Drug|intranasal insulin|application of 160 units human insulin
45457017|NCT03929419|Drug|Placebo spray|nasal spray containing placebo solution
45833922|NCT03007758|Procedure|open ventral hernia repair|An open retromuscular ventral hernia repair involves an incision through your abdominal wall, most often through a prior surgery scar. The contents of the hernia, which may include intestine or fatty tissue, are returned into the abdominal cavity. The posterior (inner-most) layer of the abdominal wall is separated from the muscle and closed, which closes the abdominal cavity. Mesh is then placed over that closed layer, which is outside of the abdominal cavity, but below the abdominal muscles. The anterior (outer-most) layer of the abdominal wall is then closed over the mesh, which closes the hernia.
45457018|NCT02299102|Device|Jamshidi Manual Standard Device|Jamshidi Manual Standard Device
45457019|NCT02299102|Device|OnControl Powered Ported Device|OnControl Powered Ported Device
45674540|NCT04647058|Procedure|Supercharged end-to-side (SETS) nerve transfer|The SETS group will undergo the same procedure as described above, with the addition of the SETS procedure consisting of a end-to-side transfer of the anterior interosseous nerve to the ulnar nerve motor branch. Decompression of Guyon's canal during the SETS procedure is at the discretion of the treating surgeon.
45674541|NCT01473394|Drug|Dose-matched placebo|Dose-matched placebo was supplied as tablets.
45674542|NCT01473394|Drug|Vilazodone|Vilazodone was supplied as tablets.
45993912|NCT04261218|Drug|tomivosertib|Tomivoserib is supplied as a 100 mg capsule, to be taken orally.
45993913|NCT04261218|Drug|paclitaxel|Taken weekly according to the current market label in combination with experimental tomivosertib.
45993914|NCT05274620|Behavioral|IntelliCare|A mobile intervention that use principles of computerized therapy to decrease symptoms of depression
46002352|NCT04501328|Behavioral|CIC+VA-CRAFT|CIC+VA-CRAFT consists of four 45-min. telephone coaching calls over 8-12 weeks, delivered by a coach following a manual, while participants are completing the VA-CRAFT for PTSD web-based course.
46084671|NCT00614250|Drug|AVE0657|capsules once a day at bedtime
46084672|NCT00614250|Drug|placebo|capsules once a day at bedtime
45674543|NCT04598529|Other|A2 milk|a variety of cow's milk that contains only A2 beta-casein (and therefore lacks of A1 beta-casein).
45674544|NCT04598529|Other|Conventional milk|cow's milk with a mixture of A1 and A2 beta-casein.
45993915|NCT05262998|Procedure|Plate fixation|"Procedure: plate fixation~Plate fixation was performed by the regular on-call team surgeons and adhered to standard principles of fracture fixation. A standard surgical protocol was used, the approach was moved inferiorly, the fracture was reduced, sometimes with osteosutur and fixed with an antero-superior anatomical plate. 3.5mm Locked and cortical screws were used on both sides of the fracture. Fluoroscopy was used during the procedure. Intradermal suture was used to close the skin~Other: post-intervention All patients were discharged the day after the surgery. Interruption of work was given for 45 days. The same analgesics were administered in both groups for three weeks. Graduated exercises for the shoulder joint with pendular movements in a range of 15°-20° with the protection of a forearm sling were commenced from the postoperative second day. The sling was removed when X-ray films showed growth of callus or an indistinct fracture line."
46084673|NCT04640948|Device|High flow nasal therapy|Controlled oxygen administration using at least 20 L/min of flow rate and titrated up as tolerated. Titration of supplemental oxygen to an arterial saturation between 88 - 92%.
46084674|NCT04640948|Device|Low flow oxygen|Controlled oxygen administration using (venturi mask or nasal cannulae) titrated to an arterial saturation between 88 - 92% as the initial oxygen administration method with a flow rate of <20 L/min.
46084675|NCT04177563|Other|whole body cryostimulation|Whole-body cryotherapy
46084676|NCT04276974|Other|Organic diet|Organic plant-rich foods (2000kcal for women, 2500kcal for men)
46084677|NCT04276974|Other|Non-organic diet|Likewise Non-organic plant-rich foods (2000kcal for women, 2500kcal for men)
46084678|NCT00915551|Drug|PEP005 (Ingenol Mebutate) gel, 0.015%|once daily for 3 consecutive days
46084679|NCT00915551|Drug|Vehicle Gel|once daily for 3 consecutive days
46084680|NCT02770196|Behavioral|CO-CSA plus Nutrition Education|Participants will receive subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year. In addition, they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
46084681|NCT04178109|Drug|Dexketoprofen/tramadol (27mg/75mg)|Postoperatively patients in Group A received the oral combination dexketoprofen/tramadol for the treatment of acute postoperative pain the first 72h
46084682|NCT04178109|Drug|Tramadol hydrochloride|Patients in group B received IV tramadol 75mg every 8h
46084683|NCT04178109|Drug|Paracetamol|Patients in group B received IV paracetamol 1g every 8h
46084684|NCT04178109|Drug|Ropivacaine Hydrochloride 7.5 MG/ML|300mg ropivacaine as periarticular injection in a dilution of 100ml n/s 0,9% was done by the orthopedic surgeon in all patients
46084685|NCT04178109|Drug|Levobupivacaine Hydrochloride|10-15mg levobupivacaine was done subarachnoidal for spinal anesthesia
46084686|NCT04253795|Other|Laryngeal mask|After the laryngeal mask will be inserted lung isolation will be achieved with an artificial pneumothorax induced during opening the pleura, which resulted to the collapse of the nondependent lung with the patient's spontaneous breathing.
46084687|NCT04253795|Other|double lumen tube|After the one lung ventilation will be started, lung isolation will be achieved by deflation of the nondependent lung.
46084688|NCT00644475|Drug|Imidapril|tablets; 5, 10, 15, 20 mg; od; 12 weeks
45457020|NCT01228279|Other|DIANEAL|"Weeks 1 to 6 (6 weeks):~CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night~CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 4-6 hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night~Weeks 7 to 18 (12 weeks):~*same regimen as weeks 1 to 6, for both CAPD and CCPD patients"
45674545|NCT04408144|Drug|Dydrogesterone 10mg Oral Tablet|oral 10mg dydrogesterone (Duphaston) 2 times daily
45833923|NCT03007758|Procedure|robotic ventral hernia repair|A robotic retromuscular ventral hernia repair involves a similar separation of the layers of the abdominal wall, similar mesh placement, and similar closure of the hernia defect. The surgical robot is a tool that allows your surgeon to place long, narrow instruments through small incisions in order to perform surgery from the inside of your abdomen. Rather than one longer incision in the middle of your abdomen, four to six small incisions, about 1 inch, are made along the outer part of your abdomen between the rib cage and hip.
45833924|NCT02395614|Drug|Chlorhexidine irrigation|- 0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles will be used to irrigate one breast pocket. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
46084689|NCT00644475|Drug|Candesartan|tablets; 8, 16, 24, and 32 mg; od; 12 weeks
46084690|NCT04223492|Diagnostic Test|Liquid biopsy|A blood sample containing circulating tumor DNA and circulating tumor cells.
46084691|NCT04223492|Diagnostic Test|Multi-parametric MRI|Multi-parametric MRI combines different imaging protocols in one session to measure more functional items than perfusion alone, addressing different aspects of tumor biology.
45674546|NCT01449682|Drug|Ozurdex|0.7 mg intravitreal DEX implant on first visit, then PRN if evidence of macular edema on OCT studies
45674547|NCT01449682|Drug|Ozurdex|0.7 mg intravitreal DEX implant on first visit then every 16 weeks
45833925|NCT02395614|Drug|triple antibiotic irrigation|"-triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.~80 mg of gentamicin in 500 mL of NS. If the patient is allergic to either component - the allergen will not be used in the solution - to irrigate one breast pocket"
45833926|NCT04396938|Drug|Lamotrigine|Active Drug Capsule
45833927|NCT04396938|Drug|Placebos|Placebo Capsule
45833928|NCT00639678|Drug|placebo|40 mg/kg intravenously, double dose (day 0 and 14), Group 3
45674548|NCT01449526|Device|B&L Investigational Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
45674549|NCT01449526|Device|B&L PureVision Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
45674550|NCT01440322|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
45674551|NCT01440322|Device|Lotrafilcon B contact lens|Silicone hydrogel contact lens
45674552|NCT02985580|Dietary Supplement|Blueberry|
45674553|NCT02985580|Dietary Supplement|Placebo|
45993916|NCT05262998|Procedure|Intramedullary Screw|"Procedure: Intramedullary screw fixation~Intramedullary screw fixation was performed by the regular on-call team surgeons and adhered to standard principles of fracture fixation. Intramedullary screw fixation was performed by using a 1.6 or 2.8 mm-diameter threaded guide pin and a 85-100 mm long, 4.5 or 6.5 mm-diameter cannulated screw tapped in along the guide pin. Fluoroscopy was used during the procedure. Intradermal suture was used to close the skin.~Other: post-intervention All patients were discharged the day after the surgery. Interruption of work was given for 45 days. The same analgesics were administered in both groups for three weeks. Graduated exercises for the shoulder joint with pendular movements in a range of 15°-20° with the protection of a forearm sling were commenced from the postoperative second day. The sling was removed when X-ray films showed growth of callus or an indistinct fracture line."
45993917|NCT04260243|Other|Experimental-Myofascial + Respiratory rehabilitation|6 sessions of: Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
45993918|NCT04260243|Other|Sham Myofascial + Respiratory rehabilitation|6 sessions of: Sham Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
45993919|NCT05258903|Procedure|Ulnar artery cannulation|Ulnar artery will be cannulated under USG guidance
45993920|NCT05258903|Procedure|Radial artery cannulation|Radial artery will be cannulated under USG guidance
45993921|NCT04687410|Device|ProControl, MediGlobe|standard 22G FNA needle
45993922|NCT04687410|Device|TopGain, Medi-Globe|novel 22G crown-cut FNB needle
45993923|NCT00532766|Drug|Jusline|
45993924|NCT04687449|Dietary Supplement|Curcumin therapy|Clear capsules (made of vegetable cellulose) with turmeric extract (500 mg, 95% curcuminoids), Bioperine (5 mg, improves absorption), and inactive ingredients (microcrystalline cellulose, vegetable magnesium stearate, silicon dioxide).
45993925|NCT04687449|Other|Placebo|Clear capsules (made of vegetable cellulose) with inactive ingredients (lactose monohydrate and food color); the capsules will be matched in size and color of the content to the preparation used in the Curcumin capsule.
45993926|NCT04687449|Other|Standard care|The standard of care for COPD.
45993927|NCT05258786|Behavioral|Pre-labor ultrasound as a visual biofeedback device for maternal pushing education and pelvic floor training|"Ultrasound examination with the screen turned to the provider will assess the bladder movements at rest and during contraction of the pelvic floor and fetal head descent at rest and during pushing.~The provider will turn the screen to the patient and explain the anatomical landmarks: bladder, fetal head, birth canal direction.~A repeat of the first stage (1) with the screen turned to the patient: the biofeedback process. Bladder displacement will serve as a marker of pelvic floor contraction, and the delta in the progression angle will serve as a marker for effective pushing.~Finally, the provider will turn the screen again from the patient and repeat the first stage."
45993928|NCT04221009|Behavioral|MI and CBT 4-session manualized intervention|This is a 4-session intervention derived from Motivational Interviewing and Cognitive Behavior Therapy and adapted with cognitive accommodations.
45993929|NCT05258279|Drug|Pembrolizumab|IV infusion Q3W
45993930|NCT05258279|Drug|Lenvatinib|Oral capsule once daily
45993931|NCT05258279|Drug|Carboplatin|IV infusion Q3W
45993932|NCT05258279|Drug|Pemetrexed|IV infusion Q3W
45993933|NCT04203693|Drug|Tildrakizumab|The study physicians will choose the treatment independently of the enrolment in the study according to routine care.
45993934|NCT05257967|Diagnostic Test|Lumbar puncture and Phlebotomy|Sampling of cerebral spinal fluid and plasma.
45993935|NCT04200924|Other|Biodex Balance System|For the computerized evaluation of postural control, Biodex Balance System will be used.
45993936|NCT04200924|Other|Balance Error Scoring System (BESS)|For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
45993937|NCT05230979|Other|Common bean baked snack|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
46084692|NCT03655704|Drug|Apabetalone|A 4-week pre-treatment phase will allow ensuring that patients are on stable doses of medication. Patients will be given doses of apabetalone 100mg BID for 16 weeks. Patients will be regularly followed (Fig.1). At baseline and week 16, a cardiac catheterization and MRI will assess changes in pulmonary hemodynamics and RV function.
46084693|NCT04177719|Drug|Oxytocin|oxytocin will be given intranasally. The order of administration will be counterbalanced
46084694|NCT04177719|Drug|Placebo|Saline placebo will be given intranasally. The order of administration will be counterbalanced
46084695|NCT04695899|Device|Dental Implant|"See Section Procedures."
46084696|NCT02762240|Other|DHQP 2016|DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
46084697|NCT02762240|Other|DHQP 2018|DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
46084698|NCT00644553|Drug|Clarithromycin|Clarithromycin Extended-Release 500 mg tablet (2 tablets QD)
46084699|NCT00644553|Drug|Amoxicillin|Amoxicillin-clavulanate 875/125 mg tablet (1 tablet BID)
46084700|NCT02762474|Drug|nab-paclitaxel group|Weekly Regimens of Nab-paclitaxel Plus Cispaltin Combined With Concurrent IMRT
46084701|NCT03581604|Diagnostic Test|Allergy work-up|Allergy work-up
46084702|NCT03581604|Other|Blood samples and microbiological samples.|Blood samples and microbiological samples
46084703|NCT00915473|Drug|bupivicaine|2.5 mL 0.5% bupivicaine
46084704|NCT00915473|Drug|normal saline|2.75 mL normal saline
46084705|NCT00915473|Drug|methylprednisolone|0.5 mL 20 mg methylprednisolone
46084706|NCT00915473|Drug|lidocaine|0.25 mL 1% lidocaine
45993938|NCT05230979|Other|Cooked beans|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
45993939|NCT05230979|Other|White bread|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
45993940|NCT05230979|Other|Anhydrous glucose (first session) (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume a reference glucose solution containing 25 g of anhydrous glucose per 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to drink the reference glucose solution. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
45993941|NCT05230979|Other|Anhydrous glucose (second session) (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume 54 g of common bean baked snack with 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to eat the test food. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
45993942|NCT05230979|Other|Common bean baked snack (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume 54 g of common bean baked snack with 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to eat the test food. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
45993943|NCT00532818|Drug|Hydralazine and magnesium valproate|Cisplatin + Topotecan plus hydralazine valproate
45993944|NCT00532818|Drug|Placebo|Cisplatin + Topotecan plus placebo
45993945|NCT04687397|Behavioral|Rehabilitation|Multidisciplinary rehabilitation
45993946|NCT05209035|Drug|Trazodone|Trazodone 50mg daily
45993947|NCT05209035|Other|Placebo|Starch 50mg
45993948|NCT04687202|Other|follow up and record|None additional intervention was applied to the subjects.
45993949|NCT00534261|Drug|Interferon beta-1a|IM injection
45993950|NCT04687319|Biological|bronchial mucus collection|mucus resulting from respiratory physiotherapy sessions for patients with cystic fibrosis or COPD, bronchial aspirations resulting from the bronchial fibroscopy programme
45457021|NCT01228279|Other|EXTRANEAL|"Weeks 1 to 6 (6 weeks):~CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night~CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night~Weeks 7 to 18 (12 weeks):~CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of EXTRANEAL during the night~CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and one 8-12-hour dwell of EXTRANEAL during the night"
45457022|NCT03514342|Procedure|Interscalene brachial plexus block|Under ultrasound guidance, the 5th to 7th cervical nerve roots are identified between anterior and middle scalene muscles and subsequently blocked.
45457023|NCT03514342|Drug|0.75% ropivacaine|Placement of 25 to 30 ml of 0.75% ropivacaine around the 5th to 7th cervical nerve roots
45833929|NCT00639678|Drug|raxibacumab|40 mg/kg intravenously, double dose (day 0 and 14), Group 1
45833930|NCT00639678|Drug|placebo|40 mg/kg placebo, single dose (day 0), Group 4
45833931|NCT00639678|Drug|raxibacumab|40 mg/kg intravenously, single dose, day 0, Group 2
45833932|NCT02914158|Drug|Goserelin|
45833933|NCT02914158|Drug|Tamoxifen|
45833934|NCT02914158|Drug|Aromatase Inhibitors|
45833935|NCT02914158|Drug|Leuprolide|
45833936|NCT03136146|Drug|Bortezomib|Given SC
45993951|NCT04687280|Other|non interventional|non interventional, study on data
45993952|NCT04686708|Other|Emergency general surgical admissions|All emergency general surgical admissions are admitted initially to the emergency department and then referred to the general surgery department for further management (medical, interventional, or surgical approaches).
45993953|NCT00534300|Drug|Omegaven|Lipid emulsion (omegaven) for intravenous use, 100 ml (25 mL/h)
45993954|NCT00534300|Drug|Isotonic saline|Intravenous infusion, 100 mL, 25mL/h
45993955|NCT05213780|Other|No intervention is involved|No intervention is involved
45993956|NCT05202405|Drug|AD-221|AD-221 Oral Tablet
45993957|NCT05202405|Drug|AD-221A and AD-221B|AD-221A Oral Tablet + AD-221B Oral Tablet
45833937|NCT03136146|Drug|Clofarabine|Given IV
45833938|NCT03136146|Drug|Cyclophosphamide|Given IV
46084707|NCT04691726|Drug|lidocaine 10mg/ml|bolus i.v. + continuous i.v. infusion
45457024|NCT01228045|Drug|Trastuzumab in Combination with TS-ONE and cisplatin|Subjects will receive treatment that combined TS-ONE, cisplatin and trastuzumab every 3 weeks in this study. This 3 weeks period of time is called a cycle. The cycle will be repeated until subject experience disease progression or unbearable toxicities or they choose to withdraw from the study. Each cycle is numbered in order.
45457025|NCT03514264|Procedure|Gutta Percha and AHPLUS cement (group A)|"First intervention: endodontic instrumentation and introduction of intact medication that will remain inside the tooth for 4 weeks.~Second intervention: removal of intracanal medication and canal filling with cement AHPLUS and guttapercha"
45457026|NCT03514264|Procedure|PBS CIMMO cement (group B)|Single intervention: endodontic instrumentation and obturation with cement PBS CIMMO
45457027|NCT03925987|Behavioral|Exposure therapy|10 weekly sessions of group-based exposure therapy
45833939|NCT03136146|Drug|Dexamethasone|Given IV or PO
45833940|NCT03136146|Drug|Etoposide|Given IV
45833941|NCT03136146|Biological|Ofatumumab|Given IV
45833942|NCT03136146|Biological|Pegfilgrastim|Given SC
45833943|NCT03136146|Biological|Rituximab|Given IV
45833944|NCT03136146|Drug|Vincristine Sulfate Liposome|Given IV
45833945|NCT02765802|Drug|Peginterferon Lambda-1A|
45833946|NCT05241210|Device|AI program for colonoscopy|Provides real-time feedback on the endoscopist moniter during colonoscopy.
45833947|NCT05241132|Drug|Tislelizumab plus chemotherapy|"Cisplatin: 100mg/m2, injected intravenously every 3 weeks, 8 cycles (period 21 days)~Paclitaxel (albumin-bound) : paclitaxel, 175mg/m2, given intravenously every 3 weeks for 8 cycles (period 21 days).~Tislelizumab: 200mg, given intravenously every 3 weeks until disease progression or unacceptable toxicity or death or subject withdrawal of informed consent."
45993958|NCT00532857|Drug|Paclitaxel/Gemcitabine/Trastuzumab|80 mg/m2 of paclitaxel 1,200 mg/m2 of gemcitabine, day 1, day 8 every 3-week. trastuzumab at a dose of 4 mg/kg IV on D1 of first treatment cycle subsequently given weekly at a dose of 2 mg/kg
45993959|NCT05201300|Drug|Remimazolam Besylate 6 mg/kg/hr|Patients will receive remimazolam at 6 mg/kg/hr by continuous infusion until loss of consciousness.
45993960|NCT05201300|Drug|Remimazolam Besylate 12 mg/kg/hr|Patients will receive remimazolam at 12 mg/kg/hr by continuous infusion until loss of consciousness.
45993961|NCT05201300|Drug|Propofol|Patients will receive propofol at a target controlled infusion 4 µg/ml until loss of consciousness.
45993962|NCT05200377|Diagnostic Test|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
45993963|NCT05190458|Other|High Velocity Nasal Insufflation|High velocity nasal insufflation (HVNI), a form of HFNC that utilizes a small bore nasal cannula to generate higher velocities of gas delivery than HFNC which uses large bore cannula, has the ability to accomplish complete purge of extra thoracic dead space at flow rates of 35 litres/min and may be able to provide ventilatory support in patients with respiratory failure in addition to oxygenation support in patients with overlap syndrome.
45993964|NCT05190458|Other|Non-invasive mechanical ventilation|Noninvasive ventilation (NIV) refers to the administration of ventilatory support without using an invasive artificial airway (endotracheal tube or tracheostomy tube).
45993965|NCT04169334|Behavioral|Prolonged planned program for the stay at the obstetric department|A five day planned and designed program delivered to the family while at the obstetric department.
45993966|NCT05180903|Other|X-tra base & GrandioSO reinforced by Ribbond|The missing peripheral tooth structure will be built up via 2-mm wedge-shaped a universal hybrid resin composite, GrandioSO . Then the polyethylene fibers will be wetted with an unfilled resin first . After removing the excess resin, fibers will be covered with a very thin layer of flowable composite X-tra base . After that, fibers will be bonded immediately against the peripheral missing walls and cured for 20 seconds. Then a bulk-fill flowable resin composite lining X-tra base will be applied in approximately 4 mm thick in bulk increments as needed to fill the cavity 2 mm short of the occlusal cavosurface and each increment will be light cured for 20 s. The remaining occlusal part of the cavity will be restored with a universal hybrid resin composite, GrandioSO . The shade of the composite will be selected according to the teeth to be restored. All cavities will be restored with open-sandwich technique (Deliperi, et al. 2017).
45993967|NCT05191251|Diagnostic Test|HEMSTOP questionnaire|A HEMSTOP questionnaire is obtained during the anesthesia consultation.
45993968|NCT04686513|Other|Observation|observational study
45993969|NCT05152004|Drug|Pariet|Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
45993970|NCT05152004|Drug|Amolin|Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
45993971|NCT05152004|Drug|Klaricid|Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
45993972|NCT05152004|Drug|Flagyl|Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
45993973|NCT00534339|Device|Easyband (Telemetrically adjustable gastric banding device)|EasyBand
45993974|NCT05132153|Drug|Milrinone|will be given by nebulization
45993975|NCT05132153|Drug|Normal saline|will be given by nebuliztion
45993976|NCT00534378|Drug|Midazolam|The study drug was administered IM into the anterior thigh using the preloaded autoinjector. The autoinjectors were preloaded with midazolam 5 mg or 10 mg with a total volume of 1 or 2 mL. Healthy subjects were assigned to one of six target dosage groups (0.10, 0.18, 0.25, 0.33, 0.40, 0.49 mg/kg) and, based on their weight, received the necessary combination of fixed 5 or 10 mg doses to provide the assigned target dose.
45993977|NCT05131997|Drug|AD-221|PO, Once daily(QD), 8 weeks
45993978|NCT05131997|Drug|AD-221A|PO, Once daily(QD), 8 weeks
45993979|NCT05131997|Drug|AD-221B|PO, Once daily(QD), 8 weeks
45993980|NCT05131997|Drug|AD-221C|PO, Once daily(QD), 8 weeks
45993981|NCT00534456|Drug|Placebo|Placebo group to receive volume and dose frequency changes resembling titration dosing in the treatment group.
45993982|NCT00534456|Drug|Darbepoetin alfa|Starting dose: 0.75 mcg/kg subcutaneously Q2W. Subsequent doses: Darbepoetin alfa group to receive darbepoetin alfa titrated to achieve Hb target of 13.0 g/dL, not to exceed 14.5 g/dL.
46084708|NCT04691726|Drug|Placebo|bolus i.v. + continuous i.v. infusion
46084709|NCT04691726|Drug|Metamizole|2,5 g i.v. BD
45457028|NCT02292394|Behavioral|Multicomponent Cognitive Behavioral Telephone Intervention|
46084710|NCT04691726|Drug|Morphine|continuous i.v. infusion adjusted to VAS scale score
46084711|NCT00614328|Drug|Naltrexone, Baclofen, Placebo and Behavior Therapy|Naltrexone 50mg/day for 12 weeks Baclofen 10mg tid = 30mg/day for 12 weeks Behavior Therapy 9 sessions
46084712|NCT04177173|Drug|Simvastatin 20 mg|improvement of disease activity
46084713|NCT04177173|Drug|Methotrexate 10 mg|improvement of disease activity
46084714|NCT04224818|Drug|Dual trigger|Dual trigger: human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once) + Gonadotropin-Releasing Hormone agonist (Triptorelin 0.3 mg subcutaneous once)
46084715|NCT04224818|Drug|hCG (standard)|human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once)
46084716|NCT02672085|Procedure|PRP infiltraiton|Two time with 1 month interval, PRP will be extracted from own blood's patients with Regenlab® extraction kit, and injected into supraspinatus interstitial lesion.
45674554|NCT01832493|Device|Cardiac Resynchronization Therapy|All study patients were evaluated for the optimal atrial-ventricular (AV) programmed interval using various methods.
45674555|NCT01831791|Drug|Dutasteride 0.5 mg|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of Dutasteride and it will be packaged in high-density polyethylene (HDPE) bottles with plastic child-resistant closures.
45674556|NCT01857531|Drug|Ganaxolone|"Pre-Quit Period:~Beginning at Session P1, subjects will receive ganaxolone at a dose of 400mg total daily (200mg bid) for the first three days, 800mg total daily (400mg bid) for the next three days and 1200mg total daily (600mg bid) for the remainder of the first four weeks.~Post-Quit Period:~Following the quit-day, subjects will receive ganaxolone at a dose of (1200mg total daily) for the next week. Down-titration of ganaxolone will begin at post-quit week two. Subjects will receive ganaxolone at a dose of 800mg total daily (400mg bid) to take for three days and 400mg total daily (200mg bid) to take for three."
45833948|NCT03132792|Genetic|Autologous genetically modified AFPᶜ³³²T cells|Infusion of autologous genetically modified AFPᶜ³³²T cells
45833949|NCT05241054|Drug|Bupivacaine|With patient in supine position, the patient will be placed on the operating table with a head-up tilt to reduce venous congestion at the operative site. Skin will be disinfected, the patient will receive local anesthesia by paranasal infiltration at the incision site with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine.
45833950|NCT05241054|Drug|Nitroglycerine|This group includes 32 patients (anticipated), infusion of Nitroglycerine (TNG) (0.2-1µg/kg/min) will be started and adjusted to maintain mean arterial blood pressure between 55-65mmHg.
45993983|NCT05104229|Drug|Aspirin 81Mg Ec Tab|Aspirin 81Mg Ec Tab by mouth twice daily starting the day after surgery until hospital discharge, then for 30 days
45993984|NCT05104229|Drug|Standard of Care|Standard of Care VTE prophylaxis
45993985|NCT05167773|Device|tonometer|A subject undergoes intraocular pressure measurement with tonometer
45993986|NCT05163990|Other|transcutaneous acupoint electrical stimulation|The corresponding transcutaneous acupoint electrical stimulation is given to different groups before spinal anesthesia, which last from 10 minutes before anesthesia to 30 minutes after subarachnoid administration.
45993987|NCT05077631|Drug|ACD856|Single oral doses of ACD856 administered in a fasted state in escalation schedule of dose 1, dose 2, dose 3, dose 4, dose 5, dose 6 and dose 7. The escalation schedule may be adapted based on evaluation by internal Safety Review Committee.
45993988|NCT05077631|Drug|Placebo|Placebo oral solution
45993989|NCT05077631|Drug|ACD856 (fed cohort)|Single oral dose of ACD856 in fed state of either dose 4 or dose 5.
45993990|NCT04153032|Drug|Diltiazem|DTZ is a calcium channel blocker for the treatment of chronic anal fissure
45993991|NCT04153032|Drug|Mebo|Moist exposed burn ointment (MEBO) is a tropical Chinese medicine composed of sesame oil and herbal plants that is clinically used for the treatment of burn wound.
45993992|NCT00532961|Drug|Loteprednol etabonate 0.5% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals(1-2 drops per eye)for a total of 28 days
45993993|NCT00532961|Drug|Dexamethasone 0.1% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals (1-2 drops/eye) for a total of 28 days.
45993994|NCT04138524|Other|SAFIR©|Early Supportive intervention for families of patients with acquired brain injuries.
45993995|NCT05121792|Behavioral|Web Based Therapist Tutorial on Prolonged Grief Disorder Therapy|The tutorial consists of 10 online modules following the main procedures of the Prolonged Grief Disorder Therapy (formerly known as Complicated Grief Treatment). Each module includes didactic information and interactive activities and videos, and takes approximately 30 minutes to review. Participants can study the material at their own pace.
45993996|NCT05063435|Diagnostic Test|Carotid ultrasonography|"Study takes 10 - 15 minutes to complete~Subject will be asked to lay still and quietly during procedure~The ultrasound probe will be placed on one side of the neck to capture images of the carotid artery. When images from one side have been captured, the probe will be moved to the other side of the neck to capture images from the other carotid artery.~Blood pressure and heart rate will be obtained during the study~Results will be anonymized, digitized and stored on CD with unique identifier"
46084717|NCT02672085|Procedure|Needling|Two time with 1 month interval, saline water will be injected into supraspinatus interstitial lesion.
46084718|NCT02766062|Other|metabolic syndrome|metabolic syndrome
45457029|NCT02292394|Behavioral|Telephone Intervention Pleasant Activities|
45457030|NCT03929497|Drug|Lu AF11167|Lu AF11167 - 2 or 4 mg/day; tablets, orally
45457031|NCT03514030|Diagnostic Test|serum AQP4-antibody testing method|there are different methods of testing serum AQP4-antibody
45833951|NCT05241054|Drug|Propofol|General anesthesia will be induced using IV propofol at dose of 1-2 mg.kg
45993997|NCT05063435|Diagnostic Test|Echocardiography, transthoracic|"Study takes 15 - 20 minutes to complete~Subject will be asked to lay still and quietly during procedure~The technician will apply an ultrasound probe to the chest. Images and movies will be acquired.~Results will be digitized and stored on CD"
45993998|NCT05063435|Procedure|Venipuncture|"10 mL of blood total will be drawn (5 mL in a blue top citrate tube, 5 mL in a purple top EDTA tube). Measurements of cytokines, clusterin, lipidomics, cathepsin S protease, and elastin (previously identified potential biomarker candidates) will be performed.~Blood will preferably be drawn via venipuncture, but if patient has a port-a-cath already implanted and is having blood drawn via port-a-cath for clinically required reasons, then study-related blood draw via port-a-cath can take place concurrently with clinically required blood draws."
45993999|NCT00534534|Behavioral|Repeated behavioural intervention without any drugs|"All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion as those in the standard group. No drugs will be used as part of the intervention. They also will undergo repeated interventions at outpatient visits at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period."
45994000|NCT05062070|Drug|TolaSure Topical Gel|TolaSure Topical Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
45994001|NCT05062070|Drug|Vehicle Topical Gel|TolaSure Vehicle Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
45994002|NCT00534573|Drug|Amisulpride, Moclobemide|Amisulpride 400 mg/d; Moclobemide 300 mg/d every medication for 2 week aith 2 week washout
45994003|NCT04686890|Procedure|erector spinea plane block administered preoperative open nephrectomy|erector spinae plane block applied in this group before open nephrectomy
45994004|NCT04686890|Procedure|intravenous analgesic ( 1 mg/kg tramadol + non-steroid antiinflamatuar paracetamol )drug + 10 mg.kg|intarvenous analgesic administered in this group for analgesia end of the open nephrectomy
45994005|NCT00533000|Procedure|Smoking cessation|Weekly smoking cessation by professional counseling and nicotine substitute on request
45994006|NCT04136340|Other|In-person in clinic follow-up visit|Patient will be seen in-person (i.e. an IR/NV or AFX visit) in the clinic by a Supportive Care Specialist for at least 3 follow-up visits over 14 weeks. Any patients randomized to the in-person group who experience an extraordinary burden and/or are physically unable to attend their in-person visits will be able to be seen by their Supportive Care Service clinician via a home telemedicine visit (patients will return to their original group assignment if possible).
45994007|NCT04136340|Other|Telemedicine follow-up visit|"i. Patients will be seen by video telemedicine at home by a Supportive Care Specialist for at least 3 follow-up visits over 14 weeks.~ii. Patients will have access to a clickable link that will initiate a video telemedicine call to the clinician's office. The clinical team will be responsible for answering such calls and for ensuring the clinician and the patient connect and begin the actual visit."
45994008|NCT00534612|Procedure|aspiration biopsy|fine needle aspiration biopsy of the parotid gland masses
45994009|NCT00533039|Drug|Varespladib (A-002)|250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.
45994010|NCT00533039|Drug|placebo|250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.
45994011|NCT05103306|Drug|Empagliflozin 25 MG|Empagliflozin 25mg/day add-on to triple combination oral antidiabetic agents consisted with metformin, glimepiride, and DPP4 inhibitor
46084719|NCT04082091|Behavioral|SELECT mHealth Program|"Individuals will be screened via the telephone, using a mobile-based algorithm that prompts questions about hypertension, risk of Diabetes Mellitus, use of smokeless tobacco and smoking, level of physical activity, and main nutritional choices. These questions are based on tools that have been validated in studies undertaken in this population and will be directly administered by trained research staff of Aga Khan University. Screening will prompt triage into three categories: high - referred to the conveniently located integrated medical center for a medical teleconsultation and fasting glucose test; medium - receive fasting glucose test and BP measurement; and low risk. All subjects in each category will be enrolled in an e_Prescription intervention for lifestyle change tailored to their individual risk profile."
46084720|NCT03651804|Procedure|Radiofrequency ablation of the medial branch nerves|A radiofrequency ablation (RFA) is a procedure in which a heat lesion via a needle is created on the nerve that transmits the pain signal in order to interrupt the brain to interrupt the painful signal to the brain. We will target the medial branch nerves.
46084721|NCT03651804|Drug|Non-steroidal anti-inflammatory drugs|Some of the most commonly used pain medicines in adults. NSAIDs block proteins, called enzymes, in the body that play a role in pain and inflammation. They include aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), and many other generic and brand name drugs.
46084722|NCT03651804|Drug|Bisphosphonates|A class of drugs that prevent the loss of bone density and are used to treat osteoporosis and similar diseases.
46084723|NCT03651804|Drug|Acetaminophen|A medicine used to treat pain and fever. It is typically used for mild to moderate pain relief. Commonly known as Tylenol.
45833952|NCT05241054|Drug|Fentanyl|fentanyl 1 microgram.kg
45833953|NCT05241054|Drug|Atracurium Besylate|Atracurium besylate 0.5mg.kg to facilitate intubation followed will top up dose of atracurium(0.1mg/kg).
45674557|NCT01857531|Drug|Nicotine Patch|"Pre-Quit Period:~Beginning at Session P2, subjects will receive active 21mg/24h nicotine patches to apply daily for the next two weeks.~Post-Quit Period:~Following the quit-day, subjects will continue to apply active nicotine patches daily for the remainder of the study (21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week)."
45833954|NCT05241054|Procedure|Mechanical ventilation|Patient will then be mechanically ventilated using a volume control mode with tidal volume 6-8ml/kg, respiratory rate 10-14 breath/min and I.E ratio1:2 to maintain end tidal CO2 around 35 mmHg
45674558|NCT02166047|Drug|Vesatolimod|Vesatolimod tablet administered orally
45674559|NCT02166047|Drug|Placebo|Placebo to match vesatolimod tablet administered orally
45674560|NCT01493284|Device|Transcatheter Aortic Valve Implantation|Placement of the SJM Portico aortic valve with a transfemoral delivery system
45833955|NCT05241054|Drug|Sevoflurane|Anesthesia will then be maintained using sevoflurane 2%, and 60% air in oxygen mixture and top up dose of
45833956|NCT05241054|Drug|Lactated Ringers|Intravenous infusion of Lactated Ringers will be given per body weight and according to intraoperative loss
45994012|NCT05103306|Drug|INS|Basal insulin add on the background OADs
45994013|NCT05042999|Device|Oculus Go Virtual Reality Goggles|Oculus Go is a standalone portable Virtual Reality device that enables the user to immerse in different virtual environments. Non pharmacological technique to reduce pain and anxiety during a procedure.
45994014|NCT05016791|Device|Apple Watch-based heart rhythm monitoring|"For the duration of the study, participants in the active arm will be asked to make ECG recordings in three circumstances:~Routinely once per day from the day of randomisation till the 12-month visit after AF CA (they will be encouraged to do so at the same time each day with the option to set a reminder on the watch).~If the AW requests them to do so (the automatic AF-notification algorithm will be active throughout the study period and if AF is suspected based on the tachogram, it will trigger notification for the participant to make an ECG recording). This will be till the 12-month time point.~If the patient has symptoms of palpitations, pre-syncope or syncope. This will be till the 12-month time point. Monitoring should continue even if AF has been diagnosed to characterise arrhythmia burden and profile. Participants will be given the contact details of a dedicated email inbox to which to send ECGs recorded through the AW."
45994015|NCT05102097|Behavioral|Warm-up|Participants will walk on treadmill at a speed of 1.7 mile per hour (MPH) and 0 inclination each session for 6weeks 3 times in a week
45994016|NCT05102097|Behavioral|Main exercise|Participants will walk on a treadmill with a starting speed of 1.7 mile per hour with inclination of 1 to 4% starting with 1% and increased by 1% each week until 4 weeks and at week 5 and 6 speed will be increased to 5mile per hour starting from 1.7mile per hour and increased by 0.5 mile per hour each 1minute while inclination will be increased to 5% in week 5 and 6% in week 6. Main exercise will be perform 3 times in a week for 6 weeks
45994017|NCT05102097|Behavioral|Cool down|Participants will walk on treadmill at the speed of 1.7 mile per hour 0 inclination each session for 6 weeks 3 times in a week
45994018|NCT05102097|Behavioral|Standard of care|Participants will perform Abdominal hollowing, isometric back extension exercise, bridging exercise, graded active flexion, graded active extension by holding for 5seconds and repeated 10times
45994019|NCT05007002|Device|Robot-based therapy|Active and passive therapy tasks for proprioception and sensory processing, with use of the Kinarm End-Point Lab (BKIN Technologies Ltd., Canada)
45994020|NCT04106037|Other|Data extraction from medical files|Data extraction from medical files
45994021|NCT05097885|Other|Sub Acute Whole Body Vibration Training|Participants will be given a personal vibration plate to take home with them for training which will last for 12 weeks. For the first four weeks, participants will be asked to complete 10 minutes of WBV per day (1 minute on and up to 1 minute of rest), at least 3-4 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 14 minutes and/or reduce the duration of rest. Beginning at week 9, participants will be asked to increase WBV time to up to 20 minutes and/or reduce the duration of rest.
45994022|NCT04980443|Diagnostic Test|CELTiC test|The CELTiC test is a blood-based test consisting of four mRNA markers and the risk factor age.
45994023|NCT00534651|Drug|Paracetamol|Paracetamol 3x1000mg daily or Placebo for two weeks in a crossover design with a two-week washout-phase in between.
45994024|NCT04971980|Drug|hUC-MSC infusion (BC-U001)|The participants are intravenously administered a single infusion of hUC-MSC at 0.5x10^6 cells/kg body weight, 1.0x10^6 cells/kg body weight, 1.5x10^6 cells/kg body weight for low-dose cohort, medium-dose cohort and high-dose cohort respectively.
45994025|NCT04965779|Device|Abdominal Binder|Women in the intervention group use an abdominal binder from postpartum hour 1 to 48, and will be checked every 6 hours. The abdominal circumference of the women is measured at the anterior superior iliac spine and umbilicus level with a tape measure before the application, and the binder size is adjusted to be 5% smaller (approximately 0.5-1 cm) than the measurement obtained.
45994026|NCT04965779|Other|Postpartum nursing care|Postpartum nursing care the follow-up protocol includes the evaluation and record between postpartum 1. and 48. hours of pain level, analgesic administration, follow-up of the puerperal bleeding, and uterine tone, measure of hemodynamic parameters measuring, hemoglobin level and hematocrit ratio, and assessment breastfeeding.
46084724|NCT03651804|Behavioral|Physical therapy|Physical Therapy.
46084725|NCT03651804|Drug|Opioids|Opioids are narcotics that act on opioid receptors to produce morphine-like effects and medically they are primarily used for pain relief.
46084726|NCT02765750|Behavioral|Intraoperative positive messages|"The message You are in the operating room. Everything is going very well. When you wake up you will be very calm, you will not feel pain and you will not have nausea will be played in greek language by headphones to the patient when the Bispectral Index (BIS) is 40-60."
45457032|NCT03925909|Dietary Supplement|Eriocitrin|The responsible nutritionists will do 1) Anthropometric Assessment, in which weight data will be collected (kg); height (m); waist circumference (cm), waist circumference (cm) and hip circumference (cm), muscle mass (kg /%) and percentage of fat by means of bioimpedance equipment; 2) Dietary assessment, which will be performed through a 24-hour Food Recall, a 3-day Food Record and a Food Consumption Frequency Questionnaire; 3) Evaluation of the microbiota, for which stool will be collected from the last 24 hours on the day before the beginning of the experiment and at the end of the study (week 12); 3) Biochemical evaluation, which includes the collection of 30 mL of blood to be performed by trained and qualified technicians.
45457033|NCT03517462|Drug|Ivermectin 3Mg Tab|ivermectin tablet
45457034|NCT03929653|Other|Personalized therapy model with Molecular Tumor Board and Next Generation Sequencing|This study is to observe this therapy model outcomes
45457035|NCT03925129|Device|high frequency TENS treatment|Treatment with high frequency for minimum of 1 hour after misoprostol administration
45833957|NCT05241054|Other|Head-up tilt|The patient is placed on the operating table with a head-up tilt to reduce venous congestion at the operative site
45833958|NCT05241054|Drug|Paracetamol|paracetamol infusion (15 mg/kg) will be given by IV infusion in both groups
45833959|NCT04760106|Diagnostic Test|gastric ultrasound|"For the qualitative assessment, every participant was scanned once by both examiners. Each scan session lasted no longer than 5 minutes to mitigate the confounding effect of gastric emptying time.~For the quantitative assessment, the participants were put in a right lateral decubitus position and the antral cross-sectional area (CSA) is measured in the sagittal plane."
45994027|NCT04960241|Procedure|Homebased telerehabilitation|The telerehabilitation intervention is based on sensor technology, developed by ICURA. The technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patients with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. The patients will receive a suitcase with five sensors (to be placed bilaterally on lower legs, thighs and one around the waist), a smartphone to record the exercises and a charging station free of charge during the 6-week intervention. At the end of the intervention the material will be returned at the first follow-up (t1). For more information please visit https://icura.dk.
45994028|NCT04960241|Procedure|Homebased rehabilitation|The unsupervised rehabilitation group will receive a written exercise program in order to perform daily exercises at home. The exercise program will be made using Exorlive (for more information about Exorlive please visit https://www.exorlive.com). In addition to the written program, patients will able to use a link provided to see small video-instructions on the internet of each exercise on the program. No feedback or supplementary instructions will be given after the initial face-to-face appointment.
45994029|NCT04960241|Procedure|No physical rehabilitation|Patients allocated to the no intervention group will receive encouragement to stay active and be encouraged to gradually return to activities of daily living. This will be the only exercise-encouragement given to the no-intervention group.
45994030|NCT05080959|Drug|CPL-01|Subjects will receive a single dose
45994031|NCT05080959|Drug|Naropin 150 MG Per 20 ML Injection|Subjects will receive a single dose
45994032|NCT05080959|Drug|Placebo|Subjects will receive a single dose
45994033|NCT00533078|Dietary Supplement|omegaven|Trial participants are prescribed TPN by the attending physician as soon as indicated, which will be administered via a central venous line over a time period of approximately 20 hours per day. The formulation given to all patients is Nutriflex lipid spezial®, an emulsion containing the full supply of carbohydrates, amino acids and lipids (SO:MCT = 1:1) with a total energy content of 2215 kcal in a 1875 ml volume, see Investigator's Brochure. In addition, they receive daily infusional Omegaven® 100 ml over 4 hours, which equal FO 10 g/d or omega-3 PUFA 3-6 g/d.
45994034|NCT05064267|Diagnostic Test|phlebotomy|phlebotomy will be performed to obtain coagulation labs of interest. Specifically, in addition to standard clinical labs, the following will be drawn on study participants: thrombelastography with platelet mapping, antithrombin, DIC panel, factor VIII, vWF antigen, Protein C antigen and activity, Protein S antigen and activity, and ferritin.
45994035|NCT04942730|Drug|Fludarabine|30 mg/m2/day iv x 6 days, days -7 through -2 of HSCT
45994036|NCT04942730|Drug|Bendamustine Hydrochloride|130 mg/m2 iv x 2 days, Days -7 through -6 of HSCT
45994037|NCT04942730|Drug|Busulfan|1 mg/kg po qid x 3 days, Days -5 through -3
45994038|NCT04942730|Drug|Cyclophosphamide|50 mg/kg iv x 2 days, Days +3 through +4
45994039|NCT04942730|Drug|Mycophenolate Mofetil|45 mg/kg/day, maximum 3 g/day, iv or po x 30 days, Days +5 through +35
45833960|NCT05240820|Procedure|multi-layer wound closure|We prospectively analyze clinical outcome data from 30 subjects who perform multi-layer wound closure using polyglactin 910 and polypropylene, and polydioxanone and combination of 2-octyl cyanoacrylate and polyester mesh following excision of giant benign tumors.
45994040|NCT04942730|Drug|Tacrolimus 5Mg Cap|0.03 mg/kg/day iv or po, Days +5 through +100 with with further correction by concentration. Target concentration 5-15 ng/ml.
45994041|NCT04068402|Device|Vivio System|The Vivio System is an electronic auscultatory device and optical sensor, plus software application intended to provide support to the physician in the evaluation of heart sounds in patients. The product will analyze the acoustic signals of the heart and signals from a captured arterial (carotid) waveform. The analysis procedure will identify and analyze specific heart sounds and arterial waveform features captured by the Vivio device, to devise a scoring system for severe aortic stenosis.
45994042|NCT04917302|Drug|NMDAE plus AIFA|Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of schizophrenia.
45994043|NCT04917302|Drug|NMDAE plus Placebo Cap|Use of an NMDA enhancer plus placebo as a comparator
45994044|NCT04049760|Drug|migalastat HCl 150 mg|migalastat HCl 150 mg capsule
45457036|NCT03925129|Device|Sham TENS treatment|Treatment with sham TENS device for minimum of 1 hour after misoprostol administration
45457037|NCT02295202|Device|CPAP (REMstar System One Plus - Philips Medical Systems)|Standard device for treating obstructive sleep apnea.
45833961|NCT03182400|Behavioral|Neurophysiological assessment|Assessment of cerebral electrical activity Assessment of ocular exploration Neurovegetative assessments
45833962|NCT03182400|Behavioral|Neuropsychological assessment|sub-tests, scales, surveys, reaction time measurement
45833963|NCT00638508|Drug|Ketorolac|Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
45833964|NCT00638508|Drug|Ketorolac and Ropivacaine|Patients will receive Ketorolac at 5 mg/hr plus 0.5% Ropivacaine
45833965|NCT05240430|Drug|Mesenchymal Stem Cell Antigen-1, Human|Human umbilical cord-derived MSCs were used in the study. MSCs were prepared/obtained/produced/provided by Atigen-Cell Technology Center, Trabzon, Turkey. MSC for patients was calculated as a single dose, 1x106 cells per kilogram. MSC was infused in 100 ml of normal saline at 2 ml/min over 40 min, as described in previous studies
45833966|NCT00637806|Drug|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
45833967|NCT00637806|Drug|Megestrol acetate concentrated suspension 60 mg/mL|Megestrol acetate concentrated suspension 60 mg/mL given as an oral dose of 300 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
45833968|NCT00637806|Drug|Placebo|Placebo oral suspension, 5 mL once daily
45833969|NCT04396782|Other|Physioterapy rehabilitation with IVR|This program includes: static bicycle with virtual reality glasses, analytical lower limb exercises, global lower limb exerciseswith virtual reality glasses and activities to be done at home.
45994045|NCT04909190|Procedure|Increased saline flush volume|Additional flushing of the stentgraft delivery system.
45457038|NCT02295202|Device|Nasal strips|
45457039|NCT03929575|Dietary Supplement|Placebo of calcium|Ingestion of 250 mg of calcium
45994046|NCT04034901|Device|Monitoring of cardiorespiratory parameters with BORA Band|"The subjects will continuously wear a connected wrist-worn pulse oximeter which will remotely collect the following measurements :~Activity~Step count~Heart rate~Respiratory rate~Skin temperature~SpO2"
45994047|NCT05062590|Other|Recommendations|Ressources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP
45994048|NCT04903964|Other|family-centered nutrition education|There is a training program prepared by the researcher to increase the nutritional knowledge of mothers with children aged 0-3. The definition and importance of nutrition in the session, respectively, adequate and balanced nutrition, insufficient and unbalanced nutrition damages, grouping of nutrients, feeding 0--6 months old baby, feeding premature baby, breastfeeding, situations to be considered while breastfeeding, starting additional foods, 9-12 monthly baby nutrition, 1-3 years old child nutrition and nutritional nutrition support.
45994049|NCT00534690|Procedure|One-Lung ventilation|Low Vt, High PEP
45994050|NCT00534690|Procedure|One-Llung ventilation|High Vt, low PEP
45994051|NCT04901936|Drug|Pegcetacoplan|Complement (C3) inhibitor
45994052|NCT04033497|Device|MRI|Magnetic Resonance Imaging will generate imaging of the brain to identify recurrence of tumor.
45994053|NCT01272193|Drug|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily prior to the largest meal of the day as monotherapy or combined with no more than 2 oral anti-diabetic drugs (OADs).
45994054|NCT01272193|Drug|insulin glargine|Administered according to approved labelling either as monotherapy or combined with no more than 2 OADs.
45994055|NCT04899206|Drug|With an Antidepressant Drug|Current users of an antidepressant drug.
45994056|NCT04899206|Drug|Without an Antidepressant Drug|Non-current users of an antidepressant drug.
45457040|NCT03929575|Dietary Supplement|Rhodiola|Ingestion of 250 mg of Rhodiola
45994057|NCT04019613|Diagnostic Test|Lung ultrasound|Lung ultrasound will be performed at baseline (resting), prior to exercise with passive leg elevation, after 1.5 minutes of 20 Watts exercise, during each subsequent stage, at peak workload and at 1 minute recovery. Pulmonary thermodilution will be performed at rest, peak stress and at 1 minute recovery.
45994058|NCT04687163|Drug|HAIC of 130 mg/m² Oxaliplatin, and 5-fu|Hepatic arterial infusion of 130 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU
45994059|NCT04687163|Drug|HAIC of 85 mg/m² Oxaliplatin, and 5-fu|Hepatic arterial infusion of 85 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU
45994060|NCT04687163|Drug|TKI|sorafenib 400mg bid or lenvatinib 12 mg/day (for bodyweight ≥60 kg) or 8 mg/day (for bodyweight <60 kg)
45994061|NCT04017117|Procedure|under local anasthesia,Ridge Augmention of posterior atrophic mandible by using mix of autogenous bone graft and bone substitutes is used under PEEK mesh|comparing between PEEK mesh and Titanium mesh for augmentation of posterior atrophic mandible using mix of autogenous bone graft and bone substitute.
45994062|NCT00533156|Device|Vascular access site closure (7F Ensure)|
45994063|NCT04686812|Behavioral|Worksite health promotion program|Physical activity, nutrition, and stress management programs
45994064|NCT01270828|Drug|Pregabalin|Tablets, 82.5 to 660mg, once per day. Duration: 19 weeks
45994065|NCT01270828|Drug|placebo|Placebo, 82.5 to 660mg, once per day. Duration: 13 weeks
45994066|NCT03995862|Other|Questionnaire|A questionnaire should be completed by the patient the day of inclusion. Health data will be collected in patients medical file from inclusion to the date of the end of study (i.e. no follow-up for the last patient included and a maximum of three years of follow-up for the first patient included).
45457041|NCT03929575|Dietary Supplement|Rhodiola and Cordyceps|Ingestion of 250 mg of Rhodiola and 225 mg of Cordyceps
45457042|NCT02292472|Drug|Botulinum Toxin Type A|Inject intramuscularly once in visit 2
45457043|NCT02292472|Drug|Placebos|Inject intramuscularly once in visit 2
45994067|NCT00533195|Drug|5-Methoxypsoralen|1,2 mg/kg 2 hours before UVA irradiation p.o. 3 times weekly for 5 weeks
45994068|NCT00533195|Device|UVA1 phototherapy|"Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability.~No maintenance therapy except emollients."
45994069|NCT03987165|Other|Music Therapy|"Music therapy will be conducted once daily using a Song of Kin, a familiar song used to lull the infant to sleep. If no Song of Kin is provided, Twinkle Twinkle Little Star will be the default lullaby."
45994070|NCT03982407|Drug|68Ga-PSMA-11 PET/MRI|The PET/MRI exam-related patient visit will last approximately 2 to 2.5 hours, including 30-minute nursing assessment, 45-60 minutes for PSMA uptake and 60 minutes for PET/MRI scan. They will be contacted within the next 72 hours to complete a brief phone survey.
45994071|NCT00533234|Device|ExploR® Modular Radial Head|The ExploR® Modular Radial Head is a modular head and stem radial head/neck replacement.
45994072|NCT03980262|Behavioral|Healthy Children, Healthy Families+ (HCHF+)|HCHF+ integrates healthful eating and physical activity with parenting education (parent role modeling and child feeding practices) and was recently shown to improve parent and child nutrition behaviors for participants in the Expanded Food and Nutrition Education (EFNEP) program. OrganWise Guys (OWG) will be used for children in first and second grades (ages 6-8). Choose Health: Food, Fun and Fitness (CHFF), developed by Cornell University, will be used for children in grades three through five (ages 8-10). HCHF+ includes 9 sessions to be delivered weekly.
45994073|NCT03980262|Behavioral|Money Smart|Money Smart is a financial literacy education program developed by the Federal Deposit Insurance Corporation (FDIC). Curricula are available for both adults and children.
45457044|NCT03517384|Behavioral|I-CBT for Body Dysmorphic Disorder|The current intervention, is a therapist guided, Internet Cognitive Behavioral Therapy treatment for Body Dysmporhic Disorder which consists of 8 treatment modules administered over the course of 12 weeks.
45457045|NCT02299180|Behavioral|ACP|
45457046|NCT01225471|Biological|CDCA1|CDCA1-A24-56 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. This peptide conjugated with Montanide ISA 51 as an adjuvant.
45457047|NCT03519958|Diagnostic Test|Plasma-tissue testing|EGFR T790M mutation plasma-tissue testing in NSCLC patients who progressed on previous EGFR TKI
45994074|NCT04687124|Dietary Supplement|Fish oil|Dietary counseling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)
45994075|NCT04687124|Other|standard care|No specified intervention
45994076|NCT01269385|Biological|alemtuzumab|Given subcutaneously
45994077|NCT01269385|Biological|rituximab|Given IV
45994078|NCT01269385|Drug|PGG beta-glucan|Given IV
45994079|NCT01269385|Other|flow cytometry|Correlative studies
45994080|NCT01269385|Other|laboratory biomarker analysis|Correlative studies
45994081|NCT01269385|Genetic|DNA analysis|Correlative studies
45994082|NCT01269385|Genetic|fluorescence in situ hybridization|Correlative studies
45994083|NCT01269385|Genetic|polymerase chain reaction|Correlative studies
45994084|NCT01269385|Genetic|polymorphism analysis|Correlative studies
45994085|NCT01269385|Genetic|mutation analysis|Correlative studies
45994086|NCT03865836|Biological|ATB200|
45994087|NCT03865836|Drug|AT2221|
45994088|NCT02715635|Biological|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
45994089|NCT02715635|Dietary Supplement|Concentrate beetroot Juice|140 ml containing ~8 mmol of inorganic nitrate
45994090|NCT02715635|Dietary Supplement|Concentrate beetroot Juice (Placebo)|140 ml which is nitrate-depleted
46084727|NCT02765750|Behavioral|Intraoperative positive messages|"The message You are in the operating room. Everything is going very well. When you wake up you will be very calm, you will not feel pain and you will not have nausea will be played in greek language by headphones to the patient when the Bispectral Index (BIS) is 20-40."
45674561|NCT02165735|Behavioral|patient activation training|Patient activation training involves six, 90-minute, group (8-12 person) training sessions facilitated by trained peers and training staff and one (20-30 minute) pre-visit coaching session conducted by staff. The hands on group training includes: 1) HIV education; 2) use of a handheld smart device; 3) use of an HIV electronic personal health record app that runs on the smart device; 4) identification of patients' visit need priorities and skills for communicating with their HIV provider. The pre-visit coaching includes identification of patient concerns and patient behavioral rehearsal for asking about these concerns.
45674562|NCT02165735|Other|Usual care|Usual HIV care
45674563|NCT02069899|Drug|Emapalumab|Treatment with emapalumab is not planned for all enrolled participants. For participants who will continue receiving emapalumab in the context of this study (NI-0501-05), the dose and timing will be either carried forward from the last administered emapalumab dose as part of the parent study in which the participant was enrolled, or an adjusted dose will be administered, if necessary.
45674564|NCT01831089|Drug|PM01183 + paclitaxel +/- bevacizumab|"PM01183: 1 mg and 4 mg vials. Powder for concentrate for solution for infusion~paclitaxel: 6 mg/ml concentrate for solution for infusion~bevacizumab: 25 mg/ml concentrate for solution for infusion~Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a prospectively selected cohort of patients"
45674565|NCT02112877|Device|Veniti Vici™ Venous Stent System|
45994091|NCT05060562|Other|COVID 19 positive|Diagnosed as COVID 19 patient using Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab with suggestive symptoms.
45833970|NCT04396782|Other|standard physiotherapy rehabilitation|"static bicycle, analytical lower limb exercises, global lower limb exercises and activities to be done at home.~This group will perform only five minutes of virtual reality play, but will not use their lower limbs. This way, the results of rehabilitation will not be affected and therapists and patients will be blinded."
45994092|NCT05060562|Other|COVID 19 negative|Suspected COVID 19 patients who were tested negative using either Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab.
45994093|NCT04685954|Device|Filtek Bulk-Fill Posterior|Bulk-fill restorative composite
45994094|NCT04685954|Device|Filtek Ultimate Universal|Incremental restorative composite
45994095|NCT00532974|Biological|EP1090|Low dose
45994096|NCT00532974|Biological|EP1090|High dose
45994097|NCT00533013|Other|Usual Care|Management of heart failure is provided by primary practitioners and consultant cardiologists
45994098|NCT00533013|Other|Disease Management and Tele-Monitoring|Management of heart failure is provided by cardiologists at regional heart failure clinics and by nurse practitioners at regional heart failure clinics and a designated call center. Decisions on treatment are guided by designated protocols and information derived for tele-monitoring of blood pressure, body weight and pulse rate.
45994099|NCT02071862|Drug|CB-839|CB-839 monotherapy
45994100|NCT02071862|Drug|Pac-CB|CB-839 in combination with standard dose paclitaxel
45994101|NCT02071862|Drug|CBE|CB-839 in combination with standard dose everolimus
45994102|NCT02071862|Drug|CB-Erl|CB-839 in combination with standard dose erlotnib
45994103|NCT02071862|Drug|CBD|CB-839 in combination with standard dose docetaxel
45994104|NCT02071862|Drug|CB-Cabo|CB-839 in combination with standard dose cabozantinib
45994105|NCT00535691|Drug|Tacrolimus Ointment 0.03%|Twice daily, 14 days treatment.
45994106|NCT00535691|Drug|Tacrolimus Ointment 0.03%|Once daily, 14 days treatment.
45994107|NCT05051085|Behavioral|"Internet-delivered treatment: SpilleFri."|The guided internet program consists of 8 modules over a period of 10 weeks. The content is written psychoeducation, videos with patients and experts, and exercises (encouraging reflection, cognitive restructuring, and exposure). The program is therapist-guided; hence all patients will receive support primarily from a specific therapist during the 10 weeks.
45994108|NCT01268683|Drug|Glyburide for Injection|Administered as specified in the treatment arm.
45994109|NCT05037201|Behavioral|Text message|The intervention arm will receive a text message stating that the vaccine is reserved for them on a specific date. They will have the ability to reschedule to a different day, opt-out of this text messaging intervention, or if previously vaccinated they can upload documentation to the Ascension website.
45994110|NCT02021474|Drug|AGX-201|Subcutaneous injection
46084728|NCT02765750|Behavioral|No message|The headphones will be placed on patient's ears but no message will be played.
45994111|NCT02021474|Drug|Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).|Subcutaneous injection
45994112|NCT01268566|Drug|MEDI-575|MEDI-575 as an IV infusion.
45994113|NCT05010291|Behavioral|Standard of Care (SOC) text message reminder to attend clinic appointment|SOC one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
45994114|NCT05010291|Behavioral|Loss aversion framed text message reminder to attend clinic appointment|Loss aversion framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
45674566|NCT02098369|Behavioral|Written education material (basic)|Education material on COPD distributed to all participants.
45994115|NCT05010291|Behavioral|Social norms framed text message reminder to attend clinic appointment|Social norms framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
45994116|NCT05010291|Behavioral|Altruism framed text message reminder to attend clinic appointment|Altruism framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
45994117|NCT01268488|Device|Ninja 2 Investigational Blood Glucose Meter|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
45674567|NCT02098369|Behavioral|Additional education material|Additional education material sent to participants in the proactive and reactive arms.
45994118|NCT04686071|Other|PNF method|Treatment in the study group was conducted with PNF method with a use of indirect training based on irradiation phenomenon. The program included: proprioceptive stimulation of the operated limb, improving trunk stabilization and active control, active foot training, muscle strength facilitation of lower limbs in closed kinematic chain with considering periarticular stabilization within the operated knee joint as well as exercises improving mobility of the operated knee, verticalization and locomotion with emphasis on the stance phase.
45994119|NCT04686071|Other|Standard rehabilitation|In the control group standard rehabilitation protocol was used in patients following TKA, which is mainly based on activities in open chains (passive exercises with continuous passive motion (CMP) device, active exercises, isometric, active resistance, patella mobilization, deep tissue massage, verticalization and gait relearning).
45994120|NCT05000385|Other|Assesment of masticatory efficiency with optical scanning method|Participants will chew a standardized silicone tablet controlled by the examiner for 20 masticatory strokes. By scanning the comminuted particles, data on each particle size will be obtained. Enhanced masticatory performance is presented by a decrease in the chewed particle areas and an increase in the number of chewed particles.
45994121|NCT05000385|Diagnostic Test|body mass index|as an indication of nutritional status
45994122|NCT01803152|Biological|Dendritic Cells Vaccine|Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
45994123|NCT01803152|Biological|Lysate of Tumor|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
46084729|NCT00917501|Drug|OMega 3|Individual omega-3 capsules contain 400 mg EPA and 200 mg DHA taken twice a day
46084730|NCT00917501|Drug|Placebo|Placebo given twice a day which will be compared to Omega 3
46084731|NCT02670681|Behavioral|Aerobic Exercise Training|8 week of aerobic exercise training in different intensities.
45674568|NCT02098369|Behavioral|PELICAN-Proactive|In the proactive arm, calls will be initiated by the coach. The phone calls will involve educational and social support components. PELICAN is grounded on the social cognitive theory of behavior change and seeks to improve patient adherence by addressing patient self-efficacy and outcome expectancy.
45674569|NCT02098369|Behavioral|PELICAN-Reactive|Participants allocated to the reactive PELICAN group will be offered the opportunity to access the COPD Foundation Infoline toll-free.
45674570|NCT02111785|Drug|Dexamethasone|Treatment with a short course of oral dexamethasone
45994124|NCT01803152|Drug|Gemcitabine|Post-surgery, Leukapheresis and clearance of subject. Gemcitabine 1000 mg/m2 IV will be administered once weekly for 3 weeks per study protocol.
45994125|NCT01803152|Drug|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
45994126|NCT01803152|Procedure|Leukapheresis|Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
45994127|NCT01268098|Drug|NPSP558|All patients will inject NPSP558 25 or 50 µg SC QD into alternating thighs in the morning via a multidose injection pen device.
45994128|NCT00533052|Behavioral|Affective and Cognitive Skills Training|24-week, weekly, group behavioral weight loss treatment with affective and cognitive skills training
45994129|NCT01674803|Device|Orsiro|biodegradable polymer sirolimus eluting stent
45994130|NCT01674803|Device|Synergy|biodegradable polymer everolimus eluting stent
45994131|NCT01674803|Device|Resolute Integrity|durable polymer zotarolimus-eluting stent
45994132|NCT04959825|Drug|Melatonin 5 mg|study the effect of preoperative oral melatonin 5mg on isoflurane consumption and postoperative pain
45994133|NCT04959825|Drug|Sugar Coated Tablets|the control group patients will receive placebo tablets one hour before induction of anesthesia
45457048|NCT01131247|Drug|ofatumumab + bendamustine|Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
45833971|NCT03180216|Biological|Virus Specific T cells (VSTs)|"This Phase I dose-escalation trial is designed to evaluate the safety of rapidly generated multivirus-specific T-cell products with antiviral activity against CMV, EBV, adenovirus, HHV6, BK virus, JC virus, and human parainfluenza-3 (HPIV3), derived from eligible HSCT donors.~In this trial, we will utilize a rapid generation protocol for broad spectrum multivirus-specific T cells for infusion to recipients of allogeneic hematopoietic stem cell transplant (HSCT), who are at risk of developing EBV, CMV, adenovirus, HHV6, BKV, JCV and/or HPIV3, or with PCR/culture confirmed active infection(s) of EBV, CMV, adenovirus, HHV6, BKV, JCV, and/or HPIV3 that has failed to resolve with at least 14 days of standard antiviral therapy (if available and tolerated). These cells will be derived from HSCT donors, and the study agent will be assessed at each dose for evidence of dose-limiting toxicities (DLT)."
45833972|NCT01922388|Device|Bilateral deep brain stimulation of the subthalamic nucleus|
45833973|NCT00637728|Drug|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
45833974|NCT00637728|Drug|Placebo|Placebo oral suspension, 5 mL once daily
45994134|NCT00968747|Behavioral|Fasting|Participants will fast for 72 hours and may consume only water and vitamins.
45994135|NCT00968747|Behavioral|Fasting|Participants will fast for 72 hours and may consume only water and vitamins.
45994136|NCT00968747|Behavioral|Diet|Participants will follow a low-calorie diet until they lose 3-5% of their body weight.
45994137|NCT00968747|Dietary Supplement|oral carbohydrate challenge|Participants will fast for 16 hours and then drink a beverage containing glucose, fructose or a mixture of both
45994138|NCT04959201|Drug|NMDAE plus AO|Use of an NMDA enhancer plus a drug with antioxidant property for the treatment of schizophrenia.
45994139|NCT04959201|Drug|NMDAE plus Placebo Cap|Use of an NMDA enhancer plus placebo as a comparator.
45994140|NCT00823277|Other|Chronic care multidisciplinary intervention of childhood obesity|Overweight and obese Children, 5-20 Years old, followed by Paediatricians and other Health Personals (multidisciplinary team). Included at their first visit in the clinic (baseline)and follow-up after ~ 1 Year.
45994141|NCT04955184|Device|non-invasive monitoring|non-invasive measurements of cardiac output
45994142|NCT05471453|Dietary Supplement|DHEA|75 mg DHEA supplementation per day for 3 months before IVF
45994143|NCT05471453|Dietary Supplement|DHEA+CoQ10+Tocotrienol|75 mg DHEA supplementation + 30 mg CoQ10 + 300 mg Tocotrienol per day for 3 months before IVF
45994144|NCT04949607|Dietary Supplement|Inulin fructooligosaccharide|Subjects will be administered inulin at a starting dose of 1g twice daily (2g/day) and ramping up an additional 2g/day until the final dose of 4g twice daily (8g/day), which will continue on until the end of month 3 (week 12). After the month 3 study visit, inulin dosing will begin to ramp down over the next week.
45994145|NCT03457233|Drug|Gonadotropins|1) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration
45994146|NCT03457233|Drug|GNRH antagonist|cetrorelix 0,25mg s.c is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
45994147|NCT03457233|Drug|Human chorionic gonadotropin Chorimon|10000 IU of HCG are given intramuscular when 2 or more mature follicles reach 18 - 20 mm
45994148|NCT03457233|Drug|Natural progesterone|400 mg vaginal tablets twice daily from the day of ovum pick up till HCG tesing
45994149|NCT00535808|Drug|nitroprusside|Administration of nitroprusside
45994150|NCT00535808|Drug|nitroglycerine|Administration of nitroglycerine
45994151|NCT00535808|Drug|sevoflurane|Administration of Sevoflurane
45674571|NCT02111785|Procedure|Burr Hole Craniostomy|Treatment with surgical burr hole craniostomy and evacuation of SDH
45674572|NCT02068885|Behavioral|Feeding study|Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum
45994152|NCT04920903|Drug|COR588|Increasing doses of COR588 will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
45994153|NCT04920903|Drug|Placebo|Placebo will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
45994154|NCT05471063|Drug|Amphotericin B Colloidal Dispersion|Amphotericin B Colloidal Dispersion 3.0-4.0 mg/kg/d (subject to adjustment, maximum dose not exceeding 6.0 mg/kg/d) . The course of induction therapy is at least four weeks.
45994155|NCT05471063|Drug|flucytosine|Flucytosine 100 mg/kg/d for induction therapy and consolidation therapy of cryptococcal meningitis. The course of induction therapy is at least four weeks, and consolidation therapy for at least 6 weeks.
45994156|NCT05471063|Drug|fluconazole|Fluconazole (400-600 mg/d) for consolidation therapy for at least 6 weeks.
45994157|NCT04920396|Device|E>Eye IRPL|Regulated intense pulsed light therapy
45994158|NCT04920396|Device|Warm compress|Fabric mask with anti-bacterial coating filled with BodyBeads® heated in a microwave for 30 seconds before application over the eyes for 5 minutes
45994159|NCT05471024|Procedure|Digitized Mounted Articulator Scan|Conventional articulator facebow mounting will be digitized using extraoral digital 3d scanner and used to position the maxillary cast on the virtual articulator. This positioning will be utilized during design of the occlusal surface of the restoration.
45994160|NCT05471024|Procedure|Average Positioning on Virtual Bonwill Triangle|"Virtual Bonwill triangle will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
45994161|NCT05471024|Procedure|Digital Face Scan|"Digital face scan will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
45994162|NCT04912206|Diagnostic Test|Point-of-Care Ultrasound|Abdominal clinician-performed Ultrasound
45674573|NCT02068495|Drug|Candesartan cilexetil/Amlodipine besilate|Candesartan cilexetil/Amlodipine besilate tablets
45674574|NCT02097823|Drug|Olanzapine|
45674575|NCT02097823|Drug|Aprepitant|
45674576|NCT01830855|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 1)
45674577|NCT01830855|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 2)
45994163|NCT05470946|Device|Double balloon enteroscopy|Double balloon enteroscopy (EN-580T, Fujifilm, Japan)
45674578|NCT01830855|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 3)
45674579|NCT01830855|Biological|Havrix (HAV)|0.5 mL dose or 1.0 mL dose dependent on age given at month 0 and 6.
45674580|NCT01830855|Biological|Saline|0.5 mL dose of sterile normal saline for injection.
45994164|NCT04910100|Drug|Nebivolol Ophthalmic Suspension 1 Percent|1 drop instilled into each eye twice daily
45994165|NCT04910100|Drug|Nebivolol Ophthalmic Suspension 0.5 Percent|1 drop instilled into each eye twice daily
45994166|NCT04910100|Drug|Timolol Ophthalmic Suspension 0.5 Percent|1 drop instilled into each eye twice daily
45994167|NCT04910100|Drug|Timolol Ophthalmic Solution 0.5 Percent|1 drop instilled into each eye twice daily
45457049|NCT03513874|Drug|Metformin|Patients will be subscribed with 850mg metformin orally twice daily. Insulin will be continued as routine therapy.
45457050|NCT03513874|Drug|Insulin|Patients will continue insulin therapy following physicians' instructions.
45674581|NCT01857063|Drug|Montelukast|Montelukast 5 mg chewable tablets, taken orally once daily at bedtime for 7 days
45674582|NCT01857063|Drug|Placebo|Matching placebo chewable tablets, taken orally once daily at bedtime for 7 days
45674583|NCT01856907|Drug|Sitagliptin-Metformin|Experimental -dipeptidyl peptidase-4 (DPP-4) inhibitor- oral medication
45833975|NCT01922466|Procedure|Bee Venom Acupuncture|"Bee Venom 1:20,000 under BVA Increment Protocol~- Increment Protocol as~1st week - SC 0.2cc/day, 2 days/week~2nd week - SC 0.4cc/day, 2 days/week~3nd week - SC 0.8cc/day, 2 days/week"
45833976|NCT01922466|Drug|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
45833977|NCT05248074|Other|High-fat meal (over 900 kcal)|High-fat meal (over 900 kcal with over 35 percent fat content of total calorie) will be provided prior to IP administration. The IP will then be administered 30 minutes after the subject begins the meal.
45833978|NCT05248074|Drug|ABN401 (investigational product)|The investigational product, ABN401 800 mg (3 x 250 mg + 2 x 25 mg) will be administered orally with approximately 240 mL of water in fasted or fed condition in accordance with the order of IP administration in an allocated sequence.
45833979|NCT00637572|Drug|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)
45833980|NCT00637572|Drug|Megestrol acetate oral suspension 40 mg/mL|Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)
45674584|NCT01856907|Drug|Metformin|Biguanide- insulin sensitizer
45674585|NCT01856907|Drug|Placebo pill|Will evaluate effect of lifestyle and diet only
45674586|NCT02212457|Biological|Bexsero|Two doses administered intramuscularly into the deltoid area at Months 0 and 2 in rMenB_0_2 Group.
45674587|NCT02212457|Other|Saline Placebo|One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY_ 0_2 Group and rMenB_0_2 Group, Month 2 in ABCWY_0_6 Group and ABCWY_0_11 Group and Month 6 in ABCWY_0_1 Group.
45833981|NCT00637416|Drug|Lansoprazole|Lansoprazole 30 mg taken by mouth daily for 3 months
45833982|NCT00637416|Other|Placebo|placebo taken by mouth daily for 3 months
45833983|NCT03154320|Other|Same-Day Treatment|Treatment with ART or TB medication on day of HIV diagnosis
45833984|NCT03154320|Other|Standard treatment|Standard treatment
45833985|NCT00636792|Drug|VELCADE|VELCADE administered as a 3- to 5-second intravenous (IV) bolus prior to Bendamustine and Rituximab on Days 1,8,15 and 22 of each cycle.
45833986|NCT00636792|Drug|Bendamustine|Bendamustine administered IV over 30-60 minutes after VELCADE on Days 1 and 2 of each cycle
45457051|NCT03924583|Diagnostic Test|Duplex ultrasonography|Ultrasound examination of whole vena cava venous system with central venous catheter inserted, using duplex US method to detect catheter related thrombosis
45994168|NCT01268059|Drug|Carboplatin|Carboplatin (carboplatin area under the plasma concentration-time curve [AUC] of 6 milligram per milliliter into minute [mg/mL*min] administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal.
45994169|NCT01268059|Drug|Paclitaxel|Paclitaxel 200 milligram per square meter (mg/m^2) administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal.
45994170|NCT01268059|Drug|MEDI-575|MEDI-575 at a dose of 25 milligram per kilogram (mg/kg) administered as an IV infusion once every 21 days on Day 1 for a total of 6 cycles until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for participant withdrawal. MEDI-575 alone continued in those participants who achieved stable disease or better at the completion of carboplatin/paclitaxel therapy and did not demonstrate toxicity to MEDI-575.
45994171|NCT04901598|Other|Running anaerobic sprint test and aerobic test|subjects walk a mile with maximum steps and their heart rate will not exceed 180 beats per minute during the test and the execution time will not be less than 9 minutes (RAST test)
45994172|NCT00535886|Dietary Supplement|Man-made Trans FA|EA as 6% of total energy
45994173|NCT00535886|Dietary Supplement|Natural Trans FA|VA as 6% of total energy
45994174|NCT00535886|Dietary Supplement|Oleic Acid|OA as 6% of total energy
45994175|NCT01267825|Drug|CT-guided corticosteroid+ bupivicaine|CT-guided corticosteroid+ bupivicaine Also get standard medical care
45457052|NCT05170516|Procedure|4 °C colled saline irrigation|In Experimental Group A , 4 °C colled saline irrigation was used during impacted third molar surgery
45457053|NCT05170516|Procedure|10 °C cooled saline irrigation|Experimental Group B, 10°C colled saline irrigation was used during impacted third molar surgery.
45457054|NCT05170516|Procedure|Room temperature saline irrigation|In Control Group A and B, salin irrigation at room temperature was used during impacted third molar surgery.
45994176|NCT01267825|Drug|Standard medical care|Naproxen + Oxycodone/ Acetaminophen
45994177|NCT02889406|Behavioral|Motivational intervention|motivational interviewing schema
45994178|NCT00593242|Biological|infusion of autologous cord blood|infants who meet study enrollment criteria for history of moderate to severe hypoxic ischemic encephalopathy in the neonatal period will receive up to 4 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells. The dose for each infusion is 5x10e7 cells/kg
45994179|NCT00593242|Other|Neurodevelopmental outcomes|historical controls, no experimental intervention, standard therapies of hypoxic ischemic encephalopathy in the newborn period with autologous cord blood
45994180|NCT04895475|Behavioral|SARS-CoV-2 vaccine|Baseline demographics, baseline breast milk samples, and blood collection will be obtained at the initial visit. Serial collections of breastmilk and blood as well as weekly self-administered monthly surveys will occur
45994181|NCT05470829|Drug|ZM-H1505R|"Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1~ Day 28"
45994182|NCT05470829|Other|ZM-H1505R Placebo|"Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1~ Day 28"
45457055|NCT01228357|Drug|SSRI treated group|Antidepressant administration of SSRI class for 12 weeks under therapeutic dose
45457056|NCT01228357|Drug|non-SSRI treated group|Antidepressant administration of non-SSRI class for 12 weeks under therapeutic dose
45457057|NCT03925597|Dietary Supplement|Fiber supplement|3 week sequential supplementation with each fiber supplement
45457058|NCT03517306|Other|No Interventions|No Interventions
45457059|NCT01228123|Other|RRT for acute kidney failure using the CVVH method|patients randomized to receive CVVH
45457060|NCT01228123|Other|RRT for acute kidney failure using the IHD (intermittent HD)|patients randomized to receive IHD
45994183|NCT00593281|Drug|Hylenex|Add Hylenex to SC injection of Morphine
45994184|NCT04327102|Behavioral|Health education tools combined with health literacy intervention|On the basis of the control group, the intervention measures to improve the health literacy of patients were implemented and self-made health education tools were used. During hospitalization, health knowledge lectures shall be organized for patients. Before the activity, the theme of the activity shall be clarified. Each participant shall be organized by the educator to sit on the tool chart in a U-shape. According to the theme of the tool map, patients interact with educators. And learn the knowledge content related to hypertension health literacy. Before the end of the activity, the educator will review all the contents discussed in the activity quickly, answer the questions in the activity, and help the participants to sort out and consolidate the knowledge acquired in the education. Follow up intervention for patients after leave hospital.
45994185|NCT00536003|Drug|progesterone|vaginal capsules containing 200 mg of natural progesterone, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
45994186|NCT00536003|Drug|placebo|vaginal capsules containing placebo, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
45994187|NCT00593476|Other|PCD|pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
45994188|NCT00593476|Other|DSE|12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
45994189|NCT00593515|Behavioral|Family cognitive behavioral therapy|12-16 weekly sessions of family cognitive behavioral therapy, 60-80 minutes each
45994190|NCT00593515|Behavioral|Child-focused cognitive behavioral therapy|12-16 weekly sessions of child-focused cognitive behavioral therapy, 60-80 minutes each
45674588|NCT02212457|Biological|Havrix|Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY_0_1 Group, Month 1 and 12 in Group ABCWY_0_6 Group and ABCWY_0_2_6 Group , Month 0 and 6 in ABCWY_0_11 Group and Month 6 and 12 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
45994191|NCT00533091|Biological|MEDI-545|"MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
45994192|NCT00533091|Other|Placebo|"Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 12 weeks.~Thereafter, subjects will receive MEDI-545, at the dose specified in the dose cohort they are assigned, every 2 weeks for an additional 12 weeks."
45994193|NCT00536042|Drug|Minocycline|addition of 150 mg to 250 mg po bid to standard asthma care regiment
45674589|NCT02212457|Biological|MenABCWY|Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY_0_1 Group, Month 0 and 6 in ABCWY_0_6 Group, Month 1 and 12 in ABCWY_0_11 Group, Month 0, 2 and 6 in ABCWY_0_2_6 Group, Month 0 and 2 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
45674590|NCT02097745|Drug|methotrexate|a 10-25 mg stable dose given orally or parenterally throughout study
45674591|NCT02097745|Drug|rituximab [MabThera/Rituxan]|1 g given by intravenous infusion on Days 1 and 15 of each treatment course
45674592|NCT02111083|Biological|Insulin Lispro|LY275585 administered SC.
45674593|NCT01629563|Drug|PGL4001 5 mg|PGL4001 5 mg daily administration
45674594|NCT01629563|Drug|PGL4001 10 mg|PGL4001 10mg daily administration
45674595|NCT02097277|Biological|BMS-986036|
45674596|NCT02097277|Biological|Placebo (Matching with BMS-986036)|
45674597|NCT02212379|Drug|raltegravir and etravirine|"Raltegravir (RAL, ISENTRESS®) 400 mg tablets will be administered as one 400 mg oral tablet PO twice daily (800 mg per day) after a meal.~Etravirine (ETR, INTELENCE®) 200 mg tablets will be administered as one 200 mg oral tablet PO twice daily (400 mg per day) after a meal."
45994194|NCT01606384|Drug|VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)|Pharmaceutical form: Capsule Route of administration: oral
45994195|NCT01606384|Drug|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
45994196|NCT01606423|Drug|Placebo|Administered orally, single dose
45994197|NCT01606423|Drug|LY2409021|Administered orally, single dose
45994198|NCT01606462|Drug|Oxytocin|intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT
45994199|NCT00533130|Procedure|clinical evaluation|analyze the x ray from each patient and evaluate the treatment y development of bone healing.
45994200|NCT00533130|Procedure|observational study|evaluate the walk patron, bone healing and range of motion at 1,3,6,12 months
45994201|NCT05470595|Drug|Atezolizumab|Atezolizumab (IMP) will be added to Platinum/Etoposide (Standard-of-Care). Four cycles of combined immunochemotherapy 3qw will be follows by maintenance with atezolizumab monotherapy until progression.
45994202|NCT01606540|Drug|Tablets Ibumetin and placebo|"Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after reposition.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after reposition. The following days placebo tablets.~Group C: Placebo tablets 1 week after reposition."
45994203|NCT01606540|Drug|Tablets Ibumetin and placebo|"Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after surgery.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after surgery. The following days placebo tablets.~Group C: Placebo tablets for 1 week after surgery."
45674598|NCT02110693|Other|Interviewer and tablet administration of the TAPS Tool|All participant will self-administer substance use screening instrument (TAPS Tool) on a tablet computer and will be administered the TAPS Tool by an interviewer.
45674599|NCT02212301|Device|senofilcon A|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
45674600|NCT02212301|Device|lotrafilcon B|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
45674601|NCT02211209|Drug|Volanesorsen|
46084732|NCT04082013|Other|Hamstring Flexibility|"The active knee extension test has been proposed as the gold standard for assessment of hamstring flexibility, as it utilizes readily available equipment and offers a quick, reliable, and low-cost alternative for measurement of hamstring flexibility (Connor et al; 2015).~The subject will be instructed to maintain 90° hip flexion in the supine position.~Then asked to actively extend the knee joint.~The degree of achieving active knee extension will be measured using a universal goniometer.~The average of three active knee extension measurements will be used as the hamstring muscle length for the data analysis (Dong-Kyu Lee, et al; 2018).~the procedures will be done with opposite-leg flexed, then repeated with opposite-leg extended."
46084733|NCT02765828|Other|Observational study|The following exams will be done in all cohorts: tongue manual muscle testing (MMT), tongue quantitative muscle testing, tongue ultrasound measurements
46084734|NCT04176003|Other|Qualitative interview|Qualitative interview to explore experiences and perceptions of living with CPPD, and outcome measures to use in future studies
45674602|NCT02211209|Drug|Placebo|
45674603|NCT02187809|Drug|Clobazam|
45833987|NCT00636792|Drug|Rituximab|Rituximab administered by IV infusion after VELCADE and Bendamustine on Days 1, 8, 15 and 22 of Cycle 1, and on Day 1 of Cycles 2, 3, 4 and 5
45833988|NCT03153462|Biological|Axicabtagene Ciloleucel|Axicabtagene Ciloleucel and A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
45833989|NCT03558984|Drug|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline (active ingredient)
45833990|NCT03558984|Other|Standard of Care|"The SOC prophylactic antibiotic treatment will be consistent and standardized for all sites in the clinical study. is based on The society of thoracic surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: antibiotic choice."
45994204|NCT01606579|Drug|PRI-724|PRI-724
45994205|NCT01606579|Drug|PRI-724|PRI-724 in combination with dasatinib
45994206|NCT01606579|Drug|PRI-724|PRI-724 in combination with low dose ara-C therapy
45674604|NCT02110225|Drug|rhNGF 60 µg/ml eye drops solution|rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
45674605|NCT02110225|Drug|rhNGF 180 µg/ml eye drops solution|rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
45674606|NCT02110225|Drug|Placebo|Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes
45674607|NCT02187029|Drug|PF-06743649|Daily dosing (dose level 1) tablet for 14 days
45674608|NCT02187029|Other|Placebo|Daily dosing (tablet) for 14 days
45674609|NCT02187029|Drug|PF-06743649|Daily dosing (dose level 2) tablet(s) for 14 days
45674610|NCT02187029|Other|Placebo|Daily dosing (tablets) for 14 days
45674611|NCT02163395|Device|FullCeram implant|FullCeram implantation
45674612|NCT04756505|Drug|Bintrafusp Alfa|Given IV
45674613|NCT04756505|Biological|Immunocytokine NHS-IL12|Given SC
45674614|NCT04756505|Radiation|Radiation Therapy|Undergo radiation therapy
45674615|NCT04750655|Drug|Moxifloxacin (Topical)|We are using moxifloxacin as indicated and as intended for use as an antibiotic during surgery. Frequency of postoperative antibiotics dependent on group randomization.
45674616|NCT04750265|Device|Robotic assisted early mobilization|Robotic assisted early mobilization Robotic assisted early mobilization started within 72 hours of ICU admission.
45674617|NCT02162771|Biological|Rituxan|
45674618|NCT02162771|Biological|CT-P10|
45833991|NCT03108924|Drug|Gefapixant|After an overnight fast participants receive a single oral dose of 50 mg gefapixant, in one 50 mg tablet.
45833992|NCT04506918|Other|IVR survey|Participants will receive an IVR survey
45833993|NCT04506918|Other|SMS survey|Participants will receive a SMS survey
45994207|NCT00533169|Drug|ZD6474|Part A = Starting dose 50 mg/m^2 by mouth daily for 28 days; Part B, C = Starting dose 50 mg/m^2 by mouth daily on days 2-28.
45994208|NCT00533169|Drug|Retinoic Acid|Part B, C = 80 mg/m^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
45994209|NCT01606696|Behavioral|HIIT|Higher intensity interval training.
45994210|NCT01606696|Behavioral|Standard intensity non-interval training|Standard intensity non-interval training.
45994211|NCT00593632|Dietary Supplement|Uncle Sam Cereal|two 3/4 cup servings daily of Uncle Sam Cereal dietary instruction on high fiber diet
45994212|NCT00533208|Drug|MK0524|
45994213|NCT00593671|Procedure|Preimplantation genetic screening after embryo biopsy|Preimplantation genetic screening after embryo biopsy
45994214|NCT02892721|Other|Training with feedback|"One-day workshop of face to face training, comprising a mixture of theory and real-world CTC cases. Radiologists will complete four interpretation assessments lasting 2 to 3 hours: one set of 10 CTC cases immediately prior to training and a further test set of 10 immediately after, with tests repeated at 6 and 12 months (using different CTC cases for each set). Radiologists will be asked to identify colorectal cancer and polyps on the scans and complete an online answer form, including questions regarding diagnostic confidence, site of abnormality and management.~The intervention group will receive online, confidential, individualised feedback after each test, which will include a case by case breakdown of their performance with explanatory answers and learning points."
45994215|NCT05470205|Drug|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
45994216|NCT05470205|Drug|SHAPE measurement (Definity ultrasoud contrast agent)|Two vials with 3 mL of Definity will be mixed and diluted in 50 mL of normal saline, yielding a concentration of 49.4 μL/mL, and infused at a rate of at least 4 ml/min.
45994217|NCT00593710|Drug|Losartan|Losartan (25mg OD)
45994218|NCT00593710|Drug|Atenolol|Atenolol (25-50mg OD)
45994219|NCT04885686|Device|Endomethasone N RCS|Root canal sealer
45994220|NCT04885686|Device|Endomethasone SP RCS|Root canal sealer
45994221|NCT00593749|Behavioral|Healthy Corner Store Initiative|modification of snacks and beverages offered in corner store surrounding 10 schools
45994222|NCT00593749|Behavioral|Control|control group in study
45994223|NCT00536081|Drug|pegfilgrastim|6 mg s.c. 24-36 h post-chemotherapy
45994224|NCT02892643|Procedure|Laparoscopic proximal gastrectomy|Laparoscopy proximal gastrectomy with esophago-jejunostomy, gastro-jejunostomy and jejuno-jejunostomy (double tract reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
45994225|NCT02892643|Procedure|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with esophago-jejunostomy and jejuno-jejunostomy (Roux-en-Y reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
45994226|NCT04883970|Other|124I-18B10(10L) PET/CT|Study participants will undergo 124I-18B10(10L) PET/CT scans
45994227|NCT00593944|Biological|MDX-1342|MDX-1342 is given as a 90 minute i.v. infusion. Patients will receive one of the following dose levels, 0.7, 7, 40, 200, 1000, 2000 mg/dose.
45994228|NCT00536159|Other|Medicaid Maternal and Infant Support Services|Enhanced services include home visiting, transportation, psychosocial counseling, multidisciplinary planning, case management, nutritional guidance, and pregnancy and parenting education during pregnancy and infancy. The services are delivered primarily by nurses with occasional visits by social workers or nutritionists. In the county of the study (Kent), women who were assessed were provided intervention services.
45674619|NCT02162771|Drug|Cyclophosphamide|
45833994|NCT04499508|Device|Optima Coil System|Patients who have qualified for endovascular coiling in effort to treat intracranial aneurysms were treated with
45994229|NCT00536159|Other|Nurse-CHW team|A nurse and two CHWs functioned as a team, using visit and clinical guidelines that detailed expected care. Each team provided services for approximately 50-60 families. While occasional visits were made by both providers, most visits were made by either provider alone. Nurses guided the CHW care, led a multidisciplinary team assessment (with social workers, nutritionists, and others), provided crisis intervention and case management, assessed and managed health problems (including screening for depression and mental health care), and had periodic office visits with prenatal providers. CHWs provided relationship-based support by attempting weekly prenatal contact that alternated phone and face-to-face visits and used peer role modeling and personal empowerment approaches.
45674620|NCT02162771|Drug|Vincristine|
45674621|NCT02162771|Drug|Prednisone|
45674622|NCT02161757|Biological|Tralokinumab|Subcutaneous injection
45674623|NCT02161757|Other|Placebo|Subcutaneous injection
45674624|NCT02160977|Procedure|total knee arthroplasty|
45674625|NCT02160899|Drug|ISIS-APO(a)Rx|ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
45994230|NCT00594139|Biological|Autologous neobladder construct|provision of an autologous neo-bladder construct
46084735|NCT04176003|Other|Member checking|Participants will be sent a short report with the researchers' findings from the qualitative interview, and asked to check the accuracy of these and provide brief written feedback.
45994231|NCT04882449|Device|Bodyport Scale|The Bodyport scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient's home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF.
45994232|NCT00594217|Drug|oral micronized progesterone suspension|oral micronized progesterone suspension, single 100 mg oral dose
45994233|NCT00594217|Other|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
45994234|NCT01606774|Other|Modernized prenatal care|Home monitoring/phone surveillance/28 week ultrasound in place of 4-5 routine prenatal visits between 18 and 36 weeks
45994235|NCT00536237|Drug|Comparator: niacin / Duration of Treatment: 17 Weeks|
45994236|NCT00536237|Drug|MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks|
45994237|NCT00536237|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks|
45994238|NCT01606813|Other|Usual Care|Standard care
45994239|NCT01606813|Behavioral|Brief Physician Counseling|Primary Care Physician (PCP) will review a goal setting worksheet for weight loss with the participant and then collaboratively set a goal for weight loss.
45994240|NCT01606813|Behavioral|Referral and access to an internet weight control program|Participants will receive a login and password for the weight loss website. The website will encourage patients to set a new weight goal every 3 months and work towards a total weight loss goal of 10%. Patients will also receive an email prompt each week alerting them to new content and reminding them to check-in to the website to report their weight, intake and activity.
45994241|NCT01606813|Behavioral|Brief follow up email notes from PCPs|Patients will receive a biweekly email from their primary care physician on how they are doing with their weight loss.
45994242|NCT04874376|Device|IOL implantation experimental (Isopure 1.2.3.)|Implantation of Premium Monofocal Isopure 12.3 with retrospective data collection
45994243|NCT00533247|Drug|Celecoxib|
45994244|NCT01260181|Drug|Erlotinib|Erlotinib 150 mg tablet will be given orally daily.
45994245|NCT00536276|Dietary Supplement|Vitamin D2|Daily enteral dose of 100IU/kg
45994246|NCT00536276|Dietary Supplement|Vitamin D3|Daily enteral dose of 100IU/kg
45994247|NCT02892565|Other|Blood sample|
45994248|NCT02690064|Dietary Supplement|Acute Antioxidant|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
45994249|NCT02690064|Dietary Supplement|Chronic Antioxidant|Flow-Mediated Dilation will be determined at baseline, week 4, week 8, and week 12.
45994250|NCT02690064|Other|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
46084736|NCT04688762|Other|e-consult application (tool)|A numeric application used as a support in consultation to explain the surgical management of the patient.
45674626|NCT02160899|Drug|Placebo|Normal saline as Placebo, subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
45994251|NCT00594373|Drug|Tenofovir gel|1 gm/100 ml of 1% tenofovir gel vaginally daily
45994252|NCT00594373|Drug|Tenofovir gel placebo|1 gm/100 ml of placebo gel vaginally daily
45994253|NCT00594412|Procedure|Diagnostic Radiology: 1H-MRS of the liver|
45994254|NCT02892799|Other|NICOM-Guided Diuresis|NICOM-based assessment of PLR-induced change in cardiac index
45994255|NCT02892799|Other|Standard of Care|
45994256|NCT05470166|Drug|Lidocaine IV|lidocaine infusion as bolus 1.5mg/kg then 2mg/kg/hr
45994257|NCT05470166|Other|saline IV|saline infusion same volume as lidocaine
45994258|NCT00594529|Procedure|Surgery|Liver resection for metastatic liver lesions
45994259|NCT05470127|Device|Prostate biopsy needle|Prostate tissue biopsy with a biopsy needle
45994260|NCT02496585|Drug|Nintedanib|
45994261|NCT02496585|Drug|Prednisone|
45994262|NCT02496585|Other|Placebo|
45994263|NCT05470049|Drug|SHR8554 Injection and SHR0410 Injection|Treatment group A: SHR8554 Injection and SHR0410 Injection; high dose
45994264|NCT05470049|Drug|SHR8554 Injection and SHR0410 Injection|Treatment group B: SHR8554 Injection and SHR0410 Injection; low dose
45994265|NCT05470049|Drug|SHR8554 Injection and Placebo for SHR0410 Injection|Treatment group C: SHR8554 Injection and Placebo for SHR0410 Injection
45994266|NCT02412579|Other|None - Standard of Care|
45994267|NCT01260142|Drug|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 6.5 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 0.65 mg/kg IV bolus, or propofol injectable emulsion 0.65 mg/kg IV bolus followed by fospropofol disodium 6.5 mg/kg IV bolus.
45994268|NCT01260142|Drug|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 10.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.0 mg/kg IV bolus, or propofol injectable emulsion 1.0 mg/kg IV bolus followed by fospropofol disodium 10.0 mg/kg IV bolus.
45994269|NCT01260142|Drug|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 15.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.5 mg/kg IV bolus, or propofol injectable emulsion 1.5 mg/kg IV bolus followed by fospropofol disodium 15.0 mg/kg IV bolus.
45994270|NCT01259869|Drug|PX-866|1 cycle = 8 weeks on study PX-866 - 8mg PO Daily
45994271|NCT05469932|Device|Rexon device|Rexon device for 20 minutes each session. A total of 4 sessions with one week apart from each other.
45994272|NCT00594607|Device|AN69ST dialysis membrane|AN69ST is the filter that the blood goes through during hemodialysis
45994273|NCT00594607|Device|Fx8 (Fresenius)|Polysulphone dialysis membrane
45994274|NCT02116335|Drug|Bosentan|Stress response and vascular function will be assessed 3 days following 125 mg twice per day of Bosentan
45994275|NCT02116335|Drug|Placebo|Stress response and vascular function will be assessed 3 days following twice per day placebo
45994276|NCT05469776|Procedure|bicruciate-retaining total knee arthroplasty|
45994277|NCT05469776|Procedure|posterior-stabilized total knee arthroplasty|
45994278|NCT05469659|Drug|Tofogliflozin|Tofogliflozin 20 mg is orally administered once daily for 104 weeks before or after breakfast.
45994279|NCT05469659|Drug|Metformin|Metformin is started at 500 mg daily and orally administered in 2 to 3 divided doses immediately before or after meals. The dose during the maintenance period is determined by observing the effect, but is usually 750 to 1,500 mg daily. Metformin is orally administered for 104 weeks throughout post-start period. The dose may be adjusted according to the patient's condition, but the maximum daily dose should be 2,250 mg.
45994280|NCT04686006|Drug|Potassium Iodide|
45994281|NCT05469620|Dietary Supplement|Meal|Either a meal kit low in sodium, potassium, and phosphorus; or a meal kit low in sodium only is provided based on predefined logic. Meal kits are delivered in bulk twice a week, meant to replace one meal a day.
45994282|NCT05469620|Other|Education|Leaflet or video education materials on seven nutrition-related topics are provided, based on predefined logic. Materials are sent throughout the week, via SMS links.
45994283|NCT00535704|Behavioral|Strong African American Families-Teen Program|5 week educational program for teens and their caregivers.Each meeting lasts approximately 2 hours.
45994284|NCT00535704|Behavioral|FUEL|5 week educational program for teens and caregivers. Each weekly session lasts approximately 2 hours
45994285|NCT05469542|Device|Everbeat Ring|The primary objective of this study is to assess the concordance of specific ECG parameters obtained in the everbeat nine-lead ECG waveform with those obtained in the comparable leads from a standard 12-lead ECG recorder.
45674627|NCT02160041|Drug|BGJ398|BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
45674628|NCT02186873|Drug|Placebo|Participants will receive matching placebo.
45994286|NCT01808820|Biological|Dendritic Cell Vaccine|Between 1.2 to 12 million DC per dose administered once a week via intradermal injection for 4 weeks.
45994287|NCT01808820|Biological|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
45994288|NCT01808820|Drug|Imiquimod|5% topical cream applied to vaccine site before and after administrations of DC vaccine or lysate
45994289|NCT01808820|Procedure|Leukapheresis|Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
45994290|NCT05469386|Drug|Methylphenidate Hydrochloride ER|Methylphenidate Hydrochloride ER (.3 mg/kg dose q.d.)
45994291|NCT05469386|Behavioral|Behavioral classroom|Enhanced positive behavior supports implemented in classroom
45994292|NCT05469386|Drug|Placebo|Placebo capsule
45994293|NCT05469386|Behavioral|General Classroom|General education classroom procedures
45994294|NCT05469386|Behavioral|Academic Accommodations|Accommodations are introduced to support the child's independent seat work completion and quiz scores
45994295|NCT05469347|Drug|Alirocumab|A 600 mg dose of alirocumab (which is equivalent to 8mg/kg for a 75kg patient) will be administered once via IV over an approximately 30 ± 10 minute infusion using an infusion pump.
45994296|NCT05469347|Drug|Placebo|A placebo to match a 600 mg dose of alirocumab will be administered once via IV over an approximately 30 ± 10 minute infusion using an infusion pump.
45994297|NCT01462890|Biological|Bevacizumab|15 mg/kg, iv on day 1 every 3 weeks up to and including cycle 22 vs cycle 44
45994298|NCT01462890|Drug|Paclitaxel|175 mg/m², iv on day 1 every 3 weeks for 6 cycles
45994299|NCT01462890|Drug|Carboplatin|AUC 5, iv on day 1 every 3 weeks for 6 cycles
45674629|NCT02186873|Drug|Golimumab|Participants will receive 2mg/kg of intravenous infusions of golimumab .
45674630|NCT02096263|Biological|Infanrix hexa|3 doses administered intramuscularly in the right thigh.
45674631|NCT02096263|Biological|Pediarix|3 doses administered intramuscularly in the right thigh
45674632|NCT02096263|Biological|ActHIB|4 doses administered intramuscularly in the upper left thigh
45833995|NCT01922778|Procedure|Endometrial Biopsy|"Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. During the interview, the purpose of the study will be explained as well as the surgical technique used for obtaining an endometrial sample. If the patient consents to the procedure, then this will usually be a D&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD can be inserted at the time of her bariatric surgery.~For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting using an endometrial suction catheter."
45994300|NCT01462890|Other|specialized pathology review (Germany only)|before randomization
45994301|NCT05469152|Diagnostic Test|ds-MCE and EGD|"Procedure of ds-MCE: The ds-MCE system mainly consists of two parts: the NaviCam magnetic capsule endoscopy guidance system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. The capsule then could be detached from the string system through injecting air into the hollow string with the syringe after completing the examination of esophagus. Then, the examination of stomach under magnetic control and small bowel under the natural action of peristalsis follows.~Procedure of EGD: The EGD will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session."
45994302|NCT01410825|Biological|Retrovirus-mediated gene transfer|Two procedures: 1) Bone marrow harvest from the patient's posterior iliac crests or collection of peripheral blood stem cells via apheresis procedure. 2) One time infusion of patient's transduced bone marrow cells.
45994303|NCT05469113|Drug|Repaglinide|Administered orally.
45994304|NCT05469113|Drug|Selpercatinib|Administered orally.
45994305|NCT01259713|Drug|Liposomal amphotericin B|Ambisome 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week during induction chemotherapy
45994306|NCT01259713|Drug|Placebo|Placebo to match liposomal amphotericin B administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
45994307|NCT05469074|Device|Active tDCS + Active TUS|"Device: Active comparator device: Active transcranial Direct Current Stimulation (tDCS). Subjects will receive 20 minutes of active tDCS. During each Active stimulation session, stimulation will be applied for the full 20 minutes.~Device: Active comparator device: Active Transcranial Ultrasound (TUS). Subjects will receive 20 minutes of active Transcranial Ultrasound (TUS). During active stimulation the (TUS) will be active for the full 20 minutes."
45833996|NCT00636636|Drug|Gabapentin Extended Release tablets|Once-Daily; 300 mg and 600 mg tablets
45994308|NCT05469074|Device|Device: Sham|"Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of sham tDCS. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of sham TUS. During sham stimulation the ultrasound will not be active for the full 20 minutes."
46084737|NCT05188755|Other|Indirect calorimetric test during submaximal exercise|"metabolic evaluation by indirect calorimetry at rest and during exercise~evaluation of cardiac output~peripheral quantitative computed tomography (pQCT) of the muscle cross section~evaluation of body composition~assessment of physical capacity (chair test and 3 min step-test)~blood test~assess the level of physical activity"
45994309|NCT00594724|Procedure|MRI|Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging
45994310|NCT00622882|Other|infectious disease specialist consultation|Randomised trial to determine the utility of an early Infectious disease Consultation in Staphylococcus aureus bacteremic patients ( in the first 48 hours of a positive blood culture)
45994311|NCT01052727|Procedure|Laparoscopic Cholecystectomy|
46084738|NCT04540952|Device|Total Capture Drape|Surgical drape created by Principal Investigator to adequately collect fluid during hysteroscopy procedure
46084739|NCT04540952|Device|Standard Hysteroscopy Drape|Standard surgical drape used to adequately collect fluid during hysteroscopy procedure
46084740|NCT00917267|Drug|exenatide once weekly|2.0mg subcutaneous injection, once a week
46084741|NCT00917267|Drug|exenatide twice daily|5mcg subcutaneous injection twice a day (4 weeks), 10mcg subcutaneous injection twice a day (22 weeks)
46084742|NCT03606252|Other|Blood sampling|6 blood sample, 3 at J0 and 3 at J7 ( 2 tubes EDTA of 7mL, 1 tube Blood RNA of 3 mL)
46084743|NCT03606252|Other|urine sampling|2 urine sample (1 at J0 and 1 at J7)
46084744|NCT02670759|Drug|Continuous infusion of bupivacaine|The infusion of local anesthetics will be initiated using a conventional infusion pump and will be transferred on a portable elastomeric pump before discharge from the hospital if the patient is discharged the day after surgery or at the latest on the second morning following surgery. The infusion will continue on the portable pump for 30 hours.
46084745|NCT02670759|Drug|Single dose of bupivacaine|A single dose of bupivacaine will be administered at the end of surgery before skin closure.
45833997|NCT00636636|Drug|Placebo|Once daily; 300 mg and 600 mg tablets
45833998|NCT05244954|Drug|Dihydroartemisinin-Piperaquine|Treatment of females less than 10 years old and all males in Arm 2 and those who test positive in Arm 1.
45833999|NCT05244954|Drug|Chloroquine|Treatment of females 10 years old and older in Arm 2 and those who test positive in Arm 1.
45994312|NCT00622921|Behavioral|Couples-based behavioral psychotherapy|12 weeks of Couples-based behavioral psychotherapy
45994313|NCT05469035|Other|Mobile-based video|Nurses in the experimental group participated in mobile-based video learning.
45994314|NCT05469035|Other|Face-to-face|Nurses in the experimental group participated in face-to-face learning.
45994315|NCT02892526|Other|Abdominoplasty with exeresis of cutaneous tissue|
45994316|NCT02892526|Other|Collection of cutaneous tissue|
45994317|NCT01259401|Behavioral|Sleep Intervention Program|Sessions focused on: 1) sleep consolidation and sleep schedule optimization, 2) sleep hygiene education, 3) cognitive therapy, and 4) maintenance of sleep improvements and coping with future bouts of insomnia.
45994318|NCT01259401|Behavioral|Sleep Education control|During sessions, participants reviewed two educational brochures that focused on changes in sleep with age and sleep hygiene education.
45994319|NCT05471466|Procedure|Surgical incision|Surgical incisions to the neck as part of the management of the head and neck condition.
45994320|NCT00594841|Procedure|Open Reduction Internal Fixation of AC joint dislocation|"Definitive surgical treatment (i.e., ORIF) will be performed within 28 days of the injury. In all cases the procedure will be performed by an orthopedic staff surgeon with the assistance of a fellow/resident(s). The operating surgeon will determine the positioning of the patient for surgery. ORIF of the AC joint dislocation will be carried out as follows:~Anatomic reduction of the AC joint~Definitive fixation with a hook plate and screws"
45994321|NCT00594841|Other|Non operative treatment of AC joint dislocation (sling)|Standard protocol for conservative treatment will consist of the implementation of a sling, for shoulder support and patient comfort, for four weeks followed by physiotherapy. Pendulum exercises may be implemented at any time as dictated by the attending surgeon.
45994322|NCT05582590|Drug|Fludarabine|Lymphodepletion Chemotherapy on Days -5, -4, and -3 before Cycle 1 ONLY
45834000|NCT00635778|Drug|dalotuzumab|Administered as an IV infusion over one to two hours
45994323|NCT05582590|Drug|Cyclophosphamide|Lymphodepletion Chemotherapy administered on Days -5, -4, and -3 before Cycle 1 ONLY
45994324|NCT05582590|Biological|NEXI-003 T cells|Adoptive Cell Therapy specified dose on specified day(s)
45994325|NCT05468879|Drug|Glimepiride|Glimepiride is a sulfonylurea, indicated as an adjunct to proper dietary management, exercise and weight reduction to lower the blood glucose in patients with type 2 diabetes whose hyperglycemia cannot be controlled by diet and exercise alone.
45994326|NCT05468879|Drug|Amaryl®|Amaryl®
45994327|NCT05471427|Drug|Taxane chemotherapy|Patients underwent taxane chemotherapy according to clinical practice for metastatic prostate cancer
45994328|NCT04130074|Device|duplex doppler ultra sound and CT|graded compression US done in different positions then take MSCT with contrast on abdomen to compare with
45994329|NCT00536354|Other|Postural Orientation|
45994330|NCT04320433|Diagnostic Test|Oral glucose tolerance test|Participants will ingest 75g anhydrous glucose dissolved in a volume of 200mL of water (NUTER.TEC GLUCOS, Subra, Toulouse, France).
45994331|NCT05471388|Diagnostic Test|serum asprosin|assessment of serum asprosin by a commercially available double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.
46084746|NCT03300492|Other|NK-DLI|"Application of three infusions of ex vivo expanded NK cells on days~+10, +15 and +20 with increasing NK cell doses (1x107/kg, 1x108/kg and the remaining cells up to 1x109/kg) following haplo-HSCT. Maximal cumulative T-cell dose is fixed at <1x105/kg."
45674633|NCT02096263|Biological|Pentacel|4 doses administered intramuscularly in the right thigh
45674634|NCT02096263|Biological|Engerix-B|2 or 3 doses administered intramuscularly in the upper left thigh
45834001|NCT04396470|Device|tVNS|Participants will be randomized to either the tVNS treatment condition or the sham tVNS (placebo) condition. An identical non-invasive tVNS device will be used in both groups. In the active condition, the device is placed on the external earlobe (tragus), which directly stimulates the vagus nerve. In the sham condition, the device is placed on the external earlobe, providing the same sensations as in the treatment condition, but no stimulation to the vagus nerve. Intervention period: Participants will use the device 1-hr per day for 12 weeks per manufacturer's instructions.
45834002|NCT01929252|Drug|Dexmedetomidine|2mcg.kg-1 dexmedetomidine wound infiltration
45994332|NCT05558449|Device|Hypnosedation|"Hypnosedation session with a virtual reality headset during the regional anesthesia technique and during the surgery (approximately 60 minutes). The VRH module used will be Silva, i.e. the same scenario of a walk in the forest through the 4 seasons with a voice accompanying the hypnosis session."
45994333|NCT05558449|Drug|Midazolam injection|Midazolam intravenous injection 1 mg until RASS -3
45994334|NCT05558449|Device|Virtual reality|"Only virtual reality without a hypnosedation session. The virtual reality headset will be used on these patients without external voice or hypnosis device. The virtual reality module used will be Silva, i.e. a scenario of a walk in the forest through the 4 seasons."
45994335|NCT04326907|Procedure|Autologous centrifuged adipose tissue (CAT) injection after anal fistulectomy|Collection and injection of autologous adipose tissue in complex anal fistulas in one surgical step under locoregional or general anesthesia.
46084747|NCT04079829|Other|Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data|No interventions
46084748|NCT04521738|Drug|SAR441255|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
46084749|NCT04521738|Drug|placebo|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
45674635|NCT02096263|Biological|Infanrix|1 dose administered intramuscularly in the right thigh
45834003|NCT01929252|Drug|Levobupivacaine|0.25% levobupivacaine (40ml) wound infiltration
45834004|NCT04275960|Drug|Selitrectinib (BAY2731954)|Selitrectinib is administered orally as liquid suspension (20 mg/mL) on Day 1 of each period. Each period lasts 4 days, both periods of each arm are separated by at least 3 days.
45674636|NCT02096263|Biological|Hiberix|1 dose administered intramuscularly in the left thigh
45674637|NCT02096263|Biological|Prevnar13|3 doses administered intramuscularly in the lower left thigh
45674638|NCT02096263|Biological|Rotarix|2 doses administered orally
45674639|NCT01830543|Drug|rivaroxaban 2.5 mg|One 2.5 mg tablet twice daily for up to twelve months
45674640|NCT01830543|Drug|rivaroxaban 15 mg|One 15 mg tablet once daily for up to twelve months
45674641|NCT01830543|Drug|rivaroxaban 10 mg|One 10 mg tablet once daily for up to twelve months
45994336|NCT05468801|Other|Individualized Homeopathic Remedy|An individualized homeopathic remedy selected for each subject according clinical homeopathic parameters will be administered daily in the form of oral globules as an add on to conventional treatment.
45994337|NCT05468801|Other|Placebo|Placebo plus Standard Pharmacologic Treatment
45994338|NCT04326946|Device|Alfapump|alfapump implementation
45994339|NCT04326985|Biological|Autologous Mesenchymal Stem Cells Treatment (MSCs)|The MSCs treatment group patients will receive an intra-articular injection of a mesenchymal stem cell (MSCs) suspension in the affected knee.
45994340|NCT04326985|Drug|Hyaluronic acid (HA)|The HA group patient will be given a single intra-articular injection of hyaluronic acid sodium salt, Synvisc-One (TRB Chemedica Ltd.)
45994341|NCT05547178|Other|Qualitative interview - eurythmy group|Participants will be interviewed about self-perceived changes in everyday life during participation in the eurythmy intervention of the ENTAiER study.
45994342|NCT05547178|Other|Qualitative interview - tai chi group|Participants will be interviewed about self-perceived changes in everyday life during participation in the tai chi intervention of the ENTAiER study.
45994343|NCT05547178|Other|Qualitative interview - standard care group|Participants will be interviewed about self-perceived changes in everyday life during participation in the standard care group of the ENTAiER study.
45994344|NCT00536393|Drug|Doxorubicin|
45994345|NCT00536393|Drug|Doxorubicin pegylated|
45994346|NCT00595387|Other|Supportive Psychotherapy|Participants will attend 18 supportive therapy sessions over 5 months. Supportive psychotherapy focuses on reflecting and expressing feelings about current life issues. Participants are supported and comforted when coping with difficult situations, depression, mood swings, or anger.
45457061|NCT01130701|Other|Neoadjuvant capecitabine, panitumumab and radiation|"Patients will receive six weekly doses of panitumumab (2.5mg/kg) in conjunction oral capecitabine 825 mg/m2 PO bid Mon-Friday and external beam radiation therapy. Panitumumab and oral capecitabine will begin on the first week of external beam radiotherapy and will continue throughout the course of external beam radiation therapy, and will be discontinued following the conclusion of external beam radiation therapy.~Patients will be reevaluated for surgical resection 4-6 weeks after completion of neoadjuvant therapy.~After surgical resection, adjuvant systemic chemotherapy with gemcitabine for six months is strongly recommended for all patients."
45457062|NCT03519880|Device|Custom Mask Interface|Subjects enrolled in the study will received a custom designed, 3D printed, non-invasive ventilation mask interface.
45457063|NCT03929263|Behavioral|Real-time fMRI neurofeedback|Participants will attempt to regulate own and/or their partner's brain activation in a specified brain region via real-time fMRI neurofeedback.
45457064|NCT03929107|Biological|Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells|patient's T cells were seperated and engineered into Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells, and retransfused into the patient for treatment of their B cell lymphoma.
45674642|NCT01830543|Drug|aspirin (ASA)|Low-dose aspirin tablet once daily for twelve months
45834005|NCT04276038|Device|B-Cure laser pro|The B-Cure laser pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2. The device is used at home and is self-applied by the patient. The device is AMAR approved (approval # 14810408) for pain reduction and for ulcer treatment. The device is also approved for marketing in Canada and as a medical device in Europe (CE medical mark).
45834006|NCT04275804|Device|Low Magnitude High Frequence Vibration Platform|with low-magnitude high-frequency vibration (35Hz, 0.3g peak-to-peak displacement <0.1mm)
45834007|NCT04275804|Other|Conventional Dressing|Alternate Day Dressing
45834008|NCT00634920|Drug|everolimus|Everolimus (Certican®) tablets administered orally in two divided doses (b.i.d.) at a starting dose of 4 mg/day adjusted to target a trough blood concentration between 6 and 10 ng/mL in period 2.
45994347|NCT00595387|Other|Cognitive Behavioral Therapy (CBT)|Participants will attend 18 CBT sessions over 5 months. CBT for depression targets depressive symptoms through a range of different treatments. This includes psychoeducation about the disorder and educating patients about the role of thoughts and behaviors in the maintenance of depressed mood. CBT also includes mood and activity monitoring, activity scheduling, and teaching participants to critically investigate and challenge negative thoughts and core beliefs that help to maintain depression.
45994348|NCT00595543|Drug|Bromfenac|1 drop (in the eye) Instill one drop in the affected eye twice daily for three months
45994349|NCT00595543|Drug|Ketorolac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
45994350|NCT00595543|Drug|Diclofenac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
45994351|NCT05519098|Device|COLO-SW-1|Patient will undergo a CADe-assisted colonoscopy procedure with use of the COLO-SW-1 software.
45994352|NCT04207801|Drug|AUR101|Inhibitor of RORγ
45994353|NCT04207801|Drug|Matching Placebo|Drug-Placebo of AUR101 tablet
45457065|NCT01128673|Device|mRI|
45457066|NCT02292550|Drug|Ribociclib|CDK 4/6 inhibitor
45457067|NCT02292550|Drug|Ceritinib|ALK inhibitor
45457068|NCT03929185|Diagnostic Test|blood analysis with SCENT B1|analyze blood samples with chemoresistive sensors
45674643|NCT01830543|Drug|vitamin K antagonist (VKA)|Dose-adjusted VKA tablet (target International Normalized Ratio (INR) 2.0 to 3.0) once daily for twelve months
45674644|NCT01830543|Drug|clopidogrel|One 75 mg tablet once daily for up to twelve months
45674645|NCT01830543|Drug|prasugrel|One 10 mg tablet once daily for up to twelve months
45674646|NCT01830543|Drug|ticagrelor|One 90 mg tablet twice daily for up to twelve months
45674647|NCT02109445|Drug|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Doses: 100 -150 mg BID
45834009|NCT00634920|Drug|cyclosporine A|CsA (Sandimmun Neoral), based on C0-h levels 75-200 ng/mL or C2-h levels 700 900 ng/mL from randomization to Month 6, or C0-h levels 50-150 ng/mL or C2-h levels 600 800 ng/mL from Month 6 to Month 36, according to local method
45834010|NCT00634920|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|Target dose 1440 mg in the control group, target dose 1080 in the everolimus group (higher dose in the CsA group because of interactions of CsA on gastric reabsorption of mycophenolate)
45994354|NCT00595660|Procedure|FNA - fine needle aspiration|Fine Needle aspiration
45674648|NCT02109445|Drug|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
45994355|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
45674649|NCT02109445|Drug|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
45834011|NCT00634920|Drug|corticosteroids|For both groups: minimum corticosteroid dose of 10 mg until week 12, 5-10 mg until month 12, month 12-36 corticosteroid treatment on investigator's descretion.
45674650|NCT02109445|Drug|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Phase 2 dose will be the recommended phase 2 dose defined in phase 1.
45834012|NCT00634920|Drug|Basiliximab|Induction therapy 20 mg basiliximab on Day 0 prior to reperfusion and 20 mg on Day 4 post-TX.
45994356|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
45834013|NCT01923012|Drug|Vitamin K2 (Menaquinone)|
45834014|NCT01923090|Drug|Finasteride|Finasteride 5mg once daily for 3 weeks
45834015|NCT01923090|Drug|Dutasteride|Dutasteride 0.5mg once daily for 3 weeks
45834016|NCT01929330|Drug|GI198745 0.1 mg|It is available as soft gelatin capsule to be administered as 5 X 0.1 mg capsules as single oral dose with approximately 250 mL of water.
46084750|NCT00644943|Drug|cefdinir (Omnicef)|oral suspension (7 mg/kg, ql2hr) for 5 days
45674651|NCT02109445|Drug|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
45674652|NCT02109445|Drug|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
45674653|NCT02109445|Drug|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
45674654|NCT02109445|Drug|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
45674655|NCT02109133|Procedure|deep neuromuscular blockade|deep neuromuscular blockade using rocuronium and reverse with sugammadex
45834017|NCT01929330|Drug|GI198745 0.5 mg|It is available as soft gelatin capsule to be administered as 1 X 0.5 mg capsules as single oral dose with approximately 250 mL of water.
45834018|NCT01929564|Other|Beneforte broccoli|Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
45834019|NCT01929564|Other|Parthenon Broccoli|Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
45994357|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
45994358|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
45994359|NCT05504746|Drug|SHEN26 capsule|"Specification: 50mg/capsule and 200mg/capsule. Participants will receive SHEN26 capsule(s) orally for a single dose.~The specification of 50mg/capsule will only be used for the 50mg dose group in the SAD part. For the other dose groups and other parts of the study, 200mg/capsule will be used."
45994360|NCT05504746|Drug|SHEN26 capsule|Specification: 200mg/capsule. Participants will receive SHEN26 capsules orally for Q12h X 5.5 days.
46084751|NCT00644943|Drug|amoxicillin|oral suspension (45 mg/kg/day, q l2 hours) for 10 days
45994361|NCT05504746|Drug|SHEN26 placebo|"Placebo matching the SHEN26 capsule. Specification: 50mg/capsule and 200mg/capsule.~Participants will receive SHEN26 placebo orally for a single dose."
45994362|NCT05504746|Drug|SHEN26 placebo|"Placebo matching the SHEN26 capsule. Specification: 200mg/capsule.~Participants will receive SHEN26 placebo orally for Q12h X 5.5 days."
45994363|NCT02892370|Drug|SHR0302|SHR0302 tablets (10 mg)
45994364|NCT04326868|Drug|Benzimidazole Anthelmintic|The participants diagnosed positive will be randomly assigned to one of the following treatment arms of the study. Parents or guardians of eligible children will be asked to bring them to the CERMEL (clinic). after a brief clinical examination child fulfilling inclusion criteria will be randomly assigned to one of the following treatment regimens of the study.
45994365|NCT05468762|Procedure|Transfemoral tranScatheter aortic valvE implantation|Transcatheter aortic valve implantation (TAVI) is an established treatment modality in patients ≥ 75 years old with severe symptomatic aortic stenosis after Heart Team evaluation
45994366|NCT00595738|Other|Standard of care therapy for severe decompensated heart failure|Standard of care therapy for severe decompensated heart failure
45994367|NCT00595777|Behavioral|EPAT© Educational Package|The EPAT package consists of an education programme, which deals with the known common barriers to effective pain control and the bedside pain tool. The pain tool is uniquely incorporated into the vital signs chart to enable a systematic approach to cancer pain assessment and review. EPAT consists of 2 steps: step 1 is a colour-coded pain assessment on the bedside vital signs chart. Patients with moderate or severe pain on step 1 will progress to to step 2, which helps to identify the aetiology of the pain, screening for opioid side effects and is linked via flags to simple management plans. The intervention will be delivered to the clusters randomised to the intervention, after collection of baseline data (pre-intervention data) on 50 patients.
45994368|NCT05470998|Drug|L-Arginine|L-Arginine 1000 mg free form, rapid release capsules
45994369|NCT00595816|Other|physical training and counselling|Neuromuscular training program 3 times per week 30 minutes per session and counselling on back problems and other musculosceletal injuries
46084752|NCT02762006|Drug|Durvalumab|Durvalumab is a programmed cell death ligand-1 monoclonal antibody which has demonstrated anti-tumor efficacy renal cell carcinoma and other malignancies via activation of the immune system.
45834020|NCT00634842|Drug|insulin detemir|Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 70-90 mg/dL
45834021|NCT00634842|Drug|insulin detemir|Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 80-110 mg/dL
45834022|NCT03108066|Drug|PT2385 Tablets|PT2385 inhibits HIF-2α and is a novel approach to treatment of VHL disease-associated ccRCC.
45834023|NCT04396548|Drug|Midodrine Oral Product|Patients will receive oral 10 mg tablet of midodrine with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine.
46002353|NCT04501328|Behavioral|CIC|Coaching Into Care is an existing national VA program that provides telephone consultation and coaching to family members of Veterans with mental health needs who want to help connect them with mental health care by providing referrals, educational information, and a unique coaching service to help callers talk to their Veterans about their decision to seek care.
46084753|NCT02762006|Drug|Tremelimumab|Tremelimumab is a CTLA-4 monoclonal antibody.
46084754|NCT02769884|Device|MMPPC algorithm artificial pancreas|An artificial pancreas system using the MMPPC algorithm, Roche insulin pump, and Dexcom CGM
46084755|NCT05154981|Behavioral|Education communication skills (ECS) training|Education communication skills (ECS) training videos were developed from LEAPS (Listen, Educate, Assess, Partner and Support), a set of 10- to 20- sec videos that help patients and physicians communicate health concerns and treatment plans to each other. ECS training videos target parent-teacher communication during the transition to school for children with autism.
46084756|NCT05154981|Behavioral|Partners in School|Partners in School is a problem-solving consultation that encourages parents and teachers to implement the same evidence-based interventions across home and school
46084757|NCT05213507|Drug|aerosol inhaled Amikacin Sulfate Injection|0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 7-10 days per month, for 3 months.
46084758|NCT05213507|Other|conventional therapy|According to the personal characteristics of subjects and guidance of The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2021, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled corticosteroids and long-term oxygen therapy.
46084759|NCT02765984|Device|Transvaginal ultrasound|transvaginal ultrasound done before 10 weeks gestational age measuring the distance between the lower end of the hyperechoic trophoblast ring of the gestational sac and the inner cervical os
45674656|NCT02109133|Procedure|moderate neuromuscular blockade|moderate neuromuscular blockade using atracurium and reverse with neostigmine
45994370|NCT05468723|Device|Carecube Negative Pressure Isolation Chamber|Subjects will be tasked to stay within the Carecube Isolation Chamber for at least 4 hours and have 3 consecutive timepoints illustrating a plateau level for all participants parameters. Environmental data will be collected by physicians and nurses [which may include physicians, physician assistants, Registered Nurses, Licensed Practical Nurses, medical technicians and emergency medical technicians (EMTs)] . Additionally, atmospheric Oxygen, Carbon Dioxide, humidity, and room temperature will be monitored and recorded on an hourly basis. External to the room humidity and temperatures will also be recorded. The participant will be exposed to room temperature (° Fahrenheit) and humidity (RH%), ranging from 65°- 90° Fahrenheit and 30%-60% RH. Participants will also be asked to record on a questionnaire, in order to demonstrate that the Carecube Negative Pressure Isolation chamber is a safe and non-hostile environment for the patients that will be contained during normal operations.
45994371|NCT00595855|Procedure|trabeculectomy|Cairns-like trabeculectomy, limbus based, with 5_FU supplementation and argon laser suturelysis
45994372|NCT00595855|Procedure|deep sclerectomy|deep sclerectomy with no implant and no sutures to the superficial flap, limbus based with suppplementation of FU (if needed)
45994373|NCT00595972|Drug|ECF-endostar|Epirubicin 50mg/M2 D1, Cisplatin 60mg/M2 D1, FU 500mg/M2 D1-5, endostar 7.5mg/M2 D1-14, treatment cycle repeat every 3 weeks. Treatment should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
45994374|NCT00596050|Drug|ketamine and midazolam|ketamine 1 mg/kg/dose, midazolam 0.05 mg/kg/dose max 2 mg
45994375|NCT00596050|Drug|etomidate, fentanyl, and lidocaine|etomidate 0.2 mg/kg/dose, fentanyl 1 microgram/kg/dose, lidocaine 0.5 mg/kg/dose
46084760|NCT00614796|Behavioral|Coach, using a stepcounter with exercise counseling|5 counseling meetings of 30 min in the first 3 months. In counseling, patients will be stimulated individually to enhance a physically active lifestyle.
45994376|NCT05468684|Other|no intervention|there are no interventions planned, we observe the patients in a cohort study which is named inception cohort study because we test participants before the condition develops.
45994377|NCT02888899|Behavioral|Biofeedback|
45674657|NCT02109133|Drug|Rocuronium|
45994378|NCT02888899|Drug|Loperamide|
45994379|NCT02888899|Drug|Stool bulking agent (sterculia or ispaghula husk)|
45994380|NCT02888899|Other|PTNS|
45994381|NCT05470959|Other|ACTIVA bioactive|bioactive ionic resin composite
46084761|NCT02670603|Drug|EVONAIL® solution|
45457069|NCT03929185|Diagnostic Test|tissue analysis with SCENT B1|analyze tumor biopsies collected during surgery with chemoresistive sensors
46084762|NCT02761928|Other|Beighton score for hypermobility|The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.
45457070|NCT03925519|Other|Supervised aerobic exercise|
45457071|NCT02295436|Drug|minodronic acid|comparison of different doses, ages and medication conditions
45674658|NCT02109133|Drug|Sugammadex|
45674659|NCT02109133|Drug|Atracurium|
45674660|NCT02109133|Drug|Neostigmine|
45674661|NCT01623271|Drug|Gabapentin|
45994382|NCT05470959|Other|Riva LC|resin-modified glass ionomer
45994383|NCT00624091|Procedure|Cardiac surgery|Cardiac surgery within 48 hours of randomization
45994384|NCT00624091|Procedure|State-to-the-art treatment|Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
45994385|NCT05468645|Drug|[14C]Hemay005|Name: [14C]Hemay005 Dose: 60 mg/100 µCi Storage: store at -10℃ to -30 °C, tightly closed and protected from light.
45994386|NCT04320394|Diagnostic Test|QuantiFERON Monitor®|The test will be realised to evaluate sepsis induced immunosuppression on patient with septic shock
45994387|NCT02892487|Other|Swallowing therapy|Patients will undergo active swallowing therapy with a speech and language therapist (twice a week) combined to a detailed program of swallowing auto-exercises (twice a day) from start of radiotherapy to one month after the end.
45994388|NCT00596128|Behavioral|Implementation of SOP|SOP for blood sugar monitoring and intervention will be defined and ICU nurses will be educated to use this SOP in clinical routine
45994389|NCT00596206|Drug|leflunomide|20 or 100 mg per os, Film coated tablet, for 3 days + matching placebo, then 20 mg once daily for 3 months
45994390|NCT00596245|Drug|MT400|MT 400, naproxen sodium 550mg
45994391|NCT00596284|Behavioral|Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)|Cognitive behavioral therapy (CBT) will consist of 8 to 10 sessions over a period of 10 to 12 weeks. Each CBT session will last about 1 hour and will include meeting with a study staff member to discuss anxiety and how to cope with it. Participants will also complete practice activities at home for about 20 minutes per day.
45994392|NCT00596284|Behavioral|Enhanced Usual Care (EUC)|Following in-person meetings, participants will receive weekly phone calls for 3 months, followed by biweekly phone calls for the next 3 months.
45994393|NCT05438914|Device|Repair of the subscapularis|"The subscapularis will be repaired using the suture through bone and prosthesis holes surgical technique."
46084763|NCT04253639|Other|Questionnaires|"Patients must fill questionnaires to collect socio-demographics, aetiology and characteristics of pain, efficacy and tolerance regarding the TENS.~Study sites must fill questionnaires to collect information regarding the type of pain management centre, the characteristics of the clinician, the characteristics of the TENS prescribed."
45994394|NCT05468528|Procedure|catheter radiofrequency ablation(individualized stepwise linear without pulmonary vein isolation)|individualized stepwise linear ablation without pulmonary vein isolation
45994395|NCT05468528|Procedure|catheter radiofrequency ablation(PVI)|pulmonary vein isolation
45994396|NCT05427448|Diagnostic Test|Measurement of amyloid and pTau blood biomarkers|Detection of plasma Amyloid beta 1-40 and 1-42 peptide and phosphorylated tau isoforms.
45994397|NCT00624130|Drug|Yasmin 20|Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral)
45994398|NCT00624130|Drug|Mercilon|Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral)
45994399|NCT05468450|Drug|Ultrasound-guided-foam sclerotherapy (UGFS) using Polidocanol sclerosant|Direct injection Foam sclerotherapy
45994400|NCT05468450|Device|Endovenous Laser Ablation (EVLA)|EVLA using a 1470nm generator and 600-micron radial fibres (Biolitec® Biomedical Technology, Jena, Germany), under tumescent local anaesthesia (TLA)
45994401|NCT04686123|Other|Active Stretching or Self-stretching exercises|Pectoralis minor muscle was actively stretched under the supervision of a physiotherapist as follows: - 2 sets of 3-stretches/session/day, for 5 consecutive days a week, for 3 weeks
45994402|NCT04686123|Other|Active strengthening Or Self-Strengthening exercises|Lower trapezius muscle was strengthened under the supervision of a physiotherapist as follows: -2 sets of 5-rep./session/day, for 5 consecutive days in 1st week, progressed to 10 and 20 reps./session/day for 2 weeks and 3 weeks respectively.
45994403|NCT05409664|Behavioral|Physical activity adoption|webMFT will be delivered via a web-based platform. Coaches will be trained to deliver the intervention prior to being assigned a study participant. Upon successful completion of the informed consent for coaches and participants, coaches will be assigned a participant for their 3-month duration in the study. Coaches and participants will complete weekly phone calls focused on increasing the participants' MVPA up to the recommended 150 min/week.
45994404|NCT05409664|Behavioral|Self monitoring|Participants will be asked to gradually increase their activity up to the recommended 150 minutes of moderate-intensity/week during the 12-week intervention. Self-monitoring will be completed using a Fitbit tracker.
46084764|NCT02670369|Behavioral|Sitting time prompt|Participants will receive a device that prompts them to take breaks from sitting approximately every 15-20 minutes.
46084765|NCT03385902|Other|optimal start time|patients will start hemodialysis when their DIFE reach 35, and can not wait if the DIFE decline to 30.
46084766|NCT03385902|Other|late start time|patients will start hemodialysis when their DIFE less than 30
46084767|NCT04253873|Drug|Apatinib|Apatinib mesylate (0-14 days, 500 mg, qd), taken half an hour after a meal (the daily dose should be as much as possible), one week apart, and then given temozolomide (150mg/m2 for 5 Days); every 28 days is a cycle, medication to disease progression, intolerable toxicity, etc.
46084768|NCT05147727|Drug|Fluconazole、Famitinib|Fluconazole, once daily on Days 12 to 24; Famitinib, once daily on Days 1 and 15
46084769|NCT02769650|Procedure|CTO coronary angioplasty|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
45834024|NCT04396548|Drug|Inert tablet containing sugar (placebo)|: Patients will receive Inert tablet containing sugar (placebo) with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine
45834025|NCT01923246|Behavioral|Single WEB intervention|Brief WEB intervention recieved once
46084770|NCT02769650|Drug|Optimal medicamentous treatment|
46084771|NCT02769650|Procedure|Stress-MRI|A standard stress-MRI test with adenosine
46084772|NCT04444362|Device|Inspiratory Muscle Training|IMT underwent 5 days of 30 breaths twice daily at 50% (+5% increase each week) of maximum inspiratory pressure (MIP)
46084773|NCT04175535|Procedure|Percutaneous Posterior Endoscopic Cervical Discectomy|The most common alternative in the case of soft cervical disc herniations.
46084774|NCT04175535|Procedure|Anterior cervical decompression and fusion|The standard procedure for operation of cervical disc herniations.
45834026|NCT01923246|Behavioral|Repeated WEB intervention|WEB intervention recieved twice.
45994405|NCT05399329|Drug|Palbociclib|Palbociclib plus ET as first-line/second-line treatment for hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) ABC
45994406|NCT05399329|Drug|Endocrine therapy|Palbociclib plus ET as first-line/second-line treatment for HR+/HER2- ABC
45994407|NCT04320355|Other|Soft tissue manual therapy|The intervention is a type of massage.
45994408|NCT00535860|Drug|Teriparatide|Daily for 96 days
46002354|NCT03566017|Drug|pegunigalsidase alfa|Recombinant human alpha galactosidase A
45994409|NCT05388721|Other|Clinical data and specimen collection|"Questionnaire survey and clinical data was conducted when pregnant women were enrolled in the first trimester, and blood and urine were collected. Furthermore, we will follow up the pregnant women until delivery, blood and urine were collected during the third trimester (after 28 weeks), and clinical information was collected.~Umbilical cord blood and placental tissue will be collected if possible."
45994410|NCT02892331|Behavioral|Moderate intensity exercise training (MOD-INT)|Participants in the MOD-INT group will exercise at the heart rate associated with 45-55% VO2 max. The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)
45994411|NCT02892331|Behavioral|High Intensity exercise training (HI-INT)|Participants in the HI-INT group will exercise at the heart rate associated with 70-80% VO2 max (heart rate ranges will be updated at mid-intervention CRF assessment). The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)3
45994412|NCT00536549|Device|Guardian RT|
46084775|NCT02765906|Other|Graphic card|A randomized controlled trial comparing patient education on preeclampsia with a graphic card vs. patient education with a written pamphlet vs. no patient education showed that patient education improved significantly when patients were provided with a graphic card depicting signs and symptoms of preeclampsia and that this improvement occurred regardless of health literacy score (You WB, Wolf MS, Bailey SC, Grobman WA. Improving patient understanding of preeclampsia: a randomized controlled trial. American Journal of Obstetrics & Gynecology. 2012;206:431.e1-431.e5.). The graphic card is now available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/market-place/educational-illustrated-signs-symptoms-pad-detail).
46084776|NCT02765906|Other|Video|This an informational video available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/component/allvideoshare/video/featured/7-symptoms-every-pregnant-woman-should-know?Itemid=479). The effectiveness of this video has not yet been tested as an educational tool.
46084777|NCT04151394|Procedure|Duodenojejunostomy|Resection of duodenal lesions and reconstruction by duodenojejunostomy
46084778|NCT02669979|Other|Intervention|Professional oral care
46084779|NCT03631290|Behavioral|Deprescribing Intervention|Participants who are taking specific potentially inappropriate medications and their nephrologist will be engaged in the deprescribing process. The process involves deprescribing decision-making, implementation of deprescribing, and monitoring for adverse drug withdrawal events. The specific details of the deprescribing process are TBD.
46084780|NCT02765594|Drug|Hydroxychloroquine Sulfate|200mg bid
46084781|NCT02765594|Drug|Valsartan|160mg qd
46084782|NCT00920699|Drug|CoQ10|Capsules containing 300 mg of CoQ10 or matching placebo taken orally twice a day. All participant will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
46084783|NCT02670057|Procedure|Transnasal SPG block|
46084784|NCT03493464|Drug|BR55|A novel targeted ultrasound contrast agent
46084785|NCT02769728|Device|EndoBarrier|implantation of a duodeno-jejunal bypass liner for weight reduction in obese subjects with type 2 diabetes mellitus
46084786|NCT02670135|Drug|Triclosan Containing Toothpaste|Active formula containing 0.3% triclosan in a1450 ppm sodium fluoride/silica base
45457072|NCT03925363|Device|Physical activity mobile-application|The active group will be given the feedback app and the control group the blind app
45457073|NCT03517150|Device|mandibular advancement device|
45457074|NCT03925285|Drug|Bevacizumab-800CW|Two to four days prior to surgery bevacizumab-800CW will be administered intravenously
45834027|NCT01923246|Behavioral|Single IVR intervention|IVR intervention recieved once
45834028|NCT01923246|Behavioral|Repeated IVR intervention|IVR intervention recieved twice
45834029|NCT01923324|Behavioral|Physician telephone consultation|Pain physician support for family physician treating patient
45834030|NCT01923324|Behavioral|Usual family physician care|Usual family physician care without telephone consultation with pain physician
45834031|NCT04395456|Drug|AMY-101|C3 complement inhibitor
45834032|NCT04395456|Other|WFI 5% glucose|Placebo
45834033|NCT01929720|Behavioral|Cognitive-behavioral therapy for worry, uncertainty & insomnia|This intervention involves teaching the participant in-person strategies for managing worry, uncertainty, and insomnia and involves home practice.
45834034|NCT01929798|Device|portable Artificial Pancreas|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels.
45834035|NCT01929954|Biological|Gintuit|One time placement of Gintuit over socket graft.
45834036|NCT01929954|Device|Bio-Gide|One time placement of Bio-Gide over socket graft.
45834037|NCT04395690|Procedure|Dental Implant Placement in the posterior mandible|Surgery done in the posterior mandible with missing teeth for placing dental implants.
45994413|NCT00536549|Behavioral|Education about the self monitoring blood glucose|
45994414|NCT04208074|Other|Exercise Intervention|Participants will exercise under the supervision of expert personal trainers and follow an optimized exercise program tailored to the strength and fitness level of each participant. Participants will exercise for 16 weeks; 2 days a week at the gym for an hour and 2 days of the week at home for 45 minutes.
45994415|NCT00596479|Drug|Filgrastim (rG-CSF)|
45994416|NCT05387668|Drug|BGB-23339|Administered orally as a tablet.
46084787|NCT02670135|Drug|Triclosan Free Toothpaste|Control toothpaste with no triclosan ingredients in a 1450 ppm sodium fluoride/silica base - matching placebo
45994417|NCT05387668|Drug|Placebo|Administered orally as a tablet.
45994418|NCT05468372|Drug|Posaconazole 600 mg followed by posaconazole 300 mg once daily|Posaconazole will be given as a delayed release tablet, the dose would be 600 mg in two divided doses on day 1, followed by 300 mg once a day from then on. If a subject vomits within 15 minutes of posaconazole tablet administration, the dosing should be repeated as soon as possible, following appropriate antiemetic treatment. The drug will be administered after a meal.
45994419|NCT05468372|Drug|Liposomal Amphotericin B|"All study subjects will be administered intravenous liposomal amphotericin B [5 mg/kg/day infusion in 5% dextrose solution] over at least 2 hours, as per recommendations. Amphotericin B will be administered for the first seven days in the experimental arm, whereas it will be administered atleast for four weeks in the active comparator arm. Premedication or intravenous hydration will not be routinely administered. For patients experiencing chills, fever, hypotension, nausea, or other non-anaphylactic immediate infusion-related reactions, premedication (acetaminophen, diphenhyramine or hydrocortisone) will be administered 30 to 60 minutes prior to the next dose of amphotericin infusion.~The dose of intravenous amphotericin B will be modified further if required, based on the tolerability, and response to treatment."
45994420|NCT04207957|Drug|Olorofim|150 mg
45994421|NCT05383339|Other|Blood collection|- 56mL blood collected additionally to routine care
45994422|NCT00535977|Dietary Supplement|Broccoli|400g ITC-enriched broccoli per week for 12 months
45994423|NCT00535977|Dietary Supplement|Peas|400g frozen garden peas per week for 12 months
45994424|NCT05342077|Behavioral|Virtual Reality-Reward Training (VR-RT)|Participants will complete verbal recounting (present-tense, field perspective, positive details) and guided imaginal recounting of positive details for rewarding VR experiences and positive autobiographical memories.
45994425|NCT05342077|Behavioral|Virtual Reality-Memory Training (VR-MT)|Participants will complete verbal recounting (past-tense, observer perspective, objective details) and guided imaginal recounting of neutral details for neutral VR experiences and neutral autobiographical memories.
45994426|NCT05468333|Other|Cigarette trial|Per NIH Program Official, this is not an ACT and thus full protocol info is not required at this time (and would be detrimental to the study if details were disclosed during recruitment).
45994427|NCT00596518|Drug|PF-00734200|The drug is administered as a single dose of four 5-mg tablets
46084788|NCT01816152|Other|Tailored Active intervention|Subjects experience a baseline for 1 week and an active intervention for 4 weeks. The active intervention is a bluish white light source delivering at least 300 lux at the eye of the patient during at least 2 hours daily.
46084789|NCT01816152|Other|Inactive intervention|Subjects experience a baseline for 1 week and an inactive intervention for 4 weeks. The inactive intervention is a yellowish white light source delivering at most 50 lux at the eye of the patient during at least 2 hours daily.
46084790|NCT02769494|Drug|Mesalazine Sustained-Release Tablets|Mesalazine sustained-release tablets 500mg and 0.02L glycerol mixed, the preparation of 2.5% the mesalazine glycerol suspension liquid, gently apply to the ulcer surface, 3 times/day. The application time of the drug is 8:00,12:00, 16:00. Daily 20:00 measure the size of the mouth ulcers and record the symptoms in the diary card.
46084791|NCT02769494|Drug|Riboflavin Sodium Phosphate Injection|gently apply the riboflavin sodium phosphate injection to the ulcer surface, 3 times/day. The application time of the drug is 8:00,12:00, 16:00. Daily 20:00 measure the size of the mouth ulcers and record the symptoms in the diary card.
46084792|NCT04334772|Device|Muscle belly Microelectrolysis|three applications of direct current at 600 µA interrupted by intervals of 30 seconds between application at the level of the muscular belly of the shortened hamstrings.
46084793|NCT04334772|Device|Tendon Microelectrolysis|three applications of direct current at 600 µA interrupted by intervals of 30 seconds between application in the tendon of the shortened hamstrings.
46084794|NCT04334772|Other|Stretching exercises|5 sets of passive static hamstring stretches using the straight leg extension (SLR) test for a time of 30 seconds and interval of 30 seconds for each
46084795|NCT02765516|Other|Plant sterols|2.0g/day of plant sterols incorporated into margarine to be consumed for 28 days
46084796|NCT02765516|Other|Placebo|Identical margarine without additional plant sterols to be consumed for 28 days
45834038|NCT00633984|Behavioral|Cognitive Behavioral Group Therapy (CBGT)|The patient will then receive 12 weekly sessions of Cognitive Behavioral Therapy lasting approximately two and a half hours each. During these sessions, patients will receive information on the nature of social phobia and a model of treatment and will receive weekly training in how to become more comfortable with social situations, with the goal of achieving confidence in social interactions. As part of this training, the therapist will practice social interactions with the patient, who will also be asked to practice what they have learned outside of the therapists' office.
46084797|NCT05131971|Drug|GSK3888130B|GSK3888130B will be administered.
46084798|NCT05131971|Drug|Placebo|Placebo will be administered.
46084799|NCT04669223|Device|Seldinger chest drain insertion|Different sizes of chest drain will be inserted with seldinger technique
46084800|NCT00614562|Device|Neurally adjusted ventilatory assist (NAVA)|NAVA for 72 hours
45457075|NCT03924505|Behavioral|Implementation Manual with External Facilitation Intervention|Participating organizations will receive the implementation manual and the external facilitation (EF) intervention. The manual provides instructions for organizations wanting to implement a high quality naloxone program. The EF will assist syringe service programs to integrate naloxone delivery within their organization. As part of these efforts, we will use a measurement framework to understand naloxone delivery within SSPs along the four phases of the implementation process-exploration, preparation, implementation and sustainment (EPIS).
45834039|NCT00633984|Drug|D-Cycloserine|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a 50mg pill of d-cycloserine. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
45994428|NCT00536016|Drug|JSM6427|Weekly intravitreal injections for up to 4 weeks, first dose strength is one dose below the MTD. Dose strength concentrations: 1.5 mg/ml, 3 mg/ml, 7.5 mg/ml 04 15 mg/ml.
45994429|NCT00596557|Drug|everolimus|reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
45994430|NCT04326556|Other|Prospective cohort for etiological and prognostic purposes|Subjects benefit from a standardized, comprehensive geriatric evaluation in accordance with the recommendations of good practice during a geriatric consultation. It is completed by a measurement of the gripping force using a dynamometer and a measurement of the respiratory parameters (vital capacity) using a spirometer. The following acts are added to the consultation: the completion of questionnaires, a semi-directed interview focused on the perception of air pollution, the wearing on the chest for one week of an individual mobile physiological signal sensor (DM with CE marking) and the wearing (on the belt or in a bag) for one week of a portable device with two air pollution sensors.
45994431|NCT00596596|Drug|prucalopride|0,5 mg once daily
45994432|NCT00596596|Drug|prucalopride|1 mg once daily
45994433|NCT00596596|Drug|2 mg prucalopride|2 mg once daily
45994434|NCT00596596|Drug|4 mg prucalopride|4 mg once daily
45994435|NCT00596596|Other|Placebo|placebo once daily
45994436|NCT05468294|Drug|F16IL2|F16IL2 infusion will be always administered in 180 minutes i.v. on day 1, 8, 15 and 22 of each 28-days cycle.
45994437|NCT05468294|Drug|Nivolumab, fixed dose|Patients will receive 3 mg/kg of Nivolumab as a 60 minutes i.v. infusion on day 1 and day 15 of each 28-days cycle.
45994438|NCT00596674|Behavioral|Lifestyle Counts|8 weeks of classes focused on health behavior change, individualized goal setting and 3 months of follow-up phone support
45994439|NCT00596674|Other|Attention Control|8 weeks of classes on general health information topics followed by 3 months of phone calls to solicit questions
45994440|NCT02892175|Procedure|Advance Directives on End of Life|after information transmitted orally by the doctor (Dr P.Priollet) and agreement of the patient to participate, patients will be interviewed (Questionary) and data collected during visits to consultations City office of Dr. Priollet by Dr. Priollet assisted by Mrs. Helena Sanson (internal medicine), anonymized and handled within the vascular medicine department of Dr. Priollet to GHPSJ.
45457076|NCT03924505|Behavioral|Implementation Manual only|Participating organizations will receive the implementation manual.The manual provides instructions for organizations wanting to implement a high quality naloxone program.
45994441|NCT00536588|Genetic|SCH 721015 with SCH 209702|Each subject receives a single intravesical administration of SCH 721015 with SCH 209702 at dose levels of 1 x 10^9 to 3 x 10^11 particles/mL (based on assessment of tolerability, intermediate dose levels may be used).
45994442|NCT00596791|Drug|tafluprost|prostaglandine analoque
45674662|NCT01856673|Behavioral|Common Elements Treatment Approach|It was developed for treating symptoms related to violent trauma, i.e. symptoms of depression, anxiety and distress, among a population victimized by violence and torture in Colombia. The most relevant components for treatment of these 3 problematic issues were identified from literature review and a panel of experts. Descriptions and schemes have been developed in order to guarantee facility of use by community counselors who have little background in mental health skills. These counselors, who will be called Lay Psychosocial Community Workers (LPCW), will receive training in this technique before beginning of interventions. Application of this technique will be supervised constantly by mental health professionals (psychologist or social worker) from the project team.
45994443|NCT05312866|Procedure|Standard analgesia (paracetamol +fentanyl)|Patients will receive standard analgesia (paracetamol 15mg/kg plus fentanyl 1ug/kg) iv
45994444|NCT05312866|Procedure|Retrolaminar block with bupivacaine + magnesium sulfate + dexamethasone|Patients will receive intraopertative retrolaminar block: 15 ml of bupivacaine 0. 25 % plus 2ml magnesium sulfate 10% (200mg) plus 2ml (8mg) dexamethasone on each side by slipping the needle of injection on the bone of spinous process and lamina.
45994445|NCT05470803|Biological|AstraZeneca/Fiocruz|4th dose of SARS-CoV-2 vaccine
45994446|NCT05470803|Biological|Pfizer/Wyeth|4th dose of SARS-CoV-2 vaccine
45994447|NCT05470803|Biological|Clover SCB-2019|4th dose of SARS-CoV-2 vaccine
45994448|NCT00622960|Other|High-MUFA diet|The effects of high monounsaturated fat diet on body weight, body composition, lipid profile, and glycemic control.
45994449|NCT00622960|Other|High-CHO diet|The effects of high carbohydrate diet on body weight, body composition, lipid profile, and glycemic control.
45994450|NCT05468255|Other|removal of exercise|Subjects will stop doing their normal exercise routines for 3 or 5 days and then subjects will resume doing their normal exercise routines for 3 days.
45994451|NCT04326790|Drug|Colchicine|Low-dose colchicine treatment, 0.5 mg bid
45457077|NCT03929341|Diagnostic Test|Coronary Computed Tomography Angiography (CCTA)|Cardiac imaging test that is able to detect changes is cardiac vessels and the heart.
45994452|NCT04326790|Drug|Standard treatment|Standard treatment
45994453|NCT05468177|Combination Product|neoadjuvant chemotherapy|"Cetuximab: 500mg/m2,day1, every 2 weeks. mFOLFOX: oxaliplatin 85mg/m2, day 1;LV 400mg/m2, day 1;5-FU 400mg/m2, day 1, then 1200mg/ (m2•d) ×2days(total 2400mg/m2, infusion 46-48h) (every 2 weeks).~Anti-PD-1(Sintilimab Injection):200mg every 3 weeks. Surgery will be performed after 4 cycles for locally advanced or initially resectable metastatic right colon cancer.If the initial unresectable metastatic right colon cancer were converted into resectable metastases, and surgery will be performed. Patients who failed to convert after 6 cycles of treatment will be withdrawn from the study.Cetuximab +mFOLFOX was treat for 8 cycles, and Anti-PD-1 was treated for one year in the perioperation period unless disease progression, toxicity intolerance, initiation of new anti-tumor therapy."
45994454|NCT00596986|Drug|Duloxetine|Duloxetine 30mg up to 120mg per day.
45994455|NCT00596986|Behavioral|Cognitive Behavioural Analysis System of Psychotherapy|Cognitive Behavioural Analysis System of Psychotherapy (CBASP): 20 sessions of psychotherapy, beginning with twice weekly, then weekly sessions.
45994456|NCT00597025|Dietary Supplement|Protein Food Bar Intelligent Indulgence|Patients will be given one protein bar at each dialysis treatment, 3 times per week for 3 months
46002355|NCT03555279|Behavioral|PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm|HIV Prevention Behavioral Health Intervention delivered by Probation Staff
45457078|NCT03929341|Other|Cardiac Link|Clinical patient flow pathway that will enable radiologist to activate expedited cardiology referral for patients who exhibit clinically significant changes during CCTA.
45994457|NCT00597025|Dietary Supplement|Protein Food Bar Intelligent Indulgence|Patients will be given 7 bars per week. In addition to the the three bars given on Hemodialysis each week, the patients will be given on the first treatment of the week four protein bars to be eaten on non-dialysis days
45994458|NCT00597025|Dietary Supplement|Protein Food Bar Intelligent Indulgence|Patients will be given a monthly supply of protein bars to provide for daily intake of one protein bar.
45994459|NCT04326517|Procedure|Nephrectomy|Different therapeutic options are described in literature for emphysematous pyelonephritis. In our center, medical treatment (no invasive procedure), ureteral stent (endourologic procedure), percutaneous drainage (minimally invasive procedure), and nephrectomy are the therapeutic options for this disease.
45994460|NCT00597064|Drug|prednisone|oral prednisone 40 mg/day for 15 +/- 5 days
45994461|NCT00536627|Biological|DNA vaccine pCMVS2.S|Patients will receive injections of 1 ml of vaccine (1 mg/ml) at weeks 0, 8, 16, 40 and 44
45994462|NCT00597103|Other|Cognitive Function Testing-10 Tests|Trailmaking A, Trailmaking B, Rey Auditory Verbal Learning, Letter Number Sequencing, Digit Symbol Substitution, Grooved Pegboard, Controlled Oral Word Association, Beck Depression Index, Feeling Thermometer, Modified Mini-Mental Status
45994463|NCT00597103|Other|Sleep Assessment Testing|"Sleep Assessment will be performed using an Actiwatch with subjects wearing the watch for 72 hours continuously"
45994464|NCT00597103|Other|Periodic Leg Movement Syndrome Assessment|"Subjects will wear and Actiwatch on both legs for three consecutive nights."
45994465|NCT00597142|Device|Express™ Renal Premounted Stent System|"This device is indicated for use as an adjunct to percutaneous transluminal renal angioplasty (PTRA) of a:~Single, de novo or restenotic (from PTRA) atherosclerotic lesion in the ostium of the renal artery~Lesion length ≤15mm~Lesion involving the aortorenal ostium or the leading edge of the stenosis is located within 5 mm of the opacified aortic lumen~RVD 4.0-7.0mm"
45994466|NCT02909595|Device|Balloon catheter|Balloon stone extraction was carried out with a balloon catheter [Extractor Pro RX [M00547000, M00547010, or M00547020]; Boston Scientific,Shang hai,China). The Extractor Pro has multiple sizes (9-12, 12-15, and 15-18mm), the choice being made on the basis of the CBD diameter. It has a contrast-injection hole above the balloon for the performance of balloon occlusion cholangiography (BOC).
45994467|NCT02909595|Device|Basket catheter|Basket stone extraction was performed with a basket catheter (Flower Basket V [FG-V435P or FG-V425PR]; Olympus Corp., Shang hai,China).
45994468|NCT04326712|Other|conventional manufactured socket|Presssure disturubition will be measured in conventional manufactured socket during walking and stairing up and down activities in unilateral transtibial amputees
45994469|NCT04326712|Other|3D manufactured socket|Presssure disturubition will be measured in 3D manufactured socket during walking and stairing up and down activities in unilateral transtibial amputees
46084801|NCT02765438|Device|BOBO|"Each subject will play four games with the BOBO system."
46084802|NCT02769572|Other|real moxibustion|3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
46084803|NCT02769572|Drug|placebo gel|4 grams per knee, 4 times per day, for 4 weeks
46084804|NCT02769572|Drug|diclofenac sodium gel|4 grams per knee, 4 times per day, for 4 weeks
45457079|NCT04464694|Drug|Ranibizumab|Patients will receive single intravitreal injection of Ranibizumab 0.5 mg 3~7 days before vitrectomy.
45457080|NCT04464694|Other|Sham injection|Patients will receive single sham injection 3~7 days before vitrectomy.
45457081|NCT04464694|Procedure|Pars plana vitrectomy|Surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina
45994470|NCT04326595|Procedure|surgical and medical evacuation|surgical evacuation:the dilation of the cervix and surgical evacuation of the uterus (potentially including the fetus, placenta and other tissue) medical evacuation: induction of abortion by the use of ecbolics
45994471|NCT00597181|Procedure|Trabeculectomy with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
45994472|NCT00597181|Procedure|Ex-Press mini shunt with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
45457082|NCT03924349|Device|ICG-coated clip|Tumor localization using ICG-coated clip prior to surgery
45457083|NCT02292628|Drug|Infusion of mesenchymal stem cells from adipose tissue|
45457084|NCT02292628|Other|Infusion of placebo|
45457085|NCT03924271|Diagnostic Test|Iron deficiency testing|Blood sample for complete iron status
45457086|NCT01130779|Drug|Erlotinib (TARCEVA®)|Erlotinib 150mg/day, everyday
45457087|NCT03513484|Drug|Azacitidine|Given IV or SC
45457088|NCT03513484|Other|Laboratory Biomarker Analysis|Correlative studies
45457089|NCT03513484|Drug|Nintedanib|Given PO
45994473|NCT00597220|Dietary Supplement|Omega 3 (n-3 PUFA)|1 gram of n-3 PUFA containing DHA and EPA
45994474|NCT00597220|Drug|Placebo|Placebo
45994475|NCT02892097|Device|tDCS|tDCS is a form of noninvasive brain stimulation. Electrodes are placed on the scalp (parietal or primary motor cortex) and deliver a low level of direct current (2mA). tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
46084805|NCT02769572|Other|sham moxibustion|3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
46084806|NCT02669823|Other|None, treatment as actual best practice|
46084807|NCT02769338|Other|Quality Improvement Program|The Intervention is a QI Program that will include multiple components as described above.
46084808|NCT02669589|Drug|Heparin|
46084809|NCT02669589|Drug|Citrate|
46084810|NCT00635336|Biological|MPHOSPH1 and DEPDC1|DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.
46084811|NCT02765204|Drug|Dapagliflozin|
46084812|NCT02765204|Drug|Saxagliptin|
46084813|NCT02765204|Drug|Glucose|
46084814|NCT00910377|Behavioral|counseling sessions|The intervention groups received counseling sessions about breastfeeding and complementary feeding at maternity ward and at home with 7,15,30,60 and 120 days.
45994476|NCT02892097|Device|sham tDCS|Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
45994477|NCT02892097|Behavioral|Repetitive task-specific practice (RTP)|Participants will practice using their paretic arm/hand to complete functional movements during each (3) 30 minute training session.
45994478|NCT00597259|Drug|Pegasys plus Entecavir|Pegasys 180 mcg in 0.5 mL solution administered sc once weekly for 24 weeks plus entecavir (0.5mg mg/capsule) 0.5 mg administered po daily for 24 weeks
45994479|NCT00597259|Drug|Entecavir|ETV 0.5 mg daily monotherapy for 144 weeks
45994480|NCT05468060|Drug|PA1010|Placebo as control
45674663|NCT01856673|Behavioral|Narrative Community Group Therapy|It consists on teaching skills to people in the community to provide mental health therapy. Therapy will be performed by LPCW under constant supervision of mental health professionals (psychologists or social workers). Sessions will begin with a series of introductory activities that motivates participants to propose different problems that they would like to solve in the group. A participant proposed a problem and he/she will be asked to talk about it. LPCW and/or psychologist will support individuals if anyone needs help to solve a psychological crisis. At the end of this narration, participants will be asked about who has had a similar situation, and how they solved it. In this way, proposed solutions will be collected by the LPCW. Finally, session closes with a motivating activity.
46084815|NCT02765282|Device|Algorithm based programming using Kinesia-based assessment|DBS-Expert includes a tablet-based software application (app) for guiding DBS programming and a Kinesia motion sensor unit for automated motor assessment. Algorithms search the programming parameter space to resolve an optimal set of programming parameters.
46084816|NCT04175223|Dietary Supplement|Vivomixx|probiotic administration: administration of two sachets per day (one in the morning and one in the evening) during 6 months
46084817|NCT03342456|Drug|Doxycycline Hyclate Enteric-Coated Capsules|group 1,0.1g*10 capsules/box, produced by Yung Shin Pharm.Ind.(Kunshan) Co.,Ltd.
46084818|NCT03342456|Drug|Amoxicillin Capsules|group 2,0.5g*24 capsules/box, produced by United Laboratories（Zhuhai）
46084819|NCT03342456|Drug|Ilaprazole Enteric-Coated Tablets|group 1 and group 2,5mg*6 capsules/box, produced by Livzon Pharmaceutical Group Inc
46084820|NCT03342456|Drug|Furazolidone Tablets|group 1 and group 2,0.1g*100 tablets/bottle,produced by Shanxi Yunpeng Pharmaceutical co.,Ltd.
46084821|NCT03342456|Drug|Potassium Citrate Tablets|group 1 and group 2,110mg*40 tablets/bottle,produced by Livzon Pharmaceutical Group Inc
45457090|NCT03740269|Other|oral health educational program|poster education about the important of oral health status, different brushing technique, different tooth paste, the balanced diet, changes occur to their mouth during the puberty period
45674664|NCT01856673|Other|Standby group|Standby group: they will be assessed at baseline with the initial survey and they will wait between 10 and 12 weeks; an exit assessment will be performed with the study instrument. After the exit survey, control group participants will have an appointment with a professional psychologist to determine whether they require a mental health treatment. Those with such necessity will receive treatment in the ACOPLE center by professional psychologists or they will be referred to other health care level according to the type of psychopathology (e.g., psychosis) or its severity. Also, participants in the control group will be monitoring monthly by phone calls and if they have any psychological problem, they will be assessed in the ACOPLE center.
45674665|NCT02095951|Drug|Ethanol lock therapy (ELT)|Participants will be randomized to receive early (preemptive) ELT (after 12 hours from time blood culture drawn, but before blood culture positive, R/O sepsis) with systemic antimicrobials versus standard ELT (placed in catheter when blood culture is positive for growth of a germ) with systemic antimicrobials.
45674666|NCT02095873|Dietary Supplement|Glyoxalase 1 (Glo1) inducer|Dietary bioactive
45674667|NCT02095873|Dietary Supplement|Placebo|Mannitol, 108 mg
45674668|NCT02094937|Drug|Fluticasone Furoate/Vilanterol|FF/VI 100mg/25 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
45674669|NCT02094937|Drug|Fluticasone Furoate 100 mcg|FF 100 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
45674670|NCT02094937|Drug|Fluticasone Propionate 250 mcg|FP 250 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
45834040|NCT00633984|Drug|Placebo|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a placebo. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
45834041|NCT04395612|Drug|niraparib combined with brivanib|Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Brivanib will be administered as a dose of 400mg orally every day.
46084822|NCT02669199|Biological|MSCs|The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects
46084823|NCT04224662|Other|No intervention|There is no intervention for this study
46084824|NCT05106413|Other|BiCROS fitting|Each participant will be fitted with the experimental CROS device on the poorer, unaidable ear and with a compatible hearing device on the other ear.
46084825|NCT05106413|Other|Monaural fitting|"Each participant will be fitted with a hearing aid on the better hearing ear and no device on the poorer, unaidable ear.~Monaural hearing aid fitting acts as control intervention."
45834042|NCT04395612|Drug|niraparib combined with toripalimab|Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Toripalimab will be administered as a dose of 240mg Intravenously every 21days.
45834043|NCT01923558|Drug|Donepezil|Donepezil Hydrochloride tablets,23 mg
45834044|NCT01920048|Procedure|Percutaneous Coronary Intervention|
46084826|NCT05106413|Other|Unaided condition|"No treatment, i.e. the participants are not fitted with a CROS device and/ or hearing aid.~Unaided condition acts as control intervention."
45457091|NCT03519724|Drug|Sugammadex|Reversal of deep NMB
45457092|NCT03519724|Drug|Neostigmine|Reversal of moderate NMB
46002356|NCT03555279|Behavioral|PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm|HIV Prevention Behavioral Health Intervention delivered by Youth Representatives
46002357|NCT03548467|Biological|VB10.NEO|VB10.NEO is a vaccine and is supplied as a sterile, ready to use solution (14 vaccinations will be given).
45457093|NCT02292862|Procedure|Lymph node and blood sampling|"By bipolar dissection 1 portal and 1 mesenteric lymph node are removed from the infant.~Blood (1ml) is taken from mother and infant."
45457094|NCT03516916|Other|Questionnaires on HRQoL and sociodemography|All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.
45457095|NCT01131091|Drug|SK-0403|SK-0403 400 mg
45457096|NCT02293018|Drug|0.75% (w/w) MTC896 Gel Once Daily|
45457097|NCT02293018|Drug|0.75% (w/w) MTC896 Gel Twice Daily|
45457098|NCT02293018|Drug|1.5% (w/w) MTC896 Gel Once Daily|
45457099|NCT01228201|Behavioral|Moderate continuous training|Three training sessions per week in a total of 12 weeks
45457100|NCT01228201|Behavioral|Aerobic interval training|Three training sessions per week in a total of 12 weeks
46084827|NCT05106413|Other|CROS baseline|"Each participant will be fitted with the experimental CROS device on the poorer, unaidable ear and with a compatible device on the other ear. The difference to the BiCROS condition is the setup of the microphones in the CROS device and the compatible hearing device.~This test condition is only tested for speech intelligibility in diffuse noise and acts as control intervention."
45674671|NCT02094937|Drug|Fluticasone Propionate 100 mcg|FP 100 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
45674672|NCT02094937|Drug|Fluticasone Furoate Placebo|Matching placebo of Fluticasone Furoate will be given once daily in the evening via dry powder inhaler
46084828|NCT02765048|Behavioral|GAIN Program|Receives GAIN, a 10-session program that incorporates cognitive behavioral therapy skills in a group format to address symptoms of trauma such as PTSD and depression related to histories of child maltreatment. GAIN includes the following elements: 1) assertive communication skills and relationship boundaries, 2) understanding the connection between feelings, thoughts, and behaviors, 3) increased personal confidence, 4) how to have healthy relationships and personal safety, and 5) how to cope with stress and anxiety.
46084829|NCT03462576|Combination Product|Methacetin Breath Test|A breath analyzer will be used to measure changes in carbon 12 to carbon13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.
46084830|NCT03462576|Drug|Emricasan|Investigational drug for NASH treatment in Main Conatus protocol
45674673|NCT02094937|Drug|Fluticasone Propionate Placebo|Matching placebo of Fluticasone Propionate will be given twice daily (morning and evening) via dry powder inhaler
45674674|NCT04724629|Biological|Ixekizumab|80 mg of IL-17 inhibitor
45674675|NCT04724629|Biological|Aldesleukin|1.5 million IU (low-dose) of IL-2
45834045|NCT01920048|Drug|Drug Therapy for Heart Failure|The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines
45834046|NCT01920048|Device|Device Therapy for Heart Failure|The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.
46084831|NCT03462576|Drug|Placebo oral capsule|Placebo versus emricasan in Conatus NASH treatment trial
46084832|NCT02669277|Drug|IVIG prepared by minipool technology|Drug: To demonstrate the efficacy of new product IVIG prepared by minipool technology as assessed by Bleeding Score and platelet count at 3 days, 1 week, 2 weeks and 4 weeks.
46084833|NCT02669277|Drug|standard IVIG product|to compare efficacy and safety with the minipool IVIG
46084834|NCT02769104|Drug|Letrozole (Aromatase Inhibitors)|Letrozole (Aromatase Inhibitors) for 5 years
46084835|NCT02769104|Drug|AC*4-T*4|CTX800mg/m2 d1+Anthracyclines75mg/m2 d1, every 3 weeks*4 cycles, be sequential with Docetaxel 75mg/m2 d1, every 3 weeks*4cycles
46084836|NCT02545842|Drug|INSULIN GLARGINE|"Pharmaceutical form: solution~Route of administration: subcutaneous"
46084837|NCT00645255|Drug|placebo|placebo one capsule daily
45834047|NCT01926990|Device|perfusion computed tomography|Undergo perfusion CT
45834048|NCT01923480|Drug|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
45834049|NCT01923480|Drug|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
46002358|NCT03548467|Drug|Bempegaldesleukin|0.006 mg/kg bempegaldesleukin (NKTR-214) will be administered intravenously q4w for up to 11 doses starting from week 11 or at any dosing visit up to week 34 and for up to week 50 (up to 11 doses). The first 2 doses will be in a Q3W interval and following doses in Q4W intervals.
46084838|NCT00645255|Drug|sibutramine or placebo|one capsule daily
46084839|NCT04679012|Drug|Polatuzumab Vedotin|Polatuzumab vedotin will be administered as an IV infusion at 1.8mg/kg on Day 1 of each cycle, every 21 days.
46084840|NCT04679012|Drug|Rituximab|Rituximab will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
46084841|NCT04679012|Drug|Etoposide|Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
45457101|NCT03920449|Drug|Botulinum Toxins|In group I (BT injection), 21 U will be injected in 3 divided doses through the internal anal sphincter at 3,9, and 12 o'clock. In the Egyptian market two commercial forms are available; botulinum toxin type A (Botox 100 IU/vial; Coolock, Dublin, Ireland), and abobotulinumtoxin A (Dysport 500 U/vial; Ipsen Biopharm Ltd, Wrexham, UK). In case of Dysport it should be remembered that dosing is on a ratio of approximately 1 to 3, meaning that 50 IU of Botox have the same effect as 150 IU of Dysport.
45457102|NCT03920449|Procedure|Posterolateral internal sphincterotomy|In group II (PIAS), A 1.5 to 2-cm circumferential skin incision will be placed at 5 o'clock position outside the anal verge using an electrocautery device. Dissection will be proceeded through the intersphincteric groove to separate both IAS and external anal sphincter (EAS). Then, the IAS will be identified by its characteristic white fibers, separated from the anal mucosa, and assessed under direct vision. Subsequently, about 50 % of the IAS will be divided at 5 o'clock position and any skin tags or hypertrophied anal papillae will be removed leaving the skin incision open to allow drainage.
45834050|NCT01923480|Drug|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
45994481|NCT02892253|Device|Near Infrared Camera (NIR)|Surgical field is examined with NIR, during a few minutes (<5') with room lights switched off, to avoid parasite lights, then open thyroidectomy is resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, are checked visually. NIR consists of a 750 nm class 1 laser excitation, with a power <20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international standard IEC 60601-2-41). It is provided by the Fluobeam® camera, which is inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 2A device).
45994482|NCT05470764|Drug|PERINDOPRES® TRIO, 8 mg perindopril tert-butylamine / 2.5 mg indapamide / 10 mg amlodipine tablets|Oral, generic fixed-dose combination of perindopril tert-butylamine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
45994483|NCT05470764|Drug|TRIPLIXAM® 10 mg /2.5 mg/10 mg, 10 mg perindopril arginine / 2.5 mg indapamide / 10 mg amlodipine film-coated tablets|Oral, innovative fixed-dose combination of perindopril arginine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
46084842|NCT04679012|Drug|Prednisone|Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
46002359|NCT03525990|Other|Questionnaires|Quality of life questionnaires on iPads with CHES (Computer-based Health Evaluation System), paper-based questionnaire (EORTC QLQ-COMU26)
46084843|NCT04679012|Drug|Cyclophosphamide|Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
46084844|NCT04679012|Drug|Hydroxydaunomycin|Hydroxydaunomycin will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
46002360|NCT03490669|Biological|MSC-1|humanized monoclonal antibody for intravenous administration
46084845|NCT00910455|Drug|SRX246|single oral dose of SRX246 capsule
45994484|NCT00597298|Device|Threshold|Inspiratory muscle training program using a variable pressure device. An inspiratory muscle training device comprises a chamber having an opening for the passage of air to be inhaled and exhaled, and an inlet permitting air to be inhaled to enter the chamber and to pass to the opening. A one-way exhaust valve permits exhaled air entering through the opening to escape from the chamber, and another valve is provided to resist the entry of air to be inhaled into the chamber, the latter valve serving to vary the degree of resistance in dependence upon the volume of air that has passed through the inlet.
45994485|NCT00597298|Device|sham threshold|non-training physical activity
45994486|NCT04320550|Diagnostic Test|abdominal ultra sound|non invasive tests to exclude pathological causes
45994487|NCT05271019|Device|Threshold load device|"Inspiratory Muscle Training (IMT) for 3 months:~Though a threshold loading device (5 sets of 6 repetitions, 1session/day, 5 days/week). the inspiratory load will start at 30% of MIP, or up to the maximum patient-tolerable load (max 60% of MIP), no more than 3-5/10 on the modified Borg scale."
45994488|NCT05470725|Drug|CIN-107|A single 10 mg CIN-107 oral dose (2 X 5 mg tablets).
45994489|NCT04326634|Other|controlled exercises|controlled exercises
45994490|NCT04326634|Other|non controlled exercises group|non controlled exercises
45994491|NCT00597337|Behavioral|FearNot|Behavioral: Three sessions of FearNot!v.2.0 software interaction over a three-week period (each session lasting approximately 30 minutes)
45994492|NCT00597415|Drug|celecoxib|celecoxib 200mg
45674676|NCT04724629|Drug|Colchicine|0.5 mg of indirect IL-6 inhibitor
45994493|NCT00597415|Drug|placebo|placebo
45457103|NCT02295514|Biological|PTP1B dosage|PTP1B sampled and dosed during sepsis
45674677|NCT04724629|Drug|Standard of care (SOC)|Active comparator (Corticoids and antiretrovirals)
45994494|NCT00597454|Other|Patient Navigation|"we will conduct a detailed analysis of how the patient navigators' time is actually utilized by having them record a detailed log categorizing their activities as it relates to the elimination of recognized barriers to care. Second, we will measure the time interval from receipt of a suspicious mammogram to appropriate diagnostic evaluation and or treatment.~We will measure the number of women who experience diagnostic and or treatment delay and whether the presence of a Patient Navigator enables delivery of coordinated care that avoids delays. Third, we will measure patients' satisfaction with aspects of their care, focusing particularly on care coordination using validated instruments designed for this purpose."
45994495|NCT04686110|Other|angiographic optical coherence tomography|angiographic optical coherence tomography
45994496|NCT00597532|Dietary Supplement|Soy|soy (soy protein supplementation 50 grams/day)
46084846|NCT00910455|Drug|Placebo|Single oral dose of placebo capsule
46084847|NCT05086679|Device|Compression Stockings with 25-30 mm Hg pressure|The group will have compression stockings with 25-30 mm Hg pressure. All the participants' size for compression stocking will be measured at the first visit. Three points will be measured: below and above their knees and above their ankle. Subsequently, Right Arian Farmed Co (Tehran, Iran) will provide compression stockings for patients based on their sizes. Participants will be asked to use compression stockings as long as they could (ideal would be the majority of the time they are upright). In addition, a CD included some videos and booklets about instructions on how to wear CS and how to keep them will be provided for the participants with their compression stockings.
46084848|NCT05086679|Device|Compression stockings with up to <=10 mm Hg pressure|The group will have compression stockings with up to 10 mm Hg pressure. All the participants' size for compression stocking will be measured at the first visit. Three points will be measured: below and above their knees and above their ankle. Subsequently, Right Arian Farmed Co (Tehran, Iran) will provide compression stockings for patients based on their sizes. Participants will be asked to use compression stockings as long as they could (ideal would be the majority of the time they are upright). In addition, a CD included some videos and booklets about instructions on how to wear CS and how to keep them will be provided for the participants with their compression stockings.
45674678|NCT04724395|Other|Hospitalization|Hospitalization in intensive care and non-intensive care units for COVID-19 followed by usual care
45674679|NCT04723537|Drug|Part A: Upamostat 200 mg|1 capsule comprising 200 mg of upamostat and 1 capsule comprising matching placebo.
45994497|NCT00597532|Dietary Supplement|Milk|placebo (milk protein supplementation 50 grams/day)
45994498|NCT05470686|Biological|blood gas via arterial catheter|Patients will have a blood sample plus a lung ultrasound before and after the physical therapy session combined with non invasive ventilation the morning after the heart surgery
45994499|NCT00597610|Other|Transrectal ultrasound 3-D (TRUS)|Transrectal ultrasound (TRUS) is widely accepted as an accurate and effective technique for staging of rectal cancer. The decision to administer pre-operative chemotherapy/radiation therapy is often made based on the results of the TRUS. Three-dimensional TRUS (3-D TRUS) is a new modality that provides all of the information of traditional TRUS as well as the ability to provide three dimensional views of the tumor.
45994500|NCT00597649|Drug|Bicifadine|SR dosage form of 400 mg bid or tid for one year
45994501|NCT04686032|Other|Advanced early Rehabilitation Program|Patient education, Ambulation, In bed exercises, Deep breathing exercises: (5 rep x 3set), Connective tissue manipulation for intestinal motility (5 min) and TENS* for incisional pain (30min)
45994502|NCT04686032|Other|Early ambulation|Patient education & Assisted ambulation out of bed including walking away from bedside for at least 15 min gradually moving to Unsupervised ambulation for 30 min
45994503|NCT00597688|Drug|Chlorhexidine gel|Oral mucosal application of chlorhexidine gel
45994504|NCT00597688|Drug|Placebo gel|Oral mucosal application of placebo gel
45994505|NCT00597844|Other|voice evaluation and fMRI|will undergo voice evaluation and fMRI prior to surgical rehabilitation of UVCP and in approximately one month and six months following treatment.
45994506|NCT00597844|Other|undergo voice evaluation and fMRI prior|in approximately one month and six months
45994507|NCT05467982|Behavioral|Integrated Illness Management and Recovery|Education and skills training groups on illness management of chronic medical and psychiatric illness. Subsample of 75 will also receive COVID-specific Integrated Illness Management and Recovery module.
45994508|NCT05467982|Behavioral|Chronic Disease Self-Management Program|Education and skills training groups on illness management of chronic conditions
45994509|NCT05470530|Drug|Dexamethasone|Dexamethasone was given either intrathecal or intravenous in spinal anesthesia during ceaseran section while normal saline was given in control group
45994510|NCT00598000|Behavioral|questionnaires|"QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits."
45994511|NCT00598000|Behavioral|questionnaires|"QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits."
45994512|NCT02909517|Other|cSLO imaging|
45994513|NCT02891902|Other|hygienist response|The daily presence of a public health nurse in the intensive care unit would implement such a strategy for prevention of infections and reduce the incidence of bloodstream infections acquired in intensive care.
45994514|NCT00598117|Behavioral|Questionnaires|"Newly diagnosed patients will be assessed at four points Time 1 (prior to treatment)~Initial QOL form~FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 2 (initial post-op)~Follow up QOL form~FACT-E, PAR, Symptom Assessment Scale, MDSS Time 3 (6 months post op)~Follow up QOL form~FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 4 (1 year post op)~Follow up QOL form~FACT-E, PAR, Symptom Assessment Scale, MDSS"
45994515|NCT02891980|Biological|Ad26 Zaire Ebola Vaccine|A recombinant adenovirus vector comprising a polynucleotide encoding a filovirus antigenic protein, wherein the recombinant adenovirus vector comprises an adenovirus 26 capsid protein.
45834051|NCT01921218|Drug|Belatacept|Belatacept, dosing 10mg/kg- day 0, 2 weeks, 1 month, 2 months, 3 months; subsequent doses 5mg/kg monthly through duration of trial or until retransplantation, whichever is first.
45994516|NCT02891980|Biological|MVA Multi-Filo Ebola Vaccine|A multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus.
45994517|NCT00536666|Drug|Iron oligosaccharide|
45834052|NCT01921218|Drug|Calcineurin inhibitor therapy|Upon enrollment, wean calcineurin inhibitor (CNI) to target tacrolimus trough of 3-5 nanogram/milliliter (ng/ml)or equivalent cyclosporine trough. Upon initiation of hemodialysis, discontinue CNI therapy over 5 days.
45834053|NCT01921218|Drug|Mycophenolate mofetil|Continue current dose at enrollment. Upon initiation of dialysis, decrease dose by half, then discontinue 2 weeks later
45834054|NCT01921218|Drug|prednisone|Begin steroid withdrawal one month after initiation of dialysis, with monthly reduction in dose by half, with plans to discontinue prednisone by 3 months after initiation of dialysis
45834055|NCT03129828|Drug|Ibrutinib and Bortezomib + R-CHOP|A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. for individuals < 65 years and 420 mg p.o. for individuals ≥ 65 years (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
45834056|NCT01922076|Drug|Adavosertib|Given PO
45834057|NCT01922076|Other|Laboratory Biomarker Analysis|Correlative studies
45834058|NCT01922076|Other|Pharmacological Study|Correlative studies
45834059|NCT01922076|Radiation|Radiation Therapy|Undergo radiation therapy
45834060|NCT01920438|Procedure|Percutaneous Endoscopic Gastrostomy|PEG
45834061|NCT01920438|Procedure|Radiologically-guided insertion of Gastrostomy|RIG
45834062|NCT00633750|Drug|erlotinib hydrochloride|Tarceva will be given orally at a dose of 150 mg/day for 5-14 days. Patients are to undergo surgical resection of their tumor within 24 hours of the last dose of Tarceva.
46084849|NCT05086679|Behavioral|Lifestyle modification|All patients will receive standard treatment of VVS despite their randomization(drink 2-3 liters of fluids, consume 10 grams 120 mmol/day of sodium chloride, and practice counter-pressure maneuvers (squatting, leg crossing, handgrip, and arm-tensing))
45994518|NCT04207762|Diagnostic Test|18F-AmBF3-TATE PET/CT|Blood pressure, heart rate, and oxygen saturation levels and EKG monitoring (vital signs) will be recorded prior to the injection and at three other stages of the scan visit. Each study subject will have an intravenous catheter inserted. Prior to the radiotracer injection an ultra low dose CT will be taken. Subjects are positioned supine, arms down. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site. A Dynamic PET scan will be taken of the heart. Then a serial whole body PET scan will be done. Vital signs will be taken again and the subject will have a bathroom break. The patient will return to the scanner bed for a standard low dose CT and whole body PET scan. Vital signs will be taken again, and subject will be allowed to use the washroom again. The subject will return to the scanner bed for the final time for an ultra low dose CT and whole body PET scan. A final set of vitals will be taken and the subject will be discharged.
45994519|NCT04207762|Diagnostic Test|Routine blood draw|Complete blood counts and routine clinical chemistry performed before and repeated within 18-72 hours after [18F]AmBF3-TATE administration.
45994520|NCT04128943|Other|symptom questionnaire|"A weekly filled in symptom questionnaire for reported symptoms of AA and/or PNH (yes/no, grade, date). Grading according to current grading systems (Common Terminology Criteria for Adverse Events,CTCAE).~Data collection and processing via the ePRO application by Kaiku Health Ltd"
45994521|NCT04128943|Other|recording of vital signs|Record function for vital parameters (blood pressure, temperature and pulse); Data collection and processing via the ePRO application by Kaiku Health Ltd
45994522|NCT04128943|Other|European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 questionnaire|The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue, Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties). All of the scales range in score from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems.
45994523|NCT04128943|Other|interview|Interview with the patients and responsible medical team by phone or during hospital visit about functional problems regarding the application (duration: 15-30 min) to avoid incorrect use of the application, at week 3 and month 3 and month 6
45994524|NCT05467826|Drug|Sofosbuvir/Velpatasvir + Ribavirin|Sofosbuvir 400mg/velpatasvir 100mg + ribavirin 1000mg/1200mg for 12 weeks
45994525|NCT05467826|Drug|Sofosbuvir/Velpatasvir/Voxilaprevir|Sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg for 12 weeks
45994526|NCT04127734|Procedure|The efficacy of various interventions for anastomotic leakage after rectal cancer resection are investigated|Investigated interventions comprise conservative, radiological, endoscopic and surgical (including stoma formation) interventions
45994527|NCT00598156|Drug|erlotinib (Tarceva)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
45994528|NCT00598156|Drug|bevacizumab (Avastin)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
45994529|NCT00598195|Drug|Ketamine|subject will then receive an intravenous bolus dose of ketamine 2 mg/kg as a rapid intravenous bolus, over less than two minutes just prior to CPB. In the non-CPB patients, ketamine will be administered just prior to the skin incision. All doses will be rounded to the nearest tenth of a milligram. Timed blood samples will be collected at standardized times after the completion of the ketamine infusion and samples will be obtained from an indwelling arterial line. Each blood sample for pharmacokinetic analysis will be 1 mL.
45994530|NCT00598234|Drug|Celecoxib (Celebrex)|The study group received 400mg oral celecoxib about 1 hr prior to surgery, and 200mg every 12 hrs, along with PCA morphine, over the first five post-operative days. The control group received placebo, along with PCA morphine over the same postoperative period. All patients received Acetaminophen 500mg qid for pain control.
45994531|NCT00598390|Drug|[11C]MePPEP|
45994532|NCT05467397|Drug|[11C]acetate|Positron Emission Tomography (PET)
45994533|NCT04326205|Device|transcranial direct current stimulation, tDCS|"The participants will receive a-tDCS over the ipsilesional M1, without any active arm practice for 20 minutes.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice."
45994534|NCT04326205|Device|functional electrical stimulation, FES|"The participants will start the FES-assisted MT. During this period, participants will perform simple wrist or finger extension with their unaffected UE while the affected wrist or fingers will receive FES within the mirror-box.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without FES followed by 30 minutes of functional task practice."
45994535|NCT04326205|Other|no stimulation|Both tDCS and FES will not be used in this section.
45994536|NCT00598429|Drug|Inhaled Prostaglandin E1|Delivery of one dose of either high dose PGE1 (300 ng/kg/min), low dose PGE1 (150 ng/kg/min), or placebo (normal saline, the diluent for the drug) via nebulizer over a 72-hour period
45994537|NCT05470452|Other|The reading process is assisted by ENDOANGEL|Diagnosis of benign and malignant lesions with the help of ENDOANGEL
45994538|NCT05470452|Other|No ENDOANGEL assistance during the reading process|Diagnosis of benign and malignant lesions without the help of ENDOANGEL
45457104|NCT03920059|Drug|Mycophenolate Mofetil|"Description Each capsule contains Mycophenolate mofetil 250 mg. Presentation / Packing Cap 250 mg (white to off white powder, light blue/peach hard gelatin, imprinting with MMF on cap and 250 on body) x 10 x 10's.~Storage Store below 30 degree Celcius."
45457105|NCT03519568|Biological|EV71 (inoculation vaccine)|EV71 vaccine 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 10μg HepB 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 30ug MPSV-A 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China MR 0.5ml per dose, Beijiing Biological Products Co., Ltd., Beijing, China JE-L 0.5ml per dose, Chengdu Biological Products Co., Ltd., Chengdu,Sichuan Province, China
45457106|NCT01132027|Drug|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
45457107|NCT03136484|Drug|Semaglutide|Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
45457108|NCT03136484|Drug|Canagliflozin|Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
45674680|NCT04723537|Drug|Part A: Upamostat 400 mg|2 capsules, each capsule comprising 200 mg of upamostat
45834063|NCT00633750|Genetic|TUNEL assay|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
45834064|NCT00633750|Genetic|protein expression analysis|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
45834065|NCT00633750|Other|immunohistochemistry staining method|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
45674681|NCT04723537|Drug|Part A and B: Placebo|1 or 2 capsules, each capsule a matching placebo
45674682|NCT04723537|Drug|Part B: Upamostat 200 or 400 mg|"Based on dose selection from Part A, Part B Upamostat will be EITHER a single 200 mg dose of upamostat OR two 200 mg doses of upamostat, for a total of 14 days."
45834066|NCT00633750|Other|laboratory biomarker analysis|Used to assess level of expression of genetic markers in pre-therapy and surgical specimens
45834067|NCT00633750|Other|liquid chromatography|Used to determine blood plasma levels of Erlotinib on the day of surgery
45834068|NCT00633750|Other|mass spectrometry|Used to determine blood plasma levels of Erlotinib on the day of surgery
45834069|NCT00633750|Other|matrix-assisted laser desorption ionization mass spectrometry|After treatment and following surgery, intervention will be used to determine Tarceva levels in tissue
45834070|NCT00633750|Procedure|therapeutic conventional surgery|Surgical treatment will occur within 24-hours following completion of therapy.
45834071|NCT01922856|Biological|LTR192G with dscCfaE|Recombinant fimbrial adhesin (dscCfaE) with Modified Escherichia coli (E coli) heat labile enterotoxin (LTR192G)
45834072|NCT01922856|Other|No Intervention|Controls only receive challenge
45834073|NCT00633360|Drug|Drospirenone and ethinyl estradiol|Once daily by mouth
45834074|NCT00633360|Drug|Placebo|Once daily by mouth
45834075|NCT00988260|Drug|Ganirelix|Ganirelix 0.125 mg subcutaneous daily (SC OD) for up to 14 days
45834076|NCT00988260|Drug|Ganirelix|Ganirelix 0.25 mg subcutaneous daily (SC OD) for up to 14 days
45834077|NCT00988260|Drug|Ganirelix|Ganirelix 0.5 mg subcutaneous daily (SC OD) for up to 14 days
45834078|NCT00633126|Drug|ceftaroline|Single parenteral infusion at a dose of 8 mg/kg for subjects weighing less than 75 kg or at a dose of 600 mg for subjects weighing greater than or equal to 75 kg infused over 60 minutes.
45994539|NCT00598546|Behavioral|EORTC QLQ-C30, QLQ-STO22, and MSK-10|QLQ-C30 is the generic QOL tool for patients with cancer undergoing clinical trials.QLQ-STO22, containing 22 questions specific to gastric cancer, is currently the only standardized disease-specific questionnaire to measure the QOL of gastric cancer and must be used in conjunction with the QLQ-C30.MSK-10 consists of ten additional questions that were developed by surgeons on the GMT service to answer specific questions about outcomes related to proximal subtotal, distal subtotal, and total gastrectomies. These questions focus on eating capabilities, work status and major life changing events.
45994540|NCT05466656|Other|Continuous quality improvement cycle model|The continuous quality improvement cycle model consist in a process of improvement by reference to a prior baseline clinical audit. It implies a local situation analysis, identifying barriers to improvements in clinical practice, and drawing up and implementing a plan of action for improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the barriers that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles.
45994541|NCT00598624|Drug|Treosulfan IV|Treosulfan i.v.: 14 g/m²/d from day -6 to day -4
45834079|NCT00989664|Biological|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST, of which 1-2 mg had been labeled with 5 mCi of Iodine-131) infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST labeled with enough Iodine-131 to administer the specified whole body radiation dose determined for the subject) infused over 30 minutes (inclusive of a 10-minute flush). The desired total body dose was 65 cGy for subjects with a baseline platelet count of 100,001-149,999/mm3 and 75 cGy for patients with a baseline platelet count ≥150,000/mm3. Obese patients received an attenuated dose by not including subject mass over 137% of their calculated lean body mass in their calculated lean body mass in the dose calculation."
45994542|NCT02891785|Behavioral|ANtiPain|After the implementation of ANtiPain, patients will receive cancer pain self-management support by trained staff nurses who follow the ANtiPain protocol. ANtiPain is based on 3 key strategies: Provision of information, skill building and nurse coaching. It consists of an in-hospital one-to-one session before discharge and a telephone follow up according to a clinical algorithm based on pain intensity, patient satisfaction with pain management and patient adherence. Patients will be given a booklet with corresponding info. The implementation process will include training of designated staff nurses, coaching activities based on case discussions on the ward, as well as measures to ensure sustainability of the implementation (e.g., training of ward managers and clinical nurse specialists).
45994543|NCT00536094|Behavioral|Cognitive behavioral therapy (CBT)|CBT includes 45-minute psychotherapy sessions once a week for a period of approximately 12 weeks.
45994544|NCT00536094|Behavioral|Treatment as usual (TAU)|TAU includes 45-minute psychosocial treatment sessions once a week for a period of approximately 12 weeks.
46084850|NCT04175379|Other|group 40|During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 40 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
46084851|NCT04175379|Other|group 50|During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 50 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
45834080|NCT01923870|Drug|Androxal 25 mg|
45834081|NCT00632736|Drug|Ropinirole XL (formerly CR)|
45834082|NCT01923948|Drug|Pregabalin|One 150 mg oral dose of Pregabalin given before surgery
45834083|NCT01923948|Drug|Placebo (for Pregabalin)|One oral dose of placebo given before surgery
45834084|NCT03100656|Other|A breakfast sandwich|A meat-based breakfast sandwich
45834085|NCT00989196|Biological|Human-cl rhFVIII|50 IU/kg for PK dose
45834086|NCT00989196|Biological|Kogenate FS|50 IU/kg for PK dose
45834087|NCT04288362|Other|Intervention Group|Participants in this arm will undergo the new care model for management of diabetes mellitus polyclinics.
45834088|NCT04288362|Other|Control Group|Participants in this arm will continue to undergo the existing care model for management of diabetes mellitus in the polyclinics.
45994545|NCT05466344|Device|Herbst Group|"Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured leaving an extended part of the plate in the oral cavity which contain the soldered ball housing.~The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint.~Cementation of upper Herbst splint with connecting the telescopic piston through fitting of the plunger into the tube bilaterally.~When reactivation of the telescopic piston is needed, extension rings are used."
45994546|NCT05466344|Device|TFBC Group|"The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months.~Finally follow finishing steps for each patient."
45994547|NCT02891746|Other|non invasive sampling|
45994548|NCT00598741|Other|DCE-MRI|"Patients will undergo DCE-MRI prior to, and within 18-24 days of starting chemotherapy. These studies are designed to determine if the DCE-MRI data will provide an a priori or early prognostic marker of tumor response. The dynamic MRI is done on a standard clinical scanner using standard techniques described below.~MR imaging studies will be acquired on a 1.5T GE (Milwaukee,WI) Signa LX scanner."
45994549|NCT00598858|Drug|Docetaxel|Given IV
45994550|NCT00598858|Drug|Prednisone|Given PO
45994551|NCT02909166|Drug|aliskiren|
45994552|NCT05466305|Device|Gold plated chrome cobalt alloy|Acrylic resin complete denture having a metal chrome cobalt palatal plate which plated by gold
45994553|NCT04207684|Drug|Testosterone injection|250 mg of testosterone cypionate (equivalent to 174,8 mg of testosterone) administered via intramuscular injection in a single dose (2 mL)
45994554|NCT02909400|Drug|KH176|
45994555|NCT02909400|Drug|placebo|
45994556|NCT05604950|Diagnostic Test|Since the data were collected retrospectively, there were no interventions|Since the data were collected retrospectively, there were no interventions
45994557|NCT03135067|Behavioral|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for offering to selected sexual partners. The self-test kits will be given to participants on a monthly basis as needed. The intervention is designed to facilitate partner and couples testing, with resulting reduction in risky sexual behavior and HIV incidence among participants.
45994558|NCT00536133|Drug|Zinc|5 ml of syrup containing zinc gluconate equivalent to 10 mg of elemental zinc per day for 60 days
45994559|NCT00536133|Other|placebo|5 ml of syrup, identical in taste, color and consistency to the syrup given to zinc group, but containing no zinc
45994560|NCT05603858|Procedure|Tenodesis by end button|open reduction of the dislocated hip and stabilization by end button
45994561|NCT02909478|Drug|Aprepitant+Tropisetron|"Patients will receive the chemotherapy drugs oxaliplatin,leucovorin and 5-fluorouracil as well as the following antiemetic drugs:~aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus Tropisetron (5mg IV of day1)"
45994562|NCT02909478|Drug|Dexamethasone+Tropisetron|"Patients will receive the chemotherapy drugs oxaliplatin, leucovorin and 5-fluorouracil as well as the following antiemetic drugs:~Dexamethasone (10 mg IV on day 1 and 5 mg IV days 2, 3) plus Tropisetron (5mg IV of day1)"
45994563|NCT05603819|Device|EDIT-B|To perform EDIT-B test, questionnaires and 2x0.5 mL whole blood are collected from each patient.
45994564|NCT03005626|Other|Therapeutic education|
45994565|NCT03005626|Other|Standard follow-up|
45994566|NCT00536211|Behavioral|Exercise|Exercise training will consist of walking and/or jogging on a treadmill 5 out of 7 d each week at ~60% of each subject's predetermined VO2max (75% maximal heart rate as monitored by heart rate monitors), 45 min/session, for 12 weeks. The exercise training will follow a three-stage progression: 1. wk 1 = 30 min, 3 d/wk, 60% VO2max; 2. wk 2 = 30 min, 5 d/wk, 60% VO2max; and 3. wk 3-12 = 45 min, 5 d/wk, 60% VO2max.
45994567|NCT00536211|Drug|Metformin|oral tablet, 1000 mg daily for 17 days
45994568|NCT02914873|Procedure|Active surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
45994569|NCT00536705|Drug|montelukast|montelukast 5-mg chewable tablet with matching placebo once daily in the evening at bedtime.The study consisted of a 2-week, single-blind placebo baseline period and a 12-week double-blind, active treatment period
45994570|NCT00624208|Drug|droperidol and saline|droperidol 20 mcg.kg-1 and saline
45994571|NCT00624208|Drug|ondansetron and saline|ondansetron 0.1 mg.kg-1 and saline
45994572|NCT00624208|Drug|droperidol and ondansetron|droperidol 20 mcg.kg-1 and ondansetron 0.1 mg.kg-1
45994573|NCT00624208|Drug|saline and saline|saline and saline
45994574|NCT00624247|Other|routine HIV testing|Potential subjects are offered swabbing as part of HIV testing by jail medical staff or study staff. All potential subjects are told HIV results can now be made available within a short period of time using an oral swab. Anyone not wanting HIV test results is allowed to refuse at the time of offering the HIV test and not be swabbed. If the inmate agrees to be swabbed and tested, he or she then meets with a member of the research study staff who discusses two separate informed consents - one for study participation and one for HIV testing.
45994575|NCT00536783|Drug|Quetiapine|
46084852|NCT04175379|Other|group 60|During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 60 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
46084853|NCT02764892|Drug|V81444|Single oral dose of V81444
46084854|NCT04663373|Other|Step counting|Patients are given a physical activity tracker (wrist band) that they are asked to wear for two weeks after discharge from percutaneous coronary intervention.
46084855|NCT02668887|Behavioral|Quality of Life, status of employment|
46084856|NCT02765126|Biological|Seasonal influenza vaccine|Intramuscular standard seasonal influenza vaccine
46084857|NCT02765126|Biological|Diphtheria-tetanus-acellular pertussis vaccine|Intramuscular DTaP vaccine
46084858|NCT04489199|Other|Questionnaire and semi-structured interview|questionnaire submitted by telephone 3 months, 6 months, 1 year, 5 years, and 10 years after the stroke/TIA. interview duration 20 to 40 minutes
46084859|NCT02668965|Procedure|Intrauterine hCG (pregnyl)|
45994576|NCT05243641|Drug|Neratinib|Nertatinib will be supplied as 40 mg tablets, equivalent to 48.31 mg neratinib maleate.
45994577|NCT05243641|Drug|Capmatinib|Capmatinib will be supplied at 200 mg and 150 mg tablets
45994578|NCT00536289|Device|Blunt needle|Blunt tipped suture needle
45674683|NCT04183465|Other|Health Education|Current gold standard in older patients admitted to hospital for MI. The group will receive a 20-minute session with one of the study physicians. Both the patient and relatives will attend these sessions. The study physician will stress the major issues related to a heart-healthy lifestyle and will explain the importance of PA as a powerful and independent factor to improve cardiovascular health and minimize cardiovascular risk. A detailed brochure explaining the benefits of physical activity will be provided to all patients
46084860|NCT02668809|Other|oral health assessment|A baseline oral health assessment of both residents and direct care workers will be conducted before interventions are initiated. Data will be entered directly into a spreadsheet format using the chairside software program to be developed as part of this proposal.
46084861|NCT02668809|Other|Questionnaires|Age, sex, race, nutrition (mini-nutri), quality of life (SF-36), OHIP-14, GOHAI, sources of payment for the NF residency, comorbid conditions (e.g., constipation, arthritis), weight, medications, cognitive status (mini-mental) , dry mouth sensation, x-ray documented pneumonia;
46084862|NCT02668809|Other|Clinical Exam|Dentate status, dental/denture plaque index, DMFS (including root surfaces), gingival bleeding index, plaque index, presence of oral lesions, verification of mouth dryness;
46084863|NCT02668809|Other|Microbiological sampling|Samples will be collected by swabbing patients intra-oral tissues. Samples will be separately collected from dentures and oral tissues for edentulous patients, also using swabs. All samples will be suspended in saline solution.
46084864|NCT02668809|Other|Monitoring Adherence|Adherence to the protocol will be evaluated through unannounced observations at the NF by study personnel twice per month. Adherence is determined by direct observation of the DCW administering the intervention.
45457109|NCT03136484|Drug|Placebo (canagliflozin)|Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
45834089|NCT03100110|Device|NeuroCognitive Communicator|Comprises an electrode array in prefrontal cortex, another in motor cortex, Blackrock NeuroPort system and connectors, augmentative assistive communication application, robotic arm, and virtual reality environment.
45834090|NCT00632502|Drug|Navarixin|Navarixin 30 mg capsule to be taken by mouth once daily in the morning for 4 weeks.
45834091|NCT00632502|Drug|Placebo|Placebo capsule to match navarixin to be taken by mouth once daily in the morning for 4 weeks.
45994579|NCT02824471|Other|SCD Group|No Intervention. Use of discard blood/tissue
46084865|NCT02668809|Other|Varnish application|"1% chlorhexidine varnish application group will receive the educational program described above. In addition, residents who need supervision or are unable to perform oral hygiene procedures will receive 1% chlorhexidine varnish application monthly by the dental hygienist. No additional time commitment will be necessary.The direct care workers will NOT receive any varnish."
45834092|NCT00632502|Drug|Rescue medication|Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms
45834093|NCT00632424|Drug|Ixabepilone (oral formulation)|Capsules, Oral, Dose escalating (Phase 1), 3 doses on 1 day every 3 weeks, until disease progression or unacceptable toxicity
45834094|NCT00631488|Drug|MK-0893|Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks).
45994580|NCT05601791|Procedure|Epidural Steroid Injection|Epidural Steroid Injection transforaminal approach Drug: midazolam, fentanyl, lidocaine, levobupivacaine, methilprednisoloneacetat
45994581|NCT05601791|Procedure|Percutaneous Laser Disc Decompression|Percutaneous Laser Disc Decompression Drug: midazolam, fentanyl, lidocaine
45994582|NCT05470062|Device|arch support insoles (FootDisc)|The FootDisc insole is designed with curEVA for shock absorption and motion reduction, poron for secondary heel and metatarsal protection, and dynamic arch support for returning energy for propulsion
45994583|NCT04685642|Drug|Aspirin|Aspirin (100mg/day)
45994584|NCT04685642|Drug|Atorvastatin|Atorvastatin (20mg/day)
45994585|NCT02909244|Biological|Biological sampling|Biological sampling
45834095|NCT00631488|Drug|Sitagliptin|Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
45994586|NCT04685564|Drug|RBD1016|"Sentinel cohort design is used in each cohort: each cohort will be administered in two batches, the first 2 subjects will receive RBD1016 or placebo respectively, and safety assessment will be done on D8±1. After safety is confirmed through SRC assessment, the remaining 6 subjects will be randomly assigned to receive RBD1016 or placebo in a ratio of 5:1. SRC will assess the safety after all the subjects in each cohort complete the 28-day safety observation and the subjects may proceed to the next dose cohort with permission.~Only after all the subjects in the previous dose cohort have completed the safety assessment by SRC (observed for 28 days) may the next dose cohort be initiated with permission."
45994587|NCT04685564|Drug|Placebo|the same as RBD1016
45994588|NCT02909283|Procedure|Physical exams and blood analyzes|Blood samples collection (for DNA, plasma and cells analyzes) ; Hemorheologic analyzes ; ASL sequence on MRI ; Near Infra Red Spectroscopy (NIRS) and associated cardiofrequency analyze.
45994589|NCT02908932|Dietary Supplement|Phospholipid-bound omega-3 supplement|The dietary supplement is produced by Aker BioMarine. These krill oil capsules received a GRAS status approval from the U.S. Food and Drug Administration (FDA) in 2010. Aker BioMarine has a new pending application (2015) with the U.S. FDA for GRAS status for its new product on which this study capsule is based. Aker BioMarine markets a number of different krill-based omega-3 supplement products in the U.S. The US Food and Drug Administration (FDA) has determined that an Investigator New Drug (IND) Application is not required for this study. This phospholipid-bound omega-3 dietary supplement is provided in capsule form.
45994590|NCT02908932|Dietary Supplement|Placebo supplement|Placebo capsules that are identical in size and color to the experimental but contain an equal amount of macadamia nut oil.
45994591|NCT05595785|Behavioral|Physical-Based Yoga Practice|Physical-based yoga classes emphasized Bishnu Ghosh lineage hatha yoga. The 50 minute yoga classes were twice per week for four weeks. The yoga instructor had certifications in both Bikram and Amrit yoga practices and training in Bishnu Ghosh lineage hatha yoga as taught by Mary Jarvis
45994592|NCT05595785|Behavioral|Mindfulness-Based Yoga Practice|The mindfulness-based yoga classes included all elements of the physical-based yoga classes with the addition of mindfulness cues. The mindfulness cues included body scan, mindful movement, and yoga nidra. Certification of the instructor included the Integrative Amrit Method of Yoga Nidra that was inclusive of the use of mindfulness cues that coincided with the physical postures of yoga.
45994593|NCT02909205|Other|sensitization / educational program|the intervention program was built based on the results of the pre-intervention phase survey, about the knowledge of caregivers and parents of children with gastrostomy about gastrostomy management. It consists in booklets for caregivers and parents of children. This booklet is the support of a specific training of carers and parents of children who have recently benefitted from a gastrostomy
45994594|NCT02909205|Other|training / sensitization program|diffusion of gastrostomy in-hospital care protocols, and booklets for families. These tools have been prepared by a pilot group of professional of the investigating centers.
45994595|NCT05579795|Procedure|Detethering of the spinal cord|Release of the tethered spinal cord
45994596|NCT05312346|Diagnostic Test|seum zinic,vit B12, parathyriod function|seum zinic,vit B12, parathyriod function
46084866|NCT02668809|Other|Consent|Both the residents and primary care workers will be asked to participate on the study, and the investigators will provide information and collect signed informed consents primarily during two in person visits to each nursing facilities.
46084867|NCT02668809|Other|Educational Program|Cognitively capable residents will receive instruction on how to perform their own oral hygiene accordingly to their own needs; and 2) Direct care workers will receive instruction on how to perform oral hygiene for dependent residents or supervise the oral hygiene routines of independent patients. For both 1) and 2) above, dental hygienists will provide a short, standardized presentation and hands-on demonstration.
46084868|NCT02764658|Device|Pulmonary recovery on the AECOPD|The combination effect of negative pressure ventilation, limb muscle exercise training program and fibit monitor on acute exacerbation of AECOPD. To investigate the daily physical activity in routine care patients with after AECOPD and stable stage.
46084869|NCT02764658|Other|Routine care on the AECOPD|To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Routine care patients wtih AECOPD and stable stage.
45457110|NCT03136484|Drug|Placebo (semaglutide)|Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
45457111|NCT02295592|Procedure|TSTstarr+|"TSTstarr+ : a kind of modified STARR（stapled transanal rectal resection ） operation, compared to the traditional STARR operation, it does not need two staplers but with a larger diameter stapler,  + means better . Patients in group A with severe prolapsed hemorrhoids will undergo TSTstarr+ operation ."
45834096|NCT00631488|Drug|Metformin|Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks).
45834097|NCT00631488|Drug|Placebo for MK-0893|Matching placebo for MK-0893 was orally administered for the loading dose (200 mg) and for the following daily treatment (40 mg) over the 4 week double blind treatment period.
45834098|NCT00631488|Drug|Placebo for Sitagliptin|Matching placebo for Sitagliptin (100 mg) administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
45834099|NCT00631488|Drug|Placebo for Metformin|Metformin-matched placebo taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin-matched placebo then administered throughout the double-blind treatment period (4 weeks).
45994597|NCT05568563|Drug|Ethyl chloride|Ethyl chloride is an agent that is widely used in dental practice as the standard modality for pulp vitality tests .
45994598|NCT05568563|Other|Honey|Honey is a natural dietary product
45994599|NCT05470023|Other|OTC Toothpastes or Mouthrinses|OTC Toothpastes or mouthrinses used according to standard of care
45994600|NCT05561933|Behavioral|Healthy Minds Program Foundations Training|"The HMP was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on decades of research on well-being. The program is delivered through a smartphone application and consists of didactic (learns) and experiential (practice) components. Practice components involve contemplative practices such as mindfulness, loving-kindness, and gratitude practices. Each practice allows participants to choose duration (between 5-30 minutes). In addition to sitting style practices common in other meditation apps/programs, the HMP also provides instruction in active practices. Active practices engage the same skills as sitting practice, but focus on strengthening skills during daily routines. Learn components provide psycho-educational content about the science of well-being. HMP learns and practices are based on a four pillar model of well-being skills consisting of Awareness, Connection, Insight, and Purpose."
45994601|NCT00536861|Drug|erlotinib|"Level 1 : erlotinib 100 mg/day from day -7 to the time of completion of 10 fractions of cranial irradiation, followed by 150 mg/day until disease progression or toxicity~Level 2 : erlotinib 150 mg/day from day -7 before cranial irradiation, followed by 150 mg/day until disease progression or toxicity"
45994602|NCT05469984|Drug|Ampicillin Only Product|women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin
45994603|NCT05469984|Drug|ampicillin plus gentamicin|women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin
45994604|NCT00536900|Behavioral|Advisor-Teller Money Manager|The acronym for the functions of ATM are TTT-- Teller (storing patient funds), Training patients by making and reviewing monthly budgets, and Treatment-Linked Spending in which weekly behavioral contracts link disbursement to completion of abstinence-related activities
45994605|NCT00536900|Behavioral|FIT|FIT (finance instruction therapy) involves review of a financial workbook and budgeting sheets
45994606|NCT05312190|Drug|ZhenQi BuXue KouFuYe|Zhenqi Buxue Oral Liquid consists of sheep placenta, pearl, red ginseng, wolfberry, astragalus, angelica, coix seed, ginger and jujube. The excipients are protein sugar and sodium benzoate. Nourishes qi and blood. It is suitable for dizziness, pale complexion, fatigue, lack of energy and lazy words caused by insufficient qi and blood.
45994607|NCT05312190|Drug|Progesterone Capsules|The main ingredient of Progesterone Capsules is abbsolutely progesterone,a kind of hormone,which is the main method of western medicine for the treatment of menstrual disorders
45994608|NCT00537173|Procedure|Core Biopsy|biopsy
45994609|NCT00537173|Procedure|Blood Collection|Blood/serum sample
45994610|NCT00537173|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV, day 1, 8 and 15
46084870|NCT02764658|Other|Routine care on the stable COPD|To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Non-Pulmanary recovery patients wtih stable COPD.
46084871|NCT00916721|Drug|Propranolol|Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
45994611|NCT00537173|Drug|Avastin|Avastin 10 mg/kg IV, day 1 and 15
45457112|NCT02295592|Procedure|PPH|PPH is short fo procedure for prolapsed hemorrhoids .Patients in group B with severe prolapsed hemorrhoids will undergo PPH operation.
45994612|NCT05469828|Drug|Crizanlizumab|patients will be started on 5mg/kg of body weight to be initiated at week 1 with follow up dosing at week 3 and week 7 then q4weeks until week 23, which will be the last dose given (7 total doses).
45994613|NCT05469828|Other|control|Standard of care
45994614|NCT00537212|Other|The South Beach Diet|"Subjects will receive dietary counselling aimed at reducing simple carbohydrates and increasing weight loss. Subjects also receive a copy of The South Beach Diet."
45994615|NCT00537212|Other|The Ornish Diet|"Subjects will receive dietary counselling aimed to reduce fat consumption and increase weight loss. Subjects also receive a copy of The Ornish Diet book."
45994616|NCT00537212|Other|Control Group|This group will receive phototherapy alone. They will not be counselled or give literature on a particular diet.
45994617|NCT02503839|Drug|etoricoxib|cyclooxygenase-2 inhibitor. Anti-inflammatory
45994618|NCT02503839|Biological|H56:IC31|Therapeutic and prophylactic TB vaccine
45994619|NCT05469750|Drug|Dalpiciclib+ letrozole +capecitabine|Continue medication to disease progression
45994620|NCT05311761|Other|CogMe Personal Assistant (PA)|Twice a day, in the morning and evening, the electronic tablet with the CogMe PA will be given to the patient by the research assistant. Patients will be asked to respond to a short question and answer (Q&A) session of approximately 5-10 minutes duration. This intervention will continue throughout the hospitalization period, estimated at approximately 5 days.
45994621|NCT05530109|Other|Neuropsychological screening and high resolution EEG recording|Each participant will be assessed with a battery of neuropsychological tests including Epitrack, the Raven's progressive matrice, the MoCA, the D2-R test, the BDI-II test, the STAI and the Qolie-31. Then, a prolonged EEG recording at rest and during an attentional task (the ANT) will be realized
45457113|NCT03519490|Device|Hybrid Contact Lens|Hybrid Single Vision or Multifocal Contact Lenses in Near Center and Distance Center Designs
45457114|NCT03919591|Other|Challenge virus RSV-A Memphis 37b|Each subject will receive one titre of virus, which will be up to approximately 4.5 log10 PFU.
45457115|NCT01132105|Device|Vestibular myogenic evoked potential analyzer|
45994622|NCT05469516|Device|Ulthera System [Ulthera, Inc.]|"The Ulthera System is indicated for: - Use for noninvasive dermatological sculpting and lifting of the dermis: Upper Face, Lower Face, Neck, Décolletage.~- Non-invasive treatment of Axillary Hyperhidrosis"
45994623|NCT05469516|Device|Merz Radiesse Injectable Implant|Radiesse injectable implant is an opaque, sterile, non-pyrogenic, semi-solid, cohesive implant. The principal component is synthetic CaHA suspended in a gel carrier that consists primarily of water (sterile water for injection, United States pharmacopeia (USP)), glycerin (USP), and sodium carboxymethylcellulose (USP). Radiesse injectable implant (1.5mL syringe unit) has a CaHA particle size range of 25-45 microns and should be injected sub-dermally with a 27 gauge needle.
45994624|NCT05514587|Behavioral|Meaning of Life Questionnaire (MLQ)|Completion of questionnaires at crisis centre entry and 3 months later.
45994625|NCT02143830|Drug|Busulfan|"A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity."
45994626|NCT02143830|Drug|Cyclophosphamide|Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
45994627|NCT02143830|Drug|Fludarabine|Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.
45994628|NCT02143830|Drug|rabbit ATG|Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment.
45994629|NCT02143830|Drug|G-CSF|All patients will also receive G-CSF post-transplant to foster engraftment.
45994630|NCT02143830|Biological|Peripheral blood stem cell|The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).
46084872|NCT00916721|Drug|Placebo|Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
46084873|NCT03207672|Drug|E7389-LF|intravenous infusion
46084874|NCT04175457|Other|e-cigarette|E-cigarette inhalation for 30 minutes using e-cigarette with and without nicotine
46084875|NCT02764814|Other|Cryopreserved amniotic membrane|subjects will receive cryopreserved amniotic membrane
46084876|NCT05345340|Other|Telemedicine|"The 5-day rehabilitation program will consist of exercises to re-establish standard movement patterns within a multidisciplinary etiological framework, according to a validated rehabilitation protocol for FMDs. Treatment will be tailored to the needs of each patient, following general treatment principles in physiotherapy for FMDs.~Telemedicine sessions: the patient will perform specific exercises under the supervision of a qualified physiotherapist to provide feedback on the execution and adapt the treatment according to clinical changes/improvements.~Polar Vantage M devices will collect the objective measurement after the 5-day rehabilitation program (for five consecutive days), week 12 (for five consecutive days), and week 24 (for five consecutive days)."
46084877|NCT05345340|Other|Usual care|The 5-day rehabilitation program will be the same as the telemedicine group. A self-management paper log will be given to the patient at the end of the 5-day rehabilitation program. It will include goals, activity plans, and strategies to be used for retraining movements and redirecting attention. Videos stored on the patients' digital device (i.e., tablet, mobile) will include exercises demonstration and execution and strategies to retrain movements. Patients will be encouraged to perform the self-management plan at home on their own (or with their caregivers' help) which will be reported in a paper log and video recorded. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.
46084878|NCT05054075|Biological|Marine liquid and fluids|Marine liquid and fluids extracted from freshwater bivalve of A. cygnea (under very specific conditions)
45457116|NCT02295670|Device|Vividtrac|video-laryngoscopy
45457117|NCT02295670|Device|MIL|direct-laryngoscopy
45834100|NCT01924104|Drug|Low molecular weight heparin|2500 mIU/day, subcutaneously
45834101|NCT01924104|Drug|Low dose aspirin|75 mg/day, orally
45834102|NCT01924104|Drug|Heparin & aspirin|Aspirin (70 mg/day, orally) & heparin (40 mg/day, subcutaneously)
46084879|NCT05054075|Biological|Impregnation|SARS / COVID-19 fluid/liquid - impregnation
45834103|NCT01924104|Other|NaCl|Equivalent volume of NaCl 0.9%, subcutaneously
45834104|NCT03482310|Device|Using the Neuroport cortical recording array to determine the desired grasp pattern for a functional electrical stimulation (FES) system|Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes
45834105|NCT03098628|Biological|PCV Vaccine|PCV vaccination
45834106|NCT00988884|Biological|V503|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm at Day 1, Month 2, and Month 6
45834107|NCT00988884|Biological|Comparator: Menactra™ (Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
45457118|NCT01132183|Drug|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
45457119|NCT03923881|Device|MSOT Acuity Echo|Optoacoustic imaging with the MSOT Acuity Echo
45834108|NCT00988884|Biological|Comparator: Adacel™ (Concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
45834109|NCT00988884|Biological|Comparator: Menactra™ (Non-Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
45834110|NCT00988884|Biological|Comparator: Adacel™ (Non-concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
45994631|NCT03457181|Other|music|effect of music on anxiety scores
45994632|NCT03457181|Other|operating room noise|effect of operating room noise on anxiety scores
45994633|NCT00537251|Drug|Insulin glargine|
45994634|NCT05311410|Other|Non-bloody dental procedures (control group)|Control group composed of 30 positive patients for SARS-CoV-2, from the same ICU, submitted to non-bloody procedures.
45994635|NCT05311410|Procedure|Bloody dental procedures (study group)|Study group consisting of 30 patients who require open dental treatment and with a positive PCR test for SARS-CoV-2 prior and admitted to the Intensive Care Unit.
45994636|NCT05490290|Other|Active|In the active intervention condition, decision support is provided during the referral procedure of medical imaging exams.
45674684|NCT04183465|Other|Multi-domain lifestyle intervention|The intervention includes diet counselling, smoke cessation program, aggressive CV risk control and PA intervention. The PA intervention consisted of supervised sessions combined with an individualized home-based PA program. Centre-based sessions will be supervised by a sports physician and a nurse, and will take approximately 30 to 40 minutes, including a moderate standardized treadmill-walk, and strength and balance exercises. Based on the practice sessions, patients will receive a walking program to perform at home, unsupervised. The PA programs will be individualized, and consistent with current international recommendations. A selection of calisthenic exercises will be prescribed. Participants will be encouraged to perform the exercises three times per week (approximately 20 minutes). Adjustment of the type and intensity of the home-based PA regimen will be made at each visit. The PA program will be extensively described to the patient and family members.
45994637|NCT03457194|Biological|Quadrivalent Influenza Vaccine|Inactivated quadrivalent influenza vaccine that is used for active immunisation against influenza A, B virus strains (contained in vaccine). Single dose administration by intramuscular injection to all enrolled pregnant women as part of routine antenatal care.
45994638|NCT03457194|Biological|DTP Vaccine (Multiple Actives)|Pertussis vaccine acellular combined with diphtheria and tetanus toxoids. Single dose administration by intramuscular injection, to all enrolled pregnant women who are 28 weeks or greater gestation at time of enrolment, as part of routine antenatal care.
45834111|NCT00631020|Behavioral|CBME|6 weeks of once a week one-on-one CBME
45994639|NCT05478707|Drug|Dulaglutide|GLP1-RA
45994640|NCT05478707|Drug|Placebo|Saline placebo
45994641|NCT05478707|Behavioral|exercise training|supervised high intensity interval training
45457120|NCT03516682|Behavioral|Reminders|Automated reminders for the 6 month and 12 month vaccine visits for parents experiencing logistic barriers to vaccination.
45674685|NCT02093923|Drug|DX-2930|Participants will receive SC injection of DX-2930 (a recombinant, Chinese hamster ovary [CHO] cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody) once and followed by the second dose after 2 week into the upper arm.
45834112|NCT00631020|Drug|Optional NRT|NicoDerm CQ nicotine transdermal patch
45834113|NCT00987402|Other|Plain soap and water (PSW)|Presence or absence of infection
45834114|NCT00987402|Other|Alcohol-based hand rub (ABHR)|Presence or absence of infection
45834115|NCT00630864|Drug|Fx-1006A|During Part 1, patients will receive Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for two weeks. During Part 2, patients will receive Fx-1006A 20mg soft gelatin capsules once daily to complete a total of 12 months of dosing
45457121|NCT03924115|Device|Transmedial Psychoeducational Program to improve adherence full or partial (PS)|Intervention consists of a transmedial Psychoeducational Program, which includes cognitive, behavioral and affective aspects to generate knowledge and skills that improve self-efficacy in the elderly, it is a program based on communication in health. The proposed transmedial narrative will allow older adults to assemble information from messages arranged through various media, including audiovisual capsules that will be transmitted on screens located in the Health Center and the development of a mobile application incorporated in the cellular that will be delivered with a data plan for one year. This intervention is designed to strengthen the personal resources of the elderly (such as self-efficacy, empowerment, knowledge) that promote self-care in health.
45994642|NCT05469399|Other|Experimental Group|"Students will be given a knowledge test and an objective structured clinical exam for skill assessment (Initial knowledge and skill assessment). After these applications, the students will be given a theoretical course on the admission of the patient to the clinic after the operation. After the theoretical lesson, a link for the virtual reality game application consisting of three different cases will be sent to the students for them to play on the phone and computer. Students will play this game application for a week. After the game application process, students will be given a knowledge test, an objective structured clinical exam for skill assessment (final knowledge and skill assessment)."
45994643|NCT05469399|Other|Control Group|"Students will be given a knowledge test and an objective structured clinical exam for skill assessment (Initial knowledge and skill assessment). No application will be made to the students for one week. One week later, students will be given a knowledge test, an objective structured clinical exam for skill assessment (final knowledge and skill assessment)."
46084880|NCT05054075|Biological|Incubation|SARS / COVID-19 fluid-bivalve-incubation
46084881|NCT05054075|Biological|Manipulation|Bivalve Manipulation - Stress inducing
45457122|NCT02295748|Drug|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.
45994644|NCT05469204|Drug|Midazolam oral solution|2 mg single-dose before and during estradiol treatment.
45994645|NCT05469204|Drug|Digoxin Oral Tablet|0.25 mg single-dose before and during estradiol treatment.
45994646|NCT05469204|Drug|Acetaminophen Oral Tablet|500 mg single-dose before and during estradiol treatment.
45994647|NCT05469204|Drug|Midazolam Injectable Solution|1 mg intravenous single-dose before and during estradiol treatment.
46084882|NCT05054075|Biological|Refrigeration|Refrigerated fluid to check for maintained response
46084883|NCT02668341|Other|non-interventional|non-interventional survey study
46084884|NCT00613782|Drug|Reandron 1000|1000mg at 0,6,18,30 weeks
45457123|NCT03923803|Diagnostic Test|C- reactive protein|the measurement will be done by chemileumeniscence
45457124|NCT03923803|Diagnostic Test|Pro calcitonin|the measurement will be done by chemileumeniscence
45994648|NCT05454137|Behavioral|Shared medical appointment|Shared medical appointment
45994649|NCT05451641|Behavioral|Blood flow restriction resistance training|The participants will receive a 2-week exercise training program (3 times per week). Each training session will consist of 3 resistance training exercises with two blood flow restriction devices (wide-rigid cuff and narrow-elastic band). For both arms, the participants will perform the same exercise with different BFR devices.
45994650|NCT03457064|Behavioral|PA+Social Adherence Intervention(PASAI)|While both physical activity programs were tailored to match participants' physical needs and abilities, the PA+Social Adherence Intervention(PASAI) introduced elements to promote and strengthen self-efficacy and social interaction among participants.
45994651|NCT05469165|Drug|Cyproheptadine 4 Mg Oral Tablet|Cyproheptadine treatment for 3 months
45994652|NCT05469165|Other|Placebo|Placebo administration for 3months
45994653|NCT05433740|Device|Proseal Laryngeal mask fixation|fixation with Proseal Laryngeal mask adjustable ligament
45994654|NCT05294133|Behavioral|physical activity|physical activity
45994655|NCT05422235|Other|Routine Medical Treatment|Subjects will continue their routine medical treatment.
45457125|NCT03519100|Other|quality of life evaluation|quality of life evaluation post surgery
45457126|NCT03923569|Diagnostic Test|Overnight polysomnography|Overnight polysomnography with evaluation of each form of epileptiform activity during each vigilance state and memory scores at the overnight retention test
45457127|NCT03923569|Diagnostic Test|blood sample|blood sample for genetic testing of the Apolipoprotein E
45994656|NCT05422235|Other|Aerobic Exercise|Symptom-limited peak heart rates of subjects will be determined using the modified Bruce Protocol. For aerobic training, subject will be carried out on the treadmill according to the results of exercise tests. Initially, 40-60% of the peak heart rate will be trained and progression will be made in subject training programs every 2 weeks. Training will consist of warm-up, main exercise and cool-down periods. Aerobic training will be done 3 days a week for 12 weeks. Subjects will be followed for 24 weeks. The room temperature will be fixed at 25°C in order to keep the impact of environmental factors at a minimum. In addition, individuals will be asked to come with appropriate shoes and clothes for the training.
45994657|NCT05422235|Other|Aerobic Exercise+ Foot-Related Exercise|In addition to walking training specific to the subject in the aerobic exercise group, special exercises will be given to the feet and ankles. These exercises will be aimed at stretching, strengthening, increasing sensory input. Treatment program will be done 3 days a week for 12 weeks. Subjects will be followed for 24 weeks.
45994658|NCT00537368|Drug|CNTO 888|
45994659|NCT05399342|Other|No Intervention|Patients in the LAAOS III trial either had or did not have their left atrial appendage occluded at the time of surgery in that trial. No further intervention is required in this cohort, it is observational follow-up only.
45994660|NCT05285709|Diagnostic Test|Biomarker|blood and urine sampling before and after surgery (1-admission to operating ward, 2-leaving operation ward, 1st day postop, 2nd day postop, 5th day postop, or the day patient leaves hospital, whichever is first)
45994661|NCT05285709|Diagnostic Test|RRI measurement|patients able to cooperate will have renal resistive index measured before and after surgery (admission to operating ward, leaving operating ward)
45994662|NCT05391581|Other|GIPR antagonist / study tool|Selective antagonist of the GIPR, GIP(3-30)NH2
45994663|NCT05391581|Other|GLP-2R antagonist / study tool|Selective antagonist of the GLP-2R, GLP-2(3-33)
46084885|NCT00613782|Drug|placebo|placebo injection 0,6.18.30 weeks
45457128|NCT03923569|Diagnostic Test|high-resolution MRI scan|Evaluation of anomalies in brain structure and functional resting state connectivity
45674686|NCT02093923|Drug|Placebo|Participants will receive matching placebo subcutaneously.
45674687|NCT02186561|Device|Pipeline™ Embolization Device/ Pipeline™Flex Embolization Device|
45674688|NCT02066467|Device|Left Ventricular lead implant: ACUITY X4® Lead Family|Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment
45674689|NCT02186171|Biological|Romosozumab|Administered by subcutaneous injection once a month.
45674690|NCT02186171|Drug|Placebo|Administered by subcutaneous injection once a month.
45674691|NCT02186015|Drug|Cholecalciferol|Enrolled women will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
45994664|NCT05391581|Other|Placebo|Saline
46084886|NCT02761616|Other|eBC treated participants|No intervention administered in this retrospective observational study.
46084887|NCT02668263|Procedure|Surgery alone|Surgery
46084888|NCT02668263|Procedure|Surgery and Drain(s)|Drains inserted as per standard practice
46084889|NCT02668263|Procedure|Surgery and Quilting Sutures|Quilting sutures to mastectomy flaps
45994665|NCT05282238|Diagnostic Test|Nasal pressure assessment|Once the patient is enrolled nasal pressure will be measured through a dedicated pressure line located at the nostril entrance and connected to a dedicated pressure transducer (OptiVentTM, SIDAM, Mirandola, Italy). Measured nasal pressure will be the result of the variation between inspiratory and expiratory pressure (DeltaPnose). The measurement of DeltaPnose will be obtained considering the average of 3 values registered during 3 breath after at least 3 minutes of stable and constant respiratory pattern. Pnose values will be measured before extubation (T0) and 30 minutes (T1), 2 hours (T2), 4 hours (T3), 12 hours (T4) , 24 hours (T5) and 48 hours (T6) after extubation.
45994666|NCT00536367|Other|No intervention - observational study only|
45994667|NCT05386901|Procedure|Conventional positive end-expiratory pressure(PEEP)|Positive end-expiratory pressure is the mechanical ventilator that generates positive pressure during the inspiratory phase to pass gas into the lungs. When the airway opens at the end of expiration, the airway pressure remains above atmospheric pressure to prevent the alveoli from shrinking and collapsing.In this intervention arm It will be set to 5 cmH2O until the end of the operation.
45994668|NCT05386901|Procedure|Lung dynamic compliance guided positive end-expiratory pressure(PEEP)|Positive end-expiratory pressure is the mechanical ventilator that generates positive pressure during the inspiratory phase to pass gas into the lungs. When the airway opens at the end of expiration, the airway pressure remains above atmospheric pressure to prevent the alveoli from shrinking and collapsing.In this intervention arm It will be set to individual value until the end of the operation.The individualized values are obtained by observing the maximum Lung dynamic compliance during PEEP titration.
45994669|NCT05468775|Behavioral|Naked eye 3D vision training|20 minutes of naked eye 3D vision training every day
45994670|NCT05384717|Other|Fidget Device|Fidget spinner, stress ball, pop-it, or fidget cube
45994671|NCT05384717|Other|Control group|No intervention
46084890|NCT04106388|Behavioral|Virtual Behavioral Health Integration|The virtual behavioral health integration program, implemented in primary care settings, is a structured mental illness treatment program that includes both behavioral treatment and counseling components aimed at reducing cost of care, developing and sustaining adaptive coping strategies, and improving short term acute care utilization.
46084891|NCT02769260|Other|Toothbrushing|Normal toothbrushing without toothpaste or antiseptic mouthwash.
46084892|NCT02420964|Other|video instruction|Patient Directed Video Instruction
46084893|NCT02420964|Other|Nurse instruction|Nurse directed instruction
45674692|NCT02066389|Drug|Placebo|Tablets for oral administration
45994672|NCT02399839|Drug|lomitapide|As prescribed by Physician.
45994673|NCT04321486|Other|The study does not have an intervention, but observe the dementia incidence of the UK disease-free population.|The study does not have an intervention, but observe the dementia incidence of the UK disease-free population.
45457129|NCT03923569|Behavioral|neuropsychological evaluation|neuropsychological evaluation including episodic memory tests before an overnight polysomnography
45674693|NCT02066389|Drug|Upadacitinib|Tablets for oral administration
45674694|NCT02106403|Other|Prototype disinfectant spray formulation|0.13% w/w BAC and 1% MGA. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
45834116|NCT01924338|Device|MRI scan|Acquisition of a high-resolution MRI scan (0.15 x 0.15 x 1.0 mm³) aligned with the AC-PC (anterior commissure-posterior commissure) line
45674695|NCT02106403|Other|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
45834117|NCT01924338|Device|Laser scan|A near-infrared laser scan of the subject's forehead is acquired
45834118|NCT01924338|Procedure|Dental cast creation|A dental cast made of PMMA (polymethyl methacrylate) of the subject's maxilla is created
45834119|NCT01924416|Behavioral|Enhanced Care (intervention group and comparison group)|Decision aid coupled with immediate QL-PRO results
45834120|NCT01924416|Behavioral|Usual care (routine chemotherapy cycles and imaging studies)|Usual care does not receive intervention
45834121|NCT00630786|Drug|Panitumumab|Administered by intravenous infusion
45834122|NCT00630786|Drug|Conatumumab|Administered by intravenous infusion
45674696|NCT02106403|Other|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
45674697|NCT02133131|Drug|Grazoprevir/Elbasvir FDC|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken q.d. by mouth.
45674698|NCT02133131|Drug|Sofosbuvir|Sofosbuvir 400mg tablet taken q.d. by mouth.
45674699|NCT02106325|Drug|Ketamine|IV of Ketamine (.25mg/kg)
45674700|NCT02106325|Drug|Diphenhydramine|Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department
45674701|NCT01625689|Biological|SIIL LAIV (live, trivalent seasonal influenza vaccine)|Dose: 0.5 mL, The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season
45674702|NCT01625689|Biological|Placebo|Inactive placebo will be identical to SII LAIV in appearance, ingredients, and concentrations, except it will be missing attenuated influenza virus.
45674703|NCT02184611|Drug|Umeclidinium bromide|Blended with lactose and magnesium stearate dry white powder of umeclidinium 62.5 mcg to be inhaled via a NDPI
45674704|NCT02184611|Drug|Placebo|Blended with lactose and magnesium stearate dry white powder to be inhaled via a NDPI
45834123|NCT00630396|Drug|Minocycline|"Dose level 1 = 3mg/kg intravenous (IV) initial dose, followed by 1.5mg/kg every 12 hours times 5 more doses.~Dose level 2 = 4.5mg/kg intravenous (IV) initial dose, followed by 2.25mg/kg every 12 hours times 5 more doses.~Dose level 3 = 6 mg/kg intravenous (IV) initial dose, followed by 3 mg/kg every 12 hours times 5 more doses.~Dose level 4 = 10 mg/kg intravenous (IV) initial dose, followed by 5 mg/kg every 12 hours times 5 more doses"
45834124|NCT00636480|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate (2% w/v) in an aqueous base, 26 ml applicator. Active drug contains alcohol and the placebo contains no drug. Administered topically.
45457130|NCT04437680|Device|Votiva device|A retrospective chart review of the medical records
45834125|NCT00636480|Drug|ChloraPrep One Step|Administer topically
45834126|NCT00636480|Drug|Sterile saline|0.9% NaCl solution
45834127|NCT01924572|Procedure|cord clamping at 2 minutes|
45834128|NCT01924572|Procedure|cord clamping at 5 minutes|
45834129|NCT01924572|Procedure|cord milking|
45834130|NCT01924728|Device|Magnetic stimulation|50Hz active magnetic stimulation (coil position 100%) delivered to the pelvic floor muscles
45834131|NCT01924728|Device|Sham magnetic stimulation|50Hz sham magnetic stimulation (coil position 0%) delivered to the pelvic floor muscles
45994674|NCT05468658|Other|Designing the birthing unit according to the philosophy of Feng Shui|"The cabinets will be painted using salmon and pastel green.~It is planned to make designs specific to the philosophy of Feng Shui on the doors and walls of the birthing unit.~Live nature videos and sounds will be projected onto the wall.~Fabric curtains will be replaced with curtains designed according to the philosophy of Feng Shui.~Natural plants will be placed.~Lighting will be used.~Bed linen will be designed according to the Feng Shui.~Wooden bell will be used.~Turtle, elephant and Wu Lou objects will be placed.~The Bagua mirror will be placed.~Crystals will be placed.~Natural stones will be placed.~The fountain will be placed in the east compass direction of the unit.~Straw bamboo separator will be used."
45994675|NCT04319926|Drug|lidocaine topical system 1.8%|One topical system is applied to the subject's back for 12 hours.
45994676|NCT04319926|Drug|lidocaine patch 5%|One generic lidocaine patch is applied to the subject's back for 12 hours.
45994677|NCT05384132|Other|SRP + Livfresh Dental Gel|SRP at baseline with use of LDG (test dentifrice) for twice daily brushing between study visits. Scaling and root planing is the physical removal of dental plaque, calculus, and bacterial exotoxins embedded onto the root surface of effected teeth with hand instruments and ultrasonic devices. In addition to scaling and root planing, the participants will use LDG as their primary dentrifice (toothpaste) for the next 6 months. They're instructed to use LDG twice daily with toothbrushing for 2 minutes. LDG in previous studies have been reported to be superior to conventional over-the-counter toothpaste in terms of reducing bacterial plaque and gingival inflammation due to its EDTA (ethylenediaminetetraacetic acid) ingredient. EDTA prevents adhesion of bacterial plaque to teeth.
45994678|NCT05384132|Other|SRP + standard flouride dentifrice|SRP at baseline with use of standard fluoride dentifrice (control dentifrice) for twice daily brushing between study visits. Scaling and root planing is the physical removal of dental plaque, calculus, and bacterial exotoxins embedded onto the root surface of effected teeth with hand instruments and ultrasonic devices. In addition to scaling and root planing, the participants will use standard fluoride toothpaste (commercial over-the-counter toothpaste) as their primary dentrifice (toothpaste). They're instructed to use standard fluoride toothpaste twice daily with toothbrushing for 2 minutes.
45834132|NCT00985686|Other|LEAP Project|In collaboration with experts from Alberta Health Services, the University of Calgary, and Mount Royal University, the Canadian Institute of Natural and Integrative Medicine (CINIM) has created the LEAP Project, a spirituality informed e-mental health intervention, for young people with major depressive disorders (see Appendix for sample materials). It is an online, eight module, multimedia intervention delivered over eight weeks, requiring a weekly commitment of 2-3 hours. The intervention is non-denominational and avoids a focus on any religious traditions. The program aims to treat depression by guiding depressed young people through an exploration of spiritual concepts and principles.
45994679|NCT04320043|Procedure|Anterior cervical decompression|Any of the following anterior surgical techniques used to decompress the cervical nerve roots or spinal cord; corpectomy, Anterior Cervical Discectomy (ACD), Anterior Cervical Decompression and Fusion (ACDF) or ACDF with Plating
46084894|NCT02668419|Device|Neuromuscular Electrical Stimulator|"Quadriceps and calf muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. Stimulation parameters were set up as follows: biphasic current of 40 Hz, 400-µs pulse duration, mode on-time 10s and off-time 20s and maximal amplitude of 60 mA. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min."
45994680|NCT05382416|Behavioral|SHARE! Peer Toolkit Training|The SHARE! Peer Toolkit training is designed to improve the performance of peer workers in their provision of peer support. The training covers each of the 12 tools in the Peer Toolkit, which are taught through brief presentations followed by group discussions and interactive exercises to help people competently use each of the tools. Training sessions are typically two hours each, three times per week for 10 weeks.
45674705|NCT02066311|Drug|Nelfinavir|
45674706|NCT02184455|Biological|DermGEN|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
45674707|NCT02184143|Behavioral|CBPT|Changing Behavior through Physical Therapy (CBPT) is a cognitive-behavioral based self-management program.
45994681|NCT05194579|Combination Product|PF-06881894 by on-body injector|PF-06881894 given by on-body injector (OBI), 6 mg administered as a single SC injection
45674708|NCT02184143|Other|Education|Patient education
45674709|NCT01625611|Drug|Naltrexone|Naltrexone 100 mg titrated over one week
45674710|NCT02159807|Drug|Bupivacaine|The dose of bupivacaine administered intrathecally during placement of the spinal anesthetic.
45674711|NCT02159807|Drug|Fentanyl|20 micrograms routinely administered in combination in the spinal anesthetic
45674712|NCT02066233|Device|EG Scan II (transnasal endoscopy)|
45674713|NCT02066233|Procedure|Standard Endoscopy|
45994682|NCT05194579|Combination Product|PF-06881894 by prefilled syringe|PF-06881894 given by prefilled syringe (PFS), 6 mg administered as a single SC injection
45994683|NCT04320472|Other|Follow up|Follow up up to day 90 (Glasgow outcome scale, Glasgow outcome scale extended, functionnal impairments : Barthel index, Disability Rating Scale)
45994684|NCT05212155|Behavioral|family-based behavioral treatment (FBT)|Individual and group treatment of parent/child dyads to improve dietary choices, minimize sedentary behaviors, increase physical activity levels, and identify social support environments that reinforce healthy lifestyle choices.
45994685|NCT05378594|Diagnostic Test|Nasal allergen challenge|graded nasal allergen challenge to increasing concentrations of allergen with monitoring of nasal symptoms and peak nasal inspiratory flow
45994686|NCT05468580|Procedure|Endoscopic Coeliac Artery Release (eCAR)|Endoscopic Coeliac Artery Release (eCAR); The Median Arcuate Ligament will be cleaved via an endoscopic retroperitoneal approach using a 4 trocar technique described in detail by van Petersen (12). To rule out learning curves and procedural variation all the procedures will be performed by two experienced eCAR surgeons in the MST-Dutch Expert Centre of Gastrointestinal Ischemia. All procedures will be videotaped. Both eCAR surgeons will not be involved in the follow up procedures.
45994687|NCT05468580|Procedure|Sham Operation|The sham operation consists of making 4 incisions up to the fascia similar to endoscopic AC release (eCAR). After 60 to 75 minutes of general anesthesia, in accordance with the average operating time of eCAR, the sham operation is ended. This study design allows for patient and observer blinding and for the sham group the eCAR approach is still feasible if the CARoSO outcome support this without applying additional scar tissue.
46084895|NCT02668419|Other|Physical Therapy Session|each session consisted of breathing exercises and global active exercises of the upper and lower limbs in bed. The treatment was applied twice a day during the hospitalization period. The protocol was interrupted if the patient had signs or symptoms suggestive of poor tolerance to exercise: 1) cyanosis, pallor, dizziness, nausea or pre-syncope; 2) chest pain; 3) bradycardia; 4) a drop in systolic blood pressure >15 mmHg in comparison to baseline; 5) an excessive rise in systolic blood pressure defined as >200 mmHg; 6) a rise in diastolic blood pressure during exercise >110 mmHg; 7) fatigue rated ≥6/10 on the perceived exertion Borg scale (PEB); and/or 8) electrocardiographic signs of cardiac ischemia or ventricular arrhythmias.
45674714|NCT04755491|Device|Continuous veno-venous hemofiltration|Treatment of KDIGO stage 3 AKI by CVVH, in which renal replacement therapy is applied using a convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVH treatment.
45994688|NCT05366114|Other|No intervention, additional video data collection only|No intervention will be used. Consenting participants will have video recordings taken during their exam of joint hypermobility which will be analyzed at a later time
46084896|NCT02768714|Drug|Eurofarma's pegfilgrastim|Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
45994689|NCT04206943|Biological|Car-T Cell Therapy|"Lymphodepletion Protocol:~-6. Day: Cyclophosphamide 300 mg / m^2 i.v.~-5. -4. and -3. Days: Fludarabine 30 mg / m^2 i.v. In addition, one day before the lymphodepletion protocol, xanthine oxidase enzyme inhibitor tablets received 100 mg / day p.o. and 0.9% sodium chloride solution 2000 ml / day i.v. infusion on protocol day received and continues for 2 weeks~Car-T cells are administered in 3 split doses. Day 0: 20% or 40% (20% in patients with high tumor burden - in patients with bulky disease and / or more than 15% blast in bone marrow, 40% in patients with low tumor burden) Day 2: 30% or 50%, (the total amount of Car-T cell dose that should be given in the first 2 days should be 70%.) Third dose (%30);is given on the 7th day in the absence of cytokine release syndrome, or if cytokine release syndrome occurs, Car-T cells are given within 1 month if the number of copies falls below 5,000 / ml in 2 consecutive measurements."
45674715|NCT04755491|Device|Continuous veno-venous hemodialysis|Treatment of KDIGO stage 3 AKI by CVVD, in which renal replacement therapy is applied using a diffusion technique (dialysis). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVD treatment.
45994690|NCT01313923|Drug|Sirolimus (formerly known as Rapamycin)|For low to moderate immunologic risk, the loading dose is 6mg immediately after transplantation, followed by 2mg PO Qday in conjunction with cyclosporine and corticosteroids. After 2-4 months, cyclosporine should be discontinued over 4-8 weeks while titrating sirolimus drug concentrations within the target-range with whole blood trough concentrations every 1-2 weeks. Monitoring is needed because cyclosporine inhibits the metabolism of sirolimus, and discontinuation of cyclosporine can lead to lower levels of sirolimus. In high immunologic risk patients, the loading dose is 15mg after transplantation, followed by 5mg PO Qday in conjunction with cyclosporine and corticosteroids for 12 months. A whole blood trough level is recommended between days 5 and 7 with adjustment to the daily dose.
45994691|NCT05200962|Device|transcranial direct current stimulation|In tDCS, direct electrical currents are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
45994692|NCT01313884|Drug|Irinotecan|50 mg/m2/day x 5 days
45994693|NCT01313884|Drug|Vincristine|2 mg/m2 to a maximum of 2 mg
45834133|NCT00635934|Device|A-MAV™ disc|The A-MAV™ device is a spinal arthroplasy system intended to replace a damaged spinal disc. It is inserted using an anterior surgical approach and aims to reduce low back pain and maintain disc height at the affected level.
45834134|NCT00630552|Other|Placebo|Inactive dummy of AMG 655.
45834135|NCT00630552|Drug|AMG 479|AMG 479 is fully human monoclonal antagonist antibody targeted against insulin-like growth factor receptor type 1 (IGF-1R).
45834136|NCT00630552|Drug|AMG 655|AMG 655 is a fully human monoclonal agonist antibody directed against TRAIL Receptor 2 (TR-2).
45834137|NCT01924962|Device|revascularisation|revascularisation of chronic occluded coronary artery
45674716|NCT04755491|Device|Continuous veno-venous hemodiafiltration|Treatment of KDIGO stage 3 AKI by CVVHDF, in which renal replacement therapy is applied using a combination of diffusion technique (dialysis) and convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVHDF treatment.
45674717|NCT02159729|Drug|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
45674718|NCT02159729|Drug|ATX-101 (1 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
45674719|NCT02159729|Drug|ATX-101 (2 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
45674720|NCT02159729|Drug|ATX-101 (4 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
45674721|NCT04749563|Drug|IGC AD1|IGC AD1 oral Solution
45834138|NCT03098394|Device|Cepheid Xpert CT/NG Rapid Turnaround Test|This diagnostic test will be used to help clinicians determine the need for antibiotic prescriptions in patients with a suspected sexually tract infection.
45834139|NCT03098394|Device|Polymerase chain reaction (PCR)|This is the standard of care for diagnosis of a suspected sexually transmitted infection.
45834140|NCT01925040|Device|Placement of restoration|Placement of restorations
45834141|NCT03399396|Behavioral|Practice facilitation for HPV vaccine|The practice facilitation intervention provides coaching support to pediatric practices to guide them through quality improvement projects to increase HPV vaccination rates.
45834142|NCT01920126|Drug|sodium bicarbonate|0.5 mmol/kg for 1 hr, and then 0.15 mmol/kg/h for 23 hrs The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
45834143|NCT01920126|Drug|Saline|
45834144|NCT00984594|Other|Primary injury site|Autograft will be placed in the primary defect site.
45834145|NCT00984594|Other|Backfill site|Autograft will be placed in the primary defect site; CR-Plug will be placed in the harvest site.
45834146|NCT01925118|Biological|Irradiated donor lymphocyte infusion|
45834147|NCT01925352|Drug|Ad-HGF|5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection into five left ventricular sites.
45834148|NCT03096054|Drug|LY3143921 hydrate|LY3143921 hydrate will be administered orally on a daily schedule. Each cycle of treatment will consist of 21 days, and patients may initially receive up to 12 cycles. If the patient is benefitting, they may continue beyond 12 cycles.
45834149|NCT03095352|Biological|Pembrolizumab|200 mg Given IV
45834150|NCT03095352|Drug|Carboplatin|Arm A: AUC 5 IV every 3 weeks Arm B: AUC 5 IV every 3 weeks
45834151|NCT03095352|Biological|Trastuzumab|For HER2+ patients: IV every 3 weeks using standard approved dosing
45834152|NCT01925430|Device|Screening device|Non-invasive device worn over clothes during sleep. Used to screen for sleep-disordered breathing conditions.
45834153|NCT01925430|Device|Comparative product|A non-invasive device worn on the arm or leg. It monitors body movement and sleep/wake states
45834154|NCT03092856|Biological|Anti-OX40 Antibody PF-04518600|Given IV
45834155|NCT03092856|Drug|Axitinib|Given PO
45834156|NCT03092856|Other|Laboratory Biomarker Analysis|Correlative studies
45994694|NCT01313884|Drug|Temozolomide|100 mg/m2/day x 5 days followed by 2 weeks treatment-free
45994695|NCT01313884|Drug|Doxorubicin|Starting dose 75 mg/m2 to a maximum of 450mg/m2
45994696|NCT01313884|Drug|Cytoxan|1200 mg/m2
45674722|NCT04749563|Drug|Placebo|Placebo of IGC AD1 oral Solution
45674723|NCT02159183|Device|Standard Plus ESTA STL Roxolid implant|The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA). At 8-12 weeks after insertion, the implant will be loaded.
45834157|NCT03092856|Other|Placebo|Given IV
45834158|NCT01920204|Drug|Midostaurin,|Midostaurin, twice daily 100 mg orally, continuously for 6 months
45834159|NCT00984204|Device|Therapy Cool Path Duo|All patients will be treated with Therapy Cool Path Duo Ablation System for the treatment of typical atrial flutter.
45834160|NCT04508010|Other|IVR|Participants will receive an IVR survey
45834161|NCT04508010|Other|CATI|Participants will receive a CATI survey
45834162|NCT00983892|Behavioral|Caregiver website|Website receives patient symptom assessment data from IVR and provides caregivers with weekly updates on patient status, allowing caregivers to access tailored symptom management advice and formulate an action plan.
45834163|NCT02984202|Device|auditory midbrain implant (AMI)|
45994697|NCT01313884|Drug|Pegfilgrastim|6 mg subcutaneous within 24 to 48 hours after each Regimen A cycle
45994698|NCT05352659|Behavioral|Face-to-face and online LGBTQ+ training|The intervention consists of Organization-level technical assistance in regard to LGBTQ climate of the organization AND Clinician-level face-to-face virtual workshop LGBTQ competency training, virtual clinical consultations, and links to publicly available LGBTQ training.
45994699|NCT05352659|Behavioral|On-line training|This study arm receives only links to publicly available on-line LGBTQ training.
45994700|NCT01158664|Device|0.6 mm tread pitch implant|0.6 mm tread pitch implant will be used
45994701|NCT01158664|Device|0.1 mm tread pitch implant|0.1 mm tread pitch implant will be used
45994702|NCT00537524|Biological|H5N1 Influenza Vaccine|Two 0.5mL injections of H5N1 influenza vaccine containing 7.5μg of H5N1 antigen (A/Vietnam/1194/2004), administered 3 weeks apart, and one 0.5mL injection of H5N1 vaccine 12 months after the second dose, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
45994703|NCT00537524|Biological|H5N1 Influenza Vaccine|Two 0.25mL or 0.5mL injections of H5N1 influenza vaccine, administered 3 weeks apart, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
45994704|NCT05193240|Diagnostic Test|preliminary swallowing test|"Patients will be included before the surgery. During this inclusion visit, we will perform a preoperative swallowing test.~Immediately after surgery (H2-H24 after extubation), we will perform a preliminary swallowing test, an ultrasound examination of the vocal cords and a nasofibroscopy to determine the mobility of the vocal cords. A physiotherapist will carry out the first two assessments. An ENT physician will perform the nasofibroscopy. The ENT physician performing the nasofibroscopy will not know the conclusions of the tests carried out by the physiotherapist immediately after the operation.~At last, on day 4 after extubation, we will repeat the preliminary swallowing test and the ultrasound examination to measure the evolution of cord mobility.~30 days after the surgery, we will realize a follow-up on medical file and mark the end of the research."
45994705|NCT05350514|Drug|PI-2620 tracer|Following published manufacturer guidelines for Flutemetamol (VizamylTM), Flortaucipir (TauvidTM) and PI-2620 tracer administration162, all participants will be given a 370 MBq (10 mCi) single intravenous bolus (total volume 10mL) of the radiotracer, followed with an intravenous flush of 0.9% sodium chloride injection. Radiotracer administration and participant monitoring will be conducted by trained personnel from the CU-RIC.
45994706|NCT00537563|Drug|Telithromycin|
45994707|NCT00536406|Behavioral|BE-ACTIV|BE-ACTIV is 10-week behavioral treatment involving increasing pleasant events.
45994708|NCT00536406|Behavioral|Treatment as usual (TAU)|TAU includes usual treatment in nursing care facility.
45994709|NCT01135459|Drug|CEP-33457|CEP-33457 will be administered per dose and schedule specified in the arm description.
45994710|NCT01135459|Drug|Placebo|Placebo matching to CEP-33457 will be administered per schedule specified in the arm description.
45994711|NCT00537602|Drug|miglustat|
45994712|NCT00537602|Drug|placebo|
45994713|NCT05178667|Dietary Supplement|High dose|Food supplements are consumed during 3 months by healthy volunteers.
45994714|NCT05178667|Dietary Supplement|Low dose|Food supplements are consumed during 3 months by healthy volunteers.
46084897|NCT02768714|Drug|Neulastim|Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
46084898|NCT05044793|Device|OMNI® Surgical System|The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
45674724|NCT02159183|Device|Standard Plus STL implant|The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck. At 8-12 weeks after insertion, the implant will be loaded.
45674725|NCT02183675|Drug|Telmisartan/Amlodipine|Telmisartan/Amlodipine fixed-dose combination
46084899|NCT00614640|Biological|DermaVir patch|DNA Vaccine
46084900|NCT00614640|Biological|Placebo patch|10% dextrose (D-glucose) solution
46084901|NCT02761460|Drug|PEG-rhG-CSF|PEG-rhG-CSF 6mg is given for patients Greater than or equal to 45 kg, 3mg is given for those less than 45kg 24-48 hours after chemotherapy
46084902|NCT00631865|Biological|Melanocyte transplantation|Injection of melanocytes directly in Epidermis
46084903|NCT02354274|Radiation|Escalated: Inhomogeneous dose plan|
46084904|NCT02354274|Radiation|Standard: Homogeneous dose plan|
46084905|NCT02764736|Drug|Atorvastatin|Patients will be given 20mg atorvastatin daily for 12 weeks and then increased to 40mg atorvastatin daily for an additional 12 weeks.
45674726|NCT02183675|Drug|Telmisartan/Amlodipine/HCTZ|Telmisartan/Amlodipine/HCTZ fixed-dose combination
45674727|NCT02183675|Drug|Telmisartan/HCTZ|Telmisartan/HCTZ fixed-dose combination
45674728|NCT02183519|Drug|Capsaicin|For reflex cough testing, all participants will receive various concentrations of nebulized capsaicin. Delivery of multiple concentrations and doses of capsaicin allows for accurate assessment of both the strength (airflow measures) of reflex, as well as cough sensitivity.
45994715|NCT05178667|Dietary Supplement|Maltodextrin|Food supplements are consumed during 3 months by healthy volunteers.
45994716|NCT00221572|Procedure|Determination of bot density of Cystic Fibrosis patients|Determination of bot density of Cystic Fibrosis patients.
45994717|NCT00536445|Device|NAVA|Neurally Adjusted Ventilatory Assist (mechanical ventilation controlled by the diaphragm electrical activity)
45994718|NCT01259284|Drug|Atorvastatin|1 capsule by mouth every morning 5 days before surgery, and 9 days after surgery or until discharge.
45994719|NCT01259284|Dietary Supplement|Fish Oil Supplement|3 capsules by mouth in the morning and evening 5 days before surgery, and 9 days after surgery or until discharge.
45994720|NCT01259284|Other|Placebo|"Placebo group: 4 capsules by mouth every morning and 3 every evening for 5 days before surgery and 9 days after surgery or until discharge.~Atorvastatin group: 3 capsules by mouth every morning and evening, 5 days before surgery and 9 days after surgery or until discharge.~Fish Oil Supplement group: 1 capsule by mouth every morning 5 days before surgery and 9 days after surgery or until discharge."
45994721|NCT03457025|Drug|Oral Corticosteroids|Prednisone 10 day taper: 60mg for 5 days, then taper for five days to 0mg
45994722|NCT03457025|Drug|Oral antivirals|acyclovir 400mg: one pill 4 times daily for 7 days
45994723|NCT03457025|Device|Hyperbaric Oxygen Therapy|2.4atm administered for twice daily dives for 5 days, 10 dives total. To be begun in the first 1 week after onset of paralysis.
45994724|NCT01259245|Other|Tai chi + PRP|The exercise content was totally identical to PRP group except 15 minutes of 5 Sun Style Tai Chi were substituted to 15 minutes of relaxation exercise
45994725|NCT01259245|Other|PRP|Formal pulmonary rehabilitation program consisted of overview of COPD management, aerobic exercises, breathing control exercises, Thera-Band strengthening exercises, safety precautions for physical training and goal setting
45994726|NCT00537719|Drug|GSK716155|albiglutide subcutaneous injection
45994727|NCT00537719|Drug|Placebo|placebo injection
45994728|NCT05468385|Device|Vagus nerve stimulation via tragus|The device will send stimulus intensity of around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.5 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
45994729|NCT05468385|Device|Sham stimulation via earlobe|The device will send stimulus intensity of around 0.5mA via the earlobe in the left ear (based on participants' subjective reports), delivered with a pulse width of 0.5 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
45994730|NCT04685603|Biological|AV-COVID-19|Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
45994731|NCT04685837|Other|therapeutic exercise|"As soon as the study investigators have obtained a significant sample of patients with non-specific sub-acute low back pain, the intervention will begin.~The principal investigator will perform an individual assessment of the patients. At the end of the assessment, he will randomly distribute them into two groups. Tele-rehabilitation group and face-to-face group.~On the one hand, the main researcher will explain the application works to the tele-rehabilitation group. For 8 weeks, they have to perform 2 therapy exercise training sessions following the instructions on the application.~On the other hand, the researcher will explain the protocol to be followed by the group face to face. In addition, he will provide a schedule to follow a correct development of the protocol. Like the tele-rehabilitation group, they will carry out 16 sessions over 8 weeks.~At the end of the protocol, the principal investigator will perform an individualized assessment of each of the study participants."
45994732|NCT00536562|Behavioral|Comprehensive Cardiac Rehabilitation (CR)|6-month Comprehensive Cardiac Rehabilitation program consisting of: 1) initial medical assessment by case manager and physician to determine CR strategies; 2) entry exercise stress test; 3) multi-disciplinary assessment and intervention to achieve risk factor targets in nutrition & psychological services as needed; 4) twice per week supervised exercise training and twice per week home-based exercise following an individualized, progressive prescription; 5) Exit assessment at 6 months.
45994733|NCT04685174|Device|Invos Model 5100C Cerebral/Somatic Oximeter|To measure the correlation between post arterial and venous anastomoses (reperfusion) NIRS values of transplanted kidney and post-transplant graft failure as manifested in initiation of renal replacement therapy post transplant
45994734|NCT00537758|Behavioral|Cognitive Behavior Therapy|
45994735|NCT00537758|Behavioral|CBT and BWL|
45994736|NCT00537758|Behavioral|Behavioral Weight Loss Treatment|
45994737|NCT04685096|Other|Test product creme|twice daily application of creme containing 2% NMN
45994738|NCT04685096|Other|Reference creme|twice daily application of reference creme
45994739|NCT05121090|Behavioral|Educational program|"The educational program is based on dietary, physical activity, psychology, and sophrology approaches dispensed by health care professionals. Evaluations will consist of anthropometric measurements (height, weight, body mass index), behavioural questionnaires, and basic physical tests (handgrip, squats, balance, …).~Optionally, a saliva collection will be proposed to obtain the DNA required for genetic analyses."
45994740|NCT00537797|Other|FDG-PET Scan|Positron emission tomography with 18F-fluorodeoxyglucose
45994741|NCT00537836|Drug|BAY 86-5310 (ZK 283197)|3 mg (3 x 1 mg tablet) or 2 mg (2 x 1 mg tablet) ZK 283197 in respective treatment group, once daily p.o. over 8 weeks
45994742|NCT00537836|Drug|Placebo|Placebo, once daily p.o. over 8 weeks
45994743|NCT00537836|Drug|17ß-estradiol|1 mg (2 x 0.5 mg tablet) 17ß-estradiol, once daily p.o. over 8 weeks
45994744|NCT05468268|Device|20 Hz rTMS|rTMS stimulation
45994745|NCT05468268|Device|Sham rTMS|Sham stimulation
45994746|NCT05338658|Drug|Peptide Alarm Therapy (PAT)|PAT is given on Day 1 by IT injection after the 1st anti PD-1/PD-L1 infusion and again 36-48 hours later on Day 3.
45994747|NCT02277171|Device|Nitric Oxide impregnated catheter|Patients undergoing radical prostatectomy will be catheterized for 7-14 days with Nitric Oxide impregnated Foley catheters
45994748|NCT00537875|Dietary Supplement|Ginger|Capsule, 1000 mg, BID, 3 days
45994749|NCT00537875|Dietary Supplement|Placebo|Capsule, 1000 mg, BID, 3 days
45994750|NCT00551564|Drug|rosiglitazone maleate|Rosiglitazone tablets 4 mg dose will be administered orally by subjects
45994751|NCT05105061|Drug|Ketamine (Ketalar)|0.5 mg/kg of body weight
45457131|NCT02295826|Drug|Dabigatran|Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
45457132|NCT02295826|Drug|Acetylsalicylic acid|participants randomized to ASA therapy will be loaded with 325 mg of ASA, followed by 81 mg/day
45457133|NCT03923647|Device|Laparoscopy|Laparoscopic insertion with carbon dioxide via open technique at the umbilicus
45994752|NCT05105061|Drug|Placebo|IM injection of matching placebo
45994753|NCT04870463|Procedure|Maxillary and mandibular Cone Beam Computed Tomography record|A Cone Beam Computed Tomography image of each patient of each group at three different moments of the study (baseline/T0, 8-9 months of treatment/T1 and end of treatment/T2)
45457134|NCT01343576|Dietary Supplement|milk fat|45 g milk fat per day in 4 weeks
45457135|NCT03923491|Behavioral|Healthy Feeding, Healthy Eating|Home Based Motivational Interviewing to Improve Diet Quality of Preschoolers
45457136|NCT03923491|Behavioral|Reading Readiness|Active Control that uses Motivational Interviewing to improve Reading Readiness of Preschool Children
45457137|NCT01348724|Drug|[14C] NKTR-118|Single 25 mg oral dose administered on Day 1
45457138|NCT03519022|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and duloxetine.
45457139|NCT03519022|Drug|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
45457140|NCT03519022|Drug|Methylphenidate|The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
45994754|NCT05095740|Device|repetitive transcranial magnetic stimulation (rTMS)|Repetitive transcranial magnetic stimulation used to regulate the contribution of the laryngeal motor cortex to voice production and laryngeal motor muscle activation.
45994755|NCT05095740|Device|sham rTMS|Repetitive transcranial magnetic stimulation used to a cortical area not associated with change in outcomes at an intensity substantially lower than that of the established threshold.
45834164|NCT04275258|Other|Provide assistance to subject's rural PCP pertaining to subject/patient pain management goals and opioid taper plan|"PA checks in with PCP at 1,2,4,8, 12, 16, and 20 weeks post hospital discharge by secure e-mail, fax or phone to provide opioid taper and pain management guidance until patient has tapered off opioids or returned to pre-trauma doses. PCP may contact PA whenever needed.~If PCP requests assistance or reports deviation from the planned opioid taper, PA will provide individualized consultations, which may include a revised taper plan and/or adjunctive therapy recommendations.~If there is continued deviation from the planned taper, the PA will facilitate a UW TelePain multidisciplinary telemedicine consultation.~The collaborative pain care and opioid taper intervention ends at 20 weeks."
45994756|NCT00551603|Drug|switch (epoetinum beta, darbepoetinum)|switching from epoetinum beta once weekly to once-fortnightly darbepoetinum
45994757|NCT00551603|Drug|continuation (darbepoetinum)|continuation of the previous darbepoetinum administration schedule
45994758|NCT05093712|Other|Educational Intervention|Watch educational video
45994759|NCT05093712|Other|Survey Administration|Complete surveys
45994760|NCT04864262|Other|Photovoice|Photovoice is a method that uses photographs and dialogue to share experiences, understand an issue and promote positive change. Group meetings will be held four times throughout the photovoice intervention. The goals of the group meetings are to share knowledge about falls and fall prevention, identify commonalities in the issues raised by the participants, and discuss ways in which these issues could be addressed, both at individual and societal levels. For two photo assignments, participants will be asked to take 4-6 pictures for an assigned question. The question for photo assignment #1 will be 'What decreases your likelihood of falling?' The question for photo assignment #2 will be 'How do you reduce the risk of falling so that you can participate in meaningful activities?' Following each photo assignment, participants will complete an individual semi-structured interview with the peer mentor and the research trainee, who will have a background in physical or occupational therapy.
45994761|NCT04853264|Device|Ultrasound-guided peripheral venipuncture|Ultrasound-guided peripheral venipuncture performed by a proficient vascular access registered nurse. The procedure will be performed according to the standard operational protocol for ultrasound guided peripheral venipuncture instituted at the hospital where the study will be conducted. Site Rite 8 or Site Rite 5 ultrasound machines (Bard Access Systems, Inc., USA) will be used on the procedures.
45994762|NCT04853264|Device|Conventional peripheral venipuncture|Conventional peripheral venipuncture performed by a registered nurse at the clinical inpatient unit. The procedure will be performed according to the standard operational protocol for peripheral venipuncture instituted in the hospital where the study will be conducted.
45994763|NCT05075811|Drug|Ossium vBM-MSC|Vertebral bone marrow derived mesenchymal stem cells
45994764|NCT05075811|Other|Placebo|Normal Saline
45994765|NCT04806191|Other|Evidence based treatment strategy|Evidence-based clinical examination and treatment plan
45994766|NCT04806191|Other|Targeted patient information package|GPs will in cooperation with the patients tailor a information package targeted to the patients needs regarding their clinical shoulder diagnosis and individual implications and needs (Pain, sleep, exercises etc.).
45994767|NCT04806191|Other|Treatment as usual (TAU)|Usual care as provided by the GP
45994768|NCT05067426|Other|Exercise|high-intensity interval training sessions
45994769|NCT00551681|Device|biventricular pacemaker with epicardial left ventricular lead|epicardial left ventricular lead placement
45994770|NCT00551681|Device|transvenous left ventricular lead placement|implantation of biventricular pacemaker with transvenous left ventricular lead placement
45994771|NCT04686045|Other|observational study|observational study
45994772|NCT00551720|Behavioral|Standard Care|Brief advice and follow-up provided a smoking-cessation trained Health Educator PLUS nicotine patch
45994773|NCT00551720|Behavioral|Motivational Enhancement|Brief advice and follow-up, nicotine patch, and the addition of a tailored motivational intervention and behavioral skills counseling for smoking cessation.
45457141|NCT04415294|Diagnostic Test|Critical flicker frequency|Measure the critical flicker frequency as a screening test for hepatic encephalopathy using a portable self administered device
45457142|NCT01228669|Drug|NNC 0172-0000-2021|Single dose injected i.v. (into a vein). Each treatment dose is assessed for safety before escalating to next dose
45994774|NCT04686201|Device|Diabetes Mobile Application|incorporating mobile application usage in managing diabetes mellitus patient in health clinics
45994775|NCT00551798|Procedure|TEP au MIBI|Intravenous injection of MIBI.The review lasted 30 min, during which the patient should not move.
45994776|NCT05056584|Biological|Glucagon infusion|One hour glucagon-clamp followed by one hour of blood sampling
45457143|NCT01228669|Drug|NNC 0172-0000-2021|Single dose injected s.c. (under the skin). Each treatment dose is assessed for safety before escalating to next dose.
45457144|NCT01228669|Drug|placebo|Single dose injected i.v. and s.c. Each treatment dose is assessed for safety before escalating to next dose.
45457145|NCT01354574|Other|High Glycemic Index meals|Dietary intervention with meals containing high glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only high glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
45994777|NCT05056584|Biological|Primed tracer infusion|Infusion of primed isotopically labelled glucose, amino acids and lipids. From 2 hours prior to glucagon infusion and throughout the test day,
45994778|NCT05467995|Biological|AK111|AK111 administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
45674729|NCT02183519|Other|Voluntary cough test|Participants will be fitted with a facemask covering their mouth and nose, and instructed to cough into the facemask.
45674730|NCT02132195|Drug|ACTH|Patients will receive ACTH twice weekly for 6 months, with a 50% dose reduction allowed for side effects. The dose will be reduce by 50% at 6 months and continued for an additional 6 months.
45994779|NCT05467995|Biological|Placebo|Placebo administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
45994780|NCT00551915|Biological|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
45674731|NCT02182973|Dietary Supplement|donor human milk|"Infants with NAS requiring pharmacologic management will be fed donor human milk instead of formula for 2 weeks.~GI-subscores from the Finnegan NAS Scoring system will be computed."
45674732|NCT02182895|Drug|Saxagliptin|2.5-5 mg daily
45674733|NCT01625377|Drug|tacrolimus|Arm 1 : tacrolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to month 6 post-transplantation. Arm 2 : tacolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to 16 weeks post-transplantation at the latest.
45674734|NCT01625377|Drug|everolimus|Arm 1: no everolimus Arm 2: everolimus (C0 6-10 ng/ml) from randomization to month 6 post-transplantation
45674735|NCT01625377|Drug|Basiliximab|Basiliximab was supplied to the participating centers as marketed, i.e. in packs containing one vial of 20-mg powder, and water for injection (WFI). 20 mg at D0 and D4
45674736|NCT01625377|Drug|Mycophenolic Acid|Dose of 1440 mg/day from transplantation to month 6 post- transplantation
45674737|NCT01625377|Drug|Corticosteroids|Administration of oral corticosteroid therapy was at the discretion of the centers according to their usual practice
45994781|NCT00551915|Biological|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
45994782|NCT00551915|Biological|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
45994783|NCT00551915|Biological|PENTACEL™|licensed vaccine for diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b, administered open-label
45994784|NCT00551915|Biological|RECOMBIVAX HB™|licensed vaccine for hepatitis, administered open-label
46084906|NCT04652999|Behavioral|Muscle Relaxation with Guided Imagery|Relaxation intervention session begins with diaphragmatic breathing, followed by Jacobson's progressive muscle relaxation, which involves the contraction and subsequent relaxation of the 16 muscle groups of the body (forearm, arm, upper forehead, eye, mouth, jaw and throat, neck, shoulder, chest, stomach, thigh, leg and foot). The contraction is performed for 7 seconds while the relaxation lasts for about 40 to 50 seconds. The relaxation of the foot muscle group is only performed on the healthy foot, because dressing and bandages may bandage the foot with the DFU, which together with the typical joint stiffness of the diabetic foot, make it difficult to perform. After muscle relaxation, begins the guided imagery focused on DFU healing. The patient is instructed to think about his/her current state of health and to imagine the DFU as a dark area and the healing relaxation as a light associated to pleasant sensations, which will focus on the foot with DFU to heal it.
45674738|NCT02158949|Behavioral|mROAD|
45994785|NCT00551954|Drug|acarbose|100 mg (tablets) t.i.d.
45994786|NCT00551954|Drug|placebo|one tablet t.i.d.
45994787|NCT05467956|Other|Covid-19|Covid-19 disease
45994788|NCT04981236|Procedure|Pericapsular nerve group block|A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. A total volume of 20 ml of ropivacaine 0.3% will be injected.
45994789|NCT04981236|Procedure|Periarticular block|The periarticular injection solution contained 20mL of 7.5 mg/mL ropivacaine, 30mg of ketorolac, and 0.3mL of 1.0 mg/mL epinephrine. These agents were mixed with normal saline to a combined volume of 50mL. The surgeon injected this mixture into the tensor fascia lata, subcutaneous tissues, abductors, short external rotators muscles, and structures in the capsule.
45994790|NCT00551993|Procedure|robotic laparoscopic sacrocolpopexy|Da Vinci Robot
45994791|NCT00551993|Procedure|Laparoscopic Sacral Colpopexy|Standard laparoscopy
45994792|NCT00552149|Drug|Gemox, Cetuximab|"GEMOX (Arms 1 and 2), every two weeks:~Day 1: gemcitabine 1000 mg/m² intravenous (IV) infusion over 100 minutes (10 mg/m²/min) Day 2: oxaliplatin 100 mg/m² IV infusion over 2 h~Cetuximab (ErbituxÒ) (Arm B only) every two weeks:~(chemotherapy will be started one hour after the end of the cetuximab infusion).~Day 1 or Day 2: 500 mg/m² IV infusion over 150 minutes"
45994793|NCT05467878|Other|The anesthesia and analgesia technique preferred by the anesthetist will be recorded.|In the study, the anesthesia method applied by blind anesthesiologists in the peroperative period, the drugs or techniques used for analgesia will be recorded and their effects on the postoperative period and hospital stay will be examined.There will be no intervention in the perioperative and postoperative process.
45994794|NCT03455699|Device|VenaSeal SCS|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
45994795|NCT03455699|Device|ClosureFast Radiofrequency Ablation (RFA)|Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.
45994796|NCT03455699|Device|Roll-In (VenaSeal SCS)|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
45994797|NCT00536640|Drug|Erlotinib|150 mg per os, given daily until tumor progression
46084907|NCT04652999|Behavioral|Neutral Guided Imagery|This placebo consists on neutral guided imagery focused on themes of the patient's daily life before having DFU. Each session has a theme associated with the patient's life - family, work, friends and leisure. Initially, the patient is asked to think about an event related to the theme of the session of his/her choice, be it positive or negative, which occurred before patient has the current DFU. Then, questions are asked which allow a more detailed reconstruction of the event and the patient is asked to imagine according only to the instructions given. When the whole episode is remembered, the patient is asked to tell what he or she imagined/remembered in each of the questions given.
46084908|NCT00646737|Drug|Mycophenolate sodium|Mycophenolate sodium
45994798|NCT00536640|Drug|Bevacizumab|15mg/kg i.v. on day 1 (three-week cycle) until tumor progression
45994799|NCT00536640|Drug|Gemcitabine|1250 mg/2 i.v. on day 1 and day 8 (three-week cycle) until tumor progression for a maximum of 6 cycles
45994800|NCT00536640|Drug|Cisplatin|80 mg/m2 i.v. on day 1 (three-week cycle) until tumor progression for a maximum of 6 cycles. (The administration of 40 mg/2 Cisplatin on day 1 and day 8 is also possible)
45994801|NCT00552227|Drug|ruboxistaurin|oral 32 mg daily
45994802|NCT00552227|Other|placebo|placebo
45994803|NCT00536679|Drug|GSK163090 capsule, fasted|GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 milliliters (mL) of water.
45994804|NCT00536679|Drug|GSK163090 Tablet, fasted|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 mL of water.
46084909|NCT04705376|Device|Breg Polarcare|The Breg Polarcare device is a type of cryotherapy machine that circulates ice cold water into a patch that can be worn by the patient on their affected joint (e.g., shoulder, knee).
46084910|NCT04705376|Device|Thermazone|ThermaZone is a compact device that uses thermoelectric technology to provide heating and cooling therapy without the use of ice.
46084911|NCT00646815|Drug|growth hormone (genotropin)|Dosage regulation will follow the local recommendations of GHD treatment
46084912|NCT02764502|Device|Pressure Gauge Manometer|Identification of epidural space
46084913|NCT04033185|Other|virtual reality, robot assisted gait training|study group: 15 sessions virtual reality, robot assisted gait training
46084914|NCT04033185|Other|conventional treatment|study group: 15 sessions conventional treatment control group: 30 sessions conventional treatment
45674739|NCT02132117|Drug|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 29 days.
45834165|NCT01925664|Behavioral|Doula|This intervention included doulas providing weekly home visits during the last trimester of pregnancy and up to three months postpartum. Home visits focused on prenatal health, preparation for childbirth, breastfeeding education, and developing a relationship with the baby. Doulas also were present in the hospital during labor, delivery, and postpartum providing emotional support, non-medical comfort measures, and breastfeeding counseling.
45834166|NCT03474744|Drug|Copanlisib|Solution for IV infusion
45834167|NCT03474744|Drug|Rituximab|Solution for IV infusion
45834168|NCT01925742|Other|Integrated prenatal screening for Down's syndrome|Analysis of several serum biochemical markers, and fetal nuchal translucency by ultrasound, with computation of an individual risk of fetal aneuploidy.
45674740|NCT02132117|Drug|Vehicle to Oxymetazoline HCL Cream|Vehicle to Oxymetazoline HCL Cream (AGN-199201) applied to the face once daily for 29 days.
45834169|NCT01925742|Other|Serum QUAD Assay for aneuploidy screening|Series of biochemical markers with results integrated into a computational estimate of risk of fetal aneuploidy
45834170|NCT01925742|Other|Semiconductor MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using a targeted NIPT assay.
45994805|NCT00536679|Drug|GSK163090 Tablet, fed|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.
45994806|NCT04793477|Device|instrumentation technique in pulpectomies|comparison of three file systems for pulpectomies in primary molars
45994807|NCT04974801|Device|Provox Life|Use of Provox Life range of HMEs for different situations and their attachments (adhesives and laryngectomy tubes)
45994808|NCT04974801|Device|Usual Care|Continued Usual Care routines.
45994809|NCT04788680|Other|Dietary intervention 1|Participants receive a beverage with a defined amount of non-nutritive sweetener.
45994810|NCT04788680|Other|Dietary Intervention 2|Participants receive a beverage with a defined amount of non-nutritive sweetener and maltodextrin.
45994811|NCT04788680|Other|Dietary Intervention 3|Participants receive a beverage with a defined amount of monosaccharide.
45994812|NCT04788680|Other|Dietary Intervention 4|Participants receive a beverage with a defined amount of disaccharide.
45994813|NCT04967430|Drug|Peginterferon Lambda-1A|"Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain.~Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose."
45994814|NCT04967430|Other|Placebo|The placebo will be 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
45994815|NCT04783103|Device|a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil|3 weeks home use
45994816|NCT01259089|Drug|erlotinib hydrochloride|Given orally
45994817|NCT01259089|Drug|Hsp90 inhibitor AUY922|Given IV
45994818|NCT01259089|Other|laboratory biomarker analysis|Correlative studies
45994819|NCT01259089|Procedure|needle biopsy|Undergo image-guided needle biopsy (correlative studies)
45994820|NCT01259089|Genetic|mutation analysis|Correlative studies
45994821|NCT01259089|Other|pharmacological study|Correlative studies
45994822|NCT05467839|Device|derma pen|Derma pen is automatic and rechargeable device (vibrating frequency:6500-10000 r/m, vibration speed level 5, model: Ultima A6, company: Dr. Pen and country: Korea). With every case the needle should be replaced. Needle length is adjustable from 0.25mm to 2mm according to the treated areas. The pen is convenient in treating narrow areas such as the nose, around the eye and the mouth. The vibration speed of the pen can be controlled in 5 levels
46084915|NCT02764346|Behavioral|iCanCope app|"In addition to standard medical care, adolescents in the experimental group will receive access to the iCanCope smartphone app for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component."
46084916|NCT02764346|Behavioral|iCanCope attention control app|"The control group is designed to control for the potential effects on outcomes of time, attention, and smartphone use during the intervention. In addition to standard medical care, adolescents in the attention control group will receive access to the iCanCope control app, with limited functionality."
46084917|NCT00646893|Procedure|Preimplantation Genetic Diagnosis (PGD)|"one-cell embryo biopsy on day 3 of development. The cell will be analyzed by FISH using probes for X,Y,13,15,16,17,18,21,22 chromosomes. Cells with dubious results will be reanalyzed by no result rescue (Colls et al. 2007)"
46084918|NCT02769182|Device|Monitoring and training using the system|subjects and caregivers will be trained on using the system and receive a 'user manual' delineating all procedures and possible applications of the system, as well as operations for daily charging of the sensors and smart phone. They will then be fitted with the sensors. The clinician will set all necessary applications, including setting the cognitive games application and the 'network of users'. Users and care givers will be informed of the personalized recommendations system that will provide the user with daily feedback on activity and weekly recommendations and goals for duration of the study. A helpline will be provided in case technological problems occur or for routine support.
46084919|NCT02769182|Behavioral|Standard of care|Subjects in this group will not receive the system but will encouraged to continue with their daily living routine and provided with recommendations for stretching and strengthening exercises. The control group subjects will be assessed at the same three time points as those in the experimental group. Subjects in both groups will also receive written information about the importance of activity, cognitive enhancing tasks, avoidance of falls and home hazards. In Israel, this information combined with an exercise prescription is considered the 'standard of care' for community-dwelling older adults.
46084920|NCT00915005|Radiation|Photon Therapy|Group 1: 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.
46084921|NCT00915005|Radiation|Proton Therapy|"Group 2: 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.~Group 3: 66 Gy with conventional fractionation given 5 days a week for about 6-7 1/2 weeks.~Each daily treatment should take about 20-30 minutes to complete."
45834171|NCT01925742|Other|Optical-based MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using an un-targeted NIPT assay.
45834172|NCT01925742|Other|Harmony™ Test (Ariosa Diagnostics)|Test that is commercially available (Ariosa Diagnostics). (will be used for benchmarking purposes in a subset of each arm)
45834173|NCT01925820|Drug|Pegasys&Entecavir|180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks.
45834174|NCT01925898|Drug|Midazolam - active comparator|Oral midazolam - 0.7mg/kg single dose
45994823|NCT04781504|Behavioral|Exercise|intervention groups will complete supervised virtual exercise sessions for 12 weeks using the platform preferred by the patient (Zoom care, Zoom business, Google duo, google meet, FaceTime, join.me, WhatsApp Call, etc). The appointment will be scheduled and conducted 2 days per week. The first class will be conducted on-site to teach the patient how to take vitals and to do an in-person exercise session
45994824|NCT05142436|Other|Product A: Non-Combusted Cigarette Variant 42001402 and product use Mode B|42001402, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
45457146|NCT01354574|Other|Low Glycemic Index meals|Dietary intervention with meals containing low glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only low glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
45994825|NCT05142436|Other|Product B: Non-Combusted Cigarette Variant 42001399 and product use Mode B|42001399, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
45994826|NCT05142436|Other|Product C: Non-Combusted Cigarette Variant 42001401 and product use Mode B|42001401, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
45994827|NCT05142436|Other|Product D: Non-Combusted Cigarette Variant 40007386 and product use Mode B|40007386, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
45994828|NCT05142436|Other|Product E: Non-Combusted Cigarette Variant 42001402 and product use Mode A|42001402, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode A
45994829|NCT04960176|Procedure|Acupuncture|Acupuncture will be applied by using 0,25x25mm needles.
45994830|NCT04960176|Procedure|Non-invasive Sham Acupuncture|Non-invasive sham acupuncture will be applied by using blunted 0,25x25mm needles.
45994831|NCT05466513|Other|Facial tactile stimulation|Tactile stimulation was given around the face with soft tissue paper for two minutes.
45457147|NCT02293252|Device|Remote patient monitoring (Motiva)|interactive bi-directional home telemonitoring system that provides remote monitoring
45994832|NCT00552266|Drug|Methylphenidate|tablets 10-60 mg/day administered once or twice daily 6 weeks
45457148|NCT03923257|Drug|177Lu-DOTA-tyr3-OCTREOTATE|This is a peptide receptor radiotherapy that targets somatostatin receptors on tumor cells.
45457149|NCT03923257|Procedure|Peptide Receptor Radiotherapy (PRRT)|PRRT is internal radiation that is individually dosed according to patient body surface area, kidney function and bone marrow status.
45457150|NCT01348802|Behavioral|Push + Pull|Push + Pull is evidence on pain that is extracted from medical, nursing, psychology and rehabilitation journals, appraised for quality and relevance, and delivered to clinicians by e-mail alerts or available for searches of the accumulated database.
45994833|NCT04943757|Drug|Bendamustine Hydrochloride|50 mg/m2 iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
45994834|NCT04943757|Drug|Cyclophosphamid|25 mg/kg iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
45994835|NCT00552383|Procedure|NIDCAP based developmental care|"Infants in the intervention arm will receive care in the NICU by nursing staff who have received basic education in NIDCAP - based developmental care. They will also have NIDCAP behavioural observations performed by NIDCAP - Certified staff [this includes 3 of the investigators], at intervals during their stay at the study site NICU. These behavioural observations form the basis for behaviourally guided baby -friendly care, so that the timing and pace of caregiving is synchronised to the infant's readiness. Parents are actively encouraged to become the infant's primary caregiver in the NICU."
45994836|NCT04942704|Other|Non interventional Imaging - MRI|MRI Scanning using short protocols
45457151|NCT01348802|Behavioral|Pull|Pull will be an intervention with a similar front-face but requires clinicians to go to the site and extract evidence from an electronic database.
45457152|NCT03516526|Drug|Natalizumab|Extending dose intervals of natalizumab from 4 weeks to maximum of 8 weeks based on trough natalizumab concentrations
45457153|NCT02295982|Procedure|Hand assisted laparoscopic nephrectomy|patients with renal cancer will undergo hans assisted laparoscopic nephrectomy
45834175|NCT01925898|Drug|Experimental Arm: Ketamine|Oral Ketamine 5mg/kg Single dose
45834176|NCT00983580|Drug|Aspirin|Given PO
45834177|NCT00983580|Drug|Eflornithine|Given PO
45834178|NCT00983580|Other|Laboratory Biomarker Analysis|Correlative study
45834179|NCT00983580|Other|Placebo|Given PO
45834180|NCT00983580|Other|Telephone-Based Intervention|Ancillary studies
45834181|NCT01920672|Behavioral|Timed Planned Activity|
45834182|NCT01920672|Behavioral|Home Safety and Education Program|
45834183|NCT00982878|Drug|Maraviroc|150mg twice daily
45834184|NCT00982488|Drug|Dasatinib|Dasatinib was supplied as 20- and 50-mg tablets.
45834185|NCT00982488|Drug|Imatinib|Imatinib was supplied as 100- and 400-mg tablets.
45834186|NCT00982410|Behavioral|cognitive-behavioral treatment|cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse
45834187|NCT00982410|Behavioral|educational supportive group|A control condition providing social support and education about pain and/or drug use.
45834188|NCT00982020|Drug|Olanzapine|2.5 milligrams (mg) to 20 mg given orally, daily for 52 weeks
45994837|NCT00552461|Drug|rituximab|IV, 1000 mg, two weeks, 2 times
45994838|NCT04935528|Biological|serology and ELISPOT test|27 mL blood sample to study the humoral and the cellular immune response
45994839|NCT04935528|Biological|serology|7 mL blood sample to study the humoral response
45994840|NCT00552500|Drug|Depakote (valproate)|500 mg -2000 mg QD based on individual tolerance and VPA levels
45994841|NCT05465265|Behavioral|Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs)|Cases: Navigation of PWID into PrEP-Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs) Control group: Provision of PrEP information to PWID through pamphlets on PrEP uptake, adherence and retention among PWID.
45994842|NCT00552539|Other|'educational video'|'educational video'
45994843|NCT04917783|Behavioral|Passport Card|"After receiving neurocognitive testing, caregivers in the health-literacy group will be provided with a color-coded passport (a two-sided wallet-sized card) highlighting key findings and recommendations along with their written report. Then, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback passport card and evaluation report."
45994844|NCT04917783|Behavioral|No Passport card|After receiving neurocognitive testing and verbal feedback from the psychologist, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback and evaluation report, but not the passport card.
45994845|NCT02277314|Procedure|Manual Small Incision Cataract Surgery|This cost-effective solution for removing cataracts, also known as Manual Small Incision Cataract Surgery (MSICS), is a positive alternative when Phaco is not an option due to costs. The procedure takes approximately 30 minutes and involves a mid-size incision and an intraocular lens (IOL), or artificial lens, replacing the natural lens. Following the procedure, patients may need glasses, and most will need bifocals, but overall vision will be significantly improved.
45994846|NCT04756388|Other|Strategy Development|Participants engage in cognitive strategy discussions to develop new executive function strategies that can be used in daily life, and track their strategies between sessions. No computerized cognitive training.
45994847|NCT04756388|Other|Computerized Cognitive Training|Participants practice computerized training exercises targeting executive functioning skills, and complete computerized exercises between sessions.
45457154|NCT02730416|Drug|Nintedanib or Placebo; Carboplatin, Paclitaxel|Arm A: Nintedanib: 200mg orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD Arm B: Placebo: orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD In both arms: 6 courses of standard carboplatin and paclitaxel: Carboplatin AUC 5 iv every 21 days; Paclitaxel 175mg/m2 iv every 21 days. Both drugs are continued for maximum six courses or until unacceptable toxicity
45994848|NCT01258738|Biological|etanercept|In Period 1, subjects will receive in a prefilled syringe with 1.0 ml (test article Etanercept (SC) once weekly . Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
46084922|NCT00915005|Drug|Paclitaxel|50 mg/m2 by vein 1 time each week for 7 weeks.
46084923|NCT00915005|Drug|Carboplatin|AUC 2 by vein 1 time each week for 7 weeks.
45457155|NCT02293330|Drug|continuous infusion of levobupivacaine|continuous infusion of levobupivacaine 0,125% at 5 ml/h , bolus dose 6 ml, lock out 30 minutes 4 hours limit: 60 ml/h
45834189|NCT00982020|Behavioral|Standard behavioral weight intervention|One time counseling and basic counseling information on healthy eating and exercise habits at randomization visit only.
45834190|NCT00982020|Behavioral|Intense behavioral weight intervention|Counseling provided at randomization and at all subsequent study visits by appropriately trained individual regarding healthy lifestyle habits. Participants also provided with simple tools to help enable healthy eating and exercise habits.
45834191|NCT01926054|Drug|Acthar gel|
45834192|NCT01926132|Drug|ascorbic acid 10g/20ml|ascorbic acid 10g/20cc intravenous injection for 40mins
45834193|NCT01926132|Drug|Normal Saline 150ml|Normal Saline 150ml intravenous injection for 40mins
45834194|NCT02984358|Other|Animal protein based diet|
45834195|NCT02984358|Other|Low-nucleotide mycoprotein based diet|
45834196|NCT02984358|Other|High-nucleotide mycoprotein based diet|
45834197|NCT01920906|Procedure|Skin biopsy and blood test|Analysis of histology and gene expression in affected and unaffected skin
45834198|NCT01926210|Other|mild stimulation protocol|letrozole is used from cycle day 3 to 7 and low dose recombinant FSH(no more than 150 IU/d) is used on cycle day 4,6 and 8 onwards. GnRH antagonist is only applied in case of premature LH rise might happen.
45994849|NCT01258738|Drug|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by their attending physician. The name and dose of this NSAID is the decision of the attending physician.
45994850|NCT01258738|Other|PLACEBO|In Period 1 will receive a prefilled syringe of Placebo for Etanercept Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
45994851|NCT01258738|Drug|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by attending physician (dose drug selection as tolerated and agreed upon by the attending Physician).
45994852|NCT04900077|Device|Carriere® Motion™ Appliance|class II malocclusion corrector
45994853|NCT00552656|Device|Firebird(TM) Sirolimus-Eluting Stent|balloon expandable stent that made of stainless steel.The length is from 13mm-33mm,and the diameter from 2.5mm-4.0mm
45994854|NCT05604456|Procedure|secondary ear reconstruction based on Nagata method|Secondary auricular reconstructions based on Nagata method were conducted on patients who sought for secondary revision.
45994855|NCT04663724|Behavioral|Computer-Based Treatment|A 4-week (8 30-minute sessions) course of computer-based treatment involving viewing pictures of faces while music may play. Participants will receive research treatment twice a week.
45994856|NCT01824537|Biological|HPV vaccine, Gardasil 9|Once recruited, both individuals in a couple will be randomized independently to Gardasil 9 or placebo (Avaxim).
45994857|NCT01824537|Biological|Hepatitis A vaccine|Provided by Sanofi Pasteur.
45994858|NCT04863339|Drug|Tranexamic acid|Single preoperative dose of 1 gram of Tranexamic Acid in 100 mL of saline given 0-30 minutes prior to surgery.
45994859|NCT04863339|Drug|Placebo|Single preoperative dose of 100 mL of saline placebo given 0-30 minutes prior to surgery.
45994860|NCT04684277|Drug|antidepressant treatment|depression recieve antidepressant treatment
45994861|NCT04684277|Other|antidepressant treatment combined with Internet-based interventions|depression recieve antidepressant treatment combined with Internet-based interventions
45994862|NCT05604183|Procedure|non-invasive hyperspectral retinoscopy|The Principal Investigator or a trained medical nurse (under the supervision of the principal investigator) will take an image of the retina of the patient with the Mantis Photonics hyperspectral retinoscopy camera.
45994863|NCT05604183|Procedure|blood sample|The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will draw a small blood sample according to the standard medical procedures for drawing blood samples.
45994864|NCT05604183|Diagnostic Test|Test of cognitive ability on tablet computer with CoGNIT software|The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will give the patient to perform the digital cognitive test on a commercial tablet computer. The Principal Investigator or the medical nurse will be available for the patient to ask questions while the test is ongoing.
45994865|NCT05603871|Procedure|ligamentoplasty of ligamentum teres|"An addition to the steps of the open reduction, the following were done:~Identification of ligamentum teres~Ligamentoplasty of ligamentum teres"
45457156|NCT02293330|Drug|Intermittent bolus infusion of levobupivacaine|Intermittent bolus of levobupivacaine 0,125%: 0.1 ml /h and 9,8 ml bolus every two hours. Optional patient controlled bolus dose 6 ml, lock out 30 minutes, 4 hours limit: 60 ml/h
45994866|NCT04651985|Other|Eccentric strengthening exercises of the Achilles tendon|This exercise will require the completion of slow active eccentric plantar flexion exercises with the forefoot positioned over the edge of a step. These exercises will be repeated twice daily (three sets of 15 repetitions with the knee in extension and three sets of 15 repetitions with the knee in flexion) during a three-month period. The amount of loading will be calibrated and progressed on a weekly basis by the physiotherapist according the participant's perceived effort and pain intensity.
45834199|NCT01926210|Other|controlled ovarian stimulation|After fully downregulation by using short-acting GnRH agonist, 300 IU/d recombinant FSH is administrated for 5 days, then the dose is adjusted according to ovarian response.
45994867|NCT04853940|Other|Data collection and clinical testing of subjects|6-months follow-up with clinical testing at 3 and 6 months
45457157|NCT01348880|Drug|Vardenafil ODT, (Staxyn, BAY38-9456)|Single dose of 10 mg of vardenafil ODT, taken without water
45457158|NCT01348880|Drug|Placebo|Single dose of placebo to match 10 mg vardenafil ODT. taken without water
45457159|NCT03516448|Drug|Gan Fu Le Tablets|6 Tablets，tid,po
45834200|NCT01926288|Drug|Entecavir maleate tablets|
45834201|NCT01926288|Drug|blank Baraclude tablets|
45834202|NCT01926288|Drug|Blank maleate entecavir tablets|
45834203|NCT01926288|Drug|Baraclude tablets|
45834204|NCT03118674|Drug|Harvoni|One capsule of Harvoni/ ledipasvir, 90 mg + sofosbuvir, 400 mg administered daily for 8, 12, or 24 weeks
45834205|NCT01926366|Drug|AZD6423|Drug: AZD6423 Single or Multiple doses via infusion.
45994868|NCT04647968|Procedure|Primary closure of tracheo-cutaneous fistula|This procedure will follow protocoled steps. It consists of a sutured closure of the tracheotomy following local anesthesia, done at bedside.
46084924|NCT00910533|Drug|ceftriaxone|ceftriaxone 2 g od i.v. for 14 days
45994869|NCT04647968|Procedure|Secondary closure of tracheo-cutaneous fistula|This procedure will follow protocoled steps. It consists of removing the tracheotomy canula and applying ointment and an Elastoplast on the site, which will be changed regularly until full healing of the wound.
45994870|NCT04634513|Biological|strain CVD 1208S-122|Live, attenuated, vaccine strain of S. flexneri 2a expressing CFA/I and LT of enterotoxigenic E. coli
45994871|NCT04634513|Other|Placebo|Sodium bicarbonate buffer
45994872|NCT04630184|Behavioral|Exposure intervention in virtual reality|6 sessions of 45 minutes weekly and 2 follow-up meetings (3 and 6 weeks after the weekly follow-up) with cognitive restructuring and VR exposure supervised by psychologists
45994873|NCT04630184|Behavioral|Exercise|Participants will have to go twice a week, for 12 weeks to carry out 2 individual endurance training sessions of 45 minutes (moderate to vigorous intensity), supervised by a kinesiologist. Participants will also have to complete a 3rd 60-minute endurance session at home (or two 30-minute sessions).
46084925|NCT02696642|Drug|Anetumab ravtansine (BAY94-9343)|All subjects received anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks
45457160|NCT03516448|Drug|Tyroserleutide for injection|6mg/d, 5days,ivgtt
45457161|NCT03516448|Drug|Placebo|0mg/d, 5days,ivgtt
45457162|NCT03923179|Drug|Pyrotinib|Pyrotinib, 400mg qd
45457163|NCT03923179|Drug|Etoposide|Etoposide, 50mg，qd,d1-21,Q4W
45674741|NCT02093689|Drug|Part 1 OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
45457164|NCT03923413|Other|Blood samples|Blood samples for MP evaluation
45457165|NCT01348958|Device|iDXA knee software|"Following surgery, subjects who have undergone knee arthroplasty will have the knee that has undergone arthroplasty (post-operative) scanned at least 8 weeks after surgery.~During one visit, each subject will have the post-operative knee scanned 1 time using Lunar orthopedic application, and 3 times with the subject repositioned between scans using the Lunar orthopedic knee application (total of 4 scans). Lunar iDXA measurement procedures will be done"
45457166|NCT01357304|Behavioral|Group treatment and PAR|Group treatment (8-12 patients per group) involving an empowerment-based process and the 5-A model and including PAR. Two group sessions, 6 months apart. The estimated total time for both group sessions together is 100 minutes.
45457167|NCT02296060|Procedure|6 minutes walking test|
45457168|NCT01318304|Other|Vaginal lavage specimen|Collection of 3cc of saline used in the vagina to collect innate immunity markers
45457169|NCT03518788|Procedure|Pleur-X|Permanent drainage
45834206|NCT01926366|Drug|Placebo|Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion
45834207|NCT00981084|Drug|armodafinil|Half of the patients will be randomized to receive a single oral dose of placebo prior to the first testing session. After a washout period of one week, they will then receive 250mg of armodafinil prior to a second testing session (P/A group). The other half of patients will be randomized to receive the active drug first. After a washout period of one week, they will receive the placebo prior to a second testing session (A/P group). As plasma levels of armodafinil peak between 2-4 hours after administration, participants will be asked to take a single 250mg capsule 2 hours prior to the scheduled testing sessions.
45834208|NCT03115086|Drug|Cholbam|Cholbam prescribed according to the approved label.
45834209|NCT00980148|Drug|Azithromycin|FDA approved, a 1 gm single dose, two 500 mg tablets.
45457170|NCT03518788|Procedure|Pleurodesis|Pleurodesis with talc in permanent VATS
45457171|NCT01318460|Drug|Levosimendan infusion|Prophylactic 24h infusion of levosimendan at a dose of 0.1 mg/kg/min
45457172|NCT01318460|Drug|Placebo infusion|Twenty-four hour administration of placebo
45834210|NCT00980148|Drug|Doxycycline|FDA approved, a 100 mg capsule twice a day for 7 days.
45834211|NCT03064854|Drug|PDR001|Powder for solution for infusion
45834212|NCT03064854|Drug|Cisplatin|Intravenous infusion
45834213|NCT03064854|Drug|Gemcitabine|Intravenous infusion
45834214|NCT03064854|Drug|Pemetrexed|Intravenous infusion
45834215|NCT03064854|Drug|Carboplatin|Intravenous infusion
45834216|NCT03064854|Drug|Paclitaxel|Intravenous infusion
45834217|NCT03064854|Drug|Canakinumab|Subcutaneous injection
45834218|NCT03063606|Behavioral|Cognitive-Behavioral Therapy (CBT)|CBT specialist treatment
45994874|NCT04630184|Behavioral|Placebo|6 sessions of 45 minutes weekly and 2 follow-up meetings (3 and 6 weeks after the weekly follow-up) Discussion around social physical anxiety, stress management (relaxation and breathing) supervised by psychologists
46084926|NCT00646971|Device|CPAP device|for 4 weeks
46084927|NCT00646971|Device|Placebo device|for 4 weeks
46084928|NCT04439045|Biological|VPM1002|VPM1002 is a recombinant BCG (rBCG)
46084929|NCT04439045|Other|Placebo|0.9% sodium chloride
46084930|NCT04112030|Diagnostic Test|Digital image analysis|
46084931|NCT00647049|Drug|methotrexate|8000mg/m2 i.v., max. 2 cycles
46084932|NCT00647049|Drug|Rituximab|375mg/m2, max. 8 times
46084933|NCT00647049|Drug|Cytarabine|3000mg/m2 die i.v., 2 days (max. 2 cycles)
46084934|NCT00647049|Drug|Thiotepa|40mg/m2 i.v. (max. 2 cycles) 2 x 5mg/kg/die i.v. for 2 days
46084935|NCT00647049|Drug|Carmustin|400mg/m2 i.v. for 1 day
45994875|NCT00552734|Device|Insulin Guidance Software|At baseline a healthcare provider reviewed the features of the software on the PDA and loaded a subject specific insulin dosing algorithm into the software based on the physician's recommendations. The program advised basal, bolus and correction insulin dosages based on individual patients' prescriptions in addition to being alerted for SMBG testing. Subjects in the experimental group were also asked to input their blood glucose values into the PDA via the touch screen. Subjects then received a recommended insulin dose based on their prescription which was programmed by the healthcare provider. The patients were asked to either agree with the recommended insulin dose or disagree, and manually enter the insulin dose they took for a given event.
45994876|NCT00552773|Drug|Cyclamen Europaeum|Nasal spray 10% (V/V),one spray per nostril daily for 7 days.
45994877|NCT04603352|Other|Hip Helpers home program|Home program: Infants will wear Hip Helpers 30 minutes, twice per day.
46084936|NCT02696330|Drug|clopidogrel|clopidogrel 75mg tablets with 300mg loading dose followed by 75mg oral tablets daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
45994878|NCT00536718|Genetic|gene expression analysis|
45994879|NCT00536718|Genetic|molecular diagnostic method|
45994880|NCT00536718|Genetic|polymorphism analysis|
45994881|NCT00536718|Genetic|protein expression analysis|
45994882|NCT00536718|Other|medical chart review|
45994883|NCT00536718|Other|questionnaire administration|
45674742|NCT02093689|Drug|Part 2 OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
45674743|NCT02093689|Drug|Part 2 Placebo|Placebo drug product is a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL of solution containing 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
45994884|NCT04602572|Behavioral|Lifestyle course.|Pharmacotherapy
45994885|NCT04602572|Procedure|Bariatric surgery.|Sleeve gastrectomy or gastric bypass.
45994886|NCT04831164|Other|NA (not an interventional study)|(not an interventional study)
45994887|NCT04592120|Behavioral|Coalition Check-Up|The Coalition Check-Up identifies and addresses coalition and implementation capacity deficiencies that frequently lead to failure, following recommendations from the audit and feedback literature.
46084937|NCT02696330|Drug|enoxaparin|enoxaparin 40 mg by subcutaneous injection once daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
45994888|NCT04816617|Behavioral|Aerobic exercise intervention|The whole exercise lasts for 12 months, consisted of 6-month supervised exercise and 6-month maintenance period. It is moderate -intensity exercise (60-80% Maximum heart rate), each time last for 30 mins (plus 10-minutes for warm-up and cool-down), 3-4 times a week, for the first six months, which will be supervised in person by physical educators and/or physical professionals. In the maintenance period, participants are asked to exercise at the same intensity and frequency, but will not be supervised in person by physical educators/professionals. They will receive reminder on a weekly basis and their physical activities be recorded by accelerometer. Types of exercise will be chosen according to individual school's facility and feasibility, including jogging, fast walking, badminton, running, football etc.
45994889|NCT04816617|Behavioral|Psycho-education|It consists of 6 sections of psycho-education, with topics covering mood regulations and mental well-being. Approximately 1 section in every two months.
45994890|NCT04543682|Drug|0.125 ng/kg/min Iloprost|Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.125 ng/kg/min Iloprost for a duration of 24 hours
46084938|NCT02696330|Drug|placebo|starch tablets with no active drug material is given daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
45457173|NCT03516370|Drug|Saccharomyces Boulardii 250 MG|all the patient first recived scaling and root planning as a prophylactic mesaure later after that patient received intrapocket delivery of Saccharomyces Boulardii mixture.
45674744|NCT02047045|Procedure|acupuncture|Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 minutes, 5 times/week for the first 2 weeks and 3 times/week for the next 6 weeks. Each treatment cycle will include 28 sessions for continuous 8 weeks.
45674745|NCT02047045|Drug|Prucalopride|Prucalopride Succinate will be taken orally at the dose of 2mg/day in the morning before breakfast. Each treatment cycle will be given for continuous 32 weeks.
45834219|NCT03063606|Drug|NB Medication (on-going from acute treatment)|Naltrexone/bupropion combination (on-going blinded pharmacotherapy from acute treatment consisting of either naltrexone/bupropion or placebo)
45457174|NCT01318616|Other|Strength training of the hip adductors|Adductor strength training
45834220|NCT01921530|Procedure|Interbody Fusion|The interbody fusion (IF) procedure requires exposure and removal of the disc, curetting the end plates, inserting a cage filled with bone graft, as well as stabilization with rods and screws.
45834221|NCT01921530|Procedure|Posterolateral Fusion|In posterolateral fusion stabilization is achieved using pedicle screws joined by rods. The graft used to facilitate fusion is placed between decorticated transverse processes and can be an autograft of iliac bone or local bone, allograft, or a synthetic expander.
45834222|NCT01926678|Other|Swedish massage therapy|
45834223|NCT01926678|Other|Light touch therapy|
45834224|NCT01926756|Procedure|Straight catheterization|Patient will receive the current standard practice of straight catheterization intraoperatively.
45457175|NCT02299726|Drug|Spironolactone|
45457176|NCT02299726|Other|Placebo|Matching placebo
45457177|NCT03647852|Drug|Methylprednisolone|1.methylprednisolone pulse (15-30mg/kg/d) for 3 days with continued oral prednisolone(2mg/kg/d) 2.if the patients still complain abdominal pain and feel abdominal tenderness on the third day after intervention , patients would be given IVIG(2g/kg/d)as a change
45994891|NCT04543682|Drug|0.25 ng/kg/min Iloprost|Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.25 ng/kg/min Iloprost for a duration of 24 hours
45994892|NCT04543682|Procedure|open reduction and internal fixation with an angular stable plate (PHILOS)|open reduction and internal fixation with an angular stable plate (PHILOS)
45994893|NCT05603676|Other|Intermittent hypoxia-hyperoxia conditioning|The IHHC protocol consist of 6 bouts of 6 min breathing hypoxia (FiO2 = 11.5%) following by 3 min breathing hyperoxia (FiO2 = 31.5%) (Figure 2). The total duration of a session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with hypo and hyperoxic gas mixture. Participants will be instructed to relax and breath normally throughout the session.
45994894|NCT05603676|Other|Placebo intervention|Placebo intervention will be like the IHHC protocol but with mixing chambers full of ambient air. The total duration of a placebo session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with ambient air. Participants will be instructed to relax and breath normally throughout the session.
45994895|NCT04526639|Behavioral|Virtual Reality-based Interactive Cognitive Training Program|Three virtual reality-based games designed to train inhibitory control, working memory, and cognitive flexibility among children with TBI
45994896|NCT04526639|Behavioral|Placebo Virtual Reality Game|A virtual playground for control group to interact without training executive functions
45994897|NCT04802616|Drug|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24).
45994898|NCT04802616|Drug|Placebo|Matched tablets without any active substance.
46084939|NCT04857593|Behavioral|Melodies for Mums|"Classes start with a chat between mothers and the artist. The singing session will include welcome songs, introducing the babies and mothers to one another, and then involve a range of singing and music activities. These will include learning songs from around the world, ranging from short vocal exercises that use motherese style noises and sound effects (including sound baths where the mothers sang a sustained note providing a relaxation technique), to simple lullabies that can be picked up very quickly and sung in basic harmonies or rounds, to longer or more complex songs that will be learnt gradually over the weeks. Instruments such as guitar and ukulele will also be used by the artist for a small number of songs. Mothers will also work to write some of their own songs over the weeks, developing lyrics together about their babies or experiences of motherhood and creating simple melodies. Classes will be led by workshop leaders trained by Breathe, with support of assistants."
45994899|NCT04473092|Device|TMVR|Patients who undergo TMVR for MR at the PI´s site
46084940|NCT04172727|Drug|Bupivacaine Hcl 0.25% Inj|ultrasound-guided bilateral TFP block with 20 mL of 0.25% bupivacaine
46084941|NCT04172727|Drug|saline 0.9%|ultrasound-guided bilateral TFP block with 20 mL of saline 0.9%
46084942|NCT04648319|Drug|BMS-936558|BMS-936558 followed by 30 grays of 3 to 5 fractions of high dose SBRT followed by monthly BMS-936558 until progression
46084943|NCT02761226|Procedure|Platform Matched Design (Group A)|10 patients with missing upper posterior teeth will receive dental implant with platform matched design (the patients will receive implant 4.2mm with same abutment diameter 4.2mm)
46084944|NCT02761226|Procedure|Platform Switching Design (Group B)|10 patients with missing upper posterior teeth will receive dental implant with platform switching design(the patients will receive implant 4.2mm with smaller abutment diameter 3.5 mm
45674746|NCT02131259|Drug|Afatinib dimaleate|20mg - 50mg
45674747|NCT01856595|Drug|PF-06291874|The dosing schedule is 5, 15, 50, 100 and 150 mg QD for 14 days for the first 5 cohorts in Part A. The dosing schedule for the first cohort in Part B is 15 mg QD for 14 days and 30 mg QD for 28 days
45674748|NCT01856595|Drug|Placebo|Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1- 5 and Part B cohort 1) or 28 days (Part B cohort 2).
45674749|NCT04589559|Behavioral|Heart Rate Variability Biofeedback Training|First, participants are taught how to do relaxed, abdominal breathing. Second, they are taught how to breathe at a slow rate of 0.1 Hz (i.e., one completed breath cycle every 10 seconds). Third, they are taught how to monitor their heart rate variability (HRV) in real time using the smartphone app, which receives data wirelessly via Bluetooth from the heart rate monitor. Participants are instructed that their goal is to increase their HRV during the three weeks of at-home practice.
45674750|NCT01829295|Drug|Mycophenolate mofetil|For the first two weeks, an introductory dose of 500 mg BID orally. After two weeks, the dose will be increased to 1.5 g BID.
45994900|NCT05599581|Behavioral|Tu'Washindi|"Tu'Washindi consists of 3 primary components:~PrEP Adherence Support Clubs: Eight 2-hour sessions that occur over the intervention period: twice per month for the first 2 months & once per month for the remaining 4 months. Sessions will use structured & unstructured activities designed to improve outcomes expectations, increase self-efficacy to use PrEP safely & consistently, increase peer support for PrEP use, provide access to community IPV resources & provide skills for healthy communication & PrEP disclosure with male partners.~Community Male Sensitization conducted weekly over the first 3 months of the intervention period aimed to increase PrEP knowledge, reduce stigma, & promote healthy relationship communication.~Buddy Days, which take place 3 months into the intervention period, designed to bring participants & their male partners together to learn about PrEP, discuss community attitudes & concerns regarding PrEP use, & promote HIV prevention & family well-being."
45994901|NCT01258660|Drug|EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|Combination EE/DRSP/ Metafolin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
45994902|NCT01258660|Drug|EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid|Yasmin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
45994903|NCT04772274|Drug|Ustekinumab|45 mg, single-dose
45994904|NCT04398797|Other|PATINA algorithm|Once a week community nurses receive a list of community dwelling citizens deemed at risk of deterioration that can lead to hospital admission. Nurses assess each citizens situation and initiate intervention if needed (not part of the intervention).
45994905|NCT03457311|Drug|G.S.P. Oral Solution 400 mg/ml|Oral 1.25 ml/kg BW G.S.P. oral solution after fasting for 6 hours.
45994906|NCT04370327|Other|Pain Free Exercise (PF)|Patients will exercise until the onset on claudication (1 on the rating scale)
45994907|NCT04370327|Other|Moderate Claudication Pain Exercise (MOD-P)|Patients will exercise until they experience moderate claudication pain (2 on the rating scale)
46084945|NCT02764424|Device|NIPE (MDoloris®)|Each file consists of a simultaneous recording of an electrocardiogram signal according to usual practice (cardiac monitor PHILIPS), coupled with a concomitant registration of NIPE (Newborn Infant Parasympathetic Evaluation - MDoloris®). The electrocardiogram signal, respiration rate, oxygen saturation (SpO2) and NIPE are recorded simultaneously on a computer with a capture card. The other indices of Heart Rate Variability will be analyzed offline.
46084946|NCT00647127|Drug|Buprenorphine|Buprenorphine: 20microg/h
45674751|NCT01829295|Drug|Methotrexate|For the first two weeks, an introductory dose of 15 mg/week (7.5mg BID once a week) orally. After two weeks, the dose will be increased to 25 mg/week (12.5mg BID once a week)
46084947|NCT00647127|Drug|Fentanyl|Fentanyl: 25microg/h
46084948|NCT00647127|Drug|Placebo|Placebo: '5microg/h' (not active drug, it is just called '5microg/h')
46084949|NCT04172883|Other|Treatment arm|All pts are implanted with rATP enabled devices prior to the study start , the only intervention in both arms is switching on rATP and in the treatment arm programming changes done to optimize the rATP sequence delivery of therapy and prevent the patient from going into permanent or persistent AF
45674752|NCT01829295|Drug|Prednisone|All patients enrolled in the study will be initially taking concomitant oral corticosteroids at 1 mg/kg or 60 mg daily, whichever is less. Initial corticosteroid dose will be continued for 2 to 4 weeks at which point prednisone will be gradually tapered. Prednisone will be tapered to and held at 7.5 mg/day for the first 6 months of the study.
45674753|NCT02157935|Drug|Symbicort|Budesonide/formoterol pMDI, 160/4.5 μg x 2 actuations BID, for oral inhalation, 120 doses
45674754|NCT02157935|Drug|Formoterol turbohaler|Formoterol Turbuhaler 4.5 μg x 2 actuations BID, for oral inhalation, 60 doses
45674755|NCT02157935|Other|Placebo for Symbicort pMDI|pMDI, aerosol for oral inhalation, placebo, 120 doses
45674756|NCT02157935|Other|Placebo for Formoterol Turbohaler|PLacebo powder for oral inhalation, 60 doses
45674757|NCT04589403|Drug|OPT101|15-mer peptide with sequence based on the mouse CD154 domain interacting with CD40
45674758|NCT02157779|Behavioral|Cognitive Behavioral Intervention|Includes individual therapy sessions using cognitive and behavioral strategies addressing problems with anger intensity / frequency / management
45834225|NCT01926756|Procedure|No straight catheterization|Patients will not be catheterized which is an experimental change from the current practice at our hospital.
45834226|NCT01926834|Drug|Erigeron Injection|Erigeron Injection, 30ml, iv, qd, for 7days
45834227|NCT01926834|Drug|placebo|normal saline, 500ml,i.v.,qd, for 7 days
45834228|NCT01921608|Device|PrePex™ device|PrePex™ device for adult male circumcision programs. The PrePex™ device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures.
45834229|NCT01926912|Drug|No intervention|This is an observational study. Participants prescribed with paliperidone palmitate by the treating physician as per local labeling information in the hospital setting will be observed and data will be collected.
45834230|NCT04395378|Device|Continuous Glucose monitoring DEXCOM G6|Continuous glucose monitoring during flight and normal living life
45674759|NCT02157779|Behavioral|Supportive Intervention|Includes individual therapy sessions using supportive and problem-solving strategies.
45994908|NCT04370327|Other|Maximal Claudication Pain Exercise (MAX-P)|Patients will exercise until they experience maximal claudication pain (4 on the rating scale)
45994909|NCT00536835|Drug|GSK461364|GSK461364 will be given intravenously as a 4 hour infusion in either a final volume of 500 or 1000 mLs. The starting dose for Stage A - Schedule 1 was 50 mg and doses were to be escalated as described in protocol until maximum tolerated dose established.
45994910|NCT04362527|Drug|Milrinone 1 Mg/mL Solution for Injection|Blinding procedure will be set up for the administration of the treatment
45674760|NCT02093221|Biological|180 mg/kg Alpha1-PI|
45674761|NCT02093221|Biological|90 mg/kg Alpha1-PI|
45674762|NCT02093221|Biological|Placebo|
45674763|NCT02092909|Drug|IMO-8400|IMO-8400 at escalating dose levels by subcutaneous injection
45994911|NCT04362527|Drug|Saline solution for injection|Blinding procedure will be set up for the administration of the treatment
45994912|NCT04769466|Other|LifeBio Memory|LifeBio Memory is a digital reminiscence therapy platform designed to collect the life stories of older adults to generate personalized life storybooks that capture their unique narratives and social histories. Life story booklets, summaries, and materials are also developed as mechanisms for sharing this story and for staff to provide enhanced person-centered care.
45994913|NCT04360538|Other|Quality of Life|Physical disability assessment tool
45994914|NCT04360538|Other|Impact Event Score|Psychological Sequelae assessment tool
45994915|NCT04360538|Other|Hospital anxiety and depression scale|Psychological Sequelae assessment tool
45994916|NCT05579145|Other|5-Second Expiratory Pause|Patients on mechanical ventilation for more than 24 hours will be randomized for the first technique to be applied. This technique consists of closed system aspiration and expiratory pause with mechanical ventilator for 5 seconds. After randomization and before the application of the technique, all patients will be positioned in supine position with the headboard elevated at 30 degrees and will be aspirated once with closed aspiration system and with vacuum of -40 cm H2O.
45994917|NCT05579145|Other|10-Second Expiratory Pause|Patients on mechanical ventilation for more than 24 hours will be randomized for the first technique to be applied. This technique consists of closed system aspiration and expiratory pause with mechanical ventilator for 10 seconds. After randomization and before the application of the technique, all patients will be positioned in supine position with the headboard elevated at 30 degrees and will be aspirated once with closed aspiration system and with vacuum of -40 cm H2O.
45994918|NCT04758975|Drug|Venetoclax|VENETOCLAX: Ramp-up than 400 mg QD
45674764|NCT04706533|Diagnostic Test|Biomarkers of inflammation|Biomarkers were measured on blood samples collected within 48 hours of admission
45994919|NCT04758975|Drug|Rituximab|RITUXIMAB: Cycle 7 Day 1 375 mg/m2; Cycles 8-12 Day 1 500 mg/m2
45994920|NCT04758975|Drug|Ibrutinib|IBRUTINIB 420 mg QD
45674765|NCT01623115|Drug|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
45674766|NCT01623115|Drug|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
45834231|NCT03385512|Behavioral|OPEN High Touch|This arm will contain three components: (a) a pre-visit questionnaire delivered through the patient portal of the EHR, asking patients what they most want to discuss with their physician in the upcoming visit; (b) an animated video for patients providing coaching on how to best prepare for their upcoming visits and get the most from the visits; and (c) Standardized Patient Instructor (SPI) providing communication coaching for physicians on how to incorporate what matter most to patients in the visit, with empathy, and clarity.
45834232|NCT03385512|Behavioral|OPEN High Tech|The patient components of the intervention will be identical to the patient components of the High Touch arm (i.e., the pre-visit survey and patient coaching video). The difference will be in the PCP training: we will replace the in-person SPI with a mobile app program.
45994921|NCT04755114|Other|Turkish Music|Turkish Music;In choosing the music, patients will be asked about their favorite vocalist and music pieces before the procedure. The researcher will then download these music pieces from YouTube and create a 30-minute list and listen to patients.
46084950|NCT04223102|Procedure|Tissue collection|A flexible sigmoidoscopy is a procedure in which a flexible tubularized camera approximately 1 cm in diameter is inserted into the anus and advanced proximally to the sigmoid colon (approximately 20 cm). At that time a rectal biopsy of the tumor will be obtained as well as a sample from >5cm proximal to the tumor, with a separate biopsy forcep. Tattoo injection, as standard of care, will be performed within 1 cm distal to the tumor to identify the location in the future or for surgical intervention. If there is inability to get proximal to the tumor then a location at least 5 cm adjacent in any direction will be sufficient so long as it is grossly normal appearing.
45674767|NCT01623115|Drug|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
45674768|NCT02092285|Drug|Golimumab|50mg or 100mg solution for injection; subcutaneous injection
45674769|NCT02091739|Drug|IncobotulinumtoxinA (100 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
45994922|NCT04755114|Other|comedy movie|Prior to the research, attention will be paid to the selection of comedy films that do not contain violence, swearing and obscene scenes that may adversely affect patients. Prior to the research, attention will be paid to the selection of comedy films that do not contain violence, swearing and obscene scenes that may adversely affect patients. In the selection of comedy films, the opinions of two experts from Mimar Sinan University, Faculty of Fine Arts, Department of Cinema and Television and İnönü University will be preferred, and the films Kemal Sunal and Şener Şen, one of the actors that Turkish people know closely, laugh most and have settled into their culture, will be preferred.
45674770|NCT02091739|Drug|IncobotulinumtoxinA (75 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
45674771|NCT02091739|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
45994923|NCT04748952|Device|Densah burs|Osseodensification is a non-excavating implant site preparation technique. It creates a densified layer of surrounding bone through compaction autografting while simultaneously plastically expanding the bony ridge at the same time facilitating for placement of large diameter implants and also avoiding fenestration and dehiscence defects. The autografting occurs along the entire length of the osteotomy through a hydrodynamic process with the use of irrigation. The result is a consistently cylindrical and densified osteotomy.
45994924|NCT00552851|Drug|pegvisomant|booster dosage 80 mg once sc., than 10 mg once per day, uptitration in steps of 5 mg up to an IGF-1 level in the normal range (every 4 weeks), max. 30 mg once per day. Duration of treatment: one year
45994925|NCT01614171|Biological|Human recombinant growth hormone|growth hormone treatment for 6 months (daily, weight based)
45994926|NCT05567367|Combination Product|Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)|RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.
45994927|NCT05567367|Drug|Vardenafil Oral Tablet|20 mg oral vardenafil tablet.
45994928|NCT05562024|Biological|T cell injection targeting B7-H3 chimeric antigen receptor|The subjects will be administered once.
45994929|NCT00536952|Drug|Pulmozyme|Pulmozyme 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
45994930|NCT00536952|Drug|Placebo|Placebo 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
45674772|NCT02045875|Drug|Dulera|Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.
45674773|NCT01597635|Drug|Dose 1 GSK2586881|Low dose GSK2586881 administered intravenously
45994931|NCT00536952|Radiation|Radiation Therapy|5 days per week for 4 weeks
45994932|NCT04684004|Other|To report number of HF events and deaths|In these two cohorts of study authors will evaluate at 2 years of follow-up the number of HF events and of deaths.
45834233|NCT03385512|Behavioral|ASK Poster in Exam Rooms|This arm is intended to activate patients by encouraging them to ask three questions during their primary care visit: (1) What are my options? (2) What are the possible benefits and risks of each option? (3) How likely are the benefits and risks of each option to occur to me? This will involve placing posters with these questions in all exam rooms used by providers in clinics randomized to the ASK arm of the trial.
45834234|NCT01921764|Behavioral|Workplace physical exercise|
45994933|NCT04286438|Drug|Bentracimab (PB2452) Infusion|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration.~In subjects with potential drug interaction from recent concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36g infusion.~In patients presenting with intracranial hemorrhage (ICH), brain imaging within 2 hours of initiation of study drug and at least one follow-up brain imaging performed 12-24 hours post completion of PB2452."
45994934|NCT04675632|Procedure|Endovascular Therapy|the most commonly used surgical options include: ordinary balloon dilatation， drug-coated balloon (DCB) dilatation and bare stent implantation.
45834235|NCT01921764|Behavioral|Home physical exercise|
45994935|NCT04675476|Behavioral|Provider Prompt & Patient Outreach and Education|To target lack of provider-prompted discussion about lung screening, an electronic medical record (EMR) message will be sent to primary care providers prior to scheduled visits with screening-eligible patients to notify them of the patient's eligibility and to encourage discussion of the benefits and limitations of the test. To target patient-level knowledge about lung screening, an outreach specialist will educate screening-eligible patients about the benefits and limitations of the test prior to their visit.
45834236|NCT00983814|Drug|Droxidopa+Carbidopa|Droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) in combination with carbidopa (25mg or 50mg TID, provided as oral capsules taken TID from Baseline to end of Week 8
45834237|NCT00983814|Drug|Placebo|Placebo matched oral capsules taken TID from Baseline to end of Week 8
45994936|NCT04282616|Other|Home-based unstructured physical activity program|Counselling on physical activity according to American College of Sports Medicine guidelines
45994937|NCT04282616|Other|Home-based structured low-intensity physical activity program|Structured home-based low-intensity intermittent walking program
45994938|NCT04282616|Other|In-hospital structured supervised physical activity program|Supervised exercise training program
45994939|NCT00537147|Biological|WN/DEN4delta30 vaccine|Live attenuated WN/DEN4delta30 vaccine (one of two doses)
45994940|NCT00537147|Biological|Placebo|Placebo for WN/DEN4delta30 vaccine
45994941|NCT04656951|Drug|Daratumumab|Daratumumab added to induction regimen of bortezomib, cyclophosphamide and dexamethasone (VCD), to bortezomib and dexamethasone during maintenance and to lenalidomide and dexamethasone at progression/relapse.
45994942|NCT00537186|Drug|Iron oligosaccharide|
45994943|NCT04251260|Other|Positioning in flexion|"The intervention group will be positioned in flexion (i.e. lower limbs in flexion, hand in midline) with an aid, the Snuggle up (Philips, USA). With positioning, the neonates bottom is tucked down in the snuggle up pocket, legs are aligned and gently flexed and hands towards midline and near the face.~Positioning will be demonstrated to the nursing staff of the Neonatal Intensive Care Unit (NICU). The intervention group will receive positioning during day and night throughout the intervention period."
45674774|NCT01597635|Drug|Dose 2 GSK2586881|Medium dose GSK2586881 administered intravenously
45994944|NCT04244786|Device|Transcranial direct current stimulation|tDCS is a low-cost, portable, well-tolerated, non-invasive form of brain stimulation that delivers a low current to a specific area of the brain via electrodes.
46084951|NCT02765360|Other|Treatment Group|"Participants will be established on the randomised mode of ventilation and will have continuous assessment of the following during the assessment period:~Electrical impedance tomography~EMGpara~SpO2~tcCO2~Pneumotachography~End-tidal CO2 monitoring"
45674775|NCT01597635|Drug|Dose 3 GSK2586881|Medium-High dose GSK2586881 administered intravenously
45674776|NCT01597635|Drug|Dose 4 GSK2586881|High dose GSK2586881 administered intravenously
45674777|NCT01597635|Drug|Placebo (saline)|Administered intravenously to match intervention
45994945|NCT04642014|Biological|COVID-19 convalescent plasma treatment|"The donor's blood will be collected after four weeks post-onset of illness. 600 ml ABO-compatible plasma sample will be harvested during apheresis from each donor and each sample will be divided and stored as 200 mL aliquots.~Patients who meet the criteria receive one dose (200 mL) of ABO compatible inactivated convalescent plasma with a confirmed neutralization activity."
45994946|NCT04234334|Other|Consume 2 eggs with spinach per day|Participants will be randomly allocated to consume either 2 eggs or 2 egg substitutes with spinach daily for 4 weeks and after a 3-week wash out, they will be allocated to the alternate treatment
45994947|NCT04234334|Other|Egg Subsitute with spinach per day|Egg Subsitute with spinach per day
45674778|NCT01828281|Device|CPAP|All subjects will undergo ultrasound examination of the abdomen the day after overnight polysomnography (PSG) and then at 3 months after completion of therapeutic or subtherapeutic CPAP treatment of 4 cm water.
45994948|NCT00552890|Other|modified Atkins diet|subjects assigned to follow modified Atkins diet for 1 year
45994949|NCT00552890|Other|ADA recommended diet|subjects assigned to follow ADA recommended diet for period of 1 year
45994950|NCT04225520|Device|Cardiac resynchronization therapy ON|Implantation of a CRT device. Bi-ventricular pacing will be turned ON.
45994951|NCT04225520|Device|Cardiac resynchronization therapy OFF|Implantation of a CRT device. Bi-ventricular pacing will be turned OFF.
45994952|NCT04200755|Drug|Dupilumab 300Mg Solution for Injection|First dose: 600 mg (2 syringes); subsequent doses: 300 mg (1 syringe)
45994953|NCT04200755|Other|Placebo|First dose: 2 syringes, no active substance; subsequent doses: 1 syringe, no active substance
45994954|NCT04185974|Radiation|C12 re-irradiation|51 Gy(RBE) or 54 Gy
45994955|NCT04185974|Radiation|Photon re-irradiation|54 Gy(RBE) or 60 Gy
45994956|NCT04173533|Drug|Oral azacitidine|Oral azacitidine (CC-486) 200 mg tablet
45994957|NCT04173533|Drug|Matched placebo|Oral azacitidine (CC-486) matched placebo tablet
45994958|NCT05544591|Drug|611 Q2W|subcutaneous injection, 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 2 to Week 14, 7 cycles)
46084952|NCT04172493|Procedure|Hyperspectral Endoscopy (HySE)|Undergo hyperspectral endoscopy
45674779|NCT01827267|Drug|neratinib|
45674780|NCT01827267|Drug|temsirolimus|
45674781|NCT01855425|Radiation|Radiation|Subjects to receive standard of care CT scan and additional Cone Beam CT scan.
45674782|NCT01854879|Device|Nucleus 6 sound processor|
45834238|NCT01921842|Behavioral|NAP-SACC Child Care Wellness Program|Nutrition And Physical activity Self-Assessment for Child Care
45674783|NCT01827111|Drug|ABI-007|Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. The cycle length for ABI-007 is 28 days.
45674784|NCT01827111|Drug|Ipilimumab|3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses.
45674785|NCT01827111|Behavioral|Phone Call|Every 2 months for 6 months, then every 3 months for up to 2 years, participant contacted by telephone. Each call should last about 5 minutes.
45834239|NCT03088332|Procedure|Endoscopic gastroplasty|Vertical endoscopic gastroplasty
45834240|NCT01921920|Drug|Omeprazole|Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)
45834241|NCT04275414|Drug|Bevacizumab Injection|Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip ≥90min
45994959|NCT05544591|Drug|611 Q4W|subcutaneous injection, 600mg (loading dose, Day1) + 300mg Q4W (maintenance dose, on week 4, 8, 12) + placebo Q4W (on week 2, 6, 10, 14)
45994960|NCT05544591|Drug|Matching placebo|subcutaneous injection, Q2W, from Week 2 to Week 14, 7 cycles
45994961|NCT01534065|Device|Barricaid|Implanted intra-operatively during discectomy
45994962|NCT04137107|Drug|Oxaliplatin|Given standard of care oxaliplatin
45994963|NCT04137107|Drug|Duloxetine Hydrochloride|Given PO
45994964|NCT04137107|Drug|Duloxetine|Given PO
45994965|NCT04137107|Other|Quality-of-Life Assessment|Ancillary studies
45994966|NCT04137107|Other|Questionnaire Administration|Ancillary studies
45994967|NCT04137107|Other|Placebo|Given PO
45994968|NCT05539794|Behavioral|lifestyle and physical exercise|"the intervention group will follow a physical exercise and health counselling intervention--see below.~The exercise program will be performed in the hospital gymnasium (3 supervised sessions/week of aerobic and muscle strength exercises) or in the patients' room (during phases of treatment-induced immunodepression, where isolation is needed to prevent infections). It will also include specific training of the respiratory ('inspiratory') muscles (e.g., diaphragm) on 5 days/week. The counselling program will include psychological (once weekly), nutritional (twice monthly), support (with survivors of adolescent cancer, twice/month) and educational (for relatives/caregivers, once monthly) sessions."
45994969|NCT01258348|Drug|Drug: LY573636-sodium|"Participant specific dose based on height, weight and gender to target a specific exposure range, administered intravenously on Day 4 of a 42-day (6-week) cycle.~Dose will be escalated to reach the maximum tolerated dose (MTD). A cohort of participants enrolled after MTD will receive albumin-tailored doses.~Participants may continue on treatment until clinical or objective disease progression."
45994970|NCT01258348|Drug|Sunitinib|"37.5 or 50 milligrams (mg), administered orally, daily for a 42-day (6-week) cycle.~Participants may continue on treatment until clinical or objective disease progression."
46084953|NCT04172493|Device|White Light Endoscopy (WLE)|Undergo white light endoscopy
46084954|NCT00647205|Device|QuantiFERON TB Gold In-Tube|
46084955|NCT00647205|Device|T-SPOT.TB®|
45994971|NCT05141266|Behavioral|Patient Navigation|PN involves 8 weekly telephonic sessions lasting 30-45 minutes (telephonic to support lower-costs/sustainability). In session 1, the navigator reviews with the participant a report of scores from the baseline assessment to understand the participant's current health needs/challenges; session 1 also involves development of therapeutic alliance/rapport and goal setting. Sessions 2-4 focus on goal setting and identifying barriers and problem resolutions. The navigator elicits motivation and discusses this in context of readiness to change heath behavior and self-management skills. Sessions 2-4 also involve navigators supporting/assisting patients to fill out paperwork and enroll in needed social services and/or mental/behavioral/physical healthcare, including but not limited to primary care. Sessions 5-7 focus on encouraging and reinforcing treatment adherence, review-ing and identifying other care needs, and offering linkages to service providers as applicable
45994972|NCT05141266|Other|Standard Medication Counseling (SMC)|SMC participants receive a single medication information/counseling session delivered by a University of Utah pharmacist to: (1) offer counseling, (2) document counseling was offered, (3) offer a counseling process for patients not present (not applicable to this study given all patients must screen in person), and (4) discuss generic substitution.
45994973|NCT05513352|Device|tACS - transcranial alternating current stimulation|"TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The stimulation will be applied over the left temporo-parietal cortex at participants' individual alpha frequency. The stimulation intensity will be 2 milliampere (mA, peak-to-peak value, corresponding to a sine wave of ±1 mA amplitude). Stimulation will be delivered through conductive rubber electrodes."
45994974|NCT05513352|Device|sham - transcranial alternating current stimulation|"During sham stimulation (placebo), tACS will be ramped up and down for 12 seconds , that is, no electric stimulation wil be applied during the actual experiment. The up and down ramping will be repeated at the end of the experiment.~The sham condition serves to evoke sensations associated with tACS stimulation, but without stimulating during the actual experiment."
45994975|NCT05513352|Device|NF - Neurofeedback|"Neurofeedback (NF) is a non-invasive approach that combines neurophysiological recordings with real-time sensory feedback (most studies use visual feedback). Through real-time NF, individuals thus can learn to regulate their brain activity.~In this study, NF will be based on concurrent EEG recordings. During NF, participants will observe a space ship automatically navigating through a narrow tunnel. The modulation of their neural alpha power lateralization into the trained direction will be rewarded by the acceleration of the space ship, a modulation in the opposite direction will reduce speed and autopilot accuracy."
46084956|NCT02768636|Dietary Supplement|Omega-3|Omega-3 or Fish oil (1000 mg.) is taken for one capsule a day in 30 days duration. Heart rate variability is tested before at starting day and later follow up it again in the next 30 days appointment.
46084957|NCT00647283|Procedure|Gradual immunosuppression drug withdrawal|After the obtention of biological samples (peripheral blood, liver tissue), enrolled patients undergo gradual weaning of all immunosuppressive therapy over a 6-9 month period under close medical supervision.
46084958|NCT02761304|Procedure|Ultrasound|
45457178|NCT03647852|Drug|IVIG|1. IVIG 2g/kg and oral prednisolone 2mg/kg/d 2.if the patients still complain abdominal pain and feel abdominal tenderness on the third day after intervention , patients would be given methylprednisolone pulse (15-30mg/kg/d) for 3 days
45457179|NCT03647852|Drug|other basic supportive treatment|"Omeprazole 0.8mg/kg.d.The maximum dose is less than 40mg per day~Low molecular weight heparin calcium 50IU/kg.d"
45834242|NCT04395924|Diagnostic Test|Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta|"During labor and delivery~Sample of amniotic fluid~2 samples of blood cord after the birth of the new born~2 samples of placenta~These samples will be tested with A RT-PCR COVID-19 test and / or serology's A sample of blood cord and placenta will be frozen at -80 degree C and studied for PCR and viral proteome, cytokines , D-dimers and others inflammatory markers in the PRIMMO Laboratory (Prof. TOUMI and LESPESSAILLES) and after in the Centre of molecular biophysics of CNRS of Orleans (Prof. PICHON)"
45834243|NCT04395144|Procedure|Awake Prone Positioning|Patients will receive instruction to remain in prone position as long and as often as possible, up to 16h/24h
45457180|NCT03518710|Other|Neuropsychological evaluation|"Neuropsychological evaluation (about 60 min) the same day realized by a student in Science Thesis under the responsibility of Prof. Yves Chaix and including:~Process evaluation:~Oculomotors: DEM test (5min)~Visuo-attention: computerized STROOP (15min)~Visuo-Perceptive: DTVP3 (30min)~Phonological & lexical: Exalang (10min)"
45994976|NCT05136898|Drug|UGN-102|"UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL)."
45994977|NCT01258075|Drug|High-dose colesevelam|3.75 grams colesevelam hydrochloride in oral suspension
45994978|NCT01258075|Drug|Low-dose colesevelam|0.625 grams colesevelam hydrochloride in oral suspension
45994979|NCT01257568|Device|Rejuvenate Modular Hip|Rejuvenate Modular Hip
46084959|NCT00647361|Device|Neurally adjusted ventilatory assist (NAVA) provided by a commercially available mechanical ventilator (Servo i, Maquet Critical Care, Solna, Sweden).|Neurally adjusted ventilatory assist (NAVA) and pressure support ventilation (PSV)
46084960|NCT04736745|Biological|IPN59011|Powder and solvent for solution for injection
46084961|NCT04736745|Biological|Azzalure|Powder for solution for injection
45834244|NCT04395144|Procedure|Standard care|Patients will not receive any special instructions with regards to proning.
45834245|NCT04395768|Dietary Supplement|Vitamin C|In addition to the active comparator, which is a combination of 2 drugs and 3 dietary supplements, the experimental treatment arm will also receive Vitamin C (intravenous or oral)
46084962|NCT04736745|Drug|Placebo|Powder for solution for injection
45674786|NCT02045095|Drug|MLN7243|"Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing)."
45674787|NCT04183309|Other|Measure the transpulmonary pressure in pediatric patients|Esophageal pressure will be measured by an esophageal ballon to assess transpulmonary pressure during laparoscopy surgery. Lung collapse will detected when transpulmonary pressure became negative and using lung ultrasound images. Lung ultrasound examinations will be performed at different times-points: after anesthesia induction, 10 minutes after pneumoperitoneum insufflation, and at the end of surgery. A lung recruitment maneuver will be applied if these patients present atelectasis during surgery.
45674788|NCT02181803|Drug|MK-8189|MK-8189, oral, 2 mg and/or 10 mg tablets, taken QD for a total daily dose of 2 mg, 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, 20 mg, or 40 mg
45674789|NCT02181803|Drug|Placebo|Placebo matching oral 2 mg and/or 10 mg MK-8189 tablets, taken QD
45834246|NCT04395768|Drug|Hydroxychloroquine|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
45834247|NCT04395768|Drug|Azithromycin|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
45834248|NCT04395768|Dietary Supplement|Zinc Citrate|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
45834249|NCT04395768|Dietary Supplement|Vitamin D3|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
45834250|NCT04395768|Dietary Supplement|Vitamin B12|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
45834251|NCT04396158|Radiation|radioactive iodine|80-200 mCi of radioactive iodine will be given to thyroid cancer patients
45994980|NCT04687878|Drug|Insulin|20 IU twice a day, intranasally, every day for 12 weeks
45994981|NCT04687878|Drug|Normal saline|twice a day, intranasally, every day for 12 weeks
45994982|NCT05118802|Other|Interview|Attends Interviews
46084963|NCT04750070|Drug|Dopamine|Children will receive dopamine, 8 microgram/kg.min (increasing the dose after 15 minutes to 12 microgram/kg/min to a maximum of 15 microgram/kg/min)
46084964|NCT04750070|Drug|adrenaline|Children will receive adrenaline, 0.1 microgram/kg/min (increasing the dose after 15 minutes to 0.2 microgram/kg.min to a maximum of 0.3 microgram/kg.min)
46084965|NCT04750070|Drug|Blood Transfusion|Children will receive a transfusion of whole human blood in a dose of 10 mL/kg over 2-3 hours. While the blood transfusion is being arranged, IV fluid would be given @ of 3 ml per kg per hour
46084966|NCT04172415|Other|Retrospective cohort|Chart Review
46084967|NCT04222400|Diagnostic Test|Frailty Assessment|Bioelectrical Impedance Analysis 6 Minute Walk Test Grip Strength Questionnaires Muscle Mass Evaluation via CT
46084968|NCT04172337|Behavioral|Healthier Choice Symbol|The HCS is intended to improve diet quality by signaling to consumers which products are healthier options within a specific category (e.g., which are the healthier biscuits or the healthier beverages). Manufacturers must meet category-specific criteria before a product can display the HCS and an associated tagline. The labels were displayed at the bottom of the product images.
45674790|NCT02181803|Drug|Base Monotherapy|For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone [not to exceed daily dose of 6 mg], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.
45674791|NCT01826487|Drug|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
45834252|NCT01927224|Drug|Nifurtimox (BAYa2502) (4 x 30 mg tablet)|120 mg single dose as four 30 mg tablets after a high fat, high calorie meal
45994983|NCT05118802|Other|Survey Administration|Complete Survey
45994984|NCT05116774|Drug|BCX9930|Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily
45994985|NCT05116774|Drug|Eculizumab|Administered by intravenous infusion per current dose regimen
45994986|NCT05116774|Drug|Ravulizumab|Administered as intravenous infusion per current dose regimen
45994987|NCT04687839|Procedure|Induction of suction blister|For each subject, 2 superficial wounds will be made on the inner aspect of each forearm using the suction blister model.
45834253|NCT01927224|Drug|Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)|120 mg single dose as aqueous slurry in tap water produced from four 30 mg tablets; ingestion after a high fat, high calorie meal
45994988|NCT04687839|Other|Transepidermal water loss (TEWL)|"At V1, before blister suction use (T0) and after blister withdrawal before product application (T1)~For subsequent visits, before product application"
45994989|NCT04687839|Other|Macrophotography|"At V1, before blister suction use (T0) and after blister withdrawal before product application (T1)~For subsequent visits, before product application"
45994990|NCT04687839|Device|Wound healing medical device|Twice daily application on superficial wounds
45994991|NCT01256788|Device|Euflexxa|4 injections of 2ml of Euflexxa
45994992|NCT01256788|Other|Saline|4 injections of 3 ml of sterile saline
45994993|NCT01256671|Drug|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 52 weeks.
45994994|NCT04687566|Drug|Dextromethorphan|The participants will take dextromethorphan 60 mg per day, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
45994995|NCT04687566|Drug|Memantine|The participants will take memantine 5 mg per day, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
45994996|NCT04687566|Drug|Dextromethorphan and memantine|The participants will take dextromethorphan (60 mg per day) and memantine (5 mg per day) combination, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
45994997|NCT04687566|Drug|Placebo|The participants will take the placebo pills, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
45994998|NCT04683809|Other|Telerehabilitation|Patients will attend rehabilitation sessions through online programmes for rehabilitation
45834254|NCT01927224|Drug|Nifurtimox (BAYa2502) (120 mg tablet)|120 mg single dose as one 120 mg tablet after a high fat, high calorie meal
45834255|NCT03831750|Other|Stress Reduction Intervention|The tri-component intervention is comprised of guided videos for breath-work (5-15 min), stretching (5-15 min), and meditation (10-30 min). The intervention will be delivered online via an access restricted website.
45834256|NCT01921998|Procedure|Biomarker and health economics|Biomarkers CK18 and FLT3 Ligand will be collected
45674792|NCT01826487|Drug|Placebo|Placebo will be administered as per the schedule specified in the arm.
45674793|NCT02064439|Drug|BAY 59-7939|10 mg tablet once daily for 12 months
45674794|NCT02064439|Drug|BAY 59-7939|20 mg tablet once daily for 12 months
45674795|NCT02064439|Drug|ASA|100 mg tablet once daily for 12 months
45834257|NCT01927458|Device|Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
45994999|NCT01256593|Drug|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
45995000|NCT01256476|Drug|pitavastatin|pitavastatin 4 mg once daily (QD)
45995001|NCT01256476|Drug|pravastatin|Pravastatin 40 mg once daily (QD)
45995002|NCT05507892|Drug|canagliflozin|Canagliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is a used to treat type 2 diabetes. Canagliflozin lowers blood sugars by causing the kidneys to excrete more glucose in the urine.
45995003|NCT05507892|Drug|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure renal plasma flow (RPF) PAH (Basic Pharma, Geleen, Netherlands) has been used to measure RPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.
45995004|NCT05590000|Device|Gemini rechargeable Spinal Cord Stimulation (SCS) System|Patients with chronic pain will be implanted with Gemini rechargeable SCS System
45995005|NCT04128371|Biological|Nucala (mepolizumab)|Mepolizumab is a fully humanized monoclonal antibody (IgG1, kappa mAb) supplied as 100 mg of lyophilized powder in sterile, single-dose vials. Mepolizumab 100 mg vials will be reconstituted with 1.2 ml sterile water for injection (according to the product labeling) and secondarily diluted in 100-250 ml of 0.9% normal saline (NaCl) for infusion (to a final concentration of 0.3-7.5 mg/ml).
45995006|NCT01368588|Radiation|radiation therapy|Undergo RT using IMRT or 3D-CRT
45995007|NCT01368588|Radiation|Whole-pelvic radiotherapy (WPRT)|Undergo whole-pelvic radiotherapy (WPRT)
45995008|NCT04684043|Device|Percutaneous coronary intervention|PCI was performed using drug-eluting stents
46084969|NCT04172337|Behavioral|Physical Activity Equivalent label|"For the study, we designed a simple PAE logo (Appendix Figure A1) and added a description encoded into the NUSMart user interface to ensure that participants would understand the contents of the label. Participants saw the following description whenever their cursor hovered over the PAE label: The Physical Activity Equivalent (PAE) refers to the number of minutes that a typical adult would need to jog to burn off the calories associated with one serving of the product. Previous studies have shown this labelling approach to be effective.~The labels were displayed at the bottom of the product images."
45995009|NCT04684082|Device|Colonic irrigation with the Colon Hydromat|"A designated health professional will administer to the patient the colonic irrigation procedure - using the Colon Hydromat device, a CE certified device for colonic irrigation and cleansing before endoscopic procedures."
45995010|NCT04683887|Device|Tape application|Application of the tape with lymphatic technique to the fingers, both dorsally and volarly, of wrist fractured patients treated with a forearm cast
45995011|NCT05506956|Drug|Flotetuzumab|Patients enrolled on dose level 1 (DL1) will receive flotetuzumab by continuous infusion using multi-step lead-in dosing, and then 500 ng/kg/day on days 7-28. After one cycle, all patients will undergo a bone marrow biopsy to assess response including assessment of minimal residual disease (MRD). Patients who fail to achieve a CR, CRi, CRh (complete remission with partial hematologic recovery), or MLFS may continue with subsequent induction cycles as a continuous infusion up to a total of five cycles. If there is evidence of response (CR, CRi, CRh, or MLFS) and the toxicities of treatment are acceptable, patients will be eligible for two consolidation cycles. Additional bone marrow biopsies for response assessment will be performed after the second cycle. If there is a need to de-escalate dosing based on toxicity, then patients will be enrolled on DL-1 using multi-step lead-in dosing, and then 300 ng/kg/day on days 5-28 of the first cycle and days 1-28 of subsequent cycles.
45995012|NCT05506722|Device|Testes shocker|It is a device that give electric shocks (up to 5 milli Amperes) and it is designed to contain both the testes within it.
45995013|NCT05504616|Other|Health technology-based intervention strategy|Patient-centered, technology-based intervention strategy aimed at increasing physical activity in patients with axSpA
45995014|NCT04108364|Behavioral|Voice adaptive training for aphasia|Training with the VoiceAdapt tablet-based therapy app 25 hours (1 hr/day x 5 days/week x 5 weeks)
45995015|NCT05502276|Procedure|Endoscopic Full-Thickness Resection (EFTR)|Full Thickness Endoscopic Resection using the FTRD Ovesco Device
45995016|NCT05502276|Procedure|Endoscopic Submucosal Dissection (ESD)|Standard Endoscopic Submucosal Dissection using standard procedure described in international guidelines.
45995017|NCT05491083|Drug|Pembrolizumab & ADG106 (Phase Ib)|"Drug: ADG106~Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.~Pembrolizumab~Administered as an intravenous infusion over 30 minutes"
45995018|NCT05491083|Drug|Pembrolizumab & ADG106 (Phase II)|"Drug: ADG106~Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.~Pembrolizumab~Administered as an intravenous infusion over 30 minutes"
45995019|NCT05486169|Procedure|Sleeve Gastrectomy|surgery of laparoscopic sleeve gastrectomy
45995020|NCT04106999|Drug|Dexmedetomidine|Drug infusion will be delivered intra-operatively
45995021|NCT04106999|Drug|Placebos|Normal Saline will be infused as a control drug
45995022|NCT05478720|Drug|6-diazo-5-oxo-L-norleucine (DON)|Single intravenous dose ranging from 0.1-10 mg/kg per dose
45995023|NCT05478720|Drug|Placebo|Single intravenous dose of saline
45995024|NCT04105049|Other|Observation of psychological aspects|Motivational, socioeconomic, family, stress, and other aspects are tested.
45995025|NCT05003089|Drug|BAY1834845|Tablet, oral.
46084970|NCT02763722|Other|Emollient spray product|All patients will be instructed to use emollients spray on entire skin at least twice a day for four weeks.
46084971|NCT01143246|Drug|Terlipressin|Each 6 mL vial contains 1 mg lyophilized terlipressin acetate and 10 mg mannitol in sterile 0.9% sodium chloride solution.
45834258|NCT04396080|Procedure|Partial restoration in posterior teeth|Teeth in need of onlays that will be treated with this type of treatment, choosing the most suitable material for each patient and following the manufacturer's instructions for their cementing and adhesion.
45834259|NCT01927536|Device|White LED Flashlight|white light setting
45834260|NCT01927536|Device|Red/Green Green Dominant LED Flashlight|Green LED light dominant setting
45834261|NCT01927614|Radiation|Cardiac CT|"A 128-slice dual-source CT system will be used (Somatom Definition Flash, Siemens Healthcare, Germany).~The CT scan protocol will comprise 3 steps.~Prospectively gated calcium scoring.~Stress-myocardial CT perfusion.~Rest Coronary CT angiography and myocardial CT perfusion. Automated computed tomography dose index (CTDIvol) and dose- length-product (DLP) will be collected from the scanner, and effective dose will be calculated using the DLP conversion factor (0.014) for each component of the cardiac CT protocol. Based on local dose audits the predicted dose range will be 3.5 mSv to 8 mSv depending on patient body habitus."
45995026|NCT05003089|Drug|BAY1830839|Tablet, oral.
45995027|NCT05003089|Drug|Prednisolone|Tablet, oral.
45995028|NCT05003089|Drug|Placebo|Tablet, oral.
45995029|NCT04985968|Drug|Cobitolimod 250 mg|Rectal administration
45995030|NCT04985968|Drug|Cobitolimod 500 mg|Rectal administration
45995031|NCT04985968|Drug|Placebo|Rectal administration
45995032|NCT01256008|Behavioral|CBT|The subjects will receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a month in the second and third months), and each session will last for about 60 minutes.The treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with the subjects; Skills acquisition and repeat stage (the third session to the 8th session): clarification of sources of stress, patients' cognitive and behavioral response to stress. Application and complete price segment (the 9th session): return visit to test efficacy of psychological intervention.
45995033|NCT01256008|Behavioral|Clinical Management|"Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview and lasting for 20-25 minutes each session. Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention.~Following are major elements:~Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction. Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible."
45995034|NCT04066127|Device|Non-ischemic heart preservation (NIHP)|The device is a miniaturized and fully automated heart-lung machine, housed in a portable device (weight 32 kg), that enables transportation between hospitals. The reservoir is filled with 2.5 liters of the perfusion solution plus approximately 500 mL compatible washed and leucocyte-filtered red blood cells from the hospital blood bank. The NIHP system software is adjusted to maintain a mean blood pressure of 20-25 mmHg in the aortic root, giving a coronary flow between 150 mL/min and 250 mL/min.
46084972|NCT01143246|Drug|Placebo|11 mg mannitol reconstituted with 5 ml of sterile 0.9% sodium chloride solution.
46084973|NCT00647517|Drug|Ultracet|"For the treatment arm: Tramadol 37.5 mg/APAP 325 mg combination tablets (Ultracet®) one tablet twice a day plus aceclofenac tablet per oral 100 mg twice a day.~For the control group: Placebo plus aceclofenac tablet per oral 100 mg twice a day."
45995035|NCT04066127|Device|Standard ischemic cold static storage (SCS)|The device is a cool box that enables transportation between hospitals. The heart is stored on ice slush in the box at a temperature of approximately 4-8 °C.
46084974|NCT04656392|Diagnostic Test|Breath test (eNose) followed by uTNE.|All participants will receive the breath test with the eNose in the general practice, followed by the uTNE in the hospital.
45995036|NCT04982965|Drug|Active Cannabis|400 mg of vaporized and inhaled active cannabis (5.1%)
45995037|NCT04982965|Drug|Placebo Cannabis|400 mg of vaporized and inhaled placebo cannabis (<.1%)
45995038|NCT04976101|Device|Sinosuidal Galvanic Vestibular Stimulation|stimulus will be given by applying paste electrodes over the mastoid processes and plugging the leads into a battery driven-stimulus box, which when activated by a switch, will provide a very low frequency (VLF) bipolar, ± 2 mA, 0.025 Hz oscillating current sGVS between the mastoids
45995039|NCT04976101|Device|Placebo|When assigned to placebo arm of the study, the patients will undergo same procedure as the treatment, only current will not be passed. (the device will still be placed on the mastoid process)
45995040|NCT04206826|Device|PREDELFI|It's a natural film which contains a concentrated alpha-GOS (alpha-galacto-oligosaccharide) soy extract, a milk protein concentrate containing caseins and whey proteins and vegetable glycerin
45995041|NCT04206826|Device|CONTROL|It's a natural film which is devoided of active ingredient. It contains sodium alginate; vegetable glycerin, caramel, beta carotene and water.
46084975|NCT00647595|Behavioral|Experimental group|Intervention group will exercise 3 times per week at moderate-vigorous intensity for 45 minutes per session. Control group women will continue their usual physical activity throughout pregnancy.
45995042|NCT04060355|Behavioral|Savvy program|Caregiver program (Savvy) is an evidence-based dementia family caregiver psychoeducation program. Provided to groups of 8-12 (typically) individuals caring for family members living with Alzheimer's disease or related dementias (PLWD), Savvy employs a mechanism of action based in Social Cognitive theory to promote caregivers' solution-focused coping behaviors through the acquisition of appropriate knowledge, skills, and outlook and the enhancement of caregiving mastery.
45995043|NCT04060355|Behavioral|Semi-structured video interviews|Semi-structured video interviews will assess the preliminary efficacy of programs led by system-trained interventionists in producing anticipated outcomes in caregiver participants - reduced depression and burden and enhanced caregiving mastery. It will also focus on sense of the completeness and adequacy of the training program, including the training methods, videos, and materials
45995044|NCT04207021|Dietary Supplement|Experimental: Curcumin derivate|two capsules per day, one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
45995045|NCT04207021|Dietary Supplement|Placebo|two capsules per day (containing no bioactive compound, only hydroxypropyl methylcellulose, gellan gum, pigment), one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
46084976|NCT04654754|Device|high-flow high humidity oxygen device with tracheostomy adapter|This device can provide heat and humidified gas for spontaneous breathing patients with tracheostomy at a high gas flow rate.
46084977|NCT00647673|Drug|Verapamil HCL Extended-Release Capsules 300 mg|300mg, single dose fasting
46084978|NCT00647673|Drug|Verelan® PM Extended-Release Capsules 300 mg|300mg, single dose fasting
46084979|NCT03100890|Other|Preoperative training (hospital)|Preoperative hospital training
46084980|NCT03100890|Other|Preoperative training (home)|Preoperative in-home training
46084981|NCT02664675|Procedure|Crown lengthening|After a local anesthesia, gingival tissue is removed around the teeth to extend the length of the crown for aesthetic or prosthetic matter.
46084982|NCT02664675|Procedure|Open Flap Debridement|"After local anesthesia, intra-sulcular incisions are done and a flap is released to access to the intra-bony defect.~Granulation tissue is removed and carefully laid aside for further analysis. Interrupted sutures are done to close the flap."
45457181|NCT03518710|Other|Evaluation of the reading assistance technique|"Evaluation of the reading assistance technique (about 30 min) and comprising:~- Reading evaluation:Test lark (3min) Experimental task: 3-way help with reading (without help, color help and highlight help (25 min)"
45457182|NCT02299804|Drug|Levophencynonate Hydrochloric|this drug is M receptor inhibitor
45457183|NCT02299804|Drug|Placebo|No active ingredient
46084983|NCT04736888|Other|extended-reality CPR training|extended-reality technologies based CPR training module
46084984|NCT04736888|Other|conventional CPR training|conventional CPR training with video
46084985|NCT02102022|Drug|ADI-PEG 20 plus modified FOLFOX6|
45457184|NCT01354808|Drug|Dual Anti-Platelet Therapy (DAPT)|"Loading: aspirin 300mg + clopidogrel 600mg~Maintenance: aspirin 200mg/d + clopidogrel 75mg/d for 1 month"
45834262|NCT01927692|Other|Skin biopsy|An optional skin biopsy will be performed in up to 5 subjects at baseline and 2 weeks after therapeutic plasma exchange is completed.
45834263|NCT01927692|Other|Single Fiber Electromyography|An optional SFEMG study will be performed at baseline and 2 weeks after therapeutic plasma exchange is completed.
45834264|NCT01922154|Drug|intravitreal ranibizumab|The patients received IVR (0.5 mg in 0.05 ml) injection through the pars plana in the operating room. A fornix-based conjunctival flap technique trabeculectomy with intraoperative mitomycin C was performed within 2 weeks after IVR.
45834265|NCT01922154|Procedure|Trabeculectomy with mitomycinC|All participant underwent trabeculectomy with mitomycinC , which is the standard procedure for refractory glaucoma.
45834266|NCT04554576|Behavioral|Chronic Disease Self-Management Program (CDSMP) for chronic pain in Spanish|"The CDSMP meets for 2.5 hours for 6 weeks. Topics covered are: understanding pain, finding resources, mindfulness, pain science, pacing, exercise, relaxation, communication, sex/intimacy, healthy eating, weight and medication management, making treatment decisions and confronting fears.~Participants are encouraged to create their own personal health goals and make weekly action plans to meet their personal goals. Each week participants learn new tools and problem-solving techniques to meet their health goals and themes are repeated throughout 6-week period to ensure understanding and integration. Participants are encouraged to problem-solve and ask questions to the group about creating and carrying out their self-management plan.~The intervention follows the content of the book Programa de Manejo Personal del Dolor Crónico (Living a Healthy Life with Chronic pain)"
45834267|NCT04554576|Behavioral|Remote feedback active group|After the 6-week self management program, half the participants will be randomized to an every 6 weeks for 6 months phone or video visit from a health care provider, in Spanish. The phone or video sessions will include: review previous action-plans (goals) and provide support in forming new action-plans (goals)
45834268|NCT04554576|Behavioral|Remote feedback control group|After the 6-week self-management program, half the participants will be randomized to a control group for 6 months.
45834269|NCT03060642|Device|Tethered capsule sponge|Subjects swallow a tethered capsule sponge sampling device, which is then withdrawn through the mouth after an interval of 5 minutes.
45834270|NCT03060642|Device|Electronic nose device|Subjects breathe into the device, which then records an exhaled volatile organic compounds (VOC) signature.
45834271|NCT03059940|Behavioral|Questionnaires|Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
45834272|NCT03059940|Procedure|Low Dose Computed Tomography Scan|Participants have a CT scan of chest to look for signs of lung cancer.
45834273|NCT03059940|Other|Shared Decision Making + Video|Participants given shared decision making and discussion about screening with the LDCT provider. Participants watch a short video about lung cancer, CT scans, and smoking cessation.
45834274|NCT03059940|Behavioral|Cessation Counseling|Brief cessation counseling given by LDCT provider.
45834275|NCT03059940|Behavioral|Quitline|Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks.
45834276|NCT03059940|Behavioral|Pharmacotherapy Discussion|Participant informed of the risk, benefits and relative efficacy of cessation medications and to assess their medication preferences, expectations and medical suitability for either option. At the conclusion of this conversation the patient is provided with an initial supply of the medication jointly decided between provider and patient.
45834277|NCT03059940|Drug|Nicotine Patch|Nicotine patch dispensed. Dosing at physician's discretion.
45834278|NCT03059940|Drug|Anti-Smoking Drug|Varenicline or Buproprion prescribed by study doctor with directions of when and how much of anti-smoking drug that should be taken each time.
45834279|NCT03059940|Behavioral|Tobacco Treatment Program|Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,
45834280|NCT03059940|Other|Carbon Monoxide (CO) Level Test|Participant asked to blow air through a CO-measuring device.
45834281|NCT01927848|Dietary Supplement|Rosehip|Rosehip powder made from the fleshy orange walls (hypanthiums) of Rosehips with the achenes (seeds) removed, from the wild growing species Dog Rose (Rosa canina L.), in addition to vitamin C as sodium ascorbate. The active ingredient complex is Rosenoids®, Vitamin C, flavonoids, carotens, triterpene acids, and galactolipids. Rosenoids® is the registered name for the bioactive complex isolated from the rose-hip (Rosa canina) used in RH01. It is being supplied as capsules containing 750 mg of the Rosehip powder and 26.7 mg vitamin C.
45834282|NCT01927848|Dietary Supplement|Placebo|The placebo used in this study will be identical to the Rosehip capsules in both appearance and taste, except that it will not contain the active Rosehip powder ingredient Rosenoids® or vitamin C.
45834283|NCT01927926|Dietary Supplement|Whey-protein & polydextrose snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
45995046|NCT03457272|Other|New risk assessment|"Consists of a simple physiological scoring system and an assessment of patients who should assist healthcare professionals in identifying patients at risk of clinical deterioration earlier and support timely response and escalation of observation, care and treatment and thereby prevent the development of severe clinical deterioration.~The patients included in the study will be monitored using the new risk assessment tool with different intervals according to the patients' conditions. Underlying the tool are algorithms of action for intervention in the critically ill patient, inter professional guidelines and guidance for standardized monitoring, escalation plans and huddles."
45995047|NCT05467683|Behavioral|Exposure-Based Therapy|"Treatment will consist of 12 one-hour sessions, delivered over the course of 12 weeks. EBT will be delivered by trained and experienced license-eligible clinicians. The study clinician will develop a personalized assessment and treatment plan for each patient. Consistent with contemporary models of EBT, exposure practice aims to help patients reestablish a sense of safety around feared cues. Hence, exposure exercises are planned to ensure violation of threat expectancies. That is, exposure practice is deemed appropriate and effective if it allows the patient to learn that what they feared would happen does not happen. Practice will occur across relevant contexts both within and outside the session (i.e., homework) and clinicians will guide patients in processing practice to facilitate the consolidation of safety learning. To achieve these ends, study clinicians will use the manual Personalized Exposure Therapy: A Person-Centered Transdiagnostic Approach."
45995048|NCT01255423|Drug|Diclofenac sodium topical gel 1%|Diclofenac sodium topical gel 1%, 4 times daily
45995049|NCT01255423|Drug|Placebo|Placebo, 4 times daily
45995050|NCT01255306|Other|Optical coherence tomography|"Optical coherence tomography will be performed in all study patients following pars plans vitrectomy and silicone oil tamponade. A fellow eye of each patient will serve as a control. Each patient enrolled in a study will receive 4 measurements:~On 7th postoperative day~On 30th postoperative day~On 90th postoperative day~On 180th postoperative day"
45995051|NCT01255306|Drug|Local medical treatment of raised intraocular pressure|"In patients with raised intraocular pressure following medications will be employed in order to control the intraocular pressure:~Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution; b.i.d.) Ganfort (Bimatoprost, timolol maleate ophthalmic solution; once daily) Alphagan (Brimonidine ophthalmic solution; b.i.d.) In patients with intraocular pressure less than 27 mmHg Alphagan will be prescribed. In patients with intraocular pressure greater than 27 mmHg either Cosopt, or Ganfort will be prescribed under the discretion of treating physician. If intraocular pressure in patients treated with either Cosopt or Ganfort does not drop under 21 mmHg, Alphagan will be added."
45995052|NCT04006964|Device|Resmon PRO FULL v2|Measurement of lung impedance by the Forced Oscillation Technique
45457185|NCT01354808|Drug|Triple Anti-Platelet Therapy (TAPT)|"Loading: cilostazol 200mg + aspirin 300mg + clopidogrel 600mg~Maintenance: cilostazol 100mg bid+ aspirin 200mg/d+ clopidogrel 75mg/d for 1 month"
45834284|NCT01927926|Dietary Supplement|Control snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
45834285|NCT01922310|Behavioral|Communication intervention|"The intervention is a modification of current standard practice procedures for requesting consent for donation.~The intervention period commences when the possibility of organ donation is first raised with the family, and includes the time for families to make a decision. This time may last up to 72 hours."
45834286|NCT04552470|Drug|Placebo|3 matching placebo tablets taken twice a day (BID)
45834287|NCT04552470|Drug|PF-06882961|Participants will be randomized to one of 3 active doses (40, 80, or 120 mg), taking 3 tablets twice daily for 8 weeks.
45834288|NCT04550130|Device|TLA Gut™|The medical device to be investigated is named Tailored Leukapheresis (TLA) Gut™. The device comprises a column that has been designed for extracorporeal leukapheresis to specifically remove chemokine (C-C motif) receptor 9 (CCR9) expressing immunological cell populations including human leukocyte antigen DR isotype (HLA-DRhi ) monocytes from the circulation. This is achieved by integrating a strong affinity binding between the gut homing cell receptor, CCR9, and its cognate ligand, thymus-expressed chemokine (TECK) or chemokine ligand 25 (CCL25). Those blood cells that express CCR9 will bind to presented Biotinylated thymus-engineered chemokine (bTECK) on the matrix by a strong receptor ligand interaction, remaining bound to the matrix. Blood cells that do not express the receptor pass through the column unchanged and are returned to the patient.
45834289|NCT04556916|Diagnostic Test|Blood sample|"Per patient 49 ml of peripheral blood sample :~21ml divided into 3 TransFix or EDTA 7ml tubes will be sent to Hamburg for subsequent CTCapture analysis;~28ml divided into 4 EDTA 7ml tubes will be sent to Montpellier for subsequent EPIDROP analysis (21 ml), PHI analysis (7 ml) and plasma isolation."
45834290|NCT03423342|Dietary Supplement|nicotinamide riboside|nicotinamide riboside capsule
45834291|NCT03423342|Drug|Placebo|matching placebo capsule
45834292|NCT03058146|Behavioral|Mobile Health Walking Condition|Physically inactive older adults in this condition (N=30) will perform 3 months of prescribed brisk walking (to increase cardio respiratory fitness) in their real world environments, using mobile health (mHealth) devices during each exercise session to achieve and maintain a minimum of 150 minutes of moderate to vigorous physical activity (MVPA) per week.
45834293|NCT03058146|Behavioral|Healthy Aging Education Condition|The education control condition (N=30) will provide participants with printed materials and homework assignments on issues related to successful aging, such as nutrition, social activity, cognitive and social engagement.
45834294|NCT01928160|Drug|pemetrexed disodium|Given IV
45834295|NCT01928160|Drug|carboplatin|Given IV
45834296|NCT01928160|Drug|cisplatin|Given IV
45834297|NCT01928160|Drug|erlotinib hydrochloride|Given PO
45834298|NCT01928160|Other|laboratory biomarker analysis|Correlative studies
45995053|NCT05463042|Behavioral|Intermittent Hypoxia|During the intermittent hypoxia session, participants will be sitting during the entire breathing protocol. Hypoxic air will be inhaled through a mask connected to a two-way non-rebreathing valve, which will itself be connected to a 5-liter non-diffusing gas bag (Hans Rudolph, Inc, USA). The rebreathing bag will be connected to a certified medical grade gas tank containing 11% oxygen and a balance of nitrogen. The intermittent hypoxia protocol will consist of eight 4-min cycles of breathing hypoxic air interspersed with normoxic cycles breathing room air. After four min of hypoxia, participants will be switched back to breathing room air until resaturation, which takes approximately one minute. Once arterial oxygen saturation reaches baseline levels, participants will be switched back to breathing hypoxic air, beginning the next hypoxic cycle.
45995054|NCT05463042|Behavioral|Normoxia (sham)|During the sham condition, compressed air (21% oxygen) from a gas tank will be delivered throughout the protocol instead of 11% oxygen. Participants will not receive information about which condition (Intermittent hypoxia or sham) they are experiencing during the trials.
45995055|NCT01254721|Drug|Quetiapine fumarate|eXtended Release(XR) 50mg, 200mg, 300mg and/or 400mg tablet, oral, once daily in the evening, from assignment to the end of the study.
45995056|NCT01254721|Drug|lithium|300mg tablet, oral
45995057|NCT04005053|Drug|N-acetyl cysteine|3600 or 5400 mg/day N-acetyl cysteine
45995058|NCT04005053|Drug|Placebo oral tablet|Placebo
45995059|NCT04519671|Drug|Mesenchymal Stem Cells|Direct injection of adult allogeneic bone marrow derived mesenchymal stem cell product, at a dose of 75 million cells into perianal fistula(s)
45995060|NCT04519671|Other|Placebo|Normal saline
45995061|NCT04207099|Device|MolecuLight i:X Imaging Device|The MolecuLight i:X Imaging Device uses built-in light-emitting diodes (LEDs) emitting 405 nm violet excitation light to illuminate the wound during fluorescence imaging in (FL-Mode). The light excites biological components of the wound and surrounding tissues. Non-biological components may also fluoresce although their presence in wounds is less common, provided the wound has been cleaned following standard care protocols. The resulting wound fluorescence wavelengths emitted are typically between 420 - 700 nm in the visible wavelength spectrum. In FL-mode, a customized fluorescence emission filter, which is mechanically placed in front of the built in imaging sensor and allows real-time capture of wound, limits the visualization of fluorescence to wavelengths between 500-545 nm, which typically appears green in color, and 600-665 nm, which typically appears red in color.
45995062|NCT04896385|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
45995063|NCT04896385|Drug|Vehicle Cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
45995064|NCT04003805|Drug|Standardized Research E-cigarette (SREC)|The device operates at a single output voltage (3.30 ± 0.05 V) and uses sealed disposable 3-mL cartridges with tobacco-flavored e-liquid (~350 puffs/cartridge). The concentration of nicotine in e-liquid is 15 mg/mL, and the vehicle composition is 50:50 propylene glycol and glycerin. The device uses a battery that can be recharged via a micro USB port. A single charge is designed to sustain more than 400 puffs, which is more than the capacity of an e-liquid cartridge. The e-liquid and the aerosol are well-characterized in terms of chemical impurities and by-products (such as aldehydes), which are minimal. Additional information, including the results of pharmacokinetics study is available via NIDA website: https://www.drugabuse.gov/funding/supplemental-information-nida-e-cig
45995065|NCT04003805|Drug|Nicotine Mini-Lozenge|We will use commercially available nicotine mini-lozenges containing 2 or 4 mg nicotine/lozenge (Nicorette, manufactured by GlaxoSmithKline). Dose will be determined per instructions on the package (e.g, if smoking within 30 minutes upon awakening, then 4 mg dose will be prescribed).
45995066|NCT05575258|Other|44-Day Diet Conventionally Sourced - YELLOW Diet|Food for the conventional diet will be sourced from local grocery stores (non-organic produce) around Logan, UT, USA.
45995067|NCT05575258|Other|44-Day Diet Agro-Ecologically Sourced - GREEN Diet|Food for the agro-ecological diet will be sourced predominantly from the Greenacres farm (Cincinnati, OH, USA) and a limited number of other retailers that sell select foods from agro-ecological producers (Seal the Seasons, General Mills, Pecan Shop, Sol Simple).
45995068|NCT05454852|Other|Survey|Interviewer-administered survey
45995069|NCT05454852|Other|Focus group|Focus group for selected participants
45995070|NCT04862533|Drug|Beta-Alanine|Participants will receive 1150mg of beta-alanine three times a day
45995071|NCT04862533|Drug|Placebo|Participants will receive matching placebo three times a day
45995072|NCT04862533|Procedure|Pelvic floor muscle training (PFMT)|Participants in both groups will undergo PFMT training program
45995073|NCT05570656|Device|XSENS-Awinda|"The participant wears inertial sensors X-Sens that measure the kinematic data and the amplitude of joint movements during different movements (flexion and extension of the spine, walking, picking up an object on the ground, tying their shoelaces, getting up from a chair... ) Each movement will be repeated 3 times.~Participants will also have self-questionnaires to complete (BASDAI and BASFI).~The exams are carried out on one day."
45995074|NCT04853095|Procedure|Peritoneal fixation (PerFix)|PerFix involves suturing the free end of the peritoneal flap left after RARP + ePLND to the pelvic wall near the symphysis of the pubic bones leaving two lateral openings for directing the lymphatic fluid out of the pelvis to the abdominal cavity.
45995075|NCT04853095|Procedure|Standard of care|ePLND without peritoneal flap fixation
45995076|NCT04842604|Drug|Glasdegib|25 mg or 100 mg tablet
45834299|NCT04274946|Procedure|Sentinel lymph node biopsy|Sentinel lymph node biopsy(SLNB) procedure with different mapping methods using combination of radioactive colloid, patent blue, indocyanine green associated with intraoperative ultrasound.
45995077|NCT04842604|Drug|Azacitidine|100 mg/vial powder for 25 mg/mL suspension for injection
45995078|NCT05540314|Procedure|robotic bariatric surgery|robotic bariatric surgery
45834300|NCT01928238|Device|Noninvasive neurally adjusted ventilatory assist (NIV-NAVA).|
45834301|NCT01928238|Device|Noninvasive pressure support ventilation (NPSV)|
45834302|NCT01928316|Drug|Mizolastine domestic (made in China)|Healthy male volunteers will receive 10 mg domestic (made in China) mizolastine tablets on Day 1 and Day 8
45834303|NCT01928316|Drug|Mizolastine (imported)|Healthy male volunteers will receive 10 mg imported mizolastine tablets on Day 1 and Day 8
45995079|NCT04785469|Other|Low-load eccentric training|"Aerobic exercise training on a downhill walking treadmill with the following settings: 10% negative incline and constant speed corresponding to 75% of the average speed recorded during the initial 6-Minute walk test.~Resistance training: 5 minutes of warm-up on the manual ergometer, then 3 sets for 10 repetitions of the leg extension (performed unilaterally in eccentric phase) with a load of 75% of 1 repetition maximum (concentric) for the first two weeks. The following two weeks, 3 sets for 10 repetitions will be performed on the leg press (performed unilaterally in the eccentric phase) with 75% load of 1 repetition maximum (concentric). In addition, patients will perform 3 upper extremity strengthening exercises (free weights or elastic bands), including 2 sets of 10 repetitions for each exercise."
45834304|NCT04346472|Other|Repeated Measurements of the relative regional cerebral blood volume|Repeated Measurements of the relative regional cerebral blood volume variation through an every 6 monts Magnetic Resonance Imaging use.
45834305|NCT03050736|Drug|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 20 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
45995080|NCT04785469|Other|Usual care|"Aerobic exercise training using the cycle ergometer at an intensity calculated as follows: 2 minutes with load equal to 20% of maximum load, then 25 minutes with initial load at 50% of maximum load calculated as 103.217 + (30.500xGender) + (-1.613xAge) + [0.002x6-Minute walk work (6MWW)]. [Sex: female = 0; male:1] [6MWW = 6-Minute walk distance x weight in kg].~Resistance training: 5 minutes of warm-up on the manual ergometer, then 5 exercises for upper and lower limbs performed with free weights or elastic bands. For the first 2 weeks will be performed 2 sets X 20 repetitions with 1 minute break between sets and a load that allows to perform no more than 20 repetitions. For the following 2 weeks, 3 sets of 10 repetitions x 10 repetitions with 2 min break between sets and a load that allows for no more than 10 repetitions."
45995081|NCT03989102|Biological|PfSPZ Vaccine|PfSPZ vaccine is comprised of aseptic, metabolically active, non-replicating, purified, cryopreserved P. falciparum sporozoites.
45995082|NCT03989102|Other|Normal Saline|Sterile isotonic (0.9%) normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe; and will be used as a placebo, rather than a comparator vaccine
45995083|NCT01254643|Biological|V503|V503 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
46084986|NCT04223336|Behavioral|Brief physical activity and diet intervention|The intervention is an integrated care pathway that provides a computerized prompts for practitioners in the STOP program via their online portal. For a participant who is in the intervention group, the online portal will screen the participant for their physical activity and fruit/vegetable consumption and provide the practitioner (who is seeing this participant for their visit) with computerized alerts for physical activity and fruits/vegetable consumption. Specifically, the portal will prompt practitioners to provide a brief intervention for these two behaviours using risk communication and will also suggest brief intervention language designed based on the Elicit-Provide-Elicit framework. The portal will also have available a self-monitoring resource for physical activity and fruits/vegetable consumption and will prompt practitioners to provide this self-monitoring resource to the participant during their visit.
46084987|NCT04172181|Procedure|cord blood stem cell transplantation|Unrelated cord blood stem cell selection； Reduced intensity conditioning； GVHD prevention； Infection prevention.
46084988|NCT05345028|Dietary Supplement|lecithin-based delivery form of Boswellia serrata|250 mg for 5 days
46084989|NCT05345028|Combination Product|Placebo|250 mg for 5 days
46084990|NCT00561925|Drug|nevirapine IR|200 mg BID
46084991|NCT00561925|Drug|nevirapine XR|400 mg QD
46084992|NCT02760992|Drug|IV Baclofen|Baclofen intravenous solution 2 mg/mL manufactured and provided by Allaysis, LLC
46084993|NCT02760992|Drug|Oral Baclofen|10 mg tablet
46084994|NCT04172259|Drug|Doxorubicin liposome|PLD
46084995|NCT04172259|Drug|Cyclophosphamide|CTX
46084996|NCT04172259|Drug|Trastuzumab|H
46084997|NCT04172259|Drug|Docetaxel|DOC
46084998|NCT04172259|Drug|Epirubicin|EPI
46084999|NCT02768480|Other|Primary Care|Patients will be followed by primary care team according to the usual health system routine.
46085000|NCT02768480|Other|Phone Calls Support and Primary Care|Patients in intervention group will receive periodic phone calls (every three months) and will have a toll-free number to resolve questions about the disease management. The phone-calls will be performed by trained nurses and will follow a structured format. Nurses will address some topics: patient's treatment adherence, technique of insulin administration, disease understanding, hypoglycaemia management, healthy diet, smoke cessation and foot care.
46085001|NCT02761538|Behavioral|AVIITAM|"The purpose of the project is to test the medico economic impact related to the utilization of the Aviitam online platform in primary care.~.~."
46085002|NCT04171947|Device|Matuzalem ovule|vaginal ovule with 2 mg tea extract
46085003|NCT04171947|Device|Vehicle ovule|polyethylene glycol vaginal ovule
46085004|NCT02995668|Other|Strength-Function|Preoperative functional and strength capabilities training.
46085005|NCT02995668|Other|Balance-Proprioception|Preoperative proprioceptive and balance capabilities training
46085006|NCT00647751|Drug|Lamotrigine Tablets 25 mg|2x25mg, single dose fed
46085007|NCT00647751|Drug|Lamictal® Tablets 25 mg|2x25mg, single dose fed
46085008|NCT05344794|Diagnostic Test|Enzyme-linked immunosorbent assay|Serum N/OFQ , IL-6 and NE levels were detected.
46085009|NCT02696018|Device|Ultrasonography|Ultrasonographic assessment of the diaphragm function
46085010|NCT02536989|Drug|omeprazole|receive intravenous omeprazole 80 mg stat and then 8mg/hr infusion for 3 days
46085011|NCT02536989|Drug|omeprazole|receive intravenous omeprazole 40 mg stat and then 40 mg q12h for 3 days
46085012|NCT04073004|Behavioral|Rapid Resolution Therapy|psychotherapy that includes trance states
46085013|NCT02763878|Procedure|Uncut Roux-en-Y anastomosis|Uncut Closure devices would be used to close the intestinal cavity on the input less than 5cm distance from the loop gastrojejunostomy anastomosis.
46085014|NCT02763878|Procedure|Billroth II anastomosis|Typical Billroth II anastomosis would be made after the Distal gastrectomy.
45834306|NCT04559646|Procedure|Pacemaker implantation|Implantation of the pacemaker due to indications in patients with atrioventricular block, sick sinus syndrome, atrial fibrillation with impaired atrioventricular conduction or other.
45995084|NCT04491825|Diagnostic Test|Skin suction blistering and skin biopsies|Skin suction blistering and skin biopsies will be used for the identification of potential proteomic biomarkers that can distinguish MF from eczema, psoriasis and healthy control skin.
45995085|NCT01254604|Drug|Preservative-Free Tafluprost or vehicle|Preservative-free tafluprost (0.0015%) ophthalmic solution; Preservative-free vehicle ophthalmic solution (contains no active drug)
45995086|NCT01254604|Drug|Preservative-Free Timolol maleate|Preservative-free timolol maleate (0.5%) ophthalmic solution
45995087|NCT03980093|Behavioral|Education|Online medical education on the benefits of anti-hormonal medication, potential side effects, and how to manage them.
45995088|NCT03980093|Behavioral|Values|An Acceptance and Commitment Therapy (ACT)-based intervention consisting of brief online sessions plus a visual cue-based intervention focused on personal values.
45995089|NCT00537264|Other|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
45995090|NCT00537264|Other|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
45995091|NCT03945734|Behavioral|Expressive Helping|Expressive helping harnesses the benefits of helping others (e.g., support giving) through writing or voice-recording. Expressive helping integrates two distinct areas of research showing that writing or speaking about ones' negative experiences and engaging in support giving behaviors can improve psychological well-being.
45995092|NCT03939065|Device|Sensor Augmented Pump Therapy|Incorporating both insulin pump and CGM technology together (also known as SAP therapy) has the potential to better optimize glycemic control than each device alone. Participants in this arm will receive their insulin dosing via insulin pump and their blood sugars will be monitored using a Continuous Glucose Monitor.
45995093|NCT03939065|Device|Standard of Care with CGM|Participants assigned to this arm will receive conventional diabetes management with daily insulin injections (or on an insulin pump if already on an insulin pump in the outpatient setting) and capillary blood glucose monitoring. These participants will also wear a blinded Continuous Glucose Monitor (CGM) for outcome assessment.
45995094|NCT05425290|Behavioral|Single-session emotion regulation training|The single-session emotion regulation skills training will blend psychotherapeutic approaches that emphasize effective ER. First, participants will be taught to adopt a detached (i.e., 'distanced') and nonjudgmental attitude towards an emotional situation. Detachment, or 'distancing' as it will be introduced to participants, will be taught by examining the situation with objectivity or putting spatial or temporal distance between the current moment and the situation. Second, research participants will be taught reframing. Specifically, they will be introduced to the relationship between thoughts and emotions and how to find interpretations that are less upsetting in order to be more effective when upset. Participants will identify elements of a situation that they did not pay attention to or information that was missing, and to reframe their thoughts based on the full picture. The emotion regulation training is expected to take approximately 30-45 minutes.
45995095|NCT01220583|Drug|cisplatin|Given IV
46085015|NCT00647829|Drug|valdecoxib|valdecoxib 20 mg tablet by mouth twice daily (BID) for 2 doses over a 24-hour period
46085016|NCT00647829|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth once daily (QD) for 2 doses over a 24-hour period
46085017|NCT00647829|Drug|placebo|placebo tablet by mouth for 2 doses over a 24-hour period
46085018|NCT02517918|Drug|Sirolimus combined with CP, MT and ZA|"Cyclophosphamide, Methotrexate and Sirolimus will be administrated orally. Zoledronic Acid will be administrated by infusion (IV).~Trial based on a dose escalating study design assessing two dose levels of sirolimus when prescribed in combination with metronomic cyclophosphamide (CP), methotrexate (MT) and zoledronic acid (ZA) followed by an expansion cohort once the MTD is established."
46085019|NCT02764034|Device|Low level Laser diode machine|wavelength 635 Low level diode laser power control time control Continuous mode
46085020|NCT04012489|Procedure|Breath Stacking|Patients were connected to a unidirectional valve coupled to artificial airway (tracheostomy), with bacteriological filter. The ventilator was coupled to the unidirectional valve to measure inspiratory volume mobilized in each cycle and a connection to adapt a manometer. The patient performed successive inspirations for a maximum period of 30 seconds or until unidirectional valve opening or volume increase was observed for 2 consecutive efforts. Ten cycles of the technique were performed, with an interval of 30 seconds.
46085021|NCT04012489|Procedure|Air Stacking|The same system of monitoring and adaptation of the ventilometer and manometer was carried out. A manual resuscitator coupled to a unidirectional valve was used, both connected to the tracheostomy, with a filter interface. Slow and successive inspirations were performed through slow compression of the resuscitator until the maximum inspiratory pressure reached 40 cmH2O. Ten cycles of the technique were performed, with an interval of 30 seconds.
45834307|NCT04559646|Drug|"Haemostatic solution Haemoblock application"|"Haemostatic solution Haemoblock will be used after pocket formation during pacemaker implantation."
45834308|NCT04559646|Drug|Saline solution application|Saline solution will be used after pocket formation during pacemaker implantation.
45834309|NCT04559646|Diagnostic Test|Ultrasound of pacemaker pocket|Pacemaker pocket ultrasound examination to diagnose pocket hematoma 3-5 days after surgery.
45834310|NCT04559646|Diagnostic Test|Blood sampling|Blood sampling for Platelet, Prothrombin, Fibrinogen, International Normalized Ratio, Creatinine, Albumin evaluation.
45834311|NCT04559646|Diagnostic Test|Echocardiography|Heart ultrasound examination for left ventricular ejection fraction measurement.
45834312|NCT04551846|Dietary Supplement|Oligomeric enteral feeding|Oligomeric enteral feeding will be administered to the PICU patients
45834313|NCT04551846|Dietary Supplement|Polymeric enteral feeding|Polymeric enteral feeding will be administered to the PICU patients
46085022|NCT00647907|Drug|Voriconazole|Oral or intravenous voriconazole. Oral tablets 400 mg twice daily loading dose on first day, followed by 200 mg twice daily taken at least 1 hour before or after a meal. Oral doses could be increased to a maximum of 300 mg twice daily if there was no clinical improvement after at least 3 days of treatment, no serious adverse events were reported, and clinical chemistry parameters were within the acceptable range for study entry. Intravenous treatment was initiated with a loading dose of 6 mg/kg twice daily for the first day followed by 4 mg/kg twice daily for at least 3 days (maximum infusion rate of 3 mg/kg/hr if administered by peripheral intravenous line). An intravenous loading dose was not required in patients who were restarted after oral treatment. Total duration of therapy (intravenous and oral) was 12 weeks.
46085023|NCT02763800|Drug|BIA 3-202|BIA 3-202 (50, 100 and 200 mg) was administered in the form of oral tablets, given with 200 ml potable water.
46085024|NCT02763800|Drug|Placebo|Matched placebo was administered in the form of oral tablets, given with 200 ml potable water
46085025|NCT04017546|Drug|CYC065|intravenous infusion
46085026|NCT04017546|Drug|Venetoclax|oral capsule
46085027|NCT00949585|Other|Dietary intake of potassium|Comparison of two diets: one contains 100 mmol potassium per day, and the other contains 40 mmol potassium per day
45995096|NCT01220583|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
45995097|NCT01220583|Radiation|intensity-modulated radiation therapy|Undergo radiotherapy
45457186|NCT03518632|Behavioral|Interval training|Patients in experimental group will perform a 6 weeks' physical activity program with 3 sessions per week. Physical activity intervention will consist in 2 different interval training programs on cycloergometer: Interval training 1 and Interval training 2, with a difference in exercise intensities.
45995098|NCT03911414|Drug|Open-label Treatment with Omega-3 Fatty Acids + Inositol|Open-label Treatment with Omega-3 Fatty Acids + Inositol
45674796|NCT02130557|Drug|Bosutinib|Bosutinib (Bosulif®) is an orally bioavailable, potent, multi-targeted, dual Src-Abl tyrosine kinase inhibitor (TKI) that has been approved for the treatment of adult patients with Philadelphia positive (Ph+) chronic phase (CP), accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) previously treated with other TKI inhibitor therapy.[1] This study will investigate the use of bosutinib as first-line treatment for patients with Ph+ CP CML.
45995099|NCT03911414|Drug|Open-label Treatment with N-acetylcysteine|Open-label Treatment with N-acetylcysteine
45834314|NCT04550520|Diagnostic Test|Glucagon|Glucagon with the empirical formula of C153H225N43O49S, and a molecular weight of 3483 g/mol, is a single-chain polypeptide containing 29 amino acid residues. Glucagon is provided in a single dose vial as powder. One container contains 1 mg of glucagon which results in a concentration of 1 mg/ml after dissolution in a volume of 1 ml (Glucagen NovoNordisk (Hypokit)). The currently used standard dose regimen is 1 mg of glucagon in adults. The solution for subcutaneous injection will be prepared by the study personnel according to the attached package leaflet.
45834315|NCT04550520|Diagnostic Test|Placebo|As placebo 1 ml sodium chloride (NaCl) 0.9% to inject subcutaneous is used. It has the same optical appearance as glucagon.
45834316|NCT04759482|Diagnostic Test|polysomnography|Polysomnography consisted in recording sleep parameters during one night, using a non-invasive multi-channels device, including respiratory sensors, electrocardiogram and electroencephalogram
45834317|NCT01928628|Drug|Lercanidipine 10mg|
45834318|NCT01928628|Drug|Lercanidipine10mg /Valsartan 80mg|
45995100|NCT01254565|Drug|Etelcalcetide|Administered intravenously (IV) at the end of hemodialysis
46085028|NCT04171791|Drug|ABT-199 (venetoclax)|Eligible patients will be enrolled into the study and receive venetoclax daily per the US FDA package insert guidelines of venetoclax, with dose escalation up to 400 mg. To minimize the risk of tumor lysis syndrome (TLS), and following the package insert directions for dose escalation over 5 weeks, the initial dose is 20 mg daily, and may be progressively increased as tolerated to 400 mg by week 5.
46085029|NCT04222946|Other|Dry needling|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle
46085030|NCT04003818|Drug|TEICOPLANIN|Pharmaceutical form:solution for oral administration Route of administration: oral
46085031|NCT00949663|Drug|Placebo|Intravenous infusion of 1% human albumin in normal saline
46085032|NCT00949663|Drug|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
45457187|NCT03518632|Other|Standard Oncologic care|Patients in control group will follow the standard oncologic care. They will perform only 2 sub-maximal exercises.
45834319|NCT01928628|Drug|Lercanidipine 10mg /Valsartan 160mg|
45834320|NCT01928628|Drug|Lercanidipin 10mg Placebo|
45995101|NCT01254565|Drug|Placebo|Administered intravenously at the end of hemodialysis
45457188|NCT01354886|Drug|FSH-GEX™|single dose
45457189|NCT01354886|Drug|Gonal-f|150 IU single dose
45457190|NCT01354886|Drug|Bravelle|150 IU single dose
45457191|NCT01354886|Drug|Placebo|single dose
45834321|NCT01928628|Drug|Lercanidipine10mg /Valsartan 80mg Placebo|
45834322|NCT01928628|Drug|Lercanidipine 10mg /Valsartan 160mg Placebo|
45995102|NCT04772053|Procedure|Tumor biopsy|Archived or fresh tumor biopsy samples will be collected.
45995103|NCT02889055|Device|patient requiring the MIRUS (mechanical ventilation)|
45995104|NCT01254409|Biological|PRM-151|Intravenous PRM-151 administered over 30 minutes on study days 1, 3, 5, 8, and 15 at doses of 1.0, 5.0, or 10.0 mg/kg.
45995105|NCT01254409|Other|Placebo|Intravenous 0.9% normal saline administered over 30 minutes on study days 1, 3, 5, 8, and 15.
45995106|NCT04324177|Other|Demographic data, morbidity data|To detect association between the demographic data of pediatric patients including age ,sex,hospital stay and clinical data including the diagnosis and co morbidity with the outcome of pediatric patients admitted to ICU of Assiut University children hospital
45995107|NCT04684160|Device|Fixed-bearing TKA|
45995108|NCT04684160|Device|Mobile-bearing TKA|
45995109|NCT04390698|Procedure|paravertebral block|Paravertebral block will be performed at T2,T4 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.4% ropivacaine 20ml at each injection site.
45995110|NCT04390698|Drug|opioid free anesthesia|propofol, lidocine and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained.
45995111|NCT04390698|Procedure|sham block|Local infiltration at the same site of paravertebral block will be performed, with 1% lidocaine 3ml on each injection site.
45995112|NCT04390698|Procedure|opioid general anesthesia|propofol, sufentanil and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained .
45834323|NCT01928706|Other|Denture liner Mucopren Soft; Group 1|Complete denture wearers had their existing mandibular dentures relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22)
45995113|NCT01254331|Drug|tocilizumab [RoActemra]|tocilizumab 8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
46085033|NCT00949663|Drug|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
45995114|NCT03795701|Drug|Saxenda®|Receiving escalating dose of Saxenda® for the first 4 weeks (0.6mg, 1.2mg, 1.8mg, 2.4 mg) and receiving full-dose (3.0 mg) for 12 weeks.
45995115|NCT03795701|Other|Placebo|Receiving equivalent volumes of the pre-filled solutions from pen-injector as Liraglutide 3.0 group .
45995116|NCT04673578|Drug|Celecoxib|Selective COX-2 inhibitor; nonsteroidal anti-inflammatory drug (NSAID)
45834324|NCT01928706|Other|Denture liner Kooliner; Group 2|Complete denture wearers had their existing mandibular dentures relined with a hard acrylic resin based denture liner (Kooliner; Group 2;n=22) with chairside procedures.
45995117|NCT04673578|Other|Placebo|Microcrystalline cellulose
45995118|NCT05414058|Drug|Apo-Methylphenidate ER|The study medication will be administered by a clinical registered nurse (RN), alongside their other medications. Patients will continue their regular medications as per standard of care.
45995119|NCT03757403|Drug|RDD1609|RDD1609 to be applied on the perianal area BID
45995120|NCT03757403|Drug|Mebendazole 100 MG|Mebendazole 100 mg single dose (single prophylactic dose of the anthelmintic medicine)
45995121|NCT04381923|Device|Helmet Continuous Positive Airway Pressure (CPAP)|Helmet CPAP will be initiated at a pressure of 5 cmH20 and fraction of inspired oxygen (Fi02) of < 60%. If oxygen saturation (Sp02) remains < 92%, pressure will be increased to 10 cmH20. FiO2 will then be tapered to target a SpO2 ≥ 92%. Breaks with intervening HFNO use will be provided as needed for meals and during hours of sleep.
45995122|NCT04381923|Device|High Flow Nasal Oxygen (HFNO)|HFNO will be initiated at a flow rate of 40 LPM and a fraction of inspired oxygen (Fi02) of < 60%. If oxygen saturation (SpO2) remains < 92%, the flow rate will be increased to 60 LPM. FiO2 will then be adjusted to target a SpO2 ≥ 92%. Patients with discomfort due to HFNO may have their flow rate decreased until the discomfort resolves.
45995123|NCT03728699|Diagnostic Test|Sample Collection Blood|Collected from each patient twice weekly.
45995124|NCT03728699|Diagnostic Test|Stool Sample|Collected from each patient twice weekly.
45995125|NCT00537342|Biological|Immunotherapy with modified extract of O. europaea pollen|Sublingual (2 drops daily during 2 months)
45995126|NCT04338516|Device|Ossix™ Bone|a resorbable sponge-like matrix of 80% hydroxyapatite and 20% sugar cross-linked porcine collagen
45995127|NCT04338516|Device|Bio-Oss® Collagen|90% bovine derived xenograft granules and 10% porcine collagen
45995128|NCT00537420|Drug|Nasal Placebo|Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.
45995129|NCT00537420|Drug|Placebo Capsule|Placebo capsules will be taken once daily with or without food.
45995130|NCT00537420|Drug|PYY3-36|Nasal PYY3-36, three times a day, 30 minutes before a meal for 24 weeks.
45995131|NCT00537420|Drug|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
45995132|NCT00537420|Drug|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
46085034|NCT00949663|Drug|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
46085035|NCT02664519|Behavioral|Forearm exercise training|Subjects will be asked to squeeze a tennis ball repeatedly for at least 30 min/day for 28 days at an approximate rate of 20 squeezes/min.
45995133|NCT00537420|Drug|Sibutramine|Sibutramine will be taken once daily with or without food
45995134|NCT03645122|Procedure|Noninvasive neuromodulation via paired corticospinal-motoneuronal stimulation (PCMS)|This study is a novel approach to studying neuroplasticity after stroke. Previous work in humans with incomplete spinal cord injury demonstrates that the resulting plasticity transiently enhances motor output, indicating that there is also therapeutic potential. This study will attempt to induce bi-directional plasticity in corticospinal-motoneuronal synapses serving an intrinsic hand muscle of the hemiparetic limb. Control experiments will be completed to provide evidence of the neurophysiological mechanism(s) mediating the effect and to examine behavioral effects.
45995135|NCT04295889|Diagnostic Test|Approach A (PeeSpot urine collection device).|The participant will receive the PeeSpot urine collection device (Hessels+Grob B.V., Deventer, The Netherlands), which consists of a holder containing a urine collection pad (consisting of hygroscopic material containing). The holder can be placed back into the tube and can be easily sent to the laboratory by mail. In this urine, albumin, creatinine, and the ACR will be measured in the laboratory of the Amphia hospital.
46085036|NCT02763332|Other|Upper trunk group (UTG)|This bandage was placed over the upper trapezius muscle.
45834325|NCT01928784|Device|Radial Extracorporeal Shock Wave Therapy 2000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 2000 impulses
46085037|NCT02763332|Other|Global trunk group (GTG)|This bandage was placed globally along the back
45457192|NCT02299882|Drug|Vancomycin|Patient will be randomized to either vancomycin or no vancomycin. This treatment will take place prior to the closure of the incision from back surgery.
45834326|NCT01928784|Device|Radial Extracorporeal Shock Wave Therapy 4000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 4000 impulses
45995136|NCT04295889|Diagnostic Test|"Approach B (ACR | EU Test kit)."|"The participant will receive the ACR | EU test kit (Healthy.io Ltd, Tel-Aviv- Yafo, Israel), which consists of a urine test strip, a urine cup, a color calibrator and instruction to download a smartphone application. The participants have to download the smartphone application according to the instructions included in the kit. Results will be directly shown to the participant in the app."
46085038|NCT02033616|Biological|AVOVA-1|Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
46085039|NCT02033616|Biological|MC|Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
46085040|NCT00647985|Drug|Fexofenadine Tablets 180 mg|180mg, single dose fed
45995137|NCT03641924|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD.
45995138|NCT03534284|Behavioral|Cognitive Behavioral Therapy for Insomnia|Once weekly treatment sessions for 6 weeks. The content of each of these sessions will be adapted to include changes in behavior during HD treatments (such as napping) and to help patients better adjust to treatment schedules. The CBT-I sessions will be delivered by a therapist face-to-face with the patient via a fully interactive video telehealth platform.
45995139|NCT03534284|Drug|Trazodone|trazodone tablet
45995140|NCT03534284|Drug|Placebo|Inactive pill manufactured to mimic trazodone tablets.
45995141|NCT00537459|Drug|16448|
45995142|NCT03504215|Other|Exercise Intervention|Assigned intervention : 14-week supervised intervention of aerobic and resistance training.
45995143|NCT03457038|Biological|Blood Test|"Addition to the current care but during the normal follow-up visit :~At the entrance to the service: search for bacterial 16S RNA in the blood~Additional blood tests (4) at T6-12-18 and 36h~At each visit: Sampling of an additional heparinized blood tube for the assay PAMPs.~1 time per day: Assay of CRP and PCT from samples taken in common practice~J30: Assessment of the vital status of the patient"
45995144|NCT04218279|Other|Sleep Health Education|Intervention materials include 10 brief education modules that the target population will review/view on a secure study-specific website.
45995145|NCT04183374|Other|Life style|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
45995146|NCT01254292|Drug|Levonorgestrel IUD (LCS, BAY86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 18 months with optional extension to 36 months for subjects in this group only.
45995147|NCT01254292|Drug|Yasmin (EE30/DRSP, BAY86-5131)|Combined oral contraceptive (COC; Yasmin; 0.03 mg ethinyl estradiol and 3 mg drospirenone); Subjects will start taking COC at / on the day of visit 2 and continue taking one pill / day without any breaks for the entire study duration of 18 months.
45995148|NCT04178538|Procedure|ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation|ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation with all inside technique
45995149|NCT04178538|Procedure|Standard ACL reconstruction with all inside technique|Standard ACL reconstruction with all inside technique
45995150|NCT03208478|Procedure|Adductor Canal perineural catheter placement|Patients will receive an Adductor Canal Block intervention for pain control following ACL reconstructive surgeries.
45995151|NCT03208478|Procedure|Femoral Nerve perineural catheter placement|Patients will have a Femoral perineural catheter placed for pain control following ACL reconstructive surgery.
45995152|NCT03208478|Device|Nimbus pump (Infutronix)|This is a FDA approved infusion device that is used in standard of care to store pain medication and to provide patients with continuous pain control medication at a set rate. This pump will be used for both the Adductor Canal and Femoral Nerve block participants.
46085041|NCT00647985|Drug|Allegra® Tablets 180 mg|180mg, single dose fed
45995153|NCT04092777|Behavioral|Strong Minds|The proposed intervention integrates cognitive behavioral therapy techniques combined with mindfulness exercises and promotion of behavioral activation through pleasant activities and developing supportive relationships. The intervention is led by CHWs and organized into 10 sessions, tailored to the participant using a collaborative approach, to improve mood symptoms, augment self-reported functioning, and increase self-reported quality of care among participants with moderate to severe symptoms of depression and/or anxiety. It is complemented by a care manager that links participant to services for needs related to social determinants of health (i.e. education, housing). The intervention has been tailored for delivery by CHWs in Spanish, Mandarin, Cantonese, and English.
45995154|NCT04092777|Other|Enhanced Usual Care|Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. The Care Manager will call the participant 4 times over the course of 6 months to administer the PROMIS depression (8 item) and anxiety (7 item) short forms, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group. With patient's permission, the care manager will inform the PCP about screening and other assessments and determine if participants should be referred to mental health or substance services and removed from control group given symptom severity.
45995155|NCT00553007|Procedure|Periodontal therapy|Normal periodontal therapy is performed.
46085042|NCT02768402|Device|Caisson TMVR System|Transcatheter mitral valve replacement is a percutaneous procedure used to treat mitral valve regurgitation with a prosthetic valve implantation.
46085043|NCT01844232|Drug|arbaclofen|Arbaclofen ER tablets, 20 mg, 30 mg and 40 mg
46085044|NCT04225039|Drug|INCMGA00012|500mg IV neoadjuvant treatment; 500 mg adjuvant treatment
46085045|NCT04225039|Drug|INCAGN01876|300mg IV neoadjuvant treatment; 300 mg adjuvant treatment
46085046|NCT04225039|Drug|SRS|administered over the course of 3 consecutive business days (8 Gy x 3 fractions, one fraction per day, total dose 24 Gy).
46085047|NCT04225039|Procedure|Brain surgery|maximal safe surgical resection of the tumor.
46085048|NCT02664285|Other|closure of subcutaneous tissue|the subcutaneous fat will be closed with three to five interrupted sutures. The sutures were tied until the tissue was adequately re-approximated, but not as hard as possible to avoid necrosis after cesarean section in diabetic patients.
46085049|NCT02664285|Other|No closure of subcutaneous tissue|the subcutaneous fat will not sutured after cesarean section in diabetic patients.
46085050|NCT02763410|Other|PRBC transfusion|
45457193|NCT02293486|Dietary Supplement|Pomegranate juice|Intake of 200 ml of pomegranate juice or pomegranate juice dilution during 21 days after exercise.
45457194|NCT01355120|Drug|Ipilimumab|Ipilimumab monotherapy 3mg/kg by four infusion every 3 weeks
45457195|NCT02299960|Device|Endo-PAT|Analysis of endothelial function through pulse-amplitude-tonometry
45995156|NCT04075383|Procedure|immediate dental implant|Replacement of a lost tooth with a titanium screw retained in the alveolar bone in the same session of tooth extraction.
45995157|NCT04075383|Procedure|immediate-delayed dental implant|Replacement of a lost tooth with a titanium screw retained in the alveolar bone 8 weeks after tooth extraction.
45674797|NCT02130557|Drug|Imatinib|"Imatinib mesylate (referred to in this protocol as imatinib) is an inhibitor of the BCR-ABL kinase and been the standard first-line therapy for patients with chronic-phase CML. Imatinib was granted approval by the European Commission in November 2001 and by the FDA in December 2002 for the treatment of newly diagnosed patients with CP Ph+ CML based on results from the IRIS trial.~Imatinib is considered the standard of care for both first-line and later line settings, and consequently is an appropriate active comparator."
45674798|NCT01854645|Drug|GFF MDI|GFF MDI administered as two puffs Bis in Di.e. Twice Daily (BID)
45834327|NCT03085524|Diagnostic Test|Platelet function testing|The investigators will test platelet reactivity at the beginning and midpoint of the first year after revascularization
45834328|NCT03085524|Diagnostic Test|Vascular ultrasonography|The investigators will test bypass graft and stent patency at 30 days, 6 months, and 1 year.
45834329|NCT03084900|Other|Arm 1|Patient-Centered Decision Support to Improve Diabetes Mgmt. We will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures.The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
45834330|NCT01929096|Drug|Compound Edaravone Injection|
45834331|NCT01929096|Drug|Edaravone Injection|
45834332|NCT03083652|Device|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (30 minutes per day, 5 days/week) of the quadriceps femoris and gluteus maximus
45995158|NCT00537498|Drug|Urokinase|"Daily intravenous application of urokinase over 30 minutes~Dosage:~If plasma fibrinogen is > 2,5g/l application of 1 000 000 IU Urokinase If plasma fibrinogen is < 2,5g/l application of 500 000 IU Urokinase If plasma fibrinogen is < 1,6g/l treatment must be stopped and continued after rising up to >2g/l"
45995159|NCT01254019|Drug|GSK2402968 6mg/kg/week|subcutaneous
45995160|NCT04687644|Behavioral|Online education|Education group
45995161|NCT03055871|Behavioral|Habit formation intervention|In addition to the control content and the planning content, this intervention will include material provided to the family that assists with creating physical activity support habits. The material contains a discussion of what habits are, straightforward examples, planning and pointers for forming habits. A key component of the habit intervention will be planning for context-dependent repetition.
45674799|NCT01854645|Drug|GP MDI|GP MDI administered as two puffs BID
45995162|NCT03055871|Behavioral|Physical activity planning intervention|This arm will receive the control education content, but will also be provided with family PA planning material. This material will include skill training content (workbook on how to plan for family PA). The material includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past, as well as activities that they would find enjoyable to do as a family. We also have Canadian parental survey data on the most preferred co-physical activities for children 3-6. We will provide this material as prompts/suggestions. This list helps create the template for PA planning by contextualizing what the parents would like to do with their kids.
45834333|NCT03083652|Other|Sham|Conventional physiotherapy with NMES device NOT activated
45995163|NCT04605055|Dietary Supplement|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.
45995164|NCT04605055|Dietary Supplement|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.
45834334|NCT05602662|Behavioral|Music|Music therapy during mechanical ventilation
45995165|NCT04683458|Device|Drug-coated device|The endovascular (intraluminal) application of a medical-device that was coated with paclitaxel
45995166|NCT04319497|Device|Subjective refraction|Subjective refraction measurements will be performed by two testers for all the patients included
45995167|NCT04319497|Device|Autorefraction|Five autorefraction measurements will be performed for all the patients included
45995168|NCT04319497|Device|Wavefront aberrometry|Five wavefront measurements will be performed for all the patients included
45995169|NCT01253317|Drug|rhIGF-1|1) Multiple ascending dose (MAD) period (4 weeks): Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the open-label extension period.
45995170|NCT00537537|Drug|Telbivudine|
45995171|NCT02863874|Device|VicrylPlus®|Suture
45995172|NCT02863874|Device|Vicryl®|Suture
45995173|NCT04566445|Drug|GT005: Medium Dose|The study will test two doses of GT005: Medium Dose and High Dose.
45995174|NCT04566445|Drug|GT005: High Dose|The study will test two doses of GT005: Medium Dose and High Dose.
45995175|NCT04319770|Device|enamel matrix derivative (EMD)|periodontal regenerative surgery with enamel matrix derivative (EMD) (control)
45995176|NCT04319770|Device|hyaluronic acid (HA)|periodontal regenerative surgery with hyaluronic acid (HA) (test)
45995177|NCT04551469|Behavioral|music|Music intervention for 30 minutes
45995178|NCT04073472|Drug|mesenchymal stem cells (MSCs)|Allogeneic bone marrow derived mesenchymal stem cells (MSCs) direct injection to an ileal pouch fistula in the setting of Crohn's disease of the pouch
46085051|NCT02664051|Drug|Nalcrom|"Drug: disodium cromoglycate 100mg 4x2 daily~Other Names:~• Nalcrom"
45457196|NCT02299960|Device|NICOM|Non-invasive measurement of cardiac output
45834335|NCT05600868|Behavioral|A comprehensive third-generation intervention EMDR + dual attention|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with double attention.
45834336|NCT05600868|Behavioral|A comprehensive third-generation intervention EMDR + fixed point|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with fixed point.
45834337|NCT05600868|Behavioral|A comprehensive third-generation intervention EMDR + exposition|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with exposition.
45834338|NCT05600790|Behavioral|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
45834339|NCT04558554|Other|pharmacy-based PrEP delivery|The intervention is a new model of PrEP delivery that has never been tried before in an African setting: pharmacy-based PrEP delivery.
45995179|NCT04548349|Drug|Altreno|Acne patients will be assigned to Altreno once daily.
45995180|NCT04548349|Drug|Benzoyl peroxide|Acne patients will be assigned to BPO leave-on gel once daily.
45995181|NCT02722616|Device|Ultrasound scan of the pancreas|A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the pancreas motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup can be reproduced during treatment delivery.
46085052|NCT02664051|Drug|placebo|100mg 4x2 daily mannitol
46085053|NCT00953485|Biological|Allogeneic Mesenchymal Stem Cells (AlloMSC)|Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10^6 cells/kg body weight).
46085054|NCT05344638|Drug|AGS (Experimental)|tid
46085055|NCT05344638|Drug|AGU (Active Comparator)|tid
46085056|NCT04223180|Device|Robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
45995182|NCT02722616|Device|Ultrasound scan of the Liver|A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the liver motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup could be reproduced during treatment delivery. The ultrasound probe in the CT image will be contoured and radiation beams that directly pass through the ultrasound probe will be avoided.
45995183|NCT02722616|Drug|Reference ultrasound|A reference ultrasound scan will be conducted on each subject during breath-hold. Subjects will be required to lie in supine position and engaged with ABC; an ultrasound probe will be placed at the abdomen area with minimal pressure applied. Continuous motion monitoring is achieved by acquiring 4D ultrasound images using a motorized 3D ultrasound probe to image the pancreas, liver and other intra-abdominal organs continuously. Several 4D ultrasound scans will be collected during subsequent breath-holds that serve as secondary images.
45995184|NCT01253200|Device|Blazer® Open-Irrigated Ablation Catheter|Blazer® Open-Irrigated Ablation Catheter
45995185|NCT01253200|Device|Control Catheter|Open-irrigated radiofrequency ablation catheters that have received FDA market approval for the treatment of type 1 atrial flutter
45995186|NCT00553046|Other|survey administration|application of a family survey on last 3 months of life for their relatives under HMV
45995187|NCT04515901|Drug|2% lidocaine|Viscous lidocaine
45834340|NCT03059004|Behavioral|TeMPO Home Exercise Program|This exercise program includes quadriceps, gluteus medius, gluteus maximus, and core exercises. The program includes a DVD and multi-page instruction pamphlet.
45457197|NCT02300038|Drug|Lidocaine (Xylocaine)|perineuromally administration of 1 ml lidocaine
45995188|NCT04515901|Other|Placebo|Methylcellulose and cherry flavouring
45995189|NCT01253044|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
45995190|NCT01253044|Behavioral|Present Centered Therapy|Present Centered Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
45995191|NCT02646527|Behavioral|Dignity Therapy|Dignity Therapy (DT) is a brief psychotherapeutic intervention developed by Chochinov (2012) which has been shown to enhance the end of life experience in people with life-limiting conditions. DT focuses on helping patients with terminal illnesses to go over things that are most meaningful to them and document their legacy. Dignity Therapy+ (DT+) involves patient and partner/family asking questions about their most important achievements, roles and other important aspects of life. DT+ encourages patients saying things to loved ones that have remained unsaid. DT+ consists of 3 sessions (1. introduction (30'); 2. main session (60'), 3. final session (30')) and will be conducted by a trained therapist. All therapy session will be audio-taped, transcribed verbatim by the study coordinator, edited by the therapist and returned to the patient or the patient and partner/family as a 'generativity document'.
45995192|NCT04685889|Procedure|Resin infiltration|"A sufficient amount of HCl was applied to the lesion using the icon etch syringe included in the set and was allowed to sit for 2 minutes. After washing with water for 30 seconds, the tooth was dried using an air spray. Once the enamel surface appeared chalky, Icon® dry application was initiated.~Ethanol was applied to the lesion using the Icon® dry syringe included in the set, and after 30 seconds it was dried using an air spray. Sufficient amount of resin infiltrant was applied to the lesion using the Icon® infiltrant syringe. The resin infiltrant was applied to the lesion surface by massaging with the tip of the syringe in circular movements for 3 minutes such that it penetrates the surface thoroughly. The resin infiltrant was polymerized for 40 seconds with a light device."
45457198|NCT02300038|Dietary Supplement|NaCl|perineuromally administration of NaCL
45834341|NCT03059004|Behavioral|Motivational SMS Messages|The motivational SMS messages will be sent three times per week encouraging participants to complete their exercises.
45995193|NCT04206514|Behavioral|Person Centered Care - Post Abortion Support|Post abortion phone based support
45995194|NCT05504902|Device|Vibrotactile coordinated reset|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants with Advanced stage Parkinson's disease
46085057|NCT00648063|Drug|Letrozole Tablets 2.5 mg|2.5mg, single dose fasting
46085058|NCT00648063|Drug|Femara® Tablets 2.5 mg|2.5mg, single dose fasting
46085059|NCT01129362|Biological|Pentacel® (DTaP-IPV/Hib)|0.5 mL dose, Intramuscular
46085060|NCT01129362|Biological|Other Pertussis Vaccines|0.5 mL, Intramuscular
46085061|NCT00953563|Device|Unite Biomatrix|collagen based, decellularized equine pericardial dressing for skin surface wounds
46085062|NCT00648141|Drug|Celecoxib|200 mg oral capsule once daily for 12 weeks
46085063|NCT00648141|Drug|Celecoxib|200 mg oral capsule twice daily for 12 weeks
46085064|NCT00648141|Drug|Diclofenac|75 mg oral capsule twice daily for 12 weeks
45457199|NCT01355198|Dietary Supplement|Cysteine (as n-acetylcysteine) and glycine|Cysteine and glycine will be supplemented at doses of 0.81 mmol/kg/d and 1.31 mmol/kg/d for 2 weeks each
45457200|NCT01355198|Dietary Supplement|Cysteine/glycine|Subjects will receive oral dietary amino-acids (cystiene as n-acetylcysteine, and glycine)
45834342|NCT03059004|Behavioral|In-Clinic Topical Therapy|Subjects will be assigned to a physical therapist and will attend 14 in-clinic topical therapy sessions. Sessions will include application of ultrasound, gel, and manual therapy.
45834343|NCT03059004|Behavioral|In-Clinic Exercise Therapy|Subjects will be assigned to a physical therapist and will attend 14 in-clinic exercise and manual therapy sessions. Sessions will include the same exercises from the Home Exercise Program but the in-clinic therapy setting will allow for more personalization.
45457201|NCT03516136|Device|EndoFast Reliant SCP|POP repair procedure with the EndoFast Reliant SCP system
45457202|NCT01355276|Drug|Cinitapride|cinitapride 1 mg for each dose, 3 mg/daily, for 4 weeks
45457203|NCT01355276|Drug|domperidone|10 mg for each dose ,30 mg/daily, for 4 weeks
45457204|NCT02293564|Drug|gevokizumab|Solution for subcutaneous injection
45457205|NCT03922711|Drug|Pridopidine|Oral capsule
45457206|NCT03922711|Drug|Placebo|Oral capsule
45995195|NCT05630365|Diagnostic Test|Panbio™|The Panbio™ COVID-19/Flu A&B Rapid Panel device, hereafter referred to as the Panbio™ Rapid Panel, is a visual lateral flow assay for the rapid immuno-chromatographic qualitative detection of COVID-19 antigen, Influenza A antigen, and Influenza B antigen in mid-turbinate nasal swabs
45995196|NCT02605421|Drug|Thiotepa|Thiotepa by IV once daily for 3 doses on Days -7, -6 and -5. Given as part of Consolidation Course #1 along with Cyclophosphamide.
46085065|NCT03865602|Behavioral|Sepsis Transition And Recovery (STAR)|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 30 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 30 days following their discharge and then will be transitioned back to the next appropriate care location.
45995197|NCT02605421|Drug|Cyclophosphamide|Cyclophosphamide by IV once daily for 4 doses on Days -5, -4, -3 and -2. Given as part of Consolidation Course #1 along with Thiotepa.
45995198|NCT02605421|Drug|Melphalan|Melphalan by IV once daily for 3 doses on Days -8, -7, and -6. Given as part of Consolidation Course #2 along with Etoposide and Carboplatin.
46085066|NCT03865602|Behavioral|Usual care|Patients and their providers will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
45995199|NCT02605421|Drug|Etoposide|Etoposide by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Melphalan and Carboplatin.
45995200|NCT02605421|Drug|Carboplatin|Carboplatin by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Etoposide and Melphalan.
45995201|NCT02605421|Biological|Autologous Stem Cell Infusion|On Day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
46085067|NCT03743155|Biological|mesenchymal cells|Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out. The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration
46085068|NCT02768090|Device|Skin Patch|Sweat will be collected by applying a diagnostic skin patch to inflammatory and neoplastic cutaneous lesions for proteomic analysis with mass spectrometry.
46085069|NCT00949897|Device|Biofoam|Device
46085070|NCT00949897|Other|Iliac Crest Allograft with locked plate|
46085071|NCT02763488|Device|DelfiPTS tourniquet system|
46085072|NCT02763488|Other|Standard physical therapy|
45457207|NCT03637010|Other|Breakfast in the Classroom|For all breakfasts, the students will use the 'grab and go' approach from hallway kiosks. The students will take the breakfasts back to their respective classroom and consume them there.
45457208|NCT03518554|Drug|JAB-3068|JAB-3068 will be orally administered on a daily basis. Patients need to fast 2 hours before （6 hours for PK days) and 2 hours after each dosing.
46085073|NCT02692326|Procedure|Cyclic parenteral nutrition|Cyclic parenteral nutrition was provided according to a method described by Longhurst et al. Patients were initially cycled of PN for 1 hour per day with increased rate of 1 hour with a maximum time out of PN of 4 hours for preterm babies < 37 weeks GA and 6 hours for term newborns. Glucose was monitored at half the time without PN to detect the hypoglycemia.
45834344|NCT04554888|Drug|Doxepin Topical|Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours
45834345|NCT04554888|Drug|Papain|Papain will be applied by 1 SPT prick thought the skin
45834346|NCT04554888|Drug|Histamine|Histamine will be applied by 1 SPT prick thought the skin
45995202|NCT02605421|Biological|Granulocyte colony stimulating factor|Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF SQ or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir ANC > 2000/μL for 3 consecutive days.
45995203|NCT04001556|Diagnostic Test|Minor Salivary gland Biopsy|Minor salivary gland biopsy with injection of lidocain
45995204|NCT04001556|Diagnostic Test|ARFI|Acoustic Radiation Force Impulse on Major Salivary Glands
45995205|NCT04001556|Diagnostic Test|MSG US|Ultrasonography of Major Salivary Glands
45995206|NCT04320589|Drug|Dexmedetomidine|which in addition to the orally prescribed drugs; on admission to the ICU, the Pheo-patient has serum-Mg level measurement & a bolus of 40 mg/kg MgSo₄ is given I.V. & may be repeated until the therapeutic level of MgSo₄ 2-4 mmol/Liter is reached (7&10). Dexmedetomidine sedation is started the evening prior to surgery by loading dose of 1µg/Kg followed by 0.2-0.7 µg/Kg/hour according to each patient
45457209|NCT01357382|Other|Low carbohydrate diet|restrict carbohydrate consumption to < 20 grams / day while not restricting their caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
45457210|NCT03922633|Drug|E3112|Intravenous infusion.
45457211|NCT03922633|Other|Placebo|Intravenous infusion.
45457212|NCT02296294|Drug|Elo-mel® (Fresenius Kabi Austria)|an iv isotonic crystalloid fluid therapy at a rate of 0,50ml/kg/min for one hour.
45834347|NCT04554888|Other|Cowhage|Cowhage spicules are 1-2 mm in length and have diameter of 1-3 µm at their tip. 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
45674800|NCT01854645|Drug|FF MDI|FF MDI administered as two puffs BID
45674801|NCT01854645|Drug|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 µg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
45995207|NCT04320589|Drug|General anesthetic|1) Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ & β-adrenergic blockers [Prazocin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day &/or Labetalol (Trandate)200-600 mg/day, ACI & ACRB e.g. Tritace 2.5-10 mg/day & Atacand 4-16 mg/day]
45995208|NCT04319458|Behavioral|Fotonovela|Secret Feelings/Sentimientos Secretos
45995209|NCT04319458|Behavioral|Control|NIH Brochure: Depression: What You Need to Know
45995210|NCT01252966|Behavioral|Cognitive Training|The computerized cognitive training intervention is a 12-week standardized course of internet-based computerized cognitive exercises designed to enhance executive cognitive function.
45457213|NCT02296294|Device|Body Composition Monitoring|BCM measurements every 10 minutes for 6 hours.
46085074|NCT02664129|Other|Video self-observation|Patients will watch the video of them in acute decompensation phase then they will be asked about their emotions, their understanding and awareness of mental illness
45457214|NCT02589860|Other|Melphalan kinetic study|Concentration of Melphalan in plasma samples
45674802|NCT01854645|Drug|Placebo MDI|Inhaled placebo administered as two puffs BID
45457215|NCT02589860|Genetic|Oral bacterial study|DNA from oral buccal mucosal cells will be sequenced for bacterial composition
45457216|NCT02589860|Genetic|Gene expression study|RNA from oral buccal mucosal cells will be analyzed to compare gene expression
45834348|NCT04553016|Biological|Vaccine|IM vaccination with ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVconsv4
46085075|NCT02664129|Other|Non Self video observation|Patients will not watch the video of them in acute decompensation phase.
46085076|NCT00953641|Drug|Misoprostol|Misoprostol 400ug, suspended in a base (Witepsol 15) as a vaginal suppository Single dose 12h or more prior to the procedure
46085077|NCT00953641|Drug|Placebo|Witepsol 15 base, vaginal suppository, Single dose, 12h or more prior to the endometrial biopsy
45457217|NCT02296372|Device|Continuous glucose monitoring|"Continuous glucose monitoring by subcutaneous or intravasal device for 72 hours.~In use MEDTRONIC SENTRINO® and Edwards GlucoClear® systems."
45457218|NCT01128751|Procedure|Embol-X intra-aortic emboli filter|Patients in this arm receive intra-aortic filter designed to catch solid debris for neuroprotection during surgery.
45457219|NCT01128751|Procedure|DBT dynamic bubble trap|Patients in this arm receive a dynamic bubble trap to reduce gaseous micro-emboli from cardiopulmonary bypass for neuroprotection during surgery
45457220|NCT01128751|Procedure|Control group|In comparison to arm 1 and 2, patients in this arm do not receive an additional intervention during surgery
45457221|NCT01355354|Drug|Digoxin|oral tablets, 0.25mg bd on Day 1 and 0.25 Once daily from Day 2 to 15
45457222|NCT01355354|Drug|Fostamatinib|oral tablets, 100mg (2 X 50mg) bd from Day 9 - 15
45457223|NCT03928795|Procedure|elective caesarean section|elective caesarean section
45457224|NCT01715324|Drug|Adjuvant Growth Hormon|The treatment group will receive 2.5 mg of Saizen daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering
45457225|NCT03513172|Drug|topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc)|The rapid hypotensive effects of topical alpha2-agonists such as brimonidine tartrate on decreasing aqueous production and increasing uveoscleral outflow, in addition to their neuroprotective properties, make them an attractive option for prophylactic treatment of post-injection IOP spikes.
45674803|NCT04418089|Drug|Simvastatin 40mg|The administration of Simvastatin 40 mg in addition to neoadjuvant chemoterapy CAF
45674804|NCT04418089|Drug|Placebo oral capsule|The administration of Placebo capsule 40 mg in addition to neoadjuvant chemoterapy CAF
45674805|NCT01825941|Drug|metoclopramide|10 milligrams, administered intravenously over 15 minutes
45674806|NCT01825941|Drug|diphenhydramine|50 milligrams, administered intravenously over 15 minutes
45674807|NCT01825941|Drug|placebo|
45674808|NCT02064205|Dietary Supplement|12.5 g polydextrose|Appetite suppressing supplement is added in yogurt and provided with breakfast (four hours before lunch) or 1.5h before lunch. Also yogurt with control (glucose syrup) is tested for its satiating effect.
45674809|NCT02064205|Dietary Supplement|glucose syrup|Glucose syrup is used a control product for the polydextrose
45834349|NCT04553016|Biological|Placebo|IM administration of 0.9% sterile sodium chloride solution
45834350|NCT03374592|Radiation|Volumetric Intensity-Modulated Arc Therapy|Advanced radiotherapy technique
45834351|NCT03374592|Radiation|Conventional Radiotherapy|Conventional radiotherapy technique
45834352|NCT04553406|Drug|SPR720|Capsules for oral administration
45834353|NCT04553406|Drug|Placebo|Capsules for oral administration
45834354|NCT04553406|Drug|Open-label Standard of Care|"Standard of Care regimen is at the Investigator's discretion; recommended 2-drug or 3-drug SOC, consisting of either:~Clarithromycin 500-1000 mg, plus ethambutol hydrochloride (HCl) 15 mg/kg orally once daily or~Azithromycin 250-500 mg plus ethambutol HCl 15 mg/kg orally once daily.~Optional rifampin 600 mg or rifabutin 300 mg orally once daily may be added to the SOC regimen for up to 28 days."
45834355|NCT04552704|Biological|CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc|Given IV
45834356|NCT04552704|Drug|Placebo Administration|Given IV
45834357|NCT04395300|Other|Web Based Survey|On line survey distributed electronically
45995211|NCT01252966|Behavioral|Control training|The computerized control training intervention is a 12-week standardized course of internet-based deep breathing exercises which does not contain the cognitive exercises designed to enhance executive cognitive function.
45995212|NCT00537615|Drug|PD 0332334|
46085078|NCT02763098|Drug|Remi 0.1|Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.1 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
46085079|NCT02763098|Drug|Remi 0.2|.Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.2 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
46085080|NCT02763098|Drug|Remi 0.3|Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.3 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
46085081|NCT00648219|Drug|Olmesartan Medoxomil Tablets 40 mg|40mg, single dose fed
45995213|NCT02582957|Other|Sigh breaths|Sigh breaths delivered once every 6 minutes, as part of usual invasive mechanical ventilation.
45995214|NCT03990909|Dietary Supplement|Branched Chain Amino Acids|60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to21days (42 total drinks).
46085082|NCT00648219|Drug|Benicar® Tablets 40 mg|40mg, single dose fed
46085083|NCT04423783|Behavioral|7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted)|Confrontation with spiders via gamified app
46085084|NCT04423783|Behavioral|Therapist-guided one-session online exposure therapy according to (Öst, 1989)|Massed exposure therapy over the course of one single session, applied in a remote-online context
46085085|NCT02763020|Other|Fruit extracts high in polyphenols|
46085086|NCT02763020|Other|placebo|
45674810|NCT02090959|Drug|Ataluren|Ataluren will be administered per the dose and schedule specified in the arm.
45674811|NCT02044159|Drug|Hydrocortisone|Hydrocortisone will be made up as a 10 mg/ml solution so the volume of added fluid will be very small (2 to 10 mls even for the initial dose of 2 mg/kg).
45995215|NCT03990909|Dietary Supplement|Rice Protein|60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
45995216|NCT03990909|Dietary Supplement|Microcrystalline Cellulose|60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
45995217|NCT01252810|Drug|GE-145|GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.
45674812|NCT02044159|Other|Placebo|The placebo (normal saline) will be identical in appearance, volume and smell to the active study drug (hydrocortisone).
45674813|NCT02090725|Drug|3-4 Diaminopyridine|
45674814|NCT02180165|Drug|Posaconazole|300 mg posaconazole twice on Day 1, either by oral tablet or IV solution; followed by 300 mg once daily for up to 84 days
45674815|NCT02180165|Drug|Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
45674816|NCT04753931|Other|Sensory Training in addition to Bobath Training|Trunk-focused exercises will be applied for different senses (tactile, proprioceptive, etc.) in addition to Bobath exercises. Bobath exercises will be determined individually according to the evaluation results. In general, exercises aiming to muscle tone regulation, increase balance, walking, and functionality will be applied. Trunk-focused Bobath exercises will be selected.
45995218|NCT02306993|Other|Healthy volunteers without SCT|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
45995219|NCT02306993|Other|Healthy volunteers with SCT|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
45995220|NCT02306993|Other|Volunteers with SCD|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
45995221|NCT04206709|Procedure|aerobic effort|Active upper limbs pedaling while maintaining a pulse calculated to be approximately 60% of the predicted maximum heart rate of each patient for 20 minutes.
45995222|NCT04206709|Other|passive pedaling|20 minutes passive pedaling by upper limbs.
45995223|NCT00537654|Drug|Treatment sequence A|Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fed state
45995224|NCT00537654|Drug|Treatment sequence B|Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fed state
45995225|NCT00537654|Drug|Treatment sequence C|Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fasted state
45995226|NCT00537654|Drug|Treatment sequence D|Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fasted state
45995227|NCT04397692|Device|Nitric Oxide delivered via LungFit™ system|Patients will receive inhalations of 80 ppm for 40 min 4 times a day
45995228|NCT02203643|Drug|Carfilzomib|
45995229|NCT02203643|Drug|Cyclophosphamide|
45995230|NCT02203643|Drug|Lenalidomide|
45995231|NCT02203643|Drug|Dexamethasone|
45995232|NCT01252186|Drug|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
45995233|NCT01252186|Drug|28-day Levonorgestrel Oral Contraceptive|21 combination tablets containing 150 µg LNG/30 µg EE.
45995234|NCT01252186|Drug|28-day Desogestrel Oral Contraceptive|21 combination tablets containing 150 µg DSG/30 µg EE.
45995235|NCT02188745|Drug|17B-estradiol|Anti-estrogen
45995236|NCT02188745|Drug|Letrozole|Aromatase inhibitors work by blocking estrogen receptors; they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
45995237|NCT02188745|Drug|Anastrozole|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
45674817|NCT04753931|Other|Bobath Training|Bobath exercises will be determined individually according to the evaluation results. In general, exercises aiming to muscle tone regulation, increase balance, walking, and functionality will be applied. Trunk-focused Bobath exercises will be selected.
45674818|NCT04748705|Drug|IMC-1|Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
45995238|NCT02188745|Drug|Exemestane|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
45995239|NCT03988335|Drug|RIST4721|RIST4721 oral solution
45995240|NCT03988335|Drug|Placebo|Placebo oral solution
46085087|NCT04149054|Behavioral|"Mobile health app called Hola Bebe"|For the pilot, all participants received a mobile app that contained 6 interactive audio/written modules in Spanish and English on the following topics: healthy eating; physical activity; portion control; eating healthy while eating out; eating out in Chinese, Italian, Mexican restaurants; and eating out in fast food restaurants. As noted above, the mobile app was customizable to include personalized activity reminders/notifications, and tailored action plans, along with videos for easy at-home exercises and user-friendly, easy-to-follow recipes.
45457226|NCT03740113|Behavioral|Kids SipSmartER|Kids SIPsmartER is grounded by the Theory of Planned Behavior as well as health literacy, media literacy, numeracy, and public health literacy concepts
45674819|NCT04748705|Drug|Placebo BID Tablet|Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
45674820|NCT02155985|Drug|Aspirin|Aspirin is a nonsteroidal antiinflammatory drug (NSAID) effective in treating fever, pain, and inflammation in the body.
46002361|NCT03471143|Drug|2-Hydroxypropyl-Beta-Cyclodextrin|"VTS-270 (2-Hydroxypropyl-Beta-Cyclodextrin) will be administered intravenously to specifically target liver disease. In the first phase of the study, dosing frequency will be twice a week with IV VTS-270 for six weeks for a total of 12 administrations. Subjects will be evaluated at each study visit for evidence of adverse effects.~Doses to be studied are 500, and 1000 mg/kg. Six subjects will be studied at each dose level. Cohort 1: Subjects 1-6, 500 mg/kg Cohort 2: Subjects 7-12, 1000 mg/kg"
46002362|NCT03456882|Drug|RNS60|normal saline plus oxigen in nanobubble
46085088|NCT04655313|Drug|ARQ-151 cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
46085089|NCT02760758|Drug|CDI-31244|NNI
46085090|NCT02760758|Drug|Placebo|no active ingredients
45995241|NCT02089607|Device|Thoracoabdominal Aortic Aneurysm Arm|"The Zenith Fenestrated-Branched System is a tubular graft made of polyester fabric sewn to stainless steel stents that keep the graft open. The graft will be inserted through arteries in the leg (called endovascular repair). This procedure uses catheters that go inside the blood vessel to place a stent graft above and below the aneurysm.~The graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches). The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches."
45995242|NCT02089607|Device|Aortic Arch Aneurysm Arm|The endovascular graft includes the main aortic arch portion and one to three cuffs (side branches) that allow the graft to be located in the aortic arch. The number of cuffs is decided based on the anatomy of your aneurysm. The arteries in the aortic arch are the innominate artery (Zone 0), left common carotid artery (Zone 1) and the left subclavian artery (Zone 2). These arteries supply the right arm and right side of the brain, the left side of the brain and the left arm, respectively. The main aortic endovascular graft will be connected into the innominate artery, left common carotid artery and left subclavian artery using additional stents into the branch vessels.
45995243|NCT00537693|Procedure|Continuous Renal Replacement Therapy|Patients will be randomized to either arm for the first 24 hours of the study and then crossover to the second arm for the second 24 hours of the study.
45995244|NCT04320316|Drug|Crysvita (burosumab-twza) Treatment|KRN23 is a fully human IgG1monoclonal antibody that binds to and inhibits the activity of FGF23, leading to an increase in serum phosphorus levels. It is a potential therapeutic candidate for the treatment of XLH, Tumor-Induced Osteomalacia (TIO), and the rickets/osteomalacia resulting from Epidermal Nevus Syndrome (ENS). All of these conditions are diseases of bone hypomineralization, caused by urinary phosphate wasting due to elevated levels of FGF23.
45995245|NCT04365556|Behavioral|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
45995246|NCT01731782|Drug|bupivacaine|
45995247|NCT01731782|Drug|normal saline placebo (for bupivacaine)|Normal saline to mimic bupivacaine
45995248|NCT02889211|Behavioral|Gambling Task|
45995249|NCT01251952|Drug|Denileukin Diftitox (Ontak)|"After receiving their stem cell transplant on Day 0, participants will receive study agent via a 30 minute infusion. Participants will also receive a 30 minute infusion of study agent on Day 21.~Follow-up visits for clinical assessment, blood draws for routine clinical laboratory studies and for immuno-correlative studies will also take place on days 42, 90, 180 and 360."
45995250|NCT04356430|Drug|Abiraterone Acetate|1000 mg orally daily for 24 weeks before robotic assisted radical prostatectomy
45995251|NCT04356430|Drug|Prednisone|5 mg oral low dose prednisone, once daily
45995252|NCT04356430|Drug|Goserelin 10.8 mg|10.8 mg goserelin hypodermic once per 12 weeks
45995253|NCT01352195|Behavioral|Forever Free Booklets|Randomized 3-arm design, with 660 smokers recruited into each condition. Assessments will occur at six-month intervals, through 30 months.
45995254|NCT03974139|Drug|Metformin Oral Tablet|Day 1 to day 3: 500 mg/day Day 4 to day 6: 500 mg/twice a day Day 7 to day 9: 500 mg three times a day Day 10 until next lumbar puncture : 850 mg three times a day
45995255|NCT04321135|Behavioral|Guided Lifestyle Program Intervention|The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly.They will also receive a participant informational binder (wellness guide) with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
45995256|NCT04321135|Behavioral|Self-Guided Lifestyle Program (Control Arm)|In the self-guided weight loss program, participants will be given the sane informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines but they will not receive in-person classes or text messaging
45995257|NCT04320238|Drug|recombinant human interferon Alpha-1b|recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.
45995258|NCT04320238|Drug|thymosin alpha 1|thymosin alpha 1 subcutaneous injection 1 time per week.
45995259|NCT04320121|Dietary Supplement|Nelutri™|Nelutri™ 2,000 mg/day for 12 weeks
45995260|NCT04320121|Dietary Supplement|Placebo group|Placebo 2,000 mg/day for 12 weeks
45995261|NCT04320004|Behavioral|Education|Subject receives education
45995262|NCT04320004|Behavioral|Education with Reminder|Subject receives education with reminder
45995263|NCT04320004|Behavioral|Education + Disposal Bag|Subject receives education and disposal bag
45995264|NCT04320004|Behavioral|Education + Disposal Bag with Reminder|Subject receives education + disposal bag with reminder
45995265|NCT01229072|Biological|Heparin sodic|Heparin sodic 150UI/kg
45457227|NCT03518476|Behavioral|intensive multi-disciplinary education program on tobacco treatment for pharmacists|Participants in the intervention group will participate in an intensive education program delivered by a multi-disciplinary group of educators, researchers, and clinicians with expertise in tobacco control and tobacco dependence treatment. The program will be delivered over 4 days (run over 2 weekends) with an average of eight contact hours per day (a total of 32 contact hours) at Qatar University.
45674821|NCT02155985|Drug|Placebo|Placebo for aspirin
45674822|NCT02155829|Drug|Riluzole|
45674823|NCT02155829|Drug|Placebo (for Riluzole)|
45674824|NCT02129777|Drug|Namilumab|Namilumab subcutaneous injection
45995266|NCT01229072|Biological|heparin liquemine|Heparin sodic 150UI/kg
45995267|NCT04685733|Device|Non-invasive hemodynamic measurements|Non-invasive hemodynamic measurements
45995268|NCT01228643|Biological|Pancreatic enzimes|- Norzyme ® (product testing) composition: 20.000USP lipase, 65.000USP of 65.000USP amylase and protease.
45995269|NCT01228643|Device|Creon ®|- Creon ® (reference product) composition: 25.000UI lipase, amylase 74.700UI 62.500UI and protease
46002363|NCT03433807|Drug|Idebenone|900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)
45674825|NCT02129777|Drug|Placebo|Placebo subcutaneous injection
45995270|NCT04685460|Other|customized 3D-printed bolus fabricated based on reconstruction of computed tomography (CT) images|customized 3D-printed bolus fabricated based on reconstruction of computed tomography (CT) images were used in this study.
45995271|NCT01199978|Radiation|Fractionated proton radiation|Given daily for approximately 5.5 weeks
45995272|NCT01199978|Drug|Losartan|25mg or 50mg daily, oral administration, for approximately 6 months.
45995273|NCT00532116|Drug|EMSAM (Selegiline Transdermal System) 6mg|STS 6mg/24hr
45995274|NCT00532116|Drug|EMSAM (Selegiline Transdermal System) 12mg|EMSAm 12mg/24Hr
45995275|NCT04283513|Drug|Virazole|Virazole (Ribavirin), USP Injection 0.1 g/mL in a phosphate buffer solution. Each vial contains 1.2 g of Ribavirin in 12 mL
45995276|NCT01251367|Biological|Botulinum toxin type A|I.M. (intramuscular) injection on day 1 of each treatment cycle.
45995277|NCT03910998|Drug|Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery|Bolus of rocuronium 0.1 mg/kg at the discretion of anesthetist to keep the TOF between 1-3 out of 4 during surgery
45995278|NCT03910998|Drug|Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2|Bolus of rocuronium 0.1 mg/kg IV will be given during surgery for a TOF 0/4 and a PTC ≤ 2 (parameters measured every 10 minutes).
45995279|NCT04685148|Drug|Transdermal patch estradiol|Estradiol patches (200 μg per day by transdermal delivery) will be administered at day 0 (+1) to day 21 postpartum.
45995280|NCT04685148|Drug|Transdermal patch placebo|Placebo patches will be administered at day 0 (+1) to day 21 postpartum.
45995281|NCT04258358|Other|CASCADE ways of working|Technology, learning and development resources and nursing and therapeutic care are the key drivers for the CASCADE ways of working promoting community integrated dementia care and support to optimise safety and independence for people living with dementia.
45995282|NCT02888548|Procedure|botulinum toxins (Dysport°) alone|botulinum toxins (Dysport°) alone
45995283|NCT02888548|Procedure|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined
45995284|NCT03888222|Drug|Placebo Oral Tablet|"Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) tablet orally once daily for 3 months (90 days) ."
45995285|NCT03888222|Drug|Bosutinib Oral Tablet|Fifteen (15) patients in group 1 will receive the 100 mg of Bosutinib one (1) tablet orally once daily for 3 months (90 days) .
45995286|NCT01250509|Behavioral|Craving and Lifestyle Management through Mindfulness|A preliminary, novel intervention was developed drawing on components from Mindfulness-Based Stress Reduction (MBSR), Mindfulness-Based Cognitive Therapy (MBCT), and Mindfulness-Based Eating Awareness Training (MB-EAT). The intervention program consisted of nine 2.5-hour classes and one 7-hour silent day of guided meditation practice after class 6.
45995287|NCT04239638|Diagnostic Test|Cervical Spinal MRI|Cervical Spinal MRI images of 500 patients will be entered into the system for modeling
45995288|NCT04246684|Drug|Oxaliplatin, 85 mg/m2|85 mg/m2,2h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapy
45674826|NCT02178995|Drug|Methylphenidate|"Participants with epilepsy will first receive blinded, single-dose capsules which contain either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate.~At each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed."
45674827|NCT02128997|Device|Closed incision wound vacuum (Prevena)|wound vacuum to be placed on a closed incision
45674828|NCT02155283|Device|Continuous Passive Motion|Daily self-treatments at home for 3 weeks, with up to three 10-minute treatment sessions per day
45674829|NCT02154581|Device|SLActive implant|
45674830|NCT02154425|Procedure|Breast milk sampling|Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose for mothers on CZP Q2W), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).
45457228|NCT03518476|Other|Control arm|Participants in control arm will receive a non-tobacco related training or educational session
45457229|NCT01355432|Other|Observation|There is no intervention, this is an observational study.
45995289|NCT04246684|Drug|5FU; 2400 mg/m2|2400 mg/m2, 46h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, 134 of therapy for Control arm
45995290|NCT04246684|Drug|5FU, 250 mg/m2|250 mg/m2 per day, civ, on day 1-14, day 22-35 of radiotherapy;
45995291|NCT04246684|Drug|5FU, 2400 mg/m2|2400 mg/m2,46h-civ, d64, d78, d92, d106, d120, d134 of therapy
45995292|NCT04246684|Drug|Oxaliplatin 50 mg/m2|50 mg/m2, 2h-civ, d1, d8, d21, d29 of radiotherapy and
45995293|NCT04246684|Drug|Folinic Acid, 400 mg/m2|2h-civ day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapyfor Control arm; 400 mg/m2, 2h-civ d 64, d78, d92, d106, d120, d134 of therapy for experimental arm
45995294|NCT04246684|Radiation|Radiotherapy control, 5x5 Gy: 25 Gy|Control arm: 5x5 Gy (total: 25 Gy) 5 fractions
45995295|NCT04246684|Drug|Capecitabine, 1000 mg/m2|1000 mg/m2 (twice daily) day1-14 every three weeks instead of 5FU optional
45995296|NCT04246684|Drug|Oxaliplatin 85 mg/m2|85 mg/m2, 2h-civ, d64, d78, d92, d106, d120, d134 of therapy
45995297|NCT04246684|Radiation|radiotherapy experimental, 30 x 1,8 Gy: 54 Gy|30 x 1.8 Gy (total: 54 Gy), 5 fractions per week
45995298|NCT04246684|Drug|Capecitabine, 825 mg/m2|825 mg/m2 bid, per os, on day 1-14, 22-35 of RT instead of 5FU optional
45995299|NCT04246684|Drug|Oxaliplatin, 130 mg/m2|day1every three weeks (optional)
45995300|NCT04232228|Other|No intervention|No intervention was used in this study.
45995301|NCT03883893|Drug|Intravenous acetaminophen|Intravenous acetaminophen will be given in the OR.
45995302|NCT03883893|Other|Normal saline|Normal saline will given if randomized to this group.
45995303|NCT04319575|Drug|root canal treatment and intracanal medicament|"after the access preparation and cleaning and shaping was done in 1st appointment using k files,Mani and protapers,Dentsply then in, chitosan calcium hydroxide paste, or ciprofloxacin metronidazole minocycline paste placed in the canal and kept for 4 weeks."
45995304|NCT04191655|Device|High Definition Colonoscopy|A colonoscopy that used high definition (HD) camera
45995305|NCT04191655|Device|Dye Spraying Chromocolonoscopy|A colonoscopy that used high definition camera in addition to dye spraying on the interior colon surface.
45995306|NCT00537732|Drug|omeprazole|20 mg daily
45995307|NCT00537732|Drug|omeprazole|20 vs. 60 mg daily, genotype dependent
45995308|NCT04203017|Biological|allogeneic fecal microbiota|All patients receive autoHSCT with RIC (Cyclophosphamide, Antithymocyte globulin, Rituximab). After immune system reconstitution (approximately starting D+60 up to D+120), patients will receive FMT from healthy donor via po capsules.
45457230|NCT01132261|Other|"brain preservation' diet"|dietetic evaluation and advice in small group for health diet
45457231|NCT01349270|Drug|Immunoglobulin perfusion|patient who received monthly 2g/kg intravenous cure of immunoglobulin
45457232|NCT01349270|Drug|Prednisone|patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
45674831|NCT02154425|Biological|Certolizumab Pegol|Mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.
45674832|NCT02154347|Drug|KAD-1229|
45834358|NCT04124796|Other|Semi-structured interviews|Based on an interview grid previously built, the interviews will investigate the factors governing the decision to consult and methods of intervention to reduce the time to consult.
45834359|NCT04124718|Genetic|high caries experience|DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit
45995309|NCT04180436|Drug|rivaroxaban 20 mg once daily 8 days|Blood samples for the measurement of rivaroxaban PK parameters
45995310|NCT00537927|Procedure|laparoscopic correction of hernia with mesh|Correction of hernia with mesh and fixation of mesh using one of the arms.
45457233|NCT03513094|Other|Transversus Abdominis Contraction|Participants were educated on how to contract their transversus abdominis (TA) muscle after having a surface EMG biofeedback device placed on their abdomen to provide audible biofeedback. Participants were asked to ambulate while maintaining TA contraction while ambulating at 50% of maximal volitional isometric contraction.
45457234|NCT03516058|Other|Simulation-Based Education|"Participating residents receive lectures on TAP block and the use of ultrasound devices from an expert before training, and then receive simulation-based training for an hour from the anesthesiologist's staff. The residents performed three ultrasound guided TAP blocks using an anesthetized porcine model during the training session.~The residents filled out a questionnaire before and after the training session. Ten multiple-choice questions tested general knowledge in abdomen ultrasound and TAP block. Subjective comfort levels with ultrasound machine and block device functionality, patient positioning, proper block technique, image documentation, needle safety and overall procedural confidence and anxiety levels were reported on a 5-point Likert scale before and after training."
45995311|NCT01250119|Drug|erlotinib [Tarceva]|150 mg daily, orally
45674833|NCT02154347|Drug|Placebo|
45674834|NCT02154347|Drug|Insulin|
45674835|NCT01627067|Drug|Everolimus|10 mg by mouth once daily.
45674836|NCT01627067|Drug|Exemestane|25 mg by mouth once daily.
45674837|NCT01627067|Drug|Metformin|500 mg by mouth per day for three days. If there are no dose limiting toxicities, the dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily.
45834360|NCT03246126|Device|Valiant™Thoracoabdominal Stent Graft System|The Visceral Manifold System is comprised of the Thoracic Bifurcation and Visceral Manifold to treat a thoracoabdominal aortic aneurysm or TAAA. The experimental procedure to implant the stent graft will be done in an operating room and will last anywhere from four to eight hours, but may take longer.
45834361|NCT04394052|Diagnostic Test|MR imaging|Medical imaging
45834362|NCT05601960|Other|anti-acne dermocosmetic|Topical application once daily for 2 months
45995312|NCT04682444|Drug|Enisamium Iodide|Patients ingested Amizon tablets after meal without chewing as follows: 2 tablets (total dose 0.5 g) 3 times a day, for 7 days. Each tablet contains 0.25 g of Nmethyl- 4-N-methyl-4-benzylcarbamidopyridinium iodide (INN enisamium iodide).
45995313|NCT04682444|Drug|Placebo|Patients ingested placebo tablets after meal without chewing in the dose 0.5 g (2 tablets), 3 times a day, for 7 days.
45995314|NCT04320277|Drug|Baricitinib|Baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. Baricitinib tablets 4 mg were administered in the morning.
45995315|NCT05300529|Other|Vestibular Rehabilitation Exercises|The Vestibular Rehabilitation program focuses on stabilizing the gaze and gaining the Vestibular Ocular Reflex (VOR). The general mechanisms of recovery from vestibular injuries are vestibular adaptation and replacement exercises, which are designed to improve gaze stability and the interaction between sight and the vestibular system during head movements. The exercises will be carried out progressively according to the tolerance of the patient, varying the stimulus in intensity and frequency.
45995316|NCT05300529|Other|Conventional Rehabilitation exercises|The conventional rehabilitation program in which exercises are performed to improve joint range, flexibility, and gait. It will always be done with the eyes open, on a firm surface and will not include training in sensory strategies
45995317|NCT04163549|Behavioral|Safe at Home|Discussion-based intervention
45995318|NCT01250002|Drug|Placebo|Placebo will receive the same volume of saline infusion.
45995319|NCT01250002|Drug|Lidocaine|Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
45995320|NCT05491876|Other|Chest physiotherapy with breathing exercises and ACBT|Group A got chest physiotherapy with breathing exercises and ACBT
45995321|NCT05491876|Other|Chest physiotherapy with breathing exercises|Group B got chest physiotherapy with breathing exercises.
45674838|NCT02178059|Drug|terbutaline sulphate delivered dose|0.4 mg terbutaline sulphate (delivered dose) per inhalation
45674839|NCT02178059|Drug|terbutaline sulphate metered dose|0.5 mg terbutaline sulphate (metered dose) per inhalation
45674840|NCT01626989|Device|BiPAP auto Advanced|Auto Servo Ventilation Device
45674841|NCT01626989|Device|BiPAP auto SV4|Auto Servo Ventilation Device
45834363|NCT05605002|Drug|SSRIs|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
45834364|NCT05605002|Procedure|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
45834365|NCT05605002|Procedure|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20*1.5mm or φ0.20*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
45834366|NCT05604846|Dietary Supplement|ProPrems|The intervention product, commercially known as ProPrems®, is a combination of (one billion freeze-dried bacteria per 0.5 g in a maltodextrin base powder: Bifidobacterium infantis Bb-02 (DSM 33361) 300 million, Bifidobacterium lactis (BB-12®) 350 million, and Streptococcus thermophilus (TH-4®) 350 million will be given daily once to eligable infants born extremly preterm (<28weeks of gestation) once they tolerate 3ml of enterla feeds until the age of 34 weeks of gestation.
45834367|NCT03238248|Drug|Azacitidine Subcutaneous Injection or Intravenous Infusion|75 mg/m2
45834368|NCT03238248|Drug|Pevonedistat Infusion|20 mg/m2
45834369|NCT03238248|Procedure|Bone Marrow Biopsy & Aspirate|Removal of a small piece of bone and bone marrow by inserting a needle into hip bone.
45834370|NCT04124484|Drug|DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)|One DBPR108 tablet(50mg) administered orally once a day + Two Placebos matching DBPR108 tablet(100mg) administered orally once a day for 12 weeks
45834371|NCT04124484|Drug|DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)|One DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
45674842|NCT04748237|Diagnostic Test|Coronary computed tomopraphic angiography|CCTA as soon as possible, preferably within 24 hours, but not later than within 7 days.
45674843|NCT02128217|Drug|Sofosbuvir|Participants received one 400 mg tablet of sofosbuvir (SOF) orally every morning with food
45995322|NCT05491759|Drug|Product 1 - AquaCelle Fish Oil Triglyceride|1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.4g AquaCelle.
45995323|NCT05491759|Drug|Product 2 - AquaCelle Fish Oil Ethyl Ester|1 dose of 2 capsules equivalent to 1.6g Fish Oil Ethyl Ester (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.28g AquaCelle
45995324|NCT05491759|Drug|Product 3 - Standard Fish Oil Triglyceride|1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)).
45995325|NCT05295810|Drug|Sequential Gas Delivery|Sequential Gas Delivery will be controlled using the RespirAct™ system (Thornhill Research Inc., Toronto, Canada)
45995326|NCT04171141|Drug|PF-07062119|PF-07062119
45995327|NCT04171141|Drug|Anti-PD1|Anti-PD1 PF-06801591
45995328|NCT04171141|Drug|Anti-VEGF|Anti-VEGF IV (bevacizumab)
45995329|NCT04157153|Device|Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold|Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold
45995330|NCT05338242|Device|Real-Time Exposure Feedback|Participants will receive real-time exposure monitors that continuously display real-time air concentration information and a color-coded designation for the current risk level.
45995331|NCT04119596|Diagnostic Test|16S rRNA gene sequencing|Taking a stool sample for gut microbiome DNA sequencing
45995332|NCT04119596|Genetic|DNA-microarray genotyping|Taking a saliva sample for genotyping
45995333|NCT05331456|Device|Unilateral alveolar cleft repair|Early secondary alveolar cleft repair is performed in children with a unilateral alveolar cleft using eirther autologous bone or a calcium phosphate based putty
45995334|NCT04107389|Behavioral|Art Psychotherapy, Art Therapy|Art Therapy is a form of psychotherapy, based upon the premise of utilising art materials as a form of expression and communication; the roots of the theoretical approach lie in a psychodynamic approach to working with the unconscious.
45995335|NCT04107389|Behavioral|Wait List|Wait list control group. Participants randomised to Wait List group or Intervention group.
45995336|NCT05329116|Drug|Lidocaine 2% Injectable Solution|"Patients will be administered 1.5 ml of 2% lidocaine, 1.5 ml of 30 mg of pentoxifylline.~Among the injection techniques, profundal intradermic injection (IDP, injection depth: 2-4 mm) and superficial intradermic injection (IDS, injection depth: 1-2 mm) will be used.~8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection"
45995337|NCT05329116|Biological|Platelet-rich plasma|8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection
45995338|NCT04107116|Behavioral|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
45995339|NCT04107116|Other|Usual Care|Usual care as provided by local oncologists
45995340|NCT04105595|Device|Septal defect closure|Device closure of atrial septal defect
45995341|NCT05270148|Other|HIIT|12 weeks training High-Intensity Interval Training consists of 3 sessions per week in a cycle ergometer, with 1-2days off between sessions, under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes).Depending on the number of training session, the loadand the series will increase up to 40% more than the maximum load.
45995342|NCT05270148|Other|Fat Max|12 weeks training Fatmax consist in 3 sessions per week in a cycle ergometer, with 1-2days off between sessions, under the supervision of a personal trainer. MICTprogram will consist of sessions of approximately ˜45min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
45995343|NCT04096274|Behavioral|Leadership for Organization Change and Implementation (LOCI)|LOCI is a leadership training and coaching program designed to support leaders and foster a climate that implements and sustains use of evidence based practices.
45995344|NCT04096274|Behavioral|Leadership web-based seminars|A set of 4 leadership training web-based seminars will be provided that cover topics ranging from effective leadership, to giving effective feedback.
45995345|NCT04069637|Combination Product|Growth-sparing instrumentation and titanium levels|Patients with growth-sparing instrumentation as treatment for early onset scoliosis, will have their titanium (serum and urine) levels tested, to evaluated if they have elevated titanium levels compared to a control group.
45995346|NCT00537849|Device|Sonablate 500(SB-500)|
45995347|NCT04002830|Drug|Elelyso|Taliglucerase alfa is currently an approved therapy in the United States and many other countries for adults and children with a confirmed diagnosis of Type 1 GD ,and is also approved for use in Type 3 GD in a small number of countries.
45995348|NCT03995771|Other|Questionnaire delivery|A questionnaire including questions regarding prognostic factors for knee pain will be delivered to children and adolescents (8-19 years old) presenting to general practice with knee pain
45995349|NCT00537888|Drug|fluconazole|Intravenous or oral 400 md/d
45834372|NCT04124484|Drug|DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)|Two DBPR108 tablets(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
45995350|NCT03880955|Device|ReUnion RSA System|The ReUnion RSA System is designed as a reverse total shoulder endoprosthesis to address unrepairable gross rotator cuff tear, rotator cuff arthropathy with pseudoparalysis of the shoulder joint, advanced arthritic and rheumatic disorders affecting the shoulder joint, and failed previous shoulder arthroplasty. The ReUnion RSA System is comprised of a Humeral Cup, Humeral Insert, Glenosphere, Glenoid Baseplate and Screws. The intended purposes of the ReUnion RSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
45995351|NCT05307510|Device|Prefabricated splint|Subjects will be provided either a prefabricated splint
45995352|NCT05307510|Device|Custom Orthosis|Subjects will be evaluated by an occupational therapist who will fabricate a custom orthosis.
45995353|NCT05264142|Drug|Voriconazole 200mg|Voriconazole is a weak CYP2C19 inhibitor. It is used in study session 2 to study the impact of a weak inhibitor on the phenotype switch among the different genotypes included in the study.
45995354|NCT05264142|Drug|FluvoxaMINE 50 Mg Oral Tablet|Fluvoxamine is a strong CYP2C19 inhibitor. It is used in study session 3 to study the impact of a strong inhibitor on the phenotype switch among the different genotypes included in the study.
45995355|NCT05264142|Drug|Omeprazole 10 MG Oral Tablet|Omeprazole is a CYP2C19 probe substrate. It is used in the study as a tool for CYP2C19 phenotyping at each of the sessions.
45995356|NCT01246960|Biological|Ramucirumab|Administered intravenously
45995357|NCT01246960|Drug|Placebo|Administered intravenously
45995358|NCT01246960|Drug|Oxaliplatin|Administered intravenously
45995359|NCT01246960|Drug|Leucovorin|Administered intravenously
45995360|NCT01246960|Drug|5-Fluorouracil|Administered intravenously
46085091|NCT00953797|Device|Enhanced External Counterpulsation|A non-invasive method currently used for the treatment of ischemic coronary disease. During EECP therapy three compressive pneumatic cuffs are wrapped around the calves, lower thighs, and upper thighs. The cuffs inflate sequentially during diastole causing retrograde aortic flow, and increased venous return. At end diastole, the cuffs rapidly deflate resulting in unloading of the left ventricle and a decrease in systolic blood pressure.
45995361|NCT03870269|Device|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
45995362|NCT00544986|Drug|Anastrozole|
45995363|NCT03851588|Other|Placebo|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is not given with a supplementary dose of dolutegravir 50 mg.
45995364|NCT03851588|Drug|Dolutegravir 50 mg|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is given with a supplementary dose of dolutegravir 50 mg.
45995365|NCT05239182|Drug|9-ING-41|9-ING-41 is a small molecule potent selective GSK-3β inhibitor
45995366|NCT05239182|Drug|Retifanlimab|Humanized, hinge-stabilized, IgG4κ monoclonal antibody that recognizes human PD-1.
45995367|NCT05239182|Drug|Gemcitabine|cytotoxic chemotherapy agent
45995368|NCT05239182|Drug|Abraxane|cytotoxic chemotherapy agent
45995369|NCT01244620|Drug|sitaxentan|sitaxsentan 100 mg QD for 6 days
45995370|NCT01244620|Drug|tadalafil|tadalafil 40 mg QD for 6 days
45834373|NCT04124484|Drug|Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)|Two Placebos matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
45834374|NCT04124016|Dietary Supplement|Inulin|Powder of inulin fractions dissolved into 250 ml of water
45834375|NCT04124016|Dietary Supplement|green tea extract|Powder of green tea extract dissolved into 200 ml of water
45995371|NCT01244620|Drug|sitaxsentan|sitaxsentan 100 mg QD for 6 days
45995372|NCT01244620|Drug|tadalafil|tadalafil 40 mg QD for 6 days
45995373|NCT01244620|Drug|sitaxsentan|sitaxentan 100 mg QD for 6 days
45995374|NCT01244620|Drug|sildenafil|sildenafil 20 mg TID for 6 days
46085092|NCT00648297|Drug|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fed
46085093|NCT00648297|Drug|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fed
45995375|NCT04682717|Device|perfusion index monitoring for postinduction hypotension|Hemodynamic parameters will be recorded at 1-min intervals till 10 min after intubation. Hypotension will be defined as a drop in SBP to <30% of baseline or absolute MAP <60 mmHg. MAP <55 mmHg (severe hypotension) will be treated immediately by rapid intravenous fluid administration (10 ml/kg) and ephedrine sulphate 6 mg IV boluses. Bradycardia will be defined as HR <50 bpm or decrease by more than 30% below baseline value, whichever will be lower and will be treated with atropine 0.6 mg IV boluses. The incidence of hypotension will be calculated in 2 sets - 5 min after induction of anesthesia (effect of induction agent) and first 15 min after induction (effect of induction process and endotracheal intubation).
45995376|NCT04319692|Dietary Supplement|Fermented Prunus Mume Vinegar group|This group takes Fermented Prunus Mume Vinegar for 8 weeks
45995377|NCT04319692|Dietary Supplement|Placebo group|This group takes placebo for 8 weeks.
45995378|NCT05238480|Device|XC mouthguard|Use of a Xtreme Conventional custom-made mouthguard while playing rugby
45995379|NCT05238480|Device|XP mouthguard|Use of a Xtreme Pro custom-made mouthguard while playing rugby
45674844|NCT02128217|Drug|Ribavirin|Participants received weight-based ribavirin RBV orally, 2 times a day, every morning and every evening, with food. Weight under 75 kg, 600 mg (3 tablets) morning and 400 mg (2 tablets) evening. Weight over 75 kg, 600 mg (3 tablets) morning and 600 mg (3 tablets) evening. The dose of RBV was based on subject's weight at entry. Changes in weight after entry did not require a change in dose. Doses were only changed for toxicity management.
45995380|NCT04682327|Other|Response to anti-PD-1/PD-L1|Response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
45674845|NCT02128217|Drug|Ledipasvir/Sofosbuvir|Participants received one daily fixed-dose combination tablet orally every morning of 90 mg of Ledipasvir (LDV) and 400 mg of SOF.
45995381|NCT04682327|Other|Non-response to anti-PD-1/PD-L1|Non response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
45995382|NCT02889640|Other|SAGA Innovations|An intensive math tutoring program
45995383|NCT02889640|Other|Scale-up tutors|Tutors who have been selected for hire via the one in three-and-a-half randomization process
45995384|NCT02889640|Other|Standard Tutors|Tutors who have been selected for hire via SAGA's standard hiring process, which does not entail randomization
45995385|NCT00545142|Drug|Abilify(Aripiprazole)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
45995386|NCT00545142|Drug|Depakote(Divalproate)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
45995387|NCT01267201|Drug|methylprednisolone|powder for oral suspension 4 mg/mL single dose (8 mL)
45995388|NCT01267201|Drug|methylprednisolone|powder for oral suspension 4 mg/mL singe dose (8 ml)
45995389|NCT01267201|Drug|methylprednisolone|tablet 32 mg single dose
45995390|NCT03778931|Drug|Elacestrant|400 mg/day once daily oral dosing
45995391|NCT03778931|Drug|Standard of Care|"Fulvestrant: 500 mg administered intramuscularly (IM) into the buttocks as two 5 mL injections on C1D1, C1D15 and C2D1 and Day 1 of every subsequent 28-day cycle~Anastrozole 1 mg/day on a continuous dosing schedule~Letrozole: 2.5 mg/day on a continuous dosing schedule~Exemestane: 25 mg/day on a continuous dosing schedule"
45995392|NCT04323514|Dietary Supplement|Vitamin C|10 gr of vitamin C intravenously in addition to conventional therapy.
45995393|NCT05198895|Device|Near-infrared (NIR)|NIR spectral assessment of glycated nail keratin vs glycated haemoglobin (HbA1c)
45995394|NCT03768128|Device|Journey™ II UNI Unicompartmental Knee System|"Journey™ II UNI UKS is a CE Marked medical device. The device has been designed to treat both medial and lateral unicompartmental disease.~It is a comprehensive system designed to allow surgeons to perform UKA. It is comprised of the following anatomic components: Oxidized zirconium femoral components Titanium tibial components with a grit-blasted surface Polyethylene tibial insert components The device is asymmetric and is available in oxidized zirconium to reduce wear and increase implant longevity."
45995395|NCT00545220|Behavioral|problem-solving training|
45995396|NCT00545220|Behavioral|sham intervention|
45995397|NCT03755492|Other|Absorbent pad for urinary incontinence|6 month supply provided to patients as needed for urinary incontinence after radical prostatectomy
45674846|NCT01629953|Other|Group vocational intervention|Group based manualized vocational rehabilitation
45995398|NCT05175573|Device|SuperNO2VA Et Nasal Positive Pressure Mask|Nasal mask with capnography providing continuous positive airway pressure at 10LPM
45995399|NCT05175573|Device|Supplemental Oxygen Face Mask|Face mask with capnography providing oxygenation at 10 LPM
45995400|NCT03736616|Drug|Carboplatin|Chemotherapy
45995401|NCT03736616|Drug|Ifosfamide|Chemotherapy
45674847|NCT01629953|Other|Supported Employment Condition|Veterans in this condition will receive a proven group based manualized vocational rehabilitation intervention
45674848|NCT02127281|Device|Prevena|Device will be applied at end of procedure over closed incision.
45674849|NCT01628549|Drug|50 mg P005672-HCl|P005672-HCl administered as an oral capsule(s) once daily
45995402|NCT03736616|Drug|Etoposide|Chemotherapy
45674850|NCT01628549|Drug|Placebo|Dose-matched Placebo capsule administered as an oral capsule(s) once daily
45995403|NCT03736616|Biological|Rituximab|Anti-CD20 mAb
45995404|NCT03736616|Drug|Carmustine|Chemotherapy
45995405|NCT03736616|Drug|Cytarabine|Chemotherapy
45995406|NCT03736616|Drug|Melphalan|Chemotherapy
45674851|NCT01628549|Drug|100 mg P005672-HCl|P005672-HCl administered as an oral capsule(s) once daily
45995407|NCT03736616|Other|Autologous HSCT|Cellular Therapy
45995408|NCT03736616|Drug|Acalabrutinib|Bruton's Tyrosine Kinase Inhibitor
46085094|NCT02760680|Device|WatchPAT 200 (TM)|The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.
46085095|NCT02760680|Other|Polysomnography|"The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines."
46085096|NCT00648453|Drug|Clopidogrel (Plavix)|
46085097|NCT00549445|Drug|Azithromycin|250 mg daily
46085098|NCT00549445|Drug|Placebo|Daily
46085099|NCT05344014|Procedure|Photobiomodulation|In experimental groups, before topical anesthesia, PBMT was applied by utilizing a diode laser (EpiX; Biolase technology, inc., USA) with a continuous wavelength of 940 nm on a 400-μm fiber with only biostimulation properties. In accordance with the recommendations of the device's manufacturer, it was applied using circular motions in a manner as slowly as possible (an average of 33-36 circular movements in 60 s)
46085100|NCT05344014|Procedure|Placebo|In the control group (placebo), the laser probe was directed to the mucosa for (buccal and palatal area), but not activated, and the sound of the laser device previously recorded on the mobile telephone was played for the same time of experimental group in order to provide similar conditions
46085101|NCT02660151|Device|Hyper-CL™ lens|
45457235|NCT01355666|Device|DermaTherapy® Linen and underpads.|"DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics."
45674852|NCT02127125|Drug|Maltodextrin|Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.
45674853|NCT02127125|Drug|Synbiotic|Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.
46085102|NCT02660151|Device|Regular soft contact lens|
45674854|NCT02127125|Drug|Sevelamer|Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks
45674855|NCT04417751|Behavioral|Cognitive Stimulation|The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 45 minutes and they will be developed according to the following structure: welcoming and greeting the participants (5 minutes); reality orientation therapy (10 minutes), cognitive stimulation [CS] activity (25 minutes); return to calm and closure of the session, and session evaluation (5 minutes). CS sessions will be conducted in an individual intervention format. The intervention sessions will include several activities based on different non-pharmacological therapies (e.g., reminiscence therapy, reality orientation therapy, cognitive training) whose effectiveness in older adults with neurocognitive disorders has been scientifically proven. All individual CS sessions will be conducted by one therapist (clinical psychologist) with more than five years of experience in CS.
45674856|NCT02090413|Drug|dimethyl fumarate|
45674857|NCT02090413|Drug|acetylsalicylic acid|enteric-coated capsule
45674858|NCT02090413|Drug|ASA-Placebo|matched placebo
45674859|NCT04702165|Device|lung resection with Lung Resection Marker Locator Kit|Nodules eligible for surgical resection using the Lung Resection Marker Locator Kit
45674860|NCT02063737|Behavioral|Text-message assessments only|Text message assessments only. No intervention for high level fatigue.
45674861|NCT02063737|Behavioral|Text-message interventions for high level fatigue|Intervention messages to promote alertness while on duty at work including activities. Additionally at the end of the shift, participants were queried on their adoption of the suggested activities and perception of the activities' effectiveness.
45995409|NCT04684680|Dietary Supplement|zamzam water|will receive the normal need of daily requirement of water (2.5 liter) in form of zamzam water till patients deliver or till term
45995410|NCT04684680|Dietary Supplement|tap water|will receive the normal need of daily requirement of water (2.5 liter) in form of tap water
46085103|NCT02660151|Drug|Salt solution|
46085104|NCT00956449|Biological|Seasonal Influenza Vaccine|1 dose of Influenza Vaccine Surface Antigen, Inactivated
46085105|NCT00637026|Drug|Gefitinib|Iressa
45995411|NCT03718403|Drug|Theophylline|Theophylline will be given to maintain a peak level between 10-15 mcg/mL
45995412|NCT00545259|Drug|AEB071|
45995413|NCT00537966|Drug|Dolutegravir|In this arm patients with primary HIV-1 infection are treated with standard antiretroviral combination therapy (only drugs that have been approved by Swiss Medic)
45995414|NCT00537966|Drug|Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamid Fumarate|standard dosage
45995415|NCT00537966|Drug|Raltegravir|standard dosage
45995416|NCT00537966|Drug|Darunavir|standard dosage
45995417|NCT00537966|Drug|Ritonavir|used only as booster for the protease inhibitors that are prescribed in this study according to standard boosting
45995418|NCT00537966|Drug|Rilpivirine|standard dosage
45995419|NCT00537966|Drug|Lamivudine|standard dosage
45995420|NCT00537966|Drug|tenofovir|standard dosage
45834376|NCT04124016|Dietary Supplement|grape seed|Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol monomers) dissolved into 200 ml of water
45457236|NCT01225627|Other|Coordinated discharge|In intervention group, a discharge coordinator contacts hospitalized patients the day after randomization. During hospitalization, discharge coordinator visits are scheduled according to patients' problems and home-care needs. At 48 hours after hospital discharge, a discharge coordinator calls patients by phone to check the process of adjustment to home environment and to inquire about additional needs patients might have. Thereafter, phone contacts are scheduled according to the patients' needs and 7-10 days after the hospital discharge a home visit is performed by discharge coordinator, respectively.
46085106|NCT02768012|Behavioral|mindfulness-based cognitive therapy|Six two-hour small group sessions (6-9 participants) will be administered over 8 weeks focusing on MBCT. The intervention follows a written protocol to ensure fidelity of delivery. Participants will receive detailed manuals summarizing session content and home assignments (HAs), including mindfulness practices, audio versions of which will be available on an internet link.
45995421|NCT00537966|Drug|Emtricitabine|standard dosage
45995422|NCT00537966|Drug|Abacavir|standard dosage
45995423|NCT03682523|Behavioral|Sedentary behavior reduction intervention|Participants will be provided with a device to measure physical activity and sedentary behaviours. A tablet will be in the research office and each afternoon, it will be synced to the device to assess the activity progress of the patient. The research team will deliver an upright time goal and will target a 20% increase in upright time from the previous hospital day. Physiotherapist research assistants will visit the participants every afternoon to monitor progress and safely mobilize participants to their maximum ability if they have not met their daily goal (including weekend). The maximum level of ability will be determined in consultation with the healthcare team. Participants who do not meet their goal will be mobilized in the late afternoon/ early evening.
45995424|NCT03456492|Diagnostic Test|serum sodium|Serum sodium will be measured on admission, assesment of mental status by Modified Mini-Mental score and measurement of glutamate in CSF sample taken while dripling during spinal anathesia for surgical intervention.
45995425|NCT01266967|Drug|GSK2118436|Subjects in this study receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
46085107|NCT00649155|Drug|Ciprofloxacin Extended-Release Tablets 500 mg|500mg, single dose fasting
46085108|NCT00649155|Drug|Cipro® XR Tablets (500 mg|500mg, single dose fasting
45457237|NCT01225627|Other|Control|Patients in control group will be managed by attending physician, primary care physician, and/or pneumologist in accordance with established clinical practice.
46085109|NCT00956527|Behavioral|Modified traditional martial arts training|"Twice weekly hour-long training sessions. Classes will not vary significantly from those classes already taught at the karate school, with the following exceptions: 1) the focus of training will be primarily on the non-combative components of martial arts training, 2) there will be a higher instructor to student ratio, 3) belt advancement will be based not only on mastery of karate techniques, but also on achieving the predetermined goals as described above, and 4) weekly 5-10 minute talks will be delivered by the primary instructor and will consist of concepts relevant to substance abuse treatment (including both issues directly relating to drug use and the common skills deficits seen in at risk youth) and how these issues relate to martial arts concepts."
46085110|NCT02758340|Drug|Misoprostol|Women would be given misoprostol tablet by mouth
45457238|NCT03515980|Drug|BMS-986231|Intravenous (IV) administration
45457239|NCT01132417|Drug|In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance|studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
45457240|NCT01355822|Drug|PETN|Pentaerythrithyltetranitrate: 80 mg orally twice a day
45457241|NCT01355822|Drug|Placebo control|orally, twice daily
45457242|NCT04465474|Other|Non Intervention|It's an observational study, no intervention involves.
45457243|NCT03922399|Procedure|Laser and Surgery|Laser and Surgery in patients with major burn scars Evaluating after three years treatment
45834377|NCT04124016|Dietary Supplement|grape seed extract|Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol oligomers) dissolved into 200 ml of water
45834378|NCT04124094|Drug|Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals)|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
45834379|NCT04124094|Drug|Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK)|2 inhalations in one study period
45834380|NCT04124094|Other|Activated Charcoal suspension|oral suspension before and after inhalation of study Investigational Products
45834381|NCT05604612|Procedure|Corticision|Incisions in the cortical plate of maxillary bone
45995426|NCT03628703|Device|Repetitive TMS|Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation over the right Pre-supplementary Motor Area
45995427|NCT05154318|Procedure|Pericapsular Nerve Group Block|Nerve block targeting major hip joint sensory nerves.
45995428|NCT05154318|Procedure|Fascia iliaca compartment block|Routine nerve block for hip fracture surgery.
46085111|NCT02758340|Device|foley's balloon catheter|foley's balloon catheter would be inserted through vagina into cervix.
45995429|NCT03615326|Biological|Pembrolizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion.
45995430|NCT03615326|Biological|Placebo|Solution for IV infusion on Day 1 of each 3-week cycle.
45995431|NCT03615326|Drug|Cisplatin|80 mg/m^2 on Day 1 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen.
45995432|NCT03615326|Drug|5-FU|800 mg/m^2/day continuous on Days 1-5 of each 3-week cycle (120 hours or per local standard), administered as part of FP chemotherapy regimen.
45995433|NCT03615326|Drug|Oxaliplatin|130 mg/m^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of CAPOX chemotherapy regimen and as part of SOX chemotherapy regimen.
45995434|NCT03615326|Drug|Capecitabine|1000 mg/m^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of CAPOX chemotherapy regimen.
45995435|NCT03615326|Drug|S-1|Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): <1.25 m^2 BSA =40 mg, 1.25 to <1.5 m^2 BSA=50 mg, ≥1.5 m^2 BSA=60 mg. Administered as part of SOX chemotherapy regimen.
45995436|NCT03615326|Biological|Trastuzumab|8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.
45834382|NCT03343236|Radiation|Radiotherapy|All patients will undergo radiotherapy or surgery, or combined modality treatment
45995437|NCT03456414|Other|Virtual reality exercise during hemodialysis|Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis treatment
45995438|NCT00538005|Biological|bevacizumab|
45995439|NCT00538005|Drug|oxaliplatin|
45995440|NCT00538005|Drug|sorafenib tosylate|
45995441|NCT03610412|Other|Cinnamomum Cassia|The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and the main effect sought is on IGF1 levels, in addition to metabolic control.
45995442|NCT03610412|Other|Placebo (calcined magnesia)|The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and comparison with placebo. The main effect sought is on IGF1 levels, in addition to metabolic control.
45995443|NCT00538044|Drug|simvastatin|medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation
45995444|NCT03504956|Device|Cardiac MRI|MRI with/without administration of a contrast agent and beta-blocker based upon the stage of method development, if no contraindications are present.
45457244|NCT01355900|Procedure|Total knee arthroplasty performed under tourniquet|Comparison of the different tourniquet tactics.
45674862|NCT02125877|Drug|Deferasirox dispersible tablet|Deferasirox DT was provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use.
45674863|NCT02125877|Drug|Defearisox film-coated tablet|Deferasirox FCT was provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
45674864|NCT01598987|Drug|Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.|Immunosuppression after liver transplantation. Pediatric transplant recipients received a starting dose of 0.8 mg/m^2/dose in combination wit Cyclosporine A or 2.0 mg/m^2/dose in combination with tacrolimus, twice-daily. Thereafter, doses were adjusted to achieve everolimus C-0h blood trough level between 3 to 8 ng/ml.
45834383|NCT03033576|Biological|Ipilimumab|Given IV
45834384|NCT03033576|Biological|Nivolumab|Given IV
45995445|NCT03504956|Drug|Contrast|The intravenous gadolinium based contrast agent to be used in this study is Gadavist (up to 0.2 mmol/kg).
45674865|NCT02063659|Drug|Telotristat etiprate|Telotristat etiprate tablets
45674866|NCT02063659|Drug|Placebo|Placebo-matching telotristat etiprate tablets
45674867|NCT02062879|Drug|Ketamine|Ketamine administered as patient-controlled analgesia.
45834385|NCT05604378|Procedure|Gastrectomy|All patients in our study underwent gastrectomy.
45995446|NCT03504956|Drug|Beta blocker|Based upon the focus of the study at the time of the scan, a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the heart rate. The slower heart rate may improve image quality and lessen motion artifact.
45995447|NCT00538083|Other|Chocolate|74 grams of single dose solid dark chocolate versus placebo
45834386|NCT04123782|Device|F-ESW Treatment|The biological principles on which is based Focused Shockwave Treatment (F-ESWT) is has been demonstrated mostly in terms of improvement of Platelet Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), Insulin Growth Factor-1 (IGF-1) and Transforming Growth Factor b1 (TGF-b1).
45995448|NCT00538083|Other|Chocolate|22 grams of single dose sugared cocoa, sugar-free cocoa, and placebo
45995449|NCT00538083|Other|Chocolate|22 grams of sugared cocoa, sugar-free cocoa, & placebo given for six weeks
45995450|NCT00545337|Drug|Insuline glulisine|
45834387|NCT04123782|Device|Placebo F-ESW Treatment|Very low concentration of F-ESW.
45995451|NCT01266850|Biological|Rotarix®|Each 1-mL dose of Rotarix® contains a suspension of at least 10^6 median Cell Culture Infective Dose (CCID50) of live, attenuated human G1P rotavirus after reconstitution. The lyophilized vaccine contains amino acids, dextran, Dulbecco's Modified Eagle Medium (DMEM), sorbitol, and sucrose. The liquid diluent contains calcium carbonate, sterile water, and xanthan. The diluent includes an antacid component (calcium carbonate) to protect the vaccine during passage through the acid environment of the stomach. Rotarix® contains no preservatives. Once reconstituted, the vaccine will appear white and turbid.
46085112|NCT00614952|Device|PSG (polysomnography)|POLYSOMNOGRAPHY
46085113|NCT00614952|Other|PR (respiratory polygraphy)|respiratory polygraphy: level III of AASM
45457245|NCT01131481|Device|Intraocular lens|
45674868|NCT02062879|Drug|Hydromorphone|Hydromorphone administered as patient-controlled analgesia.
45674869|NCT02062645|Drug|amlodipine/valsartan|Fixed combination of amlodipine and valsartan in tablet; 5/160/mg, 10/160 mg
45995452|NCT01266850|Biological|RotaTeq®|2-mL ready-to-use oral solution of live reassortant rotaviruses, containing G1, G2, G3, G4, and P1A, which contains a minimum of 2.0 to 2.8 x 10^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10^6 IU per aggregate dose. The buffered stabilizer solution contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq® contains no preservatives. RotaTeq® is a pale yellow clear liquid that may have a pink tint.
45995453|NCT00538122|Device|24 Holter Monitor Recording|"All subjects will be fitted with a device to obtain 24-hour Holter EKG continuous recordings of bipolar leads C5C5R. They will also receive a standard 12-lead EKG recording prior to the placement of the Holter device. The subjects will be asked to keep a diary during the course of the 24 hours to record information such as wake and sleep times and symptoms such as shortness of breath, heart palpitations, lightheadedness, etc.~From each recording, 12 sets of 10 consecutive QRS epochs, plus QRS samplings obtained during sleep will be analyzed by a cardiologist blind to the medication status of subjects."
45995454|NCT03431480|Biological|Autologous Human Placental Cord Blood Mononuclear Cells|Autologous human placental cord blood mononuclear cells are infused into the coronary artery during the Norwood heart operation
45995455|NCT00545376|Procedure|Osteopathic Manipulative Treatment - in clinic|I will do a thoracic/rib screening and treatment with muscle energy or facilitated positional release, a diaphragm soft tissue release, suboccipital release, and a thoracic compression. This treatment takes 10 minutes and is only done at the first visit.
45995456|NCT00545376|Procedure|Osteopathic Manipulative Treatment - at home|One group will learn how to do three home OMT techniques: suboccipital release, pectoral traction, and rib raising. They will be asked to do this at least 4 times a week for two weeks.
45995457|NCT00545376|Other|Education to physicians|I will educate physicians using demonstration and reading material as to the possible benefits of incorporating it into the treatment of asthma.
45995458|NCT00538161|Other|Ventilation strategy|
45995459|NCT00545415|Dietary Supplement|Order 1|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
45995460|NCT00545415|Dietary Supplement|Order 2|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
45995461|NCT00545415|Dietary Supplement|Order 3|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
45457246|NCT03513016|Drug|UBX0101|Investigational drug intra-articular injection
46085114|NCT00956605|Behavioral|Computer attention training systems for children with ADHD|Computer attention training systems for children with ADHD, one with and one without EEG-biofeedback, were delivered via approximately 20 sessions to the participants
46085115|NCT02659995|Other|No intervention|No interventions will be performed on these patients.
46085116|NCT02768168|Drug|dezocine|receive dezocine 0.1 mg/kg
45674870|NCT04700839|Drug|SGLT2 inhibitors|Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.
45457247|NCT03513016|Other|Placebo|Diluent intra-articular injection
45674871|NCT04700839|Drug|Metformin|Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
45674872|NCT02088697|Drug|Placebo|
45674873|NCT02088697|Drug|ASC-01|
45674874|NCT01825785|Drug|Romosozumab|Administered by subcutaneous injection
45674875|NCT01825785|Drug|Placebo|Administered by subcutaneous injection
45674876|NCT02043301|Biological|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the abdomen
45674877|NCT02043301|Biological|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the upper arm
45834388|NCT04123548|Biological|StrataGraft skin tissue|StrataGraft skin tissue is delivered as a single topical application to no more than 3 separate burn sites, totaling up to approximately 1000 cm^2 of treatment area using no more than 10 tissues.
45457248|NCT02347202|Other|Online counseling via Zoom teleconferencing|
45834389|NCT03001362|Radiation|Radical external beam radiotherapy|pelvic radiotherapy to a dose of 45 Gy in 25 fractions with a tumor boost to a dose of 9 Gy in 5 fractions (thus total of 54 Gy/30 fractions to the primary tumor), combined with radio sensitizing chemotherapy.
45834390|NCT04275024|Drug|Calcipotriol ointment|The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
45834391|NCT04275024|Drug|PSORI-CM01 Granule|PSORI-CM01#YXBCM01# granule 5.5g os once a day for 12weeks.
45457249|NCT02347202|Other|Telephone support as needed|
45674878|NCT02043301|Biological|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the thigh
45674879|NCT01598753|Drug|Tramadol|"50 mg tablets titrated up to 2 tablets four times per day for a maximum dose of 400mg per day.~Minimum accepted dose of 200mg per day"
45674880|NCT01598753|Drug|Placebo|Pharmacological inactive tablet, 50mg tablets titrated to 2 tabs per day up to 400mg
45674881|NCT01598753|Behavioral|Cognitive Behavior Therapy for FM|Subjects will be seen for 8 weekly 50 minute sessions of Cognitive Behavior Therapy that has been specifically tailored for Fibromyalgia patients.
45995462|NCT00545415|Dietary Supplement|Order 4|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
45995463|NCT00545415|Dietary Supplement|Order 5|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
45674882|NCT01598753|Behavioral|Health Education|Subjects will receive 8 weekly 50 minute sessions of Health Education on Fibromyalgia
45995464|NCT00545415|Dietary Supplement|Order 6|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
45995465|NCT03397667|Other|ABC ANSWERS|Primary Care plus ABC ANSWERS
45995466|NCT03397667|Other|Control|Primary Care as usual
45995467|NCT00545493|Drug|Tacrolimus|tacrolimus capsules, dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter
45995468|NCT00545493|Drug|i.v. immunoglobulins|infusions, dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months).
45995469|NCT01266460|Biological|Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001|Given IV
45995470|NCT01266460|Other|Laboratory Biomarker Analysis|Correlative studies
45995471|NCT05120739|Drug|2% CHX cloths|skin preparation in 2% CHX cloths
45995472|NCT03373916|Behavioral|Peer mentorship|The peer mentor will meet with the participant for the first time while the participant is still in the hospital. Sessions will be scheduled according to the participant's preferences, with a suggested maximum frequency of twice weekly for the first two weeks, weekly for weeks 3 to 8, and then every other week for the last month. Allowable meeting locations include public places in the community (e.g., coffee shop, park), the participant's home, or a research clinic space or by phone. Session content is flexible and allows for the peer mentor to provide general supportive listening, validation, and sharing. Session duration is on average 1 hour with at least 15 minutes discussing hope or belongingness according to semi-structured conversation guides. The session structure and content are intentionally highly flexible to allow for genuineness in the peer relationship, thereby increasing acceptability and implicit belongingness.
45995473|NCT03373916|Behavioral|Enhanced Usual Care|"The EUC condition will consist of a caring message from the study team via e-mail or text message (based on the participant's preference) 24-72 hours after discharge. An example message is, We hope things are going well for you since you left the hospital. If you wish to reply, we'd be glad to hear from you. A list of local mental health resources will be available if participants reply and during the 3 and 6-month follow-up assessments. The EUC condition is modeled on prior studies of caring letters and brief contacts by health professionals after suicidal crisis and national recommendations to provide post-crisis follow-up contacts."
45995474|NCT05119257|Biological|Bispecific antibodies (bsAB)|BsAbs equipped with a target-specificity directed to a TAA and an effector-specificity for an activating receptor on T cells, such as CD3 or CD28, are applied intravenously in repeated cycles until disease progression or dose limiting toxicity.
45995475|NCT01266265|Drug|inhaled prostacyclin|Tyvaso
45995476|NCT01266265|Drug|inhaled prostacyclin|As prescribed by the physician
45674883|NCT02177123|Device|InnFocus MicroShunt implantation|Implantation will include the use of Mitomycin C applied with sponges.
45834392|NCT04275024|Biological|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg
45834393|NCT03831438|Drug|AVID200|Intravenous infusion of AVID200 Q2 weeks for 3 doses
45995477|NCT01266265|Drug|prostacyclin|As prescribed by the physician
46085117|NCT02768168|Other|normal saline|receive matching placebo (equal volume of normal saline)
46085118|NCT02660073|Device|NMES+FES|12 weeks of electrically evoked resistance training followed by 12 weeks of functional electrical stimulation cycling.
46085119|NCT02660073|Device|Control+FES|12 weeks of passive movement followed by 12 weeks of functional electrical stimulation cycling.
46085120|NCT00956683|Procedure|Ultrasound Guided Infraclavicular Nerve Block|Use of Ultrasound to help guide needle placement and local anesthetic injection during infraclavicular nerve block.
45674884|NCT01824693|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
45834394|NCT04123392|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
45834395|NCT04123392|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
45834396|NCT04123392|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
45834397|NCT04393038|Drug|ABX464|ABX464 50mg QD for 28 days + Standard of Care
45834398|NCT04393038|Drug|Placebo|Placebo 50mg QD for 28 days + Standard of Care
45834399|NCT03030924|Device|Solace|Noninvasive physiologic monitor
45674885|NCT01824693|Drug|Busulfan|Given IV
45674886|NCT01824693|Drug|Cyclophosphamide|Given IV
45674887|NCT01824693|Drug|Fludarabine Phosphate|Given IV
45674888|NCT01824693|Other|Laboratory Biomarker Analysis|Correlative studies
45674889|NCT01824693|Drug|Melphalan|Given IV
45674890|NCT01824693|Drug|Mycophenolate Mofetil|Given IV or PO
45674891|NCT01824693|Other|Pharmacological Study|Correlative studies
45674892|NCT01824693|Drug|Tacrolimus|Given IV or PO
45834400|NCT05601258|Other|Age, gender, hospitalization and mortality rates will be compared|Age, gender, hospitalization and mortality rates will be compared
45834401|NCT05601180|Other|Respicure®|Respicure® is an inhalation solution that contains two natural extracts: quercetin and resveratrol in a concentration of 0.38%/0.38%.
45834402|NCT05601180|Other|Standard of care|standard treatment is prescribed by the treating physician.
45995478|NCT01266265|Drug|subcutaneous and intravenous prostacyclin|As prescribed by physician
45995479|NCT01266265|Drug|oral ERA|As prescribed by physician
45995480|NCT01266265|Drug|oral PDE5 inhibitors|As prescribed by physician
45995481|NCT03338387|Drug|Acipimox|Acipimox
46085121|NCT00956683|Procedure|Dual-Endpoint nerve stimulation|Use of dual-endpoint nerve stimulation to guide needle placement and local anesthetic injection during infraclavicular nerve block.
45995482|NCT03338387|Drug|Placebo|Placebo Other Names: Placebo (for Olbetam)
45995483|NCT05112549|Drug|Nivolumab [Opdivo]|Nivolumab (OPDIVO®) is a marketed pharmaceuticals material authorized in the European Union. This study uses an off-label route of administration of nivolumab. Subjects with leptomeningeal disease in solid tumours with an approved indication for intravenous treatment with the PD1 antibody will receive an intrathecal application of nivolumab. A total of six i.th. applications will be performed every 14 days. The intrathecal administration will be performed via an Ommaya reservoir or another intraventricular catheter.
45995484|NCT00538200|Dietary Supplement|Oral Nutritional Supplements (Fortisip)|These products are classified as non-medicinal, borderline substances, foods for special medical purposes. A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 3 month period.
45995485|NCT00538200|Other|Dietary Advice|Standard dietary advice
45457250|NCT03928717|Behavioral|Text-Based Adherence Game|A mobile health intervention facilitated by a cloud-hosted web application and designed to promote adherence to HIV care through text message-delivered gamification strategies including peer comparison, point reinforcement, feedback on adherence outcomes, facilitation of social support, and use of an engaging and culturally-relevant story-line.
45995486|NCT00545649|Behavioral|Exercise and education|
45995487|NCT00545649|Behavioral|Education|
45995488|NCT03268382|Drug|APR-246|Intravenous infusion
45995489|NCT03268382|Drug|Pegylated Liposomal Doxorubicin Hydrochloride (PLD)|Intravenous infusion
46085122|NCT03739554|Drug|CYC065|intravenous infusion
45674893|NCT02176655|Drug|VVD-101|All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
45674894|NCT02176655|Drug|Placebo|All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
45674895|NCT02125331|Procedure|Device: Blood pressure monitoring with GE Healthcare CARESCAPE B650 Patient Monitor-Patient Side Module (PSM) or Patient Data Module (PDM)|3-15 Non-Invasive Blood Pressure readings on the CARESCAPE B650 Patient Monitor equipped with PSM-Datex-Ohmeda and PDM-SuperSTAT NIBP measurement devices during non-emergent heart catheterization
45674896|NCT01622569|Drug|Fluticasone Propionate|Delivered via Optinose Exhalation Delivery System
45674897|NCT01824303|Drug|LiRIS 400 mg|LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.
45834403|NCT05607966|Device|ORIGIN® CR devices|It is planned to include consecutive eligible subjects which will be treated with the ORIGIN® CR devices.
45674898|NCT01824303|Other|LiRIS Placebo|LiRIS Placebo contains lactose, inactive substance.
45674899|NCT01853397|Device|Liposonix System (Model 2)|
45995490|NCT01266148|Drug|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
45995491|NCT01266148|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
45995492|NCT01266148|Drug|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
45995493|NCT01266148|Drug|Everolimus|Everolimus 0.75 mg twice a day as starting dose up to a target blood level: 3-6 ng/mL (7-11 weeks) and 6-10 ng/mL for remaining of study
46085123|NCT03739554|Drug|Venetoclax|oral capsule
46085124|NCT02758418|Other|TAO|"TAO is a self-applied online treatment program and consists on the computerized version of the traditional CBT protocol for Adjustment Disorders.~The treatment protocol comprises different therapeutic components (see section Intervention) which are presented to the patients through 7 modules (one of them introductory). The Internet platform allows audiovisual resources (videos, illustrations, music and exercises that provide quick feedback) to be included, that makes the program more interactive."
46085125|NCT00956917|Device|Akern USA EFG|Impedance measurement device
46085126|NCT00956917|Device|RJL Impedance analyzer|Impedance analyzer
45674900|NCT02088073|Drug|Sodium zirconium cyclosilicate|Sodium zirconium cyclosilicate
45674901|NCT02088073|Drug|Placebo|Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)
45834404|NCT04760262|Drug|Sevoflurane|Sevoflurane %2-3 for general anesthesia maintenance, BIS values were arranged 40-60 until the end of operation, In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
45834405|NCT04760262|Drug|Propofol|BIS values were arranged 40-60 until the end of operation, In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
45995494|NCT01266148|Drug|Anti Thymocyte Globulin|Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.
45995495|NCT00538239|Drug|ridaforolimus|Four 10 mg tablets taken by mouth for 5 days per week continuously
45995496|NCT00538239|Drug|Placebo|Four 10 mg tablets taken by mouth for 5 days per week continuously
45995497|NCT03263897|Device|insufflation|mobile interface driven insufflation of the ear canal
45995498|NCT03263897|Device|placebo insufflation|mobile interface driven placebo insufflation of the ear canal
45995499|NCT00545727|Behavioral|Diet|Whole-foods, low glycemic index diet
45995500|NCT00545727|Other|Standard diet|Standard diet meeting American Diabetes Association guidelines
45995501|NCT01266070|Drug|Dovitinib|500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle (i.e. 5 days on, 2 days off schedule).
45995502|NCT03263351|Behavioral|Cognitive-behavioral therapy group|Psychoeducation on depression; cognitive restructuring of negative thoughts; engagement in pleasant activities; healthy rewards; stress and coping.
45995503|NCT03263351|Behavioral|Health education group|Didactic health knowledge about interpersonal violence; basic nutrition guidance; sun safety; depression and signs of suicide; gang violence; substance use.
45995504|NCT00538278|Other|Database|database
46085127|NCT02659683|Drug|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
45995505|NCT03261050|Behavioral|Counter Attitudinal Therapy|8 weekly 60 minute sessions of dissonance-based treatment wherein women with any eating disorder complete verbal, written, and behavioral activities.
45995506|NCT03261050|Behavioral|Interpersonal Therapy|8 weekly 60 minute sessions of interpersonal-based treatment wherein women with an eating disorder complete verbal, written, and behavioral activities.
45995507|NCT00538317|Drug|tirofiban|bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
45995508|NCT00538317|Drug|tirofiban|bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
45995509|NCT03228563|Other|Probioics|CKD Patients were supplemented with two capsules of probiotics containing 2.5*10^9 CFU Lactobacillus acidophilus (TYCA06), Bifidobacterium longum (BLI-02) and Bifidobacterium bifidum (VDD088) twice daily for 12 months.
45995510|NCT01265953|Drug|SFN-rich broccoli sprout extract capsules|Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of SFN, 2 capsules (1 capsule B.I.D.) daily
45995511|NCT01265953|Dietary Supplement|Gelatin capsule containing microcrystalline cellulose.|Four weeks placebo capsules: 2 capsules (1 capsule B.I.D.) daily
45674902|NCT01823991|Drug|VitaBlue™|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
45995512|NCT01265875|Drug|Human Secretin|Dose Escalation
45995513|NCT00545805|Procedure|Roux-en-Y Gastric Bypass plus total omentectomy|Roux-en-Y Gastric Bypass plus total omentectomy
45995514|NCT00545805|Procedure|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass without omentectomy
46085128|NCT02659683|Drug|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
46085129|NCT05343780|Drug|Heptex|Dukung Anak 200 mg + Milk thistle 100 mg
46085130|NCT05343780|Other|Rice bran|Placebo
46085131|NCT02758262|Device|Noninvasive brain stimulation|
46085132|NCT00957073|Device|Rheos® system|Implant procedure
46085133|NCT02659839|Other|Cancer patients admitted to the ICU|There will be no change in the standard ICU treatment.
46085134|NCT04701476|Drug|TATE and pembrolizumab|All liver metastatic lesions will be treated with TATE for maximally debulking. Pembrolizumab IV infusion per standard schedule every 3 or 6 weeks until progression or maximally 2 years.
46085135|NCT04701476|Drug|TAS-102 pill|The comparator of the mCRC arm is TAS-102 at 60 mg BID 5 days per week for 2 weeks then 2 weeks off.
46085136|NCT04701476|Drug|Regorafenib Pill|As an alternative to TAS-102 per treating physician's discretion. If selected, Regorafenib 160 mg oral daily for 3 weeks on and one week off, every 4 weeks per cycle. Do not take Regoarefnib if taking TAS-102.
45674903|NCT01823991|Other|Placebo|"Self administration of placebo for 3 months.~Investigators use a placebo to make sure that it really is the study medicine that is making a difference in the participant's condition. It does not have anything in it that would normally help or harm most people."
45674904|NCT01823991|Drug|Lovaza®|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
45995515|NCT01265797|Device|Cranial Electrostimulator|participant wears active cranial electrostimulation device for 20 minutes daily for 28 days
45995516|NCT01265797|Device|Sham Device|participant wears sham device for 20 minutes daily for 28 days
45995517|NCT00538356|Device|ICD or CRT-D with Home Monitoring feature deactivated|Standard care
45457251|NCT03928717|Behavioral|Standard of Care (SOC)|A 10- to 20-minute in-person intervention led by a trained HIV treatment adherence counselor focused on providing basic knowledge of HIV and HIV treatment, motivating participants to engage in HIV treatment, and problem-solving barriers to adherence.
45995518|NCT00538356|Device|ICD or CRT-D with Home Monitoring feature activated|Standard care + patient management by Home Monitoring
45995519|NCT01265719|Other|No intervention other than routine medical care|Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.
45995520|NCT01265719|Other|No intervention other than routine medical care|Subjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period.
45995521|NCT03148496|Device|Biologic Mesh|Biologic mesh placed during surgery
45995522|NCT03148496|Procedure|Small Bites|0.5 cm x 0.5 cm sutures used
45995523|NCT03148496|Procedure|Large Bites|1.0 x 1.0 sutures used
45995524|NCT03123731|Behavioral|Control Arm|Wearing Physical Activity Monitor
45995525|NCT03123731|Behavioral|iSTEP|Physical Activity Intervention
45995526|NCT03123731|Behavioral|iSTEP|Physical Activity and Diet Intervention
45995527|NCT00538395|Drug|Adriamycin, Taxol and Cytoxan|Chemotherapy
45995528|NCT01265563|Drug|N-acetylcysteine placebo and silibin placebo|Dietary Supplement: N-acetylcysteine placebo excipient and silibin placebo orally twice daily for three months
45995529|NCT01265563|Drug|N-acetylcysteine active and silibin placebo|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin placebo orally twice a day for three months
45995530|NCT01265563|Drug|N-acetylcysteine placebo and silibin active|Dietary Supplement: silibin 480 mg orally twice daily and N-acetylcysteine placebo orally twice a day for three months
45995531|NCT01265563|Drug|N-acetylcysteine active and silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 480 mg orally twice daily for three months
45995532|NCT01265563|Drug|N-acetylcysteine active + high-dose silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 960 mg orally twice daily for three months
45995533|NCT03025139|Other|Educational Intervention|Attend survivorship education
45995534|NCT03025139|Other|Laboratory Biomarker Analysis|Correlative studies
45995535|NCT03025139|Procedure|Meditation Therapy|Attend mindfulness meditation
45995536|NCT03025139|Other|Questionnaire Administration|Ancillary studies
46085137|NCT05343702|Drug|priming with rocuronium|Following induction (paralysis after onset of the induction effect) in routine rapid sequence intubation protocols While paralysis is applied, it is aimed to shorten the half-life of rocuronium by administering a subparalytic dose of rocuronium approximately 3-5 minutes before induction in the priming technique
45995537|NCT00545922|Behavioral|Cognitive behavioral therapy|Seven weekly sessions (2 hrs) in groups
46085138|NCT02659761|Drug|dolutegravir/abacavir/lamivudine|600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine single tablet taken orally, once daily, during 96 weeks
46085139|NCT00957151|Drug|Creon|
45995538|NCT00545922|Behavioral|Minimal Telephone Contact|Telephone contact (max. 10 minutes) every other week during the 7-week intervention
45995539|NCT01265056|Drug|Gabapentin|"On Study day 1: 1200mg (single dose).~Study day 2,3: 300mg TID, 900mg daily.~Study day 4-7: 600mg TID 1800mg* daily.~Study day 8-11: 800mg TID 2400mg* daily [Optional increase to 2400 if pain scores are still 4 on NRS]~Study day 11: 1200mg TID 3600mg* daily [Optional increase to 3600 if pain scores are still >4 on NRS]~* May revert back to prior dose if adverse symptoms occur and are thought to be drug related. Up titration then will be preformed in 48 hours following deexcalation."
46085140|NCT05343546|Device|Use of either copper T380A or Levonorgestrel LNG 52 IUS after medical management of first trimester incomplete abortion|"Use of either copper T380A or Levonorgestrel LNG 52 IUS after medical management of first trimester incomplete abortion within seven days of giving Misoprostol Early insertion or 2-4 weeks after Misoprostol use Standard insertion"
45995540|NCT01265056|Drug|Placebo|Sugar Pill is administered similar to the protocol used for the investigational drug.
45995541|NCT05656651|Behavioral|High intensity interval exercise training|Endurance training adapted to age, resting heart rate
46085141|NCT00953953|Device|Phillips ultrasound system|The tissue doppler imaging color images will be acquired from two, three, and four-chamber apical views to assess the longitudinal contraction of the left ventricle.
46085142|NCT02659917|Other|Glass ionomer|Application of preventive agent
45995542|NCT02942498|Drug|Vitamin C 10mg/Kg Vitamin E 10 mg/Kg|
45457252|NCT02300194|Drug|Topic Morphine|Topical application of a 0.1% morphine gel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
45457253|NCT02300194|Drug|Placebo|Topical application of a placebo hydrogel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
45457254|NCT01225705|Drug|raltegravir|Patients will be randomized 1:1 to either the experimental or the active control arm
45457255|NCT01225705|Drug|Atazanavir/ritonavir|Patients will be randomized 1:1 to either the experimental or the active control arm
45457256|NCT03512938|Procedure|Non-surgical periodontal therapy|Patients were motivated and instructed to brush with modified Bass technique and use interdental toothbrushes, dental floss. Each patient underwent quadrant scaling and root planning (SRP) under local anaesthesia over a 4-week period. Root planing (RP) was performed under local anaesthesia (2% lidocaine, epinephrine 1:100.000) and a standard curette set newly sharpened with Arkansas stone was used for each patient.
45674905|NCT04729855|Diagnostic Test|serum HOTTIP ,EIF4EBP1 and serum SNP HOTTIP rs1859168|5 ml fresh blood sample
45674906|NCT02087059|Drug|Ruxolitinib|
45995543|NCT02942498|Drug|Placebo|Placebo
45995544|NCT00545961|Drug|placebo|mixture, 0.28125 ml/kg twice a day for 7 days
45995545|NCT00545961|Drug|amoxicillin clavulanate acid|mixture 0.28125 ml / kg twice a day for 7 days
45995546|NCT02935517|Biological|AGTC-402|AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.
45995547|NCT00538551|Other|Database|Database
45995548|NCT01264939|Drug|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
45995549|NCT01264939|Drug|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
46085143|NCT02659917|Other|Glass ionomer cement|Application of preventive agent
46085144|NCT02659917|Other|-Glass ionomer-|Atraumatic Restorative Treatment
46085145|NCT02659917|Other|-Glass ionomer cement-|Atraumatic Restorative Treatment
46085146|NCT02758106|Device|Vest Airway Clearance System Model 105|HFCWO for 15 minutes then sputum suction.
46085147|NCT02758106|Device|placebo intervention|CCPT for 15 minutes then sputum suction.
46085148|NCT02659371|Dietary Supplement|Low energy diet|
46085149|NCT03736746|Behavioral|Motivational Interviewing|An investigator-led discussion about the participant's pain experience which is focused on the participant reporting of functional pain goals (FPGs)
46085150|NCT02758028|Behavioral|Brief counseling|"Peer counselling is delivered based on the queries and the needs of individual clients, according to the smoking status, dependency level and the perceived barriers of each individual with the use of motivational intervention approach.~The subjects will be followed up at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month via telephone assessing their smoking status and reinforce intervention."
46085151|NCT00954265|Drug|10000 IU urinary HCG|ovulation triggering
46085152|NCT00954265|Drug|250 mcg recombinant HCG|ovulation triggering
45674907|NCT02152631|Drug|Abemaciclib|Administered orally
45674908|NCT02152631|Drug|Erlotinib|Administered orally
45676746|NCT04686331|Diagnostic Test|Biomarkers for pneumonia|"Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of surfactant protein D, Krebs von den Lungen (KL-6), and YKL-40. Laboratory staff will be blinded to participant diagnosis and outcome. None of the biomarkers will be available to the treating physician.~Diagnostic test of surfactant protein D - will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis~Diagnostic test of KL-6: will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis~Diagnostic test of YKL-40 - will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis"
46085153|NCT02768246|Device|BVGA|The BVGA enables the direct connection of a bag valve device to a guedel, eliminating the need for a face mask during ventilation
45995550|NCT01264939|Drug|H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist|Participants were required to maintain stable doses of their pre-randomization combination therapy with an H1 antihistamine and either an H2 blocker or leukotriene receptor antagonist, or all 3 drugs in combination, throughout the 24-week treatment period and 16-week follow-up period of the 40-week study.
45995551|NCT01264939|Drug|Diphenhydramine|Participants were provided with diphenhydramine 25 mg for itch relief on an as-needed basis, up to a maximum of 3 doses within 24 hours for the duration of the 40-week study.
45995552|NCT00538668|Drug|117Lu-J591|There will be 9 groups of patients. The first group will receive 20 units of test drug and the 9th group will receive 55 units of the test drug. The exact dose of the test drug will depend upon how many patients have been included in this protocol at the time of patient enrollment. Patients will receive 20-55 units (or millicuries) of radioactivity depending upon patient specific height and weight. The assignment of each patient for a specific dose level is purely based on the sequence of recruitment basis and does not depend on the clinical status of the patient.
45995553|NCT02889367|Drug|Odalasvir 100 mg|Participants will receive odalasvir 2*50 mg tablet, orally once on Day 1.
45995554|NCT02889367|Drug|Placebo|Participants will receive odalasvir matching placebo, tablet, orally once on Day 1.
45995555|NCT02889367|Drug|Odalasvir 500 mg|Participants will receive odalasvir 10*50 mg tablet, orally once on Day 1.
46085154|NCT02768246|Device|Face Mask|Classic face mask
45995556|NCT02889367|Drug|Odalasvir (Up to maximum 1000 mg)|Participants will receive odalasvir to be decided up to maximum of 20*50 mg tablet, orally once on Day 1.
45995557|NCT02922647|Device|suprapubic catheterization|Experimental Arm: Suprapubic catheterization after rectal resection with low anastomosis for cancer in males
46085155|NCT00954343|Procedure|Extracorporeal Shock Wave|
45457257|NCT03922867|Behavioral|CBT|A web-based educational platform to deliver cognitive behavioral therapy (CBT) for insomnia
45457258|NCT04465006|Other|Hippotherapy Simulator|Patients in the hippotherapy simulator group received 30 sessions of treatment for 6 weeks, 5 days a week and 1 hour a day. 45 minutes of Neurodevelopmental treatment exercises and 15 minutes of hippotherapy simulation exercise program were applied to the participants in this group.
45995558|NCT02922647|Device|transurethral catheterization|Active comparator: Transurethral catheterization after rectal resection with low anastomosis for cancer in males
45457259|NCT04465006|Other|Conventional Exercise|Patients in the conventionnal exercise group received 30 sessions of treatment for 6 weeks, 5 days a week and 1 hour a day. 60 minutes of Neurodevelopmental treatment exercises were applied to the participants in this group.
45457260|NCT01357538|Drug|Posiformin 2 %, bibrocathol|A strip of 5 mm eye ointment applied 3 times per day to the eye lid
45457261|NCT01357538|Drug|Placebo Comparator|corresponding vehicle, eye ointment applied to the eye lid
45457262|NCT01128985|Drug|Canagliflozin 50 mg|50 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
45457263|NCT01128985|Drug|Canagliflozin 100 mg|100 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
45457264|NCT01128985|Drug|Canagliflozin 300 mg|300 mg capsule once daily for 7 consecutive days from Day 1 to Day 7.
45457265|NCT01128985|Drug|Placebo|matching canagliflozin placebo once daily for 7 consecutive days from Day 1 to Day 7
45457266|NCT03518398|Device|Intense Pulsed Light|E> Eye (E-SWIN, Paris, France) IPL machine
45676747|NCT01823835|Drug|GDC-0810|GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).
45995559|NCT05543356|Biological|Tozinameran|A single standard dose (30mcg) will be administered on day 0 of the study.
45995560|NCT05543356|Biological|Elasomeran|A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.
45995561|NCT05543356|Biological|Tozinameran|A single standard dose (30mcg) will be administered on day 0 of the study.
46085156|NCT00954343|Procedure|Extracorporeal Shock Wave|
46085157|NCT00954343|Procedure|Extracorporeal Shock Wave|
46085158|NCT00954343|Procedure|Extracorporeal Shock Wave|
46085159|NCT02659137|Other|HV measurement|Electrophysiology (EP) study during the TAVI procedure
46085160|NCT00954499|Behavioral|Tactile stimulation added to Standard care|"Parent rubs the infant's skin near the injection site just before, during and after the injection.~Fast injection technique without aspiration.~Oral sucrose 2 minutes before first injection.~Parent holds infant close."
46085161|NCT00954499|Behavioral|Standard care|"Fast injection technique without aspiration.~Oral sucrose 2 minutes before first injection.~Parent holds infant close."
45834406|NCT04127292|Behavioral|Emotional Self Awareness (ESA) Individual Feedback|Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
45995562|NCT05543356|Biological|Elasomeran|A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.
45457267|NCT03518398|Combination Product|Standard treatment|warm compression, lid scrub and non-preservative ocular lubricants
45457268|NCT01604876|Device|light therapy 30 min morning and evening, three months|"Light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) [dimensions 50.2 x 32 x 15.4 cm] equipped with 3x36W Fluorescent bulbs (Osram 954), reflectors and a diffuser screen providing 10,000 lux at 30 cm eye level distance.~therapy consists of 30 minutes light exposure in the morning and evening during 3 months."
45457269|NCT01604876|Device|light therapy 30 min morning and evening, three months|"200 lux light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) [dimensions 50.2 x 32 x 15.4 cm] To lower the intensity to 200 lux the bulbs are enwrapped with one layer of L299s neutral density filter (LEE Filters, Andover, UK).~Therapy consists of 30 minutes light exposure in the morning and evening during 3 months."
45457270|NCT03922555|Drug|ASTX727|ASTX727 is made up of the 2 study drugs cedazuridine and decitabine. Cedazuridine is believed to work by slowing down how fast decitabine is broken down by the body. Decitabine is believed to work by blocking abnormal cells or cancer cells from growing.
45457271|NCT03512860|Drug|E4/DRSP|Administered as specified in the treatment arm.
45457272|NCT03512860|Drug|VAL|Administered as specified in the treatment arm.
45834407|NCT04123002|Other|Miswak chewing sticks|Chewing stick are routinely used by this population
45834408|NCT04123236|Other|Age 0-18|Patients under 18 years of age
45834409|NCT04123236|Other|Age 18-26|Patients over18 years of age
45834410|NCT04123236|Other|Girls|Girls
45834411|NCT04123236|Other|Boys|Boys
45834412|NCT03047928|Drug|Nivolumab|Nivolumab 3 mg/kg is administered biweekly as long as there is clinical benefit.
45834413|NCT03047928|Biological|PD-L1/IDO peptide vaccine|The vaccine is administered biweekly for a total of 6 times, then every fourth week up to 47 weeks, whereupon no additional vaccinations will be given. A total of 15 vaccines will be administered. A vaccine consists of 100 μg PD-L1 long1 peptide, 100 μg IDO long peptide and 500 μl Montande as adjuvant.
45834414|NCT04122846|Behavioral|Emotional Awareness and Expression Therapy|"Very much based on Unlearn your pain by Howard Schubiner."
45834415|NCT05607810|Genetic|ADVM-022|Long term follow-up of subjects who previously received ADVM-022
45834416|NCT04126278|Drug|Barbotage|Administered as per standard of care
45834417|NCT04126278|Drug|Dexamethasone|4 mg of dexamethasone
45834418|NCT04394910|Dietary Supplement|Pomegranate Juice|
45834419|NCT04394910|Dietary Supplement|Placebo Juice|
45834420|NCT05607654|Device|active iTBS|"Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
45834421|NCT05607654|Device|sham rTMS|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
45834422|NCT04127682|Other|Antibiotic KAP questionnaire|• Self-administered questionnaire will be used and containing following Physician information (age, sex, place of work, specialty, years of experience, place of work, and post graduate studies and trainings), Practice information (number of days for outpatient's practice/week, average number of patients /day and average percentage of children with ARIs/day), Antibiotic prescription practice (using of guidelines and causes of prescribing antibiotics in acute URIs), Knowledge about antibiotic resistance and attendance of any conference or educational activities concerned with antibiotic use during the last year, Attitude as regard antibiotic prescription.
45834423|NCT05607576|Other|Uncovered CGM during radiologic procedures|Dexcom G6 CGM will not be covered during radiologic procedures.
45834424|NCT04122144|Behavioral|ENHANCED -SPS intervention|a) Enhanced VL counseling: Explanation of VL & Importance of VL suppression,assessment of adherence, counseling based on VL result and schedule for next VL testing and the role of VL and the MTCT risk; b).Standardized peer mother support: includes training of peer mothers on mandatory enhanced VL counseling during the routine peer counseling and education, follow up of mothers and continued adherence counseling and disclosure support and bi-weekly phone calls to mothers to provide VL counseling and follow up
45834425|NCT04122066|Drug|sofosbuvir \daclatsvir|study the effect of the new oral antihepatitis C drugs on the respiratory system
45834426|NCT03228264|Device|teleSLT|The teleSLT intervention consists of a daily training session with a tablet computer at the patients' home. The teleSLT application that will be used for this study was developed within a multidisciplinary team of speech and language therapists, neurologists and computer engineers that have transferred well-established SLT exercises to a tablet computer. The investigators call this application Bern Aphasia App (BAA). During the four weeks the training time with the BAA differs between the two arms. The experimental group trains for 96 minutes per day (80% of two hours) and the control group for 24 minutes per day (20% of two hours).
45834427|NCT03228264|Device|teleCT|For the cognitive training the investigators will use two custom-made versions of popular commercial casual puzzle video games: Flow Free (Big Duck Games LCC) and Bejeweled (PopCap Games). The video games are also delivered on tablet-computers. Again, during the four weeks the training time differs between the two arms. The experimental group trains for 24 minutes and the control group for 96 minutes per day.
45995563|NCT05543356|Biological|Bivalent Pfizer-BioNTech|A single standard dose (BNT162b2 15μg +BNT162b2 OMI 15μg) will be administered on day 0 of the study.
45995564|NCT05543356|Biological|Bivalent Moderna|A single standard dose (BNT162b2 15μg + BNT162b2 OMI 15μg)will be administered on day 0 of the study.
45995565|NCT05543356|Biological|Bivalent Pfizer-BioNTech|A single standard dose (BNT162b2 15μg + BNT162b2 OMI 15μg) will be administered on day 0 of the study.
45995566|NCT05543356|Biological|Bivalent Moderna|A single standard dose (BNT162b2 15μg +BNT162b2 OMI 15μg) will be administered on day 0 of the study.
45995567|NCT00546039|Drug|Genistein|Capsule, 30 mg, oral daily for 3 to 6 weeks
45457273|NCT01357694|Behavioral|psychotherapeutic contacts|psychotherapeutic contacts during inpatient hospital stay and up to 3 months outpatient appointments after discharge
45457274|NCT03923335|Other|DNA methylation detection|detecting the methylation status of colorectal cancer specimen
45995568|NCT00546039|Drug|Placebo|Capsule
45995569|NCT02916719|Device|MRI|MRI examination after the neo-adjuvant radiotherapy, but before the surgical treatment
45995570|NCT01264081|Drug|Lapatinib|500 mg PO (orally) twice a day for 28 days (1 cycle). Up to 27 cycles allowed if response seen.
45995571|NCT00538707|Behavioral|2-minute Bondet test|2-minute Bondet test
46085162|NCT04500236|Other|General anesthesia|Surgery under general anesthesia with the use of propofol
46085163|NCT04500236|Other|Hypno-analgesia|Surgery under Hypnosis session and analgesics
46085164|NCT00954577|Behavioral|Nutrition, health, and exercise education|The classroom intervention is part of the routine science curriculum and consists of 14 sessions taught by the investigators. Topics covered include the development of type 2 diabetes, nutrition education, exercise education, and overall healthy lifestyle education (both at home and in school). The intervention is offered in each year to all grades and to all students, regardless of whether or not they are enrolled in the study. The exercise intervention is optional and consists of 2-3 sessions per week of aerobic exercise (dancing) taught by pediatric trainers and offered in lieu of regular gym classes.
46085165|NCT04224506|Other|No intervention|There is no intervention for this study.
46085166|NCT02760446|Behavioral|CAM-ICU.fr|Neuropsychological testing
46085167|NCT04011319|Behavioral|group culture|Four embryos were cultured in the same droplet by a special dish.
45674909|NCT04747301|Device|Double-balloon catheter (UTAH CVX-RIPE) for cervical ripening|"Sweeping the membranes by UTAH CVX-RIPE® (Utah Medical Products, Inc, 7043 South 300 West, Midvale, Utah 84047 USA). The catheter will be inserted manually until the proximal balloon is in the cervical canal, the distal balloon should be intrauterine and in the extra-amniotic space. The intrauterine balloon is inflated with 40mL saline and retracted so that it rests against the internal oz. The proximal balloon should now be outside the external oz and is inflated with 20mL saline. If the balloons are correctly situated on both ends of the cervix, they can be inflated with up to 80mL saline each.~Cardiotocograph will be performed 30min, 2 hours after insertion and every 6 hours. The balloon is placed for a maximum of 24 hours.~If it is expelled in the first 12 hours and the patient has no contractions or still shows an unfavorable cervix, another balloon is placed for a maximum of another 24 hours.~The patients will be examined in case of extremely painful or membranes ruptured."
45834428|NCT05607264|Other|Kinsiotaping|Patients received the kinesiotaping over supraspinatus muscle and deltoid muscle, tape will be removed every three days and subjects will return back to the clinic to reapplication of tape again. Patients received the same therapeutic treatment 3 times/ week for four weeks. KT is air permeable and water resistant, allowing it to stay in place for three to five days.
45834429|NCT05607264|Other|Motion-controlled VR games|Virtual Rehab utilizes the unique characteristics of Microsoft Kinects motion technology to track and capture the movements of the patients so that patients become immersed in a 3D environment where they interact with the game. Subjects will include in a supervised virtual reality exergaming program for shoulder movements for 4 weeks, 3 days per week and 10 minutes for session.
45834430|NCT05607264|Other|Conventional treatment|patients received conventional treatment for chronic shoulder impingement syndrome only.
45834431|NCT04122300|Drug|Euphrasia Officinalis Preparation|At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of Euphrasia is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
45834432|NCT04122300|Drug|Placebo|At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of placebo is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
45834433|NCT04121910|Drug|Savolitinib|On Study Day 1 and Study Day 18, savolitinib will be administered as single dose after a high-fat, high-calorie breakfast
45834434|NCT04121910|Drug|Itraconazole|Twice daily on first day of dosing (Study Day 15) followed by once daily for 4 days (Study Day 16 - Study Day 19) administered 1 hour before any breakfast (and 1 hour before dinner on Study Day 15)
45834435|NCT04274478|Device|Auditive cueing|Based on gait measurement, auditive cueing is generated automatically to check its impact on patients with Freezing Of Gait.
45834436|NCT03830736|Combination Product|Oat Beverage 1|Oat based beverage with added different concentration of extracted oat component.
45834437|NCT03830736|Combination Product|Oat Beverage 2|Oat based beverage with added different concentration of extracted oat component.
45834438|NCT03830736|Combination Product|Oat Beverage 3|Oat based beverage with added different concentration of extracted oat component.
45834439|NCT03830736|Combination Product|Oat Beverage 4|Oat based beverage with added different concentration of extracted oat component.
46002364|NCT03416179|Drug|glasdegib|"Daily Glasdegib (100 mg, PO), beginning on Day 1 and is to continue up to 2 years post randomization.~Following consolidation therapy, glasdegib or placebo will be administered daily for up to 2 years after randomization or until they have minimal residual disease (MRD) negative disease, whichever comes first.~Daily Glasdegib (100 mg, PO) or matching placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy."
45995572|NCT02905370|Behavioral|Progressive Multi-Component (PMC)|"Participants in the Progressive Multi-component intervention group will receive 1) high intensity physical therapy, 2) protein supplement, and 3) emphasis on functionally enhanced transitions of care following discharge from post-acute setting. High intensity physical therapy will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Functionally enhanced transitions of care protocol includes a personal health record with 5 domains that are addressed in an interdisciplinary manner with the patient. Participants will receive 12 intervention visits over 60 days. Participants will also receive a home exercise program."
46085168|NCT05343312|Drug|AL (Coartem)|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21 and 28 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
46085169|NCT05343312|Drug|AS-AQ (Carsucam)|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, and 28 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
46085170|NCT05343312|Drug|DHP|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
46085171|NCT05343312|Drug|PA|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
46085172|NCT02658825|Drug|JNJ-63623872 2400 milligram (mg)|Participants will receive JNJ-63623872 2400 mg tablet orally once on Day 1 of Panel 1.
45834440|NCT03830736|Combination Product|Control product|Glucose based beverage without added test components is used as control product
45834441|NCT04393818|Behavioral|Intervention App|Participants allocated to the intervention App will receive access to a fully operational mobile phone App. The App will be used to deliver psychoeducational materials (written and audio-visual), including: emotional training (mindfulness, moral harm, skills to manage emotions), lifestyles behaviour promotion (physical activity, diet, substance abuse, sleep disorders), work environment, and social support.
45834442|NCT04393896|Behavioral|WeChat-based integrative family intervention (WIFI)|The WIFI program will include three key components: psycho-education through WeChat Official Account publications, peer-support through a WeChat chat group, and professional support through WeChat private chat and video call
45834443|NCT04129788|Drug|Bisacodyl 5 milligram|three doses taken, one per day on three consecutive days
45995573|NCT02905370|Behavioral|Usual Care (UC)|"Participants in the Usual Care group will receive standard physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 60 days. Participants will also receive a standardized home exercise program and standard nutritional education."
45995574|NCT00538746|Device|BIPAP|
45995575|NCT00538746|Device|PSV|
45995576|NCT00538746|Device|PSV + CPAP|
45995577|NCT02862431|Drug|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
46085173|NCT02658825|Drug|JNJ-63623872 3000 mg|Participants will receive JNJ-63623872 3000 mg tablet orally once on Day 1 of Panel 1.
46085174|NCT02658825|Drug|JNJ-63623872|Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.
45995578|NCT02862431|Drug|Placebo|Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
45995579|NCT05042778|Other|Auriculotherapy|A licensed acupuncturist (holder of civil liability insurance) with more than nine years of experience with this technique will apply auriculotherapy. Indwelling fixed semipermanent needles embedded in a skin-coloured adhesive tape will be used at the actives auricular points around the vagus nerve area.
45457275|NCT03919513|Device|inspiratory pressure threshold device|The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
46085175|NCT02658825|Drug|Moxifloxacin|Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.
45834444|NCT04129788|Drug|Placebo oral tablet|three doses taken, one per day on three consecutive days
46085176|NCT02658825|Drug|Placebo (Matching with JNJ-63623872 2400 mg)|Participants will receive placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1 of Panel 1.
46085177|NCT02658825|Drug|Placebo (Matching with JNJ-63623872 3000 mg)|Participants will receive placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1 of Panel 1 and 2.
46085178|NCT02658825|Drug|Placebo (Matching with JNJ-63623872 Dose)|Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.
45834445|NCT03831126|Drug|Betamethason Sodium Phosphate|First measurement: 12-36 hours after betamethasone treatment Second measurement: within five days after betamethasone treatment and two weeks Third measurement (neonatal measurement): 1-8 weeks after birh
46085179|NCT02658825|Drug|Placebo (Matching with Moxifloxacin)|Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.
46085180|NCT02760524|Behavioral|NET Intervention|Neuro-emotional Technique
46085181|NCT00954655|Genetic|mutation analysis|
46085182|NCT00954655|Genetic|polymorphism analysis|
46085183|NCT00954655|Other|laboratory biomarker analysis|
46085184|NCT05343234|Drug|Placebo|tree different placebo drugs with tree different names and scheduled will be given
46085185|NCT02760212|Device|Radial Shockwave Therapy|5 treatments in total scheduled weekly; RSWT to the painful areas will be undertaken with 500 shocks (1.5 bar, 15 Hz), then 1000 shocks (2 bar, 8 Hz), and finally 500 shocks (1.5 bar, 15 Hz) to the most painful spot within each of the 3 most painful regions as described by the participant.
46085186|NCT02760212|Other|Placebo Comparator: Group 2 - Placebo Group|5 treatments in total scheduled weekly; placebo to the painful areas will be undertaken with 2000 shocks to the most painful spot within each of the 3 most painful regions as described by the participant.
45834446|NCT05607186|Radiation|neoadjuvant long course chemoradiotherapy|neoadjuvant long course chemoradiotherapy consist of radiosensitizing 5FU or capecitabine and 50.4 Gy in 28 fractions over 5 weeks
45834447|NCT05607108|Drug|ZEN003694|ZEN003694 60mg po qd on a 5 days on/2 days off schedule in an every 21-day cycle
45995580|NCT02711969|Drug|Apatinib mesylate|1,000mg Apatinib mesylate p.o. qd
45995581|NCT00538941|Dietary Supplement|Nestlé Noir intense 40 grx2|daily intake of 40gr chocolate (Nestlé Noir intense or Nestlé Placebo Chocolate) in the morning and 40gr chocolate in the evening.
45995582|NCT00538941|Dietary Supplement|Nestlé Placebo Chocolate 40 grx2|Nestlé Placebo Chocolate 40 gr in the morning and 40gr chocolate in the evening.
45995583|NCT01263925|Drug|Alprostadil (Prostaglandin E1)|"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours."
45995584|NCT01263925|Drug|Pentoxifylline|"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets."
45995585|NCT01263925|Drug|Placebo to Pentoxifylline oral|"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets."
45995586|NCT01263925|Drug|Placebo to Alprostadil (Prostaglandin E1) intravenous|"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours."
45995587|NCT04323631|Drug|Hydroxychloroquine|Oral
45995588|NCT04323631|Other|The control group will not receive hydroxychloroquine|The control group will not receive hydroxychloroquine
45995589|NCT00546234|Drug|tiotropium|18 mcg daily via Handihaler
45995590|NCT00546234|Drug|long acting beta agonist|Turbohaler, 6 & 12 mcg
45995591|NCT01263769|Drug|Axitinib|Starting dose: 5 mg by mouth twice each day for 12 weeks.
45995592|NCT03455348|Other|catheter insertion|catheter insertion one to less than 4 four centimeters to the wrist joint (Group A) and the other, to more than four centimeters to the wrist joint. (Group B)
45995593|NCT00539019|Other|calories measured 5x following wound healing|measure REE at various time points postburn
46085187|NCT03700242|Biological|HDCV|Pharmaceutical form:Solution for injection Route of administration: Intramuscular
46085188|NCT03700242|Biological|HDCV|Pharmaceutical form:Solution for injection Route of administration: Intradermal
45834448|NCT04073784|Drug|Gemcitabine combined with Aptinib and Toripalimab|"Gemcitabine injection, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles.~Apatinib for oral administration, 250mg, once a day. Apatinib maintenance.~Toripalimab injection, 240mg, Day 1 each 21day. Toripalimab maintenance."
46085189|NCT03700242|Biological|PVRV|Pharmaceutical form:Solution for injection Route of administration: Intramuscular
46085190|NCT03700242|Biological|PVRV|Pharmaceutical form:Solution for injection Route of administration: Intradermal
46085191|NCT00649233|Drug|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg|100/50mg, single dose fed
46085192|NCT00649233|Drug|Lopressor HCT® Tablets 100/50 mg|100/50mg, single dose fed
46085193|NCT02757716|Other|Questionnaire|Every patient who undergo surgery will fill out a questionnaire containing validated scales concerning food, alcohol, nicotine, internet and exercise and drug addiction prior, 6 months and 24 months after surgery.
46085194|NCT00954811|Drug|300IU rec-LH|luteal alternate doses
46085195|NCT00954811|Drug|progesterone 600mg|luteal support
46085196|NCT02658903|Device|Oxys Catheter|The study catheter is inserted over the urethra in the bladder as a foley catheter. The study foley catheter delivers electromagnetic therapy.
46085197|NCT02658903|Device|Covidien Mona-Therm Foley catheter|The control arm catheter is inserted over the urethra in the bladder. The control catheter is a Mona-Therm catheter from Covidien.
45457276|NCT03512782|Other|CARDIOENF|The patients listed in interventional group will have access to software Cardioenf that is a app used in a device (cel phone, tablet) to monitoring signs and symptoms of the heart failure patients after discharge from hospital. In this software, their signs and symptoms will be inserted in three moments during the first 30 days after discharge. Nurses will monitor these data in the follow-up period.
45834449|NCT05606796|Drug|Latanoprost 0.005% Ophthalmic Solution|1 drop of 0.005% Latanoprost (preserved or preservative-free) would be instilled into the conjunctival sac daily for 12 weeks.
45834450|NCT04121208|Drug|JNJ-40346527|Active study drug
45834451|NCT04121208|Other|Placebo|Non-active study drug
46085198|NCT02757638|Other|Stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
46085199|NCT00954889|Drug|tamsulosin|Treatment: tamsulosin 0.2mg, 2T /day Posology: two 0.2 mg tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
46085200|NCT00954889|Drug|placebo|(tamsulosin 0.2mg + placebo)/day Posology: two tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
46085201|NCT03666000|Genetic|PBCAR0191|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
46085202|NCT03666000|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
45834452|NCT04393740|Diagnostic Test|scheimpflug imaging using pentacam|corneal tomography imaging using pentacam device (based on Scheimpflug principle )
45834453|NCT03831204|Device|biopac|"Acoustic cardiography was performed for all participants using the BIOPAC system with Student Lab software version 3.7.2. An electrocardiogram was obtained by two electrodes placed at the right upper limb and the lower left limb. Simultaneously heart sounds were recorded with a specific sensor placed at the mitral focus."
45995594|NCT02674217|Procedure|Hematopoietic stem cell transplantation|autologous transplant using non-frozen peripheral blood stem cells
45995595|NCT00539097|Dietary Supplement|Juven (Ross Products) protein supplement|Juven supplement oral x 3 weeks postop
45995596|NCT02664506|Behavioral|Word repetition after a time delay.|This is a behavioral intervention, Word repetition after a time delay. Individuals listen to words and repeat them after 5 or 10 seconds.
45995597|NCT05042037|Dietary Supplement|(Microbial cell preparation) probiotics|Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)
45995598|NCT05042037|Other|Placebo|Placebo sachet with no microbial cell preparation
45995599|NCT02664038|Behavioral|Cognitive Remediation Training|Up to 65 hours of computer based cognitive training of attention, verbal and visual memory, verbal and visual working memory, and executive functions
45995600|NCT02623439|Drug|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
45995601|NCT00546312|Device|Thoracic EXCLUDER Endoprosthesis|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
45995602|NCT02599922|Biological|rAAV2tYF-PR1.7-hCNGB3|rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
45995603|NCT00539175|Device|infrared light|pulsed infrared light will be applied to feet, ankles and popliteal fossae of patients with diabetic neuropathy
45995604|NCT00539175|Device|infrared light; placebo|patients will be exposed to the same machine used to provide pulsed infrared light, but the light emitting diodes will not be activated. All other aspects of the treatment will be the same. The patient and investigator will be blind to treatment assignment.
45995605|NCT02277353|Other|Fluid loading to evaluate fluid responsiveness|loading of hydroxyethyl starch 6ml/kg over 10-15min to all patients
45995606|NCT02577302|Device|CAN-Stim - Protect CAN-Stim System|CAN-Stim subjects will be implanted unilaterally (implantation side is up to the investigators discretion) with the CAN-Stim System. Subjects will be educated on the use of the transmitter and programmer. Therapy will be delivered for a minimum of 8 hours per day for 2 weeks. Subjects who are considered a responder at the 2-week follow-up, will continue therapy and followed for a total of 12 months.
45995607|NCT02577302|Device|SNS - InterStim® System|"Subjects randomized to SNS will have their Stage I device implanted and tested during a 2-week period. Stage I will have a tined, quadripolar lead placed in the S3 (preferred) or S4 (alternate) foramen in the standard fashion using fluoroscopic guidance and motor response. Motor responses can include a contraction of the levators (bellows response) with or without plantar flexion of the great toe. Subjects who are not demonstrating an appropriate motor response will not have the device implanted and will be exited from the study.Therapy will be delivered for a minimum of 8 hours per day for 2 weeks. Subjects who are considered a responder at the 2-week follow-up, will receive a full implant and followed for a total of 12 months."
45995608|NCT00539292|Procedure|Primary placement of a spring-loaded silo|
45995609|NCT00539292|Procedure|Primary Closure|primary closure of abdomen
45995610|NCT00539331|Drug|AZD2171|oral tablet
45995611|NCT00539331|Drug|Paclitaxel|intravenous infusion
45995612|NCT00539331|Drug|Carboplatin|intravenous injection
45995613|NCT00546468|Procedure|laparoscopy assisted distal gastrectomy|under general endotracheal anesthesia, Five laparoscopic ports are made. Lymph node dissection and ligations of vessels are done in laparoscopic field. A 5-6cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, stomach is taken out and resected. A Billroth I gastroduodenostomy using EEA stapler and GIA is performed. Abdomen is closed after hemostasis.
45995614|NCT00546468|Procedure|Open distal gastrectomy|Open distal gastrectomy is performed under general endotracheal anesthesia. A long midline incision is made. omentectomy is skipped and D2 lymph node dissection is performed. Anastomosis is done in same manner as LADG. Abdomen is closed after hemostasis
45995615|NCT02236013|Drug|Gilteritinib|Oral
45995616|NCT02236013|Drug|Idarubicin|lyophilized powder administered intravenously
45995617|NCT02236013|Drug|Cytarabine|solution administered intravenously
45995618|NCT02236013|Drug|Daunorubicin|solution administered intravenously
45995619|NCT03456999|Biological|MAU868|MAU868 infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses.
45995620|NCT03456999|Biological|Placebo|Solution containing no active excipients, infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses
45995621|NCT00539409|Procedure|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
45995622|NCT01263691|Biological|BioThrax|BioThrax
45995623|NCT01263691|Biological|AV7909 Formulation 1|AV7909 Formulation 1
46085203|NCT03666000|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
46085204|NCT05279755|Drug|prosetin|oral solution
45457277|NCT02528695|Radiation|18F-FDG PET/CT|18F-FDG PET/CT
45995624|NCT01263691|Biological|AV7909 Formulation 2|AV7909 Formulation 2
46085205|NCT05279755|Drug|placebo|oral solution
46085206|NCT02757560|Other|SFA diet|SFA versus control diet
46085207|NCT02757560|Other|MUFA diet|MUFA versus control diet
46085208|NCT02757560|Other|CARB diet|CARB versus control diet
46085209|NCT00954967|Behavioral|Lifestyle Counseling|The intervention is based on lifestyle advice, motivational interviewing and the use of medications, using the Clinical Practice Guidelines of the Catalan Institute of Health. Health professionals in the intervention group receive a training on the abovementioned techniques.
46085210|NCT02692248|Drug|Ibrutinib|Ibrutinib 560 mg daily for 14 days during induction cycles. Maintenance phase: Continuous cycles until disease progression or unacceptable toxicity (maximum of 2 years).
46085211|NCT02692248|Drug|Rituximab|Rituximab 375 mg/m2 IV day 1 during 4 cycles.
45457278|NCT02528695|Device|euglycemic clamp|euglycemic clamp
45457279|NCT02528695|Device|hypoglycemic clamp|hypoglycemic clamp
45457280|NCT03574454|Other|Machine Learning (ML)|Application of ML support algorithm to accelerate and enhance human interpretation of WB-MRI scans in patients with myeloma
45995625|NCT01263691|Biological|AV7909 Formulation 3|AV7909 Formulation 3
45995626|NCT01263691|Biological|AV7909 Formulation 4|AV7909 Formulation 4
45995627|NCT01263691|Drug|Control|Saline control
45995628|NCT02178410|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
45995629|NCT02178410|Drug|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
45995630|NCT02178410|Dietary Supplement|Fish oil placebo|Fish oil placebo
45995631|NCT02178410|Dietary Supplement|Vitamin D3 placebo|Vitamin D3 placebo
45995632|NCT00539448|Drug|insulin glargine|in combination with insulin Glulisine as bolus regimen
45995633|NCT00539448|Drug|insulin glulisine|in combination with insulin Glargine as bolus regimen
45995634|NCT02100254|Behavioral|behavioral intervention|View personal narrative informational video
45995635|NCT02100254|Behavioral|behavioral intervention|View fact-based informational video
45995636|NCT05108844|Procedure|Videocapsule endoscopy|Endoscopic drop of videocapsule in duodenum after initial negative gastroscopy
45995637|NCT05541484|Drug|SGLT2 inhibitor|See above.
45995638|NCT05541484|Device|Biosense Breath Ketone Analyzer|The hand-held device tests ketones in exhaled breath
45995639|NCT04323358|Diagnostic Test|Biometry|Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.
45995640|NCT04323358|Diagnostic Test|Keratometry|Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.
45995641|NCT05539846|Procedure|modified blood collection method|The bevel of the needle head of the blood collection needle was downward, and the needle was inserted into the skin with the bevel of the needle parallel to the skin.
45995642|NCT01808456|Biological|influenza trivalent inactive vaccine|one time IM injection of standard influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
45995643|NCT01808456|Biological|influenza trivalent inactive vaccine high dose|one time IM injection of high dose influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
45995644|NCT01781741|Combination Product|therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT)|Undergo TEMLA and SBRT
45995645|NCT01781741|Other|quality-of-life assessment|Ancillary studies
45995646|NCT01715714|Drug|Statin Recapture Therapy|Given 12h and 2h before CABG
45995647|NCT01715714|Drug|Placebo|Given 12h and 2h before CABG.
45995648|NCT01540253|Drug|PI3K inhibitor BKM120|Given PO
45995649|NCT01540253|Drug|docetaxel|Given IV
45995650|NCT01540253|Other|pharmacological study|Correlative studies
45995651|NCT01540253|Other|questionnaire administration|Ancillary studies
45995652|NCT01540253|Other|laboratory biomarker analysis|Correlative studies
45995653|NCT01497392|Drug|dovitinib lactate|Given PO
46085212|NCT02692248|Drug|Gemcitabine|Gemcitabine 1000 mg/msq IV (30-minute infusion) on day 1 or 2, 4 cycles every 14 days.
46085213|NCT02692248|Drug|Oxaliplatin|Oxaliplatin 100 mg/msq (3-hour infusion) on day 1 or 2, after Gemcitabine infusion, 4 cycles every 14 days.
45457281|NCT02296762|Drug|Sirolimus|Sirolimus tablets 2 mg
45834454|NCT03831204|Diagnostic Test|prognostic scores|Effect and GWTGHF were calculated for every patient
46085214|NCT02692248|Drug|Dexamethasone|Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3, 4 cycles every 14 days.
45457282|NCT03515902|Device|mouthguard|mouthguard
45457283|NCT03515902|Device|mouthguard with desensitizing toothpaste|mouthguard with desensitizing toothpaste containing 8% arginine with calcium carbonate
45834455|NCT05606640|Diagnostic Test|Biopsychological pain assessment|At baseline (T0) patients underwent the somatosensory pain assessment, joint structure and function assessment and filled in all questionnaires. During one month after baseline (T1) patients wore an activity tracker and filled in the Illness Perceptions Questionnaire and the International Physical Activity questionnaire. During one year after the baseline assessment (T2) patients filled in every month The Brief Pain Inventory, Illness Perceptions Questionnaire and the EQ-5D-5L quality of life questionnaire.
45834456|NCT04129710|Drug|Ibrutinib|Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.
45995654|NCT01497392|Drug|gemcitabine hydrochloride|Given IV
45995655|NCT01497392|Drug|capecitabine|Given PO
45995656|NCT01497392|Other|laboratory biomarker analysis|Correlative studies
45995657|NCT01497392|Other|enzyme-linked immunosorbent assay|Correlative studies
45995658|NCT01497392|Other|pharmacological study|Correlative studies
46085215|NCT04477772|Biological|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|Part A: including dose escalation (1mg/kg JS004; 3mg/lg JS004; 10mg/kg JS004), dose expansion (3mg/kg JS004 and 200mg JS004) and indication expansion. Part B: including dose escalation (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001), dose expansion (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001) and indication expansion.
46085216|NCT04477772|Biological|Drug：JS001, Intravenous infusion|Part B: including dose escalation (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001), dose expansion (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001) and indication expansion.
45457284|NCT01132573|Drug|entinostat|Given PO
45457285|NCT01132573|Drug|clofarabine|Given IV
45457286|NCT01132573|Other|pharmacological study|Correlative studies
45995659|NCT01349582|Procedure|flow diversion|endovascular treatment with flow diversion including standard management of thrombo-embolic risk
45995660|NCT01349582|Other|conservative management|conservative management is watchful observation of the aneurysm until indication for intervention arises
45995661|NCT01349582|Procedure|endovascular coiling|standard endovascular coiling of aneurysm with any type of already approved coil. High porosity stents may be used as an adjunct technique to coiling
45995662|NCT01349582|Procedure|balloon parent vessel occlusion|sacrifice of parent artery of aneurysm by endovascular balloon occlusion with or without bypass
45995663|NCT01349582|Procedure|surgical clipping|clipping of the aneurysm following invasive brain surgery
45995664|NCT01310192|Device|Fluourine-18 Fluoromethylcholine PET/CT Imaging|Single-dose Study
45995665|NCT01129544|Biological|Gene transfer|Three procedures: 1) Bone marrow harvest from the patient's posterior iliac crests. 2.) Chemotherapy conditioning with Busulfan 3)One time infusion of patient's transduced bone marrow cells.
45995666|NCT05106855|Radiation|Low Laser Radiation|One group will receive laser application to check if there is acceleration of healing.
45995667|NCT05106855|Other|Changing the implant surface|Changing the treatment surface of the dental implant to see if osseointegration occurs more quickly.
45995668|NCT05106855|Radiation|Low Laser Radiation off|This group will receive laser application off.
45995669|NCT05106855|Procedure|Implant placement immediately after tooth extraction|When the last alternative is tooth extraction, this will be done, and in the same surgical intervention the dental implant will be placed.
45995670|NCT05106855|Procedure|Installing the dental crown with early loading|The installation of the dental crowns will be performed in a period of 6 to 8 weeks, after the dental implant has been installed.
45995671|NCT00539565|Drug|prednisolone|"2 mg/kg /day from post-op day 7 - day 21~1 mg/kg /day from post-op day 22 - day 30"
45995672|NCT00539565|Drug|placebo|
46085217|NCT02851290|Procedure|Caudal block anesthesia|After induction of general anesthesia, a caudal block will be performed using 0.75-1 mL/kg of 0.2% ropivacaine without epinephrine
45834457|NCT04129710|Drug|Lenalidomide|Oral lenalidomide 25mg/day between days 4 and 24 of each cycle for six cycles. Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.
45995673|NCT00539604|Procedure|MDCT and Coronary Angiography|
45995674|NCT00539760|Drug|GSK1827771|GSK1827771 will be administered using injection via subcutaneous (SC) route.
45995675|NCT00539760|Drug|Placebo|Placebo to GSK1827771 for Injection will be administered via SC route
45995676|NCT00539799|Drug|prednisolone|5 - 7.5 mg/day
45995677|NCT00539799|Drug|Placebo|Matched placebo to prednisolone
45995678|NCT00945152|Drug|Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R)|Topical use for open wounds culturing out MRSA. One to three applications of the compound over a weeks time. Consists of Vancomycin 1.25-1.50% in a complex gel formulation.
45995679|NCT00945152|Drug|Placebo, complex gel formulation without Vancomycin|Complex gel formulation applied as the placebo and is unknown because of the trial design. Complex gel formulation without Vancomycin
45995680|NCT00546507|Drug|TDS-943 (topical diclofenac sodium 4% spray)|
45995681|NCT00546507|Drug|celecoxib|
45995682|NCT00546507|Other|placebo|
45995683|NCT00546546|Drug|early immunosuppressants (azathioprine, methotrexate)|azathioprine 2.5 mg/kg/day SC methotrexate 25 mg/week if aza not tolerated
45995684|NCT00659711|Drug|Januvia (Sitagliptin) 100 mg|The first group will be started on 100 mg sitagliptin daily for 12 weeks
45995685|NCT00659711|Drug|Placebo|will be placed on a placebo for 12 weeks.
45995686|NCT00546624|Drug|MK0777|
45995687|NCT00580346|Device|Placement of laryngeal implant|Placement of stimulator over anterior chest wall, and electrodes around recurrent laryngeal nerve, and tunneling leads between both
46085218|NCT02851290|Procedure|Dorsal penile nerve block anesthesia|After induction of general anesthesia, a dorsal penile nerve block will be performed using 0.75-1 mL/kg of 0.2% ropivacaine without epinephrine
46085219|NCT02757404|Drug|Ultrasonography guidance injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the ultrasonography guidance.
46085220|NCT02757404|Drug|Electrical stimulation guidance injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the electrical stimulation guidance.
46085221|NCT02757404|Drug|Manual needle placement injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the manual needle placement.
46085222|NCT00955045|Drug|istradefylline|
46085223|NCT02686554|Other|Neuropsychological assessment|The patients perform tests to assess their cognitive abilities
46085224|NCT00601107|Drug|Doxercalciferol|
46085225|NCT00601107|Drug|Placebo|
46085226|NCT02699424|Radiation|External radiation therapy|
45457287|NCT01132573|Other|laboratory biomarker analysis|Correlative studies
45834458|NCT04129710|Drug|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
45834459|NCT04129710|Drug|Rituximab|Rituximab 375 mg/m2 conventional infusion on day 1
45834460|NCT04129710|Drug|Etoposide|Etoposide 250 mg/m2 over 3 hours on day3
45834461|NCT04129710|Drug|PEGylated recombinant human granulocyte colony|PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
45995688|NCT00546663|Drug|inhaled 7% hypertonic saline (HS)|"7% hypertonic saline administered twice daily for 14 days by nebulization.~A Pari Sprint Junior nebulizer equipped with a Pari Baby face mask and a Pari Proneb compressor will be used to administer the HS (PARI Respiratory Equipment, Inc., Midlothian, VA).~To minimize the risk of cough and bronchospasm with HS inhalation, infants will be pre-treated prior to each dose of HS with albuterol by metered dose inhaler"
45995689|NCT00300599|Device|Continuous Positive Airway pressure|Continuous positive pressure device with a time clock
45995690|NCT00300599|Other|Placebo|Placebo
45995691|NCT00546702|Drug|Insuline Glulisine|
45995692|NCT02581007|Drug|Fludarabine|fludarabine (30mg/m2) given every day starting on Day -6 through Day -2;
45995693|NCT02581007|Drug|Melphalan|
45995694|NCT02581007|Drug|Cyclophosphamide|cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.
45995695|NCT02581007|Procedure|peripheral blood stem cell transplant|
45995696|NCT00546741|Drug|Dapagliflozin|Tablets, Oral, 20 mg, once daily single dose
45995697|NCT00546741|Drug|Metformin|Tablets, Oral, 1000 mg, once daily, single dose
45995698|NCT00546741|Drug|Dapagliflozin + Metformin|"Tablets, Oral, once daily, single dose~Dapagliflozin: 20 mg~Metformin: 1000 mg"
45995699|NCT02540330|Drug|Fulvestrant|
45995700|NCT00546858|Other|Physical Examination|Patients will be invited to be evaluated in the Urology Research office at a future date.
45995701|NCT02467361|Drug|BBI608|Patients in this trial will receive BBI608 at assigned dose-levels according to the study arm the patient is enrolled into. BBI608 Dose Level 1: 240 mg twice daily, Dose Level 2: 480 mg twice daily. The assigned dose of BBI608 will be administered twice daily with approximately 12 hours between doses.
45995702|NCT02467361|Drug|Ipilimumab|Ipilimumab 3 mg/kg is administered intravenously over 90 minutes every 21 days for a total of 4 doses.
45995703|NCT02467361|Drug|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes every 14 days.
46085227|NCT02696486|Behavioral|Exercise Training|Study subjects will receive medically supervised aerobic and resistance exercise training for 1 hour per session, 3 times per week for 6 weeks at the Cardiac Rehab center and then transition to home or YMCA partnership based exercise with staff follow-up contact for an additional 3 weeks.
46085228|NCT02704728|Other|Thetanix|Thetanix is an encapsulated lyophilised formulation of a pure culture of Bacteroides thetaiotaomicron with excipients.
45995704|NCT02467361|Drug|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every 21 days.
45995705|NCT00546936|Drug|ranibizumab|0.5mg ranibizumab
45995706|NCT00546936|Drug|verteporfin|Photodynamic therapy with verteporfin every 3 months for 1 year
46085229|NCT02704728|Other|Placebo|Placebo is encapsulated microcrystalline cellulose without Bacteroides thetaiotaomicron.
45995707|NCT02438891|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy is a form of tinnitus psychotherapy which aims to help patients control negative thoughts or emotions associated with tinnitus.
45995708|NCT00546975|Dietary Supplement|Resource Support®|
45995709|NCT00546975|Dietary Supplement|Resource Protein®|
45995710|NCT00546975|Dietary Supplement|Placebo|
45995711|NCT02232620|Drug|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
45995712|NCT02231723|Drug|BBI608|Administered continuously twice daily with doses separated by 12 hours
45995713|NCT02231723|Drug|Nab-paclitaxel|Nab-paclitaxel 125 mg/m^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
45995714|NCT02231723|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
46085230|NCT04169685|Procedure|bronchoscopy|during flexible bronchoscopy
46085231|NCT00957385|Drug|Revlimid|10mgs PO daily for 21 days of each 28 day cycle. Number of cycles: total of 24 or until subject relapses or unacceptable toxicity develops.
46085232|NCT04169841|Drug|olaparib, durvalumab, tremelimumab|"STEP 1:~Olaparib 300 mg BID during 8 weeks. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food~STEP 2:~Olaparib 300 mg during 4 months as per same requirement as below. Durvalumab 1500 mg plus tremelimumab 75 mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination and in response or stable after prior molecular target therapy by olaparib based on molecular sequencing."
45834462|NCT03200808|Drug|mixed methylene blue compound injection|Every patient received intradermal mixed methylene blue compound injection twice.
45834463|NCT05603598|Drug|LEAP-2 Protein, Human|Intravenous infusion, mixed meal test, ad libitum meal test
45834464|NCT02983656|Biological|live attenuated varicella vaccine|
45995715|NCT02231723|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
45995716|NCT02231723|Drug|Leucovorin|Arm C, D: Leucovorin 400 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
45995717|NCT02231723|Drug|Irinotecan|Arm B: Irinotecan 165 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Irinotecan 165 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
46085233|NCT02622438|Other|Followed with an initial assessment, six months and followed annually for 3 years corresponding to the usual follow-up of the patient.|
46085234|NCT04011397|Other|Exercise intervention|Exercise intervention (reduced-exertion, high-intensity interval training) delivered within an NHS setting. Consisted 10 min of cycle ergometry (inclusive of warm-up and cool down) including very brief maximal cycle sprints.
45834465|NCT04121130|Device|F-ESWT Group|3 F-ESWT sessions, 1 per week (0,10 mJ/mm2; 2000 impulses; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
45834466|NCT04121130|Device|sham F-ESWT|3 sham F-ESWT sessions, 1 per week (0,01 mJ/mm2; 2000 SW; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
45995718|NCT02231723|Drug|Fluorouracil|Arm B, D: Fluorouracil 2400 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Fluorouracil 400 mg/m^2 I.V. bolus followed by 2400 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
45995719|NCT02231723|Drug|MM-398|MM-398 70 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
45995720|NCT05006313|Device|Intraoperative fluorescence angiography|Intraoperative fluorescence angiography will be used to assess tissue perfusion following initial debridement of wound.
45995721|NCT01263496|Drug|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks.
45995722|NCT01263496|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks.
45995723|NCT01263496|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks.
45995724|NCT01263496|Drug|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks.
45995725|NCT01263496|Drug|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
45995726|NCT00547014|Drug|Placebo Comparator: Cohort 1 Placebo|Drug: placebo for cohort 1 as single dose
45995727|NCT00547014|Drug|52364 3 mg|3 mg capsule single dose administered orally as a single dose
45995728|NCT00547014|Drug|Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo|Drug: Placebo for cohorts 2, 3, 4 and 5 administered as a single dose
45995729|NCT00547014|Drug|52364 10 mg|Drug: 52364 30 mg capsule as a single dose
45995730|NCT00547014|Drug|52364 30 mg|Drug: 52364 30 mg capsule administered as a single dose
45995731|NCT00547014|Drug|52364 100 mg|Drug 52364 100 mg capsule administered as a single dose
45995732|NCT00547014|Drug|52364 1 mg|1 mg powder diluted in liquid or placebo (liquid alone) administered orally as a single dose
45995733|NCT04681937|Combination Product|Subacromial Injection (hyaluronic acid) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
45995734|NCT04681937|Combination Product|Subacromial Injection (Platelet-Rich-Plasma) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
46085235|NCT04011397|Behavioral|Usual care|Members of a multi-disciplinary team including a consultant, diabetes specialist nurse, clinical psychologist, physiotherapist, and dietician worked together to promote patient self-management. Care was tailored to the specific circumstances of each patient after initial assessment and focussed on weight management, dietary education, behavioural therapy, and supported pharmacotherapy initiation as appropriate.
46085236|NCT02462538|Drug|Brentuximab vedotin|Brentuximab vedotin is given in a 21 day cycle intravenously starting at 1.8 mg/kg on day 1 of the first cycle and will be administered by IV infusion given over approximately 30 minutes on day 1 of each 21-day cycle.
46085237|NCT02462538|Drug|Imatinib|Imatinib will be given orally at a dose of 100mg daily starting from day 1 of the first cycle. The dose will be increased to 200mg daily starting from day 1 of the second cycle if no DLT occurs during the first cycle and will be continued at 200mg for 48 weeks.
46085238|NCT05300425|Other|Blood sample collection|Blood sample collection (at baseline and approximately two years after baseline). Enzyme-linked immunosorbent assays will be used to screen for IgG and IgM antibodies directed against the three pathogens (Leptospirosis, Tularemia, Hepatitis E).
45995735|NCT04681937|Combination Product|Subacromial Injection (methylprednisolone acetate) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
45995736|NCT04681937|Combination Product|Subacromial Injection (Serum Saline) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
46085239|NCT05300425|Other|Data collection|Data collection on sociodemographic questions e.g. profession, leisure activities, animal contact
46085240|NCT02752646|Drug|nepafenac 0.3%|Patients in this group will receive nepafenac 0.3% eye drops once daily after cataract surgery.
46085241|NCT02752646|Drug|ketorolac|Patients in this group will receive ketorolac 0.5% eye drops four times daily after cataract surgery.
46085242|NCT04169919|Drug|Povidone-Iodine|Povidone-Iodine 5% eye wash
45834467|NCT04129476|Behavioral|Cooperative Education Program based on Precede-Proceed Model|The study population is pregnant women in Gonabad city between 30 and 35 weeks of gestation. In the experimental group, the training program was based on the PRECEDE-PROCEDURE model, including training on anatomy and prenatal physiology, prenatal and postnatal care, prenatal and postnatal mental health, as well as prenatal and postnatal events, and Mothers' feelings and attitudes, as well as postpartum problems and strategies will be discussed. The training period is 60 minutes in 4 consecutive sessions. Predisposing, reinforcing and enabling factors inventory, General health questionnaire (GHQ), Edinburgh depression inventory Will be filled Before the intervention, immediately after the intervention and 4 to 6 weeks after the intervention.
45834468|NCT04128852|Device|MagnetOs Putty|MagnetOs Putty has a CE-mark (2115660CE01) as well as FDA 510(k) clearance (K171563/K181958).
45834469|NCT04129008|Drug|Indobufen and aspirin mimetic|Day 1 to 84±7: The first time: indobufen 100mg + aspirin mimetic; The second time: indobufen 100mg
45834470|NCT04129008|Drug|Aspirin and indobufen mimetic|Day 1 to 84±7: The first time : aspirin 100mg+ indobufen mimetic; The second time: indobufen mimetic
45834471|NCT04121052|Drug|JNJ-64417184|Participants will receive single dose of JNJ-64417184 as oral tablet.
45995737|NCT00547053|Drug|Amiloride Solution for Inhalation|4.5 mL, Amiloride Solution for Inhalation, Inhaled via Omron Ultrasonic Nebulizer, TID, 6 months
45995738|NCT02131649|Device|18F-FCH PET/MRI Scan|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo a PET/MRI scan using 18F-FCH as the radiolabeled tracer. If prostate cancer is detected outside the prostate, patients may undergo a biopsy or follow-up 18F-FCH PET/MRI to confirm the results.
45995739|NCT00547092|Drug|tadalafil|10 mg or 20 mg tadalafil tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
45995740|NCT00547092|Drug|sildenafil|25 mg, 50 mg, or 100 mg sildenafil citrate tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
45995741|NCT00547131|Drug|temozolomide|
46085243|NCT04169919|Drug|Normal Saline Flush|Normal Saline eye wash
46085244|NCT02704338|Biological|Regulatory T cells|Regulatory t cells will be injected back to autoimmune hepatitis patients
46085245|NCT02757482|Other|training|
46085246|NCT04169997|Drug|IMP4927|IMP4297 tablet.The starting dose from 100mg QD
46085247|NCT04169997|Drug|Placebos|Placebos tablet.The starting dose from 100mg QD
46085248|NCT02704260|Genetic|GENETIC ANALYSIS|prélevement blood to search for a genetic cause of vascular endofibrose. Search genetic mutations in 5 subjects.
45995742|NCT00547131|Other|laboratory biomarker analysis|
45995743|NCT00547131|Other|liquid chromatography|
45995744|NCT00547131|Other|mass spectrometry|
45674910|NCT04747301|Drug|Dinoprostone 10mg (Propess)|"Propess® 10mg Vaginal delivery system (Ferring Controlled Therapeutics Ltd., 1 Redwood Place, Peel Park Campus, East Kilbride, Glasgow, G74 5PB, UK) is a vaginal insert containing 10mg of dinoprostone in a timed-release formulation (the medication is released at 0.3 mg/hour).~A Propess vaginal system is inserted by a research doctors. As in the catheter procedure, Fetal Heart Rate is monitored 30min before and 2 hours after placement. Cardiotocograph and vaginal examination will be performed every 6 hours. The vaginal system is placed for a maximum of 24 hours.~If it is expelled in the first 12 hours and the patient has no contractions or still shows an unfavorable cervix, another vaginal system is placed for a maximum of another 24 hours.~The patients will be examined in case of extreme pain or membranes ruptured."
45834472|NCT04120896|Behavioral|Karate group|Children in the karate group will receive the basic Goju Ryu Karate training that includes basic stances (dachi), punching (zuki), blocking (barai) and kicking techniques (keri), form training (kata), supervised sparring (kumite), and conditioning exercises (for warm up and cool down).
45995745|NCT00547131|Other|pharmacological study|
45995746|NCT00547131|Procedure|conventional surgery|
46085249|NCT02757248|Drug|Volasertib|Volasertib 75-150mg/m2 given intravenously on days 1 and 8
46085250|NCT02757248|Drug|Romidepsin|Romidepsin 12-14mg/m2 given intravenously on days 1, 8 and 15
46085251|NCT00649311|Drug|eplerenone|Eplerenone 50 mg oral film-coated tablet once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to eplerenone 100 mg oral film-coated tablet once daily for 4 weeks.
46085252|NCT00649311|Drug|Losartan|Losartan 50 mg oral capsule once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to losartan 100 mg oral capsule once daily for 4 weeks
46085253|NCT02704494|Drug|Resveratrol|Resveratrol 500mg daily
46085254|NCT02704494|Drug|Placebo|Placebo 1 capsule daily
46085255|NCT02704494|Drug|Losartan|Losartan 12.5mg daily
46085256|NCT04221620|Device|Zengar Electroencephalogram (EEG) Neurofeedback device|Electroencephalogram (EEG) Neurofeedback is a noninvasive way to allow the central nervous system to self regulate and calm the brain enough to allow the frontal cortex to function in an ideal state, which is the part of the brain that controls important functions including behavior, problem solving, memory, language, emotions, and judgment. EEG Neurofeedback is performed via a musical medley that lasts for about 34 minutes, with baseline numbers taken at the beginning and after the music finishes. During this time, the participant will wear headphones, sensory clips on the ears (3 total), and two sensors on their head while receiving traditional occupational therapy services.
45834473|NCT04120896|Behavioral|Kung fu group|Children in the Ving Tsun kung fu group will receive the basic Wong Shun Leung style Ving Tsun training that includes basic stances (ma), footwork (bu), punching (quan), kicking (jie) techniques and conditioning exercises (for warm up and cool down).
45834474|NCT04128930|Device|PAP titration at home|Fixed CPAP or APAP titration at home
45995747|NCT00547131|Radiation|stereotactic radiosurgery|
45995748|NCT01964495|Drug|Discontinuation of treatment according to CRP levels|The cutoff point is a CRP below 100 mg/L and a reduction to 50% of the initial value.
45995749|NCT01964495|Drug|Discontinuation of treatment according to PCT levels|The cutoff point is a PCT below 0.25 mcg/L or a reduction to 10% of the initial value.
45995750|NCT01964495|Drug|Treatment according to current guidelines|Often a 7 days course of antibiotics, treatment may be extended if the attending physician deems it necessary.
45995751|NCT01775423|Drug|BBI608|
45995752|NCT00547170|Drug|Doxycycline pre-operatively|"Two capsules of Doxycycline 100 mg before vacuum aspiration Placebo 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)"
45995753|NCT00547170|Drug|Doxycycline post-operatively|"Two capsules of placebo 100 mg before vacuum aspiration Doxycycline 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)"
46085257|NCT02658747|Other|No intervention|No intervention administered in this study
46085258|NCT02704416|Procedure|Catheter Ablation|catheter ablation of fragmented signal in the right ventricular outflow tract
46085259|NCT04033341|Drug|LY3214996|Administered orally
46085260|NCT04033341|Drug|[14C]-LY3214996|Administered orally
46085261|NCT00615888|Procedure|Fast track patient management|no bowel washout, patient controlled epidural anesthesia, early enteral feeding
46085262|NCT00615888|Procedure|Traditional management|preoperative bowel washout, patient controlled analgesia, delayed start of enteral feeding
45995754|NCT00900809|Biological|Neukoplast™ (NK-92)|The Neukoplast™ (NK-92) cells will be administered intravenously over 60 minutes. The starting dose of Neukoplast™ (NK-92) cells will be 1 x 10e9 ZRx-101 cells/m2 (The 3 dose levels are: 1 x 10e9 cells/m2, 3 x 10e9 cells/m2 and 5 x 10e9 cells/m2). The second infusion will only be administered after 24 hours if no unacceptable or dose limiting toxicities side effects due to the infusion of Neukoplast™ were encountered after the first infusion.
45995755|NCT01263223|Drug|LY2216684|Administered orally
45995756|NCT01263223|Drug|Placebo|Administered orally
45995757|NCT00547209|Drug|air|60% air combined with 40% oxygen for ventilation
45995758|NCT00547209|Drug|Nitrous oxide|60% nitrous oxide combined with 40% oxygen for ventilation
45995759|NCT00547287|Drug|tadalafil|20 mg tadalafil as needed by mouth no more than once a day for a 4 week initiation period and a 4 weeks treatment period.
45674911|NCT02152163|Drug|IV Ibuprofen|
46085263|NCT04221698|Other|Gait retraining|5 gait retraining sessions of continuous feedback in real time during running sessions; using videotape feedback, a digital metronome to increase step rate, and verbal feedback to reduce the tendency to heel strike upon ground contact. Verbal feedback is offered during the 25- to 30-minute running sessions following a series of drills aimed at improving running mechanics.
45995760|NCT00547287|Drug|sildenafil|Current dosage of sildenafil is continued for 4 weeks (no more than once a day) of treatment assessment then the wash-out period will begin.
45995761|NCT02908958|Biological|PEG-somatropin|High dose group: PEG Somatropin 0.2 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
45995762|NCT02908958|Biological|PEG-somatropin|Low dose group: PEG Somatropin 0.14 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
45995763|NCT01263106|Drug|LY2216684|18-mg LY2216684 oral dose
45995764|NCT01263106|Drug|Theophylline|200-mg theophylline oral dose
45995765|NCT00547326|Procedure|treated with osteopatic cranial techniques|treated with osteopatic cranial techniques
45995766|NCT00547326|Procedure|Treatment with placebo|Treatment with placebo
45995767|NCT05534971|Procedure|Central venous catheter insertion|The clinical team will use the technique to establish central venous access
45995768|NCT01263028|Drug|Ergocalciferol supplementation|Vitamin D in the form of ergocalciferol will be the drug utilized in the study. This medication is a Vitamin D analog and is normally used in the current study population to help augment those who are deficient in Vitamin D.
45995769|NCT00547404|Drug|P276-00|IV drug infusion over a period of 30 min on day 1,4,8 and 11 in21 day cycle for 6 cycles
46085264|NCT00649467|Drug|Topiramate Sprinkle Capsules 25 mg|25mg, single dose applesauce
46085265|NCT00649467|Drug|Topamax® Sprinkle Capsules 25 mg|25mg, single dose applesauce
46085266|NCT02757170|Device|Thromboelastography|Patients whole blood will be subjected to undergo coagulation process under monitoring with thromboelastography and various tracings will be recorded and will be interpreted as results.
45834475|NCT05603130|Other|routinely collected clinical information|medical history, epidemiological characteristics, clinical examination, biological assessment (blood glucose, NFS, CRP, D-dimer,etc...)
45834476|NCT04128462|Drug|MNK-6105|L-Ornithine Phenylacetate for IV infusion
45834477|NCT04128462|Drug|Placebo|Matching placebo for IV infusion
45674912|NCT02152163|Drug|placebo|
45674913|NCT02152007|Drug|1% sirolimus cream (TD201 1%)|1% sirolimus cream (TD201 1%)
45674914|NCT02151851|Biological|Certolizumab Pegol|"Active substance: Certolizumab Pegol~Pharmaceutical Form: Prefilled syringes~Concentration: 200 mg/ml~Route of administration: Subcutaneous injection"
45674915|NCT02151851|Drug|Methotrexate|"Active substance: Methotrexate~Pharmaceutical form: Tablet~Concentration: Maximum dose 10 mg per week~Route of administration: Oral"
45674916|NCT02151851|Other|Placebo|"Active substance: Placebo~Pharmaceutical form: Prefilled syringes~Concentration: 0.9 % saline~Route of Administration: Subcutaneous injection"
45674917|NCT02176421|Device|VOLBELLA® with lidocaine|VOLBELLA® with lidocaine administered to correct skin depression during initial treatment and optional top-up treatment 14 days later.
45834478|NCT04128462|Drug|Standard of Care|Lactulose ± rifaximin as SoC treatment for overt HE should be administered per the clinical judgement of the investigator and usual institutional practice.
45995770|NCT02908919|Procedure|Colonoscopy|The quality of bowel preparation, which is checked during colonoscopy
45995771|NCT04323319|Device|ESWT, Graston Technique|"The treatment period for each group was determined as 4 weeks. Stretching program for each group will be given as home exercise program. Stretching exercises will be completed in 3 sets, 2 sets per day, stretching for 30 seconds.~Graston Technique Group will take treatment 2 times per week, ESWT group will take treatment 1 time per week."
45995772|NCT01262989|Drug|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
45995773|NCT01262989|Drug|Reference formulation|tamsulosin 0,4 mg (Boehringer Ingelheim)
45995774|NCT00547443|Drug|carboplatin|Given IV
45995775|NCT00547443|Drug|paclitaxel|Given IV
45995776|NCT00547443|Drug|sorafenib tosylate|Given orally
45995777|NCT00547443|Radiation|radiation therapy|Given 5 days a week for 7.5 weeks
45995778|NCT02908997|Other|MindMate|A dementia-specific mobile reminding application
45995779|NCT00547482|Device|TANTALUS(TM) System|"All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation)."
45995780|NCT02909075|Device|PET/CT scans|
45995781|NCT02909075|Device|MRI|
45995782|NCT03456258|Diagnostic Test|Complete blood count|To measure hemoglobin difference and serum ferritin levels .
45995783|NCT02909114|Radiation|Stereotactic body radiotherapy|"All patients will undergo planning CT simulation. 4-dimensional CT will be used for tumors in the lungs or liver. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging +/- PET. A Planning Target Volume (PTV) margin of 3-5 mm will be added depending on site of disease, immobilization, and institutional set-up accuracy.~The prescirbe dosage was as following: Lung lesion DT50-60 Gy/5 fractions; liver 50-60Gy/5-8 fractions; brain DT 40Gy/4-5fractions. All will be treated with SBRT"
46085267|NCT02699346|Device|HS-1000 recording|
46085268|NCT04169607|Procedure|Dynamic compliance guided individualized positive end-expiratory pressure titration strategy|"Basic ventilation: Volume-controlled ventilation (VCV) mode with positive end-expiratory pressure (PEEP) of 8cm H2O after induction of anesthesia，~Recruitment maneuver (RM): Pressure-controlled ventilation (PCV) mode increasing PEEP from 10 to 25cmH2O in step of 5cmH2O per 30s.~PEEP-titration maneuver: ventilation parameters reset as basic ventilation with PEEP still 25cmH2O.Decrease PEEP to 5cmH2O in step of 2cmH2O per 10 respiratory cycles to confirm the highest dynamic lung compliance (Cdy).~After titration: A new RM will be performed and the final PEEP will be the one related to highest Cdy plus 2cm H2O.~Randomized after the second RM. Individualized PEEP arm: maintain individualized PEEP; PEEP8 arm: maintain a fixed PEEP of 8cm H2O.~VCV with other ventilation parameters the same as basic ventilation until extubation .~After discharged from postoperative anesthesia care unit (60 to 90 minutes after extubation): chest CT ."
45457288|NCT02877680|Behavioral|T1Doing Well|Strengths-based mobile health (mHealth) app for parents of adolescents with type 1 diabetes, which will prompt parents to recognize and reinforce their adolescents' diabetes-related strength behaviors
45457289|NCT02293720|Device|EndoBarrier|The EndoBarrier is indicated as an adjunct to diet and exercise to achieve weight loss and improve glycemic control in obese adults with type 2 diabetes whose anti-diabetes medications have not achieved adequate glycemic control.
45995784|NCT02277210|Other|Flushing|aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
45995785|NCT04682171|Other|Low level laser therapy|"Gallium aluminium arsenide laser device will be used with wavelength of 850nm, power 100 mW, spot size of 1.0 mm and energy of 6J/point for 60seconds. Total 8 points will be irradiated. It will take 20 minutes.~Patient will receive treatment in supine position with the affected knee(s) slightly flexed supported by the pillow or rolled towel.~On the affected knee the laser probe will placed with full contact with skin at 8 points. Three points at medial side of the knee, three points at lateral side and two points at the medial edge of the bicep femoris muscle tendon and semitendinosus muscle tendon in the popliteal fossa"
45995786|NCT04682171|Other|Conventional Exercise Therapy|"Quadriceps isometric strengthening exercises.~Range of motion and active stretching exercises applied to hamstring and quadriceps muscle.~Hamstring muscle isometric exercises~Active ankle pump.~Short arc terminal extension exercises for the knee joint.~Static and dynamic strengthening exercises for the hip abductors, adductors and extensor group of muscles.~Non-weight bearing progressive resistance exercises with weighted cuffs, with progression to closed chain exercises as patient's pain allows.~Isometric exercises were applied with 6 second contractions and rest period of 2 seconds. Isotonic exercises were started as 10 repetitions with half of weight of 10 RM, 10 repetitions with three fourth of this weight and 10 repetitions with whole 10 RM"
45995787|NCT02277288|Other|Filled bladder arm|Bladder to be instilled with 200 cc fluid during cystoscopy and no catheter for all mid-urethral sling procedures.
45995788|NCT00547560|Drug|GSI-953|Oral capsule, 10- and 50-mg, either once a day for 14 days or twice a day for 14 days, depending on cohort assignment.
45995789|NCT02908607|Device|Thermal imaging|Examination of the cervix by thermal imaging camera
45995790|NCT00547599|Drug|tadalafil|20 mg tadalafil tablet by mouth as needed, no more than once a day for 8 weeks.
45995791|NCT02908451|Biological|AbGn-107|Antibody Drug Conjugate
45995792|NCT00547677|Radiation|stereotactic radiosurgery|
45995793|NCT02908763|Drug|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
45995794|NCT00547716|Dietary Supplement|Omega-3 Fatty Acids|Omega-3 Fatty Acids - 4 grams per day
45995795|NCT00547716|Drug|Placebo comparator|
45995796|NCT02908802|Dietary Supplement|Probiotic|Probiotic
46085269|NCT02756858|Drug|ANAVEX2-73|
46085270|NCT02658513|Other|Lancet blood sampling|Blood samples will be obtained using a finger-prick (lancet) technique.
46085271|NCT02658513|Other|Standard intravenous blood sampling|Blood samples will be obtained using a standard intravenous technique.
46085272|NCT02699502|Other|matching an appropriate drug therapy to patients with osteoporotic hip fractures|The process involves reviewing patients characteristics virtually and finding the right drug for them while they are still in the hospital. After matching an appropriate drug, getting it through regulatory authorities to the family physician
46085273|NCT02658591|Dietary Supplement|Crackers/pasta with added faba bean protein concentrate|Protein concentrate treatment
46085274|NCT02658591|Dietary Supplement|Crackers/pasta with added faba bean protein isolate|Protein isolate treatment
46085275|NCT02658591|Dietary Supplement|Crackers/pasta with added faba bean starch|Starch treatment
46085276|NCT02658591|Dietary Supplement|Crackers/pasta with added faba bean flour|Flour treatment
46085277|NCT02658591|Dietary Supplement|Crackers/pasta with no faba bean fraction|Control treatment
45457290|NCT01229917|Other|Fruit juice with Lactobacillus rhamnosus GG, version 1|
45457291|NCT01229917|Other|Fruit juice with Lactobacillus rhamnosus GG, version 2|
45995797|NCT02908802|Dietary Supplement|Placebo|Probiotics capsules without the active ingredient
45995798|NCT02908646|Procedure|microcoil localization|CT-guided localization by placing a microcoil into the lung parenchyma
45995799|NCT02908646|Procedure|hookwire localization|CT-guided localization by placing a hookwire into the lung parenchyma
45995800|NCT02908568|Device|Spring device|Brisk dilatation of fhe mouth.
45995801|NCT02908568|Device|Mandible stimulator|Stimulation of fhe mouth.
45995802|NCT02908412|Drug|Digital nerve block with bupivacaine|The aim of the study, the way it will be conducted, and the complications and possible risks are explained to them. written informed consent is obtained from them. Then, after induction of anaesthesia, an arterial line will be inserted in order to monitor blood pressure and to take blood samples. During the surgery, two rainbow adult ReSposable sensors will be attached to the third or fourth fingers of both hands, and each of sensors will be attached to a monitor. Patients will be randomly assigned to two groups: group A will receive DNB in left hand and group B will receive DNB in right hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
45995803|NCT04686474|Drug|Azadirachta indica leaves extract containing ointment intervention.|Azadirachta indica leaves extract containing ointment, white petroleum, bee wax, stearyl alcohol
45995804|NCT04686630|Other|Video based observational gait analysis and SCALE Test|Twenty-four spastic diparesis and eighteen spastic hemiparesis cases were included in the study. Data was collected from 84 lower extremities. There were 22 female and 20 male patients aged between 4-18 years. Personal and disease-related information of 42 individuals with diplegic or hemiparetic CP were recorded by using the data collection form. Information collection form; The patient's name-surname, age, gender, height, weight, history, gestational age, birth weight, SCALE Test, GMFCS, Modified Ashworth Scale (MAS), Range of Motion (ROM), EVGS, affected side and previous surgical histories were recorded and their functional levels were determined and recorded.
45995805|NCT02908256|Drug|Geloplasma (PVI)|In the PVI group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the PVI>15% during more than 5 minutes. The bolus will be repeated if the PVI remains over 15%.
45995806|NCT02908256|Drug|Geloplasma (delta PP)|In the delta PP group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the delta PP> 13% during more than 5 minutes. The bolus will be repeated if the delta PP remains over 13%.
45995807|NCT00547872|Procedure|exercise testing - coronary angiography - revascularization|Those patients with a positive exercise ECG test will be studied by coronary angiography and treated according to the severity of coronary lesions by percutaneous stenting or surgery
45995808|NCT02908295|Drug|Rectal Misoprostol|Rectal Misoprostol Misoprostol 400 mcg (200 mcg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
45995809|NCT02908295|Drug|Placebo|Rectal Vitamin B6 Vitamin B6 (Placebo) 200 mg (100 mg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
45995810|NCT03809442|Drug|Ropivacaine + Ketamine|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 1mg/kg ketamine (8 mL per incision) (ketamine group).
45995811|NCT03809442|Drug|Ropivacaine + Tramadol|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 2mg/kg tramadol (8 mL per incision) (Tramadol group).
45995812|NCT03809442|Drug|Ropivacaine + Midazolam|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 50 μg/kg midazolam (8 mL per incision) (Midazolam group).
45995813|NCT03809442|Drug|Ropivacaine + Dexmedetomidine|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% Ropivacaine + 0.5μg/kg dexmedetomidine (8mL per incision) (Dexmedetomidine group).
45995814|NCT03809442|Drug|Ropivacaine + Dexamethasone|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine+ 8mg dexamethasone (8 mL per incision) (Dexamethasone group).
45995815|NCT03809442|Drug|Ropivacaine|Patients will receive subcutaneous wound infiltration with 24ml of 0.25% Ropivacaine in three divided doses (i.e. 8 mL per incision) (control group). Total dose of Ropivacaine will be 60 mg.
46085278|NCT02699268|Other|Lung function measurement|The infants will be exposed to lung function measurements performed by a new metod (Volusense Pediatrics) and a validated method (EcoMedics Exhalyzer D). The two Methods will be compared. This is not an intervential study, but a study aiming to validate a New Method versus an old method
46085279|NCT02759900|Device|Non-thermal, atmospheric plasma to treat skin lesions and acne|Non-thermal, atmospheric plasma treatment of affected area or lesions using a nanosecond dielectric barrier discharge plasma device
46085280|NCT02759900|Device|Indirect non-thermal, atmospheric plasma to treat hair loss and acne|A compound of non-thermal, atmospheric plasma and medium is delivered to or generated at the target area. Plasma is generated using either microsecond dielectric barrier discharge plasma device or PiezoBrush (a helium jet plasma). The medium is an aqueous alcohol solution
46085281|NCT00649545|Biological|adalimumab|40 mg every other week
46085282|NCT02760134|Procedure|Super-Mini Percutaneous Nephrolithotomy|Patients undergo Super-Mini Percutaneous Nephrolithotomy
45457292|NCT01229917|Other|Standard fruit juice|
46085283|NCT04169763|Drug|Cisplatin|Given IV
46085284|NCT04169763|Radiation|External Beam Radiation Therapy|Undergo EBRT
46085285|NCT04169763|Drug|Nelfinavir|Given PO
45457293|NCT03512704|Other|Collection of possible predictors from patient data|Collection of sociodemographic and clinical parameters, from medical records, and health related quality of life data, that may predict the outcomes of interest (mortality, complications, readmissions)
45457294|NCT01131559|Drug|Lisdexamfetamine|Oral; 20-70mg/day
45457295|NCT01131559|Drug|Placebo control|Oral; 20-70mg/day
45457296|NCT03922009|Device|Virtual Reality|The primary objective of this study was to evaluate the use of VR to reduce anxiety in spinal anesthesia patients compared with controls
45995816|NCT02908217|Drug|Tocilizumab|6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
45995817|NCT02908217|Drug|Placebo|6 Intravenous infusions of placebo every 4 weeks.
45995818|NCT00547950|Drug|:Deng Zhan Sheng Mai Capsule|capsule，0.18g，2＃，po，Bid*1year.
45995819|NCT02908373|Other|Implementation of the coaching model|20 hours methodological help for each nursing home and an implementation kit
46085286|NCT02759978|Other|diagnostic workup|Our primary objective is to test whether the proportion of patients diagnosed correctly with the use of 18F-FDG-PET/CT, MD-CTA, and 18F-FDG-PET/MD-CTA added to the gold standard in current clinical practice, the modified Duke criteria by Li et al. 2000, is significantly higher as compared with the modified Duke criteria on itself. The gold standard is clinical judgement after clinical follow-up by a multidisciplinary team with medical specialists.
45995820|NCT00534729|Drug|Weekly Carboplatin & Taxol w/concurrent RT|Chemotherapy
45995821|NCT02908139|Device|BR-102 plus PWA|Monitoring of Arterial Stiffness and Central Aortic Pressure
46085287|NCT03316638|Drug|W0101 - Cohort A1|Administered once every 2 weeks
46085288|NCT03316638|Drug|W0101 - Cohort A2|Administered every 3 weeks
46085289|NCT03316638|Drug|W0101 - Expansion Phase|Administered according to the recommended dose for expansion
46085290|NCT00635414|Drug|Esomeprazole|40mg oral
46085291|NCT00635414|Drug|Esomeprazole|15 minute intravenous infusion
46085292|NCT02658435|Drug|Tafenoquine 150 mg|Tablet contains TQ as tafenoquine succinate. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
46085293|NCT02658435|Drug|Matched placebo 150mg|It is the matched Placebo tablet. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
46085294|NCT02692170|Biological|CVI-HBV-001|"Investigational product: CVI-HBV-001~Dose: 5, 10, 20 or 40ug~Frequency: 3 times~Vaccination schedule: at 0, 1, 6 months~Administration route: Intramuscular injection"
46085295|NCT02692170|Biological|Conventional Hepatitis B vaccine (20 μg)|"Active comparator: Conventional Hepatitis B vaccine (20 μg)~Dose: 20ug~Frequency: 3 times~Vaccination schedule: at 0, 1, 6 months~Administration route: Intramuscular injection"
46085296|NCT02759822|Procedure|Haploidentical Stem Cell Transplantation|Haploidentical Stem Cell Transplantation from a related donor (partially matched sibling, father, mother, son or daughter).
46085297|NCT02704182|Device|tDCS|25 patients received real anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
46085298|NCT02704182|Device|Sham tDCS|25 patients received sham anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
46085299|NCT02658123|Other|Pre-operative education (standard of care)|
46085300|NCT02658123|Other|Home health care visits (standard of care)|
46085301|NCT02658123|Other|Follow-up post-operative visits|
45995822|NCT02908139|Device|Tanita MC780 MA S|The device measured the size of total body water (TBW), Extra Cellular Water (ECW), Intra Cellular Water (ICW), fat mass (FM%), visceral fat%, fat free mass (FFM) and basal metabolic rate, (BMR) (kcal).
46085302|NCT02658123|Other|Patient Data Collection Form|-Form that contains date, area to record number of pouches, and if home health care visit took place.
46085303|NCT02658123|Other|Healthcare Utilization Form|"Form for patient to record if they visited an emergency room or urgent care or if they were hospitalized~Form allows patient to record reason for visit and date of visit"
45674918|NCT02042443|Drug|Capecitabine|Given PO
45674919|NCT02042443|Drug|Fluorouracil|Given IV
45995823|NCT00534768|Procedure|active debridement|debridement on 1st, 3-5th and 7th postoperative days
45995824|NCT00534768|Procedure|control group|Postoperative debridement on 7th postoperative day
45995825|NCT00547989|Drug|standard anaesthesia (bupivacaine)|Local infiltration with bupivacaine and Piritramide and Paracetamol as postoperative analgesic, and ondansetron as required
45995826|NCT00547989|Drug|additional pvb (ropivacaine) and elastomeric disposable infusion pump|Patients in group 2 will receive PVB with ropivacaine and postoperative pump 5ml/h.
45995827|NCT00547989|Drug|additional pvb (ropivacaine)|Patients in group 1 will receive PVB with ropivacaine
45995828|NCT00534807|Drug|Vinflunine|
45995829|NCT00534807|Drug|Rifampin|
45995830|NCT02908022|Device|Electroacupuncture Analgesia|"For the MRI sessions, acupuncture needles will be inserted next to the cuff placed on the left leg and will be connected to electrodes. Low-amplitude electrical current will be activated when a button is pressed via a handheld device, controlled by the acupuncturist, in order to reduce pain, acting as an analgesic.~Additionally, electroacupuncture-induced analgesia will be used for the treatments. During the treatment sessions the acupuncturist will insert needles in several locations aimed to reduce the patient's fibromyalgia pain. Low-amplitude electrical current will be activated by the acupuncturist using the same electroacupuncture device as in the MRI machine."
45995831|NCT02908022|Device|Hokanson Rapid Cuff Inflator|The Hokanson Rapid Cuff Inflator will be placed on the lower right leg of the subject and utilized for pain testing purposes according to the protocol. Ascending pressures will be administered using the cuff to elicit different pain intensities.
46085304|NCT02658123|Other|The City of Hope QOL Survey for Ostomy Patients|"Consists of 47 questions asking various physical, psychological, sexual, work-related, and demographic questions.~Additional 34 questions on how the ostomy affects quality of life. Answers range from 0=not at all to 10=severe problem."
45995832|NCT00534846|Drug|toremifene|The medication is given in tablet form, and the participants are instructed to take one tablet daily from cycle day 15 until the next menstruation. The active (toremifene 20 mg) and control (placebo) tablets were identical in appearance.
45457297|NCT03518320|Drug|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 will be placed in the bladder through an inserter and gradually release gemcitabine for four consecutive 21-day dosing cycles for a total period of approximately 84 days
46085305|NCT02658123|Other|Phone call with CWOCN or PA|
45457298|NCT03518320|Drug|Nivolumab Injection [Opdivo]|Nivolumab will be given intravenously on specified days for four consecutive 21-day dosing cycles for a total period of approximately 84 days
45457299|NCT01134289|Procedure|lumbar sympathetic block|unilateral lumbar sympathetic block at L3 level using 0.2% chirocaine under C-arm fluoroscopy
46085306|NCT02756936|Drug|Daclatasvir Zeta|1 tablet contains 60 mg Daclatasvir
46085307|NCT02756936|Drug|Clatazev|1 tablet contains 60 mg Daclatasvir
45457300|NCT02300272|Device|Polysomnograph|Participants will be screened for sleep disorders other than chronic insomnia with an in-home overnight sleep monitoring. Monitoring will consist of six electroencephalography (EEG) measures, two electrooculography (EOG), and chin electromyography (EMG) according to standard placements. Other channels will include oxygen saturation level, bilateral anterior tibialis EMG, heart rate (EKG), thoracic strain gauge, and a nasal/oral thermistor. A single night of polysomnography will be collected during the 2 weeks of assessment.
45834479|NCT04394520|Other|Modified Introduction|A variation in the introductory content to motivate participants to complete the survey. Participants will be presented with modified introductory language based on the findings from local focus groups and key informant interviews.
45995833|NCT00534846|Drug|placebo|tablet equal to toremifene, one tablet daily from cycle day 15 to menstruation during three cycles
45995834|NCT00548067|Drug|Valsartan/hydrochlorothiazide (HCTZ)|
46085308|NCT01675908|Procedure|Stent Dysfunction|Rate of stent dysfunction (%) which includes persistent hyperbilirubinemia or cholangitis that warrant stent exchange by another ERCP.
46085309|NCT01675908|Procedure|Complications|Rates of procedural complications (%) such as pancreatitis, perforation or hemorrhage during stent placement will be assessed.
46085310|NCT02658045|Device|Standard Oximeter|Oxygen saturation will be measured by standard oximeter
46085311|NCT02658045|Device|Oxitone oximeter|Oxygen saturation will be measured by Oxitone oximeter
46085312|NCT02752568|Procedure|endometrial scratch|midluteal endometrial scratch using Novak curette under general anesthesia in the cycle preceding stimulation
46085313|NCT02752568|Procedure|assisted hatching|using Octax laser 20120644-laser 5452
46085314|NCT02752568|Procedure|controlled ovarian hyperstimulation|using merional&/ or fostimon doses individualized as judged by patient age & ovarian reserve & monitored by follicular size & serum estradiol
46085315|NCT02703870|Device|verum tDCS|real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes
46085316|NCT02703870|Device|sham tDCS|sham transcranial direct current stimulation, 10 sessions, for 20 minutes
46085317|NCT02703870|Behavioral|VRT|Vision restoration training, 10 sessions, 20 minutes
46085318|NCT02658201|Device|MRI|Ultrafast MRI to assess constipation
46085319|NCT02756780|Other|Tenovus Cancer Choir|Choir sessions will take place at both of the Royal Marsden Hospital sites on a weekly basis. Sessions typically consist of learning popular songs with messages of support. Songs are learnt without sheet music, using specially created backing tracks. These are also made available to participants at home so they can continue singing away from the sessions. No singing experience is required and the main aim of the sessions is enjoyment and meeting other people. Sessions will take place in the early evening so that participants have the option of staying to socialise afterwards.
45457301|NCT02300272|Device|Actiwatch|This device will be worn on the wrist for 14 continuous days to measure limb movements and ambient light.
45457302|NCT01231789|Procedure|RIPC|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
45995835|NCT00548067|Drug|Valsartan/amlodipine|
45995836|NCT00548067|Drug|Amlodipine/hydrochlorothiazide(HCTZ)|
45995837|NCT00548067|Drug|Valsartan/amlodipine/hydrochlorothiazide(HCTZ)|
46085320|NCT02704026|Other|Assesment of nutritional status and body composition|At the time of enrollment and after 1 year, anthropometric measurements and assessment of body composition by bioelectrical impedance will be performed for each child
46085321|NCT04169217|Behavioral|Prehabilitation|A combination of on off workshop and mentored prehabilitation
46085322|NCT02757014|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number - R84-087)
46085323|NCT02756546|Drug|Cyclophosphamide|
46085324|NCT02756546|Drug|Hydroxychloroquine|
45674920|NCT02042443|Other|Laboratory Biomarker Analysis|Correlative studies
45834480|NCT04394520|Other|Active Opt-in|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to actively opt-in to the survey, if they do not respond, the survey will terminate.
45834481|NCT04394520|Other|Active Opt-out|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to actively opt-out to the survey, if they do not respond, the survey will continue.
45834482|NCT04394520|Other|Passive Opt-in|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to passively opt-in to the survey, if they do not hang-up, the survey will continue.
46085325|NCT02756546|Drug|Hydrocortisone|
46085326|NCT02703558|Drug|Phenazopyridine|
46085327|NCT02703558|Drug|Fluorescein|
45834483|NCT04128618|Device|CyMedica e-vive NMES|Neuromuscular Electrical Stimulation (NMES) therapy
45995838|NCT02907866|Device|Ultrasound with EBUS scope and with linear ultrasound probe|All subjects will have an ultrasound of the chest performed with the tip of the EBUS scope as well as the linear ultrasound probe, which will be used as a reference for comparison. At the end of the procedure, while the patient in the supine position, the transducer of the EBUS bronchoscope will be placed on the anterior thorax, superficial to the skin and in a sagittal direction that is perpendicular to 2 ribs. The depth of the ultrasound beam will be increased to identify the pleural sliding sign and B lines (vertical lines) when present.This will be followed by use of linear ultrasound probe to scan the chest wall for normal lung sliding, B-lines and potential pneumothorax. The patient will remain in supine position. The linear probe will be placed on anterior thorax at the level of second intercostal space. The depth of the ultrasound beam will be adjusted to identify lung sliding and B-lines.
45995839|NCT02907827|Other|follow up DW MRI|Whole-body diffusion-weighted magnetic resonance imaging and cfDNA analysis
45995840|NCT00534885|Biological|Healive® Lot 1|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
45995841|NCT00534885|Biological|Healive® Lot 2|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
45995842|NCT00534885|Biological|Healive® Lot 3|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
45995843|NCT00534885|Biological|Havrix|Inactivated hepatitis A vaccine manufactured by GlaxoSmithKline Biologicals; two-dose regimen with 6 months apart
45995844|NCT02907671|Procedure|carpal tunnel corticoanesthetic injection|Different Injection Sites (between the flexot tendons or around the median nerve with hydrodissection)
45995845|NCT00548106|Dietary Supplement|partially hydrolyzed whey|Total infant feeding by study formula.
45995846|NCT00548106|Dietary Supplement|Nan HA|Total infant diet by study formula.
45995847|NCT02907749|Drug|Spironolactone and carvedilol|Patients are treated with carvedilol in combination with spironolactone.
45995848|NCT02907749|Drug|Carvedilol|Patients are treated with carvedilol only.
45995849|NCT00534924|Drug|Vit C|
45995850|NCT00534924|Procedure|Postconditioning|
45995851|NCT00534924|Other|no intervention|
45995852|NCT00548223|Drug|Dengzhan Shengmai capsule|Capsule, 0.18g, 2#, Bid*1year
45995853|NCT00548223|Drug|placebo|Capsule, 0.18g, 2#, Bid*1year
45995854|NCT02907593|Drug|Budesonide in Calfactant|Budesonide in Calfactant
45995855|NCT00548301|Drug|cyclosporine|
45995856|NCT02907710|Drug|Endostar|intravenous infusion
45674921|NCT02042443|Drug|Leucovorin Calcium|Given IV
45995857|NCT02907710|Drug|DDP|
45674922|NCT02042443|Drug|Trametinib|Given PO
45674923|NCT04747145|Device|Radiation|60 Gy to be delivered over 30 daily treatments in six weeks. Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
45457303|NCT01231789|Procedure|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min without any inflation procedure.
45674924|NCT04747145|Drug|Concurrent Chemotherapy (Temozolomide)|75mg/m^2 x 42 days (concurrent chemotherapy with radiation). Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
45834484|NCT03309306|Other|Natural Environment/Stress Management|Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will capture baseline data for 4-7 days. After a 1-week break, participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also receive information on stress management
45834485|NCT03309306|Behavioral|Natural Environment/Reduce Food Waste|"Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also be provided with the following:~Feedback on the amount of food waste their household created during the first week,~A goal to reduce the next week's food waste by 20% or more, and~Tips on how to reduce household food waste adapted from current consumer campaigns"
45995858|NCT03781362|Drug|CPI-100|CPI-100 will be administered via intravenous infusion on Day 1 of a 14-Day cycle
45674925|NCT04747145|Drug|Adjuvant Chemotherapy (Temozolomide)|Starting no sooner than 4 weeks after completion of chemoradiation, 150-200mg/m^2, days 1-5 of 28-day cycle, for minimum of six cycles and up to 12 cycles.
45674926|NCT02118896|Drug|FK506E|oral
45674927|NCT02124707|Drug|Cetuximab|400mg/m2 IV (in the vein) on day 1 of week 1 and 250mg/m2 IV (in the vein) on day 1 of weeks 2-6. Patients with stable disease may continue on maintenance therapy at the 250mg/m2 dose until disease progression.
45674928|NCT02124707|Drug|Paclitaxel|135mg/m2 IV (in the vein) on day 1 of each 1 week for 6 weeks.
45674929|NCT02124707|Drug|Carboplatin|AUC2, IV (in the vein) on day 1 of each 1 week for 6 weeks.
45995859|NCT03781362|Drug|Capecitabine|Capecitabine will be administered 1000 mg/m2 orally twice a day for 2 weeks followed by a 7-day rest period
45995860|NCT02907515|Device|cm-loc attachment|cm-loc is a new implant attachment mechanism with resin matrix housing to retain the overdenture
45995861|NCT02907515|Device|ball attachment|ball attachment is the gold slandered attachment mechanism with nylon cap and metal housing to retain the overdenture
45674930|NCT04723862|Drug|Spironolactone|Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
45674931|NCT04723862|Drug|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
45674932|NCT02067728|Behavioral|FNPA tool|Intervention practice will train to use FNPA screening paired with Brief Action Planning. They will implement this approach during well child visits.
45674933|NCT02067728|Behavioral|Usual Care|Practices not undergoing intervention with FNPA tool will provide usual care to patients during well-child visits.
45674934|NCT02118428|Device|Mirasol-treated Whole Blood|Transfusion with fresh Whole Blood treated with the Mirasol Pathogen Reduction Technology System for Whole Blood
45995862|NCT03767907|Behavioral|Computer-based Training for Cognitive Behavioural Therapy|Interactive content organized into seven modules, illustrating real-life scenarios associated with common risky situations, which illustrate the application of targeted skills and strategies
45995863|NCT03767907|Behavioral|Treatment As Usual|Treatment as usual will include standard psychosocial care determined to be appropriate or necessary, on an individual patient basis.
45995864|NCT04682249|Drug|Systemic Chemotherapy|Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
45995865|NCT04682249|Drug|Sintilimab|Sintilimab
45995866|NCT04682249|Drug|Apatinib|Apatinib
45674935|NCT02118428|Biological|Untreated Whole Blood|Transfusion with untreated fresh Whole Blood
45995867|NCT00548379|Drug|vitamin D|vitamin D 100,000 units once in 3 months
45995868|NCT00548379|Drug|placebo|olive oil 1ml
45995869|NCT04682054|Procedure|ocular surgery|surgery to remove the pathological eye tissue
45995870|NCT04972617|Diagnostic Test|albumin function analysis (ABIC)|After centrifugation (10 minutes at 4000 rpm), the plasma is aliquoted and stored at minus 80° C until further analysis. The free as well as the total furosemide concentration is determined by HPLC. In addition to the characterisation of the albumin function by means of the ABiC, these samples can also be used for the determination of the albumin concentration (prerequisite for the determination of the ABiC) and free furosemide concentration as well as for the determination of further parameters relevant for the albumin function.
45995871|NCT04682210|Drug|Sintilimab|Sintilimab 200mg IV Q3W
45995872|NCT04682210|Drug|Bevacizumab|Bevacizumab 7.5mg/kg IV Q3W
45995873|NCT04682015|Other|WeChat platform group|Participants in the intervention group will receive educational messages related to hypertension, such as impact of hypertension on cardiovascular system, lifestyle adjustment and side effects of antihypertensive drugs. Participants will be reminded to take their blood pressure regularly and enter the blood pressure readings into the WeChat platform. If participants enter extremely high or low readings, they will be asked to seek medical help from doctors. Participants can also consult doctors online via WeChat platform by text and voice messages, or voice calls.
45995874|NCT03664089|Behavioral|Ankle weights (2.5 pounds [1.1 kg]/ankle)|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds [1.1 kg]/ankle), documentation for ankle weight usage, an accelerometer, and instructions for accelerometer usage.
45674936|NCT02067104|Drug|Vismodegib|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
45674937|NCT02067104|Drug|Placebo|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
45674938|NCT02092220|Device|Bionic Pancreas|
45674939|NCT02092220|Device|Insulin pump with or without CGM|
45674940|NCT02066402|Drug|Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Tedizolid once daily i.v to oral from 1-6 days
45674941|NCT02066402|Drug|Placebo Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Placebo Tedizolid once daily i.v to oral from 7-10 days
45674942|NCT02066402|Drug|Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Linezolid twice daily i.v. to oral from 1-10 days
45674943|NCT02066402|Drug|Placebo Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Placebo Linezolid twice daily i.v. to oral from 1-10 days
45674944|NCT02060383|Drug|Pasireotide s.c.|Administered to Cushing's disease participants.
45995875|NCT03664089|Behavioral|Control|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
45995876|NCT04682132|Diagnostic Test|COVID-19 antigen and antibody tests, and influenza rapid test|Study volunteers will be offered free COVID-19 and influenza testing and the opportunity to complete an electronic survey about any symptoms.
45995877|NCT00548496|Drug|SB-751689|SB-751689
45995878|NCT00548496|Other|Placebo|Placebo to match
45995879|NCT03661905|Other|Cognitive therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Twelve treatment sessions include components to foster cognitive (i.e. thinking) and behavioural changes.
46085328|NCT02657811|Device|Miri, Benchtop Multi-room incubator|Bench Incubation - Morphologic Assessment These embryos will undergo multiple evaluations using light microscopy and traditional morphologic assessment.
45457304|NCT02300350|Drug|Treatment A digoxin|0.5 mg digoxin administered on Day 1 and Day 20
45457305|NCT02300350|Drug|Treatment B LX4211|400 mg LX4211 administered daily on Day 14 through Day 25
45457306|NCT02300350|Drug|Treatment C Digoxin + 400 mg LX4211 administered concomitantly|0.5 mg Digoxin + 400 mg LX4211 administered concomitantly on Day 20
45457307|NCT01349348|Drug|Tolvaptan|tablet, 15 mg, Qd, for 7 days
45674945|NCT02060383|Drug|Sitagliptin|Taken for approximately 16 weeks during the core study phase or until the drug was found not to be effective
45995880|NCT03661905|Behavioral|Exposure and Response Prevention|Exposure therapy in which individuals confront their fears and discontinue their escape response. Twelve treatment sessions implementing exposure which is prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
45995881|NCT02907476|Behavioral|Iyengar Yoga|
45995882|NCT02907476|Behavioral|Walking|
45995883|NCT04971876|Device|HLR-1|Initial injection of HLR-1 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 3mL.
45995884|NCT04971876|Device|HLR-2|Initial injection of HLR-2 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 3mL per NLF.
45995885|NCT04971876|Device|HLR-3|Initial injection of HLR-3 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 4mL per cheek.
45995886|NCT02907554|Drug|cyclosporine A|the intervention group receives 2.5 mg/kg of cyclosporine
45995887|NCT02907554|Drug|Placebo|control group receives a placebo
45995888|NCT03657303|Device|Magnetic resonance imaging (MRI)|Participants will undergo an initial (baseline) MR examination, followed by repeat MR examinations at approximately 1 month and 1 year following the baseline examination.
45995889|NCT02907632|Drug|Metoclopramide|"Metoclopramide Solution 4 mg / ml; 30 ml canister (1 drop equals 0.2 mg). Dose: 0.2 mg / kg / dose (1 drop per kg) every 8 hours orally 15 minutes before lactation.~Duration: Until the child completes 40 weeks of post menstrual age."
45995890|NCT02907632|Drug|Placebo|Oral solution: 1 drop per kg of placebo 15 minutes before lactation with identical presentation appearance, taste and color than Metoclopramide. Duration: Until the child completes 40 weeks of post menstrual age.
45995891|NCT02907437|Drug|Minocycline|Minocycline as an add-on drug (200 mg/day)
45995892|NCT02907437|Drug|Placebo|(200 mg/day)
45995893|NCT02907437|Other|Probiotics|(450 mg/day)
45995894|NCT00548535|Procedure|Reliability of complication assessment|
45995895|NCT02907047|Other|tourniquet inflated|
45995896|NCT02907047|Other|tourniquet not inflated|
45995897|NCT01262872|Biological|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
45995898|NCT01262872|Biological|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
45995899|NCT01262872|Biological|Synflorix™|Intramuscular injection
45995900|NCT01262872|Biological|Prevnar13™|Intramuscular injection
45995901|NCT01262872|Biological|Tritanrix™-HepB/Hib|Intramuscular injection
45674946|NCT02060383|Drug|Liraglutide|Participant switched to liraglutide if sitagliptin was found not to be effective.
45834486|NCT04120662|Procedure|Intramedullary screw fixation|A Kirschner wire was introduced in the proximal tuberosity under anteroposterior and lateral fluoroscopic control, following the bone axis and passing through the fracture line; a cannulated compressor screw in a diameter between 45 - 55 mm in the more satisfactory position to achieve the optimal fragments compression.
45834487|NCT04120662|Device|Focused Shock Wave Treatment|3 weekly session, one per week, of focused shock waves, using an electrohydraulic device.
45834488|NCT04120506|Drug|VPRIV|Safety, pharmacokinetics, and efficacy of rapid intravenous infusion of velaglucerase alfa (VPRIV) in adult patients with type 1 Gaucher disease
45995902|NCT01262872|Biological|Polio Sabin™|Orally
45995903|NCT01262872|Biological|M-Vac™|Intramuscular injection
45995904|NCT01262872|Biological|Stamaril™|Intramuscular injection
45674947|NCT02060383|Drug|Insulin|"Participant took insulin for 16 weeks. Insulin was also administered as rescue therapy in the incretin-based therapy arm if required.~Insulin was administered to the BL-insulin group at the discretion of the Principal Investigator.~Note: OAD and No OAD groups within the non-randomized arm did not take Insulin."
45995905|NCT03622320|Other|Blood sample|Blood sample for fasting blood sugar (FBS), High density lipoproteins (HDL), Triglycerides (TG) ,HOMA-IR, serum leptin
45995906|NCT00534963|Procedure|cervical vs. uterine placement of balloon catheter|
45995907|NCT02907125|Behavioral|SEHER Intervention delivered by TSM|"SEHER Intervention The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
45995908|NCT02907125|Behavioral|SEHER Intervention delivered by SM|"The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
45834489|NCT04120350|Drug|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
45834490|NCT04120350|Drug|Rituximab|375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
45995909|NCT02907125|Behavioral|Tarang AEP|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
45995910|NCT02907320|Drug|CYCLO 3 ® FORT|
45995911|NCT02907320|Drug|MPFF|
45457308|NCT01349348|Drug|Tolvaptan|tablet, 7.5 mg, Qd, for 7 days
45674948|NCT02060383|Drug|Pasireotide LAR|Administered to Acromegaly participants.
45995912|NCT02907320|Drug|placebo CYCLO 3 ® FORT|
45995913|NCT02907320|Drug|placebo MPFF|
45995914|NCT02907164|Behavioral|Email invitation|Receive emails encouraging them to sign up
45995915|NCT02907164|Behavioral|Social norm|Receive information about how many people have signed up
45995916|NCT02907164|Behavioral|Intrinsic, health motive|Receive information about how the challenge helps people to stay fit in a fun way
45995917|NCT02907164|Behavioral|Extrinsic, reward motive|Receive information about how the challenge helps people to stay active and earn rewards
45995918|NCT04323085|Behavioral|Speech-in-Noise Treatment Program|Speech therapy program for hypophonia.
45995919|NCT04323085|Behavioral|Speech-to-Noise Feedback Device Program|Speech Feedback device program for hypophonia.
45995920|NCT05519488|Behavioral|Rubato Life Music|Participants will listen to music using Rubato Life app at least 45 minutes per day, for a period of 2 weeks coming up to their scheduled restaging appointment (or at least 12 total hours of listening), and for one hour immediately after the appointment. Patients in the Intervention group will wear smartwatches to monitor heart rate variability throughout the study
45995921|NCT05519488|Behavioral|Music of their desire|patients will be asked to listen to a minimum of 45 minutes per day of music (or a total of 12 hours), of their desire, which the participant considers as stress relief music for a period of a 2 weeks (or a total of 12 hours)
45995922|NCT02907281|Other|Observational|Observational
45995923|NCT04323241|Other|Controlled cord traction|In group 2, Spontaneous removal will be performed by massaging on the uterine fundus and applying gentle traction on the umbilical cord.
45995924|NCT02899637|Device|Active high-frequency Transcranial Magnetic Stimulation|Active intervention, 5Hz on the lower limbs area of the motor cortex, during one week
45995925|NCT02899637|Device|Sham high-frequency Transcranial Magnetic Stimulation|Sham intervention, 5Hz on the lower limbs area of the motor cortex, during one week
45995926|NCT03574623|Device|Electrical Stimulator|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to turn on and off in a repetitive cyclic fashion (i.e., cNMES) or be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).
45995927|NCT03574623|Behavioral|Occupational Therapy|Task practice that requires movement and use of the paretic hand under the guidance of a trained therapist.
45995928|NCT02899676|Other|neuropsychological testing|
45995929|NCT02899676|Other|functional magnetic resonance imaging|
45995930|NCT02899676|Other|simple arithmetic operations|
45834491|NCT04120350|Drug|Lenalidomide|"In phase 1b study, a 3+3 design dose- escalation will be taken. 3 levels should be tested, 15/20/25mg orally d1-14, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol.~[update 02-Jun-2020: the phase Ib trial has finished,and no MDT was obsevered in 25mg group. So the recommanded phase II dose was 25mg.] In phase II study, 25mg daily is considered as an experiment dose for the induction cycles.~In both phase Ib and II study, the does of lenalidomide maintenance is fixed to 25mg orally d1-21 every 28 days for 1 cycle. The duration of maintenance is 2 years."
45995931|NCT00548574|Drug|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
45995932|NCT00548574|Drug|Mesalazine|
45995933|NCT02899559|Behavioral|Message|Participants will receive one of three messages at the end of a survey, two of which are experimental messages and one of which is a control message.
45995934|NCT03527433|Procedure|New closure technique|In the intervention arm, an average of two sutures will be placed at each cm length of the wound, thus the number of sutures placed should be equal to at least double the length of the wound in cm.The aim is to have a ratio of 4:1 between the overall lengths of the suture to the length of the wound being closed
45995935|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
45995936|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 11 days
45995937|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 330 mg, once per day (QD) for the remainder of the double-blind treatment phase (max is 12 weeks)
45995938|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 7 days
45995939|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
45995940|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for the remainder of the up-titration and double-blind treatment and taper phases (max 14.5 weeks)
45995941|NCT01262677|Drug|placebo|matched to the active drug
45457309|NCT01349348|Drug|placebo|tablet, 7.5/15mg , Qd, 7days.
46002365|NCT03416179|Drug|daunorubicin + cytarabine|"'7+3' (cytarabine 100 mg/m2, IV for 7 days by continuous infusion and daunorubicin 60 mg/m2 for 3 days).~If a second induction is needed, Investigators may choose either a 5 day cytarabine continuous infusion plus daunorubicin for 2 days ('5+2') or a 7 day cytarabine continuous infusion plus daunorubicin for 3 days ('7+3');"
45995942|NCT02899442|Other|collective prevention in workplace|From countermeasures referenced in guidelines, some tools were also created by the committee to standardize all preventive actions and to define measurable indicators. A specific monitoring for checking their applicability and for evaluating the duration of implementation is planned.Collective actions are classified in 7 categories:1)Standardized information of night work risk on health and countermeasure to prevent them, 2)Acknowledgement of the existence of the risk, thereby helping to raise general awareness, 3)Improvement of characteristics of night work (rhythm, rest, time to start and to end, schedule forecasted, duration of night work),4)Improvement of related conditions at night work (Job strain, monotonous or repetitive tasks, manager's help, collective co-operation; Light environment; Occupational physical activities, 5)Sleep improvements ,6)Improvement of dietetic intakes at work, 7)Improvement of leisure physical activity's practice within the work site
45995943|NCT00535041|Drug|Chemotherapy, radiation therapy & surgery|radiation and chemotherapy
45995944|NCT02899364|Drug|Sodium thiosulfate|see description under experimental arm
45995945|NCT02899364|Drug|Sodium chloride 0.9%|see description under placebo comparator arm
45995946|NCT02899364|Procedure|primary percutaneous coronary intervention|Primary treatment of the ischemia-related coronary artery is left to discretion of the operator and might consist of thrombus aspiration, balloon inflation and stent implantation. Additional balloon angioplasty or stenting of the culprit or other lesions will be performed when necessary.
45995947|NCT02899364|Other|cardiac magnetic resonance imaging|CMR-imaging will be used for assessment of infarct size, left ventricular function, quantification of myocardial scar and diffuse myocardial fibrosis. CMR-imaging examinations will be performed on a 3 Tesla scanner using a phased array cardiac receiver coil at 4 months after randomization according to standard protocols. The full study protocol lasts approximately 45 minutes and includes anatomy and function, LGE and T1-mapping.
45995948|NCT00548613|Biological|MESENDO|Intracoronary transplantation of autologous stem cells via balloon catheter
45995949|NCT00548613|Biological|MESENDO|Intracardiac transplantation of autologous stem cells via direct injection
45995950|NCT04206865|Drug|Sacubitril-Valsartan|Patient's will be randomized to ICU initiation of sacubitril-valsartan vs. alternate oral vasodilator therapy in 1:1 fashion
45995951|NCT04206865|Drug|Standard Oral Vasodilators|Patient's will be randomized to ICU initiation of sacubitril-valsartan vs. alternate oral vasodilator therapy in 1:1 fashion. Alternate vasodilators will include ARBs, hydralazine and isosorbide dinitrate, and ACEi
45995952|NCT02899247|Procedure|Surface sealant|"Device:~Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA).~The composite surface and 1 mm external limit will be etched with a 37% acid phosphoric and after will be covered using a nanotechnology liquid polish system (Lasting Touch, Dentsply Caulk, Milford, DE, USA)."
45995953|NCT02899247|Procedure|No surface sealant|"Device:~Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA)."
45995954|NCT00535080|Drug|Metvix (methyl aminolevulinate)|Metvix (methyl aminolevulinate) (MAL), Photodynamic Therapy (PDT), cream, 160 mg/g. MAL cream will be applied for 3 hours then will be removed. The target area will then be exposed to red light (using a large-field LED light source: Aktilite 128) for 7 to 10 minutes at a dosage of 37 J/cm².
45995955|NCT02899403|Other|Rapid Visual Information Processing (RVIP) test|Rapid Visual Information Processing is a measure of sustained attention.
45457310|NCT02300428|Dietary Supplement|oral iron|BNF code for section 9.1.1.1 (Oral iron preparations for iron-deficiency anaemias)
45674949|NCT02060383|Drug|Metformin|"If previously normo-glycemic participants experienced increase in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they started anti-diabetic treatment using metformin. If they continued to experience increase in their fasting blood glucose within the first 16 weeks, they were randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks. Metformin treatment was not required for the BL Insulin and OAD groups, within the non-randomized arm, but may have been prescribed at the discretion of the investigator.~Note: No OAD group within the non-randomized arm did not take metformin."
45674950|NCT02086591|Drug|Doxycycline|
45674951|NCT02065622|Drug|Adalimumab|
45995956|NCT01262638|Drug|ETC-1002|ETC-1002 daily for 12 weeks
45995957|NCT01262638|Drug|Placebo|Placebo daily for 12 weeks
45995958|NCT02899520|Other|Reference method|Electrostimulation associated to perineal training
45995959|NCT02899520|Other|CMP ® method|Method based on Knowledge and Control of Perineum
45995960|NCT00535119|Drug|Carboplatin|Given IV
45995961|NCT00535119|Other|Laboratory Biomarker Analysis|Correlative studies
45995962|NCT00535119|Drug|Paclitaxel|Given IV
45995963|NCT00535119|Other|Pharmacological Study|Correlative studies
45995964|NCT00535119|Drug|Veliparib|Given PO
45457311|NCT01356056|Device|Kinesia HomeView|Quantifies motor symptom severity in the home
45457312|NCT01131637|Drug|rhNRG-1|day1~day10:0.6ug/kg/day,10hours per day for vein infusion; week3~week25:0.8ug/kg/day,10minutes per time per week for vein injection
45457313|NCT01131637|Drug|placebo|day1~day10:0.6ug/kg/day,10hours per day for vein infusion; week3~week25:0.8ug/kg/day,10minutes per time per week for vein injection
45674952|NCT02065622|Other|Placebo|
45995965|NCT00535158|Drug|Ergocalciferol (Vitamin D 2)|50,000units once weekly for 8 weeks then every other week for 4 weeks
45995966|NCT00535197|Biological|Infusion of autologous CD34+ stem cells into middle cerebral artery|intra-arterial infusion into ipsilateral MCA, via trans-femoral approach
45995967|NCT04684407|Procedure|ROOT CANAL TREATMENT|TWO TYPE OF INTRA CANAL MEDICATION PLACEMENT
45995968|NCT04942080|Biological|CALR allele burden quantification|"DNA extraction from blood sample for CALR mutation quantification (fragment analysis)~at diagnosis and follow-up (inclusion period: 3 years)~max 1 sample/year~secondary outcome: mutational landscape by Next Generation Sequencing (NGS) analysis at diagnosis"
45995969|NCT00548730|Procedure|Bronchoscopy|The endoscopic examination of the bronchial tree will be performed using a commercially available flexible fluorescence bronchoscope and the flexible white light video-bronchoscope. Biopsies are taken of a normal region and all abnormal regions.
45995970|NCT03436992|Dietary Supplement|Antioxidant Cocktail|Vitamin C, Vitamin E, alpha lipoic acid
45995971|NCT03436992|Dietary Supplement|Resveratrol|1500 mg trans-resveratrol
45995972|NCT03436992|Other|Placebo|placebo
45995973|NCT00548769|Drug|Formulation A|Formulation A will contain firategrast drug substance from native drug batch Irvine. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.1 square meter per gram. The tablets will be administered with 240 milliliters of water.
45995974|NCT00548769|Drug|Formulation B|Formulation B will contain firategrast drug substance from native drug batch Tonbridge. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
45995975|NCT00548769|Drug|Formulation C|Formulation C will contain firategrast drug substance from Tonbridge single pass micronized drug. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 3-4 square meter per gram. The tablets will be administered with 240 milliliters of water.
45674953|NCT02117648|Drug|Abemaciclib|Administered orally
45674954|NCT02117648|Drug|Clarithromycin|Administered orally
45674955|NCT02124161|Biological|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
45674956|NCT02124161|Biological|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
45674957|NCT02124161|Other|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
45674958|NCT02124161|Other|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
45834492|NCT04128306|Behavioral|Behavioral task|In the task, participants will see an object approaching toward them. During its movement, the object disappears, and the participants have to press a button to indicate when they estimate the object to contact with them. The motion parameters of the ball will be varied. The pre and post-surgery phases will test the participants in a long duration version of the task, approximately 30 minutes. The per surgery phase will be made of a 5 minutes version of the task, and the participants will receive a direct cortical stimulation for 4 seconds, at an intensity of 1 to 10 milliampere (mA), in the premotor ventral area, or posterior parietal cortex or somesthetic associative areas.
45995976|NCT00548769|Drug|Formulation D|Formulation D will contain firategrast drug substance from Tonbridge with reduced tablet size. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
45995977|NCT01262560|Drug|Manuka honey in liquid form|Patients swallow 10 cc (approximately 2 level teaspoons) of liquid Manuka honey 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
45995978|NCT01262560|Drug|Manuka honey in lozenge form|Patients place 2 lozenges (the equivalent of 10 cc of liquid Manuka honey), one at a time, in the mouth, allowing each lozenge to dissolve on the tongue/in the mouth, swallowing the honey as it dissolves. Patients do this 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
45995979|NCT01262560|Drug|Standard supportive care|"Patients receive standard supporting care for esophagitis-related pain as needed during concurrent chemotherapy and radiation treatment. The following regimen is recommended, but the local standard of care is permitted.~A compound containing viscous lidocaine and magnesium aluminum oxide (Maalox®);~Liquid or solid oxycodone, 5-10 mg, every 3 hours as needed."
45995980|NCT03429894|Device|Percutaneous Coronary Intervention|Drug eluting stent implant
46002366|NCT03416179|Drug|azacitidine|Azacitidine (75 mg/m2, SC or IV) daily for 7 days, in 28 day cycles for as long as they do not meet the criteria for disease progression, unacceptable toxicity, consent withdrawal, or death.
45674959|NCT02124161|Biological|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
46085329|NCT02657811|Device|Miri TL, Time-Lapse incubator|Time Lapse Incubation - Morphologic/Morphokinetic Assessment These embryos will remain in the TLI and undergo both morphologic and morphokinetic evaluation and grading according to a hierarchical multivariable model. They will not be removed from incubation for the duration of culture.
45995981|NCT04083118|Diagnostic Test|clinical evaluation, blood markers, pulse wave analysis, 18F sodium fluoride PET/CT and PET/MRI|Patients will receive a structured clinic history, examination, blood sampling, pulse wave analysis, pulse wave velocity, 18F-sodium fluoride PET/CT, 18F-sodium fluoride PET/MRI with detailed cardiac magnetic resonance imaging and magnetic resonance imaging of the aorta
45995982|NCT04083118|Diagnostic Test|Repeat 18F sodium fluoride PET/MRI|as per first study visit but without the PET/CT
45995983|NCT04686669|Drug|FOR-6219 capsule formulation|FOR-6219 capsule formulation will be available as a soft gelatine capsule with a single dose of 50 milligrams, administered orally.
45995984|NCT04686669|Drug|FOR-6219 tablet formulation|FOR-6219 tablet formulation will be available as a tablet with a single dose of 50 milligrams, administered orally.
45995985|NCT04207450|Other|Placebo gel|Placebo gel application followed by placebo solution application (distilled water)
45995986|NCT04207450|Other|Placebo Gel + 5% Glutaraldehyde Aqueous Solution|Placebo gel followed by 5% aqueous glutaraldehyde solution
45995987|NCT04207450|Other|Phosphoric Acid 37% + Solução aquosa de glutaraldeído a 5%|37% phosphoric acid application followed by 5% aqueous glutaraldehyde solution
45995988|NCT04322929|Drug|Roflumilast Oral Tablet|Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor is approved worldwide (including Hong Kong) for treatment of severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations. Roflumilast has been shown to have anti-inflammatory effect in patients with COPD, with significant reduction of sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Roflumilast can also improve the lung function parameters in patients with COPD and reduce the rate of moderate-to-severe exacerbations.
45995989|NCT04686396|Device|Demineralized bone matrix|Demineralized bone matrix
45995990|NCT04322773|Drug|RoActemra iv|single dose treatment with tocilizumab 400 mg intravenously
46085330|NCT02657811|Device|Miri TL, Time-Lapse incubator|Time Lapse Incubation - Morphologic Assessment These embryos will remain in the TLI and undergo only traditional morphologic assessment according to accepted criteria with no additional imaging. They will also not be removed from incubation for the duration of culture. The time points and evaluated parameters will be identical to those in arm 1 of the study.
46085331|NCT04222244|Other|No intervention will be administered. We are only performing tests and measures.|No intervention will be administered. We are only performing tests and measures.
46085332|NCT04756752|Other|Fit and Vitaal program|Intervention type: training
46085333|NCT02759666|Drug|SHR3162|SHR3162 capsule(s) is administered orally QD.
45834493|NCT04128306|Procedure|Awake surgery|"The patient is first anesthetized for opening the scalp and skull, then awake. During this waking phase, the surgeon passes a few quick and simple tests to the patient, visual (for example, line bisection), language (for example, repeating a list of words) etc. While doing this task, the neurosurgeon disrupts the functioning of certain brain regions by direct electrical stimulation of the cortex in order to identify the regions whose dysfunction will have an impact on the current task.~During the operation, the areas involved in the construction of the peri-personal space will be stimulated by direct electrical stimulation, for a duration of 4 seconds at an intensity of 1 to 10 mA. These areas are:~Ventral premotor cortex (with the exception of the primary motor cortex controlling the dominant hand, so as not to interfere with the motor response of the patient)~Posterior parietal cortex~Associative somesthetic areas"
45834494|NCT04128306|Other|Neurological assessment|The Mini Mental State Evaluation, which generally assesses the cognitive state of an individual through his 6 subtests testing both working memory, episodic and semantic praxies as well as spatio-temporal orientation capacity.
45995991|NCT04322773|Drug|RoActemra sc|single dose treatment with tocilizumab 2 x 162 mg subcutaneously
45995992|NCT04322773|Drug|Kevzara sc|single dose treatment with sarilumab 1 x 200 mg subcutaneously
45995993|NCT04322773|Other|Standard medical care|management as usual
45995994|NCT04322812|Device|Active PBMT|The Active PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA) will be used. The ACTIV PRO emits 30mW of 905nm, 300mW of 850nm, 200mW of 660nm and 0mW of 455nm light via an electric diode energy source. PBMT will be applied using the direct contact method with light pressure on the skin. The PBMT application time will be 120 seconds per region and the total time will vary according to the number of regions to be treated. Only the painful regions on that day will be treated (according widespread pain index [WPI] ), which can comprise a minimum of 3 and a maximum of 18 regions in total. The dose used for applications during the treatment will be 60 Joules (J) per region. The total dose might vary between patients and each session.
45995995|NCT04322812|Device|Placebo PBMT|The placebo PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA). The ACTIV PRO emits 905nm, and 850nm via an electric diode energy source with outputs to 0%. The 660nm light via an electric diode energy source with outputs to >1% to appear like the active comparator. PBMT will be applied using the direct contact method with light pressure on the skin. The placebo PBMT application time will be 115 seconds per region and the total time will vary according to the number of regions to be treated. Only the painful regions on that day will be treated (according WPI), which can comprise a minimum of 3 and a maximum of 18 regions in total. The dose used for applications during the treatment will be 0 Joules (J) per region. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
45995996|NCT04070443|Drug|Ponatinib|30mg/day; 6 months. Dose adaptation procedures are planned in case of toxicity.
45995997|NCT04070443|Drug|Imatinib|400 mg/day; at least 30 months (M7 to M36), then depending of MR4.5 . Dose adaptation procedures are planned in case of toxicity.
45995998|NCT02888782|Other|Pharmacist Consultation|
45995999|NCT04686591|Drug|AZD9977 capsule 50 mg|100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capusles)
45996000|NCT04686591|Drug|[14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)|One 100 µg dose of [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)
45996001|NCT04686591|Drug|[14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)|One 100 mg dose of [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)
45996002|NCT04043494|Drug|Cyclophosphamide|Part of standard chemotherapy and included in the experimental treatment phase protocol Ib* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
45996003|NCT04043494|Drug|Cytarabine|"No involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase protocol Ib* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2).~Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)"
45996004|NCT04043494|Drug|Dexamethasone|Part of the experimental therapy in Randomization R1 (Protocol Ia-Dexamethasone) and in Randomization R2 (Intensified Protocol M)
45996005|NCT04043494|Drug|Daunorubicin|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
45457314|NCT03515746|Device|Exergaming in virtual environment|"The 10 cubes task will be performed in virtual environment - either in 2D on a laptop computer or in 3D using 3D goggles"
45457315|NCT02293876|Device|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
45457316|NCT02293876|Device|LIPOSIC®|Carbomer and Sorbitol based gel, used in the treatment of dry eye.
45834495|NCT04128306|Other|Neurological assessment|The Wechsler Adult Intelligence Scale was selected for two of its subtests: The Subtest Codes checking the processing of information, visuo-constructive abilities but also attention. The subtest Cubes evaluates the capacities of visuospatial and constructive organizations as well as the referencing of the space in relation to the subject.
45834496|NCT04128306|Other|Neurological assessment|The State-Trait Anxiety Inventory, consisting of two self-administered questionnaires: Questionnaire A, measuring the state of anxiety of the person on the present moment and B measuring anxiety as a character trait of the person
45834497|NCT04128306|Other|Neurological assessment|The Verbal Fluences test, in its oral version. Categorial and lexical fluences make it possible to quickly realize a possible lack of the word of the person as well as disturbances of working memory or the capacity of inhibition.
45834498|NCT04128306|Other|Neurological assessment|The board of the Corsi cubes that evaluates the non-verbal visual-spatial working memory of the participants with a reminder location that tests the visuo-spatial notebook and a reminder to who tests the central administrator of the working memory.
45834499|NCT04128306|Other|Neurological assessment|The neurocognitive naming test was chosen to verify correct access to both semantic memory and lexicon, as well as to test the early visual process of image processing necessary for our task.
45996006|NCT04043494|Drug|Doxorubicin|Part of standard chemotherapy
45996007|NCT04043494|Drug|Ifosfamide|Part of the experimental therapy in Randomization R2 (Intensified Protocol M)
45996008|NCT04043494|Drug|6-Mercaptopurine|Part of standard chemotherapy and included in the experimental treatment phase protocol Ib* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
45996009|NCT04043494|Drug|Methotrexate|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
45996010|NCT04043494|Drug|PEG asparaginase|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1) and in the experimental treatment phase Protocol Ib* (Randomization R2)
45996011|NCT04043494|Drug|Prednisone|Part of standard chemotherapy
45996012|NCT04043494|Drug|Prednisolone|No involvement of CNS: Part of standard chemotherapy. Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2
45996013|NCT04043494|Drug|Thioguanine|Part of standard chemotherapy
45996014|NCT04043494|Drug|Vincristine|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
45996015|NCT04043494|Drug|Vindesine|Part of the experimental therapy in Randomization R2 (Intensified Protocol M)
45996016|NCT04686357|Diagnostic Test|EMMA/ALICE|"Before randomization, an endometrial biopsy (EB) sample will be collected from all participants between day 15 and 25 of a natural cycle or after around 120 hours of progesterone (P) impregnation during a standard HRT cycle. The results of the EMMA/ALICE test will be provided to participants and their gynecologists. Depending on the test results, there are 3 different possibilities:~Normal result~Ultralow or Dysbiotic result~Abnormal result (pathogens) All probiotics and antibiotics that will be used in the study are already authorized by the local health authorities and will be prescribed under their technical data sheet/brochure conditions following the medical indications."
45996017|NCT04686357|Diagnostic Test|EMMA/ALICE|Before randomization, an endometrial biopsy (EB) sample will be collected from all participants between day 15 and 25 of a natural cycle or after around 120 hours of progesterone (P) impregnation during a standard HRT cycle. The results of the diagnosis will not be disclosed with the patients randomized into this arm nor with their gynecologists.
45834500|NCT04128306|Other|Neurological assessment|Benton lines are commonly used to determine possible deficits in the localization of isolated objects or judgment of line direction.
45834501|NCT04128306|Other|Neurological assessment|The patient will finally pass a depression assessment test, answering Beck's questionnaire.
45834502|NCT04394598|Drug|Dendrobium Huoshanense Granules|3g tid per day for 5weeks
45834503|NCT04394598|Radiation|Pelvic Radiation|50Gy/25Fx
45834504|NCT04394598|Drug|Capecitabine|625mg/m2 bid Monday-Friday per week
45834505|NCT04394598|Drug|Irinotecan|80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
45834506|NCT04394598|Other|Placebo|3g tid per day for 5weeks
45834507|NCT04120272|Procedure|Spine surgery|Eligible Surgeries: lumbar spine fusion surgery, posterior cervical spine fusion surgery, or anterior cervical spine fusion surgery
45834508|NCT04394832|Behavioral|Brief cognitive intervention|See the information provided in the experimental arm description.
45457317|NCT02293876|Device|Glad wrap|A clear plastic wrap occluding eye and orbital area, turning the space into a moisture chamber.
45834509|NCT04127916|Drug|Bendamustine|To investigate the efficacy and safety of bendamustine plus rituximab in patients with mantle cell lymphoma.
45996018|NCT02899481|Other|Transabdominal and transperineal ultrasound|Transabdominal ultrasound, for determining fetal head position, is performed with the pregnant women in supine position after bladder emptying, with the transducer placed transversely on the suprapubic region of the maternal abdomen. For the sonographic determination of the fetal descent we will perform a transperineal ultrasound achieved by placing the ultrasound transducer on the perineum in a mid sagittal position between the labia below the pubic symphysis.
45996019|NCT02899286|Biological|PEG-BCT-100|PEGylated recombinant human arginase
45996020|NCT04322461|Dietary Supplement|Betaquik MCT supplement|50g/day divided in 3. Breakfast, lunch and dinner
46085334|NCT02657733|Device|Radical-7|"Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time.~Radical-7- measures respiratory rate according to acoustic respiratory rate (RRa)."
45996021|NCT00535275|Drug|Chemotherapy with platine|Docetaxel 75 mg/m² D1 + Cisplatine 75 mg/m² or Carboplatin AUC5 D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
45996022|NCT00535275|Drug|Chemotherapy without Cisplatine|Docetaxel 75 mg/m² D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
45996023|NCT04322344|Drug|Escin|treatment with escin or escinate sodium
45996024|NCT04322344|Drug|standard therapy|antiviral drugs
45996025|NCT04322422|Drug|Inhaled corticosteriod/long-acting beta-agonist plus Montelukast|Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma; Montelukast is benefitial for allergic disease
45996026|NCT04322422|Drug|Inhaled corticosteriod/long-acting beta-agonist only|Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma
45996027|NCT02899169|Drug|Realgar-Indigo naturalis formula|
45996028|NCT02899169|Drug|all-trans retinoic acid|
45996029|NCT02899169|Drug|Arsenic trioxide|
45996030|NCT02899169|Drug|Hydroxyurea|
45996031|NCT00535314|Drug|RTA 402 Dose1|
45996032|NCT00535314|Drug|RTA 402 Dose2|
45996033|NCT05517031|Other|ASDAS score , VAS score, BASFI score , Katz ADL index|Scores that done on patient to fullfill criteria of diagnosis , and measure affection of disease on patients and their daily living activity
45996034|NCT04322188|Other||this is an observational study. No intervention is applicable; patients are managed as per clinicians' best judgement and best practice
45996035|NCT02899130|Drug|Polyherbal|Each capsule contains 3 herbs. Phyllanthus niruri, Boerhaavia diffusa, picrorhiza kurroa
45996036|NCT02899130|Drug|Placebo|Inactive compound that is similar looking as the intervention
45674960|NCT02124161|Biological|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
45996037|NCT00548964|Drug|Lithium|600-900mg of Li carbonate
45996038|NCT00548964|Drug|Ketamine|0.5mg/kg of ketamine
45996039|NCT04322227|Drug|Foliglurax 10 mg (treatment A)|Foliglurax 10 mg, (BID) capsules, orally
45996040|NCT04322227|Drug|Foliglurax 30 mg (treatment B)|Foliglurax 30 mg, BID capsules, orally
45996041|NCT04322227|Drug|Placebo (treatment C)|Placebo, BID capsules, orally
45996042|NCT02889601|Other|Psycho-behavioural assessment|DAPHNE Scale
45996043|NCT02898896|Biological|blood test|Additional 21 ml of blood will be collected
45996044|NCT03391362|Radiation|Stereotactic Radiation|Stereotactic radiation involves using a high dose of radiation that only targets the specific metastases
45996045|NCT02899013|Other|No intervention|Observational study to describe Perianal Lesions in a Cohort of Crohn's Disease Patients.
45996046|NCT03382938|Drug|Dexmedetomidine|WOUND INFILTRATION IN CESAREAN SECTION
46085335|NCT02657733|Device|Nellcor™ Bedside Respiratory Patient Monitoring System|"Comparison between 3 different monitors that measure repiratory rate. The participant is connected to 3 monitors at the same time.~Nellcor™ Bedside Respiratory Patient Monitoring System - measures respiratory rate according to oximetry respiration rate (RRoxi)."
45996047|NCT03382938|Drug|Ropivacaine|WOUND INFILTRATION IN CESAREAN SECTION
45996048|NCT03382938|Drug|Dexmedetomidine - Ropivacaine|WOUND INFILTRATION IN CESAREAN SECTION
45996049|NCT03382938|Other|0,9% saline|placebo WOUND INFILTRATION IN CESAREAN SECTION
45996050|NCT02899091|Biological|CB-AC-02|"Stage1:~① Group1: CB-AC-02, 2.0 x 10^8 cells on day 0~② Group2: CB-AC-02, 2.0 x 10^8 cells, on day 0 and on week 4 (repeated injection)~Stage2~① Arm1: K-MMSE 20~26 CB-AC-02, 2.0 x 10^8 cells on day 0 and on week 4 (repeated injection)~② Arm2: K-MMSE 10~19 CB-AC-02, 2.0 x 10^8 cells on day 0 and on week 4 (repeated injection)"
45996051|NCT02899091|Biological|Placebo|"Stage2:~Placebo on day 0 and on week 4 (repeated injection)"
45996052|NCT04323007|Diagnostic Test|Nephrotic patients|Laboratory measures will include Blood sugar Urine analysis with 24hrs protein in urine Complete blood count Liver function tests Kidney functions test Plasma lipid levels Thyroid functions test Abdominal ultrasound Antithyrperoxidase Renal biopsy
45996053|NCT04684290|Procedure|Alcohol Septal Ablation|Participants will be treated with alcohol septal ablation.
45996054|NCT04684290|Procedure|Surgical Septal Myectomy|Participants will be treated with surgical septal myectomy.
46085336|NCT02657733|Device|Capnostream 20p|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream 20p- measures respiratory rate according to Capnography (RRetco2).
45674961|NCT02175641|Behavioral|Peer-Led Group Lifestyle Balance|The intervention follows the Group Lifestyle Balance curriculum derived from the Diabetes Prevention Program and The intervention will be delivered by trained peer-specialists employed at the supportive housing agencies and supervised by the study team. Peer GLB is a 12-month group intervention that focuses helping people lose weight by improving people's diet and increasing their physical activity and consists of weekly core group sessions (3 mo.), bi-monthly transitional group sessions (3 mo.), and maintenance monthly sessions (6 mo.).
45996055|NCT00535353|Drug|irinotecan hydrochloride|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
45996056|NCT00535353|Drug|olaparib|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
45996057|NCT00549003|Device|Rapid Diagnostic Test for P. falciparum malaria|
45996058|NCT02898857|Other|biopsies|The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches in Six with demonstrated down-staging of a KRAS mutant adenocarcinoma, Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma and Six with or without non-staging and triple negative adenocarcinoma
45996059|NCT00549081|Dietary Supplement|DHEA|oral DHEA tablets 75 mg daily
45996060|NCT02898779|Drug|Primaquine, R-Primaquine, S-Primaquine, SR Primaquine|"Cohort 1: Eighteen individuals (6 per group) Cohort 2: Eighteen individuals (6 per group)~Group 1-15 mg of S-Primaquine followed by one-week washout, 15 mg of R-Primaquine followed by one week washout, and 30 mg of RS-Primaquine.~Group 2- 15 mg of R-Primaquine followed by one-week washout, 30 mg of RSPQ followed by one week washout, and 15 mg of SPQ.~Group 3- 30 mg of RS-Primaquine followed by one week washout,15 mg of SPQ followed by a one week washout, and 15 mg of RPQ."
45996061|NCT00535431|Drug|AER 001|60 mg (in nebuliser), twice daily for 28 days
45996062|NCT00535431|Drug|placebo|Sterile saline nebulised, twice daily for 28 days
45996063|NCT02898701|Behavioral|Motor Practice of a Standing Serial Reaction Time Task|Subjects will perform a standing serial reaction time task on a step reaction mat. Subjects will step to a series of targets, based on a series of stimuli that are presented. One trial is composed of two 12-step sequences. One of the 12-step sequences is random, while the other is a repeated sequence; sequences are presented in random order. After each trial, the subject rests for 25 seconds. Six trials equal 1 block of practice, which is followed by a 4 minute rest break. After each block, feedback is provided about average response time (RT) on all steps included in the block. One complete day of practice consists of 6 blocks of practice in which each block consists of 6 trials.
45996064|NCT00549120|Drug|Propranolol|40 mg tablets
45996065|NCT00549120|Drug|Salbutamol|Metered dose inhaler (600 μg)
45996066|NCT00549120|Drug|Ipratropium|Metered dose inhaler (40 μg)
45996067|NCT00549120|Drug|Placebo|Placebo for propranolol tablets
45996068|NCT04680884|Drug|Experimental for steroid|2 mg/kg/day of IV methylprednisolone for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0,5 mg/kg/day from day 8 to day 14 + IV placebo of isavuconazole
45996069|NCT04680884|Drug|Experimental for antifungals|IV placebo of methylprednisolone + IV isavuconazole (200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
46085337|NCT02699112|Other|Parasternal EMG (EMGpara) and Transthoracic Echocardiography|OHS patients recruited will have EMGpara and Transthoracic Echocardiography at admission and when established on NIV at 3 months.
46085338|NCT02657655|Device|Kinesia 360|Kinesia 360 includes a mobile app and wireless motion sensors worn on the patient's wrist and ankle to quantify tremor, dyskinesias, and mobility throughout the day as he or she goes about normal activities. The app includes electronic diaries enable patients to rate their symptoms and log when medications are taken. Data is transferred to a cloud server where motor symptom reports are generated for clinician review.
45457318|NCT03919201|Other|Resistance band exercise intervention|Resistance band exercise intervention (12 weeks, 5x per week, 60 minutes per day)
45457319|NCT03919201|Other|No exercise intervention group|Control group: no exercise intervention
45457320|NCT03141086|Drug|LML134|LML134
45457321|NCT03141086|Drug|Placebo|placebo
45457322|NCT03518164|Procedure|Allograft|Bone graft
45674962|NCT02175641|Behavioral|Usual Care Services|The usual care condition encompasses the regular services offered at supportive housing agencies to help clients with their physical health and wellness.
45674963|NCT02117570|Biological|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
45996070|NCT04680884|Drug|Experimental for steroids and antifungals|IV methylprednisolone 2 mg/kg/day for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0.5 mg/kg/day from day 8 to day 14 + IV isavuconazole 200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
45996071|NCT04680884|Other|Standard of care|IV placebo of methylprednisolone + IV placebo of isavuconazole. This group receives the treatment that is currently recommended.
45996072|NCT03318588|Procedure|Vitrectomy|Pars plana vitrectomy
45996073|NCT02898428|Device|Continuous glucose monitoring (CGM)|
45996074|NCT00549159|Device|Thermal Balloon Endometrial Ablation|Thermal balloon endometrial ablation
45996075|NCT00549159|Device|Transcervical Resection of the Endometrium|Transcervical resection of the endometrium
45996076|NCT02898311|Device|immediate loading of posterior implants with chairside CAD-CAM composite crown|
45996077|NCT00549237|Dietary Supplement|Glucose load (Nutricia)|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
46085339|NCT02752724|Drug|Ketamine|Ketamine anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
46085340|NCT02752724|Drug|Methohexital|Methohexital anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
46085341|NCT02698878|Dietary Supplement|lupin protein|19g of lupin crunchy every day for the whole duration of the intervention phase (60 days)
46085342|NCT02698878|Other|Neuromuscular electrical stimulation|Individual neuromuscular electrical stimulation training had to be performed twice a day (morning and evening) over the whole duration of the intervention phase (60 days). Subjects were asked to continuously increase the intensity until a maximum intensity of 100mA per training.
46085343|NCT02698878|Device|HEPHAISTOS unloading orthotic device|Orthotic device which unloads the muscles of the lower leg. Subjects had to wear the device for the whole duration of the intervention phase (60 days).
46085344|NCT02657577|Other|There is no intervention|There is no intervention
46085345|NCT02756468|Other|pts operated for pancreatic cancer|measuring CRP and PCT in 3rd and 5th POD after pancreatic cancer resection
46085346|NCT02699034|Procedure|ablation for typical atrial flutter|
46085347|NCT02699034|Device|Vision-MR ablation catheter|
46085348|NCT00649623|Drug|Olmesartan Medoxomil Tablets 40 mg|40mg, single dose fasting
46085349|NCT00649623|Drug|Benicar® Tablets 40 mg|40mg, single dose fasting
45996078|NCT00549237|Other|Post operative early enteral feeding|Enteral feeding starting 6 hours post surgery
46085350|NCT02756312|Other|IV Anesthesia|The patients will receive intravenous anesthesia
46085351|NCT02756312|Other|IH anesthesia|The patients will receive inhalation anesthesia
46085352|NCT02698956|Device|TAVI (Transcatheter Aortic Valve Implantation)|Edwards SAPIEN 3 Transcatheter Heart Valve (S3 THV) and Edwards Commander Delivery system (transfemoral) and Certitude Delivery system (transapical/transaortic). The Edwards S3 THV is indicated for use in patients with severe, symptomatic, calcific aortic stenosis with STS Score ≥ 8 or Logistic EuroSCORE ≥15
46085353|NCT02657421|Procedure|Oblique Lateral Interbody Fusion|The oblique lateral interbody fusion (OLIF) procedures at L2-L5 (OLIF25™) and L5-S1 (OLIF51™) is a minimally invasive surgical option for degenerative lumbar disease. This approach allows for psoas-preserving access to the lumbar spine and minimizes the need to reposition the patient during surgery for accessing additional spinal levels for the interbody fusion portion of the procedure
46085354|NCT02657499|Other|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
46085355|NCT02756390|Behavioral|CBTI-CS|CBTI-CS is a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia. Cognitive factors are addressed via cognitive restructuring and psychoeducation. Behavioral factors are addressed by structured sleep restriction, stimulus control and sleep hygiene techniques. Cancer treatment late-effects affecting sleep are addressed as potential contributors to these cognitive and behavioral factors, and as symptoms that may benefit from referral for medical evaluation/management. Participants are instructed in these cognitive-behavioral strategies as a group, but using analysis of personal sleep-log data, symptom self-reports and targeted workbook exercises, they are helped to tailor the intervention to address their specific needs.
46085356|NCT02756390|Behavioral|Sleep Hygiene|Education on health behaviors, sleep habits and environmental practices intended to promote good quality sleep. Recommendations target exercise and natural light exposure,use of stimulants and alcohol, daytime napping, timing of meals, creating a comfortable non-stimulating sleep space, and creating sleep rituals.
46085357|NCT02756390|Behavioral|CBTI-CS via Telehealth|The CBTI-CS intervention, a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia, will be administered via live video. conferencing. Participants will have a single in-person training session and subsequent CBTI-CS group sessions will be conducted by live video conference.
45674964|NCT02117570|Biological|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
45996079|NCT02898545|Device|SEEQ monitor|An external cardiac rhythm monitor
45996080|NCT00535470|Drug|0.04% Mechlorethamine gel|Mechlorethamine 0.04% PG applied to affected skin areas (lesions) once daily for up to seven (7) months. The frequency of application may be adjusted for toxicity. After seven (7) months, they will be terminated from the study.
45996081|NCT02898467|Other|diabetics|additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
45996082|NCT02898467|Other|non-diabetics|additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
46002367|NCT03416179|Drug|Placebo|"Matching placebo (PO) given on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, placebo will be administered daily for up to 2 years after randomization or until they have MRD negative disease, whichever comes first.~Daily placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy."
45674965|NCT02117570|Biological|Placebo|Placebo (0.9 percent saline) given as a 0.5 mL intramuscular injection on day 1, day 8, and day 30.
46085358|NCT00649701|Behavioral|Standard Text-Based Prevention Web Page|A link to the CDC.gov web page which describes HIV prevention among men who have sex with men.
46085359|NCT00649701|Behavioral|The Morning After|A dramatic video about 4 gay men addressing sexual risk reduction within the context of alcohol use.
46085360|NCT00649701|Behavioral|Talking About HIV|A documentary video addressing HIV disclosure, HIV testing, and condom use with the sub-context of drug use.
46085361|NCT00649701|Behavioral|Both Videos|Morning After and Talking About HIV videos
46085362|NCT01655784|Procedure|Coil Embolization with larger Diameter Coils|Eighteen Coils placed in cerebral aneurysm
46085363|NCT01655784|Procedure|Coil Embolization with Standard Diameter Coils|Cerebral aneurysms will be embolized with standard diameter coils.
46085364|NCT02752178|Other|MA|Monoaminergic antidepressant use
46085365|NCT02752178|Other|DEP|Depression measured using the Hamilton Depression (HAM-D) questionnaire
46085366|NCT02657187|Device|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) after fast for eight hours.
45457323|NCT02296996|Drug|Dabrafenib + Trametinib|
45674966|NCT02123459|Drug|Cephalexin|Administered orally
45674967|NCT01853475|Drug|PQP tablets 960mg|Piperaquine phosphate tablets 960mg
45674968|NCT01853475|Drug|PQP tablets 1440mg|Piperaquine phosphate tablets 1440mg
45834510|NCT04127760|Radiation|radiotherapy|Radiotherapy would start within 2 months after the operation, and 5 days of radiotherapy is performed every week. The dose of each radiotherapy is 1.8 Gy for 6 weeks, and the total dose is 54 Gy.
45834511|NCT03302130|Behavioral|Mood induction (using own memories)|Subjects deliver three positive, three negative and three neutral memories 30 seconds reliving a memory - answering questions about the memory - reliving memory for 2 minutes during ASL-MRI
45834512|NCT03302130|Device|Arterial spin labeling MRI|Single PLD PCASL
45457324|NCT01329601|Behavioral|StaCog, stage specific cognitive Intervention|StaCog intervention to improve cognitive performance and activities of daily living in AD and MCI
45834513|NCT03302130|Device|Physiological monitoring|During MRI: heart rate, end-tidal CO2, respiratory rate and skin conductance
45834514|NCT04127370|Procedure|Bariatric Surgery|The Role of Bariatric Surgeries in Management of Nonalcoholic Fatty Liver Disease
45834515|NCT02984046|Drug|Protein CC16|
45996083|NCT03284112|Behavioral|Old SCHOOL Hip-Hop|"A school-based intervention called Old S.C.H.O.O.L. Hip-Hop (OSHH) or Seniors Can Have Optimal aging and Ongoing Longevity, to educate 4th and 5th grade students (ages 9-11y) about key dementia signs and symptoms, basic pathophysiology of Alzheimer disease, and the importance of early recognition, care-seeking behavior, and preventative measures (lifelong healthy lifestyle decisions). The intervention is delivered in a classroom or school auditorium setting, using an innovative, modular, multimedia program and home-based activities, to increase parental and family dementia literacy."
45996084|NCT03284112|Behavioral|My Plate|"The program selected for the control arm, My Plate, will address nutrition, physical activity, and obesity education. This program was selected because nutrition, physical activity, and wellness programs are now being incorporated into New York City public school curriculums as part of a legislative directive. Trained facilitators will conduct My Plate as an entry point for the USDA's My Plate nutrition program. Students will learn about My Plate across the 3-day one-hour-a-day program."
45996085|NCT02898584|Other|BP Track|
45996086|NCT03455309|Biological|NDV-3A|Single dose administered by intramuscular injection
45996087|NCT03455309|Biological|Placebo|Single dose administered by intramuscular injection
46085367|NCT02657187|Drug|Rocuronium|The individual dose method was used for the determination of the dose response of rocuronium. After induction of anesthesia, four groups of 40 patients each received randomly one of the four doses of rocuronium ( 0.24, 0.32, 0.40, 0.48mg/muscle mass(kg))
46085368|NCT02657109|Other|physical therapy procedure|physiotherapy exercises conducted in early way for the rehabilitation of patients in the postoperative period of cardiac valve replacement.
46085369|NCT01291134|Biological|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft.
45457325|NCT01329601|Behavioral|booklet based training|Home based training of episodic memory using paper-pencil exercizes
45674969|NCT01853475|Drug|OZ439+TPGS 800mg|OZ439+TPGS prototype formulation 800mg
45674970|NCT01853475|Drug|OZ439 PIB 800mg|OZ439 Powder in Bottle Aqueous Solution 800mg
45674971|NCT04411160|Drug|Vitamin C|4 gram of vitamin c slowly intravenous once daily for 4 days duration.
45674972|NCT04411160|Drug|Nitric Oxide|nitric oxide stared by 50 parts/billion(ppb) as starting dose titrated according to patient's saturation reaching to 90 ppb as a maximum dose
45996088|NCT00549315|Device|Valiant Endoluminal Stent-Graft Stent-Graft Balloon Catheter|VALIANT stent-graft endoprosthesis is inserted by the Xcelerant Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
45996089|NCT00535509|Radiation|Cisplatin-Docetaxel ± Trastuzumab|Chemo & RT
45996090|NCT00535509|Other|Cisplatin-Docetaxel ± Trastuzumab|Chemo & RT
45674973|NCT04411160|Device|ventilators|All selected patients received conventional ventilation with protective lung strategy for 10 days with Controlled mechanical ventilation mode(CMV), fraction inspired oxygen (FIO2) of 100%, Positive end expiratory pressure(PEEP) of 10 cm H2O or more to achieve target arterial oxygen saturation(SPO2) of 90%
45834516|NCT04122690|Behavioral|PDAE|Participants with PD will dance the follower role only and will dance with new partners (individuals without PD) every 15-20 minutes, a widely practiced method considered by the dance teaching community to enhance learning. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Frequent repetition and musical stereotypes may foster implicit learning or muscle memory (i.e., motor learning, or procedural memory that involves consolidating a specific motor task into memory through repetition). Participants will not be required to memorize specific step patterns but will learn new steps in each class
45996091|NCT00535509|Drug|Cisplatin-Docetaxel ± Trastuzumab|Chemo & RT
45996092|NCT02898350|Device|Pulsed dye laser treatment|Scar minimization with Pulsed dye laser treatment on suture removal day
45996093|NCT02898350|Device|CO2 laser treatment|Scar minimization with CO2 laser treatment on suture removal day
45996094|NCT02898350|Device|Combined PDL and CO2 laser treatment|Scar minimization with Pulsed dye laser and CO2 laser treatment on suture removal day
45996095|NCT02898350|Device|Split PDL and CO2 Laser treatment|Split-scar with CO2 treatment after surgery and combined PDL and CO2 treatment on suture removal day
45996096|NCT00549354|Device|Endoluminal Graft|
45996097|NCT02898038|Dietary Supplement|AYMES PARIS|AYMES PARIS is a powdered, high energy, oral nutritional supplement to be mixed with milk as a drink. It provides 320 kcal and 12.2 g protein per 139 ml serving. It is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
45996098|NCT00535548|Biological|Stem cell therapy|Injection of a hematopoietic stem cell suspension (50'000 CD 34+ cells per microliter) into the wound (1 microliter per cm2 of wound surface)
45996099|NCT02897999|Biological|QBKPN|QBKPN Site Specific Immunomodulators
45996100|NCT02897999|Other|Placebo|Placebo
45996101|NCT01262365|Drug|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
45996102|NCT01262365|Drug|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
45996103|NCT01262365|Drug|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
45996104|NCT03244176|Drug|Avelumab|"All participants will receive the following treatment:~Induction phase Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 2 cycles Plus Rituximab at a dose of 375mg/m2 as an IV infusion over at least 1 hour once every 2 weeks for 2 treatments~Then:~RCHOP - All participants will receive RCHOP chemotherapy treatment for 6 cycles. Each cycle will last for 21 days. Rituximab, cyclophosphamide, doxorubicin, and vincristine are given on the first day of each cycle by intravenous infusion. Prednisone is given orally from Day 1 until Day 5 of each cycle.~Then:~Maintenance phase - All participants will receive Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 6 cycles."
45996105|NCT02898155|Other|measure of access to primary care and of the Interface Between Primary ans Secondary Care|
45996106|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 14 days apart: 5 microgram per dose
45996107|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 5 microgram per dose
45996108|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 10 microgram per dose
45996109|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 15 microgram per dose
45996110|NCT03971110|Drug|Zoladex and Casodex|The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.
45996111|NCT00549432|Device|TALENT Enhanced LPS Endoluminal Stent-Graft System|roadmapping, and angiography for proper implant positioning. The TALENT endoluminal stent-graft endoprosthesis is inserted by delivery catheter and introducer sheath via a surgical cutdown (e.g., external iliac artery, femoral artery) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
45996112|NCT05651737|Behavioral|Sui App (SRK)|"The Sui app contains the following chapters:~6 well-being chapters on: stress, sleep, resources throughout the day, chronic pain, emotion regulation, audio exercises 9 Swiss-specific information chapters on: housing, health (two sub-chapters), finances, asylum process, residence status, social integration, occupational integration, family reunification"
45674974|NCT02151773|Drug|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
45674975|NCT02151461|Drug|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
45674976|NCT02151461|Drug|Metformin|500 mg metformin BID until day 14 with dose escalation at day 14 to 850 mg metformin BID
45674977|NCT02151461|Drug|Mid Metformin|1100 mg of Leucine in combination with 250 mg Metformin BID
45674978|NCT02151461|Drug|High Metformin|1100 mg of Leucine in combination with 500 mg Metformin BID
45674979|NCT02117414|Device|MRI scan sequences of the head and chest regions|Non-diagnostic MRI scans
45674980|NCT02117414|Other|Waiting Period Visit|Waiting period time will equate to 1 hour
45674981|NCT02091986|Drug|Symbicort pMDI|Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
45996113|NCT02897882|Other|Lung transplant|Pain evaluation
45996114|NCT03932812|Behavioral|Options Counselor Health Educator (OC-HE) Intervention|The OC-HE will meet in person with the participant one time and five times via telephone to provide options counseling based on modules developed by the research team
45996115|NCT03456024|Other|Questinnaire|
45996116|NCT04322266|Drug|HCP1701|Ezetimibe / Rosuvastatin / Amlodipine / Losartan potassium
45996117|NCT04322266|Drug|HCP1306|Ezetimibe /Rosuvastatin
45996118|NCT04322266|Drug|HGP0904|Amlodipine
45996119|NCT04322266|Drug|HGP0608|Losartan potassium
45996120|NCT02897726|Drug|NVP-1402|Oral
45996121|NCT02897726|Drug|NVP-1402R|Oral
45996122|NCT03932032|Behavioral|Attention Bias Modification Treatment|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in social anxiety.
45996123|NCT03932032|Behavioral|Neutral Control Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of neutral stimuli is presented simultaneously and then followed immediately by a probe. NCT matches ABMT on duration, format, and number of trials, but does not engage attention to social threat and does not train attention.
45996124|NCT03208959|Drug|HTI-1090|IDO/TDO inhibitor
45996125|NCT04322110|Other|PronoKal Method|Multidisciplinary program of weight loss based on diet (initially ketogenic diet), physical activity and emotional support
45996126|NCT04322110|Other|Low calorie diet|Balanced hypocaloric diet (caloric intake 10% below basal metabolic rate) accompanied by physical exercise.
45996127|NCT05516524|Diagnostic Test|Home sleep apnea test|Level II home sleep apnea testing evaluates for obstructive sleep apnea in the home environment with parental supervision.
45996128|NCT05516524|Diagnostic Test|PSG|Overnight sleep study in the sleep laboratory with continuous monitoring by clinical staff.
45996129|NCT02897804|Behavioral|Knowledge alone|Increase knowledge related STIs, STI risk, alcohol impairment, condom use skills, alcohol use behavior tracking skills, testing & treatment services.
45996130|NCT02897804|Behavioral|Self-efficacy alone|Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45996131|NCT02897804|Behavioral|Perceived benefits alone|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
45996132|NCT02897804|Behavioral|Perceived benefits and self-efficacy|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45996133|NCT02897804|Behavioral|Injunctive norms|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
45996134|NCT02897804|Behavioral|Injunctive norms and self-efficacy|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45996135|NCT02897804|Behavioral|Injunctive norms and perceived benefits|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45996136|NCT02897804|Behavioral|Injunctive norms, perceived benefits, and self-efficacy|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45996137|NCT02897804|Behavioral|Descriptive norms alone|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
45996138|NCT02897804|Behavioral|Descriptive norms and self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45996139|NCT02897804|Behavioral|Descriptive norms and perceived benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
45996140|NCT02897804|Behavioral|Descriptive norms,perceived benefits,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45996141|NCT02897804|Behavioral|Descriptive and injunctive norms|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
45996142|NCT02897804|Behavioral|Descriptive norms, injunctive norms,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45996143|NCT02897804|Behavioral|Descriptive and injunctive norms, benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
45996144|NCT02897804|Behavioral|Descriptive and injunctive norms, benefits,efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45996145|NCT02897804|Behavioral|Expectancies alone|Decrease the expectation that alcohol is needed to have good sexual encounter.
45996146|NCT02897804|Behavioral|Expectancies and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45996147|NCT02897804|Behavioral|Expectancies and Perceived Benefits|Decrease the expectation that alcohol is needed to have good sexual encounter and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
45996148|NCT02897804|Behavioral|Expectancies, perceived benefits, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45996149|NCT02897804|Behavioral|Expectancies and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
45996150|NCT02897804|Behavioral|Expectancies, injunctive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45996151|NCT02897804|Behavioral|Expectancies, injunctive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
45996152|NCT02897804|Behavioral|Expectancies, injunctive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45996153|NCT02897804|Behavioral|Expectancies and descriptive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
45996154|NCT02897804|Behavioral|Expectancies, descriptive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45996155|NCT02897804|Behavioral|Expectancies, descriptive norms, and benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
45674982|NCT02091986|Drug|Symbicort pMDI|Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
45674983|NCT02091986|Other|Budesonide pMDI|Budesonide pMDI 80µg, 2 acuations twice daily
45674984|NCT02091752|Drug|Ruxolitinib|Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. loss of response or AE) and baseline platelet count. For participants who previously discontinued ruxolitinib due to loss of response, the starting dose was determined based on baseline platelet counts as follows: participants with a baseline platelet count of ≥ 200 x 109/L began dosing at 20 mg po bid; participants with a baseline platelet count of 100 x 109/L to <200 x 109/L began dosing at 15 mg po bid. Participants who previously discontinued ruxolitinib due to an AE initiated therapy at a total daily dose 5 mg lower than the total daily dose prior to discontinuation.
45996156|NCT02897804|Behavioral|Expectancies,descriptive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45996157|NCT02897804|Behavioral|Expectancies, descriptive and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
45996158|NCT02897804|Behavioral|Expectancies, descr& injun norms, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45996159|NCT02897804|Behavioral|Expectancies, desc & injun norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
45996160|NCT02897804|Behavioral|Expectancies,desc & injun norms,benefits,efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
45996161|NCT02889250|Device|Medtronic Activa SC DBS, Lead Model 3387|Deep Brain Stimulation
45996162|NCT02889094|Other|Routine care|Routine care recommended for patients co-infected with HIV and hepatitis B virus (per European Association for the Study of the Liver and European AIDS Clinical Society guidelines).
45996163|NCT02897687|Behavioral|Facebook Group|A closed, invite-only group within Facebook facilitated by an interprofessional team that not only reinforces skills, but also aims to promote bonds and a sense of community and connectedness between participants.
45996164|NCT02897687|Behavioral|Book Club Group|A topical book club group discussing Autism-related material conducted by a single healthcare professional.
45996165|NCT01262287|Drug|Dutasteride|dutasteride 4 mg loading dose followed by 1 mg daily for 8-week treatment period
45996166|NCT01262287|Drug|Placebo|placebo capsules in same number as active drug, daily for 8-week treatment period
45996167|NCT03201549|Dietary Supplement|oral fructose challenge|Participants will consume fructose for two weeks and fast for 8 hours before study visits where they will drink a fructose beverage.
45996168|NCT01262092|Drug|Buprenorphine|Induction onto buprenorphine to a stable dose of 12mg/day. Then induction onto either 0 or 1600mg of gabapentin. Once the maintenance dose of gabapentin is reached a 10-day buprenorphine detoxification will begin.
45996169|NCT04322071|Other|Interview|Qualitative interviews only
45996170|NCT03455946|Behavioral|DASH cloud with Alexa|"Participants will download and install the Alexa and Nutritionix application (app) onto their smartphone and study staff will setup the study-specific account to send data to Duke's software system called Prompt. Participants will be instructed to invoke through voice their dietary intake daily for three months using the Nutritionix app through the Amazon Alexa personal assistant. DASH Cloud will access participant's dietary intake data through the Nutritionix application programing interface (API) for three months. Participants' data will automatically be uploaded from the Nutritionix app via the API that links the device with DASH Cloud. DASH Cloud will run an algorithm and send a daily or weekly feedback text message with a score reflecting DASH adherence for the prior days or week's food consumption using a previously validated scoring system."
45996171|NCT03898180|Biological|Pembrolizumab|IV infusion
45996172|NCT03898180|Drug|Lenvatinib|oral capsule
45996173|NCT03898180|Drug|Placebo for lenvatinib|oral capsule
45996174|NCT03165279|Procedure|Zenith Alpha Abdominal stentgraft|
45996175|NCT04680962|Biological|MabionCD20 (candidate biosimilar to rituximab)|Intravenous infusion, 10 mg/ml concentrate, 500 ml
45996176|NCT04680962|Biological|MabThera®|Intravenous infusion, 10 mg/ml concentrate, 500 ml
45996177|NCT04680962|Biological|Rituxan®|Intravenous infusion, 10 mg/ml concentrate, 500 ml
45674985|NCT02117024|Drug|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
45996178|NCT01261975|Procedure|Coaxial Micro-Incision Cataract Surgery|1.8 mm coaxial micro incision
45996179|NCT01261975|Procedure|Coaxial Small Incision Cataract Surgery|2.75 mm coaxial incision
45674986|NCT02117024|Drug|Metronomic Cyclophosphamide|One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks
45996180|NCT03881098|Procedure|Bronchoscopies|"Bronchoscopy: Your nose, throat, vocal cords and windpipe are sprayed with Lidocaine (numbing medicine) to help keep you from coughing and to numb your airways. A tube with either a white light or the fluorescent light (bronchoscopy) is put down through your nose or mouth into your throat. Your nose, throat, vocal cords and lungs will be checked for any unusual areas while the tube goes down. You might have medicine sprayed into your mouth. You may be given a shot into your vein or muscle to help you be more comfortable.~Endobronchial Biopsy: Very tiny pieces of lung tissue (about the size of the head of a pin) will be taken from the lining of your lungs using forceps and a small brush. These tissues will be taken to a laboratory and tested."
45996181|NCT03881098|Procedure|Sputum Sample|Subjects will be asked to perform the early morning spontaneous cough technique over a six-day period to provide for pre-screening evaluations. If moderate atypia is detected in a pre-screening specimen, additional sputum samples will be collected prior to each subsequent bronchoscopy. If this cannot be performed prior to bronchoscopy with adequate results, the sputum collection may be done after bronchoscopy. The sputum will be collected in containers containing Saccomanno's fixative.
45996182|NCT03881098|Procedure|Venipuncture|Thirty milliliters of blood will be withdrawn from each subject, and the blood will be sent to the biorepository for analysis and storage.
45996183|NCT02897531|Procedure|ES anastomosis|The side wall of the transverse colon will be anastomosed to the end of the distal ileum with one circular stapler, and the blind end of the transverse colon will be closed with one linear stapler.
45996184|NCT02897531|Procedure|SS anastomosis|The side wall of the transverse colon will be anastomosed to the side wall of the distal ileum with two linear staplers.
45996185|NCT00549471|Other|physiotherapy|CG children will undergo a program of intensive physiotherapy
45996186|NCT00549471|Other|Botulinum Toxin A and physiotherapy|BG children will be given Botox, as clinically required, in addition to an equivalent program of intensive therapy. Botox injection will be tailored according to the specific child. Generally injection site will include biceps and brachioradialis, while flexors of the wrist and digits will be injected according to abnormal postures during function. Maximal total dose will be 23 IU per kg.
45996187|NCT01261780|Device|MC-5A|45 minutes daily x 10 treatments (given over the course of 2 weeks)
45996188|NCT01261780|Drug|Sham device|Sham therapy daily x 45 minutes for 10 treatments (given over course of 2 weeks)
45996189|NCT03880435|Device|Hyalobarrier® gel endo|Intra-uterine application of 10ml sterile gel containing 30mg APC. It will be administered once, peroperatively immediate after the complete hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception
45996190|NCT02897843|Device|transcranial magnetic stimulation|tDCS stimulation will involve ten 20 minute stimulations daily, characterized by 2 milliamps (mA) anode over the left dorsolateral prefrontal cortex (DLPFC), with the cathode placed over the right suborbital region.
45996191|NCT02897843|Device|sham tDCS|sham tDCS
45996192|NCT03088410|Drug|Zidovudine|neonatal 4 weeks prophylactic
45996193|NCT03088410|Drug|Nevirapine|neonatal 4 weeks prophylactic
45996194|NCT02897765|Biological|NEO-PV-01|Personal cancer vaccine
45996195|NCT02897765|Biological|Nivolumab|monoclonal antibody against PD1
45996196|NCT02897765|Other|Adjuvant|immune adjuvant
45996197|NCT03075072|Radiation|Whole brain radiation|Treatment of the whole brain with radiation. When possible the hippocampus will be spared from radiation.
45996198|NCT03075072|Radiation|Stereotactic radiation (SRS)|Focused radiation to each individual brain metastasis without treatment of the remainder of the brain.
45996199|NCT02897570|Dietary Supplement|Glucose|50g of glucose dissolved in 250 to 300ml of water was drunk. Prior and upon completion of each glucose tolerance test, an EEG was performed.
45674987|NCT02117024|Drug|Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)|"Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:~Vinorelbine~Erlotinib~Gemcitabine~Paclitaxel~Docetaxel~Pemetrexed"
45834517|NCT04122690|Behavioral|WAE|The participants will receive equal contact and monitoring from study staff. WAE participants will report to the same facility and interact with the same interventionist and assistants. The participants will participate in sessions focused on at least 60 minutes of walking with breaks ad libitum, and 1/2 hour balance and stretching. The investigators have a designated, safe and non-cluttered area for walking. WAE will also take place in groups, with research volunteers and assistants to ensure that PDAE and WAE participants both receive a socially engaging intervention
45996200|NCT02897570|Dietary Supplement|Milk & Cereals|A breakfast (B1) including a glass of milk (125ml) and 30 g-corn flakes was consumed. Prior and upon completion of each tolerance test, an EEG was performed
45996201|NCT02897570|Dietary Supplement|Milk, apple & snack|A breakfast (B2) including a glass of milk (220ml), an apple (200g), a cream chocolate filled sponge cake (30g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
45996202|NCT02897570|Dietary Supplement|Milk, apple & bread w/ cream|A breakfast (B3) including a glass of milk (125ml), an apple (150g), bread (50g, hazelnut chocolate cream (15g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
45996203|NCT02897570|Device|EEG_pre|Electroencephalography (EEG) was performed prior each tolerance test to assess frontal P300-evoked potentials
45996204|NCT02897570|Device|EEG_post|Electroencephalography (EEG) was performed upon completion of each tolerance test to assess frontal P300-evoked potentials
46002368|NCT03416179|Drug|Placebo|Matching placebo (PO) is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue placebo until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.
45996205|NCT04686162|Other|bae application|"Patients will be assisted by a research team member to install and configure the application bae on their smartphone; then, they will be trained to use it.~Bae proposes 4 types of assessments :~5 times a day during 3 days, every month (5 minutes) : patients can assess their emotions, their thoughts, their behavior and their occurrence context.~Weekly (7 minutes) : consists of a summary of the week, about their emotions, thoughts, behavior, their relationships (family, work, friends), and their quality of life.~Monthly (5 minutes): assessment of the usefulness and satisfaction about the application.~Assessment available at any time An action plan is designed to support the participants, to help them facing difficult emotions and feelings, and to encourage them to ask for help.~They can contact a relative or call the psychiatric emergency service directly by clicking on a button.~Patients can try to identify their own warning signs, to prevent suicidal behavior."
45996206|NCT02897492|Other|Blood testing in a newly described method|"To exploit detection strategy termed Magnetic Modulation Biosensing, or MMB) to develop a novel, low-cost platform that can detect biomarkers, such as proteins and specific DNA sequences, rapidly and directly from real samples at very low concentrations."
45674988|NCT02091440|Device|Implant of the HW005 Ventricular Assist System.|The HW005 Pump is in implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use.
45996207|NCT02897180|Biological|Nyaditum resae(R)|Capsules containing Nyaditum resae(R)
45996208|NCT02897180|Biological|Placebo|Capsules containin Placebo
45996209|NCT00549588|Other|After-sun-lotion with DNA repair enzymes|2 mg/cm2 immediately after UV exposure
45996210|NCT00549588|Other|SPF30 sunscreen|2 mg/cm2 2o min before UV exposure
45996211|NCT00549588|Other|Placebo after-sun-lotion|2mg/cm2 immediately after UV exposure
46085370|NCT04221308|Device|Single port laparoscopic systems|The first assistant handles the scope from the patient's right side. The second assistant, who is positioned between the legs of the patient, inserts a uterine manipulator (Rumi System; Cooper Surgical, CT). At the beginning of the surgery, a 1.5 to 2.5 cm vertical incision is made within the umbilicus using the open Hasson approach. After the bottom retractor ring of the wound retractor component of the Octo-Port is inverted (DalimSurgNet, Seoul, Korea), it is inserted through the incision deep in the peritoneum. Carbon dioxide is insufflated through the gas valve of the Octo-Port to maintain intra-abdominal pressure at 10 to 12 mm Hg. Through the 10 mm channels of the Octo-Port, a 10 mm, 30° rigid laparoscope is introduced. Rigid laparoscopic instruments are introduced through the 5 mm channels of the Octo-Port. The utero-ovarian ligament or infundibulopelvic ligament, uterine vessels, and uterine ligaments are transected by using the 5 mm LigaSure vessel sealer device
46085371|NCT00649779|Drug|albuterol sulfate extended-release 8 mg tablets|8mg, single dose fasting
45996212|NCT00549588|Other|Intervention: none (only UV)|
46085372|NCT00649779|Drug|VoSpire™ ER 8 mg tablets|8mg, single dose fasting
45996213|NCT02897102|Behavioral|Training|Training program based on abacus and other activities
45996214|NCT02897102|Other|Different group activities|ballroom dancing (5 participants), belly dancing (4 participants), chorus (16 participants), Spanish classes (8 participants) and chorus and Spanish classes (6 participants).
46085373|NCT00615186|Drug|Neuradiab + Radiotherapy + Temozolomide|"Prior Surgery~Rickham Catheter placement 99mTc-DTPA Flow Study~Neuradiab Dosimetry Study~Neuradiab Therapeutic Dose Administration~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + temozolomide (75 mg/m2/day) over 6.5 weeks.~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
45674989|NCT02064920|Drug|Placebo|Placebo for donepezil hydrochloride capsule
45674990|NCT02064920|Drug|Donepezil|5 mg donepezil hydrochloride capsule.
45674991|NCT02064920|Drug|Donepezil|10 mg donepezil hydrochloride capsule.
45996215|NCT01261624|Drug|Givinostat|1.0 mg/kg daily (0.5 mg/kg twice a day) in fed condition 1.5 mg/kg daily (0.75 mg/kg twice a day) in fed condition
45996216|NCT02888938|Other|pelvic radiography|
45996217|NCT02888938|Other|pelvic MRI|
45996218|NCT02888938|Other|pelvic CT-scan|
45996219|NCT04322032|Drug|Reference drug|D759 Tab. 1 Tab. and D308 Tab. 1 Tab.(Total 2 Tab.), Single oral administration under fasting condition.
45996220|NCT04322032|Drug|Test drug|CKD-389 Tab. 1 Tab.(Total 1 Tab.), Single oral administration under fasting condition.
45996221|NCT03711331|Other|FilmArray® Pneumonia panel plus|Early adjustment of antimicrobial therapy according to the results of the Unyvero® testing for patients suspected with VAP or HAP requiring MV.
45996222|NCT03711331|Other|Standard care|Standard care, with broad-spectrum antimicrobial therapy unchanged until reception of traditional microbiology results
45674992|NCT02151149|Drug|nab-paclitaxel|
45674993|NCT02151149|Drug|Carboplatin|
45674994|NCT04746131|Drug|IMM0306|IMM0306 is an bi-specific antibody
45674995|NCT02150213|Procedure|MRI, CT or ultrasound was permitted if MRI was contraindicated|MRI/CT/ultrasound of abdomen
46085374|NCT00615186|Drug|Radiation Therapy + Temozolomide|"Prior Surgery: Gross total resection (< 1 cm. enhancing rim)~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + 42 days of temozolomide (75 mg/m2/day) over 6.5 weeks~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
46085375|NCT04017429|Procedure|Open flap debridement with osteoplasty|Treatment of furcation grade III defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to >90 degrees relative to the apico-coronal axis of the tooth.
46085376|NCT04017429|Procedure|Open flap debridement without osteoplasty|Treatment of furcation grade III defect with open flap debridement only.
45996223|NCT02887053|Device|MRI|
45996224|NCT04321798|Behavioral|Physical Activity|Four group sessions and one individual session delivered over a period of 12 weeks in a primary care setting. Each session includes patient education and support for behaviour change as well as a supervised practical exercise component. The intervention is based upon a combination of self-determination theory and COM-B framework (capability, opportunity, motivation and behaviour) and employs motivational interviewing techniques.
45996225|NCT05532982|Other|Interviews and Surveys|Qualitative interviews and surveys
45996226|NCT02897336|Procedure|ultrasound-guided|ultrasound-guided caudal epidural corticosteroid injection
45996227|NCT02897336|Procedure|interlaminar|interlaminar epidural corticosteroid injection
45996228|NCT04321642|Drug|Entonox|Entonox gas with mouth piece
45996229|NCT04321642|Drug|Not receive Entonox|Not receive any gas
45996230|NCT02884791|Dietary Supplement|oral carbohydrate challenge|Participants will fast for 8 hours and then drink a beverage containing fructose.
45996231|NCT04321681|Other|no intervention|no intervention
45996232|NCT02897219|Drug|ipragliflozin|Oral administration once daily
45996233|NCT02897219|Drug|Placebo|Oral administration once daily
45996234|NCT02897219|Other|Insulin Therapy|Continuous subcutaneous insulin infusion or multiple daily injections as standard of care
45996235|NCT04321603|Behavioral|Walking|Moderately paced walking of approximately 100 steps/minute for 30 minutes three times weekly for six weeks.
45996236|NCT02882685|Procedure|Roux-en-y gastric bypass|
46085377|NCT02698644|Drug|Isoamyl-2-cyanoacrylate|Isoamyl-2-cyanoacrylate will be injected inside fallopian tube hysteroscopically through ureteric catheter
46085378|NCT04221386|Behavioral|Melodic Intonation Therapy (MIT)|Subjects will receive at least 6 MIT sessions in group of 3-5 subjects. In the sessions, experimenter will sing songs with the subjects. Songs used in the intervention are familiar to elderly and are rewritten and embedded with everyday phrases and vocabularies. The whole intervention will span 3-4 weeks.
45996237|NCT02882685|Procedure|Single anastomosis gastric bypass|
46085379|NCT00616044|Procedure|continuous spinal anesthesia|bupivacaina isobaric 0.5%, 5 mg
46085380|NCT00616044|Procedure|Spinocath a catheter for continuous spinal anesthesia|Continuous spinal anesthesia with low dose of bupivacaine isobaric Combined epidural spinal anesthesia with low dose of bupivacaine isobaric
46085381|NCT00616044|Procedure|combined spinal epidural anesthesia|CSE was performed with the needle-through-needle technique using a single interspace (Espocan, B.Braun Melsungen, Germany
46085382|NCT02536911|Drug|eliglustat|"Pharmaceutical form: capsule~Route of administration: oral"
45996238|NCT04321720|Other|3-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g mustard flour (3 g per l), followed by a ten-minute post-intervention rest period.
45996239|NCT04321720|Other|6-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g mustard flour (6 g per l), followed by a ten-minute post-intervention rest period.
45996240|NCT04321720|Other|12-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g mustard flour (12 g per l), followed by a ten-minute post-intervention rest period.
46085383|NCT02755922|Biological|Application of autologous mesenchymal stem cells|within the surgical procedure, mesenchymal stem cells, were applied on the fracture site. Imaging by X-ray and CT and imaging analysis was done after fracture repair, at week 4 and week 12
46085384|NCT02703402|Other|Exercise protocol|Control group will complete all the protocol of exercises with orientation and attendance directly from a professional of physical education, in the Service of Physiatry and Rehabilitation in HCPA.
45996241|NCT04321720|Other|Warm water only|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
45996242|NCT04321837|Dietary Supplement|Coral Complex 3|Coral-derived calcium supplement fortified with vitamin D3
45996243|NCT04321837|Drug|Ibandronate|Bisphosphonate
45996244|NCT04321837|Dietary Supplement|Vitamin D3|Oral vitamin D3
45996245|NCT02897414|Other|Surveillance of state medical examiner databases|
45996246|NCT02858934|Radiation|Tomotherapy|"Dose prescription:~Whole breast irradiation: 25 Gy in 5 daily fractions of 5 Gy Boost: 30 Gy in 5 daily fractions of 6 Gy The boost will be delivered as a simultaneous integrated boost (SIB).~Target volumes:~Clinical target volume (CTV) breast: defined by the soft tissue of the breast down to the pectoralis fascia, but excluding the skin and the underlying muscle, ribs, lung and heart.~Gross tumor volume (GTV) boost: includes all gross tumor volume, as visible on computer tomography, mammography and/or magnetic resonance imaging (MRI). MRI imaging is preferentially performed in treatment position.~CTV boost: includes the primary tumor, with a margin of 1.0 cm in all directions to encompass potential microscopic disease extension. The CTV boost excludes the skin, pectoralis muscle, ribs, lung and heart.~Planning target volume (PTV): CTV plus a margin of 5 mm in all directions, but limited at 5 mm below the skin surface."
45996247|NCT02897453|Device|The Spinal Tethering System|An implant comprised of: vertebral body screws, vertebral body staples (washers), and a PET (polyethylene-terephthalate) cord.
45996248|NCT00549627|Device|Pediguard|PediGuard™ is a hand-held drilling tool that allows real-time detection of vertebral pedicle and body breaches in all directions.
45674996|NCT02150213|Procedure|Dexamethasone Supression Test|Low dose of dexamethasone is administered in the evening; the next morning, a blood sample is collected to measure cortisol
45674997|NCT02150213|Procedure|Sonogram|Sonogram of the uterus (females only)
45674998|NCT02150213|Procedure|Biopsy|Uterine endometrial biopsy (females only)
45996249|NCT02896829|Behavioral|Interruption of the treatment by Imatinib|
45996250|NCT02854566|Device|osteosynthesis|Fracture reduction and fixation with screws/plates/cables (standard of care)
46085385|NCT02703402|Other|Manual of exercises|Treatment group will complete one session of the protocol of exercises with orientation and attendance directly from a professional of Physical Education, in the service of Physiatry and Rehabilitation of HCPA, to clarify any doubts about the protocol. The further sessions will be completed at home, along weekly monitoring of the researchers through phone calls, the patients of this group will receive a manual with the sequence of the exercises
45674999|NCT02150213|Drug|BGG492|No study-drug was administered in this study
46085386|NCT04221152|Drug|Empagliflozin Tablets|The administration is oral administration with water before or after breakfast.
45834518|NCT04127526|Other|Connection to Environment with Cognitive Therapy (CONNECT)|8 sessions of strategies to reduce dissociation. Flexible, toolbox approach including but not limited to grounding strategies using objects, therapy oils and naming objects in the room.
46085387|NCT02656563|Radiation|Radium 223 Dichloride (Xofigo®)|Radium 223 Dichloride (Xofigo®) monthly for six months
45675000|NCT02091362|Drug|LY2409021|Administered orally
45675001|NCT02091362|Drug|Placebo|Administered orally
45675002|NCT02091362|Drug|Metformin|Administered as background therapy.
45675003|NCT02150057|Device|Breg Fusion Unloading Brace|This group is assigned to wear an unloading brace and report pain and quality of life by completion of a pain diary and related questionnaires.
45675004|NCT02064296|Device|Needle acupuncture (Traditional Acupuncture)|This group will receive needle acupuncture at 3 pairs of sites. The needles will be stimulated with low intensity, low frequency electric current using a constant-current electro-acupuncture device (AS Super 4 digital needle stimulator).
45675005|NCT02064296|Device|Laser acupuncture (Non-traditional Acupuncture)|For non-traditional acupuncture, a laser acupuncture device (Vita Laser 650, Lhasa OMS) will be positioned over all of the same acupoints used in EA. There will be no palpation prior to positioning these devices, and there will be no physical contact between device and skin.
45834519|NCT05602506|Drug|Biktarvy 50 mg/200 mg/25 mg film-coated tablets|The duration of the study treatment will be 48 weeks.
45834520|NCT04274790|Procedure|Scheduled and planned surgery|Collection of tumour samples from samples collected as part of standard patient management. Diagnostic pathological analysis will be a priority. These samples will be taken by experienced staff during the hospital visit scheduled as part of standard care.
45834521|NCT05602428|Drug|esketamine sub-anesthetic,|the use of esketamine sub-anesthetic dose combined with hip capsule peripheral nerve block
45834522|NCT05602428|Drug|esketamine sub-anesthetic|Esketamine subanesthetic dose combined with lumbar plexus block was used
45834523|NCT05602428|Drug|esketamine sub-anesthetic|general anesthesia was performed with esketamine subanesthetic dose.
45996251|NCT00549666|Drug|Lurasidone 40 mg|Lurasidone 40 mg days 12-21 once daily
45996252|NCT00549666|Drug|Placebo 40 mg|Placebo 40 mg once daily during treatment period
45996253|NCT00549666|Drug|Ortho Tri-Cyclen|Ortho Tri-Cyclen during 28-day lead in period
45996254|NCT04680923|Procedure|CPPLAI|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
45996255|NCT04680923|Other|Placebo|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal 40 ml of sterile water.
45996256|NCT04680923|Drug|Bupivacaine 0.25%|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
45834524|NCT02983890|Drug|Dicloxacillin|"Tablets containing dicloxacillin are taken 500mg 2x 3 times per day, for 10 days. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned"
45996257|NCT04680806|Device|Er,Cr:YSGG laser 2780 nm|The depigmentation procedure essentially involves laser ablation of epithelial layer of buccal gingiva containing melanin pigmentation.
45996258|NCT04680806|Device|Diode laser 940 nm|The depigmentation procedure essentially involves laser ablation of epithelial layer of buccal gingiva containing melanin pigmentation.
45996259|NCT04680767|Drug|LY3502970|Administered orally.
45996260|NCT04680767|Drug|[¹⁴C]-LY3502970|Administered orally.
45996261|NCT00551538|Drug|Lispro mix 75/25|Lispro mix 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
45996262|NCT00551538|Drug|Glargine|SC injection, once-daily, given in conjunction with oral antidiabetic medications.
45996263|NCT04680494|Other|moderate intensity physical exercise|
45996264|NCT04680494|Other|high intensity physical exercise|
45996265|NCT04680494|Other|rest|
45996266|NCT03694522|Biological|Bemarituzumab|Administered by intravenous infusion over approximately 30 minutes
45996267|NCT03694522|Drug|Placebo|Administered by intravenous infusion over approximately 30 minutes
45996268|NCT03694522|Drug|Modified FOLFOX6|"mFOLFOX6 regimen consists of the following:~Oxaliplatin 85 mg/m² IV infusion over 120 minutes~Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours"
45996269|NCT04891419|Device|JUVÉDERM® VOLUMA® with Lidocaine|JUVÉDERM® VOLUMA® with Lidocaine injectable gel
45996270|NCT00551577|Procedure|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
45675006|NCT02063984|Behavioral|Intensive Outpatient Treatment (IOP) + Contingency Management (CM)|Multiple group sessions weekly, one individual counseling session weekly with teen to review and discuss contingency management abstinence-based incentives
45996271|NCT00551577|Procedure|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
45996272|NCT03686215|Combination Product|Study Device Arm|LUM015 will be administered 2 to 6 hours prior to surgery. The LUM Imaging device will be used to assist in the removal of additional tumor tissue.
45996273|NCT04931901|Device|EMG TOF device|Use of Stimpod NMX450X as an electromyographic neuromuscular monitor
45996274|NCT04207645|Diagnostic Test|Modified RIPASA score|Clinical Prediction Rules consist of clinical and laboratory parameters to aid diagnosis of acute appendicitis
45996275|NCT05512585|Other|awake prone positioning with advanced respiratory support (high-flow nasal cannula or continuous positive airway pressure)|in this group, healthy subjects will stay in prone position for 20 mins with respiratory support of high-flow nasal cannula or CPAP
45996276|NCT04207723|Other|Transcutaneous posterior tibial nerve stimulation|Three (3) sessions per week per twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual.
45996277|NCT04207723|Drug|Paroxetine|paroxetine 20 mg / day taken in the morning hours, per 12 weeks.
45996278|NCT02896790|Other|Interviews with 2 oncologists and 10 patients|
46085388|NCT02656641|Behavioral|Continuous Client Feedback|Clients complete rating scales before each therapy session. The therapist then views these results and discusses treatment progress with the client during the session.
45675007|NCT02063984|Behavioral|Working Memory Training|25 computer-delivered sessions of neurocognitive training
45675008|NCT02091284|Device|transcranial Direct Current Stimulation|Direct currents were transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current will be delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode was placed over F3 according to the 10-20 international system while the anode was placed over the contralateral F4 region. The currents flowed continuously for 20 minutes with an intensity of 2 milliamperes.
45834525|NCT02983890|Drug|Placebos|"No drug are taken for 10 days. Non-blinded. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned"
45834526|NCT03022968|Drug|[18F]T807 PET|Imaging with [18F]T807 PET
45834527|NCT04129944|Drug|UBX0101|Investigational drug intra-articular injection
45834528|NCT04129944|Other|Placebo|Placebo intra-articular injection
45834529|NCT05602350|Behavioral|Self-administered survey|Subjects will self-administer questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
45834530|NCT05602350|Behavioral|Enumerator-administered survey|Subjects will have enumerator-administered questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
45834531|NCT04127994|Other|Comparing 3 versus 6 meals in type 2 diabetes patients|We will compare a 3 meals regimen versus a 6 meal regimen in patients with type 2 diabetes and overweight or obesity, to analyze which of the regimens have better outcomes in glycemic variability
45834532|NCT04124172|Device|Real rTMS (Magstim)|See arm description
45834533|NCT04124172|Device|Sham rTMS|See arm description
45996279|NCT02896790|Other|Interviews with 15 patients|
46085389|NCT02656641|Behavioral|Continuous Self Feedback|Clients complete rating scales before each therapy session. Progress is not reviewed with the therapist.
46085390|NCT02755688|Procedure|Thoracoscopic Surgical ablation|Thoracoscopic approach to isolate pulmonary veins, ganglionic plexi ablation and left atrial appendage exclusion
45996280|NCT04207528|Behavioral|Writing|After completing the baseline questionnaire, participants will be randomized to one of two conditions-a peer helping condition or a facts-only writing control. Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 5 minutes per session. Topics covered in each session will vary and are related to common themes relating to life as a first-year university student (e.g., academics, adjusting to university, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 day apart and take place all within the same week.
46085391|NCT02755688|Procedure|Catheter ablation|Ablation using contact force technology to isolate pulmonary veins and create linear lesions.
45996281|NCT04319848|Other|TE-EK treatment group|Transplantation of tissue-engineered endothelial graft through DSAEK procedure.
46085392|NCT04221854|Diagnostic Test|Stool-based SDC2 DNA methylation test|Stool-based SDC2 DNA methylation test
46085393|NCT04221854|Diagnostic Test|Fecal immunochemical test|Fecal immunochemical test
46085394|NCT02759510|Drug|Norepinephrine|Hypotension (systolic BP <80% of baseline) will be treated with intravenous boluses of norepinephrine 2 μg.
46085395|NCT02759510|Drug|Phenylephrine|Hypotension (systolic BP <80% of baseline) will be treated with intravenous boluses of phenylephrine 40 μg.
46085396|NCT02759432|Other|High-intensity interval exercise training|
45996282|NCT05529979|Device|EPIONE® CT-Guided Percutaneous procedures|The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures.
45996283|NCT02897024|Other|Physical Therapy|One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
45996284|NCT05529901|Device|GORE® CARDIOFORM Septal Occluder|Patients for whom the device is used (implanted or used by not implanted) during the enrollment period of this post-marketing surveillance will be considered eligible for the study
46085397|NCT04220528|Drug|Capecitabine/Tiggio|"Drug: Capecitabine/Tiggio~Radical chemoradiotherapy：Induction chemotherapy plus Concurrent chemoradiotherapy~Induction chemotherapy：Gemcitabine (1000mg/m2) D1 D8+ nida platinum (80mg/m2) D2 q3w ×3cycle~Concurrent chemoradiotherapy：IMRT was used for radiotherapy, during which D1 and D22 were given two cycles of single drug concurrent chemotherapy with nidapatin (100mg/m2)."
46085398|NCT02759042|Drug|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
45675009|NCT02115386|Drug|Nilotinib|supplied in 150 mg capsules to be taken orally
45675010|NCT02091206|Drug|GWP42003-P 5 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/milliliter (mL) cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
45675011|NCT02091206|Drug|Placebo control|Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
45675012|NCT02091206|Drug|GWP42003-P 10 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
45834534|NCT04393194|Drug|Vaginal Cream with Applicator [Dose Form]|Patients with symptomatic POP will be assigned as outpatients. After the initial pessary fitting, the patients will be followed up in 2 weeks. If the prolapse is supported, no discomfort, and the patient decides to continue to use the pessary, the pessary fitting is successful. Patients with successful ring pessary fitting, who agree to participate and sign written consent, will be randomized into the vaginal estrogen group and the placebo group. The patients will be followed up every 3 months after wearing pessary combined with vaginal medication, until 1 year after wearing the pessary.
45834535|NCT04126980|Behavioral|Rates of readmission and reoperation|All patients were then followed-up for 180 days after the indexed surgery of lumbar fusion. All-causes of re-hospitalization and re-operations for lumbar spine fusion, were analyzed at 30, 60 and 180 days for comparison between the ED group and the comparison group.
45834536|NCT04127058|Drug|Iloperidone|Oral Tablet
45834537|NCT05600010|Other|Microplastics|Detection of microplastics as a yes/no value
45834538|NCT03012360|Drug|ceftriaxone|2 g iv every 24h
45834539|NCT03012360|Drug|ciprofloxacin|400 mg iv every 8h
45834540|NCT03012360|Drug|imipenem|1 g iv every 8h
45834541|NCT03012360|Drug|linezolid|600 mg iv every 12h
45834542|NCT03012360|Drug|placebo|The SSI 0.9% or dextrose 5% used are based on routine procedure in different participating centers.Placebo will be prepared using IV bags, with the same of quantity as IMP
45834543|NCT04121598|Other|Observational|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.
46085399|NCT02755454|Device|Perfusion CT Imaging|
46085400|NCT04365218|Drug|MEDI8367|Subjects will receive subcutaneous (SC) single dose of MEDI8367, depending upon dose escalation strategy and Safety Review Committee results. The maximum dose will not exceed 600 mg. The dose will be administered as a single injection or multiple injections in the abdomen region.
46085401|NCT04365218|Drug|Placebo|Saline solution for injection and the placebo volume to be administered will be equivalent to the MEDI8367 volume administered for each dosing cohort.
45996285|NCT04207489|Procedure|endoscopic submucosal injection of indocyanine green before laparoscopic radical operation of colorectal cancer|Indocyanine green was injected under endoscope within 24 hours before operation. Four points were evenlyinjected in four quadrants at the edge of the tumor. The patients with obstruction were injected at two points on the anal side of the tumor. The diluted concentration of indocyanine green was 0.625mg/ml or 1.25mg/ml. The injection method was direct submucosal injection and sandwich method. According to the imaging effect, it can be divided into local imaging and lymphatic drainage imaging. Tumor body: 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation. Lymph drainage area imaging 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation.
45996286|NCT04925583|Radiation|Stereotactic body radiotherapy (SBRT)|"level 0 (de-escalation): 10 x 5.0Gy~level 1 (start): 10 x 5.5Gy~level 2: 10 x 6.0Gy~level 3: 10 x 6.5Gy"
45996287|NCT04320160|Procedure|Platelet rich plasma|"Eight milliliters of blood sample will be aspirated from the patient's peripheral vein, and the sample will be centrifuged at 1,500 rpm for 5 minutes.~A 30-G needle will be used for superficial intradermal (ID) microinjections (0.1 mL per injection and space about 1 cm apart)"
45996288|NCT04320160|Procedure|Fractional CO2 laser|"Fifteen lesions will be treated by Fr: CO2 laser (10,600 nm; KES Corporation, Beijing, China).~Scanner spot size will be adjusted based on the lesion size. Density selected will be 0.6 in the static mode.~Two passes with minimal overlap will be delivered. The laser will be applied to the vitiligo lesion and over a thin rim of healthy skin"
45996289|NCT03678493|Biological|Fecal Microbiota Transplant (FMT)|Oral Capsule
45996290|NCT03678493|Other|Placebo|Oral Capsule
45996291|NCT02896946|Radiation|Diffusion-weighted nuclear magnetic resonance imaging|All MRI examinations will be carried out using a Siemens Magnetom Avanto syngo MR B15 1.5 Tesla (Erlangen, Germany) or a Philips Intera 1.5 Tesla (Eindhoven, The Netherlands) and will include the following sequences: (i) T2 fat sat, with a FOV of 350 x 262, and a matrix of 384 x 207; slices, 30 per sequence, 6 mm thick; (ii) T1 in-phase and out-of-phase with a FOV of 380 x 262, and a matrix of 256 x 158; slices, 30 per sequence, 6 mm thick; (iii) T1 water excitation (= T1 ProSat), with a FOV of 300 x 300, and a matrix of 320 x 220; obtaining 20 slices of 4 mm; (iv) VIBE and THRIVE (dynamic T1 axial 3D EG after injection, during the arterial, portal venous, and late phases, in an axial plane, and optionally in a coronal plane during the portal venous phase), with a FOV of 400 x 312, a matrix of 384 x 192, and with fat suppression and breath-hold; slices 3 mm thick, with liver and pancreatic coverage. Contrast agent: gadobenate dimeglumine (MultiHance, Bracco Imaging, France).
45996292|NCT04321447|Other|Clinical practice guideline for prevention and management of extravasation injury|Implementation of an evidence-based clinical practice guideline and delivery of an educational programme for nurses
45675013|NCT02091206|Drug|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
45996293|NCT00624169|Procedure|An optimized perioperative course|A number of interventions before, during and after surgery
45996294|NCT03627130|Drug|Potassium Nitrate|Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
45996295|NCT03627130|Drug|Potassium Chloride|Potassium Chloride capsules for 5 days
45996296|NCT02896868|Drug|LY3041658|Administered IV.
45996297|NCT02896868|Drug|Placebo|Administered IV.
45996298|NCT04321096|Drug|Camostat Mesilate|Serine protease inhibitor that blocks TMPRSS-2 mediated cell entry of SARS-CoV-2
45996299|NCT04321096|Drug|Placebo oral tablet|Placebo
45996300|NCT00549861|Procedure|Cardiac Magnetic Resonance study|Cardiac MRI study
45996301|NCT04321018|Dietary Supplement|Mixed meal with medium chain triglycerides|Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) with medium chain triglycerides (3g/100 kcal). An amount with energy supply equivalent to their 50% basal metabolic rate.
46085402|NCT02755532|Drug|Bupivacaine 0,25%|Venous blood samples were collected prior to blocking , every 15 min during the first hour after completion of the blocking and every 30 min during the second hour after completion using an exclusive cannula. Then, 5 ml was drawn off and was stored in two EDTA tubes (BD, Franklin Lakes, NJ, USA). The EDTA tubes were centrifuged at 3,500xg for 10 min to obtain the blood plasma. This plasma was then stored in cryogenic tubes in a freezer at -80 °C until the time of the analysis. A high-performance liquid chromatography apparatus (Shimadzu, Kyoto, Japan) coupled to a Bruker mass spectrometer (MS), model Amazon (USA), with electrospray source ionization and a sequential mass spectrometry system (MS/MS) were used for the analysis. After obtaining the precursor ion, a fragment was obtained via a collision-induced dissociation process. The following molecular ions were selected: 289.0 m/z==>140.1 m/z. The methodology was validated according to the international FDA recommendations.
45457326|NCT02297074|Other|Ordinary white bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
45675014|NCT04417790|Diagnostic Test|Lung ultrasound and EVLW measurement by transpulmonary thermodilution.|Lung ultrasonography by 8 Quadrant protocol of Volpicelli et al. Transpulmonary thermodilution for extravascular lung water measurement
45675015|NCT02090426|Other|Link2Care|
45996302|NCT04321018|Dietary Supplement|Mixed meal with the replacement of medium chain triglycerides with unsaturated tryglicerides|Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) without medium chain triglycerides (replaced it with long chain triglycerides). An amount with energy supply equivalent to their 50% basal metabolic rate.
45996303|NCT04320784|Other|Time restricted eating|TRE group consumed 100% of its estimated daily energy needs in an 8-hour time window: from 10:00 AM to 6:00 PM
45996304|NCT04320784|Other|Control|CTRL group consumed 100% of its estimated daily energy needs in 3 meals between 7:00 AM and 9:00 PM
45996305|NCT03556696|Device|ANI-REMI-loop|experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index for automatic remifentanil administration
46085403|NCT02755532|Drug|Bupivacaine 0,5%|Venous blood samples were collected prior to blocking , every 15 min during the first hour after completion of the blocking and every 30 min during the second hour after completion using an exclusive cannula. Then, 5 ml was drawn off and was stored in two EDTA tubes (BD, Franklin Lakes, NJ, USA). The EDTA tubes were centrifuged at 3,500xg for 10 min to obtain the blood plasma. This plasma was then stored in cryogenic tubes in a freezer at -80 °C until the time of the analysis. A high-performance liquid chromatography apparatus (Shimadzu, Kyoto, Japan) coupled to a Bruker mass spectrometer (MS), model Amazon (USA), with electrospray source ionization and a sequential mass spectrometry system (MS/MS) were used for the analysis. After obtaining the precursor ion, a fragment was obtained via a collision-induced dissociation process. The following molecular ions were selected: 289.0 m/z==>140.1 m/z. The methodology was validated according to the international FDA recommendations.
46085404|NCT02755610|Other|PD Product Check List|PD Product Check List was developed based on the 28 routine steps of standard orientation manual for new Thai PD patients. Of these, step 2 (weighting the PD solution bag), step 3 (checking expiration date, volume, glucose concentration, clarity, and color, step 27 (weighting the PD solution bag), and step 28 (recording time, volume, and any abnormality encountered) are relevant to product defect report.
46085405|NCT02755376|Biological|Cartistem(TM)|ACL reconstruction and injection of Cartstem(TM), human cord blood derived mesenchymal stem cell under arthroscopy.
45675016|NCT02063828|Device|Group A - Device guided breathing low dose|Group A: 15 minutes once a day, 5 days a week for 12 weeks.
45675017|NCT02063828|Device|Group B - Device guided breathing high dose|Group B - 15 minutes twice a day, 5 days a week for 12 weeks.
46085406|NCT02755376|Biological|hyaluronic acid|ACL reconstruction and injection of hyaluronic acid under arthroscopy.
45996306|NCT03556696|Device|remifentanil pK/pD target administration device|standard practice, remifentanil administration using Minto's pK/pD model
46085407|NCT02755376|Procedure|ACL reconstruction only|ACL reconstruction only without any injection under arthroscopy
45996307|NCT03556696|Drug|Remifentanil|Remifentanil Ce target can range from 0 to 10 ng.ml-1. Remifentanil target is adapted in order to maintain Analgesia Nociception Index (MDMS, Loos, France) in the [50-70] range.
45996308|NCT03556696|Drug|Propofol|propofol is used for induction and maintenance of general anesthesia using Schnider pK/pD model. Propofol Ce target is adapted in order to maintain BiSpectral Index in [40-60] range
45996309|NCT03556696|Device|ANI monitor|"ANI (Analgesia Nociception Index) value is used in the std_practice arm for guidance of the remifentanil Ce target"
46085408|NCT02752334|Drug|Magnesium Sulphate|Magnesium has antinociceptive effects in animal and human models, principally related to blocking the N-methyl-D-aspartate (NMDA) receptors and regulation of calcium influx into cells.
45996310|NCT04320706|Drug|Oral Oxytocin|Administration of oxytocin (24 international units) orally
45996311|NCT04320706|Drug|Oral Placebo|Administration of placebo orally
46085409|NCT02755298|Drug|Acetazolamide|
45457327|NCT02297074|Other|Precooked-Frozen White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
45675018|NCT02063828|Device|Group C - Usual Breathing Control Group|Group C - 15 minutes per day, 5 days a week for 12 weeks.
45675019|NCT02063672|Device|Lutonix DCB|
45675020|NCT02063672|Device|Standard Uncoated Balloon Angioplasty Catheter|PTA Catheter
45675021|NCT02062658|Drug|Ketamine|0.5mg/kg IV
45996312|NCT03523819|Drug|CS1002|Dose levels will be escalated following a modified 3+3 dose escalation scheme
45996313|NCT03523819|Drug|CS1003|Fixed dose at 200mg in combination with CS1002 on a specified dose level
45996314|NCT04207567|Behavioral|Bodyweight exercises (push-ups, angled-rows, bodyweight squats) on weekdays|Participants will be instructed to perform one set each of push-ups, angled-rows, and bodyweight squats every weekday. They will be given the equipment and training necessary to properly perform the exercises. They will also be trained in the Tiny Habits® Method and receive digital coaching.
46085410|NCT02755298|Drug|Placebo|
46085411|NCT02755142|Biological|Gliolan|
46085412|NCT02759198|Drug|YH23537|Drug: YH23537 750mg Drug: YH23537 1500mg Drug: YH23537 3000mg
46085413|NCT02759198|Drug|Celecoxib|Drug: Celecoxib 200mg
46085414|NCT02759198|Drug|YH23537 placebo|Drug: YH23537 750mg placebo Drug: YH23537 1500mg placebo Drug: YH23537 3000mg placebo
45996315|NCT04923477|Other|Therapeutic Exercise for Rotator Cuff Tendinopathy / Subacromial Pain Syndrome|Therapeutic exercise of resistance and mobility via a combination of HEP and in-person/virtual visits 5 days/ wk. Exercise program instruction in person, then 2-3 visits /wk x 8 wks (in-person or virtual) with a trained professional for the progression of exercises. Adherence to exercise will be measured daily via text and recorded in a mobile app. Patients will start with Phase 1 exercises of shoulder external & internal rotation, scapular stabilization, and active shoulder elevation; resistance levels of elastic bands will be assigned and progressed based on patient-reported shoulder pain and perceived difficulty. Patients will be advanced to Phase 2 when they complete Phase 1. The exercise protocol will be delivered with the methods previously published by Tate, 2010 and Mintken 2016.
45996316|NCT02896673|Procedure|ventilatory conditions and measures with scanner and EIT|"Different ventilatory conditions are studied and measures are acquired with scanner and EIT~Time A: measure under basal conditions (TVbasal=6ml/kg of predicted weight), basal PEP, basal inspiratory time / total time = 30%)~Time B: different PEP are applied for 4 minutes: 5, 10, 15, 20 cm of H2O conserving the basal TV~Time C: different TV are applied for 4 minutes: 4, 7, 10 ml/kg of predicted weight conserving the basal PEP and the basal inspiratory time~Time D: recruitment in continuous positive airway pressure at 45 cm of H2O is performed for 30 seconds~Time E: return to adjustment period A"
45996317|NCT02888704|Drug|ADSTEM Inj. (Adult human mesenchymal stem cells)|Comparison of different dosages of the drug in the aspect of safety and efficacy.
45996318|NCT03512158|Other|Non-invasive respiratory support mode|A mode of providing respiratory support via nasal masks or prongs
45996319|NCT02889172|Behavioral|Problem Solving Therapy|It will be apply a Brief Intervention (PST) for patients with Type II Diabetes Mellitus and Obesity who receive treatment in primary care centers from Mexico City to evaluate if PST improvement the depressive and anxiety symptoms and help to adhere to treatment and stabilize their metabolic variables
45996320|NCT02896439|Device|Neurophysiological MONITORING|"The neurophysiology team perform:~Implementation of the stimulation electrodes and collection (needle electrodes) SEP and EMG as described above.~Acquisition of data by the machine and the software Protektor® (Natus) in the following format:~A PES stimulation every 10 minutes consistently. Meanwhile, important surgical time and known to be at risk for neurological injury will be noted and their exact schedule specified:~Establishment of a spacer or forceps in the greater or lesser sciatic notch~Traction layout~For the ways of Kocher-Langenbeck, a collection of potential nerve sciatic trunk upstream of the critical region:~At the end of the incision~On the establishment of a spacer or forceps in the greater or lesser sciatic notch~When towing layout~At the end of the intervention"
46085415|NCT02758964|Other|MRI, neurocognitive Testing|A cerebral MRI and neurocognitive testing will be performed before TAVR, before hospital discharge and after 3 months
46085416|NCT02752100|Procedure|Percutaneous transluminal angioplasty|
45996321|NCT03482479|Drug|Naltrexone Hydrochloride|Naltrexone Hydrochloride will be taken daily (dose 4.5 mg) for six weeks
45675022|NCT02062658|Behavioral|Exposure and Response Prevention|A type of Cognitive Behavioral Therapy called Exposure and Response Prevention.
45675023|NCT02115308|Drug|Regadenoson|Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging.
45996322|NCT03482479|Other|Placebo Comparator|A placebo tablet which matches the drug will be taken daily for 6 weeks.
45996323|NCT04807842|Device|vaginal gel|The placebo gel is a non-buffered gel. The active device is an acidic gel.
45996324|NCT02896478|Other|No intervention. Only observational study|
45675024|NCT02114684|Drug|moxifloxacin|[isoniazid (H), rifampicin (R), pyrazinamide (Z), moxifloxacin (M)]
45996325|NCT04922736|Device|UVA-1 Phototherapy|All patients will receive UVA-1 Phototherapy treatments
45996326|NCT02896322|Radiation|Partial breast irradiation with cyberknife|
45996327|NCT04800198|Procedure|non-invasive ventilation|none, measurements only
45996328|NCT02896166|Other|microwave ablation|eligible patients will be treated with microwave ablation in the primary tumor sites
46085417|NCT02758886|Behavioral|Animal assisted activity|Allowed to interact (e.g. talking, petting, scratching, feeding treats, playing with) live animals
46085418|NCT02758886|Behavioral|Animal photos|A 10 minute, silent, PowerPoint slide show of a variety of dogs and cats
46085419|NCT02758886|Behavioral|Observing human-animal interaction|Participants watched others participate in petting dogs and cats, while they waited in line for 10 minutes. Participants did not physically touch any animals during this time.
45675025|NCT02090114|Drug|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.
45675026|NCT02090114|Drug|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days.
45675027|NCT02090114|Drug|Abiraterone acetate|Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.
45675028|NCT02090114|Drug|Enzalutamide|XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.
45675029|NCT01623050|Device|SinuSys Dilation System|Sinuplasty
45676748|NCT01823835|Drug|LHRH Agonist|LHRH agonist administered once monthly until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years). Choice of LHRH agonist will be an institutional choice approved for use in breast cancer.
45996329|NCT00553709|Drug|Nicotine|Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
45996330|NCT02896244|Other|no intervention|
45996331|NCT00551694|Drug|GSK256073A tablets|
45996332|NCT00551733|Drug|carboplatin|Given IV
45996333|NCT00551733|Drug|paclitaxel|Given IV
45996334|NCT00551733|Drug|paclitaxel poliglumex|Given IV
45675030|NCT02089334|Drug|RX-0201|"RX-0201 will be administered in a dose up to 250mg/m^2/day as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles in Stage 1.~In Stage 2, RX-0201 will be administered the dose determined in Stage 1 as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles."
45675031|NCT04742036|Drug|Capivasertib|Part A Cycle 0: Single dose 480 mg(3 x 160 mg tablets) on Day 1 of Cycle 0 Cycle 1 (monotherapy): 480 mg(3 x 160 mg tablets) twice daily given on an intermittent weekly dosing schedule (4 days on, 3 days off for 7 days) Part B Cycle 2 (in combination therapy with paclitaxel): 400 mg (2 x 200 mg tablets) twice daily given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Capivasertib treatment will continue until disease progression, unacceptable toxicity or the participant requests to stop treatment.
45457328|NCT02297074|Other|Candeal-flour White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
45675032|NCT04742036|Drug|Paclitaxel|"Part B Cycle 2: Patients will receive 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.~Paclitaxel treatment will continue for at least 6 cycles, unless the participant experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel, or disease progression."
45996335|NCT02896283|Radiation|Low-level laser therapy|Low-level laser therapy with the following parameters: Wavelength:660 nanometer, power: 200 mW, continuous mode, tme of irradiation: 32 seconds
45675033|NCT02114606|Device|Cytosponge™ Cell Collection Device|The Cytosponge™ Cell Collection Device (Cytosponge) is intended to collect surface cells from the esophagus. The device consists of a swallowable capsule, which dissolves in the body cavity, releasing a self-expandable sponge. The sponge is then retrieved from the esophagus using an attached cord. During the retrieval process, the sponge collects cells from the most superficial layer of the esophageal mucosa. Once removed from the body cavity, the sponge and cells are retained for investigation and/or testing. The Cytosponge™ Cell Collection Device (Cytosponge) received 510(k) clearance from the FDA on November 26, 2014 (K142695). The Cytosponge ™ Cell Collection device is a Class II product under 21 CFR 874.4710 esophagoscope (flexible or rigid) and accessories.
45675034|NCT04729634|Other|Mobilization|Mobilization and breathing exercises according to clinical care
45675035|NCT02113436|Drug|FP/ SLM HFA MDI 50/25 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate and 25 mcg of salmeterol per inhalation
45675036|NCT02113436|Drug|FP HFA MDI 50 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate per inhalation
45996336|NCT02896283|Radiation|Turned-off laser|Laser device is turned-off. All parameters are like experimental group, however the laser in turned-off.
45457329|NCT02297074|Other|Alfacar White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
46085420|NCT02754986|Other|Analysis of the holter electrocardiogram|
46085421|NCT04220606|Drug|Glyceryl trinitrate (I.V. infusion 0.5 µg/kg/min over 20 min)|
45458728|NCT03492502|Biological|Autologous Fecal Microbiota Transplantation|"Consenting allo- SCT patients with acute steroid-resistant GI-related GVHD grade III-IV will receive autologous FMT by nasogastric tube. Standardized stool suspension will be given once a day for two consecutive days.In order to prevent aspiration, patients will be kept in a 45ᵒ upright position for four hours. Participants will fast the night before and be treated with proton pump inhibitors prior to each FMT.~In cases where complete response was not obtained within 7 days after autologous FMT, patients may be eligible for another trail of autologous FMT or to switch to other pharmacological interventions. Stool samples will be collected before and after the intervention for microbial analyses."
45675037|NCT02087774|Behavioral|6 minutes activity|Group added 6 minutes of physical activity daily during school day.
45996337|NCT00551772|Drug|SB-742457|
46085422|NCT02755064|Drug|Erythromycin lactobionate|In Phase 1 of the study, during the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. Thereafter, an infusion of 1.5 or 2.5 mg/kg was given over the next 50 min with the same infusion pump. The goal of testing 2 different doses was not to assess dose-related effects but to compare glycemic indices against a spectrum of gastric emptying rates.
45996338|NCT02896205|Drug|Mycophenolate mofetil|Subjects will be given oral Mycophenolate Mofetil starting at 500mg twice a day and increased gradually to a target dose of 2gram per day for 6 months
45996339|NCT02896205|Drug|Placebo|Subjects will be given matching placebo for 6 months
45996340|NCT04922424|Drug|Atorvastatin|Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential carryover effects.
45996341|NCT04922424|Other|placebo|Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential
45996342|NCT00550056|Behavioral|Narrative Exposure Therapy|Six session of Narrative Exposure Therapy
45996343|NCT00550056|Behavioral|Trauma Counselling|Six sessions of Trauma Counselling, using a variety of skills incl. exposure methods following the skills of the therapist
45996344|NCT02896634|Biological|clinical biology analyzes spectrometry mass|clinical biology analyzes spectrometry mass
45996345|NCT00551811|Drug|SB-656933-AAA|SB-656933-AAA tablets will be available with a dose strength of 50 milligrams, administered orally.
45996346|NCT00551811|Drug|Placebo|Placebo tablets will be intended to be administered orally.
45996347|NCT00553748|Drug|F-18 FLT|One - 10 mci dose of F-18 FLT is administered IV over about 5 seconds prior to PET imaging. Each imaging dose contains no more than 6.1 micrograms of FLT.
45996348|NCT00551850|Drug|AV-412|oral solid dosage form administered three times weekly for 4 weeks (1 cycle)
45675038|NCT02111564|Drug|Rivaroxaban, 10 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening greater than or equal to (>=)50 mL/min will receive 10 mg rivaroxaban tablet with or without food.
45675039|NCT02111564|Drug|Rivaroxaban, 7.5 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from >=30 to less than (<)50 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.
45675040|NCT02111564|Drug|Placebo|All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.
45675041|NCT02087150|Device|Acclarent Eustachian Tube Balloon Catheter (ETBC)|
45996349|NCT02896049|Device|Hyperthermia|treatment with the Celsius42 Hyperthermia System additional to radiotherapy and/or chemotherapy
45996350|NCT00550095|Drug|valsartan|
45996351|NCT02895893|Behavioral|PrEP Smart|Men who have sex with men and already prescribed and taking oral PrEP will use an application on their smart phone for 4 weeks.
45676749|NCT01823835|Drug|Palbociclib|Palbociclib administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).
45834544|NCT04127214|Other|ITA Integrated Treatment|The ITA Model combines outpatient intervention (mainly psychotherapy), day hospital care and hospitalization as a function of patients' characteristics. Case conceptualization of the psychological processes of patients is formulated and revised within a team including psychologists, psychotherapists, psychiatrists, nutritionists, physicians, nurses, and social workers. The major emphasis of the ITA model is on psychological interventions which include individual psychotherapy, family therapy and/or guidance, and group therapy of various formats and contents (e.g., drug abuse, mindfulness, emotion work) tailored to the needs of each patient. However, when required, drugs are prescribed adjusting type of medication and dosage to the need of the patient.
45996352|NCT00551889|Drug|celecoxib|
45834545|NCT04120974|Behavioral|Optimal insulin injection|subjects receive training in optimal injection technique.
45834546|NCT05609838|Other|Hot water foot bath|A 15 minutes hot water foot bath was applied to the experimental group patients 3 hours after the cesarean section.
45834547|NCT04392882|Behavioral|Legume enriched diet group|"Replacing 1/3 refined rice intake with legumes three times per day~Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake~Regular 30-min walk after dinner each day"
45996353|NCT00551889|Drug|cyclophosphamide|
45996354|NCT00551889|Other|laboratory biomarker analysis|
45996355|NCT00550212|Drug|neratinib|HKI-272, Single-dose capsule and solution
45996356|NCT02895932|Radiation|PET imaging|Serotonin, Dopamine and Amyloid PET imaging
45996357|NCT00551967|Procedure|Hip replacement|Surgical implantation of hip replacement components for the treatment of osteoarthritis
45996358|NCT02896010|Other|Sweetch App + DBWS|Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).
45996359|NCT02896010|Other|Sweetch App Alone|Usual care for prediabetes management, Sweetch app alone.
45996360|NCT00552006|Behavioral|Narrative Exposure Therapy|"Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. In cooperation with the therapist the clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
45675042|NCT04728620|Other|Diabetes Care Gaps Patient Portal Intervention|The Diabetes Care Gaps Patient Portal Intervention involves a new feature embedded with the My Health At Vanderbilt (MHAV) native app (on Epic's MyChart platform) for mobile devices that allows patients to: (a) receive notifications when the patient is due for certain types of diabetes monitoring and preventative care and (b) initiate an order for the care. Automated notifications will be sent to patients if, according to the evidence-based guidelines, the patients are due for a hemoglobin A1C blood test, microalbumin urine test, diabetes eye exam, or pneumonia vaccination. Once notified patients can initiate orders for the care within the MHAV app. The patient will receive confirmation when the order has been processed and will be provided instructions to receive the relevant care.
45834548|NCT05609604|Device|tDCS|Electric current will be delivered to the pre-frontal cortex for 30 minutes.
45834549|NCT04126668|Drug|CM082 with fed or fasting|The two groups of subjects were given an equal dose of CM082 tablet (200 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of CM082.
45996361|NCT00552006|Behavioral|Academic Counseling|"Missing time in educational life is one major issue for formerly abducted people. The Academic Counseling (AC) intervention is an active Control condition and improves English skills and works at the same time on concentration, learning and memory abilities. The clients will gain some of the abilities and skills they might have lost or developed weaknesses in due to their abduction.~AC will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
45996362|NCT02895854|Radiation|Hypofractionated RT 5 x 7,25 Gy|
45996363|NCT02895854|Radiation|LDR-brachytherapy with I125 seeds|
45996364|NCT00550251|Device|Acupressure Wrist Bands (Sea-Bands)|Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
45996365|NCT00550251|Device|Placebo wristbands|Elasticated wrist bands without active bead.
46085423|NCT02755064|Drug|Placebo IV|In Phase 1 of the study, during the second visit, saline was given as an initial bolus over 10 min immediately before the meal. Thereafter, an infusion of saline was given over the next 50 min with the same infusion pump.
46085424|NCT02755064|Drug|[13C]-Spirulina|The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
45996366|NCT01261390|Behavioral|Conservative Medical Therapy (CMT)|All participants will meet with a research assistant who will provide 30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breathe Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
45675043|NCT02111174|Device|Scrambler Therapy|
45675044|NCT02111174|Device|Sham Therapy|
45834550|NCT04126434|Device|mask|facemask
45834551|NCT04126512|Other|PDA ligation|PDA ligation was performed at bedside, if a local cardiac surgery team was available, or in the case this service was not available, infants were referred to off-site specialist paediatric cardiac surgical services, where PDA ligation was performed.
45996367|NCT01261390|Device|Sham PAP (Sham)|In addition to receiving CMT, participants in this treatment arm will receive a sham PAP unit. Sham devices look like active PAP devices, however, the exhalation port is increased and an orifice-resistor is inserted between the pump and tubing, creating a marginal pressure. A heated humidifier will be provided with this device and PAP masks will be fit and provided following the same procedures as for the active-PAP arms.
46002369|NCT03416179|Drug|glasdegib|"Glasdegib 100 mg PO QD is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment.~Subjects will continue glasdegib until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first."
46085425|NCT02755064|Drug|Erythromycin Ethylsuccinate Suspension|In Phase 2 of the study, subjects randomized to this arm will receive Erythromycin Ethylsuccinate Suspension 250 mg tid orally for a total period of 7 days.
45675045|NCT02111096|Drug|LY2409021|Administered orally
45675046|NCT02111096|Drug|Sitagliptin|Administered orally
45675047|NCT02111096|Drug|Placebo|Administered orally
45675048|NCT02111096|Drug|Metformin|Administered orally
45834552|NCT02979678|Other|Questionnaire|The questionnaire should be updated with respect to wording, terminology.
45996368|NCT01261390|Device|Active PAP with RT Support (Active-Beh)|In addition to receiving CMT, participants will receive active-PAP and meet with a PAP-specialist . The CPAP specialist would meet with the participant in person throughout the course of the study (set-up, 1-week, 1-month, 3-month, 6-month, and 9-month). Using the available data from the PAP monitor, the PAP specialist will discuss PAP use, mask leaks, and residual AHI to assist with troubleshooting. Adjustments to equipment would be performed as needed to improve adherence. It is estimated that each in-person follow-up adherence visit with the PAP-specialist would last 30 minutes.
45996369|NCT01261390|Device|Active PAP with Behavioral Modification (Active+Beh)|In addition to receiving CMT and active-PAP, participants will meet with a behavioral interventionist in addition to PAP-specialist visits. Participants also would speak with the behavioral interventionist over the course of the study (set up, 1-week, 3-week, 1-month, 2-months, 3-months, 5-months and 8-months). The duration of the first 2 behavioral intervention sessions are estimated to be 1-hour long, with subsequent 30-minutes intervention sessions. The intervention will be based on social cognitive theory and feedback concerning adherence with targeted problem solving training.
45996370|NCT02895815|Combination Product|CNTO 2476 (6.0 * 10^4 cells)|Participants will receive a single subretinal administration of CNTO 2476 (6.0 * 10^4 cells) in 50 mcL given by subretinal delivery system (subretinal access kit [SRAK-02 kit] and third arm accessory).
45675049|NCT02111096|Drug|Sulfonylurea|Administered orally
45675050|NCT02110706|Drug|Rituximab|Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
45996371|NCT02895815|Combination Product|CNTO 2476 (3.0 * 10^5 cells)|Participants will receive a single subretinal administration of CNTO 2476 (3.0 * 10^5 cells) in 50 mcL given by subretinal delivery system (SRAK-02 kit and third arm accessory).
45996372|NCT02895503|Behavioral|Yoga|Participate in yoga
45996373|NCT02895503|Behavioral|Support Group Therapy|Participate in emotional support group therapy
45996374|NCT02895503|Other|FACT-L|This is a 44-item self-report instrument which measures multidimensional HRQOL. There are 5 sections dealing with physical, family, emotional, and functional well-being and their relationship with the doctor. There are nine questions in a sixth subscale that are specific to lung cancer (LSC), including shortness of breath, cough, etc. The TOI is the sum of the scores on the LCS and the physical well-being and functional well-being subscales of the FACT-L scale. The FACT-L has been shown to be reliable and valid and sensitive. (Cella, Bonomi, Lloyd, DS, Kaplan, & Bonomi, 1995). The instrument has been used with patients with lung cancer in the Massey Cancer Center.
45996375|NCT02895503|Other|Pulmonary function test|The pulmonary function test includes forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and peak expiratory flow rate (PEFR). Use of a digital spirometer provides an objective and reliable measure of the patient's vital capacity.
45996376|NCT03455764|Drug|MCS110|MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.
45996377|NCT03455764|Drug|Dabrafenib|Dabrafenib attack different proteins that promote the growth of cancerous cells
45996378|NCT03455764|Drug|Trametinib|Trametinib attack different proteins that promote the growth of cancerous cells
45996379|NCT04902495|Other|MTA Pro Root|pulp therapy
45675051|NCT02110706|Drug|Placebo|The placebo group will receive a vehicle control infusion
45996380|NCT04902495|Other|MTA HP Repair|pulp therapy
45996381|NCT04902495|Other|Biodentine|pulp therapy
45996382|NCT03433183|Drug|Selumetinib|Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low-grade gliomas and NF1 plexiform neurofibromas. MEK is a critical kinase in the mitogen activated protein (MAP) kinase signal transduction pathway for many growth factor receptors that provide growth signals to cancer cells.
45996383|NCT03433183|Drug|Sirolimus|Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus and inhibitor of mammalian Target of Rapamycin (mTOR) serine threonine kinase, which plays a critical role in regulating cellular energy sensing, growth and metabolism.
45996384|NCT00552162|Procedure|NOTES Transvaginal Cholecystectomy|The gallbladder will be dissected free and will be removed through an incision in the vagina.
45996385|NCT00552162|Procedure|NOTES Transvaginal Appendectomy|The appendix will be dissected free and will be removed through an incision in the vagina.
45996386|NCT02895659|Procedure|perioperative hemodynamic management with vasoactive medications (norepinephrine, adrenaline ect)|Perioperative hemodynamic management will be performed according to a specified treatment protocol.
46085426|NCT02755064|Drug|Placebo Suspension|In Phase 2 of the study, subjects randomized to this arm will receive an oral placebo prepared to mimic the Erythromycin Ethylsuccinate Suspension for a total period of 7 days.
45675052|NCT02110238|Device|Supartz|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
45675053|NCT02110238|Device|Euflexxa|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
45675054|NCT02108912|Other|ESTT|ESTT is early-standardized task-specific training is a treadmill and over ground gait protocol for gait recovery after stroke
45675055|NCT02108912|Other|Traditional outpatient|Traditional physical therapy includes standard of care for gait recovery after stroke such as pre-gait activities, standing balance activities, strengthening, walking with assistive devices.
45675056|NCT02108600|Drug|Tocilizumab|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
45675057|NCT02107898|Drug|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
45675058|NCT02107898|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
45675059|NCT02107898|Drug|Lipid-Modifying Therapy (LMT)|Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.
45675060|NCT02059148|Drug|LY2835219|Administered orally.
45675061|NCT04721600|Device|Evoke Radiofrequency Device|Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments.Treatment area will include face and under chin
45996387|NCT00552201|Drug|Tacrolimus|Administration Twice a day after adjustment to blood level
45996388|NCT02895464|Other|Exercise|The sessions will be led by a physiotherapist, in the older person's home. The sessions will consist of inspiratory muscle training with a resistance starting from 50% of their maximal capacity (30 breathes, 2 times/day). The training session will also consist of high-intensity individually adjusted functional strength and endurance training: chair-stand; stair climb/step up with weight belts, interval walking indoor and/or outdoor. This will be combined with functional task-exercises. The training will be conducted 2-3 times week, for at least two weeks or until they undergo surgery. During the remaining days, the participants will be instructed to follow the recommendation of 30 minutes of moderate physical activity per day, as well as to perform inspiratory muscle training.
45996389|NCT03391882|Drug|APL-130277|APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
45996390|NCT03391882|Drug|subcutaneous apomorphine|subcutaneous apomorphine Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
46085427|NCT02754830|Drug|LY3303560 - IV|Administered IV
45996391|NCT00550329|Drug|Glipizide GITS|
45996392|NCT02895620|Biological|Xpert bladder Test|Xpert test positive or negative on urine samples of NMIBC patients treated by BCG
45996393|NCT00550485|Drug|escitalopram|escitalopram 4 mg
45996394|NCT01261000|Drug|Pegvisomant|Pegvisomant used as indicated
45996395|NCT00550524|Biological|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 20-25 million cells; in a maximum volume of 4-6 ml. Cells will be injected in the knee joint with a 21 gauge needle.
46085428|NCT02754830|Drug|Saline Solution - IV|Administered IV
45675062|NCT04720820|Other|Early Supported discharge with home based Rehabilitation|Treatment by Physiotherapist and occupational therapist at least 30 minutes each, per week provided at home.
45834553|NCT05609448|Procedure|MRI-guided radioembolization|Catheter placement will be performed using fluoroscopy, after which patients are transferred to the MRI scanner, where holmium microspheres are administered based on MRI dosimetry. Thereby, patients get a personalized dose administration.
45834554|NCT04126122|Diagnostic Test|Ultrasonography to assess fetus and mother|to assess fetal growth and maternal outcome
45675063|NCT04720820|Other|Conventional rehabilitation|Treatment will be provided according to current hospital's stroke rehabilitation program.
45834555|NCT04758936|Drug|Clonidine|The doses administered (clonidine 1500mg diluted in NaCl0.9% solution of 50 ml) ranged from 0.01μg/kg/min to 0.03μg/kg/min.
45834556|NCT04758936|Drug|Dexmedetomidine|The doses administered (dexmedetomidine 200mg diluted in NaCl0.9% 50ml) ranged from 0.4μg/kg/h and can be titrated up to 1.4μg/kg/h.
45996396|NCT02895737|Device|TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra|
45996397|NCT02895737|Device|TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra; Sentinel™ Cerebral Protection Systems|
46085429|NCT02754830|Drug|LY3303560 - SC|Administered SC
46085430|NCT02754752|Procedure|Electroacupuncture Therapy|Undergo electroacupuncture therapy
46085431|NCT02754752|Procedure|Electroacupuncture Therapy|Undergo modified electroacupuncture therapy
46085432|NCT02754752|Other|Laboratory Biomarker Analysis|Correlative studies
46085433|NCT02754752|Other|Quality-of-Life Assessment|Ancillary studies
45675064|NCT04720742|Drug|Analytical Treatment Interruption + bNAbs infusion|The participant will perform an Analytical Treatment Interruption (ATI) of up to 18 months of duration. During the first 8 months, the participants will be infused once per month with a combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074
45675065|NCT02058992|Drug|Ramelteon|Ramelteon 8 mg tablets
46085434|NCT02754752|Other|Questionnaire Administration|Ancillary studies
46085435|NCT02751944|Dietary Supplement|NEM|Dietary supplement for the support of joint health.
46085436|NCT02751944|Dietary Supplement|Placebo|Placebo
46085437|NCT02706132|Biological|Mesenchymal Stem Cells(MSCs)|Six doses of 1*10^6/kg body weight MSCs are given, intravenously.
46085438|NCT02754908|Behavioral|musical training|The subjects in the experimental group will receive weekly 45-minute lessons on musical training for one year (52 weeks), conducted by the Music Children Foundation.
46085439|NCT02754908|Behavioral|tutoring classes|They will be invited to attend free, weekly 45-minute tutoring classes organised by the community for one year (52 weeks).
46085440|NCT04221074|Procedure|PECS II versus ESP|compare between :ultrasound guided Pectoralis nerve(pecs) II block or erector spinae plane (ESP) block in surgical treatment for gynecomastia patients under general anaesthesia.
45675066|NCT04719416|Behavioral|Guided Meditation|Approximately 10 minute recording of guided meditation focuses on muscle relaxation.
45675067|NCT02058836|Drug|Botox Injection|One-time injection of 100 Units of Botox in 10 mL of saline. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
45834557|NCT03830814|Procedure|Echocardiography|Basal two dimensional and three dimensional echocardiographic parameters were compared to those obtained 3 months after starting the sacubitril/valsartan treatment
45834558|NCT04126044|Drug|PF-06439535 (CN)|This is the test drug Pfizer biosimilar of bevacizumab-EU.
45834559|NCT04126044|Drug|bevacizumab - EU|This is the reference drug bevacizumab sourced from EU
45834560|NCT04131036|Other|assessment of joint health and bone density|We propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A.
45996398|NCT02895737|Device|TAVI: CoreValve® Evolut R™, CoreValve Medtronic|
45996399|NCT02895737|Device|TAVI: CoreValve® Evolut R™, CoreValve Medtronic; Sentinel™ Cerebral Protection Systems|
45996400|NCT02895425|Other|Registry (No intervention)|
45996401|NCT00550563|Dietary Supplement|cholecalciferol|Oral
45996402|NCT00550563|Genetic|polymerase chain reaction|companion study
45996403|NCT00550563|Genetic|polymorphism analysis|companion study
45996404|NCT00550563|Genetic|protein expression analysis|companion study
45996405|NCT00550563|Genetic|reverse transcriptase-polymerase chain reaction|companion study
45996406|NCT00550563|Genetic|western blotting|companion study
45996407|NCT00550563|Other|high performance liquid chromatography|companion study
45996408|NCT00550563|Other|laboratory biomarker analysis|companion study
45996409|NCT00550563|Other|pharmacological study|companion study
45996410|NCT00550563|Procedure|adjuvant therapy|Additional therapy
45996411|NCT00550563|Procedure|immunoscintigraphy|additional testing
45996412|NCT02895698|Device|Dry cupping|Dry cupping. First, the therapist identified the trigger point on calf muscle.After identification of the trigger point, the participant was in prone with the ankle outside the edge of the bed. Ultrasound gel was then placed over the trigger point as a lubricant to increase the suctioning of the plastic vacuum cup, after which the cup was placed. Air was withdrawn from the cup to create a suction force. The cup was maintained for 10 minutes, and the participant was asked to do active ankle dorsiflexion exercise after 5 minutes of placing the cup. The therapist held the cup in place while the participant performed exercise.
46085441|NCT04333472|Drug|Piclidenoson|Piclidenoson 2 mg orally every 12 hours for up to 28 days
46085442|NCT04333472|Drug|Placebo|Placebo orally every 12 hours for up to 28 days
45675068|NCT02058836|Procedure|Normal saline injection|One-time injection of 10 mL of 0.9% sodium chloride (normal saline) solution. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
45675069|NCT02107274|Drug|Azithromycin|Azithromycin (C38H72N2O12 MW 749) is a 15-membered azalide, a subclass of macrolide antibiotics
46085443|NCT04215042|Drug|sodium chloride infusion|
45675070|NCT02107274|Drug|Placebo for Azithromycin|In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
45675071|NCT02174627|Drug|Roxadustat|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
45675072|NCT02174627|Drug|Placebo|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
45996413|NCT02895698|Other|Stretching exercises|"The participant was in prone with the ankle outside the edge of the bed. The participant was asked to do active ankle dorsiflexion exercise after 5 minutes of lying on bed.~Standing self-stretching of the calf muscles.~Plantar fascia-specific self-stretching.The participant was instructed to start gently at first and then to work more aggressively as long as the pain is tolerable.~All stretches were done six times and the duration of each stretch is 30 seconds."
45996414|NCT02895191|Drug|ulinastatin|Patients will receive the study drugs for 7 to 14 days
45996415|NCT02895191|Drug|placebo|Patients will receive the placebo for 7 to 14 days
45996416|NCT04765800|Behavioral|weekly sessions of face to face outpatient psychotherapy|according the German Richtlinie des Gemeinsamen Bundesausschusses über die Durchführung der Psychotherapie
45996417|NCT02895269|Behavioral|Collaborative shared care|Collaboration between complementary alternative health providers and primary health care providers in the care of persons with psychosis.
46085444|NCT02698722|Other|End-stage renal disease treatment options|This group will receive the intervention which is a 11.5 minute video about dialysis and non-dialytic therapies.
45675073|NCT02173769|Drug|Spiriva® Respimat®|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
45675074|NCT02173769|Drug|Striverdi® Respimat®|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
45675075|NCT02121509|Drug|Linagliptin|1 x Linagliptin tablet
45675076|NCT02121509|Drug|Linagliptin/Metformin ER FDC|2 x Linagliptin/Metformin ER FDC tablet
45675077|NCT02121509|Drug|Metformin ER|3 x Metformin ER tablets
45675078|NCT02149199|Drug|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
45996418|NCT04765020|Behavioral|Experimental: moderate to high-intensity exercise|"Four parts:~Initial consultation with recommendations for general physical activity, brochure with exercise recommendations~Once per week multi-modal group-based exercise (endurance, strength, mobility, coordination)~Once per week supervised multi-modal individual training session (endurance, strength, mobility, coordination). Intensity: 60-80% of max. HR~Activity trackers with individual movement goals that will be adjusted every two weeks"
46085445|NCT02758574|Procedure|CDT without ultrasound acceleration|A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus a standard infusion catheter will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus.
45996419|NCT00550641|Other|physical therapy|physical therapy in warm pool performing stretching
46085446|NCT02758574|Procedure|CDT with ultrasound acceleration|A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus an infusion catheter that incorporates an ultrasound emitting wire will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus. The wire will be connected to an ultrasound generating device.
46085447|NCT02698488|Procedure|Morphology|
46085448|NCT02698488|Procedure|Morphology and Mass Spectroscopy|
46085449|NCT02702934|Other|Test meal|Participants received in random order a test meal (900Kcal, 100g carbohydrates) containing rusks prepared with amylose-rich wheat flour or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.
45996420|NCT00550641|Other|physical therapy|physical therapy in warm pool performing Ai Chi
45996421|NCT04680650|Drug|Anesthesia was maintained with sevoflurane|After endotracheal intubation, anesthesia was maintained with 1.5-3% sevoflurane, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DS.
45996422|NCT04680650|Drug|Anesthesia was maintained with propofol|After endotracheal intubation, anesthesia was maintained with 2-4 μg/mL target-controlled infusion of propofol, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DP.
46085450|NCT02758730|Biological|AFFITOPE® PD01A + Adjuvant|s.c. injection
45834561|NCT03822390|Device|CAD-CNN system|The CAD-CNN system will be trained in predicting the histology of diminutive polyps. Before training, the dataset will be split up into a training set and a test set. To ensure a completely independent test and training set there will be no overlap between patients (i.e. if polyps from a patient A is present in the training set it cannot be in the test set as well).
46085451|NCT02758730|Biological|Adjuvant without active component|s.c. injection
45457330|NCT02297074|Other|Wholemeal Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
45457331|NCT02297074|Other|Glucose|50 g of glucose were administered as a reference
45834562|NCT03822858|Drug|Intrathecal MSC-NP injection|"Between 5 to 10 million MSC-NPs will be administered intrathecally in each dose.~10 million cells is the maximum dose. Treatment will consist of 3-5 doses spaced 3 months apart."
45834563|NCT03829878|Drug|CP101|Orally administered donor derived full spectrum microbiota
45834564|NCT03829878|Drug|Placebo|Placebo for CP101
45834565|NCT03829800|Dietary Supplement|Ensure® Abbott Nutrition|Effect of the intake of Ensure® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
45834566|NCT03829800|Dietary Supplement|Glucerna® Abbott Nutrition|Effect of the intake of Glucerna® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
45834567|NCT03829800|Dietary Supplement|Diasip® Nutricia Advanced|Effect of the intake of Diasip® Nutricia Advanced on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
45996423|NCT00550758|Drug|Methachoine|inhalation of triple-concentration increments (0.06 to13.9mg/ml/methacholine)
46085452|NCT02703012|Other|Adjustment of ventilator settings by EIT|Diagnostic maneuvers (change in tidal volume, recruitment maneuvers) will be performed to detect overdistention, tidal recruitment and recruitability. Tidal volume will be reduced if overdistention is detected by EIT. Positive end-expiratory pressure will be increased if tidal recruitment or recruitability are detected.
46085453|NCT02705976|Other|Experimental|The algorithm is based on a model, which is designed to handle time series of daily warfarin intakes and INR values measured at designated time points. Based on these inputs the model is able to suggest a warfarin maintenance dose to achieve target INR value. Model parameters are initially set to population values and gradually, as data is entered into the model, these parameters become patient specific.
45996424|NCT00550758|Device|spirometry|spirometry
45996425|NCT04680572|Procedure|arthroplasty|arthroplasty for fracture neck of femur
45996426|NCT00552435|Device|Laser photocoagulation|Laser therapy is applied using a slit lamp and specific laser contact lens.
45996427|NCT02895308|Behavioral|Online psychoeducation|The online intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
46085454|NCT02705976|Other|Active Comparator|Participants were (previously) educated in monitoring the INR values and to adjust the warfarin treatment accordingly to achieve a designated target INR range.
46085455|NCT02752412|Drug|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45996428|NCT02895308|Behavioral|Face-to-face psychoeducation|The intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
45996429|NCT00550797|Biological|TPI ASM8|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
46085456|NCT02752412|Drug|Insulin glargine U100 (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
46085457|NCT02752412|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
45457332|NCT01132729|Drug|Valacyclovir Hydrochloride|1000 mg caplet
45457333|NCT02297152|Device|FLIP HOLE|The subjects had to use the masturbator aid at least five times per week for six weeks, during a minimum of five minutes without never overcoming half daily hour and during intercourse. The device Flip Hole is a masturbation aid made from Thermoplastic Elastomer (a silicone like substance) that the user inserts their penis in to for stimulation.
45675079|NCT02149199|Drug|terbutaline 'as needed' + placebo budesonide bid|Terbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
45996430|NCT00550797|Biological|placebo|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
45675080|NCT02149199|Drug|budesonide bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
45675081|NCT02120417|Drug|Ruxolitinib|"5 mg tablets to be administered by mouth~Ruxolitinib 15 mg BID (starting dose)"
45675082|NCT02120417|Drug|Capecitabine|Capecitabine 2000 mg/m^2 daily given as 1000 mg/m^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle
45675083|NCT02120417|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
45834568|NCT03829800|Dietary Supplement|Glicolab®|Effect of the intake of Glicolab on the glycemic index, insulin and subjective appetite in subjects with type 2 diabetes
45834569|NCT04125810|Biological|Probiotic|Probiotic
45834570|NCT04125810|Other|Placebo|Placebo
45996431|NCT02895113|Drug|Aspirin|Patients suffering from type 2 diabetes will be randomized to receive 100 mg/day or placebo for one year
45834571|NCT04758858|Other|Insulin treatment optimization with participant's usual diet|Two weeks before the intervention phase, insulin dose optimization and revision of participants' knowledge on carbohydrates counting, hypo- and hyperglycemia prevention and treatment will be done with a nurse and a dietitian under a physician's supervision. Once to twice a week, participants will be contacted to review if glucose values are in target.
45996432|NCT02895113|Other|Placebo|Patients in this arm will be treated with placebo
46085458|NCT02705820|Drug|Pembrolizumab|Switch maintenance pembrolizumab treatment
46085459|NCT02705898|Behavioral|LPA+Fitbit|
46085460|NCT02705898|Behavioral|HEC|
46085461|NCT02703090|Drug|Remifentanil|
46085462|NCT02703090|Drug|Normal saline|
46085463|NCT02754362|Drug|Bevacizumab|Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), a proangiogenic factor which aids in tumor vessel formation.
46085464|NCT02754362|Biological|Peptide Vaccine|"Vaccine of long synthetic peptides encoding T cell epitopes in tumor associated antigens.~Vaccine Consists of:~EGFRvIII peptide 100 mcg IL13Ralpha peptide 100 mcg EphA2 peptide 100 mcg Her2/neu peptide 100 mcg YKL-40 peptide 100 mcg"
45458729|NCT01236079|Behavioral|Assisted referral & IVR|includes assistance in enrolling in outpatient cessation services, pharmacy orders for cessation medication, interactive voice recognition follow-up
45458730|NCT04496908|Procedure|amniotomy|Artificially rupturing membranes
45675084|NCT02148263|Device|senofilcon A|
45675085|NCT05135585|Other|Blood sample collection|Blood sample collection at 1 month and 6 months after vaccination
45675086|NCT05135585|Other|Questionnaires|data collection (health data, vaccination data, etc.)
45675087|NCT02147561|Biological|botulinum toxin Type A|Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
45675088|NCT02058368|Drug|Dutasteride 0.5mg capsules|Dutasteride 0.5mg capsules will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
45675089|NCT02058368|Drug|Dutasteride placebo capsules|Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
45996433|NCT00552552|Behavioral|Fatigue Patient Education Program (FIBS)|6 weekly sessions, 90 min each
45996434|NCT00552552|Behavioral|Fatigue Patient Education Program (FIBS)|Participation in the program after the second follow-up
45996435|NCT02895386|Device|ROX Coupler|ROX Coupler will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
45996436|NCT02895386|Other|Sham procedure|Sham procedure + continuing current antihypertensive medications.
45996437|NCT00550875|Biological|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 1000 DPP/ml 2 years
45996438|NCT00550875|Biological|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 10000 DPP/ml 2 years
45996439|NCT00550875|Biological|placebo|Sublingual. 2 drops/daily 2 years
45996440|NCT02894996|Drug|fluid challenge|fluid challenge realized after induction of anesthesia at a steady state, to assess fluid responsiveness and correct hypovolemia. The usual fluid bolus of 15ml/kg in 10 minute will be fragmented in 2 fluid boluses (3ml/kg in 2 minutes followed by measurement of hemodynamic parameter after 1 minute of the end of the 1st fluid bolus and followed by 12 ml/kg in 8 minutes then followed by measurement of hemodynamic parameters after one minute after the end of the 2nd fluid fragmented fluid challenge. Total administered: 15 ml/kg in 11 minutes. end of the study at 12 minutes.
45675090|NCT02058368|Drug|Tamsulosin 0.2mg tablets|Commercially available tamsulosin 0.2mg tablets will be supplied.
45996441|NCT00552630|Device|d-penicillamine|d-penicillamine twice daily, 15 mg/kg/day, for 6 weeks
45996442|NCT00552630|Drug|placebo|placebo with same characteristics as drug
45675091|NCT02058368|Drug|Disintegrating placebo tamsulosin tablet|Disintegrating placebo tamsulosin tablet will be supplied for the run-in period.
45996443|NCT02894957|Drug|Varenicline|: Patients will be randomized either to receive varenicline (uptitrated to 1 mg twice daily) for smoking reduction or smoke as usual for 4-6 weeks before quitting. After quit-day, the two groups will receive standard 12-week varenicline treatment. Non-treatment follow-up will continue to 6 months.
45675092|NCT02107196|Drug|Ibodutant 10 mg|Oral tablet, to be given once daily.
45675093|NCT02107196|Drug|Placebo|Oral tablet, (identical in appearance and weight to ibodutant tablets), to be given once daily.
45996444|NCT02894879|Device|BreatheMAX®|"Modify chest physical therapy~oscillated incentive spirometry (OIS) with inspiratory load of 5-8 cm H2O 30 times/set~oscillated positive expiratory pressure (OPEP) with expiratory load of 5-8 cm H2O 30 times/set~Coughing with splinting 3 times/set~Chest mobilization with overhead both arms rises 10 times/set total 5 set/day"
45996445|NCT02894879|Other|Routine treatment|"Routine chest physical therapy~Deep breathing exercise (upper and lower costal and diaphragmatic breathing exercise) as deep as possible for 10 times/set/level~Coughing with splinting 3 times/set~Chest mobilization with overhead both arms raised 10 times/set total 5 set/day"
45996446|NCT00550992|Biological|anti-thymocyte globulin|
45675094|NCT04185428|Behavioral|Integrative Therapy|still meditation, meditative movement, relaxation techniques, and massage therapy
45996447|NCT00550992|Drug|asparaginase|
45996448|NCT00550992|Drug|busulfan|
45675095|NCT02058290|Drug|IV morphine sulfate or Sponsor-approved equivalent|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to a floor if the stay in the PACU is less than one hour.
45996449|NCT00550992|Drug|cyclophosphamide|
45996450|NCT00550992|Drug|cyclosporine|
45996451|NCT00550992|Drug|cytarabine|
45675096|NCT02058290|Drug|EXPAREL|"Patients will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 40 cc administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
45675097|NCT02082158|Other|Study Procedures|Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.
45675098|NCT04417322|Other|observation of serum A.actinomycetemcomitans levels|Analysis of serum A.actinomycetemcomitans levels
45675099|NCT04718480|Drug|Placebo|po placebo tablets
45675100|NCT04718480|Drug|Fluvoxamine|po fluvoxamine tablets
45996452|NCT00550992|Drug|daunorubicin hydrochloride|
45996453|NCT00550992|Drug|etoposide|
45996454|NCT00550992|Drug|leucovorin calcium|
45996455|NCT00550992|Drug|melphalan|
45996456|NCT00550992|Drug|mercaptopurine|
45996457|NCT00550992|Drug|methotrexate|
45996458|NCT00550992|Drug|mitoxantrone hydrochloride|
45996459|NCT00550992|Drug|pegaspargase|
45996460|NCT00550992|Drug|prednisolone|
45996461|NCT00550992|Drug|prednisone|
45996462|NCT00550992|Drug|therapeutic hydrocortisone|
45996463|NCT00550992|Drug|thioguanine|
45996464|NCT00550992|Drug|vincristine sulfate|
45996465|NCT00550992|Procedure|allogeneic bone marrow transplantation|
45996466|NCT00550992|Procedure|allogeneic hematopoietic stem cell transplantation|
45996467|NCT00550992|Procedure|umbilical cord blood transplantation|
46002370|NCT03416179|Drug|cytarabine|Consolidation with single agent cytarabine 3 g/m2 IV for adults <60 years and 1 g/m2 for adults 60 years over 3 BID on Days 1, 3, and 5, every 28 days for up to 4 cycles or alternative single agent cytarabine consolidation schedules may be used per local prescribing information.
46002371|NCT03416179|Procedure|HSCT|If required, and done per standard of care post Induction(s).
45675101|NCT02106884|Drug|Nab-paclitaxel|
46085465|NCT02754362|Drug|Poly-ICLC as immune adjuvant|Poly-ICLC is a toll like receptor 3 agonist which directly activates dendritic cells and triggers natural killer cells to kill tumor cells.
45996468|NCT02895074|Procedure|Femtosecond laser-assisted cataract surgery|A femtosecond laser (Alcon-Lensx, Alcon-Lensx, Inc.) was used in this study. After pupil dilation and topical anesthesia, the laser was docked to the eye using a curved contact lens to applanate the cornea. With the integrated OCT imaging system, the locations of the cornea and the anterior and posterior surfaces of the crystalline lens were determined. A 5.0-mm-diameter capsulotomy was created by scanning a cylindrical pattern and followed by lens fragmentation. The laser was disconnected, and the remainder of the surgery was performed as phacoemulsification (Infiniti® Vision System; Alcon, USA). Folded intraocular lenses (IOLs) were implanted in the capsular bags.
45996469|NCT02895074|Procedure|Conventional phacoemulsification cataract surgery|Phacoemulsification was performed through a temporal 3.2-mm clear corneal incision with the same machine and followed by IOLs implantation.
46085466|NCT02754362|Drug|Keyhole limpet hemocyanin (KLH)|Potent Immunogen used in vaccine approaches for a number of diseases including cancer, AIDS, and infectious diseases
45675102|NCT02106884|Drug|Gemcitabine|
45675103|NCT02081846|Other|Nurse Home Visit|We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a nurse home visit program, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants) and re-engineered through Aim 2, in improving pediatric patient transitions from hospital to home
45996470|NCT02895074|Drug|Tropicamide|After pupil dilation, 1 drop of tropicamide (0.5%) was applied every 15 minutes for 3 applications
45996471|NCT02895074|Drug|Proparacaine hydrochloride|topical anesthesia with proparacaine hydrochloride (0.5%) was applied.
45675104|NCT02081846|Other|Standard of Care|Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.
45675105|NCT02081690|Drug|Macitentan|Macitentan tablet, dose of 10 mg, once daily
45675106|NCT02057666|Drug|Tasquinimod|A patient initially received a 0.25 mg/day dose which was then titrated through 0.5 mg/day (from Day 15) to a maximum of 1 mg/day (from Day 29). If tolerability issues arose at 0.5 or 1 mg/day, patients had their dose reduced to 0.25 or 0.5 mg/day, respectively.
45675107|NCT02057666|Drug|Placebo|Placebo capsules were identical to tasquinimod capsules in appearance and excipients but excluded the active compound (tasquinimod).
45675108|NCT04417400|Behavioral|medicines use review|The provision of MUR service as defined in the SOP MUR (Slovene Chamber of Pharmacies). It is classified as a type 2a review (PCNE typology) and it is intended for the patients to support them in regular and proper medicines use. MUR is performed based on medication history and information provided by the patient in a purposely scheduled conversation with the pharmacist. Pharmacists must be certified to provide MUR. MUR goal is to identify DRPs and recommend interventions to resolve them. During the MUR interview, the pharmacist completes a working sheet that records information regarding medicines, identified DRPs and recommended interventions. After the MUR interview, patients are provided with a personal medicines card that contains all the information that is needed to support effective and safe medicines use (dosing regimen, taking with/without food, special warnings, recommendations, etc.).
45996472|NCT04701645|Combination Product|Microdevice|"Placement of 1 to 6 implantable microdevices with multiple miniature drug reservoirs into a tumor mass 24 +/- 8 hours prior to surgery. Drugs will be released over 24 (+/- 8) hours while the microdevice is in the tumor prior to retrieval. The local tissue is retrieved along with the microdevice and no residual drug will remain.~Each microdevice will harbor up to 20 drugs and drug combinations relevant to the treatment of ovarian cancer.~Each drug or drug combination will be released from a single, separate reservoir. At least two reservoirs will harbor a drug vehicle only.~Drugs will include all or a subset of the following: Cisplatin, Carboplatin, Paclitaxel, Doxorubicin or pegylated liposomal doxorubicin (PLD), Cyclophosphamide, Etoposide, Gemcitabine, Ifosfamide, Pemetrexed, Topotecan, Vinorelbine, Olaparib, Niraparib, Rucaparib, Carboplatin + paclitaxel (combination), Carboplatin + doxorubicin (combination),Carboplatin + gemcitabine (combination)"
45996473|NCT02894918|Drug|Peginterferon alfa-2a|180ug/0.5ml,hypodermic injection once a week
45996474|NCT04688385|Biological|Multipeptide Vaccine+ XS15|Peptide vaccination will take place in CLL patients that achieved at least a partial remission with detectable MRD after at least 6 and less than 9 months of an ibrutinib-based treatment regime. MRD will be determined by flow cytometry. MRD positivity is defined as > 10-4 CLL cells in peripheral blood or bone marrow. Patients will receive either ibrutinib monotherapy or combinational therapy before study treatment. Vaccination will be done under ibrutinib monotherapy (i.e. after the end of e.g. anti-CD20 treatment, if applicable).
45996475|NCT00551109|Drug|placebo|placebo, oral administration, once daily for 8 weeks
45996476|NCT00551109|Drug|SA4503 Low|Low dose, oral administration, once daily for 8 weeks
45996477|NCT00551109|Drug|SA4503 High|High dose, oral administration, once daily for 8 weeks
45996478|NCT02894723|Dietary Supplement|L-arginine|30 ml arginoline contains 5 gr l-arginine
46085467|NCT02698332|Device|Algorithm for UTI|The algorithm consists of one sheet of laminated paper with instruction in how to diagnose UTI
45675109|NCT01625000|Drug|MP-214 3mg|Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.
45675110|NCT01625000|Drug|MP-214 6mg|Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.
45675111|NCT01625000|Drug|MP-214 9mg|Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.
45675112|NCT01625000|Drug|Risperidone 4mg|Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.
45457334|NCT02270840|Device|CRT-D|Biventricular upgrade. Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only).
45457335|NCT02300506|Other|No intervention|
45675113|NCT01625000|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.
45675114|NCT02081534|Drug|AZD1722|AZD1722, oral tablet
45996479|NCT02894723|Dietary Supplement|syrup|The same bottle of the experimental group, but without l-arginine
45996480|NCT00551187|Biological|V504|V504 0.5 ml injection in 3 dose regimen for 6 month treatment period.
45996481|NCT00551187|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period.
45996482|NCT00551187|Biological|Comparator: Placebo (unspecified)|V504 Placebo in 3 dose regimen for 6 month treatment period.
46085468|NCT02754284|Biological|Autologous fat transplantation|Autologous abdominal fat will be injected into vocal cord beneath mucous under surgery microscope.
45675115|NCT02081534|Drug|Placebo|Placebo bid, double dummy technique
45675116|NCT02057198|Drug|Fidaxomicin|
45675117|NCT02057198|Drug|Metronidazole|
45675118|NCT02057198|Drug|Vancomycin|
45675119|NCT04417478|Other|Scaling and root planning|Periodontal debridement was performed in all patients.
45996483|NCT02894528|Drug|BioMend and ReproBone|Post-extraction sockets was filled by synthetic bone substitute ReproBone, and after the sockets were covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
45996484|NCT02894528|Drug|BioMend without ReproBone|Post-extraction the socket was filled only by clot and covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
45996485|NCT02894450|Other|blood test|bioassay xaban
45996486|NCT00551265|Drug|Cyclophosphamide|Given IV
45675120|NCT02056652|Device|Bioteque cup pessary|
45675121|NCT02056340|Drug|Atorvastatin|
45675122|NCT02056340|Drug|Placebo|
45675123|NCT04705220|Dietary Supplement|MERIVA® Tablets|The treatment corresponds to 1 g / day of experimental product (corresponding to about 200 mg of curcuminoids).
45996487|NCT00551265|Procedure|Laboratory Biomarker Analysis|Correlative studies
45996488|NCT00551265|Biological|Oregovomab|Given IV
45996489|NCT02894489|Device|corneal lenses|wear corneal lenses on daily basis
46085469|NCT02754284|Biological|Functional collagen scaffold transplantation|Injectable collagen scaffold combined with adipose derived stem cells that are isolated from abdominal adipose tissue will be injected into vocal cord beneath mucous under surgery microscope.
45675124|NCT04705220|Other|Placebo Tablets|The composition of placebo includes the same components of the treatment tablets, except for the active substance.
45675125|NCT04727060|Device|patient with knee arthroplasty|
45675126|NCT04726592|Drug|Clorazepate Dipotassium|Clorazepate Dipotassium : 20 mg intravenous injection
45675127|NCT04726592|Drug|Placebo|Placebo IV
45675128|NCT04726592|Drug|Ketoprofen|Ketoprofen 100 mg IV
45675129|NCT04726592|Drug|Metoclopramide|Metoclopramide 10 mg IV
45996490|NCT02894489|Device|large diameter lenses|
45996491|NCT00551304|Device|Ardian Catheter|
45996492|NCT02894606|Drug|Thymoglobulin Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Thymoglobulin treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
45996493|NCT02894606|Drug|Basiliximab Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Basiliximab treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
45996494|NCT02894567|Device|Intraoperative test during a deep brain stimulation surgery|The spiderSTN lead is inserted in a selected track in the brain, and is connected to external neuro-recorder/stimulator . Once the intraoperative test phase is completed, the test devices are removed and the DBS surgery resumes.
45996495|NCT00551343|Drug|Exenatide|10ug Exenatide single s.c. injection
45996496|NCT00551382|Drug|Muntelukast|Tablets or granules; 4 mg once a day for 12 weeks
45996497|NCT00551382|Drug|Placebo|Look alike tablets or granules 1 per day for 12 weeks
45996498|NCT02894684|Drug|Aztreonam|14 days of AZLI: 75mg TDS PLUS IV Colistin
45996499|NCT02894684|Drug|Standard Care|14 days of IV Colistin plus one of Tazocin/Ceftazidime/Meropenem/Aztreonam/Fosfomycin
45996500|NCT02894645|Drug|Prednisolone|Oral
45996501|NCT02894645|Drug|Dexamethasone|Oral
45996502|NCT02894645|Drug|L-Asparaginase|Intramuscular injection
45996503|NCT02894645|Drug|Vincristine|Intravenous
45996504|NCT02894645|Drug|Methotrexate|Intrathecal/ Intravenous/ Oral
45996505|NCT02894645|Drug|Daunorubicin|Intravenous
45996506|NCT02894645|Drug|Doxorubicin|Intravenous
45996507|NCT02894645|Drug|Cyclophosphamide|Intravenous
45996508|NCT02894645|Drug|Cytarabine|Intravenous/ Subcutaneous injection
45996509|NCT02894645|Drug|6-Mercaptopurine|Oral
45996510|NCT02894645|Drug|Thioguanine|Oral
45996511|NCT02894645|Drug|Fludarabine|Intravenous
45996512|NCT02894645|Drug|Imatinib|Oral (For BCR-ABL ALL only)
45996513|NCT04895631|Drug|18F-Fluorocholine|One-time injection of 4-7 millicurie (mCi)
45996514|NCT04895631|Procedure|Positron emission tomography (PET)|Imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities
45996515|NCT02894372|Device|Oral spray 1|Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
45675130|NCT02046122|Drug|Idarubicin|"Eligible subjects will receive induction chemotherapy with idarubicin (12 mg/m2 intravenously for 3 days) and cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who experience no remission or partial remission will receive a second course of the identical induction chemotherapy."
45675131|NCT02046122|Drug|Cytarabine|"Cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who achieve a complete remission (CR) will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
45834572|NCT04758858|Device|Abbott's FreeStyle Libre|During the whole trial, blood glucose will be assessed by intermittent scanning Continuous Glucose Monitors (isCGM; Abbott's Freestyle-Libre glucose sensor). Participants will be asked to record or download, in their Freestyle Libre reader or in their insulin pump, their insulin doses being injected each day.
45996516|NCT02894372|Device|Oral spray 2|Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
45458370|NCT01350986|Behavioral|Cognitive-Behavioral Self-help Workbook + Counseling Telephone Calls|"In intervention period of 5 months parents work through 8 cognitive-behavioral self-help booklets (FLOH) and additionally receive 10 counseling telephone calls. Primary purpose of telephone calls is to clarify content of the booklets and support parents in managing their homework assignments accompanied with each booklet. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on the therapy manual Treatment program for children with hyperactive and oppositional problem behavior (THOP) (Döpfner, Schürmann, & Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, & Lehmkuhl, 2006)."
45834573|NCT04758858|Other|Three-day food journal|Two weeks before the intervention phase, participants will be asked to complete a 3-day food journal, using the Keenoa mobile application, with carbohydrates (CHO) content of food and blood glucose measures to optimize their insulin doses. Analysis of the food journal will allow us to quantify the participants' usual diet.
45834574|NCT04758858|Other|Medical visit|During visit 1, a short medical interview will be done to establish if the subject is eligible to participate in the study. A list of current medications, presence of complications, as well as comorbidities associated with their diabetes will be collected in their medical file during the visit with the endocrinologist.
45834575|NCT04758858|Other|Blood pressure measurements|Blood pressure (systolic and diastolic blood pressure) will be measured during all visits (visits 1 to 4).
45834576|NCT04758858|Other|Anthropometric parameters measurements|Weight, height, BMI and waist circumference will be measured during all visits (visits 1 to 4).
45996517|NCT00552747|Drug|fenofibrate|fenofibrate 160 mg capsules qd
45996518|NCT00552747|Drug|placebo|capsules placebo
46085470|NCT03373188|Biological|Anti-SEMA4D Monoclonal Antibody VX15/2503|Given IV
46085471|NCT03373188|Biological|Ipilimumab|Given IV
46085472|NCT03373188|Biological|Nivolumab|Given IV
45996519|NCT00004553|Procedure|Electromyography|
45996520|NCT00551499|Device|CRT + AOP|The CSA group will undergo 2 sleep evaluation on two consecutive nights, during which the device will be programmed according to the randomization scheme (one night CRT, DDD/45 and the other CRT, DDD/15 bpm over mean nocturnal heart rate). The mean nocturnal heart rate over the last week is derived from the device memory.
45996521|NCT02277327|Behavioral|Plans of Action and Care Transitions|"Subjects randomized to the intervention will participate in action planning and care transitions (if hospitalized during the study period)"
45996522|NCT02277327|Behavioral|Routine Care|"Subjects randomized to the control group will continue to receive routine care within the medical home program"
45996523|NCT05428163|Other|Biological sampling|3ml of blood
45996524|NCT05428124|Other|In vitro fertilisation|In vitro fertilisation
45996525|NCT05427851|Procedure|pulpotomy|coronal pulp tissue removal followed by radicular pulp hemostasis them applying a pulp capping material
45996526|NCT05427851|Device|Diode laser - fonalaser|diode laser beam application
45996527|NCT04584333|Behavioral|Brief intervention|Group 1 (intervention group): depending on the willingness to change evaluated with the RCQ at each visit, the characteristics of the intervention to be performed will be established. Prochaska and DiClemente (1983) proposed a transtheoretical model of change in which different stages of change are identified that have been found to be predictive of adherence to treatment and its efficacy (Prochaska, Norcross and DiClemente, 1994). The RCQ includes three of the stages of change: Precontemplation, Contemplation and Action. In the Precontemplation stage, the person does not consider that he has a problem and has no intention of changing, in the Contemplation stage, he begins to contemplate that he has a problem and the possibility of change is raised and in the action stage, he has already started actively make a change in your behavior.
46085473|NCT03373188|Procedure|Surgery|Undergo therapeutic conventional surgery
46085474|NCT02695940|Drug|LEO 124249 ointment 30 mg/g|
45996528|NCT03455790|Diagnostic Test|Aerobic Capacity|"Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests."
45996529|NCT05427617|Drug|Control group|Physician chosen treatment
45996530|NCT05427617|Drug|Case group|Druggable ctDNA alterations-guided therapy
45996531|NCT04581018|Other|Health supplements|28 days of health supplements (synbiotic), 4g daily
45996532|NCT05427500|Drug|5 mL of 0.5% preservative-free bupivacaine|IV will be inserted. Patient will be connected to cardiorespiratory monitors. The neck will be cleansed twice. A high frequency (15-6 MHz) linear ultrasound probe will be used to identify the arteries, jugular vein, and other important vasculature. Once a clear path for the needle is identified, the skin is anesthetized. A cutting tip spinal needle is then inserted at the lateral aspect of the field and advanced in-plane under ultrasound visualization. A test injection is injected to verify placement, then 5 mL of 0.5% preservative-free bupivacaine will be injected. Per standard SGB procedure, vitals will be measured post-SGB and participants will remain in the clinic for approximately 15 minutes to monitor for any serious adverse events.
45996533|NCT04564482|Radiation|CRT|50 Gy in 2 Gy fractions over 25 working days + capecitabine 1650 mg/m2/d PO
45996534|NCT04564482|Radiation|SCPRT|25 Gy in 5 Gy fractions over 5 working days
45996535|NCT04564482|Radiation|CROSS Protocol|41.4 Gy in 1.8 Gy fractions over 23 working days + carboplatin AUC of 2 mg/ml/min + paclitaxel 50 mg/m2 IV Q1W
45834577|NCT04758858|Other|Indirect calorimetry test|Both resting metabolic rate and respiratory quotient will be measured after a 10-hour fast by indirect calorimetry. The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
45996536|NCT04564482|Diagnostic Test|PD-L1 PET|10 mg atezolizumab IV followed by 37 MBq 89Zr-atezolizumab IV. PET imaging will be done before neoadjuvant CRT/SCPRT (day 0) and between day 10-14 during CRT/SCPRT.
45996537|NCT05427383|Drug|KN026/Placbo Injection|IV KN026/Placebo at 30 mg/kg on D1, Q3W
45996538|NCT05427383|Drug|Paclitaxel Injection|IV Paclitaxel at 175 mg/m² on D1, Q3W
45996539|NCT05427383|Drug|Docetaxel Injection|IV Docetaxel at 75 mg/m² on D1, Q3W
45996540|NCT05427383|Drug|Irinotecan Injection|IV Irinotecan at 125 mg/m² on D1, D8, Q3W
45996541|NCT04564404|Other|Survey|Questionnaire to ask about the willingness-to-buy applications in neuromuscular monitoring.
45996542|NCT03455751|Genetic|PGx-guided post-operative pain management|Post-operative pain management as indicated by pharmacogenomic testing results.
45834578|NCT04758858|Other|Well-being questionnaire|Participants will be asked to complete a well-being questionnaire (nausea, fatigue, etc) during visits 2, 3 and 4.
45996543|NCT03455712|Behavioral|Gestational Weight Gain Card|The Gestational Weight Gain Card is designed to be an educational and weight gain tracking tool. Study subjects will be highly encouraged to use the GWG card to gain both important clinical information and to document weight measurements throughout their pregnancy.
45996544|NCT05427305|Drug|TAB008|15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
45996545|NCT05427305|Drug|Bevacizumab|15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
45996546|NCT05427188|Behavioral|Stress paradigm|HV will receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator
46085475|NCT02695940|Other|LEO 124249 ointment vehicle|
46085476|NCT02698098|Drug|Methadone|
45834579|NCT04758858|Other|Diet appreciation questionnaire|Participants will be asked to complete a diet appreciation (appetite, fullness, etc) questionnaire during visits 3 and 4.
45834580|NCT04758858|Device|Pedometer (PiezoRxD)|Participants will be asked to wear a pedometer (PiezoRxD) that will record their steps every day during the whole trial. Also, they will have to install Piezo: Achieve the Guidelines!, a free mobile application, on their smartphone or tablet. It will connect to their pedometer via bluetooth and will help the research assistant track their data remotely
45996547|NCT05427188|Behavioral|Sham paradigm|HV will receive mental arithmetic challenges where threat components from the program and/or the investigator are absent
45996548|NCT01099449|Drug|calcium gluconate|Given IV
45996549|NCT01099449|Drug|magnesium sulfate|Given IV
45996550|NCT01099449|Other|placebo|Given IV
45996551|NCT01099449|Drug|oxaliplatin|
45996552|NCT05427071|Device|Magnetic seed localization|Magnetic seed guided localization
45996553|NCT04471740|Procedure|CSF shunt diversion|Clinical response to a CSF shunt insertion
45996554|NCT04680143|Drug|Systemic erythropoietin injection|Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
46002372|NCT03408964|Other|biological samples collection and analysis|Participants to the study will be assigned to 4 cohorts according to the stage of disease and planned antitumor treatment at time of study entry; they will be followed up and sampled according to a defined time schedule
45996555|NCT05426798|Drug|TQB2618 injection azacitidine, AZA decitabine, DAC|"Drug1: TQB2618 injection is a novel tim-3 inhibitor.~Drug2: Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DeoxyriboNucleic Acid methyltransferases at low doses, resulting in gene promoter hypomethylation.~Drug3: Decitabine is a cytidine deoxy nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation."
45996556|NCT05426759|Device|Pulsed Field Ablation of epicardial Ganglionated Plexi.|Using Pulsed Field Ablation (PFA), delivered via an epicardial catheter, to selectively ablate the ganglionated plexi (GP) on the epicardial surface of the heart.
45996557|NCT01234402|Biological|Ramucirumab DP|"10 mg/kg I.V.~Day 1 of every-21-day cycle"
45996558|NCT01234402|Biological|IMC-18F1|"12 mg/kg I.V.~Days 1 and 8 of every-21-day cycle"
45996559|NCT01234402|Drug|Capecitabine|"1000 mg/m^2 orally~Twice a day for 14 days"
45996560|NCT05464017|Device|Optimized version of the mHealth screening tool (intervention) using the machine learning approach|"An improvement to the mHealth triage tool using a machine learning approach, optimizing the efficiency of call schedule and the prediction of which patients are most likely to benefit from follow-up care given data collected at the hospital through the Cameroon Trauma Registry, as well as post-discharge phone contact attempts and survey information. The backbone of the estimators is the ensemble machine learning algorithm the Superlearner, which has been applied to medical contexts, including injury and trauma. It is a theory-driven method based on cross-validation, which combines potentially many different learners (e.g., standard regression, tree regression, random forest, neural nets) such that the model chosen (a weighted average of the learners) is asymptotically equivalent to the so called Oracle - the learner that fits optimally for the data-generating distribution. Note, double-robust CV-TMLE versions of this estimator are available as the tmle3mopttx function in tlverse."
45996561|NCT05426720|Other|no intervention|no intervention; This study is a observational study. All patients received routine anti-tuberculosis regimen. Researchers will observe the clinical manifestation, pulmonary function and pulmonary CT manifestation within a few years after the cure of tuberculosis.
45996562|NCT01260922|Drug|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
45996563|NCT01260922|Drug|Aricept®|10 mg Orally Disintegrating Tablet
45996564|NCT05426642|Other|E-health Video KaSEH|The e-health video KaSEH is produce based on Protection Motivation Theory to enhance women's motivation towards cervical cancer screening.
45996565|NCT05426642|Other|Brochure|The brochure contain the information regarding cervical cancer and its screening
45996566|NCT01233817|Other|Progressive strength training|the systematic increase in resistance weights
45996567|NCT04454697|Device|tissue retractors|Patients receive a tissue retractor to spare healthy tissue during the course of radiation
45996568|NCT04206748|Device|iGlucose Smart Meter System|Subjects will have routine care enhanced by use of theThe iGlucose Smart meter system. This is an example of integration of a SMBG system with internet-based technology; including cell phone notifications for reminders, feedback, and communication with clinicians
46085477|NCT04220996|Drug|Vortioxetine|Vortioxetine 10 and 20 mg/day, tablets, orally Patients will receive 10 mg vortioxetine once daily for the first week. At Visit 2, the dose will be increased to 20 mg/day. The dose may subsequently be adjusted to 10 or 20 mg/day at scheduled or unscheduled visits depending on patient's response as per investigator judgment.
45675132|NCT02046122|Biological|DLI|"HLA-mismatched DLI will be administered Day 9, approximately 24-48 hours following completion of chemotherapy at a dose of 1x10^8 cluster of differentiation 3 (CD3+) cells; however, due to logistics of planning infusions with staffing, donor availability, weekends/holidays, etc., it may be necessary to postpone cell infusion up to 96 hours.~Given the time constraints presented by the need to start induction chemotherapy as soon as possible, in some cases, it may not be logistically possible to administer cells with induction. In these cases, patients would just receive standard induction chemotherapy and cells would be administered after consolidation 1 in addition to consolidation 2~Subjects who achieve a CR will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
45675133|NCT04704362|Behavioral|Ensuring Quality in Psychological Support|Trainees are evaluated with the Enhancing Assessment of Common Therapeutic factors structured role play tool and the results are shared with trainers and/or supervisors to modify training based on strengths and weakness on the competency scores.
45675134|NCT04704362|Behavioral|Standard Training and Supervision|Trainees are trained using a manual for non-specialist-delivered psychological interventions.
45675135|NCT02080832|Drug|Citalopram|20 mg or 40 mg daily for 8 weeks
45996569|NCT04206748|Device|Routine Care-RX meter|Subjects will receive routine care with the insurance prescribed glucose meter. They will self manage with traditional diabetes diary.
46085478|NCT02702856|Other|ExoIntelliScore Prostate|
45458731|NCT04496908|Device|Foley Catheter|Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline.
45996570|NCT05426603|Procedure|Pulmonary vein isolation|The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode
46085479|NCT02754128|Behavioral|BeFAST|The motor learning (ML)-based gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined training/home imagery) will be five per week.
46085480|NCT02754128|Behavioral|BeSTRONG|The functional strength training program is designed to improve gait-related skills. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down. Children will be given a 3- to 5-min home program of strength exercises to practice on days when they do not have active training sessions. The total number of sessions (combined training/home program) will be five per week.
46085481|NCT02705742|Biological|Mesenchymal Stem Cells|1.000.000 (one million) cells/kg, IV of dose in the Peripheral vein and 3.000.000 (three million) cells/kg of dose into the right hepatic artery)
46085482|NCT02702700|Drug|Cisplatin, liposomal|Lipoplatin IV 200 mg/m2
45996571|NCT05426603|Procedure|Substrate ablation(PRISM based)|Substrate modification will be guided by waveform periodicity analysis. The User Defined Map of waveform periodicity analysis will be also created by CARTO 3 system (version 6) with and VISITAG ODP module. Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). Substrate modification based on waveform periodicity analysis will be performed by using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
46085483|NCT02702700|Drug|Verteporfin|Visudyne® IV 3 mg/m2
46085484|NCT02702700|Device|Device for Intrapleural Visudyne-mediated Low-Dose Photodynamic Therapy with integrated in situ light dosimetry|Intrapleural photo-induction will be realized in the chest cavity with low-dose PDT using Visudyne® 3mg/m2 as photosensitizer, activated by 689 nm laser light with a fluence of 10J/cm2 and a fluence rate of <10mWcm2.
46085485|NCT02758496|Other|MeRT Efficacy Chart Review|There will be not intervention. This is a chart review.
46085486|NCT02702622|Other|Provitamin A-biofortified transgenic bananas|
46085487|NCT02697942|Other|cognitive training|The investigators will provide participants with tablets to play brain games through Lumosity.
46085488|NCT02697942|Other|exercise training|The investigators will provide participants with foot peddlers.
46085489|NCT02695784|Dietary Supplement|Probiotic Continuation|This arm will continue to receive probiotics beyond 34 weeks corrected gestation until two months after discharge
46085490|NCT04214808|Drug|AD-208|Dutasteride 0.2mg
46085491|NCT04214808|Drug|Avodart Soft Capsule 0.5mg|Dutasteride 0.5mg
46085492|NCT04221776|Other|Group toilet training in daycare|During the training, children wore underpants, were informed about potty training, were encouraged to drink often and were asked regularly if they felt the need to void. Tutors looked for elimination signals in the child and quickly responded by putting the child on the potty when he/she expressed the need to void or to defecate. Children were positively rewarded. Parents received a leaflet containing practical tips concerning TT and their child's successes of the past two days. They were asked to continue TT at home during the following weekend and longer if necessary. Daycare workers were asked to pay more attention on the TT during the following days and weeks to ensure the effect of the intervention.
46085493|NCT04221776|Other|Individual toilet training at home|Parents were encouraged to start TT their child, because they were considered as being ready to initiate TT. Children did not receive any intervention, but parents were asked to start TT in their own manner. Parents were allowed to search for information on methods of TT with their relatives, internet, books,...
46085494|NCT04215744|Behavioral|Ice water immersion|Ice water immersion of the left hands
46085495|NCT04192448|Other|Alcohol Administration|The clinical trial does not involve any treatment. Participant will be randomly assigned to receive alcohol (BAC = .08%) or water (BAC = .00%).
45675136|NCT02080832|Drug|Placebo|Placebo daily for 8 weeks
45996572|NCT01233232|Drug|Placebo|Oral dose bid
45996573|NCT01233232|Drug|AZD5069 50mg|Oral dose bid
45996574|NCT01233232|Drug|AZD5069 80mg|Oral dose bid
45996575|NCT01233076|Device|Nelfilcon A contact lens|Commercially marketed, spherical contact lens for daily wear, daily disposable use
45996576|NCT01233076|Device|Narafilcon B contact lens|Commercially marketed (US), spherical contact lens for daily wear, daily disposable use
45996577|NCT04389879|Other|Bonding of either CAD/CAM or conventional multistranded stainless steel fixed retainer|Investigate and compare the clinical effectiveness of two types of fixed retainers; CAD/CAM vs. multistranded wire.
45996578|NCT05426018|Drug|SY-009 capsules|3 capsules each time (3 test drugs), 3 times a day (oral administration before breakfast, lunch, dinner or with meals)
45996579|NCT01212094|Drug|Rituximab|
46085496|NCT04192448|Other|Mood Induction|The clinical trial does not involve any treatment. Participants will be randomly assigned to receive an anger emotion induction or a control (neutral) mood induction.
46085497|NCT02697864|Drug|tafamidis|
46085498|NCT02696174|Other|HMI|A defined priced package of primary care services, including investigation and treatment such as procedures and medication, available at a selected clinic for 6 months
46085499|NCT02753894|Drug|ASP1585|Oral
46085500|NCT02698020|Procedure|Room-air|Provision of room-air
46085501|NCT02695706|Device|Laboratoires Mercurochrome Reparador|Developed for the treatment of damaged or fragile skin.
46085502|NCT02702544|Device|CardioScreen 1000 - Haemodynamic Measurement System, Medis|Impedance cardiography (ICG)
46085503|NCT02702544|Device|SCHILLER, BR-102 plus - Ambulatory Blood Pressure Monitoring System|Blood pressure monitoring every 1 min during leg elevation
46085504|NCT02753972|Behavioral|Mindful Eating and Living|8 week mindfulness skills intervention
46085505|NCT02753972|Behavioral|Active Weight Loss Control|8 week active weight loss control group
46085506|NCT02754050|Device|Tandem Snare|
46085507|NCT02702778|Drug|Delayed-Release (DR) Prednisone|delayed release prednisone
46085508|NCT02702778|Drug|Immediate Release (IR) Prednisone|standard prednisone
45675137|NCT02080364|Drug|Azeliragon|Azeliragon 5mg administered orally, once daily for 18 months
46085509|NCT04220372|Drug|Tongxinluo|Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD
45996580|NCT01212094|Other|normal saline|normal saline
45996581|NCT05425706|Other|application of SNAGs technique|in experiment group, the SNAGs technique was applied to 16 participants in addition to conventional therapy.
45996582|NCT05425628|Device|"NeoChord Transcatheter Mitral Repair System (or NeoChord System)"|"The NeoChord Transcatheter Mitral Repair System is a system of delivery devices and implantable Neochordae and Anchor. The system is designed to percutaneously deliver and deploy the implantable ePTFE sutures, Neochordae as artificial chordae at the mitral valve and connect them to the implantable ventricular anchor, Anchor, using a catheter based system placed into the left side of the heart through the interatrial septum."
45996583|NCT05457426|Procedure|robotic right hemicolectomy with CME|The distribution of trocars was placed according to the position of Intuitive Surgical Inc. for robotic colectomy. The robot was set to come and dock from theright shoulder of the patient. Three robotic 8-mm trocars (R1, R2 and R3) and two 12-mm trocars (camera and assistant port) were used for the robotic procedure. One working arm carrying a monopolar cautery hook for dissection was located in the left upper quadrant port (R1). The other two working arms carried bipolar forceps in the suprapubic port (R3), and Cadiere's fenestrated forceps in the right lower quadrant port (R2) that was used to keep the superior mesenteric axis in traction. After gentle cephalad traction on the transversemesocolon with the grasp in R2, the assistant grasped the ileocecal valve through the assistant port to put the ileocolic vascular pedicle on tension and the ileocolic vessels were identified and lifted up with R3.
45996584|NCT04372797|Device|Diagnostic test|A battery of oculomotor tests
45996585|NCT05425589|Procedure|Adjustable strabismus surgery|Our objective was to assess the long-term success of adjustable suture strabismus surgery in terms of postoperative alignment and complications.
45996586|NCT05425394|Behavioral|Delay first bath|Newborns delay first bath to 8 hours after birth
46085510|NCT04220372|Drug|Placebo|Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD
46085511|NCT04215822|Diagnostic Test|Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression.|Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression.
46085512|NCT02753738|Drug|Escitalopram|Tablet 10mg, 21 days
46085513|NCT02753738|Drug|Placebo|Tablet, 21 days
46085514|NCT02753738|Other|3xMR scan (fMRI, DTI, strucutral MRI)|3 Tesla PRISMA MAGNETOM MR scanner; performed at baseline, after 21 days of performing learning paradigms and after 21 days of drug/placebo treatment and re-learning paradigms
46085515|NCT02753738|Behavioral|Association learning paradigm|21 daily internet-based sessions (20min) of learning associations (pairs) of stimuli
46085516|NCT02753738|Behavioral|Association re-learning paradigm|21 daily internet-based sessions (20min) of learning new associations (pairs) of stimuli performed during escitalopram/placebo treatment
46085517|NCT02702466|Other|SPA Therapy|Immersion bath and shower ( 1 treatment ) Underwater shower with localized massage on the painful area ( 1 treatment ) or equivalent underwater massage Illutations ( 1 treatment ) or equivalent ( poultice ) Mobilization Pool ( 1 care) Education to exercise
46085518|NCT02751632|Behavioral|Support and Problem Solving Therapy|Support and Problem Solving Therapy involves providing participants with emotional support and helping them to resolve their problems in day-to-day life.
45675138|NCT02080364|Drug|Placebo|Placebo administered orally, once daily for 18 months
45675139|NCT02079038|Device|Totalis|
45675140|NCT02079038|Procedure|Comparator Surgical Procedure|
46085519|NCT02751632|Behavioral|Cognitive Behavioural Case Management|CBCM has a number of different elements including: strategies to help with stress management; therapy that targets thinking and behavioural patterns; practical assistance, as well as yoga and mindfulness.
46085520|NCT02751632|Drug|Fluoxetine|Participants will commence on 1 capsule of fluoxetine 20 mg, to be taken in the morning. The medication can be increased to fluoxetine 40 mg daily if there has been a poor clinical response after the first 6 weeks of treatment.
45996587|NCT05427123|Other|Medication or psychosocial treatment|Youth included in this naturalistic study will be offered medication management from study psychiatrists. The study's Network Oversight Committee, consisting of PI psychiatrists and consultants, has created guidelines on best practice medications, dosing, and adjustments for the study. The Network Oversight Committee will also offer ongoing consultation to study psychiatrists. The treating physician will take these guidelines and recommendations under consideration but will use clinical judgment and have the final say, in consultation with the parents and child, as to what treatments are prescribed. While psychosocial interventions are of interest as a predictor of outcomes, no universal psychotherapy or other psychosocial treatment will be provided by sites. There is no limitation on participant enrollment in psychosocial treatments. Investigators and their clinical partners may offer these interventions based on clinical judgment and availability.
46085521|NCT02751632|Drug|Placebo|Participants will commence on 1 capsule of the placebo pill, to be taken in the morning. The medication can be increased to 2 placebo capsules if there has been a poor clinical response after the first 6 weeks of treatment.
45675141|NCT02045732|Biological|PF-06342674 0.25 mg/kg|Bi-Weekly Subcutaneous Injections X 6
45996588|NCT04369794|Biological|BCG|0.1 ml of lyophilized, live and attenuated intradermal BCG vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose
45996589|NCT04369794|Biological|Placebo|0.9% saline in the same volume as the BCG vaccine in a single dose
46085522|NCT02751632|Behavioral|3-monthly monitoring|Study participants will be contacted on a 3-monthly basis by a study clinician who will be assessing the participant's risk.
46085523|NCT04805268|Diagnostic Test|18F FDG PET/CT|18F FDG PET/CT imaging (fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography).
46085524|NCT02753582|Dietary Supplement|SOD+Gliadin Capsule|
46085525|NCT02753582|Dietary Supplement|Placebo|
46085526|NCT02697786|Device|Transcranial doppler|Prolonged de airing to decrease the number of MES
46085527|NCT02751476|Other|Point of Use (PoU) water treatment flocculent disinfectant.|A household level point of use water treatment of a flocculent disinfectant will be tested.
46085528|NCT02751476|Other|Point of Use (PoU) water treatment chlorine disinfectant|A household level point of use water treatment of a chlorine disinfectant will be tested.
45675142|NCT02045732|Biological|Placebo|Bi-Weekly Subcutaneous Injections X 6
45675143|NCT02045732|Biological|PF-06342674 1.5 mg/kg|Bi-Weekly Subcutaneous Injections X 6
46085529|NCT02751476|Device|Point of Use (PoU) ceramic water filter|A household level point of use water treatment of a ceramic water filter will be tested.
46085530|NCT02751476|Other|Standard Severe Acute Malnutrition Treatment|Standard CMAM treatment.
46085531|NCT02697708|Dietary Supplement|Potassium control diet|No additional potassium.
46085532|NCT02697708|Dietary Supplement|Potassium gluconate diet|1000 mg K from potassium gluconate.
46085533|NCT02697708|Dietary Supplement|Potato Diet|1000 mg K from potatoes.
46085534|NCT02697708|Dietary Supplement|French Fries Diet|1000 mg K from French Fries.
46085535|NCT04220762|Drug|WIN-1001X|"This study has been designed as a randomized, double-blind, and placebo-controlled study.~Once the patients who have voluntarily singed an informed consent form are enrolled in this study, their eligibilities for the study are assessed and those who have satisfied the inclusion/exclusion criteria are randomized to the test group 1 (400mg), 2 (800mg), and 3 (1200mg), or the control group (placebo group) in a ratio of 1:1:1:1. The randomized patients are administered 3 tablets of the investigational product twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated."
45675144|NCT02045732|Biological|PF-06342674 6.0 mg/kg|Bi-Weekly Subcutaneous Injections X 6
45675145|NCT02044874|Drug|APD356-lorcaserin hydrochloride|
45675146|NCT02044874|Drug|Placebo|
45675147|NCT04716920|Other|Tai Chi|Attend Tai Chi exercise classes
45675148|NCT04716920|Device|FitBit|Wear FitBit
45675149|NCT04716920|Other|Support Group Therapy|Join Tai4Chijoint group
45675150|NCT04716920|Other|Questionnaire Administration|Ancillary studies
45675151|NCT04716920|Other|Quality-of-Life Assessment|Ancillary studies
45675152|NCT04716608|Other|physiotherapy program|"physiotherapy program with Myofascial Release Massage, stretching, strengthening.~2 sessions per week (duration 30 minutes per session) for 8 weeks, supervised by a physiotherapist; complemented by a home training program."
45675153|NCT04716608|Other|usual care treatment|stretching,strengthening; 2 sessions per week (duration 30 minutes per session) for 8 weeks
45996590|NCT05425316|Behavioral|Home Recordings|If patients are willing to download the Winterlight application to their personal iOS devices this will be done at study visit 1. The application will send a notification to the patient once per month, requesting that they perform a paragraph reading task, a picture description task, and an animal naming task.
46085536|NCT04220762|Drug|Placebo|"This study has been designed as a randomized, double-blind, and placebo-controlled study.~Once the patients who have voluntarily singed an informed consent form are enrolled in this study, their eligibilities for the study are assessed and those who have satisfied the inclusion/exclusion criteria are randomized to the test group 1 (400mg), 2 (800mg), and 3 (1200mg), or the control group (placebo group) in a ratio of 1:1:1:1. The randomized patients are administered 3 tablets of the investigational product twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated."
46085537|NCT02705430|Dietary Supplement|EPA and DHA capsules of 2 g/day|EPA and DHA capsules of 2 g/day
46085538|NCT02705430|Behavioral|Stress management phone application (Eco Fusion Mentally)|Stress management phone application (Eco Fusion Mentally)
46085539|NCT02705430|Behavioral|life style program using a mobile phone (Eco Mentally and NewMe)|life style program using a mobile phone (Eco Mentally and NewMe)
46085540|NCT02705430|Device|mobile phone|mobile phone
46085541|NCT02753660|Procedure|Traditional sitting position|Subjects were set on traditional sitting position before spinal anesthesia begun.
46085542|NCT02753660|Procedure|Pendant position|Subjects were set on pendant position before spinal anesthesia begun.
45996591|NCT05425316|Behavioral|In-patient Recordings|If patients are admitted to UM hospital for suspected or confirmed OHE, with patient assent, physician study staff will assist the patient in recording a paragraph reading task, a picture description task, and an animal naming task.
45996592|NCT05425316|Behavioral|Same-Day Study Visit - Regular Appointment|Staff will call patients in anticipation of in-person regular visits to set up a same-day study visit. Patients will record the three speech tasks at this time.
46085543|NCT02705664|Drug|Loceryl Nail Lacquer|Topical over entire toenail plates of affected toenails once weekly in the evening (at bed time) after having filled down affected toenails to gently remove as much as affected nails and having cleaned toenails surfaces with the provided cleansing swab
46085544|NCT02705664|Drug|Urea Ointment|Topical over the infected part of the toenails only once daily under occlusion in the evening (at bed time) after having soaked toenails in warm water and having removed the soften infected toenail plates and dried the toenails
45996593|NCT05425316|Behavioral|Same-Day Study Visit - Procedure|Staff will call patients in anticipation of in-person procedure visits to set up a same-day study visit, prior to procedure if sedation is planned. Patients will record the three speech tasks at this time.
45996594|NCT05425316|Behavioral|Phone Call Follow-up Visits|Non-physician study staff will call the patients every 3 months and, using a phone script, will ask them survey questions about their hepatic health.
46085545|NCT02705664|Drug|Bifonazole Cream|Topical, to be rubbed sparingly over the affected toenail skin (nail bed) once daily in the evening (at bed time) after having cleaned and dried thoroughly toenails
46085546|NCT02753348|Other|Echocardiography|
45675154|NCT02078960|Drug|Omacetaxine mepesuccinate|3.5 mg omacetaxine mepesuccinate and 10 mg mannitol; The first dose of the day for cycle 1 will be administered at the investigational center. Subsequent doses (in prefilled syringes) may be administered on an outpatient basis after training takes place
46085547|NCT02753348|Other|Blood analysis from umbilical cord blood|
46085548|NCT02753348|Other|ECG|
46085549|NCT02753348|Other|Measurement of oxygen saturation|
46085550|NCT02697552|Drug|HBI-8000|Oral doses of 30mg, 40mg, 50mg twice weekly [BIW].
46085551|NCT02753426|Drug|Doxycycline|Doxycycline 20mg capsule by mouth, twice a day for 30 days.
46085552|NCT02753426|Drug|Placebo (for Doxycycline)|Inactive pill manufactured to mimic Doxycycline 20mg. Capsule by mouth, twice a for 30 days.
46085553|NCT02702232|Other|Ultrasonography|Ultrasonography is applied for normal subjects and patients with Parkinson's disease
46085554|NCT02753504|Drug|CKD-519|
45675155|NCT02078102|Drug|Meloxicam|15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.
45675156|NCT02078102|Drug|Filgrastim|Filgrastim will be subcutaneously injected in one or two sites at home.
46085555|NCT02753504|Drug|placebo|
46085556|NCT02702154|Device|High-frequency rTMS|20 Hz active stimulation, twice daily
46085557|NCT02702154|Device|Low-frequency rTMS|1 Hz active stimulation, twice daily
45675157|NCT02054702|Drug|Brexpiprazole|Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
45675158|NCT02054702|Drug|Aripiprazole|Up to 20 mg/day, once daily dose, tablets, orally
45675159|NCT02044094|Drug|Buprenorphine|A subcutaneous depot injection of buprenorphine 300 mg was delivered using the ATRIGEL® Delivery System on study days 1 and 29. As the depot degrades, buprenorphine is released into systemic circulation over an extended period of time.
45996595|NCT05425238|Other|Blood flow restriction|"strengthening protocol but with Blood flow restriction technique~.Standard BFR Application: a standard pressure (used for all patients) for e.g. 180~mmHg; a pressure relative to the patient's systolic blood pressure, for e.g. 1.2 - or 1.5-fold greater than systolic blood pressure.40% cuff pressure as percentage of LOP.(4) And performing BFR-RE with low load exercises. So 30% of 1 RPM would be enough 4 times a week for 6 week"
45996596|NCT05425238|Other|Conventional physical therapy|Resistance exercise 75 repetitions across four sets of exercises, with30 repetitions in the first set and 15 repetitions in each subsequent set. 4 times a week for 6
45996597|NCT05419401|Drug|Capivasertib film-coated tablet, 200 mg|400mg dose, oral, fasted
45996598|NCT05419401|Drug|[14C]AZD5363 (Capivasertib)|"Solution for Infusion 20 µg/mL (NMT 37.0 kBq/5 mL) - 100 µg; 5 mL, Intravenous~Oral Solution, 400 mg (NMT 4.8 MBq) - 400mg; 100mL, oral, fasted"
45996599|NCT04436393|Diagnostic Test|Guardant360 test|tumor cfDNA testing
46085558|NCT02702154|Device|Sham rTMS|Sham stimulation, twice daily
46085559|NCT02753270|Procedure|Short catheter|Ultrasound Guided Foam Sclerotherapy in Great Saphenous Vein, measuring from 6 to 10 mm, with Short Catheter.
46085560|NCT02753270|Procedure|Long catheter preceded by tumescence|Ultrasound Guided Foam Sclerotherapy Transcatheter in Great Saphenous Vein, measuring from 6 to 10 mm, Preceded by Tumescence.
45996600|NCT04330560|Device|Exercise telemonitoring connects to healthcare platform|The participant is required to wear the fitness tracker every day during waking hours throughout the 12 weeks of intervention (except during sleeping, bathing, and swimming) link to the healthcare practitioner
45996601|NCT04330560|Device|Exercise self-monitoring|The participant is required to wear the fitness tracker every day during waking hours throughout the 12 weeks of intervention (except during sleeping, bathing, and swimming) for exercise self-monitoring.
45996602|NCT04330560|Device|Exercise teleconsultation|Conducted through smartphone video call app.
45996603|NCT04330560|Procedure|Other CR components|Including dietary, psychology, education conducted at the center.
45996604|NCT04330560|Procedure|Standard care|Undergoing standard care by cardiac rehabilitation at the center
45996605|NCT05409885|Other|General anesthesia|Evaluate the effects of general anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
45996606|NCT05409885|Other|Spinal anesthesia|Evaluate the effects of spinal anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
45996607|NCT04427306|Drug|T-Vec|T-Vec will be given prior to surgery
45996608|NCT04327479|Diagnostic Test|Assessment of cardiovascular diseases and cardiovascular risk factors|At inclusion, patients will be screened for pre-existing cardiovascular diseases and cardiovascular risk factors, as well as medication.
45458371|NCT01350986|Behavioral|Non-Directive Self-Help Workbook + Counseling Telephone Calls|"In intervention period of 5 months parents are provided 8 non-directive self-help booklets and additionally receive 10 non-directive counseling telephone calls. If the telephone calls are used to clarify content of the booklets or to discuss other child and parenting related topics is at the parents' discretion. Main focus for counselor is to be congruent, empathic and to have unconditional positive regard toward the parents. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on Parent effectiveness training (Gordon, 1970) and Teaching children self-discipline at home and at school (Gordon, 1989)."
45675160|NCT02044094|Drug|buprenorphine and naloxone|Buprenorphine and naloxone (SUBOXONE® sublingual film) is given to participants on days -14 to day -1 (the SUBOXONE sublingual film stabilization period) or as soon as they start to experience withdrawal symptoms. SUBOXONE sublingual film may be initially administered several times daily until a stable dose between 8 mg and 24 mg daily is established.
45996609|NCT01232569|Drug|Tocilizumab 162 mg|Tocilizumab will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
45996610|NCT01232569|Drug|Placebo|Placebo will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
45996611|NCT00552864|Drug|Ropivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
45996612|NCT00552864|Drug|Levobupivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
45996613|NCT04419584|Drug|Modified Qing-Ying Decoction|Herbal granules
45996614|NCT04419584|Drug|Identical looking placebo|Placebo granules
45458372|NCT03494452|Other|No intervention|There is no intervention in this cross-sectional study
45996615|NCT04416542|Diagnostic Test|Home Sleep Testing|"Two-night Home Sleep Tests (HSTs) will be conducted using commercially available Home Sleep Test equipment. The HST will be ordered by the clinical center through a HIPAA compliant HST service that has been selected by the study sponsor.~The HSTs will be scored and interpreted according to AASM Guidelines by board certified sleep physicians affiliated with the HST service. The HST will be scored using the 4% oxygen desaturation rule."
45996616|NCT01211665|Drug|Methylprednisolone|In intravenous form (for a daily dose of 1 g/day on treatment days).
45996617|NCT01211665|Drug|Prednisolone|Oral prednisolone used as a taper, with suggested dosages starting at 80 mg and tapering to 5 mg.
45996618|NCT04401176|Drug|Heparin & Alkalinized Lidocaine Bladder Instillation|Bladder instillation instilled via catheter and to dwell for minimum of 30 minutes prior to spontaneous void
45996619|NCT04401176|Drug|Onabotulinum Toxin A|Intradetrusor onabotulinumtoxinA injection (0.5mL x 20 sites)
45996620|NCT02887612|Other|ctDNA test|
45996621|NCT04393922|Behavioral|Acoustic stimuli (Startle)|A startle stimulus (120 dB, 500 Hz, 50 ms) will be delivered through headphones
46085561|NCT02705040|Other|Normal|bone mineral density T>=-1.0
46085562|NCT02705040|Other|Osteopenia|bone mineral density -1.0>T>=-2.5
45458373|NCT03501394|Other|Magnetic Resonance Imaging|Patients will undergo 4 MRI sessions during NACT treatment. The first scan will take place at treatment baseline before their first cycle of NACT treatment. The second scan will take place following the first treatment cycle prior to the second treatment cycle. Likewise, the third and last scan will take place after the third treatment cycle and sixth (final) treatment cycle prior to surgery. MRI scan sessions will be composed of research scans including diffusion and lipid profiling MR imaging methods and MR spectroscopy (MRS) methods.
45458374|NCT03501394|Other|Histopathological Analysis|Study specific analysis will be performed on the core biopsy and tissue removed in surgery following the completion of NACT treatment. Standard routine histological analysis will be performed, as well as study specific analysis for immunostaining, grading and slide scan imaging for measurement of cellularity markers.
45675161|NCT02044094|Drug|hydromorphone|"Hydromorphone IM challenges are administered during the screening period (days -17 to -15), on days -3 to -1 during the buprenorphine and naloxone (SUBOXONE sublingual film) stabilization period, and weekly during the 12-week treatment period after administration of RBP-6000. Each challenge consists of 3 days during which participants are randomly administered 0 mg (placebo), 6 mg and 18 mg hydromorphone via intramuscular (IM) injection daily in varying blinded sequences.~Additionally, hydromorphone can also be earned during the afternoon Reinforcing effects tasks sessions up to the same randomized dose received in the hydromorphone challenge that morning (or money can be chosen)."
45996622|NCT04389905|Behavioral|Dental education - Motivational Interviewing|Motivational Interviewing - Focusing on oral/dental health
45996623|NCT01232491|Drug|Insulin detemir|Individually adjusted insulin detemir subcutaneously (under the skin) once daily. Subjects continue their pre-trial metformin treatment.
45996624|NCT01232491|Dietary Supplement|Dietary regimen|Subjects receive dietary consultation by a dietician at six occasions during the trial.
46085563|NCT02705040|Other|Osteoporosis|bone mineral density T<-2.5
45675162|NCT02044094|Drug|placebo|Placebo for hydromorphone administered via intramuscular injection during each challenge.
45996625|NCT04305834|Drug|Abemaciclib|Given PO
45996626|NCT04305834|Other|Questionnaire Administration|Ancillary studies
45996627|NCT05388591|Other|Musicotherapy|Music listening with the application Music Care (style of music chosen by the patient) during wound suturing
45996628|NCT04355234|Diagnostic Test|identify SARS-CoV-2 infection by serology|Blood samples at delivery to identify SARS-CoV-2 infection by serology
45996629|NCT04355234|Biological|collection of biological samples|Creation of a specific collection of biological samples for new investigations thanks to the collection of several biological samples at the time of maternal SARS-CoV-2 infection, at delivery and in the postpartum period in the parturient and her newborn.
45996630|NCT04297137|Dietary Supplement|Protein ingestion|Ingestion of various sustainable non-animal derived protein sources compared to animal-based milk protein.
46085564|NCT05169164|Other|No intervention, observational|No intervention, observational
46085565|NCT04219124|Drug|IMP oral tablet|Dapagliflozin 10 MG
46085566|NCT04219124|Drug|Placebo oral tablet|Matching placebo tablets
46085567|NCT00914927|Drug|Avatrombopag|Avatrombopag first Dose 80 mg followed by 10 mg a day for up to 6 additional days
46085568|NCT00914927|Drug|Avatrombopag|Avatrombopag first Dose 80 mg followed by 20 mg a day for 3 days and then Placebo for 3 additional days
46085569|NCT00914927|Drug|Placebo|Placebo or inactive substance once a day for up to 7 days
46085570|NCT02702076|Drug|Apomorphine|Continuous subcutaneous infusion of apomorphine during waking day
45996631|NCT04335305|Drug|Tocilizumab|IV infusion over 60 minutes; 8 mg/kg (up to a maximum of 800 mg per dose); single dose
45996632|NCT04335305|Biological|Pembrolizumab (MK-3475)|IV infusion over 30 minutes, 200 mg; single dose
45996633|NCT04288089|Drug|Palbociclib (75, 100, 125 milligram [mg])|Palbociclib orally, once daily (QD).
45996634|NCT04288089|Drug|H3B-6545 (150, 300, 450 mg)|H3B-6545 orally, QD.
45996635|NCT04287738|Behavioral|Navigated Care|Telephone-based collaborative dementia care was delivered by a trained care team navigator, who provided education, support and care coordination with a team of dementia specialists (advanced practice nurse, social worker, and pharmacist). For more details, please see references below.
45996636|NCT04253951|Diagnostic Test|Lung Ultrasound (LUS)-monitored feeding trial|LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities. All pulmonary fields will be explored according to semeiotics and previous literature.
46002373|NCT03406767|Other|GLA:D Canada Program|The GLA:D® program consists of 1) pre- and post-program outcome measurement (self-reported and functional outcomes); 2) 2, 1-1.5 hour education sessions including information on OA disease characteristics, treatments and self-help strategies; and 3) a neuromuscular exercise (warm-up, circuit training, and cool down) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks. The goal of the exercises is to restore neutral, functional alignment of the legs by building compensatory functional stability and improving sensorimotor control.
45996637|NCT05388045|Other|Patient Reported Outcome Measure|A Recovery Patient-Reported Outcome Measure (PROM, 19 items and 2 questions for each item, collected via online survey) will be completed by eligible patients at baseline and again at months 3 and 6. The initial Recovery PROM will be shared with the clinician, at the visit most closely scheduled following the baseline visit, for review and discussion with the patient. At the 3- and 6-month visits, the clinician will be asked to re-review and compare the earlier Recovery PROM(s) as well as the current Recovery PROM. The clinician is encouraged to use the PROM results during interim clinical visits with the patient. Efforts will be made to contemporaneously track how often the PROM is discussed in clinical sessions conducted during the 6 months.
45996638|NCT05371899|Drug|Chiauranib|Take Chiauranib 50mg orally once daily
45996639|NCT04248530|Device|Renal denervation|DENEX catheter is a device to treat resistant hypertension which delivers high-frequency energy through the three electrodes connected to the catheter in order to cauterize sympathetic nerve bundle.
45996640|NCT04255212|Other|Soft tissue treatment|Participants will be asked to sit in front of a medical table with their forearms supinated and relaxed. 5 minutes of deep tissue manual flossing on the proximal and medial aspect of the forearm of each side will be administered by keeping the hands contact on the skin of the participants for all the treatment duration. Direction of the gentle repeated manual compressions and shifts will be proximal to distal or vicerversa depending on the symptom reduction reported by the participants. Stimuli frequencies will be about 0,2-03 Hz. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
46085571|NCT02702076|Drug|Placebo|Continuous subcutaneous infusion of placebo during waking day
45996641|NCT04255212|Other|Mechaninsms explanation|Participants will be instructed with a 10 minutes lesson on mechanisms hypothesized to generate Delayed Onset Muscle Soreness. To trigger the most the bottom down pain modulation given by the placebo effect lesson will be concluded stressing the fact that DOMS have a good prognosis and that in a short amount of time they will be pain free and also that no drugs are effective to reduce pain intensity in DOMS condition suggesting them to stay physically active.
45996642|NCT04255212|Other|Control Group|Participants will be asked to wait 10 minutes and to relax until the tests will be performed again.
45996643|NCT04255212|Other|Neurodynamic treatment|Participants will be asked to lay supine on a medical table and keep their arms relaxed. 30 repetitions of gentle upper limb nerves mobilization, performed through a combination of neck and arm physiological movements, will be administered with cycles of tensions and relaxation of 1/5 seconds for 3 minutes in total for each arm. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
45996644|NCT04207268|Behavioral|Gardening and Nutrition Advice|Participate in gardening activities, gardening instructions and nutrition advice
45996645|NCT04207268|Behavioral|Nutrition Advice|Participate in only nutrition advice
45996646|NCT05353803|Other|Digital App and Platform for Supporting Medicines Control and Optimizationin Older Individuals With Heart Failure|Digital App and Platform for Supporting Medicines Control and Optimizationin Older Individuals With Heart Failure
45996647|NCT00552903|Behavioral|Health coaching|Personal health coach providing advice and counselling by telephone, weekly contacts
45996648|NCT04176029|Device|lung ultrasound|Lung ultrasound is performed using an 12-regions technique i.e. six areas on each side of the chest, two ventral, two lateral and two posterior. The lung ultrasound examination is estimated to take around 10 minutes of time.
45996649|NCT04152980|Drug|Pentoxifylline|The intervention consists of intravenously administered pentoxifylline. Pentoxifylline , a methylxanthine, is an off patent drug for neonates and currently registered for peripheral artery disease treatment in adults. Pentoxifylline acts as a cyclic adenosine monophosphate(cAMP)-phosphodiesterase inhibitor that suppresses tumor necrosis factor alfa (TNF-α) and modulates important parts of the inflammatory response and also reduces the production of other inflammatory cytokines, such as IL-1α, IL-6, and IL-8.
45996650|NCT01232452|Drug|Pemetrexed|Administered intravenously (IV)
45996651|NCT01232452|Drug|Cisplatin|Administered IV
45996652|NCT01232452|Drug|Cixutumumab|Administered IV
45996653|NCT05345613|Drug|Tranexamic acid|Submucosal injection of standard solution including TXA during EMR procedure
45996654|NCT05345613|Drug|Standard|Injection of standard solution
45996655|NCT01211197|Drug|C: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet after a high fat, high caloric meal
45996656|NCT01211197|Drug|B: BI 10773 tablet and metformin tablet|BI 10773 and metformin single tablets, administered together in fasted state
45996657|NCT01211197|Drug|A: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet in fasted state
45996658|NCT04208802|Other|Use of fluoridated toothpaste|Use of fluoridated toothpaste
45996659|NCT04208802|Other|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
45996660|NCT04208802|Other|Wearing of an intraoral device with resin samples|Wearing of an intraoral device with resin samples
45996661|NCT04679519|Other|Drop Jumps|Perform 100 drop jumps from 40 cm height. The protocol is divided into 5 sets of 20 repetitions. Between each repetition participants get 10 seconds, and between each set 2 minutes rest. Stand on the box, drop of the box and land with feet shoulder width apart. Then immediately bend knee to approx 45 degrees and jump straight up. Throughout each jump hands are placed on hips and should not move.
46085572|NCT02751398|Drug|Dapagliflozin 10mg|
46085573|NCT02751398|Drug|Placebo 10mg|Matching placebo for dapagliflozin 10 mg
46085574|NCT02753114|Drug|Ketamine|Intranasal Ketamine administered via mucosal atomization device at 0.5 - 1 mg / kg IN.
46085575|NCT02753114|Drug|Normal Saline|Intranasal Normal Saline administered via mucosal atomization device.
46085576|NCT03288324|Drug|Tofacitinib|Tofacitinib 5 mg twice daily
46085577|NCT04215354|Device|Magnetic field|Low pulsed electromagnetic field induced by BEMER machine model type: B.BOX Professional, model NO: 420200, 12-15 Volt, with maximum 300 Watt and average flux density around 35 microtesla- (BEMER Liechtenstein product, USA). Mattress which is flexible, 6 flat coil was used for whole body therapy.
46085578|NCT04215354|Device|Virtual reality|Wii Fit plus machine which required balance board . It is a video game console designed by Nintendo 2009
45996662|NCT05345067|Behavioral|Experimental: Laughter yoga session parts-1|Section 1: Deep breathing exercises: A deep breath is taken as far as possible by raising the arms up to the sky. Breathing is held for 4-5 seconds after deep inspiration. Breathing is performed rhythmically and slowly, while the arms are placed in a normal position. After deep inspiration, one can exhale either by forming the lips in the whistling position or by laughing. In each deep breathing exercise technique, the expiration time of the exhalation process should be longer than the inspiration time.
45996663|NCT05345067|Behavioral|Experimental: Laughter yoga session parts-2|Section 2: Warm-up exercises (10 minutes): Hands are clapped by holding parallel to each other. The fingertips and the palms touch each other, stimulating the acupuncture points on both hands, and the individual's energy level rises. In order to further raise the energy level and synchronize the movements of the group, a rhythm is added in the form of 1-2, 1-2-3. After several rhythmic hand-clapping movements, one more movement is added. Hands are clapped by swinging left and right. Then, an audible rhythm in the form of ho, ho, ha-ha-ha is also added to the hand-clapping movement. People in the group look at each other, and smile.
45996664|NCT05345067|Behavioral|Experimental: Laughter yoga session parts-3|"Section 3: Childish games (10 minutes): Childish games are used that will help to laugh for no reason, just like a child. Imagining these games and plays, the arms are raised upwards in the form of a Y with palms facing the sky, motivating the group by saying very good (clap), very good (clap), yes. The leader of laughter yoga speaks out very good (clap), very good (clap), hey (arms to the right and left) to keep the group's energy high and generate enthusiasm in the deep breathing exercises and laughter exercises sections. According to the energy and desire of the group, this section is completed after about 10 minutes."
45996665|NCT05345067|Behavioral|Experimental: Laughter yoga session parts-4|"Section 4: Laughter exercises (15 minutes): This section contains a variety of laughter exercises that will laugh, such as greetings, laughter cream, exploding balloon laughter, preparing and drinking strawberry milk, bonuses, hot soup, lion, aloha, bird, appreciation, elevator, and cream pie. A laugh is raised by doing only laughter exercises for no reason at all. At the end of this section, relaxation is achieved for about three minutes using deep breathing exercises. The group is given verbal guidance Put your hand on your heart, feel your heartbeat, let's exhale with a smile, make a wish or pray, smile as if we had achieved our wish, and the laughter yoga session is terminated."
45996666|NCT04679792|Diagnostic Test|Dynamic posturography|Balance evaluation
45996667|NCT04679363|Other|Active release technique|ART will be performed on upper trapezius and sternocleidomastoid, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. ART will be performed in supine position with a pillow under knees. After the shortened area of the targeted muscle is identified, soft tissue mobilization with active movement and passive overpressure will be applied. The active movement in technique will be from shortened position of muscle to lengthened position.
46085579|NCT02753192|Other|Patients|Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks will be recorded to obtain acoustic and perceptual measures. Self-evaluation questionnaires will be used to assess the psychosocial impact of dysarthria on quality of life.
46085580|NCT05324748|Drug|Methylprednisolone|Injection with prednisolon
46085581|NCT05324748|Drug|Saline solution|0,9%
46085582|NCT02753036|Drug|Chemotherapy|standard combination chemotherapy (paclitaxel +/- carboplatin) if necessary according to treatment guidelines
46085583|NCT02705274|Drug|Bevacizumab|"Drug: 1.25-mg Bevacizumab Intravitreal injection of 1.25 mg Bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.~Other: Deferred panretinal photocoagulation PRP is deferred until failure/futility criteria for intravitreal injection are met."
46085584|NCT02705274|Procedure|Panretinal photocoagulation|Panretinal photocoagulation (full session completed within 42 days).
46085585|NCT00914849|Drug|AMD3100|
46085586|NCT00914849|Procedure|Leukopheresis|
46085587|NCT00914849|Procedure|Stem cell transplant|
46085588|NCT02751086|Procedure|Robotic Gastrectomy|Minimally invasive surgical approach, related to the availability of a robotic surgical system (eg Da Vinci surgical system), that allows a surgeon to perform surgery through a console and dedicated devices.
46085589|NCT02751086|Procedure|Laparoscopic Gastrectomy|Minimally invasive surgical approach performed through traditional laparoscopy.
45675163|NCT02043938|Device|SedLine EEG sensor|Test subjects in each group will receive the same device intervention (SedLine EEG) to monitor their EEG waves.
45675164|NCT04702646|Drug|Bowel preparation before colonoscopy|one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylene glycol solution, 2 Liters of PEG-Ascorbic acid or 2 Liters Picosulfate.
45675165|NCT04702646|Procedure|Colonoscopy|colonoscopy will be performed to every patient included in the study
45675166|NCT02053610|Drug|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
45996668|NCT04679363|Other|Post isometric relaxation|PIR will be performed on upper trapezius and sternocleidomastoid muscles, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. The patient will be instructed to move the ear towards the shoulder of the affected side, against the resistance of the therapist's hands with minimum force (only 20% of their total force). The patient will be instructed to perform isometric contraction of the affected side along with inhalation and position for 10 seconds. Then the patient will exhale completely and relax. During this relaxation phase head and neck are taken further away from ipsilateral shoulder and ipsilateral shoulder is pushed downward until next restriction is met.
45996669|NCT00553137|Drug|fluconazole|750 mg (5 tablets of 150 mg tablets)taken once
45996670|NCT00553137|Drug|fluconazole|150 mg fluconazole tablets once daily for 14 days
45996671|NCT04679246|Behavioral|Participatory intervention|Surveillance in compliance with the regulation of the sale of food in school buildings, according to official guidelines Training for the preparation of hygienic and healthy food for the personnel in charge of food sale Promotion of the consumption of simple water and healthy foods Reconditioning of the infrastructure for the consumption of simple water, free and healthy food, and the realization of physical activity Organization of events and support in the coordination of groups that promote physical activity at the community level Optimization of physical education classes at school sites Implementation of health promotion and care actions in the school context Development of skills in the school community for health care and generation of healthy school environments Creation and strengthening of health and nutrition committees in schools, with the participation of directors, teachers and parents to generate necessary and permanent conditions that favor healthy environments
45996672|NCT04090775|Drug|Opdivo Injectable Product|"Opdivo (nivolumab): PD-1 inhibitor antibody~Injectable 10mg/mL, only 1 mL injected."
45457336|NCT03921853|Other|Behavioral|The 20-week RT program will consist of three sessions per week, each lasting for 1 hour that will be applied to both control obese (CG) and morbid obese (MO) group. All sessions will start with 15 minutes warm-up with continuous walking and joint mobility and flexibility exercises, 5 minutes of cool down and stretching, in order for preventing injuries. Sessions will include 4 to 8 RT exercises targeting different muscle groups; 1. forearm, 2. knee flexors and 3. extensors, 3. trunk, 4. chest, 5. shoulder elevators, 6. horizontal shoulder flexors and 7. extensors, and 8. plantar flexors. The exercises for each muscle group will be performed in 3 sets of as many repetitions (continuous concentric/eccentric voluntary contraction) possible in 1 minute followed by 2.0 minutes of passive recovery. Before the RT program, each participant will be measure using the subjective modified Borg scale (1-10 points), in order of identifying the muscle failure into 1 minute of exercise.
45457337|NCT03512626|Device|OptiVis, Aaren Scientific|All the surgeries were performed under topical anesthesia using a standard phacoemulsification procedure with Infiniti Vision System (all from Alcon Laboratories, Inc, Fort Worth, TX).
45996673|NCT04090775|Drug|Yervoy Injectable Product|"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 1 mL injected."
45996674|NCT04090775|Drug|Cytoxan|"Cytoxan (cyclophosphamide): Chemotherapy agent~Both Injectable and Oral low dose:~Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: option of either 50mg once daily pill or 25mg twice daily pill for two weeks on, then two weeks off, then two weeks on again."
45996675|NCT04090775|Procedure|Cryosurgical freezing (cryosurgery)|Cryosurgery, also known as cryoablation, for prostate cancer works by freezing the cancer cells inside the prostate gland. Cryoablation will release intact antigens to prime the immune system.
46085590|NCT02705118|Device|Automatic Imaging fusion of ultrasonography and MRI|Radiofrequency ablation for hepatic malignancies will be performed with automatic registration registration. Except the imaging registration, all other procedures for RF ablation is same.
46085591|NCT02705118|Device|Manual Imaging fusion of ultrasonography and MRI|Radiofrequency ablation for hepatic malignancies will be performed with manual registration registration. Except the imaging registration, all other procedures for RF ablation is same.
45457338|NCT03512626|Device|Monofocal IOL|All the surgeries were performed under topical anesthesia using a standard phacoemulsification procedure with Infiniti Vision System (all from Alcon Laboratories, Inc, Fort Worth, TX).
45457339|NCT03620240|Behavioral|Sleep Education|Assessing the effectiveness of a Sleep Education Program in improving sleep behaviors in secondary school students.
45457340|NCT02294110|Other|spinal anesthesia|non diabetes mellitus
45457341|NCT01229059|Dietary Supplement|Lipovenös lipid infusion|Lipid enriched infusions will be applied for 2-6 hours.
45457342|NCT02302300|Device|Manufacturer STELLAR 150|5 days of non-invasive ventilation at two levels of pressure from it pre-operative, followed by 5 days in post-operative.
45675167|NCT02053610|Drug|rituximab|375 mg/m^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6.
46085592|NCT02704962|Drug|full-dose olanzapine|trifluoperazine 5mg/d
45457343|NCT01283438|Device|Barricaid|Annular closure device
45457344|NCT01283438|Device|Standard of Care|Standard Limited discectomy
45675168|NCT02053610|Drug|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle
45996676|NCT00553176|Other|No intervention|At six-month intervals (January and July), physicians will document disease characteristics, changes in Crohn's therapy, disease progression, key events, the use of ancillary services, and hospitalizations
45996677|NCT04166136|Other|Transition from the Rearfoot to the Forefoot and Midfoot|Participants in this group will perform a training aimed at the transition of foot strike pattern from the rearfoot to the forefoot and midfoot progressively. Initially a ten-minute race will be held at a comfortable warm-up speed. Then the participants in this group will run continuously at the usual treadmill speed for thirty minutes in a 12-week progressive training program. Participants will run shod and barefoot alternately. Each week the barefoot running time increased to 30 minutes.
45996678|NCT04166136|Other|Usual Treatment Group|This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.
45675169|NCT02075606|Drug|lanreotide acetate|Somatuline Autogel injection 120mg for first 3 months then 120, 90 or 60 mg administered via the deep subcutaneous route every 28 days
45996679|NCT04166136|Other|Muscle Strengthening Group|The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
45675170|NCT02043782|Device|Coloplast Test|Newly developed 1-piece convex ostomy product
45996680|NCT04089839|Other|Non-Interventional|Non-Interventional
45457345|NCT03512548|Drug|Relacorilant 350mg|Relacorilant 350mg
45675171|NCT02043782|Device|Own product|The subjects Own product is used as baseline performance in this investigation. The products are commercial and available on the market, and are products manufactured by manufactures who produce convex ostomy products i.e. Coloplast, Convatec, Dansac, B.Braun, Hollister and more.
45834581|NCT04758858|Other|Hepatic imaging (MRI)|Imaging of participants' liver will be done by MRI at the Centre Hospitalier de l'Université de Montréal (CHUM). The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
45834582|NCT04758858|Other|Glucagon efficiency test|The glucagon efficiency test will be done twice, before (visit 2) and after (visit 4) the intervention phase. A subcutaneous insulin injection based on individual insulin correction factor will be given to induce hypoglycemia down to 3 mmol/L (based on plasma glucose). A subcutaneous injection of 300 µg of glucagon will be administered.
45834583|NCT04758858|Other|Body composition : Dual Energy X-ray absorptiometry (DEXA)|Lean body mass and fat mass will be measured by Dual Energy X-ray absorptiometry (DEXA). The DEXA test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
45996681|NCT04045145|Drug|NBI-74788|NBI-74788 administered orally for 14 consecutive days.
45457346|NCT03512548|Drug|Itraconazole|Itraconazole 200 mg
45457347|NCT03512548|Drug|Relacorilant 300mg|Relacorilant 300mg
45457348|NCT03919357|Behavioral|BMT-i|Passing the BMT-i test
45457349|NCT02300584|Behavioral|Tele-Savvy|as a program delivered on an iPad with daily instructional video segments (8-12 minutes each)
45457350|NCT02300584|Behavioral|Tele-Savvy|as a program delivered on an iPad with daily instructional video segments (8-12 minutes each). Videos may be modified after feedback from Prototype arm.
45457351|NCT02300584|Other|iPad|a tablet computer with an internet connection
45675172|NCT02043782|Device|Competitor soft convex|A commercially available soft convex product
45675173|NCT04701008|Drug|Ketamine|IV ketamine - 10mg bolus may be repeated repeated 2-3 times depending on clinical judgement
45675174|NCT04700696|Behavioral|Peer Recovery Support|Weekly visits with peer who has lived experience related to child welfare and addiction
45675175|NCT04700696|Behavioral|Family Treatment Drug Court with Medications for Opioid Use Disorders (MOUD)|Incentivized to participate in Family Treatment Drug Court with option for Medications for Opioid Use Disorders (MOUD)
45675176|NCT04700696|Behavioral|Relational Skill Building based on the Nurturing Parenting Program (NPP)|Home-based parenting support
45996682|NCT01232296|Drug|dovitinib|500 mg p.o. o.d. 5 days on/2 days off
45996683|NCT01232296|Drug|sorafenib|400 mg p.o. b.i.d.
45996684|NCT04041011|Drug|1.Experimental: A (Part 1): Fluzoparib and SHR -1316|1．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
45457352|NCT03515668|Drug|Ritalin 20 mg Tablet|Single dose for all participants
45457353|NCT03515668|Drug|Placebo Oral Tablet|Placebo with same appearance/taste
45457354|NCT01356212|Drug|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
45457355|NCT01356212|Drug|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
45457356|NCT01356212|Drug|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
45834584|NCT04758858|Other|Blood tests|Blood tests will be done to assess participants' diabetes control as well as to assess other biochemical markers (blood lipids as well as markers of inflammation and liver function). Blood will be collected and analyzed during all visits (visits 1 to 4).
45996685|NCT04041011|Drug|2.Experimental: B (Part 1): Fluzoparib and SHR -1316|2．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
45996686|NCT04041011|Drug|3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion|3．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
45996687|NCT02888236|Drug|LEO 32731|
45996688|NCT02888236|Drug|LEO 32731 Placebo|
45996689|NCT04136379|Diagnostic Test|INR monitoring using a CoaguChek POC device|INR monitoring using a CoaguChek POC device
45996690|NCT04134390|Drug|Cabozantinib|Subjects will receive cabozantinib 40mg p.o. as long as they continue to experience clinical benefit or until unacceptable toxicity, the need for alternative anticancer treatment, or other reasons for treatment discontinuation
45996691|NCT04016558|Behavioral|StreamLine|"StreamLine is an education/disease management program that focuses on systematic methods to identify and resolve specific blood glucose problems, primarily through changes in carbohydrate consumption, and use of basal and bolus insulin. Participants will attend a brief, four-hour meeting with a Certified Diabetes Educator (CDE) and, using standardized blood glucose data, will learn how to employ a five-point blood glucose management system to identify and resolve blood glucose problems (e.g., excursions, lows) that have the greatest HbA1c or hypoglycemic impacts.~Participants will then meet individually (30 minutes) with their CDE to review their blood glucose data, identify a specific blood glucose problem, and use the five-point program to create a plan to address the problem. Four additional individual meetings (30 minutes) will occur at approximately two to three-week intervals to best support individualized and participant-tailored management-change efforts."
45996692|NCT04016558|Behavioral|TunedIn|"TunedIn utilizes emotion regulation-based strategies to help participants observe that how they feel affects what they do regarding diabetes management. Participants will attend two highly interactive group workshops (6 hours followed by 2 hours) facilitated by a psychologist or social worker experienced in diabetes. Each will identify and discuss common emotional responses related to blood glucose management (e.g., over-reacting, avoiding, and lack of mindfulness).~Between the two workshops (two weeks), participants will complete a feeling log to document feelings, situation/context, and resolution around specific management events. Two individual meetings with the interventionist (30 minutes) will allow participants to identify and address a specific diabetes distress-related problem. Four web-based video group meetings (60 minutes, monthly) will continue to support participants over time."
45996693|NCT04016558|Behavioral|FixIt|"FixIt combines components of StreamLine and TunedIn to allow participants to explore feelings and expectations alongside the identification of problematic blood glucose patterns. StreamLine will be co-facilitated by a psychologist/social worker experienced in diabetes and a CDE. Participants will attend two group workshops (six hours followed by four hours), separated by two weeks.~Between the two workshops, participants will record their blood glucose data and keep a parallel feeling log to provide context. Four individual meetings with an interventionist (30 minutes) will allow participants to identify and address a specific blood glucose problem and create a plan to address it. Full discussion of diabetes distress-related aspects of the plan will take place to enhance mindfulness and identify typical emotion regulation strategies to ease problem resolution. Three web-based video group meetings (60 minutes, monthly) will continue to support participants over time."
45996694|NCT01231984|Device|4 mm x 32G Pen Needle|During the 12 week study period, subjects use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are advised to inject straight in when using the 4mm PN, with no pinch up.
45996695|NCT01231984|Device|8mm x 31G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
45834585|NCT04758858|Other|Stool sample collections (optional)|Participants will be asked to collect and immediately freeze their stool sample until it is given to the study team (for intestinal microbiota composition analysis). This will be done three times during the study, during phase 1, between week 1 and 6 of phase 2 and between week 6 and 12 of phase 2.
45458375|NCT03501394|Other|Health Questionnaire|Health and demographic information will be collected.
45458376|NCT05188742|Drug|mirabegron|mirabegron 50mg QD
45834586|NCT04758858|Other|Hypoglycemia journal|During the whole trial, participants will be asked to keep a log of their hypoglycemia episodes, which are defined by the need to consume CHO. They will be asked to note the time, symptoms (including time taken for disappearance after treatment), capillary glucose measurement and the amount of CHO consumed.
45834587|NCT04758858|Other|Ketone journal|During the intervention phase, participants will be asked to measure their ß-hydroxybutarate level (mmol/L) with their Abbott's Freestyle-Libre scanner at least twice per week before breakfast. Participants will be asked to check their ketone bodies for sensor or capillary glucose levels exceeding 15 mmol/l, when their sensor indicates high without a specific glucose value and when they have symptoms of ketoacidosis (regardless of glucose reading).
45458377|NCT05188742|Procedure|TTNS|transcutaneous tibial nerve stimulation
45996696|NCT01231984|Device|12.7mm x 29G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. When using the 12.7mm PN, subjects are instructed to insert either at an angle of 45 degrees, or to pinch up and hold the pen device at a 90 degree angle (straight in).
45996697|NCT04684095|Behavioral|electronic patient report outcome|ePRO was conducted every two weeks in addition to routine follow-up
45996698|NCT03998501|Behavioral|Cognitive Behavioral Therapy with Mindfulness Class|The CBTm classes are five, 90-minute sessions focused on strategies to reduce symptoms of anxiety and depression.
45996699|NCT01210807|Device|One-Piece Tecnis Multifocal IOL|One-piece Tecnis Multifocal IOL, Model ZMB00, implanted lens.
45996700|NCT01210807|Device|One-Piece Tecnis monofocal IOL, Model ZCB00|Control lens: One-Piece Tecnis monofocal IOL, Model, ZCB00, implanted lens.
45996701|NCT05307744|Dietary Supplement|PS128|Each PS128 capsule contained >3 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg.
45996702|NCT05307744|Other|Placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.
45996703|NCT03973697|Drug|Penn Microbiome Therapy - 001|Fecal Microbiota for Transplant, enema product
45996704|NCT03973697|Drug|Penn Microbiome Therapy - 002|Fecal Microbiota for Transplant, suspension product
45996705|NCT03973697|Drug|Penn Microbiome Therapy - 003|Fecal Microbiota for Transplant, capsule product
45996706|NCT00552942|Procedure|laparoscopic gastric bypass plus omentectomy|
45996707|NCT03969095|Behavioral|Tongue Pressure Resistance Training|2 supervised sessions per week: Each session will be a maximum of one hour in length and will include: 1) 20 repetitions of maximum isometric presses (MIPs) with rapid rise in pressure at the anterior location. 2) 15 regular saliva swallows with the IOPI bulb in place. 3)15 effortful saliva swallows with the IOPI bulb in place. 4) 10 generalization tasks with mildly thick liquid and IOPI.
45457357|NCT05402137|Behavioral|Weight stigma intervention|Those undergoing the weight stigma manipulation will be exposed to an interaction partner (a trained confederate) who will endorse anti-fat attitudes. The purpose of this interaction is to examine the causal effects of weight stigma on eating behaviors, physical activity, and sleep.
45996708|NCT05302479|Other|COMPASS 31 questionnaire|A 31 question questionnaire that measures autonomic symptoms.
45996709|NCT00554138|Drug|placebo|1 dd for 7-10 days
45996710|NCT00554138|Drug|rosuvastatin|1 dd 20 mg for 7-10 days
45996711|NCT03455595|Procedure|Endoscopic exams|Coloscopy
45996712|NCT03923387|Device|MynxGrip|Vascular Closure
45996713|NCT03923387|Other|Manual compression|Manual compression is a commonly used method to achieve hemostasis of femoral artery
45996714|NCT01231555|Drug|GSK2248761 100 mg once daily|1x100 mg capsule plus matching placebo
45996715|NCT01231555|Drug|GSK2248761 200 mg once daily|2x100 mg capsules
45996716|NCT01231555|Drug|Efavirenz 600 mg once daily|1x600mg tablet
45996717|NCT04116528|Drug|Ketamine|0.5mg/kg
45996718|NCT04116528|Drug|Buprenorphine|Buprenorphine (0.2-0.8mg/day) or Placebo orally dissolving tablet
45996719|NCT04116528|Drug|Placebo oral tablet|Buprenorphine or Placebo orally dissolving tablet
45996720|NCT05288907|Drug|Lidocaine Ointment|Composite over-the-counter lidocaine ointment administered twice daily for 2 weeks.
45996721|NCT03912272|Behavioral|High-intensity Interval Training|In the high-intensity interval training group, subjects will receive respective prescribed exercise once a week.
45996722|NCT03912272|Behavioral|Usual Care Control|In the usual care control group, obesity-related health briefing, dietary caloric restriction advice, and lifestyle counseling/consultation will be provided.
45996723|NCT04683861|Procedure|Spinal cord stimulation|Paddle-shaped Spinal cord stimulation electrode with 16 contacts (AdaptiveStim® 39, 565; Medtronic, USA) will be implanted into the epidural space at the thoracic levels ranging from T10 to T12.
45996724|NCT01210651|Behavioral|Hatha Yoga Practice Group|The hatha yoga intervention was a sequence of classical yoga practices, comprised of breathing techniques, mindful body postures, and a final deep relaxation pose. The same sequence was used in all sessions. Yoga practices were broken down into component elements and taught progressively to each student in accordance with his or her ability. Participants were encouraged to remain within their range of motion or comfort. Accommodations were made for those with limitations in tolerance or flexibility for any exercise. Blocks, bolsters and other props were used to support participants in learning and holding yoga poses safely, particularly during back-bends or inverted poses. The intervention was delivered by a licensed, registered nurse, who was also a registered yoga teacher.
46002374|NCT03406767|Other|JointEffort Program|The JointEffort program consists of: 1) one appointment aimed at individualized program design (1-1.5 hours); 2) a nutritional seminar taught by a registered dietician explaining dietary recommendations for OA patients and inflammatory conditions, including weight loss and/or management (1 hours); and 3) an individualized exercise (strength and neuromuscular training, balance training, and range of motion exercises) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks.
45996725|NCT01210651|Behavioral|Attention Control Education Group|The educational seminars taught to participants covered the history and philosophy of the main branches of yoga. Documentary films were used during the seminars to enhance lectures, and interactive dialogue was encouraged between instructor and participants. Seminars were designed to control for non-specific mood benefits of study participation, such as attention from instructors, peer interaction, time spent away from routine activities, and anticipation/interest related to mastering novel yoga-related information. Since participants would join the attention control group on a rolling basis, seminars were designed to function as stand-alone educational modules, rather than requiring presentation in a specific sequence. The instructor for the seminars was a registered yoga teacher.
45996726|NCT03911336|Drug|Group A - test:Tooth extraction and intake of NSAID and a non-NSAID|Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
46085593|NCT02750774|Behavioral|Low-glycemic index group|"The dietary intervention consisted of the prescription of a Mediterranean style, low-glycaemic, low-fat, exchange diet (3 main meals and 3 snacks) with a total intake of 1500 kcal/day. In light of the PA, the dietitian adds 200 kcal/day for obese, 300 kcal/day for overweight women. The diet had a target macronutrient composition of 55% carbohydrates (80% complex carbohydrates with a low glycaemic index and 20% simple carbohydrates), 20% protein (50% animal and 50% vegetable) and 25% fat (12% mono-unsaturated, 7% polyunsaturated and 6% saturated) with moderately low saturated fat levels. The daily intake of carbohydrates was at least 225 g/day. The exercise intervention was focused on developing a more active lifestyle. The PA prescription is consistent with recommendations by the ACOG and ACSM for pregnant women. The talk test (being able to maintain a conversation during activity) was suggested to monitor the exercise intensity."
46085594|NCT02750774|Other|Standard Care Group|Women randomized to the Standard Care Group received general information about healthy lifestyle during pregnancy, according to the Guidelines
45834588|NCT04758858|Other|Adherence to the diet (Keenoa)|During the whole dietary intervention phase (phase 2), participants will confirm that they have followed their menus by taking before and after pictures of their meals every day and indicating the percentage of their meal consumed (25-50-75-100%) via the Keenoa mobile application.
45996727|NCT03911336|Drug|Group B - Control 1: tooth extraction and intake of NSAID and a non-NSAID|Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 PM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8 AM and 2 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
45996728|NCT03911336|Drug|Group C - Control 2: tooth extraction and intake of a Non-Nsaid|Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
45996729|NCT04683822|Other|Telerehabilitation|Patients will attend telerehabilitation sessions
46085595|NCT04240145|Device|MSCT Abdomen|Visceral fat volumetry using MSCT and it's relation to NASH
46085596|NCT04438226|Procedure|Surgical approach|The surgical approach of hemiarthroplasty after femoral neck fracture
45996730|NCT05288634|Other|Progressive relaxation exercise|Progressive relaxation exercise is a type of exercise that involves voluntary stretching and relaxation of major muscle groups in the human body, from the hands to the feet.
46085597|NCT02704884|Dietary Supplement|probiotic soy milk|
46085598|NCT00631943|Drug|Pregabalin (Lyrica)|Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days.
46085599|NCT05429684|Drug|Trastuzumab|Trastuzumab (6mg/Kg, iv.drip, d1, q3w)
46085600|NCT05429684|Drug|Pertuzumab|Patuzumab (420mg iv.drip, d1,q3w)
46085601|NCT05429684|Drug|Nab paclitaxel|nab-paclitaxel (200mg iv.drip, d1,d8, q3w)
46085602|NCT05429684|Drug|Pyrotinib|Pyroltinib (400mg po qd)
46085603|NCT05429684|Drug|Capecitabine|Capecitabine (1250mg/m2, po, bid, d1-d14, q3w).
46085604|NCT05429684|Drug|T-DM1|T-DM1(3.6mg/Kg, iv.drip, d1, q3w)
46085605|NCT05429684|Drug|Everolimus|Everolimus (4mg, po, qd)
46085606|NCT05429684|Drug|CDK4/6 inhibitor|Palbociclib (125mg, po, qd)
46085607|NCT05429684|Drug|AI|Letrozole (2.5mg, qd).
46085608|NCT05429684|Drug|Anti-PD-1 monoclonal antibody|Cindilimab (200mg, iv.drip, d1, q3w)
45834589|NCT04125888|Drug|Allergy immunotherapy (AIT)|Immunotherapy for different types of allergies
45834590|NCT04759092|Device|transcranial direct current stimulation (tDCS)|Apply 30min low dose (2mA) transcranial current stimulation on the scalp every day for four months.
45834591|NCT02975310|Procedure|Endoscopic polypectomy in clinic (EPIC)|The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic.
46085609|NCT05324592|Drug|9MW0813|"The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~One dose(2mg) of the drug will be injected intravitreously."
46085610|NCT05324592|Drug|Aflibercept|"Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer. It is a fusion protein of human VEGFR1 and VEGFR2 extracellular domains and human immunoglobulin Fc segment genes.~One dose(2mg) of the drug will be injected intravitreously."
46085611|NCT04433858|Drug|Psilocybin|open-label
46085612|NCT02701998|Behavioral|mHealth-Enhance Physical Activity Intervention|
46085613|NCT02701998|Other|Physical Activity Intervention|
46085614|NCT04191044|Other|A complete cardiovascular and liver characterization will be carried out|A complete cardiovascular and liver characterization will be carried out, including some supplementary tests with minimal risks (e.g. hemodynamic study). If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.
46085615|NCT00615576|Drug|SB-656933|SB-656933 will be available as white film coated, round tablet and will be available in strengths of 50 milligrams, administered orally once daily.
45834592|NCT02975310|Procedure|Endoscopic Sinus Surgery (ESS)|The control intervention is endoscopic sinus surgery (ESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia.
46085616|NCT00615576|Drug|Placebo|A placebo tablet to visually match the SB-656933 tablet will also be supplied, administered orally once daily.
46085617|NCT02750696|Drug|Fixed-dose oral tablet of codeine/ acetaminophen every 4 hours for 3 days|Patients in this group received opioid/ non-opioid analgesic combination.
45996731|NCT03850535|Drug|Idasanutlin|Participants will self-administer idasanutlin tablets by mouth (PO) once daily (QD) for 5 days of each 28-day treatment cycle for up to 2 cycles of induction, up to 4 cycles of consolidation, and 12 cycles of maintenance, according to the study's protocol.
45996732|NCT03850535|Drug|Cytarabine|Cytarabine will be administered for 7 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 200 milligrams per meter squared (mg/m^2) of body surface area, once daily (QD) by intravenous (IV) infusion. At the investigator's discretion, cytarabine will also be administered as part of chemotherapy consolidation at a dose of 1.5 g/m^2 QD as IV infusion for 5 days of each 28-day cycle and for up to 4 cycles of treatment.
45996733|NCT03850535|Drug|Daunorubicin|Daunorubicin will be administered for 3 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 60 mg/m^2 QD as IV infusion.
45457358|NCT02302378|Procedure|Lumbar paramedian approach at L3-L4 interspace|Spinal anesthesia will be performed via a lumbar paramedian approach at L3-L4 interspace using 12.5mg 0.5% Bupivacaine (preservative free)
45996734|NCT03850535|Procedure|Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)|After induction treatment, participants who achieve remission will either receive chemotherapy consolidation treatment or undergo Allo-HSCT (as per local guidelines) at the investigator's discretion.
46085618|NCT02750696|Drug|Fixed-dose oral tablet of tramadol/ acetaminophen every 4 hours for 3 days|Patients in this group received opioid/ non-opioid analgesic combination.
46085619|NCT02704572|Biological|Zostavax|Zostavax will be administrated by subcutaneous injection.
46085620|NCT04217720|Drug|SNS-301|SNS-301 (1x 1011 dose/1ml) ID injection every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, and thereafter every 12 weeks up to 24 months.
46085621|NCT02704650|Procedure|fluid sample|taking a vaginal fluid sample
46085622|NCT02695550|Drug|CT-707|
46085623|NCT00912743|Drug|olaparib|400 mg po bid continuously
46085624|NCT04213872|Behavioral|Meditative Movement|The Meditative Movement program is a blend of meditation and exercise based on Tai Chi and Qigong.
46085625|NCT04432610|Drug|Bisoprolol versus Nebivolol|All subjects will receive both drugs, but at different time periods determined by randomization, with 1 week washout period
46085626|NCT02701686|Behavioral|quit immediately (QI)|advise to quit immediately using the AWARD model
46085627|NCT02701686|Behavioral|cut down to quit (CDTQ)|advise to reduce cigarette consumption and quit eventally using the AWARD model
46085628|NCT04643093|Drug|Pitavastatin|Pitavastatin, QD
46085629|NCT04643093|Drug|Ezetimibe|Ezetimibe, QD
46085630|NCT04643093|Drug|1PC111|1PC111, QD
46085631|NCT02750462|Other|Immediate coronary angiography|Immediate coronary angiography in survivors of out-of-hospital cardiac arrest without ST-segment elevation
45457359|NCT02302378|Procedure|Taylor's approach (paramedian approach at L5-S1 interspace)|Spinal anesthesia will be performed via Taylor's approach (paramedian approach at L5-61 interspace) using 12.5mg 0.5% Bupivacaine (preservative free)
45996735|NCT05285436|Device|CloudCath System|The CloudCath System enables drainage and measures turbidity, reported as a numeric score, in peritoneal dialysate effluent.
45996736|NCT05263089|Other|PALFIQUE® Universal Flow; Tokuyama, Tokyo, Japan (super low flowability)|"Supplied in L-syringe with nozzle and dispensing Tips. Super Low has low flowability, non-slumping, non-running, and precision stacking properties. The layer dispensed will be 2 mm. in thickness and cured for 40 s."
45834593|NCT02975310|Other|General Anesthesia|ESS will be performed under general anesthesia in the operating room
45834594|NCT02975310|Other|Local and topical anesthesia|EPIC will be performed under topical and local anesthesia in a clinic setting
46085632|NCT02750462|Other|Delayed/selective coronary angiography|Initial intensive care evaluation to further stratify the etiology of out-of-hospital cardiac arrest with delayed/selective coronary angiography if indicated
46085633|NCT02701842|Device|ImPACT Online/Paper Pencil Tests|
46085634|NCT02701842|Device|ImPACT Online|
46085635|NCT02701920|Device|HeartLight hat|HeartLight hat will be worn for up to 1 hour.
45834595|NCT05609136|Other|Bobath+Scapular Stabilization Exercises|Scapular stabilization exercises will be given to patients in addition to Bobath therapy. It will be applied with the patient in a sitting position, with the shoulder at 90 degrees and the elbow extended. The patient will be given exercises with isometric contraction while the shoulder is in protraction and retraction by the physiotherapist. Isometric contraction will last for 5 seconds and each exercise will be repeated 2x15 times. There will be a 1-minute rest period between sets. The exercises will be performed in 2 different positions, in the flexion position and in the diagonal position.
45834596|NCT04394208|Drug|Silymarin|Silymarin Oral at a dose of 420 mg/day in 3 divided doses.
46002375|NCT03372902|Device|Breast MRI|Participants with dense breast tissue will get a mammogram and MRI
46085636|NCT02701920|Device|The HeartLight hat with in-built sensor|The HeartLight hat with in-built sensor will be worn.
46085637|NCT02701920|Device|HeartLight|Electronic stethoscope will be used to estimate heart rate with HeartLight sensor/hat
46085638|NCT02701920|Device|HeartLight device|HeartLight sensor/hat will be used with ECG/Pulse oximetry/electronic stethoscope
46085639|NCT02701920|Other|parental feedback|Questionnaire
46085640|NCT02701920|Other|healthcare provider feedback|Questionnaire
46085641|NCT04220138|Procedure|Anterior chamber illumination in cataract surgery|This will be a prospective interventional case series, patients with cataract and poor red reflex will undergo phacoemulsification assisted by anterior chamber illumination to overcome the problem of poor red reflex.
46085642|NCT04217642|Procedure|Osteosynthesis|The specific surgical technique -osteosynthesis, hemiarthroplasty, or total hip arthroplasty- will depend on the characteristics of the proximal femur fracture in each patient.
45834597|NCT04394208|Drug|Placebo|Placebo comparator
45834598|NCT05608980|Drug|0.01% hypochlorous acid|once daily 0.01% hypochlorous acid topical treatment via ultrasonic atomization for 2 weeks
45834599|NCT05608980|Drug|Placebo|once daily eyelid wipes for 2 weeks
45834600|NCT03829566|Drug|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
45996737|NCT05263089|Other|ESTELITE® Alpha; Tokuyama, Tokyo, Japan|The composite was inserted using the incremental technique. Each increment of 2 mm was cured for 40 s.
45996738|NCT03850301|Drug|XBD173|7 days treatment
45996739|NCT03850301|Drug|Etifoxine|7 days treatment
45996740|NCT04114929|Other|Threshold-based Training|Specific ventilatory markers determined from a cardiopulmonary test and the correlating heart rate will be used to determine exercise intensity
45996741|NCT04114929|Other|Standard Care|Using the standard care cardiac rehabilitation guidelines exercise will be based on estimated heart rate maximum followed by the karvonan method to calculate 40-70% heart rate reserve
45996742|NCT03792932|Procedure|Laparoscopic distal pancreatectomy|Laparoscopic distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
46085643|NCT00616824|Procedure|Dermamatrix to cover lateral aspect of tissue expander|Dermamatrix used to cover lateral aspect of breast tissue expander after mastectomy
45675177|NCT02052596|Biological|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.
45675178|NCT02052596|Biological|Boostrix|1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.
45675179|NCT04681118|Biological|NurOwn (MSC-NTF cells)|Intrathecal administration
45675180|NCT02052440|Drug|Baclofen|Treatment arm: baclofen 10mg tid
46085644|NCT00616824|Procedure|Serratus anterior to cover lateral aspect of tissue expander|Traditional use of serratus anterior for coverage of lateral aspect of tissue expander
46085645|NCT02750384|Drug|DSM265 50% SDD granules|Single oral dose 400 mg
46085646|NCT02750384|Drug|DSM265 25% SDD powder for suspension|Single oral dose 400 mg
45675181|NCT02052440|Drug|Placebo|Sugar pill by mouth three times daily
45675182|NCT04712318|Procedure|Relex Smile|Procedure/Surgery: Relex Smile The residual myopic refraction on Pseudophakic patients after 6 months using Relex-Smile surgery by VisuMax femtosecond laser. The residual refractive power was min -0.75D.The optical zone (lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker(ViscotMedster).
45675183|NCT04712318|Procedure|Relex smile with fresh corneal lenticule implantation|"VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule.~The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision.~In pseudophakic patients with hyperopic astigmatism residual refraction, corneal topography-guided intrastromal fresh lenticular implantation should be performed according to the low K values."
45675184|NCT02049944|Drug|Cefazolin|Participants who are undergoing an elective cesarean section at term will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision administered through an intravenous line.
45675185|NCT02043548|Drug|tocilizumab|given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
45457360|NCT03919279|Device|active tVNS|tVNS using TENS device from Schwa-Medico (TENSeco2) + auricular electrode applied on the left ear (Schwa-Medico) + conductive gel class I; 25 Hz stimulation 1 hour daily for 1 month
45457361|NCT01356368|Drug|Cisplatin, Gemzar, Docetaxel, Alimta|Patients will be assigned to treatment according to the molecular biological results which will analyze excision repair cross-complementing (ERCC1), ribonucleotide reductase subunit M1 (RRM1) and beta-tubulin genes in primary tumor cells which are present in tissues and peripheral blood.
45675186|NCT02043548|Drug|placebo|given by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
45834601|NCT03829566|Drug|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
45834602|NCT03829566|Drug|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
45834603|NCT03829566|Drug|rATG|A rabbit polyclonal antibody to lymphocytes
45834604|NCT03829566|Drug|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
45834605|NCT03829566|Drug|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
45834606|NCT03829566|Biological|IVIg|Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
45996743|NCT03792932|Procedure|Open distal pancreatectomy|Open distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
45996744|NCT05255367|Combination Product|(poly)phenols rich foods|"Prior to start the intervention (initial time of the study) the volunteers will follow their habitual diet during 30 days as a control period, and then they will start with the intervention period (baseline) following their habitual diet supplemented with (poly)phenol rich products during 60 days (after intervention).~At the beginning of the study (initial time), at the beginning of the intervention (baseline) and at the end of the intervention (after the intervention) with rich (poly)phenols foods, biological samples (blood, urine and feces) and anthropometric measurements will be taken. In addition, the participants will record the food intake weekly with a 24 h dietary-recall form."
45996745|NCT03753620|Device|simultaneous fMRI and EEG + peripheral measures|Hemodynamic activity recorded with fMRI, cerebral electric activity recorded with EEG as well as peripheral physiological parameters will be recorded during music listening.
45996746|NCT03753620|Device|EEG and peripheral measures|cerebral electric( with EEG) as well as peripheral physiological parameters will be recorded during music listening.
45996747|NCT04095156|Diagnostic Test|In vitro assays.|Biochemical and flow-cytometry analysis of specimen collected.
45996748|NCT03750266|Other|No intervention data collected through routine scans|No intervention, we wish to use the images a mother would have done as part of her normal medical care and make both 3D animations and 3D models of the baby and it's CDH.
45996749|NCT04679129|Drug|ASC42|Oral tablets
46085647|NCT05324202|Device|Cynosure Cynergy Nd:YAG Laser 1064nm|The Nd:YAG Laser 1064nm is intended to be used as a treatment option in individuals suffering from low-risk basal cell carcinoma(s).
45996750|NCT04679129|Drug|Placebo|Oral tablets
45996751|NCT05236452|Other|Training for traditional and modern care providers|The intervention arm includes training for traditional and modern care providers, patient education, screening, and referring to TB suspected cases plus the usual care. The training will be provided three times which will be delivered every three months. In the first round, traditional practitioners will be trained for 5 days. In this round, the training will be also delivered to modern health care providers on how to communicate and work with traditional care providers for 2-day. Then, a one-day interactive discussion session will be prepared for both traditional and modern care providers. In the second round and third rounds, one-day training will be carried out at three and six months. TB suspected cases at traditional foster and holy water and patients who need spiritual support from health care providers will be screened every case in every day for one year. Referring to TB suspected cases will also apply for every case every day for one year
45996752|NCT04678934|Procedure|TAVR|Transcatheter aortic valve replacement
45996753|NCT04679090|Other|Exercise Program|Participants will exercise twice a week for twelve weeks total.
45996754|NCT04017936|Drug|Anakinra|Active Treatment
46002376|NCT03372902|Device|Breast Mammogram|State-of-the-art full-field digital mammography (FFDM) and or digital breast tomosynthesis (DBT) comprising both raw and post-processed images as well as ultrasound and MRI images from the initial screening study will be collected and sent to the MSKCC Breast Radiology Department.
46085648|NCT00914459|Biological|Moroctocog alfa ( AF-CC)|Dosing is at the discretion of the Investigator
46085649|NCT00914459|Procedure|Laboratory tests|Factor VIII PK samples, Hematology, Chemistry and Coagulation testing, FactorVIII Inhibitor and Anti Factor VIII antibody
46085650|NCT02701608|Drug|Levofloxacin|levofloxacin 500 mg x1/day (for patients ≤70kg) or levofloxacin 750 mg x1/day (for patients >70kg)
46085651|NCT02701608|Drug|Rifampicin|rifampicin 600mg x1/day (for patients ≤70kg) or rifampicin 900mg x1/day (for patients >70kg)
46085652|NCT02701608|Procedure|Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine|Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
46085653|NCT02750150|Drug|Freezed-dried plasma|early transfusion of 4 units of freezed dried plasma
45675187|NCT01622348|Drug|IMO-3100 at 0.16 mg/kg|IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection
45675188|NCT01622348|Drug|Saline for Injection|Saline for Injection 0.01 mL/kg SC q wk x 4 wk based on body weight at screening, not to exceed 1.25 mL
46085654|NCT02750150|Drug|Fresh-frozen plasma|
46085655|NCT00635960|Drug|Growth Hormone (Somatropin)|The initial dose will be 2U s.c. every other day. The dose will be progressively increased to reach 1.5-2x the normal levels of IGF-I.
45457362|NCT03921697|Device|Werable sensors|Parkinson Disease Patients monitored by werable sensors
45458378|NCT02960737|Device|Oral screen|The oral screen is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial muscles.
45675189|NCT01622348|Drug|IMO-3100 at 0.32 mg/kg|IMO-3100 at 0.32 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 40 mg per injection
45834607|NCT03829566|Biological|Autologous Stem Cells|Infusion of patient's own stem cells
46085656|NCT00635960|Drug|Placebo|Same as for Growth hormone group
45834608|NCT03933306|Drug|Dexmedetomidine|Loading dose dexmedetomidine (0.6 mcg/kg for 10 min) administered before anesthesia induction, followed by a continuous infusion (0.5 mcg/kg/h) until 1 hour before the end of surgery.
45834609|NCT03933306|Drug|Placebo|Loading dose placebo administered before anesthesia induction, followed by a continuous infusion until 1 hour before the end of surgery.
45834610|NCT03933306|Other|Goal-directed blood pressure management|Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
45834611|NCT03933306|Other|Routine blood pressure management|Blood pressure is maintained according to routine practice, i.e., systolic blood pressure > 90 mmHg or within ±30% of baseline within intermittent ephedrine or phenylephrine.
45834612|NCT04125576|Diagnostic Test|magnetic resonance imaging(MRI)|magnetic resonance imaging(MRI) will be used to evaluate cerebral blood volume(CBV) of pain network
45996755|NCT03724331|Behavioral|Light Physical Activity 1|"Light (mild) physical activity program that corresponds with normal every day activities of daily living (< 3.0 metabolic equivalents, METs), with a time commitment starting at 5 minutes a day 5 days a week gradually increasing to 30 minutes a day 5 days a week as you are able by week 6 as guided by your Registered Nurse researcher.~The program begins approximately within one week after discharge from the hospital with the physical activity program starting approximately within the first week post-discharge from the hospital."
45996756|NCT03724331|Behavioral|Light Physical Activity 2|"Light (mild) physical activity program that corresponds with normal every day activities of daily living (< 3.0 metabolic equivalents, METs), with a time commitment starting at 5 minutes a day 5 days a week gradually increasing to 30 minutes a day 5 days a week as you are able by week 6 as guided by your Registered Nurse researcher.~The program begins approximately within one week after discharge from the hospital with the physical activity program starting approximately 7 weeks post-discharge from the hospital."
45996757|NCT03724331|Behavioral|Support Education Activity|"Participate in a supportive cancer-related education activity including a direct 10 - 15 minute phone conversation with a Registered Nurse researcher each week for 6-weeks after returning home from the hospital. Wear a pedometer each day of the study.~Recording pedometer steps in the daily diary each day."
45996758|NCT04017039|Other|Targeted Sleep Intervention|
45996759|NCT05228535|Dietary Supplement|Human milk fortifier|Human milk fortifier added to human breast milk at day 1 vs day 8 of feeds
45996760|NCT05211141|Device|HLS KneeTec Deep Dish|total knee arthroplasty with HLS KneeTec Deep Dish prosthesis
45996761|NCT03697070|Other|INSPIRE CPOE Smart Prompt|"Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having PNA due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards."
45834613|NCT04125654|Device|mNGS for pathogen detection|This assay is a metagenomic test undertaken by BGI Genomics Co., Ltd. for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
45996762|NCT03697070|Other|Routine Care|Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
45996763|NCT03696680|Radiation|FSRT Stereotactic radiation therapy|For each metastasis, dose of 30 Gy in 3 fractions at 10 Gy / fraction over 7 days
45996764|NCT03689660|Other|Virtual Reality Training|Participants will be given a game-based workout program that includes balance and weight transfers using the XBOX Kinect ™ device in a low-to-medium intensity for 3 weeks, 3 days a week, 30 minutes per day.
45996765|NCT03689660|Other|Biofeedback Training|biofeedback training will be applied to participants in 10-minute sessions with 10 seconds of voluntary contraction and 15 seconds of rest at each session. Training will last 12 weeks.
45996766|NCT03689660|Other|Conventional rehabilitation|Participants will receive a 12-week conventional rehabilitation program.
45996767|NCT05209893|Other|Telerehabilitation|Application based video home exercise for the knee osteoarthritis
45996768|NCT05209893|Other|Paper Based Rehabilitation|Paper instruction based home exercise for the knee osteoarthritis
45996769|NCT05199870|Device|Echo FX Stem with RingLoc Bipolar Acetabular Cup and Femoral Head|Patients that have been implanted with a Echo FX stem with RingLoc Bipolar acetabular cup and femoral head.
45996770|NCT03688100|Behavioral|Behavioral Activation Therapy|The therapy group will consist of an introductory in person 50-minute treatment session, followed by 12 weekly telephone 50-minute outpatient treatment sessions, then 3 monthly telephone 50-minute outpatient maintenance sessions. A typical BA session will last 50 minutes and include a review of the previous session and completed daily monitoring record forms, an in-depth discussion of life areas and value, and verbal reinforcement of activity engagement.
45996771|NCT03688100|Drug|Medication Management|Collaborative care model will be used. The medication management group will meet with the patient in a one 50 minute in person introductory antidepressant medication treatment session to educate the patient about depression and medication options. Patients will get prescribed a standard of care anti-depressant medication by treating physician, followed by 12 weekly follow up telephone visits, then on a monthly basis for 3 months, and then as needed thereafter.
45996772|NCT04000503|Behavioral|Self-collected HPV testing for cervical cancer screening|Self-collection cervical cancer screening, STI screening, and education on HIV by a community health worker. Women who test positive for high-risk HPV types will be referred to a designated health centre for VIA follow-up and treatment if indicated.
45834614|NCT04394442|Drug|Hydroxychloroquine|400mg BD first day then 200 mg BD for 5 days
46085657|NCT04639895|Procedure|Virtual Reality|The Virtual Reality group will be involved in the Standard treatment protocol and will perform personalized activities of daily living in a virtual city environment (Reh@City).
46085658|NCT04639895|Procedure|Paper and Pencil|The paper and Pencil group will be involved in the Standard treatment protocol and will perform personalized cognitive paper-and-pencil tasks, using the Task Generator tool.
46085659|NCT04639895|Procedure|Control Group|The standard treatment protocol.
45834615|NCT04125264|Device|Intense Therapeutic Ultrasound|Application of 1000 pulses, until 5000 joules (5 joules per pulse), during approximately 15 minutes, with the possibility of 5 minutes rest, depending on the tolerance of the patient.
45834616|NCT02972424|Drug|Teriparatide Prefilled Syringe|TPTD 20 mcg
45834617|NCT02972424|Drug|Placebo|Matching placebo as a prefilled syringe with all inactive ingredients
45834618|NCT04393428|Other|[TIMP-2]*[IGFBP-7]|[TIMP-2]*[IGFBP-7] mesurement in urine sample relicates of COVID-19 patients admitted to the Montpellier University Hospital
45834619|NCT05608590|Drug|Lipiodol UltraFluid|The investigational product is an oil-based contrast medium, Lipiodol® (Guerbet). Lipiodol® is a solution of ethyl esters of iodized fatty acids of poppy seed oil equivalent to 480mg I /ml and is a licensed contrast agent in the Netherlands (RVG 02806, see SmPC D2). The maximum amount of Lipiodol® per HSG procedure is 15 ml.
45834620|NCT04393584|Drug|Irinotecan|d1 Irinotecan 180mg/m² every two weeks
45834621|NCT04393584|Drug|5-FU|d1-2 5-FU 2450 mg/m² every two weeks
45834622|NCT04393584|Drug|Leucovorin|d1 Leucovorin 200 mg/m² every two weeks
45834623|NCT04393584|Drug|Oxaliplatin|d1 Oxaliplatin 85 mg/m² every two weeks
45996773|NCT03981705|Radiation|Standard Trimodality Breast Imaging|Standard breast imaging with or without core needle biopsy after neoadjuvant chemotherapy (NAC).
45996774|NCT03653117|Device|Transperineal laser ablation|Minimal invasive coagulation of prostatic tissue by laser
45996775|NCT03653000|Procedure|Ultrasound guided brachial plexus blockade|Ultrasound probe disposed on the shoulder, on the deltoid muscle. in plane puncture toward the brachial artery and injection of local anaesthetics around the brachial artery
45996776|NCT03653000|Drug|local anaesthetic injection|Local anesthetic injection (ropivacaine) at this new site
45996777|NCT03963687|Other|Standard Nursing Education Intervention|Genetics Education Program for Nurses (GEPN) which is available free online for more than 20 years
45996778|NCT03963687|Other|New Nursing Education Intervention|Web-based Genomics/ Genetics Nursing Education is a free online course that will be designed by the research team.
45996779|NCT03639389|Drug|Bupivacaine|Spinal anesthesia with a combination of bupivacaine and fentanyl or sufentanil
45996780|NCT03639389|Drug|Analgesics|Combination of paracetamol + non-steroidal anti-inflammatory drug + morphine to all patients
45996781|NCT03455673|Diagnostic Test|ATE score|"The Atrial Thrombus Exclusion (ATE) combine thromboembolic risk factors (hypertension, cardiac insufficiency, history of stoke) and d-dimer level for the prediction of intra-atrial thrombus :~Hypertension = 1 Heart failure = 1 History of stroke = 1 High plasma d-dimer level (> 270 ng/ml) = 1"
45996782|NCT05174091|Other|Functional Movement Screen, Spinal Mouse, Core Endurance, Funcitonal Capacity|Due to the difficulties in the diagnosis and treatment of NSLBP, it has been causing many problems such as limitation of activation, socioeconomic burden, and biopsychosocial factors for years. It is thought that the effectiveness of treatment will increase if the needs and problems of individuals with NSLBP are clearly revealed beforehand. Although there are studies on core endurance and physical capacities in individuals with NSLBP in the literature, the number of studies examining functional movement analysis and spinal mobility in individuals with NSLBP is very few. Therefore, aim of this research is to compare functional movement analysis, physical capacity, core endurance, and spinal mobility in individuals with and without NSLBP. With the results we will reveal, we aim to contribute to the evaluation and treatment of patients with NSLBP. Thus, the negative effects of this pathology, which causes serious labor and financial losses, can be minimized.
45996783|NCT03616145|Procedure|Osteopathic Manipulative Treatment (OMT)|Experimental Condition
45996784|NCT03616145|Other|Light Touch|Comparator Arm
45996785|NCT03603665|Biological|NTM-1633|NTM-1633 is an equimolar mixture of three IgG1 monoclonal antibodies (mAb), referred to as XE02, XE06, and XE17 which bind to non-overlapping epitopes on Botulinum Neurotoxin (BoNT/E). Administered as a single intravenous infusion of NTM-1633 over one hour.
45996786|NCT03603665|Other|Placebo|0.9% Sodium Chloride Injection administered as a single intravenous infusion over one hour.
45996787|NCT03943641|Other|This is not an intervention study|This study is based on retrospective analysis of linked routinely-collected healthcare data
45996788|NCT03579173|Diagnostic Test|Infant PFT|Assessed through the raised volume rapid thoracoabdominal compression technique and plethysmography
45996789|NCT03579173|Diagnostic Test|Lung Clearance Index|The Lung Clearance Index is derived from the Multiple Breath Washout test. It is the cumulative exhaled volume (the volume of gas needed to wash out resident gas mixture out of the lungs) divided by the FRC. The FRC is the amount of air left in the lungs after normal exhalation.
45996790|NCT03579173|Diagnostic Test|Passive tidal breathing|During quiet sleep, tidal breathing flow-volume curves are obtained. The tPEF/tE is calculated by taking the time it takes to reach peak expiratory flow divided by the total peak expiratory time.
45996791|NCT05172531|Drug|Cisatracurium Besylate|Participants in the test group received Cisatracurium Besylate 0.12mg/kg/hr continuous infusion during intubation。
46085660|NCT04219202|Radiation|Proton radiation|Therapeutic radiation Treatment with Protons
45834624|NCT04393584|Drug|Docetaxel|d1 Docetaxel 50mg/m2 every two weeks
45996792|NCT05172531|Drug|saline 0.12ml/kg/hr|saline 0.12ml/kg/hr
45996793|NCT03570983|Drug|Allopurinol|Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.
45996794|NCT03570983|Drug|Carmustine|Dosage: Carmustine 300 mg/m2 IV x 1 will be infused over 3 hours on autografting day -7. Carmustine should not be infused with solutions or tubing containing or previously containing bicarbonate solution.
45834625|NCT02316366|Device|Astoflo Plus fluid warmer|A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius
45834626|NCT03828864|Device|Pulsed Shortwave Therapy|Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
45834627|NCT03828864|Device|Placebo Pulsed Shortwave Therapy|Placebo Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
45834628|NCT02315352|Drug|L-PZQ ODT|L-PZQ ODT (MSC2499550A) tablet at a dose of 150 milligram (mg) put and disintegrated in the mouth without water
45834629|NCT02315352|Drug|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg put and disintegrated in the mouth without water
45834630|NCT02315352|Drug|L-PZQ ODT|L-PZQ (MSC2499550A) tablet at a dose of 150 mg dispersed in water
45834631|NCT02315352|Drug|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg dispersed in water
45834632|NCT02315352|Drug|Cesol®|Cesol® tablet at a dose of 150 mg crushed in water
45834633|NCT02965950|Drug|Cyclophosphamide|I.v. infusion
46085661|NCT04219202|Radiation|Carbon Ion radiation|Therapeutic radiation Treatment with Carbon Ions
46085662|NCT02701374|Drug|TRK-700|
46085663|NCT02701374|Drug|Placebo|
45996795|NCT03570983|Drug|Etoposide|Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 cc normal saline over 2 hours on autografting days -6, -5, -4, and -3 for a total dose of 800 mg/m2. Etoposide may not be infused with sodium bicarbonate solutions.
45996796|NCT03570983|Drug|Cytarabine|Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on autografting days -6, -5, -4 and -3. Availability and administration: Cytarabine is available in a reconstituted form in solutions containing 20, 50 and 100 mg of cytarabine per mL.
46085664|NCT00631553|Drug|perflutren lipid microspheres|1.3 ml in 30 ml of saline, infused into vein at 2ml / min and titrated for optimal image quality (not to exceed 10 ml/ min at any time).
45996797|NCT03570983|Drug|Melphalan|Melphalan will be administered at a dose of 200 mg/m2 IV x 1 infused over 30 minutes on autografting day -2.
45996798|NCT03925389|Procedure|External septorhinoplasty|A surgical procedure to repair defects or deformities of both the nasal septum and the external nasal pyramid through an external incision at the columella.
45458379|NCT02324452|Drug|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patient that are a heterozygous carrier of a DPYD variant will receive a reduced dosage of capecitabine or 5-fluorouracil (25-50% reduction, depending on which SNP is identified). The dose will be titrated in subsequent cycles, to achieve maximal safe exposure. Patients that are wild type (not carrying any of the for DPYD variants) will receive a normal (full) dose.
45996799|NCT05170815|Procedure|Spine surgery|Implantation of spine Interbody Fusion Devices and/or Posterior fixation System.
45996800|NCT03540758|Drug|Diazoxide|"Non-diabetic participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study."
46085665|NCT05429294|Drug|Pyrotinib|Patients with HER2-positive advanced/metastatic breast cancer are treated with pyrotinib combined with trastuzumab and albumin paclitaxel in the first-line setting.
46085666|NCT04219046|Drug|Naloxégol oxalate|Oral administration once daily
46085667|NCT04219046|Drug|Placebo oral tablet|Oral administration once daily
46085668|NCT00912509|Drug|riboflavin|riboflavin 0.1% is applied every 2 minutes for 30 minutes
46085669|NCT00912509|Device|UVX Light|UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%
46085670|NCT05076032|Drug|OXO-001|OXO-001 oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks approximately.
46085671|NCT05076032|Drug|Placebo|Placebo oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks, approximately.
46085672|NCT04217330|Behavioral|Choice of home-based or centre-based pulmonary rehabilitation|Participants will be offered the choice of HomeBase, a home-based pulmonary rehabilitation program, or the traditional centre-based pulmonary rehabilitation program.
45996801|NCT03540758|Drug|Nicotinic acid|T2D participants will have their blood sugar levels normalized and will additionally receive nicotinic acid infusion based on weight (0.01 mg/kg/min) to lower free fatty acid levels before undergoing the pancreatic clamp study.
45996802|NCT03540758|Drug|Placebo|"Non-diabetic participants will receive placebo and undergo the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive a taste-matched placebo for diazoxide before undergoing the pancreatic clamp study."
45996803|NCT05154045|Other|Experimental Formula|Diabetes-specific study formula
46085673|NCT04217330|Behavioral|Centre-based pulmonary rehabilitation|Participants will be offered a traditional centre-based pulmonary rehabilitation program
46085674|NCT04628741|Behavioral|Dynamic Coaching Model|This is a behavioral intervention which includes metacognitive strategy training and personalized strategy and external aid use training.
46085675|NCT04628741|Behavioral|Apprenticeship Approach|This is a behavioral intervention which includes explicit education about traumatic brain injury, its symptoms, and individuals who may provide assistance post-injury, metacognitive strategy training and personalized strategy and external aid use training.
46085676|NCT02873598|Drug|FOLFIRINOX or gemcitabine/abraxane|Patients will have received induction chemotherapy for 3+ months with either FOLFIRINOX or gemcitabine/abraxane with at least stable disease.
46085677|NCT02873598|Radiation|SBRT|After completion of induction chemotherapy, stereotactic body radiation therapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.
46085678|NCT04622969|Behavioral|Healthy Child Development Program|The Healthy Child Development Program is a family-based intervention focused on strengthening positive behaviors in children, managing misbehavior, and addressing healthy lifestyle choices.
46085679|NCT02701530|Behavioral|Targeted smoking cessation|Smoking cessation program developed in cooperation with and aimed at smokers with low education.
45996804|NCT05154045|Other|Test Meal|Instant oatmeal
46085680|NCT04217486|Other|Patient will be shown a photograph of their knee at 2 weeks postop|Patients who undergo primary TKA surgery will then be shown a photograph of their knee at 2 weeks postoperative.
45996805|NCT05135481|Procedure|phrenectomy|The qualification for phrenectomy in group 1 will be made based on the Amir scale, i.e. a score of 4 and fewer points for the language function (2).
45996806|NCT05135481|Other|Increased lactation support|Management in group 2 will include increased lactation care both during hospital stay and post discharge.
45996807|NCT04678778|Behavioral|Physical and Cognitive Activity|There are three sessions a week for the course of 12 weeks. Each session consists of 5 trials.
45996808|NCT03787797|Diagnostic Test|Echocardiography|Assessment of epicardial adipose tissue thickness
45996809|NCT03187379|Drug|Exparel|Exparel liposomal bupivacaine - 20cc Exparel® + 60cc Bupivicaine
45996810|NCT03187379|Drug|Bupivacaine|60cc Bupivacaine
45996811|NCT03182231|Radiation|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
45996812|NCT03182192|Radiation|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT scan
45996813|NCT05124288|Other|Observations on Relapsed AML Allogeneic Transplanted patients|This is not an interventional clinical study. This is a retrospective/prospective observational study on Relapsed AML Allogenic Transplanted patients. Additional samples will be collected during the standard practice.
45996814|NCT03077360|Behavioral|Lifestyle|Lifestyle changes to lose weight or become more fit
45996815|NCT03722511|Dietary Supplement|Amino Acid Based Medical Food/Drink|Study Compound Enterade® is a medical food drink/beverage composed of a proprietary blend of electrolytes and amino acids.
45996816|NCT02964884|Drug|Lovastatin|Those in the Lovastatin group will receive 20mg of Lovastatin per day for the first two weeks and 40mg of Lovastatin per day starting at week 3 through week 11.
45996817|NCT02964884|Behavioral|reading tutoring intervention|After the initial 12 weeks of Lovastatin or placebo, children will return for one week of intensive, one-on-one tutoring intervention (either reading or sham; Visit 2)
45996818|NCT02964884|Drug|Placebo Oral Tablet|Those in the placebo group will receive a tablet daily
45996819|NCT02964884|Behavioral|"Other Academic sham tutoring"|No reading (sham) tutoring. Children will receive intensive tutoring on a subject other than reading.
45996820|NCT05116176|Device|Implantable cardioverter-defibrillators|500 patients age >65 receiving new primary prevention implantable cardioverter-defibrillators (ICDs).
45996821|NCT02869802|Procedure|Tumour Biopsy|If there is the presence of a tumour lesion amenable to core needle biopsy as judged by a staff interventional radiologist, a minimum of 3 tumour cores will be obtained under CT or US guidance.
45996822|NCT02869802|Other|Serial Collection of Plasma and Serum Samples|Participants will undergo serial collection of plasma and serum samples at baseline and every 4 weeks until end of study.
45996823|NCT04683705|Diagnostic Test|Ultrasound|"High-resolution ultrasound evaluation of the shoulder region to recognize the biceps tendon, subscapularis tendon, supraspinatus tendon, and infraspinatus tendon.~High-resolution ultrasound evaluation for the C5, C6 and C7 nerve roots and the suprascapular nerve over the supraclavicular fossa , in the supraspinatus fossa and in the infraspinatus fossa to obtain the nerve cross-sectional image.~Collecting the shoulder pain-related information, including physical examination results (bicipital groove tenderness, Speed test, Yergason's test, Empty can test, Neer test, Hawkins-Kennedy test and painful arc test) and status of disability using Shoulder Pain and Disability Index (SPADI)."
45996824|NCT02837042|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks.
45996825|NCT04683744|Other|Semi-structured interviews-Patients|The interview guide will consist of questions to elicit the patients thoughts about getting preventive healthcare during the COVID-19 pandemic, including perception of risk, barriers to getting healthcare, and information needed for decision making.
45996826|NCT04683744|Other|Semi-structured interviews-Health system|The interview guide will consist of questions to elicit thoughts from health system leadership, providers, and staff about implementing decision aids, provider notifications, and cancer risk assessments in their health center or healthcare system. The questions may be specific to colorectal cancer screening or more generally about other cancer screenings. The investigators may also ask questions about cancer screening initiatives their health center or healthcare system engaged in during the COVID-19 pandemic.
45996827|NCT02821286|Other|Observational study|Blood sampling
45996828|NCT02750072|Procedure|Infrapatellar Approach|Infrapatellar approach using the surgeon's incision of choice (i.e. patellar tendon split, tendon retraction medial, tendon retraction lateral)
45996829|NCT02750072|Procedure|Suprapatellar Approach|Semi-extended suprapatellar approach using quadriceps split combined with purpose designed percutaneous instrumentation
45996830|NCT05098470|Drug|Metformin|1500-2000 mg per day for 8 weeks
45996831|NCT05098470|Drug|Insulin Glargine|Long-acting insulin for 8 weeks
45996832|NCT05098470|Drug|Dorzagliatin|Oral Glucokinase Activator 75 mg twice daily for 8 weeks
45996833|NCT02710643|Drug|OFATUMUMAB|8 weekly infusion of 1000 mg total dose
45996834|NCT05093205|Drug|PF-06882961|Tablets
45996835|NCT05093205|Drug|Atorvastatin|Tablets
45996836|NCT05093205|Drug|Midazolam|Syrup
45996837|NCT05093205|Drug|Levonorgestrel & Ethinyl Estradiol|Tablet
45996838|NCT00552981|Procedure|inhalation of warm air in a Finnish sauna|three times on three following days, each 2-3 minutes
45996839|NCT00552981|Procedure|inhalation of ambient air in a Finnish sauna|three times on three following days, each 2-3 minutes
45996840|NCT02623751|Drug|KHK2375|"KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily."
45996841|NCT02623751|Drug|Exemestane|"KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily."
45996842|NCT00553215|Procedure|quality-of-life assessment|
45996843|NCT00553215|Procedure|questionnaire administration|
46085681|NCT04217486|Other|Patient will not be shown a photograph of their knee at 2 weeks postop|Patients who undergo primary TKA surgery will not be shown a photograph of their knee at 2 weeks postoperative.
45675190|NCT01621880|Drug|bevacizumab|Patients receive bevacizumab 5mg/kg intravenously over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
45996844|NCT02469155|Drug|ITI-007|
45996845|NCT02469155|Drug|Risperidone|
45996846|NCT02469155|Drug|Placebo|
46085682|NCT04241003|Device|SmartDrive Mx2+|Rear-mounted power assist
45834634|NCT04125108|Other|pulmonary rehabilitation|Pulmonary rehabilitation programs were designed to include both 30 minutes resistance and 30 minutes aerobic exercises. Eight basic resistnace exercises were used incorporating, bench press, leg press, leg curl, leg extension, toe raises, biceps curl, triceps curl, shoulder press. Additionally each exercise training session also included aerobic conditioning exercises ona treadmill or cycle ergometer. Aerobic exercise training was carried out 5 days per week, with each session lasting 30 minutes. All exercise sessions were preceded by a 5-minutes warm up period on a treadmill set.
45996847|NCT03506451|Other|Demographics questionnaires and the FACT HN questionnaire|Patients will complete a baseline survey assessing socioeconomic household information, baseline symptoms, QOL, and financial toxicity, as well as attitudes toward cost conversations and educational handouts.
45834635|NCT05608356|Biological|injectable platelet rich fibrin(i-prf)|I-prf is a second-generation PRP where autologous platelets and leukocytes are present in a complex fibrin matrix and can be obtained from blood using low-speed centrifugation without adding anticoagulants.
45996848|NCT02465606|Drug|Lebrikizumab|Lebrikizumab Dose Level 1 subcutaneous monotherapy was administered SC once every 4 weeks for a total of 3 doses.
45996849|NCT02465606|Drug|Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)|Triamcinolone acetonide 0.1% cream will be supplied as single 454-g jars to be used on the body. Hydrocortisone 2.5% cream will be supplied as single 28-g tubes to be used on the face and intertriginous areas as indicated.
46085683|NCT02701452|Other|COAGO|blood samples for haemostasis and hormonal data
46085684|NCT02749994|Drug|Rosuvastatin|
46085685|NCT02749994|Drug|Ezetimibe|
46085686|NCT04417049|Drug|Pentoxifylline 400 MG|All patients will be provided with pentoxifylline 400 mg to be orally ingested twice daily for 8 weeks.
46085687|NCT00615654|Other|aquatic physical therapy|The aquatic physiotherapy program for the SG was applied twice a week, in groups of six to seven people, with sessions lasting 40 minutes, over a 12-week period. The Control Group protocol included maintenance of the individuals' medication therapy and absence of any physical activity during the study period.
46085688|NCT04217408|Device|Deep brain stimulation|Active continuous deep brain stimulation of the ventral capsule/ventral striatum
46085689|NCT00615732|Procedure|Qigong|18 therapy sessions, during the first 3 months once a week, month 4 to 6 once every second week
46085690|NCT00615732|Procedure|exercise therapy|18 therapy sessions, during the first 3 months once a week, month 4 to 6 once every second week
46085691|NCT04931576|Procedure|no drainage tube applied|No drainage tube implacement after TOETVA
46085692|NCT04214496|Device|Sedline|Intraoperative EEG monitorization
46085693|NCT05429138|Other|biological sampling|Biological sampling: blood and semen
46085694|NCT05429060|Procedure|Hemorrhoidal surgery|All surgical interventions under general or local anesthesia, either in the office or operation room, including any type of injection, excision, ligation, ablation, mucopexy and suturation.
46085695|NCT02862210|Drug|Lithium Carbonate|Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.
45675191|NCT01621880|Drug|Corticosteroid|Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by oral prednisone 60 mg for five days and gradually tapered 15mg every 5 days. When the prednisone dose reached 30mg per day, it was tapered down more slowly (tapered 5mg every week), until a maintenance dose of 10mg per day was reached. The entire intervention lasted two months. At 2 months, prednisone was stopped.
45834636|NCT05608356|Drug|Sham Injection|Sham injection as a placebo injection
45834637|NCT03828474|Drug|Acetazolamide Pill|Acetazolamide pill
45996850|NCT05080530|Drug|Cholecalciferol|Effect of Vitamin D on diabetic neuropathy symptoms
45996851|NCT02464007|Biological|rSIFN-co|Artificial recombinant super-compound interferon (rSIFN-co) is a product of patented technological research made possible through protein modulation by spatial conformation control technology, and was developed by Sichuan Huiyang Life Science and Technology Corporation.
45996852|NCT03495882|Drug|AGEN1884 + AGEN2034|AGEN1884 + AGEN2034 according to protocol design
45996853|NCT00554177|Drug|Medicane (mifepristone)|2 doses of 1200mg, Administered 2-3 days apart
45996854|NCT00554177|Drug|Placebo|2 doses of 1200mg, administered 2-3 days apart
45996855|NCT03487692|Other|Diabetes MESSAGES Program|Health centers in the 2018 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
46002377|NCT03372902|Other|Blood draw|Participants will donate approximately 60ml of peripheral blood. Mononuclear cells from peripheral blood will be used to extract germline DNA. Germline genomic testing will be employed as a matched control for tumor sequencing and for germline breast cancer susceptibility testing.
45996856|NCT03487692|Other|Diabetes MESSAGES Program (second trial)|During the first trial period, health centers in the 2020 Training Cohort will collect data on patients receiving usual care. After the first trial period, health centers in the 2020 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
45996857|NCT02456675|Drug|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
45996858|NCT02456675|Drug|INCB040093|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
45996859|NCT02456675|Drug|itacitinib|The dose of itacitinib will be given orally once daily (QD).
45996860|NCT05074173|Behavioral|Text|These blood pressure values will be automatically uploaded twice daily from a Bluetooth device to a phone application to allow the participant and healthcare team track their blood pressure.
45996861|NCT02456480|Drug|CLS001|topical gel
45996862|NCT02456480|Drug|Vehicle|topical gel
45996863|NCT03425565|Drug|Pembrolizumab|3 weekly cycles of Pembrolizumab administered by IV
45996864|NCT04678700|Other|Chest physiotherapy post-covid19|"The sessions are divided into the following modules;~Directed abdominal-diaphragmatic ventilation (10 times).~Costal expansion exercises with the help of flexion and abduction of the upper limbs. (10 times)(1).~Self-passive stretching of the ribcage and neck muscles, accessory to inspiration. The purpose of the stretching will be to increase the flexibility of the muscles to improve the vital capacity as has already been evidenced in other respiratory diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (25)(26).~Relaxation time;Jacobson's progressive relaxation; we scan the body's condition.~Post-session evaluation by taking the respiratory frequency/ min and the Borg's dyspnea index, and level oxigen after the exercises."
45996865|NCT05073627|Drug|Dicloxacillin|Healthy volunteers will take 2x500 mg dicloxacillin 3 times a day for 30 days. The investigators will measure the baseline concentration of dabigatran and dicloxacillin before start of 30 days of dicloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of dicloxacillin. On day 10 and 28 the investigators will measure the concentration of dabigatran.
45996866|NCT04678739|Drug|Remdesivir|Remdesivir 100 IV Infusion as a lyophilized powder
45996867|NCT04678739|Drug|Tocilizumab|Actemra IV Infusion
45996868|NCT00554255|Drug|SB751689|
45996869|NCT00554333|Biological|Flu-ID 15μg|Inactivated Split-Virion Influenza Vaccine for Intradermal Route
45996870|NCT00554333|Biological|Inactivated adjuvanted Influenza Vaccine|Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
45996871|NCT03418701|Behavioral|Health Smart for Weight Loss|We will test the effectiveness of a culturally sensitive, evidence-based, multi-component, behavioral program for treating obesity called Health-Smart. This program will be implemented for 6 months in 20 UF Health Jacksonville primary care clinics by Community Health Workers (CHWs) with Black women patients who have obesity, and followed by either of two physician-implemented behavioral counseling weight loss maintenance programs that are applied quarterly over 12 months to prevent weight gain. Specifically, we will compare the effects on weight-loss and weight-loss maintenance of (1) Health-Smart plus the Patient-Centered, Culturally Sensitive Weight Loss Maintenance Program (PCS-WLM), and (2) Health-Smart plus the Standard Behavioral Weight Loss Maintenance Program (SB-WLM).
45675192|NCT01621802|Biological|Priorix|One dose administered subcutaneously in the triceps region of the right arm.
45675193|NCT01621802|Biological|M-M-R II|One dose administered subcutaneously in the triceps region of the right arm.
45996872|NCT03368196|Drug|DS-8201a|An antibody drug conjugate
46085696|NCT02862210|Drug|Placebo|Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels.
46085697|NCT04875806|Drug|NC762|NC762 is an experimental antibody drug that may make the immune response more active against cancer
46085698|NCT05323422|Procedure|intravenous Ketamine induction|preoperatively ketamine wll administer in group 1-3
46085699|NCT04834154|Behavioral|Mindfulness|6 weekly 2.0 hour video-conferenced group sessions with the following components: 1) short grounding meditation, 2) check in/review of prior weeks practice and symptoms, 3) educational topic, 3) main meditation, 4) reflection on meditation, and 5) action plan formation
45996873|NCT02436824|Drug|AB001 patch|Two AB001 patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
45996874|NCT02436824|Other|Placebo patch|Two placebo patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
46085700|NCT04834154|Behavioral|Control group|Wait list control
45675194|NCT01621802|Biological|Kinrix|One dose administered by deep intramuscular injection in the upper left deltoid.
45996875|NCT02433158|Drug|Rivipansel|Rivipansel will be infused intravenously every 12 hours up to a maximum of 15 doses.
45675195|NCT01621802|Biological|ProQuad|One dose administered subcutaneously in the triceps region of the left arm.
45996876|NCT05029479|Other|Bonding in NCCLs|bonding agent which can resist moisture and has shorter decalcifying and curing time
45996877|NCT02428088|Drug|Dasotraline|Dasotraline 2 mg once daily
45996878|NCT02428088|Drug|Dasotraline|Dasotraline 4 mg once daily
46085701|NCT04215198|Dietary Supplement|Move3™ (NEM® brand eggshell membrane + KD PUR® brand fish oil)|Dietary supplement combination for the support of joint health.
46085702|NCT04215198|Dietary Supplement|Placebo|Placebo
46085703|NCT02749916|Other|Methods of carotid wall imaging|
46085704|NCT02701140|Procedure|Coronary stenting|Within 1h after the first PCI, patients will be randomized to either ticagrelor or clopidogrel.
45675196|NCT02059291|Drug|Canakinumab|Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution.
45675197|NCT02059291|Drug|Placebo|Matching placebo to canakinumab solution for subcutaneous injection
45675198|NCT02042924|Radiation|FLT PET/CT|Functional marrow imaging using the FLT PET/CT will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
45996879|NCT02428088|Drug|Placebo Comparator|Placebo once daily
45996880|NCT03261609|Other|preterm birth|The study compares young adult subjects born premature (< 29 weeks) versus term (-> 37 weeks)
45996881|NCT02422979|Combination Product|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2|
45996882|NCT02422979|Combination Product|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2|
45996883|NCT02422979|Combination Product|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2|
45996884|NCT02422979|Combination Product|PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
45996885|NCT02422979|Combination Product|PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
45996886|NCT02422979|Combination Product|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
45996887|NCT03230565|Drug|Ropivacaine|Patient will be given a continuous infusion of local anesthetic.
45996888|NCT03230565|Drug|Ropivacaine|Patient will be given a scheduled intermittent bolus of local anesthetic.
45996889|NCT02416076|Device|Ulthera Treatment at EL2|Focused ultrasound energy delivered below the surface of the skin.
45996890|NCT02416076|Device|Ulthera Treatment at EL4|Focused ultrasound energy delivered below the surface of the skin.
45996891|NCT02389985|Drug|CRLX101|
46085705|NCT02701140|Procedure|intracoronary ECG recording|Measurement of ST segment elevation using intracoronary ECG recording
46085706|NCT02701140|Procedure|Coronary Flow reserve|measured with an intracoronary pressure/temperature sensor-tipped guidewire
46085707|NCT02701140|Procedure|Index of Microcirculatory Resistance|measured with an intracoronary pressure/temperature sensor-tipped guidewire
46085708|NCT02701140|Procedure|Fractional Flow Reserve|measurement of Fractional Flow Reserve during hyperemic phase.
46085709|NCT04217564|Behavioral|Nutritional counselling|Nutritional counselling based on the nutritional assessment will be conducted. A booklet that contains the whole instructions and dietary records will be provided to help remembering information and record their application of the plan.
45457363|NCT03515590|Other|Emulsion with solid droplets|This will be a 500 mL beverage emulsion in which the droplets are crystalline. It will have identical composition to the other intervention, i.e. in one the lipid droplets are solid (i.e. crystallized) and the other in which they remain liquid will be introduced at least 7 days apart. The differences in physical state will be achieved simply by changing the temperatures the emulsions are held at. The emulsion will contain 10 % of the lipid palm stearin with 0.4% of the emulsifier sorbitan monostearate (Span60).
45675199|NCT02042924|Device|MRI|MRI imaging will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
45996892|NCT02389985|Drug|Paclitaxel|
45996893|NCT03147612|Biological|Blinatumomab|Given via central catheter
45996894|NCT03147612|Drug|Cyclophosphamide|Given IV
45996895|NCT03147612|Drug|Cytarabine|Given intrathecally or IV
45996896|NCT03147612|Biological|Filgrastim|Given SC
45458380|NCT01351142|Other|blood test and cognitive tests|Specific cognitive tests are performed at day 1, month 6, one year and 2 years Specific Blood samples tests are performed at inclusion, 1 years and 2 years
45996897|NCT03147612|Drug|Methotrexate|Given intrathecally or IV
45996898|NCT03147612|Biological|Pegfilgrastim|Given SC
45996899|NCT03147612|Drug|Ponatinib|Given PO
45996900|NCT03147612|Biological|Rituximab|Given IV
45996901|NCT03147612|Drug|Vincristine|Given IV
45996902|NCT02377895|Drug|Nasapaque Nasal Solution|
45996903|NCT02377895|Drug|Placebo Saline Nasal Solution|
45996904|NCT02365649|Drug|Placebo|Oral Dosing
45996905|NCT02365649|Drug|ABT-494|Oral Dosing
45996906|NCT05018832|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
45996907|NCT03455075|Drug|Dimethandrolone-Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate administered in 100 mg capsules.
45996908|NCT03455075|Drug|Levonorgestrel 0.03 MG|Single doses of LNG administered in 30 mcg capsules.
45996909|NCT03455075|Drug|Placebo oral capsule|Placebo capsules that look like DMAU and LNG capsules but with no active ingredients.
45996910|NCT05007132|Biological|Panitumumab 20 milligram/ML|Participants receive Panitumumab at 6mg/ kg intravenously (IV) on Day 1 and 15 of each 28-day cycle. Treatment is continued until occurrence of progression according to RECIST 1.1 criteria as evaluated by the investigator or unacceptable toxicity.
45996911|NCT05007132|Biological|Bevacizumab|Participants receive bevacizumab at 5 mg/ kg intravenously (IV) on Day 1 and 15 of each 28-day cycle. Treatment is continued until occurrence of progression according to RECIST 1.1 criteria as evaluated by the investigator or unacceptable toxicity.
45996912|NCT05007132|Drug|Trifluridine/Tipiracil Hydrochloride|Participants receive Trifluridine/tipiracil at 35 mg/m² BSA, twice daily, orally on days 1-5 and 8-12
45996913|NCT04684017|Drug|Anlotinib hydrochloride|anlotinib 10 mg/day orally (from days 1 to 14 in a 21-day cycle)
45996914|NCT04684017|Drug|Etoposide|100mg/m2 iv on days 1-3 every 21 days for 4 cycles
45996915|NCT04684017|Drug|Carboplatin|AUC 5 iv on day 1 every 21 days for 4 cycles
45996916|NCT00554450|Drug|Dapagliflozin|Tablets, Oral, once daily
45996917|NCT04683666|Procedure|Bariatric surgery|Laparoscopic Roux-en-Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG), as primary bariatric procedures, were performed. ^Postoperative complications were assessed.
45996918|NCT00554489|Behavioral|exercise intervention|participation in physical activity intervention program weeks 2 through 5
45675200|NCT02041520|Drug|omega 3 fatty acids|omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
46085710|NCT04414280|Device|Medtronic MiniMed 670G|The Medtronic Minimed 670G system is a form of hybrid closed-loop insulin delivery. The Medtronic MiniMed 670G system automatically adjusts basal insulin every five minutes based on CGM readings to reach a glucose target of 120 mg/dL, the SmartGuard Auto Mode. Patients still need to enter their carbohydrate intake and administer meal-time and correction boluses. Before Auto Mode is introduced, the Medtronic MiniMed 670G system has to be worn in Manual Mode. In contrast to Auto Mode, Manual Mode features an insulin stop up to 30 minutes before or when reaching preset low limits (suspend before/on low) and an automatic insulin restart when blood sugar levels recover. During Manual Mode the pump 'becomes familiar with' the daily insulin need of the patient. This information will be used when in Auto Mode.
46085711|NCT04414280|Device|Medtronic MiniMed 780G|The Medtronic Minimed 780G system differs in several aspects from the MiniMed 670G system. In Auto Mode, the user can choose from two target levels for even more stricter glucose control (100 mg/dL and 120 mg/dL) and correction boluses are now automated without the need of user interaction. When administering meal boluses, no capillary blood glucose value is required. The safety feature to exit from Auto Mode to Manual Mode was too strict in the Minimed 670G. In the Minimed 780G this is more flexible to overcome this frequently reported patient frustration.
46085712|NCT04414280|Device|Tandem Control-IQ|The Tandem t:slim X2 Control-IQ consists of the Tandem t:slim X2 insulin pump with Control-IQ technology, and integrates with the Dexcom G6 CGM-device via Bluetooth. Blood glucose readings for calibration are not required. The Tandem t:slim X2 Control-IQ automatically adjusts basal insulin based on CGM readings to reach a glucose target range between of 112-160 mg/dL. Patients still need to enter their carbohydrate intake and administer meal-time boluses, but the system automatically increases the basal insulin dose or gives automated correction boluses in case of high blood glucose levels. The technology offers optional settings for sleep and exercise, with different glucose targets in order to match the insulin need during these activities. New versions of the pump software can be downloaded and installed remotely via the user's own computer.
46085713|NCT03239418|Device|Neuromuscular electrical stimulation|A low level electrical current is applied to the muscle that control eyelid function through small electrodes applied to the skin over the target muscles. Treatment is applied daily for 5 consecutive days and exercises for eyelid function are performed in conjunction with the stimulation.
45675201|NCT02041520|Other|placebo|olive oil in similar presentation of omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
45675202|NCT04699994|Drug|FLOT therapy|Preoperative FLOT therapy
45675203|NCT04711226|Drug|AT-1501|AT-1501 IV infusion
45675204|NCT04699292|Procedure|Surgery|Surgery
45675205|NCT04699292|Radiation|Preoperative RT 36Gy|Preoperative radiotherapy to 36Gy (equivalent)
45675206|NCT04699292|Radiation|Preoperative RT 50Gy|Preoperative radiotherapy to 50Gy (equivalent)
45996919|NCT00553020|Drug|Insulin glargine|"Lantus (commercial formulation, Reference):~10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)~NPH-insulin (Protaphan) (Test):~10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)"
45996920|NCT00554528|Device|cervical disc prosthesis with a mobile insert named Mobi-C|"Stage 1: partial discectomy~stage 2: location of the medial axis~stage 3: centering pin~stage 4: installation of the caspar spacer~stage 5: total discectomy~stage 6: parallel distraction~stage 7: depth measurement~stage 8: trial implant~stage 9: assembly~stage 10: implant insertion~stage 11: anchorage optimization"
45675207|NCT04699292|Radiation|Postoperative RT 50-66Gy|Postoperative radiotherapy to 50-66Gy (equivalent)
45675208|NCT04699292|Radiation|RT 36Gy|Definitive radiotherapy to 36Gy (equivalent)
45675209|NCT02041429|Drug|Ruxolitinib|
45675210|NCT02041429|Drug|Paclitaxel|
45675211|NCT04699981|Other|Control (Patients colonized rectally with ESBL-producing enterobacteria without antibiotic pressure)|"For patients included in the Control group on discharge from hospitalization and 60 days after inclusion of patients, data will be collected either from the patient's medical file (T1Control) or during '' a telephone call from the patient (T2Control). The data collected concerns the occurrence of an infectious episode. They will also benefit from a stool sample at T1 control in order to assess the evolution kinetics of the relative fecal abundance of ESBL-producing enterobacteria in these patients who are not subjected to antibiotic pressure but subjected to other drug pressures (PPI, corticosteroids, etc.)."
45675212|NCT04699981|Other|Case (Patients colonized rectally with ESBL-producing enterobacteriaceae, with antibiotic pressure)|"A stool culture is performed on the first stool emitted after the start of antibiotic therapy. 72 hours after the start of antibiotic therapy, a blood sample (5 ml) and a stool sample will be taken. A stool sample will be taken at the end of the antibiotic therapy and 60 days after the end of the antibiotic therapy. In the event of normal transit (daily bowel movements), the stool emitted 48 hours after the start of antibiotic therapy will be analyzed. If the patient does not pass stool, an eswab rectal swab will be taken. In the event of discharge from the hospital before the end of the antibiotic therapy and / or the D60 after the end of the antibiotic therapy, the patient will be given a prescription and an appointment at the collection center of the center concerned for the sample stool."
45675213|NCT02083783|Drug|TRI102|formulation containing active moiety (amphetamine)
45675214|NCT02083783|Other|Placebo|formulation without active moiety
45996921|NCT00554528|Procedure|arthrodesis - cervical disk surgery|discectomy and arthrodesis
45996922|NCT04683198|Drug|camrelizumab|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6) and maintenance phase ,until PD.
45996923|NCT04683198|Drug|Apatinib Mesylate|Apatinib capsules 250 mg given orally , once daily in 21-day cycle and maintenance phase,until PD.
46085714|NCT03239418|Device|Sham neuromuscular electrical stimulation|Electrodes are applied to the skin over the target muscles and patient perform the exercises for eyelid function for 5 consecutive days just as in the experimental group, However participants do not receive the electrical stimulation. Due to the low intensity of the stimulation all participants regardless of group allocation are told they may or may not feel the electrical stimulation.
46085715|NCT02701218|Procedure|Canalith repositioning procedure|Canalith repositioning procedure; single or multiple cycles
46085716|NCT04515212|Other|Optic Nerve Ultrasounds|Patients will have up to four ultrasounds of the optic nerve.
46085717|NCT00616980|Biological|CD34-positive cells|
46085718|NCT00616980|Biological|CD34-positive cells|
46085719|NCT00616980|Biological|Saline and 5% autologous plasma|
45996924|NCT04683198|Drug|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6).
46085720|NCT02700906|Drug|Corticosteroid|triamcinolone (10mg/ml) 1 ml will be injected to the lateral epicondyle of the affected elbow.
45675215|NCT04698109|Other|Biological sample collection|Collection of faeces, urine, saliva, vaginal swab for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
45996925|NCT04683198|Drug|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6).
46085721|NCT02700906|Drug|Lidocaine|For lidocain injection, 1ml 1% lidocain will also be peppered on the same area.
46085722|NCT04217252|Diagnostic Test|PMseqTM high-throughput sequencing technology|high throughput sequencing of infectious pathogens
46085723|NCT02700672|Other|Observational study|Observational study: kinematic variables, falls and executive function were analyzed
46085724|NCT02749760|Other|Strengthening program|Strengthening programs may be established to target the stabilizers of the elbows
46085725|NCT02749760|Other|Exercise program|Exercise program may be established to target the stabilizers of the elbows.
46085726|NCT04213638|Other|Single Microneedle Radiofrequency therapy|Subjects are treated with three consecutive sessions of Single Microneedle Radiofrequency therapy at 2-week intervals, with a follow-up visit 12 weeks after the final third treatment. Each treatment session took approximately 30-60 minutes.
46085727|NCT04213638|Other|Photodynamic therapy|Subjects are treated with three consecutive sessions of Photodynamic therapy at 2-week intervals, with a follow-up visit 12 weeks after the final third treatment.
45996926|NCT00554567|Behavioral|HIV Testing and Care Services|Fully-decentralized HIV Voluntary Counseling and Testing and referral for care
45996927|NCT02346422|Genetic|MYDICAR Phase 1|Single dose of MYDICAR
45996928|NCT02346422|Genetic|MYDICAR Phase 2|Single dose of MYDICAR
45996929|NCT02346422|Genetic|Placebo Phase 2 only|Single dose of placebo
45996930|NCT03075423|Drug|Ipilimumab plus nivolumab|Ipilimumab every 3 weeks for 4 times Nivolumab every 3 weeks for 4 times followed by maintenance therapy with nivolumab every 2nd or 4th week
46085728|NCT04753424|Procedure|Surgical technique|Description of novel surgical technique using autologous semitendinosus graft as meniscus transplant.
46085729|NCT02700750|Device|OCT exam|OCT exam
46085730|NCT00636038|Dietary Supplement|corn beta-carotene|yellow corn beta-carotene in a 1 mg level to be taken as corn porridge in one meal by volunteers
45458381|NCT02324530|Device|Continuous positive airway pressure (CPAP)|CT simulation with and without CPAP
45675216|NCT04698109|Other|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
45996931|NCT03075423|Drug|Standard Therapy|Standard of Care therapy is administered according to the physician´s decision.
45996932|NCT03048552|Behavioral|Family CONNECT|Linkage specialists, who are clinical social workers and embedded within the probation departments, will work with specifically caregiver-youth dyads in the Family CONNECT arm to link youth to substance use services.
46085731|NCT00616512|Procedure|GF Strong Water Protocol|The Purpose of the GF Strong water protocol is to allow clients who have thin liquid dysphagia to drink water under certain specified conditions according to the rules of the water protocol.
45996933|NCT02342249|Drug|VX-787 300 mg|A oral dose of 300 mg VX-787 tablet will be administered over 5-6 days.
45996934|NCT02342249|Drug|VX-787 600 mg|A oral dose of VX-787 600 mg (formulated as 2*300 mg tablets) will be administered over 5-6 days.
45996935|NCT02342249|Drug|Oseltamivir 75 mg|A oral dose of 75 mg Oseltamivir capsule will be administered over 5-6 days.
45996936|NCT02342249|Drug|Placebo|Subjects will receive matching placebo of Oseltamivir
46085732|NCT04723004|Combination Product|Toripalimab combined with Bevacizumab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Bevacizumab 15mg/kg, IV infusion, every 3 weeks (q3w), Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
46085733|NCT04723004|Drug|Sorafenib|"Control group:~Sorafenib 400mg, po, Bid, continuous administration, until occurrence of termination event specified in the protocol."
46085734|NCT04188054|Behavioral|Change in sleeping position|The new sleeping position requires you to re-position yourself in your bed when lying on your back so that your feet (and ankles) hang over the end of the mattress, i.e. off the end of the bed.
45996937|NCT04683276|Procedure|pars plana vitrectomy with ILM inverted flap|Complete vitrectomy was done with the aid of triamcinolone acetonide followed by fluid-air exchange. Staining of the ILM was carried with 0.05% solution of Brilliant Blue dye (BBG), (Ocublue plus, Aurolab, India) for 30 seconds, ILM peeling was proceeded leaving a circle of ILM measuring approximately 1-2 DD in SF groups and >2 to 4DD in LF group, centered around the MH. The ILM outside the parafoveal area was peeled to the arcade. The ILM around the hole was then detached from the retina up to the edge of the hole. The ILM flap around the edge of the hole was inverted over the MH using a scraper.
45996938|NCT02933970|Other|Telemedicine|Patients will be linked with the provider via two-way video-teleconferencing facilitated by an onsite OAT program staff member
45996939|NCT02339129|Drug|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
45457364|NCT03515590|Other|Emulsion with liquid droplets|This will be a 500 mL beverage emulsion in which the droplets are liquid. It will have identical composition to the other intervention, i.e. in one the lipid droplets are solid (i.e. crystallized) and the other in which they remain liquid will be introduced at least 7 days apart. The differences in physical state will be achieved simply by changing the temperatures the emulsions are held at. The emulsion will contain 10 % of the lipid palm stearin with 0.4% of the emulsifier sorbitan monostearate (Span60).
45457365|NCT01349426|Device|LigaSure Force Triad Vessel Sealing System|Quality of parenchymal pneumostasis comparison after fissure closure: LigaSure vs automatic staplers
45675217|NCT04698109|Other|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
45996940|NCT02339129|Drug|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
45996941|NCT04678622|Device|Bioferula3D|Custom splint with 3D technology classified as a custom medical device
45996942|NCT04971798|Biological|Cell-free Stem Cell-derived Extract Formulation (CCM)|Intraarticular injection
45996943|NCT04678388|Drug|Reference drug|1 Cap., single oral administration under fasting condition
45996944|NCT04678388|Drug|Test drug 1|1 Tab., single oral administration under fasting condition
45996945|NCT04678388|Drug|Test drug 2|1 Tab., single oral administration under fasting condition
45996946|NCT02884206|Drug|LCZ696|LCZ696 50, 100, and 200 mg tablets taken orally twice daily with matching placebo for valsartan
45996947|NCT02884206|Drug|Valsartan|Valsartan 40, 80, and 160 mg tablets taken orally twice daily with matching placebo for LCZ696
45996948|NCT02884206|Drug|Placebo of LCZ696|Placebo to match LCZ696 50 mg, 100 mg, and 200 mg tablets
45996949|NCT02884206|Drug|Placebo of Valsartan|Placebo to match valsartan 40 mg, 80 mg, and 160 mg tablets
46002378|NCT03372902|Procedure|Breast Biopsy|Tissue specimens from the biopsy of the BI-RADS 4 mammographic lesion and (among women undergoing surgical excision) the surgical specimen(s) will be subjected to genomic profiling at GRAIL, Inc. or MSKCC. The tumor specimens from the participants diagnosed with cancer during the follow-up period will also undergo molecular profiling.
46002379|NCT03372902|Behavioral|online participant reported questionnaire|Participants will be asked to complete a questionnaire that covers the topics of breast health, general health and lifestyle, genetic testing, personal, and family history of cancer.
46085735|NCT04188054|Behavioral|No change in sleeping position|No change to your normal sleeping position
46085736|NCT04702100|Other|instrument assisted soft tissue mobilization|the patients will receive instrument-assisted soft tissue mobilization:The subject was seated in a relaxed sitting position. M2T blade was used to find specific areas of restriction on RT upper trapezius. Then treatment plane 1 - 2 and 3 were used.The lubricant (Vaseline) was applied to the skin around the neck area prior to treatment and the tool was cleaned with an alcohol preparation pad. Then by using M2T blade with angle 45, we were giving long slow strokes without causing any discomfort or pain over muscle starting from its insertion up to its origin approximately for 2 to 3 min repeated two times.
45996950|NCT04678973|Behavioral|Self-compassion mindfulness practice|"Guided Mindfulness Practice: Participants in the intervention group will receive compassion-based guided meditation audio recordings. Recordings will target self-compassion and body concerns simultaneously.~Psychoeducation: Participants in the intervention group will receive psychoeducation delivered via daily PDF over days 1-6. Psychoeducation will orient users to their upcoming experience, provide education about internalized weight bias, the chronic stress system, the utility of self-compassion practice to regulate physiological and psychological targets, and guidance on establishing, maintaining, and generalizing a mindfulness practice.~Daily prompts: Participants will receive a text message every morning indicating their task for that day.~Weekly prompts: Participants will receive a text message at the end of every week (Days 7, 14, 21, and 28) with a link to a brief adherence survey."
45996951|NCT04961541|Biological|ICC Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
45996952|NCT04961541|Biological|qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant|Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70.
45675218|NCT02083081|Behavioral|Community level intervention|Community intervention plus individual counseling
45996953|NCT04961541|Biological|SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant|Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56.
45996954|NCT02326454|Drug|talaporfin sodium|1 mg/kg
45996955|NCT02326454|Drug|Saline|
45996956|NCT02326454|Device|Drug Activator 100 J/cm|Light Dose: 100 J/cm
45996957|NCT02326454|Device|Drug Activator 200 J/cm|Light Dose: 200 J/cm
45996958|NCT02871219|Drug|Lenalidomide|Given PO
45675219|NCT02040805|Behavioral|Group Cognitive Behavioral Therapy|"Group therapy over approximately 20 weeks, based on a structured manual adapted from the individual CBT workbook for hoarding by Steketee and Frost (2006). Each session will be 2 hours in length and consists of weekly check-ins, psychoeducation about hoarding, developing understanding and awareness of one's hoarding symptoms and patterns, behavior modification, cognitive restructuring, goal-setting, motivational enhancement, in vivo and imaginal exposure for discarding and acquisition, executive skills training (organization, sorting, planning, decision-making, problem-solving, etc.), guidelines on establishing clutter buddies, and relapse prevention. Groups will be led by clinical postdoctoral psychology fellows in the Department of Psychiatry at UCSF."
45675220|NCT02040805|Behavioral|Peer Facilitated Support Group|Fifteen sessions of peer facilitated, group support, over the course of 20 weeks, based on a structured manualized approach (Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding). Each session will be 2 hours in length. In this model, two trained peers, usually, but not necessarily, with personal lived experience of hoarding, will guide the group chapter by chapter through the Buried in Treasures manual.
45675221|NCT02059135|Biological|Recombinant human antithrombin (ATryn)|Atryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days
45834638|NCT04394364|Device|Bispectral index|The BIS monitor will be attached to patients' forehead before anesthetized and kept until the end of the surgery
45834639|NCT05608122|Other|Obervation|This study is an observational study without any intervention
45996959|NCT02871219|Biological|Obinutuzumab|Given IV
45996960|NCT02324309|Drug|BIOD-531|
45996961|NCT02324309|Drug|Humalog Mix 75/25|
45996962|NCT02324309|Drug|Humulin R U-500|
46085737|NCT04702100|Other|integrated neuromuscular inhibition technique|will receive integrated neuromuscular inhibition technique: from supine lying position.we the patients will perform ischemic compression at trigger points then positional release technique and finally muscle energy technique.
46085738|NCT04702100|Other|conventional therapy|the patients will receive hot back for 10 minutes, active range of motion exercise, chin tuck, stretches
45457366|NCT02302456|Drug|Tranexamic Acid|Intravenous administration of a 10 mL solution containing 1g of tranexamic acid within 2 minutes of birth and routine prophylactic IV injection of oxytocin
45834640|NCT05608122|Other|Obervation|This study is an observational study without any intervention
45834641|NCT04120818|Procedure|secondary IOL implantation|reopened the fibrotic, closed capsular bag and achieve IOL placement
45834642|NCT04120818|Procedure|primary IOL implantation|lensectomy and anterior vitrectomy and primary IOL implantation
45834643|NCT03043950|Drug|Panitumumab|Patients will be scheduled to receive first line therapy with the combination of Panitumumab (6 mg / kg i.v, given once every two weeks) and FOLFIRI or FOLFOX, according to current SmPC.
45834644|NCT03822156|Other|Observation of AFB smear/culture|Observation of the patients from group for their AFB smear/culture results
45834645|NCT03822234|Procedure|Modified ileal conduit|Modified ileal conduit (Extraperitonealization)
45834646|NCT02923206|Device|TheraSorb sFlt-1 adsorber|Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis.
45996963|NCT02324309|Drug|BIOD-531|
45996964|NCT04941456|Other|Open Tracheostomy|Participants will perform the six minute walk test with an open tracheostomy. Participants will complete 1 to 3 session over approximately three-weeks.
45996965|NCT04941456|Device|PMV in place|Participants will perform the six minute walk test with a PMV in place. Participants will complete 1 to 3 sessions over approximately three-weeks.
45996966|NCT02307851|Biological|Quadrivalent VLP Vaccine|
45996967|NCT02307851|Biological|Comparator TIV|
45996968|NCT02826213|Device|LifePort® perfusion device|Renal Perfusion with LifePort® perfusion device
45996969|NCT02826213|Device|Waves perfusion device|Renal Perfusion with Waves perfusion device
45996970|NCT02306291|Drug|GMI-1271|E-selectin antagonist
45996971|NCT02306291|Drug|Mitoxantrone|induction chemotherapy
45996972|NCT02306291|Drug|Etoposide|induction chemotherapy
45996973|NCT02306291|Drug|Cytarabine|induction chemotherapy
45996974|NCT02306291|Drug|Idarubicin|induction chemotherapy
45996975|NCT02302079|Drug|ASP8232|oral capsule
45996976|NCT02302079|Drug|ranibizumab|intravitreal (IVT) injection
45996977|NCT02302079|Drug|Placebo|oral capsule
45996978|NCT02302079|Other|Sham intravitreal (IVT) injection|intravitreal (IVT) injection
45996979|NCT01210495|Drug|Axitinib (AG-013736)|Axitinib [tablet, 1 mg, 5 mg] will be given twice daily [BID] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
45675222|NCT02059135|Other|Normal Saline 0.9%|Placebo Comparator: Normal Saline 0.9%
45996980|NCT01210495|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
45834647|NCT03827928|Behavioral|Yoga/meditation|A 6-week yoga and meditation program with psychoeducation components, delivered through community-based yoga sessions. This program offers structured instruction: 10 minutes of breathing exercises to calm the nervous system, 45 minutes of gentle yoga to improve strength, flexibility, and balance, 15 minutes of guided meditation to enhance attention control, emotional regulation, and self-efficacy, and 20 minutes of facilitated discussion with psychoeducation to build community connection and skills in resilience.
45996981|NCT01210495|Drug|Placebo|Placebo [tablet, 1 mg, 5 mg] will be given twice daily [BID] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
45996982|NCT01210495|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
45996983|NCT02289716|Drug|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
46085739|NCT02700594|Other|Joint mobilization|"Mobilization and manipulation are manual therapy techniques comprising a continuum of skilled passive movements to the joints and/or related soft tissues that are applied at varying speeds and amplitudes, including a small-amplitude/high- velocity therapeutic movement.16 The term joint mobilization, or nonthrust mobilization, often refers to slow, rhythmic, repetitive passive movements to the patients' tolerance, in voluntary and/or accessory range and graded according to examination findings."
46085740|NCT05428748|Other|1 serving of test product|Participants will consume 1 serving/day of the test product for 28 days
45996984|NCT02289716|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
46085741|NCT05428748|Other|2 servings of test product|Participants will consume 2 servings/day of the test product for 28 days
46085742|NCT05428748|Other|3 servings of test product|Participants will consume 3 servings/day of the test product for 28 days
45457367|NCT02302456|Drug|Placebo|Intravenous administration of 10 mL of 0.9% sodium chloride solution within 2 minutes of birth and routine prophylactic IV injection of oxytocin
45675223|NCT02081677|Device|ACUVUE 2|worn in a daily wear modality; lenses will be replaced after 2 weeks
45675224|NCT02081677|Device|Prototype E1|worn in a daily wear modality; lenses will be replaced after 2 weeks
45675225|NCT02081677|Device|Prototype E2|worn in a daily wear modality; lenses will be replaced after 2 weeks
45834648|NCT04392414|Biological|COVID-19 convalescent hyperimmune plasma|Subjects to receive double convalescent hyperimmune plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
45996985|NCT02289716|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
45996986|NCT04922697|Other|Educational Intervention|Watch educational videos and use wearable air pollution sensor
45996987|NCT04922697|Other|Questionnaire Administration|Complete questionnaires
45996988|NCT02289092|Behavioral|Family Check-Up|Parents fill out questionnaires about their child and families and then participate in a videotaped interaction with their child. Clinicians then observe the video and analyze the questionnaires to establish family needs based on supports, stress, parenting, values, and strengths. Therapists then use this information to inform the intervention process and provide feedback to families with the use of motivational interviewing. parents identify goals for parenting and/or child behavior and to connect them with resources when needed. Feedback includes a discussion of goal attainment and plans to achieve goals. Goal achievement includes options such as (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
46085743|NCT05428748|Other|Placebo|Participants will consume 1 serving/day of the placebo for 28 days
46085744|NCT04213716|Combination Product|silver nano particulate solution mixed with calcium hydroxide powder|1ml of nanosilver solution 30ppm concentration mixed with 100 mg of calcium hydroxide powder used as intracanal medication
46085745|NCT04213716|Combination Product|conventional calcium hydroxide|1ml of distilled water mixed with 100 mg of calcium hydroxide powder and used as intracanal medication after root canal retreatment
46085746|NCT04218890|Diagnostic Test|Urinary tissue factor (TF), tissue factor pathway inhibitor (TFPI) and plasmin|urinary sample
45675226|NCT02081677|Device|Prototype E3|worn in a daily wear modality; lenses will be replaced after 2 weeks
45996989|NCT04918095|Device|CareCOPD Platform|The subjects will be provided with CareCOPD devices for home monitoring of airway impedance, medication use, and symptoms data.
46085747|NCT02774538|Other|Agreement between oral and cervical HPV infection|"A total of 165 women will have a Pap test and an oral brushing performed on the day of inclusion. Risk factors for oral HPV infection will be defined using a self-administered survey summarizing the demographics and sexual behaviors.~A second oral brushing up to 18 months will be performed during a standard follow-up visit."
45996990|NCT02267642|Biological|AbGn-168H|monoclonal antibody
45996991|NCT04917822|Behavioral|Emotion regulation|Emotion regulation arm will provide the parents and children with four 2-hour weekly sessions. For the parents, the main topics include raising awareness of emotions (e.g., learning emotions theories), developing skills to manage emotions (e.g., attention deployment, cognitive changes, response modification), and facilitating parent-child relationship (e.g., gratitude). For children, the main topics are similar to that in parents' intervention. In this arm, we give more specific examples and simple explanations to the children.
45996992|NCT04917822|Behavioral|Information provision|Information provision arm will provide the parents and children with four 2-hour weekly sessions. For the parents, the main topics in these four sessions include learning the general information about Hong Kong such as education and medical care, housing condition, employment and training. For children, the main topics include learning the general information about Hong Kong, such as education, community facility, and learning method.
45996993|NCT02267525|Drug|Velusetrag|
45996994|NCT02267525|Drug|Placebo|
45996995|NCT04678076|Drug|Ketoprofen Lysine|A single oral dose of test product - ketoprofen 25 mg/5 ml oral gel stick pack - will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
45457368|NCT01356446|Procedure|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implemented
45675227|NCT04720105|Drug|Duobrii®|Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) will be provided at weeks 0,2,8,16 for a total of 24 weeks.
45675228|NCT04720027|Diagnostic Test|Duplex imaging|Completion of AVVQ and EQ5D questionnairs
45996996|NCT04678076|Drug|Ketoprofen Oral Product|A single oral dose of reference product as a single dose of half of a bipartite sachet of OKi® 80 mg granules for oral solution will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
45996997|NCT00554645|Behavioral|multi-disciplinary group intervention|children:weekley session in 6 months, monthly sessions for 6 months parents: bi-monthly sessions for 6 months, monthly sessions for 6 months
45996998|NCT00554645|Other|traditional information|1 session of nutritional advise for parents and child and 1 follow-up after one month
45675229|NCT04695769|Drug|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin|Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir with weight-based Ribavirin for 12 weeks.
45675230|NCT04695769|Drug|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]|Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir for 12 weeks.
45996999|NCT02257619|Drug|Itacitinib|Itacitinib tablets administered orally at 400 mg QD for Part 1 of the study.
45997000|NCT02257619|Drug|docetaxel|Administered as an intravenous infusion in the clinic at 75 mg/m^2 Q3W for Part 1 of the study.
45997001|NCT04683471|Device|Stimulator|Neuromodulation
45997002|NCT04683471|Device|Sham|Sham
45997003|NCT02235272|Drug|XG-102|Comparison of XG-102 versus placebo sub-conjunctival injection efficacy
45997004|NCT02235272|Drug|Placebo|comparison of XG-102 versus placebo sub-conjunctival injection efficacy
45997005|NCT04891302|Drug|Clevudine|Clevudine 150mg (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
45997006|NCT04891302|Drug|Placebo|Matching Placebo (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
45997007|NCT02229929|Drug|Part A: Placebo|Part A: Single i.v. dose of Placebo administered after each dialysis session over a 1 week treatment period (3 times per week)
46085748|NCT04217018|Diagnostic Test|Prediction of molecular pathology|Prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI
45997008|NCT02229929|Drug|Part A: CR845 0.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
45997009|NCT02229929|Drug|Part A: CR845 1.0 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
45675231|NCT04417309|Behavioral|Experimental|Behavioral: Moderate Intensity Exercise The moderate-intensity aerobic exercise session will consist of walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes.
46085749|NCT00636116|Biological|Crotalinae (pit viper) equine immune F(ab)2|Anavip with Anavip Maintenance Therapy
46085750|NCT00636116|Biological|Crotalinae (pit viper) equine immune F(ab)2|Anavip with Placebo Maintenance Therapy
46085751|NCT00636116|Biological|Crotalidae Polyvalent Immune Fab, ovine|CroFab with CroFab Maintenance Therapy
46085752|NCT04772196|Drug|Vitamin D3|50,000 IU Vitamin D3 weekly for 8 weeks
46085753|NCT02749448|Other|mesenchymal stem cell|There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers
46085754|NCT04215510|Procedure|endonasal endoscopic surgery|143 patients will undergo endonasal endoscopic surgery
45457369|NCT02300662|Device|Cycle Ergometer|Passive movement of the cycle ergometer will execute alternate flexions and extensions of the patients' knee and hips bilaterally for 20 minutes consecutively.
45457370|NCT02300662|Other|Conventional physiotherapy|Manual bronchial hygiene exercises: vibrocompression, manoeuvres with a manual resuscitator (bag squeezing) and aspiration of secretions where necessary.
45675232|NCT04417309|Behavioral|Active Control|Behavioral: Low Intensity Exercise Control participants will maintain light-intensity activity (i.e., walking at ~50% of MHR) for 30 minutes.
46085755|NCT04215510|Radiation|radiation therapy(IMRT)|143 patients will undergo radiation therapy.
45997010|NCT02229929|Drug|Part A: CR845 2.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
45997011|NCT02229929|Drug|Part B: Placebo|Part B: Single i.v. dose of Placebo administered after each dialysis session over a 2 week treatment period (3 times per week)
45997012|NCT02229929|Drug|Part B: CR845 1.0 mcg/kg|Part B: Single i.v. dose of CR845 administered after each dialysis session over a 2 week treatment period (3 times per week)
45997013|NCT04857645|Drug|ASTX727|Eligible patient started ASTX727 between 40 and 130 days after allogenic stem cell transplantation
45997014|NCT04857645|Other|Donor Lymphocyte Infusions|In absence of previous grade 2-4 or chronic graft-versus-host disease (GVHD), DLI will be administered at increasing doses the first day of ASTX727 cycles
46085756|NCT02749604|Procedure|Non-ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate
45457371|NCT01356524|Drug|Additional vaginal progesterone|The progesterone dose will be raised from 200 mg daily to 300 mg daily
45675233|NCT04694911|Behavioral|Focus Group|Participate in focus group
45675234|NCT04694911|Other|Interview|Complete cognitive interview
45675235|NCT04694911|Other|Research or Clinical Assessment Tool|Receive OOCAT
45675236|NCT04694521|Procedure|openSide to end colorectal anastomosis .|open Side to end colorectal anastomosis
45675237|NCT04694521|Procedure|open end end to end stapler anastomosis|open end to end stapler anastomosis
45675238|NCT02038933|Drug|Nivolumab|
45675239|NCT02081599|Drug|Teneli (Teneligliptin)|
45457372|NCT02302534|Device|MRI|MRI
45675240|NCT02081599|Drug|Placebo|
45675241|NCT02081599|Drug|Insulin|
45997015|NCT02224235|Drug|Aspirin|75-325 mg q.d. aspirin until study completion (recommended indefinitely for stent patients)
45997016|NCT02224235|Device|Resolute Integrity DES|Resolute Integrity DES
45997017|NCT02224235|Device|COBRA PzF|
46085757|NCT02749604|Procedure|Ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate with preservation of the ejaculatory hood
46085758|NCT05428670|Drug|Zanubrutinib+Rituximab+Lenalidomide|Zanubrutinib is a bruton' s tyrosine kinase inhibitor independently developed in China.
46085759|NCT05428670|Drug|RCHOP/RCDOP|RCHOP/RCDOP is the classic treatment of diffuse large B cell lymphoma.
46085760|NCT02700282|Behavioral|Backpack Carrying|A 12,5% of body weight backpack will be used for each measurement. Lung function will be assessed while carrying a double strap backpack, a mono shoulder backpack and without a backpack.
46085761|NCT00635726|Drug|Methotrexate|Methotrexate intravenous (IV) 30 mgr/m2 on day 1 every 2 weeks for 6 courses
46085762|NCT00635726|Drug|Vinblastine|Vinblastine IV 3 mgr/m2 on day 1 every 2 weeks for 6 courses
46085763|NCT00635726|Drug|Doxorubicin|Doxorubicin IV 30 mgr/m2 on day 2 every 2 weeks for 6 courses
46085764|NCT00635726|Drug|Cisplatin|Cisplatin IV 70 mgr/m2 on day 2 every 2 weeks for 6 courses
46085765|NCT00635726|Drug|Cisplatin|Cisplatin IV 70 mgr/m2 on day 1 every 3 weeks for 4 courses
45457373|NCT01232023|Drug|Indobufen|Single Oral Dose of
45834649|NCT04392414|Biological|Non-convalescent fresh frozen plasma (Standard plasma)|Subjects to receive double standard plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
45834650|NCT03828084|Drug|Decitabine|Combination drugs containing decitabine and tetrahydrouridine
45834651|NCT03827772|Other|Fecal Microbiota Transplantation|30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
45834652|NCT03827772|Other|Standard of care treatment|Nutritional supplementation, supportive management.
45834653|NCT03822000|Other|Survival|Elderly patients with fall-induced femoral fracture who were survived.
45834654|NCT03822000|Other|Death|Elderly patients with fall-induced femoral fracture who were dead.
45997018|NCT02224235|Drug|DAPT|At the discretion of the investigator as to which DAPT is administered (per local practice)
45997019|NCT02585622|Biological|Mesenchymal Stromal Cells|Cells will be administered intravenously at 3 different doses (80, 160, or 240 x 10^6, fixed dose) over 10-20 minutes. Volume total of fluid infused: 40 ml
45997020|NCT02585622|Other|Placebo|Volume total of fluid infused: 40 ml
45997021|NCT02529852|Drug|Lenalidomide|"Phase I Starting Dose Level: 15 mg by mouth on Days 1 - 14 of each 21 day cycle.~Phase II Starting Dose Level: Maximum tolerated dose from Phase I."
45457374|NCT01318772|Device|Radiography and Fluoroscopy Imaging System|"KALARE (DREX-KL80) is a new high resolution digital system designed for digital spot imaging, with the primary goal to address R/F and DSA clinical applications and produce images in a digital format.~The system includes a new digital camera and a new image processor."
45457375|NCT02300740|Dietary Supplement|Nicotinamide riboside|NIAGEN, ChromaDex
45997022|NCT02529852|Drug|Obinutuzumab|Phase I and II: 1000 mg by vein on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6.
45457376|NCT05401981|Other|Story checklist|The story checklist consists of a couple of questions that gives the physician something to keep in mind while visiting the patients.
45457377|NCT01318850|Behavioral|Cognitive Remediation Therapy|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.
45457378|NCT01318850|Behavioral|Psychoeducation|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
45457379|NCT01318850|Other|Healthy controls|No intervention
45834655|NCT02315430|Drug|Cabozantinib S-malate|Given PO
45834656|NCT02315430|Other|Laboratory Biomarker Analysis|Optional correlative studies
45997023|NCT02529852|Drug|Cyclophosphamide|Phase I and II: 750 mg/m2 vein over about 1 hour on Day 1 of all cycles.
45834657|NCT04274244|Drug|Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML|"Regenerative periodontal therapy + Cross-linked hyaluronic acid 1.8%:~The modified minimal invasive surgical technique, described by Cortellini 2011, will be used to raise the interdental papilla over the bone defect.~Measurement of bone defect with a 0.5mm periodontal probe (PCP-UNC 15, Hu-Friedy Manufacturing, Illinois, USA) to characterize the defect anatomy.~Inflammatory tissue will be debrided and the root carefully planed using Gracey curettes.~The site will be washed with physiologic sterile solution, dried and the root wil be conditioned with 24% Ethylenediamine tetraacetic acid (EDTA) for two minutes, then the defect area will be carefully rinsed with sterile saline to remove any residual EDTA.~Application of Hyadent BG® 1,8% filling the bone defect from the bottom upwards in the test group.~Single internal modified mattress suture (5/0 Vicryl, Ethicon).~Sutures will be removed after two weeks."
45997024|NCT02529852|Drug|Doxorubicin|Phase I and II: 50 mg/m2 by vein over about 15 minutes each on Day 1 of all cycles.
45997025|NCT02529852|Drug|Vincristine|Phase I and II: 1.4 mg/m2 by vein on Day 1 of all cycles.
45997026|NCT02529852|Drug|Prednisone|Phase I and II: 100 mg by mouth daily on Days 1 - 5 of each 21 day cycle.
45997027|NCT02223182|Biological|Viaskin Milk 150 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 150 mcg cow's milk proteins.
45997028|NCT02223182|Biological|Viaskin Milk 300 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 300 mcg cow's milk proteins.
45997029|NCT02223182|Biological|Viaskin Milk 500 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
45997030|NCT02223182|Biological|Viaskin Placebo|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
45997031|NCT02222948|Drug|Vatelizumab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45997032|NCT02222948|Drug|Placebo (for Vatelizumab)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45997033|NCT02221232|Drug|Chloraprep|Apply topically.
45997034|NCT02221232|Drug|ZuraPrep|Apply topically.
45997035|NCT02221232|Drug|ZuraPrep Vehicle|Apply topically.
45997036|NCT02206100|Drug|PER977|reversal of edoxaban-induced anticoagulation
45997037|NCT02206100|Drug|Placebo|Reversal of edoxaban-induced anticoagulation
46085766|NCT00635726|Drug|Gemcitabine|Gemcitabine 1000 mgr/m2 on days 1 and 8 every 3 weeks for 4 courses
45997038|NCT02206100|Drug|enoxaparin|
45675242|NCT04727593|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|Experimental group: MBCT is program developed by Zindel Segal, Mark Williams, and John Teasdale , based on Jon Kabat-Zinn's Mindfulness-based Stress Reduction (MBSR) program. Participants learn to acknowledge their unhelpful thoughts and feelings, allowing the mind to move from an automatic and spiraling thought pattern to a more conscious emotional processing. Mindfulness practices include breath awareness, sitting and walking meditations, and mindful yoga. In this study, the following MBCT structure will be followed: group setting of 12 participants (maximum); 8 online weekly meetings of 2 hours via a videoconference platform (e.g., Cisco Webex), each one mediated by a trained mindfulness instructor(s); daily home practice of the learned skills; 2 hours of retreat after the fifth week; 6 months of home practice; 4 monthly consolidation sessions of 90 minutes each.
45997039|NCT02421159|Behavioral|Seek and Test Phase|The primary endpoint for this phase is the proportion of newly identified HIV infections of the RDS-ASTN intervention. Components for eligible and willing participants are a computerized baseline interview, counseling session, blood draw for HIV testing, HIV pre-test counseling, use of blood samples for clinical lab tests if found to be HIV infected, semi-structured interviews (if selected), the opportunity to recruit peers for the study, and the post-test counseling session.
45997040|NCT02421159|Behavioral|Treat and Retain Phase|The primary endpoints for this phase are: proportion linked to care within three months and time to the HIV care appointment. Participants with HIV infection who are interested in participating will be enrolled in this phase and navigated to HIV primary care over three months. Components are the locator form, patient navigation and support contacts, medical report form, follow-up contacts to update locator information, semi-structured interviews, follow-up interview, and blood draw for clinical lab testing.
45997041|NCT02409303|Behavioral|Screen-Refer-Treat Intervention|This intervention is healthcare system intervention that trains providers on validated screening tools (Online M-CHAT-R/F and STAT) and an evidence-based behavioral intervention (RIT). PCPs receive a 2-hour training workshop on the Online M-CHAT-R/F and EI Providers receive 2 day-long training workshops, one on the STAT/expedited assessment and one RIT.
46085767|NCT02700204|Device|PicoWay 532nm fractional treatment|is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
46085768|NCT02700204|Device|PicoWay 1064nm fractional treatment|is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
46085769|NCT04216940|Device|mechanical preparation of root canal system|Assess the pain intensity in a two-visit treatment of molars with irreversible pulpitis after instrumentation with two different rotary Nickle Titanium systems
46085770|NCT00616590|Other|medical chart review|
46085771|NCT00616590|Other|questionnaire administration|
45834658|NCT04274244|Drug|Enamel Matrix Proteins (Active comparator group)|"Regenerative periodontal therapy + Enamel matrix proteins:~The modified minimal invasive surgical technique, described by Cortellini 2011, will be used to raise the interdental papilla over the bone defect.~Measurement of bone defect with a 0.5mm periodontal probe (PCP-UNC 15, Hu-Friedy Manufacturing, Illinois, USA) to characterize the defect anatomy.~Inflammatory tissue will be debrided and the root carefully planed using Gracey curettes.~The site will be washed with physiologic sterile solution, dried and the root wil be conditioned with 24% Ethylenediamine tetraacetic acid (EDTA) for two minutes, then the defect area will be carefully rinsed with sterile saline to remove any residual EDTA.~Application of Emdogain® filling the bone defect from the bottom upwards in the active comparator group.~Single internal modified mattress suture (5/0 Vicryl, Ethicon).~Sutures will be removed after two weeks."
45997042|NCT00554723|Drug|NeuroAid|4 capsules 3 times daily, for three months
46085772|NCT00616590|Procedure|fatigue assessment and management|
46085773|NCT00616590|Procedure|quality-of-life assessment|
46085774|NCT02749292|Drug|Rituximab|re-dosing dependent on interventional arm parameter.
46085775|NCT05322798|Procedure|High-frequency SCS|Continous high-frequency stimulation (frequency - 1kHz, pulse width - 30 µs).
46085776|NCT05322798|Procedure|Low-frequency SCS|Continuous conventional stimulation (frequency - 30-60 Hz, pulse width - 250-500 µs).
46085777|NCT05428514|Other|Maternity Housing|Receives a bed in the maternity home, wrap-around services, etc.
46085778|NCT04219982|Drug|DPI-386 Nasal Gel|Nasal gel
45457380|NCT02300818|Device|Pulsed Electromagnetic Field Therapy|Pulsed Electromagnetic Field Therapy widely termed as (PEMF) is a reparative technique used for treatment of eye therapy has proved to be a beneficial treatment for those suffering from glaucoma. This therapy helps in increased blood flow and show positive results on latent, initial and advanced glaucoma with ten sessions of seven minutes' each.
45834659|NCT04274322|Other|Nutrition support|Calories and proteins are given to patients by using ways as parenteral nutriton, enteral nutrition, oral nutrition supplement
45834660|NCT04273698|Behavioral|Parent-infant psychotherapy|Brief psychoanalytic parent-infant psychotherapy
45997043|NCT00554723|Drug|NeuroAid matched Placebo|NeuroAid matched Placebo, 4 capsules 3 times daily, for three months
45997044|NCT00554762|Drug|GW842166X|Administer
45997045|NCT01231516|Drug|GSK1349572|50mg once daily
45997046|NCT01231516|Drug|Raltegravir|400mg twice daily
46085779|NCT04219982|Drug|DPI-386 Placebo Nasal Gel|DPI-386 Placebo Nasal Gel
46085780|NCT04219982|Drug|Transderm Scop®|Transderm Scop®
46085781|NCT02700438|Drug|Glyceryl trinitrate ointment|Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
46085782|NCT02700438|Procedure|Urgent PC Neuromodulation System®|Subjects underwent one 30-min session of percutaneous posterior tibial nerve stimulation 2 days per week for 8 consecutive weeks in an outpatient clinic, with a Urgent PC Neuromodulation System®. Patients were placed in the supine position without anesthesia. PPTNS was delivered using a needle electrode that was inserted 3-4cm cephalad and 2 cm posterior to the medial malleolus at a 60º angle towards the ankle joint to a depth of approximately 0.5-1cm. Successful placement was confirmed by the presence of electric sensation 5 cm above and below the insertion site or a digital plantar flexion.
45457381|NCT02300818|Drug|Seawater eyedrops|Eye-drops daily 1 time a day for 12 weeks
45997047|NCT01231516|Drug|GSK1349572 Placebo|Inactive placebo tablet once daily
45997048|NCT01231516|Drug|Raltegravir Placebo|Inactive placebo tablet twice daily
45997049|NCT04668911|Other|Swab|PCR test for SARS-CoV2, oral and nasal swab
45997050|NCT01962636|Drug|Fludarabine|25 mg/m^2 IV of Fludarabine will be given over 1 hour on days -8, -7, and -6 pre-UCB transplant.
45997051|NCT01962636|Drug|Cyclophosphamide|60 mg/kg IV of Cyclophosphamide will be given over 2 hours on days -7 and -6 pre-UCB transplant.
45997052|NCT01962636|Radiation|Total Body Irradiation|165 cGy of total body irradiation will be given twice a day on days -4, -3, -2, and -1.
45997053|NCT01962636|Drug|Cyclosporine A|Cyclosporine A (CSA) will start day -3 and will be administered PO/IV maintaining a trough level between 200 and 400 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
46085783|NCT04216706|Drug|tailored pharmaceutical treatment|Tailored medication is advised in women with inadequate hemodynamic adaptation to pregnancy. Type of medication depends on total peripheral vascular resistance and heart rate. In short, women with a low peripheral vascular resistance in parallel with a high heart rate are advised a betablocker (labetalol), while a vasodilating agent (calcium channel blocker, nifedipine) was advised in women with a high total peripheral vascular resistance in combination with a low heart rate. Women with suboptimal adaptation to pregnancy without an extreme pronounced vascular profile are advised a centrally acting sympatholytic agent (methyldopa).
45997054|NCT01962636|Drug|Mycophenylate mofetil|Mycophenylate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3.
45997055|NCT01962636|Biological|Umbilical cord blood|Pre-medications and UCB infusion will be per current institutional policies/guidelines. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. If 2 units are used, both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending or designee.
45675243|NCT04727593|Other|Treatment as Usual|In this case, participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral, and intervention for people with significant distress difficulties. Regarding pharmacological intervention, medication intake will be monitored during the study and changes will be registered. The engagement in non-pharmacological interventions such as psychological and psychosocial interventions will also be monitored.
46085784|NCT00617136|Device|Intraoperative warming (Bair Hugger)|Intraoperative warming
45997056|NCT04669106|Other|laboratory clinical trial study|The research stage consisted of two stages, the first stage was the initial screening of the primary data of the research subjects, namely by analyzing food intake including mineral intake data, the diet of the research subjects, mineral and enzyme levels, and data on soil conditions in the area. The second stage was to analyze the relationship between the existing variables so that the most significant relationship was seen between the differences in diet, mineral content, enzyme levels, and soil content between the two groups.
45675244|NCT04693663|Procedure|Relex-Smile surgery|surgery using Relex-Smile
46085785|NCT00617136|Device|Pre- and intraoperative warming (HotDog)|Pre- and intraoperative warming by HotDog
45997057|NCT01736748|Behavioral|Sensor based PA intervention|Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.
45997058|NCT01736748|Behavioral|Traditional PA counseling|Children will be encouraged to enhance their physical activity levels using traditional behavioral approaches.
45834661|NCT04274166|Drug|secukinumab 150 mg (2 injections per dose|secukinumab 150 mg (2 injections per dose
46085786|NCT00617136|Device|Intraoperative warming (HotDog)|Intraoperative warming
45834662|NCT04274088|Procedure|Cataract surgery|Phacoemulsification surgery
45834663|NCT02983968|Other|Description of the cirrhosis management|
45834664|NCT02959164|Drug|Decitabine|"Dose escalation starting at 0.1mg/kg, subcutaneously administered on twice weekly schedule for three weeks of a 28 day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~*Starting Dose Level"
45997059|NCT04668755|Device|Charcot Restraint Orthotic Walker 3d printed sole|"The Charcot Restraint Orthotic Walker (CROW) consists of anterior and posterior shells creating a total contact environment based on a rocker sole. the sole is manufactured by 3d printed Metamaterial .~Manufacture of the 3d printed sole of the CROW paths through two stages ;Computer aided designing (CAD) and computer aided manufacturing (CAM) ."
46002380|NCT03361215|Other|Biosampling for molecular analysis|Observational study with no therapeutic intervention. Biosampling for molecular analysis
45834665|NCT02959164|Drug|Gemcitabine|"Fixed infusion rate of 900 mg/m2, IV over 90 min, on Days, 1, 8 and 15 of a 28-day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~*Starting Dose Level"
45997060|NCT04668755|Device|Generic Charcot Restraint orthotic walker|It is a clamshell (two piece) design that provides complete/total contact over the shin, calf and foot. The CROW reduces all motion in the ankle and foot to reduce potential for further injury. It is fully padded on the inside, and the bottom is covered with a material similar to shoe soling. It is not worn with a shoe.
45997061|NCT01231321|Drug|adalimumab|Adalimumab 40 mg in 0.8 ml in pre-filled syringe for under the skin of the abdomen or the thigh injection every other week.
45997062|NCT01722240|Drug|Liraglutide 1.8mg|
45997063|NCT01722240|Drug|Placebo|
45997064|NCT04668677|Other|On-line questionnaire|On-line questionnaire about working life, medical care, functional recovery, quality of life and psychological state.
45997065|NCT04668482|Device|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
45997066|NCT04668482|Device|SCS is switched on|Spinal cord stimulator is functioning
45997067|NCT01666080|Drug|Busulfan|0.4 mg/kg (0.5 mg/kg if <4 years of age) intravenously (IV) every 6 hours on Days -8 and -7.
45997068|NCT01666080|Drug|Fludarabine|40 mg/m^2 intravenously (IV) over 1 hour on days -6 through -2.
45997069|NCT01666080|Radiation|Total body irradiation|200 cGy on Day -1
45997070|NCT01666080|Biological|Stem cell transplant|stem cell infusion on day 0
45997071|NCT01666080|Drug|Keppra|Keppra will be given for seizure prophylaxis during busulfan administration as per the standard institutional protocol.
45997072|NCT04668560|Behavioral|Five ways to wellbeing course|A behavioural course over six sessions. Teaching the participants in doing avtivities to promote wellbeing
45675245|NCT02038543|Drug|Hydroxyproline and Leucine|Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the CRTU. The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
45675246|NCT02038153|Other|Laboratory Biomarker Analysis|Correlative studies
45675247|NCT02038153|Drug|Lenalidomide|Given PO
45997073|NCT01627548|Behavioral|Structured Approach Therapy|The SAT treatment is provided in 12 weekly 50-minute sessions and is fully manualized. First, couple-based exposure techniques are used to address anxiety about intimacy, increasing the traumatized person's ability to engage in social and relational behaviors that promote bonding and satisfaction. Second, as anxiety decreases, couple-based techniques are also used to increase the positive experiences the couple is having. These activities expose the traumatized person to positive feelings instead of anxiety, so that he/she may become desensitized to the anxiety caused by the closeness, and more comfortable engaging in intimate behaviors.
45997074|NCT04668404|Diagnostic Test|Sonoclot|Sonoclot machine
45997075|NCT01484730|Device|Multi-Spectral & Laser Speckle Imaging|Changes in skin tissue and blood flow.
45997076|NCT01210222|Biological|Trebananib|Given IV
45997077|NCT04668287|Behavioral|Increasing self-esteem|During 5 weeks, participants will be part of one of the working groups in which they'll be taught by a counselor about how a low self-esteem develops and what have to be done for improving self-esteem, based on the Melanie Fennel' model.
45997078|NCT01210144|Drug|Gonal -f® [r-hFSH]|On Day 2 of the menstrual cycle, a pre-defined fixed dose of 150 International Units (IU) per day of recombinant human follicle stimulating hormone (r-hFSH) will be administered until follicles are recruited and developed.
45997079|NCT01210144|Drug|Ovitrelle® [r-hCG alfa]|Ovulation triggering will be performed using a single injection of 250 microgram (mcg) recombinant human chorionic gonadotropin (r-hCG) alfa as soon as follicles satisfy the criteria for follicular development, that is at least 3 follicles greater than (>) 16 millimeter (mm), and with estradiol (E2) > 1 microgram per liter (mcg/L) if gonadotropin releasing hormone (GnRH) agonist will be used.
45997080|NCT01210144|Drug|Gonadotropin-releasing hormone (GnRH) Agonist|To prevent premature ovulation in participants undergoing a controlled ovarian stimulation (COS), 0.1 milligram (mg) GnRH agonist daily will be given after endometrial biopsy, 7 days after the peak day of luteinizing hormone (Day LH + 7) as per summary of product characteristics (SmPC), in long agonist protocol.
45997081|NCT01210144|Drug|Gonadotropin-releasing hormone (GnRH) Antagonist|To prevent premature ovulation in participants undergoing a COS, 0.25 mg GnRH antagonist daily will be given from Day 6 of Gonal-f® stimulation treatment as per SmPC, in multi-dose antagonist protocol.
45997082|NCT05423470|Behavioral|Intermittent hypoxia|The intermittent hypoxia protocol will consist of three 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with 4-minute normoxic cycles.
45997083|NCT05423470|Behavioral|Intermittent normoxia|The intermittent normoxia protocol will consist of three 4-minute normoxic cycles (compressed air) interspersed with 4-minute normoxic cycles (room air).
45997084|NCT04668053|Other|Traditional training protocol|Mobility and core strengthening and the steps and lunges As per athletes requirement Body weight squat with 12 reps, Body weight split squat with 8 each side, Bilateral hip raise with 12 reps, Push-up with15 reps and Cricket related skills as per coach advised
45997085|NCT04668053|Other|Hip flexor resistance protocol|"Warm up prior to training The loop bands (Resistance-band©) that were used are in several colors-Red, black, yellow, blue and green extended from strongest type to weakest.~Athletes executed 3 training sessions of 3 sets per week for 6 weeks.~The relative load was:~Week 1----15 RM Week 2-4----10 RM Week 5-6----8 RM The Therapist has ensured a concentric contraction of 3-s, an isometric contraction of 2-s, eccentric contraction of 3-s, rest for 2-s prior to the next repetition and rest for 2-min prior the next set.~It took 10 min to complete each session, with rest between sets."
46002381|NCT03349528|Biological|Probiotic Supplement|Probiotic supplement 1 tablet by mouth daily
45675248|NCT02038075|Behavioral|Brief Cognitive Behavioral Therapy (BCBT)|
45675249|NCT02038075|Behavioral|Treatment As Usual (TAU)|
45675250|NCT02058589|Biological|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
45675251|NCT02058589|Drug|Placebo|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
45675252|NCT02079805|Drug|Azilsartan|Azilsartan tablets
45675253|NCT02079805|Drug|Telmisartan|Telmisartan tablets
45675254|NCT02037295|Drug|Vancomycin|Vancomycin 125mg orally four times per day for 12 days
45997086|NCT01209949|Drug|Adapalene 0.1% and Benzoyl Peroxide 2.5% gel|Apply adapalene BPO gel once daily in the evening for 12 weeks
45997087|NCT04667936|Other|Treatment group|None, solely treatment documentation
45997088|NCT04667975|Drug|CKD-702|In principle, based on 1 cycle of 28 days (4 weeks), administer CKD-702 Inj. once every 2 weeks over 4 weeks.
45997089|NCT04831593|Other|Group El|Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
45997090|NCT04831593|Other|Group Em|Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
45997091|NCT04667858|Device|Home Ovulation Test|Visual read home ovulation test
45675255|NCT02037295|Drug|Placebo oral tablet|Placebo pills orally four times per day for 12 days
45997092|NCT04825509|Device|Ultrasound|"Diaphragm ultrasound will be done while patient is supine on T-piece during SBT 30 minutes after disconnecting mechanical ventilation. The measurements will be done by placing the transducer in the eighth or ninth intercostal space, between the anterior axillary and the mid-axillary lines.~Diaphragmatic excursion (DE) will be measured in M-mode using a 1- to 5- Megahertz (MHz) ultrasound curved transducer during maximal breathing. The amplitude of diaphragmatic excursion will be measured as the point of maximal height of the diaphragm to the base line.~Diaphragmatic thickness (DT) will be measured at both end of maximal inspiration and end of maximal expiration using a high frequency 7-11 MHz ultrasound linear transducer in M-mode. The diaphragm thickness will be measured from the middle of the pleural line to the middle of the peritoneal line."
45997093|NCT04667897|Drug|601 1.25mg|Solution for injection (intravitreal use)
45997094|NCT04667897|Drug|Ranibizuman 0.5 mg|Solution for injection (intravitreal use)
45997095|NCT04683081|Device|mechanical cervical ripening|mechanical cervical ripening methods have been used to make the cervix more eligible for vaginal delivery
45997096|NCT01209832|Drug|Tasisulam|Patient specific dose, administered intravenously, on Day 1 of a 28-day cycle. Minimum of one (1) 28-day cycle. Patients may continue to receive tasisulam until disease progression or until discontinuation criteria are met.
45997097|NCT01209832|Drug|Midazolam|1.2 milligrams (mg), administered orally once prior to the initiation of tasisulam therapy and once on Day 8 after initiation of tasisulam therapy
45675256|NCT02037295|Other|Overfeeding diet (OF)|Diet in which the calories are 150% of their weight maintaining energy requirements
45997098|NCT04667819|Drug|Sodium Hyaluronate|We usage a special type of anterior eye drug delivery system to conduct the transmission of sodium hyaluronate in dry eye patients.
45997099|NCT04683159|Drug|Brimonidine Tartrate 0.15% Oph Soln|1 drop of brimonidine 0.15% (~0.05mL) 15 minutes prior to surgery
46085787|NCT00913835|Biological|Olaratumab|20 milligrams per kilogram (mg/kg) administered by intervenous (IV) infusion every 2 weeks (14 days). Treatment will continue until there is evidence of progressive disease (PD) or development of unacceptable toxicity
45675257|NCT02037295|Other|Underfeeding diet (UF)|Diet in which the calories are 50% of their weight maintaining energy requirements
46085788|NCT00913835|Drug|liposomal doxorubicin|40 milligrams per square meter (mg/m²) administered according to the manufacture's instructions every 4 weeks (28 days). Treatment will continue until there is evidence of PD or development of unacceptable toxicity
45675258|NCT02079649|Drug|AL-53817 Ophthalmic Solution, 0.1%|
45675259|NCT02079649|Drug|AL-78843 Ophthalmic Solution, 0.03%|
45675260|NCT02079649|Drug|Dexamethasone Ophthalmic Suspension, 0.1%|
45997100|NCT04683159|Drug|Brimonidine Tartrate 0.025% Oph Soln|1 drop of brimonidine 0.025% (~0.05mL) 15 minutes prior to surgery
45997101|NCT01230892|Drug|Nebivolol|10 mg PO qday
45997102|NCT01230892|Drug|Atenolol|100 mg PO qday
45997103|NCT04667624|Drug|Twynsta|Manufactured by Boehringer Ingelheim
45997104|NCT04667624|Drug|LodineT|•Manufactured by Hanlim Pharm. Co., Ltd, Seoul, Korea
45997105|NCT03455400|Device|Swisstom BB2 EIT device|Swisstom BB2 EIT device with NEO SensorBelts will be used to measure ventilation distribution during spontaneous breathing and position changes in healthy newborn infants.
45997106|NCT04667351|Drug|2400 mg/m² 5-fu|Hepatic arterial infusion of oxaliplatin,leucovorin and 2400 mg/m² 5-FU
45997107|NCT04667351|Drug|1200 mg/m² 5-fu|Hepatic arterial infusion of oxaliplatin,leucovorin and 1200 mg/m² 5-FU
45997108|NCT01230814|Drug|Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)|Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate), co-formulated vaginal suppositories containing metronidazole 750 mg with miconazole 200 mg and excipients (Witepsol S 55). Witepsol S 55 is a hard fat suppository base. Such bases consist mainly of triglyceride esters of the higher saturated fatty acids along with varying proportions of mono- and diglycerides. 117 subjects receive nightly for 5 consecutive night each month.
45997109|NCT01230814|Drug|Placebo|Placebo vaginal suppositories, identical in appearance to the active product; contains Witepsol S 55, Titanium Dioxide and D+C yellow #10 with no metronidazole or miconazole.117 subjects receive nightly for 5 consecutive nights each month.
45997110|NCT04811235|Device|Near Infra-Red Spectroscopy (NIRS) Sensor|The NIRS sensor is laid on top of the dura, at the site of the SCI, and emits near-infrared light signals into the cord to measure tissue oxygenation and tissue hemodynamics in real-time.
45675261|NCT02079649|Drug|AL-53817 Vehicle|Inactive ingredients used for masking purposes
45675262|NCT02036515|Drug|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
45675263|NCT02036515|Drug|Ertugliflozin 15 mg|Ertugliflozin, oral, 5 mg and 10 mg tablet once daily for 52 weeks
45997111|NCT01230307|Drug|Vitamin D3|Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
45997112|NCT01230307|Drug|Placebo|A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months.
45997113|NCT04810377|Procedure|EUS-guided gastroenterostomy|First after an upper endoscopy is performed, a catheters passed throughout the endoscope channel and with x-ray verification, a guide wire is passed up to the third portion of duodenal loop. then small intestinal is filled with saline solution up to 1500cc and contrast solution. Then an endoscopic ultrasound examination will be carried out where a loop of the small intestine that is located less than 2 cm apart from the gastric wall will be looked for. Once the intestinal loop is identified a direct antegrade puncture will be performed with a luminal apposition prosthesis release system . Finally, correct position is verified with x-ray and we will look for any misplacement or leakage during this process or the presence of bleeding. Endoscopic treatment will be performed if necessary. Subsequently, the participants will go to monthly follow-up with clinical evaluation, laboratory and radiological test will be carried out until the participants dies.
45997114|NCT00556595|Procedure|primary electrophysiological approach|primary ablation of atrio-venous breakthrough sites followed by circumferential ablation around pulmonary vein orifice
45997115|NCT00556595|Procedure|primary anatomical approach|primary circumferential ablation around the pulmonary vein orifice followed by ablation of possible conduction gaps
45997116|NCT01209598|Drug|Palbociclib 200mg|Schedule 2/1: Palbociclib 200mg given once daily by mouth for 14 consecutive days, followed by 7 days of rest. A cycle will be defined as 21 days.
45997117|NCT01209598|Drug|Palbociclib 125mg|"Schedule 3/1: Palbociclib 125mg given once daily by mouth for 21 consecutive days, followed by 7 days of rest. A cycle will be defined as 28 days. Following the positive results of the study, a new Expansion Cohort has been added to permit enrollment of up to 20 additional patients.~Expansion Cohort: Dosed as per Schedule 3/1. Capsules should be taken with food."
45997118|NCT04809090|Behavioral|SMT|Standard 8 SMT (Stress Management Training) psychological interviews.
45997119|NCT04809090|Device|App CA|An APP together a CA (Conversational Agent).
45997120|NCT00556634|Drug|Efavirenz|"Efavirenz given in a stepped dosage over 2 weeks (200 mg qd for 6 days plus placebo, 400 mg qd for 7 days plus placebo and 600 mg qd from day 14 forward)~OR~Efavirenz usual dosage (600 mg/day from the first day)"
45997121|NCT01209520|Drug|Cisplatin|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
45997122|NCT01209520|Drug|Carboplatin|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
45997123|NCT01209520|Drug|Paclitaxel|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
45997124|NCT01209520|Drug|Vidaza|Patient will receive 5-azacitidine at a dose of 75 mg/m2 intravenously daily on day 1-5 every 28 days for 6 cycles
45997125|NCT01209520|Procedure|Tumor Specimen for Methylation Analysis|Obtained from tissue of resected NSCLC tumor.
45997126|NCT01209520|Procedure|Blood Sample for Methylation Analysis|Pre-Surgery, Post-Surgery, Post-Vidaza Therapy and during follow-up.
45997127|NCT01209520|Drug|Vinorelbine|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
45997128|NCT01209520|Drug|Docetaxel|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
45997129|NCT01209520|Drug|Pemetrexed|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
45997130|NCT04805736|Procedure|Microwave Ablation|Image-guided microwave ablation 7-10 days prior to surgery
45457382|NCT03919123|Other|Evaluation of laparoscopic promontofixation|Evaluation of Functional Outcomes and Quality of Life After Laparoscopic Promontofixation (PFL). Unicentric Retrospective Cohort Study (PeSuLife)
45457383|NCT02302612|Behavioral|CREATE Wellness|Patients allocated to the intervention arm will receive three group sessions with between visit contacts designed to increase activation and engagement with their care plans. They will also continue to be enrolled in the KP PHASE program
45457384|NCT02302612|Other|Usual Care Control|Patients allocated to the control arm will continue to receive usual care, including disease management within the KP PHASE program.
45457385|NCT01134445|Device|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
45997131|NCT04805736|Drug|Camrelizumab|Camrelizumab 200 mg was given a few days after microwave ablation
45997132|NCT04805736|Procedure|Breast Surgery|Standard of care breast conserving surgery or radical mastectmoy
45997133|NCT01209325|Biological|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|
45997134|NCT01209325|Other|laboratory biomarker analysis|
45997135|NCT04805541|Procedure|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
45997136|NCT04805541|Drug|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
45997137|NCT04805541|Device|Diabetic retinopathy screening|"Screening for existence of More than mild or Vision-threatening Diabetic Retinopathy, and/or Diabetic Macular Edema."
45997138|NCT04667273|Procedure|Neuromuscular Electrical Stimulation (NMES)|"In Neuromuscular Electrical Stimulation (NMES) application, 4 surface electrodes will be placed in the swollen part of the lower trapezius and serratus anterior muscles of each patient.~NMES will be applied for 20 minutes in rehabilitation mode with a 4-channel device.~Frequency: 80 Hz Amplitude: 0-100 mA (0-0.01 V) Current time-Pulse: 200 μsec Wave form: Biphasic Cycle time: 8 seconds of tetanic muscle stimulation for all patients, with a 2 second rise and fall time and stimulation It will be set as 3 seconds between. It is important to visually observe the contraction to determine the intensity of stimulation."
45457386|NCT01358006|Drug|JNJ-40411813|Cohort 1: Type=2 to 3, unit=mg, number=200 to 300, form=capsule, route=oral use.Capsule(s) taken in the fed state Capsule(s) taken in the fed state.
45997139|NCT04667273|Procedure|Exercise Training (ET)|"Patients will do Wand exercises under the supervision of a physiotherapist. Wand exercises will include shoulder flexion, external rotation and abduction in the scaption position. In the first and second week, these exercises will be performed on the back, and from the third week on standing exercises.~Exercises with the Theraband will be done in 3 sets, each set will consist of 10 repetitions. There will be a 1 minute rest period between sets. When the three sets are easily completed and there is no reported fatigue by the patient, the resistance will be increased by moving from yellow to red, from red to green, respectively, after 4 weeks.~*For shoulder external rotators and serratus anterior muscles are strengthened without weight for the first 2 weeks, then 0.5 kg of dumbbells, in the supine position.~While standing, the lower trapezius, upper trapezius and shoulder external rotators will be strengthened with theraband."
45675264|NCT02036515|Drug|Placebo for ertugliflozin 5 mg|Matching placebo for ertugliflozin 5 mg, oral, once daily for 52 weeks
45675265|NCT02036515|Drug|Metformin|Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period.
45675266|NCT02036515|Drug|Sitagliptin|Participants are to remain on their stable doses of sitagliptin (oral, 100 mg once daily) while receiving blinded investigational product during the double-blind treatment period.
45675267|NCT02036515|Drug|Glimepiride|Glimepiride rescue medication, oral, once daily, open-label glimepiride; dose determined per the investigator's discretion
45997140|NCT04798677|Dietary Supplement|ABBC1 Immunoessential|Powder for dissolution in water, based on a yeast beta-glucan complex and a consortium of Saccharomyces cerevisiae rich in selenium and zinc + excipents. Lemon flavor
45997141|NCT04798677|Dietary Supplement|Placebo|Powder for dissolution in water, excipents. Lemon flavor
45997142|NCT04667429|Other|Food|HEC83518 40mg will be taken orally fasted or with food
45997143|NCT04667429|Drug|HEC83518|HEC83518 will be taken orally before sleep for 15 days
45997144|NCT04667429|Drug|placebo|The placebo will be administered before sleep for 15 days.
45675268|NCT02036515|Biological|Insulin|Insulin glargine rescue medication, injectable, as required. In the event that an investigator considers use of glimepiride to not be appropriate for a participant meeting protocol specified glycemic rescue criteria, insulin glargine can be initiated as the rescue medication, and managed by the investigator according to clinical practice guidelines of the local country.
45457387|NCT01358006|Drug|JNJ-40411813|Cohort 2: Type=up to 7, unit=mg, number=up to 700 mg, form=capsule, route=oral use. Capsule(s) taken in the fed state.
45457388|NCT02297386|Drug|[18F] DIHYDRO-TESTOSTERONE|
45457389|NCT02297386|Device|PET scan|
45457390|NCT02297386|Device|MRI|
45457391|NCT02297386|Other|Blood draw|
45675269|NCT02036515|Drug|Placebo for ertugliflozin 10 mg|Matching placebo for ertugliflozin 10 mg, oral, once daily for 52 weeks
45457392|NCT00972608|Other|Anatomic Reconstruction and Surgical Planning|Standard of care patient-images will be acquired and used to construct a model of the patient anatomy. The model will then be used to simulate surgical options and allow the surgeon to visually evaluate the optimal approach.
45457393|NCT05401825|Biological|pfizer, astrazeneca,moderna,sinofac|effect of COVID 19 vaccination on pregnancy outcomes
45997145|NCT04667546|Other|Survey|Patients or their parents will complete a survey at D2, D5, D10 and D28 to assess the presence or absence of a symptom
45457394|NCT04464616|Procedure|spinal anaesthesia|spinal anaesthesia will be performed with the patient in sitting position at the L3-L4 or L4-L5 interspaces with a 25 or 27 G spinal tip needle with the study drug in the total volume of 3 ml.
45457395|NCT01356680|Drug|BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)|
45457396|NCT01356680|Drug|ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)|
45457397|NCT01356680|Radiation|30Gy IF-RT (Involved-Field Radiotherapy)|
45457398|NCT01356680|Radiation|30Gy IN-RT (Involved-Node Radiotherapy)|
45457399|NCT01229995|Device|dental implants - zirconia abutmetns - prefabricated abutments|
45457400|NCT02300896|Other|Group-based exercise training during hospitalization|Exercise training. Individual program training 5 days a week during hospitalization
45457401|NCT03918967|Drug|CT-G11|oral tablet of CT-G11 Experimental Drug
45457402|NCT03918967|Drug|CT-G20|oral tablet of CT-G20 Experimental Drug
45457403|NCT03918967|Drug|CT-G11 Placebo|oral tablet of Placebo
45457404|NCT03918967|Drug|CT-G20 Placebo|oral tablet of Placebo
45675270|NCT04417075|Behavioral|Impacto (Mobile App)|This is the mobile app to be developed and evaluated in this project. It is designed for Spanish-speaking, Latinx smokers with high anxiety sensitivity and will be built for the Android platform. The app will include components to address and remediate anxiety sensitivity, as well as having smoking cessation components.
45675271|NCT04417075|Behavioral|Dejar de Fumar Asistente (Mobile App)|Dejar de Fumar Asistente (English version called: Quit Tracker: Stop Smoking) is a popular, free third party mobile application aimed at helping smokers quit smoking. This is the mobile app that will serve as the control condition in evaluating the efficacy of Impacto. This mobile app is well established as a smoking cessation app for Spanish-speaking, Latinx smokers. The app includes smoking cessation components but does not have a specific emphasis on anxiety sensitivity.
45997146|NCT04784754|Drug|Melatonin|Melatonin capsules will be prepared using hypromellose capsules containing 3 mg or 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
45675272|NCT02078713|Behavioral|Contraceptive Decision Support Tool|"The decision support tool:~Provides an educational session about different aspects of contraception~Elicits patient preferences about different aspects of contraception~Identifies potential contraindications to certain contraceptive methods~Allows the patient to view details about and compare available contraceptive methods~Suggests methods most appropriate based on the patient's preferences~Collects questions the patient may have for her provider~Generates a printout the patient can bring to her contraceptive counseling visit"
45675273|NCT02035267|Drug|Deoxycholic Acid|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
45675274|NCT02035267|Drug|Placebo|Phosphate buffered saline placebo for injection.
45997147|NCT04784754|Drug|Placebo|Placebo capsules will be prepared using hypromellose capsules, filled using microcrystalline cellulose. This is the same excipient used in the preparation of the interventional drug. Placebo will be administered orally three times a day for 14 days in the same regimen used for the intervention.
45997148|NCT04666883|Other|Review of records and follow up|Follow up to identify patients who developed splenic hilar nodal metastases
46085789|NCT02700360|Dietary Supplement|high-fat diet|This trial is conducted as a randomized, open-label, single -dose, crossover, phase I to evaluate the effect of food on the safety, tolerability and pharmacokinetics of EC-18. EC-18 is given at an oral, once daily in condition of empty stomach and a high fat diet(900~1,000 kcal, contains 50~60%lipid).This trial is divided into Part 1(1,000mg dose) and Part 2(500mg dose and 2,000mg dose), 12 subjects are included in each dose and cross-over period is 7 days. After Part 1 study, If primary PK parameters of EC-18 is affected by food and AEs meeting study discontinuation criteria are not reported, Part 2 will proceed in consecutive order with registering new subjects.
46085790|NCT02700360|Drug|EC-18|This trial is conducted as a randomized, open-label, single -dose, crossover, phase I to evaluate the effect of food on the safety, tolerability and pharmacokinetics of EC-18. EC-18 is given at an oral, once daily in condition of empty stomach and a high fat diet(900~1,000 kcal, contains 50~60%lipid).This trial is divided into Part 1(1,000mg dose) and Part 2(500mg dose and 2,000mg dose), 12 subjects are included in each dose and cross-over period is 7 days. After Part 1 study, If primary PK parameters of EC-18 is affected by food and AEs meeting study discontinuation criteria are not reported, Part 2 will proceed in consecutive order with registering new subjects
45675275|NCT05887596|Other|Patient education|The education given to the intervention group included preoperative preparation, operating room environment, breathing exercises, cough exercises, etc. to be performed after surgery, non-pharmacological methods related to pain management (cold application, positioning, distraction), and pharmacological methods related to pain management.
45675276|NCT05887583|Behavioral|The Rising New York Road Runners program|The Rising New York Road Runners program provides lesson plans covering fundamental movement skills that are intended to build competence, confidence, and motivation to be physically activity. Family engagement materials (emails, text messages, videos, social media) complement school materials to communicate what children are learning at school related to physical activity and what activities families can do at home together to reinforce these concepts.
45675277|NCT05887570|Behavioral|Educational intervention|intervention through extra education, modules, instruction on models
45675278|NCT05887570|Other|Control - Regular Instruction|participants receive usual training
45675279|NCT05887544|Other|Exposure: Plant-based diet pattern|From dietary records average intake across food groups will be calculated and a plant-based diet index score will be generated to group participants.
45675280|NCT05887544|Other|Intervention: Fermented dairy products|1000g of the product to be consumed 1-2 days prior to spot urine sample.
45834666|NCT05607732|Diagnostic Test|MyCog|MyCog uses well-validated, self-administered, iPad-based measures from the NIH Toolbox for the Assessment of Neurological Behavior and Function Cognition Battery to provide an efficient and sensitive cognitive screen that can be easily implemented in primary care. Preliminary data shows these tests can discriminate between cognitively normal older adults and those with CI (specifically mild cognitive impairment); enabling physicians to assess CI in ways currently not available.
45458382|NCT03497884|Device|rTMS|For the l-Hz sessions (low frequency), stimulation is delivered at 100% of the subject's resting motor threshold at 1 Hz continuously over 30 min for a total of 1,800 pluses. The 10-Hz stimulation (high frequency) is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses per train).
45458383|NCT01363154|Other|Mozart K448|Subjects will receive auditory stimulation by exposure to Mozart's Sonata for Two Pianos in D Major, K448.
45675281|NCT05887544|Other|Exposure: individual foods and food groups|From the dietary records, average intake of specific foods or food groups will be calcualted.
45675282|NCT05887479|Drug|Botulinum toxin type A|Toxin of Clostridium Botulinum
45675283|NCT05887479|Drug|%0,9 NaCl|%0,9 NaCl
45834667|NCT05606952|Device|Color Doppler|color Doppler with pulsed wave Doppler to accurately detect the position of epidural catheter
45834668|NCT02983734|Drug|D-cycloserine|Partial agonist of N-methyl-D-aspartate (NMDA) receptor
45834669|NCT02983734|Drug|Placebos|Sugar pill
46002382|NCT03349528|Biological|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
45458384|NCT01363154|Other|Beethoven's Für Elise|Subjects will receive auditory stimulation by exposure to Beethoven's Für Elise.
45834670|NCT03821454|Drug|Capecitabine|Oral capecitabine (at a dose of 1250 mg per square meter of body-surface area, twice per day, on days 1 to 14) every 3 weeks for eight cycles.
45834671|NCT03821454|Drug|Placebos|Oral Placebos (twice per day, on days 1 to 14) every 3 weeks for eight cycles.
45834672|NCT03827148|Other|Pharmaceutical Care|Pharmaceutical care is an individualized patient-centric health service delivered by pharmacists that incorporates, but is not limited to, disease education, therapy management, self-care and self-management of disease and therapy as well as motivational guidance.
45997149|NCT04775199|Behavioral|Language Intervention|The examiners will target vocabulary and grammar in the context of preschool science instructions.
45997150|NCT04666805|Drug|Tamoxifen|20 mg/d, oral administration
45997151|NCT04666805|Drug|Toremifene|60 mg/d, oral administration
45997152|NCT04666805|Drug|Anastrozole|1 tablet (1 mg) per day, oral administration
45997153|NCT04666805|Drug|Letrozole|Adjuvant therapy with letrozole for 5 years or until the disease relapses. Patients who have received tamoxifen adjuvant therapy for 5 years should continue to take Letrozole until the disease relapses. The recommended dose of Letrozole tablets is one 2.5 mg tablet administered once a day, without regard to meals. For patients with advanced breast cancer, treatment with Letrozole should continue until tumor progression is confirmed. Patients with liver and/or renal dysfunction (creatinine clearance rate ≥ 10 mL/min) do not need to adjust the dosage.
45997154|NCT04666805|Drug|Exemestane|The recommended dose of Exemestane for adult and older patients with early and advanced breast cancer is one 25 mg tablet administered orally once a day after a meal. After 2-3 years of tamoxifen treatment, patients with early breast cancer should continue to use Tamoxifen in the case of no recurrence or contralateral breast cancer, until the completion of 5-year sequential adjuvant therapy with tamoxifen and exemestane. Patients with advanced breast cancer should continue to take Exemestane until the tumor progresses.
45997155|NCT04766853|Drug|Dexamethasone|Dexamethasone 5mg/ml
45997156|NCT04766853|Drug|Hyaluronic acid|Hyaluronic Acid 20mg/2ml
45997157|NCT04666376|Other|evaluation of the effectiveness of vitrification technique on ovarian tissue quality|there are 3 types of experiments in each group, including Follicle survival evaluation by Neutral red staining, Histological evaluation by Hematoxylin and Eosin staining, 2.4. Evaluation GDF-9 and Caspase-3 gene expression by real-time PCR.
45997158|NCT04666337|Procedure|ultrasound-guided supraclavicular brachial plexus blockade|Ultrasound-guided supraclavicular brachial plexus block was done using an ultrasound machine (Philips; Model: OTD020, AcBel Polytech Inc., Taiwan) with a 5-10 MHz linear probe. The brachial plexus and its relation to the surrounding structures were viewed while the patient was supine and the head turned 45° to the contralateral side. In the supraclavicular fossa, the probe was placed in the coronal plane to visualize the subclavian artery and the brachial plexus in a transverse sectional view. After skin sterilization and local anesthetic administration, an insulated needle was then introduced lateral to the ultrasound probe and parallel to the long axis of the probe. Once the needle penetrated the brachial plexus cluster, the local anesthetic mixture was injected incrementally after negative aspiration for blood or air just next to the artery, then the needle was repositioned to inject on the upper pole of the artery.
45997159|NCT04739319|Other|N/A Observational study|N/A Observational study
45997160|NCT00556790|Procedure|Standard Care|standard fluid regime, delayed feeding
45997161|NCT00556790|Procedure|Fast Track care|restrictive fluid regime, early oral feeding, enforced mobilisation
45997162|NCT04738461|Other|Telerehabilitation|The Posterior Glenohumeral Capsule Stretching Exercise, Pectoral Stretching Exercise, Push-up Against Wall Exercise, Scapular Plan Exercise, 90 Degree Shoulder Flexion Exercise, Isometric External Rotation Exercise and Isometric Internal Rotation Exercise will be applied according to the severity of the disease and the size of the disability.
45997163|NCT04738461|Other|Standard Physiotherapy|Active-passive exercises accompanied by a physiotherapist and physical therapy methods (electrotherapy and thermotherapy) will be applied in accordance with the standard procedure according to the patient's needs.
45997164|NCT04738461|Other|Home Exercise Group|The same exercise program applied to telerehabilitation group.
45997165|NCT00556868|Other|Breakfast/no breakfast|"A: Breakfast on the first day of intervention. Fasting (no breakfast) on the second day of intervention.~B: Breakfast on the second day of intervention. Fasting (no breakfast) on the first day of intervention"
45997166|NCT00556907|Radiation|Intraoperative radiotherapy|20Gy to surface of tumor bed and 5Gy at depth of 1cm from surface of tumor bed
45997167|NCT00556907|Device|Intraoperative radiotherapy|20gy to tumor bed, 5gy at depth of 1cm from surface of tumor bed
45997168|NCT04721457|Drug|Distilled Water|Control group
45997169|NCT04721457|Drug|1% Povidone Iodine (PVP-I)|Over-the-counter antiseptic mouth rinse
45997170|NCT04721457|Drug|1.5% Hydrogen Peroxide (H2O2)|Over-the-counter antiseptic mouth rinse
45997171|NCT04721457|Drug|0.075% Cetylpyridinium Chloride (CPC)|Over-the-counter antiseptic mouth rinse
45997172|NCT04721457|Drug|0.1% Sodium Hypochlorite|Over-the-counter antiseptic mouth rinse
45997173|NCT04721457|Other|No rinse group|second control group
45997174|NCT04666415|Other|Osteopathic treatment|Targeted osteopathic protocol for AN : 5 sessions of osteopathic treatment that are spaced around one week between 2 sessions. Soft specific palpatory techniques on the diaphragm, digestive system and cervical region will be realized during the session of 25 minutes.
45997175|NCT00557024|Procedure|RFA|radiofrequency ablation
45997176|NCT00557024|Procedure|radiotherapy after RFA|radiotherapy after RFA
45997177|NCT04720989|Procedure|Bathing With Baby Cleanser and water|Late preterm and term newborns, whose informed consents are obtained by their parents to participate in the project, will be given their first baths according to the intervention group they are assigned to. Before the first bath / after birth, preterm newborns in all groups will be wiped only once with a clean towel without removing the vernix caseosa. Newborns who were bathed before the application of the study will be excluded from the study. As the most appropriate time for bath time, 30 minutes after the end of the feeding and treatment of the newborns, the bath application will be made at any time between 9 pm and 3 pm.
45997178|NCT04720989|Procedure|Bathing With only Water|Preterm infants will have their first baths only with water.
45997179|NCT04666493|Other|Cognitive behavior therapy (CBT), specifically using the Facing Your Fears (FYF) curriculum|The Facing Your Fears program (FYF; Reaven et al. 2011) is a CBT-based group treatment program that has been adapted for the needs of children with high-functioning ASD. The current project will adapt the FYF program for virtual delivery and examine its effectiveness.
46085791|NCT04506164|Other|Multicomponent Implementation Strategy|The eScreening MCIS was developed over the past seven years and consists of: 1) eScreening software provision, 2) training, 3) RPIW, and 4) ongoing blended facilitation. The investigators developed our MCIS to address specific eScreening implementation barriers found in the investigators' prior research.
46085792|NCT04506164|Other|eScreening|eScreening is a clinical patient self report system that allows Veterans to complete clinical reminders and other self report screens using a secure connection from any internet connected device.
45997180|NCT04711785|Behavioral|Multicomponent exercise program|"The exposed group will carry out the following program of specific muscle strength and cardio physical activity aimed at reducing frailty.~For 2.5 hours per week."
45997181|NCT04666220|Other|VETC evaluation|We will evaluate VETC presence on tissue specimens
45997182|NCT04684758|Other|Self-completion of a questionnaire|The questionnaire will be translated into 5 languages (English, Spanish, Portuguese, Arabic, and Russian) in order to allow almost all of the participants to answer the survey themselves, without assistance. In order to not exclude those who cannot read, or those who do not master any of the 6 languages offered, the questionnaire may be administered with the assistance of a member of the research team of the associated center, including through a telephone interpretation service, if necessary.
45997183|NCT04666142|Other|Comparison of the personal characteristics of the experimental and control groups|General characteristics of the individuals in the experimental and control groups were compared.
45997184|NCT04666142|Other|Light applied experimental group, control group treated with standard intensive care lighting|"According to the results of randomization, the group to which the lighting system will be applied was assigned as experiment, and the group that will continue standard ICU lighting as control"
45997185|NCT04650126|Biological|ATM001|monovalent anti-TNF-receptor 1 antibody format
45997186|NCT04650126|Biological|ATM001 Placebo|ATM001 Placebo
46002383|NCT03338764|Drug|SM-1|SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam self-administered as needed to promote sleep
45675284|NCT05887466|Drug|A9-DPC|"IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~Main ingredients and quantities: A9-DPC~7.0X10^6 cells (Use 3.15X10^6 cells of this)~1.4X10^7 cells (Use 6.30X10^6 cells of this)~Formulation: milky white cell suspension~Storage method: Refrigerated storage (5±3℃)~Expiration date: within 24 hours of manufacture~Dosage:~1st Stage Dosage: 3.15X10^6 cells/body (6 tracks in total, 52.5X10^4 cells per track)~2nd Stage Dosage: 6.30X10^6 cells/body (6 tracks in total, 105X10^4 cells per track)~Frequency: single dosing~Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
46002384|NCT03338764|Drug|Placebo|Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials, self-administered as needed to promote sleep
46002385|NCT03313544|Drug|Nivolumab|NIVOLUMAB
45675285|NCT05887453|Device|Magnetocardiography|Magnetocardiography is a device used to exam the dynamic magnetic map of the heart for the diagnosis of some heart diseases
46085793|NCT05322720|Biological|EOC202|EOC202 will be SC injection
46085794|NCT05322720|Drug|albumin-bound paclitaxel|albumin-bound paclitaxel will be Iv injection
45675286|NCT05887440|Behavioral|isokinetic strength training of knee extensor and flexor muscles|"Patients underwent an isokinetic strength training program with 3 sessions per week during five weeks.~Program consists of excentric contraction of knee flexor and extensor muscles (4 x 7 Contractions at 30°/s) and concentric contractions at maximal speed where patients can perform 40% of his maximal isometric torque for knee flexor and extensor muscles (2x10 for knee flexors and 2x10 for knee extensors)"
45675287|NCT05887427|Other|Neural Mobilisation|Transcutaneous Electrical Stimulation, hotpack, ultrasound and neural mobilization(radial,ulnar,median)
46085795|NCT05428280|Other|Physiotherapy|Conventional treatment consisted of Transcutaneous Electrical Nerve Stimulation and Progressive Back Strengthening Exercise
46085796|NCT04213170|Drug|sintilimab|Sintilimab 200mg d1 and Bevacizumab 15mg/kg d1 q21d
46002386|NCT03313544|Device|MRI|Cardiac MRI 6 MONTHS
46002387|NCT03313544|Biological|BLOOD SAMPLES|biological (BNP and troponin)
46002388|NCT03313544|Device|trans-thoracic echocardiography|1, 3 and 6 months
46002389|NCT03309579|Other|Liberal RBC Transfusion Strategy|RBC transfusion is triggered by a Hemoglobin value of ≤100g/L
46085797|NCT02749214|Other|Blood Sample Collection|Participants will have two to three tablespoons (30 cc) of peripheral blood drawn to test for inflammatory markers.
45997187|NCT04646616|Other|Community popular opinion leader (POL) based intervention|A community popular opinion leader (POL) based intervention to promote measures to reduce COVID-19 risk, transmission, access to testing and treatment, reduction of the impact of COVID-19, and addressing the Substance Abuse, Violence, HIV/AIDS, and MEntal health (SAVAME) syndemic in the community. POLs will interact within their networks counseling regarding COVID-19 and SAVAME factors. The POLs will refer individuals to appropriate community services. POLs will record basic sociodemographic characteristics of all community contacts, the issue addressed, and their response to it. The first 300 community contacts will be invited to complete a baseline and 3-month follow up surveys (via internet or phone). The content of the surveys includes: 1) COVID-19 related questions (knowledge, impact, symptoms, risk factors, access to testing and care, acceptability contact tracing, vaccine) 2) Biological risk factors, 3) Social determinants of health, 4) SAVAME outcomes and access to services.
45457405|NCT03477890|Diagnostic Test|Stratified medicine involving a diagnostic intervention|"Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or no-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017)."
46085798|NCT02749214|Other|Breath Sample Collection|Participants will be asked to breathe into the Breath Sampler containing a rapid passive volatile organic compounds (VOC) sampling device. A disposable mouthpiece is placed over a portion of the sampler where the participant placed his/her mouth. The mouthpiece will be disposed of after each use and a new one will be used for each participant. Prior to sample collection, the participant will be asked to rinse his/her mouth with water. Then the participant will breathe deeply into the sampler five times with breaths being five minutes apart to collect the alveolar breath.
45675288|NCT05887427|Other|Conservative physiotherapy|Hotpack,Transcutaneous Electrical Stimulation ,Ultrasound
45675289|NCT05887401|Behavioral|Core|The core intervention will include behavioral lessons, activity tracker, weekly adaptive physical activity goals, weekly tailored feedback summary.
46085799|NCT04866329|Other|Blood sample|Additional blood sampling at the end of ovarian stimulation monitoring (the eve of the oocyte pick-up)
46085800|NCT04866329|Other|Urine sample|Collection of the first urine in the morning on the day of the oocyte pick-up
46085801|NCT04866329|Other|Follicular fluid and granulosa cells sample|Collection of follicular fluid and granulosa cells during oocyte pick-up.
46085802|NCT05322564|Other|Standardized opiate prescription|The standardized prescription will include a single opiate, with a fixed dose and number of tablets. It will also include non-opiate adjuncts commonly prescribed at our institution, namely acetaminophen and an anti-inflammatory medication.
46085803|NCT05251649|Device|tACS combined with 40 Hz sound stimulation|"The tACS instrument (model: XPNS208-B). Two electrodes are placed in the dorsolateral prefrontal cortex and the contralateral supraorbital area. and connected to the tACS device via a thin cable. The intervention will be performed using tACS (40 Hz, 1.5 mA) for 15 sessions of 20 min over 3 weeks (21 days).~Sound stimulation apparatus: Two sponge earplugs were placed in the ears and the sound stimulator was set to (40Hz, 60dB). Sound stimulation was turned on simultaneously at the beginning of tACS. The duration of sound stimulation was set to 5 min stimulation, 5 min rest, 5 min stimulation, 1 min rest, and continued stimulation until the end of electrical stimulation while sound stimulation was turned off."
46085804|NCT05251649|Device|Transcranial alternating current stimulation|The tACS instrument (model: XPNS208-B). Two electrodes are placed in the dorsolateral prefrontal cortex and the contralateral supraorbital area. and connected to the tACS device via a thin cable. The intervention will be performed using tACS (40 Hz, 1.5 mA) for 15 sessions of 20 min over 3 weeks (21 days).
46085805|NCT05251649|Device|40 Hz sound stimulation|Sound stimulation apparatus: Two sponge earplugs were placed in the ears and the sound stimulator was set to (40Hz, 60dB). The duration of the sound stimulation was set to stimulate for 5 min, rest for 5 min, stimulate for 5 min, rest for 1 min, and last for a total of 20 min. 15 sessions of 20 min were performed over a period of 3 weeks (21 days).
46085806|NCT00616668|Device|Air- Limb|
46085807|NCT02749136|Drug|Preoperative modified FOLFIRINOX and postoperative gemcitabine|"Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles~Oxaliplatin IV 85 mg/m2 Day (D) 1~Irinotecan IV 180 mg/m2 D1~5-FU continuous IV infusion 2,400 mg/m2 over 46 hours D1-2~Leucovorin IV 400 mg/m2 D1~Postoperative gemcitabine, every 4 weeks, 3-6 cycles - Gemcitabine 1,000 mg/ m2 D1, 8, and 15"
45997188|NCT04665908|Other|Assessment by PT/Orth surgeon|Assessment by orthopaedic surgeon or a PT
45997189|NCT04644744|Device|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
46002390|NCT03309579|Other|Restrictive RBC Transfusion Strategy|Optional RBC transfusion is triggered by a Hemoglobin value of ≤80g/L
46002391|NCT03309150|Drug|M6620|Participant will either receive M6620 intravenously as a monotherapy on Day 1, 8 and 15 OR as a combination therapy on Day 2 and 9 of the study.
46085808|NCT00631631|Drug|Mifamurtide (L-MTP-PE)|Solution for intravenous infusion
46085809|NCT04219592|Diagnostic Test|IgG4 measurement (non-interventional, just obtaining data from medical records)|IgG4 measurement in mg/dL
46085810|NCT04720469|Device|MRgFUS thalamotomy|Ablation of untreated thalamus using focused ultrasound to abate tremor.
46085811|NCT03030612|Drug|ARGX-110|ARGX-110 will be administered intravenously.
46085812|NCT03030612|Drug|AZA|AZA will be administered subcutaneously/intravenously.
45997190|NCT04644744|Device|Normothermic machine perfusion (NMP)|End-ischemic NMP will be continued throughout the recipient hepatectomy and until the transplanting team is ready to implant the liver. The minimum protocol-stipulated NMP duration is 4 hours, the time needed for ATP repletion in animal studies. Total NMP preservation time will be according to the official recommendations of the manufacturer (4-24 hours) and at the discretion of the local transplant centre. The liver allograft will be disconnected from the OrganOx metra® device immediately prior to transplantation and flushed with three litres of HTK via the hepatic artery and the portal vein.
46085813|NCT02748746|Device|Bio Impedance Analysis Measurement|Self-adhesive electrodes will be placed to related side's hand dorsum and foot dorsum regarding to calculate for left or right upper extremity's impedance. After completing the measurements for each side, results will be saved by device and documented on paper. A patient total measurement time lasts approximately 3 minutes.
45997191|NCT04665986|Drug|Navelbine|Navelbine 25mg/m2 on day 1 and 8, every 3 weeks
45997192|NCT04665986|Drug|Docetaxel|Docetaxel 90mg/m2 on day 1, every 3 weeks
45997193|NCT04638309|Drug|APR-548 + Azacitidine|APR-548 monotherapy period followed by APR-548 in combination with Azacitidine
45997194|NCT04666103|Procedure|Intraoperative thermal ablation|"After the thyroid lobectomy, the contralateral benign thyroid nodule was treated with intraoperative thermal ablation. The hydrodissection technique'' was used during the ablation process to prevent recurrent laryngeal nerve, esophageal and other important structures from being destroyed by heat energy."
45997195|NCT04633473|Behavioral|SIB-Time Web-Application Tool|Parent-child dyads will use the SIBTime app in a 4-week intervention to test its relevance, acceptability, cultural appropriateness, and potential for efficacy.
45997196|NCT04666064|Diagnostic Test|Covid19 RT-PCR|patients admitted to ER for suspicion of COVID-19 infection will have a SARS-CoV-2 RT-PCR test
45997197|NCT04666064|Other|lung ultrasound|patients admitted to ER for suspicion of COVID-19 infection who has a SARS-CoV-2 RT-PCR test and for whom the emergency doctor decide to perform a lung ultrasound
45997198|NCT04632927|Biological|Secukinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
45997199|NCT04632927|Biological|Ustekinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
45997200|NCT04665830|Drug|Evolocumab|treated patients with evolocumab for high cholesterol
45997201|NCT04631133|Device|Lumbar Implant for Stiffness Augmentation (LISA)|The LISA Posterior Dynamic Stabilization System is intended to treat low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification).
45997202|NCT04665791|Biological|Intranasal inoculation with Neisseria lactamica|Lyophilised Neisseria lactamica will be reconstituted and administered to participants intranasally.
45997203|NCT04665674|Other|Standard of care|Standard of car of pulmonary Langerhans cell histiocytosis (PLCH)
45997204|NCT04683237|Drug|Liraglutide Injection|Initiate liraglutide with a dose of 0.6 mg daily for one week. After one week at 0.6 mg per day, increase the dose to 1.2 mg daily in a week, and increase the dose to 1.8 mg daily after at least one week of treatment with the 1.2 mg daily dose. If the patients can not tolerate 1.8mg per day, decrease the dose to the max tolerable dose.
45997205|NCT04683237|Drug|Megestrol Acetate 160 MG|160mg po qd
45997206|NCT04665518|Other|Acupressure|Acupressure will be applied to the patients in the acupressure group for 10 min before the venipuncture procedure. Venipuncuture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 * 38 mm (21G x 1½, green).
46085814|NCT02748746|Device|Tissue Dielectric Constant Measurement|In this study, TDC device (Moisture Meter-D compact-MMDc will be implemented to upper extremity both affected and unaffected side. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. A gentle pressure must required to have accurate sub-tissue fluid percent. Triplicate measurements will be done and taken those average value for each point in order to reach sensitive screening. Computer software simultaneously save these measurements results automatically. A patient total measurement time approximately lasts 5 minutes.
46085815|NCT04238429|Drug|Toothpaste containing 10% high cleaning silica base, 0.5% sodium phytate and 0.5% sodium pyrophosphate|Use the toothpaste to brush teeth twice a day for 8 weeks
46085816|NCT04238429|Drug|Control toothpaste|Use the toothpaste to brush teeth twice a day for 8 weeks
45675290|NCT05887401|Behavioral|Simplified Nutrition Monitoring (Green)|Simplified diet monitoring using smartphone tracking of green foods using a traffic light approach.
45997207|NCT04568694|Procedure|Delayed Lung Transplantation|Transplants with a planned recipient anesthesia start time between 10:00 pm and 6:00 am will be allowed to move to a start time between 6:00 am and 8:00 am at the earliest. Donor lung(s) cross clamp time must occur between 5:00 pm and 4:00 am. Lungs that meet criteria will be transported in the usual fashion in a cooler of ice at 4oC. Upon arrival to NYULH, the lungs will be transferred to cold static preservation at 10oC within a specific incubator located in a NYULH OR (MYTEMP™65HC, Benchmark Scientific).
45997208|NCT04568694|Procedure|Conventional Lung Transplantation|Reference Therapy
45997209|NCT04549701|Other|CAVAL US-guided Therapy|Patients randomly assigned to this group will receive a daily CAVAL US exam guided decongestive therapy accessible to treating medical team, in addition to the standard care.
45997210|NCT04549701|Other|Standard of care|Standard of care will be provided.
46002392|NCT03309150|Drug|Carboplatin|Participant will receive carboplatin intravenous infusion as a combination therapy on Day 1 of the study.
46085817|NCT04216862|Other|Exercise|Different type of exercises for treatment of Forward Head Posture
45997211|NCT04665362|Drug|Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib|"Drug: Recombinant oncolytic virus M1~Recombinant oncolytic virus M1 is administered intravenously 1×109 CCIC50 once daily on day1-5, every 28 day cyle.~Other name：M1-c6v1~Drug：Anti-PD-1 antibody~Anti-PD-1 antibody is administered intravenously 200 mg once every 2 weeks.~Other names：SHR-1210, Camrelizumab~Drug: Apatinib~Apatinib is administered orally 250mg once daily.~Other name: Apatinib"
45997212|NCT04683120|Diagnostic Test|Zenith FLIM Diagnostics|In-vitro
45997213|NCT04665401|Behavioral|Tailored MERIT|see arm description
46085818|NCT02999022|Drug|Lithium Carbonate|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
45997214|NCT04665401|Behavioral|Standard MERIT|see arm description
46085819|NCT02999022|Drug|Lactose Placebo|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
46085820|NCT02748902|Drug|ingenol mebutate 0.05% gel|Ingenol mebutate 0.05% gel applied to a minimum of two and a maximum of five common warts on days 1 and 2.
46085821|NCT04238741|Other|Audio-recording of consent for anaesthesia for elective caesarean section|Antenatal women will be invited to attend 5-15 days before their caesarean section for an anaesthetic consent discussion with audio-recording. Participants will complete a questionnaire immediately following the recorded discussion and again within the 48 hours following their surgery, to establish their views on the process of audio-recording of consent and the potential usefulness/acceptability of the audio-recording.
45997215|NCT04506255|Device|Silicone tape|Medical grade tape with silicone adhesive
46085822|NCT02691858|Drug|Hydrocortisone|10 mg/kg with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
45997216|NCT04503291|Procedure|Metal stent placement|Non-covered biliary metal stents are placed by endoscopy. The distal ends of metal stents are located above the major ampulla in the common bile duct or below the major ampulla in the duodenum.
46085823|NCT02691858|Drug|Saline|100 ml with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
46085824|NCT04218500|Other|Niacinamide 4%|cream moisturizer
45834673|NCT05603988|Device|Intracanal Diode laser irradiation|After endodontic retreatment, root canals will be irradiated with a 980 nm diode laser coupled with optical fibre 200 μm (Litemedics, Italy) with setting 1.2-watt power, in pulsed mode. The irradiation protocol will be of 5-sec irradiation followed by a 10-sec pause, which constituted one lasing cycle. The lasing cycle will be performed four times for each tooth. The tip will be positioned 1 mm short of the apex. Followed by activation during which it will be slowly dragged at a speed of approximately 2 mm/ sec in a way that the root canals will be irradiated from the apical to the coronal portion, in a helicoidal movement touching the canal walls.
45997217|NCT04498182|Drug|AR15512|Administered via topical ocular instillation, one drop per eye, twice daily for 84 days. Both eyes will be treated.
46085825|NCT04218500|Other|Virgin Coconut oil 30%|cream moisturizer
46085826|NCT04077671|Biological|CHF6467 active|CHF6467, is mutated form of the human Nerve Growth Factor (NGF).
46085827|NCT04264208|Drug|68-Ga RM2.|PET radiopharmaceutical
46085828|NCT04264208|Drug|68-Ga PSMA11|PET radiopharmaceutical
46085829|NCT04264208|Device|PET/MRI|PET/MR scanner by GE healthcare
46085830|NCT04598633|Dietary Supplement|Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289)|Supplementary intake of Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) 2 times per day for 12 weeks
45997218|NCT04498182|Drug|Vehicle|Administered via topical ocular instillation, one drop per eye, twice daily for 84 days. Both eyes will be treated.
45997219|NCT04494555|Device|Static socket|For the static socket configuration, both the microprocessor control and user control are disabled, and the panels are positioned in their flush configuration to create the user's as-prescribed socket shape.
45997220|NCT04494555|Device|User adjusted socket|Sockets are configured for user control by disabling automated control and enabling push buttons on the side of the socket to adjust socket size. Each button push effects a socket size change of approximately 0.3% volume. An upper button effects a socket size increase, and a lower button a socket size decrease. The buttons are countersunk so reduce risk of accidental pushes, and they do not function unless the user is stationary. An additional button push will not be executed until motor motion from the prior push has been completed. If a button is continuously held then the motor will continue moving until the button is released. Limits are set on cable length to ensure that sockets sizes threatening to the user's residual limb (too tight) are avoided. The push buttons effect inner-loop control that operates completely within the mechanism, achieving high-resolution adjustment of cable length with minimal error.
46002393|NCT03309150|Drug|Paclitaxel|Participant will receive paclitaxel intravenous infusion as a combination therapy on Day 1, 8 and 15 of the study.
46002394|NCT03266783|Drug|Apixaban|Refer to Apixaban group
46002395|NCT03266783|Drug|Rivaroxaban|Refer to Rivaroxaban group
46085831|NCT04598633|Dietary Supplement|Placebo-lozenges (BioGaia)|Placebo-lozenges (BioGaia) 2 times per day for 12 weeks
46085832|NCT05412056|Drug|Metformin|as in arm/group description
46085833|NCT05412056|Drug|Placebo oral tablet|as in arm/group description
46085834|NCT04541381|Other|Availability of clinical decision support based on pharmacogenomic results.|Availability of clinical decision support based on pharmacogenomic results. These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.
46085835|NCT04453046|Device|Hemopurifier|Two Hemopurifier treatments on Day 1 and Day 21
46085836|NCT04453046|Drug|Pembrolizumab 200mg IV|Pembrolizumab 200mg IV will be administered every 21 days. One cycle is 21 days. All patients will be treated with Pembrolizumab for up to 34 cycles
46085837|NCT02748590|Device|InterStim II Neurostimulator Model 3058|The neuromodulation will be carried out according to the usual protocol: Hospitalization for the establishment of percutaneous electrode in the operating room under general anesthesia with fluoroscopic control. The pacemaker startup will be performed within 12h after surgery
46085838|NCT00913523|Device|Experimental - Tampon with GML|Regular and Super Tampon with Glycerol Monolaurate (GML) added to the cover
45997221|NCT04494555|Device|Microprocessor-adjusting sockets|"A strategy for automatically controlling the size of the socket during walking to compensate for unknown changes in limb volume will be used. The controller is essentially a regulator that continuously measures socket fit, and adjusts the socket to maintain a prescribed reference set point. Because the fit is automatically sustained, the prosthesis user is unaware of its operation."
45997222|NCT04665050|Biological|pPCV|pPCV vaccine 1.0 mL solution, at a dose to be determined, for intramuscular (IM) injection.
45997223|NCT04665050|Biological|PNEUMOVAX™23|PNEUMOVAX™23 0.5 mL solution, at a dose to be determined, for IM injection.
45997224|NCT04665167|Behavioral|Body image exposure|Exposure therapy is a key element of evidence-based cognitive behaviour therapy for eating disorders . Body image exposure intervention involves deliberate, planned, and systematic exposure to the body image. Participants will be asked to stand so that they can see their whole body - far enough back. Participants will be asked to look at their bodies on screen. Participants will be continually encouraged by the facilitator for looking at and talking about the body parts.
45997225|NCT04665167|Behavioral|Self-compassion|The self-compassion intervention condition consists of Neff's self-compassion exercises. These exercises are part of the self-compassion intervention condition. Meditation text used in this study is obtained from the following link https://self-compassion.org/category/exercises/.
45997226|NCT04459884|Procedure|mechanical ventilation|mechanical ventilation > 48h
45997227|NCT04665011|Device|Indicor|A simple, non-invasive tool to report pulse response to a Valsalva maneuver
45997228|NCT04665011|Device|Caretaker|non-invasive blood pressure monitor
45997229|NCT04665284|Drug|Empagliflozin|Group A: Empagliflozin 10/25 mg once daily with or without antidiabetic drugs
45997230|NCT04665284|Drug|Usual care group|Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
45997231|NCT04432974|Device|Automatic closed-loop anesthesia|Total intravenous anesthesia performed with the ACTIVA automatic control system
45997232|NCT04664894|Drug|Sofosbuvir|the occurrence of AEs (AE) and their severity among chronic HCV patients has assessed in patinets receiving different combinations of DAAs in Pakistani Population
45997233|NCT04424394|Device|DualStim Therapy|6 DualStim Therapies over a period of 7 weeks.
45997234|NCT04424394|Biological|Umbilical cord-derived Wharton's Jelly|2 intracavernosal injections over a period of 7 weeks.
45458385|NCT01363154|Other|No music exposure|Subject's will not receive an intervention and will therefore, not receive auditory stimulation and/or exposure to music.
45675291|NCT05887401|Behavioral|Behavioral: Simplified Nutrition Monitoring (Red)|Simplified diet monitoring using smartphone tracking of red foods using a traffic light approach.
45997235|NCT04424394|Other|Saline|2 intracavernosal injections over a period of 7 weeks.
45997236|NCT04664660|Other|Retrospective analysis of obstetrics outcomes|Retrospective analysis of clinical records including general medical and gynecological history, pregnancy course, delivery mode and newborn conditions.
45997237|NCT04421625|Diagnostic Test|Diagnostic test for SARS-Cov2 for patients and health staff|"Diagnostic test for SARS-CoV2 :~Blood test to analyse the IgG and IgM with an immediate qualitative analysis (serological test) and a differed quantitative analysis (ELISA test)~Results of nasal swab that will allow extracting the RNA and realizing a RT-PCR (only if the participants present symptoms). It will be obtained by standard local laboratories.~Questionnaires (based on serology, clinic, economy (socio-demographic and lifestyle questionnaire) and epidemiology)"
45997238|NCT04664699|Device|Plethymographic Variability Index|"All patients were monitored with the electrocardiogram (ECG), Non Invasive Blood Pressure (NIBP), Pulse oximetry (SpO2) and invasively with an arterial line and central venous line as per institutional protocol. In the PVI group, a pulse oximetry probe was connected to the fourth finger of the hand that did not have an arterial cannulation. The pulse oximeter was connected to a monitor The Massimo ® pulse oximeter (Massimo Corp., Irvine, CA, USA), which has a module for PVI measurements.~PVI ≥13% indicates volume responsiveness, and PVI < 13% indicates adequate volume"
45997239|NCT04664699|Device|Standard Monitoring|All patients were monitored with the electrocardiogram (ECG), Non Invasive Blood Pressure (NIBP), Pulse oximetry (SpO2) and invasively with an arterial line and central venous line as per institutional protocol. Patients were resuscitated according to mean arterial pressure/ heart rate and urine output.
45834674|NCT05603988|Other|Placebo|"After endodontic retreatment, mock laser application (Placebo group) will be applied:~The fiberoptic tip will be inserted inside the root canal, mimicking the laser irradiation group, but not activated"
45834675|NCT04392492|Device|MANTA vascular closure device|Femoral access site closure using the MANTA closure device
45997240|NCT04416204|Other|High Carbohydrate (glycogen loading)|Subjects will consume an isocaloric diet [60% carbs, 20% protein, 20% fat (33 kcal/kg/day)] for 3 days prior to the overnight study.
45997241|NCT04416204|Other|Low carbohydrate (No Glycogen Loading)|Subjects will consume an isocaloric diet [40% carbs, 20% protein, 40% fat (33 kcal/kg/day)] for 3 days prior to the overnight study.
45997242|NCT04664504|Combination Product|Concurrent Chemoradiotherapy Radiotherapy|50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. Concurrent chemotherapy: Capecitabine 1650 mg/m2/d.
45997243|NCT04664504|Radiation|Short-course Radiotherapy|25Gy in 5 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.
46002396|NCT03251859|Drug|Ticagrelor 90 mg|Ticagrelor 90 mg twice daily
45675292|NCT05887401|Behavioral|Nutrition Goals (Yes)|Participant will be assigned a personalized weekly nutrition goal related to nutrition monitoring condition.
45675293|NCT05887401|Behavioral|Nutrition Goals (No)|Participant will not be assigned a personalized weekly nutrition goal.
45834676|NCT04392570|Diagnostic Test|Fasting|blood samplings will be taken 08:00 am and again 2 hours before breaking the fast
45834677|NCT03827304|Device|Virtual Reality Distraction from Burn Pain|Patients wore a VR headset while undergoing a burns dressing change
45834678|NCT02675244|Procedure|TV Annuloplasty|TV Annuloplasty will be performed using standard surgical techniques
45834679|NCT02675244|Procedure|MVS|MVS will be performed using standard surgical techniques
45997244|NCT04664504|Radiation|Local dose increase of Short-course Radiotherapy|25Gy in 5 fractions to the of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. And 4Gy in 1 fractions to the PGTV of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.
45997245|NCT04664504|Drug|Consolidation chemotherapy|Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 4 cycles. 4 courses*3 weeks per course.
46085839|NCT00913523|Device|Sham Control - Tampons without GML|There is no intervention associated with these arms - they are sham controls.
45997246|NCT04664504|Drug|Adjuvant chemotherapy|2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles. 6 courses*3 weeks per course
45997247|NCT04664504|Procedure|TME|Total mesorectal excision
45997248|NCT04415073|Drug|SNDX-6352|SNDX-6352
45997249|NCT04415073|Drug|Placebo|Placebo comparator
45997250|NCT00557102|Biological|cetuximab|
45997251|NCT00557102|Biological|filgrastim|
45997252|NCT00557102|Drug|fluorouracil|
45997253|NCT00557102|Drug|irinotecan hydrochloride|
45997254|NCT00557102|Drug|leucovorin calcium|
46085840|NCT04213482|Radiation|Panoramic Radiography|Diagnostic Panoramic Dental Radiographs were taken.
46085841|NCT04216628|Other|Amniotomy|Artificial rupturing of membranes and IV infusion of Oxytocin
45997255|NCT04682808|Drug|FCN-338|FCN-338 will be given orally in ascending doses starting at 50 mg QD until the maximum tolerated dose or recommended dose is reached.
45997256|NCT04664543|Other|Free diet|To follow the regular dietary habits with no restriction nor modification.
45997257|NCT04664543|Other|Three days low residue diet|To follow the three days before colonoscopy a diet with low content in fiber or residues.
45997258|NCT04682613|Behavioral|"Experimental: Prevention Program young In Favor of Myself, active teachers"|"Prevention program: young In Favor of Myself, with teacher participation"
45997259|NCT04682613|Behavioral|"Experimental: Prevention Program young In Favor of Myself, no teacher involvement"|"Prevention program: young In Favor of Myself, without teacher participation"
45997260|NCT04664816|Drug|n-3PUFAs Treatment|Omega-3 plus (1200 mg) orally, twice a day for at least 12 months.
46085842|NCT04217096|Drug|Paclitaxel liposome|Patients receive paclitaxel liposome 175 mg/m^2 (iv, 3h) on day 1 for 3 weeks. Treatment repeats every 3 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic
46085843|NCT04217096|Drug|S-1|Patients receive S-1 at a dose according to the body surface area（<1.25m^2，40mg Bid；1.25~1.5m^2,50mg Bid；>1.50m^2,60mg Bid）on days 1-14 for 3 weeks. Treatment repeats every 3 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
46085844|NCT02748278|Procedure|Transvaginal ultrasound-guided oocyte retrieval|Transvaginal ultrasound-guided oocyte retrieval will be performed 34-36 hours after hCG injection.
46085845|NCT02748278|Procedure|Embryo transfer|One or two embryos will be replaced on day 2-5 after oocyte retrieval.
46085846|NCT02699814|Behavioral|H3 Services|A community-based integrated care model to improve the prevention, early detection and treatment of child mental health problems
45458386|NCT03501316|Device|Hand Instrumentation Treatment|Provision of treatment for periodontal disease using hand instrumentation. Following this, data will be collected relating to various factors, principle of which being systemic immune response.
46085847|NCT05411978|Drug|Idebenone+ placebo|Participants will receive Idebenone 30 mg+ placebo 60 mg for 12 weeks.
46085848|NCT05411978|Drug|Idebenone|Participants will receive Idebenone 90 mg for 12 weeks.
45458387|NCT03501316|Device|Ultrasonic Instrumentation Treatment|Provision of treatment for periodontal disease using ultrasonic instrumentation. Following this, data will be collected relating to various factors, principle of which being systemic immune response.
45675294|NCT05887401|Behavioral|Supportive Text Messages (Yes)|Participant will receive up to 5 supportive text-messages from the study staff per week.
45997261|NCT04664816|Drug|Placebo Treatment|Placebo orally, twice a day for at least 12 months.
45997262|NCT04682691|Drug|Erythromycin (400mg)|parturients will receive oral Erythromycin (400mg)
45997263|NCT04682691|Drug|metoclopramide (10mg)|will be receive oral metoclopramide (10mg)
45997264|NCT04682691|Dietary Supplement|naturally flavored water|will be receive naturally flavored water
45997265|NCT04664348|Other|Posteroanterior mobilization (neutral)|"Positioning of the patient: Prone position with the lumbar area uncovered.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain.~Both groups: The patient will be provided with a list of exercises focused on improving resistance to mechanical load in the lumbar region. The completion of the exercise will be in the 6 weeks of the duration of the treatment."
45997266|NCT04664348|Other|Posteroanterior mobilization (extension)|"Positioning of the patient: Prone position with the lumbar area uncovered. The head of the stretcher will be raised upwards, placing progressively to extend the lumbar region, until the patient communicates the reproduction of its symptoms.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain."
45997267|NCT04682886|Diagnostic Test|diagnosis|there is no intervention diagnosis or treatment for patients
46085849|NCT05411978|Drug|Placebo|Participants will receive Placebo 90 mg for 12 weeks
45834680|NCT03820674|Other|Energy Conservation plus Problem Solving Therapy|EC-PST is a client-centered intervention aiming to guide people with chronic fatigue to create their own solutions so that they can generalize those learned solutions and strategies to other fatigue-related problems even after completing the study participation. Some of the topics covered during the first two introductory sessions are facts regarding fatigue, budgeting and banking energy, and the introduction of EC+PST Intervention.
45834681|NCT03820674|Other|Health Education Intervention|The interventionist will be the PI, an occupational therapist (co-I), or OT graduate student who will be trained in the health education topics. During the Health Education sessions, participants will be educated on health-related topics relevant to CHF and EC strategies, although they will not learn how to apply the information to their daily life. Health Education Workbook containing information on the topics taught during the sessions will be provided during the Pretest visit and used throughout the Health Education sessions.
45834682|NCT03820518|Drug|Calcitriol|
45834683|NCT03820440|Diagnostic Test|End-expiratory occlusion test (EEOT)|The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
45834684|NCT03820440|Diagnostic Test|Lung recruitment manovre (LRM)|The LRM is performed by using a single act of mechanical ventilation in pressure-controlled mode at 30 cmH20 for 30 seconds
45834685|NCT01453764|Procedure|Harvesting and Implantation of SVF|The cell therapy in this study is composed of stem cells derived from a patient's own adipose tissue that are harvested by liposuction using tumescent technique and isolated in the laboratory. The Adipose SVF will be delivered via intravenous injection.
45834686|NCT03820206|Drug|Tranexamic Acid|1 g (10 mL) tranexamic acid stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
45834687|NCT03820206|Procedure|Cesarean section|Lower segement transverse cesarean section
45834688|NCT02955654|Behavioral|Acceptance and commitment therapy|Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.
45834689|NCT02955654|Drug|Aripiprazole|Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.
45834690|NCT02955654|Behavioral|Stress management training|Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
45834691|NCT01453842|Dietary Supplement|Diet oil|Carrot and diet oil (containing 2-OG) and 1½ g of paracetamol
45834692|NCT01453842|Dietary Supplement|Olive oil|Carrot and olive oil and 1½ g of paracetamol
45834693|NCT01453842|Dietary Supplement|Carrot|Carrot and 1½ g of paracetamol
45834694|NCT03826836|Behavioral|Mindfulness-based stress reduction|Mindfulness-based stress reduction (MBSR) is a structured programme of 8 weekly sessions of 2-2,5 hours in groups of 8-16 participants organized at the hospital sites. Additionally, participants are encouraged to practice each day for 30-45 minutes using audio-recordings of the guided exercises. The programme is provided by experienced mindfulness teachers according to the standard MBSR protocol, except for the all-day session.
45834695|NCT04392648|Drug|TAK-573|TAK-573 intravenous infusion.
45834696|NCT04392648|Drug|Pomalidomide|Pomalidomide capsules orally.
45834697|NCT04392648|Drug|Bortezomib|Bortezomib injection subcutaneously.
45834698|NCT04392648|Drug|Cyclophosphamide|Cyclophosphamide tablets orally.
45834699|NCT04392648|Drug|Dexamethasone|Dexamethasone tablets orally.
45834700|NCT03826602|Drug|Tucatinib|150mg administered orally twice daily
45834701|NCT03826602|Drug|Metformin|850mg administered orally
45834702|NCT03826602|Drug|Iohexol|1500 mg administered intravenously (IV)
45834703|NCT03820128|Other|Early diet intervention|Participant's diet includes several low-fiber and low-fat commonly available meals and products. Patients will choose what they want to eat with no amount or calories restriction.
45834704|NCT01453920|Drug|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
45834705|NCT01453920|Drug|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
45834706|NCT02916966|Other|Patient Registry|Patient Registry
45834707|NCT03821220|Behavioral|Motivational Interview support and Dietitian support|Three sessions of a structured motivational support intervention. Each patient will be required to set a SMART physical activity personal objective. The sessions will cover possible barriers and facilitators, enhancing self-efficacy, and feedback. In addition two sessions with a dietitian to discuss ways to improve current health habits.
46002397|NCT03251859|Drug|Ticagrelor 60 mg|Ticagrelor 60 mg daily
46002398|NCT03186638|Drug|Ibuprofen|Given PO
46002399|NCT03186638|Other|Placebo|Given PO
46002400|NCT03186638|Other|Questionnaire Administration|Ancillary studies
45675295|NCT05887401|Behavioral|Supportive Text Messages (No)|Participant will not receive supportive text-messages.
45675296|NCT05887401|Behavioral|Lesson Delivery (Once)|All behavioral lessons will be made available to participant simultaneously.
45834708|NCT03821220|Behavioral|Activity tracker plus usual care|Each patient will receive their own activity tracker (vivofit 3) with instructions on use, in addition to usual care, and written handouts for pre-diabetic patients.
45834709|NCT03821220|Behavioral|Personalized physical activity prescription|Each patient will receive a personalized prescription of recommended physical activity including type of activity, duration and frequency.
45834710|NCT03820908|Drug|Bisantrene|The patients will receive bisantrene 250mg/m2/d for 7 days in conjunction with the conventional supportive care.
45834711|NCT02953548|Drug|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
45834712|NCT02953002|Device|Calibrated Automated Thrombogram (CAT)|The Calibrated Automated Thrombogram (CAT). Thrombogram describes the concentration of thrombin in clotting plasma and is therefore a general physiologic function test of the thrombotic hemostatic system. The CAT measures thrombotic as well as bleeding tendency.
45834713|NCT02952456|Other|interview with a psychologist|interview with a psychologist in Bereaved families, Patients with épilepsy and relatives of patients with epilepsy Relatives (Parents / spouse/ Husband) of patients with epilepsy
45997268|NCT04664114|Behavioral|Virtual Reality|Ultrasound images of the fetus in the 28th week of pregnancy of the women in the intervention group were recorded. These images were shown to the woman through virtual reality glasses during the labor. Routine practices in the hospital were made to the women in the control group. VAS (Visual Analog Scale) was applied to women in both groups when cervical dilatation was 4 and 9 cm. Approximately two hours after giving birth (to allow mothers to breastfeed their babies and to stabilize the mother's vital signs), the Women's Perception of Supportive Care at Birth Scale (POBS) and Perinatal Anxiety Screening Scale (PASS) were administered.
45997269|NCT04682418|Device|xvision Spine sytem|pedicle screw placement will be performed using the XVS navigation system
45997270|NCT04664036|Diagnostic Test|ultrasound|ultrasound to check for NAFLD according to Saverymuttu criteria
45997271|NCT04664036|Diagnostic Test|elastography|elastography to compare liver stiffness indices
45997272|NCT04664036|Diagnostic Test|controlled attenuation parameter (CAP)|CAP is a non-invasive additive on Fibroscan (trademark) which can quantify hepatic steatosis
45997273|NCT04664036|Diagnostic Test|FLI|the FLI is a score panel designed to screen for NAFLD
45997274|NCT04664036|Diagnostic Test|FIB-4|the FIB-4 is a score panel designed to screen for significant fibrosis
45997275|NCT04664036|Diagnostic Test|NFS|the NFS is a score panel designed to screen for significant fibrosis
45997276|NCT04383912|Drug|Botox Injectable Product|The side randomized to receive treatment will be injected with onabotulinum toxin A. Wound healing, scar characteristics, and patient satisfaction will be assessed post operatively. Scarring will be assessed by the patient, medical observers and a lay observer, all masked to the treatment vs placebo side. Standardized scales will be used, and pre-operative, intra-operative, and post-operative photographs will be taken for all participants. ImageJ software will be used to analyze the photos and measure the degree of brow lift achieved on each side, to ensure this has not been affected by onabotulinum toxin injection.
45997277|NCT04383912|Other|No intervention (placebo)|This group (of brows) will be receiving placebo injections containing normal saline. They will be assessed in the same manner as the treatment side.
45997278|NCT01209286|Biological|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
45997279|NCT05423080|Drug|Bolus injection of remimazolam|Participants in this group are administered 0.2 mg/kg remimazolam via the bolus injection method for 20 seconds during anesthesia induction. If loss of consciousness (LOC) does not occur, the investigators will administer additional doses of 0.05 mg/kg repeatedly until LOC occurs.
45997280|NCT05423080|Drug|Infusion of remimazolam|Participants in this group are administered remimazolam at a rate of 6 mg/kg/hr via the continuous infusion method during anesthesia induction. If loss of consciousness (LOC) does not occur, the investigators will escalate infusion dose to 12 mg/kg/hr until LOC occurs.
45997281|NCT04376736|Other|Home visit|Home visit by medical provider
45997282|NCT04663763|Drug|PD-1 antibody|Sintilimab is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor. Usage: 200mg ivgtt d1 q3w.
45997283|NCT04663763|Drug|Capecitabine|Usage: 1000mg/m2 d1-14 q3w
45997284|NCT04663763|Drug|Oxaliplatin|Usage: 130mg/m2 d1 q3w
45675297|NCT05887401|Behavioral|Lesson Delivery (Weekly)|A new behavioral lesson will be made available to participant weekly throughout the 12 weeks.
45675298|NCT05887388|Behavioral|Connect-Home Plus|Connect-Home Plus will introduce organizational structure to support delivery of transitional care processes. New elements of structure include:electronic health record (EHR) template, Connect-Home Plus Toolkit, and Staff Training. After structural elements are added, SNF staff will use Connect-Home Plus care processes to deliver the 2-step transitional care intervention.In Step 1, SNF nurses,therapists, and social workers will develop a Transition Plan of Care and prepare the patient and caregiver to manage the illness and functional needs. In Step 2, a dementia caregiving specialist will call the patient's home three times within 30 days of discharge. Both intervention steps will focus on key care needs, such as 1) home safety; 2) care of symptoms of ADRD; 3) symptom management; 4) medication reconciliation; 5) function and activity; and 6) coordination of follow-up medical care.
45675299|NCT05887375|Drug|Sugammadex|Sugammadex will be used to reverse rocuronium neuromuscular blockade (NMB). Dose will be according to participant actual body weight.
45675300|NCT05887375|Drug|Neostigmine|Neostigmine will be used to reverse rocuronium NMB. Dose will be according to participant actual body weight.
45675301|NCT05887375|Drug|Glycopyrrolate|Glycopyrrolate will be co-administered with neostigmine during reversal of rocuronium NMB. Dose will be according to participant actual body weight.
45997285|NCT04663880|Other|Exposure to placebo in EEC|Patients are exposed to placebo (saline solution) in the EEC for 4h maximum
45675302|NCT05887375|Drug|Rocuronium|To achieve NMB, participants will receive the steroidal neuromuscular blocking agent Rocuronium Bromide administered via IV infusion and dosed according to participant actual body weight. It will be used per label to maintain muscle relaxation as an adjunct to general anesthesia.
45997286|NCT04663880|Other|Exposure to three concentrations of HDM allergen in EEC|Patients are exposed to different concentrations of airborne HDM allergen (Der p1) in the EEC for 4h maximum
45997287|NCT04663880|Other|Exposure to a single concentration of HDM allergen in EEC|Patients are exposed to a single concentration of airborne HDM allergen (Der p1) in the EEC for 4h maximum
45997288|NCT04663919|Procedure|Bariatric surgery-RYGB|"After the creation of a 15-25-cc gastric pouch from the upper stomach, transection of proximal jejunum 70 cm from Treitz ligament also called alimentary tract and anastomosis of the distal end of jejunum to the gastric pouch, and thereafter, anastomosis of the proximal end of transected jejunum to the distal part of the jejunum at 150 cm below the site of transection (jejunoileal anastomosis)."
45997289|NCT04663919|Behavioral|Dietary intervention|High-calorie medical nutrition program to ensure weight gain
45997290|NCT04353102|Drug|YH002|YH002 will be administered intravenously every three weeks (Q3W) for up to 2 years at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F, Dose G, and Dose H.
45997291|NCT04663958|Diagnostic Test|Detection / Screening|The patients were followed up in the postoperative care unit. The presence of postoperative pulmonary complications was evaluated, and the time of discharge was recorded. On the 30th day after discharge, patients were called and checked their status in terms of mortality.
45997292|NCT04351737|Drug|Intracanalicular Dexamethasone, (0.4 mg) Insert|To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo bilateral pterygium surgery.
45997293|NCT04351737|Drug|Prednisolone Acetate|To reduce post-surgical pain and inflammation in patients who undergo bilateral pterygium surgery.
45997294|NCT04347915|Drug|Clevudine|Clevudine 120mg once a day for 14 days (up to 21 days)
45997295|NCT04347915|Drug|Placebo|Matching Placebo once a day for 14 days (up to 21 days)
45997296|NCT03455361|Procedure|Stark Implant with low primary stability|
45997297|NCT04663685|Other|Exercise program|Participants will start with receiving two 1-on-1 exercise sessions per week. Each session is anticipated to last 30 minutes. As progress is made, participants will be encouraged to exercise independently outside the structured sessions while continuing to receive a 1-on-1 session each week. The individualized exercises are aligned with functional movements to promote personal relevance: balance, pull, squat, push, hinge, lift & carry and calf raise.
45997298|NCT04663685|Other|Nutrition education|Participants will receive a nutrition education booklet and have access to 5 online videos that correspond to key topics in the booklet, including: reading nutrition labels, types of protein, foods containing protein, incorporating protein into meals, spreading protein in meals throughout the day. Participants will attend three 60-minute nutrition seminars led by a dietitian, where the group will review content from the booklet and videos, and discuss personalized strategies for protein intake.
45997299|NCT04663334|Other|inverse myocardial remodeling|a myocardial reverse remodeling is described, generating a decrease in hypertrophy, interstitial oedema, and inflammation. Its effect on coronary microcirculatory reserve is not known. Some studies have shown improvement in coronary reserve immediately after TAVI and this effect seemed to last long after treatment
45997300|NCT04663451|Radiation|radioacive iodine therapy|Hyperthyroid patients who have undergone radioactive iodine treatment to cure them from their hyperthyroidism.
45997301|NCT04185051|Drug|JNJ-67953964|Participants will receive JNJ-67953964 as oral capsules.
45997302|NCT04185051|Drug|Placebo|Participants will receive matching placebo oral capsules.
46002401|NCT03156660|Behavioral|Weight gain prevention (Group 1)|"Participants will be asked to keep their weight stable during the initial 8 weeks of the study.~Intervention Components:~Lesson materials adapted from the Small Changes intervention, which will provide guidance for meeting the goals of this intervention (i.e., increasing steps by 2000 steps per day, making one Small dietary Change each day).~Daily self-monitoring of steps and number of Small Changes~Daily weight self-monitoring on the BodyTraceTM e-scale~Fit Bit Alta activity trackers to self-monitor steps"
45675303|NCT05887362|Behavioral|Hand Reflexology|Reflexology is a well-known, safe, and noninvasive alternative medicine technique. It alludes to a treatment that is applied to particular areas of the hands and feet. The compression on the hands or feet serves as a sensor linked to particular body areas. These sensors are activated by the reflexology technique to improve blood flow, energize, relax, and maintain homeostasis.
45997303|NCT04663412|Other|Sentinel lymph node mapping with indocyanine green fluorescence imaging in vulvar cancer (FIGO Stage IB)|Patients diagnosed with vulvar squamous cell carcinoma (FIGO IB stage) underwent bilateral radical vulvectomy, SLN search and removal, and bilateral inguinal lymphadenectomy at the Cannizzaro Hospital Operative Unit of Obstetrics and Gynecology Department (Catania, Italy). 3 ml of indocyanine green (ICG) 0.5 mg/mL was administered in 3 peritumoral injections under general anesthesia to screen the SLN. The images were acquired using an intraoperative infrared camera system, which allowed intraoperative visualization of the SLN. An SLN was identified for each patient. The lymph nodes examined by the pathologist were negative for metastatic localization of the disease. However, patients underwent bilateral inguinofemoral lymphadenectomy, as this procedure is not currently codified as a gold standard for the detection of SLN in vulvar cancer.
45997304|NCT04175028|Device|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
45675304|NCT05887349|Other|Neck Stabilization Exercise|"1. Control Group exercise program (Cervical Stabilization exercises group)~The patients in the control group will be given cervical stabilization exercises consisting of 3 levels and increasing difficulty. The exercises will be taught to the patients level by level by the physiotherapist for 6 weeks. The subjects will perform the exercises for a total of 6 weeks. Before each exercise session, stretching exercises will be performed on the subjects."
45834714|NCT03112044|Drug|Sofosbuvir-velpatasvir (400 mg/100 mg)|Patients will have standard monitoring with HCV RNA and liver panel assessment at 2 week intervals until HCV is undetectable and then at the end of treatment and 3 and 6 months following its completion. Post-operative transplant care and immunosuppression will be carried on as usual transplant practice at Toronto General Hospital.
45834715|NCT03112044|Device|Ex Vivo Lung Perfusion (EVLP)|Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions.
45834716|NCT02952222|Drug|Dexmedetomidine|Patients in Group DP will receive 0.5 mcg/kg DEX administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of BIS 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
45997305|NCT04663490|Diagnostic Test|Neutrophil to Lymphocyte Ratio|Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
45997306|NCT04662983|Device|VR-training|A musical game called Beat Saber was used to conduct training sessions. The participant's task was to cut through the blocks of various colors in his direction to the rhythm of music, using two virtual swords. The swords were controlled by the player with controllers of different colors. Blocks had to be cut with a sword whose color matches the block and in the right direction which is indicated by an arrow on the block. The training session consisted of 4 music tracks with different pace and intensity of objects. In addition, during the song, the participant had to avoid objects-objects that randomly appeared in the game scenario - forcing the whole body to move.
45997307|NCT04119765|Biological|Blood sampling|blood sampling will be used to perform oxalemia and FGF23 quantitative analysis
45997308|NCT04119765|Biological|Urine sampling|urine sampling will be used to measure glycolate urinary rate (glycolaturia) and to perform urinary inflammation markers quantitative analysis
45997309|NCT04119765|Procedure|Pulse Wave Velocity (PWV) measurement|PWV will be measured thank to the Complior® device
45997310|NCT04119765|Procedure|central pressure measurement|central pressure will be measured thank to the Complior® device
45997311|NCT04663139|Drug|Xla1|Xla1 is a Live Biotherapeutic Product (LBP) containing a strain of the bacteria Christensenella minuta (C. minuta)
45997312|NCT04663139|Drug|Placebo|Matching placebo
45997313|NCT04095780|Other|Advanced oral hygiene care programme|"Brush teeth with standardized power tooth brush twice a day.~Rinse mouth with chlorhexidine twice a day.~Oral hygiene education"
45997314|NCT04095780|Other|Oral hygiene instruction|Oral hygiene education
45997315|NCT04663178|Other|Warm Salt Water Foot Bath|A training booklet about chemotherapy-induced fatigue + 20-minute warm salt water application to their feet for a week after the treatment by explaining and showing the video prepared about the preparation and practice of warm salt water foot bath.
46085850|NCT05228873|Drug|Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)|Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.
45834717|NCT02952222|Drug|Propofol (Group P)|Patients in Group P will receive intravenous propofol in bolus increments (2.0 mg/kg bolus over one minute then 0.5 mg/kg bolus q 1 minute titrated to a BIS of 40-50). These patients will be maintained with a continuous intravenous infusion of propofol starting at 200 mcg/kg/min and will be titrated to an endpoint of maintaining a BIS level of 40-50.
45834718|NCT02952222|Drug|Propofol (Group DP)|Patients in Group DP will receive 0.5 mcg/kg DEX administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of BIS 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
45997316|NCT04662788|Drug|NK cells/Combined Monoclonal Antibodies|Each subject receive NK cells/Combined Monoclonal Antibodies
45997317|NCT04088994|Other|AOT Pathological Model Experimental Group|The children will participate in a rehabilitation intervention based on the observation of unimanual and bimanual actions performed by a model with the same degree of motor impairment, but an improvement on the participant's current abilities.
45997318|NCT04088994|Other|AOT Healthy Model Control Group|The children assigned to the healthy group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a healthy model
45997319|NCT04065516|Procedure|ARAT technique|After an initial endoscopic evaluation, ARAT technique will be performed with marking, submucosal elevation at esophagogastric junction and then ablation with 100-120w of 270-300 degrees at esophagogastric junction, once the application of the therapy is performed mucosal lavage and immersion technique will be made to corroborate integrity and continuity of the gastrointestinal tract and rule out immediate complications.
45997320|NCT04037007|Procedure|Fistulotomy - High experienced.|We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
45997321|NCT04037007|Procedure|Fistulotomy - Low experienced.|We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
45997322|NCT04037007|Procedure|Conventional (guidewire) cannulation- High experienced|We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
45997323|NCT04037007|Procedure|Conventional (guidewire) cannulation - Low experienced|We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
45997324|NCT04662827|Dietary Supplement|Palmithylethanolamid|PEA 3x/d
45997325|NCT04662827|Other|placebo|placebo 3x/d
45997326|NCT04010253|Device|SIMEOX|Instrumental airway clearance by the medical device SIMEOX
45997327|NCT04010253|Other|Autogenic drainage|Manual aiway clearance by autogenic drainage
45997328|NCT04662866|Drug|Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg|Comparison of 4 different antihyperglycemic drugs
45997329|NCT04662476|Dietary Supplement|Vitamin D3|Vitamin D3 supplement
45997330|NCT04008927|Diagnostic Test|HCV screening|All patients will have HCV screening using rapid tests. HIV and HBV testing will also be conducted and patients will be appropriately referred to appropriate health services.
45997331|NCT04008927|Diagnostic Test|Diagnosis of hepatitis C|HCV-RNA assay (GeneXpert, Cepheid) will be performed for all participants with positive HCV serology to determine if patients have chronic hepatitis C (defined by HCV-RNA>10 UI/mL). In addition a measure of the liver stiffness will be performed.
45997332|NCT04008927|Drug|HCV treatment|Direct-Acting Antiviral drugs will be prescribed for 8 or 12 weeks according to liver assessment.
45997333|NCT04662437|Diagnostic Test|Venous blood was collected for biochemistry testing|From the people in the healthy control group, 10 ml of venous blood was collected from the venous vein in the forearm of all individuals in the study. Parathyroid hormone, calcium, phosphorus, alkaline phosphatase levels were measured from this blood.
45997334|NCT03986424|Drug|Akatinol Memantine 20 mg|Akatinol Memantine 20 mg to be taken orally, once daily, in the same time of the day
46085851|NCT04219748|Behavioral|Case Management|"Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team (Psychiatry, Social Work, Nursing) during 2 months. The intervention will encompass attending weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes.~This CM intervention will include referral to Hospital Clínic de Barcelona Addiction Outpatient Clinic and a personalised assessment of the medical, psychiatric and social situation of each individual by the CM team. An individualised care plan will be established and periodically reviewed by the multidisciplinary team in response to a better understanding of patient needs or to a change in patient health condition.~The intervention will offer motivational interviewing psychotherapy to enhance motivation to reduce or to quit alcohol use, in crisis intervention, coordination of care, patient education and self-management support, and assistance to navigate in the healthcare system."
45997335|NCT03986424|Drug|Akatinol Memantine 10 mg|Akatinol Memantine 10 mg to be taken orally, twice daily
45997336|NCT04662593|Behavioral|Whole Health Program|A mind-body-spirit intervention to improve health and well-being including weight loss.
45997337|NCT03974451|Device|IOL implantation experimental|Implantation of of PhysIOL trifocal FineVision® POD F IOL
45997338|NCT03974451|Device|IOL implantation active comparator|Implantation of the Abbott Medical Optics, Inc. Tecnis Symfony® IOL
45997339|NCT03954678|Behavioral|Exercise Group|For the first two days after their pre-operative visit, participants will be asked to continue their present level of exercise and activity, which will be monitored by pedometer. Participants will begin the activity intervention on study Day 3. Participants will be instructed to take 10,000 steps per day, recording their daily steps with a pedometer. Participants also will be provided with resistance bands and instructed on how to safely perform 10 whole-body strength training exercises. They will be instructed to perform the exercises once per day, three days a week. Participants will complete the exercise intervention until they have surgery, which is typically 12 to 48 days after the pre-operative visit.
45997340|NCT03954678|Dietary Supplement|Nutrition Group|Participants in the nutrition group will be provided with a liquid over-the-counter nutrition supplement (i.e. Boost or Ensure) to consume. Participants will be instructed to consume 1 bottle, 2 times per day, beginning 5 days before surgery and continuing 5 days post-operatively.
46085852|NCT00631709|Other|CareLink Remote Monitoring|Substitution of CareLink Remote Monitoring of Pacemakers for in-clinic pacemaker follow-up visits
45997341|NCT04661969|Procedure|Surgery|(group 1) In-bloc excision and primary closure (group 2), Resection plus Vacuum assisted closure (VAC) and split thickness skin graft (STSG) (group 3) and In-bloc excision and microsurgical reconstruction (group 4).
45458388|NCT01351220|Behavioral|Educational program and FOBT kits|Subjects will participate in a CRC small group educational program and receive FOBT kits from community health advisors who have received a one-time training session.
45997342|NCT03943368|Device|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
45997343|NCT04662164|Drug|hepalatide|3 different dosage will be given sequentially to T2D patients
45834719|NCT03826446|Procedure|Surgery|laparoscopic and open complete mesocolic excision with central vascular ligation in right colon cancer.
45997344|NCT03918252|Drug|Nivolumab Injection|Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
45997345|NCT03918252|Drug|Ipilimumab Injection|Receive preoperative nivolumab, 3mg/kg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) + ipilimumab 1mg/kg IV on Day -42 prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
46085853|NCT02649972|Drug|Cobimetinib|Cobimetinib will be administered at a dose of 60mg daily for 21 days on, then 7 days off, in a 28 day treatment cycle. Patients will have the option to discontinue treatment after 12 cycles and will be monitored for disease relapse for an additional 12 months. In the event that disease relapse occurs within the 12 month monitoring period, patients will restart treatment and continue on study. Upon restarting, the assessment schedule will restart at rechallenge cycle 1(RC-1) and all assessments will occur at the frequency and intervals. Cycle 1 Day 15 visits will not be required for patients that restart treatment after relapse. Participants will re-sign consent upon rechallenging.
45458389|NCT01351220|Behavioral|Educational program and FOBT kits, and technical assistance|In addition to subjects' receipt of a CRC small group educational program and FOBT kits, leadership training and technical support will be provided to the community health advisors and selected leaders and members of the organization.
45834720|NCT03826056|Behavioral|Current standard discharge educational intervention|The patients will receive the current hospital standard discharge educational material which explains the diagnosis, new medications, follow up and any activity/diet restrictions. A member of the study team will explain this material to the patient and answer any questions.
45834721|NCT03826056|Behavioral|Personalized discharge educational intervention|The patients will receive a new personalized discharge educational material which will explain the specifics of their disorder, the treatment, and prognosis. The materials will contain simple, organized explanations and graphics. A member of the study team will explain this material to the patient and answer any questions.
45834722|NCT03821688|Procedure|SAS-JB|single anastomosis sleeve jejunal bypass
46085854|NCT03955367|Radiation|Prophylactic extended-field Irradiation|CTV covers pelvis and para-aortic lymph nodes region.
46085855|NCT03955367|Radiation|Pelvic irradiation|CTV covers pelvis.
45458390|NCT01363232|Drug|BKM120 + MEK162|
45834723|NCT03821688|Procedure|OAGB|one anastomosis gastric bypass
45834724|NCT03821688|Procedure|LSG|laproscopic sleeve gastrectomy
45834725|NCT03826368|Dietary Supplement|Hemp-derived botanical dietary supplement|Subjects currently taking phytocannabinoid Hemp-derived botanical dietary supplements during recovery from brain injury.
45997346|NCT04662125|Drug|Oral prednisolone|Patients will receive three tablets per day (one oral tablet prednisolone 20 mg plus two tablets of vitamins to maintain blinding) for three days.
45997347|NCT04662125|Drug|oral Pregabalin|Patients will receive three tablets per day (oral tablet pregabalin 100 mg) for three days.
45997348|NCT04662125|Drug|caffeine, paracetamol tablet|Patients will receive good hydration, recumbent positioning, three tablets per day (combined paracetamol and caffeine tablet) for three days and stool softener.
45997349|NCT03899181|Device|Translumbosacral Neuromodulation Therapy (TNT)|A probe with 2 pairs of bipolar steel ring electrodes, will be placed in the rectum. At each site a mapping procedure is performed with single stimulus coil to assess the motor threshold intensity, defined as the minimum level of magnetic stimulation intensity required to achieve an anal and rectal MEP response of 10 microvolts and an anterior tibialis MEP of 20 microvolts with 50% of trials.The intensity for TNT at each site is capped at a maximum of 150% above this threshold to comply with safety guidelines. Thus, intensity of magnetic stimulations will be individualized. Bilateral lumbar stimulations (rTLMS) are administered at L2/L3 disc space, and sacral stimulations (rTSMS) at S2/S3 level. Next a 70 mm double air film self-cooling coil is positioned randomly over one of the 4 sites, held in place by a coil fixator and 300 or 450 stimulations are delivered. After a 5 min rest the cycle is repeated (Total =600-900/site).The coil is moved to the opposite side and it is repeated.
45997350|NCT03899181|Other|Sham TNT Therapy|This is the sham TNT treatment as mentioned in the different ARMs using the fake coil with no magnetic stimulations.
45834726|NCT03825354|Behavioral|BIC|World Health Organization, WHO, Brief Intervention and Contact (BIC)
45997351|NCT03883230|Diagnostic Test|GLYWD|As mentioned in the group description, GLYWD is a plastic test tube and a chromatic test that contains two solutions. When combined with a wound exudate and incubated at RT, it will change colour to red if there is a pathological bacterial wound infection present.
45834727|NCT04391478|Drug|Milrinone|milrinone lactate, 1mg/ml, for intra venous use only
45997352|NCT00557180|Drug|Beclomethasone dipropionate HFA|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
45997353|NCT00557180|Drug|Tiotropium bromide|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
45997354|NCT00557180|Drug|Salmeterol xinafoate|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
45997355|NCT03818724|Device|CoolLoop® cryoablation system|Cryoablation of Atrial Fibrillation using the CoolLoop® Cryoablation System
45997356|NCT00557219|Drug|fenoldopam (Corlopam)|continuous intravenous infusion of 0.3 μg/kg/min fenoldopam for 24 hours
45834728|NCT04391478|Drug|Sildenafil|50mg sildenafil citrate/tablet, crushed in water taken by nasogastric tube
45834729|NCT03828006|Dietary Supplement|Red Rice Yeast|Participants will take one tablet per day of a dietary supplement based on red rice yeas for a period of six months
45834730|NCT03828006|Other|Placebo Group|Participants of this group will take one tablet of placebo per day for a period of six months
45834731|NCT03823014|Device|Elator|Measurement for device, use of device
45834732|NCT04346706|Device|Extraction and Implant insertion (test)|"The surgical procedure was conducted under local anesthesia. Intrasulcular incisions were performed around the mesial and distal tooth to the implant recipient site. Buccal and palatal mucoperiosteal flaps were elevated. Tooth extractions were carried out atraumatically using periotomes. Implant site preparation was completed in compliance with the general surgical principles and protocols defined by the manufacturer and screw-shaped implants (UFII, DIO™) were inserted at no less than 35 Ncm. Final insertion torque (IT) was measured and recorded using a manual hand wrench (DIO™). Resonance frequency analysis (RFA) was performed using an Osstell device (Sävedalen, Sweden). For each implant, three Implant Stability Quotient (ISQ) readings were recorded by the same operator to calculate the mean ISQ, at implant placement (T0) and 3 months after implant insertion (T3) prior to final abutment torque and crown cementation.~Absorbable interrupted 4.0 sutures were used for flap closure."
45997357|NCT00557219|Drug|placebo|continuous intravenous infusion of 2 mL/hour of 0.9% natrium chloride solution for 24 hours
45997358|NCT00557219|Drug|ketanserin (Sufrexal)|continuous intravenous infusion 0.1 mg/kg/hour ketanserin for 24 hours
45997359|NCT03799302|Behavioral|SIC Coaching|Sites receiving consultation to implement either TFCO or MDFT will also receive consultation on their implementation fidelity as measured and tracked by the SIC.
45997360|NCT00539877|Drug|irinotecan|"Postoperative day 1, IP CPT-11 chemotherapy will be given by CAPD catheter. CPT-11 in 1L of normal saline, prewarmed to 37°C will be given intraperitoneally.~If there is no DLT and patients agree with the treatment, patients can receive 3 more times of IP chemotherapy with same dose of CPT-11 at 3 weeks interval. After total 4 cycles of IP chemotherapy, peritoneal disease will be reassessed with abdominal-pelvis CT. Pharmacokinetic study is not planned with this treatment."
45997361|NCT03798405|Behavioral|Proactive Analgesic Inpatient Narcotic-Sparing|Medications suggested to the physician with enhanced ease of ordering.
45997362|NCT03796338|Device|Sleep Profiler|Patients are observed through a Sleep profiler, routinely used in the intensive care unit (ICU). This device is applied at every patient in the ICU and it acquires EEG, electrooculography, and electromyography from three frontopolar EEG signals.
45997363|NCT00557336|Drug|somatropin|
45834733|NCT04346706|Device|Implant insertion (control)|"The surgical procedure was conducted under local anesthesia. Intrasulcular incisions were performed around the mesial and distal tooth to the implant recipient site. Buccal and palatal mucoperiosteal flaps were elevated, the implant site preparation was completed in compliance with the general surgical principles and protocols defined by the manufacturer and screw-shaped implants (UFII, DIO™) were inserted at no less than 35 Ncm. Final insertion torque (IT) was measured and recorded using a manual hand wrench (DIO™). Resonance frequency analysis (RFA) was performed using an Osstell device (Sävedalen, Sweden). For each implant, three Implant Stability Quotient (ISQ) readings were recorded by the same operator to calculate the mean ISQ. This was done at implant placement (T0) and 3 months after implant insertion (T3) prior to final abutment torque and crown cementation.~Absorbable interrupted 4.0 sutures were used for flap closure."
45997364|NCT00539916|Behavioral|Regular orange juice consumption|600 mL /day.
45997365|NCT04661618|Device|Gym Tonic programme and Gym equipment|12 week progressive training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol twice a week 12 weeks maintenance training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol once a week
45997366|NCT00539955|Behavioral|Standard Batterer Intervention|Standard state-mandated batterer intervention program (40 hours)
45997367|NCT00539955|Behavioral|Brief Alcohol Intervention|Brief alcohol intervention combined with state mandated batterer intervention program
45997368|NCT04661696|Drug|Paclitaxel (albumin-bound)|The dose of intravenous chemotherapy drug is calculated according to the body surface area.When patients have serious adverse events, dose suspension and dose reduction are allowed. Paclitaxel (albumin-bound) was allowed to be reduced only twice (20% standard dose reduction in the first dose and 20% lower in the second dose).Once the dose is reduced, all subsequent doses should be maintained at reduced dosage.
45997369|NCT03776136|Drug|lenvatinib|Administered orally once a day during each 21-day cycle.
45997370|NCT03776136|Biological|pembrolizumab|Administered as an IV infusion on Day 1 Q3W.
45997371|NCT04661774|Other|reflexology massage|reflexology massage of the foot zone implicated in diaphragm stimulation
45997372|NCT04661774|Other|sham massage|traditional massage of the foot
45997373|NCT03775980|Device|Emprint Microwave Ablation System|Microwave Ablation of colorectal liver metastases
45997374|NCT04661462|Other|online survey|We invite volunteers after COVID-19 to participate in an online survey.
45997375|NCT03766191|Behavioral|Food Ads|Exposure to foods ads embedded in an age-appropriate TV program
45997376|NCT03766191|Other|Non-food Ads|Exposure to non-food ads embedded in an age-appropriate TV program
45997377|NCT04661228|Diagnostic Test|Composite International Diagnostic Interview 5th version (CIDI 5.0)|Observational study assessing prevalence of mental and substance use disorders in the general population
45997378|NCT04661189|Behavioral|Physical exercise training|Participants will be encouraged to complete exercise training programs in the form of video capsules available via Facebook or Youtube, created by kinesiologists of the Montreal Heart Institut EPIC prevention center. The videos last about 15 minutes and include a warm-up of 3 to 5 minutes, followed a 10-minute training and finally a 2-minute cool-down period. The exercises on video do not require any equipment and integrate, depending on the video, aerobic, muscular strengthening, flexibility and/or balance exercises. Several intensities are described according to the participants' level. Participants will be invited to perform exercise sessions at least 5 times a week, and will be monitored weekly by phone by a member of the research team. The exercise sessions can be performed at home using the video training program, as well as in sports centre or outdoors. For each session, participants have to report its duration, intensity, and the nature of the activity via a follow-up agenda.
45458391|NCT02321176|Drug|trans-resveratrol|"patients received 100mg Longevinex everyday,total of three days~1 capsule daily for one day containing 100 mg of trans resveratrol active ingredient"
45997379|NCT04661189|Behavioral|Cognitive training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed different mnemotechnic, as well as be taught about memory in aging in general. The memory training will be provided by videos capsules. To track adherence to cognitive training, participants will be asked to complete a journal and mark days and times where they took part in the various cognitive training sessions.
45997380|NCT00540033|Dietary Supplement|infloran|Study group was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
45997381|NCT00540033|Dietary Supplement|infloran|Study group was fed with infloran [Lactobacilli acidophilus (CFU 109 NCDO 1748, obtained from the National Collection of Dairy Organisms)] and Bifidobacteria bifidum [(CFU 109, NCDO 1453 obtained from the National Collection of Dairy Organisms)]; Laboratorio Farmaceutico S.I.T S.r.I ITALY] 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
45997382|NCT04661345|Other|Proteomic analysis of synovial fluids|Characterization of the proteome of infected/aseptic synovial fluid for the identification of molecular hallmarks strictly related to the presence of a bacterial infection mediated by coagulase-negative Staphylococci
45997383|NCT04661345|Other|Proteomic analysis of the isolated coagulase-negative Staphylococci|Characterization of the secretome of coagulase-negative Staphylococci isolated from infected prosthetic implants
46085856|NCT03955367|Radiation|Intracavitary brachytherapy|The total dose delivered to point A or high-risk CTV is ≥80Gy. For patients with larger-volume cervical tumor, the total dose is ≥85Gy.
46085857|NCT03955367|Drug|Concurrent chemotherapy|Cisplatin based concurrent chemotherapy, including cisplatin as a single agent or cisplatin plus Paclitaxel.
46085858|NCT02748044|Device|CC-Cruiser|An artificial intelligence to make comprehensive evaluation and treatment decision of congenital cataracts
46085859|NCT04213560|Device|weighted waist-hooping|weighted waist-hooping
45834734|NCT03825900|Device|Sham OR active Transcranial direct current stimulation|Sham OR active transcranial direct current stimulation over the motor cortex
45997384|NCT00540072|Drug|daptomycin|
45997385|NCT03759405|Biological|iPS differentiated cardiomyocytes|Repair of injured myocardium by vein transplantation with autologous iPS differentiated cardiomyocytes
45997386|NCT04661111|Device|Hymovis® ONE (32 mg/4 ml)|Hymovis® ONE is a clear hydrogel. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process. Hymovis® ONE is a CE-marked Class III Medical Device intended for intra-articular injection.
45997387|NCT03689946|Drug|Evolocumab|"Evolocumab: In patients without homozygous familial hypercholesterolemia (FH), evolocumab will be self-injected as follows: 140mg every 2 weeks or 420mg once a month subcutaneously.~Patients with homozygous FH will be instructed to administer 420mg subcutaneously once a month by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector."
45997388|NCT03689946|Diagnostic Test|18F-NaF PET|18F-NaF PET: Baseline (pre-treatment) and follow-up dual cardiac and respiratory-gated PET- imaging of the thoracic aorta. Dose of 250 MBq 18F-NaF intravenously.
45997389|NCT03689946|Diagnostic Test|CCTA|CCTA: Baseline (pre-treatment) and follow-up CCTA. Bolus injection of 80-100 ml contrast (Omnipaque or Visipaque). Possible beta blocker(metoprolol)administered to achieve a target heart ≤70 beats/min (bpm) and/or 0.4 or 0.8 mg of sublingual nitroglycerin administered, if medical safe.
45997390|NCT04660916|Drug|Isotretinoin|The effects of isotretinoin on morphology, growth rate, and thickness of the nail plate
45997391|NCT00540111|Dietary Supplement|soluble fiber® (partially hydrolyzed guar gum)|HIV-positive individuals with hypertriglyceridemia and who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study,received 20g/day of soluble fiber for 4 months at pre-established times.
45997392|NCT04660838|Other|ACB intervention|Stopping and/or switching ACB medication to an alternative
45997393|NCT00540150|Biological|specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot)|We treat each patient with mite-allergen following the two different protocols.
45997394|NCT04660994|Other|Educational game|"The Yapouni educational game is based on a hot air balloon that will fly according to the number of hours the child has slept with his/her CPAP / NIV. Thus, the longer the child sleeps with his/her CPAP / NIV, the farther and higher his/her hot air balloon will fly in the sky. The game includes wild cards and rewards that are worked out with the child and his/her parents for an optimal individualized adaptation.~The game is explained at Necker Hospital during the therapy education for CPAP/NIV and used at home for 1 month."
46085860|NCT02748122|Other|MMT 723|Subjects will have the insulin pump inserted. With the aid of a small needle, the catheter (tube) of the insulin pump will be inserted through the skin into fatty tissue and will be taped in place. The subject will be required to wear the pump for three (3) months.
46085861|NCT04513223|Drug|SHR-A1811|There are six pre-defined dose regimens . Subjects will be enrolled with an initial dose
46085862|NCT00617370|Drug|epirubicin, cyclophosphamide, Paclitaxel,|EC (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg). Paclitaxel (175 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg).
46085863|NCT02699658|Drug|Levofloxacin|
45997395|NCT05102253|Procedure|Dense cranial electroacupuncture stimulation (DCEAS)|"DCEAS will be conducted for 2 sessions per week for 12 consecutive weeks. Electrical stimulation will be conducted on six pairs of forehead acupoints located on the frontal, parietal, and temporal scalp areas. The acupoints includes: Bai-Hui (GV20), Yin-Tang (EX-HN3), left and right Si-Shen-Cong (EX-HN1), Tou-Lin-Qi (GB15), Shuai-Gu (GB8), Tai-Yang (EX-HN5) and Tou-Wei (ST8).~Disposable acupuncture needles will be inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation, followed by electrical stimulation. The stimulation intensity will be adjusted to a level at which patients felt most comfortable. Each session of treatment will last 30 min."
45675305|NCT05887349|Other|Neck Stabilization Exercise + Rocabado Exercises|"2. Intervention group exercise program (the group to which Robacado exercises will be added in addition to cervical stabilization exercises) The exercises to be applied to the control group for 6 weeks will be given to the intervention group in the same order and at weekly intervals. In addition, individuals in this group will be given Robacado exercises.~Robacado exercises:~Resting position for the tongue: The tip of the tongue is placed on the upper palate, just behind the front teeth (resting position for the tongue).~When the body is in an upright position, scapular retraction and depression movements are performed without disturbing the position of the cervical region.~When the body is in an upright position, at C2-C7 levels, hands are clamped on the neck and cranio-cervical flexion is studied."
45675306|NCT05887336|Device|Walther System|Walther System providing INMEST treatment
45675307|NCT05887336|Device|Sham Walther System|Walther System not providing INMEST treatment, but otherwise behave as the active comparator.
46085864|NCT00912197|Dietary Supplement|Oligofructose|Participants will be asked to consume 30g of oligofructose daily for six weeks after a 2-week run-in.
46085865|NCT00912197|Dietary Supplement|Placebo|Participants will be asked to consume 3 doses (a total of 30g dietary fibres) of the placebo product daily for six weeks after a 2-week run-in
45675308|NCT05887336|Drug|Non preserved ocular lubricants|"Hyaluronic acid (HyloGel)~Hyaluronic acid and Ectoin (Hylo Dual Intense)~Hyaluronic acid and Trehalos (Theloz Duo)"
45675309|NCT05887336|Procedure|Eye lid procedure|Lid hygiene, warm eye bag, lid massage and Omega 3
45997396|NCT05102253|Procedure|Transcutaneous electrical acupoint stimulation (TEAS)|"TEAS will be done for 3 times per week for 12 consecutive weeks by participants at home. A training workshop will be conducted to instruct participants how to use TEAS stimulator. Briefly, TEAS will be delivered on the bilateral Nei-Guan (PC6), which is located on the anterior forearm, between the tendons of the palmaris longus and ﬂexor carpi radialis, at the junction of the distal sixth and proximal ﬁve sixths of the line connecting the middle points of the wrist and elbow crease.~Constant current electrical impulses will be produced from a TEAS apparatus. Two electrode pads will be adhered onto the acupoint skin. The pulse amplitude will be adjusted to a level at which the perception of 'strong but comfortable' is achieved. Each session of treatment will last 30 min."
45997397|NCT05102253|Other|Wait-list control: Routine care|The routine care may include medications, advocacy intervention, and CBT. Post-trial treatment of TEAS+DCEAS will be offered to serve as a compensation for their participation.
45997398|NCT04660604|Device|Graston Technique®|Graston technique, one of the soft tissue mobilization techniques, has also been found to be effective method that affects muscle strength, performance and endurance through activation of muscle and nervous systems.
45997399|NCT05099367|Diagnostic Test|Microdialysis, current induced vasodilation|"CIV will be applied over all microdialysis fibers: one perfused with saline, one perfused with a preferential COX-1 blocker; and one perfused with a preferential COX-2 blocker.~CIV will be applied over all fibers in the following conditions: one perfused with saline, one perfused with fluconazole and L-NMMA, and the last one perfused with lidocaine.Dialysate collection will be performed after each CIV: dermal PGI2 metabolite (6-ketoPGF1α) and other COX-dependent prostanoids or metabolite (e.g. 11-dehydroTXB2) will be collected in the dialysate fluid and quantified. One hour after the last condition, treprostinil will be perfused over all fibers."
45997400|NCT05099367|Diagnostic Test|Skin biopsy|Skin biopsy will be proposed. It will be performed on the internal superior calf (medial gastrocnemius), at a reasonable distance from the foot
45997401|NCT05099367|Diagnostic Test|peri-ulcerated skin biopsy|Non-ulcerated skin from the peri-wound area will be collected. These patient will not undergo all the procedures included in this protocol.
45997402|NCT04660253|Behavioral|LTP Plus Dads|
45997403|NCT04660292|Other|Maitland's mobilization|Maitland's techniques involve the application of passive and accessory oscillatory movements to spinal and vertebral joints to treat pain and stiffness.It has Five grades
45675310|NCT05887323|Device|Implantation of the Tendril 2088 lead in the LBBA|Conduction system pacing is achieved by delivering a pacing stimulus to the Left Bundle Branch area of the heart with Abbott's Tendril 2088 lead.
45997404|NCT04660292|Other|Traditional Physical therapy|BASELINE TREATMENT INCLUDES TENS and Hot PACKS
45997405|NCT00540189|Procedure|Initial appendectomy|
45675311|NCT05887297|Behavioral|Cognitive behavioural therapy for insomnia|CBT-I is a multi-component, evidence-based intervention which incorporates both cognitive and behavioural techniques to address symptoms of insomnia, aiming to improve satisfaction with the duration and quality of sleep by reducing trouble falling and/or staying asleep. CBT-I will be delivered over 4 weekly 1-hour sessions, via videoconferencing. Session 1 will include psychoeducation about sleep (the relationship between sleep and mental health, the '3P' model of insomnia), and begin to explain components of CBT-I (sleep restriction and relaxation). Session 2 will reinforce previous learning about these components and introduce stimulus control. Session 3 will introduce sleep hygiene and its importance in preventing poor sleep. Session will 4 discuss cognitive therapy techniques and relapse prevention.
45675312|NCT05887284|Radiation|low dose radiotherapy (0.5 Gy)|12 times 0.5 Gy
45834735|NCT03826134|Drug|[11C]PXT012253|Single intravenous bolus injection. The injected amount will be less than 5 μg. The radioactive dose is approximately 400 MBq per 70 kg body weight.
45834736|NCT01454154|Drug|Glyburide|Administered as specified in the Treatment Arm.
45834737|NCT01454154|Drug|Placebo|Administered as specified in the Treatment Arm.
45834738|NCT03825978|Behavioral|Prenatal Genetic Counseling|In this study prenatal genetic screening counseling was provided from the begining of the pregnancy, different from the other studies in the literature. In the literature, most of the study evaluated pregnant women's anxiety, information status about the test and decisional conflicts, only prenatal screening process or prenatal diagnosis process. In this study pregnant women were evaluated both in prenatal screening test and prenatal diagnosis procedures.
45834739|NCT03826212|Dietary Supplement|Soybean Germ Extract|Soybean Germ Extract 1,600 mg/day for 12 weeks.
45834740|NCT03826212|Dietary Supplement|Placebo|Placebo 1,600 mg/day for 12 weeks.
45834741|NCT02951598|Drug|Florbetapir F 18 PET Scan|Florbetapir F 18 positron emission tomography (PET) scan performed at baseline to confirm amyloid status. Participants who previously tested amyloid positive were exempt. No therapeutic investigational drug(s) intended to treat AD will be administered.
45834742|NCT03078348|Other|Fecal Immunochemical Test (FIT) Kit|Free FIT Kits distributed at study entry.
45997406|NCT00540189|Procedure|Interval appendectomy|
45997407|NCT04660409|Diagnostic Test|Blood test for serum Adropin|Blood test for serum Adropin
45997408|NCT01208233|Drug|PF-03049423|1 mg of PF-03049423 daily for 90 days
45997409|NCT01208233|Drug|PF-03049423|3 mg of PF-03049423 daily for 90 days
45997410|NCT01208233|Drug|PF-03049423|6 mg of PF-03049423 daily for 90 days
45997411|NCT01208233|Other|Placebo|Placebo of PF-03049423 daily for 90 days
45997412|NCT04660565|Drug|Prednisone and Belimumab|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 5mg per day in 3 months. Belimumab will start at the same time as the prednisone induction.
45675313|NCT05887284|Radiation|mock radiation treatment|6 times 0.0 Gy
45997413|NCT04660565|Drug|Prednisone|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 5mg per day in 3 months.
45997414|NCT04660370|Drug|CKD-348|QD, PO
45997415|NCT04660370|Drug|CKD-828, D097, D337|QD, PO
45997416|NCT04319341|Other|To study the prognostic value on the occurrence of pre-eclampsia, ADAMTS13 (ADAMTS13 protein and autoantibodies) in patients diagnosed with oAPS|ADAMTS13 activity, ADAMS13 antigen and anti-ADAMTS13 autoantibodies: U/ml.
45675314|NCT05887284|Radiation|low dose radiotherapy (1.0 Gy)|6 times 1.0 Gy
45834743|NCT03078348|Behavioral|Culturally targeted Photo Novella Booklet|Culturally targeted Photo Novella Booklet + culturally targeted reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
45834744|NCT03078348|Behavioral|Screen for Life Brochure|Screen for Life Brochure + standard reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
45997417|NCT04660136|Biological|contrast enhanced ultrasound|We injected the second generation, ultrasonic contrast agent (SonoVue, Bracco, Milan, Italy) as a bolus of 0.03 ml/kg through a three-way 20-gauge catheter in an antecubital vein, followed by a bolus of 5 ml saline solution (0.9% NaCl).CEUS was performed with a 7.5MHz linear probe and contrast-tuned technology, based on allow mechanical index and a real-time scan to ensure the preservation of the contrast agent. A low acoustic power setting was used, expressing a low mechanical index (MI), 0.09-0.14, of a 7.5 MHz linear probe.
45457406|NCT03477890|Diagnostic Test|Stratified medicine involving a diagnostic intervention|"Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or non-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017)."
45675315|NCT05887271|Drug|Low calorie meal replacement plan|Meal replacement diet containing ~850 kcal/day (40% protein, 50% carbohydrate, 10% fat) supplied by Counterweight® (www.counterweight.org).The meal replacement plan will comprise of 3-4 meal packs/day (to equate to 850 kcal) with sweet and savoury options, and an allowance of 100ml semi-skimmed milk or a non-dairy alternative.
45834745|NCT03829956|Device|Intraoral tongue stimulator (Snoozeal)|Electrical stimulation of the tongue muscle to improve muscle tone to treat primary snoring and mild obstructive sleep apnea.
45834746|NCT04391868|Drug|Viagra Tablet|50 mg tablet on Day 1 of each period
45834747|NCT04391868|Drug|Sildenafil Citrate ODF|50 mg ODF on Day 1 of each period
45997418|NCT05420935|Diagnostic Test|IgG group|"Will be performed :~a blood sampling of 5 ml (for realization of a basophil activation test)~a blood sampling of 250 ml"
45997419|NCT05420935|Diagnostic Test|IgE group|"Will be performed :~a blood sampling of 5 ml (for realization of a basophil activation test)~a bone marrow sampling"
45997420|NCT05420935|Diagnostic Test|IgG group + IgE group|"a blood sampling of 5 ml (for realization of a basophil activation test)~a blood sampling of 250 ml~a bone marrow sampling"
45997421|NCT01208038|Drug|Intrinsa Transdermal testosterone patch|300 microgram transdermal testosterone patch, applied twice weekly for 12 weeks
45834748|NCT04391868|Drug|Sildenafil Citrate ODF|50 mg ODF on Day 1 of each period
45997422|NCT00540267|Other|No Intervention|No Intervention
45997423|NCT04659980|Device|hilotherapy|continuous cooling of hands and feet at a constant temperature
45997424|NCT04659980|Device|frozen gloves|cooling of hands and feet using frozen gloves
45834749|NCT03827616|Radiation|Hypofractionated IMRT using helical Tomotherapy.|70 Gy in 28 fractions intensity-modulated radiotherapy (IMRT)
45997425|NCT04659785|Drug|Fluzoparib|Take Fluzoparib orally（either at 50,100mg bid）until disease progression or appearance of unbearable toxicity
45997426|NCT04659785|Drug|Apatinib|Take apatinib orally (either at 375mg、500mg、750mg qd）until disease progression or appearance of unbearable toxicity
46085866|NCT04131920|Device|handheld ultrasound: Philips Lumify integrated tele-ultrasound powered by Reacts collaborative platform|Patients receive training by the physical therapist to operate a handheld ultrasound (HHUS) including proper probe placement. Subjects will be tested on their knowledge at the HTC to demonstrate proficiency, and will then repeat the testing at home via tele-ultrasound.
45997427|NCT03609021|Procedure|Screening Mammography|Provide bilateral mammogram
45997428|NCT03609021|Procedure|Biospecimen Collection|Undergo collection of blood sample
45997429|NCT04659395|Other|Emergency nurses|Emergency nurses who are trained for one-day in ultrasound-guided femoral nerve block
45997430|NCT01207687|Biological|bevacizumab|Given IV
46085867|NCT04218578|Diagnostic Test|speckle tracking analysis of transthoracic echocardiogram|analysis at workstation with 2D strain-Speckle tracking echocardiography of transthoracic cardiac echo at baseline and one-year follow up examination
46085868|NCT04500353|Other|Face mask application for CPAP and/or PPV delivery|Face mask application for CPAP and/or PPV delivery
46085869|NCT04218734|Drug|DBPR108|DBPR108: 100 mg, once daily for 24 weeks.
45675316|NCT05887271|Diagnostic Test|Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy|CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue. Cardiac 31P magnetic resonance spectroscopy imaging to assess cardiac muscle energetics according to a standardised operating procedure
45834750|NCT03827616|Radiation|Hypofractionated IMRT using helical Tomotherapy.|60 Gy in 20 fractions intensity-modulated radiotherapy (IMRT) using helical Tomotherapy.
45834751|NCT03823794|Other|No intervention|Observational analysis of usual care only
45834752|NCT03821532|Other|Constipation Action Plan|Action plan, adapted from Autism Speaks Network, demonstrating Red, Yellow, and Green levels of symptoms with corresponding steps for treatment or action by parent/guardian, tailored by care provider to the child's condition.
45834753|NCT03821766|Device|Ballistocardiography and seismocardiography|SCG and BCG signals will be recorded by the mean of an unobtrusive and friendly device consisting of two houses, the first one placed on the sternum and the second one place on the lumbar region near the subject's center of mass. The signal will be transferred to a tablet by Bluetooth and tracings will be analysed automatically with Matlab. The SCG+BCG signals are synchronized to the intracardiac pressure tracings in order to allow a comparative interpretation between the two tracings.
45834754|NCT01454310|Device|Wound coverage by acellular skin substitute|Burn wounds are covered by an acellular skin substitute and remains 10-14 days that peals away in line with re-epithelialisation
45834755|NCT01454310|Device|Autologous skin|Matched burn wound is covered by autologous skin after tangential excision.
45834756|NCT03827382|Behavioral|Lifestyle Intervention|Physical activity program: 3-5 aerobic training sessions (15-40 minutes each) per week, combined with 2 resistance training per week as well as motivational coaching via telephone Nutritional counseling
45834757|NCT03829332|Biological|Pembrolizumab|IV infusion
45834758|NCT03829332|Drug|Lenvatinib|oral capsule
45834759|NCT03829332|Drug|Placebo for lenvatinib|oral capsule
45834760|NCT03825666|Other|ProvideXtra® Fresenius Kabi|Improving wellbeeing
45834761|NCT03069924|Combination Product|Gain-framed messaging plus NRT|Gain-framed messaging materials and NRT
45834762|NCT03069924|Behavioral|Unframed messaging materials|Unframed smoking cessation materials
45834763|NCT01454388|Other|breakfast|
45997431|NCT01207687|Other|laboratory biomarker analysis|Correlative studies
45997432|NCT01207687|Procedure|quality-of-life assessment|Ancillary studies
45997433|NCT04659434|Drug|Sintilimab|"Patients receive sintiliman+R-GemOx three weeks for a cycle, detailed as follows:~Combination therapy~Anti-PD-1 antibody (sintilimab): Fixed dose of 200 mg every 3 weeks, d0, intravenous drip (without pretreatment), infusion time: 30 mintutes (no less than 20 mins, no more than 60 mins), for 4 cycles~R-GemOx: Rituximab 375mg/m2, d1; Gemcitabine 1000mg, d2; Oxaliplatin 100mg/m2, d2; every 3 weeks for a cycle, 4 cycle as protocol specified.~Monotherapy:~-Anti-PD-1 antibody (sintilimab): Fixed dose of 200 mg every 3 weeks, d0, intravenous drip (without pretreatment), infusion time: 30 mintutes (no less than 20 mins, no more than 60 mins), for 8 cycles"
45997434|NCT01207453|Drug|Milnacipran|Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.
45997435|NCT01207453|Drug|Placebo|
45997436|NCT00540345|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 4 weeks followed by pegylated interferon alpha 2a 180 mcg/week and Ribavirin 800 mg/day for 12 weeks, follow up for 24 weeks
45997437|NCT00540345|Drug|Pegylated interferon alfa-2a and ribavirin|pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 16 weeks, follow up for 24 weeks
45997438|NCT00540345|Drug|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
45997439|NCT00540345|Drug|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 48 weeks, follow up for 24 weeks
45997440|NCT04659356|Other|Patients admitted in Intensive Care Units|Data will be collected computerized patient records by the clinicians in charge of the patient.
45997441|NCT01207414|Drug|iloperidone|Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.
45997442|NCT00540384|Drug|Placebo|Placebo
45997443|NCT00540384|Drug|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
45997444|NCT01207219|Behavioral|Yoga therapy|3 sessions per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
45997445|NCT01207219|Behavioral|Aerobic exercise|3 session per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
45997446|NCT04659551|Drug|Epirubicin|Epirubicin 90 mg/mq i.v. every 3 weeks for three cycles
45997447|NCT04659551|Drug|Cyclophosphamide|Cyclophosphamid 600 mg/mq i.v. every 3 weeks for three cycles
45997448|NCT04659551|Drug|Triptorelin|Triptorelin 3.75 mg i.m. every 4 weeks until surgery
45997449|NCT04659551|Drug|Exemestane|Exemestane 25 mg oral continuous daily dose until surgery
45997450|NCT04659551|Drug|Nivolumab|Nivolumab 240 mg flat dose i.v. every two weeks for 8 cycles
45457407|NCT04464850|Drug|Intravenous iron|"Iron sucrose will be given by continuous infusion for 1 hour during the last 1 hour of dialysis session. Iron sucrose will be given for 24 weeks during study period.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~The dosage of intravenous iron will be adjusted according to serum ferritin levels as follows.~Serum ferritin <500 mg/dl: iron sucrose 100 mg every 2 weeks Serum ferritin 500-800 mg/dl: iron sucrose 100 mg every 4 weeks Serum ferritin >800 mg/dl: discontinue iron sucrose"
45457408|NCT04464850|Drug|Oral iron|"1 tablet, three times a day, of iron fumarate will be prescribed for 24 weeks of study period.~The dosage of iron fumarate will be adjusted according to serum ferritin levels as follows.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~Serum ferritin <500 mg/dl: iron fumarate 200 mg three times daily Serum ferritin 500-800 mg/dl: iron fumarate 200 mg once daily Serum ferritin >800 mg/dl: discontinue iron fumarate"
45675317|NCT05887271|Diagnostic Test|Transthoracic echocardiography|Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function
45675318|NCT05887271|Diagnostic Test|Blood test|Collection of blood samples from each participant to characterise the participant's health status and fibroinflammatory markers.
45997451|NCT04659668|Device|MMG-23-04-2019|"The dermal filler MMG-23-04-2019 is applied to the female intimate area (intramucosal administration) of vaginal vestibule, vaginal walls, clitoris, G spot."
45997452|NCT05411146|Drug|[14C]-etrumadenant|Administered as specified in the treatment arm.
45997453|NCT01206517|Drug|Asenapine 2.5 mg|Asenapine tablet, sublingually (SL), 2.5 mg b.i.d. on Days 1-6 and one 2.5 mg tablet, SL, on Day 7.
45997454|NCT01206517|Drug|Asenapine 5 mg|Asenapine tablet, SL, 5 mg b.i.d. on Days 1-6 and one 5 mg tablet, SL, on Day 7.
45997455|NCT01206517|Drug|Asenapine 10 mg|Asenapine tablets, SL, in a rising dose schedule to 10 mg b.i.d. (with a single 10 mg dose on final day). For Cohorts 3b, 3c and 3d, rising dose schedule begins with asenapine 5 mg b.i.d. on Day 1 and dosing occurs through Day 8. For Cohort 3a, rising dose schedule begins with asenapine 2.5 mg b.i.d. on Day 1 and dosing occurs through Day 12.
45997456|NCT00540462|Procedure|gastric bypass|
45997457|NCT00540462|Procedure|sleeve gastrectomy|
45997458|NCT04659473|Other|Online survey|This study aims to apply a rapid online survey to determine the Spanish situation in this third wave of the pandemic.
45457409|NCT03921463|Other||This is an observational study
45675319|NCT05887271|Diagnostic Test|Electrocardiogram|An ECG will be obtained to assess for baseline rhythm.
45675320|NCT05887271|Diagnostic Test|Accelerometery|Accelerometer (GeneActiv) measured daily activity levels continuously for 7 consecutive days.
45675321|NCT05887271|Diagnostic Test|6 minute walk test (6MWT)|Supervised 6MWT will be performed with symptom assessment using dyspnoea scale (Borg's).
45997459|NCT01206439|Drug|nebivolol|nebivolol 5 or 10 mg oral, daily
45997460|NCT01206322|Drug|Intranasal insulin|The acute effects of a single 40-IU dose of intranasal insulin
45997461|NCT01206322|Drug|Placebo|The acute effects of intranasal sterile saline.
45997462|NCT03514485|Behavioral|Yes We Can Children's Asthma Program|The Yes We Can Children's Asthma Program intervention is a medical-social model based on a chronic care approach, including risk stratification, clinical care management, social care coordination by a community health worker, and primary care physician asthma champions. This intervention includes asthma education, trigger reduction visits and care coordination. There will be five clinic visits and four home visits over 12 months implemented by the primary care CHW who is integrated into the primary care practice.
46085870|NCT04218734|Drug|metformin hydrochloride|metformin hydrochloride: 500 mg, 1-3 times daily for 24 weeks.
45457410|NCT01356758|Drug|biological treatment|patients treated with anti-psoriatic biological agents
45997463|NCT03514485|Behavioral|School-Based Asthma Therapy|School-Based Asthma Therapy includes enhanced care coordination for prescribed daily controller medication. The school nurse will coordinate with teachers and the school CHW to schedule daily controller asthma medication administration. The school CHW will assist in obtaining a current asthma care plan and medication administration form from the primary care provider.
45997464|NCT03514485|Behavioral|Open Airways for School Plus|"Open Airways for Schools Plus was designed to improve the asthma self-management skills in children and enhance control of asthma in the school. The school intervention includes:~Open Airways for Schools curriculum for all students with asthma. Classes will be conducted by the school CHW once each semester.~Environmental classroom assessments conducted by school CHWs for students enrolled in the study. These teachers will receive classroom supplies to create a more asthma-friendly classroom environment.~Asthma education for school staff/personnel at the start of each school year.~School facility walk-through assessments to detect potential environmental asthma triggers will be conducted by the School District of Philadelphia."
45997465|NCT04659200|Diagnostic Test|Venous blood was collected for biochemistry testing.|For the measurement of blood tests, 10 ml of blood samples were taken from the right forearm veins with a syringe.
45997466|NCT01206166|Drug|Olimel (5.7%E / N9E)|OLIMEL(Amino Acids, Dextrose, Lipids, with / without Electrolytes) is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.
45997467|NCT00540501|Drug|Oseltamivir and Intravenous Zanamivir|"Oseltamivir will be administered PO q12h for 3 days (for a total of 5 doses ending the morning of day 3.~Both drugs will be administered simultaneously starting on Day 1 of Period 3. Zanamivir will be administered IV q12h for 3 days (for a total of 5 doses ending on the morning of day 3.~Zanamivir to be given four (4) hours after the oral dose of oseltamivir and infused over 30 minutes."
45675322|NCT05887271|Diagnostic Test|Skeletal muscle strength using handgrip strength and quadriceps (Cybex dynamometer)|Skeletal muscle strength will be measured using a cybex dynamometer.
45675323|NCT05887271|Other|Assessment of quality of life and heart failure symptoms|Quality of life and HF symptoms will be assessed using the Minnesota Living with Heart Failure (MLWHF) questionnaire, which is used as a standardised measure of self-reported health status, and HF symptoms and is considered to have a good discriminatory power and validity
45997468|NCT04659239|Biological|Inactivated SARS-CoV-2 Vaccine (Vero cell)|The inactivated SARS-CoV-2 vaccine (vero cell) was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
45997469|NCT04659239|Biological|Placebo|The placebo was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
45997470|NCT03513783|Other|measurement of human movement|"The objective measurement of human movement through the use of kinematic markers and electromyography is a clinical exam commonly performed to analyze the movements of patients with motor control disorders. The different steps are the following:~A clinical exam is performed by the Physical Medicine & Rehabilitation clinician (passive range of motion , spasticity, muscular force, etc.).~Intramuscular and surface electromyography and kinematic markers are placed on the upper limb of the participant. A maximum of two intramuscular electrodes will be inserted with guiding of an echography system.~The participant will be asked to perform several upper limb movements: specifically, he will be asked to perform consecutive cycles of elbow extension-flexions with the shoulder at different levels of abduction. Times of rest will be given to the participants.~Time of the procedure is estimated to 1h, with only about 2 minutes of active effortless movements from the participants."
45997471|NCT04659083|Device|Neurally adjusted ventilatory assist ventilation mode|This technique uses the electrical activity of the diaphragm (Edi) to control respiratory support and the NAVA level as an amplification factor that converts the Edi signal into a proportional pressure.
45997472|NCT03511248|Dietary Supplement|Nitrate-rich Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
45997473|NCT03511248|Dietary Supplement|Nitrate-deplete Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
45997474|NCT04658810|Other|Assessment of post-traumatic stress disorder using the Perinatal Post-traumatic Stress Disorder)|Patients identified as women with cytomegalovirus (CMV) seroconversion during pregnancy will be called on the phoned and ask to participate to the study and to answer the Perinatal Post-traumatic Stress Disorder
45997475|NCT00540618|Drug|MEDI-507|Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)
46085871|NCT04218734|Drug|placepo|placebo:100 mg, once daily for 24 weeks.
46085872|NCT03499691|Device|Theranova 500 medium cut-off dialyzer|The patients randomized in this group using the Theranova 500 medium cut-off dialyzer, and blood flow rate and treatment duration will be maintained stable during the observation period. However, other prescriptions will vary based on the Principal Investigator's (PI's) judgment. If other dialyzers need to be temporarily used during the study period it shall be recorded which alternative dialyzers are used and for how long the study patient is on a different dialyzer. However, prior to Week 12 laboratory assessment it is recommended that the patient undergoes three dialysis sessions on the designated treatment mode.
46085873|NCT03499691|Device|Hemodiafiltration|The patients randomized in this group using the on-line high-flux HDF dialyzer, in post dilution mode, will continue to receive treatments according to their current treatment prescriptions for the duration of the study.
46085874|NCT04066478|Drug|Dehydroepiandrosterone|75mg Dehydroepiandrosterone daily
46085875|NCT04066478|Drug|Placebo|Placebo
45457411|NCT01229137|Device|SRD-1 conversion|
45457412|NCT02302690|Biological|Blood sample for immunology|
45457413|NCT02529007|Device|Endo-cuff|Colonoscopy performed with endo-cuff attached to the colonoscope
46085876|NCT03911297|Other|Women with polycystic ovary syndrome|Prospective cohort study in women with polycystic ovary syndrome to identify the risk of developing metabolic disease
46085877|NCT04185272|Biological|analysis of BTN and BTNL status|analysis of BTN and BTNL expression in colon cancer and hepatic metastasis
46085878|NCT05227235|Other|3D Telemedicine|Clinical consultation with patient performed with 3D Telemedicine
45997476|NCT00540618|Other|Placebo|
45997477|NCT00540618|Drug|MEDI-507|Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)
45997478|NCT00540618|Drug|MEDI-507|Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)
45997479|NCT04658459|Procedure|Proximal Interphalangeal Joint Arthroplasty with the Tactys Prosthesis|
45997480|NCT00557453|Drug|Antibiotic treatment|Cefuroxime 750mg X3/d, Ampicillin 2G X4/d, Flagyl 500mg X3/d, Augmentin 1G X3/d, Gentamycin 240mg X1/d, Clindamycin 600mg X3/d, Ciprofloxacin 400mg X2/d All drugs will be administered IV until clinical improvement.
45997481|NCT00557453|Drug|No antibiotics|Allowed medications for both groups will include PPI / H2 blockers, home medication, SC insulin for diabetes, and SC clexane if indicated.
45997482|NCT01207102|Drug|Abraxane|Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days
45997483|NCT01207102|Drug|Carboplatin|area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days
45997484|NCT00540657|Drug|CCX282-B|250mg capsule, twice daily, 13 weeks
45997485|NCT00540657|Drug|Placebo|Placebo capsule, twice daily, 13 weeks
45997486|NCT04658732|Drug|Administration of Alprazolam , Gabapentin , Dexmedetomidine|Patients will be allocated into one of the 3 groups: Alprazolam (A group), Gabapentin (G group) and Dexmedetomidine (D group) as control group. Alprazolam group (n=15): patients in this group will receive 0.25 mg Alprazolam (2 tablets of Xanax 0.125 mg manufactured by Pfizer). Gabapentin group (n=15): patients in this group will receive 600mg Gabapentin (2 capsules of Neurontin 300 mg manufactured by Pfizer).Control group (n=15): patients in this group will receive 2 tablets of multivitamin (Vitamax manufactured by GlaxoSmithKline S.A.E) as placebo to ensure blindness of the study. The study drug will be received 120 minutes before the operation.
45997487|NCT00540696|Drug|darbepoetin alfa|"Darbepoetin alfa 3.0mcg/kg every 2 weeks for 3 doses. At week 7, if the subject has not experienced an increase of at least 1.0g/dL in hgb from week 1, increase dose of darbepoetin alfa to 5.0mcg/kg every 2 weeks for 5 doses.~Otherwise, maintain darbepoetin alfa 3.0mcg/kg every 2 weeks for 5 doses."
45997488|NCT04658615|Procedure|Non-surgical periodontal therapy|A single 1-hour session of full-mouth debridement with an ultrasonic device under local anesthesia
45997489|NCT04658420|Drug|Ketamine Hydrochloride|Individuals in the ketamine group will receive ketamine 0.5 mg/kg infused over 40 minutes
45997490|NCT04658420|Other|Music|"A playlist by composer Nils Frahm will be played for 60 minutes. The music is instrumental, relaxing and subjectively thought to be uplifting by patients who have listened to the music during ketamine infusions performed previously by the PI for treatment of resistant depression. Music can be previewed at the link below:~https://open.spotify.com/playlist/37i9dQZF1DWVbGPBkXJYHF"
45997491|NCT00540735|Procedure|photodynamic therapy|
45457414|NCT02529007|Other|Standard colonoscopy|Standard colonoscopy without end-cuff
45457415|NCT01358084|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
45457416|NCT01358084|Drug|Placebo|Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
45675324|NCT05887271|Other|Assessment of sarcopenia|Participants will be assessed for presence of sarcopenia using the Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls (SARC-F) questionnaire. It is a robust tool for diagnosis of sarcopenia and prediction poor physical function, with excellent specificity in multimorbid individuals.
45675325|NCT05887271|Other|Assessment of frailty|Frailty will be assessed using the Edmonton Frail Scale (EFS). The EFS is a multidimensional frailty assessment which assesses multiple domains of frailty including functional independence, social support, cognition, medication use, and mood.
45997492|NCT03440775|Behavioral|Digital stories|Digital story telling videos
45997493|NCT03440775|Behavioral|Informational videos|Informational videos
45997494|NCT00557531|Device|BL-1040|2 mL of BL-1040
45997495|NCT04658264|Dietary Supplement|Wheat-Barley Composite flour|A combination of wheat and barley flour with 0.5% food grade xanthan gum as replacement for lost gluten, tested for sensory properties, nutrient profile, and rheology
45997496|NCT04657913|Other|cold water spray application|It will be sprayed into the mouth of patients every hour.
45997497|NCT04657913|Other|cold saline spray application|It will be sprayed into the mouth of patients every hour.
46085879|NCT05227235|Other|2D Telemedicine|Clinical consultation with patient performed with 2D Telemedicine as standard of care
45997498|NCT03432936|Device|MRI guided procedure software evaluation|MRI guided ablation/biopsy using standard MR imaging along with Philips Interventional iSuite software tools.
45997499|NCT04657874|Other|Bromelains and Escin Oral Tablet|Supportive care after oral surgery
45997500|NCT04657874|Other|Placebo|Oral tablet without the active principle
45997501|NCT03324438|Behavioral|Home Telehealth T1D C2oYoT1-HR|1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
46085880|NCT04218344|Other|60mls of blood donated for research analysis|All patients presenting with a possible Acute Coronary Syndrome will be invited to donate 60 mls of blood at the time of their angiogram.
45997502|NCT03324438|Behavioral|Personalized Behavioral Health|1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
45997503|NCT03324438|Behavioral|Personalized Adherence Feedback|1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
45997504|NCT00540813|Device|drug eluting balloon|drug eluting balloon bifurcated coronary lesions single arm study
45675326|NCT05887271|Other|Qualitative interview|Participants in the MRP and control groups will be invited to attend a focused semi-structured, 1-2-1 interview aimed to elicit barriers and enablers to the MRP and describe their perspective on the relationship between healthy eating and health interview during the 12-week visit. Participants who complete or drop out will be eligible. Inclusion of participants in the control arm will allow us to compare the experiences of MRP versus health coaching and detect any specific issues people face when trying to introduce lifestyle changes themselves.
45675327|NCT05887271|Diagnostic Test|Skeletal muscle magnetic resonance spectroscopy|Assessment of skeletal muscle volume (quadriceps and calf muscle) using MRI, and 31P-magnetic resonance spectroscopy (31P-MRS) of the skeletal muscle using fysiometer and during isometric exercise at rest and after 5 minutes of exercise to assess changes in muscle energetics at rest and on exercise.
45997505|NCT04658030|Device|VR 360 video surgery preparation|Preparing children on the surgery by a virtual reality 360 degrees video tour from the pediatric ward to the surgery room. In this video all information is given necessary for the surgery. This takes a maximum of 30 minutes and will be performed 1 time.
45997506|NCT04658030|Other|Care as usual|Preparing the children for surgery with the care as usual. A booklet that can be viewed by the children and parents at home.
45997507|NCT00540852|Device|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging
45997508|NCT00540891|Drug|ALFUZOSIN|
45997509|NCT04658225|Procedure|0.12% chlorhexidine|the patients were randomly allocated into two groups of 15 individuals to rinse with antimicrobials twice a day for a period of four weeks. Group A, received 0.12% chlorhexidine antimicrobian in a vial previously identified as solution 1 and group B, received saline solution identified as solution 2.
45997510|NCT00540930|Drug|Ranibizumab|Intravitreal Ranibizumab 0.5mg at the time of radioactive plaque insertion
45997511|NCT04657952|Procedure|Sphenopalatine Ganglion Block|Sphenopalatine Ganglion Block will be performed by a transnasal approach. Few drops of lidocaine 2% will be instilled into both anterior nares. Then a cotton-tipped applicator soaked in 4% lignocaine & adrenaline (1 to 200000 will be passed through both the nares and the end of the applicator tip will be positioned just superior to the middle turbinate and anterior to the pterygopalatine fossa and sphenopalatine ganglion for 5 min with the patient in the supine position.
45997512|NCT04657952|Drug|Medical Treatment|Patients will receive paracetamol 1 gm 6 hours daily intravenously for a day. If adequate pain relief will not be achieved, intravenous diclofenac 75 mg twice daily will be added.
45675328|NCT05887258|Drug|Opioid free anesthesia|Administer a combination of drugs in substitution for morphine
45997513|NCT00541008|Drug|sunitinib malate|
45997514|NCT04657796|Device|High Flow Nasal Cannula|use of high flow nasal cannula as a weaning mode from invasive mechanical ventilation to deliver oxygen
45997515|NCT03256227|Behavioral|Family Supported Prolonged Exposure|The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
45997516|NCT03256227|Behavioral|Standard Prolonged Exposure|Standard Prolonged Exposure for PTSD as delivered in routine VA care.
45997517|NCT00541047|Drug|bicalutamide|
45997518|NCT00541047|Drug|goserelin acetate|
45997519|NCT00541047|Drug|leuprolide acetate|
45997520|NCT00541047|Procedure|adjuvant therapy|
45997521|NCT00541047|Procedure|quality-of-life assessment|
45457417|NCT01358084|Other|Best Supportive Care|Where applicable and as appropriate according to Institutional clinical practice and literature guidelines. Best supportive care includes antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
45675329|NCT05887232|Procedure|Fractional CO2 laser|Patient in group A received FCL treatments four sessions with four weeks apart
45675330|NCT05887232|Procedure|Fractional CO2 with Platelet Rich Plasma|Group B received four PRP and FCL sessions 4 weeks apart
45675331|NCT05887219|Drug|Group A 4 % Hydroquinone Cream Topically and Oral Tranexamic Acid|Group A was managed with 4% hydroquinone cream as an adjuvant to oral tranexamic acid (250 mg twice daily) for 6 months
45675332|NCT05887219|Drug|Group B Azelaic Acid 20 % Cream for 6 months|Group B was managed with topical 20% azelaic acid (daily at night) for six months.
45997522|NCT00541047|Radiation|radiation therapy|
46085881|NCT04496063|Drug|Ustekinumab|Intravenous induction (6mg/kg) followed by Ustekinumab subcutaneous 90mg every 8 weeks
46085882|NCT04496063|Drug|Placebo|Placebo intravenous followed by Placebo subcutaneous every 8 weeks
46085883|NCT04032626|Drug|Lenalidomide 10 mg|Lenalid
46085884|NCT04032626|Drug|Placebo|Placebo
46085885|NCT03904472|Behavioral|Web-based CBTI|Sessions comprise a range of cognitive and behavioral techniques and psychoeducation including sleep hygiene. During the intervention period the participant will complete daily online sleep diaries. Additionally, participants will be asked to complete multiple questionnaires.
46085886|NCT04213950|Other|Rabies PEP quality improvement bundle|The rabies PEP quality improvement bundle consists of (1) electronic health record enhancements to support rabies PEP treatment selection, administration, and discharge process; (2) education to ED staff on rabies PEP; and (3) education to patients on rabies PEP and follow-up care.
46085887|NCT05225987|Behavioral|Postpartum Nurse Navigation Program based care|In addition to routine hospital care, the intervention group will receive navigation program-based nursing care that includes three home visits, three phone calls, and sending text messages at five different times.
45675333|NCT05887206|Other|Collection of datas|The collected data are : sex, age, date of first immunotherapy cycle, dose, date of first consultation, objective refraction in spheric equivalent, keratometry, visual acuity, microcyst-like epithelial changes (MECs), location and density, corneal toxicity grade and complementary exams (topography, in vivo confocal microscopy).
45997523|NCT04657718|Device|KODEX-EPD system|Cardiac pacing leads implantation for PM, ICD, CRT, HBP and LBBP
46085888|NCT04160351|Device|Theranova 400|medium cut-off dialyser
46085889|NCT04160351|Device|Elisio-19H|high flux dialyser
46085890|NCT04214106|Drug|intravenous Thiamine|patients who received Thiamine,100-500 mg/day for at least one day
46085891|NCT02747732|Drug|Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6|"Therapy initiation 30 days max from screening.~Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT"
45458392|NCT04418882|Other|management and follow up of all open fractures|to evaluate the development of sepsis after an open fracture and then, if there is a development of a pseudarthrosis too.
45458393|NCT03494296|Drug|patients received D-COP regimen chemotherapy|patients received D-COP regimen chemotherapy
45458394|NCT01359878|Drug|Fibrinogen Concentrate|2 gram intra venous
45458395|NCT01359878|Drug|Isotonic Saline|Isotonic saline in equivalent volume - 100 ml
45675334|NCT05887193|Device|Biothesiometry|Biothesiometry using Biothesiometer (Bio Medical Instrument Co, Ohio, United States of America), placed on glans penis and second finger of nondominant hand.
45675335|NCT05887193|Device|Near Infrared Spectroscopy|Penile oxygen pressure using TCM5 Flex and tc84 electrode (Radiometer Medical ApS, Brønshøj, Denmark) placed on glans penis.
45997524|NCT00541086|Drug|anastrozole|1 mg per day, orally
45834764|NCT01454466|Procedure|Partial posterior hyaloidectomy (a modified procedure of vitrectomy)|The core vitrectomy entails more extensive removal of vitreous gel, in contrast to the conventional core vitrectomy. IPVD was conducted by engaging the attached posterior cortical vitreous with a 23-gauge needle with angulated tip in the area adjacent to the optic disc followed by gently moving the tip to approximately 3 disc diameters away from the margin of the optic disc. After then, slightly elevating the tip in a posteroanterior direction with slowly proceeding it to the extent that we planned. With IPVD, the surgeon was able to visualize a floating Weiss ring in all of the cases. Active suction to initiate IPVD was not used in any of the cases. In the temporal direction, the extension of a PVD was restricted to approximately 2 disc diameters distance beyond the margin of temporal major vascular arcade
45834765|NCT01454544|Biological|AIT Tablet|1 tablet per day in 12 months
45997525|NCT00541086|Drug|exemestane|25 mg per day, orally
45997526|NCT00541086|Drug|letrozole|2.5 mg per day, orally
45997527|NCT00541086|Drug|tamoxifen citrate|20 mg per day, orally
45997528|NCT04657484|Drug|Medium dose prednisolone|Same as arm description
45997529|NCT04657484|Drug|Low dose prednisolone|Same as arm description
46085892|NCT05219591|Device|EPR|application of EPR technology during CPAP treatment
46085893|NCT02747810|Device|NewTENS Design|This device functions the same as the FDA approved TENS unit, but provides a small, inexpensive unit that will be easy for a child to use. The stimulation characteristics include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for inducing toe twitching - or the intensity that the subject feels comfortable with. The subjects will also be instructed how to use the stimulator and where to attach the electrodes on the foot at the beginning of the study. The investigator will provide the stimulator and electrodes. The subjects will be asked to wear socks to prevent the electrodes from detachment and to stop the stimulation during walking or in any non-resting situation. Subjects will be asked to use the stimulator for a MINIMUM of 60 minutes in the evening prior to bedtime at home for two weeks. They will be encouraged to use the stimulator for more time than the minimum as long as they accurately record the total duration.
46085894|NCT03934619|Device|Dolores One|Dolores One, which is a will be applied personal sounds amplification device, will be used to determine if it improves the ability to communication and improves intelligibility
46085895|NCT02747654|Genetic|genotype|Patients were randomly assigned to a standard treatment group; INH dose of 300 mg or 200 mg based on the body weight) or model-based treatment group; INH dose determined based on developed model,
46085896|NCT02695862|Drug|Terlipressin|
46085897|NCT04315727|Genetic|WGS Diagnostic Blood take for genetic diagnostic.|Blood sampling, shot clinical characterization, WGS based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA Sequencing (RNA-seq).
45997530|NCT00541125|Biological|bevacizumab|
45997531|NCT00541125|Biological|filgrastim|
45997532|NCT00541125|Drug|fluorouracil|
45997533|NCT00541125|Drug|irinotecan hydrochloride|
45997534|NCT00541125|Drug|leucovorin calcium|
45997535|NCT00541164|Drug|Coenzyme Q10|300 mg CoQ10 twice a day for 48 weeks
45997536|NCT00541164|Dietary Supplement|Coenzyme Q10|300mg CoQ10 twice a day for 24 weeks beginning at week 24 of the study
46085898|NCT04315727|Genetic|Hair collection|Hair including root will be collected from the scalp (~15-20) and transferred to cultivation medium for the organoid cultivation
46085899|NCT02695472|Drug|80 Milligrams NSI-189|Orally Administered
46085900|NCT02695472|Drug|Placebo|Orally administered
45834766|NCT03824730|Device|Stenting of the Common and/or External Iliac Arteries|"Stenting of the Common and/or External Iliac Arteries was performed in the angiographic suite. Under local anesthesia, arterial access was obtained through standard percutaneous puncture of the common femoral artery, brachial approach, or simultaneous brachial and femoral approach.~Iliac lesion crossing was achieved through intraluminal or subintimal manner depending on the behavior of the lesion intraoperatively.~Predilatation of the occlusion before stent deployment was performed at the discretion of the operator.~Balloon-expandable stents were used for proximal, ostial lesions, whereas self-expanding stents were deployed in all other lesions.~Both stents were used in long lesions involving heavily calcified common iliac arteries."
46085901|NCT02695472|Drug|40 Milligrams NSI-189|Orally Administered
46085902|NCT00617448|Procedure|diathermy haemorrhoidectomy under espinal anesthesia|For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan).For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
45675336|NCT05887193|Device|Cycling on a home trainer|Riding a static bike Wahoo Bike (Wahoo Fitness LLC, Atlanta, Georgia, United States of America) for 3x 10 minutes at 65-85% of each individual subjects maximal heart rate.
45834767|NCT03824886|Other|Implementation of skin care algorithm|Implementation of structured and standardized skin care regimen
45834768|NCT02983188|Drug|Berberine|Berberine tablets, 0.3g every time, two times daily
45834769|NCT02983188|Drug|Placebos|Placebo tablets, 0.3g every time, two times daily
46085903|NCT00617448|Procedure|diathermy haemorrhoidectomy under local anesthesia|For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan). For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine [20 mL, 7.5 mg/mL] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1
45997537|NCT04657757|Other|Intraoral apparatus|Eight platelets with different material composition and surface properties are fastened in a holder (carrier rondell) with 15 mm diameter and inserted into the braces. Braces are to be worn for 28 hours in the oral cavity except for meals and oral hygiene procedures. Platelets then are removed and analyzed. After a first course the braces are to be cleaned in chlorhexidine solution in an ultrasonic bath; followed by a second identical course (Braces to be worn for 28 hours in the oral cavity except for meals and oral hygiene procedures).
45997538|NCT04657601|Device|DiLumen C2 Endolumenal Interventional Platform|Dual balloon accessory to an endoscope and related instruments
45997539|NCT03231072|Device|Electrical Impedance Tomography record|Monitoring of pleural effusion evacuation by means of EIT
45834770|NCT02983188|Drug|Antipsychotic Agents|Antipsychotic agents prescribed at the discretion of the patients' psychiatrists with respect to patients' conditions. Concomitant use of other psychotropic drugs, including antidepressants, anxiolytics, and mood stabilizers for mood disorders, benzodiazepines and non-benzodiazepines for insomnia, and anticholinergics for extrapyramidal symptoms, was allowed as usual. For those who were under anti-hyperlipidemic, antihypertensive and anti-diabetic treatment, they were allowed to continue their current medications throughout the study.
46085904|NCT00617448|Procedure|Ligasure haemorrhoidetomy under spinal anestesia|For surgery: ligasure haemorrhoidectomy For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
46085905|NCT00617448|Procedure|Ligasure haemorrhoidectomy under local anesthesia|For surgery: haemorrhoidectomy with Ligasure For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine [20 mL, 7.5 mg/mL] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1
46085906|NCT04308863|Drug|Chitosan scaffold/ MTA pulp dressing material|Chitosan 3-D porous scaffold will be prepared. The chitosan scaffolds will be examined with the Scanning electron microscopy (SEM) to analyze the surface of the chitosan scaffolds. The scaffolds will be sterilized by Ethylene oxide and stored until further use. A piece of 2-mm thick chitosan scaffold will be gently placed onto the pulp chamber floor and covering the canal orifices, and then a 2-3 mm thick layer of fast setting EndoCem Zr MTA will be applied onto the chitosan scaffold and will be gently condensed with moistened cotton pellet to attain adequate thickness which will be confirmed radiographically. MTA will be allowed to set for 4-5 mins.
46085907|NCT04308863|Drug|MTA pulp dressing material|MTA will be gently placed over the fresh pulp wound using an MTA carrier to a thickness of 2-3 mm. It will be condensed lightly with moistened cotton pellet to attain adequate thickness and confirmed radiographically. MTA will be allowed to set for 4-5 mins.
45675337|NCT05887193|Device|Bike Fitting|Setting standardized posture of the rider on the bike using Retül technology (Retül, Specialized Bicycle Components Inc., Boulder, Colorado, United States of America)
45675338|NCT05887180|Other|PräVaNet-Intervention|interdisciplinary and digitally supported prevention concept
45675339|NCT05887167|Biological|autologous hematopoietic stem cells added to planned CAR T|Autologous hematopoietic stem cells (aHSCs) infused on Day 10 after CAR T (any FDA-approved CAR T product) infusion on Day 0.
45675340|NCT05887154|Device|Microwave ablation|microwave ablation
46085908|NCT04166162|Behavioral|Brief Intervention Motivational Interviewing (BIMI) Intervention|BIMI is a 15-minute brief interview in person or via video chat with participating youth. The interview will be focused on discussing the impact of drinking alcohol on one's health and how to set personal goals so that alcohol use does not become a problem. A follow up phone or video call at 3 and 6 months post initial interview will also be conducted which will track on the progress of setting and keeping personal goals.
46085909|NCT04166162|Behavioral|Tomando Buenas Decisiones (TBD) Intervention|The program is adapted from the Guiding Good Choices (GGC) program and will be conducted by a trained facilitator lasting for about 2 hours per session. The program discusses about the best ways to help one's child make good decisions with regards to avoiding alcohol, drugs, and other problem behaviors that may not be healthy to them as well as ways to have good communication and good connections within one's family.
46085910|NCT04166162|Behavioral|Social Development Strategy (SDS) Intervention|SDS is a 2 hour broad-focused environmental intervention consisting of short presentations and workshops designed to provide skills and models for positive human interaction between employees to fellow employees, employees to their children and employees to their supervisors.
46085911|NCT04166162|Behavioral|BTC Training Session|BTC training session consists of trainings, discussions and tools focused on community mobilization for the assessment and implementation of evidence-informed preventive interventions addressing community health and behavior problems. Each training session lasts about 4 hours.
46085912|NCT00615810|Drug|Atripla|Open label once daily for oral administration to be taken on an empty stomach
46085913|NCT00615810|Drug|Kivexa plus Sustiva|Open label once daily for oral administration
46085914|NCT03355157|Drug|Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)|Drug intervention
46085915|NCT04215432|Device|Gel containing propolis extract, nanovitamin C and nanovitamin E|The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis. during 1 month.
46085916|NCT04215432|Device|Placebo|The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis.
46085917|NCT02747342|Drug|SHR3680; SHR3162|"SHR3680 will be administered orally in dose escalation/expansion phase,~SHR3680 will be administered orally at a fixed dose together with SHR3162 in combination phase."
46085918|NCT02699580|Device|lateral rectus recession with biodegradable collagen implant|Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done. After lateral rectus recession, no degradable collagen implant was placed in the area, where lateral rectus was original inserted. One eye was randomly selected for the comparison.
45834771|NCT01450176|Drug|Olopatadine hydrochloride 0.2%|1 drop in each eye once daily for 2 weeks
45834772|NCT01450176|Drug|Bepotastine besilate ophthalmic solution 1.5%|1 drop in each eye twice daily for 2 weeks
45834773|NCT01450254|Device|AposTherapy Biomechanical System|The system is a rehabilitation program implementing a device comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center of pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
45834774|NCT01450254|Other|Control|No intervention will be prescribed to the control group during participation in the study.
45834775|NCT01454622|Drug|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
45834776|NCT01454622|Drug|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
45834777|NCT01450332|Device|Knee-T-Nol|The ACL prosthesis is intended for the treatment of ruptured ACL. It will be used as an implant to replace the native, torn ACL. Implantation will be done using arthroscopy
45834778|NCT01450410|Drug|Nicotinic acid|Nicotinic acid / laropiprant (Tredaptive 1000 mg/20 mg modified-release tablets). Patients treated with nicotinic acid 1g/day receive one dose of one month and 2 g / day thereafter. Nicotinic acid treatment will last for 12 weeks.
45834779|NCT01450410|Drug|Placebo|Placebo treatment will last for 12 weeks.
45834780|NCT02950818|Behavioral|Take Heart|Participants receive an evidence-based heart disease self management program consisting of a combination of five two and a half hour group sessions and telephone counseling offered by a trained facilitator employed by the Detroit Area Agency on Aging. The program is designed so that participants select an area to work on (e.g., diet, exercise, medication taking, communication with health care professionals) and receive support, information, and encouragement from group members and program facilitators, to help them reach their goals.
45834781|NCT03824418|Procedure|Surveillance colonoscopy with chromoendoscopy|Surveillance colonoscopy with chromoendoscopy
45834782|NCT04391712|Device|MLS Laser|Treatments will be delivered to the participants days 1-4, in a prone position using a 10 by 25 cm laser field across each lung with 7j/cm2 at 1500 Hz.
45834783|NCT04391712|Other|Regular Inpatient Medical Care|Regular inpatient medical care
45834784|NCT04391634|Other|volume guarantee|volume guarantee assist-control mechanical ventilation
45834785|NCT04391634|Other|pressure-controlled|pressure-controlled assist-control mechanical ventilation
45834786|NCT01450488|Drug|masitinib|masitinib 3 mg/kg/day
45834787|NCT01450488|Drug|masitinib|masitinib 6 mg/kg/day
45834788|NCT01450566|Drug|Lidocaine|Use of lidocaine
45997540|NCT04656977|Other|VR|The proposed intervention will consist in three weekly sessions of 2h focused, respectively, on: (1) gathering information about the loss and psychoeducation about perinatal grief, and introduction to the virtual environment; (2) through the use of the virtual environment, women will be assisted in the elaboration and acceptation of loss; (3) recreate, using the features of the virtual environment (i.e., a series of different virtual landscapes and symbolic elements personalized to each participant as personal pictures, sounds or videos) a new and positive metaphor representing the woman's future life.
45997541|NCT04656977|Other|TAU|The TAU condition is a homogenous standard program proposed by the CERIF at UQO based on group counseling offered to women and men who experienced a perinatal loss.
45997542|NCT03221322|Behavioral|Superlean|Behavioural data will be collected on all subjects in either control group or superlean group. Blood or saliva samples will be collected for DNA extraction and genotyping.
45997543|NCT04656938|Behavioral|Pre-frail intervention|Pre-frail partiipants will undergo 4 month intervention consisted of group-based physical exercise and nutritional classes.
45997544|NCT00541281|Drug|docetaxel|35mg/m² on day 2 and 9 (21days in a cycle)
45997545|NCT00541281|Drug|estramustine|140mg caps x3 bid from day 1to 5 and day 8 to 12 of each cycle
45997546|NCT00541281|Drug|prednisone|2x5 mg a day
45997547|NCT04656860|Dietary Supplement|Juice Plus+|Participants will receive encapsulated fruit and vegetable juice concentrates or a placebo for a 24-month period
45997548|NCT00541320|Drug|GW813893|
46085919|NCT02699580|Procedure|Lateral rectus recession without biodegradable collagen implantation|Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done in the other eye without placing biodegradable collagen implantation.
46085920|NCT02747030|Drug|Ocriplasmin intravenously|Retinal vein cannulation with Ocriplasmin infusion
46085921|NCT04810013|Procedure|non-invasive measurement of cerebral autoregulation|Non-invasive measurement of the cerebral autoregulation in the postoperative period in 80 neonates and infants with complex congenital heart disease undergoing cardiopulmonary bypass surgery. A continuous, moving Pearson's correlation coefficient will be calculated between the arterial pressure and near-infrared spectroscopy signals and displayed continuously during surgery using a laptop computer and the ICM+ software (Cambridge Enterprise).
45834789|NCT01450566|Drug|Saline|Saline
45834790|NCT03824262|Device|HICO-VARIOTHERM 550|Warming during perioperative period.
45834791|NCT03824262|Device|Mistral-Air Plus forced air warming device|Warming during perioperative period.
45834792|NCT02947386|Other|Laboratory Biomarker Analysis|Correlative studies
45834793|NCT02947386|Biological|Nimotuzumab|Given IV
45834794|NCT02947386|Biological|Nivolumab|Given IV
45834795|NCT03043014|Drug|Mifépristone versus Misoprostol|The women will be randomized into two groups: Mifépristone group and Misoprostol group. The main endpoint will be the per-operating pain. The other endpoints are the pre and post-operative pain, the complications (cervical tearing, uterine perforation, hemorrhage requiring the use of blood products or an hemostatic intervention), the surgical time necessary to terminate the pregnancy, the side-effects of the drugs. The amount of per-operating bleeding and the duration of the intervention . The investigators assume that the use of Mifepristone in the cervical preparation of the surgical abortion under LA would reduce the per-operating pain. The number of patients required is 55 in each arm.
45834796|NCT03824184|Procedure|manipulation of endometrium|Manipulation of endometrium with saline
45834797|NCT02978118|Device|Immune cell and CTC detection procedures|Immune cell profiling assays (in blood and archival tumor samples) and circulating tumor cell assays (in blood samples)
45834798|NCT01450644|Other|The Hospital2Home Service|This intervention is a new multiprofessional, patient case conference that is organised for people nearing the end-of-life. Evidenced based guidelines for the management of the physical, psychological, spiritual and end of life-planning needs for these patients will be used in the H2H case conference. A case conference will be organised in their home (or place of their choice). The patient, informal caregiver, H2H CNS, GP, district nurse, social worker and community palliative care nurse are invited to attend. Current and anticipated care needs are discussed, and an action plan is agreed allocating a responsible health care professional for each item. During the case conference, individualised care plans will be made. This is then communicated with local services, primary and specialist teams resulting in streamlining of transfer of data and codifying responsibility for the patient, hospital and community care professionals.
45834799|NCT02983344|Drug|Ropivacaine|Fascia iliaca compartment block using ropivacaine
45834800|NCT02983344|Drug|Fentanyl|Intravenous fentanyl
45675341|NCT05887115|Behavioral|Nurse Family Partnership|During NFP visits, the nurse: 1) engages in a therapeutic nurse-client relationship focused on promoting client abilities and behavior change to protect and promote her own health and child's health; 2) provides service coordination based on client's identified needs, referring to available community services; 3) follows NFP Visit Guidelines tailoring them to the strengths and challenges of each family; 4) works with client to support a healthy pregnancy by recognizing and reducing risk factors and promoting prenatal health care, healthy diet, exercise, and stress management; and 5) gathers data on program implementation and maternal and child health. The visits include content from six domains: personal health, environmental health, life-course, maternal role, family and friends, and health and human services. Nurses use educational materials to address the content from the six domains with their clients.
45675342|NCT05887102|Behavioral|PACHA Program|Pharmacists in this group will complete the 85-minutes web-based training, schedule and realize at least 2 telephone consultations with participating women in their pharmacy (in the first month and 4 months after randomization) using standardized consultation guides based on the principles of motivational interviewing and, if necessary, the evidence-based web sheets about strategies to cope with side effects and other AET-related concerns. Women in this group will have access to a web site that includes video capsules to inform women about AET, evidence-based web sheets describing strategies to cope with side effects and other AET-related concerns, testimonies of women who had breast cancer and an AET and a list of resources available for women.
45675343|NCT05887089|Other|drone transport|additional transport of samples at room temperature by drone (departure from the CHU Amiens-Picardie, 1 hour flight in the CHU Amiens-Picardie air perimeter, return to the CHU Amiens-Picardie)
45997549|NCT04657172|Drug|Pilocarpine Ophthalmic|Pilocarpine 1% or 2% ophthalmic solution administered with the Optejet microdose dispenser
45997550|NCT04657172|Drug|Placebo|Vehicle ophthalmic solution administered with the Optejet microdose dispenser
45997551|NCT03199794|Biological|OBIZUR|Treating physician will determine treatment regimen and frequency of laboratory and clinical assessments according to routine clinical practice.
45997552|NCT04656821|Drug|Control Rx|Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed
46085922|NCT04215276|Other|Valsalva maneuver|pressure during Valsalva maneuver was measure using sphygmomanometer
46085923|NCT04215276|Other|Control|patient was not given any intervention
45834801|NCT02983344|Device|Ultrasound|Ultrasound-guided fascia iliaca compartment block
45834802|NCT01450878|Drug|beta-epoietin|100 000UI beta-epoietin injection one hour before organ retrieval
46085924|NCT02747264|Device|eRAPID|eRAPID is an online system for patients to self-report symptoms and AE during and after cancer treatments. eRAPID allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
46085925|NCT03324035|Drug|Amitriptyline|Administer amitriptyline on flexible doses variating from 25mg to 75mg, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
46085926|NCT03324035|Drug|Placebo oral capsule|Administer amitriptyline on flexible doses variating from 1 to 3 capsules, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
46085927|NCT03324035|Drug|Tramadol|"Administer to both arms on as needed scheme, to a maximum of 150mg/day."
45834803|NCT02914314|Drug|perampanel|oral suspension.
45834804|NCT01451034|Procedure|WHYX cancer group|WHYX cancer diagnosed by pathologic report
45834805|NCT03824340|Drug|Doxycycline before ICSI|Extra medication (Doxycycline ) group before ICSI :,women who will receive more medications (Doxycycline ) before starting the ICSI process
45834806|NCT03824028|Device|Clareon® IOL AutonoMe™ automated preloaded delivery system|Disposable injector preloaded with the Clareon IOL for precise IOL insertion during cataract surgery
45834807|NCT03823872|Other|Time restricted feeding|Time restricted feeding= consume food only from 12:00pm-8:00pm
45997553|NCT04656821|Procedure|Erector Spinae Block|Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.
45834808|NCT03823872|Other|Normal feeding|Normal feeding= consume food per normal schedule
45997554|NCT04656821|Procedure|Thoracic Paravertebral Block|Patients of this group will receive 25 mg bupivacaine 0.5% , plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at desired level under ultrasonography
45997555|NCT04656509|Other|4-s sprint inertial load training|A program employing 30 bouts of 4s inertial load sprint training with progressively reduced recovery time (30 to 15 s) between sprints is effective for improving blood volume, VO2peak and maximal power.
45997556|NCT00541359|Drug|bortezomib|Given IV
45997557|NCT00541359|Drug|topotecan hydrochloride|Given IV
45997558|NCT00541359|Other|immunohistochemistry staining method|Correlative studies
45997559|NCT00541359|Other|pharmacological study|Correlative studies
45997560|NCT04656743|Procedure|intra-articular injection|The injection will be performed under ultrasound guidance by placing the patient's knee in approximately 90° of flexion with the leg hanging off the side of the bed (left). A high-frequency linear transducer ultrasound probe is placed in the superolateral corner of the patella, directed medially toward the patellofemoral joint space. In the extended leg, from anterior to posterior, the right image shows the quadriceps femoris tendon (QF), suprapatellar fat pad (SF), suprapatellar bursa (SB), prefemoral fat pad (PF), and femur (F). When the knee is flexed to 90°, the size of the suprapatellar bursa image is increased. Using an in-plane approach, the needle will be directed into the suprapatellar joint space, and 20 ml of bupivacaine 0.25% will be injected.
45997561|NCT04656743|Procedure|genicular nerve block|The transducer will be first placed parallel to the long bone shaft and moved up or down to identify the epicondyle of the long bone. The genicular arteries will be identified near the periosteal areas, confirmed by color Doppler ultrasound. Accordingly, genicular nerve block target points should be next to each genicular artery. After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view. a gentle aspiration will be performed and a 2 mL injection volume will be administered.
45997562|NCT03111927|Other|Infant Formula: enriched level of myelin-relevant nutrients|"Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months."
45997563|NCT03111927|Other|Infant formula: standard level of myelin-relevant nutrients|"Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months."
45997564|NCT04656782|Other|Imaging survey|Participation as expert panelist in the imaging survey.
45997565|NCT04656782|Other|Facilitation|Moderation and evaluation of the expert panel's answers. Adoption and moderation of further survey rounds.
45997566|NCT00541398|Behavioral|Implementation of guideline|Outreach visits with interactive education for health staff
46085928|NCT00616746|Drug|Nicotine|1.0 microg/kg/min IV x 10 minutes
45675344|NCT05887063|Other|Dementia Awareness Course UK|An online course delivered to a small group of informal caregivers in between 3 and 4 hours. The course is made up of three modules: what is dementia, positive engagement and caring for someone with dementia. The course is delivered by one facilitator and includes teaching, discussions and activities.
45675345|NCT05887037|Diagnostic Test|mNGS|mNGS is the direct extraction of nucleic acid from clinical samples. High-throughput sequencing technology and bioinformatics analysis were adopted to complete the detection of pathogens such as bacteria, fungi, viruses and parasites at one time
45675346|NCT05887037|Diagnostic Test|The traditional microbiological cultures|Traditional microbial culture is the gold standard for the diagnosis of central nervous system infection, but the traditional microbiological culture time is long and the detection rate is low.
46085929|NCT00616746|Drug|Ethanol|IV
46085930|NCT02695316|Other|Focus Group Discussion in native Language|Group Interview with semi-structured key question, moderated in the native language of the participants. Interpreters translate the discussion for the Researcher analogically and adapt it culturally. The discussions are audio-recorded, summarized, translated and transcribed into German.
46085931|NCT02695316|Other|Focus Group Discussion|Group Interview with semi-structured key question, audio-recorded and ad verbatim transcription
46085932|NCT02695316|Other|One-to-one Interview|One-to-one Interview with semi-structured key question, audio-recorded and ad verbatim transcription.
46085933|NCT02695316|Other|Retrospective Quantitative Analysis|Retrospective Quantitative Analysis of questionnaires (Telephone Interpreting Protocols)
45675347|NCT05887024|Device|Radial Extracorporeal Shock wave Therapy|Shock wave therapy: (BECO) S/N 16B011375
45675348|NCT05887024|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|EME (Therapic 9400) TENS
45675349|NCT05887024|Procedure|McKenzie Back exercises|Graduated Progressive back exercise program.
45675350|NCT05887024|Device|electric heating pads|electrical conducting heat pack.
45675351|NCT05886998|Drug|Heparin|Heparin sodium (Generic, 5000 IU/ml ampoules)
45834809|NCT01455246|Drug|Daptomycin + Meropenem|Daptomycin will be administered at the dose of 6 mg/kg every 24 hours and 6 mg/kg every 48 hours for an estimated creatinine clearance (CKD-EPI) of > 30 ml/min and < 30 ml/min respectively. Meropenem will be administered at the dose of 1 g t.i.d., 1 g b.i.d., 0.5 g every 24 hours for an estimated creatinine clearance of >50 ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours will be added a rescue therapy with fluconazole. In patients in which cultures shown a bacterial species resistant to therapy, daptomycin and meropenem will be discontinued and replaced by a therapy based on antibiotic susceptibility of isolated species.
45675352|NCT05886998|Other|Normal Saline|0.9% sodium chloride solution (normal saline)
45997567|NCT04656626|Behavioral|brief mindfulness based intervention|The 20 minute daily mindfulness sessions for 2 weeks consist of the following guided meditation practices: 1. Bring your attention to a primary object of focus 2. Maintain a moment-moment awareness 3. When your mind naturally drifts into thinking (mind wandering); just notice you are thinking, and then bring your attention back to your object of focus 4. When a strong sensation arises, again, notice the sensation or emotion and return to your breath. 5. As you gain confidence, you may practice maintaining this focus while observing thoughts flowing through your mind or sensations in your body while showing no concern for the content 6. You may even label your thoughts 7. Thank yourself for your efforts and for taking this time.
45997568|NCT04656626|Behavioral|Progressive muscle relaxation|"Control group:~Control group will be given an mp3 audio recording of a 20-minutes of progressive muscle relaxation will be sent directly as SMS messages and emails to be heard by the participants through their personal device of their choice, such as a smart phone."
45997569|NCT03456921|Other|"End-of-life conversation game called Hello"|To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').
45997570|NCT04658069|Other|no specific interventions|no specific interventions
45997571|NCT04656704|Drug|hyaluronidase injected intradermally|Patients will receive 200 units of hyaluronidase injected intradermally to the cutaneous lips on Weeks 0, 4, 8, 12, and 16, and 20
46085934|NCT04404023|Biological|UB-221|UB-221 (75 mg/ml)
45457418|NCT04464382|Procedure|Outpatient (OA)|"Patients who are candidates for OA and therefore pre-selected based on the primary data and characteristics of the clinical signs, will be admitted to the surgical observation in charge of our service. The patient will be informed in detail of the intervention to be performed and discharge on an outpatient basis and will sign the informed consent understanding and thus accepting all the information. The patient will undergo surgery using a laparoscopic or open technique with minimal incision.~Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed. In this case, we will perform the blind randomization of the patients. If all the inclusion requirements for the study are met, and the patient belongs to the OA group (case group), he will be discharged on an outpatient basis from the post-surgical stay unit without requiring hospital admission."
45675353|NCT05886959|Other|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
45675354|NCT05886959|Other|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
45834810|NCT01455246|Drug|Ceftazidime|Ceftazidime will be administered at the dose of 2 g t.i.d, 2 g b.i.d and 2 g at every 24 hours by intravenous infusion for an estimated creatinine clearance (CKD-EPI) of >50 ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours, or in which cultures shown a bacterial species resistant to therapy, ceftazidime will be discontinued and replaced by a rescue therapy with meropenem and daptomycin as provided for the experimental arm
45834811|NCT01455324|Device|Novel conformable woven inner socket|Prosthetic socket liner fabricated from novel materials to allow passive conformability for the user
45997572|NCT03096249|Drug|Oxytocin|Syntocinon nasal spray: single dose of 24IU (3 puffs of 4IU per nostril)
45997573|NCT03096249|Other|Placebo|Placebo spray: single dose (3 puffs per nostril).
45997574|NCT04656548|Device|HydroPICC|PICC lines
45997575|NCT04656665|Drug|Aspirin|For patients at high risk of pre-eclampsia, start taking aspirin from 12-20 weeks of pregnancy
45997576|NCT03057054|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
45997577|NCT03057054|Biological|Lactobacillus plantarum strain 299|Given PO or via NJ, NG or G tube
45997578|NCT03057054|Biological|Lactobacillus plantarum strain 299v|Given PO or via NJ, NG or G tube
45997579|NCT03057054|Other|Placebo Administration|Given PO or via NJ, NG or G tube
45997580|NCT03014622|Biological|Botulinum Toxins, Type A|Intramuscular injection
45997581|NCT03014622|Biological|Placebos|Intramuscular injection
45997582|NCT04656314|Diagnostic Test|Functional MRI scan|Functional MRI scan: Phase contrast, BOLD, Arterial Spin Labeling, Diffusion weighted MRI, T1 mapping, T1rho mapping
45997583|NCT04656119|Other|there is no intervention in our study|there is no intervention in our study
45997584|NCT04656197|Other|Ocular microbiome|Taxonomical and functional characterization of the ocular microbiome
46085935|NCT05173038|Behavioral|second ejaculate|group patients received IUI for pregnancy assistance 1 hour after the first sperm extraction. The two semen were mixed and treated.
46085936|NCT02746952|Biological|UCART19|
46085937|NCT04393259|Other|Rainbow Clinic Model of Antenatal Care|Rainbow Clinic Model is an antenatal model of care with initial ultrasound scan at 23 weeks' gestation including uterine artery Doppler, frequency of subsequent scans determined using data from this initial scan. Continuity of care is provided by obstetricians and midwives.
45997585|NCT04655846|Behavioral|Nursing intervention outcome: Breastfeeding Counseling (5244)|"Educational sessions: The nursing professional will carry out 1 educational session per week, for 4 weeks; each lasting between 45 and 60 minutes. The topics that make up each of the activities are:~Educational Session: Awareness towards the process of breastfeeding. Inform about the psychological and physiological benefits of breastfeeding.~Educational session: Teach the composition of breast milk. Teach the baby's correct alignment, latch, and areolar understanding of the breast. Instruct on breastfeeding positions.~Educational Session: Explain the extraction and conservation of breast milk.~Educational session: Explain the signs, symptoms, and management strategies for duct obstruction, mastitis, and nipple trauma. Talk about your needs for rest, hydration, and diet during breastfeeding."
45997586|NCT04655846|Behavioral|Nursing education about maternal care and usual education in maternity preparation course|Educational intervention by a nursing professional on the provision of adequate care at the level of growth and development in infants under one year of age, activities not related to the breastfeeding process
45997587|NCT04655534|Other|Inspiratory Muscle Warm-up (IMW)|The IMW protocol applied before each inspiratory muscle training (IMT) session by using a threshold inspiratory muscle trainer. The IMW protocol consists of 2 sets of 30 breaths in 40% of the maximal inspiratory pressure (MIP), with 1 min rest between sets. The intensity of MIP adjusted by two weekly MIP measurements.
45997588|NCT04655534|Other|Inspiratory Muscle Training (IMT)|The IMT applied twice a day as 30 breath repetitions at 60% of the maximal inspiratory pressure (MIP). The intensity of MIP adjusted by two weekly MIP measurements.
45997589|NCT04655534|Other|Respiratory exercises and aerobic exercise program|Then the respiratory exercises and aerobic exercise program performed in both groups in each session. Aerobic exercise program; After 5 min of general body warming, applied 20 min with a load of 4-6 according to the modified Borg scale on the treadmill, finished with 5 min whole body cool-down. All program applied to 3 days a week for 8 weeks under the supervision of a physiotherapist and other days of the week without a supervisor.
45997590|NCT03013218|Drug|Evorpacept (ALX148)|Evorpacept (ALX148)
45997591|NCT03013218|Drug|Pembrolizumab|Keytruda
45997592|NCT03013218|Drug|Trastuzumab|Herceptin
45997593|NCT03013218|Drug|Rituximab|Rituxan
45997594|NCT03013218|Drug|Ramucirumab + Paclitaxel|Standard of care chemotherapy
46085938|NCT04217876|Diagnostic Test|post-processing analysis of cardiac imaging (strain echocardiography)|"A dedicated software package for two-dimensional speckle tracking strain analysis (XStrain™, Esaote, Florence, Italy) was used to quantify both ENDO and EPI strains. Our echocardiographic imaging acquisition protocol for 2DSTE consisted in the acquisition of three consecutive cardiac cycles from non-foreshortened apical views (4, 2, and 3 chambers) obtained during breath hold. Frame-by- frame displacement of ENDO and EPI points was automatically evaluated, generating strain curves for each segment.~The tracking quality was verified for each segment, and subsequent manual adjustments were performed, when required. All data were analyzed with the aid of Fourier techniques, which ensure greater accuracy using the periodicity of the heart motion."
46085939|NCT03007511|Device|Fidmi enhanced enteral feeding device|Fidmi enhanced enteral feeding device is intended to provide nutrition to a patient directly into the stomach through a stoma. The Fidmi PEG device would be investigated in this study on patients suffering from dysphagia, who are scheduled for PEG procedure in order to improve surgical initial insertion, device replacement and removal.
45997595|NCT03013218|Drug|5-FU + Cisplatin|Standard of care chemotherapy
46085940|NCT00777582|Drug|AZD2281|Oral single dose formulation
45997596|NCT04655807|Drug|JNJ-64304500|JNJ-64304500 will be administered as SC injection.
45458732|NCT04496908|Drug|Misoprostol|Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg.
45834812|NCT01451112|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
45997597|NCT04655807|Drug|Placebo|Matching placebo will be administered as SC injection.
45997598|NCT04655807|Drug|Adalimumab|Adalimumab will be administered as SOC biological therapy.
45997599|NCT04655807|Drug|Ustekinumab|Ustekinumab will be administered as SOC biological therapy.
45997600|NCT04655417|Drug|Sodium Tetradecyl Sulfate|DRUG WILL BE INJECTED TO ALLAPTIENTS ACCORDING TO STANDARD PROTOCOL
46085941|NCT04219436|Procedure|esthetic crown leghthening|two different suturing technique used for flap closure after esthetic crown lengthening
45834813|NCT02910648|Behavioral|Modified Go/No-Go Task|Participants in the experimental group and control sham sound cues group will complete a computerized training task to facilitate learning to respond (press a computer key) to healthy food stimuli and to inhibit responses (not press a computer key) to unhealthy food stimuli. Participants in the control sham go/no-go group will complete a similar task with common office supplies (approach) and tools (inhibit). All participants will also complete a 24 hour dietary recall as described below.
45997601|NCT00541515|Device|continuous glucose sensors and insulin pump|continuous glucose sensors and insulin pump
45997602|NCT04655729|Drug|Infliximab|Blood collection
45997603|NCT02937831|Biological|RIXUBIS|
45997604|NCT00541554|Drug|Abilify (aripiprazole)|
46085942|NCT00632255|Drug|Imatinib|Conventional therapy with imatinib
46085943|NCT03348878|Other|assessment of drug compliance|assessment of drug compliance using electronic monitoring devices (2 months duration)
46085944|NCT04072289|Device|Visumax spherocylindrical treatment|treatment of low cylinder (<0.75D)
45458733|NCT01144117|Drug|Erythropoietin|Erythropoietin 48000 IU given I.V. in 17 courses
45997605|NCT04655339|Drug|Bilateral abdominal Lap-TAP|A total of 30ml of anesthetic (0.25% Bupivacaine HCL), 0.25% Liposomal Bupivacaine (Exparel®) or control will be injected into the transversus abdominis plane bilaterally. A long spinal needle attached to a 30cc syringe with the TAP block solution or control will be used to inject the patient. The needle puncture will be halfway between the subcostal margin and anterior superior iliac spine at the midclavicular line. With laparoscopic guidance, needle will enter through the skin, external oblique and internal oblique. Once the needle is in place, injection of 30 ml on each side will be applied between the internal oblique and transversus abdominis muscle. The injection of bupivacaine into this abdominal wall induces an observable bulge, indicating accuracy of the procedure. These steps will be repeated on the contralateral side of the abdomen. All patients will receive 10 ml bupivacaine 0.25% pre-incision infiltration.
45997606|NCT04655105|Device|root canal rotary files|post operative pain evaluation using different rotary file system
45997607|NCT04655183|Drug|Niraparib|Niraparib will be administered orally, once daily.
45997608|NCT04655183|Drug|M4344|M4344 will be administered once daily or on an intermittent schedule in combination with niraparib.
45997609|NCT04655183|Drug|Niraparib|Niraparib will be administered orally once daily at the RDE as determined in Part 1 of this study.
45675355|NCT05886959|Other|Session 3: Unraveling the Knots of Desire and Patterns|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application"
45675356|NCT05886959|Other|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
45997610|NCT04655183|Drug|M4344|M4344 will be administered at a dose and schedule that was determined as RDE in Part 1A in combination with niraparib.
45997611|NCT04655183|Drug|Niraparib|Niraparib will be administered orally, once daily. Dose of niraparib will be escalated beyond the dose in Part 1A.
45675357|NCT05886959|Other|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
45834814|NCT02934282|Drug|HBOC-201|Hemoglobin Based Oxygen Carrier (HBOC)
45997612|NCT04655183|Drug|Niraparib|Niraparib will be administered as single agent at the approved dose.
45997613|NCT00541710|Dietary Supplement|genistein|pills of 27 mg, twice per day for 12 months
45997614|NCT00541710|Dietary Supplement|placebo|sugar pills twice per day for 12 months
45997615|NCT04654949|Other|Horticultural Therapy|The horticultural therapy sessions are conducted by the occupational therapists or therapy assistants using the mobile horticultural kits. The horticultural activities are designed to stimulate the senses through interaction with specific tasks and the environment, promote social interaction, mobility and also promote a sense of self-worth through various horticultural activities such as planting seeds, transplanting plants, trimming and watering plants.
45997616|NCT04654871|Dietary Supplement|Chondroitin Sulfate|Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
45458734|NCT03491878|Procedure|Three dimensional laparoscopic|Three dimensional laparoscopic cholecystectomy including segments IVB and V
45458735|NCT03491878|Procedure|Open|Open cholecystectomy including segments IVB and V
45834815|NCT01455480|Drug|RPh201, botanical drug product|topical
45834816|NCT03823950|Drug|Granulocyte Colony-Stimulating Factor|Begin G-CSF 72 hours following chemotherapy
45834817|NCT02914782|Other|Observational Study|
45997617|NCT04654871|Procedure|Resistance exercise training|"Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~Supervised exercise thrice a week and Home Exercise 4 times a week Leg press knee extension Knee flexion Terminal knee extension Mini squats 3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
45997618|NCT04654871|Procedure|Manual therapy / Joint Mobilization|Ant. tib-fem glide Post tib-fem glide thrice a week Pattelo-femoral joint mobilization
45997619|NCT04654871|Procedure|THE therapy|Interferential and Heating for 20 min
45997620|NCT00541749|Drug|rhuMAb IFNalpha|Intravenous repeating dose
45997621|NCT04654793|Device|Robot assisted inclined bed treatment and FES|FES was performed at the same time as the robot-assisted inclined bed treatment once a day for 30 minutes, 5 days a week for 4 weeks.
45834818|NCT01451190|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
45834819|NCT01451268|Drug|Panobinostat|10mg upto 40mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every week; duration: one year
45834820|NCT01451268|Drug|Panobinostat|Start of Arm B after completion of Arm A; initial dose-level: one level below MTD of Arm A; 10mg upto 60mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every other week; duration: one year
45997622|NCT04654793|Device|conventional inclined bed treatment|conventional inclined bed treatment for 30 minutes once a day for 4 weeks, 5 days a week
46085945|NCT05271578|Device|Standardized Electronic Research Cigarette|Standardized Research Electronic Cigarette Device, Standardized Research Electronic Cigarette Tobacco 5%, Standardized Research Electronic Cigarette Tobacco (placebo) 0% (NJOY, LLC, Tobacco Product Master File #STN MF0000274)
46085946|NCT05271578|Device|Nicotine Research Cigarette|Conventional Nicotine Tobacco Cigarette (National Institute of Drug Abuse, Drug Supply Program, Tobacco Product Master File #NRC600)
45997623|NCT04654520|Other|Drug therapy concurrent radiotherapy for primary tumor omitted CTV|Thoracic intensity modulated radiotherapy for primary tumor omitted CTV+Chemotherapy or Targeted drug therapy
45997624|NCT00541788|Other|Administration of Common Sage|Administration of Common Sage
45997625|NCT04654598|Other|BPA levels|BPA (bisphenol A) in urine, blood and follicle fluid samples
45997626|NCT02731716|Behavioral|New Payment Model|Providers will no longer be paid based upon FFS, but on the new payment model, which includes PMPM and quality incentives.
45997627|NCT02731716|Behavioral|Social Comparisons|Providers will receive weekly emails showing comparisons in quality metrics and total cost of care. They will be compared to other providers in their provider organization.
45997628|NCT02731716|Behavioral|A1c Member/Provider Incentive|Attributed members and their PCPs will receive up to $75 for a reduction of a1c by 0.5% per quarter (2 quarters).
45997629|NCT04654481|Device|HCFWO|The Afflovest device is a High Frequency Chest Wall Oscillation (HFCWO) device, a medical vest that uses vibrations to loosen and mobilize mucus in the lung secretions and help clear the airways.
45997630|NCT04654481|Other|Standard Care Plus Monitoring|Monitoring via home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments.
45997631|NCT04654676|Drug|Vildagliptin|Vildagliptin added on to stable doses of pre-mixed insulin with or without metformin
45997632|NCT04654637|Behavioral|Nutrition and Exercise Strategies|Multiple Interactive with Nutrition and Exercise Strategies
45997633|NCT00541905|Drug|NT 201|Subjects to receive up to 5 injection sessions, with a total dose of up to 300 Units each. No more than 50 units should have be given at any one injection site during one session.
45997634|NCT04654403|Drug|Camrelizumab|Eligible patients receive Camrelizumab 200 mg by intravenous (iv.) infusion every 2 weeks (Q2W) for 4 cycles.Imaging will be performed 2-3 weeks after the 4th Camrelizumab administration.Patients who achieve PD and SD will be not included in the data statistics of this trial.The follow-up treatment according to investigator's and patients's choice(chemotherapy, Camrelizumab plus chemotherapy or Camrelizumab monotherapy).Other patients whose BOR is in remission (CR+PR) will be randomly assigned in a 1:1 ratio to receive Camrelizumab (200 mg every 2 weeks), or Camrelizumab plus chemotherapy(Camrelizumab 200 mg every 3 weeks,docetaxel 75mg/m2/d plus cisplatin 75 mg/m2/d on day 1 every 3 weeks),)Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years).
46085947|NCT04203485|Biological|Camrelizumab 200mg|Camrelizumab 200mg q2w ivgtt
46085948|NCT04203485|Drug|Apatinib Mesylate 250mg|Apatinib Mesylate 250mg po qd
46085949|NCT04203485|Drug|Pemetrexed disodium for injection|Pemetrexed disodium for injection 500 mg/m2 q3w
46085950|NCT04203485|Drug|Paclitaxel injection|Paclitaxel injection 175 mg/m2 q3w
46085951|NCT04203485|Drug|Carboplatin|Carboplatin AUC 5 mg/mL/min q3w
46085952|NCT03851627|Drug|Testosterone Undecanoate|1000mg/4ml i.m. initial, after 6 weeks, every 10 weeks thereafter
46085953|NCT03851627|Drug|Placebo|Placebo Arm
46085954|NCT02742116|Genetic|DNA screening before Pregnancy|"Saliva/swab shall be collected from couple for Hereditary Disease DNA screening test. Blood sample shall be taken by venipuncture of women for Fragile X carrier screening A pre-test questionnaire will be conducted to assess subject's knowledge, views and preferences in receiving expanded carrier screening, choice of having concurrent or sequential screening, factors affecting their choices, anxiety level, and their willingness to pay for the test.~A post-test self-administered questionnaire shall be filled in by the patient on receiving the test results.~Couples who receive a screen positive result shall be subsequently referred to Queen Mary Hospital for joint counselling by clinical geneticist and gynaecologist. This consultation shall be audiotaped or videotaped."
46085955|NCT03116126|Drug|Guanfacine|2mg oral daily tablet
46085956|NCT03116126|Drug|Placebo|inactive oral daily tablet
46085957|NCT02983682|Drug|Lidocaine Infusion|Patients will receive lidocaine infusion of 42 micrograms/kg/minute over tow hours for a total of 5 mg/kg.
46085958|NCT00910247|Drug|Eslicarbazepine acetate|800 to 2400 mg once daily (QD)
46085959|NCT04217798|Drug|Niraparib|Subjects will receive niraparib combined with oral etoposide (on day 1-20, every 30 days). After 6-8 cycles, oral etoposide will be terminated. Niraparib will be still given to subjects until disease progression, intolerable toxicity or withdrawal of informed consent.
46085960|NCT02746640|Procedure|Cardiopulmonary resuscitation (CPR)|If there is a cardiopulmonary arrest, investigators observe the working processes of cardiopulmonary resuscitation.
46085961|NCT02742350|Device|IMT - POWERbreathe Plus Light Resistance®, SP, BR|POWERbreathe Plus Light Resistance®, SP, BR
46085962|NCT02742428|Device|Systematic ascites evacuation|Systematic ascites evacuation via indwelling catheter inserted into abdominal cavity, sutured to the skin. Drainage performed by the patient, on demand with day limit of 2000ml, in ambulatory settings.
46085963|NCT02742428|Procedure|Acute paracentesis.|Evacuation of a large (>5000ml) volume of ascites via single abdominocentesis. Allowed in observational arm only, in case of acute symptoms concerned with ascites.
45997635|NCT02626377|Behavioral|Support provided by social worker|Caregivers randomized in intervention arm will receive an information booklet (which informs about existing structures and actions) and will receive support provided by a social worker schedule every 6 months during two years. The support duration will be one hour and will be defined as two parts: administration of the LASA questionnaire, and a standardized semi directive interview to assess needs.
45997636|NCT02626377|Other|Information booklet receipt|Caregivers will only receive an information booklet (which informs about existing structures and actions)
45997637|NCT04654559|Other|Unobtrusive data collection using wearable non-invasive sensors|Two wearable non-invasive sensors will be mounted to the patients skin (lateral rib cage and foot). These wearable non-invasive sensors are measuring unobtrusively skin based parameters (no diagnosis will be made), which will be used for fever detection algorithm development..
45997638|NCT00541983|Drug|XOMA 052|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
45997639|NCT00541983|Drug|Placebo|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
45997640|NCT01205776|Device|Percutaneous Coronary Intervention|Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS
45997641|NCT01205776|Procedure|CABG|Those patients receiving CABG
45997642|NCT04654715|Procedure|Gracilis flap interposition for rectouretral fistula management|Gracilis flap interposition is a surgery for rectouretral fistula
45997643|NCT00542022|Drug|MK0812 / Duration of Treatment: 12 Weeks|
46085964|NCT02742428|Behavioral|Interview.|Interview according to provided chart in order to collect data concerning symptoms, co-morbidities.
45675358|NCT05886959|Other|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
45675359|NCT05886959|Other|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
45834821|NCT01451346|Dietary Supplement|B. Infantis 35624|One sachet daily for 12 weeks
46085965|NCT02742428|Behavioral|Quality of life.|Patients will be asked to fill in a quality of life questionnaire (EORTC-C15-PAL) before randomization and 7 days later.
46085966|NCT02742428|Behavioral|Nutritional status.|Patients will be asked to fill in (together with a physician) a questionnaire to assess risk of malnutrition (SGA) before randomization and 7 days later.
45834822|NCT03823638|Dietary Supplement|Oral D-Mannitol of Placebo|Gradually increased doses of oral D-Mannitol of Placebo (Dextrose monohydrate)
45997644|NCT00542022|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks|
45997645|NCT04654442|Diagnostic Test|TestNPass|Patients will undergo saliva sampling. Grenoble University Hospital lab will perform diagnosis using TestNPass IVDMD. Results won't be used for patient care (only recorded for RESEARCH purpose).
45997646|NCT00542061|Device|half-yearly monitoring routine|A written expert advice for GPs on additional diagnostic, treatment, and referral of patients with asthma and COPD based on half-yearly monitoring routines (lung function assessments including extensive anamnese) supported by half-yearly visits of an AC nurse consultant to the general practices.
45997647|NCT02546583|Drug|Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide)|An increase to 2.5x the Visit 1 dose of loop diuretic (bumetanide or furosemide).
45997648|NCT02546583|Drug|IV Chlorothiazide|
46085967|NCT04298957|Procedure|Cone biopsy|Cone biopsy if transformation Zone (TZ) 2 or TZ 3
46085968|NCT04401410|Biological|Dose Finding Phase (MTD)|Enrollment to the dose escalation phase will be staggered. The first patient enrolled on each of the 3 dose levels (DL1, DL2 and DL3) will have to complete the 14-day toxicity monitoring window prior to enrollment of the next patients. Prior to dose escalation, all patients at a particular dose level should have completed the minimum 14-day toxicity monitoring window before enrolling to a higher dose level.
46085969|NCT04401410|Biological|Partially HLA-matched SARS-CoVSTs|Infusion of SARS-CoVSTs at the MTD level as determined in the Dose Finding Phase
45834823|NCT01455558|Drug|Pletaal|"Part 1: a single dose of the SR (200mg x 1 tablet, QD) and IR (100mg x 2 tablets, BID) formulation of cilostazol orally 7 days apart in a fasted state~Part 2: a single dose of the SR (200mg x 1 tablet, QD) formulation of cilostazol 7 days apart in a fasted and a fed state~Part 3: multiple doses of the two formulations for eight consecutive days 21 days apart"
45997649|NCT01205581|Biological|Fluzone High Dose Vaccine|Two doses of Fluzone HD will be administered to children with leukemia, solid tumor, or HIV.
45997650|NCT01205581|Biological|Fluzone Standard Dose Vaccine|Two doses of Fluzone Standard Dose Vaccine will be administered to children with leukemia, solid tumor, or HIV.
45997651|NCT00557648|Behavioral|Group CBT for children|CBT for children consists of 9 weekly group CBT sessions. All sessions occur in the school building during after-school hours.
45997652|NCT00557648|Behavioral|Group CBT for children plus parent training|CBT involving children and parents consists of 9 weekly group CBT sessions for the children and 9 weekly concurrent group parent training sessions.
45997653|NCT00542100|Device|PCMRI|
45997654|NCT01205269|Drug|AZD8683, 50 mcg|Dry powder for inhalation, single dose
45997655|NCT01205269|Drug|Placebo|Dry powder for inhalation, single dose
45997656|NCT01205269|Drug|AZD8683, 200 mcg|Dry powder for inhalation, single dose
45997657|NCT04654286|Procedure|Nerve transfer procedure|"Identification of potential donor nerves: phrenic nerve, accessory nerve, intercostal nerve, motor branch nerve innervating long head of triceps muscle, motor branch of ulnar nerve innervating flexor carpi ulnaris (FCU) muscle, and motor branch of median nerve innervating flexor carpi radialis (FCR) muscle.~Donor nerve is checked for its viability with an electric stimulator during surgery~Viable donor nerve is dissected, transferred to the recipient area, and sutured with end-to-end anastomosis."
45997658|NCT04654286|Procedure|Nerve transfer with HAM-AdMSC composite wrapping|When the nerve transfer procedure is finished, the end-to-end anastomosis is wrapped by a composite consisted of human amniotic membrane and allogeneic adipose-derived mesenchymal stem cells (HAM-AdMSC)
46085970|NCT04401410|Other|Routine care (no SARS-CoVSTs)|Patients receive routine care for COVID19 per institutional standards (including antivirals such as remdesivir or other FDA-EUA approved products and thromboprophylaxis).
45997659|NCT02888431|Device|bedside point-of-care device|A bedside point-of-care device is routinely used in the operating room to measure lactate, base deficit, and pH.
46085971|NCT00659334|Drug|Ferumoxtran-10 (Combidex)|2.6 mg/kg
45997660|NCT00542139|Drug|Betamethasone|Intraarticular injection of 2ml Diprospan (wich contains 4mg Betamethasone sodium phosphate and 10mg Betamethasone dipropionate)
45997661|NCT00542139|Drug|Bupivocaine|Intraarticular injection of 10ml of Bupivocaine
45997662|NCT04653974|Behavioral|Needle-free injection|"This study was performed among children aged 4-11 years who required dental treatment and were treated at the Department of Pedodontics, Faculty of Dentistry, Gaziosmanpasa University. A total of 70 patients were evaluated in accordance with the exclusion criteria and 56 children (31 girls and 25 boys) were included in this study. Children who needed dental treatment were randomly divided into two groups. All dental injections were administered by the same operator (MB), a pediatric dentist with two years of experience in using the Comfort-In system.~In both groups, the children were asked to rate their pain intensity by choosing the closest statement on the Wong-Baker Pain Scale at three time points: immediately after injection (Pain 1), during treatment (Pain 2), and at the end of the treatment (Pain 3)."
45997663|NCT02499354|Drug|Ferumoxytol intravenous|IV iron, 2 vials of 510 mg given 2-7 days apart
45997664|NCT02499354|Drug|Ferrous sulfate|Oral iron, 325 mg tabs taken morning and evening
45997665|NCT00542217|Biological|Imprime PGG|
45997666|NCT04654247|Behavioral|Quality audit and feedback|Endoscopists received quality report generated by Endo.Adm.
45997667|NCT04654247|Behavioral|Control|None feedback.
45997668|NCT04654091|Procedure|Cryoteraphy with liquid nitrogen|"Weekly, at each visit, before applying the treatment, a debridement of the hyperkeratotic tissue covering the wart will be performed with a scalpel handle of number 3 and a scalpel blade of number 15, and then the treatment will be applied.~Subsequently, the application of cryotherapy with liquid nitrogen will be carried out using CryoPen b® (HO Equipment, Hhislenghien-Belgium). To analyze the homogeneous application in all the patients in the study, perform 2 applications of 15 seconds per session, with an interval of 30 seconds between each application, such and as manufacturers recommend. The number of sessions in which the product is applied will be a maximum of 5, following the procedure of previous studies."
46085972|NCT00659334|Procedure|Neurosurgery|neuro-surgical tumor biopsy or resection to assess particle localization. Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v. Combidex administration. Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared. The tissue will be obtained by either resection or needle frameless stereotactic biopsy.
45675360|NCT05886959|Other|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
45997669|NCT04654091|Procedure|Nitric-zinc complex|"Weekly, at each visit, before applying the treatment, a debridement of the hyperkeratotic tissue covering the wart will be performed with a scalpel handle of number 3 and a scalpel blade of number 15, and then the treatment will be applied.~Subsequently, the application of nitric acid-zinc complex with Verrutop® (Isdin, Barcelona-Spain) will be carried out. The preparation is applied by making small touches with the applicators included in the product.~The number of sessions in which the product is applied will be a maximum of 5, following the recommendations of the manufacturers in the product data sheet."
45457419|NCT04464382|Procedure|Hospitalization appendectomy (HA)|"Patients who are candidates for HA and therefore pre-selected based on the primary data and characteristics of the clinical signs, will be admitted to the surgical observation in charge of our service. The patient will be informed in detail of the intervention to be performed and discharge on an outpatient basis and will sign the informed consent understanding and thus accepting all the information. The patient will undergo surgery using a laparoscopic or open technique with minimal incision.~Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed. In this case, we will perform the blind randomization of the patients. If all the inclusion requirements for the study are met, and the patient belongs to the case group (HA), he will be admitted in hospital beds."
45675361|NCT05886946|Other|ABG|ABG
45675362|NCT05886933|Drug|Fexuprazan Hydrochloride|Patient treated with Fexuprazan Hydrochloride (Fexuclue Tablet)
45675363|NCT05886920|Drug|D3S-002|Oral
45675364|NCT05886894|Device|Lotrafilcon B multifocal soft contact lenses|Commercially available soft (hydrophilic) contact lenses indicated for the correction of presbyopia, with or without myopia or hyperopia
46085973|NCT02742038|Other|Fluoride varnish plus education|Biannual varnish every 6 month/ 24 months plus educational component
46085974|NCT02746562|Procedure|Freeze all|Freezing of all blastocyst stage embryos with thawing and transfer in a subsequent natural cycle
46085975|NCT02022098|Drug|Cisplatin|A total of three cycles of cisplatin will be administered in a 1-hour IV infusion on days 2, 23 and 44. Cisplatin will be administered 0.5 hours after Debio 1143.
46085976|NCT02022098|Radiation|Radiotherapy|Standard fraction radiotherapy to the primary tumour will be delivered daily for 5 days per week over 7 weeks.
46085977|NCT02022098|Drug|Debio 1143|Debio 1143 solution
46085978|NCT02022098|Drug|Placebo|Matching placebo solution
45675365|NCT05886894|Device|Comfilcon A multifocal soft contact lenses|Commercially available soft (hydrophilic) contact lenses indicated for the correction of refractive ametropia (myopia and hyperopia) and emmetropia with presbyopia
45997670|NCT04654169|Procedure|Ultrasound-guided IAI|Ultrasound-guided IAI was applied with a posterior glenohumeral joint in-plane injection technique.
45997671|NCT04654169|Procedure|Ultrasound-guided SSNB|Ultrasound-guided SSNB was carried out with a supraspinatus fossa level in-plane injection technique
45997672|NCT00542256|Device|Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 weekdays of up to 6 hours of training of the affected arm combined with application of tDCS over the primary motor cortex for 40 minutes.
45997673|NCT00542256|Device|Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 days of up to 6 hours of training in the affected arm and sham tDCS applied over the primary motor cortex for 40 minutes with active current applied for 30 seconds.
45997674|NCT02469129|Drug|[18F]FluorThanatrace|"For the Dosimetry Studies, 10 mCi of [18F]FTT will be injected intravenously, and participants will be placed in the following groups to be imaged with PET at the specified time points: 0 minute group--image at 0 and 120 min. after tracer injection; 30 minute group--image at 30 and 150 min. after tracer injection; 60 minute group--image at 60 and 180 min. after tracer injection; and 90 minute group--image at 90 and 210 min. after tracer injection.~For the Kinetic Studies, 10 mCi of [18F]FTT will be injected intravenously, and a 60-minute dynamic PET scan will be obtained starting at the time of injection."
45997675|NCT04653935|Behavioral|Self-management app with all intervention components|A behavioural self-management app, containing multiple cognitive- and behavioural self-management techniques for those living with Sjögren's syndrome. The intervention is comprised of several components and modules that holistically target several key symptoms: fatigue, sleep disturbances, chronic pain, and dryness. The app has been developed using user-centred methods, and is theory- and evidence-based.
45997676|NCT04653935|Behavioral|Self-management app with Information component only|self-management app for those with Sjögren's syndrome, includes Symptom and Lifestyle Information, only.
45997677|NCT00542295|Drug|alverine citrate and simeticone|
45997678|NCT00542295|Drug|placebo|
45997679|NCT03454841|Drug|Prasugrel|Patients with myocardial infarction will receive a 60 mg prasugrel loading dose, followed by a maintenance dose of 10 mg once daily
45997680|NCT03454841|Drug|Ticagrelor|Patients with myocardial infarction will receive a 180 mg ticagrelor loading dose, followed by a maintenance dose of 90 mg twice daily
45997681|NCT03454802|Diagnostic Test|Passive Leg Raising|See above
45997682|NCT03454763|Drug|PRRT every 5 weeks|PRRT (radiolabelled somatostatin analogues) every 5 weeks for 5 cycles
45997683|NCT03454763|Drug|PRRT every 8-10 weeks|PRRT (radiolabelled somatostatin analogues) every 8-10 weeks for 5 cycles
45997684|NCT02293980|Drug|MK-3795|Oral administration
45997685|NCT02293980|Drug|Nivolumab|IV infusion
45997686|NCT02293980|Drug|Cabozantinib|Oral administration
45997687|NCT04653506|Drug|Paracetamol 1000 mg|Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
45997688|NCT04653506|Drug|Ibuprofen 400 mg|Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
45997689|NCT00542412|Drug|Riluzole|
45997690|NCT04653701|Combination Product|Chemoembolization with preloaded microparticles 100 micron and reflux control microcatheter|We will perform chemoembolization technique in those patients (during 1 year) with indications for this treatment in relation with guidelines (early and intermediate hepatocellular carcinoma). Specific microcatheter and microparticles will be use (Mentioned above)
46085979|NCT04336826|Drug|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
46085980|NCT01639508|Drug|Cabozantinib|Patients will receive cabozantinib at an initial dose of 60 mg orally daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. Dose modifications for drug toxicity are permitted as per a prescribed algorithm. During the Treatment Period subjects will receive cabozantinib until either disease progression, the occurrence of unacceptable drug-related toxicity or for other reason(s) for subject withdrawal.
46085981|NCT02741882|Other|Questionary|Questionary with clinical, demographic and behavior outcomes at the pregnancy period
46085982|NCT02746484|Other|Ability platform program|The Ability program is an at home participant-tailored and technology-enhanced platform a) delivering tablet-based intensive (five days/a week for six weeks) motor and cognitive activities; b) monitoring from remote vital and physical health parameters (i.e., weight, Heart Rate, O2 saturation, daily steps, sleep activity).
46085983|NCT02746484|Other|Usual care program|Usual care at home program (paper and pencil cognitive activities; promotion of physical activity according to healthcare professional's advice)
45834824|NCT02884908|Drug|Pregabalin plus BBCET|Medication; BBCET = Brief Behavioral Compliance Enhancement Treatment
46085984|NCT02746250|Drug|Amitriptyline|The investigator recruits patients who have already discussed and agreed to the amitriptyline treatment with their physician. The patients start the treatment after the investigator have measured them once.
45457420|NCT02297464|Other|Eggs - 2 per day for breakfast|11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
45834825|NCT02884908|Other|Placebo plus BBCET|Placebo; BBCET = Brief Behavioral Compliance Enhancement Treatment
45834826|NCT01451580|Drug|Lipo-Dox|
45834827|NCT01451658|Drug|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
45834828|NCT01455792|Procedure|Biopsies using image fusion|MRI and soft image fusion guided biopsy
45834829|NCT01455792|Procedure|Gold standard biopsy|Gold standard TRUS biopsy
45834830|NCT01451892|Other|Dance Therapy|overweight individuals participating in a patient education program for obese people combined with specific dance-therapy
45834831|NCT01451892|Other|patient education|overweight individuals participating in a patient education program
45997691|NCT05081895|Device|Electrical Impedance tomography|Patients will be monitored with electrical impedance tomography during routine care with special attention to effects of neuromuscular blockade and postural changes.
45997692|NCT05081895|Other|Lung mechanics and gas exchange|Patient lung mechanics and gas exchange will be monitored during routine clinical care, with specific attention to postural changes and use of neuromuscular blockade.
45997693|NCT04653623|Procedure|High tibial osteotomy|Treatment option for medial compartment osteoarthritis of knee
45997694|NCT04653623|Drug|Tranexamic acid|Medication used to treat or prevent excessive blood loss from major trauma, postpartum bleeding, surgery, tooth removal, nosebleeds, and heavy menstruation
45997695|NCT00542529|Biological|Imprime PGG TM for Injection|Doses of 2.0 and 4.0 mg/kg intravenous Imprime PGG administered over 1-2 hr for up to 4 consecutive days
46085985|NCT02741960|Drug|metformin|500 mg metformin three times daily
46085986|NCT02741960|Drug|placebo|500 mg placebo three times daily
46085987|NCT00910091|Drug|BN83495|BN83495 will be administered as a 40 mg tablet once a day orally
46085988|NCT00910091|Drug|Megestrol Acetate (MA)|MA will be administered orally as 160mg daily
45997696|NCT04653740|Procedure|specimen sample collection|"Before and during treatment, and at progression, collection of :~Blood~Exhaled air~Saliva~Sweat~Tears~Urine"
46085989|NCT04216550|Drug|Apatinib|Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death
46085990|NCT02746328|Drug|GTx-024 9 or 18 mg|Patients enrolled in G200802 receiving GTx-024 9 or 18 mg
45997697|NCT02015832|Device|Coronary stent|
46085991|NCT01442792|Drug|UFH|Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds
46085992|NCT01442792|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10 mg single dose Rivaroxaban (per os)
46085993|NCT01442792|Drug|Rivaroxaban (Xarelto, BAY59-7939)|20 mg single dose Rivaroxaban (per os)
46085994|NCT01442792|Drug|Rivaroxaban (Xarelto, BAY59-7939) and UFH|10 mg single dose Rivaroxaban (per os) followed by bolus 50 IU/Kg unfractionated heparin (UFH)
46085995|NCT01315106|Device|Magnetic Resonance Image Scanner|Magnetic Resonance Imaging; 1.5 Tesla or 3 Tesla MRI scanner
46085996|NCT02741648|Device|Near Infrared Spectroscopy|INVOS 5100C Cerebral/Somatic Oximeter is an FDA-approved device used to measure renal and mesenteric tissue oxygenation, as defined by regional oxygenation saturation levels (rSO2). Two probe site monitoring will be used to evaluate differential tissue bed oxygenation. Adhesive sensor probes are applied to the periumbilical area for mesenteric monitoring and to the flank area for renal monitoring.
46085997|NCT00582530|Other|Whole Blood Draw|The plan is to obtain the research blood sample at the time of routine preoperative and postoperative blood testing, typically performed 1-2 weeks prior to surgery and then again 6 weeks to 12 months after surgery
46085998|NCT00909857|Drug|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one tablet SH T00658ID for 28 days per cycle in the respective treatment period; no tablet-free interval
46085999|NCT00909857|Drug|Ethinyl estradiol, Levonorgestrel (Miranova)|Daily oral administration of one tablet for 28 days per cycle in the respective treatment period; no tablet-free interval
45457421|NCT02297464|Other|1 packet of oatmeal per day|11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
45997698|NCT02015832|Radiation|Multi Slice Computed Tomography|A coronary non-invasive Multi Slice Computed Tomography will be performed in patients
46086000|NCT00909857|Drug|Placebo Match to SH T00658ID|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
46086001|NCT00909857|Drug|Placebo Match to SH D593B|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
46086002|NCT05629988|Device|IA with TheraSorb ® column|IA cycle is 5 days, repeat cycles will be given to responders at months 3 and 6
46086003|NCT02741726|Device|acupoint stimulation|Electric stimulation was given through electrode attached to acupoints
45457422|NCT01134523|Drug|Epirubicin, CTX, Paclitaxel|Epirubicin 90mg/m2 and CTX 600mg/m2 on day1 of each 21-day cycle, 4 cycles; followed by Paclitaxel 175mg/m2 on day1 of each 21-day cycle, 4 cycles.
45457423|NCT01134523|Drug|Epirubicin, Paclitaxel|Epirubicin 75mg/m2 on day1 and Paclitaxel 175mg/m2 on day2 of each 21-day cycle, 6 cycles.
45457424|NCT01349738|Drug|Antibiotic|Antibiotic (drug) sensitive to most recent culture for these subjects testing ASB positive and also experience Signs and symptoms of a UTI
45675366|NCT05886881|Device|Lotrafilcon B spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
45997699|NCT02015832|Device|instantaneous wave-free ratio|Pressure-derived, adenosine-free index on physiological assessment of stenosis severity
45997700|NCT02015832|Device|Fractional flow reserve|Pressure-derived index on physiological assessment of stenosis severity
45997701|NCT02015832|Device|Intravascular Ultrasound|Allows the application of ultrasound technology to see from inside blood vessels out through the surrounding blood column, visualizing the inner wall of blood vessels
45997702|NCT00542568|Biological|EPODURE (dermal Biopump for erythropoietin)|Subjects will undergo similar study procedures and evaluations; however each dosage group will receive a different targeted dose of EPO delivered via EPODURE Biopump
46086004|NCT02741726|Device|no stimulation|patients were only attached electrodes without electric current
46086005|NCT02741804|Dietary Supplement|BBH-1001 Brain Health Supplement|Treatment with supplement consisting of turmeric, fish oil, vitamin D and green tea extract OR placebo.
46086006|NCT02741804|Other|Lifestyle Intervention|All patients will be given lessons on 6 areas of lifestyle: nutrition, physical activity, meditation, sleep hygiene, cognitive activity, and social activity.
46086007|NCT02741804|Dietary Supplement|Brain Health Placebo|Treatment with placebo consisting of soybean oil
46086008|NCT05629130|Device|embolization with spherical microparticles embosphere|embolization of affected joints with spherical microparticles embosphere
46086009|NCT00911807|Drug|Cerebrolysin + donepezil|"Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg."
45997703|NCT04653779|Drug|Evogliptin 5mg/Metformin 1000mg|Size reduction of a tablet formulation
45997704|NCT00542607|Drug|levocetirizine dihydrochloride|
45997705|NCT00542646|Procedure|Endovascular Intervention|Peritoneal Lined Stent Endovascular Intervention
45997706|NCT04653428|Device|Interventional treatment of tricuspid regurgitation|Interventional treatment for tricuspid regurgitatin with CE-certified products, e.g. edge-to-edge repair
46086010|NCT00911807|Drug|Cerebrolysin + placebo|"Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Placebo for donepezil was given PO once daily during the whole study duration (28 weeks)."
45997707|NCT04685031|Drug|Nitroglycerin ointment|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
45997708|NCT04685031|Drug|Clobetasol Topical|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
45997709|NCT01972932|Dietary Supplement|Bio K+® 2 capsules orally (or via nasogastric tube)|Bio-K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
45997710|NCT01972932|Dietary Supplement|Placebo|Placebo Comparator: 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
45997711|NCT04653311|Device|Endomina®|Endoscopic sleeve gastroplasty (Endomina) at J0 with multidisciplinary follow-up for 1 year
45997712|NCT00542763|Drug|Mycophenolate sodium|Medical treatment is initiated with one tablet of 360 mg mycophenolate sodium orally per day for eligible patient. The dosage will be increased weekly by 360 mg up to a maximum stable dose of 1440mg daily. In patients not well tolerating the drug the dosage can be reduced to 720 mg per day.
45997713|NCT04653155|Behavioral|Cognitive behavioural therapy for insomnia|Cognitive behavioural therapy for insomnia
46086011|NCT00911807|Drug|Donepezil + placebo|"Placebo for Cerebrolysin was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg."
46086012|NCT02746016|Other|Infant Formula supplemented with Oligosaccharides|sole source nutrition
46086013|NCT04203251|Device|Caption Health Guidance Technology|
45997714|NCT01965249|Device|Long stitch|AWC with the long stitch technique using MonoMax USP 1, 150 cm loop, HR48 mm
46086014|NCT02746094|Device|8 bi-weekly LIESWT sessions|"LIESWT = Low-Intensity Extracorporeal Shock Wave Therapy~The treatment protocol consists of eight bi-weekly treatment sessions (weeks 0 ot 4). During each session 3600 shocks at 0.09 mJ/mm are applied. Shocks are applied to the penis shaft at the right corpus cavernosum and the left corpus cavernosum, and at the crura at the right crus and the left crus. 900 shocks are administered to each area. The treatment areas are the same for each session, so that at the end of the full treatment (8 sessions) each area will have received 7200 shocks at 0.09 mJ/mm.~In general, the patient is placed on an examination table. A series of focused shockwaves produced by the electromagnetic transducer are coupled to a patient's penile shaft and crura and are made to converge along the penis/crura volume. The operator controls treatment parameters including shockwave intensity and shockwave rate.~mJ = millijoule."
46086015|NCT03295565|Drug|Cabazitaxel|Cabazitaxel 25mg/m2 IV, once every 3 weeks
46086016|NCT03295565|Drug|Abiraterone|Abiraterone 1000mg oral, taken daily + Prednisone 5mg oral, 2 times a day
45997715|NCT01965249|Device|Short Stitch|Short stitch suture technique using MonoMax USP 2/0, 150 cm, HR26 mm
45997716|NCT00557804|Device|MUSE clinical system|non-invasive external monitoring device
45997717|NCT01854684|Drug|Temoporfin|Given IV
45997718|NCT01854684|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
45997719|NCT01854684|Drug|Photodynamic Therapy|Undergo intraoperative PDT
45997720|NCT01854684|Other|Laboratory Biomarker Analysis|Correlative studies
45997721|NCT01854684|Other|Pharmacological Study|Correlative studies
46086017|NCT03295565|Drug|Enzalutamide|Enzalutamide 160mg oral taken daily
46086018|NCT02751164|Other|Day/time of admission to the critical care unit|
45997722|NCT04653077|Other|stem cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
45997723|NCT01827579|Biological|CD25/71 allodepleted donor T-cells|CD25/71 allodepleted donor T-cells will be administered at a dose of 10^5 /kg at day 30 post-SCT, 3 x 10^5 /kg at day 60 and 10^6 /kg at day 90 post transplant
45997724|NCT01536522|Dietary Supplement|Nutritional approach for asthma|participants will be provided a medium chain triglyceride supplement or placebo
45997725|NCT01536522|Dietary Supplement|Low Caloric Shake|participants will be provided a low caloric dietary shake
46086019|NCT04127981|Diagnostic Test|18F-FDG PET + Dexa Scan|18F-FDG PET will be compared with Dexa Scan result within and between arms.
46086020|NCT04203095|Diagnostic Test|the level of plasma cfDNA CINs|The extracted cfDNA from PB will be analyzed by UCAD to determine the level of CINs.
46086021|NCT03934775|Device|Finapres Nova|Non-invasive mesurement of hemodynamic parameters and heart rate variability
45997726|NCT01536522|Biological|whole lung allergen challenge|inhalation of allergens by allergic patients with or without asthma, will be used to define mechanisms underlying the development of airway inflammation
45997727|NCT04653233|Device|3D Systems Touch Haptic Simulator|This simulator is computer-aided and allows us to see this application on the computer screen while practicing with a haptic arm. It gives real-like feedback in hand manipulations. The simulator has a choice of 45 minutes of full instruction, 5 minutes of haptic arm only, or the option.
45997728|NCT00542802|Drug|Levetiracetam|Levetiracetam tablets 250-500 mg. The drug dosage will be up-titrated from 250 mg bid in the first 2 weeks to 500 mg bid during the rest of the treatment period. The dosage can be incremented until 1500 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
45997729|NCT00542802|Drug|Carbamazepine|Carbamazepina tablets 200 mg. The drug dosage will be up-titrated from 100 mg die in the first 3 days to 100 mg bid during days 4 to 7, to 200 mg bid in the 2nd week, to 300 mg bid during the rest of the treatment period. The dosage can be incremented until 800 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
45997730|NCT04652648|Drug|Hydroxychloroquine|Randomization was 2:1 to HCQ 200 mg BID or 41 observation for 10 days
45997731|NCT00542841|Procedure|Hydrocortisone withdrawal|This is considered a non-standard treatment. On Day 1, participants will receive one 10-mg pill of hydrocortisone. On Day 3, participants will receive intravenously a medicine called cosyntropin, a synthetic form of a hormone that the body makes. Participants will receive one last pill of hydrocortisone prior to the end of the study.
45997732|NCT04652765|Drug|Camostat Mesilate|Camostat 600mg by mouth four times a day, for a total of 7 days
45997733|NCT04652765|Drug|Bicalutamide 150 mg|Bicalutamide 150mg by mouth once daily, for a total of 7 days
45997734|NCT00542958|Drug|NK012|9.0, 12.0, 16.0, 21.0, 28.0 mg/m^2, and to be determined. Intravenous infusion
45458736|NCT03756259|Behavioral|Mobile Health (mHealth) for Pneumonia|Audiovisual mobile based application will be used to counsel caregivers of children under five on pneumonia and its prevention. This will be coupled with text and voice message dissemination to the cell phones of caregivers and active pneumonia case finding by the LHWs which will be managed according to severity.
45675367|NCT05886881|Device|Lotrafilcon B spherical soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
45997735|NCT04652492|Drug|Tislelizumab in combination with cTACE|On-demanded cTACE in combined with tislelizumab (200mg q3w ivgtt on day 4 of each 21-day cycle)
45997736|NCT01185210|Dietary Supplement|Placebo|Subjects will receive placebo (mix of sugar and salt) 20 minutes before consuming fructose.
45997737|NCT01185210|Dietary Supplement|Alanine|Subjects will receive 12.5 grams of alanine 20 minutes before consuming fructose.
45997738|NCT01185210|Dietary Supplement|Alanine|Subjects will receive 25 grams of alanine 20 minutes before consuming fructose.
45997739|NCT04652336|Procedure|laparoscopic sleeve gastrectomy|Comparator arm - will receive standard laparoscopic sleeve gastrectomy
45997740|NCT04652336|Procedure|ligamentum teres cardiopexy with sleeve gastrectomy|experimental arm - Ligamentum teres will be divided from umbilicus to up to umbilical fissure. The ligament will then be wrapped around lower esophagus and sutured.
45997741|NCT00543036|Device|H-Coil deep TMS|
45997742|NCT04652297|Drug|HS-10356|Single dose of HS-10356
45997743|NCT04652297|Drug|Placebo|Single dose of Placebo
45997744|NCT04652297|Drug|HS-10356|Multiple doses of HS-10356
45997745|NCT04652297|Drug|Placebo|Multiple doses of Placebo
45997746|NCT04652024|Device|Anorectal manometry|, patients are instructed to isolate the anal sphincter and puborectalis muscles and improve its strength by using modified Kegel exercises in lying position with a probe in situ. Visual and verbal feedback techniques are used to reinforce the maneuvers, as they are being performed. The anal and rectal pressure changes displayed on the monitor provides visual feedback to the patient.
45997747|NCT00543075|Drug|Genasense (oblimersen, G3139)|3 mg/kg/day by intravenous infusion for up to 48 hours
45997748|NCT04651907|Other|acupuncture|use disposable sterile steel needles to insert to the acupuncture point
45997749|NCT04651907|Other|minimal acupuncture|The sham-controlled group will be performed with minimal acupuncture (superficial needling) at non-acupoints.
45997750|NCT00543114|Drug|Lenalidomide|Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period
45997751|NCT00543114|Drug|Fludarabine|Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days
45997752|NCT00543114|Drug|Rituximab|Given intravenously on Day 1 of each 28 day cycle
45997753|NCT03454724|Device|MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System|MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System used in the treatment of patients with coronary artery disease along with standard percutaneous angioplasty procedure.
45675368|NCT05886881|Device|Lotrafilcon B toric soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
45997754|NCT03454724|Device|Xience EES Everolimus Eluting Coronary Stent System|Xience EES Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
45997755|NCT00543153|Behavioral|Interview|Interview lasting approximately 30-45 minutes.
45997756|NCT04652258|Drug|Actemra|Dosage: 8mg/kg (max. 800mg) Actemra administered intravenously as an infusion over 60 min.
45997757|NCT01014546|Drug|Arsenic Trioxide|Given PO
45997758|NCT01014546|Dietary Supplement|Ascorbic Acid|Given PO
45997759|NCT01014546|Other|Laboratory Biomarker Analysis|Correlative studies
45997760|NCT01014546|Other|Pharmacological Study|Correlative studies
45997761|NCT04652141|Diagnostic Test|AsthmaTuner|AsthmaTuner consists of a treatment-adjusting algorithm that gives patient immediate feedback on the status of symptom control (i.e. controlled, partly controlled or uncontrolled) and a treatment recommendation with an image of the correct inhaler or other type of medication and the dose based on lung function (FEV1) and symptom scores (0-4 points).
45997762|NCT04651946|Diagnostic Test|DNA methylation testing|Methylation testing of host DNA, namely, OPCML, FODX3 and CDH13, in the peripheral serum
45997763|NCT00845442|Device|pacemaker|Placement of pacemaker over the chest wall to stimulate the larynx in the neck via a tunneled electrode
45997764|NCT04651829|Other|oral food challenge 1|First oral food challenge after a short period of several weeks of avoidance of CMP to confirm diagnosis of CMPA
45675369|NCT05886881|Device|Comfilcon A spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
45675370|NCT05886881|Device|Comfilcon A toric soft contact lenses|Commercially available silicone hydrogel contact lenses
45675371|NCT05886868|Drug|BL0020|"Dose Escalation Stage: BL0020 will be administered via intravenous infusion on days 1 and 8 of a 21-days treatment cycle for up to 6 dose levels using an accelerated titration method followed by a conventional 3 + 3 study design.~Dose Expansion Stage: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation Stage."
45675372|NCT05886842|Other|Test-retest|Test-retest
45675373|NCT05886829|Combination Product|Chlorpheniramine Maleate 0.4% Nasal Spray|Chlorpheniramine Maleate 0.4% Nasal Spray
45834832|NCT03539094|Other|Intermittent fasting|the subjects randomized to this group will do IF by restricting their diet and consuming few calories two days per week. During the days of fasting, subjects will be allowed to drink water, calorie-free beverages, and eat fresh, steamed or roasted non-starchy vegetables.
45834833|NCT02861898|Drug|Intra-arterial Cetuximab|
45834834|NCT02861898|Drug|Intra-arterial Mannitol|
45997765|NCT04651829|Other|oral food challenge 2|Second oral food challenge to test tolerance after 4 months of age if confirmed CMPA
45997766|NCT04651517|Device|XACT ACE Robotics study arm|Subjects will undergo lung procedures with the physician utilizing the XACT ACE Robotic System.
45997767|NCT00543231|Drug|G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide|
45675374|NCT05886829|Combination Product|Placebo|Placebo nasal spray
45997768|NCT00557843|Drug|Bupivacaine|Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
45997769|NCT00557843|Drug|Saline|Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
46086022|NCT04117451|Other|Propolis|Investigating the impact of propolis mouthwash on oral and cardiovascular health
46086023|NCT03690089|Drug|Atropine Sulfate|Atropine sulfate 0.01% eye drops which consist of 10mls of a clear colourless solution of atropine sulfate 0.01% w/v and benzalkonium chloride 0.01% w/v in sterile water.
45675375|NCT05886816|Drug|Mitoquinone/mitoquinol mesylate|Mitochondrial antioxidant
45675376|NCT05886816|Other|Placebo|Placebo pills
45675377|NCT05886803|Other|Spontaneous ventilation test|The purpose is to mimic ventilation conditions after extubation and thus to help the clinician predict the outcome of an extubation decision.
45834835|NCT04392258|Diagnostic Test|TSH determination|Determination of serum concentration of thyrotropin (TSH)
45834836|NCT04392258|Diagnostic Test|FT4 determination|Determination of serum free thyroxine (FT4) concentration
45997770|NCT04651478|Behavioral|Action Observation+Motor Imagery through BCI|Patients will undergo the treatment through the NeuRow platform. NeuRow is a gamified Brain-Computer Interface training paradigm in Virtual Reality (or neurogame) that allows patients to perform the same actions as they would do in real-life by imaging the movement. In NeuRow, patients will see a boat and two high fidelity virtual arms gripping two oars in the first-person view. Patients will have to imagine the movement of each corresponding hand to rotate each oar and progress, observing the movement imagined on screen. The goal of the task is to collect as many flags as possible in a fixed amount of time. In order to improve adherence, the number of flags collected will be recorded in each session. It will be able to adapt the boat speed, turn speed, and cut-off angle, to help patients not to deviate in excess from the target. The treatment itself will be performed for 20 minutes each session, divided into 4 series of 5 minutes to prevent fatigue.
45997771|NCT04651478|Behavioral|Action Observation through non-related with movement illustrations|The same configuration will be applied to simulate a BCI task, but playing a video about graphic illustrations, people's faces, and landscapes, never related to human movement. They will address interesting and changing topics to avoid patient's boredom. The control session will last 20 minutes, also divided into 4 series of 5 minutes and the therapist will give the instructions of observing and relax.
45997772|NCT00419328|Drug|NGR-hTNF|"Drug: NGR-hTNF~NGR-hTNF was administered every 3 weeks by a 1 hour intravenous iv infusion. NGR-hTNF in PBS was diluted in 0.9% NaCl, containing human serum albumin.~Step 1:~starting dose: 0.2 μg/m2~following doses: 0.4, 0.8 and 1.6 μg/m2.~number of patients: 4 per dose level~Step 2:~starting dose: 3.2 μg/m2~following doses: 6.4 and 12.8 μg/m2~number of patients: 3 per dose level~Step 3:~starting dose: 19.2 μg/m2~following doses: 28.8, 43.2 and 64.8 μg/m2~number of patients: 3 per dose level~Step 4:~starting dose: 86.2 μg/m2~following doses: 114.6 and 152.4 μg/m2~number of patients: 3 per dose level"
45997773|NCT04651751|Behavioral|Facilitating an Exercise Habit and Identity via the Multi-Process Action Control Model- A Randomized-Controlled Trial|Participants attended a workshop which consisted of a presentation and an exercise planning exercise.
45997774|NCT00543270|Device|Powerlink infrarenal bifurcated stent graft delivery system|Endovascular abdominal aortic aneurysm repair
45997775|NCT00543270|Procedure|Open Surgery|Open surgical abdominal aortic aneurysm repair
45675378|NCT05886790|Biological|Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation|Containing two adenovirus type 5-based vaccines delivering the spike proteins of SARS-CoV-2 wild type and Omicron BA.4/5 mutant, respectively
46086024|NCT03690089|Other|Placebo|Placebo eye drops which consist of 10mls of a clear colourless solution of benzalkonium chloride 0.01% w/v in sterile water.
45997776|NCT04651556|Drug|Magnesium Sulfate & bupivacaine|intraperitoneal instillation of a combination of Magnesium sulphate with bupivacaine
45997777|NCT04651556|Drug|paracetamol & ketorolac|parenteral analgesics
45997778|NCT02587767|Device|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle.
45997779|NCT02587767|Device|HD-PDT|5 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will been performed in HD-PDT arm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds.
45997780|NCT04651322|Device|upper robot Robot assisted upper arm training(RAT)|"The training group received an additional upper robot Robot assisted upper arm training(RAT) with Armeopower® 5 times per week for 4weeks.~*Robot Assisted Arm training + Conventional occupational therapy"
45997781|NCT04651322|Behavioral|Conventional therapy|The control group received the usual conventional therapy *Only Conventional occupational therapy
45997782|NCT03456765|Diagnostic Test|Ultrasound|US will be made to assess kidneys
45997783|NCT04651049|Drug|propranolol|This retrospective study included 128 patients treated with oral propranolol at a dose of 2.0 mg/kg per day.
46086025|NCT03812588|Drug|Escitalopram|Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI) medication that appears to help with symptoms of depression by increasing the availability of specific chemicals in the brain.
46086026|NCT03812588|Drug|Placebo|A placebo (or dummy pill) is an inert (inactive) substance, typically a tablet, capsule or other dose form that does not contain an active drug ingredient.
45675379|NCT05886790|Biological|Bivalent COVID-19 mRNA Vaccine|Containing two mRNA-based vaccines delivering the spike proteins of SARS-CoV-2 Beta and Omicron BA.4/5 mutant, respectively
45675380|NCT05886790|Biological|Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation|Containing adenovirus type 5-based vaccine delivering the spike proteins of SARS-CoV-2 wild type
45675381|NCT05886764|Other|Digital Intervention|Digital messages (email, text, etc.) which include general educational information about clinical trials and available resources.
46086027|NCT04295525|Dietary Supplement|400 mg mucoadhesive oral tablet|AqualiefTM (Metis Healthcare s.r.l., Milano, Italy)
45675382|NCT05886764|Other|Community Outreach|Invitation to contact a Community Ambassador for further information and support in the decision to participate in a clinical trial.
45675383|NCT05886751|Other|Black Doctor Screening Video|Participants will view an online video with a Black doctor speaking about prostate cancer screening.
45997784|NCT04651049|Device||
45834837|NCT04392258|Diagnostic Test|FT3 determination|Determination of serum free triiodothyronine (FT3) concentration
45834838|NCT04392258|Diagnostic Test|SPINA-GT|Calculation of thyroid's secretory capacity (SPINA-GT)
45834839|NCT04392258|Diagnostic Test|SPINA-GD|Calculation of total deiodinase activity (SPINA-GD)
45834840|NCT01455948|Device|Relieva Balloon Sinuplasty™ System|Catheter-based devices used to dilate blocked paranasal sinus ostia (openings).
45997785|NCT02497443|Biological|Autologous mesenchymal stem cells|Autologous bone marrow-derived mesenchymal stem cells, expanded ex vivo and neuroinduced (a portion of the cells). The final autologous cultured MSCs (0.7 -1.4 x 106 cells/kg of weigh) and autologous neuroinduced MSCs (0.04 - 0.1 x 106 cells/kg of weigh) were used for intravenous administration (cultured MSCs) and a subsequent endolumbal injection (neuroinduced MSCs) one week later in the patients in an autologous manner.
45997786|NCT04651205|Dietary Supplement|vitamin B1 and magnesium supplements|vitamin B1 - 100 mg/day magnesium - 400 mg/day
45997787|NCT03456648|Drug|apixaban|non-vitamin K oral anticoagulant (NOAC)
46086028|NCT04295525|Dietary Supplement|placebo mucoadhesive oral tablet|placebo
45457425|NCT03515434|Procedure|ESP Block|ESP block will be performed at the finishing of surgery under spinal anesthesia. A convex ultrasound transducer will be placed in a longitudinal parasagittal orientation 2-3 cm lateral to T10 spinous process. The erector spinae muscles will be identified superficial to the tip of T10 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of bupivacaine/lidocaine mixture will be injected.
45675384|NCT05886751|Other|White Doctor Screening Video|Participants will view an online video with a White doctor speaking about prostate cancer screening.
45675385|NCT05886751|Other|Black Patient Screening Video|Participants will view an online video with a Black patient speaking about prostate cancer screening.
45834841|NCT01455948|Procedure|Functional Endoscopic Sinus Surgery|Specialized probes are used to cannulate closed ostia (openings), and small forceps are used to resect periostial bone and tissue to enlarge the sinus ostia.
45997788|NCT04651283|Other|Traditional seat group|"Each child in the control group was asked to conduct or follow instructions given for him or her to conduct the following hand function tasks for three successive months of treatment, three times per week (every other day):~Building towers and shapes with different textures weights and bright colors.~Inserting different shapes in the correct hole.~Dropping pellets.~Stringing beads.~Copying square and triangle.~Opening the bottle and close it.~Folding and Crumpling paper.~Cutting paper by scissors.~Tracing line and connecting dots.~Reaching above the level of shoulder.~Reaching across the midline.~Squeezing water out of a sponge.~Buttoning and unbuttoning button.~Playing clapping games.~Turning pages in a book.~Lacing string.~Picking up a small piece of food and bringing it into the palm.~Moving a penny from the palm to the fingers.~Removing socks.~Brush the teeth."
46086029|NCT04341701|Procedure|MRI|The procedure to study lung and heart MRI, performed on a 1.5T magnet (Siemens), without any injection or inhalation of contrast agent
46086030|NCT02750852|Procedure|Total hip arthroplasty, blood loss analysis|Data analysis about blood loss in total hip replacement
45675386|NCT05886751|Other|White Patient Screening Video|Participants will view an online video with a White patient speaking about prostate cancer screening.
45675387|NCT05886751|Other|Black Doctor Clinical Trials Video|Participants will view an online video with a Black doctor speaking about prostate cancer clinical trials.
45675388|NCT05886751|Other|White Doctor Clinical Trials Video|Participants will view an online video with a White doctor speaking about prostate cancer clinical trials.
45675389|NCT05886751|Other|Black Patient Clinical Trials Video|Participants will view an online video with a Black patient speaking about prostate cancer clinical trials.
45675390|NCT05886751|Other|White Patient Clinical Trials Video|Participants will view an online video with a White patient speaking about prostate cancer clinical trials.
45997789|NCT04651283|Other|Adaptive seating equipment group|"Each child in the study group was asked to conduct or follow instructions given for him or her to conduct the following hand function tasks for three successive months of treatment, three times per week (every other day):~Building towers and shapes with different textures weights and bright colors.~Inserting different shapes in the correct hole.~Dropping pellets.~Stringing beads.~Copying square and triangle.~Opening the bottle and close it.~Folding and Crumpling paper.~Cutting paper by scissors.~Tracing line and connecting dots.~Reaching above the level of shoulder.~Reaching across the midline.~Squeezing water out of a sponge.~Buttoning and unbuttoning button.~Playing clapping games.~Turning pages in a book.~Lacing string.~Picking up a small piece of food and bringing it into the palm.~Moving a penny from the palm to the fingers.~Removing socks.~Brush the teeth."
45997790|NCT02428491|Biological|Hexaxim®|DTaP-IPV-Hep B-PRP-T combined vaccine, 0.5 mL, Intramuscular
45997791|NCT00557921|Drug|CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin|(CGT-2168 active and Comparator placebo, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
45997792|NCT00557921|Drug|Plavix (clopidogrel 75 mg) and aspirin|(CGT-2168 placebo and Comparator active, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
45997793|NCT03456609|Drug|shenqifuzheng injection|500ml shenqifuzheng daily（at day 1-14 and day22-36）through intravenous infusion.
45997794|NCT03456609|Drug|Sodium Chloride Injection 0.9%|500ml sodium chloride（0.9%）daily（at day 1-14 and day22-36）through intravenous infusion.
45997795|NCT02352558|Drug|BBI608|Patients will receive BBI608 orally twice daily, with doses separated by approximately 12 hours. The starting dose for all cohorts will be 240 mg twice daily. Subsequently, cohorts at alternate dose-levels (480 mg twice daily) may be enrolled as determined by the criteria for dose-escalation.
45997796|NCT02352558|Drug|Dexamethasone|Dexamethasone will be taken orally at a dose level of 40 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Patients over the age of 75 years are allowed to begin dexamethasone at a dose of 20 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Dexamethasone should be taken with food or milk, and a minimum of 2 hours should separate a dose of dexamethasone from a dose of BBI608.
45997797|NCT02352558|Drug|Bortezomib|Bortezomib will be administered at 1.3 mg/m2/dose as a 3-5 second bolus intravenous (IV) injection or subcutaneous injection twice weekly for 2 weeks (Day 1, 4, 8, and 11) followed by a 10-day rest period (Day 12-21).
45997798|NCT02352558|Drug|Imatinib|Imatinib will be taken orally once daily with a meal and a large glass of water. For patients having difficulty swallowing, imatinib can be dissolved in water or apple juice for intake. The dose of imatinib is 400 mg for CML patients in the chronic phase and 600 mg for CML patients in the accelerated phase or in blast crisis. A minimum of 2 hours should separate a dose of imatinib from a dose of BBI608.
45997799|NCT02352558|Drug|Ibrutinib|Ibrutinib will be taken orally once daily with water. Do not open, break, or chew the capsules. The dose of ibrutinib is 420 mg for patients with normal liver function and is 140 mg for patients with mild liver impairment (Child-Pugh class A). A minimum of 2 hours should separate a dose of ibrutinib from a dose of BBI608.
45997800|NCT02346162|Behavioral|Weight management|Phone counseling for pre-pregnancy weight loss and weight maintenance when BMI </=25, and when pregnant, weight gain within IOM guidelines.
45997801|NCT02346162|Other|Usual Care Control|Usual care control participants receive general dietary advice as it relates to planning for a healthy pregnancy (e.g. folate requirements, prenatal vitamins, smoking cessation, alcohol cessation, and prenatal food safety).
45997802|NCT02324283|Drug|desflurane|"Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia.~Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia."
45997803|NCT02324283|Drug|propofol|Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.
45997804|NCT00557960|Drug|Mixed salts of a single-entity amphetamine|
45997805|NCT00557960|Drug|Atomoxetine hydrochloride|
45997806|NCT00543426|Drug|Fuzheng Huayu Tablets|Tablet,three times a day,four tablets one time
45834842|NCT02851056|Biological|Survivin Vaccine|"Pre-transplant vaccination : The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, Human Leukocyte Antigen - antigen D Related (HLA-DR)+ by flow-cytometry) is 15 x 10^6 cells. A minimum of 1 x 10^6 cells and a maximum of 20 x 10^6 cells will be administered.~Post-transplant vaccination: The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, HLA-DR+ by flow-cytometry) is 15 x 10^6 cells. A minimum of 1 x 10^6 cells and a maximum of 20 x 10^6 cells will be administered."
45997807|NCT00543426|Drug|sham Fuzheng Huayu Tablets (placebo)|Tablet, three times a day, four tablets one time
45997808|NCT02311998|Drug|Bosutinib|Given PO
45997809|NCT02311998|Biological|Inotuzumab Ozogamicin|Given IV
45997810|NCT02311998|Other|Laboratory Biomarker Analysis|Correlative studies
45997811|NCT00543465|Drug|MK0782|
45997812|NCT00557999|Other|Application of mechanical ventilation weaning protocol|Application protocol for 8 months in experimental group
45997813|NCT02232633|Drug|BBI503|
45997814|NCT00558077|Drug|Metformin plus clomiphene citrate|Metformin administration will start from 3rd day of a P-induced withdrawal bleeding with a dose of 850 mg (1 tablet daily) and increasing the dosage after one week up to 1700 mg/day (two tablets daily). Clomiphene citrate CC will be administered for five days beginning on cycle day 3rd of a P-induced withdrawal bleeding using a starting dose of 50 mg daily. If ovulation will not occur, the dose will be increased by 50 mg in successive cycles until the ovulation will be achieved or up to a maximal dose of 150 mg daily.
45997815|NCT00558077|Procedure|Laparoscopic ovarian drilling|Laparoscopic ovarian drilling will be performed as follows: according to ovary size three to six punctures will be performed at each ovary inserting an insulated needle cautery of 36 mm perpendicularly as possible to the ovarian surface with a cutting current of 100 watt power. Then, the needle will be activated for 2-3 seconds at each point using a coagulating current of 40 watt power. At completion of the procedure, the ovarian surface will be washed with a crystalloid solution and all injured areas will be completely covered with hyaluronic acid gel.
45834843|NCT02851056|Procedure|Autologous Hematopoietic Cell Transplantation|The participant's own cells are collected from their blood, frozen, and then given back to them after they receive chemotherapy.
45675391|NCT05886738|Other|Fasting|Obese and lean groups will fast for 48 hours, followed by a 3-hour refeeding period.
46086031|NCT03571958|Behavioral|BMI|A derivative of motivational interviewing (MI), which is a patient-centered, collaborative counseling approach to strengthen an individual's intrinsic motivation towards a positive behavior change. BMI is intended for healthcare providers with limited time (5-10 minutes) to support a positive behavior change.
46086032|NCT02387099|Drug|3 weeks Dose Induction of Everolimus|"Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio"
46086033|NCT02387099|Drug|3 weeks Conventional Everolimus Dosing|"Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio"
46086034|NCT02387099|Drug|Open Label Phase with conventional 10mg Everolimus Dosing week 4-24|All patients will receive open label Everolimus with Exemestane for 21 weeks according to label
46086035|NCT02387099|Drug|Standard Care after 24 weeks|It is up to the discretion of the investigator to continue with Everolimus+Exemestane beyond 24 weeks
46086036|NCT03568448|Other|Response monitoring (no intervention)|Response monitoring (no intervention)
46086037|NCT04229147|Radiation|Radiotherapy|Patients who received a total dose of 30 Gy
46086038|NCT02746172|Device|Cochlear implant with in-situ audiometry|
45997816|NCT00558116|Device|Dynamic splinting|The Dynasplint carpal tunnel device will be worn for 30 minutes, twice daily, for 60 consecutive days.
45997817|NCT05077254|Biological|Pfizer-BioNTech Bivalent COVID-19 Vaccine|Administration: One dose administered intramuscularly.
45997818|NCT05077254|Biological|Moderna Bivalent COVID-19 Vaccine|Administration: One dose administered intramuscularly.
45997819|NCT05077254|Drug|SOC IS Regimen|Participants will continue to take their prescribed immunosuppression (IS) medications without alterations in schedule and dosing, per protocol instruction.
46086039|NCT04116983|Device|Deep Ensemble for the Recognition of Malignancy (DERM)|An AI-based diagnosis support tool
46086040|NCT02745704|Drug|Peginterferon alfa|peginterferon alfa-2b 80 micrograms/week or peginterferon alfa-2a 180 micrograms/week
46086041|NCT02745860|Drug|Selexipag (adult formulation)|One selexipag film-coated tablet of 200 µg
45675392|NCT05886725|Other|Patients using Step Test Application and Accelerometer|Patients who are scheduled to have surgery at University of Chicago Medical Center (UCMC) who agree to use the step test application and study accelerometer before and after their surgery.
46086042|NCT02745860|Drug|Selexipag (pediatric formulation)|Four selexipag film-coated tablets of 50 µg
46086043|NCT03078023|Device|swallowed sponge device|Swallowed sponge: Subjects having a clinical upper endoscopy will be asked to swallow the sponge 2 hours prior to EGD
46086044|NCT04370444|Device|Phallus Length Reducer|Phallus Length Reducer
45675393|NCT05886699|Other|PRP combined with DFDBA|Periodontal intrabony defects were treated with open flap debridement followed by placement of PRP combined with DFDBA
45675394|NCT05886699|Other|DFDBA|Periodontal intrabony defects were treated with open flap debridement followed by placement of PRP combined with DFDBA
45675395|NCT05886660|Drug|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel.
45675396|NCT05886660|Drug|Placebo Nasal Gel|Subjects will self-administer Placebo Nasal Gel.
45675397|NCT05886660|Drug|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel. Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject.
45675398|NCT05886660|Drug|Placebo Nasal Gel|"Subjects will self-administer Placebo Nasal Gel.~Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject."
45675399|NCT05886647|Other|Active non-invasive stimulation and inspiratory muscle training|Simultaneously with the current application, the patient will perform inspiratory muscle training (IMT) by KH2; PowerBreathe International Ltd. UK along with a feedback Breathelink, consisting of three series of two minutes of maximum and deep inspirations followed by two minutes of rest between them, totaling six minutes of TMI.
46086045|NCT04370444|Other|Self-assessment of dyspareunia|Use of a vaginal insert to self assess dyspareunia
46086046|NCT04788641|Drug|Tacrolimus|Each subject in this cohort will receive a single dose of oral capsules of tacrolimus on 2 occasions, once alone and once in combination with oral suspension of SZC. Drug administrations will occur after a 12 hour overnight fast.
46086047|NCT04788641|Drug|Cyclosporin|Each subject will receive a single dose of oral capsules of cyclosporin on 2 occasions, once alone and once in combination with oral suspension of SZC. Drug administrations will occur after a 12 hour overnight fast.
46086048|NCT04788641|Drug|Sodium Zirconium Cyclosilicate|Each subject will receive single oral doses of SZC with tacrolimus (cohort 1) or cyclosporin (cohort 2) under fasted conditions. The doses will be administered after an overnight fast of at least 12 hours.
46086049|NCT05629754|Diagnostic Test|MRI, radiological assessment|MRI and radiological assessment of the involved knee
46086050|NCT02736734|Drug|CRH|CRH injection: 100 µg CRH powder for injection (CRH Ferring) dissolved in 1ml NaCl 0.9%, administration intravenously over the course of 1 minute to avoid side effects.
45997820|NCT05077254|Drug|SOC IS Reduction|Participants will reduce their standard of care immunosuppression medications (IS) before and after the COVID-19 vaccine booster (1 dose), per protocol instruction.
45997821|NCT04650971|Biological|UniFluVec|Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks
45997822|NCT04650971|Biological|Placebo|Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks
45997823|NCT00543504|Drug|Bevacizumab|2.5 mg/kg By Vein Over 90 Minutes.
45997824|NCT00543504|Drug|Sorafenib|200 mg By Mouth Daily for 28 Days
45457426|NCT03515434|Procedure|TAP Block|TAP block will be performed at the finishing of surgery under spinal anesthesia. A linear ultrasound transducer will be placed to lateral aspect of abdomen. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane between transversus abdominis and internal oblique muscles..A total of 30 mL of bupivacaine/lidocaine mixture will be injected.
45997825|NCT00543504|Drug|Erlotinib|50 mg By Mouth Daily for 28 Days.
45997826|NCT00543504|Drug|Trastuzumab|Loading 2 mg/kg by vein then Maintenance 1 mg/kg by vein on Day 1
45997827|NCT00543504|Drug|Lapatinib|250 mg By Mouth Daily for 21 Days.
45997828|NCT00543504|Drug|Sunitinib|12.5 mg orally daily for 4 weeks, then 2 weeks off.
45997829|NCT00543504|Drug|Cetuximab|Loading 100 mg/m² by vein and Maintenance 75 mg/m² by vein on Days 1, 8, 15, 22
45997830|NCT04651127|Drug|Toripalimab + Chidamide|In combination dose finding phase, phase 1b will begin with Dose Level 1: chidamide 30 mg/day orally (twice a week) and toripalimab (240mg q3w, intravenously) will be administered to eligible subjects on a 21-day treatment cycle. Two dose de-escalation steps are included: Dose Level 2 (chidamide 25 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously) and Dose Level 3 (chidamide 20 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously). If RP2D was reached in Part A, eligible patients would be enrolled and receive toripalimab (240mg q3w, intravenously) plus chidamide (RP2D, twice a week).
46086051|NCT02736812|Biological|French Lyophilized Plasma|"During the pre-hospital phase, the main events related to this arm are~Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)~Usual pre-hospital care according to recommendations in best practices~Administration of FLYP"
46086052|NCT02736812|Biological|Normale Saline Solution|"During the pre-hospital phase, the main events related to this arm are~Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)~Usual pre-hospital care according to recommendations in best practices~Administration of Normale Saline Solution"
45997831|NCT04650776|Other|Heat strain|The experimental procedure comprised 15 min baseline seated rest (23.2 ± 0.3°C, 24.5 ± 1.6% relative humidity), followed by 15 min seated rest and cycling in a climatic chamber (35.4 ± 0.2◦C, 56.5 ± 3.9% relative humidity; to +1.5◦C or maximally 38.5°C rectal temperature, duration 20-60 min), with a final 30 min seated rest outside the chamber.
45997832|NCT00543621|Other|daily enteral nutritional product and/or behavioral changes|
45997833|NCT00543660|Procedure|Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)|
45997834|NCT04650737|Drug|single shot ESBP with dexmedtomidine|Patients in this group will receive errector spine plane block with 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine
45997835|NCT04650737|Drug|continous ESPB|Patients in this group will receive erector spine plane block with 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs.
45675400|NCT05886647|Other|Sham compatorator and inspiratory muscle training|As for the patients allocated in the control group, they will receive the HD-tDCS sham for 20 minutes associated with IMT, following for the same training, duration and load increment used in the experimental group.
45675401|NCT05886634|Drug|Etrumadenant|Will be administered PO daily for 24 weeks
45675402|NCT05886634|Drug|Zimberelimab|Will be administered IV every 2 weeks for 24 weeks
45997836|NCT00543738|Drug|MK0767|
45997837|NCT04650503|Other|No intervention|No intervention
45997838|NCT00543816|Drug|MK0767|
45997839|NCT04650620|Device|Plenhyage® thin|0.75%
45997840|NCT04650620|Device|Plenhyage® medium|2%
45997841|NCT04650620|Device|Plenhyage® strong|2.5%
46086053|NCT04331288|Drug|PT150|Intervention 1 includes PT150 with alcohol consumption
46086054|NCT04331288|Other|Beverage|The alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in juice or another flavored beverage. Participants will be allowed 30 minutes to consume the beverages.
46086055|NCT02745782|Other|Observational Study|Observational Study
46086056|NCT04364126|Device|Home blood pressure apparatus|Target <125/80 mmHg
45834844|NCT02851056|Biological|Prevnar 13|13-Valent Pneumococcal Conjugate Vaccine (PCV13, Prevnar13). Co-Immunization: All participants will be co-immunized with Prevnar at each time they receive the survivin vaccine. This vaccine will be administered intramuscular (IM) 0.5cc.
45997842|NCT04650386|Behavioral|Psychosocial support determined by adaptive treatment algorithm|Participants assigned to the adaptive intervention condition will be scheduled for buprenorphine medication management appointments according to the clinic protocol described above for TAU. The adjunctive psychosocial treatment that participants in this condition receive are (1) CBT delivered by behavioral health specialists and/or (2) peer support delivered by certified recovery specialist. The active intervention period will span 3 months post-study entry. Participants will continue to receive TAU following the active intervention period.
45457427|NCT03515434|Other|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded and followed by 0., 1.-3.-6.-12.-18.-24.hours. it is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
45997843|NCT00665769|Other|Hypercapnia|transcutaenous CO2 50-60 mm Hg
45997844|NCT00665769|Other|Normocapnia|transcutaneous CO2 35-45 mm Hg
45997845|NCT04650308|Diagnostic Test|Neuropeptide Y examination|This examination was conducted by drawing blood serum from research subjects and performing centrifugation with 2000-3000 revolutions per minute (RPM) for 20 minutes. Furthermore, we carried out blood serum tests to check neuropeptide Y levels using the Human Neuropeptide Y Enzyme-link Immunosorbent Assay (ELISA) kit
45457428|NCT05401747|Other|Healthy lifestyle|Nutrition consultation and teaching: A registered dietitian has the responsibility of teaching and explaining the diet. Plan: One meeting per 12 weeks. The exercise program is based on the Physical Activity Guidelines Advisory Committee and American Heart Association guideline and a modified version of Dose-Responses to Exercise Training study protocol for older adults summarized our weekly plans in detail. Plan: 2 meetings per week. Cognitive enhancement: Participants can select any of the following activities:methods requiring mental activities, physical activity, and social activity, enjoying music and our weekly dance classes (Waltz).
46086057|NCT04364126|Other|Clinic blood pressure|Target <130/80 mmHg
46086058|NCT02745470|Drug|Lixisenatide|Colorless, transparent liquid contained in a glass prefilled syringe pen-like injection (GLP-1 receptor agonist)
45997846|NCT00543933|Drug|iNO administered|iNO at 40 ppm through a non-rebreather mask for 5 minutes
46086059|NCT02745470|Other|Placebo|Normal saline injection before performing fMRI
46086060|NCT02745236|Other|Nurse Practitioner Led-Care|Diagnosis and treatment plan decisions will be determined by Nurse Practitioner Led-Care.
45834845|NCT02851056|Drug|Granulocyte-colony Stimulating Factor|After the first survivin vaccination, participants will be mobilized with G-CSF.
46086061|NCT02745236|Other|Cardiologist Led-Care|Diagnosis and treatment plan decisions will be determined as per usual care by the Cardiologist
46086062|NCT02741414|Device|The result of H pylori culture based on gram staining and enzyme activity testing|This intervention aimed at patients with the positive result of 13C-urea breath test. Patients with negative result of H pylori culture was H pylori culture negative group. Patients with positive result of H pylori culture were belonged into the first successful eradication group and the refractory infection of H. pylori group.
46086063|NCT02741414|Device|The result of 13C-urea breath test after treatment based on the selection of clarithromycin, levofloxacin, metronidazole, amoxicillin，tetracycline，furazolidone and the dose of esomeprazole|The intervention focused on the results from the result of 13C-urea breath test after treatment. The first successful eradication group and the refractory infection of H. pylori group were treated according to the antibiotic susceptibility testing and CYP2C19 gene polymorphism. Eight weeks after treatment, a 13C-urea breath test was performed on patients. The first successful eradication group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients with positive in 13C-urea breath tests after the second standardized treatment.
46086064|NCT02741414|Device|The result of Amoxicillin resistance in vitro based on antibiotic susceptibility testing|The intervention focused on the results from the result of Amoxicillin susceptibility testing in vitro. In this study, the investigators selected the patients with Amoxicillin resistance from the first successful eradication group and the refractory infection of H. pylori group.
45457429|NCT01358162|Other|Placebo|Placebo given orally, daily for 14 consecutive days
45457430|NCT01358162|Drug|SQ109|A single oral dose of 300 mg of SQ109 given daily for 14 consecutive days.
45457431|NCT02302768|Dietary Supplement|Selenomethionine|
45457432|NCT02302768|Other|Placebo|
45457433|NCT03921775|Drug|Remimazolam Tosilate|For induction and maintenance of general anesthesia
45457434|NCT03921775|Drug|Propofol|For induction and maintenance of general anesthesia
45834846|NCT02937948|Other|Adaptative treatment plan|"Each patient will have 3 scanners before treatment initiation. One corresponding to an empty bladder, one to an intermediate one, one to a full bladder."
45834847|NCT02937948|Radiation|External radiotherapy|At the time of each fraction of external radiotherapy, the most appropriate plan (empty, intermediate, full bladder) covering the target and sparing the organs at risk is chosen.
45997847|NCT04650347|Procedure|visualized internal urethrotomy|incision of a urethral stricture to treat urinary obstruction using Quanta Holmium device or Sache cold knife, 18 Fr silicon catheter was kept for 7 days following the prodecure.
45997848|NCT00543972|Drug|AVE9633|Intravenous Infusion
45997849|NCT04650230|Device|nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV) and high flow nasal cannula (HFNC) devices|
46086065|NCT02741336|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"Cognitive-behavioral therapy is a short-term, focused psychotherapy for a wide range of psychological and behavioral issues including depression, anxiety, anger, and non-compliance. The focus of the intervention is on how one thinks, behaves, and communicates in real time, as opposed to a focus on one's early childhood experiences. The therapist assists the patient in identifying specific distortions and biases in thinking and provides guidance on how to modify these beliefs. CBT helps the patient learn effective self-help skills that are used in homework assignments that ultimately help change the way one thinks, feels and behaves. The~￼ intervention is action-oriented, practical, rational, and helps the patient gain independence and effectiveness in dealing with real-life issues. Techniques utilized in CBT-I include psychoeducation, sleep hygiene, cognitive restructuring, stimulus control, sleep restriction, and relaxation training."
46086066|NCT02741336|Behavioral|Self-Monitoring|
46086067|NCT02736500|Drug|28 GBq 177Lu-DOTATATE|Patients without risk factors (particularly long standing and poorly controlled diabetes and hypertension) for late renal toxicity will be administered with 5 cycles of 5.5 GBq (150 mCi) each, up to the total cumulative activity of 28 GBq (750 mCi) of 177Lu-DOTATATE.
45834848|NCT02936466|Behavioral|Bipolife® group|"The participant is proposed to play to the serious game Bipolife® with following instructions :~At least one connection per week during 4 weeks~Connection time is free On add on of usual treatment After the 4 weeks and the first visit (V1), the participant can continue to participate to the serious game as much as he wishes, without any specific instructions.~After connecting to the site www.bipolar.ubi.com, the participant is proposed to create his avatar and conduct him on his house. He realizes different kind of daily actions (like sleeping, sport activity, cooking) ; every action lead to win or to loose energy and mood points. The final aim is to stabilize the avatar's mood. Thanks to this experience, the participant can learn to distinguish positive and negative actions impacting on his condition."
45834849|NCT02935374|Drug|Amoxicillin|The children with acute otitis media will be treated with amoxixillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
45997850|NCT00595491|Biological|Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage|Bronchoalveolar lavage is performed in the lingula without instillation of diluent or allergen. A 2ml aliquot of diluent is instilled into the right upper lobe. The procedure is repeated in the right middle lobe with instillation of 2ml of Cat or Mite allergen. A test dose of allergen is administered first. This will consist of 2ml allergen at 1/10th the threshold concentration for Cat or DF Mite Allergen or at 1/30th the threshold concentration for DP Mite Allergen. If on visual inspection through the bronchoscope there is no evidence of reaction to the test dose, a 2nd allergen challenge is done in the right middle lobe using 2ml of full-dose allergen. After a 1,6, or 24hr recovery period, a single 2nd bronchoscopy is performed after delivery of allergen extract and diluent and 1 Tbsp of blood is obtained. Bronchoalveolar lavage will be obtained from the lobes in which the diluent and allergen were instilled. OFDI and endobronchial brushing of the airways will also be performed.
45997851|NCT02909010|Device|BIS™ Brain Monitoring System|The intervention group using BIS monitoring to adjust sedation in order to maintain values between 50-60
45997852|NCT02909010|Other|RASS|control group in which sedation was adjusted with the exclusive use of Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2
45997853|NCT04649762|Behavioral|activating consciousness technique (hypnosis)|activating consciousness technique (hypnosis)
46086068|NCT02736500|Drug|22 GBq 177Lu-DOTATATE|Patients with risk factors for late renal toxicity will be administered with 6 cycles of 3.7 GBq (100 mCi) each, up to the total cumulative activity of 22 GBq (600 mCi)177Lu-DOTATATE
46086069|NCT04326530|Device|Pneumopipe® (European patent 12425057.2, Rome, Italy)|Collection of VOCs on a cartridge after that the child has normally breathed in it for 3 min, both at the baseline and at the last visit.
46086070|NCT04326530|Other|Other assessments|"Spirometry, both at the baseline and at the last visit.~24-hour urine collection, both at the baseline and at the last visit."
46086071|NCT02741492|Procedure|Transversus Abdominis Plane Block|Continuous Nerve Block
46086072|NCT02741492|Procedure|Sham Block|Continuous Sham Catheter
46086073|NCT05629598|Biological|Recombinant human erythropoietin injection|The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).
46086074|NCT05629598|Biological|Human erythropoietin injection|Refer to the product instructions
46086075|NCT02745314|Other|Frailty measurement|Frailty measurement under Fried at el criteria
46086076|NCT02745314|Other|Comprehensive Geriatric Assessment|Multidimensional Geriatric Assessment
45834850|NCT02935374|Drug|Amoxicillin-Potassium Clavulanate|The children with acute otitis media will be treated with amoxixillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
45834851|NCT02935374|Drug|Macrolide|The children with acute otitis media with a know allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored separately
45834852|NCT01452204|Other|Pulsed Electromagnetical Field and Exercise|G1: MT, three times per week lasting 30' each session. G2: placebo MT, 3 X week lasting 30'each session. After 3 weeks of application of MT, will begin a program of exercises.
45997854|NCT00544011|Biological|bevacizumab|
45997855|NCT00544011|Drug|capecitabine|
45997856|NCT00544011|Drug|fluorouracil|
45997857|NCT00544011|Drug|irinotecan hydrochloride|
45997858|NCT00544011|Other|diagnostic laboratory biomarker analysis|
45997859|NCT04650113|Combination Product|MTA material|Partial pulpotomy is a procedure in which the inflamed tissue beneath an exposure is removed to a depth of 1 to 3 mm or deeper to reach healthy pulp tissue.
45997860|NCT00544050|Drug|Levetiracetam|
45457435|NCT01356992|Drug|Enoxaparin|Drugs will be provided by the sponsor to the study's patients on the reference presentation: 40 mg/0.4mL, 60 mg/0.6 mL and 80 mg/0.8 mL (solution for injection of enoxaparin sodium, 1 mg/ kg Sanofi-Aventis) or Eurofarma enoxaparin sodium (1 mg/ kg). The patients will use the drug corresponding to the arm of the study to which they were allocated. The drug administration must be performed through subcutaneous via on the dose of 1 mg/kg every 12 hours for at least 2 days and kept until the patient is discharged.
45997861|NCT04649996|Procedure|Appendectomy|comparison between operative and conservative treatment
45997862|NCT02908971|Behavioral|soy based formula at infancy|The intervention is only past history of soy consumption
45997863|NCT04649723|Drug|Rifampin|single oral dose, 600 mg, fasted.
45997864|NCT04649723|Drug|SHR1459|single oral dose, 200 mg, fasted.
45997865|NCT02908893|Behavioral|In-app and push notification mobile messages|Short messages (100-250 characters) are to be delivered to a mobile app both by push notification (i.e., appearing on the phone dashboard like a text message if the user has allowed notifications from the app) and in-app messages (visible in the news feed of the wellness program app when the app is opened). Messages contain a short title (30 characters) and 2-3 lines of text in the body (30 characters each).
45675403|NCT05886621|Behavioral|Smiling instead of Smoking - HIV|"Participants will be onboarded to the smartphone app Smiling instead of Smoking - HIV (SiS-H) and will be asked to complete the integrated SiS-H program while they quit smoking. The integrated SiS-H treatment consists of: (1) face-to-face onboarding to the SiS-H app, (2) one face-to-face session discussing app usage and antiretroviral therapy (ART) adherence (Life Steps), with direct linkage to tools in the app supporting ART adherence, and (3) an 8-week course of the SiS-H app. The SiS-H app is a smoking cessation app that uses a positive psychology framework in conjunction with with the US Clinical Practice Guidelines for smoking cessation to guide participants through the process of quitting smoking."
45834853|NCT01452438|Biological|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
45834854|NCT01452594|Drug|Diphenylcyclopropenone|Topical administration
45997866|NCT04649684|Device|Conventional robot-assisted gait training|They got conventional robot-assisted gait training, guidance force given equally to both limbs, and then gradually reduce the degree of guidance force to the extent that the patient is tolerable equally .during 4- week treatment session
45997867|NCT04649684|Device|Lower CIMT robot-assisted gait training group|They got robot-assisted gait training based on CIMT concept; 100% guidance force is given on the unaffected side and then verbal ques are given not to contract unaffected muscle voluntarily as much as possible are provided, automatically according to the predetermined joint trajectory. In contrast at the affected side, gradually reduce the degree of guidance force to the extent that the patient is tolerable.
45997868|NCT02909088|Drug|Ecopipam 50mg|
45997869|NCT02909088|Drug|Ecopipam 100mg|
45997870|NCT04649528|Behavioral|Effective endurance 4x4 training - Supervised|Exercise intervention utilizing 4x4min aerobic high-intensity interval training
45997871|NCT04649528|Device|Effective endurance 4x4 training - APP|Exercise intervention utilizing 4x4min aerobic high-intensity interval training
45997872|NCT04649645|Other|TOBACCO CIGARETTES|Participants in Arm A will continue smoking their own cigarette brand as usual.
45997873|NCT04649645|Other|COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)|Participants in Arm B will trial and familiarize with a selection of C-F NDS in order to choose the product of their preference. They will be trained and counselled on the chosen C-F NDS. Prior to check-out, participants wishing to use a heated tobacco device will receive one kit and a full 2 weeks supply of tobacco sticks of their choice (they will receive a number of tobacco sticks per day corresponding to the number of cigarettes smoked at baseline); those wishing to use a vaping product will receive one vaping kit and a full 2 weeks supply of e-liquids of their choice (they will receive twelve 10 ml refill containers).
45997874|NCT04649645|Other|NOT SMOKING|Participants in Arm C will continue not smoking or use any form of tobacco or nicotine-containing products.
45997875|NCT00544128|Drug|lamivudine, abacavir , ritonavir, atazanavir|Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
45457436|NCT02297542|Biological|Flu Vaccine|
45834855|NCT01452594|Drug|Placebo|Placebo
45834856|NCT01452750|Drug|TAK-438|TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
45834857|NCT01452750|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
45834858|NCT01452750|Drug|TAK-438|TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
45834859|NCT01452750|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
45834860|NCT01452750|Drug|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
45834861|NCT01452750|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
45834862|NCT04273308|Device|whole-body vibration training|The experimental group participated in a 12-week whole-body vibration training that was conducted 3 times per week, with 5-min continuous vibration at 12-Hz frequency and 3-mm amplitude each time. The control group were provided home DVDs on resistance exercise and manuals for preventing frailty
45834863|NCT01452828|Drug|TR-701 FA single infusion|Single IV infusion, 200 mg daily for 7 days
45457437|NCT03739879|Device|Inspiratory Muscle Trainer Philips Respironics|Subjects exercised using inspiratory muscle trainer (Philips Respironic®) for 8 weeks. Training dose with IMT was determined by inspiratory muscle strength result and adjusted in every evaluation visit. The subject was expected to do exercise twice daily for 15 minutes each session with 30-70% intensity from determined MIP score. Exercise is monitored and noted in a logbook.
45457438|NCT01350050|Drug|articaine|"Articaine is intermediate-acting local anesthetic (amide type). Like other local anesthetic drugs, articaine causes a transient and completely reversible state of anesthesia (loss of sensation) during (dental) procedures.~In dentistry, articaine is used both for infiltration and block injections."
45457439|NCT01350050|Other|9% Sodium Chloride solution for injection|9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer.
45457440|NCT03510754|Procedure|Eus guided biliary drainage|"After reaching the cardia or the lesser curvature of the stomach, for the transgastric approach, or the duodenal bulb, for the transduodenal one, intrahepatic left and extrahepatic bile ducts were punctured with a 19-gouge needle and the access was confirmed the injection of contrast under fluoroscopy to obtain an anterograde cholangiogram.~A 0.035-inch guide was advanced into the selected bile duct and under EUS and fluoroscopic view a stent was placed through the hepatogastrostomy between a left bile duct and the gastric lumen or through the choledochoduodenostomy between the common bile duct and the duodenal lumen."
45457441|NCT03918889|Drug|Dexmedetomidine Injectable Product|dexmedetomidine infusion at 0.5 µg•kg-1 for 10 min before tracheotomy then adjusted to 0.3µg•kg-1•h-1
45457442|NCT03918889|Drug|Midazolam injection|midazolam infusion at 0.05 mg•kg-1 ten minutes before tracheotomy then adjusted to 0.02mg•kg-1•h-1
45457443|NCT01357070|Dietary Supplement|Brocco-sprout homogenate|Participants will be asked to orally consume on three consecutive days a brocco-sprout homogenate (70g dry weight).
45457444|NCT01357070|Dietary Supplement|Alfalfa sprout homogenate|Participants will be asked to orally consume on three consecutive days an alfalfa sprout homogenate.
45834864|NCT01452828|Drug|TR-701 FA|Two separate infusions of 200 mg
45834865|NCT01452828|Drug|TR-701 FA|Single IV infusion, 200 mg daily for 7 days
45834866|NCT01452906|Drug|PA21 and Omeprazole with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Omeprazole will be 40 mg/day
45834867|NCT01452906|Drug|No PA21; Omeprazole with food|The maximum dosage of Omeprazole will be 40 mg/day
45834868|NCT01452906|Drug|PA21 with food, Omeprazole 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Omeprazole will be 40 mg/day
45834869|NCT01453218|Drug|ATeGe-Fresenius|Administered at 1 , 3, 5 and 7 day post-transplant at 2-3mg/kg with dose adjustment according to CD2/CD3 levels
45834870|NCT02837250|Behavioral|Pos4Health|This is a personalized, interactive, patient-centered Internet intervention targeting nonadherence to ART among substance users living with HIV.
45997876|NCT00544128|Drug|emtricitabine, tenofovir, ritonavir, atazanavir|Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg.
45997877|NCT00544206|Other|standard enteral feeding product|16 hrs daily x 5 days
45997878|NCT00544206|Other|Diabetes specific feeding product|16 hrs daily for 5 days
46086077|NCT02740946|Other|Exercise therapy|5 months of exercise therapy with two strengthening exercises focusing on m. deltoideus anterior and m. teres minor. Furthermore, a warm up exercise was applied.
45997879|NCT02909127|Other|SWALLOWING EVALUATION|Swallowing function of the CP patients will be imaged and recorded with Videofluoroscopic Swallowing Study (VFSS). The oral cavity, pharynx, larynx and just below the upper esophageal sphincter are visible. 3 trials of 3 ml of liquids will be used and the worst score will be considered for calculation. The Penetration-Aspiration Scale (PAS) will be used to assess dysphagia severity. The PAS is an ordinal scale consisting of eight scores. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.
45457445|NCT02297620|Drug|Suglat®|oral
45834871|NCT02837250|Behavioral|Patient Education|This is a patient education website with content about nonadherence to ART pertinent to substance users living with HIV.
46086078|NCT02744690|Drug|Mitomycin-C (MMC)|Mitomycin-C is routinely applied to the eye prior to trabeculectomy at Menelik II Hospital
45997880|NCT02909127|Other|The Functional Independence Measure|The Functional Independence Measure for Children (Wee-FIM) will be used to assess the functional independence level of the CP children. The Wee-FIM is developed to emphasize habilitative and developmental aspects of children with special health care needs, genetic disorders, developmental disabilities, and acquired disabilities.
45997881|NCT02909127|Other|The PEDI-EAT-10|The PEDI-EAT-10 will also be administered.
45997882|NCT02908854|Other|Adding spices and herbs to school lunch vegetables|Direct measurement of school lunch vegetable intake among students both before and after spices and herbs are added.
46086079|NCT02736266|Drug|Pembrolizumab (MK-3475)|Pembrolizumab given intravenously in 30 min. infusion every 3 weeks
45457446|NCT01134679|Behavioral|Multi-disciplinary disease management approach|Follow up with phone calls
45457447|NCT03739801|Drug|Liposomal Irinotecan|Given IV
45457448|NCT03739801|Other|Quality-of-Life Assessment|Ancillary studies
45457449|NCT03739801|Other|Questionnaire Administration|Ancillary studies
45457450|NCT03739801|Biological|Ramucirumab|Given IV
45457451|NCT03512236|Drug|BC Pram Ins|Injection of BC Pram Ins
45997883|NCT01240915|Drug|placebo|once every 7 days for 1- 3 doses
46086080|NCT02736032|Procedure|Embryo transfer|The transfer of cryopreserved-thawed embryos inside the uterus aiming to achieve pregnancy
46086081|NCT02736032|Procedure|Serum Estradiol and Progesterone levels|Serum estradiol and serum progesterone levels in blood on the day of start of progesterone supplementation
45834872|NCT02795598|Procedure|Single injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~30 milliliters of mepivacaine 1.5% will be injected incrementally in 5ml boluses at this location looking for spread of local anesthetic under and medial to the subclavian artery. The needle may be slightly repositioned to improve the distribution of the injectate at the discretion of the attending anesthesiologist."
45834873|NCT02795598|Procedure|Double injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~15 milliliters of mepivacaine 1.5% will be injected incrementally at the same, above-mentioned location. The needle will then be redirected to the superolateral aspect of the brachial plexus, and an additional 15ml will be injected here. Again, the needle may slightly repositioned at the discretion of the attending anesthesiologist in order to obtain adequate spread."
45997884|NCT01240915|Drug|MultiStem low dose|1-3 doses
45997885|NCT01240915|Drug|placebo|Single dose at week 8
46086082|NCT02736032|Drug|GnRH agonist|GnRH agonist given on day 21 of the cycle preceding the embryo transfer
46086083|NCT02736032|Drug|External Estradiol|Estradiol started on day1 of the cycle for endometrial prepartaion
45997886|NCT01240915|Drug|MultiStem low dose|Single dose at week 8
45997887|NCT01240915|Drug|placebo|Single dose Day 1
45997888|NCT01240915|Drug|MultiStem high dose|Single dose Day 1
45997889|NCT01240915|Drug|placebo|Single dose at week 8
45997890|NCT01240915|Drug|MultiStem high dose|Single dose at week 8
45997891|NCT01240915|Drug|placebo|Single dose Day 1
45997892|NCT01240915|Drug|MultiStem high dose|Single dose Day 1
45997893|NCT01240915|Drug|placebo|Single dose at week 8
45997894|NCT01240915|Drug|MultiStem high dose|Single dose at week 8
45997895|NCT00544245|Behavioral|Self monitoring of estimated energy balance|Participant estimation of energy intake and energy expenditure
45997896|NCT00558155|Drug|peptisorb|standard isocaloric eteral diet (1 ml = 1 kcal)
46086084|NCT02736032|Drug|Progesterone|progesterone as luteal phase support start after endometrium is well prepared
46086085|NCT04287920|Drug|Acomprosate|Acamprosate will be administered orally and will be dosed at 333 mg three times a day, if tolerated it will be increased to 666 mg three times a day. Acamprosate will be administered for a total of 3 months
46086086|NCT05598944|Behavioral|The MBSR program|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA. It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction), together with a day of intensive practice.~The program is structured along the following topics: The Underpinnings of MBSR; The Perception of Reality; Power in Being Present; Understanding Stress: The Mind-Body Relation; Responding to Stress; Communication and Personal Relations; Daily Life Management; My Personal Plan: What lies ahead."
45834874|NCT02781090|Behavioral|PSFW+|PSFW+ is an eight session motivational/educational web-program promoting cessation for HIV-infected smokers. It includes a professionally administered social network/online support community.
45997897|NCT00558155|Drug|Stresson|Oligopeptic, enteral diet (1 ml=1.25 kcal)
45997898|NCT00558155|Drug|Parenteral nutrition|Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
45457452|NCT03512236|Drug|Symlin® and Humulin®|Injection of pramlintide and human insulin
45997899|NCT00558155|Drug|Omegaven, Dipeptiven|Immunostimulating components: Omegaven (omega-3-fatty acids) and Dipeptiven (Glutamine Arginine) Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
45997900|NCT05476432|Procedure|HAIC|The microcatheter was advanced into the hepatic artery, and patients were transferred to the inpatient ward for drug infusion via the hepatic artery
45997901|NCT05476432|Drug|FOLFOX 2d|Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 46 hours
45997902|NCT05476432|Drug|FOLFOX 1d|Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 23 hours
45457453|NCT03512236|Drug|Humalog®|Injection of lispro
45457454|NCT03512236|Drug|Placebo|Injection of 0.9% NaCl
45457455|NCT01230073|Device|Home-Monitoring|Home-Monitoring
45457456|NCT01230073|Device|Follow-up by Home-Monitoring|Follow-up by Home-Monitoring
45997903|NCT02908815|Device|rTMS active treatment|Repetitive Transcranial Magnetic Stimulation uses magnetic pulses to active neurons.
45997904|NCT02908815|Device|rTMS sham treatment|A fake treatment designed to mimic the sensations of rTMS
45675404|NCT05886621|Behavioral|QuitGuide|"Participants will be onboarded to the NCI smartphone app QuitGuide(QG) and will be asked to use it for 8 weeks to support them in quitting smoking. The QuitGuide app follows the US Clinical Practice Guidelines. The app is freely available on NCI's Smokefree.gov website, which is a recommended resource for treating smokers in the healthcare setting. The QuitGuide app is frequently used as a comparison app in smartphone app smoking cessation studies. It asks participants to set a quit day, track their mood and cravings, and log their cigarettes. It provides app users with guidance on quitting (i.e., Learn to Quit information), offers strategies to counter smoking triggers, and allows users to set reminders to stay smoke free (time and location based)."
45675405|NCT05886608|Device|AI 500™ SINGLE-DOSE GEL|AI500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, intended to provide relief in cases of pain due to tension in muscles and adjacent tissues, to improve movement and function.
46086087|NCT05598944|Behavioral|Más Presente, the UGRComp program|"Más Presente, the UGRComp program is based upon the European LifeComp framework (Sala, Punie, Garkov and Cabrera Giraldez 2020) and covers intra and interpersonal, emotional, cognitive and metacognitive aspects. Created at the University of Granada by an interdisciplinary group of experts, it focuses on three core elements (self-regulation, empathy and growth mindset) as they are the pre-requisites for developing all other elements across framework areas. It consists of 8 weekly classes, 2 hours each, together with a day of intensive practice.~The program is structured along the following topics: The Underpinnings of Más Presente; Awareness and Concentration: our Body; Managing our Emotional Laberynth; Walking with Directionality, Sense and Conscience; Empathy, Presence and Connection; Empathic Listening and Honest Expression: Non-violent communication; Growth Mindset, Creativity and Divergent Thinking; And Now what? The First Day of the Rest of My Life."
45997905|NCT01239745|Drug|Aromasin|Aromasin® one 25 mg tablet to be taken once daily
45997906|NCT01239472|Drug|Everolimus|Replacement of tacrolimus by everolimus, 30 days after transplat. It was done after kidney biopsy (excluding acute rejection), blood and urine analysis.
46086088|NCT05598944|Other|Neuro-muscular stimulation|Subjects will receive weekly sessions with a combination of educational sessions and specific physical exercises to enhance physical wellbeing and prevent neuro-degeneration . After spotting the therapeutic targets for each subject, a 4-phase program will be designed for each subject aimed at improving lifestyle habits and general wellbeing.
45997907|NCT04649450|Other|Music|Participants in the music group will receive headphones with music 30 minutes before surgery. Patients will be able to choose music from a preselected list composed by a team consisting of researchers and dedicated music therapists. The headphones will be removed just before entering the operating room. Once in the operating room they will receive earphones after intubation, compatible with the Mayfield and site of operation. The intraoperative music intervention will be continued during the surgical procedure and discontinued just before detubation. The duration of the intraoperative music intervention depends on the duration of surgery and will be documented. After surgery, during recovery at the post-operative care unit (PACU) another 30 minutes of music through headphones will be given. The following 3 days at the neurosurgical ward they will receive music twice a day for 30 minutes.
45997908|NCT00544284|Drug|bortezomib|
46086089|NCT02741102|Procedure|Uterine Transplant|Treating Absolute Uterine Factor Infertility by Uterus Transplant. Potential recipients undergo IVF to obtain 6 embryos for cryopreservation followed by live donor uterine transplant. After 1 year, embryo transfer is done to achieve pregnancy. Delivery is by Caesarian section. The recipient may have up to 2 children by these methods and then the uterus is removed so that immunosuppression can be stopped.
45457457|NCT03132844|Other|Analysis records of patients over 75 years of age|Demonstrate the percentage of patients over 75 years of age attending general medicine in the Somme, with an up-to-date vaccination schedule, in view of the HAS 2016 recommendations, for the following vaccines: DTp, influenza, pneumococcus, shingles.
45834875|NCT02781090|Behavioral|AHA|The AHA Getting Healthy website is a health-promoting, seven-module website developed by the American Heart Association to encourage healthy behaviors in the general population
45834876|NCT02781090|Drug|Nicotine polacrilex|All participants, in both study arms, will be offered a 3-month supply of nicotine patches
45834877|NCT03849378|Dietary Supplement|Sargassum Horneri Extract group|This group takes 1,000 mg/day of Sargassum Horneri Extract for 12 weeks.
45834878|NCT03849378|Dietary Supplement|Placebo group|This group takes 1,000 mg/day of Placebo Extract for 12 weeks.
45834879|NCT02730780|Dietary Supplement|Low-Salt Diet|The low-salt diet (7 days) will consist of meals, snacks, and sodium free water provided by the study staff.
45834880|NCT02730780|Dietary Supplement|High-Salt Diet|The high-salt diet (7 days) consists of each subject's usual diet, supplemented each day with 2 bouillon broth packets, which will be provided to the subject by the study staff.
45834881|NCT03823092|Diagnostic Test|polarization sensitivity|test of polarization vision as described in Study Description
45834882|NCT03823248|Drug|MoLuoDan|oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day
45997909|NCT00544284|Drug|temozolomide|
45997910|NCT00544284|Other|pharmacological study|
45997911|NCT02888275|Drug|Dexmedetomidine|
45997912|NCT02888275|Drug|normal saline|
45997913|NCT03456531|Device|pulsed radiofrequency|The patient will have pulsed radiofrequency to suprascapular nerve for 6 minutes
45997914|NCT03456531|Drug|"NSAIDs ibubrofen,Aspirin"|"medical treatment as NSAIDs ibubrofen,Aspirin"
45997915|NCT02909049|Drug|MIDAZOLAM|Intravenous bolus anesthesia 5 minutes previous to saturation prostate biopsy.
45997916|NCT02909049|Drug|MEPIVACAÍNE|Local periprostatic anesthesia infiltration, previous to saturation prostate biopsy.
45457458|NCT01229293|Procedure|Articular Surface Replacement (ASR)|Articular surface replacement, DePuy, posterolateral approach used
45997917|NCT02909049|Drug|FENTANILE|Intravenous bolus anesthesia 3 minutes previous to saturation prostate biopsy.
45834883|NCT03823248|Drug|Sanchi powder|oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day
45997918|NCT02909049|Drug|KETAMINE|Intravenous bolus anesthesia 1 minute previous to saturation prostate biopsy.
45997919|NCT04649216|Drug|PCO371|PCO371 Capsule
45997920|NCT04649216|Drug|[14C]PCO371|[14C]PCO371 Oral solution
45997921|NCT04649216|Drug|[14C]PCO371|[14C]PCO371 Solution for infusion
45997922|NCT01229449|Drug|Ibuprofen/acetaminophen|One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet, single dose taken orally with 300 ml water
45997923|NCT01229449|Drug|Ibuprofen/acetaminophen (higher dose)|Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg, single dose taken orally with 300 ml water
45997924|NCT01229449|Drug|Nurofen Plus®|Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®), single dose taken orally with 300 ml water
45997925|NCT01229449|Drug|Panadeine® Extra|Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra), single dose taken orally with 300 ml water
45997926|NCT01229449|Drug|Placebo|Two placebo tablets, single dose taken orally with 300 ml water
45997927|NCT04648865|Drug|LY3537031|Administered SC.
46086090|NCT02744768|Drug|Dasatinib|Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84.
46086091|NCT02744768|Drug|Blinatumomab|"Upon induction:~patients in CHR will receive Blinatumomab at a dose of 15 µg/m²/day as continuous intravenous infusion (CIVI) at a constant flow rate for four weeks, followed by a two-week infusion-free interval, defined as one treatment cycle. At least 2 cycles should be administered, up to a maximum of 5 cycles, if deemed necessary."
45457459|NCT01229293|Procedure|Standard Total Hip Arthroplasty (THA)|Device: Biomet 28mm
45457460|NCT02301052|Drug|Leek topical cream|Leek (Allium Ampeloprasum Spp.Iranicum) topical cream 2 cc twice daily for 3 weeks
45457461|NCT02301052|Drug|placebo topical cream|placebo topical cream 2 cc twice daily for 3 weeks
45834884|NCT03823248|Drug|Folic Acid Tablet|oral administration of folic acid tablets half an hour after meal for 5 mg each time for 3 times a day.
45834885|NCT03823248|Drug|MoLuoDan simulation|oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day
45997928|NCT04648865|Drug|Placebo|Administered SC.
45997929|NCT04648982|Other|Admission to inpatient psychiatric unit|All persons in the study are hospitalized at the only inpatient mental health hospital in Rwanda - Ndera. Data will be collected when the person is being discharged.
45997930|NCT01239316|Other|Laboratory Biomarker Analysis|Correlative studies
45997931|NCT01239316|Other|Pharmacological Study|Correlative studies
45997932|NCT01239316|Drug|Vismodegib|Given PO
45997933|NCT01239160|Device|Flexitouch System|"A segmental, programmable, gradient pneumatic compression device. It consists of a controller and garment set. The garments are constructed of nylon and have 27-32 chambers, depending upon garment size. The pressure setting is variable between normal and increased. The device is intended to be used for 60 minutes per day"
45997934|NCT01239160|Device|Hydroven FPR|The FH is an intermittent sequential external pneumatic compression system. The garment contains 3 compression chambers. The pressure range of the compressor device is 30-100 mmHg. It is intended to be used for 60 minutes per day.
45457462|NCT02301052|Drug|Anti-hemorrhoid topical cream|Anti hemorrhoid topical cream 2 cc twice daily for 3 weeks(This cream consists of lidocaine (5% w/w), hydrocortisone acetate (7.5% w/w), aluminium sub-acetate (3.5% w/w), and zinc oxide (18% w/w). 30 g )
45457463|NCT01134835|Other|placebo|placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks
45457464|NCT01134835|Drug|IMP Pioglitozone|Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
45834886|NCT03823248|Drug|Sanchi powder simulation|oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day
45997935|NCT01239121|Other|HIE-Enhanced Medication Reconciliation|Medication reconciliation enhanced by regional health information exchange, implemented by a pharmacist
45997936|NCT01239121|Other|Optimal Medication Reconciliation without HIE|Medication reconciliation implemented by a pharmacist without regional health information exchange
45997937|NCT01239043|Biological|Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
45997938|NCT01239043|Biological|Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
45997939|NCT01238848|Drug|Hypertonic saline|3 cc nebulized hypertonic saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
45997940|NCT01238848|Drug|Normal saline|3 cc nebulized normal saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
46086092|NCT00909779|Drug|Arformoterol|Arformoterol Tartrate Inhalation Solution 15 mcg twice daily (BID) for a duration of one year
46086093|NCT00909779|Drug|Placebo|Placebo inhalation solution, twice daily (BID) for a duration of one year.
46086094|NCT02744924|Behavioral|Physical activity intervention|"The intervention is comprised of 5 steps:~Goal setting: Over a step-counter (smartphone app) participants learn about their daily average step count. They are coached to set individual goals~Fitness assessment: To recommend suitable frequency and intensity of walking program using mapped trails~Structured walking groups: Promoted and communicated via app. Participants can additionally organize walking groups of their own.~Feedback: Participants will see individual and group data over the step-counter app, and they can communicate with others via a communication app. They will be incentivized to reach goals through a gamification approach.~Invite friends: After 12 weeks, participants are encouraged to invite people who fulfil the inclusion criteria to join the project"
45997941|NCT02908542|Genetic|genetic analysis with massively parallel sequencing|
46086095|NCT05629442|Other|ctDNA|initial research biopsy, quality of life assessments and ctDNA collection
45997942|NCT01238575|Other|placebo|Administered for up to 8 weeks.
45997943|NCT01238575|Drug|extended-release guanfacine|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks
45997944|NCT00544323|Device|oral implant|
45997945|NCT02888158|Other|Robotic assistance|Robotic assistance will be implemented during Pelvic Trainer training sessions.
45997946|NCT02888158|Other|Pelvic Trainer|The standard Pelvic Trainer simulator for surgical training.
45997947|NCT01237951|Drug|Palifermin|"60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.~60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient."
46086096|NCT04096391|Device|Flowonix Prometra® II Programmable Infusion System|The Flowonix Prometra® II Programmable Infusion System consists of an implanted infusion pump and catheter, and external components including a clinician programmer, refill and catheter access port kits, the PTC™(a subject operated controller).
46086097|NCT04096391|Drug|Pain Medicine|Injections, spinal cord stimulation, peripheral nerve stimulation, pain medication, etc.
46086098|NCT02744378|Drug|Tacrolimus 0.1%|This group was randomly allocated to receive topical Tacrolimus 0.1% for 3 consecutive weeks
46086099|NCT02744378|Drug|Clobetasol 0.05%|This group was randomly allocated to receive topical Clobetasol 0.05% for 3 consecutive weeks
46086100|NCT04202939|Other|nutrition|type and amount of food eaten or type of oral nutritional supplements as well as enteral or parenteral nutrition
46086101|NCT04318730|Drug|Camrelizumab|Camrelizumab was administered 200mg iv every 3 weeks, Apatinib was administered 250 mg p.o. qd.
46086102|NCT00632333|Biological|URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil|Escalating dose of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 will be administered by subcutaneous injection on days 15, 22, 28 and 35 of treatment cycle. Doses of each peptide are planning 0.5mg, 1mg and 3mg/body. Chemotherapy plus radiation therapy will be done as follows: fluorouracil (400mg/m2) on day1-5 and 8-12, cisplatin (40mg/m2) on days 1 and 8, radiation (2Gy) on days 1-5, 8-12 and 15-19. Two cycles of combination of chemoradiation therapy and epitope peptide vaccine therapy will be done.
45997948|NCT01237951|Drug|Dexamethasone|8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient.
46086103|NCT02744456|Drug|Losartan|An angiotensin II receptor antagonist drug used mainly to treat high blood pressure.
46086104|NCT02744456|Drug|Amlodipine|A calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension.
45675406|NCT05886582|Drug|Rotigotine Transdermal System [Neupro]|Neupro® 2mg/24h transdermal patches for the first seven days, followed by the target 4mg dose for the subsequent 35 days (five weeks) of dosing up to the follow-up assessments, followed by two days of 2mg/24h ramp-down dose.
45997949|NCT01237951|Drug|Gemcitabine|1875 mg/m^2 IV (75 mg/ m2 bolus followed by 1800 mg/m^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.
46086105|NCT02744456|Drug|Hydrochlorothiazide|A diuretic medication often used to treat high blood pressure and swelling due to fluid build up.
45675407|NCT05886582|Drug|Placebo|Placebo drug
45675408|NCT05886569|Device|DIGIPREDICT Physiopatech|Application of the DIGIPREDICT Physiopatch investigational device
45997950|NCT01237951|Drug|Busulfan|"32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.~Busulfan AUC 4,000 by vein on Days -8 to -5 as an outpatient or inpatient."
45997951|NCT01237951|Drug|Melphalan|60 mg/m^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.
45997952|NCT01237951|Procedure|Stem Cell Transplant|On Day 0, stem cells returned to body by vein over 30-60 minutes.
45997953|NCT01237951|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
45997954|NCT02908581|Drug|Placebo|Administered orally once daily
45997955|NCT02908581|Drug|Iron 150 mg and Folic acid 0.5 mg|Iron will be administered with folic acid orally
45997956|NCT00544362|Biological|cetuximab|
45997957|NCT00544362|Drug|cisplatin|
45997958|NCT00544362|Drug|fluorouracil|
46086106|NCT04270565|Behavioral|In-Field Gait-Training|The intervention will deliver a series of vibrations on the participants' wrists through the Garmin when the sensors indicate that their contact time in milliseconds exceeds a threshold. The runners will be asked to reduce the amount of time their foot is in contact with the ground by picking their feet up more quickly. Participants will also receive a series of exercises based on noted impairments at baseline. The feedback during running will be completed twice per week for four weeks.
46086107|NCT04270565|Behavioral|Home Exercise|Participants will receive a series of exercises based on noted impairments at baseline. Exercises will be completed twice per week for four weeks.
45997959|NCT00544362|Procedure|conventional surgery|
45675409|NCT05886543|Behavioral|Conventional chest physical therapy|Conventional chest physical therapy: The patients performed four series of five breath with 3 seconds of sustained breathing interspersed with periods of quite breathing followed by two or three coughs or huffs (with wound support by a pillow or his/her hands), twice a day in the first two postburned days and once a day from the third to the tenth days.
45997960|NCT02908776|Dietary Supplement|Probiotic|Sachets with Streptococcus thermophilus DSM 32245: 70 billion, bifidobacteria (Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247) 40 billion, lactobacilli (Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 29575, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961): 90 billion.
45997961|NCT02908776|Other|Placebo|Sachets of maltose, flavors and sylicium dioxide, indistinguishable from ecoviesel sachets.
45997962|NCT04648943|Procedure|Ex-Press mini shunt insertion|
45997963|NCT04648943|Procedure|Trabeculectomy|
45997964|NCT02908503|Other|Placebo Film|placebo vaginal films
45997965|NCT04648670|Behavioral|Cognitive stimulation|The intervention was applied to the experimental group and consisted in 10 sessions of 45 minutes/week during 10 weeks. Each session included four parts: (a) Reality orientation therapy, (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises..
45997966|NCT01239394|Drug|ofatumumab|Weekly infusion for 8 weeks
45675410|NCT05886543|Behavioral|Pilates exercise|The Pilates technique, which stretched laterally and to the back, stressed costal breathing, in which the ribs climb and drop throughout the ventilatory stream. The transverse muscle had to work harder to avoid abdominal distension, provide more support to the diaphragm to promote lower rib movement, and provide more diaphragmatic excursion, During the expiratory phase, the transversus abdominis, the multifidus and the pelvic floor musculature were contracted.
45997967|NCT00553293|Drug|recombinant luteinizing hormone (Luveris)|75 iu/day form cycle day 6
46086108|NCT02744222|Biological|BCD-054 180 mcg|180 mcg intramuscularly once every two weeks
46086109|NCT02744222|Biological|Avonex®|30 mcg intramuscularly once a week
46086110|NCT02744222|Biological|BCD-054 240 mcg|240 mcg intramuscularly once every two weeks
46086111|NCT02744222|Other|Placebo|intramuscularly once a week (0,5 ml)
46086112|NCT05581355|Behavioral|Abdominal breathing training|In the sleep center, it is carried out in a one-on-one manner by the trainer. At home, self-training through abdominal breathing training videos (10 minutes per day, you can accumulate up to 10 minutes in divided doses)
46086113|NCT02741024|Drug|Amodiaquine-Artesunate (ASAQ)|Treatment on site with Amodiaquine-Artesunate according to the manufacturer's dose and instruction and follow-up for a period of 42 days. Drugs will be given under direct supervision, either at the clinic or at home
45458737|NCT05072743|Device|Photobiomodulation Therapy|PBMT will be applied to the cervical spine using the BIOFLEX® DUO+ system that utilizes a Light Emitting Diode (LED) array pad followed by laser probes. Both delivery methods will be applied to the cervical spine and will entail the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided twice per week for 6 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for the treatment of the cervical spine soft tissue injuries.
45675411|NCT05886530|Other|No intervention|Observational data collection only.
45675412|NCT05886517|Device|Transfemoral transcatheter aortic valve implementation|ranscatheter aortic valve implantation, a percutaneous treatment for severe aortic valve stenosis, is increasingly performed worldwide. The pacemaker should be able to perform overdrive pacing which is essential to reduce cardiac output and transvalvular blood flow which are critical during balloon aortic valvuloplasty and valve deployment of the balloon- expandable valve. Minor adjustment may be needed for ideal positioning, but importantly this has to be done before valve implantation
45997968|NCT00553293|Drug|recombinant follicle stimulating hormone (Gonal-f)|rFSH 150 iu/day
45997969|NCT04648514|Procedure|Using of hydraulic lifter device for closed sinus lifting|Using of recent closed minimally invasive technique (hydraulic left technique) by hydraulic lifter device for closed sinus lifting then evaluation of the amount of bone height gain will be done radiographically (by panorama and CBCT) after implant placement for patients with posterior edentulous maxilla .
46086114|NCT02741024|Drug|Artemether-Lumefantrine (AL)|Treatment on site with Artemether-lumefantrine combination according to the manufacturer's dose and instruction and follow-up for a period of 42 days.
46086115|NCT02761187|Other|No Intervention|
45675413|NCT05886504|Other|Community-based psychiatric intervention|intervention will take place in CBO offices instead of mental health department, medication will be given freely and psychiatric consultations will be free. Trained CBO members will provide individual and collective support including recall of appointments and tracing of those lost to follow-up, information on mental health, main psychiatric disorders, psychiatric medication, their potential side effects and expected benefits, contact with families and continuous support
45675414|NCT05886491|Drug|GDX012|GDX012 suspension for IV infusion.
45997970|NCT04648514|Behavioral|patient satisfaction evaluation after using hydraulic lifter device|Evaluation of patient satisfaction numerically will be done after using hydraulic lift technique by hydraulic lifter device for closed sinus lifting in posterior edentulous maxilla
45997971|NCT00544401|Other|Hypnopuncture (Hypnosis+Acupuncture)|hypnosis and acupuncture
45997972|NCT02908737|Device|Bass and Treble|Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively
45997973|NCT04648358|Drug|Bupivacaine|The control group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus normal saline 1 ml. The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.
45457465|NCT03920917|Procedure|Cryoballoon Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a cryoballoon catheter.~Esophageal temperature will be monitored to prevent esophageal injury.~A 28mm second or third cryoballoon catheter will be used.~Esophageal temperature will be monitored to prevent esophageal injury.~Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~The procedure and cryoablation times will be evaluated.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
45675415|NCT05886491|Drug|Chemotherapy Agents|Chemotherapy agents (fludarabine/cyclophosphamide) as per standard of care.
45997974|NCT04648358|Drug|Dexamethasone combined with bupivacaine|The DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus 4 mg dexamethasone (1 ml). The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.
45997975|NCT04648397|Other|Low glycaemic load, high fibrous product|Test-lunch of 370 grams of chickpeas, seasoned with a herb- and spice mix to increase palatability. Glycaemic load 18.5. Consumed in duplicate.
45997976|NCT04648397|Other|High glycaemic load, low fibrous product|Test-lunch of 257 grams of brown rice, seasoned with rice-oil and a herb- and spice mix to increase palatability. Glycaemic load 44.9. Consumed in duplicate.
45997977|NCT00544518|Drug|metformin|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time
45997978|NCT00544518|Drug|benfluorex|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time, one of 2 tablets is dummy tablet.
45997979|NCT04648592|Dietary Supplement|Low salt diet plus sodium chloride supplements|Patients will receive a low salt diet plus salt supplements.
45997980|NCT04648592|Dietary Supplement|Low salt diet plus placebo|Patients will receive a low salt diet plus placebo.
45997981|NCT02908698|Drug|Prednisone|"Total treatment duration: 15 days~Doses are as follows:~5 days daily treatment with 0.75 mg/kg of body weight 5 days daily treatment with 0.5 mg/kg of body weight 5 days daily treatment with 0.25 mg/kg of body weight"
45675416|NCT05886465|Drug|Atezolizumab|1200 mg, iv.drip, Q3W
45997982|NCT02908698|Drug|Placebo Control|Total treatment duration: 15 days. Doses will appear identical to prednisone arm.
45997983|NCT00544596|Drug|R-(-)-gossypol acetic acid|Given orally
45997984|NCT00544596|Drug|cisplatin|Given IV
45997985|NCT00544596|Drug|etoposide|Given IV
45997986|NCT00558194|Behavioral|Standard Behavioral Weight Loss Treatment with Affective and Cognitive Skills Training|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
45997987|NCT00558194|Behavioral|Standard Behavioral Weight Loss Treatment|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
45675417|NCT05886465|Drug|Bevacizumab|15mg/kg, iv.drip, Q3W
45997988|NCT00544635|Device|no intervention|no intervention
45675418|NCT05886465|Procedure|HAIC with FOLFOX|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries, Q3W
45675419|NCT05886452|Device|DT1fA contact lenses|Subjects will be fitted with DT1fA contact lenses
45675420|NCT05886439|Drug|LK101 injection (personlized neoantigen pulsed DC vaccine )|LK101 will be administered in a prime-boost schedule of 4 priming vaccination followed by 3 booster vaccinations.
45997989|NCT00544635|Device|light|scars will be treated with light
45675421|NCT05886439|Drug|Pembrolizumab|Patients will receive pembrolizumab(200mg IV) Q3W until disease progression (PD), intolerable toxicity.
45997990|NCT00558233|Behavioral|CHOICE decision aid|computer-based patient decision aid about colorectal cancer screening delivered immediately before a healthcare provider visit
45997991|NCT00558233|Behavioral|YourMeds patient education program|computer-based patient education program about prescription drug safety seen immediately before a healthcare provider visit
45997992|NCT02908425|Other|Statin user|Subjects will be studied on 2 occasions with both being identical. One will be after 7 days or more of cholesterol lowering statin administration and the other occasion will be after at least 4 weeks of cholesterol lowering statin discontinuation. All study visits include (but are not limited to) blood draws, urine collection, and stable isotope infusions.
45997993|NCT02908191|Drug|ABI-H0731|
45997994|NCT02908191|Drug|Placebo for ABI-H0731|
45997995|NCT02908191|Drug|Entecavir|Used to treat adults with chronic hepatitis B virus
45675422|NCT05886439|Drug|Durvalumab|Patients will receive durvalumab (1500mg IV) Q3W until disease progression (PD), intolerable toxicity.
45675423|NCT05886426|Diagnostic Test|4DCT wrist and standard CT wrist|Dynamic CT aquistion of wrist during movement and standard static wrist CT
45997996|NCT02908191|Drug|Tenofovir disoproxil fumarate|Used to treat adults with chronic hepatitis B virus
45997997|NCT02908191|Drug|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
45997998|NCT02908191|Drug|Nucleos(t)ide|Used to treat adults with chronic hepatitis B virus
45997999|NCT04648007|Diagnostic Test|Kaihani Score|Assessment of neuromodulatory chemicals in peripheral blood plasma samples.
45998000|NCT00544752|Other|16|indoor temperature of 16 degrees celcius
45675424|NCT05886413|Other|VentilO application|"This educational application provides clinicians with combinations of tidal volume and respiratory rate based on gender, height, weight, body temperature and patient type. The algorithm used is based on published data regarding ventilatory requirements in different populations (i.e. from intubated patients for scheduled surgery to the most severe ICU patients) and anatomical and instrumental dead space.~The objective of this application is to help implement personalized protective ventilation in intubated patients according to their characteristics.~After patient data entry in the VentilO application we will compare the recommended settings (for mechanical ventilation) vs the real clinician settings done by clinician after patient admission in ICU after cardiac surgery.We will evaluated the potential effect of the VentilO recommendation on the first arterial (or capillary) blood gases compared to the real settings."
45998001|NCT00544752|Other|indoor temperature of 20 degrees celcius|indoor temperature of 20 degrees celcius
45998002|NCT00544752|Other|indoor temperature of 24 degrees celcius|indoor temperature of 24 degrees celcius
45998003|NCT00544791|Drug|melatonin|5 mg, oral, daily dose for 6 months
46086116|NCT02744300|Behavioral|BABI-2 Lifestyle Intervention|Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips.
45675425|NCT05886400|Other|SCAT5|The SCAT5 is a standardized assessment tool to diagnose a concussion. This tool will be used for the experiment utilizing the 5th edition to recreate the methods used in an athletic situation. The SCAT5 is broken down into multiple subtests to focus on specific aspects of a person's wellbeing that could be affected by a possible concussion. The assessments are created to measure an athlete's subjectively experienced symptoms, cognitive functioning and balance and postural stability (mBESS).
46086117|NCT02743988|Drug|Oxygen|Adapt inspired oxygen to achieve desired SpO2 target range
46086118|NCT02735954|Other|Marijuana|This is an observational study looking at the effects of marijuana on health, including lung health and sleep.
46086119|NCT02735876|Drug|acalabrutinib|
45675426|NCT05886400|Other|Visual/ Auditory Distraction|The purpose of this study is to examine the effect of environmental distractions on one's ability to complete the SCAT5. The environmental distractions will be visual and auditory by playing a sports event or sports clips during the completion of the assessment. The goal of this is to simulate the distraction of a sideline like a SCAT5 is typically used within athletic training.
45675427|NCT05886374|Drug|HMPL-415S1|HMPL-415S1 will be supplied as 0.5 mg, 5 mg and 25 mg capsules
45998004|NCT00544791|Drug|placebo like melatonin tablets|
46086120|NCT02735876|Drug|ibrutinib|
45998005|NCT04647812|Behavioral|Technology-assisted rehabilitation|Augmented exercise therapy with novel technology and home-based telerehabilitation
46086121|NCT02735876|Drug|rituximab|
46086122|NCT02740556|Other|HepCure ToolKit|"HepCure is a web-based tool kit in the form of a dashboard for providers and an application (or app) for patients. The app allows patients to become active participants in their treatment by enabling them to enter prescribed treatment, add medications to Pill Box, log doses, visualize adherence, and includes several additional resources."
45998006|NCT04647812|Behavioral|Conventional rehabilitation|Traditional multidisciplinary in-patient rehabilitation
45998007|NCT04684797|Behavioral|Virtual T-maze task|Patients will have to perform the virtual T-maze task, which is known to elicit reward positivity. During this task, the patients will see a virtual T-maze on a computer screen and have to choose at every junction whether they go right or left. Depending on the direction they choose, they either get positive or negative feedback (reward or no reward). This feedback is chosen completely at random, on a 50% reward/50% no reward basis.
45998008|NCT04647773|Drug|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 13-weeks fixed dose.
45998009|NCT04647773|Drug|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 13-weeks fixed dose.
45998010|NCT04647773|Drug|HSK16149 60mg BID|HSK16149 60mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
46086123|NCT02740556|Device|AdhereTech Active Features|AdhereTech, a wireless pill monitoring device that measures the dosage and time a medication was taken. It is a HIPAA-compliant, FDA-registered Class I medical device. Using cellular technology, AdhereTech can be used passively to collect data on when a medication is taken, when a refill is needed, and how often the bottle is opened. AdhereTech also can be used actively to monitor adherence and provide feedback to subjects using the device. When actively monitoring, AdhereTech can be set up to provide live feedback to a subject by lighting up, sounding chimes, and sending phone/text/email alerts to remind patients to take their medication.
46086124|NCT02740556|Other|AdhereTech Passive Monitoring|AdhereTech passively monitors adherence (no chimes or reminders)
46086125|NCT00910871|Drug|TMC207|TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks.
45998011|NCT04647773|Drug|HSK16149 80mg BID|HSK16149 80mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
46086126|NCT00910871|Drug|Background Regimen (BR) for MDR-TB|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as specified in the protocol for up to 96 weeks.
45998012|NCT04647773|Drug|Pregabalin 150mg BID|Pregabalin 150mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
45998013|NCT04647773|Drug|Placebo BID|Placebo, orally twice a day, treatment period; 13-weeks fixed dose.
45675428|NCT05886361|Other|No intervention involved|No intervention involved
45675429|NCT05886348|Device|Novel spectacle lens|wearing spectacle lenses correct myopic ametropia, and may slow the progression of myopia and axial length elongation
45675430|NCT05886348|Device|Single vision spectacle lens|wearing spectacle lenses correct myopic ametropia
45675431|NCT05886322|Diagnostic Test|patient reported outcome measures|MIAH, mHI, Manotiba IBD Index, p-HBI/SCCAI, IBD-control
45675432|NCT05886322|Diagnostic Test|fecal calprotectin|fecal calprotectin point-of-care test and laboratory test
45675433|NCT05886322|Diagnostic Test|colonoscopy|endoscopic activity scores (SES-CD, UCEIS, MES)
45675434|NCT05886309|Diagnostic Test|Collection of Blood samples|"The following samples will be drawn from each study participant immediately after the venipuncture performed for the whole blood donation:~1 sample with no anticoagulant (5 ml) for SF measurement with the CDMS method~1 EDTA (Ethylendiamintetraazetat) sample (7,5 ml) for a complete blood count with red blood cell indices and reticulocytes~1 EDTA sample (2,7 ml) for the measurement of hepcidin~1 Li-Heparin-Gel sample (4.7 ml) for the measurement of SF with the ECLIA (Electrochemiluminescence-enzymeimmunoassay) and of the complete set of iron biomarkers (Transferrin Saturation, serum iron, Soluble Transferrin Receptor)~1 Li-Heparin-Gel sample (4.7 ml) for the measurement of CRP (C-reactive Protein)~1 sample with no anticoagulant (5 ml) for the measurement of SF with the CMIA (Chemiluminescence Immunoassay)~1 sample with no anticoagulant (5 ml) for storage"
45998014|NCT01237678|Drug|IMGN901|Phase 2 regimen is IMGN901, Carboplatin, and Etoposide. IMGN901 to be given on days 1 and 8 every 21 days.
45998015|NCT01237678|Drug|Carboplatin and Etoposide|Patients assigned to Arm 2 were to receive carboplatin at the same AUC as utilized in Arm 1
45998016|NCT04647461|Drug|Brimonidine Tartrate 1.5mg|1 drop 3 times a day for 12 weeks to target eyes
45998017|NCT04647461|Drug|Brimonidine Tartrate 1.5mg|1 drop 3 times a day for 12 weeks to target eyes
45998018|NCT04684992|Device|GEBT Telehealth Administration Usability|Establish the usability of a telehealth platform for the administration of GEBT
45998019|NCT01229371|Biological|Inflexal V influenza vaccine (CSL HA Antigen) 2010|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
45998020|NCT01229371|Biological|Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
45458738|NCT04411576|Diagnostic Test|Throat swab sample for measuring current infection with SARS-CoV-2|Throat sample taken by the study participant to be analyzed with RT PCR for the presence of SARS-CoV-2 viral nucleic acids.
45458739|NCT04411576|Diagnostic Test|Blood sample for serology to measure past infection with SARS-CoV-2|Blood samples for serology to be analyzed for the presence of SARS-CoV-2 antibodies.
45458740|NCT01239199|Other|Measure of the exhaled NO|The exhaled NO will be measure by chemiluminescence in current ventilation by an indirect method (off-line)
45998021|NCT02908230|Behavioral|Enhanced Care|8-week (nutrition, physical activity, and mental health) summer curriculum/program
45998022|NCT02908230|Behavioral|Standard Care|8-week (nutrition and physical activity) summer curriculum/program
45998023|NCT02908230|Behavioral|Active Control|8-week (non-nutrition, physical activity or mental health) summer curriculum/program
46086127|NCT05579561|Other|Diet|Participants, in both groups, will be required to eat a diet that is very low in carbohydrates, moderate in protein, with added healthy fats. They will also have to breath in the device to estimate the level of different exhale gaz.
46086128|NCT02743754|Other|Standard therapy|The standard of care for improving oxygen delivery to the kidney. These may include blood transfusions for anemia, treatment of low blood pressure and oxygen for low blood oxygen levels.
46086129|NCT02743754|Other|Hyperbaric Oxygen|The standard of care therapies and in addition will be treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 ATA.
46086130|NCT04230707|Other|Endogenous Melatonin Levels|High Endogenous Melatonin Levels is Group 1 Low Endogenous Melatonin Levels is group 2
45675435|NCT05886296|Behavioral|Evaluation of the impact of a pre-surgical information session for people who must undergo shoulder rotator cuff surgery on empowerment for their functional rehabilitation process.|To evaluate the effect of the implementation of an information session for people who have to undergo rotator cuff surgery of the shoulder on the post-operative evolution of functionality, quality of life, empowerment and self-efficacy in the three months of the surgical intervention.
45998024|NCT04647422|Behavioral|Analysis of executive functioning and of social cognition processes|"Investigation of executive and social cognition processes using a comprehensive, neuropsychological assessment, An Eye tracking investigation and Task-based MRI exams.~Evaluation of addictive, psychiatric and neurological comorbidities.~Neuropsychological assessment establishing the participants' cognitive profiles of executive functions and of social cognition~An Eye tracking investigation aiming at a better understanding of participants' emotional processing~Task-based MRI exams identifying participants' neuroanatomical and neurofunctional correlates of executive functions and of social cognition processes"
45998025|NCT02908152|Dietary Supplement|curcumin|"1500 mg~1 capsule / day for 12 weeks"
45675436|NCT05886257|Drug|Candonilimab|10mg/kg, iv.drip, every 3 week
46086131|NCT03943667|Drug|Gemcitabine|1000 mg/m² in IV infusion over 30-40 minutes at Day 1, 8 and 15 followed by one week of rest.
45675437|NCT05886257|Drug|Bevacizumab|15mg/kg, iv.drip, every 3 week
45675438|NCT05886244|Drug|Eculizumab|Participants will receive 600 milligrams (mg) once a week on Day 1, 8, 15, and 22 followed by 900 mg every 2 weeks from Day 29 to Day 435.
45675439|NCT05886231|Other|music sound therapy|investigate the effects of music on intraoperative hemodynamic parameters, anesthesia depth, muscle relaxant consumption, analgesic consumption and pain and side effects (nausea, vomiting, tremor) in the early postoperative period in patients undergoing thyroidectomy operation under general anesthesia.
45998026|NCT02908152|Dietary Supplement|placebo|"1500 mg~1 capsule / day for 12 weeks"
45998027|NCT01237327|Drug|Megestrol acetate|Megestrol Acetate 160 mg oral tablets Qd
45998028|NCT01237327|Drug|exemestane (Aromasin)|exemestane (Aromasin) 25 mg oral tablets Qd
45998029|NCT02907021|Drug|standard-of-care treatments for LV impairment|Treat patients with mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
45998030|NCT01237054|Drug|18-NaF PET|The patient will receive 5mCi of F-18 NaF IV (intravenous) bolus, followed by a ~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of ~20 seconds. Serial dynamic imaging (2 minutes/bed position) will be obtained over a 1-hour period. The patient will be permitted an imaging break until a static PET/CT is performed beginning at 2-hours post F-18 NaF injection.
46086132|NCT03943667|Drug|Paclitaxel|80 mg/m² in IV infusion over 60 minutes at Day 1, 8 and 15 followed by 1 week of rest.
46086133|NCT02735798|Drug|MM-302|
46086134|NCT02735798|Drug|Trastuzumab|
46086135|NCT02735564|Procedure|Bariatric Surgery|
46086136|NCT02867735|Drug|LKA651|Interventional
45675440|NCT05886218|Device|Quantitative Neuromuscular Function Monitoring|Quantitative electromyographic (EMG) monitoring
45675441|NCT05886205|Drug|iPSC-Exos|iPSC-Exos were administrated for nasal drip, bid for 12 weeks.
45675442|NCT05886192|Drug|norepinephrine+vasopressin|Norepinephrine combined with vasopressin to maintain blood pressure
45675443|NCT05886192|Drug|Norepinephrine|norepinephrine
45675444|NCT05886179|Other|cross-sectional study|analytical cross-sectional study with retrospective collection of epidemiological surveillance data on COVID-19 in Niger.
45834887|NCT03823248|Drug|Folic Acid Tablet simulation|oral administration of folic acid simulation tablets half a hour after meal for 5 mg each time for 3 times a day.
45834888|NCT03822936|Drug|Preoperative chemotherapy|Preoperative chemotherapy, carbon ion therapy, surgery
45834889|NCT03822936|Radiation|Preoperative radiotherapy|Preoperative chemotherapy, carbon ion therapy, surgery
45834890|NCT03822624|Dietary Supplement|Probiotic|Probiotic mixture with three bacterial strains with maltodextrin as a carrier.
45834891|NCT03822624|Other|Placebo|Placebo comparator with maltodextrin as a carrier.
46086137|NCT02867735|Other|Sham Comparator|
46086138|NCT04067843|Procedure|Photodynamic treatment|Photosensitiser application, followed by fluorescence photography Photodynamic therapy (PHT) (1x) over 15 minutes
46086139|NCT03760718|Drug|Preservative free 1% Chloroprocaine|40 ml of preservative-free 1% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
46086140|NCT03760718|Drug|Preservative free 2% Chloroprocaine|40 ml of preservative-free 2% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
46086141|NCT03760718|Drug|Preservative free 3% Chloroprocaine|40 ml of preservative-free 3% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
46086142|NCT05575895|Dietary Supplement|Ingestion of the energy drink (Red Bull®)|Ingestion of 250 ml of the energy drink (Red Bull®)
45998031|NCT01237054|Other|DCE-MRI|An FDA (Food and Drug Administration) approved gadolinium chelate (e.g. Magnevist, Berlex Laboratories, NJ, USA) will be administered intravenously at 3 cc/sec using an automated pump injector (Medrad, Pittsburgh, PA, USA).
45998032|NCT01237054|Drug|18-FDG PET/CT|The 18F-FDG injection procedure will be injected and be followed by a ~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of ~20 seconds. The injection site will be evaluated pre- and post administration for any reaction (e.g. bleeding, hematoma, redness, or infection). Whole body (vertex to toes) static PET/CT imaging will be performed beginning at 1-hour, and again at 2-hours post injection.
45998033|NCT02906982|Other|Gum health formulation in intra-oral device|The intervention is a gum health formulation for periodontal disease care and teeth whitening to be used within an accelerating intra-oral device.
46086143|NCT05575895|Dietary Supplement|Ingestion of mineral water|Ingestion of 250 ml of mineral water (Minalba®)
45675445|NCT05886166|Other|robot assisted training|Rebless® (H-ROBOTICS, KOREA) is a knee or ankle robot for range of motion (ROM) and strength training that can operate in passive or active mode in knee or ankle flexion and extension. The patients underwent 30 min of robot training using Rebless® with 30 min conventional therapy, 5 days a week for 8 weeks.
45998034|NCT02906982|Other|Gum health formulation on toothbrush|The intervention is a gum health formulation for periodontal care and teeth whitening to be used on a toothbrush alongside standard toothpaste.
45998035|NCT04319536|Other|no intervention|self-sampling
45998036|NCT04647695|Drug|Interferon beta-1b|a 5-day course of subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
45998037|NCT04647695|Drug|Remdesivir|a 5-day course of IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
45675446|NCT05886153|Device|Vitaliti Continuous Vital Sign Monitor Model CVSM-1A|Measurements recorded by the Vitaliti CVSM device will be compared to the recordings from various standardized comparator devices.
45675447|NCT05886140|Drug|Carrilizumab with albumin-binding paclitaxel|All enrolled patients received carrilizumab combined with albumin-binding paclitaxel.
45675448|NCT05886127|Device|A novel hemostatic agent (Purastat®)|A novel hemostatic agent (Purasta®) will be applied on cutted ampulla of Vater
45998038|NCT02908113|Behavioral|collection data|
45998039|NCT02908113|Behavioral|IRM|
45675449|NCT05886101|Behavioral|Health Education|Health education will be provided to the intervention group on health literacy, self care, productivity improvement
45675450|NCT05886088|Drug|LID104|Experimental
45675451|NCT05886088|Drug|Dapagliflozin|Active comparator
45675452|NCT05886088|Drug|Linagliptin|Active comparator
45998040|NCT04647305|Other|Closed face shield with Surgical face mask use|Use of a closed face shield with a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and proper use of the closed face shield and the surgical face masks.
45998041|NCT04647305|Other|Surgical face mask use only|Use of a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and the proper use of surgical face masks.
45998042|NCT04647344|Drug|AK104 plus Carboplatin and Pemetrexed|Subjects receive AK104 15mg/kg intravenously (IV) plus pemetrexed 500 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV plus pemetrexed 500 mg/m^2 IV Q3W until progression.
45998043|NCT04647344|Drug|AK104 plus Carboplatin and paclitaxel|Subjects receive AK104 15mg/kg intravenously (IV) plus paclitaxel 175 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV IV Q3W until progression.
46086144|NCT05590286|Drug|Vonoprazan Tablets|Vonoprazan 20 mg, tablets, orally，QD
46086145|NCT05590286|Drug|Amoxicillin Capsules|Amoxicillin 750mg, Capsules ,orally，QID
46086146|NCT05590286|Drug|Esomeprazole|Esomeprazole 20mg, Capsules ,orally，BID
46086147|NCT05575193|Other|Acupressure|The patients will receive 4 acupuncture points, including Quchi acupoint, Xuehai acupoint, Sanyinjiao acupoint, and Zusanli acupoint. Each acupoint will be pressed for 3 minutes, and totally 4 acupuncture points are 12 minutes.
45675453|NCT05886075|Drug|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
45675454|NCT05886062|Other|Motor Imagery to Facilitate Sensorimotor Re-Learning Training|In order to motor imagery to facilitate sensorimotor re-learning training will be given for 20 minutes a day, 3 days a week, for a total of 8 weeks. Basketball-specific movement patterns will be used (squat, single leg jump, side stepping, standing on one leg, squat on one leg, etc.). Exercises will be started from easy and progressed to more advanced levels. During the exercise, the person will not only be physically active, but will be asked to dynamically visualize the determined scenario. Thus, a holistic exercise program will be applied both physically and psychologically.
45675455|NCT05886062|Other|Control Group|They will only continue their routine basketball technical-tactical training.
45675456|NCT05886023|Dietary Supplement|High nitrate vegetables|Vegetable burger containing high nitrate vegetables
45998044|NCT02906748|Procedure|injection with a syringe in new-site for parathyroid autografting|new-site for parathyroid autografting, close to the antecubital vein
45998045|NCT02906748|Procedure|injection with a syringe in traditional site for parathyroid autografting|traditional-site for parathyroid autografting,not intensively close to the antecubital vein
45998046|NCT04647149|Behavioral|Dietary Approach|Dietary approaches with energy restriction performed at different times of the day.
46086148|NCT03439748|Behavioral|Positive Affect Treatment|Sessions 1-7: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects (continued for sessions 8-15) Sessions 8-10: Cognitive exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention.
45675457|NCT05886023|Dietary Supplement|Low nitrate vegetables|Vegetable burger containing to low nitrate vegetables
45675458|NCT05886010|Device|prototypes 1 everyday|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
46086149|NCT03439748|Behavioral|Negative Affect Treatment|Sessions 1-7: Exposure therapy to feared or avoided situations, sensations, or memories (continued for sessions 8-15) Sessions 8-10: Cognitive restructuring of probability, cost, and attributional biases Sessions 11-14: Capnometry-assisted respiratory training Session 15: Relapse prevention
45675459|NCT05886010|Device|prototypes 1 every week|Application on brown spots located on the face and/or the hand (12 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
45834892|NCT03822546|Other|Conventional cigarette|Subject's own conventional cigarette brand smoked with puffs taken at 30 seconds intervals
45834893|NCT03822546|Other|myblu 25 mg freebase|E-cigarette used for 10 inhalations every 30 seconds
46086150|NCT02735408|Other|Kinesiotape (KT)|
46086151|NCT03937193|Diagnostic Test|computerized tomography|abdomen contrast computerized tomography performed for both emergency and elective purposes in HK public hospitals.
45457466|NCT03920917|Procedure|Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation|"Pulmonary vein isolation will be performed using a radiofrequency catheter.~Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.~Additional superior vena cava-right atrial septal linear ablation will be performed with a radiofrequency catheter.~If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~Evaluated the procedure and radiofrequency ablation time.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
45457467|NCT03510676|Device|NiTiDES|
45457468|NCT03918733|Procedure|surgical treatment|surgical treatment will be done of failed root canal treated teeth
45457469|NCT03918733|Procedure|Non surgical retreatment|Non surgical retreatment will be done.
45834894|NCT03822546|Other|myblu 16 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
45834895|NCT03822546|Other|myblu 25 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
45834896|NCT03822546|Other|myblu 40 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
45834897|NCT03822546|Other|blu PRO 48 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
45834898|NCT04391088|Other|vaccine coverage assessment|vaccine coverage assessment
45998047|NCT02906865|Other|Proximal hamstring tendons repair|Proximal hamstring tendons repair
45998048|NCT04647266|Procedure|endoscopic submucosal dissection|endoscopic submucosal dissection
45998049|NCT02907957|Device|FLIR ONE|Thermographic assessment of the lower extremities is obtained using the FLIR ONE smartphone camera and software.
45998050|NCT02907957|Procedure|Regional Anesthesia - Caudal Nerve Block|Nerve block placement as a pain management strategy indicated for certain urological and lower extremity surgeries.
46086152|NCT02743286|Behavioral|Frequent sit-to-stands|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 15 2-minute standing interruptions, 3 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
46086153|NCT02743286|Behavioral|Walking breaks|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 2-minute walking interruptions, 3 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
45998051|NCT04646954|Diagnostic Test|Host DNA methylation testing|Host EPB41L3, JAM3 and PAX1 methylation testing by cytology sample
45998052|NCT04646954|Diagnostic Test|Cervical cytology and/or high-risk human papillomavirus assays|Cervical cytology and/or high-risk human papillomavirus assays
45998053|NCT04647188|Other|Robotic assisted surgery with IDR data capture|Robotic assisted surgery with digital point of care data capture using Intuitive Data Recorder (IDR) technology
45998054|NCT04646876|Drug|Magnesium Sulfate|Prospective , comparative , double blind study
45675460|NCT05886010|Device|prototypes 1 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
46086154|NCT02743286|Behavioral|Stand more|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 10-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
46086155|NCT02602769|Diagnostic Test|Transcriptome profiling|The investigators will obtain blood to extract peripheral mononuclear cells. These cells will be used to generate patient specific hypothalamic cells that will be used for transcriptome profiling.
45675461|NCT05886010|Device|prototypes 2 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
46086156|NCT02695238|Procedure|Prophylactic Manual Rotation of persistent occipital posterior presentation|prophylactic manual rotation of persistent occipital posterior presentation on operative delivery will be performed in the experimental group
46086157|NCT04051073|Device|Continuous non-invasive blood pressure monitoring|Continuous non-invasive blood pressure monitoring using CNAP
45458741|NCT04371640|Drug|Sirolimus 1 MG/ML|Oral solution
46086158|NCT02743208|Device|Short stem hip arthroplasty (SHA)|Furlong Evolution femoral stem
46086159|NCT02743208|Device|Total hip arthroplasty (THA)|Furlong H-A.C. femoral stem
46086160|NCT02743130|Dietary Supplement|Blackcurrant Nectar|Consumption of a single dose (300 ml)
46086161|NCT02743130|Dietary Supplement|Lingonberry Nectar|Consumption of a single dose (300 ml)
46086162|NCT02743130|Dietary Supplement|Reference|Consumption of a single dose (300 ml)
46086163|NCT02965469|Behavioral|Breathe2Relax|The app teaches diaphragmatic breathing and has audiovisual coaching
45998055|NCT04646876|Drug|Placebo|Prospective , comparative , double blind study
45998056|NCT04646915|Other|Day surgery|Patients with CuRC who meet the standards will be assigned to day surgery center for surgery
45998057|NCT02906904|Other|Case Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, triggering of parasomniac episodes by auditory stimulations, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, parasomniac episodes, NREM stage 2 ans SWS
45998058|NCT02906904|Other|Control Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, NREM stage 2 ans SWS
45998059|NCT02908035|Drug|Temsirolimus|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
45998060|NCT02908035|Drug|Saline|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
46086164|NCT02735486|Dietary Supplement|Ginger drink|300 ml ginger drink
46086165|NCT02735486|Dietary Supplement|Placebo: Super pure water|Placebo: Super pure water
46086166|NCT04784585|Behavioral|Enhanced Education|"The Enhanced Education intervention option seeks to: 1) enhance understanding of personal health-behavior links, 2) improve health literacy by checking the adequacy of participant understanding, and 3) remind participant of important elements of Behavioral Obesity Treatment (BOT) dietary goals."
45458742|NCT04371640|Drug|Placebo|Oral solution
45458743|NCT04356196|Drug|Verapamil|Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina
45458744|NCT04356196|Drug|Bisoprolol|Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.
45998061|NCT04646759|Drug|Fulvestrant combined with Pyrotinib|Fulvestrant 500mg was injected intramuscularly on D1, D15, D28 and D28 Pyrotinib 400mg daily
45998062|NCT04646759|Drug|Capecitabine combined with Pyrotinib|Capecitabine 1000mg/m^2 bid d1-d14，every 21 days Pyrotinib 400mg daily
45998063|NCT02906826|Device|Video game|Video game operated by performing therapy correctly
45998064|NCT04646798|Other|Hemiarthroplasty|standard surgical approaches to repair of fractured elbows
46086167|NCT04784585|Behavioral|Self-Efficacy|"This intervention option is based on a previously established self-efficacy intervention for weight loss, which is a multi-component intervention for increasing self-efficacy. To provide variety in this intervention option and limit time spent in a single intervention, components are split into independent modules that either prompt: 1) attainable intention setting related to dietary adherence (e.g., I will focus on eating mostly fruits/vegetables in my next meal/snack in order to take back control of my eating); 2) barrier identification for adhering to dietary goals along with a brief problem-solving exercise; 3) devising a small self-reward; OR 4) self-assessment of thoughts/behaviors that could interfere with dietary adherence in the next several hours with coping strategies (e.g., stimulus control, social support)."
45457470|NCT03511924|Behavioral|Intradialytic resistance training|Progressive resistance training programme performed during haemodialysis, taking into account subject´s medical review summarizing: A. full medical history, B. clinical examination including cardiovascular assessment, C. detailed medication usage history, D. review of recent biochemistry and haematology records and results of lower extremity muscle strength assessments. Construction of intradialytic training programme followed recommendations published by the Exercise & Sports Science Australia (Smart et al., 2013).
45675462|NCT05886010|Device|prototypes 3 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
45675463|NCT05885997|Behavioral|Supported HBPM program plus multifaceted implementation strategy|"Supported HBPM Progam:~Wireless home BP devices~Navigator support for onboarding and engaging patients in HBPM~Nursing support for monitoring home BP data for extreme readings~Multifaceted implementation strategy:~EHR integration of HBPM order and data~Clinician education about the benefits of the program as well as training in how to refer and manage patients who are enrolled~Prompts and reminders to increase clinician referrals~Instructional materials for patients~Problem-solving meetings to tailor implementation for individual practices"
45998065|NCT04646798|Other|Total elbow arthroplasty|standard surgical approaches to repair of fractured elbows
45457471|NCT02303002|Biological|Botulinum Toxin Type A|Intramuscular injection (IM)
45457472|NCT02303002|Biological|Active Comparator botulinum toxin|IM injection
45457473|NCT02303002|Biological|Placebo Comparator|IM injection
45457474|NCT02297854|Drug|Valganciclovir Hydrochloride|Valganciclovir Hydrochloride Tablets 450 mg
45675464|NCT05885997|Other|Usual care|Usual care
45834899|NCT04273152|Diagnostic Test|advanced glycation endproducts reader|advanced glycation endproducts reader
45834900|NCT01453452|Behavioral|behavioral dietary intervention|Reduce caloric intake by 500 kcal/day, increase fruit and vegetable intake to 5 or more servings per day, and limit daily calories from fat to be < 30%. Diet will be measured using 3 repeated 24-hr diet recalls. Participants will receive information on the recommended dietary modifications via mailed materials and telephone counseling sessions.
45834901|NCT01453452|Behavioral|exercise intervention|150 min/wk of moderate exercise through use of the Curves® centers, engage in physical activity outside of Curves®, and use pedometers to track activity.
45834902|NCT01453452|Other|counseling intervention|14 40-min behavioral counseling sessions via telephone with the goal of increasing intervention adherence and increasing participant retention.
45834903|NCT01453452|Procedure|quality-of-life assessment|PROMIS-43 - online questionnaire to assess quality of life.
45834904|NCT02910024|Device|Magstim Super Rapid2 System, intermittent theta-burst-stimulation (iTBS) protocol|iTBS applied over ipsilesional M1
45457475|NCT05401669|Procedure|Trans-radial access|Cerebral angiography performed by trans-radial access
45457476|NCT05401669|Procedure|Trans-femoral access|Cerebral angiography performed by trans-femoral access
45834905|NCT02910024|Device|Magstim Super Rapid2 System, sham-stimulation (in iTBS)|iTBS applied with tilted coil over parieto-occipital vertex
45998066|NCT02907801|Behavioral|Perception-Action Approach|Environmental set-up, gentle manual guidance, and caregiver education
45458745|NCT04356196|Drug|Placebo oral tablet|Placebo oral tablet
45998067|NCT04646525|Diagnostic Test|Physical examination|Pediatric patients diagnosed with COVID-19 and who have had infection will be examined, adenoid and tonsillar tissues will be evaluated in terms of hypertrophy, chronic, or recurrent infection.
45675465|NCT05885984|Behavioral|Acceptance and Commitment Therapy (ACT) plus health education|Session 1: Reviewing experiences on struggles with CRF, realising consequence of controlling, introducing acceptance as an alternative, adopting virtual mindfulness. Education (patient): epidemiologic features of advanced lung cancer. Session 2: Separate thoughts/feelings related to CRF. Education (patient): treatments and symptoms of advanced lung cancer. Session 3: Reviewing caregiver's experiences of struggling with caregiving burden,introducing acceptance as an alternative. Education (caregiver): epidemiologic features of advanced lung cancer. Session 4: Separate caregivers' thoughts/feelings related to caregiving burden. Education (caregiver): treatments and symptoms of advanced lung cancer. Session 5:Understand the importance of values and clarifying personal values for dyads. Education (dyads): eating suggestions. Session 6: Emphasise ongoing value-based goals and commitment to actions for a meaningful cancer life for dyads. Education (dyads): exercising suggestions.
45675466|NCT05885984|Other|Health education|Session 1: health education on the epidemiologic features of advanced lung cancer will be taught to patients. Session 2: health education on treatments and related symptoms of advanced lung cancer will be taught to patients. Session 3: health education on the epidemiologic features of advanced lung cancer will be taught to caregivers. Session 4: health education on treatments and related symptoms of advanced lung cancer will be taught to caregivers. Session 5: health education on eating suggestions for advanced lung cancer patients and caregivers will be taught. Session 6: health education on exercising suggestions for advanced lung cancer patients and caregivers will be taught.
45998068|NCT02906514|Drug|Non balanced Hydroxyethyl starch 130/0.4 (Voluven®, Fresenius)|1000mL used for cardiopulmonary bypass priming
45998069|NCT02906514|Drug|Sodium Chloride 0.9% (Fresenius)|1000mL used for cardiopulmonary bypass priming
46086168|NCT04784585|Behavioral|Motivation|"To provide variety in this intervention option and limit time spent in a single intervention, components are split into independent modules that either: 1) guide participants in identifying values related to weight control (e.g., longevity, quality of life, being a role model) and connect those values to their behavior in the current moment.; 2) use a collaborative non-judgmental approach to explore the consequences of letting barriers drive behavior (e.g., Take a moment to consider the effect on your longevity if you let your preference for sweets determine your behavior.); 3) prompt participants to identify reasons for change, thereby eliciting change talk; OR 4) engage participants in a brief self-assessment of motivation for dietary adherence (i.e., On a scale of 1-10, how important to you is it to stick to your dietary goals today)."
46086169|NCT04784585|Behavioral|Self-Regulation|"There are 4 independent modules that prompt self-monitoring and self-awareness efforts: 1) advise participants to record everything that they eat before they eat it, with attention to eating in the subsequent few hours; 2) use the traffic light model to enhance awareness of dietary intake. This module provides the traffic light categories of foods (i.e., green=healthiest choices, yellow=sometimes choices, and red=rare choices), and asks participants to check-off foods that they intend to eat vs. stay away from in the next few hours; 3) advise participants to track portion sizes carefully and provide a portion size guide that is available to them until the following EMA survey; OR 4) provide a tutorial on noticing hunger/satiety cues and slowing down rate of eating, with an experiential exercise for use during their next eating episode."
45457477|NCT03515356|Behavioral|MI-Walk Intervention|Eight-week motivational enhancement therapy and home-based aerobic walking intervention
45675467|NCT05885971|Diagnostic Test|Administration of the SCOFF-F and EDE-Q questionnaires|The participants will answer to the SCOFF-F and EDE-Q questionnaires as well as socio-demographic questions
45675468|NCT05885958|Other|Time|Patients will be given up to 30 minutes to void.
45998070|NCT02907840|Device|Swisstom BB2|Electrical impedance tomography lung monitoring uses a dedicated belt placed around patient's thorax to detect change in impedance due to change in aeration within the thorax
45998071|NCT02906475|Other|standardized skin care regimen|"Application of a standardized daily skin care regimen:~milk lotion once daily and~application of addendum for bathing as needed"
45998072|NCT04646252|Other|Perfused Boundary Region of sublingual microvessels|Measurement of Perfused Boundary Region of sublingual microvessels to assess thickness of endothelial glycocalyx
45998073|NCT02907723|Device|Sleep Recording|the device records movements during patients' sleep
45998074|NCT02907567|Drug|CT1812|Active study drug
45998075|NCT02907567|Drug|Placebo|non-active study drug
45998076|NCT04646018|Other|Lumbar Spine Manipulation|Lumbar non-thrust manipulation is a passive movement that is performed with a rhythm and a grade in a manner in which the patient is able to prevent the technique from being performed.
45998077|NCT04646018|Other|Sham Manipulation|Lumbar non-thrust manipulation without force applied
45998078|NCT02906436|Device|Xvivo Chamber|
45998079|NCT04646135|Drug|Lorazepam 4 mg/ml|Lorazepam will be administered intravenously according to the scheduled sequences.
46086170|NCT04784585|Behavioral|Generic Risk Alert (Active Comparator)|"Participants will be notified that the JITAI algorithm has determined heightened lapse risk in the following 2-3 hours (i.e., We have detected that your risk of lapsing from your weight loss diet is higher than usual and may require attention.)."
45998080|NCT02906553|Drug|Glyceryl Trinitrate|
46086171|NCT04784585|Behavioral|Online Behavioral Obesity Treatment|The online BOT consists of: (a) 12 weekly multimedia lessons for training in behavioral weight loss skills; (b) online tools for self-monitoring weight, diet, and physical activity; and (c) weekly automated text-based feedback on progress to date. Participants are given a goal of losing 1-2lbs per week to achieve a total weight loss of ≥10% of initial body weight. Participants are prescribed a calorie goal of 1200-1800 kcal/day tailored on initial weight. Participants are given guidelines to follow a lowfat or Mediterranean diet to meet the prescribed calorie goal. Participants are given a physical activity goal tailored on initial activity level that gradually increases to 200 min/wk of activity, emphasizing brisk walking as the primary form of activity. They also receive a primer in self-monitoring weight, diet, and physical activity. Participants are instructed to self-monitor and follow the prescribed diet for the 6-month study period.
45998081|NCT02906553|Drug|Placebo|
45998082|NCT04646291|Device|Insemination with the Mosie Baby Kit|The participant will have performed at least one cycle of insemination using the Mosie Baby Kit.
45998083|NCT02907684|Dietary Supplement|Almonds|Participants to consume almonds as snacks to contribute to 20% of their energy requirements daily for 4 weeks
45998084|NCT02907684|Dietary Supplement|Muffins/Crackers|"Participants to consume muffins/crackers as snacks to contribute to 20% of their energy requirements daily for 4 weeks~NB all participants will have a run in period for 2 weeks whereby muffins are consumed, this is prior to randomisation."
45998085|NCT04646096|Device|MAKO THA 4.0 System|"Measure how the accuracy and precision of robotic arm-assisted total hip arthroplasty (THA) for placement accuracy of implant position in both the anterior and posterior approach.. The intervention will assess the precision of the MAKO system in placing hip components according to plan. It will compare hip angles executed by the Mako system intraoperatively with the 'gold standard' of 3D computer tomography (CT) scans.~The postoperative CT scan can show the precision of the MAKO system by accurately determining the location of hip replacements in patients after surgery."
45998086|NCT04681989|Behavioral|Moving On After Breast Cancer|"After the MOVE-ABC interventional group participant completes their baseline assessment (T0) and been given the study survey by a research staff member she will receive the following:~Instructions on how to use the physical therapy-based education materials by a research staff member~a range of motion wand~a small ball~MOVE-ABC education booklet and video~The intervention group will complete 4 weekly follow-ups with a research staff member over the phone. The follow-ups will be completed in between the T0 (baseline) assessment, and the T1 (1 month after baseline) assessment."
45998087|NCT04646447|Dietary Supplement|L-serine|"L-Serine Arm L-serine is considered as GRAS (generally recognized as safe) by the FDA and has been approved as a normal food additive under CFR172.320.~All patients will receive the same L-serine dose treatment over 12 months. Arm: Experimental: L-Serine 250 mg / kg / day during the first two weeks. From week 3 to 52, 500 mg / kg / day. L-serine orally administered, divided into three doses a day.~The L-Serine will be manufactured, packaged, labeled and/or distributed by NUTRICIA or delegated contractors. It will be presented in a powdered form of 100 gr of the amino acid L-serine. For oral use.~Sufficient L-serine will be dispensed at home considering the dose according the weight of the patient."
45998088|NCT04682184|Drug|Propranolol|Administered orally.
45998089|NCT04682184|Drug|Pseudoephedrine|Administered orally.
45998090|NCT04682184|Device|Wearable Biosensor Patch Device|Biosensor patch device attached to the chest and worn throughout the trial with replacement of biosensor every 7 days.
45998091|NCT02907450|Device|TwiCare®.|
45998092|NCT04645901|Drug|Drug: SYHA1805 tablets|Oral tablets of SYHA1805 with several doses
45998093|NCT04645901|Drug|Placebo|Oral tablets of placebo with matching several doses
45998094|NCT04645940|Drug|fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole|"fruquintinib 5 mg with food on Day 1 and fruquintinib 5 mg without food on Day 15.~40 mg rabeprazole from Day 23 to Day 28. 40 mg rabeprazole one hour before 5 mg fruquintinib Day 29."
45998095|NCT04645940|Drug|fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole|"fruquintinib 5 mg without food on Day 1 and fruquintinib 5 mg with food on Day 15.~40 mg rabeprazole from Day 23 to Day 28. 40 mg rabeprazole one hour before 5 mg fruquintinib Day 29."
45998096|NCT02906280|Device|EBUS-TBNA needle|tissue sampling
45998097|NCT02906085|Drug|Endothelin-1|
45998098|NCT02906085|Drug|Placebo|Isotonic saline
46086172|NCT03744728|Diagnostic Test|Accelerate PhenoTest™ BC kit|The Accelerate PhenoTest™ BC kit with the Accelerate Pheno™ System is a fully-integrated in vitro diagnostic system. It is FDA-cleared to perform ID of bacteria and yeast in less than 90 minutes and AST in less than 7 hours, on average, directly from positive blood culture
46086173|NCT03744728|Diagnostic Test|Standard of Care|Standard culture and AST of positive blood culture bottles plus the Verigene® BC-GP/GN
46086174|NCT05580029|Device|Triamcinolone Topical|The treatments will consist of fractional ablative CO2 laser therapies followed by topical application of triamcinolone dosed at 40 mg/ml.
46086175|NCT05580029|Procedure|Fractional Ablative CO2 Therapy|1st pass: 30-40 mJ at 5% density. 2nd pass: 120 mJ at 1% density
45998099|NCT00558506|Drug|abatacept|intravenously 750mg (in patients with weight of 60- 100kg)
45998100|NCT02907411|Other|Quadrivas Therapy|Quadrivas therapy will be applied to subjects. Quadrivas therapy is a intensive massage therapy for different tissues. Subjects will receive 12 treatments. The first lasting 2.5 hours and the remaining 11 lasting 1.5 hours.
45998101|NCT00558545|Drug|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly only on weeks when paclitaxel is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
45998102|NCT02907645|Behavioral|Local educational information|Adult patients in this arm receive educational information regarding influenza vaccination based on local data
45998103|NCT02907645|Behavioral|National educational information|Adult patients in this arm receive educational information regarding influenza vaccination based on national data
46086176|NCT05580029|Drug|EMLA 5% cream|2 g/10cm2 Topical 30 minutes before each fractional ablative CO2 session
46086177|NCT02740400|Procedure|EBUS-GS|The equipment for EBUS-GS includes super-thin bronchoscope BF-P260F, endobronchial ultrasonic system EU-M30S, ultrasonic probe UM-S20-17S, and guided sheath kit K201. All facilities are provided by Olympus Co. The EBUS-GS procedure was performed by thoracic surgeons. The patient was in supine position, under general anesthesia, and provided ventilatation through laryngeal mask. First, the operator placed super-thin bronchoscope into the bronchus of interest, inserted the probe covered with GS through a work channel. Later, adjusted the bronchoscope and probe to obtain classical ultrasonic graphs. The assistant fixed the bronchoscope, pulled the probe out, and placed the brush and biopsy forceps, respectively, through the GS. This process was assisted using x-ray fluoroscope or not.
45998104|NCT00558623|Dietary Supplement|calcium carbonate|daily supplement of 1,200 milligrams calcium (two-600 mg tablets calcium carbonate at bedtime)
45998105|NCT02905968|Device|transanual tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
45998106|NCT00558662|Device|Coban 2|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
45998107|NCT00558662|Device|SSB|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
45457478|NCT03515356|Behavioral|Physical Activity Education Pamphlet|Physical activity education pamphlet only
45675469|NCT05885958|Other|Time|Patients will be given up to 60 minutes to void.
45675470|NCT05885932|Procedure|Drug-eluting stenting plus aspirin and clopidogrel or ticagrelor|All the participants in this group will be performed with extracranial vertebral artery sirolimus-eluting stenting plus medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
45998108|NCT02906046|Device|Weight in Lower Limbs|
45998109|NCT00558740|Other|high protein intake|acute high protein intake chronic (6-day) high protein intake acute+chronic high protein intake control
45998110|NCT02907528|Biological|Bone|Furcation defect regenerated with bone graft material
45998111|NCT02907528|Biological|EMD|Furcation defect regenerated with EMD
45998112|NCT04645472|Device|CT-Ultrasound|For patients with kidney stones who are planning to undergo PCNL, perform a preoperative simulated CT-ultrasound fusion examination to further clarify the condition of the kidney stones and simulate and optimize the puncture route. Apply CT- Ultrasound fusion precise positioning to guide the intraoperative PCNL puncture process.
45998113|NCT02905890|Drug|Norethisterone enantate|Noristerat® 200mg, solution for intramuscular injection given every 8 weeks
45998114|NCT02905890|Device|Condoms|Latex male condoms
45998115|NCT04645706|Other|Characteristics of innate T cells|functional and phenotypic characteristics of innate T cells
45998116|NCT02906163|Drug|Thymalfasin (Thymosin alpha 1, Ta1)|In Phase I patients will be randomized to one of two different dosing regimens of Thymosin alpha 1 for a treatment duration of 4 months. At the completion of Phase I, data will be reviewed and a single dosing regimen will be carried forward into Phase II.
45998117|NCT02906163|Drug|SoC (tyrosine kinase inhibitor)|In Phase II patients will be randomized to SoC or Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 18 months.
45675471|NCT05885932|Drug|Aspirin and clopidogrel or ticagrelor|All the participants in this group will be given medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
45675472|NCT05885932|Procedure|mono anti-platelet therapy|mono anti-platelet therapy
45675473|NCT05885919|Drug|Edaravone Dexborneol Concentrated Solution for injection|Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.
45675474|NCT05885919|Drug|Edaravone Dexborneol placebo|Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.
45998118|NCT04645745|Dietary Supplement|myo-inositol, alpha-lactalbumin, folic acid|Evaluating the improvement vs the baseline after three and six months of treatment
45998119|NCT02907060|Device|Mechanical cervical ripening|"The mechanical cervical ripening is a double transcervical balloon. The device used in the study is the Cook® Cervical Ripening Balloon with CE marked (commercialized by the Cook® laboratory, ref JCRBS-184000). It is a silicone double balloon catheter. Maximum balloon inflation is 80 mL/balloon.~It will be used in accordance with user manual"
45998120|NCT02907060|Drug|Pharmacological cervical ripening|"The comparative pharmacological procedure is a vaginal slow releasing system of dinoprostone. The form used in the study is Propess (Ferring pharmaceuticals) containing 10mg of dinoprostone (prostaglandin E2).~It will be used in accordance with Summary of Product Characteristics"
45998121|NCT04645277|Device|Scanning with magnetic resonance imaging|Facial nerves and adjacent blood vessels are scanned using MRI in the patients with hemifacial spasm (HFS). Then multiplanar reconstruction (two dimensional), along with curved planar reconstruction and magnetic resonance virtual endoscopy (three dimensional), will be performed in the different groups of HFS.
45457479|NCT05401591|Dietary Supplement|Protein shake|Participant will drink a protein shake made using each of the four protein types.
45998122|NCT02905851|Other|Feedback group|Monitoring ability to use teledermatology to modify antibiotic burden
45998123|NCT02905851|Other|Non Feedback group|To use as control to see if antibiotic burden has been reduced in the active feedback group
45998124|NCT04645043|Other|US_Eso|After applying ultrasound guided esophageal pressure, the peak inspiratory pressure increased from 10cmH2O to 24cmH2O (increased by 2 cmH2O) during mask ventilation.
45998125|NCT02905695|Drug|Chirocaine|
45675475|NCT05885906|Drug|Aloevera|Mouthwash
45675476|NCT05885906|Drug|Thyme honey|Mouthwash
45998126|NCT02905695|Other|Placebo|
45998127|NCT04645238|Other|Static Stretching|Static hamstring stretching exercise lasting 30 seconds and 10 repetitions under the supervision of the physiotherapist
45998128|NCT04645238|Other|PNF Stretching|PNF hold-relax stretching technique that consists of 10 seconds isometric contraction, 30 seconds hamstring stretching and 10 repetitions under the supervision of the physiotherapist
45998129|NCT02907333|Behavioral|Advice to use condoms|
45998130|NCT00558779|Procedure|OBCAB (Off Pump Coronary Artery Bypass Grafting)|OPCAB with sparing of aortic manipulation (eg, no aortic cannulation for cardiopulmonary bypass, no aortic cross-clamp, no side-clamping of the aorta). Graft anastomosis to the central circulation with y-grafts on the arteria thoracica interna or on the aorta with help of the Heart-string-system (Guidant)
45998131|NCT00558779|Procedure|CABG (coronary artery bypass grafting)|conventional CABG with cardiopulmonary bypass
45998132|NCT04645082|Diagnostic Test|x-ray examination|A total of 40 individuals who underwent an axial x-ray examination of the lower extremity following ankle sprain were included.
45675477|NCT05885906|Drug|Saline|Mouthwash
45675478|NCT05885880|Other|Blue-button screening|Patients will be screened for clinical trial matches using the Blue-button tool
45834906|NCT01453686|Drug|Hydrocortisone 1%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
45834907|NCT01453686|Drug|Clobetasol Propionate 0.05%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
45834908|NCT02983266|Device|InTENsity MicroCombo|An electrotherapy device.
45834909|NCT01459926|Drug|TD-1211|once daily
45834910|NCT01459926|Drug|TD-1211|Once daily
45834911|NCT01459926|Drug|TD-1211|Once daily
45834912|NCT01459926|Drug|Placebo|Once daily
45834913|NCT01456182|Drug|AFX-2|Dose level 1
45834914|NCT01456182|Drug|AFX-2|Dose level 2
45834915|NCT01456182|Drug|AFX-2|Dose level 3
45834916|NCT01456182|Drug|AFX-2|Dose level 4
45834917|NCT01456182|Drug|AFX-2|Dose level 5
45834918|NCT01455870|Drug|ITCA 650 60 mcg/day|exenatide in DUROS
45834919|NCT01455870|Drug|sitagliptin|oral sitagliptin 100 mg/day
45834920|NCT01456260|Drug|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
45998133|NCT02905773|Other|root canal therapy|effect of devices ( ProTaper and Reciprocal Files)
45998134|NCT02905773|Other|root canal retreatment|effect of devices ( ProTaper and Reciprocal Files)
46086178|NCT02740400|Procedure|CT-TTNB|The devices for CT-TTNB includes Lightspeed VCT spiral CT(GE co.) and Quickcore(COOK Co.) biopsy kit. The kit includes a sheath(5cm in length and 16G in outer diameter) and a automatic biopsy needle(15cm in length and 18G in outer diameter). The patient stays in supine, prone or lateral position according to the lesion's location. The first chest CT scan is performed to confirm the location of the lesion and make an optimal entry point. Then, after sterilization and 2% lidocaine local anesthesia, the sheath is stabbed into chest wall through the entry point. The second CT scan is performed to make sure that the sheath stays in proper angle and depth. The operator places the needle through the sheath and enter the lesion. Then fire the biopsy needle and repeat the procedure twice or third time. The last CT scan is conducted to determine whether pneumothorax or hemorrhage occurred.
45675479|NCT05885867|Behavioral|Seniors with mild cognitive impairment over 65 years of age|"A total of 30 subjects will perform four tasks per person for a single task (motor task) and a double task (motor task + cognitive task), and the test order will be randomly assigned. The subject's prefrontal cortex activity will be measured using fNIRS (NIRSIT, OBELAB).~The single task will be to perform a 10-meter walk test and an 8-way walk test as exercise tasks. as not affected by acceleration and deceleration. The dual task will be carried out together with the exercise task and the cognitive task. The cognitive task will be a simple calculation problem so that it can be performed without much difficulty when walking.Subjects will perform a total of three iterations and have a break of 20 seconds before each task begins."
46086179|NCT02743052|Drug|Anticoagulation treatment.|Details of anticoagulation treatment information will be gathered including low molecular-weight heparin (enoxaparin 1 mg/kg) vs. NOAC (rivaroxaban 15 or 20 mg), vs. warfarin (target INR2.0-3.0) or no use of anticoagulation per physicians' decision and patients' conditions.
46086180|NCT02742896|Other|Erectile dysfunction|"The changes of erectile function by using official questionnaire-The International Index of Erectile Function (IIEF)-5 1 year after conversion to sinus rhythm.~The changes of cognitive function by using validated assessment form-The Montreal Cognitive assessment (MoCA) 1 year after conversion to sinus rhythm."
46086181|NCT02740244|Device|active iTBS|Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a figure-eight coil (MCF-B65)
46086182|NCT02740244|Device|sham iTBS|Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a sham figure-eight coil (MCF-P-B65)
46086183|NCT02742974|Device|FloTrac™ and EV1000™|Interventions to improve cardiovascular performance will be made in all patients whose cardiovascular function is sub-optimal in accordance with routine clinical management during trauma resuscitation. Patients who meet inclusion criteria will be assigned to the intervention or control arm of the study based on the process outlined in the protocol. Patients assigned to the intervention arm will have intra-operative hemodynamic monitoring performed by the anesthesia staff and cardiovascular interventions will be based off of the algorithm described in the protocol. Members of anesthesia or the surgical team can initiate interventions as indicated during routine ICU care or intra-operatively.
45675480|NCT05885854|Drug|XTR003|"Enrolled subjects were required to fast for ≥ 6 hours before drug administration at rest;~Initial intravenous injection of 18F-FDG to each subject with a dose range of 2.0-3.0 mCi (74-111 MBq). Each patient will be imaged with PET for 10 minutes at 50-70 minutes after the injection.~In few minutes, a single intravenous bolus injection of XTR003 will follow and administer to each patient with a dose range of 6.0-8.0 mCi (222-296 MBq). Each patient will be immediately imaged with PET for 15 minutes."
46086184|NCT02742740|Behavioral|Chemo Buddy|The Study Buddy ECA acts as an advisor to patients on chemotherapy regimens, promoting protocol adherence and retention, providing anticipatory guidance and answering questions, serving as a conduit to capture information about complaints or adverse events, providing a venue for communicating about updates.
45675481|NCT05885841|Drug|XTR004|"At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi~At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi."
45675482|NCT05885828|Other|White bread|After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.
45675483|NCT05885828|Other|Whole wheat bread|After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.
45675484|NCT05885828|Behavioral|Plant-based diet|After wearing CGM on Day 1, participants will be asked to follow the plant-based diet in next 30 days.
45675485|NCT05885828|Other|Conventional diabetic diet|Volunteers will be asked to have a diet following 2023 Chinese Diabetes Society guidelines in next 30 days.
45675486|NCT05885828|Other|Follow-up visit every 1-2 years|Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted.
45675487|NCT05885802|Other|No specific intervention other than routine anesthesia protocol|No specific intervention other than routine anesthesia protocol
45834921|NCT01456260|Drug|Placebo|Lansoprazole placebo matching capsules, orally, once daily for 28-80 weeks.
45834922|NCT01456260|Drug|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
45998135|NCT04644848|Diagnostic Test|Ultrasonographical tattooing of suspicious axillary lymph nodes.|"Patients with clinically negative axillae scheduled for sentinel lymph node biopsy (SLNB) will have axillary ultrasonographical imaging of the ipsilateral axilla with a high-frequency linear probe. Suspicious lymph nodes are identified according to any of the following criteria:~Round shape.~Cortical thickness > 3 mm~Eccentric cortical thickness.~Loss of hilum.~For each patient, node dimensions and the presence of each of the above-mentioned criteria are recorded. Tattooing of all suspicious nodes is done using I ml of sterile liquid charcoal."
45998136|NCT04644848|Procedure|Sentinel lymph node biopsy|Sentinel node biopsy is performed with peri-areolar subdermal injection of 3 ml methylene blue 5%. The lymphatics are tracked to the first blue lymph node. All blue, enlarged and /or tattooed nodes are separately biopsied and labelled as SLN and/or tattooed node.
45834923|NCT01456260|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
45834924|NCT01456260|Drug|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
45834925|NCT01456260|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
45834926|NCT01452516|Device|nanOss Bioactive Bone void filler|Instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
46086185|NCT02740322|Procedure|Hum Test|The subject will be brought into an exam room. The subject will then be asked to hum for a few seconds in a low pitch. They will then be asked if the nose was heard more so in one ear compared to the other. The subject will then be asked to hum for a few seconds in a high pitch. They will then be asked again if the noise was heard more so in one ear compared to the other.
46086186|NCT02740322|Procedure|Weber Test|Using a 512 Hz tuning fork, the tuning fork will be vibrated and placed on the subject's glabella (forehead landmark). The subject will then be asked if the vibration was heard more so in one ear compared to the other.
46086187|NCT02740322|Device|Audiogram|A standard audiogram will be administered by an audiologist.
46086188|NCT05574764|Behavioral|Cultivating Awareness and Resilience in Education (CARE)|CARE provides teachers and staff with tools and resources to reduce stress, prevent burnout, enliven teaching, and help students thrive socially, emotionally, and academically. CARE blends instruction with experiential activities, reflection, and discussion.
46086189|NCT03724994|Drug|Gemcitabine|Adjuvant or palliative chemotherapy according to national guidelines
45675488|NCT05885776|Drug|Pyrrolidine、trastuzumab、AI|Subjects who met the inclusion criteria underwent surgery after 6 cycles of treatment with pirotinib+trastuzumab+AI, and their postoperative pathological remission was evaluated.
45998137|NCT04644848|Diagnostic Test|Histopathological examination of the axillary nodes|"All tattooed nodes are excised and sent to frozen section examination; labelled tattoo node.~All enlarged or blue stained nodes are excised and sent to frozen section examination; labelled sentinel node.~All nodes are bisected and a single 5 um section examined. All frozen section examinations are followed by routine paraffin section examination."
45998138|NCT04644848|Procedure|Further axillary management|Further axillary management is performed as per institutional guidelines. If SLNB is negative, no further surgery is required. Axillary lymph node dissection is performed if sentinel lymph node is positive or not identified. Management of positive SLNB as per the American College Of Surgeons' Oncology Group (ACOSOG) Z0011 protocol is not currently adopted on routine basis at the investigators' institution. In this study, patients with tattooed nodes with positive histopathological findings are offered full axillary dissection even if their sentinel nodes are negative.
45998139|NCT02907294|Drug|PBF-999 / 160 mg|2 capsule 80 mg x 8 days
45998140|NCT02907294|Drug|PBF-999 / 320 mg|4 capsule 80 mg x 8 days
45998141|NCT02907294|Drug|Placebo|2 capsules of placebo x 8 days 4 capsules of placebo x 8 days
45998142|NCT04644887|Other|Dietary intervention: Healthy diet|Dietary guidance in the intervention group is based on the Nordic and Finnish nutrition recommendations with an emphasis on the quality of dietary fat. The aims for the intake of fatty acids will be SFA < 10 % of energy intake (E%) and mono- and polyunsaturated fatty acids (UFA) >2/3 of the total fat intake. The key food products such as vegetable oil-based spread, liquid margarine and canola oil are provided to the participants. The participants are recommended to use fat free (e.g. milk, sourdough milk and yogurt) and low fat (e.g. cheese ≤ 17%) dairy products and low-fat meat, poultry, and fish as well as natural nuts and seeds.
45998143|NCT04644887|Other|Dietary intervention: Control diet|The control diet corresponds to the average nutrient intake in the Nordic countries, i.e. the intake of SFA about 15 E% and the proportion of UFA about 50 % of total fat intake. The participants of the control group will get butter-based spread for bread and cooking. They are recommended to use semi-skimmed milk (1,5 %), normal fat yogurt (~2%), normal fat cheese (~24-35 %) and avoid consumption of vegetable oils. They are allowed to eat a portion of fish and nuts once a week.
46086190|NCT02742662|Device|Wearable technology, smartscale|
46086191|NCT02742662|Behavioral|Smartphone applications|
46086192|NCT02742662|Behavioral|Standard Weight Management Visits|
46086193|NCT03845660|Behavioral|Electronic Alert|"Patients randomized to the intervention will have an alert of their prognosis based on the best available prognostic models for inpatient and 1-year mortality generated with information from their electronic health record, which will consist of a pop-up when the provider accesses a patient record to enter a progress note after the definitions for inclusions into the study have been registered."
46086194|NCT02740088|Other|Imaging test: 18F-NaF PET/CT|18F-NaF PET/CT as an imaging test
46086195|NCT02742584|Procedure|Cough Stress Test|Varying bladder volumes during cough stress test.
46086196|NCT02735330|Procedure|celiac plexus neurolysis using absolute alcohol|celiac plexus blockade with 40 ml of diluted absolute alcohol(50%) 20 ml on either side of celiac axis in a 4 quadrant fashion
45675489|NCT05885763|Drug|Difelikefalin Injection|Participants receive Difelikefalin three times a week (0,5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
45998144|NCT00553371|Other|biomarker analysis|
45998145|NCT00553371|Procedure|computed tomography|
45998146|NCT04644926|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) procedure comprise three repetitions of brachial cuff inflation to 200 mmHg for five minutes following deflation to 0 mmHg for another five minutes. The procedure overall took 30 minutes.
46086197|NCT02735330|Procedure|Placebo celiac plexus injection using saline|Placebo celiac plexus injection with 40 ml of saline 20 ml on either side of celiac axis in a 4 quadrant fashion for blinding
45675490|NCT05885750|Behavioral|Unprocessed|Participants will consume unprocessed or minimally processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
46086198|NCT02735330|Procedure|Frey's procedure|Pancreatic head is partially resected (cored) along with longitudinal opening of duct along its entire length with limit of excavation of the head in the plane of the posterior wall of the Wirsung's duct and duct of Santorini is opened in the uncinate process. All the tissue above the plane, including the duct of Santorini is excised. The reconstruction is done with covering with a loop of jejunum in Roux-en-Y fashion which continues with the main pancreatic duct in the pancreatic body and tail.
46086199|NCT03696992|Procedure|Tandem colonoscopy|Tandem colonoscopy with different image modalities
46086200|NCT00636350|Dietary Supplement|Pepper|pepper carotenoids as meals
46086201|NCT02631941|Drug|Z7200 without oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).
45675491|NCT05885750|Behavioral|Mildly processed|Participants will consume mildly processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
45998147|NCT04682262|Procedure|Cervical dilatation|Patients undergo to cervical dilatation prior to the hysteroscopy under general anaesthesia with using Hegar dilator (no.10)
45998148|NCT00558818|Drug|Clevudine|clevudine 30 mg qd
45998149|NCT02907138|Other|Medical Yoga|
45998150|NCT02907138|Other|Treatment as Usual (physical therapy)|
45998151|NCT04644341|Combination Product|cardiovascular and respiratory systems monitoring|only one group of individuals to observe the impact of COVID-19 on their cardiovascular and respiratory systems in long term.
45998152|NCT04681911|Drug|Inetetamab|Inetetamab: 8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.
45998153|NCT04681911|Drug|Pyrotinib|Pyrotinib: 400mg, oral, every day.
45998154|NCT04681911|Drug|Capecitabine|Capecitabine, 1000 mg/m2, d1-d14, 3-week cycle
45998155|NCT04681911|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2, D1, D8, 3-week cycle
45998156|NCT04681911|Drug|Vinorelbine|Vinorelbine, 25-30 mg/m2, D1, D8, 3-week cycle
45675492|NCT05885750|Behavioral|Heavily refined|Participants will consume heavily refined processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
45675493|NCT05885737|Drug|Difelikefalin Injection|Participants receive Difelikefalin three times a week (0,5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
45998157|NCT04681911|Drug|Carboplatin|Carboplatin, AUC = 6, 3-week cycle
45998158|NCT04681911|Drug|Albumin paclitaxel|Albumin paclitaxel, 100 mg/m2, weekly
45998159|NCT04681911|Drug|Eribulin|Eribulin, 1.4 mg/m2, D1, D8, 3-week cycle
45998160|NCT04644302|Diagnostic Test|microcirculation recording|non-invasive recording of sublingual microcirculation and blood sampling together with regular withdraws
45998161|NCT02907255|Device|Oximetry monitor|Wireless respiratory monitoring system
45998162|NCT04644458|Other|Measuring the ulna length using meauring tape|the left ulna will be measured with a measure tape from the olecranon to mid point of styloid process.
45998163|NCT02905656|Behavioral|Brief Advice|Psychoeducation
45998164|NCT02905656|Behavioral|Motivational Interviewing|Guides participants toward choosing to make a change in their behavior with a collaborative conversation.
45457480|NCT03515278|Procedure|SCNB group|IACI can provide rapid effect in pain reliving, reducing inflammation and improving ROM that could increase the compliance of exercise therapy.
45675494|NCT05885737|Drug|Placebo Injection|Participants receive Placebo three times a week (0,5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
45675495|NCT05885711|Other|self-management|self-managing a pessary: removing, cleaning and inserting
45675496|NCT05885672|Behavioral|Online psychoeducational lifestyle intervention|A webpage-baed intervention focused on lifestyle interventions that aim to reduce metabolic syndrome severity.
45834927|NCT01452516|Device|Interbody FCage|Lumbar fusion using interbody cages with autograft. This will be done in conjunction with the posterolatreal gutter fusion
45834928|NCT04842786|Other|Coconut oil|Coconut oil, Parachute oil composition: 92% lauric (C12) fatty acid, 6% oleic fatty acid, 2% linoleic fatty acid
45834929|NCT01890408|Drug|wound infusion ropivacaine|"Laparotomy Hepatic surgery :~Bolu of 10 ml de ropivacaine 0,2% + infusion with elastomeric pump with ropivacaine 0,2% at a 10ml/h during 48 hours."
45834930|NCT01890564|Other|Pressure controlled ventilation|For pressure controlled ventilation, the peak inflating pressure (PIP) is set for each tidal breath.
45834931|NCT01890564|Other|Volume controlled ventilation|For volume controlled ventilation, the tidal volume is set.
45834932|NCT01890564|Other|PRVC ventilation|Pressure-regulated, volume-controlled (PRVC) is an auto-regulated pressure-controlled mode of mechanical ventilation with a user-selected tidal volume target.
45834933|NCT01456338|Behavioral|Cognitive Behavioral Therapy for PTSD|Individual CBT, approx. 12 sessions, one session per week
45834934|NCT01456338|Behavioral|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
45834935|NCT01890798|Drug|Drisapersen|Drisapersen will be supplied as 3 millilitre (mL) vials containing 1mL sterile solution for subcutaneous injection. The strength of drisapersen solution will be 200 mg/mL.
45998165|NCT02905656|Behavioral|Rate Reduction|Reducing the number of cigarettes consumed.
45998166|NCT02905656|Drug|Pharmacological|Nicotine Replacement Therapy in the form of gum.
45998167|NCT02905656|Behavioral|MI+RR|Combination of reducing the number of cigarettes consumed while guiding the participant to make a change in their behavior.
45998168|NCT00558857|Device|Dynamic Substrate Mapping-guided ablation|Radiofrequency ablation
45998169|NCT02905539|Drug|Iron Isomaltoside 1000|
45998170|NCT02905539|Drug|Ferric Carboxymaltose|
45998171|NCT02905734|Drug|Nicotine patch|Single administration of an active treatment (nicotine patch)
45998172|NCT02905734|Other|placebo patch|Single administration of a placebo treatment
45998173|NCT04644380|Device|INVOcell|Female participants undergoing in vitro fertilization (IVF) and or/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproductive will be asked to participate
45998174|NCT04644107|Drug|Marizomib|Marizomib will be administered via IV
45998175|NCT02899572|Procedure|Sexology consultation|a sexology consultation is planned in the 15 days after inclusion
45998176|NCT04644146|Genetic|GENETIC|It is a retrospective study on patients which has been hospitalized since the beginning of the COVID-19 pandemic in Lyon (march 2020). The blood samples have been collected I the frame of the regular follow-up of the patients and DNA extracted and conserved for the various research protocols ongoing in the University Hospital. The DNA will be analyzed by next generation sequencing
45675497|NCT05885659|Other|Control group (waiting list)|T2DM in the control group will receive brief psychoeducation advice about smoking cessation as well as a general smoking cessation brochure/ booklet. Participants assigned to this control group will participate in the scheduled assessments (pre- and post-treatment, 1-month, 6-months and 12-months follow-ups) but without receiving any of the intensive treatments previously described (CBT vs. CBT+DiME-SALUD2 protocol).
45834936|NCT01890876|Other|Walking uphill|ascending about 500 m
46086202|NCT02631941|Drug|Symbicort Turbohaler without oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2 denote Symbicort without oral activated charcoal administered in two different periods).
46086203|NCT02631941|Drug|Z7200 with oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).
45998177|NCT04644185|Drug|SCTA01|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
45998178|NCT04644185|Other|Placebo|all SCTA01 excipients without active component+best supportive care
45998179|NCT04643795|Drug|MGL-3196|Once daily oral dose for 6 days
45998180|NCT02899494|Other|Antenatal classes|
45834937|NCT01890876|Other|Walking downhill|descending about 500 m
45998181|NCT02899494|Other|Physical and psychic preparation|
45998182|NCT02899260|Device|Peanut Exercise Ball|A Peanut shaped exercise ball.
46086204|NCT02631941|Drug|Symbicort Turbohaler with oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).
45998183|NCT04643756|Other|conventional physiotherapy|Classical electrotherapy method consisting of tens, hotpack and ultrasound.
45998184|NCT04643756|Other|conventional physiotherapy plus kinesiotaping|Conventional physiotherapy plus kinesiotaping
45998185|NCT02905461|Behavioral|Contraceptive text messages|
45998186|NCT02905461|Other|Text messages not about contraception|
46086205|NCT02740010|Device|EDOF Mini WELL Ready IOL|implant
46086206|NCT02742194|Dietary Supplement|Dry extract of ginger|Restrictive diet plus three capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.
45998187|NCT04643873|Other|physical activity counseiling +pilates exercise group|It is planned to do the pilates exercises for 50 minutes a day, 2 days a week during 12 weeks with physiotherapist. Pilates group patient will make pilates exercise once a week alone During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided
45834938|NCT04849806|Diagnostic Test|Assessments of the sympathetic nerve activity axis|"For assessment sympathovagal balance (SVB), HRV and dBPV will be analysed using a 3-lead electrocardiogram (sampling rate 1000Hz) and a continuous non-invasive arterial blood pressure signal (CNAP® technology, sampling rate 100Hz). HRV (ms2 based on continuously recorded variability in RR intervals) and (diastolic) BPV (expressed as mmHg2 based on continuously recorded variability in diastolic BP) will be computed by time domain analysis and by frequency domain analysis and presented as the high frequency component (HF; 0.15-0.4 Hz), low frequency component (LF; 0.04-0.15 Hz), their relative ratio (LF/HF), and the very low frequency component (VLF; 0.0-0.04 Hz) for both HRV and dBPV .~Muscle SNA will be recorded via a tungsten microelectrode carefully placed in the peroneal nerve. Plasma catecholamines will also be assessed."
45998188|NCT04643873|Behavioral|physical activity counseiling group|During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided. Patients make aerobic and strengthening exercises by theirself based on phyiotherapist's suggestions
45998189|NCT02899533|Drug|[18F] FES|[18F] FES PET/CT scan, imaging tracer
45998190|NCT02905383|Other|Exercise|A multi-component exercise program that consists of endurance training, progressive strength exercises and balance exercises.
45998191|NCT04643717|Other|Electronic pupillometer analysis|Electronic pupillometer analysis
45998192|NCT04643522|Other|Clinical assessment|Comparison of semen analysis results and sex-related hormone levels between the dependent groups which were defined as before COVID-19 and after COVID-19 (the data of the same patient group were compared as before and after the diagnosis of COVID-19).
45998193|NCT02905305|Device|Contour Advance electrode with controlled dose of dexamethasone base|The Combined Device consists of a standard cochlear implant receiver-stimulator coupled to a Contour Advance electrode loaded with a controlled dose of dexamethasone base.
45998194|NCT02905305|Device|Contour Advance electrode|Standard Contour Advance electrode
45998195|NCT04643444|Diagnostic Test|Blood sampling|Testing for the presence of SARS-CoV-2 antibodies
45998196|NCT04643444|Other|Online Questionnaire|Questions on working place, risk profiles and PPE
45998197|NCT02899182|Drug|Nitrous Oxide NO|The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve
45998198|NCT02899182|Other|O2|the conventional group (C) will receive local anesthesia at the puncture site plus inhalation of 100% oxygen a face mask.
45834939|NCT04849806|Diagnostic Test|OSA severity|OSA is defined as apnoea-hypopnoea index [AHI] >15/h and obstructive apnoea index [OAI] >5/h) and sleep architecture
45998199|NCT00558935|Dietary Supplement|Red Wine|20g alcohol daily/red wine for 4 weeks
45998200|NCT02905227|Drug|CVT-427 (zolmitriptan inhalation powder)|Each subject received 2 self-administered doses of 3.0 mg CVT-427 (zolmitriptan inhalation powder), 2 hours apart.
45998201|NCT04643600|Drug|L-Arginine, 500 Mg Oral Capsule|The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength.
45998202|NCT02899455|Drug|HGP0904|
45998203|NCT02899455|Drug|HGP0608|
45998204|NCT02899455|Drug|HGP0816|
45998205|NCT02899455|Drug|HGP0904 Placebo|
45998206|NCT02899455|Drug|HGP0816 Placebo|
45998207|NCT04643561|Other|Travelan OTC|5 days of treatment with Travelan food supplement 3 times a day, blood will be drawn prior and after intervention
45998208|NCT02898909|Device|nuclear lens fragmentation in 8 pieces|
45998209|NCT02898909|Device|nuclear lens fragmentation in 16 pieces|
45998210|NCT04643483|Drug|Certolizumab pegol|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous~Subjects will receive certolizumab pegol in a pre-specified sequence during the Treatment Periods."
45998211|NCT04643483|Drug|Adalimumab|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous~Subjects will receive adalimumab in a pre-specified sequence during the Treatment Periods."
45998212|NCT04643483|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous~Subjects will receive placebo in a pre-specified sequence during the Treatment Periods."
45998213|NCT02905071|Other|filling of Serenat at baseline (T1)|Patients who consult occupational doctor complete the serenat questionnaire.The time taken to complete the serenat scale is about 5 minutes.
45998214|NCT02905071|Other|Serenat at baseline T1 and 3 others questionnaires|Subjects who consult occupational doctor complete the 4 questionnaires.The time taken to complete the 4 questionnaires is about 15 minutes.
45998215|NCT02905071|Other|filling of Serenat, HADS, STAY-Y and BDI at baseline T1|Patients who consult a psychiatrist in a stress anxiety unit complete the 4 questionnaires.
45998216|NCT00559052|Drug|VIOKASE 16|The VIOKASE 16 is to be taken as 3 tablets with the perfusion procedure.
45998217|NCT02899104|Drug|Xofigo (Radium-223 dichloride, BAY88-8223)|Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.
45998218|NCT00559130|Device|CytoSorb Hemoperfusion|Daily hemoperfusion for 6 hours with CytoSorb device
45998219|NCT04643132|Drug|Normal saline|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
45998220|NCT04643132|Drug|S-ketamine (low-dose)|After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.
45998221|NCT04643132|Drug|S-ketamine (high-dose)|After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.
46086207|NCT02742194|Dietary Supplement|Placebo|Restrictive diet plus three capsules of 200 mg of cellulose to be taken three times a day for six months.
46086208|NCT02690987|Drug|Exenatide|"Exenatide is a commercially available GLP-1 receptor agonist. It is a synthetic form of exendin-4, a protein extracted from the saliva of a Gila monster lizard, which exhibits 53% sequence identity to human GLP-1.~The planned intravenous Exenatide infusion dose is expected to be 0.06 pmol/kg/min aiming for maintenance plasma concentrations of ~130-190 pg/mL."
45834940|NCT04849806|Diagnostic Test|Determination of PH and right HF severity|(defined as tricuspid annular plane systolic excursion ≤14 mm) and pulmonary arterial pressure (PAsys) using transthoracic echocardiography
45998222|NCT02904993|Other|L2 paravertebral block|nerve block group will receive preoperatively a L2 paravertebral block with indwelling catheter
45998223|NCT02904993|Other|periarticular injection group|periarticular injection group will receive the injection cocktail towards the end of the total hip replacement prior to skin closure.
45998224|NCT04643171|Device|high intensity elliptical training|30 patients will receive 30 minutes of high intensity interval training on elliptical trainer, 5 times per week, for 12 week
45998225|NCT04643171|Device|electrocaupuncture|30 patients will receive 30 minutes of electroacupuncture on bilateral PC 4 and PC 6 for 5 times per week, for 12 week
45998226|NCT02899143|Drug|Antibiotic|Targeted antimicrobial therapy
45998227|NCT04643288|Procedure|open flap debridement|open flap debridement for managing two and three walls intrabony periodontal defects
45998228|NCT04643288|Procedure|n-HA bone graft|Nanocrystalline Hydroxyapatite bone graft substitute for managing two and three walls intrabony periodontal defects
45998229|NCT02899026|Drug|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukumab, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
45834941|NCT04849806|Diagnostic Test|Comprehensive lung function and inspiratory muscle function testing.|Respiratory Muscle strength and function testing as previously established by our group and Assessment of daytime hypoxia (PaO2 <55 mmHg) and hypercapnia (PaCO2 >45 mmHg) using capillary blood gas analysis.
45834942|NCT04849806|Diagnostic Test|Assessment of systemic inflammation|Based on blood samples taken.
45998230|NCT02899026|Drug|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
45998231|NCT02899026|Drug|Prednisone /Prednisone placebo|Prednisone will be provided as tablets with dosage level up to 20 mg/day. All subjects will receive 20 mg prednisone at Baseline (Randomization) and follow predefined taper regimen (6 weeks or 52 weeks) based on treatment assignment. Placebo to match prednisone will be provided as tablets
45998232|NCT04643054|Dietary Supplement|Ovotransferrin|Administering 200 mg of ovotransferrin orally in addition to the standard of care therapy for 10 days
45998233|NCT02904837|Behavioral|Experimental training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
45998234|NCT02904837|Behavioral|Control training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
45998235|NCT04643210|Behavioral|F2F MoB EI|"The MoB F2F EI will comprise a total of 12 educational F2F sessions. Each session will have a duration of 1.5 hours and the maximum number of participants in the groups will be 12 patients.~The intervention group will receive the MoB F2F EI on group or personal form according to the participant's choice. The implementation methodology of the MoB F2F EI will include videos and power point presentations, as well as interactive learning methods such as role-playing, empowerment exercises, live discussions."
45998236|NCT04643210|Other|MoB DP|This is a technology-based intervention, which regards access to a dfigital platform, the MoB DP. The structure of the Digital platform has been partially based on the preferences and needs of the participants (as described in the qualitative part of the study) and its goal is to create an ecosystem where users will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile. The Digital platform will be in the form of a dynamic website with user generated content as well as static information.
45998237|NCT02904798|Drug|Polypodium Leucotomos|- PL 240mg to be taken by the patient for 28 days prior to irradiation with visible light
45998238|NCT00559169|Drug|verapamil hyrochloride|80 mg daily by mouth, 5 days prior to menses for 3 months
45998239|NCT02898948|Biological|Procalcitonin (PCT) as a diagnostic marker of bacterial infection|
45998240|NCT02898831|Other|Cold Compress|Cold Compress placed on lower abdomen prior to and during IUD insertion.
45998241|NCT02904876|Radiation|Diffusion Magnetic Resonance Imaging at 6 months|2-year follow-up MRI of patients initiating treatment with Tysabri with anti-JCV antibody positive or negative. Patients enrolled will benefit from diffusion MRI at 6 months, in addition to conventional MRI.
45998242|NCT04642664|Drug|Apatinib plus Camrelizumab|Patients received apatinib orally at 250 mg once a day irrespective of the patient weight. During the treatment, apatinib can reduced to half of piece or once every other day considering the grade of treatment related adverse events. Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks. The intermittent period of camrelizumab was no longer than 6 weeks. All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason.
45998243|NCT04642742|Dietary Supplement|Chewable plant sterol|Chewable plant sterol (gummy)
45998244|NCT02904759|Drug|Desmopressin|
45998245|NCT02904759|Drug|Placebo|
45998246|NCT04642547|Drug|Lenvatinib and Gefitinib|"First week: Gefitinib: 125mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight > 60Kg), oral.~One week later: Gefitinib: 250mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight > 60Kg), oral."
45998247|NCT02898792|Drug|Targeted infusion of remifentanil|Remifentanil dosing will be calculated using ideal body weight and infused to achieve brain concentrations of 0.5, 1, 2, 3, and 4 ng/ml; approximately 10 minutes at each concentration.
45998248|NCT04642391|Drug|Cosyntropin|Administer 0.25mg Cosyntropin to determine adrenal sufficiency vs. insufficiency in patients with decompensated cirrhosis
45457481|NCT03515278|Procedure|IACI group|SCNB is a new choice for treatment of frozen shoulder.As radiology techniques advance, ultrasound-guided SCNB becomes more popular. It provides a cost and time-effective way to infiltrate the nerve accurately without injury to the nerves or vessels.
45998249|NCT02904642|Behavioral|SMS reminder|Caregivers will receive two text message reminders for their child's measles immunization scheduled for 9 months of age
45998250|NCT02904642|Behavioral|Unconditional Incentive|A mobile-money incentive in the amount of 150 Kenyan Shillings will be transferred to the enrolled caregiver's mobile phone when the child reaches nine months of age
45998251|NCT04642313|Other|Magnesium and/ or Potassium|Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia
45998252|NCT02904447|Other|x-ray and pedobar foot pressure mapping|
46086209|NCT02690987|Biological|Desacyl ghrelin|"Ghrelin is a 28 amino acid stomach-derived peptide hormone, with the desacyl ghrelin (DAG) form inactive at the GHSR1a receptor. Good Manufacturing Practice (GMP)-grade DAG is obtained from Clinalfa (Bachem AG, Bubendorf, Switzerland).~The planned intravenous DAG infusion dose is expected to be 4.0 mcg/kg/hour aiming for maintenance plasma concentrations of ~13-19 ng/mL."
45998253|NCT04642157|Other|ELIOS|"ELIOS is a suicide prevention system worldwide entirely tailored to the AYA contemporaneous modes of interaction on social media.~This includes~A systematic initial contact with an ELIOS web-clinician~Systematic recontacts by the ELIOS web-clinicians scheduled at 24h, 72h and/or 7 days, depending on the participants' level of suicide risk~The opportunity to spontaneously contact the ELIOS system and get in contact with a web-clinician"
45998254|NCT04642157|Other|other resources contacts|"Three types of resources will be suggested via the ELIOS website:~The General Practitioner (GP)~The closest medico-psychologic center (CMP)~The emergency services The order of presentation of the resource contacts will depend on the participants' intensity of suicidal ideation."
45998255|NCT02904525|Device|7 Tesla MRI, no contrast agent|Patients with newly diagnosed glioblastoma undergo a 7Tesla MRI
45998256|NCT04642118|Procedure|Pulmonary recruitment maneuver|Using setting pressure form ventilator to increase pulmonary pressure by compress balloon bag 5 times, 5 seconds per time
45998257|NCT04641884|Other|Not concerned|Not concerned
45998258|NCT04641923|Other|Adhesion barrier|Adhesion barrier application at the time of first surgery
45998259|NCT02904564|Drug|MMP with 5-FU|MMP with 5-FU using tattoo device
45998260|NCT02904564|Drug|MMP with Saline infusion|MMP with saline infusion using tattoo device
45998261|NCT04642040|Other|Pulmonary Rehabilitation|Positioning,breathing techniques (diaphragmatic breathing, alternate breathing, and pursed-lip breathing),respiratory muscle exercises, joint ROM exercises, early-mobilization and progressive ambulation, peripheral muscle strengthening exercises
45998262|NCT02904486|Behavioral|change behavior|Modified Health Belief Model Based Intervention to Reduce Body Mass Index for Age
45998263|NCT04642001|Other|Photon Laser III-DMC (without radiation emission) + My First- Colgate|Positioning of the FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.
45998264|NCT04642001|Other|Photon Laser III-DMC (without radiation emission) + Sensodyne® Rapid Relief / GSK|Positioning of FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
45998265|NCT04642001|Radiation|Photon Laser III-DMC (with irradiation emission) + My First- Colgate|Emission of FBM therapy (Photon Laser III / DMC), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.
45998266|NCT04642001|Combination Product|Photon Laser III-DMC (with irradiation emission) +Sensodyne® Rapid Relief / GSK|Emission of FBM therapy (Photon Laser III / DMC), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
45998267|NCT02904681|Other|No intervention. Observational and descriptive study|
45998268|NCT02904408|Behavioral|psychotherapy|Group psychotherapy
45998269|NCT04641845|Other|Cork inlay wedge|
46086210|NCT02690987|Biological|Saline|The placebo visit will involve an intravenous infusion of normal saline.
46086211|NCT04020731|Behavioral|Hypnosis|several blocks of hypnosis including entry into a hypnotic state (= induction), the hypnotic trance and the exit from hypnosis (= reassociation).
46086212|NCT02740166|Drug|propranolol|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
46086213|NCT02735018|Drug|Epinephrine 1:100,000|Inferior alveolar nerve block with Epinephrine 1:100.000
46086214|NCT02735018|Drug|Epinephrine 1:200,000|Inferior alveolar nerve block with Epinephrine 1:200.000
46086215|NCT04189874|Diagnostic Test|Conventional Stool Testing|Stools are tested using conventional culture techniques
45998270|NCT04641689|Device|Desk Only|Provision of height-adjustable desk
46086216|NCT04189874|Diagnostic Test|BioFire FilmArray Gastrointestinal Panel|Molecular-based stool assay
45998271|NCT04641689|Behavioral|Program Only|Online modules will promote goal setting, self-monitoring, habit formation, social support, barrier identification, and environmental modifications
45998272|NCT02898753|Drug|VAL-1221|VAL-1221 3, 10, or 30 mg/kg as per the dose and schedule specified in the arm group description
45998273|NCT02898753|Drug|RhGAA|Active comparator
46086217|NCT02732054|Biological|Recombinant Hepatitis B vaccine [(CIGB) La Habana, Cuba]|Different HBV vaccine regimen in each group
46086218|NCT00908375|Drug|Pregabalin|One pregabalin 75mg capsule will be prescribed twice daily for the first week of the study (150mg/day). For the subsequent 2 weeks, the dose will be increased to 2 pregabalin capsules twice a day (300mg/day). The total duration of the treatment will be 3 weeks.
46086219|NCT00908375|Drug|Sugar Pill|One sugar pill will be prescribed twice daily for the first week of the study. For the subsequent 2 weeks, 2 placebo(sugar pills) capsules twice a day. The total duration of the treatment will be 3 weeks.
46086220|NCT03903497|Device|NBI|optical assessment of diminutive colorectal polyps by NBI mode using the WASP assessment
45998274|NCT04641572|Other|Choose comfortable position|Standing or walking, Squatting, Sitting, Hands /knees, and Kneeling, positions will be taken by the participant during labor.Then the researcher will register the time ( minutes/hours) will be taken and which that will be more preferable by the participant
45998275|NCT02898324|Other|KiVa program|KiVa program is an anti-bullying intervention developed in University of Turku, Finland. It is based on the participant role model, where bullying is seen as a group process focused on the bystanders' reactions to the bullying. This program includes universal and indicated actions. Universal actions include ten students lessons given by teachers where pupils learn the role of bystanders in the bullying process, how to increase empathy towards the victim, and safe strategies to supports victims. Indicated actions are delivered by a school team of three staff members, who handle acute cases of bullying.
45998276|NCT04641533|Procedure|L-PRF + DPSC|After surgical removal of impacted mandibular third molars, extraction sockets were filled with L-PRF membranes + DPSCs.
45998277|NCT04641533|Procedure|L-PRF|After surgical removal of impacted contralateral mandibular third molars, each extraction sockets were only filled with L-PRF membranes.
46086221|NCT02734784|Procedure|Photodynamic Therapy|After a surgical access, the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). Teeth with furcation lesion will increase over 60 seconds into the lesion. Before the application, the supragingival plaque will be removed.
45998278|NCT02898675|Device|Platelet rich fibrine|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
45998279|NCT02898675|Device|Open Flap Debridement|Only open flap debridement treatment the bone loss limitedly
45998280|NCT02898558|Behavioral|Magnification hand size|Participants will use magnifying lenses while completing a jigsaw puzzle for 30 min a day for 14 days.
45998281|NCT02898558|Device|magnifying lenses|
45998282|NCT04641494|Dietary Supplement|Conjugated linoleic acid|CLA Mixture capsule (50:50, c9, t11-CLA: t10, c12-CLA)
45457482|NCT01230151|Device|GUIDE software, Version 0.1|The GUIDE software uses computer-based models to determine the spread of stimulation from DBS therapy into surrounding nuclei of the brain. The software models stimulation and is not used to program or communicate with the patient's implanted DBS System. The software was recently validated in a multi-center clinical study.
45457483|NCT01230151|Device|Clinically defined stimulation parameters|Stimulation parameters clinically determined prior to start of clinical study
45457484|NCT03511768|Drug|18F-AlF-NOTA-octreotide|One injection of 18F-AlF-NOTA-octreotide
45457485|NCT03511768|Device|PET/CT|Following injection of 18F-AlF-NOTA-octreotide the participants will be subjected to whole body PET/CT
45457486|NCT01134991|Drug|Topical Minocycline Foam FXFM244|FXFM244 - 1%, FXFM244 - 4% or Placebo to be applied twice daily during 12 weeks
45457487|NCT02303080|Other|Control (WPM 0)|85.0 % maltodextrin,15.0% fat, 0% WPM
45998283|NCT04641494|Dietary Supplement|High oleic acid safflower oil capsules|
45998284|NCT02898636|Other|autopsy|At autopsy achieving adequate sampling of lesions and healthy skin
45998285|NCT04641416|Diagnostic Test|Routinely performed echo, ECG and hemodynamic monitoring|The pump data of patients on the ICU or normal ward are stored in a continuous data acquisition system (CDAS) on a notebook which is operated in battery operation, and analyzed afterwards with a mat-lab based software. For outpatients a mobile data-recorder will allow a continuous data acquisition for a period up to 2 months on a SD card. During this non-invasive pump data monitoring, routinely available hemodynamic monitoring, ECG and echo data will be collected.
46086222|NCT02734784|Procedure|Sham Photodynamic Therapy|After a surgical access, the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. Before the application, the supragingival plaque will be removed.
46086223|NCT04247867|Device|medium cut-off (MCO) dialysis membrane|Medium cut-off dialysis (MCO) membrane is a dialysis membrane with a higher molecular weight retention onset and similar cut-off as standard high-flux dialysis membranes. It is capable of providing increased clearance of medium sized uremic toxins and some plasma proteins (cytokines, inflammatory mediators).
46086224|NCT04247867|Dietary Supplement|Dietary fiber mixture (Plantago Psyllium and Inulin)|Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.
46086225|NCT04247867|Dietary Supplement|Sodium propionate|Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.
46086226|NCT02731664|Biological|GLP-1|Intravenous infusion of GLP-1
46086227|NCT02731664|Biological|Intravenous saline|Control
45457488|NCT02303080|Other|WPM 30|43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM
45834943|NCT04844658|Dietary Supplement|NASAFYTOL®|Dietary supplement presented as green soft gel capsules of 1008 mg, containing a bioactive mixture of turmeric extract or curcumin, natural quercetin from Sophora japonica L. and vitamin D3.
45834944|NCT04844658|Dietary Supplement|FULTIUM® -D3 800|Vitamin D , FULTIUM® - D3 800 is a blue soft capsule that contains 800 UI (20 µg) of D3 vitamin (cholecalciferol).
45834945|NCT04844658|Drug|Strandard of care treatment|Strandard of care treatment for Covid-19 infection
46086228|NCT04242563|Other|VIRTUAL REALITY|Patient equipped with virtual reality in transfer room
45457489|NCT02303080|Other|WPM 50|16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM
45457490|NCT02303080|Other|MC 50|16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC
45457491|NCT01135147|Behavioral|Diet|Dietary therapy and physical education
45457492|NCT01135147|Procedure|Surgery|Adenotonsillectomy along with diet and physical therapy
45457493|NCT03515200|Drug|Palbociclib Oral Capsule|Given orally or nasogastrically (NG).
45834946|NCT04841538|Drug|ES101|The active ingredient of ES101 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
45457494|NCT03515200|Drug|Intrathecal Triple Therapy|Given intrathecally (IT).
45998286|NCT02898363|Other|Information campaign|During a two-year information program, physicians, mainly general practitioners, carers in and outside institutions, associations and families will be informed on cancer frequency, on cancer particularities and on cancer detection in persons with intellectual disabilities by means of documents, mails and e-mails, meetings and a website providing all available useful information on cancer in persons with intellectual disabilities.
45675498|NCT05885659|Behavioral|Cognitive Behavioral Treatment (CBT) for smoking cessation|CBT for smoking cessation will be implemented in group-based sessions of four to six patients, once a week over an eight-week period (Becoña, 2007), and includes three different components: (1) Motivational interviewing to stop smoking; (2) Smoking cessation, focused on nicotine fading from the first to the fourth session; (3) Maintenance of abstinence and relapse prevention strategies from the fifth session onwards. This modality of treatment also includes the following components, among others: Therapeutic contract, self-monitoring and graphical representation of tobacco consumption, psychoeducation about tobacco and specific characteristics of smoking behavior, stimulus control, strategies for coping with nicotine withdrawal symptoms, physiological feedback of consumption (using CO and cotinine in urine levels), social reinforcement when meeting nicotine reduction and abstinence goals, training in alternative behaviors to consumption and strategies for the prevention of relapses.
45998287|NCT04641377|Other|Multicomponent exercise intervention plus health education|The multicomponent training will be performed twice a week, on pre-established and non-consecutive days. The sessions will be held by video call (approximately 60 min) in small groups (maximum three participants) and will be taught by students of the Physical Education course, previously trained to carry out the intervention. The order of the multicomponent training will be: joint mobilization, aerobic stimulus, balance exercise, strength exercises and stretching of the main muscles used during the training session. Health education will also be carried out on one of the two days. The conversation on the topic of the week will take place during stretching.
45998288|NCT04641377|Other|Health Education|Once a week, participants in the health education group will be sent a message with a material with various topics related to the management of breast cancer diagnosis and physical activity. In addition, two days after this material is sent, members of ABRACE: Telehealth will have a conversation with the participants of this group, at a google meet of approximately 30 minutes, about the theme sent by message. The themes will be: depression, pain, fatigue, body image, symptoms in the arm and breast, vasomotor symptoms, neuropathy, arthralgia, sexual dysfunction, quality of life, physical activity and eating habits.
45998289|NCT02898441|Device|Low Dose Computed Tomography|LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm.
46086229|NCT05472272|Other|Formula diet|Participants will receive a low-calorie (815-835 kcal/day; approximately 43% carbohydrate, 29% protein, and 29% fat) formula diet product for 12 weeks, followed by a gradual food reintroduction phase combined with physical activity support for 12 weeks.
46086230|NCT05472272|Other|Food-based diet|Participants will receive a low-calorie (815-835 kcal/day; 45-50% carbohydrate, 20-30% protein, and 20-30% fat) food-based diet created by dietitians for 12 weeks. After 12 weeks, participants will increase energy intake gradually and be encouraged to increase daily physical activity to maintain weight loss for another 12 weeks.
46086231|NCT02543255|Drug|Abiraterone acetate with prednisone|Abiraterone acetate will be administered orally as a tablet at 1000 mg/day with prednisone (5 mg oral tablet, twice daily) for 24 weeks.
46086232|NCT02543255|Drug|Leuprolide|Leuprolide will be administered by subcutaneous injection at 22.5 mg dose every 12 weeks for 24 weeks.
46086233|NCT02543255|Drug|Cabazitaxel with peg-filgrastim|Cabazitaxel will be administered in 6 cycles, with 20 mg/m2 per cycle and 3 weeks between cycles.
46086234|NCT02695004|Drug|DKF-310|
46086235|NCT02695004|Drug|Placebo|
46086236|NCT02512913|Behavioral|Adapted/enhanced MAPS|The plan is for recruitment at the first prenatal care visit followed by a proposed eight-session phone counseling sequence for the women, consistent with the session frequency in the original MAPS intervention: 1st call at 14 weeks gestation (75% of Romanian women begin prenatal care in 1st trimester), three monthly calls through the 2nd trimester (18-22-26 weeks gestation), a 5th and 6th calls in the 3rd trimester (32 and 36 weeks), and two postnatal calls (2 and 6 weeks postpartum). Four calls are planned for the partners: at 14-, 22-, and 32-weeks, and at 2-weeks postpartum.
46086237|NCT00909389|Drug|Vytorin (R) (Ezetimibe + Simvastatin)|Vytorin (R) (Ezetimibe + Simvastatin) 1 tablet once daily to be taken by mouth in the evening for 28 days
45457495|NCT03515200|Drug|Dexamethasone|Given orally, nasogastrically (NG) or intravenously (IV).
45457496|NCT03515200|Drug|Bortezomib|Given intravenously (IV) or subcutaneously (SC).
45834947|NCT02450292|Procedure|Bioabsorbable screw fixation|
45834948|NCT04849650|Drug|Amisulpride IV|A single 10mg IV dose of Amisulpride given over 1 minute
45834949|NCT04849650|Drug|Amisulpride Oral Tablet|A single 10mg dose given as an oral tablet
45834950|NCT05587140|Device|Acupuncture like TENS|Frequency: 4 Hz, pulse duration: 200 μs, intensity: 3/10 painful sensation with muscle contraction , time: 30 minutes
45834951|NCT05587140|Device|Conventional TENS|Frequency: 100 Hz, pulse duration: 200 μs, intensity: strong but comfortable tingling sensation , time: 30 minutes
45834952|NCT05587140|Device|Sham TENS|Frequency: 4 Hz, pulse duration: 200 μs, intensity: tingling sensation, time: turn on the electricity for 15 seconds, then turn off the machine for 30 minutes
46086238|NCT02694614|Behavioral|smartphone-assisted dietary coaching|
46086239|NCT00910715|Drug|doxycycline|doxycycline 100 mg bid, 10 days
46086240|NCT00910715|Drug|doxycycline|doxycycline 100 mg bid, 15 days
46086241|NCT00910715|Drug|placebo|control subjects without a history of Lyme borreliosis
46086242|NCT02731586|Drug|Allogenic Mesenchymal stem cells|Allogenic mesenchymal stem cells are introduced during placement of dental implants.
46086243|NCT02576795|Biological|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
45998290|NCT04641455|Drug|Espumisan, N acetylcystein|Administration of mucolytic solution before upper endoscopy (Espumisan 320 mg, ACC long 600 mg)
45998291|NCT04641455|Drug|Espumisan, N acetylcystein|Administration of mucolytic solution before upper endoscopy (Espumisan 20 mg, ACC long 200 mg)
45998292|NCT04641455|Drug|Water|Administration of water before upper endoscopy
45457497|NCT03515200|Drug|Dasatinib|Given orally or nasogastrically (NG).
45998293|NCT02898480|Procedure|Remote ischemic conditioning|Briefly reversible restricting of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
45998294|NCT04641182|Other|Prone position|Prone position as indicated by the treating physician as specified in the institutional protocol
45998295|NCT02898402|Procedure|blood sample and questionnaire|In addition to normal blood sample performed at entry before delivery, an extra 5 ml blood sample will be taken to establish Q fever serodiagnosis and a short questionnaire will be filled in for clinical and epidemiological data.
45998296|NCT00559286|Drug|Telmisartan|application of 80mg or 20mg Telmisartan per day for 30 days
45998297|NCT02898519|Other|cohort|Blood sampling
45998298|NCT00559403|Behavioral|HIV/STD Risk-Reduction|Let Us Protect Our Future consists of twelve 1-hour sessions to increase knowledge, motivation, and skills in practicing abstinence and condom use. It is highly structured, and Xhosa-speaking male and female co-facilitators implement the program using standardized manuals. Treatment sessions include mixed-gender and single-gender activities, games, brainstorming, and role-playing. Comic workbooks are used to address abstinence, condom use, and how risky behavior affects goals and dreams. The Xhosa culture is taken into account, including cultural transformations in urban township settings. Take-home assignments enlist parents' help to empower their children to reduce their STD risk and ensure that parents are aware of the nature of the treatment program.
45998299|NCT00559403|Behavioral|Health Promotion|The health promotion treatment is structurally similar to the HIV/STD treatment: each has the same number of sessions and sessions led by Xhosa-speaking male and female co-facilitators. It focuses on behaviors linked with risk of heart disease, diabetes, high blood pressure, certain cancers, and alcohol and drug abuse, which are all leading causes of morbidity and mortality among South Africans. Participants are taught that healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance use, can prevent these health problems. Comic workbook story lines are used to increase risk perception and awareness of health risks. Take-home assignments are used to foster communication with parents about healthful lifestyle.
45998300|NCT02898285|Behavioral|Team sports|Participants will choose from a list of team sports and will be signed up with the team.
45998301|NCT02898285|Behavioral|Individual sport condition|Participants will choose from a list of individual sports.
45998302|NCT02898285|Behavioral|Night out|"Participants in this group will be asked to go out to have a weekly night out or personal time of choice, such as dinner or a movie (only restrictions are they cannot go do a sport or physical activity and time must be spent without children)."
45998303|NCT04640870|Drug|Afatinib|Treatment with Afatinib, any line, in metastatic, EGFR mutated patients with NSCLC
45998304|NCT04640831|Drug|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
45998305|NCT04640558|Device|Muscle strength measurement|The bilateral gluteus medius muscle strength of each participant will be measured by the assessor (MB) blinded to the participants using the Lafayette manual muscle tester. (Lafayette Instrument Company, Lafayette IN, USA). In the participant's side-lying position, the practitioner applied resistance from the upper ankle to the abduction movement with slight flexion of the upper hip. During the measurements, the participants were asked to perform the maximum isometric contraction for 3 seconds. Gluteus medius muscle strength measurements were repeated three times, one minute apart, on the right and left sides. The mean of the measurements was calculated and recorded
45998306|NCT02898168|Device|WA group|Conventional rehabilitation therapy and gait training with WAIntervention with WA is scheduled 40min/day, five times a week, for 8 weeks.
45998307|NCT02898168|Other|Control|Conventional rehabilitation therapy and gait training without WA.
45998308|NCT02897973|Other|Activity of daily living|walking, sitting-to-standing and standing-to-sitting, stairs ascending and descending
45998309|NCT04640207|Device|Facial skin treatment|Facial skin treatment using the Alma Hybrid system with a unique pattern that includes both ablative and non-ablative wavelengths
45998310|NCT02897934|Drug|Bupivacaine continuous infusion|The use of continuous wound infusion of bupivacaine
45998311|NCT04640129|Drug|PEG-Interferon Alfa, Tenofovir Disoproxil Fumarate|Combination therapy group was treated with PEG-interferon Alfa in addition to TDF monotherapy
45998312|NCT04640129|Drug|Tenofovir Disoproxil Fumarate|TDF monotherapy
45998313|NCT02898012|Drug|Temozolomide|Temozolomide (TMZ) Temozolomide (TMZ) administered at 130-150 mg/m2 for 5 consecutive days every 4 weeks up to 12 cycles. IV or oral administration was allowed according to the clinical status. TMZ starts at 130 mgs/m2 and increase to 150 mgs/m2 during the second cycle in the absence of hematologic toxicity. In the case of grade 3 or 4 toxicity, the dose for the next cycle is decreased to 110 mg/m2. If the grade 3 or 4 toxicity persists at a dose of 110 mg/m2, treatment is discontinued.
45457498|NCT03515200|Drug|Doxorubicin|Given intravenously (IV).
45457499|NCT03515200|Drug|Ruxolitinib|Given orally or nasogastrically (NG).
45457500|NCT03918265|Drug|Tacrolimus|On refractory autoimmune cytopenia patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study
45457501|NCT03920839|Drug|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks.
45998314|NCT02898012|Drug|Bevacizumab|Bevacizumab (Bev) administered at a dose of 10 mgs/kg every 2 weeks. Bev was interrupted in cases of wound healing disturbances, gastrointestinal perforation, intestinal occlusion, fistula, uncontrolled hypertension, nephrotic syndrome, grade 4 or recurrent grade 3 thromboembolic events, arterial thrombosis, hemorrhage > grade 2, left ventricular failure, or posterior reversible leukoencephalopathy.
45998315|NCT04640324|Drug|Nutraceutical therapy|Oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day for six months
45998316|NCT02897895|Biological|levels of CNI in whole blood|
45998317|NCT02897895|Biological|Calcineurin activity (CN-a) in peripheral blood mononuclear cells (PBMCs)|
45457502|NCT03920839|Drug|Gemcitabine|Gemcitabine administered intravenously on Days 1 and 8 of 21-day cycles.
45998318|NCT04640285|Other|RELX ENDS Tobacco Flavor|Ad libitum use of RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
45998319|NCT04640285|Other|RELX ENDS Menthol Flavor|Ad libitum use of RELX ENDS Menthol flavor product during 8-hour and 5-minute use sessions
45998320|NCT04640285|Other|Usual Brand Cigarette|Ad libitum use of subjects usual brand product during 8-hour and single cigarette use sessions
45998321|NCT04640285|Other|Nicorette White Ice Mint nicotine polacrilex gum|Ad libitum use of Nicorette White Ice Mint nicotine polacrilex gum product during 8-hour and 30-minute use sessions
45998322|NCT02898129|Other|Questionnaire|
45998323|NCT02898129|Device|Lung function test|Basic lung function test performed with a micro-spirometer, without broncho dilatator
45998324|NCT00559442|Other|Altitude Exposure:|rapid ascent to Margherita Hut (4559 m) within 24 h
45998325|NCT00559481|Drug|dexamethasone|
45998326|NCT00559481|Drug|ketoconazole|
45998327|NCT00559481|Drug|therapeutic hydrocortisone|
45998328|NCT00559481|Procedure|pharmacological study|
45998329|NCT02897739|Procedure|Magnetic resonance imaging|Cardiac MRI and short MRI following USPIO infusion
45998330|NCT02897739|Biological|Acute Inflammatory Activation study|Blood sampling for exploration of type and level of inflammatory response
45998331|NCT02897739|Radiation|PET CT|PET study for metabolic pathway study
45998332|NCT02897739|Behavioral|Psychological assessment|Assessment by a psychologist
45998333|NCT00559520|Dietary Supplement|Impact|"Patient receiving 3 drinks Impact a day during 5 days before surgery"
45998334|NCT00559520|Dietary Supplement|Oral Impact|"Patient receiving 3 drinks Oral Impact a day during 5 days before surgery"
45998335|NCT01236352|Drug|BMS-911543|
45998336|NCT02897856|Drug|Buccal midazolam|Study subject will receive Buccal midazolam, Intramuscular placebo.
45998337|NCT02897856|Drug|Intramuscular midazolam|Study subject will receive Intramuscular midazolam,Buccal placebo
45998338|NCT00559559|Device|ICD implant + Patient Notifier turned OFF|ICD implant, plus standard care, i.e. Patient Notifier turned off
45998339|NCT00559559|Procedure|ICD Implant + Patient Notifier turned ON|ICD implant. The Patient Notifier™ feature will be turned ON.
45998340|NCT00559598|Genetic|proteomic profiling|
45998341|NCT00559598|Other|medical chart review|
45998342|NCT02897661|Procedure|WMT|Washed microbiota transplantation (WMT) through mid-gut
45998343|NCT02897661|Dietary Supplement|EEN|Exclusive enteral nutrition (EEN) through feeding tube
45998344|NCT03454685|Other|without intervention type|Without intervention,this study is just an observational study.
45457503|NCT03920839|Drug|Cisplatin|Cisplatin administered intravenously on Day 1 of 21-day cycles.
45457504|NCT03920839|Drug|Pemetrexed|Pemetrexed administered intravenously on Day 1 of 21-day cycles.
45998345|NCT02897505|Behavioral|Music Workshop|At each music workshop, the study staff will collect participants' pre- and post-session Physiological and Emotional Thermometer Surveys. The pre-session survey will be conducted prior to the start of the music workshop, and the post-session survey will be conducted within 15 minutes after the conclusion of the workshop.
45998346|NCT04639934|Genetic|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
45998347|NCT02897544|Behavioral|Individualized Manualized Health Education Intervention|
45998348|NCT04640090|Behavioral|Smartphone app (Wysa)|The commercially available smartphone application, Wysa, offers evidence-based wellness tools such as supportive listening, deep breathing techniques, guided meditation, yoga, and more. Users can communicate via text to a virtual artificial intelligence (AI) chatbot and/or a human well-being coach.
45998349|NCT02897622|Other|Case management|Case management by Eira unit
45998350|NCT04639739|Biological|anti-CD19 CAR NK|2×106 /kg、6×106 /kg、2×107/kg Treatment follows a lymphodepletion, the recommended chemotherapy regimen consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion，the actual regiment is determined by the statue of patients.
45998351|NCT04639700|Behavioral|Psycho-educational intervention|"Participant will be sent a baseline survey, and will then be contacted by the interventionist to complete 4 sessions, which feature the following areas:~Session 1: Identifying CG Needs for Information & Support, Communication with Healthcare Team~Session 2: Communication with Patient and Family~Session 3: Self-care: Emotional & Spiritual Needs, Self-care: Physical Needs~Session 4: Re-Assessing Needs, Planning for the future"
45998352|NCT01236118|Drug|LY2439821|Administered subcutaneously
45998353|NCT02897583|Procedure|YAG vitreolysis|
45998354|NCT04206631|Drug|Doxycycline Capsule|Doxycycline capsule 100 mg/day, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
45998355|NCT04206631|Procedure|Comedone extraction|Comedone extraction, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
45998356|NCT05510128|Other|Pharmacist management|"When a patient comes to the pharmacy with signs of urinary burning, the following will follow:~Completion of the acute cystitis symptoms score (ACSS) questionnaire.~Measure the temperature.~Perform a urine dipstick.~If the patient's temperature is normal, the urine dipstick is positive, and the absence of pain in the lumbar fossa is verified, the pharmacist can dispense an appropriate antibiotic himself. A reminder of the hygienic-dietary rules is also issued, and a communication to the patient's general practitioner will be made."
45998357|NCT04639817|Drug|Levofloxacin|Levofloxacin administration
45998358|NCT04639817|Drug|trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole administration
46086244|NCT02731430|Drug|intrathecal morphine|received 0.3mg morphine (0.3ml) added to 1.2ml of bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
45998359|NCT02897154|Diagnostic Test|In-vitro|
45998360|NCT05496634|Behavioral|Sedantary|An informative presentation
45998361|NCT05496634|Behavioral|Exercise therapy|Pilates exercise therapy
45998362|NCT05472961|Behavioral|Target and Stimulus|The investigators manipulate the difficulty of search for the target object by manipulating the number of distractor objects and/or the similarity between the target and distractors. The investigators manipulate the difficulty of the decision about a feature by manipulating the similarity of the feature to a criterion. The investigators manipulate the timing of when the decision feature appears on the object relative to the onset of the array and/or the onset of the saccade away from fixation in a gaze-contingent manner.
45998363|NCT02897193|Device|ICE dental implant 4.2 mm|ICE dental implant 4.2 mm diameter
45998364|NCT02897193|Device|NICE dental implant 3.2 mm|NICE dental implant 4.2 mm diameter
45998365|NCT02897193|Device|Alpha Bio's Graft Bovine bone|Alpha Bio's Graft Bovine Bone
46086245|NCT02731430|Drug|intrathecal saline|received 0.3ml saline added to 1.2mlof bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
46086246|NCT04232969|Drug|Exenatide extended release 2mg (Bydureon)|Subcutaneous Injection
46086247|NCT02734706|Dietary Supplement|LRC™ capsule|Twice per day (BID), 9 weeks
46086248|NCT02734706|Other|Placebo capsule|Twice per day (BID), 9 weeks
45998366|NCT02897193|Device|Alpha Bio's Graft resorbable membrane|Alpha Bio's Graft resorbable collagen membrane
45998367|NCT04639856|Procedure|Coronary Artery Bypass Grafting|on-pump vs off pump Coronary artery Bypass Grafting
45998368|NCT01236001|Drug|Lacosamide|
45998369|NCT04639349|Behavioral|exercise group|the exercise group (20 patients) will receive a exercise session contains a fifty minutes exercise training at home with moderate intensity on the available training devices as bicycle or treadmill in addition to 30 minutes of exercising of upper and lower limb, the session will be repeated three times per week for eight weeks.
45998370|NCT04639349|Other|control group|the control group will not be trained
45998371|NCT02897466|Other|Direct Antimicrobial Susceptibility Testing|An antibiotic susceptibility testing will be performed directly on respiratory samples with Gram negative bacilli on direct smear examination of intensive care patients suspected of ventilator-associated pneumonia. The result of this test associated with GNB identification using mass spectrometry will be given to the physician in charge of the patient at Day 1, one day earlier than the conventional AST. This rapid method will allow a re-evaluation (adequation and/or de-escalation) of the antibiotic probabilist treatment one day earlier than the conventional method.
45998372|NCT04639544|Dietary Supplement|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
45998373|NCT04639544|Dietary Supplement|Lactobacillus strain|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
45998374|NCT02897232|Other|Survey|Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination
45998375|NCT01229254|Drug|Amiodarone|Patients on Amiodarone
45998376|NCT01229254|Drug|Betrixaban 60 mg|Betrixaban 60 mg once a day with food on Day 0 through Day 25
45998377|NCT01229254|Drug|Betrixaban 90 mg|Betrixaban 90 mg once a day with food on Day 0 through Day 25
45998378|NCT01229254|Drug|Betrixaban 30 mg|Betrixaban 30 mg once a day with food on Day 0 through Day 25 with concomitant amiodarone treatment.
45998379|NCT04639232|Dietary Supplement|Placebo|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
45998380|NCT04639232|Dietary Supplement|Prob-milk|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
45834953|NCT01456728|Dietary Supplement|Progastria|"All subjects will receive 2 x 20 mg omeprazole per day for 28 days.~L. reuteri ProGastria will be delivered at a dose of 1x108 CFU of 2 strains of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One chewable tablet is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. This dose of L. reuteri has been shown to be effective in a series of conditions earlier, including inhibition of H. pylori in humans, and is considered the optimal dose. The study products will be taken daily for 28 consecutive days."
45998381|NCT04639232|Dietary Supplement|Voluntas-Prob|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
45998382|NCT02897388|Other|breast milk consume promotion|(1)Team building: organize a multidisciplinary breast milk consume improvement team；(2) Staff education: one nurse to train in Canada for 1 month as lactation coordinator, lactation consultant from Canada to teach NICU staff for 1 month; (3) Send breastmilk teaching materials for parents to teach mothers about breast milk feeding;(4) allocate an area in the NICU as a breast pumping room with breastfeeding pumps and chairs to support mothers pumping milk and feeding their babies; (5)purchase 10 breast pumps from Medela and establish a loaner program for mothers; (6)provide lactation counseling & promote consistent communication about the benefits of mothers' milk to encourage mothers to provide milk for their infants;(7)Coaching by lactation coordinator and nursing staff
45998383|NCT01235728|Drug|MK-0873 2% Cream|Approximately 3 to 5 mg of MK-0873 2% cream per cm^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
45998384|NCT01235728|Drug|MK-0873 vehicle (placebo) Cream|Approximately 3 to 5 mg matching placebo to MK-0873 2% cream per cm^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
45998385|NCT01235728|Drug|Calcitriol Cream|Approximately 3 to 5 mg of Calcitriol 0.0003% (3 µg/g) per cm^2 of body area once daily for 28 days. The maximum area for one treatment will be approximately 5% of body surface area
45998386|NCT00559676|Drug|capecitabine|
45998387|NCT00559676|Drug|fluorouracil|
45998388|NCT00559676|Drug|irinotecan hydrochloride|
45998389|NCT00559676|Drug|leucovorin calcium|
45998390|NCT00559676|Drug|oxaliplatin|
45998391|NCT00559676|Other|laboratory biomarker analysis|
45998392|NCT00559676|Other|pharmacological study|
45998393|NCT04639271|Drug|Pyrotinib Plus And|Pyrotinib::400mg/d,qd,po
45998394|NCT04639271|Drug|Trastuzumab|8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle
45998395|NCT04639271|Drug|Abraxane|Abraxane 125mg/M2, qw iv
45998396|NCT02896764|Device|Cone-beam CT|
45998397|NCT02896959|Procedure|Arthroscopic rotator cuff repair|
45998398|NCT04639076|Behavioral|Behavioral Weight Loss Program|The BWL group will receive a standard weight loss intervention based on the evidence-based interventions currently being recommended for clinical practice, with general recommendations for caloric reductions based on starting weight and progressive weekly increases of physical activity (PA). Supporting behavioral lessons based on materials used in the Diabetes Prevention Program (DPP) will also be delivered. The weight loss 'prescription' will remain consistent throughout the 3 month trial. Participants will receive digital tools including a study smart phone app that incorporates diet self-monitoring, tracking of behavioral goals, behavioral lessons and resources, and integration of data from a study-provided Wi-Fi enabled scale and physical activity tracker.
45998399|NCT04639076|Behavioral|Personalized Behavioral Weight Loss Program|The PBWL group will receive a calorie goal based on measured resting energy expenditure and baseline PA. In Weeks 1-4, participants will be randomly assigned to test patterns that manipulate diet composition (low-fat or low-carbohydrate), meal frequency (3 or 5-6 meals/day), and PA goals (weekly minutes or daily minutes goals). Following this period, the optimal combination will be identified by the participant and interventionist, based on weight loss, blood glucose, hunger and ability to adhere to the prescription. This group will receive the same supporting behavioral lessons as the BWL group along with additional resources specific to their personalized prescription. The weight loss 'prescription' will vary across the 3-month trial based on response to treatment. Participants will receive the same digital tools as the BWL group with resources specific to following the prescription they are following during any given program week.
45998400|NCT02896725|Device|Keratin dressings|Wool-derived keratin matrix dressings applied with each change of the compression bandage until healing or the trial ends
45998401|NCT02896725|Device|Usual care dressings|Dressings chosen from study centres' formulary of non-medicated moist wound dressings (non-adherent dressings, hydrogel, alginate, hydrofibre or polyurethane foam dressings) applied with each change of the compression bandage until healing or the trial ends
45834954|NCT01456728|Dietary Supplement|Placebo|The placebo will have identical in appearance and taste with the active study product only lacking the bacteria. It will be prescribed the same way as ProGastria: omeprazole 2x20mg and Placebo 1 tablet per day for 28 consecutive days
46086249|NCT02734628|Drug|Dexpanthenol (Bepanthen® Wund- und Heilsalbe, BAY81-2996)|30 g of 5% of the active ingredient dexpanthenol plus other ingredients as ointment
46086250|NCT02734628|Drug|Placebo|Placebo to Bepanthen® ointment without active ingredient dexpanthenol
45834955|NCT04272372|Drug|Ketoprofen|PO and local therapy
45998402|NCT04639154|Procedure|Erector spinea plane block|ESPPB will be performed at the T5 and T8 levels of the spine using an in-plane approach. A real-time ultrasound machine will be used to evaluate block performance. A high frequency linear ultrasound probe will be placed longitudinally at a distance of 3 cm from the midline. After identifying the erector spinae muscle and transverse processes, we will insert a 22 G, 100-mm needle after standard skin disinfection. It will be inserted in a caudal-to-cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep into the erector spinae muscle. This plane will be opened following hydrolocalization with normal saline then 30 mL of 0.25% bupivacaine will be injected slowly, with or without adjuvants, and aspirate every 5 ml to ensure block performance.
45998403|NCT04681053|Drug|Ivermectin Powder|- Administration through inhalation (6mg) BID for 3 days
45998404|NCT04639193|Drug|Acetazolamide|Acetazolamide tablet (encapsulated)
45998405|NCT04639193|Drug|Eszopiclone|Eszopiclone tablet (encapsulated)
46086251|NCT03364868|Drug|Oral Insulin|treatment starting at 4 months - 7 months until age 3.0 years; dose escalation scheme: daily treatment with 7.5 mg or placebo for 2 months; increasing to daily treatment with 22.5 mg or placebo for the following 2 months; increasing to daily treatment with 67.5 mg or placebo until the end of the treatment period.
45998406|NCT04639193|Drug|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide/Eszopiclone
45998407|NCT04639193|Drug|Venlafaxine|Venlafaxine capsule
45998408|NCT01235689|Biological|Adalimumab|If adalimumab was initiated, it was administered subcutaneously as a 160 mg induction dose the first week, followed by 80 mg 2 weeks later, followed by 40 mg every other week as a maintenance dose. The dose of adalimumab was increased from 40 mg eow to 40 mg every week in participants with an inadequate response and de-escalated to 40 mg eow in participants who met success criteria.
45998409|NCT01235689|Drug|Prednisone|The suggested regimen for participants initiating prednisone consisted of a maximum dose of prednisone 40 mg/day for 2 weeks, followed by a fixed taper for 6 weeks.
45675499|NCT05885659|Behavioral|CBT for smoking cessation + DiMeSALUD2 protocol|In this group, a training protocol on healthy lifestyle habits and self-management of T2DM will be carried out added to usual care (CBT for smoking cessation). CBT plus DiMe-SALUD2 protocol will be developed as in the precedent group, but with the addition of a psychoeducational protocol for monitoring nicotine fading and abstinence specifically designed to address the particular needs of T2DM smokers. The main components of this protocol will be focused on strengthening healthy lifestyle habits as well as structured around the following core elements: dietary control and healthy nutrition, physical exercise, and glycemic control through daily self-registration of both glycemic variability and nicotine fading or abstinence. If necessary, the therapist will adapt these guidelines according to the established medical advice that the smokers receive from their own endocrinologist, so that this program is developed in accordance with their usual medical care.
45998410|NCT01235689|Drug|Azathioprine|Participants with normal thiopurine methyltransferase (TPMT) enzyme activity could receive oral azathioprine 2.5 mg/kg/day. In participants with intermediate TPMT enzyme activity azathioprine was initiated at a dose of 1.25 mg/kg/day. The dose of azathioprine was adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase [ALT], aspartate transaminase [AST], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.
45998411|NCT04638686|Drug|Dolutegravir 50 MG|The subjects started their antiretroviral treatment containing dolutegravir once a day.
45998412|NCT04638686|Drug|Lamivudine 300 MG|The subjects started their antiretroviral treatment containing lamivudine once a day
45998413|NCT04680819|Dietary Supplement|Anatolian Propolis|Health workers who agree to participate in the study will be accepted as the study group, and healthcare professionals who do not agree to participate in the study will be considered as the control group. The study group will be asked to take 20 drops of Propolis drop form twice a day in the morning / evening, and the control group will not receive any treatment and both groups will be followed. In this process, patients diagnosed with COVID-19 will be determined. PCR test positivity taken from the throat for the diagnosis of COVID-19 will be accepted. The research will cover a period of 1 month. At the end of 1 month, patients diagnosed with COVID-19 in the study and control groups will be compared. Thus, the protective properties of Anatolian propolis will be determined.
46086252|NCT03364868|Other|Placebo|treatment starting at age 4 months - 7 months until age 3.0 years; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
45457505|NCT03920839|Drug|Carboplatin|Carboplatin AUC5 or AUC6 administered intravenously on Day 1 of 21-day cycles.
45457506|NCT03920839|Drug|Paclitaxel|Paclitaxel administered intravenously on Day 1 of 21-day cycles.
45675500|NCT05885646|Drug|Sulthiame|Sulthiame add-on according to good clinical practice in these childhood epilepsy syndromes
45675501|NCT05885633|Procedure|endometrial sampling with pipelle|Following oocyte retrieval while the patient was under anesthesia, endometrial tissue sampling was performed with the help of pipelle cannula. A portion of the endometrial tissue was put into RNA stabilization buffer (RNAlater) to be used in qPCR and stored at -20°C until the analysis. The remaining endometrial tissue was first fixed with 10% formalin, followed by paraffin blocking and prepared for immunohistochemical analysis.
45675502|NCT05885620|Device|drinking reminder and cognitive task (smartwatch-based application)|task A: prompt to drink some water task B: prompt to circle bells on a sheet
45998414|NCT04638764|Other|Aerobic interval training combined with high intensity resistance training|Patients enrolled in arm of the study will perform 12 weeks of combined aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing) combined with high intensity resistance training (3 sets of leg press at the intensity of 70 %- 80 % of one repetition maximum (1-RM)).
45998415|NCT04638764|Other|Aerobic interval training combined with low intensity resistance training|Patients enrolled in arm of the study will perform 12 weeks of combined aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing) combined with high intensity resistance training (3 sets of leg press at the intensity of 30 %- 40 % 1-RM).
45675503|NCT05885594|Drug|[18F]NOS|[18F]-6-(2-fluoro-propyl)-4-methylpyridin-2-amine, also known as [18F]NOS, is a positron emitting radiopharmaceutical that has been studied in animals and humans which permits the visualization and measurement by positron emission tomography (PET/CT) imaging of in vivo iNOS expression as a marker of inflammation.
45998416|NCT04638764|Other|Aerobic interval training|Patients enrolled in arm of the study will perform 12 weeks of aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing).
45675504|NCT05885568|Biological|blood sampling|Blood sampling from healthy volunteers
45998417|NCT04680858|Other|DECT|Use of a digital enhanced telecommunication headset for team communication
45998418|NCT04680429|Drug|RP7214|Participants will receive single and multiple ascending doses of RP7214
45998419|NCT04680429|Drug|Placebo|Participants will receive single and multiple ascending doses of matching placebo
45998420|NCT02896842|Drug|Posology dose modification|
45998421|NCT02896842|Other|active comparator|
45998422|NCT04638530|Other|Education on breaking bad news to family members remotely|Participants will receive a combination of surveys, pre- and post-tests, lectures and didactics to increase their awareness of techniques to communicate difficult topics with patients remotely as well as skill building exercises.
45457507|NCT01131793|Device|PowerAssert RF wire in crossing coronary in-stent chronic total occlusions|Radio frequency ablation of chronic total occlusions within a stent of a coronary artery using Niobe Magnetic Navigation System (MNS) and the PowerAssert Radiofrequency Guidewire
45457508|NCT03135548|Drug|Spesolimab (low dose)|12 weeks treatment
45457509|NCT03135548|Drug|Placebo|12 weeks treatment
45675505|NCT05885568|Other|drone transportation|drone transportation
45675506|NCT05885568|Other|car transportation|car transportation
45675507|NCT05885555|Biological|Ianalumab|Intravenous infusion, prepared from concentrate solution
45675508|NCT05885542|Drug|Cannabidiol oral solution|Double-blind cannabidiol oral solution 800 mg administered once
45675509|NCT05885542|Drug|Placebo|Double-blind placebo oral solution administered once
45998423|NCT00559715|Drug|bevacizumab|1.25 mg intravitreally monthly/on demand
45998424|NCT00559715|Drug|ranibizumab|0.5 mg intravitreally monthly/on demand
45998425|NCT02896998|Procedure|Removal on demand of the syndesmotic screw|The syndesmotic screw will only be removed in case of a symptomatic implant (e.g. implant causing pain or restricted range of motion)
45998426|NCT02896998|Procedure|Routine removal of fhe syndesmotic screw|The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
45998427|NCT00559832|Other|Hypoxic Exposure|Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
45998428|NCT02896803|Drug|mFLOX|5-fluorouracil 500 mg/m2 and folinic acid 20 mg/m2 infused both bolus weekly for 6 weeks (d1, 8,15, 22, 29 and 36) and oxaliplatin 85 mg / m2 infused over 2 hours at weeks 1,3 and 5 (d1,15 and 29). The scheme will be repeated every 8 weeks.
45457510|NCT03135548|Drug|Spesolimab (high dose)|12 weeks treatment
45457511|NCT01135225|Device|PROMUS(TM) Element (TM) Stent System|The PROMUS Element Everolimus-Eluting Coronary Stent System is a device/drug combination product composed of two components: a device (coronary stent system) and a drug product (a formulation of everolimus contained in a polymer coating.
45675510|NCT05885529|Other|UCH-L1 GFAP|measurment of UCH-L1 GFAP within 12 hours in adult patients after a mild traumatic brain injury
45998429|NCT02897037|Drug|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
45998430|NCT02897037|Drug|heparin|heparin monotherapy
45834956|NCT01891110|Procedure|ES of the abdominal muscles|ES was applied with surface electrodes and fixed stimulation parameters with individual mA, depending on each patients´ sensibility.
45998431|NCT00559871|Drug|fipamezole|Fipamezole in Zydis formulation three times per day for up to 28 days
45998432|NCT00559910|Drug|PH-797804|PH-797804 at four dose levels
45998433|NCT00559910|Drug|Placebo|Placebo
45998434|NCT02896530|Other|No intervention. Description study|
45675511|NCT05885516|Procedure|intrauterine insemination|Giving washed sperm concentrate into uterine cavity via a soft catheter
45998435|NCT04680624|Procedure|Fecal sample collection|During the study, patients will be ask to collect fecal samples using sample collection kits. A total of 4 stool samples per patient will be collected.
45998436|NCT04638608|Other|EMBRACE (relatives)|Online support program for both relatives
45998437|NCT04638608|Other|EMBRACE (Health care providers)|Online support program for health care providers
45998438|NCT00553683|Drug|cyclophosphamide|
45998439|NCT00553683|Drug|poly ICLC|
45834957|NCT01891110|Procedure|ES of the limb muscles|Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
45675512|NCT05885503|Biological|RC-28E|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
45675513|NCT05885503|Biological|Aflibercept|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
45675514|NCT05885451|Drug|AMG 592|Administered as SC injection
45675515|NCT05885451|Other|Placebo|Administered as SC injection
45675516|NCT05885438|Behavioral|ACT workshop|This workshop is a brief behavioral intervention that teaches acceptance and commitment therapy skills (e.g., values clarification, acceptance, committed action) to approach healthy living.
45834958|NCT01891110|Procedure|ES of limbs & abdomen|The combination of the ES of the lower limb muscles and the abdominal muscles.
45834959|NCT01891266|Procedure|Non-tourniquet assisted TKA|The intervention group will undergo non-tourniquet assisted total knee arthroplasty, which means that blood flow to the lower limb is maintained throughout surgery.
45834960|NCT01891266|Procedure|Tourniquet assisted TKA|The procedure involves the use of a tourniquet around the thigh. During surgery the tourniquet will be inflated above the systolic blood pressure to ensure a complete bloodless surgical field.
45834961|NCT01891500|Drug|Inhaled nitric oxide|Drug is initiated at 20ppm. Patients randomized to receive iNO at OI 10-15.
45998440|NCT00553683|Procedure|hepatic artery embolization|
45998441|NCT00553683|Radiation|3-dimensional conformal radiation therapy|
45998442|NCT04638179|Other|Not intervention.Use retrospective case contrl study.|Use retrospective case contrl study.
45675517|NCT05885425|Behavioral|Telemedicine correction of medical treatment|On the basis of telemedicine data, the doctor will remotely correct medical treatment by adjusting the dose or supplementing or by omitting the medicine in order to improve the state of health, or to alleviate the symptoms of the disease monitored by telemedicine
45675518|NCT05885425|Behavioral|Education for proper lifestyle|Based on telemedicine data, the doctor can consider periodic education of the patient with the innervated group in order to improve lifestyle
45675519|NCT05885412|Genetic|RP-A601|RP-A601 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, human plakophilin 2 (PKP2), transcript variant 2a (PKP2a)
45675520|NCT05885399|Drug|Penpulimab|Penpulimab will be administered intravenously at a dose of 200 mg every 3 weeks. Treatment continued until the patient exhibited radiographic or clinical disease progression or unacceptable adverse events.
45834962|NCT01891500|Drug|Nitrogen Gas|Placebo gas (bioinert), Patients randomized to bioinert inhaled gas at OI 10-15.
45834963|NCT01891500|Drug|Crossover iNO|Patients who deteriorate (OI >20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
45834964|NCT02439450|Biological|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
45834965|NCT02439450|Drug|Nivolumab|Nivolumab 240mg IV q2weeks for 18 weeks or until disease progression or unacceptable toxicity. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
45834966|NCT02439450|Drug|Pembrolizumab|The recommended dose of KEYTRUDA (pembrolizumab) is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
45998443|NCT01229176|Biological|Vi-CRM197 vaccine|
45998444|NCT01229176|Biological|Vi Polysaccharide (PS) vaccine|
45998445|NCT01229176|Biological|Pneumococcal conjugate vaccine|
45998446|NCT02896686|Radiation|Control CT|"At the end of the follow up (12 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the abdominal wall seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for fascial closure."
45998447|NCT02896686|Other|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
45998448|NCT02896686|Procedure|Reinforcement with Light Polypropylene Mesh|Reinforcement with Light Polypropylene Mesh
45998449|NCT04638101|Behavioral|Mindfulness-based intervention|Mindfulness-based intervention: The proposed MBI was designed based on well-known MBI programs including Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy and adapted to adolescents' needs and language. The program consisted of 8 weekly sessions in groups of up to 8 participants, lasting 1h30. Two MBI groups were offered per week (Wednesdays and Fridays) and participants had the possibility to choose the most convenient day for them. Two instructors were present for each group throughout the intervention.For each session one theme was addressed, such as attention and the stabilisation of the focus of attention, bodily sensations, breath, emotions, thoughts, compassion, stress, stress reactivity and coping strategies.
45998450|NCT01228747|Drug|Levetiracetam|Oral dose at flexible increase doses: 1000 mg/day or 2000 mg/day or 3000 mg/day, twice daily, 28 weeks
46086253|NCT05528822|Procedure|ultrasound-guided high fascia iliaca compartment block|H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 ~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct. If the needle tip was correctly positioned, 0.375% ropivacaine 30 mL of local anesthetic was injected. The H-FICB was performed under ultrasound guidance by the same anesthesiologist.
46086254|NCT05528822|Procedure|ultrasound-guided pericapsular nerve group (PENG) block|A low-frequency curvilinear transducer was placed in the transverse plane over the anterior inferior iliac spine (AIIS) and moved over inferiorly to visualize the pubic ramus. The femoral artery and ilio pubic eminence (IPE) were then visualized (Figure 1). Using in-plane technique 10 cm echogenic 21 gauge needle was advanced from lateral to medial direction, and 20 ml of local anesthetic 0.5% ropivacaine was deposited between the psoas tendon anteriorly and pubic ramus posteriorly.
46086255|NCT02731118|Dietary Supplement|Salovum|AF-enriched egg yolk
46086256|NCT02731118|Dietary Supplement|Placebo|egg yolk
45457512|NCT01135225|Device|Evolution Stent System|The Evolution Everolimus-Eluting Monorail Coronary Stent System is a device/drug combination comprised of two regulated components: a device (coronary stent stent) and a drug product (a formulation of everolimus contained in a biodegradable polymer coating).
45457513|NCT02297932|Behavioral|Strength training|Participants will engage in a home-based strength training program.
45998451|NCT01228747|Drug|Placebo|Matching oral placebo tablets twice daily for 28 weeks
45998452|NCT02896413|Drug|Dexmedetomidine group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
45998453|NCT02896413|Drug|Control group|0.9% saline infusion
45998454|NCT01228591|Device|Acuvue Advance Plus|Silicone hydrogel contact lens.
45998455|NCT01228591|Device|Acuvue Advance|Silicone hydrogel contact lens
45998456|NCT02896374|Behavioral|Theory of mind without visual cues|Theory of mind stimulation without visual reinforcement while performing EEG recordings
45998457|NCT02896374|Behavioral|Theory of mind without visual cues|Theory of mind stimulation with visual reinforcement while performing EEG recordings
45998458|NCT00553722|Drug|Eplerenone|Administer Eplerenone, 25 mg,orally twice daily for 4 weeks.
46086257|NCT02694770|Biological|Neihulizumab Treatment|Monoclonal antibody
45457514|NCT02297932|Behavioral|Stretching|Participants will engage in a home-based stretching training program
45457515|NCT02301130|Biological|mogamulizumab|Mogamulizumab will be administered intravenously (IV).
45457516|NCT02301130|Biological|MEDI4736 (Durvalumab)|MEDI4736 will be administered intravenously (IV).
45457517|NCT02301130|Biological|tremelimumab|Tremelimumab will be administered intravenously (IV).
45457518|NCT03920605|Drug|Tenofovir Disoproxil Fumarate|Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.
45998459|NCT00553722|Drug|Placebo|Administer a placebo tablet orally twice daily for 4 weeks.
45998460|NCT01235338|Drug|LDX + Venlafaxine XR|"Day 1-5 LDX 30mg~Day 6-10 LDX 50mg~Day 11-15 LDX 70mg~Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily~Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily~Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily~Day 31-34 Venlafaxine XR 150mg daily~Day 35-38 Venlafaxine XR 75mg daily."
45998461|NCT01235338|Drug|Venlafaxine XR + LDX|"Day 1-5 Venlafaxine XR 75mg~Day 6-10 Venlafaxine XR 150mg~Day 11-15 Venlafaxine XR 225mg~Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily~Day 21-25 Venlafaxine XR and LDX 50mg daily~Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily~Day 31-34 Venlafaxine XR 150mg~Day 35-38 Venlafaxine XR 75mg."
45998462|NCT04638296|Other|Interviews|The investigators designed 3 versions of the semi structured interview guide for each of the surgeons/anesthesiologists (Appendix A.1), residents (Appendix A.2) and nurses (Appendix A. 3). All versions were subdivided into 3 general categories: 1) participant demographics such as participant's age, years of experience, specialty, years of employment at the institution 2) participant's perceptions of noise in the OR, what they considered as sources of noise, the loudness level, whether they thought this impacted their concentration, performance, communication, whether this was distracting or helpful in different stages of the operation, and 3) perceptions on music.
45998463|NCT02896491|Radiation|Exposure with non-ionizing electromagnetic fields|In a cross-over design subjects will be exposed to sham (placebo), GSM 900 MHz (2W/kg) and TETRA (6W/kg)
45457519|NCT03920605|Drug|Peginterferon Alfa-2a|Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
45457520|NCT03920605|Drug|Peginterferon Alfa-2b|Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
45457521|NCT02301208|Drug|Nedaplatin|Nedaplatin combine with IMRT
45457522|NCT02301208|Drug|Cisplatin|Cisplatin combine with IMRT
45458746|NCT04338178|Behavioral|Cognitive Remediation Therapy (CRT)|This intervention consists of mental exercises aimed at improving executive function via practice. Simple cognitive tasks that encourage reflective learning and insight into patient's own thinking process are administered. Exercises target set-shifting (i.e., cognitive flexibility), estimating, organization and planning.
46086258|NCT02694770|Biological|Conventional Treatment|2nd line therapy for aGvHD at the discretion of attending physician, including but not limited to biologics such as ATG, TNF-alpha inhibitors, pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis.
45834967|NCT02439450|Drug|Pemetrexed|The recommended dose of ALIMTA (pemetrexed) when administered with carboplatin and pembrolizumab for the initial treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m2 administered as an intravenous infusion over 10 minutes prior to carboplatin on Day 1 of each 21-day cycle for 4 cycles. Pembrolizumab should be administered prior to ALIMTA when given on the same day.
45998464|NCT04638023|Device|Arabin pessary|Arabin pessary was inserted intravaginally electively in women with cervical insufficiency (history based) or as emergency in those with short cervix on ultrasound.
45998465|NCT01234675|Drug|Milnacipran|50 mg twice daily
45998466|NCT01234675|Drug|Placebo|50 mg twice daily
45998467|NCT02895984|Behavioral|Single-session alcohol intervention (BMI)|The intervention recipients will receive a 1-hour individual BMI. The BMI will follow the central principles of Motivational Interviewing (MI) and will include all the components determined to be efficacious in existing multi-component BMIs (e.g., personalized feedback on indicators of alcohol-related risk, including signs of alcohol dependence and family history of alcohol risk; normative comparisons of the participant's alcohol consumption with same-sex peers in his/her dorm and throughout campus, and protective behavioral strategies). Additional components will include reviewing the pros and cons of the participant's current pattern of alcohol use, providing estimates of the participant's recent Blood Alcohol Concentration (BAC), and providing information about risks of specific negative outcomes at different levels of drinking. Participants will identify goals for behavior change, and with the counselor will develop a plan to achieve the goals and to address barriers to success.
45998468|NCT04638452|Behavioral|Video & movements recording|Video recording of face, body movements and physiological parameters (heart rate, conductance using a wireless watch) of the participants during the blood test
45834968|NCT02862132|Drug|Vedolizumab|
45457523|NCT01230229|Procedure|Stenting|The stent should be deployed percutaneously, appropriate stent(s) size selected based upon the angiogram. The diameter must be 1-2 mm larger than the vessel. Length is chosen to cover lesion with one stent if possible. The choice of brand will be made through random selection among those offering possibility to cover the lesion with one stent. If more than one stent is required, overlap between 0.5 and 1 cm is acceptable. Postdilatation must be performed with a PTA balloon shorter than the length and less than the diameter of the stent. An angiogram should be made to compare the pre- and post-implant minimum lumen diameters. The non-diseased artery diameters shall be measured and residual % stenosis calculated.
45834969|NCT02859402|Drug|Busulfan|intravenous, 3.2 mg/kg + 5% DW (the diluent quantity should be 10 times the volume of Busulfan, so that the final concentration of busulfan becomes approximately 0.5 mg/mL), once daily for 3 hours for 3 days (days -7 to -5)
45834970|NCT02859402|Drug|Fludarabine|intravenous, 30 mg/m2 + 5% DW 100㎖, over 1 hour once daily for 6 days (days -8 to -3)
45998469|NCT04638452|Behavioral|Questionnaires|Passing self and hetero questionnaires of emotion felt and perceived.
45998470|NCT02896101|Drug|Pimecrolimus Cream, 1%|
45998471|NCT02896101|Drug|Elidel® (pimecrolimus) Cream|
45998472|NCT02896101|Drug|Placebo of Pimecrolimus Cream, 1%|
45998473|NCT04637789|Behavioral|the whole body vibration|most people stand on the platform with knees bent at about a 30-degree angle, while the surface beneath their feet vibrates an astounding 30 times per second.
45998474|NCT04637789|Behavioral|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity,bands, weighted bars or dumbbells.
45998475|NCT04638218|Device|Rehabilitation Training System|The system can capture useful biomechanical data accurately, such as the location of body centre of mass (COM), the body joint angles, and the body posture. These useful data are stored in a database and can be conveniently accessed by the therapists, which facilitate the follow-up of the patients' therapeutic progress.
45998476|NCT02896062|Behavioral|sleep-coaching|Sleep-coaching with elements of cognitive behavioral therapy for insomnia and general information about sleep
45998477|NCT04638257|Biological|Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14|Daily oral Lactobacilli starting at =<18 weeks of gestation in singleton pregnancy
46086259|NCT02731274|Other|Regular physical activity in Motor memory consolidation|After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training. For the analysis of the results, descriptive and inferential statistics were used.
46086260|NCT02731196|Behavioral|Exercise Intervention|Early versus later stabilization and neurodynamic exercise intervention following a post-op lumbar microdiscectomy
45998478|NCT04638257|Other|Placebo|Daily oral placebo starting at =<18 weeks of gestation in singleton pregnancy
45998479|NCT02896179|Device|Robot-assisted gait training group+VR|The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
45998480|NCT02896179|Device|GEO|The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GE-O System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles
45998481|NCT04637906|Dietary Supplement|Bioarginina®|Food supplement based on 1,66 grams of L-arginine
45998482|NCT02896023|Drug|human menopausal gonadotropin|Induction of ovulation followed by ICSI
45998483|NCT04637750|Behavioral|Educational intervention|The GPs randomized to the intervention arm will receive a feedback informing on their absolute number of patients treated with at least one PPI during the baseline period and if they have been prescribed above or below the median of appropriate prescriptions rate in their local area. They will be also provided with a scientific document including technical details on AIFA reimbursement criteria (NOTA 1 and 48), short hints about adverse events related to PPI long- term use in older patients and recommendation on how to discontinue PPI therapy (i.e. gradual step down administration to avoid paradoxical effect).
45998484|NCT02896140|Other|Type 2 diabetes in WhyWAIT Program|The sum of servings per day of milk, cheese, yogurt, and other dairy foods.
45998485|NCT04637633|Drug|topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California)twice daily dose,|topical preservative free artificial tears Q.I. D.
45998486|NCT02896218|Other|Pharmacists consultation|Pharmacists consultation of vancomycin individualized dosing strategy
45998487|NCT04637867|Other|Collection of blood, salivary and nasopharyngeal samples.|"Each visit M6 and M12~Blood: 1 PAXgene tube (2.5mL) 1 EDTA tube (4mL), 1 dry tube with gel (5mL), 3 EDTA tubes (10mL each)~Salivary sample~Nasopharyngeal sample"
45834971|NCT02857374|Procedure|Diagnostic Microscopy|Undergo intravital microscopy
45998488|NCT01228318|Drug|Zoledronic acid|"A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.~A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes."
45998489|NCT02895867|Other|Full fat dairy|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of full fat dairy products into their diet
45998490|NCT02895867|Other|Low fat dairy|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of low fat dairy products into their diet
45998491|NCT02895867|Other|Control|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will not be asked to include a specified amount or type of dairy products
45998492|NCT04637828|Drug|GNS561|study drug
45998493|NCT04206475|Other|rehabilitation|"the rehabilitation program consisted of an intensive treatment lasting 4 weeks, and including 3 daily interventions each working day (5 working days per week, for a total of 20 days of treatment and 60 sessions). The 3 daily sessions were organized as follows:~1 physio-kinesis and/or occupational therapy, 1 speech therapy, and 1 neuro-psychology treatment.~Each session lasted 45 minutes."
45998494|NCT04206475|Other|Intensive Memory-Focused Training Program (IM-FTP)|During each session, the patient was engaged in a one-to-one interaction with the therapist. Overall, the treatment targeted the following memory subfunctions: verbal and visuo-spatial short-term memory, verbal and visuo-spatial long-term memory, working memory and procedural memory
46086261|NCT02694926|Other|Education|During a session of 90 minutes duration, patients are educated in basic knowledge on adrenal insufficiency including the correct behaviour in emergency settings.
46086262|NCT02734472|Other|Incidence and risk factors of hypertension|During the follow-up period,General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness,IMT, FMD) will be collected.
45834972|NCT02857374|Drug|Fluorescein Sodium Injection|Given IV
45834973|NCT02857374|Other|Laboratory Biomarker Analysis|Correlative studies
45834974|NCT02857374|Procedure|Sentinel Lymph Node Biopsy|Undergo standard of care sentinel node biopsy
45834975|NCT04273074|Radiation|sonographic assessment|preoperative sonographic assessment to airway
45834976|NCT04843722|Biological|hAd5-S-Fusion+N-ETSD vaccine|Vaccine containing both full length wild type SARS-CoV-2 spike gene optimized for better spike protein expression, and full length wild type SARS-CoV-2 nucleocapsid gene modified to also contain an enhanced T cell stimulation domain (ETSD) to enhance cell-mediated immunity.
45998495|NCT05512624|Behavioral|Common Elements Treatment Approach|"For treatment group participants, they will then have weekly meetings with a counselor lasting no more than 1.5 hours per session, and a total of approximately 10 sessions. Both treatment and wait list participants will then complete the assessment instrument at 3 months and 6 months post-enrollment (each lasting no more than 1.5 hours). All total, it is expected that treatment group participants will have up to 13 meetings with a study team member or counselor over the course of their participation.~Wait list group participants will have 3 meetings with a study team member over the course of their participation. If the treatment is deemed to be effective these wait list participants will be the first adults to be offered the intervention after trial completion."
45998496|NCT02895828|Other|Core Stabilization Exercise|the participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks
45998497|NCT02895828|Other|General Strengthening Exercise|the participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks
45834977|NCT04844268|Biological|Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine|Intramuscular injections of 1 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT (HDT-301)) at a dose of 1 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
45834978|NCT04844268|Biological|Cohort 2 RNA VACCINE MCTI CIMATEC HDT(HDT-301) vaccine|Intramuscular injections of 5 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT(HDT-301)) at a dose of 5 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
45998498|NCT02895672|Drug|GLP-1 therapy|The investigators will assess the efficacy and safety of 12 months of GLP-1 therapy added to the therapeutic regimen of a group of T2DM patients who have received basal insulin therapy for a minimum of one year.
45998499|NCT04637711|Procedure|Focus clearing + whole breast exploration and washing + one-stage micro plastic surgery No Intervention: Extensive lesion excision|Only visible lesions and necrotic tissues, such as abscess cavity, sinus tract and fistula, were removed intraoperatively, while normal glands and fat were retained. Preoperative ultrasound was used to locate the lesion area and then the surgical incision was designed. Intraoperative ultrasound examination of latent small lesions, resection of lesions visible under ultrasound, and then a full breast exploration, one finger page incision interval.Radially cut from the base to the subcutaneous, lesions were found and treated locally. After removal of lesion, fully using the syringe, in turn, use of 3% hydrogen peroxide solution, 1% eniodine, saline water is widely jet pulse washing, and around the lesions base. After rinsing, soak in 1% active iodine for 10min, then rinse with normal saline until the liquid is clear. Breast tumor Surgery (Oncoplastic Breast Surgery, OBS) core technology (volume replacement and volume replacement).
45998500|NCT02895516|Device|Vibrating capsule|Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
45998501|NCT04637516|Device|"Animation program BlinkBlink"|Computer program that presents horizontal bars on the computer screen that move from above and below towards each other, mimicking a blink movement.
45998502|NCT01227967|Drug|Amantadine, Ribavirin, Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg, three capsules of Ribavirin 200 mg for total of 600 mg, and one capsule of Amantadine 100 mg.
45998503|NCT01227967|Drug|Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
45998504|NCT02895555|Procedure|i-FACTOR|Between 5-10 CC i-FACTOR putty mixed with local harvested autograft pr level spondylodesis compared to 30 grams of allograft pr level mixed with local harvested aulograft.
45834979|NCT04844268|Biological|Cohort 3 VACCINE RNA MCTI CIMATEC HDT(HDT-301) vaccine|Intramuscular injections of 25 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT(HDT-301)) at a dose of 25 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
45834980|NCT04844268|Biological|Placebo|Intramuscular (IM) injection of saline (0.9% sodium chloride) on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3), in each cohort.
45834981|NCT04842552|Drug|Hydralazine hydrochloride 25mg tablets|Hydralazine hydrochloride 25mg tablets three time daily for 365 days (one year)
45834982|NCT04842552|Drug|Placebo|Placebo
45998505|NCT02895555|Procedure|Allograft|Approx 50 g of allograft bone in the fused site
45998506|NCT00560027|Other|Case Management by Family Support Counselor (not RCT)|N/A. Had planned to study RCT of case management intervention but unable to carry out RCT. Instead studied screening practice and healthcare utilization in mothers with PPD, IPV or both.
45998507|NCT00560144|Drug|RG1507|3mg/kg iv weekly
45998508|NCT00560144|Drug|RG1507|9mg/kg iv weekly
45998509|NCT00560144|Drug|RG1507|Pharmacokinetic-derived dose, <=16mg/kg iv weekly
45998510|NCT02895477|Device|hearing aid|
45998511|NCT04317391|Behavioral|Pain management program|Mindfulness based stress reduction
46086263|NCT03695510|Drug|Afatinib Oral Tablet|40mg oral, daily, continuously
45998512|NCT00553761|Device|Pattern electroretinogram|Full field and hemifield (nasal and temporal) stimulation transient pattern electroretinogram (PERG) were recorded both in patients and controls.
45998513|NCT04637477|Behavioral|Virtual ELM|Participants will attend 1.5-hour virtual group-based sessions for 12 weeks. The program includes physical activity, cooking demonstrations, and group discussions. All sessions are led by a registered dietitian and health psychologist.
45998514|NCT04637204|Drug|Cabozantinib|oral therapy
45675521|NCT05885113|Behavioral|NIDCAP Developmental Care|The intervention of Individualized Developmental Care (IDC) is designed to minimize the mismatch between the fragile infant brain's expectations and the experiences of stress and pain inherent in the hospital environment. An ICU that provides individualized, developmentally-supportive care includes a soothing environment, supports parents as their child's primary caregiver, providing continual adjustment of caregiving in support of the child's wellbeing by reading the infant's cues and providing interventions to calmness throughout caregiving, capitalizing on the infant's strengths, and providing supports toward healing, growth and learning. NIDCAP is the experimental intervention to be tested in the current study. NIDCAP is the only evidence-based, comprehensive, internationally recognized program of IDC.
45998515|NCT04637204|Drug|Axitinib|oral therapy
45998516|NCT02895633|Other|Ecography|Standard Doppler ultrasound and perfusion imaging after injection of Sonovue
45998517|NCT02895633|Other|CT scan|With injection of Iomeron 400
45998518|NCT02895633|Other|MRI|With injection of gadolinium (Multihance)
45998519|NCT04637126|Other|Cardiac output measurement by transpulmonary thermodilution and transthoracic echocardiography|Cardiac output is measured for all patients with transpulmonary thermodilution TPTD and transthoracic echocardiography TTE according to the recommendations
45998520|NCT01227928|Drug|Pazopanib|Pazopanib 800 mg daily for 24 months
45998521|NCT01227928|Drug|Placebo comparator|Placebo 800 mg daily for 24 months
45998522|NCT02895438|Dietary Supplement|gluten|
45998523|NCT04637360|Drug|Cinacalcet Tablets|All study subjects were treated with a fixed dose of oral Cinacalcet (25 mg/day) from baseline to 6 months.
45998524|NCT04637360|Drug|calcitriol|All hyperparathyroidism were treated as traditional therapy with oral calcitriol 0.25 mcg(dosage according to IPTH serum level) from baseline to 6 months.
45998525|NCT05656885|Device|Soft Spherical Hydrogel Contact Lens A|Soft Spherical Hydrogel Contact Lens A - first period of 15 minutes
45998526|NCT05656885|Device|Soft Spherical Silicone Hydrogel Contact Lens B|Soft Spherical Silicone Hydrogel Contact Lens B - second period of 15 minutes
45998527|NCT04317703|Drug|Gemigliptin tartrate sesquihydrate and metformin|Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
45998528|NCT04317703|Drug|gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release|"Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base)."
45998529|NCT02895399|Other|Cervico-Vaginal Smears analysis|Cervico-Vaginal Smears analysis
45998530|NCT05656846|Device|PulseNmore ES™|The patients will be instructed on the mode of operation of home ultrasound device (pulsenmore), the frequency and means of communication with the study team.
45998531|NCT05656846|Device|Standard Ultrasound|These patients will not receive the additional intervention and will use the Standard Ultrasound. A population of patients between 12 and 22 weeks of gestation with history of recurrent pregnancy losses who will be subjected to routine antenatal care as per clinic protocol. These patients will not receive the additional intervention.
45998532|NCT04317352|Procedure|MVR|Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
45675522|NCT05884437|Procedure|Chiropractic adjustment|Participants will receive 6 weeks of chiropractic care. The frequency of care will be determined by the field clinician. Participants will have their spine assessed for the presence of vertebral subluxations per their clinician's normal and customary procedures. The adjustment technique(s) utilized by the field clinician will be at their discretion.
45998533|NCT00624598|Behavioral|SMART|Use of measured resting metabolic rate from indirect calorimetry for personalized diet program and use of a computer application for journalizing food and exercise.
45998534|NCT02895126|Behavioral|"Appui Parental program"|
45998535|NCT02895126|Behavioral|Regular parental support|
45998536|NCT04636892|Other|MindMics earbud|Novel noninvasive wearable infrasound sensor
45998537|NCT05656690|Other|Exposure to disability|Disability status assessed by functional measures
45998538|NCT05656612|Other|Written, Oral and Visual Education|Before the training, state anxiety levels were measured with a questionnaire. The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.
45998539|NCT05656612|Other|Written, Oral and Visual Education|Before the training, state anxiety levels were measured with a questionnaire. The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.
45998540|NCT05656612|Other|Written, Oral and Visual Education|"Before the initial training was given, state anxiety levels were measured with a questionnaire.~The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale."
45998541|NCT04636580|Behavioral|parent accompanying the child during treatment|After the parents were divided into two groups, anxious and non-anxious, the groups were equally divided randomly and the parents accompanied their children during the treatment
46002402|NCT03156660|Behavioral|Weight loss intervention (Group 2)|"Participants will be asked to achieve a weight loss goal of at least 5% of their baseline weight by week 8.~Intervention Components:~Tailored calorie and fat goals based on their baseline weight.~Daily dietary intake and physical activity self-monitoring using a website or app.~Daily weight self-monitoring on the BodyTraceTM e-scale~Lesson materials for each session, drawn from the Look AHEAD intensive lifestyle intervention~Meal replacements for two meals and one snack for 8 weeks as a method to achieve the study's calorie and fat goals and as a strategy to control portions~Graded physical activity goals of 175 minutes of moderate intensity exercise (e.g., brisk walking) per week, or 10,000 steps per day~Fit Bit Alta activity trackers to self-monitor steps"
46086264|NCT03695510|Drug|Pembrolizumab Injection|200mg, intra-venous injection, every 3 weeks, for 35 cycles
45998542|NCT05656573|Drug|CART-PSMA cells|"This study consists of 2 parts:~Part A (Dose Escalation): The investigators are looking the highest dose of the study intervention that can be administered safely without severe or unmanageable side effects in participants that advanced prostate cancer.~Up to 4 dosing cohorts, with up to 3 subjects enrolled in each cohort, will be explored as follows:~cohort 1： CART-PSMA cells 1-3x10^7 on Day 0;~cohort 2： CART-PSMA cells 1-3x10^8 on Day 0;~cohort 3： CART-PSMA cells 1-3x10^7 on Day 0,following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given over 3 days;~cohort 4： CART-PSMA cells 1-3x10^8 on Day 0,following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given over 3 days;~Part B (Expansion Cohort): Participants will be treated at the respective dose (at or below the Maximum Tolerated Dose), as determined during Part A (Dose Escalation)."
45675523|NCT05884372|Drug|Eldecalcitol|the same as arm descriptions.
45675524|NCT05884372|Drug|Native Vitamin D|the same as arm descriptions.
45675525|NCT05884372|Drug|Denosumab|the same as arm descriptions.
45675526|NCT05884372|Drug|Calcium|the same as arm descriptions.
45675527|NCT05884346|Other|Ultrahigh-frequency ultrasound|Arterial remodeling of the digital arteries will be measured by ultrahigh-frequency ultrasound and will be compared in heart failure patients with preserved ejection fraction with and without identified macroscopic coronary disease
45675528|NCT05884307|Other|Trans Care Web App|an educational and interactive website designed to improve coping strategies of TNB individuals
46086265|NCT02739464|Other|Exercise + SOC PT/OT|
46086266|NCT02739464|Other|SOC PT/OT|
46086267|NCT02731040|Drug|Bisphosphonate|
46086268|NCT02734316|Other|endoscopic procedure|Evaluation of adverse events in patients on DOACs undergoing GI endoscopy
45998543|NCT05656534|Drug|Suvorexant|This study is a double-blind study. Participants will complete an initial screening visit and pre-treatment lab visits (EMG, fMRI). Suvorexant (SUV) will be placed in opaque capsules with dextrose filler. After the pre-treatment visits participants will take one pill of SUV at the Acute Drug Challenge under medical supervision. Ninety minutes post ingestion participants will complete an EMG. Laboratory assessments will occur during peak concentration, 2 hours post-ingestion. At the end of the visit, participants will be given a blister pack with 28 pills. Participants will be instructed to take one pill orally about 30 minutes prior to sleep time each night for 28 days. Participants will be provided education about common side effects. Participants will complete daily surveys to monitor side effects and potential drug-drug interactions. At the end of the 28 days, participants will complete post-treatment lab visits.
45998544|NCT05656534|Other|Placebo|This study is a double-blind study. Participants will complete an initial screening visit and pre-treatment lab visits (EMG, fMRI). The placebo pill will be identical in appearance to suvorexant but will contain only dextrose. Following the pre-treatment visits, participants will take one pill at the Acute Drug Challenge under medical supervision. Ninety minutes post ingestion participants will complete the EMG paradigm. At the end of the visit participants will be provided a blister pack with 28 pills. Participants will be instructed to take one pill orally about 30 minutes prior to sleep time each night for 28 days. Participants will be provided education about common side effects. Participants will complete daily surveys to monitor side. At the end of the 28 days, participants will complete post-treatment lab visits.
45998545|NCT05656456|Other|Y-BOCS or FAS online survey, interview|Y-BOCS or FAS and online survey will be administered interview will be conducted
45998546|NCT05656339|Dietary Supplement|CHO+WP|Oral supplement containing carbohydrates plus whey protein
45998547|NCT05656339|Dietary Supplement|CHO|Oral supplement containing carbohydrates
45998548|NCT05656339|Dietary Supplement|Fast|Fast condition of 12 hours
46086269|NCT02730806|Behavioral|NLP|NLP techniques, such as VKD, visual/auditory/kinesthetic swishes, modified especially for PTSD, will be implemented one-on-one with each woman in this arm.
46086270|NCT02734160|Drug|Galunisertib|Administered orally
45675529|NCT05884216|Device|Entarik Feeding Tube System|"Entarik Feeding Tube:~The Entarik Feeding Tube is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition.~Entarik Feeding Tube System:~The Entarik Feeding Tube System is designed to aid qualified operators in the placement of the Entarik Feeding Tube (Entarik FT) into the stomach of patients requiring enteral feeding. The Entarik FT is equipped with sensors designed to provide information about the location of the tube tip relative to the stomach, thus assisting in reducing the incidence of misplacement during first positioning. The Entarik Monitor also monitors the feeding tube position continuously during the course of feeding and automatically and in real-time alerts of tube migration."
45998549|NCT05656300|Diagnostic Test|MRI scan using USPIO particles|Diagnostic imaging
46002403|NCT03156660|Behavioral|Self-guided intervention (Group 3)|"Participants randomized to Group 3 will wait for 8 weeks before initiating the same smoking cessation intervention as the other two conditions, while they review the provided weight management focused book.~Intervention Components:~EatingWell Diet book.~Daily weight self-monitoring on the BodyTraceTM e-scale"
45675530|NCT05884216|Device|Entarik Feeding Tube System without monitoring|"Entarik Feeding Tube:~The Entarik Feeding Tube is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition.~Entarik Feeding Tube System:~The Entarik Feeding Tube System will collect data from the Entarik Feeding Tube. There will be no monitoring or dislodgement alerts, and no placement guidance."
46002404|NCT03118349|Drug|MVT-1075|MVT-1075 administered in two fractions, with each administration of MVT-1075 preceded by blocking dose of MVT-5873.
46086271|NCT02734160|Drug|Durvalumab|Administered IV
46086272|NCT02739308|Other|Proprioceptive Training|In this study the training program will be developed for 12 weeks and will be applied during the heating of the athletes , three times a week and the duration of each session is 30 minutes. Each week will be chosen three of the 14 exercises adapted for fencing athletes , and preferably one of each category.
46086273|NCT02739308|Other|Control Group|The control group will not make the intervention and will continue with usual training fencing.
46086274|NCT02730650|Other|Platelet Rich Therapy (PRT)|Platelet Rich Therapy (PRT) involves injection of patient's own platelets and fibrin.Topical anesthetic will be applied to the face for a period of fifteen minutes prior to the injection. For PRP preparation, 8 cc of blood will be collected from each patient just before each procedure. Approximately 0.3-0.4 cc of PRP will be injected into each standardized injection point in a superficial manner. The injections points are 6 points on each side of the face along the inferior border of cheek and mid-cheek (12 total). The PRP injection will be followed by 10-15 minutes of icing.
46086275|NCT02730494|Device|Lcr Regenerans® vaginal capsules|
46086276|NCT02730494|Device|Lcr Regenerans® vaginal tablet|
46086277|NCT02730572|Drug|Concerta|This is an observational study. Participants who have been on Concerta for at least 60 days will be observed.
46086278|NCT02730572|Drug|Concerta AG formulation|This is an observational study. Participants who have been on Concerta for at least 60 days and switch to authorized generic will be observed.
45998550|NCT04636541|Behavioral|Goal Management Training|Goal Management Training® (GMT) has been developed to improve executive functions. It was validated in patients presenting executive dysfunction following many conditions: acquired traumatic brain injury, neurodevelopmental spina bifida, attention deficit and hyperactivity disorder (ADHD), subjective cognitive complaints and multiple sclerosis. GMT includes self-instruction strategies, self-monitoring exercises, cognitive training techniques, psychoeducation on cognitive processes, mindfulness exercises and assignments between sessions. It has been shown to increase patient awareness of deficits and improve cognitive control in goal-directed behaviors. The original GMT is a nine-week program administered to dysexecutive patients in 90-to-120-minute group sessions. Thus, it might be suitable for PD-MCI patients presenting with executive dysfunction.
45998551|NCT04636541|Behavioral|Psychoeducation|See the Arm section for full details. For a justification of how we designed this intervention: Many clinical guidelines include general recommendations about giving information to PD patients and family so they can take part into decision process. However, few standardized psychoeducation interventions are available, and they don't include information on PD cognitive decline. Some studies investigated Mindfulness Based Stress Reduction (MBSR) and other related mindfulness interventions in PD patients. In this approach, formal meditative exercises are included to develop non-judgmental attention to experiences in the present moment. In elderly patients with MCI unrelated to PD, mindfulness interventions show positive effects on cognitive functioning, including attention, executive functioning and memory (Gard et al., 2014). Therefore, non-pharmacological interventions for PD-MCI including both education on cognitive symptoms, as well as mindfulness exercises, are promising.
46086279|NCT02730572|Drug|Concerta EG formulation|This is an observational study. Participants who have been on Concerta for at least 60 days and switch to equivalent generic will be observed.
45998552|NCT02895009|Device|experimental group|Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 1st hour and completed at the 3rd hour, and the TR Band is removed at the 12th hour.
45998553|NCT02895009|Device|control group|Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 2nd hour and completed at the 6th hour, and the TR Band is removed at the 24th hour.
45998554|NCT04638959|Other|collect gastric tissue and stool samples|collect gastric tissue and stool samples
45998555|NCT00624637|Other|aromatherapy massage|Ten minutes massage of hands, arms or feet with mandarin essential oil 1% (Citrus reticulata) or with carrier oil only
45998556|NCT05656144|Device|Cadonilimab|AK104, 6mg/kg, Q2W
45998557|NCT05656105|Drug|DPA-714 PET/MRI|DPA-714 PET/MRI
46002405|NCT03118349|Drug|MVT-5873|MVT-5873 administered intravenously as a non-radioactive blocking agent prior to administration of MVT-1075.
46002406|NCT03053115|Drug|Liothyronine|Cases will take liothyronine drops in the morning and two hours after dinner
46086280|NCT04225988|Drug|Extended-release tacrolimus|Patients will receive the extended-release formulation of tacrolimus for maintenance immunosuppression.
46086281|NCT04225988|Drug|Immediate-release tacrolimus|Patients will receive the immediate-release formulation of tacrolimus for maintenance immunosuppression.
46086282|NCT02739230|Drug|Exparel|
46086283|NCT02739230|Drug|On-Q pain intra-articular catheter|
46086284|NCT03690674|Behavioral|Lifestyle Enhancement for ADHD Program|The LEAP intervention consists of 3 components: 1) an enhanced 8-week, group-based BMT curriculum, 2) parent and child use of the Garmin daily activity tracker accompanied by personalized goal setting, and 3) parent participation in a private Facebook group to encourage PA goal achievement and promote social support and positive parenting.
46086285|NCT04187612|Device|Bioelectrical Impedance Analysis (BIA)|BIA will be used to determine total body water
46086286|NCT02730182|Other|altitude exposure|altitude exposure
46086287|NCT02738996|Behavioral|Sedentary time breaks either every 60 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min
45457524|NCT01230229|Other|Best medical treatment|Patients randomised to conservative treatment will receive appropriate medication with target levels of cholesterol 4,5 mmol/l, LDL 2,5 mmol/l and blood pressure level of 130/80 mmHg in addition to instruction how to engage in an exercise program. Each patient will receive a 'step-meter' which has to be carried during all activity during the first month and then during one week before each follow up visit. Step-meter read-outs will be recorded during each follow up visit. Smokers will be actively advised to quit smoking.
45675531|NCT05884060|Other|No intervention|No interventions
45675532|NCT05883566|Behavioral|experimental|During the procedure, the chairside assistant can capture video recordings of the child's behavior and facial expressions. These videos can be later reviewed by a trained observer who can evaluate the child's pain experience
45675533|NCT05882643|Other|moderate to deep neuromuscular blockade|"Maintaining moderate to deep neuromuscular blockade during an intraoperative period (Train-of-four 0-3 count, post-tetanic count > 1)~Rocuronium (intravenous, 1.0 mg/kg at induction period)"
45998558|NCT05656066|Behavioral|The Vibration Intervention|The vibration frequency of the massager, which accelerates blood circulation, is 6000 / min, it works with a 1.5 volt battery. Can be used easily with one hand. The vibration simulator design is based on the gate-control theory, which allows for a reduction in the perceived amount of pain experienced during injection by closing the pain gate in the spinal cord in creating a stimulus on the skin.
45998559|NCT05656066|Behavioral|The Pressure Intervention|Pressure was placed in the ıntramuscular area properly 30 seconds before injection. Then the injection process was completed.
45998560|NCT04680663|Diagnostic Test|Peripheral Perfusion index|Peripheral Perfusion index is the ratio between pulsatile blood flow to non pulsatile blood flow or static blood in the peripheral tissue
45998561|NCT04680663|Diagnostic Test|serum lactate level|Blood lactate (product of metabolism) level is maintained by a cycle of continuous production and metabolism allowing it to be kept within normal values
45998562|NCT00560222|Dietary Supplement|bovine lactoferrin|1gm of lactoferrin will be given each day
45998563|NCT00560222|Dietary Supplement|placebo [maltodextrin]|placebo that appears identical to lactoferrin will be given daily
45998564|NCT04317508|Drug|Topicale GelPatch (Benzocaine 18%)|Intervention group
45998565|NCT04317508|Drug|Benzocaine oral gel 20%|control group
45998566|NCT05655988|Diagnostic Test|inguinal ultrasonography|After a total extraperitoneal inguinal hernia operation performed using a fixation-free mesh, ultrasonography will be performed on all patients to calculate the slip size of the mesh.
45998567|NCT04636658|Other|Incentive spirometer training|Incentive spirometer training 5 sessions a week, each session of 15 minutes, for 4 weeks
45998568|NCT04636658|Other|diaphragmatic resistance exercises|"Incentive spirometer with diaphragmatic resistance exercises. Resistance is applied through the different Thera bands and then performing the pursed lip breathing exercise. Resistance increased weekly as per tolerance by the patient.~Digital spirometer training for 15 minutes. diaphragm breathing exercises with resistance for 30 minutes. 5 sessions a week, for 4 weeks"
45998569|NCT05655910|Dietary Supplement|Ensure Surgery Immunonutrition shake|Nutrition shake to support immune health and recovery from surgery.
45834983|NCT01891656|Behavioral|Motivational Interviewing|"MI is a client centered, directive style of interacting with a person to help explore and resolve ambivalence about change (Miller & Rollnick, 2002). MI borrows from Client-Centered Counseling in its emphasis on empathy, optimism, and respect for client choice (Rogers, 1961). MI also draws from Self-Perception Theory, which says that a person becomes more or less committed to an action based on the verbal stance he or she takes (Bem, 1972). The effects of MI tend to be in the small-to-medium range when compared to no treatment, and nonsignificant when compared to more extensive treatment."
45998570|NCT04317274|Behavioral|Good high cholesterol video|The short video illustrated key components of a high quality shared decision making conversation between a doctor and patient actor around treatment of high cholesterol.
45998571|NCT04317274|Behavioral|Poor high cholesterol video|The short video illustrated a typical conversation between a doctor and patient actor that did not cover key aspects of share decision making around treatment of high cholesterol.
45998572|NCT04317274|Behavioral|Good colon cancer screening video|The short video illustrated key components of a high quality shared decision making conversation between a doctor and patient actor around screening for colorectal cancer.
45998573|NCT04317274|Behavioral|Poor colon cancer screening video|The short video illustrated a typical conversation between a doctor and patient actor that did not cover key aspects of share decision making around screening for colorectal cancer.
45998574|NCT04636463|Procedure|Intraoperative Music|Hand Surgery performed with the participant awake, using local anesthesia. Headphones will be worn by the participant and surgery will be performed while the participant is listening to music
45457525|NCT03511612|Diagnostic Test|Measure ankle brachial index (ABI)|This is a head-to-head comparison of 2 methods of determination of the ABI, taking the Doppler method as the standard and the oscillometric device AVP as the challenger
45675534|NCT05882643|Other|shallow to minimal neuromuscular blockade|"Maintaining shallow to minimal neuromuscular blockade during an intraoperative period (Train-of-four 4, post-tetanic count < 0.9)~Rocuronium (intravenous, 0.3 mg/kg at induction period)"
45834984|NCT01891656|Behavioral|Motivational Computer|The growing use of technology has led to the development of automated interventions for behavior change, including some that target drug and alcohol use (Elliott, et al, 2008; Lustria, et al, 2009; Revere & Dunbar, 2001; Walters, et al, 2006) and treatment interest (Lieberman & Massey, 2008). As discussed by Hester & Miller (2006), automated interventions have several potential advantages over face-to-face interventions: (I) They require little or no staff contact, which may increase cost-effectiveness; (2) they can allow for automatic data collection and follow-up; and (3) they can be disseminated with little loss of fidelity.
45834985|NCT02535312|Drug|Cisplatin|Given IV
45834986|NCT02535312|Drug|Methoxyamine|Given PO
45834987|NCT02535312|Drug|Pemetrexed Disodium|Given IV
45998575|NCT04636736|Diagnostic Test|HIV drug resistance testing|HIV drug resistance testing in people newly diagnosed in HIV in Poland
46086288|NCT02738996|Behavioral|Sedentary time breaks either every 30 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min
46086289|NCT02738996|Behavioral|Sedentary time breaks every 15 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min
45457526|NCT01135303|Device|VistaO2 device|Full night VistaO2 device monitoring synchronized with the gold standard polysomnography.
45675535|NCT05882305|Biological|(Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell line lysate|Patients will receive approximately （2.5-10）x10^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times.
45457527|NCT01361438|Other|Total therapy approach|Total therapy approach
45457528|NCT03511534|Behavioral|Psychotherapy|Evidenced based psychotherapy by a trained psychologist
45457529|NCT03511534|Other|Pharmacotherapy|Pharmacotherapy by a psychiatrist
45675536|NCT05881993|Drug|CBP-4888|siRNA therapeutic
45675537|NCT05881993|Other|Placebo|Normal Saline
45675538|NCT05881161|Behavioral|Adherence self-efficacy-enhancing exercise|This exercise aims to increase self-efficacy to adhere to an internet intervention. It consists of a video and two text-based tasks. The contents are grounded in Social-Cognitive Theory.
46086290|NCT02733926|Other|Adding of vegetation into the backyards of kindergarten|Living plants are transferred into the backyards of kindergartens. This is assumed to affect the measured variables of children.
45998576|NCT04680702|Diagnostic Test|Sims Score|Evaluation Of siMS Score As Amarker Of Metabolic Syndrome In Children With Simple Obesity
45998577|NCT00560261|Other|NO-CO inhalation and expiration|NO-CO inhalation and expiration
46086291|NCT02733848|Drug|Creon|"Creon is a porcine derived pancreatic enzyme supplement that comes in in fixed dose combinations of lipase, protease, and amylase, respectively. Dosing is based on lipase per kilograms per meal (i.e. lipase units/kg/meal). Subjects will be started at a dose of 500 units of lipase/kg/meal and snacks at week 4 and continued until week 8. A follow-up visit at week 6 will assess patient for tolerance to Creon and need for dosage adjustment.~Formulations come in different fixed dose combinations as follows:~Creon: Lipase 3000 USP units, protease 9500 USP units, and amylase 15,000 USP units~Creon: Lipase 6000 USP units, protease 19,000 USP units, and amylase 30,000 USP units~Creon: Lipase 12,000 USP units, protease 38,000 USP units, and amylase 60,000 USP units~Creon: Lipase 24,000 USP units, protease 76,000 USP units, and amylase 120,000 USP units~Creon: Lipase 36,000 USP units, protease 114,000 USP units, and amylase 180,000 USP units"
46086292|NCT02733848|Other|Diet|A registered dietician will meet with the subject and take a thorough review of the patient's dietary history. The subject will then be counseled on a lower carbohydrate and higher protein diet. This diet will be continued for the entire 12 week of the study. The registered dietician will reinforce dietary recommendations by phone on week 2, 4 and 8, respectively.
46086293|NCT02733848|Other|Placebo|Placebo will be given to the patient in single blind fashion with the subject unaware but PI aware of study drug assignment from week 8-12. Placebo tablets will be given with meals and snacks similar to CREON to maintain patient blinding to study drug assignment. A follow-up visit on week 10 to review patient tolerance, side effects and possible drug adjustment.
45998578|NCT00560261|Other|NO-CO inhalation and expiration|NO-CO inhalation and expiration
45998579|NCT00560300|Drug|1 alpha D2|Vitamin D sterol
45998580|NCT00560300|Drug|1,25 dihydroxy vitamin D3|Active vitamin D sterol
45998581|NCT00560300|Drug|Sevelamer HCl|Phosphate binder
46086294|NCT02733770|Procedure|Laparoscopic sleeve gastrectomy|Doppler ultrasound.
46086295|NCT02733770|Procedure|Laparoscopic mini gastric bypass|Doppler ultrasound.
46086296|NCT02730026|Drug|Ketoprofen|Clinical efficacy of the Ketoprofen 100 mg was study after lower third molar surgery.
46086297|NCT02730026|Drug|Ketoprofen and Omeprazole|Clinical efficacy of the Ketoprofen 200 mg and Omeprazole 20 mg will be study after lower third molar surgery.
46086298|NCT03682406|Behavioral|CAMS-G|Group-based suicide-specific intervention based upon the Collaborative Assessment and Management of Suicidality.
45675539|NCT05881161|Behavioral|Med-Stress Student|Med-Stress Student is an intervention that spans over 4 weeks and aims to enhance resources to cope with job stress and promote well-being in medical students.
45998582|NCT00560300|Drug|Calcium Carbonate|Phosphate binder
45998583|NCT02895243|Other|Prehabilitation|The study will use a generic prehabilitation program which will include the following components: Warm-up, cardiovascular training, strength training, flexibility training, and cool down. Prehabilitation will occur once per week and approximately 1 hour in duration. Participants will take part in prehabilitation until they receive a kidney transplant which by study design is approximately for 3-6 months.
45998584|NCT02904369|Drug|Emtricitabine|
45998585|NCT02904369|Drug|Tenofovir alafenamide|
45998586|NCT02904369|Drug|Tenofovir disoproxil|
45998587|NCT02904330|Drug|K1-70 intramuscular or K1-70 intravenous|Each subject will receive one dose of K1-70 by IM injection or one dose of K1-70 by IV infusion on the morning of Day 1.
45998588|NCT00560378|Drug|Tacrolimus ointment 0.1%|Topical
45998589|NCT00560456|Other|Chronic sleep restriction and driving simulator|"One night of normal sleep~Driving simulator~Night 1: night of total sleep deprivation~Night 2: night of sleep recovery~Night 1 to 5: nights of sleep restriction~Driving simulator after night 1 to 5~Night 6: night of sleep recovery~Driving simulator"
46086299|NCT02729948|Other|Survey Administration|Ancillary studies
46086300|NCT02729948|Device|Tethered Capsule Endoscope|Undergo TCE
46086301|NCT02694692|Procedure|Vaccinations at 2, 6, 12 and 18 month|Participants will be invited back to IWK Health Centre at time points that correspond to their 2, 6, 12 and 18 month vaccinations and will receive their vaccinations according to Nova Scotia schedule.
46086302|NCT02694692|Behavioral|Neurodevelopment assessment at 18 corrected age|During the 18 month follow-up visit, the infants will also undergo neurodevelopmental assessment. Trained medical assessors also blind to original study group assignment will examine the child using the BSID-III Cognitive and Motor Sections. Participants will also be contacted at the infants 18 month corrected postnatal age for the BSIDIII. Parents will be asked to complete the Early Childhood Behaviour Questionnaire and the Brief Infant Toddler Social Emotional Assessment.
45998590|NCT00560534|Procedure|Whole body magnetic resonance angiography|Magnetic resonance angiography using a paramagnetic contrast agent.Venous compression performed with a blood-pressure cuff around both thighs.
45998591|NCT04636814|Drug|CHF6001 1600µg|CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg) and Roflumilast matching placebo, 1 tablet once daily
46086303|NCT02738918|Drug|Nulojix (Belatacept)|Nulojix Administration will start the day of transplantation (day 1 and first dosing day);10 mg/kg : (day1, 5,14,28 ), Week 8 and 12 and then 5 mg/kg every 4 weeks until Month 12
45998592|NCT04636814|Drug|CHF6001 3200µg|CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg) and Roflumilast matching placebo, 1 tablet once daily
45998593|NCT04636814|Drug|Placebo|CHF6001 matching placebo, 2 inhalations bid and Roflumilast matching placebo, 1 tablet once daily
46086304|NCT02733536|Device|Standard endotracheal tube|1) Direct laryngoscopy using a Macintosh laryngoscope with size 3 blade (Mercury Medical, Clearwater, FL, USA) with a conventional 7.0 mm internal diameter (ID) tracheal tube
46086305|NCT02733536|Device|C-MAC|C-MAC introduced with a h size 3 blade.
46086306|NCT03207776|Other|Usual Care|Treatment of patients in the usual manner based on their diagnosis and resources available at that site.
46086307|NCT03207776|Other|COPD Clinical Pathway|A group of 4 Usual Care components that are applied consistently and completely amongst all patients who present with COPD acute exacerbation symptoms, plus access to navigator services.
46086308|NCT03195374|Other|Prescription Opioid Misus Index|Opioid misuse will be assessed by the Prescription Opioid Misuse Index (POMI) scale. A score ≥ 2 is considered positive and will define a misuse behavior.
46086309|NCT02739386|Biological|Ipilimumab|Intravenous monoclonal antibody injection
46086310|NCT04185038|Biological|SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel|Autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
46086311|NCT00636428|Drug|Midazolam|oral midazolam, was prepared into a final solution (2.5 mg/mL) from injectable midazolam hydrochloride and a orange flavored syrup. For preparation, midazolam injection (5 mg/mL) was diluted 1:1 with the flavored syrup.
46086312|NCT02733692|Behavioral|Understanding Reproductive Health for Ladeez (GURHL) Code|Understanding Reproductive Health for Ladeez (GURHL) Code is an acceptability study to test a web-based application designed with and for young women of color 18 to 25 years old.
45998594|NCT04636814|Drug|Roflumilast|- 1 tablet of Roflumilast (Daliresp®), 250µg, once daily during the first 4 weeks of treatment then 1 tablet of Roflumilast (Daliresp®), 500µg, once daily for the remaining treatment period and CHF6001 matching placebo, 2 inhalations bid
45998595|NCT04636424|Other|assesment of gait|speed and weight distribution during gait
45998596|NCT04636346|Behavioral|Acceptance and Commitment Therapy|Seven group sessions
45998597|NCT04636346|Other|Questionnaires|Outcomes measured include anxiety, depression, fear of recurrence, psychological flexibility, mindfulness; values based living, and quality of life. Participants completed surveys at 4 time points, pre and post, and two follow-up time points.
45998598|NCT02895321|Other|Cavex Bite&White ExSense|a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
45998599|NCT02895321|Other|Colgate, Protection Caries|a fluorine-based toothpaste gels
45998600|NCT02895321|Other|Placebo gel|a glycerin and water gel
45998601|NCT04636385|Other|Observational study no intervention|No intervention
45998602|NCT02894970|Device|Pulmonary PPG|Five minutes check with a lights source with two wave lengths of infrared and a detector.
46086313|NCT02738762|Other|glutamine supplementation|glutamine supplementation guided by glutamine levels in plasma
46086314|NCT02729870|Drug|Oral Glucose Gel|This group will receive the following: are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
46086315|NCT02729870|Other|Placebo|This group will receive carboxymethylcellulose (2%) oral gel. The subjects who are less than than 3 years of age will receive carboxymethylcellulose (2%) oral gel, 20ml which will be a one time dose and the subjects ages 3-7 will receive carboxymethylcellulose (2%) oral gel, 40ml which will be a one time dose.
46086316|NCT02729792|Device|rTMS|intermittent theta burst stimulation (iTBS)
46086317|NCT05628662|Device|Automated Insulin Delivery System (SAFE-AP)|Each subject will undergo a 32-hour in-hospital study, including 4 meals (60 grams of carbohydrates each, except 50 grams for breakfast), one overnight period and 2 unannounced aerobic exercise sessions. Each exercise session consists of three 15-minute sets on a cycle ergometer at 70% of maximum heart rate with 5 minutes of rest between sets.
46086318|NCT02729558|Radiation|local SRT|local stereotactic radiotherapy in three fractions of 8 Gy to the surgical cavity
46086319|NCT02690402|Behavioral|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
46086320|NCT02729246|Procedure|Laparoscopic Gastric Bypass|
46086321|NCT02694848|Drug|Salvianolate injection|Traditional Chinese medicine injection，a kind of innovative drugs developed by Shanghai institute of materia medica, Chinese academy of sciences after 13 years of research and development.the content of magnesium acetate was 80%, and the other 20% were magnesium acetate.It has the function of promoting blood circulation,removing blood stasis and blood stasis,and is used for treating coronary heart disease with stable angina pectoris.
46086322|NCT02694848|Drug|Aspirin|Molecular chemical formula: C9H8O4,molecular structure type: CH3COOC6H4COOH. It has the role of anti thrombosis In vivo, and it can inhibit the release of the platelet reaction, inhibit platelet aggregation, which is related to the reduction of TXA2 generation. Clinically itused to prevent the onset of cardiovascular and cerebrovascular diseases.
45998603|NCT02904174|Behavioral|Healthy Living Programme|A 6-week Healthy Living Program (HLP) was developed and implemented for all the participants. There was one 45 minutes weekly session over 6 week. Week 1 & 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 & 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 & 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies. Interactive activities such as games, puzzles and question & answer session were included in the group education.
45998604|NCT04635722|Behavioral|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
46086323|NCT04189718|Procedure|osseodensification protocol|Local anaesthesia was administered and mucoperiosteal flap was reflected. Implant osteotomies was performed with sequential drilling with osseodensification protocol at 1100 rpm. The pilot drill was used in clockwise direction and the other sequential drills were used in counter clockwise direction under copious irrigation. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
46086324|NCT04189718|Procedure|conventional implant site preparation protocol|Local anaesthesia was administered and mucoperiosteal flap was reflected. Implant osteotomies was performed with sequential drilling with conventional implant site preparation protocol at 1100 rpm. The pilot drill was used in clockwise direction and the other sequential drills were used in clockwise direction under copious irrigation. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
45998605|NCT02894931|Dietary Supplement|monosaccharides|The monosaccharides; Glucose, Fructose, Galactose and mannose, will be administrated after O.N fasting, 50gr, once.
46086325|NCT02738528|Other|Mental practice and brushing guidance in patients with Parkinson Disease|
46086326|NCT02729324|Drug|Medical Radiation Protectants (FORRAD®)|Medical Radiation Protectants (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start topical application of Medical Radiation Protectants (FORRAD®) on irradiated skin at the onset of radiotherapy, three times a day (30 minutes before radiotherapy, after radiotherapy, and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. When grade 2 or higher radiation dermatitis is developed, patients can continue using Medical Radiation Protectants (FORRAD®). When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
45998606|NCT02894931|Dietary Supplement|Disaccharides|The Disaccharides; Lactose, Maltose and sucrose, will be administrated after O.N fasting, 50gr, once.
45998607|NCT02894931|Dietary Supplement|Amino acids|The Amino acids; Leucine, Isoleucine, and Valine, will be administrated after O.N fasting, 5g, once.
45998608|NCT02894931|Dietary Supplement|Artificial Sweeteners|The Artificial sweeteners: Saccharin, Aspartame, Sucralose and Steviol, will be administrated after O.N fasting, 300 mg, once.
45998609|NCT02894931|Other|Control- water|Chilled water flavored with lemon juice as control
45998610|NCT04635956|Drug|Drug therapy|6 courses of platinum/etoposide/bevacizumab/camrelizumab and a total period of 12 months bevacizumab/camrelizumab
45998611|NCT02904018|Other|teleconsultation|Patients performing oral care required as a result of their diagnosis by teleconsultation in vulnerable populations (elderly, disabled adults).
45998612|NCT02903979|Other|HVGIC|In experimental group, the researches will be performed a restoration, after partial caries removal, with high viscosity glass ionomer cement in the teeth with deep caries lesion.
45998613|NCT02903979|Other|Indirect pulp capping|In control group, the researches will be performed a indirect pulp capping with calcium hydroxide cement and high viscosity glass ionomer cement in the teeth with deep caries lesion.
45998614|NCT04635488|Procedure|lateral lymph node dissection|All participted would receive lateral lymph node dissection for rectal cancer.
45998615|NCT02895204|Dietary Supplement|Fermented Maillard reacted whey protein (F-MRP)|6g of powder containing 4.2g fermented maillard reacted whey protein
45998616|NCT02895204|Dietary Supplement|Placebo|6g of maltodextrin
45998617|NCT04635371|Device|Non-invasive Monitoring|Wearable, wireless, non-invasive chest-patch devices will be attached to the patients following recruitment and aigning an informed consent form, and from that moment on, vitals will be collected automatically and analyzed retrospectively.
45998618|NCT02894892|Drug|(A)Bismuth|
45998619|NCT02894892|Drug|(B)Bismuth|
45998620|NCT02894892|Drug|(C)Bismuth|
45998621|NCT02894892|Drug|(D)Esomeprazole and Bismuth|
45998622|NCT02894892|Drug|(E)Esomeprazole and Bismuth|
45998623|NCT02894892|Drug|(F)Esomeprazole and Bismuth|
45998624|NCT02894892|Other|(G)Control|
45998625|NCT04635566|Drug|mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.|mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening. 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
45998626|NCT04635566|Drug|Placebo|Placebo one time/day at the evening.
45998627|NCT02894853|Genetic|Liquid (blood) biopsies and tumor biopsy (optional)|Liquid (blood) biopsies: 40 ml (maximal 10 times per patient) Tumor biopsy (optional)
45998628|NCT04635293|Procedure|preoperative infusion of levosimendan|the study group will consist of patients who have received a continuous infusion of levosimendan 0.1 μg/kg/min for 24 hours before cardiac surgery
45998629|NCT04635293|Procedure|no preoperative infusion of levosimendan|the control group will consist of patients who proceeded to the cardiac operation without any infusion for 24 hours preoperatively
45998630|NCT02894736|Device|Soterix tDCS machine|Soterix tDCS machine - miniCT supervised neuromodulation system
45998631|NCT04635215|Device|Sensura Mio Bodyfit technology ostomy pouches|The use of medical devices, the ostomy pouches from Sensura Mio Bodyfit technology range, will be studied from inclusion visit (less than one month after the beginning of use) and during 3 months.
45998632|NCT02903862|Behavioral|Mindoula|The Mindoula intervention is a combination of case management and a messenger application. Case managers monitor how the participant is doing and any needs and provide 24/7 support & assistance, including care coordination, treatment adherence, and matching the participant with providers and community resources. Each participant will be given an intake questionnaire to establish goals and behavioral health history. Participants will use the app and work with the case manager for 12 weeks.
45998633|NCT02903862|Device|DANA|DANA is an FDA-cleared neurocognitive assessment software administered on a smartphone or tablet to measure changes in cognitive efficiency. DANA also includes Ecological Momentary Assessments to track mood, sleep, stress, and memory. Intervention participants will take DANA weekly. The Waitlist Control arm will take DANA weekly 12 weeks after enrollment.
45998634|NCT04635410|Other|ULTRASOUND IMAGING|SCAN LABOURING WOMEN BY ULTRASOUND
45998635|NCT01227889|Drug|GSK2118436|150 mg twice daily
45998636|NCT01227889|Drug|Dacarbazine (DTIC)|Intravenous (IV), 1000 mg/m2 every 3 weeks until initial progression
45998637|NCT02894814|Behavioral|One-Stop Dispensing|Use of own medication, review of the patient's medication, partly or self-administration of medication during hospitalization under support from the health personnel to improve adherence, knowledge and feeling safe about the medication.
45998638|NCT02894814|Behavioral|One-Stop Dispensing and focused dialogue|Besides the elements of One-Stop Dispensing focused dialogue about the patient's medicine during hospitalization and at discharge to improve adherence, knowledge and feeling safe about the medication
45998639|NCT04635332|Behavioral|Food literacy and physical activity promotion interactive group sessions + Developed health promotion intervention materials (booklet)|"Information, skills training, goal setting and feedback interactive group sessions to improve food literacy aimed at increasing consumption of fruits and vegetables~Information, skills training, goal setting and feedback interactive group sessions to increase engagement in moderate physical activity~Information and skills training to increase ability to evaluate nutrition information~In general, focus will be on increasing knowledge, skills and self-efficacy to develop a lifelong healthy and gastronomic relationship with food and physical activity."
45998640|NCT04635332|Behavioral|Developed health promotion intervention materials (booklet).|In the control arm, participants will only be given the developed intervention materials (designed in form of the usual awareness programs). No group sessions will be conducted
45998641|NCT02894541|Drug|CKD-519 100mg|
45998642|NCT02894541|Drug|CKD-519 200mg|
45998643|NCT02894541|Drug|CKD-519 100mg|
45998644|NCT02894541|Drug|CKD-519 200mg|
45998645|NCT02888392|Other|Kiwifruit|2 green kiwifruit cultivar 'Hayward'
45998646|NCT02888392|Dietary Supplement|Psyllium|Pysllium seed husk; ispaghula, isabgol, or psyllium, are portions of the seeds of the plant Plantago ovata, (genus Plantago), a native of India, Bangladesh and Pakistan. They are hygroscopic, which allows them to expand and become mucilaginous. Psyllium is a faecal bulking agent used to treat constipation. It absorbs liquid in the intestines, swells and forms a bulky soft stool that is easy to pass
45998647|NCT04635020|Procedure|iStent|2 trabecular Stent injected at the end of the cataract surgery to the trabecular meshwork
45998648|NCT04635020|Procedure|SLT-laser|1 month after cataract surgery laser treatment to the trabecular meshwork (100 applications, 360 degrees)
45998649|NCT04635020|Procedure|Cataract surgery|Conventional cataract surgery
46086327|NCT02729324|Drug|Trolamine (Biafine)|Trolamine (Biafine) is prescribed at the beginning of radiotherapy. Patients are asked to start topical application of trolamine (Biafine) on irradiated skin at the onset of radiotherapy, three times a day, until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. No other prophylactic creams, lotions, or gels are allowed. When grade 2 or higher radiation dermatitis is developed, patients cannot use trolamine any more, and they will receive other conventional medical care for treatment of radiation dermatitis in the investigators institution. When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
46086328|NCT02729402|Other|Cognitive Testing|We will use a battery of neurocognitive tests to assess cognitive function before and after surgery
46086329|NCT02738372|Other|Diagnosis/Prognosis|The present study will be a 24 months multi-center, triple-blind, prospective, cohort study which will be carried out between April 2016 and March 2018. Subjects diagnosed of rotator cuff (RC) tendinopathy, adhesive capsulitis (AC), glenohumeral instability, SLAP lesion, and/or acromioclavicular pathology and fulfill the inclusion criteria will be asked for participating in our study. Several questionnaires that will test the influence of different biopsychosocial factors and the presence of Central Sensitization will be administrated to these subjects. The outcomes will be assessed at baseline and 5 follow-ups (after 3, 6, 12, 18 and 24 months, t1-t6).
46086330|NCT02729168|Biological|Human rabies vaccine|
46086331|NCT02733458|Drug|GELAD|Gemcitabine, 1.0g/m2/d IV, day 1 Etoposide, 60mg/m2 IV, day 1 to day 3 Dexamethasone, 40mg/d IV, day 1 to day 4 Pegaspargase, 2000IU/m2/d IM, day 4
46086332|NCT02733458|Radiation|Radiotherapy|Radiotherapy: 50-56Gy
46086333|NCT02733146|Other|cardiac arrest|
45457530|NCT01132963|Other|Outdoor Shoes|Patient will be wearing sturdy outdoor shoes to complete balance tests
45998650|NCT05655871|Other|Transtheoretic Model Based Video Exercise Training|Initial follow-up 1-3. Between weeks 4-6, the second follow-up. Between weeks 7-9, the third follow-up. was done within weeks. Participants 10-12. No application will be made between weeks and the last test will be done in the 12th week.
45998651|NCT05655871|Other|Standard Maintenance Practice|Initial follow-up 1-3. Between weeks 4-6, the second follow-up. Between weeks 7-9, the third follow-up. was done within weeks. The final test will be done at week 12.
45998652|NCT04681716|Other|ELDOA|For Spinal Segment L4-L5 and L5-S1 proper ELDOA position was instructed to the experiment group patients.ELDOA stands for Elongation Longitudinaux Avec Decoaption Osteo Articulaire, or LOADS (Longitudinal Osteo-articular De-coaptation Stretching). ... They can be described as fascial stretch that localizes tension at the level of a specific spinal segmental.
45998653|NCT04681716|Other|CONVENTIONAL PHYSIOTHERAPY|"Transcutaneous Electrical Nerve Stimulation (TENS):~120Z dual channel TENS unit made in Japan was used in the research. Electrodes of TENS were placed on lumbar region and TENS was given for 15 minutes on Constant mode. Intensity was adjusted according to patient's comfort.~Hot pack was applied on the lumbar region for 10 - 15 minutes.Lumbar Mobilization (CPA) was given on spinous process of L1- L5 vertebrae and L5-S1. For every session given 3 sets of 10 repetitions of each lumbar vertebra was performed."
45998654|NCT04681521|Other|Hot and Cold compress, nursing interventions|using thermal compress at 38-39 °C (hot) and 15-16 °C (cold) on the distal regions of both lower extremities of the patients
45998655|NCT04634942|Device|Cryos REF 0971 Cold Spray|Cold Spray Coolant spray is manufactured from liquefied gases with high pressure. It acts by rapidly reducing the temperature in the body area where it is applied. The liquefied gas in the tube spreads on the skin in liquid form and takes the heat of the skin by turning into gas. The temperature of the area where it is applied drops from 30-32 degrees to 10-15 degrees. With the effect of the cold, the excitability of the nerve endings decreases, and thus the pain on the skin is felt by the person. Cold sprays, whose analgesic effect occurs immediately, are applied parallel to the muscle fibers in the area to be applied, from a distance of 15-45 centimeters, by squeezing for approximately 5-15 seconds. Cold sprays are suitable for long-term and multiple uses.
45457531|NCT01132963|Other|Pillow Paw Slippers|Patient will be wearing Pillow Paws slippers to complete balance tests which are issued to patients who do not have shoes in NHS hospitals in the UK
45457532|NCT02298010|Drug|Capecitabine, oxaliplatin|
46086334|NCT03658772|Drug|grapiprant|Cohort 1 will be treated for 1 week with oral grapiprant as a single agent, followed by 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.
45998656|NCT04634942|Device|ShotBlocker BIONIX Press Firmly USA|ShotBlocker ShotBlocker is a plastic tool with a small and flat shape, with short and non-sharp protrusions on one side that connect with the skin. It resembles a horseshoe (C shaped) with its structure designed to expose the area to be injected. It is suitable for all age groups. It does not have any side effects. ShotBlocker can be used for both intramuscular and subcutaneous injections. The protruding surface of the ShotBlocker is held by pressing the skin during the injection and the process is performed from the part where the opening is.
45998657|NCT01227577|Drug|Nilotinib|Nilotinib was supplied as 150 mg and 200 mg hard gelatin capsules.
45998658|NCT04681599|Device|Filter|Filter is used to capture any individual bacteria or viruses that might be suspended within inhaled or exhaled gases
45998659|NCT04681599|Device|Scavenger face tent|A face tent is connected to a vacuum resource to continuously suction the exhaled gas from the subject, in order to reduce the transmission risk of virus or bacteria
45998660|NCT04635137|Procedure|Ablation and Cementoplasty|Percutaneous thermal ablation with subsequent cementoplasty in a single procedure
45834988|NCT04390932|Other|Enhanced TA|The enhanced TA is characterized by the personalization of the conversation, the verbalization of a joint participation in the process, the full presence of the therapist in the development of the exercise protocol, and the inclusion of behaviors such as active listening, empathy, and encouragement. In addition, therapist's body language transmits confidence, security, and attention.
45998661|NCT05655832|Device|Vivalink wearable device|a CE marked device modified to add a temperature measurement algorithm in addition to ECG and respiratory rate measurements
45998662|NCT05655793|Diagnostic Test|Tear Fluid collection (Schirmer's strip)|Tear fluid will be collected non-invasively form all participants with the use of Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes.
45998663|NCT05655793|Diagnostic Test|Retinal imaging|The retina from all participants will be visualised with the use of a standard (Clarus 700 Zeiss), ultra-wide field (Optos), and cross-sectional (Optical Coherence Tomography) retinal images.
45998664|NCT00624676|Drug|Lipo Hydroxy Acid|Twice a day
45998665|NCT00624676|Drug|5% benzoyl peroxide gel|Once a day
45998666|NCT04634903|Behavioral|Supportive Therapy SSI|Online, 30-minute self-administered program for youth
45998667|NCT04634903|Behavioral|Behavioral Activation SSI|Online, 30-minute self-administered program for youth
45457533|NCT03510520|Device|Medium Cut-Off Haemodialysis|Treatment with medium cut-off haemodialysis using the Theranova dialysis membrane 3 times per week for 6 months
45457534|NCT03510520|Device|On-Line Haemodiafiltration|Treatment with on-line haemodiafiltration (HDF) 3 times per week for 6 months (Conventional treatment)
45457535|NCT01131871|Behavioral|Standard Behavioral Weight Loss Intervention|Subjects in this group will receive our standard behavioral weight control program that is delivered in an in-person group-based format. At month 7 subjects will also be given access to a study website to monitor eating and activity behaviors, and to have electronic access to standardized intervention materials. At month 7 subjects will also receive targeted study-related text messages that otherwise would have been provided in paper format.
45998668|NCT04634903|Behavioral|Growth Mindset SSI|Online, 30-minute self-administered program for youth
46086335|NCT03658772|Drug|grapiprant and pembrolizumab|Cohort 2 will be administered 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.
45457536|NCT01131871|Behavioral|Enhanced Weight Loss Intervention|Subjects in this group will participate in a weight loss intervention that includes technology enhancements. These enhancements will include the addition of intervention specific targeted and tailored text messaging and the BodyMedia Fit System® beginning at Month 7. At month 7 subjects in EWLI will also receive the same targeted study-related text messages provided to SBWP that otherwise would have been provided in paper format.
45998669|NCT05655754|Drug|Methohexital|anesthesia during ECT
45998670|NCT05655754|Drug|Ketofol|anesthesia during ECT
45998671|NCT02894385|Drug|BAY1841788|600 mg single dose, administered as 2 x 300 mg tablets on Day 00.
45998672|NCT05655715|Radiation|Stereotactic body radiotherapy|8 Gray x 3
45998673|NCT05655715|Drug|Ipilimumab Injection [Yervoy]|1 mg/kg IV Q3W for four doses,
45998674|NCT05655715|Drug|Nivolumab Injection [Opdivo]|Nivolumab 3mg/kg IV Q3W for four doses, then then Nivolumab 480mg IV Q4W
45998675|NCT05655715|Procedure|Biopsies|From soft tissue metastases.
45998676|NCT05655676|Drug|89Zr-NY008|Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY008
45998677|NCT04634864|Device|Anodal tDCS|40 minutes of 2mA intensity direct current stimulation was delivered over both the right and left motor cortex simultaneously
45998678|NCT04634864|Device|sham tDCS|The stimulator was switched off after 2 minutes of stimulation.
45998679|NCT02894463|Other|questionnaire|
45998680|NCT04317235|Drug|Ropivacaine 0.5% Injectable Solution|Is to put 3 ml or 5 ml and show the difference
45998681|NCT00560690|Drug|Metformin|500 mg oral three times a day for 6 months
45998682|NCT00560690|Drug|pegylated interferon|180 micrograms, or 1.5 micrograms/kg body weight weekly SQ injection for 6 or 12 months depending on genotype
45998683|NCT00560690|Drug|Ribavirin|800-1200 mg PO given in 2 divided doses for 6 to 12 months depending on weight and genotype
46086336|NCT02738060|Dietary Supplement|Baked Milk|"The patients in case group will be received baked milk daily in the form of muffin(30 cc milk (equal to 1/3 of milk's proteins) heated in 350 F or 180 C for 30 mints) for 6 months. They will be visited weekly in the first month and every 2 weeks in other 5 months. At the end of the 6 months, the patients will undergo oral food challenge by 30 grams baked cheese in the form of pizza cheese. If the test will be negative, they will receive pizza cheese 4 or 7 days per week for other 6 months. The patients will be followed every 2 weeks during this period.~Skin prick test and serum IgE levels will be done at the beginning of the study, at 6 and 12 months. IgG4, being specific for milk allergens, will also measured at the beginning and at 12 months of the study."
45998684|NCT01227421|Drug|Nitazoxanide|Tablets, 300 mg (one 300 mg tablet + 1 placebo tablet) with food twice daily for 5 days
45998685|NCT01227421|Drug|Nitazoxanide|Tablets, 600 mg (two 300 mg tablets) with food twice daily for 5 days
45998686|NCT01227421|Drug|Placebo|Tablets, (2 tablets) twice daily with food for 5 days
45998687|NCT05655559|Other|Questionnare|Measurement of Dyspnea and Fatigue during submaximal exercise with The Modified Borg Scale (MBS).
45998688|NCT05655559|Device|Moxy Muscle Oxygen Monitor|Measurement of muscle oxygenation with Moxy Muscle Oxygen Monitor.
45998689|NCT00560729|Dietary Supplement|Renutryl 500|
46086337|NCT03320876|Drug|filgotinib|one filgotinib oral tablet once daily.
46086338|NCT02729090|Other|Device: treadmill|Aerobic training on a treadmill continuously with speed and wave periodization. Frequency twice per week ( 2x ) for twelve weeks. Device: treadmill.
45998690|NCT00560729|Dietary Supplement|Generique|
45998691|NCT00560729|Dietary Supplement|Generique + Renutryl 500|
46086339|NCT02729090|Other|Device: treadmill Train_Comb_aerobic|Device: treadmill Train_Comb_aerobic. strength training with free weights, followed by active recovery on a treadmill with fixed intervals of 60 to 120 seconds between each workforce of series. Device: treadmill Train_Comb_aerobic
46086340|NCT02729012|Drug|hypertonic saline solution (NACL 3%+NAHCO3)|Treatment with nebulized hypertonic saline solution (NACL 3%+NAHCO3)
46086341|NCT02729012|Other|Saline Solution (NACL 0,9%)|Treatment with nebulized Saline Solution (NACL 0,9%)
46086342|NCT02728856|Other|Sunscreen Spray SPF50 Z15-034(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
46086343|NCT02728856|Other|Shampoo Control|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
46086344|NCT02728856|Other|Sunscreen Spray SPF50 Z15-038(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
46086345|NCT02728934|Biological|Golimumab Intravenous (IV)|This is an observational study. Patients who will receive golimumab IV will be observed for 3 years.
46086346|NCT02728934|Biological|Infliximab|This is an observational study. Patients who will receive infliximab will be observed for 3 years.
46086347|NCT02728934|Biological|Biosimilar Infliximab|This is an observational study. New patients who will receive biosimilar infliximab will be observed for 3 years (maximum). Biosimilar Infliximab patients will be included in Exploratory analyses only and will not be included in Primary or Secondary outcome measures analyses.
45998692|NCT02903901|Drug|Melatonin|10 mg liquid Melatonin IR-SL at 7 pm for 1 week
45998693|NCT02903901|Drug|Placebo|10 mg liquid placebo at 7 pm for 1 week
45998694|NCT00560768|Device|Ovatio VR 6250 or DR6550|"The study requires the implantation of locally approved material:~A right ventricular defibrillation lead~In case of use of a dual chamber ICD a right atrial pacing lead~A single chamber or dual chamber ICD manufactured by SORIN Group. At begin of the study this will be OVATIO VR model 6250 and OVATIO DR model 6550. Any new devices of same type manufactured by SORIN Group which will become locally approved during the conduction of the trial can be used in the study.~Holter recording will be performed with a market approved recording system allowing high resolution ECG recording compatible with the analysis software for TVar."
45998695|NCT02904213|Biological|ComBe Five (Liquid)|
46086348|NCT02728778|Drug|incobotulinumtoxin A|Application of botulinum toxin A into the forehead
46086349|NCT02728778|Procedure|Acupuncture|Application of acupuncture into the forehead
46086350|NCT04179500|Drug|Pretomanid|pretomanid 200 mg (once daily) for 26 weeks (with meal)
46086351|NCT04179500|Drug|Bedaquiline|bedaquiline 200 mg (once daily) for 8 weeks (with meal), then bedaquiline 100mg (once daily) for 18 weeks (with meal)
46086352|NCT04179500|Drug|moxifloxacin|moxifloxacin 400 mg (once daily) for 26 weeks (with meal)
45998696|NCT01227265|Drug|Preladenant|Preladenant 2 mg or 5 mg oral tablet taken twice daily
45998697|NCT01227265|Drug|Placebo|Preladenant-matching placebo oral tablet taken twice daily
45998698|NCT00560807|Procedure|Mobilization|Mobilizations are passive movements performed in such a manner that the patient can volitionally prevent the movement. Types of mobilization include: a) passive oscillatory movements (2-3 Hz) of small or large amplitude, applied anywhere in a range of movement, typically for anything between 30 seconds and several minutes depending on the response and desired effects, and b) sustained stretching (glides) with or without tiny amplitude oscillations at the limit of the range.
46002407|NCT03053115|Drug|Levothyroxin|Both cases and controls will take levothyroxine in the morning (entire dose for controls, reduced dose for cases)
46086353|NCT04179500|Drug|pyrazinamide|pyrazinamide 1500 mg (once daily) for 26 weeks (with meal)
46086354|NCT02731976|Other|Dietary intervention|
46086355|NCT02737904|Other|APT|APT for 30 minutes per day on 5 days per week for 4 weeks: 2 minute warm up consisting of passive cycling, where the legs of the participant are moved passively by the APT at 10 revolutions per min (rpm). Next, the participant will cycle for up to 26 minutes, at 60rpm. In this phase, the participant is required to actively cycle and to maintain a symmetrical pattern of movement using the feedback on the display. If the participant is unable to actively cycle at any point during the 26 minute exercise period, or if they have a spasm, the MOTOmed APT will revert to the passive mode. The final phase is a cool down where participants again will have 2 minutes of passive cycling at 10rpm.
46086356|NCT02737904|Other|Usual care|Personalised in-patient rehabilitation programme
46086357|NCT02728700|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
46086358|NCT02728700|Other|Laboratory Biomarker Analysis|Correlative studies
45457537|NCT05091398|Other|Regional analgesia of thoracic surgical patients|ultrasound-guided erector spinae block on T4 and T6 levels ,paravertebral block or intercostal nerve block after the anesthesia induction and turning the patient in the lateral position with 30 mL 0.5% bupivacaine +50 µ adrenaline will be injected by the surgeon through the thoracoscope .
46086359|NCT02728700|Drug|Mycophenolate Mofetil|Given IV
45457538|NCT02303314|Drug|Trigonella Foenum-graecum Seed Extract|
45457539|NCT02303314|Drug|Drug: Placebo|
45457540|NCT02528929|Dietary Supplement|Gluten-free diet|Patients with IBS-D will commence a gluten-free diet for 6 weeks following dietetic input. They will be informed they do not have coeliac disease. They will however be blinded to whether or not they have any markers of at-risk serology. They will self-complete validated questionnaires over 6 weeks. Any subjects who opt to continue with a gluten-free diet thereafter of their own volition will be kept under observation as per routine clinical care.
45457541|NCT05189678|Other|No intervention|No intervention
45457542|NCT01229605|Drug|Cyclophosphamide and docetaxel|Cyclophosphamide and docetaxel every 3 weeks as neoadjuvant chemotherapy
45457543|NCT01319006|Drug|GSK1278863A|100mg (x90=13um), oral tablet, single-dose with 7 day wash-out
45457544|NCT01319006|Drug|GSK1278863A|100mg (x90=29um), oral tablet, single-dose with 7 day wash-out
45457545|NCT01319006|Drug|GSK1278863A|100mg (x90=41um), oral tablet, single-dose with 7 day wash-out
45457546|NCT05401435|Other|Resting measurement of blood pressure and heart rate|Simultaneous blood pressure and heart rate measurement every morning and evening during the duration of the experiment (28 days).
45457547|NCT03511456|Procedure|PELD operation|"Under local anesthesia, the introduction of 20G needles could be performed with fluoroscopy. After the needle traveled through TFS space, extremely care was needed to avoid nerve root injury.~Discography was recommended. The following steps were performed as usual: the needle was replaced by a guide wire; a 9 mm incision was made in the skin; a tapered cannulated dilator was inserted along the guide wire; and finally a working cannula was inserted.~The remove of disc was performed carefully under endoscope. The first step was to locate the annulus fibrosis of L5/S1 disc, then by using nerve dissector and bipolar elliquence, soft tissue including fat tissue, muscle and fibers of ligaments were pushed cephalad until the blue stained herniated disc was visible and removed."
45457548|NCT01232101|Device|covered or uncovered stents|Patients are randomized to covered or uncovered stent. Stent patency is monitored and compared as well as complications, efficacy and technical success.
45998699|NCT04319302|Procedure|Isolated Vascularized Gastric Tube (IVGT) graft|A conduit was created by tubularising a vascularized segment of the greater curve of the antrum of the stomach and this was used between the remaining common hepatic duct and the duodenum.
46002408|NCT03053115|Drug|Placebos|Controls will take placebo two hours after dinner
46002409|NCT03049969|Device|tDCS stimulation|up to 4.0 mA, dorsolateral prefrontal cortex (montage dependent on specific area of deficit) while completing cognitive training tasks
46002410|NCT03043872|Drug|Durvalumab|IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until PD or other discontinuation criteria.
46002411|NCT03043872|Drug|Tremelimumab|IV infusions every 3 weeks for 12 weeks(4 cycles). An additional dose of tremelimumab will be administered in the week 16.
46086360|NCT02728700|Drug|Sirolimus|Given PO
46086361|NCT04168736|Other|Feasibility and Acceptability of Genetic Counseling Materials|"To determine the feasibility and acceptability of a communication aid in sharing genetic test results with family members.~To determine the utility of a communication aid in sharing information. To determine the impact of patient focused information sheets on patient knowledge of genetic testing."
46086362|NCT02737982|Procedure|percutaneous coronary intervention|coronary angiography with or without stent implantation, measurement of indexes of epicardial and microvascular reperfusion
46086363|NCT02728622|Drug|Tamoxifen|endocrine treatment
45998700|NCT05655403|Behavioral|Step training program|The program will consist of 3 phases: (1) getting familiar, (2) increasing complexity, and (3) consolidating skills. In Phase 1, the participants will be asked to use one foot to step on single-colored stepping panels located in a specific region of the plastic mat (e.g., upper quadrant). In Phase 2, the exercise will progress by introducing the following 4 cognitively challenging stepping tasks. After finishing the 4 stepping tasks in Phase 2, the exercises will progress to Phase 3, which will consolidate the participants' stepping and cognitive skills. The following 4 additional stepping tasks will be introduced. The instructor will tailor the exercises for each participant, based on their training performance.
45998701|NCT04634981|Procedure|anesthesia of emergency cesarean section|compare General versus spinal anesthesia
45998702|NCT05655286|Drug|38% SDF treatment|Children with active caries will receive 38% silver diamine fluoride treatment
45998703|NCT05655286|Behavioral|not to rinse for at least 30 minutes after SDF treatment|After receiving 38% silver diamine fluoride treatment, Children will be asked not to rinse their mouths for at least 30 minutes.
45998704|NCT05655286|Behavioral|rinse mouth immediately after SDF treatment|After receiving 38% silver diamine fluoride treatment, Children will be asked to rinse their mouths immediately.
45457549|NCT03511300|Behavioral|Goal-Setting Instructions|"In the goal-setting instruction condition, participants will be asked to increase their performance by 20% from the previous similar test (e.g., On this task, you generated 10 words when I asked you to name as many words as you could that start with the letter 'F.' Now, I want you to aim to generate at least 12 words for the letter 'F'.)"
45457550|NCT03511300|Behavioral|Standard Instructions|Participants in this group will receive the standardized instructions for completing the tests, as outlined in the test appendices.
45457551|NCT01358240|Drug|Econazole Nitrate Foam 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
45998705|NCT02904252|Other|Transient elastography|Transient elastography (TE) is an ultrasound-based device used for measuring the degree of liver stiffness. A transducer probe is used to create mild amplitude and low frequency vibrations (50 Hz) that transmitted through the liver tissue. This results in an elastic shear wave that propagates through the underlying liver tissue. The probe then utilizes pulse-echo ultrasound to follow the propagation of the shear wave and to measure its velocity. The velocity of the wave is directly related to tissue stiffness which correlates with fibrosis. The sensitivity and the specificity of TE is between 68%-88% and between 66%-100%, respectively for the detection of significant liver fibrosis (METAVIR score F>2).
45998706|NCT04318990|Procedure|Distal radial artery access|Patients undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized 1:1 to distal or proximal radial access for cardiac catheterization.
46086364|NCT02728622|Drug|Chemotherapy|Paclitaxel or pegylated liposomal doxorubicin
46086365|NCT02728466|Dietary Supplement|Flavanol and procyanidin supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing flavanols (monomers) and procyanidins (dimers to decamers)
46086366|NCT02728466|Dietary Supplement|Procyanidin-containing supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing procyanidins (dimers to decamers)
46086367|NCT02728466|Dietary Supplement|control supplement deprived of flavanols and procyanidins|Placebo comparator: flavanol and procyanidin deprived supplement Sustained intake (2x daily over 1 month) of a macro-and micronutrient matched supplement
46086368|NCT02728544|Other|exercise and blood tests|At an initial one-hour meeting study participants will learn to perform aerobic (treadmill) exercise and resistance training under the supervision of an experienced exercise physiologist. Exercise intensity will be assessed by direct measurement of VO2 m
46086369|NCT02733302|Behavioral|Hope theory|Adapted Physical Activity
46086370|NCT02733380|Drug|Chidamide|30mg , Oral twice a week(with an interval of no less than 3 days,;e.g. Monday and Thursday，Tuesday and Friday) until disease progression or unacceptable toxicity develops
46086371|NCT02733380|Drug|Vinorelbine|20mg/m2， IV on day 1 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles
46086372|NCT02733380|Drug|Liposomal Doxorubicin or mitoxantrone|20mg/m2, IV on day 1 of each 14 day cycle（Note：for patients who can not afford the liposomal doxorubicin，may be replaced into mitoxantrone 8mg/m2, IV on day1 of each 14 day cycle） until disease progression or unacceptable toxicity develops, up to 12 cycles
46086373|NCT02733380|Drug|Dexamethasone|10mg/m2 , IV on day 1-5 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles
46086374|NCT02733380|Drug|Thalidomide|100mg,Oral at night on each day until disease progression or unacceptable toxicity develops, up to 24 weeks
46086375|NCT02737670|Drug|Sulodexide|25 mg morning and evening for 40 days
46086376|NCT02737670|Drug|Placebo|1 tablet morning and evening for 40 days
46086377|NCT02737748|Drug|TWB-103 add-on Tegaderm|TWB-103 is the primary therapeutics with the use of Tegaderm as a wound-site protection
46086378|NCT02737748|Drug|Placebo+Tegaderm|Placebo to TWB-103 with the use of Tegaderm as a wound-site protection
46086379|NCT02732990|Behavioral|Exercise training|All gruoups will undergo 6 weeks of training intervention either with a small musclemass (one-legged exercise) or whole body exercise (two-legged cycling)
46086380|NCT02728310|Drug|Levobupivacaine|An infusion rate of 10 ml/h of 1500 mg of 0.5 % of levobupivacaine for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
46086381|NCT02728310|Drug|Saline|An infusion rate of 10 ml/h of 300 ml of saline solution for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
46086382|NCT00636584|Drug|sodium nitroprusside|sodium nitroprusside infusion at 1 microgram/kg/min dose during rewarming period of cardiac operations
45998707|NCT04318990|Procedure|Proximal radial artery surgery|Patients undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized 1:1 to distal or proximal radial access for cardiac catheterization.
45998708|NCT04319107|Other|ophthalmological examinations using a slit lamp bio microscopy and a three-mirror lens, standard procedure.|Pupillary dilatation was performed with instillation of tropicamide and phenylephrine. The ophthalmological examination included visual acuity measurement, using a slit lamp biomicroscopy to analyse the anterior segment and a three mirror lens to appreciate the quality of the dilation validated by the absence of pupillary reflex and to search for ectopia lentis. Ectopia Lentis grade is evaluated according to the 5-grade classification.
45998709|NCT00553449|Drug|rabeprazole|
45998710|NCT04319263|Drug|induction regimen of intravesical BCG|intravesical instillation of 6 weekly doses of BCG
45998711|NCT05655169|Procedure|Piezosurgery and GaALAs diode laser|"One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla.~After six weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\point) 10 seconds per point will be applied."
45998712|NCT05655169|Procedure|Piezosurgery|One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla.
45998713|NCT05655169|Other|Fixed orthodontic appliance|"After the levelling and alignment phase is completed, the rectangular stainless steel archwires (0.019 × 0.025) will be inserted, then after two weeks, the en masse retraction will be started via closed nickel-titanium coil springs applying 250 g of force per side."
45998714|NCT04634630|Genetic|Exposure to lung cancer stem cells|The exposure to lung cancer stem cells was measure as the percentage of Aldehyde dehydrogenase (ALDH) on all viable cells extracted from surgically resected tumor specimens
45998715|NCT05655130|Drug|Dexamethasone|Intraoperative 10 mg IV Dose
45998716|NCT05655130|Drug|Methylprednisolone|"The oral methylprednisolone taper course will begin on the day of surgery and will taper as noted below:~Day 1: 24 mg orally (8 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 8 mg at bedtime) Day 2: 20 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 8 mg at bedtime) Day 3: 16 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 4 mg at bedtime) Day 4: 12 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg at bedtime) Day 5: 8 mg orally (4 mg before breakfast; 4 mg at bedtime) Day 6: 4 mg orally (4 mg before breakfast)"
45834989|NCT04390932|Other|Limited TA|The limited TA does not consider the personalization of the conversation, uses a unidirectional verbalization and is imperative about the instructions provided to the participant, the therapist is intermittently absent during the therapeutic exercise sessions and uses a neutral or negative nonverbal language cues.
45834990|NCT04390932|Other|Therapeutic exercise protocol.|Three 45-60 minute sessions of supervised therapeutic exercise (combination of aerobic, isometric, and isotonic exercise) delivered within a one-week period.
45998717|NCT05655130|Other|Standard of Care|standard of care surgery
45998718|NCT02903589|Other|observational|
45834991|NCT01456884|Behavioral|Live guitar and vocal music therapy|Live guitar and vocal music therapy. Subject is passive recipient for 30 minutes.
45834992|NCT01456884|Behavioral|Vibroacoustic Music Therapy|30 minutes using vibroacoustic mat.
45998719|NCT05658406|Drug|Ringer's Lactate|infusion of 15 mL/kg/hour Ringer's lactate intraoperative
45998720|NCT05658406|Drug|Ringer's Lactate|infusion of 10 mL/kg/hour Ringer's lactate intraoperative .
45998721|NCT05658406|Drug|Ringer's Lactate|infusion of 6 mL/kg/hour Ringer's lactate intraoperative .
45998722|NCT05658406|Drug|normal Saline|standard fluid management: 4 ml for 1st 10 kg, 2 ml for the next 10 kg , 1 ml rest of body weight
45998723|NCT05658367|Procedure|Aromatherapy massage with sesame- lavender oil mixed|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with sesame- lavender oil mixed for 15 minutes with classical massage manipulations.
46086383|NCT00636584|Drug|placebo|placebo
45457552|NCT01358240|Drug|Vehicle Foam|Vehicle Foam applied once a day for 4 week
45834993|NCT04842630|Drug|SHR-1916|All participants receive SHR-1906 alone
45834994|NCT02813928|Genetic|ccfDNA analysis|The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance
45834995|NCT01891812|Drug|Nitrous oxide 50%|
45998724|NCT05658367|Procedure|Aromatherapy massage with sesame oil|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with sesame oil for 15 minutes with classical massage manipulations.
45998725|NCT05658367|Procedure|Massage with parraffin oil|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with paraffin oil for 15 minutes with classical massage manipulations.
45998726|NCT04319146|Procedure|robot-assisted radical prostatectomy|robot-assisted radical prostatectomy as first-line treatment
45998727|NCT04206592|Device|Oropharyngeal leak pressure during pneumoperitoneum.|Oropharyngeal Leak Pressure (OLP) will be measured by closing the expiratory valve of the circle system at a fixed gas flow of 3 litres/min (maximum allowed 40 cmH2O) recording the pressure at which equilibrium has been reached or audible air is leaking.
45998728|NCT02894697|Device|Angiography-guided PCI with BVS|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
45998729|NCT02894697|Device|Optical coherence tomography-guided PCI with BVS|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before stent implantation. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
45998730|NCT05471206|Other|Milk and SmartPill intakes|During visit V2, the subject will ingest the SmartPill capsule. Then, subjects will drink milk.
45998731|NCT04634474|Behavioral|Suction|Is DAS an accurate pain descriptor for every application in intensive care unit?;. This question guides the study. This study was planned with the thought that the result may be misleading in applications such as eye care and aspiration that will trigger reflex movements in intensive care. In addition, creating new evidence on whether endotracheal suction is a painful application is the basis of the application.
46086384|NCT04173104|Diagnostic Test|PET/MR with [18F]PARPi|One PET/MR study (with up to 3 scan times) with [18F]PARPi
46086385|NCT04173104|Drug|[18F]PARPi|Injection of <100ug of [18F]PARPi prior to 1 PET/MR
46086386|NCT02728232|Procedure|internal iliac artery ligation|
46086387|NCT02728232|Procedure|Cesarean Hysterectomy|
46086388|NCT03577418|Behavioral|Clinician-facilitated educational intervention|People with dementia (PWD) will complete the Preferences for Everyday Living (PELI). Care partners will complete the PELI from the perspective of the PWD (i.e., as if acting as surrogate decision-makers). Research staff will then review these assessments, highlighting areas of discrepancy in the importance of various preferences. A 30-minute preferences-based discussion will then be facilitated by the research clinician. This discussion will include review of the discrepancies identified in the assessments. The PWD and the care partners will then be encouraged to identify one area of discrepancy and to come together with a concrete action plan to resolve that area of discrepancy. A standardized document describing neuropsychiatric symptoms and reviewing the unmet needs hypothesis will be discussed with PWD and the care partners.
45457553|NCT01358240|Drug|Econazole Nitrate Cream 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
45834996|NCT01457274|Other|Sedation depth|"The intervention is the depth of sedation targeted in this study.~Patients enrolled in this study will be sedated with the same medications (fentanyl bolus and propofol target controlled infusion), and at the same starting doses, in each study arm. However, the depth of sedation targeted will differ between the arms, and this depth will be guided by the BIS monitor.~It is expected that those patients randomised to deep sedation will require a higher dose of sedative medication to achieve their target BIS value (<60) than those in the light sedation group (BIS 70-80)."
45834997|NCT01892046|Drug|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety. Maintenance doses at the maximum tolerated dose.
45834998|NCT04389996|Other|No intervention|Patients will be sent a survey incl. EORTC QLQ-C30
45834999|NCT01892124|Behavioral|Motivational Interviewing/Cognitive Behavioral-based Therapy|
45835000|NCT01892202|Other|Cohort|
45835001|NCT01892358|Behavioral|SKIN Intervention|
45835002|NCT01892358|Other|Treatment as Usual|
45835003|NCT02811198|Other|No intervention|
45457554|NCT01358240|Other|Placebo Cream|Placebo cream applied once a day for 4 weeks
45835004|NCT02809716|Other|Biomarker Analysis|Correlative studies
45835005|NCT02809716|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and tissue samples
45835006|NCT04840914|Drug|LY3461767|Administered SC.
45835007|NCT04840914|Drug|Placebo|Administered SC.
45835008|NCT04840836|Behavioral|Telehealth-supported LARC provision|"Provision of LARC in routine care will include a hybrid model of telehealth-supported long-acting reversible contraception (LARC) service provision in a network of 6 school-based health centers (SBHCs) in New York City that serve adolescents and young adult high school students age 13-22 years (hereafter referred to as adolescents)."
45835009|NCT04272684|Other|Driving Assessment|Participants will undergo a driving assessment approximately two months after returning home from hospital
46086389|NCT03577418|Behavioral|Enhanced usual care|In addition to the usual clinical care, the standardized document describing NPS and reviewing the unmet needs hypothesis will be given to the PWD and the care partner to review.
45998732|NCT05658250|Device|CRE8 polymer-free Amphilimus-eluting stent|Percutaneous coronary intervention using a Cre8 stent for long lesions
45998733|NCT05469997|Behavioral|Mediterranean-Ketogenic Diet|In the MeDi-KD group, the participants will adhere to a modified Mediterranean-ketogenic diet. The ketogenic component of the diet will require limiting the intake of carbohydrates to about 10% of all calories consumed in a day, while obtaining most of the energy from healthy fats, mostly from plant-based sources (~70-75% of your daily caloric intake) and lean proteins (~15-20% of your daily caloric intake). The ketogenic ratio (the ratio of fat to carbohydrates) will be gradually increased during the first week from 1:1 to 3:1. The Mediterranean component of the diet will encourage the participants to consume more green leafy vegetables, nuts, and olive oil, while limiting the consumption of processed or fried food, red meat, full-fat dairy, and sweets.
45457555|NCT01131949|Drug|Lamotrigine|Lamotrigine Tablets (chewable, dispersible), 25 mg
45457556|NCT03511222|Drug|Vorolanib|Patients should take vorolanib at approximately the same time every day with food.
45457557|NCT03511222|Drug|Nivolumab|Standard of care
45457558|NCT03511222|Drug|Pembrolizumab|Standard of care
45457559|NCT01230385|Drug|Lersivirine|Lersivirine 500 mg QD fasted (wet granulated tablet) for 21 days
45457560|NCT01230385|Drug|Lersivirine|Lersivirine 500 mg QD fed (wet granulated tablet) for 21 days
45457561|NCT01230385|Drug|Lersivirine|Lersivirine 750 mg QD fasted (wet granulated tablet) for 21 days
45457562|NCT01230385|Drug|Lersivirine|Lersivirine 750 mg QD fed (wet granulated tablet) for 21 days
45457563|NCT01230385|Drug|Lersivirine|Lersivirine 500 mg QD fasted (dry granulated tablet) for 21 days
45457564|NCT01350206|Procedure|hepatic resection|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
45457565|NCT01350206|Procedure|TACE|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg )mixed with iodized oil lipidol
45457566|NCT04464148|Drug|Pregnenolone 250 mg|Pregnenolone 250 mg capsule BID (500 mg QD total)
45457567|NCT04464148|Drug|Pregnenolone 400 mg|Pregnenolone 400 mg capsule BID (800 mg QD total)
45457568|NCT01230463|Drug|Ketorolac Tromethamine|15 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
45457569|NCT01230463|Drug|Ketorolac Tromethamine|30 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
45457570|NCT01358318|Other|Satiety|Single consumption of snack bars to determine satiety and food intake at next meal.
45457571|NCT04464460|Drug|TAK-671|TAK-671 intravenous infusion.
45457572|NCT04464460|Drug|TAK-671 Placebo|TAK-671 placebo-matching intravenous infusion.
45457573|NCT03920371|Other|gamma camera imaging|Following the administration of the routine radiopharmaceutical and the standard wait before clinical diagnostic imaging, additional research gamma camera imaging is carried out
45457574|NCT01358396|Other|Respond to therapy for diabetic macular edema|Correlate HBA1c with visual acuity outcome to therapy.
46086390|NCT02732756|Behavioral|Healthy Sleep Duration|This study examines healthy sleep duration as related to improved functioning in adolescents with ADHD. Adolescent participants will be instructed to go to bed at a time such that they are able to obtain 9 hours of nightly sleep (9.5 hours in bed, leaving up to ½ hour to fall asleep). Researchers will work with the adolescent and their family to problem-solve how to accomplish this sleep duration goal.
45457575|NCT03510364|Behavioral|Dietary intervention|For the feeding intervention, participants consumed a meal that contains 60% of their energy daily energy requirement as a lunch time meal for 14 consecutive days under observation except during the weekends. To ensure the participant receives 60% of the daily energy requirement as a lunch meal we added a supplemental shake to the standard 1200 kcal meal.
45457576|NCT01135615|Drug|Sevelamer|The starting dose for sevelamer was 1-2 capsules (800 mg) three times a day
45457577|NCT01135615|Drug|calcium acetate|calcium acetate (1000 mg) 1 tablet three times a day
45457578|NCT03511144|Device|Unity Knee™ TKR using measured resection|Total knee replacement using the Unity Knee™ implanted with the measured resection surgical technique
45457579|NCT03511144|Device|Unity Knee™ TKR using ligament balancing|Total knee replacement using the Unity Knee™ implanted with the ligament balancing surgical technique
45457580|NCT01229683|Procedure|Interscalene Nerve Block|Patients undergoing shoulder surgery will be given an Interscalene Nerve Block. The patients' strength and sensation in their hand and forearm will be tested to determine if the nerve block is affectively delivering anesthetic to the nerves that serve these areas.
45457581|NCT01361516|Other|Anaesthesia and Lithotripsy|The efficacy of stone fragmentation during lithotripsy procedure is compared under two types of anaesthesia
45998734|NCT05469997|Dietary Supplement|Mediterranean diet supplemented with medium-chain triglyceride oil|"The participants will adhere to the Mediterranean diet. In addition, they will be asked to take two daily doses of medium-chain triglyceride oil (MCT oil).~The MCT oil supplement (Nutiva MCT oil, Nutiva Inc.) is approved by Health Canada (NPN: 80086912) and will be used according to its approved condition of use (i.e., source of medium-chain fatty acids which supports energy production in the body at a cellular level [ATP]). Each serving of this product provides 130 Calories from MCTs (14 g) with a C8-C10 ratio of 60:40. Nutiva MCT oil can be mixed into any beverage of choice, but cannot be used for cooking.~participants will start the intervention by taking 5 mL of MCT oil twice daily for the first day to acclimate their bodies to the supplement and gradually increase the dose to 14 g BID by the end of week 1. The participants may be asked to increase the dose to 20 mL of MCT twice daily if tolerability remains positive."
45998735|NCT04633967|Drug|Alemtuzumab Injection|"This observational study is collecting clinical data focusing on infusion associated reactions and changes in vital signs in MS patients Novel Infusion protocol: The protocol consisted of the following Pre-infusion Protocol~Premedication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days prior to the infusion.~Premedication with 50 mg of prednisone orally for 5 days before the infusion.~During Infusion Protocol During infusions methylprednisolone is administered in a dosage of 500 mg on every day of the infusion.~Post Infusion Medication~Post-medication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days after the infusion.~Post-medication with 50 mg of prednisone orally for 5 days after the infusion.~Medications to be used PRN throughout the peri-infusion protocol Benadryl, acetaminophen or other analgesics were allowed"
45998736|NCT00560846|Dietary Supplement|Impact|Preoperative 5 day oral Impact and early post-operative enteral Impact
45998737|NCT00560846|Dietary Supplement|Glucose load|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
46086391|NCT02732756|Behavioral|Shortened Sleep Duration|This study examines shortened sleep duration as related to poorer functioning in adolescents with ADHD. Adolescent participants will be instructed to go to bed at a time such that they are in bed for 6.5 hours per night. Researchers will work with the adolescent and their family to problem-solve how to accomplish this sleep duration goal.
46086392|NCT02732522|Drug|Sublingual misoprostol|
46086393|NCT02732522|Drug|Vaginal misoprostol|
46002412|NCT03043872|Drug|Carboplatin|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
46002413|NCT03043872|Drug|Cisplatin|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
46086394|NCT02738294|Device|ME-NBI observation and ME-NBI targeted biopsy|The endoscopist assessed lesions which were suspected EGC carefully with ME-NBI. After assessing suspected EGC in ME-NBI view, ME-NBI targeted biopsy was performed where abnormal phenomenon was identified in ME-NBI view.
46086395|NCT02732678|Drug|PROPRANOLOL|
46002414|NCT03043872|Drug|Etoposide|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
46086396|NCT02727920|Dietary Supplement|Energy drink|
45457582|NCT03920137|Behavioral|UP-ST Therapy|Phase 1 analyses will focus primarily on demonstrating feasibility and utility of the new UP-ST intervention. Feasibility will be determined by examining the proportion of individuals who 1) complete each module of the UP-ST treatment, 2) complete a full course of the UP-ST treatment, and by 3) benchmarking participant ratings of treatment credibility, expectancy, and satisfaction with corresponding ratings from our previous clinical trials examining the UP or ST interventions. The investigators will include and examine outcomes on the same measures that will be used in phase 2, but due to the sample size our analyses for Phase 1 will focus on intraindividual effect sizes (with 95% CI) for continuous smoking, anxiety, and depression outcomes
46002415|NCT03022032|Device|Fitbit Zip|Fitbit Zip
46086397|NCT02727920|Other|Placebo|placebo drink
45457583|NCT03920137|Behavioral|Standard Therapy|In the control group therapists will hold standard smoking cessation therapy sessions.
46002416|NCT03022032|Other|HOPE App|HOPE App
46086398|NCT02727764|Genetic|ART-I02|Single Intra-articular injection in the carpometacarpal (CMC), metacarpophalangeal (MCP), proximal interphalangeal (PIP), or distal interphalangeal (DIP) joint
46086399|NCT02727686|Other|Water Load (WL) Post-Operative Day 1|Patient will have normonatremic 0600 hr sodium level (Serum Sodium = 135 - 145 mmol/L), ability to safely take water by mouth, and cleared to continue by treating surgeon. WL will be calculated (20 mL/kg body weight) and supplied at the bedside. Vasopressin level will be determined. Patient will have 30 minutes to consume WL, or will be excluded. Included patients will have data collected as follows: 1 hour - serum sodium, urine output; 2 hour - serum sodium, urine output, vasopressin level; 6 hours - serum sodium, urine output.
46086400|NCT02727608|Drug|Eculizumab|Intravenous infusion (1200 mg) over 35 minutes. Consecutive infusions (900 mg) on Days 1, 7 and 14.
46086401|NCT02727530|Other|VISCERAL MANUAL THERAPY-ADVICES|The subjects of this group will receive an amount of two sessions of visceral manual therapy that will be applied within two weeks. In the first session will be applied procedures in the most superficial body structures. And, in the second session will be applied procedures in the most deep body structures.
46086402|NCT02727530|Other|ADVICES|Advices for parents to improve the management of infant colic
46086403|NCT04189406|Other|Venapunction|A blood sample of 3.5 mL (0.2 mL serum for FSH and LH, 0.15 mL serum for E2, 0.15 mL serum for T, 0.15 mL serum for AMH and 0.25 mL serum for Inhibin B) will be collected of all girls with TS at 3 months and 9 months of age. For the girls with TS, this will be collected with an extra venapuncture during a regular outpatient visit within the usual care.
45998738|NCT04634006|Device|Home-based transcranial direct current (tDCS) device|tDCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes in order to modify the cerebral activity of the stimulated zones. Twenty sessions (active/sham) will be self-administered by parent or caregiver on twenty consecutive business days. The parameter of electrode size, current strength and current duration were previously tested for safety in children. The investigators use the Soterix Medical tDCS devices of the home-based miniCT 1x1 type.
46086404|NCT02727374|Other|Physiotherapy intervention|Physiotherapy intervention consists of conventional exercise program administered to this kind of patients at Hospital Clinico, including strengthening and balance exercises
45998739|NCT05428098|Other|education|Oral and written education according to the life model
45998740|NCT04633850|Drug|Dexamethasone|Intravenous dexamethasone 8 mg. Given once at the end of surgery.
45998741|NCT04633850|Drug|Bupivacain|"Bupivacaine dose according to weight. <60 kg: Total dose 100mg 60-90kg: Total dose 150mg >90kg: Total dose 200mg~Given once at the end of surgery."
45998742|NCT04633538|Device|Smartphone app|Use of smartphone app to measure 6 minute walk test (6MWT)
45457584|NCT03920137|Device|Nicotine Patch|Nicotine patches will be worn in tandem with UP-ST therapy
45457585|NCT03739957|Device|BPCO Media Kit|Telemonitoring system for patients with COPD
45998743|NCT02903784|Device|fMRI|Patient with grade 2 glioma and healthy volunteers use a brain imaging (fMRI)
45998744|NCT02903784|Procedure|tractography|Patient with grade 2 glioma and healthy volunteers use a brain imaging (tractography)
45998745|NCT02903784|Other|neuropsychological examination|Patient with grade 2 glioma and healthy volunteers use a neuropsychological examination
45998746|NCT04633382|Combination Product|Enhanced recovery after biliary tract surgery|Patients with malignant and benign diseases of the bile ducts, who have formed various types of anastomosis in two options for managing the postoperative period: traditional and based on the principles of enhanced recovery after surgery
45998747|NCT02903628|Behavioral|eye health education|give a lecture and issue knowledge manual for children and parents ,6 months once , 2.5 years
45998748|NCT02903706|Other|Measure of Plasmodium prevalence (PCR)|
45998749|NCT04633733|Drug|HL237 tablet|HL237 400mg will be administered orally twice a day.
45998750|NCT04633733|Drug|tacrolimus capsule|tacrolimus 5mg will be administered orally once a day.
45998751|NCT02903745|Other|observational|
45998752|NCT05428059|Other|mobile education|The training content prepared by the researchers will be presented to the expert opinion. After the necessary arrangements, it will be installed on the mobile application. The mobile application will be downloaded to the patients' phones for one month. It will be in live consultation.
46086405|NCT02727374|Behavioral|Cognitive-behavioural Intervention|Psychological treatment consists of group talks to treat the fear to fall
46086406|NCT02727296|Drug|sevoflurane|General anesthesia with sevoflurane
46086407|NCT02727296|Drug|propofol|General anesthesia with propofol
45998753|NCT04633265|Device|ECG-I Mapping of Atrial Fibrillation|Catheter ablation of Atrial Fibrillation guided by ECG-I
45998754|NCT05427942|Drug|Adalimumab|Stable and treated for at least 3 months prior to inclusion either with an adalimumab biosimilar or originator adalimumab (40 mg dose injections only) and for whom the treating physician has decided to switch to Yuflyma® (40 mg / 0.4 mL) on the day of their inclusion (decision independent from the study)
45998755|NCT04632875|Behavioral|Loving-Kindness Meditation|Approximately 15-minute sessions are administered 6 days per week
46086408|NCT02732132|Drug|Ketamine and Midazolam|This group was injected intravenous midazolam 0.1 mg/kg (maximum 4 mg), two minutes later, ketamine 1 mg/kg was given intravenously before the start of endoscopy.
46086409|NCT02732132|Drug|Propofol and Fentanyl|This group was injected intravenous fentanyl 1 mcg/kg, and two minutes later, propofol 1 mg/kg was given intravenously before the start of endoscopy.
46086410|NCT02737514|Procedure|Air insufflation|Insufflation during colonoscopy including insertion phase
46086411|NCT02737514|Procedure|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
46086412|NCT02737514|Procedure|water exchange|Water will infused and removed during insertion phase of colonoscopy
46086413|NCT03086876|Behavioral|Level 4 Stepping Stones Triple P (SSTP)|Stepping Stones Triple P is a system of psychoeducational and behavioural approaches to parenting a child with LD and challenging behaviour that aims to increase parental confidence and skills so that parents are able to manage the child's behavior effectively. SSTP comprises different levels based on increasing family complexity.
46086414|NCT02737280|Device|Airvo (TM, Fisher & Paykel Healthcare) - High flow oxygen therapy|High flow nasal cannula therapy with Airvo (TM, Fisher & Paykel Healthcare) device
45457586|NCT03132610|Drug|andrographolide sulfonate|Conventional Therapy+Xiyanping injection
45457587|NCT03132610|Drug|andrographolide sulfonate simulation|Conventional Therapy+Xiyanping injection simulation
45457588|NCT01133041|Other|Observation using NBI system|NBI system can improve the patterns of mucosal surface and vascularity of colonic polyp.
45457589|NCT01133041|Other|Observation using i-Scan system|I-Scan system can improve the patterns of mucosal surface and vascularity of colonic polyp.
45458747|NCT04338178|Behavioral|Emotional Skills Training (EST)|EST places emphasis on the improvement of inner emotion awareness, facial and body expression recognition and intra- and interpersonal emotion regulation skills. Different modules and interactive exercises are designed to help patients learn about i) the functions and manifestations of emotions, ii) the identification and labelling of own's and others' emotions, iii) tolerating and communicating emotions, and iiii) balancing between negative and positive emotions.
46002417|NCT03022032|Other|Standard of Care|Standard of Care
46086415|NCT02737280|Device|MedKit Finland - Usual oxygen therapy|Oxygen therapy with normal nasal cannula (for example MedKit Finland) 0-2 l/min
46086416|NCT02727218|Procedure|Chest tube removal|chest tube removal post thoracoscopic surgery
46086417|NCT02721446|Behavioral|Standard|"Investigators will develop a standard informational stroke risk message that will not undergo iterative review. This will inform the patient that based on information in the healthcare system, the patient is at higher risk of stroke than many others receiving care in the patient's healthcare system; it will describe options for working with their health care team to reduce the risk of stroke; and encourage the patient to call the health navigator to discuss these options and make a decision about next steps to take to reduce the patient's risk of stroke."
46086418|NCT02721446|Behavioral|Incentive|Investigators anticipate that the baseline incentive stroke risk message will inform the patient that they are at higher risk of stroke than many others receiving care in the patient's healthcare system, and will provide information about obtaining an incentive if the patient calls to make contact with a health navigator who will help them plan a next step to reduce their stroke risk. The investigators also anticipate including information that all patients who call will also be entered in a random drawing to receive an additional incentive, with up to six patients receiving this incentive.
46086419|NCT02721446|Behavioral|Salience|"Investigators anticipate that the baseline salience stroke risk message will inform the patient that they are at higher risk of stroke than many other patients receiving care in the patient's healthcare system, and will specifically focus on the patient's own risk factors (rather than all stroke risk factors). The salience message will also include visual depictions of stroke patients that are gender and ethnically matched to each subject. This is intended to prompt action by emphasizing that stroke is a real possibility for patients like me."
46086420|NCT02721446|Behavioral|Incentive + Salience|Combined message of incentive plus salience.
46086421|NCT02727140|Behavioral|Yoga with Asana (yoga postures)|Yoga intervention consisting of asana, breathing and relaxation, meditation
46086422|NCT02727140|Behavioral|Yoga without Asana (yoga postures)|Yoga intervention without asanas, consisting only of breathing, relaxation and meditation
46086423|NCT02737202|Drug|saracatinib|Subjects will receive enough tablets for 90 days +/- 14 days at each visit. Subject will have visits every 90 days for drug accountability as well as safety and efficacy testing to include pulmonary function testing, laboratory testing to include liver and kidney profile, urine pregnancy testing at each visit, vital signs, physical examination - any medically significant changes from baseline visit will be recorded, all adverse events will be monitored until resolution.
46086424|NCT02721602|Behavioral|Families Preventing Diabetes Together|Families in the intervention group will be asked to participate in four in-person sessions at a local Fairview North metropolitan area clinic over the course of two months. Sessions will focus on age-appropriate nutrition and diabetes education, meal planning and cooking skills, healthful eating, and eating meals as a family. All family members will be asked to attend and will be involved in all four, two-hour sessions. The parent with diabetes will also complete one goal setting telephone call based on motivational interviewing techniques during the intervention period.
46086425|NCT02721368|Device|Neuramis® Volume Lidocaine|hyaluronic acid filler
46086426|NCT02721368|Device|Juvederm® Voluma® with Lidocaine|hyaluronic acid filler
46086427|NCT05189054|Radiation|stereotacitic body radiation therapy|The patients were treated with high-dose and low fractionated radiotherapy, using modern precision radiotherapy technology.
45998756|NCT04632875|Behavioral|Relaxation Meditation|Approximately 15-minute sessions are administered 6 days per week
45998757|NCT05427903|Procedure|Cryotherapy|Ice packs application for 5 minutes after IANB injection
45998758|NCT05427903|Procedure|Buccal local anesthetic infiltration using articaine 4% 1:100000 epinephrine|Buccal infiltration after IANB
45998759|NCT04633109|Procedure|taste bud biopsy|Taste buds will be surgically removed a) during a planned and medically induced elective surgery under full anesthesia; b) by local anesthesia in subjects without a medically induced surgery
45998760|NCT04633109|Diagnostic Test|oral glucose tolerance test|75g glucose will be applied in drinking water following blood sample collection to evaluate glucose, insulin and C-peptide level.
45998761|NCT04633109|Diagnostic Test|Taste sensitivity|Subjects are given taste strips with 4 concentrations per each taste quality of sweet, sour, salty, bitter and umami in a pseudo-randomized manner. Subjects are asked to identify the taste quality, state the intensity, preference and certainty.
45998762|NCT04633109|Diagnostic Test|olfactory function|Subjects will be presented 16 different sniffing sticks in a randomized order, each for about 4seconds. People are then asked to identify the smell by choosing one out of 4 options (forced choice).
45457590|NCT02301442|Behavioral|Exercise + behaviour change intervention|In addition to the same exercise intervention as the control group, this group will receive a behaviour change intervention. This will be delivered after each exercise session and will incorporate the elements: self-efficacy, outcome expectations, impediments and goal-setting. On the weeks when the participants do not attend group sessions, they will receive telephone calls from physiotherapists. This will consist of guided conversations that consider content delivered in previous sessions.
45458748|NCT04338178|Behavioral|Cognitive Behavioral Therapy|CBT intervention aimed to manage food craving by teaching group members cognitive (e.g., restructuring of urge-related thoughts) and behavioural strategies (e.g., increasing awareness through food diaries, relaxation skills, identification of cues that trigger craving, avoidance of high-risk situations for craving, distraction).
45998763|NCT04633109|Diagnostic Test|taste bud density|The number of taste buds on the anterior tongue will be determined by colouring the tongue surface with food colour. Taste buds will apply more reddish as compared to non-taste tissue. Based on a digital photography the number of taste buds per subjects is counted manually.
45998764|NCT04633109|Diagnostic Test|anthropometry|Anthropometric data collection will include measures of body height, body weight, arm-, upper- and lower leg circumferences, waist- and hip circumferences and a bioimpedance analysis to obtain data about body composition.
45998765|NCT04633109|Other|biospecimen collection|Blood and saliva samples will be taken as well as a tongue swab.
45998766|NCT04633109|Other|questionnaires|Through the use of several questionnaires, data about eating behavior, food preferences, life style factors and other will be obtained.
46086428|NCT02737124|Drug|Acetaminophen|Acetaminophen will be given 24 hours before scheduled surgery.
46086429|NCT02737124|Other|Placebo|Placebo will be given to subjects 24 hours before scheduled surgery.
46086430|NCT02721524|Procedure|Tricuspid Annuloplasty|Patients will undergo repair of tricuspid regurgitation
45998767|NCT04633070|Behavioral|Gamification|Gamification (including, but not limited to a ranking system, badges and achievements, points, social media interaction, and leveling up) within mobile and web-based applications (also referred to as 'apps') for lifestyle modification (diet, physical activity, smoking cessation etc).
45998768|NCT05427747|Drug|cefotaxime|"One group will be given cefotaxime and another group meropenem.~The efficacy of antibiotic therapy will be checked with:~Follow-up paracentesis after 48 hours of initiation of empiric antibiotic treatment showing reduction in neutrophil count of at least 25% .~Decrease of peritoneal fluid PMN count to < 250 cells/μ at end of treatment and negative previously positive ascitic fluid culture."
45998769|NCT04633031|Device|Boston|
46086431|NCT02716532|Dietary Supplement|Peptamen AF|Each patient will receive Peptamen AF throughout the trial.
46086432|NCT05152784|Device|Octaray catheter|A high density diagnostic catheter used for substrate and activation mapping.
45998770|NCT04633031|Device|Cheneau|
45998771|NCT04632914|Other|trunk stabilizing exercise|trunk stabilizing exercise is a group of exercise which train the anterior thoracic cage and abdominal muscles in the form of static contraction of these muscles from a different position supine, sitting and standing.
45998772|NCT04632914|Other|cardiac rehabilitation programe|all patients continue this routine physiotherapy program for 40-60min.the patients incorporated into a variety of exercises conducted through arm ergometer,leg ergometer and treadmill.also the patients perform deep breathing exercise and coughing ececise
46086433|NCT05152784|Device|Standard of care|VT ablation guided by substrate-mapping alone.
46086434|NCT02721056|Radiation|NBTXR3, IL or IA injection + SBRT|Patients will receive a single administration of NBTXR3 on day of injection, as intralesional or super selective transcatheter arterial injection activated by Stereotactic Body Radiation Therapy starting 24 hours post injection. The total radiotherapy dose will be 45 or 50 Gy, delivered as three fractions of 15 Gy or 5 fractions of 10 Gy each, over 5 to 15 days (45 or 50Gy, 15GyX3 or 10GyX5).
46086435|NCT02721290|Procedure|Femoral nerve block using Ultrasound and neurostimulator|
45457591|NCT02301442|Behavioral|Exercise + control education|The control group will receive exercise and education components. The exercise intervention includes aerobic & strengthening components and are in line with MS exercise guidelines (Latimer-Cheung et al 2013). The aerobic activity is walking, measured using pedometers & exercise logs. The strengthening programme consists of 10 exercises targeting major muscle groups for the upper and lower extremities using elastic resistance band. Over the 10-week programme participants will attend 6 group exercise class, supplemented with telephone calls in the weeks without classes. After each group exercise class this group will receive an education session about the following: diet, vitamin D, sleep, temperature and hydration, and immunisations and vaccinations.
45457592|NCT01350284|Dietary Supplement|Cinnamon|acute oral administration of 3 g cinnamon
45835010|NCT01457664|Drug|Placebo|Placebo to RO4995819 once daily for 14 days
45835011|NCT01457664|Drug|RO4995819|RO4995819 doses once daily for 14 days
45998773|NCT05427591|Procedure|"The chemomechanical caries removal agent BRIX3000® in group (1A)"|"In group(1A), the chemomechanical caries removal agent BRIX3000® was used for caries removal in primary molars."
45998774|NCT05427591|Procedure|The traditional surgical treatment in group (1C)|In group(1C), the traditional surgical method (high-speed and low-speed air-rotors) was used for caries removal in primary molars.
45998775|NCT05427591|Procedure|"The chemomechanical caries removal agent Carie-CareTM in group (2B)"|"In group(2B), the chemomechanical caries removal agent Carie-CareTM was used for caries removal in primary molars."
45998776|NCT05427591|Procedure|The traditional surgical treatment in group (2C)|In group(2C), the traditional surgical method (high-speed and low-speed air-rotors) was used for caries removal in primary molars.
46002418|NCT03022032|Device|Fitbit Charge 2|Fitbit Charge 2
46086436|NCT02721290|Procedure|Femoral nerve block using Ultrasound|
46086437|NCT02721290|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% (20cc total) will be injected for the performance of the block in the two arms of the study.
46086438|NCT02721212|Device|Armeo Spring|"All patients of experimental group were treated according to an established protocol for ARMEO Spring. In the first session the device was adjusted for patients arms. The physiotherapist controlled functional space of upper limb movement and correct position of working station.~Each training session consisted of two parts with 30 minutes per session with Armeo Spring and 30 minutes per session with conventional treatment 5 days per week, for 6 weeks."
46086439|NCT02721212|Other|Conventional Rehabilitation|"The conventional treatment, under control of physiotherapist, consists of passive and active assisted mobilization of the upper limbs traditional training based on the Bobath concept (neuromuscular facilitation, postural control and proprioception exercises, verticalization and gait training).~Each training session consisted of 60 minutes with conventional treatment 5 days per week, for 6 weeks in a control group.~The conventional session in the experimental group lasted 30 minutes with the same techniques and methods."
45457593|NCT01350284|Dietary Supplement|Placebo control|3 g wheat flour (placebo)- separated by 28 days from cinnamon intervention
45457594|NCT02298088|Drug|Ticagrelor 180 mg|Ticagrelor, 180 mg as early as possible after the index event and not >24 h post event followed by 90 mg twice daily for 12 months.
45835012|NCT04390464|Drug|Ravulizumab|Ravulizumab (Ultomiris, Alexion Pharmaceuticals) is a monoclonal antibody that binds to terminal complement protein C5 and prevents the complement-mediated destruction of cells. It is administered by intravenous infusion. Ravulizumab has a marketing authorisation in the UK for treating Paroxysmal Nocturnal Haemoglobinuria in adults.
45835013|NCT04390464|Drug|Baricitinib|Baricitinib is administered orally once daily. It is licensed for treatment of rheumatoid arthritis, it is a relatively fast acting disease modifying anti-rheumatic drug and has the potential to be scaled up for use for a pandemic.
45835014|NCT04390464|Other|Standard of care|Regular standard of care for COVID-19 patients
46002419|NCT03022032|Other|SMART Study Intervention|SMART study app + Beiwe study app + Fitbit
46086440|NCT02855060|Device|Pelvic Binder|
46086441|NCT05150912|Other|Manual therapy|strching neck
46086442|NCT02720978|Drug|Intravenous oxytocin|"Intravenous oxytocin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery."
45998777|NCT04632602|Other|physiological effects of awake prone position in COVID 19 patients|"Study of physiological effects of awake prone position in COVID 19 patients on lung inhomogeneity assessed by Electrical Impedance Tomography (EIT), gas exchange and dyspnea score (Borg Scale).~Measurements will be performed at baseline (on supine position), then patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours. EIT records will be performed during the last 30 minutes of each period, blood gas and dyspnea score at the end of each period."
45998778|NCT02903316|Procedure|Fluids|
45998779|NCT02903199|Dietary Supplement|Whey Protein|Whey protein (18 g) administered immediately prior to breakfast and lunch meals.
45998780|NCT02903199|Dietary Supplement|Hydrolysed Protein|Hydrolysed whey protein (19.1 g) administered immediately prior to breakfast and lunch meals.
46086443|NCT02720978|Drug|vaginal prostaglandin|"Vaginal prostaglandin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery."
46086444|NCT02727062|Device|OM Pain App|"Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed. Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.~Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels."
46086445|NCT02727062|Device|Accelerometer|Each patient will be issued an accelerometer and will be encouraged to wear it continuously during the study period (weekly during radiation therapy and four weeks following radiation therapy).
46086446|NCT02726984|Drug|18F-sodium fluoride PET/MR|18F-sodium fluoride PET/MR combining 3Tesla (3T) MR and PET producing 127 slices of 2 mm on an axial field of view of 26 cm. 18F-sodium fluoride (2 à 4 megabecquerel/kilogram (MBq/kg)) will be injected 60 min before.
46086447|NCT02726828|Drug|intrathecal morphine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg intrathecal morphine1 ml volume.
46086448|NCT02726828|Drug|intrathecal ketamine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg intrathecal ketamine in 1ml volume.
45457595|NCT02298088|Drug|Clopidogrel|"300 mg clopidogrel as early as possible after the index event and not > 24h post event, followed by 75mg/day for 12 months.~For patients with > 75 years the recommended load dose is 75 mg instead 300 mg."
46086449|NCT02726828|Drug|intrathecal morphine + ketamine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and intrathecal morphine + ketamine 0.3 mg and 0.1 mg/kg respectively in 1 ml volume.
45457596|NCT01133119|Drug|Standard of Care|Subjects will have femoral sheaths removed under general anesthetic but without subcutaneous infiltration of bupivacaine.
45457597|NCT01133119|Drug|Standard of Care plus bupivacaine|"Subcutaneous dose of 0.25% bupivacaine infiltrated around the entry site of the femoral artery/vein sheath, just prior to sheath removal.~Participants will receive a dose of up to 0.8mL/kg (up to 2.0 mg/kg) of 0.25% bupivacaine, with the final amount at the discretion of the physician."
45835015|NCT04390542|Behavioral|Psychoeducation|"6 sessions (in-person, videoconference, or phone delivery per the caregiver's choice) between the interventionist and caregivers. Topics covered in sessions include:~Session 1: Communication, Support, Self Care, Symptom Management~Sessions 2-4: Communication, Symptom Management, Support~Sessions 5-6: Self-Care, Symptom Management, Communication, Support, Future Planning"
45835016|NCT04845750|Device|Rodeo Micro Mapping Catheter|The Rodeo Micro Mapping Catheter is used during cryoablation of atrial fibrillation patients for determination of pulmonary vein isolation
45835017|NCT04844424|Drug|Milvexian|Milvexian will be administered orally or via nasogastric route as tablets or capsules.
45835018|NCT02851992|Device|GTS cementless stem|Total Hip Arthroplasty
45998781|NCT02903199|Dietary Supplement|Placebo|Placebo intervention administered immediately prior to breakfast and lunch meals.
45998782|NCT02903433|Other|High-intake avocados|Families will receive 14 avocados on a weekly basis.
45998783|NCT02903433|Other|Low-intake avocados|Families will receive 3 avocados on a weekly basis.
46086450|NCT02799134|Drug|Dexamethasone|
45457598|NCT01350362|Drug|tideglusib|1000 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
45457599|NCT01350362|Drug|tideglusib|1000 mg of tideglusib as a powder for oral suspension once every other day in an overnight fasted state for 26 weeks/extension
45457600|NCT01350362|Drug|tideglusib|500 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
45835019|NCT01892670|Other|Donation of 1 whole blood unit|Donation of 450-500 mL of whole blood according to local blood bank procedures and national guidelines.
45998784|NCT02903433|Behavioral|Diet tips|Diet tips will come from educational materials including culturally appropriate dietary and nutritional education materials, and personalized recommendations taken from http://www.choosemyplate.gov.
45998785|NCT02903433|Behavioral|Avocado consumption advice|Recipe book with healthy recipe suggestions that include avocado.
45998786|NCT00445406|Drug|bevacizumab + doxorubin hydrochloride liposme|Patients receive bevacizumab IV over 30-90 minutes and doxorubicin hydrochloride liposome IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses
45998787|NCT00445406|Drug|Bevacizumab|Patients then receive bevacizumab alone IV over 30-90 minutes on days 1 and 15. Courses with bevacizumab repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
46086451|NCT02799134|Drug|Vitamin C|
45998788|NCT00445445|Other|physiologic testing|Urine samples will be assessed for levels of bisphenol-A
45998789|NCT00445445|Other|screening questionnaire administration|Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.
45675540|NCT05880953|Behavioral|Parent-to-parent coaching|Parents and parent coaches will meet as needed via the family's preferred method. Engagement may include text messaging, phone conferencing, Zoom conferencing, or occasional in-home or hospital visiting as preferred. Coaching sessions will vary based on family desired frequency and location, but may include: on-site in the family home or hospital room, telephone or video conferencing, or asynchronous contacts via email or text messaging. The template for the intervention includes an initial introductory session which is intended to build rapport and orient the parent to our program. Subsequent session topics may include: addressing specific needs including topics of interviewing and selecting home health agencies, expectation setting for home based nursing care, recruiting for home health team from inpatient settings, and recruiting for home health team from professional and personal networks.
45835020|NCT01892748|Drug|Cholecalciferol|All patients and physicians were blinded to group assignment and treatment allocation. The first group received oral cholecalciferol of 50,000 IU/week and for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
45998790|NCT00445445|Procedure|breast imaging study|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
45675541|NCT05880862|Behavioral|Pelvic Floor Muscle Training|A 12-week, 6 visit, outpatient program of physical therapist delivered behavioral and pelvic floor muscle training (PFMT)
45675542|NCT05880862|Drug|Mirabegron|Individually titrated Mirabegron, starting at 25 mg daily and increased to 50 mg daily at 6-weeks, during the 12-week intervention period.
45998791|NCT00445445|Procedure|radiomammography|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
45998792|NCT00445445|Procedure|study of high risk factors|"Questionnaire: Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.~Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis."
45998793|NCT05427435|Device|Marshall ethanolisation|Destruction of Marshall bundles by ethanol 96% infusion (3 separate injections of 3.3ml)
45998794|NCT00445523|Biological|TroVax® (Immunological Vaccine Therapy)|16 Intramuscular injections of TroVax® over 47 weeks
45835021|NCT01892748|Drug|Placebo|The second group received identical placebo tablets for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
45835022|NCT01892826|Drug|hCG|5000IU
45835023|NCT01892904|Drug|EE20/DRSP(BAY86-5300)|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day
45998795|NCT00445523|Drug|Interferon-alpha|36 subcutaneous IFN-α injections for 12 weeks. sc injection three times per week (5MU each)
46086452|NCT02720822|Drug|Placebo|Treatment with placebo is given as one double-blind capsule in the morning.
46086453|NCT02720822|Drug|Morphine Sulfate|Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
46086454|NCT02720822|Drug|Plus laxative (Docusate with senna)|If patients are taking morphine, a laxative will be offered. This applies whatever the dose of morphine being taken (8mg, 16mg, 24mg or 32 mg).
46086455|NCT02720822|Drug|Plus placebo laxative|If the patients are taking placebo, a placebo laxative will be offered.
46086456|NCT02720822|Device|FitBit charge HR (Accelerometer)|A Fitbit will be worn by patients during week 1 and week 3.
46086457|NCT02720900|Dietary Supplement|B-GOS|1.8 g/day for 6 weeks
46086458|NCT02720900|Dietary Supplement|Maltodextrin|1.8 g/day for 6 weeks
46086459|NCT02720666|Drug|K-001|In case of severe adverse reactions associated with the test drug, or if half of the participants show adverse reactions at Ⅲ level and above, the test should be terminated. The maximum dosage not causing the above-described situation shall be considered as the maximum tolerated dose or the biologically effective dose. After the test, continuous medication shall be given upon request from patients.
45457601|NCT01350362|Drug|Placebo|Powder for oral suspension administered once daily in an overnight fasted state for 26 weeks/extension.
45457602|NCT01361750|Procedure|gastric tube|the stomach will be cut into a narrowed tube-shape conduit
45457603|NCT01230541|Drug|Placebo|Daily, oral tablet
45457604|NCT01230541|Drug|Udenafil|Daily tablet
45457605|NCT01361828|Procedure|Electrophysiology|Visual Evoked Potential and Elctroretinogram
46086460|NCT02757872|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
46086461|NCT02757872|Drug|Omega-3 Fatty acids|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
46086462|NCT02757872|Dietary Supplement|Vitamin D3 placebo|Vitamin D3 placebo
46086463|NCT02757872|Dietary Supplement|Fish oil placebo|Fish oil placebo
46086464|NCT02746796|Drug|ONO-4538|
45457606|NCT01361906|Behavioral|Sensomotoric training|"The intervention will be given once a week (2h per occasion) for twelve weeks.~Each occasion is planned to have the following structure:~10 min initial conversation about how participants are feeling today and how it felt after the last time.~70 min guided sensory motor learning. 10 min final talks, reflections on how it felt today."
45457607|NCT01229761|Drug|cotrimoxazole prophylaxis|100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
46086465|NCT02746796|Drug|Oxaliplatin|
46086466|NCT02746796|Drug|Tegafur- Gimeracil-Oteracil potassium|
46086467|NCT02746796|Drug|Capecitabine|
46086468|NCT02746796|Drug|Placebo|
45835024|NCT01892982|Behavioral|Problem Solving Education tailored to NICU|
45998796|NCT05427357|Other|Non-selective closed kinetic chain exercises (NSKCE) and selective closed kinetic chain exercises (SCKCE)|"Non-selective closed kinetic chain double-leg semi-squat exercise In this exercise, the standing patient leans his or her back against the wall and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats. The knee stayed at flexion position for 10 seconds in each repeat, which aimed the contraction of quadriceps muscle. There is a relaxation period for 5 seconds between each repeat.~Selective closed kinetic chain double-leg semi-squat exercise with hip adduction In this exercise, the standing patient leans his or her back against the wall, forces the knees for adduction by squeezing the pillow placed between the knees and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats."
45998797|NCT02903082|Biological|Residue of blood further to NFS|
46086469|NCT04167176|Procedure|Erector spinae plane block|Patients will be placed on their right side. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. A 21G 10-cm needle will be inserted using an in-plane approach in a cranial to caudal direction. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
46086470|NCT04167176|Procedure|Port site infiltration|After the induction of anaesthesia, pre-incisional port-site infiltration will be performed by the same surgeon every time with 20 ml of the LA mixture. The volume will be divided equally between port sites. A total of four ports-supraumbilical, subxiphoid and two ports in the right subcostal area at mid-clavicular and anterior axillary line will be made.
46086471|NCT04167176|Device|Ultrasound machine (Mindray DP 9900 plus; Mindray Bio-Medical Electronics, Shenzhen, China)|Ultrasound will be used to identify the erector spinae muscles and to guide the LA mixture injection.
46086472|NCT04167176|Drug|Bupivacaine 0.5%|Bupivacaine 0.5% will be included in the injected LA mixture.
45998798|NCT02903082|Biological|Residue of blood further to preoperative workup|
45998799|NCT02903082|Biological|Bone marrow collected during a myelogram carried out for hematological pathology workup|
45998800|NCT02903082|Biological|Bone marrow collected during myelogram routinely performed during hospitalization in ICU|
45998801|NCT00445562|Other|biologic sample preservation procedure|
45998802|NCT00445562|Other|informational intervention|
45675543|NCT05880862|Drug|Trospium Chloride|A 12-week course of Trospium XL -extended release, 60mg once daily.
45998803|NCT02903004|Drug|Trabectedin|
45998804|NCT02903004|Drug|Pegylated Liposomal Doxorubicin|
45835025|NCT01893060|Drug|Povidone-Iodine|Povidone-Iodine, USP, Swabstick Singles, applied twice a day to cord stump while umbilical line(s) are in place
45835026|NCT01893060|Drug|Chlorhexidine gluconate|Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied twice a day to cord stump while umbilical line(s) are in place
45835027|NCT01893060|Drug|Pluronic Cream|Pluronic cream - (F68, Polymyxin, Nystatin, Nitrofurantoin )applied twice a day to cord stump while umbilical line(s) are in place
45835028|NCT01893060|Other|control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
45998805|NCT02903004|Drug|Topotecan|
45998806|NCT02903004|Drug|Gemcitabine|
45998807|NCT02903004|Drug|Weekly Paclitaxel|
46086473|NCT04167176|Drug|Lidocaine 2%|Lidocaine 2% will be included in the injected LA mixture.
46086474|NCT02726438|Drug|Debio 1450|Debio 1450, 40 mg, powder for oral solution, for reconstitution in 5% dextrose in water.
45998808|NCT02903004|Drug|Carboplatin|
46086475|NCT02726516|Dietary Supplement|PRJ-205|1 sachet per day
45457608|NCT01229761|Drug|cotrimoxazole placebo|100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
45998809|NCT00445718|Procedure|computed tomography|
45998810|NCT00445718|Procedure|3-Tesla magnetic resonance imaging|
46086476|NCT02726516|Other|Placebo|1 sachet per day
46086477|NCT02726672|Device|respiratory rehabilitation using Powerbreathe|10 minutes 2 times a day : 30 inspirations per session during 10 weeks
45675544|NCT05880758|Behavioral|Intermittent Short Sleep (ISS)|Restricted sleep duration of <5.5 h/night for 5 nights (SR) followed by 2 nights of 9.5 hours of time in bed (TIB) (recover sleep) each week.
46086478|NCT02726750|Procedure|Biospecimen Collection|Undergo collection of blood samples
46086479|NCT02726750|Other|Laboratory Biomarker Analysis|Correlative studies
46086480|NCT02720120|Drug|Ocrelizumab|Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.
46086481|NCT02720120|Drug|Placebo|Participants will receive single IV infusion of placebo.
45675545|NCT05880758|Behavioral|Social Jetlag (SJL)|2-hour delayed sleep timing.
45675546|NCT05880758|Behavioral|Sustained Adequate Sleep (SAS)|Goal of ≥7 hours of sleep/night with 8 hours of time in bed (TIB).
45675547|NCT05880524|Drug|Dornase Alfa|Patients will receive an intravenous dose of Dornase alfa twice within within 24±6 hours after symptom onset, administered as a bolus.
45675548|NCT05880524|Drug|Isotonic Saline Solution|Patients will receive an intravenous dose of Isotonic saline solution twice within within 24±6 hours after symptom onset, administered as a bolus.
45675549|NCT05878405|Other|Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse|Given PO
45675550|NCT05878405|Other|Methylene Blue Oral Rinse|Given PO
45675551|NCT05878275|Behavioral|Parent Informational Session|Parents will receive a brochure on the importance of tummy time and limiting baby gear and watch a video on the importance of tummy time and limiting baby gear and receive support for implementing tummy time if requested.
45835029|NCT01457742|Device|Ivivi SofPulse|15 minute Pulsed Radio Frequency (PRF) treatment twice per day
45998811|NCT00445718|Procedure|Abdominal Sonogram|Sonogram of the abdomen area
46086482|NCT02720276|Other|Training after acute stroke|Outdoor walking: Participants will receive daily training instructions via Short message Service (SMS) over 12 weeks. The walks are increased in frequency and intensity. The intensity are rated using the Borg scale to 12-15. The first 2 weeks begins with daily walks of 10 minutes. The last 4 weeks the walk training will partly be performed in intervals in combination with conventional outdoor walks. The interval training includes warming-up (5 minutes), fast walking for 4 minutes alternated with slower walking for three minutes. This is repeated 3 times, followed by cooling down for about five minutes. Strength training: to repeatedly get up from sitting. Number of repetitions will increase from 5-20 per set and will be performed daily in 3 sets with a short rest between each set.
45998812|NCT00445757|Procedure|conventional surgery|Two months after completion of radiotherapy, patients undergo preoperative assessment of tumor response followed by partial nephrectomy.
45998813|NCT00445757|Radiation|stereotactic radiosurgery|Patients undergo stereotactic radiotherapy to 1 tumor. Cohorts of 4-8 patients receive escalating doses of radiotherapy twice daily for 2 days until the maximum tolerated dose (MTD) or upper limit is reached.
45998814|NCT05427318|Behavioral|PATH|The intervention integrates two theoretically-grounded interventions - one with a strong peer navigator component and the other with a scalable mHealth component - into the intervention called Peers plus mobile App for Treatment in HIV (PATH)
45998815|NCT04699175|Drug|HR021618|Treatment group A:HR021618; high dose
45998816|NCT04699175|Drug|HR021618|Treatment group B:HR021618; low dose
45998817|NCT04699175|Drug|Placebo|Treatment group C: HR021618 blank preparation.
45998818|NCT05427084|Drug|Canagliflozin|Canagliflozin tablet 300mg PO daily
45998819|NCT05427084|Drug|Placebo|Placebo tablet
46086483|NCT04189250|Device|Automatized carbonmonoxide rebreathing machine - OpCO Detalo instruments|The automatized protocol (aCO) will be conducted with automated system OpCO of Detalo instruments. The intended use of the OpCO Detalo instrument is to quantify hemoglobin mass in human. The principle behind the machine is the widely used CO rebreathing technique. The machine applies automatically the desired CO dose to the patient to determine hemoglobin mass. The Detalo Instruments OpCO is certified conform to the following CE norms: Electromagentic compabilitiy: DIN EN 60601-1-2 and electrical Safety test: LVD 2014/35/EU.
45998820|NCT03277781|Other|Screening|Screening for AAA
45998821|NCT02902887|Device|Controlled Intermittent Alternate Occlusion (CIAO ) glasses|Monitored CIAO therapy glasses
45457609|NCT01229761|Behavioral|exclusive breastfeeding until 6 months of age|Breastfeeding for 6 months, followed by formula feeding for 6 month. Breastfeeding infants will be prophylaxed with maternal highly active antiretroviral therapy (HAART) (if available) or with infant nevirapine.
45457610|NCT01229761|Behavioral|breastfeeding for 12 months|Breastfeeding infants will be prophylaxed with maternal HAART (if available) or with infant nevirapine.
45835030|NCT01457742|Device|Ivivi SofPulse|15 minute simulated treatment using Sham Device twice per day
45457611|NCT03510286|Diagnostic Test|Test-it™ PrCr Urinalysis Strips|The LifeAssay Diagnostics prototype PrCr dipstick has been designed to provide the measurement of both protein and creatinine while retaining a very low estimated cost that is comparable to the current protein-only dipsticks at $0.06-0.10 per test. In 2015, an initial laboratory-based validation study of the prototype LAD PrCr test was used on more than 500 characterized urine samples from pregnant women. This validation study demonstrated comparable accuracy for detection of severe proteinuria of the LAD PrCr test to the much more expensive commercial POC test available for PrCr determination, the Siemens Multistix® PRO 10LS. These results were compared to laboratory-based reference standard assays for proteinuria measurement.
45457612|NCT01358552|Other|Néevo®/ NéevoDHA®|Néevo®/NéevoDHA® is an orally administered medical food indicated for the dietary management of impaired metabolic processes in women under a doctor's care who face high to intermediate risk pregnancies and are unable to fully metabolize or absorb folic acid. Néevo®/ NéevoDHA® contains L-methylfolate, the biologically active and immediately bioavailable form of folate.
45457613|NCT01229839|Other|Embolization|embolization with lipiodol and polyvinyl alcohol particles (PVA)
45835031|NCT02344290|Drug|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food
45835032|NCT02344290|Drug|Placebo|One tablet taken once daily, orally with or without food
45835033|NCT02848560|Drug|Hyperpolarized Xenon|Inhaled contrast for MRI occurring at each of 4 visits.
45998822|NCT00445796|Drug|Artesunate|
45998823|NCT00445796|Drug|Amodiaquine|
45998824|NCT01225822|Drug|Enoxaparin|Enoxaparin 40 mg s.c once a day for 5-10 days of treatment period
45457614|NCT01229839|Other|Infusion of anticancer agent|infusion with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg ) desolved in water
45835034|NCT02314650|Other|acupoint stimulation|stimulation was given at acupoints
45835035|NCT02314650|Other|non-acupoint stimulation|stimulation was given at non-acupoints
45998825|NCT01225822|Drug|BIBR 1048|50 mg b.i.d BIBR 1048 capsule twice a day for 5-10 days of treatment period
45835036|NCT02314650|Other|electrodes attached|electrode were attached to skin
45835037|NCT01457820|Drug|Allopurinol|Stat dose Allopurinol 800mg, then 400mg BD for 5 days
45835038|NCT01457820|Drug|Allopurinol|Stat dose Allopurinol 400mg, then 300mg BD for 5 days
45835039|NCT01457820|Drug|Placebo|Matched placebo, stat dose, then 5 days of matched placebo BD.
45998826|NCT01225822|Drug|BIBR 1048|150 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
45998827|NCT01225822|Drug|BIBR 1048|225 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
45998828|NCT01225822|Drug|BIBR 1048|300 mg q.d BIBR 1048 capsule for 5-10 treatment period
45998829|NCT00445835|Other|Arterial doppler for screening asymptomatic and significant extracoronary arterial stenoses in all arterial beds|A strategy of systematic screening of these extra-coronary asymptomatic lesions combined with a specific treatment if needed and an aggressive secondary prevention pharmacological treatment of atherothrombosis
45998830|NCT00445835|Other|Conservative arm|Conservative medical approach
45998831|NCT05427045|Other|home - exercise program|Home exercise program
45998832|NCT00445874|Drug|Ketotifen with a Contact Lens (no generic name)|
45998833|NCT02902731|Drug|PLACEBO|subcutaneous injection of placebo every day during 16 weeks
45998834|NCT02902731|Drug|ANAKINRA|subcutaneous injection of anakinra every day during 16 weeks
45998835|NCT00445913|Biological|Diabetes-suppressive dendritic cell vaccine|The dendritic cells will be treated ex vivo with the antisense oligonucleotides and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to the dendritic cell vaccine will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
45835040|NCT01457898|Device|VPAP II®|VPAP group:inspiratory pressure to generate 6ml/kg of weight and expiratory pressure of 7cmH2O plus oxygen therapy (FIO2=40%) during three hours.
45998836|NCT00445913|Biological|control dendritic cells|The dendritic cells will be treated ex vivo with vehicle and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to these control dendritic cells will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
45998837|NCT02902926|Behavioral|Low FODMAPs Diet|Instruct to design and eat Low Fermentable，Oligo-，Di-，Mono-saccharides And Polyols(FODMAPs) Diet
46086484|NCT02693990|Radiation|Intensity Modulated Proton Therapy (IMPT)|Radiation Therapy - Intensity Modulated Proton Therapy (IMPT)
46086485|NCT02719964|Other|Visual Attention Program (UCR Games)|This program is an individual-directed computerized cognitive rehabilitation program based on perceptual learning approaches to enhance visual attention. Training incorporates a diverse set of stimuli, optimized stimulus presentation, multisensory facilitation, and consistently reinforcing training stimuli. This will be completed in a group setting with an instructor available to facilitate questions.
45675552|NCT05877430|Drug|CJRB-101|In Phase 1, one or two capsules of CJRB-101 will be given every day. In Phase 2, the CJRB-101 dose selected from Phase 1 will be given every day.
45835041|NCT04758156|Drug|CleanViewAL|1L PEG + ascorbic acid bowel preparation for colonoscopy
45835042|NCT04758156|Drug|SUPREP|Oral sulfate solution for colonoscopy bowel preparation
45457615|NCT01229839|Other|Infusion of mixture of anticancer agent and lipiodol|infusion of mixture of lipiodol and chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water
45457616|NCT01350440|Biological|IVIG|Intravenous Immune Globulin
45457617|NCT03514810|Combination Product|Combined Sertraline & Ketoprofen|The first group of patients has administered sertralin (50mg)+placebo. The second group has administered sertralin (50mg)+ketoprofen (100mg) (Sertraline & Ketoprofen) daily.
45457618|NCT03514810|Other|Interleukins in MDD after treatment|Some interleukine levels were estimated in the first group of patients (administered sertralin,50mg+ketoprofen,100mg) and compared with their level in the second group (administered sertralin (50mg)+placebo).
45675553|NCT05877430|Drug|Pembrolizumab injection|200 mg given by intravenous (IV) infusion once every 3 weeks
45835043|NCT05020782|Drug|Belimumab|INTERVENTION DRUG: BELIMUMAB 10 MG/KG
45835044|NCT05029986|Behavioral|Socialization phase|Control condition: does not involve speech-related exercises
45675554|NCT05877222|Drug|Daridorexant 10 mg|Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 10 mg.
45675555|NCT05877222|Drug|Daridorexant 25 mg|Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 25 mg.
45675556|NCT05876260|Behavioral|Greek yogurt|Following 2 days of controlled diet, participants will consume greek yogurt following high-intensity interval exercise
45675557|NCT05876260|Behavioral|Carbohydrate-based study supplement|Following 2 days of controlled diet, participants will consume a carbohydrate-based study supplement following high-intensity interval exercise
45675558|NCT05876260|Behavioral|Exercise|Following 2 days of controlled diet, participants will perform high-intensity interval exercise following an overnight fast
45835045|NCT05029986|Behavioral|Speech breathing intervention|Experimental condition: involves speech-related exercises
45835046|NCT01893294|Drug|gemcitabine hydrochloride|Given IT
45835047|NCT01893294|Drug|fluorouracil|Given IV
45835048|NCT01893294|Radiation|radiation therapy|Undergo radiation therapy
45835049|NCT01893294|Other|laboratory biomarker analysis|Correlative studies
45835050|NCT02792322|Device|Transoral Robotic Surgery (TORS) with the daVinci Robotic Surgical System device|Patient's will be having TORS surgery in a seated position
45998838|NCT02902926|Behavioral|Diet instruction|Answer the doubt and help the patient get the diet knowlege about the IBS.
45998839|NCT00445952|Other|clinical observation|
45998840|NCT00445952|Procedure|management of therapy complications|
45998841|NCT01225549|Drug|AZD5423|Suspension for nebulisation once daily 7 days
45998842|NCT01225549|Drug|Budesonide 200 microgram|Dry powder for inhalation twice daily 7 days
45998843|NCT01225549|Drug|Placebo|Solution for nebulisation once daily 7 days
46086486|NCT02719964|Other|Speech Pathologist-Directed Therapy|This is a speech pathologist-directed arm and will provide a traditional clinician-directed individualized cognitive rehabilitation program. Cognitive treatment is a systematic, functionally oriented program of therapeutic activities that focuses on strengthening previously learned patterns of behavior, establishing new patterns through use of internal and external compensatory cognitive strategies, and enabling the individual to adapt to the changes in his or her revised approaches to cognitive functioning. Increased performance success is reinforced through repetition, errorless learning, and gradually increasing task stimuli and complexity in a structured systematic approach.
46086487|NCT02719964|Other|General Cognitive Rehabilitation Games (Lumosity)|Lumosity is a commercially available computerized program purported to enhance cognitive functioning through a variety of computerized programs that utilize various cognitive abilities.
46086488|NCT02720354|Other|[11C]-DMDPA|
45457619|NCT02306434|Behavioral|Therapy by iCBT|Internet Cognitive behavioral therapy (iCBT) is given by a psychologist in the U-CARE platform. The intervention will focus on management of childbirth related fear. This means that the participants read texts and do homework assignments instructed from an internet page. Additional resources such as pictures, animations, videos and sounds will be a part of the treatment program. A psychologist will communicate with the participants through internal text-messages and will give feed back on their home work assignments. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment.
45457620|NCT02306434|Other|Standard care-counselling|Standard care (Counselling by midwives)
45457621|NCT01233193|Behavioral|Health education, Home blood pressure monitoring|Health education (on hypertension, smoking, healthy diet, obesity, physical inactivity and adherence to antihypertensive medications and home blood pressure monitoring) . The patient will be referred to physician when needed. The patient will be followed up during 6 months.
45457622|NCT01232179|Procedure|conventional prp|pan retinal photocoagulation
45457623|NCT01232179|Procedure|targeted prp|1200-1600 spot in far periphery retin, anterior equator
45457624|NCT01137487|Procedure|monitoring of residual gastric volume|measurements of residual gastric volume every six hours in patients receiving early enteral feeding and mechanical ventilation
45835051|NCT01458054|Drug|Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)|GSK2336805 and Omeprazole
45835052|NCT01458054|Drug|Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)|GSK2336805 and Ritonavir
45457625|NCT01137487|Procedure|not monitoring of residual gastric volume|no measurements of residual gastric volume
45457626|NCT02301598|Procedure|FS-ALK (Femtolaser-assisted anterior lamellar keratoplasty)|The procedure was a non-penetrating transplantation of 80% thickness corneal graft
45835053|NCT05024916|Dietary Supplement|Intervention|26 g packets of freeze-dried blueberries (equivalent to 1 cup of fresh blueberries) will be given to participants to be consumed daily. Participants will be asked to consume 1 packet per day for 3 months.
45835054|NCT05024916|Dietary Supplement|Control|26 g packets of isocaloric carbohydrate-matched powder will be given to participants to be consumed daily. Participants will be asked to consume 1 packet/day for 3 months.
45998844|NCT01225549|Drug|Placebo|Solution for nebulisation once daily 7 days
45998845|NCT05469685|Drug|Vonoprazan|Potassium-competitive acid blocker
45998846|NCT05469685|Drug|Amoxicillin|Antibiotic for H. pylori eradication
45998847|NCT02956772|Drug|TACE|After the puncture of femoral artery via Seldinger method, a catheter was inserted and digital celiac axis or hepatic arteriography performed. Then a microcatheter was used to infuse chemotherapeutic agent (30 to 60 mg of pirarubicin) mixed with 5 to 20 mL of Lipiodol Ultra-Fluid. Embosphere microspheres (size of 100 to 300 um) were inserted for embolization.
45998848|NCT02956772|Drug|Arsenic trioxide|Arsenic trioxide 10 mg is put into 500 ml saline solution and then administrated by continuous intravenous drip for 5 hours during a treatment day.
45998849|NCT04680234|Procedure|DMEP kit|Superficial Cryotherapy using dimethyl ether and propane (DMEP) at -57C
45998850|NCT04680234|Device|Dermapen|Under aseptic precautions, the dermapen was moved on the alopecic patches diagonally, vertically and horizontally 4 to 5 times in each direction Pin point bleeding was taken as an end point
45998851|NCT01225159|Drug|TGC|TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
45998852|NCT01225159|Drug|Conventional glycaemic control|Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
45998853|NCT00446069|Drug|Morphine Sulphate|Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks
46086489|NCT02719886|Device|Ultrasound|Estimation of fetal weight by ultrasound
45998854|NCT02902692|Other|Brief Mindfulness|15 minutes psycho-education about mindfulness and a small experiential exercise using a raisin. Following this, participants listen to a 30minute pre-recorded sitting meditation which encourages them to focus on their breath and the sounds around them. Participants will be randomly assigned to either receive the brief mindfulness intervention immediately or will be asked to wait one week before receiving the intervention.
45998855|NCT05658016|Drug|TK-112690|TK112690 treatment Pre & Post Radiation
46086490|NCT02719730|Behavioral|Reimbursement for whole grain purchases|All participants will receive education about whole grain foods. Those in the experimental arm will have a monthly financial incentive for purchases of specific whole grain foods foods during the 12-week study period, whereas the control group will not have a financial incentive for whole grain purchases during the study period.
46086491|NCT00636662|Other|Non-invasive diagnostic testing|No patient treatment is altered by enrollment in this trial
45998856|NCT05658016|Drug|Placebo|TK112690 Placebo treatment Pre & Post Radiation
45457627|NCT03510130|Other|Routine leg movement|Routine leg movement to the right and left in the supine position during the second stage of labor, for 3 minutes every 20-30 minutes by the attending physician or nurse.
46086492|NCT02726204|Other|Gravity Elimination Alone|CAREX will compensate for the gravity of the subject's arm, i.e. subject can move their arm to a specific position and relax all the arm muscles, CAREX will hold the arm in that configuration
46086493|NCT02726204|Other|Path Assistance Alone|CAREX will push subject's arm to a pre-specified path. If the arm is not in the path, CAREX will generate some force that is proportional to the distance between the hand and the path. The subject will feel like having a spring connected between his hand and the path
46086494|NCT02726204|Other|Path Assistance and Gravity Elimination|
46086495|NCT02726126|Drug|Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy|
45998857|NCT05464459|Procedure|Novel elbow procedure|A general anaesthetic plus upper limb nerve block is used with no tourniquet. Antibiotics and tranexamic acid are administered intravenously prior to procedure. Skin prepared by standard technique with alcoholic chlorhexidine. A posterior midline incision is made and lateral paraolecranon approach made to the elbow joint. Lateral ligament complex released for access and repaired at the end of the procedure. A 5mm high speed burr and HAPY burr instrument prepares the distal humerus. The trochlea spool and/or capitellum are resected to receive Pyrocarbon spherical prosthesis, size determined from pre-operative planning. The greater sigmoid notch is prepared in a similar manner with burr. A trial prosthesis is used to assess joint movement/stability before the Pyrocarbon spherical spacer inserted. Wound closed in layers with heavy vicryl. Skin closure with subcutaneous monocryl. Physiotherapist advice within 24 hours and immediate active mobilisation is commenced as comfort allows.
45998858|NCT01224925|Procedure|Direct pulp capping with Dycal|Capping over carious exposure with Dycal. Dycal: covered with Fuji IX. After one week, part of the temporary filling was left under the permanent filling
45998859|NCT01224925|Procedure|Direct pulp capping|WMTA capping over exposed pulp, wet pellet, Fuji IX. After one week, the entire temporary filling was removed,the cavity was permanently restored with a composite resin material used at the study clinic.
45998860|NCT02902653|Drug|Oral misoprostol|hourly titrated misoprostol
45998861|NCT02902653|Drug|Vaginal misoprostol|Administration of 25 microgs every 6 hours, maximum 150 microgr
45998862|NCT02902653|Drug|Vaginal dinoprostone|Vaginal delivery system of 10mg of dinoprostone
45998863|NCT00446303|Drug|Azacitidine|"Azacitidine 60mg/m2 /d for 5 days every 28 days, for 24 months (parallel study to the ongoing NMDSG study.~Extension of maintenance in responders after 24 courses until relapse or death."
46086496|NCT02694458|Other|Early vancomycin monitoring and bayesian dosage adjustment|Measure of vancomycin serum concentration at the 3rd hour of treatment and adjustment of vancomycin dosage at the 6th hour of treatment using a bayesian approach. Then measure of vancomycin serum concentration at the 24th hour of treatment.
46086497|NCT02694458|Other|usual vancomycin dose and monitoring strategy|Vancomycin serum concentration will be measured at the 24th hour of treatment.
46086498|NCT02694302|Device|Walkbot|Walkbot(robot assisted gait training) 30 minutes and conventional physical therapy 30 minutes each per day to be administered 5 times a week for 3 weeks.
45457628|NCT05401123|Device|milking pump|"n the study, all mothers who come to the Lactation/Relactation outpatient clinic will be informed about the study, and mothers who accept the study will have to fill out the Conformity to Criteria Form created by the researcher. Between the ages of 20-35, postpartum 1-5. Participants who gave birth after the 37th week of pregnancy, did not have literacy problems, mental disabilities and communication problems, did not have chronic diseases, did not use any medication, and volunteered to participate in the study will be included in the study. by milking, 2 ml of first milk will be taken from the participants in the control group (via the milking pump). The collected milk will be taken to the laboratory for analysis by the researcher."
45998864|NCT04680351|Procedure|phrenic stimulation|measurements of the hemodynamic effects of phrenic stimulation
45998865|NCT01223404|Drug|Placebo|Participants are administered a placebo patch and a placebo capsule
45998866|NCT01223404|Drug|Nicotine|Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule
45998867|NCT01223404|Drug|Mecamylamine|Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine
45998868|NCT00446342|Drug|SNS-032 Injection|"Stage 1: Escalating doses of SNS-032 on days 1, 8 and 15 per 28 day cycle~Stage 2: Same as stage 1 except SNS-032 administered at the maximum tolerated dose established in stage 1"
45998869|NCT05657821|Dietary Supplement|Pumpkin seeds extract capsules|the intervention group was given pumpkin seed capsules for 12 weeks, and the intervention group was given iron tablets for 12 weeks
45998870|NCT00446381|Drug|Macugen (pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively
46086499|NCT02694302|Device|Conventional physical therapy|Conventional physical therapy 30 minutes to be administered twice a day, 5 times a week for 3 weeks.
46086500|NCT02716220|Device|Percutaneous Coronary Intervention|Implanttaion fo the DREAMS 2G Scaffold
46086501|NCT02719808|Drug|Tenofovir1|receive tenofovir （300mg/d）from （28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
46086502|NCT02719808|Drug|Tenofovir2|receive tenofovir （300mg/d）from（28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
46086503|NCT02719808|Drug|Tenofovir3|receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
46086504|NCT02719808|Drug|Tenofovir4|receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one week after delivery, it is the observational exposure.
46086505|NCT02261792|Procedure|24 hours Trendelenburg position|Trendelenburg position
46086506|NCT02261792|Procedure|24 hours bed rest|24 hours bed rest after EBP
45998871|NCT00446381|Drug|Macugen (Pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively.
45998872|NCT04680273|Drug|[14C]-GDC-9545|Participants will receive a single oral dose of [14C]-GDC-9545 capsule, 30 milligrams (mg) (not more than [NMT] 4.6 megabecquerel [MBq]; 124 microcurie [μCi]) with approximately 240 millilitres (mL) water in the fasted state.
45998873|NCT04680273|Drug|GDC-9545 Solution for Infusion|Treatment B: 30 mg GDC-9545 as a solution for infusion, 3 mg/mL administered intravenously (IV) in 10 mL as an infusion over 30 minutes.
45675559|NCT05875870|Behavioral|Daylight exposure combine walking|"Out-door of bright-light exposure in the morning (36 min/day, 7 times/week) for six weeks.~Tailored to the individual patient with moderate intensity of walking (3 sessions/week) for six weeks. Duration of each session depends on one-on-one exercise consultation via communication software (LINE App). The duration of walking in week 1 is 15 minutes, then increasing 5 minutes each week if the patient has tolerance. If the patient cannot tolerate the duration, the coach will instruct to keep the same duration for the following week. Basically, the goal of duration in week six is 40 minutes.~Weekly exercise consultation via communication software (LINE App).~Teaching strategy includes one-on one instruction (hard-copy of teaching manual), video, and webpage."
45998874|NCT04680273|Drug|GDC-9545/F12 Capsule|Treatment C: GDC-9545/F12 capsule, 30 mg, administered orally with approximately 240 mL water.
45998875|NCT04680273|Drug|GDC-9545/F18 Capsule|Treatment D: GDC-9545/F18 capsule, 30 mg, administered orally with approximately 240 mL water.
45998876|NCT00446420|Drug|Propofol, midazolam, fentanyl|All drugs administered in doses according to anaesthetists' discretion during sedation for colonoscopy
45998877|NCT00446498|Device|CPAP and Non Invasive Ventilation|
45998878|NCT04679922|Procedure|Soft Tissue Enhancement around dental implant|Sixteen sites that are indicated for peri-implant mucosal augmentation at the time of implant placement will be selected. Sixteen sites that were met the subsequent inclusion criteria were eligible to contribute in our study were classified randomly by the sealed envelope technique into two treatment groups, 8 sites in each group. Group I (Control Group): Autogenous SCTGs harvested from the palate +dental implants *. Group II (Experimental Group): FLA **+dental implants. The allocation was withheld from the surgeon (M.H.) until just before the surgical appointment. The clinical examiner (M.S.) was masked to the treatment group for the extent of the study.Three months after implantation, the sites were located, and the thickness of the mucosa will be evaluated using the customized stent. The operculectomy will be performed following the method of Flatebo et al.,22 collecting biopsy specimens of almost constant quality and evaluating clinical thickness without mucosal distortions
45998879|NCT00446537|Procedure|Methylphenidate|
45998880|NCT05426889|Procedure|subdural hematoma burr hole drainage|For patients with larger hematoma, remove the hematoma by burr hole drainage
45998881|NCT05426889|Drug|drug conservative treatment|The patient did not receive surgical treatment and chose conservative treatment
45998882|NCT00446576|Drug|Epoetin Alfa|
45998883|NCT02902419|Other|Wound dressing removal.|
45998884|NCT00446615|Behavioral|computer decision support tool|
45998885|NCT00446615|Behavioral|audit and feedback|
45835055|NCT05028270|Procedure|Balloon technology;Microcatheter technology|Describe each group's intervention in sufficient detail, including how and when to give the intervention Suspend or modify the criteria for interventions that have been assigned to the subject (such as changing the dose of the drug due to hazards or subject requirements or improvement/deterioration of the condition, etc.) Strategies to improve the compliance of intervention programs, and other measures to monitor compliance (such as the return of drug tablets, laboratory inspections, etc.) Related care and interventions allowed or prohibited during the trial
45998886|NCT00446615|Behavioral|group learning session|
45998887|NCT02902341|Dietary Supplement|Nutrition Therapy|Nutrition based on measured caloric needs.
45835056|NCT05026554|Genetic|Tape stripping|Optional genetic analysis for chronic hand eczema
45998888|NCT02902341|Dietary Supplement|Control|Standard protocol nutrition based on calculated caloric needs.
45835057|NCT01458444|Device|Non invasive ventilation (VNI)|BIPAP® vision
45835058|NCT01458444|Device|Non invasive ventilation|OPTIFLOW system
45998889|NCT03277664|Behavioral|intervention group|"All the device-monitored adherence data from the previous week were downloaded from the background database and calculated by a qualified asthma nurse. Through free IMS (WeChat; Tencent, Shenzhen, CHN) available on mobile, the nurse offered feedback to the caregivers weekly according to the adherence rate and reminded them to keep taking the ICS. Caregivers were asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
45998890|NCT02902302|Drug|Ibuprofen 400 mg/10 mL oral suspension|
46086507|NCT02261792|Procedure|EBP|Autologous Epidural Blood Patch
46086508|NCT02719496|Drug|IBEROGAST|
46086509|NCT02726048|Device|Simplus/Eson|Released product Simplus and Eson masks
45457629|NCT02301676|Behavioral|Korean version of telephone interview for cognitive status|The telephone interview for cognitive status (TICS), developed by Brandt et al. (1988), is one of the most popular telephone interview-based screening instruments. Especially, the Korean version of TICS is translated more suitable for Korean culture with the permission of the authors of the original version. The Korean version of TICS consists of 11 items, total score is 41.
45998891|NCT02902302|Drug|MOMENT 400 mg coated tablet|
46086510|NCT02716454|Procedure|Ileocaecal resection|laparoscopic ileocaecal resection with primary anastomosis
46086511|NCT02725970|Other|survey|Cross-sectional survey
45675560|NCT05875870|Behavioral|Stretching exercise|"The stretching exercise includes two movements for the upper body and two movements for the lower body, 10 minutes each time, three times a week, for 6 weeks.~The researcher will explain to the participants about how to perform the stretching exercise, according to an instruction manual (hardcopy) for the exercise regimen.~A video is shown to the participants (the content same as hardcopy of education manual)."
46002420|NCT03003026|Other|Novel task-specific bike skills training program|Participants randomised to the intervention group will participate in a novel task-specific bike skills training program. The intervention involves seven key components: it is group-based, intensive (2 hours per day for 3 days plus a home program for the remaining days of the one week period), task-specific, goal-directed, and therapist led, with parent involvement and conducted in an ecological setting. Each program will be run by a physiotherapist and allied health assistant during the school holidays.
46086512|NCT02719418|Drug|Tinzaparin|3500 Unit or 4500 Unit subcutaneous once daily
46086513|NCT02129348|Drug|Lithium|
46086514|NCT02129348|Drug|Placebo|
46086515|NCT02716064|Behavioral|TAP-CM Intervention|The intervention includes: 1) Healthy Lifestyle App Goal Setting and Prioritization and modules, 2) TAP-CM Report triage Huddle with Interprofessional Team 3) The connection of patients to appropriate community resources 4) Volunteer helping with technology use
46086516|NCT02719262|Device|installing ventilation in the workplace|Environmental improvement by installing/ exhaust ventilation (FUDIN SYSTEM ENGINEERING CO.,LTD.)
46086517|NCT02719340|Procedure|short segment fixation|posterior short-segment decompression and reconstruction (instrumentation on 1 level above and 1 level below the fractured vertebrae with posterolateral fusion)
46086518|NCT05128526|Behavioral|exercise|Short foot exercises without respiratory exercises
46086519|NCT05128526|Behavioral|respiratory|Short foot exercises with respiratory exercises
46086520|NCT02718872|Behavioral|Tobacco cessation online training|"The original course has been developed in the online platform e-oncologia (http://www.e-oncologia.org/en/) based on the in-person courses offered during the last 10 years by the Tobacco Control Unit of the Catalan Institute of Oncology. The theoretical framework underpinning the training program is the Stages of Change Model and the curriculum was developed with the content of numerous meta-analysis and clinical practice guidelines. We created a fully referenced curriculum online, with feedback from an expert advisory group that oriented in the instructional design to ensure the course content was palatable for an online format and aligned with the learning objectives. The final curriculum content of the Brief Intervention for Smoking Cessation Training Program is composed of 4 modules."
45457630|NCT02301676|Drug|Sevoflurane|Sevoflurane is one of the most commonly used volatile anesthetic agents, particularly for outpatient anesthesia, and including in anesthesia of children and infants, and in veterinary medicine.
45457631|NCT02301676|Drug|propofol|Propofol is highly protein-bound in vivo and is metabolized by conjugation in the liver. The half-life of elimination of propofol has been estimated to be between 2 and 24 hours.
45675561|NCT05869682|Procedure|Bright White Light Therapy|Wear AYOpro BWL therapy
45675562|NCT05869682|Drug|Combination Drug Therapy|Receive SOC ADT combination therapy
45835059|NCT05029518|Drug|SMP-100|In each period, subjects will receive a single dose of SMP-100 on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3), under fasting or fed conditions, followed by 48 hours of PK and safety assessments.
45835060|NCT02785848|Other|Interviews and Surveys|The investigators will perform semi-structured interviews and surveys on this cohort
45835061|NCT02784756|Device|Quantiferon-CMV assay|
45835062|NCT01893450|Drug|Methimazole|
45835063|NCT01893450|Drug|Bromocriptine|
45835064|NCT01893450|Drug|Pentoxifylline|
45835065|NCT05027100|Drug|Anlotinib Tislelizumab Irinotecan|Anlotinib 10mg QD 2W stop 1W Tislelizumab injection200mg Q3W Irinotecan (2 cycles) 100mg/m2,d1,d8,Q3W
45835066|NCT02778750|Procedure|Two-Bronchoscope Technique|Used to validate the use of sputum to sample the lower airway microbiome
45835067|NCT02374944|Procedure|Hardware removal|Comparison of implant retention vs. scheduled implant removal in skeletally mature patients with previously operatively treated Lisfranc injuries requiring screw and/or plate fixation.
45835068|NCT02887794|Other|Clinical and psychoacoustic measures|Our study focuses on psychoacoustic tests, specialist care protocols (psychotherapy, neuromodulation ...) being made independently of our study, as part of medical activity of Cerletti care unit or differentiated protocols. Thus, our study shows no individual benefit for the patient. However, a better understanding of the neurophysiological mechanisms underlying auditory hallucinatory phenomenon could allow a better management of these patients in the near future
45835069|NCT05020938|Other|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
45835070|NCT05027568|Drug|Single ascending doses of IOA-289|Single dose, oral administration of liquid-filled capsules, with a starting dose of 30 mg
45835071|NCT05027568|Drug|Placebo single doses|Single dose, oral administration of liquid-filled capsules, matching placebo
45835072|NCT02775162|Device|Normothermic Machine Perfusion (NMP)|
45835073|NCT02775162|Other|Standard of Care (Ice)|
45835074|NCT01458600|Drug|Diclofenac|T Diclofenac 50 mg twice daily for 12 months
45835075|NCT01458600|Drug|Methimazole|T Methimazole 5 mg 3x2 for 18 months
45998892|NCT03277625|Procedure|modified omega-shaped single-loop|A double-layer, end-to-side, duct-to-mucosa PJ using interrupted polydioxanone 5-0 suture (PDS II, Ethicon, Somerville, USA) for the outer layer and interrupted polypropylene 5-0 suture (Prolene, Ethicon, USA) for the inner layer is the standard technique during PD at our Institution. For the modified omega-shaped single-Loop reconstruction the loop between PJ and HJ is left intentionally longer at about 25-30 cm and an additional side-to-side jejunojejunal anastomosis is performed at the lowest point between the afferent and efferent loops of the HJ This intestinal anastomosis is done in a double-layer continuous PDS 5-0 suture technique. Neither sealants, nor stents are being applied at the PJ. In cases of thin walled and tiny hepatic ducts, the HJ is splinted using an externally diverted T-tube.
45835076|NCT01458600|Drug|L-thyroxin|L-thyroxin approximately 100 to 200 micrograms/day. The dose is adjusted to reach euthyroidism during concomitant treatment with methimazole for 18 months
45998893|NCT02902458|Other|Individual interview with a qualified psychologist|Individual, recorded interview with a qualified psychologist to discuss any and all subjects related to the ICD implantation, or any other topics deemed relevant by the patient.
45998894|NCT02957318|Dietary Supplement|FiberBind|Potato pulp consisting of 68% fiber (5.5 soluble, 76.7% insoluble and 17.8% resistant starch), 9.7% water, 0.3% fat, 7.2% protein and 14% carbohydrates (starch).
45998895|NCT02957318|Dietary Supplement|RG-I fiber|Soluble fiber extracted from potato pulp consisting of 95% fiber and 5% water.
45998896|NCT02957318|Dietary Supplement|Placebo|Low-fiber control
45998897|NCT01223365|Drug|Hydrocodone ER|Hydrocodone bitartrate extended-release tablets were administered at doses of 15, 30, 45, 60, and 90 mg orally every 12 hours. During the open-label titration period, doses were adjusted until a stable pain control was achieved. In general, the dose of hydrocodone extended release tablets could be adjusted for efficacy or tolerability, as necessary, at any time during the open-label treatment period; however, participants were required to visit the study center before increasing the dose of study drug.
45998898|NCT02956811|Drug|Dapagliflozin|SGLT2 inhibitor
45998899|NCT02956811|Drug|Placebo|Matching Placebo
45998900|NCT04319419|Dietary Supplement|Supplement with micronutrients|Obese children were divided in 2 groups. A group received the supplement plus nutrition education and other group was a control, only received nutrition education.
45835077|NCT01458600|Drug|Propranolol|T Propronalol 40mg 1x1-3 during during 1-3 weeks until the patient has responded to thyrostatics
45835078|NCT01458600|Drug|Metoprolol|T Metoprolol 50 mg 1x3 for 1-3 weeks until the patient has responded to thyrostatics
45998901|NCT04319419|Other|Nutrition education|Group received nutrition education program during 6 months
45998902|NCT05657782|Biological|PanChol|PanChol is a new second generation live-attenuated oral cholera vaccine (OCV) that circumvents limitations of previous live-attenuated OCVs. In contrast to other live OCVs, PanChol is derived from a current circulating pandemic V. cholerae strain, thus eliminating the risk of vaccine-derived genes from extinct V. cholerae strains (such as CVD 103-HgR) recombining with circulating V. cholerae strains.
45998903|NCT05426694|Other|Scapular clock exercises|In scapular clock exercises, the hand is placed on the wall in front of your body. Move the hand in direction of 12 and 6 o'clock to elevate and depress the scapula. Then move hands towards 9 o' clock and 3 o'clock direction to protract and retract the scapula. Hold each position for 10 seconds. From 3rd week and onward the patient will use thera-band and then perform clock exercises.
45998904|NCT05426694|Other|Stretching and strengthening exercises|Stretching and strengthening exercises of shoulder and scapular muscles was performed including wall washes, corner stretch, pectoral muscles stretch and wall push ups.
45835079|NCT01893528|Drug|REGN2009|
45835080|NCT01893528|Other|placebo|
45835081|NCT02771028|Behavioral|Emotional Freedom Techniques|
45835082|NCT02765880|Other|fMRI|Connectivity between the areas related to information processing over time and the areas activated during the rest activity. We will verify whether the activation anomalies observed during time tasks predict anomalies in spontaneous activity dynamics.
45998905|NCT05657743|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
45998906|NCT00446693|Device|EndoFast Reliant™ system for Pelvic Organ Prolapse repair|The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with proprietary mesh and soft-tissue Fasteners in a minimally-invasive procedure.
45998907|NCT04319029|Behavioral|Pharmaceutical care plan|"The design of the intervention was based on a stepwise approach to address the following point in each participant: set priorities for patient care, assessment of patient's educational needs, and development of a comprehensive and achievable pharmaceutical care plan.~The participants will be educated about their illness and informed about the proper use of their medication in a structured manner (it involved the following items: dyslipidemia as a disease, complications, who therapy reduces its risk and complications, goal of therapy). Behavioral modifications will involve the following: physical exercise, diet, smoking cessation. Patients will obtain this information verbally and provided in a written manner through a brochure that design for this study."
45998908|NCT05657704|Drug|The patients in experimental group will be genotyped before surgery and treatment will be prescribed according to the CYP2D6 phenotype|Treatment will be prescribed according to the CYP2D6 phenotype. Normal Metabolizers (NM): Tramadol 100 mg every 8 hour; Ultrarapid Metabolizers (UM): Tramadol 50 mg every 8 hours Intermediate and poor metabolizers (IM/PM): dexketoprofen 25 mg every 8 hours
45998909|NCT04319185|Other|Assistance to perform Peritoneal Dialysis (PD) at home|The patient receives assistance of up to one visit per day for three months depending on the patient's needs, as assessed by the interdisciplinary team, the nephrologist, and the primary investigator or delegate.
45998910|NCT00446732|Device|UroSshield|Attachment of the UroShield device to the external part of the urinary catheter
45998911|NCT05426616|Device|collagen membrane (Creos Xenoprotect , Nobel Biocare AB, Göteborg, Sweden)|A mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector. DBBM particles soaked in blood are mixed with autogenous bone chips to a ratio of 1:1. After having made multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied. An individualized collagen membrane is attached on top using membrane fixation pins. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved.
45998912|NCT05426616|Device|titanium reinforced d-PTFE membrane (Creos Syntoprotect , Nobel Biocare AB, Göteborg, Sweden)|A mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector. DBBM particles soaked in blood are mixed with autogenous bone chips to a ratio of 1:1. After multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied.A titanium reinforced d-PTFE membrane is attached on top using membrane fixation pins. Care is taken to leave a distance of at least 1 mm between the membrane and neighboring teeth. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved. The membrane is removed after 9 months, prior to implant placement.
45998913|NCT00446771|Drug|Mannitol|
45998914|NCT01222078|Biological|otelixizumab|Two treatment courses of otelixizumab given 6 months apart. Each treatment course will consist of 8 consecutive days of otelixizumab intravenous infusions (each given over 30 minutes).
45998915|NCT03277586|Drug|Probio'Stick|Probiotic supplement containing Lactobacillus helveticus and Bifidobacterium longum
46086521|NCT02725736|Drug|Atosiban|"After random allocation to a treatment group, women will receive Atosiban as follows:~Atosiban was given as a single loading intravenous dose, 6.75 mg in 0.9% sodium chloride solution, followed by an intravenous infusion of 300 micrograms/min in 0.9% sodium chloride solution for the first 3 hours and then 100 micrograms/min for another 45 hours. The choice of the dose regimen for Atosiban was consistent with the recommendations of the product labeling."
46086522|NCT02725736|Drug|Nifedipine|"After random allocation to a treatment group, women will receive Nifedipine as follows:~Nifedipine was given as a loading dose of 20 mg orally followed by another two doses of 20 mg, 20-30 minutes apart as needed. Maintenance was started after 6 hours with 20-40 mg four times a day for a total of 48 hours."
46086523|NCT02716142|Drug|rectal misoprostol|patients will take 2 tablets of rectally misoprostol 400 microgram 60 minutes before the procedure
46086524|NCT02716142|Drug|sublingual misoprostol|patients will take 2 tablets of sublingual misoprostol 400 microgram 60 minutes before the procedure
46086525|NCT03015974|Drug|Corticosteroid|
45675563|NCT05869682|Other|Electronic Health Record Review|Ancillary studies
46086526|NCT03015974|Drug|Cyclophosphamide|
45675564|NCT05869682|Other|Quality-of-Life Assessment|Ancillary studies
45675565|NCT05869682|Other|Questionnaire Administration|Ancillary studies
46086527|NCT03015974|Drug|Mycophenolate mofetil|
46086528|NCT03015974|Drug|Dipyridamole|
46086529|NCT03015974|Drug|ACE Inhibitor or Angiotensin receptor antagonist|
46086530|NCT02718950|Drug|Liraglutide 3.0 mg|Subjects will use liraglutide 3.0 mg for 2 weeks
45457632|NCT02301676|Device|dexmedetomidine|Dexmedetomidine is a sedative medication used by intensive care units and anesthesiologists. It is relatively unusual in its ability to provide sedation without causing respiratory depression.
45457633|NCT01135771|Other|glucose and insulin IV to alter blood glucose|
45457634|NCT01137565|Drug|AMG 853|Single dose administration of AMG 853 or placebo in tablet form to adolescent and adult subjects with asthma
45675566|NCT05868772|Device|Active Sentry Handpiece|With low IOP settings
45835083|NCT02765880|Other|EEG|link between EEG response anomalies related to information processing over time and response anomalies recorded during rest activity. We will check whether anomalies in EEG oscillatory responses during time tasks predict anomalies during the rest task.
45835084|NCT02764788|Other|Specific auriculotherapy|Specific auriculotherapy with needles
45835085|NCT02764788|Other|non-specific auriculotherapy|non-specific auriculotherapy with needles
45835086|NCT02764788|Other|seed auriculotherapy|non-specific auriculotherapy with seeds
45457635|NCT01137565|Drug|Placebo|Placebo to AMG 853
45457636|NCT02301754|Biological|INVAC-1|intradermal injection combined with electroporation
45675567|NCT05868772|Device|Ozil Handpiece|With high IOP settings.
45675568|NCT05867719|Other|Hypoxic breathing conditions|Participants will undergo three separate hypoxic conditions, along with a normoxic condition, simulating 8,000 foot elevation, 12,0000 foot elevation, and a ramp condition starting at 8,000 feet and then ascending to 12,000 feet.
45675569|NCT05864976|Device|Support Vector Machine|Machine learning algorithm
45675570|NCT05864703|Procedure|Adjustment|Instrument-assisted, high velocity, low amplitude adjustment
45835087|NCT04272528|Other|uniform care|The leader develops training plan and trains nurses, who provide uniform care and education to patients according to the training.
45835088|NCT04272528|Other|conventional care|Nurses carry out the routine care procedures.
46086531|NCT04908878|Procedure|Pectoral nerve (PECS) block -transversus thoracic plane (TTP) block|Patients will receive unilateral US-guided PECS II block and TTP block on the side of the operation after induction of general anesthesia.
45675571|NCT05864703|Procedure|Sham|Instrument-assisted light touch to neck
45998916|NCT03277586|Drug|Placebo|Identically formulated and packaged inactive substance
45998917|NCT02902536|Other|No interventions|
45998918|NCT04317157|Dietary Supplement|Caffeine|Specific dosage of caffeine for each participant (6 mg.kg-1).
45998919|NCT04317157|Other|Placebo|Placebo pill.
45998920|NCT04318873|Other|Packed Promise Demonstration Benefits|Monthly: Home-delivered food box, nutrition education handout, and $15 monthly voucher for fruits and vegetables
45998921|NCT04317079|Dietary Supplement|Hydroxytyrosol|Administration of hydroxytyrosol in doses 15mg and 5 mg compared to placebo for 6 months
45998922|NCT04317079|Other|Diet|Consultation by a dietitian was offered to all participants
45998923|NCT03277430|Procedure|Live donor uterus transplantation|Transplantation of uterus from a living donor.
45998924|NCT03277430|Procedure|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor.
45998925|NCT03277430|Drug|Tacrolimus|Maintenance immunosuppression in UTx recipient will be reduced to tacrolimus monotherapy to minimalize fetal compromise.
45998926|NCT02902575|Procedure|Laparoscopic-assisted gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed with curative treated intent.The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
45998927|NCT05657431|Other|essential oils (Ylang ylang oil)|inhaler aromatherapy
45998928|NCT05657431|Other|placebo (saline solutions)|placebo saline solutions
45998929|NCT05657431|Other|essential oils (lemon oil)|inhaler aromatherapy
45998930|NCT04699214|Drug|Endostar (recombinant human endostatin injection)|The experimental group is Endostar combined with AI
45998931|NCT04699214|Drug|Chemotherapy AI|AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W
45998932|NCT02902380|Drug|dexmedetomidine group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery
45457637|NCT03510052|Behavioral|Diet Modification Pilot Program (DPM)|Investigator will administer DMP which will include a review of the booklets and any targeted recommendations based on the participant's food and symptom diary. The participant will follow the DMP for 6 weeks and report for a follow-up visit.
45675572|NCT05863741|Device|Implantation of GMK Sphere with conventional instrumentation|Implantation of GMK Sphere with conventional instrumentation (control group)
45457638|NCT01133353|Drug|Tetrabenazine MR|Modified-Release (MR) tablets containing 15 mg or 30 mg tetrabenazine, dose-escalating up to a maximum of 150 mg depending on weight, once per day for 12 weeks
45457639|NCT01133353|Drug|Placebo|1 to 5 tablets once per day depending on weight for 12 weeks
45675573|NCT05863741|Device|Implantation of GMK Sphere using the NextAR guidance system|Implantation of GMK Sphere using the NextAR guidance system (NextAR group)
45457640|NCT01135927|Drug|insulin degludec|NN1250 (insulin degludec) injected s.c. (under the skin) once daily for 6 days
45998933|NCT02902380|Drug|control group|0.9% saline infusion
45998934|NCT03277235|Behavioral|Resilience model-based total care plan|12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
45998935|NCT05426577|Diagnostic Test|ELISA, LAMP, Cytokine Release Assay|"IgG1 ELISA: ELISA that employs soluble Leishmania lysate or protein antigen.Results are recorded as antibody titres, which are measured by the absorbance values of products generated using enzyme conjugated anti-human antibodies.~Cytokine release assay (CRA): In this assay whole blood is stimulated for 24 hours with leishmania antigen. Cytokine levels are then assessed in the plasma fraction using flow cytometry with the BD™ Cytometric Bead Array for Human Cytokines or standard ELISA kits for human cytokines commercialized by Sigma-Aldrich (RAB0268-IL-2, RAB0222-IFN-g, RAB0224-IL-10, RAB0476-TNF-a, RAB0119-IP-10).~LAMP test for VL: We will use the LoopampTM Leishmania Detection Kit, CE-marked and produced Eiken Chemical Co., Japan."
45998936|NCT01221727|Drug|Denosumab|Eighteen (18) subjects will receive 1 fixed dose administration of denosumab.
45998937|NCT01221727|Drug|Midazolam|All subjects will receive two oral dose administrations of midazolam.
45998938|NCT03277157|Dietary Supplement|B. lactis B94|A probiotic dose of 15 billion per capsule.
45998939|NCT03277157|Dietary Supplement|Placebo|Placebo capsule
45998940|NCT02902614|Procedure|Vegetal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
45998941|NCT02902614|Procedure|Animal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
46002421|NCT03003026|Other|Parent-led home-based bike skills training program|The comparison group will involve a parent-led home-based bike skills training program. Parents of children randomized to the comparison group will receive written information and telephone support from a physiotherapist on training bike skills. They will be encouraged to work with their child towards their bike skills goals for at least 30-45 minutes per day over a one week period during the school holidays in home and community environments.
46002422|NCT02953301|Drug|resminostat|
46002423|NCT02953301|Drug|Placebo|
45998942|NCT05342701|Behavioral|Motor Skills Intervention|"The behavioral motor skill intervention (CHAMP) is an intervention strategy that uniquely address differences in children's development. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to development improvement in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP consists of 35 minutes/day X 3-4 days/week for 19 weeks (dose of 1995 - 2240 minutes). Each session will consist of three parts: (a) 3-5 min of motor skill introductory activity, (b) 25 min of motor skill instruction and practice, and (c) 3-5 min motor skill closure activity."
45998943|NCT05657392|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment. Last few decades, it has been revealed that rTMS accelerates motor recovery and may reduce stroke-related symptoms.
45998944|NCT05657392|Other|32 electrode electroencephalography (EEG)|32-electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting
45998945|NCT03277118|Device|Wireless Wearable Device|Wireless Wearable Device will be placed on the wrist of the patient prior to extubation in the ICU to record patient activity in terms of steps and sleep quality.
45998946|NCT01221181|Drug|Eculizumab|Dosage/Frequency: 900 mg IV once a week for 4 weeks, 1200 mg IV week 5, then 1200 mg IV every 2 weeks through week 53.
46086532|NCT04908878|Procedure|Serratus anterior plane (SAP) block|Patients will receive US-guided SAP block after induction of general anesthesia.
45998947|NCT05657314|Dietary Supplement|Active Comparator|Consists of 15 grams of pea protein
45998948|NCT03277079|Drug|statin + ezetimibe|Combination of two drugs
45998949|NCT03277079|Drug|statin + ezetimibe + Nutraceuticals|Combination of two grus plus nutraceuticals
45998950|NCT05657236|Other|medical treatment|traditional medical treatment and regular follow-up
45998951|NCT05657236|Other|plyometric exercise|Each session starts with a 5-minute warm-up of flexibility exercises (active range motion and stretching exercises).The main plyometric exercise set will be applied for 20-30 minutes and consisted of 10 exercises directed at the lower body that gradually progress by increasing the set/repetition number in two exercise blocks, each continue for 1 month .The cool down period is 5 minutes and includes walking at self-preferred speed and static stretches of the major muscle groups.
45998952|NCT02902224|Dietary Supplement|Tap water|300ml tap water via nasogastric tube
45998953|NCT02902224|Dietary Supplement|Glucose|300ml tap water with 75g glucose via nasogastric tube
45998954|NCT02902224|Dietary Supplement|Fructose|300ml tap water with 25g fructose via nasogastric tube
45998955|NCT01220557|Behavioral|PRIMAS|PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
45998956|NCT01220557|Behavioral|DTTP|The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
45998957|NCT04317001|Drug|Modafinil|Treatment will be with 100mg of modafinil for the two week primary phase of the study
45998958|NCT04317001|Drug|Placebo|placebo
45998959|NCT03277040|Other|CSA membership|Bi-weekly fresh food delivery
45998960|NCT02887339|Other|Training Website|Additional training website can be found at gtextraing.org
45998961|NCT02887339|Other|Control|Standard training given by OPOs and GTEx staff
45998962|NCT05426499|Drug|Patients requiring cefotaxime treatment|Dosage according to SmPC
45998963|NCT05426499|Drug|Patients requiring meropenem treatment|Dosage according to SmPC
45998964|NCT05426499|Drug|Patients requiring fluconazole treatment|Dosage according to SmPC
45998965|NCT05426499|Drug|Patients requiring isavuconazole treatment|Dosage according to SmPC
45998966|NCT05426499|Drug|Patients requiring anidulafungin treatment|Dosage according to SmPC
45998967|NCT05658094|Device|Exosome|Each patients will receive 4 injection with an interval of 14 days during two months
46002424|NCT02932332|Other|High-flow Oxygen|Optiflow Respiratory Humidifier used to deliver HFOx. Oxygen flow will be maximized (set between 20 and 60 L/min), if tolerated, to minimize dyspnea. FiO2 will be set at 100%.
45457641|NCT01135927|Drug|insulin detemir|Insulin detemir injected s.c. (under the skin) once daily for 6 days
45457642|NCT02301910|Drug|Recombinant staphylokinase|15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
45457643|NCT02301910|Drug|Tenecteplase|"50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)~55 to <60 30 mg 6 ml~60 to <70 35 mg 7 ml~70 to <80 40 mg 8 ml"
45835089|NCT02839278|Biological|Blood sample|
45835090|NCT02836080|Behavioral|Integrated Collaborative Care Team (ICCT)|An integrated, collaborative pathway of needs-based services. ICCTs will offer a wide variety of services, including Solution-Focused Brief Therapy (SFBT) on a scheduled and walk-in basis, care navigators, various clinician-guided interventions, psychiatry, nurse practitioner services, access to primary care, and peer support, all co-located in youth-friendly, community-based clinics. For each intervention, standardized intervention protocols will be used.
45998968|NCT01220401|Behavioral|exposure, relaxation, and rescription therapy|veterans reporting chronic nightmares at least once per week for the past month who consent to participate will attend four consecutive weekly sessions lasting approximately two hours each. Participants will log their sleep events and associated symptoms (i.e. PTSD, depression, etc.)
45675574|NCT05861232|Behavioral|Behavioral|fear and anxiety during inhalation therapy
45835091|NCT02836080|Other|Treatment as Usual (TAU)|Standard out-patient treatment provided at each participating hospital site. This typically entails referral to a psychiatrist at the participating hospital, who will provide assessment and treatment, with referral to appropriate services, guided by local treatment protocols.
45998969|NCT00446810|Drug|Benfotiamine|
45998970|NCT00446810|Drug|Placebo|
45998971|NCT05657197|Behavioral|Exercise intervention|A 12-week exercise program consisting of three times per week 1-hour sessions, including 30-minutes aerobic- and 30-minutes progressive resistance training. The intensity of training will be adjusted to each individual, based on a cardiopulmonary exercise test. Training sessions will be performed in groups of 10 participants under supervision of a sports physical therapist.
45998972|NCT05657197|Other|Usual care|Usual care, including general advice concerning chronic fatigue.
45998973|NCT00446888|Behavioral|Standardized Meals for Diet Stabilization|Subjects will eat prepared meals for 3 days prior to their study; or they will document their dietary intake over this period.
45998974|NCT00446888|Dietary Supplement|Forticare|400 ml of commercially-available nutritional supplement.
45998975|NCT00446888|Dietary Supplement|Product 4808|400 ml Forticare, to which has been added extra protein and the amino acid leucine.
45998976|NCT02887300|Behavioral|Mantra Meditation|"Week 1:~20 minute meditation session. Prescribed text discussion. Encouraging a daily practice; the log, daily readings, timer etc.~Week 2:~Review of the practice followed by a 20 minute meditation period. Challenges to learning meditation. Second 20 minute meditation. Discussion of prescribed text.~Week 3:~20 minute meditation. Review of Atul Gawande's lecture. Second 20 minute period of meditation. Discussion of prescribed text.~Week 4:~20 minute meditation session. Discussion of prescribed text. A second 20 minute meditation. End of programme review."
45998977|NCT05657158|Other|Brolucizumab|Participants with cases of RV and/or RO reported to Novartis Patient Safety following brolucizumab use in routine clinical practice for which images were provided to Novartis and read by the Reading Centre were included
45998978|NCT01220167|Drug|Ondansetron 8 mg ODFS without water|Single dose of Ondansetron 8 mg (ODFS) administered without water
45998979|NCT01220167|Drug|Ondansetron 8 mg ODFS with water|Single dose of Ondansetron 8 mg (ODSF) was orally administered, allowed to dissolve, swallowed with saliva, followed with water
45998980|NCT01220167|Drug|Zofran ODT (ondansetron 8 mg) without water|Single dose of Zofran ODT (containing ondansetron 8 mg) administered without water
45998981|NCT00447044|Behavioral|Resistance Exercise|Subjects will lift weights with their legs.
45998982|NCT00447044|Dietary Supplement|diet orange soda|Subjects drink diet orange soda 3x day for 2 days.
45998983|NCT00447044|Dietary Supplement|essential amino acids|Subjects drink 15 grams of EAA mixed into diet orange soda 3x day for 2 days.
45998984|NCT02902185|Drug|ART plus Chidamide|Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
45998985|NCT02902185|Drug|ART plus Placebo|Placebo will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
45998986|NCT00447161|Drug|Bacillus Clausii Multi ATB Resist|Twice daily dose of 1 vial of 1x10^9 of Bacillus clausii spores, orally suspension in water
45998987|NCT00447161|Drug|Placebo|Matched placebo
45998988|NCT00447200|Procedure|Esophagus Doppler monitoring|
45998989|NCT00447200|Procedure|Fluid optimization|
45998990|NCT00447239|Procedure|glucontrol (insulin therapy)|
45998991|NCT02901873|Device|Electrical Impedance Spectroscopy|
45457644|NCT01585753|Drug|NRTI + PI|tenofovir zidovudine abacavir lamivudine emtricitabine ritonavir darunavir atazanavir lopinavir fosamprenavir
45998992|NCT00447317|Behavioral|BalanceWise-PD|Dietary counseling based on Social Cognitive Theory, paired with PDA-based dietary self-monitoring
45998993|NCT00447317|Behavioral|Attention control|Standard peritoneal dialysis dietary education
45998994|NCT05425914|Drug|Vitamin D|New treatment option for dry eye patients with low serum vitamin D Level
45998995|NCT05425914|Drug|Artificial tear|Conventional dry eye treatment
45998996|NCT00447356|Drug|recombinant interferon alfa|
45998997|NCT02902068|Device|NICaS Bio Impedance|"Hemodynamic monitoring will be carried out using non invasive NICaS cardiac impedance by the use of two electrodes stickers which are pasted on the wrists for about 6 minutes.~Monitoring will be done with women lying down or sitting up half an hour preoperatively (in the woman's surgery waiting room) intraoperatively, and postoperatively in the PACU.~Preoperative data will be compared to intraoperative and postoperative data, and will be analyzed in order to evaluate the dynamic cardiac output changes in women undergoing cesarean sections."
45998998|NCT05425875|Procedure|Bronchoalveolar lavage using wall mount suction|BAL will be performed using wall mount suction with a pressure <100 mmHg
45998999|NCT05425875|Procedure|Bronchoalveolar lavage using manual suction|A 50-mL syringe will be used to apply suction through the working channel of a bronchoscope
45999000|NCT05425875|Procedure|Bronchoalveolar lavage using manual suction with rubber tubing|A 50-mL syringe with an attached rubber tubing will be used to apply suction through the working channel of a bronchoscope
45999001|NCT00447434|Drug|Natto extract (Nattokinase)|
45999002|NCT00447473|Drug|GM-CSF|GM-CSF will be administered as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) on weeks 2 and 3 each 21 day cycle (total of 14 days).
45457645|NCT01585753|Drug|maraviroc + PI|maraviroc ritonavir darunavir atazanavir lopinavir fosamprenavir
45835092|NCT02832570|Drug|Sildenafil 100mg single oral dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
45835093|NCT02832570|Drug|Placebo, Oral intake single dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
45835094|NCT02832492|Behavioral|pupil near response|
45999003|NCT00447473|Drug|Ketoconazole|Ketoconazole will be administered daily at a dose of 400 mg po tid (either 1 hour before or 2 hours after meals), ascorbic acid 250 mg po tid (given with ketoconazole) and replacement doses of hydrocortisone (20 mg po in the morning and 10 mg po in the evening).
45999004|NCT00447473|Drug|Mitoxantrone|Mitoxantrone will be given at dose of 12 mg/m2 every 3 weeks, up to a maximum cumulative dose of 140 mg/m2
45675575|NCT05860257|Behavioral|PeerLearning.net|PeerLearning.net provides an easy-to-use, scalable, and widely accessible means to support teachers in effectively designing and delivering high-fidelity Cooperative Learning (CL) lessons and, in turn, it has the potential to amplify the positive effects of CL found in previous research. Using PeerLearning.net, teachers design their lesson by selecting from among a set of typical CL lesson templates (e.g., jigsaw, peer tutoring, group projects) which they can customize and populate with their own curriculum and materials. These design templates represent the optimal, high-fidelity design that is required in order for CL to be successful. During lesson delivery, PeerLearning.net manages membership in learning groups, distributes instructional materials, directs student activities according to a pre-specified timetable, supports teacher observations of student behavior, and delivers post-lesson group activities and reviews.
45999005|NCT05425602|Drug|MAX-40279-01: 50mg/70mg|[Stage 1]The starting dose of MAX-40279 was 35 mg BID, and three dose levels were initially set: 35 mg, 50 mg, and 70 mg administered twice daily (BID) continuously, and the dose of KN046 was 5 mg/kg as a fixed dose administered every 3 weeks. [Stage 2]When the RP2D dose is obtained in the dose-finding phase, the trial will enter the dose expansion phase.
45999006|NCT00447512|Drug|ghrelin|acylated ghrelin
45675576|NCT05858151|Behavioral|Food system and demand generation|The Global Alliance for Improved Nutrition (GAIN) will implement the Transforming Food Systems to Improve Diet Quality and Resilience for the Most Vulnerable program, which will use a market-based approach to improving diets through food systems. The set of interventions proposed is based on characteristics and challenges of the food environments of bottom of pyramid consumers in Mozambique. GAIN will focus on elements of the food environment related to accessibility, affordability, and desirability of animal source foods (ASFs) in Mozambique.
45835095|NCT02763150|Behavioral|Lifestyle intervention|Intervention group will receive comprehensive behavioral weight loss program.
45999007|NCT00553488|Drug|Regular insulin (Humulin)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
45835096|NCT02763150|Other|Health Promotion|The health promotion group will receive education on healthy eating and activity
45999008|NCT00553488|Drug|Insulin lispro (Humalog)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
45999009|NCT00447551|Drug|Poly-L-Lactic Acid|Deep dermal injection
45999010|NCT00447629|Drug|PPM-204|
45999011|NCT00553527|Procedure|Humeral Stem replacement surgery|Patient will receive humeral stem replacement.
45999012|NCT00447668|Behavioral|Yoga|Yoga for back pain
45999013|NCT00447668|Behavioral|Exercise|exercises for back pain
45999014|NCT00447668|Behavioral|Self-care book recommendations|Self-care book for back pain
46086533|NCT02725502|Drug|Linagliptin|Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with continuous glucose monitoring system (CGMS). Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
46086534|NCT02725502|Drug|Placebo|Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo. Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP-1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with CGMS. Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
46086535|NCT02718716|Drug|UCB7665|"Intervention Type: Biological/Vaccine~Pharmaceutical Form: Powder for solution for infusion~Concentration: 100 mg/ml - Route of Administration:~Subcutaneous infusion"
46086536|NCT02715674|Device|Plasti-med TRIFLO|
45457646|NCT01585753|Drug|maraviroc + NRTI|maraviroc tenofovir zidovudine abacavir lamivudine emtricitabine
45999015|NCT05425407|Dietary Supplement|whey protein|Daily 45g of whey protein supplementation during a three week eccentric training period
45999016|NCT05425407|Dietary Supplement|whey protein + collagen peptide|Daily 15g of whey protein and 20g collagen peptide supplementation during a three week eccentric training period
45999017|NCT00447707|Behavioral|Positive Choice|
45999018|NCT03455322|Drug|norepinephrine versus midodrine & octreotide|either intravenous infusion (IVi) norepinephrine in a dose of 0.05-0.3ug/Kg/min. to keep mean arterial pressure ≥ 80-100mmHg & continued either until HRS reversal or for maximum 10 days or oral midodrine 5mg three times/day & can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous & if needed increased to 200ug/6h.
45999019|NCT00447746|Procedure|D1 or D2 lymphadenectomy for gastric cancer patients|
45999020|NCT05425368|Drug|Silver diamine fluoride|First permanent molars in this group will receive 38% silver diamine fluoride as an indirect pulp capping material.
45999021|NCT05425368|Drug|Mineral trioxide aggregate|First permanent molars in this group will receive mineral trioxide aggregate as an indirect pulp capping material.
45999022|NCT02901522|Other|telemonitoring|Patients is evaluated by telemonitoring (phone call nurse - 45 and 90 days).
46086537|NCT02715674|Device|BIPAP VISION|
46086538|NCT02715674|Device|Plasti-med oxygen therapy mask|
45999023|NCT02901522|Other|Spirometry (baseline)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
45999024|NCT02901522|Other|Spirometry (20 - 22weeks)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
45999025|NCT02901522|Other|Teleconsultation|The general practioner received phone call to asthma care.
46086539|NCT02718794|Procedure|Simulation training|spend 3 hours for each of 10 nurse anesthetist students with 4 scenarios
46086540|NCT02718794|Procedure|Problem-based learning|spend 3 hours for PBL steps with each of 10 nurse anesthetist students
45999026|NCT00447824|Procedure|Introduction of better conditions during blood sampling|
45999027|NCT04681326|Device|biological prosthesis|retro-muscular positioning of a swine dermal collagen prosthesis
45999028|NCT00447863|Drug|Levonorgestrel/Ethinyl Estradiol|
45999029|NCT02901600|Other|Detection of the expression of DMTB1 by immunohistochemistry|
45999030|NCT00447941|Drug|SCA-136|
46086541|NCT04125758|Behavioral|Mindfulness training|Brief audio recordings discussing mindfulness or guided mindfulness practices.
45675577|NCT05857761|Device|Active repetitive transcranial magnetic stimulation (rTMS)|Five sessions of active rTMS therapy will be distributed over 2 weeks (20 Hz, 2000 pulses, 90% resting motor threshold) will be delivered to left dorsolateral pre-frontal cortex (DLPFC) around 6 months post-trauma.
45675578|NCT05857761|Device|Sham repetitive transcranial magnetic stimulation (rTMS)|Five sessions of sham rTMS therapy will be distributed over 2 weeks
45675579|NCT05855382|Other|Persistent COVID-19|To determine the prevalence of persistent COVID-19 diagnosis in the current study, we will identify adults between 18 and 100 years of age who have had at least one positive SARS-CoV-2 RT-qPCR test from the COVID-19 database maintained by the SEREMI of Health in Punta Arenas between July 2022 and July 2023.
46086542|NCT04125758|Behavioral|Tracking time spent on mobile device|Participants will record each day how much time they estimate they spent on their smart phone in the past 24 hours.
45675580|NCT05855122|Drug|Tocilizumab|Pateients enrolled in Tocilizumab group will receive tocilizumab(8mg/kg) at day -7 before transfusion of stem cells.
45675581|NCT05852691|Drug|RO7247669|Participants will receive intravenous (IV) RO7247669 every 3 weeks (Q3W) until disease progression or treatment discontinuation.
45675582|NCT05852691|Drug|Pembrolizumab|Participants will receive IV pembrolizumab Q3W until disease progression or treatment discontinuation.
45675583|NCT05852691|Drug|Nab-Paclitaxel|Participants will receive IV nab-paclitaxel weekly for 3 weeks, followed by 1 week off, until disease progression or treatment discontinuation.
45675584|NCT05837117|Behavioral|Patient's Perspective|"Participants will complete a questionnaire about sexual wellbeing, sexual dysfunction, and communication with your provider on this topic.~Participants/Researchers will learn about your attitudes, beliefs, and feelings about sexual well-being"
45457647|NCT02306512|Procedure|H&E|Sample will be stained with H&E according to standard procedures
45457648|NCT02306512|Procedure|IHC MART-1|Samples will be stained with immunohistochemistry antibody: MART-1 according to standard procedures.
45675585|NCT05833438|Drug|VEN+AZA-5|Up to 6 cycles: Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally)
45675586|NCT05831189|Drug|RBX2660|RBX2660 should be administered to the right side of the colon (i.e., between the ileocecal valve and the hepatic flexure of the colon).
45999031|NCT05425329|Dietary Supplement|I3.1|Capsule containing bacterial strains Lactobacillus plantarum (CECT7484 and CECT7485) and Pediococcus acidilactici (CECT7483) at a ratio of 1:1:1.
46086543|NCT02718560|Behavioral|Writing|Writing exercise with or without cues for 1 hour per day for 4 days at week for 4 weeks
45675587|NCT05827016|Drug|Iberdomide|Specified dose on specified days
45999032|NCT05425329|Dietary Supplement|Placebo treatment|Capsule containing maltodextrin.
45999033|NCT00448097|Drug|cetuximab|No verifiable data available, PI relocated
45999034|NCT00448097|Drug|docetaxel|No verifiable data available, PI relocated
45999035|NCT03455283|Drug|Clariscan|Clariscan 0.5 mmol/ml solution for injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
45999036|NCT03455283|Other|Gadolinium-Based Contrast Agents|All GBCAs will be selected by the sites and recorded as by the brand names.
45999037|NCT00448214|Drug|YM150|Oral
45999038|NCT00448214|Drug|warfarin|Oral
45457649|NCT02306512|Procedure|IF MART-1|Samples will be stained with immunofluorescence antibody: MART-1 according to standard procedures.
45457650|NCT02306512|Procedure|IF cocktail|The fluorescent primary antibodies may include HMB-45, SOX10, Ki-67 and MART-1. However other markers will be considered to make the most visually remarkable cocktail; these may include S-100, MiTF, lamin and nestin. Primary antibodies will be tagged with secondary antibodies labeled with fluorescent signals. A fluorescent organelle stain and/or 4',6-diamidine-2-phenylindol (DAPI) may also be used to enhance cellular architecture.
45457651|NCT03509818|Other|plyometric exercise|acute plyometric exercise
45457652|NCT03509818|Other|Aerobic exercise|acute aerobic exercise
45999039|NCT02901639|Other|counseling|
45999040|NCT00448253|Biological|NP-015|"Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA, or placebo.~And a Fourth Cohort at 840 units TNA with 2 additional product lots."
45999041|NCT05425212|Other|Functional activation with kinesio tapping|These exercises will be carried out thrice a week for 4 weeks. The exercises will be performed for approximately 35-45 minutes, 1 to 2 times a day, in sitting or standing position
45999042|NCT05425212|Other|Conventional physical therapy|strengthening and stretching, combined with Ankle ranges and Hip strengthening. (6) The exercises performed will be Calf stretches, Heel and Toe raises, Hip marching in sitting/standing; 4 days a week for 4 weeks
45999043|NCT00448292|Drug|PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
45999044|NCT00448292|Drug|Placebo for PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
45999045|NCT00553566|Procedure|medical chart review|
46086544|NCT02718638|Other|physical exercises|Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months. The first exercise was knee extension from 90° to 0°. The patient remained in the 0° position for 5 seconds (an isometric contraction) and then returned to the starting position (90º). 2) The second exercise consisted of a triple flexion followed by extension of the lower limbs. The patient flexed the thigh, knee and ankle (elastic band placed at the level of the metacarpals) followed by a double extension of the thigh and knee. 3) In a co-isometric contraction, the patient performed a leg extension against the ankle-cuff resistance (located under the distal third of the leg at the level of the malleolus) for 10 seconds. 4) The patient performed a unilateral hip joint flexion of the lower limb with the knee extended by rising to their functional limit.
46086545|NCT02725346|Procedure|Acromioplasty with planning|
46086546|NCT02725346|Procedure|Acromioplasty without planning|
46086547|NCT04153136|Drug|Sacubitril-Valsartan 49-51Mg Oral Tablet|By mouth twice daily
45675588|NCT05827016|Drug|Lenalidomide|Specified dose on specified days
45457653|NCT01136005|Other|dexpanthenol 5% cream|Apply at least two times a day on face, chest and upper arms during the 6 week treatment period
45457654|NCT01136005|Other|Cetomacrogol cream|Apply at least two times a day on face, chest and upper arms during the 6 week treatment period
45457655|NCT03507868|Procedure|Nonsurgical periodontal therapy|Nonsurgical periodontal therapy includes oral hygiene education and scaling and root planning approaches to eliminate microbial dental plaque that is the primary etiology of periodontal diseases.
45457656|NCT05400967|Drug|68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy|Patients with positive results were screened with 68Ga-FAPI PET / CT, and 1.11GBq(30mci) 177Lu-EB-FAPI was injected intravenously for therapy after contraindications were excluded and informed consent was signed.
45457657|NCT02306590|Dietary Supplement|Calogen|
45675589|NCT05826600|Drug|OMX-0407|Dose escalation
46086548|NCT04153136|Drug|Placebo oral tablet|Placebo oral tablet By mouth twice daily
46086549|NCT02715830|Procedure|Angioplasty of distal arteries|angioplasty of the arteries bellow-the-knee
46086550|NCT05113862|Biological|LD Vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
45457658|NCT02306590|Dietary Supplement|Placebo|
45457659|NCT01233271|Device|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
45457660|NCT03917953|Device|Transcutaneous Electrical Acupoint Stimulation|"Patients in the experimental group will be treated for 20 min TEAS, twice a week, for a total of 4 weeks of treatment.The same intervention was performed in the sham group (electrode patches were attached at corresponding acupoints without electrical stimulation).~Acupoint selection: baihui (GV 20), taichong (LR 3), taixi (KI 3)."
45457661|NCT03509740|Drug|tramadol|100 mg tramadol in 100 ml saline with slow infusion
45675590|NCT05825209|Drug|Food-Grown Magnesium|1 daily dose of 2 capsules equivalent to 80mg food-grown magnesium (40mg per capsule)
45675591|NCT05825209|Drug|Microcrystalline cellulose|1 daily dose of 2 capsules containing microcrystalline cellulose
45675592|NCT05824858|Drug|LY3537982|Administered orally.
45999046|NCT00553566|Procedure|questionnaire administration|
45999047|NCT00553566|Procedure|study of socioeconomic and demographic variables|
45999048|NCT02901561|Drug|misoprostol 200|
45999049|NCT02901561|Drug|misoprostol 400|
45999050|NCT00448409|Biological|TroVax|11 Intramuscular injection of TroVax® over 45 weeks. A single dose of 5 x 108 pfu/ml, will be given by an intramuscular injection into the deltoid muscle of the upper arm.
45999051|NCT00448409|Drug|GM-CSF|168 subcutaneous GM-CSF injections over 45 weeks. Administered every day as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) in weeks 1 and 2 of each 28 day cycle (total of 14 days per cycle with a total of 12 cycles).
45999052|NCT02901678|Device|Intrusion by 400 g|using miniscrews and coil springs to apply the intrusive force on maxillary posterior segment intrusion.
45999053|NCT02901756|Dietary Supplement|Antemig|Participants were instructed to take one tablet every morning for three months.
45999054|NCT00448526|Behavioral|low protein diet|
45999055|NCT05424939|Procedure|Colectomy|Colon resection
45999056|NCT05424939|Procedure|Stoma procedures|Any type of colostomy or ileostomy with or without bowel resection
45675595|NCT05816330|Biological|L9LS (VRC-MALMAB0114-00-AB)|Administered one time via subcutaneous route.
45675596|NCT05816330|Other|Normal Saline|Administered one time via subcutaneous route.
45999057|NCT05424939|Procedure|By-pass/laparotomy/laparoscopy/biopsy|Any palliative surgery without bowel resection
45999058|NCT05424705|Diagnostic Test|OCT, NIRS|
46086551|NCT05113862|Biological|LD PepGNP-Covid19|Two intradermal injections in the upper arm spaced 21 days apart
46086552|NCT05113862|Biological|HD Vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
45675597|NCT05807841|Procedure|percutaneous coronary intervention|IVUS-guided stent implantation
46086553|NCT05113862|Biological|HD PepGNP-Covid19|Two intradermal injections in the upper arm spaced 21 days apart
46086554|NCT01959464|Drug|Crinone vaginal progesterone gel|Crinone vaginal progesterone gel is inserted in the female vaginal using the pre-filled applicator.
45675598|NCT05804201|Procedure|EUS-guided hepatico-gastrostomy would be performed with Niti-S HOT Giob|(2) The EUS procedure will be performed with a therapeutic echoendoscope with a large working channel under guidance of ultrasound, endoscopy, and fluoroscopy. The echoendoscope will be positioned in the stomach or duodenum. Liver segment III, or sometimes segment II, will be punctured with an 19G needle. After puncture, a guidewire will be introduced in the dilated bile duct, and a Hot Giobor will be placed. All procedures will be performed with the patient and in the supine or prone position under monitored anesthesia.
45675599|NCT05802056|Biological|Aldesleukin|Given IP
45675600|NCT05802056|Procedure|Biopsy|Undergo biopsy
45675601|NCT05802056|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
45675602|NCT05802056|Procedure|Computed Tomography|Undergo PET/CT
45675603|NCT05802056|Procedure|Diagnostic Laparoscopy|Undergo diagnostic laparoscopy
45675604|NCT05802056|Drug|Fluorouracil|Given IV
45675605|NCT05802056|Drug|Leucovorin Calcium|Given IV
45675606|NCT05802056|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
45999059|NCT03276884|Other|Experimental Infant Formula|amino acid-based infant formula powder
45999060|NCT03276884|Other|Control Infant Formula|amino acid-based infant formula powder
45999061|NCT02901366|Drug|14C-FYU-981|14C-FYU-981, (Oral single dosing)
46086555|NCT01959464|Drug|Placebo vaginal gel|Placebo vaginal gel is inserted in the female vagina using the pre-filled applicator.
46086556|NCT02715752|Dietary Supplement|Gene-Eden-VIR/Novirin|
46086557|NCT02718482|Drug|Gemcitabine and Docetaxel|Treatment with gemcitabine and docetaxel at day 1 and day 8 n a 3 weeks cycle
46086558|NCT02718482|Drug|Ifosfamide|Treatment arm with high doses of ifosfamide continous infusion for 14 days in a 3 weeks cycle
46086559|NCT02725190|Behavioral|Sleepless night|Each subject will undergo 28 hours of sleep deprivation.
46086560|NCT02725190|Behavioral|Normal sleep night|Normal sleep at home before trial.
46086561|NCT02725034|Device|Standard endoscopy|
46086562|NCT02725034|Device|High definition endoscopy with Optic Enhancement|
46086563|NCT01921166|Drug|clomiphene plus gonadotropins|clomiphene plus gonadotropin ovulation induction
46086564|NCT01921166|Drug|Leuprolide flare|Leuprolide flare ovulation induction
46086565|NCT05087030|Drug|RGB-14-P|Participants will receive RGB-14-P into the thigh, abdomen, or upper arm as per the arm assigned.
46086566|NCT05087030|Drug|Prolia®|Participants will receive Prolia® into the thigh, abdomen, or upper arm as per the arm assigned.
46086567|NCT02715986|Device|3T MRI|Four visits will be conducted during the prospective follow during which will be carried out a 3T MRI examination, assessment of assessment of depressive symptomatology and anterograde memory: within 7 days prior to the first session of ECT, within 48 hours after the first ECT session, within 48 hours after the first effective ECT session and within 10 days of the last session of ECT.
46086568|NCT02718014|Other|scaling and root planing (srp)|
46086569|NCT02718092|Device|Plastic Stent|Subjects who are randomized to this arm will receive a plastic stent
45675607|NCT05802056|Biological|Nivolumab|Given IV
45675608|NCT05802056|Drug|Oxaliplatin|Given IV
45675609|NCT05802056|Procedure|Positron Emission Tomography|Undergo PET/CT or PET/MRI
45675610|NCT05800665|Drug|RO7656594|RO7656594 will be administered orally at specified dose on specified days.
45675611|NCT05795192|Drug|SB17170|Taking SB17170 orally once a day
45675612|NCT05795192|Drug|Placebo|Taking Placebo orally once a day
45999062|NCT03276806|Behavioral|tobacco dependence/smoking cessation counseling|Standard of care tobacco dependence/smoking cessation counseling offered to all smokers at Boston Medical Center.
45999063|NCT03276806|Behavioral|SDM|SDM is three-fold to: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with CMS requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context.
45999064|NCT03276806|Other|Decision Aid|The decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about trade-offs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW).
45999065|NCT03276806|Other|LDCT brochure|A informational brochure developed by the BMC screening program about low dose CT screening for lung cancer.
46002425|NCT02932332|Other|Low-flow Oxygen|Low-flow Oxygen will be delivered by Optiflow in an identical manner to high flow, except provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
45999066|NCT03276767|Other|Endre|"The online intervention, Endre, a digital smoking cessation counsellor that communicates with the user primarily through interactive web-sessions. Intervention content is tailored based on user input and individual usage pattern. Up to 14 unique sessions is assigned to the users during the study period, one each day. If a user does not start a session by noon on the second day a reminder will be sendt."
45999067|NCT05424666|Procedure|Harvesting method and Fat graft preparation method|"The procedure begins by identifying the areas where the fat will be collected Then the sample is collected by micro-incision using a fine suction cannula or during conventional liposuction. The fat cells are taken from an area of the body where there is a reserve (generally, in the abdomen, hips, knees, inner thighs, buttock) The collected fat cells are then subjected to a sterile centrifugation for a few minutes so as to separate the cells that will be injected (intact fat cells) from the elements that must not be injected (fat cells destroyed by the sample, non-fat cells such as than blood cells).~Injection of fat cells into the breasts The reinjection of fat (lipofilling) is performed using micro-cannulas allowing incisions of the order of 1-2 mm in different angles and in multiple directions so as to increase the contact area between the grafted cells and the recipient tissues allowing a good grip of the injection."
45999068|NCT03276689|Drug|Duloxetine|The patients will take duloxetine for 8 weeks.
45675613|NCT05794984|Other|Focus group discussions and survey questionnaire|Questions regarding internet and social media usage, as well as telemedicine concept and knowledge. Assessment of the feasibility, acceptability and accessibility of social media and telemedicine as methods to obtain healthcare. Perceptions for high-quality healthcare access, confidentiality, privacy, and security, will also be explored.
46086570|NCT02718092|Device|Axios Fully Covered Self Expanding Metal Stent|Subjects who are randomized to this arm will receive the Axios FCEMS
45999069|NCT03276689|Drug|Pregabaline|The patients will take pregabaline for 8 weeks.
45675614|NCT05794477|Biological|Adebrelimab|Specified dose on specified days
45675615|NCT05794477|Biological|SHR-1802|Specified dose on specified days
45675616|NCT05794477|Drug|Carboplatin/Cisplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
45999070|NCT03276689|Other|Placebo|The patients will take placebo for 8 weeks.
45999071|NCT03276650|Other|data collection|biological, administrative, clinical, outcome date
45999072|NCT04699370|Other|cognition-targeted exercise|"All Standardized physical therapy exercises will be performed in a time-contingent .~Goal setting is essentially done together with the patient, focussing on functionality instead of fatigue relief. Progression to a next level of (more difficult) exercises will be preceded by an intermediate phase of motor imagery.~The treating physical therapist will be advised to address patients' cognitions about their problems during the cognition-targeted exercise training, so that patients will have positive perceptions regarding their illness and treatment outcome.~The treating physical therapist will be advised to discuss the patient's perceptions about each exercise. This include discussion of the anticipated consequences of the exercises and challenging the patient's cognitions in relation to the exercises"
45999073|NCT04699370|Behavioral|Cognitive behavioral therapy|In the first and second sessions, patients will learn about fatigue-related symptoms as well as Cognitive behavioral therapy and its effectiveness. The third and fourth sessions will be devoted on the introduction of behavioral strategies. The fifth session will introduce cognitive strategies to decrease fatigue. The last three sessions will be about how to adopt the proposed strategies consistently.
46086571|NCT02717936|Procedure|Immunohistochemistry using Pancytokeratin Staining|
45675617|NCT05794477|Drug|Paclitaxel/Nab-Paclitaxel/Pemetrexed|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
45999074|NCT04699370|Other|Standardized physical therapy|The standardized physical therapy will consist of eight half-hour individualized face to face physiotherapy sessions, over a 4-week period. this program will consist of twice-weekly supervised general aerobic, strengthening and flexibility exercise sessions .This exercise program is reflective of the general exercises typically undertaken within routine clinical practice.
45999075|NCT02901210|Procedure|Modified delorme procedure|
45999076|NCT04699448|Other|Nutritional intervention.|Diets designed for body weight loss, based on different macronutrient content.
45999077|NCT01220128|Biological|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A|6 or 8 injections at 3 weeks apart, injected intramuscularly in the deltoid or lateral region of the thigh.
45999078|NCT01220128|Drug|Placebo|6 or 8 doses at 3 weeks apart of sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion, injected intramuscularly in the deltoid or lateral region of the thigh.
46086572|NCT02717858|Drug|liraglutide|Injected s.c./subcutaneously (under the skin) Dose escalation period starting with liraglutide 0.6 mg per day and escalated with weekly increments of 0.6 mg until the target dose 3.0 mg is reached.
46086573|NCT02717858|Drug|placebo|Injected s.c./subcutaneously (under the skin) once daily.
46086574|NCT02725112|Drug|Pregabalin ER|A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
46086575|NCT02725112|Drug|Pregabalin ER|B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
45457662|NCT03509740|Drug|paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with slow infusion
45675618|NCT05789381|Procedure|Magnesium sulfate|This drug is commonly used on labor and delivery and in the postpartum period and is easily ordered through the electronic medical record and provided. This drug requires no specific storage for research study purposes as the drug is already being administered per standard of care and national and international guidelines. The only change is in the duration of therapy. This is NOT considered an off label use of the drug and does not require any form of exemption determination. Magnesium for severe preeclampsia is often given for anywhere from 12 to 24 hours postpartum depending on the clinical scenario, provider preference, and patient symptoms/adverse reactions to the medication.
46086576|NCT02725112|Drug|Pregabalin ER|C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
46086577|NCT02725112|Drug|Pregabalin ER|D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
46086578|NCT02725112|Drug|Pregabalin ER|E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
46086579|NCT02725112|Drug|Pregabalin ER|F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
45999079|NCT01220128|Drug|Aromatase inhibitor|This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).
45999080|NCT01220128|Drug|5-Fluorouracil|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
45999081|NCT01220128|Drug|Carboplatin AUC|Administered intravenously in Cohort C Groups in 6 doses at 3 weeks apart, on the same day as WT1 ASCI/placebo administration (Day 1 of each cycle).
45457663|NCT01136083|Behavioral|Exercise training|Subjects in exercise group will undergo individualized high aerobic interval training on treadmill for 30 minutes under the supervision of an experienced physical therapist 3 times a week and home exercise twice a week with accelerometer.
45999082|NCT01220128|Drug|Cyclophosphamide|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohorts A Placebo, B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
45457664|NCT01136083|Other|Usual care|Subjects in control group will not undergo individualized high aerobic interval training on treadmill. They will receive usual care as normally does in hospital.
45675619|NCT05788666|Procedure|GeriKit Mobile Application|Digital health app used for comprehensive geriatric assessment (CGA). The app includes a series of brief, well-validated instruments: the MiniCog, 30-Second Chair Stand, Activities of Daily Living, Instrumental Activities of Daily Living, Patient Health Questionnaire (PHQ-9), Mini Nutrition Assessment, 2-Item Fall Screen, and Polypharmacy screen.
45999083|NCT01220128|Drug|Docetaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
45999084|NCT01220128|Drug|Doxorubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
45999085|NCT01220128|Drug|Epirubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
45999086|NCT01220128|Drug|Paclitaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: only in the 8 WT1 ASCI-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
45999087|NCT01220128|Drug|Trastuzumab|Administered intravenously in Cohort C Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
45999088|NCT04699409|Other|stroke educational campaign: FAST|After randomization, study staff provided 15-minute education on the selected campaign to each individual participant using educational pictures.
45999089|NCT04699409|Other|stroke educational campaign: STROKE 112|After randomization, study staff provided 15-minute education on the selected campaign to each individual participant using educational pictures.
46002426|NCT02932332|Other|High-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
46002427|NCT02932332|Other|Low-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
46002428|NCT02923128|Drug|Dexmedetomidine|Dexmedetomidine 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
46002429|NCT02923128|Drug|Sufentanyl|Sufentanyl 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
45457665|NCT03507712|Procedure|Symmetrical IO weakening|Bilateral IO Myectomy / Bilateral equal graded IO Recession
45457666|NCT03507712|Procedure|Asymmetrical IO weakening|IO Myectomy in one eye - IO Recession in the fellow eye / Bilateral IO Recession (different amounts) in each eye
45457667|NCT03918187|Drug|Bupivacaine|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
45999090|NCT05424588|Diagnostic Test|clinical evaluation, bioelectrical impedance analysis (BIA), cardiopulmonary exercise testing (CPET) and venipuncture for blood samples collection|Total body dual-energy X-ray absorptiometry (DEXA) was taken BN and AN to measure total (FM) and segmental fat (truncal FM), visceral adipose tissue (VAT) and lean mass (LM). Tetra-polar dual frequency BIA (InBody 120; Cerritos, USA) was used BPP, BN and AN to measure weight and to estimate FM, FFM, and MM. Impedance measurements were performed. CPET was carried out on a cycle ergometer with clip-on pedals. Blood samples were collected in the morning BPP, BN, AN. Biochemical parameters considered in this study were: ALT, AST, creatinine, 25-hydroxy vitamin D, total cholesterol, HDL, LDL, triglycerides concentrations. We isolated CPCs from heparinized blood, as previously reported (14). After the collection of peripheral blood mononuclear cells (PBMCs) by a gradient centrifugation. (15). Differentiating Human Skeletal muscle cells were cultured with or without pooled sera of participants at 5% final concentration. 146b and 34a miRNAs were extracted from PBMCs.
45999091|NCT04698941|Drug|Albumin Paclitaxel|Albumin Paclitaxel intravenous infusion was administered at a dose of 260 mg/m^2 on Day 1 of each 21-day cycle.
45999092|NCT04698941|Drug|Simvastatin|20mg daily oral tablet taken.
45999093|NCT04206202|Device|3D-Printed Patient-Specific Intramedullary Guide|The 3D-printed patient-specific intramedullary guide is used in TKA to control femoral component rotation.
45999094|NCT02901288|Drug|Isoniazid|Isoniazid is a widely used anti-tuberculosis medication. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique components of mycobacterial cell wall.
45999095|NCT02901288|Drug|Rifampicin|Rifampicin is a widely used anti-tuberculosis medication.
45999096|NCT02901288|Drug|Pyrazinamide|Pyrazinamide is a commonly used medication for tuberculosis, with bactericidal effect against intracellular mycobacterium tuberculosis.
45999097|NCT02901288|Drug|Ethambutol|Ethambutol is a widely used medicine in anti-TB regimens with bacteriostatic effect against M. tb.
45999098|NCT02901288|Drug|Levofloxacin|Levofloxacin is a commonly used antimicrobial for TB and other infections, which acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
45457668|NCT03918187|Drug|Nalbuphine|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
45457669|NCT03918187|Drug|Midazolam|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
45457670|NCT02302144|Behavioral|Balance & Strengthening Exercises|Progressive balance and strengthening exercises conducted in a group format yet tailored to each individual
45457671|NCT01233349|Device|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
45457672|NCT01233349|Device|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
45457673|NCT05472181|Device|rTMS (Repetitive TMS)|TMS stimulation produce electromagnetic pulses that can directly changes the neural firing in the brain. The rTMS applies the magnetic pulses in a repetitive manner, and can induce either an inhibitory or excitatory effect on cortical neurons. In this study we use high frequency rTMS (10 Hz) to provide the excitatory effect.
45457674|NCT05472181|Behavioral|Speech training|The behavioural training will include reading sentences in which a syllable is spoken in time to a rhythmic beat.
45457675|NCT03507634|Drug|Opioid free Anesthesia dexmedetomidine and lidocaine|Opioid free anesthesia with dexmedetomidine and lidocaine
45457676|NCT03507634|Drug|Opioid based anesthesia Fentanyl and Remifentanyl|Opioid based anesthesia with Fentanyl and Remifentanyl
45999099|NCT00448643|Radiation|Vaginal Brachytherapy|High-Dose Rate [HDR] or Low-Dose Rate [LDR], no earlier than during last cycle of Carboplatin/Taxol chemotherapy; or no later than 1 week before cisplation and WAR therapy
45999100|NCT00448643|Drug|Cisplatin|Weekly at 40 mg/m2 (maximum of 70 mg) for 6 weeks, start no later than 6 weeks from last cycle of standard of care carboplatin and taxol chemotherapy
45999101|NCT00448643|Radiation|Whole Abdominal Radiation [WAR] Therapy|Whole Abdominal Radiation Therapy, Dose Escalated [2-Levels]; 6 -8 hours after administration of Cisplatin chemotherapy
45999102|NCT03276455|Genetic|Autologous CD34+ cells genetically modified|Autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene. The target dose in the transduced product is 3x10^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10^6/Kg and a maximum dose of 20 x 10^6/Kg, depending on the yield of cells. The product will be injected intraosseously following intravenous BU ±Flu ±Cy.
45999103|NCT05424471|Behavioral|Family Spirit Nurture (FSN)|The FSN intervention lesson is taught to participants previously randomized into the FSN intervention group during the PECO 1 study. Intervention group participants receive 1 Family Spirit Nurture lesson taught by Family Health Coaches. Mothers will receive the 1 - 45 minute lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The lesson focuses on age-appropriate parental feeding practices, including snack routines, avoidance of SSBs and promotion of water consumption. The lesson is highly visual and interactive, and incorporates cultural teachings related to child feeding and nutrition that support aims. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
45999104|NCT05424471|Other|Control Group - Vehicle Safety|The control (vehicle safety) lesson is taught to participants previously randomized into the control group during the PECO 1 study. Control group participants receive 1 - 30 minute lesson with vehicle safety information, taught by Family Health Coaches. Mothers will receive the lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
46002430|NCT02923128|Drug|Saline|Saline is used to dilute other drugs
45999105|NCT00448799|Radiation|[123-I] AV-83 Injection and Imaging Procedures|Evaluation of [123I] AV83 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
45999106|NCT02901327|Procedure|Lumbar Stabilisation Exercise|"McGill protocol starting with:~'cat-camel' exercise exercise 10 repetitions with 7 seconds hold each~'curl-up' exercise 10 repetitions with 7 seconds hold each~'side-bridge' exercise 10 repetitions with 7 seconds hold each~'cat-camel' exercise 10 repetitions with 7 seconds hold each progression was based on subjects' tolerance and endurance."
45999107|NCT02901327|Procedure|treadmill walk exercise|"Bruce protocol~This include:~'5 minutes warm up' at zero degree inclination.~'20 minutes active exercise with increasing speed and inclination'~'5 minutes cool down'"
45999108|NCT05424393|Drug|YISAIPU® ( An etanercept biosimilar)|YISAIPU®, an etanercept biosimilar produced by 3SBio Inc., is a TNF-α inhibitor targeting soluble TNF-α to inhibit its interaction with cell-surface receptors. It has been widely used in clinical practice for 17 years in China. According to the prescription information, YISAIPU should be given as 25mg, biw, pc.
45999109|NCT05424393|Drug|csDMARDs|csDMARDs include methotrexate, sulfasalazine, hydroxychloroquine and leflunomide The use of csDMARDs complies with clinical routine practice and treatment strategy of treat-to-target.
45999110|NCT05424354|Device|Altrazeal (R) Transforming Powder Dressing|After informed consent and the subject is determined to meet all selection criteria, randomization will occur in a 1:1 ratio, to determine the treatment arm of the study. Half of those randomized will receive burn care with Altrazeal TPD.
45999111|NCT05424354|Other|Standard of Care burn dressing|After informed consent and the subject is determined to meet all selection criteria, randomization will occur in a 1:1 ratio, to determine the treatment arm of the study. Half of those randomized will receive burn care with the institution's standard of care burn dressing.
45999112|NCT00448838|Biological|Cetuximab|Cetuximab: an initial loading dose of 400 mg/m2 will be given followed by 250 mg/m2 administered weekly. Cetuximab will be given first followed by gemcitabine on the weeks the patient receives cytotoxic chemotherapy on day 1. Cetuximab will be given as a single agent on Day 8. The treatment will be given on two-week cycles.
45999113|NCT00448838|Drug|Gemcitabine Hydrochloride|Gemcitabine 1000 mg/m2 IV day 1. The treatment will be given on two-week cycles.
45999114|NCT00448838|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV day 2. The treatment will be given on two-week cycles.
46002431|NCT02918409|Drug|Colistin|
46002432|NCT02918409|Drug|Tobramycin|
46002433|NCT02901574|Device|Anodal or Cathodal tDCS|2 mA or Anodal or Cathodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge (anode in group anode or cathode in group cathode) is placed on the right cerebellum. The stimulation will be delivered at an intensity of 2 mA in a ramp-like fashion for a maximum of 20 minutes.
46086580|NCT02724722|Behavioral|Assigned intervention|a simple flyer plus face-to-face health education and give one bag containing stainless steel-made tableware for eating out use
46086581|NCT02724722|Behavioral|No intervention|a simple flyer only with no face-to-face health education and give one bag not containing stainless steel-made tableware for eating out use
46086582|NCT02715908|Drug|LBEC0101|Etanercept 50mg
45457677|NCT03917875|Behavioral|Personalized feedback intervention|The novel integrated PFI will be developed and modeled from past PFIs targeting hazardous drinking. Participants will view feedback on the computer screen. The computer program/algorithm will determine the proper normative feedback to participants.
45457678|NCT03507556|Procedure|Triple paste and induced bleeding|
45457679|NCT03507556|Drug|Triple Paste metronidazole, ciprofloxacin and minocycline mixed with sterile glycol|triple paste of metronidazole, ciprofloxacin and minocycline mixed with sterile glycol
45457680|NCT01232257|Drug|N-acetylcysteine|4 gifts of N-acetylcysteine 600 mg BID
45835097|NCT02761746|Behavioral|MESA|MESA is tailored based on how important and how confident the participant feels about taking medications as prescribed. If the participant does not believe taking medications is important, they engage in a decisional balance exercise. If the participant believes taking medications is important, they move directly to confidence modules and goal setting. If the participant does not feel confident about taking medications, they engage in activities to boost self-efficacy. Participants are also offered personalized feedback regarding immune status and HIV knowledge with actual adherence feedback provided in the second session. Finally, goal setting is an option, and feedback regarding adherence behavior over the previous month.
45835098|NCT02759484|Behavioral|Home Based Enhanced Education|The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home. Participants receive 24 visits: 12 biweekly visits in the first 6 months, followed by 12 monthly visits in months 6 through 18 of the study. The self-management program is derived from two pragmatic evidence-based frameworks for behavioral change.
45835099|NCT02759484|Behavioral|Clinic Based Enhanced Education|The Clinic Based Enhanced Education arm consists of two two-hour-long sessions of group diabetes self-management education, delivered by a Certified Diabetes Educator. Participants in this arm will also receive 24 newsletters with diabetes self-management education.
45835100|NCT02757300|Device|Hypopharyngeal packing|After introduction and orotracheal intubation a hypopharyngeal packing soaked with Chlorhexidinbis (D-gluconat) is placed.
46086583|NCT02724566|Drug|apelin|Assessing the difference between the insulin sensitivity measured during hyperinsulinemic euglycemic clamps in the presence of a 2 hours continuous infusion of (PYR1)-apelin-13 (30nmol/kg) versus a 2 hours continuous infusion of placebo (vehicle alone).
45999115|NCT03455244|Device|FFRangio|"FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure.~The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques."
45999116|NCT03276338|Behavioral|HOLA|To increase condom use and HIV testing
45999117|NCT01219933|Drug|methylprednisolone|starting dose >/= 1 mg and </= 20 mg orally daily, according to dose-reduction schedule
45999118|NCT01219933|Drug|tocilizumab [RoActemra/Actemra]|background therapy: 8 mg/kg iv every 4 weeks
45999119|NCT00448877|Device|fNIR light emitting and sensing device|
45999120|NCT05373901|Drug|Dinutuximab Beta|Administered via intravenous infusion
45999121|NCT05373901|Drug|13 cis retinoic acid|Administered orally
45999122|NCT05368441|Drug|Midazolam|Patients of midazolam group will be treated with midazolam premedication (3 cc mixture of 0.1 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given.Before the patients were given muscle relaxants, the patients were evaluated with the Han scale.
45999123|NCT05368441|Drug|Saline|Control group patients are treated with 3 cc normal saline at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given. Before the patients were given muscle relaxants, the patients were evaluated with the Han's grading scale.
45999124|NCT00448955|Drug|ARD-0403|ARD-0403
45999125|NCT05468359|Drug|Atezolizumab|Atezolizumab intravenously, every 3 weeks, Day 1
45999126|NCT05468359|Drug|Sorafenib|Sorafenib by mouth every 12 hours, Days 1-21
45999127|NCT05468359|Drug|Bevacizumab|Bevacizumab intravenously, every 3 weeks, Day 1
45999128|NCT05468359|Drug|Cyclophosphamide|Low-dose cyclophosphamide by mouth once daily, Days 1-21
45999129|NCT05657080|Device|Cytosponge-TFF3|Cytosponge is a less invasive procedure than endoscopy and consists of an expandable, spherical mesh, which is attached to a string and contained within a soluble capsule. Five minutes after swallowing (once the capsule has dissolved), the spherical mesh, which measures around 3cm in diameter can be retrieved by pulling on the string. Upon retrieval the Cytosponge scrapes against the surface of the top of the stomach and oesophagus and collect epithelial cells. The Cytosponge sample is then placed into a preservative fluid and the specimen is processed for molecular tests. Trefoil Factor 3 (TFF3) is a protein that is expressed in intestinal type epithelia of the gastrointestinal tract. TFF3 is the best biomarker, which can be coupled to the Cytosponge to diagnose intestinal metaplasia.
45999130|NCT02901015|Behavioral|Assessment battery A|"Social cognition tests version A are administered to the patients"
45999131|NCT02901015|Behavioral|Assessment battery B|"Social cognition tests version B are administered to the patients"
45999132|NCT05466877|Drug|MG-K10|MG-K10 Humanized Monoclonal Antibody Injection
45999133|NCT05466877|Drug|Placebo|MG-K10 Humanized Monoclonal Antibody Injection
45999134|NCT04316845|Diagnostic Test|18F-fluorocholine PET/CT|Patients undergo both 18F-fluorocholine PET/CT and Single isotope dual phase Tc-99m sestamibi scan (both planar scan and SPECT/CT)
45999135|NCT05423886|Other|Personalized screening invitation interval|Time to receive the next invitation for fecal immunochemical testing screening, will depend based on individuals risk determined by fecal Hemoglobin concentration
45999136|NCT00449228|Procedure|-preoperative education and total hip replacement|-preoperative education and total hip replacement
45999137|NCT01218802|Drug|Rosuvastatin 10 mg. daily for 96 weeks|Participants will take Rosuvastatin 10 mg. daily for 96 weeks.
45999138|NCT01218802|Drug|Placebo|participants will take a sugar pill daily for 96 weeks
45999139|NCT00449267|Device|Intraocular Lens|Phacoemulsification with in the bag implantation of the IOL
45835101|NCT02757300|Device|Without Hypopharyngeal packing|After introduction and orotracheal intubation the patient will pass the operation without hypopharyngeal packing with a short tip coming out the mouth to imitate a packing.
45835102|NCT02509260|Device|Prevena wound management system|Patients will have the Prevena wound management system applied post-operatively.
45835103|NCT02509260|Other|Standard wound dressings|Control patients with standard wound dressings will have gauze and tape dressings applied
45999140|NCT02887222|Drug|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
45835104|NCT01458834|Behavioral|Attention bias modification task|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (< or >). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the active training task, the arrow will replace the neutral pictures 80% of the time.
45835105|NCT01458834|Behavioral|Control Condition|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (< or >). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the control training task, the arrow will replace the neutral and smoking-related pictures with equal frequency.
45999141|NCT01218646|Biological|Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
45999142|NCT01218646|Biological|Investigational Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
45999143|NCT01218646|Biological|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
45999144|NCT01218646|Biological|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
45999145|NCT02901171|Behavioral|ACT group treatment combined with smartphone application|The Acceptance and Commitment Therapy (ACT) group treatment for smoking cessation will be delivered in six weekly 90-min sessions. Smoking cessation will be promoted in each session by targeting core processes of the ACT model including acceptance, cognitive defusion, mindfulness, flexible perspective taking, values clarification and committed action. In addition, participants will receive an ACT-based smartphone application for smoking cessation. The application will foster core processes of the ACT model through daily exercises, tips and tools.
45999146|NCT02901171|Behavioral|ACT group treatment|
45999147|NCT02901171|Behavioral|Group based Behavioural Support Programme|The Behavioural Support Programme will be facilitated by stop smoking experts and delivered in six weekly 90-min sessions in a group format. During the sessions, advice, support and information on smoking cessation will be given to participants and behavioural techniques will be reviewed.
45999148|NCT00449345|Procedure|Blood test for Quantiferon-GOLD assay|
45999149|NCT05656963|Other|Grouping based on previous laboratory results, no intervention.|The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken.
45999150|NCT02900937|Device|AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
45999151|NCT00449384|Behavioral|Diagnostic Screening|
45999152|NCT00449423|Drug|acipimox|
45999153|NCT05423847|Diagnostic Test|POCUS|POCUS of lungs, pericardium and abdomen
45999154|NCT00449462|Procedure|consumption of CLA enriched food|
45999155|NCT00449501|Drug|Budesonide/formoterol pMDI|
45457681|NCT03509662|Drug|Vitamin C|Vitamine C will be administered intravenously as ascorbic acid (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands).
45457682|NCT03509662|Drug|Thiamine|All patients will receive thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate.
45457683|NCT03509662|Drug|Placebos|One group receives a placebo.
45457684|NCT01137799|Drug|JNJ-39393406|50mg nanosuspension (sort of liquid formulation) once daily (single dose)
45457685|NCT01137799|Drug|placebo|Once daily (single dose)
45457686|NCT01137799|Drug|JNJ-39393406|200mg nanosuspension (sort of liquid formulation) once daily (single dose)
45457687|NCT01137799|Drug|JNJ-39393406|100mg nanosuspension (sort of liquid formulation) once daily (single dose)
45999156|NCT00449501|Drug|Budesonide HFA pMDI|
45999157|NCT03276299|Other|six minute walking test|six minute walking test
45999158|NCT03276299|Other|six minute walking test|six minute walking test with encouragement
45999159|NCT04680078|Procedure|Placement of three interrupted sutures after Triangular Three-snip Punctoplasty of the lower punctum|A Nettelship dilator is used to enlarge the stenotic lacrimal punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is removed and three sutures are placed, in an interrupted manner, at the posterior wall of the ampulla using 10-0 nylon. The sutures are removed 1 week after the surgery.
46086584|NCT02724566|Drug|placebo|2 hours continuous infusion of placebo (vehicle alone) to compare with 2 hours infusion of apelin
45457688|NCT01137799|Drug|JNJ-39393406|10mg nanosuspension (sort of liquid formulation) once daily (single dose)
45457689|NCT01137799|Drug|JNJ-39393406|30mg nanosuspension (sort of liquid formulation) once daily (single dose)
45675620|NCT05786508|Other|Partners4Pain program|"Partners4Pain is a self-management program of evidence based complementary and integrative health approaches for pain including pain education, mindfulness, cognitive behavioral approaches, and neck/back specific exercises.~The intervention program will include nine, 90-minute group sessions that occur weekly for 9 weeks"
46086585|NCT05321108|Other|Group A (GA)(Aerobic exercise group)|Aerobic Exercise has been demonstrated to be a safe strategy to improve several health outcomes in Systemic lupus erythematosus (SLE)SLE, including depressive symptoms or, even more importantly, fatigue and quality of life.
45999160|NCT04680078|Procedure|Conventional Triangular Three-snip Punctoplasty of the lower punctum|A Nettelship dilator is used to enlarge the stenotic lacrimal punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is then removed .
45999161|NCT03276260|Device|PMD-200|Patient will be connected to PMD-200 by finger-probe before induction of anesthesia or sedation. Recording will continue during surgery until extubation or awakening. Recording will be initiated again as soon as the patient arrives to the PACU until discharge to the surgical ward or home.
45999162|NCT02900820|Other|Discontinuing antibiotic therapy|Patients assigned to this group will be asked to discontinue antibiotic therapy.
45999163|NCT02900820|Other|Continuing antibiotic therapy|Patients assigned to this group will be asked to complete antibiotic therapy.
45999164|NCT03276182|Device|Lipiview 2|Tear film lipid layer thickness and meibomian gland dropout were measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
45999165|NCT01188772|Drug|Sofosbuvir|Sofosbuvir tablets were administered orally once daily.
45999166|NCT01188772|Drug|Placebo to match sofosbuvir|Placebo tablets to match sofosbuvir were administered orally once daily.
45999167|NCT01188772|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
45999168|NCT01188772|Drug|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert dosing recommendations (Genotype 1: < 75kg = 1000 mg and ≥ 75 kg = 1200 mg; Genotype 2/3: 800 mg).
45999169|NCT00449579|Device|Excercise stress test with high frequency ECG recording (HyperQ™ System)|
45999170|NCT04679883|Drug|5% GLH8NDE|5% GLH8NDE as eye drops
45999171|NCT04679883|Drug|Placebo|Placebo as eye drops
45999172|NCT01188655|Drug|Enbrel|"The patients will be treated in accordance with the requirements of the labeling of Enbrel® in Austria. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.~To record complete dosing information, initial dose will be documented at baseline and any change will be documented with date, dose and reason at the subsequent visits."
45999173|NCT02900703|Biological|stool samples|
45999174|NCT00449618|Drug|Aspirin 100 mg|dose of 100 mg administered on awakening or at bedtime
45999175|NCT00449618|Device|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
45999176|NCT00449618|Procedure|Chronotherapy, timing of medication|Dosing on awakening versus bedtime
45999177|NCT00449618|Drug|Placebo|Use of placebo on awakening versus bedtime
45999178|NCT01188538|Drug|Epiduo gel|Once daily application on the face in the evening for 12 weeks
45999179|NCT01188538|Drug|BPO|Once daily application on the face in the evening for 12 weeks
45999180|NCT04316767|Behavioral|App Intervention|Participants will receive access to a self-care app for use on their smartphone. The app provides a suite of tools based on cognitive behavioral therapy and mindfulness. The app guides users through a variety of short lessons (3-5 minutes) that teach users to self-manage stress, mood, anxiety, and depression. Participants will be encouraged to use the app on a daily basis and will be able to use the app at their discretion.
45457690|NCT03505138|Device|Group intervention|"GROUP 1 (telematic group):~These patients will have a tablet connected via internet (Telefónica-e-Health). They have to measure their lung function, temperature, pulse oxymetry and symtoms questionnaire every week. The device (tablet) asks them about possible COPD exacerbation. If the patient has an exacerbation, the device offers them a treatment for this exacerbation and it begins a following of this exacerbation until resolution, every day.~The pneumologists will receive an alert in other tablet when the patients have an exacerbation or worsening of their diseases.~The period of monitoring is 1 year."
45999181|NCT00449657|Drug|Taxol (paclitaxel)|paclitaxel 15mg/m2 Q am on Mon/Wed/Fri
45999182|NCT00449657|Procedure|Radiotherapy|"Off cord thoracic radiotherapy 200cGy (total dose 1000cGy). Mon/Wed/Fri: radiotherapy is delivered at least 6 hrs after chemotherapy. Tue/Thurs: radiotherapy is delivered 24 hrs or less from the paclitaxel dose the day before.~Off-cord and off-esophagus concomitant boost radiotherapy 100 cGy (total dose 500 cGy)Mon/Wed/Fri of week 5"
45999183|NCT00449657|Drug|Carboplatin|Carboplatin AUC 5mg/min/ml, prior to Gemcitabine on Wed of weeks 8 & 9
45999184|NCT00449657|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 at a fixed dose rate of 10mg/m2/min on Wed during week 8 & 9
45999185|NCT04318444|Drug|Hydroxychloroquine|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
45999186|NCT04318444|Drug|Placebo oral tablet|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
45999187|NCT02900898|Other|Dynamic exercise and Mediterranean diet|DE, MD
45999188|NCT02900898|Other|Dynamic exercise|DE
45999189|NCT02900898|Other|Mediterranean diet|MD
45999190|NCT02900898|Other|Control|Control
45999191|NCT05423613|Procedure|Microneedling|A 5% lidocaine anesthetic cream will be applied to the scar to be treated and will be wrapped with an occlusive dressing (saran wrap) for 30 minutes prior to the procedure. The same scar will be subjected to the ACS-Pen treatment at a depth of 1.5 mm or less depending on the results of the thickness measurement performed prior to treatment. Within 5 minutes after the microneedling treatment, a thin layer of triamcinolone acetonide and 2% xylocaine (1:3 ratio) suspension will be spread over the scar. The physician will then gently massage the product into the microneedling columns. The same amount will be used for each subsequent treatment. The patient will also be given a small amount of hydrocortisone 2.5% (low potency corticosteroid) to be applied to the treated site at 12 hours and 24 hours post-treatment.
45999192|NCT03276143|Drug|Enoxaparin|40 mg enoxaparin administered as subcutaneous injection once daily
45999193|NCT03276143|Drug|Apixaban|2.5 mg apixaban administered as tablet orally twice daily
45999194|NCT03276143|Drug|BAY1213790|Single dose of BAY1213790 administered as intravenous infusion
45999195|NCT05423574|Procedure|robotic Trans Abdomino Pre Peritoneal prothesis repair|The treatment of primary and incisional ventral hernia using the robotic assisted laparoscopy technique
45999196|NCT01188343|Biological|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each; Subcutaneous (SC)
45999197|NCT01188343|Biological|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, Subcutaneous (SC)
45999198|NCT01188343|Biological|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, subcutaneous (SC)
46086586|NCT05321108|Other|Group B (GB) (Whole-body vibration (WBV) group)|(WBV) has been growing over the years. WBVE occurs when the subject is in contact with the vibrating platform in operation and is exposed to the generated mechanical vibrations. WBV has a positive action on muscle strength, bone formation, balance, flexibility, functional capacity and fatigue.
45999199|NCT00449774|Drug|Lamotrigine IR tablets|Lamotrigine IR tablets will be available in dose strength of 200 mg.
45675621|NCT05786508|Other|Key to Wellbeing program|"Keys to Wellbeing is a general health and wellbeing education program addressing topics such as keeping socially connected, finding meaning and purpose, addressing mental health, and keeping physically fit. The program was designed to control for time, attention, and many other key contextual factors (e.g., program format, materials).~The intervention program will include nine, 90-minute group sessions that occur weekly for 9 weeks"
45835106|NCT01458912|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
45999200|NCT00449774|Drug|Lamotrigine ODT tablets|Lamotrigine ODT tablets will be available in dose strength of 200 mg.
45999201|NCT02900742|Drug|YiQiFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable.
45835107|NCT01458912|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
45835108|NCT01458912|Drug|BI 54903 MD|2 puffs MD b.i.d. via Respimat inhaler
45835109|NCT01458912|Drug|BI 54903 HD|2 puffs HD p.m. via Respimat inhaler
45835110|NCT02747862|Other|Chart Review|"Database queried for the presence of cases meeting criteria (attenuated FAP, classical AFP [i.e. identifiable APC mutation], and/or a compatible family history or personal adenoma burden of > 50 adenomas).~The data related to the patients with attenuated FAP and classical AFP who underwent endoscopic surveillance or surgery collected through chart review and all data is retrospective as of February 15, 2016."
45835111|NCT02743728|Device|Magnetic Resonance Imaging|Anatomical and Diffusion Tensor Imaging Analysis.
45999202|NCT02900742|Drug|YangYinFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable.
45999203|NCT02900742|Drug|YiQiYangYinFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable.
45999204|NCT02900742|Drug|Gemcitabine®|"Gemcitabinie®,Gemzar,1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days until progression or unacceptable toxicity develops."
45675622|NCT05785624|Drug|Vixarelimab|Vixarelimab will be administered as per the schedule specified in the respective arms.
45675623|NCT05785624|Drug|Placebo|Placebo will be administered as per the schedule specified in the respective arms.
45835112|NCT02743728|Device|Transcranial Magnetic Stimulation|Assessment of brain (cortical) excitability
45835113|NCT02743728|Behavioral|General Movement Assessment|Spontaneous movement assessment of infant while lying in unperturbed state.
45999205|NCT02900742|Drug|Pemetrexed®|"Pemetrexed®,Alimta,500 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity develops."
45999206|NCT02900742|Drug|Docetaxel®|"Docetaxel®,Taxotere,75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity."
45999207|NCT02900742|Drug|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
45999208|NCT00449813|Drug|Pantoprazole|40 mg Pantoprazole
45999209|NCT01188226|Device|Denture teeth|Denture teeth made of nano hybrid composite material
45999210|NCT02900547|Other|Patients with systolic heart failure|
45999211|NCT05423067|Procedure|bilateral permanent occlusion of uterine arteries|bilateral permanent Occlusion of uterine arteries through abdominal route
45999212|NCT01218100|Drug|nebivolol and lisinopril (free combination)|"nebivolol 5-mg and lisinopril 10-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 10-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 20-mg and lisinopril 40-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 10 weeks~nebivolol 5-mg and lisinopril 40-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 6 weeks~nebivolol 20-mg and lisinopril 10-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 10-mg tablet/QD/oral administration/up to 6 weeks"
45999213|NCT01218100|Drug|nebivolol monotherapy|"nebivolol 5-mg (non-trade 5-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 10-mg (non-trade 10-mg tablet/QD/oral administration/for 1-week down-titration period only)~nebivolol 20-mg (non-trade 20-mg tablet)/QD/oral administration/up to 10 weeks"
45999214|NCT01218100|Drug|lisinopril monotherapy|lisinopril 10-mg (overencapsulated 10-mg tablet)/QD/oral administration/up to 12 weeks lisinopril 40-mg (overencapsulated 40-mg tablet)/QD/oral administration/up to 10 weeks
45999215|NCT01218100|Drug|placebo|Placebo tablet, oral administration/QD/oral administration/up to 12 weeks Placebo capsule, oral administration/QD/oral administration/up to 12 weeks
45999216|NCT02900508|Other|Exergaming training|
45999217|NCT02900508|Other|Physical therapy intervention|
45999218|NCT02900196|Other|1 - Fermented dairy drink|1 - Fresh fermented dairy drink containing yoghurt ferments and probiotic strains consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
45999219|NCT02900196|Other|2 - Acidified dairy drink|2 - Acidified dairy drink without ferments consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
45999220|NCT02900313|Other|cardiac surgery|Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
45999221|NCT00449852|Behavioral|Interactive Voice Response|The IVR group will receive a telephone call from the IVR system three, 14, 30, 90, 120 and 150 days after hospital discharge.
45999222|NCT04681209|Behavioral|DRT Condition|"Children were asked to provide five descriptors of two children who each engaged in defending behaviors. Two weeks later they were told the top seven descriptors given by the hundreds of children participating in the project. This was followed by a brief discussion of how one could best help another kid who was getting bullied. Children then made posters to share with younger grades as to what friendship heroes are like, using the descriptor words shared with them, and how to be a friendship hero (i.e., how to help someone who is being bullied). Posters were hung for two-to-four months after the intervention activity."
45999223|NCT04681209|Behavioral|Empathy Condition|Children in the empathy-based condition were asked to provide five descriptors of how two children who were bullied would fee. Two weeks later they were told the top seven descriptors given by the hundreds of children participating in the project. This was followed by a brief discussion of how one could best help another kid who was getting bullied. Children then made posters to share with younger grades as to what being bullied feels like, using the descriptor words shared with them, and how to be a friendship hero (i.e., how to help someone who is being bullied). Posters were hung for two-to-four months after the intervention activity.
45999224|NCT05423028|Procedure|Ultrasound-guided nerve hydrodissection|Peri- median nerve injection for hydrorelease and decompression
45999225|NCT02900235|Drug|MT-3995|
45999226|NCT00449969|Device|Zoll AED pro|Arm one (Extended feedback) offers full feedback guidance during CPR
45999227|NCT00449969|Device|Zoll AED pro|In arm two (limited feedback) feedback is modified lacking several elements of feedback
45999228|NCT05422989|Diagnostic Test|X-ray, CT|Just a diagnostic procedure to confirm the diagnosis
45999229|NCT00450008|Drug|GM-CSF|fixed dose of 250 mcg/m2, 3 days per week by subcutaneous injection
45999230|NCT00450008|Drug|thalidomide|Thalidomide by oral administration at a fixed dose of 200 mg. Prophylactic Coumadin® by oral administration at a fixed dose of 2.5 mg to prevent thromboembolic events (DVT and TIA/stroke) during Thalidomide administration. Thalidomide and Coumadin will be given daily at bedtime without interruption.
45999231|NCT00450008|Drug|docetaxel|Docetaxel will be administered by intravenous piggyback over 1 hour at 75mg/m² every 3 weeks. Pre-medication for the docetaxel infusion will consist of dexamethasone 8 mg administered orally 12 hours, 3 hours and 1 hour before docetaxel.
45999232|NCT02900469|Biological|denosumab|denosumab: 120 mg subcutaneous injection
45999233|NCT02900469|Procedure|Surgery|Surgery: approximately 2-4 weeks after dosing of denosumab
45999234|NCT00450047|Device|Speed-feedback therapy system with a bicycle ergometer|
45999235|NCT00450047|Device|Ergometer at conventional settings|
45999236|NCT00450086|Drug|Budesonide|9 mg per day
45999237|NCT00450086|Drug|Mesalazine|3 g per day
45999238|NCT00450086|Drug|Placebo|0 g per day
45457691|NCT03505138|Other|health care system|"GROUP 2 (conventional group or control group) Patients with a COPD exacerbation can go to their family physicians or emergency services and these physicians will establish a treatment and a monitoring of these exacerbation (conventional group).~The period of monitoring is 1 year."
45457692|NCT02303626|Drug|BCX4161|
45999239|NCT05422950|Other|Relationship between physical condition and functionality in post-covid patients|Correlation study between the physical condition and functionality of patients after intubation due to covid 19
45999240|NCT05422911|Drug|Abiraterone acetate|YONSA® (abiraterone acetate), YONSA® 500 mg (four 125 mg tablets) or 625 mg (five 125 mg tablets) administered orally once daily in combination with methylprednisolone 4 mg administered orally twice daily + physician's choice GnRH agonist/antagonist [unless the Veteran has had prior bilateral orchiectomy].
45999241|NCT05422911|Drug|Apalutamide|Apalutamide, 240 mg (four 60 mg tablets) administered orally once daily + physician's choice GnRH agonist/antagonist [unless the Veteran has had prior bilateral orchiectomy].
45999242|NCT05422911|Drug|Enzalutamide|Enzalutamide, 160 mg (four 40 mg capsules) administered orally once daily + physician's choice GnRH agonist/antagonist [unless the Veteran has had prior bilateral orchiectomy].
45999243|NCT00450125|Other|Six-Minute Walk Test|Six-Minute walk tests at least one hour after vigorous exertion (such as exercise stress test) and at least 20 minutes in between the first and second six-minute walk tests
45999244|NCT00450125|Other|Exercise stress test|Scheduled gold standard exercise test, i.e. stress test, cycle ergometry with incremental workloads or oxygen consumption exercise studies
45999245|NCT00450164|Procedure|esofagic varices ligation|
45999246|NCT00450164|Drug|Nadolol|
45999247|NCT00450164|Drug|Isosorbide mononitrate|
45999248|NCT00450164|Drug|Prazosin|
45457693|NCT02303626|Drug|Placebo|
45457694|NCT05456347|Behavioral|Low-calorie and high-protein diet with the majority of protein coming from animal sources.|Diet was prescribed to the participant and menus and recipes were also provided.
45457695|NCT05456347|Behavioral|Low-calorie and high-protein diet with the majority of protein coming from plant sources.|Diet was prescribed to the participant and menus and recipes were also provided.
45457696|NCT02311426|Other|Observational study|Function, health related quality of life and rehabilitation needs will be analysed in the two country region groups
45835114|NCT02743338|Behavioral|Sleep Restriction|Behavioral component of CBT-i. Sleep restrictions includes curtailing bed time to match sleep time as registered during the first week of treatment, and expanding bed time contingent upon increased sleep efficiency, until optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
45835115|NCT02743338|Behavioral|Sleep Compression|Behavioral component of CBT-i. Sleep compression includes gradually compressing bed time over several weeks to approach sleep time as registered during the first week of treatment, and stopping compression when optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
45457697|NCT01137877|Other|Milk based infant formula powder|milk based infant formula ad lib
45835116|NCT02743338|Behavioral|Additional CBT-i components|After 5+5 weeks of either Sleep Restriction or Sleep Compression, a randomized sample from each treatment Group is offered additional components of CBT-i, such as Stimulus Control, Cognitive Restructuring, Relaxation and Visualization for 10 weeks, without therapist support. Component allocation based on individual analysis.
45999249|NCT05422872|Other|Delphi study|A Delphi study will be conducted with several rounds up to expert consensus.
45999250|NCT02900430|Other|Patients without antifungal prophylaxis|Epidemiology data: clinical and biological informations collecting
45999251|NCT02900430|Drug|Patients with antifungal prophylaxis|Hospitalized patients between 2012 and 2015 received Posaconazole prophylaxis during neutropenia period induced by induction or salvage chemotherapy.
45999252|NCT05422833|Other|Evaluation and analysis of clinical data|Evaluation and analysis of clinical data (baseline demographic features (sex, age at diagnosis, age at first symptoms, age at first visit), initial presenting symptoms, affected bone sites (monostotic FD or polyostotic FD), renal phosphate wasting, MAS, Mazabraud syndrome, endocrine disease, fractures, bone specific treatment especially bisphosphonate and surgery, pain and disease's severity.
45999253|NCT02900040|Other|kidney transplantation|
45999254|NCT00450203|Biological|bevacizumab|7.5mg/kg IV Day 1 of each 21 cycle of chemotherapy (6 cycles) plus day 1 of each maintenance dose every 21 days for 6 doses.
45457698|NCT01137877|Other|Investigational Infant Formula #1|Milk based infant formula ad lib
45457699|NCT01137877|Other|Investigational Infant Formula #2|Milk based infant formula powder ad lib
45999255|NCT00450203|Drug|capecitabine|dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)
45999256|NCT00450203|Drug|cisplatin|60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
45999257|NCT00450203|Drug|Epirubicin|50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
45999258|NCT00450203|Procedure|adjuvant therapy|3 cycles of ECX chemotherapy post operatively
45999259|NCT00450203|Procedure|conventional surgery|Surgery undertaken after 3 cycles of pre-operative chemotherapy. Followed by 3 cycles of chemotherapy.
45999260|NCT00450203|Procedure|neoadjuvant therapy|3 cycles of pre-operative ECX chemotherapy.
45999261|NCT00450203|Drug|Lapatinib|1250mg/day Day 1-21 of each cycle of chemotherapy (6 cycles) plus day 1-21 of each maintenance course every 21 days for 6 doses.
45999262|NCT05422677|Drug|Hanmi Tams® Capsule|Hanmi Tams®, Once daily administered per the locally approved product information
45999263|NCT00450281|Genetic|chromogenic in situ hybridization|
45999264|NCT00450281|Genetic|gene expression analysis|
45999265|NCT00450281|Genetic|mutation analysis|
45999266|NCT00450281|Genetic|polymerase chain reaction|
45999267|NCT00450281|Genetic|polymorphism analysis|
45999268|NCT00450281|Other|fluorescent antibody technique|
45999269|NCT00450281|Other|immunohistochemistry staining method|
45999270|NCT00450281|Other|laboratory biomarker analysis|
45999271|NCT00450281|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
45999272|NCT00450281|Other|study of socioeconomic and demographic variables|
45999273|NCT00450281|Procedure|study of high risk factors|
45999274|NCT02900274|Device|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
45999275|NCT05422248|Device|Series Topical Oxygen Therapy|Standard care provided to the whole wound followed by intervention device care to the whole wound.
45999276|NCT05422248|Device|Paired Topical Oxygen Therapy|Care provided to one portion of wound by intervention device and standard care to remaining portion of wound.
45999277|NCT05421390|Other|Reduced fat dairy|Serving sizes will be: 250 mL milk, 175 g yogurt, and 50 g cheese. Skim milk, fat-free yogurt, and ≤22 % fat cheese
45999278|NCT05421390|Other|Regular fat dairy|Serving sizes will be: 250 mL milk, 175 g yogurt, and 50 g cheese. 3.25% fat milk, ≥2% fat yogurt, and ≥28% fat cheese
45999279|NCT04699097|Drug|Azithromycin|250 mg tablet, 5 ml / 200 mg 30 ml suspension
45999280|NCT02900001|Procedure|early coronary angiography|Routine coronary angiography and revascularization if appropriate within 24 hours
45999281|NCT02900001|Procedure|delayed coronary angiography|Routine coronary angiography and revascularization if appropriate after 72 hours
45999282|NCT04698746|Procedure|Pericapsular nerve group block|PENG block will be made with 10 ml 0.5% bupivacaine + 2 mg dexamethasone + 9.5 ml NaCl under US-guidance
45999283|NCT04698746|Procedure|Intra-articular local anesthetic injection|Intra-articular local anesthetic injection will be made with 10 ml 0.5% bupivacaine + 2 mg dexamethasone + 9.5 ml NaCl
45999284|NCT02899923|Other|Data collection|
45999285|NCT00450320|Drug|sirolimus|The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen. Subjects will continue on study protocol for six cycles as long as their KS is stable or continuing to respond to study medication. Treatment will be extended for up to six additional cycles if the subject has met criteria for a response. Subjects with no more than stable disease will have treatment discontinued after six cycles. Protocol treatment will be discontinued if the subject develops tumor progression, unacceptable toxicity or develops one of the protocol-defined reasons for treatment discontinuation at any time during the study.
45999286|NCT05421234|Other|diagnostic test and sperm analysis|"Diagnostic Test: 2x14 ml of peripheral blood collected in the tube with anticoagulant, for platelet isolation, respirometry mitochondrial analysis, antioxidants (coenzyme Q10, vitamin E, gamma-tocopherol, beta-carotene) and TBARS estimation.~Sperm analysis: standard spermiogram examination (volume, pH, number, motility and pathology) in the broker chamber, as well as extended examinations: mioxsys for redox potential, Vitalsperm (eosin-nigrosine staining) for sperm vitality and anti-sperm antibody (IgG) test."
45999287|NCT00450359|Procedure|breast imaging study|
45999288|NCT00450359|Procedure|comparison of screening methods|
45999289|NCT00450359|Procedure|radiomammography|
45999290|NCT00450398|Drug|YSPSL|YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient prior to arterial reperfusion of the liver.
45999291|NCT00450398|Drug|Placebo|Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient prior to arterial reperfusion of the liver.
45999292|NCT05421195|Drug|corticosteroids therapy|Oral corticosteroids
45999293|NCT05421195|Other|Olfactory training|repeat and deliberate sniffing of a set of odorants
45999294|NCT00450476|Device|Hi-Lo Evac Endotracheal Tube|
45457700|NCT01137877|Other|Human Milk|Human milk ad lib
45999295|NCT00450515|Drug|capecitabine|
45999296|NCT00450515|Drug|vinflunine|
45999297|NCT05420259|Behavioral|Combined Exercise and Dietary Intervention (CEDI)|The exercise program will be planned by an exercise physiologist and implemented by physiotherapists prior to rehabilitation physician assessment. In the first session patients will be evaluated by physiotherapist in order to allow personalization of exercise according to patient's age and functional capacity. In regard to diet, written materials will be given to patients and caregivers, namely a dietary plan, standard menus, recipes, and standard portions information.
45999298|NCT05420259|Behavioral|Standard Care|Standard Care
45999299|NCT02899845|Other|postural task|
45999300|NCT02899845|Other|walk task|
45457701|NCT03504982|Drug|Vericiguat (BAY1021189)|A : 2.5 mg vericiguat A*: 2.5 mg vericiguat B : 5 mg vericiguat C : 10 mg vericiguat C*: 10 mg vericiguat
45999301|NCT03276104|Procedure|IOL repositioning|Intraocular lens repositioning by scleral suturing
45999302|NCT03276104|Procedure|IOL exchange|Intraocular lens exchange with retropupillary iris-claw lens
45999303|NCT03275987|Behavioral|Mammography direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
45999304|NCT03275987|Behavioral|Usual care|Group received usual care, and direct mail 15 months after treatment group received intervention.
45999305|NCT03275987|Behavioral|Colonoscopy direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
45999306|NCT02956850|Other|Placebo|Placebo matching to RO7020531 will be administered as per schedule specified in the respective arm.
45999307|NCT02956850|Drug|RO7020531|RO7020531 will be administered as per schedule specified in the respective arm.
45999308|NCT04699019|Other|Four speeds|Four speeds ranging from a set walking speed up to 9 mph
45999309|NCT04699019|Other|Foot Strike Pattern|Foot strike sequences (rearfoot strike, midfoot strike, forefoot strike)
45999310|NCT04698863|Device|Oxygen reserve index|eveluating oxygen reserve in blood
45999311|NCT02899806|Other|Written Information|A written information on peridural anesthesia is delivered
45999312|NCT02899806|Other|Video Information|A link to a video explaining peridural anesthesia is delivered to the pregnant woman. The patient can watch the video several times.
45999313|NCT00450593|Genetic|gene expression analysis|
45999314|NCT00450593|Genetic|microarray analysis|
45999315|NCT00450593|Genetic|molecular genetic technique|
45457702|NCT03504982|Drug|Moxifloxacin|D: 400 mg moxifloxacin
45457703|NCT03504982|Drug|Placebo|A : vericiguat placebo 10 mg A*: vericiguat placebo 10 mg + moxifloxacin placebo B : vericiguat placebo 10 mg C : vericiguat placebo 2.5 mg C*: vericiguat placebo 2.5 mg + moxifloxacin placebo D : vericiguat placebo 2.5 mg + vericiguat placebo 10 mg
45835117|NCT02742324|Drug|Ruxolotinib|Ruxolitinib is administered orally twice a day (bid) everyday in 28-day treatment cycles. The starting dose is 10 mg BID and may go up to 20 mg BID. Ruxolotinib therapy starts on Cycle 1 day 1.
45835118|NCT02742324|Drug|peg-IFN alpha -2a|Peg-IFN-alpha-2a is administered subcutaneously once a week. The doses tested are 45, 90 and 135 mcg/week. .Peg-IFN-alpha-2a therapy starts at Cycle 1Day 15.Of note, Peg-IFN-alpha-2a will only be started if the platelet count is ≥ 50x109/L at C1D15.
45835119|NCT05026632|Drug|NPI-002 Intravitreal Implant|Implant inserted during vitrectomy.
45835120|NCT01459146|Drug|Artemether-lumefantrine combination plus albendazole|AL: 20mg/120mg 12-hourly orally for 3 days ABZ: 400mg oral stat
45835121|NCT01459146|Drug|Artemether-lumefantrine plus Praziquantel plus Albendazole|Artemether-lumefantrine 20mg/120mg 12 hourly for 3 days, plus praziquantel 40mg/kg stat, plus albendazole 400mg stat oral
45835122|NCT01459146|Drug|Albendazole plus Praziquantel|Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
45835123|NCT05020158|Other|Family Talk Intervention|A psychosocial family-based intervention that is designed to give support to an entire family when a child has life-threatening illness.
45835124|NCT05028894|Other|No intervention|No intervention
45999316|NCT00450593|Genetic|mutation analysis|
45999317|NCT00450593|Other|laboratory biomarker analysis|
45999318|NCT00450593|Procedure|mutation carrier screening|
45999319|NCT00450593|Procedure|study of high risk factors|
45999320|NCT04679844|Device|MagnetOs Putty|MagnetOs Putty use in instrumented posterolateral fusion, 7cc-10cc mixed with autograft bone in a 1:1 ratio per spine level at the randomized assigned side.
45999321|NCT04679844|Device|Autograft Bone|Autologous bone graft used in instrumented posterolateral fusion, 7cc-10cc per level mixed with bone marrow aspirate/blood per spine level at the contralateral side.
45999322|NCT05419713|Other|Visual Stimuli for Space Perception|The visual environment (e.g., target locations and texture backgrounds) will be varied and human behavioral responses (judged distances) will be measured to reveal the space perception and cognitive processes underlying space perception and navigation.
45999323|NCT00450671|Procedure|Collagen Plug Placement|
45999324|NCT00450671|Procedure|Seton placement|
45999325|NCT05419167|Behavioral|STEP-COVID|The program is offered by two facilitators to groups of three to six women, online in a synchronous mode. The intervention is divided into two phases, each including three sessions. The first 3 sessions aim to explore how the participants feel, to better understand what makes them feel this way, to allow them to exchange with other people who are going through similar experiences, and to support the ability to manage stress and more unpleasant emotions. The following three sessions aim to enable participants to refocus on their experience of pregnancy and motherhood by giving them the opportunity to reflect upon how they wish to be as mothers, upon how their personal history influences their experience of pregnancy and motherhood, upon the moments that, as mothers, might be the most pleasant and those that will require more adaptations, and upon identifying the needs they have or expect to have after childbirth as well as the resources available to them to meet these needs.
45999326|NCT00450710|Procedure|ileal interposition with a sleeve gastrectomy|
45999327|NCT04698824|Procedure|Hypnosis session|"At least one session of hypnosis in the internal medicine unit at the hospital Groupe Hospitalier Mutualiste de Grenoble"
45999328|NCT00450827|Biological|bevacizumab|
45999329|NCT00450827|Biological|filgrastim|
45999330|NCT00450827|Procedure|autologous hematopoietic stem cell transplantation|
45999331|NCT00450827|Radiation|iodine I 131 monoclonal antibody 3F8|
45999332|NCT05418894|Device|Device: Directional Deep Brain Stimulation|Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
45999333|NCT00450905|Device|PRIMA Device|
45999334|NCT00450944|Biological|deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins|
45999335|NCT05417607|Behavioral|P-ESDM informed caregiver coaching|Caregiver coaching informed by P-ESDM done remotely (via telehealth)
45999336|NCT00451061|Drug|Alfuzosin|
45999337|NCT00451061|Drug|Tamsulosin|
45999338|NCT05386719|Other|Prescreening|Eligible patients (history of early stage breast cancer and at least 3 months from completion of local and systemic therapy at Johns Hopkins, reads and speaks English) complete survey for demographics, smoking status & questions about cardiovascular disease.
45999339|NCT05386719|Other|Screening and Enrollment|Consent
45835125|NCT05025774|Other|Physical activity|Participant Reported Physical Activity and Outcomes (completed via REDCap or on paper)
45999340|NCT05386719|Behavioral|Baseline|Behavioral Battery and Patient Reported Outcome Quality of Life questionnaires (EORTC QLQ-C30 and QLQ-BR23) Labs (Hba1c + lipid panel if not done within 12 months or if abnormal within 1 year) Abstract vitals from chart review
45835126|NCT05024136|Device|Limon essential oil aromatherapy|Subjects receive three times 30 mins aromatherapy of Limon essential oil per time for the month. Anthropometric measurements such as blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), autonomic nerve parameters including a. SDNN (standard deviation of all normal to normal intervals index); b. HRV（heart rate variability）; c. LF（0.04-0.15 Hz）and HF（0.15-0.4 Hz）were measured every week. PSQI（Pittsburgh sleep quality index）and HADS (Hospital Anxiety and Depression Scale) were measured initial and ten ends.
45835127|NCT05024136|Device|Vetiver essential oil aromatherapy|Subjects receive three times 30 mins aromatherapy of vetiver essential oil per time for the month. Anthropometric measurements such as blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), autonomic nerve parameters including a. SDNN (standard deviation of all normal to normal intervals index); b. HRV（heart rate variability）; c. LF（0.04-0.15 Hz）and HF（0.15-0.4 Hz）were measured every week. PSQI（Pittsburgh sleep quality index）and HADS (Hospital Anxiety and Depression Scale) were measured initial and ten ends.
45999341|NCT05386719|Behavioral|Interpret BMI|Refer to Healthful Eating, Activity and Weight Program (HEAWP) if BMI ≥25 and not already on lifestyle intervention
45999342|NCT05386719|Other|Interpret HbA1c|"HbA1c results categorized as follows:~HbA1c <5.7%; HbA1c 5.7-6.4%; HbA1c 6.5%+; or Known diabetic on medication"
45999343|NCT05386719|Other|Interpret lipid panel and assess other risk factors|"Based on above categories:~HbA1c <5.7%: Any of these cardiovascular disease risk factors: current/former tobacco use, total cholesterol >200, family history of Coronary Artery Disease/Heart Attack in first degree family <55 year old male or <65 year old female, systolic blood pressure >130 HbA1c 5.7-6.4%: Refer to Primary Care Provider and consider Healthful Eating, Activity and Weight Program (HEAWP) HbA1c 6.5%+: Refer to Endocrinology if HbA1c ≥8% Known diabetic on medication: Refer to Endocrinology if HbA1c ≥7%"
45999344|NCT05386719|Behavioral|Assess 10 year risk of cardiovascular event|If risk factors are present - refer to Cardiovascular Disease Prevention Program
45999345|NCT05386719|Behavioral|Recommendations|Provide individual patient handout based on all above interventions
45999346|NCT05386719|Behavioral|Follow-Up|6 and 12 month labs (if prior abnormal) and Patient Reported Outcome questionnaires
45675624|NCT05778396|Procedure|Active spinal manual therapy protocol|The chiropractor will start by (1) placing one hand over L4-L5 or L5-S1 and then will apply a high-velocity, low-amplitude (HVLA) thrust with a therapeutic line of drive. Side-lying lumbar manipulation will be performed bilaterally, with the treating clinician choosing any suitable technique and with or without occurrence of the characteristic audible joint cavitation associated with spine manipulation. The chiropractor will then perform (2) prone lumbar mobilisation by placing the contact hand and applying downward pressure over L4-L5 or L5-S1 with the other hand guiding a manual flexion-distraction piece to apply therapeutic mobilization of the lumbar spine. The chiropractor will deliver (3) a prone thoracic manipulation by placing two hands over the transverse processes of T5-T6 or T6-T7 and applying a HVLA thrust in a posterior-to-anterior direction.
45675625|NCT05778396|Procedure|Control spinal manual therapy protocol|(1) Control side-lying lumbar manipulation will be operationalised as the application of a low-velocity broad push manoeuvre to the gluteal region following a non-therapeutic line of drive. The chiropractor will then perform (2) control prone lumbar mobilisation, consisting of a non-therapeutic manual manoeuvre involving minimal oscillations (0 to ±2°) of the flexion-distraction piece with light touch over the lumbar spine region, and (3) control prone thoracic mobilisation consisting of two-handed left and right scapula pushes with a nontherapeutic line of drive.
45675626|NCT05773989|Drug|CYP2C19 genotype guided P2Y12 monotherapy|Patients without a LOF-allel will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months. Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.
45999347|NCT03455127|Other|FSI ECD|Households will be visited by a trained community based lay worker on a weekly to biweekly basis to deliver the 15 module curriculum covering a range of topics from nutrition, water and sanitation, hygiene, early stimulation, conflict management, to good communication. The intervention seeks to promote healthy child development via active coaching to individual beneficiary households, delivering modules on a one on one basis and engaging all family members.
45675627|NCT05773989|Drug|Clopidogrel|Standard DAPT according to current guidelines with clopidogrel (tablet of 75mg once daily) for 6 months and acetylsalicylic acid (tablet 80mg one daily) for 6 months.
45999348|NCT02931578|Other|Glucose100|
45999349|NCT02931578|Other|Glucose50|
45999350|NCT02931578|Other|Glucose42|
45999351|NCT02931578|Other|Oral Glucose Tolerance Test|For each OGTT, subjects will consume 50g of sweetener dissolved in water at a comfortable pace within 10 minutes. Blood samples for plasma glucose and insulin will be taken at -20, 0, 15, 30, 45, 60, 90 and 120 min after consuming the glucose drink. Plasma fructose will be tested at baseline, 30, 60, 90 and 120 minutes.
45999352|NCT02931344|Dietary Supplement|Dietary Supplement: Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
45999353|NCT02931383|Drug|Liraglutide 3 mg (Saxenda)|
45999354|NCT02931383|Drug|Liraglutide 3 mg placebo|
45675628|NCT05772169|Drug|Mifepristone 300 MG [Korlym]|Mifepristone tablets for once daily oral dosing
45675629|NCT05772169|Drug|Placebo for mifepristone|Placebo tablets for once daily oral dosing
45999355|NCT02931422|Behavioral|Financial incentive|Conditional cash transfer upon HIV testing
45999356|NCT02931461|Procedure|Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration|
45999357|NCT04593641|Biological|CT-P59|administered
45999358|NCT04584632|Device|Efemoral Vascular Scaffold System (EVSS)|Balloon-expandable, bioresorbable vascular scaffolds coated with sirolimus
45999359|NCT04341441|Drug|Hydroxychloroquine - Daily Dosing|"The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.~All treatment groups will receive placebo pills to have the patients take 2 pills a day."
45999360|NCT04341441|Drug|Hydroxychloroquine - Weekly Dosing|"The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400 mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria~All treatment groups will receive placebo pills to have the patients take 2 pills a day."
45675630|NCT05769478|Drug|Amifampridine|a single dose of amifampridine (20mg) will be orally administered
45999361|NCT04341441|Other|Placebo oral tablet|"Participants randomized to this arm will be provided with daily dosing of oral placebo to have the patients take 2 pills a day..~Participants will receive a monitoring phone call at 4 weeks post study entry to monitor for COVID-19 symptoms and medication side effects. At week 8, participants will provide additional samples of whole blood.~Additional studies will include serology, inflammatory and other disease associated markers. Clinical data and location of main work area will be collected."
45999362|NCT04341441|Diagnostic Test|Monitoring Visit - Baseline|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
45999363|NCT04341441|Diagnostic Test|Monitoring Visit - Week 4|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
45999364|NCT04341441|Diagnostic Test|Monitoring Visit - Week 8|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
45999365|NCT04341441|Other|Weekly Assessment|Participants will be asked to contact the study team if COVID-19 infection is established at any time during the study. For study weeks 1,2,3,5,6 &7, Participants will receive a monitoring questionnaire to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects. These monitoring visits will be done by telephone and/or electronic encounters (virtual visits, email), whichever method the patient prefers to encourage adherence to the monitoring.
45999366|NCT04525937|Other|Patient Questionnaire|Patient Questionnaire
45999367|NCT04525937|Other|Provider Questionnaire|Provider Questionnaire
45999368|NCT01187953|Drug|Prograf (tacrolimus)|Administered per current product labeling
45999369|NCT01187953|Drug|LCP-Tacro|Tacrolimus, once-per-day The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
45999370|NCT05381259|Behavioral|hortitherapy in people living with Alzheimer's taking place in three different day care|"6 users benefiting from the horticultural workshop and 6 others from a usual workshop (control group) This control group will benefit from its usual workshop while the other group will participate in the horticultural workshop.~If it is impossible to carry out the workshops outdoors (rain or high heat), the day reception centers will provide a room to allow the workshops to be carried out. They will be adapted in terms of activities and materials."
45999371|NCT02900157|Biological|MEDI9090|MEDI9090 will be administered by IV infusion
45999372|NCT02900157|Biological|Durvalumab|Durvalumab as a single agent will be administered by IV infusion after patients have completed the prescribed doses of Medi9090.
45999373|NCT05347719|Behavioral|MBCT Intervention|Eight weekly two-hour mindful MBCT intervention sessions involving training in mindfulness meditation and cognitive-behavioral methods. Sessions will be designed to increase participant awareness of internal reactions that trigger relapse in MDD and to provide participants with techniques to detach from dysfunctional cognitive processes and redirect their attention to experiences. Outside of the sessions, participants will be assigned daily homework exercises and provided with handouts and audio recordings of mindfulness exercises to use in their practice.
45999374|NCT02931305|Drug|Epimedium Prenylflavonoids Extract|Each Epimedium Prenylflavonoids Extract capsule contains 370 mg of EPIMEDIUM EXTRACT
45999375|NCT02931305|Drug|Placebo|Use iron oxide (brown, black and yellow) to mimic Epimedium Prenylflavonoids Extract.
45999376|NCT04262817|Drug|Nicotine form|participants will receive 36mg/ml nicotine salt and freebase nicotine
45999377|NCT04262817|Other|E-cigarette experimental flavor|Participants will receive menthol and tobacco flavored e-cigarettes
45999378|NCT04679259|Diagnostic Test|Blood sampling for assessment of the level of D-Amino Acid Oxidase, D-serine and Serine in blood|Blood sampling is done before surgery and at 1, 2, and 7 day after surgery. The level of D-Amino Acid Oxidase, D-serine and Serine in blood are assessed.
45675631|NCT05769218|Behavioral|CHORUS+|The CHORUS+ intervention will include a baseline interview with a peer recovery coach to encourage uptake of HIV PrEP (pre-exposure prophylaxis) and medications for opioid use disorder (MOUD) through motivational interviewing (MI). Participants will also be offered HIV self-testing on the day of recruitment, HIV PrEP (if they are HIV negative) and MOUD. Participants will then receive peer coaching for 6 months to increase adherence to PrEP and or MOUD.
45999379|NCT04679259|Diagnostic Test|Neurocognitive test|Neurocognitive test is performed before surgery and at 7 day after surgery
45999380|NCT04679259|Diagnostic Test|Assessment of delirium|Postoperative delirium is assessed daily during 7 days after surgery.
45999381|NCT02931149|Drug|Platelet-rich plasma|Submucosal injection with PRP was performed prior to endoscopic resection
45999382|NCT04679766|Procedure|Ice cream cone technique with immediate implant as a flapless bone regenerative method in management of patients with labial plte dehiscence|Atraumatic extraction will be done The extraction socket will be debrided to remove any residual debris using surgical curettes Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence. Implant placement will be done. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability Resorbable collagen membrane will be cut confirming to the size and shape of the defect of labial bone plate dehiscence. The membrane will be placed against internal surface of the extraction socket against the remaining buccal plate of bone. The gap between the collagen membrane and the implant fixture will be filled with xenograft particulates.The membrane will be folded in palatal direction to seal the socket in an ice cream cone shape, then will be secured using non-resorbable sutures
45675632|NCT05769218|Other|Standard of care|Normal protocols for care of participants who inject opioids will be followed.
45675633|NCT05765175|Device|Varian Cardiac Radioablation (CRA)|Subjects randomized to CRA will be treated with the Varian CRA system according to a uniform CRA protocol. A dose of 25 Gy in a single fraction is prescribed to the planning target volume (PTV), and delivered using a stereotactic body radiotherapy (SBRT) technique.
45999383|NCT02931188|Drug|Anacetrapib|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
45999384|NCT02931188|Drug|Statin|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
45999385|NCT02931188|Drug|Placebo|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
45999386|NCT01217944|Drug|Ranibizumab|0.5 mg ranibizumab intravitreal injection
45999387|NCT01217944|Drug|Verteporfin PDT|Verteporfin (6 mg/m2) intravenous infusion
45999388|NCT01217944|Drug|Sham Ranibizumab|Empty vial to mimic the intravitreal injection
45999389|NCT01217944|Drug|Sham verteporfin PDT|Sham vPDT intravenous infusion of dextrose 5% solution followed by light application (PDT).
45999390|NCT04238013|Other|Whole Body Vibration (WBV)|The WBV session will consist of 8 bouts of 45s vibration (50Hz) with a minute of rest in between each bout.
46086587|NCT05302310|Other|integrated care|"i) Screening of older people for risk of frailty using a frailty screening tool, to identify the appropriate care they will require:~Older adults with low risk of frailty will receive health promotion and preventive care from the Information and Advice Center nurse and/or social worker.~Older adults at risk will receive the following:~ii) a Comprehensive Geriatric Assessment (CGA) delivered by the Information and Advice Center nurse and social worker over the course of multiple appointments, to identify the health and social care needs and goals of the older person; iii) Development of an individualized care plan by a multidisciplinary team, which will include evidence-based interventions and be coordinated by the Information and Advice Center nurse and/or the social worker; and iv) follow-up depending on the situation of each older person, and adaptation of the individualized care plan, as needed."
46086588|NCT02724332|Drug|Rapamycin|2mg,po,bid
45675634|NCT05765175|Procedure|Catheter Ablation (CA)|Subjects randomized to the CA arm will be treated according to a uniform CA protocol.
45999391|NCT04238013|Other|Electrical Stimulation|The electrical stimulation intervention serves to account for any effects of standing and/or of repeated performance of the sit-to-stand behavior on neurophysiological outcomes. In the electrical stimulation intervention, participants will receive electrical stimulation while standing on the vibration platform for 8 bouts for 45s with a minute of rest in between without vibration.
45457704|NCT01133431|Drug|CKD-501 0.5 mg tablet, Glimepiride 4 mg tablet|From day 1 to day 4, CKD-501 0.5mg is administered daily to Group 1 patients during period 1. Then on day 5,CKD-501 0.5mg and glimepiride 4mg is co-administered to overnight-fasting Group 1 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 placebo and glimepiride 4mg in Group 1.
45999392|NCT04689737|Drug|Doravirine|Participants will be told to take one tablet of doravirine (Pifeltro, MDS) once daily, with or without food, approximately at the day time that they usually finish the hemodialysis sessions. The rest of their antiretroviral regimen and concomitant medications will remain unchanged
45999393|NCT05342220|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning through inflation of a blood pressure cuff to systolic blood pressure values > 200mmHg for 5 minutes (3 times) each before electrocardioversion Electrical cardioversion for atrial fibrillation (100, 150, 200 Joule)
45999394|NCT05342220|Procedure|Sham preconditioning|Inflation of a blood pressure cuff to systolic blood pressure values ~ 20mmHg for 5 minutes (3 times) each before electrocardioversion
45999395|NCT04689815|Drug|Oral Arsenic Trioxide Formulation|Eligible subjects with NPM1 MRD positivity will receive oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day, from days 1 - 7 per cycle) plus azacitidine (75mg/m2 per day subcutaneously, from days 1 to 3 per cycle). Each cycle of oral-As2O3 plus azacitidine will be given once every 28 days. The total duration of treatment is 12 months (12 cycles). Treatment will be day-care and outpatient based. Reduction in the dosage and duration of oral-As2O3 is required if the subject is experiencing adverse events (AEs). In case of grade 3 or above toxicity, the dosage of oral-As2O3 will be reduced to 5mg per day.
45999396|NCT05341557|Drug|BPI-371153|Subjects will receive BPI-371153 until disease progression
45999397|NCT01187446|Radiation|Total skin electron beam therapy (TSEBT)|TSEBT is administered as 12 Gy fractionated at 2 grey (Gy)/cycle (each cycle requiring 2 days of treatment); 4 days each week; for 3 weeks.
45999398|NCT01187446|Drug|Vorinostat|Starting doses of is vorinostat 400 mg/day, continuing for 8 weeks.
46086589|NCT02717468|Device|Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the digital artery (ClearSight®)|
45835128|NCT05026398|Drug|Fenfluramine|Fenfluramine (30mg daily) will be dispensed in a cherry flavoured aqueous solution. Fenfluramine is both a serotonin releasing agent and sigma-1 receptor agonist. Fenfluramine is FDA approved for the treatment of Dravet syndrome, a rare form of epilepsy.
45835129|NCT05026398|Other|Placebo|The placebo is a liquid designed to be identical to the interventional drug fenfluramine in terms of both taste and visual appearance. It will be administered at 30mg daily and dispensed in a cherry flavoured aqueous solution
45835130|NCT01895244|Drug|Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells|If no active alveolitis: mobilisation with 2x1g Cyclophosphamide If active alveolitis: mobilisation with 2x1.5g Cyclophosphamid If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
45835131|NCT02724930|Behavioral|Enhanced facilitation of COPES|Enhanced facilitation of COPES implementation consists of promotional meetings, automated case finding and proactive outreach to recruit patients, marketing and educational materials, local champion, and academic detailing.
45835132|NCT05586750|Drug|Atorvastatin 40 Mg Oral Tablet|40 mg atorvastatin (2 x 20 mg atorvastatin daily), taken orally
45835133|NCT05586750|Drug|Placebo|2 x 20mg placebo (daily), taken orally. Identical appearance to study drug
45675635|NCT05762133|Behavioral|African-American Social Support Effectiveness Treatment-Partners alleviating Perinatal Depression (ASSET-PPD)|This proposed novel intervention has four prenatal modules and two postpartum review sessions addressing key correlates of PND with the largest effect sizes by targeting fathers': 1) prenatal and postpartum family involvement; 2) mental health psychoeducation; 3) interparental communication and relationship skills; and 4) balanced division of family tasks. The intervention is based on the stress-generation and cognitive-behavior theories to frame skill-based individual sessions of didactics, interactive training, and trackable objectives.
45675636|NCT05758181|Other|Apical Undermining|The skin at the tip of the wound will be freed to reduce tension.
45835134|NCT02720094|Drug|Cabotegravir Oral Tablet|30 mg tablet
45835135|NCT02720094|Drug|TDF/FTC tablets|300 mg/200 mg fixed-dose combination tablets
45999399|NCT02931110|Drug|CBL0137|CBL0137 administered IV weekly on Days 1 and 8 of repeated 21 day treatment cycles. Number of Cycles: 2 or until progression or unacceptable toxicity develops
45999400|NCT04224285|Other|Dayzz app|Personalized sleep training app that evaluates sleep issues and offers a complete, holistic sleep improvement solution
45999401|NCT04207437|Device|Vibration therapy|vibration therapy using hand held vibration device
45999402|NCT02930993|Biological|anti-mesothelin CAR T cells|Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, patients are intravenously infused with anti-mesothelin CAR T cells in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
45999403|NCT02931227|Procedure|temperature obtained by the non-invasive method of zero-heat flux|
45999404|NCT02931227|Procedure|esophageal temperature|
45999405|NCT02931227|Procedure|intracerebral temperature|
45835136|NCT02720094|Drug|Placebo for TDF/FTC tablets|
45999406|NCT02931227|Procedure|arterial temperature|
45835137|NCT02720094|Drug|Placebo for cabotegravir oral tablet|
45835138|NCT02720094|Drug|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
45675637|NCT05758168|Procedure|Addition of Tie-Over Bolster Dressing|Bolster will be sutured into place using peripheral non-absorbable anchoring sutures.
45999407|NCT04191798|Behavioral|Telerehabilitation using the KinexConnect system for rehabilitation after TKA.|KinexConnect subjects are asked to Perform CPM therapy for 4 weeks. Perform a KCK home exercise program (HEP) for 6 weeks.
45999408|NCT04191798|Behavioral|Traditional outpatient PT for rehabilitation after TKA.|Control subjects are asked to undergo standard outpatient physical therapy (PT) with a licensed physical therapist plus supplemental home exercises as directed. Nominally patients are expected to have 3 PT sessions per week for 4 weeks.
45999409|NCT02931071|Drug|filgrastim|G-CSF (12 μg/Kg/12 h) 8 days.
45999410|NCT02931071|Drug|plerixafor|Plerixafor 0,24 mg/kg/day after the fourth day of G-CSF, and until 5 cells CD34+/μL, max 4 doses of plerixafor
45999411|NCT02931032|Procedure|Sampling of dental plaque / infected dentine|A sample of dental plaque / infected dentine will be taken during routine dental treatment and cultivated in a lab. The headspace above the culture will be sampled and analyzed in GC-MS for the detection of unique volatile organic compounds emitted by the plaque components.
45675638|NCT05752825|Radiation|HR-pQCT|HR-pQCT is a 3-dimensional imaging modality that can be applied to bone and joints in vivo, in order to non-invasively assess the quantity and quality of trabecular and cortical bone compartments separately. HR-pQCT will be applied to peripheral skeletal sites, namely the distal radius and tibia, where image slices equivalent to 9 mm of bone will be acquired. From this, parameters such as volumetric bone mineral density (vBMD), cortical density, cortical porosity, trabecular density, trabecular thickness, trabecular spacing and others will be calculated using specialized software. In the same scanning session, images of the wrist and ankle joints will be produced and analyzed for features of arthrosis, such as erosions, osteophytosis and others.
45835139|NCT02720094|Drug|Placebo for CAB LA|Administered as one 3 mL IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
45835140|NCT01893606|Drug|N-acetyl-D-glucosamine|
45835141|NCT01893606|Drug|placebo|
45835142|NCT02085720|Device|CPAP therapy|As OSA may increase the risk of cardiovascular mortality, all elderly subjects with AHI ≥ 15 or those with AHI ≥ 5 plus either cardiovascular risk factors or ESS score ≥ 10 received patient education program. Elderly subjects who agree for home CPAP treatment were prescribed nasal CPAP units with time clocks to assess objective compliance (run time). ESS, sleep apnea specific quality of life index (SAQLI), and cognitive function tests were performed at baseline, 3 months, 6 months and 12 months after CPAP treatment.
45835143|NCT02716974|Drug|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
45999412|NCT01187407|Drug|LY2216684|
45835144|NCT02716974|Drug|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
45835145|NCT02716974|Drug|Docetaxel|Docetaxel (taxotere) 75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles.
45835146|NCT02716974|Procedure|Prostatectomy|Removal of the entire prostate gland, plus some surrounding tissue.
45835147|NCT02716974|Radiation|Radiation|5 high dose radiation treatments to the metastatic (tumor has spread to other parts of the body) sites.
45999413|NCT01187407|Drug|Placebo|
45999414|NCT01187407|Drug|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
45999415|NCT00554034|Drug|periopatch|Patients enrolled in the study will be given 1, 2, 3 or 4 patches in a cycle by the order they enter the study.
45999416|NCT02930681|Dietary Supplement|Glucosanol 500mg|
45999417|NCT02930681|Dietary Supplement|Placebo|
45999418|NCT05310058|Dietary Supplement|C6 ketone di-ester|C6 ketone di-ester
45999419|NCT05308576|Biological|SCTV01E|D0; intramuscular injection
45999420|NCT05308576|Biological|Placebo|D0; intramuscular injection
45457705|NCT01133431|Drug|CKD-501 placebo tablet, Glimepiride 4 mg tablet|From day 1 to day 4, CKD-501 placebo is administered daily to Group 2 patients during period 1. Then on day 5,CKD-501 placebo and glimepiride 4mg is co-administered to overnight-fasting Group 2 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 0.5mg and glimepiride 4mg in Group 2.
45457706|NCT03507478|Device|BPI1000013|Foam insole
45457707|NCT05610007|Drug|Prilocaine|Patients in the prilocaine group were given 50 mg hyperbaric 2% prilocaine (2.5 ml volume) + 25 mcg fentanyl (0.5 ml volume) before undergoing the cystoscopy procedure.
45457708|NCT03507400|Behavioral|Introvision: mental and emotional self-regulation|Participants learn Introvision
45457709|NCT02306746|Dietary Supplement|TARGET protocol EN 1.5 kcal/mL|Enteral feed 1.5 kcal/mL
45675639|NCT05752825|Radiation|DXA scan|Through DXA scans, we will obtain information regarding body composition, hip and spine bone mineral density, as well as examine any previous vertebral fractures using vertebral fracture assessment (VFA). VFA is a function of DXA scanners which allows for visualization of thoracic and lumbar vertebrae (usually T4-L4) in order to detect vertebral fractures34. Vertebral fractures can then be classified as either mild, moderate or severe using the method described by Genant et al35.
45675640|NCT05752825|Diagnostic Test|Bone microindentation|Using the OsteoProbe®, we will by microindentation measure the bone material strength index (BMSi), an in vivo surrogate measure of the fracture resistance of the cortical bone in the tibia. The participant is placed in a supine position with the examined leg rotated slightly outward. After identifying the site of interest, located midway between the medial tibial plateau and the medial malleolus, disinfectant is applied to the skin of the tibia being examined. Finally, under local anesthesia and fully sterile conditions, a test probe is inserted through the skin and onto the midshaft of the tibia, and the fracture resistance of the bone tissue is measured.
45835148|NCT01890096|Radiation|HDR 2 Fraction|High dose-rate brachytherapy using real-time intra-operative transrectal ultrasound guidance. Patients will receive 27 Gy as a minimal Clinical Target Volume (CTV) dose delivered as two fractions of 13.5 Gy 7-13 days apart. The CTV is the ultrasound defined prostate with a 0-2 mm margin.
45457710|NCT02306746|Dietary Supplement|TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL
45457711|NCT01232413|Drug|Placebo|Oral
45835149|NCT01890096|Radiation|HDR 1 Fraction|High Dose-Rate Brachytherapy delivered in same manner as Arm 1, but to a prescribed CTV minimal dose of 19 Gy in a single fraction
45835150|NCT01459380|Biological|Bevacizumab|Given IV
45835151|NCT01459380|Drug|Carboplatin|Given IV
45999421|NCT05452642|Behavioral|DASH diet|Participants in this arm will be taught a DASH diet plus psychological skills to support dietary adherence.
45999422|NCT05452642|Behavioral|Very low-carbohydrate diet|Participants in this arm will be taught a very low-carbohydrate diet plus psychological skills to support dietary adherence.
45999423|NCT02930876|Behavioral|Resistance training|Set of muscle strengthening exercises of all major muscle groups, guided by physiotherapists.
45457712|NCT01232413|Drug|ASP1941|Oral
45457713|NCT01232413|Drug|Moxifloxacin|Oral
45457714|NCT02303782|Drug|OTX015|
45457715|NCT02303782|Drug|Vidaza (azacitidine)|
45457716|NCT01233505|Drug|veliparib|Given PO
45457717|NCT01233505|Drug|capecitabine|Given PO
45457718|NCT01233505|Drug|oxaliplatin|Given IV
45457719|NCT01233505|Other|pharmacological study|Correlative studies
45457720|NCT01233505|Other|laboratory biomarker analysis|Correlative studies
45457721|NCT02311504|Device|OCT examination|
45457722|NCT01138033|Drug|GSK2256098|GSK2256098 is a potent focal adhesion kinase inhibitor that will be administered orally as 20, 100 or 250 mg capsules. The starting dose in Part 1 is 80 mg twice daily. The dose will continue to be increased until the maximum tolerated dose is identified.
45457723|NCT02303860|Drug|ORM-12741 MR A|Modified release formulation of ORM-12741
45457724|NCT02303860|Drug|ORM-12741 MR B|Modified release formulation of ORM-12741
45457725|NCT02303860|Drug|ORM-12741 IR|Immediately release formulation of ORM-12741
45457726|NCT03917563|Device|WATCHMAN LAA occluder|WATCHMAN LAA occluder
45457727|NCT03134222|Drug|Lanraplenib|30 mg tablets administered orally once daily with or without food
45457728|NCT03134222|Drug|Filgotinib|200 mg tablets administered orally once daily with or without food
45457729|NCT03134222|Drug|Lanraplenib placebo|Tablets administered orally once daily with or without food
45457730|NCT03134222|Drug|Filgotinib placebo|Tablets administered orally once daily with or without food
45457731|NCT04463602|Drug|Desidustat|100 mg once daily
45457732|NCT04463602|Other|Standard of Care|Standard of care as per local authority
45835152|NCT01459380|Other|Laboratory Biomarker Analysis|Correlative studies
45999424|NCT05329311|Procedure|ERATS protocol applied|Inflammatory parameters (such as; C-reactive protein (CRP), white blood cell count, neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), lymphocyte/monocytes ratio (LMR) of the operated patients by applying the ERATS protocol will be investigated.
46086590|NCT02717468|Device|Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the radial artery (Pulsioflex®).|
46086591|NCT02717780|Drug|Fentanyl and sevoflurane|
45675641|NCT05752825|Diagnostic Test|Hand grip and leg extension strength|Hand grip strength will be assessed using a digital hand dynamometer as a measure of peripheral muscle strength. Leg extensor strength will be examined using the peak torque measured by an isometric dynamometer mounted on a fixed chair. 3 attempts will be given for each method, and the maximum value recorded.
45999425|NCT05329311|Procedure|ERATS protocol not applied|Inflammatory parameters (such as; C-reactive protein (CRP), white blood cell count, neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), lymphocyte/monocytes ratio (LMR) of the operated patients by applying without the ERATS protocol will be investigated.
45999426|NCT01186978|Radiation|Radiation Therapy|1.5-2 Gy per fraction to a total dose of 19.8-20 Gy with radiation given 5 days/week
45999427|NCT04506905|Drug|MK-8189|MK-8189, oral, 4 mg and/or 12 mg tablets for a total daily dose of 8, 16 or 24 mg QD according to randomization
45999428|NCT04506905|Drug|Placebo|Oral tablets of dose-matched placebo to MK-8189 according to randomization
46086592|NCT02717780|Drug|Remifentanil and desflurane|
45999429|NCT05326230|Device|Paradise™ (PRDS-001) Renal Denervation Ultrasound System|Following renal angiogram according to standard procedures, subjects remain blinded and are randomized to treatment with renal denervation or sham control
46086593|NCT02717390|Behavioral|Bright By Three (BB3)|The purpose of the BB3 intervention (annual home visit, written materials, and BB3 mobile application 'app') is to increase parental talking, reading, playing, and praise (TRPP) behaviors and improves children's social-emotional and language development at ages 2, 3, and 4 years.
46086594|NCT02717390|Behavioral|Texts for Child Safety (TCS)|The purpose of the injury prevention arm is to reduce the prevalence of safety hazards in the home and car environments, decrease the number of self-reported and medically-attended injuries among children, and increase caregiver's self-reported safety behaviors and knowledge of child safety. The Investigators will compare the results of our tailored child safety intervention (Texts for Child Safety [TCS]) among participants in the injury prevention arm with those randomized to the BB3 arm.
46086595|NCT02724254|Drug|AP611074 5% gel|
45457733|NCT01230619|Drug|RV568|RV568 400 ug administered as nasal drops twice daily on Day 1, RV568 800 ug administered as nasal drops once daily on Day 2
45457734|NCT01230619|Drug|Placebo|Placebo administered as nasal drops twice daily on Day 1, Placebo administered as nasal drops once daily on Day 2
45457735|NCT03917719|Drug|Edasalonexent|100 mg/kg/day
45457736|NCT03507322|Other|Ultrasound texturization|Along several visits to the clinic, the patients will be subjected to 2D/3D ultrasound scanning.
45675642|NCT05752825|Diagnostic Test|Timed up-and-go test|The TUG test is a functional test frequently used to assess balance in older individuals and is performed by measuring the time it takes for an individual to go from sitting to standing position, walk 3 meters, turn around and return to sitting position. A TUG score of >13,5 seconds is associated with an increased risk of falls.
45835153|NCT01459380|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
45835154|NCT01459380|Drug|Veliparib|Given PO
45999430|NCT05326230|Device|Renal Angiogram|Following renal angiogram according to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure
45999431|NCT01186939|Drug|Azacitidine|Azacitidine was injected subcutaneously (SC) for 7 days. The 7-day dosing was repeated every 28 days with dose adjustments allowed. The initial dose during the primary study was 75mg/m^2/day.
45999432|NCT04318483|Other|survey|parents' telephone interview to collect medical history
45999433|NCT04316338|Device|Intermittent theta-burst stimulation (iTBS)|Non-invasive brain stimulation technique
45999434|NCT00554112|Behavioral|Exercise|Exercise
45999435|NCT05463172|Other|abdominal strengthening exercises|abdominal strengthening exercises
45999436|NCT05463172|Other|pelvic floor muscles strengthening exercises|to strengthen pelvic floor muscles
45999437|NCT05461105|Drug|rencofilstat, 75 mg|1 softgel capsule
45999438|NCT05461105|Drug|rencofilstat, 150mg|2 softgel capsules
45999439|NCT05461105|Drug|rencofilstat, 225 mg|3 softgel capsules
46086596|NCT02724254|Drug|AP611074 matching placebo|
46086597|NCT02724176|Drug|carbon nanoparticles|0.1 ml of CN suspension was injected per spot into the tissue surrounding the tumor using a skin test syringe. Two or three randomly selected spots were injected slowly for each tumor, and the total amount injected was no more than 0.5 mL per lobe.
45457737|NCT04925180|Drug|Cyproterone Acetate (Androcur, BAY94-8367)|As prescribed by the treating physician
45835155|NCT04346004|Drug|Normal saline|"Participants in Control group are administered IV 100cc normal saline & IM normal saline (1cc) 1 day before surgery."
45835156|NCT04346004|Drug|Iron isomaltoside|"Participants in Iron isomaltoside group are administered IV Iron maltoside diluted in 100 cc normal saline (20mg/kg, maximum dose: 1g) & IM Vitamin B12 (1mg) 1 day before surgery."
45835157|NCT02680314|Drug|Misoprostol|Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.
46086598|NCT02724098|Drug|Dexmedetomidine|
46086599|NCT04189328|Procedure|dental implant placement using magnifying loupes and microsurgical instruments|microsurgical dental implant placement employin splt finger technique by Misch
46086600|NCT04189328|Procedure|macrosurgical dental implant placement|macrosurgical placement of single dental implants
45999440|NCT04447040|Drug|Acetaminophen/naproxen sodium Dose A|Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
45999441|NCT04447040|Drug|Acetaminophen/naproxen sodium Dose B|Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.
45999442|NCT04447040|Drug|Acetaminophen/naproxen sodium Dose C|Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.
45999443|NCT04447040|Drug|Acetaminophen/naproxen sodium Dose D|Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.
45999444|NCT04447040|Drug|Acetaminophen/naproxen sodium Dose E|Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.
45457738|NCT03509428|Behavioral|SRETP|SRETP will involve short periods of exercise at a high intensity interspersed with short periods of exercise at a moderate intensity (aerobic interval training). We will also include resistance training in each session. Exercise intensities during the interval exercise-training program are specific to each patient and derived from CPET. Moderate intensity exercise is below the anaerobic threshold (AT). Patients will exercise at 80% of oxygen uptake (VO2) obtained at the anaerobic threshold (80%AT) for moderate intensity exercise - 3 minutes. Severe exercise intensity is recognised as 50% of the difference between the VO2 AT and VO2 Peak (50%∆) - 2 minutes.
45999445|NCT04447040|Drug|Placebo|Placebo tablets administered as a single two-tablet dose.
45999446|NCT05321043|Other|Vitamin B2 labeling|Using medical non-toxic fluorescent agents, VB2 solution, to mark the patient's hands before endoscopy examination.
45999447|NCT02930642|Behavioral|Mindful Eating|Mindful eating is a behavioral strategy in which food is eaten slowly, with deliberate and focused attention on the features of food, the process of eating, and physiological responses to eating. Objectivity is key.
45457739|NCT03509428|Behavioral|Psychological support|Support sessions will be patient-centred, giving the patient an opportunity to raise any issues/concerns they are having, this may include (but will not be limited to) ways of coping with their reactions to cancer, family and relationship issues, exploring personal issues and dealing with practical issues. Patients will have access to other resources available at the cancer centres including but not restricted to further information about their condition and how to access financial support. These processes reflect the best practice currently being delivered by cancer support centre staff in the Wessex region. Any patient deemed at risk (i.e. from suicidal ideation or self harm) will be reported to their GP, followed up by a letter.
45999448|NCT02930642|Other|Nutrition DVD|Participants watch a 50 minute video on nutrition to control for verbal aspects of food.
45457740|NCT01133509|Drug|Gardasil|0.5ml IM for three doses, Second and third dose to be given at 2 months and 6 months
45999449|NCT03455205|Drug|shenqifuzheng|500ml shenqifuzheng daily（at day 1-7and day22-28）through intravenous infusion.
45999450|NCT03455205|Drug|0.9%sodium chloride|500ml sodium chloride（0.9%）daily（at day 1-7 and day22-28）through intravenous infusion.
45457741|NCT02306902|Drug|fenofibrate|130mg, Capsules
45457742|NCT02306902|Drug|ANTARA® (fenofibrate)|130mg, Capsules
45457743|NCT01136161|Biological|RUTI|dose:5 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
45457744|NCT01136161|Biological|RUTI|dose:25 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
45457745|NCT01136161|Biological|RUTI|dose:50 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
45675643|NCT05752825|Diagnostic Test|Stabilometry|Postural control will be assessed by means of a force platform that registers Center of Pressure (CoP) as a measure of postural stability. Measurements are performed under a variety of conditions, including eyes open/closed and on different surfaces. From the CoP measurements, parameters such as CoP range and CoP velocity in both antero-posterior and medial-lateral directions will be calculated using specialized software.
45675644|NCT05752825|Diagnostic Test|Nerve conduction test|To fully examine all components of balance, nerve conduction will be tested using a handheld device called NC-stat DPN-Check in order to assess any peripheral neuropathy.
45835158|NCT05586672|Device|EEG-HR|Passation EEG-HR
45835159|NCT05586672|Diagnostic Test|ADI-R|Passation of ADI-R scale
45835160|NCT05586672|Diagnostic Test|ADOS-2|Passation of ADOS-2 scale
45835161|NCT05586672|Diagnostic Test|IDE|Passation of IDE scale
46086601|NCT02723942|Biological|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen.
46086602|NCT04138316|Drug|Candesartan|Treatment with Candesartan
45835162|NCT05586672|Diagnostic Test|MSEL|Passation of MSEL scale
45835163|NCT05586672|Diagnostic Test|Dunn|Passation of Dunn scale
46086603|NCT05291390|Drug|Pyronaridine Tetraphosphate|Via oral capsules.
46086604|NCT05015972|Biological|CTA30X UCAR-T injection|CTA30X UCAR-T injection is an allogeneic CAR-Ttargeted CD19 . A single infusion of CART cells will be administered intravenously.
46086605|NCT02541968|Behavioral|Cognitive-behavioral therapy (face-to-face)|
46086606|NCT02541968|Behavioral|Internet-based Cognitive-behavioral therapy|With therapist support
46086607|NCT02541968|Behavioral|Internet-based Cognitive-behavioral therapy without therapist support|
45835164|NCT02707692|Biological|Fluarix|Intramuscular injection with Fluarix® .
45835165|NCT02707692|Biological|Pneumovax|Intramuscular injection with Pneumovax.
45835166|NCT02707692|Other|Placebo|Intramuscular injection with sterile saline (placebo).
45835167|NCT02706678|Drug|Tacrolimus sustained-release capsule|Oral
46086608|NCT04189484|Biological|Evolocumab|Evolocumab 21 mg administered SC
45999451|NCT02930954|Drug|Gefitinib|Patients received Gefitinib 250mg Qd orally until disease progression, intolerable toxicity or death.
45999452|NCT02930954|Drug|pemetrexed or gemcitabine plus carboplatin,|doublet chemotherapy with pemetrexed or gemcitabine plus carboplatin per 3 weeks
46086609|NCT04189484|Biological|Evolocumab|Evolocumab 35 mg administered SC
46086610|NCT04189484|Biological|Evolocumab|Evolocumab 70 mg administered SC
46086611|NCT04189484|Biological|Evolocumab|Evolocumab 140 mg administered SC
46086612|NCT04189484|Biological|Alirocumab|Alirocumab 15 mg administered SC
46086613|NCT04189484|Biological|Alirocumab|Alirocumab 25 mg administered SC
45457746|NCT01136161|Biological|RUTI Matching Placebo|Placebo of the vaccine RUTI; given subcutaneously twice, on days 28 and 56.
45457747|NCT01350518|Dietary Supplement|Benefiber|"Benefiber® powder will be used as our dietary supplement intervention. Benefiber® powder contains wheat dextrin, a 100% natural fiber. Participants in the intervention arm will receive 3 supplement packets to be consumed per day.~Each active dietary supplement packet contains 8 grams of Benefiber® powder and 3 grams of TRUE® lemon flavoring, a 100% natural with no artificial ingredients or sweeteners, preservatives, sodium or gluten."
46086614|NCT04189484|Biological|Alirocumab|Alirocumab 50 mg administered SC
45457748|NCT01350518|Dietary Supplement|TrueLemon|Each placebo dietary supplement packet contains 8 grams of Splenda and 3 grams of TRUE® Lemon sweetener. Each packet is designed to be added to 8 oz of fluid. The three packets should be consumed each day in a total of 24 fluid ounces.
45457749|NCT02306980|Other|Colostrum|Mother's own colostrum (0.2 ml) will be administered into the mouth of the infant every 2 hours for 48 hours.
45457750|NCT01358786|Procedure|quilting suture|"quilting sutures and drains~quilting sutures but no drains"
45457751|NCT01230697|Drug|Sorafenib|Sorafenib 800mg/die oral
45457752|NCT03432364|Genetic|ST-400 Investigational product|Single dose of ST-400 following chemotherapy conditioning with busulfan
45457753|NCT01361984|Drug|Nebulized arformoterol|Arformoterol tartrate 15 µg/2ml (Brovana) nebulized via PARI-LC Plus® nebulizer with a mouthpiece, connected to a PRONEB® Ultra compressor. The nebulization time is ~9 minutes
45999453|NCT02930954|Drug|bevacizumab|bevacizumab 7.5mg/kg intravenously per 3 weeks
45999454|NCT05290467|Behavioral|Online antenatal care|ANC will be provided by obstetricians, and health education will be provided online by midwives. Obstetricians will schedule appointments for the succeeding contacts/visits of the participants. CSOG-recommended prenatal care services will be provided to both the experimental and control groups, using different delivery strategies. Participants in the control group will be scheduled for 12 routine ANC visits, and those in the experimental group will be scheduled for 9 outpatient visits and additional 3 times of services through an online medical service platform. The obstetricians/midwives will train pregnant women how to monitor and record their weight, heart rate, blood pressure, urinary protein, blood glucose, and fetal movement at home. Messages, audio and video chats will be used at online ANC contacts to ensure service quality and accuracy of monitoring the results.
46086615|NCT04189484|Biological|Alirocumab|Alirocumab 100 mg administered SC
46086616|NCT04189484|Biological|Placebo|Placebo administered SC
46086617|NCT02715440|Drug|Immediate intervention|Gradual withdrawal of benzodiazepines or related drugs
46086618|NCT02716844|Other|Exercise|Clinical Pilates exercise were given for 6 weeks, 3 days in a week
46086619|NCT02723552|Behavioral|Aerobic Exercise|40 minute aerobic exercise sessions 3x/week.
46086620|NCT02715596|Dietary Supplement|EPA supplementation|2.7 g EPA supplementation in a 15 cc emulsion stick-pack
46086621|NCT02715596|Other|Placebo|placebo in 15 cc emulsion stick-pack
46086622|NCT04162964|Behavioral|Chair Yoga|8-week dyadic chair yoga program for one hour per week. Chair yoga is an effective way to offer modified yoga postures and relaxation techniques to individuals with limited mobility and/or advanced age for whom mat-based classes may not be accessible. The weekly yoga classes will be lead by a certified instructor and will include 4-10 participants (or 2-5 patient-caregiver dyads).
46086623|NCT02716922|Procedure|Cervical cerclage|Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix Cerclage type: McDonald Cerclage Suture: Permanent monofilament Pericerclage antibiotics: none Pericerclage tocolytics: none Bed rest: not recommended (in both groups)
46086624|NCT00636740|Drug|Zoledronic Acid 20mg Tablets|Oral enteric coated tablets, 20mg, weekly, 8 weeks
45457754|NCT01361984|Drug|Salmeterol|Salmeterol 50 mcg (Serevent) via Diskus dry powder inhaler
45457755|NCT02311660|Device|Vagus Nerve Stimulation Device|Cyberonics VNS System
45835168|NCT02705196|Genetic|delolimogene mupadenorepvec|oncolytic virus encoding TMZ-CD40L and 4-1BBL
45835169|NCT02705196|Drug|gemcitabine|chemotherapy
45835170|NCT02705196|Drug|nab-paclitaxel|chemotherapy
46086625|NCT00636740|Drug|Zoledronic Acid|Zoledronic Acid infusion, 4mg, every 4 weeks for 8 weeks
45457756|NCT01136239|Drug|N-acetycysteine (600mg twice daily)|N-acetycysteine (600mg twice daily) for one year
45457757|NCT01136239|Drug|Placebo|Placebo (600mg twice daily)
45835171|NCT02705196|Biological|atezolizumab|anti-PD-L1 antibody
45835172|NCT02703948|Device|Restylane Silk with Lidocaine|
45835173|NCT02697006|Device|i-cor Synchronized Cardiac Assist Device|The i-cor Synchronized Cardiac Assist Device delivers pulsatile cardiac assist synchronized to the ECG during diastole and provides enhanced oxygenation through a membrane oxygenator.
45835174|NCT02677038|Drug|Olaparib|Given PO
45999455|NCT04151433|Procedure|Comparison between 2 different laparoscopic techniques in conservative surgical treatment of endometriomas (both arms are existing and accepted surgical strategies).|cf. different arms
46086626|NCT00636740|Drug|Zoledronic Acid 20mg Tablets|Oral enteric coated tablets, 20mg, once a day for 4 consecutive days during week 1, weekly for weeks 5, 6, 7, 8
46086627|NCT01002014|Procedure|Nipple Sparing Mastectomy|Skin sparing mastectomy with preservation of the nipple areolar complex
46086628|NCT02716688|Drug|S-1|S-1 will be administered orally twice daily for 14 days at a dose of 70 mg/m2/day with concurrent radiotherapy for 2 cycles. Patients who showed a response greater than that of stable disease underwent additional S-1 until disease progression, serious adverse events, or patient refusal up to four cycles.
46086629|NCT02716688|Radiation|radiotherapy|Radiotherapy wiil be delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy.
45457758|NCT02303938|Behavioral|physical exercise|Patients in the intervention group will undergo a 6-month home-based exercise intervention. Patients will exercise (e.g., running, biking, swimming) three times per week for 6 months. Session duration will vary between 20 minutes and 45 minutes.
45675645|NCT05752825|Diagnostic Test|Visual acuity test|Visual acuity will be tested using an automated refractometer (KR-800S Auto-kerato-refractometer, Topcon Healthcare, The Netherlands).
45675646|NCT05751993|Behavioral|ADAPT|The intervention is testing the feasibility of a reinforcement learning tool to pull in participants' behavioral data (calories, activity, and weight) and use this data along with participants' past behavioral goal achievements to deliver the type of message that should be most effective for a given participant at a given time. At each decision point (early morning, morning, midday, and evening on a daily basis), the system evaluates which intervention options a participant is eligible to receive, and randomly chooses one intervention option from that list. Then the participant is randomly assigned to either receive or not receive that intervention message (with a 50-50 probability).
45675647|NCT05745701|Drug|PF-07081532|Oral Tablet
45675648|NCT05745701|Device|Cyclosporine|Oral Solution
45999456|NCT02930759|Drug|BAY987516|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z46-096)
45999457|NCT03457649|Biological|ARGX-113|
45999458|NCT03457649|Biological|Placebo|
45999459|NCT04141917|Combination Product|Point-of-care molecular testing and treatment of influenza|Eligible individuals will be tested on site with a point-of-care molecular influenza test and, if positive, offered antiviral treatment with baloxavir for those aged ≥12 years, or oseltamivir for those aged <12 years; pregnant; breastfeeding; liver disease; or are immunosuppressed. Follow-up nasal swabs and symptom diaries will be collected from participants 2 or 3 days after receiving the antiviral, and again 5, 6, or 7 days after receiving.
45999460|NCT02930525|Other|High Flow nasal cannula|Application of humidified heated ambient air with flow rates adapted to body weight of respective subject. Incremental increase of fraction of inspired oxygen as appropriate to maintain oxygenation (defined as transcutaneous pulse oximetry above 93%).
45999461|NCT02930525|Other|Standard respiratory care|Standard respiratory care. Oxygen delivered via low flow nasal cannula, increase of fractions of inspired oxygen to maintain desired oxygenation as defined per protocol.
45999462|NCT04117659|Other|withdrawal of oral medication (phosphodiesterase-5 inhibitor) in pretreated patients|discontinuation of the oral medication with a phosphodiesterase-5 inhibitor
45999463|NCT02930798|Drug|BAY987516|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code:Z46-116)"
45999464|NCT05289492|Drug|EOS884448|EOS884448 will be administered in arm A,B and C
45999465|NCT05289492|Drug|Iberdomide|Iberdomide will be administered in arm B and C
45999466|NCT05289492|Drug|Dexamethasone|Dexamethasone will be administered in arm C
46086630|NCT02716766|Drug|Sorafenib|PO
46086631|NCT02716766|Drug|Capecitabine|PO
46086632|NCT02716766|Drug|Oxaliplatin|IV
46086633|NCT02723240|Drug|NUC-3373|
46086634|NCT02716610|Drug|INH 69 U (low)|inhaled human insulin
46086635|NCT02716610|Drug|INH 69 U (high)|inhaled human insulin
46086636|NCT02716610|Drug|INH 139 U|inhaled human insulin
46086637|NCT02716610|Drug|INH 208 U|inhaled human insulin
45999467|NCT02930408|Procedure|electrocardiogram|
45999468|NCT02930408|Procedure|Echocardiography|
45999469|NCT04116606|Drug|Active JNJ-54175446|JNJ-54175446 is a novel, potent, selective, and brain-penetrant antagonist of the adenosine triphosphate (ATP)-gated P2X7 channel.
45999470|NCT04116606|Drug|Placebo|Matching placebo containing the same excipients
46002434|NCT02901574|Device|Sham|2 mA of Anodal tDCS or Cathodal tDCS is induced between two 5cm X 5cn saline soaked sponges where one sponge (anode in group Anode and cathode in group Cathode) is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
45999471|NCT02930915|Device|Hand-held laser scanner|The laser scanning is non-intrusive and the scan can be completed in approximately 15 minutes. The scanning process involves the patient sitting in a chair while a researcher performs the scan. As a precautionary measure we require the patient to wear an eye mask as although the scanner is CE marked and completely safe . The process can be completed in stages (e.g. 3 x 5 minutes) with a break of 2-3 minutes between each session. The laser scanner will then be moved around the patient to obtain a set of 3D points forming the surface of the patient's head. We believe the laser scanning to be the most accurate way to acquire the surface of the patient's face / head and we wish to compare the models we obtain with surfaces rendered from the patient's CT data set.
45999472|NCT02930447|Device|Autologous glue|Patients will undergo abdominoplasty according to the procedure routinely used in the Department of Plastic, Reconstructive and Aesthetic Surgery of HUG. At the end of the procedure, patients assigned to the experimental group will be additionally treated with an application of autologous glue prepared with RegenKit®-Surgery in the undermining region space between fascia and skin, just before closure of the surgical wound.
45999473|NCT04679571|Biological|Albumin|Patients with serum albumin <3 g/L with recurrent ascites - Will receive 20 % albumin at 60 grams/week until target serum albumin of 3.0 g/L is achieved following this patients would get 40 grams of albumin every week until ascites resolution or serum albumin >3.5 g/L. Patients who achieve this target will continue with 20 gm/week until patient has complete resolution of ascites and serum albumin >3.5 gm/L this patients would receive albumin 20 gms once every 2 weeks.
45675649|NCT05745701|Drug|Itraconazole|Oral Capsule
45675650|NCT05742594|Drug|Lazertinib|Lazertinib will be administered orally.
45675651|NCT05742334|Procedure|Robot-Assisted Radical Prostatectomy with MLG-COMPLETE Allograft Implantation|The intervention will be administered on an inpatient basis. Participants receiving MLG-Complete™ will have it placed around the neurovascular bundle. Placement of the graft should not take more than 5 minutes, therefore, there should be minimal impact to overall surgical time.
45675652|NCT05742334|Device|MLG-COMPLETE Allograft Implantation|The MLG-Complete™ allograft will be placed on each neurovascular bundle (NVB) bilaterally as shown on the above picture after excision of the prostate prior to completing the urethrovesical anastomosis.
45675653|NCT05741918|Diagnostic Test|Fick's method|Cardiac output measurement by Fick method
45675654|NCT05741918|Diagnostic Test|Echocardiography|Cardiac output measurement by echocardiography
45675655|NCT05741086|Drug|Evolocumab|evolocumab (140 mg every 2 weeks)
45675656|NCT05741086|Drug|Atorvastatin|Atorvastatin 20-40mg
45675657|NCT05741034|Device|JUVÉDERM® VOLITE™|Injection, subdermal and/or intradermal
46086638|NCT02716610|Drug|LIS 18 U|subcutaneous insulin lispro
45675658|NCT05741034|Other|Control|No-treatment control
45675659|NCT05731388|Diagnostic Test|Push enteroscopy|A push enteroscopy using a pediatric colonoscope will be performed along with capsule endoscopy. These are part of the standard of care.
45675662|NCT05722262|Drug|K-001|K-877-ER and CSG452 combination tablet
45675663|NCT05722262|Drug|K-877-ER|K-877-ER tablet
45675664|NCT05722262|Drug|CSG452|CSG452 tablet
45835175|NCT02666742|Drug|DOAC|DOAC is a blood thinning drug, also called direct oral anticoagulant. These group of drugs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of stroke prophylaxis in atrial fibrillation and deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.
45835176|NCT02666742|Drug|Aspirin|Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.
45835177|NCT04390776|Drug|PF-06651600|PF-06651600 100 milligrams (mg) will be provided as Tablets and Capsules.
45675665|NCT05715528|Drug|Obeldesivir|Tablet administered orally without regard to food.
45675666|NCT05715528|Drug|Obeldesivir Placebo|Tablet administered orally without regard to food.
45675667|NCT05714891|Drug|JDQ443|Dose will be assigned at enrollment
45675668|NCT05714059|Device|Insulin Pump with Continuous Glucose Monitoring|MiniMed™ 780G insulin pump in combination with the DS5 CGM
45675669|NCT05713994|Procedure|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
45675670|NCT05713994|Drug|Bevacizumab plus Atezolizumab|Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
45835178|NCT01893762|Biological|Aerobic exercise|Aerobic exercise: 2x30 min on an indoor rowing machine at 75% of Maximum heart rate
45835179|NCT01893762|Biological|Anaerobic exercise|Anaerobic exercise: 3x1000m maximum effort, on an indoor rowing machine
45675671|NCT05713994|Drug|Bevacizumab Biosimilar IBI305 plus sintilimab|Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
45675672|NCT05713994|Drug|Lenvatinib|8mg; p.o.; q.d.
45675673|NCT05713994|Drug|Sorafenib|400mg; p.o. bid
45675674|NCT05713994|Drug|Donafenib|200mg; p.o. bid
45675675|NCT05713994|Drug|Regorafenib|160 mg; p.o.; q.d.
45999474|NCT04679571|Drug|Standard Medical Treatment|"Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.~Follow up: 2 week, 4 weeks then every 3 months for 1 year."
45999475|NCT02930369|Procedure|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with idiopathic macular hole (IMH)
45999476|NCT02930486|Device|ZipTight suture endobutton|Zimmer Biomet ZipTight suture endobutton
45999477|NCT02930486|Device|Tricortical 3.5 mm syndesmotic screw|Depuy Synthes 3.5 mm screw
45999478|NCT04679415|Drug|hzVSF-v13|Dosage form: hzVSF-v13 40 mg/mL in a 5 mL vial Frequency: Dose at Day 1, 3, 7
45999479|NCT04679415|Drug|Placebo (Normal saline solution)|Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7
45999480|NCT02930330|Behavioral|INT|"5 min warm-up (40% Pmax*)~30 min high intensity interval training (1 min 100% Pmax, 1 min 20% Pmax, in alternating sequence)~10 min cool-down (30% Pmax)~Pmax*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
45999481|NCT02930330|Behavioral|CONT|"5 min warm-up (40% Pmax*)~30 min moderate intensity continuous training (60% Pmax)~10 min cool-down (30% Pmax)~Pmax*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
45999482|NCT05280600|Other|Not applicable - non-interventional study|Not applicable - non-interventional study
45999483|NCT02929940|Other|No intervention|No Intervention, observational
45999484|NCT05278260|Dietary Supplement|Hydrogen tablets|Participants will drink up to 1000 ml (34 fl. oz.) of water daily supplemented with a tablet that releases molecular hydrogen, for the duration of the radiation therapy
45999485|NCT05278260|Dietary Supplement|Control|Participants will drink up to 1000 ml (34 fl. oz.) of water daily supplemented with a tablet that does not release any molecular hydrogen, for the duration of the radiation therapy
45999486|NCT02930057|Drug|Celestone|all of the patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed
45999487|NCT02930057|Procedure|pulsed radiofrequency treatment|all of the patients who will participate in the study will receive pulsed radiofrequency treatment adjacent to lumbosacral dorsal root ganglion(s).
45999488|NCT02930057|Drug|Control|all of the patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
45999489|NCT05238363|Drug|HLX07|HLX07 1500mg ivgtt Q3W
45999490|NCT02930135|Procedure|Indirect pulp capping|Removal of superficial caries in young permanent molars that my expose tooth pulp if totally removed leaving deep carious layers to be sealed inside with two step bonding system and bulk fill composite as a final restoration
45999491|NCT04080492|Other|QOL Survey|The Cardiac Quality of Life (QOL) survey measures health status in five domains: global, physical, emotional, social, and spiritual health. It also includes questions that assess self-efficacy and resilience. The global section asks about your overall quality of life and satisfaction with health. The physical section asks about symptoms and difficulty performing day-to-day tasks. The emotional section asks about depression, anxiety, and stress. The social section asks about social support and relationships. The spiritual section asks about the spiritual outlook on the burden of heart disease. Responses on a 5-level scale.
45999492|NCT04049721|Procedure|HBO|2.5 atmospheres absolute (ATA) with 90 minutes of hyperbaric oxygen will be given over the course of two weeks.
45999493|NCT04049721|Other|Standard of Care|20 patients will be included in the retrospective review arm. The retrospective chart review will be performed to determine the outcomes of patients with crush injuries treated at NYU Winthrop Hospital without HBO from 1/1/2012-12/31/2018.
45999494|NCT04038294|Dietary Supplement|ISOlution protein supplement|EXPERIMENTAL ARM: Protein supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home.
45999495|NCT04038294|Dietary Supplement|Placebo Supplement|PLACEBO COMPARATOR ARM: Placebo supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home
45999496|NCT02930252|Device|Niti-S Biliary ComVi Stent|Endoscopic placement of biliary fully covered metal stents
45999497|NCT02930252|Device|Niti-S stent (D type)|Endoscopic placement of biliary uncovered metal stent
45675676|NCT05713994|Drug|apatinib plus camrelizumab|Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
45999498|NCT04017000|Diagnostic Test|Bladder Shape Test|Capturing images of bladder under natural filling conditions images are analysed at a later date for shape change.
45999499|NCT04017000|Other|Calibration images|Capturing images of bladder under artificial filling conditions during Urodynamic assessment images are analysed at a later date to inform shape change technology.
45999500|NCT04007406|Drug|DP13|DP13 systemic administration
45999501|NCT02929901|Dietary Supplement|caffeine and chlorogenic acid|caffeine plus chlorogenic acid
45835180|NCT02694666|Other|Controlled whole-body vibration training|The intervention is an 8-week program
45999502|NCT02929901|Dietary Supplement|caffeine|caffeine plus placebo
45999503|NCT02929901|Dietary Supplement|chlorogenic acid|chlorogenic acid plus placebo
45999504|NCT02929901|Dietary Supplement|placebo|placebo plus placebo
45675677|NCT05713994|Drug|Anti-PD-1 monoclonal antibody|HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
45675678|NCT05711446|Other|Double Voiding|Participant will be instructed to void twice.
45675679|NCT05711446|Other|Regular Voiding|Participant will void as usual
45999505|NCT05237661|Dietary Supplement|Moon Balance|Moon Balance is a blend of 6 food ingredients
45999506|NCT02929784|Device|Intervention|Device: neuroConn_CE_DC-STIMULATOR. Anodal stimulation to affected hemisphere.
45999507|NCT02929784|Device|Sham|no meaningful stimulation will be given.
45999508|NCT02929706|Genetic|Pre-genotype NUDT15 and optimize azathioprine dosage|Pre-genotype NUDT15 and optimize azathioprine dosage.The wild type use azathioprine(Imuran，2-2.5mg/kg/d),the CT genotype use half dose of azathioprine（Imuran，1-1.5mg/kg/d).The TT genotype avoid use of azathioprine.
45999509|NCT03993132|Drug|Empagliflozin|new users (initiators) of Empagliflozin
45835181|NCT01893684|Behavioral|Exercise|PRO+EX and CARB+EX groups will be prescribed an exercise program with required attendance of 3 nonconsecutive days per week. Exercise sessions will be supervised and conducted by trained graduate students in the Department of Kinesiology. Based on recommended practice, a program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last ~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, ~30 min of resistance training, and finally, a ~10 min of balance and flexibility exercises during the cool-down period. Endurance training activities will vary but will all be weight-bearing.
45999510|NCT03993132|Drug|Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA)|initiators of Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA)
45999511|NCT02929628|Device|Beijing PINS Programming|Using the programming control the Stimulator to change the parameter
46086639|NCT02715362|Drug|TAI-GPC3-CART cells|TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
46086640|NCT02694224|Drug|vismodegib|Smo inhibitor
45999512|NCT00553878|Drug|Dutasteride|dutasteride 0.5mg capsule daily until serum PSA rises to 5ng/ml in the off treatment interval
45999513|NCT04407689|Drug|Interleukin-7|Intramuscular (IM) administration of CYT107 at 3 μg/ kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or
45999514|NCT04407689|Drug|Placebo|Intramuscular (IM) placebo (normal saline) at the same frequency
45999515|NCT05225064|Behavioral|Incentives to be vaccinated|Individuals will be provided with a guaranteed cash payment, entry into a cash lottery, or guaranteed gift of food if they are vaccinated
46086641|NCT02694224|Drug|Paclitaxel|Paclitaxel (80 mg/m2) weekly x 12 doses followed by sequential dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide (600 mg/m2) each 2 weeks x 4 doses with granulocyte macrophage colony stimulating factors (GM-CSF) support
46086642|NCT02694224|Drug|Epirubicin|dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide each 2 weeks x 4 doses with GMCSF after Paclitaxel
46086643|NCT02694224|Drug|Cyclophosphamide|dose dense Cyclophosphamide (600 mg/m2) together with Epirubicin each 2 weeks x 4 doses with GMCSF after Paclitaxel
46086644|NCT00782288|Drug|digitoxin|0.05mg tabs, once daily for 28 days
45999516|NCT05225064|Device|Mask|Individuals are given cloth masks
46086645|NCT00782288|Drug|digitoxin|0.1mg pills, once daily for 28 days.
46086646|NCT00782288|Other|placebo|pill taken once daily for 28 days
46086647|NCT04078178|Dietary Supplement|Niagen|Vitamin B3
45999517|NCT05225064|Behavioral|Encouragement to wear a mask|Individuals who are not wearing masks over their mouth and nose are stopped in public places and encouraged to wear a mask
45999518|NCT05225064|Behavioral|Vaccination made more convenient|Vaccines are conducted at the household-level rather than the village-level
45999519|NCT05225064|Behavioral|Social mobilization campaign to be vaccinated|Village-level social mobilization campaign to be vaccinated
45999520|NCT05222919|Dietary Supplement|Bare performance supplement|dietary supplement
45999521|NCT05222919|Dietary Supplement|Placebo|Placebo
45999522|NCT02929862|Drug|LYC-55716|For Phase 1, increasing doses of oral 55716 given BID for a 28 day cycle. For Phase 2A, the RP2D will be administered to patients for 28 day cycles.
45999523|NCT04381052|Drug|Clazakizumab|Dose is 25mg intravenously over 30 minutes.
45999524|NCT04381052|Other|Placebo|Intravenously administered over 30 minutes.
45999525|NCT03956940|Device|Intplex test|Blood sample at baseline, 15 days, 4-8-16 weeks and then every 12 weeks
45999526|NCT00624325|Drug|interferon alfa-2b|12 MU daily continuously subcutaneous
45999527|NCT00624325|Drug|interferon alfa-2b|9 MU daily continuously subcutaneous
45999528|NCT00624325|Drug|interferon alfa-2b|6 MU daily continuously subcutaneous
46086648|NCT02723318|Behavioral|Financial Coaching|One-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
46086649|NCT02723318|Behavioral|Access to Referrals to Social Services|
46086650|NCT04189094|Drug|Sintilimab|Etoposide and cisplatin (carboplatin) plus Sintilimab induction therapy will be administered for 2 cycles and then thoracic radiotherapy (45 Gy/30 fractions) be administered with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).Sintilimab maintenance therapy will be administered once every 3 week for 13 cycles.
46086651|NCT04189094|Drug|Etoposide|Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
46086652|NCT04189094|Drug|Cisplatin|cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
46086653|NCT04189094|Radiation|radiotherapy|Thoracic radiotherapy (45 Gy/30 fractions) and prophylactic cranial irradiation (25 Gy/10 fractions).
45999529|NCT02929745|Procedure|Skin biopsy|Four 4-5 mm punch biopsies of the skin
45999530|NCT02929745|Procedure|Blood draw|Blood will be drawn to test for HLA-cw6 status
45999531|NCT05204823|Other|Experimental product|Chocolate milk shakes
45999532|NCT05204823|Other|Control product|Glucose
45999533|NCT04322279|Diagnostic Test|Serology|SARS-CoV-2 serology
45999534|NCT04322279|Genetic|Sequencing|Whole exome sequencing
45999535|NCT03934398|Diagnostic Test|Cardiovascular Assessments|Participants will undergo the following cardiovascular assessments: 24-hour blood pressure monitoring, arterial stiffness measurements, endothelial function measurements.
46086654|NCT03984500|Other|Education|SCTaware education (Phase II) will be compared to Ohio's current in-person SCT education (Phase I).
45999536|NCT03934398|Diagnostic Test|Actigraphy|Participants will wear an actigraph device for 7 days to measure participant's activity and sleep.
45999537|NCT03934398|Diagnostic Test|Laboratory assessments|Participants will provide blood and urine samples for laboratory assessments.
45999538|NCT03934398|Diagnostic Test|Emotional/Behavioral Assessments|Participants and parents will fill out questionnaires for emotional/behavioral assessments
45999539|NCT02929550|Other|Well-controlled|Both groups got treatment but well-controlled reached target of LDL-C<1.8 mmol/l
45999540|NCT05200572|Behavioral|Dyadic Life Review (DLR)|DLR will consist of 8 sessions delivered by a trained licensed clinician (i.e, the PI or other trained clinician) via video-conferencing in weekly sessions of 60 minutes. Each session will facilitate a recall of each phase of life: childhood, adolescence, young adulthood, mid-life, earlier later life, and later life. While together, the patient and caregiver will each be asked structured questions to prompt reminiscence of memories from that phase of life.
45999541|NCT02929511|Procedure|Reciprocating single-file system|The device is moving in CW and CCW direction with different angles. It is a single-file endodontic file. The intervention is Reciproc Blue reciprocating single-file system.
45999542|NCT02929511|Procedure|Rotational single-file system.|The device is moving in continuous rotational. It is a single-fie endodontic file.
45999543|NCT02929511|Procedure|Active comparator Protaper multi-file system|
46086655|NCT02715128|Device|Transcranial direct current stimulation (tDCS)|non-invasive electric brain stimulation method
46086656|NCT00611312|Behavioral|Cognitive Training|Intense cognitive training, two consecutive weeks, each weekday, 6 hours/day
46086657|NCT02712944|Drug|Testosterone|Testosterone
46086658|NCT02712944|Drug|Saline|Placebo
46086659|NCT02712866|Drug|Vedolizumab|Administration of intravenous Vedolizumab in inflammatory bowel disease patients
46086660|NCT02693678|Other|Massage|
46086661|NCT02693678|Device|DIathermy|
46086662|NCT02693678|Device|Sham diathermy|
46086663|NCT02693912|Procedure|Bronchoscopy|Bronchoscopy will be implemented under sedation in both groups.
46086664|NCT00600483|Drug|gentamicin-collagen sponge dipped in saline|100-cm2 sponge
46086665|NCT04132232|Diagnostic Test|knowledge of expired maternal carbon monoxide and fetal carboxyhemoglobin levels|Will use the Smokerlyzer® device at each visit and be provided information on exhaled carbon monoxide and fetal carboxyhemoglobin. Risks of adverse perinatal outcomes related to maternal carbon monoxide and fetal carboxyhemoglobin level will be provided.
46086666|NCT02656719|Device|Ultrasound guided percutaneous tracheostomy|Ultrasound guided percutaneous tracheostomy
45675680|NCT05710887|Drug|Nitrous oxide gas for inhalation|Administration of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
45835182|NCT01893684|Behavioral|Higher Protein Diet|PRO diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; ~30% of energy intake) with a ratio of carbohydrate/protein of <1.5 and dietary lipids at ~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams. This amount of lean cooked beef provides an average of ~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). Our dietary prescription to the PRO groups that they add 3 ounces (and perhaps up to 3.5 ounces pending body size) of lean beef daily will provide an additional 25-30 grams of protein. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit.
45999544|NCT03934281|Device|Honey dressing Melectis G|"The protocol includes rinsing the wound with the saline, gently drying the edge of the wound, applying a thin Mélectis®G film to the entire wound surface and covering with a secondary dressing.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended."
46086667|NCT02656719|Device|Bronchoscopy guided percutaneous tracheostomy|Bronchoscopy guided percutaneous tracheostomy
46086668|NCT00649857|Drug|Cetirizine HCl Tablets 10 mg|10mg, single dose fed
46086669|NCT00649857|Drug|Zyrtec® 10 mg|10mg, single dose fed
46086670|NCT04856618|Biological|Massive Transfusion of Allogeneic Blood|Massive Transfusion of Allogeneic Blood, > pRBCs
46086671|NCT02656407|Device|Ultrasound device|Ultrasensitive Doppler acquisition obtained with the Aixplorer ultrasound device
46086672|NCT00611390|Dietary Supplement|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the larynx.
46086673|NCT00611390|Dietary Supplement|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the larynx.
46086674|NCT04167735|Device|Hearing Aid without Reverberation Canceller (RevC).|Each participant will be fitted with the 2 different Sound Changing principles on the same hearing aid, saved to 2 manual programs (ensures exact same hearing loss compensation for each intervention). Reverberation Canceller principle is a sound processing algorithm to remove reverberation from a speech signal to improve the speech intelligibility and comfort. The active comparator condition is without Reverberation Canceller principle enabled.
45675681|NCT05710887|Drug|Placebo|Administration of the placebo (oxygen-air mixture [FiO2 ≈0.3]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
45999545|NCT03934281|Device|HAS recommendation dressing|"Patients included in the standard arm will receive the best available dressing according to the HAS recommendations.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended."
45999546|NCT04689893|Drug|68Ga-Dotatate|68Ga-Dotatate was injected into the patients before the PET/CT scans
45675682|NCT05707351|Biological|Adynovate|Adynovate will be injected intravenously using an appropriately sized syringe as a bolus infusion over a period of less than or equal to (<=) 5 minutes (maximum infusion rate, 10 milliliters per minute [mL/min]).
45675683|NCT05699044|Diagnostic Test|Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)|"Bloodtest: Troponin I, NT-pro-BNP, electrolyte status, renal function, kampda/lambda free chain + ratio, M-komponent.~DPD-scintigraphy. (Echocardiography)"
45675684|NCT05697627|Device|Computerized cognitive training (CCT) using EndeavorRx|"The EndeavorRx video game is a digital therapeutic designed to improve attention and related cognitive control processes by training interference management.~~25 minutes of EndeavorRx video game play per day, for 5 days/week, for up to 4 weeks"
45675685|NCT05693272|Biological|COVAC-1|Intramuscular vaccine against SARS-CoV-2
45675686|NCT05693272|Biological|Saline Placebo|Intramuscular injection of saline placebo
45675687|NCT05692635|Diagnostic Test|MRI of the Brain|An MRI brain scan with and without gadolinium contrast. Three scans are planned for each participant.
45675688|NCT05692635|Other|Blood draws|Before each MRI, participants will give about a teaspoon of blood to test for clinical purposes.
45999547|NCT04689893|Drug|68Ga-DOTA-JR11|68Ga-DOTA-JR11 was injected into the patients before the PET/CT scans
45999548|NCT03922854|Other|Non-interventional data collection only|There is no clinical intervention. This study is just capturing data from devices used part of routine clinical care. The results of this data collection will be analysed to inform study results.
45999549|NCT05184426|Diagnostic Test|Echocardiogram|Ultrasound study to assess cardiac anatomy and function
45999550|NCT05184426|Diagnostic Test|Cardiac magnetic resonance|MR to assess cardiac anatomy, function and tissue damage
45999551|NCT05184426|Diagnostic Test|Coronary angiography|Cathteterization to assess coronary anatomy. Intravascular ultrasound to obtained a detailed assessment of vessels anatomy. Guidewire pressure to assess microcirculation
45999552|NCT05184426|Diagnostic Test|Endomyocardial biopsy|Optic microscopy, immunofluorescence, transmission electron microscopy
45999553|NCT04689425|Drug|Umbilical cord blood mononuclear cell gel（MNC）|Local wound treatment by combination of PRP and MNC, once;
45999554|NCT04689425|Drug|The platelet rich plasma（PRP）|Local wound treatment by PRP alone, once.
45999555|NCT05184192|Drug|Gabapentin gelatin capsules 300mg|Gabapentin is an anti-epileptic also used for nerve pain. This study will investigate the efficacy of gabapentin for olfactory nerve recovery and improvement in post-Covid-19 olfactory dysfunction.
45999556|NCT05184192|Drug|Placebo|lactose monohydrate NF
45999557|NCT04689581|Other|Ultrasound guided bi-level erector spinae plane block|Bi-level ultrasound (US)-guided Erector spinae plane block (ESP) with 30 ml 0.25% bupivacaine at the T2 andT4 vertebral level will performe preoperatively to all patients in the ESP group.
45999558|NCT04689581|Other|Ultrasound guided modified pectoral nerve block|Ultrasound (US)-guided modified pectoral nerve block (PECs) with 30 ml 0.25% bupivacaine will performe preoperatively to all patients in the PECs group.
45999559|NCT03887676|Drug|Arbaclofen|Administered orally as disintegrating tabs, round, white and beveled edges, at the following strengths: 5mg, 10mg, 15mg and 20mg
45999560|NCT03887676|Other|Placebo|Administered orally as disintegrating tabs, round, white and beveled edges
45675689|NCT05692635|Other|Quality of Life Questionnaires|Participants will fill out two questionnaires about their health. These questionnaires will tell investigators about any symptoms participants may be having that might be related to cancer spreading to their brain. This will take about 10-15 minutes to complete.
45675690|NCT05692635|Drug|Gadolinium|Given intravenously
45675691|NCT05691465|Procedure|Biospecimen Collection|Undergo collection of blood
45999561|NCT04689620|Device|laser|treating the venous ulcer with laser
46086675|NCT04167735|Device|Hearing Aid Reverberation Canceller enabled (RevC_1)|Each participant will be fitted with the 2 different Sound Changing principles on the same hearing aid, saved to 2 manual programs (ensures exact same hearing loss compensation for each intervention). Reverberation Canceller principle is a sound processing algorithm to remove reverberation from a speech signal to improve the speech intelligibility and comfort. The experimental condition applies the Reverberation Canceller and is predicted to provide a benefit in reverberant room simulations.
45675692|NCT05691465|Procedure|Computed Tomography|Undergo CT scan
46086676|NCT00764270|Dietary Supplement|R-alpha lipoic acid|300 mg R-alpha lipoic acid or placebo twice daily for 12 weeks, followed by a washout period of 12 weeks, followed by another treatment phase of the other treatment placebo or 300 mg R-alpha-lipoic acid for 12 weeks
45835183|NCT01893684|Behavioral|Conventional Carbohydrate Diet|For the CARB group, the diet will provide dietary protein at 0.8 g.kg-1.d-1 (~ 18% of energy intake) with a ratio of carbohydrates/protein > 3.5 and dietary lipids at ~ 30% energy intake. Through nutrition education and counseling we will ensure that the CARB group meets the RDA for protein for women of 46 grams per day from a variety of plant and animal sources. Again, energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. Additional recommendations will include 5 servings/day of vegetables and 2-3 servings/day of fruit. Beef intake will be discouraged in the CARB group.
46086677|NCT02652039|Other|Questionnaires|Questionnaires
46086678|NCT02651961|Procedure|Exchange of total hip or knee arthroplasty on same time|Removal of the index implants, extensive debridement, reimplantation of a new prosthesis
46086679|NCT02651961|Procedure|Exchange of total hip or knee arthroplasty in two time|Removal of the index implants in first time, extensive debridement, reimplantation of a new prosthesis in seconde time
46086680|NCT04188938|Other|Evaluation of occult pneumothorax in who had a blunt or penetrating chest trauma|
45835184|NCT02684292|Biological|pembrolizumab|IV infusion
45999562|NCT02929472|Behavioral|Physical exercise|The intervention group (INT, n = 17, 7 boys) who attended at least 75% of PA classes and met more than 50% of food goals.The exercise sessions took 90 minutes, in order to assure at least 60 minutes of physical exercise, during 12 weeks. The sessions were always taught by the same staff, and were composed of: 10 minutes of warm-up; 30 minutes of circuit training; 15-minute of pre-sports and recreational games;and 5 minutes resting activities.
46086681|NCT02712710|Device|functional knee brace|The functional knee brace for OA can decrease abnormal varus torque by external force.
46086682|NCT02651883|Behavioral|Screening invitation (with education)|The participant will be provided with brief education about the importance and effectiveness of cervical cancer screening, and invited to schedule an appointment for a free in-clinic screening
45835185|NCT02684292|Biological|brentuximab vedotin|IV infusion
45999563|NCT02929472|Behavioral|without physical exercise|The control one (CONT, n = 18, 6 boys), with a minimum or less than 49% attendance in PA classes, and were not involved in the nutrition education program.
45999564|NCT05167032|Behavioral|Cognitive Multisensory Rehabilitation (CMR)|The goal of CMR is to restore proprioception (i.e., sense of joint position and movement), body awareness, and awareness of the paralyzed limbs and trunk in space, in order to improve sensory and motor function. For example, CMR tasks will have the participant solve exercises related to: (i) where the legs are situated in space; where the legs are in relation to the pelvis and the upper part of the body (ii) the dimensions and length of the legs, the dimension of the pelvis, and sensation of the pelvis as a central body reference. (iii) the relationship between the left and right side of the body, and the relationship between the pelvis and the feet. Further, improvements in touch and pressure sensation are obtained with (v) texture discrimination tasks, and (vi) discrimination of sponges with varying resistance. Given the importance of sensory feedback for movement, sensory improvements create the opportunity for motor recovery to occur.
46086683|NCT02651883|Behavioral|Self-collection for HPV testing|Participant is provided with a kit to take a self-collected sample at home and return it by mail for HPV testing. Results are provided to participant by phone.
45675693|NCT05691465|Drug|Lutetium Lu 177 Dotatate|Given IV
45675694|NCT05691465|Procedure|Positron Emission Tomography|Undergo PET
45675695|NCT05689164|Biological|fordadistrogene movaparvovec|gene therapy administered in a previous study.
45675696|NCT05665530|Drug|PRT2527|PRT2527 will be administered by intravenous infusion once weekly on a 21-day treatment cycle
45675697|NCT05662306|Drug|Aripiprazole Lauroxil|1064 mg 2-month long-acting injectable administered as an intramuscular injection over a 12-month period.
45835186|NCT04391010|Other|Surgical masks|Surgical masks will be applied in health care providers
46086684|NCT02722850|Behavioral|ALIVE|ALIVE is an email-based platform designed to help participants increase their physical activity, increase fruit and vegetable consumption, and decrease their intake of saturated and trans fats and added sugars. This automated system contains content and tailoring that is delivered in the form of emails obtained directly from cancer patients. Additional information they will receive included: tips for achieving those goals, health information, and opportunities for interaction and engagement.
46086685|NCT00650481|Drug|Oxybutynin Chloride Extended-release Tablets 5 mg|4x5mg, single dose fasting
46086686|NCT00650481|Drug|Ditropan XL® Tablets 5 mg|4x5mg, single dose fasting
45457759|NCT01230775|Drug|Anagrelide retard|"Week 1:~1x1 tablet/d of Anagrelide retard (1 tablet = 2mg; total dose = 2mg/d) will be administered in week 1.~Week 2 Anagrelide retard: Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.~Week 3 - Week 4 Anagrelide retard In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.~Maintenance Phase Anagrelide retard During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range."
45675698|NCT05662306|Behavioral|Computerized cognitive and functional skills training|Self-administered cognitive and technology focused skills training, administered at home for 2 hours per week for the first 12 weeks of the 12-month study period.
45675699|NCT05658458|Drug|Vericiguat (Verquvo, BAY1021189)|The recommended starting dose of vericiguat is 2.5 mg once daily, taken with food. The dose of vericiguat would be doubled approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the participant.
45835187|NCT04391010|Other|Filtering respirators|Filtering respirators will be applied in health care providers
45835188|NCT02983032|Behavioral|BBTI|3 group sessions over 4 weeks
45835189|NCT05586516|Drug|IOA-289|IOA-289 will be administered orally twice daily (BID), starting from C0D1. Gemcitabine and nab-paclitaxel will be administrated by IV infusion, weekly for 3 weeks of a 4 week cycle starting at C1D1.
45835190|NCT01459692|Other|Music Exposure|Twenty-seven subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
45999565|NCT05167032|Behavioral|Adaptive fitness|The Courage Kenny Rehabilitation Institute centers provide access to state-of- the-art adaptive gym equipment in their fitness center to promote fitness and recreation. Equipment includes treadmills, elliptical, NuSteps, SciFit upper body ergometers, Ski Erg and Rowing Machine, Upright and recumbent stationary bicycles, chest press, rear row, leg extension, leg curl, leg press, uppertone, free weights, and kettlebells. The equipment is spaced to allow for movement and is accessible for use from a wheelchair. They allow for transfers and caregiver assistance.
45999566|NCT02929433|Other|Cycloergometer|Daily training of the RCT patients was provided by the use of a cycloergometer at home. Educational support once a month was guaranteed by a nurse of the telemedicine service
46086687|NCT02715050|Device|Active or Placebo Phototherapy (MR4)|
45835191|NCT04390074|Other|COVID-19 and Intensive Care|No intervention, observational.
46086688|NCT04248231|Other|CINSARC signature|CINSARC molecular signature analysis
46086689|NCT02651805|Device|Mechanical Insufflation-Exsufflation|Mechanical Insufflator-Exsufflator (MI-E): 6 assisted cough with expiratory pressure of -40cmH2O and inspiratory pressure defined by the therapist as the maximum pressure defined as comfortable; inspiratory time 3s and expiratory time 4s, using a manual cycle. Patients will be instructed to cough during exsufflation phase, with exception of Chronic obstructive pulmonary disease patients which will be instructed to exhale slowly. An oral-nasal mask will be used as interface, but in patients with tracheotomy, the device will be connected to it. A trained physiotherapist will conduct the therapy. During the night and weekends, patients will not start this therapy, however, if they have already started the therapy in MI-E group, or if they have already finished the period of follow-up they will be able to request this therapy, which will be provided by hospital staff . The equipment (Cough Assist®, Respironics, Phillips), will be available in the ward for the interventions.
45835192|NCT02649426|Device|The Paradise® Renal Denervation Ultrasound System|Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using the Paradise System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.
45835193|NCT02649426|Device|Sham Procedure|Randomization will occur following the diagnostic renal angiogram. For blinded patients randomized to control, the diagnostic renal angiogram will be considered the sham procedure.
45675700|NCT05657041|Drug|Clopidogrel|Body weight adjusted clopidogrel dosing
45675701|NCT05656599|Drug|Letermovir|Patients received letermovir as prophylaxis or received preemptive therapy for CMV depends on clinical needs and patients' wishes
46086690|NCT02651805|Other|Usual Care|The patients will receive the treatment according to the hospital protocol to deal with hypersecretive patients (suctioning that can be preceded by respiratory physiotherapy and nebulisation). A trained member of the nurse staff or a physiotherapist will be responsible for providing the therapy. A member of the research team will collect in the patients' records all the therapies provided by the staff to control hypersecretions.
45999567|NCT04291469|Drug|Probiotics（Live combined bifidobacteria, lactobacillus and maltodextrin tables)|The probiotic compound will consist of tables containing approximately 10^9 colony forming units of the probiotic organisms, Lactobacillus and Bifidobacteria lactis strain，mixed maltodextrin(oral, daily for 14 weeks).
45999568|NCT04291469|Dietary Supplement|Prebiotics (Combined inulin and maltodextrin tables)|The prebiotic compound will consist of tables containing inulin and maltodextrin (oral,daily for 14 weeks)
45999569|NCT04291469|Dietary Supplement|maltodextrin|Maltodextrin tables (oral,daily for 14 weeks)
46086691|NCT02712476|Drug|mannitol|This drug is in our routine use of neuroanesthesia, are given in peroperatifyl brain relaxation
45999570|NCT03882294|Other|Probiotics|Participants will be requested to consume the drinks (80 ml) twice a day - after lunch and dinner for 12 weeks.
45999571|NCT03882294|Other|Placebo|Participants will be requested to consume the drinks (80 ml) twice a day - after lunch and dinner for 12 weeks.
45999572|NCT02929121|Drug|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg)
45999573|NCT02929121|Drug|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
45999574|NCT02929277|Other|blood sampling, skin prick tests, assesment of atopic dermatitis, questionnaires|
46086692|NCT02712476|Drug|Furosemide|This drug is can be used alone or with mannitol for brain relaxation
45835194|NCT01459770|Other|Medication Information Transfer Intervention|A pharmacist will visit participants randomized to the intervention group in their homes within 5 days of hospital discharge to administer the 5As Medication Self-Management intervention: Assessment, Advise, Agreement, Assistance, Arrangements.
45835195|NCT01459770|Other|Usual care for hospital discharge|Patients will receive medication information according to standard practice for discharge of hospitalized patients.
45835196|NCT02377206|Other|ADAS-Cog evaluation|[18F]DPA-714 PET imaging
45999575|NCT03871998|Other|Skin barrier protection in the first 2 months of life|Skin barrier protection in the first 2 months of life using a commercially available moisturiser from birth 2 months. Twice daily, whole-body application.
45999576|NCT02929394|Drug|Trabectedin|Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity
45999577|NCT05159037|Behavioral|Gaze Contingent Music Reward Therapy|Feedback according to participants' viewing patterns, in order to modify their attention.
45999578|NCT05159037|Behavioral|Music Booster|Participants listen to a musical track they ranked as highly liked before a stressful situation
45999579|NCT02929316|Drug|Vedolizumab|IV infusion week 0, 2 and 6
46086693|NCT02712476|Drug|placebo|mannitol alone is compared with placebo
46086694|NCT02714972|Device|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
46086695|NCT02715206|Behavioral|keepin' it REAL classic|keepin' it REAL consists of 10 classroom lessons implemented in 7th grade and 4 booster sessions implemented in 8th grade by the classroom teacher following training
45835197|NCT01894074|Behavioral|Intensive Dietary Intervention|Intensive dietary intervention of 800 kcal/day using liquid meal replacement for a total of 12 weeks to reduce weight to 15% from baseline weight.
45835198|NCT01894074|Behavioral|Placebo|Lifestyle counseling: standard dietary education and counseling with a goal of reducing to 1500-1800 kcal/day
45835199|NCT01459848|Behavioral|block play|30 minutes of block play
45835200|NCT01459848|Behavioral|baby dvd|30 minutes of dvd viewing
46086696|NCT02715206|Behavioral|keepin' it REAL rural|keepin' it REAL rural drug prevention curriculum consists for 10 lessons taught in 7th grade and 4 booster sessions taught in 8th grade.
45999580|NCT03841539|Behavioral|Mediterranean Diet|Diet consisting of fruits, vegetables, whole grains, low-fat dairy, olive oil, seafood, nuts and beans. It is low in red and processed meats, solid fats and added sugars.
45999581|NCT03841539|Dietary Supplement|Study Supplement|Randomized to take a daily dose of either 2 grams of Omega 3 fatty acids or 2 grams of a Placebo.
45999582|NCT03841539|Behavioral|Low-fat Diet|Diet consisting of fruits, vegetables, whole grains, low-fat dairy, and low-fat protein, with fat contributing no more than 25% of calories.
46086697|NCT02715206|Behavioral|control|control group continues to teach whatever prevention curriculum they were using prior to study
46086698|NCT00600171|Drug|GW642444M|GW642444M
45999583|NCT02929238|Other|Polypropylene Suture Right Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
46086699|NCT00600171|Drug|Placebo|Placebo mulit-dose dry powder inhaler
46086700|NCT02722538|Drug|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical drug delivery system, regulated as a drug, whose primary mode of action is the controlled release of gemcitabine into the bladder over a 7-day period.
46086701|NCT02651727|Drug|Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine|IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1
46086702|NCT02651727|Drug|Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine|IV treatment for the first 2 cycles, followed by IV treatment and oral VS-4718 BID continuously starting on Day 1 of Cycle 3
46086703|NCT02651727|Drug|Part A- VS-4718, nab-paclitaxel, gemcitabine|Part A- intravenous (IV) treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 twice-daily (BID) continuously starting on Cycle 1 Day 2. The starting dose of VS-4718 will be 200 mg BID.
45835201|NCT04390854|Biological|Blood clot scaffold|"Bleeding will be induced in the canal by passing a size 30 sterile K-file 3 mm beyond the apex with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. Bleeding will be stopped just below the cemento enamel junction.~Biodentine will be placed approximately 3-4 mm below the cementoenamel junction."
45999584|NCT02929238|Other|Polypropylene Suture Left Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
46086704|NCT02651649|Device|Continuous Positive Airway Pressure (CPAP)|FGR diagnosed parturients who are diagnosed with OSA will be prescribed CPAP as per standard of care.
46086705|NCT02651493|Device|photographs|computer based program to analyze photographs (computer-aided diagnosis (CAD) software)
46086706|NCT02651181|Device|HLCL- Hybrid Logic Closed Loop System|All subjects wearing the HLCL System and using it with the closed loop algorithm
46086707|NCT00650559|Procedure|Chest wall enlargement|Widening sternotomy
46086708|NCT02536131|Other|Gut-directed hypnotherapy|relaxation technique with hypnotic induction and suggestions aimed at fostering sense of control, acceptance and calming of bowels.
46086709|NCT04167657|Drug|Sintilimab|"Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 12 months.~Before enrollment, patient should undergo radiation no less than dose 30Gy/5f. Sintilimab shall be started no later than 3 weeks after radiation."
45999585|NCT05152836|Device|Vibrotactile stimulation at tremor frequency|Mechanical vibrations are applied at brief bursts of 80Hz that occur at the individual tremor frequency. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
45999586|NCT05152836|Device|Vibrotactile stimulation at tremor frequency*1.5|Mechanical vibrations are applied at 80Hz bursts at individual tremor frequency*1.5. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
45999587|NCT05152836|Device|Vibrotactile stimulation at continuous stimulation|Continuous 80Hz stimulation is applied via a small device worn on the wrist of the most-affected arm.
45999588|NCT05152836|Device|Vibrotactile stimulation 10% below and above step frequency|This intervention is applied during assessment of gait. Two devices are worn on both ankles which allows alternating stimulation of both ankles with brief bursts of 80 HZ at the individual step frequency plus or minus 10%.
45999589|NCT02929199|Other|All ceramic crown|Pressed E-Max coping veneered with E-max veneering system
45999590|NCT02929199|Other|Hybrid crown|pressed Bio HPP veneered with Visio-Lign Veneering system
45999591|NCT03791112|Drug|BPI-16350|BPI-16350 capsules administered orally
45999592|NCT02929355|Other|carotid assesment by duplex ultrasonography|
45999593|NCT02929043|Other|air puffs|
45675702|NCT05653362|Device|Coconut Oil|Coconut oil was applied to the patients' abdomen during the ultrasound to serve as a conducting medium. When applied topically, coconut oil is not absorbed systemically by the subject and will not affect the fetus. There are no studies showing a potential risk of the use of topical coconut oil in pregnancy. Subjects with a coconut allergy will be excluded from this study due to risk of allergic reaction.
46086710|NCT02651025|Other|Resistance Exercise Program|"During the first week of training will be conducted two sets of 10 repetitions, and from the second week of training until the twelfth will be performed three sets of 10 repetitions. The work rate will set to the tolerance of each patient as established by his/her inability to maintain Borg ratings for dyspnea and effort (10-point category-ratio Borg scale) scores between 4 and 6."
45999594|NCT05134974|Drug|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
45999595|NCT05134974|Drug|Phentolamine Ophthalmic Solution Vehicle|Phentolamine Ophthalmic Solution Vehicle
45999596|NCT02928926|Other|intravenous thrombolysis|patients who are eligible with intravenous thrombolysis or admitted within the timeframe to receive thrombolysis but not eligible due to other reasons
45999597|NCT05099211|Procedure|Muscle biopsies|"Optional~In pre-training:~Biopsy performed during the digestive surgery procedure~Final evaluation (minimum 1 day and maximum 7 days after the last training session): biopsy performed in the digestive surgery department."
45675703|NCT05653362|Device|Commercial Ultrasound Gel|Room-temperature Aquasonic 100 (Parker Laboratories, Inc., Fairfield, NJ) applied to patients' abdomen during the ultrasound to serve an another conducting medium.
45999598|NCT05099211|Other|Muscle Strengthening|3 sessions per week for 18 weeks. Duration: 1 hour Training on different strength training machines for the main muscle groups of the lower and upper limbs. The training load will be gradually increased over the sessions.
45999599|NCT05099211|Biological|Blood and urine samples|fasting blood sample taken at assessments 1, 2, 3 and 4 for patients and assessment 1 for controls
45675704|NCT05644665|Drug|Ozanimod|Specified dose on specified days
45675705|NCT05644665|Drug|Placebo|Specified dose on specified days
45675706|NCT05643573|Drug|Asundexian (BAY2433334)|Once a day
45835202|NCT04390854|Biological|Blood clot scaffold combined with PRF|Platelet-rich fibrin will be prepared by drawing the patient blood into a 10mL test tube without the addition of an anticoagulant. To prevent the blood from coagulating after coming in contact with the glass tube, it will be centrifuged immediately using a table top centrifuge** at 400 g force for 12 minutes. Then platelet-rich fibrin membrane will be placed into the canal space to a level 3 mm below the cemento-enamel junction using hand plugger following the induction of apical bleeding by passing a number 30 sterile hand file 3 mm beyond the apex of the tooth. Biodentine cap will be placed over the platelet-rich fibrin scaffold.
45457760|NCT01230775|Drug|Placebo|"Week 1:~x1 tablet/d of placebo will be administered in week 1.~Week 2~Placebo:~x1 tablet/d of placebo will be administered in week 2.~Week 3 - Week 4~Placebo:~In week 3 and week 4 the maximum dose is 4 tablets per day.~Placebo:~In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/"
45675707|NCT05643573|Drug|Apixaban|5 mg or 2.5 mg, twice a day, according to product label.
45999600|NCT05099211|Other|Aerobic Training|"3 sessions per week for 18 weeks. Duration: 1 hour Training on a classic pedal bicycle (called an ergocycle). The intensity and duration of the training will be gradually increased over the sessions and according to the patient's abilities."
45999601|NCT05099211|Other|Evaluation 1 pre-surgery|"Carried out at least 15 days before surgery~st visit:~Nutritional assessment~Body composition~Psychometric tests of quality of life + IPAQ Test~VO2pic~nd visit:~Neuromuscular tests~Functional tests"
45999602|NCT05099211|Other|Evaluation 2 post-surgery|"st visit:~Body composition~Nutritional assessment~Psychometric tests of quality of life~nd visit:~neuromuscular tests~Functional tests~Familiarization with training equipment if patient participates in re-training"
45999603|NCT05099211|Other|Intermediate Evaluation 3|performed 9 weeks after the beginning of training Identical tests to evaluation 1 + TM6
45999604|NCT05099211|Other|Final post-training evaluation 4|Tests identical to evaluation 1 + TM6
45999605|NCT02928809|Device|low-level laser therapy|Three points will be irradiated over the masseter muscle (upper, middle and lower bundles) and one point will be irradiated over the anterior temporal muscle of each side of the face in the groups submitted to pre-fatigue laser. The following parameters will be employed: wavelength: 780 nm; energy density: 25 J/cm2; output power: 50 mW; power density: 1.25 W/cm2; and exposure time: 20 seconds per points, resulting in a total energy of 1 J per point. The laser will be applied punctually with a conventional tip in contact with the skin considering an area of 0.04 cm2.
45675708|NCT05643573|Drug|Asundexian matching placebo|Placebo to asundexian, once a day
45675709|NCT05643573|Drug|Apixaban matching placebo|Placebo to apixaban, twice a day
45835203|NCT02465736|Drug|Docetaxel|25mg/ m2 Docetaxel dose administered on days 1, 8, 15, and 22.
45835204|NCT02465736|Drug|Cisplatin|25mg/ m2 on days 1, 8, 15 and 22.
45835205|NCT02465736|Radiation|Radiation|Patient will receive 4 weeks of radiation therapy (44 Gy/20 fractions).
45835206|NCT02465736|Procedure|Surgery|McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 4-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
45835207|NCT02465736|Drug|Vinorelbine|25mg/ m2 on days 1, 8 of each cycle (i.e. every 21 days).
45835208|NCT02465736|Drug|Cisplatin|75mg/ m2 on day 1 of each cycle only (i.e. every 21 days).
45835209|NCT02630316|Drug|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
46086711|NCT02650947|Dietary Supplement|Sucralose|Consumption of capsules containing either 200 mg sucralose (equivalent to diet soda 3 cans) per day for four weeks
45999606|NCT02928809|Other|Placebo comparator|The same equipment will be used in the placebo group, but with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
45999607|NCT03731598|Procedure|bed rest|Volunteers will be physically inactive on bed rest at the clinical research center
45999608|NCT02928731|Other|Questionnaires set 1|Participants were asked to respond to the Chinese version of the Coping Behavior Checklist for Chinese Children, the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth, and the Pediatric Quality of life Inventory: cancer module.
46086712|NCT02650947|Dietary Supplement|Placebo|Consumption of empty capsule everyday for 4 weeks
45999609|NCT02928731|Other|Questionnaires set 2|Participants were asked to respond to the Chinese version of the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth,and the Pediatric Quality of life Inventory: generic module
45999610|NCT02928965|Drug|Minocycline|Capsules containing 100mg minocycline (modified release), administered orally by the patient, two per day for the first two weeks and then three per day for the reminder of the 12 month treatment period in addition to standard therapy.
45675710|NCT05635097|Behavioral|Motivational Interviewing counseling on the Mediterranean diet and weight checks at regular intervals|Each participant will meet virtually on Zoom with the DNP project leader and receive 1:1 counseling on pairing the Repnho smart scale and tape measure with the Renpho application. The expectations of the weight management program will be explained in detail during the first session, which will last one hour (session one= week zero). The weight loss goal will be at least 1-2 pounds per week as recommended by the Centers for Disease Control and Prevention (CDC) (2022).
45999611|NCT02928965|Drug|Placebo|Matching placebo with appearance of over - encapsulated minocycline
46086713|NCT02650791|Drug|Tranexamic Acid|
45457761|NCT02311738|Other|Training intensity intervention|High intensity training group describes the group performing high intensity exercise intervention. Moderate intensity training group describes the the group performing moderate exercise intervention
45835210|NCT02630316|Drug|Placebo|Placebo administered four times daily
45835211|NCT02875704|Other|Anterior Chamber (AC) Tap|Aqueous Samples will be collected for measurement of biomarkers
45835212|NCT02359968|Drug|FOLFOX|radiochemotherapy before surgery
45835213|NCT02359968|Drug|CarboP-pacliT|radiochemotherapy before surgery
45835214|NCT02354820|Other|Evidence Based Constipation Reminders|
45999612|NCT04679220|Procedure|Preheating|For preheating RC prior to placement, a device called Therma-flo TM RC warming kit (Vista, Wisconsin, USA) was used according to manufacturer's instructions to preheat resin composites
45999613|NCT02928692|Drug|Minocycline|
45999614|NCT02928692|Drug|Placebo|
45999615|NCT04679142|Drug|Baclofen Tablets|Enrolled patients will receive treatment and evaluations for their disease as determined by their physicians in accordance with local standard of care. Visits will be scheduled by their physician according to patient-specific needs and national clinical practice.
45457762|NCT03504904|Behavioral|Internet-Delivered ACT and CFT|An 8-week internet-based intervention focused on acceptance and compassion. Psychological intervention based on Acceptance and commitment therapy and compassion focused therapy
45457763|NCT01136317|Drug|Omeprazole|
45999616|NCT02928653|Dietary Supplement|Beverage|Participants will receive 1.25 - 1.75 L of sweetened beverage a day for 12 weeks
45999617|NCT02928419|Drug|Eltrombopag/Revolade|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral eltrombopag for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of eltrombopag. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts < 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
45999618|NCT02928419|Other|Placebo|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral placebo for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of placebo. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts < 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
46086714|NCT02650869|Dietary Supplement|Probiotics|probiotics at a dose of 3x109 CFU/day. (Cap TS6 probiotic + contain Bifidobacterium spp., Lactobacillus at 6x109 CFU = 6 billion CFU manufactured by TENSALL BIO-TECH CO.LTD.Taiwan, distributed by Century Health Care, Bangladesh)
46086715|NCT02650869|Dietary Supplement|Breast milk|Normal breast milk will be given as part of standard care
45457764|NCT01136317|Drug|Rabeprazole|
45457765|NCT01136317|Drug|Lactose|
45835215|NCT04757376|Biological|CT-P41|60 mg/mL single dose, Solution for injection in PFS
45835216|NCT04757376|Biological|US-licensed Prolia|60 mg/mL single dose, Solution for injection in PFS
45835217|NCT02624544|Drug|esomeprazole|esomex 40 mg twice daily
45835218|NCT02624544|Drug|desonide|topical corticosteroid desonid 0,1% b.i.d
45835219|NCT02620410|Device|Axonics Sacral Neuromodulation (SNM) System|The implantable components of the Axonics Sacral Neuromodulation (SNM) System consist of an IPG and tined lead. Additional components include a clinician programmer, surgical tool kit, recharging kit, and patient remote control.
45835220|NCT01893840|Device|FlowOx|Boot-shaped pressure chamber generating pulsating negative pressure
45835221|NCT02613936|Device|Anodal tDCS|Anodal tDCS lowers neuronal membrane potentials, leading to increased probability of depolarization from incoming stimuli.
45835222|NCT02613936|Behavioral|Cognitive training|Cognitive training involves solving executive function tasks on a computer.
45999619|NCT02928419|Drug|Lenalidomide|All patients will receive oral lenalidomide 10 mg/day for 21 days every 28 days. Patients will receive lenalidomide dosing according to the lenalidomide product information. Patients obtaining an erythroid response according to IWG 2006 criteria within the first 24 weeks will continue lenalidomide treatment until progression or other reasons for permanent discontinuation
45999620|NCT00554151|Device|Adjustable Annuloplasty Ring|The investigational device is intended for use in the treatment of mitral valve regurgitation.
45999621|NCT02928614|Drug|Liraglutide 3 mg (Saxenda)|
46086716|NCT04035668|Drug|Remibrutinib|Remibrutinib 100 mg was administered orally as two 50 mg hard gelatin capsules. Patients in the remibrutinib 100 mg bid dose group took 2 capsules of active medication in the morning and 2 capsules of active medication in the evening. Patients in the remibrutinib 100 mg qd dose group took 2 capsules of active medication in the morning and 2 capsules of the placebo in the evening.
45675711|NCT05634707|Drug|Fluoxetine|"Patients randomized to the experimental arm will receive fluoxetine 20mg/day for 5 days before escalation to a maintenance dose at day 6. On day 6, patients will start treatment with 50 mg/m2 TMZ daily for 7 days (Days 6-12)~Arm 2A (n=10) - Escalate to maintenance 40mg/day fluoxetine on day 6~Arm 2B (n=10) - This arm will be opened as long as there are less than 3/10 dose limiting toxicities in Arm 2A. Patients will escalate to maintenance 60mg/day fluoxetine on day 6"
46086717|NCT04035668|Drug|Placebo|Placebo was administered orally as two hard gelatin capsules. Patients in the placebo dose group took 2 capsules of placebo in the morning and 2 capsules of placebo in the evening.
45999622|NCT02928614|Drug|Liraglutide 3 mg placebo|
46086718|NCT02650713|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion.
45999623|NCT02928458|Drug|Omnipaque|
45999624|NCT02928458|Drug|MD-Gastroview|
45457766|NCT02304016|Behavioral|Pelvic floor physical therapy|Patients in this arm will be receiving pelvic floor physical therapy
45457767|NCT05393947|Other|patient education|It is planned to provide education to patients about the side effects of chemotherapy.
45675712|NCT05634707|Drug|Temozolomide|Patients randomized to the control arm will receive 50 mg/m2 temozolomide daily for 7 days (Days 1-7), followed by resection or biopsy 21 days after initiation of the temozolomide cycle.
45675713|NCT05747794|Biological|eftilagimod alpha|APC activator, MHC II agonist
45675714|NCT05747794|Drug|Paclitaxel|paclitaxel will be given as standard of care (chemotherapy)
45675715|NCT05747794|Other|placebo|placebo matching eftilagimod alpha
45675716|NCT05632484|Biological|Cord blood sampling|Collection of 2 milliliters (mL) of cord blood on an Ethylenediaminetetraacetic acid (EDTA) tube, on the day of delivery and after cutting the umbilical cord, for genetic testing
45835223|NCT02606526|Biological|BCG at birth|See previous description
45835224|NCT02606526|Biological|Control arm: Delayed BCG|See previous description
45999625|NCT03685500|Drug|Symtuza® (TAF/FTC/DRV/c)|Treatment with TAF/FTC/DRV/c during 8 weeks since randomized
45999626|NCT03685500|Drug|ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to TAF/FTC/DRV/c for 8 weeks
45457768|NCT02307214|Other|BaroReflex Sensitivity, endothelial function measurement|no other
45835225|NCT02603328|Drug|Atorvastatin|40-80 mg OD
45999627|NCT02928575|Drug|Sunitinib|Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks.
45835226|NCT02603328|Other|Placebo|inactive
45457769|NCT03917641|Biological|Khat leaves|One of the two compressions (one per each eye) the patient will use will contain the Khat leaves.
45675717|NCT05632484|Biological|Cord blood sampling|Collection of 50 to 100 mL of cord blood from the cord blood collection bag
45675718|NCT05632484|Biological|Cord sampling|Collection of 20 centimeters (cm) of umbilical cord
45835227|NCT02335788|Device|The EMBA Peripheral Embolization Device|arterial and venous embolization in the peripheral vasculature
45999628|NCT02928575|Drug|Temozolomide|Temozolomide (75 mg/m2 daily) will be administered along with sunitinib (12.5 mg once daily) and radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.
45675719|NCT05622461|Behavioral|Road-to-recovery|R2R-TBI is a self-guided web-based intervention that targets caregiver psychological functioning, parenting behaviors, and family functioning in the first three months following pediatric traumatic brain injury.
45675720|NCT05621889|Procedure|virtual group speech therapy intervention guided by a patient partner|virtual group speech therapy intervention guided by a patient partner
45675721|NCT05614492|Behavioral|Individual PrEP Decision Aid|Participant engages with the decision support tool designed to optimize PrEP uptake among Black cisgender women who have experienced IPV independently. They also enter data independently.
45999629|NCT02928575|Radiation|Radiation Therapy|Patients will receive a concomitant treatment of radiotherapy (60 Gy in 30 fractions), sunitinib (12.5 mg once daily) and temozolomide (75 mg/m2 daily) over a period of 6 weeks.
45999630|NCT05052918|Behavioral|Exercise|1 hour of moderate-intensity aerobic exercise 3 days a week for 12 weeks
45999631|NCT02928302|Other|TVU CL screening|Transvaginal ultrasound cervical length screening
45999632|NCT02928263|Other|Non-Interventional|Other
45999633|NCT02928146|Procedure|Hernia Repair|
45999634|NCT05048433|Behavioral|implementation strategy for active learning to promote physical activity|The experimental arm includes using a multifaceted implementation strategy to support the use of active learning approaches. The strategy will consist of a series of skills-based staff trainings, identifying program champions to help lead efforts within the school, establishing an audit and feedback system to monitor the use of active learning, and a reinforcement system to recognize staff who are successfully implementing.
45999635|NCT05048433|Behavioral|Usual Implementation support|Usual support consists of the potential to access general resources from the district wellness department. These resources include access to funds to send staff to external trainings and general guidance for how to use active learning approaches.
45999636|NCT04276415|Drug|DS-6157a|Administered as a single agent intravenously (IV) every 3 weeks
45999637|NCT02928068|Behavioral|Occupational Performance Coaching (OPC)|OPC focuses on increasing positive child-caregiver interactions and child learning opportunities in everyday routines and contexts, which positions families for improved trajectories over time. OPC capitalizes on families' strengths, while supporting caregivers in using their own resources and ideas to advance child function. Caregivers identify goals, while therapists ask reflective questions and make reflective comments, affording caregivers an opportunity to gain a deeper understanding of their own current knowledge and the impact of their strategies on their children's adaptive behavior. Thus, families generate their own solutions and are ultimately responsible for carrying out the intervention and evaluating its effectiveness.
45999638|NCT03558438|Other|No interventions|No interventions
45999639|NCT02927951|Drug|Pregabalin|150mg bid
45999640|NCT02927951|Drug|Placebo|150mg bid
45999641|NCT02927678|Other|white blood cell SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography) imaging|
45999642|NCT03457532|Drug|Glumetinib for tablet|25mg; 50mg; 100mg; 200mg; 400mg; 600mg BID or QD(Decided by SMC accroding to the safty and PK data)
45999643|NCT02927600|Other|Low GI Breakfast|Intake of low GI breakfast
45675722|NCT05614492|Behavioral|CDC PrEP Video|A video from the Centers for Disease Control and Prevention that provides basic, general information on PrEP
45675723|NCT05614492|Behavioral|Shared PrEP Decision Aid|Domestic violence service advocate (DVA) engages with the decision support tool designed to optimize PrEP uptake among Black cisgender women who have experienced IPV with the participant and enters data
45675724|NCT05607420|Biological|UCART20x22|Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors given following a lymphodepletion regimen
45999644|NCT02927600|Other|High GI Breakfast|Intake of high GI breakfast
45999645|NCT02927600|Other|Low GI Dinner|Intake of Low GI dinner
46086719|NCT02650713|Drug|RO6958688|"RO6958688 is administered by IV infusion~In Part IA: RO6958688 is administered weekly (QW) on days 1,8 and 15 of each 21-day cycle.~In Part 1b: RO6958688 is administered weekly (QW) or every 3 weeks (Q3W). Cohort A: RO6958688 starting dose will be 100 mg either QW or Q3W.~Step Up dose cohorts: RO6958688 starting dose will be 40mg and increase with each administration up to the MTD or 1200 mg whichever is lower."
46086720|NCT02650635|Drug|Cyclophosphamide|Given IV
46086721|NCT02650635|Other|Laboratory Biomarker Analysis|Correlative studies
46086722|NCT02650635|Biological|Pegfilgrastim|Given SC
45999646|NCT02927600|Other|High GI Dinner|Intake of high GI dinner
46086723|NCT02650635|Other|Pharmacological Study|Correlative studies
46086724|NCT02650635|Drug|TLR8 Agonist VTX-2337|Given SC
46086725|NCT02650557|Procedure|angiography|angiography or arteriography is a medical imaging technique used to visualize the inside, or lumen, of blood vessels and organs of the body, with particular interest in the arteries, veins, and the heart chambers. This is traditionally done by injecting a radio-opaque contrast agent into the blood vessel and imaging using X-ray based techniques such as fluoroscopy.
46086726|NCT00650637|Drug|Calcium Carbonate|Calcium carbonate 500 mg oral tablet twice a day; given in combination with the following antiretroviral combination: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day); If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly; All study drugs continued through to Week 12
46086727|NCT00650637|Drug|nelfinavir|1250 mg twice a day
46086728|NCT00650637|Drug|lamivudine|lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
46086729|NCT00650637|Drug|loperamide|If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly;
45457770|NCT03507244|Drug|Pemetrexed|Pemetrexed, 10 mg,intrathecal injection, plus dexamethasone 5 mg, once per week, 5 to 8 times, 4 to 7 weeks in total.
45675725|NCT05607420|Biological|CLLS52|A monoclonal antibody that recognizes a CD52 antigen
45835228|NCT02327286|Behavioral|Promote and support healthy behaviors|"Exclusive breastfeeding for 6 months and partial breastfeeding for at least 3 additional months.~Personally monitored weight loss and maintenance with goal: return to pre-pregnancy weight and, if overweight pre-pregnancy, loss of an additional 5% of body weight.~Healthy eating: avoidance of ultra-processed foods, limited intake of oils, sugars and processed foods, increased intake of foodstuffs in their natural state, regular intake of water, dairy products, unsweetened coffee and tea.~A progressive increase in physical activity of at least 150 minutes of moderate or vigorous physical activity/week (7500 steps/day) and reduction of sedentary behavior with monitoring by personally worn devices."
45999647|NCT02927561|Other|Diabetic Retinopathy screening|Diabetic Retinopathy screening
45999648|NCT05036616|Device|Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy|Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy
45999649|NCT02927405|Drug|Gabapentin|anticonvulsant drug that is used for neuropathic pain.
45999650|NCT02927405|Procedure|TAP Block|a procedure done anesthetize the anterior abdominal wall
45999651|NCT05005299|Drug|Venetoclax|Venetoclax is administered as an oral tablet once daily.
45999652|NCT05005299|Drug|Fludarabine|Fludarabine is administered as an intravenous infusion at a dose of 30mg/m2 daily, to be administered over 30 minutes.
45999653|NCT05005299|Drug|Cyclophosphamide|Cyclophosphamide is administered as an intravenous infusion at a dose of 750mg/m2 daily, to be administered over 30 minutes and to commence 1 hour after fludarabine infusion.
45999654|NCT02927444|Biological|NBP606|A single intramuscular injection into the thigh
45999655|NCT02927444|Biological|Prevnar13|A single intramuscular injection into the thigh
45999656|NCT04967820|Other|resilience and institutional support|psychological inherent resilience and institutional support during COVID-19 outbreak
45999657|NCT02927483|Dietary Supplement|Endolex Forte®|Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.
45999658|NCT02927483|Dietary Supplement|A combination of diosmin and hesperidin|A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
45457771|NCT03507244|Drug|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection, simultaneously with pemetrexed, once per week, 5 to 8 times, 4 to 7 weeks in total.
45999659|NCT02927210|Drug|Dimethandrolone Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate injections intramuscularly (IM) (80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC) (50 mg, 100 mg and 200 mg).
45675726|NCT05607316|Drug|Metformin Hydrochloride|"Consistent with previous studies and clinical recommendations, subjects will initiate treatment at metformin 500 mg twice daily and increase to 1000 mg twice daily only after they have tolerated the treatment (details below).~Study Visit 1 (Week 1) - Study Visit 2 (Week 2) Subjects will be directed to take metformin 500 mg twice daily.~Study Visit 2 (Week 2) - Study Visit 5 (Week 24) If initial metformin dose is tolerated, subjects will be directed to increase the dose to 1000 mg by mouth twice daily at bedtime for the remainder of the study."
45999660|NCT02927210|Drug|Placebo|Placebo injections that look like the DMAU injections but with no active ingredients
45999661|NCT04679649|Other|Manual spinal mobilisation physiotherapy|Manual spinal mobilisation is a physiotherapy technique to improve spinal mobility by gently applying pressure manually on the each segmental vertebrae by hands-on treatment of a physiotherapist.
45999662|NCT02927522|Drug|Donepezil|Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
46086730|NCT00650637|Other|Calcium carbonate not administered|Prophylaxis with calcium carbonate not administered in this group; The following antiretroviral combination was administered: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
46086731|NCT00650637|Drug|nelfinavir|nelfinavir 1250 mg twice a day
46086732|NCT00650637|Drug|lamivudine + zidovudine|lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
45835229|NCT01451970|Other|High Fat Diet|Subjects will adhere to their specific diet for four weeks. For both diet treatments, the diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
45835230|NCT02323698|Drug|Caffeine|Subjects will ingest capsules containing caffeine (up to 6mg/kg). Experiments will begin 30min after consumption to approximately coincide with peak plasma concentrations.Throughout the 30min wait time and experimentation, blood pressure and heart rate will be monitored.
45835231|NCT02323698|Other|AIH|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.10±0.02 (hypoxia). Throughout experimentation, blood pressure and heart rate will be monitored.
45675727|NCT05607238|Procedure|Ultrasound Guided Vascular Access - Midline catheter|Ultrasound guided vascular access with a midline IV catheter
45999663|NCT02927522|Drug|Placebo|Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
45999664|NCT04679688|Other|descriptive|Those who apply for IVF treatment and have an antral follicle number of 4-10 will be included in the treatment. The reason for including patients with this number of antral follicles in the study is to determine the follicle locations and to determine each growing follicle separately on the day of hCG and egg collection.
45999665|NCT04679493|Drug|XC7 100 mg single|The volunteers will receive a single dose of the ID (1 capsule once, 100 mg)
45999666|NCT04679493|Drug|XC7 200 mg single|The volunteers will receive a single dose of the ID (2 capsules once, 100 mg each)
45999667|NCT04679493|Drug|Placebo single|The volunteers will receive a single dose of the ID (1 or 2 capsules once)
45999668|NCT04679493|Drug|XC7 200 mg multiple|The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily, 100 mg each)
45999669|NCT04679493|Drug|Placebo multiple|The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily)
45999670|NCT02927132|Behavioral|Expressive Writing|Expressive writing is a brief intervention that has been linked to various health and social benefits. Expressing emotions through writing can lead to decreased levels of stress and negative affect, thereby serving as a coping mechanism. Furthermore, expressive writing allows participants to reconstruct their traumatic experiences and reorganize their memory of these events into a narrative. Expressive writing has been used to target drinking. Research has found that students have reduced drinking intentions after writing about a negative drinking event compared to control,suggesting that a narrative intervention may be effective in reducing drinking. Other research suggests that feelings of guilt were more strongly associated with intentions to reduce drinking after writing about a negative drinking event, and that this event-related guilt mediated intervention effects.
46086733|NCT02650479|Drug|Exenatide|6 hour IV infusion (double infusion of 0.1250 mcg/kg/hour for 30 min followed by infusion rate (1X) of 0.0625 mcg/kg/hour for 5.5 hours).
46086734|NCT02650479|Drug|Placebo|6 hour IV infusion.
46086735|NCT02650479|Drug|Moxifloxacin|400 mg oral dose moxifloxacin within 1 min of start of infusion of exenatide
46086736|NCT02650479|Drug|Palonosetron|0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide
46086737|NCT02722772|Drug|Etanercept|Intra-articular injection of etanercept of 25mg/w/joint for 5 weeks.
46086738|NCT02722772|Other|Health education, exercise and diet guidance|Health education, exercise and diet guidance in patient; treatment: 5 weeks
46086739|NCT02650167|Biological|Colostrum feeding|
46086740|NCT02650167|Biological|formula for preterm infants|
46086741|NCT00650715|Device|Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. The Whole-body vibration intensity was kept constant at 30 Hz of frequency and 2 mm of amplitude.
45999671|NCT02927132|Behavioral|Personalized Normative Feedback|"PNF approaches use information designed to correct normative misperceptions to reduce heavy drinking. Three pieces of information are necessary when providing personalized normative feedback: information about a student's own drinking, information about the student's perceptions of others' drinking, and information about others' actual drinking. The presentation of this information is designed to change students' perceptions of normal drinking by exposing their misperceptions of the norm as well as by comparing their behavior with normal behavior."
45999672|NCT04941300|Other|Mailed FIT Outreach|We will mail an introductory letter to eligible individuals describing the importance of CRC screening and noting that follow-up mail will include a FIT Kit. Two weeks later they will receive a packet via mail containing the FIT kit, a one-page invitation inviting FIT completion and FIT instructions, COVID-19 messaging, and a postage-paid envelope for return.
45999673|NCT04941300|Other|Standardized navigation|"The standardized navigation includes, but is not limited to, the following key components:~Identification of individuals with abnormal FIT~Results review and colonoscopy order by provider~Results reporting to patient~Insurance approval for colonoscopy~Colonoscopy scheduling~Bowel preparation & colonoscopy completion~Colonoscopy results provided to patient and CHC~Referral-to-Care for patients with CRC (if necessary)"
45999674|NCT02927054|Other|Sepsis Education|Education provided to hospital residents for the recognition and treatment of systemic inflammatory response syndrome (SIRS), sepsis and severe sepsis
45999675|NCT04938648|Behavioral|Pharmacist-led deprescribing intervention|1) direct-to-consumer deprescribing educational materials designed to activate the care partner and people living with dementia PLWD; 2) a telehealth visit in which a clinical pharmacist discusses benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP
45999676|NCT02926976|Drug|Risperidone with Clozapine|Risperidone may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
45999677|NCT02926976|Drug|Aripiprazole with Clozapine|Aripiprazole may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
45999678|NCT02926976|Drug|sodium valproate with Clozapine|sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
46086742|NCT00650715|Device|Placebo Whole-body vibration exercise|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. All exercises were performed without the influence of a vibratory stimulus.
46086743|NCT02650245|Dietary Supplement|EAS Myoplex Protein Drink + 10gm lactulose|
45457772|NCT03507244|Radiation|Radiotherapy|The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
46086744|NCT00611546|Other|Photo-protection|Parenteral solutions are protected from day light using aluminum covers
45675728|NCT05607238|Procedure|Ultrasound Guided Vascular Access - peripheral IV|Ultrasound guided vascular access with a peripheral IV catheter
45457773|NCT01136395|Drug|Rituximab|375mg/m2 4 weeks before ABOi LD transplantation
46086745|NCT00611546|Other|Photo-exposure|Perenteral nutrition bottles and tubings are allowed to be exposed to day light.
45675729|NCT05606887|Behavioral|Wearable Device and Ecological Momentary Assessments|The intervention will ask participants to wear a wrist-based wearable device that will collect real-time biometric data related to stress and well-being, including heart rate variability, stress scores, and sleep quality. Based on these values as well as ecological momentary assessment results, participants will receive curated resources intended to support their well-being.
45675730|NCT05605587|Drug|Leflunomide 20 mg|once daily for 6 months
46086746|NCT02712242|Other|Platelet Rich Fibrin|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after PRF placing on palatal wounds.
46086747|NCT02712242|Other|Butyl cyanoacrylate|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after Butyl Cyanoacrylate application on palatal wounds.
45675731|NCT05605483|Other|Salad bar|Schools where the school district has installed salad bars
45675732|NCT05605483|Other|Waitlisted control|Schools where the school district has not yet installed salad bars
45835232|NCT02323698|Other|Placebo|This is a placebo counterpart to the caffeine drug. Subjects will ingest capsules containing dextrose. Experiments will begin 30min after consumption to mimic the caffeine drug protocol. Throughout experimentation, blood oxygenation, blood pressure and heart rate will be monitored.
45675733|NCT05605483|Other|Salad bar post-COVID|Schools where the school distract has re-opened salad bars will have methods repeated in a subset of schools post-COVID-19
45675734|NCT05597878|Drug|Oxycodone|Given after surgery 5 mg every 6 hours as needed for severe pain.
45835233|NCT02323698|Other|SHAM|This is a placebo counterpart to breathing intermittent low oxygen. Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.21±0.02 (normoxia). Throughout experimentation, blood pressure and heart rate will be monitored.
45835234|NCT02598258|Other|Sauna and cold water bath|Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after, subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
45999679|NCT02926976|Device|modified electroconvulsive therapy(MECT) with Clozapine|modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
45675735|NCT05597878|Drug|Acetaminophen|Given after surgery 1000 mg by mouth 4 times daily (every 6 hours)
45675736|NCT05597878|Drug|Ketamine|Given before and during surgery 1.5 mg/kg intravenously
45999680|NCT02926976|Device|Magnetic seizure therapy(MST) with Clozapine|Magnetic seizure therapy(MST) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
45999681|NCT02926976|Device|clozapine|clozapine may be used in the treatment of treatment-resistant schizophrenia
45999682|NCT04917393|Device|iRF System Multi-organ Denervation|If assigned to the treatment arm, subjects will remain blinded and recieve angiography prior to catheter based RF ablation to circumferentially disrupt the sympathetic nerves surrounding the target arteries
45999683|NCT04917393|Other|Control Procedure|If assigned to the control group, subjects will remain blinded and recieve angiography of the target arteries prior to sheath removal.
45999684|NCT03455166|Diagnostic Test|Serum Markers|Serum Markers
45999685|NCT02927015|Other|Purple Majesty potato chips|Purple Majesty potato chips
45999686|NCT02927015|Other|Mountain Rose potato chips|Mountain Rose potato chips
45999687|NCT02927015|Other|White potato chips|White potato chips
45999688|NCT02927015|Other|Crackers|Crackers
45999689|NCT02926820|Behavioral|Cogmed QM|The intervention consisted of 25 Cogmed sessions, typically completed over a five week period (i.e. 5 days per week), with each session lasting between 40-50 minutes per day. The program consists of 12 exercises that target visuo-spatial or verbal working memory. At each training session, participants completed 8 of the 12 exercises (order selected by the user), with 15 trials per exercise. Cogmed QM is an adaptive program, wherein task difficulty is adjusted to performance on each trial. The level of difficulty adjusts continuously and automatically, ensuring that each session provides an engaging, challenging level of WM capacity. Breaks were permitted, and encouraged, at the participants' discretion throughout the session.
45999690|NCT04910412|Device|transcranial direct current stimulation|Transcranial direct current stimulation will be use for the intervention. Anodal and sham tDCS will be applied in 2 mA through a pair of saline-soaked surface sponge electrode 35 cm square for 20 minute over the primary motor area for modulating the cortical excitability before apply the rehabilitation training
45999691|NCT02926781|Device|Dask Advanced Sinus kit|a kit of specially designed drills for closed sinus lift
45999692|NCT00553956|Behavioral|Narrative Exposure Therapy/Interpersonal Psychotherapy|The experimental group will receive 5 weekly individual sessions of NET in addition to 3 weekly individual sessions of IPT.
45675737|NCT05597878|Drug|Ketorolac|Given during surgery 15 mg or 30 mg intravenously 3 times daily (every 8 hours). After surgery 15 mg IV three times daily (every 8 hours).
45675738|NCT05597878|Drug|Acetaminophen|Given during surgery 1 mg intravenously 4 times daily (every 6 hours). After surgery 1000 mg by mouth four times daily (every 6 hours)
45999693|NCT02926742|Device|EkoSonic Endovascular System|Ultrasound catheter-directed thrombolysis.
45999694|NCT04887246|Biological|COVID-19 vaccines|COVID-19 vaccines available at Colombia
45675739|NCT05596682|Device|supplementary intraocular lenses|Implantation of supplementary intraocular lenses into the ciliary sulcus in previously pseudophakic eyes.
45675740|NCT05588700|Behavioral|Physical activity recommendations|At the baseline, all participants will receive the international recommendations in terms of physical activity for promoting health in the general population.
45675741|NCT05588700|Behavioral|Connected activity tracker|At baseline, all participants will receive a connected activity tracker to wear 24 hours a day during one year. Patients will be asked to download an application, dedicated to the study so that the physical activity data (ie. number of steps per day) will be synchronized in the application.
45835235|NCT01450722|Procedure|bypass surgery, stent placement|bypass surgery, stent placement
45999695|NCT02926703|Other|Serum lactate and CK concentrations in blood samples|Serum lactate and CK concentrations in blood samples were measured routinely at admission
45999696|NCT04878549|Diagnostic Test|5-gene transcription signature|This is a prospective multisite diagnostic evaluation study to assess a novel approach to the diagnosis of enteric fever. The index test of host gene transcription responses by a 5 gene-signature will be compared to the reference test of blood culture confirmation for a diagnosis of enteric fever in patients with AUFI.
45999697|NCT02926664|Other|measurement of qSOFA|qSOFA will be measured at H0, H1 and H3
45999698|NCT02926625|Behavioral|Systematic follow-up|"Febrile children without a diagnosable illness and without danger signs do not need to return to the HEW unless they are still sick, as over 90% of fevers resolve by themselves.~HEW advice and procedures~Children with unclassified fever should come back for re-assessment after 2 days only if the child still has fever or is sick~Children who are getting worse should come back immediately or at any time for a re-assessment~All children who come back for re-assessment, regardless of when they come back, should have a full assessment of their condition again.~HEW should fill out a loose child assessment form~If child still has fever and a negative rapid diagnostic test for malaria (mRDT), the HEW should refer the child to the nearest health centre."
45999699|NCT02926625|Behavioral|Conditional follow-up|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should have a conditional follow-up visit, i.e. only to come back for re-assessment after 2 days if the child still has fever or is sick. This is in line with national IMNCI guidelines.
46086748|NCT02712242|Other|Wet gauze|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after wet gauze pressure on palatal wounds.
45835236|NCT01450722|Procedure|stent placement|placement of paclitaxel eluting stent in long superficial femoral artery obstruction
45835237|NCT01456104|Biological|Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)|Patients will receive a total of 5 vaccinations, comprising a primary immunization followed by four boosters at 3 week intervals with a window of ± 4 days. Vaccines will be dosed at 10x106 LCs per vaccine x 5.
45835238|NCT01451736|Drug|paliperidone palmitate|long-acting injectable
45835239|NCT01451736|Drug|risperidone|oral
45835240|NCT02589600|Drug|Zoledronic acid|Annual intravenous 5.0 mg
45835241|NCT02589600|Dietary Supplement|vitamin D|800 IU daily
45999700|NCT02926508|Dietary Supplement|Bimuno (BGOS)|"The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; <01g Fat; <0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless.~Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink."
45999701|NCT02926508|Other|Maltodextrin|"Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria.~The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.~This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention."
45999702|NCT02926469|Device|Virtual Reality|Using Virtual Reality during labor
45999703|NCT04680195|Drug|Thalidomide|"The patients were treated with thalidomide tanken orally every night for 4 months, and the treatment period was divided into induction period and maintenance period, as follows:~Induction period:~The oral dose of thalidomide started at 50 mg, and increased to 100 mg after one week if tolerable, and maintain 100 mg for three weeks. The medication time was 1 month.~Maintenance period: The oral dose of thalidomide was 50-75mg/d. The medication time was 3 months."
45999704|NCT02926313|Other|Individualized Seating provision|Seating system selected and adjusted to meet individual needs.
45999705|NCT04867434|Drug|RZL-012|small synthetic molecule for submental fat reduction
45999706|NCT04867434|Drug|Placebo|Placebo
45999707|NCT04864431|Dietary Supplement|Vitamin D|Vitamin D capsules: each capsule contain 2 tablets of vitamin D 1000 IU. One capsule will be taken on day 1 through 180
45999708|NCT04864431|Other|Placebo|Placebo capsule: Each capsule contain saccharum lactis. One capsule will be taken on day 1 through 180
46086749|NCT04147143|Other|Documentation|Retrospective chart review of patients who have already completed treatment with cabozantinib after nivolumab or nivolumab plus ipilimumab before inclusion.
46086750|NCT00650793|Drug|Extended Release OROS® Paliperidone|
46086751|NCT02712164|Device|Modified NPWT dressing|Use of negative pressure wound therapy on split-thickness skin graft (STSG) donor sites
46086752|NCT02712164|Device|Tegaderm|Standard of care for STSG donor sites.
46086753|NCT02650089|Other|Resistance Exercise Low intensity|The 40% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
46086754|NCT02650089|Other|Resistance Exercise High intensity|The 80% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
46086755|NCT02650089|Other|Control|In the control session, the participants remained seated in a comfortable chair in the same environment of the resistance exercise sessions.
46086756|NCT02649933|Device|Watch PAT 200|screening of OSA with Watch PAT 200
45999709|NCT02926118|Dietary Supplement|Low glycemic load|Low glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
45999710|NCT02926118|Dietary Supplement|High glycemic load|High glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
45999711|NCT00553995|Drug|salsalate|Salsalate 3-4 grams per day as tolerated for nine days
45999712|NCT00553995|Drug|Placebo|
45999713|NCT02926430|Biological|Ad26.RSV.preF 5*10^10 vp|Ad26.RSV.preF will be given at a concentration of 5*10^10 vp/0.5 milliliter (mL).
45999714|NCT02926430|Biological|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be given at a concentration of 1*10^11 vp/0.5 milliliter (mL).
45835242|NCT02589600|Dietary Supplement|calcium|approximately 1200 mg (dietary and supplement)
45835243|NCT02589600|Other|Saline|Annual intravenous saline placebo
45835244|NCT02310594|Other|cytology specimen collection procedure|Undergo blood sample collection
45999715|NCT02926430|Drug|Placebo|Participants will receive placebo as formulation buffer.
45999716|NCT04798287|Drug|Tofacitinib|First eligible prescription for treating rheumatoid arthritis (RA)
45999717|NCT04798287|Drug|TNF Inhibitor|First eligible prescription for treating rheumatoid arthritis (RA)
45999718|NCT02926157|Behavioral|Life Style and Sleep Intervention|
45999719|NCT04798209|Drug|ACT-777991 (SAD)|ACT-777991 administered as hard capsules for oral use.
45999720|NCT04798209|Drug|ACT-777991 (MAD)|ACT-777991 administered as hard capsules for oral use, once daily.
45835245|NCT02310594|Other|laboratory biomarker analysis|Correlative studies
45835246|NCT02868918|Drug|biodentine|tricalcium silicate cement used to replace the carious dentin
45835247|NCT02868918|Drug|glass ionomer cement|high viscosity glass ionomer used as a base material
45835248|NCT02868918|Device|DigoraH optium|digital Xray for follow up
45835249|NCT02586870|Device|Intravascular Ultrasound|
45999721|NCT04798209|Drug|Placebo (SAD)|ACT-777991 matching placebo administered as hard capsules for oral use.
45999722|NCT04798209|Drug|Placebo (MAD)|Matching placebo administered as hard capsules for oral use, once daily.
46086757|NCT02693756|Other|Motor imagery|"The motor imagery intervention is a non-pharmacological and non-invasive treatment often used in sport, music, or physical rehabilitation (Schuster, Hilfiker et al. 2011). Proposed tasks to be imagined by the participants are for example:~Imagine you are walking on ice. During the first steps, you are slipping quite often, but as you walk on, your steps become more stable and you walk without problems over the ice. Try to imagine how you react when you slip on ice, how you try not to fall and to continue to walk normally The motor imagery intervention will be performed independently by the study participants at home without supervision three times a week for three weeks."
45999723|NCT04798209|Drug|14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)|Single dose of 14C-ACT-777991 microtracer, administered intravenously.
46086758|NCT00910767|Device|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
45999724|NCT04798209|Drug|Microtracer matching placebo (SAD - Absolute Bioavailability)|Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.
45999725|NCT04798209|Drug|14C-ACT-777991 microtracer (MAD - ADME)|Single dose of 14C-ACT-777991 microtracer, oral solution..
45835250|NCT02378766|Behavioral|Website A|"Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé (TAVIE : Traitement, Assistance Virtuelle Infirmière et Enseignement).~TAVIE en santé is a web-based tailored multicomponent intervention addressing smoking cessation, physical activity and healthy eating. Each component consists of seven interactive computer sessions lasting 5-10 minutes. The sessions, hosted by a virtual nurse, aims to develop and strengthen skills required for behavior change."
46086759|NCT00910767|Device|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
45999726|NCT04798209|Drug|Microtracer matching placebo (MAD - ADME)|Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.
45999727|NCT04784013|Procedure|Conventional CLOSE-guided pulmonary vein isolation|Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in a temperature and flow-controlled mode (QMODE, target temperature 45°C, low flow temperature 40°C, cut-off temperature 50°C) with a power of 35W(posterior)/50W(anterior) (irrigation flow at 4-15ml/min). RF will be delivered until an ablation index (AI) of ≥400 at the posterior wall/roof/south pole and ≥550 at the anterior wall.
45999728|NCT04784013|Procedure|High power short duration pulmonary vein isolation|Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in temperature-controlled mode (QMode+, target temperature 55°C, cut-off temperature 65°C) with a power of 90W (irrigation flow at 2-8ml/min). RF will be delivered for 4 sec at both the posterior and anterior wall.
45999729|NCT02926040|Procedure|Irreversible electroporation|
45999730|NCT04783350|Device|Transcranial alternating current stimulation (tACS)|tACS will be administered to the left angular gyrus at gamma frequency to improve cognitive functioning (MoCA score) and resting-state EEG signatures.
45999731|NCT02925767|Device|311-nm Ti:Sapphire laser|Pallas, LaserOptek, South Korea
45999732|NCT02925767|Device|308-nm excimer laser|XTRAC, PhotoMedex, US
46086760|NCT02722694|Drug|Subcutaneous(SC) Abatacept|Subjects received 125mg weekly SC abatacept injections for 24 weeks. All subjects who complete 24 weeks double-blind treatment are eligible to enter open label period. During this period, subjects in placebo group will be switched to receive abatacept 125mg administered SC weekly till week 52. Subjects in abatacept group will continue to receive abatacept 125mg weekly.
45999733|NCT04764708|Behavioral|Compassion and Metacognition Based Therapy|The intervention is a Third Wave Cognitive Therapy targeting metacognitive dysfuctions (through Metacognitively Oriented Psychotherapy) and self-criticism (through Compassion Focused Therapy).
45999734|NCT04764708|Behavioral|Cognitive Behavioral Therapy|Standard Cognitive Behavioral Therapy for Personality Disorders plus Standard Psychopharmacological Treatment.
45999735|NCT02925962|Other|Clinical Decision Support System (CDSS)|A targeted, automated CKD clinical decision support system (CDSS) designed to improve bloodpressure (BP) level, disease awareness, staging, processes of care, and knowledge among persons with documented reduced eGFRcreat (creatinine-based estimated glomerular filtration rate) in primary care setting.
45999736|NCT02925962|Other|Clinic Decision Sup System + Pharmacist|Includes everything in the CDSS intervention but adds a follow-up call from a pharmacist, who is part of the clinical team. The rationale for this third arm is based on the evidence that clinical pharmacists have been shown to be more effective than physicians alone at achieving BP control in other settings.
45999737|NCT04748445|Diagnostic Test|SARS-CoV-2/Influenza/RSV RT-PCR|nasal swab
45835251|NCT02378766|Other|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites offering information about the health behavior they chose: being physically active, following a healthy diet or quitting smoking. These websites offers reliable information and their content were validated by experts.
45999738|NCT02925845|Device|Neuromuscular electrostimulation|The device CompexTheta 400i provided with various developmental programs rehabilitation exercise with different phases, types and current is used. an adaptive program (heating, toning, muscular atrophy, strength-endurance) will be established for each patient during the study period. It shall apply at the level of the muscle bellies of the flexor and extensor muscles of the forearm dela upper extremity AV created. Electrodes are positioned at the anatomical reference positions. The intensity of the current will increase until a tolerable muscle contraction and painless by the patient.
46086761|NCT02722694|Other|Placebo|Subjects received weekly SC placebo injections for 24 weeks
46086762|NCT02722694|Drug|Methotrexate|All Subjects received backup Methotrexate treatment.
46086763|NCT02650011|Other|Acute deterioration of liver function|development of new ascites within 4 weeks or re-emergence of ascites who have previous well controlled ascites (greater than or equal to grade 2 or 3; International ascites club criteria) development of hepatic encephalopathy development of gastrointestinal hemorrhage development of jaundice (serum bilirubin greater than or equal to 3mg/dl) development of bacterial infection
46086764|NCT02714582|Behavioral|Bedside shift report|Bedside shift report is a process where shift-to-shift report between nurses is, if approved by the patient, executed at the patient's bedside in order to improve the patient's involvement (Anderson & Mangino 2006).
45999739|NCT04679454|Radiation|Phase I|To establish the recommended dose defined as the maximum tolerated dose (MTD)The dose-limiting toxicity (DLT) is defined as any G3-G4 event according to NCI CTCAE Version 4.03 scale. Dose escalation is designed as a 3+3 rule-based study. Dose escalation will be initiated from a baseline dose of 18 Gy and increased to reach 21 Gy and 24 Gy. The population size includes 18 patients.
45999740|NCT04679454|Radiation|Phase II|The recommended dose from the phase I study is delivered, using Cyberknife in order to evaluate the efficacy measured in terms of pCR rate. The population size includes 61 patients.
45999741|NCT02925728|Other|Finger-Food|Finger-Food at lunch and having diner
45999742|NCT02925728|Other|Without Finger-Food|Without finger-food
45999743|NCT02925884|Device|Gunnar OTC Glasses Condition|Gunnar Over-The-Counter Computer Glasses have optical power of 0.5 diopter for reducing accommodation demands at typical computer-viewing distance. The lens also have a partially transmissive yellow tinting and anti-reflective coating for filtering part of the spectral peaks in typical fluorescent or incandescent light. The frame has a wrape-around design meant to reduce air flow in the vicinity of the eyes.
45999744|NCT04744974|Behavioral|Diet intervention|Participants will be given dietician counseling on their assigned diet
46086765|NCT00650871|Drug|GW679769|
45999745|NCT04242251|Other|SPARKLE Model of care|Patients will receive the SPARKLE model of care in addition to usual oncologist-led care. The SPARKLE model will be led by a palliative medicine doctor and administered by nurses and staff without specific nursing or medical training. It utilizes a stepped care approach where all patients will initially have low-intensity model focused on weekly symptom monitoring through a patient-reported questionnaire. If any problems are identified, then patients step up to a higher-intensity care model where a nurse will conduct a phone assessment of the symptom problems. If the presence of symptoms is confirmed, patients step up again to an even higher-intensity care model where treatment of symptoms will be initiated by the SPARKLE nurse, depending on the severity of the problems. If the symptoms are not fully resolved, the patients will then step up to the highest-intensity care model which is an existing palliative care service- either palliative care outpatient clinic or home hospice.
45999746|NCT04725786|Other|thoracic echography|The research intervention corresponds to the performance of a thoracic echography to diagnose an incipient pulmonary interstitial syndrome.
46086766|NCT00650871|Drug|Placebo|
46086767|NCT02722382|Other|Patient-Centered Kidney Transitions Care|In a multi-faceted pragmatic approach, the intervention will 1) implement new electronic health information tools to help providers recognize patents in need of Kidney Transitions Care and focus their attention on patients' values and treatment preferences; and 2) implement a Kidney Transitions Specialist who will provide and facilitate integrated delivery of patient support programs that provide patients with knowledge, skills, and assistance to manage their disease, make high-quality treatment decisions, obtain needed psychosocial support, and navigate complex treatment plans.
46086768|NCT04111263|Dietary Supplement|FP|Fiber and polyphenol blend
46086769|NCT04111263|Dietary Supplement|Placebo|Matched placebo
46086770|NCT04111263|Other|High altitude|Simulated high altitude in altitude chamber using hypobaric hypoxia
45835252|NCT04757844|Device|Functional Near-Infrared Spectroscopy (fNIRS)|The hemodynamic response in prefrontal cortex will be measured using an Octamon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
45835253|NCT04758000|Drug|Metformin Hydrochloride|"Metformin will be administrated according with patients body mass index (BMI).~Patients between 14 and 18 years old or with BMI ≤ 20: 500 mg two times a day Patients older than 18 years or with BMI > 20: 850 mg two times a day.~In all cases, metformin will be administrated for 3 years maximum, unless there is a progression disease or if toxicity is verified."
45835254|NCT04758078|Other|Inhaled corticosteroids|Budesonide 2 mL = 1000 microgram will be given within 6 hours of birth and the second dose will be given after 12 hours
45999747|NCT04723524|Combination Product|Jinhua Qinggan (JHQG) Granules, Traditional Chinese Medicine|Jinhua Qinggan granules: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
45999748|NCT04723524|Other|Placebo Comparator|Jinhua Qinggan granules simulation (placebo) agent: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
46086771|NCT04111263|Other|Sea level|Sea level environment in altitude chamber
46086772|NCT02711774|Device|ultrasonography|ONSD will be measured by a 6-13 MHz linear probe of the ultrasound machine.
46086773|NCT02649543|Procedure|Primary Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. Subcutaneous tissue was approximated with Polyglycolic Acid 3-0, and the skin is sutured using Polypropylene 2-0.
46086774|NCT02649543|Procedure|Vacuum Assisted Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia is closed with a continuous Polyglycolic Acid 0 suture. The VAC® system is then used, with change of dressings every 48 hrs. The wound is closed using Polypropylene 2-0 only after healthy granulation tissue and no signs of infection are present.
45835255|NCT04758078|Other|Placebo|Nebulized 0.9% saline will be given four times per day
45835256|NCT01450956|Drug|Sevoflurane|Sevoflurane will be given at a concentration of 2% through oxygenator during CPB
45999749|NCT04719897|Behavioral|FIRST: Repairing Thoughts|"This intervention uses the Repairing Thoughts cognitive restructuring module of the FIRST (Feeling Calm, Increasing Motivation, Repairing Thoughts, Solving Problems, Trying the Opposite) cognitive behavioral therapy protocol. This psychotherapy module teaches adolescents that thoughts are linked to feelings and behaviors, and that thoughts are often guesses to interpreting the world around us. Adolescents are taught to notice their thoughts in real-time and evaluate the evidence that supports or contradicts the thoughts and interpretation. Adolescents are then taught strategies to re-interpret thoughts in a more realistic manner and notice changes in emotional and behavioral responses. Clinicians are provided with examples to enhance learning, and between-session practice is assigned as homework."
45999750|NCT02925806|Other|Non-interventional study - retrospective database review|
45999751|NCT04706754|Other|Questionnaires|Prospectively enrolled participants will be provided with survey packets comprised of different questionnaires at the initial/baseline visit and every 3 months and/or whenever there is an update in their treatment protocol
45675742|NCT05588700|Behavioral|Physical Activity (PA) Intervention|"The intervention will last 1 year and will have 2 phases. Phase 1: At each cycle of chemotherapy, patients will be proposed to perform 2-4 sessions per week. This program will be individual, supervised, performed at a moderate intensity. Between cycles, patients will be asked to perform 1-2 supervised collective live online physical activity sessions per week, proposed by a partner specialized in online PA.~Phase 2: After chemotherapy, patients will be asked to perform 2-3 PA sessions per week at a moderate intensity. Patients will be offered 2 options of PA practice: in the supervised collective live online PA session (as already performed in the phase 1), and/or in a fitness center (this practice will take place in a classic environment with a 9-month free access for patients thanks to a partnership).~In addition, patients will benefit from 4 individual motivational interviews, conducted by videoconference and/or by phone call with a professional."
45999752|NCT04689308|Drug|MH048|Soft gel capsules 5 mg and 25 mg，oral MH048 should be administered after an overnight fast.
45999753|NCT04674189|Biological|CVnCoV Vaccine|Intramuscular injection
45675743|NCT05586477|Drug|Placebo|A placebo pill (i.e., sugar) will be consumed 2 h before intervention.
45999754|NCT04674189|Drug|Placebo|Intramuscular injection
45675744|NCT05586477|Drug|Diphenhydramine|Extra strength Benadryl (DIN 02470144) will be consumed 2 h before intervention
45675745|NCT05585515|Behavioral|Sleep deprivation|Total sleep deficit of consecutive 8 hours
45675746|NCT05585515|Behavioral|Sleep restriction|Total sleep deficit of cumulative 8 hours
45999755|NCT04672122|Device|Transcranial direct current stimulation|Cathodal tDCS will be applied for 20 mins.
45675747|NCT05584163|Device|Extracorporeal shock waves|3 times of extracorporeal shock wave therapy is performed, and 1 cycle of extracorporeal shock wave therapy is performed (every 6 weeks) every 2 cycles of chemotherapy. Echocardiography is performed at baseline and every 4 cycles of chemotherapy.
45675748|NCT05582993|Biological|Recombinant von Willebrand Factor (rVWF)|rVWF administered by intravenous injection.
45675749|NCT05582993|Biological|ADVATE|ADVATE administered by intravenous injection.
45999756|NCT04689191|Biological|Experimental Group A and C meningococcal polysaccharide vaccine|One dose of Experimental Group A and C meningococcal polysaccharide vaccine
45999757|NCT04689191|Biological|Control Group A and C meningococcal polysaccharide vaccine|One dose of Control Group A and C meningococcal polysaccharide vaccine
45999758|NCT04671498|Procedure|Biospecimen Collection|Undergo collection of blood sample
45675750|NCT05582642|Device|Inspiratory Muscle Training (IMT)|"The training itself includes 2 x 30 breathing cycles per day. The whole training should take place daily, 7 days a week. The initial training intensity in the treatment arm (resistance of the respiratory muscle training) is set to 50% of the maximum respiratory muscle strength (measured using PImax). Once a week the present investigators get a picture of patient's training, pay attention to shortness of breath, potential for adaptation.~In the control arm of the study, this force adjustment would not take place, i.e. it is an endurance training of the diaphragm (10% of PI Max over the whole 6 weeks) with, however, also the control dates of the training twice a week. At least in the 6 weeks of the study (see above)."
45675751|NCT05582369|Behavioral|Affective Rewards Messages|Messages about the affective rewards of exercise
45675752|NCT05581758|Drug|AMG 510|Oral Tablet
45835257|NCT01450956|Other|Control|Patients will receive only oxygen and air through oxygenator
45835258|NCT02300922|Drug|Antibody TF2|injection of a recombinant antibody CEA specific. Three injections. Each injection are separate by one week
45835259|NCT02300922|Drug|90-Y-IMP-288|Injection of the peptide 90-Y-IMP-288, 24 Hours after injection of TF2. 2 injections by patients separated by one week (week 2 and week 3)
45835260|NCT02300922|Drug|111-In-IMP-288|Injection of the peptide 111-In-IMP-288, 24 Hours after the first injection of TF2 (week 1)
45835261|NCT02297724|Other|Oxygen|Administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan.
45999759|NCT04671498|Procedure|Droplet-BC Test|Undergo Droplet-BC Test
45999760|NCT04671498|Other|Electronic Health Record Review|Medical records are reviewed
45999761|NCT04689113|Behavioral|Incontinence Health Belief Development Program|After the applied interventions, it is desired to develop kegel exercise behavior in women.
45999762|NCT02925572|Other|Cycling exercises|All measurements are performed before and after the training program (12 weeks)
45999763|NCT04664673|Behavioral|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|motor learning-based, intensive therapy originally developed for hemiplegic children.
45999764|NCT04664673|Behavioral|Regular care|customary or usual treatment given to any adult stroke survivor
45999765|NCT02925377|Behavioral|Neuromuscular warm-up|The intervention group replaced their regular warm-up routine with seven neuromuscular warm-up exercises performed for 15 minutes prior to each practice session (3x/week) over a period of eleven weeks.
45999766|NCT02925377|Behavioral|Standard warm-up|Athletes in the control group followed their regular 15 minutes warm-up routine provided by the team coaches.
45999767|NCT04654299|Procedure|External biliary stent|The biliary stent consisted of a multi-perforated, natural rubber tube, measuring 3.5 mm in diameter, that we placed transanastomotically, with exteriorization sited at 20 cm utilizing the Witzel jejunostomy approach
46086775|NCT02649543|Procedure|Delayed Primary Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. The wound is left open for at least 7 days, after which closure with Polypropylene 2-0 takes place if considered suitable by a board certified surgeon.
45999768|NCT04622670|Other|Media Intervention|Receive DVD
46086776|NCT02711696|Behavioral|GCED, Gluten Contamination Elimination Diet|"A Gluten Free diet based exclusively on naturally gluten-free products and foods, with the elimination from the diet of all commercially available processed food and products labeled gluten free  (Gluten Contamination Elimination Diet, GCED)."
45999769|NCT04622670|Other|Quality-of-Life Assessment|Ancillary studies
45999770|NCT04622670|Other|Questionnaire Administration|Ancillary studies
45999771|NCT04622670|Other|Survey Administration|Ancillary studies
45999772|NCT04622670|Procedure|Yoga|Attend yoga class
46086777|NCT02711540|Procedure|Balloon Aortic Valvuloplasty|Some patients receive BAV prior to TAVI implantation to facilitate better deployment of the TAVI valve
45999773|NCT02925299|Device|FlorenceM (US) and FlorenceX (UK)|"The automated closed loop system (FlorenceM in US) will consist of:~Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Guardian3 CGM and glucose suspend feature.~The automated closed loop system (FlorenceX in UK) will consist of:~The DANA Diabecare R insulin pump (Sooil Development, Korea) incorporating the Dexcom G6 CGM.~An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device."
45999774|NCT02925299|Device|Insulin pump therapy|Subjects will continue using their own insulin pump for 6 months.
46086778|NCT02649699|Other|3D MRI Scans|Patients will receive additional MRI scans before commencing their radiation treatment, at 3-4 months, 6 months and 12 months post RT as well as at recurrence or suspected recurrence.
46086779|NCT02714660|Other|none, observational study|
46086780|NCT02649621|Biological|Amniotic Membrane Extract Eye Drop (AMEED)|Use of use Amniotic Membrane Extract Eye Drop (AMEED) on in vivo cultured limbal stem cells in the treatment of unilateral corneal stem cell damage.
46086781|NCT00605150|Radiation|TheraSphere-Yttrium 90 microsphere|TheraSphere is delivered to the liver via a catheter placed into the femoral artery and guided by fluoroscopy to the hepatic artery. Once the catheter is properly positioned, the physician infuses TheraSphere, which localizes preferentially in the tumor.
46086782|NCT02649465|Drug|Tofogliflozin|The group receiving Tofogliflozin (at a dose of 20mg once daily) for 48 weeks
45675753|NCT05564364|Device|Recumbent Bike|The first group will exercise with a recumbent bike for 20 minutes, 3 sessions/week for 6 weeks.
45835262|NCT01453530|Drug|Sugammadex|A single dose of sugammadex 2 mg/kg iv
45835263|NCT01453530|Drug|Neostigmine/Glycopyrrolate|A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv
45835264|NCT01453530|Other|Placebo|Placebo
45835265|NCT02983422|Drug|aminophylline|To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)
45999775|NCT02925416|Drug|oritavancin|
45999776|NCT02925416|Drug|placebo (D5W)|
45999777|NCT02925533|Drug|B-701|B-701 is a phage-derived, affinity-matured, human monoclonal antibody (mAb) specific for FGFR3. It is based on a human immunoglobulin G1 (IgG1) framework containing heavy chain VHIII and light chain VκI subgroup sequences.
45999778|NCT02925533|Drug|Pembrolizumab|Pembrolizumab is an mAb that binds to the programmed cell death protein 1 (PD-1) receptor and blocks its interaction with programmed death-ligand 1 (PD-L1) and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
45999779|NCT02925260|Other|MRI with ileal pouch contrast and enema.|Pre enema 20mg IV or IM Hyoscine Butylbromide (Buscopan) Pre enema Small Field of View (SFOV) T2 sagittal series Pre enema SFOV T2 axial series Pre enema SFOV T1 sagittal series (fat suppressed) Pre enema SFOV T1 axial series (fat suppressed) Enema infiltration started During enema filling Dynamic T1 sagittal single image, fat suppressed, aligned on pouch-anal anastomosis During enema filling T1 sagittal series (fat suppressed) During enema filling T1 axial series (fat suppressed) Jelly infiltrated and held Evacuating series Oblique sagittal T2 evacuating series of the mid and distal pouch, aligned to the pouch-anal anastomosis
45999780|NCT02917889|Drug|Caffeine|Volunteers will consume 300 mg of caffeine in pills fifteen minutes before treadmill aerobic exercise.
45999781|NCT02917889|Drug|Placebo|Volunteers will consume 300 mg of placebo in pills fifteen minutes before treadmill aerobic exercise.
45999782|NCT02917889|Other|Cardiopulmonary test|"assessment of the maximum oxygen consumption (VO2max) on a treadmill (Inbrasport / Millennium), using Buce protocol.~."
45835266|NCT02983422|Drug|frusemide|Use frusemide with Syringe pumps,maximum dose to 15mg/h
45835267|NCT02983422|Drug|normal saline|Placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
45999783|NCT02917889|Other|Treadmill aerobic exercise|30 mim of aerobic exercise (5 minutes at speed of 5.0 km/h for warming-up followed by 25 minutes at 60% of VO2max ).
45999784|NCT04573842|Other|Ultrasound assessment of SCV|An ultrasound examination of the SCV will be performed before anesthesia induction. Apart from this, the protocol does not differ at all from the ordinary fashion
45999785|NCT04564092|Drug|DaTSCAN™ Ioflupane (123I) Injection|Each subject will receive a single administration of DaTSCAN™ ioflupane (123I) injection by bolus IV injection with a nominal iodine (123I) activity of 111 MBq ±10%, in a maximum volume of 5 mL.
45999786|NCT02917967|Drug|Botulinum toxin injection|"BoNT-A will be injected into two hamstring and/or gastrocnemius muscles under the guidance of ultrasonography or electrical stimulation.~Maximal total dose and dose regimen for each muscle would follow the recommendation of international consensus.~A. Semitendinosus 5 to 7.5 units/kg of body weight B. Semimembranosus 5 to 7.5 units/kg of body weight C. Gastrocnemius 10 units/kg of body weight D. Maximal total dose per patient : unilateral injection 500 units, bilateral injection 1,000 units E. The dosage of two hamstring muscles will depend on the severity of spasticity and gait abnormalities of children with CP"
46086783|NCT02649465|Drug|Glimepiride|Sulfonylurea dosage (Glimepiride): dosing from 0.5 mg for initial 4 weeks. Then, if there is no adverse effect or no improvement of glucose metabolism, glimepiride is escalated to 6 mg once daily.
46086784|NCT02711462|Drug|PF-06687234|PF-06687234 will be administered via the SC or the IV route and in either single dose or multiple doses
46086785|NCT02711462|Drug|Placebo|In Cohorts 1 and 2, up to 1 subject will receive placebo. In all other Cohorts (Cohorts 3 to 11), up to 2 subjects will receive placebo.
46086786|NCT02649309|Procedure|RIPre|Preconditioning 200 mmHg x 5 minutes before procedure
46086787|NCT02649309|Procedure|Sham-Pre|Sham 10 mmHg x 5 minutes before procedure
46086788|NCT02649309|Procedure|RIPost|Postconditioning 200 mmHg x 5 minutes after procedure
46086789|NCT02649309|Procedure|Sham-Post|Sham 10 mmHg x 5 minutes after procedure
45675754|NCT05564364|Device|Upright Bike|The first group will exercise with a upright bike for 20 minutes, 3 sessions/week for 6 weeks.
46086790|NCT02714738|Procedure|Ultrasound guided peripheral nerve block|Ultrasound guided peripheral nerve block
46086791|NCT04167501|Other|biological sample analysis|HPV Prevalence analysis
46086792|NCT02711618|Device|UltraShape Contour I V3|Tissue selectivity is achieved by a proprietary knowledge of parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
46086793|NCT00651027|Drug|PF-868554|200 mg, Child-Pugh Class A
46086794|NCT00651027|Drug|PF-868554|200 mg, Child-Pugh Class B
46086795|NCT00651027|Drug|PF-868554|200 mg, healthy volunteers
46086796|NCT02722226|Other|Simulation|High fidelity simulation based sedation learning program
45675755|NCT05559749|Behavioral|collaborative care|a 24-week neurology based collaborative care program consisting of: 1. a series of every 2 weeks care management calls by the care manager to evaluate anxiety, depression, seizures and side effects and deliver brief therapy interventions to the participant, and 2. collaborative care conferences including a psychiatrist to generate expert recommendations for anxiety and depression management and communication of recommendations between the care manger, psychiatrist and neurologist.
45675756|NCT05559749|Behavioral|usual neurology care|ongoing usual neurology care, without the addition of the collaborative care program
45675757|NCT05557591|Drug|BNT116|BNT116 is administered by IV injection.
45675758|NCT05557591|Drug|Cemiplimab|Cemiplimab is administered Q3W by IV infusion
46086797|NCT02722226|Device|Airway management|Workshop on using airway management and oxygenation devices.
46086798|NCT02722226|Behavioral|Crisis resource management|Learning crisis resource management principles
46086799|NCT00651105|Drug|Vildagliptin|
45999787|NCT04536909|Other|Non-surgical|We have constructed a training program with help from physiotherapists from Rikshospitalet in Oslo, tailored for kyphotic- and scoliotic patients.
45999788|NCT04536909|Procedure|Surgical|Surgery for correction of kyphotic- or scoliotic deformity.
45999789|NCT04688840|Procedure|hip arthropalsty|follow up of patients with primary hip arthroplasty with at least one year follow up electronically and by routine method
46002435|NCT02901574|Behavioral|Computerized naming therapy|Computer delivered naming treatment requires matching (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red button if the word does not match the picture.
46086800|NCT00651105|Drug|Placebo|
46086801|NCT02694146|Drug|Platelet rich plasma|Platelet rich plasma (PRP) is a platelet concentrated obtained from autologous blood centrifugation. This concentration technique provides larger amounts of biologically active molecules, mainly growth factors that are responsible for tissue repair. PRP (platelet rich plasma) contains a higher concentration of platelets from baseline (150,000-350,000 / ul).
46086802|NCT02694146|Drug|Hylan G-F 20|Hylan G-F 20 is a viscous, sterile and non-pyrogenic elasto fluid containing hylan. Hylans are byproducts from hyaluronate (hyaluronic acid sodium salt), consisting of repeating disaccharides of N-acetylglucosamine and sodium glucuronate. Hylan G-F 20 replaces and supplements the synovial fluid. It is effective at any stage of the joint pathology.
46086803|NCT04167267|Drug|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
46086804|NCT04167267|Drug|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
46086805|NCT02714270|Procedure|modified partograph|
46086806|NCT02714270|Procedure|paperless partograph|
45999790|NCT04688879|Procedure|intra-arterial urokinase thrombolysis|Under local anaesthesia, the right femoral artery was punctured in accordance with the Seldinger technique, and a 6-Fr sheath, 10 cm in length, was implanted. Selective catheterization of the SMA was performed with 4-Fr catheter. The SMA angiography was performed to identify the filling defect. Thrombolysis was performed using a 5-Fr multiple-sideport infusion catheter (100cm with sideport of 7cm, 14 ports or 100cm with sideport of 15cm, 30 ports, Cook, Bloomington, IN, U.S.A). The tip of the microcatheter was embedded in the thromboembolism, which was fragmented at the time of thrombolysis. Thrombolysis was performed locally in the SMA with a bolus of urokinase
46086807|NCT02649075|Other|Serum-derived Bovine Immunoglobulin / Protein Isolate|Serum-derived bovine immunoglobulin protein isolate (SBI) is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients. Two packets (each packet contains 5 g of SBI) BID.
46086808|NCT02649075|Other|Placebo|Matching placebo with control hydrolyzed gelatin protein. Two packets BID.
45999791|NCT04526418|Device|24/7 EEG™ SubQ system|Electrographic seizure recording sensitivity of an ipsilaterally implanted 24/7 EEG™ SubQ system: proportion of identified ipsilateral seizures as compared to ipsilateral video-EEG during admission to the Epilepsy Monitoring Unit
45999792|NCT04688957|Procedure|oseodensification sinus lifting|application of first densah bur with densifying mood (reverse) counterclockwise, 1200 revolution per minute until the sinus is reached then use a wider densah bur with the same mode and bouncing motion to elevate the sinus floor up to 3 mm in 1mm increments.
45999793|NCT04688957|Procedure|osteotome sinus lifting|drilling implant site with consecutive drills short of the sinus floor by 1-2mm , using osteotome in appropriate size and application of one tap until sinus floor is elevated, using the final drill for the desired implant diameter
45999794|NCT04517721|Other|Nurse-Led Transitional Burns Rehabilitation Programme (4Cs-TBuRP)|The nurse-led transitional burns rehabilitation programme (4Cs-TBuRP) is presented as an 8-week interventional programme that supports holistic care for adult burn survivors led by a specialist burn care nurse and supported by the burn care team. The intervention posits that as the adult burn survivor transitions, several physiological, psychosocial, health-related behaviour and environmental needs emerge which lead to poor quality of life. Despite this, they may be unable to return to utilise available healthcare services or have inadequate contact with rehabilitation services. To facilitate their recovery and enhance the attainment of rehabilitation outcomes, the 4Cs-TBuRP views the burn care nurse as the link between rehabilitation services and the adult burn survivor. Thus, the burn care nurse serves as the coordinator of care and actively collaborates with the burn care team and the patient/ family to ensure that continuous care is delivered in a timely manner.
45999795|NCT02917733|Drug|LY3039478|Administered orally
45999796|NCT04486989|Behavioral|Cardiovascular Conditioning Protocol|Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
45999797|NCT04486989|Other|Voice Production Exercises|Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
45999798|NCT02917655|Behavioral|Womac|Answer WOMAC at baseline, 6, 12 and 24 months.
45999799|NCT02917655|Behavioral|Lequesne|Answer Lequesne at baseline, 6, 12 and 24 months.
45999800|NCT02917655|Behavioral|Numerical Rating Scales (NRS)|Answer NRS at baseline, 6, 12 and 24 months.
45999801|NCT02917655|Behavioral|IPAQ|Answer IPAQ at baseline, 6, 12 and 24 months.
45999802|NCT02917655|Behavioral|STS30|Perform the STS30 at baseline, 6, 12 and 24 months.
45999803|NCT02917655|Behavioral|TUG|Perform the TUG at baseline, 6, 12 and 24 months.
45999804|NCT02917655|Behavioral|Six-minute Test|Perform the six-minute test at baseline, 6, 12 and 24 months.
45999805|NCT02917655|Behavioral|Two days of lectures|Participate in two days of classes about KOA, with the seven teams (orthopedics, psychology, physical therapy and fitness, occupational therapy, social workers and nutritionist).
45999806|NCT02917655|Behavioral|Session with the psychologists|Participate in a extra session group with the psychology team about their experiences with the program
45999807|NCT02917655|Behavioral|Sessions with the physical therapy team|Participate in a extra session group with the physical therapists
45999808|NCT02917655|Behavioral|Sessions with the physical educators team|Participate in a extra session group with the physical educators
45999809|NCT02917655|Behavioral|Nutritional habits to be improved|Attend 3 extra meetings about nutrition.
45999810|NCT02917655|Behavioral|Tampa Scale for Kinesiophobia (TSK)|Answer Tampa Scale for Kinesiophobia (TSK) at baseline, 6 months, 12 and 24 months.
45999811|NCT02917538|Procedure|RFA|Both groups will receive radiofrequency ablation treatment
45835268|NCT02295540|Radiation|hypofractionated radiation therapy|Undergo hypofractionated IMRT
45835269|NCT02295540|Radiation|intensity-modulated radiation therapy|Undergo hypofractionated IMRT
45835270|NCT02295540|Procedure|therapeutic conventional surgery|Undergo surgery
45835271|NCT02295540|Other|laboratory biomarker analysis|Correlative studies
45835272|NCT05585892|Other|Elaboration and individual mailed feedback|see above
45835273|NCT05585814|Drug|Capecitabine|Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3weeks for 3 cycles
45835274|NCT05585814|Drug|Oxaliplatin|Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 3cycles
46086809|NCT02648841|Radiation|Adjuvant Concurrent Chemo-radiotherapy|Adjuvant concurrent chemo-radiotherapy will be given to the patients in the Experimental group after 4-6 cycles of SOX chemotherapy. Total dose of 45Gy is delivered by IMRT Radiotherapy technique. The concurrent chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral.
45999812|NCT04485273|Device|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.
45999813|NCT04485273|Drug|Sevoflurane|Sevoflurane in air/oxygen mixture of 40% is titrated to achieve adequate depth of anesthesia.
45999814|NCT04485273|Procedure|Subtenon's Block|Subtenon's block is performed in the eye undergoing surgery under sterile conditions where a 19-gauge curved blunt metallic cannula (25 mm) is inserted into sub-tenon's space.
45999815|NCT04485273|Drug|Local Anesthetic Solution and Dexmedetomedine|The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg), in addition to dexmedetomedine (0.5 μg /kg)
45999816|NCT04485273|Drug|Local Anesthetic Solution|The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg).
45999817|NCT02917577|Biological|Avaxim Pediatric®|2 doses (0.5 mL each) 6 months apart of Avaxim Pediatric® vaccine.
45999818|NCT02917577|Biological|Avaxim ® (adult)|2 doses (0.5 mL each) 6 months apart of Avaxim ® (adult) vaccine.
45999819|NCT02205840|Drug|SI-614|1 drop in each eye
45999820|NCT02205840|Drug|Vehicle|1 drop in each eye
45999821|NCT02205528|Drug|Liraglutide|Liraglutide will be self-administered daily via SC injection according to manufacturer specifications.
45999822|NCT02205528|Drug|Metformin|Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.
45999823|NCT02205528|Drug|Placebo|Matching placebo to NNC0090-2746 will be self-administered daily via SC injection.
45999824|NCT02205528|Drug|NNC0090-2746|NNC0090-2746 solution will be self-administered in daily doses of 1.8 mg via SC injection.
45999825|NCT03532022|Drug|Chronocort®|Hydrocortisone modified release capsules - 5mg, 10mg and 20mg.
46086810|NCT02648841|Drug|Adjuvant chemotherapy for active comparator group|8 cycles of SOX adjuvant chemotherapy will be given to the patients in the active comparator group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
46086811|NCT02648841|Drug|Adjuvant chemotherapy for experimental group|6 cycles of SOX adjuvant chemotherapy will be given to the patients in the experimental group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
45675759|NCT05554146|Other|Receipt of Coupon for Placebo Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for placebo soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
45675760|NCT05554146|Other|Receipt of Coupon for High THC Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for high THC soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
45999826|NCT03532022|Drug|Standard Care|The subject's standard care regimen upon entering the study; this could consist of hydrocortisone, dexamethasone, prednisone or prednisolone.
45999827|NCT02205099|Drug|SKL15508|
45999828|NCT02205099|Drug|Placebo|
45999829|NCT02200380|Drug|CDX-301|Related donors will receive CDX-301 for 5 days or 7 days.
46086812|NCT02722070|Device|3 Tesla Siemens Skyra MRI scanner|Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging
46086813|NCT02645331|Behavioral|Remind-to-move|
45675761|NCT05554146|Other|Receipt of Coupon for Equal THC and CBD Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for equal THC and CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
45999830|NCT02200380|Drug|CDX-301 and plerixafor|Related donors will receive CDX-301 for 5 or 7 days plus plerixafor.
45999831|NCT02196792|Device|E-Poly liner|E-Poly liner with a titanium cup
45999832|NCT02196792|Device|ArComXL liner|ArComXL liner with a titanium cup
45999833|NCT02196792|Device|32 mm femoral head|Stem with a 32 mm CoCr femoral head
45999834|NCT02196792|Device|36 mm femoral head|Stem with a 36 mm CoCr femoral head
45999835|NCT02917499|Device|TMS|Transcranial magnetic stimulation
45999836|NCT02191878|Drug|TKM-080301|TKM-080301 intravenous infusion
45999837|NCT03411083|Procedure|Total or unicompartmental knee replacement|Fast-track Knee replacement surgery including same day surgery
46086814|NCT02645331|Behavioral|Modified constraint induced movement therapy|
46086815|NCT02645331|Behavioral|Conventional rehabilitation|
46086816|NCT02644785|Drug|protamine|Protamine infusion exposures
45999838|NCT02187003|Drug|Rivipansel|Rivipansel (GMI-1070) will be infused intravenously every 12 hours up to 15 doses maximum. Subjects aged 12 and over who weigh more than 40 kilograms will receive a dose of 1680 mg of rivipansel, followed by a dose of 840 mg of rivipansel every 12 hours. All subjects aged 6 to 11 years and any subject who weighs 40 kilograms or less, will receive weight-based dosing (mg/kg) of 40 mg/kg of rivipansel (maximum of 1680 mg) followed by a dose of 20 mg/kg of rivipansel (maximum of 840 mg) every 12 hours.
45999839|NCT02187003|Other|Placebo|Placebo (phosphate buffered saline) will be infused intravenously every 12 hours up to 15 doses maximum.
45999840|NCT03330509|Other|SPARK intervention|An integrated model of care (SPARK care) in which the palliative care team co-rounds with the medical oncology team, supporting them in their delivery of basic palliative care, seamlessly stepping in and out to deliver specialist palliative care directly to patients when needed.
46086817|NCT02711150|Device|PLL Length Measured through US|The PLL will be measured for each allocated position: EPD or Flexed Position
45999841|NCT03313817|Device|Additional MRI sequences|"Patients will be hospitalized for suspicion of CRAO. An optimized MRI will be performed with specific sequences: 3D T1 MSDE (Motion Sensitized Driven Equilibrium) dark blood; 3D Optimized diffusion centered on the optic nerves; 3D PD T1 after injection. A consultation of ophthalmology and a control MRI will be carried out one month after the CRAO. Again, specific sequences will be added: 3D T1 MSDE (Motion Sensitized Driven Equilibrium) dark blood; 3D Optimized diffusion centered on the optic nerves; DTI (Diffusion Tensor Imaging); 3D PD T1 after injection."
46086818|NCT02644707|Dietary Supplement|L-selenomethionine|The group will be randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months
46086819|NCT02644707|Other|Placebo|The group will be randomized to receive placebo (control group) for 6 months
46086820|NCT02711228|Biological|Subcutaneous Immune Globulin (Human) (Hizentra)|Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.
46086821|NCT04612712|Drug|Donafenib Tosilate Tablets|In the dose exploration phase (phase I) : three doses of Donafenib tosylate tablets [50 mg twice a day; 100 mg twice a day; 200 mg twice a day ] will be explored. In the dose expansion phase (phase II), patients with advanced hepatocellular carcinoma will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.
46086822|NCT04612712|Biological|KN046 Injection|5mg/kg Q3W
46086823|NCT02644863|Drug|Paclitaxel|Paclitaxel 175mg/m2 IV over 2 hours,day 1; Repeat every 3 weeks;regimen for 3 cycles
46086824|NCT02644863|Biological|DC-CIK|Antigen-sensitized DC-CIK 8×10^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
46086825|NCT02644863|Drug|Cisplatin|Cisplatin 30mg/m2 IV on 1-3 days, Repeat every 3 weeks;regimen for 3 cycles
46086826|NCT00652587|Procedure|hepatectomy and transcatheter arterial chemoembolization|partial hepatectomy with adjuvant transcatheter arterial chemoembolization
46086827|NCT00652587|Procedure|hepatectomy|hepatectomy alone
46086828|NCT02711072|Drug|control group|spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 100 µ of intrathecal Morphine+ infiltration catheter with saline 5 ml/h
46086829|NCT02711072|Drug|infiltration group|spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 1ml of saline + infiltration catheter with 5 ml/h of Bupivacaïne 0,125%.
46086830|NCT02710994|Drug|CDFR0209|Immediate release omeprazole 40 mg and sodium bicarbonate 1,100 mg
46086831|NCT02710994|Drug|Losec|Losec 40 mg
46086832|NCT03524235|Radiation|Total Body Irradiation|Pre-Transplantation Total Body Irradiation
45675762|NCT05554146|Other|Receipt of Coupon for High CBD Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for high CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
46086833|NCT03524235|Procedure|Haploidentical Stem Cell Transplantation|Haploidentical Stem Cell Transplantation
46086834|NCT03524235|Biological|CD56-Enriched Donor Lymphocyte Infusion|CD56-Enriched Donor Lymphocyte Infusion
46086835|NCT03524235|Drug|Bendamustine|Pre-Transplantation Bendamustine
46086836|NCT03524235|Drug|Fludarabine|Pre-Transplantation Fludarabine
46086837|NCT03524235|Drug|Rituximab|Pre-Transplantation Rituximab (Rituximab for lymphoma diagnosis only)
46086838|NCT02714348|Other|Effect of helminth infection on vaccine immunogenicity|Observational; immunology
46086839|NCT00302744|Drug|Psilocybin (drug)|One placebo session (niacin) and one active drug session (.2 mg/kg). Treatment sessions are six hours.
46086840|NCT00302744|Other|Active Niacin Placebo|
45999842|NCT00554814|Drug|Bledilait Biofer®|Bledilait Biofer® 2 mg/100 kcal
45999843|NCT00554814|Drug|Milk supplemented with ferrous sulphate|Milk supplemented with ferrous sulphate (2mg/100kcal)
45999844|NCT00554814|Drug|Blédilait Biofer®|Blédilait Biofer® milk (1,1mg/100kcal)
45999845|NCT02161419|Drug|Roniciclib (BAY1000394)|Patients will receive roniciclib treatment as a 3 days on / 4 days schedule off with two 2.5 mg tablets twice daily for a total dose of 10.0 mg/day during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study.
46086841|NCT02644629|Drug|Placebo|Saline 0.9%, Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
46086842|NCT02644629|Drug|Ketamine (1st phase)|Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
46086843|NCT02644629|Drug|Ketamine (2st phase)|Patients failing to achieve response (<50% MADRS score) in the parallal phase, will be offered additional 4 session (twice a week, 2 weeks) of 0.5 mg/kg ketamine over 40 minutes.
46086844|NCT02710838|Device|infrared endoscopy|Firstly use standard white light and narrow-band imaging to observe the lesion, and then inject the contrast medium ICG, after 2 minutes,switch to infrared light to observe, record the image data, then accomplish the examination.
46086845|NCT00652665|Drug|Leflunomide|Tablets, 20mg, single-dose
46086846|NCT00652665|Drug|ARAVA|Tablets, 20mg,single-dose
46086847|NCT02721992|Other|No intervention|No intervention
46086848|NCT02644551|Drug|CELEXT07|
45999846|NCT02161419|Drug|Placebo|Patients will receive placebo treatment as a 3 days on / 4 days schedule off with two tablets twice daily during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
45999847|NCT02917616|Other|Alkaline drinking-water|
45999848|NCT02917616|Other|Neutral drinking-water|
45999849|NCT02160678|Drug|Vehicle|Cream Vehicle (placebo) (G & W Laboratories, Inc.)- vehicle
45999850|NCT02160678|Drug|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G & W Laboratories, Inc.) - test product
45999851|NCT02160678|Drug|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
45999852|NCT02917304|Biological|GC3110A vaccine|0.5mL, Intramuscular
45999853|NCT02917226|Other|Clinical decision support and monitoring system|
45999854|NCT02153502|Drug|AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)|AVP-786 capsules administered twice a day over a 10-week period
45999855|NCT02153502|Drug|Placebo|Placebo capsules administered twice a day over a 10-week period
45999856|NCT02917343|Behavioral|mirror therapy and repetitive task training|
45999857|NCT02917148|Other|Peripheral Venipuncture or Blood draw from Central Line|
46086849|NCT02644551|Drug|Penlac|
46086850|NCT02644551|Other|vehicle solution|
46086851|NCT02721914|Procedure|GROUP RECEIVING MASSOTHERAPY- HYPOPRESSIVE ABDOMINAL GYMNASTIC|The subjects of this group will receive an amount of eight sessions that will be applied within five weeks; four massotherapy sessions and another 4 of H.A.G. The three first weeks one session of each methodology will be applied, starting always with massotherapy (with sessions on Mondays and Thursdays or on Tuesdays and Fridays). On the fourth week a session of massotherapy will be applied on the same day as usual. And, finally, on the fifth week a session of H.A.G will be applied on the same day as massotherapy is applied.
46086852|NCT02721914|Procedure|GROUP RECEIVING MASSOTHERAPY|"The sessions will be applied for 5 weeks. The first three weeks 2 sessions per week will be applied (whether on Mondays and Thursdays or Tuesdays and Fridays), and during the remaining two weeks only a session will be applied per week, on the first day of the week same as applied before.~Massotherapy technics will be applied all over the back, covering the thoracolumbar area as well as upper areas reaching the cervix and occiput.~In particular, posterosuperior iliac spines, iliac crests, ribs, shoulder girdle and the entire spine (sacral bone- lumbar area-backbones-cervical vertebrae) and its attached tissues will be worked down.~Massotherapy protocol will be applied by the physical therapist, always respecting the postural ergonomics. This enables the verticality of the body (avoiding the slopes) which makes work much easier thanks to the inertia triggered by the load transfer in the lower extremities in both sagittal and horizontal plane."
45675763|NCT05553301|Biological|Quadrivalent Influenza mRNA Vaccine MRT5407|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular Injection"
45999858|NCT02151474|Drug|INCB047986|
45999859|NCT02151474|Drug|Placebo|
45999860|NCT02917070|Other|Patients|In this study we aimed to investigate effect of family history and consanguineous marriage in the development of CKD in the adult Turkish population.
45999861|NCT02144181|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
45999862|NCT02917109|Behavioral|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
45999863|NCT02916992|Radiation|CT scan of the thorax|A low dose CT scan of the thorax (2mSv) wil be performed once.
45999864|NCT02916992|Genetic|blood sample for FLCN mutation analyses|A venous punction in order to withdraw 16ml blood is undertaken once.
45999865|NCT02916914|Other|Q2 feeding|Infants are going to be fed every 2 hours
45999866|NCT02130687|Drug|Placebo|"Subjects will receive two capsules of placebo to preserve the blinding of the study.~In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin."
45999867|NCT02130687|Drug|Sitagliptin|Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.
45999868|NCT02130687|Drug|Aprepitant|Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.
45999869|NCT02130687|Other|Mixed Meal Test (MMT)|The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.
45999870|NCT02916836|Other|therapeutic drug conciliation sheet (TDC)|Use of therapeutic drug conciliation sheet (TDC)
45999871|NCT02916836|Other|No Use of therapeutic drug conciliation sheet (TDC)|
46086853|NCT02721914|Procedure|GROUP RECEIVING HYPOPRESSIVE ABDOMINAL GYMNASTIC|"The subjects of this group will receive a total of 8 sessions of 30 minutes each; sessions will be applied for 5 weeks. The first three weeks 2 sessions per week will be applied (whether on Mondays and Thursdays or Tuesdays and Fridays), and during the remaining two weeks only a session will be applied per week, on the first day of the week same as applied before.~The techniques applied are an assembly of rhythm, postural and breathing exercises that have to be done in a systematically. The physical therapist will check that all of the group subjects have assimilated properly the H.A.G and the breathing patterns from the exercises protocol. If they have, then the practical session which comprises 6 hypopressive exercises, can be started.~The subjects must remain in each position between 10 and 30 seconds and repeat the exercise three times, with a rest period among each that will last at least 20 seconds."
46086854|NCT02644395|Drug|Chlorthalidone|Drug
45999872|NCT02916758|Other|Let's Go Community Mobility Program|Four week multi-modal education and experiential program to improve community mobilty
45999873|NCT01228656|Drug|mometasone furoate + salicylic acid|Dermatologic ointment applied once a day.
45999874|NCT01228656|Drug|Mometasone furoate|Dermatologic ointment applied once a day
45999875|NCT01177761|Procedure|physical exercise|Two sessions/week, 50 weeks/year over 12 years of high intensity exercise training
46086855|NCT02644395|Drug|Amlodipine|Drug
46086856|NCT04166565|Drug|Daratumumab|Daratumumab 16 mg/kg will be administered by i.v. infusion. Daratumumab will be administered weekly in Cycles 1 and 2, then every 2 weeks for Cycles 3-6, and thereafter every month up to 36 months.
46086857|NCT04166565|Drug|Bortezomib|Bortezomib 1.5 mg/m2 bortezomib will be administered by a subcutaneous injection once weekly (Days 1, 8, 15 and 22) in all cycles.
46086858|NCT04166565|Drug|Cyclophosphamide|"Cyclophosphamide 300 mg/m2 will be administered as a p.o. or i.v. weekly dose (Days 1, 8, 15, and 22) in every 28-day cycle (maximum weekly dose 500 mg).~Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o."
46086859|NCT04166565|Drug|Dexamethasone|Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o.
46086860|NCT02721836|Behavioral|Yoga|Yoga intervention 12 weeks, twice weekly 75-minute intervention Yoga postures, breathing, relaxation, and meditation
45835275|NCT05585814|Drug|Bevacizumab|Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 3 cycles
46086861|NCT02721836|Behavioral|Nutrition Counselling|Evidence-based Nutrition Counselling, 3 appointments within 12 weeks
46086862|NCT02644239|Dietary Supplement|ketogenic diet|Ketogenic diet with high fat (90%)
45835276|NCT05585814|Drug|Pembrolizumab|Pembrolizumab is given intravenously at 200 mg on day 1 every 3 weeks for 3 cycles
45835277|NCT02567292|Other|Human Milk|Participants will receive an exclusive human milk diet comprised of mother's own milk (MOM, pasteurized donor human milk (DM) fortified with a donor-milk based fortifier (DMBF): Prolact+ for infants <37 weeks PMA and/or or weight <2,200g or PBCLN-002 for infants >37 weeks PMA and/or weight >2,200g)
45835278|NCT02566122|Other|measurements|
45835279|NCT02013648|Drug|Dasatinib|
45835280|NCT02013648|Drug|Cytarabine|
45835281|NCT02013648|Drug|Daunorubicin|
45999876|NCT02916641|Drug|Fuzhenghuayu|
45999877|NCT02916641|Drug|UDCA|
45999878|NCT02128113|Drug|Vehicle Ophthalmic Solution|Opthalmic suspension manufactured to mimic RTA 408 suspension
45999879|NCT02128113|Drug|Omaveloxolone Ophthalmic Suspension 0.5%|0.5% ophthalmic suspension of RTA 408
45999880|NCT02128113|Drug|Omaveloxolone Ophthalmic Suspension 1%|1% ophthalmic suspension of RTA 408
45999881|NCT02916680|Procedure|Pancreatic islet transplantation in the anterior chamber|Transplantation of allogeneic pancreatic islet cells into the anterior chamber of a severely visual impaired diabetic human eye
45999882|NCT02125266|Drug|V404|Sustained Release
45835282|NCT02013648|Drug|Idarubicin|
45835283|NCT05585736|Drug|Cycloplegics|they are drugs that paralyze the ciliary muscles and cause relaxation of accommodation.
45835284|NCT01989780|Drug|Paclitaxel|
45835285|NCT01989780|Drug|Bevacizumab|
45835286|NCT01989780|Drug|Letrozole|
45835287|NCT01989780|Drug|Anastrozole|
45835288|NCT01989780|Drug|Exemestane|
45835289|NCT01989780|Drug|Fulvestrant|
45835290|NCT01989780|Drug|Goserelin|
45835291|NCT01989780|Drug|leuprorelin|
45835292|NCT02276430|Other|Vena punction|Once 90 ml
45835293|NCT02270814|Drug|nab-paclitaxel|
45835294|NCT02270814|Drug|Cisplatin|
45835295|NCT02270814|Drug|Carboplatin|
45835296|NCT02270814|Biological|Cetuximab|
45999883|NCT02916524|Behavioral|Semantic Feature Analysis (SFA)|SFA training entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, action associated with item). Treatment is applied to a set of items in the context of single-subject, multiple baseline designs so that replication of treatment effects could be evaluated within and across participants. Treatment will be administered two times per week until prescribed accuracy levels were met during treatment probes or a maximum number of treatment sessions was completed.
46086863|NCT02710760|Other|Adoption Encouragement Treatment|Households in the Adoption Encouragement Treatment received child nutrition focused guidance on the nutritional and agronomic benefits of Quality Protein Maize (QPM) adoption, and the opportunity to order up to 6 kg of QPM seed to plant in their own fields.
45999884|NCT02116998|Biological|GEN-004 with Aluminum Hydroxide Adjuvant|"GEN-004: 100 µg of each antigen, with adjuvant, 350 µg aluminum hydroxide, administered as a 0.5 mL intramuscular (IM) injection.~GEN-004 is a recombinant S. pneumoniae protein subunit vaccine consisting of 3 recombinant T cell antigens:~GB104: ABC transporter, substrate-binding protein~GB144: Maltose/maltodextrin binding protein, ABC transporter~GB152: Hypothetical protein~GEN-004 is filled in 2 mL vials containing 0.5 mL (350 µg/mL of each antigen).~Aluminum hydroxide adjuvant is filled in 2 mL vials containing 1 mL at a concentration of 5 mg/mL."
45999885|NCT02116998|Biological|Placebo|Placebo: normal saline, 0.5 mL per dose, IM.
45999886|NCT02116998|Biological|Streptococcus pneumoniae inoculation|Intranasal inoculation of S. Pneumoniae (80,000 CFU/100μl per nostril) serotype 6B.
45999887|NCT02916329|Other|68Ga-NODAGA-Ac-Cys-ZEGFR:1907|68Ga-NODAGA-Ac-Cys-ZEGFR:1907 (Ac-Cys-ZEGFR:1907 : Ac-CVDNKFNKEMWAAWE EIRNLPNLN GWQMTAFIASLVDDPSQSANLLAEAKKLNDAQAPK-NH2)
46086864|NCT02710760|Other|Consumption Encouragement Treatment|Households in the Consumption Encouragement Treatment received the same guidance as households in the Adoption Encouragement Treatment, as well as additional guidance on the importance of specifically targeting foods made with QPM to young children and tools to help households keep the grain separate and remember to feed QPM-based foods to the young children.
46086865|NCT02644473|Drug|Tranexamic Acid|
46086866|NCT02644473|Drug|Normal saline|Control
45999888|NCT02110368|Drug|Testosterone Topical Gel, 1.62% Metered Pump|
46086867|NCT02710916|Device|SD-OCT Spectralis|All patients will undergo a complete ophthalmological examination with SD-OCT complete evaluation
46086868|NCT02644083|Drug|Dimethyl fumarate|
46086869|NCT04005872|Drug|Nano Silver Fluoride|Nano silver fluoride (NSF) is a new material consisting of nano silver particles, chitosan and sodium fluoride. It is a bacteriostatic and bactericidal compound.
46086870|NCT04005872|Drug|Calcium hydroxide|Calcium hydroxide is a gold standard for indirect pulp capping which induces hard tissue.
46086871|NCT02644317|Device|Modified shoe inserts|For experimental arm: wear modified shoe inserts and shoes for balance test.
45457774|NCT01136395|Procedure|living donor transplantation|living donor transplantation (ABO compatible) to be compared with deceased donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK/JC), respectively
45835297|NCT02265588|Behavioral|Cognitive behavioral therapy|A disease specific cognitive behavioral therapy program called PASCET-PI: The PASCET-PI model focuses on behavioral activation, cognitive restructuring and problem solving skills to change maladaptive behaviors, cognitions and coping strategies specific for IBD.
45835298|NCT02549898|Drug|Feraheme|Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.
45999889|NCT02110368|Drug|AndroGel (testosterone gel) 1.62% Metered-Dose Pump|
45999890|NCT02916485|Device|Bioresorbable scaffold|Percutaneous coronary intervention (PCI)
45999891|NCT01709214|Drug|Cebranopadol (GRT6005) Low-Dose Range|Capsules
45999892|NCT01709214|Drug|Cebranopadol (GRT6005) High-Dose Range|Capsules
46086872|NCT00652821|Drug|Tramadol/ APAP|Tablets 37.5mg /325mg
46086873|NCT00652821|Drug|Ultracet|Tablets, 37.5mg/325mg
46086874|NCT02714192|Other|Exercise stress test (BCTT)|Participants are assessed for exercise tolerance using a treadmill with gradually increasing angle to increase workload. Stress test is stopped when there is symptom exacerbation or when participant experiences voluntary exhaustion.
46086875|NCT04608812|Drug|OS2966|OS2966 is a humanized monoclonal antibody antagonizing CD29 (Beta 1 integrin)
46086876|NCT04608812|Drug|Gadoteridol|Gadoteridol is a contrast agent which will be added to OS2966 to allow investigators to observe how OS2966 distributes within the brain tumor. Gadoteridol is approved by the FDA for intravenous injection during an MRI scan. It is not approved by the FDA for administration directly into a tumor.
46086877|NCT02644161|Procedure|Dense cranial electroacupuncture stimulation|"DCEAS is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.~Six pairs of acupoints are used: Baihui (GV20, +) and Yintang (EX-HN3, -), left Sishencong (EX-HN1, -) and Toulinqi (GB15, +), right Sishencong (EX-HN1, -) and Toulinqi (GB15, +), bilateral Shuaigu (GB8, L+, R-), bilateral Taiyang (EX-HN5, L+, R-), and bilateral Touwei (ST8, L+, R-).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz, 100 µs)."
45457775|NCT01136395|Procedure|deceased donor transplantation|deceased donor transplantation (ABO compatible) to be compared with living donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK virus (BKV), JC virus (JCV)), respectively
45457776|NCT02304094|Drug|methylprednisolone|the steroid group shall receive a single injection of 1 mL methylprednisolone [40 mg] and 1 mL 2% lignocaine
45835299|NCT02549898|Drug|Cilostazol|Cilostazol will be applied to provoke migraine attacks in migraineurs
45835300|NCT02549898|Other|USPIO-MRI|USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.
45999893|NCT01709214|Drug|Placebo|Capsules that did not contain active substance but appeared identical to the cebranopadol and oxycodone CR capsules
45999894|NCT01709214|Drug|Oxycodone CR|Capsules containing oxycodone CR 10 or 20 milligrams
45999895|NCT02916602|Drug|HCP1401|amlodipine, Losartan, Chlorthalidone FDC
45999896|NCT02916602|Drug|HCP0605|amlodipine, Losartan FDC
45999897|NCT02110212|Procedure|U/S Surgery and CCC|Subjects will receive the standard of care for U/S cataract surgery and CCC to facilitate removal of the crystalline lens.
45999898|NCT02110212|Device|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery.
45999899|NCT02916797|Other|Stepping training with feedback|Stepping training with the use of external feedback. The subjects will be instructed to shift/take their body-weight onto the affected leg until the green zone of the displayed section is lighting and a beep sound to alarm the subjects to step the non-affected leg forward and backward as much as they can.
46086878|NCT02644161|Procedure|Body acupuncture|"Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Qu-Chi (LI11), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation at 15 min. No electrical stimulation is delivered."
46086879|NCT02644161|Drug|Antidepressant|Patients will continue their existing antidepressant therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
45999900|NCT02916290|Drug|Fuzhenghuayu|
45999901|NCT02916290|Drug|UDCA|
46086880|NCT02644161|Other|Rehabilitation|Patients will continue their existing rehabilitation therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
45999902|NCT01708551|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
45675764|NCT05553301|Biological|Quadrivalent Recombinant Influenza Vaccine|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular Injection"
45675765|NCT05553301|Biological|Quadrivalent Influenza Standard Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular Injection"
45675766|NCT05553301|Biological|Quadrivalent Influenza High-Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular Injection"
45675767|NCT05552430|Device|RelieveVRx|Participants will complete daily skills-based Virtual Reality (VR) sessions for 8 weeks (an average of 6 minutes per day) to determine the feasibility of at-home VR technology to aid the recovery of acute orthopedic musculoskeletal injuries. The VR device software is equipped with pain-specific treatment modules (e.g., Pain Education, Relaxation/Interoception, Mindful Escapes, and Pain Distraction Games) derived from evidence-based principles of cognitive behavioral therapy (CBT), mindfulness, and pain neuroscience education.
45999903|NCT02916251|Drug|ZP4207(dasiglucagon) glucagon analogue|Cross-over design with single s.c. administration in euglycemic and hypoglycemic T1D
45999904|NCT02916251|Drug|Glucagon (Native glucagon)|Cross-over design with single s.c. administration in euglycemic T1D
45999905|NCT01707264|Drug|NEOD001|Monoclonal antibody administered by intravenous infusion every 28 days.
45999906|NCT02916095|Drug|Kanitinib|Oral administration of Kanitinib tablets.
45999907|NCT02106546|Drug|Carboplatin|Carboplatin administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.
45999908|NCT02106546|Drug|Veliparib|Capsules taken orally twice a day, 12 hours apart.
45999909|NCT02106546|Drug|Paclitaxel|Paclitaxel administered intravenously over 3 hours at a dose of 200 mg/m².
45999910|NCT02106546|Drug|Placebo to veliparib|Capsules taken orally twice a day, 12 hours apart.
45835301|NCT02549898|Other|BBI-MRI|Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.
45835302|NCT02549820|Device|GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter|Fetoscopic Endoluminal Tracheal Occlusion (FETO) in CDH with GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
45835303|NCT02545608|Device|Restylane Vital|
45835304|NCT02538198|Drug|Lenalidomide|
45835305|NCT01894464|Behavioral|Teacher led intervention|
45835306|NCT05585580|Drug|Serplulimab|300mg d1 q3w
45835307|NCT05585580|Drug|Lenvatinib|8mg po qd
45835308|NCT05585580|Drug|Paclitaxel|135~175mg/m2 d1 q3w
45999911|NCT02916173|Drug|Recombinant Human Chorionic Gonadotrophin|250 unit intramuscular
45999912|NCT02916173|Drug|human chorionic gonadotrophin + gonadotrophin releasing hormone agonist|250 unit intramuscular + 1 mg subcutaneous
45999913|NCT02916134|Procedure|Laparoscopic +/- Open Appendicectomy|Laparoscopic +/- open appendicectomy , with antibiotics at induction (intravenous co-amoxiclav 1.2g, or if penicillin allergic, cefuroxime 1.5g + metronidazole 500mg ), followed by 3 further intravenous doses of the same antibiotic. If a perforation is identified at the time of surgery, microbiology will be contacted regarding choice and duration of of antibiotic.
45999914|NCT02916134|Drug|Antibiotic treatment|"Intravenous co-amoxiclav 1.2g three times daily, then 625mg, orally three times daily. If penicillin allergic, intravenous cefuroxime 1.5g three times daily + metronidazole 500mg three times daily, then oral cefuroxime 500mg twice daily + oral metronidazole 400mg three times daily.~The patient will receive inpatient intravenous antibiotics until sufficient clinical improvement is noted by the surgical team, who will be assessing the patient twice daily. After discharge the patient will receive 5 further days of oral antibiotics."
45999915|NCT02916212|Other|Optimized alarm profiles|
45999916|NCT04688606|Diagnostic Test|Circulating tumor cell capture technology|CTCBIOPSY® automatic testing platform
45999917|NCT02104245|Drug|Ciprofloxacin dispersion for inhalation|
45999918|NCT02104245|Drug|Placebo|
45999919|NCT04688489|Dietary Supplement|Carbloading and maltodextrin|The intervention is a dietary intervention that consists of a supplement of maltodextrin and added dietary carbohydrates. The supplement (20 g for women and 30 g for men) will be given to patients before and after a scheduled training, while the carbohydrates are given with meals. The extra carbohydrates given at meal time consists of extra potatoes, rice, bread, fruit, juice or other carbohydrate-rich food items.
46086881|NCT02644161|Procedure|Least acupuncture stimulation|The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (BI7, L+, R-), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (BI7) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
46086882|NCT04166175|Procedure|botox injection in intersphincteric space|injection of 80 IU of botox in the intersphincteric space in 5,7,11 and 1 O'clock position
45999920|NCT01699737|Drug|JTT-851|
46086883|NCT04166175|Procedure|lateral internal sphincterotomy|lateral internal sphincterotomy under GA in lithotomy position
46086884|NCT02714114|Other|First-void urine collection|One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
45835309|NCT01981044|Device|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
45999921|NCT01699737|Drug|Glimepiride|Encapsulated Glimepiride tablets
45999922|NCT01699737|Drug|Placebo for Active|
45999923|NCT01699737|Drug|Placebo for comparator|
45999924|NCT04688723|Drug|Dabigatran + Ticagrelor|Patiënt interventional treatment, with dabigatran + ticagrelor (Brilique) 90mg twice daily up to 12 months.
45999925|NCT04688723|Drug|Dabigatran + clopidogrel|Patiënt interventional treatment, with dabigatran + clopidogrel (plavix) 75mg once daily up to 12 months.
45999926|NCT01699464|Drug|AR-12286 Ophthalmic Solution 0.7%|Ophthalmic Solution
45999927|NCT01699464|Drug|AR-12286 Ophthalmic Solution 0.5%|Ophthalmic Solution
45999928|NCT01699464|Drug|Timolol maleate ophthalmic solution 0.5%|Ophthalmic Solution
45999929|NCT04688645|Drug|Balanced crystalloid solution|Balanced crystalloid solution (Plasmalyte) given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
45999930|NCT04688645|Drug|Normal saline|0.9% sodium chloride solution given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
45999931|NCT00555282|Device|central venous catheter|coated central venous catheter
45999932|NCT00555282|Device|central venous catheter|standard central venous catheter
46086885|NCT02714114|Other|Blood draw|One time blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccinations (CEV).
45835310|NCT04756986|Drug|malic acid|1% malic acid spray
45835311|NCT02513784|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate is a germicidal mouthwash that reduces bacteria in the mouth.
45835312|NCT02510742|Device|Neurostimulation|Neurostimulation of sphenopalatine ganglion (SPG) of 20 Hz
45999933|NCT04688372|Other|Surge Index|See study description above
45999934|NCT02104050|Drug|Placebo Gel|6 mL of Placebo Gel administered TID for 6 weeks
46086886|NCT02535975|Drug|Metformin|Tablets metformin 500 mg PO three times a day for 24 weeks
46086887|NCT02535975|Drug|Placebo|Tablets placebo PO three times a day for 24 weeks
46086888|NCT02714036|Drug|ibudilast|Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration16. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.
45835313|NCT02510742|Device|Sham stimulation|Sham stimulation of sphenopalatine ganglion (SPG) with amplitude=0
45999935|NCT02104050|Drug|OLT1177 Gel|6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
45999936|NCT02915861|Other|Non-invasive eschar samples + blood|EXPa (n=12) will have blood and non-invasive eschar samples collected (consent to study, declined biopsy).
45999937|NCT02915861|Other|Non-invasive eschar samples+eschar biopsy+blood|EXPb (n=12) will have blood, non-invasive eschar samples, and an eschar biopsy collected (consent to study, draining LN inaccessible).
45999938|NCT02915861|Other|Non-invasive eschar samples+eschar biopsy+lymph node fine-needle aspiration biopsy+blood|EXPc (n=12) will have blood, non-invasive eschar samples, eschar biopsy, and LN FNA collected (consent to study, draining LN accessible).
45999939|NCT02915861|Other|Blood+Skin sample|Controls (EXC, n=12) are healthy individuals, attending hospital for elective/minor surgery or treatment of minor skin injury, and normally reside in a scrub typhus endemic region. Blood and a skin sample will be collected at baseline only.
45999940|NCT02102802|Drug|Full dose MDMA|Participants receiving 125 mg MDMA
45999941|NCT03200132|Diagnostic Test|Cardiac PET/MRI|For patients undergoing 18-Fluor- fluorodeoxyglucose (18F-FDG) PET/MRI or PET/Computed Tomography (CT), additional cardiac PET/MRI scans are acquired.
45999942|NCT01694277|Drug|Masitinib|12 mg/kg/day
45999943|NCT01694277|Drug|Sunitinib|50 mg/day
45999944|NCT02100150|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (3g in 30 milliliter vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
45999945|NCT02100150|Drug|Placebo|Strawberry flavored solution 0.5% v/v in Water for Injection
45999946|NCT03103490|Drug|18F-FSPG|Patients receive 8mCi of 18F-FSPG and undergo PET/MRI imaging (or PET/CT for patients with metal implants) to determine the ability of 18F-FSPG to localize to cardiac sarcoidosis or myocardial inflammation.
46086889|NCT02644005|Device|Smart Vent Control|Smart Vent Control (SVC) was designed to automatically control the following ventilator settings: mechanical breathing frequency, inspiratory pressure, pressure support, inspiratory time, trigger sensitivity. SVC adjusts the ventilator settings with the aim to keep a patient stable in a target zone (TZ). Numerous predefined TZs exist that can be set according to the current therapeutic situation. All TZs are adoptable by the user for each individual patient and consist of upper and lower limits for tidal volume and for the partial pressure of end-tidal carbon dioxide (PetCO2). Based on these limits, the system classifies the current quality of ventilation, called Classification of Ventilation, and derives new ventilator settings accordingly. SVC is available as a software option on Zeus Infinity Empowered anesthesia machines (Drägerwerk AG & Co. KGAa, Lübeck, Germany) and is approved as a medical product according to 93/42/European Economic Community.
45999947|NCT01669980|Drug|Ceftaroline fosamil|"Subjects ≥ 6 months: IV ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour)~Subjects < 6 months: IV ceftaroline fosamil 10 mg/kg infused over 120 (± 10) minutes q8h (± 1 hour)~Optional Oral Switch:~PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~PO clindamycin 13 mg/kg/dose~PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
45999948|NCT01669980|Drug|IV Ceftriaxone and Vancomycin|"IV ceftriaxone 75 mg/kg/day (up to 4 g/day) divided equally every 12 hours (q12h) (± 2 hours) infused over 30 (± 10) minutes AND~IV vancomycin 15 mg/kg every 6 hours (q6h) (± 1 hour) infused over at least 60 minutes.~Optional Oral Switch:~PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~PO clindamycin 13 mg/kg/dose~PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
46086890|NCT02643927|Behavioral|standard 8-weeks MBSR|A 8 weekly sessions of 120 min based on the standard protocol of Kabat Zinn was performed. The adapted program did not include a one-day retreat in silence, but one session in silence plus extra kindly awareness (compassion-based) and value-based exercises. Home practice was not systematically assessed, but recommended to be of 45min per day, most of the days. It was administered by a trained (3-y experience) and certified MBSR teacher (MMPD).
46086891|NCT02643927|Behavioral|4-week shortened MBSR|This protocol was made up of 4 sessions of 120 mn administered by the same trained MBSR programme therapist to avoid variables associated to the therapist. The rationale behind the shortened version of MBSR was to keep the core content and practices of the program, in fewer sessions: raisin exercise (experiential concept of mindfulness); and main anchors of attention (breathing, body sensations, body movements).
45999949|NCT02915666|Drug|Digoxin Combination|Digoxin 0.25 mg PO daily will be given for 8-week cycles
45999950|NCT02915666|Drug|Dabrafenib|dabrafenib 150mg PO twice daily for 8-week cycles
45999951|NCT02915666|Drug|Trametinib|trametinib 2 mg PO daily for 8-week cycles
45999952|NCT02915822|Procedure|Minimally Invasive Chevron/Akin osteotomy|Minimally invasive technique for hallux valgus correction
45999953|NCT02915822|Procedure|Open Scarf/Akin osteotomy|Open technique for Hallux Valgus correction
45999954|NCT02098473|Drug|RPC4046|
45999955|NCT02098473|Drug|Placebo|
45999956|NCT02915627|Device|Application of Antishock garment|anti-shock garments are applied. Participants will then be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
45999957|NCT02915588|Other|early isometric loading after rotator cuff surgery|
45999958|NCT02915588|Other|passive motion after rotator cuff surgery|
46086892|NCT02710448|Drug|Metformin|Metformin (Glucophage ®), oral antidiabetic, will be administered as it is usually recommended: engaged during or at the end of the meal in the evening for the single dose 500 mg (Phase 1), the evening and morning for total doses of 1000 mg, 2000 mg and 3000 mg (with, respectively, 2 tab. 500 mg, 2 tab. to 1000 mg, 1 tab. to 1000 mg and 2 tab. to 1000 mg), a fourth dose is also scheduled to stage one (3000 mg / d)
46086893|NCT00652977|Procedure|Ritgens maneuver|Delivery of the fetal head should be managed by Ritgens maneuver, i.e. lifting the fetal chin anteriorly, using the fingers of one hand placed between the anus and the coccyx, and thereby extending the fetal neck, whereas the other hand should be placed on the fetal occiput to control the pace of the expulsion of the fetal head. The maneuver was used during a uterine contraction
45999959|NCT02915510|Dietary Supplement|Glycomacropeptide-based protein substitute|
45999960|NCT02098278|Drug|CAT-2003|
45999961|NCT02098278|Drug|Placebo|
45999962|NCT02915471|Behavioral|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 45 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 1.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
45999963|NCT04677894|Device|Laryngoscopy|During the intubation, the head of the patient was kept in a neutral position, patients were nasotracheally intubated
45999964|NCT02915276|Procedure|Blastocentisis|Removal of blastocoelic fluid from the blastocoelic cavity
45999965|NCT02915276|Procedure|Trophectoderm biopsy|Removal of trophectoderm cells from the blastocyst
45999966|NCT02915315|Dietary Supplement|salt|The protocol comprise a questionnaire survey and physical examination during a 3-day baseline observation period, a low-salt diet for 7 days (3g of salt per day) and a high-salt diet for 7 days (18g of salt per day). During the baseline period, each subject is given detailed dietary instructions to avoid table salt, cooking salt, and high-salt foods for the 17-day study duration. To ensure compliance of study participants with the intervention program, they are required to have their breakfast, lunch, and dinner at the study kitchen under supervision of the study staff during the entire study period. All foods are cooked without salt. Onsite study staff members add repackaged salt to the meals of individual subjects as indicated by the study protocol.
45999967|NCT02092935|Drug|SMT19969|
45999968|NCT02092935|Drug|Vancomycin|
45999969|NCT02915237|Dietary Supplement|Concord grape juice|Daily dietary supplementation with a commercially available Concord grape juice.
45457777|NCT02304094|Other|Manual manipulation|the manipulation group shall have the lesser MTPJs of the affected foot manually manipulated using a high velocity, low amplitude thrust technique
45999970|NCT02915237|Dietary Supplement|Placebo Beverage|Daily dietary supplementation with a placebo beverage consisting of water, sugar, artificial flavoring and color that is formulated to look and taste like grape juice and have the same carbohydrate composition and energy load.
45999971|NCT01666977|Drug|AMG 386|15mg/kg
45999972|NCT01666977|Drug|AMG 386|30 mg/kg
45999973|NCT01666977|Drug|AMG 386 Placebo|AMG 386 Placebo
45999974|NCT01666977|Drug|Pemetrexed|Pemetrexed 500 mg/m2
45999975|NCT01666977|Drug|Carboplatin|Carboplatin AUC 6
45999976|NCT02915354|Drug|Etanercept|Etanercept must be discontinued. Cotherapy with disease modifying anti-rheumatic drugs or non-steroidal anti-inflammatory drugs could be continued if maintained at a stable dose for at least 4 weeks.
45999977|NCT01661634|Drug|Ularitide|
45999978|NCT01661634|Drug|Placebo|
45999979|NCT02915081|Other|Blue light|"Illumination: High illumination lighting will be instituted with a Day*Light Classic Light (Uplift Technologies, Dartmouth, NS)~Blue wavelength: Each subject will be fitted with blue filtered goggles (Lee Filters, Burbank, CA). These goggles ensure the transmission of a bright (1700 lux) blue (peak 442 nm) spectrum light when the subject is within 12 inches.~Photoperiod: A 24-hour photoperiod will be used that commences at 0800 the morning prior to surgery and continues for 24 hours. To account for potential variability in the exposure of interest, each subject will complete a diary to catalogue duration and distance of light exposure. Postoperatively the same photoperiod will be instituted and continued for one 24 hour period."
45999980|NCT02914847|Behavioral|Functional Imagery Training (FIT)|Functional Imagery Training comprises of three elements: a) formulation of idiosyncratic drivers of self-harming behaviour and reasons for change; b) motivational interviewing combined with mental imagery techniques that enhance motivation to change the self-harm dysfunctional habit; c) formulation of goals for change (i.e. the goal is a desired behaviour alternative to self-harm) and practice of functional imagery to support goal achievement.
45999981|NCT01661166|Drug|Fesoterodine|4 mg
45999982|NCT01661166|Drug|Placebo oral tablet|Placebo
45999983|NCT02915003|Behavioral|E-health website|e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
45999984|NCT01659138|Drug|SAR339658|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
45999985|NCT01659138|Other|Placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45999986|NCT02915042|Drug|Dexmedetomidine|Analgesic Efficacy
45999987|NCT02915042|Drug|Placebo|Saline placebo
45999988|NCT01658826|Drug|AIC316|100 mg oral administration
45999989|NCT01658826|Drug|Valacyclovir|500 mg oral administration
45999990|NCT02914769|Drug|Ayahuasca|patients will receive a single dose of ayahuasca.
45999991|NCT02914769|Drug|placebo|patients will receive a single dose of a passive placebo.
45999992|NCT04677582|Behavioral|Vidas Activas, famiLias saludablEs (VALE)|Families and Children allocated to the intervention will receive weekly group-based meetings over a 10-week period consisting of education and activities on healthy lifestyles. Graduate students/Research Assistants trained in nutrition, exercise and clinical psychology will lead the meetings. All activities will be culturally relevant (i.e. cooking healthy Latino recipes) and Spanish speaking students will be recruited to deliver the intervention. Participants will be involved on deciding activities and projects and while some sessions will meet as a family group with parents/guardians, others will meet separately.
45999993|NCT02914925|Device|ArmeoSpring/CIT|Participating group will receive therapy with the Armeo®Spring Pediatric and CIT for 6 hours per day, 5 days per week for three weeks, totaling 90 hours
45999994|NCT02092077|Drug|TV-1106|TV-1106 0.554mg, TV-1106 0.924 mg, TV-1106 1.20 mg
45999995|NCT02092077|Drug|somatropin|Dose may be adjusted as required
45999996|NCT02914964|Behavioral|Swank Diet|A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling to study participants to assist them in following the Swank Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
45999997|NCT02914964|Behavioral|Wahls Elimination Diet|A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling using to study participants to assist them in following the Wahls Elimination Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
45999998|NCT01651143|Drug|SAR100842|"Pharmaceutical form: tablets~Route of administration: oral"
45999999|NCT01651143|Drug|Placebo (for SAR100842)|"Pharmaceutical form: tablets~Route of administration: oral"
46000000|NCT02914886|Drug|Apidra|Half of patients with lipoatrophy will be switched randomly to insulin Apidra for 12 months. Any site other than the lipoatrophic site would be used for delivering the insulin for the purpose of this study.
46000001|NCT02914886|Drug|current insulin|Half of patients with lipoatrophy will still use their current Insulin for 6 months. After 6 months the current insulin will be switched to insulin Apidra for the next 6 months.
46000002|NCT01650051|Drug|Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
46086894|NCT00652977|Procedure|Standard care (Manual support of the perineum)|The protocol entailed our standard care: using one hand to apply pressure against the perineum, and the other hand on the fetal occiput to control the expulsion of the fetal head, and only to use Ritgen´s maneuver in case of labor arrest or abnormal fetal heart rate pattern when the fetal head was at the pelvic floor.
46086895|NCT04602026|Other|Best Practice|Receive standard of care
45457778|NCT01138345|Genetic|gene expression analysis|blood samples will be analyzed for the expression of the p16 gene.
45457779|NCT01138345|Genetic|reverse transcriptase-polymerase chain reaction|perform reverse transcriptase-polymerase chain reaction on all blood samples.
46000003|NCT01650051|Drug|Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
46000004|NCT01643226|Drug|riboflavin solution|0.12% riboflavin ophthalmic solution
46000005|NCT01643226|Drug|placebo solution|0.0% riboflavin ophthalmic solution
46000006|NCT01643226|Device|KXL System|30 mW/cm2
46000007|NCT02089425|Drug|K-103-IP|
46000008|NCT02089425|Drug|Placebo|Placebo comparator
46000009|NCT02914652|Drug|Salbutamol|Ventoline(R), inhalation spray, 0,1 mg/dose, 9 doses administered as coherent single doses.
46000010|NCT02914652|Drug|Norflouran (Placebo Evohaler(R) )|Placebo Evohaler(R) MDI, inhalation spray, 60 mg/dose, 9 doses administered as coherent single doses.
46000011|NCT02081703|Drug|AYX1 Injection 660 mg / 6 mL|6 mL solution for intrathecal injection with 660 mg of AYX1
46000012|NCT02081703|Drug|AYX1 Injection 1100 mg / 10 mL|10 mL solution for intrathecal injection with 1100 mg of AYX1
46000013|NCT02081703|Drug|Placebo Injection 6 mL|6 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
46000014|NCT02081703|Drug|Placebo Injection 10 mL|10 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
46086896|NCT04602026|Behavioral|Exercise Intervention|Complete home exercise intervention
46000015|NCT02914691|Drug|Dapagliflozine 10 mg once daily tablet treatment|
46086897|NCT04602026|Procedure|Physical Therapy|Undergo physical therapy
46086898|NCT04602026|Other|Questionnaire Administration|Ancillary studies
46086899|NCT02643771|Procedure|Full Mouth Scaling and Root Planing|This procedure was performed as described by Quirynen et al. 2005 with some modifications
46086900|NCT02710058|Behavioral|one-time qualitative assessment|The study involves a one-time qualitative assessment to explore key cultural influences on AMBER breast cancer survivors' health behavior. We will focus on self-efficacy in healthcare, coping with breast cancer, social networks of support, and culturally-sensitive support groups. The study investigator will administer questions from the structured interview guide, estimated to take 90 minutes.
46086901|NCT04166253|Drug|Vitamin D|Alfacalcidol oral tablets once daily
46086902|NCT03954236|Drug|topical ruxolitinib 1.5% cream|Patients will be prescribed twice daily use of topical ruxolitinib 1.5% cream (randomized half of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days. Topical ruxolitinib will be provided as topical cream. At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
46086903|NCT03954236|Other|Topical vehicle/moisturizer cream|Patients will be prescribed twice daily use of vehicle/moisturizer (for contralateral side of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days.At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
45675768|NCT05551325|Other|Chronobundle - light|"Bright daytime light from 09:00 to 13:00 starting on day 1. The light will be 10,000 lux at 12 and provide a minimal intensity of 1,250 lux at the angle of the eye (30 to 36 distance). The light has a temperature of 5,000 Kelvin indicating a high blue wavelength content which should maximize circadian effects (validated device Sunbox Lighting, Maryland). Following the 09:00 to 13:00 bright light, the room lights will remain on and the curtains will remain open to maximize daytime light exposure while not decreasing bright light tolerance."
45675769|NCT05551325|Other|chronobundle - feeding|Time restricted (daytime) intermittent feeding will include 4 meals delivered at 09:00, 12:00, 15:00 and 18:00. Each meal will include one-fourth of the recommended daily tube feed volume.
45835314|NCT02283996|Other|Physical Therapy|"The following link contains the protocol for physical therapy that will be used in the study. There are no other ancillary devices or drugs used in this study aside from the depot methylprednisolone listed under interventions.~Brigham and Women's/Massachusetts General Standard of Care Guidelines for Physical Therapy in Treatment of Adhesive Capsulitis:~http://www.brighamandwomens.org/Patients_Visitors/pcs/rehabilitationservices/Physical%20Therapy%20Standards%20of%20Care%20and%20Protocols/Shoulder%20-%20Adhesive%20capsulitis.pdf"
46000016|NCT02914691|Drug|Placebo identical once daily tablet treatment|
46000017|NCT02081118|Drug|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
46000018|NCT02081118|Drug|Placebo|Placebo for HM11260C
46000019|NCT02078310|Drug|ITI-007|ITI-007 for Part 1
46000020|NCT02078310|Drug|Placebo|ITI-007 for Part 1
46000021|NCT02078310|Drug|ITI-007|ITI-007 for Part 2
45835315|NCT02283996|Drug|Depot Methylprednisolone|40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine
45835316|NCT02253030|Device|Optical Coherence Tomography|
46000022|NCT02078310|Drug|Placebo|Placebo for Part 2
46000023|NCT02914574|Other|PowersTM strap|The powers strap aims to decrease knee varus through supporting femoral abduction and external rotation. Participants will wear the Powers strap while performing functional tasks (running, squatting, single leg step down).
46000024|NCT02077881|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m^2 given intravenously over 30-40 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
45835317|NCT02251704|Procedure|Blood sampling|Capillary blood samples collected by finger/heel prick for determination of parasite prevalence at the time of survey.
45835318|NCT02251704|Diagnostic Test|Assessment of body temperature|Axillary body temperature of all subjects recorded by a digital thermometer at the time of survey.
46000025|NCT02077881|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
46000026|NCT02077881|Drug|Indoximod|"Indoximod will be administered in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth~Indoximod in the form of 200 mg capsules will be given (3, 5, and 6 capsules depending on the escalated dose). Indoximod should be taken with water by mouth one hour before breakfast and one hour prior to dinner. The medication should be taken twice daily for 28 days each cycle. Patients will continue until they experience disease progression or toxicity."
46000027|NCT02914418|Device|Transcranial Magnetic Stimulation using iTBS Paradigm|TMS is a non-invasive, painless method of stimulating the central and peripheral nervous system. ITBS is a form of TMS which is delivered for ~200sec and can promote changes in neural activity.
46000028|NCT02914379|Drug|[¹⁴C]-LY3337641|Administered orally
46000029|NCT04677699|Diagnostic Test|Combined Risk Score|Several factors will be analyzed to assign each subject combined risk score. This will assess the subject's risk of developing Type 1 Diabetes and/or Celiac Disease.
46000030|NCT02074410|Drug|OMS643762|
46000031|NCT02074410|Drug|Placebo|
46000032|NCT02914340|Device|Spiration Valve System|
45675770|NCT05551325|Other|chronobundle - mobility|Exercise/mobility sessions will occur twice per day between 09:00 and 16:00; intensity will be determined by clinical status and documented in the chart by our physical therapy service.
46000033|NCT02914262|Drug|AKB-4924|Comparison of different dosages of AKB-4924
46000034|NCT02914262|Other|Placebo|Placebo comparator
46000035|NCT02915900|Other|Gonadotropin removal test|Patient receives hormone dosage adjusted according to the results of the Gonadotropin removal test.
46000036|NCT02915900|Other|Routine IVF method|Patient receives hormone dosage according to the standard dosage regimen, without revealing the results of the Gonadotropin removal test to the clinician.
46000037|NCT01632228|Drug|Bevacizumab|Participants will receive bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
46000038|NCT01632228|Drug|Onartuzumab|Participants will receive onartuzumab 15 mg/kg IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
46000039|NCT01632228|Drug|Placebo|Participants will receive placebo matched with onartuzumab until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
46086904|NCT04165707|Device|Keyto device + app|Keyto is a self-monitoring and app-enhanced intervention to help individuals learn about and monitor their breath acetone (a measure of ketosis) levels to promote a very low carbohydrate diet and weight loss.
46086905|NCT04165707|Other|Weight Watchers app|The Weight Watchers app helps people to monitor their food intake, track points and provides recipe ideas to support weight loss.
46086906|NCT04472858|Drug|Donafenib|dose escalation: Donafenib 100 mg QD/100 mg BID/200 mg BID (p.o.). dose expansion: Patients will be assigned to specific tumor types and treated at the recommended dose for dose escalation.The recommended dose for dose escalation will be determined by the dose escalation study.
46086907|NCT04472858|Drug|CS1001|CS1001 will be administrated by intravenous (i.v.) infusion once every 28 days
46086908|NCT00653055|Drug|Cabergoline|Tablets, 0.5 mg (2 x 0.5 mg dose),fasting
46086909|NCT00653055|Drug|Dostinex|Tablets, 0.5 mg (2 x 0.5 mg dose), fasting
46086910|NCT02708576|Biological|NGM313|
46086911|NCT02708576|Other|Placebo|
46086912|NCT04165785|Device|OPT IPL|Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 24 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
46086913|NCT04165785|Device|Sham OPT IPL|Sham Optimal pulsed technology intense pulsed light IPL will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 24 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
45675771|NCT05551325|Other|chronobundle - sleep|Overnight sleep promotion will occur between 22:00 and 06:00 with a more restricted sleep period between 00:00 and 04:00. This will be achieved by rescheduling non-urgent care. There will be no changes to urgent care. Additionally, room lights will be dimmed, curtains drawn, and room doors closed. Television screens will be fitted with blue light-blocking filters.
45835319|NCT02369484|Drug|Afatinib|40mg p.o./ day until documented progression or unacceptable toxicity
45457780|NCT01138345|Other|laboratory biomarker analysis|perform laboratory biomarker analysis on all blood samples
45835320|NCT04390152|Drug|Wharton's jelly derived Mesenchymal stem cells.|IV Wharton's jelly derived Mesenchymal stem cells, two doses
45835321|NCT04390152|Drug|Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)|Standard therapy as per hospital protocol, hydroxychloroquine 400mg + Lopinavir/Ritonavir 400/100 or azithromycin 500mg and Placebo
45835322|NCT04390230|Procedure|Penile prostheses implantation|Penial implantation with either Coloplast or Boston Scientific - AMS IPPs between 2014 and 2019, by 2 surgeons of the University Hospital of Nice, France
45835323|NCT02238834|Drug|FP-025|Subjects will receive single doses of 200 to up to 800 mg of FP-025 (API-in-capsule) in a dose escalation format (cohorts 1-3). Subjects will receive single doses of 50 to up to 450 mg of FP-025 (ASD-in-capsule) in a dose escalation format (cohorts 4-8).
45835324|NCT02238834|Drug|Placebo|Subjects will receive single doses of FP-025 matching placebo (capsule) in a dose escalation format.
45835325|NCT02238834|Drug|FP-025|Subjects will receive doses of FP-025 (capsule) twice daily for 5 days.
45457781|NCT01138345|Other|medical chart review|perform medical chart review for all subjects
45835326|NCT02238834|Drug|Placebo|Subjects will receive FP-025 matching placebo (capsule) twice daily for 5 days
46000040|NCT02914223|Drug|Cenerimod|Oral formulation of cenerimod (2mg) containing 100 μCi (3.7 MBq) of 14C-radiolabeled cenerimod
46000041|NCT01628094|Drug|RO5024048|
46000042|NCT01628094|Drug|RO5190591|
46000043|NCT01628094|Drug|RO5466731|
46000044|NCT01628094|Drug|ribavirin [Copegus]|
46000045|NCT01628094|Drug|ritonavir|
46000046|NCT02914106|Other|Observational Study|Patients were diagnosed for AIS by a certified neurologist at the Emergency Room of the Central Military Hospital. Neurological, cognitive and functional status were determined by NIHSS score, Photo test, Pfeiffer mental status score and by modified Rankin score respectively. A sample of venous blood was withdrawn in the early morning (07 to 09 AM) after assessment of neurological and cognitive status.
46000047|NCT01627314|Biological|ProHema-CB|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
46000048|NCT01627314|Biological|Untreated CB|Cord Blood
46000049|NCT03026504|Drug|Baricitinib|4 milligrams oral Baricitinib daily for 52 weeks
46086914|NCT04165785|Procedure|MGX|Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of stainless steel jaeger lid plate positioned in the inferior fornix space between the tarsal and bulbar conjunctiva, and a cotton swab in another side.
46086915|NCT02713724|Behavioral|physical exercise|DAPS-group will follow a personal adjusted training program including instructions from a personal trainer Standard-group will receive a membership at a gym but limited instructions
46086916|NCT02713724|Behavioral|limited physical exercise|The standard group will receive a membership at a gym but limited instructions and no access to a personal trainer
46000050|NCT02073123|Drug|Indoximod|"Initial dose of 600mg BID by mouth with escalation planned to 1200mg BID by mouth~Dose escalation:~If 0 of the 3 subjects forming the first cohort experience RLT, 1200mg BID cohort will be enrolled~If 1 of the 3 subjects in any cohort experiences a RLT, then enrollment into that cohort will increase to a total of 6 subjects~If > 1 of the 3-6 subjects experience a RLT, then the MTD has been exceeded and further enrollment into the cohort will cease~If >1 subject at 600mg BID experiences a RLT, the dose will be de-escalated to 400mg BID. If >1 subject at this level experiences a RLT, one additional de-escalation to 200mg BID is allowed~Dosing cycles are 21 days in length during the combination immunotherapy component (first 4 cycles) and 28 days during indoximod monotherapy. Patients will continue until they experience disease progression or limiting toxicity~Phase 2 Treatment Plan (Cohort 2) Will receive fixed dose of indoximod determined in phase 1"
46000051|NCT02073123|Drug|Ipilimumab|Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.
46000052|NCT02073123|Drug|Nivolumab|Nivolumab administered intravenously at 240 mg every 2 weeks.
46086917|NCT02643147|Drug|CA125 guided strategy|Initial dose of intravenous furosemide ≤80 mg / day regardless of prior dose of loop diuretics who were receiving.
46086918|NCT02643147|Drug|CA125 guided strategy|Initial dose of intravenous furosemide ≥120 mg/day or 2.5 times the dose the patient was taking at home.
46086919|NCT02643147|Drug|Conventional Strategy|The dosage of loop diuretics is done according to the presence of symptoms and signs of systemic congestion and current recommendations
46000053|NCT02073123|Drug|Pembrolizumab|Pembrolizumab administered intravenously at 2 mg/kg every three weeks.
45457782|NCT01138345|Other|questionnaire administration|each cohort will be given the same questionnaire
46000054|NCT02914145|Drug|Dihydroartemisinin-piperaquine|Mass drug administration
46000055|NCT02913989|Other|Smoking habits characterization|
46000056|NCT00554892|Procedure|bowel preparation|oral laxatives, retrograde enemas
46086920|NCT03932630|Other|Low carbohydrate diet|The study intervention will be an eucaloric low carbohydrate diet (15-20 % of carbohydrates) for 2 weeks.
46086921|NCT03932630|Other|balanced diet|The control intervention will be a energy-matched balanced diet (50 % of carbohydrates) for 2 weeks.
46086922|NCT02643069|Other|Intervention Geriatric Program|The investigators will implemented programs to detected and manage care for older patients in four settings: Emergency room, oncology department, surgery departments making major surgery and Cardiology. The core intervention will consist of the following elements: comprehensive geriatric assessment, coordination with primary ans social care, integrated and continued care, access to rehabilitation facilities, management of drug treatment avoiding polypharmacy and stressing adherence.
46086923|NCT02709980|Behavioral|Sleep Education|The sleep education intervention will parallel the CBT-I intervention in number, format (in-person) and length of sessions. It is intended to disseminate information about sleep including sleep hygiene information that is widely available. Subjects will be instructed to read and review 6 publications from the American Academy of Sleep Medicine; sessions will review the material to ensure complete access to the information.
46086924|NCT02709980|Behavioral|Cognitive Behavior Therapy for Insomnia|Treatment will involve a standardized 6-session intervention, with demonstrated efficacy, that combines education and behavioral techniques to reduce insomnia. The core components include (1) education about sleep and insomnia, stimulus control, and sleep restriction (session 1); (2) sleep hygiene education (session 2); and 3) relaxation training, cognitive therapy, adherence monitoring, adjusting the recommended sleep-wake schedule, and addressing any problems in implementation (session 3-5). The final session will include a review of treatment content and relapse prevention.
45457783|NCT03507166|Drug|RC48-ADC|2 mg/kg IV every 2 weeks
46086925|NCT04165551|Biological|Probiotic|Volunteers will take 1 capsule a day of the Probiotic during lunch without any restrictions on diet or lifestyle.
46086926|NCT04165551|Biological|Placebo|Volunteers will take 1 capsule a day of the Placebo during lunch without any restrictions on diet or lifestyle.
45457784|NCT03507088|Drug|Fluoroestradiol (18F)|A FES-PET/(CT) will be performed twice during protocol execution. Patients will be injected with approximately 222 MBq 18F-FES each time.
45457785|NCT01233583|Drug|Dovobet, neotigason, etanercept, adalimumab. infliximab|Dovobet ointment 15g/day for 6 weeks Neotigason capsule 50mg per day (oral) for 6 weeks Enbrel 50mg twice weekly subcutaneous injection for 6 weeks Humira 80mg week 0, 40 mg week 1 then every other week therafter subcutaneous injection for 6 weeks Remicade 3 separate doses of 5mg/kg intavenous injection for 6 weeks
45457786|NCT02312050|Drug|GCS-100|1 mg, 3 mg, or 9 mg IV push injections
45457787|NCT02312050|Drug|Placebo|
46086927|NCT04503902|Drug|Donafenib Tosilate Tablets|In the dose exploration phase (phase I)，three doses of Donafenib tosylate tablets [100 mg once a day (QD); 100 mg twice a day (BID); 200 mg, BID] will be explored. In the dose expansion phase (phase II), patients will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.
46086928|NCT04503902|Drug|Toripalimab Injection|JS001 will be administrated by intravenous (i.v.) infusion once every 21 days
45675772|NCT05548127|Drug|ARV-471|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until the recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
46000057|NCT00554892|Procedure|no preparation bowel|no preparation bowel
46086929|NCT02642913|Drug|Enzalutamide|
46086930|NCT02642913|Drug|Enzalutamide with Sorafenib|
46086931|NCT04165629|Drug|Aspirin 300mg and Clopidogrel 300mg|Aspirin 300mg and Clopidogrel 300mg on the day of the PTA
46086932|NCT00611702|Procedure|Kidney biopsy|Kidney biopsy (recipients only) will be obtained for RT-PCR, microarray analyses and histology.
46000058|NCT01626573|Drug|Itacitinib|
46000059|NCT01626573|Drug|Itacitinib Placebo|
46000060|NCT02913950|Other|validation of pediatric stool scale|validation of pediatric stool scale
46000061|NCT01621152|Other|Conventional management arm|Based on KDIGO guidelines and as per primary physician in the ICU
46000062|NCT01621152|Other|AKI sniffer instigated AKI management|After identification of patients with AKI by the sniffer, primary physicians will be notified about the development of the syndrome and will be given a copy of the KDIGO guidelines for management of AKI.
45675773|NCT05548127|Drug|Abemaciclib|Daily oral dosages of Abemaciclib continuously, cycles lasting 28 days
46000063|NCT02914028|Procedure|transversus abdominis plane block|A peripheric block needle is inserted entering the facia between musculus rectus abdominis and musculus transversus abdominis with ultrasonography and local anesthetics are injected in the facia.
46000064|NCT02914028|Drug|Tramadol and paracetamol|Tramadol 100 mg and paracetamol 1000 mg are applied to the patients at the end of the surgery
46000065|NCT02913911|Other|feedback|Sit to stand training with external feedback
46000066|NCT02065284|Other|Rhythmic Auditory Stimulation (RAS)|Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.
46000067|NCT02913833|Other|Pain evaluation|Pain will be assessed four times per day on a visual analogic scale.
46086933|NCT03395925|Device|Celon Pro Surge|bipolar coagulation electrode intended for tissue heating
45675774|NCT05541315|Drug|JNJ-88260237|JNJ-88260237 will be administered orally.
46086934|NCT02708420|Device|Glidescope|This standard GlideScope (GS) technique involves a midline laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
46086935|NCT02708420|Device|Macintosh Laryngoscope|This technique involves a laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
45675775|NCT05541315|Drug|Placebo|Matching placebo will be administered orally.
45675776|NCT05538741|Drug|Bolus of remimazolam|0.19-0.25 mg/kg for 60-80 years old 0.14-0.19 mg/kg for >80 years old
45675777|NCT05538741|Drug|Continuous infusion of remimazolam|12 mg/kg/hr until loss of consciousness
46000068|NCT02913755|Behavioral|Preparatory video|5 minute Preparatory video to increase motivation, awareness and engagement in ABI rehabilitation
46000069|NCT02064426|Drug|Molidustat (BAY85-3934)|Subjects will continue with the same treatment they were receiving in the parent study (16208). BAY85-3934 will be administered daily as oral tablets. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits, the dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose. Total treatment time is up to 36 months. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
46000070|NCT02064426|Biological|Epoetin alfa/beta|Subjects will continue with the same treatment they were receiving in the parent study (16208). Epoetin alfa / beta will be administered as intravenous (IV) or subcutaneous (SC) injections per individual subject regimen according to the local label. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits,dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose.Total treatment time is up to 36 months.
46000071|NCT00899301|Other|biologic sample preservation procedure|Tissue, urine and blood collection.
46000072|NCT02913677|Dietary Supplement|nutrition|Feeding was started in the first 48 hours. Fed with 10-15 ml/kg/d MEN for 5 days and than feed volumes were advanced by 20-25 ml/kg/d until 150ml/kg/d feed volume was achieved.
46000073|NCT02913716|Drug|defactinib|Single oral dose of 400 mg [14C]-defactinib
46000074|NCT02063997|Drug|Arhalofenate 600 mg|Arhalofenate 600 mg tablets once daily for 12 weeks
46000075|NCT02063997|Drug|Allopurinol 300 mg|Allopurinol 300 mg tablets once daily for 12 weeks
46000076|NCT02063997|Drug|Colchicine 0.6 mg|Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks
46000077|NCT02063997|Drug|Placebo|Placebo tablets once daily for 12 weeks
46000078|NCT02063997|Drug|Arhalofenate 800 mg|Arhalofenate 800 mg tablets once daily for 12 weeks
46000079|NCT02913443|Drug|RO7051790|RO7051790 will be given orally. Treatment will be continued until disease progression/treatment failure, unacceptable toxicity, or study discontinuation.
46000080|NCT00585507|Drug|Fulvestrant|500mg into the muscle on days 1, 15 and 29 and then every 28 days thereafter.
46000081|NCT02913287|Dietary Supplement|Aquamin/Aquamin MG|Marine-based nutraceutical
46000082|NCT02913287|Other|Maltodextrin Placebo|Maltodextrin Placebo
46000083|NCT02063685|Drug|R-CHOP or R-bendamustine|"As induction therapy all patients will receive 6 courses of:~Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days.~or 6 courses of:~Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days."
46000084|NCT02063685|Drug|Observation|not maintenance therapy and followed-up with MRD monitoring.
46000085|NCT02063685|Drug|Maintenance weekly x4|Four weekly doses of Rituximab (375 mg/m²). Rituximab could be repeated for MRD positive for a maximum of three courses
46000086|NCT02063685|Drug|Ibritumomab Tiuxetan + Maintenance|single dose of (90)Y Ibritumomab Tiuxetan (0.4 mCi/kg). Following RIT patients will continue maintenance with Rituximab (375 mg/m² every 2 months) for a total of 11 infusions.
45675778|NCT05536323|Drug|Remimazolam bolus|Remimazolam bolus 0.14-0.33 mg/kg 0.25-0.33 mg/kg, <40 years 0.19-0.25 mg/kg, 60-80 years 0.14-0.19 mg/kg, >80 years
46000087|NCT02063685|Drug|Standard Maintenance|Rituximab 375 mg/m² every 2 months for 2 years. Maintenance will have to be started no more than 12 weeks after the last induction chemoimmunotherapy infusion.
46000088|NCT02913248|Procedure|Conventional periodontal treatment|Non-surgical periodontal treatment including thorough instruction in self-performed oral hygiene
46000089|NCT02063295|Drug|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
45457788|NCT03504748|Device|deep rTMS|
45675779|NCT05536323|Drug|Remimazolam continuous|Remimazolam 12 mg/kg/hr
45675780|NCT05535738|Drug|Squaric Acid Dibutyl Ester|Sensitization dose: 2% Elicitation doses: {0.0001%, 0.00025%, 0.00075%, 0.001%, 0.0025%, 0.005%, 0.0075%, 0.01%, 0.025%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6% 0.7%, 0.8%, 0.9%, 1.0%, 1.2%, 1.4%, 1.6%, 1.8%, 2.0%}
45675781|NCT05535738|Other|Known patch test allergens|Positive patch test allergens during the course of clinical patch testing will be re-applied on the back followed by skin sampling
45675782|NCT05535738|Drug|Dupilumab|300mg
45675783|NCT05535738|Drug|Adalimumab|40mg
45675784|NCT05535738|Drug|Ustekinumab|45mg
45675785|NCT05535738|Drug|Guselkumab|100mg
45675786|NCT05535738|Drug|Canakinumab|150mg
46000090|NCT02063295|Drug|ZGN-440 for injectable suspension|
46000091|NCT00539643|Device|Bead Block microspheres|Bead Block (Beads) microsphere, 100-300 micron with additional larger size beads as necessary to achieve stasis
46000092|NCT00539643|Other|Bead + Dox Arm|Bead + Dox Arm: Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.
46000093|NCT02913170|Dietary Supplement|Nattokinase|
46000094|NCT02913170|Dietary Supplement|Placebo|
46000095|NCT02057172|Drug|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
46000096|NCT02057172|Drug|liraglutide|Liraglutide is a GLP-1 agonist.
46000097|NCT02057172|Drug|Placebo|Placebo
46000098|NCT02913404|Procedure|ACL Reconstruction|standard surgical procedure
46000099|NCT02913404|Procedure|ACL Recon. extra-articular-tenodesis|standard surgical procedure and extra-articular-tenodesis will be used for a randomized portion of participants
46000100|NCT02053116|Drug|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
46000101|NCT02053116|Drug|Placebo|Tablet, 0 mg, twice daily, 2 weeks
46002436|NCT02877433|Device|Roxolid short implant, 4 mm length (4)|Placement of a combination of four short implants (in positions 35/45, 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
46000102|NCT02912975|Other|Mirror treatment|The mirror treatment: The patient sits on a chair, both knees in 90 degrees flexion, both lower limbs undressed, and places a mirror of 100 cm x 25 cm along the trans-tibial amputation stump so that the uninjured limb is reflected in the mirror while the amputation stump can not be seen by the patient. The patient then performs slow repeated movements of the foot from neutral position into maximum flexion while closely observing the reflected image of the uninjured limb - the illusion of a limb regained - in the mirror. The procedure goes on uninterrupted for five minutes in the morning and in the evening in the home of the study patient.
46000103|NCT02912975|Other|Tactile treatment|In Tactile Treatment five different sensory stimuli is applied repeatedly to the skin of the affected part of the limb, in the actual case to the amputated limb from ten cm above the knee joint and distally to include the entire amputation stump: gentle touch with a feather, a brush, a piece of paper, a stone and a wooden stick. The stimuli are applied two times daily for five 5 minutes each time, one minute per material.
46000104|NCT02894307|Drug|Rivaroxaban|In patients with mechanical valves and unstable INR
46000105|NCT02913014|Other|No AAD post Ablation.|Subjects will not resume their pre-ablation anti-arrhythmic medications during the 90 following cryo ablation for Atrial Fibrillation
46086936|NCT02642757|Behavioral|AUDIT brief intervention|Intervention will be provided following the Chilean ministry of health implementation manual on the AUDIT associated brief intervention. The pamphlet on alcohol use will be provided to participants.
46086937|NCT02642757|Other|Pamphlet on alcohol use|Only the pamphlet on alcohol use will be provided (the same received by participants on the intervention group). This is not an active intervention based on the current literature.
46086938|NCT02708264|Device|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB
46000106|NCT02052648|Drug|Indoximod|
46000107|NCT02052648|Drug|Temozolomide|
46000108|NCT02052648|Drug|Bevacizumab|
45457789|NCT03504748|Device|placebo deep rTMS|
45457790|NCT01230853|Drug|Active Comparator: A|Lecanemab Single Dose Ascending Single intravenous infusions at sequentially ascending doses on Day 1 (dose levels: 0.1, 0.3, 1, 3, 10, and 15 mg/kg)
45457791|NCT01230853|Drug|Placebo Comparator B|Placebo Matching Placebo Infusion
45675787|NCT05535738|Drug|Sarilumab|200mg
46000109|NCT02052648|Radiation|Stereotactic Radiation|
46000110|NCT02913053|Behavioral|Aerobic exercise|Patients with mild cognitive impairment will undergo a one-year aerobic exercise program of 3 units of 45 min / week
46000111|NCT02913053|Behavioral|Non-aerobic exercise|Patients with mild cognitive impairment will undergo a one-year stretching and toning (non-aerobic) exercise program of 3 units of 45 min / week
46000112|NCT02894112|Dietary Supplement|non-fat milk|1 serving of non-fat fluid milk
46000113|NCT02894112|Dietary Supplement|carbohydrate control beverage|1 serving of carbohydrate control beverage (Carbohydrate powder + water)
46000114|NCT02894112|Dietary Supplement|caloric control beverage|1 serving of caloric control beverage (carbohydrate powder + protein powder + water)
46000115|NCT01186744|Drug|CP-690,550|10 mg of CP-690,550 oral BID or placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
46000116|NCT01186744|Drug|CP-690,550|10 mg oral BID
46000117|NCT01186744|Drug|CP-690,550|5 mg of CP-690,550 oral BID or Placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
46086939|NCT02642523|Drug|Nesiritide|Subjects will receive an intravenous infusion of recombinant human b-type natriuretic peptide (BNP) (Nesiritide) over 2 hours at 2 doses: 0.003 ug/kg/min for 1 hour, followed by 0.01 ug/kg/min for 1 hour. Nesiritide (Johnson and Johnson) is FDA-approved for the treatment of heart failure. Study investigators received approval from the FDA for an IND exemption for nesiritide in this study. While receiving the BNP infusion, subjects will also receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
46086940|NCT02642523|Drug|Insulin|The hyperinsulinemic-euglycemic insulin clamp, which will last between 2-2.5 hours, involves continuous intravenous infusions of human regular insulin and of dextrose solution. Simultaneously, subjects receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
45675788|NCT05535738|Drug|Triamcinolone Acetonide|0.1% ointment
45675789|NCT05535738|Drug|Betamethasone Valerate|0.1% ointment
45675790|NCT05535738|Drug|Fluticasone Propionate|0.005% ointment
46000118|NCT01186744|Drug|CP-690,550|5 mg oral BID
46000119|NCT02912936|Dietary Supplement|Ketogenic medium chain triglyceride drink (MCT drink)|10 days supplementation with the MCT drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
46000120|NCT02912936|Dietary Supplement|Placebo|10 days supplementation with the placebo drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
45675791|NCT05535738|Device|Microneedle|Painless and non-scarring skin sampling with a 7mm x 7mm patch of hydrogel-coated poly-l-lactide microneedles (<2mm length) will be used to collect interstitial fluid
46000121|NCT02044341|Drug|AR01|drops administered an needed for pain
46000122|NCT02044341|Drug|Glycerin ear drops|placebo drops administered for ear pain
46000123|NCT02912819|Other|Open-lung approach|Increase and decrease in airway pressure to open the lung and keep them opened.
46000124|NCT00555399|Drug|Vorinostat|"Phase I/Arm 1: Level 0 = 300 mg PO x 14 days; Level I = 400 mg PO x 14 days; Level II = 500 mg PO x 14 days.~Phase I/Arm 3: Level -II = 300 mg PO x 14 days; Level -I = 400 mg PO x 14 days; Level 0 = 400 mg PO x 14 days; Level I = 500 mg PO x 14 days."
46000125|NCT00555399|Drug|Isotretinoin|"Phase I/Arm 1: Level 0 = 100 mg/m^2/day PO x 21 days; Level I = 100 mg/m^2/day PO x 21 days; Level II = 100 mg/m^2/day PO x 21 days.~Phase I/Arm 2: Level 0 = 100 mg/m^2/day PO x 21 days; Level I = 100 mg/m^2/day PO x 21 days; Level II = 100 mg/m^2/day PO x 21 days.~Phase I/Arm 3: Level -II = 100 mg/m^2/day PO x 21 days; Level -I = 100 mg/m^2/day PO x 21 days; Level 0 = 100 mg/m^2/day PO x 21 days; Level I = 100 mg/m^2/day PO x 21 days; Level II = 100 mg/m^2/day PO x 21 days."
46000126|NCT00555399|Procedure|Surgical Resection|Surgical Resection for recurrent Glioblastoma Multiforme
46086941|NCT02642523|Other|Saline|Subjects will receive an intravenous infusion of normal (0.9%) saline over 2 hours at a rate of 0.25 ml/kg/min. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
46086942|NCT02713802|Drug|Cudafol(R) (propofol, 1% [10 mg/mL])|Test product Cudafol(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
46086943|NCT02713802|Drug|Diprivan(R) (propofol, 1% [10 mg/mL])|Reference product Diprivan(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
46086944|NCT02642445|Device|Renal Sympathetic Denervation|We applied a ablation catheter for discrete radiofrequency ablations of 8 W or less and lasting up to 2 min each to obtain up to four-six ablations separated both longitudinally and rotationally from the adventitia
46086945|NCT02713958|Other|Telerehabilitation|Telerehabilitation: Telerehabilitation treatment using a computerized system (MediTouch) for improving the elbow motion
45675792|NCT05535738|Device|Suction blistering|Suction blistering is a technique to induce and collect blister fluid using a negative pressure instrument (Electronic Diversities Finksburg, MD). It does not require local anesthetic, stitches or pain medication following the procedure. The blisters will be no greater than 1cm in diameter and no deeper than the epidermis (<1mm deep). This process of inducing blisters is typically less than 1 hour. After the formation of blisters, the blister fluid will be extracted using a syringe. The blister roofs will be left attached to the skin and covered with petrolatum and a bandage.
46000127|NCT00555399|Drug|Temozolomide|"Phase I/Arm 2: All Levels = 150 mg/m2/day PO X 14 days.~Phase I/Arm 3: Level 0 = 150 mg/m2/day PO X 14 days; Level I = 150 mg/m2/day PO X 14 days; Level -I = 125 mg/m2/day PO X 14 days; Level -II = 125 mg/m2/day PO X 14 days; Level -III = 100 mg/m2/day PO X 14 days."
45675793|NCT05535738|Procedure|Skin punch biopsy|A skin biopsy is the removal of a small piece of tissue, under local anesthetic.
46000128|NCT03454932|Other|Blood sampling|
46000129|NCT02912663|Drug|Verapamil and Magnesium Sulfate|Single dose strategy will be used
46000130|NCT02912663|Other|Placebo|Single matching dosing strategy will be used
46000131|NCT02026401|Biological|NGM282|
46000132|NCT02026401|Biological|Placebo|
46000133|NCT02912741|Drug|Vanish xt Extended Contact Varnish|resin modified glass- ionomer cement varnish applied as a thin layer coating and cured
46000134|NCT02912741|Drug|resin infiltration|low viscous light cure resin applied in layers and cured
46000135|NCT05355298|Drug|AMP945 ascending doses|Part A is a phase 1b dose-escalation design that will enrol at least 3 participants in each of 4 dose-level cohorts, to determine the RP2D of AMP945 to be explored in Part B. Dose escalation decisions will be made using a standard 3+3 dose-escalation phase 1 oncology study design.
46086946|NCT02713958|Other|Rehabilitation|Traditional Occupational Therapy treatment: Active exercises for elbow motion
45457792|NCT01230853|Drug|Active Comparator B|Lecanemab Multiple Dose Ascending Intravenous infusions once every 4 weeks at sequentially ascending doses (dose levels: 0.3, 1, 3, and 10 mg/kg)
46000136|NCT05355298|Drug|AMP945 RP2D|Part B will determine the efficacy of the AMP945 priming regimen at the recommended phase 2 dose (RP2D) determined in Part A.
46000137|NCT04318522|Device|Transcranial Direct Current Stimulator|Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation device that can excite or inhibit the brain activity depending on the stimulation protocol. It has mainly two variants including conventional c-tDCS and High-Definition HD-tDCS.
46000138|NCT02894151|Drug|Depot medroxyprogesterone acetate|
46000139|NCT02894151|Device|LNG-IUS|
45457793|NCT01230853|Drug|Placebo Comparator A|Placebo Matching Placebo Infusion
45457794|NCT02304172|Device|Thunderbeat (Group A)|hemostatic device utilized intraoperatively
45457795|NCT02304172|Device|Harmonic (Group B)|hemostatic device utilized intraoperatively
45457796|NCT02304250|Drug|Dexamethasone|dexamethasone 1ml (5mg)
45457797|NCT02304250|Drug|saline|saline 1ml
45457798|NCT01133587|Other|wait list control|"Patient-guided admissions contract regarding patient-guided admissions starting a year after."
45457799|NCT01133587|Behavioral|admissions contract|"contract regarding patient-guided admissions starting immediately"
45675794|NCT05533814|Drug|Perampanel|Perampanel tablets.
45675795|NCT05518110|Drug|Trametinib|2mg of Trametinib (orally) daily.
45675796|NCT05518110|Drug|Hydroxychloroquine|1200mg of Hydroxychloroquine (orally; 600mg twice a day (BID)) daily.
46000140|NCT02912858|Device|geko plus R-2|"The gekoTM plus R-2 devices (acting on the common peroneal nerve) and IPC devices will be activated for 10mins prior to measuring blood flow.~The sequence of application of IPC and gekoTM plus R-2 devices will be randomly selected with 10 minutes recovery between active therapies."
46000141|NCT02894229|Behavioral|Mindfulness Based Stress Reduction|A modified version of traditional MBSR. The current study's version of MBSR is shortened to 6-weeks.
45675800|NCT05508867|Biological|favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
45675801|NCT05508867|Drug|bendamustine|IV infusion
45675802|NCT05508867|Drug|gemcitabine|IV infusion
45675803|NCT05505734|Drug|BDA MDI|Participants will receive Budesonide and Albuterol Sulfate MDI 80/90 μg per Actuation 1 to 6 doses (2 inhalations/dose) per day as needed via Oral inhalation route.
45675804|NCT05505734|Drug|AS MDI|Participants will receive Albuterol Sulfate MDI 90 μg per Actuation 1 to 6 doses (2 inhalations/dose) per day as needed via Oral inhalation route.
46000142|NCT02894229|Behavioral|Cognitive-Behavioral Therapy (CBT) Group|A 6-week, 2-hour per group, skills group that focuses on various cognitive-behavioral skills for stress reduction (e.g., progressive muscle relaxation; cognitive restructuring).
46086947|NCT02642601|Drug|Indomethacin(KAHIRA PHARMA&CHEM,IND,CO.CAIRO-EGYPT)|one dose of indomethacin 100 mg rectal suppository 1- 2 hours before embryo transfer
46086948|NCT02709902|Drug|Adapalene/BP gel, 0.3%/2.5%|Gel
45675805|NCT05490329|Behavioral|Tough Talks COVID|Intervention participants will download the TT-C app from the iOS or Google Play store and complete the intervention within one month.
46000143|NCT02021370|Drug|BAY85-3934|25mg Tablet
45675806|NCT05486481|Drug|Venetoclax|Given orally (PO)
45835327|NCT02234934|Biological|Lentiviral G1XCGD Gene Therapy|"The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector in their final suspension. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.~The G1XCGD vector is used to transduce autologous CD34+ cells ex vivo. These transduced cells are then frozen, and an aliquot tested and characterized for quality. If the cell product passes release criteria, it is thawed at bedside and infused into the patient after the patient has received myelo-ablative conditioning. The cell/product dose will consist of at least 3 x 10^6 cells per kg of body weight transduced ex vivo with 1 x 10^8 IG/mL of lentiviral vector to achieve > 0.3 integrated copies per cell."
46086949|NCT02709902|Drug|EPIDUO® FORTE|Gel
45675807|NCT05486481|Drug|Dexamethasone|Given PO
46086950|NCT02709902|Drug|Placebo|Gel
45675808|NCT05486481|Drug|Daratumumab|Given Subcutaneously (SC)
46086951|NCT02710604|Drug|CMX157|tablet
45675809|NCT05485987|Drug|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
45457800|NCT03504670|Procedure|Early Amniotomy|This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed prior to the cervix being dilated 4cm.
45675810|NCT05481879|Drug|DYNE-101|Administered by IV infusion
45675811|NCT05481879|Drug|Placebo|Administered by IV infusion
45675812|NCT05477082|Other|Observational group|Includes blood draws and data collection only
46000144|NCT02021370|Drug|Placebo|Matching placebo tablet
46000145|NCT02912702|Drug|Pegaspargase|2000U/m2 day5
46000146|NCT02912702|Drug|doxorubicin hydrochloride liposome injection|25 mg/m2 day 1
46000147|NCT02912702|Drug|etoposide|100 mg/m2 was administered once on the first day of every week
46000148|NCT02912702|Drug|methylprednisolone|15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
46000149|NCT02912702|Drug|Etoposide|150 mg/m2 twice weekly for 2 weeks and then weekly
46000150|NCT02912702|Drug|dexamethasone|initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
46000151|NCT02894073|Device|skin transilluminator|VeinViewer
46086952|NCT02710604|Drug|TDF|300mg tablet
46086953|NCT02709824|Drug|Chlorhexidine gluconate with ADS|Oral rinsing, twice a day, for 21 days
46086954|NCT02709824|Drug|Chlorhexidine gluconate without ADS|Oral rinsing, twice a day, for 21 days
46086955|NCT02642367|Device|McGrath videolaryngoscope|without use of stylet
46086956|NCT02642367|Device|McGrath videolaryngoscope with Intubating stylet (Mallinckrodt)|use of stylet
46086957|NCT02642367|Drug|rocuronium|tracehal intubation was performed 2 min after rocuronium injection with McGrath videolaryngoscope
46086958|NCT04699136|Other|6 minutes step test (ST6)|Performing a 6 minutes step test at different intervals and comparing with respect with the 6 minutes walk test and cardiac stress test
46000152|NCT02912585|Biological|Oropharyngeal administration of own mother's colostrum|
46000153|NCT02912585|Other|Oropharyngeal administration of sterile water (placebo)|
46000154|NCT02912585|Biological|Oropharyngeal administration of donor human milk|
46086959|NCT02642289|Dietary Supplement|Lactobacillus acidophilus|"Probiotic 5000, a commercial probiotic product provided by the company Complementos Fitonutricionales, S.L."
46000155|NCT02912507|Device|Cutera enlighten laser|high-powered, Q-switched 670nm Picosecond laser system indicated for tattoo removal
46086960|NCT02642289|Dietary Supplement|Lactobacillus Rhamnosus GG ®|"Ergyphilus confort, a commercial probiotic product provided by the nutritional supplements lab Laboratorios Nutergia"
45675813|NCT05466123|Behavioral|Virtual Reality|Simulated travel destination or activity of the participants choosing that would otherwise be inaccessible
46000156|NCT02912507|Device|CynoSure PicoSure 755nm laser|high-powered, Q-switched Alexandrite system that delivers laser energy in the 755 nm wavelength and has received FDA clearance (K133364) for tattoo and benign pigmented lesion removal.
46000157|NCT02016534|Drug|AMG 337|AMG 337 300mg orally daily.
46000158|NCT02912429|Device|Patellofemoral Arthroplasty|
46000159|NCT02010333|Drug|Ha44 Gel 0.74% w/w|HA44 Gel 0.74% comprises of Abametapir as the active pharmaceutical ingredient and Benzyl Alcohol as one of the excipients.
46000160|NCT02912390|Procedure|Cerclage|Macdonald cerclage placed in standard fashion
45675814|NCT05462639|Drug|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
45835328|NCT02227992|Biological|EVARREST™ Sealant Matrix|EVARREST® Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
46000161|NCT02912390|Other|Expectant management|placed on activity restrictions: no heavy lifting, frequent reclining, and pelvic rest.
46000162|NCT02894346|Other|Teachers|Teachers are exposed to the WTMST survey that based on the theory of Self-Determination (SDT) will categorize them according to the elements of the SDT: Intrinsic, identified, introjected, external and a motivation.
46000163|NCT02912273|Other|Baseline Participant Assessment|"Section 1 contains demographic questions~Section 2 contains daily activity questions with multiple choice answers, multiple physical function questions, and if the participants has fallen and how many falls have occurred in the last 6 months~Section 3 has the participant list all medication~Section 4 contains several questions about participant health (lists of illnesses and indicate if illness interferes with their activities)~Section 5 contains several questions about participant fall concerns with answers ranging from 1=Not at all to 4=Very~Section 6 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
46086961|NCT02642289|Other|Placebo|Innocuous substance
46086962|NCT00611780|Radiation|tube voltage|standard 120 kV
46086963|NCT00611780|Radiation|tube voltage|reduced voltage of 100 kV
45675815|NCT05459129|Drug|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
45675816|NCT05459129|Drug|Tiragolumab|Tiragolumab will be administered intravenously at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
45835329|NCT02227992|Device|SURGICEL®|SURGICEL® Absorbable Hemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
45835330|NCT02498730|Behavioral|Interval Training|High Intensity Interval Training at 100% VO2Max
45835331|NCT02498730|Behavioral|Continuous Training|Continuous Stimulous at 60% VO2Max
45675817|NCT05459129|Drug|Carboplatin|Carboplatin will be administered intravenously at a dose of area under the concentration-time curve (AUC) 5 mg/mL/min on Day 1 of each 21 day cycle.
45675818|NCT05459129|Drug|Paclitaxel|Paclitaxel will be administered intravenously at a dose of 175 mg/m2 on Day 1 of each 21 day cycle.
45675819|NCT05457283|Drug|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 540 ±7 days.
45835332|NCT02498730|Behavioral|Control|Only Dependent Variables Measures
45835333|NCT02496936|Other|SFA|High saturated fatty acid/SFA oil source
45835334|NCT02496936|Other|MUFA|High monounsaturated fatty acid/MUFA oil source
45835335|NCT02496936|Other|PUFA-LA|High polyunsaturated fatty acid (linoleic)/PUFA-LA oil source
45835336|NCT02496936|Other|ALA|High polyunsaturated fatty acid (alpha-linolenic)/ALA oil source
46002437|NCT02877433|Device|Roxolid short implant, 4 mm length (2)|Placement of a combination of two short implants (in positions 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
46002438|NCT02868450|Biological|Blood Sample|
46002439|NCT02868411|Other|Rectal Swab|
46086964|NCT04165395|Device|Five-layer foam dressing|Five-layer foam dressing applied on the sacrum within 48 hours of spinal surgery
46086965|NCT04165395|Device|Heelmedix boot|Heelmedix boot will be installed alternately from one foot to the other.
46086966|NCT02642133|Procedure|Lingual Frenotomy and/or maxillary labial frenectomy|The procedure is performed with a 1064nm InGaAsP semiconductor diode laser which is a soft tissue laser with variable pulsed wave and wattage settings. The procedure was performed at 0.7-0.8 pulsed watts, 200 microseconds on and 100 microseconds off (actual wattage: 0.47 to 0.53 W) using a 300 micron laser fiber. The tongue is elevated using a grooved director while the laser tip is applied to the frenulum. If present, the anterior frenulum is divided until the submucosal portion of the tie is identified (this is the posterior tongue-tie). A small window in the central mucosa is made and the lateral mucosal walls of the posterior tongue-tie are released, taking care to not disturb the fascia of the underlying genioglossus muscle.
46086967|NCT02642211|Procedure|cataract surgery|Eyes (one eye per patient) randomized to either phacoemulsification and intraocular lens insertion or small incision cataract surgery and intraocular lens insertion
46086968|NCT00653367|Procedure|Nerve section|Intercostal nerve is divided during surgery
46086969|NCT02642055|Behavioral|Neuro+ Attention Training|Attention training program with Neuro+ software
46086970|NCT02642055|Other|Treatment as Usual|Continuation of current ADHD treatment
46086971|NCT00653445|Drug|Rosuvastatin|40mg
46086972|NCT00653445|Drug|Ezetimibe|10mg
46002440|NCT02868346|Other|Anal swab|
46002441|NCT02866565|Drug|adipose-derived regenerative cells (ADRCs)|injection of the experimental treatment
46002442|NCT02866201|Other|Rectal swab|
46002443|NCT02861768|Biological|Pharyngeal swab|
46086973|NCT02641899|Drug|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 20 mcg/day for 14 days, followed by ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day.
46086974|NCT02641899|Drug|Acetaminophen|Oral acetaminophen 1000 mg on Day 1 and Day 27
46086975|NCT02641899|Drug|Atorvastatin|Oral atorvastatin 40 mg on Day 2 and Day 28
46086976|NCT02641899|Drug|Lisinopril|Oral lisinopril 20 mg on Day 2 and Day 28
46086977|NCT02641899|Drug|Warfarin|Oral warfarin 25 mg on Day 2 and Day 28
46086978|NCT02641899|Drug|Digoxin|Oral digoxin 0.5 mg on Day 2 and Day 28
46086979|NCT04165005|Behavioral|decentering|examined a mindfulness-based intervention focused on a decentering component, that is suitable for elders, aimed to influence on cognitive measures and psychological distress.
46086980|NCT04165005|Behavioral|guided imagery|relaxing guided imagery including breathing exercises.
46086981|NCT02641821|Drug|Nifedipine GITS|
46086982|NCT02641743|Dietary Supplement|Inslow|carbohydrate adjusted liquid food using palatinose as the major carbohydrate (>50%)
46086983|NCT02641743|Dietary Supplement|standard balanced formula|
46086984|NCT01320345|Drug|Fenofibrate|145 mg tablet of fenofibrate administered once daily for 36 months.
46086985|NCT01320345|Drug|Inert lactose placebo|Insert lactose tablet matching active tablet administered once daily for 36 months.
46086986|NCT00655161|Biological|GI-4000|subcutaneous injection, 40YU weekly for 3 weeks followed by monthly for 6 months them quarterly until recurrence
46086987|NCT04164615|Drug|GB221|"GB221:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study."
45835337|NCT02496936|Other|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
45835338|NCT02496780|Drug|novolog insulin|3x daily rapid-acting insulin
45835339|NCT02496780|Drug|levemir insulin|basal insulin once a day
45835340|NCT02496780|Drug|placebo|once or 3x daily
45835341|NCT01953588|Drug|fulvestrant|Fulvestrant 500 mg IM
45835342|NCT01953588|Drug|anastrozole|Anastrozole 1 mg oral tablet
45835343|NCT02487966|Device|transcranial Direct Current Stimulation (tDCS): active (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. For active tDCS, the subject will undergo stimulation for 20 minutes.
45835344|NCT02487966|Behavioral|Mirror Therapy: active|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist.
46002444|NCT02859792|Drug|Riluzole|Riluzole capsules (25 or 50 mg) will be administered in the four dose level groups (i.e. 25 mg bid; 50 mg bid; 75 mg bid; 100 mg bid).
46002445|NCT02859792|Drug|Placebo|placebo capsules 25 or 50 mg
46002446|NCT02859792|Biological|Blood Samples|v1;v2;v3;v4
46002447|NCT02858687|Other|Nasopharyngeal swab|
46002448|NCT02858661|Other|Nasopharyngeal swab|
46002449|NCT02858609|Other|Nasopharyngeal Swab|
46086988|NCT04164615|Drug|Placebo control|"Placebo control:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study."
46000164|NCT02912273|Other|Baseline Healthcare Provider Assessment|"Cognition: Orientation-Memory-Concentration Test which contains 6 questions that the provider will ask the participant. Form items 1-3, the response is either correct (score 0) or incorrect (score 1). For items 4-6, subtract one point for each error. Total score of 11 or greater indicates cognitive impairment (maximum score =28)~Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
46000165|NCT02912273|Other|Follow-up Participant Assessment|"Section 1 contains multiple choice questions about daily actives and several physical function questions~Section 2 asks the participants how many medications they take on a daily basis, indicate any medication for depression, anxiety, nausea , and other stomach conditions~Section 3 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
45675820|NCT05451589|Behavioral|RESET|RESET consists of 7 weekly group phone sessions led by Community Health Workers, along with an accompanying podcast series.Topics will include positive psychology, physical activity, social connection, eating well, relaxation, and more. There will be one individual session with the Community Health Worker to screen for unmet social needs and to offer connections to resources as needed. In the group sessions, participants will set goals incorporating positive activities and strategies to improve daily functioning. Up-to-date information related to COVID-19 prevention and treatment will be provided.
45675821|NCT05451589|Behavioral|Wellness Check Control|"After completing the baseline survey, control group participants will be mailed an educational packet consisting of information about COVID-19 prevention and treatment, as well as essential community resources. Control group participants will also be invited to take part in a wellness check telephone session with a Community Health Worker, about a half-hour long, at which a social needs screener will be administered, and any needed referrals will be made. After completing the 8-month follow up, they will have the opportunity to participate in the full intervention."
46000166|NCT02912273|Other|Follow-up Healthcare Provider Assessment|"Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
46000167|NCT02912273|Other|End-of-study Participant Assessment|"Section 1 contains multiple choice questions about daily actives and several physical function questions~Section 2 asks the participants how many medications they take on a daily basis, indicate any medication for depression, anxiety, nausea , and other stomach conditions~Section 3 contains multiple questions about the participant's concern about falling with answers ranging from 1=Not at all to 4=Very~Section 4 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
45675822|NCT05451017|Drug|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition|a single dose of 1 mg AEF0117 in fed condition
45675823|NCT05451017|Drug|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition|a single dose of 1 mg AEF0117 in fasting condition
46086989|NCT04164771|Other|Aerobic training and Moringa Oleifera|Aerobic exercises/training refers to any type of rhythmic, continuous physical activities that use large group of muscles like walking, running, cycling, and swimming consuming additional amount of energy while Moringa Oleifera a plant from the family Moringacea, its products are used as a health supplement introduced in Africa and south Asian countries to cure many diseases and improve health status
46086990|NCT04164459|Drug|Xalost S|One drop one times a day in study eye
46086991|NCT04164459|Drug|Xalatan|One drop one times a day in study eye
46086992|NCT04164459|Drug|Taflotan-S|One drop one times a day in study eye
45675824|NCT05446870|Biological|Pembrolizumab|200 mg by IV infusion on Day 1 of each 21-day cycle
45675825|NCT05446870|Drug|Paclitaxel|175 mg/m^2 by IV infusion on Day 1 of each 21-day cycle
45675826|NCT05446870|Drug|Carboplatin|AUC 5 to 6 by IV infusion on Day 1 of each 21-day cycle
45675827|NCT05446870|Biological|Avastin|According to local practice and at the choice of the investigator.
45675828|NCT05446870|Biological|MK-4830|800 mg by IV infusion on Day 1 of each 21-day cycle
46000168|NCT02912273|Other|End-of-study Healthcare Provider Assessment|"Cognition: Orientation-Memory-Concentration Test which contains 6 questions that the provider will ask the participant. Form items 1-3, the response is either correct (score 0) or incorrect (score 1). For items 4-6, subtract one point for each error. Total score of 11 or greater indicates cognitive impairment (maximum score =28)~Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
46000169|NCT02008344|Drug|favipiravir|"Administered twice daily over 5 consecutive days for a total of 10 doses.~Day 1: 1800 mg twice daily (loading doses)~Days 2 through 5: 800 mg twice daily"
46000170|NCT02008344|Drug|placebo|"Administered twice daily over 5 consecutive days for a total of 10 doses.~Day 1: 1800 mg twice daily (loading doses)~Days 2 through 5: 800 mg twice daily"
46000171|NCT02912546|Procedure|MRI|A 1.5 Tesla MRI device with a large magnet bore (70 cm) allowing positions change will be used. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and CBF maps reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers
46000172|NCT02912156|Drug|Vaway FC Tablets 200mg (Voriconazole)|
45675829|NCT05446870|Drug|Docetaxel|75 mg/m^2 by IV infusion on Day 1 of each 21-day cycle
46086993|NCT04164693|Drug|Low molecular weight heparin|patients began to use low molecular weight heparin or warfarin sodium tablets.
46000173|NCT02912156|Drug|VFEND FC Tablets 200mg (Voriconazole)|
46000174|NCT03455049|Other|Andrographis Paniculata Ext|Give the Androgaphis paniculata in prediabetes and normal subject for 14 days.
46086994|NCT04164693|Other|non anticoagulant therapy group|no anticoagulant was used after operation.
46086995|NCT02637921|Other|Hypoxia|21 days confinement in normobaric hypoxic (FiO2 = 14%)
46086996|NCT02637921|Other|Ambulatory|Participants hava a standardized activity level throughout the intervention
46086997|NCT02637921|Other|Normoxia|21 days confinement in normobaric normoxic (FiO2 = 21%) environment
45675830|NCT05445219|Diagnostic Test|RespirAct|The RespirAct device is an automated breathing circuit that uses a gas bladder to control and deliver CO2 to measure cerebrovascular reactivity
45835345|NCT02487966|Device|transcranial Direct Current Stimulation (tDCS): sham (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. The subject will undergo stimulation for 20 minutes. This is the same parameters as the active one, except the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
45835346|NCT02487966|Behavioral|Mirror Therapy: Sham|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb, only the mirror will be covered. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist. We will use the same all of these techniques as active Mirror Therapy only the mirror will be covered during all activities.
45835347|NCT01953510|Biological|PCV10|PCV10 includes serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and protein D is the main carrier protein
46086998|NCT02637921|Other|Bed Rest|Participants remain on supine bed rest throughout the intervention
45675831|NCT05444257|Drug|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
46086999|NCT02637921|Other|Standardised nutritional intake|Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant
45675832|NCT05441410|Drug|Pyronaridine Tetraphosphate, Artesunate Drug Combination|Combination drug for treatment of uncomplicated malaria
46087000|NCT00655239|Behavioral|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
45675833|NCT05441410|Biological|PfSPZ Challenge (NF54)|cryopreserved Plasmodium falciparum sporozoites injected by intravenous inoculation
45675834|NCT05441410|Biological|MVA ME-TRAP|virally vectored subunit vaccine candidates where ME-TRAP is expressed by the non-replicating viral vector Modified Vaccinia Ankara (MVA)
46087001|NCT00655239|Behavioral|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 8 weeks.
46087002|NCT04164381|Device|Robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
46087003|NCT04164147|Procedure|Total knee replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior Cruciate Ligament sacrificing or retaining implant
46087004|NCT04164147|Diagnostic Test|CT scan|CT scans of the affected knee joint before and after the surgical procedure
46087005|NCT04164147|Diagnostic Test|Biomechanics|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
45675835|NCT05441410|Biological|ChAd63 ME-TRAP|virally vectored subunit vaccine candidates where ME-TRAP is expressed by the non-replicating viral vector Chimpanzee Adenovirus 63 (ChAd63)
45675836|NCT05441410|Biological|Sodium chloride (NaCl) 0.9%|0.9% NaCl solution for injection
46000175|NCT02912234|Drug|Apixaban|Multiple-dose clarithromycin and single-dose Apixaban
46000176|NCT02912234|Drug|Clarithromycin|Multiple-dose clarithromycin and single-dose Apixaban
46000177|NCT04676139|Drug|Fluoxetine|Fluoxetine 10 mg capsules once daily for 12 months
46000178|NCT04676139|Drug|Placebo|placebo for 12 months
46000179|NCT01999764|Drug|QLT091001|QLT091001 administered orally at multiple time points.
46000180|NCT01999764|Other|Placebo|Placebo is administered orally at multiple time points.
46000181|NCT02912039|Device|TetraGraph|A sequence of 3 sets of Train of four (TOF) stimuli delivered (every 20 sec) at the pre-determined current amplitude (for instance, 40 mA, then 30 mA, then 50 mA, then 20 mA).
46000182|NCT02912039|Device|TOF Watch|A sequence of 3 sets of TOF stimuli delivered (every 20 sec) at the pre-determined current amplitude (for instance, 40 mA, then 30 mA, then 50 mA, then 20 mA).
46087006|NCT04164147|Device|one of the Persona MC Retained PCL, Persona MC Sacrificed PCL and NexGen PS total knee implant|Participant are randomly allocated to receive one of the Persona MC Retained PCL, Persona MC Sacrificed PCL and the NexGen PS total knee implant for treatment of end-stage knee osteoarthritis.
46087007|NCT02637843|Device|Slender Sheath|Comparing outcomes for two different sheaths used during radial CAG/PCI
46087008|NCT04163679|Procedure|Vaginal Preparation|"One sponge stick will be inserted into the vagina, where it will stay during the scrubbing of thighs and genitals.~One sponge will be used to scrub the right inner thigh from mid-thigh to right labia majora. This sponge will then be discarded.~A second sponge will be used to scrub the left inner thigh from mid-thigh to left labia majora. This sponge will then be discarded.~A third sponge will be used to scrub the mons pubs, labia majora and minor, perineum and rectum in that order then will be discarded. This will be repeated with a fourth sponge.~The existing sponge stick in the vagina will be rotated in the vagina twice then removed. This will be discarded.~A second sponge stick will be inserted in the vagina, rotated twice then removed. As it is removed from the vagina, the perineum and rectum will be swabbed with the stick in that order then discarded. This will be repeated using a third sponge stick."
46087009|NCT04163913|Other|Change in User interfaces of Cirvo compression device application.|Comparison of 2 versions of the Circo user interface
46000183|NCT02911961|Drug|Acetaminophen|1 gram acetaminophen 4 times a day with at least 6 hour intervals between doses for the 3 days prior to the embolization procedure.
46087010|NCT04163913|Other|Change in Satisfaction in use of Cirvo device|Comparison of how satisfied patients are with the Cirvo device to a different compression device (ActiveCare)
46087011|NCT00655317|Other|Acupuncture|Treatment acupuncture group: therapeutic acupuncture treatment with actual needles
46087012|NCT00655317|Other|Sham acupuncture|SHAM (control) acupuncture group: non-therapeutic acupuncture treatment
46087013|NCT00655395|Drug|Laromustine (VNP40101M) and Ara-C|"Laromustine 300 mg/m2 (cohort 1), 400 mg/m2 (cohort 2), 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
46087014|NCT00911079|Procedure|Hyperthermia|Single course of Catheter-based Ultrasound Hyperthermia (within approximately 2 hours of a Standard-of-care High Dose Rate (HDR) Brachytherapy)
46087015|NCT00911079|Radiation|HDR brachytherapy|Completion of standard-of-care high dose rate (HDR) Brachytherapy treatments (radiation fractions) using Session #1 catheter implants
46087016|NCT02637453|Procedure|PVI|Pulmonary vein isolation
46087017|NCT02637453|Procedure|CPVI+6L|After PVI, 6 ablation lines were added with an extension from pulmonary vein ostium at 1, 3 and 6 o'clock (from internal view) of left PV and 6, 9 and 11 o'clock of right PV
46000184|NCT01998828|Drug|Momelotinib|Momelotinib tablet administered orally once daily
46087018|NCT02637609|Other|Likert Scale|Respondents receive questions asking them to rate each barrier or facilitator for diabetes self-management.
46087019|NCT02637609|Other|Best-Worst Scaling (Case 1)|Respondents receive questions asking them to choose the best and worst factors that affect their diabetes self-management among a list of barriers and facilitators.
46087020|NCT04163757|Dietary Supplement|crocin|2 tablets crocin per day
46000185|NCT02912000|Behavioral|TEACH intervention|The TEACH intervention screens family for three modifiable behaviors ahead of the clinical encounter: parental tobacco use, children consumption of sugar-sweetened beverages and child dental health. The information from the screening is then shared with clinicians.
46000186|NCT04676061|Drug|Norethindrone acetate (NTA)|norethindrone acetate, 5 mg tablet, orally, once daily for 7 consecutive days, every 4 weeks
46000187|NCT04676061|Drug|Placebo|Placebo, tablet, orally, once daily for 7 consecutive days, every 4 weeks
46000188|NCT04675944|Drug|BIA 5-1058|200 mg (2 x 100 mg tablets), oral route
46000189|NCT04675944|Drug|treprostinil|1 mg (1 extended-release tablet), oral route
46000190|NCT02911766|Drug|Chlorhexidine 0.2% Mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
46000191|NCT02911766|Drug|Chlorhexidine 0.12% mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
46000192|NCT02911766|Drug|Chlorhexidine 0.06% mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
46000193|NCT01993641|Drug|pracinostat|Histone deacetylase inhibitor (HDACi) Pracinostat is to be taken before HMA administration 3 times/week (e.g., Monday, Wednesday, and Friday) for 3 weeks, followed by 1 week of rest as a 28-day cycle. Pracinostat administration will be at the clinic on Day 1 of Cycles 1 and 2 and subject will self-administer at home on all other days
46087021|NCT04163757|Dietary Supplement|placebo|2 tablets placebo per day
46087022|NCT02637765|Behavioral|Increased Physical Activity|Patients will receive a program of increased physical activity starting from 5000 steps/day up to 12000 steps/day after 8 weeks and an 8-week recreational program of brisk walking/running (3 times a week).
46087023|NCT00655785|Biological|VEGFR1-1084, VEGFR2-169|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 in group A, on days 3, 10, 17, 24 in group B, or 5, 12, 19, 26 in group C
46000194|NCT01993641|Drug|Azacitidine|All patients will receive the dose and schedule of azacitadine to which they previously failed to respond. (e.g. 75 mg/m2 via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable; 7 days of each 28 day cycle, either Days 1-7, or Days 1-5, rest on Days 6-7, and azacitadine dosing on Days 8-9)
46000195|NCT01993641|Drug|Decitabine|"All patients will receive the dose and schedule of decitabine to which they previously failed to respond. Common 28 day treatment regimens include: 20 mg/m2 IV for either 5 or 10 days of each 28-day cycle, 10 mg/m2 given intravenously daily for first 10 days of each 28 day cycle, or 20 mg/m2 given subcutaneously daily for the first 5 days of each 28 day cycle.~The 6-week regimen utilizes a dose of 15 mg/m2 by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days repeated every 6 weeks."
46087024|NCT00655785|Drug|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 3, 10 and 17
46087025|NCT00885495|Drug|darunavir, ritonavir, rosuvastatin|darunavir 600 mg twice daily for 7 days ritonavir 100 mg twice daily for 7 days rosuvastatin 10 mg once daily for 7 days Combination of all three drugs for 7 days
46000196|NCT00555516|Other|EW02|"Name: EW02~Dosage form: capsule.~Dose(s): 350mg per capsule, 2 capsule tid.~Dosing schedule: 2 capsule tid; 15 days (D3 to D17) of EW02 or placebo in Cycles 2 and 3."
46087026|NCT00885495|Drug|rosuvastatin, darunavir, ritonavir|rosuvastatin 10 mg daily for 7 days; darunavir 600 mg twice daily for 7 days with ritonavir 100 mg twice daily for 7 days; Combination of all three for 7 days
46087027|NCT00655941|Behavioral|Dietary instruction|Weekly instruction by dieticians
46000197|NCT01991184|Drug|GDC-0853|Multiple escalating doses
46087028|NCT00655941|Other|Exercise|Supervised exercise in groups
46087029|NCT02637297|Procedure|Hypnotherapy|Undergo hypnotherapy
45675837|NCT05437419|Drug|TCK-276|Patients will receive an oral dose of TCK-276 (Dose A, B, C, and D) QD under fed conditions from Day 1 to Day 7.
46000198|NCT04676100|Other|Cardiac rehabilitation|"A CR program is defined as one that offers initial assessment, structured exercise (can be supervised or unsupervised) and at least one other strategy to control risk factors. The registry pertains to phase II CR.~Quality of care and patient outcomes are benchmarked with other countries anonymously, through 2 registry dashboards (real-time). The dashboards will also show change over time in 6-month increments; Sites will be encouraged to continue to provide data on new patients until all indicators show quality as possible.~Sites will be supported in quality improvement by the ICRR user sub-committee. High-performing programs will be recognized on ICRR's website and ICCPR's social media accounts. This mechanism may be used in future to support program accreditation."
46000199|NCT02911727|Procedure|Fast-track discharge|As described above
46000200|NCT02911883|Device|Optical Coherence Tomography Angiography|
46000201|NCT04675905|Other|no intervention (cohort study)|Explanatory variables include preoperative comorbidities, baseline disability, surgical risk, postoperative complications, sex, rural/urban area of residency, Oslo Social Support Scale; Clinical Frailty Scale in patients aged >= 65 years
46000202|NCT02911649|Other|Wearable Technology - Garmin Vivosmart|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
46087030|NCT02637297|Other|Questionnaire Administration|Ancillary studies
46087031|NCT02637375|Drug|Ganetespib|
46087032|NCT02637375|Drug|Paclitaxel|
45457801|NCT03504670|Procedure|Late Amniotomy|This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed once the cervix is at least 4cm dilated.
45675838|NCT05437419|Drug|TCK-276 Placebo|Patients will receive an oral dose of TCK-276 matching placebo (Dose A, B, C, and D) QD under fed conditions from Day 1 to Day 7.
45675839|NCT05431595|Drug|Haloperidol|Given by Vein (IV)
45835348|NCT01953510|Biological|PCV13|PCV13 includes serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, individually linked to non-toxic diphtheria CRM197 carrier protein
45835349|NCT02475252|Procedure|hysteroscopy on a training model|Diagnostic hysteroscopy on a diagnostic hysteroscopy training model using a pelvic dummy and all surgical instruments also used in the original procedure. The performance of all participants will be scored using an OSATS scoring sheet developed for assessing surgical proficiency.
45835350|NCT01943994|Drug|Psilocybin-assisted treatment|Participants will be administered 30 mg/70 kg psilocybin. Preliminary evidence from our ongoing psilocybin dose-effects study suggests that this dose is associated with mystical-type experiences.
46000203|NCT02911649|Other|Online Educational Group|A workshop leader will lead participants through an educational workshop and group discussion on topics related to reducing sedentary behaviour
46000204|NCT02911649|Other|Wearable Technology - FitBit Alta|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
46087033|NCT02637375|Drug|Doxorubicin|
46087034|NCT02637375|Drug|Cyclophosphamide|
46087035|NCT04163523|Drug|Zanubrutinib|
46087036|NCT04163445|Device|MicroPort Orthopedics EVOLUTION Medial Pivot TKA|Subjects will have been implanted with the Microport Evolution Medial Pivot TKA
46087037|NCT04163445|Device|Depuy Synthes ATTUNE PCR TKA|Subjects will have been implanted with the Depuy Attune PCR TKA
46087038|NCT04163211|Procedure|Abdominal drain|A latex-free drain (size 20F)
46087039|NCT00885105|Biological|Influenza Virus Vaccine|0.25 mL, Intramuscular
46087040|NCT00885105|Biological|Influenza Virus Vaccine|0.25 mL, Intramuscular
46087041|NCT03945188|Drug|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
46087042|NCT03945188|Drug|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
46087043|NCT02709668|Dietary Supplement|Enlyte|gel cap of reduced B vitamins
46087044|NCT02709668|Other|placebo|identical to Enlyte
46087045|NCT04188782|Drug|Sevoflurane|Describe how a reiterative anesthesia exposure could induce tolerance to the anesthetic.
46087046|NCT02709590|Drug|diclofenac potassium + lidocaine|patients will have of oral diclofenac potassium 60 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before HSG
46087047|NCT02709590|Drug|placebo|patients will have of oral placebo tablet 60 minutes before the procedure plus placebo cream placed into their cervix immediately before HSG
46000205|NCT02911649|Other|Wearable Technology - Polar Loop 2|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
46000206|NCT01989429|Drug|M518101|8-week comparative treatment period ( twice daily application) followed by a maximum 8-week period to evaluate time to relapse
46087048|NCT02713568|Other|Ultrasound examination|"Prenatal Ultrasound examinations will be carried out using transabdominal sonography only by experienced consultants in MFM. Ultrasound-Estimated Fetal Weight will be obtained between 36.0-36.6 weeks of gestation, according to Hadlock et al.~Operators performing the Ultrasound-Estimated Fetal Weight will be blinded to the results of Magnetic Resonance-Estimated Fetal Weight. The participants, general practitioners, obstetricians and midwifes of the patients will be aware of the results of Ultrasound-Estimated Fetal Weight which will be used for clinical management.~For the primary outcome measure, macrosomia during Ultrasound-Estimated Fetal Weight will be defined as ≥ P95 based on Yudkin et al. For secondary outcome measures, it will be redefined as ≥ P90 or ≥ P99 based on Yudkin."
46000207|NCT02911532|Procedure|Tissue engineering conjunctiva transplantation|During the operation,transplant the tissue engineering conjunctiva to the conjunctiva loss position
45675840|NCT05431595|Drug|Chlorpromazine|Given by Vein (IV)
46000208|NCT01989234|Drug|YKP10811|
46000209|NCT01989234|Drug|Placebo|
46000210|NCT02911493|Behavioral|Reducing Sedentary Behavior|The experimental group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to reduce sedentary time.
46000211|NCT02911493|Behavioral|Physical Activity Group|The Active Comparative group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to increase exercise time.
46000212|NCT04675671|Other|Preoperative and postoperative anxiety measurement [Spielberger's State Anxiety Scale (STAI-S)] and [ Spielberg's State-Trait Anxiety Inventory (STAI-T) ]|The postoperative pain is measured and evaluated by Visual Analog Scale (VAS= 0 = no pain to 10 = worst pain)
46000213|NCT02911298|Drug|Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation|
46000214|NCT02911298|Drug|Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation|
46000215|NCT01984788|Drug|BCX4161|
46000216|NCT01984788|Drug|Placebo|
46087049|NCT02713568|Other|Magnetic resonance examination|"MRI will be performed the same day as the Ultrasound examination, using a clinical 1.5T whole-body unit.~Operators performing Fetal Body Volume measurements will be blinded from Ultrasound-Estimated Fetal Weight results. Magnetic Resonance-Estimated Fetal Weight will be calculated using the equation 0,12+1,031*Fetal Body Volume = MR imaging weight (g) developed by Baker.~General practitioners, obstetricians and midwifes of the patients will be blinded to the results of the Magnetic Resonance-Estimated Fetal Weight.~For the primary outcome measure, macrosomia will be defined as ≥ P95 based on Yudkin et al. For secondary outcome measures, it will be defined as ≥ P90 or ≥ P99."
46087050|NCT02713412|Other|Glucose|75g glucose and 150 mg of 13C-acetate made up to 300 ml with water
46087051|NCT02713412|Other|Water|300ml water
45457802|NCT02312128|Other|Questionnaire|DASH Score, PRWE Score, Mayo Wrist Score
46000217|NCT02911337|Dietary Supplement|lifestyle modification|Subjects will be given meal replacements (shakes and bars) to be consumed twice per day for 8 weeks, and then once per day for an additional 3 weeks, and then transitioned to a structured diet.
46000218|NCT01983306|Drug|SP-333 1 mg|Tablet
46000219|NCT01983306|Drug|SP-333 3 mg|Tablet
45457803|NCT02312128|Radiation|X- Ray|X-ray exposures in two planes 6., 9., 12. postoperative week, half and one year after surgery
45457804|NCT02312128|Other|Grip Strength|Grip strength measurement
45457805|NCT02312128|Other|VAS Score|Measurement pain according to the visual analogue scale (VAS)
45675841|NCT05431595|Drug|Valproate|Given by Vein (IV)
46000220|NCT01983306|Drug|SP-333 6 mg|Tablet
46000221|NCT01983306|Drug|Placebo|Tablet
46000222|NCT02911220|Genetic|demonstration of genetic mutations causing non-atopic asthma|recruitment of familial forms of non-atopic asthma (patients with non-atopic asthma and their relatives) to perform genetic analysis of exome sequencing
45675842|NCT05431595|Drug|Placebo|Given by Vein (IV)
45675843|NCT05429164|Other|Self Myofascial Release|In the self-myofascial release technique, a tennis ball will be placed on the 4th rib on the shoulder side to be applied on the wall, and the participants will be asked to move the ball using their body along the pectoralis minor.
45675844|NCT05429164|Other|Myofascial Release|A slight caudal force will be applied by the physiotherapist until the pectoralis minor muscle meets the comfortable elastic limit of the soft tissue.
46000223|NCT02911454|Other|Infant formula|
46000224|NCT01982175|Biological|Alemtuzumab|"Escalation Phase: Initial Doses of Alemtuzumab 3mg/day by intravenous(IV) infusion until tolerated, then Alemtuzumab 10mg/day IV infusion until tolerated, then Alemtuzumab 30mg IV infusion until tolerated.~Escalation to 30mg/day should be accomplished in 3~7 days.~Stable dose Phase: Once 30mg/day infusion of Alemtuzumab was tolerated, then continue 3 times per week. The total duration of Alemtuzumab therapy including escalation and stable dose phase is 12 weeks.~More than 30mg daily or 90mg weekly dose is prohibited~--------------------------------------------------------------------------------"
46000225|NCT01975818|Drug|Molidustat (BAY 85-3934)|Oral doses of BAY85-3934 will be available in multiples of 25,50,75 and 150 mg tablets
46000226|NCT01975818|Biological|Epoetin alfa/beta|
46000227|NCT02911259|Device|Suction is set to -2 cmH2O|Post-operative suction is set to -2 cmH2O (intervention).
46000228|NCT02911259|Device|Suction is set to -10 cmH2O|Post-operative suction is set to -10 cmH2O (standard treatment).
46000229|NCT04676919|Device|phonophoresis therapy with pulsed mode ultrasound|phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks
46087052|NCT02709278|Biological|BCG|BCG SSI (Groups 1A, 1B, 1C and 1D) & BCG Bulgaria (InterVax) (Groups 2A, 2B, 2C, 2D and 2E)
46087053|NCT02709278|Other|Saline placebo|Saline placebo
46087054|NCT02709434|Behavioral|Psychoeducational programme|Activity diary analysis and a structured programme of intervention
46087055|NCT02709434|Other|Standard care|Usual IBD management
46087056|NCT02709356|Dietary Supplement|1-month of 60-40 MCT oil|1-month supplementation of 30 g MCT oil (60% C10 + 40% C8)/day
46000230|NCT04676919|Device|phonophoresis therapy with continuous mode ultrasound|phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks
46000231|NCT04676919|Device|sham ultrasound|sham ultrasound therapy, five days a week for three weeks
46087057|NCT02709356|Dietary Supplement|1-month of C8 MCT oil|1-month supplementation of 30 g MCT oil (100% C8)/day (1-month of C8 MCT oïl)
46000232|NCT02911415|Procedure|blood sampling collection|It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
46087058|NCT02707718|Biological|blood sampling|during the usual blood sampling performed in the ED in patients suspected of sepsis, two additional tubes will be sampled for a panel of biomarkers measurement
46087059|NCT02708030|Other|Ketogenic Diet|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. The patients in KD arm will be admitted to the hospital for initiation of diet.
45675845|NCT05429164|Other|Instrument Assisted Soft Tissue Mobilization|Instrument-assisted soft tissue mobilization will be performed with the specified instruments for the pectoralis minor muscle.
46000233|NCT02911181|Other|BIVA measurement|
45675846|NCT05407311|Drug|64Cu-SAR-BBN|64Cu-SAR-BBN
45675847|NCT05406921|Behavioral|MIND at Home|Maximizing Independence at Home-MIND at Home (MIND) is a comprehensive care coordination program born from geriatric psychiatry. This model takes an interdisciplinary, collaborative care approach to care by systematically assessing and addressing a wide range of dementia-care related needs of both PLWD and their care partners that place both at increased risk for poor outcomes.
45675848|NCT05399459|Drug|Rimegepant 25 MG|Single dose of 25 mg orally disintegrating tablet of rimegepant
45675849|NCT05399459|Drug|Rimegepant 75 MG|Single dose of 75 mg orally disintegrating tablet of rimegepant
45675850|NCT05399459|Drug|Placebo|Matching placebo tablet
45675851|NCT05399368|Drug|RPT193|RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
45675852|NCT05399368|Other|Placebo|Nonactive placebo tablet
46000234|NCT02910947|Procedure|ultrasound guided quadratus lumborum or Transversus Abdominis plane block|The intervention consists of giving ultrasound guided local anaesthetic (0.125% bupivacaine ) in the quadratus lumborum plane or the transversus abdominis plane after randomization. These planes and technique for these procedures are well described in literature.
46000235|NCT01973049|Drug|Daclatasvir|
46000236|NCT01973049|Drug|Asunaprevir|
46000237|NCT01973049|Drug|BMS-791325|
46000238|NCT01973049|Drug|Ribavirin|
46000239|NCT01973049|Drug|Placebo matching Ribavirin|
46000240|NCT01185964|Biological|Olaratumab|Olaratumab 15 mg/kg by intravenous transfusion (I.V.) on days 1+8 of a 21-day cycle
46000241|NCT01185964|Drug|doxorubicin|Doxorubicin 75 mg/m2 by intravenous injection on day 1 of the 21-day cycle.
46000242|NCT02910869|Genetic|Pathway Genomics FIT test|
46000243|NCT01972854|Drug|riboflavin solution|0.12% riboflavin ophthalmic solution
46000244|NCT01972854|Drug|placebo solution|0.0% riboflavin ophthalmic solution
46000245|NCT01972854|Device|KXL System|30mW/cm2
46000246|NCT01217476|Drug|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is >6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
46000247|NCT04677075|Procedure|mastectomy|mastectomy either simple or modified radical
46087060|NCT02708030|Other|MAD|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. MAD will be initiated on out patient basis.
46087061|NCT02708030|Other|LGIT|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. LGIT will be initiated on out patient basis.
46087062|NCT02707796|Procedure|Hemicolectomy|
46087063|NCT02707874|Drug|CI 0.2% ropivacaine|Patients in Group CI will receive continuous infusion of 0.2% ropivacaine at 5 mL/hour; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
46000248|NCT04318756|Behavioral|Translation and cultural adaptation go the cancer worry scale|To develop and validate the Italian version of Cancer worry scale using high risk subjects for familiarity/genetic predisposition and patients with premalignant lesions.
46000249|NCT02888002|Behavioral|Guide to better alcohol habits|A 5-module therapeutic program wich includes self-help material in printed or web-based form with interactive exercises. The program includes instructions for the therapist.
46087064|NCT02707874|Drug|PIB 0.2% ropivacaine|Patients in Group Programmed intermittent bolus (PIB) will receive automated programmed intermittent boluses of 10 mL of ropivacaine 0.2% every 2 hours; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
45457806|NCT02312128|Other|Range of Motion measurement|Angle measurement of the active range of motion in the wrist
46087065|NCT02709200|Drug|Dexmedetomidine|
46087066|NCT02708888|Other|Trunk training|The experimental group receives 16 hours of additional trunk training (4 days/week, 4 weeks) focusing on trunk muscle strength, coordination and selective movements executed on stable and unstable surfaces.
46087067|NCT02708888|Other|Cognitive exercises|The control group will be receiving the same amount of repetitive cognitive exercises within arm's range to ensure no anticipatory postural adjustments of the trunk.
45835351|NCT01943994|Drug|Nicotine Replacement Therapy (NRT)|
45835352|NCT02463708|Behavioral|BHL COTP|The BHL COTP starts with an initial baseline assessment; following the baseline assessment, it is then divided into several core services. CG receive care management services, which includes contact, support, and active listening, as well as written material regarding caregiving and dementia and referral to appropriate community services. CGs also are offered the Telehealth Education Program (TEP) a manualized program developed to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
45457807|NCT05198635|Device|local cerebral oxygen saturation|minimum SctO2, SctO2 drop/rise defined by different thresholds, and area under/above the threshold
45457808|NCT01136551|Drug|Huperzine A|Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.
45457809|NCT02307292|Device|POLARIS Peripheral Vascular Self Expanding Stent System|
45457810|NCT01233739|Drug|Chondroitin sulfate|Administration of 2 capsules of 400 mg of chondroitin sulfate orally.
45457811|NCT01233739|Drug|Placebo|Administration of 2 capsules of placebo orally.
45457812|NCT02304328|Other|Clinical assessment|Patients will be clinically assessed whether they present clinical signs of brain herniation syndromes
45835353|NCT02177292|Radiation|Radiation Therapy|A high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
45835354|NCT02177058|Other|INTERACT Quality improvement program|INTERACT training and implementation between APR 2013 and MAR 2014
45835355|NCT02177058|Other|Quarterly surveys/data reporting|The nursing homes are asked to complete quarterly surveys between APR 2013 to MAR 2014
45835356|NCT02174016|Dietary Supplement|Ketogenic diet|
45835357|NCT01894854|Procedure|Stem collar|The stem has two versions, one with and one without a collar. The classical Furlong HAC had a collar.
45835358|NCT02456532|Drug|placebo|
45835359|NCT02456532|Drug|Zolpidem CR|
45835360|NCT02456532|Drug|Eszopiclone|
45835361|NCT01936272|Device|Chhabra Shunt Placement|
45835362|NCT01936272|Procedure|ETV/CPC|
46000250|NCT04675437|Other|Aerobic exercise|12-weeks aerobic exercise program
46000251|NCT02605538|Biological|Vaccination with vaccine against hepatitis A and B|Vaccination against hepatitis A and B
46087068|NCT02709044|Drug|Ringer lactate|
46087069|NCT00611936|Drug|Placebo|Placebo
46087070|NCT00611936|Drug|Atomoxetine|20mg maximum of d-amphetamine
46087071|NCT02713100|Behavioral|level of agitation|psychological pain
46087072|NCT00611156|Dietary Supplement|ginger|added to a brunch meal
46087073|NCT00611156|Dietary Supplement|black pepper|Added to a brunch meal
46000252|NCT04677192|Combination Product|Microwave Ablation combination with chemotherapy|Microwave Ablation combination with chemotherapy. Maximum tumor diameter ≤ 3cm, single microwave needle, maximum tumor diameter> 3cm, double ablation needle, the ablation range completely covers the lesion ≥ 0.5cm in order to obtain a satisfactory ablation margin. After the operation, contrast ultrasound is performed again to confirm the ablation edge. Enhanced MRI or CT to evaluate the ablation effect 4 weeks after surgery. Selection of chemotherapy regimen refers to the 2020 NCCN Guidelines for Pancreatic Cancer. First-line chemotherapy regimen: gemcitabine combined with albumin-bound paclitaxel or FOLFIRINOX; second-line chemotherapy regimen: If first-line chemotherapy based on gemcitabine, 5-FU-based regimen for second-line, If 5-FU-based regimen for first-line, gemcitabine for second-line.
46000253|NCT02550470|Device|Carbon Dioxide Absorbents|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
46000254|NCT02550470|Device|Micropore SpiraLith|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.
46000255|NCT02550470|Drug|Sevoflurane|
46000256|NCT04688216|Other|risk factors of infection with multidrug-resistant organisms|"General information: age, gender, length of stay in ICU, method of admission, tubes taken at the time of admission, APACHEⅡ score, surgery, laboratory tests (PCT, CRP, WBC), pressure sores, etc.~Iatrogenic factors: days of using ventilator, days of using antibacterial drugs, types of antibacterial drugs, use of glucocorticoids, use of immunosuppressants, days of central venous intubation, days of indwelling catheters, days of arterial catheterization, and other indwelling catheters.~The patient's own related factors: diagnosis, whether complicated with hypertension or diabetes; whether exist malignant tumor, primary lung infection, hypoproteinemia; whether antibiotic treatment before admission; fever and fever days, whether diarrhea occurs"
46000257|NCT04675359|Procedure|Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint|Injections of the two adipose tissue derived products containing MSCs into the knee joints with osteoarthritis
46087074|NCT00611156|Dietary Supplement|horseradish|Added to a brunch meal
46000258|NCT04675203|Procedure|Tooth extraction|Tooth extraction
46000259|NCT02910518|Drug|Insulin glulisine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
46000260|NCT02910518|Drug|Insulin glulisine|"Pharmaceutical form: solution~Route of administration: subcutaneous"
46000261|NCT02910518|Drug|Insulin aspart|"Pharmaceutical form: solution~Route of administration: intravenous/subcutaneous"
46087075|NCT00611156|Dietary Supplement|mustard|Added to a brunch meal
46000262|NCT02910518|Drug|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
46000263|NCT02910518|Drug|Glucagon|"Pharmaceutical form: Powder and solvent for solution for injection~Route of administration: subcutaneous"
46000264|NCT02910518|Drug|Glucose|"Pharmaceutical form: solution~Route of administration: intravenous"
46000265|NCT02910518|Drug|Heparin|"Pharmaceutical form: solution~Route of administration: intravenous"
46087076|NCT00611156|Dietary Supplement|placebo|Added to a bruch meal
46087077|NCT02707406|Other|NEOX®CORD 1K|use of human tissue product wound covering
46087078|NCT02707406|Other|standard of care|standard wound coverings
46087079|NCT05185076|Device|CureSight|watch CureSight treatment for 90 minutes per day, 5 days a week for 16 weeks
46000266|NCT01217437|Biological|Bevacizumab|Given IV
45457813|NCT03132142|Drug|Capsaicin|4x4 cm patch of 8% topical capsaicin applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
45457814|NCT03132142|Drug|Trans-cinnamaldehyde|1mL of 10% trans-cinnamaldehyde applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
46000267|NCT01217437|Drug|Irinotecan Hydrochloride|Given IV
46000268|NCT01217437|Drug|Temozolomide|Given PO
46000269|NCT04675281|Other|2 post-mortem transcutaneous lung biopsies (1 anterior ; 1 posterior) using anatomical landmarks|All specimens are fixed with 4% neutral formaldehyde and embedded in paraffin wax in the department of pathology of each participating centre. Afterwards, all samples are sent for analysis to the department of pathology of Nantes university hospital. All biopsies are independently analysed by a group of pathologists who are experts in lung tissue and blinded to clinical information. All biopsies will be analysed using a predetermined semi-quantitative histological scoring grid. The pathologists are asked to assess the degree of: edema, cell necrosis, hyaline membrane formation, proliferation of alveolar type 2 cells, fibrosis, capillary congestion, alveolar edema, neutrophilic infiltration, and microscopic thrombosis. Finally, the following patterns are recorded: exudative diffuse alveolar damage (DAD), proliferative DAD, fibrosis, intra-alveolar haemorrhage, lymphocytic pneumonia, organizing pneumonia, acute fibrinous organizing pneumonia (AFOP), thrombotic microangiopathy.
46087080|NCT00612092|Radiation|Spiral image acquisition|standard spiral scan protocol
46087081|NCT00612092|Radiation|sequential image acquisition|sequential CT scan protocol
45457815|NCT03132142|Drug|L-Menthol|1mL of 40% L-menthol applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
45457816|NCT03132142|Drug|Vehicle patch|Inert vehicle patch applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
46087082|NCT04189016|Device|Inhalation from a salt particle inhaler with or without content|Inhalation from inhaler with (active) or without (placebo) content
46087083|NCT03707054|Diagnostic Test|Study Arm|Measurements of optic nerve diameter, serum and urine osmolarity, serum vasopressin
46087084|NCT02707562|Drug|GLPG1837 dose 1|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
46087085|NCT02707562|Drug|GLPG1837 dose 2|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
46000270|NCT02910479|Device|E-Celsius thermometer|comparison of temperature between e-celsius and thermometer, rectal thermometer, esophageal thermometer, vital sense capsule thermometer
46000271|NCT02910479|Device|Rectal thermometer|
46000272|NCT02910479|Device|Esophageal thermometer|
46087086|NCT02707562|Drug|GLPG1837 dose 3|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for two weeks
46087087|NCT02707328|Drug|Gemcitabine|
46000273|NCT02910479|Device|Vital sense capsule thermometer|
46087088|NCT02707328|Drug|nab-paclitaxel|
45675853|NCT05397691|Other|Modified Family Talk|The Modified Family Talk intervention consists of six modules, each lasting approximately 60 minutes. Family Talk is intended to be delivered over a period of 12 weeks, with meetings occurring every 1-2 weeks.
46000274|NCT00624364|Drug|biphasic insulin aspart|
46000275|NCT00624364|Drug|metformin|
46000276|NCT02910596|Drug|bethanechol chloride|bethanechol chloride(10) 2 tablets oral tid, ac. Start on3rd - 5th postoperative day
46000277|NCT02910596|Device|early bladder training|early bladder training start on 3rd - 5thpostoperative day
46000278|NCT02910596|Other|early bladder training and bethanechol chloride|bethanechol chloride 2 tablets oral tid, ac and early bladder training start on 3rd - 5th postoperative day
46000279|NCT02910596|Other|no early bladder training and no bethanechol chloride|no bethanechol chloride and no early bladder training
46000280|NCT04316377|Drug|Hydroxychloroquine Sulfate|400 mg hydroxychloroquine sulphate (equalling 310 mg base) twice daily for seven days
46000281|NCT04677036|Other|No intervention is given|No intervention given
46000282|NCT02886988|Drug|Botulinum toxin type A|50 units of botulinum toxin diluted in 1 ml of normal saline will be administered. 0.1mlof BTA will be injected with a 30G needle.
46000283|NCT02886988|Drug|normal saline|0.1mlof normal saline will be injected with a 30G needle.
46087089|NCT02707328|Radiation|CyberKnife|
45675854|NCT05397691|Other|Control-like parameter estimation|Parameter estimation is designed to emulate best practices around comprehensive, high quality, patient-centered care for adults and youth. Participants will have access to collaborative adult Office Based Addiction Treatment (OBAT) clinical services, multidisciplinary adolescent primary care clinics with co-located adolescent substance use specialists, high quality social work services, integrated behavioral health, and access to patient navigators for assistance connecting to community resources.
46000284|NCT02887144|Device|SenSura|SenSura is a Commercial and CE-marked ostomy product (1pc) manufactured by Coloplast A/S
46000285|NCT02887144|Device|SenSura test product|SenSura test product is a CE-marked ostomy product (1pc) manufactured by Coloplast A/S
46000286|NCT02910440|Drug|DCL-101 vs Golytely|
46000287|NCT04676997|Biological|Camrelizumab|200mg on days1,15 of Cycles 1-4 (Q2W); IV infusion. 200mg on day 1 of Cycles 5-8 (Q2W); IV infusion.
46000288|NCT04676997|Drug|Nab paclitaxel|125 mg/m² on day 1, 8 and 15 of Cycles 1-4 (QW 3/4); IV infusion.
46000289|NCT04676997|Drug|Epirubicin|90 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.
46000290|NCT04676997|Drug|Cyclophosphamide|600 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.
46000291|NCT01217047|Device|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
46000292|NCT01217047|Device|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
46000293|NCT01217047|Procedure|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
46087090|NCT00612638|Drug|Temodar, O6-BG, and Irinotecan|2 separate strata accrued independently: Stratum 1-pts receiving Dilantin, Tegretol or phenobarbital. Stratum 2-pts on anti-convulsants other than Dilantin, Tegretol/phenobarbital/pts not on any anti-convulsants. O6-BG administered intravenously 120mg/m2, over 1hr, prior to administration of Temozolomide on day 1 of 21day cycle. O6-BG administered intravenously 30mg/m2/day, over 48hrs, immediately after completion of CPT-11 infusion on day 1 of 21-day cycle. Temozolomide administered orally 355mg/m2 within 60 mins of end of 1hr O6-BG infusion. Treatment cycles may be repeated every 3wks following dose of Temozolomide from previous cycle. CPT-11 administered intravenously in fasting state over 90mins. CPT-11 infusion will begin 1hr after Temozolomide administration. Initial doses 60mg/m2 for stratum 1 & 40mg/m2 for stratum2. Treatment cycles repeated every 3 wks following dose of CPT-11 from previous cycle.
46087091|NCT05151848|Drug|Adalimumab Injection|Adalimumab Injection injected subcutaneously every other week for 52 weeks
46087092|NCT05151848|Drug|Tofacitinib 5 MG|Tofacitinib 5 MG BID taken orally for 52 weeks
46087093|NCT05134688|Drug|Magnesium sulfate|Tocolytic to stop preterm labor
46087094|NCT05122754|Drug|B/F/TAF|Bictegravir/emtricitabine/tenofovir alafenamide once daily, 1 tablet at a time, with or without food for 48 weeks.
46087095|NCT05122754|Drug|TDF-based triple ART regimen switching to B/F/TAF|Tenofovir disoproxil fumarate was administered once daily, one tablet at a time, with or without food. After Week 24, control subjects were also switched to bictegravir/emtricitabine/tenofovir alafenamide once daily, one tablet at a time, with or without food for the later 24 weeks.
46087096|NCT05116670|Other||this is an observation study, no intervention is needed
46000294|NCT01217047|Behavioral|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
46087097|NCT02693288|Procedure|Local infiltration anesthesia|Local infiltration by the surgeon at the end of surgery of perifracture site. A solution of 10 mL of ropivacaïne 0,75% is injected in the fracture site, tendon's synovial sheaths, subcutaneous tissue and skin.
46000295|NCT00624403|Device|Laryngeal mask insertion (LMA ProSeal)|Laryngeal mask insertion
46000296|NCT00624403|Device|Laryngeal mask insertion (I-Gel)|Laryngeal mask insertion
46000297|NCT02910128|Behavioral|chiquichefs|A project based learning using healthy trough cooking as the core of the curriculum, so children learn the academic content through cooking workshop of mediterranean diet in their school.
46000298|NCT01968720|Drug|CAT-2003|
46087098|NCT02693054|Device|HALO|Laser Treatment
46000299|NCT01968720|Drug|Placebo|
46000300|NCT02910206|Drug|Etomidate|etomidate is given intravenously
46000301|NCT02910206|Drug|propofol|propofol is given intravenously
46000302|NCT02910206|Drug|Sufentanil|sufentanil is given intravenously
46000303|NCT02910206|Drug|Cisatracurium|Cisatracurium is given intravenously
46087099|NCT05108480|Other|Experimental group|This study followed the protocol designed for patients with hemophilic knee arthropathy. For its implementation, a 30-cm long15-cm diameter foam roller was used, and a ball 22 cm in length and 8 cm in diameter. The total duration of the intervention was 15 minutes, with 7 sessions per week over a period of 8 weeks. The physiotherapist who supervised the intervention followed up on all patients by telephone on a weekly basis to check for the absence of haemarthrosis during the intervention and to detect the possible need for protocol adaptations depending on the clinical situation of each patient. Each patient was individually provided with instructions as to how perform the exercises during the pretreatment evaluation, customizing the program if necessary. All patients had access to a mobile application, designed ad hoc for the research study (He-Foam®), where they could learn about the exercises through demonstration videos.
46000304|NCT04675086|Drug|alpha1-proteinase inhibitor|Alpha1-Proteinase Inhibitor (Human), AralastÔ, is a sterile, stable, lyophilized preparation of purified human alpha1-proteinase inhibitor (a1-PI), also known as alpha1-antitrypsin.
46000305|NCT04675086|Drug|Antiviral Agents|a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization
46000306|NCT02909972|Drug|ALRN-6924|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days.
46000307|NCT02909972|Drug|ALRN-6924 in combination with cytarabine|Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.
46000308|NCT01961778|Device|Radio-Frequency Ablation|
46000309|NCT01961778|Device|Cryotherapy|
46000310|NCT04687943|Combination Product|PELOID therapy, kinesio tape, exercise|126 patients diagnosed with lateral epicondylitis will be divided into 3 groups. Totally 15 sessions of peloid therapy for 42 patients in 1 group for 3 weeks, 5 days a week, 2 sessions of muscle and fascia correction techniques for 3 weeks in the second group for 3 weeks, and 3 sets per day for 42 patients in the third group for 3 weeks. You will be given 10 repetitive home workouts.
46087100|NCT02693210|Drug|Cyclophosphamide|Participants will receive 750 mg infusions of cyclophosphamide on Days 3 and 17
46087101|NCT02693210|Drug|Methotrexate|Participants will receive >= 10 mg/week methotrexate orally up to 24 weeks
45457817|NCT03917173|Procedure|Surgery plus HIPEC CO2|Prophylactic surgery plus HIPEC CO2 performed with mitomycin and cisplatin v
45457818|NCT03917173|Procedure|Standard surgery|Standard surgery without HIPEC CO2
45457819|NCT03509272|Device|remote monitoring|"Intervention Description: Patients can participate in the study when they're 10 weeks pregnant. At 10 weeks: a NICCOMO, Maternal Venous Doppler Echography and Maltron measurement will be taken. This measurement will be repeated at 20 weeks of pregnancy, and 30 weeks of pregnancy when they're aberrant.~When the measurements are abnormal, the patients will be included in the remote monitoring study. The following protocol and devices will be applied:~Device What When Withings Wireless Blood Pressure Monitor Blood Pressure 2x/day Withings Pulse O² Activity Day and night Withings Smart Body Analyzer Weight~1x/day"
45457820|NCT03917329|Other|ACT and PBS group workshop|Acceptance and Commitment Therapy and Positive Behaviour Support Group Workshop. Three sessions of approximately three hour duration. Groups will consist of 5-10 parents or 5-10 members of education staff. The group will include both didactic and experiential elements.
45457821|NCT01232647|Drug|Phylloquinone|1.0 mg daily of vitamin K1
46000311|NCT04674657|Drug|blood drug concentration|blood drug concentration
46000312|NCT04688060|Diagnostic Test|Falls Efficacy Scale-International (FES-I)|The FES-1 was used to assess the fear of falling level of participants about falling during indoor or outdoor activities. It has 16 items scored on a four-point Likert scale. The Turkish validated version of the FES-I was used in this study. The total score (sum of the 16 responses) ranging from 16 to 64 points was used for data analysis. A higher score indicates better mobility performance. A cut-off score of 27 points on the 16- item FES-I was used to differentiate high concern for falling from low concern
46000313|NCT04674735|Drug|APSLXR|Oral coated tablets once a day for 60 days.
46000314|NCT00555594|Drug|Bevacizumab (Avastin)|One dose of 0.1cc of subconjunctival Bevacizumab was applied
46000315|NCT02910050|Drug|Bicalutamide|50mg once a day orally
46000316|NCT02910050|Drug|Aromatase Inhibitor|participants will receive any kind of aromatase inhibitor which has not been received before (steroidal AI change to nonsteroidal AI and vice versa), Letrozole 2.5mg once a day orally, Anastrozole 1mg once a day orally, Exemestane 25mg once a day orally
46087102|NCT02693210|Other|Placebo Cyclophosphamide|Participants will receive placebo in place of cyclophosphamide on Days 3 and 17
46087103|NCT02693210|Other|Placebo Methotrexate|Participants will receive weekly oral placebo in place of Methotrexate
46000317|NCT04674930|Other|Exercise program|Home based exercise program including aerobic and resistance training will be carried out for a period of 6 weeks. Duration of aerobic exercise will be starting at 20 min/session, and progress to 30 ruin/session, with an increased pace according to the patient's capabilities. Resistance training with thera-band for 1 set of 10 repetitions twice a week. One RM will be reassessed weekly, and the program will be adjusted accordingly.
46087104|NCT02693210|Other|Placebo Rituximab|Participants will receive placebo in place of rituximab on days 1 and 15
46000318|NCT02909933|Drug|liraglutide|
46000319|NCT02909933|Drug|metformin and liraglutide|
46000320|NCT01960686|Biological|Low dose RSV F Antigen|
46000321|NCT01960686|Biological|High dose RSV F Antigen|
46000322|NCT01960686|Biological|Dose 1 of Aluminum Adjuvant|
46087105|NCT02693210|Drug|Rituximab|Participants will receive 1g infusions of rituximab on Days 1 and 15
45457822|NCT01232647|Drug|Menatetrenone (MK4)|Menatetrenone (MK4) 45 mg daily
46000323|NCT01960686|Biological|Dose 2 of Aluminum Adjuvant|
46000324|NCT01960686|Biological|Dose 3 of Aluminum Adjuvant|
46000325|NCT01960686|Biological|Dose 4 of Aluminum Adjuvant|
46000326|NCT01960686|Biological|Placebo|
46000327|NCT02910245|Drug|Mercaptopurine (Purinethol)|
46000328|NCT02910245|Drug|Placebo|
46000329|NCT02910245|Drug|Mesalamine|
46000330|NCT02910245|Drug|Prednisone|
46000331|NCT04674891|Other|baseline physical therapy treatment|Group A was control group and the patients received Conventional treatment protocol for 4 weeks which included 3 sessions per week. Patients received hot pack for 15 min and TENS (Transcutaneous Electric Nerve Stimulation) for 10 min. After that Cervical isometric exercises will be performed in sitting (10sec hold,10 to 15 reps)
46000332|NCT04674891|Other|Cervical Stabilization exercises|"Group B was experimental group and received baseline physiotherapy treatment in addition to Cervical Stabilization exercises. Pillow was placed beneath cervical spine in supine position and guided patients to nod head as though they said 'yes' and asked them to hold for 10 seconds. 10 repetitions were done before progressing to the next target level.~4 weeks (3 sessions per week)~Hot pack: 10 min~TENS: 10 min~Cervical isometric exercises in sitting (10sec hold,10 to 15 reps)~Cervical Stabilization exercises (10 sec hold, 10 reps)~On eligible participants baseline assessment was taken on day 1, post intervention assessment was taken at the end of 4th week."
45457823|NCT01232647|Drug|placebo|placebo vitamin K1 and placebo MK4 given daily for 18 months
45457824|NCT03504592|Behavioral|Completion of Glucose logs|Glucose logs will be assessed by provider for completeness and accuracy
46000333|NCT01185340|Drug|LY2216684|
46000334|NCT01185340|Drug|Placebo|
46000335|NCT01185340|Drug|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
46000336|NCT02910284|Biological|Observational|
46000337|NCT01959282|Drug|Placebo|Participants will receive placebo once daily
46000338|NCT01959282|Drug|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily
46000339|NCT01959282|Drug|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily
46000340|NCT01959282|Drug|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily
46000341|NCT01959282|Drug|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily
46000342|NCT01216189|Radiation|Preoperative radiotherapy|Preoperative radiotherapy (RT) was administered as either short course (5Gy x5) or long-course (2Gy x25 or 1.8 Gy x25 with or without 3 fractions of boost to the primary tumor and radiologically malignant lymph nodes) treatment with or without concomitant or sequential chemotherapy. Oncological treatment was decided at a multidisciplinary team conference.
46000343|NCT02909738|Other|Volunteer to pedal a bicycle|
46000344|NCT04674696|Other|Approach|Patients will receive 2 CAPOX cycles, followed by short-course radiotherapy and 4 CAPOX cycles.
46000345|NCT02909699|Other|Observation|In this trial, cardiovascular function will be measured without drug administration. The drug will be administered within the main trial.
46000346|NCT01958853|Device|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
46000347|NCT01185301|Biological|adalimumab|Pre-filled syringe every other week
46000348|NCT01185301|Drug|methotrexate|weekly oral capsule dosing
46000349|NCT02909855|Other|No intervention|Participants in this study will not receive any interventions as part of the study.
46000350|NCT01957722|Procedure|Microfracture|Surgical procedure which creates a marrow clot in the prepare cartilage defect.
46000351|NCT01957722|Biological|NOVOCART 3D|combination product- biologic (autologous chondrocytes) /device (scaffold) implant
46000352|NCT02909660|Other|Cognitive-behavioural therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Includes components to foster cognitive (i.e., thinking) and behavioural changes.
46087106|NCT05068778|Behavioral|Artificial Intelligence Application|AI application through smart phone
46087107|NCT05057624|Other|Placebo GC-MRT|Participants will hear music continuously throughout the trials, without regard to the faces they look at.
46087108|NCT05057624|Other|GC-MRT|Participants will hear music as a reward for looking at neutral faces and the music will stop when they focus on angry faces.
46087109|NCT05057624|Other|Exposure|Participants will hear music of their choice when they focus on angry faces, and when they look at neutral faces the music will stop.
46087110|NCT03706976|Device|Tissue Oxygenation Monitoring|The NIRS sensor will be applied to the abdomen of the study population. To ensure good skin contact the sensor will be placed underneath the diaper. If that should not provide enough measurement stability, additional fixation will be given by employing aforementioned flexible bandage routinely employed in neonatal care. Once good skin contact is ensured, the sensor will measure aStO2 for up to seventy-two hours. The presence of this sensor will not disturb daily clinical activities or medical treatment in any way. Should good skin contact be endangered by movements, clinical interactions or such, the sensor will be removed and re-attached to the infants' abdomen as a consequence.
46087111|NCT05045456|Device|Cardiologs Platform|Two Apple Watch recordings (one recording with the watch on the wrist and one on the left side of the abdomen) interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
45675855|NCT05372484|Device|Multimodal optical imaging|Women referred for colposcopy due to abnormal cervical screening will be recruited into the experimental group of the study. Imaging of study participants will take place during the colposcopy examination.
45675856|NCT05372003|Drug|Dupilumab|dupilumab injections will be prescribed and managed by dermatology as standard of care
46087112|NCT05029466|Drug|Psilocybin|Participants will receive a single dose of psilocybin and be assessed weekly for six weeks and biweekly for 18 weeks. Participants who relapse may receive up to two repeated doses of psilocybin.
46000353|NCT02909894|Other|Prolonged Sitting|Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow investigators to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. Following this, a lunch meal will be provided and investigators will continue taking blood samples and blood pressure at 30, 60, 120 and 180 minutes after this lunch meal. In total, 10 blood samples will be taken over the 7 ½ hour testing period. There will also be a cognitive test in the morning and afternoon.
46000354|NCT02909894|Other|Light arm ergometry breaks|Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of light intensity arm ergometry on a desktop arm ergometer every 30 minutes following breakfast and lunch. In total they will do 12 five minute arm ergometry breaks throughout the 7 ½ hour test period (60 minutes of arm ergometry in total). In total 10 blood samples will be taken on the day.
46000355|NCT01955616|Drug|RM-131|
46000356|NCT01955616|Drug|Placebo|
46000357|NCT02909621|Dietary Supplement|FLEXOFYTOL®|The product FLEXOFYTOL® is bio-optimized curcumin.
45675857|NCT05372003|Other|Photo therapy|light therapy will be prescribed and managed by dermatology as standard of care
45457825|NCT03917095|Device|The Colonic Transendoscopic enteral Tubing.|The medications were infused into the colon through the Colonic Transendoscopic enteral Tubing(TET).
46000358|NCT02909621|Other|PLACEBO|
46000359|NCT04675008|Drug|Dacomitinib|Secondary generation EGFR-tyrosine kinase inhibitor (TKI) (Dacomitinib) for EGFR mutant NSCLC patients with non irradiated brain metastasis
46000360|NCT02909543|Other|Observation and Interviwe|The research data will be conducted by using a semi structured interview of the participants in the study.
46000361|NCT01954173|Radiation|3D conformal radiation therapy|Undergo conformal radiation therapy
46000362|NCT01216072|Drug|Fingolimod|0.5 mg/day oral capsule
46000363|NCT01216072|Drug|Standard MS DMTs|
46000364|NCT02909582|Procedure|Cohen Incision|This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
45457826|NCT03917095|Drug|Glutamine|The medications were infused into the colon
45675858|NCT05371652|Drug|Rimegepant 75mg Orally Disintegrating Tablets (ODT)|One rimegepant (BHV3000) 75mg orally disintegrating tablet (up to 1 tablet per day) at the time of their migraine attack
46000365|NCT01940991|Drug|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
46000366|NCT01940991|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A, dose applied to the lateral canthal lines
46000367|NCT02909465|Drug|Midazolam|Using Midazolam as a premedication for reducing ketamine-induced agitation
46000368|NCT02909465|Drug|Haloperidol|Using Haloperidol as a premedication for reducing ketamine-induced agitation
46000369|NCT02909465|Drug|placebo|distilled water
45457827|NCT03917095|Drug|Mesalazine|The medications were infused into the colon
45675859|NCT05370521|Drug|Tildacerfont|Oral tablet formulation taken once daily.
45675860|NCT05370521|Drug|Placebo|Non-active dosage form taken once daily.
45675861|NCT05353452|Behavioral|Neurology Based Collaborative Care|Twenty-four week, evidence-based remote collaborative care model initiated around the time of a neurology visit. The collaborative care team roles include the care manager, psychiatrist, and psychologist/social worker who interact with the patient participant and the patient's neurologist.
45675862|NCT05353452|Behavioral|SOC Neurological care|Usual neurology care means ongoing, epilepsy provider-recommended clinic visits, prescriptions, testing and referrals from their epilepsy provider. Mental health referrals or prescribing of antidepressants may potentially occur in this group; these types of interventions will be tracked at outcome assessments.
45675863|NCT05351489|Drug|Dexmedetomidine|Patients will receive intrathecal 2 mL heavy bupivacaine 0. 5% together with either dexmedetomidine 5 μg or10 μg dexmedetomidine .
45675864|NCT05345717|Drug|Belatacept Injection|Patient will initiate belatacept therapy and will received 2 cycles of proteasome inhibitor therapy
46000370|NCT02909465|Drug|Ketamine|Ketamine is routinely used for all procedural sedation in the patients.
46000371|NCT04312555|Drug|Alprostadil|Alprostadil intravenous administration. (0.5 mg/1ml of Alprostadil + 49cm saline 0.9%) and 4 cm direct intravenously / 8 hours
46000372|NCT04674579|Device|MRI|magnetic resonance imaging
46000373|NCT01184989|Drug|Dabigatran etexilate|once daily approved dose by EMEA and Health Canada
46000374|NCT02909192|Device|Light Therapy Device|
46000375|NCT04674423|Drug|Tenofovir Alafenamide|Tenofovir Alafenamide treatment for 144 weeks
46000376|NCT02909387|Behavioral|Project UPLIFT|UPLIFT is an 8-week distance-delivered mindfulness-based cognitive therapy intervention.
46000377|NCT00555828|Genetic|Allogeneic Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection
46087113|NCT05024006|Drug|Remdesivir|Two intravenous loading doses, then daily infusion for 10 days
46087114|NCT05024006|Drug|Hydroxychloroquine|Two oral loading doses, then orally twice daily for 10 days
46087115|NCT05024006|Drug|Lopinavir / Ritonavir|Orally twice daily for 14 days
46087116|NCT05024006|Drug|Interferon beta-1a|Daily injection for 6 days
46087117|NCT05024006|Drug|Acalabrutinib|Orally twice daily for 10 days
46087118|NCT02707250|Drug|Placebo|Tap Block performed with normal sterile saline 20 ml on the right side and 20 ml on the left side
46087119|NCT02707250|Drug|Bupivacaine|Tap Block performed with Bupivacaine 0,25% 20 ml on the right side and 20 ml on the left side.
46000378|NCT00555828|Procedure|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
46000379|NCT00555828|Genetic|Allogeneic Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection
46087120|NCT02707250|Drug|Pethidine|Tap Block performed with pethidine 1% 10 ml on the right side and 10 ml on the left side
46087121|NCT02707250|Drug|Pethidine Local Infiltration (L.I)|Local infiltration of port sites (trocar insertion sites) with pethidine 1% 5ml each port (trocar site) ,4 ports total 20 ml pethidine 1%
46000380|NCT00555828|Procedure|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
46000381|NCT00555828|Genetic|Allogeneic Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
46000382|NCT00555828|Procedure|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
46000383|NCT02909426|Device|Ultrasonography|Radiologists' hand-held bilateral breast ultrasonography for each participant for one time
46087122|NCT03781544|Drug|Tramadol|A single i.v. infusion of Tramadol (dose: 400mg/100ml) will be administered to the participants (treatment arm).
45457828|NCT03504514|Device|speech trials during different ventilation conditions|ventilator parameters are modified
45457829|NCT03504514|Other|speech trial|reading duration, vocal flow, intelligibility and voice quality will be evaluated during speech
45675865|NCT05340426|Device|UKidney|The intended clinical product is a kidney derived from a domestic pig that contains an intentional genomic alteration (IGA) to protect it after transplantation from the human immune response via inactivation of endogenous porcine genes responsible for expression of pig epitopes and inclusion of human transgenes to inhibit host immunogenic response.
45835363|NCT02157480|Device|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 3 days per week .|outpatient biquadricipital electrostimulation 3 days per week with an electrostimulator Compex2* (DJO, Vista, CA, USA)
46000384|NCT02909426|Device|Digital mammography|Full-field digital mammography using one of the equipments from General Electric (GE), Hologic, and Medi-future companies for each participant for one time
46087123|NCT03781544|Drug|Paracetamol|A single i.v. infusion of Paracetamol (dose: 1g/100ml) will be administered to the participants (control arm).
46087124|NCT03781544|Drug|Diclofenac|A single i.v. infusion of Diclofenac (dose: 75mg/100ml) will be administered to the participants (treatment arm).
46087125|NCT02707094|Device|Biomodulator|The Biomodulator is a type of very low frequency TENS known as pulsed electromagnetic field therapy (PEMF). Unlike TENS devices that deliver 1-80 milliamperes of electrical current, PEMF devices deliver short bursts of electrical microamperes (millionths of an ampere) to injured tissues without producing heat or interfering with nerve or muscle function. Micro-current levels between 20-500 microampere appear to be most effective at relieving pain and inflammation and promoting tissue healing by realigning the natural electrical balance that exists within the cells that has become disrupted due to injury.
45457830|NCT01133743|Drug|Lenalidomide and Dexamethasone|Starting Lenalidomide dose 2.5 mgs or 5 mgs (based on baseline calculated creatinine clearance)PO daily on a 28 day cycle. Dose escalations will take place at the start of subsequent cycles as frequently as tolerated but not more frequently than at the start of each cycle to a target dose of 25mg daily. Oral dexamethasone at 12 mg PO daily will be administered on days 1-7, 14 and 21 of each cycle
45457831|NCT02307604|Genetic|Tumour markers testing|
45457832|NCT01138423|Drug|Aliskiren|Once daily treatment with aliskiren for 8-weeks, according to the following regiment: once daily (morning time) 150 mg during the first 2 weeks, followed by once daily (morning time) 300 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 150 mg on day 1, 2, 3, 4, 5 and 7.
45457833|NCT01138423|Drug|Moxonidine|Once daily treatment with moxonidine for 8-weeks, according to the following regiment: once daily (morning time) 0.2 mg during the first 2 weeks, followed by once daily (morning time) 0.4 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 0.2 mg on day 1, 2, 3, 4, 5 and 7.
45675866|NCT05332613|Behavioral|TRE plus SOC|Participants will undergo time restricted eating (TRE) each day for 12 weeks and will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).
45835364|NCT02157480|Device|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 5 days per week|outpatient biquadricipital electrostimulation 5 days per week with an electrostimulator Compex2* (DJO, Vista, CA, USA)
45835365|NCT02153580|Biological|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
45835366|NCT02153580|Drug|Bendamustine Hydrochloride|Given IV
45835367|NCT02153580|Drug|Cyclophosphamide|Given IV
45835368|NCT02153580|Drug|Etoposide|Given IV
45835369|NCT02153580|Drug|Fludarabine Phosphate|Given IV
45835370|NCT02152956|Biological|Flotetuzumab dose escalation|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.
46000385|NCT00555867|Drug|Anastrozole|oral
46000386|NCT02909309|Device|JAWAC system + Capnoline + Spo2|measure mandibular mouvements + etCO2 + pulse oxymetry, respectively
46000387|NCT01932099|Device|Transcatheter aortic valve replacement|Direct Flow Medical Transcatheter Aortic Valve System is indicated for use in aortic stenosis for patients at extreme surgical risk for aortic valve replacement.
46000388|NCT03457376|Diagnostic Test|Hand Grip Force|Hand Grip Force
46000389|NCT03457376|Diagnostic Test|Maximal Inspiratory Pressure|Maximal Inspiratory Pressure
46000390|NCT03457376|Diagnostic Test|Maximal Expiratory Pressure|Maximal Expiratory Pressure
46087126|NCT02707094|Other|Usual Care (Medication + Exercise)|The study LP will prescribe an analgesic medication regimen based on the participant's needs. These medications may consist of Non-steroidal anti-inflammatory Drugs (NSAIDs) (ibuprofen, naproxen sodium, etc.), muscle relaxants (Flexeril, Robaxin, valium, etc.), non-narcotic analgesic medications (acetaminophen, aspirin, tramadol, etc.), or narcotic medications (Tylenol #3, Percocet, Vicodin, etc.) depending on the severity of their pain and co-morbid conditions. The RC will also provide instructions for LBP stretching and strengthening exercises. The following exercises will be recommended as a daily regimen: the partial curl, cat and camel, pelvic tilt, quadriceps, arm/leg raises,trunk rotation, single knee to chest stretch, standing hamstring stretch, and double knee to chest stretch.
46000391|NCT00555945|Procedure|Gamma3 intramedullary nail (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
46000392|NCT00555945|Procedure|Sliding Hip Screw|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
46000393|NCT02909270|Device|Mediclore|to apply mediclore fully around thyroid gland
46000394|NCT00555984|Drug|Propofol + Remifentanil|Administered intravenously during surgery for maintenance of General Anesthesia
46000395|NCT00555984|Drug|Sevoflurane + Remifentanil|the (Sevoflurane + Remifentanil) arm: Sevoflurane as inhalational agent and Remifentanil as intravenous agent for maintenance of General Anesthesia
46000396|NCT01917825|Drug|MDT-15|
46000397|NCT01912560|Drug|CAT-2003|
46087127|NCT02707016|Other|Sevoflurane 8%|Sevoflurane 8% (high dose) during anesthesia induction
46087128|NCT02707016|Other|Sevoflurane 5%|Sevoflurane 5% (low dose) during anesthesia induction
46087129|NCT02706704|Drug|Adalimumab|
46087130|NCT02706782|Drug|TAI-meso-CART|TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And meso-CART is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator
46087131|NCT04175444|Diagnostic Test|VisuALL Field Analyzer|Each participant will conduct a visual field test with the visuaALL headset.
46087132|NCT04175444|Diagnostic Test|Humphrey Field Analyzer|Each participant will conduct a standard of care Humphrey Visual Field.
45675867|NCT05332613|Behavioral|SOC|Participants will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).
46000398|NCT01912560|Drug|Placebo|
46000399|NCT01912560|Drug|Statin|All patients being treated with a stable dose of a statin prior to enrollment continue on their dosing regimen.
46000400|NCT01910025|Drug|ADI-PEG 20|
46000401|NCT03457337|Drug|S-1 plus Gefitinib|S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally Gefitinib: 250mg, 1 day, orally, fasting or with the same service
46000402|NCT03457337|Drug|Gefitinib|Gefitinib: 250mg, 1 day, orally
46000403|NCT04674540|Other|No Intervention|No Intervention
46000404|NCT02274779|Drug|ELIGARD|"Hormone therapy is recommended Eligard 45 mg acting for 6 months. It will be ideally administered the day of start of radiation therapy or within 3 months before the first day of radiotherapy.~Nevertheless, free prescription is left to investigators. When using other hormonal strategies (anti-androgen agonists, LHRH antagonists or LHRH), an administration for six months will be critical."
46087133|NCT04156100|Drug|AGEN1223|AGEN1223 is a bispecific antibody.
46087134|NCT04156100|Drug|AGEN1223 and balstilimab|AGEN1223 is a bispecific antibody and balstilimab an anti-PD-1 Monoclonal Antibody.
46087135|NCT04956146|Drug|Fruquintinib，Sintilimab，Pemetrexed，Carboplatin|Fruquintinib,fruquintinib at the dose determined in phase safety lead-in,5mg-intermittent (2 weeks on/ 1 week off) ，po，every 3 weeks(q3w) ; Sintilimab at the dose 200mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=4~5，iv，d1；given every 3 weeks (q3w); Maintenance treatment：After 4~6 cycles of carboplatin treatment, Sintilimab 200mg, iv, d1, q3w；Fruquintinib RP2D intermittent(2 weeks on/1 weeks off), po，q3w； pemetrexed 500mg/m2, d1,iv, q3w until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
46087136|NCT00612794|Drug|exenatide once weekly|subcutaneous injection, once weekly
46087137|NCT00612794|Drug|placebo|subcutaneous injection, once weekly
46000405|NCT04674501|Procedure|Cardiac evaluation and blood sampling|"Patients in this cohort will undergo cardiac evaluation before and after thoracic irradiation.~The dose-volume parameters for each cardiac substructures will be estimated using artificial intelligence-based auto-segmentation of the heart in CT images. Dose-volume parameters that predict cardiotoxicity will be analyzed.~The patients who developed cardiotoxicity will undergo blood sampling to establish cardiomyocytes derived from induced pluripotent stem cells, which will be used for identifying the mechanisms of radiation-induced cardiotoxicity and therapeutic targets."
46000406|NCT03455010|Other|Increased load|Participants walk with 120% body weight achieved with a weight vest
46000407|NCT03455010|Other|Reduced load|Participants walk with 80% body weight achieved by a dynamic unloading system
46000408|NCT05311280|Other|high intensity interval training plus myotherapy|"High intensity interval training (HIIT) has been proved its same effect on lower down body fat as moderate intensity continuous training (MICT). In addition, HIIT has the additional benefit of being a time-efficient program which can increase exercise adherence and the participants were more likely to intend to continue. Previous two studies show that HIIT could improve the severity of OSA in both obese adults and obese children.~Myotherapy: MT is composed of isotonic and isometric exercise related to oral, oropharyngeal, and respiratory exercise. Based on previous review and meta-analysis, MT can decrease not only AHI score, but also ESS score. It means that MT is beneficial to release the symptom of sudden apnea and hypopneas."
46000409|NCT05311280|Other|home exercise plus myotherapy|Home exercise: ambulation by patients themselves Myotherapy: MT is composed of isotonic and isometric exercise related to oral, oropharyngeal, and respiratory exercise. Based on previous review and meta-analysis, MT can decrease not only AHI score, but also ESS score. It means that MT is beneficial to release the symptom of sudden apnea and hypopneas.
46087138|NCT03773276|Drug|Norepinephrine boluses|"On portal vein declamping, We will inject NE boluses in the C.V.P port of the pulmonary artery catheter with 5 ml saline flushing after each. After reperfusion, we will start bolus noradrenaline 20 µg if mean arterial blood pressure (mABP) decreases by 10 % or more of the basal reading (immediately before portal vein declamping after ensuring withholding of the surgical manipulation). Additional NE boluses will be given as follow;~If mABP rises to 65 mmHg (lowest target level), we will hold NE boluses.~If mABP remains constant or begins to rise but did not reach 65 mmHg, we will give 20 µg after 10 seconds from the previous bolus~If mABP continues to drop, we will add 10 µg to the previous dose after 10 seconds and can be repeated.~If mABP remains below 65 mmHg more than 1 minute, we will give the scheduled bolus NE with adding 10 µg adrenaline boluses."
46087139|NCT02706860|Drug|Atorvastatin|
46087140|NCT02706548|Behavioral|Integrative Medication Self Management (IMedS) Intervention|Half of participants received a manualized 30-minute occupational therapy intervention, Integrative Medication Self-Management Intervention (IMedS). During IMedS, the interventionist and client progress through three steps in which the pair: 1) reflect on past performance of medication management, 2) set a medication goal, and 3) generate strategies to reach the goal. During strategy generation, the interventionist uses therapeutic use of self and motivational interviewing to help the client self-generate new medication management strategies, specifically addressing 1) altering the activity, 2) advocacy, 3) education, 4) assistive technology, 5) environmental modifications, and 6) securing timely refills.
46087141|NCT02706548|Behavioral|Standard Care Educational Intervention|The standard care educational intervention was a 30-minute pamphlet based educational session. In the standard care intervention group, participants and interventionist first reviewed the pamphlet, Managing Your Medicines: Our Guide to Effective Medication Management (American Heart Association & American Stroke Association, 2013). Then, the interventionist engaged in active listening, where she asked open-ended questions about the participant's medication routines and provided simple reflections. For the standard care procedures, the interventionist was prohibited from providing affirmations, complex reflections, summaries, problem-solving, or suggesting any specific interventions.
46087142|NCT02706470|Drug|Cyclosporin A|Patients will receive oral CsA in a dose of 50mg three times a day for 20-30 days since the occurrence of positive result in human chorionic gonadotropin (HCG) test in urine and 14 consecutive days of elevated basal body temperature. The dosage of CsA will be adjusted according to baseline and peak value of CsA blood concentration. If the baseline blood concentration of CsA is lower than 40ng/ml or the peak blood concentration of CsA is lower than 500ng/ml, the dosage of CsA will be increased to 75 mg three times a day.
46000410|NCT01908738|Drug|paracervical block with 1%lidocaine|"To determine effectiveness of paracervical block, lidocaine spray and only oral analgesic drugs for pain relief during endometrial biopsy.~Pain score(NRS) immediately after procedure and 15 minutes Group 1(1%Lidocaine) Group 2(10%Lidocaine spray) Control group(Placebo) Pain score immediately Pain score 15 minutes"
46000411|NCT01908738|Drug|10%lidocaine spray|
46000412|NCT04673955|Drug|Encorafenib|Observation of real-life treatment with encorafenib and cetuximab
46000413|NCT04673955|Drug|Cetuximab|Observation of real-life treatment with encorafenib and cetuximab
46000414|NCT04673838|Other|neurodevelopmental therapy|Considering the individual needs and wishes of the patient, an exercise program will be created for each patient in accordance with their functional levels and supporting active participation of the person. The treatment program tailored to the patient; It will include weight transfer to the affected side in different positions, functional reaching out activities, stepping forward and walking activities.
46000415|NCT04673838|Other|Lower extremity sensory training|Lower extremity sensory training will only be applied to the Intervention Group for 4 weeks, 3 days a week and 12 sessions in total. In the lower extremity, 3 sets of soft tissue needing, stroking and fascia stretching will be applied on 5 areas as Quadriceps, Hamstring, Gastrosoleus Group, Peroneal muscles, ankle and foot. In addition, sensory stimulation will be applied in the same five regions of the lower extremity with 3 repetitions and 3 sets with a knurled ball, brush and sponge. Lower extremity mobilizations of PANat Therapy approach will be used with traction and gliding applications in all joints in the ankle and foot. Finally, intrinsic muscle stimulation will be performed for 3 minutes with a bottle and towel under the sole of the foot.
45457834|NCT01138423|Drug|Hydrochlorothiazide|Once daily treatment with hydrochlorothiazide for 8-weeks, according to the following regiment: once daily (morning time) 12.5 mg during the first 2 weeks, followed by once daily (morning time) 25 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 12.5 mg on day 1, 2, 3, 4, 5 and 7.
45835371|NCT02152956|Biological|Flotetuzumab dose expansion|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.
45675868|NCT05332613|Behavioral|TRE|Participants will undergo time restricted eating (TRE) each day for 12 weeks plus 4 extra visits with the registered dietician and repeat Fibroscan, InBody composition scan, and MRI-PDFF.
45675869|NCT05332054|Biological|Allogeneic CAR-T therapy|N/A this is an observational study
45675870|NCT05330975|Biological|Placebo|0.9% sodium chloride (normal saline) injection
45675871|NCT05330975|Biological|mRNA-1345|Sterile liquid for injection
45675872|NCT05330975|Biological|Afluria® Quadrivalent|single-dose, pre-filled syringe for injection
45675873|NCT05330975|Biological|mRNA-1273.214|Sterile liquid for injection
45675874|NCT05327127|Drug|K-877-ER|K-877-ER tablet
45835372|NCT02152956|Drug|Ruxolitinib|Ruxolitinib will be administered at the assigned dose.
45835373|NCT05578950|Drug|itraconazole|100 mg two capsules of itraconazole were givev twice daily to 50 patients in group A for one week per month . baseline LFTs were also monitered
45835374|NCT05578950|Drug|terbinafine|one 250 mg tablet of terbinafine were given once daily to 50 patients in group B for 12 weeks continously
45835375|NCT05586126|Drug|Sevoflurane|sevoflurane inhalation
46000416|NCT05298293|Device|ONCOLAXY Follow-up|"The operation of Oncolaxy© is based on the principle of e-PRO (electronic patient reported outcome) which is able to assess the symptoms declared by patients treated for cancer, to detect an evolution, a recurrence or the toxicity of a therapy. Alerts are sent to the healthcare team if the algorithm detects suspicious symptoms or worsening of these symptoms.~Oncolaxy© records symptoms using an electronic questionnaire that allows them to be graded. Questionnaires are sent out on a regular basis. The algorithm analyzes the responses and processes them taking into account the score of the response and its evolution over time. The combination of the results makes it possible to send information to the healthcare teams in charge of the patient that will alert them, enlighten them and help them guide their decisions which remain under their sole control. The summary of the results can be viewed at any time on a dashboard."
46087143|NCT02706470|Drug|Dydrogesterone|Patients will receive oral dydrogesterone 10 mg three times a day for 30 days since the occurrence of positive result in HCG test in urine and 14 consecutive days of elevated basal body temperature.
46000417|NCT01904409|Drug|Placebo|
46087144|NCT03769766|Drug|Curcumin|Take medication one 500 mg pill of BCM-95 taken twice daily
46000418|NCT01904409|Drug|Rifaximin SSD 40 mg IR tablet|
46000419|NCT01904409|Drug|Rifaximin SSD 80 mg IR tablet|
46000420|NCT01904409|Drug|Rifaximin SSD 40 mg SER tablet|
46000421|NCT01904409|Drug|Rifaximin SSD 80 mg SER tablet|
46087145|NCT03769766|Drug|Placebo|Take medication one 500mg pill twice daily
45675875|NCT05327127|Drug|CSG452|CSG452 tablet
45675876|NCT05327127|Drug|Placebo|Placebo tablet
45675877|NCT05319717|Dietary Supplement|Ready-to-use therapeutic food with heat stabilized rice bran|Children assigned to the experimental group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food that contains 5% heat stabilized rice bran.
45675878|NCT05319717|Dietary Supplement|Ready-to-use therapeutic food (no rice bran)|Children assigned to the active comparator group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food (no rice bran).
46000422|NCT01904409|Drug|Rifaximin SSD 80mgIR/80mgSER tablet|
46000423|NCT02277158|Drug|Chemoradiotherapy|S-1 CCRT
46000424|NCT01902381|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
46000425|NCT05296538|Other|Broad-Minded Affective Coping Intervention|The Broad-Minded Affective Coping (BMAC) is a six session intervention that uses mental imagery and rehearsal of memories of past positive experiences to generate positive emotions in the moment. A further follow-up session is provided in the eight weeks following the end of treatment.
45835376|NCT01893996|Drug|Adalimumab|Patients will be randomized 1:1 to receive either adalimumab or placebo for the first 26 weeks of the trial, and then after a 26 week washout period, will be crossed over into the other arm (either placebo or adalimumab) for weeks 52-78.
46000426|NCT05296538|Other|Risk Assessment and Signposting|A therapist will meet with participants over two 50 minute sessions to conduct a comprehensive risk assessment, and develop a collaborative plan with the participant around managing any risk, including identification of sources of support and signposting.
46087146|NCT03711890|Procedure|Optical Coherence Tomography|Undergo OCT
46087147|NCT03711890|Procedure|Therapeutic Conventional Surgery|Undergo resection will be undertaken
46087148|NCT03711890|Diagnostic Test|Laboratory Evaluation|Labs will be obtained to test for cancer cell derived exosomes
46087149|NCT04924790|Behavioral|COVID-19 Pandemic|Comparison of the intervention preferences of patients diagnosed with obstructive urinary stones in the urology clinic and recommended for intervention during and before COVID-19
46087150|NCT03764540|Drug|Cabazitaxel plus prednisone|"Cabazitaxel 25 mg/m² intravenously on day 1 of each cycle, plus prednisone 10 mg orally given daily.~A cycle is defined as a 3-weeks period for a maximum of 10 cycles."
46087151|NCT03764540|Drug|Docetaxel plus prednisone|"Docetaxel 75 mg/m² intravenously on day 1 of each cycle, plus prednisone 10 mg orally given daily.~A cycle is defined as a 3-weeks period for a maximum of 10 cycles."
45675879|NCT05310565|Procedure|HVLA cervical chiropractic adjustments|Chiropractic high velocity low amplitude adjustment
46000427|NCT04673916|Drug|Healing evaluation|Treatments were topically applied for 5 days
46000428|NCT05294276|Other|no intervention related|no intervention related
46000429|NCT01887366|Drug|TV-1380 150 mg|Subjects assigned to TV-1380 150 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. The injection volume will be the same for all treatment groups. Therefore, to accommodate the volume required for the highest dosing group (3.0 mL), subjects in this group will receive 3.0 mL IM injection of TV-1380 150 mg (1.5 mL TV-1380 and 1.5 mL placebo/diluents).
45457835|NCT01138423|Drug|Placebo (for aliskiren)|Once daily treatment with placebo tablets for 8-weeks, according to the following regiment: once daily (morning time) 1 tablet during the first 2 weeks, followed by once daily (morning time) 2 tablets during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
45675880|NCT05298423|Biological|pembrolizumab/vibostolimab|Administered as an intravenous (IV) infusion
45675881|NCT05298423|Biological|durvalumab|Administered as an IV infusion
45675882|NCT05298423|Drug|cisplatin|Administered as an IV infusion
45675883|NCT05298423|Drug|pemetrexed|Administered as an IV infusion
45675884|NCT05298423|Drug|etoposide|Administered as an IV infusion
45675885|NCT05298423|Drug|carboplatin|Administered as an IV infusion
45675886|NCT05298423|Drug|paclitaxel|Administered as an IV infusion
45675887|NCT05298423|Radiation|thoracic radiotherapy|Administered as an external beam radiation
45675888|NCT05297201|Drug|CPL500036 - low dose|CPL500036 will be given orally. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
45835377|NCT01893996|Drug|Placebo|
45835378|NCT02442180|Drug|G-CSF (Filgrastim injection)|G-CSF (Filgrastim injection) 5ug/kg subcutaneous injection daily for 5 days and every 3 days (total 12 doses)
45835379|NCT02442180|Drug|steroid|oral prednisolone 40mg qd or iv methylprednisolone 32 mg if oral medication is not tolerable
45835380|NCT02442180|Drug|placebo|equivalent to G-CSF doses
45835381|NCT01924260|Drug|alisertib|Given PO
45835382|NCT01924260|Drug|gemcitabine|Given IV
46087152|NCT03763370|Drug|Belantamab mafodotin (GSK2857916) anti-BCMA-immunoconjugate|Dose and schedule: belantamab mafodotin 2.5 mg/kg IV Q3weeks
46087153|NCT02706236|Drug|Pancrelipase|Oral Pancrelipase, 720,000 units spread throughout the day with meals and snacks, taken daily PO for 4 weeks
46000430|NCT01887366|Drug|TV-1380 300 mg|Subjects assigned to TV-1380 300 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL TV-1380.
46087154|NCT02706236|Drug|placebo|Placebo will consist of lactose, spread throughout the day with meals and snacks, taken daily PO for 4 weeks
46087155|NCT03684512|Behavioral|Group Exercise Sessions|Remote exercise sessions delivered over group video conference
46087156|NCT03684512|Behavioral|Individual Support Sessions|Individual education/support/feedback sessions delivered over video chat
46087157|NCT03684512|Behavioral|Facebook Group|Facebook group for parents to provide additional support and education
46087158|NCT04141982|Diagnostic Test|T-Cell SelectTM Kit|The T-Cell Select kit is intended for the isolation of mononuclear immune cells from whole blood, using positive selection via a magnetic bead-based cell separation system, for use in the T-SPOT.TB assay.
46087159|NCT00613496|Drug|irbesartan|Irbesartan-tablet (150 mg) 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8 if no contraindication for up titration (investigator will decide on the basis of creatinin, urea and potassium after taking a blood sample) for 9 weeks.
46087160|NCT00613496|Drug|placebo|Placebo-tablet, 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8.
45675889|NCT05297201|Drug|CPL500036 - high dose|CPL500036 will be given orally. Each patient is to take 4 capsules with active substance daily.
46087161|NCT04128566|Procedure|walking stress test|walk for 30 minutes on a treadmill with either one of the three loading conditions (reduced load = 80% Bodyweight (BW), normal load = 100% BW, increased load = 120% BW). The order of experimental condition will be applied in randomized order determined by block randomization, and the same self-selected walking speed will be used for all conditions.
45675890|NCT05297201|Drug|Placebo|Placebo will be given orally. Each patient is to take 4 capsules of placebo daily.
46087162|NCT04823780|Dietary Supplement|nutrient solution|For the patients with esophageal and gastric varices after endoscopic treatment，start taking the nutrient solution at the fourth hour.
46087163|NCT04820894|Other|Electronic Medical Record|Medical records are reviewed
46087164|NCT04820894|Other|Survey Administration|Complete surveys
46087165|NCT02692976|Biological|mDC vaccination|Intranodal mDC vaccination
45675891|NCT05283564|Other|Percussive Ventilation Breathhold SABR (PVB-SABR)|Number of lung cancer patients with successful administration of PVB technique in PVB-SABR treatment
45675892|NCT05278663|Drug|E6742|E6742 tablet.
46000431|NCT01887366|Drug|Placebo|Subjects assigned to placebo will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL placebo.
46000432|NCT05293925|Behavioral|announcement of cessation of treatment|"The first 40 outpatients for whom an announcement to stop anti-tumour treatments is made at the Institut Curie Paris, in a conventional oncology consultation or in Palliative Care Day Hospital.~Categorical variables will be described by numbers and percentages. Quantitative variables will be described by the mean, standard deviation, median of the distribution as well as the minimum, maximum and interquartile range and compared by a Student's t test or a Wilcoxon test according to the normality of the variables."
46000433|NCT04674072|Other|Reverse Nordic curl exercise|The reverse Nordic curl is a body-weight exercise which mainly works the quadriceps and hip flexors. It has a large eccentric component, meaning the muscles are working whilst lengthening.
46087166|NCT02692976|Biological|pDC vaccination|Intranodal pDC vaccination
46087167|NCT02692976|Biological|mDC and pDC vaccination|Intranodal mDC/pDC vaccination
46000434|NCT04674072|Other|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
46000435|NCT04674150|Device|ARISE with AR|An augmented reality game for mobile devices with AR experiences enabled
46000436|NCT04674150|Device|ARISE without AR|An augmented reality game for mobile devices with AR experiences disabled as an control
46000437|NCT01885260|Drug|ISIS-GCGRRx - Dose Level 1|3 doses on alternate days during the first week and then once weekly for 12 weeks
46087168|NCT00612872|Drug|[123I]CLINDE|Subjects will be injected with up to 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) of 123-I CLINDE followed by serial SPECT imaging.
46087169|NCT04789928|Drug|Gentamicins-EDTA|Patients included in this study will receive daily injection (up to 10 days) of genta-EDTA-Na2 lock associated with systemic antibiotics.
46087170|NCT04780022|Other|Clinical events at last follow-up|Clinical events (stroke, transient ischemic attack, peripheral embolism, deep venous thrombosis, atrial fibrillation, myocardial infarction, bleeding episode, death) at last follow-up
45675893|NCT05278663|Other|Placebo|E6742-matching placebo tablet.
45675894|NCT05278156|Drug|CPL500036 - low dose|CPL500036 is to be oral administered. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
45675895|NCT05278156|Drug|CPL500036 - high dose|CPL500036 is to be oral administered. Each patient is to take 4 capsules with active substance daily.
45675896|NCT05278156|Drug|Placebo|Placebo is to be oral administered. Each patient is to take 4 capsules of placebo daily.
45675897|NCT05276362|Device|Study Watch|The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
45675898|NCT05276362|Device|Actiwatch|The Actiwatch is a wrist worn activity device designed to collect general activity and sleep information. This device received 510(k) clearance from the FDA as a wearable medical data collection device for research and clinical use.
46087171|NCT04188704|Procedure|Interference screw|Anterior cruciate ligament reconstruction (anterior screw fixation or posterior screw fixation)
45675899|NCT05272176|Behavioral|Coping Long Term with Active Suicide Program (CLASP)|Telehealth-based case management intervention designed to reduce suicidal behavior among individuals at high risk for suicide across the transition from inpatient hospitalization to the community.
46000438|NCT01885260|Drug|ISIS-GCGRRx - Dose Level 2|3 doses on alternate days during the first week and then once weekly for 12 weeks
46087172|NCT00884949|Drug|BMN 110|"Subjects will receive a weekly 4- to 5-hour intravenous infusion of BMN 110 in 3 consecutive 12-week dosing intervals, using the following regimen:~Weeks 1-12: 0.1 mg/kg/week~Weeks 13-24: 1.0 mg/kg/week~Weeks 25-36: 2.0 mg/kg/week~Subjects who complete the 36-week Dose-Escalation Period will have the option to continue drug treatment for an additional 36 to 48 weeks. Subjects continuing on treatment after the Dose-Escalation period will receive weekly 4- to 5-hour intravenous infusions of BMN 110 at a dose of 1.0 mg/kg/week."
46087173|NCT04742816|Diagnostic Test|IHX-CL measurements|The distribution of measured IHX-CL values and other continuous variables will be assessed to ensure a parametric distribution.
46087174|NCT04742816|Drug|Iohexol|Iohexol clearance measurement
46087175|NCT00612950|Drug|glucagon-like peptide-1,|GLP-1:continuous infusion of ½ pmol/kg/min for a total time of 120 minutes.
46000439|NCT01885260|Drug|Placebo|3 doses on alternate days during the first week and then once weekly for 12 weeks
46000440|NCT01876719|Drug|AR08|
46087176|NCT00612950|Drug|glucose dependent insulinotropic polypeptide|continuous infusion of GIP (1½ pmol/kg/min) for 120 min.
46087177|NCT00612950|Drug|Saline|continuous infusion of Saline for 120 min
45457836|NCT01138423|Drug|Placebo (for moxonidine and hydrochlorothiazide)|Once daily treatment with placebo capsules for 8-weeks, according to the following regiment: once daily (morning time) 1 capsule during the first 2 weeks, followed by once daily (morning time) 2 capsules during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
45675900|NCT05265169|Device|Microwave ablation|Microwave ablation of colorectal liver metastases (CLM)
45675901|NCT05256537|Other|Omission of the drug mycophenolate mofetil|Elimination of the immunosuppressive drug mycophenolate mofetil (MMF) from the post-transplant regimen.
45675902|NCT05245968|Drug|Pimitespib|Pimitespib will be administered orally in 5 consecutive days followed by 2 days off treatment (QD 5) on an empty stomach at least 1 hour before or 2 hours after a meal. The doses in the Dose Escalation Part will be 80, 120 (starting dose), and 160 mg. The doses used in Arm A will be MTD or recommended dose (RD) based on the information, including the safety and the pharmacokinetics (PK) data in the Dose Escalation Part. In Expansion Part-B, pimitespib will be administered with the starting dose of 160 mg daily.
45675903|NCT05245968|Drug|Imatinib|Imatinib will be administered orally, after a meal and large glass of water QD. The doses in Dose Escalation Part will be 400 mg or 300 mg (De-escalation). The doses used in Expansion Part-A will be MTD or RD based on information, including the safety and PK data in the Dose Escalation Part. In Expansion Part-B, imatinib will be administered post after pimitespib discontinuation with the starting dose of 400 mg daily.
45675904|NCT05245968|Drug|Sunitinib|Sunitinib will be administered orally QD with a starting dose of 50 mg, on a schedule of 4 weeks on treatment followed by 2 weeks off, and will be taken with or without a meal in Expansion Part-C.
45675905|NCT05243342|Drug|XmAb24306|XmAb24306 will be given via intravenous (IV) infusion
45675906|NCT05243342|Drug|Daratumumab|Participants will receive daratumumab via subcutaneous (SC) injection every week for Cycles 1-4, every 2 weeks for Cycles 5-12, and every 4 weeks thereafter (cycle length = 2 weeks for Cycles 1-12 and 4 weeks thereafter)
46087178|NCT00884793|Drug|raltegravir|The baseline ART regimen will be intensified with raltegravir 400mg orally (PO) twice daily (BID) (all participants) +/- a study NNRTI or protease inhibitor (PI) (at the option of the participant and the study clinical team).
46087179|NCT00884793|Drug|Study NNRTI|Subjects who are not already on an NNRTI and who are suitable candidates will have the option of adding a study NNRTI (either efavirenz or etravirine).
45675907|NCT05232682|Dietary Supplement|Seed DS-01 Daily Synbiotic|Daily administration of Seed DS-01 Daily Synbiotic (dietary supplement)
45457837|NCT03509038|Other|Exploratory pathophysiology Study|Urodynamic tests before and after bariatric surgery in obese incontinent women before and after bariatric surgery
46000441|NCT01876719|Drug|Placebo|
46000442|NCT05285540|Drug|DT-216|DT-216 will be administered by intravenous (IV) injection
46087180|NCT00884793|Drug|Study PI|Subjects who are not on a PI and who are suitable candidates will have the option of adding a study PI. PIs used as study drugs will include atazanavir (+/- ritonavir), fosamprenavir (+/-ritonavir), lopinavir/ritonavir, and darunavir/ritonavir.
46087181|NCT04730336|Device|Tixel|Peri-Orbital fractional treatment on the Eye-Lid to assess the effect on Dry Eye symptoms
46087182|NCT00656253|Drug|Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.)|12 months period of Herbal Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
46087183|NCT00656253|Drug|Placebo|12 months period of placebo plus 1 month period without placebo
46000443|NCT05285540|Drug|DT-216 matching Placebo|Placebo will be administered by intravenous (IV) injection
46087184|NCT04717076|Behavioral|App-based nutritional concept and fitness tracking|The App-based nutritional concept based on menu plan, which are personalized according to participants age, gender, physical activity. The App is coupled with a Smartwatch to encourage and track physical activity over the study period.
46087185|NCT04717076|Behavioral|Nutritional concept with individual nutritional counselling|Nutritional concept based on personalized menu plans and individual nutritional counselling every four weeks (4 times during the study)
46000444|NCT04673799|Drug|MV088 injection|MV088 injection (60mg) by subcutaneous injection once on the first day
46000445|NCT04673799|Drug|Prolia® injection|Prolia® injection (60mg) by subcutaneous injection once on the first day
46000446|NCT04673487|Diagnostic Test|1. SD Bioline Salmonella Typhi IgG/IgM Fast test, 2. Typhidot Rapid IgG/IgM combo test, 3. TUBEX TF test, 4.Typhoid IgG/IgM Combo Rapid Test CE, 5. Enterocheck WB test, 6. Test-itTM Typhoid IgM test|Evaluation of 11 different Typhoid Rapid Diagnostic Tests that are commercially available internationally and use Blood culture as standard for comparison
46000447|NCT01873677|Drug|M518101|
46000448|NCT01873677|Drug|Vehicle|
46000449|NCT05236400|Device|unmanned electric phlegm suction system procedure using an investigational device (LMECA.A1000)|Subjects who have passed the screening test will receive the test device (LMECA.A1000) within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through bronchoscopy before application for clinical trials and 72 hours after application.
46000450|NCT05236400|Procedure|Manual phlegm suction system|Subjects who have passed the screening test will receive a manual phlegm suction system procedure using a catheter by professional medical staff within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through a bronchoscopy before application to clinical trials and 72 hours after application.
46087186|NCT04717076|Behavioral|Nutritional concept without individual nutritional counselling|Nutritional concept based on personalized menu plans
46087187|NCT05265338|Drug|KC1036|60mg QD
46000451|NCT04673526|Procedure|Laparoscopic intersphincteric resection|Laparoscopic intersphincteric resection for ultra low rectal cancer in elderly patients
46000452|NCT04673526|Procedure|Laparoscopic abdomino-perineal procedures|Abdominoperineal resection + colostomy in left iliac fossa or perineum
46000453|NCT01215955|Drug|Insulin lispro|Administered subcutaneously, up to three times daily for 24 weeks
46000454|NCT01215955|Drug|Glargine|Administered subcutaneously, dosage determined by investigator once daily for 24 weeks
46000455|NCT01873404|Drug|BG00010|As specified in the treatment arm
46000456|NCT01873404|Drug|Placebo|As specified in the treatment arm
46000457|NCT05212220|Behavioral|EMA-based intervention|A personal quit plan includes (1) self-help techniques on handling craving; (2) suggestions to avoid the reported pro-smoking cues; (3) whether to quit progressively or abruptly; (4) referral for existing smoking cessation service; and (5) instruction of using over-the-counter (OTC) nicotine replacement therapy (NRT), if OTC-NRT is preferred by the participant will be designed and give to the participants via a nurse-led phone call.
46000458|NCT05212220|Behavioral|EMA-based intervention|Participants will receive 10-week tailored quitting reminder instant messages via WhatsApp and voluntarily discuss their quit plan with the research staff.
46000459|NCT04677270|Behavioral|Digital problem solving tool|Digital problem solving tool - adapted for practical and emotional problems during the COVID-19 pandemic
46000460|NCT02887105|Other|Standard neuropsychological assessment|
46087188|NCT00656331|Drug|Amlodipine and Hydrocholorothiazide|Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide
46087189|NCT05264948|Diagnostic Test|Polymerase chain reaction|Covid-19 genetic material detection from mouth and nose swab
45835383|NCT02439762|Behavioral|Cognitive Behavioral Therapy (CBT)|The therapeutic intervention group consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
45835384|NCT02439762|Behavioral|Supportive Psycho-education (SPC)|This active control condition consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained therapist. The sessions will provide detailed information about substance use, suicide risk, and depression to those enrolled.
46000461|NCT02887105|Other|Brain MRI|
46000462|NCT05194592|Drug|Dapagliflozin|The patients assigned to the Dapagliflozin group will take Farxiga Pill 10mg for 6 months.
46087190|NCT02636829|Other|QALCIMUM questionnaire|All patients will fill out the QALCIMUM questionnaire.
46000463|NCT05194592|Drug|Gemigliptin|The patients assigned to the Gemigliptin group will take Zemiglo Pill 50mg for 6 months.
46000464|NCT01871415|Drug|aleglitazar|150 mcg orally daily
46087191|NCT02636829|Other|Determination of calcium intake by a dietician interview|"All patients will have an interview with a dietician who performs a food survey serving as a reference (gold standard) and based on data from CIQUAL *.~* CIQUAL Data: Nutritional food composition table available on the website of the ANSES (National Agency for Sanitary Security of Food, Environment and Labour), published by the Observatory of the Nutritional Quality of Foods. This table includes 1500 sheets of 58 nutritional components. The data is integrated into the software (DATAMEAL) for calculating the ingesta parameters at the Nîmes University Hospital."
46087192|NCT00884325|Drug|Levocetirizine dihydrochloride (Xyzal)|One tablet 5 mg taken orally at night for 28 days
46087193|NCT00884325|Drug|placebo|One tablet taken orally at night for 28 days
46087194|NCT03691220|Behavioral|Telemetric Intervention|Calls, scripted by a manual; the frequency of the calls varies with patient's MLVI status and preferences.
46087195|NCT00656409|Drug|Conjugated pneumococcal vaccine (Prevenar)|
46087196|NCT05264558|Device|Xpert HCV Viral load finger stick point of care test (Cepheid)|Xpert HCV VL Fingerstick is an in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of Hepatitis C Virus (HCV) RNA in human venous and capillary fingerstick EDTA whole blood. Appropriate pre and post testing counselling will be provided to participants.
46087197|NCT05264558|Drug|Epclusa 400Mg-100Mg Tablet|Same day HCV test and treatment
46087198|NCT05264558|Other|Standard of care|Clinical services will receive additional education and have the option of providing incentives to attendees of service.
45457838|NCT03506854|Drug|ISIS 681257|Xmg dose administered as a subcutaneous injection
45457839|NCT03504436|Device|LEO +|LEO +: self-expanding intracranial stent
45835385|NCT02983110|Procedure|Anoscopy with Rectal Tissue Sampling|All subjects will provide 10 pieces of rectal tissue
45835386|NCT02983110|Procedure|Phlebotomy|• Procedure: Blood plasma/serum collection Approximately 17 mL of blood will be taken from each subject just prior to tissue sampling.
45835387|NCT02983110|Procedure|Female Genital Tract Sampling|Cohorts B only will have cervical cells, cervical tissue, and vaginal tissue collected
46000465|NCT01871415|Drug|metformin|pre-existing background regimen and dose
46000466|NCT01871415|Drug|placebo|matching aleglitazar placebo orally daily
46000467|NCT05189717|Drug|HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus|During HRS-8080 monotherapy period, the dose of HRS-8080 would be increasing. In the combination therapy period, HRS-8080 will be administered at flat dose of RP2D-1 and RP2D.
46087199|NCT04705844|Drug|Adalimumab|adalimumab (160 mg administered as 4×40 mg subcutaneous [SC] injections at separate sites on the thigh or abdomen)
45835388|NCT02432742|Device|Restylane Perlane|Intradermal injection
46000468|NCT05182463|Drug|Peginterferon Alfa-2B|Different usage of peginterferon Alfa-2B and/or Nucleos(t)ide analogs in arm/group descriptions are depended on the wishes of the patient and the advice of the attending doctor.
46000469|NCT05182463|Drug|Nucleoside Analogs|Nucleos(t)ide analogs refer to one of the first-line drugs, including ETV, TDF and TAF.
46000470|NCT04673643|Device|Transcutaneous Auricular Vagus Nerve Stimulation|to use taVNS to treat Reflux Esophagitis
46000471|NCT05133128|Other|blood samples|blood samples
46087200|NCT04705844|Drug|Placebo|placebo (4 SC injections of equal volume administered at separate sites on the thigh or abdomen)
46087201|NCT03997760|Drug|SHP655|Participants will receive SHP655 as a single IV infusion at one of the 3 dose levels of 40 IU/kg, 80 IU/kg, or 160 IU/kg.
46087202|NCT03997760|Other|Placebo|Participants will receive placebo matched to SHP655 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion.
46087203|NCT02693366|Other|Bone marrow stem cell|Endovascular infusion of bone marrow derived cells in both renal arteries.
45835389|NCT02432742|Device|Restylane|Intradermal injection
46000472|NCT01856049|Other|Collection of umbilical cord blood|Cord blood will be processed in the temperate state it was collected to produce a pure, stem cell product identifiable to patients with Hypoplastic Left Heart Syndrome, and will be stored at a frozen state for their potential, future use in a clinical trial.
46000473|NCT05125484|Other|experimental Bowen Technique|"Patient was in lying position. Therapist placed thumb on the effected side muscke. Then hooked thumb on lateral edge of muscle to apply pressure against the muscle. Took a pause. Thumb flattened in a medial direction and pluck was created in muscle.~Set of 15-20 bowen moves on upper , middle and lower fibres each with 2 mins gap between each set.~Total treatment time: 20 mins"
46000474|NCT05125484|Other|Experimental Myofacial release technique|"Patient was in lying position. MFR applied via ulnar border of both palms while patient being in contralateral side flexion.~20 mins"
46087204|NCT03494348|Device|Medial Congruent Polyethylene (MC)|One group receives the conventional CR surface and the other the new MC articular surface
46000475|NCT04673097|Other|Icon® resin infiltration|low viscosity resin that can flow through the pores in the enamel surface
46000476|NCT04673097|Other|MI paste plus|s a superior form of fluoride ions as it also contains CPP-ACP, enhances mineral release without encouraging the formation of calculus.
46000477|NCT05108129|Procedure|M-TAPA block|"After tracheal intubation, a high-frequency linear probe will be placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will be inserted with in-plane technique and 25 ml 0.25% bupivacaine will be injected between the transversus abdominis muscle and the lower aspect of the costal cartilage. The same procedure will be repeated on the contralateral side.~Standard perioperative and postoperative multimodal analgesia The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, dexketoprofen, and tramadol."
46087205|NCT04076384|Behavioral|Guided Self-Determination|Structured team-based consultations
46087206|NCT04076384|Behavioral|Standard care|Standard consultations
46087207|NCT03986216|Device|ReIn-Hand device assisted home-based practice|Practice reach-grasp-retrieve-release at home with the aid of ReIn-hand device
46087208|NCT00613184|Device|Nylon Flocked swab (Nasal secretion sampling)|Nasal Aspirate Nylon Flocked swab
46087209|NCT00613184|Device|Nylon Flocked swab (Nasal secretion sampling)|Nylon flocked swab Nasal Wash
46087210|NCT04616768|Other|PRO questionnaire|These text message surveys will inquire about seven symptoms, requesting a response rating the patient's response. The seven symptoms have been selected by lung and GI oncology clinicians at PCAM from a list of twelve validated symptoms from the National Cancer Institute's Common Terminology Criteria for Adverse Events and will be scored on a five point scale from 0 (no present) to 4 (disabling). The patients will also receive a question asking about their activity level over the prior month
45835390|NCT02430558|Biological|OD-PHOENIX|Decellularized, freeze-dried, irradiated osteochondral allograft
45835391|NCT05585970|Diagnostic Test|procalcitonin|The PCT level in healthy individual without infection is below the limit of detection (0.01 ng/mL), and it is significantly elevated under the stimulation of pathogens
45835392|NCT02086500|Drug|Tranexamic Acid|1 gram of prehospital Tranexamic Acid
45835393|NCT02086500|Other|Saline control|Saline Control
45835394|NCT04757064|Other|standard rehabilitation protocol|they will receive knee flexion exercises and increase the extensor strength
46087211|NCT04616768|Other|Step monitoring|A CRC will provide patients with a Fitbit at enrollment and instruct them on how to wear the Fitbit device and periodically sync the device with their phone which will send updated step data to the research team.
46087212|NCT04616768|Other|Active nudge text feedback|"Intervention patients in arm c will receive text feedback describing worsening or severe symptoms collected from their remote PRO questionnaires (i.e. Your following symptoms are severe or have gotten worse:) and their step count (Your Fitbit step count compared to last week is worse.). They will also receive an active nudge question on their upcoming visit (i.e. Do you plan on discussing these symptoms with your oncologist at your upcoming visit? Type 1 if you plan to discuss them; Type 2 if you do not plan to discuss them.)."
46087213|NCT04616768|Other|PROStep Dashboard (clinicians)|"The study team will provide an updated PROStep Dashboard to lung or GI oncology clinicians for each patient enrolled in the intervention arms prior to their appointments. W2H will generate the dashboards and the study team will physically deliver it to their office or touchdown space or send electronically. The Dashboard will include:~Home-based PRO report, including the weekly survey results for each question in tabular and graphical form~Step data report, including a summary of number of daily steps in graphical form (with rolling weekly averages) and weekly averages in tabular form~A list of all acute care utilization in the UPHS system in the prior 6 months including Oncology Evaluation Unit visits, Emergency department visits, Inpatient admissions~Whether the patient has had an outpatient palliative care visit~Whether the patient has had a documented Serious Illness Conversation"
46087214|NCT00612248|Other|Splint|Patients in the study group received the splint on the day of the first evaluation and took it with them for use during activities of daily living and patients in the control group only used the splint during the evaluations
46000478|NCT05108129|Procedure|OSTAP block|"The patients will receive oblique subcostal TAP block in the supine position immediately after the endotracheal intubation. The anesthesiologist of the operating room will place the ultrasound with a linear probe subcostally and from the xiphoid to the right iliac crest obliquely. Rectus abdominis muscle and underlying transversus abdominis muscle, will be identified near the costal margin. The needle will be directed to the transversus abdominis fascia. Local anesthetic solution of 25 ml 0.25% will be injected to between rectus abdominis and transversus abdominis muscles along the oblique subcostal line. The same procedure will repeated to the contralateral side.~Standard perioperative and postoperative multimodal analgesia The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, dexketoprofen, and tramadol."
46087215|NCT03964610|Diagnostic Test|color fundus photography (CFP) and OCT-A|Included patients will have an ophthalmologic assessment (OCT-A and CPF) after stabilization and at 3 months follow-up.
46087216|NCT03963908|Behavioral|AtEase|AtEase is a tailored pain self-management mobile app that tailors participant's feedback based on readiness to engage in pain self-management and preference for self-management strategies.
46000479|NCT01854294|Drug|GM604|GM604 treated group subject will receive a slow IV bolus injection (~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
45457840|NCT03504358|Procedure|Liver resection|Partial hepatectomy comprised single or multiple hepatic resections aiming at excising all visible malignant tissue.
46000480|NCT01854294|Drug|Placebo comparator|Placebo comparator group subject will receive a slow IV bolus injection (~1min) of 6.4 mL bacteriostatic saline for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
46000481|NCT02277197|Drug|Ficlatuzumab|"Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2o C- 8oC)"
46000482|NCT02277197|Drug|Cetuximab|"Cetuximab is supplied as a 50-mL, single-use vial containing 100 mg of cetuximab at a concentration of 2 mg/mL in phosphate buffered saline. The solution should be clear and colorless and may contain a small amount of easily visible white amorphous cetuximab particulates. Cetuximab can be administered via infusion pump or syringe pump, it must not be administered as an IV push or bolus. Cetuximab must be administered with the use of a low protein binding 0.22-micrometer in-line filter. Maximum infusion rate should not exceed 5 mL/min.~Store vials under refrigeration at 2C to 8C (36F to 46F). DO NOT FREEZE. Following the cetuximab infusion, a one-hour observation period is recommended."
46000483|NCT00555087|Drug|Testosterone Undecanoate and/or PDE-5|Testosterone Undecanoate 1000 mg IM injection; PDF5 tab, 20 mg
46000484|NCT04672902|Procedure|Single-operator cholangioscopy guided electrohydraulic lithotripsy|Single-operator cholangioscopy guided electrohydraulic lithotripsy has the advantage of providing direct visualization of the bile ducts, enabling a single physician to diagnose and perform the therapeutic intervention in a single procedure.
46087217|NCT03963908|Behavioral|Chronic Pain Education|CBT-based Education on Pain Self-Management for Veterans
46087218|NCT00636896|Drug|Olanzapine plus modafinil|Olanzapine 10 mg/d plus modafinil 200 mg/d
46087219|NCT00636896|Drug|Olanzapine plus placebo|Olanzapine 10 mg/d plus placebo
46087220|NCT02709122|Device|ThoraQuik atraumatic set for pneumothorax decompression|pneumothorax decompression in case it is found in accordance with the actually recommendations
46087221|NCT05264090|Other|Ambulatory blood pressure monitoring|The ambulatory monitoring (7-day ABPM) was performed with ambulatory blood pressure monitoring devices TM-2430 (A&D; Tokyo, Japan) based on both the cuff-oscillometric and Korotkoff sound method. The cuff was placed on the non-dominant arm according to the same rules applying to casual auscultation measurement. The monitoring device with a weight of 250 g was worn by the monitored subjects in a waist-fixed case continuously for 7 days except for times involving personal hygiene. During every automatic measurement, the arm was resting and hung along the body. The device automatically recorded all the regular measurements for seven days, between 6:00 a.m. and 10:00 p.m. every 30 minutes and between 10:00 p.m. and 6:00 a.m. every 60 minutes. Such short intervals are necessary to obtain a sufficient number of representative measurements.
46000485|NCT04673253|Other|Passive leg Raise|The intervention will be performed immediately after spinal anesthesia, and passive leg raise will be performed using two standard pillows placed under the heel so that the leg is approximately 30 cm above the horizontal plane of the table. The passive leg raising position will continue until the cord is clamped.
46000486|NCT04673253|Other|control|The controlled group was positioned in the normal supine position.
46000487|NCT05096897|Other|Self-administrated questionnaires|GOHAI, IBD-Q, IBD-disk
46000488|NCT04673214|Drug|Azithromycin / Ivermectin / Ribaroxaban / Paracetamol|In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group A of Azithromycin / Ivermectin / Ribaroxaban / Paracetamol to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
45457841|NCT01136863|Drug|Felodipine|
45675908|NCT05225337|Other|Time restricted feeding (TRF)|8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
46000489|NCT04673214|Drug|Azithromycin / Ribaroxaban / Paracetamol|In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group B of Azithromycin / Ribaroxaban / Paracetamol, to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
46000490|NCT04672473|Biological|DC-CTL|DAC combined with Ag-CTL
46000491|NCT05040113|Drug|CBP-307|CBP-307 capsules oral administration
46000492|NCT01845987|Drug|Placebo|Placebo, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
46000493|NCT01845987|Drug|CNTO 1959|CNTO 1959 200 mg, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
46000494|NCT00556023|Drug|CP-675,206 and gemcitabine|Escalating doses of CP-675,206 will be administered by IV infusion on day 1 of each 84-day treatment cycles (doses of 6, 10 and 15 mg/kg are planned). Gemcitabine will be administered by IV infusion, at a fixed dose of 1000 mg/m2 on days 1 (prior to CP-675,206) and again on days 8, 15, 29, 36, 43, 57, 64, and 71. Repeated cycles of gemcitabine and CP-675,206 will be administered until patients develop progressive disease or unacceptable toxicity, or for a maximum of 4 cycles, whichever occurs first.
46000495|NCT05011214|Drug|Sevoflurane|All patients received 0.01 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.5% sevoflurane(FIO2=100%, 3L·min-1) was used to induce anaesthesia by mask inhalation and 3-4 % sevoflurane (adjusted according to the depth of the anaesthesia,FIO2=100%, 2L·min-1) was maintained
46000496|NCT05011214|Drug|Esketamine|All patients received 0.1 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.0.5mg·kg-1 esketamine was administered by vein in one minute, and 0.25mg·kg-1 esketamine was given at the beginning of the surgery.
45457842|NCT01136863|Drug|Placebo|
45457843|NCT03961516|Device|Frequently Sampled Oral Glucose Tolerance Test and CGM|Patients will undergo a 2 hour frequently sampled oral glucose tolerance test while wearing an active FreeStyle Libre Pro sensor. Using as a tool to collect data.
45457844|NCT03961516|Radiation|MRI Pancreas and Liver|Patients will undergo an MRI of the pancreas and liver
45457845|NCT01133899|Dietary Supplement|guanidinoacetic acid|2.4 grams of guanidinoacetic acid
45457846|NCT01133899|Dietary Supplement|GAA-4|4.8 grams of guanidinoacetic acid
45457847|NCT01133899|Dietary Supplement|GAA-1|1.2 grams of guanidinoacetic acid
45835395|NCT01894386|Drug|FF 400 mcg|100 mcg powder for inhalation delivered by Dry Powder Inhaler (DPI)
45835396|NCT01894386|Drug|UMEC 500 mcg|125 mcg powder for inhalation delivered by DPI
45835397|NCT01894386|Drug|UMEC 250 mcg|62.5 mcg powder for inhalation delivered by DPI
45835398|NCT01894386|Drug|VI 100 mcg|25 mcg powder for inhalation delivered by DPI
45675909|NCT05225337|Other|Daily calorie restriction|25% energy restriction every day Diet counseling provided
45675910|NCT05220514|Drug|(R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)|Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
45675911|NCT05220514|Drug|2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)|Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
45835399|NCT02104986|Drug|Velbe-Bleomycin-Cisplatin|Limitation of the number of chemotherapy courses (≤ 4) after the achievement of a clinical and biological response in NSMGCT patients treated with cisplatin-based chemotherapy, in order to reduce treatment long-term effects
45835400|NCT02104986|Drug|Vepeside-ifosfamide-Cisplatin|
45835401|NCT02425566|Drug|Trimethaphan|Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
45835402|NCT02425566|Drug|Nitroglycerin|Sublingual nitroglycerin (0.3-0.6 mg) will be given after baseline measurements.
45835403|NCT02414178|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
46000497|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
46000498|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
46000499|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
46000500|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
46000501|NCT04672668|Diagnostic Test|duplex ultrasound for the common femoral artery|duplex ultrasound for the common femoral artery before and after the angiography
46000502|NCT04965155|Drug|Isatuximab-dexamethasone|Isatuximab 10 mg/kg IV: 1,8,15 and 22 at cycle 1; days 1 and 15 at cycles 2-3 Dexamethasone 40 mg OS: 1,8,15 and 22 at cycle 1; days 1 and 15 at cycles 2-3
46000503|NCT04676841|Device|Conventional ventilation + instrumental tables with integrated laminar airflow|Surgical instruments protected from contamination by local laminar airflow
46000504|NCT04676841|Device|Conventional ventilation + standard instrumental tables|Control
46000505|NCT04676841|Device|Laminar airflow ventilation + standard instrumental tables|Control
45675912|NCT05219617|Drug|Carisbamate|"Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to < 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg (not to exceed a total of 400 mg per day).~Subjects 4 to < 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg (not to exceed a total of 600 mg per day)."
46000506|NCT04949438|Drug|AZD4831|Participants will receive a single dose of AZD4831 administered with 240 mL of water after an overnight fast of at least 10 hours.
46000507|NCT04676763|Drug|Substance P|Participants will receive Substance P
46000508|NCT04676763|Drug|Normal Saline|Participants will receive normal saline as Negative control
46000509|NCT04676763|Drug|Histamine|Participants will receive histamine as Positive control
46000510|NCT04944563|Procedure|Segmentectomy|Patients receive segmentectomy
46000511|NCT04944563|Procedure|Lobectomy|Patients receive lobectomy
46000512|NCT04672707|Drug|Bromhexine Hydrochloride Tablet|32 mg
46000513|NCT04672707|Drug|Bromhexine Hydrochloride Tablet|48 mg
46000514|NCT04672707|Drug|Bromhexine Hydrochloride Tablet|64 mg
46000515|NCT04672707|Drug|Bromhexine Hydrochloride Tablet|80mg
46000516|NCT04932083|Drug|Bupivacaine|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of sterile water will be added."
46000517|NCT04932083|Drug|Fentanyl|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of fentanyl (25µg) will be added."
46000518|NCT04932083|Drug|Nalbuphine|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.8 mg nalbuphine hydrochloride in 0.5 ml sterile water will be added."
46000519|NCT04932083|Drug|Midazolam|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.4 ml of midazolam (2mg) + 0.1 ml of sterile water will be added."
46000520|NCT04672629|Device|echocardiography|follow up echocardiography
46000521|NCT00555126|Device|Forced Air Warming|Warming after Randomization
45675916|NCT05208762|Drug|SGN-PDL1V|Given into the vein (IV; intravenously)
45675917|NCT05207865|Drug|Rimegepant|rimegepant ODT 75mg daily
45835404|NCT02408952|Behavioral|Primary Care Physician|The screening, brief intervention and referral to treatment is delivered by the Primary Care Physician
45835405|NCT02408952|Behavioral|Behavioral Medicine Specialist|The screening, brief intervention and referral to treatment is delivered by the Behavioral Medicine Specialist.
45835406|NCT04757454|Diagnostic Test|5-item SARC-F questionnaire|Administration of the 5-item SARC-F questionnaire in patients admitted to an acute care unit
46000522|NCT00555126|Device|Warming with endovascular catheter + forced air warming|Warming after Randomization
45457848|NCT01133899|Dietary Supplement|PLACEBO|celulose
46000523|NCT04920071|Device|Visual acuity and contrast sensitivity measurement|Those subjects who meet the inclusion criteria will undergo the study tests. These measurements will be performed on one eye only. Visual acuity will be quantified using two forms of the MAC chart (MAC 1 and 2) and two forms of a conventional letter design chart (C1 and 2). Contrast sensitivity will be measured using the two forms of the Pelli-Robson chart (CS1 and CS2). The order with which the test charts will be presented, in addition to the charts used (i.e. MAC 1 or 2, C1 or 2, and CS1 or 2), will be selected at random. Finally, a measurement of eye length will be collected using an IOL Master (Carl-Zeiss Meditec, USA).
46000524|NCT04672785|Behavioral|SF36 questionary|patients who underwent a posterior fossa craniectomy for a cerebellar hematoma at Grenoble University Hospital between 01/01/2010 and 01/01/2020 were enrolled in this study. The main objective is to assess the level of disability and the quality of life of patients who have had a posterior cranial fossa craniectomy.
46000525|NCT01825980|Drug|BZF961|There will be 2 parts to the study: Part 1: BZF monotherapy. Part 2: Cohort IIa: BZF961 monotherapy at 3 TBD doses; Cohort IIb: BZF961 in combination with ritonavir at TBD doses.
46000526|NCT01825980|Drug|Ritonavir|Ritonavir will be given as a boosting agent in Part 2, Cohort IIb in combination with BZF961
46087222|NCT05264090|Other|Combined aerobic-resistance exercise|Combined aerobic-resistance exercise (group 2) was scheduled twice weekly in the form of 60-minute workouts with a load intensity at the level of sub-maximum heart frequency (75-85% SFmax). The minimum time span between the workouts was 24 hours. The workout consisted of a 10-minute warm-up, 25 minutes of aerobic exercise (spinning bicycle or bicycle ergometer), 15 minutes of resistance exercise on gym machines (bench press, leg extension and pull down) with 40-50% 1-RM (one repetition maximum) intensity (3 series of 10 exercises), and a 10-minute cool-down (stretching of the main muscle groups).
46087223|NCT05264090|Other|The cardiovascular exercise|The cardiovascular exercise (group 4) took the form of sixty-minute workouts scheduled two to three times weekly. The nature of the workouts was similar, combined aerobic-resistance exercise (a 10-minute warm-up, aerobic endurance on bicycle ergo meter for 25 minutes, resistance exercise on multifunctional gym machines for 15 minutes, and a 10-minute cool-down). The workout intensity was set at the level of the first ventilation threshold (VAT-1), corresponding to the following workout parameters: load (W) and heart rate (HR).19,20 The resistance exercise intensity was specified by the 1-RM (one repetition maximum) method. The maximum load lifted across the full range of motion for every exercise was used as the benchmark for the workload intensity specification, corresponding to 30 - 60% 1-RM.
46087224|NCT05264012|Procedure|Neurosurgery|Neurosurgery
46000527|NCT01825980|Drug|Placebo|Placebo
45457849|NCT01231009|Drug|Corticosteroids|Intravenous Dexamethasone, 8mg three times per day tapering down for 7 days Per os dexamethasone, 2mg per day tapering down for 7 days
46000528|NCT04672200|Other|Group exercise|Weekly group exercises delivered online and face to face
46000529|NCT04676685|Drug|E2730|E2730 capsules.
46000530|NCT04676685|Drug|E2730-matched placebo|E2730-matched placebo capsules.
46000531|NCT04672317|Drug|Immunotherapy combined with chemotherapy|"Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy.~Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy~Other Names:~• anti-PD-1 monoclonal antibody Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible.~Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy"
46000532|NCT04791878|Drug|Mesenchymal stem cells|Direct injection of 75 million allogeneic bone marrow derived mesenchymal stem cells at baseline and again after 3 months if not completely healed
45457850|NCT01231009|Other|Vestibular exercises|Vestibular exercises in order to enhance vestibulo-ocular reflex for 15 days under the suspicion of physiotherapist
46000533|NCT04672278|Dietary Supplement|Shanzha Fruit drink or placebo drink|The dosage of Shanzha fruit drink or the placebo is 3 cans per day
46000534|NCT04790045|Drug|Venetoclax|Core-needle biopsy to be performed before starting treatment in patients candidates to venetoclax-based regimens
45675918|NCT05194969|Other|Wet-to-Dry Dressings|This dressing technique involves moistening a piece of gauze with normal saline or other cleansing solution, placing the moistened gauze on the wound, allowing the gauze to dry, and then removing and replacing the bandage regularly over a period of days to weeks
45675919|NCT05194969|Other|Petrolatum with Non-Stick Gauze|This dressing approach involves applying a thick layer of petrolatum to the wound once or twice daily to maintain a moist wound base. After placement of petrolatum, the wound is covered with nonadherent gauze and tape or another bordered dressing.
45675920|NCT05189418|Device|Ambulatory blood pressure monitoring (ABPM)|Periodic (quarterly) 48h ABPM evaluation during follow-up
45675921|NCT05189418|Device|Home blood pressure monitoring (HBPM)|Periodic (monthly) 7-day HBPM, both during awake and sleep spans, during follow-up
46000535|NCT04676568|Procedure|Extravesical VVF repair|Both standard transvesical and extravesical approach for VVF repair will be utilised
46000536|NCT04676295|Behavioral|Face-to-face and web-based lifestyle intervention|Families are provided at baseline with one 60 min face-to-face dietary counseling session with nutritionist using family-oriented motivational interviewing and solution focusing techniques. The intervention continues in an interactive web-based portal where different modules include assignments, activities, and tests and related videos targeting five cardiovascular health-linked behaviors: 1) improving quality of fat in the diet, 2) increasing the consumption of foods rich in fiber, 3) decreasing the use of salt, 4) increasing physical activity and 5) reducing smoking.
46000537|NCT01655225|Drug|LY3023414|Administered orally. Dose of 20 to 600 mg, as determined in Part A.
46000538|NCT01655225|Drug|Midazolam|0.2 mg administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
46000539|NCT01655225|Drug|Fulvestrant|500 mg administered IM on Day 1 and Day 15 in cycle 1 and Day 1 every 28 days for additional cycles.
46000540|NCT01655225|Drug|Pemetrexed|500 mg/m2 administered IV once on Day 1 every 21 days
46000541|NCT01655225|Drug|Cisplatin|75 mg/m2 administered IV once on Day 1 every 21 days
46000542|NCT01655225|Drug|Abemaciclib|Administered orally
46087225|NCT05263856|Device|laser acupuncture|The parameter setting of 810nm wavelength laser acupuncture device in 1) ear were irradiated with a 4mm probe, adjusted to Nogier A frequency for acute treatment, and the pulsed mode was irradiated with an emission frequency of 200mW for 10seconds, each acupoint provided 1 joule of energy with total of 12joules,and 2) myofascial trigger point were irradiated with a 10mm probe, adjusted to Nogier C frequency for muscle treatment, and the pulsed mode was irradiated with an emission frequency of 500mW for 20 seconds, each acupoint provided 5 joule of energy with total of 50 joules, providing a total of 62 joules of one intervention session.
46000543|NCT01655225|Drug|Letrozole|Administered orally
46087226|NCT00612326|Procedure|MRI and PET scanning procedures|a CT scan, MRI, and C-11 Acetate PET scan. All these scans will be done as an outpatient. After you finish these scans, your doctor will schedule you for surgery to remove your bladder and lymph nodes.
46087227|NCT00613262|Other|Narrow Band Imaging|Narrow Band Imaging Colonoscope offers an alternative lightsource to view colon polyps in real time
46087228|NCT03909698|Other|Blood and urine sampling|During a period of maximum 6 days blood is sampled at different time points and urine is collected during documented time intervals.
46087229|NCT04470674|Drug|Durvalumab|Durvalumab 1500 mg
46087230|NCT04470674|Drug|Carboplatin|carboplatin AUC 5
46087231|NCT04470674|Drug|Pemetrexed|pemetrexed 500 mg/m2
46087232|NCT03729518|Radiation|Radiation Therapy (IMRT or IMPT)|"Treatment of the primary tumor bed will be omitted in appropriate patients, as per the initial TORS de-intensification protocol. In those patients requiring treatment of the primary site, reduced dose (50 Gy) will be delivered.~Receipt of concurrent chemotherapy per current guidelines. Chemotherapy may be omitted in patients with focal or microscopic ENE (defined as ≤ 1 mm ENE), at the discretion of the treating Medical Oncologist.~Blood samples will be obtained at time of enrollment, and at two time points during RT, to quantify circulating HPV DNA and perform immune profiling."
46087233|NCT03884816|Other|Determine the Incidence and Retention Rate|Determine the incidence of HIV and the retention rate of MSM/TGW/TGM/Intersex at risk for HIV infection
46087234|NCT00883779|Drug|Placebo|po on days 15-28 of each 4 week cycle until disease progression
46000544|NCT00555165|Device|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
46000545|NCT03457298|Device|Ossix Volumax|Ossix Volumax is intended to be used for Lateral ridge augmentation
46087235|NCT00883779|Drug|Platinum chemotherapy (cisplatin or carboplatin)|cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles
46087236|NCT00883779|Drug|erlotinib [Tarceva]|150mg po on days 15-28 of each 4 week cycle until disease progression
45675922|NCT05185440|Behavioral|GIFTSS Training|training for college health center staff and clinicians on GIFTSS intervention (Giving Information for Trauma Support and Safety -- universal education and brief counseling to address sexual violence prevention and intervention)
46000546|NCT03457298|Device|FDBA with collagen membrane|freeze-dried bone allograft (FDBA) with collagen membrane
46000547|NCT04759625|Other|Novel biscuit enriched with mushroom powder containing 3g of β-glucans|Daily consumption of a novel biscuit enriched with mushroom powder containing 3g of β-glucans
46000548|NCT04759625|Other|Placebo biscuit|Daily consumption of placebo biscuit
46000549|NCT04754282|Other|Position of labouring women for epidural analgesia catheter placement : Traditional Sitting Position (TSP)|"Labouring women admitted to the delivery room of Necker Enfants Malades hospital, requesting an epidural analgesia for labour, and willing to participate in our study will be randomized in the Traditional Sitting Position (TSP) group on odd days or in the Cross-legged Sitting Position (CSP) group on even days.~Patients in the TSP group seat on the edge of the bed, their feet laid on a support set next to the bed. Patients in the CSP group also seat on the edge the bed, but in a so-called tailor position, their knees bent, their hips flexed and in abduction, their feet under each contralateral thigh.~The epidural catheter will be placed according to standard local practice in either of the groups."
46087237|NCT00883779|Drug|gemcitabine|1250mg/m2 iv on days 1 and 8 of each 4 week cycle for 6 cycles
46087238|NCT04418258|Device|Capillary Endoscopy Aspiration Catheter|Small intestinal fluid will be suctioned with using a capillary endoscopy aspiration catheter[#CSL2182; Hobbs Medical,Inc. Connecticut, US] during upper endoscopy
46087239|NCT04418258|Device|Endoscopy Aspiration Catheter|Small intestinal fluid will be suctioned with using an endoscopy aspiration catheter[#2182; Hobbs Medical,Inc. Connecticut, US] during upper endoscopy
46087240|NCT05263778|Drug|Bempedoic Acid / Ezetimibe Oral Tablet|Bempedoic acid 180 mg/ezetimibe 10 mg by mouth once daily for 12 weeks
46087241|NCT05263778|Drug|Placebo|Matching placebo by mouth once daily for 12 weeks
46087242|NCT02693600|Procedure|Ligamentoplasty with partial trapeziectomy|
46087243|NCT02693600|Procedure|Ligamentoplasty with total trapeziectomy|
46087244|NCT04163133|Procedure|two days later trigger than regular timing|During ovarian stimulation, two days later of trigger after three follicles reach 17mm bilateral with contineous using of Gonadotrophin in antagonist protocol.
46087245|NCT04405934|Other|Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures|Rapid or standard (time to return to sites) receipt of virus (Covid-19) genomic sequencing reports
46087246|NCT04163055|Device|Moleculight i:X|This device is used to visualize the bacteria in the wound. Patients do not need consume any contrast agent prior to imaging. The device does not come in contact with the wound.
46000550|NCT04754282|Other|Position of labouring women for epidural analgesia catheter placement : Cross-legged Sitting Position (CSP)|"Labouring women admitted to the delivery room of Necker Enfants Malades hospital, requesting an epidural analgesia for labour, and willing to participate in our study will be randomized in the Traditional Sitting Position (TSP) group on odd days or in the Cross-legged Sitting Position (CSP) group on even days.~Patients in the TSP group seat on the edge of the bed, their feet laid on a support set next to the bed. Patients in the CSP group also seat on the edge the bed, but in a so-called tailor position, their knees bent, their hips flexed and in abduction, their feet under each contralateral thigh.~The epidural catheter will be placed according to standard local practice in either of the groups."
46000551|NCT04671888|Other|exercises|COPD patients will be asked to wear a data logger system to collect EMG data and respiration parameters during exercise that simulate daily activity (i.e., walking, cycling)
46000552|NCT04722653|Drug|NNC0194-0499|1 single dose administered subcutaneously (s.c. - under the skin)
46000553|NCT04722653|Drug|Placebo (NNC0194-0499 )|1 single dose administered subcutaneously (s.c. - under the skin).
46000554|NCT01818921|Drug|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
46000555|NCT01818921|Drug|1.2 mg ZGN-440 for injectable suspension|1.2 mg beloranib
46000556|NCT01818921|Drug|1.8 mg ZGN-440 for injectable suspension|1.8 mg beloranib
46000557|NCT04700345|Device|Onyx|Embolization of the Middle Meningeal Artery using the liquid embolic material
46000558|NCT04700345|Procedure|Burr-hole|Burr-hole drainage of subdural hematoma
46000559|NCT04700345|Other|Medical Management|best medical management
46000560|NCT01815450|Drug|BLI1100|BLI1100 topical cream
45675923|NCT05185440|Behavioral|Learning Collaborative|learning collaborative (anticipated meeting monthly) with college health center staff and clinicians to address common barriers to implementation of GIFTSS intervention, reinforce GIFTSS training
45835407|NCT01894932|Behavioral|Mindfulness-based cognitive Group therapy|In this study, groups of Mindfulness-based cognitive psychotherapy, will based on Segal, Williams & Teasdale (2002)'s work to redesigned an eight-week group course which adapted the local Taiwanese culture and add the appropriate revision of the content in a more easy to understand learning materials available to patient. The group would lead by 2 clinical psychologist and each session is about 2 hours.
46000561|NCT01815450|Drug|BLI1100 - modified formulation|BLI1100 topical cream
46000562|NCT01815450|Drug|Placebo|Placebo topical cream
46000563|NCT01810575|Drug|WC3036-11F/Alprostadil in Vehicle 2.5%|330 mcg alprostadil in 2.5% vehicle
46000564|NCT01810575|Drug|WC3036-12F/Alprostadil in Vehicle 0.5%|330 mcg alprostadil in 0.5% vehicle
46000565|NCT01810575|Drug|WC3036-13P/Vehicle Only 0.5%|100 mg cream vehicle 0.5%.
46000566|NCT04671524|Other|Exercise protocol|a combination of stretching, range of motion, and strengthening exercise.
46000567|NCT04671849|Drug|SIM1803-1A|SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles.
46000568|NCT04664777|Device|Masimo Model RDS7A|Masimo monitoring platform equipped with Radical-7 Pulse CO-Oximeter fingertip probe for measurement non-invazive hemoglobin level (SpHb) an perfusion index (PI)
46000569|NCT01785771|Drug|ITCA 650 (exenatide in DUROS)|
46000570|NCT04664582|Procedure|Sentinel Lymph Node Biopsy|see intervention group description
46000571|NCT04671537|Drug|Preloading with crystalloid fluid|crystalloid fluid at 10 ml/kg of ideal body weight was administered intravenously in 30 min before the BCP for patients
45457851|NCT03508882|Drug|Botulinum Toxin Type A 100Unit/Vial (Product)|Botulinum Toxin Type A 100Unit/Vial (Product) comes as a dry powder and is routinely reconstituted with Saline Solution for Injection
45675924|NCT05185440|Behavioral|Provider Scripts|scripts and prompts for college health center staff and clinicians to encourage implementation of GIFTSS intervention
45675925|NCT05183490|Drug|Rapidly generated virus specific T (R-MVST) cells|"The R-MVST products will be manufactured individually for each patient from a selected donor; it is an anti-viral prophylaxis and treatment of viral reactivation.~SCT dose escalation:~Cohort / R-MVST dose~(-1A) 0.25x10^6 R-MVST TNC/kg~(1A) 0.5x10^6 R-MVST TNC/kg~(2A) 1x10^6 R-MVST TNC/kg~SOT dose escalation:~Cohort / R-MVST dose~(-1B) 1x10^6 R-MVST TNC/kg~(1B) 2x10^6 R-MVST TNC/kg~(2B) 4x10^6 R-MVST TNC/kg"
46000572|NCT00556101|Procedure|Whole body magnetic resonance angiography|
46000573|NCT04627415|Behavioral|Promoting Engagement with ADHD Pre-Kindergarteners|Optimism Training includes the following strategies: 1) Identifying situations and associations 2) Determining consequences of beliefs 3) Use distractions to interrupt negative thinking 4) dispute current thinking 5) substitute positive, productive thoughts 6) practice skills to recognize/modify self-talk 7) Maintain positive changes in self-talk
45675926|NCT05181735|Drug|Luspatercept Injection [Reblozyl]|All patients will receive Luspatercept subcutaneously on day 1 of each 21 day cycle (every 3 weeks) at the selected dose according to part A : 1.75mg/kg or 1.33 mg/kg or 0.8 mg/kg
45675927|NCT05181735|Drug|Eprex|Epoietin alfa will be adminstered as a subcutaneous injection at the selected dose according to part A : 30 000 UI/week or 60 000 UI/week, every week
46000574|NCT04620356|Device|DryNites Pyjama Pants|DryNites Pyjama Pants are disposable, absorbent youth pants designed to help children manage bed wetting by absorbing involuntary urine loss and protecting the child's garments and bedding. DryNites Pyjama Pants are underwear-like alternatives that can be discreetly worn beneath pyjamas or nightwear during the bedwetting phase.
46000575|NCT01784874|Biological|Purified Vero Rabies Vaccine (VRVg) - Serum Free|0.5 mL, Intramuscular
46000576|NCT01784874|Biological|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
46000577|NCT01784133|Drug|omiganan|
46000578|NCT01784133|Drug|placebo|
46000579|NCT04607252|Drug|Metformin plus Megestrol acetate|metformin 1500mg, per day, oral; megestrol acetate 160mg per day, oral
46000580|NCT04607252|Drug|Megestrol Acetate|megestrol acetate 160mg per day, oral
46000581|NCT01782729|Drug|Tacrolimus|Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
46000582|NCT04601285|Drug|JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection)|"Dose escalation period: JS108 is administered intravenously every three weeks (Q3W) at the dose corresponding to the enrolled dose cohort.~Dose expansion period: JS108 is administered intravenously Q3W at the corresponding dose.~Clinical expansion period: JS108 is administered intravenously Q3W at the recommended dose."
46000583|NCT04671264|Device|Sallowing VC during six weeks|"follow-up was required for at least 6 times, once every two weeks through the whole study.~For patients who had no colonoscopy examination within a year, colonoscopy was a must to exclude organic diseases.~These included blood routine, blood biochemistry, urine routine, fecal routine, fecal occult blood, thyroid stimulating hormone (TSH), blood pregnancy test and ECG examination. Patients should finish all the examination in the run-in period and at the end of treatment period.~Dairy cards were designed mainly for the record of the daily defecation of patients and filled out by the enrolled patients, and the content included date, whether the patients swallow capsules (time), whether the patients discharge capsules (time), defecation, defecation time, degree of defecation exertion(0~4), BSF scale, complete or incomplete defecation, whether the patient had the sense of anal obstruction, whether manual assistance was applied, and whether first-aid medicine was used (bisacodyl)."
46000584|NCT04671303|Drug|Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets|"Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Allitinib Tablets：The dose of allitinib mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.~Take medicine continuously for 3 weeks (21 days) for 1 cycle."
46000585|NCT01780428|Drug|CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
46000586|NCT01780428|Drug|Placebo|
46000587|NCT04578392|Procedure|high ligation of ileocolic artery|Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing
45675928|NCT05178082|Behavioral|Educational Video-based Pain Program|Educational videos with 10 modules with information about pain.
45675929|NCT05178082|Behavioral|Empowered Relief Program|Educational online session for skills acquisition to manage pain. Empowered Relief TM by Beth Darnall ©2013-2022 Stanford University
46000588|NCT04578392|Procedure|mesenteric sparing|Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing
46000589|NCT04671420|Drug|HLX01|Patients will receive HLX01 intravenous (IV) infusion once a week for 4 weeks induction treatment (on Days 1, 8, 15, and 22), and then continue to receive maintenance treatment at Weeks 12, 20, 28, 36, and 44.
46000590|NCT04671420|Drug|Mabthera®|Patients will receive Mabthera® intravenous (IV) infusion once a week for 4 weeks induction treatment (on Days 1, 8, 15, and 22), and then continue to receive maintenance treatment at Weeks 12, 20, 28, 36, and 44.
46000591|NCT04573556|Drug|Lemborexant|Lemborexant oral tablets.
46000592|NCT04671108|Device|Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)|Daily disposable contact lens wear for 1 week
46000593|NCT04573166|Procedure|Personalized atrial septostomy with combined use of radiofrequency-ablation and balloon-dilation|After left and right catheterization, CURB procedure will be performed in all patients. The first step is RFA on fossae ovalis; and then graded BAS is carried out after transseptal puncture; finally, RFA is repeated around the fenestration-rim created with BAS. The fenestration-size will be determined based on the level of MLAP, and the immediate size of fenestration will be evaluated with intra-cardiac echocardiography. The patency and size of fenestration will be followed up for 6 months. During the period of follow up, the other evaluations will include the improvement in exercise tolerance, major adverse cardiac and/or cerebrovascular events (MACCE), reduction of PAWP/MLAP at rest, cardiac remodeling, myocardial injury, and so on.
46000594|NCT01779453|Drug|ETC-1002|Week 1-2, 60 mg/day; Week 3-4, 120 mg/day; Week 5-6, 180 mg/day; Week 7-8, 240 mg/day
46000595|NCT01779453|Drug|Placebo|Placebo once daily for 8 weeks
46000596|NCT01779453|Drug|Atorvastatin|Atorvastatin 10mg once daily for 8 weeks
46000597|NCT04687982|Biological|modified donor lymphocytes infusion (mDLI)|"The planned number of mDLI is 3.~Day +50 (+/- 7 days) from allogenic transplant, 1st mDLI 5x105CD3+/kg of recipient.~4-6 weeks after 1st DLI, 2nd mDLI 1x106CD3+/kg of recipient.~4-6 weeks after 2nd DLI, 3rd mDLI 5x106CD3+/kg of recipient."
46000598|NCT04671147|Procedure|Preoperative traction|Compare two methods of preoperative traction (Cotrel traction exercises and skull tongs femoral traction)
46000599|NCT04571723|Behavioral|Diabetes Prevention Program|This is the established Diabetes prevention program curriculum.
46000600|NCT04571723|Behavioral|Health Mindset modified diabetes prevention program|This is the established diabetes prevention program curriculum with the addition of curriculum focused on the role of mindset in health.
46000601|NCT01776606|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A; dose applied to the lateral canthal lines
46000602|NCT01776606|Drug|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
46000603|NCT04567160|Drug|Propofol|"In the propofol group, general anesthesia will be induced using target-controlled infusion (TCI) of propofol and remifentanil. Marsh pharmacokinetic model will be used to set the initial target predicted effect-site concentration of propofol at 3.0 mcg/ml in flash mode. Simultaneously, target-controlled infusion of remifentanil will be started to reach an initial target predicted effect-site concentration of 3 ng/mL using the Minto pharmacokinetic model.~After tracheal intubation, TCI of remifentanil is paused."
46000604|NCT04567160|Drug|Sevoflurane|In the sevoflurane group, induction of general anesthesia will be carried out by spontaneous breathing through a mask while progressively opening up the dial of the sevoflurane vaporizer up to 8%. Like in the propofol group, target-controlled infusion of remifentanil is simultaneously started to reach an initial target predicted effect-site concentration of 3 ng/mL. Vaporizer is adjusted when gas equilibration reaches the patient-specific concentration 1.0 MAC of sevoflurane. After tracheal intubation, TCI of remifentanil is paused.
45675930|NCT05173272|Drug|Neoadjuvant Therapy|Cisplatin 50 mg/m^2 d1 q21+ Paclitaxel 175 mg/m^2 d1 q21+serplulimab 300mg d1 q21
45457852|NCT03508882|Drug|Saline Solution for Injection|The placebo consists of vehicle only. Saline Solution for Injection is the vehicle substance normally used to reconstitute Botulinum Toxin Type A (see 1st Intervention above).
45457853|NCT05553145|Diagnostic Test|Autoimmune Antibody Assays|GAD-65, Islet cell-Ab, IA-2 Ab, anti-insulin Ab, and ZnTn8 Ab
46000605|NCT04670952|Other|Low Pressure Laparoscopic Cholecystectomy|Low Pressure Laparoscopic Cholecystectomy (10mmHg) is set as the experimental group.
45675931|NCT05173272|Radiation|CCRT|weekly cisplatin for 4 or 5 weeks is administered concomitant with EBRT (45-50.4Gy) in 1.8-2 daily fractions and a 10-20 Gy boost to reach a total dose of 65 Gy when there was unresectable lymph nodes.
46000606|NCT04670952|Other|Standard Pressure Laparoscopic Cholecystectomy|Standard Pressure Laparoscopic Cholecystectomy (14mmHg) is set as the control group.
45675932|NCT05173272|Radiation|Brachytherapy|The primary cervical tumor is the boosted, using image guided 3D brachytherapy or 2D brachytherapy, with an additional 30-40 Gy to HRCTV (3D brachytherapy) or to point A (2D brachytherapy), to achieve a total dose of 80 Gy for small-volume cervical tumors or 85 Gy for larger-volume cervical tumors.
46000607|NCT01774578|Drug|Docetaxel|Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.
46000608|NCT01774578|Biological|HyperAcute®-Lung Immunotherapy|"HAL-1, HAL-2 and HAL-3 immunotherapy components.~Up to 16 immunizations of 300 million immunotherapy cells."
46000609|NCT01774578|Drug|Gemcitabine|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
46000610|NCT01774578|Drug|Pemetrexed|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
46000611|NCT04545593|Behavioral|Positive Minds Strong Bodies Enhanced|The Positive Minds Strong Bodies Enhanced intervention (PMSB-E) was designed to provide a single, integrated program that could address the dual challenges of mental health and disability among minority elders. PMSB-E seeks to improve mood symptoms, identify and correct negative distortions or cognitions, promote behavioral activation through engaging the participant in pleasant activities, and encourage developing supportive relationships. All sessions are tailored to the participant's needs using a collaborative approach.
46000612|NCT04545593|Behavioral|Enhanced Usual Care|Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. Research staff will call the participant 4 times over the course of 6 months to administer mental health items, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group.
46000613|NCT01756482|Drug|GS-5806|GS-5806, powder for oral solution
46000614|NCT01756482|Drug|Placebo|
46000615|NCT04543994|Drug|Remestemcel-L|An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis
46000616|NCT04543994|Drug|Remestemcel-L|An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis
46000617|NCT04543994|Other|Placebo|Normal saline
46000618|NCT04519697|Drug|Mesenchymal Stem Cells|Adult allogeneic bone marrow derived mesenchymal stem cells for the treatment of rectovaginal fistulas in the setting of Crohn's disease.
46000619|NCT04519697|Other|Placebo|Normal Saline
46000620|NCT04670601|Drug|Flurbiprofen Test 8.75 MG|Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
45835408|NCT01894932|Behavioral|psycho-physiological stress regulation group|Physical and psychological stress regulation group in eight weeks, mainly to provide understanding of physical and mental effects of stress factors, self-conceptualization of stress and psychosomatic symptoms, physiological adjustment (relaxation, diet, exercise), psychological adjustment (positive primary, secondary assessment, cognitive identification), adjust negative thoughts, learn coping by using new choice. The group would lead by 2 clinical psychologist and each session is about 2 hours.
45835409|NCT04757532|Drug|Bupropion|300 mg of bupropion hydrochloride (1 tablet) administered orally in a single dose.
45835410|NCT04757532|Drug|Anastrozole|1 mg of anastrozole (1 tablet) administered orally in a single dose.
46000621|NCT04670601|Drug|Flurbiprofen Reference 8.75 MG|Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
45457854|NCT03504280|Drug|Cholecalciferol|
45457855|NCT03504202|Drug|Trimetazidine|After enrollment, experimental group will receive Trimetazidine(35mg tid) for six months .
45457856|NCT01232725|Dietary Supplement|Donor Human Milk|Donor Human Milk, obtained from the Mother's Milk of Iowa, a HMBANA milk bank
45457857|NCT02307760|Other|Human Milk Fortifier A|Acidified concentrated liquid human milk fortifier
45675933|NCT05169515|Drug|SC Mosunetuzumab|Participants will receive SC mosunetuzumab for 12 cycles (cycle length = 21 days for Cycle 1 and 28 days for Cycles 2-12)
45675934|NCT05169515|Drug|IV Glofitamab|Participants will receive IV glofitamab for 12 cycles (cycle length = 21 days)
45675935|NCT05169515|Drug|CC-220|Arm 1: Participants will receive oral CC-220 from Day 1-21 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12) Arm 2: Participants will receive oral CC-220 from Day 1-14 of Cycle 3-12 (cycle length = 21 days)
45675936|NCT05169515|Drug|CC-99282|Arm 1: Participants will receive oral CC-99282 from Day 1-14 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12) Arm 2: Participants will receive oral CC-99282 from Day 1-10 of Cycle 3-12 (cycle length = 21 days)
45675937|NCT05169515|Drug|Obinutuzumab|Participants in Arm 2 will receive pre-treatment with IV obinutuzumab on Cycle 1 Day 1 (cycle length = 21 days)
45835411|NCT04757532|Drug|Testosterone cyclopentylpropionate|100 mg of testosterone cyclopentylpropionate (equivalent to 70 mg of testosterone) administered via intramuscular injection in a single dose (2 mL).
45835412|NCT04757532|Drug|Danazol|200 mg of danazol (1 capsule) administered orally in a single dose.
46000622|NCT04670913|Drug|Camrelizumab|A human anti-PD-1 monoclonal antibody
46000623|NCT04670913|Drug|Apatinib|A tyrosine kinase inhibitor selectively targeting VEGFR-2
45457858|NCT02307760|Other|Human Milk Fortifier B|Non-acidified concentrated liquid human milk fortifier
45457859|NCT05538637|Diagnostic Test|Echocardiography|"Mitral velocity time-integral variability measurement before and after passive leg raising.~Mitral velocity time-integral variability measurement after fluid loading in preload-responsiveness patients."
46000624|NCT04671069|Drug|MGL-3196|Administered orally on the morning of Day 1; Multiple-dose administration of 100 mg MGL-3196 on Day 6 until Day 14
46000625|NCT04671069|Drug|Clopidogrel|After one-day washout period after Day 1, loading dose of 300 mg clopidogrel administered on Day 3 and then, at approximately the same time each morning, 75 mg clopidogrel administered on Days 4 to 11
46000626|NCT04374539|Biological|Plasma exchange|"Plasma exchanges with 5% human albumin and fresh frozen plasma in patients with quick <50% or only with 5% albumin in patients with quick of 50% or more. We will exchange between 1.2 and 1.5 plasma volumes, that will vary according to sex, weight, height and hematocrit.~Polyclonal immunoglobulin will be administered at a dose of 100 mg / kg ev after each plasma exchange.~Standar Medical treatment Kaletra:~lopinavir/ritonavir: 2c/12h 7 days~Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days~Azithromycin 500 mg first day, followed by 250 mg /d 4 days (oral or EV)~Tocilizumab 400 mg (weight <75Kgs) or 600 mg (weight ≥ 75 Kg)~Methylprednisolone 250 mg EV three days and 30 mg/d another 3 days~Anakinra 200mg/ 12h SBC first day, 200mg / 24h SBC two more days~Clexane 40-60 mg/d"
46000627|NCT04374539|Drug|Standar medical treatmen|"Kaletra: lopinavir/ritonavir: 2c/12h 7 days~Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days~Azithromycin 500 mg first day, followed by 250 mg /d 4 days (oral or EV)~Tocilizumab 400 mg (weight <75Kgs) or 600 mg (weight ≥ 75 Kg)~Methylprednisolone 250 mg EV three days and 30 mg/d another 3 days~Anakinra 200mg/ 12h SBC first day, 200mg / 24h SBC two more days~Clexane 40-60 mg/d"
46000628|NCT01753167|Drug|MCMV3068A|Four doses of MCMV3068A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
46000629|NCT01753167|Drug|MCMV5322A|Four doses of MCMV5322A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
46000630|NCT01753167|Drug|Placebo|Four doses of placebo matched to MCMV5322A/MCMV3068A administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
46000631|NCT01741194|Drug|AC-1204|AC-1204 taken once daily, by mouth
46000632|NCT01741194|Drug|Placebo|Placebo taken once daily, by mouth
46000633|NCT04363346|Drug|FT516|FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation.
46000634|NCT04670718|Device|Optical Coherence Tomography Probe|Use of OCT probe for examination of gastrointestinal tract
46000635|NCT04332458|Behavioral|A focus group interview|this is a qualitative study using focus group interviewing.
46000636|NCT01823016|Drug|Placebo|Placebo tablet, taken once daily
46000637|NCT01823016|Drug|JNJ-38518168|JNJ-38518168, 30 mg tablet, taken once daily
46000638|NCT04670211|Device|maxillary distractor|the type of maxillary distractor: tooth-borne, bone-borne or hybrid distractor
46000639|NCT04322123|Drug|Hydroxychloroquine Oral Product|Hydroxychloroquine 400 mg BID
46000640|NCT04322123|Drug|Hydroxychloroquine + azithromycin|Hydroxychloroquine 400 mg BID + azithromycin 500 mg once a day
46000641|NCT04670328|Diagnostic Test|not required|Diagnostic tests( hematological parameters) were assessed.
46000642|NCT04670367|Behavioral|Walk 30mins|aerobic exercise
46000643|NCT04670367|Behavioral|Walk plus Baduanjin|Walk 30mins then Baduanjin 12mins per day, 5 times per week.
46000644|NCT04670367|Other|usual care|routine care
46000645|NCT04670367|Behavioral|Baduanjin|Baduanjin exercise is moderate in intensity and short in duration (a set of Baduanjin takes about 12 minutes). Baduanjin consists of the sitting and standing practicing form. The sitting Baduanjin exercise conforms to the aspects of low-intensity and long-term aerobic activity, which is suitable for the rehabilitation training of patients who are in stable condition during hospitalization. The standing Baduanjin is more suitable for patients with sequential rehabilitation after discharge and can be adjusted based on the patient's condition
45457860|NCT03506776|Device|Education and Thermometer Group|The education will be provided in video format utilizing the Canadian Association of Wound Care (CAWC) diabetic foot management YouTube video and one-on-one teaching. Participants will be provided with an inspection mirror with an extendable handle to assist with visualizing the bottom of the feet and a pedometer to measure daily activity. One-on-one teaching with the thermometer will be provided. Participants will be given a handout for reference on using the thermometer. The foot model will be marked with a zigzag pattern on the plantar surface to illustrate the path that should be used when measuring temperature. The support person will be included in the teaching if he/she will be assisting the participant to obtain temperature readings.
45457861|NCT03506776|Other|Education Only Group|The education will be provided in video format utilizing the Canadian Association of Wound Care (CAWC) diabetic foot management YouTube video and one-on-one teaching. Participants will be provided with an inspection mirror with an extendable handle to assist with visualizing the bottom of the feet and a pedometer to measure daily activity.
45457862|NCT01136941|Drug|Zileuton|Zileuton is available as a 600 mg tablet. Dosing begins at 2.4gm/day and will be increased to 3.0gm/day. Tablets will be taken twice daily for the 6 week duration of the study.
46000646|NCT04313348|Behavioral|eMobilize-Uganda application|"Arm 1 is the Control arm. Participants will receive no SMS reminders nor social supporter notifications. Arm 2, Scheduled SMS arm: Will receive an mHealth intervention targeted to the study participant (such as health information on an eMobilize-Uganda CommCare application or messaging and SMS reminders, or a voice call if at high risk). A weekly SMS reminder on the impending ANC appointment and expected date of delivery will be sent to participants. The content of the SMS reminders will be customized at enrolment. Arm 3 social support engagement arm: Will receive an mhealth intervention targeted to the participant plus an intervention targeted to engage the social supporter. Study participants will receive health information through the eMobilize-Uganda CommCare application or messaging + weekly SMS reminders + weekly SMS notifications to the 2 pre-identified social supporters. Notifications will bear upcoming ANC visit and delivery due date for all the study follow-up period."
46000647|NCT04670289|Drug|TenoMiR (Low Dose)|Mimic of miR29a
46087247|NCT04162977|Behavioral|Personality-targeted Interventions|The Personality-targeted Interventions (i.e., Preventure programme) are selective substance use prevention programme designed to target known personality risk factors for substance misuse based on the evidence from cross-sectional and longitudinal studies which connect these personality risk factors to early initiation and escalation of substance misuse in adolescents. This selected personality-targeted approach targets four personality-specific motivational pathways to substance misuse: Hopelessness, Anxiety Sensitivity, Impulsivity, and Sensation Seeking. Each intervention will involve two 90-minute sessions, with an average of 6 personality-matched adolescents per group, and will be conducted using manuals that incorporate psycho-educational, motivational enhancement therapy (MET), and cognitive behavioural therapy (CBT) components and include real life 'scenarios' shared by high-risk local youth with similar personality profiles.
46000648|NCT04670289|Drug|TenoMiR (Medium Dose)|Mimic of miR29a
46087248|NCT02693444|Drug|Lidocaine|
46087249|NCT02693444|Drug|Saline|
46087250|NCT02636751|Behavioral|12-week prehabilitation program|stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities
45457863|NCT02304562|Biological|UCB Mesenchymal Stem Cells treatment|reduce skin injury
45457864|NCT01232803|Drug|Tenofovir 1% gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
45457865|NCT01232803|Drug|2% N-9 gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
45457866|NCT01232803|Drug|HEC Placebo gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
45457867|NCT03504046|Device|Artificial Pancreas App|The portable Artificial Pancreas System App (APS APP) is an artificial pancreas system comprised primarily of an insulin pump, a continuous glucose monitor (CGM), and a cellular phone device to connect the components.
45457868|NCT03917017|Device|Radiomics and Watson artificial intelligence|"The artificial intelligence platform developed by IBM Watson can provide treatment decisions and corresponding theoretical basis to guide surgical decisions based on the key clinical data of liver cancer patients.~The imaging histology can be used to conduct intraoperative navigation surgical resection and treatment monitoring, and established a prognosis model to predict the prognosis of patients by grading the results of postoperative follow-up and microvascular invasion of pathological liver cancer, so as to better achieve accurate diagnosis and treatment of the disease."
45457869|NCT01139203|Drug|lamivudine adefovir entecavir HBIG|lamivudine 100mg orally daily adefovir 10mg orally daily entecavir 0.5mg orally daily HBIG 2000 unit intravenously during the anhepatic phase,and followed 800 unit intramuscularly daily until day 14,then 400 unit intramuscularly twice weekly
45835413|NCT04757532|Drug|Chlorthalidone|50 mg of chlorthalidone (1 tablet) administered orally in a single dose.
46000649|NCT04670289|Drug|TenoMiR (High Dose)|Mimic of miR29a
46000650|NCT04670289|Drug|Placebo|0.9% saline
46087251|NCT02636751|Device|Walking aid adjustment|Walking aid adjustment
45457870|NCT02312362|Procedure|Combined sclerotomy ab interno and phaco|
45457871|NCT02312362|Procedure|Phacoemulsification with IOL implantation|
45457872|NCT05187715|Drug|Simvastatin 40mg|Simvastatin 40mg OD
46087252|NCT02636751|Behavioral|Information about pain control|General information about pain control, such as ice application and medication usage
45835414|NCT01901562|Device|Ductoscopic papillomectomy|Intraductal papilloma extraction through the nipple orifice by interventional ductoscopy
45835415|NCT01890954|Device|Diabetes Assistant (DiAs)|Diabetes Assistance (DiAs) is a software residing in a Smartphone that contains the algorithms to regulate and control insulin deliveries (insulin bolus for: Basal rate, meal insulin and correction bolus) with inputs glucose values from a CGM and outputs insulin infusion by an insulin pump
45835416|NCT02069730|Drug|Selinexor|"If no druggable aberrations are identified on the molecular profiling analysis, then patients will receive unmatched treatment with Selinexor, a selective inhibitor of nuclear export (SINE)."
46000651|NCT04259138|Biological|Treatment Algorithm A|"Participants who are treatment-naïve at randomization will follow treatment algorithm A. Participants, upon entry into the study, will require standard first-line therapy. Either oral 5-ASA and/or immunosuppressive (with optional oral corticosteroid in combination) will be initiated.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."
46087253|NCT03838016|Behavioral|Babble Boot Camp|The Babble Boot Camp is an experimental study to investigate whether earliest and proactive activities and routines can positively influence the speech and language development of children who were diagnosed with classic galactosemia at birth. A speech-language pathologists implements the intervention by teaching parents to foster and expand earliest signals of communication, prespeech activities such as coo and babble, vocabulary growth, sentence complexity, and use of language to communicate. Examples are intentional eye contact, reinforcing babble with rewarding play activities, and repeating a child's rudimentary sentence with slight expansions to scaffold longer sentences.
46000652|NCT04259138|Biological|Treatment Algorithm B|"Participants who are taking non-biologic UC therapies at randomization will follow treatment algorithm B.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."
46000653|NCT04259138|Biological|Treatment Algorithm C|"Participants who are taking anti-TNF, tofacitinib or ustekinumab therapy at randomization will follow treatment algorithm C.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."
46000654|NCT01741155|Drug|SPI-1620|SPI-1620 11 μg/m2 administered intravenously over one minute.
45457873|NCT05187715|Other|Placebo|Placebo
46000655|NCT01741155|Drug|Docetaxel|Docetaxel: 75 mg/m2 administered as IV infusion.
46000656|NCT04244630|Combination Product|Antioxidants|Over-the-counter anti-oxidants, namely vitamin E, NAc cysteine, L-cystine, Nicotinamide and Taurursodiol at defined doses
46000657|NCT01719744|Drug|ENMD-2076|
46000658|NCT04670406|Behavioral|acceptance and commitment therapy (ACT) combined with psychoeducation|Participants receive 8 weekly sessions, including 6 ACT sessions and 2 psychoeducation sessions, delivered by trained coaches through Zoom videoconferencing.
45675938|NCT05169515|Drug|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
46000659|NCT04239053|Drug|Bupivacaine|Measuring the plasma concentration level of bupivacaine after applying ESPB
46000660|NCT04670250|Diagnostic Test|non invasive markers|non invasive markers (IL6, serum ferritin, fecal lactoferrin) used for monitoring of newly diagnosed patients with ulcerative colitis
45675939|NCT05169411|Diagnostic Test|Blood pressure|The first anti-hypertensive prescribed will be categorized as ACEi, ARB, thiazide diuretic, loop diuretic, beta-blocker, calcium channel blocker, other, and none; secondary analyses will combine ACEi and ARB into a single RAAS blocker category. We will conduct additional secondary analyses for specific medications with sufficient sample sizes.
46000661|NCT00556179|Drug|Lactoserum (Dermacyd Femina®)|Once a day during three months
46000662|NCT04687592|Procedure|reduction and fixation|"Reduction: one trial of closed reduction under anaesthesia and image control. Open reduction will be done by anterolateral or lateral approach if closed reduction failed~Fixation: internal fixation of the fracture by appropriate implant according to the fracture state"
46000663|NCT01718145|Drug|Daclatasvir|
46000664|NCT01718145|Drug|Asunaprevir|
46000665|NCT01718145|Drug|Ribavirin|
46087254|NCT04032951|Other|Fine Needle Tissue Acquisition|diagnostic
46087255|NCT04162587|Other|Carotid duplex+/- MRA neck|Carotid duplex and or MRA neck
46087256|NCT04162587|Other|brain MRA+/-CT angio on carotid and brain|brain MRA and or CT angiography on carotid and brain
45457874|NCT05187715|Other|Standard medical Treatment|Standard medical Treatment eccluding pentoxiphylline
45675940|NCT05169411|Diagnostic Test|Urine protein|Evaluating urine protein for children with CKD and hypertension is another guideline recommendation, but the frequency, type of assessment (qualitative or quantitative urine protein), and utility for patients without hypertension are unclear. We will determine whether urine protein is evaluated at each encounter and create a dichotomous indicator.
45675941|NCT05168826|Device|SAPIEN 3 Transcatheter Heart Valve|Implantation of the SAPIEN 3 valve
45675942|NCT05167266|Behavioral|Psychoeducation|Psychoeducation refers to the process of providing education and information to those seeking or receiving mental health services.
46000666|NCT01718145|Biological|pegIFNα-2b|
46000667|NCT01718145|Drug|Telaprevir|
46087257|NCT04162587|Other|MRI brain|MRI brain with diffusion to detect asymptomatic stroke
46087258|NCT04162587|Other|DSA (digital subtraction angiography)|DSA (digital subtraction angiography) in some cases to confirm diagnosis.
46087259|NCT03661424|Drug|HER2 BATs|A test dose (1 million cells) of HER2 BATs (at one of the two dose levels: 5 million cells or 10 million cells per infusion) followed by 8 weekly infusions of Her2 BATs delivered into the ventricle of the brain. Infusions are delivered weekly over 8 weeks with brain MRIs prior to first infusion and following the eighth infusion. Blood will be drawn for immune evaluation before during and after study treatment.
46087260|NCT04162743|Drug|Trazodone|take trazodone 100mg before polysomnography
46087261|NCT04162743|Drug|Placebo oral tablet|take placebo oral tablet before polysomnography
46000668|NCT04687748|Device|Electromographic Biofeedback|Surface EMG biofeedback is an adjunct therapy to standard exercise regime for increasing muscle strength. Electromyographic biofeedback is a specific form of biofeedback. The device records muscle activity through application of vaginal probe will be inserted in vagina and the reference surface electrode would be placed over the right anterior superior iliac spine.
46000669|NCT04687748|Other|PFM exercises|Patients would be advised to maximally contract the pelvic floor muscles as forcefully a possible for about 5 seconds. Three attempts would be made with 40 seconds rest in between each contraction. The exercises would be performed with the patient initially in supine position, with hip and knee flexed at 30 and 90 degrees.
46000670|NCT00556257|Drug|Cyclosporine|Standard of care
46000671|NCT00556257|Drug|CP-690-,550|CP-690550 20 mg BID in Months 1-6 then 15 mg BID in Months 7-12
46000672|NCT04687787|Other|Core Stabilization exercises|. Each session will be given for 40 mins (20 mins for TENS and 20 Mins for exercise) Core Stability Exercises include Kegel Exercises, Modified V-sit, opposite Arm Leg Raise, Seated Side bends poses, Dumbell Side bends and Pelvic Tilt. Participants will perform 1 set of exercise having 10 repetitions with hold of 5 seconds. Session would be performed thrice a week.
46000673|NCT04687787|Other|Routinely prescribed exercises|Each session will be given for 40 mins ( 20 mins for TENS and 20 Mins for exercise Routinely prescribed exercises composed of Hamstring stretches, hip flexor stretches, hip extensor stretches, calf stretches, and back extensor stretches. Participants will perform 1 set of exercise having 10 repetitions with hold of 5 seconds. Session would be performed thrice a week.
46000674|NCT01712451|Drug|salmeterol xinafoate, fluticasone propionate|LIPO-102
46000675|NCT01712451|Drug|Placebo|Placebo
46000676|NCT01712451|Drug|salmeterol xinafoate|Salmeterol
46000677|NCT00541268|Device|ICD|Intracardioverter defibrillators from 2 different manufacturers
46000678|NCT00541268|Other|Optimal medical treatment|ACEi or angiotensin receptor blockers Betablockers Aldosterone blockers
46000679|NCT01712217|Drug|AT13387|HSP90 inhibitor
46000680|NCT01712217|Drug|Crizotinib|ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene1, receptor tyrosine kinase) inhibitor
46087262|NCT02636673|Procedure|Sigmoid Resection|
46087263|NCT03813992|Drug|MED2005|Topical Product
46087264|NCT04162821|Drug|Hydronidone|Take hydroxynitone capsule
46087265|NCT05261204|Device|Transcatheter Aortic Valve Implantation|Patients who are deemed receive TAVI first underwent evaluation of their peripheral arteries before the procedure, in order to separate those eligible for transfemoral placement (TFP) from those who would require transapical placement. Technological advances achieved in the new platforms for the treatment of SHD have allowed the use of reduced size catheters and sheaths in the new armamentarium, favoring the TFP technique. The transcatheter valve (TV) is positioned at the level of the native aortic valve during the final step of valve replacement, when the balloon is inflated within the native valve during a brief period of rapid ventricular pacing. The delivery system i traverses the aorta retrograde over a guidewire from its point of insertion in the femoral artery during the use of TFP. Before balloon inflation, the valve and balloon are collapsed on the catheter and fit within the sheath. After balloon inflation, the calcified native valve is replaced by the expanded TV
45835417|NCT02069730|Drug|EGFR or HER2 Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with EGFR or HER2 Inhibitor"
46000681|NCT04046237|Other|Periodontal treatment|"Periodontal treatment can last up to 6 months depending on the periodontal state, followed by a follow-up period of at least 6 months including a visit to M9.~Briefly, the intervention group includes initial therapy in 48 hours maximum which includes information on oral hygiene techniques (verbal + brochure), scaling and surfacing of dental roots with antiseptic irrigation and non-tooth extraction. retainable. This initial therapy is followed by a resumption of periodontal clinical measures after 6 weeks. Depending on the degree of improvement of the measurements, the treatment is either completed, or continues with further scaling-surfacing and / or performing one or more periodontal surgeries. Periodontal monitoring period often called maintenance includes repeated sessions of simple scaling whose rate does not exceed 4 per year."
46000682|NCT00555243|Procedure|Laparoscopic Simulation training|five 30-minute faculty-directed sessions at the Laparoscopic Simulator Lab
46087266|NCT05261204|Procedure|Bioprothesis|The bioprosthesis is implanted using the SAVR procedure during median sternotomy in extracorporeal circulation. Minimally invasive procedures using a thoracotomy approach and peripheral cannulation have found widespread use.
45835418|NCT02069730|Drug|FGFR Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with FGFR Inhibitor"
45835419|NCT02069730|Drug|C-KIT Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with C-KIT Inhibitor"
45835420|NCT02069730|Drug|Anti-androgen|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with Anti-androgens"
46000683|NCT00555243|Procedure|Traditional Surgical Education|Traditional surgical teaching (no simulator)
46000684|NCT04014764|Other|This is a non-interventional study|N/A. This is a non-interventional study. Following consent, the subject will have biospecimen samples taken during routine standard of care procedures, and provided to Sponsor for analysis. Optional research blood draws may occur at treating physician's discretion to obtain additional tissue samples.
46000685|NCT04669158|Drug|Idebenone|Idebenone, initially 200mg by mouth (P.O.) once a day for 2 weeks, then 200 mg twice a day for 2 weeks, then 200 mg three times per day for the remainder of the study will be used.
46087267|NCT05261204|Procedure|Sutureless|The sutureless is implanted using the SAVR procedure during median sternotomy in extracorporeal circulation. Minimally invasive procedures using a thoracotomy approach and peripheral cannulation have found widespread use.
46000686|NCT04669158|Drug|Placebo|Placebo to match Idebenone once a day for 2 weeks, then twice a day for 2 weeks, then three times per day for the remainder of the study will be used.
46000687|NCT04669821|Drug|HSK3486|Loading Dose：0.1 mg/kg，Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h.
46000688|NCT04669821|Drug|Propofol|Loading Dose：0.5 mg/kg，Maintenance Dose：Maintenance is started at1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5mg/kg/h.
46000689|NCT04670055|Drug|BCMA Targeted CAR T-cells|Each subject receive BCMA Targeted CAR T-cells by intravenous infusion
46000690|NCT00532025|Drug|Sorafenib|Sorafenib will be administered as oral formulation (200 mg tablets) at a dose of 400 mg twice daily starting 28 to 42 days after surgery or surgery plus adjuvant radiotherapy. The dose may be adjusted based on individual toxicities following a predetermined dose reduction schedule. Sorafenib therapy will be continued for 48 months, or until disease progression, patient refusal or intolerable toxicity, whichever comes first. Patients in remission after 48 months will be offered continued Sorafenib treatment in a roll-over study.
46000691|NCT04669119|Dietary Supplement|Bromelain/Boswellia Serrata Casperome|Dietary supplement already commercialized based on Bromelain/Boswellia Serrata Casperome (Arm A and B), called Siben by Agaton
46000692|NCT04669119|Dietary Supplement|Centella Asiatica/Vitamins|Dietary supplement already commercialized based on Centella Asiatica/Vitamins (Arm B), called Kardinal V by Agaton
46000693|NCT04669119|Dietary Supplement|Placebo|Placebo
46000694|NCT04669080|Behavioral|Health care provider cost navigation training|Health care providers and asthma educators in a pediatric asthma clinic will receive an online training about the importance of cost of care conversations, how to start cost of care conversations with families, how to refer families to cost navigation resources, and how to lead asthma specialty care teams in cost navigation.
46000695|NCT03954080|Device|Intraspinal-optimal stim therapy|During the trial, percutaneous lead(s) will be implanted, following standard clinical practices, in the posterior epidural space with the final lead position located in the optimal area to provide pain relief by stimulating neural tissue in order to create paresthesia(s) only on the painful dermatome(s). During Intraspinal-Optimal Stim, a set of electrodes in the stimulation lead(s) will deliver a charge-balanced, pulsed electrical signal with stimulation parameters (frequency, pulse width, and amplitude) within the FDA approved specifications of the commercially available external neurostimulator. These will be adjusted to produce paresthesia coverage of the painful area. Patients that will report equal or greater than 50% reduction in pain, relative to baseline pain, may undergo permanent implantation of a commercially available neurostimulator (INS). This will require a surgical intervention to implant stimulation leads, INS and anchoring hardware followed by therapy programming.
46000696|NCT04669353|Drug|Platelet rich plasma|approximately 15 cm of whole blood was drawn from the uninvolved arm of each patient in the intervention group (group I) into a 20 ml sterile syringe containing citrate for anticoagulation. The blood was immediately centrifuged at 3200 Revolutions per Minute (PRM). Following 15 minutes of centrifugation, 4 - 5 mL of PRP was obtained. Then, the PRP was buffered by using sodium bicarbonate.
45457875|NCT02312440|Drug|0.9% sodium chloride|The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
45675943|NCT05166239|Procedure|HAIC|Hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.
45675944|NCT05166239|Drug|Lenvatinib 1|12/8 mg (weight ≥ 60kg / < 60 kg) of Lenvatinib once daily after HAIC.
46000697|NCT04669275|Behavioral|Telephone Counselıng|Telephone counseling
46000698|NCT00532064|Procedure|Biospecimen Collection|Undergo collection of blood
46000699|NCT00532064|Other|Questionnaire Administration|Ancillary studies
46000700|NCT04669977|Dietary Supplement|Mulberry juice|One bottle (600ml/bottle) of sanitized mulberry juice would be sent to participants of the auxiliary group with instructions to consume 50ml of juice diluted with drinking water at room temperature. Also, a reminder of the next clinical visit is attached. They are expected to finish the mulberry juice in 10 to 11days instead of 12 days.
46000701|NCT04668807|Device|Connected Medical Device|Monitoring of three simple physiological parameters (SpO2, heart rate and respiratory rate) with a Connected Medical Device (DMC) in the operating room
46087268|NCT02535585|Device|knotted anchors (SutureTak biocomposite 3.0 mm)|Arthroscopic repair of the labral lesion with knotted anchors (SutureTak biocomposite 3.0 mm).
46087269|NCT02535585|Device|knotless anchors (PushLock biocomposite 2.9 mm knotless)|Arthroscopic repair of the labral lesion with knotless anchors (PushLock biocomposite 2.9 mm knotless)
46087270|NCT00613340|Procedure|Cervical medial branch blocks|Cervical medial branch blocks done with 0.25 ml of local anesthetic and contrast
46087271|NCT00613340|Procedure|Cervical medial branch blocks|Cervical medial branch blocks with 0.5 ml of local anesthetic and contrast
45675945|NCT05166239|Drug|PD-1 Inhibitors|PD-1 inhibitors injection intravenously or percutaneously before 24h of HAIC every 4 week.
46000702|NCT04668807|Device|Traditional transmission system|Monitoring of physiological parameters with a traditional wired transmission system between the sensor and the data processing device in the operating room
46000703|NCT03849248|Other|Maternal scent cloth|The babies assigned to the intervention group will have a cloth with their mother's scent on it placed under their heads.
46000704|NCT04669392|Drug|70% Ethanol Alcohol|"Ethanol, also called ethyl alcohol, grain alcohol, or alcohol, a member of a class of organic compounds that are given the general name alcohols.~Ethanol is a commonly used fixative. Fixation of the inner layers of the tissue depends on the ability of the fixative to diffuse into the tissue. Moreover, Ethanol has antibacterial antifungal, and antiviral properties.~70% Ethanol is the safest concentration because the water that has been mixed into the ethanol slows the drying time, creating a longer contact time. Ethanol needs to have a contact time of at least 10 seconds to kill Staphylococcus aureus and Streptococcus pyogenes. At a 10 second drying time."
46000705|NCT00532142|Drug|Intravitreal Triamcinolone|
46000706|NCT00532142|Procedure|Radial Optic Neurotomy|
46000707|NCT00532142|Other|Placebo - Sham Intravitreal Injection|
46000708|NCT04668963|Device|MIRROR THERAPY|patients were seated on a chair, with the mirror positioned between the upper limbs perpendicular to the subject's midline and with the unaffected upper limb facing the reflective surface. Following the physiotherapist indications, the patients observed the reflection of their unaffected limb while performing the following movements with the both arms, the affected one as good as possible: flexion and extension of the shoulder, elbow, wrist and finger, prone supination of the forearm.
46087272|NCT00613418|Device|IDev SUPERA® Interwoven Self Expanding Nitinol Stent Peripheral Vascular System|Interwoven, self-expanding nitinol stent system, including delivery system and stent
46000709|NCT04865627|Device|activity monitor|Both groups will wear three different activity monitors for one week. There is one observation moment which consists of four minutes lying, sitting, standing, walking and taking stairs. Participants will be filmed during this moment.
46000710|NCT04775264|Procedure|Pulsed Electric Field Ablation|catheter ablation of ganglionated plexi structures on the epicardial surface of the heart during cardiothoracic surgery
46000711|NCT04669509|Diagnostic Test|Liver function tests|Patients' age, gender, comorbidity, Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) scores when first admitted to the ICU, hemogram parameters (white blood cell count, neutrophil, lymphocyte, hemoglobin, platelet count), coagulation parameters (prothrombin time, activated partial thromboplastin time and D-dimer, blood biochemistry results (C-reactive protein, lactate dehydrogenase, creatine kinase , alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded. It will also be recorded whether mortality develops on day 7 and day 28.
46000712|NCT04669626|Other|Use of Ocetnilin|"Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each dressing change will be the same and will be as follows:~Removal of old dressing~Applying a soaked gaze with Octenilin® on the wound (5 minutes)~Mechanical debridement if necessary~Wound cleansing with Octenilin®~Application of new dressing (according to the wound healing phases, medical prescription)"
46000713|NCT04669626|Other|Use of NaCl 0.9%|"Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each dressing change will be the same and will be as follows:~Removal of old dressing~Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes)~Mechanical debridement if necessary~Wound cleansing with NaCl 0.9% solution~Application of new dressing (according to the wound healing phases, medical prescription)"
46000714|NCT04749641|Biological|Histone H3.3-K27M Neoantigen Vaccine Therapy|"The researched vaccine, containing H3.3-K27M-targeting neoantigen peptides and poly ICLC, will be administered through subcutaneous injection into DIPG patients after they complete surgical/stereotactic biopsy and conformal radiotherapy. The day of first vaccine injection is defined as D1 (day 1), and then the injections will be administered on D3, D15, Day 29, Day 57, Day 85 and one injection every 8 weeks thereafter. In order to determine the Maximum Tolerated Dose (MTD) of the vaccine, a 6+3 dose escalation design is applied. There are three doses for the vaccine. Dose 1: 0.5mg peptide + Poly ICLC; Dose 2: 1mg peptide + Poly ICLC; Dose 3: 2mg peptide + Poly ICLC."
46087273|NCT02636127|Other|blood samples|"one blood sample will be done for dosage and role of Fractalkine in the serum.~- Functional study of the interactions between T cells and NK cells and / endothelial cells (HMVEC): immuno mediated endothelial cytotoxicity, endothelial activation and microparticles release by the HMVEC, endothelial progenitor cells analysis and evaluation of the endothelial lysis by fluorescence release."
46087274|NCT00613652|Drug|AZD4877|10 mg IV (3 weeks treatment 1 week rest)
46087275|NCT02535663|Dietary Supplement|RG|The 100mg Korean citrus Hallabong peel polysaccharide contained 60mg rhamnogalacturonan (RG), 20mg mono- and di-saccharide, 5mg polyphenol, 5mg ash and 10mg moisture
46087276|NCT02535663|Dietary Supplement|Placebo|Same product without RG
46087277|NCT03779906|Drug|Isovue|Isovue will be given to all subjects per the standard of clinical care.
46087278|NCT02636205|Device|Armeo therapy|Participants will receive 18 sessionsx30 mins of ArmeoSpring therapy over 6weeks.
45457876|NCT02312440|Drug|tranexamic acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
46087279|NCT04156490|Other|No intervention is planned, this will be a purely retrospective trial.|Osmotic Therapy
45675946|NCT05166239|Drug|Lenvatinib 2|12/8 mg (weight ≥ 60kg / < 60 kg) of Lenvatinib once daily.
45675947|NCT05166239|Drug|PD-1 inhibitors 2|PD-1 inhibitors injection intravenously or percutaneously every 4 week.
45675948|NCT05155345|Drug|Mosunetuzumab|Participants will receive subcutaneous (SC) mosunetuzumab on either Day 1 or on Days 1 and 8.
45675949|NCT05155345|Drug|Tocilizumab|Participants will receive intravenous (IV) tocilizumab as needed to manage adverse reactions.
45675950|NCT05150691|Biological|DB-1303|Administered IV
46000715|NCT04669470|Procedure|bariatric endoscopy, mainly intragastric baloons, plication of stomach too|bariatric endoscopy, mainly intragastric baloons, plication of stomach too
46000716|NCT04669431|Other|Xbox kinect Training|Xbox kinect 360, Tennis player, Joy riding, Rally ball. Tennis player in first 2 weeks, Joy riding in 3rd and 4th weeks, and all 3 games in 5th and 6th weeks 35 minute/3 days a week for 6 weeks with Conventional physical therapy, 25 minute
46087280|NCT04302896|Drug|dolutegravir oral tablet 50mg|"Tivicay® (dolutegravir, DTG), a HIV-1 integrase strand transfer inhibitor (INSTI), is FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 30kg. Tivicay® 50mg tablets [GlaxoSmithKline] are yellow, round, film-coated, biconvex tablets debossed with SV 572 on one side and 50 on the other side. The inactive ingredients in each tablet are D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate. The tablet film-coating contains the inactive ingredients iron oxide yellow macrogol/PEG, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide."
46000717|NCT04669431|Other|Conservative Rehabilitation|Sustained Stretching, repetitive task training, activities of daily living( eating, grooming, folding of towel, basket lifting, turn key into lock, reaching forward, sideways reach, ball grasping, picking up small blocks and lifting cane and pencil) 35 minute/3 days a week for 6 weeks
46000718|NCT00533312|Drug|Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks|
46000719|NCT00533312|Drug|MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks|
46000720|NCT00533312|Drug|Comparator : niacin / Duraton of Treatment: 4 Weeks|
46000721|NCT04668612|Device|Dual-bolus|Dual-bolus (50/50% with second part over 2 hours) for all meals after 6:00 p.m.
46000722|NCT04668612|Device|Standard bolus|Standard boluses for all meals
46000723|NCT04668924|Procedure|Epi-on PiXL in high oxygen|After local anaesthetics, the keratoconus cornea is soaked in Riboflavin by repeated topical application during 10 minutes. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen googles. The UV-dosage is individually customized based upon Kmax; for < 45 Diopters (D) 7.2J/cm^2 will be used; for 45-50D 10J/cm^2 will be used; for > 50D 15 J/cm^2 will be used.
46000724|NCT04669314|Procedure|Liver resection or enucleation for liver hemangioma|Operations in which the hemangioma is selectively removed from the liver parenchyma border are named enucleation, and the operations in which the hemangioma is removed anatomically or non-anatomically with some liver parenchyma surrounding it are named liver resection
46000725|NCT00533390|Drug|efavirenz|600mg X 800mg QID during TB therapy with rifampicin associated with other antituberculosis drugs in patients concomitant treated for tuberculosis and AIDS
46000726|NCT00556296|Drug|NRP104|NRP104 30mg capsule once daily in a.m.
46000727|NCT00556296|Drug|NRP104|NRP104 50mg capsule once daily in a.m.
46000728|NCT00556296|Drug|NRp104|NRP104 70mg capsule once daily in a.m.
46000729|NCT00556296|Drug|Placebo|Placebo
46000730|NCT04709003|Diagnostic Test|Serologic test|A blood test to check antibodies type and amount
46000731|NCT04709003|Diagnostic Test|Respiratory swabs|PCR test to Covid-19
46000732|NCT00556335|Procedure|manual aspiration|air aspiration
46000733|NCT00556335|Procedure|conventional drainage|drainage, pneumocath
46000734|NCT04668456|Drug|Dexmedetomidine|the drug administered either subtenon ot iv
46000735|NCT04668456|Drug|lidocaine 2%|subtenon injection
46000736|NCT04668456|Drug|bupivacine 0.5%|subtenon injection
46000737|NCT04668456|Drug|Normal saline|either subtenon or iv
46000738|NCT04693169|Drug|11C-Choline|1、PSMA137 labeled with [Al18F] will be used as a molecular imaging tracer for PET/CT scanning。 2、11C-choline (0.05-0.1mCi/kg) was injected intravenously in a week after the [Al18F]PSMA137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
46000739|NCT04668417|Behavioral|Portal Reminders for Second Dose of Influenza Vaccine with Direct Scheduling Link|Patient proxy receives reminder/recall messages via the patient portal to get a second dose of influenza vaccine with a direct scheduling link included, enabling the patient to directly schedule a flu vaccination only visit
46000740|NCT04668417|Behavioral|Portal Reminders for Second Dose of Influenza Vaccine without Direct Scheduling Link|Patient proxy receives reminder/recall messages via the patient portal to get a second dose of influenza vaccine with no direct scheduling link included
46000741|NCT04686968|Procedure|Greenhouse Technique|First, the high-strength sutures were passed through the teared tendon, and then Crimson duvet procedure was performed on the footprint from the articular margin of the humeral head to the apex of the greater tubercle, followed by a lateral row anchor.
46000742|NCT04686968|Procedure|Microfracture Combined With Suture Bridge Technique|A three-line anchor suture method is used as in the greenhouse technique, except that the position is between the apex of the greater tubercle and the articular surface. After the rotator cuff is sutured, the bone bed beyond the suture point to the outer edge of the greater tubercle is opened with 2.0mm Kirschner wire every 5mm ( Crimson duvet), 1cm in depth, about 6 in total.
46000743|NCT00556413|Biological|cetuximab|
46000744|NCT00556413|Drug|fluorouracil|
46000745|NCT00556413|Drug|irinotecan hydrochloride|
46000746|NCT00556413|Drug|leucovorin calcium|
46000747|NCT00556413|Drug|oxaliplatin|
46000748|NCT04687085|Other|10 minute mindful meditation recording|10 minute mindful meditation recording
46000749|NCT04668573|Other|Trunk exercise|Trunk exercise includes trunk muscles stretching, trunk muscles strengthening, and task-related trunk control training for 30 minutes per session, twice a week for 12 weeks.
46000750|NCT04686695|Device|taVNS|taVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 20 Hz with pulse duration ≤ 1 ms, for 30min,administered twice daily.
46087281|NCT04302896|Drug|emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg|"Descovy® (emtricitabine/tenofovir alafenamide, FTC/TAF) is a combination of two HIV nucleoside analog reverse transcriptase inhibitors (NRTIs) FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35kg. Descovy® 200 mg/25 mg tablets [Gilead] are blue, rectangular-shaped, and film-coated with GSI debossed on one side and 225 on the other side. The inactive ingredients are croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The tablets are film-coated with a coating material containing indigo carmine aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide."
46087282|NCT04302896|Drug|tenofovir disoproxil fumarate oral tablet 300mg|"Viread® (tenofovir DF, TDF) is a nucleotide analog HIV-1 reverse transcriptase inhibitor and a hepatitis B reverse transcriptase inhibitor FDA-approved for the treatment of HIV-1 infection in combination with other antiretroviral agents and for the treatment of chronic hepatitis B in adults and pediatric patients 2 years of age and older weighing at least 10kg. Viread® 300mg tablets [Gilead] are almond-shaped, light blue, film-coated tablets containing 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil, are debossed with GILEAD and 4331 on one side and with 300 on the other side. The inactive ingredients in each tablet are croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and pregelatinized starch. Viread® 300mg tablets are coated with Opadry II Y-30-10671-A, which contains FD&C blue #2 aluminum lake, hypromellose 2910, lactose monohydrate, titanium dioxide, and triacetin."
45675951|NCT05150028|Behavioral|Patient participation|Questionnaire
46087283|NCT04302896|Drug|lamivudine oral tablet 300mg|"Lamivudine (Epivir®, 3TC) is a nucleoside analogue reverse transcriptase inhibitor FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients at least 3 months of age. Lamivudine 300mg tablets [Apotex Inc.] are gray, modified diamond-shaped, film-coated, and engraved with LMV 300 on one side and APO on the reverse side. Inactive ingredients are black iron oxide, colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose anhydrous, magnesium stearate, polyethylene glycol, and titanium dioxide."
46087284|NCT00656643|Drug|Sirolimus|Two subconjunctival injections of 440 micrograms sirolimus each.
46087285|NCT00656643|Drug|Placebo|Two subconjunctival injections of placebo.
46087286|NCT00656643|Drug|Sirolimus|Two subconjunctival injections of 220 micrograms sirolimus each.
46087287|NCT00656643|Drug|Sirolimus|Two subconjunctival injections of 880 micrograms sirolimus each.
46087288|NCT04059783|Drug|STW5 (Iberogast®, BAY98-7411)|The medication was applied 3 x 20 drops per day orally, before or at meals with some liquid, ideally three weeks
46087289|NCT04291820|Procedure|Intravenous induction and desflurane anaesthesia maintenance|Anaesthesia will be inducted with intravenous propofol + opioid and maintained with desflurane according to the BIS levels
46087290|NCT04291820|Procedure|Inhalation induction with sevoflurane and anaesthesia maintenance with sevoflurane|Anaesthesia will be inducted with sevoflurane and maintained with sevoflurane according to the BIS levels
46087291|NCT04156022|Other|Dystonia Coalition is an observational study.|This is not an interventional study.
46087292|NCT02635659|Other|Encapsulated nutrients|
46087293|NCT02635659|Other|Placebo|
46087294|NCT03712202|Drug|Bleomycin|Given IV
46087295|NCT03712202|Drug|Brentuximab Vedotin|Given IV
45675952|NCT05150028|Other|Clinician barrier reports|How many times a 7 question Survey on medication education practices is opened
46000751|NCT04668651|Other|antral ultrasound|Preoperative evaluation of gastric contents by antral ultrasound
46000752|NCT04668690|Drug|Mitoxantrone Hydrochloride Liposome Injection|Drug: Liposomal mitoxantrone hydrochloride (20 mg/m2) administered as an intravenous infusion on day 1 of each 28-day cycle.
46000753|NCT04668690|Drug|Chidamide|Drug: Chidamide tablet (30 mg) is given to the patients p.o. 30 minutes after breakfast, twice per week with 3-day intervals.
46000754|NCT04645628|Other|MRI examination|All subjects (healthy subjects and patients) will have an MRI examination with optimized sequences
46000755|NCT04668534|Device|taVNS 10|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
46000756|NCT04668534|Device|taVNS 25|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
46000757|NCT04668534|Device|Control|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
46000758|NCT04629326|Other|68Ga-WL12 PET/CT|WL12, labeled with PET radio-nuclide ( Ga-68 )will be used as a molecular imaging tracer for PET/CT scanning
46000759|NCT04658979|Other|Pulmonary tele-rehabilitation|All the participant will by include in a tele-rehabilitation program who will be based on an 12-week intervention including therapeutic education and self-management sessions and training sessions, delivered through a videoconferencing application. All interventions will be under the supervision of a rehabilitation professional from the Pavillon de prévention des maladies cardiovasculaire (PPMC) and modeled according to the recommendations of the ATS/ERS.
46087296|NCT03712202|Drug|Dacarbazine|Given IV
46000760|NCT04593992|Device|HTEMS|high-tone external muscle stimulation
46087297|NCT03712202|Drug|Doxorubicin|Given IV
46000761|NCT04593992|Device|Placebo|Placebo stimulation
46000762|NCT04668729|Other|Chiropractic Manipulation|"Lumbar vertebrae and sacroiliac joints of the participants that have lost their normal joint motion will be detected by static and dynamic palpation techniques.~Lumbal Chiropractic HVLA Spinal Manipulation: HVLA manipulation will be applied in the left transverse process of the lumbar vertebra (mammillary process) of the participants whose problem is to the left of the lumbar vertebra.~Sacroiliac Chiropractic HVLA Manipulation: Participants who lost normal joint motion in the anterior and superior directions in the left sacroiliac joint will be treated with HVLA manipulation in the left PSIS (Posterior Superior Iliac Spine: PSIS). Participants who have lost normal joint motion in the left sacroiliac joint in the posterior and inferior directions will be applied HVLA manipulation in the left ischial tuberosity.~For both applications, it will be positioned in the opposite position for the problems on the right and the application will be made in the opposite position."
46000763|NCT00533585|Drug|BAY 43-9006|Starting Dose of 200 mg orally twice a day on Day 3 through Day 19 of Cycle 1 and Days 2 through 19 of Cycle 2 and remaining cycles. Cycle is 21 days.
46000764|NCT00533585|Drug|Paclitaxel|200 mg/m^2 By Vein Over 3 Hours on Day 1.
45676750|NCT02173379|Device|Absorb BVS|"Scaffold diameters: 2.5, 3.0 and 3.5 mm~Scaffold lengths: 8, 12, 18, and 28 mm. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~Once Absorb GT1™ BVS System is commercially available, it can also be used in the ABSORB IV trial. Scaffold diameters: 2.5, 3.0 and 3.5 mm of and scaffold lengths: 8, 12, 18, 23, and 28 mm.~The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
46000765|NCT00533585|Drug|Carboplatin|Area under curve (AUC) 6 By Vein Over 30 Minutes on Day 1.
46000766|NCT00533585|Drug|Bevacizumab|Starting Dose of 5 mg/kg By Vein Over 90 minutes on Day 1.
46087298|NCT03712202|Biological|Nivolumab|Given IV
46087299|NCT03712202|Other|Quality-of-Life Assessment|Ancillary studies
46087300|NCT03712202|Drug|Vinblastine|Given IV
46000767|NCT00533624|Drug|Mycophenolate Sodium Delayed Release Tablets|Myfortic® 1,440 mg/day
46000768|NCT00533624|Drug|Mycophenolate Mofetil|Cellcept® 2,000 mg/day
46000769|NCT04585100|Drug|FM101 tablet|Bio-equivalent test (tablet vs oral solution)
46087301|NCT02635971|Procedure|Transcatheter arterial infusion|
46000770|NCT04585100|Drug|FM101 oral solution|Bio-equivalent test (tablet vs oral solution)
46000771|NCT04585100|Drug|Placebo|Placebo BID for 28 days
46000772|NCT04585100|Drug|FM101 150 mg|FM101 (150 mg) BID for 28 days
46087302|NCT02635971|Procedure|Intravenous chemotherapy|
46087303|NCT02635971|Drug|Gemcitabine|
46087304|NCT02635971|Drug|Oxaliplatin|
46087305|NCT00657423|Drug|Treated by endostar combined with docetaxel and cisplatin|recombinant human endostatin given intravenously,7.5mg/㎡,d1-14,2cycles. docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
46087306|NCT00657423|Drug|Treated by docetaxel and cisplatin|docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
46087307|NCT05260970|Procedure|Rectus muscle reapproximation at cesarean section|Rectus muscle reapproximation: Continuous Suturing of rectus muscles with 2.0 Vicryl (Ethicon) at Cesarean section.
46087308|NCT00922545|Other|Implementation of Clinical Practice Guidelines (GPC) and Health Education Program|Intervention: The program includes giving clinical results to the health care workers(doctor and nurse), from the medical records and interview. A training course (20h)that deals with aspects related to GPC, motivational interview and health education (tobacco, inhalers, alimentation, exercise and physiotherapy).
46087309|NCT00911235|Drug|Fesoterodine|Single 8 mg oral dose of fesoterodine
46087310|NCT00911235|Drug|fesoterodine plus fluconazole|On Day 1, fluconazole (200 mg oral dose) will be given 1 hour before and approximately 11 hour following a single 8 mg oral dose of fesoterodine (fesoterodine SD). Fluconazole will also be administered 200 mg BID on the Day 2 (ie, at approximately 24 and 36 hours following the fesoterodine SD treatment given on Day 1)
46000773|NCT04585100|Drug|FM101 300 mg|FM101 (300 mg) BID for 28 days
46000774|NCT04659252|Other|n/a - samples collected along routine care samples only|This is a non-interventional study.
46087311|NCT05260814|Device|Electric toothbrush with smart phone app|Scaling and root planing, oral hygiene instructions with use of Sonicare Diamond Clean Smart®.
46087312|NCT04283318|Behavioral|12h fasting|12h fasting (overnight)
46087313|NCT04283318|Behavioral|36h fasting|36h fasting ( one day and two nights fasting)
46087314|NCT04159623|Device|Belk Device|Knee exoskeleton with electrostimulation
46087315|NCT04159623|Other|Standard Rehabilitative treatment|Use the standard rehabilitative treatment
46087316|NCT00636974|Procedure|Combined spinal epidural anaesthesia|
46087317|NCT02535351|Drug|sunitinib or pazopanib|First-line treatment
46087318|NCT02535351|Procedure|Cytoreductive nephrectomy|Cytoreductive nephrectomy and first-line treatment
46087319|NCT00613964|Drug|Carperitide heart failure therapy|carperitide(alpha-human atrial natriuretic peptide, 0.025-0.05μg/kg/min)
46087320|NCT00613964|Drug|Standard heart failure therapy|Loop diuretics, Aldosterone blockers, Beta blockers, ACE inhibitors, Angiotensin receptor blockers, Nitrates, digitalis
46087321|NCT02535429|Other|massage|
46000775|NCT04668378|Other|Time restricted eating|TRE subjects consumed 100 % of their energy needs divided into three meals consumed at 1 p.m., 4 p.m. and 8 p.m., and fasted for the remaining 16 h per 24-h period.
46000776|NCT04668378|Other|Normal Diet|ND group ingested their caloric intake as three meals consumed at 8 a.m., 1 p.m. and 8 p.m.
46000777|NCT04562441|Drug|Axitinib|Axitinib: 5 mg bd po Day 1 to Day 28
46000778|NCT04562441|Drug|Avelumab|Avelumab: 10 mg/kg Day 1 to Day 15 every 4 weeks
46000779|NCT04668222|Drug|Yu-Ping-Feng formula|Yu-Ping-Feng formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08255). The intake dosage is 5g twice daily.
46000780|NCT04668222|Drug|Xiang-Sha-Liu-Jun formula|Xiang-Sha-Liu-Jun formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08252). The intake dosage is 5g twice daily.
46000781|NCT04668222|Drug|Liu-Wei-Di-Huang formula|Liu-Wei-Di-Huang formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08273). The intake dosage is 5g twice daily.
46000782|NCT04668222|Drug|"Placebo for Deficiency of Qi and Yang"|"Placebo for the group of deficiency of Qi and Yang is composed of 5% Yu-Ping-Feng formula+Xiang-Sha-Liu-Jun formula"
46000783|NCT04668222|Drug|"Placebo for Deficiency of Qi and Yin"|"Placebo for the group of deficiency of Qi and Yin is composed of 5% Yu-Ping-Feng formula+Liu-Wei-Di-Huang formula"
46000784|NCT04547309|Radiation|68Ga/18F-HER2 Affibody PET/CT scan|HER2 Affibody, labeled with PET radio-nuclide ( 68Ga or F-18) will be used as a molecular imaging tracer for PET/CT scan. All participants will undergo 68Ga/18F-HER2 Affibody PET/CT scan.
45675953|NCT05145296|Combination Product|Each patient will undergo in the first step of the study belatacept treatment and in the second apheresis and daratumumab|"Four consecutive cohorts each comprising 3 patients are planned. STEP I: Patients receive Belatacept 10mg/kg, administered on days 1, 5, end of week 2, 4 and 8 .~Patients without a significant decrease in the global cPRA (cPRA or TGI ≥99%) or significant reduction of anti-HLA Ab MF will continue to the second step.~STEP II: (15 weeks) One week after the last injection of belatacept, patients will undergo 4 sessions of apheresis (plasmapheresis (PF) or Immunoadsorption (IA)) which will be given every 48h. At week 11, patients will receive 4 doses of daratumumab (8mg/kg) every two weeks until week 17. Daratumumab will be alternated with 4 additional doses of belatacept 5 mg/kg FOLLOW-UP (24 weeks) All patients exiting the study, either having completed all treatment courses or exiting prematurely (transplanted or not), will be proposed monthly follow-up visits"
46000785|NCT04659057|Drug|Nebulized Lidocaine|will receive nebulized lidocaine 2%, 1 mg/kg with a maximum dose of 100 mg (5 ml).
45675954|NCT05143255|Behavioral|KNOW|KNow the Optimal Way (KNOW) is a manualized ADRD patient-care partner intervention designed to increase engagement in advance care planning (ACP) and completion of advance directives among early stage ADRD patients and their care partners using theoretically grounded distress tolerance techniques (inhibitory learning theory) and communication skills (cognitive-social processing theory) consistent with recommended guidelines for discussions about ACP in ADRD care.
46000786|NCT04659057|Drug|Nebulized dexmedetomidine|will receive nebulized dexmedetomidine (1 μg/kg diluted in 5 ml of saline 0.9%).
46000787|NCT04659057|Drug|Nebulized lidocaine and dexmedetomidine|will receive nebulized lidocaine 2% (0.5 mg/kg) and dexmedetomidine 0.5 μg/kg dexmedetomidine in 5 ml of saline 0.9%.
46000788|NCT04659057|Other|Placebo|will receive nebulized saline 0.9% (5 ml) as control group.
46000789|NCT04547153|Drug|5-fluorouracil|low dose
46000790|NCT04547153|Drug|Docetaxel|dose-sense
46000791|NCT04668261|Other|Advanced imaging investigation|MRI imaging
46000792|NCT04658745|Device|Intermittent theta burst stimulation|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients, by using a butterfly shape coil.
46087322|NCT05342870|Drug|Dexmedetomidine|Following a sequential allocation scheme, the dexmedetomidine dose for each patient was determined by the Dixon up-and-down method. The dexmedetomidine dose for the first patient was 0.5 µg/kg. The dose was then adjusted in 0.1 µg/kg increments for the following patients depending on the success of the previous patient's block. If a patient experienced tourniquet pain prior to T0 + 50 minutes the next patient received a higher dose. If a patient did not experience pain at T0 + 50 minutes of tourniquet time the dose for the following patient was decreased. Identical syringes containing the solution mix were prepared by the principal investigator and handed to the blinded anesthesiologist in the room. Stopping rules were set at 6 independent crossovers in the same direction (no pain to pain or pain to no pain), with a minimum number of 20 patients
46087323|NCT00657579|Drug|DE-104 ophthalmic solution, low concentration|
46087324|NCT00657579|Drug|DE-104 ophthalmic solution, medium concentration|
46087325|NCT00657579|Drug|DE-104 ophthalmic solution, high concentration|
46087326|NCT00657579|Drug|DE-104 vehicle|
45675955|NCT05139602|Biological|Lutikizumab|Subcutaneous Injection
45675956|NCT05139602|Drug|Placebo|Subcutaneous Injection
46000793|NCT04658745|Behavioral|Mirror Therapy|Participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
46000794|NCT04658745|Device|Sham intermittent theta burst stimulation|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients. However, a sham coil will be used, which is not associated with any stimulation effect on the brain.
46000795|NCT04658745|Behavioral|Sham mirror Therapy|In sham mirror therapy, the mirror will be covered. Participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to move the non-affected hand. The participants cannot receive mirror visual feedback of the paretic upper extremity movement during the therapy. Same as mirror therapy, the movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
46087327|NCT03730610|Behavioral|Exercise training|Subjects are required to exercise four times a week during six months. Exercise training consists of endurance training, resistance training and high-intensity interval training adjusted to subject's fitness level.
46000796|NCT00533741|Drug|Aluminum hydroxide|Adjuvant; administered with SARS-CoV vaccine.
46000797|NCT00533741|Drug|Placebo|Saline for injection.
46087328|NCT04160013|Behavioral|Discipline education|Discipline education using the Play Nicely program.
46000798|NCT00533741|Biological|SARS-CoV|Whole-virus vaccine, grown in certified Vero cells and doubly inactivated by treatment with formalin and ultraviolet light (UV). Supplied in liquid formulation in single dose vials with and without aluminum hydroxide as an adjuvant. Doses supplied without aluminum hydroxide will be 2.5, 5.0 and 10.0 mcg. Doses supplied with aluminum hydroxide adjuvant will be 2.5 and 5.0 mcg.
46000799|NCT04658511|Device|Ultrasound|On the spot, during the pre-op clinic visit, an ultrasound exam will be done by the PI trying to visualize the arcade of Struthers
46000800|NCT00533780|Procedure|Healing Touch|
46000801|NCT04668027|Diagnostic Test|impulse oscillation（IOS）|The patient is tested for the first IOS after the screening test, and performed the second IOS test immediately after the results of BPT or BDT. The patient takes seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calms breathing one minutes.
46000802|NCT04668027|Diagnostic Test|bronchial provocation test(BPT)|Patient needs to cooperate with the inhalation of acetylcholine stimulants with low to high concentrations, and operates in accordance with the standard nebulized administration procedure. Measure FEV1 after each inhalation and take the high value. The interval between the inhalation of two adjacent doses is 5 minutes, until the FEV1 decrease value is ≥20% of the FEV1 base value or the highest inhalation concentration. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and performs exhalation and inhalation with the greatest strength and fastest speed. After the examination,the patient should inhale the bronchodilator salbutamol sulfate (400ug).
46000803|NCT04668027|Diagnostic Test|bronchial dilation test(BDT)|The patient inhales the salbutamol sulfate (400ug). 15 minutes later, the pulmonary function tester is used for measurement. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and to exhale and breathe with the greatest strength and fastest speed. Inhale.
46087329|NCT04160013|Behavioral|Cavity Prevention|Cavity prevention using a 2 page handout.
46087330|NCT03542942|Other|treatment with EXIT-target volume|exclusion of the unaffected part of the uterus out of the treatment field
46087331|NCT05342792|Drug|PD-1 antibody|Tislelizumab：200 mg per dose, intravenous infusion over 30 minutes, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
46087332|NCT05342792|Drug|Capecitabine|Capecitabine : 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
45835421|NCT02069730|Drug|NOTCH Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with NOTCH Inhibitor"
46087333|NCT05300438|Drug|TSN084|TSN084 administered orally as a tablet.
46087334|NCT00614042|Drug|TRU-016 (anti-CD37 protein therapeutic)|TRU-016 administered via IV infusion weekly for 8 weeks and then monthly
46087335|NCT03655886|Procedure|radical prostatectomy|can be performed either open, laparoscopic or robot-assisted, which is chosen by the discretion and expertise of the performing surgeon
46087336|NCT03655886|Radiation|Whole pelvis radiotherapy|radiation of prostate bed and pelvis
46087337|NCT04159701|Drug|LY3454738|Administered IV
46087338|NCT04159701|Drug|Placebo|Administered IV
46087339|NCT02632617|Other|Computed tomographic angiography|Preoperative examination is needed in patients with valvular disease. The invasive coronary angiography is used for patients in ICA group, while the computed tomographic angiography is used as a gatekeeper and invasive coronary angiography is selectively used for patients in CTA group.
46087340|NCT05260424|Other|non-invasive ventilation|Babies who will have or won't have non-invasive ventilation failure in the first 72 hoursof life, will be compared.
45835422|NCT02069730|Drug|MEK or PI3K Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with MEK or PI3K Inhibitor"
45835423|NCT02068092|Drug|Hydroxytyrosol|
45835424|NCT02065830|Device|EKSO|"The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.~The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training."
46087341|NCT05260190|Device|tSMS|30-minute tSMS application in a comfortable seated position. The material used in the stimulation was a MAGxx1.1 helmet (Neurek Spain Toledo), with a Neodymium (NdFeB) magnet of 60mm diameter and 30mm height with Nickel (Ni-Cu-Ni) coating MAG60r+ (Neurek Spain, Toledo), placed over the primary motor cortex (M1) of the left cerebral hemisphere.
46087342|NCT05260190|Device|Sham tSMS|30-minute sham tSMS application in a comfortable seated position. The device used in sham stimulation had the same weight and shape as the real stimulation helmet.
46087343|NCT00657735|Device|H-Coil deep TMS|20 daily deep rTMS treatments
46087344|NCT00657735|Device|sham|inactive treatment
46000804|NCT00533819|Other|6 months of healthy physical activity|half an hour of healthy physical activity including 20 minutes aerobic, 5 minutes warm up and cool down, 4 days a week
46087345|NCT02811536|Device|optical coherence tomography angiography|Imaging with optical coherence tomography angiography
46000805|NCT04658589|Procedure|Laparoscopic versus open distal gastrectomy|Laparoscopic versus open distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer
46000806|NCT04545671|Other|trifocal lens|not applicable as patients are already implanted with the trifocal lens
46000807|NCT04658394|Other|Reminiscence therapy|Intervention group will receive two RT sessions per week for 13 weeks. RT sessions will last approximately 50 minutes and will be developed according to the following structure: · Welcome to the patient and reality orientation therapy (7 minutes) · Conducting the main activity of reminiscence (40 minutes) · Closure, thank you for the participation and farewell until the next session (3 minutes) Reminiscence therapy sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of RT. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of the Past and the Present.
46000808|NCT04667988|Diagnostic Test|JAK expression|JAK2 assessment in blood by PCR
46000809|NCT04536116|Device|Virtual Reality headset|MRI simulation with a Virtual Reality headset
46000810|NCT04668183|Procedure|Pudendal nerve block group|A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.
46000811|NCT04668183|Procedure|Dorsal penile nerve block group|Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis.
45675957|NCT05133440|Drug|Radium dichloride|Two cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks followed 2-3 weeks later by SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT fractions can be administered every day or every other day per institutional practice. An additional 4 cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks will then be administered, resuming 2-3 weeks after completion of the final fraction of SBRT.
46000812|NCT04521998|Device|electroacupuncture|Electroacupuncture used to reduce the inflammation was proved previously.
46000813|NCT04521998|Device|TENS|Patients who unlike needles would like to choose TENS as treatment for pain relief.
46000814|NCT04658706|Other|A supervised exercise program|is a 12-week exercise program supervised by specially trained instructors combining moderate to high intensity aerobic and strength exercises (three 1 hour sessions a week).
46087346|NCT04159311|Other|Osteopathy|testing osteopathy Vs Treating osteopathy
46087347|NCT04159389|Other|Mental visualization|Instruction in mental visualization by theoretical lessons and support of practice by audio guide and session of experience sharing.
46087348|NCT00657813|Drug|MNI-330 as a brain SPECT tracer of Beta-Amyloid|Each subject will receive a bolus injection targeted to be 5 miCi and not to exceed 5.5 mCi of MNI-330. Following injection serial dynamic imaging will be obtained over 8 hrs.
45675958|NCT05133440|Diagnostic Test|PET Scan|For both arms, the NaF PET will be used to identify discrete osseous lesions which will become index lesions for the study. The simulation scan (either baseline or after 2 cycles of Ra-223) will be used to generate a suitable SBRT radiation plan, per standard practice. If the index lesions are no longer visible after two cycles of Ra-223, we still intend to consolidate the area with radiation. If the lesions are initially radio-occult on the CT and only visible on the NaF PET, we will fuse the pre-treatment NaF PET/CT to the simulation CT after 2 cycles of Ra-223 to delineate the SBRT treatment volumes.
45675959|NCT05133180|Drug|Oxervate|Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID).
45675960|NCT05133180|Other|Vehicle|Vehicle will be instilled with the same scheme of the test product
45835425|NCT02064114|Procedure|Intervention group|Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
45835426|NCT02064114|Procedure|control group|Followed for a period of 3,6 and 12 months after the procedure.
45835427|NCT04756830|Biological|Adsorbed COVID-19 (inactivated) Vaccine|Participants will receive two doses with 14-days interval of adsorbed COVID-19 (inactivated) vaccine
46000815|NCT04658706|Other|exercise prescription|they will receive a prescription concerning healthy lifestyles and a personalized exercise plan
46000816|NCT04520594|Other|Resistant Starch|7.5 g resistant starch/m2 oral consumption
46000817|NCT04520594|Other|Placebo|Placebo oral consumption of food-grade cornstarch
46000818|NCT04520555|Device|Laryngeal mask airway|LMA Flexible is a supraglottic airway device, which can be moved out of the surgical field without displacement of the cuff, or loss of seal for the anesthetist
46000819|NCT04520555|Device|Endotracheal tube|Endotracheal tube is a plain tube, which is most commonly used in general anesthesia.
46000820|NCT04658550|Other|Remote Behaviour Modification Program|The standard of care behaviour modification program for weight loss will be offered virtually due to the COVID-19 pandemic (prospective).
46000821|NCT04658550|Other|In Person Behaviour Modification Program|The standard of care behaviour modification program for weight loss was offered in person prior to the COVID-19 pandemic (retrospective).
46000822|NCT00533858|Drug|lacidipine (4 mg) or losartan (50 mg)|lacidipine (4 mg) or losartan (50 mg), both given once daily at the same hour in the morning (approximately at 8 AM) for 12 weeks
46087349|NCT04159233|Behavioral|Brief Behavioral Therapy for Insomnia (BBTI)|Participants will receive evidence-based 'Brief Behavioral Therapy for Insomnia' (BBTI), tailored to meet the needs of former football players. BBTi is a brief, efficacious treatment that focuses on modifying behaviors, rather than cognitive domains. The treatment emphasizes education, motivational tools, and specific behavioral recommendations (e.g., restricting time in bed) and will be administered through weekly phone calls with a trained sleep interventionist over 4-weeks.
46087350|NCT00657891|Drug|Omalizumab|0.016 mg/kg/IgE(iU/ml)/4 wks, Subcutaneously
46000823|NCT04658355|Other|Chlorhexidine Gluconate|4% Chlorhexidine Gluconate vaginal cleansing solution as a surgical preparation.
46087351|NCT00657891|Drug|Placebo|Placebo Injection
46000824|NCT04658355|Other|Povidone-iodine|10% povidone-iodine vaginal cleansing solution as a surgical preparation.
46000825|NCT04498442|Behavioral|Simha Kriya|Simha-Kriya involves deep breathing exercises and meditation. It is the practice of extending the breath, expanding our lung capacity and mental concentration and energizing the body. Simha Kriya, when practiced intentionally will unite the mental, physical, and spiritual body through the breath. For the purpose of this study we advocate practice of Simha Kriya at least once a day.
46000826|NCT04498442|Behavioral|Reading a Book|Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. Reading a book is often inculcated into mindfulness research due to it's impact on the personality and attitude. The simple act of reading a book can have a significant impact on their attitudes and can help them cope better with stress. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely for 15 minutes each day. Reading a book could potentially be substituted with sitting idle for 15 minutes if participants wishes to.
46000827|NCT04667598|Drug|Modified Wenxin Decoction|Mainly including make aconite , astragalus ， Cassia twig , dried ginger , red peony root , Chuanxiong , Codonopsis codonopsis , Ophiopogon ophiopogon , Schisandra , Stamen , Asarum , licorice.
46000828|NCT04497974|Other|Dietary intervention|Varying the exposure to sweetness via diet manipulation.
46000829|NCT04667676|Device|acupoint TENS|TENS was applied bilaterally on acupoint Ex-B1, 4Hz frequency, and 200 μs pulse width and intensity was set at the best highest tolerable intensity by the patient sensitivity without a sensation of discomfort for 45 minutes, three times/week for four weeks
46000830|NCT00533936|Biological|trastuzumab|
46000831|NCT00533936|Drug|cyclophosphamide|
46000832|NCT00533936|Drug|doxorubicin hydrochloride|
46000833|NCT00533936|Drug|fluorouracil|
46000834|NCT00533936|Drug|paclitaxel|
46000835|NCT00533936|Procedure|adjuvant therapy|
46000836|NCT00533936|Procedure|conventional surgery|
46000837|NCT00533936|Procedure|neoadjuvant therapy|
46000838|NCT04686539|Drug|CBD|CBD oil not containing THC, to be administered sub-lingual.
46000839|NCT04686539|Drug|Placebo|Placebo Oil
46000840|NCT00557544|Drug|metoclopramide|metoclopramide 0,15 mg/kg
46000841|NCT00557544|Drug|placebo|placebo per os
46000842|NCT00557544|Drug|ketoprofen|ketoprofen 1 mg/Kg
46000843|NCT04474808|Other|L-Arginin containing foot cream|The participants apply one foot (randomized assignment) with the study cream twice a day (morning and evening) over a period of six weeks.
46000844|NCT04474808|Other|Urea-containing foot cream|The participants apply one foot (randomized assignment) with the control cream twice a day (morning and evening) over a period of six weeks.
46000845|NCT04667871|Procedure|cataract surgery|Eyes for cataract surgery
46000846|NCT04667832|Diagnostic Test|selective coronary artery angiography|Radial approach, invasive selective coronary angiography with selective contrast injection and filming in coronary arteries
46000847|NCT04667910|Drug|601 1.25mg|Solution for injection (intravitreal use)
46087352|NCT05221112|Other|diagonal pattern training|patients will receive proprioceptive neuromuscular facilitation technique's chopping and lifting pattern to create 10 movements.
46087353|NCT05221112|Other|single plane training|patients will receive single plane training of proprioceptive neuromuscular facilitation in control group
46087354|NCT02632773|Behavioral|Responsive Intervention|Mothers assigned to the responsive experimental condition will learn how to talk about what is in their child's focus of attention and to respond to all child communicative attempts by either: (a) assigning a presumed meaning to preverbal communication or vocalizations or (b) by repeating the child's verbal communication and adding words.
46000848|NCT04667910|Drug|Ranibizuman 0.5 mg|Solution for injection (intravitreal use)
46000849|NCT04404608|Diagnostic Test|Complete blood picture, bone marrow aspiration cytology|none except the regular routine investigations in such cases
46087355|NCT02632773|Behavioral|Directive Intervention|Mothers assigned to the directive experimental condition will learn how to: (a) set up a prompting trial through management of toys or by responding to a child request, (b) recruit the child's attention, (c) provide a discriminative stimulus (cue), (d) wait for the child's response for 5 seconds, (e) reinforce the child for correct production of the target or provide additional prompts after incorrect productions. Parents will perform one prompting trial per minute for a total of 20 trials per parent session.
46087356|NCT04905212|Drug|Telitacicept 160mg|Subcutaneous injection Telitacicept 160mg. The injection site can be at the thigh, abdomen, or upper arm.
46000850|NCT04668105|Other|High volume nordic hamstring exercise|To perform Nordic Hamstring Curls, the person will kneel on a pad (for knee comfort) and lower under control, his ankles must be stabilized and kept in a place with the help of a partner, but can also use a moveable object or a loaded barbell can also be used to achieve the stability. The person must then extend his hamstrings in order to lean forward, he should lean forward from the knee and not from the hip. The movement must be kept controlled and slow. The person should go as forward/low as possible but without the help of hands or arms. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and then repeat the procedure again.Group 1 will do the Nordic hamstring exercise with protocol 3 repetitions × 3sets× 3 times for 4 weeks.
46087357|NCT04905212|Drug|Telitacicept 240mg|Subcutaneous injection Telitacicept 240mg. The injection site can be at the thigh, abdomen, or upper arm.
46087358|NCT04905212|Drug|Placebo|Subcutaneous injection placebo. The injection site can be at the thigh, abdomen, or upper arm.
46087359|NCT05171738|Device|skeletally anchored distal jet|used from day one and activated every month
46000851|NCT04668105|Other|Low volume nordic hamstring exercise|To perform Nordic Hamstring Curls, the person will kneel on a pad (for knee comfort) and lower under control, his ankles must be stabilized and kept in a place with the help of a partner, but can also use a moveable object or a loaded barbell can also be used to achieve the stability. The person must then extend his hamstrings in order to lean forward, he should lean forward from the knee and not from the hip. The movement must be kept controlled and slow. The person should go as forward/low as possible but without the help of hands or arms. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and then repeat the procedure again. Group 2 will do the Nordic hamstring exercise with protocol 3 repetitions × 3 sets × 1 times for 4 weeks.
46087360|NCT02632695|Device|FOOTFIT|Individuals with venous leg ulcers will be instructed on physical activity movements for their lower legs to be performed over six weeks while wearing a foot based activity monitor (accelerometer) that will send them motivational messages and progress reports. For those in the FOOTFIT Plus group, individuals will have the option to communicate with their wound care provider via text messages, emails or phone calls.
46000852|NCT04333043|Diagnostic Test|audiological test, cognitive questionnaires|administration of cognitive and quality of life questionnaires and audiological test
46000853|NCT04667286|Procedure|Prone Position (PP)|Prone the patients on oxygen for at least 10 hrs a day
46000854|NCT04658238|Other|Ocular microbiome|Taxonomical and functional characterization of the ocular microbiome
46000855|NCT04658238|Other|Ocular immune system|Functional characterization of the tear fluid proteome, histology of conjunctival tissue and molecular assays
46000856|NCT04327973|Biological|ATB200|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
46000857|NCT04327973|Drug|AT2221|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
46000858|NCT04657965|Drug|LMP1 CAR T-cells|Each subject receive LMP1 CAR T-cells by intravenous infusion
46000859|NCT00534014|Dietary Supplement|Vitamin C|Arm A = 0 mg Vitamin C, Arm B = 250 mg Vitamin C, Arm C = 500 mg Vitamin C, Arm D = 1000 mg Vitamin C
46000860|NCT04658004|Drug|NKG2D CAR T-cells|Each subject receive NKG2D CAR T-cells by intravenous infusion
46000861|NCT00534053|Other|Mailed Educational Reminder|1 page educational reminder that reminds the patient to return their FOBT cards back to the VA laboratory. In addition, it also contains reasons why colon cancer screening is important.
46087361|NCT05162300|Combination Product|Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug)|Same-Day combination of VI Peel applied to the full face, followed by Botox injection per label to the face.
46087362|NCT04159077|Drug|Tamsulosin Hydrochloride|"Tamsulosin HCL is an alpha blocker. It relaxes the muscles in the prostate and bladder neck, making easier to urinate. The dosage used will be 0.4 mg (administered once daily)~Other names: Flomax"
46087363|NCT04159077|Drug|Placebos|Half of the patients will be assigned to receive placebo tablets in the same manner as the active intervention. These tablets will have no effect.
46087364|NCT00612482|Other|drug prevention curriculum|"Participants in the experimental arm of the study will receive the 5-lesson, science-based drug prevention curriculum in their science classes."
46087365|NCT04158999|Device|milk analyzer|Human Milk Sample
46087366|NCT04158999|Behavioral|Mother's nutrition values|evaluation of nutritional elements of maternal onset with Bebis Program
46087367|NCT02692820|Dietary Supplement|Probiotic|The probiotic capsule contains the two probiotics Lactobacillus rhamnosus GR-1 (GR-1) and Lactobacillus reuteri RC-14 (RC-14). The product contains freeze-dried bacteria and excipients in a gelatin capsule;
46000862|NCT04658043|Other|Intervention on socioemotional functioning|"A culturally sensitive intervention based on the train the trainer (or coach the coach) model for enhancing the social adaptive functioning of young children (aged 3-6) with ASD in China, via providing training for parents"
46000863|NCT04304066|Other|18F-WL12 PET or 68Ga-WL12 PET|WL12, labeled with PET radio-nuclide ( Ga-68 or F-18)will be used as a molecular imaging tracer for PET/CT scanning
46000864|NCT04657848|Procedure|proximal gastrectomy combined with Cheng's Giraffe reconstruction|proximal gastrectomy combined with gastric tube interposition esophagogastrostomy with reconstruction of His angle and fundus (Cheng's Giraffe reconstruction)
46087368|NCT02692820|Other|Placebo Comparator|The placebo contains excipients alone in a gelatin capsule
46087369|NCT02632539|Procedure|Manual air-impingement operation|A method which we invented to clear subglottic secretion
46087370|NCT02632539|Procedure|subglottic secretion drainage|The conventional method which we use subglottic secretion drainage to clear subglottic secretion
46087371|NCT05240378|Other|Surgery|Surgery for cancer as per the stage of the disease and protocol
46087372|NCT00658125|Procedure|Bilateral fornix DBS implantation,|Fornix DBS for Alzheimer Disease
46087373|NCT05138276|Other|Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of NEC
46087374|NCT05138276|Drug|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
46087375|NCT00658203|Device|New Living CHF|PEA CRT optimization
46087376|NCT00658203|Device|New Living CHF|Standard optimized CRT.
46087377|NCT00658281|Procedure|CBCT Scan|Cone Beam Computed Tomography (CBCT) scan performed once a week.
46000865|NCT04296110|Behavioral|Biofeedback|They will also be taught how to use the biofeedback app and Inner Balance device. Additionally, they will also be educated on the principles of biofeedback and its benefits and taught how to maximize HRV by using self-regulation breathing techniques.They will be given an Inner Balance device, which is an ear sensor that connects to an apple device that measures heart rate variability (HRV) and gives them access to an app that is designed to help them improve their HRV. They will be asked to practice breathing at their resonance frequency using the Inner Balance device daily for 5-15 mins for the duration of the 12-week intervention. Patients and the research coordinator will have access to all of their sessions and results. The research coordinator will monitor compliance via the Heartcloud associated with their device and encourage adherence throughout the intervention.
46000866|NCT04296110|Other|Music Relaxation Therapy|We will determine what genre of music is most relaxing to them and ask them to listen to this type of music using the spotify app for 5-15 mins a day for 12 weeks. If they do not have access to a device that they can listen to spotify on, an ipod will be provided. They will be asked to complete a 2-question survey via Redcap daily that asks them if they have listened to the designated music that day and for how long.
46000867|NCT04657614|Other|Neutral Alignment|Alignment that is a neutral replicate of the participants prescribed prosthesis.
46000868|NCT04657614|Other|Anterior Alignment|Alignment that is anterior displaced pylon.
46000869|NCT04657614|Other|Posterior Alignment|Alignment that is posteriorly displaced pylon.
46000870|NCT00534170|Dietary Supplement|Probiotic (Yakult)|It is a dietary supplement ,65 ml containing 15 billion lactobacillus
46000871|NCT04244513|Device|Deep brain stimulation|the HD-DBS arm will be routinely activated after surgery and then stimulated for 6 months(6 months stimulation). The HD-shamDBS arm will be re-launched 3 months after surgery, continued stimulation for 3 months(3 months stimulation), and then entered the open study.
46000872|NCT04657536|Device|high frequency fulguration equipment|All subjects will be carried out with 3 standard protocol TRF treatments to the vulvovaginal tissue using the high frequency fulguration equipment (Shenzhen Peninsula Medical co., Ltd) at 10-day to 15-day intervals. Radiofrequency energy was applied to the vaginal canal through a specialized probe combining monopolar and bipolar treatment modes. Monopolar treatment mode is for 15 minutes. Aim the three indication points A, B and C on the probe to the direction of 12 o'clock in turn. Each area should be treated for about 5 minutes. Rotate the probe clockwise when changing the area for treatment.Bipolar treatment mode is for 10 minutes. Firstly, indication point A is aimed to 12 o'clock for 5-minutes treatment and then the probe is rotated 90°clockwise for another 5-minutes treatment. The power setting will be 35-40w, and the target temperature setting will be 40 to 45℃, titrated to subject tolerance.
46000873|NCT04657536|Drug|promestriene vaginal soft capsules|Promestriene vaginal soft capsules（Zhejiang Anbao Pharmaceutical Co. LTD）will be used 10mg once a day for continuous 20 days.
46000874|NCT04236206|Behavioral|Mobile Phone Short Message Service|"SMS content will be adopted from the validated Arabic national and international diabetes educational materials (Centers for Disease Control (CDC), 2018; Diabetes Australia, 2004; Diabetes Queensland, 2012; Utah Diabetes Control Program, 2005).~The mobile phone SMSs will be pre-tested for clarity on a sample of 10 patients similar to the study population and their comments on the SMSs wording will be used to modify them to ensure acceptance.~The SMS will be sent to participants using the internet, open-source software for bulk messages and a local telephone network provider.~Patients will be encouraged to send messages/call the researcher for any queries encountered."
46087378|NCT00658281|Procedure|OBI KV Imaging|On Board Imager kilovoltage (OBI KV) Imaging performed once a week.
46087379|NCT05025410|Drug|Remimazolam|Loading for anesthesia induction: Remimazolam 6 mg/kg/h until loss of consciousness Continuous infusion for anesthesia maintenance: Remimazolam 1-2 mg/kg/h under the Bispectral index monitoring
46087380|NCT05239832|Biological|Recombinant SARS-CoV-2 Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
46087381|NCT00658437|Drug|CY-503|solution for subcutaneous injection, 350 ng twice weekly
46087382|NCT02690480|Drug|PD-0332991 (Palbociclib)|"Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first"
46087383|NCT02690480|Drug|Fulvestrant|"Fulvestrant 500mg, two 5ml intramuscular injections (one in each buttock), on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days)~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first"
46087384|NCT02690480|Drug|Placebo|"Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs firs"
45676751|NCT02173379|Device|XIENCE|"Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm. The 3.25 mm is only available for XIENCE Xpedition~Stent lengths: 8, 12, 15, 18, 23, and 28 mm~For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
46000875|NCT04657653|Procedure|core decompression|:The procedure was performed under general anesthesia with the aid of image intensifier. All patients were positioned in supine position on a fracture table. The core decompression was performed using the direct lateral approach with 2 cm skin incision. A fluoroscope guided large single drill with 8 mm diameter over a guide wire was used to remove the necrotic tissues from the femur head through the lateral cortex distal to trochanteric tubercle. After the removal of the core necrotic bone, the track was filled with 5 ml synthetic bone paste substitute (tricalcium phosphate) and an intraoperative fluoroscope was used to confirm the adequacy of the decompression and grafting.
45676752|NCT01823679|Drug|Capecitabine|Given orally
46000876|NCT04686617|Diagnostic Test|Mechanical Vibration|Oral B HummingBird device (Procter&Gamble, USA) with a modified tip was used for the application of vibration. The tip was positioned mid-buccally of teeth to perform buccally directed vibration. HummingBird is prescribed maximum period 0.00885s corresponding to 6800RPM or 113Hz of the motor. The vibration procedure was applied for 10mins/day during the period of 12 weeks.
46000877|NCT04657419|Other|survey|"Self-questionnaires will be completed by the participants :~General health and mental health~Fatigue~Burn-Out~Sleepiness~Sleep hygiene~Symptoms of COVID"
46000878|NCT04186676|Other|MINOCA registry|Prevalence, demographics, clinical profile, anginal status, presence of cardiovascular risk factors, management and outcomes
46000879|NCT04186676|Diagnostic Test|CCTA Phenotypes|"Complete normal coronary arteries~Diffuse non-obstructive coronary artery disease~Non-obstructive high-risk plaques~Myocardial bridges"
46000880|NCT00556569|Other|CHAM JAM|"CHAM JAM (previously known as Moving Smart (MS) program) is a daily, 10-minute classroom-based physical activity program led by teachers that integrates academic objectives with physical activity"
46000881|NCT04184804|Behavioral|Behavioral Intervention|"The intervention package will be consisted of:~Introduction of organic fruits and vegetables (by replacing the conventional ones) in school lunch menus~Signs in school areas about organic fruits and vegetables~Workshops and interactive games for children~Seminars for parents"
46000882|NCT00556608|Device|Sinovial® (syringe containing sodium hyaluronate solution)|2 mL 0.8% sodium hyaluronate (16 mg) solution. 3 intra-articular injections once-a-week.
46000883|NCT00556608|Device|Synvisc® ( syringe containing Hylan G-F 20 solution)|2 mL 0.8% Hylan G-F 20 (16 mg) solution. 3 intra-articular injections once-a-week.
46087385|NCT04158609|Diagnostic Test|Doppler flow indices assessment|Doppler flow indices, UA-PI, MCA-PI and CPR values, assessment performed prior to induction of labor
46087386|NCT02535507|Drug|Pyrotinib|Drug: Pyrotinib pyrotinib, single agent, 400mg p.o once daily until disease progressed
46087387|NCT04158843|Procedure|Radical resection|Radical resection is performed, and the cutting edge is negative.
46087388|NCT04158843|Radiation|Radical radiotherapy|Radical local radiotherapy is feasible (cumulative radiotherapy dose is greater than or equal to 50Gy).
46087389|NCT04158843|Other|Palliative treatment|Including palliative internal fixation, radiotherapy, systemic chemotherapy, endocrine therapy or targeted therapy
46087390|NCT05230862|Dietary Supplement|Ladder Supplement|Caffeine 200mg L-Theanine 200mg L-Citrulline 6g Creatine 5g Beta-Alanine 1.6g Phosphatidylserine 100mg
46087391|NCT05230862|Dietary Supplement|Placebo|Placebo
46087392|NCT00658593|Drug|capecitabine|
46087393|NCT00658593|Drug|gemcitabine hydrochloride|
46087394|NCT00658593|Procedure|quality-of-life assessment|
46087395|NCT05224700|Behavioral|JAPI|Each child will play on a tablet with headphones during 20 sessions lasting 30 minutes each, 2 times per week. All the activities are games with the following structure: an introduction with instructions and protagonist selection, followed by a practice exercise to ensure that the children understand what they have to do (the exercise is repeated until the child performs it correctly), and, finally, the activity itself (4 different activities with 5 tries each). The first 10 sessions jointly stimulate working memory and emotion knowledge (4 activities focused on each skill per session), while the 10 remaining sessions stimulate inhibitory control and the selection of prosocial behaviours. In the inhibitory control activities, they must suppress automatic stimuli and processes; in the emotion recognition activities, they must identify basic emotions; and in the selection of prosocial behaviours, they must choose an option to deal with a social problem.
46087396|NCT05224700|Behavioral|Painting group|Each child will play on a tablet with headphones during 20 sessions lasting 30 minutes each, 2 times per week. They will play a tablet-based painting game that involves no cognitive, emotional, or social competence stimulation
46087397|NCT00658749|Drug|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
46087398|NCT00658749|Drug|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
46087399|NCT05220800|Drug|Iron(III)isomaltoside|Weight-dependent dosage of iron(III)isomaltoside. See group descriptions
46000884|NCT00534287|Drug|meropenem|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem. Dosage is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
46000885|NCT00534287|Drug|meropenem, moxifloxacin|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem plus 1 x 400 mg intravenous moxifloxacin. Dosage of meropenem is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
46000886|NCT00556647|Procedure|fast track diagnosis|fast-track diagnosis, PET-CT, bronchoscopy
46000887|NCT00556647|Procedure|conventional diagnosis|out-patient diagnosis
46000888|NCT04667559|Device|Conformis iTotal Identity Knee Replacement System|The iTotal® Identity KRS is a tri-compartmental semi-constrained knee prosthesis composed of three components: a Femoral Component, a Tibial Component, and a Patellar Component.Using patient imaging, a patient-specific implant is designed that best meets the geometric and anatomic requirements of the specific patient. The treatment allows for the placement of a cemented metallic device designed from the patient's natural bone geometry. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation.
46087400|NCT05220800|Drug|Placebo|Isoton saline infusion
46087401|NCT00658827|Other|No intervention|This is an observational study. Patients receiving infliximab or anti-TNF as per the prescribing information will be observed.
46087402|NCT04962542|Other|ventilation|low volume positive pressure ventilation is better than continuous positive airway pressure and passive deflation on arterial oxygenation and PPD after CPB in pediatrics undergoing cardiac surgeries for non-cyanotic congenital heart defects.
45676753|NCT04414293|Radiation|Lung Low Dose Radiation|The administration of low-dose lung radiation produces anti-inflammatory effects that will decrease the pulmonary inflammatory response.
45676754|NCT01823289|Drug|Itraconazole|Itraconazole 200 milligram (mg) intravenous injection will be given twice daily for first 2 days, 200 mg once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily will be given for 2 to 4 weeks.
45457877|NCT02312440|Drug|tranexamic acid|"The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.~60 Milliliters（ml） by irrigation for 3 minutes before wound closure."
45676755|NCT01822899|Drug|Umeclidinium bromide/Vilanterol|Dry white powder of UMEC 62.5 mcg per blister and VI 25 mcg per blister as NDPI with 30 doses (2 strips with 30 blisters per strip).
46087403|NCT00658905|Drug|rhBSSL|0.15 g/L rhBSSL added to infant formula; one week treatment
46000889|NCT00534326|Procedure|Standard Reaming|Femoral reaming using standard reaming techniques of multiple reamers
46000890|NCT00534326|Procedure|Reaming/Irrigating/Aspirating|Reaming using the Reamer/Irrigator/Aspirating
46087404|NCT00658905|Drug|Placebo|One week treatment
46087405|NCT03466112|Other|endurance training|endurance training with stationary bicycles
46087406|NCT03466112|Other|balance and tone program|flexibility, core strength, balance, relaxation
45835428|NCT02063022|Drug|Standard treatment (as per protocol ISG SSG III)|Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide (450mg/m2) given every 3 weeks Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Dactinomycin (1.5mg/m2), Doxorubicin (320mg/m2), Ifosfamide (27g/m2), Cyclophosphamide (8.8g/m2), Etoposide (1.5g/m2) and peripheral Cells Steam Transplant after Busulfan and Melphalan treatment Maintenance treatment (37 week) for good responder: Vincristine (18mg/m2), Dactinomycin (6mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Cyclosphosphamide(6g/m2), Etoposide (1.8 g/m2)
46000891|NCT04686656|Other|nasal oxygen|Nasal cannula will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with nasal cannula.
46000892|NCT04686656|Other|buccal oxygen|Ring-adair-elwyn (RAE) tube will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with RAE tube.
46000893|NCT04168502|Drug|Glasdegib|After randomization patients in both arms will be randomized to maintenance with glasdegib vs clinical observation
46000894|NCT04168502|Drug|Gemtuzumab Ozogamicin|Both arms, before randomization, will receive induction and consolidation with Gemtuzumab ozogamicin, Daunorubicin and Cytarabine
46087407|NCT02632461|Behavioral|Podcasts|Participants will receive twice weekly podcasts that will cover topics related to weight loss.
46087408|NCT02632461|Behavioral|Mobile Diet Application|Participants will use a mobile application on their smartphone to track their diet.
46087409|NCT02632461|Behavioral|Bite Counter|Participants will use a wrist-worn Bite Counter to track the number of bites in their diet per day.
46087410|NCT00880269|Drug|Panobinostat/LBH589|
46087411|NCT02632383|Device|Young with Diabetes - app|"The mHealth app Young with Diabetes containes 8 main functions:~Contact your health care provider (ask questions, set the agenda for the next clinical visit)~My Department (hotline numbers, videos about the new adult department, pictures of my diabetes team)~Chatroom~Counting Carbohydrates (information and tips about carbs, introduction to apps to count carbs, quiz)~Knowledge-section (Text, links, tips and videos (animations and videoselfies) about What is diabetes?, Alcohol etc.)~Tips packages (Receive a tip about alcohol, drivers license etc.)~To parents (Text, links, tips and videoselfies to parents about what it is like to be young with diabetes and what they can do to support)~Reminder"
46087412|NCT02632149|Device|PINS Vagus Nerve Stimulator|
46087413|NCT00659217|Biological|mesenchymal stem cell|Autologous MSC transplantation
46087414|NCT04158531|Device|ECoG sensing and stimulation|Implant electrodes and a sensing+stimulation device, and use this for suppression of seizure activity
45457878|NCT05268445|Procedure|Chemical and Mechanical Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis|Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis
45457879|NCT02307994|Drug|75IU uFSH|
46087415|NCT00880191|Drug|dexamethasone|Given orally
46087416|NCT00880191|Drug|gabapentin|Given orally
46087417|NCT00880191|Other|placebo|Given orally
46087418|NCT04032015|Device|TMS|Device used to administer electromagnetic fields to the brain to alter connectivity patterns
46000895|NCT04667169|Procedure|Haemorrhoidal Artery Ligation|Post-operatively, all subjects were given tablet Paracetamol 1 gm six hourly and Capsule Celecoxib 200 mg 12 hourly as pain control for five days. They were given Syrup Lactulose 15 cc 12 hourly for one week to prevent constipation. Subjects were discharged on the same day or one day after surgery. All patients were assessed in the clinic by a nurse/medical officer blinded to the type of procedure performed on post-operative 24 hours, one week and six weeks.
46000896|NCT04667169|Procedure|Laser Haemorrhoidoplasty|Post-operatively, all subjects were given tablet Paracetamol 1 gm six hourly and Capsule Celecoxib 200 mg 12 hourly as pain control for five days. They were given Syrup Lactulose 15 cc 12 hourly for one week to prevent constipation. Subjects were discharged on the same day or one day after surgery. All patients were assessed in the clinic by a nurse/medical officer blinded to the type of procedure performed on post-operative 24 hours, one week and six weeks.
46087419|NCT00659451|Drug|Losartan|tablets; 50, 100 mg; od; 12 months
46000897|NCT04666896|Other|Tailored home-based exercise therapy|exercises were divided into four types: 1) shrug exercises; 2) external rotation exercises; 3) bench slides; and 4) wall slides.
46000898|NCT04666896|Other|Standard home-based exercise therapy|The exercise program consisted of 4 types of exercises for training 1) balance and proprioception; 2) isometric strength; 3) rotator cuff muscles; and 4) open chain elevation
46000899|NCT04166396|Dietary Supplement|Resveratrol|500 mg resveratrol, BID
45675961|NCT05122767|Drug|Dolutegravir|"Groups 1a/1b: Participants will take the FDA-approved weight-based DTG once daily + either TDF/FTC, TDF/3TC, ABC/3TC or AZT/3TC x 4 weeks. During HP treatment and for two weeks afterward, DTG dose will be increased to twice daily.~Participants will continue with the NRTI regimen they have previously tolerated, except where their age and weight allow them to transition from either AZT or ABC to TDF, as per South African National ART Guidelines. HLA-B*5701 screening will therefore not be performed, as children will be currently taking and tolerating an ABC-containing regimen at enrolment. If any clinically suspected hypersensitivity reaction to ABC is suspected by history, ABC will not be continued.~Groups 2a/2b: Participants will take weight-based DTG dosing twice or once daily, depending on the results of the modelled data for the Group 1a (for Group 2a) and/or Group 1b (for Group 2b) participants in the interim analysis."
45675962|NCT05122767|Drug|3HP|3HP Dosing is by Age and Weight Children 2-15 years of age: 10-15kg (P 300mg, H 300mg); 16-23kg (P 450mg, H 500mg); 24-30kg (P 600mg, H 600mg); 31-34kg (P 750mg, H 700mg). Children 15-17 years, >=30kg (P 900mg, H 900mg)
46000900|NCT04166396|Dietary Supplement|NR|500 mg NR BID
46000901|NCT04166396|Dietary Supplement|Placebo|Placebo
46000902|NCT04666935|Other|The Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program|Sport Injury Prevention Program.
46000903|NCT04666935|Other|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
46000904|NCT00534443|Procedure|Endoscopy of upper GI tract|"Upper GI endoscopy, one time on diagnosis and a second time 15 days after the end of the treatment. Gastric juice will be aspirated immediately after the entrance of the endoscope into the gastric lumen. Four biopsy specimens will be obtained from adjacent areas of the gastric antrum. Each biopsy will be used for in vitro culture. Blood will be sampled from one antecubital vein under aseptic conditions.~Each patient will be given antisecretory treatment and - if necessary- eradication treatment of H. pylori according to international guidelines."
45675963|NCT05122286|Procedure|Bailout angioplasty|Use balloons or stents for bailout angioplasty
45675964|NCT05122286|Procedure|Standard therapy|Stop the endovascular recanalization procedure or to perform further recanalization attempts using stent-retrievers and/or aspiration catheters
46000905|NCT04667091|Other|Physiotherapy|"Treatment will be given in 3 sessions per week for 6 weeks with home exercise program and participants will be provided with exercises sheets to remember the exercises.~The selected outcome measure will be taken on baseline (initial visit) and 6th week (post intervention)"
46087420|NCT00659451|Drug|Amlodipine|tablets; 5, 10 mg; od; 12 months
45675965|NCT05206357|Drug|Epcoritamab|Subcutaneous Injection (SC)
45675966|NCT05120284|Drug|Dichloroacetate (DCA)|"Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr."
45675967|NCT05120284|Genetic|Genotype|Participants will be genotyped to determine GSTZ1 haplotype status.
46087421|NCT00911313|Drug|Letrozole tablets (Femara; Novartis Pharma, Switzerland)|2.5 mg letrozole daily from day 3 of the menses for 5 days
46087422|NCT00911313|Drug|metformin HCl (Cidophage®; CID,Cairo, Egypt)|metformin HCl 1500 daily for 6-8 weeks
46087423|NCT00911313|Drug|CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt)|150 mg CC for 5 days starting from day 3 of menstruation
45457880|NCT01137019|Device|Biolimus-eluting stent|The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9.
45457881|NCT01137019|Device|Everolimus-eluting coronary stent|The everolimus-eluting coronary stent is a cobalt chromium platform stent with a permanent fluorinated copolymer matrix that eludes everolimus
45457882|NCT02312518|Device|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
46087424|NCT00659685|Drug|Ondansetron|ODT, single-dose, fasting
46087425|NCT00659685|Drug|Zofran ODT|
46000906|NCT00534482|Behavioral|Enhanced Office|Clinicians and office staff personally engage in AIM-HI fitness program, and promote program to patients
46000907|NCT00534482|Behavioral|Conventional Office|Conventional office: Clinicians and office staff are not personally engaged in the AIM-HI fitness program, but promote program to patients.
46000908|NCT00534482|Behavioral|AIM-HI program with enhanced feedback|Patient receives feedback on two novel indicators of their individual cardiovascular risk that: 1)appear to relate to obesity and lack of physical activity, and 2) may show relatively rapid change with improvements in these areas. These are the Homeostatic Assay - Insulin Resistance or HOMA-IR and Nuclear Molecular Resonance (NMR) lipoprotein profiles (NMRLP). These patients and their physicians also will receive periodic feedback on other outcome measures, including BMI, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
46000909|NCT00534482|Behavioral|AIM-HI program and regular feedback|Patients will not receive feedback on two specific cardiovascular risk indicators (ie, Homeostatic Assay - Insulin Resistance, Nuclear Molecular Resonance lipoprotein profiles). However, patients will receive feedback on Body Mass Index, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
46000910|NCT04667052|Drug|JNJ 64304500|Participants will receive a single subcutaneous dose of JNJ-64304500 reference formulation.
46000911|NCT04667052|Drug|JNJ 64304500|Participants will receive a single subcutaneous dose of JNJ-64304500 test formulation.
46000912|NCT04136522|Procedure|conventional pancreaticoduodenectomy|In this subgroup, the surgeon will perform pancreaticoduodenectomy without isolation of superior mesenteric artery and dissection of nerve plexus and lymph node around superior mesenteric artery.
46087426|NCT00659763|Other|Exclusion diagnosis|"Patient fulfill ROME III criteria No Alarmsignals Blood tests: FBC,CRP, ALAT, bilirubins, bas.phosphatases, Albumine, TSH, calcium, celiac screening, lactase gene test.~3 consecutive fecal samples for worm, ovaes and parasites Sigmoidoscopy with biopsy"
46087427|NCT00659763|Other|Clinical diagnosis|Patient fulfill ROME III criteria No Alarm signals Blood tests: FBC, CRP.
46087428|NCT00659841|Drug|Ciclesonide|200µg Ciclesonide versus placebo
46087429|NCT00659841|Drug|Placebo|placebo
46000913|NCT04136522|Procedure|total mesopancreas excision including superior mesenteric artery first approach|In this subgroup, the surgeon will identify and isolate superior mesenteric artery before pancreatic transection, they dissect soft tissues including nerve plexus and node around superior mesenteric artery.
46087430|NCT00659919|Drug|Placebo|
46087431|NCT00659919|Drug|Trazodone|
46000914|NCT04667130|Behavioral|Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis|Preventive program included informations of the possibilities of physiotherapy in the treatment of multiple sclerosis focused on fatigue management - recommending lifestyle changes. Program included a the treatment of psychosomatic, viscerosomatic functional disorders by reflexively poor connection through the locomotor system using computer kinesiology, psychotherapy, manual therapy - where patients are corrected into a postural position and the joints are functionally centred, and aerobic exercise to influence fatigue and improve the performance of the cardiovascular system.
46087432|NCT00659997|Drug|Albendazole|Single oral dose of 400mg
46087433|NCT00659997|Drug|Levamisole|Single oral dose of 2.5mg/kg
46087434|NCT04158453|Drug|AUT00201|Oral dose of AUT00201
46087435|NCT04158453|Drug|Placebo|Oral dose of placebo
46087436|NCT00660153|Drug|Tivozanib (AV-951) plus FOLFOX6|"Investigational product, dosage and mode of administration (1 cycle = 4 weeks of treatment):~Tivozanib (AV-951): 0.5 mg, 1.0 mg, and 1.5 mg oral once daily On Day -5 (± 2 days) subjects will receive a single dose of tivozanib (AV-951) for pharmacokinetic sampling. Beginning on Day 1 of Cycle 1, subjects will receive tivozanib (AV-951) once daily for 3 weeks followed by 1 week off. Tivozanib (AV-951) dosing repeats every cycle in the absence of disease progression or unacceptable toxicity. On days when both tivozanib (AV-951) and the FOLFOX6 chemotherapy regimen are co-administered, tivozanib (AV-951) will be administered immediately prior to the start of the FOLFOX6 chemotherapy regimen.~Subjects will receive FOLFOX6 chemotherapy every 2 weeks starting on Day 1 of Cycle 1. Subjects will receive 2 treatments of FOLFOX6 in each treatment cycle, starting on Day 1 and Day 15."
46087437|NCT00660231|Drug|bexarotene|Bexarotene daily p.o. 150mg/sq m during week 1 and 2, then 300mg/sq m if tolerated.
46087438|NCT00660231|Drug|gemcitabine hydrochloride|Gemcitabine i.v. 1000mg/sq m day 1 and day 8 of four 21 day cycles.
46087439|NCT04158063|Behavioral|Dual Task Training|"In total 12 Dual Task conditions will be performed in which 3 cognitive tasks are combined with 4 motor tasks:~Cognitive tasks:~Titrated digit span backwards~Auditory vigilance with alphabets~Subtracting by 7~Motor tasks:~Walking at self-selected speed~Walking while carrying a cup of water~Walking while stepping over obstacles~Walking crisscross"
46087440|NCT04158063|Other|Single Mobility Training|standard routine training
46087441|NCT04157907|Behavioral|Mentalization based therapy|Mentalization based therapy is a specialized treatment for patients with borderline personality disorder. The treatment program combines individual and group therapy, as well as psychoeducation
46087442|NCT04157829|Device|Scintilling lamp|Lamp with a standardized scintilling
46087443|NCT04157829|Device|Classic lamp|Lamp without a scintilling
45457883|NCT02312518|Other|Usual and Customary Practice|Usual and Customary Practice for non-healing venous leg ulcers
45457884|NCT03769753|Device|IRE Device|For use in ablating soft tissue
45457885|NCT03508804|Drug|Lidocaine-Prilocaine Cream|10ml of vaginally self-administered cream composed of an eutectic mixture of 2.5% lidocaine, 2.5% prilocaine
45457886|NCT03508804|Drug|Placebo Cream|10ml of vaginally self-administered placebo cream
45457887|NCT03508804|Drug|1% Lidocaine Paracervical Block|Paracervical block of 10ml of 1% lidocaine
46087444|NCT00597519|Drug|Fludarabine, Cyclophosphamide|"Fludarabine 25 mg/m2/day IV in the morning x 3 days (days -7, -6 and -5) for a total dose of 75 mg/m2 followed by Cyclophosphamide on days -6 and -5. 60mg/kg/day IV over 30-60 minutes x 2 days (days -6 and -5). High volume fluids should commence approximately 12 hours prior to drug and continue until 24 hours after second dose.~Total Body Irradiation: 125 cGy x 11 doses (TID on days -3, -2, -1 and BID on day 0) for a total TBI dose of 1375 cGy. Pediatric patients unable to tolerate a TID dosing schedule can receive 150 cGy x 8 doses (BID on days -3, -2, -1, and 0). All patients will receive GVHD prophylaxis with 2 drugs: Cyclosporine A and Mycophenolate mofetil (MMF).~Units should be given consecutively each over approximately 10-30 minutes.Pre-medication should include acetaminophen and diphenhydramine or hydroxyzine.G-CSF 5 mcg/kg/day IV/SQ (dose rounded to vial size to a maximum of 480 mcg) will be given from day +1 until ANC recovery."
46087445|NCT00597519|Procedure|Transplantation|The UCB ( Umbilical Cord Blood) collection known as a unit is processed to remove excess plasma and red cells, tested for sterility, HLA-typed, cryopreserved and stored. This protocol involves the administration of two UCB units from two different donors. The units will be thawed in the Cytotherapy Laboratory as per the current standard operating procedure.
46087446|NCT00660621|Drug|Temozolomide and Bevacizumab|"Between 14 and 28 days after surgery, all subjects will begin a standard course of post-operative limited field radiation therapy to the tumor site and a surrounding margin with concomitant temozolomide at a daily dose of 75 mg/m2 (7 days/week).~No later than 45 days after date of completion of radiation therapy, all subjects will begin dose dense temozolomide at dose of 150 mg/m2 on Days 1-7 and 15-21 of a 28 day cycle with concomitant bevacizumab 10mg/kg administered intravenously every other week."
46087447|NCT04157439|Other|Control Group|"Hot fermentation was applied for 10 mints Sustain pressure on trigger point was applied with thumb for 3secs hold and 2 sec release (till pain is reduced).~Self-stretches of cervical muscles (10 reps× 1set) For home plan cervical muscles stretching and postural care was guided"
46087448|NCT04157439|Other|Experimental Group|"Hot fermentation was applied for 10 mints. Integrated Neuromuscular Inhibition Technique [sustain pressure, Post Isometric Relaxation (PIR) and SCS]. Sustain pressure was applied on trigger points using thumb for 3 sec hold and 2 mints release (till pain is reduced).~Post isometric stretch (MET) was given with 4 repetitions (6-10sec hold). Strain counter strain was given in which upper trapezius shortened position was maintained by slight flexion, same side bending, opposite rotation and shoulder abduction for 90 sec and repeats this procedure till the pain is reduced to 3 out of 10.~Self-stretches for cervical muscles were done at the end of session to maintain the gained ranges (10 reps×1 set) For home plan cervical muscles stretching and postural care was guided"
46087449|NCT02632227|Procedure|TFU(transfontanel ultrasound)|The respiratory variation of the carotid artery blood flow peak velocity was measured using TFU before and after the fluid administration (10ml/kg for 20 min.)
46087450|NCT02632305|Drug|nab-paclitaxel in combination with gemcitabine + cisplatin|Patients with unresectable BTC will be treated with the triple combination of nab-paclitaxel in combination with gemcitabine + cisplatin
46087451|NCT02631993|Radiation|Photochemotherapy|Oral 8-Methoxypsoralene (8-MOP), (0.4-0.8 mg/kg), are given 1.5-2 hours before phototherapy. Ultraviolet light type A (UVA, 320-400 nm) is administered in a Waldmann UV1000 supine unit through 26 100-W fluorescent PUVA lamps (Waldmann F85), if needed, UVA is given in a half body unit with 15 100-W PUVA-lamps (Waldmann F85), (Waldmann UV3003K), (Waldmann, Villingen-Schwenningen, Germany). Eye protection is applied during 24 h after oral 8-MOP and the genital area are shielded in males during therapy.The UVA is initiated at 0.2-1.5 J/cm2 and is amplified by 0.25-0.5 J/cm2 after two treatments if photo toxicity is absent. PUVA is given to the patients 3-5 times each week.
46087452|NCT00660777|Behavioral|Deep breathing, bilateral alternate chewing, nasal lavage|Deep breathing, bilateral alternate chewing, nasal lavage
46087453|NCT00660777|Behavioral|Oropharyngeal exercises|Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
46087454|NCT00660855|Drug|parecoxib/valdecoxib|parecoxib 40 mg intravenously after recovery from anesthesia; if pain persisted, the patient could receive an optional second drug dose on Study Day 1 (only) if more than 4 hours after the first dose. When the patient was able to tolerate oral medication, one valdecoxib 40 mg tablet was administered by mouth once daily in the morning until a maximum period of 7 days.
46087455|NCT00660933|Drug|Iron sucrose|Iron sucrose 200 mg/day iv, (20 mg/ml) + 200 cc de NaCl 0,9%/day in 60 minutes per 2 days.
46000915|NCT01215916|Drug|LY573636|"Individualized dose is dependent on a patient's height, weight, and gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid [350 micrograms (µg) to 1000 µg orally, daily], Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone [4 milligrams (mg) orally, twice daily or equivalent]."
46087456|NCT00660933|Drug|NaCl|NaCl 0,9% 200 ml /day iv in 60 minutes per 2 days
46000916|NCT01215916|Drug|Pemetrexed|"375 to 500 milligrams per square meter (mg/m^2), intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid (350 µg to 1000 µg orally, daily), Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone (4 mg orally, twice daily or equivalent)."
46087457|NCT02632071|Drug|ACY-1215|An orally active, selective HDAC6 inhibitor. Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle
46087458|NCT02632071|Drug|Nab-paclitaxel|"Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer.~100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle"
46087459|NCT00661011|Procedure|Lobectomy followed by concomitant mediastinal chemoradiotherapy|Lobectomy Radiotherapy 66 Gy in 2 Gy/ fraction, 5 fractions/wk Chemotherapy Cisplatin 60 mg/m² on days 1 and 22 and Vinorelbine 15 mg/m² on days 1, 8, 22 and 29
46087460|NCT04156971|Dietary Supplement|Omega 3|
46087461|NCT04156971|Behavioral|stage-based lifestyle modification intervention|
46087462|NCT00665691|Other|Nutritional Screening Tools|To compare the nutrition risk identification abilities of two nutrition screening tools: PEDSGA tool and the standard assessment tool.
46000917|NCT00534521|Device|Posterior Tibial Nerve Device|The PTNS device (Urgent® PC) is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve (PTNS). It is a combination of a stimulator and a lead set. The stimulator is a battery powered, external pulse generator and is designed, constructed, and manufactured for multiple use in conjunction with the lead set. The lead set (comprised of the lead wires, needle electrode, and alcohol pad) transfers the electrical current from the stimulator to the tibial nerve via the needle electrode. The tibial nerve travels up the leg to the sacral nerve plexus which regulates the bladder and pelvic floor function.
46000918|NCT00534521|Device|Sham|This 2- piece needle, comprised of a needle handle and blunt-tip shaft feels like a slight prick when touched to the skin. However the shaft retracts as it appears to enter the skin but the skin is not punctured. The Streitberger needle specifically activates the dorsolateral prefrontal cortex, which is associated with the placebo effect.
46000919|NCT04666818|Device|Use of Flash Glucose Monitoring|Participants in the intervention group were advised to monitor glucose levels by means of flash glucose system.
46087463|NCT04154709|Biological|CTA101|Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.
46000920|NCT00534560|Drug|Tonabersat|Tablets, 4 week dose titration and 16 weeks treatment at target dose of 40 mg per day
46000921|NCT00534560|Drug|Tonabersat|Tablets: 4 week titration and 16 weeks at target dose of 80 mg per day
46000922|NCT00534560|Drug|Placebo|Tablets; 4 week dose titration with 16 weeks at target dose
46000923|NCT01184872|Drug|Daptomycin|"Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.~Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days."
46000924|NCT01184872|Drug|Vancomycin or Semi-Synthetic Penicillins (SSPs)|"Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.~Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days."
46087464|NCT02630979|Behavioral|Measuring satisfaction, knowledge and bias|Questionnaire based assessment.
46000925|NCT04666779|Other|Chiropractic care|Care provided by chiropractors, based on manual therapy, exercise prescription and patient advice/education/reassurance
46000926|NCT02887924|Device|Neopuff; Fisher and Paykel, Auckland, New Zealand|Following the oral and nasal aspirates, SLI at 25 cm H2O pressure will be applied for 15 seconds by using t-piece refreshing and binasal prongs and 5-cm nCPAP at H2O pressure will be applied.
46000927|NCT04117295|Device|Carmat Total Artificial Heart|Heart replacement therapy
46087465|NCT00879333|Drug|Everolimus|Everolimus was formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
46000928|NCT01215721|Drug|Vesicare|5 mg daily
46087466|NCT00879333|Drug|Everolimus placebo|Placebo was formulated to be indistinguishable from the everolimus tablets, also formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
46087467|NCT00879333|Drug|Best Supportive Care (BSC)|Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.
45457888|NCT01137097|Procedure|Lateral sentinel lymph node biopsy|Sentinel lymph node biopsy with radioisotope. Isotope injection and lymphoscintigraphy preoperatively
45457889|NCT02308150|Device|transcatheter aortic valve replacement|
45457890|NCT01232881|Procedure|Tumor Sample|Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.
45675968|NCT05115110|Drug|RO7204239|"RO7204239 will administered every 4 weeks (Q4W) by subcutaneous (SC) injection into the abdomen.~RO7204239 will be investigated at low- and high-dose in Part 1."
46000929|NCT02886910|Other|Clinical observation|Antibiotics will be started only if sepsis-related signs or symptoms are present.Clinical observation consists in a standardized physical examination protocol according to which newborns are observed by the nurses at 1, 2, 4, 8, 12, 16, 20, 24 hours of life and then every 6 hours up to 48 hours of life. The following signs and symptoms are checked: skin colour (pink/pale/cyanotic/mottled), respiratory rate (lower or higher than 60 breaths/minute) and presence or absence of respiratory distress.
46000930|NCT02886910|Other|Standard management|Antibiotics will be started at birth. Clinical observation will be carried out with the same timing and protocol
46087468|NCT00666081|Drug|GSK690693|Administered intravenously at a concentration between 0.1 - 4.8 mg/mL by slow infusion over 4 h.
46087469|NCT02630901|Drug|PRX003|
46087470|NCT02630901|Other|Placebo|
46087471|NCT02630823|Drug|MK-3475|
46087472|NCT02630823|Procedure|Surgical resection (standard of care)|
46087473|NCT02630823|Drug|Paclitaxel (standard of care)|
46087474|NCT02630823|Drug|Carboplatin (standard of care)|
46087475|NCT02630823|Radiation|Radiation (standard of care)|
46087476|NCT02630823|Procedure|Endometrial biopsy|
46087477|NCT02630823|Procedure|Peripheral blood draw|
46087478|NCT02630745|Procedure|Immediate periodontal surgery|Treatment involves immediate surgical periodontal therapy in form of open flap debridement after non surgical endodontic treatment and obturation with gutta-percha and zinc oxide eugenol (ZOE) sealer. in concurrent endodontic periodontal lesions with communication .
46087479|NCT02630745|Procedure|Delayed periodontal surgery|Treatment involves surgical periodontal therapy after 3 months of non surgical endodontic treatment and obturation with gutta-percha and zinc oxide eugenol (ZOE) sealer. in the form of open flap debridement in concurrent endodontic periodontal lesions with communication .
46087480|NCT02630511|Drug|Mannitol|Mannitol consists of inhaling 0 (empty capsule acting as a placebo), 5, 10, 20, 40, 80, 160, 160, and 160 mg mannitol, resulting in a maximum cumulative dose of 635 mg
46087481|NCT02630511|Drug|Methacholine|Methacholine consists of inhaling 0.0625 mg/mL, 0.25 mg/mL, 1 mg/mL, 4 mg/mL, and 16 mg/mL
46087482|NCT02630511|Drug|Placebo|Placebo consists of inhaling humidified air
46087483|NCT02630511|Other|Rest|
46087484|NCT02630511|Other|Exercise|
46087485|NCT00666159|Drug|tacrolimus ointment|topical
46087486|NCT00666159|Drug|pimecrolimus cream|topical
46000931|NCT02887027|Behavioral|Exercise4Mood Intervention|The Exercise4Mood Intervention was designed based on principles from the Exercise for Mood and Anxiety protocol (Smits et al., 2009) and consists primarily of a mobile application called Exercise4Mood. It will be supported by text-messages, delivered through SymTrend, reminding participants about their scheduled exercise sessions and prompting them to engage with the app. Its core features include: motivational tips to encourage exercise, reminders about scheduled exercise, tracking of exercise behavior, tracking of mood before, during, and after exercise, and post-exercise positive reinforcement statements.
46000932|NCT04113239|Diagnostic Test|16S rRNA gene sequencing|Taking a stool sample for gut microbiome DNA sequencing
46000933|NCT04113239|Genetic|DNA-microarray genotyping|Taking a saliva sample for genotyping
46000934|NCT04666506|Other|Virtual reality|"The VR intervention, Relaxation-VR, is a VR application developed by Psylaris aiming to reduce anxiety/stress and pain by distracting the patient in a relaxing environment. Relaxation-VR will be administered via a commercially available VR headset (Oculus Go). The VR headset is a piece of equipment that a person wears over their eyes that allows them to experience images and sounds produced by a computer as if they were part of real life (Cambridge Dictionary, 2020). As such, the patient is immersed in a novel, calming and distracting environment where the he/she is asked to perform tasks that will help the patients to relax when distressed before and/or during a medical procedure or during their stay in hospital.~The Relaxation-VR application consists of three modules: two modules make use of relaxation principles (i.e. breathing exercises, meditation) and one module presents a scene with different interactive animations and objects (i.e. popping bubbles, playing fetch with a dog)."
46000935|NCT04666623|Drug|esketamine nasal spray|unlabeled nasal injectors, each device will deliver 28mg of esketamine in a 200 μL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.
46000936|NCT04666623|Drug|placebo nasal spray|unlabeled nasal injectors, each device will deliver 28mg of placebo in a 200 μL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.
46000937|NCT04072211|Biological|Engerix-B|Hepatitis B vaccine administered through intramuscular injection at 0, 1, and 6 months
46000938|NCT00534677|Drug|Terlipressin|2 mg stat & then 1 mg q6h iv and Placebo of Octreotide
46000939|NCT00534677|Drug|Octreotide|Octreotide 50mcg/hr infusion & a placebo of Terlipressin
46000940|NCT00556764|Drug|[123I] IBVM and SPECT imaging|Subjects will be injected with up to 4 mCi of 123-I IBVM followed by SPECT imaging.
46000941|NCT00556764|Drug|Subjects will undergo the 123-I IBVM imaging visit|Subjects will be injected with a bolus of up to 4 mCi of 123-I IBVM followed by serial SPECT imaging.
46000942|NCT00556803|Procedure|radiofrequency ablation|radiofrequency ablation
46000943|NCT00556803|Procedure|TACE after RFA|TACE after RFA within one month
46000944|NCT00556959|Drug|high dose clonidine HCl sustained release|high dose clonidine HCl sustained release tablets for 8 weeks
46000945|NCT00556959|Drug|low dose clonidine HCl sustained release|low dose clonidine HCl sustained release tablets for 8 weeks
46000946|NCT00556959|Drug|placebo|placebo tablets for 8 weeks
46000947|NCT04008641|Other|Pediatric consultation's survey|Realization of a pediatric consultation. At the end, evaluation of comprehension and psychological impact with a survey (completed by parents).
46000948|NCT00557037|Drug|Phenoxodiol|Oral capsule, 400 mg every 8 hours daily, for 12 weeks - assement to a maximum of 12 months
46000949|NCT01184326|Drug|pazopanib|
46000950|NCT01184326|Drug|everolimus|
46000951|NCT04666350|Other|to assess the consistency and reproducibility of two consecutive direct skin feeding assays (DSFA) at 24-hour interval.|"The results from this experimental medicine study will inform whether the preferred Before-After trial design in which each human volunteer serves as their own internal control can be utilized for a follow-on Phase 2b trial."
45457891|NCT01232881|Procedure|Serum Sample|Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.
46000952|NCT01215253|Drug|Ranolazine|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at beginning of second week.
46000953|NCT03898115|Behavioral|CHG Education|"The CHG educational intervention will include educational outreach and audit and feedback implementation strategies"
46000954|NCT04666233|Procedure|Neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection|The team will perform neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection
46000955|NCT04666233|Procedure|Neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection|The team will perform neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection
46000956|NCT04666155|Device|Intermittent Colonic Exoperistalsis with MOWOOT device|Patients under the experimental arm of the study should place the belt of the Mowoot device on the abdomen and use it for 20 minutes every day for 12 weeks.
46087487|NCT00666393|Drug|fentanyl iontophoretic transdermal system (40mcg) No placebo|40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
45457892|NCT03508648|Drug|GTx-024|Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
45675969|NCT05115110|Drug|Placebo|Placebo will be administered Q4W by SC injection into the abdomen.
45675970|NCT05115110|Drug|Risdiplam|Risdiplam will be administered orally once daily (QD) for the duration of the study.
45675971|NCT05112965|Drug|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) or comparator agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study at the time of participant discontinuation from the parent study closure.
45676756|NCT01822899|Drug|Placebo ACCUHALER/DISKUS|Dry white powder of matching placebo as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
46000957|NCT04666155|Combination Product|Standard of care|Patients under the active comparator arm of the study should continue with their individualized standard of care againts constipation, for 12 weeks. The standard of care uses to be different in each patient: both in drugs and doses taken (laxatives) as well as in formulation/presentation (pills, laxative syrup, suppos, etc...) and even in other help to evacuation (micro or macro enemas, digitation, etc...).
46087488|NCT00666393|Drug|fentanyl iontophoretic transdermal system (40mcg)|40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
46000958|NCT03896867|Device|Anapod™ Humi-Therm Heated Humidification System Breathing Circuit|"For the Anapod™ group, the BairHugger™ blanket will be connected, but the unit will not be turned on. The Anapod™ will be used with a starting circuit temperature set at the standard 45°C (note, this is temperature at the unit - NOT the temperature of the gas reaching the trachea). In the event that the patient's rectal temperature falls below 35.6C, the BairHugger™ warming system will be activated (Hypothermic Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the Anapod system will be turned off - and the BairHugger turned on with the warming unit set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue)."
45457893|NCT03508648|Drug|Matching Placebo|Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
46000959|NCT03896867|Device|Bair Hugger™ Warming Blanket|"For the BairHugger™ group, the blanket will be used with a starting temperature set at HIGH. The BairHugger™ unit will be attached to the warming unit and started as soon as possible. In the event that the patient's rectal temperature falls below 35.6C, the Anapod™ warming system will be activated (Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the BairHugger™ warming unit will be set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue)."
46000960|NCT01184053|Drug|Arsenic trioxide|Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
46000961|NCT04206241|Diagnostic Test|Point of care early infant diagnosis (POC EID)|HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
46000962|NCT03895814|Behavioral|Protective Step Training|Participants will undergo 6, 1 hour visits (over the course of 2 weeks) where they will be exposed to repeated slips on a treadmill.
46000963|NCT04666194|Procedure|Cold forceps|
46087489|NCT00666471|Procedure|MICE|MICE
45675972|NCT05111041|Behavioral|Gradual Reduction to Quit|Participants in this intervention will be given the choice of following the Gradual Reduction to Quit program or to choose their own quit date within 2-4 weeks. The Gradual Reduction to Quit program will reduce smokeless tobacco use via text message support and weekly prompts guiding the participants to gradually decrease their use of smokeless tobacco until they are down to zero. A four week Nicotine Replacement Therapy (NRT) sample in the form of lozenges will also be provided to all participants. The intent of this program is to reduce the number of times participants use smokeless tobacco.
46087490|NCT00666471|Procedure|SPA ligation|SPA ligation
46087491|NCT00666627|Drug|Ibandronate|once monthly
46000964|NCT04666194|Procedure|Cold snare|
46087492|NCT00666627|Drug|Risedronate|Risedronate 35mg once weekly
46087493|NCT00666627|Drug|Alendronate|Alendronate 70mg once weekly
46087494|NCT00666783|Drug|palonosetron|receive a single, intravenous dose of palonosetron 0.25 mg, 30 minutes before receiving highly emetogenic chemotherapy.
45457894|NCT01231165|Drug|Amiloride|5mg/daily for 12th months
45457895|NCT01231165|Drug|Nitrates, clopidogrel, aspirin, statins|Comparative Efficacious Research
46000965|NCT04666194|Procedure|Hot snare|
46000966|NCT03870698|Procedure|Laparoscopic group|The patients in laparoscopic group will underwent pylorus preserving pancreaticoduodenectomy in laparoscopic manners.
46002581|NCT03456323|Behavioral|Palliative Care Consultation|The palliative care consultation team will be led by one of the board-certified palliative care physicians at Columbia University Medical Center. Over one or more visits, the palliative care consultation team will first review intervention participants' medical records and baseline Edmonton Symptom Assessment System (ESAS) scores. They will also directly assess participants' physical and psychological symptoms. They will provide supportive counseling, make treatment recommendations for burdensome symptoms to the primary team of physicians, and will address goals of care. They will document these activities in structured electronic medical record consultation notes.
46087495|NCT00666783|Drug|Granisetron|receive a single, intravenous dose of granisetron 3 mg, 30 minutes before chemotherapy.
46087496|NCT02630589|Device|Auditory brainstem implant|The ABI will be implanted by the neurosurgeon. The implant is fixed in a bed drilled in the parietal-temporal cortex, and the ABI electrode array is inserted into the lateral recess of the fourth ventricle and placed on the cochlear nucleus. Access to the cochlear nucleus will be made via retrosigmoid transcranial approach.
46087497|NCT02630433|Procedure|Index cholecystectomy|Cholecystectomy performed within 48 hours after inclusion, before discharge after admission for acute biliary pancreatitis.
46087498|NCT02630433|Procedure|Scheduled cholecystectomy|Cholecystectomy performed as a scheduled procedure 6 weeks after the first admission.
46087499|NCT00666939|Drug|Gabapentin|Gabapentin 100 mg oral capsule 30 minutes prior to bedtime
46087500|NCT00666939|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
46087501|NCT00666939|Drug|Placebo|Matched placebo 30 minutes prior to bedtime
46087502|NCT02630667|Other|SLOW Carbohydrate|Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response
45457896|NCT03506698|Other|Kangaroo Mother Care (KMC)|Skin to skin contact of newborns with mothers or caregiver for a minimum of at least eight hours over a 24-hours period, along with exclusive breastfeeding or breast milk feeding via tube or spoon
45457897|NCT01231243|Procedure|in-office bleaching with/without light|Two clinical sessions of tooth bleaching will be performed in each patient with a 1-week interval between them. In each session, three 15-min applications of the gel will be done using one of the two concentrations under investigation. In half of the sample of each concentration, the gel will be activated with a LED/laser device for a total of 3 min, as specified by the DMC manufacturer.
46000967|NCT04666077|Behavioral|Home-based MT through Supervised, Supported Singing (H3S)|"Daily singing of song of kin. The song of kin will be derived from an assessment session and evaluation inclusive of an interview under the supervision of Dr. Joanne Loewy and her team at the Louis Armstrong Center for Music and Medicine (LACMM). The interview will include the participant and their study partner who will assist in identifying musical preferences and relevant cultural experiences. A recording of prescribed song protocols will be provided. Participants and study partners will be directed to plan a minimum of 1 hour a day in which the participant will sing along with the study partner-administered song of kin. A diary will be provided to the study partner to record the time of day, amount of time spent and comments on the activity. Study staff will contact the members of this group to confirm compliance with the activity."
46000968|NCT04666077|Behavioral|Individualized Music Therapy (IMT)|The Individualized Music therapy (IMT) conducted by the LACMM staff. It will be administered by a certified music therapist twice weekly for 45 minutes. The sessions will employ extensive clinical improvisation based on the songs of kin utilized in the H3S condition. Compliance will be measured with a weekly log which will record dates and times of each condition.
46000969|NCT04666077|Other|Attention Control (AtCon)|"The attention control (AtCon) will meet with the LACMM team for an interview in which they will be asked about music preferences and music experiences. They will answer any questions from participant and caregiver about music experiences. Study staff will contact the members of this group at the same schedule as the H3S group to assess music activity engagement. This will measure unplanned exposure and minimize drop-in music activity which could contaminate the control condition."
46000970|NCT04666116|Dietary Supplement|Dietary supplementation in patients with covid disease admitted to hospital|Dietary supplementation in patients with covid disease admitted to hospital
46000971|NCT03813875|Drug|Fentanyl|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical fentanyl ranged from 0~200mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery, the patient is observed in the operation room until return of consciousness before sending them to the recovery unit.
46000972|NCT03813875|Other|Bispectral index (BIS) and analgesia nociception index (ANI)|After giving routine anesthetic medications, the investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S). BIS is maintained between 40 - 60 and MOAA/S less than 2. The vital signs, BIS, analgesia nociception index (ANI) are recorded automatically and continuously through computerized software. ANI is used to observational purposes only and do not guide anesthetic management in our protocol. Upon conclusion of the surgery or examination, the patient is observed until return of consciousness (MOAA/S = 5) before sending them to the recovery unit.
46000973|NCT03813875|Drug|alfentanil|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0~1000mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
46002582|NCT03456323|Other|Usual Care|Patient-surrogate pairs randomized to usual care will not have a palliative care consultation intervention offered, and will receive care by their primary physicians. However, if a palliative care consultation is requested after randomization to usual care by the primary team of physicians and/or the patient/surrogate, it will be provided.
46087503|NCT02630667|Other|MEDIUM Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response
46087504|NCT02630667|Other|FAST Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response
46087505|NCT00667407|Drug|Levalbuterol 1.25 mg|"levalbuterol 1.25 mg Period I: administered every 20 minutes for the first 3 doses, and then every 40 minutes for the next 3 doses; then as clinically indicated.~Period II: TID for 3 days (same time of day), then PRN to TID for 7 days"
45457898|NCT01139281|Drug|Ginkgo Biloba Extract (GBE761)|The subjects were randomized and allocated in two groups: Control Group(CG) and Study Group(SG). the study group received GBE761(120mg twice a day) plus cisplatin and was guided to ingest GBE761 just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
45675973|NCT05111041|Behavioral|Control Group|Participants will be sent the Enuf Snuff cessation manual, support text messages, as well as a four week Nicotine Replacement Therapy (NRT) sample in the form of lozenges.
46087506|NCT00667407|Drug|Racemic Albuterol Sulfate|"Racemic Albuterol 2.5 mg Period I: every 20 min for the first 3 doses, then every 40 min for the next 3 doses, then as clinically indicated.~Period II: TID for 3 days then PRN to TID for 7 days"
46000974|NCT03813875|Drug|Propofol|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical propofol ranged from 0~200mg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
46087507|NCT00667485|Drug|Rapamycin (liquid)|Weekly Rapamycin (liquid) 90mg (dose will be split 45mg on Day 1 and Day 2 of each week)
46087508|NCT00667485|Drug|Bevacizumab|Multiple doses (dose depends on time of study entry) given by IV once every 3 weeks
46087509|NCT00667485|Drug|Rapamycin (Tablets)|Daily oral rapamycin (tablets) - 2 doses will be tested 4mg and 6mg
46087510|NCT00667641|Drug|bortezomib|Starting dose level 0.70mg/m2
46000975|NCT03813875|Drug|sevoflurane|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine triple drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical sevoflurane concentration ranged from 0~3% according to patient condition. The timing and concentrations data are acquired for backend analysis. At the conclusion of the surgery, the patient is observed in the surgery room until return of consciousness before sending them to the recovery unit.
46000976|NCT03813875|Drug|midazolam|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical midazolam ranged from 0~5mg in boluses according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
46000977|NCT01183858|Drug|Erlotinib [Tarceva]|Single daily oral dose
46002583|NCT04638270|Biological|anti-CD19 FasT CAR-T cells|Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion.
46002584|NCT00545480|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (with feedback)
46002585|NCT00545480|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (without feedback)
45675974|NCT05106608|Device|Energy density photobiomodulation (7.5)|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total). In addition, a mobile health application (LAXER) will be provided.
46002586|NCT04646694|Drug|Ketamine|The use of oral Ketamine in this study is experimental.This study will look at how effective and safe Ketamine.
46087511|NCT00667641|Drug|paclitaxel|Starting dose level 40mg/m2
46087512|NCT00667797|Drug|levalbuterol HCl|Levalbuterol 1.25 mg will be prescribed every 6-8 hours, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of levalbuterol administration at their discretion.
46087513|NCT00667797|Drug|albuterol Sulfate|Racemic albuterol 2.5 mg will be prescribed per the standard of care used in the institution, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of racemic albuterol administration at their discretion.
46087514|NCT03481556|Drug|Melphalan flufenamide (Melflufen)|Intravenous infusion
45675975|NCT05106608|Device|Energy density photobiomodulation (3)|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total). In addition, a mobile health application (LAXER) will be provided.
45675976|NCT05106608|Device|Sham placebo|In addition, a mobile health application (LAXER) will be provided.
46087515|NCT03481556|Drug|Dexamethasone|Oral tablets
46087516|NCT03481556|Drug|Bortezomib|Subcutaneous administration
45675977|NCT05105958|Drug|Tideglusib|1000 mg/day per os
46087517|NCT03481556|Drug|Daratumumab|Intravenous infusion
46087518|NCT00668031|Drug|Trasylol (Aprotinin, BAYA0128)|A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of aprotinin using an IV infusion pump
46087519|NCT00668031|Drug|Placebo|A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of of placebo using an IV infusion pump
46087520|NCT02630355|Other|Remote Ischaemic Preconditioning|Inflation of blood pressure cuff in lower limb
46087521|NCT03480776|Drug|Acetylsalicylic acid|81 mg PO daily or 325 mg PO daily
46087522|NCT03480776|Other|Placebo|One tablet PO daily
46087523|NCT00668109|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg one hour prior to sexual intercourse
46087524|NCT00668109|Drug|Tadalafil|10 mg taken approximately 24 hours prior to sexual intercourse
46087525|NCT04765436|Biological|PTX-COVID19-B|Sterile solution for injection
46087526|NCT04765436|Biological|Placebo|0.9% sodium chloride (normal saline) injection
46000978|NCT04665882|Procedure|Axillary surgery based on lymphedema prediction nomogram|Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.
46087527|NCT03480620|Other|Online Telerehabilitation Platform Access|Participants will have 24/7 access to a standardized set post-discharge exercise videos and self-management instructions across multiple internet connected devices (e.g. computer, tablet, smartphone). Standardized exercises include a flexibility routine that participants learned and performed with a physical therapist while in the pain management program. Self-management instructions are also written versions of concepts learned and practiced with a member of the multidisciplinary team during the pain management program.
46087528|NCT03480620|Other|Usual care|Participants are given a DVD of the standardized post-discharge exercise videos and a written copy of the self-management instructions as described in the experimental group.
46000979|NCT04686344|Drug|intermittent boluses of Hypertonic saline|intermittent boluses every 6 hours over 30 min for 48 hours
46087529|NCT04032249|Behavioral|Control Group (CG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of having healthy habits in relation to decision making and food
46000980|NCT04686344|Drug|continuous infusion of Hypertonic saline|continuous infusion over a period of 48 hours
46000981|NCT05450536|Other|Video Model and Role Play|Video clips and role-play will be utilized to teach self-advocacy skills to autistic college students.
46000982|NCT05349136|Other|Synchronous telerehabilitation group|This group will receive Action Observation Treatment with a synchronous telerehabilitation method. Children in this group will be applied Action Observation Treatment 5 days a week for 3 weeks, for a total of 15 sessions under the supervision of a physiotherapist via videoconferencing.
46087530|NCT04032249|Behavioral|Intervention Group (IG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of having healthy habits in relation to decision making and food, but also, they will have monitored the self-control of the weight in order to compare the impact of self-weighing versus not doing it
46087531|NCT04721756|Drug|18F-LY3546117 Injection|370 megabecquerel (MBq) intravenous injection
46087532|NCT04721756|Procedure|PET Scan|positron emission tomography (PET) scan
46087533|NCT00668343|Drug|simvastatin|40 mg/ day
46000983|NCT05349136|Other|Asynchronous telerehabilitation group|This group will receive Action Observation Treatment with an asynchronous telerehabilitation method. Children in this group will be applied Action Observation Treatment 5 days a week for 3 weeks, for a total of 15 sessions under parental supervision.
46087534|NCT00668343|Drug|placebo|80 mg /day
46087535|NCT04717700|Drug|Selinexor 20 MG Oral Tablet|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
46087536|NCT04717700|Drug|Bortezomib Injection|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
46087537|NCT04717700|Drug|Lenalidomide capsule|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
46002587|NCT04646694|Other|Placebo|A placebo is given in this study to reduce the chances of believing that pain after surgery is getting better because one is receiving oral Ketamine
46002588|NCT00545519|Drug|thymoglobulin|
46087538|NCT04717700|Drug|Dexamethasone Oral|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
46087539|NCT04017507|Device|Oscillating-rotating electric toothbrush|Oscillating-rotating electric toothbrush used twice daily
46087540|NCT04017507|Device|Side-to-side electric toothbrush|Side-to-side electric toothbrush used twice daily
46087541|NCT04017507|Device|Manual toothbrush|Manual toothbrush used twice daily
46002589|NCT04637685|Device|Centurion Phacoemulsification System|Infusion Pressure
46002590|NCT00545558|Drug|Efavirenz|600 mg tablet taken orally daily
46087542|NCT02630277|Drug|Aflibercept|Intravitreal Aflibercept Injection 2.0 mg
46087543|NCT00614276|Behavioral|Focus Group|To evaluate a multimedia intervention program for women with cancer-related sexual dysfunction.
46087544|NCT00614276|Behavioral|TENDRILS|Tendrils: A Sexual Renewal Program for Women Surviving Cancer - a website designed to give women information about sexual problems related to cancer and its treatment, and the website suggests ways to overcome those problems.
46087545|NCT00614276|Behavioral|Questionnaires|The questionnaires ask about your background (such as age, education, relationships), your cancer diagnosis and treatment, and the quality of your life in terms of your health, your general emotions, and your sexual function. The questionnaires take about 30-45 minutes to complete.
46087546|NCT00614276|Behavioral|Sexual Counseling Sessions|Attend 3 sexual counseling sessions at M. D. Anderson.
45675978|NCT05100654|Drug|Doxycycline|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
46087547|NCT00668421|Drug|CEP-701 (Lestaurtinib)|Lestaurtinib (CEP-701), oral formulation. Phase 1: 80 BID - 160 BID; phase 2: 140 mg
46087548|NCT02693522|Drug|somatropin|Subcutaneous injection
46087549|NCT02693522|Drug|Eutropin|Subcutaneous injection
46087550|NCT00668499|Drug|VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin|VEGF-AS either 100 or 200mg/m2 IV days 1-5, Pemetrexed 500mg/m2 and Cisplatin 75mg/m2 IV on day 1. Cycle repeated every 3 weeks until 6 cycles completed, unless PD or toxicities
46087551|NCT05201846|Device|DIA:CONN G8 insulin pump|Subjects on continuous subcutaneous insulin infusion system with CGM
46087552|NCT05201846|Other|Multiple daily insulin injection|Subjects on multiple daily insulin injection with CGM
45457899|NCT01139281|Drug|Placebo|The subjects were randomized and allocated in two groups: control group and study group. The control group received placebo plus cisplatin and was guided to ingest Placebo just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
46000984|NCT04316416|Procedure|T7 Level Erector Spinae Plane Block|"ESP block is planned after the completion of surgery and before the extubation. Its application will be planned from the T7 level bilaterally when the patients are turned to the right lateral position. A linear ultrasound probe will be placed in the longitudinal parasagittal orientation 3 cm to lateral of T7 spinous process.~After imaging of erector spina musceles and transvers process of 7 th trorocal vertebrae, an ultrasound-guided local anaesthetic mixture ( 0.5% bupivacaine 15 cc + 2% lidocaine 5 cc) will be applied to the region between spinae muscles and transverse process using a needle of 22 gauge & 8cm directed from cranial to caudal.~After application of the same procedure to the other side, the patients will be woken-up and patient-controlled analgesia consisting of intravenous morphine will be planned for all of them.~Additionally, at postoperative 1.,4.,8.,12.,24. hours, NRS scales and morphine consumption will be recorded."
46087553|NCT03455114|Device|AssiAnchor|"The novel device, the capsular Anchor, was designed to secure the capsular bag to the scleral wall. The device is a one-piece, one-plane intraocular implant . It works like a paper clip; holding the anterior capsule between a central rod, placed in front of the capsule, and the two lateral arms, inserted through the eye surgery and placed behind the capsule."
46000985|NCT04316416|Procedure|T9 Level Erector Spinae Plane Block|"ESP block is planned after the completion of surgery and before the extubation. Its application will be planned from the T9 level bilaterally when the patients are turned to the right lateral position. A linear ultrasound probe will be placed in the longitudinal parasagittal orientation 3 cm to lateral of T9 spinous process.~After imaging of erector spina musceles and transvers process of 9 th trorocal vertebrae, an ultrasound-guided local anaesthetic mixture ( 0.5% bupivacaine 15 cc + 2% lidocaine 5 cc) will be applied to the region between spinae muscles and transverse process using a needle of 22 gauge & 8cm directed from cranial to caudal.~After application of the same procedure to the other side, the patients will be woken-up and patient-controlled analgesia consisting of intravenous morphine will be planned for all of them.~Additionally, at postoperative 1.,4.,8.,12.,24. hours, NRS scales and morphine consumption will be recorded."
46000986|NCT04316416|Drug|control group|24 hours morphine consumption will be recorded using the patient controlled analgesia device with intravenous morphine.
46000987|NCT05449522|Other|Vitamin D|High dose of vitamin D is given in divided dose orally or enterally via a feeding tube
46000988|NCT05449522|Other|Placebo|Placebo
46000989|NCT04665804|Dietary Supplement|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
46000990|NCT04665804|Dietary Supplement|Glucosamine and Chondroitin sulfate supplementation|Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
46087554|NCT00668889|Drug|Lactic acid (Dermacid)|
46087555|NCT00668967|Drug|verapamil|240 mg extended release tablets once daily at bedtime for 28 days
46087556|NCT00668967|Drug|verapamil|240 mg extended release tablets once daily at bedtime for 28 days
46087557|NCT03583658|Drug|ambroxol BIH1526|Pharmaceutical form: lozenges Route of administration: oromucosal
46000991|NCT04665804|Other|Supervised Exercise training|"Lower Extremity Resistance Exercise Training Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
46000992|NCT04665804|Other|Home Exercise Program|"2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension"
46087558|NCT03583658|Drug|placebo|Pharmaceutical form: lozenges Route of administration: oromucosal
46087559|NCT04154475|Dietary Supplement|yogurt diet|500 g yogurt/day
45675979|NCT05100654|Drug|Ciprofloxacin|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
46000993|NCT04665804|Procedure|Electrotherapy + Heating|Interferential Current therapy (2P), in combination with heating pad for 20 minutes
46000994|NCT04665804|Procedure|Joint Mobilization|Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
46000995|NCT05434468|Other|Sustained neutral apophyseal glides|gong mobilization
46087560|NCT04154475|Dietary Supplement|dairy diet|500 g non-yogurt dairy products
46087561|NCT04154475|Dietary Supplement|standard diet|500 g soya-yogurt
46087562|NCT03555968|Drug|THC 0|THC dose = 0mg
46087563|NCT03555968|Drug|THC 5|THC dose = 5mg
45457900|NCT03503890|Drug|rovalpituzumab tesirine|intravenous
45457901|NCT02304718|Behavioral|Stationary bike|
45457902|NCT01233895|Drug|AVE1642|For Part 1, AVE1642 was administered on Day 1 and then every three weeks intra-venously with the dose escalation step starting at 3 mg/kg/infusion with a classical dose escalation schema of 3+3. For Part 2, AVE1642 was administered at doses ranging from 0.5 mg/kg to 12 mg/kg
46087564|NCT03555968|Drug|THC 10|THC dose = 10mg
46087565|NCT03555968|Other|BAC 0|Blood alcohol concentration = .000%
46087566|NCT03555968|Other|BAC .025|Blood alcohol concentration = .025%
46087567|NCT03555968|Other|BAC .049|Blood alcohol concentration = .049%
46087568|NCT00669123|Drug|Chondroitin sulphate|Chondroitin sulphate 800 mg/day
46087569|NCT00669123|Drug|Placebo|
46087570|NCT04617158|Procedure|Adjustable strabismus surgery|Adjustable surgery will be done using sliding nose technique using fornix approach
46087571|NCT04154319|Behavioral|HPV Vaccination|Mothers assigned to this arm participated in educational/behavior change sessions to promote HPV vaccination among their unvaccinated 9-12 year old daughters
46000996|NCT04316455|Other|Integrative Yoga Therapy|Participants having an hour in-person weekly session with qualified yoga therapist for 6-weeks. At each session, the personalised yoga practices including straightening and relaxing posture of yoga, yoga breathing, Combinations of sound and imagery yoga practices were given and asked to continue practice at home during the week.
46000997|NCT05431192|Behavioral|Mindfulness Training + Enhanced Usual Care|"Participants will receive a 30-minute, individual, phone-delivered session once a week for 8 weeks. MT involves training in the following (1) Awareness of breath; (2) Body scan; (3) Directing attention to simple activities of daily life; (4) Becoming aware of own thoughts and emotions; (5) Open awareness - a technique by which the participant is invited to direct his/her attention to any event arising in their field of experience at a given moment.~In addition, participants will practice mindfulness techniques for 20 minutes daily on their own with the guidance of a digitally recorded, standardized guided mindfulness practice."
46087572|NCT04154319|Behavioral|Healthy Eating|Mothers and daughters assigned to this arm received education on healthy eating and how to appropriately interpret nutrition labels
46087573|NCT00614354|Drug|99mTc-glucarate solution|Patients will receive a single 22 - 27 mCi bolus intravenous dose of 99mTc-glucarate solution, as soon as possible after their arrival in the emergency department or the chest pain center
46087574|NCT04593680|Drug|Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF)|The first full PK measurement of MHT will be performed starting at week 4 and end at week 6 to assess the steady-state plasma PK of testosterone in the absence of PrEP. The second PK measurement of MHT will be performed starting at week 12 and end at week 14 to assess plasma PK of testosterone in the presence of both MHT and PrEP. The first full PK measurement of PrEP will be performed at week 12 to assess the steady-state plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the presence of both MHT and PrEP. The second measurement of PrEP will be performed at week 16 to assess plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the absence of MHT.
45675980|NCT05100654|Drug|Augmentin|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
45675981|NCT05100654|Drug|Bactrim|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
45675982|NCT05096403|Drug|Pegcetacoplan|Pegcetacoplan taken twice weekly as subcutaneous injection
46087575|NCT00669357|Device|Abiocor Implantable Replacement Heart|Replacement of heart
46087576|NCT02692742|Drug|Myelo001|Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
46087577|NCT02692742|Drug|Placebo|Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
46087578|NCT00669435|Drug|Losartan + Simvastatin|"tablets; 50, 100 mg; od; 12 months~tablets; 20 mg; od; 6 months"
46087579|NCT00669435|Drug|Amlodipine + Simvastatin|"tablets; 5, 10 mg; od; 12 months~tablets; 20 mg; od; 6 months"
46087580|NCT00669513|Behavioral|Partial sleep deprivation|Partial sleep deprivation (less than 5 hours, but no less than 3 hours and 30 minutes)
46087581|NCT00669591|Drug|Bavituximab|Weekly bavituximab infusion of 3 mg/kg combined with up to six 28-day cycles of docetaxel chemotherapy. After treatment phase, weekly bavituximab maintenance is continued until disease progression.
46087582|NCT00669747|Drug|Carboplatin i.d. Days 1 & 15|Carboplatin, 10 mg/ml, 10 ml (100 mg) infused into DCIS-involved duct on Days 1 & 15
46087583|NCT00669747|Drug|Carboplatin i.d. Day 1; Normal Saline i.d. Day 15|Carboplatin 10 mg/ml, 10 ml (100 mg) i.d. DCIS duct on Day 1 Normal Saline, 10 ml i.d. DCIS duct on Day 15
46087584|NCT00669747|Drug|Normal Saline|Normal Saline, 10 ml, i.d. on Days 1 and 15
45457903|NCT01233895|Drug|Velcade|For Part 2 ONLY, fixed dose of 1.3 mg/m² administered on Days 1, 4, 8, and 11.
45675983|NCT05095922|Drug|Heart-Protecting Musk Pill|Heart-Protecting Musk Pill (pill, 45mg, three times a day, 3 months)
45675984|NCT05095922|Drug|Valsartan Capsules|Valsartan Capsules(capsule, 80mg, once a day, 3 months）
45675985|NCT05095922|Drug|Calcium Dobesilate Capsules|Calcium Dobesilate Capsules(capsule, 500mg, three times a day, 3 months)
45675986|NCT05092347|Drug|REGN5459|Administered by intravenous (IV) infusion
45675987|NCT05092347|Drug|REGN5458|Administered by intravenous (IV) infusion
45675988|NCT05087498|Biological|autologous cord blood mononuclear cells|preterm neonates less than 32 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (2-10×107cells/kg) within 24 hours after birth
45675989|NCT05087498|Biological|normal saline|preterm neonates less than 32 weeks are assigned to receive normal saline within 24 hours after birth
45675990|NCT05084222|Drug|Buventol® Easyhaler® 200 µg/inhalation dmDPI|Two doses will be administered
46000998|NCT05431192|Other|Enhanced Usual Care|"Usual care will be enhanced in BOTH conditions with printed education materials provided to all participants using publicly available materials (the Healthier Living with Heart Failure guide available at the AHA Heart Failure Resource Center).66 The guide is organized in 7 chapters containing information on topics such as understanding HF, making healthy lifestyle changes, managing HF symptoms, taking medications, and living well with HF. Printed materials will be mailed weekly to all participants during the first 8 weeks of the study."
46000999|NCT00534755|Other|Breast Cancer database|prospective breast cancer database
46001000|NCT00534872|Drug|SB-649868|10 mg
46001001|NCT04665414|Diagnostic Test|MRI|preoperative MRI
46087585|NCT00669825|Drug|ALV003|Doses via intragastric tube at dosages of either 100 mg, 300 mg, 900 mg, or 1800 mg
46087586|NCT00669825|Drug|Placebo|Placebo to be administered via intragastric tube
45675991|NCT05084222|Drug|Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI|Two doses will be administered
45675992|NCT05084222|Drug|Ventoline® Evohaler® 100 µg/inhalation pMDI|Four doses will be administered via Volumatic spacer
46001002|NCT04665414|Diagnostic Test|transvaginal ultrasound|preoperative transvaginal ultrasound
46001003|NCT04665414|Diagnostic Test|transvaginal ultrasound elastography|preoperative transvaginal ultrasound elastography
46001004|NCT00534911|Behavioral|Cognitive Behavioral Therapy|"Participants will receive 12 weeks of CBT designed for youth with IBD. During sessions, participants will learn new ways of thinking (e.g., reconstruction of personal physical illness narratives, coping strategies, social skills) and behaving (e.g., positive activities, family communication, sleep hygiene, relaxation) to improve emotional and physical outcomes. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.~Other Name: Primary and secondary coping enhancement training (PASCET)"
45675993|NCT05072964|Device|FARAPULSE Pulsed Field Ablation System|A pulmonary vein isolation will be performed using catheter ablation
46001005|NCT00534911|Behavioral|Supportive Non-directive Therapy (SNDT)|SNDT is a 12-week non-directive therapeutic intervention. Participants will receive social support and quality information about the warning signs and risk factors for depression. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.
46001006|NCT04665609|Drug|Anlotinib and TQB2450 solution|Anlotinib is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling. TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
46001007|NCT04665609|Drug|TQB2450 solution|TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
45675994|NCT05062980|Biological|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental non-viral therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, re-establishing pathways that promote cancer cell death and modulating the immune system response against cancer cells.
45675995|NCT05062980|Drug|pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody indicated for treatment of patients with metastatic NSCLC.
45675996|NCT05062980|Drug|docetaxel|Docetaxel is a microtubule inhibitor indicated for locally advanced or metastatic NSCLC after platinum-based chemotherapy failure.
45675997|NCT05062980|Drug|ramucirumab|Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated in combination with docetaxel for treatment of NSCLC with disease progression after platinum-based chemotherapy.
45675998|NCT05062980|Drug|Investigator's Treatment of Choice|Treatment will be administered during 21-day treatment cycles. The investigator's treatment must not include investigational drugs or therapies.
45675999|NCT05046574|Other|Stroke rehabilitative therapy sessions with therapy dog present|Therapy dog will be present during stroke rehabilitative therapy sessions. This is expected to be at least three times a week per 7-day period.
45676000|NCT05044598|Other|RAFT-OS|RAFT-OS (Real Architecture for 3D Tissues Ocular Surface) is an artificial tissue, populated with limbal epithelial cells and stromal cells.
45676757|NCT01822899|Drug|Fluticasone propionate/Salmeterol|Dry white powder of fluticasone propionate 500 mcg per blister 50 mcg salmeterol per blister as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
46001008|NCT03773393|Biological|CK0801|CK0801 (a Cord blood-derived T-regulatory cell product)
46001009|NCT03745898|Drug|Oxygen|Active nocturnal oxygen concentrator
46001010|NCT03745898|Other|Room Air|Sham nocturnal oxygen concentrator (room air)
46001011|NCT03737981|Drug|Ibrutinib|Given PO
46001012|NCT03737981|Biological|Obinutuzumab|Given IV
46001013|NCT03737981|Other|Observation|Undergo observation
46001014|NCT03737981|Drug|Venetoclax|Given PO
46001015|NCT04665492|Diagnostic Test|EEG recording 1|"Multichannel EEG recording in eyes opened and eyes closed relaxed state and during imagined movement (all one experimental session). EEG device usbamp (company Guger Technologies, Austria) will be used."
46002591|NCT00545558|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally daily
46001016|NCT04665492|Diagnostic Test|EEG recording 2|"Multichannel EEG recording in eyes opened and eyes closed relaxed state and during imagined movement (all one experimental session). This intervention will take place six month after EEG recording 1. EEG device usbamp (company Guger Technologies, Austria) will be used."
46001017|NCT04665492|Diagnostic Test|Sensory Test|Test for mechanical sensations of the feet and shins of both legs as well as on the trapezoidal muscle on both sides. Semmes-Weinstein Monofilaments will be used
46001018|NCT04665492|Diagnostic Test|Brief Pain Inventory 1|This questionnaire that ask about any acute or chronic pain
46001019|NCT04665492|Diagnostic Test|Multidimensional health locus of control|Questionnaire that test personal belief about control of one's own health
46001020|NCT04665492|Diagnostic Test|Sensory test thermal|"Test of thermal sensations (thermal roller) of the feet and shins of both legs as well as on the trapezoidal muscle on both sides. A Somedic SenseLab Rolltemp device will be used"
46001021|NCT04665492|Diagnostic Test|Neuropathic pain symptoms|Questionnaire that test for neuropathic pain symptoms
45676001|NCT05030961|Behavioral|Virtual team-based clinic|Virtual team-based clinic will include consultation, counseling, and education from pediatric audiology, psychology, auditory verbal therapy, and education. Each session lasts approximately 30 minutes with a total of 3 sessions within the year.
45676002|NCT05030961|Behavioral|Remote cochlear implant programming|Remote cochlear implant programming will be provided via Zoom on a study-provided encrypted laptop.
46001022|NCT04665492|Diagnostic Test|McGill pain questionnaire|Questionnaire assess three separate components of experiencing pain; the sensory intensity, the emotional impact and the cognitive evaluation of pain.
46001023|NCT04665492|Diagnostic Test|Pain Catastrophising Scale|Questionnaire use to identify individual pain experience.
46001024|NCT04665219|Behavioral|HBM-based text messages|"The intervention in the test group will consist of a set of text messages developed based on the HBM to be sent to the parents regularly in the following 48 weeks.~During the first 24 weeks, parents will receive a text message (and feedback if deemed appropriate) each week. In the next 24 weeks, the parents will receive a text message every 4 weeks, altogether 30 messages will be sent to the parents. All messages will be sent to the parents individually through free mobile App by a research assistant."
46001025|NCT04665219|Behavioral|Standard text message|Parents in the control group will receive an oral health education pamphlet produced by the Oral Health Education Division in the Department of Health, the Government of Hong Kong SAR. In order to maintain a double-blind design in the present study, the pamphlet will be distributed in an electronic form and sent via a text message.
46001026|NCT04665102|Other|Image classification using deep learning algorithm|Image classification using deep learning algorithm
46001027|NCT04665141|Biological|Mepolizumab|Mepolizumab will be prescribed freely by the treating physician according to real-life conditions.
46001028|NCT04665141|Biological|Omalizumab|Omalizumab will be prescribed freely by the treating physician according to real-life conditions.
46001029|NCT04665141|Biological|Reslizumab|Reslizumab will be prescribed freely by the treating physician according to real-life conditions.
46001030|NCT04665141|Biological|Benralizumab|Benralizumab will be prescribed freely by the treating physician according to real-life conditions.
46001031|NCT04665141|Biological|Dupilumab|Dupilumab will be prescribed freely by the treating physician according to real-life conditions.
46001032|NCT04665063|Biological|Auto CAR-T|Biological: Auto CAR-T
46001033|NCT04665063|Drug|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
46001034|NCT04665063|Procedure|Leukapheresis|Leukapheresis
46001035|NCT04665180|Diagnostic Test|Primary knee arthroplasty|Patients who return to work after primary knee arthroplasty
46001036|NCT00534950|Radiation|5 vs 6 weekly fraction of RT|Chemotherapy
46001037|NCT04664868|Procedure|Sphinkeeper™|Sphinkeeper™ prostheses are self-expandable solid prostheses, made of inert Hyexpan (polyacrylonitrile) and are inserted into the intersphincteric anal groove.
46001038|NCT03683342|Procedure|Ankle Block|Ankle block will be performed prior to surgery under ultrasound guidance
46001039|NCT03683342|Procedure|Sciatic nerve block|Sciatic nerve block will be performed prior to surgery under ultrasound guidance
46001040|NCT04664712|Dietary Supplement|Tendisulfur Pro|Dietary supplement based on Methylsulfonylmethane (2.5 g), hydrolyzed collagen (1 g), L-arginine (1 g), L-lysine (500 mg), Vitamin C (500 mg), Bromelain (200 mg), Chondroitin sulfate (150 mg), Glucosamine (150 mg) [17, 18], dry extracts of turmeric (100 mg), Boswellia (100 mg) and Myrrh (50 mg)
46001041|NCT04664712|Device|Focused shock wave|We delivered 2000 shots per session using a low/medium energy level (range between 0.01 and 0.175 milliJoule/mm2) depending on the patient's tolerance during treatment with a frequency of 4 Hz.
46001042|NCT03663725|Drug|Intensified protocol|Early Temozolomide (TMZ) 1 cycle (150 mg/m²/ day X 5 days, per os) Started between day 2 and 15 after surgery/ biopsy RT (60 Gy, 2 Gy/fraction) + concomitant TMZ (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ Prolonged TMZ Until progression, intolerance, patient's or physician's decision (150-200 mg/m2 every 4 weeks, per os)
46002592|NCT04638426|Drug|HL237 tablet|Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day
46001043|NCT03663725|Drug|Stupp protocol|RT (60 Gy, 2 Gy/fraction) + concomitant Temozolomide (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ
46087587|NCT04154241|Diagnostic Test|PET/MR scan|"The PET will be performed with (68Ga)-labeled somatostatin analogue since it was proven to be superior to other NET PET tracers in terms of lesion detection and sensitivity [11] [12]. The 3 tesla magnet of the MRI should allow acquisition of several contrasts within a reasonable time frame. The protocol will include T1 and T2-weighted images, diffusion-weighted images with multiple b values and apparent diffusion coefficient (ADC) maps.~All images will be analyzed with big data tools such as radiomics and texture analysis in order to integrate all image parameters and different contrasts into individual tumor status. Then, accuracy, sensitivity and specificity will be evaluated by correlation of this data collection and analysis method with histological biomarkers (for example, Ki67 level) and treatment results."
46087588|NCT04154397|Device|cerebellar transcranial stimulation|Feedforward-based training benefits from a dynamic postural task by application of cerebellum transcranial electrical stimulation (ctDCS) of different modes (direct current vs. noise vs. sham) were administered using a one-channel direct current stimulator (NeuroConn DC-Stimulator PlusTM) with study mode enabled for single blinding. Following the baseline trial of posture tracking, participants of three groups were seated in a chair for 20 min to receive either active or sham cerebellar tDCS prior to the posture tracking and transfer test phases.
46001044|NCT04664439|Diagnostic Test|CT-FFR|CCTA examination will be performed by qualified medical imaging technicians, and patients will be scanned with 256rows of CT, according to standard operating norms. The coronary artery physiological function evaluation software(Keya Medical Technology, Beijing, China)will be configured in the core laboratory in advance, and the relevant imaging analysts will be trained. The core laboratory will receive the CCTA inspection data and evaluate the CCTA image quality. According to the standard operation flow of the software specification, the CT-FFR analysis will be carried out on the images that meet the requirements, and the CT-FFR value of the lesions will be measured.
46001045|NCT04664595|Drug|Propofol Fresenius|final dose of Propofol (mcg/kg) to reach the target effect-site concentration
46087589|NCT00596427|Drug|Colesevelam HCL|Colesevelam HCL 625 mg: 3 tablets twice per day
46001046|NCT04665024|Procedure|preoperative chest physiotherapy|"The patients were approached to partake in the investigation after they got full clarifications about the point of study. They were allocated into two groups and reassurance was achieved about the absence of any side effects.Furthermore, the examination was approved by the ethical committee.~Effects of preoperative chest physiotherapy were compared between two groups, by measuring the lung functions, oxygen saturation, pulmonary complications and length of hospital staying. Lung functions were completed by utilizing spirometry parameters, oxygen saturation was measured by pulse oximeter and pulmonary complications were diagnosed by specialist doctors."
46001047|NCT04665024|Procedure|postoperative chest physiotherapy|"Postoperative chest physiotherapy made in both two groups was similar to the preoperative chest physiotherapy but this was achieved by physiotherapists and made once a day for 10-25 minutes depending on the lectures of postoperative days."
46087590|NCT00596427|Drug|Placebo|Placebo tablets: 3 tablets twice per day
46087591|NCT00669981|Behavioral|Cognitive behavioral couples therapy for post-traumatic stress disorder (CBCT for PTSD)|CBCT for PTSD is a 15-session manualized couples therapy that aims to both decrease individual PTSD symptoms and improve dyadic functioning.
46001048|NCT03594734|Behavioral|Group Lifestyle Balance™|The Group Lifestyle Balance™ (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB program curriculum used in this RCT will be adapted for individuals with TBI.
46087592|NCT04154007|Diagnostic Test|kidney function tests - urine output|"AKI was classified based on the worst of either creatinine or urine output criterion as follows:~Stage I 1.5-1.9 times baseline OR ≥0.3 mg/dl increase in the serum creatinine, OR urine output <0.5 ml/kg per hour for 6 to 12 hours.~Stage II 2.0-2.9 times baseline increase in the serum creatinine OR urine output <0.5 ml/kg per hour for ≥12 hours.~Stage III 3.0 times baseline increase in the serum creatinine OR increase in serum creatinine to ≥4.0 mg OR urine output of <0.3 ml/kg per hour for ≥24 hours, OR anuria for ≥12 hours OR the initiation of renal replacement therapy."
46001049|NCT03594734|Other|Attention Control Group|"The attention control group will receive the same contact or attention as the intervention group. The attention control group will meet at the same frequency as the intervention group. Education for the sessions will be composed of content from the TBI Model Systems Knowledge Translation Center's factsheets. General topics will include discussion on (1) healthy brain and effects of TBI on cognitive, emotional, and behavioral functioning, (2) expectations for recovery, (3) preventative and management strategies for common TBI sequela (e.g. inability and impulsivity), (4) stress management, (5), signs and symptoms of depression, and (6) strategies for effective communication."
46001050|NCT01215175|Biological|Prevnar™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
46001051|NCT01215175|Biological|V114, Aluminum Adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
46001052|NCT01215175|Biological|V114, Aluminum Nonadjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) in each 0.5 mL dose.
46001053|NCT04664283|Device|DCB for de Novo Lesions in Large Coronary Arteries Guided by Optical Coherence Tomography|DCB for de Novo Lesions in Large Coronary Arteries Guided by both angiogram and Optical Coherence Tomography
46001054|NCT03580148|Drug|Cortisone|Patients randomized to receive this study intervention will undergo one ultrasound guided 80mg Depo Medrol GHJ injection
46002593|NCT04638426|Drug|Placebo of HL237 tablet|Placebo of HL237, twice a day
46001055|NCT03580148|Biological|Bone Marrow Aspirate|Patients randomized to receive this study intervention will have, under sterile conditions and after injection of local anesthetic, 10 mls of bone marrow aspirate taken from the posterior superior iliac spine and injected under ultrasound guidance to the glenohumeral joint
46001056|NCT04664517|Procedure|Flexible intramedullary nail (FIN)|Both bone FIN
46001057|NCT04664517|Procedure|Reduction auder general anesthesia and long arm cast|Reduction and cast
46001058|NCT05335915|Other|Nicotine|Nicotine pouches will be self-administered
46001059|NCT05335915|Other|Cigarette|Cigarette will be smoked
46001060|NCT03572153|Behavioral|Self-Administered Hypnosis|Participants will be listening to six 20-minute hypnosis audio recordings with hypnotic induction. Participants will be encouraged to practice daily, and each recording will build on the content of the previous recordings. They will also be provided with booklets of information about hot flashes, including treatment options.
46001061|NCT03572153|Behavioral|Self-Administered White Noise Hypnosis|Participants will be listening to the same 20-minute white noise audio recordings for 6 weeks and will be encouraged to practice daily.They will also be provided with booklets as well as an audio recording with information about hot flashes including treatment options.
46001062|NCT01215097|Drug|Linagliptin|once a day
45676005|NCT05014412|Drug|Elranatamab|BCMA-CD3 bispecific antibody
46001063|NCT01215097|Drug|placebo|once a day
46001064|NCT04664322|Device|non invasive ventilation and high flow nasal canulae oxygen therapy|patients with hypoxemic acute respiratory failure received alternatively non invasive ventilation and high flow nasal canulae oxygen therapy
46001065|NCT04318795|Procedure|minimally invasive spinal decompression (MIS-D)|lumbar spinal decompression alone using minimally invasive approach, without any fusion or implantation
46001066|NCT04318795|Procedure|minimally invasive spinal decompression and fusion (MIS-TLIF)|lumbar spinal decompression plus interbody fusion with implantation using minimally invasive approach
46001067|NCT03527576|Drug|Dexamethasone|Intravenous injection of 0.15 mg/kg of dexamethasone before the surgery.
46001068|NCT03527576|Drug|NaCl 0.0308 MEQ/ML Injectable Solution|Intravenous injection of NaCl 0.9% before the surgery.
46001069|NCT04664010|Drug|Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C|Atomized inhalation of 5 million U α-interferon and 2 mL sterilized water, twice a day; 0.2 g arbidol, three times a day, treatment course no more than 10 days; intravenous administration of ribavirin 500 mg, once every 12 hours, treatment course no more than 10 days; intravenous administration of 10 g immunoglobulin C, once a day, 3-5 days. Anti-bacterial infection treatment is given to the patients who have yellow sputum and increased levels of procalcitonin and other bacterial infection specific indicators.
46001070|NCT04664010|Drug|Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose|Buzhong Yiqi plus and minus formula: 1 dose once, twice a day, taking with warm water. Huhuang Detoxicity Paste: One dose once, twice a day, taking with warm water; Baimu Qingre Jiedu Paste: One dose once, twice a day, taking with warm water; Fumigation/inhalation of Chinese herbs and vitamin C: 30-40 minutes once, 3-7 times a day. Patients take vitamin E capsule and folic acid every day. plus invention 1
46001071|NCT04664010|Drug|Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment|invention 1 plus invention 2 plus 100 mL of 5% glucose containing vitamin C (10 g/60 kg body mass) is intravenously administered twice a day.
46001072|NCT00534989|Procedure|FDG PET|FDG PET
46002594|NCT00545597|Drug|Lorenzo's oil|4:1 glyceryl trioleate-glyceryl trierucate (Lorenzo's oil)given orally, daily as approximately 10% of nutritional calories with supplementation.
46002595|NCT04646577|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous) prime with anodal Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint induced movement therapy. Each session will last 20 minutes.
45676006|NCT05014412|Drug|Elranatamab+ dexamethasone|BCMA-CD3 bispecific antibody + corticosteroids (dexamethasone)
45676007|NCT05014360|Drug|JNJ-64251330|JNJ-64251330 tablets will be administered orally.
45676008|NCT05012098|Drug|Bintrafusp alfa / M7824|Participants will be treated with bintrafusp alfa 1200 mg every 2 weeks for 26 doses.
45676009|NCT05007106|Biological|Pembrolizumab/Vibostolimab Co-Formulation|Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W
46001073|NCT04664127|Drug|Kagocel+Valacyclovir|"Group 1-patients with simple severe herpes (HSV-infection orolabial and / or genital localization) treatment [Valacyclovir + Kagocel ° ] (n= 25).~Treatment: Valacyclovir, 1000 mg orally (2 tablets of 500 mg): 1 time per day for at least 4 months continuously (the rate of suppressive therapy). * Kagocel®, 24 mg orally (2 tablets of 12 mg): 3 times per day, 5 days continuously.~* - During the study the minimum duration of Valacyclovir suppressive therapy in instruction for medical use that drag was changed from 4 (what was using in our reserch) to 6 months, and the optimal duration of continuous antiviral therapy with PG was changed from 6 to 12 months"
46001074|NCT04664127|Drug|Valacyclovir|"Group 2 -patients with simple severe herpes (HSV-infection orolabial and/or genital localization) receiving treatment [Valacyclovir] (n= 20).~Scheme of treatment: Valacyclovir, 1000 mg orally (2 tablets of 500 mg): 1 time per day for at least 4 months continuously (a course of suppressive therapy)*.~* - During the study the minimum duration of Valacyclovir suppressive therapy in instruction for medical use that drag was changed from 4 (what was using in our reserch) to 6 months, and the optimal duration of continuous antiviral therapy with PG was changed from 6 to 12 months."
46001075|NCT04664049|Dietary Supplement|NRICM101|"Direction: Take 1 sachet 2-4 times daily directly or with 400cc water before or between meals~Indication: Externally contracted seasonal epidemic~Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm"
46001076|NCT00535028|Drug|AER 001|AER 001 25 mgs s.c. once daily for 28 days
46001077|NCT00535028|Drug|placebo|sterile saline
46001078|NCT04664088|Procedure|Acupuncture|"Patients in this group will receive acupuncture once every other day (3 days per week) over an 8-week period (a total of 24 sessions). In each session, needles will be retained for 30 minutes. The acupoints will include Baihui (DU20), Qianding (DU21), Houding (DU19), Yintang (DU29), Fengchi (GB20), Shuaigu (GB8), Tongli (HT5), Hegu (LI4), Taichong (LR3), Fenglong (ST40), Xuanzhong (GB39) and Zulinqi (GB41). The selection of acupoints is on the basis of meridian theory and patients' clinical symptoms.~Patients are not allowed to take prophylactic medications. But in case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented in the patient diary."
46001079|NCT04664088|Drug|Venlafaxine|Participants in this group will receive oral administration of venlafaxine 50 mg once a day for 8 weeks. In case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented.
46001080|NCT00535067|Behavioral|Questionnaire|Questionnaires taking 60 minutes total to complete.
46001081|NCT00557115|Other|Early pulmonary rehabilitation (EPR)|Multidisciplinary exercise programme in the format of standard pulmonary rehabilitation. Consists of 2 supervised exercise and educations sessions per week for up to 16 sessions within 3-months. Participants are encouraged to keep an exercise diary at perform at least one exercise session at home unsupervised.
46001082|NCT00535106|Device|Automated external defibrillator (Philips FR2+ AED)|Patients in this arm will be provided with immediate defibrillatory shock coupled with otherwise standard resuscitative efforts.
46001083|NCT00535106|Device|SmartCPR|Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.
46001084|NCT00535106|Other|Delayed defibrillation|In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation.
45676010|NCT05007106|Biological|Pembrolizumab|Pembrolizumab 200 mg administered via IV infusion Q3W.
46001085|NCT04663854|Drug|Trehalose|Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products. In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes.
46001086|NCT04664244|Combination Product|Combination of nimotuzumab and radiotherapy|Patients will undergo targeted radiotherapy no more than 8 weeks, and concurrent nimotuzumab 200 mg intravenous injection every one week till the ending of radiotherapy. Then patients undergo a maintaining therapy with nimotuzumab 200 mg intravenous injection every two weeks up to one year or till the disease progresses.
46002596|NCT04646577|Device|Transcranial Direct Current Stimulation (tDCS|Subjects will either undergo sham Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint-induced movement therapy.
45676011|NCT05007106|Drug|Lenvatinib|Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD
46001087|NCT04663815|Behavioral|Animal-assisted activity|The intervention is an animal-assisted activity consisting of a visit to Villa Samson (a place on the campus of the hospital specifically intended for patients to meet pets), where the child will work with a therapy dog for 1 hour. Under supervision, the animal is stroked and combed by the child, they play games together, the child feeds the animal, etc.
46001088|NCT04663815|Other|Control intervention|The control intervention reenacts a normal stay in the hospital, so the child spends one hour in the hospital room where the child can play, watch tv, etc.
46087593|NCT04153773|Diagnostic Test|OCT|"The degree of physical disability was assessed by using the Expanded Disability Status Scale (EDSS). The EDSS score ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.~Neurocognitive functions were evaluated using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) that includes the following tests:~Symbol Digit Modalities Test (SDMT) that is used for assessment of information processing speed.~California Verbal Learning Test - 2nd edition (CVLT-II) .~Brief Visuospatial Memory Test-Revised (BVMT-R)~OCT assessment was performed by spectral domain-optical coherence tomography to assess the retinal nerve fiber layer thickness and macular volume in humans .~Each eye for every patient was assessed by measuring the thickness of RNFL and GCC, respecting presence or absence of the previous history of optic neuritis (ON)."
46001089|NCT04663581|Other|Left Sided Colonoscopy|Starting colonoscopy with the patient in left decubitus
46001090|NCT04663581|Other|Right Sided Colonoscopy|Starting colonoscopy with the patient in right decubitus
46087594|NCT00670059|Genetic|single embryo transfer without aneuploidy screening|without aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
46001091|NCT04663698|Other|Baseline|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH
46087595|NCT00670059|Genetic|single embryo transfer with aneuploidy screening|with aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
46087596|NCT00670215|Drug|Ciprofloxacin single dose|Patients randomized to this regimen will receive a single-dose of ciprofloxacin MR 1000 mg PO approximately 2 to 3 hours prior to the TRNBP. Patients will also receive two doses of matching placebo approximately 24 hours prior to and approximately 24 hours after the TRNBP.
46001092|NCT04663698|Other|MESH-Resistor 5|Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (5hPa/L) to create laminar airflow
46001093|NCT04663698|Other|MESH-Resistor 10|Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (10hPa/L) to create laminar airflow
46001094|NCT04663698|Other|Perforated Resistor 7|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 7mm) to create a turbulent airflow
46087597|NCT00670215|Drug|Ciprofloxacin triple dose|Patients randomized to this regimen will receive three doses of ciprofloxacin MR 1000 mg PO. The doses will be approximately 24 hours prior to the TRNBP, approximately 2 to 3 hours prior to the TRNBP, and approximately 24 hours after the TRNBP.
46001095|NCT04663698|Other|Perforated Resistor 11|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 11mm) to create a turbulent airflow
46087598|NCT00670293|Radiation|Positron Emission Tomography (PET) using [11C]raclopride|Participants with AN will undergo three PET scans at two separate time points. The first scan will occur when participants are underweight (but not less than 75% ideal body weight), and the second and third scans will occur 2 to 4 weeks after participants have accomplished weight restoration. Healthy participants will have two PET scans at a single timepoint.
45457904|NCT02304796|Behavioral|Unified Cognitive-Behavioral Therapy|"20 weekly sessions (1.5-2 hours each), based on the principles of the Unified Protocol for Trans-diagnostic Treatment of Emotional Disorders (Barlow et al., 2011) adapted for a group format.~The treatment will include 8 different modules of varying length: motivation enhancement, understanding emotions, identifying and monitoring emotions, emotional awareness training, cognitive appraisal and reappraisal, emotional avoidance, emotion driven behaviors, awareness and tolerance of bodily sensations, relapse prevention."
46087599|NCT00670293|Drug|Methylphenidate|The second PET scan for healthy participants and third PET scan for participants with AN will be performed after administration of 60 mg of methylphenidate, a psychostimulant that allows for accumulation of dopamine (DA) extraneuronally.
46087600|NCT00670293|Procedure|Magnetic Resonance Imaging (MRI) scan|Participants with AN will undergo two MRI scans, and healthy participants will undergo one MRI scan. The scans will be conducted in conjunction with the PET scans.
45676012|NCT05007106|Drug|5-Fluorouracil|5-FU 800 mg/m^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles
46001096|NCT04663659|Other|no intervention|no intervention
45676013|NCT05007106|Drug|Cisplatin|Cisplatin administered via IV infusion
45676014|NCT05007106|Drug|Paclitaxel|Paclitaxel administered via IV infusion at investigator's choice of dose
45676015|NCT05007106|Drug|Gemcitabine|Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity
45676016|NCT05007106|Drug|Carboplatin|Carboplatin administered via IV infusion at investigator's choice of dose and frequency
46001097|NCT04663971|Procedure|Any surgery|Any surgical procedures performed for inflammatory bowel diseases
46001098|NCT04663971|Procedure|Any medical treatment|Any treatment (including non-surgical) performed for inflammatory bowel diseases
46001099|NCT04663386|Drug|Budesonide-Formoterol|Dry powder inhaler
46001100|NCT03504488|Biological|CAB-ROR2-ADC|Conditionally active biologic anti-ROR2 antibody drug conjugate
46001101|NCT03504488|Biological|PD-1 inhibitor|PD-1 inhibitor
46001102|NCT04663542|Procedure|immobilization duration|brace immobilization duration after open surgery for Achilles tendon rupture
46001103|NCT03503630|Drug|COMPOUND 2055269|COMPOUND 2055269 to be given every 2 weeks with chemotherapy for 6 cycles
46001104|NCT03503630|Radiation|Radiation Therapy|Radiotherapy 25 Gy to be given on Days 1-5
46001105|NCT03503630|Drug|mFOLFOX|Given every 2 weeks for 6 cycles
46001106|NCT03503630|Procedure|Total Mesorectal Excision|Surgery to be done 2-3 weeks after last cycle of chemotherapy and COMPOUND 2055269
46001107|NCT04663269|Drug|4mg PF Dexamethasone|analgesic provided in the erector spinae block is 20mL of 0.5% Bupivicaine with 4mg of PF Dexamethasone
46001108|NCT04663269|Drug|Control Test|Peritubal block - standard local analgesic administration
46001109|NCT03500081|Device|MRI Scan|The MRI scan will not be used for diagnostic purposes. The research team members do not use the sequences for detection of clinical conditions. This is an observational study only, with no interventions.
46001110|NCT03312738|Drug|Everolimus|Everolimus was formulated as tablets of 5-mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) are administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
46001111|NCT03312738|Drug|Exemestane|Exemestane 25 mg orally daily.
46001112|NCT03312738|Drug|Everolimus Placebo|Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) are administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
46001113|NCT03465020|Other|Observation|Safety and efficacy outcomes of patients on different treatments
46087601|NCT00670527|Procedure|[18F] Fluorocholine PET/CT|"The patients fast 6 hours before the [18F]Fluorocholine PET/CT scan. [18F]Fluorocholine will be used as tracer with a dosage of 4 MBq per kg bodyweight. PET/CT imaging will be performed after 15 and 60 after the intravenous injection of the tracer. The patient will receive 2 full body FCH PET/CT. The CT scan is with contrast.~The radiation exposure from the CT scan is 9 mSv and from the PET scan it is 3 mSv, giving a total of 12 mSv, which equals 4 times the yearly background radiation in Denmark."
46001114|NCT04686500|Device|Tidal volume measured by spirometer and DIBH surface from CT image|The SOC DIBH CT scan will be transferred to Eclipse treatment planning system for treatment planning. Tidal volume measured by spirometer and DIBH surface from CT image will be used as a reference surface for patient treatment initial setup. CBCT will be acquired before each fractional treatment for the patient alignment before beam delivery.
46001115|NCT03303339|Drug|Onvansertib|Onvansertib orally
46001116|NCT03303339|Drug|Cytarabine|subcutaneously
46001117|NCT03303339|Drug|Decitabine|intravenously
46001118|NCT04686461|Drug|Nigella sativa seeds extract containing ointment intervention|Nigella sativa seeds extract containing ointment Nigella sativa seed extract, bee wax, white petrolatum, stearyl alcohol
46087602|NCT04153695|Other|Music Therapy|to listen flamenco music during 30 minuts per day during 2 weeks
46001119|NCT03422471|Other|Hyperinsulinemic Hypoglycemic Clamp|Participants will receive two 90 minute sessions of hypoglycemia. Baroreflex sensitivity will be assessed before, after, and during the sessions.
46001120|NCT03299946|Drug|Cabozantinib|Cabozantinib (40mg) will be taken by mouth daily for 8 weeks.
46001121|NCT03299946|Drug|Nivolumab|Nivolumab 240mg intravenously every 2 weeks (days 14, 28, 42, and 56 for a total of four doses), in combination with Cabozantinib 40mg by mouth daily for 8 weeks.
46001122|NCT03399929|Other|Post Acute Rehabiltation|
46001123|NCT00535340|Drug|SR58611A|
46087603|NCT04153851|Procedure|neurectomy of nasopalatine nerve|Severing of nerurovascular bundle and pushing the nasopalatine canal content nasally and insertion of bone graft in the canal. Dental implant will be inserted in the central incisor location
46087604|NCT02629887|Device|Non-inflatable supraglottic airway|at delivery if resuscitation is required infant randomized to NI-SGA or face mask as the interface for positive pressure ventilation.
46087605|NCT02629887|Device|Face Mask|at delivery - standard airway management per Neonatal Resuscitation Program utilizing face mask.
46087606|NCT02629887|Device|T-Piece Resuscitator|T-Piece Resuscitator for providing postivie pressure ventilation via face mask or non-inflatable supraglottic airway
46087607|NCT00670605|Other|medical chart review|
45676758|NCT01822899|Drug|Placebo NDPI|Dry white powder of matching placebo as NDPI with 30 doses (2 strips with 30 blisters per strip).
46001124|NCT00535379|Drug|Sunitinib|Patients will receive SUTENT 37.5mg (3 x 12.5mg capsules) PO daily in the morning after breakfast. After 2 weeks without treatment-related adverse events grade ≥ 2 (ECOG common toxicity criteria: refer to Protocol Attachment A.4) a SUTENT dose escalation to 50mg (4 x 12.5mg capsules) PO daily has to be performed. Treatment will continue until patients develop progression of disease or until unacceptable adverse events occur.
46001125|NCT00535418|Drug|Letrozole|
46001126|NCT03288948|Other|Binocular games for treatment of amblyopia|playing binocular games on a tablet platform 1 hour per day 5 days per week with reduced contrast for the fellow eye and high contrast for the amblyopic eye
46001127|NCT03307382|Device|SpyGlass DS Cholangioscopy|SpyGlass DS Cholangioscopy includes a 10 French diameter single use digital cholangioscope and a light source with the digital sensor. During ERCP with cholangioscopic exam, the cholangioscope would be first inserted through the working channel of the duodenoscope and subsequently passed into the bile duct for direct visualization of the bile duct mucosa. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy.
46001128|NCT04679064|Drug|Niraparib|PARP-inihibitor
46001129|NCT04679064|Drug|Dostarlimab|PD-1 inihibitor
46001130|NCT04679064|Drug|Pegylated liposomal doxorubicin|Chemotherapy drug
46001131|NCT04679064|Drug|Paclitaxel|Chemotherapy drug
46001132|NCT04679064|Drug|Gemcitabine|Chemotherapy drug
46001133|NCT04679064|Drug|Topotecan|Chemotherapy drug
46087608|NCT00670605|Other|study of socioeconomic and demographic variables|
46087609|NCT00595959|Device|CLiRpath Photoablation System|Use of CLiRpath Laser Catheter to improve vessel lumen diameter.
46001134|NCT04679064|Drug|Bevacizumab|Chemotherapy drug
46001135|NCT03292289|Procedure|Pre- and post-operative consultation|Before and between the two interventions
46001136|NCT03292289|Procedure|Stomatherapy consultation|Clinical exam. At one and six months after the 2nd intervention
46001137|NCT03292289|Procedure|Questionnaires|"QLQ-C30 and QLQ-CR29 at each time defined by the study (one month before and after the first intervention, before the 2nd intervention and at 1, 3, 6 and 12 months after the 2nd intervention)~Stoma-QoL before and after the 2nd intervention~LARS score at 1, 3, 6 and 12 months after the 2nd intervention"
46001138|NCT01183780|Biological|Ramucirumab|8 milligrams / kilogram (mg/kg) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
46001139|NCT01183780|Biological|Placebo|Administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
46001140|NCT01183780|Drug|Irinotecan|180 milligrams/square meter (mg/m^2) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
46087610|NCT00670683|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46001141|NCT01183780|Drug|Folinic Acid|400 mg/m^2 administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
46087611|NCT00670761|Drug|misoprostol|comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
46001142|NCT01183780|Drug|5-Fluorouracil|400 mg/m^2 bolus immediately followed by 2400 mg/m^2 continuous infusion every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
45676017|NCT05007106|Drug|Docetaxel|For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles
46087612|NCT00670761|Procedure|MVA|comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
46087613|NCT00670839|Biological|GenHevac-B|1 intramuscular injection of Genhevac-B® 20μg on day zero, month 1,and month 6
46001143|NCT04662957|Dietary Supplement|Multi-strain probiotic mixture of four Bifidobacterium, five Lactobacillus and one Streptococcus species or placebo|Oral supplementation with multi-strain probiotic preparation
46001144|NCT04662957|Dietary Supplement|Maltodextrin|Maltodextrin as placebo
46001145|NCT00535457|Other|Preoperative Magic Tricks|"Watching magic; Study patients will watch the anesthesiologist performing tricks (magic) before anesthesia induction."
46001146|NCT04679103|Biological|Eculizumab (JSC GENERIUM, Russia)|Eculizumab
46001147|NCT04663191|Procedure|anatomical resection|Anatomical resection with systematic lymph-node dissection
46001148|NCT00535535|Dietary Supplement|Fructose|Fructose, 0.5 g/kg
46001149|NCT00535535|Dietary Supplement|Fructose and Glucose|Fructose:Glucose 1:1, 1 g/kg
46001150|NCT00535535|Dietary Supplement|Fructose and Glucose|Fructose:Glucose 1:1, 2g/kg
46001151|NCT04678713|Dietary Supplement|investigate the nutritional determinants of MFO in moderate to well-train individuals|The participants will receive a 3-day fat rich or a carbohydrate rich diet. The participants will perform a maximal fat oxidation test before and after the diet intervention to evaluate the effect of the two diets on MFO.
45457905|NCT02304796|Behavioral|Combined Cognitive-Behavioral and Dance/Movement Therapy|20 weekly sessions (1.5-2 hours each), based on combined cognitive-behavioral techniques (psychoeducation, awareness and tolerance of emotions, interoceptive exposures, in-vivo exposures, cognitive flexibility) and dance/movement techniques.
45457906|NCT05237167|Procedure|Shoulder reduction|This is standard of care and only measure as a time component outcome in the study
46001152|NCT04678713|Other|Investigate the physiological determinants of MFO in moderate to well-train individuals|Muscle biopsies will be obtained at baseline to compare muscle characteristics between well-matched train individuals with a high compared to a low maximal fat oxidation.
46001153|NCT00535574|Drug|Bexarotene (Targretin LGD1069)|75 mg per day for 6 weeks
46001154|NCT00535574|Drug|bexarotene|75 mg/day 6 weeks
46001155|NCT04678830|Drug|Placebos|Placebos
46001156|NCT04678830|Drug|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
46001157|NCT01183468|Biological|Aralast NP 45 mg dose|- 45 mg/kg/week
46087614|NCT00670839|Biological|GenHevac-B|2 intramuscular injections of Genhevac-B® 20μg on day zero, month 1,and month 6
46087615|NCT04151888|Device|Foley catheter|Thin sterile tube will be inserted in choana
46087616|NCT00670917|Other|questionnaire administration|
46087617|NCT00670917|Procedure|acupressure therapy|
45676018|NCT05007106|Drug|Bevacizumab|Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles
45676019|NCT05007106|Drug|Capecitabine|Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles
45676020|NCT05007106|Drug|Oxaliplatin|Oxaliplatin administered via IV infusion Q3W up to 35 cycles
45676021|NCT05006794|Drug|GS-9716|Tablet(s) administered orally
46001158|NCT01183468|Biological|Aralast NP 90 mg dose|- 90 mg/kg/week
46001159|NCT01183468|Biological|Aralast NP 180 mg dose|- 180 mg/kg/week
46087618|NCT00670917|Procedure|biopsy|
46087619|NCT00670917|Procedure|bone marrow aspiration|
46087620|NCT00670917|Procedure|pain therapy|
46087621|NCT04151732|Behavioral|Physical activity, alcohol, tobacco|Physical activity, alcohol, tobacco - selfreported in the 1990's
46087622|NCT04151732|Other|Hormonal factors|Hormonal factors - selfreported in the 1990's
46001160|NCT03245021|Drug|Opdivo|"All patients will receive:~Nivolumab 240mg IV q2-weekly for four cycles~Patients in complete remission (CR):~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with partial response (PR), stable disease (SD), asymptomatic or minor progressive disease (PD) post 4cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles~Patients in CR:~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with PR, SD, asymptomatic or minor PD post 4 cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles"
46087623|NCT04151732|Other|Cardiovascular disease|Cardiovascular disease - selfreported in the 1990's
46087624|NCT04151732|Other|Anthropometric measures|Height, length, BMI
46001161|NCT04678791|Drug|Nimotuzumab|Patients receive Nimotuzumab 400 mg each time, once a week, slow intravenous drip, for a total of 6 weeks.
46087625|NCT00670995|Behavioral|Interactive Tobacco Education|Increase perceived behavioral control (self-efficacy) Decrease willingness to use tobacco Decrease intentions to use tobacco
46087626|NCT04153617|Dietary Supplement|Control honey|Control honey defined as orange blossom honey. Intake daily for 3 months (40 g/day)
46001162|NCT04678791|Drug|Cisplatin|Patients receive 40 mg/m2, d1, 7 days as 1 treatment cycle, 6 treatment cycles in total
46001163|NCT04678791|Radiation|External-beam radiation|Patients undergo IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45 - 50.4 Gy; 1.8 - 2.0 Gy/f, 25 - 28 f.
46001164|NCT04678791|Radiation|Brachytherapy|Patient undergo Brachytherapy with high dose rate, with a total dose of 30-40 Gy and a cumulative dose of 80 ~ 85 Gy at point A/HRCTV D90; if the tumor diameter is ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90.
46001165|NCT01183390|Drug|Anastrozole|1 mg Tablets
46001166|NCT01183390|Drug|Anastrozole|1 mg Tablets
46001167|NCT02887807|Drug|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation|cardio-pulmonary resuscitation usual care of cardiac arrest
46001168|NCT02887807|Drug|Single intravenous bolus of placebo at the onset of resuscitation|cardio-pulmonary resuscitation usual care of cardiac arrest
46087627|NCT04153617|Dietary Supplement|Modified honey with soluble fiber and polyphenols|Honey modified with soluble fiber and polyphenols, with same organoleptic conditions as control honey. Intake daily for 3 months (40 g/day)
46087628|NCT02627391|Other|Early surgical aortic valve replacement|
46087629|NCT02627391|Other|Delayed Surgical aortic valve replacement|
46087630|NCT03239678|Drug|100% Oxygen|Conventional preoxygenation with 100% oxygen
46087631|NCT03239678|Drug|30% Oxygen|preoxygenation with 30% oxygen
46087632|NCT03239678|Drug|21% Oxygen|preoxygenation with 21% oxygen
45676022|NCT05006794|Drug|Docetaxel|Administered intravenously
46001169|NCT03237182|Drug|Individualized TB treatment with multiple drugs|"Patients with drug-resistant TB will receive a combination of any of the following drugs based on whole genome sequencing:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone"
46087633|NCT03239678|Drug|40% Oxygen|preoxygenation with 40% oxygen
46087634|NCT03239678|Drug|60% Oxygen|preoxygenation with 60% oxygen
46087635|NCT03239678|Drug|80% Oxygen|preoxygenation with 80% oxygen
46087636|NCT00680433|Drug|Ketamine|Ketamine IV will be administered after the administration of the normal anaesthetic agents for ECT.
46087637|NCT00680433|Drug|Saline|Saline (placebo) will be administered after the normal anaesthetic agents in ECT.
46087638|NCT03209258|Other|Care bundle of active management|"Intensive BP lowering to systolic target of <140mmHg;~Glucose control target 6.1-7.8 mmol/l for non-diabetic; 7.8-10.0 mmol/l for diabetic patients;~Treatment of pyrexia to a target body temperature ≤37.5 ℃;~Reversal of anticoagulation to target INR <1.5 involving use of vitamin K and prothrombin complex concentrate (PCC) or alternatively, fresh frozen plasma (FFP).~As the trial is an assessment of care bundle of physiological management, there is some flexibility in the use of particular BP lowering agents and antipyretic agents to achieve targets."
46087639|NCT03209258|Other|Usual care|Usual care decisions about the location of care delivery, investigations, monitoring, and all treatments will be made by the treating clinical team.
46087640|NCT02627157|Device|Dynamic Scheimpflug Analyzer|Measurements of Corneal Biomechanical Properties Using a Dynamic Scheimpflug Analyzer
45676023|NCT05006794|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
45676024|NCT05006794|Drug|Gemcitabine|Administered intravenously
45676025|NCT05005442|Biological|Pembrolizumab/vibostolimab coformuation|Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
45676026|NCT04954300|Other|no intervention|No intervention
45676027|NCT04949464|Procedure|Computed Tomography|Undergo LDCT
45676028|NCT04949464|Behavioral|Smoking Cessation Intervention|Use Positively Smoke Free - Mobile
46087641|NCT03322280|Procedure|TACE combined with iodine-125 seeds implantation|Conventional TACE with lipiodol was performed. Then Iodine-125 seed implantation into PVTT is conducted 7-10 days after TACE when liver function tests demonstrated values comparable to those obtained before TACE.
46087642|NCT03322280|Procedure|TACE|Only conventional TACE with lipiodol and chemotherapy drugs was performed.
45676029|NCT04945330|Drug|Larotrectinib (Vitrakvi, BAY2757556)|Follow clinical practice
45676030|NCT04944147|Device|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA)
46087643|NCT04150965|Drug|Elotuzumab, pomalidomide, dexamethasone|Study Patients with relapsed Multiple Myeloma will receive: Elotuzumab, Pomalidomide, and Dexamethasone Starting in Phase 2 Cycle 1 Day 1 forward. Each cycle is 28 days long.
46087644|NCT04150965|Drug|Anti-LAG-3|"Patients with relapsed Multiple Myeloma will receive: Anti -LAG-3 single agent for Cycle 1. Each Cycle is 28 days~Cycle 2 forward patients will receive Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days long."
46087645|NCT04150965|Drug|Anti-LAG-3 + Pomalidimide + Dexamethasone|Patients with Relapsed & Refractory Multiple Myeloma will receive: Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days.
46001170|NCT03237182|Drug|Standardized TB treatment with multiple drugs|"Patients with drug-resistant TB with receive a combination of any of the following drugs based on South African Department of Health guidelines:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone"
46001171|NCT04663035|Drug|Tislelizumab|200mg, iv. drip, Q3W. Tislelizumab will start within 3-7 days after ablation treatment. The longest course of treatment is 12 months.
46087646|NCT04150965|Drug|Anti-TIGIT|"Patients with relapsed Multiple Myeloma will receive: Anti -TIGIT single agent for Cycle 1.~Each cycle is 28 days."
46001172|NCT04663035|Procedure|Ablation|After local anesthesia and intravenous sedative injection, the unipolar needle would be gradually inserted into the lesion and placed on the deepest edge of the lesion. The ablation electrode is a unipolar needle with a bare end of 2 or 3 cm (adjusted to tumor size). The ablation power is 150 watts (range from 100 to 200 watts). In general, the average ablation time for each lesion is about 12 minutes (ranging from 10 to 15 minutes).
46087647|NCT04150965|Drug|Anti-TIGIT + Pomalidimide + Dexamethasone|Cycle 2 and beyond patients will receive Anti-TIGIT in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days..
45676031|NCT04944147|Device|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants
45676032|NCT04944147|Behavioral|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 9 sessions
45676033|NCT04944147|Behavioral|Progressive muscle relaxation (PMR)|Standardized instructed PMR training, 9 sessions
45676034|NCT04939558|Device|N-Tidal C handset|Participants are to use the 'N-Tidal C' handset every day for 14 days. This will ideally be two times a day (once in the morning and once in the evening, before using any regular inhalers). Each breath record requires the participant to breathe through the mouthpiece for 75 seconds in a relaxed manner.
45676035|NCT04931342|Drug|Ipatasertib|Ipatasertib will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 28 days)
45676036|NCT04931342|Drug|Cobimetinib|Cobimetinib will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length=28 days)
45676037|NCT04931342|Drug|Trastuzumab Emtansine|Trastuzumab Emtansine will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
46001173|NCT04662762|Other|Nursing intervention programme|educational information
46001174|NCT03191942|Device|Modified ortho-k lenses|KETT MC lens
46001175|NCT03191942|Device|Ortho-k lenses|KATT BeFree lens
46001176|NCT03181256|Procedure|Biospecimen Collection|Undergo collection of sputum
46001177|NCT03181256|Procedure|Biospecimen collection|Undergo collection of nasal epithelium
46087648|NCT05345366|Other|non-applicable|non-applicable
46087649|NCT04150575|Drug|HLX10+Albumin-Bound Paclitaxel|HLX10: 4.5 mg/kg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and HLX10 for up to 2 years.
46087650|NCT04510298|Drug|SP-624|Oral Capsule
46087651|NCT04510298|Drug|Placebo|Oral Capsule
45676038|NCT04931342|Drug|Atezolizumab|Atezolizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
46087652|NCT04451954|Biological|Quadrivalent RIV with H3 strain 1|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
45676039|NCT04931342|Drug|Bevacizumab|Bevacizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
45676040|NCT04931342|Drug|Paclitaxel|Paclitaxel will be administered intravenously on Days 1, 8, and 15 of each cycle. (Cycle length=28 days)
46001178|NCT03181256|Procedure|Biospecimen collection|Undergo collection of buccal epithelium
46001179|NCT03181256|Procedure|Biospecimen collection|Undergo collection of blood
46001180|NCT03181256|Procedure|Biospecimen collection|Undergo collection of urine
46001181|NCT03181256|Procedure|Pulmonary Function Test|Undergo pulmonary function test
46001182|NCT03181256|Procedure|Computed Tomography (CT)|Undergo chest CT
46001183|NCT03181256|Other|Laboratory Biomarker|Correlative studies
46001184|NCT04662606|Behavioral|Consumption of a standard meal prior to the fMRI data collection|Consumption of a standard meal prior to the fMRI data collection
46002597|NCT00545636|Other|education|The intervention is an education of the medical teams that instruct children to fast before the administration of general anesthesia
46087653|NCT04451954|Biological|Quadrivalent RIV with H3 strain 1 and adjuvant|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
46001185|NCT03058952|Behavioral|Mindfulness-Based Stress Reduction|An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
46087654|NCT04451954|Biological|Quadrivalent RIV with H3 strain 2|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
46001186|NCT03058952|Behavioral|Chronic Disease Self-Management Program|The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
46087655|NCT04451954|Biological|Quadrivalent RIV with H3 strain 2 and adjuvant|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
46001187|NCT04662528|Drug|Placebo|4 x 1g capsules/day
46001188|NCT04662528|Drug|MAT9001 (omega-3 pentaenoic acid)|4 x 1g capsules/day
46001189|NCT02830997|Device|Stereotactic guidance system|
46087656|NCT04451954|Biological|Quadrivalent RIV with 2018-2019 NH H3 strain|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
46087657|NCT04451954|Biological|Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
46087658|NCT05345132|Drug|Nifedipine 20 Mg|The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
46001190|NCT03098706|Procedure|Procedure control: normothermia|Temperature will be maintained between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming will be introduce to maintain temperature between the range of 36.5 - 37.5°C.
46001191|NCT03098706|Procedure|Procedure active|Therapeutic hypothermia ie targeted controlled temperature between 34° and 35°C will be induced in the active group. Usual method of controlled temperature will be used in ICU: internal active method or external active method.
46001192|NCT02802488|Procedure|Blood sampling|"A blood sampling will be performed in patients diagnosed with atrial fibrillation in order to test if having a D-dimers value superior or equal to the patient's age is predictive of a thrombus.~Thombus will be diagnosed according to the standard of care."
46001193|NCT04662333|Procedure|Transcrestal approach for sinus lift|After surgical exposure of maxillary alveolar crest, implant site preparation and transcrestal detachment of Schneiderian's membrane will be performed. Thereafter implant will be placed, protruding in the maxillary sinus with its apical part.
46087659|NCT05345132|Drug|Magnesium sulfate|Women will also receive MgSo4 as a loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
46087660|NCT00614510|Device|CardioWest temporary Total Artificial Heart (TAH-t)|The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) system is a pulsatile biventricular device that replaces a patient's native ventricles and valves and pumps blood to both the pulmonary and systemic circulation. The system consists of the implantable CardioWest TAH-t and an external console connected by drivelines.
46001194|NCT04662333|Procedure|Xenograft application|Before implant placement, xenogenic collagen membrane and bone granules will be pushed under the Schneiderian's membrane through the surgical site.
46087661|NCT04349306|Drug|RASBURICASE SR29142|Pharmaceutical form:solution for infusion Route of administration: intravenous
46087662|NCT03104192|Behavioral|Develop & Refine MOWI w/o Amulet|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks.
46087663|NCT03104192|Behavioral|MOWI Weight Loss Maintenance|Participants who successfully completed the initial MOWI program will be offered the opportunity to participate in a 6-month weight management program. This program will consist of 8 group-based skills workshop sessions occurring approximately once monthly (every 3 weeks), which will be 90-120 minutes in length. The overall structure of the program will emphasize the following evidence-based weight management components: Goal setting/action planning, self-monitoring, receiving feedback regarding performance, reviewing relevant goals in the light of feedback, and e. psychological skills for increasing behavioral commitment (acceptance, willingness, thought monitoring, mindful decision making, and values clarification).
46087664|NCT03104192|Behavioral|Develop & Refine MOWI w Fitbit|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits; and Fitbit to monitor activity. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks and will also be given Amulet to measure steps, activity type, duration and distance.
45676041|NCT04931342|Drug|Giredestrant|Giredestrant will be administered by mouth once a day on Days 1-28 of each cycle (Cycle length=28 days)
45676042|NCT04931342|Drug|Abemaciclib|Abemaciclib will be administered by mouth twice a day during each 28-day cycle
46001195|NCT05300672|Drug|fibrinogen infusion|fibrinogen infusion (2 g) in stroke patients with secondary post-rtPA hypofibrinogenemia
46001196|NCT03098589|Drug|Revlimid|Revlimid
46001197|NCT05298137|Procedure|Passive Leg Raise|A passive leg raise (PLR) is defined as raising a patient's legs to a 45-degree angle at the hip while supine.
46001198|NCT04662177|Drug|Dexmedetomidine|The study participants are divided into two groups: Group 1 starts with a bolus of dexmedetomidine 0.4 µg/kg over 10 minutes, followed by con-tinuous infusion of dexmedetomidine 0.4 µg/kg/h until the end of burst suppression. Group 2 receives the standard anaesthesia management.
46001199|NCT05292560|Other|Training in positivity|The University of Twente developed an evidence-based positive psychology app that is aimed at increasing mental well-being and resilience (Training in positivity; TiP). TiP consists of a 3-week structured intervention, in which participants do two exercises every week for 6 days, aimed at increasing resilience and mental well-being. An exercise takes an average of 15 minutes per day.
46001200|NCT03076008|Other|Observational|No intervention
46087665|NCT03104192|Dietary Supplement|Develop & Refine MOWI w Fitbit/Protein|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits; and Fitbit to monitor activity. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks and will also be given Amulet to measure steps, activity type, duration and distance. We will provide whey protein 3x/week after exercise sessions.
46087666|NCT00614588|Device|Body temperature thermometers|Temperature readings every 30 minutes during and post surgery using internal stethoscope, catheter and adhesive patches/electronic thermometer.
46001201|NCT05283512|Other|Kidney prophylaxis with IV-hydration|IV-hydration with isotonic NaCl
46001202|NCT05283512|Other|Kidney prophylaxis with oral hydration|Oral hydration with regular bottled water
46001203|NCT03026517|Drug|Dabrafenib|
46001204|NCT03026517|Drug|Trametinib|
46001205|NCT03026517|Drug|Phenformin|
46001206|NCT00537953|Drug|Miltefosine , meglumine antimoniate|
46001207|NCT05282342|Diagnostic Test|Diagnostic tests|No intervention will be carried out. Participants of the whole groups will be underwent the same tests.
46087667|NCT04171310|Drug|SAR442168|Pharmaceutical form:oral solution Route of administration: Oral
46087668|NCT04170140|Other|No intervention|Questionnaire
46087669|NCT04054310|Diagnostic Test|Liver Multi Scan|MRI to create cT1, T2* and PDFF images of patients liver.
46087670|NCT03421652|Drug|Nivolumab|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 14 days (2 weeks) for up to 14 courses (6 months) in the absence of disease progression or unacceptable toxicity. Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.
46087671|NCT03421652|Radiation|Radiation|Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.
46001208|NCT02971098|Procedure|Reduced activity|Participants will reduced their physical activity level to approximately 2000 steps or 75% of their normal activity levels.
46001209|NCT05259449|Behavioral|Nutritional education program|The education intervention will consist of individual nutritional counselling. The nutritional education program will be conducted every 2 weeks for 12 consecutive weeks, with 20-min counselling sessions by an experienced nutritionist. Participants will be provided with an introduction (in an easy-to-understand manner) regarding the association between T2DM, gut microbiome and dietary habits. Firstly, the diet of the patient should be analysed, to determine which aspects can be improved, such as, total calories intake, amount and types of carbohydrates (highlighting the relevance of fibre), etc. Moreover, some suggestions about the combination of foods and culinary technical in order to manage the glycaemic index of foods will be provided. Finally, those pattern of the Mediterranean diet and some qualitative aspects and aids (as the size of the plat or avoid having the food platter on the table) will be taught the patients.
46001210|NCT05259449|Other|The High-Intensity Interval Training (HIIT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes). Depending on the number of training session, the load and the series will increase up to 40% more than the maximum load.
46001211|NCT05259449|Other|The Moderate-Intensity Continuous Training (MICT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. MICT program will consist of sessions of approximately ˜45 min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
46001212|NCT04661943|Drug|Tucidinostat|Tucidinostat Specification: 5mg / tablet. Dosage: oral, 20 mg (3 tablets) each time, twice a week, with the interval of no less than 3 days (such as Monday and Thursday, Tuesday, Friday, Wednesday and Saturday, etc.)
46087672|NCT02699840|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
46087673|NCT02699840|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
46087674|NCT02699840|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
46087675|NCT02514668|Drug|Isatuximab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
46087676|NCT01697930|Drug|[18F] 4-L-Fluoroglutamine (2S,4R)|Thirty cancer patients will receive an injection of a 0.5 to 7.5mCi of [18F] 4-LFluoroglutamine (2S,4R) , followed by serial PET/CT scanning and blood draws, (at the direction of the investigator) over a period of 3.5 hours, on a single day. Each patient will be offered the opportunity to repeat the [18F] 4-L-Fluoroglutamine (2S,4R) injection and subsequent set of post-injection PET-CT scans, once, on a separate date. At the discretion of the investigator, scan 3 can be waived. Immediately prior to injection of the radiotracer, a blood sample will be obtained for measurement of serum glutamine level. The serum glutamine level will be assayed, if necessary, as part of an amino acid screen assay.
46087677|NCT00613808|Drug|Nitric Oxide 200ppm Group B|200 ppm, 8hrs / day for 6 weeks
46087678|NCT05344976|Biological|MSLN STAR-T cells|Patients with advanced MSLN-positive solid tumors will be recruited, and autologous-derived MSLN-STAR-T cells will be infused intravenously at escalating doses of 1×10^7-1×10^8 MSLN-STAR-T cells. The CAR-T ratio will be monitored at predetermined times (day 0, day 4, day 7, day 10, day 14, day 28).
45457907|NCT03503734|Behavioral|Integrated headache care|"The treatment can be realized on an inpatient, outpatient and/or day care basis, according to the severity level of illness and comorbidities.~The inpatient treatment takes place at the Department of Internal and Integrative Medicine. The stay is slated for 14 days.~Day care can follow the inpatient stay or can be applied as sole therapy. As part of the standard care provided at the Department for Internal and Integrative Medicine, it occurs at a semi-residential clinic for 6 hours once a week over a total of 10 weeks.~The outpatient treatment is delivered in the Department's outpatient ward. It consists of acupuncture, cupping, hydrotherapy and massages as well as nutritional counseling. The patients can additionally be offered one-to-one mind-body-medicine interventions."
45457908|NCT05235061|Behavioral|Home Based Self-management and Cognitive Training Changes lives in post traumatic epilepsy (HOBSCOTCH-PTE)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-PTE is an adaptation of the HOBSCOTCH program for people with a traumatic brain injury and post-traumatic epilepsy that incorporates education about TBI, PTE, and cognition into the education module.
46001213|NCT05252000|Device|mechanical debridement|subjects will receive traditional non-surgical mechanical debridement of tooth surfaces with scalers and ultrasonics removing supragingival and subgingival plaque
46087679|NCT05344742|Drug|Mitoxantrone Hydrochloride Liposome injection|Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle)
46087680|NCT05344742|Drug|Capecitabine|The fixed dose of oral capecitabine will be administered 1000mg/m^2, twice daily, from day 1 to day 14.
46087681|NCT05344742|Drug|Albumin-paclitaxel|The fixed dose of albumin-paclitaxel will be set as 260 mg/m^2, once every three weeks.
46087682|NCT03415412|Device|Clearfil Univesal Bond|Adhesive systems
46087683|NCT03415412|Device|IBond Universal|Adhesive systems
46087684|NCT03415412|Device|G-Premio Bond|Adhesive systems
45457909|NCT05235061|Behavioral|HOBSCOTCH-PTE for Caregivers|Select components of the HOBSCOTCH-PTE program delivered to caregivers consist of session 1 of the HOBSCOTCH-PTE (virtual) program (education module), guidance and instructions on utilizing quick relaxation, and session 8 of the HOBSCOTCH-PTE program (program wrap-up and maintenance planning).
46001214|NCT05252000|Device|adjunctive aPDT|Antimicrobial photodynamic therapy will be done at tooth sites by applying a photosensitizing dye methylene blue (0.1mg/ml) with a disposable syringe from the bottom of pocket in a coronal direction. After 3 minutes in situ, the surrounding gingival tissues will be irradiated at six sites around the tooth using a diode laser with a wavelength of 660nm, providing an energy density of 10 J/site, 100mW power, time equal to 100 seconds. After irradiation, the site will be thoroughly rinsed with saline.
46001215|NCT05252000|Device|sham aPDT|subjects will receive saline and non-light emitting laser on the tooth
46087685|NCT02046434|Drug|Glycerol Phenylbutyrate|
46087686|NCT03930446|Drug|Ethanol|The 0.8 g/kg body weight dose of oral alcohol (190-proof ethanol) will be divided into 4 servings of 0.2 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol. Women will receive a reduced dose (0.68 g/kg) to account for sex differences in total body water
45457910|NCT02308384|Behavioral|Intervention|CME, Start-package and status mail
45676043|NCT04931342|Drug|Inavolisib|Inavolisib will be administered by mouth once a day on Days 1-28 of each 28-day cycle
46001216|NCT04662138|Drug|directly acting antivirals|Different regimens given for genotype 4 relapse: Sofosbuvir/velpatasvir/voxilaprevir ±ribavirin; sofosbuvir/velpatasvir ±ribavirin; ombitasvir/paritaprevir/ritonavir+ ribavirin
46001217|NCT00557154|Device|ultrasound|ultrasound used to identify target vein
46001218|NCT00557154|Device|standard technique for venipuncture|routine equipment
46001219|NCT05237414|Device|Active tDCS|20 minutes of 2.0 mA direct current applied over the right DLPFC
46001220|NCT05237414|Device|Sham tDCS|15 seconds of 2.0 mA direct current applied over the right DLPFC
46001221|NCT05237414|Behavioral|Active CT|Active memory inhibition CT (i.e., training of memory inhibition specifically for alcohol-related memories).
46001222|NCT05237414|Behavioral|Sham CT|Sham memory inhibition CT (i.e., participants have to categorize alcoholic and non-alcoholic images but they do not have to inhibit the memories related to these images).
46001223|NCT02824263|Other|CPAP withdrawal|CPAP is discontinued for 3 nights.
46087687|NCT03930446|Other|Placebo|The placebo beverage will consist of the cranberry or orange juice plus 1% alcohol added as a taste mask. All beverages will be sprayed with an alcoholic mist to provide a strong alcoholic scent.
46087688|NCT03918122|Other|Self-Assessment via pre and post survey|Master Preceptor Fellows will assess and evaluation professional development, knowledge, clinical practices and master preceptor knowledge before the Master Preceptor Fellowship and After completion of the Master Preceptor Fellowship
46087689|NCT05344664|Biological|GPC3-CAR-T cells|The patients will receive one dose of GPC3-CAR-T.The dosage ranges from3×10^6 to 1×10^8 CAR-T+/kg.
46001224|NCT05226299|Biological|Supra-threshold and progressive doses of diluted capsaicin via a dosimeter-controlled nebulizer|Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through a dosimeter-controlled nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. Individual doses will never exceed 1000 micromolar. Cumulative doses per session will never exceed 2000 micromolar. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
46001225|NCT05226299|Biological|Saline|Participants will be repeatedly exposed to a saline through a dosimeter-controlled nebulizer during treatment sessions. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session.
46001226|NCT00557232|Drug|bevacizumab|1.25mg/month
46087690|NCT00614666|Drug|nikkomycin Z|"Stage I: Multiple rising doses. Doses packaged on a unit dose basis in 50 and 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.~50 mg BID (n=8) vs placebo capsule BID (n=2)~250 mg BID (n=8) vs Placebo capsule BID (n=2)~500 mg BID (n=8) vs Placebo capsule BID (n=2)~750 mg TID (n=8) vs Placebo capsule TID (n=2)~At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos.~Stage II will be a single dose level selected based on pharmacodynamics and safety from Stage I for 20 additional subjects using 4:1 randomization."
46001227|NCT02797119|Drug|tranexamic acid 1 g (TA1)|1 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
46087691|NCT03794336|Drug|Alogliptin|"Pharmaceutical form: tablet~Route of administration: oral administration"
46087692|NCT03794336|Drug|Acarbose|"Pharmaceutical form: tablet~Route of administration: oral administration"
46087693|NCT03794336|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral administration"
46087694|NCT03794336|Drug|Aspirin|"Pharmaceutical form: tablet~Route of administration: oral administration"
46087695|NCT03774914|Drug|Alemtuzumab (GZ402673)|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous infusion
46001228|NCT02797119|Drug|tranexamic acid 0.5 g (TA1/2)|0.5 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
46001229|NCT02797119|Drug|Saline Solution (TA0)|
46087696|NCT00956774|Procedure|HSG with acorn-tipped cannula|Use of acorn-tipped cannula for HSG to evaluate tubal patency
46087697|NCT00956774|Procedure|HSG with cervical vacuum cup|cup placed over cervix to create vacuum pressure.
46087698|NCT00956774|Procedure|HSG with balloon catheter|balloon inserted via catheter into cervic for dilation.
46087699|NCT05343884|Radiation|Myocardial perfusion imaging|Myocardial perfusion imaging
45457911|NCT05221645|Drug|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). Based on preclinical in vitro data, pembrolizumab has high affinity and potent receptor blocking activity for PD 1. Pembrolizumab has an acceptable preclinical safety profile and is in clinical development as an intravenous (IV) immunotherapy for advanced malignancies. Keytruda® (pembrolizumab) is indicated for the treatment of patients across a number of indications because of its mechanism of action to bind the PD-1 receptor on the T cell.
45676044|NCT04931342|Drug|Palbociclib|Palbociclib will be administered by mouth once a day on Days 1-21 of each 28-day cycle
45676045|NCT04931342|Drug|Letrozole|Letrozole will be administered by mouth once a day on Days 1-28 of each 28-day cycle
46001230|NCT05173259|Behavioral|F|The participant will be asked to chew the two-coloured chewing gum naturally.
46001231|NCT05173259|Behavioral|R|The participant will be asked to chew the two-coloured chewing gum on the right-side.
46001232|NCT05173259|Behavioral|L|The participant will be asked to chew the two-coloured chewing gum on the left-side.
46001233|NCT05173259|Behavioral|G05|The participant will be asked to chew the two-coloured chewing gum changing the side in 5%.
46001234|NCT05173259|Behavioral|G15|The participant will be asked to chew the two-coloured chewing gum changing the side in 15%.
46001235|NCT05173259|Behavioral|G25|The participant will be asked to chew the two-coloured chewing gum changing the side in 25%.
46001236|NCT00557388|Dietary Supplement|Protein/Amino Acids|Casein Whey Leucine
46087700|NCT03451916|Drug|PLX-PAD|PLX-PAD (120 subjects): 150×10^6 PLX-PAD cells (10×10^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte
46087701|NCT03451916|Drug|Placebo|Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO [v/v], 5% HSA [w/v], and PlasmaLyte, without cells).
46087702|NCT03687554|Drug|Venglustat GZ/SAR402671|Pharmaceutical form: Hard Capsule Route of administration: Oral
46087703|NCT03681158|Drug|sodium valproate|Pharmaceutical form:Powder for oral solution reconstituted with water Route of administration: Oral
46087704|NCT05343806|Drug|Nifedipine 20 Mg|The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
46087705|NCT05343806|Drug|Magnesium Sulfate|Women will receive only MgSo4. A loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
46087706|NCT02692430|Other|No intervention is studied|
46001237|NCT00557388|Other|Physical exercise|The physical exercise protocol will consist of low intensity cycling and light resistance-type exercise; after 5 minutes of self-paced cycling, subjects will perform 6 sets of 10 repetitions on the horizontal leg press machine (Technogym BV, Rotterdam, The Netherlands) and 6 sets of 10 repetitions on the leg extension machine (Technogym BV, Rotterdam, The Netherlands). The first 2 sets of both resistance exercises will be performed at 40% of the subjects' 1RM. Sets 3-4, and 5-6 will be performed at 55% and 75% of 1RM, respectively, with 2 minutes rest intervals between sets.
46001238|NCT05161208|Drug|OC-01 (varenicline 0.6mg/ml) Nasal Spray|Intranasal delivery of OC-01 nasal spray twice daily (BID)
46087707|NCT00881660|Device|Goldballoon Detachable Balloon and delivery microcatheter|"Between 27+0/7 - 29+ 6/7 weeks gestation for severe CDH and can be as early as 22+0/7 weeks gestational age for those deemed as extremely severe cases of CDH, placement of the Goldvalve detachable balloon. Balloon retrieval will be planned for between 32+0/7 and 34+6/7 weeks or no longer than 10 weeks after balloon placement at the discretion of the FETO center."
46001239|NCT05161208|Drug|Placebo (vehicle) nasal spray|Intranasal delivery of Placebo (vehicle) nasal spray twice daily (BID)
46001240|NCT00537992|Procedure|combined surgery|UV-filter IOL (transparent IOL group) or a blue light-filter IOL (yellow IOL group) combined with a vitreoretinal procedure
46001241|NCT00538070|Dietary Supplement|Sarcosine|You will receive two grams of sarcosine or placebo per day. Each capsule will contain 500 mg of sarcosine or placebo. You will take two capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
46001242|NCT04662021|Other|Aerobic Exercises|Participants perform one hour of regular moderate to vigorous physical activities about (70 % to 90 %) of the maximum heart rate which was calculated according to this formula (HR max= 220- age)
46087708|NCT02692352|Other|Goal Management Training|Goal Management training, 8 sessions of 2 hours
46087709|NCT02692352|Other|Brain Health Workshop|Brain Health Workshop training, 8 sessions of 2 hours
46087710|NCT02870582|Drug|Donafenib|treatment drug
46087711|NCT02870582|Drug|Placebo|Best support treatment
46087712|NCT00668577|Drug|Lactic acid (Dermacid)|
46087713|NCT02692196|Device|Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2|
46087714|NCT05343728|Diagnostic Test|Thromboelastography|Thromboelastography was done by using TEG 5000 Hemostasis Analyzer (Haemonetics Corp., USA)
46087715|NCT05343728|Diagnostic Test|Standard coagulation profile laboratory examination|Standard coagulation profile laboratory examination (platelets, PT/APTT, fibrinogen, and D-dimer) was performed by using Sysmex® CS-2500 and 5100 (Sysmex Corp., Japan)
46087716|NCT00436748|Drug|Darbepoetin Alfa|Administered by subcutaneous or intravenous injection
46087717|NCT00436748|Drug|Placebo|Matching placebo solution for subcutaneous or intravenous injection to maintain the blind in the Q2W arm.
46087718|NCT02704598|Drug|Rivaroxaban|Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
46087719|NCT02704598|Drug|Warfarin|Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
46087720|NCT04188626|Behavioral|Driving simulator sessions|The volunteers will be placed in a driving simulator that will simulate autonomous highway driving. This autonomous driving will be interrupted by take-over requests related to events that disrupt autonomous driving. During autonomous driving, the driver will have to disengage from driving by performing non-related driving tasks. During each non-related driving tasks, a take-over request will be sent. Electrophysiological (EEG, ECG, EDA, EMG, respiration) and behavioural data will be recorded before, during and after the take-over control.
46087721|NCT05343416|Procedure|Open abdomen procedure|All patients underwent to open abdomen procedure
46001243|NCT00538109|Drug|Glivec®/Gleevec®|Chemotherapy
46002598|NCT04646421|Behavioral|Motivational telephone intervention|Motivational telephone intervention to high-risk gamblers, aiming to stimulate them to reduce gambling, quit gambling, or to seek peer support or treatment.
46087722|NCT03342404|Drug|Luspatercept|Subjects will start with luspatercept at 1 mg/kg dose level every 3 weeks and can be dose escalated up to 1.25 mg/kg.
45676046|NCT04931342|Drug|Olaparib|Olaparib will be administered by mouth twice a day on Days 1-28 of each 28-day cycle
46087723|NCT03342404|Other|Placebo|Placebo, Subcutaneous, every 21 days
46087724|NCT03342404|Other|Best Supportive Care (BSC)|Best Supportive Care (BSC)
46087725|NCT02704910|Behavioral|Subthalamic stimulation|Assess difference of amplitude (in degree) of the postural deviation between both condition of unilateral condition of subthalamic nucleus
46087726|NCT02704832|Other|Geriatrician Intervention|Arm B : The duration of the geriatric intervention will be 12 months. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months.
46087727|NCT03175718|Other|Incisional Negative Pressure Wound Therapy (INPWT)|A total of 291 patients will be randomized to receive 7 days of Incisional Negative pressure wound dressing. The dressing will be removed 1 week after surgery.
46087728|NCT03175718|Other|Wound Dressing|A total of 291 patients will be randomized for standard gauze dressing. This dressing requires no pressure and is applied according to the current standard dressing procedures of the institution. The dressing will be changed every 2-3 days.
46087729|NCT03094052|Drug|Neratinib|Given orally (PO)
46087730|NCT03094052|Biological|Trastuzumab|Given Intravenously (IV)
46087731|NCT03094052|Drug|Loperamide|Given PO
46087732|NCT03094052|Drug|Diphenoxylate Hydrochloride/Atropine Sulfate|Given PO
46087733|NCT02704286|Behavioral|Internet-Based Osteoarthritis Risk Calculator|The investigators have developed a personalized risk calculator for knee osteoarthritis. This risk calculator uses the Osteoarthritis Policy Model to estimate an individual's risk of developing knee osteoarthritis within their lifetime based on demographic information and risk factors. It shows this information to the user with interactive graphs and compares their risk to the risk of an average American of the same age.
46001244|NCT04661904|Device|Continuous theta burst stimulation (cTBS)|Our active treatment will consist of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions. All enrolled patient in the cTBS group will receive 1 set simulation per day with an intersession interval (ISI) of over 30 minutes during the hospitalization after the surgery. The first set of stimulation will be given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation will be given at 8 am, 8:30 am and 9:00 am on postoperative day 1,2 and 3, respectively.
46001245|NCT04661904|Device|Sham stimulation|The sham stimulation group will receive a sham cTBS (600 pulses per session, 3 sessions per day, ISI ≥ 30mins, 4 days) with the coil set at 90 against the skull. The first set of stimulation will be given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation will be given at 8 am, 8:30 am and 9:00 am on postoperative day 1,2 and 3, respectively.
46001246|NCT04661865|Other|Health Information Package Program (HIP program )|"Fifteen minutes PowerPoint presentation will be introduced to women to increase women's educational experience and raise their level of engagement and commitment.~The principal investigator will narrate the video record with PowerPoint slides and it was recorded as a video and will include information regarding the introduction to pregnancy, causes and predisposing factors of iron deficiency anemia during pregnancy, signs and symptoms, prevention, management of iron deficiency anemia during pregnancy that includes iron therapy, iron supplementation, dietary management. Content validity for the information in the video will be done by sending it to three experts in maternity nursing. Iron supplementation will be given to all participants who will start by sixteen weeks of pregnancy and they will receive information regarding the proper usage of iron supplements."
46001247|NCT00538148|Drug|Telithromycin|
46001248|NCT04661553|Device|"Mueller's polarimetric colposcopy Group 1"|"Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population with a low-risk premature birth. This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for a normal pregnancy and, therefore, to monitor the regular advancement of the gestation."
46001249|NCT04661553|Device|"Mueller's polarimetric colposcopy Group 2"|"Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population at high-risk of preterm birth.~This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for an abnormal pregnancy and, therefore, to predict premature childbirth."
46001250|NCT05150873|Other|CTA evaluation|Any pre-operattive CTA of the patients of the cohort will be carefully evaluated to determine the theoric anatomical feasibility of an off the shelf Endograft, particularly in patients with an angulated and short aortic neck
46001251|NCT02542059|Radiation|68Ga-exendin PET/CT|68Ga-exendin PET/CT
46001252|NCT05134025|Other|Pump settings|Alteration in the pump setting prior to exercise commencement
46087734|NCT02704286|Behavioral|Generic osteoarthritis information|Subjects viewed generic (i.e. not personalized) information about osteoarthritis risk factors
46087735|NCT05343338|Drug|Sivelestat sodium|After dissolving sivelestat sodium with 0.9% sodium chloride injection, dilute the 1-day dose (4.8 mg/kg) with 50 mL of 0.9% sodium chloride injection and continue intravenously at a rate of 0.2 mg/kg/h for administration. The start time of administration was after induction of anesthesia, and at the same time, the extracorporeal circulation circuit is prefilled with 100 mg. The end time is 48 hours after admission to the ICU.
46087736|NCT05343104|Diagnostic Test|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
46087737|NCT02704520|Drug|Capecitabine|Coated tablet. Systemic chemotherapy
46001253|NCT04661670|Device|occlusal stabilization splints|an intraoral appliance that has flat surface to allow bilateral posterior contacts in coincidence with physiologic condylar seating and to produce smooth anterior guidance in excursions
45676759|NCT01822821|Drug|IV Acetaminophen|Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
46087738|NCT02704520|Drug|Oxaliplatin|Concentrate for Solution for Infusion. Systemic chemotherapy
46087739|NCT02704520|Drug|5-fluorouracil|Infusion. Systemic chemotherapy
46087740|NCT02704520|Drug|Folinic Acid|Solution for infusion.
46087741|NCT02704052|Drug|Real time enoxaparin dose adjustment|Patients will have steady state peak and trough anti-Xa levels drawn after their third enoxaparin dose. Patients with out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment followed by repeat peak and trough anti-Xa levels.
46087742|NCT02704052|Drug|Standard enoxaparin dose|Patients will be placed on enoxaparin prophylaxis per their surgeon's discretion.
46001254|NCT05119439|Drug|Mifepristone + 2 doses of misoprostol 800 mcg|Will use a mifepristone-misoprostol regimen of: 200 mg mifepristone followed in 24-48 hours by a first dose of 800 µg misoprostol buccally and then in another 4 hours by a second dose of 800 µg misoprostol buccally. For buccal administration of misoprostol, participants will place 2 misoprostol tablets in each cheek and hold them for 20-30 minutes, after which they will swallow any remnants.
46001255|NCT02470884|Device|Boston Scientific Fully Absorbable Scaffold|Attempt to implant the Boston Scientific Fully Absorbable Scaffold.
46087743|NCT02703896|Drug|Drug either PPIS or H2RA and prokinetics|"Drug intervention ( dose unit mg) Two oral doses 8:00 p.m. and 6:00 a.m. (n=60) total 10 groups~Group C (placebo),Group L (lansoprazole15 ), Group LD (Lansoprazole 15 +domperidone 10 )~Group C ,R (rabeprazole 10), RM (rabeprazole 10 + metoclopramide 10)~Group C , E (esomeprazole 20 ), and EM (esomeprazole 20 + metoclopramide 10)~Group C, P (pantoprazole 20), and PD (pantoprazole 20 + domperidone 10 mg)~Group C, O (omeprazole 20), OD (omeprazole 20 + domepridone 10), OM (omeprazole 20 + metoclopramide 10)~Group C,T (cimetidine 200), TD (cimetidine 200 + domperidone 10)~Group C , Z (ranitidine 150), ZD (ranitidine 150 + domperidone 10)~Group C , N (nizatidine 150),NM (nizatidine 150 + metoclopramide 10)~Group C, F (famotidine 20 mg), and FM (famotidine 20 mg + metoclopramide 10)~Group C,S (lafutidine 10), SD (lafutidine 10 + domperidone 10), and Group SM (lafutidine 10 + metoclopramide 10)"
46001256|NCT05114174|Other|mami-educ|The intervention corresponds to sending 3 messages a week through Telegram, with nutritional information, for 12 consecutive weeks (a different nutritional topic each week). The messages address the three domains of learning, cognitive, affective, and psychomotor for each topic.
46001257|NCT04661826|Drug|Oncofid-P-B|Paclitaxel - Hyaluronic Acid 600 mg - Solution for intravesical administration.
46001258|NCT05110391|Drug|Hormonal Therapy Agent|Consecutive patients with NOA and hypogonadism (defined by baseline total testosterone levels equal or below 350 ng/dL) subjected to microdissection testicular sperm extraction who received or not pre-sperm retrieval gonadotropin therapy.
46001259|NCT04661631|Diagnostic Test|Lung ultrasound|Lung ultrasound during the screening process for SARS-CoV-2 infection in patients with an indication for urgent surgery.
46001260|NCT00538187|Drug|obatoclax mesylate|Given IV
46001261|NCT00538187|Drug|bortezomib|Given IV
46001262|NCT00538187|Other|laboratory biomarker analysis|correlative study
46001263|NCT00538187|Other|pharmacological study|correlative study
46001264|NCT04661709|Drug|Wen Xin granule|one dose daily, two times per day.
46001265|NCT04661709|Drug|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|one tablet daily. (for patients who can't use aspirin)
46001266|NCT04661709|Drug|Atorvastatin Calcium|20 mg tablet, one tablet each night.
46001267|NCT04661709|Drug|Isosorbide Mononitrate Tab 20 MG|one tablet， twice daily.
46001268|NCT04661709|Drug|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg, two times daily.
46001269|NCT04661709|Drug|Aspirin Enteric-coated Tablets|100mg tablet, one tablet daily.
46001270|NCT04661709|Drug|WXG placebo|one dose daily, two times per day.
46001271|NCT04661709|Drug|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
46001272|NCT04661709|Drug|glyceryl trinitrate|be taken when angina pectoris attacks.
45457912|NCT05221645|Drug|Rituximab|Rituximab is a chimeric mouse/human monoclonal antibody that binds to CD20, on pre-B and mature B lymphocytes and eliminates these cells potentially via a number of different mechanisms. Anti-CD20 mAbs, like rituximab, are classified by their CD20-binding characteristics, ability to induce complement-dependent cytotoxicity (CDC), and immune effector cell effects.
46001273|NCT00538226|Device|External Electric Muscle Stimulation|
46001274|NCT02466867|Drug|Naftin® Cream, 2% (younger pediatric cohort)|Approximately 3 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 2 to 5 years, 11 months.
46001275|NCT02466867|Drug|Naftin® Cream, 2% (older pediatric cohort)|Approximately 4 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 6 to 11 years, 11 months.
46001276|NCT02462850|Drug|CL-108|
46001277|NCT00538265|Drug|tacrolimus|Tacrolimus started at 0.50 mg/kg b.i.d. starting at D0, by nasogastric tube and then 1 to 2 hours before meals. The dose of tacrolimus will be adjusted as soon as possible to obtain trough concentrations of the product between 10 and 20 µg/L between D0 and 6 months and then between 8 and 15 µg/L after 6 months
46001278|NCT00538265|Drug|tacrolimus, ATG|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combining induction therapy with 3 injections of antithymocyte globulins (ATG) (1.5 mg/kg/d at D0, D2 and D4) and tacrolimus at usual dosage.~In this group of patients, the first injection of ATG will be infused over a period of at least 6 hours and will be started as soon as vascular anastomosis has been completed. It will be preceded by an injection of 3 mg/kg/d methylprednisolone. The second injection of ATG at D2, post transplantation will also be infused over 6 hours and will be preceded by an injection of 1 mg/kg methylprednisolone, and then subsequently steroids will be excluded from the treatment. The third and last injection at D4 post transplantation will be administered over a 6-hour period but will not be preceded by steroids.~In this study arm, tacrolimus will be administered as in arm (A)"
46001279|NCT00538265|Drug|ATG+mycophénolate mofétil+tacrolimus|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combined with mycophenolate mofetil, at an initial dosage of 2 grams a day, and then adjusted to safety and tolerability in such a way so as to maintain PMN ≥ 750/mm3, and platelet counts ≥ 30000/mm3.~In this study arm, the patients will receive the same doses of ATG and steroids (and according to the same methods) as in arm B. Tacrolimus started at 0.05 mg/kg b.i.d. starting at D0 by nasogastric tube and then 1 to 2 hours before meals. In this study arm, the tacrolimus dose will be reduced: targeted trough concentrations will be between 7 and 12 µg/L between D0 and 6 months and then between 3 et 7 µg/L after 6 months."
46001280|NCT02462811|Drug|CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
46001281|NCT02462811|Drug|Placebo|
46001282|NCT02462811|Drug|Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)|
45457913|NCT05221645|Drug|Ifosfamide|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
46001283|NCT00538382|Drug|Artesunate|A 200 mg dose of orally administered artesunate at the beginning of a 48-hour clinical sampling period.
45676047|NCT04931342|Drug|Luteinizing Hormone-Releasing Hormone (LHRH) Agonists|LHRH agonists are required beginning at least 2 weeks prior to initiation of study treatment for premenopausal or perimenopausal women. Acceptable agents include goserelin or leuprolide; triptorelin is also acceptable. Monthly injections of LHRH agonist are preferred.
45676048|NCT04931342|Drug|Cyclophosphamide|Cyclophosphamide will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 21 days)
46001284|NCT00538421|Drug|Propofol|Infusion intravenously (IV) 0-10 mg/kg/h
46001285|NCT00538421|Drug|Sevoflurane|0,7-1,5 MAC
46001286|NCT04661475|Drug|Dexmedetomidine Injection [Precedex]|ECT and anaesthetic treatment protocols will be determined by the local ECT services. ECT being given twice a week. The anesthetic induction agent of choice will usually be propofol, with thiopental permissible as an alternative. For safety reasons, any drug contraindicated to be given with DEX will be avoided. Especially the once known to decrease arterial pressure and heart rate excessively. Oral psychotropic medication to be continued by the patient's treating clinical team will remain unchanged where possible for at least the first 4 ECT treatments, and ideally until end of ECT. Eligible subjects will be allocated randomly to receive either 0.5µg/kg dexmedetomidine add on (diluted to 10 ml with 0.9% saline) at a steady rate of 1 ml/min, for 10 min.Participants in the two groups will receive DEX or Saline adjunct thrice weekly for 3 weeks.
46001287|NCT04661475|Drug|Normal saline|while patients in the Control group will be infused with 10 ml of 0.9% saline at the same rate, over 10 minutes before anesthesia induction for ECT procedure.
46001288|NCT04661436|Diagnostic Test|Contrast-Enhanced Ultrasound|"The research will study the qualitative analysis indicators of contrast-enhanced ultrasound, including: enhancement uniformity, enhanced range, presence or absence of enhancement defect area, presence or absence of nourishing blood vessels, etc.; and quantitative analysis indicators, including: peak time, peak intensity, rising slope, Area under the curve, etc., analyze the correlation between the changes of various parameters before and after neoadjuvant treatment（NAT） and the pathological response of patients, and try to find indicators and cut-off values that can predict and early evaluate the efficacy.~This study will study the qualitative and quantitative parameters of MRI-enhanced scanning and the changes of DWI parameters, analyze the correlation between the parameters of patients before and after NAT and pathological response, and try to find indicators and cut-off values that can predict and early evaluate the efficacy."
46001289|NCT00554268|Drug|PBI-05204|Starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle
46001290|NCT00538499|Drug|Fentanyl citrate|
46001291|NCT00538499|Drug|Bupivacaine hydrocloride|
46001292|NCT00538499|Procedure|videothoracoscopy|
46001293|NCT00554307|Device|INVOS Cerebral/Somatic oximeter|Placement of sensors on back, abdomen and forehead for measurement of perfusion beginning 1 hour prior to initiation of drug, during medical treatment for PDA and for 24 hours after the last dose. For control infants, monitoring will continue for 48 hours.
46001294|NCT00538538|Drug|vitrectomy with subretinal lucentis|A gas bubble will be placed in the eye after the gel has been removed.
46001295|NCT00538538|Drug|vitrectomy with subretinal lucentis|These patients will have a vitrectomy where the gel is removed but will not receive the gas bubble.
46001296|NCT00554346|Drug|Arcoxia(etoricoxib 90 mg/tablet)|Arcoxia(etoricoxib 90 mg/tablet) or placebo, #1, 3 days
46001297|NCT04661046|Drug|Traditional Chinese Medicine|Chinese medicine prescription
46001298|NCT00538655|Drug|modafinil|400mg vs. 200mg (PO) daily
46087744|NCT02703896|Procedure|orogastric intubation|OGT insertion:Insertion of orogastric tube(through an endotracheal tube placed in the upper esophagus) into the stomach after general anaesthesia.
45457914|NCT05221645|Drug|Carboplatin|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
45457915|NCT05221645|Drug|Etoposide|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
45676049|NCT04931342|Drug|Inavolisib|Inavolisib will be administered by mouth once a day on Days 1-21 of each 21-day cycle
45676050|NCT04924322|Drug|Enoxaparin|Enoxaparin is a LMWH produced from UFH that exerts its anticoagulant effects by binding to and inducing a conformational change in antithrombin to accelerate the inactivation of factor Xa and thrombin. Age-specified dose of enoxaparin will be administered within 24 hours after insertion of the CVC with the dose subsequently adjusted to pre-specified anti-Xa target.
46001299|NCT04661319|Procedure|video editing training|"The subject's preoperative residency year, instrument experience, open surgery experience, laparoscopic surgery experience, and preoperative instrument proficiency are evaluated.~Basic anatomical and scientific education for laparoscopic cholecystectomy, practice laparoscopic instruments for at least 30 minutes every other week, and observe 3 cases of laparoscopic cholecystectomy.~Select a random experimental group.~For each selected group, 3 cases of surgical observation or 3 cases of video editing are performed.~Both groups operated on 10 cases, and both groups were discharged from the hospital after undergoing the same recovery procedure after the same operation."
46001300|NCT00538694|Drug|daptomycin|
46001301|NCT02436096|Drug|TNX-102 SL Tablet, 2.8mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
46001302|NCT02436096|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
46087745|NCT02806310|Other|Blood draw|blood sampling for biomarker levels
45676760|NCT01822821|Drug|Placebo|Patients will receive up to four doses placebo every six hours after surgery along with standard PCA (patient controlled) opioids.
46001303|NCT00538772|Other|Not applicable - blood tests/tissue specimen tests will be undertaken|Not applicable - blood tests/tissue specimen tests will be undertaken
46087746|NCT02737436|Drug|Intranasal Oxytocin|Intranasal oxytocin (24IU) given 50 minutes prior to behavior assessment or scanning
46087747|NCT02737436|Drug|Placebo|Intranasal placebo spray given 50 minutes prior to behavior assessment or scanning
46087748|NCT02737436|Procedure|Functional MRI scanning|All study participants underwent two functional MRI scanning visits. On one occasion this was after receiving an intranasal dose of oxytocin; on the other occasions, after receiving intranasal placebo dose.
46087749|NCT03552692|Drug|Venetoclax|"Venetoclax (ABT-199) will be administered orally (800 mg daily). Patients will receive ABT-199 until disease progression, unacceptable toxicity, withdrawal of consent and/or the investigator determines that further therapy is not in the patient's best interest.~Tumor Lysis Syndrome (TLS) is an important identified risk for Venetoclax in oncology studies. Since there are no available data on the risk of TLS in PTCL, the risk of TLS development should be closely monitored during the study.~to avoid TLS ABT-199 will be administered according the following ramp up: W eek 1 day 1: 20 mg W 1 day 2-3: 50 mg W 1 day 4-7: 100 mg W 2: 200 mg W 3: 400 mg W 4 and following: 800 mg"
46001304|NCT02435121|Drug|SAR125844|Pharmaceutical form:Concentrate for solution Route of administration: intravenous
46087750|NCT00614978|Drug|lapatinib and temozolomide|Temozolomide will be given orally for 5 days of every 28 days, at doses of either 100mg/m2/day or 150mg/m2/day or 200mg/m2/day AND Lapatinib will be given orally every day at either 1000mg/day or 1250mg/day or 1500mg/day.
46001305|NCT00538811|Drug|interferon alpha-2b, ribavirin, interferon-gamma,|
46001306|NCT00538811|Drug|interferon alpha-2b, ribavirin, amantadine|
46001307|NCT04660773|Device|NB UVB phototherapy|ultraviolet phototherapy sessions
46001308|NCT04660773|Drug|Pregabalin|oral medication
46001309|NCT00538889|Drug|Lecozotan SR|
46001310|NCT00538889|Drug|Citalopram|
46001311|NCT02413827|Drug|Combination of varlilumab and ipilimumab|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase l dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg or 3 mg/kg. Ipilimumab dose is 3 mg/kg."
46001312|NCT02413827|Drug|Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase ll dose: The planned dose of varlilumab will be established from Phase I. Ipilimumab dose is 3 mg/kg. Patients assigned to receive CDX-1401 will receive a dose of 1 mg along with 2 mg poly-ICLC."
46001313|NCT00538928|Other|lung protective ventilation|tidal volume 6 ml/kg ideal body weight
46001314|NCT04660656|Diagnostic Test|5 repetition sit-to-stand test|"The sit-to-stand test with five repetitive movements is used as standard in our clinical routine to determine the patient's mobility objectively. The first measurement is performed preoperatively during surgery (baseline). The follow-up measurement is performed six weeks after the operation and one year after the operation in the clinic.~A stool with a fixed height is used for this purpose. The patient should cross his arms over the chest and then slowly stand up until the knees are full of space. Then the patient sits down again, of course without support of the arms. The duration of the five movements is recorded using a stopwatch. The complete movement starts after the Go command and ends when the patient is fully upright after the fifth movement. This duration is written down as the patient's score."
46001315|NCT00538967|Drug|doxycycline|2 weeks once daily
46001316|NCT04660851|Behavioral|Coached|10-weeks of diet coaching weekly by telephone to improve dietary protein intake
46001317|NCT02410356|Drug|TV-1106|The volume necessary to provide the required weekly dose will be calculated by the investigator; dose will be adjusted for IGF-I in the normal range.
46001318|NCT02410356|Drug|dGH|The dose levels of dGH will be the same as the stable rhGH dose taken prior to the study.
46001319|NCT00539084|Device|MicronJet|The MicronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the layers of the skin). In this study the MicronJet will be used to inject Lidocaine or Saline.
46001320|NCT04660734|Procedure|Fractures of the posterior structures of the acetabulum treated by fixation using the Kocher-Langenbeck approach.|Fracture fixation of posterior structures of acetabulum by using the surgical procedure of Kocher-Langenbeck approach
46001321|NCT00539123|Behavioral|behavioral drug and HIV risk reduction counseling (BDRC)|BDRC utilizes short-term behavioral contracts to promote abstinence and reduce drug- and sex-related HIV risk behaviors and can be provided by nurses and medical assistants available in medical settings in Malaysia.
46087751|NCT02703818|Device|Senza|Spinal Cord Stimulation
46087752|NCT05343026|Device|Hearing aids|As for screening the hearing and tinnitus testing, the measure typically comprises PTA, SRS, DPOAE, and several widely accepted standardized tinnitus questionnaires, including the THI for tinnitus severity and VAS for tinnitus loudness.
46087753|NCT02703974|Behavioral|Early handwashing station|"A handwashing station will be a dedicated location for handwashing in each selected school and will include:~A raised concrete platform (built to child height)~A plastic container with a lid and spigot~Soap~The early handwashing stations will be constructed in weeks 1 and 2 of the study, after the baseline observations (Phase I) are complete."
45676761|NCT01822665|Drug|Ibuprofen|Liquid gelation capsules or tablets of 400 mg strength
46001322|NCT00539123|Behavioral|abstinence-contingent buprenorphine (ACB)|Participants achieving heroin abstinence documented by an opioid-negative urine test receive take-home doses of buprenorphine-naloxone, with the number of take-home doses permitted increasing depending on the number of consecutive opioid-negative urine tests. Participants who test positive receive all doses of buprenorphine-naloxone under direct observation in the clinic, using a three-times per week dosing protocol.
46001323|NCT02385201|Device|Senza|Spinal Cord Stimulation
46001324|NCT00539318|Procedure|Blood drawing|Once when enroll in study
46001325|NCT02382510|Drug|TRN-157|
46001326|NCT02382510|Other|Placebo|
46001327|NCT02382510|Drug|Tiotropium|
46087754|NCT02703974|Behavioral|Late handwashing station|"A handwashing station will be a dedicated location for handwashing in each selected school and will include:~A raised concrete platform (built to child height)~A plastic container with a lid and spigot~Soap~The late handwashing stations construction will begin after Phase 2 data collection has been finished at the end of week 3."
46001328|NCT00539357|Device|Cranial electrotherapy stimulation (CES)|Cranial electrotherapy stimulation (CES) is a noninvasive procedure that involves applying a pulsed, low-amplitude electrical current to the head using electrodes placed on the earlobes. Cranial electrotherapy stimulation CES received U.S. Food and Drug Administration (FDA) approval for the treatment of insomnia, depression, and anxiety in 1979.
46001329|NCT00539396|Drug|Technosphere Insulin|
46001330|NCT04660695|Device|EUS-guided gastroenterostomy|Firstly, un upper digestive endoscopy is performed with a conventional gastroscope. A guidewire is passed through the malignant lesion causing the gastric outlet obstruction. Once the guidewire is located in the distal duodenum/proximal jejunum, a nasobiliary drain (Nasal Biliary Drainage Sets, Cook medical, Indiana) is advanced over the guidewire until its distal end is placed in the distal duodenum/jejunum. At this point the gastroscope is substituted by a therapeutic echoendoscope. With the echoendoscope in place, the target bowel loop is filled with saline combined with methilene blue and radiopaque contrast. The echoendoscope is used to identify the target bowel loop. AFter identifying the target, a lumen apposing metal stent (Axios, Boston Scientific, Massachusetts) is deployed across the gastric and bowel using its electrocautery enhanced deployment device.
46001331|NCT03456986|Behavioral|PATH neurotraining|Tunes up the center of the motion discrimination (dorsal stream) working range
46001332|NCT03456986|Behavioral|Orientation Discrimination|Tunes up the ventral stream most sensitive to high contrast and colored patterns.
46001333|NCT02376465|Drug|BLI4600 bowel preparation|Oral bowel preparation for colonoscopy
46001334|NCT02376465|Drug|PEG based bowel preparation|Oral bowel preparation for colonoscopy
46001335|NCT00539435|Procedure|Intravenous Insulin on cardiac disease in diabetic pts|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
46001336|NCT04660578|Procedure|ACCSS|A. Chohan Continuous Squeezing Suture (ACCSS)
46001337|NCT00539474|Procedure|Radio guided occult lesion localisation|ROLL procedure using the Europrobe (Europrobe, Strassbourg, France) WGL using a hook wire
46001338|NCT04660266|Diagnostic Test|Liver Ultrasound|liver ultrasound examination, including gray-scale and seven Doppler examination
46001339|NCT00539630|Drug|Docetaxel|
46001340|NCT04660461|Drug|Lansoprazole 30mg|Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
46001341|NCT04660461|Drug|Placebo|Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
46001342|NCT04685330|Procedure|Ultrasound guided procedure|Single-arm, open-label device efficacy study to enroll 200 patients who have been ordered to have an ultrasound-guided procedure by the MGH Interventional Radiology department, including paracentesis, thoracentesis, biopsy, or ultrasound-guided drain placement. Patients will be restricted to adults who can consent.
46001343|NCT04685330|Device|Portable ultrasound|The FDA approved Healcerion SONON portable ultrasound (linear and curved) will be used during clinically indicated standard ultrasound-guided procedures following clinical standard of care. A standard clinical ultrasound will subsequently be used for image guidance as the gold standard. Images will be compared and improved. The efficacy of the portable ultrasound will be monitored by the clinical user and any complications within 30 days will be determined by chart review.
46001344|NCT00539669|Drug|Docetaxel|
46001345|NCT00554424|Drug|lignocaine|20 mls of 1% lignocaine solution for injection, 10mls into each side of upper vagina, under ultrasound guidance immediately prior to transvaginal oocyte retrieval under ultrasound guidance from each ovary
46001346|NCT00554424|Drug|normal saline|20mls of normal saline solution, 10mls injected each side into upper vagina under ultrasound guidance, immediately prior to ultrasound guided transvaginal oocyte retrieval from each ovary
46001347|NCT00539708|Procedure|Non-invasive ventilation|Non-invasive ventilation after extubation for 24 hours
46001348|NCT04660305|Drug|AT278|Concentrated rapid acting insulin aspart
46001349|NCT04660305|Drug|NovoRapid|Rapid acting insulin aspart
46001350|NCT00554502|Drug|supportive therapy with: ACE-inhibitor / ARB / Statin|"Antihypertensive therapy with a target blood pressure below 125/75 mmHg (following current clinical guidelines).~ACE-inhibitors (ARB when an ACE-inhibitor is not tolerated)~Other antihypertensive medications depending on the clinical decision and following current guidelines.~Statin therapy~Dietary counseling for a low-sodium diet and, if GFR is below 60 ml/min, for a protein intake of 0.8 g/kg/day."
46001351|NCT00554502|Drug|supportive and immunosuppressive therapy|"supportive therapy as outlined above~depending on GFR:~methylprednisolone and prednisolone~cyclophosphamide and prednisolone; after 3 months azathioprine with prednisolone~Concomitant medication with the immunosuppressive treatment following current clinical practice"
46001352|NCT00539786|Drug|Proton pump inhibitor (rabeprazole)|Patients receives rabeprazole 20mg AM and 20mg PM for 14 days
46001353|NCT00539825|Drug|GSK704838|
46001354|NCT04660071|Other|ultrasonographic Assessment,|Ultrasound assessment was performed on rectus femoris (RF), vastus intermedius (VI), vastus medialis (VM) and vastus lateralis (VL) muscles using with an ultrasound-imaging device (Philips Medical Systems EPIQ 5 Release 5.0.2, Amsterdam).
46001355|NCT04660071|Other|Echo intensity Measurements|All images were analysed using the Image J software (Version 1.48v, National Institutes of Health, Bethesda, MD, USA) by two different analysers (five years and one-year of experience in US image analysis).
46001356|NCT00554541|Other|Ankle Brachial Index Venous physiologic study|Assessment of lower extremity venous disease
46001357|NCT00540020|Other|Rehabilitation|
46001358|NCT00554580|Procedure|Continuous Positive Airway Pressure (CPAP)|"Usual treatment of acute pulmonary oedema (see arm A) + CPAP will be administered without interruption for at least one hour and will be stopped for efficacy:~stade I or II KILLIP classification and FR less or equal to 25 /min and SpO2 larger than 90 % ambient air and patient willing the stop of CPAP because of improvement of his clinical status."
46001359|NCT00554580|Procedure|usual care of acute pulmonary oedema|"Usual treatment of acute pulmonary oedema including :~Oxygen, diuretic minimum one bolus IV of 40 mg FUROSEMIDE (LASILIX) possibility to repeat the dose every 15 minutes with a maximum 120 mg.~Bolus of ISOSORBIDE DINITRATE (RISORDAN) of 1 mg maybe repeated every 3 minutes.~As soon as possible perfusion of ISDN with flow adapted to the clinical status If necessary administration of DOBUTAMINE continuous perfusion of to 5 to 20 µg/kg/min."
45676051|NCT04921449|Other|ED Physical Therapy|All ED Physical Therapy treatment classifications involve a combination of exercise, range of motion, education, prognostic guidance, and reassurance. Patients are provided with an individualized home exercise plan based on their matched treatment classification and/or active rest.
45676052|NCT04921449|Other|Usual Care|Includes any diagnostic imaging, patient education and reassurance, and administration or prescribing of analgesic medications, as per the treating physician's usual and customary practice.
45676053|NCT04907253|Drug|Quercetin|500 mg twice daily
45676054|NCT04907253|Drug|Placebo|twice daily
46001360|NCT02359227|Drug|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
46001361|NCT02341989|Drug|Bleomycin Etoposide and Cisplatin|
46001362|NCT02341989|Drug|Carboplatin|
46001363|NCT00540098|Drug|paroxetine + aerobic exercise|paroxetine, 40 mg once daily + regular aerobic exercise
45457916|NCT02308462|Behavioral|CHIMPS intervention|"CHIMPs intervention (Family-Intervention composed of 8 Topic-related sessions over a period of 6 month, based on the evaluated manual: a preliminary talk with the family, two sessions with the parents, one session with each child, three sessions with the family).~The sessions are semi-structured and cover the topics illness and coping, education, family relationships and trusting attachement figures, social network and support of the Family. A detailed description of the procedure is found in the Manual (Wiegand-Grefe, Halverscheid & Plass, 2011)."
45676055|NCT04902443|Drug|Pomalidomide|Pomalidomide will be administered as an oral planned starting dose of 3 mg daily. Pomalidomide will be given from day 1 to day 21 of each cycle
45676762|NCT01822665|Drug|Paracetamol|Paracetamol fast dissolving tablets of 500 mg strength
46001364|NCT00540098|Drug|Paroxetine + relaxation|paroxetine, 40 mg once daily + regular relaxation training
46001365|NCT00540098|Drug|Placebo + aerobic exercise|placebo pill once daily + regular aerobic exercise
46001366|NCT00540098|Drug|Placebo + relaxation|placebo pill once daily + regular relaxation training
46001367|NCT00540137|Drug|nevirapine|400mg once daily
46001368|NCT00540137|Drug|atazanavir/ritonavir|atazanavir 300 mg once daily ritonavir 100 mg once daily
46001369|NCT04660110|Drug|IPT with Dihydroartemisinin Piperaquine|A single dose/round of IPT with Dihydroartemisinin Piperaquine (40mg/320mg tabs, Fosun Pharmaceuticals)
46001370|NCT00540176|Drug|Dichloroacetate (DCA)|Oral DCA given twice daily for the 24 week period of the study. Continuation of therapy will be indefinite if efficacious.
46001371|NCT02341560|Drug|QPI-1007 Injection - 1.5 mg|
46001372|NCT02341560|Drug|QPI-1007 Injection - 3.0 mg|
46001373|NCT02341560|Other|Sham Injection Procedure|Sham Procedure
46001374|NCT00540215|Other|Glucagonlike peptide|450 nmol native form, synthetic
46001375|NCT02339064|Drug|apomorphine infusion|Treatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device
46001376|NCT00540254|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) + Insomnia plus Usual Care for Chronic Fatigue Syndrome -continues standard care for Chronic Fatigue Syndrome plus 4 sessions of CBT targeted for insomnia/sleep problems
46001377|NCT00540254|Other|Usual Care for Chronic Fatigue Syndrome (Active Control Group)|Usual Care for Chronic Fatigue Syndrome (Active Control Group) - continues standard care for Chronic Fatigue Syndrome and comes to the sleep lab for bi-weekly sessions to discuss sleep problems and to review weekly sleep logs
46001378|NCT04659954|Other|Application O'DIDE|The intervention is the use of an application that aimed to favorize contact between the patient and the care team between the consultations.
46001379|NCT00540332|Drug|Placebo|Single IV dose of placebo, 3 days before the start of RT, then once weekly placebo doses at the same dose during a planned 6 week RT course.
45457917|NCT05523115|Dietary Supplement|Heights Smart Supplement|"The ingredient list of the product includes the following:~Algae oil Blueberry Extract Methylcobalamin (Vitamin B12) Cholecalciferol (Vitamin D3) Ascorbic acid (Vitamin C) Retinol acetate (Vitamin A) Calcium L-methylfolate (Folic Acid) D-biotin Pyridoxine hydrochloride (Vitamin B6) Calcium pantothenate (Vitamin B5) Nicotinamide (Vitamin B3) Riboflavin (Vitamin B2) Thiamine hydrochloride (Vitamin B1) D-Alpha tocopheryl acetate (Vitamin E) Chromium picolinate Potassium iodide Iron Citrate Sodium selenite Zinc citrate"
45457918|NCT03503656|Device|epidural catheter placement|insertion of an epidural catheter using Compuflo System
46001380|NCT00540332|Drug|palifermin|120μg/kg, single IV, 3 days before the start of Radiotherapy (RT), then once weekly at the same dose during a planned 6-week RT course
46001381|NCT02336685|Drug|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
46001382|NCT02336685|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
45457919|NCT02312596|Device|PRP Concepts Fibrin Bio-Matrix|Application of PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
45457920|NCT02312596|Other|Usual and Customary Practice|Usual and customary care for non-healing wounds
46087755|NCT02703974|Behavioral|Nudge|"A nudge will be built in each randomly selected school and will consist of:~Connecting latrines to the handwashing station via paved pathways that are painted bright colors~Painting footprints on infrastructure guiding students to the handwashing stations and handprints on stations~The nudges will be constructed at the end of week 3 and 4, after Phase II data collection is complete within each randomly assigned nudge school."
45457921|NCT05521243|Dietary Supplement|Beam Organics Dream Powder|The Dream Powder and Dream Powder Extra Strength both use nano hemp, reishi, magnesium. L-theanine, and melatonin to promote a healthy sleep pattern
45676056|NCT04902443|Drug|Nivolumab|Nivolumab will be administered IV at a dose of 480 mg at day one of each cycle, except for cycle one when it will be administered on day 8. One cycle equals 28 days
45676057|NCT04900935|Behavioral|POISE|POISE (Patient-centered, Optimal Integration of Survivorship and palliative carE) is a brief, population-specific intervention that consists of four sessions with palliative care specialists who have been additionally trained to evaluate and address the specific psychosocial issues and health-promoting behaviors of patients with long, uncertain cancer trajectories.
46001383|NCT02336685|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
46001384|NCT02336685|Drug|Opioid|Opioids will be administered as standard of care for osteoarthritis (OA) pain therapy during the double-blind treatment phase as per investigator discretion.
46001385|NCT00540410|Drug|Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination)|Infants tablets: AS 25/AQ 67,5 mg Toddlers tablets: AS 50/AQ 135 mg Once daily, dose according to bodyweight range Duration of treatment: 3days Children tablets: AS 100/AQ 270 mg
46001386|NCT00540410|Drug|Coartem® (arthemether+ lumefantrine)|"Tablets, 20/120 mg, oral route, twice daily, dose according to bodyweight range.~Duration of treatment: 3 days"
46001387|NCT00540488|Other|Adult enteral formula|
46001388|NCT04659837|Behavioral|No-Added-Sugar Diet|All participants received a no-added-sugar dietary intervention and followed the diet during the course of the study.
46087756|NCT02703974|Behavioral|Education|"Hand hygiene education-based program: the hygiene promotion element will include a one month program of handwashing education involving weekly facilitator led sessions. Each session will be about 30-45 minutes long, and will cover the following topics:~Importance of handwashing~Method of handwashing~Critical times of handwashing~Finding solutions for handwashing in school and at home The sessions will involve use of flipcharts, and other IEC materials (e.g. videos) and participative learning methods.~The Hand hygiene education-based program will begin at the beginning of weeks 4 and 5, after Phase II data collection is complete in each randomly assigned education school."
45457922|NCT05521243|Dietary Supplement|Beam Organics Dream Powder Extra Strength|The Dream Powder and Dream Powder Extra Strength both use nano hemp, reishi, magnesium. L-theanine, and melatonin to promote a healthy sleep pattern
45457923|NCT05521243|Dietary Supplement|Placebo|"The main ingredients in the placebo are:~Coconut milk powder, cocoa, cinnamon, monk fruit, natural vanilla flavor"
46087757|NCT03188354|Diagnostic Test|18F-FDG|PET scan with 18F-FDG as a tracer, taken both for primary staging and therapy assessment.
46001389|NCT00540527|Drug|local interarterial recombinant tissue plasminogen activator|Endovascular treatment must be performed asap after random.and definitely within 6h from symp. onset.It includes intrarterial thrombolysis with rt-PA,if necessary,associated to or substituted by mechanical clot disruption and/or retrieval.Fibrinolytic therapy should be performed within 1h,the full dose of rt-PA infusion should not exceed 0.9 mg/kg (max 90 mg in the case of body weight ≥100 kg).If a complete recanalization is achieved,rt-PA infusion can be interrupted before reaching the maximum dosage.The option of performing a thrombolysis by mechanical means to obtain a mechanical disintegration/shift/detach/fissure of the thrombus and/or a retraction/aspiration can be considered on the basis of the type,location and characteristics of the occlusion.These choices may involve the use of the microguidewire as a mechanical instrument to favour the disintegration of the thrombus,using systems to capture the thrombus by extraction or more complex systems to crush and aspirate the thrombus
46087758|NCT03188354|Diagnostic Test|18F-fluciclovine|PET scan with 18F-fluciclovine as a tracer, taken both for primary staging and response to therapy assessment.
46087759|NCT03188354|Diagnostic Test|standard MRI|clinical routine MRI examination, both for primary staging and response to therapy assessment.
46087760|NCT02703506|Other|Session of Pain Education programe|Five group sessions of patient education pain of 60-120 minutes one for week with a maximum of 10 participants.
46087761|NCT02703506|Other|Control Group|Five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (TENS) on neck area an exercises
46087762|NCT02703740|Device|Hyaluronic acid dermal filler with lidocaine 0.3%|injection in labial fold of a dermal filler
46087763|NCT02535494|Other|Extensive training|We have developed a more in-depth education package to help participants better recognize and respond to an opioid overdose.
46087764|NCT02496260|Procedure|Research Cardiac MRI|Cardiac MRI has increased use in evaluating structural and functional cardiac pathologies. For detection of coronary artery disease, MRI outperforms SPECT and dobutamine stress echocardiography for the detection of ischemia. MRI also can detect wall-motion abnormalities and other dysfunction. Dynamic contrast-enhanced MRI (DCE-MRI) can evaluate microvascular parameters such as vessel permeability and fluid volume fraction as an assessment of tissue perfusion. Cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiotherapy and could potentially identify patients for intervention to prevent cardiac events. All patients will follow the protocol calendar requiring research MRIs, but will receive standard radiation treatment determined by their physician. Treatment will not be altered based on MRI.
46087765|NCT02496260|Procedure|Biomarkers|"We have identified potential candidates based on other processes affecting heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis and left ventricular dysfunction, these include galectin-3 and N-terminal-Pro brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15. Additional blood will be collected and stored for future assessment of other candidate biomarkers.~All patients will follow the calendar of protocol required research blood draws for biomarker collection, but will receive standard radiation treatment as clinically indicated by their physician. Treatment will not be altered based upon the data collected from these samples."
46087766|NCT00615368|Drug|Epoetin alfa|1 (one) intravenously injection of 40.000 IU epoetin alfa 6 days before induction of experimental hypoglycemia.
46087767|NCT00615368|Drug|Isotonic NaCl (Placebo)|1 ml. of isotonic NaCl is intravenously injected 6 days before induction of experimental hypoglycaemia
46087768|NCT02699216|Device|Electrical Stimulation of the Retina|Transpalpebral micro-current electrical stimulation treatment for 3 consecutive days followed by a short wash-out period of 2 days.
46087769|NCT00615446|Drug|SU011248; Gemcitabine|Dose finding study using SU011248 (sunitinib) daily by oral capsule in 4/2 (administered for 4 out of every 6 weeks) or 2/1 (administered for 2 out of every 3 weeks) schedule with gemcitabine administered on Days 1, 8, 22 and 29 on Schedule 4/2 and Days 1 and 8 on Schedule 2/1 until progression or unacceptable toxicity
46087770|NCT02699372|Drug|Placebo|
46087771|NCT02699372|Drug|RO6889450|
46087772|NCT02703272|Drug|Ibrutinib|Participants will receive Ibrutinib (dose 240 mg/m^2 /329 mg/m^2 per day) during part 1 and part 2.
46087773|NCT02703272|Drug|Rituximab|Participants will receive a cumulative dose of rituximab 750 mg/m^2 as a part of RICE/RVICI regimen in part 1 and part 2 per cycle.
46087774|NCT02703272|Drug|Ifosfamide|Participants will receive a cumulative dose of Ifosfamide 9 g/m^2 and 10 g/m^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.
46087775|NCT02703272|Drug|Carboplatin|Participants will receive a cumulative dose of carboplatin 635 mg/m^2 and 800 mg/m^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.
45457924|NCT03503500|Other|Laid-back breastfeeding|"At randomization the Italian version of the video Biological nurturing, which provides detailed information on LB BF, will be delivered to women with the recommendation to watch it before birth; during the maternity ward stay, adequately trained staff will support women to breastfed in relaxed, laid-back position, with her baby laying prone on her, so that the baby's body is in the largest possible contact with mother's curves. In the maternity ward a daily supervision by an external expert on LB BF will be provided"
45676058|NCT04898400|Procedure|endoscopy sleeve gastroplasty|endoscopic procedure for weight loss
45676763|NCT01822665|Other|Placebo|Placebo tablets
46001390|NCT00540527|Drug|intravenous (IV) rt-PA|IV thrombolytic treatment is started immediately after randomization, within 4.5 h of symptoms onset. IV rt-PA is administered at a dose of 0.9 mg/kg (max 90 mg), 10% of which is given as a bolus, followed by the delivery of the remaining 90% as a constant infusion over 60 mins
46087776|NCT02703272|Drug|Etoposide|Participants will receive a cumulative dose of etoposide 300 mg/m^2 in part 1 and part 2 as a part of RICE regimen per cycle.
46001391|NCT04659720|Device|Hydrolic lifter device|evaluation of implant stability after closed sinus lifting by hydraulic lift technique using hydraulic lifter device
46001392|NCT04659720|Behavioral|Patient satisfaction evalution using hydraulic lifter device|patients satisfaction will be evaluated numerically after using hydraulic lift technique by hydraulic lifter device for closed sinus lifting in posterior edentulous maxilla
45835429|NCT02063022|Drug|Intensified chemotherapy|"Induction treatment with: 4 cycle of Vincristine (10.5 mg/m2), Doxorubicin (320 mg/m2) and Ifosfamide (36 mg/m2) given every 3 weeks~Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (63g/m2), Cyclophosphamide (4g/m2), Etoposide (1.5g/m2) and Cells Steam Transplant after Busulfan and Melphalan treatment~Maintenance treatment (25 week) for good responder: Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Etoposide (1.8g/m2)"
46001393|NCT00540605|Drug|Tenofovir 1% vaginal gel|topical gel containing 1% tenofovir
45676059|NCT04898023|Drug|zinc-green tea extract-ascorbic acid|Compounded capsules containing each zinc citrate, green tea extract, and ascorbic acid.
45676060|NCT04898023|Drug|Placebo|Compounded capsules containing microcrystalline cellulose.
46001394|NCT04659915|Drug|Metformin 500 mg Oral Tablets + Prednisone 20mg Tablets|"During one phase of the study: Metformin 500mg Day 1 1-0-0 Day 2 1-0-0 Day 3 1-0-1 Day 4 1-0-1 Day 5 2-0-1 Day 6 2-0-1 Day 7 4-0-0~In combination with prednisone 20mg: day 1 to day 7 1.5-0-0."
46001395|NCT04659915|Drug|Placebo 500 mg Tablets + Prednisone 20mg Tablets|During another phase of the study: identical looking placebo pills starting day 1 500mg 1-0-0, day 2 500mg 1-0-0, day 3 500mg 1-0-1, day 4 500mg 1-0-1, day 5 500mg 2-0-1. day 6 2-0-1, day 7 4-0-0. In combination with prednisone 20mg: day 1 to day 7 1.5-0-0.
46001396|NCT00557427|Drug|hypericum|250mg tablets twice daily for 8 weeks
45835430|NCT02059668|Biological|Biomarker analyses head & neck cancer tissue, blood specimen|For biomarker analyses, tumor tissues from previous biopsies and surgery and blood specimens taken during treatment at the treating institution will be used.
46001397|NCT00557427|Drug|fluoxetine|20mg - 40mg daily for 8 weeks
46001398|NCT00540800|Drug|docetaxel|given in combination with epirubicin or capecitabine
46001399|NCT00540800|Drug|epirubicin|for patients with locally advanced breast cancer, or metastatic breast cancer not previously treated with anthracyclines
46001400|NCT00540800|Drug|capecitabine|for metastatic breast cancer patients previously treated with anthracyclines
46001401|NCT00540878|Drug|SB-751689 oral tablets (400 mg)|
46001402|NCT00540917|Procedure|cooling spray during laser treatment|skin temperature measurement
46001403|NCT04659876|Diagnostic Test|clinical features and laboratory values|Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
46001404|NCT00540956|Drug|cytarabine|
45676064|NCT04894890|Drug|secukinumab|There is no treatment allocation. Patients administered secukinumab by prescription that have started before inclusion of the patient into the study will be enrolled.
46001405|NCT00540956|Other|laboratory biomarker analysis|
46001406|NCT04678596|Device|EonAligner|EonAligner system is one stage system.
46001407|NCT04678596|Device|Clearfix|Clearfix system is three-stage system.
46001408|NCT00541073|Dietary Supplement|vitamin B12|
46001409|NCT00541073|Drug|cisplatin|
46001410|NCT00541073|Drug|pemetrexed disodium|
46001411|NCT00541073|Genetic|gene expression analysis|
45676065|NCT04889872|Device|SAPIEN 3 / SAPIEN 3 Ultra|Patients will be implanted with a SAPIEN 3 / SAPIEN 3 Ultra heart valve
45676066|NCT04882085|Drug|Zavicefta, Ceftazidime-Avibactam|CAZ-AVI 2.5 g (2 g ceftazidime + 0.5 g avibactam) administered IV as a 2 hour infusion every 8 hours. Dose adjustments are available for participants with CrCL ≤50 mL/min.
45676067|NCT04882085|Drug|Best Available Treatment|main treatment expected to be used as either monotherapy or in combination are colistin, tigecycline, fosfomycin, amikacin, and meropenem
45676068|NCT04881240|Biological|CD19-CAR(Mem) T-cells|Allogeneic CD19-CAR.CD45RA-negative T-cells Intravenous infusion
45676764|NCT02173301|Drug|XP23829 400 mg QD|active dose 1
46001412|NCT00541073|Other|laboratory biomarker analysis|
46001413|NCT00541073|Other|pharmacological study|
46001414|NCT04678323|Drug|Lifestyle Management|Participants in this group will receive lifestyle management.
46001415|NCT00541112|Biological|cetuximab|
46001416|NCT00541112|Drug|capecitabine|
45676069|NCT04881240|Drug|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.
46001417|NCT00541112|Drug|fluorouracil|
46001418|NCT00541112|Drug|leucovorin calcium|
46087777|NCT02703272|Drug|Vincristine|Participants will receive a cumulative dose of vincristine 1.6 mg/m^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
45676070|NCT04881240|Drug|Fludarabine|Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.
45676071|NCT04881240|Drug|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide.
45676072|NCT04881240|Device|CliniMACS|A CliniMACS device is used to select donor T-cells for manufacturing of the memory CAR T-cell product.
46001419|NCT00541112|Drug|oxaliplatin|
45676073|NCT04881240|Procedure|Leukapheresis|Leukapheresis is performed to collect the T cells that are needed to generate the CD19-CAR.CD45RA-negative T-cells product for the clinic study.
45676074|NCT04875715|Other|Almond Oil|Almond oil
46001420|NCT00541112|Procedure|adjuvant therapy|
46087778|NCT02703272|Drug|Idarubicin|Participants will receive a cumulative dose of idarubicin 20 mg/m^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
46087779|NCT02703272|Drug|Dexamethasone|Participants will receive a cumulative dose of dexamethasone 100 mg/m^2 in part 1 and part 2 as a part of RICE/RVICI regimen per cycle.
46087780|NCT02703194|Drug|Prednisone|Prednisone:A starting dose of 0. 5-0. 8mg/(kg*d) will be given. Following four-week period, the dose will be tapered gradually to 5mg/d until the end of 12 months of follow-up period.
46001421|NCT00541112|Procedure|conventional surgery|
46001422|NCT00541112|Procedure|neoadjuvant therapy|
46001423|NCT00541112|Radiation|radiation therapy|
46001424|NCT04678011|Procedure|Personalized surveillance and intervention protocol|This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 6 months and 2 years, depending on severity of polyposis and performed endoscopic interventions.
46087781|NCT02703194|Drug|Leflunomide|Leflunomide:A starting dose of 20 mg/day will be given. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor adverse effects occur(e.g., liver enzyme elevations).
46087782|NCT02402660|Drug|ALK-001|Daily, oral administration for 24 months
45676075|NCT04875715|Drug|Hydroquinone Topical|Hydroquinone 2% cream
46087783|NCT02402660|Drug|Placebo|Daily, oral administration for 24 months
46087784|NCT02189018|Other|Active Exercise|Active exercise on a treadmill
46087785|NCT02189018|Other|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation
46087786|NCT02189018|Other|Weight loss and active exercise|Weight loss and active exercise on a treadmill
46087787|NCT02189018|Other|Ad lib activity at home|Ad lib activity at home
46087788|NCT02702960|Procedure|living related donor partial liver transplantation|HLA matched or haploidentical related living donor partial liver transplant followed by tacrolimus, prednisone, and MMF immunosuppression for >3 wks
46087789|NCT02702960|Radiation|Total body irradiation|200 cGy total body irradiation (TBI) on Day -1.
45676076|NCT04875702|Drug|Allopurinol|"For the TTT-SU group: The dose titration algorithm for allopurinol increases every 4 weeks by 100 mg until the target serum urate of 6 mg/dL is reached or a patient requires 800 mg per day of allopurinol. Subjects will require a blood draw for SU every 4 weeks until reaching the target.~For the TTASx group: Subjects randomized to the TTASx group will receive anti-inflammatory treatments (naproxen, colchicine, and/or prednisone) for up to six flares over the ensuing three months. Urate lowering therapy (ULT) will only be offered after the third flare during the trial."
45676077|NCT04875702|Drug|Antiinflammatory Agent for Gout Flare Prophylaxis|naproxen, colchicine and/or prednisone as flare prophylaxis
45676078|NCT04874584|Behavioral|CTNSM|The Culturally Tailored Nurse-delivered telephone/text message symptom-management intervention (CTNSM) intervention is an in-person or telehealth face-to-face education session followed by a weekly telephone call and/or text message conducted for the first 12 weeks of standard of care chemotherapy .
45676079|NCT04874584|Behavioral|Standard of Care Chemotherapy Education|Standard of Care chemotherapy education is a one-time patient education session about general treatment-related side effects patients can experience from chemotherapy and the interventions to mitigate the symptoms.
45835431|NCT01895010|Device|acupoint electric stimulation|acupoint electric stimulation combined with tropisetron 6mg before TACE
46087790|NCT02702960|Procedure|Bone marrow transplant from same donor|BMT using cells from the same Human Leukocyte Antigen (HLA)-matched or -haploidentical living related donor will be performed on Day 0
45676765|NCT02173301|Drug|XP 23829 800 mg QD|active dose 2
45835432|NCT01895010|Drug|tropisetron|only tropisetron 6mg before TACE
45835433|NCT02039388|Procedure|Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle|
45835434|NCT02030028|Drug|ACTHAR gel|Subjects are given the ACTHAR gel subcutaneously twice per week for 12 weeks.
45835435|NCT04389528|Other|Neuromodulation by tDCS|The tDCS is a device for modulating cortical excitability. It consists of passing a low intensity direct electrical current over the scalp via two electrodes: an anode and a cathode soaked in a saline solution. Although there is a short-circuit effect through the scalp, a significant amount of electrical current enters the brain and changes the transmembrane potential.
45835436|NCT05413356|Drug|Ruxolitinib|Oral ruxolitinib twice daily
45835437|NCT00613860|Device|Zephyr endobronchial valve|Endobronchial valve system to redirect the airflow within the bronchial system
45835438|NCT00603330|Biological|Mesenchymal stem cells|Mesenchymal Stem Cell infusion
45835439|NCT01896336|Drug|Zolpidem Hemitartrate|"Patz - 5mg sublingual zolpidem hemitartrate~1 QD~Stilnox - 10mg oral zolpidem hemitartrate~1 QD"
46001425|NCT00541151|Device|MiniArc|sling system
46001426|NCT04659447|Drug|Platelet-Rich Plasma|36 ml of peripheral blood is extracted from patients, and 4 ml of 3.8% sodium citrate is added for anticoagulation. After centrifugation for 2 times, 4 ml platelet-rich plasma will be prepared.Four semitendinosus tendons and gracilis tendons are prepared.
46087791|NCT02702960|Drug|Cyclophosphamide|Pre-transplantation low dose cyclophosphamide given day -6 and -5 Post-transplantation high dose cyclophosphamide (PTCy; 50 mg/kg/day) will be administered on Days 3 and 4 with hydration
46087792|NCT02702960|Drug|Mesna|administered on Days 3 and 4 with PTCy
46001427|NCT05086523|Device|Programmable Hypertension Control (BackBeat Moderato)|Programmable Hypertension Control can be turned OFF without affecting regular pacing
46001428|NCT05086523|Device|Pacing (BackBeat Moderato)|Programmable Hypertension Control can be turned OFF without affecting regular pacing
46001429|NCT04659525|Drug|Evolocumab|In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
46001430|NCT04659525|Drug|Ezetimibe|Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
46001431|NCT04659525|Drug|Placebo|In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
46001432|NCT03456908|Combination Product|18F-TFB-PET|Infusion of F-18 TFB and PET / CT imaging
46001433|NCT02333643|Drug|CLS003|
46087793|NCT02702960|Drug|Filgrastim|administered daily starting on Day 5 until absolute neutrophil count (ANC) recovery
46087794|NCT02702960|Drug|Tacrolimus|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
46087795|NCT02702960|Drug|mycophenolate mofetil|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
46087796|NCT02702960|Drug|Prednisone|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
46087797|NCT02702960|Drug|Antithymocyte globulin|Given from Day -16 to Day -14 prior to bone marrow transplantation on day 0
46087798|NCT02702960|Drug|fludarabine|fludarabine given from Days -6 to Day -2 before BMT
46087799|NCT02699528|Drug|methylphenidate|The drug will be prescribed as indicated for attention deficit disorder
46087800|NCT04215770|Drug|inj co-amoxiclav 50 units/kg/day vs inj Benzyl Penicillin 25000 units/kg/day|Patients of both groups were examined and compared in terms of efficacy of treatment, safety and cost effectiveness
46087801|NCT02022566|Behavioral|A supported self management of osteoarthritis program|Three theoretical sessions, each of about 90 minutes, held as group sessions with about 10 participants in each group. After the intervention patients are offered an individual exercise program, and the opportunity to practice this program together with others under supervision of a physical therapist for 6 weeks.
46087802|NCT02699294|Other|Manual pressure release|Subjects will be positioned supine on a treatment plinth and will be encouraged to relax as much as possible before pressure is applied. A slow pressure to myofascial latent trigger point will be applied directly over the marked pectoralis minor muscle myofascial latent trigger point site until a moderate but tolerable pain value of 7 out of 10 (0= no pain, 10= severe pain) is reported. Constant pressure will be sustained for 90 seconds if the subjects report that the pain is decreased to a value of 3, the pressure will be increased to restore perceived pain to the value of 7. Then, tissue resistance (barrier) in pectoralis minor muscle will be controlled.
45676080|NCT04864054|Biological|ECT204 T cells|ECT204 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the ECT204 transgene.
45676081|NCT04862221|Drug|High-dose methylprednisolone|Subjects in the high-dose methylprednisolone arm will receive an initial dose of methylprednisolone IV 10 mg/kg/day for 3 days and 5 mg/kg/day on Day 4. Normal saline will be used as placebo pre-medications and infusions given at the same volume and duration as the eATG infusions.
45676082|NCT04862221|Drug|Equine anti-thymocyte globulin|Subjects will receive eATG IV 40 mg/kg/day on Days 1- 4. Day 1 eATG infusion is run over 8 hours and Day 2-4 infusions are run over 4 hours.
45676083|NCT04862221|Drug|Prednisolone|"Subjects will receive prednisolone 1 mg/kg on Days 5-13 followed by a gradual taper with discontinuation at 42 Days as indicated below.~Days 5 - 13 Prednisolone PO 1 mg/kg/day (max 50 mg/day)~Days 14- 20 Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)~Days 21 - 27 Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)~Days 28 - 34 Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)~Days 35 - 41 Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)~Day 42 Discontinue"
46001434|NCT02333643|Drug|Furosemide|
45676766|NCT02173301|Drug|XP23829 400 mg BID|active dose 3
45676767|NCT02173301|Drug|Placebo|control
46001435|NCT02333643|Drug|Digoxin|
46001436|NCT02333643|Drug|Vehicle topical|
46001437|NCT03456869|Device|Patient Specific Implant|The patient specific implant is used to simultaneously complete the reposition and fixation of the chin.
46001438|NCT04659330|Behavioral|Online education (BdandMe) for injection technique|patients were referred to the relevant modules on BD and Me™ (for online education)
46001439|NCT04659330|Device|4mm needles|Providing a supply of needles for single use of 4mm insulin injection needle.
46001440|NCT00541424|Procedure|PET/CT Scanning|Full-body PET/CT procedure will be performed. Gas will be pumped into the colon before the scan so the colon will be opened up (inflated) and the study doctor will be able to more easily look for any lesions. This procedure is called gas insufflation.
46087803|NCT02699294|Other|Contract-relax PNF stretch|Subjects will be in a sitting position with hands being clasped behind the head. The pectoralis minor muscle will be passively and slowly stretched until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Passive stretch will be sustained for 10 seconds followed by 6 seconds of maximal voluntary isometric contraction of the pectoralis minor muscle. Then, subjects will be instructed to relax for further 4 seconds. Subjects will maintain newly active stretched position of pectoralis minor muscle for 10 seconds with a strong but tolerable stretch discomfort intensity level of 4 out of 10. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
46001441|NCT02330445|Drug|PRTX-100|6 micrograms PRTX-100 per kilogram of body weight administered via infusion
46001442|NCT00541463|Drug|MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks|
46087804|NCT02699294|Other|Z-stretch|Subjects will be positioned supine with knee bent on a treatment plinth, and the legs will be rotated to the opposite direction of the arm to be stretched placing a stabilizing distal tension on the ribs. Then, the subjects will be slowly brought the arm in a circular motion overhead pausing at the points of tightness, maintaining close contact to the treatment table until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Self-stretch of pectoralis minor muscle, including myofascial latent trigger points will be sustained for 30 seconds. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
46087805|NCT02702882|Dietary Supplement|Fenugreek Seeds Extract|Furosap one caps OD
45676768|NCT01822587|Drug|Propranolol, 40 mg|
46001443|NCT00541463|Drug|Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks|
46001444|NCT04659486|Behavioral|Home-based exercise training|Online strength and aerobic home-based exercise training, 3 times per week, for 12 weeks. The exercise program is composed by 2 intensity-levels (starter and advanced).
46001445|NCT02324985|Drug|S-Ibuprofen Topical Gel 5%|S-Ibuprofen Topical Gel 5% applied every 6 hours
46087806|NCT02568215|Biological|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
46087807|NCT02568215|Biological|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
46087808|NCT03293498|Biological|NanoFlu|Vaccine
46087809|NCT03293498|Biological|Fluzone HD - Day 0|Vaccine
46087810|NCT03293498|Biological|Fluzone HD - Day 21|Vaccine
46087811|NCT03293498|Other|Saline - Day 21|Placebo
46087812|NCT02699138|Drug|Trazodone|100mg of trazodone to be administered orally once.
45835440|NCT00597870|Device|Endoluminal treament of thoracic lesions|Endoluminal treament of thoracic lesions with a thoracic stent-graft
46087813|NCT02699138|Drug|Placebo|Compounded sugar pill
45835441|NCT04293666|Dietary Supplement|Kefir|28 days supplementation kefir drink (prepared by inoculating pasteurized 9.2% reconstituted skim milk with powder kefir starter culture and fermented at 37 °C for 16 h. The fermented milk was then pasteurized at 100 °C for 30 min and freeze dried. The powder kefir starter culture used for inoculation was composed of defined lactic acid bacteria strains which contains Lactobacillus fermentum DSM 32784 (LF26), L. helveticus DSM 32787 (LH43), L. paracasei DSM 32785 (LPC12), L. rhamnosus DSM 32786 (LRH10), and Streptococcus thermophilus DSM 32788 (ST30)), 200ml/day
45457925|NCT03503500|Other|Standard care|"2. the standard care in use at the Institute (WHO/UNICEF 20-hours course) (control group). At randomization, the Italian version of the video Breast is best (Allattare informati), which provides detailed information on standard support to breastfeeding, will be delivered to women with the recommendation to watch it before birth; during the maternity ward stay, the staff will show to mothers how to breastfeed and will help them to attach the baby correctly to the breast"
45676769|NCT01822587|Drug|Propranolol, 80 mg|
45676770|NCT01822587|Drug|Placebo|
45676771|NCT04588077|Biological|Heplisav-B Injectable Product, 2-dose regimen|Investigators will randomly assign patients into a 2-dose regimen.
45676772|NCT04588077|Biological|Heplisav-B Injectable Product, 3-dose regimen|Investigators will randomly assign patients into a 3-dose regimen.
45676773|NCT04595331|Device|Sculptra Aethestic reconsituted with 8ml Sterile Water for Injection|Sculptra Aesthetic 8ml and Lidocaine treatment of cheek wrinkles
45835442|NCT04293666|Dietary Supplement|placebo|Maltodextrin, same calorie as kefir, 200ml/day
45835443|NCT00575718|Behavioral|Hospital Counseling + Nicotine Replacement Therapy. questionaires|"brief face-to-face or telephone tobacco cessation counseling provided by a tobacco cessation specialist prior to admission and during hospitalization (15-20 minutes per encounter)provision of multi-media self-help materials (e.g., Smoking Cessation Guide for Cancer Patients and Their Families) tailored to address cancer-specific issues such as the benefits and barriers of quitting for cancer patients; 3) tobacco cessation pharmacotherapy, unless medically contraindicated (for this study we will standardize the pharmacotherapy as transdermal nicotine patch), and; 4) two brief telephone counseling (15 minutes) sessions completed as seen clinically appropriate by the tobacco cessation specialists. The content of these counseling sessions is based on the patient's smoking status."
46001446|NCT02324985|Drug|Vehicle Topical Gel|Vehicle Topical Gel applied every 6 hours
46001447|NCT00541541|Procedure|Phrenic nerve stimulation|Patients receive a phrenic nerve stimulation
46001448|NCT02314299|Drug|MTP-131|
46001449|NCT04659681|Diagnostic Test|PVI Guided fluid management during surgery for (PVI<12) colloid bolus will be given .|PVI probe attached to finger in PVI Group
46001450|NCT04659681|Diagnostic Test|CVP Guided Fluid management during surgery for CVP<10 cms H2O colloid bolus will be given|Placement of central venous catheter
46001451|NCT04659642|Drug|Dexmedetomidine Injection [Precedex]|the drug is given 15 minutes before the estimated end of surgery
46001452|NCT04659642|Drug|Fentanyl Citrate Injection|the drug is given 15 minutes before the estimated end of surgery
46001453|NCT04659642|Combination Product|dexmedetomidine and fentanyl|the combination of the two drugs with the same used doses is given 15 minutes before the estimated end of surgery
46001454|NCT00541736|Drug|Nitroglycerine|Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min
46087814|NCT02699138|Device|Epiglottic catheter|Catheter that can be placed through the nose to a position behind the tongue to monitor for upper airway obstruction and to measure changes in pressure below the obstruction.
46087815|NCT02702648|Drug|AC-082|Hard gelatin capsules for oral administration
46001455|NCT02306811|Drug|Vatelizumab|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
45676084|NCT04862221|Drug|Placebo for prednisolone|"Subjects will receive 1 mg/kg/day of oral placebo for prednisolone on days 5-13 followed by a gradual taper to discontinuation at 42 days as indicated below. Subjects receiving oral placebo will be given a solution that closely resembles the treatment drug.~Days 5 - 13 Placebo for Prednisolone PO 1 mg/kg/day (max 50 mg/day)~Days 14- 20 Placebo for Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)~Days 21 - 27 Placebo for Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)~Days 28 - 34 Placebo for Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)~Days 35 - 41 Placebo for Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)~Day 42 Discontinue"
46087816|NCT02702648|Drug|Placebo|Matched placebo capsules for oral administration
45676085|NCT04862221|Drug|Placebo for infusions|Subjects randomized to the supportive care alone arm will receive normal saline in place of all study treatments (skin test, premedication and IV infusions) on Days 1-4 given at the same volume and duration as the eATG infusions.
46001456|NCT00541814|Drug|Cyclosporine|Target drug level 50-100 ng/ml or cyclosporine withdrawal
46001457|NCT04659564|Device|User of Dayspring device|The Dayspring™ device is a novel FDA-cleared wearable solution that is portable and easy-to-use sequential compression system.
46001458|NCT00541853|Drug|Candesartan|Candesartan upto 8mg
46001459|NCT00541853|Drug|Candesartan and Cilnidipine|Candesartan upto 8mg per day and Cilnidipine upto 20mg per day
46001460|NCT00541853|Drug|Candesartan plus non-CCB agents|Candesartan upto 8mg per day and other antihypertensive drugs except CCB and ACEI
46001461|NCT02301234|Drug|Placebo|Placebo will be administered once every 4 weeks with or without adjunctive therapy for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
45676086|NCT04862221|Drug|Diphenhydramine|Subjects in the eATG arm will receive pre-treatment medication diphenhydramine IV 1 mg/kg prior to start of eATG infusion.
45676087|NCT04862221|Drug|Methylprednisolone|Subjects in the eATG arm will receive pre-treatment medication methylprednisolone IV 1 mg/kg prior to start of eATG infusion.
45676088|NCT04861597|Behavioral|Internet based cognitive behavioral therapy|Participants with elevated psychological distress will receive 8 weeks of internet-based cognitive behavioral therapy
45676089|NCT04861597|Behavioral|Digital mood tracking|Participants with elevated psychological distress will receive 8 weeks of digital mood tracking
46001462|NCT02301234|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
46001463|NCT02301234|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
46001464|NCT02301234|Drug|Celecoxib 100 mg|Double-blind capsules taken twice daily for up to 16 weeks.
46001465|NCT02301234|Drug|Celecoxib 100 mg Matching Placebo|Double-blind capsules taken twice daily for up to 16 weeks.
46087817|NCT02702570|Behavioral|CASA|Each participant serves as his/her own control. Measures administered before and after the behavioral intervention.
46087818|NCT04220957|Other|Digital Impression Technique|Digital impressions of both arches will be taken by using an intraoral scanner (Trios 3, 3Shape, Denmark) by adhering to the scanning pattern recommended by the company for routine diagnosis and recording.
46087819|NCT04220957|Other|Conventional Impression Technique|Conventional Impression Technique of both arches will be taken with alginate (Orthoprint, Zhermack) on conventional stainless steel impression trays.
46087820|NCT02702726|Other|Congee and juice with coconut gel|25g coconut oleogel
46087821|NCT02702726|Other|Congee and juice with coconut oil|25g coconut oil
46087822|NCT02702726|Other|Congee and juice with sunflower gel|25g sunflower oleogel
46087823|NCT02702726|Other|Congee and juice with sunflower oil|25g sunflower oil
46001466|NCT00541892|Other|Medium with no human serum albumine added|See above
46001467|NCT00541892|Other|Conventional medium|See above
46001468|NCT00542048|Drug|EndoTAG®-1|EndoTAG®-1 22 mg/m² twice weekly
46001469|NCT02300142|Biological|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
46001470|NCT02300142|Biological|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
46001471|NCT02300142|Biological|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
46001472|NCT02300142|Biological|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
46001473|NCT02300142|Biological|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
46087824|NCT04217291|Drug|SY-004|Take orally once a day
46087825|NCT04217291|Other|SY-004 matching placebo|Take orally once a day
46087826|NCT02702804|Other|High Intensity Interval Training|High Intensity Interval Training
46087827|NCT04232189|Other|no intervention|no intervention, just specimen collection
46001474|NCT00539903|Behavioral|Physical activity (PA) and immigrants|
46001475|NCT01214668|Drug|LY573636-sodium|"Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28-day cycle.~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 milligrams per square meter (mg/m²) of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion is met."
46087828|NCT04215536|Drug|Empagliflozin|Empagliflozin dispensing claim is exposure
46001476|NCT01214668|Drug|Liposomal Doxorubicin|"40 mg/m² on Day 1, given intravenously of each 28-day cycle~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 mg/m² of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion are met."
46001477|NCT00542126|Drug|Decapeptyl 0.1 mg after embryo transfer|Decapeptyl 0.1 mg (Ferring, Kiel, Germany) 3 days following embryo transfer
45676090|NCT04858230|Device|LymphoPilot|"LymphoPilot is an investigational medical device composed of an implanted part (pump, drainage catheter and output catheter), implanted in the subcutaneous tissue of the arm or of the leg and draining excess fluids to the supraclavicular or abdominal subcutaneous tissue, where fluids are naturally reabsorbed by the healthy lymphatic and venous system. The implanted part is activated and controlled via a wearable device.~The subcutaneous implantation of the device is performed in loco-regional or general anesthesia, in ambulatorial settings, and the patient is dismissed from the hospital on the same day of the procedure.~Patients will wear the external controller continuously throughout the study, except 30 minutes per day, to allow taking a shower/bath. The implanted device will be removed with a surgical procedure in local anesthesia 8 weeks after device implantation."
46001478|NCT02886832|Dietary Supplement|Prostate Health formulation|
46001479|NCT02293941|Drug|JKB-122 5mg|Participants were randomized to receive JKB-122 5mg for 12 weeks
46001480|NCT02293941|Drug|JKB-122 15mg|Participants were randomized to receive JKB-122 15mg for 12 weeks
46001481|NCT02293941|Drug|JKB-122 35mg|Participants were randomized to receive JKB-122 35mg for 12 weeks
46001482|NCT02293941|Drug|Placebo|Participants were randomized to receive comparable placebo for 12 weeks
46001483|NCT00542165|Drug|Alfuzosin|
46001484|NCT02289846|Drug|IW-9179|
46001485|NCT02289846|Drug|Matching Placebo|
46001486|NCT00542204|Behavioral|Online disease management|The Personalized Health Care Program couples a multidisciplinary care management team with an EHR-integrated Online Disease Management (ODM) system.
46001487|NCT04648800|Drug|BCG-10 vaccine|"The BCG-10 anti-tuberculosis vaccine~powder and solvent for preparing a suspension for intradermal injections of Vaccinum tuberculosis (BCG) cryodesiccatum;~lyophilised BCG vaccine~one dose (0.1 ml) contains 50 micrograms of half-dried mass of BCG mycobacteria, which corresponds to 150,000 - 600,000 of live BCG bacilli- the Brazilian Moreau sub-strain."
46001488|NCT04648800|Drug|0.9% saline|0.9% saline
46001489|NCT00542243|Drug|Finasteride|Finasteride (5mg) will be given once per day for 6 months.
46001490|NCT00542243|Drug|Placebo|Placebo will be given once a day for 6 months.
46001491|NCT02286804|Device|Ultherapy|Micro-focused ultrasound energy delivered below the surface of the skin
46001492|NCT02286765|Device|Ulthera System treatment|Micro-focused ultrasound energy delivered below the surface of the skin
46001493|NCT00542360|Behavioral|Marketing program to motivate exercise class participation|Using qualitative research methods, a targeted social marketing program, including a 'marketing toolkit,' was developed to motivate participation in exercise classes by older adult members of churches. The Health Belief and Transtheoretical Models formed the theoretical basis for the social marketing planning process and guided program design. The marketing program aimed to increase exercise class attractiveness, usability, and uptake by reducing barriers and costs, and using messaging about benefits and enhanced convenience to motivate participation. The intervention was implemented through churches.
46001494|NCT02283957|Drug|CNTX-4975|
46001495|NCT02283957|Other|Placebo|
46001496|NCT04648995|Device|High energy (UltraPulse)|Half of the face that receives low energy, their central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ
46001497|NCT04648995|Device|Low energy (UltraPulse)|Half of the face that receives low energy, their central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ
46001498|NCT00542399|Drug|Levemir (insulin detemir)|Levemir once a day
46001499|NCT00542399|Drug|Levemir twice a day|Levemir twice a day
46087829|NCT04215536|Drug|DPP-4 inhibitor|DPP4 inhibitor dispensing claim is reference
46087830|NCT00615134|Drug|enfuvirtide [Fuzeon]|90mg sc bid
46087831|NCT00615134|Drug|Optimized background ARV therapy|As prescribed
46087832|NCT05572775|Procedure|Quadratus lumborum (QL) block|bilateral anterior subcostal quadratus lumborum block
46087833|NCT05572775|Procedure|Erector Spinae Plane (ESP) Block|bilateral erector spinae plane block
46001500|NCT04648722|Procedure|Hemithyroidectomy|We investigated patients who received a hemithyroidectomy at the Department of General Surgery, Division of Endocrine Surgery and a follow-up visit (3-12 months post-surgery) at the thyroid outpatient clinic of the Department of Endocrinology and Metabolism, Medical University of Vienna between 1994 and 2018.
46087834|NCT05568173|Other|Boxing Training|"In addition to boxing training, stretching exercises and posture training will be given at BG. A physiotherapist with a boxing training certificate will perform modified boxing training that progresses according to the degree of difficulty. There will be four difficulty levels. The complexity of the exercises will increase at 2-week intervals as the patient progresses. As a result, 0-2 weeks 1st level, 2-4 weeks 2nd level, 4-6 weeks 3rd level and 6-8 weeks 4th level exercises will be done.~In the first level, patients will be asked to punch the fixed boxing mat hanging on the wall with various instructions. Then, in levels 2-4, target gloves and heavy punching bags will be used to increase the difficulty level. As the sessions progress, the resistance and frequencies between the levels will be increased by the physiotherapist. There will be 3 sessions of 30-minute boxing training per week for 8 weeks at BG."
46001501|NCT00542516|Drug|Hydroxyethyl Starch|Dosage: 30ml/kg; frequency: one time; duration: 60min
46087835|NCT05568173|Other|Scapular Stabilization|"In addition to scapular stabilization training, stretching exercises and posture training will be given in SSG. Progressive strengthening training for the scapular muscles will be used in the SSG. There will be four difficulty levels. The complexity of the exercises will increase at 2-week intervals as the patient progresses. As a result, 0-2 weeks 1st level, 2-4 weeks 2nd level, 4-6 weeks 3rd level and 6-8 weeks 4th level exercises will be done.~At the first level, scapular clock exercise, obstacle crossing exercise, wall gliding exercise with teraband, push up exercise, trunk rotation and maximum hip flexion will be performed. Then at levels 2-4, as the levels increase, the exercises at the first level will be more difficult (ball weight, surface, number of hurdles and hurdle crossing exercise position, by changing the teraband elasticity, push-up position). In SSG, 3 sessions of 30-minute scapular stabilization training will be applied per week for 8 weeks."
46087836|NCT01831076|Drug|Exemestane|Given PO
46087837|NCT01831076|Drug|Exemestane and tamoxifen|exemestane 25 mg po daily and tamoxifen 20 mg po daily given concurrently for 4 months prior to surgery
46087838|NCT02025257|Other|Exercise|Individually prescribed hospital based exercise in group two times a week, home-based exercise once a week. The exercise intervention consists of interval based aerobic exercise on a bicycle ergometer 30 minutes with intensity level at 13-17 at Borg scale, resistance exercises and balance exercises
46001502|NCT00542516|Drug|Ringer's lactate|Dosage: 30ml/kg; frequency: one time; duration: 60min.After 10ml-kg-h both groups
46001503|NCT02266719|Device|Fenestrated CMD|"The CMD that will be used in this IDE is structurally the same as the commercially available Zenith Fenestrated AAA Endovascular Graft.~In general, the Zenith® Fenestrated AAA Endovascular Graft is a modular system constructed of full- thickness woven polyster fabric sewn to self-expanding stainless steel z-stents with braided polyster and monofilament polypropylene sutures. In this study, fenestrated grafts with usually up to 4 fenestrations may be used.~Device implantation will be performed using standardized endosvacular techniques used in the treatment of abdominal aortic aneurysms."
46001504|NCT02266719|Device|Type I - III TAAA|"Device implantation will be performed using standardized endosvacular techniques used in the treatment of abdominal aortic aneurysms. Devices will be implanted in patients with type I-III thoracic abdominal aneurysms.~The branches in this study will be constructed as internal/external cuffs, axially oriented and caudally or cranially directed, as necessary . Branch position will be determined by the anatomic location of the target vessels using a consistent craniocaudal and circumferential cuff position."
46001505|NCT02266719|Device|Arch cohort|Arch branched devices may be designed using one of two configurations: (1) Zone 0 device with two inner antegrade branches for the innominate artery and the left common carotid artery with or without a retrograde left subclavian artery branch and (2) Zone 1-2 device with a single retrograde subclavian artery branch with double or triple wide scallop for the left common carotid artery. These devices are designed for a of proximal landing/fixation zone of at least 20 mm of healthy aortic segment or a previous graft.
46001506|NCT03456830|Drug|ALLN-177|ALLN-177 7,500 units (2 capsules), orally, with each meal/snack, 3 to 5 times per day for 28 days
46001507|NCT03456830|Drug|Placebo|Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day for 28 days
46001508|NCT02265393|Drug|OTO-104|
46001509|NCT02265393|Drug|Placebo|
46001510|NCT00542555|Drug|Placebo|At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
46001511|NCT00542555|Drug|Naproxcinod 375 mg|
46001512|NCT00542555|Drug|Naproxen|
46001513|NCT00542555|Drug|Naproxcinod 750 mg|
46001514|NCT04648488|Other|Experimental early mobilisation|early activ assisted exercises treatment
46001515|NCT04648488|Other|Aktive comparator standrad treatmnet|standard treatment with a plaster 3 weeks and then active assisted exercises
46001516|NCT04685018|Device|fMRI acquisition|Participants from the two groups will perform an avoidance-relief task inside an MRI scanner
45457926|NCT03916861|Device|Bioelectrical Impedance Analysis|We use Inbody S20 analysis to measure fluid status before each hemodialysis session to guide fluid removal.
46087839|NCT04216160|Other|ACN cream (YUN)|Application of the facial cream ACN (YUN) twice a day, for 8 weeks +/- 2 days. Assessment before product use (T0), after 2, 4 and 8 weeks +/- 2 days of product use (T2w, T4w and T8w, respectively) and after 4 weeks +/- 2 days without product use (T12w).
46087840|NCT04216160|Other|Placebo cream (YUN)|Application of the facial placebo cream twice a day, for 8 weeks +/- 2 days. Assessment before product use (T0), after 2, 4 and 8 weeks +/- 2 days of product use (T2w, T4w and T8w, respectively) and after 4 weeks +/- 2 days without product use (T12w).
46087841|NCT04201223|Behavioral|FLARE Intervention|[See arm/group descriptions]
46001517|NCT02260674|Drug|JNJ-54861911, 10 milligram (mg)|Participants will self-administer JNJ-54861911, two tablets of 5 mg each for a total of 10 mg, orally, once daily, from Day 1 until Month 6 in treatment group 1.
46087842|NCT04216082|Drug|Anlotinib|Anlotinib is a oral small molecule receptor tyrosine kinases inhibitor with the potency of inhibiting tumor angiogenesis as well as cell proliferation simultaneously and have been approved to treat advanced non-small cell lung cancer (NSCLC) in China. Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
46087843|NCT02698982|Device|Depth of anesthesia monitoring (BIS, Covidien USA) and Continus non invasive blood pressure monitoring (Clearsight, Edwards LifeScience, USA)|
46087844|NCT02698982|Procedure|moderate risk surgery|
46087845|NCT02702336|Behavioral|EYTO-kids|To promote healthy lifestyles among young people, through the design and implementation of health promotion activities carried out by adolescents (12-14 years old) to scholars of primary education (8-10 years old), using social marketing and peer-led strategy.
45457927|NCT03916861|Procedure|Physician-guided|This intervention used physical examination as guided to adjust fluid therapy together with the chart record of intake and output per day
45457928|NCT02308618|Other|Traditional Immobilization|"After surgery subjects were immobilized in a plaster cast, with the ankle positioned in gravitational equinus; weight bearing was not allowed. Two weeks post-operatively, the cast was removed and the patient was immobilized with a new plaster cast, with the ankle in the same position. Four weeks post-operatively, the ankle was plastered in neutral position (i.e. with the sole of the foot perpendicular to the shank), and weight bearing was encouraged. Six weeks post-operatively, the plaster cast was removed~The home exercise program consisted of active exercises and stretches to improve ankle range of motion, and resistance and balance exercises"
46087846|NCT02698904|Behavioral|Guided Relaxation Technique|
46087847|NCT02698904|Other|Documentary Movie|
46087848|NCT00615524|Drug|exemestane and pazopanib|
46087849|NCT00908141|Biological|sargramostim|Given subcutaneously on varying schedule
46001518|NCT02260674|Drug|JNJ-54861911, 50 mg|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6 in treatment group 2.
46087850|NCT04215458|Other|sample collection (swap or tape strip)|collection of swap or tape strip to determine yeast colonization in skin
46087851|NCT02690909|Device|Redy™ Renal Denervation System|Renal Denervation System
46087852|NCT02702102|Drug|11C-PBR28|Up to 20 millicuries
46001519|NCT02260674|Drug|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6 in placebo group.
46001520|NCT04648410|Other|questionnaire|Members of European Society of Intensive Care will obtain an electronic survey considering their routine clinical practice regarding the administration of systemic corticosteroids among patients with COVID-19 ARDS
46001521|NCT00542711|Drug|liquid tumeric/curcumin extract|30 drops (4 participants), 50 drops (4 participants) and 70 drops (4 participants). one dose.
46001522|NCT04679025|Other|Exposure - postoperative hyperglycemia|Postoperative hyperglycemia (blood or capillary glucose > 10.0 mmol/L) within 72 hours of a surgical procedure
46087853|NCT01246310|Dietary Supplement|Inositol|
46087854|NCT01246310|Dietary Supplement|Placebo|
46087855|NCT01773707|Drug|CTLA4-Ig (Abatacept)|Given as 30 minute IV infusion
46087856|NCT01773707|Drug|Placebo|Saline given as 30 minute IV infusion
46087857|NCT03381170|Biological|Ublituximab|Enrolled Subjects will be infused with ublituximab on Weeks 1E, 24E, 48E, 72E and 96E
46087858|NCT00632567|Procedure|caesarean section|caesarean section for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
46087859|NCT00632567|Procedure|vaginal delivery|vaginal delivery for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
46087860|NCT04215926|Other|No intervention; cross-sectional study|No intervention; cross-sectional study
46087861|NCT03746873|Behavioral|COPD Web|"The COPD Web will be introduced to the participant randomized to intervention by a letter containing a code to get access to the web site and how to create an account and login. At the web site there will be an instruction movie showing/ discussing specific content on the COPD Web. The web site will be self-managed. To secure that there is no technical or user problems participants will be contacted by a researcher the first week of intervention.~Participants will receive push notifications (email) with targeted information containing links to the COPD Web and reminder to register the number of steps walked during that week. The push notifications will come every week (week 1-12), every other week (week 12 to 24) and every fourth week (week 24-52)."
46087862|NCT00700076|Drug|Ketamine and Org 25935|Oral administration of Org 25935 16 mg and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
45676091|NCT04852887|Other|Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|"Post lumpectomy radiation therapy will be external beam radiation to either the whole breast + boost, partial breast irradiation, or Accelerated Partial Breast Irradiation that must begin within 12 weeks of the last breast cancer surgery(including re-excision of margins).~Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s). Endocrine therapy may be initiated before, during, or after completion of radiation therapy at the discretion of the investigator."
46001523|NCT04678128|Behavioral|Dance4Healing Telehealth Live Zoom Sessions|"Week 1: 2-hour introduction session on Zoom platform with a live dance instructor at the participant's desired level of activity intensity (low, mild, or moderate).~Weeks 2-8: All participants will be asked to participate in a 1 hour online, instructor-led live class."
46001524|NCT04678128|Behavioral|Dance Buddy|"Following randomization (beginning of intervention period) half of the participants will be assigned a dance buddy, and will be asked to dance with their buddies using the Dance4Healing TLVP at least 2 additional times/week. This group will have 24/7 access to Dance4Healing Platform during the intervention and post-intervention periods."
46087863|NCT00700076|Drug|Placebo and Ketamine|Oral administration of placebo and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
46001525|NCT00542906|Other|localization|localization of the several types of somatosensory stimuli
46001526|NCT04678674|Procedure|tooth root augmentation|Autogenous tooth roots for lateral alveolar ridge augmentation and staged implant placement.
46087864|NCT01653899|Drug|IDN-6556|14 day oral treatment of the investigational caspase inhibitor drug IDN-6556 following first islet transplant at 50mg twice daily.
46001527|NCT00542945|Device|ICD|Implantation of an ICD
46001528|NCT00542945|Other|Optimal medical treatment|ACE-inhibitors or ARB Beta-blocker Optional aldosterone antagonist
46001529|NCT04677933|Drug|A: OLP-1002|10 patients will receive 5 µg OLP-1002 twice-weekly (BIW) OLP-1002
46001530|NCT04677933|Drug|B: OLP-1002|10 patients will receive 10 µg OLP-1002 BIW OLP-1002
46001531|NCT04677933|Drug|C: Placebo|10 patients will receive Placebo BIW
46001532|NCT00542984|Drug|teriparatide 20 micrograms/day subcutaneous|
46001533|NCT00542984|Drug|salmon calcitonin 100 IU/day subcutaneous|
46001534|NCT02257983|Drug|EPI-743|EPI-743 (2 capsules 200 mg each) taken at a dose of 400 mg P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
46001535|NCT02257983|Drug|Placebo|2 Placebo capsules P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
46001536|NCT00543023|Drug|teriparatide 20 micrograms/day subcutaneous|
46001537|NCT00543023|Drug|salmon calcitonin 100 IU/day subcutaneous|
46001538|NCT04648917|Drug|Caffeic acid|40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval(weight >50kg, 200mg per time, weight < or =50kg, 100mg per time)
46001539|NCT00543179|Drug|Somatuline (Lanreotide Autogel®)|
46001540|NCT04648527|Procedure|arthroscopic synovectomy and thermocoagulation|An diagnostic arthroscopy and an arthroscopic synovectomy and thermocoagulation of the dorsal hypertrophic synovial will be performed
46001541|NCT00543218|Drug|teriparatide 20 micrograms/day subcutaneous|
46001542|NCT00543218|Drug|calcitonin 100 IU/day subcutaneous|
46001543|NCT00543257|Other|Use of paper forms to write down information|Parents will be asked to write down information specific to their child's ADHD using paper forms.
46001544|NCT00543257|Other|Computer|Parents will use a computer to complete data entry on information specific to their child's ADHD care
46001545|NCT02252835|Drug|Arhalofenate|800 mg once daily orally for four weeks
46001546|NCT02252835|Drug|Febuxostat|40 mg once daily orally for 1 week then up-titrated to 80 mg once daily orally for another three weeks
46001547|NCT02252835|Drug|Arhalofenate|600 mg once daily orally for four weeks
46087865|NCT02698514|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
46087866|NCT02698514|Drug|Desflurane|Anesthesia was maintained with desflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
45457929|NCT02308618|Other|Early Mobilization|The physical therapy started two weeks after the surgery and lasted six weeks, during which a removable brace was used. Therapy sessions, three times per week in the six-week period, included one to two hours of exercises for regaining range of motion and muscular endurance.
46001548|NCT02252835|Drug|Febuxostat|80 mg once daily orally for 1 week then down-titrated to 40 mg once daily orally for another three weeks
46001549|NCT02252835|Drug|Colchicine|0.6 mg daily
46001550|NCT03456752|Drug|Dexamethasone|Dexamethasone 8mg intravenously prior to induction of anesthesia
46001551|NCT03456752|Drug|Normal saline|Normal saline 1.6ml intravenously prior to induction of anesthesia
46001552|NCT02227290|Drug|Naftin Cream|
46001553|NCT02227290|Drug|Placebo Cream|
46001554|NCT03456713|Biological|LY3074828|Administered SC
46087867|NCT02706158|Dietary Supplement|1500 mg Calcium and 1200 IU Vitamin D for 2 months|1500 mg Calcium and 1200 IU Vitamin D for 2 months
46087868|NCT02706158|Behavioral|balanced diet|participants will get a balanced diet according to pregnancy stage
46087869|NCT03456089|Diagnostic Test|Urodynamics Testing|Urodynamics utilizes a small catheter to fill the bladder and continuously measure pressure and volume giving information on bladder function and compliance
46087870|NCT03739853|Drug|Methotrexate|Used in all three arms of study
46087871|NCT03739853|Drug|Sulfasalazine|Used in arm 2 of study
46087872|NCT03739853|Drug|Leflunomide|Used in arm 2 of study
46087873|NCT03739853|Drug|Adalimumab|Used in arm 3 of the study only
46087874|NCT02702258|Behavioral|MB-BP|MB-BP (Mindfulness-Based Blood Pressure Reduction) customizes Mindfulness-Based Stress Reduction (MBSR) to participants with prehypertension/hypertension. MB-BP will consist of nine 2.5-hour weekly group sessions and an 7.5-hour one-day session. Some of the unique areas of MB-BP are education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of blood pressure determinants such as diet, physical activity, antihypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week.
46001555|NCT04648137|Diagnostic Test|study intervention: 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)|single administration of MDMA (100mg): 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) will be prepared as gelatin capsules with mannitol as the filler. MDMA will be administered in a single absolute dose of 100 mg corresponding to a medium high dose of (mean ± SD) 1.3 ± 0.3 mg/kg body weight.
46001556|NCT04648137|Diagnostic Test|Control intervention: Placebo|Identical placebo (only mannitol) capsules
46001557|NCT03456674|Device|LaseMD System|A non-invasive fractional thulium laser delivering a wavelength of light energy as a fractionated array of microbeams to be absorbed by and damage the target molecule, a chromophore.
45676092|NCT04852887|Drug|Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s).
46087875|NCT02702024|Procedure|Double uterine incision technique in uterus preserving surgery for placenta percreta|
46001558|NCT04648332|Drug|Bupivacaine Hydrochloride|compartment psoas block
46001559|NCT03456596|Other|ENABLE|This is an implementation science study in which an evidence-based early palliative care intervention, ENABLE (Educate, Nurture, Advise, Before Life Ends), is being implemented in rural community cancer centers that did not have a palliative care program.
45676093|NCT04847050|Biological|mRNA-1273|A rapid response, proprietary messenger RNA (mRNA)-based vaccine platform. 100 mcg administered IM on Day 1 and 29 for vaccine naive cohorts or on Day 1 for vaccine booster cohorts. Participants may receive up to 3 booster injections on study
45676094|NCT04836429|Drug|Porfimer Sodium|Given IV
45835444|NCT00575718|Behavioral|Hospital Counseling + Nicotine Replacement + Presurgical Scheduled Reduced Smoking, questionaires|Same components of HC+NRT as well as the PS/SRS enhancement.The research team will provide education about scheduled reduced smoking either in person or over the phone. Purpose of the training session, will be audio taped, to prepare participants for daily PDA use over the dur of the scheduled-reduced smoking intervention. Training will demonstrate use of PDA and simulate common technical and procedural issues that might arise during the intervention (e.g., forgetting to record a cigarette or wake time; repeating a day's schedule if needed, prior to the quit date). The simulation will reflect anticipated problems and those identified by users of the PDA. A study helpline number and instructional manual will be provided. A member of the research staff will contact the study participants, once the reduced smoking schedule has begun, to check that the patient understands the schedule and that the PDA is working properly. Estimate patient training with the PDA will require 30 minutes.
46001560|NCT04647981|Other|Xpert® Bladder Cancer Monitor Test|The urine sample is analyzed with the Xpert® Bladder Cancer Monitor test.
46001561|NCT03456557|Radiation|Perfusion computed tomography.|Using specific post treatment imaging software ( Olea® ) we will calculatell permeability parameters : the pancreatic blood flow and the k-trans, capillary membrane permeability factor.
45835445|NCT00556218|Behavioral|Tibetan Meditation Program|12 sessions of Tibetan meditation (2 times a week), over a 6-week period. Each class will last about 60 minutes.
46001562|NCT04648566|Procedure|Intrauterine administration of hCG-activated peripheral blood mononuclear cells|Administration of hCG-activated peripheral blood mononuclear cells in the uterine cavity of the patient
46001563|NCT04648566|Procedure|Intrauterine administration of sperm washing medium|Administration of sperm washing medium instead of PBMC in the uterine cavity of the patient
45676095|NCT04836429|Procedure|Video-Assisted Thoracic Surgery|Undergo VATS
45835446|NCT00556218|Behavioral|No Meditation|No meditation; usual care.
45835447|NCT00532740|Radiation|Yttrium Y 90 glass microspheres|Between 0.2 to 0.5 Curies (200-500-mCi), either single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart per treating physician's discretion.
45835448|NCT00530010|Radiation|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150 Gy (8,000-15,000 rad). Patients may receive a single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart.
46001564|NCT05078411|Behavioral|Test treatment|"Test treatment will consist of a single session structured as follows: (i) information on periodontal diagnosis (as formulated according to the classification system of the 2017 World Workshop for the Classification of Periodontal Diseases and Conditions); (ii) information on periodontal risk level (as calculated with the PerioRisk tool proposed by Trombelli et al. 2009) and profile (i.e., the magnitude of the contribution of each PerioRisk parameter to generate the patient risk level); (iii) information on treatment plan and oral hygiene instructions, with emphasis to treatment goals based on the PerioRisk output.~The operators will be trained to administer test treatment in approximately 8 minutes, but the duration of the session will be extended for additional questions and answers upon patient request."
46002599|NCT04684667|Drug|Propranolol Therapy for Infantile Hemangioma|If there are no contraindications to propranolol, it will be given at initial dose of 0.5 mg /kg/day in 2-3 divided doses with feeds and the patients will be observed for clinical signs of serious adverse reactions. If the dose is tolerated, it will be maintained for four to seven days, and then it will be increased by 0.5mg/kg/day every four days to the target dose of 2mg/kg/day. The patients will be observed for 2 hours after each dose increase for the clinical signs of severe side effects.
46087876|NCT04223453|Diagnostic Test|BIA and DXA|Patients with acute pneumonia measured simultaneously with DXA-scan and BIA-impedance
46087877|NCT00615602|Drug|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles
45676096|NCT04836429|Drug|Photodynamic Therapy|Undergo photodynamic therapy
45835449|NCT00514254|Other|questionnaire administration|
46001565|NCT05078411|Behavioral|Control treatment|"Control treatment will consist in a single session structured as follows: (i) information on periodontal diagnosis (as formulated according to the classification system of the 2017 World Workshop for the Classification of Periodontal Diseases and Conditions); (ii) information on treatment plan and oral hygiene instructions, and treatment goals. Although the general concept of risk of periodontitis incidence/progression will be explained, no mention will be made to the patient risk level as calculated with PerioRisk or any other tool.~The operators will be trained to administer control treatment in approximately 8 minutes, but the duration of the session will be extended for additional questions and answers upon patient request."
46001566|NCT04648176|Device|Moses technology|Using Holmium laser with Moses technology or conventional one
46001567|NCT00543335|Drug|Sorafenib|Starting dose 200 mg PO (by mouth) Daily
46001568|NCT00543335|Procedure|Radiation Therapy|45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
46001569|NCT02223039|Biological|AbGn-168H|AbGn-168H monoclonal antibody
45676097|NCT04836429|Device|Intraoperative PDT|Subjects will receive one course of light therapy at the time of surgery
46001570|NCT02223039|Biological|Placebo|Placebo of AbGn-168H
46001571|NCT00543413|Drug|MK8141|MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period
46001572|NCT00543413|Drug|Comparator: placebo (unspecified)|MK8141 Pbo tablet once daily. 4 week treatment period.
46087878|NCT00615602|Drug|Trastuzumab|Trastuzumab 6 mg/Kg IV over 30 min every two weeks for 4 cycles. Subsequently,trastuzumab 6 mg/Kg IV over 30 min for 12 months
46001573|NCT00543413|Drug|Enalapril|Enalapril 20 mg tablet once daily. 4 week treatment period.
46001574|NCT00554658|Drug|Quetiapine|Quetiapine will be administered open label as clinically required according to current guidelines. Target dose range: 400 - 800 mg quetiapine per day.
46001575|NCT00543452|Other|Oxygen|4 liters of oxygen a minute
46001576|NCT00543452|Other|Air from a placebo oxygen delivery|4 liters a minute of air from a placebo device
46001577|NCT00543491|Drug|MK0767|
46087879|NCT00615602|Drug|Epirubicin|Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
46087880|NCT00615602|Drug|Cyclophosphamide|Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
45457930|NCT01139359|Drug|darinaparsin|I.V. darinaparsin given in a dose escalation manner, once a day for 5 days per cycle.
45457931|NCT01139359|Drug|CHOP|Cyclophosphamide 750 mg/m2 IV Day 8 of each Cycle; Doxorubicin 50 mg/m2 IV Day 8 of each Cycle; Vincristine 1.4 mg/m2 IV Day 8 of each Cycle; Prednisone 100 mg oral Days 8-12 of each Cycle.
45676098|NCT04832152|Other|OT4ASD|Occupational therapy will focus on education and coaching of families/caregivers of children with autism spectrum disorder to help them adapt their daily routines to address their child's sensory needs.
45676099|NCT04828954|Other|Immobilization for 2-weeks postoperative|Non-removable thumb spica plaster postoperative splint immobilization worn for 2 weeks
45676100|NCT04828954|Other|Immobilization for 6-weeks postoperative|Non-removable postoperative thumb spica splint immobilization worn for 2 weeks (+/- 3 days), to be transitioned to thumb spica cast for an additional 4 weeks (Total of 6 weeks immobilization)
45676101|NCT04822467|Device|SQ53 Wipe|SQ53-based wipe to be used by the participant daily or upon dressing change
45676102|NCT04822467|Device|Ethanol Wipe|Ethanol-based wipe to be used by the participant daily or upon dressing change
45676103|NCT04819100|Drug|Selpercatinib|Administered orally.
45676104|NCT04819100|Drug|Placebo|Administered orally.
45835450|NCT00514254|Other|study of socioeconomic and demographic variables|
45835451|NCT00514254|Procedure|evaluation of cancer risk factors|
45835452|NCT00508794|Behavioral|Yoga Group|3 sessions of yoga each week for 6 weeks.
45835453|NCT00508794|Behavioral|Stretching Control Group|3 sessions of stretching each week for 6 weeks
45835454|NCT00508794|Behavioral|Waitlist Control Group|Option of participating in the yoga or stretching program after the study has ended.
45835455|NCT00508794|Other|Questionnaire|Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
45835456|NCT00494910|Behavioral|Meaning Centered Group Psychotherapy|this eight-week (1 ½ hour weekly sessions) Session 1 - Concepts of Meaning and Sources of Meaning Session 2 - Cancer and Meaning Session 3 - Meaning and Historical Context of Life Session 4 - Storytelling, Legacy Project (optional) Session 5 - Limitations and Finiteness of Life Session 6 - Responsibility, Creativity, Deeds Session 7 - Experience, Nature, Art, Humor Session 8 - Transitions, Goodbyes, Hopes for the Future
45835457|NCT00494910|Behavioral|Supportive Group Psychotherapy|The eight weekly 1 ½ hour sessions will focus on group discussion on a set of specific themes that emerge for patients coping with cancer. The session themes or topics will include such issues as: the discussion of strategies for coping with medical issues and procedures, communication with health care providers and issues related to family, friends, and occupational life.
46001578|NCT00543530|Drug|MK0831|
46002600|NCT04637919|Biological|IN-B001 EV71 A dose|Inactivated vaccine against EV71, three doses, 28 days interval
46002601|NCT04637919|Biological|IN-B001 CVA16 B dose|Inactivated vaccine against CVA16, three doses, 28 days interval
46002602|NCT04637919|Biological|IN-B001 Bivalent C dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
46002603|NCT04637919|Biological|Placebo|Placebo, three doses, 28 days interval
46002604|NCT00545675|Drug|Abilify(aripiprazole)|Abilify and Depakote in 24-week treatment of mania in patients with bipolar disorder
46087881|NCT00615602|Drug|5-fluoruracil|5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
46087882|NCT00615602|Drug|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
46087883|NCT00615602|Drug|Trastuzumab|Trastuzumab 6mg/Kg IV over 30 min every 2 weeks for 4 cycles. Subsequently, trastuzumab 6mg/Kg IV over 30 min for 6 months
46001579|NCT00554736|Biological|Lactobacillus acidophilus L-92|Nasal challenge and acoustic rhinometry will be performed at the first study visit and again at the end of the 4-month supplement period. Standardized perennial ryegrass pollen extract (Lolium perenne) (Hollister-Stier, Inc., Spokane, WA) will be used. Dilutions of the standard product will be made in sterile saline prior to use. The standard product strength is 100,000 BAU/mL. Provocation will start with 100 BAU/mL, delivered as a 100 microliter puff into each nostril nose during breath holding, followed by expiration. Acoustic rhinometry, performed in each nostril, will be recorded at 15 minutes. A change of 30% from baseline in the composite score is considered significant. The dose will be increased every 20 minutes if there is no response. The concentrations used will be 100 BAU, 330 BAU, 1000 BAU, 3300 BAU, 10,000 BAU or 33,000 BAU/mL.
46001580|NCT00543608|Drug|iclaprim|
45676105|NCT04817566|Device|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA).
45676106|NCT04817566|Device|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants.
46001581|NCT00543608|Drug|vancomycin|
46001582|NCT00554775|Drug|erlotinib hydrochloride|PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
46001583|NCT00554775|Drug|placebo|WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride
46001584|NCT00543647|Drug|Fenofibrate 160 mg tablet|
46001585|NCT00543647|Drug|Placebo|
46001586|NCT04647747|Other|Self measurement with pulse oximeter|Participant will measure peripheral saturation at home, conduct physiotherapy if desaturation occurs, and contact hospital if desatuation persists
45676107|NCT04817566|Behavioral|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 9 sessions for approximately 20 min
45676108|NCT04813926|Drug|Riociguat (Adempas, BAY63-2521)|Follow clinical practice.
45676109|NCT04811092|Drug|Sotatercept|Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1
46001587|NCT04647669|Drug|Remdesivir|200 mg intravenous loading dose on Day 1, and 100mg intravenous once-daily for subsequent doses from Day 2 up to Day 10.
46001588|NCT04647669|Drug|Acalabrutinib|100 mg capsules twice daily every 12 h for 10 days taken with or without food.
46001589|NCT04647669|Drug|Interferon beta-1a|Interferon ß-1a will be administered intravenously at the dose of 10 μg once daily for 6 days if oxygen dependent or subcutaneously at 44 ug Day 1, Day 3, and Day 6
46001590|NCT04647669|Other|Standard of Care|Treatment according to local hospital protocol
46001591|NCT00543686|Drug|Montelukast|Intake of Montelukast
46001592|NCT00543686|Drug|Fluticasone|Intake of Fluticasone
46001593|NCT04647864|Device|Transcatheter Aortic Valve Implantation|Replacement of the aortic valve of the heart through the blood vessels, delivered via one of several access methods.
46001594|NCT00543842|Drug|Bevacizumab|5 mg/kg By Vein Every 2 Weeks x 3 Doses (Weeks 1, 3, 5)
45676110|NCT04811092|Other|Placebo|Placebo
45676111|NCT04801368|Drug|Randomization of two local anesthetics.|Patients will be blinded and randomized to two different arms. One receiving ropivacaine, one receiving liposomal bupivacaine.
45676112|NCT04798989|Drug|CY6463|CY6463 Oral Tablet
45676113|NCT04798989|Drug|Placebo|Placebo Oral Tablet
46001595|NCT00543842|Drug|Capecitabine|Starting Dose 650 mg/m^2 By Mouth Twice Daily Monday-Friday x 6 Weeks
46001596|NCT00543842|Drug|Erlotinib|Starting Dose 50 mg By Mouth Daily Weeks 1-3
46001597|NCT00543842|Radiation|Radiation Therapy|30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments
46001598|NCT00543842|Procedure|Surgery|At least 8 weeks after radiation therapy, surgical removal of rectal tumor
46001599|NCT04638816|Device|Restylane Volyme|Hyaluronic Acid: Injectable gel for contouring effect (of cheek volumization).
46001600|NCT04638816|Device|Restylane Lyft Lidocaine|Hyaluronic Acid: Injectable gel for projection effect (of cheek augmentation).
46001601|NCT00543881|Device|Remote patient monitoring (Partnership for the Heart)|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits plus daily monitoring of ECG, weight, blood pressure, self-report of health status, weekly monitoring of physical fitness
46001602|NCT00543881|Device|Usual care group|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits
46001603|NCT04638855|Device|Medicurtain®|Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after hysteroscopy surgery)
46001604|NCT04638855|Device|Placebo|No device after hysteroscopy surgery
46001605|NCT00543920|Drug|MK0777|
46001606|NCT04638738|Device|SensiumVitals wearable patch sensor|Wearable sensor which measures heart rate, respiratory rate, and temperature continuously.
46001607|NCT00543959|Drug|MK0533|Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.
46001608|NCT00543959|Drug|Comparator: Placebo (unspecified)|MK0533 Placebo; MK0533 5mg; MK0533 15mg; MK0533 30mg. Study period is a total of 24 wks.
46001609|NCT00543959|Drug|Comparator: pioglitazone|pioglitazone 45mg. Study period is a total of 24 wks.
46001610|NCT04638972|Device|working length determination techniques|A total of 30 infected mandibular primary second molar teeth in twelve children aged between 5 and 8 years were included in this study. Working length determination was performed using tactile sense, radiographic method and two different varieties of electronic apex locators (ProPex Pixi® and Ipex®) separately.
46087884|NCT03718247|Other|Modified Atkins diet|High fat low carbohydrate diet.
45676114|NCT04798768|Device|mCRM Therapy System|Communication testing between S-ICD and LCP in 4 body postures as well as required electrical testing.
45676115|NCT04796337|Biological|Sotatercept|Sotatercept subcutaneous injection at a dose of 0.3 to 0.7 mg/kg.
45676116|NCT04783935|Drug|Mavenclad®|No intervention will be administered as a part of this study. Participants who had received Mavenclad® up to 2 years (Year 1 and 2) in the parent study MS700568_0022 (NCT03364036) will be enrolled into this extension study and will be assessed up to 2 years follow-up (Year 3 and 4).
46001611|NCT00543998|Device|Optical Measurement transillumination|Optical Measurement of sinus
46001612|NCT04638777|Device|rTMS with H-coil|Real repetitive transcranial magnetic stimulation with H-coil over M1 and PFC
46001613|NCT04638777|Device|rTMS with H-coil|Real repetitive transcranial magnetic stimulation with H-coil over M1 and sham repetitive transcranial magnetic stimulation with H-coil over PFC
46001614|NCT04638777|Device|rTMS with H-coil|Sham repetitive transcranial magnetic stimulation with H-coil over M1 and PFC
46001615|NCT00544037|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Standard Therapy for Multiple Sclerosis
46001616|NCT04638894|Procedure|Surgical treatment of patients with adult spinal deformity|Including all surgical interventions for patients with adult spinal deformity.
46001617|NCT04647357|Drug|SHR-1316|Anti-PD-L1 antibody，Maintenance therapy, The drug was administered every three weeks
46001618|NCT00544154|Drug|CDP870|
46001619|NCT04638582|Drug|Pembrolizumab|Neoadjuvant pembrolizumab 200 mg IV every 3 weeks, given on cycle day 1. Adjuvant pembrolizumab 400 mg IV every 6 weeks, given on cycle day 1.
46001620|NCT04638582|Drug|Carboplatin|Carboplatin AUC 6 IV (maximum dose: 900 mg) for squamous cell carcinoma, and AUC 5 IV (maximum dose: 750 mg) for non-squamous cell carcinoma, every 3 weeks, given on cycle day 1.
46001621|NCT04638582|Drug|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks, given on cycle day 1. Only given to participants with squamous cell carcinoma.
46001622|NCT04638582|Drug|Pemetrexed|Pemetrexed 500 mg/m2 every 3 weeks, given on cycle day 1. Only given to participants with non-squamous cell carcinoma.
46001623|NCT00544193|Drug|gemcitabine hydrochloride|
46001624|NCT00544193|Genetic|polymerase chain reaction|
46001625|NCT00544193|Other|immunohistochemistry staining method|
46001626|NCT00544193|Procedure|conventional surgery|
46001627|NCT00544193|Radiation|intraoperative radiation therapy|
46001628|NCT00544193|Radiation|radiation therapy|
46001629|NCT04647630|Diagnostic Test|urine test|test for pneumococcal antigen in urine
46087885|NCT03406949|Biological|obrindatamab|B7-H3 x CD3 DART protein
46087886|NCT03406949|Biological|retifanlimab|anti-PD-1 antibody
45676117|NCT04783246|Behavioral|Group Fitness|The group fitness intervention will involve streaming a group fitness class lead by a certified personal trainer. certified personal trainer and include variations of body-weight strength and aerobic exercise activities. Each work out session will be 30 minutes in duration and follow a structure of a warm-up period, alternating strength and aerobic exercises of varying intensity, and a cool-down period. The videos will be streamed to the group by a facilitator over Zoom video conferencing.
45676118|NCT04783246|Other|Nutrition education|The nutrition education intervention will involve 45-minute educational sessions involving didactic teaching, interactive goal setting, and a live cooking demonstration. Each session will be taught by a registered dietician who will also be responsible for designing the curriculum schedule.
46001630|NCT00544232|Drug|Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa|"Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel"
46001631|NCT00544232|Drug|Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa|"Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF"
46002605|NCT00545675|Drug|Depakote (divalproate)|Placebo and Depakote in 24-week treatment of mania in patients with bipolar disorder
46002606|NCT04646031|Drug|T89 capsule|T89 capsule, an medicinal product for oral use under active INDs in the US is a botanical drug containing 75mg active substance of the water extract of Danshen and Sanqi.
46002607|NCT00545831|Device|Taurolidine|2 mL of taurolidine instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
46002608|NCT00545831|Device|Physiologic Serum|2 mL of physiologic serum instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
46002609|NCT04637958|Device|THA|Total hip arthroplasty
46087887|NCT02701946|Procedure|Modified Robert Jones bandage|Modified Robert Jones bandage is defined as a three-layers of thick cotton wool and two-layers of elastic bandages. The wool layers are put on firmly and overlapped the previous one by half at each turn. The elastic layers were pulled snugly with more tension distally than proximally. Before wrapping in each turn, the elastic bandage was stretched approximately 2 and 1.5 inches at below and above tibial tuberosity level, respectively. The whole bandage attains a thickness of about two inches and extends above the ankle joint to six inches above the knee joint. Before applying this bandage, the sterile gauze pads were placed over the wound and followed by WebrilTM padding (Covidien, Mansfield, MA, US)
45676119|NCT04777266|Behavioral|Music therapy and treatment as usual|The session-based intervention programme was designed with an integrated and multimodal perspective of music therapy [37], which allows the combination of active and passive activities together with focuses and perspectives based on empirical evidence [38]. It was implemented using a process-based approach, adapting content to different phases in the process: initial contact, managing resistance, confidence building, relationships, awareness, and closure. The central focus is on the patient and to adapt and remain flexible in the sessions in accordance with the capabilities and needs of the group members. Different perspectives are integrated via nonverbal communication. The layout and any changes to the setting are made in a gradual way in keeping with the process to foster feelings of security and belonging. Sessions begin with a brief period of breathing which then moves into warming-up and free-expression using instruments, followed by the central activity and the closure.
45676120|NCT04776213|Drug|Mavenclad®|This low interventional extension study involves the follow up of participants in the parent study. The participants will be followed up for an additional 2 year period (until 4 years after initial administration of Mavenclad® tablets), during which the participants are not treated with Mavenclad®, as per European Medicines Agency (EMA) label of Mavenclad®.
45676121|NCT04769713|Procedure|Hepatic Hilar Nerve Block Needle placement|Placement of a needle within 2cm of the portal vein bifurcation along its anterior surface for injection of nerve block agent (for nerve block) or saline (placebo) under US or CT guidance.
45676122|NCT04769713|Drug|Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block|Injection of 15 ml 0.5% Ropivacaine at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.
45676123|NCT04769713|Drug|Injection of normal saline in the hepatic hilum for the sham procedure|15 ml sterile normal saline is injected at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.
45676124|NCT04756674|Other|No intervetion will be used|No intervention will be used
45676125|NCT04751370|Procedure|Computed Tomography|Undergo CT
45676126|NCT04751370|Biological|Ipilimumab|Given IV
46087888|NCT02701946|Procedure|Non compressive dressing|Non-compressive dressing is made by placing the sterile gauze pads over the wound and covering with the hypoallergenic self-adhesive, non-woven fabric tape.
45676127|NCT04751370|Procedure|Magnetic Resonance Imaging|Undergo MRI
45676128|NCT04751370|Biological|Nivolumab|Given IV
45676129|NCT04751370|Radiation|Radiation Therapy|Undergo short-course radiation therapy
45676130|NCT04751370|Procedure|Sigmoidoscopy|Undergo sigmoidoscopy
45676131|NCT04751370|Procedure|Total Mesorectal Excision|Undergo TME
45676132|NCT04750954|Procedure|Biospecimen Collection|Undergo collection of blood samples
45676133|NCT04750954|Procedure|Computed Tomography|Undergo CT
45676134|NCT04750954|Drug|Lutetium Lu 177 Dotatate|Given IV
45676135|NCT04750954|Procedure|Magnetic Resonance Imaging|Undergo MRI
45676136|NCT04750954|Drug|Peposertib|Given PO
46002610|NCT00545870|Drug|bevacizumab|intravitreal application
46002611|NCT00545870|Drug|Ranibizumab|intravitreal application
46002612|NCT04637451|Procedure|Root coverage treatment|Gingival unit graft Connective tissue graft
46002613|NCT00545909|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (+ feedback)
46002614|NCT00545909|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (- feedback)
46002615|NCT04637568|Diagnostic Test|Computerized tomography|Obtained CT scans involving the head region were analyzed retrospectively.
46001632|NCT04647318|Behavioral|Compassion focused imagery, relaxation imagery and control task|Participants will engage in three tasks (control task, relaxation imagery, and CFI) every three days on a total of 3-4 occasions. Audio-recordings of scripts will be used for both relaxation and compassion imagery. The 4-minute relaxation imagery will involve the following components (i) breathing deeply and bringing mindful awareness to the breath, (ii) relaxing the body, (iii) multisensory mental imagery of a beach or a forest, (iv) noticing feelings that arise. The 4-minute self-compassion imagery scripts will involve the following components: (i) informing participants that showing ourselves self-compassion is an effective emotional-regulation tool, (ii) breathing deeply and attending mindfully to the breath, (iii) imagining oneself embodying the four characteristics of compassion according to Gilbert5, (iv) imagine wishing oneself free of suffering using a warm voice tone and (v) noticing feelings that arise. The control task will involve reading a local city culture magazine.
46001633|NCT00544271|Biological|INFANRIX|
46087889|NCT02698748|Drug|Chloroquine|Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).
46087890|NCT02698748|Drug|Placebo|Placebo Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain
46087891|NCT04750343|Biological|GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.
46001634|NCT00544271|Biological|BOOSTRIX|
46087892|NCT04750343|Biological|GBP510 (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 (RBD 10μg/dose) on Days 0 and 28.
46001635|NCT00544271|Biological|HAVRIX|
46001636|NCT01191268|Drug|Insulin Glargine|
46087893|NCT04750343|Other|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
46087894|NCT04750343|Biological|GBP510 adjuvanted with AS03 (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.
46087895|NCT04750343|Biological|GBP510 (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.
46087896|NCT04750343|Other|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
46087897|NCT04750343|Biological|GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.
46087898|NCT04750343|Biological|GBP510 adjuvanted with AS03 (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.
46087899|NCT04750343|Biological|GBP510 (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.
46087900|NCT04750343|Other|Normal saline (0.9% sodium chloride solution)- Stage 2|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
46087901|NCT02706080|Other|emergency|
46087902|NCT04214990|Drug|Aspirin 100mg|Daily aspirin 100 mg for 5 years
46087903|NCT04214990|Drug|Placebo oral tablet|Daily placebo for 5 years
46001637|NCT01191268|Drug|LY2189265|
46001638|NCT01191268|Drug|Insulin Lispro|
46001639|NCT04647552|Drug|Drug Steroid|hydrocortisone injection
46001640|NCT04647279|Diagnostic Test|Dual-emission X-ray Absorptiometry|The recruiters were divided into osteoporosis, osteopenia and normal by dual emission X-ray absorptiometry.
46001641|NCT00544310|Biological|Anti adhesion agent|Adhesions prevention
46001642|NCT00544349|Biological|cetuximab|
46001643|NCT00544349|Drug|fluorouracil|
46001644|NCT00544349|Drug|leucovorin calcium|
46001645|NCT00544349|Drug|oxaliplatin|
46002616|NCT04637412|Other|Menu label|Participants will be shown a sample of items from a restaurant menu, displayed with labels
46087904|NCT00615212|Drug|GSK376501|GSK376501 oral tablet will be available with dosing strengths of 75 milligrams administered once daily. Biconvex, It will be a round, white film-coated tablets with both plain sides and no identifying markings.
46087905|NCT00615212|Drug|Midazolam|Midazolam oral syrup will be available with a dose of 5 milligrams administered once daily. It will be a clear, red to purplish-red, cherry-flavored syrup.
46087906|NCT00615212|Drug|Rosiglitazone|Rosiglitazone oral tablet will be available with dosing strengths of 4 milligrams administered once daily. It will be a orange colored tablet debossed with SB on one side and 4 on the other.
46087907|NCT00615212|Drug|Flurbiprofen|Rosiglitazone oral tablet will be available with dosing strengths of 50 milligrams administered once daily. It will be a blue, oval, film coated tablet.
46087908|NCT03670667|Other|Non-Interventional|Non-Interventional
46087909|NCT03670667|Other|Non-Interventional|Non-Interventional
46087910|NCT03670667|Other|Non-Interventional|Non-Interventional
46087911|NCT02706002|Device|fluoroscopy|in active group femural stem of hip prosthesis will implanted under fluoroscopy guidance during operation till maximum rasp size reached that fills the medullary canal. ordinary 3-5 sequences per operation
46001646|NCT01191190|Drug|Ofatumumab/HDMP|"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered based on specific schedule.~Each patient will receive a maximum of 3 cycles (one cycle is 28 days)"
46087912|NCT02706002|Procedure|hip prosthesis|all patients in the study will undergo hip prosthesis
46001647|NCT00544388|Drug|levocetirizine dihydrochloride|
46087913|NCT03356249|Diagnostic Test|Next-Generation Sequencing|In 500 patients with suspected or proven sepsis or septic shock (according to the Sepsis-3 definitions), patients´ characteristics and routine blood parameters will be determined at sepsis onset as well as 72 hours afterwards. At the same time points, 2 sets of blood cultures and one blood tube for Next-Generation Sequencing (NGS)-diagnostics will be collected. An evaluation of outcome will be performed at 28 days after sepsis onset.
46001648|NCT00559806|Other|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
46087914|NCT02701322|Behavioral|Medical clown|
46001649|NCT00559806|Other|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of unilateral whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
46001650|NCT00544505|Drug|Fluorouracil/Epirubicin/Cyclophosphamide|Phase III Comparison of Preoperative vs Postoperative FEC (Fluorouracil/Epirubicin/Cyclophosphamide) in Women with Operable Breast Cancer
46001651|NCT00544583|Procedure|Interrupted sutures|Interrupted sutures for abdominal fascia closure with Vicryl equivalent sutures (USP 2, 45 cm)
46001652|NCT00544583|Procedure|Continuous sutures|Continuous sutures for abdominal fascia closure with PDS II equivalent USP 1, 150 cm loops
46001653|NCT00544622|Procedure|structured therapeutic chain of stroke treatment|
46001654|NCT00544700|Biological|bevacizumab|7.5 mg/kg i.v. bevacizumab every 21 days until progression or unacceptable toxicity
46001655|NCT00544700|Other|no maintenance|No treatment until progression
46001656|NCT00559884|Drug|GSK189075 (Modified and immediate release formulations)|
45457932|NCT02304952|Procedure|Radiofrequency microtenotomy|For the minimally invasive surgery will Arthrocare Topaz MicroDebrider device be used. A small incision will be made and the tip of the device is placed on surface of the tendon to structure and activated for 0.5 second, at 5 mm distance intervals on the tendon creating a grid-like pattern.
45457933|NCT02304952|Other|Eccentric exercise|Eccentric exercise for 3 months. The exercise will be performed once a day with 3 set and 5 reps, women start with 0.5 and men 1.0 kilo with a 10 % increase every week.
45457934|NCT02304952|Device|Arthrocare Topaz MicroDebrider|
45457935|NCT03916471|Device|Solyx™ SIS System|Single-incision sling system
45457936|NCT03916471|Device|Obtryx™ II System (Halo)|Transobturator Mid-urethral Sling System
46001657|NCT05824676|Device|Variable Angle LCP Patella Plating System|FDA approved device, 510K number of, K210408. The Variable Angle LCP Patella Plating System is a device that can be formed to a patients specific need with various anchoring points to best fix what is needed for fixation.
46001658|NCT05824676|Device|Traditional Fixation|Traditional fixation methods for patellar fracture (screws, suture fixation, wire fixation, other plates).
46001659|NCT05824663|Drug|HBM1020|Intravenous (IV) Administrations on Days 1 of each 21-day treatment cycle.
46001660|NCT05824650|Other|Observational|Individuals will be evaluated observationally in a 45-minute period in one day.
46001661|NCT05824637|Device|Skin Prick Automated Test|skin prick test to detection sensitisation to aeroallergens
46001662|NCT05824637|Diagnostic Test|Skin Prick Manual Test|skin prick test to detection sensitisation to aeroallergens
46001663|NCT05824624|Other|ANIMAL-ASSISTED INTERVENTION|It will be ensured that the child is introduced to the goldfish when he is lying in the observation room, that the child will name the fish, and that he will communicate and feed the fish during his stay. Thus, it is aimed to turn the attention of the child to the goldfish while in the emergency room, to distract the child with the fish while all nursing interventions are presented, and to reduce the fear.
46001664|NCT05824624|Other|Routine Care|Routine nursing care will be provided.
46001665|NCT05824598|Behavioral|Multifunctional rehabilitation treatment|multidisciplinary approach with (OMT, psychological counseling, and therapists dedicated to swallowing disorders)
46087915|NCT02701478|Drug|N2O exposure|The aim of this study is to evaluate the nociceptive response to a standardized forearm electrical stimulus applied to patients under GA, during surgery, at different End-Tidal concentrations of N2O (ET-N2O: 0%-50%-25%-0%), and to see if ANI and NoL indices show less pain when inhaled N2O is higher.
46001666|NCT05824585|Drug|DZD8586|DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
46001667|NCT05824572|Other|Clinic visit audio recordings for self-management in older adults|The intervention is audio-recordings of primary care clinic visits that are shared with participating patients. All scheduled visits with study clinicians will be recorded and shared with patients randomized to the intervention group (AUDIO) for 12 months.
46001668|NCT05824572|Other|Usual Care|The Usual Care arm participants will receive After Visit Summaries (AVS) per the standard delivery at each institution
46001669|NCT05824533|Device|onlay patella button|Total knee arthroplasty (TKA) with a patella onlay button placed with a CORI Robotics System based on pre-operative 4DCT-imaging.
46001670|NCT05824533|Procedure|Conventional procedure; NO onlay patella button|Total knee arthroplasty (TKA) placed with a CORI Robotics System based on pre-operative 4DCT-imaging.
46001671|NCT05824520|Other|ITS plus OMT|Invasive treatment strategy plus optimal medical therapy
46001672|NCT05824520|Other|OMT|Optimal medical therapy alone
46001673|NCT05824507|Diagnostic Test|Endometrial aspiration biopsies for CE diagnosis|1 ml of aspirate will be taken from the uterine cavity for histopathological examination and immunohistochemistry for CE during general anesthesia for scheduled surgery
46001674|NCT05824481|Drug|Cadonilimab|Injectable solution
46001675|NCT05824481|Drug|Lenvatinib|Capsule
46001676|NCT05824468|Drug|Zimberelimab|Injectable solution
46001677|NCT05824468|Drug|Lenvatinib|Capsule
46087916|NCT02701244|Radiation|Permanent Breast Seed Implant (PBSI)|Patients are pre-planned using Computerized Tomography (CT) simulation. Implant is performed after surgery under light sedation and local freezing (alternatively general anesthesia). Stranded seeds are inserted using a brachytherapy template that is immobilized to the planned target volume using a 'localization' needle. Patients are released the same day and Quality Assurance involves post-implant Computerized Tomography (CT).
46001678|NCT05824455|Combination Product|JS109 combine with irinotecan|JS109 PO,QD, q3w combine with irinotecan(65mg/m2,IV,D1,8,Q3w)
46001679|NCT05824442|Biological|Blood sample for multiplex QPCR technique|Blood sampling specifically for qPCR Echino at inclusion and one year after
46001680|NCT05824429|Other|Urotherapy|Urotherapy is an umbrella term that includes components such as information about bladder function and problem, lifestyle changes including the regulation of voiding and fluid intake times, correct toilet positions, information about bladder irritants, and motivation. All participants included in our study will be given urotherapy training before starting PFM exercises and CTM with their families.
46001681|NCT05824429|Other|Diaphragmatic Breathing Exercises|In our research, diaphragm breathing exercises will be applied to both groups before starting PFM exercises in sessions for 8 weeks, 3 days a week.
46001682|NCT05824429|Other|PFM Exercises|PFM exercises will be started after children learn to contract and relax their PFM in isolation without the use of auxiliary muscles. In the exercises, fast and slow contractions targeting type 1 and type 2 muscle fibers will be taught to increase both strength and endurance of PFM.
46001683|NCT05824429|Other|Connective Tissue Manipulation|"CTM is a reflex treatment technique that is applied manually by physiotherapists to the skin area and acts on some cells and connective tissue by making short and long pulls (. In our study, CTM will be applied to our study group, where CTM and PFMR will be applied together, 3 days a week, for a total of 8 weeks.~The application will be made to the basic region (sacral), lower thoracic, abdominal and anterior pelvic region."
46001684|NCT05824416|Device|Experimental: ALBA|"Device: Improve Upper Limb Mobility~The patients will undergo treatment with the conventional therapy, consisting of four types of exercises, including supine and seated exercises, bimanual seated activity, and bipedal exercise. In addition to training with the ALBA® device, Shoulder flexion, abduction, and external rotation, elbow flexion and extension."
46087917|NCT03314363|Diagnostic Test|blood gas analysis under citrate predilution|blood gas analysis of blood on different sample points and dialysis fluid
46087918|NCT03314363|Device|filter replacement|Using local protocol: stop and disconnect CRRT, replace filter and reconnect and restart CRRT.
46087919|NCT03314363|Device|IC|monitor patients during the whole study period with indirect calorimetry
46087920|NCT03314363|Drug|NaCl predilution|Replace citrate predilution with NaCl
46087921|NCT03314363|Diagnostic Test|blood gas analysis under NaCl predilution|repeat blood gas analysis of blood on different sample points and dialysis fluid
46087922|NCT03314363|Drug|double ultrafiltration|double the ultrafiltration fluid by augmenting post dilution fluid and keeping ultrafiltration at the same rate.
46087923|NCT03314363|Diagnostic Test|blood gas analysis under citrate predilution and double ultrafiltration rate|repeat blood gas analysis of blood on different sample points and dialysis fluid
46087924|NCT03314363|Dietary Supplement|pause and restart nutritional therapy|pause parenteral and enteral nutrition before indirect calorimetry is performed. and restart after first blood analysis for vitamine status
46087925|NCT03314363|Diagnostic Test|evolution of vitamin and trace elements|blood analysis for vitamin and trace elements. Perform this blood analysis after restart of CRRT but before restart of nutritional therapy, 30 minutes after restart of nutritional therapy and 24h after restart of nutritional therapy.
46087926|NCT02700932|Device|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wave length of 785±20 nm that was added to the system
45676137|NCT04746235|Drug|Decitabine and Cedazuridine|Given PO
45676138|NCT04746235|Drug|Venetoclax|Given PO
45676139|NCT04738487|Biological|Pembrolizumab/Vibostolimab|Coformulation of pembrolizumab (MK-3475) 200mg and vibostolimab (MK-7684) 200mg. Participants receive the coformulation by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years).
45676140|NCT04738487|Biological|Pembrolizumab|Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years).
45676141|NCT04732117|Drug|Secukinumab|Secukinumab 150 mg s.c. at BSL, Weeks 1, 2, and 3, followed by administration every 4 weeks starting at Week 4.
45676142|NCT04732117|Drug|Placebo|Placebo 150 mg s.c.at BSL, Weeks 1, 2 and 3, followed by administration every 4 weeks starting at Week 4.
46001685|NCT05824416|Behavioral|Conventional Therapy|The conventionl therapy will receive conventional treatment, consisting of four types of exercises, including supine and seated exercises, bimanual seated activity, and bipedal exercise
46002617|NCT05050292|Other|Personalized cognitive stimulation|"Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser.~Performance feedback will be shown after each activity."
46002618|NCT05050292|Other|Sham cognitive stimulation|"Non-therapeutic online games based on artistic and creative tasks. Activities will match in duration to those of the experimental intervention.~Performance feedback will be shown after each game."
46087927|NCT00906347|Drug|Misoprostol|75 micrograms orally every 4 hours for up to 2 doses.
46087928|NCT00906347|Drug|Oxytocin|Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital
46087929|NCT02698592|Device|CelsiusTMDS® 8 mm catheter|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with CelsiusTMDS® 8 mm catheter, until complete isthmic block is achieved.
46087930|NCT02698592|Device|Thermocool® 3.5 mm catheter of irrigated tip|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® 3.5 mm catheter of irrigated tip, until complete isthmic block is achieved.
46087931|NCT02698592|Device|Thermocool® SF catheter|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® SF catheter, until complete isthmic block is achieved.
46087932|NCT02705768|Drug|Carbamazepine|Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
46087933|NCT02705768|Drug|Oxcarbazepine|Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.
46001686|NCT05824390|Drug|rituximab group|Rituximab is a human-mouse chimeric monoclonal antibody specifically targeting B cell surface antigen CD20. CD20 may act as a calcium channel to play a certain signal role and participate in the regulation of B cell maturation and differentiation. Once combined with CD20, RTX consumed CD20 + B fines through antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and direct induction of apoptosis. Recent studies have shown that B cell depletion therapy has a certain effect on many autoantibodies-mediated kidney diseases ( such as membranous nephropathy, lupus nephritis, etc. ). Therefore, rituximab combined with CD20 antigen on the surface of B cells can exhaust B cells that produce antibodies and play a therapeutic role by reducing antibody production, so this therapy also has potential therapeutic value for IgAN patients.
46087934|NCT02698670|Device|Rhythmia mapping system|A 3-D Cardiac Mapping system
46087935|NCT02698670|Device|IntellaMap Orion mapping catheter|A diagnostic basket mapping catheter
46087936|NCT05399849|Behavioral|Mindfulness Exercises and Meditations|Mindfulness exercises will be completed independently using the LoveYourBrain Foundation Meditation Library, a free, online resource containing traumatic brain injury-focused mindfulness-focused exercises and meditations. Mindfulness-based exercises and meditations to be completed will be chosen by study personnel based on tools utilized in mindfulness-based stress reduction programs that are provided on the LoveYourBrain Meditation Library. Specific mindfulness-based exercises and meditations will include body scan, acceptance, awareness, and breathing.
46087937|NCT05331677|Procedure|correction of deformities around the knee with external fixator|minimally invasive surgery
46087938|NCT00616070|Drug|Difluprednate|Difluprednate
46087939|NCT00616070|Other|Placebo|Vehicle
46087940|NCT03153527|Drug|Prednisone|The control intervention (standard treatment) consists of prednisone treatment in decreasing doses, starting with 7.5 mg q.d. and reducing the dose every 7 days, such that prednisone treatment is stopped after a total of 4 weeks.
46087941|NCT03153527|Other|Placebo Arm|The experimental intervention consists of stopping glucocorticoid treatment abruptly and administering matching placebo over 4 weeks.
46087942|NCT02705534|Drug|Sofosbuvir|400 mg, included in a combination pill with 90 mg ledipasvir
46087943|NCT02705534|Drug|Ledipasvir|90 mg, included in a combination pill with 400 mg sofosbuvir
46087944|NCT02705534|Drug|Ribavirin|1000 mg/day if <75 kg, 1200 mg/day for >75 kg. Divided into two daily doses
46087945|NCT02701166|Drug|Bezafibrate|bezafibrate 400mg per day
45676143|NCT04728581|Drug|Mirtazapine|Use of 3.75mg mirtazapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 7.5mg mirtazapine.
45676144|NCT04728581|Drug|Quetiapine|Use of 3.125mg quetiapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 6.25mg mirtazapine.
45676145|NCT04728581|Drug|Placebo|a gelatinous capsule without an active ingredient
46001687|NCT05824377|Other|Method of feeding|Continuous feeds will be delivered via an indwelling nasogastric/orogastric tube with a continuous infusion pump.
46087946|NCT02701166|Drug|Placebo|placebo 400mg per day
46087947|NCT03145415|Procedure|Caudal block|1 cc per kg of 0.2% ropivicaine in the caudal space given before the start of surgery.
46087948|NCT03145415|Procedure|Bilateral Pudendal block|0.5 cc per kg of 0.2% ropivicaine. Half of the volume given as a right pudendal block and the remaining volume given on the left pudendal nerve block given prior to the start of surgery
45676146|NCT04720703|Behavioral|Newsletters|Similar to prior empirical pediatric obesity interventions (Elder et al., 2009), the active attention waitlist control group will receive monthly newsletters that focus on physical activity, healthy eating, and screen time. These newsletters will be based on standard materials from the We Can program of the National Heart, Lung, and Blood Institute (NHLBI).
46001688|NCT05824377|Other|Method of feeding|Intermittent bolus feedings will be given by gravity every 3 hours over 15- 30 minutes.
46001689|NCT05824364|Other|telerehabilitation|Telerehabilitation activites will be tested with the aim to provide 1) continuation of rehabilitative care, focused on physical training and patients'monitoring , and 2) information in the mid-term about study goals.
45457937|NCT03506620|Drug|Ropivacaine injection|Naropin (Ropivacaine HCl) 0.25%; Dose: 20 cc
46087949|NCT02700854|Other|5% carbon-dioxide inhalation|5% CO2 (36 mmHg) and 95% air gas mixture inhalation, for a maximum of 12 hours or until metabolic acidosis recovery occurs as measured by BE > -5 mmol/L in arterial blood gas samples
46087950|NCT03141203|Drug|Romidepsin|10mg vial for Injection
45676147|NCT04720703|Behavioral|Family-based Telehealth Intervention|All communications related to the intervention will occur through weekly small group video conferencing calls via Zoom and emails or text messages. The intervention will include diverse topics proven effective in prior interventions (Davis et al., 2019; McLean et al., 2003), including reading food labels, eating out, eating at social gatherings, sticker charts, praising/rewarding healthy choices, healthy foods available at home, portion sizes, healthy/easy/low-cost cooking ideas, goal setting, monitoring screen time, exercise opportunities available in neighborhood, family exercise ideas, and healthy sleep. The research team will also send relevant video/audio clips, brochures, reminders (text messages and emails) every week.
45676148|NCT04717843|Other|4D Flow MRI|Acquisitions of MR imagining with special contrast phase CMR sequences. There is no need for agent contrast injection. The CMR is performed at the time of inclusion.
45676149|NCT04717843|Other|Medical consultation with 12 leads ECG|Collection of medical history, treatment, physical examination and realization of a 12 leads ECG.
45676150|NCT04717843|Other|Holter ECG|48 hours ECG recording
45676151|NCT04717843|Other|Trans thoracic echocardiography|Trans thoracic echocardiography with standard measures performes in the core lab.
46001690|NCT05824364|Other|rehabilomic|blood withdrawal (10 ml of blood, two tubes of 5 ml for serum isolation): at the hospital admission at the Cardiac Rehabilitation Unit of IRCCS Fondazione Don Gnocchi of Milan (T0) and after the rehabilitative treatment (T1)
46001691|NCT05824312|Drug|Tyrosine kinase inhibitor drugs.|TKI drugs were used at least 8 weeks. Imaging exam would be taken every four weeks.
46001692|NCT05824286|Other|HbA1c prediction|HbA1c prediction model was developed based on fasting capillary blood glucose and postprandial capillary blood glucose from self-monitoring blood glucose. Since HbA1c was measured once every 3 month, self-monitoring blood glucose records were transferred to predicted HbA1c by prediction model every month.
46001693|NCT05824247|Device|68Ga-FAPI-PET-CT|a new technology that using Fibroblast activation protein （FAP）inhibitor as the tracer of PET-CT
46001694|NCT05824234|Other|Implementation of a training centered around the notions of recovery with mental health services first year|Stepped wedge design so same procedure for both arms Stepped-wedge design with randomization stratified by cluster (training over the 1st or 2nd year) according to professional practice (intra-hospital, CMP / CATTP, day hospital, Psychosocial Rehabilitation Center, mobile team, medical sector) social) of the teams formed by the 18 centers participating in the study
46001695|NCT05824234|Other|Implementation of a training centered around the notions of recovery with mental health services second year|Stepped wedge design so same procedure for both arms Stepped-wedge design with randomization stratified by cluster (training over the 1st or 2nd year) according to professional practice (intra-hospital, CMP / CATTP, day hospital, Psychosocial Rehabilitation Center, mobile team, medical sector) social) of the teams formed by the 18 centers participating in the study
46001696|NCT05824221|Device|rTMS|Non invasive brain stimulation in Cocaine Use Disorder
46001697|NCT05824182|Device|FACE self-help App|The FACE self-help app was developed based on well-established non-invasive psychological principles that have been used in other web-based self-help interventions. The app consists of two component, emotion regulation and social information processing/social skills with four modules each. Each module includes readings describing scientific knowledge about ACEs and ACEs related topics, as well as exercises to encourage participants to actively reflect on what was learned in the readings and to apply their knowledge and practice skills. Each module is divided in several submodules that include readings and exercises.
46001698|NCT05824156|Biological|5 mg/kg CM-101|CM-101, Monoclonal Ab blocking CCL24
46001699|NCT05824156|Other|Placebo|Placebo
46087951|NCT03141203|Drug|Carfilzomib|60mg vial for injection
46087952|NCT02698202|Device|Digital Breast Tomosynthesis|twice screening examination: standard 2D mammography + Digital Breast Tomosynthesis
46087953|NCT05320991|Drug|Ketamine|Ketamine is applied with a Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA). Target plasma levels are 100 ng/ml with an initial bolus administered as a 2 mg/ml solution.
46087954|NCT05320991|Drug|Nacl 0.9%|Saline solution will also be applied with the Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA).
45676152|NCT04717843|Biological|Blood sample|Blood sample in a peripheral vein, send to medical laboratory to dosage of NT pro BNP and troponin serum level.
45676153|NCT04717843|Other|Standard MRI|Acquisitions of MR imagining
45676154|NCT04681144|Drug|Radium-223-dichloride (Xofigo, BAY88-8223)|Decision to initiate treatment with Radium-223 made as per investigator's routine treatment practice
45676155|NCT04677790|Behavioral|assigned period of specific dietary restrictions|Step by step gradual introduction of egg containing food products
45676156|NCT04677543|Drug|ALIS|Inhalation via nebulization over approximately 6 to 15 minutes.
45835458|NCT04271046|Behavioral|STAR-C-VTF|"One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study and to acquaint the caregiver with the STAR-VTF components of good dementia care; distribute printed educational material (and links to same material online);~Six 30-minute follow-up phone calls with the caregiver following each of the 6 learning modules to review STAR-VTF concepts, and further brainstorm strategies to modify identified activators and consequences with the objective of reducing behavioral symptoms;~secure message support, as needed, with the coach to help with personalizing the STAR-VTF curriculum for up to 6 months."
45835459|NCT04271046|Behavioral|Control|"One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study. Controls will receive usual care from their primary care provider and/or psychiatrist. We will give participants an information package from the Alzheimer's Association including a list of resources. To assist with retention, and to measure responses to secure messages, we will send a template secure message to control dyads once per month in which we remind participants to contact their primary care provider if they have any issues with behavioral and psychological symptoms of dementia. Dyads in the attention control may receive information and training from their primary care provider and the Alzheimer's Association. This attention control is proposed to assess the additional impact of STAR-VTF above treatment as usual. Investigators do not intend to track non-study training receipt in the control arm."
45835460|NCT04253652|Other|Fasted breath samples|Will be completed pre and post iron therapy
45835461|NCT04253652|Other|IBS-SSS|Will be completed pre and post iron therapy
45835462|NCT04253652|Other|Daily diary|Monitoring stool form, consistency and frequency on a daily basis for 4 weeks
46001700|NCT05824117|Other|Individual Placement and Support (IPS)|"IPS is an evidence-based practice for helping people with severe mental illness to gain and maintain competitive employment or/and mainstream education with nine well defined key principles that can be reliably assessed by the IPS Fidelity Scale for Young Adults.~Interventions range from engagement techniques (i.e. motivational interviewing) to individualized education/employment searches and from experience-based educational/employment assessment to benefits in counseling/work incentives planning."
45676157|NCT04677543|Drug|Azithromycin|Oral tablet
46001701|NCT05824091|Drug|MK-7762 (TBD09)|Cohort 1: 50 mg Cohort 2: 150 mg Cohort 3: 300 mg Cohort 4: 600 mg Cohort 5: TBD Cohort 6: TBD
46001702|NCT05824091|Other|Placebo|A subset of participants from each of the 6 dosing cohorts will receive placebo.
46001703|NCT05824065|Drug|OMA102|1 mg
45676158|NCT04677543|Drug|Ethambutol|Oral tablet
45835463|NCT04253652|Other|Exploratory research: stool samples|Completed pre and post iron therapy for a subset of patients enrolled in the study
45676159|NCT04677543|Drug|ELC|Inhalation via nebulization over approximately 6 to 15 minutes.
45835464|NCT02087748|Drug|1% diclofenac sodium gel|Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
45835465|NCT02087748|Drug|Placebo|Placebo gel 4gm applied topically Q6 hour for 48 hours
46001704|NCT05824065|Drug|OMA102|2 mg
46001705|NCT05824065|Drug|Placebo|OMA102 - Placebo
46001706|NCT05824013|Diagnostic Test|thromboelastography (TEG®6s)|blood samples for conventional coagulation test were obtained in vacutainer tubes from an arterial line. Two blood citrate samples (3 ml, sodium citrate solution, Vacuette® Blood Tubes) were also collected for the laboratory conventional coagulation tests (aPTT, INR, D-dimer levels, Antithrombin III) and TEG®6s assessment. The TEG parameters include reaction time (R), clot formation time (K), angle or α (K angle), maximum amplitude (MA), and amplitude at 30 minutes (LY30)
46001707|NCT05823935|Procedure|Bakay purse string|After developing the bladder flap, Vicryl polyglactin 910 sutures (Ethicon, Inc, Somerville, NJ) will be placed on the line between the cervicovaginal junction and the bladder starting at either 4 to 3 o'clock or 8 to 9 o'clock, as anchor sutures. Paying attention not to get closer than 1 cm to the bladder, the first suture will be passed from 4 o'clock to 3 o'clock and continued circumferentially in a full-thickness purse string fashion through 3, 1, 10, 8, 7, 5 o'clock completing a circle while including both uterosacral ligaments.
46001708|NCT05823935|Procedure|Cuff closure via vaginal route group|After the uterus will be removed via vaginal route, vaginal cuff ends will be grasped via vaginal approach and sutured continuous locked sutures using Vicryl polyglactin 910 sutures in one layer.
46001709|NCT05823909|Device|fabian Therapy evolution ventilators with PRICO (Predictive Intelligent Control of Oxygenation)|12 hours Automated PRICO FiO2 control
46001710|NCT05823909|Device|fabian Therapy evolution ventilators with manual FiO2 control|12 hours Manual PRICO FiO2 control
46087955|NCT02705456|Procedure|Tooth Brushing HA|"2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.~Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks)."
45835466|NCT04755738|Combination Product|Almonertinib plus microwave ablation|Patients were treated with almonertinib firstly.When almonertinib achieved the maximal response, microwave ablation was conducted on the primary lung tumors.
45676160|NCT04671511|Procedure|Targeted Axillary Dissection|Sentinel Node Biopsy (SNB; using Tc99 +/- Blue dye) + Radioactive Seed Localisation (RSL) of clipped node using I125 seed = Targeted Axillary Dissection (TAD)
45676161|NCT04671511|Diagnostic Test|Ultrasound of the axilla|Prospectively recorded preoperative ultrasound of the axilla. Number of suspicious nodes recorded. Biopsy and clipping of the positive node.
46087956|NCT02705456|Procedure|Tooth Brushing FL|"2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.~Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks)."
46087957|NCT04215614|Drug|Lidocaine and Bupivacaine solution|1:1 ratio 2% lidocaine, and 0.5% bupivacaine
46087958|NCT04215614|Device|Costoclavicular block|Ultrasound-guided costoclavicular brachial plexus block
46001711|NCT05823883|Drug|DW6014|"Drug: DW6014 Single oral administration of DW6014 in fed condition~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin in fed condition"
46087959|NCT04215614|Device|Lateral Sagittal block|Ultrasound-guided lateral sagittal brachial plexus block
46001712|NCT05823870|Drug|DW6014|"Drug: DW6014 Single oral administration of DW6014 after an overnight fast~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin after an overnight fast"
46001713|NCT05823818|Device|Catheter Ablation|Catheter Ablation of Atrial Fibrillation
46001714|NCT05823792|Diagnostic Test|Non-invasive diagnosis of ileocolic intussusception by ultrasound with indication for surgery|Non-invasive diagnosis of ileocolic intussusception by ultrasound with indication for surgery
46001715|NCT05823779|Other|Blood draw|We will be drawing blood for verify HIV status, HSV 1 or 2 antibodies, CD4 and HIV-PCR
46001716|NCT05823766|Behavioral|In-Person Outcome Assessment|Assessments will be administered to evaluate participant outcome status
46001717|NCT05823766|Procedure|3T Magnetic Resonance Imaging (MRI)|Participants will be asked to complete a 3T MRI
46001718|NCT05823766|Behavioral|Clinical Visit|Patients who screen positive for PTE will have an in-depth clinical visit
46001719|NCT05823766|Procedure|Blood Draw|Blood Draw for Plasma, DNA, Serum, RNA
46001720|NCT05823766|Procedure|EEG|An EEG will be performed on patients who screen positive for PTE at the clinical visit
46087960|NCT00906035|Drug|Dipyridamole 200mg and Aspirin 25mg bid:|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
46087961|NCT00906035|Drug|Dipyridamole 200 mg bid|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
46087962|NCT00906035|Drug|Aspirin 25 mg bid|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
46087963|NCT02698280|Drug|Bevacizumab|Bevacizumab is administered intravenously at 5mg/kg every 3 weeks.
46001721|NCT05823766|Behavioral|Telephone Outcome Assessment|Assessments will be administered over the telephone to evaluate participant outcome status and screen for PTE
46001722|NCT05823740|Other|Bioelectrical impedance Analysis (BIA)|Bioelectrical impedance analysis (BIA) is a method for estimating body composition, in particular, body fat and muscle mass, where a weak electric current flows through the body and the voltage is measured in order to calculate the impedance (resistance) of the body. BIA will be done at baseline, during the study related to routine medical imaging, and end of the study.
46001723|NCT05823740|Other|D3-Creatine Dilution (D3Cr)|The D3-Creatine dilution method is a safe and noninvasive measure of skeletal muscle mass that has previously been validated in adults, neonates, healthy children, and children. D3-Creatine Dilution will be done at baseline, during the study related to routine medical imaging, and end of the study.
46001724|NCT05823740|Other|6-Minute Walk Test (6MWT)|Cardiovascular fitness will be measured with the 6-minute walk test (6MWT). 6MWT will be done at baseline, during the study related to routine medical imaging, and end of the study.
45457938|NCT03506620|Drug|Saline Solution for Injection|20 cc of saline will be injected in the form of a QL block as a placebo.
46087964|NCT02698280|Drug|Nimustine|Nimustine is administered intravenously at 90mg/m^2 to 110mg/m^2 every 6 weeks.
46087965|NCT03087773|Drug|Empagliflozin 10 mg|The subject will receive Empagliflozin 10 mg orally once daily for 26 weeks.
46087966|NCT03087773|Drug|Placebo Oral Tablet|The subject will receive Placebo orally once daily for 26 weeks.
46087967|NCT02705612|Drug|Cisplatin|
46087968|NCT02705612|Radiation|External Beam Radiation Therapy|
46087969|NCT02705612|Radiation|Internal Radiation Therapy|
45676162|NCT04662840|Procedure|Geniculate artery embolization|Under fluoroscopic guidance and angiographic imaging, a microcatheter is used to select all the arteries feeding the affected knee and Embosphere (100-300um) particles are injected to obtaining pruning of the hypervascular tissues arteries.
45676163|NCT04662840|Procedure|Geniculate nerve ablation|Under fluoroscopic guidance, a Cool-tip RFA ablation needle is advanced such that it touches the femur at the condylar convexity on each side and the tibia at the tibial plateau convexity on the medial side. The ablation is performed to obtain an approximate zone of ablation of 2cm.
46001725|NCT05823740|Other|Timed Up and Go (TUG)|Balance and mobility will be assessed by the timed-up-and-go test (TUG). TUG will be done at baseline, during the study related to routine medical imaging, and end of the study.
46001726|NCT05823740|Other|30-second Sit-to-Stand (STS)|Strength and muscular function will be evaluated by modified 30-second sit-to-stand (STS). STS will be done at baseline, during the study related to routine medical imaging, and end of the study.
46001727|NCT05823740|Other|Hand Grip Strength (GS)|Strength and muscular function will be evaluated by grip strength (GS). GS will be done at baseline, during the study related to routine medical imaging, and end of the study.
46087970|NCT02705612|Drug|nimotuzumab|
46087971|NCT02700620|Behavioral|Internet-delivered CBT|Guided internet treatment
46087972|NCT05333159|Drug|SGLT2 inhibitor|dapagliflozin 10mg once daily dose canagliflozin100mg once daily dose empagliflozin 0mg once daily dose
46087973|NCT02700776|Other|Phlebotomy - Blood sampling for GP88 at MM|Women undergoing a screening mammogram will have a blood sample drawn to look for GP88.
46087974|NCT02700776|Procedure|SOC Tissue biopsy|standard of care tissue biopsy if clinically indicated.
46087975|NCT02698358|Device|Epic stent (Boston Scientific)|
46001728|NCT05823740|Other|PBTL p16 expression|Peripheral Blood biospecimen for PBTL p16 expression will be used for the assessment of biological aging. Blood biospecimens will be collected at baseline and end of the study for PBTL p16 analysis.
46087976|NCT02705690|Device|iOS Balance Application|"We have designed an iOS application and a belt. The application uses accelerometer data to calculate postural sway. Steps:~The phone is kept stable against the lower back of the participant using the belt.~The iOS application gives instructions to user to adopt the correct stance (eg: Standing Unsupported, legs side by side) Once the stance is adopted, the application turns on the accelerometer in the phone to sample acceleration along x (media lateral) and z (anterior posterior) axis.~These displacements from the mean are used to calculate the Root Mean Square of a person which acts a proxy score for Postural Sway. (Postural sway is defined as the phenomenon of constant displacement and correction of the position of the center of gravity within the base of support)"
46001729|NCT05823740|Other|CT, MR and PET Imaging|Participants will undergo routine imaging with either computed tomography (CT), Magnetic Resonance Imaging (MRI) of the chest or abdomen, or whole-body positron emission tomography (PET) scan. Skeletal muscle mass and fat mass will be calculated at several different vertebral levels from imaging studies.
46001730|NCT05823714|Drug|VEN+AZA+Modified BUCY|"Venetoclax: 200mg/day*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day*7days."
46001731|NCT05823701|Drug|Chidamide|20 mg (4 capsules), d1, d4, d8, d11 orally per cycle
46001732|NCT05823701|Drug|Azacitidine|100mg d1- d5 subcutaneous injection per cycle
46001733|NCT05823701|Biological|obinutuzumab|1000mg d4 intravenous infusion per cycle
46001734|NCT05823701|Drug|Liposomal mitoxantrone|20mg/m2 d5 intravenous infusion per cycle
46001735|NCT05823649|Dietary Supplement|Early feeding/intervention group|The patients will be given orally 5 to 10 ml of warm water as first feeding. If there will be no problem of swallowing and other clinical complication, they will be further provided 20 ml of water after 10 minutes. If further patients do not suffer from nausea, vomiting and other discomfort, 100 ml clear fluid or less than it will be provided as based on the protocol followed by the study. We will use oral rehydration solution (ORS) as clear fluid.
46001736|NCT05823623|Drug|Inetetamab|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
46001737|NCT05823623|Drug|Pyrotinib|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
46087977|NCT02698124|Drug|Decitabine|
46087978|NCT00905489|Drug|Nevirapine Immediate Release (IR)|200 mg Tablet or 50 mg / 5 ml oral suspension
46087979|NCT00905489|Drug|Nevirapine Extended Release (XR)|200 mg, 300 mg or 400 mg Tablet formulation
46087980|NCT04214912|Combination Product|Personalized Survivor Care Plan (PSCP)|Based the above literature review and our previous 10 years' efforts in OC patients' distress and care needs survey, we categorize OC patients' distress and needs into 6 major dimensions (1) symptoms management and dysfunction prevention (different kind of symptom, such as swallowing difficulty, eating difficulty, speaking difficulty, difficulty in opening mouth/trismus, shoulder dysfunction, mucositis, pain, fatigue, etc), (2) enhancing physical function (exercise skills, types for major parts of muscle training), (3) Confronting and dealing with psychological distress (fear, anxiety, depression, uncertainty), (4) nutrition assessment and counseling, (5) Social connection and RTW counseling (attitudes and skills for returning to work), and (6) overall needs assessment and supports.
46087981|NCT02705378|Drug|Polyethylene glycol|Intervention would be given by oro-gastric (OG) or naso-gastric (NG) tube
46087982|NCT02705378|Drug|naloxegol|Intervention would be given by OG or NG tube
46001738|NCT05823623|Drug|Oral Vinorelbine Tartrate|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
46001739|NCT05823610|Diagnostic Test|ultrasound|The ultrasound parameters to be collected included the angle of progression, head-perineum distance and head-symphysis distance at rest and while pushing during contraction and the data between measurements taken at rest and while pushing. Also anatomical scanning for the episiotomy, perineal tears and obstetric anal sphincter injuries (OASI), also trauma to the levator ani muscle. All demographic, clinical and ultrasound variables were compared between women who had a spontaneous vaginal delivery (SVD) and those who eventually had an operative delivery (OD), vacuum -assisted or cesarean section (CS).
46001740|NCT05823597|Behavioral|Sugar Intensive Treatment|see arm description
46001741|NCT05823597|Behavioral|General Health Control|see arm description
46001742|NCT05823558|Diagnostic Test|Lomber Muscle Thickness Measurement|Muscle thickness measurements will be made on the imaging of those who have lumbar MR imaging.
46001743|NCT05823519|Device|Endologix Ovation Alto Endograft|Implantation of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
46001744|NCT05823493|Behavioral|Schroth exercise therapy|The Schroth classification criteria includes four curve patterns that are determined with reference to the location of the curves, the importance of lumbar and thoracic prominences, and the effect of the scoliosis on the pelvis.
45676164|NCT04662840|Procedure|Skin infiltration of local anesthetic at groin and knee|Freezing of the skin will be performed at the groin (as prior to an arterial access for embolization procedure) and at three areas around the knee (as prior to insertion of the ablation needles for nerve ablation procedure).
45835467|NCT04755270|Device|VR Glasses|techniques of hypnofertility and VR glasses
45835468|NCT04755504|Diagnostic Test|EEG behind the ear|2 additional electrodes behind each ear will record EEG
45835469|NCT01490502|Drug|Vitamin D3|Patients will be assigned to low dose (600 IU/day) versus high-dose (5000 IU/day) of vitamin D3 as an add-on therapy to glatiramer acetate (Copaxone).
45835470|NCT02317692|Behavioral|Parent training|
45835471|NCT01435746|Behavioral|Red blood cell transfusion|The intervention of this trial is the regime of red blood cell transfusion. The control group will receive red blood cell transfusions according to a conservative regime, whereas the experimental group will receive red blood cell transfusion according to a liberal transfusion regime.
45835472|NCT01428024|Device|Restylane Lip Volume|Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
46087983|NCT03059147|Drug|SF1126|SF1126 is a dual PI3 kinase/BRD4 inhibitor small molecule. It will be administered IV twice weekly (900 mg/m2 starting dose with escalation to 1000 mg/m2 per dose and 1100 mg/m2 per dose) at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops.
46001745|NCT05823493|Device|laser therapy|Laser therapy was performed w ith a dual wavelength, high power IR laser (Multiwave Locked System (MLS®) laser, Mphi, ASA srl, Vicenza, Italy) and the laser acupuncture points include DU2, GB30, DU9, SP6, LR8, DU6, DU4, DU12. Laser puncture acupuncture points had been identified according to Traditional Chinese Medicine (TCM) and treated with handpiece optical group following the detailed treatment parameters: 900Hz, FPW mode, 60 s per point, 29.12J, spot size 3 cm2, energy density 27J/cm2. All treatments are performed five times in a week for 4 consecutive weeks.
46001746|NCT05823480|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo HCT per standard of care
46087984|NCT03059147|Drug|Nivolumab|Nivolumab is a humanized, IgG4 isotype monoclonal antibody that binds to PD-1 and blocks binding of PD-1 to its ligands PD-L1 and PD-L2. It will be administered at 240 mg IV every 2 weeks until progression or unacceptable toxicity develops.
46087985|NCT02698046|Dietary Supplement|Ferrous sulfate|200mg of ferrous sulfate three times a day for 4 months
46001747|NCT05823480|Drug|Azacitidine|Given IV
46001748|NCT05823480|Procedure|Biospecimen Collection|Undergo blood sample collection
46087986|NCT02698046|Dietary Supplement|Placebo starch|200mg of placebo starch three times a day for 4 months
46087987|NCT05333081|Other|Consumption of rice for evaluation of the glycemic index|The test of each food was carried out for a maximum time of 120 minutes, by carrying out repeated measurements of the glycaemia of all subjects at a distance of 0, 15, 30, 45, 60, 90 and 120 minutes from the administration of the sample in order to obtain a glycemic curve for each sample considered.
46087988|NCT03356834|Drug|Tenofovir alafenamide(TAF)|25 mg tablet administered orally once daily
46001749|NCT05823480|Procedure|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
46001750|NCT05823480|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
46001751|NCT05823480|Procedure|Echocardiography|Undergo ECHO
46001752|NCT05823480|Biological|Magrolimab|Given IV
45835473|NCT01428024|Device|Restylane Lip Refresh|Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
46001753|NCT05823480|Procedure|Multigated Acquisition Scan|Undergo MUGA
46001754|NCT05823480|Other|Questionnaire Administration|Ancillary studies
46087989|NCT03356834|Drug|Tenofovir disoproxil fumarate(TDF)|300 mg tablet administered orally once daily
46087990|NCT05341505|Behavioral|Emotion Regulation Intervention|We will administer a cognitive-behavioral treatment targeting emotion dysregulation, including mindfulness skills and other cognitive and behavioral emotion regulation skills.
46087991|NCT02705144|Other|analysis of the number of stem cell niches|to assess stem cell compartments in their niches and their proliferative and developmental properties in vitro
46087992|NCT02705066|Dietary Supplement|Citicoline supplement|
46087993|NCT02705066|Dietary Supplement|Placebo supplement|Cellulose
46087994|NCT02700464|Device|Bladder EpiCheck Urine Test|The Bladder EpiCheck test is an in vitro diagnostic device for the detection of DNA methylation patterns in urine that are associated with bladder cancer. It is intended for use as a noninvasive method for monitoring for tumor recurrence in conjunction with cystoscopy inpatients previously diagnosed with bladder cancer
46087995|NCT02700464|Procedure|Cystoscopy and pathology|Routine cystoscopy for bladder cancer recurrence and pathology confirmation for patients with positive cystoscopy
45835474|NCT05049174|Behavioral|Nuse-led interview and referral to municipal healthy life-centres|Usual care treatment and written information to patients and general practitionnaires about smoking cessation and the municipal healthy life-centres
45835475|NCT01419834|Biological|Humanized 3F8 Monoclonal Antibody (Hu3F8)|Hu3F8 is infused IV over ~30 minutes
45835476|NCT01895790|Device|Pancreatic Duct Stent Placement|
45835477|NCT01412970|Other|volume loading|volume loading according to functional parameters of cardiac preload, i.e. stroke volume variations measured by arterial pulse contour analysis
45835478|NCT01935414|Device|geko™ post-surgery for 48hrs then 4hrs/day until discharge.|
45835479|NCT01935414|Device|TEDS post-surgery for 48hrs then 4hrs/day until discharge.|
45835480|NCT01896414|Dietary Supplement|EPA (marine fatty acids)|Subjects will be randomized to receive either EPA or placebo, four 1 gram capsules daily.
45835481|NCT01896414|Dietary Supplement|Placebo|Subjects will be randomized to receive either EPA/ or placebo, four 1 gram capsules daily.
45835482|NCT01412190|Device|Restylane Vital Light|Treatment of up to 4 ml for one side of the face, one hand and one side of the décolletage dispensed by 10ul doses 0.5-1 cm apart. 3 treatment sessions 4 weeks apart.
45835483|NCT01412190|Other|No treatment|One side of face, one hand and one side of the décolletage is left untreated as a control.
46001755|NCT05823441|Drug|Oxytocin nasal spray|Volunteers inhale 24 units of oxytocin spray
46001756|NCT05823441|Drug|Placebo|Volunteers inhale 24 units of placebo spray
46001757|NCT05823441|Behavioral|Stranger|Volunteers watch a video of a pain test and attach a photo of a stranger
46001758|NCT05823441|Behavioral|Acquaintance|Volunteers watch a video of a pain test and attach a photo of an acquaintance
46087996|NCT02691884|Procedure|maternal abdominal pressure|The fetal cardiac response of either acceleration, deceleration or no change at all to the fetal heart- will be recorded and later on analyzed in reference to the amount of pressure applied from the 20th minute of CTG and for 5 minutes, using the FSR 400 sensor.
46001759|NCT05823428|Procedure|Augmentation with subacromial bursa + acromioplasty|Two intervention was planned. Rotator cuff debridement + acromioplasty group is mentioned as Group A (18 patients) and augmentation with subacromial bursa + acromioplasty is Group B
46001760|NCT05823428|Procedure|Rotator cuff debridement + acromioplasty|Two intervention was planned. Rotator cuff debridement + acromioplasty group is mentioned as Group A (18 patients) and augmentation with subacromial bursa + acromioplasty is Group B
46001761|NCT05823415|Procedure|Laterally Closed Tunnel with CTG|A novel minimally invasive surgical approach laterally closed tunnel technique (LCT) has been recently introduced for the management of isolated gingival recession. The laterally closed tunnel technique ensures predictability by tunneling and mobilization of flap for graft coverage.
46001762|NCT05823415|Procedure|CAF with CTG|Gold standard surgical technique
46087997|NCT02700542|Other|Integrated Pest Management|One-time, in-home, pest intervention for children with persistent asthma living in homes with parent-reported cockroach and/or mouse infestation.
46001763|NCT05823389|Procedure|Re-instrumentation with flapless Emdogain application|Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive flapless administration of EMD
46001764|NCT05823389|Procedure|Re-instrumentation with placebo application|Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive placebo application
46001765|NCT05823376|Drug|Avatrombopag|Indications for drug reduction and withdrawal: excluding blood transfusion factors, the reduction will be 20mg/d when PLT≥50×10^9/L; Drug administration will be stopped when PLT≥100×10^9/L.
46001766|NCT05823350|Other|Abdominal massage|Abdominal massage after colonoscopy
46001767|NCT05823324|Behavioral|Therapeutic play group|The dramatization method with teddy bear, one of the TP methods, was applied during the PIVC intervention
46001768|NCT05823285|Drug|QLS31903|0.01μg/kg-2.16 μg/kg QLS31903 for injection
46001769|NCT05823272|Other|ONS|oral nutritional supplement
46001770|NCT05823246|Drug|QLF31907|Intravenous infusion once every two weeks. The dose administered in part 2 will depend on the outcome of part 1.
46087998|NCT02701010|Behavioral|Structured training and leaflet|"The patients who were given both explanatory verbal instructions of the educational leaflet on the structured behavioural therapy for iOAB by continence nurse and the educational leaflet were included in this group."
46087999|NCT02701010|Behavioral|Structured training|"The patients who were given only explanatory verbal instructions of the educational leaflet on the structured behavioural therapy by continence nurse were included in this group."
46088000|NCT02701010|Behavioral|Leaflet|"The patients who were given only educational leaflet were included in this group."
46088001|NCT02701010|Behavioral|Control Group|Patients who were given unstructured explanations about continence care by a healthcare worker were included in control group.
45835484|NCT01895868|Other|Simulation-based ultrasound training|
45835485|NCT02318550|Other|MRI Scan|"The MRI will be performed with a 1.5 T scanner utilizing institutional protocols and the following settings:~Normal operating mode~SAR ≤ 2.0 W/kg per patient."
46001771|NCT05823220|Behavioral|Homeless diversion (HD)|Participants will receive services from specialty-trained community health workers and will be invited to complete monthly assessments via text and phone to assess their health and housing for 6 months and to share feedback on their experience with the intervention after completion by a text message to a link for the survey
46001772|NCT05823220|Behavioral|Treatment-as-usual (TAU)|Participants will receive a list of community resources they can contact to receive services and will be invited to complete monthly assessments via text and phone to assess their health and housing for 6 months and to share feedback on their experience with the intervention after completion by a text message to a link for the survey
46001773|NCT05823194|Procedure|Fertility sparing surgery|Sparing the uterus and/or ovaries of the patients suffering from gynecologic malignancies to keep the patients' fertility
46001774|NCT05823181|Device|laparoscopy|laparoscopic exploration of common bile duct
46001775|NCT05823168|Drug|Antiepileptic Drug|we osberve the efficacy of antiepileptic drungs on preventing seizures and their impact on rehabilitation outcome
46001776|NCT05823155|Procedure|Detailed penicillin allergy evaluation|The intervention group will undergo a detailed penicillin allergy evaluation performed by an Infectious Diseases specialist. Components of penicillin allergy evaluation include verification of allergy history (drug involved including dose and route of administration, exact manifestation of labelled allergy and timing of occurrence after use of alleged culprit, history of skin tests or in vitro testing for diagnosis of allergy, subsequent rechallenge of the same or similar antibiotics), followed by skin test (prick test and intradermal test) and oral provocation test as appropriate.
46001777|NCT05823103|Diagnostic Test|Shawki Septum Scoring System|Utilising the novel scoring system to facilitate feasibility and safety of hysteroscopic metroplasty for uterine septum
46001778|NCT05823103|Diagnostic Test|ESHRE ASRM Classification|Utilising the current classification before performing hysteroscopic metroplasty
46088002|NCT02697968|Device|Electroacupuncture|
46088003|NCT00615758|Drug|Erlotinib|Erlotinib at the dose of 150 mg orally once a day continually until progression
45835486|NCT02319174|Device|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
45835487|NCT01393314|Device|Honeywell HomMed Telemonitor|telemonitoring post hospitalization
45835488|NCT01341444|Device|Prevena Incision Management System|It is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy (NPWT).
45835489|NCT01341444|Other|Standard of Care for Surgical Incisions|Sterile 4X4 Non-Penetrable barrier
45835490|NCT01331148|Drug|Vitamin D|10,000 IU/caplet, patients receiving 240,000 IU to 600,000 IU cumulative Vitamin D dose based on weight.
46001779|NCT05823051|Other|VASIDS-TP and Counseling Practice|VASIDS-TP will be implemented online as an individual training to the intervention group through the Microsoft Teams program, to be completed in 5 days-5 sessions in the time frames determined by the participants. The consultancy practice will start with a pre-test and participants will be assured that they can call the researcher 24/7, and the consultancy practice will be continued by phone call or messaging.
46001780|NCT05822999|Device|WELT-IP|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
46001781|NCT05822999|Device|Sham|Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
45457939|NCT01232959|Device|Transvaginal Cholecystectomy|A small incision is made in the vagina. An endoscope (flexible lighted camera tube) is inserted into the abdomen. An endoscope is normally used to examine your stomach or colon. A very small camera is placed in your abdomen at the belly button (5 mm, ¼ inch). This helps the surgeons to remove your gallbladder through the vagina. The procedure to separate your gallbladder from your body will be assisted by instruments placed through your abdomen and instruments placed in your vagina. The surgeon will remove the gallbladder by passing it though your vagina.
45457940|NCT02305030|Drug|BIA 9-1067|
45457941|NCT02305030|Drug|Warfarin|
46001782|NCT05822973|Device|3.0 monocryl suture|incision will be closed with absorbable suture
46001783|NCT05822973|Device|3.0 nylon suture|incision will be closed with non-absorbable suture
46001784|NCT05822960|Device|far-infrared radiation|far-infrared radiation on foot acupoints (Yinlingquan and Sanyinjiao acupoints) during dialysis
45457942|NCT01134133|Other|Anti-gurgling intervention|1. head of bed 30 degrees or higher, 2. swallowing evaluation-based feeding, 3. sedatives titrated to minimal effective dose.
45457943|NCT03503422|Procedure|Real transcranial direct current stimulation + therapeutic exercises for back pain|"Real transcranial direct current stimulation associated with therapeutic exercises for back pain~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
45457944|NCT03503422|Procedure|Sham transcranial direct current stimulation + therapeutic exercises for back pain|"Sham transcranial direct current stimulation associated with therapeutic exercises for back pain.~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion). Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively"
45457945|NCT02305108|Other|fascial manipulation|"Recruited patients in study's group will be treated with the standard treatment and fascial manipulation.~Specific points of fascial tissue will be treated with a deep friction to improve elasticity.~The number of point treated will be refered to a specific evaluation for each patient.~Fascial manipulation provide 3 session treatment (one treatment for week)."
45457946|NCT02305108|Other|standard treatment|"Before surgery, standard physiotherapy treatment provides an education session about the rehabilitation program tha is going to be execute after surgery.~After surgery 2 daily physiotherapy treatment are implemented: bed exercise as active and passive flex-extension of lower limb, movements for postural change to reach sitting and standing position, walking training."
45457947|NCT01139437|Biological|Standard Dose HPIV2 Vaccine|10^6 tissue culture infectious dose 50% (TCID50) administered intranasally in a single dose
46001785|NCT05822947|Other|Active manual therapy|Soft tissue mobilization of the lumbar paraspinal musculature (3 to 4 minutes).
45457948|NCT01139437|Biological|Low dose HPIV2 vaccine|10^5 TCID50 administered in a single dose
45457949|NCT01139437|Other|Placebo|Matched placebo
46001786|NCT05822947|Other|Control manual therapy|Light touch and a breathing exercise (3 to 4 minutes).
46088004|NCT02700152|Device|UltraShape|Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
45457950|NCT01137253|Drug|Trimethaphan|Trimethaphan 4 mg/min IV, for the duration of the study (approximately 2 hours)
46088005|NCT02700074|Other|No Intervention|Intervention is not a part of this study.
46088006|NCT04215224|Diagnostic Test|Histopathology images based survival prediction for glioma patients|Histopathology images based survival prediction of glioma patients in the frame of molecular pathology by leveraging AI
46088007|NCT02699918|Procedure|nocturnal oximetry|nocturnal oximetry for screening of sleep apnea syndrome. Patients with abnormal nocturnal oximetry will be further explored by polysomnography.
46001787|NCT05822921|Behavioral|In-person Psychoeducation (IP)|Parents will attend two 60-minute (i.e. one day per week, for the next two weeks), in-person psychoeducation sessions on the MAC, in or near their hometown. During these sessions, a clinician will discuss a series of psychoeducation topics supplemented with PowerPoint slides. Across the two sessions, the following topics will be covered: (1) signs/symptoms and epidemiology of ASD, (2) risk factors associated with developing ASD (e.g., genetics, neurobiology, environment, social motivation), (3) navigating the IEP process, and (4) evidence-based best practices recommended for their child's profile of ASD symptoms and co-occurring conditions. This delivery method will allow parents to ask questions and receive immediate, live, and detailed answers from an expert clinician, to focus on specific examples relevant to their child, and to foster ASD knowledge and efficacy in helping their child.
46001788|NCT05822921|Behavioral|Telehealth Psychoeducation (TH)|Parents in this group will attend two 60-minute sessions, remotely via a live video chat platform, rather than in-person. Otherwise, it will follow the same format and PowerPoint materials as the IP Group. Sessions will still be facilitated by a clinician, thus maintaining the option to ask questions, discuss personalized examples, etc. For families without computer and internet access, the family will be assisted with to connecting to internet access at a private and convenient location (e.g., a church, library, or local community services agency). In the event that this is not possible, the family will be randomized to one of the other two groups.
46001789|NCT05822921|Behavioral|Psychoeducation as Usual (PAU)|Parents in this group will receive basic paper psychoeducation resources, distributed at their feedback session. It will be up to each parent how frequently and diligently these resources are reviewed. This should be akin to what a family might have access to at their pediatric or primary care office. To be consistent across study groups, the materials produced for these parents will be comprehensive and will include the same span of content as the PowerPoint slides used in the other two groups, but without structured sessions facilitated by a clinician. Upon distribution of materials, parents will be provided with our contact information and encouraged to reach out if any questions occur. Parents in the paper informational materials group will have the option to complete two in-person or video conference psychoeducation sessions after the end of the study, if preferred (i.e., 6 months later).
46001790|NCT05822908|Drug|VO659|VO659 is an antisense oligonucleotide targeting CAG repeats in mRNA transcripts
46001791|NCT05822882|Procedure|Epidural anesthesia|Postoperative pain management by epidural anesthesia via epidural catheter and pain pump
46001792|NCT05822856|Other|Blood sampling and others interventions|Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
46001793|NCT05822804|Device|Vascular Closure Device (Tonbridge)|Hemostasis treatment for femoral artery puncture with Vascular Closure Device (Tonbridge).
46001794|NCT05822804|Device|EXOSEAL Vascular Closure Device (Codis Corporation)|Hemostasis treatment for femoral artery puncture with EXOSEAL Vascular Closure Device (Codis Corporation).
46001795|NCT05822791|Diagnostic Test|Prolonged cardiac monitoring|Prolonged cardiac monitoring
46001796|NCT05822791|Diagnostic Test|ECG|Electrocardiogram
46001797|NCT05822778|Device|Formaderm Dermal Filler Injection|Dermal filler injection to facial areas
46001798|NCT05822778|Device|"Q-MED RESTYLANE"|Dermal filler injection to facial areas
46001799|NCT05822739|Drug|BBM-P002|Genetic: single- dose intracranial injection of BBM-P002 Neurosurgical delivery of BBM-P002 to the brain
46001800|NCT05822726|Diagnostic Test|Prostate biopsy|"Targeted guided puncture biopsy guided by B-ultrasound will be performed (in addition to 12-needle system biopsy, if PSMA-PET/MRI or mpMRI indicates a positive lesion, puncture biopsy should be added at the lesion displayed on image, the 12-needle system biopsy+X scheme)."
45457951|NCT01137253|Drug|Placebo|Response to intrabrachial vasodilators during IV saline infusion
46001801|NCT05822713|Drug|Amisulpride|5mg/2ml
46001802|NCT05822713|Drug|Amisulpride Placebo|2ml
46001803|NCT05822700|Procedure|Kirschner wire|Transfixing femoral head Kirschner wire
46001804|NCT05822687|Behavioral|Education|This is a constant component; all participants will get a psychoeducation digital module.
46001805|NCT05822687|Behavioral|Reappraisal Coping|This digital module will teach reappraisal coping skills.
45676165|NCT04658342|Diagnostic Test|Videofluoroscopic imaging (VFSS) with high-resolution manometry (HRM)|"The Videofluoroscopic Imaging (VFSS) is done by inserting a small catheter into the nose and down the throat. The catheter is approximately .4 millimeters in diameter. A trained speech-language pathologist will insert the catheter after applying numbing medicine, or topical anesthetic, inside the nose.~The high-resolution manometry (HRM) is a swallowing pressure test done at the same time as the VFSS. The HRM will measure how strong the throat muscle squeeze the liquids and foods that a person swallows.~The VFSS and HRM will occur about one month after surgery and three months after the completion of the radiation treatment."
45676166|NCT04646434|Procedure|Electroencephalography|Undergo EEG
46001806|NCT05822687|Behavioral|Distraction Coping|This digital module will teach distraction coping skills.
46001807|NCT05822687|Behavioral|Relaxation Coping|This digital module will teach relaxation coping skills.
46001808|NCT05822674|Drug|Sitagliptin/metformin ( 50/500mg) Oral Tablet|The drug was prescribed once daily per oral for 10 weeks
46001809|NCT05822674|Drug|Empagliflozin/metformin(10/500mg) Oral Tablet|The drug was prescribed once daily per oral for 10 weeks
45457952|NCT02312674|Dietary Supplement|Oral nutritional supplement|Beginning with the start of palliative therapy, depending on the nutritional status, one, two, or three cans per day are ingested during a period of three months.
46001810|NCT05822661|Dietary Supplement|Black Seed Oil|Dietary supplement
46001811|NCT05822661|Dietary Supplement|Placebo|placebo capsules same odor, color and size as the drug but without the active ingredient
46001812|NCT05822622|Other|echocardiography|to determine finding of heart failure with preserved ejection fraction and non alcoholic fatty liver disease
46001813|NCT05822609|Drug|Semaglutide|1.0 mg
46001814|NCT05822609|Other|Placebo|Placebo
45457953|NCT05493163|Drug|Thrombolytic|Local, catheter-directed thrombolysis with a total dose of 10mg per affected lung administered over 9 hours.
45457954|NCT05493163|Drug|Standard anticoagulation|Standard anticoagulation therapy of acute pulmonary embolism.
45676167|NCT04646434|Procedure|Electromyography|Undergo EMG
45676168|NCT04646434|Other|Questionnaire Administration|Complete questionnaire
45457955|NCT02312752|Device|Intra-epidermal stimulation electrode|"A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small sticker electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds."
45676169|NCT04633317|Device|A pneumatic nebulizer|Inhaled colistimethate sodium generated by a pneumatic nebulizer
45676170|NCT04633317|Device|A vibrating mesh nebulizer|Inhaled colistimethate sodium generated by a vibrating mesh nebulizer
45676171|NCT04630951|Other|Blood Flow Restriction Strength training with low load|Low Load (20-50% 1RM), 4 set of 30/15/15/15 repetitions, 30 seconds resting between sets.
45676172|NCT04630951|Other|High Load Strength Training|High Load (60-80% 1RM) 4 sets of 8 repetitions, 2 minutes resting between sets
45676173|NCT04614571|Dietary Supplement|Gluten Powder|Administered orally daily for 14 days
45835491|NCT01331148|Other|Placebo|placebo with daily calcium/Vitamin D soft chews
45835492|NCT01311492|Behavioral|Healthy Lifestyle Program|"The healthy lifestyle program includes upper body stretching and educational workshops. The purpose of this group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest. The rational for this placebo exercise activity is that it helps foster adherence to this arm of the study and increases the perceived benefit of the healthy lifestyle program to the participants without directly affecting the study outcomes."
46001815|NCT05820815|Device|in-bed self-exercises based on EMG-sensor feedback intervention|It presents the exercise method and amount of exercise for self-exercise and performs self-exercise while receiving feedback from muscle activity during self-exercise.
46001816|NCT05820451|Device|Impella CP, 2.5, 5.0 and 5.5 with Sodium Bicarbonate used as purge solution|US commercially approved Abiomed left sided hemodynamic support devices (Impella) will be included.
46088008|NCT02699762|Other|self rehabilitation of upper limb in experimental group|The patients in the self-rehabilitation group will be taught the self-rehabilitation program by a physiotherapist who is not involved in the patient follow-up. They will receive a log book which will be used to evaluate compliance and tolerance to the program. They will be instructed to carry out the exercises 7 days per week for the whole duration of the study and to record which exercises they carried out and for how long, after each exercise session.
46001817|NCT05820451|Device|Impella RP with Sodium Bicarbonate used as purge solution|US commercially approved Abiomed right sided hemodynamic support devices (Impella) will be included.
46088009|NCT02705222|Procedure|D&C|Cervical dilatation and fractional endometrial curettage will be done in operation theatre and the curetting will be sent for histopathological examination
46001818|NCT05820425|Other|LFP and EEG recording|STN LFP and EEG recording during the OFF and ON medication condition
46001819|NCT05820360|Behavioral|CoMBI-SMI|The first step is analysis of the behavioral problem because the core need is insufficiently compensated by the current environment or counteracted by the behavior of people within that environment. Step 2 is to choose the right core need based on this analysis. CoMBI-SMI describes the patient's self-image, the image of others, the triggering events and the problematic behavior of the patient based on personality disorders as classified by the Diagnostical and Statistical Manual of Mental Disorders. Step 3 is to choose the nursing intervention that is easily deployable so that Healthcare providers can identify the underlying core need and reduce the behavioral problems and burden on the healthcare providers. The fourth and final step is to draw up a CoMBI plan. The CoMBI-SMI is a cyclical process where it is important that the entire team is aligned with the patient's behavioral approach. Interventions are carried out by the entire team and evaluated after an agreed period of time.
46088010|NCT02705222|Procedure|Hysteroscopy|Hysteroscopy will be done in operation theatre and hysteroscopic-guided curettings will also be taken and sent for histopathological examination
46088011|NCT02704988|Procedure|Carnoy Solution|The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with Carnoy solution
46088012|NCT02704988|Procedure|GEWF Solution|The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with GEWF solution
46088013|NCT02704676|Other|marker(CA-125)|measuring CA-125 in pregnant women (normal,mild and sever pre-eclampsia)
46088014|NCT04215380|Dietary Supplement|Acacia Senegal extract|Oral Digestion of Gum Arabic dissolved in 200 ml of water to be consumed early morning in daily basis for 12 weeks
46088015|NCT04215380|Dietary Supplement|Pectin|Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks
46088016|NCT04215302|Device|laryngeal mask|the size of laryngeal mask given to the patient was based on patient's weight measurement
46088017|NCT02704754|Drug|suvorexant|First in class orexin antagonist recently approved by the FDA for the treatment of insomnia
46088018|NCT02704754|Other|placebo|Pill with inactive ingredients
46088019|NCT05192096|Behavioral|Train-the-trainer workshop|To deliver health-related information to trainees, which facilitate improving their knowledge, confidence, and ability to share and discuss health-related information with others, including service users, families and friends.
46088020|NCT05182658|Drug|Empagliflozin 10 MG|The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
46088021|NCT05182658|Drug|Placebo|The proposed intervention will be administration of placebo for a period of 12 months. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
46088022|NCT02697656|Behavioral|IPS|Individualized job support provided by an employment specialist
46088023|NCT02697656|Behavioral|Self-help|Self-help resources on obtaining employment and coping with chronic pain
46088024|NCT02697656|Behavioral|Treatment as usual|Transdisciplinary treatment at the pain clinic. This includes medical, psychological and physiotherapy treatment.
46088025|NCT04214054|Other|Moldable self-hardening biphasic calcium phosphate graft|Incision was performed in the canine area then a full thickness mucoperiosteal flap was elevated and exposure of the lateral aspect of the maxillary sinus. Osteotomy of the buccal window was performed using the piezosurgery device followed by meticulous dissection of the sinus membrane. Drilling the site were implants were to be placed, guided by the preformed surgical stent. Implants of appropriate size were torqued to engage the apical aspect of the implant recipient site. The sinus was augmented with moldable self-hardening biphasic calcium phosphate. Repositioning and suturing of the flap using 3-0 black silk suture material.
46088026|NCT04214054|Procedure|No graft material placed - Blood Clot only|A pyramidal full thickness mucoperiosteal flap was performed distal to the canine area with a crestal incision located palatally in the edentulous area and vertical extension of the incision to the buccal vestibule using Bard Parker blade number 15. The flap was reflected exposing the alveolar bone. Lateral window was performed and the sinus membrane was elevated using piezo surgery. Drilling at the sites where implants were to be placed was done using Neobiotech implant drilling Kit. Implants. Implants were placed in a self-tapping fashion using a torque wrench. Flaps were replaced back and sutured using 3-0 black silk suture material.
46088027|NCT02909036|Device|Melphalan|
46088028|NCT02909036|Drug|Pegfilgrastim|
46001820|NCT05819658|Drug|GV1001 Placebo|0.9% normal saline
45457956|NCT01134211|Device|nelfilcon A|Commercially marketed, single-vision, soft contact lens for daily disposable wear
46001821|NCT05819658|Drug|GV1001 0.56mg|Lyophilized peptide from hTERT
46088029|NCT02909036|Procedure|Autologous Hematopoietic Progenitor Cell Transplant|
46088030|NCT04213898|Drug|SHR-1210+Albumin-bound paclitaxel + epirubicin|Neoadjuvant therapy：SHR-1210, 200mg,iv, q3w, for 6 cycles; Albumin-bound paclitaxel: 125 mg/m2, iv, d1, d8, and d15, 21 days as a cycle, for 6 cycles; Epirubicin: 75mg / m2, iv, d1, 21 days as a cycle, for 6 cycles; The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
46088031|NCT04213976|Procedure|Ileostomy|Use of an ileostomy to decompress the proximal bowel, perfored either as a conventional loop ileostomy or as described by Santulli et al. or by Bishop and Koop.
46001822|NCT05819658|Drug|GV1001 1.12mg|Lyophilized peptide from hTERT
46001823|NCT05819294|Procedure|Agitated Pleural Fluid Thoracentesis|Using a 16-18 gauge cannula, a standard thoracentesis will be performed then a sample of pleural fluid will be aspirated and rapidly flushed into the pleural space and redrawn again for a few cycles before a sample is finally drawn into the collection syringe
46001824|NCT05819047|Device|Functional test with a haptic device|Volunteers will complete two tests based on the Nine Hole Peg Test with a haptic device.
46001825|NCT05819008|Diagnostic Test|Neuropsychological Assessment|"To validate Mindmore Distance (MD), the following standard neuropsychological tests will be used in a testing session with a psychologist:~Wordlist 1 and 2 from WMS-III (Wechsler, 1997). Equivalent to RAVLT in MD~Coding from WAIS-IV (Wechsler, 2008). Equivalent to SDPT in MD~Block Span from WMS-III (Wechsler, 1997). Equivalent to CBT in MD~Trail Making Test from D-KEFS (Delis et al., 2001). Equivalent to TMT-Click in MD~Color-Word Interference Test from D-KEFS. Equivalent to Stroop in MD~Verbal fluency from D-KEFS. Equivalent to FAS in MD~All participants will complete some questionnaires: Hospital Anxiety and Depression Scale (Zigmond & Snaith, 1983); Insomnia Severity Index (Bastien, Vallieres, & Morin, 2001); Cognitive Failure Questionnaire (Broadbent, Cooper, FitzGerald, & Parkes, 1982); Perceived Stress Scale (Levenstein et al., 1993); Multidimensional Fatigue Inventory (Smets, Garssen, Bonke, & De Haes, 1995)."
46001826|NCT05817474|Drug|lidocaine (2 %) 2 ml and tranexamic acid|lidocaine (2 %) 2 ml and tranexamic acid 2 ml in each tonsillar bed
46001827|NCT05812560|Other|postural changes|application of a protocol of postural changes every 30-60 min or at least two postural changes in one hour during labor.
46001828|NCT05812170|Behavioral|Educational online session about PF|The educational online session will last 90 minutes, as follows: 10 minutes of contextualization, 40 minutes of practical content about pelvic floor consciousness and 40 of theoretical content (anatomy and practices related to PFD).
46001829|NCT05824338|Drug|Spinal anesthesia for lumbar surgery: ropivacaine|The anesthesiologist will administer 4 mL of ropivacaine 0.5% plus fentanyl 15 mcg intrathecally
46001830|NCT05824338|Drug|Spinal anesthesia for lumbar surgery: bupivacaine|The anesthesiologist will administer 3 mL of bupivacaine 0.5% plus fentanyl 15 mcg intrathecally.
46001831|NCT05824338|Drug|General anesthesia for lumbar surgery|Patient will be intubated and ventilated under general anesthesia.
46001832|NCT05812157|Dietary Supplement|Daily dietary supplementation with Fibruline|Supplementation with 12 grams per day of Fibruline reconstituted with 60mL of water, once a day
46001833|NCT05812157|Drug|Anti-IL-17 therapy|Patients in both groups will be on anti-IL-17 therapy
46088032|NCT03170882|Drug|Ixazomib|Ixazomib capsules
46088033|NCT03170882|Drug|Pomalidomide|Pomalidomide capsules
46088034|NCT03170882|Drug|Dexamethasone|Dexamethasone tablets
46002450|NCT02852213|Drug|AAV2-hAADC|"Subjects will be enrolled sequentially into 2 dose groups, Group 1 followed by Group 2. Initially, up to 3 subjects initially will be enrolled in Group 1 and treated with a single dose of AAV2 hAADC (1.3x10 11 vg, delivered as an infusate volume of up to 160 μL of vector at concentration of 8.3x10 11 vg/mL) on Day 0. Enrollment in Group 2 may commence after the last subject in Group 1 is treated and followed through Month 3 post-surgery, with the approval of the data safety monitoring board (DSMB).~The final safety and clinical outcome assessments will be performed 1 year post-surgery. A follow-up analysis will be performed for 2 years post-surgery. Thereafter, subjects will be enrolled in a long-term follow-up study to assess safety and clinical status updates."
46088035|NCT05309408|Diagnostic Test|Venipuncture|Venipuncture
46088036|NCT05309408|Diagnostic Test|Lumbar Puncture|Lumbar Puncture
46088037|NCT02891564|Behavioral|Band Together|a mobile 3D video game that has been shown to reduce older adults' susceptibility to interference by augmenting sustained attention and working memory abilities (e.g. cognitive control) through targeted adaptive algorithms. This game is analogous to Project: EVO.
46088038|NCT02891564|Other|Control Mobile 3D video game|expectancy-matched control game
46002451|NCT02851771|Other|Nasopharyngeal Swab|
46088039|NCT00616850|Procedure|Continuous femoral catheter block|A constant infusion of ropivacaine 0.2% without epinephrine will be given to each subject via continuous femoral catheter in Group A.
46088040|NCT00616850|Drug|Lidocaine|Lidocaine 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
46001834|NCT05811013|Device|Transcranial static magnetic field stimulation (tSMS)|Patients will be randomly assigned to either real or sham tSMS. Real or sham tSMS will be performed daily without any interruption during each session of 60 min. Each patient will be instructed to self-administer tSMS, two sessions per day (AM and PM, 6-10 hours apart), sequentially for 60 minutes each, for 12 +12 months. Patients will choose whether to undergo stimulation at home or in the hospital on an outpatient setting. Real tSMS will be delivered with two cylindrical neodymium magnets (grade N45) of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), applied with south polarity, each pointing toward the motor cortex. To discharge the weight of the helmet from the head during the sessions, patients will be instructed to rest the back of head and helmet on an inclined surface in a comfortable position. They will be also instructed to rest, minimizing movement, and not to watch audiovisuals during the stimulation sessions.
46001835|NCT05811013|Device|Sham Transcranial static magnetic field stimulation (tSMS)|Real or sham tSMS will be performed daily without any interruption during each session of 60 min. Each patient will be instructed to self-administer tSMS, two sessions per day (AM and PM, 6-10 hours apart), sequentially for 60 minutes each, for 12 +12 months. Sham tSMS will be delivered with non-magnetic metal cylinders, with the same size, weight and appearance of the magnets (MAG45s; Neurek SL, Toledo, Spain).
46001836|NCT05808179|Device|Light|Broad-spectrum white light flashes are ~4000 lux, 2 msec long, occur every 20 s
46001837|NCT05808179|Behavioral|CBT|Cognitive behavioral therapy including psychoeducation, sleep hygiene, stimulus control, activity scheduling, motivational interviewing
46001838|NCT05808179|Device|Sham Light|Broad-spectrum white light flashes are ~4000 lux, 2 msec long, occur once
46001839|NCT05805618|Biological|Recombinant Norovirus Hexavalent Vaccine|To prevent acute gastroenteritis caused by norovirus of genotypes GI.1, GII.2, GII.3, GII.4, GII.6, and GII.17
46001840|NCT05805618|Other|Matching Placebo|matching placebo for Recombinant Norovirus Hexavalent Vaccine / KH002
46002452|NCT02846753|Procedure|trans catheter heart valve replacement|trans catheter heart valve replacement
46088041|NCT00616850|Other|Preservative free normal saline|Preservative free normal saline 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
46088042|NCT04214132|Other|Virtual Counselling Application using Artificial Intelligence|Intervention comprises of four Virtual Patients scenarios that aimed to improve nursing undergraduates communication skills in a clinical setting. These scenarios are based on authentic clinical cases (adapted from the real-life clinical case studies) focusing mainly on the communication aspects. Scenarios included 1) a middle-aged pregnant woman in her third trimester experiencing pain, 2) a middle-aged lorry driver who self-admitted to the hospital due to relapse of depressive symptoms, 3) changing a bloody dressing of a middle-aged male patient who had an operation 3 days ago, and 4) communicating with a fellow stressed student during their final preregistration clinical posting period.
46088043|NCT00618644|Drug|Ranibizumab|Ranibizumab 0.5 mg intravitreal injection
46088044|NCT02137070|Procedure|Bariatric Surgery Candidates|Participants who are intending to have bariatric surgery for weight loss
46088045|NCT02137070|Other|Non surgical/Community volunteers|Healthy adults with body mass index >35 who will not undergo bariatric surgery for weight loss
46088046|NCT02096432|Behavioral|Behavior Activation|Behavioral Activation includes the following components: empowering education, referral to treatment, care Management, and behavior activation
45457957|NCT01134211|Device|filcon II 3|Commercially marketed, single-vision, soft contact lens for daily disposable wear
45457958|NCT03506542|Device|Ologen|Ologen implant placed over scleral flap during the surgery to avoid usage of Mitomycin C
45457959|NCT03506542|Procedure|Phacotrabeculectomy|Trabeculectomy with cataract extraction
46002453|NCT02842333|Other|Additional biological samples|Blood samples
46088047|NCT02096432|Behavioral|Usual Community Care|Community standard care as usual
46088048|NCT04188470|Behavioral|person-centered care model|A multidisciplinary team (clinical pharmaceutical, expert physician on chronic management disease, and basic healthcare team) will review the frailty, complexity, the therapeutic goals of the patients to propose changes on the therapeutic plan to improve the appropriateness, these changes will we agreed with the patient or caregiver.
46088049|NCT05168696|Other|Virtual Reality Glasses|Virtual Reality Glasses
45457960|NCT03506542|Drug|Mitomycin C|Mitomycin C 0.3 mg/ml for 3 minutes during the surgery (standard procedure)
46002454|NCT02828085|Biological|Nasal swab|Nasal swab will be performed in addition to the routine diagnosis visit in order to determine the diagnosis of infective pericardite with a more specific technique: PCR
46002455|NCT02827175|Other|blood sample|
46002456|NCT02822807|Biological|Blood sampling|
46002457|NCT02820623|Behavioral|Self-report|
46088050|NCT05167838|Procedure|fresh embryo transfer|55 patients undergoing fresh embryo transfer after ovarian stimulation followed by luteal phase support
46088051|NCT05167838|Procedure|Frozen embryo transfer|55 patients undergoing frozen embryo transfer after ovarian stimulation followed by cryopreservation of all embryos and transfer in another cycle.
46088052|NCT02093312|Dietary Supplement|Home food-delivery service|A home food-delivery service is offered the intervention group of cancer patients
46088053|NCT05324774|Drug|9MW0813|"The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~9 doses(2mg) of the drug will be injected intravitreously."
46001841|NCT05805215|Combination Product|Non-invasive Temporal Interference stimulation and Face-name association training task targeting the hippocampus|"TIS relies on high frequencies which can penetrate with relatively low loss. High-frequency carriers (>1 kHz) emitted by two (or more) pairs of cutaneous electrodes can temporally interfere at deep peripheral nerve targets. The effective stimulation frequency is equal to the offset frequency between the carriers. By controlling field orientation and frequency offset, the hot spot of constructive interference can be precisely targeted. The key aspect of this method is the use of carrier waves at frequencies higher than 1 kHz. Frequencies above this range are regarded as non-stimulating and pass-through tissues with relatively low loss. While these higher frequencies do not stimulate neural tissue, the interference envelope of two phase-shifted frequencies can elicit action potentials because the offset (aka beat) frequency can be tuned accordingly to < 100 Hz."
46001842|NCT05805215|Combination Product|Non-invasive Temporal Interference stimulation and Face-name association training task targeting the Precuneus|"TIS relies on high frequencies which can penetrate with relatively low loss. High-frequency carriers (>1 kHz) emitted by two (or more) pairs of cutaneous electrodes can temporally interfere at deep peripheral nerve targets. The effective stimulation frequency is equal to the offset frequency between the carriers. By controlling field orientation and frequency offset, the hot spot of constructive interference can be precisely targeted. The key aspect of this method is the use of carrier waves at frequencies higher than 1 kHz. Frequencies above this range are regarded as non-stimulating and pass-through tissues with relatively low loss. While these higher frequencies do not stimulate neural tissue, the interference envelope of two phase-shifted frequencies can elicit action potentials because the offset (aka beat) frequency can be tuned accordingly to < 100 Hz."
45835493|NCT01311492|Behavioral|Physical Activity Intervention|The physical activity intervention consists of a general weekly physical activity goal of 150 minutes. This is consistent with the public health message from the Surgeon General's report that moderate physical activity should be performed for 30 minutes on most if not all days of the week (150-210 total minutes). This goal is approached in a progressive manner over the course of the trial.
46001843|NCT05805215|Combination Product|High-frequency stimulation (placebo) with Face-name association training task|High-frequency (>1 kHz) stimulation; Standardly used as a carrier frequency; Effects are expected to he high-pass filtered by neurons
46001844|NCT05805150|Device|Control Contact Lens (stenfilcon A)|One week wear
46001845|NCT05805150|Device|Test Contact Lens (senofilcon A)|One week wear
46001846|NCT05805137|Device|WoundWatch wound management system|eDressing will be applied along with the compression therapy and the standard absorbing dressings. The subjects will be monitored using the WoundWatch wound management system. The subjects will have two to three study visits per week until the venous ulcer has healed (surface area has decreased at least 90%) or up to two months.
46001847|NCT05805059|Device|Control Contact Lens (stenfilcon A)|one week wear
46001848|NCT05805059|Device|Test Contact Lens (senofilcon A)|one week of wear
46088054|NCT05324774|Drug|Aflibercept|"Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer. It is a fusion protein of human VEGFR1 and VEGFR2 extracellular domains and human immunoglobulin Fc segment genes.~9 doses(2mg) of the drug will be injected intravitreously."
46001849|NCT05799625|Behavioral|StepOne Smartphone Application|This smartphone application provides a 14-day program that delivers the core components of smoking cessation (i.e., counseling, education) and takes advantage of pandemic-accelerated acceptance of virtual care, videoconferencing, remote monitoring, and social networking. The program seeks to move participants from the pre-action stage (not interested in quitting) to the action stage (intention to quit) and incorporates daily reminders, gamification, and models of habit formation to engage users.
46001850|NCT05797480|Other|Real Dry needling|Real dry needling will be applied to the pelvic floor, hip and lower back muscles.
46001851|NCT05797480|Other|Non penetrating dry needling|Sham non penetrating dry needling (fixed needle in an introducer tube) will be applied to the pelvic floor, hip and lower back muscles.
46001852|NCT05794503|Drug|Neostigmine|Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, neostigmine.
46088055|NCT04213742|Other|Thanksgiving diary intervention|Record gratitude.
45457961|NCT02305186|Drug|Pembrolizumab|Pembrolizumab administered at a dose of 200 mg IV every 3 weeks on days 1, 22, and 43 during concurrent neoadjuvant chemoradiation treatment
45457962|NCT02305186|Radiation|Neoadjuvant Chemoradiation|Chemoradiation with capecitabine (825 mg/m2 orally twice daily, Monday through Friday, on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days)
45457963|NCT01137331|Drug|K301|Liquid- applied once daily prior to bed
45457964|NCT01137331|Drug|Placebo|Liquid- applied once daily prior to bed
45457965|NCT03506464|Procedure|Myofascial Release Technique|The same described in the arm description
46088056|NCT04213508|Drug|Isotonic Saline ( 0.9% Sodium Chloride Saline)|0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups. (first groups 2 times per day and second group 5 times per day ). Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
46088057|NCT04213508|Drug|Hypertonic Saline ( 3% Sodium Chloride Saline)|3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups. (first groups 2 times per day and second group 5 times per day ). Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time). So, in total 200 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
46001853|NCT05794503|Drug|Sugammadex|Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, sugammadex
46088058|NCT00616304|Drug|L-arginine hydrochloride|Patients will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo Block 1: Standard RSMM artesunate regimen for severe falciparum malaria plus 12g of L-arginine diluted to a 10% solution and given over 8 hours (n=12); Block 2: Standard RSMM artesunate regimen for severe falciparum malaria plus a 24g dose of L-arginine diluted to a 10% solution given over 8 hours (n=12) Phase 2b: To evaluate any additional benefits of a longer infusion, a further 24 patients will receive L-arginine infusion 1.5g/hour for 24 hours
46088059|NCT00616304|Other|Normal saline|Patients with severe malaria will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo. Blocks 1 and 2: Standard RSMM antimalarial artesunate regimen for severe falciparum malaria plus saline placebo, 240 ml given over 8 hours (n=12).
46001854|NCT05780567|Drug|TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen|"TQB3616 is a novel Cyclin-dependent kinase (CDK) 4/6 inhibitor and currently being used in the treatment of a variety of malignant solid tumors.~Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer."
46001855|NCT05780567|Drug|Placebo capsules, Letrozole, Anastrozole, Tamoxifen|Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer.
46001856|NCT05779397|Device|Masimo RAD-GT|Non-contact infrared thermometry device
46001857|NCT05756972|Drug|PM8002|IV infusion
46001858|NCT05756972|Drug|Placebo|IV infusion
46001859|NCT05756972|Drug|Carboplatin|IV infusion
46001860|NCT05756972|Drug|Pemetrexed|IV infusion
45457966|NCT01231711|Behavioral|Vets Prevail|"The intervention has two primary components that are both delivered over the Internet:~The first component is a structured series of brief peer-to-peer instant messaging Chats structured around ensuring effective motivation, engagement, and completion. This component was modeled after Motivational Interviewing (MI) techniques. The peer-to-peer contact was provided by a master's level social worker, as well as by trained and certified combat veterans who completed the Vet-to-Vet counseling certificate program offered by the Depression and Bipolar Support Alliance (DBSA).~The second component consists of six 30-minute e-Learning Lessons using standard Cognitive Behavioral Therapy (CBT) approaches to reducing depressive and anxiety symptoms and strengthening coping skills."
46001861|NCT05751759|Drug|Mitiperstat|Participants receive mitiperstat orally.
46001862|NCT05751629|Drug|Dostarlimab|Dostarlimab was administered.
46001863|NCT05751629|Drug|Bevacizumab|Bevacizumab was administered.
46001864|NCT05751629|Drug|Niraparib|Niraparib was administered.
46001865|NCT05746273|Drug|Transdermal Nicotine Patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
45457967|NCT02312908|Drug|Clonazepam|For experimental treatment of RBD
46001866|NCT05746273|Drug|Transdermal Placebo Patch|Participants will wear placebo transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Placebo patch dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
46001867|NCT05744271|Device|FES+VFBT|Standing balance training with the FES+VFBT system will occur 3x/week for six weeks (i.e. 18 sessions). Electrodes will be placed on the participants' plantarflexors and dorsiflexors bilaterally and FES will be administered using the device, MyndSearch, during the balance training exercises. Each session will last one hour, including 15 min to identify motor thresholds and maximum tolerable stimulation levels, 5 min to don/doff the safety harness, 5 min to calibrate the FES+VFBT exercises, 20 min to complete the FES+VFBT exercises, and 10-15 min to take rest breaks between exercises as needed.
46001868|NCT05738850|Drug|ABBV-932|Oral Capsule
46001869|NCT05738850|Drug|Placebo|Oral Capsule
46001870|NCT05736640|Drug|Denosumab|
46001871|NCT05736640|Drug|Placebo|
46001872|NCT05734014|Behavioral|Healthy Relationship|The feasibility study includes a one-group pre/post intervention that includes 10-hour long sessions with youth to promote healthy relationship knowledge, volition, and communication skills. Elders and near-peer (young adults) will assist during these sessions sharing advice and serving as role models for youth. In addition, to promote the connectedness between youth and their community, there are 3 monthly clan feeds.
46001873|NCT05732584|Other|Family voice stimulation|The structured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death. The content of the recording is developed according to the structured script.
46001874|NCT05732584|Other|Unfamiliar voice stimulation|The structured unfamiliar voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death. The content of the recording is developed according to the structured script
46001875|NCT05728294|Procedure|Femoral nerve block with ropivacaine 0.5%, 20 ml|Femoral nerve block under ultrasound guidance with ropivacaine 0.5%, 20 ml
45835494|NCT04969302|Diagnostic Test|Follow-up|"The primary outcome of this study was SSI within 30 days of surgery, as defined by the Centers for Disease Control and Prevention. Secondary outcomes were identification of the causative organism, and investigation of clinical factors such as body mass index (BMI), operation time, days of hospitalization, etc. that may be associated with SSI.~All patients were followed up for SSI until discharge from hospital and at the outpatient visits. SSI surveillance data forms were used for the collection of primary and secondary outcome data.~SSI rates and distribution of identified micro-organisms for each group will measured"
46001876|NCT05728294|Procedure|Sciatic nerve block with ropivacaine 0.5%, 20 ml|Sciatic nerve block under ultrasound guidance with ropivacaine 0.5%, 20 ml
46001877|NCT05726916|Drug|Soliris®|Eculizumab IV administration (900mg/w during 4w then 1200 mg at w5 and 1200mg/2w for 8w) + Blood pressure control with renin angiotensin system blockers
46001878|NCT05726916|Drug|Renin angiotensin system blockers|Blood pressure control with renin angiotensin system blockers
46088060|NCT04213586|Dietary Supplement|Whey protein supplementation|35 g of whey protein (7 d/wk) during a 10-wk resistance training program (3 d/wk; 3 sets of 8-12 repetitions with an interval of 1-2 minutes between sets and exercises) involving the leg press, leg extension, and arm flexion exercises. The load will be adjusted weekly.
45835495|NCT04912830|Procedure|Tension-free vaginal tape|female incontinence surgery with polypropylene tape applied
46088061|NCT04213586|Dietary Supplement|Collagen supplementation|35 g of collagen (7 d/wk) + 2 g of leucine during a 10-wk resistance training program (3 d/wk; 3 sets of 8-12 repetitions with an interval of 1-2 minutes between sets and exercises) involving the leg press, leg extension, and arm flexion exercises. The load will be adjusted weekly.
46001879|NCT05725577|Other|care via the telemedicine system|Care via the telemedicine system
46001880|NCT05725577|Other|Routine care|Routine care
46088062|NCT05324618|Drug|Tacrolimus|0.03% topical tacrolimus ointment applied on the affected areas twice daily for 4 months.
46088063|NCT05324618|Drug|Hydrocortisone|1% hydrocortisone cream applied on the affected areas twice daily for 4 months.
46088064|NCT04212338|Other|Before intravitreal injection music intervention|The patients in the Before-IVTI group listened to music for a period of 15 minutes 30 minutes before the injection.
46088065|NCT04212338|Other|during intravitreal injection music intervention|The patients in the During-IVTI group listened to music during the injection (approximately 5 minutes).
46088066|NCT00618800|Behavioral|Pharmaceutical Care|Participants receive written information about falls prevention and a personal consultation from a community pharmacist concerning their medication regimen. The pharmacist follows up, as required, with participants' physicians to coordinate any recommended medication changes.
46088067|NCT00618800|Other|Written Materials|Participants receive written information about falls prevention.
46088068|NCT03654989|Drug|Treprostinil iontophoresis|We will administer treprostinil at increasing doses by a iontophoresis.
46088069|NCT03654989|Device|Remodulin® placebo iontophoresis|"Placebo iontophoresis will be performed using Remodulin® placebo (United Therapeutics) delivered with Axion GmbH electrodes connected to a PeriIont generator (Perimed).~Part 1: 1 administration/day, on separate days, with 72h between two doses. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm².~Part 2: 1 administration/day for 10 days. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm²."
46088070|NCT04213664|Other|prognosis|cancer and overall survival cancer specific survival cancer and recurrence-free survival cancer and disease-free survival lymphocyte to monocyte ratio in non-metastatic renal cancer and progression-free survival
46088071|NCT02082782|Procedure|Irreversible electroporation (IRE)|Percutaneous (CT-guided) or open (US-guided) irreversible electroporation of central colorectal liver metastasis.
46088072|NCT00618878|Procedure|Electroacupuncture|twice a week for 26 treatments in total
46088073|NCT00618878|Procedure|Laser Therapy|twice a week for a total of 26 treatments
45835496|NCT01862718|Procedure|Thermal Ablation|On Thursday in the first week, subject will receive the radiofrequency ablation.
45835497|NCT01862718|Procedure|Standard External Beam Radiation Therapy|During those 2 weeks, subject will receive radiation on Monday, Wednesday and Friday.
46001881|NCT05712278|Drug|SAR445419|Cell suspension, by intraveneous (IV) injection
46001882|NCT05712278|Drug|fludarabine|Solution for injection , by IV injection
46088074|NCT02738216|Behavioral|Prenatal Yoga|As part of the yoga program, participants will be asked to go to one 75-minute prenatal yoga class each week for 9 weeks. The yoga classes will be designed to be safe for pregnant women. In addition to classes, the yoga teacher will ask them to practice yoga at home during the program. Each participant will be given a yoga mat and a prenatal yoga DVD to take home.
46088075|NCT02738216|Behavioral|Mother Baby Wellness|This workshop is aimed at promoting moms' and babies' good health and will involve attending one 75-minute class each week for 9 weeks. Classes will cover topics such as: child development in the first year, child eating and sleeping in the first year, maintaining good health as a mom of an infant, and recent advances in women's healthcare. In addition to classes, participants will be given materials to review/ read at home.
46088076|NCT02733068|Biological|HPV-16/18 vaccine|0.5ml of recombinant human papillomavirus virus-like particle vaccine (Type 16 and 18 L1 Proteins, Yeast) on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
46001883|NCT05712278|Drug|cytarabine|Solution for injection, by IV injection
46001884|NCT05704829|Drug|Trastuzumab deruxtecan|T-DXd i.v.
46001885|NCT05704829|Drug|Standard-of-Care|Chemotherapy+T+P
46001886|NCT05687682|Biological|AM-928|AM-928, which is a humanized anti-EpCAM monoclonal antibody developed by AcadeMab Biomedical Inc.
46088077|NCT02733068|Biological|HPV-16/18 placebo|0.5ml of placebo on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
46088078|NCT05324540|Other|Cool therapy|Application of cool therapy. A chilled (between 5C and 10C) instrument will be applied to the oblique sinus while the patient is in atrial fibrillation.
46001887|NCT05685004|Biological|TVI-Brain-1|Attenuated autologous cancer cells and activated autologous blood-derived t cells
46001888|NCT05685004|Procedure|Standard of Care|Surgery for tumor removal or debulking to minimize tumor burden
46002458|NCT02820623|Behavioral|Chart-Stimulated Recall|
46002459|NCT02820623|Behavioral|Behavioral Rehearsal|
46001889|NCT05685004|Radiation|Radiotherapy|Conformal radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks.
46088079|NCT05300594|Dietary Supplement|Plant extracts, vitamins and mineral|"Day tablet every day during 3 months : Magnesium (75 mg), Ginkgo Biloba extract (40 mg), hawthorn extract (37,5 mg), L-Theanin (50 mg) , Niacin (16mg), Quercetin (25mg), B12 Vitamin (2,5 µg), B6 Vitamin (1,4 mg), Thiamin (1,1 mg)~Night tablet every evening during 3 months : Magnesium (37,5 mg), Ginkgo Biloba extract (40 mg), Eschscholzia californica extract (40 mg), Zinc (10 mg), Melatonin (1mg), Lemon balm extract (80 mg), Tryptocetyn (65 mg)"
46001890|NCT05685004|Drug|Temozolomide|All Subjects receive 75 mg/m2 of temozolomide daily beginning on the first day of radiotherapy and continuing until the completion of radiotherapy. Standard of care Subjects will also receive adjuvant temozolomide .
46001891|NCT05681572|Drug|Midazolam|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Midazolam , by a blinded nurse.
46001892|NCT05681572|Drug|Dexmedetomidine|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Dexmedetomidine , by a blinded nurse.
46001893|NCT05681572|Drug|Placebo|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Grenadine Syrup, by a blinded nurse.
46088080|NCT05300594|Dietary Supplement|Placebo|Day tablet every morning during 3 months : Excipients; Night tablet every evening during 3 months : Excipients
46088081|NCT00907517|Drug|MK-8776|IV infusion
46001894|NCT05676840|Procedure|orthodontic treatment with fixed appliances|comprehensive orthodontic treatment with fixed orthodontic appliances for the correction of misaligned teeth.
46088082|NCT00907517|Drug|Cytarabine|IV infusion
46088083|NCT03043547|Drug|nal-IRI|nal-IRI [Irinotecan liposome] (80 mg/m2 as a 1.5 hour infusion)
46088084|NCT03043547|Drug|5-FU|5-FU [5-Fluorouracil] (2400 mg/m2 as 46 hour infusion)
46088085|NCT03043547|Drug|leucovorin|leucovorin (400 mg/m2 as 0.5 hour infusion)
46088086|NCT03632603|Radiation|No intervention|No intervention during study period.
46088087|NCT00905255|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
45835498|NCT01286922|Other|Behavioral: exercise|"Specific Aim: We will identify, recruit, assess, and randomly assign 42 sedentary, overweight-obese individuals who are at risk for pre-diabetes to an AER or INT training group in order to test the hypothesis:~• Individuals randomized to INT will have greater improvements in insulin sensitivity than individuals assigned to traditional AER.~Secondary Aim: We will measure maximal cardiorespiratory fitness (VO2max/peak) in order to test the hypothesis:~• Individuals randomized to the INT group will have a greater improvement in VO2max/peak than individuals in traditional AER group."
46088088|NCT00905255|Device|Pen auto-injector|
46088089|NCT00905021|Drug|Exemestane|Exemestane 25 mg by mouth every day.
46088090|NCT00905021|Drug|Sutent|Sunitinib 37.5 mg by mouth every day.
45457968|NCT02312908|Drug|Placebo|Placebo pill manufactured to mask clonazepam 0.5mg tablet
45457969|NCT05125003|Behavioral|FITBI|parents learn to identify high probability cues in the environment that can elicit RRBI symptoms and teach their child to inhibit repetitive behaviors and instead replace them with alternative and flexible play behaviors; and (b) teach parents how to embed this FITBI approach into their child's everyday routines
45835499|NCT01855464|Procedure|wedge resection|Complementary to parietal pleurectomy lung tissue is resected.
45835500|NCT01855464|Procedure|parietal pleurectomy|The parietal pleura is resected for treating primary pneumothorax.
45835501|NCT01266096|Drug|PET scan with 124I-cRGDY-PEG-dots|Five (5) patients with newly diagnosed or recurrent melanoma, and 18 malignant brain tumor patients (surgical (n=13) or non-surgical candidates (n=5)). Patients with either primary or metastatic brain tumors, will be i.v. injected with approximately 5 mCi (3.4-6.7 nanomoles) of 124I-cRGDY-PEG-dots (specific activity range 750.0 - 1450 mCi/mol) and undergo the microdosing study for purposes of collecting pharmacokinetic and dosimetry data. All studies will be performed using a dedicated scanner, which integrates a dedicated PET scanner and a spiral CT with proprietary fusion software.
46001895|NCT05671757|Biological|Daratumumab|Participants will receive 4 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
46088091|NCT03606083|Device|Endovascular repair|Endovascular repair of aorto-iliac or iliac aneurysms using an iliac branch device (IBD)
46088092|NCT05332847|Device|POC-US|Point Of Care Ultrasonography (POCUS) is a rapidly evolving bedside modality in which ultrasonography is utilized as a part of the bedside physical examination and the patients' clinical assessment
46088093|NCT02965313|Procedure|SSLS Procedure|Synthetic suture repair
46088094|NCT02965313|Procedure|BSSVF-M Procedure|Bilateral sacrospinous vaginal vault fixation with synthetic mesh arms
46088095|NCT02944877|Behavioral|social media intervention|social media intervention
46088096|NCT05239247|Other|Mckenzie extension exercise|"Hot pack applied on lumbar region for (ten minute). Mckenzie extension exercise performed 02 sets of 05 repetitions with 45 second hold and 15 sec rest between each set once a day.~TENS is applied on lumbar region for (ten minutes)."
46088097|NCT05239247|Other|Eldoa stretch technique|"Hot pack applied on lumbar region for (ten minute). Eldoa stretch performed 02 sets of 05 repetitions with 45 second hold and 15 second rest between each set once a day.~TENS is applied on lumbar region for (ten minutes)."
46088098|NCT05332535|Behavioral|serious game based web application education|serious game based web application education for nursing students
46088099|NCT03537131|Drug|Dapagliflozin 10 MG Oral Tablet|taken once a day
45835502|NCT00273624|Drug|Olanzapine|10 mg Olanzapin concurrent to antidepressive medication
45835503|NCT00273624|Drug|Placebo|placebo
46001896|NCT05671757|Biological|Daratumumab|Participants will receive 4-8 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
46001897|NCT05671757|Biological|Daratumumab|Participants will receive 4-16 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
45676174|NCT04592627|Other|Simulated home environment visit|During the simulated home environment visit participants will 1) participate in a simulated University of Texas (UT) Physicians Stroke Outpatient Clinic telemedicine visit using an iPAD during which participants will be audio- and visually-recorded in order for the research team to collect raw facial expression data; 2) be instructed to complete a series of activities of daily living (e.g., sitting down and brushing hair) during which participants will be audio- and visually-recorded in order for the research team to collect raw body motion tracking data; and 3) complete a participant satisfaction survey via a REDCap link and participate in an audio-recorded, semi-structured interview (e.g., asking the participants thoughts on privacy considerations related to future use of the facial expression and body motion technology in a home environment) with members of the research team.
45676175|NCT04586244|Drug|retifanlimab|retifanlimab will be administered via IV over 30 minutes (+ 15 min) on Day 1 of each 28-day cycle, up to 3 cycles,
45835504|NCT00262470|Drug|Acetazolamide|250 mg PO x 1
45835505|NCT00262470|Drug|Atomoxetine|10-40 mg PO x 1 dose
46002460|NCT02819232|Other|Blood sampling|Detection of bacteria will be performed on a blood sample
46002461|NCT02819206|Other|Blood sampling|Detection of bacteria will be performed on a blood sample
46002462|NCT02819128|Other|Swabs skin, pharyngeal, and blood sample|Collection of one blood sample with a volume of 10 mL (2 tubes of blood 5 mL ) and 2 swabs ( throat and skin ).
45835506|NCT00262470|Other|NO Drug|No intervention - just monitoring
45835507|NCT00262470|Drug|Clonidine|Clonidine 0.05-0.3 mg PO x 1 dose
45835508|NCT00262470|Drug|Entacapone|Entacapone 200-400 mg PO x 1 dose
45835509|NCT00262470|Drug|Entacapone & Propranolol|Entacapone 200-400 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
45835510|NCT00262470|Drug|Atomoxetine & Propranolol|Atomoxetine 10-40 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
45835511|NCT00262470|Drug|Indomethacin|Indomethacin 25-50 mg PO x 1 dose
45835512|NCT00262470|Drug|Mecamylamine|mecamylamine 1.25-5 mg PO x 1 dose
45835513|NCT00262470|Drug|Isosorbide Dinitrate|Isosorbide dinitrate 5-20 mg PO x 1 dose
45835514|NCT00262470|Dietary Supplement|Melatonin|melatonin 3 mg PO x 1 dose
45835515|NCT00262470|Drug|Midodrine|midodrine 2.5-10 mg PO x 1 dose
45835516|NCT00262470|Drug|Modafinil|modafinil 100-200 mg PO x 1 dose
45835517|NCT00262470|Drug|Octreotide|octreotide 12.5-50 mcg Subcutaneous x 1 dose
45835518|NCT00262470|Radiation|Placebo|lactose tablet x 1 pill
45835519|NCT00262470|Drug|Propranolol|Propranolol 10-80 mg PO x 1-2 dose
45835520|NCT00262470|Drug|Modafinil & Propranolol|Modafinil 100-200 mg PO x 1 dose AND Propranolol 20 mg PO x 1 dose
45835521|NCT00262470|Drug|Sertraline|sertraline 25-50 mg PO x 1 dose
45835522|NCT00262470|Procedure|IV Saline|1 liter IV over 2 hours
45835523|NCT00262470|Other|Drinking Water|16 fluid ounces
46001898|NCT05662371|Device|Nociception Level monitor (NOL)|NOL technology uses a multiparameter-based sensor platform, and advanced algorithm, to continuously monitor Autonomic Nervous System (ANS) functions. NOL reflects a patient's nociceptive state and analgesic effect, helping to optimize the administration of systemic and/or regional analgesics, and avoiding overdose or underuse of these drugs. The nociception level is a multiparameter monitor that combines information from the finger photoplethysmogram amplitude, skin conductance, skin conductance fluctuation, heart rate, heart rate variability, and their time derivatives into one index ranging from 0 (absence of noxious stimulation) to 100 (severe noxious stimulation).
46001899|NCT05662371|Device|Standard care|Hemodynamic changes outside of the normal range i.e., hypertension (systolic blood pressure greater than 140 mm Hg), tachycardia (heart rate greater than 90 min-1) and hypotension (mean arterial pressure less than 60 mm Hg) will be first assessed using the guidance of Bispectral index and Train of four monitors. Sufentanil in doses of 2.5 to 5 mcg (maximum of 0.6-1.2 mic/kg for the entire surgery) is administered if the Bispectral index and Train of four monitor values are within normal range and if required vasopressor infusion is used. Vasoconstrictors may be given as a continuous infusion of norepinephrine, or bolus doses of ephedrine or phenylephrine. Only when blood pressure remains, low additional crystalloids will be given. Finally, in case of bradycardia (heart rate less than 30 min-1), atropine may be given
46088100|NCT04224623|Behavioral|Raising Well at Home|The Raising Well at Home intervention was delivered via 3 core home visits designed to be delivered every 4-6 weeks, with additional support via text or phone over 6 months. The home visits were designed to engage the whole family, build skills, and promote changes in the home environment to support lifestyle behavior change. These essential behaviors focused on reducing sugary beverage intake, promoting appropriate portion sizes, improving fruit and vegetable intake, increasing walking and reducing screen time/sedentary activity.
46001900|NCT05657366|Procedure|Peritoneal lavage|Continuous abdominal flushing with normal saline
46001901|NCT05645328|Other|Iowa Cancer Affiliate Network (ICAN)|Each hospital in the intervention has undergone interviews in which the investigators elicited program goals, challenges, and readiness for change. Prior to the intervention, the cancer centers will be provided a document specifying current status for meeting Commission on Cancer (CoC) accreditation standards, gaps identified, suggestions and resources for the next steps to meet goals, and progress toward fulfilling CoC accreditation standards. The hospitals will be offered support, expertise, and resources to facilitate them in achieving the CoC standards. Support will be offered in the form of education/training regarding the standards and provision of cancer services, regular in-person/zoom check-ins with hospital stakeholders to evaluate progress, and provision of documentation/educational resources regarding standard requirements. The intervention actions will be tailored to the needs of each hospital based on standards they currently do not meet and choose to work toward.
46001902|NCT05638347|Drug|HRS-7085 tablets|Single oral administration
46001903|NCT05638347|Drug|Placebo tablet|Single oral administration
46001904|NCT05636748|Diagnostic Test|18F-GP1 PET/CT|Patient will receive 1 18F-GP1 PET/CT
46001905|NCT05636748|Diagnostic Test|Agitated Contrast Echocardiogram|Agitated saline and ultrasound contrast will be performed to assess for intracardiac shunts and left ventricular thrombus.
46088101|NCT05222321|Other|Sensory-Play Based (SenPlay) Intervention|SenPlay is a sensory-play based intervention that includes deep tactile pressure, vestibular and proprioceptive input as a therapeutic medium to facilitate optimal arousal through sensory-play based activities such as pushing, pulling, climbing, jumping, crashing, and swinging. These activities are designed to facilitate changes in the child's arousal through providing sensory input to ensure the child is reaching a threshold of moderate to vigorous physical activity. Completed at three time points, once weekly for three weeks.
46088102|NCT05222321|Other|Spontaneous, Free Play|Participant engages in spontaneous, free play with the investigator supervising only for safety within the sensorimotor gym for 15 minutes. Completed at three time points, once weekly for three weeks.
45457970|NCT05125003|Behavioral|Parental Education|Sessions will cover relevant information on young children with ASD, including understanding the ASD diagnosis, developmental changes in ASD, educational planning, advocacy, and treatment options.
45457971|NCT02305420|Device|EmbryoGen/ BlastGen media|Embryos will be cultured in media containing Gm-CSF (EmbryoGen/ BlastGen media)
45457972|NCT02305420|Device|Standard Cook sequential media|Standard Cook IVF media will be used in the control arm
45457973|NCT02308930|Dietary Supplement|Vitamins + DHA supplement (Vitamins A,D, E and algal oil)|
45457974|NCT02308930|Dietary Supplement|Vitamins supplement (Vitamins A,D, E and corn oil)|
45457975|NCT02305498|Other|Vigorous yoga practice|
45457976|NCT02305498|Other|Restorative (gentle) yoga practice|
45457977|NCT01233973|Other|video decision aid|video
45457978|NCT02309008|Drug|PAC-14028|Participants will receive PAC-14028 cream applied topically once a day for 9 days
45457979|NCT02309008|Other|Vehicle|Participants will receive vehicle cream applied topically once a day for 9 days
46001906|NCT05636748|Diagnostic Test|MRI Head|Where necessary, if the CT head is normal or the clinical diagnosis of a stroke is not definite, a research MRI head will be undertaken if this has not already been performed as part of standard care.
46088103|NCT00906971|Other|diaphragmatic breathing, isometric training of the abdominal muscles and abdominal massage|Exercises will be conducted by one physiotherapist. A one-minute rest period will be observed between each series. Isometric training of the abdominal muscles: This will consist of a contraction of the upper abdomen muscle and diaphragm and the simultaneous relaxation of the lower abdomen. Training will be carried out in two manners: with the patient lying in a left lateral decubitus position with the hip and knee flexed at 90º and sitting. Breathing exercises: With the patient in a seated position, with one hand placed on the abdomen and the other on the thorax, and will be instructed to breath in slowly,. Two series will be completed, with ten repetitions. Abdominal massage: The physiotherapist will perform slow circular clockwise movements, along the line of the colon, with a regular tennis ball, remaining on each point for one minute, beginning with the ascending colon moving in the direction of the sigmoid colon.
46001907|NCT05636748|Diagnostic Test|ECG Monitoring|All patients who do not have evidence of atrial fibrillation or atrial flutter on their 12-lead ECG will undergo an ECG Holter monitor for up to 7 days. This will be part of their standard care. If this has not been arranged by the usual care team this will be performed as a research procedure.
46001908|NCT05633017|Combination Product|CereVu Objective Dyspnea Score|Small forehead wearable and mobile app
46088104|NCT05332223|Diagnostic Test|Full Polysomnography|Overnight PSG will be conducted using Alice version 6 system (Respironics, Pittsburgh, PA, USA). During PSG, the following variables will be monitored and captured. Sleep staging using electroencephalogram (four channels: C3-A2, C4-A1, O1-A2, O2-A1), electrooculogram (two channels: LOC-A2, ROC-A1), electromyogram (two channels: submental and anterior tibialis muscles). Respiratory effort using inductive plethysmograph sensors to detect thoracoabdominal movements. Oro-nasal airflow using pressure flow transducer and thermistor. Oxygen saturation using pulse oximetry and cardiac rhythm using electrocardiography. Other parameters that will also be monitored includes body position, presence of snoring and end tidal CO2 (EtCO2) measurement to detect hypercapnia. The attended PSG will be conducted in the sleep laboratory in Respiratory Unit, Hospital Taiping
46088105|NCT02677805|Drug|Botulinum Toxin A|Injection, 20 Units divided in five 0.1mL i.m injections into the glabellar area
46088106|NCT02677805|Drug|Placebo|injection, sodium chloride 0.9% divided in five 0.1 mL i.m. injections into the glabellar area
46088107|NCT02677805|Drug|Botulinum Toxin A - Open Label|Open Label Extension Phase with Experimental Drug; Injection, 20 Units divided in five 0.1mL i.m injections into the glabellar area
46088108|NCT03474575|Other|Prevention|The purpose is to establish a safe and effective way of discharging COPD patients from emergency department by providing enhanced home care.
46088109|NCT00903929|Drug|Eltrombopag|dose escalation
46088110|NCT03458663|Device|Prevena™ og ACTIV.A.C™ Therapy System.|A vacuum assisted (negative pressure) system, Prevena ™ and ACTIV.A.C ™ therapy system have been developed to maintain drainage on closed incisions. The system also works by altering the cytokine profile locally so that it functions anti-inflammatory, by increasing local growth factors and promoting angiogenesis19. Negative pressure wound management (NPWM) such as Prevena ™ and ACTIV.AC ™ is a widely used tool with many different variations, but the evidence of effect remains sparse and more studies are required20. We believe that in a dry and closed incision such as the one after BCL surgery, in an area exposed to stretching during healing, it must be an advantage of maintaining drainage, reducing the anti-inflammatory response and increasing angiogenesis.
46088111|NCT02850497|Device|optical coherence tomography at 6 months|6-month evaluation of malapposition and endothelization with the use of intracoronary optical coherence tomography
46088112|NCT00903695|Drug|Memory XL|An over-the-counter vitamin nutriceutical patented by Univ. of Mass. that contains folic acid 400 mg, Vit. B12 6 ug, alpha-tocopherol 30 IU, S-adenosyl methionine (SAM) 400 mg, N-acetyl cysteine (NAC) 600 mg, & acetyl-L-carnitine (ALCAR) 500 mg; 2 pills per day for 12 months
46088113|NCT00903695|Drug|placebo|placebo comparator
46088114|NCT02850185|Device|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
46088115|NCT02850185|Device|Oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
46088116|NCT02850185|Drug|Conventional treatment|Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in 3 months before the study.
45676176|NCT04586244|Drug|epacadostat|epacadostat will be administered daily twice daily orally up to and including day of surgery.
45676177|NCT04586244|Drug|INCAGN02385|INCAGN02385 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
45835524|NCT00262470|Device|Breathing Device|Breathing through a dead space tube
46001909|NCT05630300|Diagnostic Test|PMC Sure Status COVID-19 Antigen Test|COVID-19 professional use kit in out-patient departments
46001910|NCT05630300|Diagnostic Test|Acon Flowflex COVID-19 Antigen Home Test|COVID-19 self-test kits
45835525|NCT00262470|Drug|memantine|memantine 5-20 mg PO x 1 dose
45835526|NCT00262470|Device|Abdominal binder|Using large blood pressure cuffs linked together, they are wrapped around the subjects abdomen and inflated to generate increased pressure to below tolerably threshold.
45835527|NCT01851642|Procedure|History and physical exam.|At every study visit, participant's will be asked about their medical history and will have a physical exam.
46088117|NCT04981925|Behavioral|MBSR treatment|"Participants will complete pre-treatment surveys followed by 8-weekly 2-hour group sessions and one 4-hour retreat (may take place virtually or in-person). Participants will also be asked to practice daily formal mindfulness at home using assigned audio recordings of 30-45 minute guided mindfulness exercises. Participants will complete surveys during treatment as well as after treatment and then at 2 months follow-up."
45676178|NCT04586244|Drug|INCAGN02390|INCAGN02390 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
46088118|NCT04202861|Diagnostic Test|In vitro antibiotic combination testing (iACT)|CRGNB isolates from the index culture will be transported to the Pharmacy Research Lab,SGH for iACT testing. iACT results will be sent to the physicians and ID specialist managing the patient once completed. A subset of results will be published in the iACT report. Participants enrolled into the intervention arm -should ideally be kept on an iACT combination for the required treatment period. However during the treatment period, the treating doctor-in-charge and or the consulting infectious disease doctor may wish to continuing iACT antibiotic combination therapy or modifying the combinations based on their best clinical judgement for the patient.
46088119|NCT02850341|Device|Pedometer|Patients receive a pedometer with instructions how to raise their number of daily steps
46088120|NCT02506127|Device|Neuronetics XPLOR system|Transcranial magnetic stimulation system
46088121|NCT04703231|Diagnostic Test|measurement of macular thickness, corneal thickness and lens opacities|The incidence of macular thickness, Corneal thickness, intraocular pressure and lens opacities will be investigated by an ophthalmologist.
46088122|NCT04975841|Device|Adipose Derived Regenerative Cells|"The Cytori Celution technology is an automated version of the process and techniques used in the research laboratory to isolate regenerative cells from adipose tissue. The Cytori Celution System uses a proteolytic enzyme blend (Celase) to disrupt the adipose tissue matrix and release the entrapped adipose derived regenerative cells (ADRCs), also referred to in the literature as stromal vascular fraction cells. Once digested, the digestate is separated into fractions (buoyant adipocytes (fat cells) and pelleted ADRCs) by centrifugation. The non-buoyant cell pellet (ADRCs) is then washed and centrifuged through several cycles to remove residual enzyme reagent and cellular debris. Although the Cytori Celution technology replicates known laboratory techniques, it offers significant improvements to the manual laboratory technique by controlling the processing in a closed system that has been validated for safety, performance, and reproducibility."
45676179|NCT04581889|Other|Diagnostic test|Presence of antibodies in saliva
46001911|NCT05628142|Radiation|Pelvic CT Scan|Pelvic CT-Scan between 6-12 months post-op
46001912|NCT05618028|Drug|ABBV-525|Oral; Tablet
46001913|NCT05608252|Drug|VS-6766|Taken Orally
46001914|NCT05608252|Drug|Abemaciclib|Taken Orally
46001915|NCT05608252|Drug|Fulvestrant|Administered by intramuscular injection
46088123|NCT04202471|Device|Chlorhexidine Cloth|2% chlorhexidine gluconate cloth
46088124|NCT02850107|Device|Medtronic HawkOne® or TurboHawk™|Use of FDA Cleared Directional Atherectomy (DA) Devices. Medtronic HawkOne® Directional Atherectomy System or TurboHawk™ Plaque Excision System. DA followed by DCB will be performed in all enrolled subjects.
45676180|NCT04580459|Behavioral|CARE Parenting Group Treatment|The CARE parenting group treatment is a 12-session, 60-minute group mentalizing-focused intervention with 3 monthly parent-child sessions.
45676181|NCT04580459|Behavioral|Treatment as Usual (TAU)|Treatment as usual (TAU) involves typical child outpatient mental health services, such as individual child appointments and medication management.
45835528|NCT01851642|Procedure|Blood draw.|At each study visit, participants will have an intravenous catheter (IV) placed in one of their veins and blood will be drawn from the IV for study testing.
46001916|NCT05596734|Biological|bivalent BNT162b2 (original/Omi BA.4/BA.5)|Intramuscular injection
46001917|NCT05596734|Biological|qIRV (22/23)|Intramuscular injection
46001918|NCT05596734|Biological|QIV|Intramuscular injection
46001919|NCT05595577|Other|Exercise with Trainerize application|1-2 sessions per week consisting of slow 15 minute aerobic warm, 20 minutes of strength training, 15 minutes progressive intensity aerobic exercise and 10 minute cool down (stretching/toning) with elastic bands.
46001920|NCT05595577|Diagnostic Test|Cardiopulmonary exercise testing|Maximal peak VO2 (to monitor the body's oxygen consumption) and 6-minute exercise walking test.
46088125|NCT02850107|Device|Medtronic IN.PACT® Admiral® DCB|FDA Approved Drug Coated Balloon (DCB) Technology. Medtronic IN.PACT® Admiral® DCB will be used after DA.
46088126|NCT02850107|Device|Medtronic Spider™ Distal Protection Device (DPD)|It is recommended that the Medtronic Spider™ Distal protection device (DPD) be paired with DA when used in complex, calcified lesions (TurboHawk™ IFU).
45676182|NCT04579224|Drug|Docetaxel|Given IV
45676183|NCT04579224|Drug|Eribulin Mesylate|Given IV
45676184|NCT04579224|Drug|Gemcitabine Hydrochloride|Given IV
45676185|NCT04579224|Drug|Paclitaxel|Given IV
46001921|NCT05595577|Diagnostic Test|MRI scan|Images of the heart will be taken.
45835529|NCT01851642|Procedure|Pulmonary function testing.|At every study visit, participants will have their lung function assessed. This is done by blowing forcefully at least 3 times into a tube. Testing will be done two times; before and after the use of an Albuterol inhaler.
45835530|NCT01851642|Drug|Albuterol inhaler.|At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.
45835531|NCT00224796|Device|V.A.C. ® System|
45835532|NCT01253070|Procedure|Biopsy|Undergo biopsy
46001922|NCT05595577|Behavioral|Quality of Life Questionnaires|Participants will be asked to complete several questionnaires that will measure fatigue, general health, social determinants of health, cognitive function (tasks that assess memory, ability to count, etc.) and physical activity. The questionnaires will take 15-40 minutes to complete.
46002463|NCT02819128|Other|Collection of body lice|For the subjects infested with body lice , if they want, their underwear will be recovered and sent to the laboratory to measure the resistance to permethrin.
46002464|NCT02816307|Other|blood samples|
46088127|NCT02850107|Device|"Volcano Visions® PV .014 IVUS catheter"|"Lesion IVUS assessment using the Volcano Visions® PV .014 IVUS catheter will be required in all cases."
46088128|NCT02850107|Device|Nitinol Stent Placement|Only FDA approved nitinol stents can be used if provisional stenting is required.
46088129|NCT02395601|Drug|CPI-1205|Small molecule inhibitor of the enzyme EZH2
46001923|NCT05595577|Behavioral|Cognitive and Brain Function Questionnaires|Participants will be asked to complete several questionnaires that will measure fatigue, general health, social determinants of health, cognitive function (tasks that assess memory, ability to count, etc.) and physical activity. The questionnaires will take 15-40 minutes to complete.
46088130|NCT02850029|Other|Observational study, no intervention|
46088131|NCT02849951|Drug|LT-02|12-weeks of 1.6 g BID delayed-release phosphatidylcholine (LT-02)
46088132|NCT02849951|Drug|LT-02 Placebo|12-weeks of 0 g BID delayed-release phosphatidylcholine (LT-02) placebo
46088133|NCT04202237|Other|Speckle Doppler imaging|Speckle Doppler Laser imaging
46001924|NCT05595577|Other|Blood draws|Approximately 2 teaspoons of blood withdrawn from either a vein in your arm or a currently placed central line port-a-cath. A portion of blood from each visit will be used to collect information about blood cell count.
46088134|NCT04202237|Other|Blood sample|Blood sampling
46088135|NCT04202315|Other|Virtual Reality|Utilizing Virtual Reality during external fixator removal in outpatient clinic setting.
46088136|NCT05173649|Other|Calisthenic Training|"Calisthenic Training Performed thrice a week after baseline assessment Standard Physical therapy treatment along with following exercises.~Abductor-Adductor leg raise~Alternate toe touch~Knee Bend~Prone leg extension~Forward Lunges~Toe Raise/ Calf raise Progressive training include following exercises.~1. Leg Lifts 2. Jack Twists 3. Side Lunges 4. Short bridge 5. Calf Raise with weight."
46088137|NCT05173649|Other|Neuromuscular Training|"Neuromuscular Training Performed thrice a week after baseline assessment Standard Physical therapy treatment along with following exercises.~Up and down step exercise in posterior and lateral directions.~Walking in anterior and posterior~Directions with eyes opened and eyes closed.~Walking in lateral direction with eyes opened and eyes closed.~Standing on one extremity~Inclination in anterior and lateral direction with eyes opened and closed. Progressive training includes following exercises.~1. Up and down on Bosu exercise. 2. Plantar flexion on minitrampoline. 3. Standing on one extremity on Bosu. 4. Standing on one extremity on minitrampoline"
46088138|NCT00632645|Drug|Olanzapine|Olanzapine Mylan oral dispersible form 5 to 10 mg / 2,5 à 20 mg per day
46088139|NCT00632645|Drug|Xenazine|Xenazine (tetrabenazine) tabs of 25mg , from 25 mg to 200 mg
46088140|NCT00632645|Drug|Tiapridal|Tiapridal (Tiapride), tabs 100 mg / from 300 to 800 mg per day
46088141|NCT02849873|Drug|IDP-123 Lotion|Lotion
46088142|NCT02849873|Drug|Tazorac Cream|Cream
45835533|NCT01253070|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspirate
45835534|NCT01253070|Drug|Cytarabine|Given IV
45835535|NCT01253070|Drug|Daunorubicin Hydrochloride|Given IV
45835536|NCT01253070|Other|Laboratory Biomarker Analysis|Correlative studies
46088143|NCT02849795|Other|bone densitometry|
46088144|NCT02849795|Other|questionnaires|
46088145|NCT02849795|Other|biological analyses|
46088146|NCT02304809|Drug|Vemurafenib|Vemurafenib is a low molecular weight, orally available, inhibitor of BRAF serine-threonine kinase. Mutations in the BRAF gene which substitute the valine at amino acid position 600 result in constitutively activated BRAF proteins, which can cause cell proliferation in the absence of growth factors that would normally be required for proliferation
46088147|NCT02849483|Drug|Ramosetron|Administer 2 ml of normal saline iv before induction. Inject ramosetron 0.3 mg iv at the end of surgery. Add ramosetron 0.6 mg to the iv PCA.
46088148|NCT02849483|Drug|Normal saline|Administer dexamethasone 10 mg iv before induction. Inject 2 ml of normal saline iv at the end of surgery. Add 4 ml of normal saline to the iv PCA.
46088149|NCT05085197|Drug|STSA-1005 injection|Intravenous injection
46088150|NCT05085197|Drug|Placebo|Intravenous injection
46088151|NCT05085197|Drug|STSA-1005 injection|Intravenous injection
46088152|NCT05085197|Drug|Placebo|Intravenous injection
46088153|NCT05085197|Drug|STSA-1005 injection|Intravenous injection
46088154|NCT05085197|Drug|Placebo|Intravenous injection
46088155|NCT05085197|Drug|STSA-1005 injection|Intravenous injection
46088156|NCT05085197|Drug|Placebo|Intravenous injection
46088157|NCT02849561|Other|Therapeutic hypothermia|With a mattress at 4°C to reach a central temperature at 33,5°C.
46088158|NCT02849561|Device|Synchronized Intermittent Mandatory Ventilation|Constant volume 6 ml/kg
46088159|NCT02849561|Other|Electroencephalography|
46088160|NCT02849561|Device|Pupillary light reflex surveillance|With Neurolight® device.
46088161|NCT02849561|Device|Transcranial Doppler|Monitoring tool for brain hemodynamic evaluation. With Philips HD15 Ultrasound system®.
46088162|NCT04518449|Procedure|medial border along the left side of SMA|to place the medial border along the left side of SMA in laparoscopic D3 lymphadenectomy for right colon cancer
46088163|NCT04518449|Procedure|medial border along the left side of SMV|to place the medial border along the left side of SMV in laparoscopic D3 lymphadenectomy for right colon cancer
45835537|NCT01253070|Other|Quality-of-Life Assessment|Ancillary studies
45835538|NCT01253070|Other|Questionnaire Administration|Ancillary studies
45835539|NCT01253070|Drug|Sorafenib Tosylate|Given PO
45835540|NCT04767282|Other|Fruit and Vegetable Prescription|$15 voucher for fruit and vegetables
45835541|NCT01252914|Device|iStent Supra Stent|Implantation of one iStent Supra Stent through a small temporal clear corneal incision
45835542|NCT01840956|Biological|HAVG|HAVG is implanted into patients' arm.
46002465|NCT02793466|Drug|Durvalumab; MEDI4736|IV Infusion every 2 weeks for a maximum of 26
46002466|NCT02774005|Drug|Idebenone|
46002467|NCT02747849|Device|TENS|Placebo had stimulator placed on hand. Active comparator had stimulator placed on foot. Amount of time, intensity, threshold voltage, pulsewidth and frequency remained the same for both arms.
46002468|NCT02700828|Drug|Hydrocortisone|4 * 0,5 mg/kg /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
45835543|NCT02087514|Procedure|Blood Transfusion|A routine medical procedure in which blood is given through an intravenous (IV) line a blood vessel.
46088164|NCT02432274|Drug|Lenvatinib|Cohort 1: Lenvatinib will be administered orally, once daily on Days 1 to 28 of each 28-day cycle at a starting dose of 11 mg/m2. Dose can be de-escalated to 9 mg/m2 or escalated to 14 and 17 mg/m2.
46088165|NCT02432274|Drug|Lenvatinib|Cohort 2A: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
46088166|NCT02432274|Drug|Lenvatinib|Cohort 2B: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
46088167|NCT02432274|Drug|Lenvatinib|Cohort 3A: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at 20% lower than RD determined in Cohort 1 (starting dose). Lenvatinib dose can be escalated to the RD from Cohort 1 or de-escalated to 40 and 60% lower than the RD from Cohort 1.
46088168|NCT02432274|Drug|Lenvatinib|Cohort 3B: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at the RD as determined in Cohort 3A.
46088169|NCT02432274|Drug|Ifosfamide|Ifosfamide 3000 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles. Ifosfamide dose can be de-escalated to 2400 mg/m2/day and 1800 mg/m2/day.
46088170|NCT02432274|Drug|Etoposide|Etoposide 100 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles. Etoposide dose can be de-escalated to 80 mg/m2/day and 60 mg/m2/day.
46088171|NCT02432274|Drug|Ifosfamide|Ifosfamide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
46088172|NCT02432274|Drug|Etoposide|Etoposide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
46088173|NCT04500665|Drug|Colchicine|Colchicine
46088174|NCT04500665|Drug|Placebo|Placebo
46088175|NCT05116007|Drug|AK112|IV infusion
46088176|NCT05116007|Drug|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
46088177|NCT05116007|Drug|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4)
46088178|NCT02849327|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
46088179|NCT02849327|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
46088180|NCT02077361|Genetic|rAAV2.REP1 vector|No additional details needed.
46088181|NCT05150574|Behavioral|Core Health Program|8-week structured stress management and health behaviour change program
46088182|NCT05150574|Behavioral|Daily resting HRV|Take regular HRV readings in the morning
46088183|NCT05150574|Behavioral|Momentary HRV feedback|Take regular HRV readings throughout the day when stressed and perform mindfulness activity
46088184|NCT05150574|Behavioral|Behavioural initiation coaching|15-minute health coaching session in first week of program to help participant set goals and create an action plan
46088185|NCT05150574|Behavioral|Practice with feedback coaching|15-minute health coaching session in week 2 or 4 of program to help participant review goals and modify action plans if needed
46088186|NCT00618696|Biological|anti-CD45 monoclonal antibody AHN-12|150 mg/m^2 cold antibody at Day 0
46088187|NCT00618696|Radiation|yttrium Y 90 anti-CD45 monoclonal antibody AHN-12|Dose per scheduled level; 2.5-12.5 mCi/m^2
46088188|NCT04212468|Other|no intervention|no intervention
46088189|NCT00618852|Drug|Furosemide|The dose of furosemide will be 1 mg/kg by intravenous bolus injection
46002469|NCT02700828|Drug|Placebo|4 * 2 ml isotonic sodium chloride solution /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
46088190|NCT00618852|Drug|Saline|1 mg/kg by intravenous bolus injection
46088191|NCT02073474|Drug|Sativex®|Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL; cannabidiol (CBD), 25 mg/mL; in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
46088192|NCT00618930|Drug|Moviprep®|use of Moviprep®
46088193|NCT00618930|Drug|Fleet|Use of Fleet
46088194|NCT04209972|Device|Precision Ultra-High-Resolution CT scanner|Patients will be divided on one of the two CT scanners. This group will be scanned on the Precision CT scanner.
46088195|NCT04209972|Device|Genesis high-end CT scanner|Patients will be divided on one of the two CT scanners. This group will be scanned on the Aquilion one Genesis.
46088196|NCT04940130|Biological|Sanaria® PfSPZ Vaccine|non-adjuvanted, live (metabolically active), radiation-attenuated, non-replicating, whole sporozoite (SPZ) vaccine designed to prevent malaria infection caused by Plasmodium falciparum (Pf).
46088197|NCT04940130|Other|Normal Saline|placebo control- saline
46088198|NCT04672044|Device|Active rTMS and exercise|active
46002470|NCT02695771|Drug|Mitomycin C|Cancer chemotherapeutic agent
46002471|NCT02695771|Drug|Gemcitabine|Cancer chemotherapeutic agent
46002472|NCT02658032|Behavioral|personalized cessation care|Individuals randomized to this condition will receive standard care (i.e., 5 counseling sessions and nicotine patch(NRT)) and 4 personalized videos with 5 packages of personalized print materials
46001925|NCT05591586|Behavioral|Web based educational modules|This strategy will consist of 6 web-based modules, clinic-specific interpreter access information, and 4 booster modules, all delivered via the internet. The online modules will cover 6 topics: 1) the importance and fundamentals of good communication; 2) the importance of professional interpreter use and disparities for LEP populations; 3) how to use an interpreter effectively; 4) what to do when the encounter is not going well; and 5) special challenges and 6) solutions related to remote interpreter use. Modules will be interactive, with tailoring to the learner, and each will be <15 minutes long. All modules will be available at once, but assigned providers will be prompted to view a new one each week. Every month for months 3-6 after randomization, a booster module will be released. The brief (<10 min) boosters will review crucial points from initial modules and feature video vignettes. Providers will be reminded to view these weekly until they are complete.
46002473|NCT02658032|Behavioral|bio feedback|Individuals randomized to this group will be provided with a personalized graph of their biomarker data from baseline, 6 and 8 weeks at the 8-week and 3-month study visits.
46088199|NCT04672044|Combination Product|Sham rTMS+Exercise|sham
45835544|NCT02087514|Other|Packed red blood cells|"Red blood cells that have been collected, processed, and stored in bags as blood product units available for blood transfusion.~A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.~The number of weeks in storage are as follows:~1 week~2 weeks~3 weeks~4 weeks~5 weeks~6 weeks"
46088200|NCT00637104|Device|Mar-Tyn TiN coated Co-Cr Numen stent implant|Implant of the Mar-tyn TiN coated stent
46088201|NCT00637104|Device|Vision Co-Cr stent implant|Implant of the Vision stent
46088202|NCT00528294|Radiation|GRID radiotherapy|GRID-radiotherapy followed by biological imaging guided IMRT
46088203|NCT04209894|Diagnostic Test|Ultrasound|Evaluation consisted of the detection of grey scale (GS) enthesitis and Power Doppler signal in enthesis areas of participants. The Madrid Sonography Enthesitis Index (MASEI) scoring system was used to quantify the extent of sonographic entheseal abnormalities
46088204|NCT00617682|Biological|PNCRM9|0.5 mL IM at 30-35 wks gestation
46088205|NCT00617682|Biological|Placebo comparator|Sucrose cake (NaCl and sucrose) in aluminum phosphate adjuvant diluent at 0.5 mg per 0.5 mL dose IM at 30-35 wks gestation
46088206|NCT02053272|Drug|GWP42004|The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
45835545|NCT01212822|Biological|bevacizumab|Given IV
45835546|NCT01212822|Drug|oxaliplatin|Given IV
45835547|NCT01212822|Drug|leucovorin calcium|Given IV
45835548|NCT01212822|Drug|fluorouracil|Given IV
45835549|NCT01212822|Procedure|therapeutic conventional surgery|Undergo surgical resection
45835550|NCT01212822|Other|laboratory biomarker analysis|Correlative studies
45835551|NCT00163566|Drug|Dihydrotestosterone (0.7%) in hydroalcoholic gel|transdermal gel, 0.7% DHT, 0.35 mg/day or 0.70 mg/day total daily dose (or placebo gel), applied twice per day
45835552|NCT01836744|Device|Survival rate dental implant (OsseoSpeed™)|
45835553|NCT04389606|Other|Study Formula (SF)|New infant formula for term infants fed ad lib
45835554|NCT04389606|Other|Comparator Formula (CF)|Commercially available infant formula for term infants fed ad lib
45835555|NCT00055224|Device|Acoustic startle|Threat condition
45835556|NCT00055224|Device|Electric Shock|Threat condition
45835557|NCT01167270|Behavioral|Child Safety Insights|A child safety intervention with messages focused on the infant's environment and interactions with parents. They will be guided by the American Academy of Pediatrics as well as the Academy's guide for health supervision, Bright Futures.
46002474|NCT02658032|Other|standard care|
46002475|NCT02568267|Drug|Entrectinib|TrkA/B/C, ROS1, and ALK inhibitor
46088207|NCT02053272|Drug|Placebo|The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
46088208|NCT04212624|Other|Human retinal pigment epithelial (HuRPE) cell injection|Human retinal pigment epithelial cell injection Dosage form and specifications: injection; 600,000 cells / branch (200μl), 1 million cells / branch (200μl), 2 million cells / branch (200μl) Transportation and storage: sealed, stored at 2-8 ° C, valid for 6 hours
46088209|NCT00617760|Biological|Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)|MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle, PCV7 (0.5 ml) to be administered in the right thigh muscle
46088210|NCT00617760|Biological|7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)|PCV7 (0.5 ml) to be administered in the right thigh muscle
46088211|NCT00617760|Biological|Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)|MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle
46088212|NCT04212546|Other|Synbiotic test drink|In a healthy male population, participants consumed a synbiotic test drink containing 200 mL milk + 16 g inulin + Lactobacillus casei431 [>106cfu/mL] per day for 21 days with their habitual diet.
46088213|NCT04212546|Other|Control drink|In a healthy male population, participants consumed a synbiotic test drink containing 200 mL milk + 16 g maltodextrin per day for 21 days with their habitual diet.
46088214|NCT02030418|Device|Leadless Pacemaker|Patients will undergo an attempted leadless pacemaker implant
46088215|NCT00617838|Other|Optimal gluten introduction|Optimization of gluten introduction by nutritional counselling
46088216|NCT00620412|Dietary Supplement|Lactobacillus rhamnosus|2 capsules by mouth 2 times a day for 28 days. Each capsule contains 1x10^10 LGG organisms.
46088217|NCT00620412|Dietary Supplement|placebo control|2 capsules by mouth twice a day for 28 days
46088218|NCT00620412|Biological|Influenza Virus Vaccine Live, Intranasal|intranasal spray, 0.1ml per nostril, one time dose
46088219|NCT02347254|Device|Transcranial ExAblate|Transcranial ExAblate MRgFUS
46001926|NCT05591586|Behavioral|mobile video interpreting (mVI) access|This strategy will involve giving assigned providers access to mobile video interpreting (mVI) on a personal device, installation and support as needed, a tip sheet, and an extra charger, optional shock-resistant case, disposable antimicrobial sleeves, and a positioning stand to support use of their personal device for clinical care. mVI-assigned providers can opt for a study-issued smartphone in lieu of using their own. Access to mVI is achieved by downloading the application from the relevant location (e.g., Apple App Store), then entering an access code that links to a billing account. The study staff would then demonstrate use and answer questions. Technical support will be offered in-person following randomization; we will then email mVI-assigned providers weekly for the first month, then monthly, to offer additional support. A tip-sheet will be sent via email during the first week of the study that will include mVI instructions and best-practices.
46088220|NCT00620490|Drug|ropivacaine|Ropivacaine 0.5% 0.1 ml/kg per hour
46088221|NCT00620490|Other|nacl 0,9%|saline 0.9% 0.1 ml/kg per hour
46001927|NCT05579314|Drug|XW014|Oral capsules
46088222|NCT00619008|Other|Ad libitum low carbohydrate diet|6 week ad libitum low carbohydrate diet
46088223|NCT00619008|Other|Ad libitum High Complex Carbohydrate Diet|6 week ad libitum high complex carbohydrate diet
46088224|NCT00619008|Other|Energy-restricted high complex carbohydrate diet|6 week energy-restricted (68% of estimated energy requirement for weight maintenance) high complex carbohydrate diet.
45676187|NCT04571814|Behavioral|Psycho-social, computerized intervention targeting error sensitivity|"A psycho-social, computerized intervention for parents and children targeting error sensitivity. This intervention will be based on the constructs in the Child Error Sensitivity Index, as well as other constructs, that relate to the error-related negativity - for example, perfectionism, fear of evaluation from others, and over-valuation of the negative consequences of errors. The parent version of the intervention will include these same basic concepts, but will also target parenting style and provide psychoeducation on the negative impact of over-reacting to children's mistakes.~The parent version will also include examples of how to model appropriate reactivity to mistakes, and provide video vignettes and examples of both critical and adaptive parenting reactions to mistakes."
45457980|NCT01139671|Drug|Remifentanil|"Wisdom teeth removal under general anaesthesia is usually suitable for ambulatory surgery.~The choice of opioid in dental day surgery is based on the need for a rapid and full recovery, as well as less morphine administration. Whether remifentanil can achieve these goals remains to be proved, especially regarding remifentanil-induced hyperalgesia, the potential prolonged Post Anesthesia Care Unit (PACU) stay, or remifentanil-induced workload for nurses."
45457981|NCT02313064|Drug|CXA-10|Part A has sequential single ascending doses will be administered in up to 5 cohorts of subjects. Each cohort of subjects will be randomized to receive a single dose of CXA-10 or placebo in, a fasted state. Part B has 2 periods and subjects will receive two doses of the selected dose of CXA-10.
45835558|NCT01167270|Behavioral|Parenting Insights|Educational program contains messages to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle that will prevent rapid weight gain in infancy and overweight at age 3 years.
45835559|NCT04705662|Diagnostic Test|Lactulose breath test|Participants will complete a 3 hour breath test pre and post iron supplementation. This will include taking 4 exploratory samples for volatile organic compound (VOC) analysis.
46088225|NCT00619086|Drug|Dexamethason Helvepharm ®|8 mg Dexamethason i.v. 45 minutes prior to surgery
45457982|NCT02313064|Drug|CXA-10 placebo|
45457983|NCT05100511|Device|ERG electrode tests for fundus image-guided focal ERG|Investigate the patient comfort, usability and signal-to-noise ratio of different commercial CE marked ERG electrodes.
45457984|NCT05100511|Device|Fundus image-guided focal ERG|Record focal ERG from a healthy retinal area and from an area with visible symptoms.
45835560|NCT04705662|Other|Stool sample|Participants will provide a stool sample pre and post iron supplementation
45835561|NCT04705662|Other|Daily Diary|Monitoring stool form, consistency and frequency on a daily basis
46088226|NCT00619086|Drug|Placebo|100 ml sodium chloride i.v. 45 minutes prior to surgery
46088227|NCT04212078|Drug|Levofloxacin Ophthalmic|0.1ml which has 0.5 mg levofloxacin will be injected via intracameral into the anterior chamber through the side port wound using a tuberculin syringe in a 27 gauge cannula.
46088228|NCT04212078|Drug|Cefuroxime|The vial contains 750 mg of cefuroxime powder is diluted with 7.5 ml of Balanced Salt Solution (BSS). 1 ml of the solution will be withdrawn and added with 9 ml of BSS. Then, 0.1 ml of solution which is equivalent to 1 mg of cefuroxime will be aspirated and kept a side. The dissolution of the antibiotic is confirmed by naked eye. Then the antibiotic of 0.1 ml will be given as intracameral to patient using a tuberculin syringe in a 27 gauge cannula at side port wound at the end of surgery.
46088229|NCT01898520|Drug|Sativex|Oromucosal spray containing THC (27 mg/mL):CBD (25 mg/mL), in ethanol: propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivered THC 2.7 mg and CBD 2.5 mg. The maximum number of daily sprays was 12.
46088230|NCT01898520|Drug|Placebo|Oromucosal spray containing ethanol: propylene glycol(50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Each 100 μL spray administered to the sub-lingual or oral mucosa delivered the colourants plus excipients. The maximum daily dose was 12 sprays per day.
46088231|NCT00903617|Drug|GSK256073|5 mg for 8 weeks
45835562|NCT04705662|Other|Irritable Bowel syndrome severity scoring system (IBS-SSS) questionnaire|Participants will complete the questionnaire pre and post iron supplementation
45835563|NCT04705662|Dietary Supplement|Ferrous Sulphate|Participants will take Ferrous sulphate 200mg (65mg elemental iron) for 4 weeks (+/- 2 days). Participants will be required to take 2 tablets per day.
45835564|NCT04687020|Drug|Viltolarsen|Received during weekly intravenous infusions
46088232|NCT00903617|Drug|GSK256073|50 mg for 8 weeks
46088233|NCT00903617|Drug|GSK256073|150 mg for 8 weeks
46088234|NCT00903617|Drug|Placebo|placebo for 8 weeks
46088235|NCT00903617|Drug|Niaspan|1500 mg for 8 weeks
46088236|NCT00903617|Drug|GSK256073|x mg for 8 weeks based from data from Part A
46088237|NCT00903617|Drug|GSK256073|optional dose based on data from Part A
46001928|NCT05579314|Drug|Placebo|Matched oral placebo capsules
46088238|NCT05088785|Drug|FES|[18F]FES PET imaging.
46088239|NCT02849405|Device|MHRC: Metabolic Hyperspectral Retinal Camera|Comparison of hyperspectral signature of retinal arterioles between subjects suffering from arteriosclerosis and healthy control subjects.
46088240|NCT00620568|Drug|SLV-313 SR|sustained release tablets taken once daily for 14 days
46088241|NCT02849093|Other|Non-invasive OCT imaging|Optical Coherence Tomography (OCT) to capture high resolution cross-sectional images of tissue microstructures using infra-red radiation.
46088242|NCT04855578|Other|In-Hopsital Patient Educational Brochure|The participant's medication list will be identified from the pharmacy database and validated with the participant's best possible medication history taken at time of admission by a pharmacist. Eligibility will be confirmed by the participant's treating medical team with support from the study investigators. Participants who are enrolled during the intervention phase will receive an educational brochure about the risks of chronic gabapentinoid use, and about how to safely discontinue use. The brochure is written using a sixth-grade vocabulary and has been validated in both English and French for comprehension and readability, including for people with mild cognitive impairment.
46088243|NCT04855578|Other|Physician Education about Gabapentinoid Prescription|An educational session about the purpose of the study and risks of gabapentinoid prescription will be delivered to physicians (staff and medical residents) on each study unit at both sites during the intervention period. The educational session will include a presentation by the chief of the medical service at the monthly teaching rounds, and an electronic message will be sent to all physicians on the medical service. Physicians will also be presented a brief overview of the educational brochure.
46088244|NCT02021357|Behavioral|hyperbolid combined with tongue exercises on the palate|
46088245|NCT02021357|Other|hyperbolid|
46088246|NCT04845516|Other|Efficacy of apheresis|Efficacy of apheresis
46088247|NCT02848937|Device|Bath with citrate|bath with citrate which allows the equivalence of mass balance (Ca_eq) compared to the concentrate with 3 mM acetate and 1.5 mM of calcium
46088248|NCT02848937|Device|Bath with citrate and Ca_eq|bath with citrate and Ca_eq of concentrate with 3 mM acetate and 1.5 mM of calcium
46088249|NCT04660500|Other|PD Drivers Using AV Technologies On-road|All drives will include events to assess the impact of in-vehicle information systems (IVIS) and advanced driver assistance systems (ADAS) on the driving performance (driving errors) of drivers with PD. For IVIS the investigators will include options to assess errors with lane maintenance (with and without the lane departure warning system) and signaling (with and without blind spot detection). For ADAS the investigators will include conditions to assess errors in speeding (with and without adaptive cruise control) and lane exceedances (with and without lane keeping assist).
46088250|NCT00343824|Procedure|aquacel AG hydrofiber versus acticoat burn dressing|Aquacel AG hydrofiber versus acticoat burn dressing will be compared.
45457985|NCT05094661|Procedure|BiPAP|The patient recives respiratory support with bilevel positive airway pressure system until treatment improves or fails (needs intubation/dies).
45835565|NCT01805076|Procedure|Breast surgery|
46001929|NCT05564221|Drug|YH35324|Subcutaneous injection of YH35324
46001930|NCT05564221|Drug|Placebo|Subcutaneous injection of None of active ingredient
46001931|NCT05564221|Drug|Omalizumab|Subcutaneous injection of Omalizumab
46001932|NCT05557357|Procedure|Electroacupuncture (EA)|"Electroacupuncture (EA) treatment following standardized procedures will be conducted for 2 sessions per week for 5 consecutive weeks. Each session of treatment will last for 25 min.~The acupoints that will be stimulated are Tinggong (SI19) and Yifeng (TE17) of the affected side, Baihui (GV20) and Yintang (GV24+), bilateral posterior temporal line (MS11), and Zhongzhu (TE3) and Zusanli (ST36) of the affected side.~For electroacupuncture (EA), electrical stimulation will be applied using an EA apparatus, with pairs of electrodes connecting the needles at ipsilateral SI19 and TE17, GV20 and GV24+, and bilateral MS11."
46088251|NCT00903383|Drug|LX3305 low dose|A low dose of LX3305; daily oral intake for 12 weeks
46088252|NCT00903383|Drug|LX3305 mid dose|A mid dose of LX3305; daily oral intake for 12 weeks
45457986|NCT05094661|Procedure|CPAP|The patient recives respiratory support with continuous positive airway pressure system until treatment improves or fails (needs intubation/dies).
45457987|NCT02309086|Biological|Autologous dendritic cells transduced with Ad encoding NS3|Patients will receive 3 different dosis of the vaccine via subcutaneous injection
46088253|NCT00903383|Drug|LX3305 high dose|A high dose of LX3305; daily oral intake for 12 weeks
46088254|NCT00903383|Drug|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
46088255|NCT04825860|Drug|SEP-363856 50 mg|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
45457988|NCT05088889|Drug|Nivolumab|Nivolumab administered IV over 30 minutes at a dose of 360mg every 3 weeks
45835566|NCT01805076|Procedure|Magnetic resonance imaging|
45835567|NCT01805076|Procedure|Mammography|
45835568|NCT04784286|Other|Telemedicine 30-day post-op visit|Consented subjects randomized to the telemedicine visit arm will do their 30-day post-op visit via secure telemedicine video application through the Center of Connected Care. A survey will be asked via telephone about their post-op care visit, costs incurred, and feedback.
46001933|NCT05557357|Procedure|Electroacupuncture Combined With Warm Needling (EAWN)|"Electroacupuncture combined with warm needling (EAWN) treatment following standardized procedures will be conducted for 2 sessions per week for 5 consecutive weeks. Each session of treatment will last for 25 min.~The acupoints that will be stimulated are SI19 and TE17 (affected side), GV20 and GV24+, bilateral MS11, and TE3 and ST36 (affected side).~For electroacupuncture (EA), electrical stimulation will be applied using an EA apparatus, with pairs of electrodes connecting the needles at ipsilateral SI19 and TE17, GV20 and GV24+, and bilateral MS11.~For warm needling (WN), two moxa sticks will be ignited and attached one by one to the needle handle of each acupoint of SI19 and TE17."
45676188|NCT04567303|Drug|Zifibancimig|"Part 1: multiple ascending doses by IVT injection. Each participant will receive zifibancimig at a constant volume of 50 microliter in the study eye.~Part 2: participants will be randomized to one of two dose levels of zifibancimig in the PD implant.~Part 3: Participants will receive one of the two dose levels of zifibancimig in the PD implant."
45676189|NCT04567303|Drug|Ranibizumab|Participants will receive ranibizumab 100 mg/mL through the PD implant
46001934|NCT05557357|Other|Waitlist Control|No treatment will be provided during the 10-week waiting period after baseline assessment.
46001935|NCT05556564|Drug|observational study|No intervention, observational study
46001936|NCT05550896|Diagnostic Test|Echocardiogaphy|Assessment of high velocity low amplitude signals on Doppler echocardiography
46001937|NCT05548972|Device|G7 Dual Mobility with Vivacit-E bearing|hip arthroplasty with G7 Dual Mobility Vivacit-E bearing
46001938|NCT05548972|Device|G7 Dual Mobility Longevity bearing|hip arthroplasty with G7 Dual Mobility Longevity bearing
46001939|NCT05540886|Behavioral|TEACH CLEAN|"The intervention is primary a training facility cleaning champions to educate and supervise other existing facility cleaners with environmental hygiene responsibilities - training of trainers (ToT).~The training content includes as much as possible the seven contextualized modules of TEACH CLEAN training package (CLEAN BOX): i) Introduction to Infection Prevention and Control, ii) Personal hygiene and dress code, iii) Hand hygiene, iv) Personal protective equipment, v) Housekeeping/control of environment, vi) Waste handling, and vii) Linen handling.~Facility training will occur in three selected wards: i) maternity ward, including labour and post-natal rooms, ii) medicine ward, iii) and medicine ward.~There is also supervision stage that refers to ongoing mentorship of cleaning champions by the local partner while they educate and supervise existing facility cleaners with environmental hygiene responsibilities."
46001940|NCT05536336|Device|Condom|Contraception
46001941|NCT05517460|Other|Auricular acupressure|The participant in Intervention period will receive acupressure on ear Shenmen point, ear Large intestine point, ear Rectumn point and ear San Jiao point.
46001942|NCT05517460|Other|health education|health education for self-care and medication adherence
46088256|NCT04825860|Drug|SEP-363856 75 mg|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
46088257|NCT04825860|Drug|Placebo|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
45835569|NCT04784286|Other|In-Person 30-day post-op visit|Consented subjects randomized to the in-person visit arm will physically come to a clinical visit with the bariatric surgery midlevel providers. A survey will be asked via telephone about their post-op care visit, costs incurred, and feedback.
45835570|NCT05391984|Other|Activity oriented treatment|15 patients will be treated with activity oriented therapy. All subjects will receive 20 therapeutic sessions, 5 times a week over the time span of 4 weeks.
46088258|NCT04218461|Diagnostic Test|PRE-DELIRIC model|To predict delirium according to risk factors in the PRE-DELIRIC model
46088259|NCT02849015|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
46088260|NCT02849015|Biological|NK immunotherapy|Natural killer cell(each treatment: about 10 billion cells transfusion in 3 times, i.v.)
45457989|NCT05088889|Drug|ipilimumab|Ipilimumab administered IV over 30 minutes at 1 mg/kg every 6 weeks
45676190|NCT04567303|Device|Port Delivery Platform|Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.
45676191|NCT04546568|Device|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - Leoni plus CLAC|"FiO2 adjustments will be made by the Leoni plus CLAC (Closed-Loop Automated oxygen Control) ventilator (Leoni plus, Löwenstein Medical, Germany).~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
45835571|NCT05391984|Other|Structural oriented treatment|15 patients will be treated with structural oriented therapy. All subjects will receive 20 therapeutic sessions, 5 times a week over the time span of 4 weeks.
45835572|NCT04783818|Radiation|Adjuvant Radiotherapy|PMRT
46001943|NCT05511792|Procedure|TAVR for BAV Using Down Sizing with the Evolut Pro platform|Down sizing strategy in Type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement with self-expanding valves
46001944|NCT05511792|Procedure|TAVR for BAV Using Traditional Sizing strategy with the Evolut Pro platform|Traditional sizing strategy in Type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement with self-expanding valves
46001945|NCT05501561|Biological|Experimental: IIV-A Investigational IIV-A will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational IIV-A Investigational Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
46001946|NCT05501561|Biological|Experimental: aIIV-B Investigational aIIV-B will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational aIIV-B Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
46001947|NCT05501561|Biological|Experimental: aIIV-C Investigational aIIV-C will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational aIIV-C Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
46001948|NCT05501561|Biological|Active Comparator: Licensed IIV IIV will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Licensed IIV Licensed Non-adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
46001949|NCT05491200|Drug|Prasugrel based short DAPT|Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus
46001950|NCT05491200|Drug|Prasugrel based standard DAPT|Prasugrel based DAPT for 1 year
46001951|NCT05491200|Device|OCT guided revascularization|OCT guided revascularization of the non-culprit lesions
46001952|NCT05491200|Device|Angio guided revascularization|Angio guided revascularization of the non-culprit lesions
46001953|NCT05490888|Drug|PHIN-214 Subcutaneous injection|Single subcutaneous injection with PHIN-214 terlipressin derivative, single ascending dose
46001954|NCT05489081|Behavioral|Positive Behavior Management Toolkit|The Positive Behavior Management Toolkit, or the implementation strategy resource package, is a set of resources provided to teachers in the intervention group that aims to support their use of positive behavior management practices in the classroom, particularly with students with hyperactive, inattentive, or impulsive behaviors.
46001955|NCT05483231|Behavioral|Family integrated care intervention group|If the very low birth weight infants' vital signs are stable at 32 weeks of corrected gestational age, parents who have been fully trained will provide all non-medical care measures and developmental care for the VLBWIs in the NICU for not less than 6 hours per day for at least 3 weeks, and other medical practice and care measures will be the same as the routine group.
46088261|NCT02849249|Biological|allergovac polimerized (100/100)|Patients will recieve a initiation phase plus a mantenaince phase for 3 months of an allergy vaccine.
46088262|NCT04704089|Other|spectrophotometer|"Calibration of the spectrophotometer (calibration of white and green color on the provided support),~Placing the patient or witness in the chair,~Placement of intraoral retractors,~Photographs of the dental arch in occlusion as well as slightly open mouth to visualize the mandibular incisors,~If MIH is suspected, occlusal images of the occlusal surfaces of the first molars will be taken with the help of a dental mirror,~Shooting with the spectrophotometer centered on each of the teeth of interest in the anterior sector with verification of the good quality of the shot according to the axis (validated in green on the camera),~Backup of images with coded identification number"
46088263|NCT04704089|Other|Biological (protein analysis by western blot or mass spectrometry of matrix proteins), structural (electron microscopy) and physico-chemical analyses|"Chemical analysis of enamel mineral.~Techniques of spectrometry and spectroscopy (Raman and FTIR)~Atomic Probe Tomography and Protein Mass Spectrometry (ICP-MS)."
46088264|NCT01474889|Device|RT-CGM|Each device is approximately the size of a pager and transmits with a subcutaneously placed sensor consisting of a 21 - 26 gauge needle 5 - 12 mm in length. Sensors are placed using sterile precautions and changed every 3 - 7 days depending on the manufacturers' instructions. All devices are approved as adjunctive tools to blood glucose monitoring that will be continued at least 4 times daily, before each meal and at bedtime.
45676192|NCT04546568|Device|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM|"FiO2 adjustments will be made by the IntellO2 Oxygen Assist Module (OAM) for Precision Flow (IntellO2, Vapotherm, USA).~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
46088265|NCT02848859|Behavioral|Go! to Sleep|This is an online interactive program that delivers cognitive behavioral therapy for insomnia via the internet.
46088266|NCT02848859|Behavioral|General Sleep Education|Providing patients information on healthy sleep and habits to promote healthy sleep.
46088267|NCT00619164|Drug|E5555|E5555, 50 mg (tablet), taken orally, once a day.
46088268|NCT00619164|Drug|E5555|E5555, 100 mg (tablet), taken orally, once a day.
46088269|NCT00619164|Drug|E5555|E5555, 200 mg (tablet), taken orally, once a day.
46088270|NCT00619164|Drug|Placebo|Placebo tablet taken orally, once a day.
46088271|NCT02848625|Other|Yoga|Yoga and breathing exercises designed for patients with IPF. Sessions will be two times per week for 12 weeks
46088272|NCT01428089|Drug|Progesterone|Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml) or placebo at 1100, 1500, and 1900 h.
46088273|NCT01428089|Drug|Placebo|Placebo
45457990|NCT05088889|Radiation|Stereotactic body radiation therapy|Three fractions of 8 Gy, treated on alternate days
45457991|NCT05088889|Radiation|Low dose irradiation|a single fraction of 2Gy will be given to the metastatic lesions at first progression
45457992|NCT02309164|Procedure|Acupuncture|10 acupuncture sessions of 30 minutes each, twice a week
45835573|NCT04783038|Other|Distance Reiki|Reiki therapy session performed remotely over a Zoom® video conferencing platform led by Reiki Practitioners who are also Health Care Providers at the Mayo Clinic, and have at least 6 months of experience in Reiki.
45835574|NCT04783038|Other|Sham distance Reiki|Session performed remotely over a Zoom® video conferencing platform led by a Health Care Provider employed at the Mayo Clinic, but will have no experience in Reiki and will not be a certified Reiki Practitioner.
45835575|NCT04783116|Dietary Supplement|Plant stanols (3g/day)|Oral consumption of 6 plant stanol enriched chews per day for 6 months (total dosage is 3g/day). Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
45835576|NCT04783116|Dietary Supplement|Placebo|Oral consumption of 6 placebo chews per day for 6 months. Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
45835577|NCT04782960|Drug|Iocal anaesthetic bupivacaine|Local anaesthetic Subconjunctival bupivacaine
45835578|NCT04782960|Drug|Placebo|0.9 saline
45835579|NCT01075230|Procedure|Total knee arthroplasty|Subject will undergo total knee arthroplasty according to established surgeon / hospital protocol.
45676193|NCT04544917|Behavioral|SmartManage for HIV+ cancer survivors|Ten weekly therapist delivered group sessions delivered via web conference. Sessions focus on cognitive behavioral stress management, psychoeducation, and management strategies for dual diagnosis of HIV and cancer. Participants will have access to the SmartManage web platform which has all intervention material, resources, and exercises.
46088274|NCT01851252|Device|Methacetin (with Breath testing device)|The methacetin is enriched with carbon 13, a stable non- radioactive isotope, and has been found to be safe in hundreds of studies. The material is very similar to acetominophen. 75 milligrams (mm) of this material pre- dissolved in water are used. This material undergoes rapid metabolism by the liver.
46088275|NCT02848547|Behavioral|Text Messaging via Short Message Service|
46088276|NCT00619320|Behavioral|Safer Sex Skills Building (SSB)|Test the effectiveness of an intervention for reducing sexual risk factors for HIV infection in two samples of pregnant drug-using women. The intervention, Safer Sex Skills Building (SSB)(El Bassel and Schilling (1991, 1992)), is a manual-driven, gender-specific group intervention delivered by mental health counselors. To date, its effectiveness has not been examined in pregnant, drug using women. The proposed study will examine the effectiveness of the intervention in both drug treatment (RBHA, N = 200) and prenatal care (PCC, N = 200) settings. Using a randomized clinical trial design, the study will compare the five-session SSB group intervention to a one-session standard group HIV Education session (ED). Study hypotheses: that women in the SSB intervention will have better outcomes (e.g., fewer unprotected penetrative sexual behaviors) than women in the control group (ED).
46088277|NCT04962971|Dietary Supplement|X|exocyan
45676194|NCT04544917|Behavioral|Educational Control|Participants in the control condition will view ten videos over ten weeks, consisting of informational and educational material relevant to cancer and HIV.
46001956|NCT05483231|Behavioral|Routine nursing care group|Routine practice and in-hospital education will be given to the very low birth weight infants and parents. All care measures will be led by the nursing staff, without the participation of parents.
46001957|NCT05468996|Drug|Remimazolam|A loading dose of remimazolam is 1mg/kg/hr. When sedation is achieved, the dose of remimazolam is adjusted to the assigned dose. The maintenance dose of remimazolam begins at 1.0mg/kg/hr. When the maintenance is not successful during the surgery, the maintenance dose will be increased by 0.1-0.2mg/kg/hr in the next patient. When the maintenance is successful, the dose will be decreased by 0.1-0.2mg/kg/hr. (maximal dose: 2mg/kg/hr)
46001958|NCT05431179|Drug|Zilovertamab|After 16 weeks in the open-label Ibrutinib phase, participants will receive zilovertamab (600mg) administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
46001959|NCT05431179|Drug|Ibrutinib|All participants will receive oral Ibrutinib (560mg) daily.
46001960|NCT05431179|Drug|Placebo|After 16 weeks in the open-label Ibrutinib phase, participants will receive placebo administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
46001961|NCT05410301|Device|Static Magnetic and Electric (sBE) device|Home-based Static Magnetic and Electric (sBE) device that is slept in
46088278|NCT04962971|Dietary Supplement|Y|exocyan
46088279|NCT04962971|Dietary Supplement|Z|exocyan
46088280|NCT04212000|Drug|Levoketoconazole|Levoketoconazole tablet
46088281|NCT04212000|Drug|Ketoconazole|Ketoconazole tablet
46088282|NCT01115387|Other|Observational-1|"Multiple questionnaires detailing family history, medical history, visual symptoms, smoking, environmental and dietary exposures.~Prospective photography of the retina to detect early ARM-related changes A saliva or blood sample for genetic testing."
45676195|NCT04544293|Drug|Molgramostim|Molgramostim 300 µg nebulizer solution
45676196|NCT04544293|Drug|Placebo|Matching placebo
45676197|NCT04543357|Other|Blood Draw|Blood Samples for NAb and ADA to AAV9
46001962|NCT05410301|Drug|Lomustine|Chemotherapy drug
46001963|NCT05410301|Drug|Bevacizumab|Chemotherapy and targeted therapy drug
46001964|NCT05409989|Device|FRED™ X™|The FRED™ X™ System is indicated for use in the internal carotid artery from the petrous segment to the terminus for the endovascular treatment.
46001965|NCT05400434|Behavioral|Standard Parent-Child Interaction Therapy (PCIT)|PCIT is an evidence-based behavioral parenting intervention. It is administered as weekly, one-hour sessions with a bilingual PCIT therapist for 18 weeks in one of three PCIT clinics embedded within neighborhood community agencies or virtually.
46088283|NCT01115387|Other|Observational-2|"A limited number of questionnaires and prior clinical documentation from eye care professionals of eye status with respect to ARM.~No prospective retina photographs but ongoing follow-up for reported changes in ARM status.~A saliva or blood sample for genetic testing."
45457993|NCT02309164|Behavioral|Orientation group|medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.
46001966|NCT05400434|Behavioral|Natural Helpers (NH)|Natural helpers are lay people to whom others naturally turn for advice, emotional support, and tangible aid. Families received weekly sessions with a natural helpers in their home or virtually for 30-45 minutes for a maximum of 18 weeks. During sessions, natural helpers work with families to (1) explain parenting principles in a culturally and responsive manner; (2) support them in their skill acquisition; and (3) troubleshoot structural barriers to service and other basic life needs.
46001967|NCT05393037|Biological|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
46001968|NCT05393037|Biological|Placebo|Saline in each 0.5 mL sterile solution
46001969|NCT05393037|Biological|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
45676198|NCT04540302|Device|Merit WRAPSODY Endovascular Stent Graft|Target lesion treated with stent graft placement
46088284|NCT04212234|Device|ultrasound propagation velocities, ultrasound fetal quality|"Obese pregnant women will be included before the second trimester fetal ultrasound examination.~Women will be allocated to one intervention group or to the control group. In the intervention group, the ultrasonographer will be able to use several ultrasound propagation velocities to perform the exam.~In the control group, exam will be performed using the conventional ultrasound velocity.~An exam will be considered to be complete if all the images recommended by national guideline are acquired. If ultrasound images are missing, other ultrasound exams may be performed until completeness is reached.~The protocol will be applied for the second and the third fetal ultrasound examination which are recommended by national guideline.~All scans will be evaluated by two independent experts who do not have performed any of the exams. They will evaluate the completeness of each exam. Each scan will be quoted using the quality score proposed by Salomon et al."
46001970|NCT05393037|Biological|PPSV23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
46088285|NCT04166513|Device|Targeted Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. The current is turned on and increased in a ramplike fashion over approximately 30 seconds until reaching a strength of no more than 2mA, with a current density equal to 0.08mA/cm2. Stimulation will be maintained no longer than 20 minutes, and stimulation will be applied to the targeted region.
46088286|NCT04166513|Device|Active Control Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. The current is turned on and increased in a ramplike fashion over approximately 30 seconds until reaching a strength of no more than 2mA, with a current density equal to 0.08mA/cm2. Stimulation will be maintained no longer than 20 minutes, and stimulation will be applied to the active control region.
46088287|NCT04166513|Behavioral|Phonologic-Focused Speech Therapy|Participants are asked to generate or choose from a list phonologic information about a target picture.
46088288|NCT04166513|Behavioral|Semantic-Focused Speech Therapy|Participants who have difficulty retrieving an object name are given hierarchical clues or asked questions about the objects function as a way of activating the semantic network for that object, leading to eventual retrieval of the target word.
46088289|NCT00619398|Drug|Prograf|Oral
46088290|NCT00619398|Drug|FK506MR capsule|Oral
46088291|NCT04213092|Procedure|ERCP+LC|Patients in this group underwent a single setting ERCP and Laparoscopic cholecystectomy.
45676199|NCT04540302|Device|PTA|Target lesion treated with standard percutaneous transluminal angioplasty (PTA)
45676200|NCT04513548|Drug|Ligelizumab|One injection every four weeks
45676201|NCT04513548|Drug|Placebo|One injection every four weeks
45676202|NCT04502082|Biological|ET140203 autologous T cell product|Autologous T cells transduced with lentivirus encoding an ET140203 expression construct
45676203|NCT04495998|Diagnostic Test|Brief Motor Scale_portuguese version (BMS_pt)|translate, adapt and validate Brief Motor Scale for portuguese population with schizophrenia
46001971|NCT05390450|Device|Ultrasound-Guided Popliteal Plexus Block|Patients in this group will receive Popliteal plexus block. Prior to Popliteal plexus block, the proximal end of the adductor canal will be identified. The transducer will be slid distally along the femoral artery until the artery deviated away from the sartorius muscle in the distal part of the adductor canal towards the adductor hiatus. The nerve block needle will be inserted from the anterolateral end of the transducer and advanced in-plane through the medial vastus muscle. The endpoint of injection will be inside the distal end of the adductor canal close to the adductor hiatus. The injection will be adjacent to the femoral artery, between the medial vastus muscle and the adductor magnus muscle. The Popliteal plexus block will be carried out with 10 mL of local anesthetic mixture, containing 50 mg of bupivacaine and 0.05 mg of epinephrine.
46088292|NCT04213092|Procedure|OC+CBD|Patients in this group underwent a single setting open cholecystectomy and open CBD exploration.
46088293|NCT02848469|Dietary Supplement|1000mg of eicosapentaenoic acid and 1000mg docosahexaenoic acid|
46088294|NCT00620646|Drug|aspirin, clopidogrel|aspirin 100 mg plus clopidogrel 150mg qd
46088295|NCT00620646|Drug|aspirin, clopidogrel, cilostazol|aspirin 100mg qd,clopidogrel 75mg qd plus cilostazol 100mg bid
46001972|NCT05390450|Device|Ultrasound-Guided Fascia Iliaca block|Patients will be placed in a supine position, and the skin will be cleaned aseptically. The inguinal ligament from the anterior superior iliac spine to the pubic tubercle will be drawn on the skin and divided into 3 parts. The injection point was 1 cm caudally from the point where the lateral and middle part of the inguinal ligament met. The skin and deep tissues were infiltrated with 1% lidocaine. A 18G nerve block needle will be inserted into the skin perpendicularly until the first (fascia lata) and second loss of resistance (fascia iliaca) will be felt. Following aspiration to exclude intravascular injection, 40 mL of 0.25% bupivacaine (1-1.5 mg/kg), which will be prepared under aseptic conditions, and then injected. Sensorial block will be evaluated using the pinprick test 20 minutes after injection for areas of the thigh innervated by the femoral, lateral cutaneous and obturator nerves.
46001973|NCT05388487|Drug|HF1K16 /Arm 45 mg/m2|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
46001974|NCT05388487|Drug|HF1K16 /Arm 90 mg/m2|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
45676204|NCT04485494|Diagnostic Test|Biochemical Analysis of Blood Biomarkers|Using established biochemical techniques, the bloods will be probed for specific biomarkers s100B, UCH-L1, GFAP, and BDNF. The techniques include individual ELISA kits for each biomarker mentioned and Luminex multiplate assay which will probe for all biomarkers in one plate. Ultimately, these techniques will be able to measure the level of these biomarkers in the blood relative to the participants baseline reading.
46001975|NCT05388487|Drug|HF1K16 /Arm 120 mg/m2|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
46088296|NCT00898313|Genetic|comparative genomic hybridization|Collection of sputum, blood, urine, and a small amount of lung tissue.
46088297|NCT00898313|Genetic|gene expression microarray analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
46088298|NCT00898313|Genetic|proteomic profiling analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
45835580|NCT04634604|Drug|Bevacizumab|For infants randomized to bevacizumab, the Intravitreous bevacizumab 0.063 mg injection will be given no later than 2 days after the diagnosis of type 1 ROP. The ophthalmologist may choose to give the intravitreous injection in the operating room or at the bedside, with or without anesthesia, after consultation with the attending neonatologist. A binocular indirect ophthalmoscope with an appropriate condensing lens should be available, and the pupils should be dilated.
46001976|NCT05388487|Drug|HF1K16 /Arm 160 mg/m2|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
46001977|NCT05387694|Other|Thrombotic risk assessment|Collection of symptomatic thrombotic events occurring during the 5 days of hospitalization and then by telephone interview at M1 +/- 3 days. Complete echodoppler (proximal and distal) performed at M1 to highlight asymptomatic thrombotic events.
46001978|NCT05377411|Device|tDCS|During tDCS, a weak electrical current is applied to the scalp that penetrates skin, bone, CSF and the meninges to stimulate underlying cortical and subcortical tissue
46001979|NCT05377411|Behavioral|cognitive training|Cognitive Training (CT) will involve up to 10 hours of training over 2-weeks (10 days). CT employs a PositScience BrainHQ suite via its researcher portal. These tasks are web-based and multi-platform (i.e., Windows, Mac). Participants will be randomly assigned to training on 4 tasks focusing on working memory or 4 tasks focusing on attention/speed of processing.
46088299|NCT00898313|Other|biologic sample preservation procedure|Collection of sputum, blood, urine, and a small amount of lung tissue.
46088300|NCT00898313|Procedure|nasal brushing|Using a brush, superficial cells are removed from the nose.
46088301|NCT00898313|Procedure|Blood draw|Venous blood will be collected
46088302|NCT00898313|Procedure|Urine collection|Subjects will be asked to provide a urine specimen.
46088303|NCT00898313|Procedure|sputum sample|Prior to their bronchoscopy, subjects will be asked for a sputum specimen. This is a collection of mucous that you cough up.
46088304|NCT00898313|Procedure|fluorescence bronchoscopy with airway biopsy|A flexible tube attached to a fluorescent light source will be inserted into the subject's mouth or nose to reach the airway. Samples of the lining of the airway will be taken, as well as bronchial secretions and epithelial cell from brushings of the lining of the airway.
45835581|NCT04634604|Procedure|Laser|For infants randomized to laser treatment, it will be given in conjunction with a binocular indirect ophthalmoscope and an appropriate condensing lens, by a study-certified ophthalmologist experienced in the use of this equipment. The treating investigator will be certified as having sufficient experience with laser for ROP, and adequacy of laser treatment will be confirmed by expert review of photographs. Special laser precautions, as mandated by OSHA and facility standards, will be followed.
46088305|NCT00898313|Procedure|fine needle aspiration of the lung|A small needle is inserted into the lung to collect tissue. This procedure will only be performed if the patient's physician orders it.
46088306|NCT00898313|Procedure|thoracentesis|A small needle is inserted into the patient's lung cavity and a small amount of fluid is collected. This procedure will only be performed if the patient's physician orders it.
46001980|NCT05375877|Device|iATROS|"The digital eHealth platform of iATROS in combination with a wearable will be used independently by the subjects of the study. In particular, the reminder function is used to remind patients to record their ECGs, take medication and perform other tasks they may have created themselves, or to use other iATROS functions, such as teleconsultation or remote medical data reporting. Furthermore, the designed training program for atrial fibrillation patients teaches them how to deal with their own disease.~If unhealthy or dangerous vital signs are detected during the use of these medical devices over a longer period of time, the patient receives feedback through the application for medical presentation. This includes the detection of atrial fibrillation recurrences."
46001981|NCT05373966|Other|Delphi Questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in the field of robotic RNU. The Delphi questionnaire will be administered via Welphi.com.~In the first survey, panel members will outline the training program for robotic RNU.~In subsequent surveys, the expert panel will evaluate the modified criteria using a 1 to 5-point Likert scale with space provided for suggested edits and comments. Multiple rounds will be conducted until consensus is reached. After each round of Likert responses, the study team will calculate the agreement and distribution of responses. Likert responses will be dichotomized with positive values indicating agreement and neutral or negative values indicating disagreement.~For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed."
46001982|NCT05369273|Other|intra-articular injection|intra-articular injection
46001983|NCT05369273|Radiation|RMI SCANS|AT 1 MONTHS BEFORE THE INTERVENTION
46001984|NCT05369273|Other|RMI SCANS|AT 1MONTH AFTER THE INTERVENTION
46001985|NCT05369273|Other|RMI SCAN|AT 6 MONTHS AFTER THE INTERVENTION
46001986|NCT05366439|Drug|AT-752|Parallel Assignment
46001987|NCT05366439|Drug|Placebo Comparator|Parallel Assignment
46001988|NCT05365230|Other|On-demand personalized follow-up care|On-demand personalized follow-up care (on demand access to a WBCP nurse and an annual follow-up by telephone.
46001989|NCT05365230|Other|Guideline-based follow-up care (standard of care)|Follow-up care based on current standard of care guidelines.
46001990|NCT05356637|Device|Werewolf Fastseal 6.0|bi-polar hemostatic wand
46001991|NCT05355909|Procedure|Individualized high intensity preoperative fitness training|The individualised training program consists of stamina training, interval training and strength training. The personalised fitness training will be designed based on the FITT-VP (frequency, intensity, time, type, volume, progression) of the American College of Sports Medicine (ACSM) and will contain 6 training session within 2 weeks under supervision of professional sport physicians.
46001992|NCT05348226|Diagnostic Test|Additional Cardiac Magnetic Resonance Scan|Standard of care medical treatment with sacubitril/valsartan (Entresto). Additional Cardiac Magnetic Resonance Imaging (CMR) Scan after 4-6 months of treatment.
46088307|NCT02314026|Device|Suspected NASH BreathID test with 13C-Octanoate|Subject will have breath measured before and after ingestion of solution of 100 mg 13C Octanoate dissolved in 150 cc of water
46088308|NCT02314026|Device|Suspected NASH Breath test with 13C Methacetin|Subject will have breath measured before and after ingestion of solution of 75 mg 13C Methacetin dissolved in 150 cc of water
46088309|NCT00810017|Drug|Etoposide|etoposide 100 mg/m2 daily for 3 days every three weeks for 6 cycles
46088310|NCT00810017|Drug|Trastuzumab|intravenous trastuzumab 8 mg/kg loading dose and then 6 mg/kg every three weeks and then single agent trastuzumab until progression of disease
46088311|NCT04800900|Other|Pharmaceutical intervention|A pharmacist will analyse patient's prescription, identify if there is prescribing omission and inappropriated drug prescribed and when necessary will require to doctors deprescribe or introduce or remove prescribed drugs
46088312|NCT02848391|Other|Environmental|hypobaric flight simulation
46088313|NCT00618150|Behavioral|Patient education|An educational program: Three lessons spaced over 2 weeks.
46088314|NCT00560651|Procedure|CCL (Corneal Cross Linking)|Apply Riboflavin 0.1% in Dextran 500 20% in NaCl solution Illuminate with UV-light of 365 nm wave-length and 3.0 mW/cm² intensity at 5 cm distance
46088315|NCT00620724|Drug|Placebo|Placebo three times daily
46088316|NCT00620724|Drug|Nifedipine|20 mg of slow-release Nifedipine three times daily
46088317|NCT00486239|Behavioral|TLE Arm 1|Behavioral/cognitive testing
46088318|NCT00486239|Behavioral|Emotion Memory Test|Behavioral/cognitive Measure
46088319|NCT00486239|Behavioral|Emotion Memory Testing|Behavioral/cognitive testing
46088320|NCT00486239|Behavioral|Emotion Memory Testing|Behavioral/cognitive testing
46088321|NCT00284310|Procedure|Anamnesis and clinical examination|Anamnesis and clinical examination to follow.
46001993|NCT05339893|Device|In Motion Rehabilitation Robot|Patients will wear the taVNS device on the left ear for the duration of the subsequent phase of the robotic training. During this phase the patient will engage the robotic device with the affected limb and complete the protocol and the stimulation or sham stimulation will occur with every extensor movement.
46001994|NCT05330793|Dietary Supplement|Oral probiotic|an oral probiotic intervention with or without a novel ADP1 toothpaste
46001995|NCT05330793|Dietary Supplement|Placebo|placebo without Oral probiotic or toothpaste
46001996|NCT05321719|Behavioral|Comparison Condition|In this Phase II project, BR2S will be evaluated for efficacy relative to a usual care control. Investigators expect BR2S to improve outcomes on behavioral change, self-efficacy, establishment of a dental home, knowledge, and attitudes in real settings relative to the usual care condition. The outcome measures include a direct clinical dental measure as well as observational measures of parental behavior. The study will also provide important information regarding the various types and combinations of BeReady2Smile product components for dissemination. The long-term goal of the program is to help parents provide the foundation for a lifetime free from preventable oral disease.
46002476|NCT02471924|Other|Trans thoraciq cardiac ultrasonography|Establish a diagnosis power of the ΔITVAo ( aortic velocity peak )measured with cardiac Trans thoraciq ultrasonography after passiv leg rising to predict hypotension after spinal anesthesia for elective caesarean. Every patients participate for 30 minutes (time to perform the echography). Outside echographic evaluation, medical taking of participating patients will be exactly the same than what is done for all elective caesarean section.
46002477|NCT02462460|Device|MRI|
46088322|NCT04809545|Other|Acusticare|Acusticare is an internet connected speaker which delivers an environmental intervention by playing sounds to adjust the soundscape in the room.
46088323|NCT04809545|Other|Treatment as usual|Usual care provided on the Specialized Dementia Unit
46088324|NCT04209426|Device|THA with SYMBOL CUP DMR HA|
45835582|NCT04480242|Drug|Inhaled Corticosteroids (ICs)|Any corticosteroid (beclomethasone, budesonide, ciclesonide, fluticasone propionate, fluticasone furoate, mometasone, and triamcinolone) prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma. The daily dose of ICs prescribed will be translated into beclomethasone equivalent.
46002478|NCT02462460|Behavioral|Optional Screening Questionnaire|
46002479|NCT02339701|Radiation|IMRT|
46002480|NCT02339701|Radiation|SBRT|
46088325|NCT04209426|Device|THA with SYMBOL CUP DM CEM|
46088326|NCT00428675|Other|ACI instrument|Following ethics approval, 17 experts in symptom management assisted with content validation during the pilot phase. In the main study, participants complete the FACT-F, the POMS-Vsf, and the ACI Instrument. A research assistant collected demographic information and assigned an ECOG score.
46088327|NCT00620802|Drug|CGT-2168|(CGT-2168, one capsule each daily)
46088328|NCT00620802|Drug|Plavix|(clopidogrel, 75 mg)
46088329|NCT00620880|Behavioral|Blood sample|
46088330|NCT04706442|Other|Supportive Parenting Application|The Supportive Parenting Application is a theory-based perinatal educational intervention for couples administered through a mobile application. The mobile app consist of knowledge-based content, informational videos and audio, discussion forum, chat groups with peer volunteers, and an experts advice section
46088331|NCT00620958|Behavioral|Individual cognitive behavioral therapy (ICBT)|ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
45835583|NCT04480242|Drug|Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA)|Beclomethasone/formoterol, budesonide/formoterol, fluticasone furoate/vilanterol, fluticasone propionate/formoterol, fluticasone propionate/salmeterol, and mometasone/formoterol. Any of these combinations prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma.
45835584|NCT04480242|Drug|Other treatments|Low-dose oral corticosteroids, long-acting muscarinic antagonist (tiotropium), low-dose macrolides (azithromycin), leukotrienes receptor antagonists (i.e. montelukast), or biologic agents (i.e. omalizumab).
45835585|NCT04480242|Drug|Inhaler device|Pressurized metered-dose inhalers (pMDIs), Breath-actuated pMDIs, Dry powder inhalers (DPIs), Nebulizers, Soft Mist Inhalers.
46001997|NCT05321719|Behavioral|BeReady2Smile video only|"The video will be viewed at the Head Start site after informed consent and T1 questionnaires and plaque assessment. The video will include concrete demonstrations and feature diversity in settings and actors in video content derived from actual peer-based parenting education sessions. Parents' ability to see themselves in the content makes them more likely to engage in discussions about dental health. Supporting these conversations has been identified as an important need. For example, in a recent environmental scan prepared by the Association of State and Territorial Dental Directors the lack of communication strategies was identified as a gap in oral health educational resources. Specifically mentioned was the lack of oral health curricula that support interactive communication between families and home visitors. Families struggle with such dialogues."
46001998|NCT05321719|Behavioral|BeReady2Smile video and BeReady2Smile app completely self-guided|In addition to the BeReady2Smile video as described above, the BeReady2Smile app includes: (a) presentation of concepts, behaviors, and examples via video and text, (b) electronically presented check-in questions recorded to a database for review, (c) capture of a 5-minute video of parent-child interactions uploaded for later review by the parent, using a mobile application, (d) daily dental activities (homework), and (e) program feedback recorded to the database. BeReady2Smile will be designed such that before the parent can go on to a new area of learning, the parent must complete the previous lesson. Participants can go back and review previous material in a non-linear format. The database and log-files record all computer activities to track use of each intervention component.
45676205|NCT04484948|Other|scleroderma health assessment questionnaire (SHAQ), BHT, and 6MWT|"Participants will perform the SHAQ.~BHT and 6MWT will be performed in the randomized way for each participant.~For BHT, the participants will be told to sit comfortably on a chair, and breath normally. After 1 minute, they were required to make a maximum expiration followed by a maximum inspiration and to hold the breath as long as possible at maximum inspiratory level. This procedure was repeated three times, with 5-minute intervals between the tests.~6MWT will be performed according to the ATS guidelines.~Information on CXR, TTE, and PFT (FVC%, DLCO%) will be obtained from the medical record if the data was obtained within 3 months. If not, the tests will be performed.~BHT and PFT will be followed by six months after the first breath-holding test to confirm the responsiveness.~Additional 30 patients with systemic sclerosis will be collected to perform the test-retest reliability of BHT."
46002481|NCT02293954|Procedure|radionuclide imaging|Given copper Cu 64 anti-CEA monoclonal antibody M5A IV
46088332|NCT00620958|Behavioral|Parent relationship training (PRT2) With Individual Cognitive Behavioral Therapy (ICBT)|Parent relationship training will teach the parent ways to communicate with the child and to solve problems to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
46088333|NCT00620958|Behavioral|Parent reinforcement training (PRT1) With Individual Cognitive Behavioral Therapy (ICBT)|Parent reinforcement training will teach the parent strategies for managing the child's behavior through the use of positive rewards and positive parental behaviors to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
46088334|NCT02848157|Drug|Dexmedetomidine|Patients are put in lithotomy position. Two separate injection points are marked at 3 and 9 o'clock, about 2 to 2.5 cm from the center of anus. After aseptic preparation, a nerve stimulator needle advanced 1.5 to 3.5 cm perpendicular to the skin, and stimulation current is 2.5 to 5 mA. The unilateral contraction of anal sphincter means the inferior anal nerve stimulation. After reducing the current to 0.5 mA, the needle is then moved deeper until an up-and-down penile movement is observed. This is stimulation of the perineal branch of the pudendal nerve. Prepared drug (0.25% ropivacaine and 0.3 mcg/kg dexmedetomidine in the experimental group, and equivalent doses of ropivacaine and normal saline in the control group) is injected in half and half bilaterally.
46002482|NCT02293954|Procedure|positron emission tomography|Undergo PET
46002483|NCT02293954|Other|laboratory biomarker analysis|Correlative studies
46088335|NCT02848157|Drug|plain ropivacaine|ropivacaine and normal saline equivalent doses of dexmedetomidine
46088336|NCT02848157|Drug|Ropivacaine|
46088337|NCT04211532|Other|Surgery|Surgical risk is calculated according to the surgery performed.
46088338|NCT04834661|Other|surgery inside the primary institution|to perform laparoscopic surgery for colorectal and gastric cancer inside the primary registered medical institution
46088339|NCT04834661|Other|surgery outside the primary institution|to perform laparoscopic surgery for colorectal and gastric cancer outside the primary registered medical institution
46088340|NCT00619632|Behavioral|Lactation Consultant|Lactation consultant- primary care based, meets with women pre-natally, in the hospital, and at home up to 6 months post-partum.
45676206|NCT04480255|Other|Group 1: Standard of Care|"Those who are in Group 1 will receive the usual care which includes:~a welcome packet from the nursing staff~access to their infant's medical team including doctors and nurse~opportunities to ask any questions and understand the care their baby is receiving through participation in daily work rounds or through setting up family meetings with the medical team."
46002484|NCT02293954|Other|pharmacological study|Correlative studies
46002485|NCT02293954|Drug|Cu 64 anti-CEA monoclonal antibody M5A IV|Cu 64 anti-CEA monoclonal antibody M5A IV
46002486|NCT02259621|Drug|Nivolumab|Anti-PD-1 Therapy
46088341|NCT00619632|Behavioral|Provider Prompt|Prompt in electronic prenatal record will appear 5 times throughout pregnancy re: up to 10 open-ended discussion points for provider to raise
46088342|NCT00619632|Behavioral|LC+ Provider Prompt|Participants in this group receive both the LC and Provider Prompt interventions.
46088343|NCT04211844|Drug|sofosbuvir plus daclatasvir|50 patients in the first group will receive 400 mg sofosbuvir plus daclatasvir 60 mg once daily for 12 weeks.
46088344|NCT04211844|Drug|Sofosbuvir plus Ledipasvir|50 patients in the second group will receive 400 mg sofosbuvir plus ledipasvir 90 mg (Harvoni) once daily for 12 weeks.
46088345|NCT04211454|Other|No intervention|There is no intervention for this study.
46088346|NCT02847923|Other|Presentation of alternative communication application|At this stage the purpose of the application is submitted, what its purpose and its features in a brief and clear manner.
46001999|NCT05321719|Behavioral|"Complete BeReady2Smile video and BeReady2Smile app guided by a Coach"|"In addition to the BeReady2Smile video and BeReady2Smile app described above, the complete intervention includes support via phone and text from a trained facilitator/coach who builds supportive one-on-one relationships with the parent and gives feedback on parent-recorded videos of parent-child interactions of tooth-brushing, designed to facilitate learning and promote engagement with their oral health professional; and tools to create a long-term follow-up plan. Dental behaviors will be tailored for children's developmental level (e.g. twice daily tooth brushing for preschoolers and limiting sugar sweetened beverages or milk in bottles at bed for infants)."
46002000|NCT05319925|Other|Patient reported outcome measure|Newly developed patient-reported instrument to measure financial effects of a cancer diagnosis and therapy of cancer patients in Germany
46088347|NCT02847923|Other|Familiarization with the software interface|At this stage, the volunteer will be asked to use the application by himself for a short time so that he can get acquainted and learn to use it
46002001|NCT05306977|Device|Open-label accelerated 1 Hz repetitive transcranial magnetic stimulation|Patients will receive a 5-day course of accelerated 1 Hz rTMS (8x session x 600 pulses/session) to the right intraparietal sulcus. Subjects will receive a continuous train of 1 Hz stimulation. They will receive a total of 600 pulses per train. Trains will be separated by ~50 min rest intervals.
46002002|NCT05306197|Behavioral|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention toward threat stimuli.
46002003|NCT05306197|Behavioral|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention toward threat stimuli using threat and neutral face stimuli.
46088348|NCT02847923|Other|Test of the software|"Then, the volunteer is instructed to use the application following a script task that will expose a simple and fast way all the application features. These tasks have easy actions to be executed, for example: The user must communicate through the application the phrase I want to drink water, so that he will be instructed to perform the actions to select the option and then drink the water option."
46088349|NCT02847923|Other|Answer the questionnaire|After performing all the tasks the user replies to a questionnaire to evaluate the usability of the application after you use.
46088350|NCT01776762|Dietary Supplement|Individual nutritional therapy|Individual nutritional therapy provided by registered dietician by means of three Home-visits
46088351|NCT05008835|Drug|ACP-044 Dose A|Oral dose of ACP-044 Dose A
46002004|NCT05306197|Behavioral|Non-Contingent Feedback Training|Participants listen to a musical track they chose with no operant conditioning.
46002005|NCT05297578|Biological|24-Valent Pneumococcal Conjugate Vaccine|0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
46002006|NCT05297578|Biological|Pneumococcal 20-valent Conjugate Vaccine|0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1
46002007|NCT05293249|Combination Product|dMAb AZD5396|Participants will receive one injection of dMAb AZD5396 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.
46002008|NCT05293249|Combination Product|dMAb AZD8076|Participants will receive one injection of dMAb AZD8076 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.
46002487|NCT02259621|Drug|Carboplatin|Anti-PD-1 Therapy
46088352|NCT05008835|Drug|ACP-044 Dose B|Oral dose of ACP-044 Dose B
46088353|NCT05008835|Drug|Placebo|Placebo
46088354|NCT00619710|Drug|Meropenem|Intravenous
45676207|NCT04480255|Other|Group 2: NICU2HOME+ app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 2 parents will be asked to download the NICU2HOME app.
46002488|NCT02259621|Drug|Paclitaxel|Anti-PD-1 Therapy
46088355|NCT00619710|Drug|Imipenem-cilastatin|Intravenous
46088356|NCT04211688|Behavioral|Group Schema therapy|Bimonthly outpatient psychotherapy delivered in individual setting
46088357|NCT04211688|Behavioral|Individual Schema therapy|weekly outpatient psychotherapy delivered in group setting
46088358|NCT04211376|Other|No Intervention|There is no intervention for this study
46088359|NCT02847377|Other|Injection of [18F]-ODS2004436 radiotracer|
45676208|NCT04478266|Drug|Amcenestrant-matching placebo|Pharmaceutical form: Tablets Route of Administration: Oral
46088360|NCT04212858|Genetic|zinc-finger protein 217 gene|search for zinc-finger protein 217 gene in myeloma patients
46088361|NCT03929627|Other|Cortisol awakening response|Cortisol awakening response
46088362|NCT00619788|Device|4.0-5.0mm AngioSculpt Scoring Balloon Catheter|The AngioSculpt Scoring Balloon Catheter is a line of innovative angioplasty catheters comprising an angioplasty balloon surrounded by a unique system of nitinol scoring elements. Creating focal concentrations of dilating force, the scoring elements score arterial lesions as the balloon expands.
46088363|NCT02847611|Device|Dynamometer LABIN|LABIN is a prototype of dynamometer containing a handle of metal strength, connected with a sensor of pressure registering(recording) the applied strength and transmitting the data in a computer showing an IT curve of the strength according to time.
46088364|NCT02847767|Procedure|Perfusion Imaging|IV contrast perfusion CT will be performed at baseline and at 1 week after completing treatment. Perfusion imaging is similar to a diagnostic CT except a smaller region is serially imaged post contrast injection with multiple data acquisitions and high temporal resolution
46088365|NCT04019015|Drug|Prothrombin Complex Concentrate, Human|Prothrombin Complex Concentrate (PCC) prepared from human plasma and contains blood coagulation factors
46088366|NCT04019015|Drug|Placebo|Normal saline solution
46088367|NCT02847845|Dietary Supplement|red ginseng powder capsule|usage : 3C bid ac 30min dose : total 3g for 1day drug administration : oral administration administration session : 6weeks
46088368|NCT02847845|Dietary Supplement|Placebo|Control (Placebo) : red ginseng powder capsule(placebo) usage : 3C bid ac 30min dose : total 3g for 1day drug administration : oral administration administration session : 6weeks
46088369|NCT02846909|Drug|Progesterone|400mg progesterone pessaries
46088370|NCT02847533|Procedure|blood sample|blood sample for concentration levels of inflammatory markers
46088371|NCT02847533|Behavioral|psychometric scales|Mini international interview MADRS, C-SSRS, QIDS-SR, BIS-10, BDHI, BART, ERD
46088372|NCT02847299|Device|"increase of cough peak flow (Astral ventilator)"|instrumental increase of cough peak flow with a ventilator by hyper-insufflation and with air stacking method
46002009|NCT05293249|Combination Product|Electroporation device|The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.
46002010|NCT05293249|Drug|Hylenex|Hylenex® recombinant will be used for dMAb AZD5396 and dMAb AZD8076 dose preparation at the clinical site.
46002011|NCT05293249|Drug|Methylprednisolone|Participants in cohort D, after completing the administration of the dMAb AZD5396 and dMAb AZD8076, will receive in addition a single injection of 120 mg of methylprednisolone
46002012|NCT05267496|Device|oscillating positive expiratory pressure device|Patients randomized to the experimental arm of the study will receive an AEROBIKA oscillating positive expiratory pressure device in addition to the standard pulmonary rehabilitation program. The patient will receive instructions pertaining to the use of the device during the first evaluation visit to the rehabilitation service and this information will be reinforced at each follow-up visit. The patient will receive a log book in order to record date and time of use to assess treatment compliance and an instructions and maintenance booklet will be handed out to ensure adequate use of the device.
46088373|NCT00632723|Drug|gefitinib (IRESSA™, ZD1839)|250 mg tablet; daily dose 500 mg daily
46088374|NCT02847143|Drug|nasal oxytocin or placebo|nasal administration of oxytocin or palcebo 45 min befor fMRI session
46002013|NCT05267496|Procedure|Pulmonary rehabilitation|"Educational ventilatory techniques will be explained in order to re-educate respiratory muscles and increase patient awareness regarding the importance of complying with the exercise schedule to improve muscular strength. Including:~Pre-surgical rehabilitation~Directed ventilation~Physical conditioning Post-surgical rehabilitation~Diaphragmatic mobilization~Thoracic expansion through incentive flow spirometry"
46002014|NCT05265715|Other|Low AGE diet|"The recommended daily AGE intake will be either:~7,500 kilounits [ku], which is a 50% reduction from the average 15,000 ku consumed by most adults or~a 50% reduction from their baseline AGE intake (based on 3-day food AGE record)"
46002015|NCT05265715|Procedure|Research blood draw|Baseline (Week 0), Week 4, Week 12, and Week 24 (end of intervention)
46002016|NCT05265611|Behavioral|low intensity psychosocial intervention - Problem Management Plus (PM+)|Syrian refugee young adults will be trained to implement Problem Management Plus (PM+). PM+ is a low-intensity mental health intervention, developed by WHO, and delivered by non-specialized CMHW. It is a transdiagnostic treatment approach that includes four evidence-based problem solving and behavioral treatment techniques: managing stress, managing problems, get going/get doing, and social support. These strategies are implemented over five weekly sessions, of 90 minutes each.
46088375|NCT02847143|Device|fMRI|FMRI during emotional image visualization
46002017|NCT05265611|Behavioral|Tutoring|Young adults will be trained to tutor students in elementary school.
46088376|NCT02847143|Behavioral|Attachement scale interview (ASI)|this scale is used to determine the attachement style of each participant
46088377|NCT02847143|Behavioral|psychometric scales|self adminstrated questionnaires which asses the level of anxiety (Spielberger State-trait anxiety interview-STAI), depression (Beck depression inventory-BDI) and alexithymia (Toronta Alexuthymia scale-TAS 20)
46088378|NCT02847455|Drug|5 mg ilaprazole|One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each
46088379|NCT02847455|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
46088380|NCT02847455|Drug|10 mg Rabeprazole|one 10-mg Rabeprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
46088381|NCT03897335|Drug|Aminophylline|Aminophylline pre cardiopulmonary bypass and immediately post cardiopulmonary bypass. The dose will be Aminophylline 5 mg/kg/dose, max 350 mg slow infusion. The infusion rate duration will be standardized to 20 minutes. There will be no other aminophylline treatments for the first post-op five days.
46088382|NCT03897335|Drug|Placebo|The placebo group will not receive any aminophylline treatments for the first post-op five days
46088383|NCT01617096|Combination Product|Dapivirine Vaginal Ring|Dosage form: vaginal ring Dosage: 25mg Frequency: monthly Duration: 12 months
46088384|NCT01617096|Combination Product|Placebo Ring|Vaginal ring containing no drug substance
46088385|NCT00619944|Drug|Lumefantrine - lopinavir/ritonavir drug interaction|Lumefantrine 480 mg co-formulated with artemether 80 mg administered as single dose to HIV-positive adults receiving lopinavir/ritonavir 400 mg/100 mg twice daily
46088386|NCT00619944|Drug|Lumefantrine only arm|Lumefantrine 480 mg co-formulated with artemether 80 mg administered as a single dose to antiretroviral naive HIV-positive patients
45457994|NCT03508492|Other|Surgical tinted Chloraprep® applicators|We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.
45676209|NCT04478266|Drug|SAR439859|Pharmaceutical form: Tablets Route of Administration: Oral
46088387|NCT02846597|Procedure|Sustained lung inflation in preterms (SLI).|Providing a positive pulmonary ventilation with an opening lung pressure for the first breath of preterm infant for a sustained period of time
46088388|NCT01606488|Drug|Florbetapir F 18 (18F-AV-45)|Single IV bolus injection of 370 MBq (10mCi) florbetapir will be administered approximately 50 minutes prior to a 10 minute PET scan.
46088389|NCT01606488|Other|no intervention|
46088390|NCT04681092|Biological|AKS-452|s.c. or i.m. vaccination
46088391|NCT02846675|Biological|autologous SVF|SVF will be obtained from lipoaspirates of subjects which will contain more than 5 millions nucleated cells.
46088392|NCT02846675|Biological|Placebo|a Placebo treatment without SVF cells
46088393|NCT00621036|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
46088394|NCT00621036|Biological|sargramostim|
46088395|NCT00621036|Drug|methotrexate|
46088396|NCT00621036|Drug|thiotepa|
46088397|NCT00621036|Radiation|radiation therapy|
45676210|NCT04478266|Drug|Palbociclib|Pharmaceutical form: Capsules/Tablets Route of Administration: Oral
46002018|NCT05260944|Device|Acapella device|patients will receive a two supervised sessions using acapella device three sets for 10 repetitions from the first day postoperative until 7 days, in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, percussion and vibration.
46002019|NCT05260944|Device|Power lung device|Group B. patients will receive a two supervised sessions using power lung device three sets for 10 repetitions from the first day postoperative until 7 days, in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, percussion and vibration.
46002020|NCT05260944|Other|routine Physical Therapy program|Group C. Thirty patients will receive only routine physical Therapy program
46002021|NCT05260112|Other|ERICA|"Over 6 weeks, participants receive evidence-based video learning modules twice a week via a secure and HIPAA-compliant text messaging platform. These modules include: patient education on interstitial cystitis, bladder training, trial of an elimination diet, pelvic floor physical therapy including at-home myofascial trigger point release, guided mindfulness practice, and cognitive behavioral therapy for chronic pain.~At the end of each week, participants receive a check-in message. They also have the opportunity to text questions and concerns, which will be answered using an algorithm-based, clinically validated responses."
46002022|NCT05256836|Other|Tablet computer-based cognitive training program|"The subject of the study executes a program mounted on a tablet personal computer (PC) (Samsung Galaxy Tab S6 Lite) and performs a cognitive training task by touching the screen with the index finger.~It consists of 10 tasks related to the activity of daily living: 1) taking medicine, 2) making a phone call, 3) taking a shower, 4) doing laundry, 5) finding directions, 6) riding the bus, 7) buying goods, 8) Money management, 9) ingredient sorting, 10) meal preparation.~It is involved in cognitive functions in various domains such as attention, working memory, processing speed, problem solving, visuospatial ability, verbal and visuospatial memory.~There are three levels of difficulty for each task, high, medium, and low, and the difficulty becomes more difficult as session 1 to 36 progresses.~One cognitive training session lasts about 30 minutes."
46088398|NCT02846831|Other|12-day intervention with sensor-augmented pump therapy|"A sensor will be inserted on the day before the start of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 12 days.~Participants will have been previously shown how to use the study insulin pump."
46088399|NCT02846831|Other|12-day intervention with single-hormone closed-loop strategy|"A sensor will be inserted on the day before the start of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 12 days."
46002023|NCT05251285|Procedure|Nipple-Sparing Mastectomy|Nipple-Sparing Mastectomy using da Vinci X/Xi Surgical System
46088400|NCT02846831|Device|Insulin pump|Tandem Diabetes Care
46088401|NCT02846831|Device|Continuous glucose monitoring system|Dexcom G5 Platinum
46088402|NCT02846831|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
46088403|NCT00621114|Device|GamCath® central venous catheter|Choice of central venous catheter type
46088404|NCT00621114|Device|GamCath Dolphin® Protect central venous catheter|Choice of central venous catheter type
46088405|NCT04647240|Biological|Dermacyte® Liquid (human amniotic fluid)|Subcutaneous injection into and/or around wound bed weekly
46002024|NCT05217004|Other|Dementia Talk mobile application|The app includes features for caregivers such as medication management, behavior symptom management and monitoring, stress management tips and strategies, and task management with other care providers.
46002025|NCT05217004|Other|CLEAR Dementia Care mobile application|The app provides information about dementia (e.g., types and symptoms of dementia) and allows caregivers to record, monitor, and chart behaviors in the care recipient.
46002026|NCT05206487|Dietary Supplement|Polydextrose|PDX will be started 2 weeks before TIPS and taken daily for a 6 month period after TIPS.
46002027|NCT05203497|Drug|SPECT|One single injection of 99mTc-ZHER2:41071, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
46002028|NCT05181709|Drug|Sodium Chloride|Administered intranasal (IN) and intramuscular (IM) in combination
46002029|NCT05181709|Biological|NDV-HXP-S IN low dose|"Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x108^8 EID50."
46002030|NCT05181709|Biological|NDV-HXP-S IM low dose|"Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x10^8 EID50."
46002031|NCT05181709|Biological|NDV-HXP-S IN high dose|Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10^9 EID50.
46002032|NCT05181709|Biological|NDV-HXP-S IM high dose|Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10^9 EID50.
46002033|NCT05180474|Biological|GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive cells.|GEN1047 will be administered as an intravenous infusion. The dose-levels will be determined by the starting dose and the escalation steps taken in the trial.
46088406|NCT01497509|Drug|Bolus 10mL 0.25% bupivacaine/ep 1:600,000; infusion 10mL/hour 0.25% bupivacaine and epi 1:800,000|
46088407|NCT01497509|Drug|Bolus 10mL 0.25% bupivacaine/ epinephrine 1:600,000;infusion 10mL/hour 0.25% bupivacaine, 2 mcg/mL fentanyl, and epinephrine 1:800,000|
46088408|NCT01497509|Drug|Bolus 10mL 0.25% bupivacaine, 10mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 2.5 mcg/mL fentanyl, and epi 1:800,000|
46088409|NCT01497509|Drug|Bolus 10mL 0.25% bupivacaine, 5 mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 3.5 mcg/mL fentanyl, and epi 1:800,000|
46088410|NCT04326335|Other|Felt-tip marking|Marking the location of the future stoma with a felt pen
46088411|NCT04326335|Other|Felt-tip marking + 3D printed ostomy button|Marking the location of the future stoma with a felt pen + 3D printed ostomy button placed on the future stoma location
46088412|NCT02844881|Drug|Apatinib|Apatinib 850 mg p.o. qd every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
46088413|NCT02844881|Biological|MASCT|Dendritic cells(DC) loaded with 17 antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
46002034|NCT05173831|Drug|MDMA|Initial dose of 120 mg MDMA HCL and optional supplemental dose of 60 mg MDMA HCL at 1.5 to 2 hours after first dose
46002035|NCT05173831|Behavioral|Therapy|Standardized non-directive psychotherapy performed by therapist team
46088414|NCT04212936|Procedure|Intraabdominal pressure|Limited intraabdominal pressure during laparoscopic cholecystectomy between 8 and 10 mmHg.
46002036|NCT05172934|Drug|intra-arterial tenecteplase|intra-arterial drug administered after mechanical thrombectomy
46002037|NCT05171816|Drug|olaparib|300 mg (2 x 150 milligrams (mg) tablets) twice daily
46002038|NCT05171816|Drug|abiraterone acetate|1000 milligrams (mg) once daily
46002039|NCT05166980|Dietary Supplement|Mutiply-fortified salt|Salt fortified with iron, zinc, vitamin B12, folic acid, and iodine
46088415|NCT04612608|Procedure|upright bed|moving the bed into an upright position
46002040|NCT05166980|Dietary Supplement|Iodized salt|Salt fortified with iodine
46088416|NCT00621270|Drug|BCI-540|BCI-540 80 mg once (q.d.) or three times (t.i.d.) a day versus placebo
46088417|NCT02846519|Drug|Esketamine|100-mcL spray of 14% esketamine solution (14 mg) for a total dose of 56 mg.
46088418|NCT02846519|Drug|Rifampin|2 capsules (300 mg each) of rifampin.
45676211|NCT04478266|Drug|Letrozole|Pharmaceutical form: Tablets Route of Administration: Orally
45676212|NCT04478266|Drug|Goserelin|Pharmaceutical form: Depot Injection Route of Administration: Subcutaneous
45676213|NCT04478266|Drug|Letrozole-matching placebo|Pharmaceutical form: Tablets Route of Administration: Orally
45676214|NCT04469231|Device|Anterior Cervical Discectomy & Fusion|ACDF
45676215|NCT04463771|Drug|retifanlimab|INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to 26 cycles.
45676216|NCT04463771|Drug|epacadostat|epacadostat will be administered orally BID.
45676217|NCT04463771|Drug|pemigatinib|pemigatinib will be administered orally QD.
45676218|NCT04463771|Drug|INCAGN02385|INCAGN2385 will be administered every 2 weeks
46088419|NCT00618228|Drug|Balsalazide|
46088420|NCT03711305|Drug|SHR-1316|SHR-1316 intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6) and maintenance phase.
46088421|NCT03711305|Drug|Carboplatin|Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
46002041|NCT05166460|Device|Kidney cooling device|renal cooling device designed to maintain renal hypothermia at or below 5ºC for 60 minutes.
46002042|NCT05139680|Drug|tafamidis|80 or 61 milligrams (mg)
46002043|NCT05129631|Behavioral|HEARTPrep|HEARTPrep is a virtually-delivered psychosocial intervention for mothers expecting a baby with CHD.
46002044|NCT05126966|Drug|Ranibizumab|Ranibizumab will be administered at a dose of 100 mg/mL delivered via the PDS.
46002045|NCT05126966|Drug|Aflibercept|Aflibercept will be administered at a dose of 2 mg in the study eye per treat-and-extend. The decision to extend, maintain, or reduce the interval until next treatment will be per investigator judgment
46088422|NCT03711305|Drug|Etoposide|Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
46088423|NCT03711305|Drug|Placebo|Placebo intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6) and maintenance phase.
46088424|NCT04605822|Device|3D imaging Total Body Photography Vectra® WB360|3D Total Body Photography Vectra® WB360 (Canfield Scientific, Parsippany, New Jersey, USA) and its digital dermoscopic camera (VISIOMED® D200evo dermatoscope) and scoring of pigmented skin lesions. All participants of this study will undergo 3D TBP at baseline and the follow-up visits up to month 24.
46088425|NCT04605822|Device|2D imaging FotoFinder ATBM® Master imaging system|2D imaging with FotoFinder® Mole Analyzer and scoring of pigmented skin lesions. All participants of this study will undergo 2D imaging FotoFinder ATBM® Master imaging system at baseline and the follow-up visits up to month 24.
45676219|NCT04463771|Drug|INCAGN02390|INCAGN2390 will be administered every 2 weeks
45676220|NCT04448951|Other|transcriptomics|transcriptomics
45676221|NCT04448951|Other|flow-cytometry|peripheral blood myeloid cells and lymphocytes flow-cytometry
45676222|NCT04448951|Other|cytokines|peripheral blood cytokine analysis
45676223|NCT04448080|Device|Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT)|Intraocular pressure will be lowered by Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT) in patients with a diagnosis of glaucoma
46002046|NCT05126966|Device|Port Delivery System with ranibizumab (PDS)|PDS is an investigation intraocular drug delivery device designed to continuously deliver anti-VEGF therapy.
46002047|NCT05126784|Biological|Denosumab|AVT03 (denosumab) or Prolia (denosumab) will be given as 1 time subcutaneous injection)
46002048|NCT05126459|Combination Product|Regimen 1|Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5- 2mg/kg) + Meperidine (1.5 -2 mg/kg) + Midazolam (0.5- 0.75 mg/kg) In combination with oral drugs stated above, administeration via inhalation of Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
46002049|NCT05126459|Combination Product|Regimen #2|Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5 - 2mg/kg) + Meperidine (1.5 -2 mg/kg). Administer Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
46088426|NCT04605822|Device|Smartphone application (SkinVision®)|Smartphone application for all dermatoscopically documented pigmented skin lesions in all study participations and record of risk assessment of the health application (low, medium or high risk) to compare the app's accuracy in risk assessment with the AI tools and the dermatologist. The SkinVision® smartphone app is CE certified.of skin lesions. All participants of this study will undergo Smartphone application (SkinVision®) at baseline and the follow-up visits up to month 12.
46088427|NCT04605822|Other|Standard-of-care clinical assessment of the skin|Clinical skin examination with dermatoscope by an experienced dermatologist and risk assessment of pigmented lesions (melanoma vs. naevus). All participants of this study will undergo Standard-of-care clinical assessment of the skin at baseline and the follow-up visits up to month 24.
46002050|NCT05126459|Combination Product|Regimen #3|Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5 - 2mg/kg) + Midazolam (0.5- 0.75 mg/kg). Administer Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
46002051|NCT05110495|Drug|Xentuzumab|The study IMP is xentuzumab, a humanised IgG1 monoclonal antibody that neutralises the IGF ligands to inhibit activation of IGF-1R and INSR-A, suppressing IGF-mediated proliferation, invasion and therapy resistance
46002052|NCT05108883|Device|MR-proADM KRYPTOR|MR-proADM ≤ 0.87 nmol/L together with routine clinical evaluation identifies patients with low disease severity who do not need to be hospitalized
46002053|NCT05102981|Procedure|emergency procedure|The difference between groups is the timing or type ie emergency as opposed to planned
46088428|NCT01210781|Procedure|deep brain stimulation (DBS)|deep brain stimulation (DBS) is in itself not part of this study but a clinical indication. The study aims at documenting DBS parameters and outcome
46088429|NCT01433016|Drug|13C Sodium Octanoate|13C labeled Sodium Octanoate Substrate is provided in powder form in doses of 100mg for single breath test, and is dissolved in 150cc of tap water before ingestion. Duration of the observation after the drug ingestion is one hour.
46088430|NCT00618384|Drug|Sorafenib|patients get transarterial chemoembolization (TACE) will get film-coated tablets of Sorafenib (2 x 400 mg/day) until progressive disease
45676224|NCT04421040|Device|Biotronic 3 implant of device|The Biotronic 3 device will be implanted by the research team physician.
45676225|NCT04421040|Device|Biotonic 3 explant of device|The Biotronic 3 device will be removed from the patient by the research team physician.
45676226|NCT04413201|Drug|Afatinib|Afatinib followed by osimertinib or ICT
45676227|NCT04413201|Drug|Osimertinib|Osimertinib followed by ICT
45676228|NCT04411251|Behavioral|Nature-near integrative day care unit programme|Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
46002054|NCT05094011|Biological|Aadipose-Derived Mesenchymal Stem Cells|Stereotactic intrastriatal implantation of 3×10^7 per hemisphere (total 6×10^7 cells) or 1×10^8 per hemisphere (total 2×10^8 cells) autologous TM01-treated adipose-derived mesenchymal stem cells (MitoCell).
46002055|NCT05086276|Drug|FX-322|Active Comparator
46002056|NCT05086276|Drug|Placebo|Placebo
46002057|NCT05065294|Drug|Psilocybin therapy|- Psilocybin administration session 10mg-25mg delivered orally with psychological support and monitoring
46002058|NCT05058287|Drug|Depo-Medrol 40Mg/Ml Suspension for Injection|40mg Depo-Medrol mixed with hemostatic matrix
46002059|NCT05058287|Drug|Placebo|1 mL of sterile normal saline mixed with hemostatic matrix
46088431|NCT03608657|Drug|Apremilast|Apremilast
46088432|NCT05000658|Drug|Dexamethasone phosphate|HSC injection of 4mL
46088433|NCT02844803|Drug|Combination of Metformin + S. Baicalensis|the combination therapy for 8 weeks
46088434|NCT02844803|Drug|Combination of Metformin + Placebo|the metformin single therapy for 8 weeks
45676229|NCT04411251|Behavioral|Conventional integrative day care unit programme|Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
45676230|NCT04373460|Biological|SARS-CoV-2 convalescent plasma|SARS-CoV-2 convalescent plasma (1 cup; minimum of 175 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320 and after July 2021 meets FDA criteria for high titer plasma.
45676231|NCT04373460|Biological|Plasma from a volunteer donor|Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.
45676232|NCT04302272|Device|Spiration Valve System (SVS)|Spiration Valves are one-way endobronchial valves indicated for adult patients with shortness of breath and hyperinflation associated with severe emphysema in regions of the lung that have evidence of low collateral ventilation. The Spiration Valve is loaded in the deployment catheter, then passed through the channel of a flexible bronchoscope and deployed at the intended target location. The SVS device is designed to relieve the symptoms of shortness of breath and hyperinflation associated with severe emphysema without surgery.
46002060|NCT05035225|Other|Survey|Multiple Pharmacy Use Survey
46002061|NCT05028179|Diagnostic Test|EchoGo|EchoGo Pro is an software Medical Device which is able to assess Stress Echocardiograms and provide a binary classification of risk of CAD
45676233|NCT04298658|Diagnostic Test|Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised|Structured Clinical Interview For DSM-5 Sleep Disorders-Revised (SCISD-R) - is a semi structured interview for diagnosing sleep disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)
45676234|NCT04298658|Diagnostic Test|Resmed ApneaLink Air device (Resmed, San Diego, CA).|Home Sleep Test (HST) will measure airflow (i.e., nasal pressure) using a nasal cannula and oxygen saturation to identify apnea and hypopnea and calculate an apnea hypopnea index (AHI; number of apnea and hypopnea per hour).
45676235|NCT04298658|Other|Quantitative Sensory testing (QST)|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
45676236|NCT04298658|Diagnostic Test|OraQuick Advance Rapid HIV 1/2 Swab test|Participants who have an HIV negative status will complete the OraQuick Advance Rapid HIV 1/2 Swab test to confirm negative status.
46002062|NCT05023135|Device|DeepView SnapShot Portable (DV-SSP)|DV-SSP assistive imaging to collect observational data
46002063|NCT05016375|Other|Interview|Interview with individuals with T2DM
46002064|NCT04990609|Device|Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA)|Endoscopic Ultrasound (EUS)-guided Radiofrequency Ablation (RFA) consists of the application of alternating current with a frequency of 350-500 kilohertz (kHz) to the target tissue via a special electrode located at the tip of an echoendoscope. The alternating current causes the vibratory movement of ionic particles in the abutting and adjoining tissue and results in the generation of heat. However, RFA induces not only local disruption of the tumor by heat, but it also produces localized coagulation necrosis of the tumor which induces the release of large amounts of cellular debris which represent a source of tumor antigens that can trigger a host adaptive immune response against the tumor.
46002065|NCT04990609|Drug|Neoadjuvant chemotherapy (NAC)|The NAC regimen will be determined clinically by the participant's physician [possible regimens are either mFOLFIRINOX or Gemcitabine Nab-Paclitaxel +/- Cisplatin (GemAbraxane)].
45676237|NCT04298658|Diagnostic Test|Cluster of Differentiation 4 (CD4) and Viral load|Participants who have an HIV positive status will have blood tested for cluster of differentiation 4 (CD4) and Viral load to confirm positive status.
45676238|NCT04280081|Drug|Selpercatinib|Administered orally
46002066|NCT04968899|Drug|Neofordex®|Oral dexamethasone (Neofordex®) 40 mg (Day1 to Day 4), ± an additional 4-days cycle of dexamethasone between days 10 and 21.
46002067|NCT04968899|Drug|Intravenous immunoglobulins|IVIg (1g/kg D1-D2) plus oral prednisone (1 mg/kg/day x 21 days (3 weeks))
46002068|NCT04965818|Drug|Futibatinib and Binimetinib|Patients will receive futibatinib once daily in combination with binimetinib twice daily by oral administration on a 21-day cycle
46002069|NCT04963205|Device|Adjustable bed backrest|The adjustable bed backrest facilitates for the individual high lying with a fowler (90 degrees raised head and trunk) and/or semi fowler position (30-45 degrees raised head and trunk) which enables patient's lung expansion. The diaphragm is pulled downwards by the gravity allowing for lung expansion and improved ventilation. In addition, the upper airways are stretched in order to prevent upper airway narrowing during sleep (flow limitation, snoring, obstructive sleep apnea). The position relaxes the tension of the abdominal muscles, allowing for improved breathing. Patients can define their own most comfortable position during the night. Elevated body position over 30 degrees from supine position is a requirement for the intervention group. No sleeping time restrictions will be applied. One week washout period between the interventions will be used.
46002070|NCT04963205|Other|Standard bed|Sleeping in a standard bed, in a position below 30 degrees from supine position. No sleeping time restrictions will be applied. One week washout period between the interventions will be used.
45676239|NCT04267939|Drug|Elimusertib (BAY1895344)|Elimusertib will be administered in 28-day cycles.
45676240|NCT04267939|Drug|Niraparib|Niraparib will be administered in 28-day cycles.
45676241|NCT04265261|Drug|Placebo|Participants will receive oral placebo matched to RG7774
45676242|NCT04265261|Drug|RG7774|Participants will receive oral RG7774
46002071|NCT04957693|Behavioral|vegan diet and lifestyle changes|vegan diet and lifestyle changes
46002072|NCT04952597|Drug|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous injection.
46002073|NCT04952597|Drug|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous injection.
46002074|NCT04952597|Drug|Concurrent Chemoradiotherapy|Cisplatin / Carboplatin and Etoposide, intravenous therapy Radiotherapy
46002075|NCT04943224|Drug|Trametinib|< 6 lat 0,032mg/kg, ≥ 6 lat 0,025mg/kg,
46002076|NCT04943211|Drug|fluorodeoxyglucose (18F-FDG)|max 6 MGBq/kg, no more than 100
46002077|NCT04943198|Drug|Vemurafenib|20 mg/kg/day
46002078|NCT04941105|Drug|Evolocumab|A single subcutaneous administration of 140 mg evolocumab
46002079|NCT04941105|Drug|Saline solution|A single subcutaneous injection of 1ml of 0,9% saline solution
46002080|NCT04933695|Drug|Sotorasib|Oral tablet
46002081|NCT04925687|Biological|Intravitreal autologous CD34+ cells|Autologous CD34+ cells harvested from bone marrow injected intravitreal
46088435|NCT04211298|Drug|Dexmedetomidine|Dexmedetomidine will be used for sedation during bronchoscopy
46088436|NCT04211298|Drug|Propofol|Propofol
45676243|NCT04254627|Drug|Etanercept|Etanercept 50 mg weekly injection
46088437|NCT04201925|Procedure|upper blepharoplasty|excision of excess eyelid skin with or without strip of orbicularis muscle ; with or without upper orbital fat
45676244|NCT04254627|Drug|Mifepristone|Mifepristone 300 mg pill
46002082|NCT04922632|Behavioral|Transcendental Meditation (TM)|TM is a mind-body program that allows the participant to experience progressively quieter, less excited states of mental activity, with growing experience of restful alertness in mind and body.
46002083|NCT04922632|Behavioral|Experience Resolution Methodology (ERM)|ERM is a specific, protocolized coaching method that aims to maximize an individual's performance, professional development and well-being by recognizing and resolving subjective stress associated with specific situations, circumstances, events or experiences.
46002489|NCT02209142|Other|blood prelevement|blood sample will be done at the inclusion then at T 2 weeks, T8 weeks, T30weeks
46002490|NCT02209142|Other|psychometric data collection|
46002491|NCT02200276|Biological|Influenza|
46002084|NCT04922632|Behavioral|Transcendental Meditation (TM) and Experience Resolution Methodology (ERM)|TM + ERM is an integrative method using both TM and ERM coaching with ERM with the aim of achieving an overall restful, alertness in mind and body and maximizing performance, professional development and well-being.
46002085|NCT04922632|Behavioral|Treatment As Usual (TAU)|TAU is the existing Duke Health & Well-being services, such as the availability of acupuncture, integrative health coaching, integrative nutrition and weight management, personal exercise training, massage therapy, yoga therapy, mindfulness-based stress reduction (MBSR), experiencing mindfulness, group fitness classes, gentle yoga, or chair yoga, as well as additional resources such as Personal Assistance Services (PAS).
46002086|NCT04922138|Drug|Aumolertinib|All subjects who meet the enrollment conditions will be included in the Aumolertinib monotherapy group: Orally 110 mg Aumolertinib tablets (55 mg/tablet, 2 tablets/day) once a day until recurrence or completion of treatment or reaching the standard of discontinuation.
46002087|NCT04906590|Drug|[18F] PI-2620|Evaluation of the radiopharmaceutical imaging agent PI-2620 in detecting TAU brain burden.
46002088|NCT04873102|Drug|Danazol Pill|"Danazol is a synthetic steroid derived from ethisterone, It suppresses the pituitary-ovarian axis by inhibiting the pituitary output of gonadotropins. The pituitary-suppressive action of danazol is reversible. Danazol has been approved in treating endometriosis, fibrocystic breast disease, hereditary angioedema, thrombocytopenic purpura, and other conditions. It is metabolized and eliminated by renal and fecal pathways. The mean half-life of danazol in healthy males is 9.7 hours. After 6 months of 200 mg three times a day dosing in endometriosis patients, the half-life of danazol was reported as 23.7 hours.~Adverse reactions from danazol include androgen like effects (i.e. weight gain, acne, mild hirsutism, edema, hair loss, voice change) and menstrual disturbances. The use of danazol in pregnancy is contraindicated. Other side effects include elevations in liver-enzyme levels and lipid abnormalities."
46088438|NCT04972344|Diagnostic Test|Ionized magnesium|Assessment of ionized magnesium level
46088439|NCT04209036|Other|0° 3D laparoscopy high-definition camera(Olympus Winter & IBE GMBH, Hamburg - Germany)|total laparoscopic hysterectomy using a 3D laparoscopy high-definition system
46088440|NCT04214405|Procedure|fixation of tripodal zygomatic fractures|One point versus two point fixation of tripodal zygomatic fractures
46002089|NCT04871516|Other|Quality-of-Life Assessment|Ancillary studies
46002090|NCT04871516|Other|Questionnaire Administration|Ancillary studies
46088441|NCT00618462|Behavioral|Cognitive behavioral therapy (CBT)|CBT will include weekly 50-minute sessions for 8 weeks. The sessions will focus on learning skills to cope with urges to gamble and developing alternatives to gambling.
46088442|NCT00618462|Behavioral|Contingency management (CM)|CM will provide incentive, such as a gift certificate to a store or restaurant, for completing activities not related to gambling. Participants and their therapists will decide upon two potential alternative activities to gambling during each therapy session.
46088443|NCT00618462|Behavioral|Psychoeducation therapy|Psychoeducation therapy will include weekly 50-minute therapy sessions for 8 weeks. The sessions will focus on education about gambling and related problems.
46088444|NCT00618462|Behavioral|Case management|Case management will assist participants in obtaining additional services from the community as needed.
46002091|NCT04871516|Radiation|Radiation Boost|Undergo radiation therapy boost
46002092|NCT04871516|Procedure|Therapeutic Surgical Procedure|Undergo standard surgery
46002093|NCT04871516|Radiation|Whole Breast Irradiation|Undergo standard WBI
46002094|NCT04871516|Other|Breast MRI|A baseline breast MRI
46002095|NCT04870710|Device|transcranial electrical stimulation|Electrical stimulation to the extrastriate visual cortex.
46002096|NCT04860375|Procedure|Multidisciplinary patient care|A holistic, multidisciplinary, patient-centered care.
46002097|NCT04860375|Other|Standard care|Standard care in Sweden
46002098|NCT04860141|Drug|Gabapentin 600mg|The patient will take gabapentin 600mg 2 hours prior to the procedure
46002099|NCT04860141|Drug|Placebo|the patient will take a pill that looks like gabapentin 2 hours prior to the procedure
46002100|NCT04858802|Device|PROPEL Contour Sinus Implant|370 mcg mometasone furoate-coated sinus implant
46002101|NCT04858802|Procedure|Balloon Sinus Dilation Alone|No PROPEL Contour Sinus Implant
46088445|NCT00618462|Behavioral|Gamblers Anonymous (GA)|All participants will be referred to GA, a support group of people who are recovering from gambling addiction, and will be encouraged to attend meetings.
46088446|NCT02844491|Other|additional biological samples|blood and tissue samples
46088447|NCT02846441|Procedure|hepatobiliary scintigraphy|99mTc-mebrofenin hepatobiliary scintigraphy with single photon emission computed tomography (SPECT)
46088448|NCT04212702|Drug|Hormonal therapy-based treatments|Hormonal therapy-based treatments, ex. HT single agent, HT plus other targeted therapy, HT plus everolimus, HT plus metronomic oral chemotherapy or oral chemotherapy only
46088449|NCT04210908|Other|Visual biofeedback|Patient will observe the descent of the fetal head as they push during contractions
45676245|NCT04250155|Drug|XmAb24306|Participants will receive intravenous (IV) XmAb24306.
46002102|NCT04858061|Behavioral|Virtual Reality Cue Exposure Therapy|Exposure to alcohol-related cues within virtual environments
46088450|NCT02846363|Other|public awareness campaign|"The public awareness campaign was based on improving knowledge and skills of public to recognize stroke symptoms. The campaign materials were:~3 posters presenting the three main symptoms of stroke and the need to call the EMS immediately~A leaflet on stroke will be created~3 participatory movies: These films will be posted on YouTube and broadcast on the website and the Facebook campaign page~Actions on social networks: A Facebook group will be created (AVC: votre appel peut sauver des vie).~A website developed with ICAP - UCBL Lyon1 (http://avc.univ-lyon1.fr/)~On the occasion of World Stroke Day, held annually on 29 October, will be organized an event in Lyon in order to educate and inform the general public about stroke: the main symptoms and reflexes to adopt in case of stroke: call the EMS urgently"
46088451|NCT02844413|Other|aerobic interval training|In the first group (G1), aerobic interval training (AIT) was undertaken for 5 months (40 professional AIT sessions performed two times per week in 50 minute sessions) and followed a specially developed program. The second control group (G2), did not attend any training sessions but received medical advice on how to maintain physical activity as outlined by JNC hypertension guidelines
46088452|NCT02846285|Other|No intervention|
46088453|NCT02846207|Drug|Yiqi huoxue|Buyang Huanwu demolition, which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
46002103|NCT04858061|Behavioral|Treatment-as-usual|Pharmacotherapy and psychotherapy
46002104|NCT04857697|Procedure|Biopsy|Undergo biopsy
46002105|NCT04857697|Procedure|Biospecimen Collection|Undergo collection of blood, stool, and tissue samples
46088454|NCT02846207|Drug|Yiqi group|Astragalus 60g.Oral administration, twice one day, for 12weeks.
46002106|NCT04857697|Drug|Probiotic|Given PO
46002107|NCT04857697|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
46002108|NCT04841291|Behavioral|Diabetes Foot Care Education (DFCE)|Virtual simulation-based DFCE sessions on seven topics (the reasons for inspecting one's feet, risk factors and prevention strategies of diabetic foot ulcer, how to wash and moisturize feet, comfortable sock and shoe choices, what to look for, and what to do during feet inspection, how to trim fingernails, and how to maintain foot health) at University of Gondar computer lab for 30 minutes.
46002109|NCT04834128|Drug|TCB008|administration of gamma delta T cells by IV bolus injection
46002110|NCT04823156|Dietary Supplement|Calcium|Daily calcium food supplement.
46002111|NCT04816825|Device|Alkit eSence|Home-based rehabilitation program including computer games and supervised by a physiotherapist.
46088455|NCT02846207|Drug|Huoxue group|Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
46088456|NCT02846207|Drug|placebo|Dextrin,oral administration, twice one day, for 12weeks.
46088457|NCT04211064|Diagnostic Test|Ultrasonographic measurement of optic nerve sheath diameter|Optic nerve sheath diameter will be measured at both neuromuscular blocks level.
46088458|NCT04211064|Procedure|Deep neuromuscular block|Deep neuromuscular block will be obtained via appropriate dose of rocuronium.
46002112|NCT04816825|Other|Standard rehabilitation|Standard rehabilitation program at the COPD-Center
45676246|NCT04250155|Drug|Atezolizumab|Participants will receive IV XmAb24306 followed by IV atezolizumab
46088459|NCT04211064|Procedure|Moderate neuromuscular block|Moderate neuromuscular block will be obtained via appropriate dose of rocuronium.
46088460|NCT02691780|Drug|Sorafenib|
46088461|NCT02846051|Procedure|venous mapping|clinical examination + doppler echo
46002113|NCT04813653|Drug|cyclosporine in combination with carfilzomib and dexamethasone|patients will be treated with cyclosporine with dose titration based on repeated determinations of whole blood concentrations to achieve a target trough concentration of 250 ng/mL, in combination with carfilzomib plus dexamethasone.
46002114|NCT04803747|Drug|Tranexamic acid (TXA)|TXA 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
46002115|NCT04803747|Drug|Placebo (0.9 % Saline)|Placebo (0.9 % normal saline) 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
46002116|NCT04790474|Drug|ixazomib-pomalidomide-dexamethasone|"Cycles 1-3: during each 21-day cycle:~ixazomib 3 mg on Days 1, 4, 8 and 11~pomalidomide 4 mg on Days 1 through 14~dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16~Cycle 4 and consequently: during each 28-day cycle:~ixazomib 4 mg on Days 1, 8 and 15~pomalidomide 4 mg on Days 1 through 21~dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23"
46002117|NCT04789161|Procedure|double kissing crush stenting|Patients with true bifurcation lesion treating with double kissing crsuh stenting technique
46002118|NCT04789161|Procedure|double kissing culotte stenting|Patients with true bifurcation lesion treating with double kissing culotte stenting technique
46002119|NCT04787055|Device|Receiver-in-canal hearing instrument|Receiver-in-canal hearing instrument
45676247|NCT04250155|Drug|XmAb24306|Participants will receive IV XmAb24306 followed by IV atezolizumab.
45676248|NCT04224493|Drug|Tazemetostat|Starting dose level of tazemetostat 400 mg PO twice daily followed by 600 mg twice daily and then 800 mg twice daily.
45676249|NCT04224493|Drug|Tazemetostat|Tazemetostat 800mg (tablets) administered orally twice daily in continuous 28-day cycles for 12 cycles.
45676250|NCT04224493|Drug|Placebo oral tablet|Placebo tablets administered PO twice daily in continuous 28-day cycles for 12 cycles.
45676251|NCT04224493|Combination Product|Lenalidomide|Lenalidomide 20 mg capsules (if creatinine clearance ≥60 mL/minute) or 10 mg capsules (if creatinine clearance <60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles.
46002120|NCT04778410|Drug|Magrolimab|Administered intravenously
46088462|NCT02845973|Biological|gut microbiota|
45835586|NCT04480242|Behavioral|Regularly monitoring of the Inhalation technique through mobile app|App users are randomized within each pediatrician into two groups of equal size defined within the subsample recruited, so that 50% of the participants are allocated to answer the inhalation techniques, and the other 50% are allocated to answer the environment support scales. Once the app is downloaded, at month 2 and every 6 months thereafter the intervention group answers the inhalation techniques scale (group 1) and the control group answers the environment support scale (group 2).
46002121|NCT04778410|Drug|Azacitidine|Administered either subcutaneously or IV, 75 mg/milligram per square (m^2) on Days 1 to 7 or Days 1 to 5, 8 and 9 during every cycle
46002122|NCT04778410|Drug|Venetoclax|Administered orally at a dose of 100 mg on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle
46002123|NCT04778410|Drug|Mitoxantrone|Administered intravenously, 8 mg/m^2 on Days 1-5 during Cycle 1 to Cycle 3
46002124|NCT04778410|Drug|Etoposide|Administered intravenously, 100 mg/m^2 on Days 1-5 during Cycle 1 to Cycle 3
46088463|NCT02845895|Other|Caregiver dedicated|Organization of nutrition screening with the help of a caregiver
45835587|NCT01026012|Drug|regadenoson|Regadenoson dose of 400 mcg will be infused over 10-20 seconds followed by a saline flush.
46088464|NCT02845895|Other|Classic strategy|Classic organization with the training of the department team
46088465|NCT02691390|Device|Active dTMS|dTMS to ACC
46088466|NCT02691390|Device|Sham dTMS|SHAM - no stimulation
46088467|NCT02845817|Other|Qualitative research|Semi-structured interviews
45835588|NCT02088216|Drug|N-acetylcysteine|600mg po twice a day for 12 months
45835589|NCT02088216|Other|On-demand treatment|receive as-needed therapy
45835590|NCT04782648|Procedure|transit bipartition|transit bipartition as revisional bariatric surgery for weight regain after sleeve gastrectomy
46002125|NCT04778410|Drug|Cytarabine|Administered intravenously, 1000 mg/m^2 on Days 1-5 during Cycle 1 to Cycle 3
46002126|NCT04778410|Drug|CC-486|Administered orally, 300 mg on Days 1-14 during each cycle
46088468|NCT02845661|Drug|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 1 was started from 0.9 µg/kg
46088469|NCT02845661|Drug|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 2 was started from 1.0 µg/kg
46088470|NCT02845661|Drug|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 3 was started from 1.1 µg/kg
46002127|NCT04778059|Drug|USB002|USB002 is pharmaceutically formulated Angiotensin 1-7 [A(1-7)], a non-hypertensive derivative of Angiotensin-II (A-II), and is suspended in a vehicle as a sterile solution of USB002. Depending upon cohort assignment, subjects in the USB002 group will receive one of four doses of USB002 administered intravenously (IV).
46088471|NCT01259544|Drug|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of powder form dissolved in one cup of tap water prior to breath test
46088472|NCT01259544|Drug|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of 13 C di peptide in single dose powder form dissolved in one cup of tap water.
46088473|NCT02845739|Other|Kidney transplanted patients|
46088474|NCT04210752|Drug|Treatment 1 (EG-HZ-001)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
46088475|NCT04210752|Drug|Treatment 2 (EG-HZ-002)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
46088476|NCT04210752|Drug|Treatment 3 (EG-HZ-003)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
46088477|NCT04210752|Drug|Treatment 4 (EG-HZ-004)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
46088478|NCT04210752|Drug|Treatment 5|"Shingrix~Suspension for injection supplied as a single dose vial of lyophilised VZVgE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. After reconstitution, a single dose of ShingrixTM is 0.5 mL.~Route of Administration: IM injection"
45676252|NCT04224493|Combination Product|Rituximab|Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.
45676253|NCT04213014|Behavioral|Guys/Girls Opt for Activities for Life (GOAL)|The 4 month (16-wk) GOAL intervention has 3 components: (1) After-school GOAL Club: 26 events (2 days/week; 120 min/event/day; 13 weeks due to no club during 3 school break weeks) for boys and girls to engage in physical activity and healthy eating and cooking activities; (2) Three parent-adolescent meetings (1st meeting at each school for parents and adolescents [Zoom option if needed]; 2nd and 3rd meetings delivered virtually for parents): to empower parents to assist adolescents with physical activity and healthy eating and cooking; and (3) GOAL social networking website: private website for parents to share with each other how they helped their adolescent increase physical activity and diet quality during a prior week.
46002848|NCT04635462|Other|Physical exercise training|Participants will be encouraged to complete exercise training programs in the form of video capsules available via Facebook or Youtube, created by kinesiologists of the Montreal Heart Institut EPIC prevention center. The videos last about 15 minutes and include a warm-up of 3 to 5 minutes, followed a 10-minute training and finally a 2-minute cool-down period. The exercises on video do not require any equipment and integrate, depending on the video, aerobic, muscular strengthening, flexibility and/or balance exercises. Several intensities are described according to the participants' level. Participants will be invited to perform exercise sessions at least 5 times a week, and will be monitored weekly by phone by a member of the research team. The exercise sessions can be performed at home using the video training program, as well as in sports centre or outdoors. For each session, participants have to report its duration, intensity, and the nature of the activity via a follow-up agenda.
46002849|NCT04635462|Other|Cognitive training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed different mnemotechnic, as well as be taught about memory in aging in general. The memory training will be provided by videos capsules. To track adherence to cognitive training, participants will be asked to complete a journal and mark days and times where they took part in the various cognitive training sessions.
46002850|NCT00549419|Drug|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine|The Control group will be assessed using the standard care of traditional vital signs
46088545|NCT02845115|Device|Conventional implantation|"Usual implantation technique of a middle ear implant. The principle of the ossicular stimulator middle ear transducer MET 7000 (Middle Ear Transducer, METTM) is to directly transmit sounds on the ossicles bypassing the outer ear. Their constraint is the surgical placement of the implant.~MET 7000 system (OTOLOGICS LLC, USA) is the implant that the investigators will use for their patients. The stimulator is usually placed against the body of the anvil by simple contact in the case of sensorineural hearing loss. In the case of mixed hearing loss, the stimulator will come in contact with the bracket using a titanium clip (ossicular prosthesis used in otologic surgery for ossiculoplasties). The optimized version corresponds to the use of the conventionally used in mixed deafness and applied to neurosensory deafness art. It is screwed onto the mastoid bone, the motor is suspended in the mastoid cavity and transmits vibrations to the body of the anvil by simple contact of the transducer."
46088546|NCT02845115|Device|optimized implantation with laser velocimetry|
45676819|NCT05133479|Behavioral|Let's Know! small-group or TierL 2 Intervention|Let's Know! is an 22-week intervention spanning 1 school year. Each week features 4-5, 30 minute lessons targeting lower-level and higher-level language skills. There are 2 narrative and 2 expository units. Within units, instructors and children progress through specific types of lessons to meet language-focused learning objectives. Lesson types include (a) Read to Me, designed to engage children with text and promote discussion, inferential language, and comprehension monitoring, (b) Words to Know, designed to unit vocabulary, (c) Integration, to teach and practice retelling, inferencing and comprehension monitoring (d) Show Me What You Know, instructors administer CAMs to monitor children's progress and (e) Stretch and Review, to provide teachers time to review key concepts. Included in the lessons are practice opportunities for students to collaborate with peers with teacher guidance and feedback. A manual provides scope of instruction, teaching strategies, lessons and materials.
46088547|NCT04288206|Drug|Cefazolin|intravenous cefazolin is being evaluated as a pre-operative prophylactic antibiotic measure with primary outcome being post operative infection rate among participants.
45676820|NCT01610271|Device|Air Barrier System|ABS is a device that emits a stream of purified air over the surgical site creating a barrier that prevents the intrusion of bacteria.
45676821|NCT02170727|Drug|DCV/ASV/BMS-791325|
45676822|NCT01847313|Drug|Liraglutide|Daily administration of liraglutide for 6 months
45676823|NCT02144285|Drug|LY3113593|Administered IV
45676824|NCT02144285|Drug|LY3113593|Administered SC
46088548|NCT04288206|Drug|normal saline|intravenous normal saline placebo
45676825|NCT02144285|Drug|Placebo|Administered IV
45676826|NCT02144285|Drug|Placebo|Administered SC
46002851|NCT00549419|Drug|Goal-directed hemodynamic therapy|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
46088549|NCT05242211|Other|exercise test|Each participants will conducted an exercise test on treadmill (using Modified Bruce Protocol) and cycle ergometer. Quark CPET metabolic cart (Cosmed, Rome, Italy) will be used to collect and analysis gas exchange. 10 minute after the graded exercise test Supra maximal exercise test (SMT) will be done for 2 minutes one stage (treadmill protocol) or 10% at cycle protocol higher than highest load achieved in the incremental test.
46088550|NCT04210440|Procedure|Core decompression procedure|Core Decompression with Bone Chips Allograft adjuvanted by Fibrin Platelet Rich-plasma (PRP) and Concentrated Autologous Mesenchymal Stromal Cells (MSCS), isolated from Bone Marrow
46088551|NCT04958772|Biological|Filgrastim Megalabs|Filgrastim Megalabs 5 μg/Kg/day, subcutaneous single dose
45676827|NCT02117687|Drug|carboxymethylcellulose 0.5%/glycerin 0.9%|1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
45676828|NCT02117687|Drug|sodium hyaluronate 0.18%|1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
46088552|NCT04958772|Biological|Granulokine|Granulokine 5 μg/Kg/day, subcutaneous single dose
46088553|NCT02771249|Drug|rifapentene (RPT)|RPT is a long-acting rifamycin used in combination with INH in the treatment of LTBI.
45676829|NCT04740593|Other|Orthoptic care with the prescription of glasses from age 12-18 months onwards|Children assigned to the intervention group (group 1) will receive orthoptic care, including exams 1-3 (depending on the refractive error) times a year, and glasses, based on accurate determinations of refractive error by retinoscopy in cycloplegia by the study orthoptists at age 12-18 months. The spectacles for the children in this study will be provided by the study via their optician without costs.
45683764|NCT01806584|Other|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure
46088554|NCT02771249|Drug|darunavir/cobicistat (DRV/c)|DRV is a protease inhibitor (PI) indicated in the treatment of HIV infection.33 DRV requires coadministration with RTV (100 mg once or twice daily) or COBI (150 mg daily), the latter of which has been coformulated into a fixed-dose tablet with DRV (DRV/c 800/150 mg).
46002852|NCT00549419|Drug|Standard of care|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
46088555|NCT02771249|Drug|Isoniazid (INH)|INH is an antimycobacterial agent that can be used alone or in combination with RPT for the treatment of LTBI. Given with Pyridoxine (vitamin B6)
45676830|NCT04740593|Other|Orthoptic care without the prescription of glasses from age 12-18 months onwards|Children with high refractive error in the control group (group 2) will also receive orthoptic care, including exams 1-3 (depending on the refractive error) times a year, but they will not receive glasses.
45676831|NCT04740593|Other|First measurement only|Children who have no or mild refractive error (group 3), the majority of all children, will be examined by the study orthoptists only once at the age of 12-18 months, after which youth health care (YHC) physicians and nurses will continue standard vision screening at CHCs, as part of screening for general health disorders and vaccinations. Visual acuity is measured routinely at 42-48 months as part of standard vision screening.
45676832|NCT04742153|Drug|MRG002|Administrated intravenously
45676833|NCT02105987|Drug|ABC/DTG/3TC FDC|Purple, oval, biconvex tablets containing 702 mg Abacavir sulphate which is equivalent to 600 mg ABC, 52.62 mg Dolutegravir sodium which is equivalent to 50 mg Dolutegravir free acid and 300 mg 3TC
45676834|NCT02105987|Drug|Ongoing cART regimen|Stable cART regimens including boosted PI (or ATV unboosted) + 2 NRTIs; NNRTI + 2 NRTIs, or INI (RAL or EVG)+ 2 NRTIs
45676835|NCT04185623|Procedure|denudation time lag|The time between ovum pickup and denudation of oocyte
46002853|NCT04635540|Behavioral|Educational Brochure|Educational brochure on decreased empathy and emotion recognition in patients with neurodegenerative disease
46002854|NCT00549458|Behavioral|Pilates|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
46002855|NCT00549458|Procedure|Pelvic muscle rehabilitation therapy|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
46002856|NCT04635150|Behavioral|Close Collaboration with Parents|Close Collaboration with Parents Training Program is an educational intervention for multidisciplinary NICU staff initially developed and implemented at Turku University Hospital to promote FCC. The intervention consists of four phases lasting 4 to 5 months each. First the healthcare staff learn to observe infant behavior. This phase aims at identifying the individual needs and features of each infant. After that, the staff observe infant behavior with the parents and learn to actively listen to parents' perceptions about their infant. During the phase III, staff learn to know the individual story of the family and their infant, which supports partnership between staff and parents. Finally, staff learn to integrate parents in decision-making and collaboratively plan the transition to home. The training is delivered through facilitator-network model in which local mentors are trained by the trainer mentors and supervisors.
45676836|NCT04737707|Other|Dialectical Behavior Therapy (DBT)|Dialectical Behavior Therapy (DBT)
46002857|NCT03456050|Behavioral|FRC exercise|The program will consist of hip joint controlled articular rotations (CARs) in standing position for 3 - 5 repetitions. Then, the participant will sit on the floor in what is called 90/90 position which is sitting in hip and flexion in 90 degrees for both the lead (front) and trail (side) leg. The participant will perform a Progressive and regressive angular isometric loadings (PAILs and RAILs) for the trail leg to increase the range of internal rotation, the contraction will be performed three times and the holding of the position will be for two minutes. After expanding the range, the participant will perform Progressive and regressive angular loadings (PALs and RALs) isometric contractions in form of a passive range hold for internal rotation and abduction, for 3 - 5 times.
46002858|NCT03456050|Behavioral|Conventional Exercise|The conventional training program in this study will be the routine training for increasing the hip rotation. By screening the scientific literature, the conventional training found to consists of static stretching and strengthening using body weight and/or a band and the time of holding a stretch is about 30 seconds. For that the flexibility exercise will consist of progressive stretching from a prone position (leg fall in a stretch), the participant will perform 3 - 5 repetitions with 30 seconds hold or as tolerated. The strengthening exercise consists of hip abduction (hip opening) using a band or ankle weight from side lying for 10 - 12 repetitions 3 times.
46002859|NCT04643691|Drug|Losartan 50 mg and Spironolactone 25 mg pillules oral use|Losartan 50 mg and Spironolactone 25 mg pillules oral use during 10 days
46002860|NCT03456011|Other|Battlefield Acupuncture|Battlefield Acupuncture gold semi permanent needles
45676837|NCT02141633|Procedure|echocardiogram plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
45676838|NCT02141633|Procedure|airway blood flow plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
45676839|NCT02141633|Drug|Fluticasone propionate|participant will be received a 4-week course of inhaled fluticasone (220 μg fluticasone twice a day administered as a MDI using a spacer)
45676840|NCT02141633|Drug|placebo|participant will be received a 4-week course of identically appearing placebo (2 puffs twice a day via spacer).
45676841|NCT01846611|Drug|Trabectedin|1.1 mg/m^2 administered intravenously over approximately 3 hours on Day 1 of each 21-day treatment cycle.
45676842|NCT01846611|Drug|DOXIL|30 mg/m^2 administered intravenously over approximately 90 minutes on Day 1 of each 21-day treatment cycle.
45676843|NCT01846611|Drug|Dexamethasone|20 mg administered intravenously on Day 1 of each 21-day treatment cycle approximately 30 minutes prior to study drug infusion.
45676844|NCT01846611|Drug|DOXIL|50 mg/m^2 administered intravenously over approximately 90 minutes on Day 1 of each 28-day treatment cycle.
46002861|NCT03455972|Biological|anti-CD19 and anti-BCMA CAR|Participants will get auto-HSCT. Hematopoietic reconstitution after auto-HSCT, participants will get the anti-CD19 CAR T cells (1×10e+7/kg on d0) and anti-BCMA CAR T cells as split-dose (total 5×10e+7/kg, 40% on d1 and 60% on d2)
46002862|NCT03455972|Drug|Immunomodulatory drugs|Maintenance therapy
46002863|NCT03455933|Other|Sham Comparator|The investigators will apply a light intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 3/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (3/10 in VAS).
45676845|NCT02141399|Drug|ALKS 5461|Sublingual tablet, taken daily
46002864|NCT03455933|Other|Experimental Intervention|The investigators will apply a moderate intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 6/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (6/10 in VAS).
45676846|NCT04586673|Biological|ChAdOx1.tHIVconsv1 (C1)|ChAdOx1.tHIVconsv1 5 x 10^9 vp
45676847|NCT04586673|Biological|ChAdOx1.tHIVconsv1 (C1)|ChAdOx1.tHIVconsv1 5 x 10^10 vp
45676848|NCT04586673|Biological|MVA.tHIVconsv3 (M3)|MVA.tHIVconsv3 1 x 10^8 pfu
45676849|NCT04586673|Biological|MVA.tHIVconsv4 (M4)|MVA.tHIVconsv4 09. x 10^8 pfu
45676850|NCT01846299|Other|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
45676851|NCT01846299|Drug|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
45676852|NCT01628393|Drug|Ozanimod|Oral capsule taken once a day
46002865|NCT03455933|Other|Control Group|Patients will place their hand, wide open and up to the wrist, into the inner part of the container and will keep it under water for a maximum time of 2 minutes. If pain is unbearable before the time ends, the participant will be able to withdraw the hand.
46002866|NCT04634994|Drug|[F-18]SDM-8|PET radiopharmaceutical. Subjects will undergo [F-18]SDM-8 PET Scanning to measure synaptic density.
46002867|NCT00549497|Drug|GW870086X|
46002868|NCT00549536|Dietary Supplement|tablets each containing of 1000mg elemental calcium (Mega-Calcium Sandoz)|1500 mg of elemental calcium per day.
45835939|NCT04592562|Device|the Terumo Hydropearl® microspheres device|"Genicular artery embolization (GAE) is a new, minimally invasive investigational not yet approved therapy. In previous studies, this procedure has provided pain relief in patients with mild to moderate OA in the short to midterm. We will be utilizing the Terumo Hydropearl® microspheres particle beads during the GAE procedures. The procedure will take place utilizing fluoroscopic and ultrasound guidance. Following catheterization of the femoral artery, angiography of the affected limb will be performed to define the genicular arterial anatomy. Genicular arteries demonstrating abnormal vascularity and corresponding to the site of the patient's pain will be catheterized and embolized using microspheres. Prior to and after embolization, parametric imaging will be performed utilizing proprietary software to quantify changes in blood flow to the target area~The intended use of the Terumo Hydropearl® microspheres device is to embolize the geniculate artery branch."
45835940|NCT00030264|Drug|Methotrexate|Methotrexate will be given at a dose of 30mg/m2/week intramuscular (IM) or intravenous (IV) for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first)
45835941|NCT00030264|Drug|Vinblastine|Vinblastine will be given at a dose of 6mg/m2/week intravenous (IV) for for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first). Maximum actual dose may not exceed 10mg.
46002869|NCT04643613|Dietary Supplement|Protison cancer nutritional formula (PCNF)|PCNF (237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks
46002870|NCT00549575|Drug|L ARG|Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories).
46002871|NCT00549575|Drug|Placebo|After double blind randomization, patients received a placebo.
46002872|NCT00549614|Drug|acipimox|capsule, 250 mg, 4 times daily for 28 days
46002873|NCT00549614|Drug|placebo|capsule, 250 mg, 4 times daily for 28 days
46037787|NCT01199822|Biological|Olaratumab|Cohort 1 10 milligrams/kilogram (mg/kg) intravenously (IV) administered on Days 1 and 8, every 3 weeks; Cohort 2 20 mg/kg IV administered every 2 weeks; Cohort 3 15 mg/kg IV administered on Days 1 and 8, every 3 weeks
46088556|NCT02771249|Dietary Supplement|Pyridoxine|
45676853|NCT01628393|Drug|Placebo|Oral capsule taken once a day
45676854|NCT01846221|Drug|Clonidine|Subjects randomized to clonidine will receive a mixture of 100 micrograms clonidine and 12.5 mg bupivacaine 10 ml of volume.
45676855|NCT01846221|Drug|Fentanyl|Subjects randomized to fentanyl will receive 100 mcg fentanyl and 12.5 mg bupivacaine in 10 ml of volume.
45676856|NCT01815099|Device|rTMS Treatment|Either 10 or 15 rTMS sessions (2 or 3 times/week for 5 weeks, respectively)
45676857|NCT01845831|Drug|Sitagliptin|Sitagliptin will be taken orally at 100 mg or 50 mg once a day per renal function.
45676858|NCT01845831|Drug|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
45676859|NCT01845831|Drug|Metformin and Sitagliptin|Janumet is a combination of metformin and sitagliptin. Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months.
45676860|NCT01845831|Drug|Glargine|"Patients with blood glucose between 140-200 mg/dL during hospitalization will receive 0.2 units per kg weight per day.~Patients with blood glucose between 201-400 mg/dL during hospitalization will receive 0.25 units per kg weight per day."
45676861|NCT01845831|Drug|Glargine 50%|Glargine will be prescribed at 50% of daily hospital dose.
45676862|NCT01845831|Drug|Glargine 80%|Glargine will be prescribed at 80% of daily hospital dose.
46002874|NCT00558987|Behavioral|Discipline Video|"The discipline video will be shown to the caregiver before the visit while they are waiting to see the doctor. The video gives specific guidance on avoiding physical discipline, setting consistent, safe and age appropriate limits.~A copy of the discipline video and the handout reinforcing the messages presented in the video will be given to the caregiver by the research staff to share with other caregivers."
45676863|NCT01627691|Device|Lotus Valve System|"bioprosthetic bovine pericardial aortic valve~delivery system"
46002875|NCT00558987|Behavioral|Nutrition Video|A brief educational video on nutrition information, a topic not related to discipline.
46002876|NCT00549653|Drug|GW856553|
46002877|NCT00560664|Procedure|Autologous chondrocytes transplantation|Cartilage was harvested, then transferred for cell isolation and culture. Cells are suspended in agarose and transferred to cylindrical molds and surgically implanted 4 weeks later.
46002878|NCT00560664|Procedure|Mosaicoplasty|Osteochondral patch are sampled and then implanted during the same surgical procedure
46002879|NCT00549692|Drug|Omega-3 fatty acid ethylester90|Dosage form :1g soft capsule Dosage : two capsules, twice a day.
46002880|NCT00560742|Procedure|Control|Coronary artery bypass grafting without bone marrow cells injection
46002881|NCT00560742|Procedure|Intramuscular administration of bone marrow cells|Coronary artery bypass grafting, and intramuscular administration of bone marrow cells into myocardial scar
46002882|NCT00560742|Procedure|Intracoronary administration of bone marrow cells|Coronary artery bypass grafting, and intracoronary administration of bone marrow cells into myocardial scar
46002883|NCT04923542|Radiation|Stereotactic Radiosurgery (SRS)|Patients will receive single session SRS to intact brain metastases and post-operative cavities. For intact brain metastases, this will be 15 Gy to lesions between 31-40 mm, 18 Gy to 21- 30 mm, and 24 Gy to lesions measuring ≤ 20 mm.
46002884|NCT04923542|Drug|Abemaciclib|Abemaciclib is an orally administered selective small-molecule inhibitor of CDK4 and CDK6 that is 14 times more potent against CDK4 than CDK6 in enzymatic assays that is approved for the treatment of advanced or metastatic breast cancers. Abemaciclib will be administered at a dose of 150 mg twice daily.
46002885|NCT04923542|Drug|Endocrine therapy|Abemaciclib will be administered with standard of care endocrine therapy. Endocrine therapy can consist of fulvestrant or an aromatase inhibitor. Dosing of concurrent endocrine therapy with abemaciclib should follow standard dosing and safety guidelines.
46002886|NCT00560781|Drug|Pregnenolone or Placebo|Pregnenolone 50 mg BID, Pregnenolone 150 mg BID, Pregnenolone 250 mg BID
46002887|NCT00559026|Biological|Melan-A|i.d. injections of Melan-A: 26-35 (A27L) and gp100: 209-217 (210M) peptides (250 µg each) formulated in Montanide ISA-51 plus s.c. injection of 3MU IFN-α, as an adjuvant on day 1 and 8 every 21 days for a total of 5 courses
46002888|NCT00559026|Other|Melan-A plus Dacarbazine|Dacarbazine plus vaccine: the vaccination schedule as in arm 1 was combined with DTIC (800 mg/mq i.v.) administered one day before each vaccine administration according to the standard treatment.
46002889|NCT00549809|Procedure|Intermittent mandatory ventilation (IMV) and synchronous IMV|Patients divided to receive two different modes of mechanical ventilation.
46002890|NCT00549887|Drug|Analog or Human Insulin|prescribed in accordance with usual clinical practice
45676864|NCT01844895|Drug|Abatacept|
46002891|NCT00549926|Drug|Fluvastatin|
46002892|NCT00549926|Drug|Pravastatin|
46002893|NCT00549926|Drug|Pitavastatin|
46002894|NCT00549926|Drug|Atorvastatin|
46002895|NCT04634448|Procedure|Interval appendectomy|interval appendectomy at 2 to 3 months after the initial non-operative treatment
45676865|NCT02116361|Biological|onabotulinumtoxinA|OnabotulinumtoxinA injected into protocol-specified areas on Day 1.
45676866|NCT02116361|Drug|Normal Saline|Placebo (normal saline) injected into protocol-specified areas on Day 1.
45676867|NCT02140775|Behavioral|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
45676868|NCT01844817|Drug|OGX-427|Three separate administrations of OGX-427 will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive 600mg OGX-427 prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. OGX-427 will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
46002896|NCT04634448|Diagnostic Test|Follow-up MRI at 1 year|follow-up MRI at 1 year for asymptomatic patients under 35 years of age not wanting to undergo surgery
46002897|NCT00549965|Drug|Risedronate Sodium|
46002898|NCT04634487|Other|No intervention|No intervention
46002899|NCT00550004|Drug|RP101|190 mg oral tablet
45835942|NCT01897116|Drug|Hydroxychloroquine (HCQ)|
45835943|NCT01897116|Drug|Vemurafenib (VEM)|
45835944|NCT00036738|Drug|Cyclosporine|Given IV or PO
45835945|NCT00036738|Drug|Dasatinib|Given PO
45835946|NCT00036738|Drug|Fludarabine Phosphate|Given IV
45835947|NCT00036738|Drug|Imatinib Mesylate|Given PO
45835948|NCT00036738|Drug|Mycophenolate Mofetil|Given PO
45835949|NCT00036738|Drug|Nilotinib|Given PO
45835950|NCT00036738|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
45835951|NCT00036738|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplantation
45835952|NCT00036738|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
46002900|NCT00550004|Drug|Gemcitabine (1000 mg/m2)|30 minute intravenous infusion
46002901|NCT04634721|Drug|bupivacaine|In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine injected . This will then be repeated on the contralateral side.
46037788|NCT05158816|Procedure|ECMO|Patients undergoing extracorporeal membrane oxygenation
46037789|NCT01096056|Biological|Influenza vaccine GSK2186877A formulation 1|Intramuscular administration, 2 doses
46088557|NCT04208958|Biological|VE800|VE800 is an orally administered (PO) live biotherapeutic product (LBP) consisting of 11 distinct nonpathogenic, nontoxigenic, commensal bacterial strains manufactured under GMP conditions. These strains were selected for their ability to induce an immune response.
46002902|NCT04643262|Procedure|Sleeve Gastrectomy|Once the left crus is reached, an optimal exposure of the hiatus is mandatory to find incidental hiatal hernias and a complete dissection of the left crus performed to prevent retained fundus. The greater omentum was opened close to the stomach wall in some part in between the fundus and the antrum to have greater curvature completely detached from the stomach; this dissection starts at 2 cm or _____proximal to the pylorus and continued along the greater curvature to the left crus. Posterior adhesions if present, were carefully divided. The left gastrophrenic ligament was divided to expose the angle of His to identify the complete hiatus and fundus. A bougie was positioned before starting resection of the stomach. We use a 36French bougie or --------- we have chosen cartridges Black at the antrum level and finished with a purple cartridge. We always checked the posterior wall before firing.
46088558|NCT04208958|Drug|Nivolumab|Nivolumab is an approved medication that blocks antibodies for certain types of cancer.
46002903|NCT04634565|Drug|PF-06651600|oral PF-06651600 tablet 200 mg once daily
46088559|NCT04208958|Drug|Vancomycin Oral Capsule|Vancomycin is an antibiotic used to treat or prevent infection.
46002904|NCT00550121|Drug|vitamin C|
46002905|NCT00550121|Drug|placebo|
45676869|NCT01844817|Drug|Placebo|Three separate administrations of Placebo will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive placebo prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. Placebo will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
45676870|NCT04594239|Device|Belotero Balance (+) Lidocaine, needle|Injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles
45676871|NCT04594239|Device|Belotero Balance (+) Lidocaine, cannula|Injection of Belotero Balance (+) Lidocaine into the infraorbital hollows using cannulas
45676872|NCT04594239|Device|Untreated-control / delayed-treatment, needle|Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles)
46002906|NCT04643028|Other|Home exercise|Exercise program will include active normal joint movements in the cervical region, postural exercises, strengthening exercises for the scapular retractor muscles, and stretching exercises for the pectoral muscles, levator scapula and upper part of the trapezius and breathing/relaxation exercises.
45676873|NCT04594239|Device|Untreated-control / delayed-treatment, cannulas|Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using cannulas)
45676874|NCT04585737|Drug|Dolutegravir / Lamivudine Pill|Experimental
45676875|NCT04585737|Drug|Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill|Active comparator
46002907|NCT04643028|Other|Mulligan mobilization|Mulligan mobilization: Mulligan mobilization will be applied to this group in addition to the exercises in the home exercise group. In painless directions, each session will be applied in 3 sets, a set of 10 repetitions.Sixty seconds of rest will be given between sets.
46002908|NCT04643028|Other|Cervical stabilization|Cervical stabilization group: In addition to the exercises in the home exercise group, this group will be given cervical stabilization training that focuses on the deep neck muscles.
46088560|NCT04048278|Drug|Lidocaine Hydrochloride|IV Lidocaine a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
46088561|NCT04048278|Drug|Saline Solution for Injection|IV Saline a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
46088562|NCT02697318|Drug|Timolol maleate 0.5% ophthalmic solution|
46002909|NCT00550160|Drug|Amodiaquine plus Artesunate co-administration|"Under the Home Management of Malaria (HMM) strategy the Community Drug Distributors (CDD) will treat all children under 5 years presented to them with measured fever or a history of fever with AQ plus AS co-administered. Children under 12 months receive 75mg of AQ co-administered with 25mg of AS daily for three days. Children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.~Asymptomatic children under 5 years in the Intermittent Preventive Treatment (IPTc) clusters will receive additional AQ plus AS co-administered during high malaria transmission season. Those under 12 months will receive 75mg of AQ co-administered with 25mg of AS daily for three days; and children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days."
46088563|NCT04095377|Other|No intervention, this is a retrospective study.|No intervention, this is a retrospective study.
46088564|NCT05662722|Other|percutaneous needle electrolysis|It´s an intervention of physiotherapy. It´s an invasive technique.
46088565|NCT05662722|Other|Dry needling|It´s an intervention of physiotherapy. It´s an invasive technique.
46088566|NCT05662722|Other|Sham needling|It´s an intervention of physiotherapy. It´s an invasive technique simulation.
46088567|NCT03968874|Device|Light box therapy|The intervention is sitting in front of a lightbox for 1 hour in the morning upon waking up.
46088568|NCT03968874|Device|Negative Ion Generator|The intervention is sitting in front of a modified negative ion generator for 1 hour in the morning upon waking up.
45676876|NCT01814553|Drug|afatinib|Daily treatment starting 40 mg per day
45676877|NCT01814553|Drug|loperamide|Follow cohort assignment and diarrhea management guidelines
45676878|NCT02116205|Biological|HTNV/PUUV DNA vaccine|HTNV/PUUV DNA vaccine mixture, composed of pWRG/HTN-M(co) and pWRG/PUU-M(s2)
45676879|NCT02116205|Biological|Placebo|0.9% sodium chloride
45676880|NCT02116205|Device|TriGrid Delivery System (TDS)|The TDS-IM is an integrated, fully automated clinical EP system designed for delivering DNA-based vaccines and therapies to target tissues, through temporary disruption of cellular membranes via electrical pulses
45676881|NCT01844583|Drug|Alisertib|Alisertib tablets
45676882|NCT01844583|Drug|Esomeprazole|Esomeprazole capsules
46002910|NCT00550199|Drug|LBH589, Gemcitabine|Phase I dose escalation: LBH589 will be administered orally twice weekly. Gemcitabine will be administered intravenously over 30 minutes on days 1, 8, and 15 every 28 days.
46088569|NCT05661630|Other|EDUCATION AND COUNSELING WITH EX-PLISSIT MODEL|"In addition to the routine procedure, the women in the experimental group of the research will be given sexual education and counseling with the EX-PLISSIT model. The steps to be followed in accordance with this model are as follows; Session 1 Permission Limited Information The Specific Suggestions The IT-Intensive Therapy Session 2 At the beginning of the interview, the data forms will be reapplied, and then the homework given in the first session will be discussed. The information that the patient needs in line with his questions will be given within the steps of the Ex-PLISSIT model, within the steps of allowing, limited information, special recommendations and, if necessary, intensive therapy.~Session 3 At the beginning of the interview, the data forms will be applied for the last time and the patient's questions, if any, will be answered and the session will be ended."
46002911|NCT04643301|Drug|Liraglutide Pen Injector|Daily subcutaneous injection of 3.0mg liraglutide (GLP-1 antagonist) for low-responders 3 months after bariatric surgery.
46002912|NCT00550355|Drug|PD 0360324|3 doses of PD 0360324 (Dose level 1) administered over 12 weeks
46002913|NCT00550355|Drug|PD 0360324|3 doses of PD 0360324 (Dose level 2) administered over 12 weeks
45676883|NCT01844583|Drug|Rifampin|Rifampin capsules
45676884|NCT02115815|Biological|Placebo|Participants will receive placebo (sterile saline for human use from commercial source liquid) on Day 1.
46002914|NCT00550355|Drug|PD 0360324|3 doses of PD 0360324 (Dose level 3) administered over 12 weeks
46002915|NCT00550355|Drug|Placebo|3 doses of Placebo administered over 12 weeks
46002916|NCT04634292|Behavioral|EEG|EEG + walking task + auditory task
46002917|NCT00550433|Device|Bazedoxifene/Conjugated Estrogens|
46002918|NCT00559143|Other|Biventricular Pacing (DDD(R)- BiV)|Subjects indicated for DDD(R) pacing due to AV conduction disturbances and preserved LV function will receive biventricular pacing DDD(R)- BiV
46002919|NCT00550472|Dietary Supplement|probiotics|Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus 74-2 Bifidobacterium animalis subsp. lactis DGCC 420
46002920|NCT04634370|Biological|Natural Killer Cells infusion|"Each patient will receive on dose of intravenous natural killer cell in following levels:~Level 1 : 1x106 cells/kg body weight (patients 1 to 3) Level 2: 5x106 cells/kg body weight (patients 4 to 6) Level 3: 1x107 cells/kg body weight (patients 7 to 24)"
46088570|NCT02696772|Other|Energy intake|
45676885|NCT02115815|Biological|RSV sF 20 mcg|Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
45676886|NCT02115815|Biological|MEDI7510 (20 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 20 mcg RSV sF by intramuscular injection on Day 1.
45676887|NCT02115815|Biological|RSV sF 50 mcg|Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
45676888|NCT02115815|Biological|MEDI7510 (50 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 50 mcg RSV sF by intramuscular injection on Day 1.
45676889|NCT02115815|Biological|RSV sF 80 mcg|Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
45676890|NCT02115815|Biological|MEDI7510 (80 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 80 mcg RSV sF by intramuscular injection on Day 1.
45676891|NCT04742075|Drug|Olaparib + durvalumab + UV1|The subjects are randomized 1:1:2 to receive treatment until progression of disease or untorable toxicity.
45676892|NCT02115113|Drug|Everolimus|Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.
45676893|NCT02115113|Drug|Tacrolimus|Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration.
45676894|NCT02114879|Behavioral|Enhanced Medical Rehabilitation|Daily PT/OT provided by therapists trained in Enhanced Medical Rehabilitation. This training focuses on improved communication, patient engagement, and intensity.
45676895|NCT02114879|Behavioral|Standard of Care Rehabilitation|Daily PT/OT provided by therapists not trained in the treatment intervention.
45676896|NCT02114177|Drug|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 12 weeks in Arm 1.
45676897|NCT02114177|Drug|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 8 weeks in Arm 2
45676898|NCT02114177|Drug|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks in Arm 1.
45835953|NCT00036738|Radiation|Total-Body Irradiation|Undergo TBI
45835954|NCT00038610|Drug|Imatinib Mesylate|600 mg by mouth on days 1 - 14 for course 1, and 600 mg by mouth daily days 1-14 (or daily if tolerated with course 1) for courses 2, 4, 6, 8.
45835955|NCT00038610|Drug|Cyclophosphamide|300 mg/m^2 by vein every 12 hours for 6 doses days 1, 2, 3 (total dose 1800 mg/m^2) for courses 1, 3, 5, 7.
45835956|NCT00038610|Drug|Doxorubicin|50 mg/m^2 by vein on day 4 after last dose of CTX for courses 1, 3, 5, 7.
45835957|NCT00038610|Drug|Vincristine|2 mg by vein on day 4 and day 11 for courses 1, 3, 5, 7.
45835958|NCT00038610|Drug|Dexamethasone|40 mg by vein or by mouth daily on days 1 - 4 and days 11 - 14 for courses 1, 3, 5, 7.
45835959|NCT00038610|Drug|Methotrexate|"12 mg intrathecally (6 mg if via Ommaya reservoir) day 2 for courses 1, 3, 5, 7.~200 mg/m^2 by vein over 2 hours followed by 800 mg/m^2 over 22 hours on day 1 of courses 2, 4, 6, 8."
45835960|NCT00038610|Drug|Cytarabine|"100 mg intrathecally day 7 for courses 1, 3, 5, 7.~3 gm/m2 by vein over 2 hrs every 12 hrs for 4 doses on days 2 and 3 for courses 2, 4, 6, 8."
45835961|NCT00038610|Drug|Mesna|600 mg/m^2 by vein daily for 24 hours for courses 1, 3, 5, 7.
45835962|NCT00038610|Drug|G-CSF|10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
45835963|NCT00156936|Drug|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks. Subjects in this dosing group also received this treatment throughout the base study.
45835964|NCT00156936|Drug|Oral naltrexone to Medisorb naltrexone 380 mg|Subjects in this dosing group received oral naltrexone 50 mg in the base study, but received only Medisorb naltrexone 380 mg in this extension study, administered via IM injection once every 4 weeks.
45676899|NCT02114177|Drug|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks in Arm 2.
46002921|NCT00550511|Radiation|Surgeon-performed ultrasound|After clinical investigation including standardized laboratory tests the patient in the intervention arm is examined with abdominal ultrasound performed by the study surgeon.
46002922|NCT04642989|Other|Sham Treatment|All movements of facial effleurage except applying pressure
45676900|NCT02138825|Drug|Riociguat (Adempas, BAY63-2521)|Active drug 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration. The starting dose will be 0.5 mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5 mg increments up to a maximum dose of 2.5 mg TID based on patient's systolic blood pressure and well-being.
46002923|NCT04642989|Other|Facial Effleurage|Facial massage to remove any lymphatic blockages
45676901|NCT02138825|Drug|Placebo|Inactive dosed at 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration for 26 weeks
45676902|NCT02138747|Drug|Mirabegron|Oral
45676903|NCT02138747|Drug|Tolterodine ER|Oral
46002924|NCT04642989|Drug|Antibiotics|"Appropriate standard-of-care antibiotics as determined by the physician."
46002925|NCT04634058|Drug|PD-L1 antibody combined with CTLA-4 antibody|After 4 cycles of PD-L1 monoclonal antibody combined with CTLA-4 monoclonal antibody treatment, PD-L1 monotherapy was maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.
46002926|NCT00550628|Genetic|DNA methylation analysis|
46002927|NCT00550628|Genetic|fluorescence in situ hybridization|
46002928|NCT00550628|Genetic|gene expression analysis|
46002929|NCT00550628|Genetic|polymerase chain reaction|
46002930|NCT00550628|Genetic|protein expression analysis|
46002931|NCT00550628|Genetic|reverse transcriptase-polymerase chain reaction|
46002932|NCT00550628|Other|diagnostic laboratory biomarker analysis|
46002933|NCT00550628|Other|immunoenzyme technique|
46002934|NCT00550628|Other|immunohistochemistry staining method|
46002935|NCT00550628|Procedure|biopsy|
46002936|NCT00550628|Procedure|therapeutic conventional surgery|
46002937|NCT00550628|Radiation|fludeoxyglucose F 18|
46002938|NCT00560820|Drug|Deferasirox|30 mg/kg/day
46002939|NCT04634097|Other|Experimental group|"Clusters will be proposed LE DECLIC EPRI intervention, which is a complex intervention, associating 3 components,:~A. DECLIC program set up in the centers, open to concerned patients.~B. 3 training sessions :~one public of primary care physicians in order to give them the opportunity to be involved in the medical care in charge of the patient suffering from cancer pain.~one public of cancer physicians, leaders of opinions in each cancer centers participating to the study and one public of health professionals in order to train them to be educators (team building).~for healthcare professionals in order to train them as educators in this program.~C. The collaboration of one primary care network, specialized in pain management, in order to reinforce the patient care pathway."
46002940|NCT04634097|Other|standrad group|Standard follow-up patient related to pain. Specific to each center : with or without existing local ETP program (standard care).
46002941|NCT00550784|Biological|filgrastim|
46002942|NCT00550784|Drug|cisplatin|
46002943|NCT00550784|Drug|cyclophosphamide|
46002944|NCT00550784|Drug|melphalan|
46002945|NCT00550784|Drug|paclitaxel|
46002946|NCT00550784|Drug|topotecan hydrochloride|
46002947|NCT00550784|Genetic|TdT-mediated dUTP nick end labeling assay|
46002948|NCT00550784|Genetic|gene expression analysis|
46002949|NCT00550784|Other|immunohistochemistry staining method|
46088571|NCT05242133|Drug|Pegylated interferon beta-1a|Pegylated interferon beta-1a (CinnaGen) autoinjector (Physioject™),125 mcg, subcutaneous (SC) injection, every 2 weeks, for 24 months
46088572|NCT05242133|Drug|Interferon Beta-1A Prefilled Syringe|Interferon Beta-1A Prefilled Syringe, CinnoVex® (CinnaGen), 30 mcg, intramuscular injection, once a week, for 24 months
45835965|NCT00076050|Dietary Supplement|Soy isoflavones|Purified soy isoflavones (phytoestrogens) in tablet form tablets; 200 mg.
45835966|NCT00076050|Dietary Supplement|Placebo|Placebo soy isoflavones
45676904|NCT02105285|Drug|OPC-1085EL ophthalmic solution|
45676905|NCT02105285|Drug|Carteolol long-acting ophthalmic solution|
45676906|NCT02104895|Radiation|Accelerated partial breast irradiation (APBI)|Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)
45835967|NCT00046566|Dietary Supplement|Soy protein-milk protein-carbohydrate|40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
45835968|NCT00046566|Dietary Supplement|Milk protein-carbohydrate-soy protein|40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
45835969|NCT00046566|Behavioral|Carbohydrate-soy protein-milk protein|40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks,
45835970|NCT00077922|Drug|LMB-2|40 micrograms/kg every other day (QOD) x 3 every 4 weeks
45835971|NCT01897974|Other|Survey|Families complete survey to measure medication compliance.
46002950|NCT00550784|Other|pharmacological study|
46002951|NCT00550784|Procedure|peripheral blood stem cell transplantation|
46002952|NCT04633941|Other|Standard Care|Standard Care
46002953|NCT00550823|Device|Cardiac CT 0BRILLIANT 64|Cardiac CT
46002954|NCT04633785|Other|No Intervention|There are no interventions in this study. The mercury sphygmomanometer and the wrist sphygmomanometer will be used in this study to collect blood pressure values from the study subjects.
46002955|NCT00550901|Drug|cisplatin|
46002956|NCT00550901|Drug|dexrazoxane hydrochloride|
46002957|NCT00550901|Other|high performance liquid chromatography|
46002958|NCT00550901|Other|laboratory biomarker analysis|
46002959|NCT00550901|Other|mass spectrometry|
46002960|NCT00550901|Other|pharmacological study|
46002961|NCT04633746|Diagnostic Test|measuring plasma Endostatin level|measuring plasma Endostatin level at the time of admission then after 48hrs and 96 hours
46002962|NCT04633629|Other|Lung ultrasound|We will perform daily a lung ultrasound to evaluate pulmonary congestion by counting B-lines.
46088573|NCT03965832|Device|HFNT during exercise|"6-minute walking test performed initially on HFNT. HFNT will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) as at baseline conditions during exercise.~Participants will then cross-over to repeat the test on baseline conditions."
46088574|NCT03965832|Device|Standard oxygen therapy/RA|6-minute walking test performed on baseline conditions. Participants will then be cross over to repeat the test on HFNT
46088575|NCT02845037|Drug|BIA 5-453|BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.
46002963|NCT04643223|Other|kinesio tape with tension|The application of kinesio tape follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following the application of kinesio tape, with tension between seventy to ninety percent on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
46088576|NCT02845037|Drug|Placebo|Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).
46088577|NCT04206917|Device|Multi Pulse Therapy|The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen MultiPulse Therapy (MPT). The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.
46088578|NCT04185870|Diagnostic Test|3D scan|All participants will receive a 360 degrees 3D scan of their chest/pectus excavatum.
46002964|NCT04643223|Other|kinesio tape without tension|The application of kinesio tape without tension follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following application of the kinesio tape, no tension on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
46002965|NCT00551018|Drug|Vicriviroc|one 30 mg tablet QD
46088579|NCT04185870|Diagnostic Test|Standard photography|All participants will receive a the standard photographs and specialised recordings of the current work-up to document their chest/pectus excavatum.
46088580|NCT02844725|Drug|VVZ-149 injections|Colorless, transparent liquid in water for injection
46088581|NCT02844725|Drug|Placebo|water for injection
46088582|NCT00621816|Drug|nitroprusside|nitroprusside continuous infusion, dose to be titrated to clinical effect
46088583|NCT00621816|Drug|placebo infusion|blinded placebo infusion, to be infused at same rate as open-label nitroprusside infusion
46088584|NCT04186104|Other|Routine diagnostic process|Patients follow the procedures of registration, waiting, attendance, waiting, examination, waiting, attendance.
46088585|NCT04186104|Other|Artificial intelligence assisted diagnosis process|Patients follow the procedures of registration, AI recommended examination items, Self-service medical history collection ,examination, waiting, AI-assisted attendance.
46088586|NCT05368974|Drug|Direct Acting Antivirals|Direct-acting antiviral exposure during documented pregnancy
46088587|NCT05662644|Procedure|Minimally Invasive Surgery for Esophageal Cancer|Assessment of minimally Invasive Surgery for Esophageal Cancer
46088588|NCT04109040|Device|slit lamp|diagnostice device to examine anterior segment of the eye and for fundus examination
45676907|NCT02104895|Radiation|Whole breast irradiation (WBI)|Conventional whole breast irradiation (WBI)
46002966|NCT00551018|Drug|emtricitabine and tenofovir disoproxil fumarate|one 200/300 combination tablet QD
46088589|NCT04108416|Procedure|Cleft lip and palate repair|The intervention is the currently used cleft lip and palate repair technique at the University Hospital Basel and University Childrens Hospital Basel
46088590|NCT04186026|Other|Saline + saline|Double saline infusion followed by an ad libitum meal
46088591|NCT04186026|Other|Neurotensin + saline|Neurotensin + saline infusion followed by an ad libitum meal
46088592|NCT04186026|Other|GLP-1 + saline|GLP-1 + saline infusion followed by an ad libitum meal
46002967|NCT00551057|Behavioral|Expression type|to investigate the expression of different inflammatory proteins in cancer and normal pancreatic tissue
46002968|NCT00551096|Drug|Gemcitabine|Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.
46002969|NCT00551096|Drug|Capecitabine|Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off.
46002970|NCT00551096|Drug|ZD6474|Administered orally at 300 mg/day once daily. One cycle will consist of 28 days
46088593|NCT04186026|Other|GLP-1 + Neurotensin|GLP-1 + Neurotensin infusion followed by an ad libitum meal
46088594|NCT00900731|Drug|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
46088595|NCT00900731|Drug|Tiotropium 18 μg|Tiotropium 18 μg was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
46088596|NCT00900731|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
45676908|NCT01621490|Biological|Nivolumab|
45676909|NCT01621490|Drug|Ipilimumab|
45676910|NCT02018887|Drug|LY2969822|Capsules administered orally
45676911|NCT02018887|Drug|Placebo|Capsules administered orally
45676912|NCT02030041|Drug|Vitamin D|Vitamin D will be given to achieve normal serum levels
46002971|NCT04642872|Other|Infant BIT|Not use of unaffected hand containment. Both hand are use to improve the bimanual coordination
46088597|NCT00900731|Drug|Placebo to tiotropium|Placebo to tiotropium was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
46088598|NCT00639054|Procedure|Bone marrow examination|7.5 ml of iliac crest bone marrow drawn in addition to diagnostic samples.
45676913|NCT02030041|Drug|Simvastatin|Simvastatin in a dose of 40 mg will be provided to the study participants
46002972|NCT04642872|Other|Infant CIMT/BIT|Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.
46088599|NCT00639054|Procedure|Blood samples|24 ml of cubital vein blood drawn in addition to diagnostic samples.
45676914|NCT02030041|Drug|Placebo|Placebo will be provided to the study participants
46088600|NCT05368662|Other|Quality of life and sleep questionnaire|Evaluation of quality of life and quality of sleep by questionnaires
45676915|NCT01844505|Biological|Nivolumab|
45676916|NCT01844505|Biological|Ipilimumab|
45835972|NCT00161382|Behavioral|HIV, STD, and pregnancy prevention curriculum|"This HIV, STD, and pregnancy intervention program entitled, It's Your Game...Keep it Real, consists of 12 lessons delivered in Grades 7 and 8. In each grade, the program integrates group-based classroom activities (e.g., role plays, group discussion, small group activities) with personalized journaling and individual tailored activities delivered on laptop computers. A life skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal limits regarding risk behaviors, to detect signs or situations that might challenge these limits, and to use refusal skills and other tactics to protect these limits."
45835973|NCT00161382|Behavioral|Standard sexual education curriculum|Control curriculum consists of standard sexual education.
46002973|NCT04642872|Other|Conventional therapy|Following the usual therapy in the baby.
46002974|NCT04642872|Other|infant cimt|use of unaffected hand containment to improve the use of affected hand with unimanual activities
46002975|NCT00551252|Drug|Imatinib mesylate plus Gemcitabine|Imatinib (400 mg daily) + Gemcitabine (500 mg/sqm, days 1 and 8 every 21 days) for a maximum of 6 cycles
46002976|NCT04642716|Other|Saliva collection of patients and salivary free amino acids analysis|
46002977|NCT00551330|Drug|Vicriviroc|One tablet of vicriviroc 30 mg once daily
46002978|NCT00551330|Drug|Placebo|One tablet of placebo once daily
46088601|NCT00622050|Behavioral|No TV viewing reduction|In the control group, no intervention will be acted upon. This group will receive the exact same protocol as the intervention group, but with observation only.
46088602|NCT00622050|Behavioral|TV viewing reduction|In the experimental arm, TV viewing time will be reduced for half of the study protocol time (3-4 weeks of a 6-8 week protocol).
46088603|NCT05241899|Drug|Fruquintinib + RC48|Fruquintinib (4mg orally, once daily for 3 wks on/1 wk off) combined with of RC48( 2.5mg/kg by intravenous infusion during 30-90 min every 2 weeks)
46088604|NCT02691234|Device|Extracorporeal Shockwave Therapy and debridement|
46088605|NCT02691234|Other|debridement and cleaning|
46088606|NCT02687568|Other|EEG monitoring|Value of EEG monitoring as adjunct to standard monitoring
46088607|NCT03856229|Drug|Conventional steroid regimen|Subjects will receive the conventional steroid regimen with prednisolone or equivalent (with methylprednisolone): Day 1 to 5: 40 mg orally every 12 h; Day 6 to 10: 40 orally every 24 hours; and Day 11 to 21: 20 mg orally every 24 h.
45342399|NCT04073160|Drug|Tremelimumab|Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Tremelimumab will be administered intravenously at a dose of 75 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.
45676917|NCT01844505|Biological|Placebo for Nivolumab|
45676918|NCT01844505|Biological|Placebo for Ipilimumab|
45676919|NCT01994720|Drug|ticagrelor|ticagrelor, 180 mg (two tablets of 90 mg) loading dose on Day 1 followed by 90 mg twice daily.
45676920|NCT01994720|Drug|Acetylsalicylic acid (ASA)|ASA, 300 mg (three tablets of 100 mg) on Day 1, followed by 100 mg once daily.
45676921|NCT01814397|Drug|Anastrozole|1 mg orally daily
45676922|NCT01814397|Drug|exemestane|25 mg orally daily
45676923|NCT01814397|Drug|letrozole|2.5 mg orally daily
45676924|NCT01814007|Device|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
45676925|NCT01844115|Drug|Placebo|
45676926|NCT01844115|Drug|Vilazodone|Viibryd
45676927|NCT02018042|Drug|Abatacept|"After the screening period, subjects will begin weekly self-administered subcutaneous abatacept and will continue treatment for 6 months. Patients will be instructed in self-administration of study medication at baseline (week zero) and will be observed self-administering medication at each visit. Instructions regarding study drug administration will be reinforced as needed.~The 6-month treatment period is expected to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with moderate to severe AAP. Responders will then be followed for 6 months off drug."
45676928|NCT04667390|Other|total knee arthroplasty|total knee arthroplasty
45676929|NCT01813305|Drug|CSTC1|vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof
46002979|NCT04642794|Other|observational study|patients admitted for AP with portosplenomesenteric vein thrombosis.
46002980|NCT04892966|Diagnostic Test|TXI Light Imaging|Standard Colonoscopy using TXI imaging
46002981|NCT04892966|Diagnostic Test|WLI Imaging|Standard Colonoscopy using White Light Imaging
46002982|NCT04642521|Device|Jamar hydraulic hand dynamometer|"The strength of the dominant hand will be recorded before and after receiving intravenous iron.~Each participant will be positioned in a straight back chair with both hand and feet flat on the ground, elbow flexed to 90 degrees with forearm and wrist in the neutral position. Patient's muscle strength will then be tested three times with an interval of one minute between testing and the average of three times will be recorded to the nearest 0.1kg."
46002983|NCT00551486|Procedure|ultrasound-guided fine needle aspiration biopsy|Fine needle aspiration (FNA)with cytologic analysis has become a mainstay of thyroid nodule evaluation was used. Nonpalpable nodules were aspirated under ultrasound guidance to facilitate precise targeting of the nodule and to sample the part most likely to improve diagnostic yield.
45676930|NCT01813305|Drug|CSTC1 Matched vehicle|
45676931|NCT01993940|Drug|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
45676932|NCT01993940|Drug|Placebo|Placebo tablet taken orally once a day
46088608|NCT03856229|Drug|Shortened steroid regimen|"Subjects with Moderate PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5);40 mg orally every 24 hours (Day 6 to 8).~Subjects with severe PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5),40 mg orally every 24 hours (Day 6 to 10); and 20 mg orally every 24 h (Day 11 to 14)."
45676933|NCT01843803|Other|patient inventory|Patients in the intervention arm will complete an inventory of their preferences, resources, and life circumstances that may affect their care. The inventory will be completed on an iPad, and a copy of the results will be given to the patient's provider at the time of their visit.
45676934|NCT01843803|Other|attention control|Patients will view a brief healthy living video on an iPad
46002984|NCT04642248|Other|Personalized Run Practice|A combination of drills, flexibility, and strength activities combined with a gait retraining program
45676935|NCT02017171|Drug|Allopurinol|
46002985|NCT03455894|Device|DETECT'CHUTE CLINIBED|The DETECT'CHUTE carpets will be positioned at night at the foot of the bed and set in motion by the nursing staff as soon as the elderly person goes to bed for the night. They will be withdrawn the next morning after the resident's rise. Each patient will benefit from the mat for 1 month.
46002986|NCT04642482|Dietary Supplement|Synbiotic (Rillus)|Participants in this group will be given a fine powder of synbiotic formula and should be taken orally without diluted with water.
46002987|NCT04642482|Drug|Placebo|Participants in this group will be given a fine powder of maltodextrin formula and should be taken orally without diluted with water.
46002988|NCT03455777|Drug|AKCEA-ANGPTL3-LRX|Single open-label cohort
46002989|NCT03455738|Other|vasoplegic syndrome|Patients with vasoplegic syndrome for whom the intensive care physician planned to decrease the norepinephrine dosage were included. Hemodynamic and uncalibrated pulse contour analysis (Volume view, FloTrac, Edwards Lifescience, Irvine) values were obtained before and after decreasing the norepineprhine dosage. Responders were defined by a >10% decrease in mean arterial pressure (MAP).
46002990|NCT04642209|Device|Aggregometry|"After evaluation at the Emergency Department the anesthesiologist immediately collects a sample of blood for TEG with ADP Platelet Mapping test.~If both MA-ADP and platelets aggregation (%) are within normal values (i.e. ≥45 mm and ≥83%, respectively), the patient could be considered as candidate for immediate surgery (within 48 hours) with neuraxial anesthesia.~If MA-ADP and/or platelets aggregation (%) are lower than normal values, the Nottingham Hip Fracture Score (NHFS) is computed, to predict the 30-day mortality after hip fracture surgery. If NHFS is ≥4 (high risk), the patient will undergo to general anesthesia and peripheral antalgic block, to perform surgery within 48 hours. In case of low risk for mortality (i.e. a NHFS <4), surgery will be postponed until the normalization of both MA-ADP and platelet aggregation."
46002991|NCT01167374|Radiation|Carbon Ion Radiotherapy|Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E
46002992|NCT04642443|Device|SENSE Device|The SENSE Device is indicated for the monitoring of intracranial hemorrhage by detecting a suspected increase in blood volume within the cranial vault. It is an adjunctive device to the clinical evaluation in the acute hospital setting of patients 22 years of age or older with suspected or known intracranial hemorrhage. The device is indicated for use to monitor patients for intracranial hemorrhage expansion between CT scans but should not serve as a substitute for these scans.
46088609|NCT02687490|Drug|Abraxane|125 mg/m2, D1, D8, D15
45676936|NCT02017171|Drug|Placebo|Inactive oral tablets identical in appearance to allopurinol tablets.
45676937|NCT04686097|Procedure|treatment: puncture of coagulation|ultrasound-guided puncture of coagulation
45835974|NCT00079326|Biological|trastuzumab|Given IV
45676938|NCT04686097|Procedure|treatment: sclerosing agent injected|ultrasound-guided sclerosing agent injected
45676939|NCT02029417|Drug|cytarabine|Given SC
45676940|NCT02029417|Drug|omacetaxine mepesuccinate|Given SC
45676941|NCT02029417|Drug|decitabine|Given IV
45676942|NCT02029417|Other|laboratory biomarker analysis|Correlative studies
45676943|NCT02016716|Drug|Romosozumab 90 mg/mL|Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe (PFS).
45676944|NCT02016716|Drug|Placebo 90 mg/mL|Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.
45676945|NCT02016716|Drug|Romosozumab 70 mg/mL|Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass PFS.
45676946|NCT02016716|Drug|Placebo 70 mg/mL|Placebo administered as 3 SC injections with the 1.0 mL glass PFS.
45676947|NCT04694846|Drug|Nicotine Replacement|Given NRT via trans-dermal patch, gum, nasal spray, inhaler or lozenges
45676948|NCT04694846|Drug|Bupropion Hydrochloride Controlled-release|Given PO
45676949|NCT04694846|Drug|Varenicline|Given PO
45676950|NCT04694846|Other|Tobacco Cessation Counseling|Receive counseling
45676951|NCT04694846|Other|Questionnaire Administration|Ancillary studies
45676952|NCT04694846|Other|Quality of Life Assessment|Ancillary studies
45676953|NCT04694846|Other|Best Practice|Receive standard treatment
45676954|NCT02050321|Drug|Acitretin|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
45835975|NCT00079326|Drug|ixabepilone|Given IV
45835976|NCT00079326|Other|laboratory biomarker analysis|Correlative studies
45835977|NCT02187354|Drug|Blinatumomab|A single cycle of blinatumomab (CIVI) treatment is 6wks, 4wks of treatment followed by a 2wk treatment-free interval. Up to 5 cycles will be administered per subject. In the first cycle, for patients with an M3 bone marrow, the initial dose will be 5μg/m2/day for the first 7days, escalated to 15μg/m2/day on D8-D29. For all subsequent cycles 15μg/m2/day will be the dose for all 4wks of continuous treatment. In case of M2 bone marrow or M1 bone marrow with an MRD relapse at screening, the initial dose will start at 15μg/m2/day for the first 7days of treatment & no dose step at D8. For all subsequent cycles the dose will remain 15μg/m2/day. A dose of 9μg/day for the initial dose (if applicable) & 28μg/day for the escalated dose after dose step should not be exceeded.
45458771|NCT03749746|Behavioral|Heart Health 4 New Moms|The intervention is comprised of four key components: (1) The online curriculum consists of 12 modules on healthy eating and physical activity adapted from the Diabetes Prevention Program and specifically targeting postpartum women. (2) Self-monitoring and tracking program, in which participants will be provided with a Bluetooth-enabled blood pressure cuff and digital scale and will be provided real-time feedback on their blood pressure and weight trends. (3) A registered dietitian will act as a lifestyle coach for participants with regular review of progress and provision of coaching notes, support and suggestions. (4) Finally participants will have access to a customized online toolbox, including dietary tracking sheets and recipes from the American Heart Association (AHA).
46002993|NCT01125761|Drug|dexamethasone 0.5 mg and 1.0 mg clemastine cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
46002994|NCT01125761|Drug|Dexamethasone 0,5 mg cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
46002995|NCT04642326|Device|Test Group: experimental - UVC Therapy applied|in addition to traditional drug therapy, apply a surgical treatment procedures with using special UVC device.(Antiviral + Antimalarial + Antibiotic Treatment + UVC Therapy)
46002996|NCT00871013|Drug|Melphalan|"Given by vein, Day 3~First Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4~Second Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4~Second Transplant Bortezomib (Velcade) By vein Day -5 and Day -2~Year 1 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 28 days~Years 2 & 3 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 56 days"
46002997|NCT00871013|Drug|Velcade|Given by vein, Days 1, 5, 8, 11
46002998|NCT00871013|Drug|Thalidomide|Given by mouth at bedtime, Days 5-8
46002999|NCT00871013|Drug|Dexamethasone|Given by mouth, once per day Days 5-8
46003000|NCT00871013|Drug|Cisplatin|Given by vein, Days 5-8 continuous infusion
46003001|NCT00871013|Drug|Adriamycin|Given by vein, days 5-8 continuous infusion
46088610|NCT03851783|Device|Solar-powered oxygen|Constant and reliable administration of oxygen, using solar panels to power an oxygen concentrator and deliver medical grade oxygen at 1-5L/min.
46003002|NCT00871013|Drug|Cyclophosphamide|Given by vein days 5-8 continuous infusion
46003003|NCT00871013|Drug|Etoposide|Given by vein days 5-8 continuous infusion
46003004|NCT00798122|Procedure|Intravascular ultrasound|intravascular ultrasound
46003005|NCT00798122|Procedure|MRI|cardiac MRI
46003006|NCT04642092|Behavioral|PsicAP protocol|The intervention will include: psychoeducation, relaxation and breathing techniques, thought management, tips to improve quality of life and relapse prevention. All of these activities will be based on scientific evidence and many of these aspects will be supported by mobile devices.
45458772|NCT03749746|Other|Usual care|Participants will be counseled on routine postpartum care and will receive additional information on cardiovascular risk following preeclampsia as well as information on support groups and registries as well as online resources for lifestyle modification.
46003007|NCT04642092|Behavioral|Conventional treatment|Typical treatment that is currently given to patients with emotional disorders in Dominican primary care units.
46003008|NCT05436080|Device|U/S|Epididymal Ultrasongraphic Findings by Scrotal U/S
46088611|NCT03843840|Device|Combined Coaxial Optical Coherence Tomography|Taking images of the retina with two wavelengths
46088612|NCT04034160|Other|vegetarian burger|"A finger prick test will be used to determine baseline levels measurements for serum lipids, glucose, and hs-CRP levels. Group 1 will be given vegetarian burgers to consume. Participants will need to remain in the room for 2 hours, postprandial (they may study, watch a movie, etc). They will not be allowed to consume anything except for water during this time. After consumption of burger, at 30 min, 60 min, 120 min, finger prick tests will be used to obtain blood. Participants will also be asked to try and identify the burger they consumed and rate the taste of the burger. Visit 2 will take approximately 3 hours.~Participants will be directed to fast for 8 hours prior to Visit 3 (the following week).~Visit 3: We will repeat the same procedure as Visit 2. However, this time the burgers will be switched."
45676955|NCT02050321|Drug|Vemurafenib|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
45676956|NCT02017015|Drug|nab-paclitaxel|nab-paclitaxel at 125 mg/m^2, by IV infusion over 30 to 40 minutes (maximum infusion time not to exceed 40 minutes)
45458773|NCT05155189|Biological|TC-CAR031|Targeting GPC3 armored CART cell injection (C-CAR031)
45676957|NCT02017015|Drug|Gemcitabine|Gemcitabine at 1000 mg/m^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
45676958|NCT02016625|Drug|Faldaprevir|
45676959|NCT02016625|Drug|Faldaprevir|
46003009|NCT04641780|Drug|Brexpiprazole|"For the treatment of schizophrenia, the recommended starting dosage for Rexulti™ is 1 mg once daily on Days 1 to 4, taken orally with or without food. The recommended target Rexulti™ dosage is 2 mg to 4 mg once daily. Titrate to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 4 mg.~The recommended starting dosage for Rexulti™ as adjunctive therapy for MDD is 0.5 mg or 1 mg once daily, taken orally with or without food. Titrate to 1 mg once daily, then up to the target dosage of 2 mg once daily. Dosage increases should occur at weekly intervals based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 3 mg. It must be periodically reassess to determine the continued need and appropriate dosage for treatment."
46003010|NCT04641624|Other|ultrasound assessment|soluble fms-like tyrosine kinase-1, proangiogenic protein placental growth factor, and niacin measurementswith a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
46003011|NCT05431127|Device|IMT therapy using the Pr02 mobile device|Inspiratory Muscle Training using a device used to measure and increase respiratory strength and performance through resisted breathing exercises.
46003012|NCT04641546|Procedure|Therapeutic Exercise|Passive range of motion (PROM), active-assistive range of motion (AAROM), active range of motion (AROM), and strengthening activities.
46003013|NCT04641546|Procedure|Occupation-Based Intervention|Collecting and placing items in cabinets, washing windows and tables, and hanging clothes on a clothesline.
45676960|NCT02016625|Drug|Cyclosporine|
46003014|NCT05427656|Radiation|[18F] TRACK|We propose to use the radiotracer [18F] TRACK to non-invasively image the concentration of TrkB/C in the living human brain with PET in the 3 cohorts. The different subgroups of healthy controls will be used to define the best quantification method for our TrkB/C ligands and to assess a possible age dependency of TrkB/C binding in the healthy population, and may be of particular importance for the future study of patients with Alzheimer's Disease or mild cognitive impairment. Each participantsubject will receive a single scan with 185 MBq [18F] TRACK injected into an antecubital vein. Dynamic PET data will be acquired in list mode for 90 minutes ([18F] TRACK) respectively on a CTI/Siemens HRRT PET scanner at the brain imaging center of the Montreal Neurological Institute following our published procedure for [18F] TRACK after a transmission scan.
45676961|NCT02016625|Drug|Tacrolimus|
46003015|NCT05427656|Device|Measurement of Arterial Input Function|The non-invasive detector, hereinafter called NID, comprises of plastic scintillating fibers (BCF-12, St-Gobain, France) wrapped in a medical-grade acrylic heat-shrink tube (Vention Medical, USA). The scintillating fibers are coupled to 5 m long transmission fibers to bring the signal out of the PET detector. The fibers will be held in place using a 3D-printed structure composed poly-lactic acid. The NID is designed to measure both positrons and photons escaping the wrist. Post-processing software is used to calculate the arterial input function.
46003016|NCT04641585|Diagnostic Test|Patients affected by Brugada Syndrome 1|ECG analysis by Machine Learning algorithms and blood collection for the transcriptomic study of markers possibly associated with the disease
46003017|NCT00559221|Drug|FLAG+IDA|Fludarabine, cytarabine, G-CSF
45676962|NCT02016482|Biological|Adalimumab|
45676963|NCT02016482|Other|Placebo|
45676964|NCT02028871|Drug|Intranasal Insulin|
45676965|NCT02028871|Drug|Placebo|
45676966|NCT04679467|Dietary Supplement|PKU sphere|"TYR sphere is a powdered, low phenylalanine and tyrosine protein substitute, containing a balanced mix of casein glycomacropeptide (cGMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and the long chain polyunsaturated fatty acid (LCP); Docosahexaenoic acid (DHA). It contains sugars and sweetener.~The product is designed to be prescribed based on its protein content, not its energy content."
46003018|NCT05408312|Biological|Experimental Vaccine 1|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
46003019|NCT05408312|Biological|Experimental Vaccine 2|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
46003020|NCT05408312|Biological|Experimental Vaccine 3|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
46003021|NCT05408312|Biological|placebo|Intramuscular injection of low-dose Recombinant placebo in the deltoid muscle of the upper arm
46003022|NCT04641468|Procedure|DCB|OCT technical guidance: if B-type or C-type dissection can be seen, Oct should be used for further evaluation, and des treatment should be conducted if necessary
46003023|NCT04683497|Other|Contrast-enhanced Intraoperative Ultrasound|Intraoperative ultrasound with the administration of a contrast agent I.V.
46003024|NCT00559260|Device|Passive monitoring with pulse-oximetry, NIBP and ECG|
46003025|NCT05381285|Other|No intervention|Non-interventional study
46003026|NCT04641117|Other|Exercise|Walking and Power Training
46003027|NCT05368844|Device|rTMS treatment using BrainsWay Model 104 system with H1-Coil|5 days of 10 daily sessions of rTMS treatment
46003028|NCT05368844|Device|sham TMS using BrainsWay Model 104 system with H1-Coil|5 days of 10 daily sessions of sham iTBS treatment
46003029|NCT04641390|Other|Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome resistant to drug treatment|The analysis of the seminal microbiome will be carried out by massive genetic sequencing
46003030|NCT04641390|Other|Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome not resistant to drug treatment|The analysis of the seminal microbiome will be carried out by massive genetic sequencing
46003031|NCT00559299|Drug|GSK163090|
46003032|NCT05358080|Drug|Entelon Tab. 50mg|twice daily for 24months
46003033|NCT05358080|Drug|Placebo|twice daily for 24months
46003034|NCT00559338|Drug|recombinant B-type, natriuretic peptide|The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
46003035|NCT00559338|Drug|placebo|The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
46003036|NCT05352737|Diagnostic Test|methylmalonic acid testing|
45676967|NCT02028715|Drug|Placebo|Normal saline (100cc) will be given IV as the placebo medication every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
46003037|NCT04641429|Behavioral|Qigong exercise|Participants in the experimental group receive 12-week group-based Qigong exercise training.
46003038|NCT04641429|Behavioral|Stretching exercise|Participants in the control group receive 12-week group-based stretching exercise training.
46003039|NCT00559416|Drug|Cell Transfer|
45458774|NCT03696550|Drug|Eravacycline (TP-434)|"Subjects will be stratified by age into 2 cohorts, as follows:~Cohort 1: from 12 to <18 years of age (N=8)~Cohort 2: from 8 to <12 years of age (N=12 or at least 60% of subjects)"
46003040|NCT05340374|Drug|Cabazitaxel|Cabazitaxel belongs to the Taxane group of drugs which function by interfering with microtubule depolymerisation and thus inhibit mitosis, which leads to cell death via apoptosis. It is the first chemotherapy agent to improve survival in patients with mCRPC with progressive disease after docetaxel-based treatment.
45676968|NCT02028715|Drug|IV acetaminophen|IV acetaminophen (1,000mg) will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
45458775|NCT01144195|Drug|Panitumumab + FOLFIRI|Panitumumab will be administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks. FOLFIRI chemotherapy will be administered once every 2 weeks after the administration of Panitumumab.
45458776|NCT05631769|Drug|Dual antiplatelet agent duration|"Patients who receive percutaneous coronary intervention for coronary artery disease will be randomized to arms with different DAPT strategies.~The randomization will be stratified according to the High bleeding risk (defined according to the ARC-HBR criteria)."
45458777|NCT01142713|Radiation|Patient Position During Radiotherapy|Two simulations, one in the supine position on a flat table and another in the prone position on belly board
45473896|NCT03652675|Behavioral|Intervention: (Clinician's Guide + HealthCall for HIV/HCV)|This intervention consists of an adaptation of the National Institutes of Health (NIH) Clinician's Guide (CG; NIAAA, 2007) in conjunction with the previously tested HealthCall smartphone app program (Hasin et al., 2013; Hasin et al., 2014). Participants will complete a brief baseline meeting (~20 minutes) with a counselor to discuss alcohol use, liver function, and HIV medication adherence. They will track their drinking using HealthCall for 60 days, with brief follow-up meetings with their counselor to check in about their drinking 30 and 60 days later.
45473897|NCT03381118|Drug|Cytarabine|Cytarabine 500-1000 mg/m2 bid IV infusion on D-4, -3, -2
46003041|NCT05340374|Drug|177Lu-PSMA-617|Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA which is expressed on the prostate cancer cell, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Multiple clinical trials have demonstrated high clinical activity and limited normal tissue toxicity using 177Lu-PSMA-617.
46003042|NCT04640883|Behavioral|Inclusion of sprints during low-intensity cycling during a 14-day training camp (high training load)|Inclusion of 12x30-s maximal sprints during five low-intensity cycling sessions with long duration (>fours hours per session). Five sessions will be performed as low-intensity cycling-only (Controll sessions, distance matched). All other sessions will be performed as low-intensity sessions and adjusted according to each participants training load goal to reach an increase of ~50% in load compared to habitual training.
46003043|NCT04640883|Behavioral|Low-intensity cycling during a 14-day training camp (high training load)|Five low-intensity cycling sessions (>four hours per session), distance-matched to sprint group.
46003044|NCT04640883|Behavioral|Recovery for 10 days (low training load)|Habitual low-intensity cycling (>0.5-2 hours per session)
45676969|NCT02016170|Drug|Ticagrelor 180mg|"After providing written informed consent, eligible patients on maintenance prasugrel meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily maintenance dose for 7±2 days"
46003045|NCT00553124|Drug|selenium|
46003046|NCT00553124|Drug|vitamin E|
46003047|NCT00553124|Procedure|biopsy|
46003048|NCT00553124|Procedure|chemoprevention|
46003049|NCT00553124|Procedure|cryopreservation|
46003050|NCT00553124|Procedure|cytology specimen collection procedure|
46003051|NCT00553124|Procedure|diagnostic procedure|
46003052|NCT00553124|Procedure|gene expression analysis|
46003053|NCT00553124|Procedure|immunohistochemistry staining method|
46003054|NCT00553124|Procedure|laboratory biomarker analysis|
46003055|NCT00553124|Procedure|medical chart review|
46003056|NCT00553124|Procedure|mutation analysis|
46003057|NCT00553124|Procedure|polymerase chain reaction|
46003058|NCT00553124|Procedure|quality-of-life assessment|
46003059|NCT00553124|Procedure|questionnaire administration|
46003060|NCT00553124|Procedure|study of socioeconomic and demographic variables|
46037790|NCT01096056|Biological|Influenza vaccine GSK2186877A formulation 2|Intramuscular administration, 1 dose
46037791|NCT01096056|Biological|Fluarix|Intramuscular administration, 1 dose
46088613|NCT04034160|Other|beef burger|"A finger prick test will be used to determine baseline levels measurements for serum lipids, glucose, and hs-CRP levels. Group 2 will be given beef burgers to consume. Participants will need to remain in the room for 2 hours, postprandial (they may study, watch a movie, etc). They will not be allowed to consume anything except for water during this time. After consumption of burger, at 30 min, 60 min, 120 min, finger prick tests will be used to obtain blood. Participants will also be asked to try and identify the burger they consumed and rate the taste of the burger. Visit 2 will take approximately 3 hours.~Participants will be directed to fast for 8 hours prior to Visit 3 (the following week).~Visit 3: We will repeat the same procedure as Visit 2. However, this time the burgers will be switched."
46003061|NCT04640649|Other|Algorithm prediction|Patients with early and intermediate AMD in at least one eye who are at risk of converting to wet AMD or GA expansion will be randomly assigned to a test group or control group. The test group will have their baseline data analyzed by an algorithm to predict the probability of conversion to wet AMD. If the probability is high for conversion at or before 3 months, patients will have earlier follow-up care than the control group (standard follow-up care every 6 months).
46003062|NCT05340335|Drug|Remimazolam|A beginning dose of remimazolam is 1mg/kg/hr. When sedation is not achieved in 10 minutes, the dose will be increased by 0.1mg/kg/hr in the next patient. When sedation is successful, the same dose will be used with the probability of 0.89, or the dose will be decreased by 0.1mg/kg/hr with the probability of 0.11 in the next patient. (maximal dose: 2mg/kg/hr)
46088614|NCT05241821|Procedure|Mechanical thrombectomy|Percutaneous intervention aimed to retrieve/treat clot affecting the cerebral circulation.
46003063|NCT04640805|Dietary Supplement|Protein supplementation|Liquid protein fortifier (Similac) will be added at 1ml per 25ml of PDHM at 130ml/kg/day of feed volume.
46003064|NCT04640805|Other|Analysis with Miris Human Milk Analyzer|PDHM macronutrient content will be analyzed using the Miris Human Milk Analyzer and PDHM with fat content of 3.8g/dL or higher will be selected and provided.
46088615|NCT05241821|Drug|Thrombolytic Agent|Drug aimed to dissolve thrombus affecting the cerebral circulation
46088616|NCT05337371|Device|ECG patch (Philips ePatch® 2.0)|The ECG patch will be put on the patients chest to monitor cardiac activity for a total time period of 14 days after cardiac arrest.
46088617|NCT04187508|Drug|AZD8154 nebulizer suspension, 20 mg/mL|Subjects will receive AZD8154 from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing and delivered dose will be 3mg.
46088618|NCT04187508|Drug|Placebo|Subjects will receive AZD8154 matching placebo (placebo nebulizer suspension, glucose solution for infusion 50 mg/mL) QD from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing.
46088619|NCT03497507|Device|Sham bracelet|Patients will wear bracelets on both hands
46088620|NCT03497507|Device|Acupressure bracelet|Patients will wear bracelets on both hands.
46088621|NCT05662488|Diagnostic Test|[68Ga]FAPI PET/CT and [18F]FDG PET/CT|To perform [68Ga]FAPI PET/CT and [18F]FDG PET/CT in patients with advanced liver and biliary cancer before and after treatment with PD-1 Based Combination Therapy
46088622|NCT00632957|Dietary Supplement|Omega-3 Fatty acid (with SRP or OHI)|1000mg capsules three times daily, duration 28 weeks.
46088623|NCT00632957|Dietary Supplement|Placebo|corn/soybean oil capsules 1g/three times daily
46088624|NCT03799770|Diagnostic Test|Optic nerve sheath diameter by ultrasound at 5 minutes post-reperfucion|"Patients were placed in the supine position with their eyes closed, and a thick gel layer was applied to the closed upper eyelid. The 7.5-MHz linear probe was placed on the gel without excessive pressure and adjusted to the proper angle for displaying the entry of the optic nerve into the globe. The intensity of the ultrasound was adjusted to display optimal contrast between the retrobulbar echogenic fat tissue and the vertical hypoechoic band. An ultrasound beam was focused on the retrobulbar area using the lowest possible acoustic power that could measure ONSD. The ONSD was measured 3 mm behind the optic disc. Measurements were performed in the transverse and sagittal planes of both eyes, and the ﬁnal ONSD value was calculated by average 4 measured values.~We measured the ONSD at 4 timings: (T1) Post induction and before surgical incision, (T2) Portal vein clamping, (T3) 5 minutes after reperfusion, and (T4) 30 min after reperfusion."
46088625|NCT00650819|Drug|Ezetimibe + Simvastatin|ezetimibe 10 mg plus simvastatin 20 mg once daily for 8 weeks
45676970|NCT02016170|Drug|Prasugrel 10mg|"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"
45676971|NCT02016170|Drug|Ticagrelor 90mg|"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"
45676972|NCT02015546|Drug|Vilazodone|All subjects will receive Vilazodone at 10, 20 or 40mg.
46003065|NCT04640844|Biological|blood sample|measuring the expression and function of lymphocyte A2A receptors.
46003066|NCT05336630|Device|Forceps|The forceps clears the redundant tissue to enable access to the papilla, as well as stabilizes the ampullary position to permit an easier cannulation. The forceps is an FDA approved instrument and does not put the patient at any higher risk for any adverse event. Please note that for the explicit purpose of the study the forceps will be used to grab tissue and not take biopsies. The forceps may still be used to take biopsies if the physician believes it is indicated.
45676973|NCT04684459|Biological|Dual-targeting HER2 and PD-L1 CAR-T cells|serosal cavity infusion
46003067|NCT04640610|Other|Storage of operating waste|Storage of operating waste of adenoidectomy / tonsillectomy
46003068|NCT05327075|Other|questionnaire|it is in the form of questionnaire and scoring tool
45676974|NCT02027701|Biological|IgPro20|
46088626|NCT00650819|Drug|Simvastatin|simvastatin 20 mg plus ezetimibe placebo once daily for 8 weeks
46088627|NCT00650819|Drug|Ezetimibe|Ezetimibe 10 mg plus simvastatin placebo once daily for 8 weeks
46088628|NCT05662410|Drug|Three monthly injections of intravitreal aflibercept|Three monthly intravitreal injection of aflibercept (2.0mg / 0.05ml) after diagnosis of pathychoroid neovasculopathy.
45683765|NCT01798706|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection"
46003069|NCT04640454|Procedure|nipple sparing mastectomy|The investigators categorized the incisions into radial, inframammary, and periareolar incisions with planned reconstruction types; direct to implant (DTI), transversus rectus abdominis myocutaneous (TRAM) flap, latissimus dorsi myocutaneous (LD) flap, or LD with implant.
46003070|NCT05326568|Other|Complementary treatment practice|Applying sesame oil to the patients assigned to the intervention group by applying 10 drops to the 10 cm circumference of the cannula for 10 minutes
46003071|NCT04640181|Drug|Enoxaparin|Subcutaneous enoxaparin While hospitalized only.
46003072|NCT04640181|Drug|Rivaroxaban|Oral rivaroxaban While hospitalized and through discharge for a total of 28 days.
46003073|NCT04640103|Other|No interventions|No interventions
46003074|NCT05317364|Drug|Estradiol 0.01% Vag Cream|1g estradiol vaginal cream 0.01% or placebo will be administered nightly for 2 weeks then twice weekly to complete 6 months therapy
46003075|NCT05317364|Drug|Placebo vaginal cream|Placebo cream
46003076|NCT00559455|Drug|Oxaliplatin|85mg/m², 2 hours IV infusion, Day 1; Every 2 weeks
46003077|NCT00559455|Drug|Fluorouracil|400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks
46003078|NCT00559455|Drug|Leucovorin|200mg/m², Day 1 and Day 2; Every 2 weeks
46003079|NCT00559494|Drug|Minocycline|Minocycline IV BID x 7 days (first 10 patients 200 mg/dose, subsequent patients adjusted based on pharmacodynamic profiling to 800 mg loading dose, tapered 100 mg each dose to 400 mg then maintain at 400mg until day 7)
46003080|NCT00559494|Drug|placebo|Normal saline 250cc via central line similar to minocycline arm administration protocol
46003081|NCT00559494|Procedure|SCPP augmentation|maintenance of spinal cord perfusion pressure at 75 mmHg with fluids and inotrope protocol
46003082|NCT00559494|Procedure|SCPP control|maintenance of Mean arterial pressure of >65 mmHg with fluids and inotropes protocol without spinal cord perfusion pressure as target or guiding therapy
46003083|NCT03455621|Procedure|Toothbrushing|Toothbrushing with different amounts of fluoride toothpaste (or a non-fluoride toothpaste as a control)
46003084|NCT00559533|Drug|RO5045337|Administered po at escalating doses (with a starting dose of 20mg/m2/day) (5-10 cohorts)
46003085|NCT05286632|Device|KidneYou APP|KidneYou is a medical device designed to deliver digital therapy (DT) to patients. The DT utilizes high quality digital technologies to stimulate lifestyle changes in patients. KidneYou has been set up to improve the commitment of patients in following therapeutic directives (i.e. nutritional programs, daily/weekly physical activities) to manage their chronic diseases like CKD. Moreover, KidneYou can improve patient's awareness about his/her disease (mindfulness) so as to increase the individual human ability to be fully present at the ongoing disease's condition and react to it in active and positive manner. Particularly, the mindfulness program contained in this App has been designed to increase the patient's psychological and mental health, aiming at decreasing the perceived stress due to the underlying disease and to the attempts of life-style changes (i.e., healthy diet and physical activity) which may initially negatively affect the subject's natural attitudes.
46003086|NCT05239598|Drug|Mouth rinse|Subjects will be asked to rinse/gargle one time with 10 mL of assigned mouth rinse for 30 seconds.
46003087|NCT00559572|Behavioral|Motivational group sessions|Motivational group sessions include 4 weeks of weekly 1-hour exercise information sessions.
46003088|NCT00559572|Other|Time and attention control group sessions|Time and attention control group sessions include 4 weeks of weekly 1-hour general health information sessions.
46003089|NCT05209412|Device|Lepu Paclitaxel coated balloon|Paclitaxel is the pharmacologically active substance for anti-neointima. The active drug coating is located on the surface of the balloon, which contains 1.5 μg Paclitaxel per 1 mm2.
46003090|NCT05209412|Device|Resolute Integrity Zotarolimus eluting stents|The device consists of a balloon-expandable intracoronary drug-eluting stent pre-mounted on the MicroTrac Rapid Exchange stent delivery system. Drug eluting stent is composed of metal stent, primer and drug coating. The Stent is manufactured from a cobalt alloy (MP35N). The strut thickness is 88.9 μm and the length elements is 0.9 mm. The drug coating consists of the zotarolimus and BioLinx polymer (C10/C19/PVP) system. A coating of polymers loaded with zotarolimus in a formulation applied to the entire surface of the stent at a dose of approximately 1.6 µg/mm2 which results in a maximum nominal drug content of 380 µg on the largest stent (4.0 x 38 mm).
46003091|NCT05209412|Drug|Aspirin|Aspirin is required for 3 months be a part of the dual antiplatelet therapy (DAPT) after PCI.
46003092|NCT05209412|Drug|Ticagrelor|Ticagrelor is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI.
46003093|NCT05209412|Drug|Clopidogrel|Clopidogrel is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI when Ticagrelor is unfeasible or contradicted.
46003094|NCT00559611|Procedure|Endobronchial Ultrasound|A small flexible scope is passed down the windpipe. Samples of lymph gland tissue will be collected through a tiny needle that is passed through the scope.
46003095|NCT00559611|Procedure|Mediastinoscopy|Performed if a tumor is not found on the opposite side of your chest from another tumor by the EBUS.
45473898|NCT03381118|Drug|Nivolumab|Nivolumab 40 mg IV infusion on D+5
45473899|NCT03381118|Drug|Cytarabine|Cytarabine 500-1000 mg/m2 bid IV infusion on D+1, +2, +3
45473900|NCT03381118|Drug|Nivolumab|Nivolumab 40 mg IV infusion on D+1
46003096|NCT05208086|Diagnostic Test|Detection of monoclonal component|Monoclonal component analysis by electrophoresis and immnuofixation on the urine sample from miction and 24h urine sample.
46088629|NCT03741179|Drug|ASA-withdrawn group|Patients whith sFlt/PlGF ratio < 38 at 24+0-27+6 weeks will be randomized into two arms of the trial. Patients allocated in the experimental arm will stop the ASA treatment.
46088630|NCT00622128|Behavioral|Preventing Aggressive Behavior in Demented Patients|Preventing Aggressive Behavior in Demented Patients
46088631|NCT02689362|Drug|Evogliptin|1 tablet per day
46088632|NCT02689362|Drug|Sitagliptin|1 tablet per day
45473901|NCT03381118|Biological|G-CSF mobilized HLA-haploidentical donor PBSC|G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells IV infusion on D0
45676975|NCT02038790|Drug|Suboxone Sublingual Film|A single Suboxone sublingual film strip containing 8mg buprenorphine and 2mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
46003097|NCT03454698|Other|Education|"Usual care as described for the CG also applies to the IG. The intervention will consist of giving patients an opportunity to learn about the use of compression bandages, wearing and putting on compression stockings, physical activity, good skin care, and a high-protein, vitamin-rich diet. This group will be supervised by a study nurse, who will not be identical with the nurse in charge of the control group."
45676976|NCT02038790|Drug|Zubsolv sublingual tablets|A single Zubsolv sublingual tablet containing 5.7mg buprenorphine and 1.4mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
45676977|NCT04693598|Biological|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
45676978|NCT04693286|Biological|novel oral polio type 2 vaccine (nOPV2)|• nOPV2 (C1) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells (S2/cre5/S15domV/rec1/hifi3). Placebo contain sucrose in buffer.
45676979|NCT04693286|Other|Placebo|Placebo contains no active ingradients, only sucrose in buffer
45676980|NCT02027623|Behavioral|Motor skill training|The participant will assist in selecting both simple and complex functional activities to practice. Difficulty will be graded to match the participant's motor capabilities. Three activities will be practiced per session. Within the practice of activities the training will emphasize 1) contraction of groups of specific trunk muscles, 2) earlier and greater movement of the hip, knee, and/or thoracic spine relative to the lumbar spine, 3) later and less movement of the lumbar spine relative to other regions. Within each activity the conditions of practice will vary based on 1) the participant's ability to perform the activity, and 2) the level of challenge the participant is faced with when performing the activity during his day. Equipment will be provided as needed.
45676981|NCT02027623|Behavioral|Strength and flexibility exercise|Exercises based on best evidence for effectiveness in people with chronic low back pain will be prescribed. Strengthening exercises will target all trunk muscles. Flexibility exercises will target all trunk and hip motions. All exercises will be performed at the intensity appropriate for the person's musculoskeletal fitness level based on the American College of Sports Medicine guidelines. Difficulty level, frequency, and number of repetitions will be modified based on guidelines described in the literature. Equipment will be provided as needed.
45676982|NCT04684381|Drug|L-glutamine|Pharmacokinetic study
45676983|NCT02015221|Device|Dual Action Pneumatic Compression Device|A novel dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an AC outlet.
45676984|NCT02015221|Device|Standard Compression Garments|Compression stockings with a 30-40mmHg level of compression.
45676985|NCT04678843|Behavioral|Virtual Family-Based Treatment|Treatment involving the youth/adolescent who has been diagnosed with anorexia nervosa and their family, delivered virtually via videoconferencing.
45676986|NCT02027311|Drug|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
45683766|NCT01798706|Drug|Placebo|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection"
46003098|NCT04639869|Drug|Phenyramydol HCl 400 mg Film Tablet|Phenyramydol HCL 400 mg Film Tablet contains 400 mg phenyramydol manufactured by Pharmactive Ilac.San ve Tic A.S
46003099|NCT04639869|Drug|Cabral 400 mg Film Tablet|Cabral 400 mg Film Tablet 400 mg phenyramydol manufactured by Recordati Ilac SAn ve Tic A.S.
46003100|NCT05186675|Procedure|superselective adrenal arterial embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure
46003101|NCT04639908|Other|Interview|interview with patient
46003102|NCT04639791|Other|No intervention|Observation only, no intervention
46088633|NCT02689362|Drug|Placebo Evogliptin|1 tablet per day
46088634|NCT02689362|Drug|Placebo Sitagliptin|1 tablet per day
46088635|NCT02687256|Device|Extended Wear infusion set|For two of the 4 weeks the Extended Wear insulin infusion set will be used.
46088636|NCT02687256|Device|Standard Infusion set|For two of the 4 weeks the Standard infusion set will be used
46088637|NCT02687256|Drug|Heparin|
46088638|NCT03621137|Other|No study-specific intervention|Treatment of atopic eczema with phototherapy or systemic immunomodulating therapy according to usual clinical practice
46088639|NCT05337215|Behavioral|kangaroo father care|The effect of postpartum kangaroo father care on paternal attachment
46088640|NCT00622206|Drug|ritonavir and saquinavir|saquinavir/ritonavir 1500/100 mg or 1500/50 mg Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
46088641|NCT03582293|Drug|Tranexamic Acid 500Mg Tablet|orally twice daily for 28 days
45473902|NCT03863171|Diagnostic Test|Arterial spin labeling (ASL) magnetic resonance imaging|Arterial spin labeling (ASL) magnetic resonance imaging test
45473903|NCT03863171|Diagnostic Test|Fundus fluorescein angiography|Fundus fluorescein angiography test
45473904|NCT03241368|Device|Capsule Endoscopy|At baseline subject will under the PillCam Crohn's Capsule Procedure
46003103|NCT04639557|Behavioral|BRIDGE Therapy Program|The BRIDGE Therapy Program is a novel manualized therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to promote self-regulation in the mother-child dyads. There are two components of the program: 1) the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and target maternal mental health symptomology, and 2) the parent skill training materials, which have been designed to correspond to the four core DBT modules (i.e., Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
46088642|NCT03582293|Drug|Placebo oral capsule|Oral placebo capsule two times a day for a total of 28 days
46088643|NCT04185636|Device|MolecuLight i:X imaging|The MolecuLight i:X Imaging Device will be used to take standard (ST) and fluorescent (FL) images of each graft site. The MolecuLight i:X will also be used to take measurements of the wound using the measurement feature of the device.
46088644|NCT00639210|Other|supervised training|Design: supervised training is organised for the exercise group once a week in groups of 10 to 15 subjects. The training is guided by an experienced physical therapist.Content: The supervised training of the exercise group consists of two different classes alternating at four week periods; step aerobics class and circuit training class. The 60-minute aerobics and circuit training classes also include warming-up and cooling-down periods both lasting 10-15 minutes.
46003104|NCT05172791|Behavioral|Antibiotic stewardship messaging|Counseling regarding antibiotics for patients prescribed antibiotics for possible pneumonia despite respiratory rates and oxygenation levels within normal ranges
46088645|NCT03574337|Drug|Sugammadex|No additional information
45676987|NCT02027311|Drug|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
45676988|NCT02027311|Drug|Meperidine|Both groups were administered same dose of meperidinie 50mg. Then elders > 80 years old were administered 25mg iv bolus.
45676989|NCT02047903|Drug|Afatinib|50, 40, 30 or 20 mg
45676990|NCT02015065|Drug|Vandetanib|Vandetanib administered orally once per day continuously using a 28 day cycle until disease progression or unacceptable toxicity
46003105|NCT05165693|Other|Experimental Formula|Diabetes-specific study formula
46003106|NCT05165693|Other|Test Meal|Instant oatmeal
46003107|NCT04639362|Drug|ibrutinib, venetoclax, obinutuzumab|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are not in CR or who have detectable MRD after 15 cycles (3 cycles lead-in and 12 cycles induction) will continue with 6 intensification cycles ibrutinib in combination with obinutuzumab day 1, 2, 8, 15 for the first cycle and with obinutuzumab day 1 for the following 5 cycles.
46003108|NCT04639362|Drug|ibrutinib, venetoclax|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are in CR or have no detectable MRD will be observed.
46088646|NCT03574337|Drug|neostigmine/glycopyrolate|No additional information
46003109|NCT04683536|Procedure|Obturator nerve blockade|We performed spinal anesthesia combined with ultrasound guided obturator nerve blockade according to the localization of bladder cancer in patients with lateral wall localized non-muscle invasive bladder cancer
46088647|NCT02689596|Drug|Oxytocin|
46003110|NCT04639401|Other|motor entrainment to auditory cues and music during walking on quality of movement|The study contains 1 descriptive and 4 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, at different tempi and alignment strategies. In the latter three sessions, apart from outcome measures of synchronization the following will be collected as well: spatio-temporal gait parameters, perceived fatigue, perceived motivation and perceived speed of walking.
45676991|NCT02026141|Drug|Dexmedetomidine|
45676992|NCT02026141|Drug|Normal Saline Placebo|
45676993|NCT02026063|Drug|Telotristat etiprate|Telotristat etiprate tablet (250 mg)
45676994|NCT02025907|Drug|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily.
45676995|NCT02025907|Drug|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily.
45676996|NCT02025907|Drug|Placebo|One placebo capsule taken orally (by mouth) once daily.
46003111|NCT04683419|Device|Modified Thoracoscopic pleural Cryobiopsy|"Thoracoscopic pleural biopsy will be taken with a modified technique raising of the parietal pleura by injection of saline, adrenaline and xylocaine, then taking the biopsy via a cryoprobe"
46088648|NCT02689596|Other|Placebo|
46088649|NCT02691312|Device|Digital Retinography System|The DRS is a portable non-mydriatic fundus camera in which children place their chin on a chin rest and the camera, after auto-focusing, takes photographs of their retinas. These photographs will be examined by an ophthalmologist (specializing in retinal disease) to assess for evidence of diabetic retinopathy.
46088650|NCT00583817|Device|Endovascular stent-graft implantation|Endovascular repair of aorta
46088651|NCT04574856|Radiation|Dose-Intensified Radiotherapy|Adaptive, dose-intensified radiotherapy targeting an advanced imaging signature, with a target, nominal radiotherapy dose of 80 Gy.
46088652|NCT04574856|Drug|Temozolomide|Temozolomide chemotherapy (75 mg/m2 daily for 6 weeks)
45676997|NCT01813071|Biological|WRSS1|
45676998|NCT02025751|Drug|Metoclopramide Nasal Spray|One 10 mg spray dose 30 minutes before meals and before bed for 28 days (QID)
45676999|NCT02025751|Drug|Placebo Nasal Spray|One placebo spray dose 30 minutes before meals and before bed for 28 days (QID)
45677000|NCT02025205|Device|Endobronchial Valve|Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
46003112|NCT04639284|Drug|Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies|Combination therapies with an anti-angiogenic agent (tyrosine kinase inhibitor or VEGF/VEGFR antibody) and an anti-PD-1/PD-L1 antibody.
45677001|NCT01812837|Device|Microneedle|The study device (Microchannel Skin System by 3M Company)is fabricated from medicalgrade polymer consisting of a rectangular array of 351 pyramidal, 700-μm-long, solid microneedles.
46088653|NCT04574856|Drug|Adjuvant temozolomide|Adjuvant temozolomide will be delivered at 150-200 mg/m2 days 1-5 every 28 days for 6 cycles, with additional cycles delivered at the discretion of the investigator.
45677002|NCT01812837|Drug|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
45677003|NCT01812837|Radiation|Blue light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA)
45677004|NCT02024971|Drug|Pioglitazone/metformin hydrochloride|Pioglitazone/metformin hydrochloride combination tablets
45677005|NCT01843023|Drug|Extended Release Naltrexone|naltrexone for extended release injectable suspension
45677006|NCT01843023|Behavioral|Psychosocial Treatment|Psychosocial treatment will consist of group and individual drug abuse counseling at MMTC and in the community.
45677007|NCT01843023|Drug|Buprenorphine|Participants assigned to TAU will receive buprenorphine for opioid withdrawal and will either be tapered off the medication or will remain on it for individualized lengths of time during the six month study.
45677008|NCT01812759|Drug|Fentanyl Nasal Spray|100 mcg nasal spray administered in each nostril.
45677009|NCT01812759|Drug|Hydromorphone PCA|Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
45677010|NCT01812759|Other|Placebo Nasal Spray|1 placebo nasal spray administered in each nostril.
45677011|NCT01812057|Drug|Dexamethasone|Dexamethasone 8 mg IV (as a one time dose)
45677012|NCT01812057|Drug|Placebo|Sodium Chloride 0.9% -5 ml
45677013|NCT01842633|Drug|Paracetamol and Caffeine|Caplets containing 500 milligrams (mg) of paracetamol and 65 mg of caffeine
45677014|NCT01842633|Drug|Ibuprofen|Caplets containing 200 mg of ibuprofen
46003113|NCT05103800|Behavioral|invasive interventions|listening the white noise during the invasive interventions
46088654|NCT05335343|Other|no intervention|no intervention
46088655|NCT04185558|Device|ActiGraft|Whole Blood Clot (WBC) gel
46088656|NCT04185558|Device|Standard of Care|Alginate dressing, a non-adherent foam dressing, and an outer gauze wrap
46088657|NCT00423995|Drug|Loratadine/montelukast combination|
46088658|NCT00380627|Drug|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
45473905|NCT03375112|Procedure|Fascia iliaca compartment block|The patient will be brought to the block room within 30 minutes of arriving in recovery. An injection of local anesthetic into the fascia iliaca compartment using ultrasound guidance will be administered. The patient will then be transported back to recovery.
46088659|NCT04185948|Behavioral|Mediterranean diet guidelines plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the Mediterranean dietary guidelines as recommended by the Mediterranean Diet Foundation in Barcelona, Spain. In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
46088660|NCT04185948|Behavioral|UK Eatwell guidelines plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the UK dietary guidelines (Eatwell Guide). In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
45677015|NCT01842633|Other|Placebo|Matching placebo caplets
45677016|NCT01810263|Dietary Supplement|high protein supplement|Dietary Supplement: high protein supplement
45677017|NCT01841697|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg oral capsule once a week for 24 weeks
45677018|NCT01841697|Drug|Sitagliptin|Sitagliptin 100 mg oral tablet once a day for 24 weeks
45677019|NCT01841697|Drug|Placebo to omarigliptin|Placebo to omarigliptin 25 mg oral capsule once a week for 24 weeks
45677020|NCT01841697|Drug|Placebo to Sitagliptin|Placebo to sitagliptin 100 mg oral tablet once a day for 24 weeks
45677021|NCT01841697|Drug|Open-label Metformin|Metformin oral tablet(s) - total daily dose of ≥1500 mg, once or twice a day
45677022|NCT01841697|Drug|Open-label Glimepiride|Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy
45677023|NCT01841073|Dietary Supplement|Inulin|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
45677024|NCT01841073|Dietary Supplement|Cellulose|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
45677025|NCT01841073|Dietary Supplement|Inulin|Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.
45677026|NCT01841073|Dietary Supplement|Cellulose|Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.
45677027|NCT01841073|Dietary Supplement|Inulin|"Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
45677028|NCT01841073|Dietary Supplement|Cellulose|"Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
46003114|NCT00559689|Drug|Budesonide,hydrofluoroalkane-beclomethasone dipropionate|receive twice-daily administration
46003115|NCT00559689|Drug|Budesonide,hydrofluoroalkane-beclomethasone|once-daily administration at bedtime
46003116|NCT05089214|Device|Intra oral cameras|Diagnostic comparison of two intra oral cameras
46003117|NCT04639440|Other|Adipose tissue|Adipose tissue sampling
46003118|NCT04629027|Drug|Immune checkpoint inhibitor|the patients receive necessary treatment without special intervention
46003119|NCT05084768|Diagnostic Test|Donor-derived cell-free DNA|As mentioned previously
45677029|NCT01809327|Drug|Canagliflozin 100 mg|One 100 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 100 mg arm) or with the evening meal (for the Canagliflozin 100 mg + Metformin XR arm).
45677030|NCT01809327|Drug|Canagliflozin 300 mg|One 300 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 300 mg arm) or with the evening meal (for the Canagliflozin 300 mg + Metformin XR arm).
45677031|NCT01809327|Drug|Metformin XR|One 500 mg tablet (Day 1 up to week 1); two 500 mg tablets (Week 1 up to Week 3); three 500 mg tablets (Week 3 to Week 6); four 500 mg tablets (Week 6 to Week 9). Tablets will be administered with the evening meal.
45677032|NCT03272139|Drug|Bupivacaine|Anesthetic that will help treat pain and sensation after shoulder arthroscopy
46003120|NCT00561249|Procedure|laser assisted hatching|Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo
46003121|NCT05076656|Dietary Supplement|Lactobacillus fermentum D3|Lactobacillus fermentum D3 in a white, gelatin capsule (orally), with lyophilized L. fermentum D3 without preservatives, sugars, or additives.
46003122|NCT05076656|Biological|Fecal microbiota transplant (FMT)|Fecal microbiota transplant (FMT) in a green, gelatin capsule (orally), with lyophilized fecal material.
46003123|NCT05076656|Drug|Placebo|Placebo in a white, gelatin capsule (orally), with powder milk
45473906|NCT03375112|Drug|Placebo|The patient will be brought to the block room within 30 minutes of arriving in recovery. An ultrasound probe will be placed to the skin and a blunt needle will be touched to the patient's skin in the area that a fascia iliaca compartment block would be performed. The patient will then be transported back to recovery.
45835978|NCT02187354|Other|Extension of LTFU as per ProtocolAmendment7 7Jun18|LTFU (Long Term Follow-Up) will extend past 18 months for patients already ended the study/still on study or to be enrolled at European sites if they did not receive a transplantation after blinatumomab treatment. For subjects to be included in the additional LTFU, data will be captured until subjects are 18yrs old (every 6 months by phone contact). The following will be captured: relapse (medullary or extra-medullary relapse and its specific location), second tumor (which type), alive/died and cause of death, hospitalization and reason for hospitalization.
45835979|NCT01898052|Drug|single anaesthetic drug|inject periarticular tissue of the knee after implantation
45835980|NCT01898052|Drug|multimodal drug injection|inject periarticular tissue of the knee
45473907|NCT03375112|Drug|Bupivacaine|A one time dose of 40 milliliters of 0.5% bupivacaine will be injected into the fascia iliaca compartment
45473908|NCT01286597|Dietary Supplement|dietary restriction|restrict intake of lactose
45473909|NCT03220581|Behavioral|Referral for care|referral for addictions support
45677033|NCT03272139|Device|Ultrasound|Ultrasound will help guide the anesthesiologist in performing the different nerve blocks
45677034|NCT01808313|Drug|ambrisentan|Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
45835981|NCT00051168|Drug|Travatan|Travoprost (0.004%) 1 drop each eye once daily
46003124|NCT00561288|Drug|acetaminophen|2 x 1000 mg doses per day
46003125|NCT00561288|Other|cornstarch|2 x 1000 mg cornstarch per day
46003126|NCT05062343|Device|Dilapan-S|Osmotic dilator
45473910|NCT03220581|Behavioral|Behavioral therapy|therapy focused on monitoring gaming behavior and replacing it with other activities and communication skills
46003127|NCT05062343|Device|Cook Cervical Ripening Balloon|Double balloon catheter for cervical ripening
46003128|NCT00561327|Drug|losartan|Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)
46088661|NCT05171465|Device|Neqstent or Contour|All patients included will be treated the same: after catheterizing the affected vessel and microcatheterizing the aneurysm with a microcatheter of 0.021'' or 0.027'', the intrasaccular device (Neqstent® or Contour®) will be positioned. Depending of the operator preference, the use of an intrasaccular device could be associated with coiling (mandatory in the case of Neqstent®). Treatment must be performed without previous double antiplatelet treatment (allowing antiplatelet after aneurysm exclusion). Before the treatment all patients should undergo a flat panel CT.
46003129|NCT05060939|Diagnostic Test|COVID-19 vaccinated people|Patients with at least one dose of COVID-19 vaccine tested for SARS-CoV-2 infection with RT-PCR on respiratory specimen. RT-PCR, serological testing and viral sequencing will be applied on patient's samples
46088662|NCT02687334|Drug|100% Oxygen|We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia with 100% oxygen
46088663|NCT00212771|Drug|asenapine|Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
46088664|NCT00212771|Drug|olanzapine|Flexible dose, 1-2 capsules oral once per day (in the morning). Each capsule contains 10 mg olanzapine or matching placebo.
46088665|NCT03710291|Drug|TRC101|Oral, non-absorbed, polymeric hydrochloric acid binder
46088666|NCT03710291|Drug|Placebo|Placebo comparator
46088667|NCT03842436|Device|Digital pill|Digital pills over encapsulating Truvada
46088668|NCT03842436|Drug|Truvada|Truvada prescribed with digital pills for PrEP
46088669|NCT03836586|Behavioral|Cognitive-Behavioral Intervention|This intervention comprises three components: 1) general education about pain (e.g., pain pathways) and a rationale for the intervention (e.g., gate control theory); 2) impact of positive and negative pain-related thoughts on neural process of pain; and 3) a guided imaginal pain exposure exercise.
46088670|NCT03836586|Behavioral|Pain Education|General information about the neurobiology of pain and knee osteoarthritis will be given to participants assigned to this intervention.
45473911|NCT02954575|Drug|Wilate|
46003130|NCT00561366|Drug|Placebo|Placebo t.i.d.
46003131|NCT00561366|Drug|Arimoclomol|capsule, 400 mg t.i.d.
46003132|NCT05057741|Behavioral|Multimodal prehabilitation|"Patients who will receive a multimodal prehabilitation program consisting of guided self-care activities at home that include exercise, nutrition and relaxation. Information Will be share by e health. Monitored by telephone daily during the first week and three times a week between the second and fourth week.~The final evaluation of the program will be performed one working day after the control appointment with surgery, which will be scheduled ten days after hospital discharge; and the satisfaction survey will be applied. At 30 days after surgery, a telephone follow-up will be made to inquire about complications and mortality. On that day, self-care recommendations will be given."
46003133|NCT00561405|Behavioral|Motor Learning Walking Program|Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner. Sessions 45 minutes, 3x per week over 5 weeks for a total of 15 sessions
46003134|NCT00561405|Behavioral|Body Weight Supported Treadmill Training|Participants practice walking on a treadmill while supported with an overhead harness system. Up to 40% body weight support. Target Treadmill speed 2.0 mph. 1 or 2 Trainers (at least one Physical Therapist plus another Physical Therapist or Physiotherapy Assistant) will help guide participants leg, foot and trunk during treatment. Aim is to practice high numbers of repetition of the normal gait cycle on treadmill. Duration of sessions - 20 minutes of treadmill training within a 45 minute session ( 4 sets of 5 minutes of training with 5 minute rests). 3 sessions per week for 5 weeks. Total of 15 sessions.
46088671|NCT03829722|Drug|Nivolumab|Given intravenously (IV), 240 mg every 2 weeks for 4 doses concurrent with radiation therapy (RT). Following completion of RT, 480 mg given every 4 weeks for 4 doses.
46088672|NCT03829722|Drug|Carboplatin|Given IV once per week during radiation therapy (AUC=1).
46088673|NCT03829722|Drug|Paclitaxel|Given IV once per week during radiation therapy (30mg/m^2)
46088674|NCT03829722|Radiation|Radiation Therapy|Given 5 days/week for a total of 35 doses (70 gray total).
46088675|NCT03822312|Device|DBT-TOBI|The DBT-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through
46088676|NCT03822312|Device|MRI-TOBI|The MRI-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through. The MRI scan is completed at the same time as the TOBI scan. Participation in this part of the intervention is optional.
46088677|NCT02690753|Procedure|A protocol tailored to individual risk factors|
46088678|NCT02690753|Device|The Prevalon® Turn and Position System 2.0|
45473912|NCT02997358|Drug|Doxorubicin|75 mg/m² Day 1 of each 3-weeks cycle
45473913|NCT02997358|Drug|Trabectedin|150 μg/m²/day s.c From day 3 to day 9
45677035|NCT01840605|Drug|Bepotastine besilate|Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day
45677036|NCT01840605|Drug|ketotifen fumarate|Two TAU-284 5 mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day
45677037|NCT04593381|Radiation|Stereotactic body radiotherapy|All patients accrued will be treated with SBRT to all sites of active metastatic disease as per CT scan or PET/CT and/or MRI. A range of schedules and doses are provided, it is advised that the maximum dose that can be achieved whilst meeting the organs at risk planning constraints is prescribed.
46003135|NCT05046704|Device|peripartum transperineal Ultrasound|The anovaginal distance (AVD) will be measured by transperineal ultrasound ,The distance between the anal edge of the internal sphincter and the probe will then be measured in millimeters The ultrasound assessment of the anal sphincters at rest and during contraction will be performed postnatally using a dynamic 2-dimensional transperineal ultrasound with the patient in a supine position, an empty bladder.
46003136|NCT00561444|Behavioral|Questionnaire|Questionnaires taking 20 minutes to complete.
46088679|NCT02690753|Device|Comfort Shield® barrier cream cloths|
46088680|NCT03621540|Device|active tDCS|Using the NeuroConn Plus tDCS device, 2 mA anodal tDCS will be applied to the right dorsolateral prefrontal cortex (F4). 15 s fade in and fade out. Total stimulation time of 1365 s. Cathode over contralateral deltoid muscle.
46088681|NCT03621540|Device|sham tDCS|Sham mode of the NeuroConn Plus tDCS device with 2 mA stimulation for 45 s at the beginning. Anode over right dorsolateral prefrontal cortex (F4), Cathode over contralateral deltoid muscle. After that, only continuous impedance checking is performed.
46003137|NCT05043974|Other|Dry immersion|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
46003138|NCT05041088|Dietary Supplement|ProdromeNeuro Plasmalogen|The product being investigated in this study is the ProdromeNeuro Omega 3 oil nutritional supplement. This product contains naturally occurring fatty acids in higher concentrations than similar products that are commercially available. The purpose of this research study is to better understand the effects of ProdromeNeuro Omega-3 nutritional supplementation among participants with age-related cognitive decline.
46088682|NCT03621540|Behavioral|Adaptive working memory training|Adaptive spatial n-back training.
46088683|NCT00622362|Biological|DEPIGOID Dermatophagoides pteronyssinus|Subcutaneous administration:0.5 ml/month during 1 year
46088684|NCT00622362|Biological|Polymerized TOL of Dermatophagoides pteronyssinus|Sublingual immunotherapy. Two drops daily during 1 year
46088685|NCT00622362|Biological|Placebo Comparator|Sublingual immunotherapy. Two drops daily during 1 year
46003139|NCT00561522|Drug|Capecitabine|Capecitabine 1,250 mg/m2 twice daily on days 1-14, followed by a 7-day drug-free interval. Treatment repeats every 21 days. The above cycle is repeated for 4-6 times.If disease recurrence or unacceptable toxicity or other criteria for withdrawal are met, treatment will be stopped.
46088686|NCT02687178|Drug|Canrenone 50 vs canrenone 100 mg|
46088687|NCT03711318|Drug|Buprenorphine/naloxone|3 week treatment with buprenorphine/naloxone
46088688|NCT03535116|Drug|Ketorolac|Toradol is a type of brand name. We will be using the generic version.
46088689|NCT03535116|Drug|Saline|injectable normal saline
45677038|NCT04585269|Behavioral|Bright IDEAS-YA|Bright IDEAS-YA is a manualized problem-solving skills training intervention conducted by a trainer who teaches the participant the Bright IDEAS stepwise approach to problem-solving and guides the participant through solving their own problems using the Bright IDEAS approach.
46088690|NCT03704298|Drug|Cyclophosphamide|Administered according to package insert
46088691|NCT03704298|Drug|Fludarabine|Administered according to package insert
46088692|NCT03704298|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
46088693|NCT03704298|Biological|Utomilumab|Administered as an IV infusion
46088694|NCT03434652|Device|Percutaneous neurostimulation|Auricular percutaneous neurostimulation
46088695|NCT04187118|Other|Quality of life|Quality of life one year post chemo-therapy
46088696|NCT02687022|Device|Peramis aberrometry|A non-invasive photographic scan sequence acquired in under 10 seconds
46088697|NCT02687022|Device|iDesign aberrometry|A non-invasive photographic scan sequence acquired in under 10 seconds
45677039|NCT02023879|Drug|Alirocumab|Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
45677040|NCT02023879|Drug|Placebo (for Alirocumab)|Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
45677041|NCT02023879|Drug|Non-statin LMT|Ezetimibe or Fenofibrate at stable dose as background therapy.
45677042|NCT02023879|Other|Diet Alone|Stable cholesterol-lowering diet as background therapy.
46003140|NCT00561522|Other|No other preventive treatment|No other preventive treatment
46003141|NCT05009264|Procedure|OMT|OMT will be performed on identified areas of trapezius trigger points
46003142|NCT03454659|Procedure|Craniotomy|Extracting the part of the sculpt
46003143|NCT03454620|Drug|irinotecan|GC1118 combination with irinotecan
46088698|NCT03351660|Diagnostic Test|connected ECG|Cardiosecur allows the realization of a 15 or 22 leads ECG with only 4 electrodes connected to a tablet with an automatic interpretation function
46088699|NCT04208568|Procedure|Laparoscopic cholecystectomy|Four ports laparoscopic cholecystectomy under general anaesthesia
46088700|NCT04185714|Other|Kinesiotaping|Kinesiotaping (KT) is an approach that supports injured muscles and joints and helps relieve pain.
46088701|NCT04185714|Other|Placebo taping|sham taping
46088702|NCT04186962|Other|Behavioral: Simple cognitive task|"A memory reactivation cue followed by playing the computer game Tetris"
46088703|NCT02681874|Behavioral|SSC Program|The Smart and Secure Children (SSC) program is a 10-week manualized intervention that uses a written validated curriculum. The program is group-based and co-led by peer leaders (Parent Leaders). Parent Leaders facilitate conversations on the SSC program content by sharing real life application, experiences, and solutions.
46088704|NCT02681874|Behavioral|Written Handouts|The handouts are a part of the SSC program that include didactic curriculum content and instruct parents to write goals and document goal progress.
45677043|NCT04417153|Behavioral|Mindfulness Based Intervention|The mindfulness-based intervention consists of either four (MF) or eight (MBSR) 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion). Participants will be provided handouts for the information covered during these talks and discussions.These can be done either face to face or online.
45677044|NCT02014441|Drug|Talimogene laherparepvec|Talimogene laherparepvec will be administered by intralesion injection at an initial dose of up to 4.0 mL of 10^6 PFU/mL. The second and subsequent doses will will be up to 4.0 mL 10^8 PFU/mL. The second dose should be administered 21 days from the initial dose. All subsequent doses should be given every 14 days.
46003144|NCT03454620|Drug|FOLFIRI|GC1118 combination with FOLFIRI
46003145|NCT04628559|Drug|Dexmedetomidine|dexmedetomidine was administered as a gradual bolus of 1 µg/kg/10ml 10 min before induction of anesthesia and then as an infusion of 0.4 µg/kg per min (30 ml/h). In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).
46088705|NCT04418232|Combination Product|Alianza Latina|The main components of Alianza Latina are 1) providing primary care providers with education, training and tools for timely dementia diagnosis and optimal treatment and 2) providing Latino dementia patients with enhanced chronic care through bilingual Health Navigators.
46088706|NCT02689050|Device|Needle based confocal laser endomicroscopy (nCLE)|During the fine needle aspiration of a suspected and a non-suspected lymph node we will obtain needle based CLE (nCLE) images within the lymph node. Fine needle aspirations will be obtained after the optical biopsy measurements. We will compare the results of the optical biopsy with the cytology results, or to histology in case an additional surgery is indicated.
46088707|NCT02687100|Drug|Beclomethasone|beclometasone, 0.8 mg of saline to a volume of 8 mL, three times through the line for suctioning above the cuff: a) after positioning the tube; b) at the arrival in the cardiac intensive care unit; c) just prior to start respiratory weaning
46088708|NCT02687100|Drug|Placebo|patients will receive 8 mL of saline without any drug
46088709|NCT00639288|Other|modified CPT-C|modified CPT-C
46088710|NCT04185480|Device|Hemopatch|Before closure of the wound this hemostatic sealant (Hemopatch), a pad of collagen derived from bovine dermis will be applied in the axilla
46088711|NCT05662098|Drug|Hydroxyurea|All participants will receive an individualized PK hydroxyurea assessment. Participants for whom the PK-process successfully generates a dose in the predicted treatment range of 15-35 mg/kg/day, will start on that personalized dose. Participants for whom the process does not generate a starting hydroxyurea dose in the predicted treatment range, due to potential pitfalls in lab draws, serum storage, sample processing, or hydroxyurea analysis, will start at a default dose of 20.0 ± 2.5 mg/kg/day. For all participants, the hydroxyurea dose will be adjusted as needed based on blood counts to establish the optimal dose. Where necessary, a weekly dosing average will be determined, so that treatment can occur solely with locally available and affordable 500mg hydroxyurea capsules.
46088712|NCT02688972|Other|cold water immersion|The volunteers stayed immerged up to the iliac crest, in the water with water. The temperature utilized was 10 degree C and the time was 10 minutes
46088713|NCT02688972|Other|Control group|The volunteers stayed in rest about 10 minutes
46088714|NCT02153645|Drug|240mg Amantadine HCl ER tablets|
46088715|NCT02153645|Drug|Placebo tablets|
46088716|NCT02153645|Drug|320mg Amantadine HCl ER tablets|
46088717|NCT02688738|Drug|Doxycycline|
46088718|NCT02688816|Device|Xpert HPV|Point-of-care HPV DNA PCR test
46088719|NCT02688816|Device|OncoE6|Point-of-care E6 oncoprotein test
45677045|NCT02013817|Drug|rituximab [MabThera/Rituxan]|Every 4 weeks for 6 cycles of induction, followed by maintenance therapy every 3 months x 8
46003146|NCT04628559|Drug|Ketamine|In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).
46003147|NCT04628559|Drug|Saline|Group S was given a bolus of saline solution in 10 ml volume 10 min before induction of anesthesia, followed by 30 mL/h serum saline infusion.
45677046|NCT02013817|Drug|fludarabine|Every 4 weeks, 6 cycles
45677047|NCT02013817|Drug|cyclophosphamide|Every 4 weeks, 3 cycles
45677048|NCT01994863|Device|Coloplast Test product|Coloplast test product is a newly developed 1-piece ostomy appliance
45677049|NCT01994863|Device|Standard Care|"Standard care consists of three already marketed 1-piece ostomy products~Coloplast SenSura Hollister Moderma/Moderma Flex B.Braun Flexima/Softima"
45835982|NCT00083382|Drug|Pamidronate|Patients will receive either pamidronate or zometa. Pamidronate is administered at a dose of 90 mg by continuous infusion over 90 minutes, every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 90 mg every 4 weeks as maintenance therapy.
45835983|NCT00083382|Drug|Thalidomide|"All Patients will receive thalidomide 200 mg as an oral, once daily dose. Dose may be reduced to as low as 50 mg qod in the event of severe toxicity. Thalidomide will continue daily as tolerated until criteria to remove from study are met.~Patients will receive appropriate regimen to prevent constipation (i.e., colace, dulcolax, milk of magnesia, or lactulose)"
45835984|NCT00083382|Drug|Zometa|Patients will receive either pamidronate or zometa. Zometa is administered at a dose of 4 mg by continuous infusion every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 4 mg every 4 weeks as maintenance therapy.
46088720|NCT05335265|Other|Treatment training|"Face-to-face:Metered-DoseInhalerTraining gave 3 times on the 1st day, 2 times on the 2nd day, once on the 3rd day.During discharge, inhaler technical evaluation were done according to the Application Steps of Inhalation Techniques Evaluation Form checklist prepared by using the Patient's Booklet of the Turkish Thoracic Society (TTS).The people who is evaluate the patient's inhaler technique (IT) on the day of discharge was someone different from the health personnel who provided the training. In IT control, the patient's performance was evaluated simultaneously by 2 observers.~Video training:Training gave 3 times on the 1st day, 2 times on the 2nd day,once on the 3rd day.The TTS-Virtual Training Video were used.During discharge,inhaler technical evaluation was done same with face-to-face training.The person who is evaluate the patient's IT was someone different from the training personnel.In IT observation,it was used same method with face-to-face training."
46088721|NCT02688582|Other|TCI group|Drug: cefepime, Device: Target Controlled Infusion pump connected to Rugloop vII software
45677050|NCT02023099|Drug|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
46088722|NCT05123183|Other|acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points exposed. The most preferred points ST36 and CV17 were selected from the points reported to affect lactation by reviewing the literature on the points to be compressed. Acupressure will be applied to CV17 point (single point) and ST36 point (bidirectional, right and left) for 2 minutes for a total of 6 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it will be moved to the other point in the symmetrical region and the application will be made without interruption. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch.
46003148|NCT04683341|Drug|Tenofovir Alafenamide Tablets|Approximately 100 adults, cirrhotic or non-cirrhotic (capped at 50), CHB patients with hepatic decompensation, will receive initial treatment (Arm A) with or switch (Arm B) to TAF 25 mg/day for 144 weeks. For Initiation Arm (Arm A), CHB patients with hepatic decompensation, who are currently not under HBV antiviral treatment will be enrolled. For Switch Arm (Arm B), CHB patients who are currently with hepatic decompensation and virally suppressed under HBV NUC treatment (HBV DNA < 20 IU/mL) will be enrolled.
46003149|NCT04628793|Drug|PF-07258669|PF-07258669 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
45677051|NCT02023099|Drug|Placebo|Tablet
45835985|NCT04506840|Other|Physical activity|Patients will participate in a program of physical exercise. Resistance training, endurance training, balance and flexibility will be trained with the objective to reduce the side effects of chemotherapy and, in order to improve their quality of life
45835986|NCT00167388|Other|feed during blood transfusion|babies receiving the intervention are fed during the PRBC transfusion
45835987|NCT00167544|Drug|Hydrocortisone|Hydrocortisone 3 mg/kg/d divided q 12h IV/PO tapered over 7 days
46003150|NCT04628793|Drug|Placebo|Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
45677052|NCT02013037|Drug|Eculizumab|"At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.~On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.~On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.~On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.~On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit."
45835988|NCT00167544|Drug|Placebo|Saline
45835989|NCT00167934|Drug|Valproate|Depakote ER 500 mg to 3000 mg taken every night
45677053|NCT01967719|Other|mTHS 2.2|Single use of mTHS 2.2
45677054|NCT01967719|Other|mCC|Single use of subject's own mCC
45677055|NCT01967719|Other|NNS|Single administration of 1 mg of nicotine
45677056|NCT04416607|Drug|Corifollitropin Alfa|Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
45677057|NCT04416607|Drug|Menotropins|Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
45835990|NCT00167934|Drug|Placebo|Placebo given at same frequency as Valproate
45835991|NCT00168324|Drug|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
46088723|NCT05123183|Other|back massage group|The mother sits in the chair and leans forward, placing her arms on the table at her level and resting her head on her arms. The mother's breasts are naked and freely released. The researcher massages the mother from top to bottom on both sides of the spine between the scapula bones. At this time, his fists are clenched and the thumb is open. While pressing firmly with his fists, small circular friction movements are made with his thumb. From the neck to the scapula, both sides of the spine are rubbed at the same time for 3 minutes. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch.
46088724|NCT05123183|Other|control group|No application will be made to the mothers in this group, and the amount of milk will be measured by weighing the baby before and after breastfeeding.
46003151|NCT04683302|Device|3DUS biplanar catheterization|biplanar view of both short and long axis view of the internal jugular vein improves anatomical awareness and potentially improves safety of venous catheterization
46003152|NCT04683302|Device|2D US catheterization|2D short axis internal jugular vein catheterization
46003153|NCT04683263|Other|Placebo|topical cream with same composition as Intervention but without active ingredients
46003154|NCT04683263|Other|Fisiocrem|a natural topical composition containing Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol
45677058|NCT01967173|Drug|Flovent Diskus® 100 mcg|Flovent is an ICS
45677059|NCT01967173|Drug|Flovent Diskus® 250 mcg|Flovent is an ICS
46003155|NCT04628676|Drug|tranexamic acid|Tranexamic acid is added to the irrigation fluid used in arthroscopic shoulder surgery.
46003156|NCT04628676|Drug|Epinephrine|Epinephrine is added to the irrigation fluid used in arthroscopic shoulder surgery.
45677060|NCT01967173|Drug|Flovent Diskus® 500 mcg|Flovent is an ICS
45677061|NCT01967173|Drug|Advair Diskus® 100/50 mcg|Advair is an ICS/LABA combination
46088725|NCT00639366|Biological|trastuzumab|
46088726|NCT00639366|Drug|chemotherapy|
45677062|NCT01967173|Drug|Advair Diskus® 250/50 mcg|Advair is an ICS/LABA combination
45677063|NCT01994629|Biological|MenACWY-CRM|MenACWY-CRM
45677064|NCT01994629|Biological|MenACWY-TT|MenACWY-TT
45835992|NCT00168324|Drug|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
45835993|NCT00168324|Other|Sham Injection|Sham injection on Day 0.
45835994|NCT00084552|Radiation|radiation therapy|Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
45835995|NCT02091882|Drug|Placebo|Oral placebo-embedded IEM tablet.
45835996|NCT02091882|Combination Product|Combination product of Aripiprazole + IEM + Sensor + MIND1 Application|Combination product of aripiprazole tablet embedded with sensor and wearable patch with MIND1 system on smartphone
45835997|NCT00085254|Drug|cilengitide|Given IV
45835998|NCT00085254|Drug|temozolomide|Given orally
45835999|NCT00085254|Radiation|radiation therapy|Undergo radiotherapy
45836000|NCT00085254|Other|laboratory biomarker analysis|Correlative studies
45836001|NCT00085254|Other|pharmacological study|Correlative studies
45836002|NCT01897272|Behavioral|Splinting|One group will have their wrist splinted after their carpal tunnel release surgery.
45836003|NCT00253890|Drug|Trazodone|50 mg 1-3 capsules at bedtime for 3 months
45836004|NCT00253890|Drug|Placebo|1-3 at bedtime
45836005|NCT00254592|Drug|Doxorubicin|60 mg/m2 IV, bolus once a day every 14 days x 2-4 cycles
45836006|NCT00254592|Drug|Cyclophosphamide|600 mg/m2 IV once a day every 14 days x 2-4 cycles
45836007|NCT00254592|Drug|Carboplatin|AUC 2 IV weekly for 9-12 doses beginning two weeks after completion of last AC dose
45677065|NCT01994395|Device|The Stride Management Assist (SMA) System|Participants will participate in 18 sessions of outpatient physical therapy + 3 sessions of testing for up to 8 weeks. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait. Treatment consists of 30 minutes high intensity gait training with device, 15 minutes functional mobility with device.
45677066|NCT01994395|Other|Impairment based therapy|Participants participate in 18 weeks of outpatient physical therapy + 3 assessment sessions. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait). Treatment will be divided into: 15 min balance training, 15 minutes functional mobility (transfers, strength or flexibility training) and 15 min high intensity gait training
46088727|NCT00639366|Radiation|radiation therapy|
46037792|NCT00866359|Drug|Apremilast (CC-10004)|"Treatment Phase Days 1-7: Titration from 10 mg BID apremilast tablets arm A (or matching placebo arm B) to 30 mg BID apremilast arm A(or matching placebo arm B) Day 8-84: Maintenance of 30 mg BID apremilast arm A (or matching placebo arm B) Dose reductions to 20 mg BID apremilast arm A (or matching placebo arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast arm A or dose reductions to 20 mg BID apremilast arm A (if not previously down titrated)"
46088728|NCT04201691|Other|classic rehabilitation|The intervention is conventional rehabilitation that included streching, balance and coordination training. The intervention is applied to participants, manually.
46088729|NCT04201691|Other|classic rehabilitation+mobilization|Another intervention is manuel therapy that included gliding technics, rotational technics at cervical region. (in addition to classic rehabilitation). The intervention is applied to participants, manually.
46088730|NCT02686788|Drug|TMP001|600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
46088731|NCT02686866|Device|bioelectrical impedance analysis (Bodystat, Quadscan 4000)|
46088732|NCT02686866|Device|dual-energy X-ray absorptiometry (Hologic, Delphi QDR)|
46088733|NCT02686866|Device|hand grip strength|
46088734|NCT05083871|Other|European Trauma Course|"Structured learning program specifically focused on Trauma management. The course provides frontal lessons, workshops for the technical skills and simulated scenarios.~Please see https://www.erc.edu/courses/european-trauma-course for additional details"
46088735|NCT02686710|Drug|Sevoflurane|
45677067|NCT01992536|Biological|MenABCWY+OMV|"Vaccine contains rMenB (50 µg per antigen) with 25 µg of OMV (a full dose) plus the fully lyophilized MenACWY vaccine"
45677068|NCT01992536|Biological|MenABCWY+¼OMV|Vaccine contains rMenB (50 µg per antigen) with 6.25 µg OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine
45677069|NCT01992536|Biological|Placebo|Saline solution for injection (0.5mL)
45677070|NCT01993927|Drug|Voglibose|Voglibose Tablets / Voglibose OD Tablets
45836008|NCT00254592|Drug|Nab-paclitaxel|100 mg/m2 IV over 30 min weekly for 9-12 doses beginning two weeks after completion of last AC dose
45836009|NCT00254592|Drug|GM-CSF|250 μg/mL IV or on day 4-13 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
45836010|NCT00254592|Drug|Trastuzumab|4mg/kg, and then2 mg/kg q wk IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
46088736|NCT02686710|Drug|Propofol|
46088737|NCT01818167|Drug|10% Benzoyl Peroxide Topical Body Wash|
45836011|NCT00254592|Drug|Bevacizumab|10mg/kg q 2 wks
45836012|NCT00255684|Biological|graft-versus-tumor induction therapy|
46088738|NCT01818167|Drug|Provodine Topical Cream|
46088739|NCT02686632|Behavioral|Palatal brushing|Brushing the palate as part of regular oral hygiene habits (behavior) among complete denture wearers.
46088740|NCT02686944|Biological|Intuvax (ilixadencel)|Therapeutic vaccine: allogeneic, proinflammatory dendritic cells, suspension for intratumoral injection
46088741|NCT01773083|Drug|unfractionated heparin|nebulized 6 times daily, daily dose 150.000 IU for the maximum duration of 14 days
46088742|NCT01773083|Drug|placebo|Placebo: Sterile saline nebulized 6 times daily for the maximum duration of 14 days
46088743|NCT02436252|Drug|DSP-7888|3.5-10.5 mg/body,Id every 2-4 weeks
45836013|NCT00255684|Drug|cyclophosphamide|
45836014|NCT00255684|Drug|cyclosporine|
45836015|NCT00255684|Drug|fludarabine phosphate|
45836016|NCT00255684|Drug|mycophenolate mofetil|
45836017|NCT00255684|Procedure|umbilical cord blood transplantation|
45677071|NCT02015390|Procedure|Autogenous RIA bone grafting|After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include autogenous bone grafting harvesting using Reamer-Irrigator-Aspirator (RIA) and packing it within the defect.
46088744|NCT04201847|Diagnostic Test|Serum test|Serum Fetuin A and fetuin B
46088745|NCT02354898|Drug|BBI503|
46088746|NCT02354898|Drug|Sorafenib|Sorafenib 400mg twice daily (800mg total daily dose)
46088747|NCT00110435|Drug|MK0653A, ezetimibe (+) simvastatin|
46088748|NCT00110435|Drug|Duration of Treatment: 4 wk placebo run in then 6 wk active|
46088749|NCT00110435|Drug|Comparator: atorvastatin|
46088750|NCT04185324|Behavioral|Standard zippering vest|Standard zippering vest used to teach zippering
46088751|NCT04185324|Behavioral|Modified zippering vest|Modified zippering vest used to teach zippering, along with related story
46088752|NCT00093899|Drug|ezetimibe (+) simvastatin|Duration of Treatment: 6 months
46088753|NCT04326660|Other|SCOPE-Chinese Women|SCOPE-Chinese Women is a smart-phone based intervention that includes a Fitbit tracking device to monitor daily activity, 12-weeks of educational modules delivered by WeChat, and Bi-weekly messages that encourage positive behavioral change. The data will be examined by the research team to assess efficacy of the intervention.
46003157|NCT04989569|Dietary Supplement|Nutritional intervention|In the intervention group, the body composition data (of day 1, 3, 8) will be given to the dietitians for adjusting the diet formula. The diet formula will be adjusted on the discretion of the dietitian caring for the septic patients based on clinical judgement. The policy adopted by the dietary treatment guidelines for sepsis is to adjust the dietary concentration when there is too much extracellular water under the premise of gastrointestinal tolerance. When the skeletal muscle mass loss is too fast, the dietitians will increase the protein intake by 1.2g/kg of body weight. For patients with acute renal failure and excess extracellular water accumulation and muscle loss, the dietitians will adjust the protein, sodium, potassium, calcium and phosphorus content in the formula. The dietitians will give appropriate nutrition prescriptions based on clinical signs, disease diagnosis and biochemical values.
46003158|NCT00561561|Behavioral|Acoustic startle testing|recording of eyeblink component of acoustic startle reflex with small surface electrodes during presentation of acoustic stimuli through headphones
46003159|NCT01214629|Drug|LY2523355|Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 alone arm is 0.125 milligrams per meter square per day (mg/m²/day).
46088754|NCT03246035|Behavioral|Intervention Group|For the intervention arm, a specialized heart failure nurse practitioner will contact the patient or their primary caregiver by telephone within 5 days post-discharge and send them an education packet by mail. During the telephone call, the nurse will (1) confirm the patient's scheduled follow-up appointment in cardiology, (2) provide recommendations for heart failure self-care behaviors that were found to be deficient at baseline. Patients will then be referred to a Geriatrics Assessment Team, who will provide individualized recommendations for frailty domains that were found to be deficient at baseline. The technique used to provide educational recommendations will be motivational interviewing.
46088755|NCT03246035|Other|Control Group (Standard Care)|For patients randomized to the Control Group (Standard Care), they will receive their follow-up visits, medications, diet and physical activity advice as they normally would. This is the care they would receive even if they were not enrolled in the study
45458778|NCT01144273|Procedure|Transversus abdominis plane block|"This intraabdominal approach to TAP block is being used regularly by gynaecological surgeons in this hospital now.~To be performed bilaterally before surgical wound closure by an experienced surgeon who initially undergo initial observation by investigator to ensure uniformity in technique.~Local anaesthetic or placebo solution will be injected to TAP with blunt needle from within abdominal cavity under visual and tactile guidance at the triangle of Petit, after feeling one 'pop' through the transversus abdominis muscle to the TAP layer.~After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0.5% ropivacaine or 0.3ml/kg of 0.9% saline placebo will be injected to each side slowly while observing for signs of toxicity."
46003160|NCT01214629|Drug|LY2523355|Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 + pegfilgrastim is 4 mg/m²/day.
46003161|NCT01214629|Drug|pegfilgrastim|6 milligrams (mg) administered subcutaneously on Day 4 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received.
46003162|NCT04628325|Drug|Furosemide|Intravenous Furosemide Plus Small Hypertonic Saline Solutions (HSS)
46003163|NCT04977869|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
46088756|NCT02266758|Other|GDM Screening Methods|
46088757|NCT04591613|Other|Questionnaire|Quality of life and chronic disease impact scales will be completed at inclusion and follow-up visits.
46088758|NCT04591613|Other|Biocollection|Total serum, plasma samples will be collected
46088759|NCT04591613|Other|Follow-up visit|All patients will make an inclusion visit (IV), then a clinical follow-up will be organized for the study at M4, M6, M12 from the day of the onset of the 1st symptoms of COVID.
46003164|NCT04977869|Procedure|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
46088760|NCT05337059|Other|PEEP and Tidal Volume Titration|PEEP and Tidal Volume Titration According to Inspiratory and Expiratory Transpulmonary Pressures
46003165|NCT04318600|Drug|human amniotic mesenchymal stem cell|human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis patients with WHO class III, IV or V LN were given hA-MSC (Peripheral intravenous infusion, dose 1×106/kg cells, once every month for three times).
46003166|NCT04657497|Drug|FOY-305|Specified Dosage and Duration of Treatment
46003167|NCT04657497|Drug|Placebo|Specified Dosage and Duration of Treatment
46003168|NCT01214434|Device|Promiseb Topical Cream|topical non steroidal cream, twice daily
46003169|NCT01214434|Other|Bland emollient|Eucerin cream twice daily
46003170|NCT04971356|Drug|Aspirin 100mg for 1-month (immediately after PCI)|Aspirin for 1-month immediately after PCI to be a part of medication treatment in the Experimental arm
46003171|NCT04971356|Drug|Ticagrelor 90mg for 6-month (immediately after PCI)|Ticagrelor for 6-month immediately after PCI to be a part of medication treatment in the Experimental arm
46088761|NCT04265664|Behavioral|Telerehabilitation|Participants in the telerehabilitation program will receive a graded exercise and self-management intervention. This program will be delivered in a ≤2:1 participant:therapist ratio. Each participant grouping will receive two 60-90 minutes telerehabilitation sessions per week for 4 weeks focusing on lower extremity recovery (total 8-12 hours), with a therapist trained in the use of technology for the provision of rehabilitation. Participants will also be asked to complete at least one additional independent self-managed exercise session each week. This independent exercise session will include selected exercises from the telerehabilitation sessions that will be safe to perform without therapist oversight, and jointly agreed upon by the participant and therapist.
46088762|NCT00092807|Drug|MK0653, ezetimibe|
46088763|NCT00092807|Drug|Comparator: placebo|
46088764|NCT05336981|Radiation|Low-Level Light Therapy|The method consists of the application extraoral of low-intensity infrared laser in the major salivary glands-parotid, submandibular
46088765|NCT04186728|Dietary Supplement|Magnesium glycinate|Daily magnesium capsule.
46003172|NCT04971356|Drug|Aspirin 100mg for 6-month (6-month post PCI)|Aspirin for 6-month at 6 months post-PCI (after the discontinuation of the 6-month Ticagrelor treatment) to be a part of medication treatment in the Experimental arm
46003173|NCT04971356|Drug|Aspirin 100mg for 12-month (immediately after PCI)|Aspirin for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
46003174|NCT04971356|Drug|Ticagrelor 90mg for 12-month (immediately after PCI)|Ticagrelor for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
46003175|NCT04318639|Combination Product|Donepazil|"Donepezil: Subjects will take 5 mg/day of donepezil in the evening for first 4 weeks, then 10 mg/day of donepezil in the evening until week 13.~Cognitive remediation therapy (CRT): This study employs a computerized program (BrainHQ) for cognitive enhancement. Participants use their program for one hour per session, up to five sessions per week, over 13 weeks (maximum of 65 sessions). They may training on site or at another quiet location of their choice."
46003176|NCT04628403|Other|massage|clinical interventions, of mechanophysiological origin for the treatment of symptoms corresponding to DOMS, after exercise
46088766|NCT04186728|Other|Placebo|Daily placebo capsule.
46088767|NCT00092729|Drug|etoricoxib (MK0663)|Two etoricoxib 60 mg tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
46088768|NCT00092729|Drug|Comparator: placebo (unspecified)|Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
46088769|NCT00092729|Drug|Comparator: naproxen sodium|Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
46088770|NCT02686476|Drug|Empagliflozin|group I (n = 50): T2DM patients receiving standard care for T2DM (metformin, sulfonylurea, DPP-4 inhibitor or insulin, in any combination) plus 10 mg of Empagliflozin per day
46088771|NCT04001075|Drug|TJ107|Patients enrolled in dose escalation part will be given 2 doses (28 days/dose) during the main-treatment period
46088772|NCT04972175|Drug|50-Hour Intervention - Rapid Insulin lispro|Subcutaneous-delivery of insulin lispro using pump therapy.
45836018|NCT00255684|Radiation|radiation therapy|
46088773|NCT04972175|Drug|50-Hour Intervention - BC LisPram|Subcutaneous-delivery of BC LisPram using pump therapy.
46088774|NCT00616382|Drug|Indomethacin|IV indomethacin starting at a dose of 0.4 mg/kg given over 30 minutes, increased daily by increments of 0.2 mg/kg/dose and given at intervals of 12 hours until a maximum dose of 1 mg/kg is reached, or until a total indomethacin dose of 6 mg/kg has been given. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later, using the same dose used in the last indomethacin infusion.
46088775|NCT00616382|Drug|Pentoxifylline|IV indomethacin will be re-started at a dose of 0.2 mg/kg to run over 30 minutes at 12 hour intervals to be given concurrently with pentoxifylline (5 mg/kg/hour to run over 6 hour once a day for a maximum of 6 days. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later and another day of pentoxifylline infusion, provided that the 6 day maximum has not yet been
45836019|NCT00256776|Drug|Velcade (Bortezomib)|
45836020|NCT00256776|Drug|Thalidomide|
45836021|NCT00256776|Drug|Dexamethasone|
45836022|NCT00257322|Drug|GM-CSF|250ug/m^2 SQ QD with a cap of 500mcg SQ QD
45836023|NCT00258180|Biological|filgrastim|Administered IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover
45836024|NCT00258180|Drug|cyclophosphamide|Administered IV over 1 hour on days 1-4
45836025|NCT00258882|Biological|Tetanus Toxoid, acellular pertussis, diphtheria toxoid|0.5 mL, Intramuscular
46003177|NCT04628403|Device|lasertherapy|lasertherapy
46088776|NCT04190394|Other|Intermittent retraining program.|Patient benefits from an intermittent retraining program for 8 weeks, with three 45-minute sessions per week.
46003178|NCT04628403|Device|shock waves|shock waves
46003179|NCT01214395|Drug|5% tea tree oil nasal ointment|daily for 5 days then weekly for 6 months
46003180|NCT04970771|Behavioral|Solving Wellness platform|Interactive wellness resources available include a wide range of curated content and resources including fitness and yoga classes, cooking classes, webinars on sleep and various mental health topics including resilience, stress management, relationships and mindfulness, and resources including e-books, videos and guided meditations. Online discussion groups will foster awareness for specific issues and allow casual discussion. A curated collection of links to additional resources including the Solving Healthcare podcast will also be provided.
46088777|NCT02690831|Other|Inspiratory Muscle training (IMT)|Inspiratory Muscle training This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)
46088778|NCT02690831|Other|IMT + Manual Therapy and Motor Control Exercise|IMT + Manual Therapy and Motor Control Exercise The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
46003181|NCT04656834|Procedure|hand incision closure using monocryl sutures and skin glue|At the end of surgery, the investigator will close the incision using monocryl sutures and skin glue
45677072|NCT02015390|Procedure|Allogeneic bone grafting|After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include defect packing with allogeneic bone graft croutons combined with demineralized bone matrix (DBM).
45677073|NCT02012959|Drug|Tolvaptan|
45836026|NCT01899222|Device|Handheld fundus photography|diagnostic imaging with two types of retina camera
46088779|NCT02690831|Device|Powerbreathe|
45836027|NCT00176202|Drug|Divalproex Sodium|Divalproex sodium is a mood stabilizer
46088780|NCT02686398|Biological|Fluad|
46088781|NCT02686398|Biological|Agrippal|
46088782|NCT01643837|Other|Osteopathic Manipulative Treatment|OMT - Sacral Ligamenotus Articular Release; OMT - Lumbar Spine (L1-L2) and Lower Thoracic Spine (T10-12) Ligamentous Articular Release; OMT - Upper Thoracic Spine Ligamentous Articular Release (T1-T8); OMT - Cervical Spine Ligamentous Articular Release (C5-C7); OMT - Suboccipital Myofascial Release; OMT - Clavicular Ligamentous Articular Release; OMT - First Rib Ligamentous Articular Release; OMT - Ribs 2-8 Ligamentous Articular Release; OMT - Pectoral Pull; OMT - Sternal Ligamentous Articular Release; OMT - Direct Myofascial Release of the Diaphragm; OMT - Thoracic Lymphatic Pump; OMT - Fascial Release of Breast Tissue
46088783|NCT01643837|Other|Osteopathic Manipulative Light Touch Protocol (LT)|LT - Sacral Region; LT - Lumbar Spine and Lower Thoracic Region; LT - Upper Thoracic Spine Region; LT - Cervical Spine Region; LT - Suboccipital Region; LT - Clavicles; LT - First Ribs; LT - Ribs 2-8; LT - Pectoralis Muscles; LT - Sternum; LT - Respiratory Diaphragm; LT - Upper Thoracic Cage; LT - Lower Thoracic Cage
46088784|NCT04213430|Other|diagnostic|Training dataset was used to train the deep learning model, which was validated and tested by other two datasets.
46088785|NCT01864746|Drug|Palbociclib PD-0332991|palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle
46088786|NCT01864746|Drug|Placebo|Arm B: Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
45836028|NCT00176202|Drug|risperidone|Risperidone is a second generation antipsychotic and antimanic drug
46088787|NCT00617318|Dietary Supplement|Pomegranate|"All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks."
46088788|NCT00617318|Dietary Supplement|Placebo|"All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks."
45677074|NCT01990742|Behavioral|Palliative Care Team (PCTeam)|Palliative care teams will be established and will round with residents in the intervention nursing homes.
45836029|NCT00176592|Drug|Betaseron|Betaseron 250 micrograms injected SQ every other day
46003182|NCT04656834|Procedure|hand incision closure using simple nylon sutures|At the end of surgery, the investigator will close the incision using simple nylon sutures
46003183|NCT01214239|Drug|Placebo|once a day
46003184|NCT01214239|Drug|Linagliptin|once a day
46003185|NCT04968314|Behavioral|Chicago Parent Program|Chicago Parent Program (ChiPP) is a 12-session group-based parenting skills program
45677075|NCT02012491|Drug|Misoprostol|
45677076|NCT02012491|Drug|Mifepristone|
45677077|NCT01990664|Device|senofilcon A|
45677078|NCT01990664|Device|senofilcon A for Astigmatism|
45677079|NCT04416139|Biological|Infusion IV of Mesenchymal Stem cells|Mesenchymal Stem cells from bank will be applied IV, at dose 1 million xKg in a single dose
45677080|NCT02038010|Drug|PI3K inhibitor BYL719|Given PO
45836030|NCT00176592|Drug|Copaxone|Copaxone 20 mg injected SQ every day (glatiramer acetate)
45836031|NCT00176826|Procedure|Stem Cell Transplant|Infusion of hematopoietic stem cells (bone marrow, cord blood, peripheral blood stem cells) following myeloablative conditioning regimen.
45836032|NCT00176826|Drug|Myeloablative conditioning regimen|Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
46088789|NCT04967573|Drug|Rivaroxaban|Rivaroxaban 20 mg or 10 mg for 3 months
45677081|NCT02038010|Biological|ado-trastuzumab emtansine|Given IV
45677082|NCT02038010|Other|pharmacological study|Correlative studies
46088790|NCT04912973|Procedure|Robotically Assisted Total Knee Arthroplasty - Knee Replacement|Robotically Assisted Total Knee Arthroplasty with a particular alignment strategy
45458779|NCT02528383|Behavioral|Vagifem|"Women participating in the study will undergo clinical assessments, blood work and complete the quality of life questionnaire at baseline, 6 weeks and 12 weeks study time points. The following will be assessed:~Effect of low dose Vagifem, 10ug tablet on vaginal atrophy.~Effect of low dose Vagifem, 10ug tablet on sex hormones and bone health biomarkers.~Impact of treatment on quality of life"
46003186|NCT04628520|Procedure|Free gingival graft|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive a free gingival graft (FGG) harvested from the palate, that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
46003187|NCT04628520|Procedure|Collagen matrix|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive either a collagen matrix (CM), that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
46088791|NCT00639444|Dietary Supplement|gluten-free, normocaloric diet from 6 to 12 months|Gluten-containing cereals (wheat, rye and barley) will be replaced by gluten-free starchy food (rice, corn, tapioca-based, etc) in a normocaloric diet
45677083|NCT02038010|Other|laboratory biomarker analysis|Optional correlative studies
46003188|NCT04628520|Procedure|Maintenance|Oral Hygiene Instruction, periodontal debridment and Supportive Periodontal Therapy
46088792|NCT04212650|Drug|Losartan|Losartan will be administered to improve the quality of hip cartilage repair following arthroscopic microfracture. Losartan is a known anti-fibrotic agent via blocking of TGF-B1.
46003189|NCT01214200|Device|Bilevel positive airway pressure (BiPAP)|This is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation(HINPPV). Participants will receive HINPPV via bilevel positive airway pressure (BiPAP) via a Synchrony ventilator if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O; or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
46003190|NCT04967534|Behavioral|WB-EMS|Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied. After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 12 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping, and lower extremity strength will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by the rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)). WB-EMS will be fully supervised one-on-one.
46003191|NCT04967534|Behavioral|social contact control group|Psycho-social intervention with participants randomized to the control group receiving (if wanted) the same social contact time (20-30 minutes/week) as the WB-EMS group. Depending on personal preferences and Covid-19 restrictions this will be done by phone or in-person one-on-one. Health-related topics and/or general chatting will be offered.
46003192|NCT01214044|Drug|placebo/escitalopram|Subjects will first complete a one week, single-blind placebo lead in phase. Subjects will then receive escitalopram for 8 weeks. Subjects will receive 10 mg/day for the first 2 weeks of active treatment, and then 20 mg/day for the remaining 6 weeks of treatment. Medication will be dispensed on a weekly basis.
46003193|NCT04628286|Other|Sham Laser|Sham Laser in plantar fascia
46003194|NCT04628286|Other|Myofascial Induction|Myofascial Induction in plantar fascia
46088793|NCT04212650|Other|Placebo|Appearance-matched microcrystalline cellulose placebo
45677084|NCT04678310|Other|Support from the hospital palliative and end of life care volunteer service (developed for this study).|Hospital palliative and end of life care volunteer service: a volunteer service to provide support to patients dying in the hospital and their families. The volunteer service has been designed to provide presence and companionship to dying patients at the end of life, and their families.
45840046|NCT03708354|Drug|DeltaGold® Tocotrienol 70%|Each TT softgel (DeltaGold® Tocotrienol 70%) contains 430 mg TT (90% δ-TT+10% γ-TT) with a 70% purity, representing 300 mg TT.
45840047|NCT03297684|Drug|Aflibercept Injection [Eylea]|Intravitreal injection aflibercept
46003195|NCT01213966|Drug|OZ439|po, single dose
46003196|NCT04628598|Behavioral|Antenatal care and prenatal education with a home visit|Providing prenatal education and care by home visits to pregnant women
46003197|NCT04966910|Behavioral|Stay Connected|Stay Connected is a menu-driven set of strategies to combat loneliness, anxiety and depression in older adults based on behavioral activation principles.
46003198|NCT04966910|Behavioral|Treatment as usual|Regular check-ins, resource/referral provision
46003199|NCT01213264|Other|No neuromuscular blockade (NMB)-reversal agent used|Participants whose reversal from NMB is spontaneous (no reversal agent used)
45458780|NCT01146067|Drug|Rivastigmine|Rivastigmine capsules 1.5 mg
45458781|NCT01237249|Drug|Melphalan|
45458782|NCT01237249|Drug|Prednisone|
45840048|NCT03262662|Drug|Varenicline|oral varenicline tablets
45840049|NCT03262662|Behavioral|Brief smoking cessation counseling|~10-minute individual counseling at each of 6 clinic visits
45840050|NCT01740648|Drug|trametinib|Trametinib will be given for 5-day lead-in period by mouth daily Monday-Friday starting at day -14 through -10 and concurrently for the duration of radiation therapy (approximately days 1-38).The dose of Trametinib will be escalated: 0.5 mg, 1.0 mg, 2mg. If the 2 mg dose level causes DLT (dose-limiting toxicity)in 2 out of 6 patients and the 1mg dose level was acceptable, then a 1.5 mg dose cohort will be used.
46088794|NCT03922529|Behavioral|MACRO-I|MACRO-I coaches engage with patients regularly while they are still inpatients, and then by telephone once they are discharged. Coaching incorporates innovative techniques for holistic risk assessment (medical, functional, psychosocial), guidance to initiate CR in a format aligned with each patient's risks and preferences (i.e., CR as either site-based, home-based, or in a hybrid format [site transitioning to home]), behavioral prompts based on their personal goals of care, and de-prescribing of sedating medications.
46003200|NCT01213264|Drug|Sugammadex|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.~As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive the NMB-reversal agent sugammadex, administered according to the local clinical practice and drug product labeling."
45677085|NCT04416698|Behavioral|Individual qualitative interview|Individual interviews will be conducted to understanding the needs and concerns of youth smokers of e-cigarette or other new tobacco products, including their risk perceptions, and the behaviour, attitudes, and experiences related to these tobacco products.
46003201|NCT01213264|Drug|Other NMB-Reversal Agents Used in Routine Anesthesiology Practice|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.~As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive any NMB-reversal agent other than sugammadex, and represents multiple drugs whose use and administration may vary according to local clinical practice, product availability and product labeling."
46003202|NCT04628247|Device|Spring gravity bar|"contain two wooden board length (160 cm) and width (15 cm)~contain pair of spring at every end of board~two wooden board connect in the middle"
46003203|NCT04954625|Procedure|Autologous Blood Patch|All patients will be assessed on the morning of postoperative Day 3 and 4 for the presence of an air leak. If an air leak is present, 60-100 ml of autologous blood will be drawn from a peripheral vein and immediately instilled into the chest tube. The individual who draws blood is that the discretion of the site principal investigator. The tubing will be elevated over an IV pole while the patient remains in bed, moving position every 15 minutes for 1 hour to distribute the blood throughout the pleural cavity. The tubing support will then be removed, allowing the chest tube to drain. After ABP intervention, the chest tube will remain to water seal, as long as the patient tolerates it.
46003204|NCT04954625|Procedure|Standard of Care (per Physician)|Patients randomized to Standard of Care will be treated as their surgeon would as routine. This may mean postoperative observation, of another type of intervention.
46003205|NCT04628637|Other|Serum protein level analysis|Serum GRP78 levels of the subjects were measured through a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Human Glucose Regulated Protein 78 (GRP78) ELISA Kit, Sun Long, SL2048Hu, China), as per the manufacturer's protocol. The detection rate of this kit is 16 pg/mL.
46003206|NCT04951700|Other|Other|This is not an intervention study
45677086|NCT04416698|Behavioral|cross-sectional survey study|structured questionnaire will be constructed for a cross-sectional survey to further explore the behaviour, attitudes, and experiences related to electronic cigarettes or other new tobacco products among youth.
45677087|NCT04678154|Drug|Standard of care|Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.
45677088|NCT04678154|Drug|Vancomycin and Tobramycin|The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden.
45840051|NCT01740648|Drug|fluorouracil|Will be administered as a continuous infusion over 120 hours at a dose of 225 mg/m2/day on Monday to Friday of every week starting day 1-38.
45840052|NCT01740648|Radiation|radiation therapy|Radiation therapy will be delivered to the pelvis during (approximately) days 1-33 (five days a week, Mondays through Fridays for 25 fractions) using a 3-field or 4-field 3-D conformal plan to the primary tumor, surrounding soft tissues, and at risk lymph node stations (peri-rectal, presacral, internal iliac, with or without external iliac) to a total dose of 45 Gy in 1.8 Gy daily fractions. A boost radiation field will be delivered during (approximately) days 36-38. The boost will encompass the primary rectal tumor and involved lymph nodes with a 2-2.5 cm margin, which should include the presacral space. The boost dose will be 5.4 Gy in 1.8 Gy fractions for a total dose of 50.4 Gy.
46003207|NCT04628208|Diagnostic Test|Spartan COVID-19 v2 System|A nasopharyngeal swab sample analyzed on the Spartan COVID-19 v2 System for the detection of SARS-CoV-2.
46003208|NCT04656912|Procedure|Hyperbaric oxygen therapy|Patients with any symptoms and signs were treated with HBO2. During the first HBO2, initial compression was performed to 2.8 atmospheres absolute (ATA) for 45 min, followed by 2.0 ATA for 60 min. If an additional HBO2 was possible within 24 h, then 2.0 ATA was administered for 90 min. Moreover, if necessary, patients were treated with HBO2, even after 24 h, until all symptoms resolved.
46003209|NCT04657107|Drug|S-ketamine|K1 group: pregnant women received 0.2mg/kg S-ketamine, intravenous drip;
46003210|NCT04657107|Other|normal saline|Saline group: pregnant women received saline, intravenous drip
46003211|NCT04657107|Drug|S-ketamine|K2 group: pregnant women received 0.3mg/kg S-ketamine, intravenous drip;
46003212|NCT04937582|Diagnostic Test|Cognitive assessment|Complete cognitive and psychological assessment
46003213|NCT04937582|Diagnostic Test|Imaging|"Brain MRI~Optional: Brain FDG PET (Brain positron emission tomography with F-18 fluorodeoxyglucose)"
46003214|NCT04937582|Diagnostic Test|Routine care|"Electroencephalogram (EEG)~Optional: polysomnography, lumbar puncture"
46003215|NCT04937582|Other|Psychiatric evaluation|Psychiatric consultation if necessary
46003216|NCT04937582|Other|Psychiatric evaluation|Psychiatric consultation if necessary (before the end of their participation in the study)
46003217|NCT04657029|Behavioral|Treadmill|30 minutes of moderate-high intensity treadmill training.
46003218|NCT04657185|Other|OR PathTrac Feedback Optimization|OR PathTrac (RDB Bioinformatics, Omaha, NE 68154) uses a systematic phenotypic approach leveraging temporal association to monitor 13 anesthesia work area reservoirs proven to be associated with high-risk intraoperative bacterial transmission events and subsequent infection development.
46003219|NCT04915157|Device|Spinal Cord Stimulator|All patients will receive an implanted spinal cord stimulator.
46003220|NCT04906460|Drug|WVE-N531|WVE-N531 is an antisense oligonucleotide (ASO)
46003221|NCT04656483|Other|Telemedicine Video Feedback Intervention|Mother-child dyads will take part into a 6 video-conference sessions of Video Feedback (vVF). The vVF will be standardized according to previously published RCTs. Specifically, the 6 vVFI sessions will be organized in two subsequent phases: 4 sessions based on sharing the focus on different relational themes, and 2 sessions of interactive integration. In more specific terms, during the first set of 4 sessions the psychologist will review with mothers' segments of the videotapes obtained during the baseline assessment and will focus on four different relational themes: responsiveness, physical stimulation, teaching, and parenting experience. During the interactive integration session, the insights developed from the first 4 videoconferences will be applied to the real-time interaction between the parent and his/her infant under the guidance of the psychologist.
46003222|NCT04656483|Other|Psychoeducational Booklet Intervention|Mothers of this condition will receive an informative booklet addressing the same themes included in the experimental intervention (responsiveness, physical stimulation, teaching, and parenting experience), but not tailored on their own infant status.
46003223|NCT00561717|Drug|Azelastine and placebo|One Astelin spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
46003224|NCT00561717|Drug|Loratadine and Placebo|One placebo spray per nostril plus one Loratadine 10 mg tablet. In Cross-Over-Design with other arms.
46003225|NCT00561717|Drug|Cetirizine and Placebo|One placebo spray per nostril plus one 10 mg Cetirizine tablet. In Cross-Over-Design with other arms.
46003226|NCT00561717|Drug|Placebo and Placebo (spray and Tablet)|One placebo spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
46003227|NCT04901351|Procedure|Smear|In addition to the routine gynecological follow-up including a cervico-vaginal smear and an HPV test (HPV-HR genome detection), the doctor will propose prospectively to all consecutive patients who meet the inclusion criteria, during a follow-up consultation (post treatment of cervical dysplasia), to participate in the study, that is to have 2 other anal and ENT samples for an HPV test
46088795|NCT03922529|Other|Usual Care|Participants will receive usual care that is recommended by their providers. MACRO study personnel will follow the participant for the course of the study to assess endpoints in comparison to the MACRO-I arm.
46088796|NCT04213352|Other|Wrist Splint|Neutral position and volar supported wrist orthosis which limits the flexion and deviation while allowing pronation, supination, and extension of the wrist.
45458783|NCT01237249|Drug|Velcade|
46003228|NCT00561756|Biological|plasmid DNA vaccine therapy|
46003229|NCT00561756|Other|flow cytometry|
46003230|NCT00561756|Other|immunoenzyme technique|
46003231|NCT04868591|Other|Single session of education and exercise provided by an advanced practice physiotherapist.|In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participant will not receive additional care by the APPT.
46088797|NCT04213352|Other|Rigid Taping|Rigid taping in the neutral position will be performed to allow pronation, supination, and extension of the wrist while limiting the flexion and deviation.
46088798|NCT05324072|Other|no intervention|observational study
46088799|NCT02574728|Drug|Sirolimus|The starting dose for sirolimus is 2 mg/m2 once daily. The dose of sirolimus will be individually adjusted to achieve a target serum trough concentration in the range of 10-15 ng/ml. Sirolimus will be given by mouth every day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
45458784|NCT01237249|Drug|Revlimid|
45458785|NCT01237249|Drug|Dexamethasone|
45458786|NCT01144351|Drug|ELND002|
45458787|NCT01144351|Drug|Placebo|
46003232|NCT04868591|Other|Multiple session of education and exercise provided by an advanced practice physiotherapist.|In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participants will receive five additional consultations with the APPT within a 12-week period. During the follow-up visits, the APPT will reassess the participants, provide further education and recommendations, review and modify the home exercise program and may provide other rehabilitation interventions.
45458788|NCT03646162|Drug|Veru-944|Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT
45458789|NCT03646162|Drug|Placebo|Placebo
45458790|NCT05019859|Behavioral|low carb diet|low carb diet
46003233|NCT04863950|Drug|Lomustine|"For surgical cohort patients, lomustine will be initiated (C1D1) within 6 weeks of surgery as soon as patient is deemed by the investigator (or designee) to be recovered enough for chemotherapy. Initiation of lomustine must be initiated within 6 weeks. If patient cannot be safely initiated on lomustine within this timeframe then they will be replaced.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), lomustine will be initiated on C1D1.~For both cohorts, lomustine will be administered as 110 mg/m2 PO once every 6 weeks."
46003234|NCT04863950|Drug|Imipramine Hydrochloride|"For the surgical cohort, imipramine hydrochloride will be initiated within a minimum of 16 days to a maximum of 3 weeks prior to surgery. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day to attain a maximum dose of 200mg/day in 16 days.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), imipramine hydrochloride will be initiated on Cycle 1 Day 1. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day, if tolerated, to attain a maximum dose of 200mg/day in 16 days."
46003235|NCT04628052|Procedure|Colonoscopy|Music vs. No-Music
46088800|NCT02574728|Drug|Celecoxib|Celecoxib 100 mg will be given by mouth twice a day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
46088801|NCT02574728|Drug|Etoposide|Etoposide 50 mg/m2 (maximum dose 100 mg) will be given daily by mouth for the first 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
46088802|NCT02574728|Drug|Cyclophosphamide|Cyclophosphamide 2.5 mg/Kg (maximum dose 100 mg) will be given daily by mouth for the second 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
46088803|NCT02572856|Device|Continuous Glucose Monitor (CGM)|Apply Dexcom Gen 6 Professional CGM sensor at least 2.5 hours prior to surgery Configure CGM so that its measurements are blinded. Setup CGM to make continuous glucose measurements during and after surgery. Download CGM measurement data after study and compare measurements against glucose measurements made for clinical care.
46088804|NCT00617474|Drug|Erythropoietin|sub cutaneous injection, 2000 unit in per injection, 3 times 1 week.
46088805|NCT00617474|Drug|Placebo|placebo
46088806|NCT04212104|Other|watch a mukbang|watch the dim sum mukbang
46088807|NCT04212104|Other|watch a non-food video|watch the Big Bang Theory video
46088808|NCT00619034|Drug|Latanoprost, diclofenac and dorzolamide (eyedrops)|1 eyedrop twice daily in one week
46088809|NCT00619034|Drug|Diclofenac|dicolfenac eyedrops twice daily i one eye
46088810|NCT00619034|Drug|Dorzolamide|dorzolamide eyedrops twice daily, in one eye for one week
45836033|NCT00176904|Procedure|Stem Cell Transplant|The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains an enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
45840053|NCT01685424|Drug|Etoricoxib|As per routine clinical practice in the United Kingdom
46088811|NCT02555540|Biological|Boostrix|Randomised assignment
45840054|NCT01327638|Drug|etoricoxib|Patients with SpA/AS who took etoricoxib
45840055|NCT01327638|Drug|Other COX-2 inhibitor|Patients with SpA/AS who took other COX-2 inhibitors
46088812|NCT02555540|Biological|Placebo (Saline)|Randomised assignment
45458791|NCT05018533|Drug|TAKC-02|Inhalation Solution
45458792|NCT05018533|Drug|Placebo|Inhalation Solution
45458793|NCT04434469|Drug|RO7297089|RO7297089 will be given via intravenous (IV) infusion
45458794|NCT02528617|Drug|Velaglucerase alfa|Enzyme replacement therapy
45458795|NCT01244347|Drug|folic acid|
45458796|NCT01244347|Drug|folic acid|
45458797|NCT01144429|Biological|Allergoid, allergenic extract of 100% Birch|Subcutaneous injections Build-up = 1 day: 0,1mL + 0,2mL + 0,2mL s.c. in intervals on 30 minutes; Maintenance = 5 x single injection of 0,5 mL s.c. every 4 weeks
45458798|NCT01763827|Biological|Evolocumab|Administered by subcutaneous injection
45458799|NCT01763827|Drug|Ezetimibe|Administered orally once a day
45458800|NCT01763827|Biological|Placebo to Evolocumab|Administered by subcutaneous injection
45458801|NCT01763827|Other|Placebo to Ezetimibe|Administered orally once daily
45458802|NCT03348514|Drug|CPX-POM - 30 mg/m^2|CPX-POM
45458803|NCT03348514|Drug|CPX-POM - 60 mg/m^2|CPX-POM
45458804|NCT03348514|Drug|CPX-POM - 120 mg/m^2|CPX-POM
46003236|NCT04860401|Device|Measurement of tissue oxygenation with novel diagnostic near-infrared spectroscopy device (OxyPrem) (no clinical decisions based on oxygenation levels)|The precision of OxyPrem is assessed by repeated measurements of tissue oxygenation and hemoglobin concentration. The accuracy of OxyPrem is assessed by comparing the measurement data to those acquired simultaneously by established NIRS devices and standard clinical monitoring devices. In substudy 1, healthy adult subjects are enrolled, in substudy 2, measurements are conducted on preterm neonates.
46003237|NCT04628130|Other|Yoga Therapy|Yoga based self managed practices personalised to chronic pain patients
46003238|NCT04827485|Other|Gluteal squeeze|During procedure, the doctor performing colonoscopy will ask for gluteal pressure. The technician will perform the maneuver, but the doctor will be blinded as the arms of the technician along with the patients behind are covered by a towel.
46003239|NCT04827485|Other|No squeeze|During procedure, the doctor performing colonoscopy will ask for gluteal pressure. The technician will not perform the maneuver, but the doctor will be blinded as the arms of the technician along with the patients behind are covered by a towel.
46003240|NCT04656756|Behavioral|Personalized Care|A clinical and standardized workflow was created for both experimental and control groups. This standardized workflow: consisted of services which included the management of basic medications, routine care regarding the postpartum period, newborn care and health education. After the standardized clinic workflow was formed, a personalized care plan was developed for the experimental group. Each care procedure was shared with the participants in the experimental group. Moreover, all potential alternative care plans were presented to the participants.
46003241|NCT04824911|Drug|Clopidogrel|300mg loading and 75mg/day from day 2
46003242|NCT04824911|Drug|Aspirin|Aspirin(100-300mg/day)
46003243|NCT04824911|Drug|Atorvastatin|Atorvastatin 40-80mg/day
46003244|NCT04824911|Drug|Rosuvastatin|Rosuvastatin 20 mg/day.
46003245|NCT04683107|Other|Eccentric protocol|Participants in this arm will perform progressive eccentric exercise protocol
46003246|NCT04683107|Other|Isometric protocol|Participants in this arm will perform progressive isometric exercise protocol
46003247|NCT04683146|Drug|Hand antisepsis with Propanolol- 1 60%.|"Pre-washing for one minute with neutral soap to remove the transient flora.~Hand antisepsis using Propanolol-1 60% in both hands.~Bacterial sample collection from right hand.~Sterile surgical glove in both hands.~Bacterial sample collection from left hand three hours later"
46003248|NCT04683146|Drug|Hand antisepsis with a solution of alcohol, chlorhexidine digluconate and potassium sorbate.|"Pre-washing for one minute with neutral soap to remove the transient flora.~Hand antisepsis using a solution of alcohol, chlorhexidine digluconate and potassium sorbate.~Bacterial sample collection from right hand.~Sterile surgical glove in both hands.~Bacterial sample collection from left hand three hours later."
46003249|NCT04656717|Other|Measure of the total cost of performing next-generation sequencing (NGS)|Resources consumed were collected for each laboratory using a standardized questionnaire. The production costs were calculated for the overall process and resources consumed for each step were identified.
46003250|NCT04816877|Drug|Opioid|Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse.
46003251|NCT00557583|Drug|VBY 376|Doses of 50mg and higher or placebo will be evaluated.
46003252|NCT04627935|Behavioral|The COPD Assessment Test|Used to assess symptoms in COPD patients.
46003253|NCT04627935|Diagnostic Test|Navicular Drop Test|It is the test used to measure the amount of pronation in the foot.
46003254|NCT04627935|Behavioral|International Physical Activity Questionnaires (IPAQ)|The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 questionnaires. The purpose of the questionnaires is to provide common instruments that can be used to obtain internationally comparable data on health-related physical activity.
46003255|NCT04627935|Behavioral|COPD and Asthma Fatigue Scale (CAFS)|CAFS is a comprehensive, brief, patient-centered questionnaire developed to capture fatigue experienced by patients with asthma or COPD.
46003256|NCT04627935|Behavioral|Saint George Respiratory Questionnaire|Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease.
46003257|NCT04800302|Procedure|Continous Quadratum Lumborum Block III|Continuous infusion of Bupivacaine 0.125 % at a rate of 0.1 ml/kg/hr (not exceeding 12 ml/hour), infused through a catheter inserted in the plane between quadratus lumborum & psoas major muscles with ultrasound guidance.
46003258|NCT04800302|Procedure|Single dose Quadratum Lumborum Block III|Single injection of a mixture solution of 20 ml Bupivacaine 0.5% + 10 ml Lidocaine 2%, injected through a needle inserted at the posterior aspect of the quadratus lumborum muscle between it and erector spinae muscle with ultrasound guidance.
46088813|NCT01614912|Drug|SM-13496|40 or 80 mg once daily orally
45458805|NCT03348514|Drug|CPX-POM - 240 mg/m^2|CPX-POM
46003259|NCT04800302|Procedure|Intra-venous Morphine|Intra-venous Morphine [0.1 mg/kg] as rescue analgesic shots when the Visual Analogue Score (VAS) for pain exceeds 4.
46003260|NCT04795037|Drug|CU06-1004, Single dose|"Single dose of CU06-1004, 7 dose levels, oral capsule : 6 Cohorts (100mg, 300mg, 600mg, 900mg, 1200mg, 300mg bid) + 1 Cohort (Food effect)＊~＊Cohort S7(TBD mg) will receive a single oral dose of CU06-1004 or placebo under fed conditions. When administered under fed conditions, CU06-1004 or placebo will be administered following a high-fat/high-calorie breakfast. Cohort S7 will be conducted following completion of Cohort S5"
46003261|NCT04795037|Drug|CU06-1004, Multiple doses|"Multiple doses of CU06-1004, 7 days, 3 dose levels＊, oral capsule~＊The dose levels, regimen (i.e., schedule), and conditions (i.e., fasted versus fed conditions) will be determined based on the safety, tolerability, and plasma PK data from SAD"
46003262|NCT04795037|Drug|Placebo|Placebo matched to CU06-1004, oral capsule
45458806|NCT03348514|Drug|CPX-POM - 360 mg/m^2|CPX-POM
46088814|NCT02688426|Device|Sham Low-Level Laser Therapy (Sham LLLT)|perform with the machine off
46088815|NCT02688426|Device|6J Low-Level Laser Therapy (6J LLLT)|irradiation will be perform with 6J
46003263|NCT04723706|Diagnostic Test|COVID-19 serology IgG|patients with SCT or CART who decide to get their vaccines we will measure response by therapy by measuring COVID-19 serology IgG at the following schedule: Baseline +5 days after vaccination; 1 month +/- 10 days (after the first dose), 2 months +/- 10 days (after the 2nd dose), 3 months +/- 10 days, 6 months +/- 10 days and 12 months +/- 10 days
45677089|NCT04178798|Drug|Acalabrutinib 100 MG Oral Capsule|Patients in Arm A will receive acalabrutinib as one capsule of 100 mg orally twice daily on a continuos Schedule.
45677090|NCT01989572|Other|Laboratory Biomarker Analysis|Correlative studies
45677091|NCT01989572|Other|Placebo|Given GM-CSF placebo SC
46003264|NCT04711304|Biological|Umbilical Cord-derived Wharton's Jelly|Intraarticular injection
46003265|NCT04711304|Device|Hyaluronic acid|Intraarticular injection
45458807|NCT03348514|Drug|CPX-POM - 600 mg/m^2|CPX-POM
46003266|NCT04711304|Other|Saline|Intraarticular injection
46003267|NCT04710719|Drug|Triamcinolone Injection|Post surgical injection at site of keloid with TAC for 3 injections
46003268|NCT04710719|Drug|Triamcinolone Injection and 5-fluorouracil injection|Post surgical injection at site of keloid with TAC and 5FU for 3 injections
46003269|NCT04649372|Procedure|EndoVE|On the day of the procedure, a review of any changes which occurred since the pre-study visit will be conducted. The patient will be placed under general anaesthesia or sedated before Bleomycin will be delivered intravenously. The patient will then be treated endoscopically with the EndoVE device. The EndoVE procedure should take no longer than 30 minutes.
46003270|NCT04627701|Device|ClearRing|ClearRing Implantation
46003271|NCT04683185|Drug|E6742|E6742 tablets.
46003272|NCT04683185|Drug|Placebo|E6742-matched placebo tablets.
46088816|NCT04184856|Diagnostic Test|fMRI|(Imaging while) performing reward related tasks.
46088817|NCT00622596|Other|Mobile Access|Subjects would access buprenorphine through mobile access. On day 1: 8 mg of buprenorphine, then on Day 2: 16 mg daily of buprenorphine sublingually.
45458808|NCT03348514|Drug|CPX-POM - 900 mg/m^2|CPX-POM
45458809|NCT03348514|Drug|CPX-POM - 1200 mg/m^2|CPX-POM
45458810|NCT01146145|Drug|Ketamine|intravenous morphine titration combined to ketamine
45458811|NCT01146535|Drug|Interferon-alpha|150 IU lozenges bid for 5 days
45458812|NCT01146535|Drug|Oseltamivir|75 mg capsules bid for 5 days
45458813|NCT01146535|Other|maltose|200 mg maltose lozenges bid for 5 days
45677092|NCT01989572|Other|Placebo|Given peptide placebo SC
45677093|NCT01989572|Biological|Sargramostim|Given SC
45677094|NCT01989572|Biological|Tyrosinase Peptide|Given SC
45677095|NCT04416776|Drug|Strabismus diagnostic system.|An AI platform based on corneal light-reflection photos to facilitate the diagnosis and angle evaluation of strabismus and to provide advice for surgical planning.
45677096|NCT02036294|Other|BREATHE program|A patient and family- centered transitional care intervention that includes a comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
45677097|NCT02036294|Other|Usual Care|Standard Healthcare Services
45677098|NCT02035748|Drug|Ocriplasmin|0.5 mg/0.2 mL solution for injection
45840056|NCT01327638|Drug|nsNSAIDs|Patients with SpA/AS who took nsNSAIDs
45840057|NCT00393354|Drug|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
45840058|NCT00393354|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
45840059|NCT00166530|Drug|ezetimibe (+) simvastatin|Vytorin® combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks. Tablets
45840060|NCT00166530|Drug|simvastatin|Zocor®; simvastatin 40 mg once daily for 12 weeks. Tablets
45840061|NCT00166530|Drug|atorvastatin|20 mg atorvastatin once daily for 12 weeks. Tablets
45840062|NCT00588900|Drug|cediranib maleate|
45840063|NCT00588900|Drug|irinotecan hydrochloride|
45840064|NCT00589056|Drug|cisplatin|
45840065|NCT00589056|Drug|etoposide|
45840066|NCT00589056|Drug|nelfinavir mesylate|
45840067|NCT00589056|Genetic|protein expression analysis|
45840068|NCT00589056|Other|immunohistochemistry staining method|
45840069|NCT00589056|Other|laboratory biomarker analysis|
46003273|NCT04656405|Other|Online real-time quality measurement and feedback video-based CPR training|"Participants in the online real-time quality measurement and feedback video-based CPR training program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. The study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) are provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing and collect real-time performance data using the QCPR mannequin device. Using this information, the instructor will provide real-time online feedback to participants."
46003274|NCT04656405|Other|Online real-time feedback video-based CPR training without quality measurement|"Participants in the online real-time feedback video-based CPR training without quality measurement program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. When study participants access the online training center, study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) is provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing. The instructor will provide real-time online feedback to participants."
45677099|NCT02014376|Drug|SD-101 dermal cream (3%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-3.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 3% and other excipients.
46003275|NCT04656405|Other|Conventional CPR training|"Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) device are provided to measure and give feedback on the participants CPR performance."
45677100|NCT02014376|Drug|SD-101 Dermal Cream (6%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
45677101|NCT02014376|Drug|Vehicle (SD-101 0%)|A white, crystalline powder that is formulated within an odorless, soft, white cream base. It contains no allantoin, only excipients.
46003276|NCT04647890|Drug|FT011|Two x 100mg capsules once daily for 12 weeks
46003277|NCT04647890|Drug|FT011|Two x 200mg capsules once daily for 12 weeks
46003278|NCT04647890|Drug|Placebo|Two placebo capsules once daily for 12 weeks
46003279|NCT04656288|Drug|BI 764198 - Formula A|BI 764198
46003280|NCT04656288|Drug|BI 764198 - Formula B|BI 764198
46003281|NCT04656288|Drug|BI 764198 - Formula C|BI 764198
46003282|NCT04656288|Drug|BI 764198 - Formula D|BI 764198
46003283|NCT04592276|Dietary Supplement|PS128|Participants took two capsules with PS128 after dinner for 30 days.
46003284|NCT04592276|Dietary Supplement|placebo|Participants took two capsules without PS128 after dinner for 30 days.
46003285|NCT04627779|Drug|preemptive analgesia with flurbiprofen axetil|give flurbiprofen axetil 15 min before surgery
46088818|NCT02688114|Procedure|Baseline surveillance endoscopy|All study participants will undergo endoscopy with NinePoint NvisionVLE volumetric laser endomicroscopy and biopsy of the esophageal mucosa and gastric cardia.
46088819|NCT02688114|Procedure|Radiofrequency ablation|All study participants will undergo radiofrequency ablation of Barrett's esophagus
46088820|NCT02688114|Procedure|Follow up endoscopy 1|All study participants will undergo follow up endoscopy 1 week after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
46088821|NCT02688114|Procedure|Follow up endoscopy 2|All study participants will undergo follow up endoscopy 2 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
46088822|NCT02688114|Procedure|Follow up endoscopy 3|All study participants will undergo follow up endoscopy 4 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
45677102|NCT02035202|Behavioral|CBT2go|CBT administered using mobile intervention.
46003286|NCT04580732|Device|Moventis PNS|Moventis PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin.
46088823|NCT02537886|Device|Patient Centered Virtual Multimedia Interactive Informed Consent tool (VIC)|Six asthma patients will comprise this post-launch focus group, with the goal of gathering opinions, beliefs, and attitudes about VIC.
46088824|NCT01446744|Radiation|Stereotactic ablative radiotherapy|Total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks.
46088825|NCT01446744|Radiation|palliative radiotherapy|"Investigators should follow the principles of palliative radiotherapy as per the individual institution. Treatment recommendations are as follows:~Brain: Whole brain radiotherapy i.e. 20 Gy in 5 fractions, 30 Gy in 10 fractions~Lung: Palliative radiotherapy as per 2011 consensus guidelines.15 i.e. 8 Gy in 1 fraction, 20 Gy in 5 fractions, 30 Gy in 10 fractions~Bone: Palliative radiotherapy as per 2011 consensus guidelines.16 i.e. 8 Gy in 1 fraction (most common), 20 Gy in 5 fractions, 30 Gy in 10 fractions~Liver: 20 Gy in 5 fractions if standard institutional practice"
46088826|NCT02688348|Other|Quality-of-Life Assessment|Ancillary studies
46088827|NCT02688348|Other|Questionnaire Administration|Ancillary studies
45677103|NCT02035202|Device|Smartphone|A smartphone platform will be used to deliver the CBT2go behavioral intervention and the surveys in the EMA-only arm.
45677104|NCT01988402|Drug|allopurinol|
45677105|NCT01988402|Drug|Placebo (sugar pill)|
46003287|NCT04656327|Other|No intervention|There is no intervention in this study. It is a cross-section study evaluating the oral health and nutritional statuses of community-dwelling elders dependent for care for their activities of daily living.
46003288|NCT04627584|Combination Product|MW33 injection|a recombinant fully human antibody to coronavirus
45677106|NCT01988090|Drug|800 IU Vitamin D Supplement|Standard Dose
45677107|NCT01988090|Drug|50,000 IU Vitamin D supplement|High Dose
45677108|NCT01988012|Biological|tocilizumab|162 milligram (mg) administered subcutaneously once weekly for 24 weeks
45677109|NCT02011945|Drug|Dasatinib|
45677110|NCT02011945|Drug|Nivolumab|
45677111|NCT04666909|Diagnostic Test|blood pressure|"The Welch Allyn ABPM 7100 is an easy-to-use 24-hour ambulatory blood pressure monitor that is designed to help avoid the effects of white coat hypertension, provide accurate sleep blood pressure readings, and tailor drug therapy regimes to your individual patient's needs.~This device is programmed to take three BP readings a minute apart. To be eligible, participants must have an average SBP > 135 mm Hg or DBP > 85 mmHg (based on the average of 3 BP readings); or average SBP > 130 mm Hg or DBP > 80 mm hg (for those with diabetes or kidney disease) based on JNC-7 criteria for uncontrolled HTN."
45677112|NCT02013830|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle.
46003289|NCT04627584|Combination Product|MW33 injection placebo|Placebo
46003290|NCT04537598|Procedure|Morphine patient controlled analgesia|30 patients will receive PCA only for postoperative analgesia
46003291|NCT04537598|Procedure|Erector Spinae plane block|30 patients will receive continuous ESPB for postoperative analgesia
46003292|NCT04627467|Drug|Chloroquine|250mg tablet (150mg base chloroquine)
46088828|NCT00638742|Drug|latanoprost|latanoprost 0.005% (1.5 ug) will be administered. A single drop of latanoprost 0.005% will be instilled into both eyes by the investigator.
45677113|NCT02013830|Drug|capecitabine [Xeloda]|1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.
46037793|NCT00866359|Drug|Placebo|"Treatment Phase Days 1-7: Titration from 10mg BID matching placebo (arm B) to 30mg BID placebo (arm B) Day 8-84: Maintenance of 30mg BID placebo (arm B). Dose reductions to 20 mg BID matching placebo (arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast or dose reductions to 20 mg BID apremilast (if not previously down titrated)"
46088829|NCT03512418|Behavioral|PrEPsteps|Smartphone-based adherence intervention based in 1) LifeSteps, 2) Contingent Reinforcement/Corrective Feedback, and 3) Screening Brief Intervention and Referral to Treatment (SBIRT).
46088830|NCT03512418|Device|Digital pill|The digital pill comprises a standard gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication (Truvada). When participants ingest the digital pill, the chloride ion gradient in the stomach activates the radiofrequency emitter which transmits direct evidence of medication ingestion to a wearable reader which relays this data to the participant's smartphone and cloud server.
45677114|NCT02010775|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
46088831|NCT03512418|Drug|Truvada|Participants receive once daily Truvada as PrEP to prevent HIV.
46088832|NCT02686242|Procedure|spinal anesthesia|bupivacaine injected by spinal puncture
45677115|NCT02010775|Drug|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.
45677116|NCT01993615|Procedure|Arthroscopic Surgery|The hip arthroscopy will consist of acetabular rim trimming, labral repair or debridement and femoroplasty, all as indicated based on the surgeon's clinical judgment with input from pre-operative imaging, exam findings and intra-operative findings.
45677117|NCT01993615|Procedure|Physical Therapy|Subjects will participate in two 45-minute sessions for six weeks (total of 12 sessions). The physical therapy treatment plan will be based on individual impairments identified during the initial evaluation, and include manual therapy to the hip, lumbar spine, and pelvis, as well as therapeutic exercise all tailored to individual patient impairments.
45677118|NCT01619059|Drug|Saxagliptin|Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
45677119|NCT01619059|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
45677120|NCT01619059|Drug|Metformin IR|Tablets, Oral, ≥ 1500mg, Twice daily, Up to 52 weeks
45677121|NCT01619059|Drug|Placebo matching with Saxagliptin|Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
45677122|NCT04691804|Drug|Fuzuloparib , Abiraterone acetate and Prednisone|"Fuzuloparib capsules (strength: 50 mg),150mg, Bid,po~Abiraterone acetate tablets (strength: 250 mg) 1000mg Qd,po~Prednisone tablets (strength: 5 mg) 5mg, Bid po"
45677123|NCT04691804|Drug|Fuzuloparib Placebo， Abiraterone acetate and Prednisone|"Fuzuloparib capsules Placebo (strength: 50 mg),150mg, Bid,po~Abiraterone acetate tablets (strength: 250 mg)1000mg Qd,po~Prednisone tablets (strength: 5 mg)5mg, Bid po"
45677124|NCT04416997|Procedure|Blood and serum samples|The blood and serum samples will taken from RA patients
45840070|NCT00589056|Procedure|biopsy|
45840071|NCT00589056|Radiation|radiation therapy|
45840072|NCT00590226|Drug|Detemir + aspart insulin before meals|Detemir insulin SQ once daily + aspart insulin SQ before meals
45840073|NCT00590226|Drug|NPH insulin + regular insulin|NPH insulin SQ + regular insulin SQ before breakfast and dinner
45840074|NCT00590460|Biological|CAMPATH-1H|Given intravenous on days -8, -7, and -6
45840075|NCT00590460|Biological|Anti-CD45|"Given intravenous on days -5, -4, -3 and -2~dose is 400 micrograms/kg"
45840076|NCT00590460|Drug|Fludarabine|"Given intravenous on days -8, -7, -6, -5 and -4~Dose is 30 mg/m2"
45840077|NCT00590460|Procedure|Stem cell infusion|Stem cells are infused on day 0
46003293|NCT04656015|Device|MRI|"cMRI will be done only to patients presented with signs of HF, with raised cardiac biomarkers and echocardiographic signs of myocardial injury~The Lake Louise diagnostic criteria for CMR in myocarditis:~CMR findings are consistent with myocardial inflammation if at least two of the following criteria are present:~Regional or global myocardial signal intensity increase in T2-weighted images~Increased global myocardial early gadolinium enhancement ratio between myocardium and skeletal muscle in gadolinium-enhanced T1-weighted images~There is at least one focal lesion with non-ischemic regional distribution on late gadolinium enhancement Presence of left ventricular dysfunction or pericardial effusion provides additional, supportive evidence for myocarditis 6. Carotid du"
45458814|NCT01245127|Drug|Ilaris|"Canakinumab 150 mg (or 2 mg/kg for patients weighing <40kg) every 8 weeks over a 6 months treatment period (i.e., weeks 0, 8, 16 and 24).~At Day 7, patients who show an improvement, but not a clinical remission, will be given another 150 mg (or 2 mg/kg for patients weighing <40 kg) injection and continue at 300 mg (or 4 mg/kg for patients weighing <40 kg) every 8 weeks beginning at Week 8.~Patients who show no improvement of symptoms and signs of Schnitzler's syndrome will not receive any additional canakinumab dose and will be offered corticosteroid therapy. These patients will return for a follow-up visit 2 weeks later (Day 21) for safety reasons and will be discontinued from the trial.~If a patient flares twice during the study, physician may optionally change the dosing frequency to every 4 weeks."
45458815|NCT01144585|Procedure|remote ischemic preconditioning and postconditioning|"RIPC is done before the use of CPB. It consists of 4 cycles of 5 minutes inflation of pneumatic cuff to 200 mmHg and deflation for 5 minutes. RIPoC is exactly same procedure done after CPB."
45458816|NCT01144585|Procedure|Control|This group has same pneumatic cuff during the surgery, but it is not inflated during the surgery
46003294|NCT04532801|Drug|Kisspeptin-10|kisspeptin-10 IV infusion
45458817|NCT03860467|Other|collection of patient data|Patient data will be collected using the in-house digital patient record systems and the local digital electroencephalogram (EEG)-database
46003295|NCT04532801|Other|mixed meal tolerance test|mixed meal tolerance test
46088833|NCT02686242|Procedure|general anesthesia|general anesthesia with intubation
45458818|NCT01239667|Other|Individual oriented planning of the rehabilitation program for patients with heart failure|Individual oriented rehabilitation plan in collaboration with the patient followed by measuring health related quality of life and self care behavior
46088834|NCT05661786|Other|Observation|Monitor every 6 months
46088835|NCT05661786|Other|Antiviral treatment|Receive first-line antiviral treatment, including entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir amibufenamide or peginterferon
46088836|NCT00639522|Drug|Liposomal paclitaxel and capecitabine|Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2、185mg/m2、195mg/m2、 200mg/m2、205mg/m2 and so on ,at the first day of chemotherapy. Capecitabine will be given on d1 to d14 with the dose of 185mg/m2、200mg/m2 or d8 to d21 with the dose of 175mg/m2、195mg/m2、205mg/m2 .Cycle duration will be 21 days. Each patient will receive 2 cycles of therapy. Only in the first cycle blood samples will be taken on 16 points in 48 hours after the infusion of liposomal paclitaxel.
45458819|NCT01237405|Drug|99mTc-EC20|Study participants underwent a one-time evaluation by FolateScan which entailed a single intravenous injection of 99mTc-EC20 (total volume of 1.0 to 2.0 ml administered over a period of 30 seconds with radioactive dose between 20 and 25 mCi). A total of three imaging scans were acquired: an early phase (at ~1 minute) SPECT/CT of both knees; a late phase (at ~60 minutes) SPECT/CT image of both knees; and a late phase (at ~80 minutes) planar image of the whole body was performed (anterior-posterior, and postero-anterior).
45458820|NCT01239823|Other|Whole Body Vibration Training|The subjects will participate in a 12-week exercise program with two sessions (1/2 hour) per week.
46003296|NCT04656093|Behavioral|Supportive counseling|"Participants in the control arm will receive 3 placebo sessions to control for the potentially confounding effect of personalized attention from the care coach on the relationship between the intervention and outcomes. The interventionist will review a patient education booklet for COPD self-management over the 3 sessions and address any question raised by the study subject."
46003297|NCT04656093|Behavioral|Education on SMB|Goal is to educate patient on SMB based on responses during 15-month interview and screener call, and assess patient's motivation for change.
46003298|NCT04656093|Behavioral|Psychoeducation on ATs for maladaptive beliefs (if applicable)|Goal is to educate patient on relationship between thoughts and SMB, and identify maladaptive beliefs, automatic thoughts, and cognitive distortions.
46003299|NCT04656093|Behavioral|Psychoeducation on emotional response (if applicable)|Goal is to educate patient on relationship between emotions and COPD + SMB, identify
46003300|NCT04531631|Drug|Dorzagliatin|tablet
45458821|NCT01239823|Other|Exercise without vibration|Participants will complete the same exercises without vibration twice a week for 12 weeks (1/2 hour sessions).
45458822|NCT01732783|Other|Panitumumab + Chemotherapy|Participants receiving panitumumab in combination with chemotherapy as prescribed by the treating physician prior to enrollment in this study and according to routine clinical practice for patients with wild-type RAS metastatic colorectal cancer.
45677125|NCT04176757|Drug|ZN-c5|ZN-c5 study drug to be administered orally daily
45677126|NCT02013206|Drug|erlotinib [Tarceva]|Erlotinib tablets taken orally once daily in the morning.
46003301|NCT04531631|Drug|placebo|placebo
46088837|NCT04186338|Device|Omnidirectional accelerometer monitor (3x3 cm and 16 g, Actical®, Philips Respironics)|All participants were instructed to wear monitors for five consecutive days except during water-based activities. Data for each participant was collected to ensure included three valid weekdays. Daily activity energy expenditure (kcal/kg/min), and sedentary, light, moderate and vigorous levels (min) were examined using a software program.
46088838|NCT00411138|Radiation|Radiation Therapy|External beam pelvic radiotherapy (48.6 Gy in 1.8 Gy fractions) Vaginal brachytherapy boost in case of cervical involvement
45458823|NCT03850015|Diagnostic Test|Standard echocardiography|Patients will undergo standard echocardiography, with and without contrast
45677127|NCT04690634|Procedure|laparoscopic sleeve gastrectomy (LSG)|Multiple studies have indicated that laparoscopic sleeve gastrectomy (LSG) was superior to nonsurgical approaches for the treatment of obese PCOS patients over both the short and long term
45677128|NCT04416854|Procedure|resection of primary tumor|resection of primary lesion with unresectablely metastatic colon cancer
45677129|NCT04416854|Drug|XELOX|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle
45677130|NCT04416854|Drug|mFOLFOX6|Oxaliplatin 85mg/m2, leucovorin 400mg/m2 ivgtt d1 and 5-FU 400 mg/m2 IV bolus d1，2400 mg/m2 CIV 46h, d1
46003302|NCT04529447|Other|Survey|The patient satisfaction survey consisted of 8 items, including 7 Likert scale questions and 1 multiple choice question.
46003303|NCT04627623|Diagnostic Test|IgM and IgG antibodies assay|5 ml venous blood sample collection to assay IgM and IgM against COVID19
46003304|NCT04627740|Drug|Retroviral vector-transduced autologous T cells to express anti-ALPP CARs|Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered
46088839|NCT00411138|Drug|cisplatin|cisplatin 50 mg/m2 i.v., 2 cycles during radiotherapy, 3 wks interval
46088840|NCT00411138|Drug|carboplatin|carboplatin AUC 5, 4 cycles after completion of radiotherapy, 3 wks interval
46088841|NCT00411138|Drug|Paclitaxel|paclitaxel 175 mg/m2, 4 cycles after completion of radiotherapy, 3 wks interval
46088842|NCT04094844|Other|Wearable activity sensor|Caregivers and patients in both arms of the study will have a Fitbit wearable activity sensor to track activity and sleep.
45458824|NCT03850015|Other|High frame rate echocardiography|Following standard echocardiography, the test is repeated using high frame rate ultrasound
46003305|NCT04656366|Diagnostic Test|Coronary Angiography|Diagnostic Coronary angiography for patients that presented angina after a previous CABG operation; eventually interventional procedure with PCI (Percutaneous Coronary Intervention)
46037794|NCT00634816|Radiation|DXA Scan|The patients will undergo total body, spine, proximal femoral, and forearm DEXA testing in a standardized fashion. Patients who have undergone limb surgery or irradiation to an extremity for local disease control will also undergo selected site DEXA or pQCT scanning, depending upon the site, of the affected extremity and the identical site on the contra-lateral extremity.
46088843|NCT04094844|Behavioral|Roadmap 2.0 information system|Caregivers and patients download the Roadmap 2.0 app on their mobile phones or tablets
45677131|NCT01807923|Drug|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
46088844|NCT04094844|Other|Survey administration|Caregivers and patients will be asked to respond to survey questions at 3 timepoints.
46088845|NCT04094844|Behavioral|Roadmap 2.0 information system with Positive Activities|Caregivers and patients download the Roadmap 2.0 app on their mobile phones. Caregivers and patients will be instructed on how to operate Roadmap 1.0 on an iPad (inpatient only) and Roadmap 2.0 on a mobile phone (inpatient and outpatient). Caregivers download the Positive Activities app onto their mobile phone to use freely throughout inpatient and outpatient (through day 120 post-transplant). Caregiver may also use an electronic tablet provided by the study team during the patient's hospital stay.
46088846|NCT02686086|Device|vibrating mesh nebuliser|The Aerogen Solo vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.
46088847|NCT02686086|Device|Standard hospital jet nebuliser|"The standard hospital jet nebuliser refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications"
46088848|NCT02686086|Drug|Combined salbutamol 2.5 mg and ipratropium 0.5mg nebule|All patients admitted to hospital with an exacerbation of COPD are administered nebulised bronchodilators (salbutamol 2.5mg/ipratropium 0.5mg combination) as standard of care
45677132|NCT01807923|Drug|Ivacaftor|Film-coated tablet
45677133|NCT01807923|Drug|Placebo|Matching placebo tablet
46088849|NCT03460158|Drug|Restylane-L®|Restylane-L® for the indication for mid-to-deep dermal implantation for moderate to severe facial wrinkles and folds, such as nasolabial folds.
46088850|NCT03460158|Drug|Restylane-L® Lyft|Restylane-L® Lyft is for the indication of implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds and malars (cheek/cheek bone area).
46088851|NCT03460158|Drug|Restylane Silk®|Restylane Silk® is for the indication for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
46003306|NCT04525469|Behavioral|Narrative Exposure Therapy|"NET involves: 1) diagnostic interview and psychoeducation, 2) laying out the Lifeline, 3) NET therapy sessions (constructing the trauma narrative in context of the life course), 4) final session rituals. Laying out the Lifeline (using rope or string) allows participants to take a bird's eye view of the events of their life using simple items such as flowers to represent positive events and stones to represent traumatic events. The focus of NET sessions is to encourage participants to describe the details of traumas and integrating the cold memories (i.e., facts) with the hot memories (e.g., cognitions, emotions, physiological feelings, and sensory information). The therapist makes notes after each session narrating the details of the traumas (stones) and reads this at the beginning of each subsequent session. Final session rituals involve re-reading the trauma narrative, hopes for the future, and laying out the final Lifeline placing flowers for hopes and wishes for the future."
46088852|NCT02697630|Drug|Pembrolizumab|200 mg administered intravenously (IV) every third week until progression or unacceptable toxicity for a maximum of 24 months
46003307|NCT04509167|Biological|Neoantigen Peptides|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of ~500ug per peptide once a week for 8 weeks.
46088853|NCT02697630|Drug|Entinostat|5 mg by mouth (PO) once weekly until progression or unacceptable toxicity for a maximum of 24 months
46003308|NCT04627155|Drug|LY03003|Rotigotine,extended-release microspheres
46003309|NCT04508972|Device|Alexa Amazon|To test the use of the Amazon Alexa device as a tool to conduct screening of employees and patients at the point of entry into the Heart Failure (HF) Clinic of the McGill University Health Center.
46003310|NCT04656249|Drug|Lenvatinib|Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing <60 kg and 12mg/d to those ≥60 kg.
46003311|NCT04481555|Drug|Azithromycin|Prophylactic azithromycin treatment 250 mg three times weekly vs placebo
46003312|NCT04481555|Drug|ICS|All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months) vs continued LABA/LAMA/ICS treatment
46003313|NCT04656054|Procedure|liposuction|liposuction procedure and observation of the hematological changes on the patients
46003314|NCT04627350|Other|Response to pulmonary finding (nodule, mass)|Follow-up low-dose CT, PET-CT, tissue sampling (transparietal biopsy, bronchoscopy, resection), contrast-enhanced CT of the thorax
46003315|NCT04472156|Procedure|Transfer of mosaic embryo|Subjects will transfer a mosaic embryo transferred to their uterus
46003316|NCT04655859|Diagnostic Test|saliva cotton swab|evaluate the role of thiol/disulfide homeostasis and oxidative stress in the saliva of children with severe early childhood caries and healthy group
46088854|NCT02685852|Drug|Exenatide|Exenatide at a dose of 5 mcg
46088855|NCT02685852|Drug|Acarbose|Acarbose at a dose of 25 mg
46088856|NCT02685852|Drug|Exenatide Placebo|Placebo for Exenatide
46088857|NCT02685852|Drug|Acarbose Placebo|Placebo for Acarbose
46003317|NCT04682951|Procedure|Decompressive Craniectomy|
46088858|NCT02685696|Device|Alexis O Retractor|A newly developed abdominal wall retractor for Caesarean Section is the Alexis O Ring which is formed of 2 rings and a interconnecting plastic polyurethane sheath where the flexible inner ring is placed into the abdomen and where the rigid outer ring is rolled to create tension on the plastic sheath providing 360° abdominal wound retraction with simultaneously a tamponade effect whilst covering the abdominal wound during the Caesarean Section and delivery of the baby.
46088859|NCT02685696|Device|Metal Retractor|The traditional self-retaining metal Collins Caesarean Wound Retractor.
46088860|NCT00639600|Procedure|human pancreatic islet transplantation|human pancreatic islet transplantation
46088861|NCT04185090|Combination Product|ID1803|Amlodipine 10mg/Valsartan 160mg
46088862|NCT04185090|Combination Product|ID1801|Ezetimibe 10mg/Rosuvastatin Ca 20.8mg
46088863|NCT04185090|Combination Product|ID1803+ID1801|Amlodipine 10mg/Valsartan 160mg Ezetimibe 10mg/Rosuvastatin Ca 20.8mg
46088864|NCT02688036|Radiation|hypofractionated concurrent chemoradiotherapy|For patients with Limited Disease Small Cell Lung Cancer, 45Gy/15F of radiotherapy with concurrent chemotherapy will be used in experimental arm.
46003318|NCT04655898|Drug|[14C]CC-90001|Oral
46003319|NCT04682756|Diagnostic Test|The model of machine learning|Early diagnosis of NTEMI patients by machine learning model
46088865|NCT02688036|Radiation|conventionally fractionated concurrent chemoradiotherapy|For patients with Limited Disease Small Cell Lung Cancer, 60Gy/30F of radiotherapy with concurrent chemotherapy will be used in the control arm.
45458825|NCT03777007|Device|SPARTA force plate|The Sparta Platform includes force plate hardware coupled with Sparta Scan software that enables quick assessment of an individual's movement and balance within minutes
45840078|NCT00590772|Drug|montelukast|10 mg po each day (compared to placebo for 2 weeks)
45840079|NCT00590772|Drug|placebo|placebo for 2 weeks
45840080|NCT00591942|Device|Full ceramic crowns or 3-unit fixed partial dentures.|Subjects who met the inclusion/excluson criteria received two ceramic crowns or one three-unit dental bridge on posterior teeth. The crowns and dental bridge were cemented using two different dental adhesives. Follow-up to assess sensitivity of the crowns/bridges occur at 24 hrs. and 1 week post seating by telephone. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
45677134|NCT01966003|Drug|Carboplatin|Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W
46088866|NCT04033848|Procedure|Arthroscopic assisted ankle fracture treatment|Any complex ankle fracture, as discriped above, will be treated arthroscopically and will be prospectively followed-up using well validated PROMs
46088867|NCT02687802|Other|mechanical ventilation|we will measure static resistance, compliance and intrinsic positive end-expiratory pressure (PEEP) and other variables as risk factors for asynchrony occurrence
46003320|NCT04682795|Device|Needle-free injector|Using needle-free injector as insulin carrier to treat T2DM
46088868|NCT02697162|Device|Antiseptic-coated catheter|Antiseptic-coated hydrophilic intermittent urinary catheter with octenidine chloride
46088869|NCT02697162|Device|Hydrophilic catheter|Hydrophilic intermittent urinary catheter
46088870|NCT02697162|Drug|Octenidine chloride|Antiseptic
45677135|NCT01966003|Drug|Paclitaxel|Administered 200 mg/m² IV Q3W
45677136|NCT01966003|Drug|ABP 215|Administered 15 mg/kg Q3W by IV infusion
45677137|NCT01966003|Drug|Bevacizumab|Administered 15 mg/kg Q3W by IV infusion
45677138|NCT01839279|Drug|Tizanidine|
46088871|NCT04186416|Other|Mostcare® device|The Moscare® system is connected to the patient monitoring devices. Data are collected just before and 5 minutes after the vascular filling.
46088872|NCT04186416|Other|Transthoracic cardiac ultrasound|Transthoracic cardiac ultrasound before and 3 minutes after the vascular filling.
46088873|NCT04185168|Dietary Supplement|soy isoflavone|100 mg soy isoflavone (as 2 tablets)
46088874|NCT04185168|Other|control|2 tablets of placebo
46088875|NCT02697084|Other|anal cancer|Anal cancer patients with TEP TDM
46088876|NCT02685930|Behavioral|Antibiotic de-escalation by ICU stewardship team with decreased exposure to broad spectrum antibiotics and shorter duration of therapy|ICU stewardship team will provide recommendations to the ICU team regarding antibiotic de-escalation and duration of therapy in attempts of improving antibiotic stewardship practices without compromising patient outcomes.Recommendations will be based on patient showing clinical improvement combined with microbial culture data.
46088877|NCT04186182|Behavioral|CICI - Feasibility trial study group|The intervention will include 7 individualized meetings with the family (2 home visits + 5 videoconferences), 2 parent group sessions and 4 meetings with school and local care providers, delivered over a 4-5 month period.
46088878|NCT00622674|Biological|cetuximab|A loading dose of cetuximab will be given on day 1 (400 mg/m2) followed by a weekly dose of 250 mg/m2.
45677139|NCT01839279|Drug|Placebo|
45677140|NCT01839279|Drug|Moxifloxacin|
45677141|NCT01807299|Dietary Supplement|Omega 3|Capsules of omega 3, 1000mg / capsules. Administered 3 times a day.
45677142|NCT01807299|Other|Physical Training|
46003321|NCT04682795|Device|Insulin pen|Using insulin pen as insulin carrier to treat T2DM
45677143|NCT01965535|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
45677144|NCT01965535|Drug|RBV|RBV (200 mg tablets) administered orally in a divided daily dose based on weight (1000 mg per day for participants weighing < 75 kg; 1200 mg per day for participants weighing ≥ 75 kg)
45677145|NCT01965535|Drug|Placebo to match LDV/SOF|Placebo to match LDV/SOF administered orally once daily
46088879|NCT00622674|Drug|bortezomib|The starting dose of bortezomib will be 1.3 mg/m2 with a 0.1 increment increase with each successive dose level to a maximum of 2.0 mg/m2.
46003322|NCT04627116|Drug|Tecarfarin|Ten (10) healthy Chinese subjects received once-daily doses of Tecarfarin on fasting every morning for 14 days.
46003323|NCT04655742|Device|VitaFlow™ Transcatheter Aortic Valve System|VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set
46003324|NCT04395482|Other|Lung CT scan analysis in COVID-19 patients|This research project will evaluate the morphological characteristics of the lung by CT scan analysis in COVID-19 patients which will be identified as specific patterns using artificial intelligence technology and their impact on outcome.
46003325|NCT04627233|Drug|Human Ezrin Peptide 1 (HEP1)|"HEP-1 will be administrated s.c. into the lower abdominal wall~induction dosage: 2 mg Ezrin in 2 ml physiological saline applied s.c.,one injection every 12 hours until symptoms disappear followed by~maintenance dosage: 0.2 mg Ezrin in 1 ml physiological saline solution s.c 1/day for 10 days"
46088880|NCT02687880|Procedure|Testicular biopsy|Subjects will undergo a surgical procedure to harvest their testicular tissue.
46088881|NCT02687724|Drug|Golimumab (GLM)|GLM is a human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology
46088882|NCT02685774|Drug|Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg|Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T oral administration
46088883|NCT02685774|Drug|CKD-395 0.25/500mg|CKD-395 0.25/500mg 2T oral administration
46088884|NCT00638976|Drug|eptifibatide|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES >33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure
45677146|NCT01965535|Drug|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
46088885|NCT00638976|Drug|placebo|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES >33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure
46088886|NCT05661708|Drug|Chitosan|Chitosan is a biodegradable, natural polyaminosaccharide with a nontoxic, non-allergenic, positively-charged polysaccharide derived from the deacetylation of chitin. Due to its molecular characteristics, chitosan has been used for improved hemostasis. Furthermore, chitosan has an antimicrobial and wound-healing effect
46088887|NCT04184700|Dietary Supplement|EHCF+LGG|Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG
46003326|NCT04627233|Drug|Placebo|placebo group received normal saline in a same volume to match corresponding HEP-1 doses. Study drug was administered by qualified staff in research clinic settings; injections were given to abdominal sites on rotating basis, by anatomic quadrant.
46003327|NCT04378244|Drug|DeltaRex-G|"This is an open label, dose-seeking phase 1/2 study using escalating doses of DeltaRex-G given intravenously for 7 days in a hospital setting.~The study will employ the standard Cohort of Three design (Storer, 1989). Three patients are treated at each dose level with expansion to six patients per cohort if DLT is observed in one of the three initially-enrolled patients at each dose level. If no DLT occurs in 3 patients, escalation to the next dose level will be permitted. The maximum tolerated dose is defined as the highest safely tolerated dose, where not more than one patient experienced DLT, with the next higher dose level having at least two patients who experienced DLT. No intra-patient dose escalation will take place. Patients who do not complete the 7-day treatment will be replaced."
46003328|NCT04655664|Diagnostic Test|not currently consumed vitamin D supplements regularly|The tests carried out were examination of 25 (OH) D and 1.25 (OH) D levels of serum and saliva, examination of demographic data, and other anthropometries. The examination was carried out by taking 5 mL of blood and 2 mL of saliva, and then checking the serum and saliva levels of 25 (OH) D and 1.25 (OH) D. Before the examination, the research subjects were asked not to consume food or drink for at least 90 minutes before being examined. Centrifugation was carried out (2500 g, 10 minutes) and the product immediately stored at -20 oC. In the serum examination, after the blood was drawn, centrifugation was carried out and the product stored at -20 oC for further determination of the levels of 25 (OH) D and 1.25 (OH) saliva.
46003329|NCT04655664|Diagnostic Test|consumed vitamin D supplements regularly|The tests carried out were examination of 25 (OH) D and 1.25 (OH) D levels of serum and saliva, examination of demographic data, and other anthropometries. The examination was carried out by taking 5 mL of blood and 2 mL of saliva, and then checking the serum and saliva levels of 25 (OH) D and 1.25 (OH) D. Before the examination, the research subjects were asked not to consume food or drink for at least 90 minutes before being examined. Centrifugation was carried out (2500 g, 10 minutes) and the product immediately stored at -20 oC. In the serum examination, after the blood was drawn, centrifugation was carried out and the product stored at -20 oC for further determination of the levels of 25 (OH) D and 1.25 (OH) saliva.
45458826|NCT04355728|Biological|Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.|UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.
45458827|NCT04355728|Other|Vehicle + Heparin along with best supportive care|Best supportive care treatment per the treating hospital protocol.
46088888|NCT00639756|Drug|Allopurinol|Allopurinol 300 mg
45458828|NCT01693783|Biological|Ipilimumab|Given IV
46088889|NCT00639756|Drug|Placebo|Placebo given for 2 weeks
46088890|NCT00622752|Drug|EVT 302, 10 mg|2 X EVT 302, 5 mg tablets
46088891|NCT00622752|Drug|placebo|2 X placebo tablets to match EVT 302 5 mg
46088892|NCT00622752|Drug|Nicotine replacement therapy (NRT)|NRT patch containing 21 mg of nicotine
46088893|NCT00622752|Device|NRT placebo|Medically inert plaster cut to match the NRT plaster
46088894|NCT00640848|Drug|almorexant|1 dose of 400 mg in two treatment sequences
46088895|NCT00640848|Drug|almorexant|1 dose of 200 mg in two treatment sequences
46088896|NCT00640848|Drug|almorexant|1 dose of 100 mg in two treatment sequences
46088897|NCT00640848|Drug|almorexant|1 dose of 50 mg mg in two treatment sequences
46088898|NCT00640848|Drug|almorexant|1 dose of 1000 mg in two treatment sequences
46088899|NCT03451578|Device|Alpha MSH assay|Assay to detect levels of alpha MSH in intraocular fluid.
46088900|NCT02686008|Drug|Olaparib|Patients will receive olaparib administered at 300 mg bid x 14 days orally
46088901|NCT02685618|Drug|Iloprost|
46088902|NCT02685618|Drug|Saline|
46088903|NCT02685618|Device|Phillips M1006B, offset by -10mmHg|Administration of blood pressure module M1006B: offset by -10 mmHg
46088904|NCT02685618|Device|Philips M1006B, No offset|Administration of blood pressure module M1006B: No offset
45458829|NCT01693783|Other|Laboratory Biomarker Analysis|Correlative studies
45458830|NCT04461574|Device|Orcellex Brush|Subjects will receive vaginal vault smear using both Orcellex Brush and Cervex Brush at the same follow-up visit, with order of smear taking decided by randomization.
45458831|NCT04461574|Device|Cervex Brush|Subjects will receive vaginal vault smear using both Orcellex Brush and Cervex Brush at the same follow-up visit, with order of smear taking decided by randomization.
46088905|NCT00602472|Drug|linagliptin|active
46088906|NCT00602472|Drug|placebo|placebo to linagliptin 5 mg
45458832|NCT04461496|Procedure|Hybrid revascularization|The first stage is performed femoral-popliteal bypass surgery above the fissure of the knee joint according to conventional technology. Conduit is at the discretion of the operating surgeon. Intraoperatively bolus is administered sol. heparin 5000 IU. The second step is the puncture of the selected CFA with a retrograde installation of the introducer sheath. The iliac segment is recanalized with angioplasty and stent implantation in the affected area
46003330|NCT04365179|Drug|Nerofe|"Up to 12 cycles of 28 days are planned. If patients are deriving benefit, treatment may continue past 12 cycles.~Cycle 1: During Cycle 1, assigned NEROFE doses will be administered by intravenous (IV) infusion over 1 hour on Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26.~Cycles 2-12: Subsequent cycles will be administered as above, presuming that patients do not meet criteria for study withdrawal during cycle 1."
46003331|NCT04655508|Drug|Seretide|"For children between 6 to 11 years (< 12 years): 50 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 50/25) :two puffs twice a day from randomisation during 6 months using inhalation chamber~- For children between 12 to 17 years (> or = 12 years) : 125 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 125/25): two puffs twice a day from randomisation during 6 months using inhalation chamber"
46003332|NCT04655508|Drug|Placebo|For children between 6 to 11 years (< 12 years): placebo of SERETIDE® 50/25 :two puffs twice a day from randomisation during 6 months using inhalation chamber For children between 12 to 17 years (> or = 12 years) : placebo of SERETIDE® 125/25: two puffs twice a day from randomisation during 6 months using inhalation chamber
46003333|NCT04355546|Other|Non-interventional|As this is a Non-interventional trial, only data obtained within the current routine management of COPD at outpatient respiratory centres or GP centres will be documented.
46003334|NCT04627272|Device|AutoDX-DR|AutoDx-DR provides basic image interpretation for the detection of DR and diabetic macular edema (DME) and a Refer or Not Refer recommendation.
46003335|NCT04655781|Procedure|idiopathic macular hole (MH) surgery|Idiopathic Macular Hole Surgery with Different Internal Limiting Membrane Peeling Patterns
46003336|NCT04626999|Procedure|Single Bundle ACL Reconstruction|"Arthroscopy Single Bundle ACL Reconstruction is a procedure to reconstruct the ACL using one bundle.~The procedure uses Hamstring (Gracillis muscle and Semitendinosus muscle) as a graft."
45458833|NCT04461496|Procedure|Full metall Jacket|The first step is the puncture contralateral CFA with a retrograde installation of the introducer. Intraoperatively bolus is administered sol. heparin 5000 IU. A conductor is placed in the contralateral iliac artery along the conductor. A stent is implanted in the iliac artery lesion. The second stage is the recanalization of the femoral-popliteal segment with angioplasty and stent implantation in the affected area.
46088907|NCT02681250|Procedure|Titanium-zirconium|Titanium-zirconium implants will be installed according to the protocol earlier described in the detailed description.
45677147|NCT04659577|Behavioral|ICBT for panic and depression|The most known type of CBT for treating PD consists of two major strategies: cognitive restructuring, and interoceptive and structured exposure to bodily sensations that have become associated with panic attacks. As for depression, the most known type of CBT for treating depression consists of two major strategies: cognitive restructuring, the relationship between thoughts and feelings, behavioural activation, sleep hygiene and relaxation. Each ICBT program includes six modules, containing psychoeducation, cognitive restructuring exposures, acceptance, and consolidation of gains and relapse prevention. The online modules include reading passages, worksheets, videos, and homework assignments. After completing each module participants practice related skills and complete homework assignments. The treatment is up to 16 weeks long; participants are encouraged to complete the treatment within this time period, and reminders are sent to monitor their progress
45458834|NCT03491644|Drug|Titrated Oxygen|Restrictive treatment with oxygen.
46003337|NCT04626999|Procedure|Double Bundle ACL Reconstruction|"Arthroscopy Double Bundle ACL Reconstruction is a procedure to reconstruct the ACL using Two bundles (Double bundle).~The procedure uses Gracillis tendon as a Posterolateral bundle graft and Semitendinosus tendon as an Anteromedial bundle graft."
46003338|NCT02906774|Biological|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation after antibiotic pretreatment
46003339|NCT02907008|Other|Polysomnography|
46003340|NCT04655040|Drug|Caffeine|100milligram (mg) tablet taken orally in period 1 and period 2
46003341|NCT04655040|Other|Ritlecitinib|200 milligrams (mg) taken orally once a day(QD) for 8 days
46003342|NCT02906735|Procedure|Surgery|Implantation of knee joint prosthesis or deviation osteotomies of the knee
46003343|NCT04626765|Drug|CD19 CAR-T|CD19 CAR-T infusion for pediatric patients with CD19 positive tumor cells
46003344|NCT04626765|Drug|CD22 CAR-T|CD22 CAR-T infusion for pediatric patients with CD22 positive tumor cells
46003345|NCT04626765|Drug|CD 19+22|CD19+22 CAR-T infusion for pediatric patients with CD19 positive and CD22 positive tumor cells
46003346|NCT04626765|Drug|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
46003347|NCT04626765|Drug|Cyclophosphamide|500mg/㎡ for D-3 and D-2
46003348|NCT02906969|Other|Colonoscopy Educational Video|Brief Video utilization to assess comprehension and evaluation bowel preparation quality
46003349|NCT02906969|Other|Placebo Educational Video|Brief Video utilization to provide placebo information and evaluation bowel preparation quality
46088908|NCT02681250|Procedure|Titanium|Titanium implants will be installed according to the protocol earlier described in the detailed description.
46088909|NCT05664048|Behavioral|Dry heat application|Self- dry heat application on the foot during menstrual period with pain.
46088910|NCT03384654|Drug|Daratumumab|Participant will receive daratumumab 16 milligram per kilogram (mg/kg) in cohort 1 and cohort 2.
46088911|NCT03384654|Drug|Vincristine|Participant will receive vincristine 1.5 milligram per meter square (mg/m^2) in cohort 1 and cohort 2.
46088912|NCT03384654|Drug|Prednisone|Participant will receive prednisone 40 mg/m^2 in cohort 1 and cohort 2.
46088913|NCT03384654|Drug|Doxorubicin|Participant will receive doxorubicin 60 mg/m^2 in cohort 2.
46088914|NCT03384654|Biological|Peg-asparaginase|Participant will receive peg-asparaginase 2500 units per meter square (U/m^2) in cohort 2.
46088915|NCT03384654|Drug|Cyclophosphamide|Participant will receive cyclophosphamide 1 gram per meter square (g/m^2) once in cohort 2.
45458835|NCT03491644|Drug|Liberal Oxygen|Liberal treatment with oxygen.
45677148|NCT01964755|Drug|Doxorubicin|Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
46003350|NCT02906891|Device|Vigilant Diabetes Management Application|The Vigilant Diabetes Management Companion by InSpark Technologies was developed to assist in the prevention of hypoglycemia by providing the individual with an unobtrusive analysis of their blood glucose values and notifying them about periods of upcoming risk for low and high blood glucose; and in particular periods of risk for severe hypoglycemia. This allows the individual to take preventive corrective action. Subjects will download the Vigilant DiabetesManagement Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
46003351|NCT04655274|Diagnostic Test|The Quality of Vision questionnaire|The Quality of Vision questionnaire rates glare, halos, starbursts, hazy/blurred/double vision, distortion, focusing difficulties, fluctuation, and depth perception conditions.
46003352|NCT04626648|Behavioral|Pause with a sugar containing drink|Three-minute long intraoperative pause, including a sugar-containing drink
46003353|NCT02906618|Drug|LY3039478|Administered orally
46003354|NCT02906618|Drug|3C 15N 2H-LY3039478 IV|Administered IV
46003355|NCT04626726|Drug|CD19 CAR-T|CD19 CAR-T infusion for patients with CD19 positive tumor cells
46003356|NCT04626726|Drug|CD22 CAR-T|CD22 CAR-T infusion for patients with CD22 positive tumor cells
46003357|NCT04626726|Drug|CD19+CD22 CAR-T|CD19+CD22 CAR-T infusion for patients with CD19 positive and CD22 positive tumor cells
45458836|NCT02528461|Drug|Galactose|A test to investigate the liver's ability to metabolize galactose to glucose by injecting galactose followed by measurements of blood glucose and the quantification of galactose in the urine.
45458837|NCT02528461|Procedure|Gastroscopy|
45458838|NCT02528461|Procedure|Liver biopsy|
46003358|NCT04626726|Drug|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
46003359|NCT04626726|Drug|Cyclophosphamide|500mg/㎡ for D-3 and D-2
46003360|NCT04655235|Genetic|Genotyping|Genotyping of glutamatergic, GABAergic, dopaminergic and other CNS-related genes
46003361|NCT04654962|Procedure|Anesthetic nerve block|iliac fascia block is an analgesic technique that uses local anesthesia, is effective and relatively safe in preoperative management. The target of this block is the femoral and lateral femoral cutaneous nerves; which innervate the anterior aspect of the thigh, as well as the muscle and periosteum that covers the femoral head, neck and proximal femur.
46003362|NCT04654884|Other|Auricular acupuncture (AA)|The add-on treatment will be administered at the treatment sessions with their caregiver (i.e. registered nurse, psychologist, curator), and at each session the participants receive 5 sterile stainless needles in each outer ear. The needling is standardised according to the NADA-protocol. The needles will remain in the outer ears for approximately 45 minutes, and will be removed by the care giver.
46003363|NCT02906501|Procedure|The Penn Web-Based Computerized Neurocognitive Battery|The Battery (PennCNP) of the Brain Behavior Laboratory at the University of Pennsylvania offers a range of probes of human neuropsychological functioning . It was designed for neuropsychological measurement of major cognitive domains. The WebCNP is administered using clickable icons on desktop or laptop computers, in a fixed order. Administrating the tests in a standard fashion fostering optimal performance without aiding the participant is required. For each domain, accuracy and speed are computed. Full battery completion takes approximately 2 hours. Each test begins with a practice module, to assure understanding of the instructions.
46003364|NCT02906501|Procedure|The Iowa Gambling Test (IGT)|The essential feature of this task is that it mimics real-life situations in the way it factors uncertainty, reward and punishment. The task involves four decks of cards, named A, B, C and D. The goal is to maximize profit on a loan of play money. Subjects are required to make a series of 100 card selections, but are not told ahead of time how many card selections they are going to be allowed to make. Cards can be selected one at a time, from any deck, and subjects are free to switch from any deck to another, at any time and as often as they wish. The decision to select from one deck or another is largely influenced by schedules of reward and punishment. These schedules are pre-programmed and known to the examiner, but not to the subject (Bechara et al., 1994, 1999a).
46003365|NCT02906540|Procedure|Transpubic symphysis reset therapy group|The patients in the treatment group will undergo daily transpubic symphysis reset therapy for 7 consecutive days.
46003366|NCT02906540|Procedure|Physiotherapy group|The patients in the control group will undergo physiotherapy and a sham treatment.
45458839|NCT02528461|Procedure|Fibroscan|
46003367|NCT02906423|Other|PROMIS-10 questionnaire|Patient completed a PROMIS-10 questionnaire
46003368|NCT02906462|Other|Early consideration of vulnerability|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
46003369|NCT02906462|Other|Usual practices|the centres applies their usual practices
45458840|NCT02528461|Procedure|Liver vein catheterization|
45458841|NCT02528461|Drug|Sofosbuvir|
45677149|NCT01964755|Drug|Methotrexate|Methotrexate administered starting on Day 2, per study protocol.
45677150|NCT01964755|Drug|Leucovorin|Leucovorin administered first intravenously 24 hours after start of Methotrexate infusion, then orally every 6 hours for at least 10 doses, per study protocol.
45677151|NCT01964755|Biological|Hydroxyurea|Hydroxyurea administered orally twice daily starting on Day 2, and continuing for a total of 10 doses, per study protocol
45677152|NCT01964755|Drug|Zidovudine|Zidovudine administered first intravenously on Day 2, and then orally twice daily for 10 doses, per study protocol.
45458842|NCT01237483|Drug|Erbitux|To begin 7 days before radiotherapy, loading dose 400 mg / m² in the first week then 250 mg / m² weekly for the duration of radiotherapy (for a total of 7 doses including the loading dose)
45458843|NCT01240057|Procedure|fetal endoluminal tracheal occlusion|percutaneous fetoscopy, positioning of endoluminal balloon at 27-30 weeks and whenever possible elective removal at 34 weeks
45458844|NCT01240057|Other|watchful waiting during pregnancy|pregnancy surveillance for fetal wellbeing, development of polyhydramnios and cervical shortening
46088916|NCT03384654|Drug|Cytarabine|Participant will receive cytarabine 75 mg/m^2 in cohort 2.
46003370|NCT04654494|Procedure|Total proctocolectomy|excision of the whole large bowel including colon and rectum and end ileostomy fashioning
46003371|NCT04654494|Procedure|Total colectomy|excision of the colon with preservation of the rectum
45677153|NCT01964755|Drug|Rituximab|Rituximab is optional and will be administered to study participants, per study protocol.
46003372|NCT04654494|Procedure|Segmental colectomy|excision of a segment of colon
46003373|NCT02906345|Device|Therapeutic Plasma Exchange (TPE)|All treated patients should treated two (minimal) to five times by TPE, depending on the need of norephinephrine for the therapy. For each session 40 ml/kg body weight plasma should be exchange. Fluid resuscitation will be done with fresh frozen plasma.
46088917|NCT03384654|Drug|6-mercaptopurine|Participant will receive 6-mercaptopurine 60 mg/m^2 orally daily in cohort 2.
45458845|NCT03492268|Biological|BCMA-CART|After a conditioning therapy, each patient will receive a treatment of BCMA-CART originated from their own peripheral blood mononuclear cells
45677154|NCT01964521|Device|Mepilex Transfer Ag|A soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
45677155|NCT04416295|Device|LifePod|LifePod consists of a Web-based E-Health platform with two interfaces, one medical for healthcare professionals and one patient interface. LifePod is accessed via a smartphone, tablets and computers via a web application where patients enter symptom parameters and vital parameters such as breathing and mucus status, weight, activity, medication or other disease-specific values. Several different validated questionnaires are sent regularly to the patient to obtain information about the patient's mood and activity. The platform contains a chat function between healthcare professionals and patients. A unique health profile is created in which the patient self-reports their health. The patient receives direct feedback in their web application if they are within the interval given for the individual. The medical interfaces are designed so that patients are automatically placed in a priority order where the person outside the given range is given top priority.
46003374|NCT04654572|Diagnostic Test|Myotonometric measurement|Myotonometric assessment can predict the muscle stiffness, tone and elasticity
46088918|NCT03384654|Drug|Methotrexate|Participant will receive methotrexate 5 g/m^2 intravenously (IV) in cohort 2.
46088919|NCT00639834|Biological|MDX-1342|One dose of active MDX-1342 (anti-CD19 fully human monoclonal antibody) will be administered to patients as an i.v. infusion. Patients will receive one dose of MDX-1342 given in combination with Methotrexate treatment.
45677156|NCT01991743|Drug|Group 2.5|Administration of bupivacaine 2.5 mg.
46003375|NCT02906306|Behavioral|Individual Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
46003376|NCT02906306|Behavioral|Group Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
46003377|NCT04626531|Other|Web-Based Education|Participants in the intervention group had unlimited access to the Web site, free of charge. The Web site was designed to run on personal computers and smartphones.
45677157|NCT01991743|Drug|Group 5|Administration of 5 mg bupivacaine
45677158|NCT01991743|Drug|Group 7.5|Administration of 7.5 mg bupivacaine
45677159|NCT01991743|Drug|Group 10|Administration of 10mg bupivacaine.
46003378|NCT04626531|Other|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
46003379|NCT02906384|Radiation|hippocampus avoidance|conformal avoidance of the hippocampal neural stem-cell compartment during prophylactic cranial irradiation
46003380|NCT04626414|Drug|Ferric maltol capsule|single dose of 30 mg capsule
46003381|NCT04626414|Drug|Ferric maltol suspension|single dose of 30mg (5ml) oral suspension
46003382|NCT02906267|Other|Diagnostic ultrasonography of gastric volume|Ultrasonic measurement of gastric insufflation during positive pressure ventilation (secondary endpoint) and final gastric volume after positive pressure ventilation (primary endpoint)
46088920|NCT02685462|Drug|Rosuvastatin|
46088921|NCT02685462|Drug|Atorvastatin|
46088922|NCT02685462|Drug|Simvastatin|
46088923|NCT02685462|Drug|Digoxin|
46088924|NCT02685462|Drug|Caffeine|
46088925|NCT02685306|Biological|Bavituximab|12 weekly doses of bavituximab given on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
46088926|NCT02685306|Drug|Taxane|12 weekly doses of taxane on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
45458846|NCT01240213|Dietary Supplement|Vitamin D|2000 IU per day of Vitamin D
45458847|NCT01240213|Dietary Supplement|Placebo|1 Placebo per day
45458848|NCT02787850|Device|CoolSculpting Treatment|The CoolSculpting device will be used to perform treatments.
45458849|NCT03760237|Other|observation only|No intervention, observational study only
46003383|NCT04654611|Drug|preservative free tafluprost 0.0015%|preservative free prostaglandin analogue option for treatment of primary open angle glaucoma and ocular hypertension patients
46003384|NCT02906228|Radiation|Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law|
46003385|NCT04654416|Drug|Corticosteroid with or without colchicine|We describe the clinical outcome of patients treated with corticosteroid and colchicine
45677160|NCT01991197|Drug|Sitagliptin|"Week 0-16: Two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the double-blind phase.~Week 16-32: Then two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the open-label phase of the trial."
46003386|NCT02906189|Radiation|MRI|
46003387|NCT02906150|Drug|Thymalfasin (Thymosin alpha 1, Ta1)|Patients will be randomized to Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
46003388|NCT02906150|Drug|SoC (chemotherapy and platinum agent)|Patients will be randomized to SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
46003389|NCT04626453|Behavioral|2-month home moderate-intensity exercise|The 2-month exercise will be conducted at the participants' homes. Participants will be recommended to perform the combined exercise, which consists of the resistance exercise and walking at a faster speed than leisure walking at a moderate-intensity, for 6 days/week. They can decide which day they won't perform the exercise. Participants will be encouraged to do progressive resistance exercise and walking twice a day, once in the morning and the other time in the afternoon. Resistance exercise will be suggested to perform every other day for three days/week and walking as the aerobic exercise will be on alternate days for three days/week.
46003390|NCT00561990|Drug|Nimotuzumab|
46003391|NCT02906072|Behavioral|Low fat plant-based diet|Conventional low fat plant-based meals three times daily. Plant-based meal replacements: Herbalife European Free From vanilla two times daily. Portion sizes and intake is unrestricted.
46003392|NCT02906072|Behavioral|Lectures on health effects of a low fat plant-based diet.|Participants attend the lectures on health effects of a low fat plant-based diet.
46003393|NCT04654728|Procedure|Active Comparator: ePTFE graft|In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
46003394|NCT02906111|Drug|estriol|"Study Group, treated with estriol~Control Group, no drug treatment~Both groups will undergo vaginal surgery for prolapse"
45677161|NCT01991197|Drug|Gliclazide|"Double-blind phase (week 0-16):~One 80mg capsule once daily for 4 weeks. The if no severe hypoglycaemic episodes one 80mg capsule twice daily for 4 weeks.~Then if no severe hypoglycaemic episodes two 80mg capsules twice daily for 8 weeks."
46003395|NCT02906111|Procedure|vaginal surgery|Control Group
46003396|NCT00562029|Procedure|Duodenal-jejunal Bypass|Patient has undergone a duodenal bypass and bypass of 60cm of proximal jejunum
46003397|NCT02905916|Drug|PEG-rhG-CSF|
46003398|NCT04626492|Diagnostic Test|Quantitative MRI imaging|Dynamic contrast enhanced magnetic resonance imaging,Intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging,Iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence
45677162|NCT01991197|Drug|Sitagliptin matched placebo|Week 0-16: Two tablets (or one tablet for those with moderate kidney disease) daily for 16 weeks during the double-blind phase.
46003399|NCT02905994|Drug|Volasertib|Polo-Like Kinase Inhibitor
46003400|NCT02905994|Drug|Cytarabine|Standard chemotherapy at dosage and schedule for 7+3 induction
46003401|NCT02905994|Drug|Idarubicin|Standard chemotherapy at dosage and schedule for 7+3 induction
45677163|NCT01991197|Drug|Gliclazide matched placebo capsule|"Double-blind phase (week 0-16):~One capsule daily for 4 weeks. Then if no severe hypoglycaemic episodes one capsule twice daily for 4 weeks. Then if no severe hypoglycaemic episodes two capsules twice daily for 8 weeks."
45677164|NCT01990573|Drug|0.3mg/kg IV methadone HCl|Group I will receive 0.3mg/kg IV methadone HCl
45677165|NCT01990573|Drug|0.4mg/kg IV methadon HCl|Group II will receive 0.4mg/kg IV methadone HCl.
45677166|NCT01990573|Other|control no methadone|The control group will not receive methadone.
45677167|NCT01990495|Other|Exercise training|Subjects will participate in a center-based and home exercise training program for 3 months.
46003402|NCT02905994|Procedure|Bone Marrow Biopsy|Bone marrow biopsy assessments scheduled during induction to assess response
46003403|NCT04626336|Procedure|Cystectomy|Cystectomy
46003404|NCT02905955|Device|Prevena, KCI, Acelity, NPWT|All patients will receive a Prevena NPWT (if inclusion criteria are met)
46003405|NCT04654767|Other|Tissue sampling|"Blood collection via venipuncture into citrate- or ethylenediaminetetraacetic (EDTA)-containing vacutainer tubes and into serum tubes. Explant lung tissue obtained from patients that underwent lung transplantation.~Non-transplanted donor lungs that had been harvested for transplantation, but not implanted because of size-reduction serve as controls."
46003406|NCT02905877|Other|Behavioural study|reaching studies and other behavioural studies.
46003407|NCT04626180|Procedure|Extubation|Extubation is the removal of an endotracheal tube (ETT), which is the last step in liberating a patient from the mechanical ventilator.
46003408|NCT04626180|Procedure|Manual Hyperinflation|Providing a larger tidal volume than baseline tidal volume to the patient and using a tidal volume which is 50% greater than that delivered by the ventilator
46003409|NCT02905682|Drug|Desmopressin|
46003410|NCT02905682|Drug|Placebo|
46003411|NCT04654377|Other|Personalised education|Patients will be explained about their disease and possible outcomes based on clinical, biochemical and imaging data.
46003412|NCT04626258|Drug|Fluconazole|Fluconazol once a month 150 mg capsule
46003413|NCT04626258|Other|L-Mesitran|The first month apply every day one sachet, the next five months apply every week one sachet.
46003414|NCT02905643|Other|Study subjects|This study does not include an intervention it is only observational.
46003415|NCT04626102|Behavioral|Healthy Eating Attitudes and Behaviours Group Program (Experimental Group Condition)|"The program has been developed by Clinical Psychologist Başak İnce and Psychiatrist Prof. Dr Başak Yücel. The session topics and contents of this program were based on the Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and 10-week online version of StudentBodies program designed by Saekow and her colleagues (2015). Program protocol was written based on Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and Fursland and her colleagues (2007)'s book titled Overcoming Disordered Eating.~This program aimed to inform participants about the causes and consequences of eating disorders, teach cognitive and behavioural techniques to change their unhealthy eating attitudes and behaviours, and provide support during their attitudinal and behavioural changes. Each week, participants were asked to complete homework activities which were related to topics covered in each session."
46003416|NCT04626102|Behavioral|Eating Disorders and Body Dissatisfaction: A Group Work (Active Control Group Condition)|"This single-session group program was designed as an active control group for the purpose of this study. The content of the program was prepared based on Stice and his colleagues (2013)'s four - sessions Body Project eating disorders prevention program. This single-session program aimed to inform participants about causes and consequences of eating disorders, and discuss thin ideal messages created by media and the negative impact of these messages on women's body images, and address possible ways of countering these messages. Detailed information regarding the covered topics and video presentations in the group session is provided below."
45677168|NCT01990495|Other|Usual Care|This group will serve as control subjects. They will receive only usual clinical care.
45677169|NCT01990339|Drug|Lansoprazole|"• Reflux esophagitis The usual adult dosage is 30 mg of lansoprazole administered orally once daily for up to 8 weeks.~For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily.~• Nonerosive gastroesophageal reflux disease Non-erosive gastroesophageal reflux disease The usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks."
46003417|NCT02905604|Device|dmPFC iTBS|2400 pulses/day over 10 week days over bilateral dmPFC using MagPro X100 and the cool D-B80 A/P coil
46003418|NCT02905604|Device|dmPFC Sham iTBS|Sham iTBS
45677170|NCT02007577|Drug|salsalate|Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
45677171|NCT02007577|Drug|Placebo|Participants will take 3 tablets with breakfast and 4 tablets with dinner
46003419|NCT04626219|Other|Imaging|Imaging - Magnetic Resonance Imaging (MRI) scan of their heads
46003420|NCT04626219|Behavioral|fast|hungry state - refrain from eating after lunch at 12 noon until 9 a.m. the next morning
46003421|NCT04626219|Behavioral|regulated meals|standardized diet from noon until 9 a.m. the next day
45677172|NCT01990261|Drug|Erlotinib|Erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
46003422|NCT04681820|Drug|Flumatinib|Flumatinib mesylate tablets 600mg qd for 24 months
46003423|NCT04681820|Drug|Nilotinib|Nilotinib Capsules 400mg bid for 24 months
46003424|NCT04626063|Drug|Magnesium|Patients were treated with etodolac 400mg twice a day plus magnesium oral supplementation once a day for acute low back pain and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
46003425|NCT04626063|Drug|NSAID|Patients were treated with etodolac 400mg twice a day for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
46003426|NCT04626063|Drug|paracetamol|Patients were treated with etodolac 400mg twice a day plus 500mg paracetamol twice a day paracetamol for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
46003427|NCT04681976|Behavioral|Telematic dance program|"Telematic dance program~The dance program will consist of 24 sessions distributed twice a week for a total period of 3 months. Each session will include:~A) Warm up: It will consist of analytical and global movements of increasing intensity and stretching exercises. It will also involve body awareness and motor control exercises.~B) Choreography part: the participants must follow and learn the choreographies. Intensity ranges shall vary between low and moderate. (3-4 in Borg's Modified Scale (0-10)).~C) Cool down: It will consist of global movements of decreasing intensity, stretching, breathing, and relaxing exercises."
46088927|NCT04184076|Behavioral|Time-restricted feeding (TRF) with dietary counseling|"Subjects will be instructed to administer time-restricted feeding.~Subjects have to compete a 3-d food record, including 2 regular day and 1 holiday. At baseline, a dietitian will provide 15 min of instruction to each participant on how to complete the food records. Subjects will be asked to measure the volume of foods consumed with household measures. The timing of food intake will be also recorded. Food records will be collected each week during the experiment and will be reviewed by the dietitian for accuracy and completeness. A database for food content will be used to calculate the total daily intake of energy, fat, protein, carbohydrate, cholesterol, and fiber. All subjects will be asked to maintain their level of physical activity throughout the entire trial.~Blood withdraw will be performed prior to the first consumption of food and analyze some biochemistry data."
46088928|NCT00641628|Procedure|mastectomy|
46088929|NCT02683044|Procedure|Low-Intensity Extracorporeal Shock Wave Therapy (Li-ESWT)|Sessions of shocks to the body of the penis
46088930|NCT00639912|Drug|sodium chloride|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 1 ml/Kg/hour for 12 hours.
46088931|NCT00639912|Drug|sodium chloride|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours
46088932|NCT00639912|Drug|sodium bicarbonate|154 mEq/L of sodium bicarbonate in dextrose solution. Rate of infusion: 1 ml/Kg/hour for 12 hours.
46088933|NCT00639912|Drug|sodium bicarbonate|154 mEq/L of sodium chloride in dextrose solution. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours.
46088934|NCT04184544|Other|Improving of quality of care at health facility and outreach level|Community Mobilization and engagement; Use of DHIS data for decision making; Capacity building of health care workers and providers and other Community level and facility level interventions to improve MNCH outcomes
45677173|NCT04658095|Device|OMNI® Surgical System|Ab-interno canaloplasty (360 degrees) and up to 360 degrees trabeculotomy using the OMNI Surgical System
45677174|NCT04658095|Device|iStent inject|Ab-interno implantation of iStent inject (2 microstents)
45677175|NCT04658095|Device|OMNI® Surgical System|Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System
46003428|NCT04625985|Drug|Metformin Glycinate|Participants randomized to metformin glycinate will take 620 mg bid (PO) for 14 days plus standard treatment
46003429|NCT04625985|Drug|Placebo oral tablet|Participants randomized to placebo will take a tablet bid (PO) for 14 days in plus standard treatment
46003430|NCT02905760|Drug|Furosemide|"Furosemide: Special LASILIX (250 mg/25 ml) solution for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)"
46003431|NCT02905760|Drug|Placebo filling|Placebo filling: Glucose 5%, 500mL infused over 30 minutes.
46003432|NCT02905760|Drug|Placebo furosemide|"Placebo furosemide: glucose 5% for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)."
46003433|NCT02905760|Drug|Vascular filling|Vascular filling: Sodium 0.9% 500mL infused over 30 minutes.
46003434|NCT04653987|Procedure|Percutaneous biliary drainage|
46003435|NCT02905526|Behavioral|Contraceptive instant messages|Contraceptive Instant messages
46003436|NCT02905526|Other|Mobile phone app|Mobile phone app
46003437|NCT02905565|Drug|NBP Softgel Capsules|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
46003438|NCT02905565|Drug|Placebo|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
46003439|NCT04654065|Drug|IN-C004|One time dose of IN-C004 taken orally.
46003440|NCT04654221|Diagnostic Test|mGFR by iohexol clearance|Iohexol 5mL injection (300 mg iodine/mL) will be administered to all subjects to determine mGFR by iohexol clearance
46003441|NCT04654182|Drug|Chlorhexidine Gluconate|Product used in accordance with manufacturers Hand Hygiene instructions
46003442|NCT02905409|Procedure|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with IMH (idiopathic macular hole)
46003443|NCT04625712|Procedure|Cholecystectomy|Cholecystectomy within the first week after a mild acute biliary pancreatitis
46003444|NCT02905448|Other|Low fat plant-based nutrition|"Conventional low fat plant-based meals free from animal source foods three times daily.~Plant-based meal replacement with Herbalife European Free From Vanilla formula two times daily.~Herbal beverage two times daily. Dietary fiber supplements is taken three times daily (10-36w) and more high fat whole plant-based foods (avocado, tofu, seeds) Conventional food intake is taken ad libitum and no calorie counts or restrictions will be applied.~From 10 to 36 weeks we added vitamin B12 and EPA+DHA fatty acid"
45677176|NCT01963117|Radiation|Combined hyperthermia and radiation therapy|
45677177|NCT02006719|Biological|Collagenase Clostridium Histolyticum|Treatment of Adhesive Capsulitis
46088935|NCT02683278|Behavioral|Cognitive-behavioral|Seven sessions of group-based treatment targeting skills to improve dysfunctional pain-related thoughts and behaviors
46088936|NCT02683278|Behavioral|Mindfulness-acceptance|Seven sessions of group-based treatment targeting skills to improve mindful awareness and acceptance of pain and stress, and increase positive emotional experiences
46088937|NCT02683278|Other|Pain Education|Seven sessions of group-based education to provide information regarding managing a chronic pain condition, but with no exercises to promote skill development
46088938|NCT02682732|Procedure|FDG-PET/CT guided bone marrow sampling|(Fluorodeoxyglucose positron-emission tomography) FDG-PET/CT guided bone marrow sampling will be used to obtain two different samples from avid and dim bone marrow areas.
46088939|NCT02680938|Drug|oxytocin|"For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~- The two groups will be compared in the following terms:~The duration of the third stage of labor by stopwatch.~Hemoglobin (Hb) difference before and 12 h after delivery.~The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery."
45677178|NCT02006719|Other|Placebo|Placebo injection
45458850|NCT03751969|Drug|HSK3486|The first 2 subjects will receive an intravenous injection of 0.4 mg/kg of HSK3486 emulsion injection (containing [14C] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg, i.e. a subject with the body weight of 60 kg is administered with a radiation dose of 300 nCi). The radiation dose for subsequent subjects can be adjusted based on the results of the first 2 subjects.
45677179|NCT01962493|Other|Sodium bicarbonate/ Sodium Fluoride|Toothpaste containing sodium bicarbonate and sodium fluoride as cosmetic
45677180|NCT01962493|Other|Sodium fluoride|Toothpaste containing sodium fluoride as cosmetic
45677181|NCT01962493|Drug|Chlorhexidine digluconate|Mouthwash containing chlorhexidine digluconate
45677182|NCT01989169|Drug|Midazolam|
45677183|NCT01989169|Drug|SSP-004184SS|
45677184|NCT01988779|Drug|oral levofloxacin|
45677185|NCT01988779|Drug|nebulized levofloxacin|
45677186|NCT01988233|Behavioral|BAILAMOS© Dance Program|
45677187|NCT01988233|Behavioral|Health Education Control Group|
45458851|NCT01375777|Biological|Evolocumab|Administered by subcutaneous injection
46003445|NCT04653870|Other|cyriax manipulation lumber|"In group A patients were treated with conservative therapy (hot pack, Kaltenborn soft tissue techniques and home plan) and Cyriax manipulation.~Exercises (Guided low back exercises, 3-5times/day). Ankle pumping (5-10 repetition with 15-20 second hold), Quads Isometric (5-10 repetition with 15-20 second hold), Hams & Calf stretching (5-10 repetition with 15-20 second hold), Bridging (5-10 repetition with 15-20 second hold), Prone Back extension (10 repetition) Precaution Prevent yourself from sitting low on ground, Sitting with support will be directed and be careful during driving and ascending stairs.~Cyriax Manipulation: 2-3 repetitions/session, 2 session/week Lumbar spinal manipulation Rotation Techniques Lumbar spinal manipulation Extension Techniques Lumbar spinal manipulation Antideviation Techniques total of 4 session were given. 2 session/week."
46088940|NCT02680938|Drug|saline|"For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~- The two groups will be compared in the following terms:~The duration of the third stage of labor by stopwatch.~Hemoglobin (Hb) difference before and 12 h after delivery.~The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery."
46088941|NCT05663970|Behavioral|VG Social ABCs|The Social ABCs is an evidence-based caregiver-mediated early intervention. This trial examines the 6-week Virtual Group Social ABCs; an adapted model of the existing evidence-based Social ABCs. The targets are functional directed vocalizations and positive emotion sharing with a caregiver. It is provided to small groups of parents (4-8 per group) who meet virtually for a series of 6 didactic learning sessions led by two trained Coaches, supported by the programs Parent Manual, PowerPoint slides, facilitated discussion, reflection, and idea generation. Each family is assigned a Coach, and one parent per family receives 9 individualized, 1:1 live coaching sessions over a 6-week period via the virtual platform with the goal of learning to implement the Social ABCs strategies with their child. 10-min video recordings of caregiver and child are taken at baseline(time 0), post intervention (time 1),and follow up (time 2) as a measurement of fidelity of implementation and child responsivity.
45677188|NCT01987765|Drug|Relestat Ophthalmic Solution 0.05%|Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.
45677189|NCT01987609|Drug|Hylenex|
45458852|NCT01375777|Drug|Ezetimibe|Administered orally once a day
45458853|NCT01375777|Other|Placebo to Evolocumab|Administered by subcutaneous injection
45677190|NCT01987609|Drug|Normal Saline|
45677191|NCT04657159|Other|Pain rehabilitation program|Effect on health related quality of life och health-care consumption after rehabilitation
45677192|NCT04174651|Behavioral|Trier Social Stress Test (TSST)|Participants randomized to receive the acute stress condition will undergo the TSST wherein the participant will be introduced to an upcoming task (i.e., job interview) and allowed to prepare (2 minutes). The participant will then be required to speak (job interview) for 4 minutes in front of 2 experimenters. After completion of the interview, participants will be asked to perform a mental arithmetic task for 4 minutes.
45458854|NCT03712969|Drug|Shenlingcao Oral Liquid|Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.
45458855|NCT01245907|Behavioral|Applied relaxation|Applied relaxation given by Internet during 10 weeks as a number of text-documents, audio-files and e-mail mediated support from therapists
45458856|NCT02431702|Drug|Aripiprazole|Aripiprazole will be administered in accordance with the label or Investigator's discretion
45458857|NCT02431702|Drug|Haloperidol|Haloperidol will be administered in accordance with the label or Investigator's discretion
45458858|NCT02431702|Drug|Olanzapine|Olanzapine will be administered in accordance with the label or Investigator's discretion
45458859|NCT02431702|Drug|Oral Paliperidone ER|Paliperidone Extended Release (ER) tablets 1.5 to 12 milligram (mg) per day will be administered orally.
45458860|NCT02431702|Drug|Perphenazine|Perphenazine will be administered in accordance with the label or Investigator's discretion
45458861|NCT02431702|Drug|Quetiapine|Quetiapine will be administered in accordance with the label or Investigator's discretion
45458862|NCT02431702|Drug|Oral Risperidone|Risperidone tablets 1-6 mg per day will be administered orally.
46088942|NCT05663892|Drug|Biktarvy 50/200/25 Tab|As the HIV ART, the combination of B/F/TAF, known as Biktarvy®, which is a widely available Single Tablet Regimen (STR) approved by Health Canada is the drug under investigation. Participants in groups 1 and 2 will either have to already be taking B/F/TAF or will be required to switch to it at baseline and they will self-administer B/F/TAF once daily in the morning, with or without food. Participants taking their dosage at night will be required to switch to a morning dose at the screening visit.
46088943|NCT05663892|Drug|Estradiol Tablets|"Oral 17(beta)-estradiol as the estrogen and an anti-androgen (pharmaceutical [e.g., spironolactone, cyproterone, finasteride, leuprolide, bicalutamide, dutasteride] and/or surgical [orchiectomy] and/or medical [hypogonadism]).Doses of estradiol range from 1 mg to a maximum of 6 mg per day.~Participants must take 2 mg until the Month 2 Visit. Trans women participants in both groups 1 and 3 must divide their dose to twice a day (BID) if they are taking > 2 mg per day and take 2 mg in the morning and the rest of the dosing in the evening. Participants who are only taking 2mg of estradiol once daily at night must switch their dosing to the morning. Participants who either crush or take the oral estradiol sublingually must switch to swallowing the tablet orally from the day after the screening visit until the Month 2 visit, otherwise the estradiol concentrations will be markedly higher."
46088944|NCT02680782|Drug|X4P-001|100 mg capsules, administered orally for 10 days either as 200 mg BID or 400 mg QD. Subjects will be randomized to determine if they will receive the drug QD or BID in the first dosing period.
46088945|NCT02685228|Drug|Decitabine|decitabine 5mg/m2,d1-d5;
46003446|NCT04653870|Other|lumber decompression|"Group B: In group B patients were treated with conservative therapy (hot pack, Kaltenborn soft tissue techniques and home plan) and Decompression Session.~Conservative therapy: Same as Group A~Lumbar spine decompression:~30 Minutes Session (generalized time for every one) . On the account of MRI description level is recommended and acknowledged by MRI the level of disc protrusion, decompression is operated. Patient is lying on table facing upward. For locking of the patient's body it was secured by pelvis and thoracic straps. One part of the decompression table is immobile other is movable. Bottom extreme part of the table is mobile.~Estimation of weight of patient is first thing to do. We calculated it by division of whole weight by 5 and that 5th segment of weight was utilized as an interventional pound for decompression. ."
46003447|NCT02905292|Other|evaluation and treatment maneuver for BPPV|
46003448|NCT04654026|Drug|Aspirin/Clopidogrel|No intervention, only observational studies
46003449|NCT04681703|Behavioral|Nurse-led program on accuracy of blood pressure self-measurement|The training program was performed in accordance with current guidelines and consisted of a 1-h educational session led by one family nurse (FN) tasked with instruction of the patients. During the training program the FN emphasized that since morning and evening blood pressure (BP) values can widely differ, especially in patients taking medications, BP should be measured twice a day, in the morning and at evening, at specific fixed times (between 6:00 am and 9:00 am and between 6:00 pm and 9:00 pm) at least during the first week of monitoring. Thereafter, measurements can be taken before antihypertensive drugs are taken.
46003450|NCT02905253|Drug|AC-084|Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
46003451|NCT02905253|Drug|Placebo|Placebo capsules matching AC-084 capsules
46088946|NCT02685228|Drug|Gemcitabine|gemcitabine 1.0g/m2, d8,d15,d22
46088947|NCT02682576|Procedure|Brachial artery ultrasound imaging|
46003452|NCT04625868|Other|Educational video|Patients will watch a preoperative educational video on proper opioid use and disposal.
46003453|NCT02905175|Procedure|blood sample|
46003454|NCT02905175|Procedure|synovial tissue|synoviocytes from synovial tissue
46003455|NCT04653909|Other|Rehabilitation|The abdominal and back strengthening exercises on the mat, the open-closed perturbation training in sitting and standing positions for trunk control. Functional exercises were performed in the same positions for simulating daily living activities. The stretching and strengthening exercises were applied to her scoliosis and also given trunk orthoses.
46088948|NCT04183686|Drug|ACT-1014-6470 (SAD)|Single dose of ACT-1014-6470; soft capsules for oral use.
46088949|NCT04183686|Drug|ACT-1014-6470 (MAD)|Multiple doses of ACT-1014-6470; soft capsules for oral use.
46088950|NCT04183686|Drug|Placebo (SAD)|Single dose of matching placebo; soft capsules for oral use.
46088951|NCT04183686|Drug|Placebo (MAD)|Multiple doses of matching placebo; soft capsules for oral use.
46088952|NCT04183686|Drug|14C-ACT-1014-6470 microtracer|Single dose of 14C-ACT-1014-6470 microtracer; soft capsules for oral use.
46088953|NCT04183686|Drug|14C-ACT-1014-6470 microtracer placebo|Single dose of matching placebo; soft capsules for oral use.
46088954|NCT05323760|Device|Cardiopulmonary exercise test (CPET)|A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute).
46088955|NCT00639990|Other|PEEP|Application of positive end expiratory pressure
46088956|NCT00639990|Other|PEEP|Application of positive end-expiratory pressure
46088957|NCT00639990|Other|PEEP|Application of positive end-expiratory pressure
46088958|NCT00639990|Other|PEEP|Application of positive end-expiratory pressure
46088959|NCT00616460|Drug|Bivalirudin|Bivalirudin: loading dose 0.75mg/kg bolus During procedure: 1.75mg/kg/hour. UFH: loading dose 60 Units /kg During procedure: keeping ACT < 250
46088960|NCT00616538|Device|Epiceram(r)|Topical barrier repair emulsion cream
45458863|NCT02431702|Drug|Paliperidone Palmitate Injection (PP1M)|Participants will receive 5 doses of PP1M. First dose at a starting dose of 234 mg on Day 1 and a second dose of 156 mg on Day 8 and then 78 to 234 mg (in 3 flexible doses), every month up to Day 92.
46003456|NCT04625595|Drug|350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
45458864|NCT02431702|Drug|Paliperidone Palmitate Injection (PP3M)|Paliperidone Palmitate injection (PP3M) will be administered once every 12 weeks intramuscularly. The initial dose will be calculated as 3.5 fold multiple of the final PP1M dose administered on Day 92 (or Day 176). Dose will be increased based on Investigator's discretion.
45458865|NCT03491566|Other|Clinic Pilates Group|"Clinical Pilates exercises include Hundreds, One Leg Stretch, Shoulder Bridge, One Leg Kick, Swimming , Double Leg Stretch, Swan Dive Circle , Arm Opening , Spine Twist , Roll Down exercises."
46003457|NCT04625595|Drug|700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
45677193|NCT04174651|Behavioral|Landscape Video|Participants randomized to receive the control condition will be watching a landscape video for 10 minutes.
45677194|NCT02013674|Biological|Allogeneic hMSCs|Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection
46003458|NCT04625595|Drug|1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
46088961|NCT00616538|Drug|Fluticasone Propionate 0.05%|Topical mid-strength steroid
46088962|NCT02680704|Other|PEEP titrated mechanical ventilation|Enrolled patients will receive a sequential, step-wise increase in positive end-expired pressure from 5 cmH2O to 15 cmH2O. Intracranial pressure, transpulmonary pressure, vitals, and mechanical ventilator data will be measured at each increment. PEEP will be increased by increments of 5 cmH2O. The mode of mechanical ventilation (pressure or volume control), inspiratory time and fraction of inspired oxygen (FIO2) will be determined by the critical care team caring for the patient. In the event that PEEP is set > 5 cmH2O, measurements will be obtained from that starting point and increased to a maximum of 15 cmH2O. The physiologic measurements will be obtained at regular intervals (within 5 minutes at each PEEP level) throughout the PEEP titration period.
46003459|NCT04625595|Drug|1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
46088963|NCT02397746|Device|total hip arthroplasty implant|
46088964|NCT02682654|Device|Dr. Scholl's Prototype Ankle Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
46003460|NCT02905058|Drug|Ketoprofen|oral non-steroidal antiinflammatory drug
46003461|NCT02905058|Drug|placebo|
46003462|NCT00557661|Drug|CD-NP|24 hr intravenous infusion
46088965|NCT02682654|Device|Dr. Scholl's Prototype Knee Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
46088966|NCT02365610|Drug|GWP42006|
46088967|NCT02365610|Drug|Placebo Control|
46088968|NCT02680548|Drug|0.9% saline|
45458866|NCT03491566|Other|Aerobic Exercise Group|Aerobic exercise with using an elliptical bike, or bike or treadmill under supervision of a physiotherapist.
46003463|NCT02905136|Other|Fundamental research|serum, whole blood, cerebrospinal fluid
46088969|NCT02680548|Drug|0.25% bupivacaine hydrochloride injectable suspension USP|
45677195|NCT01987232|Drug|Carfilzomib|Administered by intravenous infusion.
45677196|NCT01987232|Drug|Carboplatin|Administered by intravenous infusion.
45677197|NCT01987232|Drug|Etoposide|Administered by intravenous infusion.
45677198|NCT04676204|Drug|Cladribine|Cladribine is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis, to include relapsing-remitting disease and active secondary progressive disease, in adults.
46088970|NCT02680548|Drug|4mg/cc methylprednisolone acetate injectable suspension USP|
46088971|NCT00617786|Procedure|Current Perception Threshold (CPT) Testing|During the CPT testing a catheter will be placed in the bladder. The catheter has sensors to record the body's sensation of pressure. The sensation felt will be similar to a light touch and is painless. A gel pad will be placed in the general area of the vagina to record the feeling of a light touch.
46088972|NCT00617864|Drug|Human Albumin Infusion|Group will receive single infusion of albumin at the time of oocyte retrieval.
46088973|NCT00617864|Drug|Saline Infusion|Group will receive single infusion of saline at the time of oocyte retrieval.
46088974|NCT02361320|Procedure|Computed Tomography (CT)|Participants to receive 2 CT scans. One scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist.
45677199|NCT04676204|Drug|Dimethyl fumarate|Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
46003464|NCT03454854|Device|intelligent terminal APP|Applications(APP) support patients to upload the primary data contain pictures and wearable devices data. When risk-rating changes or serious adverse events(SAE) take place, APP will alert patients to seek medical advice or make a call with the doctor. Beside, terminal of patients furnishes functions like answering frequently asked questions,self-assessment of physical condition,push rehabilitation knowledge etc.
46003465|NCT02905097|Procedure|Knee Replacement|Surgical replacement of arthritic knee with an implant
46003466|NCT03454815|Procedure|Apical patency|Apical patency was maintained by passing a #10 K file 1 mm beyond working length between every instrument change while doing chemomechanical preparation
46003467|NCT02905019|Biological|R21 with Matrix-M1|Vaccine
46088975|NCT02361320|Behavioral|Questionnaire|Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit. Questionnaires should take about 10 minutes to complete.
46003468|NCT02905019|Biological|ChAd63 ME-TRAP|Vaccine
46003469|NCT02905019|Biological|MVA ME-TRAP|Vaccine
46003470|NCT03454776|Device|Unloader One brace|A knee brace used to unload affected compartments in osteoarthritic knees
46088976|NCT02680392|Procedure|Pulsed and Continuous Radiofrequency|"Preoperative pulsed radiofrequency of the saphenous nerve and Continuous radiofrequency of the genicular nerves of the knee joint.~The saphenous nerve will be approached at the adductor canal and it will be treated with Pulsed RF for 4 minutes at 42 Celsius degrees. Ropivacaine 0.5% 10ml with Dexamethasone 10mg will be injected after the RF.~The Genicular terminal branches of the sciatic and femoral nerves will be treated with Continuous RF for 3 min at 80 Celsius degrees and then with 2 ml of Ropivacaine 0.5% and 10 mg of Methylprednisolone to each nerve (5 in total) A sham catheter in the mid-thigh will be placed for patients in the RF group, infusing Normal Saline 0.9% and simulating a Continuous Adductor Canal Block. To blind the investigator to the type of treatment for the postoperative assessment , every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution."
46088977|NCT02680392|Drug|Continuous Adductor Canal Block|"The patients in the Adductor canal group, will have a catheter for peripheral nerve block inserted under strict asepsis in the adductor canal under ultrasound guidance, and will receive for postoperative analgesia a 48-h continuous infusion of Ropivacaine 0.2% at 8 ml/hour The patients will receive, intraoperatively 10 mg of Dexamethasone i.v.~To blind the investigator who will do the postoperative assessment to the type of treatment, every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution. It will be always possible to crack the code and find out to which group the patient belongs"
46088978|NCT00618020|Device|CiTop(tm) Guidewire|CiTop(tm)6 Guidewire
46088979|NCT05663736|Drug|Gemigliptin|DPP-4 inhibitor
46088980|NCT05663736|Drug|Glimepiride|Glimepiride
46088981|NCT02680470|Device|Virtual observed therapy|Virtual Observation of participants taking their medication
46088982|NCT04212182|Device|HFNC|HFNC provides warmed and humidified gas administered through slightly enlarged nasal prongs.
46088983|NCT04212182|Device|NPPV|NPPV is the standard therapy for ventilatory failure in AECOPD.
46003471|NCT03454776|Device|Placebo brace|A knee brace that feels and looks like Unloader One but without active straps facilitating unloading of the knee
45458869|NCT03132064|Procedure|total knee arthroplasty|surgical repair for end stage of knee osteoarthritis.
46003472|NCT02904941|Biological|Amniotic Membrane Dressing|Amniotic membrane dressings will be made out of donated amniotic membranes from elective cesarean sections. Screening for relevant infectious diseases and irradiation will be performed from every included sample in order to minimise infectious risks. Dressings will be provided to attending surgeons during wound care at the operating theatre and removed every 72-96 hours.
46088984|NCT02684916|Procedure|Chiropractic treatment|"The child receives chiropractic manipulation treatment in the neck and in the spine and pelvis according to individual needs. They also receive a written list of general advice regarding lifestyle and habits.~The parents and the child are unaware of group allocation."
46003473|NCT02904941|Device|Synthetic Dressing|Silicone dressings will used as an active comparator in this study. As with the amniotic membrane, dressings will be applied to wound care at the operating room and replaced every 72 to 96 hours.
46003474|NCT02904941|Procedure|Standard Wound Care|Every included participant will receive standard wound care regardless of treatment allocation. Contaminants such as clothes or other materials will be removed, and all burns will be cleaned using sterile saline solutions. Clorhexidine will also be used to clean the skin. Surgical debridement under general anesthesia or procedural sedation/analgesia will be performed to every included participant, in which nonviable tissues and blisters will be removed.
46003475|NCT03454737|Procedure|mesenchymal stem cells|"Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out.~The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration"
46003476|NCT03454737|Procedure|Pure platelet-rich plasma|"Under aseptic conditions, in surgical medium, 6 ml of P-PRP will be obtained from 36 ml of autologous peripheral venous blood sample.~The plasma coagulation will be activated by the addition of Cl2Ca at a concentration of 5%."
45458870|NCT03491488|Other|Brain Games|The Brain Games intervention package is used as a tool to improve children's self-regulation and executive function skills. Brain Games were developed as part of larger behavioral intervention package in the US, and are designed to build the fundamental self-regulation skills that children need to be successful in school as well as later in life. The games are designed to be played in the classroom between regular activities.
46003477|NCT02904980|Behavioral|Technical Training|Children will watch an instructional video focused on movement related instructions regarding the throwing and catching task.
45458871|NCT01145209|Drug|Fludarabine Phosphate|Given IV
45458872|NCT01145209|Biological|Ofatumumab|Given IV
46003478|NCT02904980|Behavioral|Quiet Eye Training|Children will watch the same video as the TT group but will also receive instructions designed to optimise their quiet eye durations.
46003479|NCT04625322|Other|HCV care provided by hospitalist during acute psychiatric admission|HCV diagnosis and treatment will be conducted by a hospitalist during an acute psychiatric admission at CAMH
46003480|NCT02904824|Biological|adipose derived regenerative cells|Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.
46003481|NCT02904824|Biological|centrifuged autologous fat|centrifuged adipose tissue which is autologous tissue is used to fill the paralyzed vocal cord. The aim is to increase the volume of the vocal fold, to reduce the glottal gap.This effect is temporary. Route of administration: injection into the thickness of a paralyzed vocal cord.
45458873|NCT01145209|Drug|Cyclophosphamide|Given IV
46003482|NCT04653519|Device|Virtually guided minimally invasive preparation|Intraoral virtually guided minimally invasive design with an occlusal reduction of 1.5mm, axial reduction will be performed with 6 degrees axial taper and a circumferential chamfer margin of 0.5mm in width and 0.5mm coronal to the gingival margin. A milled guiding occlusal resin template of the teeth will be checked for fitting then fixed using spot etching and will be used to guide the amount of axial reductions and taper degree.
46003483|NCT02904746|Behavioral|Make It!|The Make It! motivational enhancement intervention has been informed by Motivational Interviewing principles, a method that has widely demonstrated effectiveness in increasing a number of positive behavior changes, including appointment adherence. Make It! consists of a 10-15 minute intervention with 5 components: Common reactions to stressors that this exposure can lead to a range of reactions, pros and cons of attending the Information Class, visualization of the Information Class, expression of confidence that the client can progress towards change, and reiteration of main information.
45458874|NCT02086552|Other|Laboratory Biomarker Analysis|Correlative studies
45458875|NCT02086552|Drug|Lenalidomide|Given PO
45458876|NCT02086552|Drug|Sonidegib|Given PO
46003484|NCT02904785|Device|Extracorporeal Shock Waves|
45458877|NCT01146223|Other|laboratory biomarker analysis|Correlative studies
45458878|NCT03492034|Device|IUD during CS|IUD insertion during CS
46088985|NCT02684916|Procedure|Placebo|Non-therapeutic placebo treatment: a broad non-specific contact outside the spinal column is taken on subject's scapula and gluteal region lying in a side posture position, on the scapulae in a prone position and on trapezius muscles in a sitting position. In those positions the chiropractor pushes in a non-intentional and non- therapeutic directional line with a low-amplitude, low velocity push maneuver. All contacts are performed without soft tissue pre-tension and gentle contact, to insure that no joint cavitation occurs. To obtain a noise that many people associate with a chiropractic spinal adjustment, a de-activated Activator Instrument is used on the arm of the chiropractor to give a click-sound. General advice on lifestyle and habits is handed out to the placebo group as well.
46088986|NCT04211948|Procedure|robotic surgery|Pancreatectomy with robotic assisted system
46088987|NCT04211948|Procedure|open surgery|Traditional open pancreatectomy
46088988|NCT02685150|Device|Endoscopic Tri-Modal Imaging|Endoscope that combines white light imaging (WLI) with autofluorescence imaging (AFI) and narrow band imaging (NBI).
46088989|NCT02685150|Drug|Omeprazole|Omeprazole is one kind of proton-pump inhibitors. All participants undergo standard proton-pump inhibitor (PPI) tests for two weeks with Omeprazole, 20mg twice a day.
46088990|NCT02685150|Other|Analysis of gastric juice|Analysis of gastric juice including routine, biochemical and microbiological analysis.
46088991|NCT02684994|Behavioral|Cognitive Processing Therapy|Cognitive-processing therapy is a well-supported treatment for reactions following traumatic events. It includes 12 individual psychotherapy sessions and consists of 4 components: education about trauma responses, experiencing emotions related to the assault, development of skills for examining the truth of thoughts, and examination of beliefs in areas commonly influenced by the trauma.
46088992|NCT02682186|Drug|Ropivacaine after dilution with sodium chloride 0.9%|"After the anesthesic induction, the interventional team composed by at least a senior anaesthesiologist and a nurse anesthestic, will survey the patient and perform the Pecs blocks, whereas the anesthetic team is outside the room.~Realization of Pecs blocks 1 and 2 : the patient is in supine position with placing the upper limb in abduction position, a 100 mm needle is inserted under ultrasound using a linear US probe of high frequency after sheathing.~In the other group, sterilization, sheating and US are performed but the needle is not inserted."
46088993|NCT00619268|Drug|Temsirolimus|25 mg once per week administered intravenously
46088994|NCT00619268|Drug|Bevacizumab|10 mg/kg * 1 time /2 weeks administered intravenously
46088995|NCT00619268|Drug|Sunitinib|50 mg administered orally once daily in 6 weeks cycles :4 weeks of treatment followed by 2 weeks off
45458879|NCT03492034|Device|IUD after puerperium|IUD after puerperium
45458880|NCT01237561|Other|provider support tools plus spirometer|Patient Activation Tool, Provider Web-based decision support tool, academic detailing
45458881|NCT03497260|Dietary Supplement|Fructose|Intake of 20 g of fructose dissolved in 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
45677200|NCT04676204|Drug|Fingolimod|Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
45458882|NCT03497260|Other|Plain water|Intake of 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
46003485|NCT02904785|Device|Sham Extracorporeal Shock Waves|
46003486|NCT02904785|Other|Physical activities|Patients receive instructions for physical activities for strengthening of femoral quadriceps and stretching of hamstring muscles.
46003487|NCT01212991|Drug|Enzalutamide|Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
46003488|NCT01212991|Drug|Placebo|Participants received placebo, administered as four capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
46003489|NCT02904863|Biological|Extra blood draw samples|
46003490|NCT04625439|Behavioral|Personality Feedback Self-Management Intervention|The intervention is a personality feedback report that will tell participants whether they scored low (bottom third), average (middle third), or high (top third) on each of the five factor personality characteristics based on gender-matched norms. In addition to a description of general tendencies based on their level of each personality trait, the feedback will include information about how scoring in a given category may relate to an individual's cancer self-management or healthcare decision making. The feedback for each personality trait will include recommendations for how to improve key outcomes.
46003491|NCT02904551|Procedure|Free gingival graft|After infiltration anesthesia, a recipient bed was prepared with a horizontal split-thickness incision made with a 15 stainless steel blade at the mucogingival junction (MGJ) on the facial side of the selected implants. An intermediate thickness (0.75 mm) graft was taken from the palate. The graft was sutured with 6-0 polypropylene suture at the recipient site. Co-Pak® was applied on the recipient site. Analgesics (over-the-counter Tylenol or Ibuprofen) were prescribed for 5-7 days. PeridexTM (3M, St. Paul, MN) was prescribed for 7-10 days. No antibiotics were prescribed in relation to the surgery.
46003492|NCT02904551|Procedure|Oral prophylaxis|Oral prophylaxis is a regular dental cleaning. Titanium periodontal curette and superfloss were used on implant sites. Stainless steel periodontal curettes and a piezo scaler were used for natural teeth.
46003493|NCT04625400|Diagnostic Test|bronchoscope|Bronchoscopy in Assessment of Patients With Post-intubation Tracheal Stenosis.
46003494|NCT02904434|Other|Grapefruit Juice|On day 1 of the study, subjects will receive their standard voriconazole dose with no grapefruit juice. On day 2 of the study, subjects will receive approximately 240mL of reconstituted grapefruit juice by mouth or via nasogastric tube 30 minutes prior to receiving a scheduled dose of voriconazole. Blood samples will be collected during the 12 hours following voriconazole dosing on both days of the study.
45458883|NCT01146691|Other|Alternative Intensivist staffing models|During the study period, each participating ICU alternated (ABAB or BABA) between two distinct intensivist staffing formats: (i) the standard staffing model, an intensivist is responsible for care in that ICU for the entire 7 days, being present during the daytime hours, and taking call from home at night, (ii) the 24-7 in-hospital, shiftwork model, enabled by splitting each 24 hour period into two shifts. There will, as in the standard model, be a single intensivist covering the ICU during the day shifts for one week. The day shift will run 8 am to 5:30 pm on weekdays, and 8 am to 3 pm on Saturday and Sunday. The night shift intensivist will arrive and take over at 5:30 pm on weekdays, and 3 pm on weekends and remain in the hospital until 8 am.
45458884|NCT02321878|Drug|liraglutide|"Liraglutide (Victoza®) will be prescribed by the physician under normal clinical practice conditions.~No treatment given."
46003495|NCT04653792|Drug|Pregabalin 75mg|75 mg capsule
46003496|NCT04653792|Device|Placebo|75 mg
46003497|NCT02904473|Other|GROWell|The GROWell intervention is a mobile health technology, including diet tracking, skills training and tailored feedback based on digital and human support strategies. Its message content is geared toward healthy diet change during pregnancy.
46088996|NCT00619268|Drug|Interferon alpha-2a|Administered subcutaneously as 9 MU three times per week
46088997|NCT04182906|Behavioral|Care Coordination|Screening and referral for basic needs and adult mental health
46088998|NCT04182906|Behavioral|Resiliency Clinic|Mindfulness-based caregiver-child group medical care
45677201|NCT04676204|Drug|Teriflunomide|Teriflunomide is a pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis.
46088999|NCT04182906|Behavioral|Usual Care|Usual Primary Pediatric Care
46089000|NCT00619346|Drug|Placebo|Placebo tablets, BID X 14 days
46089001|NCT00619346|Drug|pafuramidine maleate|Pafuramidine maleate, 100 mg tablet BID X 14 days
46003498|NCT04625010|Other|Swaddling|Swaddling is a wrapping procedure in which a baby's arms and legs are comfortable, sometimes only the arms are wrapped inside, and two ends of fabric are crossed on the chest of the baby, generally with thin cotton and soft fabric or a blanket. In the swaddling group, neonates were placed in the supine position on a blanket. In compliance with the newborn anatomic posture, the legs were wrapped in the flexion and abduction position. The arms of the neonates were placed close to their torso with both hands, without restraining limb movements. Swaddling was carried out 1 minute before the heel stich procedure and continued 3 minutes after the procedure. The neonate remained on the examination table during the swaddling procedure. Swaddling was applied not too loose or too tight during the procedure.
46003499|NCT04625010|Other|Maternal holding|Neonates in this group were held in their mothers' lap while their mothers were seated reclining on a comfortable chair. Neonates remained clothed in their mothers' lap during the heel stick procedure, and no breastfeeding was administered during the procedure. Holding was continued for a minimum of 3 minutes during and after the procedure.
46003500|NCT02904668|Other|self-managmeent program|One session was a session supervised by a physical therapist in the Faculty of Health Sciences. The program contents were educative information about chronic neck pain and healthy lifestyle habits (application of local heat/cold, and sleeping face down, using correct sitting posture, alternating body position, and using correct lifting technique (…), which were complemented by a problem-based session.
46003501|NCT02904707|Other|Questionary EQ-5D|In addition to the pain questionary that is filled filled as usual, the EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.
46003502|NCT02904395|Other|observational (no intervention)|
46003503|NCT04653441|Behavioral|Child-Caregiver-Advocacy-Resilience [ChildCARE] intervention|"The proposed multimodal Child Caregiver-Advocacy-Resilience intervention (ChildCARE) will include three integrated components: the individual child (peer-group activities), family (caregiver parenting skill training), and the local community (community advocacy)."
46003504|NCT02904278|Other|Teen Pocket PATH® Mobile Application|Participants in the intervention group will receive the mobile application for improving adherence to their post-transplant medications. The intervention will prompt, remind, and warn participants when medications are due, inform parents when medication management is completed, and engage parents when no action is undertaken.
46003505|NCT02904278|Other|Control Group: Standard of Care|Adolescents and parents/guardians assigned to the Standard Care Condition will receive standard clinical care per standard site procedures.
46003506|NCT00557700|Drug|Administration of inhaled tiotropium bromide|Administration of inhaled tiotropium bromide
46003507|NCT00557700|Drug|Administration of placebo|Administration of placebo
46003508|NCT00557739|Drug|mometasone furoate|Topical 0.1% mometasone furoate
46003509|NCT00557739|Drug|nortriptyline HCl|Topical 0.05% or 0.1% nortriptyline HCl
46003510|NCT00557739|Drug|Vehicle (placebo)|Topical placebo
46003511|NCT02904122|Other|teleconsultation|Determine the interest of teleconsultation in dentistry tool for the diagnosis of caries. Ie whether oral teleconsultations are of the same quality as conventional consultations for the diagnosis of caries ..
46003512|NCT04624932|Behavioral|RR Digital Tool|This is the intervention condition. Participants in this condition will take the RR digital tool available at https://outsideplay.ca.
46003513|NCT04624932|Behavioral|Position Statement on Active Outdoor Play|This is the control condition. Participants in this condition will read the position statement that summarizes the issues and research regarding children's access to outdoor play.
46003514|NCT02903888|Drug|Levonorgestrel (Jaydess, Skyla, BAY86-5028)|Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
46003515|NCT02903927|Device|Implantation of CT LUCIA IOL|
46003516|NCT02903927|Device|Implantation of Acrysof IQ SN60WF IOL|
46003517|NCT04624542|Device|Electromyographic device|the EMG machine will be used to measure NCV of femoral nerve within individuals with PFPS
45458885|NCT03625141|Drug|Cobimetinib|60 mg (three tablets of 20 mg each) orally (PO) once a day (QD) on Days 1-21 of each 28-day cycle.
45458886|NCT03625141|Drug|Atezolizumab|"Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.~Only for cohort 2, no dose of atezolizumab will be given during the run-in period (cycle 1)."
46003518|NCT02904083|Behavioral|self assessment of adherence|
46003519|NCT04653168|Drug|LY3041658|Administered SC
46003520|NCT04653090|Diagnostic Test|Xray|Hip AP Xray
46003521|NCT04653012|Device|Intracranial macro-microelectrode recording|Additionnally to clinical macroelectrodes, Benkhe-Fried depth macro-microelectrodes will be implanted and recorded during the pre-surgical investigation of epileptic patients
46003522|NCT02903849|Behavioral|Drafting Motivational Messages|Write down three motivating messages
46003523|NCT02903849|Behavioral|Control Reminders|Receive standard reminders at three points during the challenge
46003524|NCT02903849|Behavioral|Treatment Reminders|Receive reminders containing the messages they leave themselves at three points during the challenge
46003525|NCT04653129|Procedure|Autologous Fat Grafting|"The fat grafts will be harvested from the abdomen or lateral thighs in a closed sterile system, then prepared according to Coleman guidelines. The blood and oil layers are then separated from the adipose tissue.~The lipoaspirate will be injected based on a technique described by Vaienti et al, by 17-gaug cannula which will be inserted through the skin around the main incision at the nerve repair site, and the fat graft will be injected after closure of the skin."
46003526|NCT04653129|Procedure|Primary Nerve Repair|Standard Epineural nerve repairs will be performed with 9/0 nylon sutures, under magnification by an operating microscope.
45677202|NCT04676204|Drug|Ozanimod|Ozanimod is a sphingosine-1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis.
46003527|NCT04681547|Procedure|Genicular nerve Block|"After the administration of spinal anesthesia, the anatomical structures of the proximal and distal region of the knee will be explored through an M- ultrasound machine Turbo® with a high-frequency 6-13 MHz linear probe.~The ultrasound transducer will be placed in a coronal orientation to the axis of the knee in the corresponding area to be blocked according to anatomical landmarks of superior medial genicular nerve (SMGN), inferior medial genicular nerve block (IMGN), superior lateral genicular nerve (SLGN), inferior lateral genicular nerve (ILGN), and recurrent genicular nerve (RGN).~It should be noted that the visualization of the genicular arteries in the femoral epicondyles and in the area of the tibial plateau, represents an accurate guide to where the sensory afferents are, however; its display is not constant.~4 ml of 0.2% ropivacaine will be administered, with adrenaline 1: 100 000 in each of the five nerves."
45677203|NCT04676204|Drug|Diroximel fumarate|Diroximel fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
46089002|NCT00910026|Procedure|low tidal volume ventilation|6 ml/kg tidal volume ventilation
46089003|NCT00910026|Procedure|high tidal volume ventilation|12 ml/kg tidal volume ventilation
46089004|NCT04182828|Drug|Lidocaine|both the drugs will be prepared in same volume, color, consistency and appearance
45677204|NCT01986920|Drug|A-101 25%|Low Dose Concentration of A-101 applied to one of 4 Target Lesions
45677205|NCT01986920|Drug|A-101 32.5%|Mid Dose Concentration of A-101 applied to one of 4 Target Lesions
46089005|NCT00619424|Drug|pazopanib|Oral tablet administered daily in dosages of 400 - 800 mg.
46089006|NCT00619424|Drug|erlotinib|oral tablet taken daily in dosages of 100-150 mg.
46089007|NCT00619424|Drug|pemetrexed|IV chemotherapeutic agent administered every 21 days in dosages of 400-500 mg/m2
46089008|NCT00641004|Drug|Rebamipide and Esomeprazole|"Rebamipide 100mg TID for 12 weeks~Esomeprazole 40mg OD + Esomeprazole-matching placebo BID for 12 weeks"
46089009|NCT02289560|Device|Transcranial ExAblate|Transcranial ExAblate
45677206|NCT01986920|Drug|A-101 40%|High Dose Concentration A-101 applied to one of 4 Target Lesions
45677207|NCT01986920|Drug|A-101 Vehicle|Placebo applied to one of 4 Target Lesions
45677208|NCT02010632|Drug|Generic clopidogrel product Apolets®|"Clopidogrel 75 mg once daily for 7 days~Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7"
45677209|NCT02010632|Drug|Original clopidogrel product Plavix®|"Clopidogrel 75 mg once daily for 7 days~Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7"
45677210|NCT01986140|Device|PAXMAN Orbis Scalp Cooler|Treatment with Orbis scalp cooling cap
45677211|NCT01986140|Other|Control No treatment|No treatment to prevent hair loss
45677212|NCT01986062|Drug|AR11|
45677213|NCT01986062|Drug|Placebo|
45840081|NCT00592176|Drug|local injection of bevacizumab|Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.
45840082|NCT00592488|Drug|Acetyl-L-Carnitine|Acetyl-L-Carnitine - 4 g IV over 30 minutes, then 8 g iv over the next 12 hours
45840083|NCT00593346|Radiation|brachytherapy|brachytherapy (radioactive implants)
45677214|NCT01985360|Procedure|Cardiac Catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
45677215|NCT01985360|Procedure|Coronary Artery Bypass Graft Surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
45677216|NCT01985360|Procedure|Percutaneous Coronary Intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
45677217|NCT01985360|Behavioral|Lifestyle|Diet, physical activity, smoking cessation
45677218|NCT01985360|Drug|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
45677219|NCT02032706|Device|Deliver therapy when the supine position is detected|Application of vibrotactile feedback to the neck when the supine position is detected
45677220|NCT04690010|Procedure|Ambulatory tubeless PCNL|Patients will be discharged the same day of surgery. No nephrostomy tube will be left in place. A ureteral stent on a string may be left for up to 5 days.
45677221|NCT04690010|Procedure|Inpatient PCNL with nephrostomy tube|Patients will be admitted to hospital for 1-3 days. A nephrostomy tube will be placed at the time of surgery that will be removed prior to discharge.
46003528|NCT04681547|Procedure|Local Infiltration Analgesia|100 ml of ropivacaine 0.2% with 1 mg of epinephrine during the period of intraoperative ischemia and, before the closure of the surgical wound, 50 ml of ropivacaine 0.2%.
46003529|NCT04624464|Other|Rectal swabs - microbiological analysis|Microbial analyses will be performed from the rectal swabs obtained.
46089010|NCT02680236|Other|Art Therapy Group|"Patients fulfilling the inclusion criteria will be made an appointment with the art therapist for the Initial Assessment session. They will be given the following Reflect Interview session Final interview session An analgesic use form will be given to the patient to take home to note their actual analgesic use~At the end of each of these art therapy sessions, patients will be given a Brief Pain Inventory form (BPI) with a stamped addressed envelope. This is to be completed twenty four hours after the appointment and returned by post."
46089011|NCT02680080|Drug|Moxifloxacin|a single 400 mg tablet of Moxifloxacin
46089012|NCT02680080|Dietary Supplement|Grapefruit group|one liter of fresh pink-grapefruit juice
46089013|NCT03112824|Dietary Supplement|Ashwagandha Root Extract Capsule|Participants will take one 300 mg capsule of Ashwagandaha Root Extract orally twice a day for 12 weeks.
46089014|NCT03112824|Other|Placebo Capsule|Participants will take one placebo capsule orally twice a day for 12 weeks.
46089015|NCT04183842|Dietary Supplement|LACIME Anti-hangover|"LACIME Anti-hangover contains the following excipients:~Purified water,~Xanthan gum,~Glycerin,~Potassium sorbate (as a preservative)~Citric acid (acidity regulator)~Aroma (flavouring agent)~LACIME Anti-hangover contains the following plant extracts and vitamin:~Curcuma longa rhizome extract (Curcuma),~Panax quinquefolius extract (Ginseng panax),~Malpighia punicifolia extract (Acerola),~Silybum marianum extract (Milk thistle),~Desmodium adscendens extract (Desmodium),~Pyridoxine chlorhydrate (Vitamin B6)."
46089016|NCT04183842|Other|Placebo|"Placebo contains the following excipients :~Purified water,~Xanthan gum,~Glycerin,~Potassium sorbate (as a preservative)~Citric acid (acidity regulator)~Aroma (flavouring agent)~Placebo contains :~- Carrot juice"
46089017|NCT02684760|Drug|PF-06651600|PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.
45677222|NCT02032238|Device|laser photocoagulation|Standard bevacizumab Injections will be combined with laser photocoagulation in a pre-defined manner
45677223|NCT04689074|Other|Biological sample collection|Collection of faeces, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
46003530|NCT04624464|Other|Examination of patient room|Only performed for cohort 2
46089018|NCT01009788|Drug|ABT-888|Capsules taken orally twice a day on days 1-7 of each 28 day cycle
46089019|NCT01009788|Drug|temozolomide|capsules taken orally once a day on days 1 through 5 of a 28 day cycle
46089020|NCT04183608|Drug|Adalimumab|Patients will all receive Adalimumab 160/80/40mg EOW until V1 (W14) followed by 40mg EOW until V2 (W26)
46089021|NCT04183608|Diagnostic Test|Calprotectin|Fecal calprotectin dosing at home with IBDoc
46003531|NCT04681391|Device|transCranial direct current stimulation|In the present study, we applied DC Brain Stimulator Plus to stimulate right temporoparietal junction (rTPJ). The target electrode was placed over the location of rTPJ; on the other hand, the return electrode was placed over the left supraorbital area. That is, during anodal tDCS, the anode was placed over CP6, and the cathode was placed over left supraorbital area; conversely, during cathodal tDCS, the cathode was placed over CP6, and the anode was placed over left supraorbital area. For the active stimulation, which are anodal and cathodal tDCS, a constant current of 1 mA was delivered through 35 cm2 electrode for 20 minutes with fade-in and fade-out of 10 seconds, producing a current density of 0.029 mA/cm2. On the other hand, same fade-in, fade-out, and current density were applied for the sham stimulation, but the duration of current-delivering only last 35 seconds. Therefore, participants could feel the skin sensation but did not have the after-effects of tDCS.
46003532|NCT04652817|Device|MMI-22-04-2019|A cross-linked form of the Hyaluronic Acid is used in intradermal injection to augment the labia majora area.
46089022|NCT04183608|Other|e-Monitoring|"e-Monitoring at Week 6, Week 10, Week 14, Week 18, Week 22, Week 26, Week 34, Week 38, Week 42 and Week 48~The patient must complete the first 2 questions of the Mayo score:~Stool frequency~The frequency of bleeding~He must also complete the information on his injections"
46089023|NCT04183608|Other|Therapy Education|Patient Education at W0, W2, W14, W26 and W38.
46003533|NCT04681586|Device|bright light therapy|using a bright light therapy device (10.000 lux) for 30min every morning for two weeks
46003534|NCT04681586|Device|dim red light|using the same device as the active group, but with an installed filter that dims light to <300 lux for 30min every morning for two weeks
46003535|NCT04624269|Drug|Hydroxychloroquine Sulfate Tablets|Hydroxychloroquine Sulfate Tablets ,0.1mg，bid po
46003536|NCT02903810|Biological|Mixed CAR-T Transfer|All subjects will be infused with αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T cells in equal number
46089024|NCT04184778|Device|Smaller tube size|Comparing how tube size affect patient's experience of postoperative sore throat and hoarseness in men and women.
45458887|NCT03625141|Drug|Vemurafenib|Participants will receive vemurafenib 960 mg (four 240 mg tablets) orally (PO) twice daily (BID) on days 1-21 of the run-in period (cycle 1); thereafter, they will receive vemurafenib 720 mg dose (three 240 mg tablets) PO BID on days 22-28 of cycle 1 and on days 1-28 of all subsequent cycles.
46089025|NCT02684682|Behavioral|Frequency of mechanical control of plaque (12h)|Performing oral hygiene 12 in 12 hours, with tooth brush and interdental device.
46089026|NCT02684682|Behavioral|Frequency of mechanical control of plaque (24h)|Performing oral hygiene 24 in 24 hours, , with tooth brush and interdental device.
46089027|NCT02684682|Behavioral|Frequency of mechanical control of plaque (48h)|Performing oral hygiene 48 in 48 hours, , with tooth brush and interdental device.
46089028|NCT00641082|Drug|Clevudine|30mg for 48 weeks
46089029|NCT00641082|Drug|Adefovir dipivoxil|10mg for 48 weeks
46089030|NCT02684526|Procedure|Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using the Eovist contrast agent. This MRI scan takes approximately 45minutes to 1 hour to complete.
46003537|NCT04652739|Drug|Lycopene Softgel, 10 Mg|Patients were given 10 mg of lycopene softgel capsules once daily for two months. The active ingredient in each capsule consists of 10 mg lycopene from natural tomato extract.
46003538|NCT04652739|Drug|Prednisolone|Patients were given 40 mg of prednisolone tablets once daily in the morning for one month, afterwards, the dose was tapered along the following month. Incremental reduction of 10 mg each week for the first three weeks, followed by 5 mg reduction in the last week, was the tapering protocol in this study. The active ingredient in each tablet consists of Prednisolone metasulfobenzoate sodium 31.44 mg (equivalent to 20 mg of Prednisolone).
46089031|NCT02684526|Procedure|Non Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using a contrast agent other than Eovist. This MRI scan takes approximately 45minutes to 1 hour to complete.
46089032|NCT00641784|Drug|Magnesium|Intravenous Magnesium 6 gram load, 3 grams/hr
46089033|NCT00641784|Drug|Nifedlipine|Oral Nifedpine 10 mgs q 20 min to effect (max 40mgs)...then 20 mgs q 4hrs
46089034|NCT00503178|Procedure|Biological imaging guided antalgic radiotherapy|Biological imaging guided antalgic radiotherapy is followed.
46089035|NCT00641160|Drug|vinorelbine tartrate|Dose Level #1 PO for at least 7 days
46089036|NCT00641160|Drug|vinorelbine tartrate|Dose Level #2 PO for at least 7 days
46089037|NCT00641160|Drug|vinorelbine tartrate|Dose Level #3 PO for at least 7 days
46089038|NCT02679924|Device|Hyaluronic Acid filler|The objective of this study is to determine the efficacy and safety of Restylane® Silk Hyaluronic Acid filler microinjections when used in a grid-like injection pattern for the correction of fine lines to the cheeks.
46089039|NCT02679924|Other|Sham Comparator|Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
46089040|NCT04182282|Behavioral|CARES Dementia-Friendly Hospitals Online Training and Certification Program|The CARES Dementia-Friendly Hospitals Online Training program is a 4-course, 16-module, video-based training program for hospital staff members. The CARES Dementia-Friendly Hospitals Online Certification Program is a 100-point certification exam evaluating knowledge from the online training protocol.
46089041|NCT02679846|Other|Standardized protocol|The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients
45458888|NCT03491410|Drug|Aspirin Low Dose|Low-Dose Aspirin is to be added in the standard patient´s treatment
45458889|NCT03491410|Drug|Placebo Oral Tablet|Placebo is to be added in the standard patient´s treatment
45458890|NCT00876031|Drug|trofosfamide, idarubicin, etoposide|oral maintenance therapy for 6 months
45458891|NCT02321956|Diagnostic Test|Ultrasound|Using ultrasound to determine the size of endotracheal tube
45677224|NCT04689074|Other|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
46003539|NCT02904005|Other|Standardized assessment on depressed patients|"At inclusion, socio-demographic characteristics, main life events, psychopathology (comorbidity, personality dimensions, characterisation of SB) and biological sample will be performed by psychiatrist and nurse. Investigators will retrieve the results of biological assays routinely made as part of standard collect biological results routinely done for all depressed patient.~At follow-up (3 months, 6 months, 12 months), they will assess thymic state, occurrence of suicidal ideation and suicide attempt and environmental stressors. In case of non response, the general physician or the psychiatrist in charge of the patient will be contacted to assess the occurrence of SB during the year. In case of death or absence of clinical information, a request for cause of death certificate will be carried out through tne National Institute of Health and Medical research (INSERM) Unit 1018 / Epidemiological center on medical causes of death (CépiDc)."
46003540|NCT02903498|Drug|UFT|UFT 360mg/m2 qd po d1-14, q3w
46003541|NCT04624347|Behavioral|Access to video and movement curves|intervention of caregivers with access to videos and motion curves of the premature infant
45677225|NCT04689074|Other|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
46003542|NCT02903459|Other|Transversal Study so there is no intervention|
46003543|NCT04623957|Device|ForgTin©|"The device is clamped behind the ear via two connected temple parts that pressed together around the connecting axis until an individual perfect wearing comfort is achieved. The pressure is adjusted so that the wearing of ForgTin© is barely noticed at all and may be changed at any time.~The aim is a slight pressure stimulation of clearly defined points behind the ear - thus wearing ForgTin© leads to a minimization of individual tinnitus noises."
45677228|NCT04688450|Device|VIGORIS Blood Pressure Management Clinical Decision Support System|Software system to optimize tight blood pressure management during vasopressor infusion
45677229|NCT01985126|Drug|Daratumumab 16 mg/kg (Part 1)|Daratumumab 16 mg/kg administered at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter by intravenous infusion
46003544|NCT04652427|Drug|Dexmedetomidine Hydrochloride 0.1 MG/ML|At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
45677230|NCT01985126|Drug|Daratumumab 8 mg/kg (Part 1)|Daratumumab 8 mg/kg every 4 weeks (Q4W) continuously by intravenous infusion
45677231|NCT01985126|Drug|Methylprednisolone|Administered in prophylactic doses intravenously (or equivalent in accordance with local standards) prior to and after study drug administration. Intravenous administration is preferred, but oral steroids may be substituted
46003545|NCT04652427|Drug|0.9% Sodium Chloride Injection|At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
46003546|NCT02903576|Procedure|injection of hESC-RPE in suspension|The first six patients will receive a sub retinal injection of hESC-RPE in solution after a complete pars plana vitrectomy to access safety of the cell implant alone.
46089042|NCT02679768|Behavioral|Circadian Reinforcement Therapy|Circadian reinforcement therapy plus electronical monitoring. Circadian reinforcement therapy is a specialized psychoeducation working with strengthening of circadian rhythms.
46089043|NCT02679768|Behavioral|Standard treatment|Standard treatment plus electronical monitoring
46089044|NCT04211870|Radiation|Low-level laser therapy|Sessions will be held twice a week for six weeks (total: 12 session). A potentiometer will be used to measure the mean power of the equipment and therapeutic dose, ensuring safety to the participant and operator. Laser will be administered at a wavelength of 786.94 nm using an energy density of 2 J/cm², intensity of 1.675 mW/cm² and power of 70 mW (0.070 W) for 20 seconds per point. The point application method will be used with a conventional tip in contact with the skin (spot area: 0.04 cm²) following the protocol suggested by Venezian et al.59 and Carvalho et al.60.
45677232|NCT01985126|Drug|Acetaminophen|650 to 1000 mg administered in prophylactic doses by mouth prior to study drug administration.
45677233|NCT01985126|Drug|Diphenhydramine|25 to 50 mg administered in prophylactic doses by mouth (or equivalent in accordance with local standards) prior to and after study drug administration.
46003547|NCT02903576|Procedure|injection hESC-RPE seeded in a substrate|Fifteen patients will receive a sub-retinal implantation of embryonic stem cell derived retinal pigmented epithelium seeded in a polymeric substrate to access safety of substrate seeded with RPE
46003548|NCT04623918|Other|Iron-biofortified rice|Iron-biofortified rice (IR68144-2B-2-2-3)
46089045|NCT04211870|Radiation|Sham treatment|Sessions will be held twice a week for six weeks (total: 12 session). During sham treatment the device will emit a guide light and sound, but no energy.
46089046|NCT02537652|Other|Blood pressure assessment|Participants will undertake an overnight fast prior to each assessment (only water is allowed to be consumed prior to the assessment). Participants will take their medication the morning of each assessment in accordance with the normal pharmacological management procedures which are used on the acute stroke ward at the Royal Hampshire County Hospital. Following this, participants will rest supine (on an electrically operated bed) for a minimum of 15 minutes. Oscillometric pressure waveforms (using the SphygmoCor XCEL), recorded on the left upper arm, will assess haemodynamic parameters including central and peripheral blood pressure, pulse pressure, and augmentation index (fasted, supine condition).
45677234|NCT01985126|Drug|Daratumumab (Part 2)|Based on the Part 1 response rate, Group A or B treatment will be selected as the treatment regimen for participants enrolled in Part 2.
45677235|NCT01984892|Drug|Poly-ICLC|"Cycle 1-Weeks 1 and 2: 1mg Poly-ICLC intratumoral (IT) injections (t=6) into same lesion over 2 weeks.~Weeks 3-9: 1mg Poly-ICLC 2x/week intramuscularly (IM) into thighs or upper arms.~Week 10: No treatment. CT scan of chest, abdomen, pelvis and extremities or neck; possible MRI brain scan.~Cycle 2-Weeks 11 and 12: 1mg Poly-ICLC IT injections (t=6) into same lesion over 2 weeks.~Weeks 13-19 - 1mg Poly-ICLC 2x/weekly IM in thighs or upper arms.~Weeks 20-26: no treatment. Week 26, evaluate response in absence of inflammation.~Maintenance - Weeks 27-36: For patients with stable disease or response; IM poly-ICLC injections; evaluation of clinical and immune response. Week 38 repeat tumor assessment, optional biopsy~Follow Up via phone every 3 months for 30months, after completion of treatments."
46003549|NCT04623918|Other|Control rice|Control rice (C4), identical in appearance
46003550|NCT02903654|Other|observational|
46003551|NCT04624308|Drug|Toripalimab|Toripalimab 240mg d1，Q3W. Given with TPF during inductive chemotherapy and definitive radiotherapy.
46089047|NCT04211792|Device|Icare Tonometer|Icare tonometers are a new class of rebound tonometers for IOP measurements. The Icare series of tonometers are hand-held tonometers, which are easy to operate and generally do not require topical anaesthesia for IOP measurements.
46003552|NCT02903693|Other|cross sectional|
46089048|NCT05663424|Other|rTMS-PTi|10 daily sessions of rTMS (1Hz, 1200 short, for totally 20 minutes) plus immediate rehabilitation programs
46003553|NCT04624425|Other|Segmental breathing exercises|Segmental breathing exercises along with the Conventional Treatment of buteyko breathing exercises for two weeks of duration. Segmental breathing exercises include 18-20 breaths in one session (6 breaths/min) with rest interval after every 6 breaths.
46003554|NCT04624425|Other|Buteyko breathing exercises|Buteyko exercises for two weeks of duration. Treatment session will be last for 10-15minutes.
46003555|NCT02903771|Drug|Part A: Dose Escalation of Cantrixil|"Cantrixil will be administered via the intraperitoneal route only. The dose of study drug that each participant will receive will depend on how far the study has progressed when the participant enrols. There are 9 potential doses of Cantrixil, they are 0.06, 0.12, 0.24 (starting dose), 0.6, 1.25, 2.5, 5, 10, or 20 mg/kg. The dose each participant receives will remain the same during the study, unless it needs to be reduced for safety reasons. The dose will not be increased.~Each participant will receive the study drug once a week during the first two cycles; each cycle is 21-days (three weeks); the MTD will be determined during Cycle 1 only. If after two cycles of monotherapy, the patient tolerates Cantrixil adequately, they may continue to receive Cantrixil once a week and will also begin combination chemotherapy for another 6 cycles. Participants will receive no more than 8 cycles of study drug."
46003556|NCT02903771|Drug|Part B: Expansion Cohort of Cantrixil|Once the MTD has been established, an expansion cohort will be recruited at the MTD. An additional 12 patients will be recruited in this cohort on top of those recruited in Part A at the MTD. These patients will be subjected to the same intervention described in Part A with 2 cycles of monotherapy followed by up to 6 cycles of combination therapy.
46089049|NCT05663424|Other|rTMS-PTd|10 daily sessions of rTMS (1Hz, 1200 short, for totally 20 minutes) plus delayed rehabilitation programs (>2hr)
46089050|NCT05663424|Other|rTMSs-PT|10 daily sessions of sham rTMS (to vertex) plus rehabilitation programs
46089051|NCT00618176|Drug|Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP)|Zidovudine (AZT) 300mg bid Didanosine (ddI) 200mg bid (W>60Kg)125mg bid (W<60Kg) Nevirapine (NVP) 200mg bid
46089052|NCT00618176|Drug|Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP)|Stavudine (d4T) 30mg bid (W>60Kg)20mg bid (W<60Kg) Lamivudine (3TC)300mg qd Nevirapine (NVP)200mg bid
45677236|NCT04440566|Biological|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
46003557|NCT04623879|Drug|Lumacaftor, Ivacaftor Drug Combination|
46003558|NCT02903537|Drug|Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)|Intranodal administration
46003559|NCT02903537|Drug|Interferon-beta|Subcutaneous administration interferon-beta
46003560|NCT04624035|Procedure|Implantable Collamer Lens (ICL) in treatment of myopia in adults.|ICL Group: After mydriatic eye drops and topical anesthesia instillation, a 3-mm temporal corneal incision was done. Viscoelastic material was injected in the anterior chamber (AC). An injector cartridge (STAAR Surgical) was used to insert the ICL V4c model with central hole). The four footplates of the ICL were positioned on the ciliary sulcus at the 180° axis. Viscoelastic material was entirely taken away.
46003561|NCT04624035|Procedure|Implantable Intraocular Lens (IPCL) in treatment of myopia in adults.|IPCL Group: Topical anesthetic and mydriatic agents were instilled before surgery. Using peripulbar anaesthesia, the IPCL (V2 model with central hole) was implanted into the AC through a 3 mm clear corneal incision after viscoelastic material injection. The footplates were subsequently tucked behind the iris, followed by a thorough viscoelastic removal.
46003562|NCT02903732|Other|observational|registry
46003563|NCT04624386|Other|Thiol disulfide level|Venous blood is collected from all subjects and thiol disulfide levels will be determined from the serum samples obtained from the venous blood.
46089053|NCT00618176|Drug|Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)|Zidovudine (AZT) 300mg bid Lamivudine (3TC) 300mg qd Nevirapine (NVP) 200mg bid
46089054|NCT02684448|Procedure|Inguinal Hernia Repair|Inguinal (unilateral or bilateral) hernia repair
46003564|NCT04681508|Diagnostic Test|Chest CT without contrast enhancement and chest X-ray|Chest CT without contrast enhancement and chest X-ray as supplement to diagnostic abdominal CT
46003565|NCT04624191|Other|Saturation at home|Clinical benefit of taking saturation at home in interstitial lung disease
46003566|NCT02903264|Other|Gestational diabetes mellitus|
46089055|NCT00616616|Procedure|single incision laparoscopic surgery|Surgery will be performed with ine laparoscopic incision
46089056|NCT05053412|Diagnostic Test|Helio Liver Test|A Helio Liver Test is used as the basis of performance evaluation for specificity and sensitivity for all patients enrolled in the study.
46089057|NCT03042650|Behavioral|Intensive Referral Intervention Group|The Intensive Referral Intervention Group will review a series of pamphlets regarding participation in 12-step meetings as well as smoking cessation that will be presented in a group setting to probationers in 3 sessions.
46089058|NCT03042650|Behavioral|Standard Practice Facilitated Group|The Standard Practice Facilitated Group will receive 3 sessions of the current standard practice for facilitated groups.
46089059|NCT04211558|Drug|Ozanimod|Ozanimod
46003567|NCT04624152|Behavioral|Soccer heading|A standardized and reliable soccer heading protocol will be used to induce subconcussive impacts for the experiment. A triaxial accelerometer (Triax Technologies, Norwalk, CT) embedded in a head-band pocket and positioned back of the head to monitor linear and rotational head accelerations. A JUGS soccer machine (JUGS Sports, Tualatin, OR) will be used to simulate a soccer throw-in with a standardized ball speed of 25 mph across all groups. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practices and games. Participants will stand approximately 40ft away from the machine to perform the heading. Participants will perform a total of 10 headers at a rate of 1 header per minute and will be instructed to direct the ball back towards the JUGS machine. Previous uses of this soccer heading model have reported an average peak linear acceleration per header of 14.5 to 33.5 g.
46089060|NCT04214522|Behavioral|Determine what the imagery levels are|Determine the motor imagery: kinesthetic and visual imagery
46003568|NCT02903225|Behavioral|Cardiac Rehabilitation|All patients included in this group attended a supervised exercise training program. A cardiologist supervised the hole training sessions. Blood pressure, pulse rate, oxygen saturation, and body weight were measured in each session. The modified Borg scale was used to measure the perceived exercise intensity
46089061|NCT03052842|Drug|C16G2 Strip|Antimicrobial Peptide
46003569|NCT00562068|Biological|alemtuzumab|
46089062|NCT03052842|Other|Placebo Strip|Placebo
46089063|NCT05048498|Drug|NEX-18a injection|"In Treatment phase 1, NEX-18a will be given as a single subcutaneous injection.~In Treatment phase 2, NEX-18a will be given as a single subcutaneous injection."
46089064|NCT05048498|Drug|Azacitidine Injection|In Treatment phase 1, azacitidine will be administered once daily for four days. In Treatment phase 2, azacitidine will be administered once daily for three days.
46089065|NCT00901901|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice daily
46089066|NCT00901901|Drug|Erlotinib (Tarceva)|Erlotinib 150 mg once daily
46089067|NCT00901901|Drug|Placebo|Matching erlotinib placebo 150 mg once daily
46089068|NCT02948400|Behavioral|pedestrian safety training in pedestrian virtual environment|pedestrian safety training
46003570|NCT00562068|Drug|cyclophosphamide|
46003571|NCT00562068|Drug|doxorubicin hydrochloride|
46003572|NCT00562068|Drug|prednisolone|
46003573|NCT00562068|Drug|vincristine sulfate|
46003574|NCT00562068|Genetic|polymerase chain reaction|
46003575|NCT00562068|Other|flow cytometry|
46003576|NCT00562068|Other|laboratory biomarker analysis|
46003577|NCT00562068|Other|pharmacological study|
46003578|NCT02903342|Other|Leaflet|A leaflet designed from data obtained from previous qualitative and quantitative studies.
46089069|NCT00619658|Other|telephone follow-up|subjects undergoing medical abortion will recieve a telephone call and be asked a series of clinical questions. Expulsion of the pregnancy will be assessed based on the answers to those questions.
46003579|NCT04623606|Biological|BOOST cells|Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.
46003580|NCT02903303|Other|Hypnosis|"It will consist in 4 hypnosis sessions within 2 weeks mainly for analgesic purpose. The main themes are :~1st session : contact with the therapist, body scan, basic suggestions~2nd session : hypnosis induction followed by suggestions tu build a safe place~3rd session : it is the first complete hypnosis session (induction and specific suggestions against pain)~4th session : very similar to the previous session for the content, focused on auto-hypnosis learning."
46089070|NCT02683980|Device|Lumenis Pulse P120H and Xpeeda side firing fiber|
46089071|NCT00619736|Drug|NSA-789|
46089072|NCT00619736|Other|Placebo|
46089073|NCT04184232|Biological|Dendritic cells|Autologous dendritic cells primed with muc-1/wt-1 peptides
46089074|NCT04184232|Other|Standard treatment according to the Clinical protocols|Standard treatment of bladder cancer according to the Clinical protocols
46089075|NCT04213040|Diagnostic Test|Serum levels of Procalcitonin, C-reactive protein, lactate|"Serum PCT, CRP, and lactate values were collected postoperatively every day starting on postoperative 12 hours, postoperative days 1 through 5.~After the operation, all postoperative complications were recorded during the first seven days period.~The relations between diagnostic tests and postoperative complications are sought by the use of the statistical analysis methods."
46089076|NCT05664438|Diagnostic Test|MRI scan|MRI scan of cervical spine
46089077|NCT04824833|Procedure|Serratus anterior plane block|local anesthetic application between serratus anterior muscle and 5th rib
46089078|NCT00618254|Drug|Granisetron|
46089079|NCT04184466|Drug|Insulin Aspart|insulin aspart in doses 0.3 IU/kg
46089080|NCT04184466|Drug|NovoRapid® Penfill®|insulin aspart in doses 0.3 IU/kg
46089081|NCT03620201|Drug|Bintrafusp Alfa|Given IV
46003581|NCT00562107|Device|Symphony DR 2550 and REPLY DR cardiac pacemakers|AAISafeR/SafeR ON
46003582|NCT00562107|Device|Symphony DR 2550 and REPLY DR cardiac pacemakers|DDD(R) (SafeR OFF)
45458892|NCT03491332|Device|conventional circuit|"The patient enters the operating room without any pretreatment and attaches a standard patient monitoring device. Anesthesia was performed by intravenous anesthesia. After induction of anesthesia, alveolar recruitment is performed in supine position in all groups with 30 cmH2O for 5 seconds. Mechanical ventilator was set with tidal volume of 8 ml / kg, the inspiratory/ expiratory ratio of 1: 2 and respiratory rate was adjusted for targeting EtCO2 around 35mmHg. Keep the fresh air flow of the ventilator at 3 L / min and set the temperature to 37 ° C for the heating circuits of group H and group SH. An arterial cannulation and subclavian jugular vein catheter is inserted.~The circuits were applied to each group as follows; conventional circuit or group C, conventional humidification circuit for group H and new humidification heat circuit for group SH, respectively. All other conditions were same among three groups."
46003583|NCT02903186|Behavioral|SMS|This is an intervention using short mobile messages (SMS)
46003584|NCT00562146|Procedure|placement of spiral nasojejunal tube|spiral nasojejunal tube will be placed after enrollment of the patients
46003585|NCT02903147|Behavioral|Functional Meta-Cognitive Intervention|Functional-Meta-Cognitive Intervention Program was focused on raising awareness to safe driving risk factors identified at pre-screening, with reference to the difficulties that the driver raises and providing coping strategies. The intervention has been customized for each driver and included three sessions of two hours.
46003586|NCT02903147|Behavioral|The employer's training|
46003587|NCT02903108|Drug|SRP plus boric acid gel|SRP followed by 0.75% boric acid placement into intrabony defect
46003588|NCT02903108|Drug|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
46003589|NCT00562185|Drug|carboplatin|
46003590|NCT00562185|Drug|doxorubicin hydrochloride|
46003591|NCT02902796|Device|Spinal cord stimulator|Spinal cord stimulator will be programmed to deliver, according to the randomization status of the patient, burst, 1000 hertz, and standard stimulation during each treatment group.
46003592|NCT00562224|Drug|PCI-24781|"Up to 7 cohorts will receive PCI-24781 orally at doses starting at 30 mg/m2 three times a day approximately 4 hours apart (TID), up to 90 mg/m2, administered 5 days/week during the first 21 days of each 28 day cycle until MTD is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 twice a day approximately 4 hours apart (BID). If a DLT occurs on the BID schedule, the subsequent cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle). If a DLT occurs on this dosing schedule, then the next cohort will receive PCI-24781 BID for 5 days/week every other week (2 times in a 28 day cycle) until the maximum tolerated dose is reached."
46003593|NCT02902718|Device|mē|The mē device will be used for self administered facial treatments that will be repeated up to 3 times every session. The duration of a treatment session is 5-10 minutes.
46003594|NCT04623645|Device|ultrasound technique|evaluate the effect of ultrasound guided technique for block of internal branch of superior laryngeal nerve
46003595|NCT02902835|Behavioral|BUP_FAST|Peer mentorship including: buprenorphine education, identifying buprenorphine providers, accompaniment at appointments, and psychosocial support (via outreach phone calls)
46003596|NCT02902835|Behavioral|Referral to treatment|Participants will receive a pamphlet describing the buprenorphine treatment program at a Montefiore community health center.
46089082|NCT04184310|Other|Modified perineal linear stapler resection for external rectal prolapse|After anesthesia and patient position, the prolapse was pulled out Two vertical incision were made in both the inner and outer walls of the prolapse (at 3and 9 o'clock)1-2 cm in size approximately 2 cm above the dentate line. We used a reloadable linear cutter stapler (GIA 100mm Covidien, Mansfield, Mass., USA) passing through the tunnel to cut the anterior aspect of the prolapse . Then, after reload the stapler by the new cartridge, we used it to do the same for posterior wall and the prolapsed rectum was completely transected . We ensure that the stapler did not fire at the dentate line to avoid post-operative pain. Multiple 3-0 PDS intermittent full thickness sutures were done for hemostasis. The prolapsed rectum falls back into place spontaneously.
46003597|NCT04623762|Other|Yoga|yoga application
46003598|NCT02903069|Drug|MRZ|"MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15, 29, and 36 during Concomitant Treatment.~MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15 every 28 days during Adjuvant Treatment.~IV hydration will be given prior to the MRZ infusion."
46003599|NCT02903069|Drug|TMZ|"TMZ will be administered once daily, 7 days/week, for 6 weeks, starting on Day 1, at a dose of 75 mg/m2 during Concomitant Treatment.~TMZ will be administered once daily on Days 1-5 every cycle, dose range 150 to 200 mg/m2 during Adjuvant Treatment."
46003600|NCT02903069|Radiation|RT|Focal RT will be administered once daily, 5 days/week, for 30 doses over 6 weeks to a total dose of 60 Gy, starting on Day 1 during Concomitant Treatment.
46003601|NCT02903069|Device|Optune|Tumor Treating Fields Therapy device to be worn ≥ 18 hours per day.
46003602|NCT04623723|Other|PS (DS-016A, EMS® Piezon, Switzerland) scaler tips. )|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using PS (DS-016A, EMS® Piezon, Switzerland) scaler tips
46003603|NCT04623723|Other|Conventional (FS-407, EMS® Piezon, Switzerland)|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using Conventional (FS-407, EMS® Piezon, Switzerland)
46003604|NCT02902679|Drug|BMS-986177|
46003605|NCT04623840|Other|Tadalafil 5Mg Tab + continuous and interval exercise|(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, in addition to 3 sessions, per week, of combined continuous and interval aerobic exercise for eight weeks
46003606|NCT04623840|Drug|Tadalafil 5Mg Tab|(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, for eight weeks
46089083|NCT02143778|Device|Methacetin Breath Test|13C labelled methacetin solution for breath test monitoring
46003607|NCT02902640|Drug|Guaifenesin|Guaifenesin will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
46003608|NCT02902640|Drug|Sulfamethoxazole|Sulfamethoxazole will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
46089084|NCT02683902|Device|Active tDCS|The anode electrode will be placed over F4 position and the cathode electrode over F3, right and left respectively (using EEG 10/20 system). The electric current will be ramped up until it reaches 2 milliampere (mA), and subjects will be stimulated for 20 min.
45836034|NCT00176904|Drug|Busulfan, Cyclophosphamide, Antithymocyte Globulin|"Subjects will receive BUSULFAN intravenously (IV)- patients < or= 12 kg 1.1 mg/kd/dose IV every 6 hours for 16 doses; patients > 12kg 0.8 mg/kg/dose IV every 6 hours for 16 doses - via the Hickman line four times daily for 4 days, CYCLOPHOSPHAMIDE intravenously (50 mg/kg/day IV over 2 hours) via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV (15 mg/kg/day over 2 hours) via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG."
46003609|NCT02902640|Drug|Trimethoprim|Trimethoprim will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
46089085|NCT02683902|Behavioral|Hypocaloric diet|A hypocaloric dietary prescription and individual counseling from a dietician in order to reduce 3% of their initial weight over 4-week treatment.
45836035|NCT00179478|Drug|interferon beta 1a 30 ug IM once weekly|Immediate treatment group refers to those patients who were randomized to the interferon beta 1a 30 ug IM once weekly treatment arm of the original, controlled phase III CHAMPS study; Delayed treatment group refers to those patients who were randomized to the placebo group during the original controlled, phase III CHAMPS study and did not start treatment, if at all, until they completed the CHAMPS study protocol at a later date.
46003610|NCT04623528|Diagnostic Test|T1 and T2 relaxometry of the liver parenchyma|Evaluate T1 and T2 relaxomatry of the liver parenchyma to depict liver congestion in the different patient groups
46089086|NCT02683902|Device|Sham tDCS|The electrodes will be placed at the same positions as in active stimulation; however, the device will be turned off after 30 s of stimulation.
46089087|NCT03009773|Other|rehabilitation multitasking walking.|rehabilitation multitasking walking.
46089088|NCT03009773|Other|Traditional walking rehabilitation|Traditional walking rehabilitation
46089089|NCT02843789|Drug|Tocilizumab|
46089090|NCT05664360|Other|Age (young versus older)|Age
46003611|NCT04623489|Behavioral|¡Vivir Mi Vida! Lifestyle Intervention|
46003612|NCT04624893|Drug|Polatuzumab Vedotin-Piiq|Patients will receive a total of six cycles of Pola in combination with rituximab and bendamustine or in combination with only rituximab. A cycle is typically 21 days for DLBCL.
46003613|NCT04623450|Other|Smoothie|Preload smoothies that are matched for taste, smell, appearance, quantity and calorie but different caloric content.
46089091|NCT04804163|Device|telesurgery by domestic robot|telesurgery of the upper urinary disease by domestic robot
46089092|NCT00641940|Behavioral|Girls in Transition (GT) program|In the 11-session after-school GT program, girls learn cognitive and behavioral skills related to intrapersonal, interpersonal, and social/contextual risk factors for depression.
46089093|NCT00641940|Behavioral|Waitlist Control|Participants in the waitlist control group will complete the GT program during the third year of the study.
46089094|NCT02843711|Genetic|Sequencing|Tumour samples are coming from routine histopathological procedure. They are used with consent of the patients. Genomic DNA extraction is performed from paraffin-embedded formalin-fixed (FFPE) tumour samples of lung adenocarcinoma. The genomic DNA mutations are identified by mass spectrometry array (Sequenom) using the LungCarta Panel. This panel could identify 214 mutations among 26 oncogenes.
46089095|NCT04201769|Drug|Netupitant/Palonosetron|NEPA is adiministered 60 minutes before chemotherapy, on day 1
46089096|NCT04201769|Drug|Dexamethasone|"Intravenous dexamethasone 12 mg is administered 30 minutes before chemotherapy initiation, on day 1.~The administration of DEX in the subsequent days (2-4) depends on the randomly assignement to treatment arm"
46089097|NCT02679534|Other|hand massage|
46089098|NCT02679534|Other|hand holding|
46089099|NCT02679534|Other|application of unscented hypoallergenic cream|
46089100|NCT02679534|Other|environmental adjustments|
46003614|NCT04623294|Procedure|Oxygen supply of high-low-high procedure|"The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2(phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters."
45458893|NCT03491332|Device|conventional humidification circuit|"The patient enters the operating room without any pretreatment and attaches a standard patient monitoring device. Anesthesia was performed by intravenous anesthesia. After induction of anesthesia, alveolar recruitment is performed in supine position in all groups with 30 cmH2O for 5 seconds. Mechanical ventilator was set with tidal volume of 8 ml / kg, the inspiratory/ expiratory ratio of 1: 2 and respiratory rate was adjusted for targeting EtCO2 around 35mmHg. Keep the fresh air flow of the ventilator at 3 L / min and set the temperature to 37 ° C for the heating circuits of group H and group SH. An arterial cannulation and subclavian jugular vein catheter is inserted.~The circuits were applied to each group as follows; conventional circuit or group C, conventional humidification circuit for group H and new humidification heat circuit for group SH, respectively. All other conditions were same among three groups."
45677237|NCT04416620|Other|The PCOS pharmaceutical care service|"The intervention was provided in the format of oral plus written information. The information provided included the importance of exercise and motivational messages to exercise more at home or in the gym.~The 2nd part was about the importance of decreasing the stress levels. Participants were informed to perform a simple breathing exercise on daily basis twice a day.~The 3rd part aimed at improving participants' diets. They were informed to follow specific diet recommendations and to avoid certain types of food, explaining to them how it may negatively affect their PCOS condition.~The 4th part was about the PCOS treatment that was discussed with the participants. Females were advised on the importance of using their correct treatment. They were informed of the importance of adhering to their prescribed medications, accepting that it was a long-term treatment plan, and to consult with their specialist if their treatment was not effective, or in the case of medication side effects."
46003615|NCT04623294|Procedure|Oxygen supply of low-high-low procedure|"The protocol consisted of 1- hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters."
45677238|NCT01807221|Drug|Finerenone (BAY94-8862)|
45677239|NCT01807221|Drug|Placebo|
46003616|NCT02902523|Drug|Viread® tablet 300mg|Single dose administration(PO) in the fasted state
45677240|NCT01807221|Drug|Inspra (eplerenone)|
45677241|NCT01838499|Biological|MEDI8968|SC injection at baseline, Week 4 and Week 8
46003617|NCT02902523|Drug|HUG116 tablet 245mg|Single dose administration(PO) in the fasted state
45677242|NCT01838499|Biological|Saline|SC injection at baseline, Week 4 and Week 8
46003618|NCT04623060|Other|Combination of Low-volume interval treadmill training and Resistance Training|"Low-volume interval training (LV-ITT) protocols included a 5 min warm-up (30%-50%VO2peak) up to 20min of LV-ITT and a 5 min cooling down (30%-50% VO2peak). The LV-ITT will repeat 60s bursts of fast treadmill walking at maximum tolerate speed (0% incline), alternate with pre-specified recovery periods about 4 minutes according to protocol. Each time the participants completed a burst successfully, treadmill speed will be increased by 0.1 mph for the next burst. The recovery periods will be 4 minutes. The intervention will be conducted for about 30 minutes.~Resistance training will be conducted by using a horizontal leg press machine. They are encouraged to focus on an explosive concentric movement and a controlled eccentric movement such that the time on each phase was in the ratio 1:2."
46003619|NCT02902562|Procedure|Contrast Enhanced Ultrasound (CEUS)|An intravenous line (IV) line will be inserted into a vein in your arm. You will be asked to lie on a table for the ultrasound imaging. First, a regular ultrasound (without contrast) will be performed and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into your IV line. We will perform another ultrasound and the images will be recorded
45677243|NCT01807065|Biological|sipuleucel-T|Given IV
45677244|NCT01807065|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
45677245|NCT01807065|Other|laboratory biomarker analysis|Correlative studies
45677246|NCT04583709|Device|ECG Belt|"ECG Belt Research System Procedure LBBP Native conduction RV pacing if available Bipolar LBBP Unipolar LBBP - nonselective and selective (different outputs) Fusion pacing with native conduction at different Atrioventricular (AV) delays~HOT-CRT Native conduction HBP / LBBP HOT-CRT AV delay optimization. Medtronic Device (pacemaker/ICD) based Holter recording during the ECG belt recording"
45836036|NCT02134782|Behavioral|Individualized Yoga Intervention Group|These children will not receive a study-supplied iPad. Use of child or hospital supplied iPad games, music, movies or books will be permitted without any modification, encouragement or discouragement of these activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
46003620|NCT02902562|Procedure|Magnetic Resonance Imaging (MRI)|For the contrast MRI, the contrast agent will be injected into your IV line The MRI scanner is a small, tunnel-like machine in which a patient will be required to lie still for a long period of time. There is little space inside the scanner, which causes anxiety and discomfort for patients who fear enclosed spaces. A technician will be present at all times during the examination to communicate with you about how you are feeling.
46003621|NCT00562263|Behavioral|Lifestyle modification|Dietary modification and regular physical activity
45677247|NCT02031458|Drug|Atezolizumab|1200 mg IV every 3 weeks
45677248|NCT02009696|Device|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
45677249|NCT02009696|Other|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine.
45836037|NCT02134782|Other|iPad Activity Control Group|These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
46003622|NCT02902367|Other|Outdoor walking and strength exercise|Exercise group: Participants are supposed to perform an outdoor walking exercise program and one strength exercise for 12 weeks. The first 2 weeks start with daily walks. The intensity and frequency of walks will progressively increase performed according to the Borg scale: 12-15, ie, moderate to strenuous. Participants will walk 5-7 days/week. Added to this is a strength exercise, i.e. chair-rising which also should be performed daily.
46003623|NCT02902367|Other|control group|Control-Group: Treatment as usual for 12 weeks, without restriction of being physically active.
45458894|NCT03491332|Device|new humidifaction heat circuit|"The patient enters the operating room without any pretreatment and attaches a standard patient monitoring device. Anesthesia was performed by intravenous anesthesia. After induction of anesthesia, alveolar recruitment is performed in supine position in all groups with 30 cmH2O for 5 seconds. Mechanical ventilator was set with tidal volume of 8 ml / kg, the inspiratory/ expiratory ratio of 1: 2 and respiratory rate was adjusted for targeting EtCO2 around 35mmHg. Keep the fresh air flow of the ventilator at 3 L / min and set the temperature to 37 ° C for the heating circuits of group H and group SH. An arterial cannulation and subclavian jugular vein catheter is inserted.~The circuits were applied to each group as follows; conventional circuit or group C, conventional humidification circuit for group H and new humidification heat circuit for group SH, respectively. All other conditions were same among three groups."
46089101|NCT02682108|Device|Diffusion-weighted magnetic resonance imaging (DW-MRI)|Magnetic resonance (MR) imaging examination of liver will be performed on a 3.0T Achieva MR scanner (Philips Medical Systems, The Netherlands). Diffusion-weighted imaging (DWI) will be performed using a single-shot echo-planar imaging during a single end expiratory breath-hold. A single observer placed circular regions of interest around 2.30 cm2 to measure mean signal intensity (SI) in the right hepatic lobe and the spleen for each b value, avoiding areas of artifact, vessels, and focal lesions. A monoexponential fit will be performed to calculate liver and spleen apparent diffusion coefficient (ADC) on the basis of ln(SI) as a function of b value, using all b values. Normalized liver ADC will be calculated as the ratio of liver ADC to spleen ADC.
46003624|NCT04623255|Drug|OCTAPLAS|plasma exchange
46089102|NCT04785365|Other|Long-Term Follow-Up of Patients who Received ATL001|Patients who received ATL001 in a clinical trial will be evaluated in this trial for long-term efficacy and safety.
46003625|NCT02902289|Drug|Ibuprofen 200 mg/5 mL oral suspension|
45836038|NCT00182754|Drug|octreotide acetate|Given subcutaneously
45836039|NCT00182754|Other|placebo|Given subcutaneously
45836040|NCT00183456|Behavioral|Peer-oriented intervention|The peer-oriented intervention program emphasized social identity and the goals of protecting family and community. The peer program also trained participants to provide HIV/STD education to their peers.
46003626|NCT02902289|Drug|MOMENT 200 mg coated tablet|
46003627|NCT04623411|Behavioral|Neonatal resuscitation training with classical method and serious game simulation method|"After the theoretical training, the participants will be given technical information on the use of web-based neonatal resuscitation serious game simulation method.~Each participant will be asked to apply this method at least three times."
46003628|NCT04623411|Behavioral|Control Group|Neonatal resuscitation training with classical method
46003629|NCT02902133|Drug|Acetazolamide|Acetazolamide 500 mg by mouth twice per day for 5 days
46089103|NCT05336825|Device|CO2 laser|Mona Lisa CO2 laser
46089104|NCT05336825|Drug|Lidocaine patch 5%|lidocaine
45836041|NCT00183456|Behavioral|Group cognitive behavioral therapy (CBT)|Group CBT will focus on teaching ways to modify thoughts and behaviors associated with risky sexual behaviors.
45836042|NCT00184548|Drug|eptacog alfa (activated)|"Sterile, freeze-dried powder in single-use vials to be reconstituted with sterile water for injection.~Three doses of 200, 100 and 100 mcg/kg to be administered bolus i.v. (intravenous) over approx. three hours."
46003630|NCT04623333|Drug|TQB2450|TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
46003631|NCT04623021|Drug|Nafamostat Mesilate|Administered intravenously as a continuous infusion
46003632|NCT02902016|Drug|GED|Four duodenal biopsies will be collected. Two biopsies will stimulated with GED (PPARgamma modulator) ex vivo during 6 hours. Two biopsies will be unstimulated (control).
46003633|NCT02902055|Drug|Neuromuscular Blocking Agents|Neuromuscular blockae
46003634|NCT02902055|Drug|Isotonic saline|Placebo
46003635|NCT04622748|Behavioral|Trier Social Stress Test|8-min oral calculation and 5-min speech
46003636|NCT04622826|Biological|immune plasma|immune covid 19 plasma infusion
45836043|NCT00184548|Drug|placebo|placebo
45836044|NCT00085410|Drug|bortezomib|Given IV
45677250|NCT01806597|Biological|secukinumab 150 mg|Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consiseds of one secukinumab 150 mg s.c. injection plus one placebo secukinumab s.c. injection and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also received two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
45677251|NCT01806597|Biological|secukinumab 300 mg|Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consisted of two secukinumab 150 mg s.c. injections and took ke place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also receives two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
45677252|NCT01806597|Biological|Placebo|Placebo were provided in 1 mL pre-filled syringes. Each dosing consisted of two s.c. injections and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then at Week 8 and at Week 12. At Week 16, ppIGA responders continued on placebo with dosing at Weeks 16, 17, 18, 19 and 20, then once every four weeks from Week 24 until Week 76 inclusive. At Week 80, ppIGA responders ended their participation in the study while ppIGA non-responders were re-randomized, to receive 150 mg or 300 mg secukinumab once every four weeks starting at Week 80 until Week 128 inclusive. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
45677253|NCT02031302|Device|Lotus Valve System|The Lotus Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area [AVA] of <1.0 cm2 or index of <0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
45677254|NCT01610037|Drug|QVA149|QVA149 110/50 µg will be supplied as capsules in blister packs for once daily inhalation using the Novartis Concept1 SDDPI
46003637|NCT02901977|Drug|Ramipril|Antihypertensive therapy
46003638|NCT02901977|Drug|Doxazosin|Antihypertensive therapy
46003639|NCT02902094|Device|Drug eluting balloons|
46089105|NCT04184388|Dietary Supplement|Hydrolysed Red Ginseng Extract|once a day for 1 p.o., after breakfast(10 ml/day, Hydrolysed Red Ginseng extract for 1g/day) for 12 week
46089106|NCT04184388|Dietary Supplement|Placebo|once a day for 1 p.o., after breakfast(10 ml/day, Hydrolysed Red Ginseng extract for 0g/day) for 12 week
45677255|NCT01610037|Drug|Tiotropium|Tiotropium 18 µg will be supplied as capsules in blister packs for once daily inhalation using the HandiHaler SDDPI
45677256|NCT01610037|Drug|placebo|placebo to QVA149A and Tiotropium will be supplied in the appropriate capsule in blister packs for use in either the Novartis Concept1 SDDPI or the HandiHaler SDDPI
45677257|NCT04687514|Drug|Dulaglutide|Dulaglutide: first week 1x 1.5mg in 0.5 ml, following 3 weeks 2 x 1.5 mg weekly in 0.5ml each, via Pen s.c.
45677258|NCT04687514|Drug|Placebo|Placebo: first week 1x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe, following weeks 2x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe once weekly for 3 further weeks.
45677259|NCT01806051|Drug|Kuvan|Only PKU participants (Arm 1) will be administered Kuvan once daily either at a dose of 20 mg/kg/day (if the PKU participant is not currently taking Kuvan) or at the subject's regular dose (if the PKU participant is currently taking Kuvan). They will remain on Kuvan for 4 weeks.
45677260|NCT04592289|Procedure|Full bowel preparation|MBP+OA
45677261|NCT04592289|Procedure|Mechanical bowel preparation only|MBP
45677262|NCT01837797|Drug|Placebo|Once daily, tablets, orally
46003640|NCT02902094|Device|Non drug eluting balloons|
46003641|NCT04622592|Biological|Instramuscular vaccine|On Day 0, subjects will receive one intramuscular (IM) injection into the deltoid region of the non-dominant (if possible) arm.
46003642|NCT04681235|Other|Training on VR|The training is aimed at improving the functioning of the motor sphere, including balance, gait, and upper limb function, as well as increasing the level of motivation and reducing the level of anxiety and depression. Game applications were selected based on therapeutic tasks of motor recovery.
46003643|NCT00553553|Drug|Morphine sulphate|Intravenous morphine titrated up to 0.25 milligrams/kilogram prior to end of resection phase or within first 2 hours of surgery
46003644|NCT00553553|Drug|Morphine hydrochloride, remifentanil hydrochloride|"Pre-induction intrathecal morphine HCl (< 3 attempts), single shot via 25 G pencil point spinal needle at 10 micrograms/kilogram~Intra-operative intravenous remifentanil HCl at titratable dose range 0.1-0.25 micrograms/kilogram/minute until start of wound closure"
46089107|NCT02791230|Drug|Tafamidis|Soft gel capsules administered once a day for 60 months
46089108|NCT04748783|Other|Water|Subject participants will rinse mouth one time for 60 seconds with 10 mL of sterile water.
46089109|NCT04748783|Other|Peroxyl|Subject participants will rinse mouth one time for 60 seconds with 10 mL Peroxyl (1.5% w/v hydrogen peroxide) rinse
46089110|NCT04748783|Drug|Periogard|Subject participants will rinse mouth one time for 60 seconds with 10 mL Periogard (0.12% Chlorhexidine Gluconate) rinse.
46089111|NCT04748783|Other|Colgate Total Zero|Subject participants will rinse mouth one time with Colgate Total Zero Fresh Breath (0.075% Cetylpyridinium Chloride) 20ml for 30 seconds
46089112|NCT02777580|Drug|Tenecteplase|Half dose Tenecteplase
46089113|NCT02777580|Drug|Clopidogrel|300 mg p.o. initial loading dose. Maintenance dose of 75 mg p.o. once daily. The maintenance dose of Clopidogrel (75 mg p.o. per day) should be continued for 1 year.
46089114|NCT02777580|Procedure|Coronary angiography|Coronary angiography followed by PCI or CABG if required, rescue PCI if required
46089115|NCT02777580|Procedure|Primary PCI|Primary PCI accoring to local standards
46003645|NCT04622982|Other|Multidisciplinary treatment of obesity (diet + vitamin D + exercise + psychotherapy)|"Body weight reduction was induced by a low-energy mixed diet (55 % carbohydrates, 30 % lipids and 15 % proteins) providing 600 kcal less than individually estimated energy requirements based on the measured REE. The energy content and macronutrient composition of the diets adhered to the nutritional recommendations of the American Diabetes Association.~Patients were administered vitamin D supplement only if they presented a value of 25-hydroxyvitamin D (25OHD) <30 ng/ml in blood tests at the beginning.~Patients were following an individualized physical activity plan within the hospital and were aided by a psychodynamic approach therapist."
46089116|NCT04628663|Drug|Dexmedetomidine|Administration
46003646|NCT02901938|Procedure|cemented femoral stem|The patients assigned even numbers will undergo implantation of cemented femoral stem.
46003647|NCT02901938|Device|cannulated compression screws|The patients assigned even numbers will undergo percutaneous internal fixation with cannulated compression screws.
46003648|NCT04622202|Drug|Pregabalin 150mg|oral capsule pregabalin 150 mg.
46089117|NCT04628663|Other|Normal Saline|Administration
46089118|NCT04201613|Device|Robotic exoskeleton|The Kinesiological Instrument for Normal and Altered Reaching Movements (KINARM) robotic exoskeleton used to provide therapy and assessment. The device has framework that supports the arms and the supports are adjustable to ensure a comfortable fit. Motors attached to the framework record shoulder and elbow movements and also move the arms.
46003649|NCT04622202|Drug|multivitamin|oral placebo in the form of oral multivitamin capsule.
46003650|NCT02901782|Procedure|Personalized titanium plate|3D models of tumor-bearing bone segments were constructed by using computed tomography (CT) and magnetic resonance imaging (MRI). The 3D models were used to design the model of personalized titanium plates. The model of the plates was transferred into a numerical control machine for manufacturing the personalized titanium plates by 3D printing technology. The plates were then surgically implanted for reconstruction assistance following microwave-induced hyperthermia to remove the bone tumor. Implementation parameters and knee function were then evaluated.
46003651|NCT04622475|Biological|Fecal Microbiota Transplant (FMT) Capsule|When enrolled in the study, subjects will ingest 20 FMT capsules/day orally for 3 consecutive days. If the syndrome is not completely recovered or relapse 14 days after the first administration, the subject will receive a booster dose (20 capsules/day for 3 consecutive days).
46003652|NCT04622358|Drug|AD-214-02|1 tablet administered before the breakfast during 7 days
46003653|NCT04622358|Drug|Rabeprazole|1 tablet administered before the breakfast during 7 days
46003654|NCT02901665|Other|FCC intervention|Communication to all NICU families that they should be in the NICU a minimum of 4 hours/day.
46003655|NCT00562341|Other|Bariatric Surgery|one time lapb-band gastric bypass surgery
46003656|NCT02901587|Drug|Lu AF35700 (10 mg/day)|tablets for oral administration once daily
46003657|NCT02901587|Drug|Lu AF35700 (30 mg/day)|tablets for oral administration once daily
46003658|NCT02901587|Drug|Quetiapine (Seroquel XR® 800 mg/day)|tablets for oral administration once daily
46089119|NCT04201613|Behavioral|Usual Care|This group will receive standard care with no additional therapy.
46089120|NCT00641238|Device|Radiofrequency ablation|Radiofrequency ablation
46089121|NCT02681952|Drug|Renamezin capsule|
45342400|NCT04073160|Drug|Durvalumab|"Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.~Eligible subjects may go on to receive a combination of durvalumab and bladder radiation during cycles 3 and 4. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 3 day 1 and cycle 4 day 1.~At the completion of radiation, eligible subjects may continue to receive durvalumab for a maximum of one year from the date of their initial dose. Durvalumab will be administered intravenously at a dose of 1500 mg on the first day of each cycle."
46089122|NCT02681952|Drug|Kremezin granule|
46089123|NCT02843321|Biological|T-cell infusion, influenza vaccination|Donor derived infection-specific T-cells (with activity against CMV,adenovirus, EBV, VZV, Influenza, BKV and Aspergillus) and vaccination (with Fluvax)
45677263|NCT01837797|Drug|Brexpiprazole 1 mg|once daily dose, tablets, orally
45677264|NCT01837797|Drug|Brexpiprazole 3 mg|once daily dose, tablets, orally
46089124|NCT02683590|Device|Ceramic Implant|The replacement of the sternum by a ceramic implant
46089125|NCT00640380|Other|Nerve stimulation|CPVB with NS
46089126|NCT00640380|Other|Loss of resistance to air|CPVB with LOR
46089127|NCT05663346|Other|Cannabis & Cancer digital educational intervention|The Cannabis & Cancer intervention is available on Moodle learning management system in French language. It aims to influence nurses' self-efficacy, attitudes, intentions, and knowledge regarding the safe and efficient use of cannabis by young adults diagnosed with cancer.
46089128|NCT05663346|Other|Standard information regarding cannabis use in oncology|Participants will be offered basic reliable non-personalized information on cannabis use in oncology (official public websites and scientific articles).
46089129|NCT05663268|Biological|Infliximab biosimilar|Remsima for subcutaneous injection is a biosimilar monoclonal antibody of infliximab that inhibits the activity of tumour necrosis factor (TNF)-alpha.
46089130|NCT02822027|Drug|human gamma globulin|human gamma globulin for preterm infants with encephalopathy of prematurities
46089131|NCT02822027|Drug|non-human gamma globulin|Non-human gamma globulin for preterm infants with encephalopathy of prematurities
46089132|NCT00642096|Drug|Metoprolol Succinate|
46089133|NCT00642096|Drug|Hydrochlorothiazide|
46089134|NCT00632801|Other|chewing gum|The patients in the gum chewing group (intervention group) will chew one stick of gum the first post-operative day, after the nasogastric tube is removed or if they patient does not have a nasogastric tube, with the head of bed elevated a minimum of 30 degrees for 30 minutes, three times a day at set intervals
46089135|NCT02679300|Other|Virtual reality exercise group|
46089136|NCT02679300|Other|Conventional exercise group (control group)|
45458895|NCT02322034|Other|Interval Training|Exercise training protocol (high intensity, interval training) is followed by the enrolled patients on hospital outpatient-based regimen 3 times/week for 24 weeks. The high intensity group will perform interval cycling for 4 minutes with 1-minute rest between intervals. High intensity exercise will be 90-95% peak heart rate. The exercise intensity will be established, and maintained throughout the 24-week exercise training period, by calculating the heart rate range as a percentage of maximum (90-95%) as obtained from the most recent cardiopulmonary exercise test. Every 4 weeks during the training program, the exercise intensity will be titrated to the same relative percentage of maximum (90-95%) as it is assumed most patients will become fitter over the training period.
46003659|NCT04622397|Drug|Tranexamic acid injection|Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision
46003660|NCT04622397|Drug|Saline|Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision
46003661|NCT02901704|Device|Renal Denervation System (AngioCare)|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
46003662|NCT02901704|Procedure|Sham procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 10 minutes prior to introducer sheath removal.
46003663|NCT02901743|Other|Scaling and Root planing|All the patients were asked to use a preprocedural mouthrinse and scaling and rootplaning was done using ultrasonic scalers.
46003664|NCT04622514|Other|People-centered integrated care|1. Reorienting the model of care: using of telemedicine platform and online consulting clinic; 2. Coordinating services: contract service by village doctor and on-line AF specialist; 3. Empowering and engaging people: provide village doctor ABC pathway training course; regular visit and drug delivery by village doctor (community support); patients and their family members education.
46003665|NCT04622514|Other|Usual care|Routine outpatient clinic by AF specialist
46003666|NCT04621734|Device|AMT BridlePro Device|A device used as an alternative securement method using the structure of the nasal cavity to secure the nasoenteric tube.
46003667|NCT04621734|Device|Adhesive Tape|Adhesive tape used to secure nasoenteric tube
45458896|NCT01146769|Other|Pelvic floor exercise|Pelvic floor strengthening exercise
46003668|NCT02901392|Procedure|AMS-800|Artificial urianry sphincter
46003669|NCT02901392|Procedure|ADVANCE/ADVANCEXP|Male sling
45458897|NCT02322112|Other|Microcrystalline Cellulose Supplementation|Fifty overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of MCC (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
45458898|NCT02322112|Other|Acacia Gum Supplementation|Seventy five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of AG (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
45677265|NCT01984424|Drug|Atorvastatin|Atorvastatin was supplied as over-encapsulated 20 mg tablets
45677266|NCT01984424|Drug|Placebo to Atorvastatin|Placebo matching to atorvastatin supplied as over-encapsulated tablets
45677267|NCT01984424|Other|Placebo to Ezetimibe|Placebo matching to Ezetimibe supplied as over-encapsulated tablets.
46003670|NCT02901392|Procedure|VIRTUE|Male sling
46003671|NCT02901392|Procedure|INVANCE|Male sling
46003672|NCT02901353|Device|Sirolimus Eluting Coronary Stent System|Patient with Angina Pectoris will be enrolled for the intervention
46003673|NCT04621773|Procedure|Preimplantation Genetic Screening(exposure)|Preimplantation genetic screening (PGS) was developed in the late 1980s as an alternative to prenatal diagnosis for couples at risk of transmitting a genetic or chromosomal abnormality to their children. In embryos created through in vitro fertilisation (IVF), cells are biopsied and analysed using genetic tests such as polymerase chain reaction and fluorescent in situ hybridisation (FISH).
46003674|NCT02901119|Dietary Supplement|Whey protein|Patients, maintaining their regular usual diet, are submitted to a protein supplementation, during 15 days. They recieve 20g packages of whey protein or casein, to take twice a day: 20g in the morning and 20g at night.
46003675|NCT04621695|Procedure|RBL|Both arms are standard care procedures in the Netherlands
46003676|NCT04621695|Procedure|Hemorrhoidectomy|Both arms are standard care procedures in the Netherlands
46003677|NCT02901197|Behavioral|Education and Reminder Posters|See arm description
45458899|NCT02322112|Other|Resistant Starch Type 4 Supplementation|Seventy five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of RS4 (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
45458900|NCT02322268|Dietary Supplement|Cosmos Caudatus|15g of Cosmos caudatus consumed with lunch or dinner
46089137|NCT05336513|Other|Diet Control|Diet following mediterranean principles, for 15 weeks
46003678|NCT02901197|Other|Policy Change|See arm description
46003679|NCT02901002|Other|Sensory testing in the two hand|spontaneous sensations while watching a hand
46003680|NCT02901002|Other|Neuropsychological evaluation|Score to anxiety-depression scale
46003681|NCT04621656|Combination Product|January Mobile Application (Sugar AI)|Sugar AI is a mobile health and fitness app the allows participants to log and record health-related data through Continuous Glucose Monitors, Heart Rate Monitors, and manual food, water, and activity logging. Using machine learning data science techniques, the Sugar AI App integrates the data collected to personalize lifestyle recommendations and help individuals optimize their health and wellness.
46003682|NCT04681664|Other|High fat diet|50 % fat
46003683|NCT04621461|Dietary Supplement|Zinc Sulfate 220 MG|220mg once daily for 5 days
46003684|NCT04621461|Drug|Placebo|Once daily for 5 days
45677268|NCT01984424|Drug|Ezetimibe|Ezetimibe was supplied as 10 mg tablets, over-encapsulated for blinding.
46003685|NCT02901236|Procedure|Standard Guarded Trabeculectomy|A fornix based conjunctival peritomy is performed. A partial thickness scleral flap is dissected. Then trabeculectomy is performed with a Kelly's punch. A surgical iridectomy is performed. The scleral flap is secured with two pre-placed 8-0 Vicryl sutures (Ethicon, Somerville, NJ). The anterior chamber (AC) is inflated with balanced salt solution and suture tension is adjusted. Finally, conjunctiva is closed with 10-0 running Nylon sutures (Ethicon, Somerville, NJ). Patients receive a subconjunctival injection of 0.4 ml dexamethasone (4 mg/ml) and of 0.4 ml gentamicin (40 mg/ml) at the end of the case. Adjuvant pharmacologic treatment to prevent episcleral fibrosis and failure of the procedure is applied according to treatment arm assignment.
46003686|NCT02901236|Drug|Mitomycin C|Sponges soaked in 0.02% mitomycin C (MMC) will be applied on bare sclera for 2 minutes. Subsequently, the area will be copiously irrigated with balanced salt solution.
45458901|NCT02322346|Other|Group S|"Peritonsillar infiltration with saline Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
46003687|NCT02901236|Drug|Bevacizumab|After conjunctival closure 1.25mg of bevacizumab will be injected into the anterior chamber through a paracentesis created earlier during the case.
46003688|NCT02900963|Other|weekly assessment of patient's weight|Biological assessment to determine biological and inflammatory status Quality of life questionary
46003689|NCT04621422|Biological|Subject carrying an amplification of nucleotide repeats in one of the following 9 genes FMR1, DMPK, ZNF9, SCA2, JPH3, HD, FXN, C9ORF72, RFC1|Biological/Vaccine: DNA Samples collection as part of usual care
46003690|NCT04621617|Drug|Albumin|Human albumin will be administered by intravenous infusion at a dose of 1.5 gm/kg/week for 2 weeks followed by HA 40 grams every 7days
46003691|NCT04621617|Drug|Midodrine|Oral Midodrine will be given at a dose of 7.5 mg three times in a day
46003692|NCT04621617|Drug|Standard medical therapy (SMT)|SMT will include nutritional support, rifaximin, lactulose or lactitol, diuretics, SBP prophylaxis with norfloxacin, restriction of sodium, multivitamins, and other supportive measures as deemed necessary. LVP will be done as needed. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
46003693|NCT02900924|Device|BioMimics 3D Stent|
46003694|NCT00562380|Biological|ganitumab|
46003695|NCT00562380|Other|laboratory biomarker analysis|
45677269|NCT01984424|Other|Placebo to Evolocumab|Placebo matching to evolocumab supplied as single-use prefilled autoinjector/pen(s)
45677270|NCT01984424|Drug|Evolocumab|Evolocumab supplied as single-use prefilled autoinjector/pen(s)
45677271|NCT01837719|Drug|Atazanavir|300-mg capsule
45677272|NCT01837719|Drug|Cobicistat|150-mg tablet
46003696|NCT00562380|Other|pharmacological study|
46003697|NCT00562380|Procedure|biopsy|
46089138|NCT05336513|Other|Diet anti-inflammatory|Diet combining food items with anti-inflammatory potential, following the principles described in Rondanelli, Clinical Nutrition, 2021 Mar;40(3):661-689. doi: 10.1016/j.clnu.2020.08.020.
46089139|NCT02679456|Drug|SCY-078|
45836045|NCT00186498|Drug|memantine|Patients received a memantine containing capsule starting the day before ECT begins and while receiving ECT
46089140|NCT02679456|Drug|Fluconazole|
46089141|NCT02681718|Behavioral|Community health worker education|Diabetes self-management education by community health workers
45677273|NCT01837719|Drug|Atazanavir/Cobicistat FDC|Atazanavir 300-mg/cobicistat 150-mg FDC tablet
46089142|NCT02681718|Behavioral|Cell phone text messaging|Diabetes self-management education through cell phone text messaging
45677274|NCT01984268|Drug|ACTHAR|
45677275|NCT04675580|Behavioral|Toy Talk|Language modeling strategy encouraging caregivers to (1) talk about the toys the child is playing with, including the states, actions, and properties of the toys and (2) give the object its name using a lexical noun phrase.
45677276|NCT04675190|Procedure|Major abdominal Surgery|Any surgery performed under general or regional anesthesia and procedures involving abdominal cavity is considered major abdominal surgery and those who have undergone any major abdominal surgery before 6 months from the date of ultrasound findings confirming the presence or absence of gall stone will be considered exposed.
46089143|NCT05335733|Diagnostic Test|Intraoral examination, saliva, dental plaque and serum collection.|"Probing pocket depth will be defined as the distance in millimeters from the gingival margin to the base of the gingival sulcus measured using a manual probe (Michigan 0 probe with Williams Markings) in all the teeth present except for third molars. Similarly, clinical attachment level (CAL) will be measured as distance from cementoenamel junction to the base of pocket and will be recorded manually to the nearest millimeter marking on probe.~1 mililiter of saliva will be obtained by each participant. Subgingival dental plaque will be collected with sterile endodontic paperpoints from mesial sides of each natural teeth without a prostethic restoration. Serum samples will be also collected at the time of visit."
45458902|NCT02322346|Drug|Group LL|"Peritonsillar infiltration with low-dose of levobupivacaine 0.25%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
45677277|NCT04674800|Biological|MYL-1701P, a proposed biosimilar to Eylea|Open label and single arm
45677278|NCT02031146|Procedure|Lumbar puncture|
45677279|NCT02009384|Drug|Ipilimumab|administration of IV ipilimumab for up to 4 cycles
45677280|NCT01805037|Drug|brentuximab vedotin|Given IV
45677281|NCT01805037|Biological|rituximab|Given IV
45677282|NCT01805037|Other|laboratory biomarker analysis|Correlative studies
45677283|NCT01803711|Drug|Desvenlafaxine|
45677284|NCT01803711|Dietary Supplement|Omega 3 Fatty acids|
45677285|NCT01803711|Drug|Placebo (for Omega 3 fatty acid supplement)|
45677286|NCT01836549|Drug|imetelstat sodium|Given IV
45836046|NCT00186498|Drug|Placebo Oral Capsule|Patients received a placebo capsule starting the day before ECT begins and while receiving ECT
45836047|NCT00265200|Drug|zoledronic acid|3.0-4.0 mg by IV (in the vein), once a month for 6 months
45836048|NCT00087672|Drug|CC-5013|10 mg orally (2 capsules) daily
45836049|NCT00265512|Behavioral|Telephone Case Monitoring|Telephone Case Monitoring involves telephone delivery of continuing care treatment post intensive outpatient SUD treatment. It includes brief weekly phone calls with a counselor for up to 6 months.
45836050|NCT00265512|Behavioral|Continuing Care as Usual|Continuing Care as Usual will include standard group outpatient SUD treatment.
45836051|NCT00265980|Drug|Subcutaneous Placebo|Twice daily injections of saline in the same volume as will be used for leptin injections.
45836052|NCT00265980|Drug|Leptin|Leptin will be given as twice daily subcutaneous injections in doses titrated to replicate 8 a.m. circulating leptin concentrations measured in the same subjects prior to weight loss.
45836053|NCT00187200|Device|Simultaneous VV Pacing|Right ventricular and left ventricular pacing delivered simultaneously.
45836054|NCT00187200|Device|Sequential VV Pacing|Right ventricular and left ventricular pacing delivered sequentially.
45836055|NCT00088218|Drug|Clofarabine|1-hour IV infusion 30 mg/m^2 daily times 5 days (Days 1-5)
45836056|NCT00088218|Drug|Ara-C|20 mg/m^2 subcutaneously daily times 14 days (Days 1-14). On Days 1 to 5 of each course, clofarabine will precede injection of ara-C by approximately 4 hours (+/- 1 hour).
45677287|NCT01836471|Drug|QAW039|QAW039 supplied as hard gelatin capsule in unit dose strength of 150 mg. Patient took 450 mg once daily (3 capsules taken with food in the morning) for the approximate period of the study (12 weeks)
45677288|NCT01836471|Drug|Placebo QAW039|Matching placebo for QAW039 supplied as hard gelatin capsule were identical in appearance to their active counterparts. Patients took 3 QAW039 matching placebo capsules once a day ( taken with food in the morning) for the approximate period of the study (12 weeks)
45677289|NCT01836471|Drug|Fluticasone 250 mcg|Fluticasone was supplied in inhalers with dose strength of 250 mcg. Patients took 250 mcg bid (morning and evening approximately 12 hours between doses) for a total dose of 500 mcg daily for the approximate period of the study (12 weeks).
45677290|NCT01836471|Drug|Fluticasone 100 mcg|Background therapy - fluticasone was supplied in inhalers with dose strength of 100 mcg. All patients in the study other than the Atopic Fluticasone 150 mcg arm were given the 100 mcg dose strength inhalers and took fluticasone 100 mcg bid (taken morning and evening with approximately 12 hours between doses) as background therapy for the approximate period of the study (12 weeks).
45677291|NCT02030600|Drug|insulin degludec|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
46089144|NCT04181892|Procedure|Coronally advanced flap + connective tissue graft|connective tissue graft covered by a coronally advanced flap with connective tissue graft apical of the cementoenamel junction level
46089145|NCT04182438|Dietary Supplement|Low potassium content vegetables|use low-potassium content vegetables
45677292|NCT02030600|Drug|insulin glargine|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
45677293|NCT01802775|Drug|edoxaban|
45677294|NCT01802775|Drug|Clopidogrel|75mg tablet
45677295|NCT01802775|Drug|Aspirin|
45677296|NCT04591041|Device|HoloSIM Software via Hololens 2|Medical students will train via a mixed reality simulated crisis scenario using the HoloSIM software on the Microsoft Hololens 2
45677297|NCT04591041|Other|Training by Mannequin Based Simulation|Medical students will train a via traditional mannequin based medical crisis scenario
45677298|NCT01802385|Drug|Sertraline|Sertraline 400mg/day for 2 weeks, then 200mg/day for 12 weeks, then tapered over 3 weeks.
45677299|NCT01773993|Drug|Pregabalin|The usual adult dosage for oral use begins at 150 mg/day of pregabalin twice daily, and should be gradually increased to 300 mg/day over 1 week or more and then maintained at 300-450 mg/day as needed. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 450 mg, and should be orally administered twice daily.
45677300|NCT01802073|Drug|Oral Vancomycin|
45677301|NCT01607073|Drug|Verapamil|"Verapamil will be prepared as a solution. A 50mg/ml oral suspension may be made with immediate release tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus will be used.~Children will start on a 4 weeks titration period:~Week 1: 1mg/kg/day divided BID Week 2: 2mg/kg/day divided BID or TID Week 3: 3mg/kg/day divided BID or TID Week 4: 4mg/kg/day divided TID~In event of adverse events, and in consultation with the family and treating physician, the dosage may be decreased to 2mg/kg/day and remain at that dose for the remainder of the study."
46089146|NCT00640458|Drug|Sildenafil 100 mg|
46089147|NCT00640458|Drug|Placebo|
45677302|NCT04583007|Drug|Lanadelumab 150 mg|TAK-743-6001: Participants will receive subcutaneous (SC) injection of lanadelumab at a dose of 150 milligrams (mg) at the same frequency (for every 2 weeks [Q2W] or for every 4 weeks [Q4W]) given at the completion of SPRING study until benefit-risk no longer favors the individual participant or an appropriate alternative therapy becomes available or lanadelumab 150 mg/ 1 milliliter (mL) becomes commercially available or the participants turns 12 years of age or participant chooses to discontinue treatment. For participants aged 6-12 years, a dose frequency may be modified based on a benefit-risk assessment and medical decision from the treating physician.
45677303|NCT04583007|Drug|Lanadelumab 300 mg|TAK-743-5012: Participants will receive SC injection of lanadelumab in prefilled syringe at a dose of 300 mg, Q2W or Q4W if well controlled for 26 weeks across Study TAK-743-3001 and this (TAK-743-5012) program.
45677304|NCT01773291|Other|acupuncture|acupuncture on GV26 and 12 Well points
45677305|NCT01773291|Other|laser acupuncture|laser acupuncture on GV26 and 12 Well points
45677306|NCT01773291|Other|control|sham laser acupuncture
45677307|NCT01801917|Drug|Placebo|Matching placebo tablet for oral administration
45836057|NCT00189228|Drug|Xolair|Patients are administered Xolair
45836058|NCT00091260|Drug|dexamethasone|dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
45836059|NCT00091260|Drug|lenalidomide|15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone
45836060|NCT00193128|Drug|Oxaliplatin|40 mg/m2 IV over 2 hours on days 1, 8, 15, 22, and 29 in both treatment cohorts
45836061|NCT00193128|Drug|Docetaxel|20 mg/m2 IV over 30 minutes was administered on days 1, 8, 15, 22, and 29 in both cohorts
45677308|NCT01801917|Drug|BAF312|BAF312 in 4 dosage strengths in tablet form: 0.25 mg, 0.5 mg, 1 mg, 2 mg for oral administration
45836062|NCT00193128|Drug|Capecitabine|In Cohort 2, capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35.
45836063|NCT00193128|Radiation|Radiation therapy|In both cohorts, radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).
45836064|NCT00193596|Drug|Etoposide|50 mg alternating with 100 mg PO, days 1 and 10 in regimen A
46003698|NCT02900612|Other|Water aerobics training.|The WA group will be trained adopting the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.
46003699|NCT02900612|Other|Water resistance training.|The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.
46089148|NCT00909948|Other|Fludarabine and total body irradiation|The patients in the second cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.
45836065|NCT00193596|Drug|Gemcitabine|1000 mg/m2 IV, days 1 and 8, in regimen B
45836066|NCT00193596|Drug|Irinotecan|1000 mg/m2 IV days 1 and 8 in regimen B
45836067|NCT00193596|Drug|Paclitaxel|200 mg/m2 by 1-hour IV infusion, day 1, regimen A
45836068|NCT00193596|Drug|Carboplatin|Area under the curve (AUC) 6.0 IV, day 1, regimen A
45836069|NCT01899378|Dietary Supplement|Lactobacillus reuteri DSM 17938|10^8 CFU
45836070|NCT01899378|Dietary Supplement|Bifidobacterium longum infantis|10^9 CFU
45677309|NCT04170075|Behavioral|Whole Body Vibration|Undergo WBV
45677310|NCT02008916|Drug|Secukinumab|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17).
45677311|NCT02008916|Drug|Placebo secukinumab|Placebo to AIN457 (Secukinumab)
45836071|NCT01899534|Other|E-screening|E-screening will be conducted on a computer tablet with wireless access. The tablet will be configured with the screening tool currently used in each clinic. The content and order of individual questions will be identical to the paper-pen version. Response options will be listed in full view under each question. Women select responses by touching the screen.
45836072|NCT00091962|Behavioral|Psychoeducation; Treatment recommendations|Counseling program
45836073|NCT00091962|Drug|Pharmacotherapy|Recommendations to patients' PCP for medication to treat depression
45836074|NCT00091962|Other|Usual Care|Physicians' Usual care
45836075|NCT00194532|Drug|Cefpodoxime|Cefpodoxime 100mg twice a day(BID)for 3 days
45836076|NCT00194532|Drug|Ciprofloxacin|Ciprofloxacin 250mg twice a day (BID)for 3 days
46003700|NCT02900612|Other|Control Group|The control group will perform relaxation classes, including meditation, balance exercises, coordination exercises.
46003701|NCT01212757|Drug|Apremilast 20mg|Apremilast 20 mg twice daily, orally
46003702|NCT01212757|Drug|Apremilast 30mg|Apremilast 30 mg twice daily, orally
46003703|NCT01212757|Drug|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
46003704|NCT01212757|Drug|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
46003705|NCT00562419|Drug|CT-322|IV solution, weekly
46003706|NCT00562419|Drug|irinotecan hydrochloride|IV solution, biweekly
46003707|NCT02900768|Behavioral|Exercise|Combination of resistance and aerobic exercises for 100 days.
46003708|NCT00562458|Drug|anastrozole|
45677312|NCT01772823|Behavioral|3MV|Many Men, Many Voices (3MV) is based on Social Cognitive Theory and the Transtheoretical Model of Behavior Change. 3MV is a group-level intervention that addresses behavioral and social determinants and other factors influencing the HIV/sexually transmitted infection (STI) risk and protective behaviors of Men having sex with men (MSM) of color. The other factors include cultural, social and religious norms, racial identity and degree of connectedness to communities, HIV/STI interactions, sexual relationship dynamics, and the social influences of racism and homophobia.
45677313|NCT01772823|Behavioral|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe in as much detail, a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
45677314|NCT01772823|Drug|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
45836077|NCT00194610|Drug|Botox|Botox 25 international units per injection injected in two places in the bladder neck, with option to inject two other tender points with 25 units each
46003709|NCT02900729|Device|Radiofrequency ablation catheter|Subjects will be treated with the renal denervation procedure using WiseGo Catheter System after randomization.
46003710|NCT02900729|Drug|Amlodipine, losartan potassium and hydrochlorothiazide|Standardised triple anti-hypertensive medications of amlodipine 5 mg per day, losartan potassium 50 mg and hydrochlorothiazide 12.5 mg per day in the first 90 days after randomization. Subjects will be allowed to adjust baseline antihypertensive medications where clinically necessary in the second 90 days after randomization.
46003711|NCT00562536|Procedure|Umbilical cord clamping|Delay of umbilical cord clamping 30 to 45 seconds
45836078|NCT00194610|Other|normal saline|Normal saline injected into the bladder neck via the perineum, 1 cc each given at positions 3 o'clock and 9 o'clock
45836079|NCT00093756|Radiation|3-dimensional conformal radiation therapy|
45677315|NCT04177082|Combination Product|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
45677316|NCT02029976|Behavioral|SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together)|attention control condition after school weight management program
45677317|NCT02029976|Behavioral|Mailed monthly newsletters|Newsletters
45836080|NCT00093756|Drug|bortezomib|Given IV
45836081|NCT00093756|Drug|paclitaxel|Given IV
45836082|NCT00093756|Drug|carboplatin|Given IV
45836083|NCT04176666|Device|NettOpp|NettOpp is a mobile application for adolescents aged 11-16 years who have been exposed to cyberbullying or cyberaggression.
45836084|NCT04389138|Other|Physiotherapy Intervention|Physiotherapy intervention will include an assessment to identify individual areas that physiotherapy should target. Intervention will be based on the core areas recommended by the European Physiotherapy Guideline for Parkinson's Disease: physical capacity (muscle power, tone, joint range of movement, exercise tolerance and pain), transfers, manual dexterity, balance and gait. Posture is incorporated as part of these 5 core areas. The intervention will be delivered over 4 visits.
45836085|NCT04145154|Other|Application of platelet rich plasma in chronic wounds of diabetic origin|Application of plasma rich in autologous growht factors after advanced healing
46003712|NCT00562614|Drug|SLx-2101|
46003713|NCT04621227|Drug|PF-06882961|120 mg and 200 mg BID
46003714|NCT04621227|Drug|Rosuvastatin|10 mg single dose
45677318|NCT01983254|Behavioral|coping skills training|6-session coping skills training program delivered by telephone w/ web augmentation
45677319|NCT01983254|Other|education program|web-based, ICU-specific education program
45677320|NCT04177004|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo-HCT
46003715|NCT04621227|Drug|Midazolam|2mg single dose
46003716|NCT01190410|Drug|certolizumab pegol|400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
46003717|NCT01190410|Drug|certolizumab pegol|200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to < 40 kg
46003718|NCT01190254|Drug|asenapine 2.5 mg|asenapine 2.5 mg tablets for sublingual administration
46003719|NCT01190254|Drug|asenapine 5.0 mg|asenapine 5.0 mg tablets for sublingual administration
46003720|NCT01190254|Drug|placebo|asenapine-matched placebo tablets for sublingual administration
46003721|NCT04315987|Biological|NestaCell®|A dose of 2x10^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.
46003722|NCT04315987|Biological|Placebo|Matching Placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.
46003723|NCT04621383|Dietary Supplement|Whey protein plus collagen|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 17 weeks. At the beginning of the experiment, two weeks and at the end three weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16), magnetic ressonance imaging (weeks 2 and 17) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
46003724|NCT04621383|Dietary Supplement|Whey protein plus maltodextrin|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 17 weeks. At the beginning of the experiment, two weeks and at the end three weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16), magnetic ressonance imaging (weeks 2 and 17) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
45836086|NCT04118556|Biological|Decidua Stroma Cells (DSC)|"Placenta-derived Decidua Stroma Cells. The product consists of a viable allogeneic DSCs frozen in 5% of human serum albumin (HSA) in sodium chloride (NaCl) 0.9% and 10% dimethylsulfoxide (DMSO), that is thawed and immediately diluted in 40 mL sodium chloride (NaCl) 0.9% prior to infusion. That will give a final concentration of 2.2% HSA and 2% DMSO.~DSC will be infused when steroid-refractory acute GVHD after allogenic stem-cell transplantation has been diagnosed. Two doses, one week apart, will be given to all patients. Additional doses will be used depending on response."
46089149|NCT00909948|Radiation|Total body irradiation|Patients will receive 200 cGy TBI on day 0,4-6 hours prior to HCT.
46089150|NCT02843009|Behavioral|Resistance Exercise Training|Resistance exercise will involve 2 sessions per week for 18 weeks. Each session will involve participants carrying out the following exercises: calf press, leg press, leg extension and leg curl
46089151|NCT02843009|Dietary Supplement|Supplementation|Participants randomised to either 3g/day of fish oil or safflower oil for 18 weeks
46089152|NCT02551146|Device|A Locator with retention elements|Insertion of GC Pilier locator abutments with retention elements
46089153|NCT02551146|Device|B Locator without retention elements|Insertion of GC Pilier locator abutments without retention elements
46003725|NCT04621305|Other|normal saline|Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered
46003726|NCT04621305|Drug|Bolus Remimazolam|Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2mg/kg remimazolam is administered.
46003727|NCT04621305|Drug|Continuous Infusion Remimazolam|Anesthesia is maintained by sevoflurane and continuous infusion of remimazolam(1mg/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered.
46003728|NCT00553592|Drug|Bicifadine|600mg/day
45836087|NCT04118556|Drug|Best available Treatment (BAT)|The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
45836088|NCT00267696|Drug|Bevacizumab|Bevacizumab(Avastin)=10mg/kg on day 1, day 15 of a 28 day cycle.
45836089|NCT00267696|Drug|Gemcitabine|A regimen consisting of gemcitabine 1000 mg/m2 will be administered on day 1 and day 15 of a 28 day cycle
45836090|NCT00267696|Drug|Carboplatin|
45836091|NCT00267774|Device|Fractional flow reserve|
45836092|NCT00267774|Procedure|Angio-guided PCI|
46003729|NCT00553592|Drug|Bicifadine|placebo tablet
46003730|NCT00553592|Drug|Bicifadine|1200 mg
46003731|NCT04620954|Drug|Oregovomab|2mg of Oregovomab is administered through IV on Weeks 1, 5, 9, 17.
45677321|NCT04177004|Drug|Cyclophosphamide|Given IV
45677322|NCT04177004|Drug|Etoposide|Given IV
45677323|NCT04177004|Radiation|Fractionated Stereotactic Radiation Therapy|Undergo FTBI
45677324|NCT04177004|Drug|Goat Milk|Given human lysozyme goat milk PO
45677325|NCT04177004|Biological|Palifermin|Given IV
45677326|NCT04177004|Drug|Sirolimus|Given PO
45677327|NCT04177004|Drug|Tacrolimus|Given IV and PO
46003732|NCT04620954|Drug|Nivolumab|480mg of Nivolumab is administered through IV every 4 weeks (Weeks 9, 13, 17, 21).
46003733|NCT04620954|Drug|Chemotherapy|Pegylated liposomal doxorubicin (PLD) and carboplatin are administered every 4 weeks through IV. The starting dose of PLD and carboplatin are 30mg/m^2 and 5 AUC (Area Under the Curve) respectively.
46003734|NCT04621032|Diagnostic Test|Polygraphy monitoring|All patients with visceral obesity have been tested for Obstructive Sleep Apnea and heart rhythm disorders by usage of polygraphy and Holter-ECG monitoring.
46003735|NCT04621032|Diagnostic Test|laboratory tests|Blood samples for sodium, potassium, calcium, magnesium concentration and fasting glyceamia assessment hae been taken from all patients with visceral obesity.
45836093|NCT00195624|Biological|Alemtuzumab (Campath )|Campath administered at a dose of 10/mg/day for 10 days
45836094|NCT00195624|Drug|Cyclosporine|Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit. Dosing will be based on ideal body weight and will be adjusted to maintain a target level of 200 - 400 ng /ml.
46003736|NCT02900261|Other|No intervention|This study is observational and does not entail any intervention. Different methods to assess sodium and caffeine consumption will be compared.
46003737|NCT00562692|Drug|Nesiritide|Nesiritide 4 hour infusion
46003738|NCT00562692|Drug|Placebo|Placebo infusion
46003739|NCT02900534|Other|Internet-based self-help|10 internet-based self-help sessions plus one supportive email a week with a cognitive-behavioural background
46003740|NCT04621110|Drug|intranasal dexmedetomidine|Dexmedetomidine (precedex®) will be administered by intranasal route in 1ug/kg each dose, repeating at most 3 times to see if it can give enough sedation to painful procedure. To assess the level of sedation the study will use Ramsay sedation scale.
45677328|NCT01771809|Drug|75mg SHP647 (PF-00547659)|75 mg sterile liquid injected subcutaneously every 4 weeks.
45677329|NCT01771809|Drug|225mg SHP647 (PF-00547659)|225 mg sterile liquid injected subcutaneously every 4 weeks.
45677330|NCT01771731|Drug|Cannabis|
45677331|NCT01982942|Drug|ibudilast|Subjects randomly assigned to the ibudilast (MN-166) cohort will receive up to 100 mg/day for 96 weeks.
45677332|NCT01982942|Drug|Placebo oral capsule|Subjects randomly assigned to the placebo cohort will receive placebo oral capsule for 96 weeks.
45677333|NCT01769469|Drug|FTC/TDF (Truvada®)|There are no interventions for this study except that subjects will be administered FTC/TDF (Truvada®) will be administered as part of ATN 110 and ATN 113.
45677334|NCT02008526|Behavioral|Text Messages Transmitted by Peer Health Educators (TXT-PHE)|"Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support (pull) are sent additional real-time messages back from the PHE. Text messages are transmitted and responded to in real time, at the peak hours of high-risk activities. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
45836095|NCT00195702|Biological|Adalimumab|Self-administered, subcutaneous injection of 20 mg adalimumab (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
45836096|NCT00195702|Biological|Adalimumab|Self-administered, subcutaneous injection of 40 mg adalimumab (1.6 mL/injection) every other week (eow) for up to 52 weeks.
46003741|NCT04621110|Drug|intranasal fentanyl|Fentanyl will be administered by intranasal route in 1,5ug/kg each dose, repeating at most 3 times to see if it can give enough pain relief for painful procedure. To assess pain control the study will use Face, Legs, Activity, Cry, Consolability scale ( FLACC)
46003742|NCT04621110|Drug|intravenous ketamine (ketalar®)|Ketamine (ketalar®) will be administrated by intravenous route in 1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.
46003743|NCT04621110|Drug|intravenous midazolam|Midazolam will be administrated by intravenous route in 0,1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.
45677335|NCT02008526|Behavioral|Text Messages Transmitted by Automation (TXT-Auto)|Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
45677336|NCT04581915|Drug|Triazavirin (Riamilovir)|Capsule - 250mg 8 hourly po
45677337|NCT04581915|Other|Placebo|Placebo capsule
46003744|NCT04620720|Drug|capule gabapentin|neuropathic analgesic
45677338|NCT01769391|Drug|Necitumumab|Administered IV
45677339|NCT01769391|Drug|Paclitaxel|Administered IV
45677340|NCT01769391|Drug|Carboplatin|Administered IV
45677341|NCT01800903|Device|ZN-D catheter|ZN-D catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
45677342|NCT01800903|Device|ZN-C catheter|ZN-C catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
45677343|NCT01800903|Device|SpeediCath catheter|The Speedicath cathere is CE-marked and commercially available.
45836097|NCT00195702|Drug|Placebo|Self-administered, subcutaneous injection of placebo (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
45677344|NCT04413747|Behavioral|morning Yoga-based breathing support|Low and deep inspiration and phonetic syllable OM laryngeal vibration ( OM technique) as expiratory exercises, sitting in easy pose. The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Bhramari pranayama n° of 5 RAc.
45458903|NCT02322346|Drug|Group HL|"Peritonsillar infiltration with high dose of levobupivacaine 0.5%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
45458904|NCT01146301|Drug|Clopidogrel|All patients will receive a loading dose of 600mg of study medication. The first group will receive 300 mg of clopidogrel and 300 mg placebo, the second group will receive 600mg of clopidogrel at least 24h before carotid stenting
45677345|NCT04413747|Behavioral|pre_lunch Yoga-based breathing support|Low and deep inspiration and OM technique as expiratory exercises, sitting in easy pose.The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Surya Bheda pranayama n° of 5 RAc.
45677346|NCT04413747|Behavioral|pre_dinner Yoga-based breathing support|Low and deep inspiration and OM technique as expiratory exercises, sitting in easy pose.The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Nadi Shodhana pranayama n° of 5 RAc.
45677347|NCT01767987|Drug|Ranolazine|Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI
45677348|NCT01767987|Drug|Placebo|Drug: Placebo Oral dose twice per day for 3 days leading up to PCI
45683767|NCT01798706|Drug|Antidiabetic background therapy|Participants received a stable regimen of anti-diabetic background therapy for at least 3 months prior to screening, during the placebo run-in period and the 24 week treatment period. Allowed background antidiabetic therapy included metformin, sulfonylurea (except glibenclamide >10 mg, gliclazide >160 mg), meglitinides (except repaglinide >6 mg), pioglitazone and basal insulin. Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.
46003745|NCT02900222|Procedure|endoscopic choroid plexus coagulation|A burr hole will be made over the frontal lobe of the brain. An endoscope will be introduced into the ventricle of the brain and the choroid plexus coagulated with an electrocautery device. The septum pellucidum separating the right and left lateral ventricles will be opened, and the choroid plexus on the opposite side coagulated as well.
46003746|NCT04620642|Biological|Registry|No specific intervention. Data of the usual care will be collected as the medical history, the demographic data, the biological analyses, imaging report, etc.
46003747|NCT02900417|Drug|Sitagliptin|All the patients will receive sitagliptin 100mg daily
45458905|NCT04461184|Behavioral|Internet Wellness Intervention for Aging|Internet technologies have emerged as a platform for performing wellness interventions that also have wide outreach. Previous studies that have used the internet for delivering health interventions have found that older adults valued this platform, used it for researching health information and social communications. Likewise, the effectiveness of delivering health-related information intended for behavior change through the internet is equal to that of print-based delivery, thereby lowering costs and expanding reach. Thus, the internet provides a unique platform for conducting interventions. The internet based wellness intervention will be a low cost method focused on older adults to help increase intrinsic motivation through autonomy, competence, and relatedness (Intrinsic Motivation) to help increase daily physical activity.
45458906|NCT00807859|Drug|AMG 386 30 mg/kg, Paclitaxel and Trastuzumab|AMG 386 30 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
45458907|NCT00807859|Drug|AMG 386 30 mg/kg, Capecitabine and Lapatinib|AMG 386 30 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
45458908|NCT00807859|Drug|AMG 386 10 mgkg, Paclitaxel and Trastuzumab|AMG 386 10 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
46003748|NCT04620876|Other|Bimodal high resolution imaging of the retina|The protocol consists of performing an Optical coherence tomography and Scanning laser ophthalmoscope system using adaptive optics (AO-SLO-OCT).The participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
45458909|NCT00807859|Drug|AMG 386 10 mg/kg, Capecitabine and Lapatinib|AMG 386 10 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
45458910|NCT01237639|Other|Red blood cell Transfusion|Transfusion of Red blood cells to based on daily complete blood count
45683768|NCT04156126|Other|Blood Collection|Blood Collection
45458911|NCT03491956|Device|DFPP|Lipid levels,platelet function，and platelet RNA sequencing in hyperlipidemia patients before and after DFPP
45677349|NCT01800201|Behavioral|Electronic Pill Bottle, Incentives, Social Influence|The intervention group (1) will use GlowCaps, a remote monitoring and reminder pill bottle; (2) assigned an engagement advisor from the study team; (3) asked to provide study team with names and contact information of up to 3 family members or friends as support partners for med adherence. The study team will contact these people in order listed until 1 agrees to this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on med adherence; and (5) will determine preferences for Way to Health platform communication methods.The group receiving the program intervention will also have their claims data analyzed for the 12 months post-enrollment.
45836098|NCT00195702|Biological|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 20 mg (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
45836099|NCT00195702|Biological|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 40 mg (1.6 mL/injection) every other week (eow) (with a placebo 1.6 mL/injection on alternate weeks) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL injection) eow for up to Week 520.
45836100|NCT00195702|Biological|Adalimumab|Self-administration, subcutaneous (SC) injection of placebo solution (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
46003749|NCT04620408|Drug|SHR4640|Subjects were randomly divided into the group A, B. On D1, D8, two groups of subjects were respectively given SHR4640 tablet.
45458912|NCT01246453|Drug|Intrapleurally Alteplase vs Intrapleurally Urokinase|Alteplase 10 mg and urokinase 100000 intrapleurally administered, once daily for three days and if necessary 6 days
46003750|NCT02900183|Drug|ARC-AAT Injection|RNA interference (RNAi)-based, liver-targeted therapeutic
46003751|NCT02900495|Device|transcutaneous electric nerve stimulation|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
45342401|NCT04073160|Radiation|Bladder radiation|During the durvalumab cycles 3 and 4, eligible subjects will receive 6.5 weeks of radiation to the bladder. Radiation will be administered at a dose of 64 Gy in daily 2 Gy fractions.
45342402|NCT04073160|Drug|Intravesicular Therapy|Subjects will receive intravesicular therapy, if clinically indicated during cycles 5 and beyond of durvalumab administration. Intravesicular therapy will consist of BCG, gemcitabine, mitomycin or a similar drug, depending on institutional standards and treating provider's discretion.
45458913|NCT03489148|Behavioral|Tamarkoz®|Tamarkoz® techniques includes six key elements: clearing the mind, breathing exercises, Movazeneh® (movement and balance exercises), deep relaxation, and visualization.
45458914|NCT03489148|Behavioral|Stress management resources|Use of the campus health center's stress management resources such as counseling, health-coaching, health and wellness groups, use of an automated massage chair, pet-an-animal a week, and online reading material about self-care for stress management.
45342403|NCT00417079|Drug|cabazitaxel (XRP6258) (RPR116258)|25 mg/m^2 administered by intravenous (IV) route over 1 hour on day 1 of each 21-day cycle
45458915|NCT02322424|Procedure|pancreaticoduodenectomy|
45458916|NCT03497182|Device|Breath sample collection|Subject exhales into breath collection container.
45458917|NCT03491098|Drug|Mometasone Furoate spray|"Mometasone Furoate spray one puff in each nostril daily for 8 weeks~hypertonic sea water solution spray one puff in each nostril daily for (8) weeks."
45458918|NCT03491098|Drug|prednisolone sodium phosphate 15mg|three times per day for 1 week then gradual withdrawal over 2 weeks
45677350|NCT01767909|Drug|Insulin (Humulin® R U-100)|20 IU bid taken twice daily (approximately 30 minutes after breakfast and dinner) for a total of 40 IU daily, which will be administered intranasally. The device used to administer insulin releases a metered dose into a chamber covering the participant's nose. The insulin is then inhaled by breathing evenly over a specified period.
45677351|NCT01767909|Drug|Placebo|Placebo taken twice daily (approximately 30 minutes after breakfast and dinner), which will be administered intranasally. The device used to administer placebo releases a metered dose into a chamber covering the participant's nose. The placebo is then inhaled by breathing evenly over a specified period.
45677352|NCT02029274|Drug|BAF312|BAF312 was provided as film-coated tablets in strengths of 0.25, 0,5, 1 and 2 mg for oral administration.
45677353|NCT02029274|Drug|Placebo|Matching placebo to BAF312 as tablets for oral administration.
45677354|NCT02008370|Drug|Exparel infiltration|Exparel infiltrated into wound and chest tube sites
46003752|NCT04620837|Drug|Tislelizumab|Tislelizumab：200mg Q3W IV. There will be no dose reduction for Tislelizumab ， if there is no disease progression or serious Treatment Related adverse events(TRAE) , patients will receive Tislelizumab (200mg,Q3W) until progression or death
46003753|NCT04620837|Drug|Anlotinib hydrochloride|Anlotinib hydrochloride capsules: Capsule; specifications 12mg; oral, once a day, every 12mg, continuous medication two weeks after 1 week deactivated. Depending tolerated dose reduction. Medication process: disease control and patients can tolerate the side effects, continued drug use; researchers believe the patient is not fit to continue medication or efficacy evaluation at the end of the clinical progression of medication.
46089154|NCT02843477|Device|ultrasonographic measurement of corrected flow time in carotid artery|Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed while the Doppler beams were adjusted to ensure < 60° of angle for the best signal. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).
46089155|NCT02681562|Drug|olaparib|
45458919|NCT03491098|Drug|hypertonic sea water solution spray|one puff in each nostril daily for 8 weeks
45458920|NCT02322502|Drug|Desflurane|inhalation with laryngeal mask to maintain anaesthesia
45458921|NCT02322502|Drug|Sevoflurane|inhalation with laryngeal mask to maintain anaesthesia
45458922|NCT02322502|Drug|propofol|intravenous injection to maintain anaesthesia
45458923|NCT03489070|Combination Product|Traumastem®|Intraoperative application as secondary hemostatic treatment
45458924|NCT03489070|Combination Product|Surgicel®|Intraoperative application as secondary hemostatic treatment
46089156|NCT00633035|Drug|esomeprazole 40 mg|esomeprazole 40 mg po given for 7 days
46089157|NCT00633035|Drug|famotidine 20 mg|famotidine 20 mg intravenous bolus q12h for 7 days
46089158|NCT04649021|Biological|BNT162b2|Intramuscular injection
46089159|NCT04649021|Other|Placebo|Intramuscular injection
45458925|NCT02307448|Procedure|Platelet Rich Plasma|Patients will receive weekly PRP treatments with standard of care.
45458926|NCT02307448|Procedure|Standard of Care|Patients will receive weekly standard of care.
45458927|NCT03490786|Drug|GT-001|PK, PD Study to Determine Safety of Escalating Doses of GT-001
45458928|NCT02445040|Device|Babylog VN500 in HFOV Mode|Treatment with high frequency oscillatory ventilation with investigational device for up to 14 days
45458929|NCT03488992|Dietary Supplement|MVM/phytochemical supplement|Consumption of an MVM/phytochemical supplement for 8 weeks
45458930|NCT03488992|Dietary Supplement|Placebo|Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
45458931|NCT02322580|Drug|etanercept|
45458932|NCT04461886|Drug|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
45677355|NCT01981616|Drug|Vedolizumab|Vedolizumab for intravenous infusion
45677356|NCT01981616|Drug|Placebo|Placebo intravenous infusion
45677357|NCT01981616|Biological|Hepatitis B vaccine|
45677358|NCT01981616|Biological|Oral cholera vaccine|
45677359|NCT02104817|Drug|Epanova® (omega-3 carboxylic acids)|Adjunct to statin therapy and diet in high risk adult patients for the prevention and reduction of major adverse cardiovascular events (MACE)
45677360|NCT02104817|Drug|corn oil control|corn oil control arm
45677361|NCT01962103|Drug|nab-paclitaxel|nab-paclitaxel 120-270 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle
45677362|NCT01962103|Drug|nab-paclitaxel|IV infusion
46003754|NCT00562731|Drug|ARD-0403|Daily transdermal ARD-0403
45677363|NCT01961323|Drug|Nebivolol|Doses will be titrated based on weekly visits during the first 2 weeks to achieve a target SBP<140 and DBP <90 mm Hg. If BP remains uncontrolled after 2 weeks of treatment, indapamide will be added at a dosage of 2.5 mg/day. If the therapeutic goal is still not achieved by 4 weeks, patients will be withdrawn from the study.Upward titration will be halted, and the previous dosage level resumed, if at any point systolic blood pressure falls to ≤ 100 mmHg, even if the individual remains asymptomatic.
45677364|NCT04656145|Device|3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing|On the day of the operation, after the procedure has concluded and the drains have been placed, the surgical drain site that has been randomized to be in the experimental group will receive the chlorhexidine gel dressing. The dressing will remain on the patient until the drain has been removed and the surgical site will be assessed for signs of infection.
46003755|NCT02900027|Drug|APOC-III-L-Rx|Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
46003756|NCT02900027|Drug|Placebo Comparator|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
46003757|NCT04620447|Other|Intelligent Virtual Reality Therapy System (IVRTS)|The approach of the Novel Intelligent Software interface approaches follows the basic premise that human beings think in terms of images rather than words. While the existing modes of treatment for phobias rely mainly on talk therapies and counseling; This novel intelligent software treatment methodology deals with the development of VR programs integrated with hardware for simulating various phobia-inducing situations, followed by novel automated integrated most effective psychotherapy; altering these images to reduce the anxiety experienced. Our treatment package includes a VR device integrated with easily comprehensible voice commands, along with a user manual and easy user interface, thereby reducing the effort of training required for operating the device. The framework is a combination of the therapy methodologies with VR, motion sensors and biofeedback.
46003758|NCT04620486|Other|Epic Best Practice Alert|This is a customized Best Practice Alert created at Mass General Brigham in the institutional Epic electronic medical record system.
46089160|NCT02842619|Biological|BonoFill-II|"Sinus augmentation - Surgery will be performed by either open or close sinus augmentation as per investigator discretion and as per common medical practice. After the elevation, BonoFill-II will be transplanted on the residual sub-antral bone.~Bone grafting after removal of cysts from jaws - Treatment will be performed according to the size of the cyst: in relatively small cyst total enucleation will be performed. In large cysts, a process of marsupialization will be performed. The entire cyst will be removed, including the epithelium layer, and the BonoFill-II product will be used for filling."
46089161|NCT05335577|Diagnostic Test|Urinary Claudin-2|A sequential non-invasive urinary molecular profiling for protein, i.e. Claudin-2 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.
46089162|NCT05335577|Diagnostic Test|Urinary Caveolin-1|A sequential non-invasive urinary molecular profiling for protein, i.e. Caveolin-1 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.
45677365|NCT04186403|Drug|Brexpiprazole|Administered as tablets.
45677366|NCT01960855|Drug|ABT-494|ABT-494 capsule administered orally twice daily (BID).
45342404|NCT00417079|Drug|mitoxantrone|12 mg/m^2 administered by intravenous (IV) route over 15-30 minutes on day 1 of each 21-day cycle
45342405|NCT00417079|Drug|prednisone|10 mg daily administered by oral route
45342406|NCT02578914|Drug|NS2 Ophthalmic Drops (0.5%)|
45342407|NCT02578914|Drug|NS2 Ophthalmic Drops Vehicle (0.0%)|
45342408|NCT00429169|Drug|Paroxetine|Dosage will be 25 mg every day for 2 weeks, then 37.5 mg every day for 2 weeks, and then optional increase to 50 mg every day for the remainder of treatment.
45458933|NCT04462042|Radiation|Proton radiotherapy|Proton radiotherapy
45458934|NCT04462042|Radiation|Photon radiotherapy|Conventional photon radiotherapy
46003759|NCT02900144|Behavioral|Modified Comprehensive Behavioral Intervention for Tics|In this arm, participants will receive the modified CBIT protocol. In addition to addressing tics, the treatment in this arm will also directly address ADHD symptoms using CBT for ADHD techniques, and quality of life concerns. The treatment itself will be modified to be more accessible to an ADHD population. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
46003760|NCT02900144|Behavioral|Comprehensive Behavioral Intervention for Tics|In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
45458935|NCT03190174|Drug|Nab-Rapamycin|Escalating doses of ABI-009 will be given IV over 30 min for 2 of every 3 weeks beginning Day 8 Cycle 2. Only nivolumab will be given in Cycle 1. At Dose Level 1, 3-6 patients will receive 56 mg/m2; at Dose Level 2, 3-6 six patients will receive 75 mg/m2; and at Dose Level 3, 3-6 patients will receive 100 mg/m2.
45458936|NCT03190174|Biological|Nivolumab|A defined dose of nivolumab, 3 mg/kg, will be given IV over 30 minutes q 3 weeks
46003761|NCT04620018|Drug|Amoxicillin|Subjects received Amoxicillin before surgery, before and after surgery ,and only after surgery.
45677367|NCT01960855|Drug|Placebo|Placebo for ABT-494 capsule administered orally twice daily (BID).
46003762|NCT02900105|Drug|Letrozole|Letrozole 2.5mg (1 tablet) once a day for 4 months
46003763|NCT04620213|Drug|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
45458937|NCT03490708|Drug|Tranilast|Subjects will be treated with tranilast
45458938|NCT00924326|Drug|Fludarabine|Days -5 to -1 (after administration of cyclophosphamide): 25 mg/m^2 intravenous (IV) over 30 minutes
45458939|NCT00924326|Drug|Cyclophosphamide|Days -5 to -4: 60mg/kg intravenous (IV) over 60 minutes
45677368|NCT02007434|Drug|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
45677369|NCT02007434|Drug|Placebo|Phosphate buffered saline placebo for injection
46003764|NCT04620213|Other|Phentolamine Ophthalmic Solution Vehicle (Placebo)|Topical sterile ophthalmic solution
46003765|NCT02899910|Behavioral|Health education|Education on lifestyle changes for treatment of metabolic syndrome
46089163|NCT05335577|Diagnostic Test|Urinary EGF|A sequential non-invasive urinary molecular profiling for protein, i.e. epidermal growth factor (EGF) as potential marker for tight junction protective regulator, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity.
46089164|NCT02511132|Biological|Vigil|Vigil 1.0 x 10e7 cells/injection, minimum of 4 to a maximum of 12 administrations.
46089165|NCT02511132|Drug|Temozolomide|oral temozolimidetemozolomide 100 mg/m2 daily (Days 1 - 5, total dose 500 mg/m2/cycle)
45677370|NCT02007434|Other|Cold Compress|A cold compress was applied to the injection area for 10 minutes before dosing and for 15 minutes after dosing.
45677371|NCT02007434|Drug|Lidocaine / Epinephrine|Lidocaine 4% topical cream applied 45 minutes prior to dosing across the area to be treated, followed by 0.4 mL SC injections of lidocaine HCl 1% / epinephrine 1:100,000 around the perimeter of the treatment area and across the treatment area in a regular pattern 25 minutes before dosing.
46003766|NCT02899910|Behavioral|Yoga|Training in the practice of yoga for treatment of metabolic syndrome
46089166|NCT02511132|Drug|Irinotecan|irinotecan 50 mg/m2 daily (Days 1 - 5, total dose 250mg/m2/cycle), orally or irinotecan 20mg/m2 daily (Days 1 - 5, total dose 100mg/m2/cycle ), intravenously
46089167|NCT02511132|Drug|Gemcitabine|675 mg/m2 IV at a rate of 10 mg/m2/min on Day 1 and Day 8 every 21 days
45677372|NCT02007434|Drug|Loratadine|Loratadine 10 mg orally from Day -7 until Day 7
45677373|NCT02007434|Drug|Ibuprofen|Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.
46003767|NCT04619940|Diagnostic Test|iHandy application|The IHandy® app is a free app with a visual display similar to that of the digital inclinometer in terms of digital size. In this study, due to its prevalence in the literature and its use in clinics, manual goniometer (gold standard) was chosen to be compared with this iPhone application.
46089168|NCT02511132|Drug|Docetaxel|75 mg/m2 IV administered on Day 8 and every 21 days
46003768|NCT04619940|Diagnostic Test|Standard Goniometer|While measuring with goniometer, the pivot point of the goniometer was placed on the olecranon, the immobile rod of the goniometer was kept parallel to the bed, while the moving rod was kept parallel to the ulna, the angle was recorded at the end point of the movement.
46089169|NCT05664282|Device|Damon self-ligating brackets|
46003769|NCT04619784|Other|Pilates Exercises|Patients will receive 12 sessions of pilates.
46003770|NCT04619784|Other|control|Their routine medical treatments were continued
46089170|NCT05664282|Device|Victory self-ligating brackets|
46003771|NCT02899871|Other|diagnosis of joint|"The diagnosis of joint pain will be established by a rheumatologist and completed:~If necessary, by a clinically guided radiological assessment (plain x-rays, joint ultrasound, bone and joint MRI).~serum assays of the anti-TNF administered, as well as screening for associated antibodies."
46003772|NCT04619667|Device|High Flow Nasal Cannula (HFNC)|HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
46089171|NCT02399124|Device|PROSENSE™|single arm, open label, PROSENSE™ treatment
46089172|NCT00896363|Drug|GSK163090 1 mg|Developed for the treatment of Major Depressive Disorder
46089173|NCT00896363|Drug|GSK163090 Placebo|Developed for the treatment of Major Depressive Disorder
46089174|NCT00896363|Drug|GSK163090 3 mg|Developed for the treatment of Major Depressive Disorder
46089175|NCT02683434|Device|Kinesio Taping application|Therapeutic taping application applied to skin affecting muscle, fascia, circulation, ligaments, tendons and joints.
46003773|NCT04619667|Device|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
46003774|NCT02899832|Device|NIRS|Near Infra Red Spectroscopy
46003775|NCT04619862|Drug|Gabapentin|See arm descriptions
46003776|NCT04619862|Drug|Placebo|See arm descriptions
46003777|NCT02899598|Biological|Extra blood draw samples|
46003778|NCT02899598|Biological|extra amniotic fluid samples|
46089176|NCT02678988|Device|AI-1000 G2|The device will contain TCZ (180 milligrams per milliliter [mg/mL]) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS and assembled in the AI (AI-1000 G2).
46003779|NCT05425121|Procedure|Core stability exercises|The intervention in the control group will core stability exercises for different back muscles and strengthening exercises of Gluteal Muscles.
46003780|NCT05425121|Device|Biofeedback training|EMG biofeedback training will be administered to the participants in combination with core stability exercise training.
45342409|NCT00429169|Drug|Bupropion|Dosage will be 150 mg every day for 2 weeks, then 300 mg every day for 2 weeks, and then optional increase to 450 mg every day for the remainder of treatment.
46003781|NCT01190839|Biological|Infliximab|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
46089177|NCT02678988|Device|PFS-NSD|The device will contain TCZ (180 mg/mL) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS-NSD.
46089178|NCT02678988|Drug|Tocilizumab|Participants will receive two single doses of 162 mg tocilizumab SC on Day 1 (Period 1) and Day 43 (Period 2), with a washout period of 6 weeks between the periods.
46089179|NCT05663190|Other|mental foramen location|location of mental foramen in relation to primary molars
46089180|NCT02678910|Procedure|Ovarian Cryopreservation|The ovarian tissue will be removed at a UK Healthcare facility and evaluated for gross disease by a pathologist, embryologist, andrologist or REI physician. The ovarian cortex will be dissected from the medulla and cut into strips in culture/holding media, washed to remove blood cells, and cryopreserved. Cryopreservation will be performed using modifications of the techniques described by Gosden et al. (1994) or will be vitrified using a modification of the techniques of Kuwayama et al., 2007.
46089181|NCT02681484|Behavioral|Anthroposophic speech therapy|"Anthroposophic speech therapy uses sound-combinations like KLSFM or OM and hexameter verse in German, spoken by the therapist and imitated by the patients, to expand and decelerate respiration. The intervention is conducted by the same qualified therapist for one patient in different days but during the same daytime for 30 minutes in upright position and walking."
45342410|NCT02575716|Device|Videolaryngoscope|Intubation with McGrath video laryngoscope after muscle relaxant
46003782|NCT01190839|Drug|Placebo|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
46003783|NCT05425082|Other|Motor relearning program|Treatment session of one hour per day for five days a week, for four weeks for each participant until 20 sessions
46089182|NCT02842775|Other|balance perturbation training|perturbation training on the split-belt balance perturbance treadmill,
46089183|NCT02681640|Other|68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE105
46089184|NCT02681640|Device|Positron Emission Tomography PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to Positron Emission Tomography PET/CT
46089185|NCT05663112|Procedure|Sentinel lymph node biopsy|Sentinel lymph node biopsy will be performed.
46089186|NCT05663112|Procedure|Breast massage|Breast massage will be performed for a duration of 5 minutes.
46089187|NCT05663112|Procedure|Blue dye injection|Isosulfan blue dye will be injected in the subareolar region of the breast
46003784|NCT05425082|Other|Neurodevelopmental therapy|Treatment session of one hour per day for five days a week, for four weeks for each participant until 20 sessions.
46003785|NCT05425043|Biological|Granulocytes|Receive granulocytes for 7 consecutive days after engraftment post transplant
46003786|NCT02887261|Device|"BardPowerPort sip Implantable Port"|capable for power injection for contrast media.
46003787|NCT02887261|Device|Conventional Port|not for power injection for contrast media.
46003788|NCT04619277|Device|drug-coated balloon|drug-coated balloon
46089188|NCT02678754|Other|No intervention required, purely observational|
46089189|NCT02678520|Radiation|3-D Conformal Radiation Therapy|"Radiation delivered after surgery to remove the prostate, using 3-D Conformal Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.~The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily ."
46089190|NCT02678520|Radiation|Intensity Modulated Radiation Therapy|"Radiation delivered after surgery to remove the prostate, using Intensity Modulated Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.~The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily ."
46089191|NCT02678520|Drug|Casodex, Zoladex , Lupron|"Hormonal Therapy (6 Months): Required for High Risk Groups, and as per Standard of Care for Low Risk Groups.~Hormonal therapy protocol regimen for the high risk adjuvant and salvage groups will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg subcutaneously once every 3 months x 2) or Lupron (22.5 mg given intramuscularly once every 3 months x 2 injections or 7.5 mg IM q once monthly x 6) to start on day 1 of the clinical trial.~Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months."
46089192|NCT00642252|Drug|Fluoride|Over-the-counter level of fluoride (226 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
46089193|NCT00642252|Drug|Fluoride|Over-the-counter level of fluoride (226 ppm) plus calcium (30 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
46089194|NCT00642330|Drug|oral ibuprofen|one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
46003789|NCT01190215|Biological|FluarixTM|One Intramuscular injection
46003790|NCT01190215|Biological|HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old)|Two Intramuscular injections
46003791|NCT04619238|Diagnostic Test|King's Health Questionnaire|patients fulfilled questionnaire
46003792|NCT04619238|Diagnostic Test|the International Consultation on Incontinence Modular Questionnaire (ICIQ-SF) Short Form|patients fulfilled ICIQ-SF questionnaire
46003793|NCT05424965|Other|no intervention|no intervention
46003794|NCT04619394|Other|Aquatic exercise - own monitors program|"Supervision of own exercises by the Monitor with its own program. Two weekly sessions, both aquatic in small glass and large. The activity carried out will be aerobic; They will work with their own body weight and the lightweight floating material they offer in these pools. Exercises will be carried out that favor flexibility, elasticity, resistance and the strengthening of the muscular ligaments. The intensity of the exercises will be moderate and adapted in each month of gestation. We will eliminate positions and exercises that overload the pregnant woman, avoiding possible injuries and obstetric alterations.~The start of the program will be established in week 10-12 of the pregnancy and the end in week 37-41.~The total number of sessions of the program will be from 25 to 31 (28 sessions of minimum compliance), with a frequency of 2 sessions per week. The duration of these will be 50 minutes and adherence to both experimental groups of ≥28 classes."
45836101|NCT00196716|Biological|Fabrazyme (agalsidase beta)|1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months
45836102|NCT00197184|Biological|Twinrix™ Adult|Intramuscular injection in the left deltoid, 2 doses, Adult formulation in primary study.
46089195|NCT00642330|Drug|intravenous ibuprofen|one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
46089196|NCT00900029|Biological|No HP802 Treatment|
46089197|NCT00900029|Other|No HP802 Vehicle Treatment|
46089198|NCT02682966|Radiation|Coronary Computed Tomography Angiography|Coronary Computed Tomography Angiography will be performed in all participants
45458940|NCT00924326|Biological|Anti-cluster of differentiation 19 (CD19)-CAR PBL|"Anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) peripheral blood lymphocytes ( PBL).~Day 0 (two to four days after the last dose of fludarabine); Cells will be infused via intravenous (IV) on the Patient Care Unit over 20-30 minutes."
45677374|NCT02007434|Other|Compression Chin Strap|A compression chin strap was applied 15 minutes after dosing for at least 24 hours.
45677375|NCT01987453|Drug|LDV/SOF|Tablet(s) administered orally once daily
45677376|NCT01987453|Drug|RBV|"Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)~Participants in the LDV/SOF+RBV 24 weeks group will dose adjust RBV according to hemoglobin and renal status as stated in the RBV package insert."
46089199|NCT00640770|Device|balloon angioplasty|balloon angioplasty
45677377|NCT02006641|Drug|Placebo|Once daily, matching placebo capsules, orally
46089200|NCT00640770|Device|drug eluting stent|Cypher Select+ Coronary or Infrapopliteal Stent
46089201|NCT00633113|Procedure|MPPA|- Medial Parapatellar Arthrotomy
46089202|NCT00633113|Procedure|SV|- Subvastus Technique
46089203|NCT02681796|Drug|Bupivacaine|
46089204|NCT02842931|Drug|R-DA-EPOCH-21|R-DA-EPOCH-21 treatment without auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
46089205|NCT02842931|Drug|R-DA-EPOCH-21 + auto-SCT|R-DA-EPOCH-21 treatment with auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
45677378|NCT02006641|Drug|Idalopirdine|Once daily, encapsulated tablets, orally
45677379|NCT04416919|Other|Assembled mask|Assembled masks consisting of 3 parts: A facemask (Respironics Performax Whole Face Mask or Hans Rudolph mask naso-oral mask) linked by a blue elbow ( RP Performax SE ELBOW) to a ventilator filter (Teleflex Bacterial/Viral filter 1605 or Iso-Gard HEPA light Filter 28022)
45677380|NCT04652167|Diagnostic Test|PCT|"Serum PCT concentration is quantified with an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas e801. Calibration (BRAHMS PCT LIA assay) is performed once per reagent lot and no later than 24 h after Cobas e pack has been registered in the instrument. Quality control is performed after each calibration."
45836103|NCT00197184|Biological|Twinrix™ Junior|Intramuscular injection in the left deltoid, 3 doses, junior formulation in primary study.
45836104|NCT00198042|Procedure|Surgical reconstruction of the ACL|Surgical reconstruction of the ACL
45342411|NCT01034761|Behavioral|Pop-up alert|Pop-up alert in the electronic medical record whenever the provider enters an order for a specified high risk medication from the Beers list.
45342412|NCT01037491|Drug|rabeprazole plus aspirin versus rabeprazole plus clopidogrel|The primary end point is treatment success (ulcer healing rate). The secondary end point is incidence of ulcer bleeding within 12 weeks.
46003795|NCT04619394|Other|Aquatic exercise - AIPAP program|"Supervised by a midwife with AIPAP method. AIPAP method is divided into 10 sessions of 50 minutes that are repeated cyclically with a total of 120 exercises. The sessions are divided into 5 groups with different objectives: 2 sessions of aerobic capacity improvement, 2 sessions of strength improvement, 2 sessions of pelvic elasticity, 2 coordination sessions and the last 4 sessions of the previous ones.~The beginning of the program will be established in week 10-12 of pregnancy and the end in week 37-41.~The total number of sessions of the program will be 25-31 (28 sessions of minimum compliance), with a frequency of 2 sessions per week. The duration of these will be 50 minutes in both experimental groups. It will be necessary to obtain an adherence to both experimental groups of ≥28 classes."
46003796|NCT00553865|Drug|OJP-2028|Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
46003797|NCT00562770|Drug|Valganciclovir|900 mg (two 450 mg capsules) po QD during therapy and for 2 months post alemtuzumab initiation.
45458941|NCT00924326|Drug|Aldesleukin|Day 0: 720,000 IU/kg intravenously (IV) every 8 hours for a maximum of 15 doses.
45458942|NCT00924326|Drug|Fludarabine|Days -5 to -3 (after administration of cyclophosphamide): 30 mg/m^2 intravenous (IV) over 30 minutes
45458943|NCT00924326|Drug|Cyclophosphamide|Days -5 to -3: 300mg/m^2 intravenous (IV) over 60 minutes
45458944|NCT03496948|Behavioral|TeGeCoach|"12-month long telephone health coaching carried out by specially trained coaches. The health coaching is a patient-centered approach based on motivational interviewing, shared decision-making and active listening techniques. Primary care physicians will be constantly involved receiving regular health reports from the coach.~The walking exercise is based on the principle of interval training. Patients will continuously wear an activity monitor device to review their exercise performance and for remote exercise monitoring by the coach. This activity information will be regularly reviewed by the coach to ensure that the patient adheres to the individual walking exercise prescription."
45458945|NCT03496870|Drug|Opicapone|catechol-O-methyltransferase (COMT) inhibitor
45458946|NCT03496870|Drug|Carbidopa Levodopa|Levodopa: dopamine precursor Carbidopa: DOPA decarboxylase inhibitor
46003798|NCT00562770|Drug|Valacyclovir|500 mg po QD during therapy and for 2 months post alemtuzumab initiation.
45458947|NCT01365572|Device|Xiene V stent, Endeavor Resolute stent|for each lesion, randomized either Xience V stent or Endeavor Resolute stent
45458948|NCT01370096|Drug|Vasopressin infusion|An intravenous infusion of vasopressin will be started at an initial rate of 0.0002U/Kg/min via the side arm of the central venous sheath. The infusion will be titrated up by 0.0001U/kg/min every minute until there has been a 20% increase in invasive mean arterial blood pressure (maximum infusion 0.002U/kg/min) and then the infusion may be titrated to maintain this blood pressure.
45458949|NCT01370096|Drug|Vasopressin infusion and epoprostenol inhalation|An intravenous infusion of vasopressin will be started at an initial rate of 0.0002U/Kg/min via the side arm of the central venous sheath. The infusion will be titrated up by 0.0001U/kg/min every minute until there has been a 20% increase in invasive mean arterial blood pressure (maximum infusion 0.002U/kg/min) and then the infusion may be titrated to maintain this blood pressure. If the target 20% increase in SBP is not achieved with vasopressin titration, the infusion will remain at 0.002U/kg/min. After a period of ten minutes of drug exposure to allow for patient equilibration, subjects will receive nebulized prostacyclin at a dose of 50ng/kg/min for 15 minutes via Aeroneb into the endotracheal tube.
45458950|NCT01361204|Dietary Supplement|Theanine|Taking 4 tablets of theanine two times daily for 16 days
45677381|NCT04652167|Diagnostic Test|suPAR|Serum suPAR was measured using suPARnostic© Turbilatex assay reagents (validated on Cobas© c111) protocol for Cobas© c702 and c502 applying the Multi-Pack cassettes (Roche Diagnostics, Mannheim, Germany). Calibration is performed at least once a month or in connection to a new batch of TurbiLatex reagents, after calibration a quality control is performed.
46003799|NCT05424770|Other|Education with crossword|Afterwards, crossword activities prepared by the researcher will be implemented and students will be actively involved in the process. The researcher will also include a collaborative learning environment where students can exchange information with each other. After the completion of each puzzle, the researcher will make the necessary checks and corrections.
46003800|NCT04619550|Other|High tibial osteotomy|Realignment surgery
46003801|NCT05424692|Drug|5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate|Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
46003802|NCT04618965|Drug|control group|Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
45458951|NCT03131570|Drug|Secukinumab|Arms: Group 1 - Group 1 will receive Secukinumab at a dose of 300 mg with injections administered once weekly at baseline and at weeks 1, 2, 3, and 4 and then every 4 weeks for 6 months of period. In order to maintain the blind for the Group 2, Group 1 will receive placebo injections at weeks 13, 14, and 15. Group 1 will discontinue Secukinumab after 6 months of period being observed from week 25 to week 72 (48 weeks).
45458952|NCT03131570|Drug|Placebo followed by Secukinumab|Arms: Group 2 - Group 2 will receive placebo injections corresponding to the Group 1 regimen until week 8 in order to maintain a double-dummy design until week 12. From week 12, Group 2 will receive Secukinumab with injections administered once weekly at week 12 and at weeks 13, 14, 15, and 16 and then every 4 weeks for 3 months of period. Group 2 will discontinue Secukinumab after 6 months of period being observed from week 25 to week 72 (48 weeks).
45677382|NCT04652167|Diagnostic Test|Standard care|Standard care is the measurement of CRP (C-reactive protein) will be measured with C - reactive protein (CRP4) immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi cobas© systems c701/702. Calibration is performed (Tina-quant® C - reactive protein IV) once per reagent lot and after 6 months using the same reagent lot. Quality control is required after calibration and according manufacturing instructions.
45458953|NCT02930018|Drug|Nerinetide (NA-1), 2.6 mg/kg|Single intravenous infusion of nerinetide over 10 ± 1 minutes
45458954|NCT02930018|Drug|Placebo|Placebo Comparator: Placebo
45458955|NCT01365728|Procedure|LASIK with the iFS femtosecond laser|Patients will undergo bilateral simultaneous LASIK surgery for myopia. One eye will have a LASIK flap created with the Intralase FS60 and the fellow eye will have a LASIK flap created with the Intralase iFS. Both eyes will undergo wavefront-guided LASIK surgery with the Visx CustomVue excimer laser.
45677383|NCT01959919|Device|Refacto FusENGO|Dosage will be chosen by PI based on patient condition.
45683769|NCT04397926|Drug|Individualized neoantigen peptides vaccine|Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks
45683770|NCT01767194|Biological|Dinutuximab|Given IV
45683771|NCT01767194|Drug|Irinotecan Hydrochloride|Given IV
45683772|NCT01767194|Other|Laboratory Biomarker Analysis|Optional correlative studies
46003803|NCT04618965|Drug|Intrathecal dexmedetomidine|Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
46089206|NCT02842931|Drug|R-mNHL-BFM-90|R-mNHL-BFM-90 without auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
46089207|NCT02842931|Drug|R-mNHL-BFM-90 + auto-SCT|R-mNHL-BFM-90 with auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
45683773|NCT01767194|Biological|Sargramostim|Given SC or IV
45683774|NCT01767194|Drug|Temozolomide|Given PO
45683775|NCT01767194|Drug|Temsirolimus|Given IV
46003804|NCT04618965|Drug|Intravenous dexmedetomidine|Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.
45458956|NCT01370720|Dietary Supplement|Recoclix|tablets; 200 mg PEA+20 mg polydatin; 2 tablets/day; 12 weeks
46089208|NCT05663034|Behavioral|Mindfulness-based treatment for insomnia (MBTI)|A 6-week intervention that uses the principles and practices of mindfulness meditation along with behavioral strategies (stimulus control, sleep restriction therapy) to reduce symptoms of insomnia
45458957|NCT01370720|Other|Placebo|tablets, 2tablets/day, 12 weeks
46003805|NCT04618926|Device|Device intubating Laryngeal Tube Suction Disposable|Resuscitation in covid 19 patients
46089209|NCT05663034|Behavioral|Cognitive behavioral therapy for insomnia (CBT-I)|Standard of care for adults with chronic insomnia. 6-week program that uses behavioral techniques to decrease psychophysiological arousal and increase sleep propensity to deepen and consolidate sleep.
45458958|NCT01370798|Drug|promestriene|Promestriene cream 1%, 1g per day during 2 months, cutaneous application
46089210|NCT02842697|Procedure|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter
46089211|NCT02842697|Procedure|CTA|Three-dimensional hepatic vein-portal vein model constructed with CTA images
46089212|NCT02842697|Procedure|Doppler ultrasound|Portal vein velocity measured by Doppler ultrasound
45458959|NCT01370798|Drug|Placebo|Placebo of promestriene cream, 1g per day during 2 months, cutaneous application
45458960|NCT01370798|Procedure|Urethroplasty|Onlay-tube-onlay urethroplasty performed by a physician expert of this technique (at least 5 years of practical ability)
45677384|NCT04176601|Behavioral|Engage coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
45677385|NCT01986985|Device|PET/MRI system|Compared to PET CT
45836105|NCT00201240|Biological|CD34+ selection with CliniMACS device|CD34+ cell selection will be performed according to procedures given in the CliniMACS Users Operating Manual and institutional Standard Operating Procedures (SOPs) in place and validated at the study sites. CliniMACS (Miltenyi device) to target CD34+ >5 x 10*6/kg and CD3+ < 1 x 10*5/kg
45836106|NCT00098670|Biological|alemtuzumab|Given SC
46003806|NCT05424653|Device|Transcatheter Aortic Valve System|Procedure: Transcatheter Aortic Valve Replacement
46003807|NCT01190449|Biological|ofatumumab|Given IV
46089213|NCT04183296|Drug|propofol|Anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
46089214|NCT04183296|Drug|sevoflurane|Anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration [Ce] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
46089215|NCT02842385|Other|Implant|One or two stages of implants within thin and thick gingiva were monitored 1.5 year after placement
46089216|NCT00642408|Dietary Supplement|Multiple micronutrient supplements (MMN)|Iron and folic acid: iron 60 mg and folic acid 400µg
46089217|NCT00642408|Dietary Supplement|IFA|Iron and folic acid (IFA)(iron 60 mg and folic acid 400µg).
46089218|NCT04181580|Device|Made-to-measure compression garment|Made-to-measure compression garment
45458961|NCT01370798|Radiation|Wrist X ray|Wrist X ray to follow the degree of bone maturation
45458962|NCT01370798|Procedure|Blood test|Hormonal dosage: Oestradiol, testosterone, FSH-LH and AMH
45458963|NCT01370876|Drug|Oxaliplatin|Oxaliplatin will be administered as a 2-hour infusion first on Day 1, followed by 5-FU i.v. infusion for 48 hours (Day 1 and Day 2), repeated every 2 weeks, 4 weeks as a cycle.
45458964|NCT01370954|Other|CerefolinNAC®|CerefolinNAC® is an orally-administered medical food, and each caplet contains 2 mg Methylcobalamin, 600 mg N-acetylcysteine, and 6 mg of L-methylfolate Calcium (as Metafolin®), which is the primary biologically active and immediately bioavailable form of folate. Dosage will be 1 caplet QD.
45458965|NCT04327466|Device|Osciflow|Osciflow is a non-invasive high frequency oscillatory ventilation support delivered via a highflow nasal cannula for four hours (one hour wash-out, three hours measurement period).
45458966|NCT04327466|Device|Highflow|Standard highflow therapy without oscillations delivered via a highflow nasal cannula for four hours (one hour wash-out, three hours measurement period).
45458967|NCT05191082|Procedure|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
45458968|NCT05191082|Device|Palatal Wound treated with Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film and 4.0 silk sutures.
45458969|NCT05191082|Device|Palatal Wound treated with Neurotensin-loaded Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film loaded with neurotensin and 4.0 silk sutures.
45458970|NCT04652882|Drug|Tasimelteon|oral capsule
45458971|NCT04652882|Drug|Placebo|oral capsule
45836107|NCT00098670|Biological|rituximab|Given IV
45836108|NCT00098670|Drug|fludarabine phosphate|Given IV
45836109|NCT04098588|Behavioral|BEAST|See Arm Description
45836110|NCT04098588|Behavioral|Descriptive Feedback|See Arm Description
46003808|NCT00562809|Drug|IRBESARTAN|150/12.5 mg tablets one or two tablets orally per day
45677386|NCT01986907|Drug|ranibizumab|All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e. stable VA for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
45677387|NCT01959841|Drug|ASP2151|200 mg once daily or 400 mg once daily
45677388|NCT01959841|Drug|valaciclovir|1000 mg three times daily
45677389|NCT02005627|Drug|Grazax|The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 SQ-T once daily.
45677390|NCT02005627|Drug|Grazax Placebo|This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
45458972|NCT04644536|Device|Bone graft substitute|Orthopaedic or Spine bony defects
45458973|NCT01319630|Device|Sidestream Dark Field (SDF)|"SDF will be applied to the sublingual microvascular network with a 5X objective providing a 167X magnification.~After the removal of saliva and other secretions using gauze, the device will be gently applied (without any pressure) on the lateral side of the tongue, in an area approximately 1.5-4 cm from the tip of the tongue. Five sequences of 20 secs each from different adjacent areas will be recorded using a computer and a video card and stored under a random number for later analysis. This will be done at baseline and then 1 hour after Fluid bolus."
45677391|NCT02104583|Drug|Eleclazine|Eleclazine tablets administered orally
45677392|NCT02104583|Drug|Placebo to match eleclazine|Placebo to match eleclazine tablets administered orally
46003809|NCT01190176|Procedure|Gynaecological follow-up|Subjects will receive a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to a maximum of four years.
46003810|NCT01190176|Biological|Cervarix|Subjects received 3 doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
46089219|NCT02678598|Drug|Micafungin|Intravenous
46089220|NCT02359019|Biological|Pembrolizumab|Given IV
46089221|NCT02359019|Other|Laboratory Biomarker Analysis|Correlative studies
45677393|NCT02074553|Drug|Part 1 (Fasted): Treatment A|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib orally as Treatment A (capsule formulation containing 50% SLS) on Day 1 of any of the four intervention periods in Part 1.
45677394|NCT02074553|Drug|Part 1 (Fasted): Treatment B|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib orally as Treatment B (capsule formulation containing 25% SLS) on Day 1 of any of the four intervention periods in Part 1.
45677395|NCT02074553|Drug|Part 1 (Fasted): Treatment C|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib orally as Treatment C (capsule formulation containing 12.5% SLS) on Day 1 of any of the four intervention periods in Part 1.
45677396|NCT02074553|Drug|Part 1 (Fasted): Treatment D|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib orally as Treatment D (capsule formulation containing 3% SLS) on Day 1 of any of the four intervention periods in Part 1.
45836111|NCT00100230|Drug|docosahexaenoic acid OR corn/soy oil placebo|daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial
45836112|NCT00201864|Drug|Exemestane|25 mg orally per day
46089222|NCT02678364|Dietary Supplement|Control eggs|Control eggs containing no additional vitamin D beyond norm
45836113|NCT00201864|Drug|Fulvestrant|250 mg IM starting on Day 8 and then every 28 days.
46089223|NCT02678364|Dietary Supplement|Vitamin D3 eggs|Vitamin D3-biofortified eggs
46089224|NCT02678364|Dietary Supplement|25-Hydroxyvitamin D3 eggs|25-Hydroxyvitamin D3-biofortified eggs
46089225|NCT02840123|Biological|Autologous dendritic cells|
46089226|NCT04182594|Drug|Degarelix|Treatment will start with two injections of 120 mg each followed by maintenance of a single injection of 80 mg administered every 28 days
46089227|NCT04182594|Drug|GnRH agonist|GnRH agonist at the discretion of the treating Urologist/Oncologist for 1 year
46089228|NCT05334875|Diagnostic Test|Electroretinogram (ERG)|Applying electrodes to assess retinal function
46089229|NCT05334875|Diagnostic Test|Visual evoked potential (VEP)|Applying electrodes to assess visual pathway function
46089230|NCT04181814|Device|Ultrasound|Use ultrasound to assess gastric contents in diabetic patients before anesthesia
45836114|NCT00202722|Drug|Remifentanil|Intravenous patient controlled analgesia (ivpca) during labour
46003811|NCT01190176|Biological|Placebo control|Subjects received 3 doses of the control [Al(OH)3] administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
46003812|NCT04206280|Behavioral|Use of a pedometer following surgery|Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.
46003813|NCT04206280|Behavioral|Standard of care|Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
46089231|NCT05334173|Procedure|Roux-en-Y Gastric Bypass (RYGB) measuring the lengh of the common limb|The patients are randomized to Type 1 laparoscopic RYGB (150cm alimentary limb and 70cm biliopancreatic limb) or type 2 laparoscopic RYGB (70cm alimentary limb and 150cm biliopancreatic limb). In both groups, the total intestinal length is measured to determine the size of the common limb. We introduce a 10 cm ruler into the abdominal cavity to measure the bowel and then extract it. LRYGB is made with linear stapler anastomosis.
45677397|NCT02074553|Drug|Part 2 (Fed): Treatment A|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after the start of the meal will receive 600 mg of alectinib orally as Treatment A (capsule formulation containing 50% SLS) on Day 1 of any of the four intervention periods in Part 2.
45677398|NCT02074553|Drug|Part 2 (Fed): Treatment B|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after the start of the meal will receive 600 mg of alectinib orally as Treatment B (capsule formulation containing 25% SLS) on Day 1 of any of the four intervention periods in Part 2.
46089232|NCT02678208|Drug|Tranexamic Acid|
46089233|NCT02678208|Drug|5% glucose|
46089234|NCT02837861|Drug|Routine Nutritional Support plus supplemental IV amino acids|Enteral nutrition as tolerated Plus supplemental IV AA infusion to meet the target of approximately 1.5-2.0gm protein/kg/day total starting within 24 hours of injury for 5 days.
45677399|NCT02074553|Drug|Part 2 (Fed): Treatment C|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after the start of the meal will receive 600 mg of alectinib orally as Treatment C (capsule formulation containing 12.5% SLS) on Day 1 of any of the four intervention periods in Part 2.
45677400|NCT02074553|Drug|Part 2 (Fed): Treatment D|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after the start of the meal will receive 600 mg of alectinib orally as Treatment D (capsule formulation containing 3% SLS) on Day 1 of any of the four intervention periods in Part 2.
46089235|NCT02837861|Other|Routine Nutritional Support|Enteral nutrition as tolerated.
45677401|NCT02073929|Drug|Liraglutide for 26 weeks|GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks
46089236|NCT00643266|Behavioral|Recollection Training|"Participants are exposed to long lists of words. Each word is presented either visually or auditorily, and each word is repeated after a variable number of intervening words (the lag), in each the same modality, or the other modality. Participants are instructed to respond yes only to words repeated in the same modality. If a performance criterion is met, the lag is increased for the next session; if the performance criterion is not met, the same lag is repeated in the next session."
46089237|NCT00643266|Behavioral|Control|Participants view PowerPoint presentations on various topics related to memory and aging (e.g., structural brain changes, diet, stress, depression) and how each of these topics affect memory, and after each presentation, play a Jeopardy-like game to test their knowledge gain
45677402|NCT02073929|Drug|placebo|Placebo s.c. daily for 26 weeks
45677403|NCT02113007|Drug|Rituximab plus Temozolomide|Treatment cycles will be repeated every 14 days (2 weeks) for the lead-in portion. If no prohibitive toxicities are observed in the first 6 patients during the first 2 treatment cycles, the study will continue enrolling patients. Treatment cycles for the Phase II portion will be repeated every 14 days (2 weeks) for a total of 12 cycles.
45677404|NCT02005471|Drug|Bendamustine|Bendamustine will be administered at a dose of 70 mg/m^2 via IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
45677405|NCT02005471|Drug|Venetoclax|"Venetoclax will be administered at an initial dose of 20 mg via tablet orally QD, incremented weekly up to a maximum dose of 400 mg during a 5-week ramp-up period. Venetoclax will be continued at 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to disease progression (PD) or 2 years, whichever occurs first.~R/C Substudy: venetoclax will be administered for 5-week dose ramp-up period to reach the target dose of 400 mg QD. Venetoclax will continue to be administered during the rituximab cycles until disease progression or for a maximum of 2 years from Cycle 1R/C Day 1 of the R/C Substudy."
46003814|NCT04618848|Diagnostic Test|Fingerstick blood draw|Each participant shall be pricked twice in order to perform CBC test
46003815|NCT04316065|Drug|YHP1906|YHP1906 Tab. 5 mg
46089238|NCT05551182|Drug|Nicergoline|The participants in both arms will receive nicergoline for treatment dysphagia 12 weeks.
46003816|NCT04316065|Drug|YHR1902|Comparator. YHR1902 Tab. 5 mg
46003817|NCT01190098|Drug|Lacosamide|"Subjects randomized to lacosamide according to the following schedule:~Treatment Phase Week Dose Week 1 LCM 50 mg bid Week 2 LCM 100 mg bid Week 3 LCM 150 mg bid Week 4 LCM 200 mg bid"
46003818|NCT01190098|Drug|Placebo|Placebo will be packaged identically to experimental drug and titrated according to the same schedule.
46003819|NCT04618887|Procedure|pallidotomy|deep brain nuclei lesion of GPi
46003820|NCT04618887|Procedure|deep brain stimulation|deep brain stimulation of GPi
46089239|NCT02676102|Behavioral|Control Group|Generic Video about organ donation
46089240|NCT02676102|Behavioral|Targeted Intervention|an educational video produced in partnership with the community of black men including customers, employees, and owners of BOBs. Video production was informed by entertainment education models and produced with experts including an Academy Award winning filmmaker.
46089241|NCT02676102|Behavioral|Tailored Intervention|Videos with content individualized to participant's pre-intervention Organ Donation Belief Index (ODBI).
46089242|NCT02842541|Drug|EBI-031|
46089243|NCT02678130|Device|InterFuse T|Transforaminal Lumbar Interbody fusion (TLIF)
46089244|NCT02678130|Device|Standard of Care TLIF (Stryker AVS Unilif)|Transforaminal Lumbar Interbody Fusion (TLIF)
46003821|NCT05312593|Other|Aftoral Oral Gel|Patients will use Aftoral® Oral Gel solution for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after gel solution application).
46003822|NCT05312593|Other|Unidea Chlorhexidine mouthwash|Patients will use chlorhexidine mouthwash 0,20% for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after mouthwash application).
45677406|NCT02005471|Drug|Rituximab|"Rituximab will be administered at a dose of 375 mg/m^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m^2 on Day 1 of Cycles 2-6.~R/C Substudy: Following the venetoclax ramp-up period, rituximab will be administered for 6 cycles consisting of a single infusion on the first day of each 28-day cycle."
45677407|NCT02104505|Drug|Gamma Tocopherol 700 mg capsules,|2 capsules daily
46003823|NCT02885857|Drug|Shenyan Kangfu Tablet|Observation period: 24 weeks. The dosage regimen: each piece weighs 0.48 g. 5 / time, 3 times daily, orally after dinner.
46089245|NCT04204733|Behavioral|Mobile application|Mobile application that incorporates biosensor feedback, teleconsultation, and online group physical activity classes
46089246|NCT00642486|Other|Portable (Embla Embletta X30 system and Respironic REMStar Auto M series with CFlex)|portable, home-based using the Embla Embletta X30 system as the diagnostic device and the Respironic REMStar Auto M series with CFlex as the PAP titration device.
45677408|NCT02104505|Drug|Placebo|Safflower oil capsules
45677409|NCT02111993|Device|Standard Defibrillation Testing|Once the ICD is implanted, Standard Defibrillation Threshold (DFT) testing will begin. A low energy shock will be delivered to the heart at the peak of the T wave to induce ventricular fibrillation (VF). Once VF is induced, a rescue shock of 25J will be delivered to restore sinus rhythm. This process will be repeated once more after 5 minutes.
45677410|NCT02111993|Device|Upper Limit of Vulnerability Testing|Once the ICD is implanted, Upper Limit of Vulnerability (ULV) testing will commence. An 18 J shock will be delivered will at different points from the t-wave. If VF is not induced with any of these shocks, then the ULV will be considered to be 18J. If VF is induced, then a 25 J rescue shock will be delivered.
45677411|NCT01959607|Other|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
45677412|NCT01959607|Other|CC|Single use of subject's own cigarette (CC)
45677413|NCT01959607|Other|NRT Gum|Single administration of the nicotine replacement therapy (NRT) 2 mg gum (Nicorette® 2mg)
46003824|NCT04314739|Dietary Supplement|Resveratrol|Participants will consume one of the treatment types daily for a period of four weeks.
45677414|NCT04186325|Procedure|DIAPHRAGMATIC exercising|inspiratory muscle training (IMT) will be initiated starting from the first ICU day. IMT will be conducted for 10 minutes two sessions per day, with an initial load of 30% of the maximum inspiratory pressure (MIP) measured immediately after changing patients to pressure support mode, and increased up to 40% in the second 5 minutes if tolerated by the patient. In addition, these patients received the usual care of MV patients.
45677415|NCT02111603|Drug|Colesevelam|Subjects will receive 1875 mg of Colesevelam orally twice daily for 10 days
46003825|NCT04314739|Dietary Supplement|Placebo|Participants will consume one of the treatment types daily for a period of four weeks.
46003826|NCT00562848|Drug|GSK962040|GSK962040 will be supplied in the following tablet strengths: 1 milligram, 5m milligrams, 25 milligrams, 125 milligrams.
46003827|NCT00562848|Drug|Placebo|Subjects will receive placebo.
46089247|NCT00642486|Other|Standard polysomnography (PSG)|laboratory-based testing
45677416|NCT04186169|Procedure|Catheter ablation|Catheter ablation
45677417|NCT04725851|Procedure|High concentration Oxygen therapy|FiO2 >80% Oxygen (Delivered with 12-15L/min Non-rebreather Mask)
46089248|NCT05334095|Device|Perclose ProGlide|After peripheral vascular diagnostic and interventional procedures, patients are randomized to receive Perclose ProGlide.
45677418|NCT04725851|Procedure|Control: Room Air or Low concentration Oxygen|FiO2 <30% Oxygen (Delivered with 0-2L/min Nasal Cannula)
46089249|NCT05334095|Device|Angio-seal VIP|After peripheral vascular diagnostic and interventional procedures, patients are randomized to receive Angio-seal VIP
46089250|NCT02842307|Procedure|Manual acupuncture implemented by senior acupuncturists|Manual acupuncture once per day. No limitation on points, manipulations and time per session. Senior acupuncturists have to have more than 15 years of acupuncture clinical practice experience.
46089251|NCT02842307|Procedure|Manual acupuncture implemented by junior acupuncturists|Manual acupuncture once per day. No limitation on points, manipulations and time per session. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
46089252|NCT02842307|Procedure|Manual acupuncture on P6 point|Manual acupuncture implemented by junior acupuncturists once per day. P6 point, bilaterally, should achieve deqi sensation by even manipulations. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
45836115|NCT00100698|Drug|recombinant human growth hormone|growth hormone dosed by weight and IGF-1 level,subcutaneously once a day, 18 months
45836116|NCT00100698|Drug|placebo|placebo subcutaneously once a day, 18 months
45836117|NCT00103116|Biological|autologous dendritic cell cancer vaccine|"Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure.~Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part."
46003828|NCT02885740|Other|Quantification assay of adenosine and methionine cycle metabolites|
46003829|NCT02885740|Genetic|Polymorphism analysis of genes related to adenosine metabolism and methionine cycle|
46003830|NCT02885740|Other|Quantitative and qualitative nutritional evaluation|Questionnaire on consumption of 208 foods and drinks
46003831|NCT02885740|Biological|Blood sample|
46003832|NCT05309785|Drug|Invokana 300 mg and 100 mg tablet|"Substudy 1 Patients who fulfill the inclusion criteria and consent to participate will receive canagliflozin 100 mg po daily for 12+2 weeks (phase 1). For participants who have tolerated the drug, canagliflozin will be increased to 300 mg po daily for an additional 12+2 weeks (phase 2) and then stopped. If not tolerated, the dose will be reduced to 100 mg until the end of follow-up.~Each phase of 12 weeks is followed by a 2-week window to ascertain surrogate efficacy outcomes.~Substudy 2 Patients who fulfill the inclusion criteria and consent to participate will receive canagliflozin 100 mg po daily for 9 days."
46003833|NCT00562926|Procedure|Extraction of 10ml blood sample for extraction of genomic DNA using DNA purification kits|
45677419|NCT02102399|Behavioral|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
46003834|NCT01190020|Drug|Lubiprostone|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
45836118|NCT00205374|Drug|Cidofovir|With regard to cidofovir concentration, the FDA has allowed us to inject a concentration of 5 mg/ml into both children and adults. The injection will add less than 2 additional minutes to the surgery time and discharge time will not be affected. Because the volumes of cidofovir injected into the airway will be reasonably small (typically less than 2 mL), the total systemic dose of cidofovir administered per visit will be far below the FDA-approved systemic limit of 5 mg/kg for HIV-related CMV retinitis.
46003835|NCT01190020|Drug|Lubiprostone Control|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
46003836|NCT01189435|Drug|erlotinib|After baseline evaluation, patients will initiate treatment with erlotinib 150 mg daily, or at maximum previous tolerated dose. Initial response assessment will be done during the fourth week of therapy, during the eighth week of therapy, and then every 8 weeks thereafter. Patients will continue on therapy until disease progression by RECIST.
45677420|NCT02102399|Behavioral|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
45677421|NCT02111369|Drug|Propranolol|After a discussion of the risks and benefits of propranolol therapy, the patient will then be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times daily (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile.
45473914|NCT01175681|Procedure|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper arm ischaemia, which was induced by an automated cuff -inflator placed on the right upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated. There was a 5- to 10-min interval between completion of the remote ischaemic preconditioning protocol and initiation of bypass.Control patients had a deflated cuff placed on the right upper arm for 30 min.
45836119|NCT00205374|Drug|Placebo|On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
45836120|NCT00103194|Drug|lapatinib ditosylate|Given PO
45836121|NCT00103194|Other|laboratory biomarker analysis|Correlative studies
45836122|NCT00277446|Drug|Soy isoflavones|
45836123|NCT00278538|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
45473915|NCT03863093|Device|Electro Medical Systems AIRFLOW®|An erythritol powder will be used by Electro Medical Systems AIRFLOW® and then Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
45677422|NCT02111369|Procedure|Botulinum Toxin|At the second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
45677423|NCT02111213|Behavioral|Virtual Advisor|The virtual advisor is named Carmen. She is an animated, computer-generated figure that speaks to participants and gives advice and support for physical activity.
45677424|NCT02111213|Behavioral|Promotora for physical activity|A promotora is a trained, lay health worker. Promotoras will be trained and supervised to provide advice, support and guidance to people to encourage them to be more physically active. They work with people face to face and by telephone to offer support and advice.
45836124|NCT00208026|Drug|Pimecrolimus 1% Cream|Open label single arm
45836125|NCT00208494|Device|Total Hip Replacement|Total hip replacement
45836126|NCT00208494|Device|Total hip replacement|Total hip replacement
45836127|NCT00106392|Drug|Tacrolimus|oral
46003837|NCT05424614|Other|Functional outcome follow-up of patients|Patients were followed up by telephone after discharge, every 4 weeks, until the end of the 3-month follow-up. Their functional status was determined based on the MRS score (modified Rankin Scale). Those with less than 3 points were defined as having a good prognosis, and those with more than 3 points were defined as having a poor prognosis
46003838|NCT05306158|Other|CC+ECIG Condition|Participants will push CC- and ECIG-related pictures.
46003839|NCT05306158|Other|CC Condition|Participants will push CC-related images and push and pull ECIG-related pictures equally often.
45473916|NCT03863093|Device|Electro Medical Systems Piezo|Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
45836128|NCT00106392|Drug|Placebo|oral
45836129|NCT00211692|Drug|consensus interferon (Interferon Alfacon-1) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
46003840|NCT05306158|Other|Sham Condition|Participants will pull and push CC- and ECIG-related pictures equally often.
46003841|NCT04619043|Device|Ankle Orthotic|
45677425|NCT04736303|Device|BIS|The implementation of BIS monitoring
45677426|NCT02110901|Drug|PRT-201|
45677427|NCT02110901|Drug|Placebo|
45677428|NCT02070965|Drug|DFD01 Spray|
45677429|NCT02070965|Drug|Comp01 Lotion|
45677430|NCT02109107|Device|Erchonia EZ6 Laser|The Erchonia EZ6 is administered 6 times across 6 consecutive weeks, each administration seven days apart, each treatment lasting 60 minutes.
46003842|NCT05304286|Behavioral|Acceptance and Commitment Therapy|The aim of ACT is to address avoidance behaviors by increasing openness to difficult experiences, such as pain, and to develop an awareness of behavioral options that will aid to facilitate behavior change processes that are in accord with living a values-based life.
45677431|NCT02100839|Drug|AEM-28|Solution for injection
46003843|NCT01165996|Other|flow cytometry|Correlative studies
46003844|NCT01165996|Other|DNA methylation analysis|Correlative studies
46003845|NCT01165996|Other|cytogenetic analysis|Correlative studies
45677432|NCT02100839|Drug|Normal Saline|0.9% saline for injection
45677433|NCT02069093|Drug|Dexamethasone based mouthwash|Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone.
45677434|NCT02069093|Drug|Everolimus|Commercially available everolimus 10 mg was prescribed to participants by the Investigator according to local regulations.
45473917|NCT03375034|Drug|NDMC 20mg|Oral administration of one NDMC 20mg capsule and two Placebo capsules
45677435|NCT02069093|Drug|Exemestane|Commercially available exemestane 25 mg was prescribed to participants by the Investigator according to local regulations.
45677436|NCT02109029|Drug|Insulin Peglispro|Administered IV
45677437|NCT02109029|Drug|Human Insulin|Administered IV
45677438|NCT02069015|Behavioral|Patient education|Patient education on hypertension delivered through a touchscreen kiosk.
45677439|NCT04734977|Device|High-intensity laser therapy (HILT)|High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of four weeks, and one session per day for a total of 20 sessions. A 3-phase treatment program was performed in each session.
45677440|NCT04734977|Device|Sham high-intensity laser therapy (Sham HILT)|Sham High intensity laser therapy was applied in five sessions a week for four weeks, with a total of 20 sessions a day, with no current flowing through the device using a HIRO 3 device (ASA Laser, Arcugnano, Italy).
45677441|NCT04734977|Other|Therapeutic Exercise|"As therapeutic exercise program; active cervical ROM, cervical isometric and progressive (self-exercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises.It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes.~Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
45677442|NCT01598129|Genetic|ONCOS-102|GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.
45677443|NCT04185935|Other|Biospecimen Collection|Provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue
45677444|NCT04185935|Other|Questionnaire Administration|Ancillary studies
45836130|NCT00211692|Drug|Consensus Interferon alfa (CIFN) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
45836131|NCT01899690|Drug|antibiotic|Patients after breast reconstruction with implant/tissue expander reconstruction who receive the intervention will be prescribed with a 7 day course of postoperative antibiotics.
45836132|NCT04378140|Other|zirconia wing bridge|The zirconia wing bridge consists of an artificial tooth made out of zirconia and porcelain on the front side with two zirconia wings that are bonded (glued) onto the back of the two adjacent teeth in the patient's mouth.
45836133|NCT01897584|Other|inverse IE|in only one group changes of I:E ratio would be applied
45836134|NCT01899846|Drug|Hydroxyprogesterone caproate 250 mg/ml|
45836135|NCT00214890|Drug|Tenofovir|300 mg once daily
45836136|NCT00214890|Drug|Abacavir|600 mg once daily
45836137|NCT00216060|Drug|Risedronate|Daily oral risedronate combined with androgen deprivation
46003846|NCT01165996|Drug|decitabine|Given subcutaneously
46003847|NCT01165996|Genetic|microarray analysis|Correlative studies
46003848|NCT01165996|Genetic|gene expression analysis|Correlative studies
45677445|NCT02068547|Biological|locally harvested autograft, demineralized bone matrix, and cadaveric allograft|
45677446|NCT02068547|Biological|Bone Marrow Aspirate|
46003849|NCT01165996|Other|pharmacological study|Correlative studies
45677447|NCT02108951|Drug|Nilotinib|Nilotinib 150mg hard gelatin capsules taken orally
45677448|NCT02107859|Drug|Ataluren|Ataluren will be administered per dose and schedule specified in the arm.
45677449|NCT02007278|Drug|vildagliptin and metformin (combination)|vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid
45677450|NCT02007278|Drug|glimepiride|
45677451|NCT02007278|Drug|Metformin|
46003850|NCT01165996|Genetic|polymorphism analysis|Correlative studies
45677452|NCT02107313|Drug|Fed Cohort PBT2|PBT2 250 mg is administered orally following a period of fasting for 10 hours and a high fat breakfast.
45473918|NCT03375034|Drug|NDMC60mg|Oral administration of three NDMC 20mg capsules
45677453|NCT02107313|Drug|Fasted Cohort PBT2|PBT2 250 mg is administered orally after a period of fasting of 10 hours and without food
45677454|NCT04740827|Drug|Atogepant 60 mg|Tablets containing 60 mg of Atogepant
45677455|NCT04740827|Drug|Placebo|60mg tablets containing Atogepant matching placebo
45677456|NCT02028338|Combination Product|placebo ring|intravaginal ring silicone elastomer intravaginal ring containing no drug product
46003851|NCT04619433|Drug|Camrelizumab;Pemetrexed and Carboplatin; Famitinib;|"Part 1:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib~Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib"
46003852|NCT04619433|Drug|Camrelizumab;Pemetrexed and Carboplatin;Placebo|"Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo"
45677457|NCT02028338|Combination Product|dapivirine ring|intravaginal ring silicone elastomer intravaginal ring containing 25 mg dapivirine
45677458|NCT05089487|Procedure|Nocturnal rest (sleep study)|Proportion of patients free of severe hypoxemia without oxygen therapy during nocturnal rest .
45677459|NCT01625897|Drug|MP-214|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg or 6mg) of MP-214 for four weeks, then flexible dose (1.5-9mg) of MP-214
45677460|NCT01625897|Drug|Risperidone|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (4mg) of risperidone for two weeks, then flexible dose (2-12mg) of risperidone
45677461|NCT02106923|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
46003853|NCT02886871|Behavioral|Step Goal Delivery by Smartphone|
46003854|NCT05424536|Other|Bone measurement by DXA and ultrasound|Measurement will be performed at radius and at tibia (ultra-distal and distal). For all the sites plus femoral neck, one measurement will be performed by DXA to get reference values of thickness and BMDs. For the distal positions and additional measurement will be performed by an innovative ultrasound device that estimates cortical thickness and porosity.
46003855|NCT04652388|Behavioral|Nutritional counseling|Nutritional counseling about mediterranean diet
46003856|NCT04619160|Drug|Propofol|TCI 4 µg/mL start until BIS-value of 50
46003857|NCT04619160|Drug|Sevoflurane|start 1 MAC, until BIS-value of 50
45677462|NCT02106923|Drug|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
46003858|NCT01165684|Drug|insulin aspart|"Insulin aspart added stepwise according to the largest meal following an evaluation of HbA1c.~Doses individually adjusted."
45677463|NCT02106923|Drug|1 tablet 10 mg Empagliflozin/3 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets
45677464|NCT02106923|Drug|2 tablets 5 mg Empagliflozin/750 Metformin XR|Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets
45677465|NCT02106923|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
45677466|NCT02106923|Drug|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
45677467|NCT02006732|Drug|olodaterol|fixed dose combination
45677468|NCT02006732|Drug|tiotropium|fixed dose combination
45677469|NCT02006732|Drug|placebo|
45677470|NCT02098733|Drug|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
45677471|NCT02028182|Biological|Lyral®|Alergen panel containing ascending doses of Lyral (0.10 mg/cm^2, 0.20 mg/cm^2 and 0.40 mg/cm^2) and negative control
45677472|NCT04684472|Biological|Modified anti-CD19 CAR T cells|intravenous infusion
45677473|NCT02098109|Drug|XM02 Filgrastim|
45677474|NCT02098109|Drug|Filgrastim|
45677475|NCT02098109|Procedure|Apheresis|
45677476|NCT02098109|Drug|Plerixafor|
45677477|NCT02098109|Procedure|Stem Cell Transplant|
46003859|NCT01165684|Drug|insulin aspart|Insulin aspart added before each main meal. Doses individually adjusted.
46003860|NCT01165684|Drug|insulin detemir|Insulin detemir as basal insulin, adminstered once daily. Doses individually adjusted.
46003861|NCT04618731|Diagnostic Test|caries prevalence def ,DMF|the examination will carried out on dental chair using diagnostic set
46003862|NCT01189201|Drug|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A1)
46003863|NCT01189201|Drug|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
46003864|NCT01189201|Drug|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
46003865|NCT01189201|Drug|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
46003866|NCT04652466|Device|farukcicekci2|To compare the incidence of for I-Gel malposition between USG and FOB, and to find the correlation between I-Gel's USG and FOB-detected malposition
46003867|NCT05424497|Other|Vignettes|Presenting vignettes with fictive cases
46003868|NCT01188967|Drug|GSK598809|Oral dose of 60 mg/day for a treatment period six weeks
45677478|NCT02097719|Drug|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
46003869|NCT01188967|Drug|Placebo|Placebo
46003870|NCT04316728|Device|VivaDiag™ COVID-19 lgM/IgG Rapid Test|VivaDiag™ COVID-19 lgM/IgG Rapid Test is an in vitro diagnostic for the qualitative determination of COVID-19 IgM and IgG antibodies in human whole blood (from vein or fingertip), serum or plasma
45677479|NCT02097719|Drug|travoprost 0.004%|Travoprost 0.004% administered to both eyes once daily for 12 weeks.
45677480|NCT02097719|Drug|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
46003871|NCT04652271|Procedure|Pancreatic surgery|Open, laparoscopic or robotic surgery of the pancreas
46003872|NCT02885935|Other|Recommended protein intake|Recommended protein intake diet contained 10% protein, 55% carbohydrate,and 35 % fat.
46003873|NCT02885935|Other|Elevated protein intake|Recommended protein intake diet contained 20% protein, 45% carbohydrate,and 35 % fat.
45677481|NCT02097719|Drug|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
46089253|NCT02681016|Device|"DES Calypso"|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
45677482|NCT01449370|Drug|TAK-117|oral administration of TAK-117, daily and intermittent schedules.
46003874|NCT05424458|Procedure|Anterior Implant Treatment|Patients received routine examinations before surgery. The surgical procedures were performed by experienced experts. Immediate loading protocol was delivered if the insertion torque was over 35 N·cm; otherwise, removable restorations with submerged implants were applied. After a healing period of 3 to 6 months, a definitive screw-retained porcelain-fused-to-metal (PFM) or a CAD/CAM zirconia restoration were performed.
45677483|NCT04724369|Drug|18F-MFBG|Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
46003875|NCT04618380|Diagnostic Test|bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity|"The following clinical indexes are evaluated:~Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance~Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and~Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS).~All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD.~Contrast sensitivity are evaluated with the Pelli-Robson test."
45677484|NCT02067533|Procedure|soft tissue repair in flexion position|
46003876|NCT05424107|Other|KIDMED|Pre-and post-intervention evaluation of the adherence to the Mediterranean diet and its effect on prediabetic state, as well as, other anthropometric values.
45677485|NCT02067533|Procedure|soft tissue repair in extension position|
45836138|NCT00216060|Drug|Placebo|Daily oral placebo combined with androgen deprivation
45677486|NCT02066129|Drug|Fluticasone 44 mcg|Fluticasone is an inhaled corticosteroid
45677487|NCT02066129|Drug|Fluticasone 220 mcg|Fluticasone is an inhaled corticosteroid
45836139|NCT00106938|Device|Carotid artery stenting with filter (interventional)|Carotid artery stenting with filter (interventional)
45836140|NCT00106938|Procedure|Carotid artery endarterectomy (surgical)|Carotid artery endarterectomy (surgical)
45836141|NCT02100072|Device|Nd:YAG 1440 nm laser|
45836142|NCT00110136|Drug|St. John's Wort|St. John's Wort 300mg tablet three times per day
45836143|NCT00282282|Drug|tacrolimus|Given orally just prior to and following stem cell transplant
45836144|NCT00282282|Drug|sirolimus|Given orally just prior to and following stem cell transplant
45836145|NCT00282282|Drug|fludarabine|Given once daily over 30 minutes for 4 days
45836146|NCT00282282|Drug|busulfex|Given intravenously over 3 hours for 4 days
45836147|NCT00282672|Device|Ablation System plus anti-secretory medication|Treatment group subjects undergo up to 4 ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI).
46003877|NCT04652232|Other|RV3466F lotion|"Code: RV3466F Formula: MF5354~Application modalities:~3 times per week, in the evening, on a dry scalp 10 sprays overall hair after having achieved hair rays in order that the product is in contact with the scalp. Then massage to promote penetration of the lotion. Don't rinse.~Shampoo should be avoided within the 2 hours after application"
46003878|NCT04652232|Other|Shampoo|"Associated neutral shampoo: Extra mild shampoo Ducray® Code: RD0057H Formula: VS4031~Application modalities:~as often as usual~For the treated group only : no shampoo within the 2 hours after lotion application"
46003879|NCT04652349|Drug|HGP1910|Take it once daily for 8 weeks orally.
45677488|NCT02066051|Device|IPL|Intense Pulsed Light (IPL) treatment from Quadra Q4 Platinum Series, made by DermaMed Solutions. With the eyes patched closed the IPL was applied to the surface of the skin by the way of a hand-held wand in 30 spots over the skin in the lower lid, cheek area, and nose area starting and ending from in front of each ear.
46003880|NCT04652349|Drug|HCP1903|Take it once daily for 8 weeks orally.
46003881|NCT04652349|Drug|HGP1909|Take it once daily for 8 weeks orally.
46003882|NCT04652349|Drug|HGP1911|Take it once daily for 8 weeks orally.
46003883|NCT01188811|Drug|lipoic acid|1200 mg taken by mouth daily starting on day one of the study and ending on the last day of study participation.
46003884|NCT01188811|Drug|Placebo|The placebo comparator will be taken by mouth daily starting on day one of the study and ending on the last day of study participation
46003885|NCT05423990|Diagnostic Test|Video-Electroencephalography|Three types of video EEG monitoring equipment produced by Nicolet, Bio-logic and Nihon Kohden were used to collect data in the multi-center. The 19-lead recording electrode was placed according to the international 10-20 system, and the average lead was used. The recording time was 24h. All patients underwent eyes open and closed test, intermittent photic stimulation and hyperventilation induction test.
46003886|NCT01183234|Drug|SPD544|two 30mg capsules, single oral dose
46003887|NCT01183234|Drug|Methylphenidate hydrochloride|one 60mg capsule, single oral dose
46003888|NCT04618497|Drug|Methoxyflurane|Each patient in the methoxyflurane group will use one Penthrox inhaler under supervision of trained personnel. After priming the inhaler with 3 mL of methoxyflurane, patient is instructed to inhale through the mouthpiece to obtain analgesia, and then exhale back into the mouthpiece so that any unmetabolized methoxyflurane can be adsorbed by activated charcoal chamber. First few breaths should be gentle and then breathe normally through Inhaler. Onset of pain relief is rapid and occurs after 6-10 inhalations. If stronger analgesia is required, patient can cover the diluter hole with a finger during inhalation. Patients are able to titrate the amount of methoxyflurane inhaled and should be instructed to inhale intermittently to achieve adequate pain control.
46003889|NCT04618497|Drug|Ketorolac|Each patient in the ketorolac group will receive one dose of 30mg intramuscular ketorolac injected at gluteal muscle by nursing staff as usual daily practice.
46003890|NCT05423873|Other|Gentle Cleansing Lotion, Revision Skincare|Gentle cleansing lotion to be used by study participants twice daily
46003891|NCT04618575|Drug|Ursodeoxycholic acid combined with total glucosides of paeony|Ursodeoxycholic acid combined with total glucosides of paeony
46003892|NCT04618575|Drug|Ursodeoxycholic acid only|Ursodeoxycholic acid only
46003893|NCT04679948|Drug|Drug Cocktail consisting of caffeine, warfarin, omeprazole and midazolam|Reference Treatment R
46003894|NCT04679948|Drug|BI 730357|BI 730357, Test treatment T
46003895|NCT04618419|Diagnostic Test|internal jugular vein distensibility index|It is a prospective observational clinical study to correlate hemodynamic monitoring between Electrical Cardiometry and internal jugular vein distensibility index by sonogram
46003896|NCT04680338|Diagnostic Test|CMR stress perfusion imaging|CMR stress perfusion imaging with feedback of clinically actionable findings to general practitioner and participant
46003897|NCT04618536|Other|Inorganic sunscreen|Inorganic sunscreen will be applied evenly to 2 areas on the back of the subject with a 1 cc syringe and gloved finger in an amount of 2 mg / cm2. In the first session, one area will be irradiated 20 minutes after sunscreen application. In the second session, the other area will be irradiated after the subject has swam for 1.5 hours.
45677489|NCT02066051|Procedure|Meibomian Gland Expression|After the IPL was applied, the eyes were numbed for 15 minutes with a numbing drop, and a sterile cotton swab was used to squeeze the eyelids and express clogged oil secretions from the miebomian glands.
45677490|NCT01980992|Drug|Wheat OIT|Vital Wheat Gluten dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
46003898|NCT04618536|Other|Organic sunscreen|Organic sunscreen will be applied evenly to 2 areas on the back of the subject with a 1 cc syringe and gloved finger in an amount of 2 mg / cm2. In the first session, one area will be irradiated 20 minutes after sunscreen application. In the second session, the other area will be irradiated after the subject has swam for 1.5 hours.
46003899|NCT04679987|Diagnostic Test|Holter ECG|all patients will be monitored for paroxysmal Af by holder ECG
46003900|NCT05423795|Other|Telemedicine-based intervention|Telemedicine-based intervention Multifaceted intervention including daily videoconferences with audit and feedback, educational interventions, and dissemination of published works
45677491|NCT04085068|Other|cranioscaral treatment|dural release
45677492|NCT02065895|Device|HIGH error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 1.33 times the true glucose value (analogous to higher gain lower target).
46003901|NCT05423795|Other|Standard of care arm|Classic expertise (as routinely performed in the participating ICU)
46003902|NCT05423561|Procedure|exchange nailing with larger, thicker nail crossing corticalization|exchange nailing with larger, thicker nail crossing corticalization
46003903|NCT04651959|Drug|AVICOD 200 MG Film Tablet|AVICOD is containing 200 mg favipiravir manufactured by Pharma Plant,Turkey.
45458974|NCT01319630|Device|Near Infrared Spectroscopy (NIRS)|Tissue oxygen saturation (StO2) will be measured by a tissue spectrometer, a noninvasive tool, which uses reflectance mode probes to measure scattering light reflected at some distance from where the light is transmitted into the tissue. The NIRS probe will be placed on the skin of the thenar eminence and a sphygmomanometer cuff will be wrapped around the arm over the brachial artery. After a 3-min period to stabilize the NIRS signal, arterial inflow will be stopped (VOT) by inflating the cuff to 50 mmHg above the systolic arterial pressure. After 3 min of ischemia, cuff pressure will be released, and StO2 recorded continuously for another 3 min period (reperfusion period=Reactive Hyperemia).This will be done at baseline and then 1 hour after fluid bolus.
45458975|NCT04230824|Dietary Supplement|Pre-workout plus and Protein recovery plus|products consumed prior and after exercise
45677493|NCT02065895|Device|NO error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL and glucose-value-used-for-control equal to the true glucose value.
45677494|NCT02065895|Device|LOW error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 0.8 times the true glucose value (analogous to lower gain higher target).
45677495|NCT04723511|Other|Global Postural Re-education|"treatment techniques include corrective exercises both local and global to correct forward head posture.~first session will be to educate participants the treatment sequence. This will be a session of Kendall exercises as described below. This will followed be performing GPR techniques of Anterior Chain stretch in the supine frog like position for 20 minutes followed by posterior chain stretch against the wall for another 20 minutes. This is repeated in the first 6 sessions. Staring from the seventh session the time of holding each position is decreased to 15 minutes and a third position (standing against the wall) is introduced and performed for 15 minutes. Starting from the eighth session a forth position of sitting on the floor position is introduced and performed for another 15 minutes. total of a session will then take a bout 90 minutes."
46003904|NCT04651959|Drug|AVIGAN 200 MG Film Tablets|AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
46089254|NCT02681016|Device|"DES Xience Prime"|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
46089255|NCT02681016|Procedure|Coronary angioplasty|
46003905|NCT01165216|Drug|Ipilimumab, 3 mg|Intervenous (IV) injection, administered every 3 weeks for up to 6 cycles
46003906|NCT01165216|Drug|Ipilimumab, 10 mg|IV injection, administered every 3 weeks for up to 6 cycles
46003907|NCT01165216|Drug|Paclitaxel|IV injection, 175 mg/m^2, administered every 3 weeks for up to 6 cycles
46003908|NCT01165216|Drug|Carboplatin|IV injection, AUC=6, administered every 3 weeks for up to 6 cycles. (AUC=area under the concentration curve)
46003909|NCT04651881|Drug|Reference drug|1 Cap., single oral administration under fed condition
46089256|NCT02677584|Drug|Prophylactic caffeine citrate|Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .
46003910|NCT04651881|Drug|Test drug 1|1 Tab., single oral administration under fed condition
45677496|NCT04723511|Other|Kendall exercises|"exercises that correct upper crossed syndrome:~Treatment sequence will be:~a) Strengthen deep Cervical Flexors via Chin tucks. Repetition will be 15 times repeated for 3 sets.~(b) Stretching the cervical extensors. This is held for 1 minute and repeated 5 times.~(c) Strengthening shoulder retraction. Repetition will be 15 times repeated for 3 sets.~(d) Stretching the pectoralis muscle. This is held for 1 minute and repeated 5 times."
45677497|NCT04723355|Device|An innovative 3-lead wireless water resistant Holter device|The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
46003911|NCT04651881|Drug|Test drug 2|1 Tab., single oral administration under fed condition
46003912|NCT05367427|Dietary Supplement|Bifidobacterium longum consumption|Regular consumption in breakfast of inactivated B. longum
46003913|NCT05367427|Dietary Supplement|Placebo|Placebo pill with maltodextrin
46003914|NCT05423405|Other|Acupressure|selected acupoint pressure
45677498|NCT04723355|Device|A conventional device|The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
45677499|NCT04417985|Device|18F-FDG PET/CT, MRI|
46003915|NCT04652310|Device|TFNA extended-short nail (235 mm)|The extended short version of the TFN-advanced proximal femoral nailing system (TFNA)
46003916|NCT04652310|Device|TFNA long nail (260-480mm)|The long version of the TFN-advanced proximal femoral nailing system (TFNA)
46003917|NCT05423288|Procedure|Distal pancreatectomy (DP)|Any scheduled distal pancreatectomy performed for any diagnosis
45677500|NCT04185545|Biological|Rotavirus RV3 Vaccine (Bio Farma)|Each 1 mL dose of the final product of oral liquid rotavirus vaccine contains > 5x10^6 fcfu/mL rotavirus vaccine strain RV3
45458976|NCT04230824|Other|Placebo|placebo product consumed prior and after exercise
45458977|NCT04230824|Other|6-week resistance training program|participants will complete a moderate-intensity warm-up, a full-body resistance training workout (2 x per week) and an interval training session (1 x per week)
45677501|NCT04185545|Other|Placebo|Each 1 mL dose of placebo contains 30% of sucrose in DMEM
45677502|NCT02106455|Drug|Sodium risedronate|Sodium risedronate tablets
46003918|NCT04652115|Drug|Defibrotide|Deibrotide via IV
46003919|NCT05423171|Other|Intensive bimanual therapy|60-hour intensive therapy promoting the use of both hands (ex: bimanual activities, games,...)
46003920|NCT04618185|Diagnostic Test|Magnetic Resonance Imaging (MRI)|MRI to study gut function and transit without the risk of exposure to ionising radiation.
46003921|NCT01580553|Drug|Levocarnitine Injection|Levocarnitine Injection:5ml:1g
46003922|NCT01580553|Drug|Levocarnitine placebo|L-Carnitine injection placebo (5ml:1g)
46089257|NCT02677584|Drug|Therapeutic caffeine citrate|Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
46003923|NCT05423054|Other|Abdominal massage|"Patients will be positioned on their back while their knees will be flexed.~Each patient will receive a 15-minute abdominal massage intervention half an hour before enteral feeding twice per day and the interval between two massages is 2 hours for consecutive 3 days.~The PR will be standed on the right side of the patient during the massage practice.~The abdominal massage technique will be delivered to each patient in four consecutive strokes including stroking, effleurage, kneading and vibration."
46003924|NCT04618107|Procedure|Wide awake surgery|Wide awake local anaesthesia was used to perform tendon repair surgeries.Local anaesthetic injections given using 27 gauze needle in subcutaneous tissue plane.Tendon repair performed using modified Kessler repair.Outcome of surgery assesed at sixth postoprative week.
46003925|NCT04618107|Procedure|General anaesthesia|Tendon repair performed under general anaesthesia using modified Kessler repair.Outcomes of surgery assesed at sixth post operative week
46003926|NCT05423015|Dietary Supplement|Lactobacillus casei strain Shirota|Probiotic product were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 15 mL of sterile water were added to the probiotic product.
46003927|NCT05423015|Dietary Supplement|Lactobacillus casei strain Shirota plus inulin|The Syn-inulin products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of inulin (BENEO GmbH) were diluted in 15 mL of sterile water and added to Syn-inulin products.
46003928|NCT05423015|Dietary Supplement|Lactobacillus casei strain Shirota plus fructans from A. salmiana|The Syn-A. salmiana products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of fructans from A. salmiana were diluted in 15 mL of sterile water and added to Syn-A.salmiana products.
45677503|NCT02006654|Drug|Placebo|Once daily, matching placebo capsules, orally
45677504|NCT02006654|Drug|Idalopirdine|Once daily, encapsulated tablets, orally
45677505|NCT01980056|Drug|Vosaroxin|Dose level 1: Vosaroxin 50 mg^m2 IV on Days 1 and 4 of 28 day cycle Dose level 2: Vosaroxin 72 mg^m2 IV on Days 1 and 4 of 28 day cycle Dose level 3: Vosaroxin 50 mg^m2 IV on Days 1, 4, 8 and 11 of 28 day cycle
45677506|NCT02027558|Behavioral|Insomnia treatment & PAP adherence|Manual-based cognitive behavioral treatment focusing on sleep, sleep apnea, and PAP adherence provided by allied health personnel in individual sessions.
45836148|NCT00282672|Device|Sham procedure plus anti-secretory medication|The Sham Control group undergo an upper endoscopy procedure with sizing of the esophageal diameter (a component of the ablation procedure steps, deemed the sham procedure) plus standard anti-secretory drug therapy (Proton pump inhibitor, PPI)
45836149|NCT00282828|Drug|Sertraline|
45836150|NCT00282828|Drug|Venlafaxine|
45836151|NCT00282828|Drug|Placebo|
46003929|NCT04618224|Diagnostic Test|DDART Testing|One randomly selected eye is included for each study participant. Participants respond to the DDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
46003930|NCT04618224|Diagnostic Test|wDDART Testing|One randomly selected eye is included for each study participant. Participants respond to the wDDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
46003931|NCT04618146|Drug|Morphine Sulfate|intrathecal low dose morphine for early return to normal activity without opioid related complications.
45836152|NCT00282828|Drug|Clonazepam|
45836153|NCT00112242|Biological|Melan-A ELA + Montanide|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
45836154|NCT00112242|Biological|Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
45677507|NCT02027558|Behavioral|General sleep education|Manual-based non-directive general sleep education program provided by allied health personnel in individual sessions.
45677508|NCT02006576|Drug|600 mg ibuprofen three times daily for 48 weeks|
45677509|NCT02006576|Other|Placebo three times daily|
45677510|NCT02027402|Procedure|Laparoscopic cholecystectomy with drain insertion|In the drain insertion group, investigators use the closed suction drain through a lateral 5-mm trocar and placed it in right subhepatic space
45458978|NCT04230434|Behavioral|Safety Plan Intervention|The SPI has 6 key steps: (1) identify personalized warning signs for an impending suicide crisis; (2) determine internal coping strategies that distract from suicidal thoughts and urges; (3) identify family and friends who are able to distract from suicidal thoughts and urges and social places that provide the opportunity for interaction; (4) identify individuals who can help provide support during a suicidal crisis; (5) list mental health professionals and urgent care services to contact during a suicidal crisis; and (6) lethal means counseling for making the environment safer (Stanley & Brown, 2012)
46003932|NCT04618146|Drug|Bupivacaine Hydrochloride|intrathecal bupivacaine 0.5%
46003933|NCT05422898|Behavioral|Gist messages on COVID-19 vaccination|Participants will receive gist-based messages on COVID-19 vaccines and have their concerns addressed by a group moderator
46003934|NCT05422898|Behavioral|COVID-19 vaccine information|Participants will receive a link to the Facebook COVID-19 Information Center via a private Facebook Group
46003935|NCT04651842|Device|PCI|Acute Insulin Resistance on Myocardial Blush in Non- Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention
46089258|NCT02839967|Other|Photobiomodulation|Intraoral photobiomodulation is applied in the temporal, medial and lateral pterygoid, bilateral, totaling 4 points of application of phototherapy. The researcher who will perform the treatments will receive the equipment with the stylus activates and pre-programmed dose, an eye protection (glasses, opaque) will be used by the participants, to protect the eyes, because the same does not cause any sensation to volunteer. The technique is used, contact an area. The individual is positioned supine on a stretcher, with the legs supported on a foam roller 20 cm in diameter, the head supported on a pillow, to accommodate her comfortably in a resting posture, prompted the opening of the mouth and placing the tip of photobiomodulation in sections as described below, with 2 minutes interval between one application and another for rest with the mouth closed.
46089259|NCT02839967|Other|Photobiomodulation placebo|The volunteers will be subjected to the same Group intervention, Photobiomodulation and the researcher will receive the equipment unaware if the pen that will apply the phototherapy is active or placebo, only the research coordinator will have this knowledge, and for this group the researcher will receive placebo pen. Fits the caveat that, when the voluntary participation, will be held with the active pen treatment.
46089260|NCT04181658|Other|Real tDCS and Physical Therapy|The participant will receive 20-minute sessions of real tDCS before each physical therapy visit for up to 10 combined sessions, over approximately 6 weeks.
46089261|NCT04181658|Other|Sham stimulation and Physical Therapy|The participant will receive 20-minute sessions of sham stimulation before each physical therapy visit for up to 10 combined sessions, over approximately 6 weeks.
46089262|NCT02840045|Device|high-density electroencephalography|Musical stimulation during electroencephalography recording
46089263|NCT02677662|Other|Diesel Exhaust|Dilute diesel exhaust
46089264|NCT02677662|Other|Filtered air|Filtered air
46089265|NCT02839655|Device|Da Vinci Xi|
45458979|NCT01371266|Dietary Supplement|Honey|60.7 grams orally daily times 14 days
45677511|NCT01448824|Drug|LY2484595|Administered orally
46089266|NCT05662956|Drug|Venetoclax in combination with azacitidine and CAG|"Induction:~VA regimen：~Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21);~Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.~CAG regimen：~Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7;~Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7;~Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC >20×10^9/L；~Consolidation:~Drug: Cytarabine 3g/m2 q12h on days 1-3."
46089267|NCT02537496|Procedure|Repetitive Transcranial Magnetic Stimulation|Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right DLPFC.
45458980|NCT01371266|Dietary Supplement|High Fructose Corn Syrup 55 (HFCS 55)|65.7 gram daily orally times 14 days
45458981|NCT01371266|Dietary Supplement|CHO (sugar)|50 grams daily orally times 14 days
45458982|NCT01365962|Genetic|gene expression analysis|
45458983|NCT01365962|Other|immunohistochemistry staining method|
46003936|NCT05422859|Other|MobiDig|"The application will contain the following modules:~information and knowledge about heart failure;~vital sign diary, which can be sent to the certified HFU~pedometer (individualized step-goal), cardiac home training videos~frequently asked questions and connection to a certified HFU provider by a heart failure hotline"
45458984|NCT01365962|Other|laboratory biomarker analysis|
45458985|NCT01365962|Other|mass spectrometry|
45458986|NCT04086758|Drug|zolbetuximab|Zolbetuximab will be administered as a 2-hour intravenous infusion
45458987|NCT02875028|Drug|Vorapaxar|10mg-20mg vorapaxar to achieve >80% thrombin-receptor activated peptide-6 (TRAP) induced platelet inhibition
45458988|NCT02875028|Drug|Placebo|
46089268|NCT02537496|Procedure|Repetitive Transcranial Magnetic Stimulation - Sham|Same stimulation parameters and site as active condition will be used, but with placebo coil which will have minimal direct brain effects
45458989|NCT02875028|Other|LPS|2ng/kg Lipopolysaccharide as a bolus infusion
45458990|NCT01371344|Drug|Tacrolimus granules|oral
45458991|NCT01371344|Drug|Tacrolimus capsules|oral
45458992|NCT03631004|Drug|Olanzapine|olanzapine 10 mg is given before surgery
45473919|NCT03375034|Drug|Clonazepam 1.5mg|Oral administration of three clonazepam 0.5mg capsules
45473920|NCT03375034|Drug|Placebo|Oral administration of three Placebo capsules
46003937|NCT04652154|Other|Transitioning young patients' health care trajectories|New intervention where the patient with multi-referrals to specialist health service meet with a complementary professional team consisting of doctor, psychologist and physioterapist aiming clarify the child's condition through shared decison-making and agreeing upon treatment plans for the child
46003938|NCT04651647|Procedure|Revision surgery with / without open bone graft|Removal of previous implant and re-alignment and re-fixation using intramedullary nail with (bone graft group) / without (non bone graft group) open bone graft
45677512|NCT01448824|Drug|Placebo|Administered orally
45677513|NCT01448824|Drug|Ketoconazole|Administered orally
45677514|NCT02005562|Drug|mycophenolate mofetil|3 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52, adapted to MPA by AUC on Weeks 2, 6, 12, 26, and 52 to obtain AUC0-12 of 50 milligrams (mg) multiplied by (*) height (h)/ liter(L).
45677515|NCT02005562|Drug|mycophenolate mofetil|2 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52.
45677516|NCT02005562|Drug|anti-IL-2R|Induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion.
46003939|NCT04651686|Other|Preoperative three-dimensional reconstruction and intraoperative protection of bronchial artery|All patients underwent chest enhanced CT examination with 64 slice spiral CT before operation. The bronchial artery was reconstructed by Mimics software. The bronchial artery was protected according to the preoperative three-dimensional reconstruction image during the lymph node dissection
46003940|NCT05421962|Drug|Ketamine|Ninety patients were included and randomized to either fentanyl-propofol (Group FP, n: 30), ketamine-propofol (Group KP, n: 30) or propofol-control group (Group C, n: 30). Group FP patients received fentanyl and propofol, Group KP received ketamine and propofol and Group C, propofol.
46003941|NCT00557817|Drug|Darbepoetin alpha (Aranesp)|Darbepoetin alpha (Aranesp) will be administered subcutaneously (s.c.) at the dose of 300 µg. The first dose will be given on day 28 and the following doses at 2-week intervals around days 42, 56, 70, 84, 98 and 112 post-transplant. Once the target Hb (13 g/dL) has been attained, the dose of Aranesp will be reduced by half to 150 µg. If the Hb increases to > 14 g/dL, Aranesp will be withheld and resumed at the dose of 150 µg when the Hb decreases < 13 g/dL. If the Hb decreases to < 12 g/dL, the dose of Aranesp will be increased to 300 µg again.
46003942|NCT00557817|Drug|Iron saccharate (Venofer)|Iron saccharate (Venofer) will be administered intravenously (i.v.) at the dose of 200 mg (2 vials of Venofer) on days 28, 42 and 56 after the transplant. Venofer will be diluted in 250 ml saline and infused over 60 minutes. Iron will be omitted in patients with severe iron overload (serum ferritin > 2500 µg/L in the absence of inflammation or liver necrosis) or elevated transferrin saturation (TS > 60%) between days 21 and 56. No iron supplementation will be allowed in arm 1. No iron supplementation will be allowed in arm 2 before day 70 after the transplant. In arms 2 and 3, if patients have evidence of functional iron deficiency (transferrin saturation < 20%) on day 70 or later, they will receive 300 mg of Venofer over 90 min, for a minimum of 2 doses.
46003943|NCT05421182|Other|Revised Impact of Event Scale|to measure the affect of routine life stress,everyday traumas and acute stress
46089269|NCT02837939|Drug|Human derived Transfer factor|"One dose (the content of one amp.) of lyophilised drug contains:~Leucocyte dialysatum 200 x 10 to the power of 6 (Lyophilized dialysate from 200 million leukocytes) pH = 7.8 to 9 after reconstitution (dissolving) of drug~To be administered subcutaneously as follows:~12 doses TF in total:~3 x TF in first week: day 1,3,5~2 x TF in week 2: day 8 , 11~1 xTF in week 3 and 4 : day 15, 22~1 x TF once a month up to 6 month"
46089270|NCT02837939|Drug|Aqua pro injectione 4ml ampules for subcutaneous injection|"12 doses in total:~3 doses in first week: day 1,3,5~2 doses in week 2: day 8 , 11~1 dose in week 3 and 4 : day 15, 22~1 dose once a month up to 6 month"
46003944|NCT05421182|Other|Hospital Anxiety and Depression scale|to measure anxiety and depression
46003945|NCT05421182|Other|36-Item Short Form Survey|SF-36 is a set of generic, coherent, and easily administered quality-of-life measures.
45677517|NCT02005562|Drug|methylprednisolone|500 mg intravenous (i.v.) was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 to Day 7.
45677518|NCT02005562|Drug|cyclosporine|100-1500 nanograms (ng) per milliliter (mL) from Day 0 to Week 4, 800-1200 ng/mL from Week 4 to Week 12 and 500-800 ng/mL from Week 12 to Week 52
45677519|NCT01448044|Drug|BMS-790052 (NS5A Replication Complex Inhibitor)|
46003946|NCT05421182|Other|satisfaction survey|satisfaction survey of the trusted person about the communication with ICU personal
46089271|NCT00643344|Behavioral|Craving and Lifestyle Management through Mindfulness(CALMM+)|MBSR is a program that provides systematic training in mindfulness meditation and gentle yoga as a self-regulation approach to reduce stress and improve medical and psychological symptoms. In this randomized controlled pilot study, we aim to test a 16-week intervention that further integrates diet and exercise into the CALMM program (CALMM+). This novel program, which includes elements drawn from MBSR, will be actively compared with the conventional diet and exercise group(TLC). Both groups will receive about 7 hours of in-class and out-of-class activities per week. The activities includes exercise, keeping dietary records, and stress reduction practices (if they are assigned to the intervention group).
46089272|NCT02838173|Procedure|serratus plane bloc : Ropivacaine 2mg/ml (0,3ml/kg)|
46089273|NCT02838173|Procedure|tissue infiltration : Ropivacaine 2mg/ml (0,3ml/kg)|
45458993|NCT01366118|Drug|Therapeutic target tailored chemotherapy|"All pts were treated with Capecitabine (Cap) 625-825 mg/m2/12h M-F.~Ch combination schema was customized based on:~Top- 1 +: Irinotecan (I) 50mg/m2 / in weekly. Top-1 - and ERCC-1 - : Oxaliplatin (O) 50gm/m2/ weekly. Top- 1 - and ERCC-1 + : Neither I nor O. K-Ras or b-Raf mutated (m) : Bevacizumab (B) 5mg/kg every two weeks. K-Ras and B-Raf native (n): Cetuximab (C) 400/250mg/m2 weekly or B (investigator option). Figure 1.~When Cap was in combination with O or I the 625mg/m2 dose was chosen. When Cap was the only chemotherapy agent in combination with B or C the 825mg/m2 dose was chosen"
45677520|NCT01448044|Drug|Placebo matching BMS-790052|
45677521|NCT01448044|Drug|Pegylated-interferon alfa 2a|
45677522|NCT01448044|Drug|Ribavirin|
45677523|NCT02025530|Other|Questionnaire|An indepth interview will be carried out and a structured questionnaire will be completed by both cases and controls
46089274|NCT02838173|Procedure|serratus plane bloc : placebo|
45677524|NCT01472380|Drug|efavirenz|600 mg
46089275|NCT02838173|Procedure|tissue infiltration : placebo|
46089276|NCT00641394|Behavioral|Psychotherapy: Emotional Freedom Techniques (EFT)|A form of therapy that includes cognitive reframing with somatic reinforcement through touch or tapping of specified points on the body
46089277|NCT00641394|Behavioral|Cognitive Behavioral Therapy (CBT)|A form of therapy that focuses on negative cognitions of problems, and reframing them in positive terms, but without somatic reinforcement.
46089278|NCT05514366|Procedure|Modifying EIP under a tOLA before pneumoperitoneum|"Phase 1:~Moment (M) 1) Standard PPV and an initial EIP of 10%~M 2) ARM with titration of optimal PEEP (PEEPop) on a decremental PEEP trial, followed by a new ARM and setting a tailored open-lung PEEP (tOL-PEEP), that 2 cm H2O higher than PEEPop~M 3) Incremental modification of the EIP in steps of 10% (from 10 to 40%)"
45677525|NCT01472380|Drug|fenofibric acid 105 mg|fenofibric acid 105 mg
45677526|NCT01978262|Biological|Seasonal Inactivated Influenza Vaccine|Quadrivalent seasonal inactivated influenza vaccine, 0.5 mL intramuscularly
45677527|NCT01447576|Drug|ADT|Once daily dosing during the duration of the study.
45677528|NCT01447576|Drug|OPC-34712|OPC-34712, Oral Tablets, 0.25 - 3 mg
46003947|NCT05421182|Other|semi-directed interview with trusted person on the general experience of the patient's medical evacuation|interview of the trusted person about the medical evacuation : evacuation announcement;organization of the medical evacuation,; concerns related to evacuations;reception and information by the center admitting the evacuated patient; arrangements of visit, patient repatriated
46003948|NCT05421182|Other|semi-directed interview with trusted person on the general experience of hospitalization in intensive care|interview of the trusted person about ICU hospitalization: reception in ICU; ICU organization; concerns related to ICU hospitalization, information and communication with ICU staff, arrangements of visit, context of ICU discharge
46003949|NCT04651530|Procedure|Phaco|phacoemulsification of cataract only
46003950|NCT04651530|Procedure|Phaco+ECP|Endoscopic cyclophotocoagulation is done in the same procedure as phacoemulsification of cataract
46003951|NCT05420480|Procedure|Two-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with Two-Field or Three-Field lymph node dissection."
45458994|NCT03431090|Device|CliniMACS® TCRαβ/CD19 Combined Depletion System|The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.
45458995|NCT03634670|Other|Interdisciplinary multimodal pain therapy (IMPT)|The IMPT-program is provided in a specialized day-clinic setting over a period of 20 treatment days. There are two different treatment programs with either 5 days per week over a period of 4 weeks or 3 days per week over a period of 7 weeks. IMPT comprises individual pharmacotherapy evaluated in regular consultations with a physician as well as a structured physiotherapy and psychotherapy programs on group level and individual level. Group physiotherapy comprises exercise therapy, movement experience and relaxation techniques. Additionally individual physiotherapy is provided in two extra sessions focusing on the individual needs and problems of the patient. Group psychotherapy comprises educational contents (e.g. pathophysiology and biopsychosocial aspects of pain) as well as cognitive-behavioral-interventions e.g. regarding stress-management. Additionally individual psychotherapy is provided in four extra sessions focusing on the individual needs and problems of the patient.
45458996|NCT04342364|Other|Vitrification via slush nitrogen|oocytes will be vitrified using slush nitrogen
45458997|NCT04342364|Other|Vitrification via liquid nitrogen|oocytes will be vitrified using liquid nitrogen which is currently routine practice
45458998|NCT01372592|Procedure|Surgery|Patients will receive standard of care surgical treatment dependent on his/her spinal condition.
45458999|NCT04305314|Other|PRI (Enhanced Recovery after surgery protocol)|Standard use of Spanish perioperative guidelines (PRI)
45459000|NCT00943618|Drug|Varenicline|On Days 1-3, .5mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, .5mg tablet by mouth in the morning and .5mg tablet by mouth in the evening (for a total of 2 doses).
45459001|NCT00943618|Drug|Bupropion|On Days 1-3, 150 mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, 150 mg tablet by mouth in the morning and 150 mg tablet by mouth in the evening (for a total of 2 doses).
45459002|NCT00943618|Other|Placebo|On Days 1-3, 1 tablet by mouth of placebo that looks like the study drug in the morning. Beginning on Day 4, and then every day after that, 1 tablet by mouth in the morning and 1 tablet by mouth in the evening for a total of 2 doses of the placebo each day.
45459003|NCT00943618|Behavioral|Counseling/Phone Calls|Brief-behavioral counseling sessions (10-15 minutes) provided to all participants once per week for 12 weeks. One support phone call conducted 3 days after the target quit date.
45459004|NCT01372670|Drug|Hydroxyzine|"Study medications (hydroxyzine/placebo) will be dosed based on participant's weight. Dosing will be according to the following body weight ranges:~15-29 Kg 10 mg TID 30-44 Kg 20 mg TID~≥ 45 Kg 30 mg TID"
45459005|NCT01372670|Drug|hydroxyzine HCL|hydroxyzine HCL dosed on weight given 3x per day
46003952|NCT05420480|Procedure|Three-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with Two-Field or Three-Field lymph node dissection."
45459006|NCT01372670|Other|Placebo|Placebo given 3 times per day
45459007|NCT02322658|Drug|Eszopiclone Tablets 3 mg|
45459008|NCT01366274|Other|Protective manual hyperinflation|Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 8mls/kg and positive end expiratory pressure in the circuit appropriate to baseline levels
45459009|NCT01366274|Other|Usual method of MHI|Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 12mls/kg and no positive end expiratory pressure in the circuit
45459010|NCT03490552|Procedure|mechanical thrombectomy|Mechanical thrombectomy whatever it type ( SRT , ASPT or Mixed )will be used to extract the thrombi from stroke causing occlusion to be preserved biologically for genomic lab. transfer to be processed by RNA sequencing analysis technique for identifying markers for its composition pointing to its source.
45683776|NCT04398784|Dietary Supplement|Freeze Dried Blueberry Powder - 71717|Single serve packets containing 22.5 grams of powdered freeze-dried whole blueberries; A mix of 2 species, Vaccinium virgatum (ashei)/Vaccinium corymbosum, provided by U.S Highbush Blueberry Council (USHBC). Powders are sealed in single serve packets to protect from light and moisture. Packets are refrigerated except for when distributed to participants; participants are asked to store packets in refrigerator until consumption.
46089279|NCT05514366|Procedure|Modifying EIP under a tOLA with pneumoperitoneum|"Phase 2:~M 4) The investigators will apply the EIP that guarantees the lowest Pdriv~M 5) After applying pneumoperitoneum and trendelenburg~M 6) Atelectasis test (see below)~M 7) M 7a) In case of atelectasis test = negative: the investigators will modify the EIP in incremental or decremental steps of 10% M 7b) In case of atelectasis test=positive: ARM~M 8) In those cases recruited (M 7b), modify the EIP (as in M 7a)~Once the EIP that guarantees the best ventilation conditions has been stablished based on the lowest Pdriv (and higher Crs), the investigators will maintain these conditions until the end of surgery, with periodic evaluation of the pulmonary collapse by means of the atelectasis test (see below) performed every 40 minutes or regardless of time if an oxygen saturation by pulse oximetry (SpO2) < 97% is detected."
46089280|NCT05514366|Procedure|Atelectasis test|It is performed during mechanical ventilation, due to suspicion of alveolar collapse. Alveolar collapse will be suspected on observation of a reduction in Crs > 10% over post-recruitment values. In these cases the atelectasis test will be performed, consisting of a reduction in FiO2 to 0.21, maintaining this FiO2 for 5 minutes. If lung collapse is >10%, a fall in SpO2 below 97% will be expected (positive atelectasis test), in which case, an ARM and a PEEPop titration test will be performed.
45459011|NCT04218656|Drug|Rivaroxaban 2.5 Mg Oral Tablet|2.5 mg rivaroxaban twice a day in addition to Aspirin 100mg once a day (standard care).
45459012|NCT04176380|Biological|RAPA-201 Autologous T cells|Autologous rapamycin resistant Th1/Tc1 cells
45683777|NCT04398784|Dietary Supplement|USHBC Blueberry Placebo Formula #114|Blueberry flavor- and color-matched placebo powder.
45677529|NCT04084834|Other|Exercise|Participants will be offered to take part in a 5-hour Learning and Mastery-course at Diakonhjemmet Hospital, receiving information about the osteoarthritis disease, symptoms and the importance of exercise and physical activity. Participants will then be given a weekly web-based exercise program (12 weeks) consisting of three aerobic exercise sessions per week. The exercise program consists of five levels, and the participants will each week be guided to the most appropriate level based on their measured physical fitness level and the weekly exercise diary. The participants will at initial assessment at Diakonhjemmet Hospital be instructed to use Borgs scale to adjust exercise level. Based on the weekly exercise diary the participants will also get motivational messages by email.
45677530|NCT01447420|Drug|peginterferon alfa-2a|180 mcg sc weekly, 48 weeks
45836155|NCT00112242|Biological|Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpG|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
45836156|NCT00112242|Biological|Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
45677531|NCT01447420|Drug|ribavirin [Copegus]|1'000 or 1'200 mg orally daily, 48 weeks
45677532|NCT01446874|Drug|0.12% chlorhexidine solution|Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution and for the duration of the hospitalization or 5 days postoperatively.
45677533|NCT01446796|Device|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to AAI 90
45677534|NCT01446796|Device|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to DDD 90-100
46089281|NCT02838095|Behavioral|Nap|A 1-hour daytime nap opportunity
46089282|NCT02675712|Other|African drumming|Rhythmic beating or tapping of a variety of percussion instruments, which often occurs within a group setting
45677535|NCT01439074|Device|Mepilex Ag|Dressing
45677536|NCT01439074|Drug|Silver Sulphadiazine Ag cream|A cream used on burnt areas.
46003953|NCT05420480|Procedure|Three-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has metastasis, esophagectomy and Three-Field lymph node dissection will be performed."
46003954|NCT04651491|Drug|Kagocel|"The researchers prescribed antiviral medications, including Kagocel, according to routine clinical practice. Patients who were assigned Kagocel were invited to participate in the study.~Kagocel administration:~for children from 3 to 6 years old (n=41): In the first 2 days - 1 tablet 2 times a day, in the next 2 days - 1 tablet once a day. Total for the course of administration 6 tablets within the period of 4 days.~for children from 6 years old (n=39) - administered in the first 2 days - 1 tablet 3 times a day, in the next 2 days - 1 tablet 2 times a day. Total for the course of administration 10 tablets within the period of 4 days."
46003955|NCT03455231|Radiation|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with complicated bone metastases
46003956|NCT04617873|Procedure|Bilateral STN-DBS and T10-T12 SCS|simultaneous stimulation of bilaterally-STN-DBS combined with spinal cord stimulation
46003957|NCT05419895|Behavioral|Early Diagnostic Response Model (EDRM)|Use of telehealth capabilities to capture and code information related to an autism diagnosis. This program evaluation will be using pre- and post-data and data collected through the process to evaluate the effectiveness of the EDRM pilot.
46003958|NCT05419739|Other|Glasgow coma scale|This scale, which consists of three parameters, includes the best eye response (1-4 points), the best verbal response (1-5 points), and the best motor response (1-6 points). Total score; It is calculated as Eye Response + Verbal Response + Motor Response and takes a value between 3-15 points. The severity of head trauma is evaluated in three categories: mild (GCS 13-15 points), moderate (GCS 9-12 points), and severe (GCS ≤ 8 points).
46003959|NCT00563004|Dietary Supplement|DBCARE|Patients receive dbcare 2 tablets TID for 3 months
46003960|NCT00563004|Dietary Supplement|DBCARE|PLACEBO PILLS 2 TABLETS TID FOR 3 MONTHS
46003961|NCT05419583|Diagnostic Test|Coronary computed tomography angiography|CT scan of the heart arteries
46003962|NCT05419583|Diagnostic Test|Invasive coronary angiography|Invasive coronary angiography via the radial or femoral approach
46003963|NCT05419583|Diagnostic Test|Transthoracic echocardiography|Ultrasound scan of the heart
46003964|NCT05419583|Diagnostic Test|Cardiac MRI scan|An MRI scan to assess the heart structure and function
46003965|NCT05419583|Drug|Antiplatelet Drug (Aspirin or Statin)|Antiplatelet therapy for coronary artery disease
46003966|NCT05419583|Drug|Anticoagulants (Apixaban, Edoxaban, Rivaroxoban, Warfarin)|Anticoagulant therapy if atrial fibrillation identified (DOAC or Warfarin)
46003967|NCT05419583|Drug|Guideline directed heart failure therapy|Use of guideline approved heart failure treatments (ACE-inhibitor / angiotensin receptor blocker (ARB) / ARB and neprilysin inhibitor, mineralocorticoid receptor antagonist, beta blocker, SGLT-2 inhibitor, diuretic therapy)
46003968|NCT05419583|Drug|Statins (Cardiovascular Agents)|Statins will be recommended for patients with coronary plaque disease or hypercholesterolaemia
46003969|NCT04651764|Device|ColubrisMX Endoluminal Surgical (ELS) System|Robotically assisted transanal endoluminal resection of rectal lesion using the ColubrisMX Endoluminal Surgical (ELS) System
46003970|NCT04617600|Drug|MTA|Survival rate using MTA in cariously exposed vital primary molars
46003971|NCT04617600|Drug|TheraCal PT|Survival rate using TheraCal PT in cariously exposed vital primary molars
46003972|NCT05408624|Procedure|ultrasound transvaginal drainage|Ultrasound-guided transvaginal drainage of TOA by a puncture under simple sedation or analgesia with/or under general anesthesia
46003973|NCT05408624|Procedure|laparoscopy|Laparoscopy for drainage of TOA under general anesthesia
46003974|NCT04651608|Behavioral|manuel acupressure|Acupressure was applied once by the researcher 30 minutes before applying the chemotherapeutic agent with medium or high emetogenicity to the randomized child. 3 fingers were placed on the child's wrist with their fingers and the region (point P6) between the flexor carpi radians and palmaris longus 1 cm below. Acupressure was applied to the wrist of the child by press for 2 minutes. The same procedure was applied to the other wrist. Then, data were recorded in accordance with the data collection procedure.
46089283|NCT02677506|Procedure|Supraclavicular|Brachial plexus block with supraclavicular approach
45677537|NCT01438996|Biological|NVGH Vi-CRM197|Vi-CRM197 glycoconjugated vaccine
45677538|NCT01438840|Drug|Avatrombopag|
45677539|NCT01438840|Drug|Placebo|
45677540|NCT01438840|Drug|Standard of care|"Permitted ITP concomitant background therapies are as follows:~Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport [P-gp] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization."
46089284|NCT02677506|Procedure|Infraclavicular|Brachial plexus block with infraclavicular approach
46089285|NCT00641472|Drug|Budesonide inhalation suspension|0.5mg
46089286|NCT00641472|Drug|Montelukast Sodium|4mg or 5mg
46003975|NCT04651608|Behavioral|sea-band acupressure|30 minutes before applying the chemotherapeutic agent with medium or high emetogenicity to the randomized child, sea-band acupress was applied by the researcher. The P6 point on the wrist was identified and marked with the child's own fingers. A sea band was attached to both wrists of the child by the researcher. The attached sea-band was allowed to remain for 15 minutes and was removed by the researcher at the end of the period. Separate sea-band was attached to each child. Acupress wrist bands, which are produced in separate sizes for adults and children, were used during the application, taking into account the physical development of the child, pediatric for the age range of 5-12, and adult size sea-band for the age of 12. Acupress application with sea-band was done once. Then, data were recorded in accordance with the data collection procedure
46003976|NCT04651608|Behavioral|placebo manuel acupressure|Placebo manual acupress was applied in the next protocol for the child who was administered manual acupressure.
46003977|NCT04651608|Behavioral|placebo sea-band|Placebo sea-band was applied in the next protocol for the child who was administered sea-band acupressure.
45459013|NCT02322970|Device|transcranial Doppler|Comparison of non invasive intracranial pressure (through use of transcranial Doppler ) vs invasive monitoring (through insertion of intracerebral catheters) with the purpose of comparing these two techniques in terms of specificity and sensitivity.
45459014|NCT04157426|Other|Percutaneous electrolysis|Ultrasound-guided percutaneous electrolysis in the active myofascial trigger point of the levator scapulae muscle
46089287|NCT04181268|Device|Percutaneous coronary Intervention|Calcified plaque modification during percutaneous coronary intervention
46089288|NCT02675556|Drug|Allo-hMSCs|a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells
46089289|NCT02675556|Drug|Placebo|a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A
46089290|NCT00896051|Drug|Atazanavir (ATV) 300 mg|Atazanavir (ATV) 300 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 300 mg by mouth following a meal each morning on Substudy Days -1 to 7.
46089291|NCT00896051|Drug|Atazanavir (ATV) 400 mg|Atazanavir (ATV) 400 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 400 mg by mouth following a meal each morning on Substudy Days -1 to 7.
46089292|NCT00896051|Drug|Ritonavir (rtv) 100 mg|Ritonavir (rtv) 100 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take rtv 100 mg by mouth following a meal each morning on Substudy Days -1 to 7.
45459015|NCT04157426|Other|Dry needling|Ultrasound-guided dry needling the active myofascial trigger point of the levator scapulae muscle
45459016|NCT03496714|Behavioral|Psychoeducation on trauma reactions|The psychoeducation handout and video on trauma symptoms will discuss reactions that are common after experiencing a trauma.
45459017|NCT03496714|Behavioral|Psychoeducation on safety behaviors|The psychoeducation handout and video on safety behaviors will discuss safety behaviors that are common in PTSD and tips for how to eliminate them.
45459018|NCT03269474|Procedure|Experimental Group|Subjects with EB diagnosis
46003978|NCT05406089|Other|Medication history|The study was retrospective and did not involve the application of interventions
46003979|NCT04651335|Device|afferent virtual reality program|When visual gaze training is applied to the left unilateral neglected patient, the gaze direction can be divided into an afferent direction closer to the body and an efferent direction away from the body. The concentric direction moves the ball from the left to the center of the body.
46003980|NCT04651335|Device|efferent virtual reality program|When visual gaze training is applied to the left unilateral neglected patient, the gaze direction can be divided into an afferent direction closer to the body and an efferent direction away from the body. The efferent direction moves from the center to the right.
46003981|NCT05404100|Procedure|Aortic valve replacement|SAVR or TAVR
46003982|NCT04651023|Dietary Supplement|Nelumbo nucifera Leaf Extract|Hot water extracted Nelumbo nucifera Leaf, mainly containing quercetin and quercetin 3-O-glucuronide.
45677541|NCT01471054|Drug|Ozurdex|"Eyes in the Ozurdex group can have a maximum total of three Ozurdex insertions in the first 12 months after enrolling into the study. The criteria for retreatment with Ozurdex are:~i.The study eye must have shown initial favorable response to prior Ozurdex implant (>10% decrease in central macular thickness with maintenance [change in BCVA of <=1 line] or improvement of visual acuity [increase of BCVA of >1 line]) ii. Interval since last Ozurdex implant should be > 4 and < 12 months. iii. The study eye must show definite evidence of recurrence of macular edema."
46003983|NCT05395832|Behavioral|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions at sea|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) 4 face-to-face sessions (1 per mounth) at sea Standard pharmacological treatment usually provided to patients with fibromyalgia."
46003984|NCT05395832|Behavioral|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions in nature|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) 4 face-to-face sessions (1 per mounth) in nature Standard pharmacological treatment usually provided to patients with fibromyalgia."
46003985|NCT05395832|Behavioral|TAU + multicomponent treatment VIRTUAL FIBROWALK|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
46003986|NCT04651062|Device|endocuff|Endocuff is a relatively new device which is intended to be attached to the end of the colonoscope.
46003987|NCT04651062|Procedure|no endocuff|colonoscopy is performed without endocuff.
46003988|NCT05394779|Device|DTXO APP|DTXO is an investigational therapeutic intervention (Digital Therapeutics - DTx) for obese patients, under clinical validation with a randomized and placebo-controlled clinical trial for confirmatory purposes. It is intended to improve weight loss, weight-loss maintenance, and overall health in patients with obesity by increasing their self-engagement, self-monitoring and adherence to dietary/exercise and behavioral programs. The App integrates different non-pharmacological approaches, engaging the patient through monitoring of her/his non-vital parameters, monitoring of patient diet and exercise, monitoring of patient psychological status, prescription of exercise and diet in a weight-loss program.
46003989|NCT05394779|Device|PLACEBO APP - Control group|The placebo App will include only the non-medical modules of the digital therapy and has been introduced to make the experience of subjects in the control arm more similar to that of subjects in the experimental arm; moreover, data collection through the placebo app (questionnaires) will streamline the data collection process, avoiding manual data entry and reducing the possibility of entry errors.
46003990|NCT04651101|Diagnostic Test|coronary angiography|extent of coronary artery disease in invasive coronary angiography
46003991|NCT04651257|Device|Contrast mammography (CEM)|Contrast mammography in pathological nipple discharge
45459019|NCT03488914|Behavioral|YMHP Intervention|
45459020|NCT03488914|Behavioral|Enhanced Treatment as Usual|
45459021|NCT03266198|Other|No intervention|No intervention
45459022|NCT03488836|Procedure|reciproc|rotary reciprocating protocol
45459023|NCT03488836|Procedure|race rotary|race rotary group protocol
45459024|NCT03229382|Drug|Obinutuzumab|Patients, in whom all inclusion criteria have been confirmed and all exclusion criteria have been ruled out, will receive 4 intravenous infusions of obinutuzumab (GA101, Gazyvaro) at a dose of 1000 mg on Days 1, 8, 15 and 22.
45459025|NCT01371422|Other|Paravertebral Block (PVB)|"The T10, T11 and T12 paravertebral spaces on the operative side will be identified with ultrasound in all patients (Sonosite MicroMax, 2-5 MHz curvilinear probe).~In the PVB group, a 90mm 22g Tuohy needle will be inserted in-plane with the live ultrasound image over the transverse process at each of these levels and 5 mL of 0.5% ropivacaine will be injected at each level."
45677542|NCT01471054|Drug|Bevacizumab|Eyes in the Bevacizumab group can have a maximum total of twelve bevacizumab injections in the first year after enrolling into the study. All patients will receive 6 monthly injections after entering the study. After the sixth injection (at month 5) the interval between injections will be extended to 6 weeks if the study eye has shown initial favorable response to prior intravitreal bevacizumab.
45677543|NCT01978184|Drug|gemcitabine|
45459026|NCT01371422|Other|Saline|Ultrasonography and local infiltration of saline will only be performed
46003992|NCT05387408|Behavioral|Best Practice Health and Employment Opioid-related Policies|The intervention will include information to promote policies and programs to prevent opioid abuse and aid recovery such as drug testing for opioids, health and employee assistance programs, job accommodations, and education to deliver training to prevent opioid use, and prevent stigma.
46003993|NCT05380700|Device|Virtual Reality Stimulation|Participants in the intervention group will be provided with up to 30 minutes of relaxing, 360-degree virtual reality (VR) stimulation and corresponding sounds, twice in 24 hours during their stay on the intermediate care unit.
45459027|NCT05190614|Diagnostic Test|The biotype of gingiva|The biotype of gingival was determined by periodontal probe.
45459028|NCT02710084|Drug|Oxytocin|Intranasal oxytocin
45459029|NCT02710084|Drug|Saline|Placebo
45459030|NCT02849990|Drug|Abiraterone Acetate|Given PO
45459031|NCT02849990|Drug|Apalutamide|Given PO
45459032|NCT02849990|Drug|Degarelix|Given SC
45459033|NCT02849990|Drug|Indomethacin|Given PO
45459034|NCT02849990|Other|Laboratory Biomarker Analysis|Correlative study
45459035|NCT02849990|Drug|Prednisone|Given PO
45459036|NCT03488680|Behavioral|Behavior change communication|Behavior change communication about optimal complementary feeding
45459037|NCT03490474|Other|Pain Inducing Massage|Participants will receive 60 seconds of manual pressure applied to one myofascial trigger point so the participant rates the pain = 5/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
46089293|NCT00896051|Drug|Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs)|2 investigator-selected NRTIs taken as specified in the individual product labels for 2 weeks during the Pre-Treatment Period followed by 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) taken as specified in the individual product label for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) mg taken as specified in the individual product label during the Substudy.
46003994|NCT05376761|Drug|Dexmedetomidine|The loading dose of DEX (0.5 µg/kg) is transfused intravenously within 15min.The maintaining concentration of DEX, which is started at 0.3 µg/kg/h in the first patient, is determined by the NRMS in the MER signal of the previous patient according to the up and down sequence. If the NRMS is higher than 2.0, a positive response is defined and the concentration of DEX will be added by 0.05µg/kg/h in the next patient. A negative response is defined as NRMS lower than 2.0, and in such cases the concentration of DEX is reduced by 0.3 µg/kg/h.
46003995|NCT04617561|Drug|Ursodeoxycholic acid|Participants received Ursodeoxycholic acid (13-15mg/kg/d po.)
46003996|NCT04617561|Drug|Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)|Participants received Methylprednisolone (12mg/d po. in induction and 2-4mg/d in maintenance) combined with Ursodeoxycholic acid (13-15mg/kg/d po.)
46003997|NCT04617483|Biological|Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|The antigen content of the commercial scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group 26-45.
46003998|NCT04617483|Biological|Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|The antigen content of the pilot scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group 18-59.
46003999|NCT04617483|Biological|Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly|The antigen content of the pilot scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group above 60.
46004000|NCT05357729|Device|MultiSense® remote monitoring|At hospital, the patient will be monitored with conventional monitoring devices as well as the MultiSense® solution (at least one hour with a reference monitor). After hospital discharge, the patients will be remotely monitored by their healthcare professional using the MultiSense® solution.
45677544|NCT01978184|Drug|abraxane|
46004001|NCT04617288|Other|Ultrasound Therapy, SNAGs|
46004002|NCT04617249|Procedure|median anesthesia|giving median anesthesia
46004003|NCT04617249|Procedure|paramedian anesthesia|giving paramedian anesthesia
45342413|NCT02578836|Procedure|Fogel Gastroplasty|The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
45677545|NCT01978184|Drug|hydroxychloroquine|
46004004|NCT05349383|Drug|Antibody-Drug Conjugate|"Compared the case reporting of sepsis-related toxicities among ADC and other common cancer drug therapies.~ADC:including Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin."
46089294|NCT00896051|Drug|Etravirine (ETR) 200 mg|Etravirine (ETR) 200 mg taken twice daily as two 100-mg tablets following a meal (morning and evening) for at least the first two weeks of the 48-week Treatment Period. If participating in the optional substudy, participants will take ETR 200 mg twice daily as two 100-mg tablets following a meal each morning and evening on Substudy Days -1 to 7.
46089295|NCT00896051|Drug|Tenofovir disoproxil fumarate (TDF) 300 mg|Tenofovir disoproxil fumarate (TDF) 300 mg taken by mouth following a meal each morning on Substudy Days 1 to 7.
45459038|NCT03490474|Other|Pain Free Massage|Participants will receive 60 seconds of light touch applied to one myofascial trigger point so the participant rates the pain = 0/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
45677546|NCT01445548|Drug|Sirolimus|
45677547|NCT01977794|Drug|Bisoprolol/Amlodipine (Bisoprolol failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure (BP) is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
46004005|NCT05349383|Drug|Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate|We would like to include other common cancer drug therapies such as chemotherapy, targeted therapy, immunotherapy and so on as a comparator group.
46004006|NCT05344820|Behavioral|Art based mandala|To the experimental group; Mandala practice will be done for 2 hours, once a week for 8 weeks.
46089296|NCT02675478|Drug|AC220|
46089297|NCT00641550|Other|Physical exercise|Walking 3 times a week during 1 hours (moderate activity)
46089298|NCT05664204|Procedure|Veno-arterial extracorporeal membrane oxygenation|Strategy would reduce the need for invasive mechanical ventilation in the first 28 days without increasing adverse events
46004007|NCT04617171|Drug|Benralizumab 30 MG/ML [Fasenra]|Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
46004008|NCT04617171|Drug|Placebos|Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
46089299|NCT02673606|Drug|Estradiol 2Mg Tablet|one 2 mg dose of estradiol (obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),
46089300|NCT02673606|Drug|Estradiol 4Mg Tablet|two 2 mg pills estradiol(obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),
46089301|NCT02673606|Drug|Placebo Pills|inactive placebo pills
45677548|NCT01977794|Drug|Bisoprolol/Amlodipine (Amlodipine failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 milligram (mg)/5 mg once daily for 6 weeks. If BP is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
46004009|NCT05339555|Other|Instructions for IUD Self-Removal Provided to Participant|The provider will offer any individual presenting for in-person IUD removal or exchange (removal-replacement) the option for self-removal. The participant will be provided a 'how to' instruction sheet with information on positioning and what to expect. The participant will first attempt removal with clean hands if desired, then utilizing non-sterile, clean gloves (not explicitly tested in prior studies) and if that fails, the use of a menstrual cup (a novel technique). If not successful, the provider will perform standard IUD removal in the clinic.
46004010|NCT04617054|Drug|AB-106|600mg QD for each subjects.
45459039|NCT03490474|Other|Coldpressor|Participants will place their non-dominant hand into water cooled by a refrigeration unit temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times.
46089302|NCT02675400|Drug|Vyvanse|Half of the participants (fathers) will be randomized to receive Vyvanse.
46089303|NCT02675400|Behavioral|Behavioral Parent Training|Half of the fathers will receive behavioral parent training.
46089304|NCT02675400|Drug|Methylphenidate|If Vyvanse is not well tolerated, methylphenidate can be prescribed.
45459040|NCT03488602|Behavioral|F-SPS+UC|"Manualized individual and family program. Weekly individual and family sessions with a therapist for 6 weeks.~Participants will continue to receive usual care."
45677549|NCT04408768|Other|standard protocol for stroke patients|Standard protocol for stroke patients
46004011|NCT05337488|Other|questionnaire with interview|They will be invited to complete a questionnaire and an individual semi-structured interviews.
46004012|NCT00557934|Other|dobutamine|dobutamine stress (10 µg/kg/min) for 10 minutes during heart catheterization
46089305|NCT05501886|Drug|Gedatolisib|Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
46004013|NCT04679753|Device|Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)|Brainsway DTMS with iTBS
46089306|NCT05501886|Drug|Palbociclib|Palbociclib 125 mg PO given daily for 3 weeks (21 days), followed by 1 week off
46089307|NCT05501886|Drug|Fulvestrant|Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
46004014|NCT04679753|Device|Brainsway DTMS with High Frequency (HF) Stimulation|Brainsway DTMS with HF
46089308|NCT05501886|Drug|Alpelisib|Alpelisib 300 mg PO (2 × 150 mg tablets) given daily for 4 weeks (28 days)
45677550|NCT02005484|Drug|Trastuzumab|4 mg/kg initial dose, followed by 2 mg/kg
46089309|NCT00894647|Drug|imiquimod cream|Imiquimod 3.75% cream (250 mg/packet) up to 2 packets applied daily Two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
46089310|NCT00894647|Drug|placebo cream|cream applied once daily for two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
46089311|NCT02839421|Drug|Scaling and Root Planing combined with moxifloxacin|Scaling and Root Planing combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days
46089312|NCT02839577|Drug|High Volume injection without corticosteroid|"Injection with 10 mls 0.5% bupivacaine hydrochloride and~• 40 ml saline around the tendon."
45677551|NCT02024750|Behavioral|Tailored Resources|Based upon PRISM screening tool results that identifies self-management barriers, patient/family will receive self-management resources matched to their barriers. These resources could be focused on: 1. Understanding and organizing care; 2. Motivation to self-manage; and 3. Family Teamwork. Group session of about 6 families with the same barrier will meet four times fo 75-minutes over a year, at the clinic site on same date as routine clinic visit.
45677552|NCT01597973|Drug|colistin and meropenem|colistin standard loading dose, maintenance dose based on patients renal function meropenem- dose based on patients renal function
45677553|NCT01597973|Drug|colistin and placebo|colistin- loading dose standard, maintenance dosed based on patients renal function placebo- mimic meropenem (blinded)
45677554|NCT04671680|Device|LiDCO CNAP Monitoring Equipment|A continuous non-invasive arterial blood pressure monitor for rapidly changing hemodynamics.
45677555|NCT02023268|Device|T2762|1 drop in each eye 3 to 6 times daily during 84 days
45677556|NCT02023268|Device|Vismed®|1 drop in each eye 3 to 6 times daily during 84 days
45677557|NCT02047253|Drug|Carfilzomib|Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.
46089313|NCT02839577|Drug|High Volume injection with corticosteroid|Injection with 10 mls 0.5% bupivacaine hydrochloride, 20 mg Depomedrol and 40 ml saline around the tendon.
45677558|NCT02047253|Drug|Dexamethasone|Administered prior to administration of Study drug
46089314|NCT02841839|Drug|Stannous Fluoride|
46089315|NCT04179942|Diagnostic Test|Fractional exhaled nitric oxide and CRP levels|measurement of FeNO and Hs-CRP after 3months of CPAP
46089316|NCT02837549|Other|Occupational therapy treatment|This intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education
45677559|NCT02047253|Drug|Acyclovir|Administered orally twice daily
45677560|NCT05127161|Behavioral|Broad Implementation of Outpatient Stewardship (BIOS) intervention|The BIOS intervention consists of 3 components: (1) online educational modules covering topics related to appropriate antibiotic prescribing for ARTIs, (2) individualized audit and feedback reports displaying clinicians' rates of antibiotic prescription with peer comparison, (3) facilitation provided by the study team and by health system champions to support effective implementation of the intervention and to encourage clinicians to engage meaningfully in the intervention activities.
46004015|NCT00558051|Biological|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 4 intradermal injections once a day for 4 days.
46004016|NCT00558051|Biological|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 1 intranodal injection.
46089317|NCT02677194|Device|LED|There are 7 mini-zones of 1,5x1,5 cm at the level of forearm, one of them is allocated to control ( only laser). Dermabrasion by fractional laser CO2 ablative, evaluation of the pain on every zone by VAS post-act. Exposition to LED (630nm, 830nm and 590 nm). Water loss measure and colorimetry before and after laser and after the exposition to LED. Clinical evaluation of local tolerance post-laser and post-LED + standardized photographs.
46089318|NCT02677194|Other|Control device|Device without any LED exposition
46004017|NCT00558051|Biological|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of a 4-day intralymphatic infusion.
45677561|NCT04707131|Drug|LEM-S401|siRNA encapsulated in DegradaBALL®
45677562|NCT04707131|Drug|Placebo|Placebo
45677563|NCT02096705|Drug|Dapagliflozin|Tablet
45677564|NCT02096705|Drug|Dapagliflozin Placebo|Tablet
46004018|NCT04679714|Device|Transcatheter mitral valve repair (PLAR Implant and Delivery System)|The PLAR Implant is placed on the mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
46089319|NCT04250831|Dietary Supplement|agglomerated glucomannan, oligofructose and chromium mixture|Participants visited the University of Roehampton on three separate occasions: visit 1 (screening), visit 2 (baseline), and visit 3 (end of the trial) in total over a period of 4-weeks. During the 4-week study period, participants were instructed to replace breakfast and lunch with a shake (206 kcal/shake) each delivering 3g of the active ingredient (Mix: agglomerated glucomannan, oligofructose and chromium picolinate), and one snack bar each delivering 1.5g of the active ingredient (112 kcal/bar) in between breakfast and lunch, and lunch and dinner following by a selection of healthy dinner according to standard nutritional guidance not exceeding 1500 kcal/day. All subjects were instructed to prepare shakes by using a shaker or blender by mixing all ingredients with 200 ml of water. Participants were also instructed to consume all shakes and bars with an extra 200 ml glass of water throughout the study period.
45677565|NCT04705571|Device|MorpheusV Applicator|1 treatment with the MorpheusV Applicator
46004019|NCT00558090|Drug|morphine|patients receive 7,5 mg morphine iv 30 minutes before intervention (turning of the patient), the day after admission in the ICU. before, during and after, the patient will be asked to rate the pain using the NRS
46004020|NCT05323604|Other|Colectomy with anastomosis of any type|Patient with colonic resection followed by ileocolic, or colo colic, or colorectal, or coloanal anastomosis for cancer by laparoscopy or laparotomy
46004021|NCT00558129|Device|X-STOP®|Surgical implantation of X-STOP IPD device
46004022|NCT00558129|Procedure|Laminectomy|Standard laminectomy techniques will be used and may include laminotomy, foraminotomy and/or laminectomy as appropriate. In some cases at the discretion of the treating physician, fusion may indicated to stabilize the segment.
46004023|NCT04616976|Biological|convalescent plasma|convalescent plasma was get from the patients who recovery from COVID-19
46004024|NCT05293847|Behavioral|Telerehabilitation exercises and postural skills|12 week based postural exercises and skills were applied to participants. The exercises were done 3 times a week. The exercises about cervical and thoracal region strengthening and stretching of muscles and structures.
46004025|NCT04616742|Drug|[14C]SHR6390|Patients will receive single dose of orally [14C]SHR6390 on Day 1.
46004026|NCT04616703|Radiation|CT imaging|CT of abdomen
46004027|NCT05292287|Device|Polar Ignite Wearable Activity Monitor|A wearable activity monitor capable of monitoring outcomes relating to physical activity sedentary time, heart rate, and sleep quality. The watch synchronises to a corresponding mobile app called Polar Flow- Sync and Analyze or to the Polar FlowSync data transfer software on a computer.
46089320|NCT02841605|Procedure|Rectosigmoidoscopy with colonic biopsies|Rectosigmoidoscopy with colonic biopsies performed for Alzheimer patient and both control groups Parkinson and PSP
46089321|NCT02841605|Procedure|Colonoscopy with colonic biopsies|Colonoscopy with colonic biopsies performed only in patient at risk of colic cancer
45677566|NCT02096471|Drug|PD-0325901|
46004028|NCT04651140|Behavioral|aerobic exercise|Participants ride an Acon-8650 model exercise bicycle 3 times a week for 1 hour each time for four consecutive weeks
46004029|NCT05287217|Other|Comparison of medication administration for pain control|Measuring pain control following FESS surgery
46004030|NCT05278403|Other|Virtual reality and video games|Use of a software in stroke patients' rehabilitation.
45677567|NCT02096003|Drug|Intrathecal morphine|0.25mg intrathecal morphine is the standard opioid medication the investigators use for analgesia for cesarean sections. It is the control arm.
45677568|NCT02096003|Drug|Intrathecal hydromorphone|50mcg intrathecal hydromorphone will be added to 1.5mg 0.75% bupivicaine for single shot spinal anesthesia.
45677569|NCT02062385|Biological|V260|V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)
45677570|NCT02062385|Biological|Placebo to V260|Placebo control
45677571|NCT02062385|Biological|OPV|Oral poliovirus vaccine administered according to the standard of care
45677572|NCT02062385|Biological|DTaP|Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care
45677573|NCT02062151|Other|Acupuncture|Acupuncture
45677574|NCT02060903|Drug|Abametapir Lotion 0.74% w/w|Abametapir Lotion 0.74% was dispensed to subjects on Day 0 for self-administration at home on the same day.
45677575|NCT02060903|Drug|Vehicle Lotion|Vehicle Lotion was dispensed to subjects on Day 0 for self-administration at home on the same day.
45677576|NCT04704557|Device|geko Neuromuscular Electro Stimulator (NMES)|Neuromuscular Electro Stimulator (NMES)
45677577|NCT02095691|Device|Celsius® ThermoCool® Renal Denervation|The investigational device is indicated for the treatment of resistant hypertension by renal denervation.
45677578|NCT02095535|Drug|Chlorhexidine gluconate|antiseptic
45677579|NCT04704323|Drug|CAP-100|CAP-100 (humanized antibody against C-C-chemokine receptor 7 [CCR]7)
45677580|NCT04703699|Device|Myval Transcatheter Heart Valve System|Myval™ THV is a newer-generation balloon-expandable THV characterized by a nickel-cobalt alloy frame composed of a single element - hexagon arranged in a hybrid honeycomb fashion.
45683778|NCT01575873|Drug|Denosumab|Administered by subcutaneous injection once every 6 months
45683779|NCT01575873|Drug|Placebo for risendronate|Administered orally once a day
45683780|NCT01575873|Drug|Risendronate|Administered orally once a day
45677581|NCT02095223|Device|Electromyographic Biofeedback|Electromyographic biofeedback is a device that enables a patient or clinician to measure the intensity of a muscle contraction using electrodes placed on the skin over a muscle of interest. In this study, participants in the electromyographic biofeedback supplemented exercise will also be instructed on correct setup and use of the electromyographic biofeedback unit. These instructions will focus on correct placement of the electromyographic recording electrodes over quadriceps muscle as well as correct tuning of the feedback threshold for each exercise to maximize the benefit of the intervention. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group.
45683781|NCT01575873|Drug|Placebo for denosumab|Administered by subcutaneous injection once every 6 months
45683782|NCT03216928|Diagnostic Test|Blood test|
46089322|NCT04179630|Biological|Aldafermin (NGM282)|Single 3 mg dose
46089323|NCT02839499|Device|RU sleeping®|Each patient included in the study has a test by RU-sleeping. The diagnosis of obstructive sleep apnea syndrome will be asked for an index of respiratory events estimated as greater than or equal to 10.
46089324|NCT02839499|Other|autonomy scale (ADL and AGGIR)|autonomy data
46004031|NCT05278403|Other|Neurological physiotherapy|Application of conventional physical therapy techniques.
46089325|NCT02839499|Other|various activity scale (IADL)|activity of life data
46089326|NCT02675322|Drug|Danlou Tablets|Danlou tablets were approved by China Food and Drug Administration for the treatment of ischemic heart disease in 2005 (Z20050244).
46089327|NCT02675322|Other|Placebo|Placebo with no chemical effects.
46089328|NCT00633191|Drug|Anti-pseudomonas IgY gargle|Gargle (solution), > 5FKU, every night after toothbrushing, life-long
46089329|NCT04178382|Diagnostic Test|PCR-CRISPR／Cas12a detection|Evaluate whether the combination of PCR and CRISPR/Cas12a detection of alveolar lavage fluid changes the choice of early antibiotics in patients with pneumonia in artificial airways, and whether it changes the prognosis compared with traditional pathogenic microbial detection techniques.
46089330|NCT02675166|Other|Pediatric cancer young adult survivors|Patients will receive a questionnaire, a consultation with an oncologist and a psychologist will be planned, and two years later, patients will have to answer again to the questionnaire.
46089331|NCT04249817|Other|Video Conferencing with Exteneded Role Practitioner (VC-ERP)|Participant goes to Ontario Telemedicine site for follow-up. At site, participant will get a physical assessment by an extended role practitioner and then will connect to their rheumatologist by videoconferencing for completion of follow-up.
46089332|NCT02837627|Other|Tube feeding|During the study period, enteral feeds will be administered according to different tube feeding modalities: bolus feeding followed by the removal of the feeding tube; bolus tube feeding with permanence of the feeding tube for the whole post-prandial period; continuous feeding over a 3-hour period.
46089333|NCT05471154|Device|High Definition transcranial direct current stimulation (HD-tDCS)|HD-tDCS is used at 2mA and during 20 minutes and with electrodes positioned on regions F4 (anode), Fp2, Fz, F8 and C4 (cathodes), according to the international 10-20 electroencephalogram system. 5 sessions are given on 5 following days. The material used in this study is the Soterix Medical 1x1 tES mini-CT and HD 4x1 splitter, produced by Soterix Medical Inc., 237 W 35th St, New York, NY 10001, United States of America.
46089334|NCT02841683|Behavioral|Tabac Info Service|A smoking cessation E-intervention, Tabac Info Service (TIS), by website and mobile application
46089335|NCT02675088|Radiation|high-dose TRT|every day, Monday-Friday, for a total of 3 weeks, 45 Gy/ 3 Gy/ 15 f
46089336|NCT02675088|Radiation|standard-dose TRT|every day, Monday-Friday, for a total of 2 weeks, 30 Gy/ 3 Gy/ 10 f
46004032|NCT04650906|Behavioral|Mindhelper - a national youth mental health promotion website|Mindhelper is a fully digital youth mental health service reaching out to a large number of young people when and where they need it, with full anonymity. Mindhelper was developed in 2014-2017 by Centre for Telepsychiatry in the Region of Southern Denmark in a partnership with four Danish municipalities. The development of the site was funded by the Danish foundation TrygFonden. The original idea behind the site was inspired by the Australian youth mental health promotion service ReachOut.com. The Mindhelper service was launched in September 2016. From January 2019 Mindhelper received permanent funding through a joint agreement between the five Danish Regions. Mindhelper is Denmark's most comprehensive youth mental health promotion website where young people can seek mental health information, advice, and self-help tools to improve their mental health and well-being. Since it was launched, the site has been very successful in attracting large numbers of visitors.
45836157|NCT00112242|Biological|Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG+ IL-2|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
46089337|NCT02841293|Procedure|Biological mesh|The intervention consists of suturing a biological mesh in the pelvic floor defect. The mesh will be sutured at each side of the coccyx or distal sacrum and directly to the residual pelvic floor muscle and fascia by using interrupted or continuous hand-sewn sutures with an appropriate amount of tension. The mesh that will be used is the Cellis prosthesis from Meccellis Biotech, reference C1015E which size is 10x15cm.
46089338|NCT02841293|Procedure|Primary perineal wound closure|The intervention consists of stitching the ischioanal and subcutaneous fat using interrupted Vicryl sutures in one or two layers similar to primary perineal closure
46089339|NCT00643422|Device|Cirrus™ HD-OCT, Carl Zeiss Meditec AG|the retinal thickness and volume is determined on two different days with the Cirrus™ HD-OCT.
46089340|NCT00643500|Drug|Levetiracetam|
46089341|NCT02837393|Procedure|Ureteral catheterization|During ureteral catheterization, urine samples will be obtain from each kidney
46089342|NCT00910104|Drug|Omegaven®|10% Omegaven® 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated
46089343|NCT02837081|Other|Prospective audit strategy of antimicrobial stewardship|applying prospective audit as a different strategy of antimicrobial stewardship
45836158|NCT00284154|Drug|Vinflunine|320mg/m2 every 21 days as a 15-20 minute infusion
46004033|NCT05273255|Biological|Fecal Microbiota Transplantation (FMT)|Single-dose of fecal microbiota from FMT-Donor transplanted endoscopically to FMT-Recipient in between two cycles of ICI.
46004034|NCT04650750|Drug|Xiao-Feng-San+Shian-Fang-Hwa-Ming-Yiin|"Xiao-Feng-San is a common Chinese herbal preparation, composed of 13 herbs, which is used to treat patients with dermatitis. The component of Xiao-Feng-San has immunomodulatory activity. Shian Fang Hwa Ming Yiin is another common Chinese herbal preparation, composed of 12 herbs, which is used to treat patients with carbuncles and acne. The component of Shian Fang Hwa Ming Yiin has anti-inflammation and anti-microbial effect."
46004035|NCT04650750|Drug|Placebo|Similar placebo 4g twice a day for two months
46004036|NCT05250128|Procedure|Catheterization|Right heart catheterization, using the Swan-Ganz standard technique, to measure mean pulmonary arterial pressure, pulmonary capillary wedge pressure, cardiac output and pulmonary vascular resistance
46004037|NCT04617015|Drug|Ipratropium Bromide|All subjects receive inhaled ipratropium once with measurement of spirometry before and after. Bronchodilator response of subjects with depression is compare to that of subjects without depression.
46004038|NCT04650711|Diagnostic Test|p16 protein expression|P16INK4A immunohistochemical staining is to be performed in residual cytology samples.
46089344|NCT02837081|Other|preauthorization strategy of antimicrobial stewardship|applying preauthorization as one strategy of antimicrobial stewardship
46089345|NCT02675010|Other|ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY|ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY
46089346|NCT00633269|Drug|AZD2281|100mg Oral Dose
45836159|NCT01899924|Behavioral|Event Related Potentials recording|
46089347|NCT02674620|Other|Aerobic Exercise|Patients are treated with progressive exercise
46089348|NCT02839187|Radiation|Neuroimaging|AV45-positron emission tomography
46089349|NCT05662254|Behavioral|Personalized Behavioral Intervention|Behavioral lifestyle intervention assigned according to each participant's mood and lifestyle data patterns.
45836160|NCT00223236|Drug|Citicoline|Citicoline or placebo will be given beginning at one table (500mg)/day with an increase to two tablets (1000mg)/day at week 2, three tablets (1500mg)/day at week 4 and four tablets (2000mg)/day at week 6. Patients will remain on 2000mg/day through week 12. Doses will be decreased if needed due to side effects.
45836161|NCT00223236|Drug|Placebo|Placebo matching active medication in all other aspects.
46004039|NCT04650828|Drug|TDF|TDF combined with telbivudine (LDT) for 12 months
46004040|NCT04650828|Drug|Tenofovir Disoproxil Fumarate 300 MG|TDF monotherapy was continued for 12 months
45342414|NCT03994237|Other|semi-structured interview|The tool used is a nurse card: there is no validated tool on the expectations of the caregiver in his memory referral. This is a pragmatic and practical questionnaire memory consultation request and domestic life with few items, practical use by telephone.
46089350|NCT02690675|Dietary Supplement|Iron fortified formula milk|One group received formula milk fortified with 1.2 mg/100 mL and the other group 0.4 mg/100mL between 6 and 12 months of age.
45677582|NCT02095223|Behavioral|Traditional Exercise|All participants will be asked to complete 3 set of 10 repetitions of isometric quadriceps contractions with a 15 second hold time, supine straight leg raises, body weight squatting, and body weight lunges daily. Participants will be required to complete the single limb exercises on the previously injured limb only.
46004041|NCT04650360|Behavioral|Postoperative Intervention Educational Program|The health educational program consisted of a single training session offered by a nursing professional to each patient and caregiver. In each educational session, the following topics were addressed: objectives for functional recovery (early mobilization, recovery of functional capacity lost prior to the fracture, etc.), mobilization exercises to start the day after the surgical procedure (lower limb exercise, respiratory physiotherapy, etc.), and tips to prevent future falls. The educational session was implemented during the postoperative hospital stay, with an approximate duration of 30-45 min. The session ended with a summary of the content and comments from the patient and relative in order to ensure understanding of the program. Written information was provided on the aspects addressed in the session (brochures). These patients were treated according to routine protocols. All patients were monitored during admission, at 1 month, at 6 months, and at 1 year after the intervention
45677583|NCT02095145|Other|Laboratory Biomarker Analysis|Correlative studies
46004042|NCT05199350|Other|Device Name: ANSiscope|Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
46004043|NCT05197556|Drug|HSG4112|Once-daily oral administration
46004044|NCT05197556|Drug|Placebo|Once-daily oral administration
46004045|NCT04650555|Drug|BIO 300 Oral Powder|Amorphous solid dispersion of genistein milled into a powder
46004046|NCT04650477|Procedure|Fixation while forearm in extension-pronation position|Fixation was performed after tenodesis in the extension-pronation position, which is the anatomically most suitable position of the biceps tendon.
46004047|NCT00553904|Dietary Supplement|Cranberry juice|480 ml of double strength cranberry juice daily for four weeks
46004048|NCT05181683|Drug|Casirivimab+Imdevimab|Randomized 1:1 for intravenous (IV) or subcutaneous (SC) administration
46089351|NCT05658978|Other|Neuromuscular training|Neuromuscular training Length: 12 weeks; Training duration: 90 minutes; Intensity: 70-75% in the last weeks' intensity will be 80 to 85%; 3 days per week. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes; Rest: 30 seconds rest between exercises and 1-minute rest between sets.
46089352|NCT05658978|Other|Control group|The Control group continues previous regular exercises for 12 weeks with a duration of 90 minutes and three days per week.
45836162|NCT00223704|Drug|HOE 140|HOE 140 (a bradykinin B2 receptor antagonist) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. HOE 140 was given as an intravenous bolus of 22 µg/kg over one-half hour followed by an infusion of 18 µg/kg/hr.
45836163|NCT00223704|Drug|Aminocaproic Acid|Aminocaproic acid (an antifibrinolytic drug) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. Aminocaproic acid was given as an intravenous bolus of 100 mg/kg over one-half hour followed by an infusion of 30 mg/kg/hr.
46004049|NCT04650516|Device|Virtual reality|20 minutes treatment in virtual reality
46004050|NCT04650516|Device|Digital control|20 minutes digital control movie on tablet without virtual reality
46004051|NCT05159375|Dietary Supplement|Elio|Elio™ supplementation, a protein hydrolysate derived from fava bean protein extract
46004052|NCT05159375|Other|SMCC|Placebo comparator
46004053|NCT04650321|Drug|Ocrelizumab at home|Patients will receive ocrelizumab infusion at home.
46089353|NCT02677350|Drug|Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)|Peri-fistula injections
46089354|NCT04181346|Drug|Pregabalin|antipsychotic
46089355|NCT04181346|Drug|Placebo|Placebo
46089356|NCT04181502|Procedure|pneumatic tourniquet|a pneumatic tourniquet around 200 mmHg after venous chase of the lower limb, during 5 minutes then deflated. Repeated twice after general anaesthesia and prior to incision.
46089357|NCT04181502|Other|No inflation|No inflation of the pneumatic tourniquet placed on the lower limb
45677584|NCT02095145|Other|Pharmacological Study|Correlative studies
45677585|NCT02095145|Other|Placebo|Given PO
45677586|NCT02095145|Drug|Pomegranate-Extract Pill|Given PO
45677587|NCT04722029|Biological|Adenovirus Specific T lymphocytes|ADV-VSTs is being proposed for the treatment of refractory ADV infection and/or disease in these populations using haploidentical donors for ease of donor selection, antiviral immunity, coupled with a high-throughput antigen stimulation/IFN-γ capture system (Miltenyi Biotec, CliniMACS Prodigy® System) for rapid and less costly isolation of ADV-VSTs.
46004054|NCT05153525|Drug|Intermittent boluses of Cisatracurium|Thirty children with ARDS will be treated with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).
46004055|NCT05153525|Drug|Intravenous infusion of Cisatracurium for 24 hours|Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.
45342415|NCT01033201|Other|Confocal imaging|At the time of the standard of care bronchoscopy, confocal images will be obtained from each consented patient.
46004056|NCT04649931|Device|Ion Mobility Spectrometry (IMS)|Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
45677588|NCT04702373|Other|passive range of motion exercise therapy|Systematic flexion-extension with gentle compression at the end of the movement is performed 10 times at the wrist, elbow, shoulder, ankle, knee, and hip joints. Ten repetitions of adduction-abduction are performed at the shoulder and hip joints.
46089358|NCT05277246|Other|Irrigant concentration|The success of endodontic treatment is directly related to infection control. In successful endodontic treatment, it is necessary to perform an ideal irrigation both in order to gain a better understanding of the complex anatomical structure of the root canals and to increase the efficiency of the instruments and methods used during the canal preparation. Sodium hypochlorite (NaOCl) solution is the standard irrigation agent for cleaning and disinfection of root canal. In this study, the effect of NaOCI on level of IL-8 different concentration will be evaluated.
46089359|NCT05277246|Drug|NaOCI|NaOCI
46004057|NCT04649970|Procedure|Antegrade double-J stent|After exchanging the nephrostomy catheter over the J-tipped guidewire, 5 F multipurpose (45° tip) diagnostic vascular catheter was inserted. Once the pelvi¬ureteric junction was crossed and the ureter accessed, a straight hydrophilic guidewire and a catheter were used. Then, the cath-eter was advanced into the bladder over the wire, this guidewire was exchanged for an ultra-stiff guidewire, an 8 or 10 F double J ureteral stent was placed over the guidewire, and the safety kit of the stent was removed. A final fluoroscopic image was stored for correcting the stent position.
45677589|NCT02059187|Drug|MK-1293|MK-1293 (insulin glargine) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate MK-1293 at 10 units daily. Participants taking insulin will initiate MK-1293 at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
46004058|NCT05127863|Behavioral|social communication intervention (pragmatic)|10 sessions of group intervention in order to improve pragmatic/social communication. one session of one hour per week. Activities will included role play, conversations, etc.
46004059|NCT04649892|Drug|Naltrexone|Patients will receive daily doses of Naltrexone, starting at 50mg and increasing 25mg per week until reaching 200mg or the maximum tolerated by the patient
46004060|NCT04649892|Drug|Placebo|Patients will receive daily doses placebo matching tablets for the 12 weeks of the study. Throughout this period, possible adverse effects will be monitored weekly.
46004061|NCT04649892|Behavioral|Psychoeducational|Participants will also attend to 4 sessions of psychoeducational intervention in weeks 2, 4, 6, and 8
46004062|NCT04649892|Device|Eye-tracking|"The attentional bias of the participants will be assessed using the Eye-tracking device in 4 moments throughout the study:~Before taking the first dose of naltrexone or placebo.~One hour after taking the first dose of naltrexone or placebo.~One week after continuous and daily use of naltrexone or placebo.~At the end of the intervention, after 12 weeks of continuous and daily use of naltrexone or placebo."
46089360|NCT00642564|Other|Observational study in Epileptic Patients|Observation study in Epileptic Patients with Migraine and Headache
46004063|NCT05125796|Drug|paracetamol|1000 mg intravenous paracetamol in 100 mL normal saline
46004064|NCT05125796|Drug|Dexketoprofen Trometamol|50 mg intravenous dexketoprofen Trometamol in 100 mL normal saline
46004065|NCT05125796|Drug|Lidocaine topical|Application of 5 gr of 5% topical lidocaine
46089361|NCT04180956|Other|Bias-reduction Intervention|A training for doctors
46089362|NCT04181190|Diagnostic Test|Total IgE|Levels of total IgE before biological treatments and at 4±2 months of treatments
46089363|NCT04181190|Diagnostic Test|Blood cell counts|White Blood Cell Count and Differential (and in particular the levels of total leucocytes, lymphocytes, eosinophils and basophils)
46089364|NCT04181190|Diagnostic Test|Asthma control assessment|Levels of asthma control assessed by asthma control questionnaire (ACT) before initiation of biological treatments and at 4± months of treatments
46089365|NCT04181190|Diagnostic Test|lung function tests|Lung function tests performed before initiation of biological treatments and at 4± months of treatments
46089366|NCT00892775|Biological|Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine)|Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
46089367|NCT00892775|Biological|GSK Biologicals' 208136, new formulation|Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
46089368|NCT02676648|Behavioral|Multicomponent online program|The core program includes information developed in earlier research with individuals with type 2 diabetes, now modified for online delivery: very low-carbohydrate diet taught with lectures on video, handouts, quizzes, and surveys. We also teach participants about the importance of physical activity and adequate sleep, in addition to psychological skills (positive affect, mindful eating) intending to help with intervention adherence.
45836164|NCT00223704|Drug|Placebo|Normal saline (placebo) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery.
45836165|NCT00224952|Other|No intervention; Urine Collection|Urine collected from children receiving carbamazepine or valproic acid as part of their clinical management
45836166|NCT00225420|Drug|docetaxel|Docetaxel will be administered per the designated cohort starting at 10 mg/m2 intravenously over 1 hour weekly for eight weeks, for a total of eight treatments.
45677590|NCT02059187|Drug|Lantus™|Lantus™ (insulin glargine [rDNA origin]) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate Lantus™ at 10 units daily. Participants taking insulin will initiate Lantus™ at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
45677591|NCT02059187|Drug|Prandial insulin|Participants taking prandial insulin will continue their current prandial insulin regimen during the insulin glargine titration. After the insulin glargine titration phase, the prandial insulin may be adjusted if the investigator determines it to be necessary for glucose control.
45677592|NCT04721405|Device|Observational Study: No intervention|Observational Study: No intervention
45836167|NCT00225420|Drug|leuprolide acetate|Leuprolide acetate will be administered at 22.5 mg IM and will be initiated 2 to 3 months prior to radiotherapy and chemotherapy with docetaxel.
46004066|NCT05125796|Drug|Placebo|100 mL intravenous normal saline infusion+ placebo topical pomade application
46004067|NCT04649814|Other|Questionnaire|Questionnaire for all, interview for part of the respondents.
45459041|NCT03488602|Behavioral|EUC|"Weekly telephone contact with parents regarding participant health care utilization. Referrals to community mental health resources provided as needed.~Participants will continue to receive usual care."
45836168|NCT00225420|Radiation|radiation therapy|The total dose will be 7800 cGy in 200 centigray (cGy) per fraction for a total of 39 treatments.
45836169|NCT00225498|Drug|ziprasidone vs risperidone or olanzapine|ziprasidone target dose is 160 mg/day risperidone target dose is 4 mg/day olanzapine target dose is 20 mg/day
45836170|NCT00225732|Other|Normal saline as placebo comparator|250 ml normal saline as a placebo comparator was administered every 6 hours for a total of eight doses over the first 48 hours. Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)
46004068|NCT04616859|Dietary Supplement|Alcohol and Energy Drink (AmED)|Multiple oral dose of alcohol mixed with ED
46004069|NCT04616859|Dietary Supplement|Alcohol and Energy drink Placebo|Multiple oral dose of alcohol mixed with ED placebo (soft drink)
46004070|NCT04616859|Dietary Supplement|Alcohol placebo and Energy drink|Multiple oral dose of alcohol placebo (water) mixed with ED
45342416|NCT01033279|Other|Self-monitoring and adjustment of oral anticoagulation|Weekly self-monitoring of oral anticoagulation with a portable coagulometer and predefined adjustment algorithms for 4 months following a training program led and designed by hospital pharmacists
46004071|NCT04616859|Dietary Supplement|Alcohol placebo and energy drink placebo|Multiple oral dose of alcohol placebo (water) mixed with ED placebo (soft drink)
46004072|NCT04616937|Dietary Supplement|GOS|Prebiotic
46004073|NCT04616937|Dietary Supplement|Placebo|Placebo
46004074|NCT05053607|Behavioral|Digital Health Coaching Program|consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
46004075|NCT05053607|Device|Fitbit|A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
46004076|NCT04616586|Drug|Siltuximab|11 mg/kg IV administered over 1 hour
46004077|NCT04616586|Other|Normal Saline|IV administered over 1 hour
46004078|NCT05045612|Other|Stop antibiotic therapy|Stop antibiotic therapy instituted by the admitting physician
46004079|NCT04616469|Procedure|Root canal treatment using TruNaomy rotary files|Trunatomy rotary files will be used for the process of cleaning and shaping of the root canal system
46004080|NCT04616469|Procedure|Root canal treatment using race rotary instruments|Race rotary files will be used for the process of cleaning and shaping of the root canal system
46004081|NCT05038787|Drug|LY3473329|Administered orally.
46089369|NCT02676648|Behavioral|Breath meter|We will send participants a breath meter to test ketones in their breath, to assess dietary adherence.
46004082|NCT05038787|Drug|Placebo|Administered orally.
46004083|NCT00563043|Procedure|PASCAL laser treatment|Patterns Scan Laser treatment in patients with PDR.
46004084|NCT05009732|Drug|GT0918|300mg once daily orally
46004085|NCT05009732|Drug|Standard of care|Local standard of care per written policies or guidelines
46004086|NCT05009732|Drug|Matching placebo|Matching placebo
46004087|NCT00563121|Procedure|Vitrectomy|Open-Sky vitrectomy, with resection of the tunica vasculosa lentis, and retinal reattachment
46089370|NCT02676648|Behavioral|Text messages|We will send participants text messages, to support intervention adherence.
46089371|NCT02676648|Behavioral|Diet-appropriate foods and cookbooks|We will send participants diet-appropriate foods and cookbooks, to support intervention adherence.
46089372|NCT04033536|Radiation|Involved Target Stereotacic Spine Radiosurgery|Image guidance spine stereotactic radiosurgery/ablative radiotherapy 1600 cGy in single fraction to Involved Target using IMRT/VMAT/RapidArc
46004088|NCT04988321|Procedure|Prolonged continuous theta burst stimulation (pcTBS)|Non-invasive brain stimulation (transcranial magnetic stimulation or TMS) which consists of a stimulating coil being held over the head. When this coil delivers a painless magnetic pulse, it feels like a quick, light tap on the head. Two different coils will be used to perform TMS. One coil will be used to determine stimulation parameters for the pcTBS protocol. The second coil will be used to implement pcTBS, which is a repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on the head. Participants will receive two procedures during one session, one with active stimulation and one with inactive stimulation.
46004089|NCT04616508|Behavioral|motor control assessment|Basic science study of control of reaching movements
46004090|NCT04616352|Other|Resistance to cefuroxime|Non susceptibility in vitro testing
46004091|NCT00553943|Drug|Rituximab|375 mg/m2 D1
46004092|NCT00553943|Drug|Cytarabine|50 mg D3
46004093|NCT00563160|Drug|gemcitabine, carboplatin|
45677593|NCT02043899|Drug|[124I]meta-Iodobenzylguanidine|Single intravenous administration of [124I]mIBG Solution for Injection on Day 1 with a maximum radioactive dose of 1.42 MBq/kg (±10%) and a maximum injected dose of 50 MBq [124I]mIBG equating to a maximum chemical dose of 10 micrograms of stable mIBG. The activity to paediatric patients will be scaled by weight based upon the EANM paediatric dose card (Lassmann et al., 2007). This will result in an activity between 10 MBq and 50 MBq depending on the patient's weight.
45677594|NCT04719611|Dietary Supplement|Probiotic|Healthy women receive a probiotic supplement containing 6 x 10^9 colony-forming units/capsule of Bifidobacterium and Lactobacillus strains.
45836171|NCT00225732|Drug|Intravenous ibuprofen|"800 mg intravenous ibuprofen diluted in 250 milliliters of normal saline was administered every 6 hours for a total of eight doses over the first 48 hours.~Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)"
46089373|NCT04033536|Radiation|Elective Target Stereotacic Spine Radiosurgery|Image guidance spine stereotactic radiosurgery/ablative radiotherapy 1600 cGy in single fraction to Elective Target using IMRT/VMAT/RapidArc
45459042|NCT05190536|Procedure|Ho:YAG lasers|Under the guidance of B-ultrasound or X-ray, the appropriate target calyx was punctured with an 18G puncture needle.Percutaneous tract was established with 18Fr suction sheath. 12Fr nephroscope and 360um Ho:YAG laser fiber was used for lithotripsy.Kidney stones were fragmented by Ho:YAG lasers, and sucked out by the suction sheath.
45836172|NCT02096718|Drug|Afatinib healthy|
45836173|NCT02096718|Drug|Afatinib severe renally impaired|
45836174|NCT02096718|Drug|Afatinib moderate renally impaired|
45836175|NCT00113022|Drug|Org 24448|250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
46004094|NCT00563160|Procedure|surgery|
46089374|NCT00642720|Drug|Pegvisomant|if the addition of 40 mg pegvisomant weekly will improve the quality of life of acromegaly patients compared to placebo weekly
46089375|NCT02674698|Other|Access to the CNH Dashboard Step 1|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
46089376|NCT02674698|Other|Access to the CNH Dashboard Step 2|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
46089377|NCT02674698|Other|Access to the CNH Dashboard Step 3|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
46004095|NCT00563199|Behavioral|nurse-delivered stage-matched smoking cessation counseling|
46004096|NCT00563238|Drug|Metoprolol|Metoprolol administered intravenously in 2.5mg boluses until the resting heart rate falls by 10% from baseline to a maximum dose of 10mg, or until there is any apparent adverse reaction.
46089378|NCT02674698|Other|Access to the CNH Dashboard Step 4|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
46089379|NCT05395338|Drug|rt-PA|Recombinant Tissue Plasminogen Activator
46089380|NCT00643656|Drug|Kalinox 170 bar|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
46089381|NCT00643656|Drug|Mix of 50% oxygen and 50% nitrogen|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
46089382|NCT04179318|Diagnostic Test|Geneswell BCT|Geneswell BCT is a precise and qualitative in vitro diagnostic test. The expression of 9 genes was obtained from the formalin fixed paraffin embedded block (FFPE) of breast cancer tissue samples by RT-qPCR, and the patients were divided into high-risk group and low-risk group.
45459043|NCT05190536|Procedure|TFL|Under the guidance of B-ultrasound or X-ray, the appropriate target calyx was punctured with an 18G puncture needle.Percutaneous tract was established with 18Fr suction sheath. 12Fr nephroscope and 360um TFL fiber was used for lithotripsy.Kidney stones were fragmented by TFL, and sucked out by the suction sheath.
45677595|NCT02043509|Behavioral|MiQuit|MiQuit is an automated responsive text message support programme lasting 12 weeks which provides tailored smoking cessation support and advice to the participant's mobile phone. This support includes motivational messages, advice about preparing for a quit attempt, how to manage cravings and withdrawal, dealing with trigger situations, information about how smoking affects babies and general encouragement.
46004097|NCT04679558|Drug|Chlorhexidine varnish added to the preventive protocol|Antibacterial agent varnish added to the preventive protocol
46004098|NCT04679558|Behavioral|Preventive protocol|Preventive protocol
45677596|NCT04719377|Device|catheter placement|catheter placement
46004099|NCT03454542|Device|Menicon Modified Lens Design|Randomized in a daily wear, single day (6 hours or more) evaluation
46004100|NCT04934228|Drug|Hydrochlorothiazide 12.5Mg Tab|"Will receive 4 week supply (35 days) of Hydrochlorothiazide Pills (12.5 mg twice a day)~Planned use in this study~Condition/disease indication(s): Hypertension~Subject population: Hypertension~Dose(s): 25 mg/day~Administration: Oral~Dosing regimen: 12.5 mg twice per day"
46004101|NCT04934228|Drug|Clonidine Pill|"Will receive 4 week supply (35 days) of Clonidine Pills (0.1 mg twice/day)~Planned use in this study~Condition/disease indication(s): Vascular function and blood flow~Subject population: Hypertension~Dose(s): 0.1 mg (oral)~Administration: Oral~Dosing regimen: 0.1 mg twice daily by mouth"
46004102|NCT04934228|Drug|Placebo|Will receive a 4 week supply (35 days) of Placebo Pills; has no active ingredients but is made to look like the study drug.
45677597|NCT02058563|Biological|Priorix®|1 dose administered as a subcutaneous (SC) injection.
46004103|NCT03454503|Drug|Imatinib|Film coated tablet contains 400 mg imatinib (as mesilate)
46004104|NCT03454464|Procedure|Conventional|Conventional operation ,Thyroidectomy was performed first, and central compartment dissection was performed. This is a routine procedure
46004105|NCT03454464|Procedure|central neck dissection first|central neck dissection first ,after FNA confirmed of thyroid carcinoma, the central compartment neck dissection was carried out before thyroidectomy , finally complement of central compartment neck dissection.
46089383|NCT00642798|Drug|sitagliptin phosphate|Sitagliptin 100mg once daily on Day 1 for single dose, and once daily on Day4-9 for multiple dose.
45677598|NCT02058563|Biological|Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine|1 dose administered subcutaneously.
45677599|NCT01622231|Drug|Fluticasone furoate|55 mcg/day, intranasal, 12 weeks
46089384|NCT05364996|Diagnostic Test|bronchial endoscopy with bronchoalveolar lavage (LBA)|Bronchial endoscopy under laryngeal mask and general anesthesia. BAL of saline at room temperature of 3 milliliters per kilogram limited to 20 milliliters x 3 according to recommendations
45836176|NCT00113022|Drug|Placebo|Inactive equivalent of 250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
45836177|NCT02097732|Drug|Ipilimumab|Ipilimumab 3mg/kg given intravenously over 90 minutes, every 3 weeks for a total of 4 doses.
45836178|NCT02097732|Procedure|Stereotactic Radiosurgery|Stereotactic radiosurgery is a type of focused radiation therapy. It requires the placement of a metal frame on the head for several hours.
46004106|NCT03454386|Behavioral|Stress Management and Resilience Training Program|"This program targets attention and interpretation of events, people and the world through the skills of gratitude, compassion, acceptance, forgiveness and understanding of a higher meaning. The program involves two phases. The 4 week training phase begins with a group session that discusses the practices that can be used to enhance awareness and engagement through the principles listed above. Participants will receive twice weekly emails with videos that described a different practice for participants to use in their daily lives. The second phase is the sustain phase that is 8 weeks in duration. Participants are expected to continue using the daily practices learned during the training phase. Weekly emails will be sent with ways to incorporate these practices into their daily lives."
45836179|NCT04752306|Other|Interviews|Semi-structured interviews will take place between June and August 2020. Eight individual interviews with healthcare workers, ten individual interviews with residents and two individual interviews with policymakers. Interviews with the healthcare workers and policymakers will take place in a meeting room at the nursing home of employment. One interview with a policymaker will take place online. Interviews with residents will be hold in their personal room.
46004107|NCT03454386|Behavioral|Self-Management Stress Reduction Program|Program participants will be given a popular stress reduction book to read over a 12 week period. Upon completion of this, they will be enrolled in the online SMART program for 12 weeks.
46004108|NCT04915781|Other|Not applicable, this is an observational study|Not applicable, this is an observational study
46004109|NCT04616157|Behavioral|ICBT-I|Cognitive-behavioral therapy for insomnia
46004110|NCT04900844|Device|CGuard Carotid Stent implantation|Implantation of CGuard carotid stent in the eligible patients
46004111|NCT04616391|Device|insulin pump Medtronic 780G|"Patients from the AHCL group will use the MiniMed 780G AHCL system. This system is already CE-marked.~The AHCL system will be initiated first in Manual Mode (i.e. without AHCL control) with suspend before low feature (Visit 1).~The AHCL system will be initiated in Auto Mode (i.e. with AHCL control) at Visit 2 with the settings in the below table. The Insulin to Carb ratio (ICR) and the Active Insulin Time (AIT) may be adjusted by the physician during the study. The glucose target may not be adjusted, unless in case of safety concerns. The patients may not adjust system settings without consulting with the physician.~At each visit, the AHCL system data will be downloaded and reviewed by the physician. The patient interaction with the system will be evaluated, included sensor calibration, bolus management (before the meals and for corrections as needed), alarms and Auto Mode exits."
46004112|NCT03455153|Other|Physical activity monitoring|COPD patients will wear an accelerometer and complete questionnaires related to daily physical activity levels for 7 days before returning for a clinic visit.
46089385|NCT05364996|Diagnostic Test|Blood sampling|collection of 5 milliliters of blood for total white cells count, C-Reactive Protein, specific immunoglobulin E assays, serum sRAGE assay
46089386|NCT02676726|Procedure|Extraperitoneal Laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
46089387|NCT02676726|Procedure|Transperitoneal Laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
45473921|NCT03184701|Other|Telehealth|Patients will be given an ipad with preloaded app (secured questions assessing their symptoms and cognitive function in a systematic timely way). The responses will be delivered to the care providers instantly, which will trigger an algorithmic clinical approach.
45836180|NCT02028468|Procedure|hemiarthroplasty|
45836181|NCT00113334|Drug|ABT-510|100 mg subcutaneously twice daily
45836182|NCT00286182|Drug|Erythropoietin alpha|Erythropoietin alpha is administered weekly by subcutaneous injection using a pre-specified dosing algorithm. The dosing algorithm is designed to make adjustments based on the rate of rise (ROR) of the hemoglobin over a one week period, as well as the absolute hemoglobin value. Subjects initially received active treatment with 7,500 units of erythropoietin given weekly by subcutaneously injection. Subjects are carefully monitored (e.g. every week) to avoid rapid increases in hemoglobin/hematocrit and/or increasing blood pressure control. Dose adjustments are made if the hemoglobin rises too rapidly (greater than 0.3 g/dL) in any given weekly interval.
46004113|NCT04616430|Drug|Topical endoxifen|topical solution
46004114|NCT04616430|Drug|Placebo|topical
46004115|NCT04891796|Other|No intervention|No intervention
46004116|NCT04616040|Drug|Camrelizumab|The recommended formulation of Camrelizumab is 200 mg every time, or 3 mg/Kg according to body weight, intravenously infused.
46004117|NCT04890236|Drug|Duvelisib|Given PO
46004118|NCT04890236|Biological|Tisagenlecleucel|Given via infusion
46004119|NCT04616118|Other|Phone Visit|Participants randomized to this arm will receive usual care via telephone only
46004120|NCT04616118|Other|Video Visit|Participants randomized to this arm will receive usual care via video call
46089388|NCT05443464|Biological|OSSM-001|Direct IV infusion of OSSM-001
46089389|NCT02673216|Other|No intervention|
46089390|NCT00643734|Drug|azithromycin sustained release|azithromycin SR 2.0 g by mouth in the form of a slurry for 1 dose
46089391|NCT00643734|Other|placebo|placebo
46089392|NCT00643734|Drug|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
46089393|NCT00643734|Other|placebo|placebo
46089394|NCT05410236|Other|3D bronchial tree model|A detachable 3D printed bronchial tree model
46089395|NCT04100694|Drug|MCLA-128|
46089396|NCT04181112|Biological|Fecal Microbiota Transplantation (FMT)|FMT using retention enema
46089397|NCT04181034|Behavioral|Adolescent Family Life Program Positive Youth Development (PYD) program|Home visiting program for pregnant and parenting teens with PYD component
46089398|NCT04181034|Behavioral|Adolescent Family Life Program (AFLP)|Home visiting program for pregnant and parenting teens
46089399|NCT02674932|Behavioral|Identifying and Using Signature Strengths|The purpose of the intervention is to identify and focus on one's morally valued strengths and utilize them (i.e. incorporate them into coping skills) to overcome challenges. The study team member and patient will discuss each top strength and ways to use them as coping skills. The patient will identify 2-4 coping mechanisms per strength, and will write his/her strengths and self-identified coping skills on index cards.
46004121|NCT00553982|Procedure|Patellar component|Resurfacing with onlay technique
46089400|NCT02674932|Behavioral|Identifying and Writing Down Coping Skills|The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify at least six coping skills and write them down on index cards.
46004122|NCT00553982|Procedure|No patellar component|Trimming of osteophytes when appropriate
46004123|NCT04615962|Drug|Hydrocortisone Acetate 1% Cream|Hydrocortisone Acetate is the synthetic acetate ester form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties.
46004124|NCT04615962|Drug|Mometasone Furoate|Mometasone is a medium-strength corticosteroid.
46004125|NCT04615962|Drug|SNG100|A combination of low potency steroid and skin barrier repair agent
46004126|NCT04881929|Drug|KN026|KN026 in Combination With Docetaxel
45836183|NCT00286182|Drug|Placebo|Placebo
45836184|NCT00286728|Behavioral|Intensive referral to dual-focused self-help|4 group sessions to introduce patients to dual focused groups
45836185|NCT00113880|Biological|FluMist|Nasal Sprayer dose of FluMist with annual follow up
45836186|NCT00113880|Biological|FluMist|Nasal Sprayer dose of FluMist with annual follow up
45836187|NCT00113880|Biological|FluMist|Nasal Sprayer dose of FluMist with annual follow up
46004127|NCT04615767|Dietary Supplement|D-chiro-inositol|as described previously
46004128|NCT04881227|Device|Chatbot on COVID-19 vaccine hesitancy|This intervention will provide to participants information on COVID-19 vaccine hesitancy consisting of the possibility of accessing a long series of questions and answers online about this vaccination.
46004129|NCT04881227|Other|Control intervention|This control intervention will provide to participants a brief text decribing the way vaccines works.
46004130|NCT04615494|Procedure|Position|Pneumoperitoneum with Steep Trendelenburg position
46004131|NCT04616001|Drug|IVIG|Patients will receive IVIG daily for four days.
46004132|NCT04615611|Drug|salbutamol|inhalation of salbutamol
46004133|NCT04615611|Drug|Placebo|administration of placebo
46004134|NCT04615728|Procedure|laparoscopic or open appendicectomy|Laparoscopic/open appendicectomy versus conservative management with antibiotic therapy with or without image-guided drainage of appendicular abscess/collection
46089401|NCT02674932|Behavioral|Treatment as Usual|The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify coping skills that could be helpful (but will not write them down).
46089402|NCT04178226|Other|Manual Acupuncture|The acupoints choose are (RN6) (RN4) (SP6) (PC6) (SP10) (SP4)
46089403|NCT04178226|Device|Laser Acupuncture|The acupoints choose are (RN6) (RN4) (SP6) (PC6) (SP10) (SP4)
45836188|NCT00226590|Drug|Gemcitabine|Induction Chemotherapy.
45836189|NCT00226590|Drug|Carboplatin|Induction Chemotherapy. Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
46004135|NCT04833959|Drug|89Zr-panitumumab|Imaging Agent
46004136|NCT04832165|Other|Inspiratory muscle strength training|Inspiratory muscle training during 8 weeks, 30 inspirations at 60% of the PIM (maximum inspiratory pressure), 2 times a day for 5 days per week.
46004137|NCT04798586|Drug|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
46004138|NCT04798040|Other|cold application|To reduce pain, cold application is applied around the drain before the drain is removed.
46004139|NCT04798040|Other|lavender oil inhalation|To reduce pain, lavender oil is inhaled prior to drain removal.
46004140|NCT04798040|Other|oxygen administration|To reduce pain, oxygen is inhaled prior to drain removal.
46004141|NCT00563277|Procedure|combined pterygium and cataract operation|
46004142|NCT00563277|Procedure|pterygium excision followed by cataract operation|
46004143|NCT04614870|Diagnostic Test|DETEC® Esterase|DETEC® Esterase is a disposable diagnostic device that is used to indicate the presence or absence of infection based on the presence or absence of the evaluated level of leukocyte esterase by testing the freshly recovered wound dressing which are soaked with wound exudate.
45836190|NCT00226590|Drug|Paclitaxel|Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
46004144|NCT04785053|Device|transcranial alternating current stimulation (tACS)|The tACS intervention (gamma stimulation, theta stimulation and active sham condition) will be administered to the participants over three visits that will be completed within one of the working days (Mon-Fri) at approximately the same time of day for all participants. Participants will be randomized and blinded to the tACS treatment.
46004145|NCT04614792|Device|Transcranial direct current stimulation|Non-invasive brain stimulation or neuromodulation.
46004146|NCT04776551|Procedure|Percutaneous fixation of acute Scaphoid fractures|Percutaneous Trans-trapezial fixation of acute Scaphoid fractures by Herbert screw
46004147|NCT04614519|Procedure|Conventional group|Insufflation pressure at 12mmHg and conventional instrumentation
46004148|NCT04614519|Procedure|Low impact laparoscopy group|Insufflation pressure at 7mmHg and micro-laparoscopy instrumentation
46004149|NCT04614675|Procedure|Distal soft tissue procedure with TALR|TALR group: Transarticular lateral release as the distal soft tissue procedure
46004150|NCT04614675|Procedure|Distal soft tissue procedure with PCLR|PCLR: Percutaneous soft tissue procedures as the distal soft tissue procedure
46004151|NCT04614285|Procedure|Partial excavation|"Operators sign up for participation at the homepage of Center for Pediatric Oral Health Research (ABC). The study will be carried out in a Practice-Based Research Network setting. All practitioners interested in participating in the study will get access to an online information about their participation after they signed up. The participation starts by answering a questionnaire on their treatment attitudes and experiences.~Patients will be identified during the routine dental examination. If a carious lesion in the primary molars is detected and in a need of a restoration, the children and parents will be asked to participate in the study.~The parents receive information about the study and give their consent. Allocation into treatment groups will be performed by random assignment by the homepage of ABC.~After the study is finished the participating dentist will be asked to answer the same questionnaire to investigate the effect of the participation on the operators attitude."
46004152|NCT04768907|Drug|MaaT013|
46004153|NCT04725812|Drug|Eculizumab|Eculizumab Intravenous Solution
46004154|NCT04614012|Other|treated with hyperimmune plasma|administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
46004155|NCT04713371|Drug|Keytruda Injectable Product|"Keytruda (pembrolizumab): PD-1 inhibitor antibody~Injectable 50mg/mL, only 2 mL injected."
46089404|NCT02674776|Drug|HuZhen Capsule|Patients should take 4 tablet once and 3 times per day for 3 days.
46089405|NCT02674776|Drug|Placebo Capsule|Patients should take 4 tablet once and 3 times per day for 3 days.
46089406|NCT02673294|Other|balance virtual rehabilitation|
46089407|NCT02673060|Drug|MBC-11|0.5 mg/kg-10 mg/kg , IV (in the vein) on day 1-5 of each 28 day cycle. Number of cycles: 2, in case of partial metabolic reaction or stable metabolic reaction - up to 4.
46089408|NCT04099446|Other|Non-interventional|There is no intervention for this study
46089409|NCT02676180|Other|Group|
45836191|NCT00226590|Procedure|Radiation|Radiation Therapy will begin on day 57 if there has been adequate hematologic recovery from Induction Chemotherapy.
45836192|NCT00114114|Drug|Testosterone|Androgel placebo or 1.25, 2.5, 5. or 10* gms topically each day
45836193|NCT00114114|Drug|Goserelin acetate|3.6 gms sc every 4 weeks
45836194|NCT00227760|Drug|Cediranib Maleate|Given PO
45836195|NCT00227760|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
45836196|NCT00227760|Other|Laboratory Biomarker Analysis|Correlative studies
45836197|NCT00227760|Other|Pharmacological Study|Correlative studies
45836198|NCT00227994|Drug|Galantamine|Participants assigned to receive galantamine will receive 4 mg twice a day for 4 weeks, 8 mg twice a day for the next 4 weeks, and 12 mg twice a day for the remainder of the study.
45836199|NCT00227994|Drug|Donepezil|Participants assigned to receive donepezil will receive 5 mg twice a day for 6 weeks, and then 10 mg twice a day for the next 6 weeks.
45836200|NCT04250454|Behavioral|CONTRACT|"The intervention will consist of four elements:~Personal meeting - detailed information to the parents before the age of 15 weeks CA (1-3 days)~Home Activity Plan (HAP)~Home-based Feedback training~Electrical muscle stimulation~Combination of these elements has been chosen in order to ensure that optimal muscle growth is achieved through multi-modal stimulation of the motor and cognitive development of the child."
45836201|NCT00114504|Drug|simvastatin|simvastatin 5-10 mg/day
45836202|NCT04247802|Other|Backwards Walking (BW) programme|A 12 week Backwards walking programme prescribed by a registered physiotherapist and completed as part of a home exercise programme.
45836203|NCT04247802|Other|Usual Care|A 12 week physiotherapy exercise programme EXCLUDING backwards walking
45836204|NCT00118248|Drug|tanespimycin|Given IV
45836205|NCT04245384|Other|Internet-based dietetic treatment with video calls|The dietitian meets the patient through video calls, no physical meetings
45836206|NCT04245384|Other|Traditional dietetic treatment|The dietitian meets the patient through physical meetings
45836207|NCT00230022|Behavioral|Brief computer-delivered intervention|20-minute interaction with voice-enabled software that could provide reflections, images, text, etc.
45836208|NCT00230100|Behavioral|The Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance abuse antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
46004156|NCT04713371|Drug|Yervoy Injectable Product|"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 2 mL injected."
46004157|NCT04713371|Drug|Cytoxan|Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: 50mg once daily pill for 5 days prior to first treatment, 3 days prior to 2nd and 3rd treatment.
46004158|NCT04713371|Procedure|Cryosurgical freezing (cryosurgery)|Cryosurgery, also known as cryoablation, for metastatic cancer works by freezing the cancer cells inside the tumor. Cryoablation will release intact antigens to prime the immune system.
46004159|NCT04713371|Drug|GM-CSF Injectable|Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days post after each treatment.
46004160|NCT04683614|Drug|Norepinephrine|5 mic/kg/hr norepinephrine
46004161|NCT04683614|Biological|Fresh frozen plasma|early administration of fresh frozen plasma
46004162|NCT04613895|Drug|DWP14012|DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks
46004163|NCT04613895|Drug|DWP14012|DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
46004164|NCT04613700|Drug|Secretin|Native hormone
46004165|NCT04613700|Other|Placebo|Saline
46004166|NCT04675151|Drug|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
46004167|NCT04675151|Drug|Pilocarpine|Pilocarpine ophthalmic solution
46004168|NCT04675151|Other|Placebo|Topical sterile ophthalmic solution
46004169|NCT04613544|Device|Voice Assist Arrhythmia Monitoring (VAAM)|application flag the potential occurrence of irregular heart rhythms suggestive of atrial fibrillation (AF) and notify to further investigate the occurrence of the suspected AF episode by prompting user to initiate ECG test to confirm.
46004170|NCT00563355|Drug|erythropoietin|
46004171|NCT04672109|Device|Transcranial direct current stimulation|Dual/Cathodal/Anodal/Sham tDCS will be applied in 2 mA, 20 mins. All experiments will be performed in random order for each subject.
46004172|NCT00563394|Drug|ofloxacin|400 mg twice a day for 14 days
46004173|NCT00563394|Drug|MSI-78|1%/2% topical cream twice a day for 14 days
46004174|NCT04660877|Dietary Supplement|Cheddar Cheese|20g of protein from cheddar cheese
45677600|NCT04417439|Other|universal goniometer. evaluate the circumference measurement. The biochemical examination of CK (creatine kinase)|The joint range of motion within the affected areas of burn patients was assessed by a universal goniometer. A 7-mm-wide tape measure was used to evaluate circumference measurement in individuals. The biochemical analysis of CK (creatine kinase) was performed by an expert on blood samples taken from patients in the hospital laboratories.
46004175|NCT04660877|Dietary Supplement|Milk|20g of protein from milk
46004176|NCT04653350|Other|High Intensity Exercises|Supervised High intensity Progressive Resistance Training, High intensity weightbearing/Impact exercises and High challenging Balance Training will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.
46004177|NCT04653350|Other|General Exercises|Supervised general fitness exercises including general body stretches, treadmill walking, mild to moderate intensity progressive resistance training & balance exercises will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months
46004178|NCT00563433|Drug|ofloxacin|400 mg twice a day for 14 days
46004179|NCT00563433|Drug|MSI-78|1%/2% topical cream twice a day for 14 days
46004180|NCT04652102|Biological|CVnCoV|Intramuscular (IM) injection.
45677601|NCT02042183|Drug|Lubiprostone|12 or 24 mcg soft capsules of lubiprostone for oral administration, depending on baseline weight and response during week 1
45677602|NCT02042183|Drug|Placebo|0 mcg soft capsules of placebo for oral administration
46004181|NCT04652102|Biological|Placebo|Intramuscular (IM) injection.
46004182|NCT04652102|Biological|Authorized/licensed vaccines for preventing COVID-19 (AV)|Intramuscular (IM) injection will be received as standard of care (SoC) outside the study.
46004183|NCT00563472|Drug|estetrol|10 mg orally per day for 28 days
46004184|NCT00563472|Drug|estetrol|20 mg orally per day for 28 days
46004185|NCT00563472|Drug|estetrol and desogestrel|20 mg estetrol and 150 microg desogestrel orally per day for 28 days
46004186|NCT00563472|Drug|estetrol and progesterone|20 mg estetrol and 200 mg progesterone orally per day for 28 days
46004187|NCT04679597|Drug|Capecitabine|comparison of two treatments
46004188|NCT00563511|Procedure|adherence intervention|
46004189|NCT00563511|Procedure|intervention without adherence advice|
46004190|NCT00563511|Procedure|control|
46004191|NCT04615910|Radiation|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
46004192|NCT04613778|Procedure|Laser acupuncture|Laser acupuncture is a low-level laser technique with no invasive procedure
46004193|NCT04613856|Other|Hydration protocol - 237 mL water bolus|Subjects consume 237 mL of water every 20 minutes during 2 hours of high intensity work in the heat.
46004194|NCT04613856|Other|Hydration protocol - 500 mL water bolus|Subjects consume 500 mL of water every 40 minutes during 2 hours of high intensity work in the heat.
46004195|NCT04609397|Drug|Hemay005|Hemay005 tables 60mg bid p.o;
46004196|NCT04609397|Drug|Hemay005|Hemay005 tables 45mg bid p.o
46004197|NCT04609397|Other|Placebo|placebo to Hemay005 tables bid p.o
46004198|NCT04592978|Behavioral|Pain-Alcohol Personalized Feeback Intervention|The intervention will be designed to enhance knowledge regarding adverse pain-alcohol-opioid interrelations as well as increase motivation and intention to reduce hazardous drinking and positive attitudes and intentions regarding concurrent use of alcohol and prescription opioid medications.
45677603|NCT01977482|Drug|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
46004199|NCT04592978|Behavioral|Control Personalized Feedback Intervention|The control intervention will incorporate personalized feedback relevant to exercise and nutrition but not address drinking reduction or pain-alcohol-opioid interrelations.
46004200|NCT04613193|Other|Blood presssure reduction|Patients will be uptitrated in antihypertensive treatment until the treatment target is achieved.
46004201|NCT04587947|Drug|sacubitril/ valsartan|Heart rate variability measurement is carried out by means of a 12-channel ECG for 30 minutes in supine position followed by 10 minutes in standing position. All parameters, including blood values and echocardiographic parameters are assessed before beginning of sacubitril/ valsartan therapy and 3 months after starting treatment
46004202|NCT04613310|Diagnostic Test|Rapid Diagnostic Test vs PCR|4 swabs taken, saliva for PCR and RDT, nasopharyngeal for PCR and RDT
46004203|NCT04578080|Device|Transcranial direct current stimulation|Anodal or Sham tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
46004204|NCT04612998|Other|left lateral decubitus position|Comparator group consisted of patients performing CSEA in the left lateral decubitus position.
46004205|NCT04612998|Other|sitting position|Active control group consisted of patients performing CSEA in the sitting position.
46004206|NCT04612998|Drug|The use of intravenous ephedrine.|Intravenous ephedrine (6 mg) was used to treat hypotension (a 30% decrease in systolic blood pressure compared to preoperative values) during surgery.
46004207|NCT04612998|Drug|The use of intravenous atropine.|Intravenous atropine (1 mg) was given in case of bradycardia (the heart rate < 45 beats/minute) during surgery.
46004208|NCT04612998|Drug|The use of intravenous metoclopramide|When nausea and vomiting were observed, intravenous metoclopramide (10 mg) was administered.
46004209|NCT04545476|Device|Participants in this group will receive the experimental APIS Biomaterial on the Head.|One layer of APIS® will be applied to the post-operative wound on the head covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
45677604|NCT01977482|Drug|Placebo|Matching placebo tablet for GSK1278863
45677605|NCT01977482|Drug|rhEPO|rhEPO will be procured from local market
45677606|NCT02058095|Drug|Tadalafil|"Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is >95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil.~At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil.~At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil."
46004210|NCT04545476|Device|Participants in this group will receive the experimental APIS Biomaterial on the Lower Extremities.|One layer of APIS® will be applied to the post-operative wound on the lower extremities covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
45836209|NCT00230100|Behavioral|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
46004211|NCT04545476|Other|Standard Secondary Intention Healing on the Head|Participants in this group will receive standard secondary intention wound healing post-operative care on the Head. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
46004212|NCT04545476|Other|Standard Secondary Intention Healing on the Lower Extremities|Participants in this group will receive standard secondary intention wound healing post-operative care on the Lower Extremities. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
46004213|NCT00563589|Drug|mycophenolate mofetil, methotrexate, cyclosporin|
46004214|NCT00563589|Drug|Methotrexate and cyclosporin|
46004215|NCT00563628|Device|Panretinal photocoagulation with PASCAL system|Use the PASCAL laser system to deliver a retina photocoagulation
45459044|NCT03496558|Other|Variability of the lipid profile in pregnant women|"The women participants will be divided into two groups. Group 1 comprised of healthy women and group 2 by pregnant women with a history of risk. A personal, family history and a detailed medical history will be taken in each group. We will proceed to see all possible variables that influence the level of biomarkers (lipids and prolactin).~At least 60 healthy pregnant women and 60 pregnant women with a history of risk (20 for each risk) x 2 series (three years) will be tried, a total of 240-300 women to whom 5 analytical tests would have to be performed."
46004216|NCT04492670|Procedure|Tui-na|For administering of Tui-na manipulation practice, responsible Tui-na CMP must have at least 2 years of clinical experience. The pre-trial workshops led by a senior practitioner will be organized to ensure standardization of Tui-na treatment manipulation and procedures.
46004217|NCT04492670|Drug|Du-Huo-Ji-Sheng-Tang (DHJST)|This study medication is derived from Du-Huo-Ji-Sheng-Tang (DHJST) and concentrated Chinese Medicine granules will be used.
46004218|NCT00563667|Procedure|pterygium excision|
46004219|NCT04613076|Behavioral|"Me cuido y me siento mejor"|A multicomponent, collaborative, computer-assisted, psycho-educational intervention for the management of depressive symptoms in primary care patients with diabetes and/or hypertension.
45459045|NCT01366352|Drug|MNTX tablet (Formulation 1)|
46004220|NCT04613076|Behavioral|Enhanced Usual Treatment|Enhanced Usual Treatment
46004221|NCT04613037|Biological|Fecal Microbial Transplantation|Fecal Microbial Transplantation in adults with Atopic Dermatitis
45459046|NCT01366352|Drug|MNTX tablet (Formulation 2)|
45459047|NCT01366430|Procedure|Gufoni|For Gufoni maneuver, the patient was quickly brought down on the healthy side from the sitting position, and the head was then turned about 45 degree down, so that the nose was on the bed. After 2 minutes in this position, the patient was returned to the upright position.
45459048|NCT01366430|Procedure|Sham|The sham maneuver the opposite of the first step for barbecue rotation; lying down from sitting position for 30 seconds, and head turn 90degree to the affected side for 1 minute, and then sit up.
46004222|NCT04465643|Drug|Nivolumab|Nivolumab 4.5 mg/kg Q3W x 2
46004223|NCT04465643|Drug|Ipilimumab|Ipilimumab 1 mg/kg Q3W x 2
46004224|NCT04612842|Behavioral|Motivational Interviewing|The PI and two study staff members (interventionists) will conduct study visits and phone calls. The same person will complete participant follow-ups to establish rapport and consistency. All of the study encounters will be audio recorded with participants' permission and study encounter notes will be completed by the interventionist. Interventionists will facilitate MI sessions using the MI guide and a participant handout. The goal of each MI session is to identify a specific fall prevention behavior, the participant's goal with this behavior, readiness to change, specific plan to move toward the goal, barriers and facilitators, and the participant's commitment level to change.
46004225|NCT04612881|Drug|fitostimoline vaginal pessaries|vaginal pessaries
46004226|NCT04612881|Other|standard of care|standard of care
46004227|NCT04464161|Dietary Supplement|Ensure|Ensure protein is a complete nutritional drink with 10g, 240 calories, and 27 vitamins and minerals. It is often used as a nutritional supplementation in many hospitals.
46004228|NCT04612959|Other|Psychosexual care|The psychosexual caring program includes interventions to promote body awareness, the meaning of sexuality, and marital relationships by gaining communication skills, sexual communication, body knowledge, information about sexual health, and its dimensions.The psychosexual caring program includes psycho-education and sexual counseling.
45677607|NCT02058095|Drug|Placebo|"Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is >95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo.~At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo.~At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo."
46004229|NCT04612803|Drug|Antihistamine|Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at 6-9AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days
46004230|NCT02204345|Drug|Carboplatin|Carboplatin by intravenous infusion q3w for 4-6 cycles and thereafter as per investigator's discretion.
46004231|NCT02204345|Drug|Paclitaxel|Paclitaxel by intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
45677608|NCT04718207|Device|Brain positron emission tomopgraphy (PET) - scan|Patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.
45677609|NCT04663022|Other|Dunn's sensory profile questionnaire|all children will complete the Dunn Sensory Profile questionnaire
45677610|NCT04670900|Procedure|Tension band wiring or plate fixation|Choice of operative treatment is TBW or PF with a precontoured anatomical plate. The treating surgeon decides if TBW or PF is chosen as operative treatment method. The surgeries are performed according to OTA principles by an experienced surgeon, a trauma fellow or a consultant as approved by the participating hospitals.
45677611|NCT04670900|Procedure|Active non-operative treatment with optional plaster cast|Patients allocated to non-operative treatment are offered a back-slab in 60 degrees of flexion for pain-relief. The back-slab is removed 7-14 days following injury.
46004232|NCT02204345|Drug|RO5479599|RO5479599 will be administered as an intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
46004233|NCT04612647|Other|12-week FMS Intervention|4 sessions, no more than 3 hours per session covering 1) Sensory Integration, 2) Communication, 3) Aquatic Opportunities, and 4) Physical activity and Sports (during intervention)
46004234|NCT04612647|Behavioral|Physical Activities & Activity Booklets|expected to engage in physical activity at least 3 hours per week
46004235|NCT02187302|Drug|CRLX101|
46004236|NCT02187302|Drug|Bevacizumab|
46004237|NCT02187302|Drug|Standard of Care (Investigator Choice)|
46004238|NCT02179151|Drug|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 28 weeks.
46004239|NCT02179151|Drug|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 28 weeks.
46004240|NCT02163746|Procedure|CO2 (carbon dioxide) laser|
46004241|NCT02163746|Procedure|Surgical Deroofing|
46004242|NCT04612257|Other|Insulin-alone closed-loop|40-hour intervention period using the insulin-alone closed-loop system.
46004243|NCT02160665|Drug|Tazarotene Cream, 0.05%|Tazarotene Cream, 0.05% (G & W Laboratories, Inc.)
46004244|NCT02160665|Drug|Vehicle|Vehicle of Test product (G & W Laboratories, Inc.)
46004245|NCT02160665|Drug|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
46004246|NCT04611984|Procedure|Piezocision|Piezocisions were performed on the mesial and distal sides of the right maxillary canines. Then canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
46004247|NCT04611984|Procedure|Control|The mesial and distal sides of the left maxillary canines served as controls and canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
46004248|NCT04633707|Device|adjunctive bright white light therapy in the morning|the participants would receive adjunctive bright white light therapy in the morning (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 7:00~9:00) for 6 weeks.
46004249|NCT04633707|Device|adjunctive bright white light therapy in the afternoon|the participants would receive adjunctive bright white light therapy in the afternoon (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 12:00~14:00) for 6 weeks.
46004250|NCT04633707|Device|adjunctive dim red light therapy in the afternoon|the participants received dim red light therapy (light intensity: <100lux, color: dark red, duration of each intervention session: 30min, time period: 12:00~14:00) for 6 weeks.
46004251|NCT02138630|Dietary Supplement|Capsaicin|
46004252|NCT02138630|Dietary Supplement|Placebo|Sugar capsule
45677612|NCT02023112|Drug|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
46004253|NCT04612023|Other|Acellular Amniotic Membrane Derived Allograft Injection (NuDYN)|Injectable acellular amniotic membrane derived allograft tissue (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) to a placebo (sterile saline) in the treatment of knee osteoarthritis. Injection is minimally invasive and is FDA regulated (HCT/P regulation).
45677613|NCT02023112|Drug|Ribavirin|Capsule
45677614|NCT04670666|Drug|MADALENA ASSOCIATION|Madalena association coated tablet.
45677615|NCT04670666|Drug|METFORMIN|Metformin 1000 mg extended-release tablet.
46004254|NCT02137343|Drug|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/SF/MET-driven activities in cells.
46004255|NCT02137343|Drug|Placebo|Placebo
45459049|NCT01366430|Procedure|Barbecue|For barbecue rotation, the head was rotated rapidly 90degree while supine in the direction of the healthy ear, which was immediately followed by a truncal rotation of 90degree in the same direction to lie on the intact side. After 30-60 seconds when the induced nystagmus was dissipated, the patients were subjected to a further 90degree rotation of the head and trunk en block in the same direction to attain the nose-down position. After a further 30-60 seconds, the head was again turned in the same direction so that the affected ear was downward. Finally, after another 30-60s, the patient was brought to sitting position. Only one maneuver was performed per session.
46004256|NCT02137343|Drug|Cisplatin|A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death)
46004257|NCT02137343|Drug|Capecitabine|A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
46004258|NCT04633512|Device|ActivSight|Use of ActivSight in patients undergoing laparoscopic or robot assisted intestinal anastomoses and patients undergoing laparoscopic or robot assisted cholecystectomy.
45677616|NCT04670666|Drug|EMPAGLIFLOZIN + LINAGLIPTIN|Empagliflozin 10 mg + linagliptin 5 mg coated tablet.
45677617|NCT04670666|Other|MADALENA ASSOCIATION PLACEBO|Madalena association placebo tablet.
46004259|NCT02125253|Drug|Mometasone Furoate Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate
46004260|NCT02125253|Drug|Nasonex Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate
45459050|NCT03490396|Device|Gelclair|Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel
45677618|NCT04670666|Other|METFORMIN PLACEBO|Metformin placebo tablet.
45677619|NCT04670666|Other|EMPAGLIFLOZIN + LINAGLIPTIN PLACEBO|Empagliflozin + linagliptin placebo tablet.
45677620|NCT01977092|Behavioral|Motivational interviewing case management|
45677621|NCT01977092|Behavioral|Resource referrals|
45677622|NCT01976624|Drug|bimatoprost/timolol|Bimatoprost/timolol (Ganfort®) treatment for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
45677623|NCT02041091|Drug|Tabalumab Auto-Injector|Administered SC
45677624|NCT02041091|Drug|Tabalumab Prefilled Syringe|Administered SC
45677625|NCT04717973|Diagnostic Test|laboratory testing of CBC, serum ferritin, and vitamin B 12|"laboratory testing of CBC, serum ferritin, and vitamin B 12, vitamin D and ionized serum calcium after the 1st month, 3rd month, 6th month, and then after one year postoperative.~The pre-operative and post-operative measures will be compared in patients who will be subjected to Laparoscopic Sleeve Gastrectomy versus Laparoscopic Gastric Bypass."
45677626|NCT02057549|Drug|Haloperidol|Intravenous dose of haloperidol 5 mg.
45677627|NCT02057549|Drug|Conventional Therapy|Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
45677628|NCT02057393|Drug|Indocyanine green|Subjects receive 0.9ml of ICG subcutaneously about the primary melanoma. The ICG has an infrared signal that is detected with the SPY Elite system (Lifecell). The ICG travels through the lymphatics to the sentinel node.
45677629|NCT02057393|Drug|Technetium99|Technetium99 is a standard, widely used radiopharmaceutical that is injected subcutaneoulsy about the primary melanoma site. Lymphoscintigraphy is performed to identify the draining nodal basin, and a gamma probe is used in the operating room to track the radioactive signal and find the sentinel node.
46004261|NCT02125253|Drug|Placebo Nasal Spray|a metered-dose, manual pump spray unit containing an aqueous suspension
46004262|NCT02116244|Drug|Civamide Nasal Spray|
46004263|NCT04633083|Other|Data collection|"Clinical Data: Registration of patient identity, sex and birth year, Body Mass Index, generic score EQ-5D-3L, Tampa Schaal voor kinesofobia and shoulder specific score like Constant Score, PROMS, ADLER, SST and postoperative ROM.~Imaging Data: A preoperative and postoperative CT scan and 1-year postoperative radiograph (all three part of standard clinical practice) will be obtained. This data is used to extract the bone geometries and implant position.~Movement Analysis: The subject should stand still followed by different motion tasks in the gait lab with collection of shoulder girdle kinematics and kinetics using a 14-camera VICON System.~Stereo Radiographic EOS Measurements: Every subject included in the study will undergo a stereo radiographic EOS exam while quite standing with their arm in various positions (van Andel et al., 2008) .~ROM simulation: With the developed ROM software, we will simulate the ROM of the 2 patient groups based on the available CT scan data."
46004264|NCT02114060|Biological|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
45677630|NCT02057393|Drug|Methylene blue|Subjects receive 0.5-2ml of methylene blue subcutaneously about the primary melanoma at the time of surgery. The sentinel node should turn blue, which is visible with the naked eye.
45677631|NCT04698161|Other|Biological sample collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
45677632|NCT04698161|Other|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
45677633|NCT04698161|Other|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
45677634|NCT02040779|Drug|Beclomethasone dipropionate breath-actuated inhaler|Beclomethasone dipropionate (BDP) breath-actuated inhaler (BAI) given in dosages of either 40 mcg/inhalation or 80 mcg/inhalation. Study drug was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
45677635|NCT02040779|Drug|Placebo breath-actuated inhaler|Placebo was provided in matching breath-actuated inhaler (BAI) devices. The placebo devices were identical to the devices used to deliver active drug. Placebo was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
45677636|NCT02040779|Drug|albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period
45677637|NCT02056301|Drug|Hydromorphone|In keeping with standard practice at the TCH, the position of the thoracic epidural catheter tip will be confirmed by real time fluoroscopy and a single injection of 1 ml of omnipaque 180 mg/mL contrast. In keeping with current practice, a bolus of 0.2% ropivacaine 0.3 ml per kg (maximum dose 20 ml) will be administered in the epidural space to the patients in the TEA group at least 10 minutes prior to surgical incision.
45677638|NCT02056301|Drug|Morphine|This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes
45836210|NCT01898676|Drug|Divalproex Sodium Extended-release 250mg|Two tablets of Divalproex Sodium Extended-Release 250mg will be given to the subject in two treatment periods
46004265|NCT02114060|Biological|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
45836211|NCT01898676|Drug|DEPAKOTE 250mg|Two tablets of DEPAKOTE 250mg will be given to the subject in two treatment periods.
46004266|NCT02114060|Biological|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
46004267|NCT02114060|Biological|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
46004268|NCT02114060|Biological|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
46004269|NCT02114060|Biological|Placebo|0.9% Normal Saline (NaCl)
46004270|NCT04677998|Procedure|Personalized surveillance and intervention protocol|This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 3-6 months and 5 years, depending on severity of polyposis and performed endoscopic interventions.
46004271|NCT00560898|Drug|ProClear Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
46004272|NCT00560898|Drug|Acuvue Advance Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
46004273|NCT00560898|Drug|Acuvue Advance Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
45677639|NCT01967888|Drug|Reparixin|Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour
46004274|NCT00560898|Drug|ProClear Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
46004275|NCT02104388|Drug|SJP-0035 Ophthalmic Solution|
45342417|NCT02046330|Device|Deep Brain Stimulation Model 3387 Model 3389|Implantation of all devices will be performed at a single session. Lead implantation will take place under local anesthesia, with implanted pulse generator (IPG) implantation under general anesthesia. The stereotaxic frame will be fitted on the day of surgery, following standard stereotactic surgical procedure. The leads will be inserted so that the stimulation sites span superolateral median forebrain bundle.
45342418|NCT00194298|Procedure|FDG-PET Imaging|
45459051|NCT03490396|Combination Product|First® Mouthwash BLM|Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash
45459052|NCT01371812|Drug|GSK2239633|Drug will be orally administered at the doses and time points detailed in the 'arms' section.
46004276|NCT02104388|Drug|Vehicle of SJP-0035 Ophthalmic Solution|
46004277|NCT04611828|Device|Philips SmartSleep|closed-loop auditory stimulation
45677640|NCT01967888|Drug|Placebo|Physiologic solution administered at 0.25 mL/kg/hour
46004278|NCT04678037|Behavioral|PROs assessment using sickle cell disease mobile app (SCD-app)|A smartphone app platform designed for patients with sickle cell disease. The SCD-app is programmed to send notification to patients to complete PROs assessment. The SCD-app is able to collect PROs data as patients complete the assessment using the app platform.
46004279|NCT04633044|Dietary Supplement|Betaine|The intervention with supplement will start during the first 48h after birth and will last for 12 weeks
45342419|NCT04071522|Other|no intervention|no intervention
45342420|NCT02576418|Other|Partosure TTD test|PartoSure TTD test and CL will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
45342421|NCT02576340|Drug|otilonium bromide|otilonium bromide was administered before the procedure
45677641|NCT01967732|Other|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
45677642|NCT01967732|Other|CC|Single use of subject's own conventional cigarette (CC)
46004280|NCT04633044|Dietary Supplement|Placebo|The intervention with supplement will start during the first 48h after birth and will last for 12 weeks
46004281|NCT02104076|Device|Evolution® Biliary Stent-Fully Covered|Implantation of the Evolution® Biliary Stent-Fully Covered in the common bile duct utilizing ERCP
46004282|NCT04632849|Behavioral|GEM + CGM|Participants follow the GEM guidebook for 4 months (1 month of intervention and 3 months of maintenance) while wearing a FitBit activity monitor and a Freestyle Libre 2 CGM to provide feedback about activity and blood glucose. The GEM guidebook covers Routine choices, Recovering from blood glucose excursions, Reducing blood glucose excursions, and Maintenance.
46004283|NCT04611438|Drug|Cannabidiol|"Intervention schedule for each patient is as follows:~Baseline Phase (2 weeks) Baseline Phase starts from the screening visit, where the patient and caregiver write permission to the trial and goes through laboratory, electroencephalography, and neuropsychological tests.~Treatment Period: Titration (2 weeks) + stabilization period (10 weeks) + maintenance period (12 weeks)~Titration: The patient would start cannabidiol on 5mg/kg/mg for 1 week and titrate dosage up to 10mg/kg/day for second week with the caregiver monitoring the patient's tolerability~Stabilization: caregiver monitoring the patient's tolerability, with no change in medication dosage~Maintenance: no change in medication dosage"
45677643|NCT01967732|Other|NNS|Single administration of 1 mg of nicotine
45677644|NCT01967576|Drug|Axitinib (AG-013736)|5 mg twice a day on a 28-day cycle.
45677645|NCT02039687|Drug|ARA 290|A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.
46089410|NCT04180800|Other|Lubben Social Network Scale - 6|One short oral interview to complete the Lubben Social Network Scale in auto-survey, translated in French. It contains 6 questions on 30 points, higher scores are associated with more social engagement, lower scores, specifically under 12/30, are associated with social isolation.
46004284|NCT02096666|Drug|AMG 337|Phase 1- AMG 337 150 mg, 200mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily. Phase 2- AMG 337 (dose determined by Phase 1)
46004285|NCT04632693|Procedure|CAF with SCTG and Vitamin C injection|Injection of vitamin C after CAF with SCTG aiming to increase gingival thickness in patients with RT1 gingival recession.
45459053|NCT01371812|Drug|Placebo|Placebo will be orally administered to 4 subjects in each treatment period of each cohort.
46089411|NCT02674542|Other|In-depth interviews|"Future family planning intentions and beliefs~Family planning experiences and beliefs:~Feasibility and acceptability of birth spacing promotion for women who experienced a still birth or early neonatal demise"
45342422|NCT02578602|Drug|Gadoxetate Disodium|Given IV
45342423|NCT02578602|Device|Magnetic Resonance Imaging|Undergo MRI with gadoxetate disodium
45459054|NCT03496480|Diagnostic Test|Questionnaires|Psychological questionnaires: BTQ, IES-R, 7-items-short Screening scale, BDI, SF-36
45677646|NCT02039687|Other|Placebo|Formulation buffer
45677647|NCT02003534|Drug|0.15% Brimonidine Tartrate|0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
45677648|NCT02055365|Biological|Hepatitis B Vaccine (Recombinant)|All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).
45677649|NCT05127473|Drug|Mim8 B, 10 mg/mL|All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
45677650|NCT05127473|Drug|Mim8 B, 100 mg/mL|All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
45836212|NCT04243902|Device|Fill and Flush Valve|"The fill and flush valve (Figure 1) is an automated valve which is designed to open in response to rising bladder pressure which occurs as the bladder becomes full. The valve is situated between the IDC and the drainage bag as a manual valve would be.~There are three variants of the valve which respond to different degrees of bladder pressure. People's bladders function at different pressure levels. One of the aims of this study is to gain preliminary data on which valve variant works and under which circumstances. Pressure ranges are as follows:~Low: 22 - 49cm H2O Medium: 35 - 61cm H2O High: 53 - 79cm H2O"
45836213|NCT04236180|Other|Specialised Paediatric Palliative Care (SPPC)|All services provided to children/families by a member of the multiprofessional SPPC team in Zurich according to local guidelines will be considered as study intervention. This includes direct consultation of the patient/family, as well as patient-/family-related consultation of the frontline care team. Bereavement support is considered an integrated part of SPPC and after the death of a child, follow-up bereavement support is routinely offered at the individual or group level as appropriate for parents and siblings.
45836214|NCT00230802|Drug|Anticipatory dose increase of levothyroxine|as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
45836215|NCT00230802|Drug|levothyroxine|patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week
45836216|NCT00230802|Drug|levothyroxine|patients will increase levothyroxine by 3 extra tablets of their current dose per week.
45836217|NCT00288366|Drug|ziprasidone vs. aripiprazole|ziprasidone vs. aripiprazole dosed according to package insert
45836218|NCT00288366|Drug|aripiprazole vs. ziprasidone|aripiprazole vs. ziprasidone dosed according to package insert
45836219|NCT00288600|Drug|Intravenous Immunoglobulin|Intravenous Immunoglobulin
46004286|NCT04632693|Procedure|CAF with SCTG alone|Coronally advanced flap with subepithelial connective tissue graft.
45677651|NCT05127473|Drug|Mim8 B, placebo|Placebo will be used to dilute the IMP to different Mim8 concentrations
46004287|NCT02093429|Drug|INCB047986|INCB047986 will be supplied as tablets.
46004288|NCT00563745|Device|telemedicine program|One year TM with continuous (h 24) on call accessibility to a nurse and/or a pulmonologist, a web-based call centre and a pulse oxymetry tracing will be provided.
46004289|NCT04677764|Other|virtual reality|Wii Fit balance board (Nintendo Inc., Kyoto, Japan).
46004290|NCT04677764|Other|Standard of care|physical therapy and occupational therapy exercises either at their own home or a gym
45459055|NCT02449148|Other|Calorie Restriction|diet intervention to reduce the risk for obesity associated diseases
45459056|NCT05358782|Device|Dental implant positioning|observational study of the effect of implant malposition
45459057|NCT03490162|Drug|DM1157|DM1157 is a novel anti-malarial drug that is derived from chloroquine. DM1157 maintains the efficacy of chloroquine and has molecular features that overcome resistance to chloroquine.
45459058|NCT03490162|Other|Placebo|Placebo
45459059|NCT01366508|Other|High calorie lunch|Subject fed a standard high calorie lunch at 1pm
46004291|NCT00563823|Drug|vatalanib|
45459060|NCT01366508|Other|Breakfast|At approximately 09:00 the subject will be given breakfast. After this, no food will be served until study procedures for the day are over. However, a 330 ml bottle of still water at room temperature will be given at ~11:00 and at ~13:00. During this period the subject will be required to remain in the unit.
45459061|NCT05354648|Procedure|Hypoxic-hyperoxic preconditioning|Patients were intubated and mechanically ventilated with the target values of PaO2 and PaCO2 (80 - 120 mm Hg and 35 - 45 mm Hg, respectively) under the inhalation anesthesia. HHP was carried out as follows: breathing with a hypoxic gas mixture for 10 min with the development of hypoxemia, then breathing with a hyperoxic gas mixture for 30 minutes, then a period of breathing with atmospheric air (normoxia and normocapnia) until the cardio-pulmonary bypass is connected.
45459062|NCT05354648|Procedure|Placebo|Patients were intubated and mechanically ventilated with the target values of PaO2 and PaCO2 (80 - 120 mm Hg and 35 - 45 mm Hg, respectively) under the inhalation anesthesia until the cardio-pulmonary bypass is connected.
45459063|NCT05136040|Drug|Bupivacaine|Two Different Low-Doses Of Isobaric Bupivacaine ( Group İzobarik bupivakain (5 mg) + fentanil and Group İzobarik bupivakain (7 mg)+ fentanyl ) were administered to the subarachnoid space
45459064|NCT03634358|Procedure|Bipolar scissors|
45459065|NCT03634358|Procedure|classic scalpel|
45459066|NCT02192762|Behavioral|Withdrawal regulation training|Withdrawal coping skills
45459067|NCT02192762|Behavioral|Relaxation training|Relaxation skills instruction
45459068|NCT02183558|Other|OGTT by randomization|
45459069|NCT02183558|Other|OGTT by indication|
45459070|NCT03496246|Diagnostic Test|serum total 25 hydroxycholecalciferol 25(OH) vitamin D|Quantitative measurement of serum total 25(OH) vitamin D by ELISA. Fasting (6-8 hours), venous blood samples(10ml) are collected from participants in the morning and after centrifugation, the serum are preserved in the deep freezer at -20 c. Serum levels will be determined by using commercially available kits.
45677652|NCT02039375|Other|"Hopkins post tPA for ischemic stroke monitoring protocol"|"The Hopkins post tPA monitoring protocol includes: vital signs and neurochecks, per standard of care for the first two hours (every 15 minutes), then on arrival to unit, in one hour, every 2 hours for 8 hours, and every 4 hours to complete 24 hours."
45459071|NCT03496246|Diagnostic Test|complete blood count (CBC)|for measurement of hemoglobin level and white blood cell count percent of neutrophils ,lymphocytes and esoinphils
46004292|NCT04677686|Behavioral|Bundle of Care|Hair removal with Clipper Glucose Control Preoperative antibiotics Repeat antibiotics after 4 Hours Optimize Body temperature Instrument change for colorectal anastomosis Use of wound protectors Experienced surgeon Preoperative showering
46004293|NCT00563862|Procedure|Conventional RT|
46004294|NCT00563862|Procedure|Accelerated RT|
46004295|NCT00563862|Drug|Cisplatin|
46004296|NCT00563862|Drug|5-fluorouracil|
46004297|NCT04677842|Drug|ART Therapy|
46004298|NCT04632342|Drug|HL301 tablet 300mg|"Experimental group 1 : 2 tablets at once, twice a day~Experimental group 2 : 2 tablets at once, three times a day"
46004299|NCT04632342|Drug|Placebo of HL301 tablet|2 tablets at once, three times a day
46004300|NCT04611711|Drug|decitabine＋ TQB2450 injection|"Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
46004301|NCT04611711|Drug|decitabine＋ TQB2450 injection＋Anlotinib|"Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.~Anlotinib Hydrochloride is a multi-target receptor tyrosine kinase inhibitor with significant inhibitory activity against angiogenesis related kinases (VEGFR1/2/3, FGFR1/2/3, etc.) and other tumor cell proliferation-related kinases (PDGFR /, C-Kit, RET, etc.), which can play a dual role in anti-tumor angiogenesis and tumor growth inhibition. "
46004302|NCT00554879|Procedure|Acupuncture|Needles placed bilaterally on the ears at the auriculotherapy points. Additional needles placed in both index fingers. A third set of needles inserted on both index fingers between LI-1 adn LI-2.
46004303|NCT00554879|Procedure|Sham acupuncture|Four needles will be placed on the left and right upper shoulder areas. Small circular adhesive tape will be placed in an ear area, but not on the acupuncture points.
46004304|NCT04632537|Drug|Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine|Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine will be diluted in preservative-free saline and given intradermally (0.1mL) in the deltoid area.
46004305|NCT04632537|Drug|Preservative-free saline|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm. Placebo will comprise 0.1 mL of the diluent (preservative-free saline) to ensure the same quantity and same color as the resuspended BCG vaccine, rendering the two indistinguishable.
46004306|NCT02092922|Drug|Filanesib, KSP (Eg5) inhibitor; intravenous|multiple dose, single schedule
45677653|NCT02054897|Drug|semaglutide|Once weekly, administrated subcutaneously (s.c. under the skin)
45459072|NCT03496246|Diagnostic Test|serum calcium level|measurement of total calcium level after correction with albumin level as it is closely related to vitamin d with its effects on its level
46004307|NCT02092922|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|standard of care
46004308|NCT04611594|Behavioral|Fluid restriction|Ingestion of approximately 20 ml / kg of ideal weight,
45459073|NCT03496246|Diagnostic Test|erythrocyte sedimentation rate (ESR)|it is an indicator of activity in inflammatory bowel disease
45459074|NCT03496246|Diagnostic Test|C-reactive protein (CRP)|it is an indicator for increased possibility of infections
45836220|NCT00288600|Drug|Normal saline solution|Normal saline solution 10 ml/Kg
45459075|NCT03496246|Diagnostic Test|serum creatinine|for assessment of renal function
45459076|NCT03496246|Diagnostic Test|serum albumin level|for possibility of malabsorbtion in patients with inflammatory bowel disease
45459077|NCT03496246|Diagnostic Test|seum alanine aminotransferase|for assessment of liver function
45459078|NCT03496246|Diagnostic Test|serum potassium level|indicator for hypokalemia increased in patients with diarrhea as result of inflammatory bowel disease
45677654|NCT02054897|Drug|placebo|Once weekly, administrated subcutaneously (s.c. under the skin)
45677655|NCT04713605|Device|Critical closing pressure detection|Observational study that determines the critical closing pressure (CrCP) of the brain by comparison of the cerebral blood flow velocity (measured by TCD) and invasive blood pressure measurement (IABP)
45677656|NCT01976312|Other|Sham injection|Sham injections referred to the imitation of an intravitreal injection using an injection syringe without needle.
45459079|NCT03496246|Diagnostic Test|serum phosphurus level|measurement of phosphurus level as it is closely related to vitamin d with its effects on its level
45459080|NCT02017964|Drug|Carboplatin|Given IV
45677657|NCT01976312|Drug|Ranibizumab 0.5 mg|Ranibizumab solution for injection was supplied in vials. Each vial contained ranibizumab concentration of 10mg/mL labeled as 0.5 mg/0.5 mL, corresponding to a 0.5 mg dose level. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial for single use only
45677658|NCT02039219|Drug|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 6 weeks.
45677659|NCT02039219|Drug|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 6 weeks.
45836221|NCT00290472|Drug|temsirolimus|
46004309|NCT02092454|Drug|Benzocaine|topical otic solution
46004310|NCT02092454|Drug|Placebo|topical otic solution
45459081|NCT02017964|Other|Cognitive Assessment|Optional ancillary studies
45459082|NCT02017964|Drug|Cyclophosphamide|Given IV
45459083|NCT02017964|Drug|Etoposide|Given IV
45459084|NCT02017964|Other|Laboratory Biomarker Analysis|Correlative studies
45459085|NCT02017964|Drug|Methotrexate|Given IV
45459086|NCT02017964|Drug|Vincristine Sulfate|Given IV
45836222|NCT04752852|Drug|Dexamethasone|8 mg/2 ml dexamethasone IV, 60 minutes before the induction of anaesthesia
45836223|NCT04752852|Drug|Placebo|2 ml normal saline (0.9%) IV, 60 minutes before the induction of anaesthesia
45836224|NCT00291876|Biological|Havrix™|2 doses at 12 months interval
45836225|NCT01899144|Drug|Albuterol Spiromax|Albuterol Spiromax® Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose dry powder inhaler (DPI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two DPIs filled with Albuterol Spiromax® were used.
46004311|NCT02083289|Drug|ONO-9054|
46004312|NCT02083289|Drug|Latanoprost|
46004313|NCT02081300|Drug|Oral testosterone undecanoate, LPCN 1021|
46004314|NCT02081300|Drug|Topical testosterone gel 1.62 %|
46004315|NCT04611360|Other|Anodal Transcranial Direct Current Stimulation Group|"Experimental group were received anodal transcranial direct current stimulation and conventional training exercises for 3 days a weeks for 6 consecutive weeks on alternate days.~Anodal tDCS were given through:~i. Anodal electrode:It has been placed over primary motor cortex(ipsilesional) ii. Cathodal electrode: It has been above contralateral eye. iii. Intensity: 2mA iv Density: 0.07C/cm2 iv. Duration:20 min vi Rectangular electrodes(25cm2 ) inserted in saline soaked sponge used"
45677660|NCT04693793|Other|Education Materials and Janssen Test|"Intervention-1- and Intervention-2-arm participants will receive educational materials duplicating what physicians would receive in the real-world market as they adopt the Janssen technology. These materials are comprised of a slide deck, a sample test report, and a frequently asked questions (FAQ) sheet.~Intervention 1 participants only will receive the Janssen test results whether they select it or not, and Intervention 2 participants will receive the Janssen test results only if they select it during the second round of case simulations."
45677661|NCT02053493|Drug|Isosorbide Mononitrate|"Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg ISMN Week 4: 60 mg ISMN Weeks 5 and 6: 120 mg ISMN~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg ISMN Week 10: 60 mg ISMN Weeks 11 and 12: 120 mg ISMN"
45677662|NCT02053493|Drug|Placebo|"Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg Placebo Week 4: 60 mg Placebo Weeks 5 and 6: 120 mg Placebo~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg Placebo Week 10: 60 mg Placebo Weeks 11 and 12: 120 mg Placebo"
45677663|NCT02003144|Biological|eculizumab|
45677664|NCT04661540|Drug|CM4620-IE (Injectable Emulsion)|Auxora is an injectable emulsion containing 1.6mg/ML of the active pharmaceutical ingredient CM4620. Auxora will be administered intravenously as a continuous infusion
45677665|NCT04661540|Drug|Placebo|Matching placebo is an injectable emulsion containing no active pharmaceutical ingredient. Placebo will be administered intravenously as a continuous infusion
45677666|NCT04175210|Radiation|Radiation therapy - 3 weeks|Patients randomized to ARM 1 will receive whole breast radiotherapy of 4050cGY and a concomitant boost to the tumor bed of 4800cGY in 15 fractions
46004316|NCT04611360|Other|Conventional Training Exercises Group|Conventional physical exercises were given for 3 days a week on alternate days upto 6 weeks. It includes: progressive Conventional Training Exercises : From Bridging,Sitting: weight-bearing, Standing: weight-bearing, Sit to stand, Squat exercises and Tandem walk.
46004317|NCT04677881|Other|Intervention group|intervention group: bread with sourdough control group: bread with yeast
46004318|NCT02074007|Drug|AR01|drops administered as needed for pain
46004319|NCT02074007|Drug|Placebo Comparator|Glycerin ear drops (placebo) drops administered as needed for ear pain
46004320|NCT00563979|Dietary Supplement|VitaluxPlus®|1 tablet daily
46004321|NCT00563979|Dietary Supplement|Omega 3|1 tablet daily
46004322|NCT02072954|Drug|Asenapine Sublingual Tablets 10 mg|White to off-white, round, uncoated,unscored, flat-faced radius edge tablet. Debossed with A on one side and 17 on the other side
46004323|NCT02072954|Drug|Asenapine Sublingual Tablets 10 mg|"Round, white to off-white sublingual tablets, with 10 on one side within a circle"
46004324|NCT04611204|Other|Descriptive cohort|NT-proBNP assay, electrocardiogram and transthoracic echocardiography before CTS surgery release. Pathological analysis for amyloid deposits of transverse carpal ligament of patients included.
46004325|NCT00554918|Drug|docetaxel|
46004326|NCT00554918|Drug|prednisolone|
46004327|NCT00554918|Drug|zoledronic acid|
46004328|NCT00554918|Procedure|quality-of-life assessment|
46004329|NCT00554918|Radiation|strontium chloride Sr 89|
46004330|NCT04632147|Other|Ujjayi pranayama, Nadi-Shodhana pranayama, Sukha pranayama|Ujjayi pranayama:It is a pranayamic application that is performed by slightly twisting the throat and breathing through the nose. Nadi shodhana pranayama is breathing alternately through the right and left nostrils.Sukha pranayama is inhaled through the nose for 5 seconds, then given through the nose for 5 seconds. Thus, 6 times of inspiration and expiration is done per minute.
46004331|NCT04632108|Drug|ASKB589 Injection|ASKB589 Injection with dose escalation stage of 0.3mg/kg up to10mg/kg,as well as dose expansion stage with recommended dose level from dose escalation stage.
45342424|NCT02574702|Procedure|application of a contralateral drainage (Penrose ® device)|application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure
45677667|NCT04175210|Radiation|Radiation therapy - 2 weeks|Patients randomized to ARM 2 will receive whole breast radiotherapy of 3200cGY and a concomitant boost to the tumor bed of 4200cGY in 10 fractions.
45677668|NCT02001194|Behavioral|Individual Incentives|
45677669|NCT02001194|Behavioral|Team Incentives|
45677670|NCT02001194|Behavioral|Individual plus Team Incentives|
45677671|NCT02038907|Biological|Hepatitis A Vaccine|Hepatitis A Vaccine IM injection
45677672|NCT02038907|Biological|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection
46004332|NCT02061332|Biological|HER-2 Pulsed Dendritic cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines will be administered to subjects in each of the 3 arms.
45677673|NCT02038829|Drug|Placebo|Placebo
45677674|NCT02038829|Drug|SUN101 3 mcg|SUN-101 3 mcg bid
45677675|NCT02038829|Drug|SUN-101 6.25 mcg|SUN-101 6.25 mcg bid
45677676|NCT02038829|Drug|SUN-101 12.5 mcg|SUN-101 12.5 mcg bid
46004333|NCT04631874|Drug|CDFF0318, Champix|CDFF0318: Varenicline salt changed Champix: Varenicline tartrate
46004334|NCT02057315|Drug|ELS-M11|One dose of 5% ELS-M11 over 3 bilateral applications.
46004335|NCT02057315|Drug|Placebo|One dose of matching placebo over 3 bilateral applications.
45677677|NCT02038829|Drug|SUN-101 50 mcg|SUN-101 50 mcg bid
45677678|NCT02038829|Drug|Aclidinium|Aclidinium 400 mcg bid
46004336|NCT04610931|Behavioral|Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)|"Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups.~In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.~Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups. Subjects in the Virtual Reality group will receive 6 weekly individual CBT sessions followed by 6 virtual therapy sessions. Virtual therapy consists of exposing the patient to 3D situations considered to cause a high risk of smoking relapse and aiming to reduce signal reactivity by extinction. At each session, a neutral exposure will be given at the beginning to facilitate immersion and emergence of the session with a duration determined according to the sensitivity of each patient. Exposure is stopped when the craving approaches the baseline level."
46004337|NCT04610931|Behavioral|cognitive behavior therapy|"Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups. In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.~Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups."
45473922|NCT01175759|Drug|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L~Estradiol 1mmol/L~Estrone 3mmol/L~Estriol 3mmol/l~Controls:~Saline (NaCl) 0.9%~Ethyl Oleate with 10% Benzyl Alcohol~Histamine phosphate 1mg/ml (epicutaneous- prick test)"
45677679|NCT04693247|Device|EQ103|Refraction device
46004338|NCT02053103|Drug|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
45677680|NCT02038049|Drug|VAY736|Single intravenous infusion of VAY736 (10 mg/kg)
45677681|NCT02038049|Drug|Placebo|Placebo to VAY736
45677682|NCT02052011|Drug|Ranolazine|Subjects will take the extended-release Ranolazine for a total of 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
45677683|NCT02052011|Drug|Placebo|
45677684|NCT02036645|Biological|MEDI1814 for IV injection|Monoclonal antibody for IV Injection
45677685|NCT02036645|Biological|MEDI1814 for Subcutaneous Injection|Monoclonal antibody for subcutaneous injection
45677686|NCT02036645|Biological|IV Placebo|Placebo for IV injection
45677687|NCT02036645|Biological|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
45677688|NCT02051933|Drug|Botulinum toxin type A|"At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL Botulinum toxin type A. The dose of botulinum toxin will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Botox will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in Botox (rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
45836226|NCT01899144|Drug|ProAir HFA|ProAir® HFA Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose metered dose inhaler (MDI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two MDIs filled with ProAir HFA were used.
45473923|NCT01175759|Drug|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L~Estradiol 1mmol/L~Estrone 3mmol/L~Estriol 3mmol/l~Controls:~Saline (NaCl) 0.9%~Ethyl Oleate with 10% Benzyl Alcohol~Histamine phosphate 1mg/ml (epicutaneous- prick test)"
46089412|NCT02674542|Other|Focus Group|"Future family planning intentions and beliefs~Family planning experiences and beliefs:~Feasibility and acceptability of birth spacing promotion for women who have experienced a stillbirth or early neonatal demise"
45677689|NCT02051933|Drug|sodium chloride|"At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL 0.9% sodium chloride solution . The dose of 0.9% sodium chloride will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Placebo will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in placebo(rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
45677690|NCT02050373|Radiation|Low-Level laser|Application of laser therapy in low power mucosa jugal right and left upper and lower labial mucosa, floor of the mouth, tongue side of the right and left and belly of the tongue.
45677691|NCT04711811|Biological|HB-adMSC|Hope Biosciences adipose derived autologous mesenchymal stem cell product
45677692|NCT02049437|Drug|tocilizumab|"Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28."
45677693|NCT02049437|Drug|Placebo|"Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 aned 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28."
45836227|NCT01899144|Drug|Placebo|Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
45836228|NCT00234078|Drug|0.5% OPC-12759|
45836229|NCT00234078|Drug|1% OPC-12759|
45836230|NCT00234078|Drug|2% OPC-12759|
45473924|NCT03376204|Other|No intervention|No intervention
45473925|NCT03247530|Drug|Placebo|Placebo was administered once daily
45836231|NCT00234078|Drug|placebo|
45836232|NCT00118404|Behavioral|Continuation phase cognitive therapy|Continuation phase cognitive therapy included 10 sessions over 8 months.
45836233|NCT00118404|Drug|Continuation phase fluoxetine|The dosage of fluoxetine was increased to 40 mg over 8 months.
45836234|NCT00118404|Other|Continuation phase pill placebo|The dosage of pill placebo was increased to 40 mg over 8 months.
45836235|NCT00118404|Behavioral|Acute phase cognitive therapy|For the first 12 weeks, all participants received between 16 and 20 cognitive therapy sessions.
46004339|NCT02053103|Drug|Placebo|Tablet, 0 mg, twice daily, 6 weeks
46004340|NCT02049164|Drug|AR08|
46004341|NCT02049164|Drug|Placebo|
46004342|NCT04611282|Procedure|surgical techniques in the treatment of localized gingival recession defects.|Micro or macrosurgical echniques were performed using a coronally positioned flap with a subepithelial connective tissue graft.
46089413|NCT00643812|Other|Installation of gun locker in household|Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Early arm received gun lockers at baseline.
46004343|NCT02047214|Drug|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
46004344|NCT02047214|Drug|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
45677694|NCT02035553|Drug|Pimavanserin tartrate|Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
45677695|NCT02035553|Drug|Placebo|Placebo, two tablets, once daily by mouth
45677696|NCT04711733|Other|Interview|The qualitative interview aims to identify the supportive care needs of patients and parents as well as their expectations with regard to a long-term follow-up.
46004345|NCT04632186|Device|EXOPULSE Mollii suit|"All sessions start with rated perceived pain with the NRS and the ShoulderQ questionnaire and assessed body function with the Fugl-Meyer UE scale, Ashworth scale and the Neuroflexor, before the start of the intervention.~Session 1. Stimulation with TENS according to best clinical practice. Session 2. Stimulation with the Mollii suit according to current best experienced practice with selective stimulation directed to the shoulder region Session 3. Stimulation using the full body Mollii suit according to current best experienced practice.~Outcome of each session is assessed with a pain drawing, the NRS (during and after treatment) and the Fugl-Meyer UE, Ashworth scale and the Neuroflexor (after treatment)."
46004346|NCT04631991|Diagnostic Test|Comprehensive ophthalmologic examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
45677697|NCT04711733|Other|Self-report questionnaire|"To assess the quality of life, anxiety/depression of former patients and relatives:~For child and adolescent patients (less than 15 years old at inclusion):~Pediatric Quality of Life Inventory Cancer module~Screen for Child Anxiety Related Emotional Disorders Revised~Children's Depression Inventory~For patients over 15 years of age at the time of inclusion and parents:~36-Item Short Form Health Survey~Hospital Anxiety and Depression Scale~To describe and evaluate the offer and use of the network of health professionals who are aware of post-treatment issues: number of consultations, speciality and location of the professionals requested following the long-term follow-up consultation, time between referral and first consultation, evaluation of the geographical accessibility of care around the patient's home."
45677698|NCT04711733|Other|Medical consultation|"To assess adherence to long-term follow-up medical consultation:~- number of patients summoned/ number of consultations carried out ; reason for refusal of long-term follow-up medical consultation To assess medical complications through clinical data collection"
46004347|NCT02046395|Drug|amlodipine, hydralazine, terazosin or hydrochlorothiazide|In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure.
46004348|NCT04631757|Drug|Camrelizumab + SOX + Radiotherapy|Camrelizumab 200mg,d1,Q3w; oxaliplatin 130mg/m2, d1, Q3w; S-1 40-60mg bid, d1-d14,Q3w; intensity modulated radiotherapy 45Gy/25d
46004349|NCT02032277|Drug|Cyclophosphamide|Cyclophosphamide
46004350|NCT02032277|Drug|Placebo|Placebo for Carboplatin
46004351|NCT02032277|Drug|Doxorubicin|Doxorubicin
45677699|NCT01445080|Other|Laboratory Biomarker Analysis|Correlative studies
45836236|NCT00121836|Drug|Capecitabine|1000 mg/m² PO BID on Days 1-15 of each 3-week cycle
45836237|NCT00121836|Drug|Bevacizumab|15 mg IV on Day 1 of each 3-week cycle
45677700|NCT01445080|Other|Pharmacological Study|Correlative studies
45677701|NCT01445080|Drug|Sorafenib Tosylate|Given orally
46004352|NCT02032277|Drug|Paclitaxel|Paclitaxel
46004353|NCT02032277|Drug|Carboplatin|Carboplatin
46004354|NCT02032277|Drug|Veliparib|Veliparib
46004355|NCT02032277|Drug|Placebo|Placebo for Veliparib
46089414|NCT00643812|Other|Installation of gun locker in household|"Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Late arm received the gun locker 12 months after baseline."
46089415|NCT02672904|Device|CO2 laser|surgical removal of carcinoma from the vocal cords with CO2 laser
45473926|NCT03247530|Drug|100mg SPN-812|100mg SPN-812 was administered once daily and compared to placebo
45836238|NCT01898910|Procedure|PVI+renal denervation|After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
45836239|NCT01898910|Procedure|PVI + GP ablation|To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
45836240|NCT01898910|Drug|Optimal medial therapy (OMT)|Antiarrhythmic and antihypertensive therapy will be administered according to the guidelines
45836241|NCT00237666|Drug|Ziprasidone|Ziprasidone 20-60 mg BID, taken orally.
45836242|NCT00296322|Drug|cisplatin, mitomycin-C, doxifluridine|"Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)~iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)"
45836243|NCT00297102|Drug|Roflumilast|500 mcg, once daily, oral administration in the morning
46004356|NCT04611009|Behavioral|motor training|In the sensorimotor training program task-specific and non-task specific aspects will be combined. It will start with assignments to improve general finger and wrist movements. After four weeks more specific writing exercises will be added.
45836244|NCT00297102|Drug|Placebo|once daily
46004357|NCT04611009|Behavioral|mindfulness exercises|The awareness training will contain mindfulness exercises. The goal is to consciously experience the here and now in sensual perception of oneself and the environment.
46004358|NCT00560976|Drug|Iron Saccharate (Venofer)|Hemodialysis with IV iron administration of 100 mg Iron Saccharate (Venofer) in 150 ml 0.9 % saline to the arterial dialysis line during first hour of mid-week dialysis session. An alternative IV iron brand in some centers participating in the study could bebe 62.5 mg ferric gluconate (Ferrlecit).
46004359|NCT02026349|Drug|favipiravir|"Administered twice daily over 5 consecutive days for a total of 10 doses.~Day 1: 1800 mg twice daily (loading doses)~Days 2 through 5: 800 mg twice daily"
46004360|NCT02026349|Drug|Placebo|Administered twice daily over 5 consecutive days for a total of 10 doses.
46004361|NCT04611048|Diagnostic Test|Thermal QST (CDT, WDT, CPT, HPT) with the method of limits|The testing will be carried out using the classical method of limits, i.e. a continuous heating/cooling stimulus will be applied to the skin at a rate of 1°C/s, until the subject signals that he/she felt the targeted sensation by pressing a button (Rolke, Baron, et al., 2006). The temperature reached by the time the subject pressed the button will be considered the threshold. Baseline temperature will be set at 32°C. The stimuli will not go lower than 0°C and higher than 50°C.
46004362|NCT04611048|Diagnostic Test|Thermal QST (cold and warm detection, heat pain) with the psi method|The Psi algorithm is a method using Bayesian statistics to determine not only the threshold but also the slope of the psychometric function (relationship between the intensity of a stimulus and its detection probability; Kingdom & Prins, 2010). The algorithm selects the next stimulus intensity to be the most informative on the parameters of interest, based on the prior probability density. After each stimulation, the subject will be asked if he/she felt it (as painful) or not. Based on that answer, a posterior probability density is computed. This posterior is then used as prior for the next stimulation. The stimuli will last maximum 1 s and temperature will be kept between 0°C and 60°C.
45836245|NCT00123162|Drug|Sildenafil Citrate|A single vaginal dose of sildenafil citrate 100 mg and monitored for 4 hours.
46004363|NCT04611048|Diagnostic Test|Neurological examination|A standardized neurological examination will be performed to assess all the items included in the Utah Early Neuropathy Scale (UENS ) (Singleton et al., 2008) and the Toronto Clinical Neuropathy Score (TCNS)(Perkins, Olaleye, Zinman, & Bril, 2001). This will include: questions about symptoms (presence or absence of foot pain, numbness, tingling, weakness, imbalance and upper limb symptoms); evaluation of knees and ankles deep tendon reflexes; evaluation of pinprick, temperature, light touch, vibration (128 Hz tuning fork) compared to that of an unaffected sites (e.g., sternum); position sensation in the big toes; mapping of pinprick sensitivity in the lower leg; and evaluation of the active extension of the big toes. Pinprick evaluation will be performed using a disposable pin designed for that purpose (Medipin, The United-Kingdom).
46004364|NCT04611126|Drug|Ipilimumab|Ipilimumab 3 mg/kg is administered 2-6 weeks before surgical removement of the tumor. The medicine is administered i.v. over 30 minutes.
46004365|NCT04611126|Drug|Cyclophosphamid|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
46004366|NCT04611126|Drug|Fludarabine Phosphate|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
46004367|NCT04611126|Biological|Tumor Infiltrating Lymphocytes infusion|Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion. The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
46004368|NCT04611126|Drug|Nivolumab|Nivolumab 240 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 30 minutes.
46089416|NCT02672904|Device|KTP laser|surgical removal of carcinoma from the vocal cords with KTP laser
45473927|NCT03247530|Drug|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
46004369|NCT04611126|Drug|Relatlimab|Relatlimab 80 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 60 minutes.
46089417|NCT02674308|Drug|Vedolizumab|
45677702|NCT02035475|Device|Intuitive Vessel Sealer|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
45677703|NCT04692779|Other|Lung Ultrasound (LUS)|Enrolled subjects will undergo LUS 1 hour before and 1 hour after prone positioning by a trained clinician and will be assessed using a LUS score based on LUS pattern. LUS will then be performed again 1 hour before supination (16 hours) and assessed by a LUS score. This process will be repeated on the first 3 prone sessions. Patients will be enrolled in the study for 4 weeks in order to observe patient outcomes.
45677704|NCT04181177|Other|Cosmetic product|"Cosmetic balm: application twice daily on the whole body in sufficient quantity to cover all the xerosis areas. It contains an I-modulia(r) complex which decreases the sensation of itching, CER-OMEGA which are lipids similar to those of the skin, help repair and nourish the skin, finally Avène Thermal Spring Water which have soothing and softening properties.~Targeted education action consist in advices and preventive measures (including hygiene) regarding xerosis and associated dermatological signs / symptoms. Emollient and application tips and other supportive care tips will be provided. The targeted educational action will be monitored by the medical and paramedical teams (specialized nurses)."
46004370|NCT02026232|Drug|Hydroxychloroquine|200mg twice daily
45677705|NCT04709549|Behavioral|Diabetes Prevention Program + Job and Legal Services|"Diabetes Prevention Program (DPP) is a one-year lifestyle modification program that helps adults at risk for developing type 2 diabetes gain tools for healthy living.~Job readiness services will be provided by YMCA SF service connectors, trained staff with expertise in employment services who are bi-lingual in English/Spanish and/or Cantonese/English to serve the needs of the community. Service Connectors will assist with providing employment services (e.g job search, potential placement and retention services, relationship development with partners and employers) and job readiness instruction/training."
45677706|NCT04709549|Behavioral|Diabetes Prevention Program|Diabetes Prevention Program (DPP) is a one-year lifestyle modification program that helps adults at risk for developing type 2 diabetes gain tools for healthy living.
45677707|NCT04748536|Drug|IRL201104|lyophilised powder for reconstitution for IV dosing
45677708|NCT04748536|Drug|Placebo|Matching placebo for IRL201104
46004371|NCT02026232|Other|Hydroxychloroquine Placebo|200mg placebo twice daily
46089418|NCT02674308|Other|Other Biologic Agents|Other biologic agents include: Adalimumab, Certolizumab pegol, Golimumab, and Infliximab
45677709|NCT01438294|Other|Video game group|The training with video game will be done with heart rate monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.Will be used Kinect games ( adventure- reflex ridge).
45836246|NCT00123162|Drug|Placebo|A single vaginal dose of placebo and monitored for 4 hours.
46004372|NCT04611165|Drug|Nivolumab|"Nivolumab 3mg/kg IV is administered as 30-minute IV infusion every 2 weeks.~EBRT begins 2-7 days after the first dose of nivolumab.~The follow-up phase begins when the decision to discontinue study is made. The follow-up phase is defined as the day after the end of study treatment until the day the subject dies."
46089419|NCT04180878|Behavioral|Intervention|Participants received a interactive physical activity monitoring system that allowed study personnel to monitor their activity level.
46089420|NCT04180878|Behavioral|Intervention 2|Participants received an interactive physical activity monitoring system, an electronic scale to report weekly body weight, weekly hour long conference calls with structured interactive educational lessons led by Health Educator, dietary recalls were completed at three different time points during their participation, and study personnel monitored physical activity levels weekly.
46004373|NCT02014649|Drug|20 mg laninamivir octanoate|
46004374|NCT02014649|Drug|Placebo|
46004375|NCT02014649|Drug|40 mg laninamivir octanoate|
46004376|NCT02014142|Drug|Latanoprost Punctal Plug Delivery System (L-PPDS)|Latanoprost Punctal Plug Delivery System (L-PPDS)
46089421|NCT02676258|Device|Si-Hy (olifilcon B)|Wear Si-Hy silicone hydrgel soft contact lens for 3 months
46004377|NCT04610580|Drug|ALXN1840|ALXN1840 will be administered orally.
46004378|NCT04631328|Other|Growing Together|Growing Together is a suite of free, online research-informed professional development modules to help early childhood educators promote deeper family engagement and enrich teacher-parent interactions.
46089422|NCT02676258|Device|Vistakon (narafilcon A)|Wear Vistakon soft contact lens for 3 months
46089423|NCT02672826|Procedure|Adipose tissue surgery|Adipose tissue (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated
45677710|NCT01438294|Other|Aerobic exercise group|A 10 minutes warm up period was performed on a treadmill at 2 km/h prior to each session. After that, exercise training was performed during 30 minutes beginning at 70% of the maximum effort determined in the maximal exercise testing. Before and after each session, 3 measures of the peak flow were performed in the standing position (AssessTM, USA). There was progression in the training intensity throughout the study: if the patient maintained 2 consecutive exercise sessions without symptoms, exercise intensity was increased by 5% of cardiac frequency by using either treadmill speed or grade as previously described (Mendes et al.2011).
45677711|NCT04709471|Drug|Nicotine|Participants will reduce their nicotine intake
45677712|NCT04709471|Device|Juul e-cigarette|Participants will switch to Juul pods containing less nicotine
45677713|NCT04709471|Behavioral|Reduction|Participants will reduce the number of Juul pods that they use
46004379|NCT02009579|Drug|Nintedanib|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.
45677714|NCT04690985|Behavioral|Dietary behaviour change|The intervention consists of dietary guidance and behaviour change techniques, which will last for 15 weeks. The experimental group will be required to adhere to a diet consisting of a 12% reduction in calorie and a 1.2-1.5 g/kg body weight/day intake of protein. The participants will receive the dietary behaviour change guidance in 6 times face-to-face meetings and weekly telephone calls. They will also be asked to take daily food diary.
46004380|NCT02009579|Drug|Placebo|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.
45677715|NCT04690985|Other|Social contact|The control group will not be required any dietary changes. The investigator will contact with the control group with the same frequency and numbers of experimental group. But the chat topic will not be related to sarcopenic obesity or dietary guidance.
45677716|NCT02033759|Device|Bio-Impedance Testing|Participants in the BIA Arm will also undergo bio-impedance testing with this device.
45677717|NCT02033759|Other|Anxiety Questionnaire|21 item questionnaire
45677718|NCT02033759|Other|Traditional Circumferential Measurements|
46004381|NCT04631250|Drug|5-Aminolevulinic Acid-Containing Product in Cutaneous Dose Form|5-Aminolevulinic Acid was applied to both sides of the face.
46004382|NCT02009423|Drug|Masitinib|
46004383|NCT02009423|Drug|Placebo|
46004384|NCT04610619|Other|Immunological challenge|In vitro immunological study of subjects with RYR1 related MH/rhabdomyolysis. Studying of circulating cytokines and cytokines production after in vitro stimulation
46004385|NCT02006030|Drug|ADI-PEG 20|
46004386|NCT02006030|Drug|Transarterial chemoembolization|
45677719|NCT04690205|Other|End of Life (EOL) Care at at Home|Remote monitoring and home-based care designed for patients with advanced hematologic malignancies
45677720|NCT01959529|Drug|insulin degludec|Injected once daily subcutaneously (s.c., under the skin)
45677721|NCT01959529|Drug|insulin glargine|Injected once daily subcutaneously (s.c., under the skin)
45677722|NCT02033369|Drug|Pramipexole|Dose will be started at 0.125 mg bid, and increased by 0.25 mg/day every 3-4 days to a target range of 1.0 - 2.5 mg/day.
46004387|NCT04631094|Other|The group holding the serrated ball in the hand on the extremity from which venous blood will be taken|Children in the experimental groups will squeeze the serrated ball during the blood draw.
46004388|NCT04631094|Other|The group holding the serrated ball in the hand on the opposite side of the extremity from which venous blood will be taken.|Children in the experimental groups will squeeze the serrated ball during the blood draw.
46004389|NCT04631094|Other|The group holding a smooth ball in the hand on the extremity from which venous blood will be taken|Children in the experimental groups will squeeze the smooth ball during the blood draw.
45677723|NCT02032901|Drug|Daclatasvir|
45677724|NCT02032901|Drug|Sofosbuvir|
46004390|NCT04631094|Other|The group holding a smooth ball in the hand opposite the extremity from which venous blood will be taken.|Children in the experimental groups will squeeze the smooth ball during the blood draw.
46004391|NCT03455036|Other|Whole body vibration training|10 x 1 min whole body vibration exposure
45836247|NCT01897818|Device|communication system P300 Speller|
45836248|NCT04751838|Other|no intervention|no intervention
45836249|NCT00123630|Drug|omalizumab|omalizumab dosed IV based on IgE level and weight every 2 - 4 weeks
45836250|NCT00123630|Drug|Placebo|Placebo given IV once every 2-4 weeks based on weight
46004392|NCT01998035|Drug|Romidepsin|"Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (10, 14 mg/m2)"
46004393|NCT01998035|Drug|Oral 5-Azacitidine|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (100, 200, 300 mg)"
46089424|NCT04180566|Other|Ultrasound Examination|Includes a regular growth ultrasound examination.
46089425|NCT04180566|Other|Antenatal Testing (biophysical profile)|Includes weekly ultrasounds with a biophysical profile, which measures fetal tone, fetal movements, fetal breathing and amount of amniotic fluid (water around baby).
45683783|NCT04135066|Other|Refine grain breakfast|After wearing continuous glucose monitoring device (CGM) on baseline, participants will be provided with breakfast A on two consecutive days in a whoe 14-day monitoring period. The appearance of breakfast A is pseudorandom. Breakfast A contains white bread (100g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
45836251|NCT00124176|Drug|Racemic albuterol (R+S albuterol)|20mg/hr continuous racemic albuterol
46089426|NCT04180644|Other|Skin tape strips|Skin tape strips will be collected from lesional and non-lesional skin. Adhesive skin sampling discs will be firmly pressed against the skin in a hairless location (not the face) followed by lifting it free of the skin. These discs will then be used to evaluate proteins and lipids in the upper layers of skin.
45459087|NCT03131752|Behavioral|Elastic Resistance Intervention in Exacerbated Patients|The intervention protocol will performed during 7 days for all patients and this will begin 24 -48 hours after the start of medication for exacerbation. Those who are hospitalized and discharged before this period will continue their treatment at the Laboratory of Spirometry and Respiratory Physiotherapy (LEFIR) of the Federal University of São Carlos. The intervention will also perform for at least 5 continuous days. The ideal elastic band for the training will be chosen through the test of 10 maximum repetitions. The test and the training will be performed in an ergonomic chair allowing the lower limbs to remain pending. After 24 hours of the test, patients will perform knee extension exercise with the appropriate elastic band. Three sets of 10 repetitions will be done in each exercise, with a minimum rest interval of 1 minute between sets or until heart rate values return to baseline. Patients will be re-evaluated 1 and 3 months after the first contact.
45836252|NCT00124176|Drug|Levalbuterol (R albuterol)|10mg/hr continuous nebulized levalbuterol
45836253|NCT00240162|Drug|PTK787/ZK 222584|
45836254|NCT00299988|Drug|Intravenous Immunoglobulin|
46004394|NCT04630899|Other|Active joint mobilization|The participants bend his knees in a prone position. The physical therapist holds the medial malleolus with one hand and the lateral malleolus with the other. At the same time, the physical therapist touches the participant's soles to the sternum area and presses them in the dorsal direction. At this time, medial malleolus glides anterior and lateral malleolus glides posterior. The first procedure is to passively recognize movement. The second procedure is accompanied by active movement of the participant.
46004395|NCT04630899|Other|Passive joint mobilization|PJM uses Maitland's Mobilization method, grade III (high amplitude in the end range of the joint and 1 second vibration in the middle range through linear motion in which tissue resistance is felt). The participant is in a supine position, and the physical therapist holds the talus with one hand and the tibia with the other hand, and performs joint mobilization in the posterior direction with the hand holding the talus.
46004396|NCT01991210|Drug|DNIB0600A|DNIB0600A will be administered at a dose of 2.4 mg/kg IV every 3 weeks.
46089427|NCT04180332|Diagnostic Test|Blood sample|5ml of venous blood was taken from the ante cubital vein from each of the study subjects
46089428|NCT05577156|Behavioral|Self-questionnaires and semi-structured interview|Patients will fill these questionnaires : BISF-W, QLQ-C30, QLQ-BR23 and if they agree answer to a semi-structured interview composed of 5 questions
46089429|NCT04179240|Other|audio and animated cartoon questionnaire|participants were asked to complete a questionnaire audio and animated cartoon on a platform
45459088|NCT03131830|Other|Online-based questionnaire|Participants receive a web-link to a questionnaire, which is active for 3 months
46004397|NCT01991210|Drug|PLD|PLD will be administered at a dose of 40 mg/m^2 IV every 4 weeks.
46004398|NCT04611243|Biological|third dose vaccination with CoronaVac vaccine|Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of CoronaVac vaccine
46004399|NCT04611243|Biological|third dose vaccination with BionTech vaccine|Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of BionTech vaccine
45836255|NCT00299988|Other|Placebo|
45836256|NCT04226352|Drug|Dextromethorphan|Dextromethorphan will be administered and its tolerability evaluated.
46089430|NCT00643890|Genetic|Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus|One-time bilateral administration of rAAV-GAD at 1X10^12 vector genomes in 35 uL.
46089431|NCT04178928|Drug|Levothyroxine|investigate the effect of replacement therapy with levothyroxine on cardiovascular risk factors in children with SCH.
45836257|NCT00300456|Drug|ABT-335|135 mg, daily, 12 weeks
45836258|NCT00300456|Drug|Simvastatin|daily, 12 weeks, see Arm Description for dosage information
45836259|NCT00300456|Drug|Placebo|Daily, 12 weeks, see Arm Description for placebo information
45677725|NCT04681469|Drug|Niraparib|"For all patient's population:~Niraparib 200 mg/day: day -49 to day -21;~Dostarlimab 500 mg iv: day -49 and day -28; At day -21, clinical evaluation will be performed and the patient will be directed to surgery with exclusion from the study in case of progressive disease. Radiological assessment will be performed according to the physician's judgement.~If no clinical evidence of disease progression:~Niraparib 200 mg/day: day -21 to day -7~Dostarlimab 500 mg iv: day -7~Radiological assessment (day -1, ± 3 days),~Surgery (original margin) at day 0 (±3 days)~Standard postoperative (chemo)radiotherapy according to pathologic report;~Maintenance Niraparib, 200 mg/day for 6 months~Maintenance Dostarlimab, 500 mg iv q3W for the first four cycles and 1000 mg iv Q6W thereafter for 3 months."
45677726|NCT04416971|Procedure|AVF puncture|For patients with mature/immature AVF on HD initiation, AVF puncture will be conducted.
45677727|NCT04690127|Other|Plyometric Exercise|Plyometric training consisting of ten different exercises [vertical unilateral and bilateral counter movement jump, horizontal unilateral and bilateral counter movement jump, drop jump (30 cm), squat jump, step-hop (20 cm), 180 degree rotation in transverse plane, frontal plane hurdle jump (20 cm) and sagittal plane hurdle jump (20 cm)] for 8 weeks, 3 sessions per week. Individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery)
46004400|NCT04611243|Biological|Vaccination with Coronavac vaccine|Healthy individuals to receive Coronavac vaccine 2 doses, 21 days apart
46004401|NCT04611243|Biological|Vaccination with BionTech Vaccine|Healthy individuals to receive BionTech vaccine 2 doses, 21 days apart
46004402|NCT01979939|Drug|DCV/ASV/BMS-791325|
46089432|NCT04179006|Dietary Supplement|LF/Erinacine A-enriched Hericium/Plain chocolate + antidepressant(s)|3 pieces per day
46089433|NCT02672670|Behavioral|Experimental: Intervention group---coping-oriented supportive programme|
46004403|NCT04610970|Drug|TQ-B3525 tablets|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
46004404|NCT04631172|Other|Coronavirus Anxiety Scale , COVID-19 Phobia Scale|Using two questionnaire completed in face-to-face interviews Participants were asked the Coronavirus Anxiety Scale (CAS), and the COVID-19 Phobia Scale (C19P-S).
46004405|NCT04677530|Drug|JNJ-40411813|JNJ-40411813 will be administered orally.
46004406|NCT04677530|Drug|Matching Placebo|Matching placebo will be administered orally.
45459089|NCT05129566|Procedure|IOL Clareon AutonoMe|Phacoemulsification of cataract with implantation of two types of IOLs - Clareon AutonoMe and Hoya iSert 251. Operations will be performed by one surgeon using the Centurion vision system under control of the Verion navigation system. The Verion system will be used for capsulorhexis and IOL centration (limbus centration).
46004407|NCT00564057|Drug|candesartan|tablet 8-16 mg once daily, one year
45459090|NCT05129566|Procedure|IOL Hoya iSert 251|Phacoemulsification of cataract with implantation of two types of IOLs - Clareon AutonoMe and Hoya iSert 251. Operations will be performed by one surgeon using the Centurion vision system under control of the Verion navigation system. The Verion system will be used for capsulorhexis and IOL centration (limbus centration).
46004408|NCT00564057|Drug|lercanidipine|tablets 10-20 mg once daily, one year
46089434|NCT02672670|Behavioral|Active Comparator: Comparison group---a didactic talk (usual care)|
46089435|NCT00643968|Drug|EFV+TDF|
46089436|NCT00643968|Drug|EFV+3TC+TDF|
46089437|NCT02672592|Drug|Anakinra|Anakinra 100mg s.c. bid
46089438|NCT02672592|Drug|Sodium Chloride 0.9%|Sodium Chloride 0.9% s.c. bid
46089439|NCT00643032|Procedure|Transcutaneous iliohypogastric|
46089440|NCT00643032|Procedure|Perioperative administration near the nerve|
46089441|NCT02676414|Behavioral|Interactive hypertension education program of the DHL©|
46089442|NCT04098900|Diagnostic Test|Click Sexual Health Test|The Click Device is a single-use (disposable), fully integrated, rapid, compact, device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for accurate, qualitative detection and differentiation of deoxyribonucleic acid (DNA) for Neisseria gonorrhea (NG), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT) organisms.
46089443|NCT02672436|Drug|ENERGI-F703|Standard of care and ENERGI-F703 are applied for treatment of diabetic foot ulcers.
46089444|NCT02672436|Drug|ENERGI-F703 matched vehicle|Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
46004409|NCT04630743|Behavioral|Cognitive and Behavioral intervention for the Management of Episodic Breathlessness|The cognitive and behavioral brief intervention comprises two parts: In a first module, the intervention and the study team is introduced, the definition of episodic breathlessness is given and the individual characteristics of breathlessness episodes are recorded. Goals of the intervention are discussed. In a subsequent module on patient education and the strategies, the patient and intervention executor discuss the patients' assumptions about episodic breathlessness including triggers and already used management strategies for breathlessness episodes. This follows the presentation of the non-pharmacological strategies: movement of air/ handheld fan, forward lean, diaphragmatic breathing, distraction, pursed lips breathing, long breaths out and relaxation training. The patient selects 2-3 strategies and trains them with the intervention executor.
45459091|NCT02450890|Drug|Placebo First, then ORADUR®|ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
45683784|NCT04135066|Other|Whole grain breakfast|After wearing CGM on baseline, participants will be provided with breakfast B on two consecutive days in a whoe 14-day monitoring period. The appearance of breakfast B is pseudorandom. Breakfast B contains plain oats (70g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
46004410|NCT04630782|Diagnostic Test|PET-MRI scan|Participants will be scanned centrally at Clinical Imaging Research Centre (CIRC, Singapore), on a Biograph mMR PET-MR scanner. Combined FDG-PET-MRI scan is critical for co-registration of peristaltic bowel for optimal image quality. The oesophagus to anorectum will be imaged. The PET-MRI scan starts 60 minutes post-FDG injection of 6mCi and immediately after injecting 10mg hyoscine butylbromide to reduce peristalsis. MRI sequences are non-contrast.
46089445|NCT02674074|Device|infrared thermography|measurement of corneal temperature by infrared thermography before and after cold provocation
46089446|NCT02674152|Drug|BI 836880|
46089447|NCT04179084|Drug|fruquintinib|5mg qd, 2weeks on, 1week off
46089448|NCT04179084|Drug|Sintilimab|200mg q3w
45459092|NCT02450890|Drug|ORADUR® First, then Placebo|ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
46004411|NCT04630704|Device|Pedra|Diffuse speckle contrast analysis perfusion system
45342425|NCT04071444|Other|Baduanjin program|The entire program continued for 6 months (December, 2018 to July, 2019), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
45342426|NCT00128856|Drug|Gemcitabine|
45683785|NCT04276636|Drug|Caltrate Pill|Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Caltrate Pill 0.6 g / d, while the other group do not interfere.
46004412|NCT00564096|Device|DEEP TMS H1 coil|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
46004413|NCT00564096|Device|Deep H1 coil TMS|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
46004414|NCT04677452|Biological|JWCAR129|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR129. During JWCAR129 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JWCAR129 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JWCAR129 administered intravenously (IV).
46004415|NCT04677296|Other|VS002A|Amino acid based ORS/Medical food
46004416|NCT04677296|Other|WHO-ORS|WHO Oral rehydration solution, which is glucose based
46004417|NCT04610541|Drug|Remdesivir-HU|Remdesivir-HU 100 mg concentrate for solution for infusion
46004418|NCT04677335|Dietary Supplement|AB-LIFE with Monacolin K|Red yeast rice extract (also known by its scientific name, Monascus purpureus) certified to contain 10 mg of monacolin K, plus 1 billion total cfu of AB-LIFE probiotic formula, which is composed of 3 Lactoplantibacillus plantarum (formerly known as Lactobacillus plantarum) strains: CECT7527 (also known as KABP011™), CECT7528 (also known as KABP012™) and CECT7529 (also known as KABP013™), all in a maltodextrin carrier. Capsules are of vegetable origin (hydroxypropylmethyl cellulose).
46004419|NCT04677335|Other|Placebo|Placebo capsules containing maltodextrin carrier only. Capsules are of vegetable origin (hydroxypropylmethyl cellulose).
45342427|NCT00128856|Drug|Adriamycine|
45342428|NCT00128856|Drug|Paclitaxel|
45677728|NCT04689659|Biological|chimeric antigen receptor T cell treatment|CD7 CAR T cells will be given once intravenously at one dose (1×106, with an allowance of ± 20%) in patients received previous HSCT donor-derived CAR T cells. Patients who received fresh donor derived CD7 CAR T cells were given initial dose of 1×106, with an allowance of ± 20%. The dose levels may be adjusted during the study based on the specific number of cells on the day of fresh CAR T cells infusion, due to at this time all the patients have completed lymphodepleting, so we adopt the allowance of ±20% for each group of absolute infusion cells. And patients who were lower than the designed dose group were also given infusion, but they will be either assigned to the lower dose group or exclude from safety analysis of designed dose group.
45677729|NCT02020967|Other|Non-interventional cross-sectional survey|This is a survey which does not involve any intervention into routine clinical practice, including the use of any investigational therapy or special examination methods.
45677730|NCT01986829|Device|Microwave ablation|"Microwave ablation will be predominantly used on metastatic soft tissue lesions and will include use of Covidien's Evident™ MWA System. Microwave ablation is performed under ultrasound, CT, and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in probe placement and CT monitoring of ablation.~Microwave antennae from Covidien (Mansfield, MA) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
45683786|NCT04397224|Diagnostic Test|Device interrogation|Ventriculo-ventricular conduction time measurement using device analyzer
45342429|NCT00128778|Drug|Pegylated liposomal doxorubicin|
45342430|NCT05673252|Diagnostic Test|Venous blood sample|Blood chemistry tests: neutrophil;lymphocyte; monocyte; platelet counts
45459093|NCT05121298|Drug|upadacitinib 15mg/day|Patients will receive upadacitinib 15mg/day and continue to receive same doses of MTX until 24 weeks. If patients achieve a European League Against Rheumatism (EULAR) moderate response or a Disease Activity Score 28 (DAS28-CRP) ≤3.2 at 12 weeks, and a DAS28-CRP of <2.6 at 24 weeks, they will discontinue MTX, and continue upadacitinib until 48 weeks.
46004420|NCT04630509|Procedure|traumatic cataract extraction|Irrigation/aspiration of traumatic cataract in children with posterior chamber intraocular lens implantation
45342431|NCT05673252|Procedure|biopsy|histopathology findings
45342432|NCT04901910|Behavioral|Physical Activity (PA) Social Media Group|Participants will have access to the secret Social Media page that will deliver health information focused on increasing healthy activities and well-being. This information will be posted by e-coaches. Participants can interact with the e-coaches as well as other study members in the group.
46004421|NCT04677023|Other|GrandioSO x-tra® bulk|The prepared cavities will be restored with GrandioSO X-tra (VOCO, Cuxhaven, Germany) in layers that are a maximum of 4 mm thick then cured for 20 seconds using using Elipar™️ S10 LED curing light (3M ESPE, St Paul, MN, USA) with light intensity of 1200 mW/cm2.
46004422|NCT04677023|Other|Admira fusion X--tra® bulk|he prepared cavities will be restored with Admira fusion X-tra®️ bulk (VOCO, Cuxhaven, Germany) in layers that are a maximum of 4 mm thick then cured for 20 seconds using usingElipar™️ S10 LED curing light (3M ESPE, St Paul, MN, USA) with light intensity of 1200 mW/cm2.
46004423|NCT04630548|Device|Intrauterine copper device|The obstetrical team will identify subjects who present in labor who meet the criteria and express interest in intrauterine contraception. Immediately after cesarean delivery, consented subjects will be randomized to immediate post placental IUD placement within 10 minutes or IUD placement at their routine standard postpartum visit (6 to 8 weeks postpartum).
46004424|NCT01975610|Drug|CC-292|375 mg PO daily (250 mg in the AM and 125 mg in the PM for 28 days)
46004425|NCT01975610|Drug|Placebo|Twice daily for 28 days
46089449|NCT04178850|Biological|GB242|GB242: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses
46089450|NCT04178850|Biological|Infliximab|Infliximab: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses
46089451|NCT04178616|Diagnostic Test|olfactory testing with specific odorants (localisation and identification)|Olfactory testing : ETOC (European Test of Olfactory capabilities)
45677731|NCT01986829|Device|Cryoablation|"Cryoablation is performed under ultrasound, CT and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in cyroprobe placement and CT monitoring of ablation.~Cryoprobes from Endocare Inc. (Irvine CA) or Galil Medical (Arden Hills MN) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
46004426|NCT04610424|Behavioral|"Cooperative Parent Mediated Therapy (CPMT)"|CMPT usually last 6 months, for a total amount of 15 sessions of 90 min; twelve core sessions (one session per week) are delivered in the first 3 months, followed by 3 monthly booster sessions. Each weekly core session had a specific focus and specific intervention strategies based on active parent coaching during parent-child interaction, and included the parent-child dyad with the parent being actively coached by a trained therapist. Live active coaching increases parents' competence in implementing strategies to enhance child development, and at the same time increases their confidence. This intervention has demonstrated evidence of effectiveness in socio-communicational improvement as measured by ADOS-G (Valeri, 2019) in a randomized controlled trial (RCT).
45459094|NCT03496090|Other|Free diet|Free diet or free demand, being comparable to the normal or zero hospital diet
45459095|NCT03496090|Other|Progressive diet|Progressive diet for 7 days, liquid diet for the first three days and soft diet without waste, from the 4th to the 7th day.
45459096|NCT05190380|Other|HIGH INTENSITY PROGRESSIVE RESISTED EXERCISE|"Intervention:Leg presses, knee extension, hip adduction and hip abduction exercises will be performed by patients. There will be a warm up sets for 1 repetition maximum with 2 min gap between both sets (leg press + knee extension exercises) (hip abduction and hip adduction) patients will ask to perform.~Both groups will receive routine physical therapy (Tens, Hot pack, Deep friction massage) in addition with experimental interventions"
46089452|NCT00644046|Behavioral|multidisciplinary predialysis education|teaching of renal knowledges, dietary support and recall of period medical visits
46089453|NCT04180410|Device|EIT|Electrical Impedance Tomography is performed before extubation, during follow-up visits of extubation and 48H after extubation. Follow-up visits are shortened in case of extubation failure.
45459097|NCT05190380|Other|LOW INTENSITY PROGRESSIVE RESISTED EXERCISE|"Intervention:Leg presses, knee extension, hip adduction and hip abduction exercises will be performed by patients. There will be a warm up sets for 1 repetition maximum with 2 min gap between both sets (leg press + knee extension exercises) (hip abduction and hip adduction) patients will ask to perform.~Both groups will receive routine physical therapy (Tens, Hot pack, Deep friction massage) in addition with experimental interventions"
45459098|NCT03495934|Drug|pracinostat|[14C]-pracinostat
45459099|NCT01981174|Procedure|30-gauge needle|
45459100|NCT01981174|Procedure|32-gauge needle|
45459101|NCT03488368|Other|observation|Observation of renal outcome parameters and adverse events in the follow-up beyond the 3-year trial phase of the original STOP-IgAN trial.
45459102|NCT03490006|Procedure|Erector Spinae Plane Block|A relatively recent alternative to the paravertebral block is the thoracic erector spinae plane block, which involves the ultrasound-guided injection of local anesthetic into the interfascial plane deep to the erector spinae muscle at the level of the transverse process. It results in a loss of somatic sensory sensation across multiple unilateral dermatomes due to local anesthetic mediated blockade of the dorsal and ventral rami of the spinal nerve roots. It is increasingly being used due to ease of placing the block and a perception of greater safety. It has been shown to provide pain relief from rib fractures, thoracotomy, and chronic neuropathic pain of the chest wall. However, to date, erector spinae plane block has not been compared with paravertebral block in regards to analgesia with mastectomy surgery, which has been extensively studied.
46004427|NCT04610424|Behavioral|As usual|Speech Language Therapy and Occuapational Therapy provided as usual by National Health Services
46004428|NCT04677101|Diagnostic Test|Liver Biopsy|Fine-needle liver biopsy
46004429|NCT04630470|Behavioral|massage therapy with lavender oil|massage therapy with lavender oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
46004430|NCT04630470|Behavioral|massage therapy with baby oil|massage therapy with baby oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
46004431|NCT04677062|Drug|GV-328|Patients with GV-328 treatment
46004432|NCT04610463|Diagnostic Test|Cardiac flow measurement|Catheterized hemodynamics evaluation - a measurement of systemic flow and pulmonary flow, R-L shunt, L-R shunt using the INNTHERM® system, prior to PFO closure using a common PFO-occluder (within one catheterization intervention).
46004433|NCT04676984|Other|Consultations|The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences.
46004434|NCT01972178|Drug|PRC-4016|
46004435|NCT01972178|Drug|Placebo|
45677732|NCT01986829|Device|Radiofrequency ablation|-Radiofrequency ablation will be predominantly used on metastatic spine lesions and will include use of the Dfine STAR ablation probe. This probe will be placed coaxially through an introducer needle into the spinal metastatic lesion.
45677733|NCT01986829|Other|BPI-Short form|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
45677734|NCT01986829|Other|FACT-G7|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
45677735|NCT01986751|Drug|Clonidine|
45677736|NCT01986751|Drug|ropivacaine|
45677737|NCT02004847|Device|PSO-CT02|The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.
45677738|NCT04670965|Biological|E-PRF/rhBMP-2 (similar ratios)|During its preparation, 1.5 mg/ml rhBMP-2 will be incorporated into standardized samples to assure similar E-PRF to rhBMP-2 ratios. To allow for consistency across all samples, standardized E-PRF volume will be established using formation templates. Following its preparation, the E-PRF/rhBMP2 scaffold will undergo a standard in vitro assay to investigate growth factor release over time (ELISA quantification assay). Briefly, the e-PRF/rhBMP2 scaffold will be placed in a shaking incubator at 37 degree Celsius and assessed for growth factor release of rhBMP-2 over time.
45677739|NCT04670965|Biological|E-PRF/ACS/rhBMP-2|rhBMP-2 diluted to account for the additional volume from the E-PRF in other samples will be loaded onto lyophilized absorbable collagen sponges as per the package insert. After the addition of the rhBMP-2, the ACS will be cut into 2mm x 2mm pieces and incorporated into the E-PRF membrane. Following its preparation, rhBMP-2 release from the E-PRF/ACS/rhBMP2 scaffold will be quantified using the ELISA quantification assay as described above.
45677740|NCT04670965|Biological|rhBMP-2/E-PRF|rhBMP-2 diluted to account for the additional volume from the E-PRF in other samples will be loaded onto lyophilized absorbable collagen sponges as per the package insert. Rh-BMP2 release will be quantified using the ELISA quantification assay as described above
45677741|NCT04670965|Biological|E-PRF only|E-PRF will be prepared and standardized, but no rhBMP-2 will be added to the material. After preparation, the E-PRF scaffold assayed via ELISA quantification assay as described above to determine the release (if any) of intrinsic BMP-2 from the platelet concentrate scaffold.
45677742|NCT01438060|Drug|Aripiprazole (BMS-337039)|"Acute Phase: Oral, Tablets (1 and 5 mg), Week 1-2: 2 mg, Week 3-4: 2 - 5 mg, Week 5-6: 2 - 10 mg, Weeks 7-10: 2 - 15 mg, Once daily, 10 weeks~Extension Phase: Oral, Tablets (1 and 5 mg), Week 11: 2 mg, Weeks 12-13: 2 - 5 mg, Weeks 14-15: 2 - 10 mg, Weeks 16-140: 2 - 15 mg, Once daily, 130 weeks"
45677743|NCT01438060|Drug|Placebo|Acute Phase: Oral, Tablets, 0 mg, Once daily, 10 Weeks
45459103|NCT03490006|Procedure|Paravertebral Block|Paravertebral block is a classic regional anesthesia technique that has been in use for over 100 years. It is performed by the injection of local anesthetic into the space between the costotransverse ligament and parietal pleura resulting in blockade of ipsilateral intercostal nerves. It results in a loss of somatic sensation over multiple unilateral dermatomes.
45459104|NCT01956110|Drug|Follitropin Delta (FE 999049)|
45459105|NCT01956110|Drug|Follitropin Alfa (GONAL-F)|
45677744|NCT04635670|Dietary Supplement|Pro-/prebiotic Mix|Soluble powder for oral use of pre-/probiotic mix 3.0 g twice daily.
45677745|NCT04635670|Dietary Supplement|Placebo|Soluble powder for oral use twice daily.
45677746|NCT01469182|Biological|SCH 39641|Rapidly dissolving tablet sublingually once daily
45677747|NCT01469182|Drug|Placebo for SCH 39641|Rapidly dissolving tablet sublingually once daily
45677748|NCT04066504|Drug|sonidegib|Sonidegib 200 mg orally taken once daily (dose modifications according to the approved local country prescribing information are permitted)
45677749|NCT01444378|Device|Stenting using Absolute Pro® and Pro LL® Peripheral Stent Systems|Stenting of the Superficial Femoral Artery (SFA) and/or proximal popliteal artery using either of these devices.
45677750|NCT02020889|Biological|Mepolizumab|Mepolizumab will be provided as a lyophilized cake in sterile vials for individual use to be reconstituted with sterile water for Injection, just prior to use.
45677751|NCT02020889|Drug|Placebo|Placebo will be available as 0.9% sodium chloride
46089454|NCT00643110|Drug|D50 glucose|D50 glucose would be administered, if necessary.
46089455|NCT02676492|Other|Actigraphy to measure sleep duration and efficiency|Actigraphy watch to be worn on participants' wrist for 14 days and nights
45459106|NCT03489928|Drug|Oral Misoprostol|Prostaglandin E1 - 100ug tablet, divided in half by pharmacy staff to be administered by mouth.
45836260|NCT00125034|Biological|Cetuximab|"Cetuximab will always be administered first, followed by oxaliplatin at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin folinic acid (FA) will be administered (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-Fluorouracil (5-FU) (as a bolus of 400 mg/m^2/day intravenously (IV) over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops"
45459107|NCT03489928|Drug|Vaginal Misoprostol|Prostaglandin E1 - 100ug oral tablet, divided in quarters by pharmacy staff, vaginal placement of one or two quarters as needed every 6 hours
45836261|NCT00125034|Drug|Oxaliplatin|"Oxaliplatin will always be administered first or simultaneously with FA (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m^2/day IV over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops"
46004436|NCT01972178|Drug|Statins|Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)
46004437|NCT01972139|Device|Renal Denervation using the Symplicity Renal Denervation System|Subjects randomized to the renal denervation group underwent angiography and renal denervation.
46089456|NCT02676492|Other|'Sleepsuite' novel cognitive learning tasks|Novel iPad-administered learning tasks, to be completed one evening and the next morning during actigraphy monitoring period.
46089457|NCT02676336|Dietary Supplement|Violet™ Molecular Iodine (I2)|
46089458|NCT02676336|Other|Placebo|
45677752|NCT01444300|Drug|Dalfampridine|10mg, bid, pill taken by mouth for 12 weeks
45677753|NCT01444300|Drug|Placebo|placebo pill, bid for 12 weeks
45677754|NCT04681001|Device|nasal spray|application of nasal spray into nostrils and mouth
45677755|NCT01443364|Biological|Certolizumab pegol|Prefilled syringes containing an injectable volume of 1ml of liquid Certolizumab Pegol (CZP) for single use at a dosage strength of 200 mg/ml. Injections will be given subcutaneously. CZP 400 mg at Week 0, 2 and 4, then continued as maintenance dose of 200 mg every 2 weeks until Week 50.
45677756|NCT04680533|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Quell TENS device. The device is worn on the upper calf right below the knee and secured by an elastic band. The device is controlled by an App and alternates between treatment periods and rest periods. Participants will be asked to wear the device 7-8 hours per day alternating legs.
45677757|NCT02020577|Drug|Cetuximab( erbitux®)|once per week
45677758|NCT02020577|Drug|Afatinib|once per day
45836262|NCT02100930|Biological|Anti-GD2 3F8 Monoclonal Antibody|
45836263|NCT02100930|Drug|GM-CSF (granulocyte-macrophage colony-stimulating factor)|
46089459|NCT00643188|Procedure|Radiofrequency ablation|Radiofrequency ablation of atrial fibrillation
46089460|NCT00643188|Other|Conventional treatment|The best medical treatment according to the ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult and the ACC/AHA/ESC 2006 Guidelines for Management of Patients with Atrial Fibrillation.
46089461|NCT05314764|Drug|Cefiderocol|Patients will receive intravenous cefiderocol every 6 to 8 hours for 4 to 6 doses.
45836264|NCT02100930|Drug|oral isotretinoin|
45836265|NCT02101008|Drug|disulfiram and chelated zinc|
46004438|NCT01972139|Other|Sham Renal Denervation|Prior to enrollment closure, subjects were treated with sham renal denervation. After enrollment closure, subjects previously enrolled were no longer eligible to cross-over.
46004439|NCT01972139|Device|Renal Angiography|Subjects who met all criteria after the screening period did undergo a renal artery angiogram to evaluate renal artery anatomy. Only subjects with eligible renal artery anatomy were randomized.
45459108|NCT03489928|Drug|Dinoprostone|Prostaglandin E2 - 1-2mg gel manufactured for vaginal use; placed vaginally every 6 hours as needed.
45459109|NCT03488212|Behavioral|Training to Identify Eligible Patients and Direct them to Online Obesity Treatment Program|Primary care clinic staff are trained to identify patients who meet study inclusion and exclusion criteria. They are then trained to provide patients with the information necessary to enroll in the study and access the online behavioral obesity treatment.
45677759|NCT02020031|Drug|Vancomycin|
45683787|NCT03028545|Behavioral|Collection of the individual narrative, semi-directed interviews|Visit one : individual interview Individual narrative Passing Psychometric Measurement Scales of Recovery: Score at Warwick and Wellness Scale Andreasen scale score Visit two Focus group
46004440|NCT04630665|Other|immediate implant placement|immediate implant placement in thin and thick buccal bony plates
45677760|NCT04179305|Behavioral|Oncolo-GIST|"Behavioral: Oncolo-GIST Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topics covered include:~Principles of introducing prognosis in the setting of worsened scan results Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months… with emphasizing that the oncology team will always provide care for you) Addressing informational needs and psychological reactions Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith."
46004441|NCT01969838|Drug|Momelotinib|Momelotinib tablet administered orally once daily
46004442|NCT01969838|Drug|Ruxolitinib|Ruxolitinib tablets administered orally twice daily
45677761|NCT04179305|Behavioral|Usual Care Arm|Oncologists will provide care in non-specific manner.
46004443|NCT01969838|Drug|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once daily
46004444|NCT01969838|Drug|Placebo to match ruxolitinib|Placebo to match ruxolitinib tablets administered orally twice daily
45677762|NCT02019719|Drug|GSK1278863|GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.
46004445|NCT04630314|Device|Percutaneus Coronary Intervention|Covered Stent
46004446|NCT01165177|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
46004447|NCT01165177|Biological|Placebo|Intramuscular injection
46004448|NCT04610385|Procedure|radical cystectomy with urinary diversion|surgical removal of the urinary bladder and other organs and perform a urinary shunt
46004449|NCT01967810|Drug|ANG1005|ANG1005 at a starting dose of 650 mg/m^2 or 600 mg/m^2 by intravenous infusion once every 3 weeks
46004450|NCT01967810|Drug|Bevacizumab|For participants enrolled in the bevacizumab-refractory recurrent GBM arm (Arm 2), treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion.
46004451|NCT04610268|Device|transcranial direct current stimulation|Depending on the location of sEEG electrode implanted in the patient's head, the tDCS electrode (5 cm×7 cm each) was placed on occipital-frontal lobe or bilateral temporal lobe. Current intensity: 2 mA and 4 mA, Stimulus time: 3 min (each stimulus session).
46004452|NCT01966601|Drug|TRV027 Dose #1|TRV027 continuous intravenous infusion Dose #1
46004453|NCT01966601|Drug|TRV027 Dose #2|TRV027 continuous intravenous infusion Dose #2
46004454|NCT01966601|Drug|TRV027 Dose #3|TRV027 continuous intravenous infusion Dose #3
46004455|NCT01966601|Drug|Placebo|Placebo continuous intravenous infusion
45677763|NCT02019719|Drug|Placebo|Film coated tablets of GSK1278863 matching placebo for oral administration.
45677764|NCT02030405|Drug|Ixazomib|Given orally (PO)
46004456|NCT04610073|Behavioral|Interactive multimedia training and illustrated booklet|The experimental groups conducted interactive multimedia training and illustrated booklet
46004457|NCT03454269|Diagnostic Test|Optical Coherence Tomography|The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).
46004458|NCT01165138|Drug|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 12 weeks
46004459|NCT01165138|Drug|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate Inhalation Powder inhaled orally once daily for 12 weeks
46004460|NCT01165138|Drug|Placebo Inhaltion Powder|Placebo Inhaltion Powder inhaled orally once daily for 12 weeks
46004461|NCT01963598|Drug|REGN1033 (SAR391786)|
46004462|NCT01963598|Drug|placebo|
46004463|NCT00561054|Drug|CETUXIMAB|400 mg/m2 starting dose, 250 mg/m2 weekly dose
46004464|NCT04206358|Biological|OrienX010 combination with JS001|"OrienX010 Produced by Oriengene Biotechnology Co., Ltd. Strength: 1.0 mL/vial. Label claim: Titer 8.0 × 10^7Pfu/mL, NMT 1 × 10 particles11VP/mL.~JS001 Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package."
46004465|NCT00561093|Drug|pentoxiphylline|pentoxiphylline 400 mg daily, anti-inflammatory and appetite-stimulating while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
46004466|NCT00561093|Dietary Supplement|Nepro|Nepro (8 ounces) one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
46089462|NCT04180254|Procedure|Effect of several processing on the auditory distance perception|The focus is a comparison of hearing instrument algorithms on the auditory distance perception
45677765|NCT01975376|Drug|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
45677766|NCT01975376|Drug|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
45677767|NCT01443130|Drug|Chloroquine|Chloroquine tablets contain 300 mg chloroquine base per tablet. Dosages: Chloroquine 1,500 mg base over 3 days twice during pregnancy or Chloroquine 600 mg loading dose followed by 300 mg orally once per week. Intermittant preventative treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34 gestation, 4 weeks apart. Participants randomized to IPTp with chloroquine will require their second and third doses of chloroquine after the initial dose given in the clinic and those assigned to chloroquine chemoprophylaxis will require weekly doses.
46004467|NCT00561093|Dietary Supplement|anti-inflammatory module (similar to Oxepa)|Oxepa-similar anti-inflammatory module (2 ounces) while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
46004468|NCT00561093|Drug|Placebo pill imitating pentoxiphylline|Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-inflammatory and appetite-stimulating pill while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
46004469|NCT00561093|Dietary Supplement|Placebo to imitate Nepro|Placebo to imitate Nepro (8 ounces), with less protein and calorie, one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
46004470|NCT00561093|Dietary Supplement|Placebo to imitate anti-inflammatory module (similar to Oxepa)|Placebo to imitate Oxepa-similar anti-inflammatory module (2 ounces), without anti-inflammatory or anti-oxidative ingredients, while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
45459110|NCT03488212|Behavioral|Training to Motivate and Support Patients' Weight Loss|Primary care clinic staff are trained in psychological and behavioral strategies for: talking to patients about weight and weight loss in a way that patients find acceptable and helpful, increasing motivation for weight loss, overcoming common barriers to weight loss, and persevering with a weight loss attempt. They are trained in strategies to provide this support by telephone in addition to during clinic visits.
45459111|NCT03488212|Behavioral|Online Behavioral Weight Loss Intervention|For 3 months, participants receive: a weekly online lessons for training in behavioral skills for losing weight; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record.
45459112|NCT03488212|Behavioral|Control Intervention for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive 9 months of: monthly online newsletters with educational information pertaining to healthy weight, diet, and physical activity habits.
45677768|NCT01443130|Drug|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine 3 tablets (1,500 mg sulfadoxine and 75 mg pyrimethamine) twice during pregnancy. Intermittant preventive treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34, 4 weeks apart.
46004471|NCT01960010|Drug|MIM-D3 Ophthalmic Solution|1% MIM-D3 dosed BID
46004472|NCT01960010|Drug|Vehicle|Vehicle dosed BID
45677769|NCT04066192|Drug|Brexpiprazole|Brexpiprazole will be used in .5mg, 1mg, 2mg, and 4mg doses as described in the study arms.
45677770|NCT04066192|Drug|Placebo|A medically inert placebo medication will be used as described in the study arms.
45677771|NCT04065256|Other|Personalized music|Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player.
46004473|NCT01165021|Drug|Pemetrexed|500 milligram per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
46004474|NCT01165021|Drug|Cisplatin|75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
46004475|NCT01165021|Drug|Folic Acid|Administered orally.
46004476|NCT01165021|Drug|Vitamin B12|Administered Intramuscular injection.
46004477|NCT01165021|Drug|Dexamethasone|Administered orally.
46004478|NCT04314622|Drug|Supaglutide|Administered SC
46004479|NCT04314622|Drug|Placebo|Administered SC
46004480|NCT00561132|Dietary Supplement|Vanadyl sulfate|50 mg twice daily orally for a period of 4 weeks
46004481|NCT00561132|Other|Magnesium oxide|Validation of similar appearance and weight to the intervention component orally 1 unit (<50 mg) twice daily for a period of 4 weeks
46089463|NCT02672358|Drug|Dabrafenib|Oral Dabrafenib 150 mg BID
45473928|NCT03735277|Biological|HPC, Cord Blood|HPC, Cord Blood is supplied as a cryopreserved cell suspension in a sealed bag containing a minimum of 5 × 10^8 total nucleated cells with a minimum of 1.25 × 10^6 viable CD34+ cells in a volume of 25 milliliters. The exact precryopreservation nucleated cell content is provided on the container label and accompanying records.
46004482|NCT02886754|Behavioral|Proficiency-based progression|Use of validated metrics and performance benchmarks to simulation training
46089464|NCT02672358|Drug|Trametinib|Oral Trametinib 2 mg QD
46089465|NCT05552352|Other|Virtual Reality assisted information|Patients in the intervention group receive a VR instructional application in the patient's room the day before TAVI implantation and in the operational suite during TAVI implantation the next day. In this application, the patient is guided through different VR parts that repeat the indication, the procedure, the localities and the post-interventional phase of the implantation with the corresponding safety instructions.
45677772|NCT04065256|Other|Personalized music plus earplug|Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player. In addition, participants will be worn earplug during night time sleep for decreasing the noise until next morning.
45677773|NCT01436500|Drug|Ifetroban Injection|Ifetroban sodium injectable, diluted in sterile water with 5% dextrose
46089466|NCT02675868|Drug|Norepinephrine|Noradrenaline is an endogenous catecholamine with sympathomimetic effects. It has mainly α-adrenergic receptor selectivity but also β-effects in higher concentrations. It will be administered at 0.05 μg/kg/min, a clinical relevant dose on the low end of the scale.
46089467|NCT02675868|Drug|Phenylephrine|Phenylephrine is a selective α-adrenergic receptor agonist. It will be administered at 0.5 μg/kg/min, based on its relative vasopressor potency in comparison with noradrenaline.
45677774|NCT01436500|Drug|Placebo|Sterile water with 5% Dextrose
45677775|NCT01958827|Biological|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
45677776|NCT01620086|Device|Active Repetitive Transcranial Magnetic Stimulation 1 Hz|active rTMS delivered at 1Hz frequency over temporal cortex
46004483|NCT02886754|Behavioral|National e-learning programme only|National e-learning programme (COMPASS)
46089468|NCT02675868|Drug|Vasopressins|Vasopressin is 8-arginine-vasopressin, a synthetic analogue of endogenous nonapeptide hormone. It exerts its action via V1 receptors (ubiquitous vasoconstriction) and V2 receptors (renal water resorption). It will be administered at 0.04 IU/min, a clinically relevant dose.
46089469|NCT02675868|Drug|Placebo|NaCl 0.9% infusion
45677777|NCT01620086|Device|Active Repetitive Transcranial Magnetic Stimulation 10 Hz|active rTMS delivered at 10 Hz frequency over temporal cortex
45677778|NCT01620086|Device|Active control site Repetitive Transcranial Magnetic Stimulation at 1Hz|active rTMS delivered at either 1 Hz frequency over the vertex
45677779|NCT01620086|Device|Sham control site Repetitive Transcranial Magnetic Stimulation|sham rTMS delivered at 1Hz frequency over the vertex
45677780|NCT01620086|Device|Active control site Repetitive Transcranial Magnetic Stimulation at 10 Hz|Active 10 Hz rTMS delivered over the vertex
45677781|NCT04670653|Drug|MAGNÓLIA NASAL GEL|Magnólia nasal gel spray
45677782|NCT04670653|Drug|MOMETASONE FUROATE|Mometasone furoate nasal spray
46004484|NCT02886754|Behavioral|Standard simulation|Paper based simulation cases
46004485|NCT01956812|Drug|IMMU-107|Arm A: gemcitabine 200 mg/m2 administered weekly x 4 and IMMU-107 administered weekly x 3 for multiple cycles
46004486|NCT01956812|Drug|placebo|placebo weekly x 3 and gemcitabine 200 mg/m2 weekly x 4 for multiple cycles
46004487|NCT01956812|Drug|Gemcitabine|Gemcitabine, 200 mg/m2, given weekly x 4 in both arms
46004488|NCT01182844|Dietary Supplement|Lactobacillus casei Shirota|3 bottles of Yakult(R) light per day
46004489|NCT01164865|Device|OPTI-FREE RepleniSH multipurpose disinfecting solution|FDA-approved, multipurpose disinfecting solution used according to provided instructions for cleaning, rinsing, storing, and disinfecting study contact lenses on a daily basis, 2 weeks.
46089470|NCT05279742|Drug|MANP|Single subcutaneous injection 5 µg/Kg
46089471|NCT05279742|Drug|Sacubitril/Valsartan|Oral single dose 97/103 mg
46089472|NCT05279742|Drug|Oral Placebo|Oral single dose that contains no active ingredient
46089473|NCT05279742|Drug|Injection Placebo|Single subcutaneous injection that contains no active ingredient
46089474|NCT04177446|Dietary Supplement|a production consist of various oligopeptides and the whey protein|patients will be given extra protein intake except the basic energy intake
46089475|NCT04177446|Dietary Supplement|basic energy intake|supplement as basic energy intake
46089476|NCT04177446|Dietary Supplement|maltodextrin|used as placebo in the control group
46089477|NCT04177056|Radiation|SBRT|Patients will received a single fraction of 15-20 Gy to bone metastases causing pain. Planning and delivery will be conducted using a volumetric modulated arc therapy (VMAT) approach on the Varian TrueBeam platform. Patients will be CT simulated, with vac-lock immobilization. Use of 4-dimensional CT will be dependent on the area being treated. Daily image guidance will be performed using cone beam CT aligning to relevant bony anatomy.
46089478|NCT02673840|Drug|Ketotifen|2 mg of Ketotifen, twice a day for a total of ten (10) doses
46089479|NCT02673840|Drug|Placebo|Identical tablets containing 0 mg of Ketotifen, twice a day for a total of ten (10) doses
45677783|NCT01436110|Drug|Fluticasone furoate 50mcg|Once daily inhalation powder via Novel Dry Powder Inhaler
45677784|NCT01436110|Drug|Fluticasone propionate 100mcg|Twice daily inhalation powder via DISKUS/ACCUHALER
46004490|NCT01164865|Device|Clear Care contact lens care system|FDA-approved, hydrogen peroxide-based, lens care system used according to provided instructions for cleaning, disinfecting, daily protein removing, and storage of study contact lenses on a daily basis, 2 weeks.
46004491|NCT01164865|Device|Contact lenses|Contact lenses per subject's habitual brand and prescription worn every day for the duration of the study, 14 days, on a daily wear basis without scheduled replacement.
46004492|NCT04630587|Procedure|Indirect restorations|see the Arm description
46004493|NCT01952990|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray device is 0.2mL (200 μL) in volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl. Subjects receiving the 100 μL dose will receive half of the contents of one device using a dose divider. Subjects receiving the 200 μL dose will first receive half of the contents of one device using a dose divider and then 4 minutes later will receive the 2nd half by removing the dose divider. Subjects receiving the 400 μL dose will first receive the entire contents of one device and then 4 minutes later will receive the contents of a 2nd device.
46004494|NCT04314310|Drug|Tenoxicam|nonsteroidal anti-inflammatory drug (NSAID)
46004495|NCT04314310|Drug|Placebo|equal volume of normal saline
46004496|NCT02886793|Drug|fludeoxyglucose|
46004497|NCT04610307|Procedure|buffered anesthesia|patients will undergo surgery under buffered local anesthesia
46089480|NCT00644124|Drug|aflibercept|in combination with standard treatment R-CHOP
46089481|NCT00910182|Procedure|splenorrhaphy|surgical treatment of splenic injuries after blunt abdominal trauma.
46089482|NCT00644202|Behavioral|Counseling Sessions|Counseling Sessions at each study visit around diet and physical activity from a registered dietician
45677785|NCT01436110|Drug|Placebo|Inhalation powder via Novel Dry Powder Inhaler and DISKUS?ACCUHALER
45677786|NCT01619852|Drug|.9 normal saline placebo|Administration of .9 normal saline placebo as a bolus and as maintenance throughout the length of the surgical procedure.
46004498|NCT01952132|Drug|OMS643762|
46004499|NCT01952132|Drug|Placebo|
46004500|NCT00561171|Drug|SPP635|oral once daily
46004501|NCT01951742|Biological|ANT-1401|Active
46089483|NCT00644202|Behavioral|Specialized Website|Specialized website that allows participants to track their eating and physical activity patterns, learn new weight management skills, interact with the dietician, and receive support from other participants
46089484|NCT00644202|Behavioral|Telephone Counseling Calls|5 telephone calls with a health counselor, lasting 15-20 minutes each.
46089485|NCT04178694|Device|non-invasive ventilation|non-invasive ventilation will be performed on every subjects
46089486|NCT02673528|Procedure|Laparoscopic appendectomy|Two types of laparoscopic surgery were performed. Total laparoscopic appendectomy or laparoscopic assisted appendectomy
46089487|NCT02670954|Drug|Dexmedetomidine, tramadol and flurbiprofen|
45677787|NCT01619852|Drug|Group L (lidocaine)|Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
46004502|NCT01951742|Biological|Vehicle|Vehicle
46004503|NCT04610229|Radiation|Hypofractionation guioded by dose painting|1
46004504|NCT01951235|Drug|Imeglimin|
46089488|NCT02670954|Drug|tramadol and flurbiprofen|
46089489|NCT04176042|Behavioral|Track 1|Intervention + Follow-up
46004505|NCT01951235|Drug|Placebo|
46004506|NCT04610502|Biological|Administration of Equine immunoglobulin anti SARS-CoV-2|The participants will receive premedication with Acetaminophen 500mg PO, Cimetidine300mg IV and Chlortrimeton 10mg IV. Then the investigators will do the Administration of Equine Imunoglobulin anti SARS Cov 2 on day 1 a vial of 10ml of the drug during 1 hour Intravenously. Then the hospitalized participants will be followed until they are discharged.
46004507|NCT01949324|Biological|Ciliary neurotrophic factor (CNTF)|Ciliary neurotrophic factor released from NT-501 encapsulated cell implant
46004508|NCT01949324|Procedure|Sham procedure|Sham surgery for Sham arm
46004509|NCT01949324|Device|NT-501 Implant|NT-501 encapsulated cell implant
45459113|NCT03488212|Behavioral|Monthly Lessons and Feedback Intervention for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive 9 months of: monthly online lessons for training in behavioral skills for maintaining weight loss and preventing weight gain; online self-monitoring of daily weight, diet, and physical activity; monthly feedback on the self-monitoring record.
45459114|NCT03488212|Behavioral|Refresher Courses for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive two month-long refresher courses with weekly online lessons for training in behavioral skills for maintaining weight loss and preventing weight gain; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record; weekly challenges focuses on specific behavior change and weight loss goals.
45459115|NCT02323282|Drug|ropivacaine|
45459116|NCT01802086|Drug|Emla-cream|Topical anaesthetic
45459117|NCT01802086|Drug|Miniderm cream|Topical
45459118|NCT02323360|Radiation|SBRT|Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to stereotactic radiotherapy in 3 or 6 daily fractions
46004510|NCT01949324|Procedure|NT-501 Implant procedure|Surgery to implant device for NT-501 encapsulated cell implant releasing human ciliary neurotrophic factor arm
45459119|NCT02323360|Procedure|TACE|Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to a new cycle of TAE or TACE
45459120|NCT05086120|Other|eCARIBOU|A 16 week remote electronically deliver Integrated Care Pathway (ICP) for adolescents (13-18 years old) with Major Depressive Disorder (MDD).
45459121|NCT05347316|Drug|Colchicine|0.5 mg per day colchicine for 12 months
45459122|NCT03495778|Other|Test Granola|50.5 Test Granola
45459123|NCT03495778|Other|Control Granola|54.3 Control Granola
46004511|NCT01164475|Drug|Granulocyte-colony stimulating factor (G-CSF)|
45459124|NCT01735942|Drug|Ingenol mebutate|
46089490|NCT04176042|Behavioral|Track 2|Wait list + Intervention
45459125|NCT01735942|Procedure|cryotherapy|
45459126|NCT03489772|Drug|ITI-214|Oral
45459127|NCT03489772|Drug|Placebo|Oral
45677788|NCT04069936|Biological|MILs™ - NSCLC|To evaluate the safety of MILs™ - NSCLC alone in subjects with locally advanced and unresectable or metastatic NSCLC
46004512|NCT01164475|Drug|Fixed Dose Plerixafor|
46004513|NCT01164475|Drug|Weight-Based Plerixafor|
46004514|NCT04609995|Behavioral|Incentives|No financial incentive
46004515|NCT01942265|Drug|AS03|Subjects will receive two doses of the A/H7N9 vaccine with or without AS03 delivered intramuscularly 21 days apart.
46089491|NCT00644436|Device|Tetrix|single topical application
46089492|NCT00644436|Device|Tetrix|Single topical application
45459128|NCT01366664|Drug|Treatment sequence 2|Treatment Period 1 (stable dose of terazosin [2, 5, or 10 mg] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin [2, 5, or 10 mg] + dapoxetine 60 mg administered orally once daily for 5 days)
45459129|NCT01366664|Drug|Treatment sequence 1|Treatment Period 1 (stable dose of terazosin [2, 5, or 10 mg] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin [2, 5, or 10 mg] + placebo administered orally once daily for 5 days)
45459130|NCT05193422|Diagnostic Test|Spirometry - baseline|"Standard spirometry using a Micro5000 spirometer to determine baseline FEV1, FVC, FEV1/FVC, FEF25-75 and PEF.~Baseline spirometry will be performed before CPET in both study arms"
45459131|NCT05193422|Diagnostic Test|Spirometry - post CPET|Standard spirometry using a Micro5000 spirometer to determine baseline % change in FEV1 after CPET and assess exercise-induced bronchoconstriction (defined as FEV1 decrease >10% at 5 minutes after CPET) Post spirometry will be performed after CPET in both study arms
46089493|NCT02670798|Procedure|Thromboelastography laboratory testing|Laboratory test that monitors clotting properties of blood
45459132|NCT05193422|Diagnostic Test|Nasal peak inspiratory flow - baseline|"Measurement of peak nasal inspiratory flow (nPIF) using a Micro5000 spirometer and a specially modified nasal mask.~nPIF will be measured before CPET in both study arms"
45459133|NCT05193422|Diagnostic Test|Nasal peak inspiratory flow - post CPET|"Measurement of peak nasal inspiratory flow (nPIF) using a Micro5000 spirometer and a specially modified nasal mask.~nPIF will be measured after CPET in both study arms"
45459134|NCT05193422|Diagnostic Test|Oxygen saturation|Continuous monitoring of SpO2 using a Nonin 7500 pulse oximeter, in both study arms
45459135|NCT05193422|Diagnostic Test|Heart Rate|Continuous monitoring of HR using a Nonin 7500 pulse oximeter, in both study arms
45459136|NCT05193422|Diagnostic Test|End-tidal CO2|Continuous monitoring of EtCO2 using a Microstream capnograph, in both study arms
45459137|NCT05193422|Diagnostic Test|Respiratory rate|Continuous monitoring of RR using a Microstream capnograph, in both study arms
45677789|NCT04069936|Biological|nivolumab|To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab in subjects with locally advanced and unresectable or metastatic NSCLC
45683788|NCT00002644|Drug|Tamoxifen Citrate 20Mg Tab|Tamoxifen Citrate 20Mg Tab
45677790|NCT04069936|Drug|tadalafil|To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab with or without tadalafil in subjects with locally advanced and unresectable or metastatic NSCLC
45677791|NCT02000882|Drug|BKM120|
45677792|NCT02000882|Drug|capecitabine|
45677793|NCT02000882|Drug|Trastuzumab|
46004516|NCT01942265|Drug|MF59|Subjects will receive two doses of the A/H7N9 vaccine with or without MF59 delivered intramuscularly 21 days apart.
46004517|NCT01942265|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Subjects will receive two doses of the A/H7N9 vaccine with or without an adjuvant delivered intramuscularly approximately 21 days apart.
46004518|NCT01164007|Drug|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Days 1 and 14 of each 28-day cycle.
46004519|NCT01164007|Drug|Dacarbazine|Dacarbazine will be given as 800 milligrams per square meter (mg/m^2) via IV infusion on Day 1 of each 28-day cycle.
46004520|NCT01941836|Drug|ETC-1002|Patients receive ETC-1002
46004521|NCT01941836|Drug|Ezetimibe|Patients receive ezetimibe
46004522|NCT04610151|Other|guided imagery|Guided Imagery CD: A guided imagery CD was prepared by a web designer with the recommendations of the researcher to include relaxing, soft and slow-paced, mixed nature sounds and photographs towards reducing pain in lower extremity surgical operation patients. The directives used for guidance, the audio recordings created as a result of literature review and the video lasted for 13 minutes (
46004523|NCT04630041|Behavioral|211 Referral|Patients with one or more reported social need will be referred to 211 for community based services. 211 will reach out and contact patients for follow-up.
46004524|NCT04629885|Drug|Oxytocin 400 IU vaginal gel|
46004525|NCT04629885|Drug|Placebo|Matching placebo gel with identical appearance to the test product, used as reference treatment.
46004526|NCT01939184|Drug|WC3055|12.5, 25, 50 or 75 mg dose
46004527|NCT01939184|Other|Placebo|Placebo
46004528|NCT04630119|Other|Questionnaires on quality of life, emotional health and presenteeism|After obtaining informed consent, a pro forma consisting of the socio-demographic details and pre-treatment assessment questionnaire (including Visual analog scale The Medical Outcomes Study Short-Form Health Survey The hospital anxiety and depression scale Work functioning impairment scale) was filled for each subject.
46004529|NCT04629768|Device|PuraStat|Purastat is applied to the EMR defect
45677794|NCT01965938|Device|RIFL (Rigid and Flexing Laryngoscope)|Patients in the RIFL group will undergo bronchoscopy using the Rigid and Flexing Laryngoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
45677795|NCT01965938|Device|Fiberoptic Bronchoscope|Patients in the control group will undergo bronchoscopy using the flexible fiberoptic bronchoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
45677796|NCT01965860|Other|additional curriculum (E-learning + simulation)|
46004530|NCT01163851|Biological|4 mg/kg|RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
46004531|NCT01163851|Biological|0.5 mg/kg|RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
46004532|NCT04609917|Procedure|trainee invlovement|Patients underwent selective biliary cannulation with trainee involvement
46004533|NCT02885662|Drug|CS-3150|CS-3150 2.5 to 5.0 mg , orally.
46004534|NCT00561210|Dietary Supplement|Crucial|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
46004535|NCT00561210|Dietary Supplement|Sondalis HP|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
46004536|NCT01938599|Drug|AM001 Cream, 7.5%|Cream, 2x daily for 12 weeks
46004537|NCT01938599|Drug|Placebo of AM001 Cream|Cream, 2x daily for 12 weeks
46004538|NCT04610034|Behavioral|"Resilient Caregivers"|"Resilient Caregivers is a 7-session group program developed for partner caregivers of patients with cancer (6 weekly sessions and 1 booster session). Each session takes place in groups of approximately 8 participants and lasts for two-and-a-half hours. Sessions 1 to 3 focuses on the caregiver and introduces the resilience components of coping strategies, meta-reflective skill and clarification of values. Sessions 4 and 5 focuses on these components in the relationship between the caregiver and the cancer patient and social support networks respectively, while Session 6 focuses on resilience in relation to self-care and care for the partner. A booster session will be scheduled one month after the end of Session 6 in order to follow-up on the intervention and allow participants to reflect on the benefits and challenges of the program."
46004539|NCT04610034|Other|Care as usual|The control arm will receive usual care, which implies no systematic support.
46004540|NCT01917383|Drug|Trabodenoson|Ophthalmic eye drop
45459138|NCT05193422|Diagnostic Test|Temperature|Continuous monitoring of Temp in the face mask using a RHT03 sensor, only in the experimental study arm
45677797|NCT01965860|Other|additional E-learning|
45677798|NCT04415827|Diagnostic Test|bicycle ergometry test with spiroergometry|"The 1st testing will be carried out on the 28-31th day of the disease, which corresponds to the period of the expected normalization of temperature, improvement of well-being, positive dynamics of radiological (with community-acquired pneumonia) and laboratory data, the 2nd test - after 3 months, the 3rd - after 6 months and IV - after 12 months.~Load testing will be carried out on a bicycle ergometer with an initial power of 25 watts with a further increase of 25 watts every 3 minutes. The cessation of the load will be carried out upon the appearance of signs set forth in the recommendations of the World Health Organization Expert Committee (1970)"
45677799|NCT04416061|Diagnostic Test|COVID 19 Diagnostic Test|COVID 19 Diagnostic Test
45677800|NCT04666129|Drug|Relugolix|"(Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day.~(Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day."
46004541|NCT01917383|Drug|Latanoprost|Ophthalmic eye drop
46004542|NCT01917383|Drug|Timolol|Ophthalmic eye drop
46004543|NCT00564135|Procedure|on Foley time|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
45677801|NCT04666129|Drug|Abiraterone|Abiraterone acetate (1000 mg [2 x 500-mg tablets]) or fine-particle abiraterone acetate (500 mg [4 x 125-mg tablets]) will be administered orally once daily.
45677802|NCT04666129|Drug|Prednisone|"(Part 1 only) For participants with mCSPC, a 5-mg dose of prednisone will be administered orally once daily, and for participants with mCRPC, a 5-mg dose of prednisone will be administered orally twice daily.~(Part 3 only) Prednisone 5 mg can be administered orally twice daily but is not required."
45677803|NCT04666129|Drug|Methylprednisolone|For participants with mCRPC taking fine-particle abiraterone acetate, methylprednisolone 4 mg will be administered orally twice daily.
46004544|NCT01163617|Device|Adalimumab delivered in current syringe|Pre-filled currently approved glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
45677804|NCT04666129|Drug|Apalutamide|Apalutamide 240 mg (4 x 60-mg tablets) will be administered orally once daily.
45677805|NCT04666129|Drug|Docetaxel|Docetaxel 75 mg/m2 dose will be administered every 3 weeks as a 1-hour intravenous infusion.
45677806|NCT04666051|Biological|Application of fibrin glue sealant|
46004545|NCT01163617|Device|Adalimumab delivered in Physiolis syringe|Pre-filled Physiolis glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
45677807|NCT01965704|Drug|Ondansetron|Pregnant women may receive a second dose of IV ondansetron if they have not delivered within 4 hours of receiving the IV study medication. 50% of the 90 mother/baby pairs will receive ondansetron; the baby will always get the same study medication as the mother.
45683789|NCT00002644|Other|Placebo|Placebo 20Mg Tab
45683790|NCT01575561|Drug|Lurasidone|Lurasidone 20-80 mg taken orally once daily
46004546|NCT01163617|Device|Adalimumab delivered in current autoinjector|Pre-filled currently approved autoinjector containing 40 mg/0.8mL adalimumab to be injected subcutaneously
46004547|NCT01163617|Device|Adalimumab delivered in Physiolis autoinjector|Pre-filled Physiolis autoinjector containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
45677808|NCT01965704|Drug|Placebo|All doses of placebo, whether IV or oral, will mimic the same volume as the ondansetron group to maintain the blind. Pregnant women may receive a second dose of IV placebo if they have not delivered within 4 hours of being given the IV study medication. 50% of the 90 mother/baby pairs will receive placebo; the baby will always receive the same study medication as the mother.
46004548|NCT01911767|Drug|Dimethyl fumarate|Administered as specified in treatment arm.
46004549|NCT01911767|Drug|Peginterferon beta-1a|Administered as specified in treatment arm.
45677809|NCT02003365|Drug|FX006 10 mg|Extended-release formulation
45677810|NCT02003365|Drug|FX006 40 mg|Extended-release formulation
46004550|NCT04629846|Drug|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.
46004551|NCT04629846|Drug|QL1209|QL1209 IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
46089494|NCT02670876|Behavioral|Anti-bullying intervention|"The title of each session were as follows :~Introduction of intervention and setting rules, building rapport~Understanding school bullying (The definition of school bullying and proper coping strategies)~Empathy of others ( Practice of understanding victims of school bullying)~Impulse control 1 (Understanding my anger patterns, finding one's true feelings behind that anger)~Impulse control 2 (Finding irrational thoughts that lead to anger and correction of them)~Conflict management (Understanding one's pattern of dealing with conflicts, finding effective strategies)~Communication skills enhancement~Increasing self esteem"
46089495|NCT00644904|Dietary Supplement|Vitamin D3|
46089496|NCT00644904|Dietary Supplement|Vitamin D3|
46089497|NCT04081584|Device|ISS Device|The ISS Device (commercial and prototype) is used to measure tissue light scattering.
46089498|NCT04080960|Behavioral|Lifestyle modification education|Lifestyle modification education and goal setting
46089499|NCT02670720|Drug|avoralstat|
46004552|NCT04629846|Drug|Pertuzumab|Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
45677811|NCT02003365|Drug|TCA IR 40 mg|Immediate-release formulation
46089500|NCT05201586|Other|Conditional Cash Transfer|CCTs will be given to participants in the form of a pre-loaded debit card.
46089501|NCT05201586|Other|Semi-structured interviews|Research team will conduct semi-structured interviews exploring how social determinants of health and social needs impact health. Participants will be asked to set a health goal. 6 months after the initial interview, the team will interview the patients again and evaluate whether that health goal was achieved.
46089502|NCT02670564|Genetic|Pharmacogenomics|"Blood samples (2x5ml EDTA tubes) should be collected just before the start of the conditioning regimen from every patient regardless of therapeutic arm by every centre and stored ≤-20°C Patient should be in remission (MRD negative) for this sampling, otherwise the sample should be taken using a mouth swab/saliva (not intravenously).~For second transplant patients, please provide DNA taken before first transplant or a fresh saliva samples."
46089503|NCT02670564|Other|Busulfan plasma level measurements|"Bu PK analysis after the first dose of IV Bu (+potential subsequent ones).~Blood sampling:~->For Bu 4 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 15 min (Time 2), 30 min (Time 3), 1 hour (Time 4) and 4 hour (Time 5) after the end of infusion~->For Bu 1 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 1 hour (Time 2), 3 hour (Time 3), 5 hour (Time 4), 7 hour (Time 5) and 11 hour (Time 6) after the end of infusion.~For centers not performing BU TDM, perform Dried Blood Sampling (DBS) analysis:~-> 0.5ml blood sample should be collected and 5µl spotted onto DBS cards in duplicate. Dry them max 5 hours and then keep in a sealed envelope and store at -80°C, as below"
45677812|NCT01975220|Drug|Empagliflozin/Metformin XR, FDC|Experimental: high dose empagliflozin/metformin XR, FDC tablet
45677813|NCT01975220|Drug|Empagliflozin/Metformin XR FDC|Experimental: low dose empagliflozin/metformin XR, FDC tablet
45677814|NCT01975220|Drug|25 mg Empagliflozin/1000 mg Metformin XR, FDC|Experimental, high dose Empagliflozin/Metformin XR,FDC Tablet
45677815|NCT01975220|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
46004553|NCT04629846|Drug|Docetaxel|Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4
46004554|NCT04629846|Procedure|surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
46089504|NCT02672202|Drug|Duloxetine|"60 mg/d - twice before surgery and once a day for post operative days 3-7~30 mg/d - once a day for post operative days 1-2"
46089505|NCT02672202|Drug|Pregabalin|"75 mg/d - twice a day for post operative days 1-2~150 mg/d - twice a day for post operative days 3-7 300 mg/d - twice before surgery"
46089506|NCT02672202|Drug|Placebo|"non-active - twice before surgery~non-active - twice a day for post operative days 1-7"
46089507|NCT02672280|Device|Medical Collagen Membrane with MSC|
46089508|NCT02672280|Device|Medical Collagen Membrane|
45677816|NCT01975220|Drug|1 tablet Empagliflozin/3 tablets Metformin XR|Active Comparator: 1x empagliflozin/3x metformin XR tablets
45677817|NCT01975220|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
46004555|NCT01910012|Drug|ADI-PEG 20|
46089509|NCT04176900|Other|Ingeo Biopolymer (PLA)|Biopolymer used for 3D-printing of rigid bolus
46004556|NCT01182337|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
46089510|NCT04176900|Other|Ecoflex 030|Polymer used for the 3D-printed flexible bolus
46089511|NCT04176822|Other|Educational animated movie group|Watching educational animation movie which were designed by the researcher before operation for fear and pain.
46089512|NCT04176822|Other|Documentary movie group|Watching documentary movie about trees before operation for fear and pain.
46089513|NCT05268978|Device|Medimonitor|A digital solution consisting of smartphone/tablet based application gathering data from medical and other devices provided to the patients. These devices are as follows: tablet, smartwatch, mobile ECG, blood pressure monitor, weight scales, pulse oximetry device.
46004557|NCT01182337|Drug|Vehicle control|Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
46089514|NCT05259150|Behavioral|Health for Hearts United Planning for Health|Participants (health leaders) receive trainings (three entitled Take Charge of Your Health, Eat Better, & Move Around More) and plan for their health ministry and cardiovascular health program to congregants.
46089515|NCT05259150|Behavioral|Health for Hearts United Preparing for Health|Research participants (church congregants) receive cardiovascular health programming prepared by health leaders that includes the following best practices: Individual Goal Setting, Training, Culturally-tailored Materials, Monitoring Tool & Recognition.
46089516|NCT05259150|Behavioral|Health for Hearts United Delivery of Health|The Organization (church) uses best practices to implement Heart Health activities (annual plans, achievements, plans for the year and practices).
46004558|NCT04609527|Procedure|Management of placenta accreta spectrum|Conservative and radical (hysterectomy) treatment of placenta accreta. Follow up to the patients to detect the impact of treatment imposed A novel technique which early identification and repait of uterine wall defects resulted from invasion of the uterine wall by the placenta.
46089517|NCT05259150|Other|Health for Hearts United Comparison Group Health Ministry Development|Participants (health leaders) have meetings to develop the health ministry. Research participants (church congregants) do not receive cardiovascular health program.
46089518|NCT04175652|Behavioral|Laughter yoga|The laughter yoga practice was initiated through clapping and warm-up exercises: hands were clapped keeping hands in parallel with each other and ensuring that the fingertips touched each other. To increase the energy level of the group, a rhythmic beat was added to the clapping in the form of 1-2, 1-2-3. While this was being sung a rhythm was tapped out on the floor by moving the feet up and down. Eye contact was constantly maintained with the participants. In the second phase, deep breathing exercises were performed. Participants were encouraged to inhale from the diaphragm. Individuals were asked to put their hands on their belly and inhale through the nose and then slowly exhale through the mouth. After the deep breathing exercise, the participants were encouraged to laugh through playing children's games in the third phase.
46004559|NCT01909427|Drug|Placebo|Placebo subcutaneous injections (SC) every 4 weeks through Week 12
46004560|NCT01909427|Drug|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks from Week 16 through Week 28
46004561|NCT01909427|Drug|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks through Week 28
46004562|NCT01909427|Drug|CNTO 6785 100 mg|CNTO 6785 100 mg SC every 4 weeks through Week 28
46004563|NCT01909427|Drug|CNTO 6785 50 mg|CNTO 6785 50 mg SC every 4 weeks through Week 28
46004564|NCT01909427|Drug|CNTO 6785 15 mg|CNTO 6785 15 mg SC every 4 weeks through Week 28
46004565|NCT01909427|Drug|Methotrexate (MTX)|MTX at the same stable dose through Week 32, that participants were receiving prior to screening.
46004566|NCT04629573|Procedure|Lumber Epidural|Epidural procedure was performed by attending anesthesiologists who had completed at least 50 epidural procedures during their training. Patient was placed in the sitting position, the skin over the lumbar area was cleaned and a sterile technique was observed throughout the procedure. Skin and subcutaneous tissue were infiltrated with 1% lidocaine 2 mL at the intended site of epidural placement (L2-3 or L3-4 interspace). The lumbar epidural space was then located, using a midline approach with an 18 gauge Tuohy epidural needle via a loss of resistance technique with 2 mL of saline, 20 gauge epidural catheter was placed in each patient. We deliver an initial bolus of 20 ml bupivacaine 0.5% plus 100 mcg Fentanyl, followed by continuous infusion of bupivacaine 0.5% plus 1mcg/ml Fentanyl (3-5 ml/hr.).
46004567|NCT04629573|Procedure|General anesthesia|Anesthesia was initiated with IV fentanyl 1 µg/kg, propofol 2 mg/kg and cisatracurium 0.15 mg/kg to facilitate endotracheal intubation. After tracheal intubation, anesthesia was maintained with sevoflurane in O2 and air (FiO2 of 0.5), cisatracurium 1µg/kg/min and fentanyl 0.5 µg/ kg /h were infused. Volume-Controlled ventilation was performed in all patients. Cisatracurium and fentanyl infusion was stopped at the end of surgery, neuromuscular blockade was reversed, and the patient was extubated and send to post-anesthesia care unit.
46089519|NCT04033458|Drug|JNJ-64140284|Participants will receive JNJ-64140284 orally.
46089520|NCT04090866|Other|PET/MRI|Positron Emission Tomograph/Magnetic Resonance Imaging - participants will undergo PET/MRI prior to initiation of pulmonary vasodilator therapy and again 4-6 months after initiation of therapy
46089521|NCT04178070|Biological|GB224 2mg|2mg (100μL), single dose, abdominal subcutaneous injection
46089522|NCT04178070|Biological|GB224 5mg|5mg (250μL), single dose, abdominal subcutaneous injection
46089523|NCT04178070|Biological|GB224 10mg|10mg (500μL), single dose, abdominal subcutaneous injection
46089524|NCT04178070|Biological|GB224 15mg|15mg (750μL), single dose, abdominal subcutaneous injection
46089525|NCT04178070|Biological|GB224 20mg|20mg (1mL), single dose, abdominal subcutaneous injection
46089526|NCT04178070|Biological|GB224 30mg|30mg (1.5mL), single dose, abdominal subcutaneous injection
46089527|NCT04178070|Other|Placebo, 2mg|2mg (100μL), single dose, abdominal subcutaneous injection
46089528|NCT04178070|Other|Placebo, 5mg|5mg (250μL), single dose, abdominal subcutaneous injection
46004568|NCT01909232|Device|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the active group, magnetic power output will be delivered to the subject through the coils.
46004569|NCT01909232|Device|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
46089529|NCT04178070|Other|Placebo, 10mg|10mg (500μL), single dose, abdominal subcutaneous injection
46004570|NCT04609449|Procedure|Long biliopancreatic limb Roux-en-Y gastric bypass.|Long biliopancreatic limb Roux-en-Y gastric bypass.
46004571|NCT04609449|Procedure|Standard Roux-en-Y gastric bypass|Standard Roux-en-Y gastric bypass
46004572|NCT01887002|Drug|ONO-2952|ONO-2952 Active tablets, every day for 2 weeks
46004573|NCT01887002|Drug|Placebo comparator|ONO-2952 Matching Placebo every day for 2 weeks
46004574|NCT00564174|Drug|Low molecular weight heparin and low dose aspirin|Fragmin 5000 IU/day by subcutaneous injection started at time of randomization and continued until 35 weeks gestation or delivery and low dose aspirin 81 mg/day started pre-conception and continued until 35 weeks gestation or delivery
46004575|NCT00564174|Drug|Low dose aspirin|81 mg enteric coated started pre-pregnancy and discontinued at 35 weeks or delivery
46089530|NCT04178070|Other|Placebo, 15mg|15mg (750μL), single dose, abdominal subcutaneous injection
46089531|NCT04178070|Other|Placebo, 20mg|20mg (1mL), single dose, abdominal subcutaneous injection
46089532|NCT04178070|Other|Placebo, 30mg|30mg (1.5mL), single dose, abdominal subcutaneous injection
46089533|NCT04176744|Other|Uni- and bilateral magnetic phrenic nerve stimulation|Uni- and bilateral magnetic phrenic nerve stimulation using different coils, stimulation patterns (frequency, intensity, number of pulses) and locations (neck, chest).
46089534|NCT02671578|Drug|Nitrous Oxide|The N2O/O2 equipment was composed by two flow meters with an anti-hypoxia system valve, 70% N2O maximum disposal and 30 L/min O2 valve to immediate oxygen dispensation. Masks were individually selected, being 100% O2 (6 L/min) dispensed until respiratory rate stabilization. N2O was incremented at 10% each 2 minutes (70% max, if necessary) until some of the following signals were noticed: silence, relax/comfort report, decreased eyelid movements, decreased spontaneous body movements, warm sensation, tingling sensation or numbness at feet, hands or oral region, and slightly euphoric sensation.
46004576|NCT01878461|Drug|Vehicle|
46004577|NCT01878461|Drug|M518101|
46004578|NCT01163266|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
46004579|NCT01163266|Drug|Placebo|Vortioxetine placebo-matching capsules
46089535|NCT00644982|Drug|sertraline|Flexibly-titrated 50 mg tablets, 50-150 mg/day and venlafaxine placebo orally for 10 weeks.
46089536|NCT00644982|Drug|venlafaxine XR|Flexibly-titrated 75 mg capsules, 75-225mg/day and sertraline placebo orally for 10 weeks.
46089537|NCT02670642|Drug|Esomeprazole|Proton pump inhibitor
46089538|NCT02670486|Other|Audiovisual stimulus|Water fountain and a video (including scenes of some common triggers for OAB) played on continuous loop throughout the test on a laptop
46004580|NCT04629456|Other|neuromuscular electric stimulation|A total of eight electrodes were placed on the quadriceps femoris muscles (four on each leg): two on the vastus medialis, one on the rectus femoris muscle, and one on the vastus lateralis muscle. The stimulation protocol of the NMES consisted of a symmetrical biphasic square pulse at 75 Hz, a duty cycle of 6 seconds (sec.) on and 29 sec. off, a pulse time of 410 sec. during a session lasting 20 min. The intensity was increased to maximum individual toleration. The muscle contractions were visible and palpable.
46089539|NCT00910260|Procedure|Blood analysis|Serum 25-hydroxyvitamin D, calcium, parathormone, phosphate, C-reactive protein and albumin levels will be measured at every visit: day 0, day 7 and day 84.
46089540|NCT04175496|Other|Blueberry Cake|Blueberry cake containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
46089541|NCT04175496|Other|Snacks with Cheese|Snacks with cheese containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
46089542|NCT04175496|Other|Spicy Crackers|Spicy crackers containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
46089543|NCT04175496|Other|Glucose Solution First Repeat|The glucose solution will be prepared by dissolving 25 g of glucose in 250 ml of water. Participants consume the glucose solution within 15 minutes after 10-hours fasting. Blood samples will be collect at time points 0,15, 30, 45, 60, 90 and 120 min.
46089544|NCT04175496|Other|Glucose Solution Second Repeat|The glucose solution will be prepared by dissolving 25 g of glucose in 250 ml of water. Participants consume the glucose solution within 15 minutes after 10-hours fasting. Blood samples will be collect at time points 0,15, 30, 45, 60, 90 and 120 min.
46089545|NCT02671734|Behavioral|video|Short (2 minute 43 second), animated videos were designed addressing nature of the procedure, risks, benefits, and alternatives for upper and lower endoscopy respectively using PowToon (www.powtoon.com). Sixth grade language was used throughout the video. Videos were shown to youth and their parents on an iPad.
46089546|NCT02670018|Drug|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg * 2 tablets, for 1 day
46089547|NCT02670018|Drug|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 25mg/metformin HCl extended release 1000mg * 2 tablets, for 1day
45677818|NCT04665583|Other|Prehabilitation|Prehabilitation will consist of careful pre-intervention assessment and personalized optimization, guided by Investigator judgment, with a specific focus on right ventricular function. This will be done by using a detailed echo acquisition protocol (Appendix 1). Assessments will be collected according to the schedule of events below (Table 1.). Therapy will include intravenous milrinone therapy and aggressive diuresis with evaluation for clinical and functional signs of improvement, according to standard of care.
46089548|NCT02671968|Device|Continuous Glucose Monitoring System|
46089549|NCT02670096|Drug|Acetazolamide|Two single dose administrations of acetazolamide (once before daytime testing, and once before nighttime testing)
46089550|NCT04078620|Diagnostic Test|Survey for drug drug interactions on medscape and lexicomp applications|Survey for drug drug interactions on Medscape and Lexicomp interaction checker applications
46089551|NCT02670174|Other|Traditional training|
45342433|NCT04901910|Behavioral|Verdi plus PA Social Media Group|Participants will have access to the secret Social Media page that will deliver health information focused on increasing healthy activities, well-being, and reducing risky behaviors. This information will be posted by e-coaches. Participants can interact with the e-coaches as well as other study members in the group.
45677819|NCT01958437|Device|Transcranial direct current stimulation (tDCS)|Active and/or sham; All participants receive both stimulation condition. Groups will be counterbalanced (half receiving active tDCS in the first session and sham in the second session; the other half receiving the opposite).
46089552|NCT02670174|Other|Separate kinetic chain training|
46089553|NCT02670174|Other|Integrated kinetic chain training|
46089554|NCT04076904|Diagnostic Test|transvaginal us with 2D and 3D SHG|transvaginal us is made to all women with SHG
46089555|NCT00645060|Other|high performance liquid chromatography|Performed on serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
46089556|NCT00645060|Other|pharmacological study|Serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
46089557|NCT00645060|Procedure|radionuclide imaging|1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post Y-90 anti-CEA antibody infusion
46089558|NCT00645060|Procedure|single photon emission computed tomography|2 days and 3-5 days post antibody infusion
46089559|NCT00645060|Radiation|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Dose escalation from 12 mCi/m2 through 18 mCi/m2 increasing by 2 mCi/m2 with each escalation
45677820|NCT01974752|Drug|75mg selumetinib|selumetinib tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
45677821|NCT01974752|Drug|placebo|placebo tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
46089560|NCT02537262|Dietary Supplement|carbohydrate beverage|Carbohydrate group drinks carbohydrate beverage 400ml(9PM~MN) the day before the surgery and 200ml three hours before the surgery.
46004581|NCT04629456|Other|Exercises|The chair-seated exercises were used in the early stages of the program because the participants were frail adults. Repetitions of toe raises, heel raises, knee lifts, knee extensions, and others were performed while seated on a chair. Hip flexions, lateral leg raises, and repetitions of other exercises were performed standing upright behind the chair and holding the back of the chair for stability. To strengthen lower extremities, a fixed weight was placed on the ankle while participants performed strengthening exercises. Weights of 0.50, 0.75, 1.00, and 1.50 kg were used in accordance with each participant's strength level as the resistance progressively increased. The exercises performed using these ankle weights included seated knee flexion and extension and standing knee flexion and extensions. Exercises using a resistance band: Resistance bands were used to strengthen lower body. Lower body exercises included leg extension and hip flexion
46089561|NCT02537262|Dietary Supplement|NPO(None Per Oral)|NPO group does not drink any water from the MN before the surgery.
46089562|NCT02676024|Device|Knowledge-based cognitive aid|"Trained on the use of a knowledge-based cognitive aid for pediatric cardiac arrests. Will be used by a dedicated team member (cognitive aid reader)."
45677822|NCT01974752|Drug|Dacarbazine|dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle taken in combination with either selumetinib or placebo tablets p.o. twice daily.
45677823|NCT01999946|Drug|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
46089563|NCT02676024|Device|Cognitive aids with roles defined (CARD)|"Trained on the use of the cognitive aids with roles defined (CARD) system for pediatric cardiac arrests. Participants are given large identification cards to be worn, which enable the code leader to quickly recognize the individuals' purpose at the code. The card identifies specific tasks associated with the role, ensuring that the participant knows exactly what their task is. Will not have a dedicated team member during the scenario (cognitive aid reader)."
45677824|NCT01958281|Drug|SOF|Tablet(s) administered orally once daily
46089564|NCT02676024|Device|Integrated cognitive aids|"Trained on the use of the cognitive aids with roles defined (CARD) system and also in the use of a protocol-based cognitive aid for pediatric cardiac arrests which will be used by a dedicated cognitive aid reader."
46089565|NCT02671656|Device|Uricemia|serum uric acid levels is measured once from venous blood samples in the biochemistry laboratory using standard automated colorimetric methods
46089566|NCT02672046|Other|Assessment at the Clinic of Sports Injuries|Assessment at the Clinic of Sports Injuries as well as a new algorithm (using patient-reported symptoms will be applied
45677825|NCT01958281|Drug|RBV|200 mg tablet administered orally once daily
45677826|NCT01958281|Drug|LDV/SOF|90/400 mg fixed-dose combination (FDC) tablet administered orally once daily
45677827|NCT04665115|Drug|Ibrutinib|Given PO
45677828|NCT04665115|Other|Quality-of-Life Assessment|Ancillary studies
45677829|NCT01958125|Device|gammaCore|Vagal stimulation
45677830|NCT02002975|Drug|Pioglitazone|Pioglitazone tablets
45677831|NCT02001181|Drug|Tofacitinib ointment 20mg/g|Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks
45677832|NCT02001181|Drug|Placebo ointment (Vehicle)|Placebo ointment (vehicle) twice daily (BID) for 4 weeks
45677833|NCT04644679|Diagnostic Test|7-day electrocardiographic monitoring|7-day external electrocardiographic monitoring
45677834|NCT04644679|Diagnostic Test|48-hr electrocardiographic monitoring|48-hr external electrocardiographic monitoring
46004582|NCT01873703|Drug|pracinostat|Histone deacetylase inhibitor (HDACi)
46004583|NCT01873703|Drug|Placebo|Placebo
45677835|NCT04176055|Drug|Haloperidol|haloperidol intervention
45677836|NCT01999465|Device|Standard NMES device|"Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~Rate(35 Hz)~Width (300 us)~Ch1 Ramp+ (2 seconds)~On Time 1 (10 seconds)~Ch1 Ramp - (2 seconds)"
46089567|NCT04176978|Drug|Rosuvastatin|Patient in this group will receive Rosuvastatin 20mg daily.
46089568|NCT04176978|Other|Treat-to-target strategy|Patient will receive treat-to-target strategy aiming at minimal disease activity (MDA). If patient cannot achieve MDA, treatment will be escalated.
46089569|NCT05283642|Dietary Supplement|DCI|Oral supplementation with D-chiro-inositol once daily
46089570|NCT05277090|Drug|2L of polyethyleneglycol|2L of polyethyleneglycol
46089571|NCT05277090|Dietary Supplement|inulin|15g inulin per day
46089572|NCT05277090|Combination Product|probiotic combination product|"participants take 2L of polyethyleneglycol, subsequently take 15g probiotics combination product (including Bifidobacterium lactis, Lactobacillus plantarum, inlulin, Vitamin C) per day. The probiotic combination product, named Mei Ri Yi Jun was produced by Wedge Pharmaceuticals."
46004584|NCT01873703|Drug|Azacitidine|Active comparator 75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable
46004585|NCT04629261|Behavioral|Use of ECOBICI (public bicycle sharing program)|Use of ECOBICI program with and without incentive.
46004586|NCT04629183|Other|integrated clinical evaluation|30-day follow-up (telephone/database query) to define outcome Patients will receive standard care, independent of study participation.
46089573|NCT00644670|Drug|Atorvastatin|In previously treated patients, starting atorvastatin doses (oral tablets given once daily) of 20 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline) or 40 mg (in patients with LDL-C levels between 165 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
46004587|NCT01870505|Drug|BYL719|
46089574|NCT00644670|Drug|Atorvastatin|In statin-naive patients, starting atorvastatin doses (oral tablets given once daily) of 10 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline), 20 mg (in patients with LDL-C levels between 165 and 174 mg/dL at baseline), or 40 mg (in patients with LDL-C levels between 175 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
46089575|NCT02671344|Other|Determination of gene profiles using arrays semen|Determination of gene profiles characterizing the set of mRNA and functional interpretation of the resulting list of genes.
46004588|NCT01870505|Drug|Letrozole|
46004589|NCT01870505|Drug|Exemestane|
46004590|NCT04629612|Procedure|Regional anesthesia|Regional anesthesia such as paravertebral block, pectoral block, superficial cervical plexus block, etc applies according to institution protocol
46004591|NCT01868516|Drug|dexmecamylamine|
46004592|NCT01868516|Drug|Placebo|
46004593|NCT00564213|Drug|PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds|Mitomycin 0.02%
46004594|NCT01861847|Drug|7-Keto Dehydroepiandrosterone|7-Keto Dehydroepiandrosterone, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
46004595|NCT01861847|Drug|Placebo|Placebo, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
46089576|NCT02669706|Drug|Pentamidine|Pentamidine is an antimicrobial medication given for prevention and treatment of Pneumocystis pneumonia (PJP) caused by Pneumocystis jirovecii
46089577|NCT02669628|Procedure|Surgical technique|Laparoscopic surgery
46004596|NCT00564252|Drug|topical finasteride|0.2%topical(cream)finasteride twice a day for six months
46004597|NCT04629144|Drug|Belimumab|"Belimumab administered subcutaneously 200mg weekly from week 0 to week 24.~Both arms will have the same corticosteroid tapering scheme, with an initial dose of 60 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:~60 mg/day week (W)0-W4,~40 mg/day W4-W6~30 mg/day W6-W8,~20 mg/day W8-W10,~15 mg/day W10-W12,~10 mg/day W12-W14,~7.5 mg/day W14-W16,~5 mg/day W16-W18~2.5mg/day W18-W20.~Stopping glucocorticoid therapy at W20 At each step, the prednisone dose will be reduced only in the absence of signs of vasculitis activity."
46089578|NCT02669628|Procedure|Alcohol sclerotherapy|US-guided sclerotherapy
46089579|NCT02669550|Device|Fiberoptic bronchoscope|In case of FOB, the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
46089580|NCT02669550|Device|Disposcope endoscope|In the DE group, the operator gripped the chin and lower incisors of patients with the fingers and thumb to open the mouth adequately wide and grasped the wire body, which was enclosed within the endotracheal tube, by the other hand and held it parallel to,then inserted into oral cavity
46004598|NCT04629144|Drug|Placebo|"Both arms will have the same corticosteroid tapering scheme, with an initial dose of 60 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:~60 mg/day week (W)0-W4,~40 mg/day W4-W6~30 mg/day W6-W8,~20 mg/day W8-W10,~15 mg/day W10-W12,~10 mg/day W12-W14,~7.5 mg/day W14-W16,~5 mg/day W16-W18~2.5mg/day W18-W20.~Stopping glucocorticoid therapy at W20 At each step, the prednisone dose will be reduced only in the absence of signs of vasculitis activity."
46004599|NCT01855880|Biological|AbGn-168H|
46004600|NCT01855880|Biological|placebo|
46004601|NCT00564291|Other|Examination with an OCT device|
46004602|NCT01851083|Biological|autologous bone marrow mononuclear cells|BMMNC infusion of either 6x10^6 cells/kg or 10x10^6 cells/kg weight.
46004603|NCT01851083|Other|Placebo Infusion|Placebo infusion of 0.9% Sodium Chloride
46004604|NCT04609839|Other|Follow-up of patients with COVID-19|"The presence of sequelae, number of re-hospitalizations, date of death and cost of health expenditure will be collected.~The Quality of life score (SF-36 questionnaire) and the Pittsburgh sleep quality index (PSQI questionnaire) will be completed by patients."
46004605|NCT01850381|Drug|GM608|For GM608: 320 mg/dose reconstituted with 6.4 mL bacteriostatic saline. Administer 6.4 mL GM608 dosing solution by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
46089581|NCT02669472|Other|Environmental Intervention|Intervention sites received regularly-scheduled, discount, fresh F&V markets for one year during the first two weeks of each month. The markets brought between 50-70 different produce items, including culturally desired ethnic produce. Markets at the senior and disabled housing complexes were held indoors as were markets at family housing complexes during inclement weather. In good weather, markets were held outside at the family complexes using a mobile retrofitted car trailer. The produce items were set up in racks on three sides of the trailer and shoppers entered through the rear door. FTY markets accepted cash, debit/credit cards and EBT cards (SNAP). Each market lasted two hours and the produce was sold at prices 15%-25% lower than local retail supermarket prices.
46004606|NCT01850381|Drug|Placebo Comparator|For Placebo: Administer 6.4 mL Bacteriostatic saline by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
45677837|NCT01999465|Device|Sham NMES device|"Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~Rate(35 Hz)~Width (48 us)~Ch1 Ramp+ (0 seconds)~On Time 1 (0 seconds)~Ch1 Ramp - (0 seconds)"
45677838|NCT01982773|Behavioral|Virtual Hope Box Smartphone App|Smartphone app
45677839|NCT01982773|Behavioral|Enhanced Treatment as Usual|Printed materials
45677840|NCT01974206|Biological|ASP0113|intramuscular injection
46004607|NCT00555074|Drug|Sodium Tungstate|Sodium Tungstate, 200 mg BID, oral route during 6 weeks
45677841|NCT01974206|Drug|Placebo|intramuscular injection
46004608|NCT00555074|Drug|Placebo|Placebo, BID, oral route during 6 weeks
46004609|NCT04609488|Diagnostic Test|Surfactant assessment|To determine surfactant levels in lung fluid
46004610|NCT04609605|Device|speckle tracking echocardiography|speckle tracking echocardiography of right ventricle
46004611|NCT01847573|Drug|HT-100|May be administered in either fed or fasted state
46004612|NCT01846793|Drug|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
46004613|NCT04609254|Drug|Paracetamol|1000 mg of paracetamol ( parol 1000mg vial-atabay chemistry-İstanbul) intravenous (IV) was given 71 patients,
46004614|NCT04609254|Drug|Dexketoprofen|dexketoprofen 50 mg arveles 50 mg ampoule -Menarini- Istanbul) intravenous (IV) was given 70 patients,
45677842|NCT04416464|Other|COVID-19 Pneumonia|Pneumonia due to proven or suspected SARS-Cov-2 infection
45677843|NCT04659278|Dietary Supplement|Endourage 1200 mg OMD ™ Oral Mucosal Drops|The CBD/THC ratio of OMD 1200 is 14:1 and the CBD/Terpene ratio is 1:1. Each ¼ dropper contains 10.2 mg of CBD and 0.7 mg of THC. The total % THC is 0.28%. These ratios indicate that the product will not cause euphoria.
45342434|NCT00709488|Drug|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
45677844|NCT04659278|Dietary Supplement|Isolate|The isolate formulation contains 0% cannabinoids (CBD 0.00%; CBDa 0.00%; detla 9 THC 0.00%; THCa 0.00%).
45677845|NCT04659278|Other|Placebo|Total CBD = CBD + (CBD-A * 0.877). Total THC = THCA-A * 0.877 + Delta 9 THC, ND = <LOQ, T-Caryophyllene = Trans-Caryophyllene, <LOQ = Less Than Limit of Quantitation, QNS = Quantity Not Sufficient. (%) = Percent, (ppm) = Parts per Million, (ppb) = Parts per Billion, (μg/Kg) = Microgram per Kilogram, (mg/g) = Milligram per Gram, ppm = (μg/g), ppb = (μg/kg),
45677846|NCT04659278|Dietary Supplement|Peppermint Oil, masking flavor|Mentha piperita Leaf /Stem Oil; Physical state: Liquid. Color: Colorless to pale yellow; Characteristic peppermint odor; Not dangerous goods.
46004615|NCT04609254|Drug|Ibuprofen|400 mg Ibuprofen (İntrafen 400 mg vial- Gen-İstanbul) intravenous (IV) was given 69 patients, which determined to be applied as a group.
46004616|NCT01846481|Drug|RBP-8000 100 mg|RBP-8000 100 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
46004617|NCT01846481|Drug|Placebo|IV infusion of Placebo administered 1 minute after cocaine infusion on either day 3 or 6.
46004618|NCT01846481|Drug|Cocaine|50 mg intravenous (IV) dose of cocaine administered over 10 minutes on Days 1, 3 and 6.
46004619|NCT01846481|Drug|RBP-8000 200 mg|RBP-8000 200 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
46089582|NCT02669472|Behavioral|Educational Intervention|Each household in the housing site received a reusable shopping bag that contained a binder with: an overview page, sleeves to store 12 newsletters, three DVDs and 48 recipe cards. The 20-minute DVDs included cooking demonstrations, tips and testimonials. A two-page, full-color newsletter was delivered each household each month. It had information about a particular F&V in season as well as other tips and recipes. Two 6-week long educational and motivational campaigns were also offered: ''Just Add 2', and 'Color Your Plate'. Both campaigns included full-color campaign booklets, goal-setting activities, educational and motivational content, and F&V trackers with incentives/prizes for completing and turning in the trackers. All materials were provided in English and Spanish.
46089583|NCT02669472|Behavioral|Control|We contracted with the Greater Providence YMCA to bring to provide physical activity and stress reduction programming. Two, six-week campaigns followed the same format and timing of the intervention group campaigns. Campaigns participants received a free, 6-week membership to the YMCA. The 'Take 10!' campaign aimed to increase participants' daily physical activity by 10 minutes per day until they reached the goal of at least 30-60 minutes per day. The second campaign was 'Stress Less' aimed to help participants reduce the amount of stress that they experienced by including relaxation activity into their daily routine.
45677847|NCT04659044|Drug|Polatuzumab Vedotin|Given IV
46089584|NCT00644514|Biological|Endotoxin - lipopolysaccharide (LPS)|Nebulized 5000EU, 10,000EU, 20,000EU endotoxin doses delivered to completion. Nebulized dose inhaled 30 minutes apart if no adverse events occur after the previous dose. Fiberoptic Bronchoscopy with Bronchoalveolar Lavage (BAL) and brush samples performed 24 hours after LPS nebulization.
45677848|NCT04659044|Biological|Rituximab|Given IV
45677849|NCT04659044|Biological|Rituximab and Hyaluronidase Human|Given SC
45677850|NCT04659044|Drug|Venetoclax|Given PO
45677851|NCT01999868|Biological|Ustekinumab|"Ustekinumab interferes with the actions of proteins, interleukin 12 (IL12) and interleukin 23 (IL23), which reduces inflammation (swelling) in the skin. Stelara™ is the trade name for ustekinumab and is approved by the U.S. Food and Drug Administration (FDA) to treat psoriasis.~Dose:~Participants who weigh <= 100 kg at study entry will receive 45 mg of ustekinumab.~Participants who weigh > 100 kg at study entry will receive 90 mg of ustekinumab."
46004620|NCT04609293|Combination Product|camrelizumab+apatinib+hyperfractionated radiotherapy|Immunotherapy, anti-angiogenesis targeted therapy combined with hyperfractionated radiotherapy
46004621|NCT01844180|Drug|ONO-2952|
46004622|NCT01844180|Drug|ONO-2952 Matching Placebo|
46004623|NCT04609059|Drug|M201-A Injection|"Active Substance: M201-A Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)"
45342435|NCT00709488|Procedure|Placement of device in prostate urethra|Placement of device in prostate urethra
45677852|NCT01999868|Biological|Abatacept|"Abatacept (one form of the protein called CTLA4-Ig) interacts with the immune system, reducing the activity of T-cells and may prevent relapse. Orencia™ is the trade name for abatacept, and it is approved by the FDA to treat rheumatoid arthritis in adults.~Dose:~125 mg sub-cutaneous injection"
46004624|NCT04609059|Drug|Placebo|"Saline Placebo: M201-A Placebo Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)"
46004625|NCT04676750|Behavioral|Mindfulness-Based Stress Reduction|yoga, meditation and psycho education
46004626|NCT04601298|Other||
46004627|NCT04601181|Biological|ThisCART22 cells injection|"Assigned Interventions Biological/Vaccine: ThisCART22 cells 0.2-60 x 10^6 CAR-T cells per kg body weight.~Intervention study"
45677853|NCT01999868|Drug|UST Placebo|The abatacept treatment group will also receive subcutaneous placebo for ustekinumab (sterile normal saline) at week 16 and week 28, corresponding to the ustekinumab dosing regimen.
46004628|NCT04676828|Diagnostic Test|Single-photon-emission CT scan|SPECT/CT scan is an established functional modality used in the diagnosis and monitoring of lung disease. SPECT/CT scan images pulmonary circulation, where perfused areas equate with normal functional lung
46004629|NCT04676789|Drug|Pegaspargase|Pegaspargase 2500IU/m2 administered by intramuscular injection on Day 1
46004630|NCT04676789|Drug|Anti-PD-1 monoclonal antibody|Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 1
46089585|NCT00645138|Procedure|Paravertebral Block|"Sedation will be provided with midazolam and fentanyl. The transverse processes of T1-T6 will be located using ultrasound guidance. The area will be prepped with betadine. At each level, a 21 Gauge, 4-inch Stimuplex needle will be inserted in order to make contact with the transverse process. Once the transverse process has been located, the needle will be walked off the process and inserted 1 cm deep to its inferior border. After negative aspiration, 3 mL of 1.5% mepivacaine with epinephrine 1:200,000 and bicarbonate and 3 mL of 0.5% bupivacaine with epinephrine 1:200,000 will be injected. Sedation will be provided with 50-100 mcg/kg/min of propofol during the surgical procedure. Approximately 20 minutes before the end of the procedure, 4 mg of zofran will be administered."
46089586|NCT00645138|Procedure|General Anesthesia|Patients in the general anesthesia group will receive midazolam preoperatively for anxiolysis. Anesthesia will be induced with propofol and fentanyl. An LMA will be inserted and anesthesia maintained with sevoflurane in air and oxygen. 4 mg of zofran will be administered approximately 20 minutes before the end of the surgical procedure. The LMA will be removed and the patient will be transported to the PACU at the conclusion of the surgery.
46089587|NCT04177368|Dietary Supplement|Theragran 60ml|history,examination and biochemical values
46089588|NCT00895895|Drug|Placebo|Capsules SAM-531 placebo and 5 mg tablet encapsulated Donepezil placebo capsules, once a day during 24 weeks.
46089589|NCT00895895|Drug|SAM-531 1.5 mg|Capsules SAM-531 1.5 mg, once a day during 52 weeks.
46089590|NCT00895895|Drug|SAM-531 3.0 mg|Capsules SAM-531 3.0 mg, once a day during 52 weeks.
46089591|NCT00895895|Drug|SAM-531 5.0 mg|Capsules SAM-531 5.0 mg, once a day during 24 weeks or 52 weeks.
46089592|NCT00895895|Drug|Donepezil|Encapsulated Donepezil 5 mg tablets, once a day during 52 weeks. After Day 42, the dose can up titrated up to 10 mg of Donepezil.
45677854|NCT01999868|Drug|ABA Placebo|The ustekinumab treatment group will also receive weekly subcutaneous injections of placebo for abatacept from week 12 to week 39, corresponding to the abatacept dosing regimen.
46004631|NCT04676789|Radiation|Definitive intensity-modulated radiotherapy (IMRT)|Definitive intensity-modulated radiotherapy (IMRT) of 50 Gy will be given in 25 days
46004632|NCT04600713|Other|PT-X and IMT|The intervention consists of PT-X, including central circulatory exercise and muscle exercises, 2 times/week, 60 min/session for 12 weeks, and homebased exercises 2 times/week logged in an exercise diary. For IMT the Threshold Inspiratory Muscle Trainer (Threshold IMT) (Respironics Inc., Murrysville, PA, USA) will be used at 30 % of maximal expiratory pressure in 15 minutes 2 times a day during 12 weeks.
46004633|NCT01811576|Drug|TV-1106|
46089593|NCT04176588|Drug|Etrasimod|Drug:Etrasimod Tablet other name:APD334
46089594|NCT04176588|Drug|Placebo|Drug:placebo Tablet
46089595|NCT02671110|Behavioral|Transforming Your Life|See Transforming Your Life Arm
46089596|NCT02671110|Behavioral|Diabetes Prevention Program|See Diabetes Prevention Program Arm
46089597|NCT02537184|Procedure|Oral Clinical conditions|caries incidence assessment dental anxiety assessment
46089598|NCT02671188|Drug|GSK3050002|The 3 mL glass vial contains white to off-white lyophilized powder which requires reconstitution with sterile water for injection.Prepared as 100 milligrams per milliliter (mg/mL) solution; lower concentrations prepared by dilution with 0.9% weight by volume (w/v) sodium chloride Injection for infusion.
45459139|NCT05193422|Diagnostic Test|Humidity|Continuous monitoring of Hum in the face mask using a RHT03 sensor, only in the experimental study arm
45677855|NCT01957579|Drug|MEDI-551|MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle
45677856|NCT03511963|Drug|HLX04 100 mg in 4 ml Injection|7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
45677857|NCT03511963|Drug|Avastin 100 mg in 4 ml Injection|7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
45677858|NCT01999322|Drug|Faster-acting insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
45677859|NCT01999322|Drug|insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
46004634|NCT01811576|Drug|Recombinant human growth hormone|Subcutaneous once daily
46004635|NCT04609371|Behavioral|self-care tools|self-care tools only
46004636|NCT04609371|Behavioral|lay telephone coaching|coaching
46004637|NCT01811498|Drug|Bevacizumab|
46004638|NCT01810484|Device|Ultherapy® treatment only|Focused ultrasound energy delivered below the surface of the skin
46089599|NCT02671188|Drug|Placebo|Normal saline (0.9% sodium chloride) will be used as placebo.
46089600|NCT00644748|Drug|gabapentin|"Gabapentin oral capsules:~Week 0: Day 1: 300 mg; Day 2: 600 mg (2 doses of 300 mg); Day 3: 900 mg (3 doses of 300 mg), maintained until the end of the week; After this point, the total daily dose was divided in 3 equal doses. Week 1: Day 1: 1200 mg; Day 2 to 7: 1800 mg Week 2: Day 1: 2100 mg; Day 2 to 7: 2400 mg Week 3: Day 1: 2700 mg; Day 2 to 7: 3600 mg Weeks 4 to 11: 3600 mg"
46089601|NCT00910338|Device|PFMT with Extracorporeal Biofeedback|"Pelvic Floor Muscle Training with Extracorporeal Biofeedback Device for 12 weeks~Twice a week for the first 4 weeks~Once a week for the next 8 weeks"
46089602|NCT04176276|Other|no interventions required.|The study does not require any interventions.
46089603|NCT00645216|Drug|CP-945,598|Subjects take CP-945,598 alone for 21 days
46089604|NCT00645216|Drug|CP-945,598|Subjects take CP-945,598 from Days 1 to 7, then take CP-945,598 and Grapefruit Juice from Days 8 to 21
46089605|NCT00910416|Drug|propofol, remifentanil, atracurium|propofol, remifentanil, atracurium dosages are adapted according to clinician's judgment
46004639|NCT01810484|Device|Ultherapy® treatment and CO2 laser treatment|"Ultherapy® treatment: Focused ultrasound energy delivered below the surface of the skin;~CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin."
46004640|NCT01810484|Device|CO2 Laser treatment only|CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin.
46004641|NCT04600830|Procedure|Dry needling|Intervention with deep dry needling on latent myofascial trigger points (MTrPs) in gastrocnemius muscle.
46089606|NCT00910416|Drug|propofol, remifentanil, atracurium, sevoflurane|dosages are adapted according to clinician's judgment
46089607|NCT00910416|Device|EEG monitoring|simultaneous monitoring with Bis and Neurosense
46089608|NCT02669160|Device|PC Innowalk|
46089609|NCT02669160|Device|Conventional passive stander|
46089610|NCT02669238|Device|Nexplanon®|Subcutaneous implant (Nexplanon®) containing etonogestrel 68 mg
46089611|NCT02669238|Drug|Minidril®/Leeloo®|continuous per os administration of oestroprogestative treatment. 1 pill a day First line: Minidril® (Levonogestrel 0.15 mg / Ethinylestradiol 0.03 mg) Second line: Leeloo® (Levonogestrel 0.1 mg / Ethinylestradiol 0.02 mg)
46089612|NCT02668614|Device|WR-22 model microwave sensor|
46089613|NCT02669004|Drug|Intermittent bolus epidural morphine|morphine given with patient- controlled intermittent bolus epidural, 50 µg/kg in 10 mL bolus, lockout time 1 hour, no infusion
46089614|NCT02669004|Drug|continuous epidural morphine|morphine given with patient- controlled continuous epidural, initial setting loading morphine 0.02mg/kg in 8mL, was maintained 0.01 mg/kg continuous infusion 4mL, 0.05 mg/kg 2mL bolus dose. 30 minute lock-out interval. 4 hour limit was 4 mg/kg.
46089615|NCT00895661|Drug|rituximab|Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).
46089616|NCT00645294|Drug|Adefovir dipivoxil|0.14 mg/kg on Day 1, followed by 0.3 mg/kg on Day 8
45836266|NCT00241176|Drug|Aripiprazole|Baseline Visit 2: Subjects btw 25-50kg start on 1.25mg/day, btw 50-70kg start on 2.5mg/day, greater than 70kg start on 5mg/day Visit 3: Titrated based on YGTSS & CGI-TS ratings at investigator discretion. Subjects who show evidence of response (reduction in CGI-TS by 1-2 points) may remain on same dose. Subjects who show no response may increase as follows: btw 25-50kg increase to 2.5mg/day, btw 50-70kg increase to 3.75mg/day, greater than 70kg increase to 7.5mg/day Visit 5: Subjects who show no response may increase as follows: btw 25-50kg increase to 3.75mg/day, btw 50-70kg increase to 5mg/day, greater than 70kg increase to 10mg/day Visit 6: Subjects who show no response may be increase as follows: btw 25-50kg increase to 5mg/day, btw 50-70kg increase to 7.5mg/day, greater than 70kg increase to 12.5mg/day Visit 7: Subjects who how no response may be increase as follows: btw 25-50kg increase to 7.5mg/day, btw 50-70kg increase to 10mg/day, greater than 70kg increase to 15mg/day
46089617|NCT00645294|Drug|Adefovir Dipivoxil|0.3 mg/kg on Day 1, followed by 0.14 mg/kg on Day 8
46089618|NCT00645294|Drug|Adefovir Dipivoxil|ADV 10 mg on Day 1
46089619|NCT02668848|Dietary Supplement|water|If USG>1.02, patients will be advised to drink water via oral or tubal feeding with a dose of 5cc/kg body weight , maximum 300cc, and repeat the same amount of water after dinner in the same day.
46089620|NCT04201535|Diagnostic Test|Protein arrays on plasma samples|Protein arrays on plasma samples obtained from RA, OA patients and controls will be performed to identify a panel of acute phase proteins, cytokines and chemokines present at systemic levels and to highlight analogies and differences in the systemic protein profile.The synovial fluid will be used to identify through high-throughput MudPIT the proteins present in the synovial fluid of RA and OA patients.
46004642|NCT04600869|Other|Naturalistic Decision-Making Model-based Oncofertility Care Education|We designed the education program according to Klein's NDM model, which explored the reasoning mechanism behind decision-making (Klein, 1993). It depends on the on-the-job training date in each unit. The education program consisted of the following: (1) Information accumulation: explanations of common cancer therapies related to subsequent infertility, psychological and mental change in cancer survivors with infertility, the necessity and method of early determination of fertility intention, and type of fertility preservation. (2) Sense-making: situational case sharing, emphasis on the guidance interaction between experienced and novice nurses to understand the patient's situation. (3) Decision-making: how to provide support, how to correspond, and attitudes toward people with strong fertility intention.
46089621|NCT00644826|Behavioral|preventive home visit|A multidimensional geriatric assessment within the dimensions: cognition, health related functioning, risk of falling, nutritional status, social situation, economic situation, mood. Two more home visits: (1) home counseling visit 2-3 weeks after assessment (2) booster session 1 month after home counseling visit
46089622|NCT05334641|Other|Listening Music|The patients in the experimental group were listened to music.
46089623|NCT05334641|Other|Not Listening Music|The control group was not listened to music.
46089624|NCT02668224|Device|Vibrasens|Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
46089625|NCT02668224|Other|Usual activities|The patients will perform their usual activities, to allow the comparison with a vibration programme. They will not have a specific training.
46089626|NCT02837315|Behavioral|Brief Motivational Intervention (BMI)|This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; a marijuana use decisional balance exercise; personalized marijuana-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students use marijuana and actual student norms, (b) a comparison of the student's marijuana use vs. norms, (c) drug-related problems experienced, (e) money spent on marijuana, and (f) alcohol norms and consequences if participants indicated they also drink alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if she or she indicates interest.
46089627|NCT02837315|Behavioral|Substance-Free Activity Session (SFAS)|The clinician initiates a discussion of the student's college and career goals. Students discuss the values that motivate them as well as how marijuana use may interfere with their ability to accomplish these goals. Students then receive information on graduation rates and income benefits for those who attend and excel in college. They receive personalized feedback on (a) the requirements for their major and intended career, (b) a list of extracurricular activities tailored to their goals, (c) a graph showing time they allocate to their activities, (d) information on stress and depressive symptoms (if applicable) and possible adaptive coping responses and (e) a list of substance-free recreational activities in which they would like to start or continuing engaging.
46089628|NCT02837315|Behavioral|Relaxation Session|The session includes a clinician-led diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (~30 minutes). At the end of the session, students are asked about their reaction to the relaxation techniques and are provided with relaxation training handouts.
46089629|NCT02666820|Procedure|Large balloon dilatation|After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 12, 15, 18 or 20 mm CRE-balloon was passed over guide wire and position across the papilla. The balloon was gradually inflated to the largest size of the bile duct stone and/or the bile duct diameter. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
46089630|NCT02666820|Procedure|Mechanical lithotripsy|After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 3x6 cm Trapezoid Rx retrieval stone basket was used to capture the stone and crushing of stones was done when simple stone extraction failed to remove the stone. The stone fragments were then retrieved with a basket and/ or a retrieval balloon. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
46004643|NCT01804829|Biological|Civacir® 10%|The active ingredient is Human Immunoglobulin G (IgG) which is a normal constituent purified from human source plasma containing a diversity of antibodies targeting the Hepatitis C Virus.
46004644|NCT00565422|Drug|Escitalopram|10 mg/day
46089631|NCT02837003|Drug|Aspirin|Discontinuation of aspirin at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
46089632|NCT02837003|Drug|Thienopyridine|Discontinuation of thienopyridine at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
46089633|NCT04174014|Procedure|Recruitment manoeuvre|PEEP increment and decrement
46089634|NCT02668926|Drug|Lisdexamfetamine, d-amphetamine, Placebo|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
46004645|NCT01804088|Device|Formula™ 535 Iliac Balloon-Expandable Stent|Treatment of symptomatic vascular disease of the iliac arteries
46004646|NCT04608747|Other|Tahini|Fifty grams of tahini were consumed by 20 healthy males
46089635|NCT02668926|Drug|d-amphetamine, Placebo, Lisdexamfetamine|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
46089636|NCT02668926|Drug|Placebo, Lisdexamfetamine, d-amphetamine|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
46004647|NCT01802723|Drug|Drug: salmeterol xinafoate|
46089637|NCT00910494|Radiation|Photon Radiosurgery System IORT|
46004648|NCT01802723|Drug|Drug: Placebo|
46004649|NCT04600908|Other|Characteristics of accidents|informations about commuting accidents were recorded either during an occupational medicine consultation or by the medical service after reception of the medical certificate and the administrative declaration
46089638|NCT00910494|Radiation|Photon Radiosurgery System IORT|
46089639|NCT02668536|Drug|Standard Sunscreen|Areas will be treated with a standard preparation, consisting of padimate O (7%) and oxybenzone (3%) will be used as the control sunscreen.
46089640|NCT02668536|Device|BNP|Additional areas will be treated with empty bioadhesive nanoparticles (BNPs).
46089641|NCT00645372|Drug|Risperidone|Oral risperidone capsules 1 and 2 mg; doses were 1 mg once daily on Days 1-2, 2 mg once daily on Days 3-4, 3 mg once daily on Days 5-7, and 1, 2, or 3 mg twice daily during Weeks 2-6
46089642|NCT00645372|Drug|Ziprasidone|Oral ziprasidone capsules 40, 60, and 80 mg; doses were 40 mg twice daily on Days 1-2, 60 mg twice daily on Days 3-7, and 40, 60, or 80 mg twice daily during Weeks 2-6
46089643|NCT02667990|Other|orthopaedic stilettoe|stilettos with orthopaedic in-sole buildt into the shoe
46089644|NCT02667990|Other|standard stiletto|standard stiletto without insole
46089645|NCT02667990|Other|comfy trainer|comfy trainer
46089646|NCT02668458|Procedure|High Flow nasal canula oxygen therapy|Pre-oxygenation with high-flow nasal canula oxygen therapy
46089647|NCT02668458|Procedure|Noninvasive ventilation|Pre-oxygenation with non-invasive ventilation
46089648|NCT02668068|Procedure|large volume whole-lung lavage (WLL)|Generally 1000 ~ 2000ml each time, 14 ~ 10 times totally, each side of the lung to 20 ~ 15 liters, until the lavage fluid from the black into a colorless clear clarification
46089649|NCT02668068|Biological|clinical grade umbilical cord mesenchymal stem cells|10^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after whole-lung lavage
46089650|NCT00645918|Drug|clopidogrel|oral, 75 mg daily for 6 months starting on day of randomization
46089651|NCT00645918|Drug|placebo|oral, 6 pill loading dose on day of randomization; one pill daily for 6 months starting on day of randomization
46089652|NCT00645918|Drug|clopidogrel|oral, 450 mg loading dose on day of randomization; 75 mg daily for 6 months starting on day of randomization
46089653|NCT02668146|Drug|Perampanel|Study drug will be administered to study subjects
46089654|NCT02668146|Drug|Placebo|Placebo will be administered to study subjects
46089655|NCT02665182|Behavioral|Up-positioning of the testes|Patients in the experimental arm are asked to elevate their testes during the treatment.
46089656|NCT02667834|Behavioral|Social Cognition and Interaction Training (SCIT)|A randomized, controled trial of social cognition and interaction training ( SCIT) for patients with schizophrenia Spectrum disorders
46089657|NCT02667834|Behavioral|therapeutic education program (ETP)|usual treatment ,30 hours with therapist, only discussion between patients
46004650|NCT01789736|Drug|PG286 Ophthalmic Solution 0.5%|PG286 Ophthalmic Solution
46004651|NCT01789736|Drug|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5%
46004652|NCT01789736|Drug|Travoprost Ophthalmic Solution 0.004%|Travoprost Ophthalmic Solution 0.004%
46004653|NCT04600947|Drug|LP002|10 mg/kg administered as IV infusion on Day 1 of each 14-day cycle.
46004654|NCT01789268|Device|Respiratory Inductive Plethysmography|Respiratory Inductive Plethysmography (RIP) will be used to document thoracoabdominal motion, relative minute ventilation, and apnea during the minimally invasive respiratory assessments (NIRAs). Both Full and Preterm Infants will undergo a respiratory assessment via RIP prior to and after a bronchodilator (albuterol)
46004655|NCT00564330|Drug|Esomeprazole|20mg bid
46004656|NCT00564330|Drug|Placebo|Placebo bid
46004657|NCT01783808|Other|Supplemental oxygen|"Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.~In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used."
46089658|NCT00646854|Drug|CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab|Cyclophosphamide 750 mg/m2 i.v. on day 1 Hydroxydaunorubicin 50 mg/m2 i.v. on day 1 Vincristin 1 mg/m2 i.v. day 1 (max. 2mg) Prednisone 50 mg/m2 p.o. day 1 to 5 Alemtuzumab 30 mg s.c.on day 1 of CHOP-14 cycles 1-4
46089659|NCT00646854|Drug|CHOP14 chemotherapy (see specification under Arm B) plus G-CSF|6 cycles of CHOP every 2 weeks
46089660|NCT04173156|Device|Labrida Bioclean|The brush bristles of the test device (Labrida BioClean®, LABRIDA, Oslo, Norway) are made of the biopolymer chitosan
46089661|NCT04173156|Device|Gracey Periodontal curettes|Regular commercially available area specific and medical grade steel Gracey periodontal curettes
46089662|NCT04033302|Biological|CD7-specific CAR gene-engineered T cells|Infusion of CD7-specific CAR-T cells
46089663|NCT04174326|Behavioral|Immediate intervention group|Participants will be randomized to either the immediate or delayed intervention group at baseline. Participants in both groups will receive CBT for chronic pain management sequentially, once a week during the 6 week intervention period. Participants will be followed-up at 18 weeks from baseline. Two in-between sessions practice assignments will be added to each group therapy session during the the CBT program.
46089664|NCT04173858|Drug|Naloxegol|25 mg oral naloxegol once daily.
46089665|NCT02667678|Biological|Cohort HIVOL, patients infected by HIV|Researchers will take blood and urinary samples from the patients of the HIVOL cohort, to look at the renal clearance. The aim of this study is to check the renal function of the patients infected by HIV.
46089666|NCT00645996|Dietary Supplement|Probiotics (L.acidophilus and B.lactis)|2.1 X 109 L.acidophilus and B.lactis
46089667|NCT00645996|Dietary Supplement|Cornflor|Cornflour 2 gram daily
46089668|NCT00646932|Drug|paricalcitol|paricalcitol 0.04 mcg/kg three times a week
46089669|NCT00646932|Drug|paricalcitol|paricalcitol 0.08 mcg/kg three times a week
46089670|NCT00646932|Drug|paricalcitol|paricalcitol 0.16 mcg/kg three times a week
46089671|NCT00646932|Drug|paricalcitol|paricalcitol 0.24 mcg/kg three times a week
46089672|NCT02665026|Procedure|stoma closure at different times|Early closure: stoma closure in 12 weeks after surgery for rectal cancer; Late group: stoma closure in 24 weeks after surgery for rectal cancer
46089673|NCT05255640|Procedure|operation of ischemia of the lower limbs|The intervention technique is left to the judgment of the investigator to treat the ischemia
46089674|NCT00910572|Device|Yttrium-90 microspheres (Therasphere MDS Nordion)|Y-90 is incorporated into very tiny glass beads (microspheres: Therasphere MDS Nordion) and is injected into the liver tumor through the hepatic arteries, which are responsible for the feeding of the neoplastic liver tissue. Since the microspheres are unable to pass through the micro-vasculature of the liver parenchyma and tumor they are trapped at those sites and exert a local radio-therapeutic effect.
46004658|NCT04600635|Procedure|Bariatric surgery|Some patients in the cohort are followed by a multidisciplinary team in preparation for bariatric surgery. Others have already undergone bariatric surgery and are being followed up postoperatively.
46004659|NCT00564369|Other|CDC HIV testing recommendations|Current vs. prior CDC recommendations
46004660|NCT01780844|Drug|ASKP1240|intravenous infusion
46089675|NCT04775472|Procedure|Early left atrial septostomy within 12 hours after VA-ECMO implantation|Early left atrial septostomy group will routinely receive left atrial septostomy within 12 hours after VA-ECMO implantation. Left atrial septostomy will be done using percutaneous technique.
46089676|NCT04775472|Procedure|Selective left atrial septostomy|Left atrial septostomy will be done in cases of deleterious effect of increased LVEDP after VA-ECMO implantation, such as refractory pulmonary edema, abnormal opening of aortic valve, left ventricular dilatation, refractory ventricular tachycardia or fibrillation.
46004661|NCT01780844|Drug|Tacrolimus|intravenous or oral
46089677|NCT00646074|Behavioral|Self-Care Talk|6 conversational sessions
46089678|NCT02667756|Other|Non-interventional|
46089679|NCT04173936|Behavioral|tai chi|12-week community-based tai chi program
46089680|NCT04174794|Device|Lung ultrasound|The two different lung ultrasound protocols are performed initially within 48 hours of internal medicine ward admission by a pair of expert-beginner echographers. In case of admission during non-working days, the first scan can be done within 72 hours from admission. Follow-up scans are repeated 4 to 6 days later or on the day of discharge if it occurs before de fourth day. Experts and beginners execute the lund ultrasound protocols in sequence, reciprocally blinded, without accessing to clinical data files.
46089681|NCT00646152|Drug|Poly-ICLC|
46089682|NCT00647166|Drug|corticosteroid and azathioprine|"Corticosteroid 1 mg/kg/day with a conventional decrease dose~Azathioprine : 2 mg/kg/day during one year in 2 to 3 times a day by oral route"
46004662|NCT01780844|Drug|Mycophenolate Mofetil (MMF)|intravenous or oral
46004663|NCT01780844|Drug|Basiliximab|intravenous
46004664|NCT01780844|Drug|Methylprednisone|Intravenous
46004665|NCT01780844|Drug|Prednisone|Oral
46004666|NCT01779947|Drug|Estradiol Vaginal Tablets 10 mcg|
46004667|NCT01779947|Drug|placebo|
46004668|NCT00564408|Drug|Carbachol|3 microgram per kg bodyweight infused intravenously
46089683|NCT00647166|Drug|corticosteroid and placebo|"Corticosteroid 1 mg/kg/day with a conventional decrease dose~Placebo : 2 mg/kg/day during one year in 2 to 3 times a day by oral route"
46089684|NCT04174950|Other|Routine nursing care|routine perioperative nursing intervention, including intensive observation of vital signs, preoperative education, postoperative communication and instruction on diet. NPO after the dinner one day before operation. Patients are instructed to NPO 3 days after surgery and patients should stay on the bed for 3 days. Urinary catheter is always kept for 48 hours or more.
46089685|NCT04174950|Other|Perioperative Enhanced Recovery After Surgery (ERAS) Based Nursing Model|Establish ERAS nursing team and formulate ERAS nursing intervention. Nothing by mouth (NPO) 6 hours before operation and no water 4 hours before operation. Patients are given fluid food 24 hours after surgery. Urinary catheter is removed within 24 hours after surgery and encourage patient to mobile 24 hours after surgery. Give support to pain control and psychological support. Intensive observation of vital signs, preoperative education, postoperative communication and instruction on diet were also given to patients.
46089686|NCT02667522|Behavioral|Parent Child Interaction Therapy (PCIT)|PCIT includes 12-16 sessions across two phases: the first focused on enhancing positive parenting during child-directed interactions, and the second focused on reducing harsh parenting during parent-directed interactions. Parents receive feedback and coaching on their interactions with the child during sessions.
46089687|NCT00647244|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil 245 mg oral tablet once daily
46089688|NCT00647244|Drug|Abacavir|Abacavir 300 mg oral tablet twice daily
46089689|NCT00895583|Drug|Tacrolimus|During the screening phase, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is from transplantation until randomization (from 90 to 150 days).
46089690|NCT00895583|Drug|Sirolimus|Following randomization, sirolimus is provided by the Sponsor in 1 and 2 mg oral tablets. Sirolimus is dosed once daily to achieve a target trough level of 7 to 15 ng/mL in the 1st year post-transplant and 5 - 15 ng/mL in the 2nd year post-transplant. Duration of treatment is from randomization through 2 years post-transplant (19 to 21 months).
46089691|NCT00895583|Drug|Tacrolimus|During the study, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is 2 years post-transplant.
46004669|NCT01773785|Drug|SPI-1620|SPI-1620 11 μg/m2 will be given intravenously over 1 minute.
46089692|NCT02664792|Other|Use of [18f]FDG - PET/CT for the diagnosis and staging of non-small cell lung carcinoma|
46089693|NCT04760652|Behavioral|Cognitive Behavioral Therapy CBT|CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT
46089694|NCT00647322|Other|Reduction of anti-epileptic medications|Reduction in anti-epileptic medications
46089695|NCT00647322|Procedure|No drug change|No change in anti-epileptic treatment
46004670|NCT01773785|Drug|Docetaxel|Docetaxel 75 mg/m2 infusion will be administered per standard of care 10 (±2) minutes after SPI-1620.
46004671|NCT04608864|Procedure|varicocelectomy|microsurgical subinguinal varicocelectomy
46089696|NCT02666196|Drug|DAA-I|
46089697|NCT02666196|Drug|Placebo|
45677860|NCT05125952|Device|Viasys Avea Ventilator|Measuring dynamic airway driving pressure and static airway driving pressure during pressure support breath, and static airway driving pressure during a volume control breath. Measuring airway occlusion pressure during pressure support breath.
45677861|NCT05125952|Device|Philips Respironics NM3 device|Measuring static airway driving pressure during pressure support breath
45677862|NCT05125952|Device|Servo U ventilator|Measuring static airway driving pressure and p0.1 during pressure support breath.
45677863|NCT05125952|Device|Vyaire SmartCath adult nasogastric tube with Esophageal balloon|Measuring static and dynamic esophageal driving pressure during pressure support breath, and esophogeal pressure change during airway occlusion maneuver.
46004672|NCT01758458|Biological|Aldesleukin|Given SC
46004673|NCT01758458|Other|Laboratory Biomarker Analysis|Correlative studies
45677864|NCT01996982|Device|CCS Device|Core Cooling System Device
45677865|NCT01965158|Drug|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
46004674|NCT01758458|Biological|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
45677866|NCT01965158|Drug|Placebo|Placebo tablet taken orally once a day
45677867|NCT01964924|Drug|Akt Inhibitor GSK2141795|Given PO
45677868|NCT01964924|Other|Laboratory Biomarker Analysis|Correlative studies
45677869|NCT01964924|Drug|Trametinib|Given PO
46004675|NCT01758458|Radiation|Radiation Therapy|Undergo radiation therapy
46004676|NCT01758458|Biological|Recombinant Interferon Beta|Given intralesionally
46004677|NCT04608981|Drug|Prednisolone 30 mg|Steroidal anti-inflammatory drug as a preoperative medication
46004678|NCT04608981|Drug|Diclofenac Potassium 50mg Tab|Non-steroidal anti-inflammatory drug as a preoperative medication
46004679|NCT04608981|Drug|Placebo|Starch
45677870|NCT01964378|Drug|Cebranopadol|Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.
45677871|NCT01964378|Drug|Morphine Prolonged Release|Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.
45683791|NCT03574480|Behavioral|Intervention (training in use of a Smartphone application)|The intervention group will be added a training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary.
46004680|NCT04600557|Behavioral|Describing a shameful experience using a self-compassionate prompt|Participants will be instructed to describe a shameful experience to two confederates using a self-compassionate prompt
46004681|NCT04600557|Behavioral|Receiving compassionate responses from confederates|Following the participant's description of a shameful experience, two confederates will respond with compassionate responses
46089698|NCT04174872|Drug|Dexmedetomidine|it has a sedative effect without significant respiratory depression , anxiolytic, analgesic, antihypertensive and sympatholytic properties. It is now being used as a neuraxial adjuvant that can be used as an effective adjuvant in epidural anaesthesia as it intensifys the motor block and prolongs the duration of postoperative analgesia.
46004682|NCT04600557|Behavioral|Describing a shameful experience using a neutral prompt|Participants will be instructed to describe a shameful experience to two confederates using a neutral (i.e., not self-compassionate) prompt
46089699|NCT04174872|Drug|Midazolam|Midazolam has been reported to have a spinally mediated analgesic effect. Clinically, single-shot epidural or spinal administration of midazolam has been shown to have an analgesic effect on perioperative pain.
46089700|NCT02664714|Other|PFMT|Participating volunteers of all groups will receive guidance about the anatomy and function of the pelvic floor muscles (PFM) and how to perform a properly contraction: as strong as possible and eliminating at the most the contraction of the gluteus, abdominals and adductors. For all groups it will be used the same protocol which was developed for this study, with progression parameters of the PFMT based on the recommendations for the strength training of the American College of Sports Medicine (VICKI, 2001).
46089701|NCT02841137|Drug|Progesterone|comparison of different dosages of drug towards the active comparator
46089702|NCT00645606|Biological|Rituximab|rituximab :500 mg/m² every 8 weeks during 2 years
46089703|NCT02836847|Procedure|biological test|mutation and signal pathway activation status analysis
46089704|NCT02836847|Drug|GEMOX|Conventional chemotherapy:gemcitabine and oxaliplatin
46089705|NCT02836847|Drug|Cetuximab|
46089706|NCT02836847|Drug|Trastuzumab|
45459140|NCT05193422|Diagnostic Test|Cardiopulmonary exercise testing|"CPET using an ULTIMA CPX device (MGC Diagnostics, Saint Paul, MI, USA) with an ergometric bike (eBike, GE Healthcare, Wauwatosa, WI, USA). Participants will be asked to exercise (steady pedaling at 60 rpm) at 30% of their predicted maximum workload (Wmax) for 4 minutes, at 50% of Wmax for 2 minutes and at 70% of Wmax for 1 minute. Wmax will be calculated as 3 Watts/kg.~CPET will be performed in both study arms"
46089707|NCT02836847|Drug|Gefitinib|
46089708|NCT02836847|Drug|Lapatinib|
46004683|NCT04600557|Behavioral|Receiving no response from confederates|Following the participant's description of a shameful experience, two confederates will not be allowed to provide any verbal response
45459141|NCT05193422|Diagnostic Test|Discomfort level|"Discomfort assessment using a special scale graded from 1 to 10 (Fikenzer, 2020).~Both study arms, after CPET."
45459142|NCT03495622|Behavioral|Motivational Interviewing/Text messaging|"The intervention is a multi-component one that is tailored to the individual and will target smoking cessation. The CHW, after identifying the individual's stage of behavior change, will provide motivational interviewing and set up an automatic text messaging system with their mobile phones that are structured around a quit date chosen by the participant.~The CHW visits are pre-determined and she monitors the progress of the individual regularly. She may restart the process of determining the stage of behavior change for those who relapse or quit the intervention midway thereby reassigning them to the appropriate phase of the trial"
46004684|NCT01737905|Drug|Epinephrine HFA-MDI (E004)|Single dose 125 mcg/inhalation, 2 inhalations
46004685|NCT01737905|Drug|Placebo-HFA|Single dose 0 mcg/inhalation, 2 inhalations
46004686|NCT03454958|Other|Measurements of body composition|Body weight (SECA digital weighing scale), height (SECA stadiometer), body composition (TANITA Bioelectrical Impedance Analyzer & skin fold thickness measurements at the biceps, triceps, subscapular and suprailiac sites) and waist circumference (Cescorf measuring tape) will be objectively measured.
46004687|NCT01730768|Drug|AQW051|
46004688|NCT01730768|Drug|Placebo|
46089709|NCT02836847|Drug|Everolimus|
46089710|NCT02836847|Drug|Sorafenib|
46089711|NCT02836847|Drug|Crizotinib|
46089712|NCT02841059|Procedure|LSH|laparoscopic subtotal hysterectomy: LSH
46089713|NCT02841059|Procedure|CLSH|laparoscopic cervical ligament sparing hysterectomy: CLSH
46089714|NCT02841059|Procedure|LAVH|laparoscopic assisted vaginal hysterectomy: LAVH
46089715|NCT04172688|Dietary Supplement|Prebiotic oligofructose-enriched inulin|Synergy1
46004689|NCT04600245|Procedure|Evaluation of CARTOSOUND-FAM software for accurate three-dimensional reconstruction of the left atrium in patients referred for atrial fibrillation ablation.|One group will undergo the procedure with assistance from the CartoSound-FAM system and the other with the M-FAM system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Either CartoSound-FAM or M-FAM software systems alongside Carto Merge 3D reconstruction will be used during the treatment for atrial fibrillation. Data will be anonymized by removing patient protected health information, only initials will be used
46089716|NCT04172688|Dietary Supplement|Placebo maltodextrin|Equicaloric dose of maltodextrin
46089717|NCT02838953|Behavioral|Pulmonary Rehabilitation|Comprehensive intervention based on a thorough patient assessment followed by patient- tailored therapies that include, but are not limited to, exercise training, education, and behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviors.
46089718|NCT02664948|Procedure|Early geriatric follow-up after discharge|Multidisciplinary assessement and intervention by physician, nurse and physiotherapist
46089719|NCT02838875|Procedure|Blood samples|After birth - taking blood sample from the umbilical cord (arterial and venous) + blood sample from the patient.
46089720|NCT05333861|Drug|hetrombopag|According to prescription
46004690|NCT04608708|Other|The data of patients who had applied to the clinic for various reasons and were diagnosed with fibro-osseous lesions|lesions diagnosed radiologically and followed up for at least one year were included in this study with the help of cone beam computed tomography.
46089721|NCT04201379|Other|quality of life assesment|The sociodemographic and clinical characteristics of the individuals who meet the study criteria will be recorded. Evaluations of the participants will be done only once
46089722|NCT02666040|Device|ULTRAPRO® meshes|The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.
46004691|NCT01730027|Drug|ADC3680|ADC3680 for 12 weeks plus montelukast for the last 2 weeks of the dosing period
46089723|NCT02666040|Device|"Prolene® meshes"|The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.
46089724|NCT02666040|Procedure|Detecting the mode of admission to hospital|Ordinary admission or day surgery
46089725|NCT02666040|Procedure|Duration of surgery|Time operating room
46089726|NCT02666040|Procedure|Anesthesia volume and type used|Anesthesias used: infiltration, followed by spinal, general, epidural.
46004692|NCT01730027|Drug|Placebo|Placebo for 12 weeks plus montelukast for the last 2 weeks of the dosing period
46089727|NCT00894413|Drug|Tadalafil|20 mg once daily for 10 - 14 days
46089728|NCT00894413|Other|Placebo Pill|Placebo
46089729|NCT04173468|Other|Moblization with Movement|patients with group 1 will receive two techniques pertaining to MWM intervention (straight leg raised with traction and tibial Gliding) Repeat it 10 times,3 sets and 1 mint interval. .For Tibial Gliding we will asks the patient to perform 10 repetitive active knee extensions. Practice will be performed by doing 10 reps for 3 sets with 1 min interval. After this home exercises will b guided stretching of hamstrings 8 to 10 reps 20 sec hold, strengthening of Quadriceps and VMO with 10 reps and 3 sets
46089730|NCT04173468|Other|Mulligan knee taping|patient with group 2 will receive Mulligan taping technique. Tape will be applied for two days then we will change it. After this home based exercise will be guided which is stretching of hamstrings 8 to 10 reps 20 sec hold , strengthening of Quadriceps and VMO with 10 reps and 3 sets.
46089731|NCT04250519|Drug|Sodium Hypochlorite|Sodium hypochlorite is used as intracanal irrigant to minimize the post operative pain
46089732|NCT04173624|Diagnostic Test|Endosonography|Endosonography (EUS) is endoscopic method for evaluated pancreatic and biliary pathology.
46089733|NCT04173624|Diagnostic Test|Magnetic Resonance Cholangiopancreatography|Magnetic Resonance Cholangiopancreatography (MRCP) is non-invasive method for evaluating pancreatic and biliary pathology
46089734|NCT02836691|Device|EKG (electrocardiogram)|Analysis of the heart rate variability with an electrocardiogram with a commercial device adapted to asthmatic patients using 12 leads, a respiratory band and a pulseoximeter.
46089735|NCT02836535|Behavioral|qualitative interviews|
46089736|NCT04172298|Other|sham electroacupuncture (EA) session|The stainless steels acupuncture needles inserted into the subcutaneous layer of Zusanli (cathode) and Shangjuxu acupints (anion) , and the needles connected to EA stimulator, but no electric discharge for 30 min.
46004693|NCT01730027|Drug|montelukast|montelukast for 12 weeks
46004694|NCT04600284|Drug|AD-2101|AD-2101 16/5mg
46089737|NCT04172298|Other|Zusanli session|The acupuncture needles inserted into Zusanli (cathode) and Shangjuxu acupoints (anion), and twisting obtain qi, and the needles then connected to EA stimulator, the frequency was 2 Hz, the duration was 30 min, and the intensity was visual slightly muscle contraction.
46089738|NCT04172298|Other|Shaohai session|The methods were identical Zusanli group, but Shaohai acupoint (cathode), and 3 cm below Shaohai (anion).
46089739|NCT04172376|Procedure|Minimally invasive puncture aspiration plus rt-PA|Stereotactic puncture aspiration to evacuate basal ganglion hematoma with use of thrombolytic agent
46089740|NCT04172376|Drug|Conservative medical treatment|Drugs for symptomatic treatment such as hemostasis and nerve nourishing.
46089741|NCT05334407|Procedure|Implant-supported full-arch fixed dental prostheses（dental intervention,DE）|Implant-supported full-arch fixed dental prostheses in at least one jaw and appropriate treatment in the opposing jaw regarding periodontal diseases, caries, replacement of missing teeth and soft tissue disorders to get at least 10 pairs of occluding teeth. The intervention is designed to provide rehabilitation of masticatory function.
46089742|NCT05334407|Behavioral|Dietary intervention tailored to the dental status (dietary intervention, DI)|"Dietary intervention based on the health Belief Model (HBM) with the behavioral goal of increasing an individual's likelihood of food intake regarding fresh vegetables, fresh fruits, and high quality protein for the potential intervention strategies.~Participants will receive 20 minutes' coordinated dietary advice in the form of the slideshow presentation . A pamphlet prepared with reference to the Supplementary Guidelines for Elderly Populations, the 4th edition of the Dietary Guidelines for Chinese will be given to the participant separately. If a participant does not prepare his or her own meals, the person who does the cooking receives the dietary advice as well."
46089743|NCT05334407|Procedure|Delayed implant-supported full-arch fixed dental prostheses（dental intervention,DE）|Delayed (4 months) implant-supported full-arch fixed dental prostheses in at least one jaw and appropriate treatment in the opposing jaw regarding periodontal diseases, caries, replacement of missing teeth and soft tissue disorders to get at least 10 pairs of occluding teeth. The intervention is designed to provide rehabilitation of masticatory function.
46089744|NCT05334407|Behavioral|Delayed dietary intervention tailored to the dental status (dietary intervention, DI)|"Dietary intervention based on the health Belief Model (HBM) with the behavioral goal of increasing an individual's likelihood of food intake regarding fresh vegetables, fresh fruits, and high quality protein for the potential intervention strategies.~Participants will receive 20 minutes' coordinated dietary advice in the form of the slideshow presentation . A pamphlet prepared with reference to the Supplementary Guidelines for Elderly Populations, the 4th edition of the Dietary Guidelines for Chinese will be given to the participant separately. If a participant does not prepare his or her own meals, the person who does the cooking receives the dietary advice as well."
45342436|NCT00709488|Device|Transurethral illumination with light emitting diodes (Litx™ BPH Device)|Patients in Cohort A will receive 50 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort B will receive 70 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort C will receive 100 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort D will receive 100 J of light treatment (with the active light emitting length increased from 10mm to 20 mm) with 1 mg/kg LS11 administration.
45342437|NCT00714246|Drug|Bortezomib|Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
46004695|NCT04600284|Drug|AD-2102|AD-2102 25mg
46004696|NCT04600284|Drug|AD-2101 + AD-2102|AD-2101 16/5mg + AD-2102 25mg
46004697|NCT01715012|Biological|ST266|ST266 is applied daily by spray to burn wound and skin graft donor site
46004698|NCT01715012|Drug|Saline|Saline is applied daily by spray to burn wound and skin graft donor site
46004699|NCT04600401|Other|Mentis Plus+ (Experimental Group)|"Each factor can be considered a module, so it is a modular program. So, each module has 3 sessions to be carried out in full. It is a systematic program, so the order of the sessions is regulated by the letters A, B and C for each module. The modules to be worked on correspond to the low-level or languising factors identified after the application of the positive mental health questionnaire (PMHQ). After the application of the PMHQ, people are grouped with the same module to work."
46004700|NCT04600440|Biological|Convalescent plasma|Plasma donated from patients recovered from Covid-19 and having high titres of antibodies
46004701|NCT00555191|Behavioral|diet restriction|each meal should contain less than 2 gm fructose
46089745|NCT04172220|Drug|Midazolam|1-2 mg of Midazolam as premedication.
46089746|NCT04172220|Procedure|PECS|"Loco-regional anesthesia: PEC I and serratus plane block with an echoguided technique.~For the PEC I: infiltration of 10 ml of local anesthetic (Levobupivacaine 0.25% or Ropivacaine 0.5%) between the bands of the pectoralis major muscle and the small pectoralis muscle at the height of the third rib on the anterior axillary line.~For the serratus plane block: identification of the fifth rib on the average axillary line and infusion of about 20 ml of local anesthetic (Levobupivacaine 0.25% or Ropivacaine 0.5%) between the bands of large dorsal muscle and of the anterior serratus muscle."
46004702|NCT04608669|Drug|Paracetamol|Give paracetamol or placebo and compare temperature
46089747|NCT04172220|Procedure|Opioid-free general anesthesia|"Induction with Propofol 1.5-2 mg/kg; laryngeal mask for airway management after eventual administration of Rocuronium 0.6 mg/kg. Anesthesia will be maintained with Propofol in Target-Controlled Infusion (TCI) of 6 mcg/ml, subsequently modified to maintain a Bispectral Index (BIS) value between 40 and 60.~Fentanyl 50ug in bolus IV, in case of mean arterial pressure or heart rate increase >20%.~In case of hypotension: 5mg ephedrine and infusion of 250 ml Lactated Ringer."
46089748|NCT04172220|Procedure|General anesthesia|"Induction with Propofol 1.5-2 mg/kg; Fentanyl 1μg/kg; laryngeal mask for airway management after eventual administration of Rocuronium 0.6 mg/kg. Anesthesia will be maintained with Propofol in TCI of 6 mcg/ml, subsequently modified to maintain a BIS value between 40 and 60.~Fentanyl 50ug in bolus IV, in case of mean arterial pressure or heart rate increase >20%.~In case of hypotension: 5mg ephedrine and infusion of 250 ml Lactated Ringer."
46089749|NCT04172220|Procedure|Postoperative analgesia|Paracetamol 1000 mg every 8 hours for the first 24 hours, Ketorolac 30 mg in case of pain control failure (Numeric Rating Scale- NRS>4) which can be administered every 8 hours at most (max 90 mg / 24 hours), Morphine 10-20 mg IV in 24 hours as rescue analgesia.
46089750|NCT02840903|Drug|Iopromide (Ultravist, BAY86-4877)|8 settings for CT Angiography as described in group description.
46089751|NCT02664636|Procedure|Physiotherapy|"Physiotherapy regimen (days 0 to 60): orthopedic maintenance, work on trunk balance, sensorimotor techniques for restoration of motor skills, exercises for standing balance and walking. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. They occur as daily sessions during the first two weeks and then two sessions / day.~This is part of routine care."
46089752|NCT02664636|Procedure|Occupational therapy|"Occupational Therapy (days 0 to 60): Orthopaedic maintenance, exercises for sitting and standing balance, sensorimotor techniques for the restoration of motor skills, grip exercises. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. 1 session is performed per day.~This is part of routine care."
46089753|NCT02664636|Procedure|Functional near-infrared spectroscopy|During the therapy protocol, cortical activation measures using the fNIRS method will be conducted every 15 days (at Day0, Day 15, Day 30, Day 45 and Day 60 for 5 sessions in total) at the technical platform of the Grau du Roi physical therapy centre, during the completion of a standardized motor task (maintaining a level of force) using the healthy upper limb and the paretic upper limb.
45459143|NCT03495544|Diagnostic Test|PD-L1 expression|IHC testing of PD-L1 expression level in tumor tissue samples
46089754|NCT02665806|Drug|Ciclesonide|intranasal ciclesonide spray 200 µg once daily
46089755|NCT02665806|Drug|Fluticasone|fluticasone propionate aqueous nasal spray 200 µg twice a day
46089756|NCT04066140|Other|No intervention|No Intervention. Observational Study.
46089757|NCT02665884|Other|Intraocular Pressure Measurement|Diurnal fluctuations of intraocular pressure will be measured and compared
45459144|NCT05216510|Biological|TNX-2110|TNX-2110 represents epitopes of multiple proteins from SARS-CoV-2 and is administered intradermally.
46004703|NCT00555230|Drug|Rosuvastatin|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
46004704|NCT00555230|Drug|Placebo|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
46004705|NCT01711346|Biological|S303 Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled S303 Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
46004706|NCT01711346|Biological|Conventional, untreated Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled Conventional, untreated Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
46004707|NCT01710644|Drug|Burlulipase|Burlulipase oral solution will be taken with meals and snacks for 5 to 7 days
45342438|NCT00714246|Drug|Carboplatin|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
45342439|NCT00714246|Drug|Docetaxel|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
45342440|NCT04071288|Procedure|total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes|total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes; Burch colposuspension and mid-urethral sling operations for stress urinary incontinence
45342441|NCT02574546|Procedure|Mastectomy|Unilateral breast cancers planning bilateral mastectomy procedures.
45342442|NCT00416455|Radiation|fludeoxyglucose F 18|Undergo FDG PET/CT
45342443|NCT00416455|Procedure|positron emission tomography|Undergo FDG PET/CT
45342444|NCT00416455|Procedure|computed tomography|Undergo FDG PET/CT
46089758|NCT00645684|Procedure|Gastrointestinal Anastomosis|Gastrointestinal Anastomosis with synthetic, absorbable, coated suture material using two different suture-techniques
46089759|NCT02665962|Other|Perioperative Caloric Restriction Program|
46089760|NCT00646386|Drug|adalimumab|40 mg eow Week 0 - Week 24
46089761|NCT00646386|Drug|placebo for adalimumab|40 mg eow Week 0 - Week 24
46089762|NCT00647634|Drug|Alprazolam Extended-Release Tablets 3 mg|3mg, single dose fasting
45459145|NCT05216510|Biological|TNX-2120|TNX-2120 represents the spike protein and is administered intradermally.
46089763|NCT00647634|Drug|Xanax XR® Tablets (3 mg|3mg, single dose fasting
46089764|NCT04172064|Diagnostic Test|Myocardial perfusion scintigraphy|
45342445|NCT00416455|Drug|ferumoxtran-10|Undergo femoxtran-10 MRI
45342446|NCT00416455|Procedure|magnetic resonance imaging|Undergo femoxtran-10 MRI
46089765|NCT00647712|Drug|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fasting
45459146|NCT05216510|Biological|TNX-2130|TNX-2130 represents non-spike proteins and is administered intradermally.
45459147|NCT05216510|Biological|CANDIN|Candida albicans antigens to be administered intradermally as a positive control.
45459148|NCT05216510|Biological|Diluent|Diluent consists of phosphate buffer, polysorbate 20 and mannitol and will be administered intradermally as a negative control.
46004708|NCT01710644|Drug|Placebo (Caramel in sterile water)|Placebo will be taken with meals and snacks for 5 to 7 days
46089766|NCT00647712|Drug|Depakote ER® Tablets 500 mg|500mg, single dose fasting
46089767|NCT02667210|Other|Medical Record Review|Medical Record Review of Behaviors Suggestive of Misuse, Diversion, Abuse and/or Addiction
46089768|NCT02537106|Procedure|1.5% NaCl|After the infusion of 1.5% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
46089769|NCT02537106|Procedure|3% NaCl|After the infusion of 3% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
46089770|NCT00647790|Procedure|PET scan with injection of 5-8 mCi of 18FES|Following injection of the tracer 18FES, dynamic images will be obtained for 30 minutes over the chest area to include cardiac region and breasts. Following the first dynamic imaging for 30 minutes, whole body images (base of skull to pelvis) will be obtained at 5 minute/bed position. An additional, longer scan after 60 minutes will be obtained for the chest (1-2-FOV for 15 minutes each). Total time from injection to completion of imaging will be about 90 minutes.
46089771|NCT04173390|Drug|Pregabalin 150mg|Preemptive use of pregabalin 150 mg starting three days before surgery up to the third postoperative day
46089772|NCT04173390|Drug|Placebo oral tablet|Preemptive use of Placebo oral tablet starting three days before surgery up to the third postoperative day
46089773|NCT02667366|Behavioral|Tel-PT|
46089774|NCT02667366|Behavioral|TAU and text messages|
46089775|NCT04895202|Other|Siponimod|Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod as by swiss label, that have started before inclusion of the patient into the study will be enrolled.
46089776|NCT02665650|Biological|AFM13|
46089777|NCT02665650|Biological|Pembrolizumab|
46089778|NCT04173234|Other|Aerobic Training|Aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 50 minutes total duration consisting of 10 min warm up and 10 min cool down period to children in treatment group.
46089779|NCT04173234|Other|Home exercise program|Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
46089780|NCT02665572|Behavioral|bladder recycling|Bladder recycling will be done by the patient after proper education. It will be started by the instillation of the sterile water in the bladder in amount equal to the estimated bladder capacity. Then the amount will be gradually increased till the patient can withstand filling the bladder with 300 cc of sterile water for 2 hours.
46089781|NCT00647868|Drug|testosterone|Intranasal testosterone, 7.6 mg (3.8 mg in each nostril) per application
45459149|NCT03495466|Procedure|Local only anesthesia vs Local with sedation anesthesia|The investigators are comparing two approved sedation types that are using during carpal tunnel surgery.
45473929|NCT01175837|Other|questionnaire administration|Ancillary studies: Pre- and post-fasting side effect questionnaires
45473930|NCT01175837|Other|preventative dietary intervention|24, 36, or 48 hour fast prior to chemotherapy
45473931|NCT01175837|Other|laboratory biomarker analysis|Correlative studies
46004709|NCT04608942|Device|Jett Plasma Medical Lift|Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
46004710|NCT04608942|Procedure|Mechanical Debridement|Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
46089782|NCT00647946|Drug|tenofovir DF|tenofovir DF 300mg once daily along with the other antiviral drugs
45342447|NCT00416455|Procedure|diagnostic lymphadenectomy|Undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy
45342448|NCT00416455|Procedure|lymph node biopsy|Undergo pelvic and abdominal lymph node biopsy
46004711|NCT04600089|Drug|Saline|Saline infusion
46004712|NCT04600089|Drug|Ketamine|Continuous ketamine infusion at a dose of 0.2 mg/kg/hr, initiated at the induction of anesthesia and continued for 48 hours postoperatively.
45342449|NCT04071210|Dietary Supplement|Probiotic tablet|Probiotic tablet twice a day for 12 weeks
45342450|NCT04071210|Dietary Supplement|Placebo tablet|Placebo tablet twice a day for 12 weeks
46004713|NCT01704365|Biological|Low dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
46089783|NCT00647946|Drug|abacavir 300mg twice daily|abacavir 300mg twice daily along with the other antiviral drugs
46089784|NCT02664480|Other|Salivary alpha-Amylases|Investigators will collect Salivary alpha-Amylases before and after ovulation
46089785|NCT04171986|Drug|Mecapegfilgrastim|Mecapegfilgrastim; 6 mg, d7, q3w, total 2 cycles.
46089786|NCT02664246|Device|percutaneous coronary intervention|
46089787|NCT04171596|Behavioral|Primary care coordination|"A registered nurse currently employed at Duke Integrative Medicine, who is also trained as an integrative health coach, will serve in the PCC role. The intervention will flow as follows:~The PCC will call study participants every 2 months during the 6 months (more frequently as needed) for a semi-structured phone check-in, and will track the intervention through the REDCap database. The PCC will use guiding questions to frame the call, but will also:~Respond Ask follow-up questions Provide suggestions that are guided by the patient response and appropriateness to the individual situation and needs and scope of practice.~Prior to the call, the PCC will review the patient chart to see if any outstanding orders, medical visits due, and review the patient health goals (known as the pre-work).~The PCC will call the patient to provide intervention. If patient is not available, the PCC will leave a message, or contact via MyChart to see about scheduling a time to talk."
46004714|NCT01704365|Biological|Low dose RSV-F Vaccine without Adjuvant|0.5ml IM Injection
46089788|NCT00648024|Drug|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fasting
46089789|NCT00648024|Drug|Agrylin® Capsules 1 mg|1mg, single dose fasting
46004715|NCT01704365|Biological|High dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
46004716|NCT01704365|Biological|High dose RSV-F Vaccine without Adjuvant|0.5mL IM Injection
46004717|NCT01704365|Biological|Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing]|0.5mL IM Injection
46004718|NCT01704365|Biological|Placebo|0.5mL IM Injection
46004719|NCT04600206|Other|Self-report questionnaires|"In this longitudinal cohort study, patients and caregivers will not receive an intervention. In addition to the outcomes named in the section Outcome Measures patients and caregivers will complete self-report questionnaires for~Existential distress (Demoralization Scale-II, Death and Dying Distress Scale, Depressive Experiences Questionnaire, Revised Loss Orientation and Life Engagement in Advanced Cancer Scale, Sense of Dignity Item, Patient Dignity Inventory, Marwit-Meuser Caregiver Grief Inventory, Caregiver Guilt Questionnaire)~Need for and utilization of psychosocial support~Resources (Sources of Meaning and Meaning in Life Questionnaire, Questionnaire on the Defiant Power of the Human Spirit) and~Control variables (Memorial Symptom Assessment Scale, PHQ-9 and GAD-7)"
46004720|NCT04600011|Other|Physical and occupational therapy (PT/OT)|"Neurologic-specialized and -certified physical and occupational therapists will provide each participant with an initial in-person PT/OT evaluation/treatment session with oversight from a Movement Disorders Neurologist, followed by 4 virtual home visits with tele-PT/OT and care partner supervision every 2 weeks, and culminating with a final in-person evaluation, all with a focus on personalized training in core areas contributing to a patient's individual fall risk, much like in-person visits. Virtual home safety surveillance with the mobile virtual platform is an additional feature of this intervention that aims to optimize the home environment to reduce external factors contributing to fall risk."
46004721|NCT04600011|Other|Home Safety Evaluation (HSE)|The VIRTUAL HOME SAFETY EVALUTIONS (HSE)-ONLY ARM where participants ONLY receive the virtual home safety evaluations and surveillance that are built into the original protocol of three of the four tele-OT visits that is being used in Arm 1. The study duration for Arm 2 is about 6 weeks of the primary intervention as described with 3-month and 6-month follow-up calls. The mobile virtual platform for Arm 2 is comprised of a tablet OR smartphone that will be guided through the home by the care partner only and not the patient.
46004722|NCT01698281|Drug|AEZS-108|"AEZS-108 (267 mg/m2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle. Allowed delay of re-treatment: up to 2 weeks.~Dose reduction: to 210 mg/m2 and 160 mg/m2, if dose limiting toxicity."
45677872|NCT01442038|Drug|Ranolazine|"Subjects will receive ranolazine 500 milligrams (mg) twice daily for 7 days, followed by 1000 mg administered orally twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
46089790|NCT04171830|Other|modified Hospital One-year Mortality Risk (mHOMR)|"Every inpatient will automatically be given the intervention (an mHOMR/HOMR Now! score) upon admission to hospital and considered for secondary interventions based on their score. Baseline threshold will be set as >0.21 (59% sensitivity and 90% specificity for 12-month mortality with mHOMR).~At minimum each individual identified by the tool will receive two assessments to screen for severe symptoms and desire to engage in advance care planning (ACP):~Edmonton Symptom Assessment System Revised: scores >6 will be flagged as severe. Clinical teams will address the symptoms as appropriate for the patient.~4-item Advanced Care Planning Engagement Survey: Scores of 3-4 indicate readiness to discuss ACP. Clinical teams may choose to discuss ACP and goals of care themselves, activate a local ACP intervention, or distribute ACP documentation.~Both of these assessments will be done by a member of the treating team within 72 hours of the patient's hospital admission."
46089791|NCT00648102|Biological|CDX-1307|
46089792|NCT02665416|Drug|Selicrelumab|Selicrelumab will be provided as concentrate for solution to be administered via SC injection
46089793|NCT02665416|Drug|Vanucizumab|Vanucizumab will be provided as solution to be administered via IV infusion.
46089794|NCT02665416|Drug|Bevacizumab|Bevacizumab will be administered via IV infusion.
46004723|NCT01698281|Drug|SCCC|"commercially available SSCC (doses below the recommended package insert at the discretion of treating oncologist), on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle).~Drugs considered acceptable as SSCC: paclitaxel; nab-paclitaxel; eribulin; pegylated liposomal doxorubicin (PLD); vinorelbine; gemcitabine; capecitabine.~Related to PLD: Per notification from EMA (dated 22-Nov-2011) no new patients should be started on treatment with Caelyx until further notice. Accordingly, this drug may be selected as SSCC treatment option only after such written notice is available."
46089795|NCT00646620|Drug|budesonide/formoterol (Symbicort)|
46089796|NCT00646620|Drug|fluticasone/salmeterol (Advair Diskus)|
46004724|NCT01698281|Drug|Dexamethasone|Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone.
46089797|NCT00646620|Drug|albuterol (Ventolin)|
46089798|NCT04173078|Behavioral|Computerized Distress Intolerance Intervention|
46089799|NCT04173078|Behavioral|Computerized Healthy Behaviors Intervention|
46089800|NCT02665104|Device|transcranial Doppler (TCD) and INVOS monitor|Bilateral transcranial Doppler measurements of the blood flow velocity within the middle cerebral arteries: 1. before local anesthesia, 2. after the onset of local anesthetic, but before skin incision, 3. intraoperatively before clamping the internal carotid artery, 4. one minute after clamping the internal carotid artery, 5. five minutes after clamping the internal carotid artery, 6. fifteen minutes after clamping the internal carotid artery, 7. directly after the restoration of blood flow in the internal carotid artery, 8. postoperatively, 4-6 hours after the intervention.
46089801|NCT04064580|Other|diagnostic test|performing a capnography examination
46089802|NCT00648180|Drug|Doxycycline Monohydrate Tablets 100 mg|100mg, single dose fed
46089803|NCT00648180|Drug|Adoxa Tablets 100 mg|100mg, single dose fed
46089804|NCT02664168|Device|Aquacel Ag Surgical Dressing|
46089805|NCT02664168|Device|Single-Use Negative Pressure Wound Therapy (PICO)|
46089806|NCT00648492|Drug|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
46089807|NCT00648492|Drug|Glucophage® XR 500 mg|500mg, single dose fed
46004725|NCT04676360|Drug|Belantamab Mafodotin|Belantamab mafodotin will be administered intravenously at calculated dose on day 1 of each 21-day cycle.
46089808|NCT04174248|Other|BCSMS App|Breast Cancer Using a Self-Management Support mHealth Application
46089809|NCT04645446|Drug|Pro-ocular gel|Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
46089810|NCT04645446|Drug|Placebo gel|Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
46004726|NCT00565461|Biological|heat-labile enterotoxin of E. coli (LT)|37.5ug patch applied on either the deltoid or the thigh
46004727|NCT01858883|Drug|itacitinib|
46004728|NCT01858883|Drug|Gemcitabine|
46089811|NCT04632732|Diagnostic Test|COVID-19 test|Nasal pharyngeal swab
46089812|NCT04632732|Diagnostic Test|Blood sampling|20cc of blood will be collected each 7 days during 28 days.
46089813|NCT02663778|Behavioral|Strength training|weight lifting to increase muscle strength
45459150|NCT05054452|Device|Echocardiographic assessment|At baseline before standardized volume expansion, a first set of echocardiographic measurements will be performed. Then, we will perform 15-second end-expiratory and end-inspiratory occlusions. Occlusions will be separated by 1 minute to allow the cardiac index to return to its baseline value. A last set of measurements will be performed after fluid administration. Ventilatory settings and other treatments will remain unchanged during the study period.
45459151|NCT01372826|Drug|NKTR118 Group1|Oral dose, 25 mg
45459152|NCT01372826|Drug|NKTR118 Group 2|Oral dose, 25 mg
46089814|NCT02663778|Behavioral|Endurance training|treadmill walking to increase endurance
46089815|NCT02663778|Behavioral|Flexibility training|stretches to improve flexibility
46089816|NCT02663778|Behavioral|Task Specific timing and coordination training|stepping and walking patterns to improve timing and coordination of gait
46089817|NCT02663778|Behavioral|Physical activity behavioral intervention|Intervention to encourage participants to be more physically active
46089818|NCT00648570|Drug|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fasting
46089819|NCT00648570|Drug|Lexapro® Tablets (20 mg|20mg, single dose fasting
46089820|NCT04664556|Other|observational study|observational study
46089821|NCT00648258|Drug|valdecoxib|valdecoxib 10 mg tablet by mouth once daily for 6 weeks
46089822|NCT00648258|Drug|naproxen|naproxen 500 mg capsule by mouth twice daily for 6 weeks
46089823|NCT00648336|Drug|Mercaptopurine 50 mg|50mg, single dose fasting
46089824|NCT00648336|Drug|Purinethol® Tablets 50 mg|50mg, single dose fasting
46089825|NCT04650984|Drug|Onfekafusp alfa|Patients will receive a fixed dose of L19TNF in combination with a fixed dose of doxorubicin.
46004729|NCT01858883|Drug|nab-paclitaxel|
46004730|NCT01858883|Drug|filgrastim|
46089826|NCT04650984|Drug|Doxorubicin|Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
46089827|NCT02663934|Behavioral|Exercise|The resistance exercise training component will follow aerobic exercise and will consist of 4 upper and 3 lower body routines. A combination of guided-motion machines and free weights will be used. Voluntary maximum strength will be measured during the first 4 sessions on each exercise station. The program will initially consist of 1-2 sets of each exercise while lifting a weight that causes muscle fatigue after 8-10 repetitions. The trainer will monitor each participant's exercise response, and when the participant can comfortably lift the weight for 12 repetitions on any exercise, the weight will be increased to cause the muscle group to fatigue after 8 repetitions. This progressive 8-12 repetition cycle is repeated for each exercise over 26 weeks.
46089828|NCT02663934|Behavioral|Stretching and Social Interaction|Participants will receive instructions on stretching, range of motion, limbering, and toning. Activities will focus on flexibility enhancement. Along with the stretching and flexibility, this group will have a social interaction component. They will have discussions and interact with trainers and coordinators during all their sessions. These participants will be supervised by the same trainer and will receive the same amount of attention and class interaction as participants in the EXS program.
46089829|NCT00648414|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1|blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow, while samples collected
46089830|NCT00648414|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2|tourniquet applied just below patch application site and above blood draw site, while samples collected
46089831|NCT00648414|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3|tourniquet applied just above patch application site, while samples collected
46089832|NCT00648414|Drug|Duragesic 25 mcg/h + Clinical Procedure 1|blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
46089833|NCT00648414|Drug|Duragesic 25 mcg/h + Clinical Procedure 2|tourniquet applied just below patch application site and above blood draw site, while samples collected
46089834|NCT00648414|Drug|Duragesic 25 mcg/h + Clinical Procedure 3|tourniquet applied just above patch application site, while samples collected
46089835|NCT04171752|Drug|elafibranor|elafibranor 120mg is a coated tablet for oral administration
45459153|NCT01372826|Drug|NKTR118 Group3|Oral dose, 25 mg
45459154|NCT01372826|Drug|NKTR118|Oral dose, 25 mg
45677873|NCT01442038|Drug|Placebo|"Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
46004731|NCT01697072|Drug|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
46004732|NCT01697072|Other|Placebo|Placebo
46004733|NCT01697072|Drug|Epirubicin|Epirubicin is an anthracycline cytotoxic agent.
46004734|NCT01697072|Drug|Cisplatin|Cisplatin is a non-cell cycle specific chemotherapeutic agent.
46004735|NCT01697072|Drug|Capecitabine|Capecitabine is an oral fluoropyrimidine.
46004736|NCT00565500|Drug|celecoxib|celecoxib capsules 200 mg bid for 1 week
46004737|NCT00565500|Drug|ibuprofen|ibuprofen tablets 600 mg tid for 1 week
46089836|NCT02666976|Drug|Ilaprazole|Patients who were diagnosed clinically as NERD and were treated with ilaprazole 20mg once daily for 4 weeks. Biopsies were obtained from 3cm above the EG junction before and after treatment. GERD Q questionnaire, histologic findings (basal cell hyperplasia, papillary elongation, dilated intercellular spaces, intraepithelial eosinophils and intraepithelial T lymphocyte) and inflammatory biomarkers (TNF-α, IL-8, IL-1β, TRPV1 and MCP-1) were accessed.
46089837|NCT04546308|Other|Resistance exercise training|Eight weeks whole-body resistance exercise training (80%1 repetition maximal, 3 sessions per week) followed by a 4-week detraining intervention
45342451|NCT00415909|Drug|Imatinib Mesylate (IM)|IM Therapy of (100 mg or 400 mg) tablets by mouth, same dose each day.
46004738|NCT00565500|Drug|placebo|placebo capsules tid for 1 week
46004739|NCT04608162|Other|Pulsed Electromagnetic Field (PEMF)|PEMF was administered to the whole body using a 1.8×0.6m mat
46004740|NCT04608162|Other|Exercise Program|Exercise program to facilitate bone health
46004741|NCT04608162|Other|Placebo PEMF|Patients received placebo PEMF
46004742|NCT04608084|Biological|Autologous platelet rich plasma eye drops|Participant own blood is used for the preparation of Autologous platelet rich plasma eye drops
46004743|NCT04600050|Other|usual care and exercise education|Provide exercise training materials after the education of exercise and health to enable home-based exercise
46089838|NCT04171362|Other|Connective Tissue Massage|Connective tissue massage (CTM) is a manipulative technique that facilitates the diagnosis and treatment of a wide range of pathologies. Observation and subsequent manipulation of the skin and subcutaneous tissues can have a beneficial effect upon tissues remote from the area of treatment.
45677874|NCT01998919|Drug|erlotinib [Tarceva]|150 mg orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by 150 mg orally daily
46089839|NCT04171362|Other|Education|Education patients were informed about migraine triggers, migraine prevention and coping strategies and exercise options. The exercises were demonstrated by the physiotherapist
46004744|NCT04600050|Other|Eccentric exercise|Under the face-to-face supervisor, the eccentric exercise using a flywheel, and the self-directed home-based eccentric overload exercise using an elastic band are performed.
46089840|NCT02663700|Drug|Artesunate|Four tablets of 50mg each, totaling 200mg will be given in a single calendar day
46089841|NCT02663700|Biological|PfSPZ Vaccine|PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
46089842|NCT02663700|Other|Placebo|Placebo
46089843|NCT00648726|Drug|cefuroxime plus erythromycin|intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days plus erythromycin ethylsuccinate 0.5 g twice daily, which was given for a total duration of 14 days for subjects with suspected pneumonia due to atypical pathogens
46089844|NCT00648726|Drug|azithromycin (Zithromax)|intravenous azithromycin 500 mg once daily for 4 +/-1 days, followed by oral azithromycin 500 mg once daily for a total duration of 9 +/-1 days
46089845|NCT00648726|Drug|cefuroxime|intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days
46089846|NCT04171674|Drug|Treatment with high-dose ceftobiprole (500mg loading dose followed by 2.5g under continuos infusion).|High-dose ceftobiprole (500mg loading dose) will be administered to patients for 30 minutes followed by 2.5g under continuous infusion for 24 hours.
46089847|NCT00648804|Drug|Ondansetron Orally Disintegrating Tablets 8 mg|8mg, single dose fed
46089848|NCT00648804|Drug|Zofran ODT® Tablets 8 mg|8mg, single dose fed
46089849|NCT02663856|Other|observational|Self assessment of ageing transition using a frailty index through MySAwH app
46089850|NCT02664012|Other|Own Brand Menthol Cigarette|combustible menthol cigarette brand style smoked most frequently by subject
46089851|NCT02664012|Other|Electronic Menthol Cigarette #1|VUSE® Digital Vapor Cigarette (menthol flavor, 14 mg nicotine)
46089852|NCT02664012|Other|Electronic Menthol Cigarette #2|VUSE® Digital Vapor Cigarette (menthol flavor, 29 mg nicotine)
46089853|NCT02664012|Other|Electronic Menthol Cigarette #3|VUSE® Digital Vapor Cigarette (menthol flavor, 36 mg nicotine)
46089854|NCT02664012|Other|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
45677875|NCT01998919|Drug|placebo|orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by daily oral application
45677876|NCT01998919|Drug|gemcitabine|1250 mg/m2 iv Days 1 and 8 of each 4-week cycle, 6 cycles
45677877|NCT01998919|Drug|cisplatin|75 mg/m2 iv Day 1 of each 4.wek cycle, 6 cycles; or carboplatin
46004745|NCT01691846|Drug|aleglitazar+metformin|150 mcg aleglitazar given orally once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
46004746|NCT01691846|Drug|placebo+metformin|Oral doses of matching placebo once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
46004747|NCT04599543|Drug|IL3 CAR T-cells|Each subject receive IL3 CAR T-cells by intravenous infusion
46004748|NCT01670981|Biological|ixmyelocel-T|12-20 transendocardial injections of 0.4 mL of ixmyelocel-T per injection into the left ventricle.
46004749|NCT01670981|Other|Placebo|12-20 transendocardial injections of 0.4 mL of vehicle control per injection into the left ventricle.
46004750|NCT01658501|Drug|50 mg PB1023|
46004751|NCT01658501|Drug|70 mg PB1023|
46089855|NCT00895037|Drug|ReFacto AF (Moroctocog alfa)|Patients will be treated with intravenous infusion of ReFacto AF per dosing and frequency as prescribed by the subjects' treating physician. ReFacto AF® will be prescribed in the context of routine clinical practice in Germany and Austria, respectively
46089856|NCT04170504|Drug|Qing Re Huo Xue (QRHX)|Qing Re Huo Xue (QRHX) XXmg bid for 24 weeks
46089857|NCT04170504|Drug|Methotrexate|Oral methotrexate 10 mg per week for 24 weeks.
46089858|NCT04170504|Drug|dummy Qing Re Huo Xue (QRHX)|dummy Qing Re Huo Xue (QRHX) XXmg bid for 24 weeks
46089859|NCT04170114|Other|Comprehensive Respiratory Physiotherapy|"All patients will receive comprehensive respiratory physiotherapy training by the physiotherapist. All patients will undergo comprehensive respiratory physiotherapy techniques twice daily for 8 weeks.~Comprehensive respiratory physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control."
45677878|NCT01998919|Drug|carboplatin|5 x AUC iv Day 1 of each 4.week cycle, 6 cycles; or cisplatin
46004752|NCT01658501|Drug|100 mg PB1023|
46004753|NCT01658501|Drug|Placebo (0.9% Sodium Chloride)|
46004754|NCT01658501|Drug|Victoza®|
46004755|NCT01658501|Other|Diet and Exercise|
46089860|NCT02836301|Behavioral|Control ending - Uplifting|The control ending is emotionally uplifting. In this video, the decedent previously registered as an organ donor through online registration and discussed his decision with family. The scene cuts to the family affirming the deceased's wish. In the next scene, the donor family and recipient meet for the first time, ending with a plea from both parties for viewers to register for donation.
46089861|NCT02836301|Behavioral|Negative Consequences Ending|A sad ending where the decedent did not register or discuss their position with family; family is asked to consider donation as an option, but they do not agree. The patient with kidney failure misses the window of opportunity, and the final scene is of both families grieving at their respective family members' grave plots…a missed opportunity.
46089862|NCT02836301|Behavioral|Unresolved Ending|In this ending, the team checks for registration status, and while searching, the scene cuts to physicians discussing the death with family and whether they might consider preservation and organ donation. The video then cuts to the potential recipient and family hoping for a kidney transplant before it is too late. The story ends without resolution, leaving viewers to contemplate how they might respond in the same situation
46089863|NCT04170270|Drug|Omeprazole|"Pre endoscopically: all patients will receive 80 mg omeprazole by 30 minute IV infusion.~After performing upper endoscopy (with initial hemostasis), the patient will be randomly allocated into two groups; group A patients will receive oral omeprazole, while group B patients are intended to receive IV omeprazole.~For patients of group A, omeprazole 40 mg will be administrated orally every 12 hours for 72 hours. Regarding group B, continuous infusion of omeprazole will be administrated at a rate of 8 mg/hour, for 72 hours."
46089864|NCT00633347|Drug|Antagonist GnRH Cetrotide|Cetrotide 0.25 mg. daily/ 7 days
46004756|NCT01658501|Drug|Metformin|
46004757|NCT01658501|Drug|Sulfonylurea|
46004758|NCT01658501|Drug|Metformin and Sulfonylurea|
46004759|NCT01656239|Drug|fedovapagon 1 mg|
46089865|NCT00633347|Drug|Agonist GnRH Acetate Triptoreline|Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose
45677879|NCT01964300|Biological|peginterferon alfa-2b|Given subcutaneously (SC)
45677880|NCT01964300|Other|laboratory biomarker analysis|Correlative studies
46004760|NCT01656239|Drug|fedovapagon 2 mg|
46004761|NCT01656239|Drug|fedovapagon 4 mg|
46004762|NCT01656239|Drug|Placebo ( sugar pill)|
46004763|NCT01651871|Drug|S-555739 Dose 1|
46004764|NCT01651871|Drug|S-555739 Dose 2|
46004765|NCT01651871|Drug|Cetirizine HCl Dose 1|
46004766|NCT01651871|Drug|S-555739 placebo|
46004767|NCT01651871|Drug|Cetirizine HCl placebo|
46004768|NCT01647308|Drug|ISIS-APOCIIIRX|3 doses of ISIS ISIS-APOCIIIRX on alternate days during the first week and then once-weekly doses for 12 weeks.
46004769|NCT01647308|Drug|Placebo|3 doses of placebo on alternate days during the first week and then once-weekly doses for 12 weeks.
46004770|NCT04599582|Device|Hip Arthroplasty|Patients are operated with hip replacement.
46089866|NCT02659722|Device|InterFuse|TRansforaminal or Posterior placement of an InterFuse S and/or T device, in combination with approved posterior fixation
46089867|NCT02839031|Behavioral|"CBT (Cognitive-Behavioral Therapy)"|
46089868|NCT02839031|Behavioral|Control (telephonic support without CBT content)|
46089869|NCT02659644|Drug|Oral L-citrulline|There will be a total of 16 patients divided into 4 equal cohorts. The first 4 cohorts will be started on a 7 day oral regimen of twice daily L-citrulline. They will return to clinic on day #7 to evaluate nitric oxide metabolite levels and pharmacokinetic (PK) profile of citrulline. After PK analysis, the next cohort of patients will be given a higher or lower dose based on their weight and also based safety and tolerability. Of note, a PK analysis will be performed for each 4 patient cohort prior to starting citrulline for the subsequent cohort. Assessment for adverse events will be done at specified times throughout the study duration via both phone and clinic encounters.
46089870|NCT02838719|Drug|Perineural Dexamethasone acetate|
46089871|NCT02838719|Drug|Intravenous dexamethasone acetate|
46089872|NCT02659488|Drug|Lisdexamfetamine|20 healthy controls and 20 women subjects with BED agreeing to a 12-week, open-label trial of LDX and fMRI assessments immediately before and after the 12 weeks of LDX treatment will be recruited
45342452|NCT00415909|Drug|TALL-104 cells|TALL-104 cells will be given intravenously over 1 hour at the dose of 109 cells daily for 4 days, on days 1 to 4 of the cycle, and then again on days 7, 10, 14, 17 and 21 of the cycle. One cycle is equal to 28 days. Patients will receive only one cycle of therapy with TALL-104 cells
45677881|NCT01964222|Behavioral|Decision Aid (DA)|Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of clinical trials in addition to usual care.
45677882|NCT04416230|Behavioral|massage|The massage included 30 minutes of gentle friction, kneading, stroking, and passive touch on the infant's accessible upper extremities, lower extremities, head, face, and back.
46004771|NCT04599738|Other|Wheat muffin|Participants consumed a control muffin made of wheat flour.
46004772|NCT04599738|Other|Finger millet grain muffin|Participants consumed a test muffin made of finger millet grain and wheat flour.
46004773|NCT01643330|Genetic|AAV1/SERCA2a (MYDICAR)|Single intracoronary infusion 1 x 10^13 DNase Resistant Particles (DRP) MYDICAR
46004774|NCT01643330|Genetic|Placebo|Single intracoronary infusion
46004775|NCT01642550|Drug|RM-131|RM-131 (100 mcg) will be administered daily by subcutaneous injection for 28 days.
46004776|NCT01642550|Drug|Placebo|
46004777|NCT04608123|Other|none (observational study)|DBS
46004778|NCT01641848|Device|INBONE™ Total Ankle Prosthesis with Long Talar Stem|INBONE™ Total Ankle Prosthesis with Long Talar Stem when used with a Calcaneal Stem
46004779|NCT04607811|Behavioral|Gamification with social incentives|Participants will select a step goal that is 33%, 40%, or 50% above their baseline step value. Participants in this group will participate in a game with points and levels to help motivate participants to meet their daily step goal. Additionally, all participants will identify a support partner to receive weekly updates on their performance and offer positive encouragement to help the participant meet their step goal.
46089873|NCT02838797|Drug|RQ-00000010|orally administered serotonin 4 receptor partial agonist
46089874|NCT02838797|Drug|Placebo|oral acetate buffer
46089875|NCT02838641|Device|GeneXpert|Real time integrated and automated nucleic acid amplification test for detection of TB
46089876|NCT00649194|Drug|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fed
46089877|NCT00649194|Drug|Aciphex® Tablets 20 mg|20mg, single dose fed
46004780|NCT00555308|Other|emergency department targeted ultrasound imaging|bedside ultrasound performed by emergency physician to identify hydronephrosis
46004781|NCT04608006|Drug|Bupivacaine-fentanyl|Initial epidural bolus of 10 ml Bupivacaine 0.125% plus 50 mcg Fentanyl, followed by continuous infusion pf Bupivacaine 0.0625%™ plus 1mcg/dl Fentanyl
46004782|NCT01640756|Device|AqueSys Microfistula Implant|Placement of the AqueSys Microfistula Implant in the study eye
46004783|NCT04599621|Diagnostic Test|Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10),Collection of blood samples to determine the level of uric acid|Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10) All study participants had blood in the morning on fasting after 8-12 hours of fasting from the cubital vein. Determination of the level of cytokines TNF-α, IL-1β, IL-4 and IL-10 in blood serum by enzyme-linked immunosorbent assay (ELISA). All participants in the study had blood drawn in the morning on fasting after 8-12 hours of fasting from the cubital vein. The level of uric acid was determined on the CYAN Start apparatus using a unified method.
46089878|NCT02838563|Other|SIWA|To investigate the scale reliability over time, SIWA are assessed twice, ten minutes apart. To investigate the validity of the tool, SIWA is correlated with another quality of life questionnaire (QoL-AD), a quality of health scale including an analog portion (EQ 5D), and a behavioral disorder scale (Neuropsychiatric Inventory, NPI).
46089879|NCT02659410|Other|Heat stress (21)|4h exposure to heat (WBGT of 21°C), no solvent
46089880|NCT02659410|Other|Heat stress (25)|4h exposure to heat (WBGT of 25°C), no solvent
46089881|NCT02659410|Other|Heat stress (30)|4h exposure to heat (WBGT of 30°C), no solvent
46089882|NCT02659410|Other|Heat Stress (21) +TOL|4h exposure to heat (WBGT of 21°C) + Toluene (concentration = TLV)
46089883|NCT02659410|Other|Heat stress (25) + TOL|4h exposure to heat (WBGT of 25°C) + Toluene (concentration = TLV)
46004784|NCT01636817|Drug|NNC0109-0012|Administered subcutaneously (s.c., under the skin) once weekly.
46004785|NCT01636817|Drug|placebo|Administered subcutaneously (s.c., under the skin) once weekly.
46004786|NCT00564525|Drug|Amitriptyline|Medication taken for 4 weeks
46004787|NCT00564525|Drug|Placebo|Medication taken for 4 weeks
46089884|NCT02659410|Other|Heat stress (21) + TOL|4h exposure to heat (WBGT of 30°C) + Toluene (concentration = TLV)
46089885|NCT02659410|Other|Heat stress (21) + ACE|4h exposure to heat (WBGT of 21°C) + Acetone (concentration = TLV)
46089886|NCT02659410|Other|Heat stress (25) + ACE|4h exposure to heat (WBGT of 25°C) + Acetone (concentration = TLV)
46089887|NCT02659410|Other|Heat stress (30) + ACE|4h exposure to heat (WBGT of 30°C) + Acetone (concentration = TLV)
46089888|NCT02659410|Other|Heat stress (21) + DCM|4h exposure to heat (WBGT of 21°C) + Dichloromethane (concentration = TLV)
46089889|NCT02659410|Other|Heat stress (25) + DCM|4h exposure to heat (WBGT of 25°C) + Dichloromethane (concentration = TLV)
46089890|NCT02659410|Other|Heat stress (30) + DCM|4h exposure to heat (WBGT of 30°C) + Dichloromethane (concentration = TLV)
46089891|NCT02659410|Other|Heat stress (21) + TOL (dermal)|4h exposure to heat (WBGT of 21°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
46089892|NCT02659410|Other|Heat stress (25) + TOL (dermal)|4h exposure to heat (WBGT of 25°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
46004788|NCT01634087|Drug|Itacitinib|Itacitinib administered orally
46089893|NCT02659410|Other|Heat stress (30) + TOL (dermal)|4h exposure to heat (WBGT of 30°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
46089894|NCT02838485|Other|Mirror|The healthy hand will be mirrored and the amputated hand unseen by the subject while performing hand movements.
46004789|NCT01634087|Drug|Placebo|Placebo administered orally
45459155|NCT03488056|Other|ICCMS|"The patient's caries risk assessment, Diagnosis of caries lesion and activity assessment~-Intraoral risk assessment, Decide on a personalized care plan for patient and clinical interventions.~After asses all the factors and defining the patient's individual risk, the system presents a personalized treatment plan, indicating the appropriate home care instructions, clinical interventions and specific treatment for each caries lesion categories.~The treatment is divided into Non-Operative Care and Tooth-Preserving Operative Care (restorations with minimal intervention to preserve maximum dental structure).~The return intervals will be scheduled according to the risk: low risk (return of 1 year), moderate risk (6 months) and high risk (3 months)"
46004790|NCT03454230|Procedure|Positioning schedule|"Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections."
45459156|NCT03488056|Other|SESC standard care|Standard care related to: Caries Diagnosis, operative and non-operative treatments, Indication of recall interval according to the dentist opinion
46004791|NCT04607733|Drug|Mirikizumab Prefilled Syringe|Administered SC by prefilled syringe
46004792|NCT04607733|Drug|Mirikizumab Autoinjector|Administered SC by autoinjector
46004793|NCT01632137|Drug|Rebamipide 2% ophthalmic suspension|Instill one drop into each eye 4 times a day for 4 weeks.
46004794|NCT01632137|Drug|Placebo (vehicle)|Instill one drop into each eye 4 times a day for 4 weeks.
46004795|NCT00565539|Drug|PEGylated recombinant interleukin 29 (PEG-rIL-29)|subcutaneous administration either weekly or every other week
46004796|NCT01626599|Device|ProGuardian|"The investigational system is composed of a sensor, patch, hub, and caregiver application. The sensor is applied externally during periods of nocturnal sleep for up to 7 nights.~The investigational system:~is not implantable and no surgical procedure is required for a human subject to use the devices;~is not for use in supporting or sustaining a human life; and~is not of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health.~Contains skin-contacting materials made of medical grade materials (e.g. sold for use as surgical or wound care) with well-established biocompatibility testing profiles."
46004797|NCT04607694|Radiation|Proton radiotherapy|Proton radiotherapy
46089895|NCT02838485|Other|Imagery|The subject will be asked to imagine performing hand movements.
46089896|NCT04249349|Device|Assisted gait with a motorized ankle foot orthosis|The motorized ankle foot orthosis is a powered lower extremity assistance device with an actuated ankle joint. A novel control software has been design and implemented in this device, which allows precise joint movement and recording of data from training session.
46089897|NCT02659254|Device|Sirolimus Target Eluting Bioresorbable Vascular Scaffold|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold
46089898|NCT04249193|Other|Transfusion|pRBC and non-pRBC transfusions
46089899|NCT02659332|Device|TURBT|Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of 1 ms)
46089900|NCT04249271|Other|serum sampling|repeated serum sampling during pregnancy and thereafter
46089901|NCT02659176|Procedure|Transperineal repair with PIS|Repair of anterior rectocele via transperineal approach followed by limited internal sphincterotomy at 6 o'clock.
46089902|NCT02659176|Procedure|Transperineal repair without PIS|Repair of anterior rectocele via transperineal approach without performing limited internal sphincterotomy
46089903|NCT02836223|Device|Interdental cleaning device|Water Flosser
46089904|NCT02836223|Device|Manual Tooth brush|Control
46089905|NCT04170192|Procedure|Cord Blood Stem Cell Transplantation|Unrelated cord blood stem cell selection; Reduced intensity conditioning regime; GVHD prevention; Infection prevention.
46004798|NCT04607694|Radiation|Photon radiotherapy|Photon radiotherapy
46004799|NCT04599699|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Very Low, Low, favorable, or Good Prognostic Intermediate prostate cancer:SBRT; Unfavorable, or Poor Prognostic Intermediate prostate cancer: SBRT accompanied 4 months ADT;High or Very High prostate cancer: SBRT accompanied 2 years ADT.
46004800|NCT01563731|Drug|all approved antihypertensive drugs; all approved statins|All drugs to be used at doses capable of bringing SBP and LDL-C to targets; only doses approved in each country.
46089906|NCT02836379|Other|No intervention|No intervention
46089907|NCT02658864|Drug|lafutidine|comparison of different doses, sex and medication conditions
46089908|NCT02836145|Other|Differentiation of hiPSCs to skeletal muscle progenitors|
46089909|NCT02658942|Procedure|Ureteroscopy|In Group A patients, Karl Storz Flex-X 7.5, FURS with a 365 µm laser fiber.
46004801|NCT04599114|Behavioral|VIRTUES|VIRTUES is a digital health platform that offers 2 way communication between clinicians and patients to address symptoms stemming from atrial fibrillation.
46089910|NCT02658942|Procedure|Shockwave lithotripsy|In Group B patients, a Siemens Lithostar Lithotriptor
46089911|NCT00892151|Device|GLUCOFACTS® Deluxe|Diabetes Data Management Software
46089912|NCT02663544|Other|Limited dairy diet|Consumption of no dairy foods other than 3 servings per week of nonfat milk for 12 weeks
46089913|NCT02663544|Other|Low-fat dairy diet|Consumption of 3.3 servings per day of low-fat milk, yogurt, and cheese for 12 weeks
46089914|NCT02663544|Other|Full-fat dairy diet|Consumption of 3.3 servings per day of full-fat milk, yogurt, and cheese for 12 weeks
46089915|NCT04248647|Behavioral|Multimodal prehabilitation|"This arm will receive a 4-week prehabilitation program consisting of:~Exercise: Participants will receive a 3x/week aerobic and strength training exercise program. They will perform 2 workouts per week at home and attend an in-hospital supervised exercise session once per week.~Nutritional counselling: Participants will meet with a registered dietician who will provide personalized nutritional recommendations and a whey protein supplement, tailored according to participants' self-reported dietary intake and anthropometric measurements.~Psychological support: Participants will receive a 90-minute session at baseline, and weekly in-hospital follow-ups throughout the preoperative period. The sessions will aim to reduce preoperative distress and improve adherence to the exercise program and nutritional recommendations. Psychological support will be delivered by a trained master's student, under the direct supervision of a registered Clinical Psychologist."
46004802|NCT04599426|Biological|Allogeneic NK cell regimen group|"10 patients with refractory MDS-RAEB were treated with allogeneic NK cell regimen.~Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10^6/kg d13，d15 ."
46004803|NCT04599348|Dietary Supplement|HRG 80 Red Ginseng|A unique form of ginseng with the high level of active ginseng components similar to those found in the wild ginseng used in earlier studies.
46004804|NCT01516346|Drug|Isosorbide Dinitrate|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 placebo capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm.
46004805|NCT01516346|Drug|Isosorbide Dinitrate + Hydralazine|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 hydralazine capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm. Subjects receiving hydralazine will be given 37.5mg PO q8am, 2pm, and 8pm and will be titrated up to 75mg PO q8am, 2pm, and 8pm.
46004806|NCT01516346|Drug|Placebo|Enrolled subjects will be randomized in a blinded fashion to 2 placebo capsules TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs.
46004807|NCT04607304|Device|ABCA2 GIRMS|Two systems (ABCA-C and ABCA-D) with run order randomized
46089916|NCT02663466|Procedure|erroneous off-midline closures|All patients with pilonidal sinus recurrent disease following Limberg flap reconstruction in the recurrent group were examined by the authors in each study center and high resolution close-up photos of the patients' sacrococcygeal area were taken. These photos were then sent to all authors to asses and reach a collective decision to classify the erroneous off-midline closure technique and precisely measuring the distance between the flap border and the midline in the cleft. Same evaluation method was applied to the patients in nonrecurrent group. Following the completion of the assessments, all digital data of the patients were permanently deleted.
46089917|NCT02663388|Procedure|gastric bypass, sleeve, gastric banding|
46089918|NCT02835833|Drug|Nintedanib|Nintedanib will be given twice daily at either 150 mg or 200 mg.
46089919|NCT02835833|Drug|Bevacizumab|Bevacizumab will be given at 15 mg/kg
45459157|NCT01371968|Drug|alfentanil|Alfentanil is administered intravenously at the end of surgery.
45459158|NCT05147818|Other|CBC ,renal function tests , fundus Examination|Laboratory investigations
46004808|NCT04599387|Other|Remote Exercise Prescription|Exercise sessions will follow the recruitment meeting as prescribed by the BioGradient system, and will be tailored to the patient progress and limitations. In the beginning of each exercise session safety criteria will be collected and will allow participation . In addition, every 8 weeks and during the first exercise session outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect session data and discuss progress and limitation with the participant.
45459159|NCT05193110|Other|Polyetheretherketone (PEEK) Sub-periosteal Implant Retaining Maxillary Fixed Prosthesis|Sub-periosteal Implant Retaining Maxillary Fixed Prosthesis fabricated by digital & milling technology
45459160|NCT04989322|Drug|Pembrolizumab|200 mg Q3W
45459161|NCT04989322|Drug|Lenvatinib|8 mg daily
45459162|NCT04989322|Drug|Pemetrexed|500 mg/m2 Q3W
46004809|NCT04599387|Other|Usual Care|Exercise sessions will be initiated by the patient only. In the beginning of each exercise session safety criteria will be collected and will allow participation . Every 8 weeks and once after recruitment outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect outcome session data
46004810|NCT01303796|Drug|Sapacitabine|Oral sapacitabine capsules
45459163|NCT04989322|Drug|Carboplatin|AUC5 Q3W
45459164|NCT01367054|Drug|Metformin|500 mg tablet
45459165|NCT01367054|Drug|Glifage|500 mg tablet
45459166|NCT03487978|Diagnostic Test|resting-state functional MRI|"To ensure inter-ictal fMRI, confirm that the subject has no migraine for at least 48 hours before the procedure.~Record the time difference between the date on the day of fMRI and the date of the last headache attack and record whether the headache on the day of fMRI is absent or not.~On the third day after MRI, examine whether the subject has headache or not."
45459167|NCT05146570|Diagnostic Test|D-lactate test|In device-associated meningitis, CSF will be aspirated before, during or after surgery related to the device, according to the standard practice. Lumbar/ventricular punctures (pre-, intra- and/or postoperatively) and external ventricular (EVD) and lumbar drainage (ELD) aspiration will be performed by neurologist or neurosurgeon according to standardized aseptic techniques. In patients with native meningitis, CSF will be aspirated by lumbar puncture, according the standard practice. The D-lactate test will be performed using spectrophotometric enzyme assay according to the manufacturer's instructions (D-Lactate Colorimetric Assay).
45677883|NCT04416230|Behavioral|quiet time|During quiet time, the infant received a 30 minute quiet time (QT) period during which non-essential caregiving tasks were restricted. During QT, clinicians were asked to avoid direct clinical caregiving activities, i.e. activities requiring physical contact with the infant.
45342453|NCT00709566|Behavioral|Exercise therapy|Participants will attend an exercise based programme once a week for 8 weeks. This will be supplemented by a home based exercise programme.
45342454|NCT00709566|Behavioral|Combined exercise and manual therapy|Patients will attend physiotherapy once a week for 8 weeks, where they will receive a combination of exercise therapy and manual therapy. Exercise will be supplemented by a home based exercise programme
45683792|NCT03574480|Behavioral|Control (Advice on healthy diet and physical activity recommendations)|Advice on healthy diet and physical activity recommendations
45683793|NCT03021460|Drug|Ibrutinib|Given PO
45683794|NCT03021460|Other|Laboratory Biomarker Analysis|Correlative studies
45683795|NCT03021460|Biological|Pembrolizumab|Given IV
45677884|NCT04416074|Behavioral|An online 5-week professional identity group psychotherapy|This is an online 5-week group psychological intervention for the nursing students during clinical rotation practice. It aims at promoting the professional identity and career sefl-efficacy for them. There are five sessions in the intervention, and each session lasts from 60min to 90min at each week. The intervention will be delivered via an online meeting software, like Zoom. There will be 15-20 students in one meeting group.
46004811|NCT01303796|Drug|Decitabine|Decitabine intravenous
45677885|NCT04416074|Other|Message push|Controlled group will receive online messages of self-care knowledge forward by researchers once per week. The knowledge contain stress regulation, strategies for relaxation, self-protection during clinical practice.
45677886|NCT01467700|Drug|Ramelteon SL|Ramelteon SL tablets
45677887|NCT01467700|Drug|Placebo|Ramelteon placebo-matching tablets
46004812|NCT04598880|Drug|Polyethylene glycol + ascorbate|Pleinvue® is administered orally in 2 doses (3 sachets) as per SmPC within the previous 18 hours to colonoscopy intervention. First dose is administered at 9 pm on the day before intervention (sachet 1: MACROGOL 3350 100 g + SODIUM SULFATE ANHYDROUS 9 g + SODIUM CHLORIDE 2 g + POTASSIUM CHLORIDE 1 g). Second dose is administered 5 hours before intervention and it is composed by 2 sachets (sachet A: MACROGOL 3350 40 g + SODIUM CHLORIDE 3,2 g + POTASSIUM CHLORIDE 1,2 g; sachet B: SODIUM ASCORBATE 48,11 g + ASCORBIC ACID 7,54 g).
45677888|NCT01972724|Drug|Pioglitazone|Pioglitazone tablets
45677889|NCT01972724|Drug|Metformin|Metformin as prescribed in clinical practice
46089920|NCT02663310|Procedure|Surgery|Surgery treatment of the injured vertebra(e), internal fixation of the vertebral column, and bilateral laminectomy for epidural decompression were followed directly by neurosurgical management, including separation of the arachnoid adhesion to restore cerebrospinal fluid flow and debridement of the spinal cord necrotic tissue with concomitant intramedullary decompression.
46089921|NCT02663310|Procedure|Rehabilitation|The patients need to do intensive rehabilitation everyday. （1）The limb comprehensive training is Kunming Locomotor exercise, 60 minutes twice per day.(2)The exercise therapy includes sit-ups by 30 times, twice per day; half bridge exercise by 10 times, twice per day; backward flight movement by 10 times, twice per day; sling exercise training by 30 minutes, twice per day; and postural transfer functional training by 10 minutes, twice per day. (3)The balance training include ball toss training by 10 minutes, twice per day; and balance board training by 10 minutes, twice per day. (4)The wheelchair training will be taken 20 minutes each, twice per day. (5)The isokinetic training needs to perform 20 minutes each, twice per day.
46089922|NCT02835755|Other|Educational Intervention|Receive standard HPV and HPV vaccine information
46089923|NCT02835755|Other|Educational Intervention|Receive mHealth HPV vaccine intervention
46089924|NCT02835755|Other|Survey Administration|Ancillary studies
46089925|NCT02663154|Drug|Aromatherapy inhaler|Inhalation of commercial essential oil preparation (QueaseEASE) delivered in the commercial inhaler package in postanesthetic care unit after surgery in paediatric patients complaining of nausea
46004813|NCT04598880|Drug|Sodium picosulfate + magnesium citrate|Citrafleet® is administered orally in 2 doses (2 sachets) as per SmPC within the previous 18 hours to colonoscopy intervention. First dose (sachet 1) is administered at 9 pm on the day before intervention. Second dose (sachet 2) is administered 5 hours before intervention. Sachets 1 and 2 have the same composition: SODIUM PICOSULFATE 10 mg + MAGNESIUM OXIDE 3,5 g + CITRIC ACID 10,97 g.
46089926|NCT02663154|Drug|Saline inhaler|Inhaler is similar in design and function as the intervention inhaler only with saline rather than essential oils. Inhaler provided by the manufacturer QueaseEASE (Soothing Scents, Inc, Enterprise, AL)
46089927|NCT02165345|Drug|Tocilizumab|162 mg tocilizumab will be administered by SC injection at the following intervals: pJIA participants less than (<) 30 kilograms (kg): every 3 weeks; pJIA participants greater than or equal to (>=) 30 kg: every 2 weeks; sJIA participants <30 kg: every 2 weeks; sJIA participants >/= 30 kg: once weekly
46089928|NCT04171284|Drug|SCT-I10|200 mg, Q3W, maximum treatment up to six cycles
46004814|NCT04598646|Behavioral|Cardio-oncology Rehabilitation (CORE)|Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
46004815|NCT04598646|Behavioral|Support|Behavioural support via professionals and peer support.
46089929|NCT04171284|Drug|Docetaxel|70-75mg per square meters of body surface area, Q3W, maximum treatment up to six cycles
46004816|NCT04598646|Behavioral|Passive Behavioural Support|Passive behavioural support, either PAI-Score or recommended physical activity guidelines for cancer survivors, to encourage physical activity.
46004817|NCT04598958|Other|IMPROVE|Health system interventions that include: (1) Multidisciplinary integrated management teams to coordinate patient-focused and outcome-oriented PMTCT and MCH services; (2) Enhanced Positive Health, Dignity, and Prevention (PHDP)-focused counseling and skills-building training and job aids; and (3) Increased early community-based counseling and support for first (antenatal care clinic) ANC attendees
46004818|NCT04607655|Drug|GB1211|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
46004819|NCT04607655|Drug|Placebo|Placebo is administered as inhalation once a day
46004820|NCT04607343|Device|Rehabilitation device based on electrical stimulation|Experimental tests with transcutaneous electrical stimulation at different intensities and at the points of the submandibular region previously explored will be conducted first of all on the five healthy volunteer subjects. During these tests, the neuromuscular thresholds of the upper airway, the most effective points of electrostimulation and the tolerance of intervention will be determined. The determination of the functional threshold will be made by clinical evaluation of the subject during stimulation.
46004821|NCT04607265|Diagnostic Test|Cardiac MRI|Comparison of scar characteristics on cardiac MRI between the two groups.
46004822|NCT04598763|Other|smell the odors of the olfactory rehabilitation kit according to the classic or intensive method|regardless of the randomization group, the patient will smell each odor for 10 seconds with a 10 second interval between odors.
46089930|NCT04171284|Drug|Placebo|200 mg, Q3W, maximum treatment up to six cycles
46089931|NCT00648882|Drug|LEVOTHYROXINE SODIUM TABLETS,|2x300mcg, single dose fasting
46089932|NCT00648882|Drug|SYNTHROID® 300 mcg Tablets|2x300mcg, single dose fasting
46089933|NCT05333705|Biological|infusion of natural killer cells|Umbilical cord blood or donated peripheral blood of healthy donors were collected and NK cells were sorted and cultured. NK cell production will be infused after chemotherapy
46089934|NCT02840669|Procedure|Cardiac magnetic resonance imaging (CMR)|
46089935|NCT02840669|Procedure|Exercise-stress test|
46089936|NCT02840669|Procedure|Echocardiography (ECHO)|
46089937|NCT02840669|Procedure|Cardiac-related blood studies|
46089938|NCT02662920|Other|No Intervention|
46004823|NCT00564564|Drug|Quetiapine|Quetiapine once a day at maximum dosage of 200mg per day asociated to a SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
46004824|NCT00564564|Drug|Clomipramine|Clomipramine once a day at maximum dosage of 75mg per day plus SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
46004825|NCT02894138|Drug|alteplase|
46004826|NCT02894138|Drug|Placebo|
46004827|NCT00565656|Drug|BEVACIZUMAB|Administration of Bevacizumab
46004828|NCT02894021|Procedure|classic closure|mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
46004829|NCT02894021|Procedure|padding|areas of padding and running sutures between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h
46004830|NCT00564603|Drug|Dexamethasone Sodium Phosphate Injection|Dexamethasone, 10mg, continuously infused up to 48h after surgeries.
46004831|NCT00564603|Other|0.9% Saline|Saline, in same volume of 2mL
46004832|NCT00565695|Device|aspheric ReSTOR multifocal intraocular lens (IOL)|Multifocal intraocular lens
46004833|NCT02894099|Other|Prolonged sitting time|Volunteers will be continuously sitting on a chair for 5 hours and should move the least possible. If the participant needs to stand from the chair, the stage will be invalidated.
46004834|NCT02894099|Other|PST+Light intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of low intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 50-60% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes) of light intensity physical activity.
46004835|NCT02894099|Other|PST+Moderate intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes)of moderate intensity physical activity.
46004836|NCT02894099|Other|PST+Moderate intensity Long bouts PA|Volunteers will have their time sitting interrupted every 75 minutes for 10 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (3 bouts of 10 minutes) of moderate intensity physical activity.
46004837|NCT00555347|Drug|Armodafinil|Dosage 150-250 mg
46004838|NCT00555347|Drug|Placebo|Placebo
46089939|NCT02662686|Other|Transfer according to morphological criteria|Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to morphological criteria (control group).
46089940|NCT02662686|Other|Transfer according to the MitoScore results|Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to the MitoScore results (experimental group).
46089941|NCT02838329|Other|warming of ropivacaine for BT|
45677890|NCT01972724|Drug|Sulfonylurea|Sulfonylurea as prescribed in clinical practice
46004839|NCT00564642|Drug|N Acetylcysteine|1200 mg, BD, 2weeks
46004840|NCT00555386|Dietary Supplement|Soy and Selenium|6g of chocolate per day Control group with no supplementation Active group 50mg of soy protein isolate + 200µg selenium in the form of MSC
46004841|NCT01580709|Procedure|Multiple brushings|Seven consecutive brush samples for cytology.
46004842|NCT01580709|Procedure|Multimodality tissue sampling|Single brush for cytology + single brush for FISH + cholangioscopy with site-directed biopsies
46004843|NCT02894294|Other|implementation of seasonal malaria chemoprevention|administration of therapeutic doses of antimalarials (Sulfadoxine-pyrimethamine [SP] + Amodiaquine [AQ]) at monthly intervals during the high malaria transmission season in children 3-59 months of age.
46004844|NCT02894177|Procedure|tcPCO2 measurement|tcPCO2 continuous monitoring during spontaneous breathing trials
46004845|NCT00565890|Drug|thyroxine|thyroxine at the dose of 5 μg/kg-wt /day
46089942|NCT02838329|Drug|Ropivicaine|
46089943|NCT02662530|Drug|Botulinum Toxin Type A|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined either by visual/clinical or by biomechanical analysis of dystonic movements for cervical dystonia therapy in neck and shoulder muscles every 12 weeks over 30 weeks. BoNT-A dose will range from 50-300 U.
46004846|NCT02894060|Other|blood tests|"Blood tests done by the nurse in the CRC (clinical research center). The quantity of blood taken wil be (3 5-mL tubes):~2 plain tubes and 1EDTA tube Arterial blood pressure will be measured at the CRC. Then, an X-ray of the profile of the abdomen will be taken without preparation to evaluate aortic calcification (in the radiology department of the Amiens hospital)"
46004847|NCT02894216|Procedure|radionuclide shuntography|the investigators retrospectively enrolled patient who received radionuclide shuntography
46089944|NCT01706705|Device|Intracavitary Applicator Placement|MRI-compatible applicator inserted using ultrasound guidance to verify tandem placement in the uterus. Tandem and ovoids, tandem and cylinders, or tandem and ring chosen to accommodate patient's tumor and vaginal anatomy.
46089945|NCT01706705|Other|Computed Tomography (CT)|CT scan performed after implant is placed in operating room. CT scan should take about 20 minutes.
46089946|NCT01706705|Other|Magnetic Resonance Imaging (MRI)|MRI scan performed after implant is placed in the operating room. MRI should take about 45 minutes.
46089947|NCT04171206|Other|Free From Abuse|Participants in the treatment arm will watch a 15-minute talk given by an adult female survivor of IPV who tells the story of her abusive relationship. After watching the video, participants will read information on 10 signs of an unhealthy relationship. The intervention will take approximately 25 minutes to complete.
46089948|NCT04171206|Other|Technology and crime|Participants in the placebo control arm will watch a 19-minute talk on technology development and crime. After watching the video, participants will read 10 facts about cyber security. The intervention will take approximately 25 minutes to complete.
46004848|NCT02894255|Device|Coronary artery bypass grafting|
46004849|NCT02894255|Procedure|Percutaneous coronary intervention|
46089949|NCT04250285|Other|descriptive method|After obtaining relevant permissions from the university and organization of education and selecting participants, the study was explained for students and their satisfaction obtained. Then questionnaires were given to participants. To observe ethical considerations, questionnaires were anonymous and has been confided that the participants' responses was maintained in the study and is not given anyone
46089950|NCT02537028|Drug|MSC2364447C|Subjects will be administered with MSC2364447C 25 milligrams orally once daily for 4 weeks.
46004850|NCT00565929|Drug|Placebo|Sterile saline (0.9%).
46004851|NCT00565929|Biological|MVA-BN|The smallpox vaccine is a liquid frozen solution formulated to contain 0.605 mg Tris and 4.090 mg sodium chloride (NaCl) per 0.5 mL dose. The concentration of the virus will be 1 X 10^8 tissue culture infectious dose 50 (TCID 50) per 0.5 mL dose and may be diluted in a solution of 0.9% saline prior to vaccination. Smallpox vaccine administered in 2 doses approximately 28 days apart in one of the following doses: 1X10^7 or 1X10^8 TCID 50.
46004852|NCT04676516|Drug|GSK3326595|GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.
46004853|NCT04606758|Procedure|PCNL under fluoroscopic control|Patients receive standard of care treatment for their urolithiasis using standard PCNL under fluoroscopic guidance
46004854|NCT04606758|Procedure|PCNL under ultrasound control|Patients receive standard of care treatment for their urolithiasis using standard PCNL under US guidance
46089951|NCT02537028|Drug|MSC2364447C|Subjects will be administered with MSC2364447C 75 milligrams orally once daily for 4 weeks.
46004855|NCT04676321|Other|Patient pathway|Investigation on the appropriateness and quality of NSCLC care among participating sites
46004856|NCT04598568|Device|balanSys UNI|Implantation of a balanSys UNI knee prosthesis implanted with a spacer block surgical technique
46089952|NCT02537028|Drug|Placebo|Subjects will be administered with placebo matching to MSC2364447C orally once daily for 4 weeks.
46089953|NCT02835521|Procedure|Reception|
46089954|NCT02835521|Drug|Joint injection with triamcinolone hexacetonide|joint injection with corticosteroids
46089955|NCT00649272|Drug|Oxybutynin Chloride Extended-Release Tablets, 15 mg|15mg, single dose fasting
46089956|NCT00649272|Drug|Ditropan XL® Extended-release tablets, 15 mg|15mg, single dose fasting
46089957|NCT02662842|Device|FlowSmart Infusion Set|Use of set for subcutaneous insulin infusion, with set change every three days.
46089958|NCT02662842|Device|Current Infusion Set|Use of set for subcutaneous insulin infusion, with set change every three days.
46089959|NCT04248959|Behavioral|Multimodal prehabilitation|"Physical Prehabilitation:~Combination facility-/home-based exercise consisting of aerobic exercise (4-5 days/week (d/wk)), resistance exercise (2-3 d/wk), and daily mindfulness practice.~Aerobic exercise~Facility-based, high-intensity interval training (HIIT), 2 d/wk, 35 min/session, 4-min work and 3-min recovery period; cycle ergometer or arm ergometer (for those who cannot weight-bear) at 75% to 95% of baseline VO2peak~Home-based, moderate-intensity continuous training (MICT), 2-3 d/wk, >=30 min/session, brisk walking (or equivalent) aiming to achieve a target HR of 40-70% of maximal HR~Resistance exercise~Home-based, moderate-intensity resistance training, 2-3 d/wk, all major muscle groups (working around tumour-related deficits), 8-10 exercises, 12-15 repetitions, resistance bands and body weight based~Psychological Prehabilitation:~Daily mindfulness practice, 20 min/session, and guided by audio file created at Mount Sinai Hospital"
46089960|NCT02666898|Drug|GA101|"Part 1 :6 cycles~Obinutuzumab/GA101:~First cycle:~D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v~Cycle 2 to 6 (every 28 days) :~D1 of every cycle: 1000 mg i.v PART 2 4 cycles~-patients have BM MRD >10-4 or PR: Cycle 1 to 4 Obitinuzumab/GA101: 1000 mg i.v on day 1"
46089961|NCT02666898|Drug|Ibrutinib|"Part 1 :6 cycles~Cycle 2 to 6 (every 28 days) :Ibrutinib:~D3 Month 1 to Day 30 Month 15: 420mg daily PO PART 2:4 cycles~patients in CR with BM MRD < 10-4 : Ibrutinib alone 420mg daily~patients with BM MRD >10-4 whatever responses or PR :Cycle 1 to 4 Ibrutinib 420mg daily with Cyclophosphamide and Fludarabine"
46004857|NCT04607031|Diagnostic Test|measurement of serum ST2 concentrations in serum of patients with acute, ischemic stroke|7 measurements of serum ST2 concentrations from day 0 to day 6, modified Rankin scale before, 6th and 90th day, NIHSS from day 0 to day 6 and 90, TOAST and OCSP classifications
46089962|NCT02666898|Drug|Cyclophosphamide|"PART 2 :~patients with BM MRD >10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days Cyclophosphamide : 250 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and fludarabine"
46089963|NCT02666898|Drug|Fludarabine|"PART 2 :~patients with BM MRD >10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days : Fludarabine : 40 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and cyclophosphamide"
46089964|NCT04248881|Behavioral|Healthy Lifestyle Education|"Healthy lifestyle information (education) is distributed to participants during the World Cancer Day Walk via brochure, lectures, and professional counseling."
46089965|NCT02658708|Other|Bright blue-green light using light visor cap|
46089966|NCT02658708|Other|Dim red light using light visor cap|
46089967|NCT02658708|Other|European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire|-Consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life
45836267|NCT00125658|Other|Control|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Functional Task Practice (FTP) followed by 10 weeks of Power training (dynamic resistance exercise). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
46004858|NCT04676165|Device|Smart About Meds (SAM)|"SAM generates a patient-friendly list of prescribed and dispensed medications and offers several features:~Drug information: Patient-friendly monographs that describe treatment indications and the harms/benefits of medications.~Adherence alerts: Alerts users to non-adherence, such as when they fill prescriptions that were stopped at hospital discharge, don't fill prescribed medications, or buy medications at the incorrect dose.~Side-effect checker: Provides a list of side effects associated with individual medications and the patient's overall drug profile.~Rate my med: Allows patients to rate medications and describe experiences with a medication. Patients can view ratings given by users.~Caregiver connect: Provides patients' caregivers with access to the app.~Pharmacy connect: Allows patients to connect with their hospital pharmacist to ask questions regarding their medications and adherence alerts.~Other: pill images, daily pill reminders, weekly dosing schedule"
46004859|NCT04606953|Behavioral|Attention Process Training (APT-II)|The exercises target different attentional components and working memory in the auditory-visual modalities. They are of increasing difficulty while being adapted to the profile of each patient in order to maximize the effects on cognitive reserve. During the sessions, the emphasis is on generalizing the gains to the most problematic daily activities in order to reduce the impact of cognitive disorders in patients' daily life.
46004860|NCT04675658|Behavioral|CBPA + family support|Classroom Based Physical Activity + family support as described in the Arm
46089968|NCT02658708|Other|Epworth Sleepiness Scale|-Consists of 8 common daily activities with a 4-point rating scale (0=would never doze to 3=a high chance of dozing) measuring usual daytime sleepiness over a recent time period
46089969|NCT02658708|Other|Pittsburgh Sleep Quality Index|-Contains 19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance
46004861|NCT04675658|Behavioral|CBPA|Classroom Based Physical Activity
46089970|NCT02658708|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance|-Consists of 8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances
46004862|NCT04598490|Device|Space closure into old extraction space|Lower first premolar extraction space was closed using elastic power chain and 0.019X0.025 Stainless steel archwire into healed bony socket
46004863|NCT04598490|Device|Space closure into recent extraction space|Lower first premolar extraction space was closed using elastic power chain and 0.019X0.025 Stainless steel archwire into fresh bony socket
46004864|NCT04675697|Drug|Platinum-etoposide+Anlotinib|Platinum-etoposide regiment consisted of etoposide 100mg/m2, d1~3 of 21-day cycle, with investigators' choice of either cisplatin (75-80mg/m2, Q3W) or carboplatin (AUC=5~6, Q3W). Anlotinib treated of 12mg Qd from day 1 to 14 of a 21-day cycle. Eligible patients received anlotinib plus platinum-etoposide for 4~6 cycles, and followed by maintenance therapy with Anlotinib. The efficacy was evaluated every 6 weeks (2 cycles) through treatment.
46089971|NCT02658708|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue|-Consists of 8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue.
46089972|NCT02658708|Diagnostic Test|Digital foot candle datalogging light meter (Extech Instrument, Model SDL400)|-The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck.
45683796|NCT03089086|Biological|Licensed 4CMenB vaccine|Two doses (0.5 mL each) of Bexsero ® vaccine at least 1 month to <3 months apart in adolescents.
46004865|NCT04606836|Drug|Bupivacaine Hydrochloride|See group descriptions
46089973|NCT02658708|Diagnostic Test|Polysomnography (Easy Ambulatory 2 Cadwell, Kennewick, WA)|-A standard sleep montage of electroencephalography following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed
46004866|NCT04675814|Other|Adapted Physical Activity (APA)|Adapted Physical Activity (APA)
46089974|NCT02658708|Other|Horne-Ostberg Morningness-Eveningness Questionnaire|
46089975|NCT02658708|Other|Daily Fatigue and Sleep Log|"Two visual analog scales (VAS) for diurnal fatigue and daytime sleepiness~Two 0-10 point rating scales (average and worst fatigue levels in 24 hours)"
46089976|NCT04248803|Other|GLUMA (Kulzer GmbH, Germany) desensitizing agent|GLUMA desensitizer is used to reduce tooth sensitivity
46089977|NCT02835053|Other|Frailty|Participants will be defined as frail based on the Johns Hopkins ACG Frailty Defining Diagnoses Indicator, which will be applied to available health administrative data in the 3 years preceding index hospital admission. If no frailty defining diagnoses are present participants will be defined as not frail
46089978|NCT04174404|Other|ICory-Circumcision|The ICory-Circumcision is specially developed for this study based on preliminary studies, other literature, and most importantly, the surgical pathway currently practiced in the study hospital. The ICory-Circumcision programme has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children. The ICory-Circumcision programme is designed to be a self-guided and healthcare professional-led. Participants will have access to BuddyCare for parents and Triumf Health from time of recruitment till 2 weeks after surgery while the healthcare professional would receive face-to-face training on how to use the BuddyCare dashboard.
46089979|NCT04174404|Other|Routine care|The routine care consists of normal consultations with the doctor, preoperative preparation, and post-operative care. During the first consultation, the child will be assessed for the need for circumcision and the doctor explains verbally to the parents about the procedure, risks, what to expect and prepare pre-operatively.
46089980|NCT02835209|Other|Work of breathing during SBT|Pulmonary function tests and work of breathing indices will be collected during the spontaneous breathing test.
46089981|NCT02834897|Radiation|EOS and CT Exam|EOS and CT Examen for pregnant women in the 8th month of pregnancy
46089982|NCT00633425|Drug|GLIMEPIRIDE|
46089983|NCT02838251|Other|No intervention|
46089984|NCT04170036|Dietary Supplement|protein supplement|Protein supplement usage for at least three preceding months in varied amounts
46089985|NCT02834585|Other|Ultrasound|
46004867|NCT04598256|Procedure|Endoscopic procedure|Esophagogastroscopy and colonoscopy
46004868|NCT01163149|Drug|asfotase alfa|Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (total of 2.1 mg/kg/week)
46089986|NCT04169724|Behavioral|Calm Meditation|10 minutes per day of meditation via the Calm app.
46089987|NCT02834741|Drug|NYX-2925|NYX-2925 is a small molecule that acts as an N-methyl-D-aspartate receptor (NMDAR) functional glycine-site partial agonist.
46004869|NCT01163149|Drug|asfotase alfa|Cohort 2: Daily SC injections of 0.5 mg/kg Asfotase Alfa (3.5 mg/kg/week total)
46004870|NCT04676126|Dietary Supplement|Lumega-Z|Medical food which contains lutein, zeaxanthin, and meso-zeaxanthin
46089988|NCT02840279|Drug|BPN14770|BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
46004871|NCT04676126|Drug|Dorzolamide Hcl 2% Oph Soln|Topical carbonic anhydrase inhibitor
46089989|NCT02840279|Drug|Placebo|
46089990|NCT04169802|Diagnostic Test|Retinal Health Monitoring System Visual Acuity Module|Assessment of corrected near visual acuity
46089991|NCT04169802|Diagnostic Test|Sloan letter, logarithmic near visual acuity chart (Reference Chart)|Assessment of corrected near visual acuity
46089992|NCT04460495|Procedure|Arterial Spin Labeling Magnetic Resonance Imaging|Undergo ASL scan
46089993|NCT04460495|Procedure|pH-Weighted amine CEST|Undergo pH Weighted amine CEST
46089994|NCT04460495|Procedure|Oxygen-weighted SAGE-EPI|Undergo Oxygen-weighted SAGE-EPI
46089995|NCT04451291|Biological|Decidual Stromal Cells (DSC)|DSCs are involved in the immune system during pregnancy. The DSCs used in this study will come from laboratory grown allogeneic human decidual stromal cells obtained from donated placentas.
45677891|NCT01441960|Drug|Succinylcholine|Succinylcholine will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments. The investigators will switch to the second compound as soon as the patient has received one neuromuscular blocking agent dose that resulted in 'acceptable muscle relaxation', and another dose that resulted in 'unacceptable' conditions'.
46004872|NCT04676126|Other|Placebo|Specially formulated non macular pigment-containing formulation which tastes similar to the commercial medical food being evaluated in this study
46004873|NCT04598373|Behavioral|interdisciplinary treatment|Interdisciplinary treatment (IDT) distinguishes itself as an interdisciplinary-coordinated (e.g., physician, occupational therapist, physiotherapist, and psychologist) intervention using a bio-psycho-social view of chronic pain. The MMR continues over a lengthy period with a common goal and generally includes patient education, supervised physical activity, simulated work training, and cognitive behavioural therapy (CBT). The exact composition of these MMR components depends on initial evaluations of the patients health status and furhter follow-up testing. The MMR interventional components can act independently and interdependently, resulting in combined effects due to known and unknown mechanisms; the effects are intended to be greater than the sum of its components.
46004874|NCT04675619|Drug|Oral pirfenidone|Treatment
46004875|NCT04675619|Drug|Standard care|Treatment
46089996|NCT00648960|Drug|Clarithromycin|Single-dose 500 mg immediate-release oral tablet
46089997|NCT00648960|Drug|Clarithromycin|Single-dose 500 mg immediate-release oral dose
46089998|NCT04437329|Drug|Docetaxel, nedaplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
46004876|NCT04675892|Procedure|A1 pulley division|"Local anesthesia with 5-10 ml of solution required (90 % lidocaine 1 % with 1 ug epinephrine, 10 % sodium bicarbonate 8.4 %).~Division of the A1 pulley.~Wound closure with absorbable sutures and application of a light dressing."
46004877|NCT04675892|Procedure|A1 pulley division + Resection of one or both slips of the FDS tendon|"Local anesthesia with 5-10 ml of solution required (90 % lidocaine 1 % with 1 ug epinephrine, 10 % sodium bicarbonate 8.4 %).~Division of the A1 pulley.~Palmar Bruner incision over the PIP joint. Distal dissection and resection of one or both slips of the FDS tendon.~Wound closure with absorbable sutures and application of a light dressing."
46004878|NCT04598100|Behavioral|FOCUS-EC|
46089999|NCT04437329|Drug|Docetaxel, cisplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Cisplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
46090000|NCT04437329|Drug|Nedaplatin|Concurrent chemotherapy. Nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
46090001|NCT04437329|Drug|Cisplatin|Concurrent chemotherapy. Cisplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
46090002|NCT04437329|Radiation|Intensity modulated-radiotherapy|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
46090003|NCT04170816|Device|Dry needling|DN and KT therapy will be applied 3 sessions in 1-week intervals
45459168|NCT05146570|Diagnostic Test|Standard diagnostic tests|In device-associated meningitis, CSF will be aspirated before, during or after surgery related to the device, according to the standard practice. Lumbar/ventricular punctures (pre-, intra- and/or postoperatively) and external ventricular (EVD) and lumbar drainage (ELD) aspiration will be performed by neurologist or neurosurgeon according to standardized aseptic techniques. In patients with native meningitis, CSF will be aspirated by lumbar puncture, according the standard practice. The standard diagnostic tests will be performed according to standard diagnostic laboratory instructions.
45677892|NCT01441960|Drug|Rocuronium|Rocuronium will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments.
45677893|NCT04069702|Behavioral|VR Blue|VR Blue provides patients with an immersive computer-generated environment that can reduce pain, tension and distress.
46004879|NCT01163032|Drug|tasimelteon|20 mg tasimelteon capsules, PO daily for 6 months
46004880|NCT01163032|Drug|Placebo|Placebo capsules, PO daily for 6 months
46004881|NCT04675736|Procedure|brushing force|Using duplication method, vertical force was applied from 1-5.5 N in linear mesial-distal brushing motion at 4 strokes per second for 5 seconds Force was increase 0.5 N in every testing until plaque was completely removed from enamel surface
46004882|NCT05305300|Biological|PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A|receive two doses of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0 and 7.
46004883|NCT05305300|Biological|PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B|receive one dose of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0.
46004884|NCT04606719|Procedure|Advanced Platelet Rich fibrin|Preparing of A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes
46004885|NCT04187755|Drug|Ceftazidime Injection|Ceftazidime was administered intravenously with usual standard dose for serious infection (50 mg/kgBW/dose, 6 hourly)
46004886|NCT04187755|Drug|Cefepime Injection|Cefepime was administered intravenously with usual standard dose for serious infection (50 mg/kgBW/dose, 8 hourly)
46090004|NCT02834507|Drug|Placebo|Matching placebo capsules
46090005|NCT02834507|Drug|BIA 3-202|Capsules containing nebicapone 75 mg or 150 mg
46090006|NCT02834507|Drug|Comtan®|Capsules containing entacapone 200 mg
46090007|NCT02834507|Drug|Sinemet®|levodopa/carbidopa (Sinemet®) dose patient used to take
46090008|NCT02662452|Drug|GLPG2222 single dose|single ascending doses, oral suspension
46090009|NCT02662452|Drug|Placebo single dose|single doses, oral suspension, matching placebo
46090010|NCT02662452|Drug|GLPG2222 multiple doses|multiple ascending doses, daily for 14 days, oral suspension
45677894|NCT04508062|Procedure|pectopexy operation|Vaginal cuff or uterine cervix will be attached to iliopectineal ligament with polypropylene mesh on both sides.
45677895|NCT04508062|Procedure|uterosacral ligaments plication operation.|At least 2/3 of the sacrouterine ligaments will be shortened with helical sutures, starting from the cervix and so douglas will be partially obliterated.
45677896|NCT04062838|Drug|Dextrose 50|As above
45677897|NCT04408534|Other|mode of noninvasive ventilation|administration of during 3 hours each 4 cycles
45677898|NCT01955707|Drug|natalizumab|Administered as described in the treatment arm
45677899|NCT01955707|Drug|Placebo|Matched placebo
45677900|NCT01435798|Drug|Dextromethorphan|0, 25, 50 and 100% of maximum tolerated dose, each administered over a 4 week period
45677901|NCT04069624|Behavioral|MOUD Pre-Treatment Telehealth|Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth
45683797|NCT04112758|Other|High-intensity interval training|2 times weekly for 5 weeks Circuit training with 4 stations
45683798|NCT04087876|Drug|derazantinib|derazantinib will be administered orally
46090011|NCT02662452|Drug|Placebo multiple doses|multiple doses, daily for 14 days, oral suspension, matching placebo
46090012|NCT04481568|Behavioral|PES-4-BPSD Model|We will conduct a non-randomized preliminary efficacy trial, enrolling N=158 patients (79 control and 79 intervention). The primary outcome will be presence of BPSD as measured by a patient's total score on the Neuropsychiatric Inventory-Questionnaire (NPI-Q) during hospitalization. A multi-modal approach (including chart review and HCG questionnaires) will be used to determine the presence and severity of BPSD.
46090013|NCT04481568|Behavioral|The attention control condition|On this unit, the management of patients who display BPSD is performed by nurse assistants, rather than PES. Therefore, in order to test the added layer of PES staff, the nurse assistants on the control unit will receive equivalent dementia care education and training as well as staff support (please refer to NCT# 04179721 for more details on this aim).
46090014|NCT02831543|Drug|Motireb 5/100 mg|
46090015|NCT02831543|Drug|Mosapride citrate|
45677902|NCT04069624|Behavioral|MOUD Pre-Treatment Telehealth and Peer Navigator|Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth. Additionally, participants will be connected with a Peer Navigator who will meet with them via telehealth prior to release and provide ongoing support by telephone post-release.
46090016|NCT02831543|Drug|Placebo|
45677903|NCT04069624|Other|Services as Usual|Medications to treat opioid use disorder (MOUD) pre-treatment.
46004887|NCT00555542|Drug|rituximab|Patients are taking stable dose of methotrexate and at least 10mg folic acid per week for at least 4 weeks. Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15. Premedication as standard prescription consists of methylprednisolone 100mg IV, Chlorpheniramine maleate(piriton 10mg IV and oral paracetamol 500mg to be given 30 minutes before each infusion of rituximab. Oral prednisolone 60mg is tob e given from day 1-6 after rituximab infusion and 30mg from day 7-13.
46090017|NCT02840591|Drug|Ramelteon|
46004888|NCT04606563|Drug|Losartan|Oral losartan 25 mg, stepped up to 50 mg and then up to 100 mg peak dose, as tolerated.
46004889|NCT04606563|Drug|Valsartan|Oral Valsartan 40 mg, stepped up to 80 mg and then up to 160 mg peak dose, as tolerated.
46004890|NCT04606563|Drug|Azilsartan|Oral Azilsartan 40 mg, and stepped up to 80 mg.
46004891|NCT04606563|Drug|Candesartan|Oral Candesartan 8 mg, stepped up to 16 mg and then up to 32 mg peak dose, as tolerated.
46090018|NCT02840591|Drug|Citicoline|
46090019|NCT02667054|Drug|RX0041 4%|Anesthetic
46090020|NCT02667054|Drug|Placebo|Placebo Comparator
46004892|NCT04606563|Drug|Eprosartan|Oral Eprosartan 400 mg, stepped up to 600 mg and then up to 800 mg peak dose, as tolerated.
46090021|NCT02667054|Drug|RX0041 8%|Anesthetic
46090022|NCT02840513|Other|Smartphone app/CO self-monitoring|Smartphone app and carbon monoxide self-monitoring (personal device)
46090023|NCT02662140|Behavioral|Mobile Health Applictaion|"Component 1: Delivering homework via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW.~Component 2: Focuses on targeting factors putative related to poor HW implementation within the Do process"
46090024|NCT02840357|Other|Purple Wheat Convenience Bars|Whole grain convenience bars manufactured with purple wheat
46090025|NCT02840357|Other|Control Wheat Convenience Bars|Whole grain convenience bars manufactured with ordinary wheat
46090026|NCT02662296|Drug|Ibrutinib|Given PO
46090027|NCT02662296|Drug|Idelalisib|Given PO
46090028|NCT02831465|Behavioral|Healthy Subjects|Subjects with normal lung function performed MVV at increasing breathing frequencies and maximal tidal volume, from 10 to 100 cycles per minute. Inspiratory capacity (IC) was measured at rest and after each 12 seconds of MVV in order to detect DH. From the moment DH appeared at a given frequency, only one additional MVV at a higher breathing frequency was conducted to confirm DH.
46090029|NCT02662374|Drug|.02% Chlorohexidine Gluconate|5ml of the drug in mouthwash form to be swished four times a day
46090030|NCT02662374|Drug|3% Sodium Bicarbonate|5ml of the drug in the form of a prepared solution to be swished four times a day
46090031|NCT02662374|Drug|Nystatin 10000U/ml|5ml of the drug in mouthwash form to be swished and swallowed four times a day
45677904|NCT01972568|Drug|Atacicept 75 milligram (mg)|Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks.
45677905|NCT01972568|Drug|Atacicept 150 mg|Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks.
45677906|NCT01972568|Drug|Placebo|Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.
46004893|NCT04606563|Drug|Irbesartan|Oral Irbesartan 75 mg, stepped up to 150 mg and then up to 300 mg peak dose, as tolerated.
46004894|NCT04606563|Drug|Olmesartan|Oral Olmesartan 10 mg, stepped up to 20 mg and then up to 40 mg peak dose, as tolerated.
46004895|NCT04606563|Drug|Telmisartan|Oral Azilsartan 40 mg, and stepped up to 80 mg.
46090032|NCT02662374|Device|Extra Soft Toothbrush|To be moistened with 0.9% normal Saline and used twice daily to remove dental plaque
46090033|NCT02662374|Drug|Supersaturated Calcium Phosphate|5ml of the solution to be swished four times a day
46090034|NCT02834117|Other|natural cycle|Ovulation is not induced by drugs
46090035|NCT02834117|Drug|moderate ovarian stimulation|Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
46090036|NCT02661906|Other|SKY|Sudarshan Kriya Yoga is a rhythmic breathing exercise with slow and fast breath at a particular pace.It is recommended for stress management as yoga is a mind body control tool. SKY is having effect on multiple organ thus causing the positive effect.
46090037|NCT02834351|Other|Muscle Biopsy|"A distal and proximal biopsy of the sartorius muscles ( 0.5 cm3 each) will be performed during surgery for saphenous vein withdrawal (cardiac group) or arterial bypass (PAD group) The samples are then treated with neurovascular and mitochondrial biology laboratory.~the activity of the complex 1 is analyzed and compared between the 2 groups."
45677907|NCT01955161|Drug|Placebo|Once daily, matching placebo capsules, orally
45677908|NCT01955161|Drug|Idalopirdine|Once daily, encapsulated tablets, orally
45677909|NCT01441414|Biological|PF-04856884|15 mg/kg/week intravenously [IV] until toxicity or disease progression
45677910|NCT01441414|Drug|Axitinib (AG-013736)|5 mg PO BID
45677911|NCT01441414|Drug|Axitinib (AG-013736)|5 mg PO BID
45677912|NCT01971554|Drug|MK-8666|MK-8666, capsules, oral, QD, Days 1 to 14
46004896|NCT02885584|Device|High frequency percussive ventilation|
45677913|NCT01971554|Drug|Placebo|Placebo, capsules, oral, QD, Days 1 to 14
46004897|NCT00565968|Drug|melphalan|
46090038|NCT02661750|Drug|Bowel Preparation|"Standard 1/2 Dose: 153 g MiraLAX + 32 oz Gatorade 2 liters, 2 liters NuLYTELY, 1 liter MoviPrep, 16 oz (1 bottle) SuPREP, 10 oz (1 bottle) MagCitrate.~Standard Full Dose: 306 g MiraLAX + 64 oz Gatorade, 4 liters NuLYTELY, 2 liters MoviPrep, 32 oz (2 bottles) SuPREP, 20 oz (2 bottles) MagCitrate.~Step 1: 51 g MiraLAX* noon the day-prior; Full dose - 51 g MiraLAX 6 PM day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 2: 1/2 dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 3: Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 4: 1/2 dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 5: Full dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy."
46090039|NCT05334251|Other|combined spinal-epidural anesthesia|Combined spinal and epidural anaesthesia is a regional anaesthetic technique, which combines the benefits of both spinal anaesthesia and epidural anaesthesia and analgesia. The spinal component gives a rapid onset of a predictable block. The indwelling epidural catheter gives the ability to provide long lasting analgesia and to titrate the dose given to the desired effect.
46090040|NCT00649350|Drug|Metformin Hydrochloride ER Tablets 750 mg|750mg, single dose fed
46004898|NCT00565968|Drug|sorafenib tosylate|
45677914|NCT04411459|Other|Invasive mechanical ventilation|Invasive mechanical ventilation for respiratory failure associated to COVID-19 pneumonia
46004899|NCT00565968|Genetic|gene expression analysis|
46004900|NCT00565968|Genetic|protein expression analysis|
46004901|NCT00565968|Genetic|western blotting|
46004902|NCT00565968|Other|pharmacological study|
46004903|NCT01162486|Drug|Rifampin & midazolam|rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
46004904|NCT01162486|Drug|rifapentine & midazolam|rifapentine - tablet, 5 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
46090041|NCT00649350|Drug|Glucophage XR 750 mg|750mg, single dose fed
46090042|NCT04169880|Device|HILT|HILT will be performed with BTL 6000 High Intensity Laser (London, UK) which is a therapeutic non-invasive neodymium: yttrium aluminum garnet laser that has a pulsating waveform and 1064 nm wavelength, 12 Watt maximum power and has the ability to penetrate 12 cm.
46090043|NCT04169880|Combination Product|HILT & EXERCISE|HILT&Exercise group will receive exercise therapy right after they receive HILT. Both groups will receive treatment for 3 days a week, on alternate days and totally 10 sessions. Patients will be asked not to use analgesic medication throughout the treatment period.
46090044|NCT00649506|Drug|Nitrofurantoin Macrocrystals 100 mg Capsules|100mg, single dose fed
46090045|NCT00649506|Drug|Macrodantin® 100 mg Capsules|100mg, single dose fed
45677915|NCT04664335|Other|questionnaire|if no Reply to questionnaire, telephone interview
45677916|NCT01998841|Drug|Crenezumab|Crenezumab will be administered as per the schedule specified in the treatment arm.
45677917|NCT01998841|Drug|Placebo|Placebo will be administered as per the schedule specified in the treatment arm.
46004905|NCT01162486|Drug|rifapentine & midazolam|rifapentine - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
46004906|NCT01162486|Drug|rifapentine & midazolam|rifapentine - tablet, 15 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
46004907|NCT01162486|Drug|rifapentine and midazolam|rifapentine - tablet, 20 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
46004908|NCT01162486|Drug|rifapentine and midazolam|rifapentine - tablet, 2.5 mg/kg lower than previously tolerated dose cohort, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
46004909|NCT00555698|Device|Deep Brain Stimulations for Depression|Deep Brain Stimulations for Depression
46090046|NCT05272722|Diagnostic Test|ECG,|Holter monitoring
45459169|NCT03495310|Behavioral|Mindfulness|Mindfulness is a method based on the concentration of attention, awareness and meditation, which has been used successfully to reduce stress, depression and anxiety in individuals with some pathology in the short term
45677918|NCT01955083|Device|Pillar implant|Subjects receive pillar implant of the soft palate under local anesthesia as an outpatient procedure on sitting position. Using the delivery tool of the pillar implant system, the mucosa of the soft palate close to the hard palate-soft palate junction (approximate 0.5 cm) was punctured in the midline. The needle was inserted to the uvular muscle and moved parallel to the curve of the soft palate towards the tip of the uvula. After reaching the insertion point, the implant was delivered steadily after which the needle was withdrawn. This process was repeated for the second and third implants in the bilateral para-midline with a 0.2 cm horizontal distance from the first implant.
46004910|NCT04314427|Procedure|Roux-en-Y gastric bypass|
46004911|NCT04314427|Procedure|Sleeve gastrectomy|
46004912|NCT04598607|Drug|Hypidone Hydrochloride tablets|30mg(10mg×3), 40mg(10mg×4) or 50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3~8.
46004913|NCT04598607|Drug|Placebo|3, 4 or 5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3~8.
46090047|NCT02658552|Device|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
46004914|NCT02885701|Other|No Splint|The no splint group received a soft dressing consisting of an occlusive petroleum gauze strip (Xeroform, Mansfield, MA) over the wound, one folded 4x4 gauze, and a single wrap of roll gauze around the hand, and the wrist was placed and secured by a Coban wrap (3M, St. Paul, MN). The dressing permitted wrist and finger motion. Patients were further instructed to remove the dressing at five days and place an adhesive bandage (Band-Aid, Johnson & Johnson, New Brunswick, NJ) over the incision.
46090048|NCT00649038|Drug|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fed
46090049|NCT00649038|Drug|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fed
46090050|NCT04169412|Diagnostic Test|Blood Collection|Blood Gas Analysis using Stat Profile pHOx® Series (nova biomedical, Waltham, U.S.) and Enzym-linked Immunosorbent Assay (ELISA) using Bio-Rad (Bio-Rad Laboratories, California, U.S.)
46090051|NCT04169256|Drug|HYR-PB21|HYR-PB21 for injection 100mg, 200mg,or 400mg by single subcutaneous injection on the abdomen
46090052|NCT04169256|Drug|Liposomal bupivacaine|Liposome Bupivacaine Suspension for injection 200mg by single subcutaneous injection on the abdomen
46090053|NCT04169256|Other|Normal Saline|Normal Saline 30ml, or 40mL by single subcutaneous injection on the abdomen
46090054|NCT02658396|Drug|GO-203-2C|
46090055|NCT02658396|Drug|Bortezomib|
46090056|NCT02661360|Behavioral|Swaddling Intervention for Preterm Infants|Procedure for swaddling includes folding one corner of the blanket down two thirds of the way down the blanket in order to make the blanket into a triangular shape. The infant will be positioned with shoulders at the fold of the blanket. The infant will be positioned with the blanket so that elbows, hips, and knees flexed with hands near the face by wrapping one side of the blanket across the chest holding the hands in place, pulling the bottom corner up toward the infant's face, and securing the blanket with the last corner pulled across the infant's chest again and around their back. The blanket will be tight enough to keep extremities in place but one finger will be able to be placed between the infant and the blanket.
46090057|NCT02661360|Behavioral|Unswaddled Control|Procedure for control is blanket loosely draped across the infant without providing containment and without touching the anterior surface of the infant.
45459170|NCT01372046|Behavioral|Booster Sessions|Provides onsite booster sessions for one year to the group after participating in standard care
45459171|NCT01372046|Behavioral|Training|memorandums, staff meetings
45459172|NCT05097196|Other|Moderate-intensity aerobic activities|The exercise intensity of the individual is planned at 50-60% heart rate reserve using the Karvonen method.
45459173|NCT05192018|Procedure|Early reversal of a defunctiong ileostomy|Early reversal of a defunctiong ileostomy after 3 weeks of its creation
45459174|NCT03487822|Behavioral|Path Pain|The intervention examines the effects of PATH-Pain on emotion regulation to improve self-management of pain and pain-related disability in older adults with chronic pain, negative emotions, and cognitive impairment. This intervention consists of 8 weekly therapy sessions by a licensed clinician trained in Path Pain, 4 monthly boosters upon completion of therapy, and optional monthly group educational sessions.
45459175|NCT03634592|Procedure|Catheter ablation|Radiofrequency catheter pulmonary vein isolation
45459176|NCT05043064|Procedure|Wet lab tasks|Robotic-assisted internal thoracic artery harvesting, mitral annulus sutures placement and atrial closure in porcine model
46090058|NCT02656368|Device|SEBORRHEAMEDIS Face Cream|SEBORRHEAMEDIS Face Cream is a barrier-based, non-steroidal cream. The cream includes plant extracts The cream was designed to manage the symptoms of facial Seborrheic dermatitis symptoms such as erythema, scaling and pruritus.
46090059|NCT02661438|Drug|Placebo to Ciprofloxacin DPI (BAYQ3939)|Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
46090060|NCT00894803|Drug|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
46090061|NCT00894803|Drug|rt-PA|Intravenous recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy.
46090062|NCT02661048|Device|CyberHeart System|The CyberHeart system uses proprietary software to assist the cardiologist to contour ablation targets. Standard radiosurgical techniques are then used to accomplish ablation
46090063|NCT02660970|Other|Acupressure|Children will have to wear a 'seasickness-band', which has the effect of acupressure
46090064|NCT02660970|Other|Placebo-band|Children will have to wear a 'placebo-wristband'
46090065|NCT02660970|Drug|Iberogast|Children will have to take Iberogast drops
46090066|NCT02660970|Other|Placebo-drops|Children will have to take placebo-drops
45459177|NCT03634514|Drug|Recombinant human growth hormone - Biomatrop|The subjects who recieve Biomatrop first, after a period maximum of 24 hours will recieve a dose of Hormotrop.
45459178|NCT03634514|Drug|Recombinant human growth hormone - Hormotrop|The subjects who recieve Hormotrop first, after a period maximum of 24 hours will recieve a dose of Biomatrop.
46090067|NCT02840435|Behavioral|Sit to Quit|Sit to Quit(STQ) is a smoking cessation program adapted from Mindfulness Training for Smokers (MTS) with core content available on the STQ video. STQ contains many elements found in traditional interventions (e.g. instruction on planning and structuring a quit day, garnering support from others, assessment of prior relapse occasions, development of strategies to avoid triggers). In addition, STQ provides instruction in various mindfulness practices and in how to apply mindfulness skills to manage common causes of relapse. Exercises are provided, and it is recommended to learn the skill experientially. STQ requests that participants practice guided meditation each day using an audio recording and employ other mindfulness practices targeted to manage relapse challenges. Participants will also receive the STQ Participant Manual, which provides all the instruction found in the STQ Video, but provides additional discussion of topics for smokers who desire additional material.
46090068|NCT02840435|Behavioral|Quit for Life|"Quit for Life integrates telephone counseling, written materials, NRT, and an online program called Web Coach. Web Coach is an interactive internet-based support system that provides health information on smoking cessation, assistance in the development of quit strategies, and an interactive blog to interact with other smokers. Web Coach is used by approximately 70% of AWI callers. Web Coach is not a complete program, but instead is designed to supplement AWI phone-based therapy. In addition, Quit for Life also provides the Quit Guide, which is a smoking cessation manual with written instructions on the use of medications, planning a quit day, and cessation-related cognitive skills."
45459179|NCT02323438|Other|Usual Brand Cigarette|Combustible cigarette brand style smoked most frequently by subject
45459180|NCT02323438|Other|Electronic Cigarette #1|Electronic cigarette
46090069|NCT02834273|Behavioral|stroke education workshops|
45459181|NCT02323438|Other|Electronic Cigarette #2|Electronic cigarette
46004915|NCT02885701|Other|Removable Splint|The removable splint group received a V-strap Wrist support (Medical Specialties, Inc., Charlotte, NC) placed over the identical soft dressing that was placed on the no splint group. The cock-up wrist splint was designed to keep the wrist fixed in a 20 degree extended wrist position. Patients were instructed to wear the splint for comfort as needed during day and night. While the patient was wearing the cock-up splint, only finger motion was permitted. Wrist motion was permitted when the cock-up splint was removed.
46004916|NCT02885701|Other|Non-removable Splint|The plaster non-removable splint group received an occlusive petroleum gauze strip placed over the wound, followed by a 4X4 gauze, and a Webril cotton roll wrap (Covidien, Inc., Covidien, Ireland). A 4- inch, 15-layer thick plaster splint was placed across the volar wrist and molded to keep the wrist in approximately 20 degrees of extension allowing full digital range of motion (ROM). The splint was to be kept dry and not removed by the patient.
46090070|NCT00601458|Drug|pregabalin|Patients will be randomized just prior to surgery to 1 of 3 study treatments: pregabalin (300 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, pregabalin (150 mg) will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
46090071|NCT00601458|Drug|naproxen sodium|Patients will be randomized just prior to surgery to 1 of 3 study treatments: naproxen sodium (550 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, naproxen sodium will be dosed starting 12 hours following T=0 and every 12 hours until 36 hours following T=0.
46090072|NCT00601458|Drug|Comparator: Placebo|Patients will be randomized just prior to surgery to 1 of 3 study treatments: placebo treatment will be administered approximately 1 hour prior to surgery. Postoperatively, placebo will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
46090073|NCT02834039|Procedure|Tidal volume 6 ml/kgBW|Tidal volume 6ml/kgBW was given to subjects after endotracheal tube was inserted properly.
46090074|NCT02834039|Procedure|Tidal volume 10 ml/kgBW|Tidal volume 10 ml/kgBW was given to subjects after endotracheal tube was inserted properly.
46090075|NCT02660736|Drug|Albiglutide Liquid Auto-injector|Albiglutide liquid is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid (50 mg). The auto-injector delivers the study treatment in an injection volume of 1.0 mL for the 50 mg dose
46090076|NCT02660736|Drug|Albiglutide Lyophilized DCC Pen Injector|Albiglutide is supplied as prefilled DCC Pen Injector. Each DCC contains lyophilized albiglutide 50 mg. When the injector pen product is reconstituted a neutral, isotonic solution is produced. The pen delivers albiglutide in an injection volume of 0.5 mL
45459182|NCT02323438|Other|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
45677919|NCT01955083|Device|Radiofrequency|Subjects receive radiofrequency under local anesthesia as an outpatient procedure on sitting position. radiofrequency energy was delivered via a generator (Somnus® Model S2, Gyrus-ACMI Corporation, Maple Grove, MN, USA) with the power set to 10 watts and the maximal target temperature to 85°C. The needle electrode was inserted through the mucosa into the muscle layer at the entry points (approximately 1 cm below the hard palate-soft palate junction). The electrode was kept in place until 600 J had been delivered at the midline and 300 J at both para-midline sites (approximately 1 cm horizontal distance).
45677920|NCT01955005|Behavioral|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
45459183|NCT01372124|Drug|NOX-E36|All subjects included in this study will receive the same dose of NOX E36. In previous clinical trials, single intravenous doses of NOX E36 up to 2 mg/kg body weight and single subcutaneous doses of up to 0.5 mg/kg body weight appeared to be safe and well tolerated in healthy volunteers. Pharmacokinetic analyses have shown dose linearity
45677921|NCT01955005|Other|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
46090077|NCT02660736|Drug|Placebo Liquid Auto-injector|Liquid albiglutide matching placebo is provided as a fixed-dose, disposable autoinjector containing placebo liquid. The auto-injector delivers the placebo in an injection volume of 1.0 mL for the 50 mg placebo dose.
46090078|NCT02660736|Drug|Placebo Lyophilized DCC Pen injector|Placebo is supplied as prefilled DCC Pen Injector. Each DCC contains matching placebo. When the injector pen product is reconstituted a neutral, isotonic placebo solution is produced. The pen delivers the placebo in an injection volume of 0.5 mL.
46090079|NCT05308511|Device|PC-I and COLON2|First swallow the trial device(PC-I) for examination, and then swallow the comparator device(COLON2) for examination at an interval of 2h.
46090080|NCT05308511|Device|COLON2 and PC-I|First swallow the comparator device(COLON2) for examination, and then swallow the trial device(PC-I) for examination at an interval of 2h.
46090081|NCT02831153|Procedure|coronary angiography|Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.
46090082|NCT04169178|Drug|HLX55|A humanized IgG2 monoclonal antibody targeting tyrosine-protein kinase MET (c-MET)
46004917|NCT00555737|Device|Capsule Endoscopy|Given® Diagnostic system with Pillcam SB
46090083|NCT02831309|Behavioral|Light-Intensity Condition|The light-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, light--intensity activity breaks performed at 25% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
46090084|NCT02831309|Behavioral|Moderate-Intensity Condition|The moderate-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, moderate-intensity activity breaks performed at 50% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
46090085|NCT02831309|Behavioral|High-Intensity Condition|The high-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, vigorous-intensity activity breaks performed at 75% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
46090086|NCT02831309|Behavioral|Sedentary Condition|The sedentary condition consisted of 8 hours of sitting interrupted with 2-minutes of screen time every 18 minutes. Standardized meals were provided.
45677922|NCT01954927|Drug|Gabapentin|Gabapentin is supplied as an oral suspension. Patients randomized to the gabapentin arm will receive a single dose of gabapentin as soon after enrollment as feasible. The gabapentin dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900 mg.
46004918|NCT01162135|Drug|Digoxin|"The participants will take study drug digoxin, which is approved by FDA for the treatment of CHF, 125 or 250 mcg orally daily, titrated to the level of 0.8 - 2 ng/ml for total of 6 cycles (4 weeks/cycle). The lower dose of digoxin (such as 125 mcg/day) will be chosen if serum level reaches 0.8 ng/ml already. Patients may continue another 6 cycles if evident of clinical benefit.~It is possible that some patients may need to receive 500 mcg per day to reach this targeted drug level. No further titration will be allowed beyond this FDA approved digoxin dose."
46090087|NCT02658162|Drug|SANGUINATE|Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
45677923|NCT01954927|Drug|Placebo|Placebo will be prepared by the SJCRH pharmacy and will be similar in appearance, quantity and taste to the gabapentin drug. Patients randomized to the placebo arm will receive a single dose of placebo as soon after enrollment as feasible. The placebo dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900mg.
46004919|NCT00555776|Drug|Gabapentin|Gabapentin, 600 mg bid for the first two weeks, increased to a maximum dose of 1800 mg per day during the next 6 weeks if necessary.
46004920|NCT00555776|Drug|placebo|placebo is given with the same definition as Gabapentin
46090088|NCT02658162|Drug|Normal Saline|Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
46090089|NCT00649584|Drug|SGN-35|IV; 0.4 up to 1.8 mg/kg weekly 3 out of 4 weeks; minimum of two 28-day cycles
46090090|NCT00649584|Drug|gemcitabine|IV; 1000 mg/m2 weekly 3 out of 4 weeks
46090091|NCT02658006|Procedure|Cardiac surgery|All cardiac surgery procedures
46090092|NCT05308433|Device|Functional MRI|The volunteer will have to imagine the smells evoked by different visual aids. This task will be carried out during 2 acquisition runs of about 10 minutes each. The volunteer should note (on a scale from 1 to 4) the pleasantness of the smell evoked.
45683799|NCT04087642|Diagnostic Test|Intraoperative Crede manoeuver|In this group, both tests will be performed but the intraoperative Crede manoeuver will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
46004921|NCT04675463|Drug|BGF Inhalation Aerosphere|Budesonide/Glycopyrronium/Formoterol: 160/7.2/4.8/ puff, twice daily with two puffs per time
46004922|NCT04675463|Drug|GFF Inhalation Aerosphere|Glycopyrronium/Formoterol: 7.2/4.8 per puff, twice daily with two puffs per time
46090093|NCT05308433|Other|Virtual Reality: control|The volunteer will be immersed in a virtual maritime environment with nauseating characteristics. In the center of the maritime scene, it will be visible the black outlines of a frame. Every minute, the volunteer will be asked to verbalize the level of his general condition via the Fast Motion Sickness Scale (1 to 20).
46090094|NCT05308433|Other|Virtual Reality: experimental|The volunteer will be immersed in a virtual maritime environment with nauseating characteristics. The visual support inserted in the center of the virtual scene will be the one defined as being the most facilitator of the olfactory imagination during the fMRI examination. The volunteer will be asked to concentrate on the smell evoked by this support. Every minute, the volunteer will be asked to verbalize the level of his general condition via the Fast Motion Sickness Scale (1 to 20).
46090095|NCT02141282|Drug|Venetoclax|Each dose of venetoclax was to be taken with approximately 240 mL of water within 30 minutes after the completion of breakfast or the participant's first meal of the day.
46090096|NCT02657850|Other|non- head and neck self reporting|non- head and neck patient self reports dysphagia symptoms
46090097|NCT02657850|Other|head neck self reporting|head and neck patient self reports dysphagia symptoms
46090098|NCT02657850|Other|provider reporting|provider reports on head and neck cancer patients' dysphagia symptoms
46090099|NCT02656212|Drug|epicatechin|30 mg (+)-epicatechin, taken orally, one pill/day in the morning
45677924|NCT01954771|Behavioral|SMBG|"Control Group Patients will receive conventional care and keep on their usual SMBG methods. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-4 Group Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-7 Group Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively."
45836268|NCT00125658|Other|Experimental|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Power training (dynamic resistance exercise) followed by 10 weeks of Functional Task Practice (FTP). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
46004923|NCT04675112|Behavioral|Cognitive Behavioral Treatment (CBT) and Tinnitus Retraining Therapy (TRT)|"CBT is a psychologically informed treatment. Depending on individual patient needs, relevant areas of tinnitus education and management/self-management strategies, such as managing the emotional consequences of tinnitus, rapid relaxation, managing fear and avoidance behaviors and changing unhelpful thoughts and beliefs, are applied in accordance to a published manual [10].~TRT is based on the neurophysiological model focusing more on education and sound therapy than on analytical cognitive and behavioral interventions. A TRT program is usually included in a management scheme with hearing aids."
46004924|NCT01161628|Drug|Rituximab|Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
46004925|NCT04598217|Other|anesthesiologist|non-interventional observational
46004926|NCT04675502|Other|supervised Exercise training|warm-up, loading (respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes), cooling, and relaxation exercises
46004927|NCT04675502|Other|home exercise trainig|Warm-up, loading (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), cooling and relaxation exercises
46004928|NCT04314505|Drug|Opioid-Sparing Protocol|After a general anesthesia procedure was performed, an experienced anesthesiologist performed ultrasound guided adductor canal block procedures on both knees. In the opioid-sparing group, a dose of Parecoxib sodium 40 mg was administrated through intravenous route before the incision. After the surgery, Parecoxib sodium 40 mg was given intravenously every 12 hours for 4 more doses. Before the wound closure, the periarticular injection (each side 10 ml of 0.25% Bupivacaine) was done. The total dosage would be recorded in the device. All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.
46090100|NCT02656212|Drug|Placebo|Placebo pill, taken orally, one pill/day in the morning
46090101|NCT02660814|Other|Non-surgical periodontal treatment|"SRP under local anaesthesia, in a total of 2-3 clinical visits.~Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
46090102|NCT02660814|Other|Gingival crevicular fluid collection|GCF collection with filter paper (Periopaper) using the intracrevicular method.
46090103|NCT00003479|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Patients with an ependymoma will receive Antineoplaston therapy (Atengenal + Astugenal).
46090104|NCT00618488|Dietary Supplement|Probiotic BB12 - Bifidobacterium lactis|Bifidobacterium lactis (3.1 oz yogurt) administered once a day for 6 weeks
46090105|NCT00618488|Dietary Supplement|Placebo|Placebo administered once a day for 6 weeks
46090106|NCT02657616|Drug|vitamin-k-antagonists|
46090107|NCT02657616|Drug|Novel oral anticoagulants|
46090108|NCT04212494|Procedure|Thrombus aspiration|Percutaneous Coronary Intervention with manual aspiration thrombectomy
46090109|NCT04212494|Procedure|Thrombus aspiration|Percutaneous Coronary Intervention without manual aspiration thrombectomy
46090110|NCT05288777|Drug|T-DM1|Dosed at 3.6 mg/kg of body weight every 3 weeks for Her2/neu+ patients for a total duration of 14 cycles.
46090111|NCT05288777|Drug|Capecitabine|Dosed at 825 mg/m2 +/- 150mg twice per day for a total duration of 6 months
46090112|NCT05288777|Radiation|External Beam Radiation Therapy 0|Dose of 40 Gy in 15 fractions to the whole breast or chest wall followed by consideration of a 10 Gy in 4 fraction boost to the lumpectomy cavity for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.
46090113|NCT05288777|Radiation|External Beam Radiation Therapy 1|Dose of 40 Gy in 15 fractions to either the breast or chest wall along with comprehensive nodal radiation followed by consideration of a 10 Gy in 4 fraction boost for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.
46090114|NCT02656056|Other|Food: (Q-Can Plus fermented soybean beverage)|Fermented soybean beverage. Dose is 8 oz, twice daily.
46090115|NCT02657694|Drug|Sofosbuvir+Ledipasvir|DAA medication treatment
46090116|NCT02657694|Drug|Sofosbuvir+Daclatasvir|DAA medication treatment
46090117|NCT02657694|Drug|Sofosbuvir+Velpatasvir|DAA medication treatment
46090118|NCT02833961|Device|Magnetic resonance imaging|
46090119|NCT02657460|Biological|tumor derived microparticles|The main difference between the two treatment groups is the biological coat, which is tumor derived microparticles.
46090120|NCT02657460|Drug|cisplatin|cisplatin is a traditional drug for lung cancer
46090121|NCT02833727|Other|Smoking|Smoking equal or greater than 10 pack/years; never smokers: lifelong history without smoking.
46090122|NCT00649896|Drug|Mylan Estradiol Transdermal System 0.025 mg/day|
46090123|NCT00649896|Drug|Climara® Transdermal System 0.025 mg/day|
46090124|NCT00618566|Behavioral|WPD and Depression Treatment Group|Intervention selected will depend on Phase I data analysis.
46090125|NCT00649662|Drug|Ciprofloxacin Extended-Release Tablets 1000 mg|1000mg, single dose fasting
46090126|NCT00649662|Drug|Cipro® XR Tablets 1000 mg|1000mg, single dose fasting
46090127|NCT02831075|Biological|Adipose-derived stem cell|stem cell acquisition, processing and reinfection, to evaluate the efficacy of adipose-derived stem cell.
46090128|NCT02831075|Biological|saline|
46090129|NCT04188158|Combination Product|CAPECITABINE AND OXALIPLATIN|Intervention Group: Neoadjuvant chemotherapy ( 3 cycles Capecitabine and oxaliplatin) + surgery + adjuvant chemotherapy (5 cycles Capecitabine and oxaliplatin)
46090130|NCT02831231|Drug|xanomeline tartrate|xanomeline tartrate, 75 mg capsule, TID
46090131|NCT02831231|Drug|Trospium chloride|trospium chloride, over encapsulated 20 mg tablet, BID
46090132|NCT02657304|Behavioral|Coaching group|patients will have a medical consultation at 2 weeks post-diagnostic and one phone call/month for duration of 5 months. The consultations will use visual support, CPAP device and its accessories.
46090133|NCT02657304|Other|Control group|patients receive only usual care (standard), it's mean: diagnosis with explanation of the disease and benefit of CPAP, entrusts a medical device provider, then an appointment proposed by the doctor or taken by the patient (5 months).
45677925|NCT01954771|Other|CGMS|In this study, according to the protocol, all the patients will follow their prespecified SMBG methods and periodically visit doctor, but therapies will not be adjusted unless they experience severe hypoglycemia or hyperglycemia episodes. The expected duration of the trial is 12 weeks.
46090134|NCT05234606|Drug|SBT6290|Escalating doses by subcutaneous (SC) injection in 21-day cycles
46090135|NCT05234606|Drug|SBT6290|Dose expansion with the recommended Phase 2 dose (RP2D) by SC injection in 21-day cycles
46090136|NCT05234606|Drug|pembrolizumab|200 mg via intravenous (IV) injection in 21-day cycles
46090137|NCT02657382|Behavioral|Heart Rate Variability (HRV) Biofeedback (BF)|Heart Rate Variability (HRV) biofeedback involves deep breathing, mindfulness (focusing on one's emotions and thoughts) and cognitive therapy (identifying and changing unhelpful or inaccurate thinking and distressing emotional responses). It is a 6-week training with one hour sessions with a certified biofeedback coach once per week. A handheld personal stress reliever device will be provided to the patients to practice at home for 20 minutes a day.
45677926|NCT01997281|Dietary Supplement|dietary fiber-enriched cereal|"provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~amount: 79g for dinner and breakfast, 38.5g for night snack (10 p.m.)~one serving of steamed egg is added for dinner and breakfast"
46090138|NCT02657382|Other|Mental Stress Protocol|Mental stress will consist of a 3-min math serial subtraction paradigm.The participants will be asked to serially subtract 7 from number specified by the researcher. For participants who have difficulty with this task, easier serial subtraction will be provided for. Throughout the task, to increase stressfulness and titrate difficulty, the participant will be prompted for faster performance and the starting number from which they were subtracting will be periodically changed. Finally, to add an evaluation component, participants will be given negative feedback during the test.
46090139|NCT04033380|Device|Resin blocs (Grandio Blocs, VOCO)|composite-base bloc (Grandio Blocs, VOCO)
46090140|NCT04033380|Device|Ceramic (Suprinity, VITA)|glass ceramic zirconia enhanced lithium silicate glass ceramics (Suprinity, VITA)
45459184|NCT01372904|Drug|Dexamethasone Phosphate|"0.7ml of Dexamethasone Phosphate 10mg/ml would be injected unilaterally to the middle ear using 25 gauge spinal needle.~The trans-tympanic membrane injection would take place at the posterior inferior quadrant of the ear drum facing the round window niche. The patient would be instructed to lie down for 20 minutes after the injection with the treated side up and to avoid swallowing or coughing. Intratympanic Dexamethasone would be delivered immediately prior to each cisplatin treatment as maximal level."
46004929|NCT04314505|Drug|Opioid-Based Patient Controlled Analgesia|After a general anesthesia procedure was performed, an experienced anesthesiologist performed ultrasound guided adductor canal block procedures on both knees. The patient was informed that the intravenous bolus of rescue morphine (4mg) was available every 4 hours if the pain was intolerable. In the PCA group, the device was applied before incision and the initial setting was 0.01mg/kg*hour, patient-controlled dose 2 mg, lock-out 5 minutes and limited 40mg in each 4 hours. After the surgery, the staff of PCA group would visit the patients and adjusted the dosage. The PCA was removed after 72 hours from the surgery. Before the wound closure, the periarticular injection (each side 10 ml of 0.25% Bupivacaine) was done. The total dosage would be recorded in the device. All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.
46004930|NCT04606641|Other|functional tasks with mirror therapy|In this group a mirror will be placed in the sagittal plane of patient. The affected or paretic arm will be placed behind the mirror and the unaffected or normal arm will be placed in front of the mirror. Then the patient will be asked to perform functional tasks
46090141|NCT02830919|Drug|Glucosamine and chondroitin sulfate combination (Eurofarma)|
46090142|NCT02830919|Drug|Glucosamine and chondroitin sulfate combination (Zodic)|
46090143|NCT04214444|Biological|Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma|The investigators aim to describe efficiency and tolerability of prime-boost vaccination against pneumococcus in patients with Diffuse large B-cell Lymphoma. The investigators search to evaluate immunogenicity of prime-boost depending on the time of prevenar administration (before or after immunochemotherapy) and on the dose (single or double dose).
46090144|NCT00649740|Drug|Topiramate Sprinkle Capsules 25 mg|25mg, single dose fasting
46090145|NCT00649740|Drug|Topamax® Sprinkle Capsule 25 mg|25mg, single dose fasting
46090146|NCT04209920|Device|CAD-CAM milled PMMA crown|the patient will receive a full coverage restoration for hypomineralized first permanent molar in patient suffering from molar incisor hypomineralization using PMMA disks using a CAD-CAM technology.
46090147|NCT04209920|Other|Cast metal coping using nickel chromium alloy|the patient will receive a full coverage restoration for hypomineralized first permanent molar in patient suffering from molar incisor hypomineralization using Nickel Chromium alloy to make a Cast Coping.
46090148|NCT04245761|Dietary Supplement|Sonidor®|Sonidor® triple layer release tablets are developed with a specialized process to improve stability and bioavailability of the formulation based on hawthorn, lavender and hop extracts. The hawthorn, lavender and hop extracts used to product Sonidor® have an elevated content of vitexin (3%), monoterpens (4% as linalool) and flavonoids (4%), respectively.
46090149|NCT02536950|Device|Fixed set point|Fixed set point arm: A fixed setpoint will be used initially. Staff will observe glucose control over 2 days while subjects remain in a hotel environment, and then over 5 more days in the same subjects in an outpatient setting. The clinical staff will adjust this target up or down by 15 mg/dl based on their glycemic control in the hotel setting.
46090150|NCT02536950|Device|Variable set point|Variable set point arm: The setpoint will be variable over a 30 mg/dl range and glycemic control will be optimized based on the preceding 24-hour window.
46090151|NCT04245917|Other|Non-interventional|Non-interventional natural history study
46090152|NCT00616694|Drug|Actonel|Actonel 5 mg orally once daily (OD), calcium 500 mg + vitamin D 200 units twice daily (BID)
46090153|NCT02660892|Dietary Supplement|Protein intake|"Oral consumption of eight hourly experimental meals~4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil~4 isotopically labeled experimental meals."
46090154|NCT02830841|Device|remote ischemic preconditioning(RIPC)|After anesthesia induction, donors or recipients will be treated with automated blood pressure cuffs on their upper arms to receive RIPC by cuff inflation (to 15mmHg above systolic pressure) for 5 minutes and left inflated for 5 minutes. The cuff will then be deflated to 0 mm Hg and left uninflated for 5 minutes. This cycle will be performed 3 times in total.
46090155|NCT02830841|Device|Sham RIPC|Only blood pressure cuff will be placed to the patient, but no inflation or deflation will be performed.
46090156|NCT04211402|Other|No Intervention|There is no intervention for this study
46090157|NCT02660658|Drug|Intrathecal dexmedetomidine|The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance
45459185|NCT01372982|Drug|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
46090158|NCT05229731|Procedure|Neurovisual evaluation|Standardized tests and scales classically used during a neurovisual evaluation,
46004931|NCT04606641|Other|functional tasks without mirror therapy|The functional tasks will be explained to patient before the start of treatment. In this group a board instead of a mirror will be placed in the sagittal plane of patient. Then the patient will be asked to perform functional tasks
46004932|NCT02885467|Procedure|Total knee arthroplasty with Saphenous nerve burial|
46004933|NCT02885467|Procedure|Standard total knee arthroplasty|
46004934|NCT02885545|Device|Watchman|If the patient is randomized to the Intervention Arm of the study the Watchman device will be implanted into the left atrial appendage of the heart
46004935|NCT02885545|Drug|Continued therapy with the prescribed oral anticoagulant|If the patient is randomized to the control arm of the study, they will continue taking the oral anticoagulant that has been prescribed (vitamin K antagonist, Apixiban 2.5mg bid or Rivaroxaban 15mg od)
46090159|NCT05229731|Procedure|Cerebral MRI|"Sequences realized :~3D T1 TFE i1.0~3D FLAIR i1.0~2D T2 0.3 coro, centré sur les orbites~3D T2 i0.6~SWIp 0.6~3D PD T2 NO, centré sur les orbites~3D ASL~DTI 64dir"
46090160|NCT00619814|Procedure|Double-contrast Barium enema, colonoscopy|This is a blinded cohort study comparing double contrast barium enema (DCBE) and colonoscopy in detecting polyps and/or cancer in patients with positive FOBT. Initial evaluation consisted of complete clinical history and physical examination. A DCBE and a colonoscopy were performed in all patients. All polyps identified during colonoscopy were removed and classified by histology. Sensitivity and specificity of DCBE for polyp and/or cancer detection was determined. Tolerability and grade of satisfaction with study procedures was assessed.
46090161|NCT02660502|Drug|Biochaperone insulin lispro 0.1 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.1 U/kg
46004936|NCT04598412|Other|No intervention|Cross-sectional
46004937|NCT04675268|Diagnostic Test|oximetry|A CE medical approved polygraphy device (Dreamscan 2 - Medatec) will be used to obtain oximetry (and PPG) data
46004938|NCT01161472|Drug|4mg fesoterodine|4mg tablet once daily for 6 days
46004939|NCT01161472|Drug|8mg fesoterodine|4mg tablet once daily for 3 days followed by 8mg tablet once daily for 3 days
46004940|NCT01161472|Drug|alprazolam 1mg|1mg tablet once on last day of treatment period at clinic
46004941|NCT01161472|Drug|Placebo|Placebo tablet for fesoterodine once daily for 6 days and placebo tablet for alprazolam once on last day of treatment period at clinic
46004942|NCT04606680|Device|Heat application at acupoints|"The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard. The hot sticker will be placed on the patient's acupoints for about 2 hours. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~The following lifestyle modification are recommended to help to establish healthy habits:~The proportion of three nutrients in total calories comprises of 55%-65% from carbohydrates, 20%-30% from oils and 15% from protein, and the energy of the whole day distributed to three meals will follow the proportion of 30% for breakfast, 40% for lunch and 30% for dinner. Meanwhile, low-to-moderate intensity physical activities will be instructed to them for at least 5 days per week continually, 30%-50% of the maximum heart rate reserve value will be required."
46004943|NCT04606680|Device|Medicated plaster at acupoints|"The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard.The chinese traditional medicine(aconite root, dried ginger, evodia rutaecarpa, clove, cinnamon, etc)in moderation will be grinded into powder，and the powder will be added with a certain amount of flour, and finally they will be blended with ginger juice to the appearance of mud. Next, 10g of the kneaded medicine mud will be taked and applied to the bottom of the ordinary sticker. They will be placed on the patient's acupoints for about 2 hours. The sticker has the same shape as the hot sticker, but it does not have the effect of thermal stimulation and infrared radiation. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~Lifestyle modification:It will be performed as the same as the heat application group."
46004944|NCT04606680|Device|Herb-partitioned moxibustion at acupoints|"The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard[18]. The chinese traditional medicine(aconite root, dried ginger, evodia rutaecarpa, clove, cinnamon, etc)in moderation will be grinded into powder，and the powder will be added with a certain amount of flour, and finally they will be blended with ginger juice to the appearance of mud. Next, 10g of the kneaded medicine mud will be taked and applied to the bottom of the hot sticker. They will be placed on the patient's acupoints for about 2 hours. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~Lifestyle modification:It will be performed as the same as the heat application group."
46090162|NCT02660502|Drug|Biochaperone insulin lispro 0.2 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.2 U/kg
46090163|NCT02660502|Drug|Biochaperone insulin lispro 0.4 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.4 U/kg
46090164|NCT02660502|Drug|Humalog®|Injection of a single dose of Humalog® at the dose of 0.2 U/kg
46090165|NCT04203524|Diagnostic Test|Procalcitonin Levels|Procalcitonin (PCT) will be measured within 48 hours of admission to the ICU or 48 hours of onset of sepsis (if developed during the ICU stay). In addition, the patients will have daily blood samples taken up to 5 days or until ICU transfer, whichever occurs first. A PCT-guided algorithm will be available to guide the management of patients in the PCT group.
46090166|NCT04203524|Other|Control|Procalcitonin (PCT) will be measured within 48 hours of admission to the ICU or 48 hours of onset of sepsis (if developed during the ICU stay). In addition, the patients will have daily blood samples taken up to 5 days or until ICU transfer, whichever occurs first.The results of the PCT levels obtained will be blinded and all clinical team members will not be able to access the results.
46004945|NCT04675385|Drug|0.2% hyaluronic acid gel|In this split mouth study, 733 periodontal pockets of 28 patients with moderate to severe chronic periodontitis were chosen for investigation. They were divided into 2 groups: control group and experimental group. The experimental group received sub-gingival administration of 1 ml of 0.2% hyaluronic acid gel into each pocket immediately after root planing and then after 1 week, 2 weeks and 3 weeks. Clinical parameters were assessed at baseline and 6 weeks after root planing. Subgingival plaque was assessed at baseline and 6 weeks after root planing. Quantitative real-time PCR for Porphyromonas gingivalis (Pg), Treponema denticola (Td), Fusobacterium nucleatum (Fn) Tannerella forsythia (Tf) were performed at the same time.
46004946|NCT04598061|Drug|Dexmedetomidine IV|Dexmedetomidine IV
46090167|NCT02830763|Dietary Supplement|CNT-02|Each subject will take 2.0g of the investigational product orally 3 times a day after every meal. Unless an apparent worsening of symptoms or unacceptable adverse event occurs, the subject will continue to take the investigational product for up to 6 months.
46004947|NCT01161043|Device|Sensor wear|All subjects to wear sensors
46004948|NCT04675073|Procedure|Ventricular tachycardia substrate-based radiofrequency ablation|The CARTO3 electroanatomic navigation system (Biosense Webster, Diamond Bar, CA, USA) will be used for ablation. An open irrigated 3.5-mm tip ablation catheter (ThermoCool SmartTouch, Biosense Webster, Diamond Bar, CA, USA) will be used for mapping and ablation. The first step of the procedure will be the acquisition of a fast-anatomical map (FAM) of the aorta. This FAM will be then used to integrate the multi-detector cardiac tomography (MDCT) reconstruction and cardiac magnetic resonance (CMR)-derived pixel-signal intensity (PSI) maps within the spatial reference coordinates of the CARTO3 system. RF will be delivered at the entrance of the border zone channels (BZCs) identified in the PSI maps (CMR-guided scar dechanneling technique). Programmed ventricular stimulation (PVS) will be always performed after substrate elimination to test for final inducibility.
46090168|NCT02655900|Other|Pelvic Floor Ultrasound|Transperineal Ultrasound (3D TPUS) and Endovaginal Ultrasound (3D EVUS)
46090169|NCT04247321|Device|Licox® Brain Tissue Oxygen Monitoring System|Invasive brain tissue oxygenation monitoring
46004949|NCT04606875|Diagnostic Test|Campbell Score|The Campbell Score is a blood based assessment of inflammatory and immunologically associated markers that is currently in development as a means of predicting suicidal ideations.
46004950|NCT04674956|Drug|Camrelizumab|PD-1 antibody（Camrelizumab）, 200mg, D1; every 21 days as a cycle.
46090170|NCT04247321|Device|Near-infrared spectroscopy (NIRS)|Non-invasive approach to monitoring brain tissue oxygenation which uses two wavelengths of near infrared light and takes measurements of the ratio of oxyhemoglobin to total hemoglobin
46090171|NCT02660346|Drug|Daptomycin|Control Arm Treatment if used as monotherapy. Study Arm Treatment if used in combination with ceftaroline.
46090172|NCT02660346|Drug|Vancomycin|Control Arm Treatment
46004951|NCT04674956|Drug|Paclitaxel(Albumin Bound) and Gemcitabine|Paclitaxel(Albumin Bound), 125 mg/m2D18; Gemcitabine, 1000mg/m2D1, 8;every 21 days as a cycle.
46004952|NCT04674956|Drug|Placebo|Placebo, 200mg, D1; every 21 days as a cycle.
46004953|NCT00564720|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV on days 1, 8, and 15 every 28 days for 6 cycles
46090173|NCT02660346|Drug|Ceftaroline|Study Arm Treatment
46090174|NCT02833649|Device|Toric Implantable collamer Lens|The toric implantable collamer lens (TICL) is conventionally indicated for the Correcting the refractive error in keratoconus using the TICL is an off label use of the lens.
46090175|NCT02828735|Device|respiration assessment|Respiration Breathing Exercise
46090176|NCT02660190|Drug|hexaminoavolunate|
45836269|NCT02102100|Drug|nicotine|In each of 3 test sessions, subjects in each arm will receive a randomized sequence of three intravenous infusions (30 sec each), one hour apart. The infusions will consist of saline, nicotine (.25 mg / 70kg) and nicotine (0.5 mg / 70 kg). The randomized sequence will remain the same between test sessions for a given subject.
45836270|NCT02102100|Drug|menthol|In each of 3 test sessions, subjects will take 6 inhalations from the study e-cigarette, one inhalation every 15 seconds, of the randomized menthol condition for that test session ust prior to each intravenous infusion. The menthol conditions are: 3.2% menthol, 0.5% menthol and tobacco-flavor only (0.0% menthol)
46004954|NCT00564720|Drug|Gemcitabine|Gemcitabine 1100 mg/m2 IV on days 1 and 8 every 21 days for 6 cycles
46004955|NCT00564720|Drug|Erlotinib|Erlotinib 100 mg by mouth (p.o.), daily until disease progression
46004956|NCT00564720|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 IV on day 8, every 21 days for 6 cycles
46090177|NCT02660190|Procedure|WL cystoscopy|
46090178|NCT04211324|Device|TENS|Volunteers in this group (n=50) will receive only one session of 5-minute extra-oral TENS applied on bilateral parotid gland with 50 HZ frequency and pulse duration 250 µs.
46090179|NCT04211324|Device|electro-acupuncture|Volunteers in this group (n=50) will receive only one session of 5-minute electro-acupuncture on local acu-points St4 and St 7 bilateraly with 2 HZ frequency.
46090180|NCT00620360|Dietary Supplement|fructose|acute administration of 4 times 0.3g fructose/kg lean body mass
46090181|NCT00620360|Dietary Supplement|Fructose|acute administration of 4 times 0.3 g/kg fat-free mass oral fructose
46090182|NCT04669418|Diagnostic Test|RNA expression signature|Whole transcriptome profiling using RNA sequencing
46090183|NCT00620438|Drug|Lumefantrine-artemether and nevirapine|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive patients receiving nevirapine 200mg twice daily as part of their antiretroviral treatment
46090184|NCT00620438|Drug|lumefantrine-artemether and efavirenz|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive adults receiving efavirenz tablets 600mg once daily
46004957|NCT04674917|Other|Decompression + Hot pack, TENS, Mobilization, Exercise Therapy|"Group A which includes the acute group to study the effects of decompression we will apply the three main basic treatments along with decompression which is our main goal..~The basic treatments are~Hot Pack~TENSE~Mobilization ( on lumbar L1 toL5 ) Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine All these treatments must given in combination with the decompression."
46090185|NCT00620438|Drug|Lumefantrine-artemether and rifampicin|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to patients receiving rifampicin as part of fixed dose combination therapy for tuberculosis
46090186|NCT05004506|Drug|Adductor Canal Block|The anesthesia provider will identify the adductor canal using ultrasound guidance and inject 15ccs of 0.5% marcaine with epinephrine around the saphenous nerve.
46090187|NCT05004506|Drug|Intra-articular Injection|receive 20ccs of 2% lidocaine with epinephrine as an intra-articular injection
46090188|NCT04172012|Biological|Labinic (R) probiotic mixture|Labinic (R) probiotic mixture containing Lactobacillus acidophilus and Bifidobacterium infantis and B. breve
46090189|NCT04172012|Other|Placebo|Placebo mixture
46090190|NCT00891839|Drug|Bendamustine|Bendamustine at 90 mg/m^2 intravenously (iv) on days 1 and 2 of each 28-day cycle. Dosage calculations for bendamustine are based on the patient's body surface area (BSA) at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
46090191|NCT00891839|Drug|Rituximab|Patients receive 375 mg/m^2 of rituximab, administered by iv infusion on day 1 of every 28-day cycle of treatment. Dosage calculations for rituximab are based on the patient's BSA at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
46090192|NCT00600756|Drug|Quetiapine XR|Oral, once daily, tablets of 400 mg to 800 mg
46090193|NCT00600756|Drug|Risperidone|Oral, once daily, tablets of 2 mg to 6 mg
46090194|NCT04246931|Other|No intervention (survey)|No intervention -> survey at 1 timepoint
46090195|NCT02830685|Device|DTI with Acellular Dermal Matrix (CELLIS® Breast)|After conservative mastectomy, a pre-pectoral subcutaneous reconstruction with definitive implant will be performed using an ADM (CELLIS® Breast), either completely covering the implant or simply covering the anterior surface of it. The implant could be of any shape, material and texture available with no restriction. After at least 6 months, a fat grafting procedure, using a wash and filter principle for fat handling, will be performed over the implant.
46090196|NCT02830685|Device|DTI with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)|After conservative mastectomy, a pre-pectoral subcutaneous reconstruction with definitive implant will be performed using a TCPM (TiLOOOP® Bra), either completely covering the implant or simply covering the anterior surface of it.The implant could be of any shape, material and texture available with no restriction. After at least 6 months, a fat grafting procedure, using a wash and filter principle for fat handling, will be performed over the implant.
45459186|NCT02323516|Drug|Acetylsalicylic acid + loperamide|In case of inefficiency in one month, according to predefined criteria, acetylsalicylic acid will be stopped and replaced by diosmectite.
45459187|NCT02323516|Drug|diosmectite + loperamide|In case of inefficiency in one month, according to predefined criteria, diosmectite will be stopped and replaced by acetylsalicylic acid.
45836271|NCT02094534|Biological|ORMD-0801 Capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules.
46090197|NCT02656914|Drug|Irlanda-2-Association|Take 10 mL every 12 hours (2x/day), oral route.
46090198|NCT02656914|Drug|Placebo|Take 10 mL every 12 hours (2x/day), oral route.
46090199|NCT02657148|Drug|Nexplanon (etonogestrel contraceptive implant)|Nexplanon is a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel indicated for postpartum contraceptive use by women to prevent pregnancy. Nexplanon is designed to be effective for 3 years.
46090200|NCT02657148|Drug|Standard postpartum contraceptive care|Condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at > 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time > 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time > 6 weeks after delivery.
46090201|NCT04247087|Drug|phytomenadione|phytomenadione 10 mg (1 vial in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
46090202|NCT04247087|Drug|placebo solution|1 vial of placebo solution (solution for injection in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
46090203|NCT00367406|Device|Gamma 3 nail versus ACE trochanteric nail|Comparing Gamma 3 nail versus ACE trochanteric nail
46090204|NCT00649116|Drug|Metoprolol Tartrate Tablets 100 mg|100mg, single dose fed
46090205|NCT00649116|Drug|Lopressor® Tablets 100 mg|100mg, single dose fed
45459188|NCT04625296|Behavioral|Semi-directive interview|Semi-directive interview, lasting a maximum of 45 minutes
45836272|NCT02094534|Other|Placebo|Fish oil capsules, identical in appearance to the experimental intervention.
45459189|NCT04625296|Behavioral|Questionnaire : Preparedness for Caregiving Scale|Preparedness for Caregiving Scale - 8 questions
45836273|NCT00242502|Drug|Bevacizumab (Avastin)|10 mg/kg IV every 14 days, repeat cycle every 28 days
46090206|NCT04115228|Device|Implantation and neuromodulation therapy|The study device is an autonomous permanent implant for neuromodulation targeting the posterior tibial nerve. It does not require an external power source or charger.
46090207|NCT04474158|Behavioral|Creating Peace|Creating Peace is a 12 session curriculum designed to support youth ages 14-19 in healing from experiences of trauma by restoring social connections, strengthening positive coping strategies that exclude all forms of violence, challenging gender norms that foster violence perpetration, and practicing positive bystander intervention skills to intervene safely with peers' disrespectful and harmful behaviors. Through 12 sessions (3 hours/session) over a 4 to 12 week period, Creating Peace offers gender transformative content combined with youth leadership development. Near program conclusion, youth will offer guidance to law enforcement on interacting with youth in a process of social restoration.
46090208|NCT04474158|Behavioral|Job Readiness|Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth.
46090209|NCT04245527|Device|Joovv Infrared Light Device|Joovv is the leading manufacturer of personal, in-home red light therapy devices
46090210|NCT00620048|Biological|Intramyocardial injection of autologous CD34-positive cells (stem cells)|Comparison between a low dose and high dose of autologous (one's own) CD34-positive cells (stem cells) delivered via injections into the heart muscle.
46090211|NCT04459416|Other|Acupuncture|Acupuncture treatments will be scheduled to cover the period of high symptom burden. Acupuncture will start on Day 0 and continue once daily to Day 15, as long as the patient is inpatient or comes to the clinic for post-transplantation follow-up. Electrical stimulation (e-acupuncture) may be applied to the ST36 and SP6 points when appropriate as per standard acupuncture practice.
46090212|NCT04459416|Drug|opioid|All study patients will receive the usual HSCT care and pain management regimens (usually opioids) as per standard practice at the study institution.
46090213|NCT04459416|Other|Assessments|Participants will be asked to complete patient reported outcomes assessments online using REDCap or, If they prefer, via pencil and paper or over the phone. Assessments at baseline (within 4 weeks before HiChemo) and on or about days 7, 15, 30, and 90 after the first dose of HiChemo.
45459190|NCT05134610|Device|AEROBIKA POSITIVE EXPIRATORY PRESSURE DEVICE|Intervention arm patients use the OPEP device twice daily for 2 weeks before and after surgery
45459191|NCT04928326|Diagnostic Test|CorWatch|Non-invasive wearable monitor for the assessment of central venous pressure
45836274|NCT00242502|Drug|Erlotinib|150 mg orally every day continuous dosing, repeat cycle every 28 days
45836275|NCT04389060|Dietary Supplement|Grape seed extract|Two capsule grape seed extract (total 600 mg)
45836276|NCT01899066|Drug|Lucentis, chemotherapy|"Lucentis:0.50mg/0.05ml, intravitreal injection,monthly for the first six months.~chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2."
46004958|NCT04674917|Other|Decompression + Hot pack , TENS , Mobilization , Exercise Therapy|"Group B which includes the chronic group to study the effects of decompression we will apply the three main basic treatments along with decompression which is our main goal..~The basic treatments are~Hot Pack~TENSE~Mobilization ( on lumbar L1 toL5 )~Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine All these treatments must given in combination with the decompression."
46090214|NCT02828501|Procedure|Spinal Manipulation|A spinal manipulation is a high velocity, low amplitude thrust through a physiological barrier in order to elicit a cavitation.
46090215|NCT00621608|Procedure|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy (HBOT) will be provided 5 days per week for 6 weeks for a total of 30 treatments on average. Subjects will be placed into the hyperbaric chamber for approximately 90 minutes of HBOT at 2.4 ATA (partial pressure of oxygen = 1,800 mmHg) when inside the chamber. Subjects will receive dressing changes as required per standard of care.
46090216|NCT00621608|Procedure|Placebo Hyperbaric Oxygen Chamber|Patients will receive HBOT placebo 5 days per week for 6 weeks for a total of 30 treatments. Each patient will be placed into the hyperbaric chamber and will receive 90 minutes of room air while inside the chamber and the initial flow of air into the chamber will produce a small increase in pressure (0.3 ATA partial pressure of oxygen = 210 mmHg) which will then be released over a period of 10 minutes. Subjects will receive dressings changes as required per standard of care.
46090217|NCT02652546|Drug|Assess Safety|Assess the safety of a 12-week course if CC-1150 in HIV-infected adults who have been on ART for greater than or equal to 1 year and have suppressed plasma viremia
45459192|NCT01367132|Procedure|Doppler ultrasound|Ultrasound using Doppler mode to detect blood flow in umbilical cord vasculature and determine the number of vessels present
45459193|NCT03489694|Procedure|Skin test endpoint titration|An allergen that is suitable to cause skin reactions when introduced to the forearm through pricking will be administered in doubling concentrations.
45836277|NCT01899066|Drug|chemotherapy|chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.
45459194|NCT01367210|Drug|Maraviroc, Darunavir/r|Maraviroc 300 mg Darunavir 800 mg Ritonavir 100 mg
46004959|NCT04674917|Other|Hot pack , TENS, Mobilization, Exercise therapy|"Group C which is our control group to compare it with the groups A and B to study the effects of decompression on lumbar radiculopathy The basic treatments are~Hot Pack~TENSE~Mobilization ( on lumbar L1 toL5 )~Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine It is kept in mind that in this group we will not apply the decompression along with the above treatments."
46004960|NCT04606485|Other|Acupressure|Acupressure is accepted as a non-invasive application that can easily be applied by trained nurses, which increases the quality of the medical care administered and contributes to physical and psychological recovery.
46090218|NCT02652546|Drug|Effect of drug on viral load|Evaluate the effect of CC-11050 on plasma HIV-1 RNA levels by both conventional and single copy assay at week 12 and over all evaluable time points
45677927|NCT01997281|Other|conventional cereal|"provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~amount: 80 g for dinner and breakfast, 40 g for night snack (10 p.m.)~one serving (40g) of steamed egg is added for dinner and breakfast"
45836278|NCT01890720|Device|iNPWT|The Incisional Negative Pressure Wound Therapy (iNPWT) will be applied over the clean closed incision immediately following the operation (caesarean section). In the intervention group the therapy will be left in situ for five days.
46004961|NCT01160770|Drug|Clobazam|Clobazam will be provided in 5 mg, 10 mg and 20 mg tablets and will be dispensed in bottles as needed at each visit. Bottles may be dispensed between visits if necessary. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After the first 48 hours of the treatment period, investigators will be able to increase, decrease or maintain the subject's dose, up to an approximate maximum daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).
46090219|NCT02652546|Drug|Effect of drug on T-cell count|Evaluate the effect of CC-11050 on CD4+ T cell counts and percentages at week 12 and over all evaluable time points
46090220|NCT02652546|Drug|Effect of drug on inflammatory biomarkers|Evaluate the effect of CC-11050 on markers of markers of systemic inflammation (TNF, IL-^, CRP, IFNg, sCD14, D-dimer) at week 12 and over all evaluable time points.
46090221|NCT02830373|Device|LVIS stents|Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
46090222|NCT04210856|Other|Contemplative landscape exposure|landscapes classified as contemplative (through a CLM psychometric measure) are expected to elicit different brainwave oscillations as compared to non-contemplative ones.
46090223|NCT02652234|Drug|Endostar|Endostar, ih, QD，day 1 of cycle 1; Endostar, ih, QD，day 2-15 of cycle 3;
46090224|NCT02652234|Drug|Chemotherapy|
46090225|NCT02830607|Device|Xiaomi Mi Band|participants will wear Xiaomi Mi Band as assessment tool for recovery after epidural steroid injection for treatment of low back pain
46004962|NCT04632758|Drug|WX-0593 Tablets|tablets, 60 mg→180mg, QD
46004963|NCT04632758|Drug|crizotinib|Capsules, 250mg, BID
46004964|NCT00566007|Procedure|Discectomy/ micro discectomy|Standard discectomy or micro discectomy
46090226|NCT04167852|Behavioral|Daily text message|Patients will receive a daily text message stating how many days they have until or since their surgery.
46090227|NCT04167852|Behavioral|Mindfulness intervention|Patients will receive a link to mindfulness meditation intervention for ten minutes.
46090228|NCT02830529|Behavioral|MAD DASH|Participants were taught mindfulness meditation including body scan, loving kindness meditation and breathing exercises. The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.
46090229|NCT02830529|Behavioral|DASH diet education|The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.
46090230|NCT02657070|Behavioral|Reinforcement-Induced Movement Therapy (RIMT)|6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS) with augmented visuomotor feedback
46090231|NCT02657070|Behavioral|VR-based motor rehabilitation in RGS without augmented feedback|6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS)
46004965|NCT00566007|Drug|Ozone therapy|Infiltration of intradiscal ozone: O3/O2 in a 27 micrograms/ml concentration + foraminal infiltration of O3/O2 + corticoid + anesthetic
46090232|NCT04211012|Drug|Toripalimab plus Nab-Paclitaxel +/- cisplatin|"Toripalimab injection (JS001): 240mg, i.v.gtt, q3w; Nab-Paclitaxel: 260mg/m2, i.v.gtt, q3w Cisplatin: total dosage of 70 mg/m2 i.v.gtt, q3w，, complete all doses within the first 2 days of each cycle.~Study treatment will be continued until disease progression or intolerable toxicity, or withdrawal at the discretion of the investigator or the subject, loss to follow-up, or initiation of other anti-cancer therapy, or death, whichever occurs first. Toripalimab will be administered no more than 2 years,and nab-paclitaxel with or without cisplatin will be administered up to 6 cycles.. If the subject is intolerable to cisplatin treatment according to the investigator's judgment, JS001 + Nab-Paclitaxel may be dosed.~Dosing sequence: Toripalimab, Nab-Paclitaxel, cisplatin"
46090233|NCT02655978|Other|Magnetic Resonance Imaging|
45459195|NCT01367210|Drug|current antiretroviral therapy with 3 drugs|To continue the assumption of previous HAART
45677928|NCT04663087|Device|XSTAT|XSTAT application will follow the manufacturer's guidance, with injection into bleeding junctional wounds. A sufficient number of sponges are used to fill the injury void. Repeated XSTAT application is performed in the event of persistent bleeding. The trial packs will contain two devices.
45459196|NCT02323594|Drug|Daclatasvir|Treatment A= single oral dose of Daclatasvir (DCV) tablet and Treatment B= single oral dose of DCV pediatric chewable tablet
45459197|NCT02323594|Drug|Daclatasvir|Treatment C= single oral dose of Daclatasvir (DCV) pediatric chewable tablet and Treatment D= single oral dose of DCV pediatric chewable tablet
45677929|NCT04663087|Other|Standard of Care|As currently provided by EMS services
45459198|NCT02323594|Drug|Asunaprevir|Treatment E= single oral dose of Asunaprevir (ASV) tablet and Treatment F= single oral dose of ASV pediatric chewable tablet and Treatment G= single oral dose of of ASV pediatric chewable tablet
45677930|NCT01953913|Drug|Afatinib|Patient will receive afatinib once daily
45677931|NCT01971476|Drug|volasertib|intravenous administration on day 1of a treatment course
45459199|NCT02323594|Drug|Daclatasvir|Treatment H= single oral dose of Daclatasvir (DCV) tablet and Treatment I= single oral dose of DCV tablets
45459200|NCT01372280|Drug|Reminyl|Galantamine Hydrobromide Tablets 4 mg
45677932|NCT01996904|Procedure|arthroscopic repair|If the subscapularis tendon was not sufficiently mobile, further anterior interval release between subscapularis and scapula was performed. LHB (long head of biceps tendon) was either treated with a biceps tenodesis or by tenotomy when there was tear or subluxation of it. The footprint area of the subscapularis tendon, which is trapezoidal in shape on the proximal part of the lesser tuberosity, was thoroughly cleaned of soft tissue and meticulous bone preparation was done prior to placement of anchor sutures.
45677933|NCT01996904|Procedure|arthroscopic debridement|Anterosuperior portal was made initially for debridement (capsulectomy and anterior bursectomy). A systematic release of the glenohumeral ligaments and the overlying subscapularis bursa was performed.The superior aspect of the tendon was freed from the surrounding structures (the coracohumeral and superior glenohumeral ligaments). The middle glenohumeral ligament was always released to identify the upper border of the subscapularis tendon.
45677934|NCT01970540|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
46004966|NCT00566007|Drug|Oxygen therapy|Intradiscal oxygen therapy: O3/O2 at a concentration of 0 micrograms/ml (only oxygen) + foraminal infiltration of O2 + corticoid + anesthetic
46004967|NCT04314154|Other|Monitoring PROM @ PREM data on participating patients|"125 patients (ages 18-55) admitted to SHALVATA mental health center and their clinicians will be recruited to participate in a prospective longitudinal assessment. Each will include PREMs, PROMs clinician rated outcomes and assessment of the degree to which clinical indicators (reflected processes of clinical guidelines) were carried out. The assessments will take place at admission, discharge and every 3 months for up for 9 months. The design is a repeated measures design with evaluating the interaction effect between assessed levels of indicators (between subject effect) and level of change in the PREMs, PROMs clinician along the research trajectory (within subject effect)."
46090234|NCT00649974|Drug|Valacyclovir Hydrochloride Tablets 1000 mg|1000mg, single dose fasting
46090235|NCT00649974|Drug|Valtrex® Tablets 1000 mg|1000mg, single dose fasting
45459201|NCT04866160|Drug|BI 1291583|BI 1291583
45459202|NCT04866160|Drug|Placebo|Placebo
46090236|NCT02830295|Other|Basic Body Awareness Therapy|Basic body awareness therapy is a health oriented and person-centred approach with focus on the patient's resources. This is a method in physiotherapy, where we search to promote movement quality in daily life through self-exploration and self-experience.BBAT conceives the person from the biomechanical, physiological, bio-psycho-social and existential aspects, using the movement quality as a witness of the link in between all these perspectives.It can be done individually or in groups, through different daily life movements: lying, sitting, standing, walking, pair movements, use of voice and massages. BBAT has validated and reliable assesment tools, as BARS and BAS-I
46090237|NCT00350714|Other|MBT and BreathID|75 mg methacetin (c13 labelled) dissolved in 150 cc water ingested and breath collected before and after ingestion.
45677935|NCT01970540|Drug|Doxorubicin|Commercially available presentations of vials containing doxorubicin will be provided as appropriate.
46004968|NCT04632719|Device|The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19|Cognitive assessment and rehabilitation will be carried out on volunteers who have healed from COVID-19.
45677936|NCT01963676|Device|tDCS|
46090238|NCT02536638|Other|Exposure to pyelonephritis|Pyelonephritis group are patients with exposure to pyelonephritis Without pyelonephritis group are patients without pyelonephritis
46090239|NCT04246775|Device|Peristeen|rectal irrigation
46090240|NCT05662670|Drug|WJ13404 tablets|"Dose escalation: 6 dose levels The dose escalation study is proposed to include 6 dose levels: 30, 90, 180, 270, 360, and 480 mg once daily.~(It can be adjusted based on clinical PK data and safety results after discussion between PI and the sponsor).~Dose-expansion: After the initial data evaluation, the Sponsor and the SMC will select 2-3 dose levels to evaluate drug safety and PK further, explore its preliminary efficacy, and determine RP2D.~Efficacy expansion: The RP2D determined in dose escalation and dose expansion will be applied."
46004969|NCT00566046|Drug|Levetiracetam|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
46004970|NCT00566046|Drug|Placebo|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
46090241|NCT02828345|Other|Specimen Collection|
46090242|NCT02536482|Dietary Supplement|Amix|Treat the children with cow's milk allergy for 5 months.
46090243|NCT04209452|Behavioral|Rehearsal strategy|Teaching children to cumulatively rehearse numbers as they are being said.
46090244|NCT04209452|Behavioral|Reinforcement|Providing reinforcement for correct recall after a delay.
46004971|NCT01160614|Drug|Oxycodone hydrochloride controlled-release (ORF) tablets|Oxycodone hydrochloride controlled-release (ORF) tablets (10 mg, 15 mg or 20 mg) taken every 12 hours
46004972|NCT00566085|Procedure|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 28-32 mCi of 99m Tc-sestamibi.
45677937|NCT01963676|Device|Sham stimulation|
45677938|NCT01996826|Drug|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
45677939|NCT01996826|Drug|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks.
45677940|NCT01996748|Drug|DF277|Two administrations daily for 7 days
45677941|NCT01996748|Drug|Placebo|Two administrations daily for 7 days
45677942|NCT01621178|Drug|Dulaglutide|Administered SC
45677943|NCT01621178|Drug|Insulin glargine|Administered SC
45677944|NCT01621178|Drug|Insulin lispro|Administered SC
46004973|NCT04632407|Dietary Supplement|"Flax milk"|See above
46090245|NCT04209452|Behavioral|Rehearsal strategy and reinforcement|Teaching children to cumulatively rehearse numbers as they are being said, AND providing reinforcement for correct recall after a delay.
46090246|NCT02536872|Other|None - this is a prospective observational study. Patients will be prescribed their usual treatment (antibiotics) and the effect on urine studied|
45677945|NCT01962974|Biological|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
45677946|NCT01962896|Drug|Erlotinib|
45677947|NCT01962896|Drug|Sirolimus|
46004974|NCT04632407|Dietary Supplement|"Oat fibre milk"|See above
46004975|NCT04123639|Procedure|PTA|Percutaneous transluminal angioplasty
46004976|NCT02885233|Behavioral|Free From Falls Online|Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.
46090247|NCT04829006|Device|Understand Me For Life|The aim of the current investigation is to test the efficacy of an app to measure sentence intelligibility in noise in speakers with Parkinson's disease and in healthy controls.
45677948|NCT01970462|Drug|Sitagliptin|Sitagliptin prior to hospital discharge and 6 weeks following discharge.
46004977|NCT02885233|Behavioral|Waitlist Control|"Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion."
46004978|NCT00566124|Drug|Insulin detemir|0.4 U/kg bw insulin detemir injected s.c. in the thigh.
46004979|NCT00566124|Drug|Insulin glargine|0.4 U/kg bw insulin glargine injected s.c. in the thigh
46004980|NCT00566124|Drug|Insulatard|0.4 U/kg bw NPH insulin injected s.c. in the thigh
46004981|NCT04632563|Other|Questionnaire including MSK-HQ (Musculoskeletal Health Questionnaire)|A questionnaire regarding musculoskeletal past medical history and current symptoms.
46090248|NCT02536716|Procedure|Platform-matched dental implant|A platform-matched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
46090249|NCT02536716|Procedure|Platform-switched dental implant|A platform-switched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
46090250|NCT00620594|Drug|BEZ235|
46090251|NCT02652000|Other|No intervention in this retrospective study|No Intervention in this retrospective Analysis.
46090252|NCT04269720|Behavioral|Biofeedback|They will also be taught how to use the biofeedback app and Inner Balance device. Additionally, they will also be educated on the principles of biofeedback and its benefits and taught how to maximize HRV by using self-regulation breathing techniques, guided imagery, and/ or self-talk.They will be given an Inner Balance device, which is an ear sensor that connects to an apple device that measures heart rate variability (HRV) and gives them access to an app that is designed to help them improve their HRV. They will be asked to use this device daily for 10 mins for the duration of the 8-week intervention. Patients and the research coordinator will have access to all of their sessions and results. The research coordinator will monitor compliance via the Heartcloud associated with their device and encourage adherence throughout the 8-week biofeedback intervention.
46004982|NCT01159912|Drug|Fluticasone propionate|Fluticasone propionate inhalation powder, 250 µg
46004983|NCT01159912|Drug|Fluticasone furoate|Fluticasone furoate inhalation powder, 100 µg
46004984|NCT01159912|Drug|Placebo|Placebo inhalation powder
46004985|NCT04606368|Device|Thermage FLX|Monopolar radiofrequency will be applied through the Thermage FLX machine to the subject's right lower jaw and submentum area.
46004986|NCT04632368|Behavioral|Transcendental Meditation|TM, a mind-body intervention that can reduce sympathetic arousal and promote a state of relaxation and calm, will be offered to HCPs dealing with COVID-19 pandemic
46004987|NCT04632680|Device|PVI followed by targeting of drivers|Patients will undergo intraprocedural ECG-I mapping. The pulmonary veins will be isolated followed by targeting of drivers aiming to terminate AF.
46004988|NCT04606212|Drug|Losartan|administration of losartan (50 mg) (oral)
46004989|NCT04606212|Drug|Placebo Oral Tablet|administration of placebo (oral)
46004990|NCT04632446|Other|Early diagnosis|Early diagnosis. Upgrade program implementation.
46004991|NCT04606251|Other|Exercise|The intervention to be carried out in the study consists of physical exercises for the neck, upper and lower extremities, and trunk; It is a program that includes the addition of cognitive tasks such as memory, word finding, processing during each repetition.
46004992|NCT04606329|Drug|LuminoMark inj.(Conc. for fluorescence)|Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
46090253|NCT00620672|Dietary Supplement|omega 3 fatty acids|The supplements are taken orally with a meal, each day. The amount of the omega 3 fatty acid docosahexaenoic acid is 400 mg/day; taken in two 500 mg capsules each providing 200 mg docosahexaenoic acid. The placebo is two 500 mg capsules soybean/canola oil. Both the supplement and placebo are a total of 1 gm/day (2x500 mg) and about 10 calories per day.
46090254|NCT00620672|Dietary Supplement|vegetable oil|The supplement is a dietary supplement of vegetable oil as a placebo
46090255|NCT04032912|Diagnostic Test|iScan|this instrument provides extra confidence for in vivo diagnosis through improved vessel and mucosal pattern characterization.
46090256|NCT04060160|Other|Self- learning software that can detect acne lesions|Self- learning software that can detect acne lesions from patients who take a picture of their face every single day for 3 months with a secure mobile phone.
46090257|NCT04060160|Other|Patient reported outcomes|Collection of patient reported outcomes and clinical data via a mobile electronic case report form
46090258|NCT02655822|Drug|Ciforadenant|100 mg orally twice daily for the first 14 days of each 28-day cycle.
46090259|NCT02655822|Drug|Ciforadenant|100 mg orally twice daily for 28 days of each 28-day cycle.
46004993|NCT04606329|Drug|Charcotrace Inj.|Injection Charcotrace Inj. about 0.3~1mL once in this study.
46004994|NCT04632251|Device|SENSEI®|SENSEI® laparoscopic tethered gamma probe is an intra-operative laparoscopic gamma probe system
46004995|NCT04597749|Diagnostic Test|PSG|In-lab sleep polysomnography test
46004996|NCT04597749|Diagnostic Test|Home Sleep Apnea Test with FDA cleared devices|In-lab HST test
46090260|NCT02655822|Drug|Ciforadenant|200 mg orally once daily for the first 14 days of each 28-day cycle.
46004997|NCT04597749|Other|Non-Contact Screening App|Non-Contact Sleep Apnea Screening Applications at bedside table to assess for sleep apnea.
46004998|NCT04632797|Device|Hilotherm Chemo Care|Application of Hilotherm Chemo Care gloves for constant cryotherapy during chemotherapy application.
46090261|NCT02655822|Drug|Ciforadenant + atezolizumab|Ciforadenant 100 mg orally twice daily in combination with atezolizumab intravenously.
46090262|NCT02655822|Drug|Ciforadenant|Start with 150mg orally twice daily for 28-day cycles; then, increase increments by 100mg/day for 6 dose levels.
46090263|NCT04209374|Device|THA with SYMBOL CUP DM HA|
46090264|NCT00650442|Drug|Estradiol Transdermal System Placebo - Alternate Adhesive|single application
46090265|NCT00650442|Drug|Estradiol Transdermal System Placebo - Current Adhesive|single application
46090266|NCT00890825|Drug|AZD6244|oral capsules, 75mg twice daily
46090267|NCT00890825|Drug|docetaxel|75mg/m2 iv on day 1 of every 21 day cycle
46090268|NCT00890825|Drug|Placebo|placebo
46090269|NCT02656758|Behavioral|intensive Executive function training|Children diagnosis of attention deficit hyperactivity disorder are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of intensive executive function training weekly no intervention :waiting participants will not be treated with intensive executive function training and keep waiting for 12 weeks for comparison
46090270|NCT04780334|Diagnostic Test|COVID-19 RT-PCR|Nasopharyngeal swabs for COVID-19 RT-PCR
46090271|NCT04780334|Diagnostic Test|Biosensor|Portable and Connected Biosensor viral
45677949|NCT01970462|Drug|Placebo|Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively
45459203|NCT04947644|Procedure|Thoracic epidural analgesia|After negative response, 10 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 5ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
45677950|NCT01958671|Drug|Ertugliflozin 5 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
45677951|NCT01958671|Drug|Ertugliflozin 10 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
45677952|NCT01958671|Drug|Placebo to Ertugliflozin|One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
45677953|NCT01958671|Drug|Metformin|500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.
45677954|NCT01958671|Drug|Placebo to Metformin|1 tablet in the morning and 1 tablet in the evening for 2 weeks, 2 tablets in the morning and 1 tablet in the evening for 2 weeks and 2 tablets in the morning and 2 tablets in the evening, thereafter.
46004999|NCT04632212|Behavioral|Explicit Tax|"To impose an explicit tax on food and beverage items that are eligible for red stop-sign food logos (explained in Intervention 2) as less healthy foods. Explicit tax shows pre-tax prices and a label indicating that the price includes a corresponding tax on the less healthy products.~Food and Beverages: we will impose a 20% tax on sales price of the food items"
46090272|NCT02656992|Device|Inspiratory muscle training group|
46090273|NCT02656602|Other|Computer Assisted Instruction|The computer assisted instruction consisted of a platform using video mimicking the patient journey with voice-over supported by photo's, 3D animation and instructive texts. The video was presented in short clips, maximal 45 seconds, to maintain the focus of patient. Patient interaction was ascertained by mandatory mouse-click after each item in the CAI. All elements of informed consent for colonoscopy (risks, alternatives) were included.
46090274|NCT04760132|Biological|COMIRNATY - BioNTech Manufacturing GmbH|Vaccination as part of the the Danish national government programme
46090275|NCT04760132|Biological|COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH|Vaccination as part of the the Danish national government programme
46090276|NCT04760132|Biological|COVID-19 Vaccine AstraZeneca suspension for injection|Vaccination as part of the the Danish national government programme
46090277|NCT04248101|Procedure|Double Ligation|
46090278|NCT04248101|Drug|Topical Silver Nitrate|
46090279|NCT00649818|Drug|Lorazepam Tablets 2 mg|2mg, single dose fasting
46090280|NCT00649818|Drug|Ativan Tablets 2 mg|2mg, single dose fasting
46090281|NCT00620906|Procedure|Manipulation|HVLA manipulation to Sacroiliac Joint
46090282|NCT02656524|Drug|Regorafenib (Stivarga, BAY73-4506)|Product is used in accordance with SmPC
46090283|NCT02833181|Device|BIS monitor|Monitoring circadian variation of EEG
46090284|NCT02828423|Procedure|EMD|Regenerative surgery with EMD
46090285|NCT02828423|Procedure|BC|Regenerative surgery with BC
46090286|NCT04246697|Drug|Tylenol|Used for both arms, scheduled
46090287|NCT04246697|Drug|Oxycodone|Used for both arms PRN
46090288|NCT04246697|Drug|Morphine|Used for both arms PRN
46090289|NCT04246697|Drug|Gabapentin|Used for Arm B
46090290|NCT04246697|Drug|toradol|Used for Arm B
46090291|NCT04246697|Drug|Bupivacaine|Used for Arm B - anesthesia block
46005000|NCT04632212|Behavioral|Food Labels (with the summary of healthiness of shopping baskets & targets)|"To provide the green circle 'healthy choice' food label to items with Nutri-Score A and B, the amber circle 'in between healthy and unhealthy choice' food label to items with Nutri-Score C, and the red stop-sign 'less healthy choice' food label to items with Nutri-Score D and E.~In the presence of food labels,~Video: subjects will watch a video briefly explaining the food labels on the store.~My Cart Summary: subjects will be provided a live visual indicator of the healthiness of shoppers' current basket with the recommended healthy baskets goals."
46005001|NCT04632212|Behavioral|Ordering|To order food items by Nutri-Score (high to low).
46005002|NCT04632212|Behavioral|Within-Group Substitution|To provide substitutes within corresponding food categories that are better than the items that subjects chose in terms of Nutri-Score based on the similarities of price, primary ingredients, flavor, and other characteristics.
46005003|NCT04606017|Drug|Caltrate Pill|VitD3 supplementation was defined as patients additionally took oral vitD3 (125 IU/d) within 3 days after the first infusion and persisted in the whole follow-up period.
46005004|NCT04597866|Behavioral|Multimodal rehabilitation|A combination of exposure in vivo and interventions directly targeting the cortical reorganization for treating CRPS.
46005005|NCT04632095|Procedure|Aortic valve replacement due to sternotomy|conventional surgery of aortic stenosis
46005006|NCT04632095|Procedure|Aortic valve replacement due to parasternal right anterior mini-thoracotomy|surgery of aortic stenosis in minimally invasive technique
46090292|NCT02656446|Device|Accuro Handheld Ultrasound|Use of an Accuro Handheld Ultrasound to identify lumbar interspaces, midline, and depth to epidural space
45473932|NCT03381040|Device|Restylane Lyft|Restylane® Lyft is a sterile gel of hyaluronic acid with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation. It is recommended that the product be used for shaping the contours of the face and the correction of folds using the co-packed needles. Given the very high lift capacity of Lyft, it is often used when the skin envelope is normal or thicker than normal, as the contours of the product may be palpable in the presence of thin skin.
46090293|NCT02656446|Device|Standard Ultrasound Machine|Use of standard ultrasound as gold standard to identify lumbar interspaces, midline, and depth to epidural space
46090294|NCT02691728|Drug|LDV/SOF FDC|
45677955|NCT01958671|Drug|Glimepiride|Dosing and titration of glimepiride as rescue therapy was determined by the investigator.
46090295|NCT05147207|Procedure|Superpath Approach|This is a minimally invasive surgical approach for THA.
46090296|NCT02656134|Procedure|Duodenoscopy and enteroscopy|All patients will undergo duodenoscopy and classified according to Spigelman. Patients classified as Spigelman III and IV will undergo enteroscopy.
46090297|NCT02656134|Genetic|Molecular analysis.|DNA analysis
46090298|NCT04235322|Drug|2LHERP®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
46090299|NCT04235322|Drug|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
46090300|NCT02830061|Other|Interviews|Individual semi-structured interviews for 30-60 minutes using an interview schedule developed from an interpretative phenomenological analysis framework.
46090301|NCT02830139|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Cisplatin 60mg/m2, 5-Fu 1500mg/m2, 43°C, 60min, During surgery and 7 days after surgery.
46090302|NCT02830139|Procedure|Radical colorectal resection|radical colorectal resection with lymphadenectomy
46090303|NCT02830139|Drug|Oxaliplatin , Capecitabine|XELOX postoperative chemotherapy Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
46090304|NCT02830139|Drug|Normal saline , Cisplatin , 5-Fu|
46090305|NCT02651766|Procedure|Cupping massage|Using suction on the skin by means of glass cups, and moving the cups after applying massage oil on the skin
45677956|NCT01995266|Drug|Asunaprevir|
45677957|NCT01995266|Drug|Daclatasvir|
45677958|NCT01969058|Drug|Isotretinoin|Isotretinoin is a drug that is approved for use in the treatment of severe acne. The aim of this study is to evaluate the role of Isotretinoin on immune activation and inflammation.
45677959|NCT01968980|Drug|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
45677960|NCT01968980|Other|Placebo|subcutaneous injection every 2 weeks for 12 months
45677961|NCT01961882|Drug|OCV-501|
45677962|NCT01961882|Drug|Placebo|
45677963|NCT04174118|Drug|belcesiran|belcesiran will be administered subcutaneously (SC) at dose levels planned.
45677964|NCT04174118|Drug|Placebo|Sterile normal saline (0.9% NaCL) matching volume of belcesiran doses will be administered subcutaneously (SC).
45677965|NCT01968434|Device|protective cough syrup|The mucoadhesive and radical scavenging properties of the components create a protective film on the pharynx which protects irritated mucosa from cough generating stimuli such as post nasal drip, irritating elements, dehydration.
45677966|NCT01968434|Drug|carbocisteine cough syrup|Mucolytic
45677967|NCT04659902|Dietary Supplement|Protein form|Protein form and absence or presence of calcium manipulated
45677968|NCT01946438|Biological|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
45677969|NCT01946438|Biological|Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),|0.1 mL, Intradermal
45677970|NCT01946438|Biological|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
45677971|NCT01946438|Biological|Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)|0.5 mL, Intramuscular
45677972|NCT01946282|Other|FIT Invitation Only|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls.
46005007|NCT04597788|Other|Protein supplemented very low calorie diet program|"Protein supplemented very low calorie meal is a shake-type meal replacement with total calories of 600 to 800 calories per day and proteins provided at 1.2g of ideal body weight per day. The four-month, very low calorie diet program schedule will be as follows. In the first two weeks, all three meals are replaced, followed by two meals replaced and one meal in food in the next six weeks, and one meal replacement is recommended for the next eight weeks. For the next eight months, the intermittent very low calorie meal replacements will be provided regularly for one week a month. If a subject gains weight more than 2kg, he or she will have an additional 1 week of two meal replacements, and if a subject gains weight more than 4kg, he or she should have an additional 2 weeks of replacement.~Individual sessions will be held 11 times during the study. Mobile counseling with dietitians or nurses will be offered to help subjects lose weight and maintain weight loss."
46090306|NCT02833025|Device|Thrombin generation and Platelet Function Testing|Point-of-care testing of thrombin generation, platelet function, and rotational thromboelastometry
46090307|NCT04245059|Device|Multi-channel Transcranial direct current stimulation|A commercial tDCS device will be use in this study. The device is a wireless multi-channel transcranial direct current stimulator that incorporates an 8-channel headcap for stimulation through gel electrodes or classic sponge electrodes. The device is integrated with a user interface for the configuration and monitoring of the stimulus parameters and a fast multifocal simulation of the tDCS electric field using an advanced brain model
46005008|NCT04597788|Other|Conventional low calorie diet program|Low calorie diet consists of 1200 to 1500 calories will be educated and lifestyle modification will be encouraged for participants in control group. Educational materials as well as recipes for low calorie diet will be provided in individual sessions. Mobile counseling will also be offered for sticking to the diet program.
46005009|NCT04631744|Drug|Cabozantinib|Subjects will receive cabozantinib orally at a (starting) dose of 40 mg once daily
46005010|NCT04597983|Dietary Supplement|2S-hesperidin|Cardiose® is a natural orange extract that due to its unique manufacturing process, maintains most of the natural hesperidin isomeric form (2S)
46005011|NCT04597983|Dietary Supplement|Placebo|Microcellulose was used, this molecule was selected to avoid affecting the glycemia, as it can occur with dextrose or maltodextrin.
46090308|NCT02651532|Device|Confocal Laser Endomicroscopy|During colonoscopic withdrawal, the colonic mucosa will be observed with white light and be evaluated on the different segments of the colon with the confocal laser endomicroscopy technology in order to search for microscopic inflammation signs (altered crypt architecture, fluorescein leaks and dilated and prominent branching vessels)
46005012|NCT04631822|Procedure|Spinal anaesthesia|spinal anesthesia shall be conducted with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position.
46090309|NCT02651610|Biological|Bavituximab|Biological: bavituximab
46090310|NCT02651610|Drug|Taxane|Drug: Taxane Other names: Paclitaxel. Taxotere, Taxotere, Docecad, Taxol
46090311|NCT02828579|Procedure|Bariatric surgery|Laparoscopic Sleeve Gastrectomy (LSG) Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)
46090312|NCT02655588|Behavioral|Interactive Media-Based Problems Solving Treatment|
46090313|NCT04208594|Drug|Ivabradine|comparing between both drugs for the effect of hypotensive anesthesia
46090314|NCT04208594|Drug|Propranolol|comparing between both drugs for the effect of hypotensive anesthesia
46090315|NCT02828189|Other|Physical Exercise|The patients were instructed to perform autonomous physical exercise program based preferences (progressive march on flat ground, dancing, cycling, etc.). They will receive written information. The program is 9 weeks with a frequency of 3 days per week and sessions about 50 minutes long.
46090316|NCT02828189|Behavioral|Therapeutic Education|Individual Therapeutic Education about healthy habits and exercise on breast cancer.
46090317|NCT02828189|Other|Therapeutic exercise-Physiotherapy|"Cardiovascular exercise~Individualized progressive strength and resistance exercises of principals muscle groups of the lower limbs, upper limbs and trunk.~Flexibilization exercises"
46090318|NCT04733144|Drug|Prednisolone|7,5 mg prednisolone (low dose) 30 mg prednisolone (high dose)
46090319|NCT04733144|Drug|Dexamethasone|1,125 mg dexamethasone 4,5 mg dexamethasone
46090320|NCT04167072|Procedure|Stent removal|This is a procedural intervention in which the stent will be removed via endoscopy.
46090321|NCT04247945|Biological|Cotransplant with MSCs|Co-transplantation of MSCs during allogeneic HSCT
46090322|NCT04724720|Drug|Famotidine|Standard or care treatment plus prescribed famotidine
45677973|NCT01946282|Other|FIT plus $5 Incentive|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
46090323|NCT04724720|Drug|Placebo|Standard of care treatment plus placebo
46090324|NCT02655432|Device|Spot photoscreener|Screening of vision problem through an automated device
46090325|NCT02655432|Procedure|Ophthalmologic evaluation|Screening of vision problem through an ophthalmologic evaluation
46090326|NCT02655432|Procedure|Cyclopleged refraction|Screening of refractive problems through a cyclopleged optometric refraction
46090327|NCT02833103|Drug|Danshu Capsules|Danshu Capsules (0.9g potid/day) for three months by oral
46090328|NCT02833103|Drug|Pinaverium Bromide|Pinaverium Bromide (100mg potid/day) for three months by oral
46005013|NCT04631822|Procedure|ultrasound-guided Adductor Canal Block + dexamethasone|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery. then, a 20-ml mixture of 0.25% bupivacaine, and 4 mg dexamethasone will be injected."
46090329|NCT03984266|Diagnostic Test|NGS panel|A next-generation-sequencing panel, which contains a group of genes that specifically cause disease, for mutational analysis in newborns.
46090330|NCT04247789|Other|Self-reported questionairres|the fatigue will be determined through self reported questionnairres
46090331|NCT02648490|Drug|HLX07|recombinant human anti-EGFR monoclonal antibody against cancers
46090332|NCT02648490|Drug|Acetaminophen|Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07.
46090333|NCT02648490|Drug|dexamethasone|dexamethasone 10 mg intravenous infusion for 10 minutes before the infusion of HLX07.
46090334|NCT02648490|Drug|diphenhydramine|diphenhydramine 30 mg intravenous infusion for 10 minutes before the infusion of HLX07.
46090335|NCT02648490|Drug|5-HT3 inhibitor|If the patient experience grade 2 or 3 nausea and vomiting during the first infusion of HLX07, the addition of 5-HT3 inhibitor may be included in the premedication before subsequent infusions.
46090336|NCT02829827|Drug|Radiprodil|Radiprodil at individualized doses.
46090337|NCT02648568|Behavioral|Hypnosis plus relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles followed by an induction of hypnosis based on the preferential channel of each patient and, during trance, recommendation to assimilter the bed room and bed to a safe place
46090338|NCT02648568|Behavioral|Relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles
46090339|NCT04965272|Drug|Cariprazine 0.75 mg/day|Oral Capsule
46090340|NCT04965272|Drug|Cariprazine 1.5 mg/day|Oral Capsule
46090341|NCT04965272|Drug|Cariprazine 3.0 mg/day|Oral Capsule
46090342|NCT04965272|Other|Placebo|Oral Capsule
46090343|NCT02829515|Procedure|tonsil surgery with or without concomitant adenoidectomy|tonsillectomy, tonsillectomy with adenoidectomy, tonsillotomy, tonsillectomy with adenoidectomy
46090344|NCT02648412|Drug|ketamine|bolus 1 mg/kg
46090345|NCT02648412|Procedure|Tetanic stimulations of incremental intensities|10-20-30-40-60 milliamps on the patient's left forearm
45677974|NCT01946282|Other|FIT plus $10 Incentive|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
45677975|NCT01945580|Procedure|Prolapse Repair|Transvaginal anterior/apical pelvic organ prolapse repair
46090346|NCT00890201|Procedure|Gallbladder bile sampling and intraoperative cholangiography|"Interventions were exactly similar for both groups, and that is how it was intended to be:~Gallbladder bile sampling: Sample 5 cc of gallbladder bile after the cystic duct has been clipped or ligated.~Intraoperative cholangiography: Perform cholangiography before the cholecystectomy is finished"
46090347|NCT02651454|Drug|Daesiho-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
46090348|NCT02651454|Drug|Chowiseungcheng-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: Hanzung Pharmaceutical. co. Ltd.
45677976|NCT01945034|Drug|Topical IBU twice daily|Topical gel administered as 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
46090349|NCT02651454|Drug|Placebo|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
46090350|NCT00621920|Drug|FM-601|Dose-escalation, split dosage, liquid
46090351|NCT02651376|Combination Product|Conventional plus AAIT|Participants received conventional (anti-opportunistic infections and ART) treatment and taken i.v., at a roud (3 times) of 2-3*10E8 MNCs/kg body at baseline, week 1 and 2.
46005014|NCT04631822|Procedure|ultrasound-guided Adductor Canal Block + dexmedetomedine|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery.then, a 20-ml mixture of 0.25% bupivacaine, and 0.5 Mg/kg dexmedetomidine will be injected."
46005015|NCT04605705|Combination Product|Optimization of the cardiac output, the temperature, the hemoglobin in order to have the NIRS value by up to 80%.|Several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
46005016|NCT00560924|Drug|estradiol, 25 mcg|
45677977|NCT01945034|Drug|Placebo twice daily|Topical gel administered as a 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
46090352|NCT04246853|Device|Transcranial direct current stimulation (tDCS) of the resting state motor network|Transcranial direct current stimulation (tDCS) delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.
46090353|NCT04672850|Dietary Supplement|Probiotic|The participants will consume 2 capsules daily for three months
46090354|NCT04672850|Dietary Supplement|Placebo|The participants will consume 2 capsules daily for three months
46090355|NCT00650520|Drug|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
46090356|NCT00650520|Drug|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
46090357|NCT00621062|Procedure|High Ligation of the GSV|Performed in local or general anesthesia in accordance to clinical praxis and the patients own preference. After high ligation the GSV is stripped from the groin to the most distant insufficient part or just under the knee joint.All proximal branches are ligated. Including the superficial epigastric vein. The stripping instrument can be inserted in either cranial or caudal direction but all veins are stripped in the cranio-caudal direction.
46005017|NCT04605900|Device|Orthopedic Footwear|The orthopedic footwear used by the OF Group was manufactured by the company J. Andrade Ferreira Neves Lda. with materials suitable for the diabetic foot, as registered with INFARMED under registration ID 279515.
46005018|NCT04605900|Device|Standard Footwear|In the SF Group, it was recommended to use standard shoes more suitable for diabetic foot, with some specific characteristics, such as sports or walking shoes. The acquisition or not of a more suitable shoes by the participants was at the discretion of each individual.
46005019|NCT04605900|Device|Plantar Orthoses|The plantar orthoses (PO) that both groups used for distribute of plantar loads was based on the principle of total contact. The confection material consisted in a liner of EVA shore 20º and polyurethane filling ELAX flexible (expandable) from OKM Química Ortopédica SL.
46005020|NCT04605900|Behavioral|Education on foot self-care|"An information leaflet with foot care was delivered, with the aim of ensuring that participants were informed about the care they should continually take with their feet during the study period. This leaflet was created based on the guidelines of the Associação Protetora dos Diabéticos in Portugal."
46005021|NCT00560963|Drug|everolimus|
46005022|NCT04597515|Procedure|Robot Breast reduction surgery|Breast reduction surgery, using a robot by removing a breast disc at the base
46090358|NCT00621062|Procedure|Endovenous Laser Ablation|Laser ablation is performed in tumescence anesthesia which is performed with a 150-200 ml (sometimes more is required, up to 400ml in patients with a poorly formed saphenous sheath) solution of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). Laser is performed under duplex guidance and the catheter is inserted percutaneously into the GSV at knee level and parked distant to the saphenofemoral junction (SFJ) just distal to the superficial epigastric vein. Laser ablation is performed down to the most distal insufficient part of GSV or just below the knee joint. We use an effect of 14 Watt administration of 70-80 J / cm at a continuous mode at a speed of 1cm/5sec.
46090359|NCT00621062|Procedure|Radiofrequency ablation|RF ablation is performed in tumescence anesthesia which is performed with a 150-200 ml solution (same as above) of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). RF is performed under duplex guidance and the Closure-FAST catheter is inserted percutaneously into the GSV at the knee level and parked distant to the SFJ just distal to the superficial epigastric vein. Probe size and length used for RF is chosen in accordance to the manufacturer's recommendation and with a probe temperature of 120 degrees C. RF closure is performed down to the most distal insufficient part of GSV or just under the knee joint.
46090360|NCT00621062|Procedure|Foam Sclerotherapy|Sclerosant foam consists of 2ml 3% aethoxysclerol mixed with 8ml air (Tessari method). A maximum of 10 ml is injected. Access to the vein for the sclerosant is gained by a duplex guided puncture or a mini incision mid-thigh or just above the knee and the amount of sclerosant foam used is 2,5-10 ml. Duplex is used prior to the operation in order to mark the vein and during the operation in order to control the extent of the sclerofoam. Duplex validates that foam is deposed to the whole length of the GSV. Blood from the veins is drained by means of elevation prior to the deposition of the sclerofoam. The leg is then bandaged with elastic bandage.
46090361|NCT04244981|Drug|Prothrombin Complex Concentrate, Human|A 4-factor prothrombin complex concentrate (Confidex®, CSL Behring, Marburg, Germany), containing a defined concentration of the four vitamin K-dependent clotting factors (II, VII, IX and X) and the thrombo-inhibitor proteins C and S. Each vial of Confidex® contains a relatively high concentration of coagulation factor II (20-48 IU/mL), factor VII (10-25 IU/mL), factor IX (20-31 IU/mL), factor X (22-60 IU/mL), proteins C (15-45 IU/mL), proteins S (13-38 IU/mL), Heparin (0.5 IU/mL), and antithrombin (0.6 IU/mL). The administration is based on the patients' body weight and INR (INR 2-4, PCC 25 IU/kg; INR 4-6, PCC 35 IU/kg; INR>6, PCC 50 IU/kg)
46005023|NCT04631978|Diagnostic Test|Comprehensive ophthalmologic examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
46005024|NCT04597281|Other|Lifestyle intervention|The intervention group, will receive education on Mediterranean lifestyle (Mediterranean diet and physical activity promotion), combined with the provision of extra-virgin olive oil and fish, in order to be consumed at least 3 times per week. Physical activity sessions with a physical activity monitor will also be offered for free to the children (2 sessions of 60 minutes of moderate-vigorous physical activity, per week)
46005025|NCT01159600|Drug|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
46090362|NCT04244981|Drug|Fresh Frozen Plasma|FFP will be given based on the patients' body weight (10-15 mL/kg).
46090363|NCT05253690|Procedure|balloon catheter insertion approach for labor induction|Parous women will be randomized to labor induction by view-guided approach using a speculum for catheter insersion versus manual guided catheter balloon insersion at cervical examination
46005026|NCT01159600|Drug|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
46090364|NCT04660448|Diagnostic Test|Bedside lung ultrasound examination|Lung ultrasound exploring 12 areas (6 in each lung) at 12 +/- 6 hours and at 48-72 hours from PICU admission. Clinical and analytical data collection coinciding with ultrasound imaging and during follow-up while admitted to PICU.
46005027|NCT01159600|Drug|BI 10773|BI 10773 tablets once daily high dose open label
46090365|NCT02651298|Device|Fractional Co2-laser|laser treatment
46090366|NCT04246385|Behavioral|CO-OP Group|"Participants in the intervention group will attend one 1:1 session where one goal will be selected from their COPM results to focus on during the group, group expectations will be reviewed, caregivers will be invited, and questions answered. The group will run six sessions as supported by the literature (Chan, 2007; Lee, Fischer, Zera, Robertson, & Hammel 2017).~Day Rehab CO-OP Group Curriculum Session Content~Introduction One on one session. COPM, introduction to group, education for caregiver. Session 1 Introduction to group and CO-OP approach, homework. Session 2 Review CO-OP approach, practice, homework. Session 3 Review CO-OP approach, plan outing, homework. Session 4 Review CO-OP approach, experiential learning according to participants' alternate COPM goals, homework. Session 5 Review CO-OP approach, outing, homework. Session 6 Review CO-OP approach, focus group, lessons learned, final COPM, homework"
46090367|NCT00147992|Procedure|Immediate loading of implants in totally edentate upper and lower jaw|Immediate loading of implants in totally edentate upper and lower jaw.
46090368|NCT02651142|Procedure|Patients receive SLNB|Patients receive sentinel lymph node biopsy
46090369|NCT04246307|Diagnostic Test|TEG® and ClotPro® parameters|"Systemic sampling is performed six times:~before the surgery (S1)~during the hepatectomy, 10 minutes before the anhepatic phase (S2)~in the anhepatic phase, before starting portal vein anastomosis: (S3)~in the neohepatic phase, 15 minutes after releasing portal vein clamping: (S4)~in the neohepatic phase, at the end of the surgery: (S5)~Regional sampling from the portal vein representing afferent flow to the liver is performed once:~• in the anhepatic phase, before starting portal vein anastomosis: (R)~Simultaneously with haemostasis and blood gas analyses, the following investigations will be performed (the following tests are also routinely performed at the given time points, independently of this study):~haemodynamic measurements by PiCCO~arterial blood gas analysis from radial artery catheter~central venous blood gas analysis from subclavian vein catheter~blood temperature measurement in the femoral artery by PiCCO catheter~hourly urinary output"
46090370|NCT00621218|Drug|tretinoin gel 0.05%|Apply tretinoin gel, 0.05% topically once or twice daily to female subjects with rosacea
46090371|NCT00621218|Drug|vehicle|Apply Atralin Gel vehicle topically once or twice daily to female subjects with rosacea.
46090372|NCT02655276|Other|microencapsulated Glycine|100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d.
46090373|NCT02655276|Other|Placebo tablets|Placebo t.i.d. from Biotiki® in a crossover-design.
46090374|NCT02651064|Other|HIP|
46090375|NCT02832947|Drug|Rivaroxaban 10 mg|At study month 7 (+/-1 month), patients receive at 8 a.m. a single dose of 10 mg rivaroxaban. Study specific blood tubes are sampled the same day at the indicated time points from T -1h to T 12h.
45473933|NCT03381040|Device|Restylane Volyme|"Restylane® Volyme is a sterile, biodegradable, viscoelastic, non-pyrogenic, clear, colorless, and homogeneous soft hyaluronic acid gel with a high lifting capacity. Volyme is intended for injection into the supraperiostic zone or subcutis to augment the volume of the cheeks.~Given Volyme's viscoelastic and lifting capacities, it is best used when there is significant loss of volume and a thin skin envelope."
46005028|NCT01159600|Drug|BI 10773|BI 10773 tablets once daily high dose
46005029|NCT01159600|Drug|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
46005030|NCT01159600|Drug|BI 10773|BI 10773 tablets once daily low dose
46005031|NCT01159600|Drug|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
46005032|NCT04631627|Drug|Aspirin|With the result of risk assessment for high risk and the risk of pregnant women, with each research center stratified random aspirin drug intervention, for each center screening high-risk and accord with the standard drug intervention study phase into eliminate pregnant women by using stochastic indicator 1:1 randomly into low-dose aspirin to prevent group and observation group, for each center in screening for risk and comply with the drug intervention study phase into the exclusion standard 1:1 by random indicator method pregnant women randomly into low-dose aspirin to prevent group and observation group.
46090376|NCT00651300|Drug|Parecoxib/Valdecoxib|A single 40mg dose of intravenous (IV) parecoxib sodium administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of valdecoxib 40 mg (2 x 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
46090377|NCT00651300|Drug|Placebo|A single dose of IV saline (placebo) administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of placebo (2 x matching valdecoxib 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
46005033|NCT00564759|Drug|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo retroviral transduced (SF71-gp91phox) CD34+ cells
46090378|NCT02832791|Procedure|QUADRICEPS TENDON|Once the limb is prepped and draped,it is exsanguinated, and the tourniquet is raised to 250 mm Hg. We will make an arthroscopic examination through an anterolateral viewing portal to corroborate the ACL injury as well as the determination of possible associated lesions. The accessory medial portal is stablished slightly above the joint line (about 2 cm of the medial edge of the patel) that is used as an instrumentation portal. Then,, a high anteromedial portal, is made higher than the previous to see the femoral footprint. Once the associated meniscal or cartilaginous lesions are addressed attention turns to the harvesting of the graft. A 4 cm vertical incision is made starting at the proximal pole of the patella and directed proximally and centered in line with the quadriceps tendon. The subcutaneous tissue is dissected and a 70-80 mm long ,10 mm wide and 7mm depth graft is obtained with the use of a n21 scalpel 2cm of both limbs of the graft are sutured
46090379|NCT02832791|Procedure|HAMSTRING TENDON|"Once the limb is prepped and draped,it is exsanguinated, and the tourniquet is raised to 250 mm Hg. The procedure begins with an arthroscopic examination through an anterolateral viewing portal to corroborate the ACL injury as well as the determination of possible associated lesions. The accessory medial portal is stablished slightly above the joint line, at about 2 cm of the medial edge of the patellar tendon. This portal is used as an instrumentation portal. A third portal, a high anteromedial portal, is made higher than the previous, this portal will allow visualization of the femoral footprint.~Once the associated meniscal or cartilaginous lesions are addressed attention turns to the harvesting of the graft.~A 4cm oblique incision is made starting 2 cm medial to the tibial tubercle and directed proximally and medially. After dissecting the subcutaneous tissue the Sartorius fascia is incised and both tendons are identified and harvested with the use of a tendon stripper"
46090380|NCT04210466|Behavioral|Acceptance & Commitment Therapy + Compassion (COMP.ACT)|8 sessions, 2h each. Intervention includes meditation exercises, behavioral exercises, group discussions, and the structure is the following Session 1: INTRODUCTION: control is the problem Session 2: THE BODY AS PRESENT: promoting body awareness through mindfulness Session 3: COMPASSION I: from self-criticism to self-care Session 4: COMPASSION II: the body as an anchor to self-compassion Session 5: ACCEPTANCE: there is more to accept than just pain Session 6: (RE)DISCOVERING VALUES: in search of a valued life Session 7: ACT NOW: from values to committed action Session 8: CARRY ON AFTER COMP.ACT: program summary
45677978|NCT01945034|Drug|Topical IBU three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
45677979|NCT01945034|Drug|Placebo three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
45677980|NCT04655768|Device|Palmar Plate Fixation|Patients are treated by surgery (palmar plate)
45677981|NCT04638062|Other|1.Post Isometric Relaxation|"For Upper Trapezius In supine position Neck flexion, contra-lateral full side bending followed by slight ipsilateral rotation will be provided towards the side being treated. while asking the patient to shrug the stabilized shoulder and contraction will be maintained for 7- 10s. Repeating it 3-5 times.~For Levator Scapulae Step One In supine position while lifting the patients neck in full flexion, lateral flexion and rotation with 7-10s isometric contraction away from side to be treated will be provided.~Step Two The patient will be instructed to take head backwards to the table while at the same time asking the patient to slightly shrug the shoulder and resistance will be provided. Repeating it 3-5 times.~2.Neck isometric strengthening exercises Intensity 5 reps Frequency at 1st week one set and second week will progress to 2 sets~3.Cryotherapy will be placed on cervical region for 10 min after the treatment."
46090381|NCT04210466|Behavioral|Acceptance and Commitment Therapy (ACT)|8 sessions, 2h each. Intervention includes meditation exercises, behavioral exercises, group discussions, and the structure is the following Session 1: INTRODUCTION: control is the problem Session 2: THE BODY AS PRESENT: promoting body awareness through mindfulness Session 3: Q&A 1 Session 4: Q&A 2 Session 5: ACCEPTANCE: there is more to accept than just pain Session 6: (RE)DISCOVERING VALUES: in search of a valued life Session 7: ACT NOW: from values to committed action Session 8: CARRY ON AFTER COMP.ACT: program summary
46005034|NCT04632017|Diagnostic Test|Computerized cardiotocography|To compare Dawes and Redman indices as determined by computer analysis of the fetal heart tracing
45683800|NCT04087642|Diagnostic Test|Preoperative prolapse reduction cough stress test|In this group, both tests will be performed but the preoperative prolapse reduction cough stress test will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
45836279|NCT01890720|Other|Standard postoperative wound dressing|A standard wound dressing will be applied over the clean closed incision immediately following the operation (caesarean section). In the control group the dressing will be left in situ for at least 24 hours as standard procedure.
46005035|NCT04314193|Drug|Methotrexate|Oral methotrexate (15 mg weekly to be increased to 25 mg weekly) for 24 weeks.
46005036|NCT04314193|Drug|Prednisolone|Oral prednisolone (start 40 mg daily, to be tapered to 10 mg daily) for 24 weeks.
46005037|NCT04597398|Device|Evaluation of blood flow with indocyanine green|
46005038|NCT04631354|Drug|Radio-labelled S-770108|99mTc radio-labelled S-770108 supplied as a capsule containing 6 mg active pirfenidone for inhalation
46090382|NCT02828033|Drug|Rilonacept|All patients will receive rilonacept with an initial loading dose of 320 mg delivered as two, 2-mL, subcutaneous injections of 160 mg each given on the same day at two different sites. The initial dose will be administered at the study site by study personnel. Dosing will then be a once-weekly injection of 160 mg administered as a single, 2-mL, subcutaneous injection by the patient at home. Patients will be dosed for 24 weeks.
46005039|NCT04631354|Device|S-770108 Inhaler A1|Dry powder inhaler
46005040|NCT01159171|Drug|bevacizumab [Avastin]|5 mg/kg intravenously every 14 days
46005041|NCT01159171|Drug|capecitabine [Xeloda]|1000 mg/m2 orally b.i.d. , Days 1 - 14 of every 28-day cycle
46005042|NCT01159171|Drug|oxaliplatin|40 mg/m2 iv weekly
46090383|NCT00621998|Drug|risperidone|0.5-6 mg/day
46090384|NCT00621998|Drug|olanzapine|2.5-20 mg/day
46090385|NCT02655198|Drug|Fenfluramine|study of efficacy and safety of add-on fenfluramine at different dosages in refractory Lennox Gastaut patients : 0.2 - 0.4 and 0.8 mg/kg/day (max 30 mg).
45836280|NCT00244140|Drug|Iopromide 370 mg I/mL|Iopromide (Ultravist 370 mg I/mL) administered intravenously
45836281|NCT00244140|Drug|Iopromide 300 mg I/mL|Iopromide (Ultravist 300 mg I/mL) administered intravenously
46005043|NCT04631315|Drug|Difluprednate Ophthalmic Emulsion 0.05%|1 drop, 2 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, once a day for the next 2 weeks.
46090386|NCT04210388|Drug|AZD5718 tablet, Formulation A|Volunteers will receive single doses of AZD5718 tablet, Formulation A under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
46090387|NCT04210388|Drug|AZD5718 tablet, Formulation B|Volunteers will receive single doses of AZD5718 tablet, Formulation B under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
46090388|NCT04210388|Drug|AZD5718 tablet, Formulation C|Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
46090389|NCT04210388|Drug|AZD5718 tablet, Formulation D|Volunteers will receive single doses of AZD5718 tablet, Formulation D under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
46090390|NCT04210388|Drug|AZD5718 film-coated tablet, Reference treatment|Volunteers will receive single doses of AZD5718 film-coated tablet, Reference treatment under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
46090391|NCT00650052|Drug|Zonisamide Capsules 100 mg|100mg, single dose fasting
46090392|NCT00650052|Drug|Zonegran® Capsules 100 mg|100mg, single dose fasting
46005044|NCT04631315|Drug|Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution|1 drop, 4 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, twice a day for the next 2 weeks.
46005045|NCT02885155|Other|Echocardiography|planned at regular intervals
46005046|NCT02885155|Other|Hemodynamic examinations (right cardiac catheterization)|planned at regular intervals
46090393|NCT00891527|Drug|Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)|"Imatinib Mesylate Orange to grayish orange, opaque, 100mg capsules dissolved in 50-100mls of mineral water or apple juice. Given at 340mg/m2 once daily, preferably with a meal.~Bevacizumab Clear to slightly opalescent liquid. Given at 10mg/kg once every 2 weeks IV. The calculated dose should be placed in an IV bag and diluted with 0.9% sodium chloride to obtain a final volume of 25-100mls. The vials contain no antibacterial preservatives. Once diluted, must be administered within 8 hrs. Initially administered over 90 mins. If no adverse reactions occur, 2nd dose administered over 60 mins. If still no adverse reactions, subsequent doses administered over 30 mins. If infusion-related adverse reactions occur, further infusions administered over the shortest period that was well tolerated."
46090394|NCT02648100|Other|biomarker study|
46090395|NCT03861078|Other|Own Brand Cigarette|Effects of own brand cigarette use.
46005047|NCT04631666|Biological|DZIF-10c|SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion
46090396|NCT03861078|Other|ECIG 15 mg nicotine, sweetened|Effects of using a 30 Watt ECIG filled with 15 mg nicotine, sweetened liquid
46090397|NCT03861078|Other|ECIG 15 mg nicotine, unsweet|Effects of using a 30 Watt ECIG filled with 15 mg nicotine, unsweet liquid
46090398|NCT03861078|Other|ECIG 0 mg nicotine, sweetened|Effects of using a 30 Watt ECIG filled with 0 mg nicotine, sweetened liquid
45473935|NCT01175915|Other|Western therapy|"Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius lasting for more than 2 hours;~No specific treatment for tetter and ulcer, but Bingpeng powder, Watermelon tablet or frost for oral herpes.~Intervention time: 3-7 days; Follow-up time: 3 days."
46005048|NCT04631666|Other|Placebo|Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
46090399|NCT03861078|Other|ECIG 0 mg nicotine, unsweet|Effects of using a 30 Watt ECIG filled with 0 mg nicotine, unsweet liquid
46090400|NCT05217797|Behavioral|Wearing glasses (any type)|Participants are asked to wear glasses in public spaces.
46090401|NCT03845166|Drug|XL092|oral doses of XL092
46090402|NCT03845166|Drug|Atezolizumab|Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once every 3 weeks (q3w)
46090403|NCT03845166|Drug|Avelumab|Supplied as 200 mg/10 mL vials; administered as an 800 mg IV infusion once every 2 weeks (q2w)
46090404|NCT04245293|Device|Ainara|Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).
46005049|NCT02885194|Other|Laser-Evoked potential|Laser-Evoked potential can document lesions of spinothalamic tract and lateral brainstem and of thalamo-cortical projections conducting nociceptive signals. The rapid heating of skin by infrared laser pulses stimulate small fibers sensory pathways. The main cortical laser evoked potential is a complex of components N2-P2. Evaluation of the registered potentials includes shape, latency and amplitude.
46005050|NCT04597203|Device|755-nm picosecond alexandrite laser with topical 2% hydroquinone|treatment one side of the face with 755-nm picosecond alexandrite laser with topical 2% hydroquinone
46090405|NCT04245293|Device|HyaloGin|"Active Comparator: HyaloGin Each administration kit (subject kit) for patients allocated to HyaloGyn® group will contain a box with: 1 tube with 30g gel and 10 single-use applicators consisting of a piston and one opaque plastic plunger.~The gel quantity is enough for one subject (3g application every three days over the course of the study)."
46090406|NCT04584866|Procedure|Endonasal endoscopic pituitary surgery in semi-sitting position|Patients will be placed in semi-sitting position. To achieve the semi-sitting position, the patient is placed in supine position. The operating table is then separated and flexed to elevate the torso (angle of 30°). The head, which is fixed in a head clamp, is slightly flexed to bring the floor of the sella right in front of the surgeon and gently rotated toward the operating team.
46090407|NCT04584866|Procedure|Endonasal endoscopic pituitary surgery in supine position|Patients will be operated in the standard supine neutral position
46005051|NCT04597203|Drug|topical 2% hydroquinone|treatment one side of the face with topical 2% hydroquinone
46090408|NCT02829359|Drug|Entecavir therapy|Patients in the antiviral group received entecavir begin in the first 3 days before surgery for at lest 1 month.
46090409|NCT03916796|Other|Exercise|-The exercise part will consist of an evaluation and treatment as prescribed by a physical therapist including aerobic & dynamic stretching warm-up, strength training, balance training, and flexibility training. Will also include a home exercise program (HEP). Physical therapists will have specialized training in cancer rehabilitation obtained through the ReVital certification process.
45836282|NCT00126750|Behavioral|VA MI Plus Interactive|The experimental intervention, customized to the individual clinician in real-time consists of Internet learning modules integrating case-based education with audit, feedback, and benchmarking of practice profiles.
46005052|NCT04313842|Device|AVATAMED|tumor specimen will be sent for in vitro drug screening experiment and the result will be analyzed by 'AVATAMED' to predict the clinical response
46005053|NCT04631237|Other|Observational, no intervention|No intervention involved
46005054|NCT04596852|Device|Assessment of the reliability of a protocol characterizing intersegmental hyper-resistance to passive stretch|"Passive solicitations of the main joints of the lower limb, of healthy children and children with cerebral palsy, are realized by two evaluators with a handheld dynamometer.~Repeated measures are performed to assess intra and inter-reliability."
46090410|NCT03916796|Other|Enhanced Recovery after surgery|-The protocols include instructions for patient care from the time of pre-surgical admission to discharge, including directives regarding diet, labs, IV fluids, pain management, prophylactic medications, management of indwelling catheters and drains, and activity.
46090411|NCT03916796|Other|Psychological screening with counselling services as needed|-The psychological screening will be completed by the Radiation Oncology nurse at the consult visit
46090412|NCT03916796|Other|Dietary Counseling Services|-Patients will have a baseline nutrition counseling visit with a Registered Dietician. This may include a nutrition assessment and nutrition counseling to set priorities, establish goals, and create an individualized plan
46090413|NCT02829749|Device|NeoChord beating heart mitral valve implantation|The NeoChord DS1000 procedure is performed in five steps: (1) Device Preparation; (2) Left Ventricular Access; (3) Leaflet Capture and Verification; (4) Suture Deployment and (5) Suture Closure. The sutures are placed via a ventriculotomy 2-4 cm postero-lateral from the apex of the left ventricle via thoracotomy. The procedure is performed on a beating heart through a 2 to 3 inch right antero-lateral thoracotomy, then one to five Goretex neochordae are introduced with a transcatheter delivery system through the apex of the heart, into the left ventricle, and fixed on the free edge of the prolapsed leaflet. This is performed with transesophageal echocardiographic guidance.
46090414|NCT02829749|Procedure|Control|traditional mitral valve repair performed under cardiac arrest
46090415|NCT00621374|Behavioral|Cognitive Behavioral Therapy (CBT) +Hypnosis (HYP)|There is also the possibility that the two treatments together may be even more helpful than either one alone. Because some of the patients in this study will get both CBT and self-hypnosis, we will be able to determine if each one facilitates the efficacy of the other. If the patients treated in this study report benefits, as we expect they will, then this will encourage us to design and complete a larger study to better understand how patients with MS would benefit from these treatments.
45473936|NCT01175915|Other|Reduning Injection|"Lifestyle counseling, vitamin supplementation if necessary, and non-use of antibiotics;~Reduning Injection, 0.5~15ml, depending on patient's condition, IV per day, or according to the instruction;~Using Ibuprofen suspension when patient's temperature higher than 39 degree Celsius lasting for more than 2 hours.~Intervention time: 3-7 days; Follow-up time: 3 days."
45836283|NCT00127062|Other|Oxford street|2 h walk around Oxford street
45836284|NCT00127062|Other|Hyde park|2 h walk around Hyde park
45836285|NCT00127218|Drug|any statin|Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months
45836286|NCT00127218|Drug|niacin|long-acting niacin daily for 18 months
45836287|NCT00127218|Drug|Placebo|matching placebo pill daily for 18 months
46005055|NCT04631159|Behavioral|Health2Sync app and report blood glucose data weekly|Patients will need to download and use the Health2Sync app and report blood glucose data weekly
46005056|NCT04631159|Other|self-manage|Patients will be asked to self-manage and there is no intervention during the tracking process
46005057|NCT04605276|Other|No intervention|No intervention
46005058|NCT04596774|Procedure|Traditional Approach|Patients received intraoperative 10 mL/kg/h IV izolen infusion. Opioids and PONV prophylaxis were applied when required.
46005059|NCT04596774|Procedure|Enhanced Recovery After Surgery (ERAS) Approach|Patients did not preoperatively smoke for 48 hours, drank clear liquids until the last 2 hours and received 6 mL/kg/h IV izolen infusion intraoperatively. In these; gastric aspiration was applied before extubation, PONV prophylaxis was supported routinely, and patient controlled analgesia was added to the routine analgesia plan for the first postoperative 48 hours.
46005060|NCT04630691|Procedure|Implantation|Patients received narrow diameter implants in posterior mandible or maxilla
46090416|NCT00621374|Behavioral|Cognitive Behavioral Therapy (CBT)|"One treatment module is we will study is called cognitive restructuring or cognitive-behavior therapy (CBT). In this treatment, people learn to identify negative thoughts that make them feel bad or anxious. Such negative thoughts lead to feelings of frustration and anxiety, and can even increase the experience of pain, because they cause a person to focus more on pain. With CBT, people learn to identify and stop these thoughts, and then replace them with more reassuring ones. When they do this, they feel more relaxed and focus less on their pain. As a result, they often say that they feel much better and are less aware of pain."
46090417|NCT00621374|Behavioral|Self-Hypnosis Training (HYP)|Self-hypnosis (HYP) is another strategy that people can learn to manage pain. With this treatment, people learn to enter a state of focused attention, and then change how they experience pain. Although we do not yet know how hypnosis works, research has repeatedly shown that the effects are real; when people report decreases in pain with hypnosis, scans and images of the brain's activity show decreases in the parts of the brain that process pain information. With hypnosis, people are not just pretending to feel less pain, they actually do feel less pain.
45459204|NCT04947644|Procedure|Ultrasound guided continuous erector spinae plane block|After verifying the correct space with hydrodissection by 5mL of saline 0.9%, lifting erector spinae muscle off the bony shadow of the transverse process, a catheter was inserted was inserted 3 cm beyond the needle tip and 20 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 10 ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
45683801|NCT04746352|Procedure|BES-SMFR|For the BES intervention, it was performed using the same Vishee neuro-muscle stimulator as the sEMG assessment with a vaginal probe was inserted into the vagina and placed close to the PFMs. At the same time, patients could learn about their neuromuscular activity through the biofeedback instrument, abdominal breathing for 5 sec was necessary when PFMs were overactive. BES was performed once every 2 days for 4 weeks.
46005061|NCT04631081|Procedure|coverage of the fingertips with bipedicled palmar island flap|The initial step is wound debridement. To design the flap, a longitudinal line is drawn at the junction of the volar and dorsal parts of the finger, starting from the distal part of the proximal interphalangeal joint flexion crease. It will be harvested from distal to proximal dissecting the digital canal plane. By releasing the Cleland and Grayson ligaments, the neurovascular bundle will be dissected. On the intermediate phalange, the dorsal branch of the neurovascular bundle must be preserved to maintain blood flow to the dorsal skin. Dissection is completed at the junction between the palmo-dorsal arteries and the collateral neurovascular bundles on both sides of the finger. A triangle may be resected at the distal edge of the flap to reshape of the pulp. Bone may be resected if needed to allow tension-free closure of the distal part of the flap. No Immobilization will be necessary.
45683802|NCT04746352|Procedure|BES|First, a standardized and structured vaginal examination was performed by digital palpation to identify pelvic floor active MTrPs, and then pain mapping was developed for the patient's use. Second, patients were required to participate in intensive training regarding myofascial release techniques. Following the training, SMFR was regularly performed by at home for 5 minutes daily for 4 weeks. SMFR was confirmed with patients at all their follow up visits.
45836288|NCT00127530|Drug|Fampridine-SR|Tablets, 10 mg, twice daily, 14 weeks
45836289|NCT00127530|Drug|Placebo|sugar pill, twice a day (b.i.d.)
45836290|NCT04346238|Other|Reuse of existing data from patients' medical records|Reuse of existing data from patients' medical records
46090418|NCT00621374|Behavioral|Education Control (CONT)|The CONT condition for this study will include lectures that are interactive and are compelling and informative enough to be both (1) credible as an attentional control condition and (2) perceived as helpful to subjects. The CONT condition will not, however, include instructions in making specific cognitive or behavioral changes related to pain management. Thus, it could control for non-specific factors related to behavioral treatment, but will not impact the primary outcome measure (pain).
46090419|NCT02650752|Drug|Lapatinib in Tandem With Capecitabine|
46005062|NCT04631081|Other|occlusive dressing|patients will be evaluated on admission and benefit from wound irrigation, debridement and placement of a simple dressing with Adaptic or Jelonet, either in the Emergency department or in the Hand Surgery department. At 48 hours, they will be addressed to the Hand Surgery department to place a self-adhesive polyurethane film. Follow-up will include a visit at 1 week for dressing change, and then weekly for further dressing change until healing. Skin proximal to the injury will be degreased to increase adherence of the dressing. Distally, the film leaves a pocket to collect wound exudate. During treatment, the foul-smelling liquid produced by the wound and clots collected in the occlusive dressing will not be removed. A gauze covers the occlusive dressing to protect the liquid pocket and cover potential smell.
45677982|NCT04638062|Other|1.Myofascial Release therapy|"For Upper Trapezius In sitting position Myofascial Release of Trapezius will be performed unilaterally with soft fist or elbow sinking and then taking up the line of tension from mid belly of Trapezius, to the acromion process, while the patient drops the head forward and will slowly rotate the head from side to side. While providing the resistance to contralateral side of rotation. Repeating for 2-3 times.~For Levator Scapulae In sitting position applying same unilateral muscle release as Trapezius, but the line of tension will be to the inferior border of Scapulae slightly laterally and will ask the patient to drop the head forward to increase resistance on Levator muscle. Repeating it 2-3 times~2.Neck isometric strengthening exercises Intensity 5 reps Frequency at 1st week one set and second week will progress to 2 sets~3.Cryotherapy will be placed on cervical region for 10 min after the treatment."
45677983|NCT04636970|Other|Home training program|Subjects randomized to the IG will participate at home training program that will last 12 weeks and consists of endurance, flexibility, balance and cardiovascular resistance training performed with low to moderate intensity, in 20-60 minutes sessions, five times a week. Study participants will be asked to wear wrist and chest unobtrusive devices during active day time or at least during the training session and two hours before and after.
46090420|NCT02832869|Other|short message service based re-education|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
46090421|NCT02832869|Other|Wechat based re-education|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as Wechat based re-education by one investigator on the day before colonoscopy.
46090422|NCT02832713|Drug|Botulinum toxin A ( BoNT-A)|Intra-articular injection of BoNT-A
45459205|NCT04989842|Behavioral|Curriculum Hannover|The methodology uses a natural variation design within the Dr. Becker Clinical Group. The interventions consist of a face-to-face or a digital psychosomatic aftercare basing upon the concept of the Curriculum Hanover. A control group is included that does not receive these two interventions (but receives a similar rehabilitation treatment to the intervention groups).
46005063|NCT04596813|Device|CytoSorb 300 mL device|Intra-and postoperative CytoSorb hemoadsorption
46005064|NCT04630457|Device|Conventional ankle prosthesis|At the first visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using the conventional prosthesis that the patient had.
45459206|NCT03487744|Other|Osmolite 1.5|Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube.
46005065|NCT04630457|Device|Meridium® (Microprocessor ankle prosthesis)|There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using Meridium®. For example, if visit 2 was evaluated using Meridium®, visit 3 was evaluated using RoFT®. In another example, visit 2 is evaluated using RoFT®, while Visit 3 is evaluated using Meridium®.
46005066|NCT04630457|Device|RoFT® (Microprocessor ankle prosthesis)|There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using RoFT®. For example, if visit 2 was evaluated using RoFT®, visit 3 was evaluated using Meridium®. In another example, visit 2 is evaluated using Meridium®, while Visit 3 is evaluated using RoFT®.
46005067|NCT01158118|Drug|Sargramostim|
46005068|NCT01158118|Drug|Plerixafor|
46090423|NCT02832713|Device|Hyaluronic acid (HA)|Intra-articular injection of Hyaluronic acid
46090424|NCT02650674|Other|Product A: NP-0148|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
46090425|NCT02650674|Other|Glucose solution|Glucose solution providing 50 g of available carbohydrates in 250 ml of water. This will be performed 3 times
46090426|NCT02650674|Other|Product B: NP-0149|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
46090427|NCT02650674|Other|Product C: NP-0150|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
46090428|NCT02650674|Other|Product D: NP-0151|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
46090429|NCT02650674|Other|Product E: NP-0152|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
45459207|NCT03487744|Other|Promote without fiber|Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube.
45459208|NCT01373060|Drug|ASP1941|oral
45459209|NCT01373060|Drug|Placebo|oral
46090430|NCT04963634|Other|Biobanking|For patients included in BRADYDIAG study, 2 blood samples will be collected at enrollment (for group 1: bradykinin angioedema and for group 2: histamine-mediated angioedema) and at 1 year visit (for group 1 only: bradykinin angioedema).
46090431|NCT02654886|Other|Resistance Exercise Training|"Resistance Exercise Training: knee extension and elbow flexion each 3 times per week 3 sets each session; 10 reps/set for 6 months~Respiratory muscle strength training: 25 repetitions -twice daily, 6 days/week for 6 months"
46090432|NCT02832635|Drug|TMZ|TMZ 75mg/m2/d from the 1st day to the last day of radiotherapy
46090433|NCT02832635|Radiation|WBRT with avoidance of hippocampus|Whole brain radiotherapy of 30Gy/10f by IMRT (Intensity Modulation Radiated Therapy), with or without boost. The maximum dose of hippocampus should be no more than 18Gy.
46005069|NCT04630340|Device|STEADES-2|In this arm, the subjects will use a novel exhaled breath carbon monoxide measurement instrument (STEADES-2) for self surveillance of their smoking status. In addition, the subjects will download the STEADES-2 mobile phone application to pay serious games relating to smoking cessation, receive push-though motivational messages and e-coaching from trained healthcare professionals.
46005070|NCT04596969|Other|Soluble Fiber Dextrin|Ingredient based on resistant starch
46005071|NCT04313920|Other|Nutritional Supplement|50 g Carbohydrate
46005072|NCT02885311|Behavioral|Motivation Enhancement Therapy|Motivation Enhancement Therapy (MET) similarly allows for goal choice in treatment, and has been shown to be effective in treating a broad spectrum of drinking problems in both abstinent and non-abstinent goal conditions. The unique goals of MET (enhancing intrinsic motivation for change and facilitating development of a self-generated change plan).
45459210|NCT04816630|Device|CBC-Diff Monocyte Volume Width Distribution|MDW is part of the CBC-Diff and will be collected but not reported to the physician. MDW will not impact standard of care.
46005073|NCT02885311|Behavioral|Modified Behavioral Self-Control Therapy|Motivational Interviewing was developed to increase self-efficacy and motivation for drinking, and Cognitive Behavioral Therapy allows for individuals to develop strategies for drinking reduction. Both are evidence-based interventions that have been combined in previous studies for drinking reduction in problem drinkers.
46005074|NCT02885311|Drug|Naltrexone|Participants, who choose medication treatment, will be offered naltrexone (50 mg per day), which is an FDA-Approved medication for alcohol use disorder. According to the package insert for NTX, the medication has been associated with liver toxicity at very high doses (up to 300 mg/day); however, a number of clinical trials and published studies suggest there are few serious adverse effects, including minimal hepatotoxicity, associated with daily dose of 50 mg of naltrexone. Its most common side effects in opioid-free individuals are nausea, vomiting, anxiety, headache, abdominal discomfort, difficulty sleeping, fatigue, irritability, and decreased appetite. A rare serious adverse effect may include minimal liver toxicity, but is more likely to occur at very high doses (300 mg/day).
46090434|NCT02832635|Radiation|WBRT without avoidance of hippocampus|Whole brain radiotherapy of 30Gy/10f by IMRT, with or without boost. The dose of hippocampus is not considered.
46090435|NCT02691806|Other|experimental protocol|"first day- VO2max test with the following measurements: anaerobic threshold, maximum oxygen consumption, heart rate and breathing indices.~second day- performing the same physical protocol of VO2max test with the measurements: leg muscles activity using a wireless EMG, hemodynamic measurements of oxygen levels in the skin and skin perfusion, the two latest using optic sensors."
46090436|NCT00650598|Drug|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) loading dose by mouth on Day 1 followed by 20 mg twice daily (BID) on Days 2-6
46090437|NCT00650598|Drug|diclofenac|diclofenac sodium delayed release tablets 75 mg by mouth twice daily (BID) for 6 days
46090438|NCT00620204|Drug|atorvastatin|atorvastatin 40mg qd for 1 year
46090439|NCT03867344|Other|Hypoglycemic Hyperinsulinemic Clamp|Participants undergo a 120-minute hypoglycemic hyperinsulinemic clamp procedure.
45836291|NCT00250926|Drug|Bortezomib|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
46005075|NCT02885311|Behavioral|Brief Advice|Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
46090440|NCT03867344|Other|Normoglycemic Hyperinsulinemic Clamp|Participants undergo a 120-minute normoglycemic hyperinsulinemic clamp procedure.
46090441|NCT02832557|Other|Salivary collection|Collection of saliva via swab for miRNA processing
46090442|NCT02832557|Other|Vineland Adaptive Behavior Scale-III Assessment|
46090443|NCT02832557|Other|Medical history questionaire|
46090444|NCT02832557|Other|Autism Diagnostic Observation Schedule -2nd edition (ADOS-2)|
46090445|NCT02832557|Other|Mullen Scales of Early Learning|
46090446|NCT02650596|Drug|GLP-1|Liraglutide were taken daily for 3 months
46090447|NCT02650596|Drug|Placebo|Placebo were taken daily for 3 months
46090448|NCT04490096|Drug|[11C]-PBR28|"A dose of ≤ 20 mCi (approximate range for most studies is anticipated to be 5-20 mCi) of [11C]-PBR28 will be administered by IV injection to the patient under the direct supervision of a Nuclear Medicine Authorized User. A lesser activity may be injected if, in the opinion of a nuclear medicine authorized user complete imaging data could be generated.~Subjects will undergo an approximately 90 minute dynamic PET/CT scan over the brain starting at approximately the same time as the [11C]-PBR-28 injection. Scans will be acquired using a Philips PET/CT time-of-flight Ingenuity scanner (Philips Healthcare, Cleveland, OH, USA). At the end of the dynamic imaging the participant will be allowed to get off the scanner."
45459211|NCT03620084|Device|Expiratory Muscle Strength Training (EMST)|The target home practice frequency on the EMST-150 is: 5 repetitions of forceful expiration each time, 5 times daily, 5 days a week for 8 weeks, following the training protocol used by Hutcheson et al. (2017).
45459212|NCT04742140|Drug|Magnesium sulfate|each patient injected 0.5ml in each TrPs of magnesium sulphate according to the treatment group by the same operator
45836292|NCT00250926|Drug|Dexamethasone|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
45836293|NCT00250926|Drug|Rituximab|Given intravenously after bortezomib and dexamethasone on day 11 of a 21-day cycle for 8 cycles
45836294|NCT00251238|Drug|Ginkgo biloba extract EGb 761|daily Ginkgo biloba extract EGb 761
46005076|NCT02885311|Other|Referral to specialty substance use disorder treatment|Participants who present with complex drinking concerns will be referred to specialty substance use disorder treatment. This treatment will be provided in a separate treatment facility that focuses on substance use disorders and will potentially provide a combination of medication management and individual/group behavioral treatment for substance use disorders.
46005077|NCT04630418|Other|NanoSilk Cosmo|Participant will receive 30 mL of NanoSilk Cosmo jar.
46005078|NCT00564837|Procedure|Home-based rehabilitation program|Home-based rehabilitation program that includes 4 physiotherapy sessions in the first 3 post-op months
46005079|NCT00564837|Procedure|Physiotherapy-supervised rehabilitation program|Physiotherapy-supervised rehabilitation program that includes 17 scheduled physiotherapy sessions in the first 3 post-op months
46090449|NCT02650518|Other|Short-course Antibiotics|3 days of amoxicillin/clavulanate, ciprofloxacin, or cotrimoxazole.
46090450|NCT02650518|Device|Catheter Change|Urinary catheter change once randomization is complete.
45459213|NCT04742140|Drug|Saline|each patient injected 0.5ml in each TrPs of saline according to the treatment group by the same operator
45459214|NCT04580992|Drug|Ajmaline|Ajmaline administration
45459215|NCT04590274|Drug|Hydroxychloroquine|Hydroxychloroquine
45459216|NCT04590274|Dietary Supplement|Vitamins and Minerals|elemental Zinc Vitamin C Vitamin D3 N-acetylcysteine Elderberry Quercetin
45836295|NCT00251862|Behavioral|Web-based decision aid plus personalized risk assessment|Patients review a computer-based decision aid that discuss the pros and cons of of 5 recommended CRC screening options and provides personalized 10-year estimates of CRC risk prior to meeting with their provider to discuss CRC screening.
46005080|NCT01157845|Device|BreathID (Methacetin breath test)|13C-labeled methacetin (75 mg) is given to the patient by mouth in a small volume of water, and expired 13C-labeled carbon dioxide is measured from a nasal cannula.
46005081|NCT00561041|Behavioral|Brief phone aftercare intervention|Interventions is composed of 5 integrated cognitive-behavioral and motivational enhancement therapies administered during a period of 3 months according to a similar schedule
46005082|NCT00561041|Behavioral|individual aftercare therapy|composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
46005083|NCT00566241|Drug|recombinant human IGF-1|rhIGF-1
46090451|NCT02832089|Drug|oral carvedilol|oral carvedilol in escalating doses for reducing ventricular rate in AF patients
46090452|NCT00622076|Procedure|postoperative catheterization|postoperative catheterization after anterior colporrhaphy for five days versus two days.
46090453|NCT02647710|Behavioral|PHAT Life Intervention|HIV Prevention behavioral health intervention
46090454|NCT02647710|Behavioral|Health Promotion Control|Behavioral health intervention control
46005084|NCT00566241|Drug|Placebo|Placebo
46005085|NCT00564915|Dietary Supplement|Ketogenic diet|Ketogenic diet
46090455|NCT04247633|Drug|Palbociclib|Palbociclib at a dose of 125 mg will be administered orally once a day for 21 days, followed by 7 days off treatment of every 28 day cycle. Investigational medicinal product (IMP) will be administered with standard adjuvant endocrine therapy (Non-investigational treatment).
46090456|NCT00117416|Procedure|controlling the MAP|
46090457|NCT04208672|Device|UMindSleep|CPAP titration will be provided for Obstructive Sleep Apneas Syndrome.
46090458|NCT02647398|Behavioral|Vigorous aerobic training|Supervised vigorous aerobic training
46005086|NCT00561119|Drug|gemcitabine , paclitaxel|"Gemcitabine 1250 mg/m2 i.v. Day 1 & 8~Paclitaxel 175 mg/m2 i.v. day 1~repeat every 3 weeks"
46005087|NCT00566280|Procedure|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 20 mCi of 99m Tc-sestamibi.
46005088|NCT00561158|Behavioral|Eat Well Live Well Nutrition Program|"12 sessions (6 group and 6 individual)over a period of 3 months with a 3 month follow-up period. The group sessions involve active learning exercises crucial to learning and utilizing nutrition information.~The group sessions included are:~Rate Your Plate: determining high fat foods~Label Reading: reading food labels~Comparison Shopping: using unit pricing labels maximize nutritional value on a limited income~Recipe Modification: preparing old recipes in new ways to reduce fat~Eating Out: order healthier fast foods~Coping with High Risk Situations: coping with situations in which these new habits may be threatened~Six individual sessions will introduce participants to low fat eating patterns or ways to lower fat in their diet, including:~Substituting fat-modified foods for high fat foods~Avoiding fat as a seasoning or flavoring~Avoiding fried foods~Modifying meat~Replacing high fat foods with fruits, vegetables, grains and breads"
46090459|NCT00891371|Drug|lanreotide (Autogel formulation)|Autogel 120mg
46090460|NCT04468880|Other|Group (A1 → A2)|"Before each start of consumption of the products under study, a wash-out period of 2 weeks (no consumption of milk) must be observed by the subjects.~25 subjects will consume A1A2 milk for 2 weeks (period 1), then they will consume A2A2 milk for 2 weeks (period 2).~During each consumption period, various questionnaires will be completed by the subjects: frequency and consistency of stool, analog visual scales on digestive comfort and dietary surveys. Stool collections will also be carried out."
45677984|NCT01618214|Drug|biphasic insulin aspart 30|Dose individually adjusted, administered subcutaneously (s.c., under the skin) twice daily.
46005089|NCT00566319|Behavioral|PREPARE with pedometer|Structured educational programme with pedometer use
46005090|NCT00566319|Behavioral|PREPARE|Structured educational programme
46090461|NCT04468880|Other|Group (A2 → A1)|"Before each start of consumption of the products under study, a wash-out period of 2 weeks (no consumption of milk) must be observed by the subjects.~25 subjects will consume A2A2 milk for 2 weeks (period 1), then they will consume A1A2 milk for 2 weeks (period 2).~During each consumption period, various questionnaires will be completed by the subjects: frequency and consistency of stool, analog visual scales on digestive comfort and dietary surveys. Stool collections will also be carried out."
46090462|NCT04437056|Procedure|Cognitive nerve transfers to spastic upper extremity muscles in stroke patients|Based on the fact that upper motor neuron syndrome after stroke is presented with variable clinical features, usually without affecting in the same way the entire upper extremity, we aim to investigate the efficacy of nerve transfers to spastic muscles after stroke using as donor nerves that innervate unaffected ipsilateral volitionally controlled muscles.
46090463|NCT04324229|Drug|Liraglutide 6 MG/ML [Victoza]|Starting dose of liraglutide 0.6 mg will be administered for one week, after which dose will be escalated to liraglutide 1.2 mg for one week and thereafter liraglutide 1.8 mg s.c. daily injections.
46090464|NCT04324229|Drug|Placebos|Starting dose of placebo 0.1 ml will be administered for one week, after which dose will be escalated to placebo 0.2 ml for one week and thereafter placebo 0.3 ml s.c. daily injections.
46090465|NCT04430894|Drug|Carfilzomib|"Induction: protocol determine dose,via IV on 3 days per cycle up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination~Maintenance: protocol determine dose,via IV on 2 days per cycle- Maintenance Cycle until progressive disease (PD) or unacceptable toxicity"
46090466|NCT04430894|Drug|Isatuximab|"Induction: At predetermined dose, via IV up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination:~-- Cycles 1 and 2 once per week, Cycles 3-4 every other week, Cycles 5 and 6 every other week, Cycles 7 and 8 once every 4 weeks.~Maintenance: At predetermined dose, via IV, once per cycle, Maintenance Cycle until progressive disease (PD) or unacceptable toxicity"
46090467|NCT04430894|Drug|Lenalidomide|- Induction Predetermined Dose, oral, days 1-21 of up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: At predetermined dose, oral days 1-21 per cycle until progressive disease (PD) or unacceptable toxicity
46090468|NCT04430894|Drug|Dexamethasone|Induction: Predetermined dosage, oral, Predetermined times per cycle up to 8 cycles dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: orally or IV will be administered as a preinfusion medication prior to isatuximab dosing
45677985|NCT01917968|Device|Uphold Lightweight Vaginal Support System|Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)
45677986|NCT01917968|Procedure|Traditional native tissue repair|Sarcrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
46005091|NCT04630223|Diagnostic Test|endocan in umbilical cord blood|After taking blood samples from the umbilical cord, centrifugation is applied to all samples for 15 minutes at 1000 rpm. The serum samples with specific identification numbers are going to be stored at -80 °C. After completing the study group, all serum samples will be analyzed using human endocan ELISA kit for the measurement of endocan levels.
46005092|NCT04605471|Drug|Iopromide(Ultravist, BAY86-4877)|The study will be conducted by using pooled data of four company sponsored non-interventional studies with iopromide.
46005093|NCT04629989|Other|Standard Oxygen Delivery System|The standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
45459217|NCT04590274|Drug|Azithromycin|Azithromycin
45459218|NCT01367288|Drug|Zometa + Neoadjuvant therapy|4 mg (in a 15 min. infusion) every 3 weeks for a total of 8 injections
46090469|NCT04200456|Drug|Rozanolixizumab|Study participants receive rozanolixizumab by subcutaneous infusion at pre-specified time points.
46090470|NCT04200456|Other|Placebo|Study participants receive placebo by subcutaneous infusion at pre-specified time points.
46090471|NCT02829281|Drug|Botulinum Toxin Type A|Joint injection of Botulinum Toxin Type A
46090472|NCT02829281|Drug|Triamcinolone hexacetonide|Joint injection of triamcinolone hexacetonide
46090473|NCT02829281|Drug|Saline|Joint injection of Saline
46090474|NCT04210544|Dietary Supplement|Experimental dietary protein|Breakfast intake consisted on a 250 g custard intake mixed with 20 g of the experimental protein accompanied by a glass with 50 mL water.
46090475|NCT04210544|Dietary Supplement|Casein|Breakfast intake consisted on a 250 g custard intake mixed with 20 g of casein accompanied by a glass with 50 mL water.
45459219|NCT01367288|Drug|Neoadjuvant therapy|4 injections of doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²) every 3 weeks (+/- 2 days), followed by 4 injections of docetaxel (100 mg/m²) every 3 weeks (+/- 2 days)
46090476|NCT04210544|Dietary Supplement|Water|Breakfast intake consisted on a 250 g custard intake mixed with 20 g of water accompanied by a glass with 50 mL water.
46090477|NCT04168944|Drug|Lenvatinib|Patients in the lenvatinib group are given lenvatinib within 1-2 months after operation
46090478|NCT04168944|Drug|Placebo|Sugar pill manufactured to mimic Lenvatinib 10mg tablet
46090479|NCT04168944|Drug|Immunosuppressive regimen|Immunosuppressive regimen consisting of calcineurin inhibitor, mycophenolate mofetil, sirolimus or ivermus
46090480|NCT04208438|Diagnostic Test|BVI Device|Non-Invasive measurement of jugular blood volume using Mespere BVI device
46090481|NCT04208438|Diagnostic Test|Point-of-Care Ultrasound|Point-of-Care ultrasound of external and internal jugular veins
46090482|NCT02536326|Device|LEPU Renal Denervation System|LEPU Renal denervation system was similar to Symplicity Catheter System (Medtronic Inc.)
46090483|NCT02697032|Drug|Bicalutamide|150mg
46090484|NCT02697032|Procedure|FDHT PET|PET scan
46090485|NCT04167384|Other|Product A|Usual brand (UB) filtered, combustible cigarette
46090486|NCT04167384|Other|Product B|Nicorette® Mint 4 mg nicotine lozenge
46090487|NCT04167384|Other|Product C|CSD1903-11, a hard nicotine lozenge, 2 mg nicotine
46090488|NCT04167384|Other|Product D|CSD1903-11, a hard nicotine lozenge, 4 mg nicotine
46090489|NCT04167384|Other|Product E|CSD1903-11, a hard nicotine lozenge, 8 mg nicotine
46090490|NCT04167384|Other|Product F|CSD1903-12, a soft nicotine lozenge, 2 mg nicotine
46090491|NCT04167384|Other|Product G|CSD1903-12, a soft nicotine lozenge, 4 mg nicotine
46090492|NCT04167384|Other|Product H|CSD1903-12, a soft nicotine lozenge, 8 mg nicotine
45459220|NCT04480216|Device|MAGUS|"An upper endoscopy will be performed with the use of fluoroscopy. The MAGUS will be placed under fluoroscopy. The good positioning and the absence of any complications will be confirmed by gastroscopy.~An injection of contrast agent will be done to be sure of the correct positioning and that no complications was happened.~The patient will be kept overnight, with liquid food for 2 and mashed food up to 7 days post procedure"
45459221|NCT04455178|Drug|Spironolactone|spironolactone 20mg once daily, up-titrated to 40mg once daily at 4-week or 8-week visit
45459222|NCT04455178|Drug|Indapamide|indapamide 1.5mg once daily, up-titrated to 3mg once daily at 4-week or 8-week visit
46005094|NCT04629989|Other|Double-Trunk Mask|The Double-Trunk Mask above the standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
46005095|NCT04629989|Other|Surgical Mask|The Surgical Mask above the standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
46005096|NCT00566358|Procedure|Duodenal exclusion surgery|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create an excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
46005097|NCT04629755|Behavioral|Intervention|The intervention was delivered via daily text messages to mobile phones during two weeks in the midst of the Covid-19 pandemic. Each message provided a link to a brief suggestion for an action or actions to take each day to improve relational closeness and well-being. Critical to the rationale for this intervention was the position that relationship science has developed key insights into what works and does not work to build and maintain closeness. These insights could be translated into brief and effective suggestions that individuals could implement daily, thereby quickly improving relational well-being and decreasing depression and loneliness at a critical time.
46005098|NCT04605042|Procedure|wet suction|Before pucturing the lesion, the stylet was removed and the needle was pre-flushed with 1-2 mL of saline using a 10-mL syringe, the endoscopist then punctured the lesion and replaced the 10-mL syringe with a 10-mL pre-vacuum syringe
46005099|NCT04605042|Procedure|standard negative pressure suction|after puncturing the lesion, the endoscopist removed the stylet and attached a 10-mL pre-vacuum syringe for aspiration.
46005100|NCT04596696|Biological|Rotavac|Rotavac Is a monovalent vaccine containing suspension of live attenuated rotavirus 116E strain, a naturally occurring reassortant strain G9P[11], containing one bovine rotavirus gene P[11] and 10 human rotavirus genes prepared in Vero cells administered orally at 6, 10 and 14 weeks of age.
46090493|NCT04208204|Other|somatocognitive physiotherapy|Somatocognitive physiotherapy (SCT) is a multimodal physical therapy approach that has been developed in an attempt at alleviating the burden of longstanding pain. The main foci of SCT include: (1) bodily exercises and techniques increasing body awareness, ability to relax and control muscle tension in different situations; (2) education about the vulvodynia and factors influencing pain experience; (3) coping with emotions and thoughts related to bodily experiences; and (4) structured homework assignments promoting application of the learned techniques in daily situation and gradual exposure to activities associated with pain. An important goal of SCT is to facilitate integration of new bodily habits into the patient's daily activities. The most important learning process thus occurs in the space between the treatment sessions. The therapeutic techniques are to be rehearsed in everyday situations.
46090494|NCT00890045|Device|HeRO Vascular Access Device|HeRO Vascular Access Device
46005101|NCT00561197|Drug|AT-101|Patients will receive AT-101 starting at 10 mg once daily for 5 of 7 days in conjunction with RT (50.4 Gy for 28 fractions) for approximately 5.5 weeks. Concurrently, patients will receive docetaxel (20 mg/m2) IV weekly (Monday) and 5-fluorouracil (300 mg/m2) as a 24 hour continuous infusion for 5 of 7 days (Monday-Friday) of each RT week for approximately 5 weeks. Patients will continue for full 5.5 weeks unless unacceptable toxicity occurs.
46005102|NCT04596618|Device|Forearm cooling|forearm cooling will be performed for active cooling assessment.
46005103|NCT04629677|Other|Electronic Health Record Review|Review of medical records
46090495|NCT00890045|Device|Conventional ePTFE hemodialysis graft|Conventional ePTFE hemodialysis graft
46090496|NCT02650362|Other|fMRI|
46090497|NCT04409834|Drug|Unfractionated Heparin IV|Unfractionated heparin IV targeting an aPTT of 1.5-2.5 times the control
46090498|NCT04409834|Drug|Enoxaparin 1 mg/kg|Enoxaparin 1 mg/kg SC Q12h
45459223|NCT01372358|Drug|CIPRO®XR|Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
45459224|NCT01367366|Procedure|PET and EBUS-TBNA|PET and EBUS-TBNA once, respectively
45459225|NCT03634046|Procedure|Percutaneous transforaminal endoscopic discectomy|The same as the descriptions in experimental group.
45459226|NCT03634046|Procedure|Radiofrequency ablation|The same as the descriptions in active comparator group.
46005104|NCT04629677|Other|Quality-of-Life Assessment|Ancillary studies
46005105|NCT04629677|Other|Questionnaire Administration|Complete questionnaires
46005106|NCT04596462|Drug|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of SAPHO by PET/CT.
46005107|NCT04629638|Other|Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scores|The results will be compared with the results of covid-negative pregnant women who gave birth in the same period.
46005108|NCT04605120|Procedure|Cervical fusion|1- or 2-level ACDF (Anterior Cervical Discectomy and Fusion) combined with bone graft
46090499|NCT04409834|Drug|Clopidogrel|Clopidogrel 300 mg PO x1, then clopidogrel 75 mg PO QD
46090500|NCT04409834|Drug|Unfractionated heparin SC|Unfractionated heparin 5,000 IU SC TID
46090501|NCT04409834|Drug|Enoxaparin 40 Mg/0.4 mL Injectable Solution|Enoxaparin 40 mg SC QD
46090502|NCT02647632|Drug|Grazoprevir/Elbasvir|
46090503|NCT02647632|Drug|Sofosbuvir|
46090504|NCT02647632|Drug|Ribavirin|
46090505|NCT02829047|Device|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (14 capsules in 3 weeks)
46090506|NCT00621452|Biological|therapeutic autologous lymphocytes|Given IV
46090507|NCT00621452|Drug|cyclophosphamide|Given IV
46090508|NCT00621452|Biological|aldesleukin|Given subcutaneously
45459227|NCT04373746|Device|NICCI|Non-invasive beat-to-beat blood pressure monitor capable of producing a waveform similar to an invasive arterial line.
46090509|NCT00621452|Genetic|polymerase chain reaction|Correlative studies
45459228|NCT01367522|Drug|SC Methylnaltrexone (MNTX)|
46005109|NCT04629560|Drug|Miracle Fruit|one miracle fruit tablet of 100 mg 10-15 minutes before lunch and dinner versus supportive measures. Patients assigned to receive the miracle fruit will receive written instructions regarding the use of the fruit. Patients should put the fruit tablet or powder in the mouth and gently chew/suck to dissolve and cover the tongue with the powder
45459229|NCT02446834|Behavioral|intensive lifestyle intervention|3 months low GI diet and exercise
45459230|NCT02446834|Drug|GLP-1 Receptor Agonists|Use GLP-1 Receptor Agonists 3 months to treat PCOS
45677987|NCT01917656|Drug|liraglutide|1.8 mg administered subcutaneously (s.c., under the skin) once daily
45459231|NCT02446834|Drug|Metformin|Use metformin 3 months to treat PCOS
46005110|NCT04605003|Device|Novel rig-S|A new device created to hold the high level disinfectant and automatically indicate when sterilisation process has been completed
46005111|NCT04605003|Device|Conventional Autoclave machine|The gold standard device to clean all medical instruments
46005112|NCT04629482|Other|Brain networks activity|The brain network activity under different conditions will be evaluated by magnetoencephalography, including resting, listen to different types of music, watch different types of videos, and interacting with cognitive stimulation conditions.
46005113|NCT04596306|Procedure|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
46005114|NCT04629287|Drug|KPCXM18|KPCXM18,blind,freeze-dried powder,ascending doses，Intravenous route
46005115|NCT04629287|Drug|Placebo|Placebo,blind,freeze-dried powder,ascending doses，Intravenous route
46005116|NCT00564993|Drug|Dobutamin|10&20 µg/kg/min
46005117|NCT04629365|Other|Ketogenic Diet|KD group consumed less than 50g/day of carbohydrates
46005118|NCT04629365|Other|Normal Diet|ND group consumed 55% of the caloric intake from carbohydrates
46005119|NCT04629170|Drug|SYNB8802|SYNB8802 is formulated as a nonsterile solution intended for oral administration
46090510|NCT00621452|Genetic|gene rearrangement analysis|Correlative studies
45459232|NCT02446834|Drug|Acarbose|Use acarbose 3 months to treat PCOS
45459233|NCT02893514|Other|Screening Only (SO) condition|Patient and PCP are not presented with screening results. The PCP does not receive clinical decision support, or clinical reminders.
45459234|NCT02893514|Other|SUSIT Condition|Following completion of substance use screening, the tablet computer presents screening results (including level of risk) to the patient for each substance used, asks them to identify their drug of most concern (DOMC), and assesses readiness and confidence to change behavior. Results are delivered to the PCP at the point of care, paired with clinical decision support tailored to the patient's screening results. This information is delivered on the tablet computer, which is handed to the PCP by a Medical Assistant. CDS guides the PCP through a brief intervention specific to the DOMC, recommends clinical actions pertaining to the substance and risk level, and generates a printed summary for the patient. At each scheduled follow-up medical visit, the PCP receives a clinical reminder containing a summary of the patient's substance use and level of risk, paired with CDS that guides them through a follow-up brief intervention.
45677988|NCT01917656|Drug|metformin|Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged
45677989|NCT01917656|Drug|sulphonylurea|Subjects will continue on their pre-trial SU tablet treatment, doses unchanged
45677990|NCT02018861|Drug|Parsaclisib|
45677991|NCT02018861|Drug|Itacitinib|
45677992|NCT02018861|Drug|Rituximab|
45677993|NCT02018861|Drug|Ifosfamide|
45677994|NCT02018861|Drug|Carboplatin|
45677995|NCT02018861|Drug|Etoposide|
45677996|NCT01944722|Device|BD Onclarity™ HPV assay on BD Viper™ LT|The BD HPV specimen will be tested with the BD Onclarity™ HPV assay on the BD Viper™ LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.
46005120|NCT04629170|Drug|Placebo|In order to maintain study blinding, matching placebo in identical packaging will be manufactured using an inactive powder
46090511|NCT00621452|Procedure|lymph node biopsy|Optional correlative studies
46090512|NCT00621452|Biological|genetically engineered lymphocyte therapy|Receive genetically modified T cells
46090513|NCT00621452|Procedure|bone marrow aspiration|Optional correlative studies
46090514|NCT00621452|Other|flow cytometry|Correlative studies
46005121|NCT04629404|Drug|LY03003|Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
46090515|NCT00621452|Other|laboratory biomarker analysis|Correlative studies
45459235|NCT03489616|Biological|rhGM-CSF|rhGM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils. rhGM-CSF can promote the maturation of dendritic cells and macrophage, increase their antigen presentation ability.
45459236|NCT03489616|Drug|Pemetrexed|Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
45459237|NCT03489616|Radiation|Local Radiotherapy|Radiotherapy promotes the release of tumor antigen
45459238|NCT03489616|Drug|Single agent|Other chemotherapy drugs,such as Docetaxel, gemcitabine
45459239|NCT02323828|Dietary Supplement|High RS cookies|High RS cookies ingestion in healthy young adults
45459240|NCT02323828|Dietary Supplement|Placebo|Placebo cookies ingestion in healthy young adults
45459241|NCT04401826|Procedure|Tunneling micro-surgical crown lengthening approach using piezo-surgery|excess gingiva is eliminated. 2 mm bone is removed from CEJ-bone crest with piezo surgery via tunneling
45677997|NCT01944722|Procedure|Colposcopy|Colposcopy will be performed on subjects that have abnormal cytology or HPV positive test results or random sampling of subject with normal cytology and HPV negative test results.
46005122|NCT04629404|Drug|Placebo|Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
46005123|NCT04595916|Drug|Polyene phosphatidylcholine injection 930 mg QD|Polyene phosphatidylcholine injection 930mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
46005124|NCT04595916|Drug|Magnesium Isoglycyrrhizinate injection 200 mg QD|Magnesium isoglycyrrhizinate injection 200mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
46005125|NCT00565071|Device|Field microscopy and Paracheck Pf®|Malaria diagnosis based on microscopy and or Paracheck Pf®. Artemether/Lumefantrine (20mg/120mg) is first-line drug in all arms
46090516|NCT00621452|Other|enzyme-linked immunosorbent assay|Correlative studies
46090517|NCT02828891|Device|Two-Dimensional Transcranial Doppler|Transcranial Doppler will be used to measure CSF pressure.
46090518|NCT00651534|Drug|Ronacaleret|
46090519|NCT02647476|Dietary Supplement|Immunomodulating nutrition (Reconvan)|protein rich, isocaloric, no-residue diet including arginine, glutamines and omega-3 fatty acids - Reconvan, Fresenius Kabi
46090520|NCT02647476|Dietary Supplement|Standard nutrition (Peptisorb)|oligopeptide, low-fat, isocaloric, non-residue diet
45459242|NCT04401826|Procedure|Micro-surgical crown lengthening approach using Piezosurgery|excess gingiva is eliminated. 2 mm bone is removed from CEJ-bone crest with piezo surgery with conventional flap elevation.
45459243|NCT02323906|Drug|CC-122|Investigational new drug
45459244|NCT02323906|Drug|Sorafenib|Kinase inhibitor
45459245|NCT02323984|Other|miRNA Testing, Microemboli Monitoring, Delirium Assessment|Delirium assessment questionnaire and blood testing for miRNA will be done for all patients postoperatively, as well as BIS monitoring during surgery. The three arms of the study indicate the allocation of each patient based on their delirium presentation (hypoactive, hyperactive, or none).
45459246|NCT02324062|Other|Questionnaires|These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months.
45677998|NCT04415918|Drug|Bezlotoxumab Injection|A single dose of Bezlotoxumab (Zinplava) 10mg/kg (actual body weight) 60-minute intravenous infusion during active CDI treatments.
46090521|NCT05176847|Behavioral|Podcasts and tips of the day (within app)|Participants will receive twice weekly podcasts and daily tips of the day, with nutrition and exercise information, audio diary and goal setting.
46005126|NCT04628819|Dietary Supplement|Babybiane Imedia or placebo|Both the investigational product as well as the placebo will be administered once daily, diluted in a nursing bottle or a glass of water or cold milk, or mixed with a food suitable for the child. It may be diluted in oral rehydration solution and is to be taken preferably before a meal. Both preparations (BABYBIANE® Imedia and placebo) will have similar consistency and taste. A supplementation unit will contain 7 packs of either products, one per supplementation day.
46005127|NCT04604964|Other|Evaluation of anastomotic leakage occurrence|Anastomotic leakage was defined as the communication between the intra and extraluminal compartments due to a defect in the integrity of the intestinal wall originating from the staple line of the neo-rectal reservoir between the colon and rectum
46005128|NCT04604886|Diagnostic Test|Passive Leg Raising|Passive leg raising is induced by rasing the legs of patients to 45° from horizontal position.
46005129|NCT04604886|Diagnostic Test|Dobutamine stress test|Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. hemodynamic data were recorded from PAC and LiDCO after 5-10 minutes of continuous infusion.
46005130|NCT04595877|Drug|Dipyrone administration|Dipyrone 2 g (Nolotil®, Europharma, Madrid, Spain); one ampoule in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
46005131|NCT04595877|Behavioral|Pain assessment|"Pain will be evaluated by the patient according to a 100-mm visual analogue scale (VAS) (from point 0 no pain to point 10 unbearable pain)."
46005132|NCT04595877|Biological|beta-endorphin immunoreactivity|Plasma beta-EPIr levels will be measured by an immunoradiometric assay (Allegro Beta-endorphin, Nichols Institute Diagnostics, SAN JUAN DE CAPISTRANO, CA) (normal values 29-40 pg/mL). It will be obtained by venous blood samples (5 mL) at the same time points at pain will be measured.
46090522|NCT05176847|Behavioral|mLIFE app (self-regulation features)|Diet (track by in app database), physical activity (tracked with FitBit and synced with mLIFE app), and weight (tracked with FitBit scale and synced with mL app) tracking app components. App notifications and reminders and newsfeeds.
46090523|NCT05176847|Behavioral|mLIFE app (social support features)|"The gamified mLIFE app contains several components to help facilitate social gaming and support. This includes a newsfeed, to view the progress of other users, the ability to send others encouragement (likes/thumbs-up) for achieving goals, user-to-user messaging system so active users of the app will be prompted to select send encouraging messages to other group members.~For the experimental group, the app also includes features that facilitate healthy competition among participants through receipt of points for provision of social support and tracking health behaviors."
46090524|NCT05176847|Behavioral|standard mLIFE app (social support features)|"The standard mLIFE app has the ability to send others encouragement (likes/thumbs-up) for achieving goals and a user-to-user messaging system so active users of the app will be prompted to select send encouraging messages to other group members."
46090525|NCT05662436|Other|Open Sky School program|Teachers lead students in 2 hours of outdoor activities per week for 12 weeks, as detailed in the arm description
46090526|NCT03803748|Device|Eyestil Plus®|• To demonstrate the non-inferiority of Eyestil Plus® compared to Vismed Multi® in terms of clinical performance as detected by a reduction of keratitis lesions objectified by staining tests after 1 month of treatment, in patients with moderate to severe dry eye syndrome with keratoconjunctivitis
45677999|NCT01917344|Other|MRI|
45678000|NCT02017535|Drug|Fluoxetine|Prozac (fluoxetine capsules, USP) is a selective serotonin reuptake inhibitor for oral administration.
46090527|NCT04244669|Device|IPG with Conventional Stimulation|In this group, a conventional stimulation with low frequency will be tried. It will be programmed according to the usual clinical practice looking for one or more combinations of poles that allow a coverage of paraesthesia with a conventional stimulation of at least 80% of the painful area. This programming will be modified until getting not only 80% coverage but also a decrease of at least 50% in that area. It can be reprogrammed as many times as necessary during the 14-21 days of margin.
45678001|NCT02017535|Behavioral|Interpersonal Psychotherapy|Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.
45678002|NCT01944098|Drug|Lidocaine|
46005133|NCT04595877|Other|Placebo administration|Placebo in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
46005134|NCT00561275|Biological|LY6K, VEGFR1, VEGFR2|1 mg/body every two week with GM-CSF, 4 cycles
46005135|NCT04595955|Other|CMyLife|CMyLife is a digital patient platform for Patients With Chronic Myeloid Leukemia.
46005136|NCT04628897|Behavioral|Exposures|"Total area of available floor space inside the home (m2)~Frequency that child plays outdoors~Total number of physical hazards in the home (presence of open stairwells, stove height)~Total number of fine-motor activity items available to the child~Presence of gross-motor activity items available to the child across each category (e.g., fixed, portable: ball equipment, push/pull equipment, riding equipment, rocking and twisting equipment)~Hemoglobin concentration (g/L)."
46005137|NCT00561509|Drug|SSRIs|Use within normal clinical practice
46005138|NCT00561509|Drug|Dual antidepressants|Use within clinical practice
46005139|NCT04604574|Other|Indigenous Healing and Seeking Safety|Indigenous Healing and Seeking Safety Intervention: Initial 90-minute meetings will be conducted with the participants; during these meetings, participants will receive information about IHSS, traditional healing, sharing circles, sweat lodge ceremonies, and program details. The sharing circles will take place at Benbowopka Residential treatment Centre in Blind River, Ontario. Each of the sharing circles will be cofacilitated by two Indigenous health-care workers. These facilitators will organize and lead sharing circles daily throughout the 28-day treatment cycle. Each sharing circle will be two hours long. The Seeking Safety program consists of up to 25 treatment topics that aim to teach participants a variety of skills. The majority of topics address the cognitive, behavioral, interpersonal, and case management needs of persons with SUD and posttraumatic stress disorders (PTSD) (Najavits, 2002a). The treatment will adhere to the concept of Two-Eyed Seeing and cultural sensitivity.
45678003|NCT01944098|Drug|Placebo|
46005140|NCT00561548|Procedure|rectosigmoïdal biopsies|rectosigmoïdal biopsies
46005141|NCT04595838|Device|Chemo Mouthpiece|Frozen tube that fills the oral cavity used during and after chemotherapy to ease and prevent symptoms of oral mucositis
46090528|NCT04244669|Device|IPG with SCS DTM|In this group the SCS DTM™ workflow will be programmed. Each SCS DTM™ program group has at least two programs with different pulse rate in the 20 to 1,200 Hz range and each having a maximum pulse width of 1ms
46005142|NCT04595838|Other|Best Supportive Care only|Standard Oral care for Chemotherapy
46090529|NCT02828969|Other|Phone call or physical consultation|
46090530|NCT02655120|Procedure|Drilling|
46090531|NCT02655120|Biological|Bone Marrow +BMP7|
46090532|NCT04336748|Drug|Hydroxychloroquine|low dose (200mg) Hydroxychloroquine once daily for 4 weeks
46090533|NCT04336748|Drug|Placebo|Placebo
45459247|NCT02324062|Other|Blood Draw and Baseline Questionnaire|Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
45459248|NCT03116828|Drug|Eslicarbazepine acetate|eslicarbazepine acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
46090534|NCT04244279|Other|Ergonomic workshop|Participants will participate in a single meeting workshop regarding ergonomic principles in baby care.
46005143|NCT04604730|Procedure|Primary anastomosis without protective stoma|Primary anastomosis without protective stoma
46005144|NCT04604730|Procedure|Anastomosis with protective stoma|Anastomosis with protective stoma
46005145|NCT03454646|Drug|cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)|"The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual. All the recruited patients will be treated by CI according to the recommendations of the French HAS and the clinician's habits to choose the type of CI and adjust the dosage. After a 6-month period under CI treatment, patients will be classified according to the evolution of the Mini Mental State Examination (MMSE) as non-responders or responders.~Responders patients will continue their treatment according to the habits of the clinician. Non-responder patients will be included in the RCT, with individual randomization in two groups: one group who stops the CI, one group who continues the CI. All randomized patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months."
46005146|NCT04604535|Dietary Supplement|Concentrated beetroot juice|70mL concentrated beetroot juice (400mg nitrate)
46005147|NCT04604535|Dietary Supplement|Placebo|70mL concentrated nitrate deplete beetroot juice (<0.01mmol/L nitrate)
46090535|NCT04244279|Other|Brochure|Participant will receive a brochure summarizing the main contents of the workshop.
45678004|NCT02017223|Device|Knowme Device Wear|
46090536|NCT04244279|Other|Videos|During the next three months after the beginning of the research, they will receive videos that will be a reminder of the principles learned in the workshop.
46090537|NCT05662748|Device|Transfemoral aortic valve replacement|aortic valve replacement
46090538|NCT00651612|Drug|Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution|Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening)
45678005|NCT01944020|Device|CPAP|use of CPAP each night for 2 months
45678006|NCT01943552|Drug|placebo|normal saline
45678007|NCT01943552|Drug|ipratropium bromide|ipratropium bromide
46090539|NCT00651612|Drug|Concurrent brimonidine 0.2% and 0.5% timolol|Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening)
46090540|NCT02832011|Dietary Supplement|olive oil|The infants fed with olive oil will have received same amount of calorie with infants who will receive eoprotin-fortified breast milk.
45678008|NCT01915940|Drug|Bimatoprost|Bimatoprost ocular insert
45678009|NCT01915940|Drug|Timolol 0.5%|Timolol 0.5% solution
45678010|NCT01915940|Drug|Placebo Eye Drops|Placebo topical eye drops
46005148|NCT00566436|Procedure|Remote endarterectomy of the superficial femoral artery|Exposure of the common femoral, superficial femoral and profunda femoral artery through a single groin incision. Arteriotomy in the proximal SFA followed by dissection of the intima core beyond the occluded segment using the Vollmar ringstripper. The ringstripper is exchanged for a Mollring cutter all under fluoroscopic guidance. With the Mollring Cutter transection of intima core is carried out, remote from the site of entry. After removal of the intima core the transection zone is secured with an aSpire stent after balloon angioplasty. A completion arteriography will verify a patent artery, and embolectomy can be performed when necessary. As indicated a common femoral artery and profundaplasty can be performed and the arteriotomy may be closed with or without patch.
46090541|NCT02832011|Dietary Supplement|Eoprotin|Low birth weight infants are premature infants that born with birth weight less than 1500 g. Because these infants have low birth weight, weight gain can be increased by fortifying breast milk after post-natal 7 with eoprotin.
46090542|NCT02696876|Device|Arthroscopic synovial brushing|The specific and novel surgical procedure that will be carried out here is synovial membrane brushing using a novel device that has been shown to release MSCs from the synovium in vitro. This technique will be carried out in the setting of therapeutic microfracture for cartilage defects.
46005149|NCT00566436|Procedure|Suprageniculate femoropopliteal bypass|Groin and suprageniculate incision, venous (Saphenous vein) or PTFE graft with end to side anastomoses. If the saphenous vein is truly applicable for grafting will ultimately be an intra-operative decision (despite pre-operative venous mapping)
46090543|NCT02696876|Procedure|Microfracture|Microfracture or marrow-stimulation is a surgical procedure to repair small isolated cartilage defects by recruiting bone marrow mesenchymal stromal cells by creating small holes ('micro fractures') in the sub-chondral bone. These cells are entrapped in the ensuing blood clot and contribute to partial repair of the cartilage.
46090544|NCT00650754|Dietary Supplement|Dehydroepiandrosterone|25 mg PO TID
45459249|NCT03116828|Drug|Eslicarbazepine Acetate|eslicarbazepine acetate acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
46090545|NCT00650754|Other|Placebo|Placebo
46090546|NCT02831933|Biological|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
46090547|NCT02831933|Drug|Valacyclovir|Prodrug of the antiviral drug acyclovir
46090548|NCT02831933|Radiation|SBRT|Low-dose SBRT
46090549|NCT02831933|Drug|nivolumab|Fully human immunoglobulin (Ig) G4 anti-PD-1 monoclonal antibody
46090550|NCT04207970|Other|Adapted Structured Clinical Management|Adapted form of a previous Evidence Based Treatment- adapted to local context, in light of input from service-users and commissioners.
46090551|NCT02650206|Drug|Victoza (liraglutide) with dietician monitoring|Victoza (liraglutide), an FDA-approved medication, is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Subjects with this intervention will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
46090552|NCT02650206|Other|Placebo with dietician monitoring|Subjects will not receive the study drug, but will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
45459250|NCT03487510|Other|NO interventions apply|does not apply
45459251|NCT03487432|Device|Super High-Pressure NC PTCA Balloon (OPN NC)|Strategy of Super High-Pressure NC PTCA Balloon (OPN NC) after unsuccessful lesion preparation with conventional NC balloon angioplasty.
46090553|NCT05368766|Other|VExUS score|The venous excess ultrasound (VExUS) score incorporates hepatic venous, intrarenal venous Doppler, inferior vena cava (IVC) assessment, and portal vein Doppler
46005150|NCT04628702|Behavioral|tablet training|1.5 year training period
46005151|NCT00566475|Other|telemedicine|School telemedicine intervention involving school personnel, the child with type 1 diabetes and at least 1 parent
46005152|NCT04628975|Device|transillumination dispositif|infrared light
45459252|NCT03487432|Device|Scoring PTCA Balloon (NSE Alpha)|Strategy of Scoring PTCA Balloon (NSE Alpha) after unsuccessful lesion preparation with conventional NC balloon angioplasty.
45459253|NCT01319942|Other|Radiotherapy combined with sorafenib|Radiotherapy: 46 Gy to 60 Gy prescribed to involved hepatic tumor Sorafenib: 2 tablet of sorafenib (200mg) twice daily (totally 800mg per day)
45459254|NCT04392232|Drug|Convalescent Plasma|"• Investigational Product~o COVID-19 convalescent plasma will be obtained from an FDA-registered blood establishment (Hoxworth) that follows donor eligibility criteria and donor qualifications as outlined in section III.C.I of the Investigational COVID-19 Convalescent Plasma Guidance for Industry."
45459255|NCT01373138|Drug|Desloratadine and pseudoephedrine|Desloratadine and pseudoephedrine 5/240 mg
45459256|NCT03489538|Procedure|laparoscopic long limb roux-en-Y gastric bypass|standard laparoscopic roux-en-Y gastric bypass (biliopancreatic limb 40 to 60 cm, alimentary limb 150 cm)
45459257|NCT01373216|Drug|Exenatide|Perioperative continuous i.v. administration of exenatide lasting for 72 hours - 40 ng/min for initial 30 min, 20 ng/min for remaining 71.5 hours
45459258|NCT04007146|Diagnostic Test|Transcutaneous oxymetry measurement|Transcutaneous oxymetry measurement with transient hyperoxia period (2 periods of 30seconds at 60% of oxygen)
45459259|NCT05159960|Procedure|SLT|A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
45473937|NCT01175915|Other|Reduning Injection plus western therapy|"General treatment including lifestyle counseling, vitamin supplementation if necessary, non-use of antibiotics, and symptomatic treatment as follows;~Symptomatic treatment by western therapy adopting the same plan in western therapy comparator group;~Symptomatic treatment by Reduning Injection adopting the same plan in Reduning Injection experimental group.~Intervention time: 3-7 days; Follow-up time: 3 days."
46005153|NCT00566514|Dietary Supplement|D-ribose|5 grams administered orally TID
46005154|NCT00566514|Other|dextrose|5 grams orally TID
46005155|NCT01157377|Drug|AGN-214868|AGN-214868 injected into the bladder.
46005156|NCT01157377|Drug|AGN-214868 placebo|AGN-214868 placebo injected into the bladder.
46005157|NCT02885116|Device|Nasal high flow (NHF) supplementation|use of NHF for 20 min/ 35 l/min, at the end of this period right heart catheterization
46090554|NCT05368766|Drug|Diuretic Effect|Response to diuretic therapy
46005158|NCT02885116|Device|oxygen supplementation|hypoxemic patients will use their normal oxygen supplementation durch right heart catheterization
46090555|NCT00891293|Drug|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)|Open-label Antara (fenofibrate) + open-label Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
45678011|NCT01915940|Device|Placebo Ocular Insert|Ocular insert without any active drug
46005159|NCT02885077|Device|High-intensity IMT + combined exercise|
45678012|NCT01914926|Drug|Metoprolol|
45678013|NCT01914926|Drug|Diltiazem|
45678014|NCT02016755|Biological|HGF Plasmid|Intramuscular injection in the affected limb.
46005160|NCT04628312|Other|Static footprint|The static footprint will measure the plantar pressures and surface area of the back of the foot, midfoot and forefoot. Subjects were instructed to stand barefoot on the force platform, participants were instructed to remain in a relaxed standing posture with feet shoulder-width apart and positioned 30 degrees from the midline.
46005161|NCT00566553|Dietary Supplement|Grape Seed Extract|200 mg dose daily for 12 weeks.
46005162|NCT00566553|Dietary Supplement|Grape Seed Extract|400 mg dose daily for 12 weeks.
46005163|NCT00566553|Dietary Supplement|Grape Seed Extract|600 mg dose daily for 12 weeks.
46005164|NCT00566553|Dietary Supplement|Grape Seed Extract|800 mg dose daily for 12 weeks.
46090556|NCT02831777|Device|non-invasive blood pressure monitor|Equivalence of CareTaker blood pressure to classical sphygmomanometry
46090557|NCT05368142|Drug|Nocardia rubra Cell Wall Skeleton|Nocardia rubra cell wall skeleton for external application
46090558|NCT05368142|Drug|Silver ions dressing|Silver ions dressing for external application
46090559|NCT00889421|Drug|Apremilast|oral dose of 30 mg BID for 6 months
46090560|NCT05367986|Device|electro-acupuncture|"Electro-acupuncture was given at the Zusanli (ST36), Guanyuan (CV4), and Qihai (CV6) acupoints, twice a day for 30 minutes, and for 5 days in total.~Acupoints were selected as follows. (1) Zusanli (ST36) belongs to zuyangming stomach meridian. It is located on the anterolateral part of the lower leg 3 inches (4 horizontal fingers) below the eye of the external knee between the fibula and the tibia, and a horizontal finger (middle finger) width from the front edge of the tibia. (2) Guan yuan (CV4) is located 3 inches below the umbilicus, on the midline of the abdomen. (3) Qihai (CV6) is located 1.5 inches below the umbilicus on the midline.~Acupuncture and electro-acupuncture methods were performed as follows. Participants were in the supine position, and needles was inserted in the skin . After the participant has acid, numbness, swelling, pain or other feelings, the electro-acupuncture device was connect to the acupuncture needle, the frequency was set to continuous wave."
46090561|NCT02827643|Drug|TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement|Once daily calcium carbonate 1,250 mg that equal to elemental calcium 600 mg and weekly vitamin D2 20,000international units are given in intervention arms for duration of 24 weeks the subjects in this arm continue previous ART before enrollment to the study
46090562|NCT02827643|Other|TDF/3TC or FTC/EFV|arm continue previous ART before enrollment to study without any intervention with standard for HIV-infected patient.
46005165|NCT01157182|Drug|Estradiol/Norethindrone acetate|1/0.5 mg Tablets
46090563|NCT02650050|Radiation|Micropulsed laser photocoagulation|Micropulsed laser photocoagulation after 3 anti-VEGF injections
45678015|NCT05119166|Dietary Supplement|Vitamin B3|ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.
46005166|NCT01157182|Drug|Activella®|1/0.5 mg Tablets
45836296|NCT00251862|Behavioral|Web-based decision aid alone|Patients review a computer-based decision aid that discuss the pros and cons of the 5 recommended CRC screening options prior to meeting with their provider to discuss CRC screening.
46005167|NCT04628390|Device|Laser|The laser application will be carried out only once, immediately after the cementation of the orthodontic appliance.
46005168|NCT04628390|Other|Placebo|Simulation laser application will be carried out only once, immediately after the cementation of the orthodontic appliance.
46005169|NCT01157065|Drug|AL-78898A|Investigational treatment
46005170|NCT01157065|Drug|Ranibizumab|Anti-vascular endothelial growth factor (VEGF) treatment
46005171|NCT04628468|Device|moveUp|Mobile application for use in the rehabilitation of primary knee and hip arthroplasty
46090564|NCT02831621|Behavioral|lifestyle intervention (diet OR diet+exercise)|diet or diet+fitness training
45459260|NCT03495076|Other|Saline injection|In the saline injection condition, acute neck pain will be induced via 0.5 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute pain. Saline will be injected into the right (or left) trapezius muscle at the level of C7 cervical level. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at the same depth. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster to ensure blinding.
46090565|NCT02646930|Procedure|Endometrial biopsy|Endometrial biopsy in women undergoing first IVF cycle
46090566|NCT04168788|Other|Blood test for genetic analysis|Drawing blood to realize a genetic analysis for susceptibility to hepatic VOD.
46090567|NCT00889265|Device|CopiOs Pericardium Membrane|CopiOs Pericardium, Puros Cancellous
46090568|NCT02646774|Drug|Micafungin|Injection
46090569|NCT04244747|Device|induction of labor by breast stimulation|
45678016|NCT05119166|Biological|Azithromycin|"ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.~VITAL Pakistan Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant."
45678017|NCT05119166|Dietary Supplement|Fortified food supplement|"VITAL Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant.~MISAMEIII Study: 2x2 cross-over efficacy RCT of fortified food supplement (folic acid/iron +/- peanut spread) during pregnancy and/or lactation; unmasked (open label)."
46005172|NCT04628468|Other|Predefined number of traditional physiotherapy sessions|exercises with a physiotherapist being physically present
46005173|NCT00566592|Other|oral ethanol, overnight|Oral ethanol before bedtime to achieve approximate BAL of 0.08%
46090570|NCT04244747|Device|induction of labor by catheter balloon|
46090571|NCT02647086|Drug|Dupilumab|
46005174|NCT00566592|Other|IV ethanol|IV ethanol before bedtime to achieve approximate BAL of 0.08%
45459261|NCT03495076|Other|Sham injection|In the sham-injection condition (nocebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin without piercing the skin. A stimulus of 512 millinewtons (mN) will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided. The stimuli will be applied in exactly the same spot as the real injection in previous experimental condition.
46005175|NCT00566592|Other|soda water|Oral Placebo before bedtime to achieve approximate BAL of 0.00%
46005176|NCT00566592|Other|soda water|Oral Placebo to achieve approximate daytime BAL of 0.00%
46005177|NCT05268406|Device|C-Scan System|Subjects will be provided with contrast agent and dietary fiber pills, and instructed to start intake approximately 48 hours prior to the planned C-Scan procedure start. C-Scan system intervention includes ingestion of the C-Scan Cap and attachment of the C-Scan track to the subject's lower back. The subject is required to keep the C-Scan Track attached to the lower back and to continue intake of contrast agent and dietary fiber pills until the C-Scan Cap's natural excretion. Standard of care optical colonoscopy will be performed within 60 days from the C-Scan Cap ingestion.
46005178|NCT02885038|Other|Platelet concentrate transfusion|
45459262|NCT04770974|Other|Biomarkers and proteomics|Biomolecular, proteomic, metabolomic and spectroscopy characterization of urothelial bladder neoplasia, on a 3D culture model (organoid) obtained from bladder tumor tissue
46005179|NCT04604457|Other|Palliative care contacts primary care|Palliative care specialist reaches out to primary care to recommend a palliative care consult. If the primary care provider agrees, he/she will write an order for a palliative care consult.
46090572|NCT02647086|Drug|Midazolam|Cytochrome P450 substrate
46090573|NCT02647086|Drug|Omeprazole|Cytochrome P450 substrate
46090574|NCT02647086|Drug|Warfarin|Cytochrome P450 substrate
46090575|NCT02647086|Drug|Caffeine|Cytochrome P450 substrate
46090576|NCT02647086|Drug|Metoprolol|Cytochrome P450 substrate
46090577|NCT02827721|Device|impulse oscillometry|
46090578|NCT02827721|Device|multiple breath washout test|
46090579|NCT02827721|Device|body plethysmography|
45459263|NCT02729480|Device|Halo Craniofacial Nerve Stimulator System|The Halo Craniofacial Nerve Stimulator System is a wirelessly powered neurostimulator for pain in the face or head (not for headaches or migraine). This technology includes an implanted stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin to the receiver.
45678018|NCT01942148|Drug|Aripiprazole|
46090580|NCT04244201|Device|Vaporous Hyperoxia Therapy|1 hour of treatment, 4 times per week
45836297|NCT00251862|Behavioral|Generic website|Patients review a generic website that discuss ways to reduce overall cancer risk.
45836298|NCT00303966|Drug|sorafenib tosylate|Given orally
46005180|NCT04628351|Behavioral|Bladder Training|"Patients in the structured bladder training group were trained on lifestyle changes (nutrition, fluid management, exercise), pelvic floor muscle exercises and bladder control techniques."
46005181|NCT01156792|Drug|FP 100|FP 100mcg BID
46005182|NCT01156792|Drug|GSK2190915 100|GSK2190915 100mg QD (AM)
46005183|NCT01156792|Drug|GSK2190915 300|GSK2190915 300mg QD (AM)
46005184|NCT01156792|Drug|montelukast|montelukast 10mg QD (PM)
46005185|NCT01156792|Drug|placebo|placebo BID
46005186|NCT01156792|Drug|FP/SAL 100/50|FP/SAL 100/50mcg BID
46005187|NCT04604145|Diagnostic Test|SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen|Obtain self-collected saliva sample, perform SARS-CoV-2 testing using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system on 30 samples associated with a positive and 30 samples associated with a negative NP sample, then compare saliva results to healthcare worker collected NP sample results evaluated on either the BioFire® FilmArray® Torch® system or the Cepheid® GeneXpert® (gold standard).
46005188|NCT04604223|Drug|Pioglitazone 45 mg|Pioglitazone will be started at 45 mg/day dose for 10 days, after 10 days, the dose will be reduced to 30 mg/day to minimize possible adverse events. The treatment will be continued for 4 weeks (28 days) total
46090581|NCT00651690|Biological|Botulinum Toxin Type A|200 U to 360 U of botulinum toxin Type A on Day 0. Patients who met retreatment criteria received a second treatment (open-label) at Week 12 or Week 18
46090582|NCT00651690|Biological|Placebo|Saline injection on Day 0
46090583|NCT04243655|Device|HA 330-II|One unit for 2-4 hours treatment, for 3 consecutive days
46090584|NCT04243655|Drug|Standard medical treatment (SMT)|SMT as per patients requirement- Management of cerebral edema/intracranial hypertension: prophylactic antibiotics, administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure, volume replacement and pressor support (noradrenaline, doubutamine, dopamine) as needed, NAC and correction of metabolic parameters.
46090585|NCT00651768|Drug|budesonide/formoterol|
46005189|NCT04628624|Dietary Supplement|Placebo control|8 week supplementation period, with participants consuming 2 capsules per day containing potato starch
46005190|NCT04628624|Dietary Supplement|GTE 1|8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract (571mg/d)
46005191|NCT04628624|Dietary Supplement|GTE 2|8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract with additional antioxidants (150mg of quercitin and 150mg of alpha lipoic acid)
46005192|NCT01156714|Behavioral|Treadmill training with aerobic exercise|walk on treadmill for aerobic exercise
46090586|NCT00651768|Drug|Symbicort pMDI + budesonide HFA pMDI|Symbicort 2 X 160/4.5mcg & budesonide HFA pMDI 4 X 160mcg
46090587|NCT02826005|Device|MRI|
46090588|NCT02646852|Drug|PLX038|
46090589|NCT02826239|Device|multiple breath washout test (MBW)|measured in upright and supine position
46090590|NCT02647008|Device|TENS|Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia.These small battery powered devices deliver alternating current via cutaneous electrodes positioned near the painful area.
46090591|NCT05660525|Drug|4 weeks of Nicotine lozenge|All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
46090592|NCT05660525|Drug|8 weeks of Nicotine Replacement Therapy Patch|All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
46090593|NCT05660525|Behavioral|QuitAid|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
46090594|NCT05660525|Behavioral|Smokefree TXT|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.
46090595|NCT05660525|Behavioral|Tobacco Quitline|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.
46090596|NCT05660525|Drug|4 weeks of Nicotine Replacement Therapy Patch|All participants will receive at least 4 weeks of the NRT Patch.
46090597|NCT05660525|Drug|8 Weeks Nicotine Lozenge|All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 8 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
46005193|NCT01156714|Behavioral|Memory training with computerized memory program|memory testing and training on computer program
46005194|NCT01156714|Behavioral|Combination of treadmill training and computerized memory|both exercise and cognitive computer training
45836299|NCT00304512|Drug|migalastat HCl|
46005195|NCT00561314|Other|questionnaire administration|
46005196|NCT00561314|Procedure|biopsy|
46005197|NCT00561314|Procedure|high-intensity focused ultrasound ablation|
46005198|NCT00561314|Procedure|magnetic resonance imaging|
46005199|NCT00561314|Procedure|quality-of-life assessment|
46005200|NCT04595643|Other|Combination of different dysphagia training modalities|Neuromuscular electrical stimulation, Masako exercises, Mendelsohn maneuver, chin down, mobilization, shaker exercises, eating different food consistencies.
46005201|NCT04628273|Procedure|encoscopic retrograde cholangio-pancreatography, extracorporeal shock wave lithotripsy|
46005202|NCT04604028|Drug|Lenalidomide [Leavdo®]|Complete remission and partial remission rate
46005203|NCT04595604|Procedure|Trimodal rehabilitation + ERAS|Prehabilitation will cover a range preoperative education and exercises (weekly) on diet, physical activity (daily walking), respiratory training (forced deep inspiration with spirometer device), as well as anxiolytic group psychotherapy.
46005204|NCT04595604|Procedure|ERAS + nutritional prehabilitation|Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.
46090598|NCT00651846|Drug|Yasmin (DRSP 3mg/EE 0.03 mg)|The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (3mg DRSP/0.03 mgEE). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
46090599|NCT00651846|Drug|Microgynon (LNG 0.15 mg/EE 0.03 mg)|The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (LNG 0.15 mg/EE 0.03 mg). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
46005205|NCT00565149|Behavioral|PROOF|dietary overfeeding with high, low or normal protein content
46005206|NCT01156675|Device|FLEXUS(TM) Interspinous Spacer|Treatment of lumbar spinal stenosis with the FLEXUS™ Interspinous Spacer
46005207|NCT01156675|Device|XSTOP® Interspinous Spacer|Treatment of lumbar spinal stenosis with the XSTOP® Spacer
46090600|NCT00603746|Drug|GW685698X|GW685698X
46090601|NCT02646696|Other|Sensory Challenge Protocol|Measurement of electrodermal activity in response to sensation
46005208|NCT01156480|Drug|hydrocortisone|Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via IV route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
46090602|NCT04167306|Drug|Varenicline Tartrate 1 mg b.i.d|Capsules for oral use
46090603|NCT04167306|Drug|Bupropion Hydrochloride 150 mg b.i.d|Capsules for oral use
46090604|NCT04167306|Other|Placebo for varenicline|Capsules for oral use
46090605|NCT04167306|Other|Placebo for bupropion|Capsules for oral use
46090606|NCT04244591|Drug|methylprednisolone therapy|Methylprednisolone 40 mg q12h for 5 days
46090607|NCT04244591|Other|Standard care|Standard care
45678019|NCT02030015|Drug|miglustat|The Syner-G therapy regimen includes treating with orally-administered miglustat for the duration of the 60-month study.
46090608|NCT02827799|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This behavioral intervention includes training on managing the sleep environment (stimulus control), managing dysfunctional beliefs and attitudes about sleep (cognitive therapy), relaxation (progressive muscle relaxation), changing sleep behaviors (sleep hygiene), and managing sleep duration and continuity (sleep restriction).
46090609|NCT02827799|Behavioral|Heart Failure Self-Management Education|This intervention includes learning about how to manage one's heart failure. This includes understanding when to seek treatment, monitoring oneself for daily signs and symptoms, daily weight, dietary changes, physical activity, and adherence to medication taking.
46090610|NCT02649582|Biological|Dendritic cell vaccine plus temozolomide chemotherapy|"When eligible after total or subtotal resection (as assessed by neurosurgeon and post-operative brain MRI):~Leukocyte apheresis (before chemoradiation): for DC vaccine production~Chemoradiation (standard treatment: initiated as soon as the patient's hematological blood values are adequate after apheresis): 2 Gy once daily 5 days/week for 6 weeks with 75 mg/m² temozolomide daily from the first until the last day of radiotherapy (no longer than 49 days in total)~Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly (+/-1 day) for 3 weeks, starting ≥ 1 week after radiotherapy~Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days +/- 2 days (max. 12 months) starting ≥3 days after the third vaccine of the induction immunotherapy + DC vaccination on day 21±3 days of every 28-day cycle"
46090611|NCT02827565|Other|KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA|10 ml blood sample
46090612|NCT04167696|Biological|CYAD-02|CYAD-02 is a Chimeric Antigen Receptor-T (CAR-T) administered after CYFLU.
46090613|NCT04167696|Drug|ENDOXAN|administered as preconditioning chemotherapy
46090614|NCT04167696|Drug|Fludara|administered as preconditioning chemotherapy
46090615|NCT02827487|Drug|Tramadol|Women will receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally 2 hours before IUD insertion.
46090616|NCT02827487|Drug|Celecoxib|Women will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) orally 2 hours before IUD insertion.
46090617|NCT02827487|Drug|Placebo 1|Women will receive a placebo similar to Tramadol orally 2 hours before IUD insertion.
46090618|NCT02827487|Drug|Placebo 2|Women will receive a placebo similar to Celecoxib orally 2 hours before IUD insertion.
46090619|NCT02827487|Procedure|IUD|IUD insertion
46090620|NCT02689388|Procedure|Femoral Nerve Block|Use of femoral nerve block as part of general anesthesia
46090621|NCT05088629|Diagnostic Test|Clinical Tests|Clinical Tests
46090622|NCT04098666|Drug|Placebo oral tablet|Placebo tablet identical to metformin, up to 4 tablets a day
46090623|NCT04098666|Drug|extended release metformin|Metformin extended release 500 mg tablets, up to 4 tablets a day
46005209|NCT01156480|Drug|placebo|Subjects in placebo group will receive a volume of placebo equal to the hydrocortisone group, on the same dosing schedule, with doses given every 8 hours via IV route for 3 days, followed by placebo every 8 hours IV for 1 day, followed by placebo every 8 hours IV for 1 day, followed by placebo every 12 hours for 1 day, followed by placebo in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
46090624|NCT00622232|Genetic|VRX496-transduced autologous CD4 T cells|The cell dose will consist of approximately 10 billion VRX496-transduced autologous CD4 T cells provided as a single bolus infusion.
46090625|NCT04273373|Biological|Low Dose Albumin|20% albumin 0.75 g/kg at diagnosis and 0.5 g/kg after 48 hours
46090626|NCT04273373|Biological|Standard dose Albumin|20% albumin1.5 g/kg at diagnosis and 1 g/kg after 48 hours (duration of infusion 6 hours).
46005210|NCT04595526|Procedure|Forced expiratory technique and induced sputum|The intervention is based on the patient's own attempt to deliver a sputum sample after instructions of proper huff forced exhalation and coughing technique. After an attempt to deliver a sputum sample the patient will receive a 0,9% isotonic saline by an inhalation mask to induce the sputum, thereafter the patient will again make an effort to expectorate a sputum sample repeating the forced expiratory technique.
46005211|NCT04595526|Procedure|Tracheal suction|Tracheal suction is often used on intubated patients at the intensive care unit to collect sputum, and this method has become the standard procedure at several emergency departments.
46090627|NCT03709862|Diagnostic Test|Whole Genome Sequencing|Residual DNA from clinical samples will be utilised for whole genome sequencing of Treponema pallidum the causative agent of syphilis
46090628|NCT04244825|Drug|BLD-2660|BLD-2660 - 150 mg capsules '00' size (PO) BID
46090629|NCT04244825|Drug|Control: Placebo|Placebo - 150 mg capsules '00' size (PO) BID
46090630|NCT02649504|Drug|Rituximab|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study
46090631|NCT02649504|Drug|Dexamethasone|Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study.
46090632|NCT02649504|Drug|Mycophenolate mofetil|Patients allocated to the active drug arm will be given Mycophenolate mofetil starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
46090633|NCT02649504|Drug|Placebo|Patients allocated to the placebo arm will be given placebo starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
46090634|NCT04260542|Behavioral|Fasting/refeeding|2-days fasting followed by 2-days of refeeding. During the fasting period the subjects will be hospitalized to control their state of health and ensure fasting compliance. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
46090635|NCT04260542|Behavioral|Fasting/refeeding|2-days fasting followed by 2-days of refeeding. During the fasting period the subjects will be hospitalized to control their state of health and ensure fasting compliance. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
46090636|NCT04260542|Behavioral|Ketogenic diet/ fasting|1 month of fasting-mimicking ketogenic diet and subsequent 2-days of refeeding. The subjects will be instructed by nutritional specialist to follow isocaloric ketogenic diet consisting of 6% carbohydrates, 17 % of proteins and 77% fat to cover individual energy demand. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
46090637|NCT04196699|Behavioral|self-management program|"Our intervention will be based on the following framework and will consist of 3 phases :~Phase I: At the end of a medical consultation, the doctor will offer the patient the opportunity to benefit from a nursing consultation and remote monitoring to better manage his COPD. A nursing consultation will be scheduled during which the nurse will explain the procedure, obtain the written consent of the patient, and develop an educational diagnosis with the participation of the patient.~Phase II: During the next six weeks education sessions will be provide to the participants and a telephone number will be available in case of emergency and for any additional information.~Phase III: A final consultation will be scheduled at the nurse office to evaluate the patient's achievements and modify his/her educational assessment. A telephone follow-up will be conducted after one month to assess the maintenance of learning."
46005212|NCT02884960|Procedure|Uterine Fibroid Embolization|This procedure involves the administration of the study device into the uterine arteries to block the flow of blood in these vessels. This deprives fibroid tumors within the uterus of their blood flow, which can cause the tumors to die. This in turn can lead to the relief of symptoms associated with fibroids.
46090638|NCT03703856|Drug|Memantine|"Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 88 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of early auditory information processing memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated."
46090639|NCT03703856|Drug|Placebo|"Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 88 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of Early auditory information processing P memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated."
46090640|NCT00650910|Drug|lapatinib|1500 mg oral lapatinib starting Day 2 continuing through Day 9. Part 2 subjects received 1500mg daily through week 10.
46090641|NCT00650910|Drug|Digoxin|0.5mg on Days 1 and 9
46090642|NCT02827253|Device|MRI|MRI will be performed during interdialysis period in the haemodialysis group. MRI will be performed at the beginning of the study in predialysis group.
46090643|NCT00622310|Behavioral|Walking exercise|Subjects will be randomly assigned to either a structured, vigorous-intensity endurance exercise training program or an intermittent, low-intensity exercise program. Individualized exercise prescriptions will be designed to target an increase of 2500 kcal/wk, and the theoretical weight loss will be approximately 15 pounds (~6.8 kg) during the 6 month intervention.
45678020|NCT02030015|Other|Ketogenic Diet|The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet for the 60-month duration of this study.
45836300|NCT00304746|Drug|Testosterone gel|AndroGel 2.5g and 5g sachets at doses ranging from 10g/day for duration of trial.
45459264|NCT02324140|Other|Whole blood analysis|In all fours groups of patients we investigate inflammatory and antiinflammatory response to the surgical and interventional treatment by analyzing changes in the concentration of interleukins, C-reactive protein, soluble CD62L and HLA-DR.
45459265|NCT03633968|Procedure|maxillary sinus lift|maxillary sinus floor elevation by using balloon through either small or large antrostomy without using graft material with simultaneous implant placement
45836301|NCT00304746|Drug|Placebo|Placebo
45836302|NCT05267730|Behavioral|Conectar Jugando Game Program|Modern Board and Card Games as Cognitive Training in Rural Elementary Classrooms
46005213|NCT04627961|Drug|TAS-102|Eligible patients who consent to participate will receive oral TAS-102 bid for days 1-5 and 8-12 of a 28 day cycle.
46005214|NCT04595253|Other|acupressure|"The acupressure involves the  Vaccaria Semen within skin-colored adhesive tape that placed on the Neiguan and Shenmen acupoints as an intervention measure. Continue to massage the acupoints with fingertips for 10 minutes, 3 times per day (8 and 12 in the morning, and 4 in the afternoon) . The adhesive tape will be retained in situ for 2 days."
46005215|NCT00561587|Drug|Seroquel®|dosage form: oral, adjusted in the range of 25 to max. 300 mg /day
46005216|NCT04595487|Procedure|Left ventricular septal pacing|"In the LVSP group, instead of placing the standard RV lead, the commercially available 3830 Select Secure (Medtronic, Minneapolis, USA) lead is introduced via standard transvenous approach and positioned against the right ventricular side of the IVS by using the commercially available non-deflectable septal delivery sheath (C315, Medtronic, Minneapolis, USA) under fluoroscopic guidance. Subsequently this pacing lead is advanced/screwed through the interventricular septum until the left ventricular septum is reached. Accurate lead position at the left ventricular septum will be determined anatomically using fluoroscopy, and electrically by evaluating local electrograms and changes in paced electrocardiogram morphology.~In case of unsuccessful lead positioning in the left ventricular septum, the Select Secure lead may be placed at the His bundle region (natural conduction system of the heart) or in the right ventricle according to the physician's discretion."
46005217|NCT04595487|Procedure|Right ventricular pacing|In the RVP group, the ventricular pacing lead is positioned in the right ventricle.
45678021|NCT02029235|Drug|Acetaminophen/Ibuprofen|Postoperatively, subjects will be given acetaminophen 500 mg / ibuprofen 400mg every 4 hours, as needed, for one week or until essentially pain-free
45678022|NCT02029235|Drug|Acetaminophen/Hydrocodone|Postoperatively, subjects will be given acetaminophen 325 mg / hydrocodone 5 mg every 4 hours, as needed, for one week or until essentially pain-free
45678023|NCT01617434|Drug|liraglutide|Maximum 1.8 mg administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
46090644|NCT02654574|Other|IADL administration by phone|The administration of IADL questionnaire by phone consists of a collection of answers given by the caregiver during the interview with the research nurse, trained for this procedure. This method of procurement will be standardized with a listing support for the phone interview to obtain the same conditions for collection of data from a caregiver to another. Questions will be asked in the same order than the questionnaire collected with the reference procedure i.e. face-to-face interview at the Memory Clinic. The IADL questionnaires in paper format used during the ace-to-face interview and by phone will be identical.
46005218|NCT01156363|Procedure|Dialysis|regular haemodialysis or peritoneal dialysis
46005219|NCT01156363|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|once monthly, subcutaneously or intravenously, for 32 weeks
46005220|NCT00561626|Dietary Supplement|high fat diet followed by low fat diet|High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
46005221|NCT00561626|Dietary Supplement|low fat diet followed by high fat diet|Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
46005222|NCT02884921|Drug|Paracetamol|Paracetamol
46005223|NCT02884921|Drug|Paracetamol|Paracetamol
46005224|NCT02884921|Drug|Placebo|Placebo
46005225|NCT02884882|Other|Emotional induction|Score (from 1 to 10) rated the felt for each target emotions for the following 6 dimensions: joy, sadness, fear, disgust, anger, no emotion, after the presentation of short sequences of standardized films.
45459266|NCT03487354|Drug|Misoprostol|Misoprostol
45459267|NCT04752800|Device|Direct Current Transcranial Stimulation - tDCS|Intervenção Ativa
45459268|NCT04752800|Device|Sham Intervention|Direct Current Transcranial Stimulation - Sham Intervention
45459269|NCT04461340|Drug|Sirolimus|oral dose of 6 mg on day1 followed by 2 mg daily for 9 days
45459270|NCT05154968|Drug|Sodium chloride|Administered SC infusion.
45459271|NCT05154968|Drug|Citrate buffer|Administered SC infusion.
45459272|NCT05154968|Drug|Mannitol|Administered SC infusion.
45459273|NCT05154968|Device|Prefilled Autoinjector|Used to administer the drug through SC infusion.
46005226|NCT04595214|Other|TTTS cases are treated by intra-uterine laser for separation.|MC twin anaestemosis separatio by laser. Vasa previa and placenta accreta are treated with steroids or other protocols, Positive trisomies by NIPS undergoes CVS or amniocentesis
45459274|NCT01903408|Radiation|Intensity-modulated radiotherapy of the pelvic lymph nodes using SIB|The intervention is the use of modern radiation techniques with simultaneous integrated boost (SIB)
45459275|NCT01373372|Drug|Acthrel|Powder for reconstitution, 1.0 mcg/kg body weight to a maximum of 100 mcg, delivered one time via IV over one minute.
45459276|NCT02324218|Other|Data collection|Data extraction from CPRD database of UK.
46005227|NCT00561704|Drug|losartan|losartan, 100mg daily,
46005228|NCT01156051|Drug|Guanfacine extended-release tablets|Guanfacine extended-release tablets will be started at 1mg and then increased at weekly intervals to 2mg, 3mg, or 4mg as needed and as tolerated
46005229|NCT01156051|Drug|Placebo comparator|Placebo tablets identical to the experimental arm guanfacine extended-release tablets 1mg, 2mg, 3mg, 4mg, but without the active ingredient (guanfacine).
46005230|NCT04595409|Drug|FYB202 (Proposed ustekinumab biosimilar)|Patients will receive 1 subcutaneous (SC) injection of FYB202 at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
46005231|NCT04595409|Drug|Stelara® (Ustekinumab)|Patients will receive 1 subcutaneous (SC) injection of Stelara® at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
46005232|NCT04628000|Other|Vitamin D|Clinical Correlation
46005233|NCT01156012|Drug|T2345|One drop of T2345
46005234|NCT01156012|Drug|Prostaglandin|One drop
46005235|NCT04627844|Dietary Supplement|Immediate Feeding|Standard tube feeds begun at an earlier time point
46005236|NCT04627844|Dietary Supplement|Delayed Feeding|Standard tube feeds begun at delayed time point
46090645|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days
45678024|NCT01617434|Drug|placebo|Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
46005237|NCT04595136|Drug|Drug COVID19-0001-USR|COVID19-0001-USR by nebulization for patients with mild and/or moderate SARS- COV-2
46005238|NCT04595136|Drug|normal saline|0.9% NS via nebulization
46090646|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
46090647|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
46090648|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD normal|G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
46090649|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD normal|G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
46090650|NCT02687672|Biological|Stem Cell Transplantation|Transplantation of autologous stem cells
46090651|NCT00888329|Drug|Aprepitant|40 mg administered orally with a sip of water prior to anesthesia induction.
46090652|NCT00888329|Drug|Placebo|Placebo
46090653|NCT04187222|Other|Mechanical debridements|Prior to the beginning of the intervention, all patients received oral hygiene instruction. Mechanical debridements were performed with titanium curette and polishing using a rubber bowl and polishing paste.
46090654|NCT04187222|Biological|Bifidobacterium animalis subsp. lactis|Capsules containing Bifidobacterium animalis subsp. lactis were chubby and subsequently ingested twice a day for 12 weeks.
46090655|NCT04169022|Other|Sample collection|Sample collection blood and/or bone marrow
46090656|NCT02654496|Other|Meal challenge|Participants will receive a liquid nutritional supplement. Before and after administration, biological variables of interest will be collected.
46005239|NCT04628117|Dietary Supplement|Oral nutritional supplementation for kidney disease|237 mls per day for 8 weeks.
46090657|NCT00603590|Drug|Polypill|Fixed dose combination therapy - aspirin 81mg, hydrochlorothiazide 12.5mg, enalapril 2.5mg and atorvastatin 20mg Once daily
46090658|NCT00603590|Drug|Placebo drug|Inactive tablet Once a day Identical in appearance to intervention drug
45459277|NCT03877978|Biological|Nephrocheck test|Nephrocheck® measurement on urine sample at different timepoints.
45459278|NCT03494998|Diagnostic Test|PAT-POPS|Emergency Department-specific screening tool
45678025|NCT01940900|Drug|E10030|
45678026|NCT01940900|Drug|ranibizumab|
46005240|NCT01155661|Drug|LY2216684 (edivoxetine)|12 to 18 milligrams (mg), administered orally, once daily for 54 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
45678027|NCT01940900|Drug|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
45678028|NCT01940354|Device|AccuCath IV Catheter System|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
45678029|NCT01940354|Device|Conventional IV Catheter System|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples
45678030|NCT01940120|Device|Percutaneous mitral valve repair using MitraClip implant|Procedure/Surgery: Mitral valve repair or replacement surgery Repair or replacement of mitral valve
46005241|NCT01155661|Drug|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
46005242|NCT04627883|Other|Inspiratory-to-expiratory (I : E) ratio of 1:2|After preoxygenation and induction of anesthesia, noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 1:2 for 5 min before endotracheal intubation.
46005243|NCT04627883|Other|Inspiratory-to-expiratory (I : E) ratio of 2:1|After preoxygenation and induction of anesthesian, noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 2:1 for 5 min before endotracheal intubation.
46005244|NCT00565188|Drug|Adenosine 5'-triphosphate|Weekly ATP infusions (in total 8 infusions) during 8 - 12 hours in a maximum dose of 50 mcg/kg.min
46005245|NCT04628078|Other|Use of echocardiography guidance for LAAC|Since August 2015, the echocardiography is routinely used by majority of operators to guide LAAC
46005246|NCT04603833|Drug|SHR3680+Docetaxel|Participants will receive SHR3680 combined with Docetaxel
46005247|NCT04603833|Drug|SHR3680|Participants will receive SHR3680
46005248|NCT04603833|Drug|Docetaxel|Participants will receive Docetaxel
46090659|NCT00650988|Procedure|Cryospray Ablation|Liquid nitrogen spray with a cryospray catheter through an upper endoscope that enables the direct visualization of mucosal freeze (cryoburn) of the mucosa treated which avoids the need for direct tissue contact. Frozen state is defined as mucosa appearing white. Cryofreeze is preformed in cycles of 10 second sprays with a minimal thaw of 60 seconds each spray. This cycle is repeated 4 times in each area of treatment.
46090660|NCT02649348|Behavioral|pre-operative prehabilitation|To climb six flights of stairs (approximately 20 meters in height) at least 6 times as a daily routine and adaptive simulated training of restrictive ventilation dysfunction (increased thoracic and decreased abdominal breathing compliance) following abdominal surgery by using a full elastic breathable abdominal bandage.
46005249|NCT04603716|Other|Eccentric Muscle Energy Technique|"Conventional Treatment given to both groups (Hot pack for 15 minutes, Mobilization, AROM Exercises 10 sets x 3days in a week)~Reciprocal inhibition of target muscle (i.e. levator scapulae ,pectoralis major, upper trapezius) causing relaxation, patient force is minimal towards maximal therapist force, 5-7 repetition for 2-4seconds 3 days in a week up to 6 weeks.~Muscle is taken from shortened to lengthened position."
46005250|NCT04603716|Other|Concentric muscle energy technique|"Group B: Concentric Muscle Energy Technique: (Autogenic inhibition of target muscle (i.e. levator scapulae ,pectoralis major, upper trapezius) patient force is greater than therapist force, 5-7repitition for 3-4seconds)Muscle is taken from lengthened to shortened position.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 1st 3rd and 6th week"
46005251|NCT04627532|Drug|PF-07304814|Participants will receive PF-07304814
46005252|NCT04627532|Drug|Placebo|Participants will recieve placebo
46005253|NCT04627766|Device|Monitoring with VTPatch (Connected device manufactured by VitalTracer)|Patients will be monitored for 24 consecutive hours and vital signs will be recorded with VTPatch and with standard of care
46005254|NCT01580748|Drug|Roflumilast|500 microgram once daily for 16 weeks
46090661|NCT04187534|Other|Albumin Fluid Resuscitation Optimization Intervention|Multi-faceted quality improvement intervention to optimize appropriateness of albumin use for fluid resuscitation
46005255|NCT04603872|Drug|CD19/BCMA Targeted CAR T-cells and dasatinib|Each subject receive CS1 Targeted CAR T-cells by intravenous infusion, and the dasatinib was combined according to the presumed regimens.
46005256|NCT04603872|Drug|CD19/BCMA Targeted CAR T-cells|Each subject receive CS1 Targeted CAR T-cells by intravenous infusion.
46005257|NCT04627688|Behavioral|Time restricted feeding|Participants will be advised to eat only during a selected window of 8 hours, and no later than 4pm, with no advice on nutrition quality, quantity or caloric intake. The intervention will include no medication, no medical device, and will last for 2 weeks prior to surgery.
46090662|NCT04187534|Other|Usual Practice|Albumin fluid resuscitation according to usual practice
45678031|NCT01911260|Dietary Supplement|Zinc amino acid chelate|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
45836303|NCT05267418|Device|Automated nasal O2 titration with FreeO2|The participant received, in a randomized, cross-over study design: 1) automated nasal oxygen titration administered by a closed loop system (FreeO2) alone, 2) or with high flow nasal therapy (Airvo2) set at 60 liters per minute with nasal canula, or 3) oxygen by nasal canula at a fixed flow of 2 liters per minute during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT)
46090663|NCT00652002|Drug|budesonide/formoterol|
46005258|NCT04627688|Behavioral|Standard dietary advices|Participants will be given standard dietary advices, as recommended by the international nutrition guidelines, and thus are not different from common clinical practice.
46005259|NCT04603794|Drug|0.5% Povidone Iodine|Commercially Available Mouth Rinses and Over the Counter Standard Formulations
46005260|NCT04603794|Drug|0.12% Chlorhexidine Gluconate Mouth Rinse|Commercially Available Mouth Rinses
46005261|NCT04603794|Drug|1% Hydrogen Peroxide|Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
46090664|NCT00652002|Drug|budesonide|
46090665|NCT00652002|Drug|formoterol|
46090666|NCT02689700|Other|Blood samples|Taking blood form the umbilical cord (fetal circulation) and from the vein of the corresponding mother.
45678032|NCT01911260|Other|Placebo|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
45836304|NCT00134004|Drug|cyclophosphamide|
45836305|NCT00134004|Drug|fludarabine phosphate|
46090667|NCT02646540|Drug|Tolvaptan 30 mg + IV Diuretics|Participants will receive oral daily tolvaptan 30 mg concomitantly with their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
45678033|NCT02015819|Biological|E. coli CD-expressing genetically modified neural stem cells|Given intracranially
45678034|NCT02015819|Drug|flucytosine|Given orally
45678035|NCT02015819|Drug|leucovorin calcium|Given orally
45678036|NCT02015819|Other|pharmacological study|Correlative studies
45678037|NCT02015819|Other|laboratory biomarker analysis|Correlative studies
45678038|NCT01939496|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
45836306|NCT00134004|Drug|mycophenolate mofetil|
45836307|NCT00134004|Drug|tacrolimus|
45836308|NCT00134004|Procedure|allogeneic bone marrow transplantation|
45836309|NCT00134004|Radiation|radiation therapy|
45836310|NCT00135798|Drug|LADR Treatment|"PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen; Rebetol (ribavirin (RBV) United States Pharmacopeia (USP)) Capsules:~Treatment was initiated with PEGIFN 0.75 µg/kg/week and RBV 600 mg/day. Dose escalations were performed at weeks 1 (PEGIFN 1.5 µg/kg/week and RBV 800 mg/day), 2 (RBV 1.0 g/day), and 3 (RBV 1.2 g/day for patients who weighed more then 75 kg) based upon patient tolerance and weekly blood counts. Once a patient reached the target RBV dose of 1-1.2 g/day (approximately 10.6 to 13.2 mg/kg/day), no further increases in RBV dose were made. Subsequent doses of PEGIFN and RBV were adjusted based upon adverse events, patient tolerability, and blood counts. If the highest tolerated dose of PEGIFN was <0.5 ug/kg, PEGIFN was permanently discontinued."
45836311|NCT00136812|Behavioral|stage-tailored intervention|This intervention consists of nicotine patch therapy during hospitalization; a stage-based self-help manual; an individualized, expert-system, feedback report at intake, 3 months and 6 months post-hospitalization with carbon copies sent to participants' outpatient clinicians; and an individual 30-min smoking cessation counseling sessions during hospitalization. Additionally, up to 10 weeks of nicotine patch is provided to intervention participants intending to stay quit following hospital discharge.
46005262|NCT04603794|Drug|0.9% Normal Saline|Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
46005263|NCT04627727|Other|low FODMAP diet|low FODMAP diet
46005264|NCT04603755|Device|Electrical Impedance tomography|Electrical Impedance tomography recording during 5 minutes every day during 7 days
46005265|NCT04627337|Drug|Saccharomyces Boulardii 250 MG|Probiotic yeast in capsules
46090668|NCT02646540|Drug|Metolazone 5 mg + IV Diuretics|Participants will receive oral daily metolazone 5 mg concomitantly with their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
46090669|NCT02646540|Drug|2.5 times the Diuretics Dose|Participants will receive two and a half (2.5) times their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
46090670|NCT04061148|Device|NIRSIT|NIRSIT is a device that utilizes Near Infrared Spectroscopy to provide a non-invasive measurement of frontal lobe blood oxygenation over time.
46090671|NCT04186052|Biological|BCMA-CART cells|Target BCMA chimeric antigen receptor T cell infusion
46090672|NCT02654418|Procedure|Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size)|
46090673|NCT00639080|Other|Stop lipid lowering therapy (statin)|Subjects will only be included in the study and thus asked to stop the statin if they are taking less than or equal to 10 mg of lipitor or an equivalent of another statin.
46090674|NCT00651066|Drug|rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1|3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg TPW 3 wks switch to 150 mg OD 4 wks);
46090675|NCT00651066|Drug|rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2|3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg OD 3 wks switch to 150 mg TPW 4 wks);
45678039|NCT01939496|Drug|Placebo|One matching placebo capsule orally in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
46005266|NCT04627337|Behavioral|Dietary advice following a low fermentation diet|Medical advice was delivered to patients to follow a low fermentation diet. A list of food and beverages to avoid was delivered along with specified instructions provided by a health professional
46005267|NCT04603638|Drug|Magnesium|40 mg/kg(peroperative), 40 mg/kg (postoperative 12 h)
46005268|NCT04603638|Drug|Isotonic|100 ml
46005269|NCT04627454|Procedure|Discectomy and insertion of dynamic cervical implant in cervical disc herniation|The surgical technique included the use of a conventional anterior cervical approach and discectomy and insertion of dynamic cervical implant after discectomy without fixation
46005270|NCT04603599|Diagnostic Test|serum soluble L1CAM (sL1CAM)|blood sample
46005271|NCT04627298|Behavioral|educational video game for preteens to support HPV vaccination|An educational video game developed for 11-12 year olds to increase interest in and decision to pursue HPV vaccination.
46005272|NCT04603170|Other|DRUG|taking drug medication prescribed by psychiatrists for at least one month
46005273|NCT04627220|Diagnostic Test|taken venous sample|Venous blood samples taken during the operation and at the 48th hour after the operation will be examined after appropriate procedures.
46005274|NCT04627259|Other|Thumb Disability Examination|Turkish Version of Thumb Disability Examination. The Turkish Version of Thumb Disability Examination consists of 20 questions related with thumb pain and functionality.
46005275|NCT04603092|Behavioral|Digital Health Literacy Intervention|"Willing women participants will be provided equipment with instructions for the intervention, including a smartphone and a 4G Wifi gadget. The health literacy intervention, delivered to the experiment group, will last three months and will include a combination of the following four components:~Component 1: Health literacy video tutorial. Component 2: Virtual one-on-one weekly meetings. Component 3: Monthly group virtual meetings and Whatsapp group. Component 4: Provision and guidance of a self-management chart."
46005276|NCT01155583|Drug|azacitidine|Given by subcutaneous injection (SC)
46090676|NCT03599648|Behavioral|BPT-M|"Participants randomized to the BPT-M condition receive the Mindfulness-Based Stress Reduction (MBSR) intervention, followed by Behavioral Parent Training (BPT). The MBSR module includes six weekly 2.5 hour group sessions, 30-45 minutes of daily home practice guided by audio CDs, and an MBSR parent workbook. In the sessions, participants practice formal mindfulness exercises, and are provided instruction on stress physiology and using mindfulness for coping with stress in everyday life.~The BPT component of the intervention includes 10 weekly sessions lasting 2.5 hours. Each session is structured around videotape vignettes and uses discussion, role-playing, modeling, and feedback to foster mastery of the material. Parents are given weekly homework assignments and practice their skills."
45678040|NCT04636268|Biological|FIB Grifols|"FIB Grifols is the IP and will be administered via slow intravenous (IV) infusion at a rate not to exceed 5 mL/minute.~Dosing will be individually calculated for each subject based on the target plasma fibrinogen level according to the type of bleeding, measured actual plasma fibrinogen level before infusion, and body weight. The IP will be administered according to the nominal potency of the product."
45678041|NCT01939028|Procedure|lymph node mapping|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
45678042|NCT01939028|Procedure|sentinel lymph node biopsy|Undergo SLN biopsy
45836312|NCT00137280|Behavioral|Collaborative Chronic Illness Care Model|A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
45836313|NCT01790334|Other|Ultrasonography|
46005277|NCT01155583|Drug|lenalidomide|Given orally
46005278|NCT01155583|Drug|dexamethasone|Given orally
46005279|NCT01155583|Other|DNA methylation analysis|Correlative studies
46005280|NCT01155583|Other|gene expression analysis|Correlative studies
46005281|NCT01155583|Other|bone marrow aspiration|Correlative studies
46005282|NCT01155583|Other|immunohistochemistry staining method|Correlative studies
46005283|NCT01155583|Other|reverse transcriptase-polymerase chain reaction|Correlative studies
46005284|NCT01155583|Other|flow cytometry|Correlative studies
46005285|NCT04603131|Biological|Inactivated Chikungunya virus vaccine 20 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
46005286|NCT04603131|Biological|Inactivated Chikungunya virus vaccine 30 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
45678043|NCT01939028|Drug|isosulfan blue|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
45678044|NCT01939028|Drug|indocyanine green solution|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
46005287|NCT04603131|Biological|Inactivated Chikungunya virus vaccine 10 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
46005288|NCT04603131|Biological|Placebo|3 doses of Placebo administered intramuscularly on Day 0, 29 and 57
46005289|NCT04626908|Drug|GC022F CAR-T cells|Each subject receive GC022F CAR-T cells by intravenous infusion
46005290|NCT04627181|Drug|Ferric carboxymaltose|Single dose of ferric carboxymaltose (Encicarb, Emcure Pharmaceuticals Ltd., Pune, India) 500 mg administered intravenously in 100 ml normal saline over 1 hour via the dialysis blood line immediately following HD
45678045|NCT01939028|Procedure|therapeutic conventional surgery|Undergo hysterectomy, bilateral salpingo-oophorectomy and/or complete pelvic lymphadenectomy
45678046|NCT01939028|Procedure|lymphadenectomy|Undergo para-aortic lymphadenectomy
45678047|NCT01938716|Drug|Gemcitabine|500 mg/m2 at a fixed dose rate of 10 mg/m2/min by vein for the first 5 patients during pancreatic surgery. Next 15 subsequent patients receive 750 mg/m2 by vein at a fixed dose rate of 10 mg/m2/min.
45678048|NCT04416152|Procedure|Pelvic reconstruction surgery|Pelvic reconstruction surgeries, such as anterior/posterior colporrhaphy, sacrospinous ligament fixation, transvaginal mesh repair and sacrocolpopexy.
45678049|NCT01937390|Drug|Tiotropium 2x2.5µg tiotropium (equivalent to 2x3.154µg tiotropium bromide monohydrate) Respimat® inhaler and cartridge Solution for inhalation|Respimat® inhaler and cartridge Solution for inhalation
45459279|NCT03993574|Other|Self- management program|"The program sessions are either adapted from the Stanford Patient Education Research Center's program called the Chronic Disease Self-Management Program (CDSMP) or from a vision self-management program.~Despite which self-management program, the format for each session will include, review of educational materials (using the CDSMP book/article), discussion via a case vignette (which is always stroke related), and participation in an activity based on that session's topic. These group sessions will be 1.5 hours each week for 6 weeks"
46090677|NCT03599648|Behavioral|BPT-E|Participants randomized to the BPT-E condition will received 6 weeks of a psychoeducation program followed by 10 weeks of the Behavioral Parent Training (BPT) used in both conditions. The psychoeducation module consists of 6 weekly 2.5-hour sessions, daily homework that includes monitoring progress on goals identified at the end of each session, and a workbook for parents of children with special needs that provides parents with information regarding their child's development, disability, and associated considerations. Each of the 6 weekly sessions includes a general topic for discussion. These include preparing for IEP meetings, navigating the regional center and developmental service agencies, communicating with teachers, advocacy, sibling issues, and community resources.
45473938|NCT03376048|Procedure|Wound infiltration plus TAP|"TAP block: At the beginning of the main surgical procedure the surgeon will perform a TAP with ropivacaine infiltration, bilaterally in the anterior axillary line, between the costal margin and iliac crest in the intermuscular plane between the internal oblique and transversus abdominis muscles, the anesthesiologist under ultrasound guidance, the surgeon under laparoscopic guidance (two pops technique).~Wound infiltration : Wound infiltration of ropivacaine will be performed by the surgeon before skin incision."
45678050|NCT01937390|Drug|Indacterol 300 µg|inhalation powder
46005291|NCT04627181|Drug|Hydroxycobalamin|Single dose of hydroxycobalamine (Trineurosol Hp, Tridoss Laboratories, Mumbai, India) 1000 mcg administered intramuscularly in the deltoid of the non-fistula arm immediately following HD
46005292|NCT04627181|Drug|Placebo|Single dose of 1 ml of distilled water injected intramuscularly in the deltoid of the non-fistula arm immediately following HD
46090678|NCT02646150|Procedure|Magnetic Resonance Perfusion Imaging|
45678051|NCT01937390|Drug|Tiotropium 18µg (equivalent to 22.5µg tiotropium bromide monohydrate) HandiHaler® device Inhalation powder, hard capsule|HandiHaler® device Inhalation powder, hard capsule
45678052|NCT01937390|Drug|Indacterol 150 µg|inhalation powder
45678053|NCT04651712|Diagnostic Test|POC-PCR|The result of the POC-PCR will be presented by the study assistant to the treating physician within four hours upon admission. The treating physician will along with the result receive a recommended action list, developed by microbiologists.
45678054|NCT04685681|Behavioral|Hiking challenge|The main intervention of interest is the provision of free access to a local hiking challenge (which is provided following baseline assessments in the experimental group and after the conclusion of the study in the control group; $20 value). If participants choose to sign up for the free hiking challenge, they receive a list of local hikes/nature walks, accompanying maps, scavenger-hunt-like activities (finding a certain landmark on each hike), and the opportunity to earn prizes and engage with other hikers on social media.
45678055|NCT04685681|Other|Activity list|The control group will receive a list of CDC-recommended activities following the baseline survey and will receive the hiking challenge as a delayed intervention following post-test.
46005293|NCT04627181|Drug|Placebo|Single dose of 100 ml normal saline administered intravenously over 1 hour via the dialysis blood line immediately following HD
46005294|NCT04626830|Other|Mobile Application Intervention|Participants appointed to the intervention group will receive the mobile application intervention for six months after enrollment. The mobile app (OKTED) intervention will consist of completing responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses.
46005295|NCT04626557|Procedure|biopsy|biopsy of the endometrium
46005296|NCT04602897|Other|forced coughing|The cough group patients were asked to cough a forced cough during different steps of IUD insertion
46005297|NCT04602741|Behavioral|A4i Intervention|6 months of the provision of A4i on the individual's own device.
46005298|NCT04626752|Drug|BCMA CAR-T|Volunteers will be treated with BCMA CAR-T cells
46005299|NCT04626752|Drug|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
46005300|NCT04626752|Drug|Cyclophosphamide|500mg/㎡ for D-3 and D-2
46005301|NCT04602663|Device|Esophageal Variceal Band ligation|Band ligation of OV
46005302|NCT04602585|Behavioral|Psycho-education|Participants will receive 6 psycho-education sessions as adjunct therapy to the use of antipsychotics
46005303|NCT01155466|Drug|Preladenant 2 mg tablet|one 2 mg tablet orally twice daily
46005304|NCT01155466|Drug|Preladenant 5 mg tablet|one 5 mg tablet orally twice daily
46005305|NCT01155466|Drug|Preladenant 10 mg tablet|one 10 mg tablet orally twice daily
46005306|NCT01155466|Drug|Placebo to Preladenant Tablet|one tablet orally twice daily
46005307|NCT01155466|Drug|Rasagiline 1 mg capsule|one 1 mg capsule orally in AM
46005308|NCT01155466|Drug|Placebo to Rasagiline capsule|one capsule orally in AM
46005309|NCT00561860|Device|Telemedicine Arm|Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
46090679|NCT02687516|Behavioral|Family-based behavioral social facilitation therapy|"Family-based Behavioral Social Facilitation Treatment (FBSFT) is founded on the principles of standard family-based behavioural therapy for obesity. FBSFT targets life-style behaviors (diet, physical activity and sedentary activity) in a family setting. FBSFT includes some cognitive elements that are considered important in relation to behavioural change for instance problem solving and cognitive restructuring. FBSFT has an intensive treatment phase including weekly family meetings with therapists over 17 consecutive weeks. Further monthly or bi-weekly follow-up sessions with a focus on social facilitation and maintenance of healthy habits are recommended. The dietary guidance of FBSFT is based on the Traffic light diet in which foods are organized into GREEN, YELLOW and RED groups. Activity guidance of FBSFT uses the same system: GREEN activities have the highest intensity and should be engaged in most often, YELLOW activities sometimes, and RED activities."
46005310|NCT04602351|Behavioral|Communication|policies on communication and informed consent in ICU
46090680|NCT02687516|Behavioral|TAU - Treatment as usual|"This is the default treatment at the obesity clinic. After initial evaluation by paediatrician, nurse, nutritionist and physiotherapist, a contract is written including weight goal, nutritional plan and activity plan. Follow up monthly in primary Health care and every 3rd month at the obesity clinic."
46090681|NCT00888173|Drug|Brivanib Alaninate|Given PO
46090682|NCT00888173|Other|Laboratory Biomarker Analysis|Correlative studies
46090683|NCT04368468|Other|biomarker evolution|analysis of a list of biomarkers on triple negative breast tumors samples before and after neoadjuvant therapy
46090684|NCT02687282|Other|Evaluate upper airway changes|Evaluate upper airway changes at several point of time before and after cesarean delivery
46090685|NCT04581668|Other|Neurally adjusted ventilatory assist first|Invasive ventilation in Neurally adjusted ventilatory assist during 60 minutes followed by a 30 minutes wash out period then ventilation in conventional mode
46090686|NCT04581668|Other|Conventional ventilation first|Invasive ventilation in conventional mode during 60 minutes followed by a 30 minutes wash out period then ventilation in Neurally adjusted ventilatory assist
46090687|NCT02825927|Other|Oral screen|The oral screen is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial muscles.
46090688|NCT02654184|Procedure|supine position|Anesthesia induction with sevoflurane for the patient while he is in supine position.
45836314|NCT00138294|Biological|live attenuated and inactivated influenza vaccines|Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination coverage in school-aged children. Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) will be offered LAIV or IIV through a school-based research vaccination program. Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites received LAIV or IIV from the local healthcare providers
45473939|NCT03376048|Procedure|Wound infiltration|Wound infiltration of ropivacaine will be performed by the surgeon before skin incision.
45473940|NCT05667025|Other|Conservative rehabilitation|Joint range of motion, strengthening, balance-coordination and stretching exercises included in the conservative physiotherapy program 5 days a week for a total of 6 weeks
45836315|NCT02103114|Drug|Anti-thrombin III|"Intraoperatively- (correcting to 100%) according to the following formula:~Units required = ((100%- baseline ATIII level*%) X body weight)/1.4~expressed as a % normal level based on functional ATIII assay"
45836316|NCT02103114|Other|Placebo|Normal saline placebo
45836317|NCT00140244|Drug|r-metHuLeptin|
46005311|NCT00561899|Drug|SP, amodiaquine, piperaquine, dihdroartemisinin|once every month during september, October and November
46005312|NCT00561899|Drug|intermittent preventive treatment|SP(500mg sulfadoxine/25mg pyrimethamine)1.25mg SP per kg stat Amodiaquine (200mg base) 25mg/kg over 3 days Piperaquine (320 mg per tablet) 16.8 g/kg daily for 3 days Du-Cotecxin ( 40mg dihydroartemisinin(DHA)/320mg piperaquine(PQP))PQP/DHA 1.6/12.8mg/kg once daily for 3 days
46005313|NCT00561899|Drug|Du-Cotecxin|Du-Cotecxin (40mg dihydroartemisinin (DHA/320mg Piperaquine (PQP) PQP/DHA 1.6/12.8mg/kg once daily for 3 days
46005314|NCT01155388|Drug|Ferumoxytol|Experimental: Ferumoxytol
46005315|NCT01155388|Drug|Oral Iron|Active Comparator: Oral iron
46005316|NCT04313725|Device|Tangible Boost|Patients will perform a monthly Tangible Boost treatment on their Hydra-PEG treated contact lenses.
46005317|NCT04313725|Other|Placebo|Patients will perform a monthly placebo (saline) treatment on their Hydra-PEG treated contact lenses.
46005318|NCT04626440|Procedure|Diagnostic stage or the Clinical outcome|After enrollment, individual subject will be assigned into one of the four groups according to the medical management received, the diagnostic stage of breast cancer (BC), or the clinical outcome of BC at enrollment.
46005319|NCT04313803|Device|CGM|Dexcom CGM system
46005320|NCT00565227|Drug|vorinostat (suberoylanilide hydroxamic acid)|Vorinostat will be administered by mouth as a pill for the first 14 days on a continuous basis during of each 21-day cycle (2 weeks of treatment, 1 week break).
46005321|NCT00565227|Drug|docetaxel|Docetaxel will be administered as an intravenous infusion (through the vein) on day 4 of each 21-day cycle.
46005322|NCT05239000|Other|geriatric co-management|Geriatric co-management involves a consultation with a geriatrician prior to initiating head and neck radiation and chemotherapy.
46005323|NCT05239000|Other|geriatric guided supportive care|Geriatric guided supportive care will be carried out by oncologists. After the patient completes the eRFA, an automated report is generated that identifies the patient's geriatric deficits.
46005324|NCT00561938|Procedure|Colonoscopy|microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist. General tolerance and potential late adverse events will be assessed by the careful inquiry performed 1 month after the procedure by consultant gastroenterologist.
46005325|NCT00561938|Procedure|Endoscopy|After obtaining a written informed consent from all the patients, standard upper GI endoscopy or colonoscopy will be performed under general anaesthesia using a videoendoscope EC-3870 (Pentax), which includes a miniaturized microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist.
46005326|NCT04123756|Behavioral|standardized exercise therapy for knee OA patients|Standardized exercise therapy for 6-8 weeks (two times per week).
46005327|NCT02884726|Drug|BMS-986148|Specified dose on specified days
46005328|NCT04602273|Drug|Azacitidine Injection [Vidaza]|
46005329|NCT00562016|Device|IMPLELLA LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5 L/min.
45678056|NCT04685291|Procedure|Ultrasound-guided block of the supraclavicular nerves|The supraclavicular nerves (SCN) arise from the 3rd and 4th roots of the spinal nerves. After emerging from the spine, they run at the rear margin of the sternocleidomastoid muscle and divide into their three terminal branches. With a high-resolution Ultrasound (US)-probe they can be visualized as a grape-like structure under the skin. At this location, patient's skin is disinfected and covered with a sterile perforated blanket. The US-probe is covered with a sterile sheath. The patient is positioned as comfortably as possible so that the broken clavicle is not mobilized. SCN are shown by US and a 0.5 mm needle is advanced through the patient's skin in order to direct it to the nerves under US-guidance. Both the nerves and the needle are permanently visualized. As soon as the needle tip is placed next to the SCN, 2-3 millilitres of a long-acting LA are injected. The distribution of the LA around the nerves is controlled.
46005330|NCT00562016|Device|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
46005331|NCT04313491|Other|Yoga|Relaxation yoga exercises, yoga breathing, yoga sound and imagery practices
46005332|NCT04313764|Drug|Bupivacaine Hcl 0.25% ESP block|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
46005333|NCT04313764|Drug|Bupivacaine Hcl 0.25% infiltration|Wound infiltration with 20 ml %0.25 bupivacaine
46005334|NCT04602234|Diagnostic Test|Lung ultrasonography|Investigators performed lung ultrasonography on patients
46005335|NCT04313569|Procedure|Arthroscopic menisctomy|Arthroscopic medial menisctomy
46005336|NCT00624793|Other|Acupuncture|Standard Acup point protocol for treating nausea
46090689|NCT02654184|Procedure|Right lateral position|Anesthesia induction with sevoflurane for the patient while he is in right lateral position.
46090690|NCT03495596|Device|Videolaryngoscopy|Videolaryngoscopy device type
45678057|NCT04685291|Drug|Conventional pain management|"oral pain medication in patients younger than 70 years: Ibuprofen 400mg (1-1-1) AND Metamizole 500mg (max. 2 tbl. every 6 hours)~oral pain medication in patients older than or equal 70 years: Acemetacin 60mg (1-1-1) AND Metamizole 500mg (max. 2 tbl. every 6 hours)~Rescue analgesic medication for all patients: oxycodone hydrochlorid (drops) p.o. (10 mg/ml) 0.1mg/kg p.o. hour~In the ED Rescue analgesic medication for all patients: Fentanyl 50mcg i.v. (max. 200mcg/hour)"
45836318|NCT00140244|Drug|Placebo|
46005337|NCT00624793|Other|Individualized Acup based on TCM diagnosis|Acup
46005338|NCT00624793|Other|Sham Acup|Sham Acup - Non-Active
46005339|NCT04626089|Drug|metformin glycinate|Participants randomized to metformin glycinate wil take 620 mg bid (PO) plus standard treatment for 14 days
46005340|NCT04626089|Drug|Placebo oral tablet|Participants randomized to placebo will take a tablet bid (PO) plus standard treatment for 14 days
46005341|NCT04626323|Procedure|Roux-en-Y gastric bypass|"Pneumoperitoneum closed with Veress needle~Identification of Treitz angle~Measurement of biliary loop (50 cm)~Bowel transection with linear stapler (white load)~Measurement of the alimentary limb (100 cm)~Laterolateral Entero-anastomoses (white load)~Construction of gastric pouch distant about 3 cm from the esophageal-gastric junction with stomach section in the small curvature.~Linear cutting anastomosis (gastrojejunostomy) from about 1 to 1.2 cm~Anastomosis integrity evaluation by methylene blue test and/or perioperative air.~Expected surgical time: 60 minutes"
46005342|NCT04626323|Drug|Best medical treatment|Patients will also receive standard of care medical therapy for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary).
46090691|NCT02827409|Procedure|Short Delay Cord Clamping|Delay cord clamping will occur for up to 1 minute. Subject will be placed on mother's abdomen for warmth and stimulation. If the subject is depressed they will be transferred to the radiant warmer for resuscitation.
46090692|NCT02827409|Procedure|Extended Delay Cord Clamping|Extended delay cord clamping will occur for at least 5 minutes and will continue until the subjects begins breathing and/or the cord stops pulsating. Subject will be placed on mother's abdomen for warmth and stimulation. If the subject is depressed they will be transferred to the LifeStart bed for resuscitation adjacent to the mother's bedside.
45678058|NCT04685057|Dietary Supplement|Placebo|Intervention with a daily dose of placebo for 6 months
46005343|NCT04602039|Dietary Supplement|Bovine Colostrum|Bovine colostrum (Neovite)
46005344|NCT04601688|Drug|Bevacizumab Ophthalmic and Intravitreal Dexamethasone|Pro re nata patients with BRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
46005345|NCT04601688|Drug|Bevacizumab Ophthalmic|Pro re nata patients with BRVO will receive Bevacizumab. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
46005346|NCT04626011|Procedure|Tooth extractions|After blood collection tests, Periodontal analysis, Orthopantomography and Anamnestic record each group will receive a full mouth disinfection and needed extractions.
46005347|NCT04601766|Drug|APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2|Phase1: Period 1 drug administration( APL-1202 50 mg, 3 tablets, orally );Washout( 7± 1 day) ; Period 2 drug administration(1501 ER Tablets 3 382 mg ASN-1324, 1 tablet); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)
46005348|NCT04601766|Drug|APL-1501 ER Tablets 3+APL-1202+APL-1501 ER Tablets 2|Phase1: Period 1 drug administration( 1501 ER Tablets 3 382 mg ASN-1324, 1 tablet );Washout( 7± 1 day) ; Period 2 drug administration(APL-1202 50 mg, 3 tablets, orally); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)
46005349|NCT04625816|Device|whole body tilt device (Spine Balance 3D)|The symmetry of the deep muscle was evaluated using a whole body tilt device (Spine Balance 3D, Cyber Medic Co., Ltd., Korea). Spine Balance 3D can evaluate the maintenance strength and maximum strength of the core muscles, and perform a personalized core muscle training program based on the evaluated results.
46005350|NCT01154452|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
46005351|NCT01154452|Other|Laboratory Biomarker Analysis|Correlative studies
46005352|NCT01154452|Other|Pharmacological Study|Correlative studies
46005353|NCT01154452|Drug|Vismodegib|Given PO
46005354|NCT04625894|Radiation|Stereotactic Ablative Radiotherapy (SABR)|To irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate. Target dose will be adjusted depending on site of the lesion and organs at risk (BED > 100Gy). Sequence of irradiation for multiple metastases will be at the discretion of the investigators based on their experience.
46005355|NCT04625894|Drug|Camrelizumab for injection (200 mg, iv), D1, Q2W, 14-day cycle|Administration of Carrelizumab will be started within one week upon SABR completion, and will be continued for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
46005356|NCT04601415|Diagnostic Test|ECG from handheld device|Acquisition of a single-lead ECG at time of presentation to GP and at echo appointment
46005357|NCT01154296|Behavioral|RESPECT-2 Counseling|Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.
46005358|NCT04601025|Dietary Supplement|Yoghurt|200 ml plain full-fat yoghurt
46005359|NCT04601025|Dietary Supplement|Chickpea+Yoghurt|80 ml plain full-fat yoghurt + 70 gr cooked chickpea
46005360|NCT04601025|Dietary Supplement|Oat+Yoghurt|80 ml plain full-fat yoghurt + 100 gr cooked oat
46005361|NCT04625855|Drug|TBPM-PI-HBr|TBPM-PI-HBr (3 x 200 mg tablets) once
46090693|NCT02646072|Drug|Ketorolac tromethamine ophthalmic solution 0.45%|Indicated for the treatment of pain and inflammation following cataract surgery.
46090694|NCT03883724|Behavioral|Brief behavioral treatment of insomnia (BBTI)|The BBTI consists of a 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later and 20-minute telephone calls after 1 and 3 weeks. The brief behavioral treatment component will focus on four behaviors that promote sleep through homeostatic, circadian, or association mechanisms. 50 These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.
46005362|NCT02884570|Other|Auto-Questionnaires|Consents and questionnaires will be sent to the parental home or filled in an interview with an investigator (or telephone consultation).
45678059|NCT04685057|Dietary Supplement|Probiotic|Intervention with a daily dose of probiotic for 6 months
45678060|NCT04685057|Dietary Supplement|Follow-up probiotic|Intervention with a daily dose of probiotic for 6 months
45678061|NCT02028767|Drug|Empagliflozin 2.5 mg|Empagliflozin 2.5 mg tablet
45678062|NCT02028767|Drug|Empagliflozin 10 mg|Empagliflozin 10 mg tablet
46005363|NCT04313452|Other|the effect of Mediterranean diet on insulin sensitivity among obese children and adolescents aged|to find the effect of Mediterranean diet on insulin resistance among obese children and adolescents aged 10-16 years with insulin resistance compared to the regular diet
46005364|NCT04313686|Behavioral|Mindfulness-based therapy|Based on randomization, those who first receive the mindfulness training program are the intervention group. Participants would meet weekly for 2-3-hour long sessions for six weeks at the patient's usual follow-up clinic.
46005365|NCT04313686|Behavioral|No-intervention|Participants who were randomized into this group would continue to receive their usual follow-up care at the usual neurology outpatient clinic.
46005366|NCT04625933|Other|No intervention|No intervention
45678063|NCT02028767|Drug|Metformin 500 mg|Metformin 500 mg tablet
45678064|NCT02028767|Drug|Empagliflozin/Metformin FDC|12.5 mg Empagliflozin / 500 mg Metformin
45678065|NCT01959932|Other|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
45678066|NCT01959932|Other|Smoking abstinence (SA)|SA for 5 days in confinement
45678067|NCT01959932|Other|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
46005367|NCT04600986|Other|Repeated dose of GnRH agonist|0.2 mg triptorelin plus a repeat dose of 0.1 mg 12 hours following the first dose.
46005368|NCT01154218|Drug|crizotinib|"Treatment A (Reference 1): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg IRT and 2 × 100-mg IRTs.~Treatment B (Reference 2): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg PIC and 2 × 100 mg PICs.~Treatment C (Test for BE, Reference for Food Effect): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 250-mg CIC.~Treatment D (Test High Fat): a 250 mg single dose of crizotinib administered with a high-fat meal as 1 × 250-mg CIC"
46005369|NCT04601142|Drug|Methylprednisolone|methylprednisolone pulse therapy: 500-1000mg/d，３-５ｄ
46005370|NCT04625582|Behavioral|Face-to-face|"The intervention has been created specifically for this group of trainees, with the aim of acquiring or improving mediating personal skills in the processes of physical and mental well-being that help them cope with more motivation, enthusiasm and personal resources professional challenges.~It is based on conducting 4-hour face-to-face workshops, every four months throughout the period of specialized health training. They will be instrumented through group dynamics, communication exercises, leadership, corporality, and reflective and emotional writing.~Audiovisual media (videos, presentations, recordings) will be used. They will be developed in person in a classroom equipped with the necessary means for training, including versatility of the space."
45678068|NCT04416893|Diagnostic Test|RT-PCR SARS-Cov2|nasopharyngeal swab will be taken for detection of SARS-CoV-2 by RT-PCR
45678069|NCT04416893|Diagnostic Test|Sars-Cov2 serology|A microsample of blood will be taken for serology
46005371|NCT04625582|Behavioral|Online|"The online intervention will pursue the same objectives and will be nourished by the same content as the face-to-face intervention. The theoretical content will be adapted for online use, with the flexibility of access and organization that this entails for the participants, including videos, presentations, recordings ...~Group techniques will be carried out online, every four months during the entire period of specialized health professional training. They will be instrumented through group dynamics, communication exercises, leadership, corporality, and reflective and emotional writing."
46005372|NCT00565305|Behavioral|Healing Touch|Healing Touch (HT) is a non-invasive therapeutic approach to healing which describes its mode of action as using touch to modulate the patient's energy system. The goal of HT is to restore harmony and balance in the patient's energy system to assist the person to self-heal.88 Healing Touch, as used here, refers to the techniques taught in Mentgen's standardized curriculum of Healing Touch offered through Healing Touch International and endorsed by the American Holistic Nurse's Association
46005373|NCT00565305|Radiation|Standard Treatment|4-6 cycles of cytotoxic chemotherapy followed by 5040 cGy of external beam whole breast radiotherapy in 28 fractions usually followed by a boost of 1000-1600 cGy
45678070|NCT04678895|Drug|Naltrexone|Capsule with doses of 1.5mg, 3mg, and 4.5 mg to allow for drug titration. Capsules of different dosages will be indistinguishable to allow for maintenance of blinding.
45678071|NCT04678895|Drug|Placebo|Naltrexone matched placebo capsule.
45836319|NCT02103270|Drug|Peanut Protein 4,000mg|"Arm A will be defined as clinically tolerant if there is no clinical reactivity at the Week 104 and Week 117 DBPCFC. Clinical reactivity is defined as any reaction ≥ Grade 1 based on the Bock's Criteria (Appendix 4). Individuals in Arm A who meet the definition of clinically tolerant will continue to avoid peanut protein (i.e. continue on 600 mg per day of oat flour) as long as each subsequent DBPCFC (performed every 13 weeks until end of study) shows no clinical reactivity."
45836320|NCT02103270|Drug|Oat Flour|"Arm C will be defined as natural loss of responsiveness if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
45473941|NCT05667025|Other|Cycling Functional Electrical Stimulation in addition to Conservative Rehabilitation|In addition to conservative treatment, cycling FES to the affected lower extremity for 20 minutes, 3 days a week for 4 weeks. During the treatment, the patient will be seated on a chair and her feet will be fixed to the pedal with velcro tape, and the comfort during the treatment will be provided with calf supports.
45678072|NCT04651244|Diagnostic Test|MRI|Gold standard for identifying inflammatory changes in patients with acute pyelonephritis
45836321|NCT02103270|Drug|Peanut Protein 300 mg|"Arm B will be defined as desensitized to a minimum of 300 mg per day of peanut protein if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
45836322|NCT01790412|Behavioral|Exercise group|Combined two land aerobic sessions and one aquatic activities session
45836323|NCT01790022|Drug|Methylprednisolone|
45678073|NCT04651244|Diagnostic Test|Ultrasound performed by a radiologist|US performed by a radiologist including standard grayscale evaluation of the kidneys, Doppler US and contrast enhanced US (CEUS).
45678074|NCT04651244|Diagnostic Test|Point of care ultrasound|Point of care US by a study assistant with basic ultrasound skills and training to access the presence or absence of hydronephrosis. If hydronephrosis is present it will be graded into one of four categories.
45678075|NCT02028065|Drug|Sugammadex|Sugammadex 4 mg/kg or 16 mg/kg administered as a single IV bolus over 10 seconds
45678076|NCT02028065|Drug|Placebo|Placebo administered as a single IV bolus over 10 seconds
45836324|NCT00140556|Radiation|Chemoradiotherapy|External beam radiation daily (M-F)
46005374|NCT04625348|Device|Ultracore Repose® mattress|residents will be placed on the Ultracore Repose® mattress for the daily care during 14 days
46005375|NCT04625348|Other|experiences and perceptions of healthcare workers|Three focus groups will be set- up at the end of the study to provide insights into how caregivers think about the product and to provide a deeper understanding of the difference between the use of the Ultracore Repose® mattress (versus the Repose overlay mattress® and an alternating air mattress)
46090695|NCT03883724|Behavioral|Information-only control (IC)|The IC condition is intended to emulate the behavioral treatment information generally to available patients. It includes instructions to review hand out on healthy sleep practices. We will also use patient education videos on insomnia developed locally and widely used in clinical research. The content of these videos overlap substantially with BBTI but without individualized behavioral instructions. Two weeks later, IC participants will receive a 10-minute follow-up telephone call to encourage continued participation. Participants will be referred to the brochures for specific sleep-related questions.
46005376|NCT04625543|Drug|Sintilimab Injection plus Paclitaxel and Cisplatin|Paclitaxel 150mg/m2 on day 1, every 3 weeks, for two cycles; Cisplatin 70mg/m2 on day 1, every 3 weeks, for two cycles; Sintilimab Injection 200mg on day 22; 4-6 weeks after completion of preoperative therapy, Mckeown esophagectomy will be performed if there is no contraindication.
46090696|NCT02646306|Other|shoulder proprioceptive rehabilitation tool|"Using of this tool to measure which is the average error in reaching back in both healthy subjects and subjects with shoulder impingement syndrome starting from the assumption that the shoulder, through the articulation scapulothoracic, helps to determine direction and distance during the reaching of an object."
46090697|NCT05073887|Procedure|Current Targets|blockade and radio frequency stimulation of genicular nerves
46090698|NCT02654106|Radiation|Fractionated Stereotactic Radiotherapy|The regular fraction modes were as follows: a. lesions≥3 cm：52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions<2cm：36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm：40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem：50-60Gy/2.5-3Gy/20f.
46090699|NCT02654106|Drug|Temozolomide|concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/m2*5d, q28d, 6cycles
46090700|NCT04244435|Procedure|CABG|coronary artery bypass grafting with and without cardiopulmonary bypass
46005377|NCT04625543|Drug|Paclitaxel and Cisplatin|Paclitaxel 150mg/m2 on day 1, every 3 weeks, for two cycles; Cisplatin 70mg/m2 on day 1, every 3 weeks, for two cycles; 4-6 weeks after completion of preoperative therapy, Mckeown esophagectomy will be performed if there is no contraindication.
46005378|NCT04601259|Combination Product|Orkla Corn Plaster with salicylic acid|Each participating subject will receive Orkla Corn Plasters for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
45678077|NCT04683965|Drug|Pemetrexed|Pemetrexed 500 mg/m2 d1
46005379|NCT04601259|Device|Orkla Corn Protector|Each participating subject will receive Orkla Corn Protector for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
46005380|NCT04625309|Other|Adaptive sports|This will be the number of hours per week the subjects actively partake in adaptive sports teams.
46005381|NCT00565383|Procedure|Combined spinal-epidural analgesia|Combined spinal-epidural
46005382|NCT00565383|Procedure|Intravenous fentanyl (50mcg)|Intravenous fentanyl
46005383|NCT04625387|Other|Dry Needle and Exercise|"A 0.25 X 15 mm acupuncture needle was used for sub occipital muscle and 0.25 X 40 mm needle was used for paraspinal and trapezius muscle. All the necessary precautions were maintained before inserting the needle. Therapists wore hand gloves for all purposes.~The exercise for the muscles of cervical group, for group A was carried out by elevating head from lying in supine position repeating 20 times in three sets and pressing a theraband forward in one set of 15 repetitions, to right side and to left side and back side"
46005384|NCT04625426|Device|3M Cavilon No-Rinse Skin Cleanser and 3M Cavilon Advanced Skin Protectant|Hypoallergenic no-rinse skin cleanser and liquid acrylic tetrapolymer skin protectant
46005385|NCT04625426|Device|Conveen EasiCleanse and Conveen Critic Barrier|Hypoallergenic no-rinse skin cleanser and zinc-oxide barrier cream
46090701|NCT04244435|Drug|thoracic epidural analgesia|thoracic epidural analgesia at the level of 1-10 thoracic vertebrae (ropivacainum 0,2-0,5% 5-10 ml/h)
46090702|NCT04244435|Drug|analgesia of opioids|Opioids will be used for perioperative analgesia
46090703|NCT03684096|Dietary Supplement|non-estrogenic pollen extract PCC-100|non-estrogenic pollen extract PCC-100
46090704|NCT03684096|Other|placebo|placebo -non-estrogenic pollen extract PCC-100
46090705|NCT04243733|Other|CEM and MTA|Pulpotomy agent
46090706|NCT04243733|Other|MTA and CEM|Pulpotomy agent
46090707|NCT03434366|Drug|ketamine and dexmedetomidine|intranasal ketamine and dexmedetomidine for treatment for autism spectrum disorder
45836325|NCT00140556|Drug|Cisplatin|Cisplatin week 1 and 5 of radiation
46090708|NCT03434366|Drug|ketamine|intranasal ketamine for treatment for autism spectrum disorder
45678078|NCT04683965|Drug|TAS-102|TAS-102, capsule, 35mg/m2, bid,p.o, d1~5,d8~12
45678079|NCT04683965|Drug|Bevacizumab|Bevacizumab 5 mg/kg d1,d14
45678080|NCT02015195|Other|Acetic Acid (5%)|
45678081|NCT02015195|Other|Sodium Bicarbonate Slurry (50%)|
45678082|NCT02015195|Other|Papain Slurry (70%)|
45678083|NCT02015195|Other|Ammonia (10%)|
45678084|NCT02015195|Drug|Lidocaine (4%)|
45678085|NCT02015195|Other|Isopropyl Alcohol (70%)|
45678086|NCT02015195|Other|Hot Tap Water (40 degrees Celsius)|
45678087|NCT02015195|Other|No treatment|
45678088|NCT02015039|Drug|BoNT Injections|
46090709|NCT03434366|Drug|Saline|intranasal saline for treatment for autism spectrum disorder
46005386|NCT04625426|Device|Standard cleansing and Conveen Critic Barrier|Hospital's standard care for IAD management
46090710|NCT04167150|Dietary Supplement|tart cherry juice concentrate is a commercial product provided by King Orchards (Central Lake, MI)|Participants were instructed to reconstitute the tart cherry juice concentrate in 8 fl oz of water and consume either 1x or 2x daily for 3 months.
45459280|NCT03993574|Other|Standard care|"All stroke patients being discharged from the acute hospital receive the following care:~1 follow-up call within 2 weeks by a nurse coordinator. The call involves checking if medications were able to be filled and how the person is feeling.~A stroke clinic appointment that is set to occur 90-days post discharge.~A list of their personal medications and generic educational materials. The educational materials are standard forms located in the Epic system. It is the nurses' responsibility to choose what forms to provide, however it is mandatory that stroke risk factor information is included.~Information on local support groups.~Referrals to start physical, occupational or speech therapy, if recommended by their physician."
46005387|NCT04625075|Diagnostic Test|Cardiac MRI|Cardiac MRI with gadolinium and manganese contrast
45459281|NCT03938272|Biological|Oxabact OC5 - Oxalobacter formigenes Strain HC-1|Live, commensal bacteria
46005388|NCT04625075|Diagnostic Test|Cardiac CT|Cardiac CT to assess coronaries
46005389|NCT04625075|Diagnostic Test|Electrocardiogram (ECG)|ECG to assess rhythm
46090711|NCT05068193|Drug|BR2008-1 (R)|After fasting at least 10 hours, two tablets of BR2008-1 will be administered orally with 150mL of water around 8 a.m.
46090712|NCT05068193|Drug|BR2008 (T)|After fasting at least 10 hours, one tablet of BR2008 will be administered orally with 150mL of water around 8 a.m.
46090713|NCT02687594|Drug|sucroferric oxyhydroxide|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
46090714|NCT00652158|Drug|MLN8054|"10 mg doses of MLN8054 were given orally once daily following a schedule of 5 days on/2 days off/5 days on repeated every 28 days"
45459282|NCT04146142|Procedure|Transperineal prostate biopsy with or without antibiotic prophylaxis|As described above.
45459283|NCT03494842|Device|Transcutaneous nerve stimulation (TENS)|The active TENS unit (delivers electrical stimulation) with indicator light
45459284|NCT03494842|Device|Placebo Transcutaneous nerve stimulation (TENS)|the placebo TENS unit (delivers no electrical stimulation) with indicator light
45678089|NCT02015039|Procedure|Occupational Therapy|
45678090|NCT02025725|Drug|Metoclopramide Nasal Spray|nasal spray formulation of metoclopramide
45836326|NCT00140556|Drug|Bevacizumab|Bevacizumab (Avastin) day 1 of weeks 1, 3, and 5 of radiation
46005390|NCT04625075|Diagnostic Test|Blood samples|renal function liver function full blood count, hematocrit glucose
46005391|NCT04591548|Diagnostic Test|proteomic analyses, ELISA validation of peritoneal fluid, blood and uterine fluid sample|All samples were collected during laparoscopy, before any intraabdominal procedure was done. Indication for surgery was clinical (not for research purpose). All sample collection procedures was mimic regular clinical procedures.
46090715|NCT04167228|Drug|Ceftazidime-Avibactam|Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated > 2 days with ceftazidime-avibactam.
46090716|NCT04167228|Drug|Best Available Therapy|Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated > 2 days with the best available treatment other than ceftazidime-avibactam.
46090717|NCT02689544|Other|intervention with static stretching|Members of static stretching group performed three sets of 30 second self hamstring stretch (IT) of both lower limbs, with 30 seconds of rest between sets, totaling 3 minute intervention so.
46005392|NCT04625192|Procedure|Trephine osteotomy|"Using a trephine on a straight implant handpiece (at approximately 1800 rpm) with copious irrigation to avoid overheating the bone, a round bone cut will be made 4 -5 mm above the crest of the alveolar ridge.~The trephine is positioned perpendicular to the lateral wall, removing the outer cortex with a very gentle touch to avoid tearing the schneiderian membrane."
46005393|NCT04591665|Other|swallowing examination|patients received swallowing examination, including high resolution impedance manometry and Video-Fluoroscopic swallowing study.
46005394|NCT04625114|Drug|Camostat|Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D1->D5);
46005395|NCT04625114|Drug|Placebo|SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D1->D5).
45459285|NCT03494764|Other|Hyperbaric Oxygen Therapy|Hyperbaric oxygen (HBO) provides 100% oxygen at a pressure above atmospheric pressure (typically twice to three times standard sea level pressure (2.0-3.0 ATA)). This dramatically increases the amount of oxygen dissolved in blood plasma, which in turn increases oxygen delivery to tissues. This effect of hyperbaric oxygen is used clinically to treat acute hypoxia in crush injuries, severed limbs, and failing skin grafts
46005396|NCT04625114|Drug|Camostat|Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D6->D10);
46005397|NCT04625114|Drug|Placebo|SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D6->D10).
46005398|NCT04592133|Diagnostic Test|Ultrasonography|Ultrasonography Examination
46005399|NCT04624880|Device|Giant magnetoresistive sensor (GMR)|Giant magnetoresistive sensor analyzes genetic polymorphisms in patient samples.
46005400|NCT04591470|Diagnostic Test|Mar test|Study of antisperm antibodies
46005401|NCT04624841|Drug|Indocyanine Green|2.5-7.5 mg (0.05 mg/kg) injection
46005402|NCT04624607|Device|Transspinal-transcortical paired-associative stimiulation combined with robotic gait training|Individuals with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also paired non-invasive transspinal stimulation and non-invasive brain stimulation during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
46005403|NCT04624607|Device|Transcortical-transspinal paired-associative stimiulation combined with robotic gait training|Individuals with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also paired non-invasive brain stimulation and non-invasive transspinal stimulation during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
46005404|NCT00567099|Drug|Aripiprzole|"Dosage form, dosage, frequency and duration:~Aripiprazole 5-30 mg tabs po qday x 3 months"
46005405|NCT04624802|Behavioral|maternal exercise|The maternal exercise is broadly practiced by pregnant women in China. It is designed by a team led by Shen Shanmei, a professor of Maternity Exercises at Department of Obstetrics and Gynecology of First Hospital in Korea.
46090718|NCT02689544|Other|intervention with Dynamic Stretching|Each subject contracting antagonist muscle (quadriceps) to the target muscle (hamstring), performing dynamic movements of hip flexion with the knee extended, repeated every 1 second. They amounted to 3 of 30 repetitions completing approximately three minutes of dynamic stretching for each lower.
45459286|NCT02324296|Drug|ifosfamide|PEI regimen may be a possible therapeutic option, with high activity and an acceptable toxicity profile.
45459287|NCT03489460|Behavioral|Specialized sleep-related message interventions|Over the course of 2 weeks' participants will receive specialized sleep-related message interventions to encourage sleep awareness via the smartphone application.
45459288|NCT03489460|Behavioral|GAD|Survey responses will be merged with objective GAD data (sleep time, time in deep sleep, physical activity) which will assist in developing message design formats for message testing.
45459289|NCT03494686|Procedure|LLETZ under local anaesthesia|Conization will be performed under local anaesthesia
45459290|NCT03494686|Procedure|LLETZ under general anaesthesia|Conization will be performed under general anaesthesia
45678091|NCT02025725|Drug|Placebo Nasal Spray|nasal spray formulation with vehicle only
45836327|NCT00140556|Drug|Erlotinib|Erlotinib daily during radiation
46005406|NCT00567177|Drug|Restasis, Refresh Plus|Restasis 0.4ml- (in the eye) Instill one drop twice daily in morning and evening Refresh Plus 0.4ml- (in the eye) Instill one drop twice daily in morning and evening
46005407|NCT04624373|Other|Molecular analysis of surnatant|"The interventional pulmonologist selects the most suspect node. The corresponding TBNA is placed in Cytolyt and tagged using a sticker to indicate the specimen from which supernatant must be saved after the initial spin.~The supernatant is transferred to the Laboratoire de Biologie Médicale Oncologique where it undergoes a further hard spin. The remaining supernatant is stored at -80°C before to send it to Foundation One for DNA extraction from 3 ml of supernatant and genotyping.~Two 7,5 mL blood tubes are transferred to the laboratory to extract plasma. Plasma was stored at -80°C and then sent to Foundation One for DNA extraction from 2 mL of plasma and genotyping.~10 slides from the cell block are shipped to Foundation One. These specimens are tested by FoundationOne®CDX (tissue), and FoundationOne®Liquid (supernatant and plasma) for genomic and TMB analyses (hybrid-capture based next generation sequencing)."
46005408|NCT04591158|Device|Butterfly iQ|The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
46005409|NCT03454607|Device|FREE robot|FREE robot to hold endoscope
46005410|NCT00567216|Drug|Nadolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
46005411|NCT00562055|Drug|Atomoxetine|
46005412|NCT00562055|Drug|PNU-165442G; [S,S]-reboxetine|
46005413|NCT04590729|Behavioral|3-min Exercise Per 30 Min|This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 30 minutes for 6 hours, totaling 36 minutes of cycling exercise.
46005414|NCT04590729|Behavioral|3-min Exercise Per 15 Min|This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 15 minutes for 3 hours, totaling 36 minutes of cycling exercise.
46090719|NCT02689544|Other|Control|The control group volunteers no received intervention
46090720|NCT02649114|Behavioral|Cognitive-Behavioural Therapy|
46090721|NCT02649114|Behavioral|Compassion-Focused Therapy|
46090722|NCT02687438|Device|Steroid-releasing sinus implant|PROPEL (Intersect ENT, Menlo Park, CA) containing 370mcg of mometasone furoate designed for gradual release over 30 days
45678092|NCT02025179|Drug|Teriparatide|Teriparatide 20 ug daily Sub-Q over 12 months
45459291|NCT03486028|Other|Adherence to ASAM protocols|ASAM Counties. These counties are requiring their providers to use ASAM criteria to assess patients and to determine level of care. These counties also use ASAM to determine the ongoing need for high-intensity services, such as residential, and approve those services for Medicaid payment.
46090723|NCT02687438|Other|Post-op standard of care|post-op standard of care including debridement, irrigation, and/or topical steroids
46090724|NCT04168554|Device|Telemedicine|Patient is examined using telemedicine
46090725|NCT02537834|Drug|Tofogliflozin|
45459292|NCT03486028|Other|Non-adherence to ASAM protocols|These counties are not implementing the ASAM criteria to assess patients and determine the level of care.
45459293|NCT03487198|Drug|Brexpiprazole|Brexpiprazole 2-3mg/day
45459294|NCT03487198|Drug|Placebo|Placebo 2-3 mg/day
45459295|NCT03978754|Diagnostic Test|ICG lymphography、CM、VD、Bioelectrical impedance technology、self-report|All of these methods are used for patients visiting the lymphedema clinic to assess whether they have developed lymphedema.
45459296|NCT03978754|Diagnostic Test|Bioelectrical impedance technology、CM|These two methods are routine evaluation methods for breast cancer patients before surgery
45459297|NCT02565914|Drug|TEZ/IVA|
45678093|NCT02025179|Device|Vibration|Vibration 10 min/day for 12 months
45678094|NCT04677179|Drug|LY3471851|administered SC
45678095|NCT04677179|Drug|LY3471851|administered SC
46005415|NCT04624022|Diagnostic Test|Anterior segment optical coherent tomography|Examination of the implanted perforated lacrimal plugs using anterior segment optical coherent tomography
45678096|NCT04677179|Drug|Placebo|administered SC
46005416|NCT04590807|Device|Posterior spinal fusion with pedicle screws|Implanting pedicle screws and rods
46005417|NCT04590807|Device|Anterior vertebral body tethering|Vertebral screws and cable
46090726|NCT02537834|Drug|GLP-1 analogue|
46090727|NCT02648802|Procedure|Cavity shaving|Resect the residual cavity circumferentially (superior, inferior, medial, lateral) and the thickness of the cavity shaving depends on the surgeon's discretion (Recommended 0.5-1.0cm). The principles of the cavity shaving includes: 1) do not compromise the cosmetic outcomes; 2) covers the entire cavity;
46090728|NCT02648802|Procedure|Standardized BCS+CM assessment.|For standardized BCS(Chen K, et al. Ann Surg Oncol. 2012), we resect a rim of 1 cm macroscopically normal tissue around the tumor. The anterior and posterior margins of the tumor-containing specimen extended up to the subdermal plane of the skin and down to the pectoralis major fascia, respectively. The anterior and posterior CMs assessment will not be needed. A surgical blade was used for resecting the CMs (superior, inferior, medial and lateral) to render the thickness of the CMs as thin as possible. No procedures were required for distinguishing the inner and outer surface. They were then frozen and cut parallel, but not perpendicular to the largest surface area. CMs were defined as positive when in situ or invasive carcinoma was found intraoperatively by frozen-section analysis.
46090729|NCT03370640|Drug|SEP-363856|An oral 25 or 50mg dose of SEP 363856
46090730|NCT02648958|Drug|Dexmedetomidine|The dexmedetomidine group received the dexmedetomidine infusion at a rate of 0.4mg/kg/h after a loading dose of 0.5mg/kg for 10 minutes.
46090731|NCT02648958|Drug|normal saline|The control group received the normal saline infusion
46090732|NCT00887549|Drug|pemetrexed|Induction Therapy: 500 milligrams per square meter (mg/m^2), intravenous, day 1 of each 21 day cycle for the first 4 cycles; Maintenance Therapy: 500 milligrams per square meter (mg/m^2), intravenous, day 1 of each 21 day cycle until progression or unacceptable toxicity occurs
46090733|NCT00887549|Drug|cisplatin|Induction Therapy: 75 mg/m^2, intravenous, day 1 of each 21 day cycle for the first 4 cycles
45459298|NCT02565914|Drug|IVA|
45678097|NCT02013791|Drug|Vehicle|Vehicle of cyclosporine administered as per protocol
45678098|NCT02013791|Other|Sham|Sham administered to non-study eye as per protocol on Day 1
45678099|NCT02013791|Drug|Cyclosporine New Ophthalmic Formulation|Cyclosporine New Ophthalmic Formulation administered as per protocol
45678100|NCT02024867|Drug|Trimethoprim-Sulfamethoxazole|3 versus 10 days of drug
45678101|NCT01953601|Drug|Verubecestat 12 mg (Parts 1 and 2)|Verubecestat 12 mg oral tablet, given once daily.
46005418|NCT00567294|Behavioral|Mailed education|Mailed education materials on osteoporosis and medication use over a 1-year period
46005419|NCT00567294|Behavioral|Telephone coaching program for patients|A telephone coaching program that will involve twelve monthly 5- to 10-minute phone calls from a health educator who is specially trained in osteoporosis. The phone calls will involve coaching participants on behavioral reinforcement strategies that will help them to continue taking their medications on schedule; phone calls will also include specially tailored education on osteoporosis and fracture prevention. A close family member or friend of the participant will also be contacted via phone two times during the study by the health educator. During these phone calls, the family member or friend will learn how to support the participant in such a way that medication adherence is more likely.
46005420|NCT00567294|Behavioral|Medication adherence alert program for doctors|Doctors of participants will receive written educational information on the rates of medication adherence, implications of nonadherence, and methods for improving adherence among people with osteoporosis. Doctors will also receive alerts on any patients who are not filling their medication prescriptions.
46005421|NCT04624412|Other|Continuous Aerobic Moderate Intensity Exercise|"Continuous Aerobic Moderate Intensity Exercise~5-10 min warm up~30 min moderate aerobic exercise (Treadmill walking exercise)~Constant intensity at 50% - 70% of max HR (3-6 METS)~5-10 min cool down"
46005422|NCT04624412|Other|Continuous Aerobic (Mild intensity Exercise)|"Continuous Aerobic (Mild intensity Exercise)~5-10 min warm up~30 min mild aerobic exercise (Treadmill walking exercise)~Constant intensity at 30-50 % of max HR (1-3 METS)~5-10 min cool down"
46005423|NCT04590924|Procedure|Hip arthroscopy|Patients that had hip arthroscopic surgery 5 years ago will be invited for 5 year follow up. The surgical procedures consisted of femoral osteoplasty, labral refixation and acetabular osteoplasty
46005424|NCT04624217|Drug|SHR-1701|PDL1/TGFβ
46005425|NCT00567333|Other|Chiropractic care|A combination of professional therapies with the scope of practice, including spinal manipulation therapy, spinal mobilization, stretching and strengthening exercises, and self-care education.
45678102|NCT01953601|Drug|Verubecestat 40 mg (Parts 1 and 2)|Verubecestat 40 mg oral tablet, given once daily. Verubecestat 40 mg given to participants in Arm C continuing to study Part 2.
45678103|NCT01953601|Other|Placebo (Part 1)|Placebo matching verubecestat, given once daily as an oral tablet.
45678104|NCT01952665|Device|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
45678105|NCT01952665|Device|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
45678106|NCT01952041|Behavioral|Device: Smartphone|
46005426|NCT00567333|Other|Multidisciplinary, integrative care|A combination of therapies which may include acupuncture/Oriental medicine, chiropractic, cognitive behavioral therapy, exercise therapy, medicine, self-care information, and massage therapy.
45678107|NCT01952041|Behavioral|Treatment as usual|
45678108|NCT04416529|Behavioral|Tele-MBCT|Please see arm/group description.
45678109|NCT04668235|Drug|AZVUDINE|5 tablets QD + standard treatment for up to 14 days
46005427|NCT04623866|Drug|Huaiqinhuang|Huaiqihuang granules are composed of Huaier fungus, Fructus lycii and Huangjing. Studies have shown that huaiqihuang treatment can reduce cytokines in children with purpura nephritis interleukins IL - 4, IL - 10 and the tumor necrosis factor alpha (TNF alpha) expression level, prompt huaiqihuang granule treating children allergic purpura nephritis can significantly improve the clinical curative effect, improve the level of cytokines and the patient's immune function, and does not increase the incidence of adverse reactions.
46005428|NCT04623866|Drug|valsartan|Valsartan granules 80mg/1.73m2 based qd 24 weeks
46005429|NCT00567372|Drug|bevacizumab (Sub-tenon´s injection)|a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)
45836328|NCT05215392|Behavioral|Family Connections program|Family members in the experimental group of this study will receive an ecological momentary intervention (EMI) derived from an ecological momentary assessment (EMA) via the Family Connections smartphone app. Family members in this condition will receive the manual of Family Connections which contains all the information on the program sessions conducted and the skills training strategies in writing.
46090734|NCT03221660|Device|F-Composite 2 system|Procedures will be done using local anesthesia (if the patients wants that). The cavity is prepared according to the principles of the adhesive technique. First the adhesive will be applied and polymerized, afterwards the flowable resin-based restorative material will be applied and polymerized and then the sculptable resin-based restorative material will be applied and polymerized; all materials will be light-cured within short time with an experimental curing light.
46090735|NCT04243811|Device|Diode Laser|LLLT with dental needle for local anesthesia during dental treatment
46090736|NCT04243811|Other|topical anesthesia|topical anesthesia with dental needle for local anesthesia during dental treatment
46005430|NCT00562133|Drug|Insulin Glulisine|100 IU/ml, 0.10 U/kg immediately before ingestion of a standardised liquid meal
46005431|NCT00562133|Drug|Insulin|100 IU/ml, 0.10 U/kg 15 Minutes before ingestion of a standardised liquid meal
46005432|NCT00567411|Drug|brimonidine 0.1%|1 drop, 1 hour prior to selective laser trabeculoplasty (SLT)
46005433|NCT00567411|Drug|Apraclonidine 0.5%|1 drop applied 1 hour prior to SLT
46090737|NCT00651222|Other|No intervention was required|Death records were reviewed, therefore, there was no intervention
45459299|NCT03881020|Drug|Silver diamine Fluoride 38%|In the intervention group 38% Silver Diamine Fluoride will be applied to the surface of the isolated lesion for a period of 1 minute followed by glass ionomer restoration at the same visit.
45678110|NCT04668235|Drug|AZVUDINE placebo|5 tablets QD + standard treatment for up to 14 days
45678111|NCT01951573|Device|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily wear, daily disposable use
45678112|NCT01951573|Device|Lotrafilcon B multifocal contact lenses|Silicone hydrogel multifocal contact lenses with a labeled indication for daily wear and extended wear use of up to 6 days with monthly replacement
45678113|NCT02023697|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|
46090738|NCT00639236|Other|hypertonic saline|inhaled hypertonic saline (at a dose of 5 ml of a 3% solution) three times a week, combined with a program of physical exercises.
45678114|NCT01951417|Drug|Adapalene/BPO Gel|Adapalene/Benzoyl Peroxide (BPO) Gel Pump (once daily)
45678115|NCT01951417|Other|Moisturizer SPF 30|Moisturizer SPF 30 (once daily)
46090739|NCT00638300|Device|large pore (FX80) compared to small pore dialyzer (F8HPS)|Effect of pore size
46090740|NCT00638300|Other|Dialysate bicarbonate of 33 mEq/L compared to 40 mEq/L|Effect of dialysate bicarbonate concentration
46090741|NCT00638300|Other|Dialysate calcium of 3 mEq/L compared to 2.5 mEq/L|Effect of dialysate calcium concentration
45678116|NCT01951417|Other|Foam Wash|Foam Wash (twice daily)
45836329|NCT00142116|Drug|Thalidomide|200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks.
45836330|NCT00142116|Drug|Rituximab|Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.
45836331|NCT05201430|Drug|FOLFOXIRI|irinotecan* 165 mg/m² iv continue for 1.5 hours, D1 oxaliplatin 85 mg/m² iv continue for 2 hours, D1 leucovorin 400 mg/m² iv continue for 2 hours, D1 5-FU 2400~3200 mg/m² cont. inf. 48h, D1 repeat every 2 weeks (Q2W)
46005434|NCT00562172|Drug|Insulin glargine|Once daily in the morning
46005435|NCT00562172|Drug|Glimepiride|Once daily in the morning
46090742|NCT00887315|Drug|Docetaxel and cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 IV repeated every 21 days for 2 additional cycles. For patients randomized to group 1, the chemotherapy is identical to that administered for the first 2 cycles
46090743|NCT00887315|Radiation|Docetaxel and cisplatin Plus Hypofractionated Radiotherapy|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 IV for 2 cycles along with hypofractionated radiotherapy to all known sites of disease
45678117|NCT01951261|Procedure|Telemonitoring and telephone control|Early assisted discharge from hospital due to an exacerbation of chronic obstructive pulmonary disease, with telemonitoring of vitals signs (oxygen saturation, heart rate, respiratory rate, blood pressure, temperature and electrocardiogram)and telephone control dairy (morning, evening)by the pulmonologist.
46005436|NCT00562172|Drug|Metformin|At least 1000 mg/day
46005437|NCT00567450|Drug|ropivacaine|30ml of a mixture of ropivacaïne 0.75%
46005438|NCT00567450|Drug|ropivacaine plus mepivacaine|30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
46005439|NCT00562211|Drug|LidoDyn|Application of 2 gram of LidoDyn to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
46005440|NCT00562211|Drug|EMLA creme|Application of 2 gram of EMLA creme to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
46090744|NCT02645916|Drug|Danggui-Sayuk-Ga-Osuyu-Saenggang-tang|Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
45678118|NCT02023151|Drug|Omalizumab|
45678119|NCT04667767|Other|WASH kit|WASH kit containing a plastic container and a supply of Aquatabs® (effervescent chlorine tablets) and training in their use and associated hygiene practices.
46090745|NCT02645916|Drug|Placebo: corn starch|Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
46090746|NCT02688998|Device|venous access PORT or PICC|Participants will receive a venous access prior to starting chemotherapy
45459300|NCT03881020|Procedure|Conventional atraumatic restorative treatment|In the active comparator group caries will be removed from primary molars using sharp excavators then teeth will be restored using glass ionomer filling material at the same visit.
45678120|NCT04667767|Other|Standard treatment|National standard outpatient treatment for uncomplicated severe acute malnutrition
45678121|NCT04667585|Radiation|De-escalated radiation dose|Reduced dose of radiation applied to remaining radiation therapy when favorable interim PET-CT signature is produced
45678122|NCT04667585|Radiation|Standard radiation dose|Standard dose of radiation applied to remaining radiation therapy when favorable PET-CT signature is not produced
45678123|NCT04667585|Other|18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT)|The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
45678124|NCT04643743|Device|Endarterectomy|Endarterectomy is a surgical procedure to remove the atheromatous plaque material, or blockage, in the lining of an artery constricted by the buildup of deposits. It is carried out by separating the plaque from the arterial wall.
45678125|NCT01979185|Drug|Simvastatin|
45678126|NCT01979185|Drug|SSP-004184SS|
45459301|NCT03485872|Other|Self-Screening and Referral Information|Urinary incontinence self-screening questionnaire, fact sheet and self-referral information will be provided by mail or email.
45459302|NCT03485872|Other|Standard Care|Demographic and quality of life questionnaires; standard care provided by participants' GPs
46005441|NCT00567528|Drug|Ibuprofen|Apply by rubbing into skin for 30 to 60 seconds placebo ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking active capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
46005442|NCT00567528|Drug|ibuprofen|Apply by rubbing into skin for 30 to 60 seconds active ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking placebo capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
46005443|NCT01154140|Drug|treatment|crizotinib 250mg orally continuous twice daily dosing
45678127|NCT01946425|Biological|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2013-2014 formulation)
45678128|NCT01946425|Biological|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.5 mL, Intramuscular (2013-2014 formulation)
45459303|NCT03841708|Device|Pleth variability index|The utility of a early goal directed therapy will be evaluate by the pleth variability index (PVI). If above>13% in a well sedated patients perfectly synchronized with the ventilator providing at least 6ml/kg of ideal body weight, a fluid challeng with 10ml/kg of NaCl 0,9% will be administrated. Patient will be constantly re-assessed until the hemodynamic goals of a mean arterial pressure above 65 mmHg, a capillary refill time below 3 seconds, a decreasing trend on lactates and a urinary output above 0.5/ml/kg/h will be achieved. The second fluid challenge will always be performed with 100 ml of albumin 20%. The third fluid challenge if necessary will be performed with 10 ml/kg of NaCl 0.9%.
46005444|NCT01154140|Drug|treatment|pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice
46005445|NCT04623749|Procedure|US|Percutaneous Ultrasound guided FNAC
46005446|NCT04623749|Procedure|EUS|Endoscopic Ultrasound guided FNAC
46090747|NCT02645994|Device|Target Controlled Infusion|Used to control intravenous propofol delivery with target plasma concentratioins changed manually
46090748|NCT02645994|Device|Closed Loop Anesthesia Delivery System|Used to deliver propofol automatically titrated to achieve a target BIS 50, and maintain it between 40 and 60.
46090749|NCT04243031|Device|QFT Access|Measure of Interferon Gamma
46090750|NCT02645838|Behavioral|Motivational interviewing|1. Structural motivational interviewing for one section (about 20 mins)，provided by family physician;2. Follow-up telephone call，provided by family physician.
46090751|NCT04242719|Device|Electromagnetic stimulation|Retinal electromagnetic stimulation A high-frequency repetitive electromagnetic stimulation protocol has been defined in the literature and was applied in groups 1 and group 2 via a novel device developed specifically for ophthalmic usage (Magnovision-TM, Bioretina Biyoteknoloji AŞ, Ankara,Turkey). The patients underwent 10 consecutive sessions of rEMS application. Parameters for the treatment were 42 hertz frequency/min, 30 minutes of duration and mild operating cycle. The power of the electromagnetic field was 2000 milligauss, which is a very low dose and within the safety limits of World Health Organisation. In group 2, sub-tenon aPRP injections were also performed immediately after the first, fifth, and tenth sessions of rEMS application.
45683803|NCT03164278|Behavioral|Independent Transfer Training|Independent Transfer Training Program: ITTP training starts with an overview and self-evaluation using the transfer assessment instrument questionnaire (TAI-Q) followed by three core modules: wheelchair setup, body setup, and flight/landing. Wheelchair setup includes factors such as the angle and distance of the wheelchair to the transfer surface, removing barriers, applying the brakes, and height of the transfer. Body setup involves positioning one's body for an optimal transfer and covers foot, hip, arm and hand positions. Flight/landing discusses how to achieve a smooth and controlled transfer, the head-hips relationship, use of transfer device, and safe landing.
45683804|NCT03164122|Drug|injection of microfat and plasma rich platelet PRP|intra-articular injections
45683805|NCT03164122|Device|MRI|MRI 3T
46005447|NCT00567606|Other|risedronate, calcium/vit D, strength weight training|G1 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week and strength/weight training exercises for upper and lower extremities and the spine. G2 group receives the calcium, vitamin D, and risedronate, but do not participate in strength/weight training exercises.
46005448|NCT04590768|Other|Fermotein based meals|various meal products: bread, soup and an occasional burgers
46005449|NCT04590768|Other|Matching control meals with whey protein and wheat bran|various meal products: bread, soup and an occasional burgers
46005450|NCT04623788|Diagnostic Test|Cardiac MRI|Cardiac MRI with contrast
46005451|NCT04590612|Drug|Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet|25mg-100mg tablets to be taken orally three times a day on an empty stomach
46005452|NCT04590612|Drug|Citalopram|20 mg tablet to be taken orally once and at the same time of the day, daily.
46005453|NCT04623476|Procedure|Pathophysiological Excision for Crohn's disease|Pathophysiological excision for Crohn's (PEC) requires a medio-lateral approach and a high vascular tie, which enables excision of lymph nodes draining the disease bowel. This procedure should not alter length of bowel resection and no additional risks are foreseen. A latero-lateral anastomosis will be fashioned following current guidelines.
46005454|NCT04590378|Other|intensive care unit admission ratio|intensive care unit admission ratio
46005455|NCT04590339|Procedure|Guided inferior Alveolar Nerve lateralization|Evaluating neurosensory recovery after Implant placement in posterior atrophic mandible by Guided inferior alveolar nerve lateralization technique
46005456|NCT04623164|Drug|Cocktail from complex phytoadaptogens (CFA)|Cocktail from complex phytoadaptogens (CFA) is composed from 70% alcohol extracts of Glycyrrhiza glabra, Rhodiola rosea, Acantopanax senticosus in the ratio 2:1:1. Application of CFA in 3 group was carried out after non-surgical periodontal therapy (NSPT). After NSPT the patient filled out an Estberg questionnaire to determine the chronotype. After processing the questionnaire, a chronotype was identified and the patient was prescribed CFA dosage. Application of CFA was carried out in the periods of exacerbation of chronic periodontitis within 28 days with a dosage of CFA depending on the chronotype of the person - morning chronotype at 45 drops in the morning before 10.00 o'clock; independent chronotype 20 drops 3 times a day; evening chronotype 30 drops at 14.00 o'clock and 20 drops at 19.00 o'clock.
45459304|NCT03841708|Device|Standard non invasive monitoring|In the control group patients will be hemodynamically resuscitated in the early phases after ROSC based on standard non invasive monitoring such as SatO2, EtCO2, non invasive blood pressure and continuous ECG. If deemed necessary by the treating physician a fluid challenge of 10ml/kg of NaCl 0,9% will be administrated. Patient will be constantly re-assessed until the hemodynamic goals of a mean arterial pressure above 65 mmHg, a capillary refill time below 3 seconds, a decreasing trend on lactates and a urinary output above 0.5/ml/kg/h will be achieved. The second fluid challenge will always be performed with 100 ml of albumin 20%. The third fluid challenge if necessary will be performed with 10 ml/kg of NaCl 0.9%.
45459305|NCT01367600|Drug|SC Methylnaltrexone (MNTX)|
45459306|NCT03720730|Other|EMA|"The mobile application (EMA) combines an explicit data collection with an implicit one.~For the explicit data collection with Memind application, patients will have to answer specific questionnaires about sleep, appetite and social factors. Some of the questions will be asked on regular basis, at the same time everyday, while others will be asked randomly during the day (between 9 a.m and 9 p.m).~The implicit data collecting will be carried out using smartphone sensors (application eB2)."
45459307|NCT01367678|Device|Laryngeal Mask Airway Supreme|Directly measured mucosal pressures
45459308|NCT01367678|Device|i-Gel extraglottic airway device|Directly measured mucosal pressures
45683806|NCT04397770|Drug|SHR1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
45836332|NCT05201430|Drug|CapeOX|oxaliplatin 130 mg/m2 iv continue for 2 hours, D1 capecitabine 1000mg/m2/d PO Bid, once every morning and evening D1-14 repeat every 3 weeks (Q3W)
45836333|NCT05188560|Other|Action observation therapy|Subject is asked to observe videos with motor contents
45836334|NCT05188560|Other|motor imagery|mental simulation of a motor task
46005457|NCT04623164|Procedure|Standard non-surgical periodontal treatment (NSPT)|Oral hygiene instructions (including brushing technique, the use of interdentally flosses, and/or brushes), NSPT (mouth scaling and root planing using an ultrasonic scaler UDS-L LED (Woodpecker, China) and Graceys curettes (Hu Friedy, Chicago, USA)). The treated periodontal pockets were irrigated with 0.12% chlorhexidine gluconate. Patients were given recommendation to rinse their mouth three times daily for 14 days using 0.12% chlorhexidine gluconate
46005458|NCT00562250|Drug|Dapagliflozin|Tablets, Oral, 20 mg, once daily, single dose
45678129|NCT01946191|Behavioral|24 months of personalized coaching through the EHR patient portal, with 24 scheduled contacts.|Participants were assigned to a specific coach, who contacted the participants via the EHR weekly for 1 month, biweekly in months 2 to 6, monthly in months 7 to 12, and quarterly in months 13 to 24, for a total of 24 scheduled contacts. Coaching group participants received brief questionnaires relevant to weight management, including a text field where they could discuss questions or barriers. On the basis of participant responses and self-monitoring data in the EHR flow sheets, coaches wrote a brief personalized note with advice on questionnaire topics and responses to any queries or barriers mentioned by the participant. Coaching participants who did not complete questionnaires or log information into the flow sheet for 2 weeks were considered inactive and were contacted by telephone or e-mail and invited to reengage at any time. Coaching participants were able to send secure messages to the coach.
45678130|NCT01946191|Behavioral|Online self-monitoring|Participants were encouraged to log in daily and enter data on weight, diet, and physical activity.
45459309|NCT03487042|Drug|Bimatoprost 0.03% ophthalmic solution|"Each patient will be subjected to the following:~One side will be treated by narrow band ultraviolet rays B sessions twice weekly for 3 months + topical bimatoprost 0.03% solution twice daily ( 1 drop for each 2 cm2 ) and the other side will be treated by topical bimatoprost 0.03% twice daily ( 1 drop for each 2 cm2 ) + narrow band ultraviolet rays B sessions twice weekly for 3 months + 10.600-nm fractional carbon dioxide laser sessions twice monthly for 3 months.~Patients' Evaluation:~The recruited patients will be subjected to:~A) Full history taking. B) General clinical examination. C) Dermatological examination of the skin lesions. D) Vitiligo area scoring index score will be calculated for each patient E) Clinical photographs will be taken at baseline, after each month during treatment and after the end of treatment by 3 months.~F) A skin biopsy from the treated lesions for histochemical examination. F) Dermoscopic evaluation of the treated sites every 2 weeks."
45459310|NCT03373084|Other|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) or ultrasound will be performed to determinate location of the lesion
46005459|NCT00562250|Drug|Glimepiride|Tablets, Oral, 4 mg, once daily, single dose
45459311|NCT03373084|Other|ultrasound|Magnetic Resonance Imaging (MRI) or ultrasound will be performed to determinate location of the lesion
45459312|NCT03373084|Other|Self-questionnaire|Self-questionnaire will be completed by patient. In this questionnaire patients will describe the circumstances of the injury and their personal characteristics and level of sporting practice.
45459313|NCT02150564|Device|Sonowand|Initially a 2D acquisition will be performed and ultrasound parameters adjusted to obtain the best image resolution. Then anatomical landmarks will be identified if possible and the lesioncharacterized. Once the lesion is identified a rapid 3D-US acquisition will be performed. Tumor resection will proceed guided by the 3D US images using a trackable pointer to navigate. Repeat 3D US images will be obtained as many times as required during the surgery to update the information as tumor debulking proceeds. A final US will be obtained at the end of the procedure and after dural closure
45459314|NCT02150564|Procedure|Navigation|Routine microneurosurgical procedures would be adopted in all cases.Sonowand system will be used for navigation control arm as well as sononavigation experimental arm. Image registration (on the previously imported DICOM images) will be done on the system and after positioning, patient-toimage registration will be completed. The Registration accuracy will be documented.
46005460|NCT00562250|Drug|Dapagliflozin + Glimepiride|Tablets, Oral, Dapagliflozin 20 mg + Glimepiride 4 mg, once daily, single dose
46005461|NCT00562289|Drug|aspirin|during the follow up
46005462|NCT00562289|Drug|Antivitamins K or rivaroxaban or dabigatran or apixaban|during the follow up
46005463|NCT00562289|Device|Devices for PFO closure|endovascular treatment no longer than 21 days after the random.
46005464|NCT01154101|Drug|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
45678131|NCT01946191|Behavioral|Real-time updates to Primary Care physicians|Referring PCPs of coaching group participants received regular support, including real-time progress reports with counseling tips delivered via the EHR, notification of weight change in increments of at least 10 pounds, and annual progress reports at 12 and 24 months.
46005465|NCT01154101|Drug|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule, packaged in dosing bottles containing a single daily dose.
45342455|NCT02573688|Behavioral|Interdisciplinary Therapy|The nutrition intervention will consist of group meetings and prescription of individual diets. Participants will have dietary lessons, with information related to the improvement of food consumption and nutritional quality. Exercise program will be focused on improving activity habits, leading to increased energy expenditure. They will undergo training sessions containing aerobic and resistance training. In Psychological program, participants will be monitored in the support group and, if necessary, individual psychological therapy is recommended. The sessions will discuss common psychological aspects commonly associated with obesity (depression, anxiety, stress, family problems, body image, eating disorders and others). The physiotherapy interventions aim to increase functional capacity.
45473942|NCT03743779|Behavioral|Mastering Diabetes|"The Mastering Diabetes provides a step-by-step program to transition to a low-fat, plant-based, whole-food lifestyle and reduce overwhelm. The program also provides direct access to expert coaches in the online community, which contains others living with all forms of diabetes. I includes access to live Q&A videoconferences twice per month to interact with coaches and personalize the experience.~The program is designed with seven core modules. Many participants continue in the program after completion of the modules for ongoing support.~The cost was $29/month or $249/year, but as of July 2018, only the $249/year option is offered."
46090752|NCT04242719|Biological|Platelet rich plasma|About 20 ml of blood was drawn from the patient's antecubital vein and inserted into two 10-ml vacutainer tubes that contain trisodium citrate (T-LAB PRP Kit, T-Biyoteknoloji, Bursa, TURKEY). These tubes were placed in a refrigerated (+4 °C) centrifuge (Nüve NF 1200R, Nüve Laboratuar Teknolojileri, Ankara, TURKEY) and spun at 2500 rpm (580×g) for 8 min within 30 min of collection. Three different layers formed in the tubes: red blood cells at the bottom, platelet-rich plasma in the middle, and platelet-poor plasma in the top layer. A total of 1.5 ml of the middle layer (which mainly contained platelets) was withdrawn by syringe and immediately injected into the sub-tenon space of each eye after topical anesthesia with proparacaine hydrochloride (Alcaine, Alcon, USA) drops.
46090753|NCT04166760|Dietary Supplement|speWHE|25 gram of a specific whey fraction (confidential)
46090754|NCT04166760|Dietary Supplement|WHE|25 gram protein of a regular whey compound
46090755|NCT04243967|Other|Music therapy|"On the surgery day, the patient is accompanied by music-therapist all the way from her room to the operating theatre in order to monitor and adapt music-therapy intervention.~The patient, prior to the anesthetic, take faces 3 phases of music therapy intervention (1 hour):~1° Phase Active Music therapy: the patient takes part in a session of live improvisational music therapy, with the therapist, to elaborate pre-operative stress.~2° Phase Relaxation with Receptive Live Music: music therapist play live to relax patients with autogenic training and tunnings breathing.~3° Phase playlist listening based on the patient's needs. Patients listen to music with an mp3 player with earphones within the ear canal (H&H CE mp3/Usb; Headphones on Air in-ear with volume control) with a maximum volume of 60 dB (previously set with a sound level meter)."
46090756|NCT04243967|Other|Control|Standard perioperative management including perioperative care (without the use of music / music therapy)
46005466|NCT04313218|Drug|Carbetocin|iv infusion of 100ug carbetocin after extraction of the fetus during cesarean section
46005467|NCT04590261|Other|Blood sampling|Peripheral Blood sampling, 25 mL
46005468|NCT04590261|Other|Nasal Brushing|Nasal Brushing, facultative
46090757|NCT00652236|Other|Physiotherapy|The two groups passed an in-patient rehabilitation and a physiotherapy: FCT function-centred vs. PCT pain-centred
46090758|NCT02645682|Device|anti-infection CVC|
46090759|NCT02645682|Device|normal CVC|
46090760|NCT03014648|Drug|Atezolizumab|Atezolizumab will be administered through an IV over 60 minutes at a dose of 1200mg on Day 1 of each 21-day cycle. If the first dose is tolerated without any infusion-related adverse events, the following doses can be administered over 30 minutes.
46090761|NCT04244045|Other|Suboccipital muscle inhibition|"The patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side; distal hand of the therapist on planter surface of foot for dorsiflexion. and proximal hand on the knee to increase the length of the muscle, maintain this stretching for 60 seconds then relax .Sub occipital muscle inhibition:~The Patient is supine, The therapist stretch the sub occipital, flexes the head of the patient to get the chin to the manibiurim sternii, maintaining this position for 60seconds then relax Slump strtch position:Patient in comfortable short sitting position at the edge of the bed with the trunk in an millitary straight position then ask the patient to slump the flex his neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot"
45678132|NCT01959698|Drug|Carboplatin|Given IV
46005469|NCT00624871|Drug|Ascorbic acid (vitamin C)|IV, 100 mg/kg/day, every day, for 3 days
46090762|NCT02645058|Procedure|RIRS|Treatment by ureterorenoscopy (RIRS) and laser lithotripsy
46090763|NCT02645058|Procedure|ESWL|Treatment by extracorporeal shock waves lithotripsy
46090764|NCT02645058|Device|Rigid and flexible ureteroscope|
46090765|NCT02645058|Device|Lithotripter|
46090766|NCT02645058|Device|Holmium laser|
45678133|NCT01959698|Drug|Carfilzomib|Given IV
46005470|NCT00624871|Drug|Ibuprofen|PO, 10 mg/kg on day 1, 5 mg/kg/day on days 2 and 3 of life
46005471|NCT00624871|Drug|Placebo|
46005472|NCT01153984|Drug|Erlotinib|Erlotinib 150 mg oral doses will be administered daily.
46090767|NCT02645058|Device|Basket for fragment removal|
46090768|NCT02645058|Procedure|General or spinal anesthesia|
46090769|NCT02645058|Drug|Intravenous pain medication|If required by the patient
46090770|NCT02645058|Device|X-ray|To focus the stone
46090771|NCT02645058|Device|Ultrasound|To focus the stone
46090772|NCT02577224|Other|Patient-initiated treatment|Please see Intervention Arm
45678134|NCT01959698|Drug|Etoposide|Given IV
46005473|NCT02884375|Other|Extensive GA|"GA includes an evaluation of nine domains according to international recommendations :~functional status (six-item Activities of Daily Living (ADL) score, Instrumental Activities of Daily Living (IADL))~mobility (timed get-up-and-go test, one-leg standing balance test, history of fall)~nutritional status (French National Authority of Health guidelines, weight loss body mass index (BMI), Mini Nutritional Assessment, albumin )~cognitive status (Mini-Mental State Examination (MMSE), history of dementia, confusion)~mood (Mini-Geriatric Depression Scale (Mini-GDS), symptoms of anxiety, depression (DSM V))~comorbidities (CIRS G)~polypharmacy (number of medications)~social environment (primary caregiver, support at home, friends , family, living alone)~urinary and/or fecal incontinence"
46090773|NCT02826785|Behavioral|Cognitive strategy training|The intervention teaches strategies in a way that promotes generalization and enhances daily function . It includes four core elements known to enhance learning transfer: (1) self-generation of broadly applicable strategies, (2) practice across multiple contexts and activities, (3) emphasis on metacognition, and (4) use of meaningful everyday activities.
45459315|NCT03486886|Diagnostic Test|PSMA -PET/CT scanning|"PET/CT scanning is performed on hybrid PET/CT scanners. Patients should fast for at least 4 hours to facilitate transit of oral contrast into the distal small bowel. An oral contrast product can be administered and [18F]-DCFPyL is injected by IV rapid bolus followed by saline flush. 80-100 minutes following [18F]-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the upper thighs. An MRI of the questioned lesion sites may be performed.~Uptake of lesions is measured with SUVmax. Hepatic and blood pool SUV is determined for the computation of tumor-to-liver and tumor-to-blood ratios.~15 patients max will undergo a second PSMA-PET scan on the same camera with the same protocol using a different tracer batch within 2 weeks of the initial PSMA-PET evaluation in order to determine test-retest repeatability of the imaging procedure using a Bland-Altman analysis (per lesion analysis)."
46090774|NCT02826941|Other|hypothermia|Systemic hypothermia by Cincinnati Sub-Zero Blanketrol II®, servo-controlled to 33.0 degrees C rectal temperature, started within 6hours of hypoxic ischemic birth, and continued for 48hours
46090775|NCT02826941|Other|normothermia|Rectal temperatures in neonates receiving normothermia were maintained at 37.0+or -0.5 degrees C, using overhead warmer or Cincinnati Sub-Zero Blanketrol II®, servo-controlled to rectal temperature of 37.0 degrees C.
46090776|NCT02825459|Behavioral|Abstinence from e-cigarettes|Abrupt cessation for 6 days
46090777|NCT02644980|Drug|Propofol|The initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40~60.
46090778|NCT02644980|Drug|Etomidate|The initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40~60.
46090779|NCT02644980|Device|Bispectral Index Monitor|BIS monitored from beginning of anesthesia induction to the end of the surgery.
45678135|NCT01959698|Drug|Ifosfamide|Given IV
46090780|NCT02644980|Drug|Induction of anesthesia|Midazolam 0.03 mg/kg injection vein，Sufentanyl 0.5~1 μg/kg, target controlled infusion of etomidate or propofol,after the consciousness of patients is lost, rocuronium 0.6mg/kg is given.
46090781|NCT02644980|Drug|Maintenance of anesthesia|After the intubation, target controlled infusion(TCI) of etomidate or propofol is maintained,rocuronium 0.15mg/kg and sufentanil is given when needed. When the operation is over, the TCI is stopped.
46090782|NCT02644980|Other|Tracheal Intubation|After the induction of anesthesia, Tracheal intubation is performed.
45459316|NCT03486808|Device|IFG stimulation|stimulating left inferior frontal cortex with transcranial direct current stimulation for 30 minutes
45473943|NCT03374878|Other|no oral contraceptive and training|10 weeks of training in a group of oral contraceptive users
45678136|NCT01959698|Other|Laboratory Biomarker Analysis|Correlative studies
45678137|NCT01959698|Other|Pharmacological Study|Correlative studies
45678138|NCT01959698|Biological|Rituximab|Given IV
45678139|NCT01910402|Drug|Dolutegravir/abacavir/lamivudine FDC|Dolutegravir/abacavir/lamivudine FDC tablets, 50 mg/600 mg/300 mg
46090783|NCT04187456|Drug|Savolitinib|Single dose (together with midazolam) on Study Day 5 after a high fat, high calorie breakfast.
46090784|NCT04187456|Drug|Midazolam|Single dose (alone) on Study Day 1 and single dose (together with savolitinib) on Study Day 5, both after a high fat, high calorie breakfast.
45678140|NCT01910402|Drug|Atazanavir|Atazanavir capsule 300 mg
45678141|NCT01910402|Drug|Ritonavir|Ritonavir tablet 100 mg
45678142|NCT01910402|Drug|Tenofovir/emtricitabine FDC|Tenofovir/emtricitabine FDC tablet 300 mg/200 mg of FTC
45678143|NCT01937312|Drug|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
45678144|NCT01937312|Drug|Vehicle|Inactive ingredients used as a placebo comparator
45678145|NCT01937312|Drug|Prostaglandin analogue|
45678146|NCT01909934|Drug|brentuximab vedotin|Brentuximab vedotin will be administered as a single intravenous (IV) infusion over 30 minutes on Day 1 of each 3 week cycle for up to a maximum of 16 cycles and should be administered for a minimum of 8 cycles for participants who achieve stable disease or better.
45678147|NCT04648904|Radiation|Radiotherapy|A total dose of 26 Gy in 5 fractions will be given once daily over 5 consecutive weekdays (or within 10 consecutive weekday to allow for treatment delays, interruptions, logistical problems, scheduling issues and weekends/holidays).
46090785|NCT02825537|Device|Compression stocking|A class III (20 to 36 mm Hg) elastic compression stocking according to the french classification
46090786|NCT02825537|Other|No use of compression stocking|No use of compression stocking
46090787|NCT03816644|Other|5-Cog|The 5-Cog is a 5 minute cognitive screen which will identify patients with 'cognitive impairment' from those with 'no cognitive impairment'.
45342456|NCT00709644|Drug|Norgestimate; Ethinyl Estradiol; Folic acid.|
45342457|NCT00415597|Drug|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)|capsules, available dosage strengths 20, 30, 40, 50, 60, 80, and 100 mg morphine sulfate with 4% by weight naltrexone hydrochloride given once or twice daily
45342458|NCT04071054|Diagnostic Test|Carnation Ambulatory Monitor (CAM)|7-day detection of arrhythmias with Carnation Ambulatory Monitor (CAM)
45342459|NCT00714480|Drug|anti-thymocyte globulin|Administration of anti-thymocyte globulin at post-operative days -6, -4, -2 and 0
46090788|NCT03816644|Other|Health Literacy & Grip Assessment|The health literacy and grip assessment will take approximately 5 minutes, and will test the patient's comprehension and pronunciation of health-related terms as well as strength in their dominant hand. The screen will sort out patients with 'low health literacy' and 'frail (low grip strength)' from those with normal health literacy and normal grip strength.
46090789|NCT04168476|Other|Interscapular muscle release or scapular mobilization technique as described by Travell and Simons.|"Patient is sidelying with the testing side up. The auditor stands in front of the patient, reaches over the patient's shoulder to grasp the upper portion of the vertebral border of the scapula, and the other arm reaches under the patient's humerus to grasp the lower portion of the vertebral border of the scapula.~The auditor then slowly moves the scapula into elevation/depression, internal/external rotation/abduction and adduction.~To standardize the technique and be able to reproduce it in each participant, a set of 10 repetitions for each movement was performed in the same order."
46090790|NCT04168476|Other|Calcaneus abduction and adduction mobilization technique|Abduction and adduction mobilization of the calcaneus is carried out in the opposite side of the upper extremity measured.
46090791|NCT02827331|Other|Exposition to hypnotics or anxiolytics benzodiazepines|"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~Benzodiazepine derivatives (N05BA)~Benzodiazepine derivatives (N05CD)~Benzodiazepine related drugs (N05CF)"
45342460|NCT00714480|Drug|anti-thymocyte globulin|anti-thymocyte globulin post-operative days -2, 0, 2 and 4
45342461|NCT00714480|Drug|anti-thymocyte globulin|Post-operative days 0, 2, 4 and 6
45342462|NCT00714558|Drug|Fentanyl citrate; Naltrexone; Naloxone|
45342463|NCT00709800|Biological|VCL-IPT1|IM, 0.1 mg/mL, 2 injections, 0 and 21 days
46090792|NCT02827331|Other|Exposition to non benzodiazepines antidepressants, hypnotics or anxiolytics|"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~Antipsychotics (N05A)~Antiepileptics with the exception of clonazepam (N03)~Drugs used for alcohol dependance (N07BB)~Drugs used for opioids dependance (N07BC)"
46090793|NCT02827331|Other|Medical consultation without prescription|Medical consultation without prescription of any drugs of interest
46090794|NCT02827331|Other|Administrative and medical data|"Gender~Birthdate~Department of residence~City of residence~Vital status (month and date of death)~Affiliation to Universal Health Coverage~Number of chronic long-term illness, medical diagnostic or pathology (CIM 10 code), onset and end dates~Drugs reimbursements (Date of care onset, drugs identification code, number of box delivered)~Data collected from medicalisation program of information system and private and public home care structures~Medical consultations, medical acts ( Common Classification of Medical Acts nomenclature)"
46090795|NCT02653950|Procedure|Endoscopic septoplasty|Endoscopic surgery; septoplasty with or without middle turbenectomy
46090796|NCT02653950|Procedure|Traditional septoplasty|septoplasty under direct vision
46090797|NCT04185818|Other|Reading a book|"Participants requested to specify usual genre of book they read.~Fiction~Non-Fiction~Other~Don't usually read a book in bed"
46090798|NCT04242797|Device|Calmare|Skin is stimulated with an electrical voltage via electrode pads, variably distorted sine wave at ~47 Hz.
46090799|NCT04242797|Device|TENS|Skin is stimulated with an electrical voltage via electrode pads, 300 micro-second rectangle pulse at 47 Hz.
46090800|NCT02645448|Other|Resistance Exercise|"Control Session~Resistance exercise at different intensities (40%1RM or 80%1RM)~Duration of effect"
46090801|NCT02687204|Drug|Twice daily enoxaparin prophylaxis|Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
46005474|NCT04623203|Other|No intervention|No intervention
45678148|NCT04622384|Other|Dialysis weaning|Dialysis weaning as planned by the attending ICU-physician.
45678149|NCT04632836|Other|quality of life questionnaires|responses for quality of life questionnaires (WHOQOL-BREF questionnaire, study specific questionnaire, PSQI index, HADS scale)
45678150|NCT04622150|Behavioral|Customized Adherence Enhancement (CAE)|CAE is comprised of a series of up to four treatment modules whose inclusion is determined based upon an individuals reasons for nonadherence (adherence barriers).The standardized modules are Psychoeducation, Modified Motivational Interviewing, Communication with Providers, Medication Routines. CAE participants will have a core series of approximately four sessions spaced about one week apart over a period of 4-6 weeks, and one booster in-person session 4 weeks after the completion of the four core sessions (total of approximately 5 sessions). Sessions 2-4 will be delivered remotely by the study interventionist. All participants will have the first session in-person. The final booster session will be conducted at the sites and will review all previously introduced materials. There will be a follow-up phone call with the study interventionist that will occur in the four-week time period between completion of four CAE core sessions and prior to initiation of the booster CAE session.
45678151|NCT04622150|Behavioral|Enhanced Treatment as Usual (eTAU)|eTAU participants will receive monthly text messages (or phone calls for participants who prefer not to receive texts) to refill medications, fill eCAPs and brief general adherence promotion messages during the follow-up period.
46005475|NCT05250271|Other|15 g dextrose|15 g dextrose tablets
46090802|NCT02687204|Drug|Real time dose adjustment|Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
46090803|NCT04242485|Other|Osteopathic manipulative treatment|Each osteopathic manipulative treatment consisted of a structured evaluation to diagnose somatic dysfunction of the pelvis, abdomen, vertebral spine, and upper and lower limbs (10 min), followed by the therapeutic application of manually guided forces to improve physiological function and homeostasis that has been altered by somatic dysfunction for 20 min, using techniques that were left at the discretion of the osteopath, including the myofascial release and cranial sacrum techniques
45678152|NCT01935128|Drug|Arm 1 Everolimus/Reduced dose tacrolimus|Immunosuppression drug intervention
45678153|NCT01934972|Other|CR + DCS (D-cycloserine)|CR + DCS
45678154|NCT01934972|Other|CR + placebo|CR + placebo
45678155|NCT01959230|Drug|Brimonidine Tartrate|Ophthalmic solution to be applied as directed.
45678156|NCT01959230|Drug|Vehicle|Ophthalmic solution to be applied as directed.
45678157|NCT01959230|Drug|Sodium Fluorescein|For use as needed during the study for evaluating corneal damage.
45678158|NCT01959230|Drug|Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP|For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
46005476|NCT05250271|Other|5 g dextrose|5 g dextrose tablets
45678159|NCT01909778|Drug|BI 201335|single oral doses
46005477|NCT05250271|Other|Protein bar|5 g carbohydrates + 10 g protein
46005478|NCT04623359|Device|High resolution manometry|High resolution manometry
46090804|NCT04242485|Other|Sham treatment|"The sham treatment consisted only in soft touch of the same body areas involved in the osteopathic manipulative treatment protocol without applying any pressure"
46090805|NCT03608826|Device|Investigational LINQ™ HF RAMware|The Reveal LINQ™ device and the 2090 programmer are market-released, but once the investigational LINQ™ HF RAMware is downloaded into the devices, they are considered investigational.
46090806|NCT02825615|Procedure|Radial artery cannulation|Radial artery cannulation done with conventional and ultrasound guidance in two respective groups of patients and their first pass success and ultimate success rates compared in different hemodynamic subsets of the patients.
46090807|NCT04242641|Behavioral|WW|WW is a structured lifestyle modification, weight-loss programme involving a programme for healthy eating, physical activity and positive mindset and support via attendance at local WW workshops and digital tools.
46090808|NCT04185740|Device|CloudUPDRS - Tapping Task|The TTT, consisting of two targets, will be presented on the screen of the smartphone. Participants will be instructed to alternate between the two targets using their index finger for 30 seconds. The task will always be performed with the left hand first and then with the right hand. The touch-sensitive screen of the smartphone will measure the timing of each touch event, its duration, the coordinates on the phone screen and the amount of pressure applied.
45678160|NCT04648202|Drug|FS120|Dosing of participants with FS120 or the combination will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) or once every 3 weeks (Q3W) until confirmed progressive disease (CPD)/immune-confirmed progressive disease (iCPD) or unacceptable toxicity.
46090809|NCT03601728|Behavioral|personalized prehabilitation|The 60-minute education session includes a 30-minute general education on exercise in older adults and a 30-minute instruction on participating in the study intervention (how to work with the personalized circadian-based activity guideline). The education session will be developed and presented by the PI and the certified exercise trainer. The general education session will be designed using materials from Go4Life program from the National Institute on Aging (https://go4life.nia.nig.gov). The personalized circadian-based activity guideline (exercise goal and plan) will be developed by the investigators and the exercise trainer based on the individual's typical daily circadian profile, functional status, preference for exercise.
46090810|NCT00650208|Drug|Lamotrigine Tablets 25 mg|2x25mg, single dose fasting
46005479|NCT01153633|Device|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|"The treatment procedures (after a 1 week run-in) include:~Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~Secondary dressing to be a semi occlusive dressing~Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
46090811|NCT00650208|Drug|Lamictal® Tablets 25 mg|2x25mg, single dose fasting
46090812|NCT02689232|Biological|Fresh Frozen Plasma|
46090813|NCT02689232|Biological|Platelets Concentrate|
45678161|NCT01977937|Drug|Gabapentin 250mg/5mL NDC:59762-5025-01|
45678162|NCT01977937|Drug|Simple Syrup|
45678163|NCT02015663|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder 112 mg (four 28-mg capsules) taken via inhaler once or twice a day, depending on study arm
45678164|NCT01978093|Biological|Hib-MenCY-TT (MenHibrix®)|4 doses administered intramuscularly (IM) in the right upper anterolateral thigh at Day 0, Month 2, Month 4 and Month 10-13 in the HibCY Group.
45678165|NCT01978093|Biological|Pediarix®|3 doses administered IM in the left upper anterolateral thigh at Day 0, Month 2 and Month 4. 2 doses administered IM in the left upper anterolateral thigh at Day 0 and Month 2 and 1 dose administered IM in the right upper anterolateral thigh at Month 4 in the PedHIB Group.
45678166|NCT01978093|Biological|Rotarix®|2 doses administered orally at Day 0 and Month 2 each in the HibCY Group and PedHIB Group.
45678167|NCT01978093|Biological|Prevnar 13®|4 doses administered IM in the left lower anterolateral thigh at Day 0, Month 2, Month 4 and Month 10-13 each in the HibCY Group and PedHIB Group.
45678168|NCT01978093|Biological|PedvaxHIB®|3 doses administered IM in the right upper anterolateral thigh at Day 0, Month 2 and Month 10-13 in the PedHIB Group.
46090814|NCT02689232|Biological|Cryo Precitipitate|
45678169|NCT01978093|Biological|Havrix®|2 doses administered IM in the left upper anterolateral thigh at Month 10-13 and Month 16-19 each in the HibCY Group and PedHIB Group.
45678170|NCT01951105|Drug|Naproxen|Take one 250mg naproxen tablet three times a day for 12 weeks.
45683807|NCT04397770|Drug|apatinib mesylate|apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
45683808|NCT04397770|Drug|Temozolomide Injection|Temozolomide is an imidazole tetrazine derivative of the alkylating agent dacarbazine.Temozolomide is not directly active but undergoes rapid, spontaneous, non-enzymatic conversion at physiologic pH to the cytotoxic compound, monomethyl triazeno imidazole carboxamide (MTIC).
45840084|NCT00595530|Drug|ketamine|"Medication administered via IV. This study will utilize 4 doses of ketamine: 0.05 mg/kg/hr, 0.1 mg/kg/hr, 0.15 mg/kg/hr, and 0.2 mg/kg/hr.~Dosing Regimen:~Patients begin the ketamine infusion at 0.05 mg/kg/hr.~4 or more hrs after infusion is started, the dose may be increased to 0.1 mg/kg/hr if:~patient's pain has not improved to an acceptable level~side effects remain acceptable~4 hrs or more after the previous increase, the dose may be adjusted to 0.15 mg/kg/hr~4 hrs or more after the previous increase, the dose may be adjusted to 0.2 mg/kg/hour~Maximum dose of ketamine is limited to 300 mg per 24 hrs~Patient may receive ketamine up to 72 hrs after initiation."
45840085|NCT00596622|Drug|Lithium|Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.
46090815|NCT02645370|Drug|Danzhen|
46090816|NCT02645370|Drug|Topiramate|
46090817|NCT00652392|Drug|budesonide/formoterol|
46090818|NCT00652392|Drug|budesonide and placebo|
46090819|NCT02490254|Other|Surveillance card|
46090820|NCT04168164|Other|aquatic therapy|The exercises of Ai Chi were performed in a specific order, until completion of the total possible movements.
46090821|NCT04168164|Other|Dry land therapy|sessions including exercises for gait, trunk mobility and exercises involving the upper and lower limbs
46090822|NCT04168164|Other|Combined therapy|alternate sessions of therapy on dry land and aquatic therapy with Ai Chi
46090823|NCT00652470|Procedure|Endoscopic Third Ventriculostomy|A standard frontal burr hole will be made and an endoscopic camera used to visualize the floor of the third ventricle. A ventriculostomy will be created in the floor of the third using the surgeon's own preferred method of perforation.
46005480|NCT01153633|Device|Normal Saline and Placebo Gel|"The treatment procedures (after a 1 week run-in) include:~Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~Secondary dressing to be a semi occlusive dressing~Secure the dressing to the wound with tubifast and short stretch compression system~Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
46005481|NCT04590183|Drug|FK-506 (Drug)|Twice a day
46005482|NCT04590183|Drug|Prednisolone Acetate 1% Oph Susp|Four times a day
46005483|NCT04623281|Device|Sixty device|Prototype wearable hydration monitor to be worn by patient during dialysis and at night
46005484|NCT01153321|Drug|AZD2423|100mg Oral dose od
46005485|NCT01153321|Drug|AZD2423 Placebo|Oral dose od
46005486|NCT04590456|Other|PEMF|group A received 60 minutes of traditional program physical therapy which consisted of passive range of motion, stretching,proprioception, isotonic and isometric and 20 minutes of placebo treatment using PEMF, while group B received the same traditional physical therapy program given to the control group in addition of 20 minutes of PEMF therapy
45459317|NCT03486808|Device|DLPFC stimulation|stimulating left dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes
45459318|NCT03486808|Device|Sham stimulation|sham stimulation over both left inferior frontal cortex and dorsolateral prefrontal cortex
45459319|NCT03165916|Device|Bard 5 Fr diameter feeding tube|A pediatric feeding tube is used as a stent over which biliary anastomosis is performed. This is not a permanent stent and generally migrates out on its own.
45473944|NCT03374878|Other|oral contraceptive and training|10 weeks of training in a group of users of oral contraceptives
45836335|NCT00142506|Drug|sildenafil citrate and questionaires|"Hormone therapy patients will be instructed to begin the study drug simultaneously or within 1 month of start of hormone therapy. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand open label, flexible dose fashion. Hormone patients will be offered on demand Sildenafil for approximately 15-21 months.~Hormone therapy patients will complete assessments at baseline (within 4 weeks of start of study treatment) each month (only IIEF and QOL) before start of radiotherapy, at start of radiotherapy and at months 3, 6, 9, 12 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
46090824|NCT00652470|Procedure|CSF Shunt Insertion|The procedure involves creating a burr hole in the frontal or occipital regions and cannulating the ventricle with a silastic catheter. This is then attached to a valve mechanism and distal silastic tubing which runs subcutaneously in the peritoneal cavity.
46090825|NCT02645526|Other|Woolen cap|
46090826|NCT02689310|Other|Leptospermum scoparium honey|No information available- PI left- study being withdrawn.
46090827|NCT02689310|Other|Standard of Care Treatment|No information available- PI left- study being withdrawn.
46090828|NCT02645214|Other|Non-antiseptic scrubs|
46090829|NCT02645214|Other|Antiseptic scrubs|
46090830|NCT02644902|Other|Avatar assisted cascade training|Training of health workers in THP through tablets including avatar characters , and cascaded supervision model.
46090831|NCT02644902|Other|Specialist led training in THP|Training and supervision of lady health workers by specialists as in original THP
46090832|NCT04166838|Biological|CD19 UCARTcells|This study did not set up a control group. The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD19 UCART cells per treatment course. The dose escalation test was designed to evaluate the three dose levels of CD19 UCART (1 × 10 ^ 6 cells/kg,3 × 10 ^ 6 cells/kg,5 × 10 ^ 6 cells/kg). Each CD19 UCART infusion will be carried out on day 0. Each subject was observed for at least 4 weeks after the last infusion. If there was no dose-limited toxicity (DLT), it is necessary to continue multiple treatment courses at this dose level. The detailed administration time and dose were decided by the researchers.
46090833|NCT02644824|Device|Biventricular Pacing (BiVp)|BiVp shortens QRS duration and synchronizes ventricular contraction; thereby decreasing wall stress and increasing CI and BP. In contrast to inotropes, BiVp does not increase myocardial VO2. Resynchronizing myocardial contraction normalizes glucose metabolism, myocardial perfusion and distribution of proteins essential to myocardial contraction and relaxation such as calcium-handling phospholamban. Overall, BiVp improves pump function, increases CI, improves myocardial perfusion and reduces VO2, improving hemodynamics.
46090834|NCT04166682|Behavioral|Home-based cardiac rehabilitation|cardiac rehabilitation done at home
46090835|NCT04166682|Behavioral|Routine care|Routine care and followup
46090836|NCT02645136|Other|Pilates|Pilates exercises
46090837|NCT02645136|Other|PFMT and AES|conventional pelvic floor muscle exercises combined with anal electrical stimulation Device: electrical stimulation (Dualpex 961 Uro®)
46090838|NCT02645136|Other|Control|
46090839|NCT02653638|Other|Control|"Transcranial Doppler~Blood Pressure~Heart Rate~Oxygen Saturation"
46090840|NCT02653638|Drug|Indomethacin|"Transcranial Doppler~Blood Pressure~Heart Rate~Oxygen Saturation"
46005487|NCT04622696|Diagnostic Test|Ultrasound imaging|Subjects in the performance cohort will undergo ultrasound imaging to assess the visibility of the HydroMARK Breast Biopsy Marker at 6-12 weeks post-implant. There is no intervention in the safety cohort (retrospective chart review).
46090841|NCT02645292|Device|1 mile walk using treadmill|Walk for 1 mile on treadmill (American Motion Fitness, 8800D) at self selected speed as fast as participant can without any inclination.
46090842|NCT02645292|Device|Stair Climbing|Climb 14 flights of stairs at self selected speed. No double step at a time and running allowed.
46005488|NCT04589871|Other|Taping technique|Fixmull stretch and Leukotape (rigid tape) were used in taping to guide the patellar trajectory orientation while performing the movement. Individuals were asked to lay down in supine position with knee in a slightly bent position. Fixomull stretch was used as an adhesive pre-wrap to protect the skin and provide some of the checking force. The main check strap was provided by stripes of rigid tape (Leukotape). The knee cap was taped, started on the outer aspect of the knee cap and pulled inwards. Finished at the back of the inside of the knee. Two further pieces of tape (Fixomull Stretch and Leukotape) applied distal to the patella unloaded the infrapatellar fat pad.
46005489|NCT04589871|Other|A supervised exercise protocol|Quadriceps Strengthening; Terminal knee extension; Ball kicking; Strengthening of Vastus Medialis;
46005490|NCT04622618|Drug|Gabapentin|Anticonvulsant, Antiemetic, Analgesic
46090843|NCT00653484|Behavioral|Physical Activity|
46090844|NCT00653484|Behavioral|Energy Restriction|
46005491|NCT04589949|Biological|ConvP|"Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products"
46005492|NCT04589949|Biological|FFP|Infusion of thawed non-convalescent plasma Plasma will be administered according to the Erasmus Medical Center quality protocol regarding the use of blood products
46005493|NCT04622852|Device|Open reduction internal fixation (ORIF) with an angular stable plate|Operative treatment of proximal humeral fracture
46090845|NCT00653484|Behavioral|Physical Activity and Energy Restriction|
46090846|NCT02644590|Drug|Melatonin|Detailed in arm description
46090847|NCT02644746|Device|acupuncture|Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57), Taixi (KI3) acupoints will be used. For bilateral Dachangshu (BL 25), the needle will be inserted vertically at approximately 40-70 mm until participants got a electric shock feeling downward to calves, then the needle should be elevated up 2 mm, without rotating or lifting. For other four acupoints (BL23, BL40, BL57, KI3), they will be inserted 10 to 15 mm in depth with three times light amplitude rotation and lift to induce a sensation of soreness. The manipulations will be performed 3 times in total during 1 session (every 10 min). There are 24 treatment sessions after baseline, 3 times a week, and the patients will undergo a 30-min treatment each session.
46090848|NCT02644746|Device|placebo needle|Acupuncturists will use blunt tip needles (Huatuo, Suzhou, China) that cannot penetrate skin and stimulate deep tissues, and the thrusting and twisting motions will be used by acupuncturists to simulate the treatment and blind the patients. Each placebo needle consists of four parts: needle handle, needle body, blunt tip and adhesive pad. The chosen of acupoints, treatment duration, and frequency of sessions will be the same as the acupuncture group. To guarantee blinding, the investigators will make appointments with each participant on alternate days to prevent crosstalk among groups.
46090849|NCT02644200|Device|Gelatin tannate|
46090850|NCT02653404|Other|IGRA test (QTF-GIT)|blood sample for QFT-GIT will be taken together with other routine blood samples
46090851|NCT02641548|Device|Sock of silicone|
46090852|NCT02641548|Other|Heel cream|
46090853|NCT04165278|Other|hyperthermic baths|Taking hyperthermic baths
46090854|NCT02644434|Procedure|Conventional Strategy|"Jailed wire technique: Both MV and SB are wired. The MV is stented with wire protection in SB. The SB is not further treated unless there is threatened SB closure, severe ostial pinching of SB (>90%), TIMI flow grade decrease in SB, or SB dissection greater than type A. If one of these criteria exists, the SB would be rewired and a kissing balloon inflation is undertaken.~Provisional two-stent strategy: Lesion preparation and MV stenting are the same as the jailed wire technique. Provisional T stenting of the SB could be undertaken if one of the following criteria exists after SB rewiring and a kissing balloon inflation is undertaken: threatened SB closure, severe ostial pinching of SB (>90%), TIMI flow grade decrease in SB, or SB dissection greater than type A."
46005494|NCT04589793|Behavioral|Life Style|Life Style intervention including physical activity, diet, sleep and stress
46005495|NCT04622891|Drug|Clarithromycin 500mg|clarithromycin 500
46005496|NCT04622891|Drug|Azithromycin|azithromycin group
46005497|NCT04622891|Drug|Placebo|control group
46005498|NCT04622579|Drug|lenalidomide combined with rituximab|lenalidomide and rituximab are dilivered as described, parameters concerning efficacy and safety are also obtained.
46005499|NCT04590066|Behavioral|Flu shot text messages|Participants will receive text messages per descriptions listed in the arms.
45678171|NCT01951105|Drug|Carbidopa/Levodopa|"12.5mg/50mg Carbidopa/Levodopa, administered orally as capsules, will be titrated up to TID over one week and then continued at that level for 4 weeks. If at the end of this initial 4 week period the participant has responded, the subject will be maintained on that dose for the duration of the treatment period (12 weeks total). If there has not been a response, the dose will be increased to 25mg/100mg Carbidopa/Levodopa TID for the following 4 weeks at which time the pain status will be re-evaluated. If a response has occurred, that dose will be maintained in a blinded manner for the following 4 weeks of treatment; if not, further dose-titration will occur to 50mg/200mg Carbidopa/Levodopa TID for the final 4 weeks. If a subject experiences an AE at higher doses, then the subject will be given the next lower dose that s/he was able to tolerate and then be maintained on that dose for the remainder of the 12 week dosing period."
46090855|NCT02644434|Procedure|Intentional strategy|"Jailed balloon technique: The technique has been detailed in previous studies. A monorail balloon that is angiographically sized to approximate the Side Branch (SB) vessel diameter is advanced into the SB. If there is TIMI flow grade decrease in the SB after MV stenting, the SB balloon is inflated to simulate attempt to reopen the SB. The procedure would be completed with the standard kissing balloon technique no matter there is SB compromise or not.~Elective two-stent strategy: Patients in this subgroup would undergo crush procedure or any other elective two-stent strategy which stenting SB before MV stenting."
46090856|NCT04168086|Other|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
46005500|NCT04622501|Procedure|posterior spinal decompression and posterior spinal instrumented fusion|posterior spinal decompression and posterior spinal instrumented fusion performed on a patient with Spinal Epidural Lipomatosis
46005501|NCT04590105|Device|"Smartphone App SB Colonoscopy Prep"|We created a smartphone app that informs patients about their colonoscopy procedure, alerts them when to take their medications throughout the hours-long colonoscopy prep process and tells them when to arrive to the endoscopy suite.
46090857|NCT04168086|Other|Sham|The investigators will simulate focused ultrasound stimulation similar to the experimental groups but without stimulation.
46090858|NCT00910806|Drug|TMC207; nevirapine|
46090859|NCT00652704|Drug|Doxycycline monohydrate|Capsules, 100 mg, fed
46005502|NCT04590105|Other|Written Instruction|Written Instruction
46090860|NCT00652704|Drug|Monodox|Capsules, 100 mg, fed
46090861|NCT00652704|Drug|Doxycycline Monohydrate|Capsules, 100 mg, fasting
46090862|NCT00652782|Drug|rolofyline|rolofyline 2.5 mg IV QD; 15 mg IV QD; 30 mg IV QD; 60 mg IV QD; 3 days
46090863|NCT00652782|Drug|Comparator Placebo (unspecified)|Matching placebo for rolofyline IV QD; 3 days
45678172|NCT01951105|Drug|Placebo|Take two placebo capsules three times a day for 12 weeks.
45459320|NCT04718948|Device|Urinary Multimodal Fiber Optic Spectroscopy|"Approach based on a physical principle, mainly spectroscopy, which is rapid non-invasive and does not require the use of additional substances or contrast media in the diagnosis of urothelial neoplasms in urine samples.~It will be administered through a appositely designed device"
46005503|NCT01153009|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
46005504|NCT01153009|Drug|Duloxetine|Overencapsulated duloxetine delayed-release capsules
46005505|NCT01153009|Drug|Placebo|Placebo-matching capsules
46005506|NCT04622111|Drug|CPL207280|IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
46005507|NCT04622111|Drug|Placebo|matching placebo tablet
46005508|NCT04622111|Drug|Metformin hydrochloride 750 mg|IMP is a tablet with Metformin hydrochloride as an Active Pharmaceutical Ingredient (API).
46005509|NCT04589715|Other|electroacupuncture|the same as described in experimental arm.
46005510|NCT04589715|Other|sham electroacupuncture|the same as described in sham comparator.
46090864|NCT04166370|Other|Control|The standard of care includes nutrition and health services provided to all pregnant women and mothers of children under-2 as provided by the GoB and their supporting partners. Services that should be provided include clinic-level infant and young child feeding (IYCF) counseling, growth monitoring and promotion, immunization, iron and folic acid distribution for pregnant women, ANC, safe delivery at community and referral for complications, vitamin-A supplements for postpartum women and children, deworming and management of common childhood illness.
45342464|NCT00709800|Biological|VCL-IPT1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
45342465|NCT00709800|Biological|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
45342466|NCT00709800|Biological|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
45342467|NCT00709800|Biological|PBS|IM, 1 mL, 2 injections, 0 and 21 days
46090865|NCT04166370|Other|Strengthened (Services and SBCC)|"Strengthening referrals to health services- Needed improvements to existing health referral networks will be assessed, identified and implemented. Peer leaders will refer PLW to nearby service delivery points.~Improving quality of health/nutrition services- Health-related service providers will be trained and supervised on nutrition best practices.~SBCC- Primarily target PLW. Delivered using traditional and digital channels. Text/voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for these messages. Female community nutrition promoters will also be deployed; delivering SBCC during group meetings and in health facilities. Mothers' groups will be established, and will be led by peer leaders, mentored in the delivery of messages on nutrition behavior."
46090866|NCT04166370|Other|Strengthened (Services and SBCC) + CCT|Will include all components of the strengthened intervention and participants will receive monthly cash transfers, which is about 25% of monthly consumption expenditure among poor rural households in Bangladesh. Cash transfers will begin when a woman enrolls (at any time during her pregnancy or until 2 months after giving birth). The monthly transfer will continue until a child is 12 months of age, thereby supporting mothers during the critical period of complementary food introduction. The transfer is contingent on having had a minimum of 4 ANC visits and monthly participation in mother's group SBCC sessions.
46090867|NCT04165044|Procedure|Leukocyte and Platelet Rich Fibrin plus Coronally Advanced Flap|The Coronally advanced flap was made following the protocol described by Zucchelli et al. in 2007. (39). When the margin of the flap was able to passively extend until more coronal of the CEJ the coronal mobilization of the flap was considered satisfactory. A double L-PRF membrane was positioned at the level of CEJ, getting the stabilization with 5-0 resorbable suture. After that, the flap was coronally advanced and stabilized with interrupted sutures (5-0 resorbable) anchored to incisal contact points (mesial and distal) created with a flowable, light-curing resin material in the treated tooth. Finally, gentle pressure over the area with a moistened gauze with saline solution was performed.
46090868|NCT04165044|Procedure|Connective tissue graft plus Coronally Advanced Flap|The Coronally advanced flap was made following the protocol described by Zucchelli et al. in 2007. (39). When the margin of the flap was able to passively extend until more coronal of the CEJ the coronal mobilization of the flap was considered satisfactory. Then connective tissue graft obtained from the palate was positioned at the level of CEJ, getting the stabilization with 5-0 resorbable suture. After that, the flap was coronally advanced and stabilized with interrupted sutures (5-0 resorbable) anchored to incisal contact points (mesial and distal) created with a flowable, light-curing resin material in the treated tooth. Finally, gentle pressure over the area with a moistened gauze with saline solution was performed.
46090869|NCT00653562|Drug|zolpidem|Oral
46090870|NCT00887159|Drug|Cisplatin|Given IV
46005511|NCT02884843|Device|Intubation laryngeal Tube Suction|Intubation laryngeal Tube Suction
46090871|NCT00887159|Biological|Cixutumumab|Given IV
46090872|NCT00887159|Drug|Etoposide|Given IV
45459321|NCT04718948|Diagnostic Test|Urine Cytology|An expert cytopathologist will analyze urine samples to detect urinary tract cancer cells. It is the current golden standard to detect urothelial cancer in urine
45678173|NCT01958918|Drug|Ranibizumab|0.5 mg intravitreal injection
45678174|NCT01958918|Drug|Aflibercept|2 mg intravitreal injection
45678175|NCT01945489|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injected into the detrusor.
46005512|NCT02884843|Device|AuraGain Laryngeal Mask|AuraGain Laryngeal Mask
46005513|NCT01152814|Biological|Seasonal flu vaccine|This phase II is performed as a multicenters study site in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22)
46005514|NCT04589442|Biological|Split thickness skin graft|standard of care graft
46090873|NCT00887159|Other|Laboratory Biomarker Analysis|Correlative studies
46090874|NCT00887159|Drug|Vismodegib|Given PO
46090875|NCT02641470|Dietary Supplement|DA9301 (Vaccinium uliginosum extract)|
45459322|NCT04718948|Procedure|Surgery|It will provide a reliable information on the presence/absence of cancer in the urinary tract (from direct visualization to pathological analysis)
45678176|NCT01945489|Drug|Normal saline|Normal saline (placebo) injected into the detrusor.
46005515|NCT04589442|Biological|microsurfaced split thickness skin graft|standard of care graft that has been microsurfaced
46005516|NCT04621994|Other|Dermabond|Dermabond will be applied after subcuticular skin closure in lieu of Steri Strips
46005517|NCT04621994|Other|Steri Strips|Steri Strips will be applied after subcuticular skin closure as routinely done at our institution
46005518|NCT04205695|Procedure|CEMP (closed-ended multiport catheter) group|The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the closed-tip multiport catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.
46005519|NCT04205695|Procedure|OESP (open-ended single port catheter) group|The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. hhe Non-Stimulating Needle and the Non-Stimulating open-ended catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.
46005520|NCT04205695|Procedure|Patient-controlled analgesia|A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
46005521|NCT02884531|Other|Patient Education and Basic Body Awareness Therapy|Patient education (1/2 day) and a Physiotherapy movement modality (12 times, once a week)
46090876|NCT02641470|Dietary Supplement|Placebo|
46090877|NCT00650286|Drug|Modafinil Tablets 200 mg|200mg, single dose fed
46090878|NCT00650286|Drug|Provigil® Tablets 200 mg|200mg, single dose fed
46090879|NCT02641158|Other|Control Group|"After screening HCV antibody positive, participants will receive an appointment and reminder card to return for their HCV RNA results. If HCV RNA positive, study staff will attempt to make an appointment for the participant's next step in the HCV continuum. If a participant attends the next step visit, the participant would be subject to whatever is the local standard of care at that clinic/agency from that point forward."
46090880|NCT02641158|Behavioral|Care Facilitation Group|"The same will occur for intervention participants, yet an HCV care facilitator will motivate them to return for their HCV RNA results; appointment reminders will be made prior to the next step visit; follow-up contact will be made for missed appointments; and the HCV care facilitator will coordinate and link the participant to available community resources (e.g., mental health, housing agencies) by scheduling appointments, arranging transportation, and helping to complete any clinic registration (or other) paperwork that agencies may require to access services."
46090881|NCT02641002|Drug|CC-90002|Monoclonal Ab to CD47
46005522|NCT02884531|Behavioral|Patient Education|Patient education (1/2 day)
46005523|NCT04589481|Other|Intake of 3 different candies against bad breath|Intake of 3 different candies against bad breath on three different days (2-days interval each) after artificially creating a temporary bad breath (by eating of chips and cheese); analysis of breathing during intake of candy both subjectively and objectively
46005524|NCT04621721|Behavioral|Gait/balance & resistive exercise|Walking forward and back, walking with head motion, static standing, Standing Partial Tandem, Tandem Standing heel to toe, Standing with head turns Single leg stance and March in place. Resistance exercises include: calf raises, lunges, supine leg curls and extensions.
46005525|NCT05244889|Behavioral|Digital CBT-I|"The digital CBT-I intervention (www.sleepio.com) consists of six weekly sessions of CBT-I delivered over the internet by an animated virtual therapist known as The Prof. The content includes behavioral (e.g. sleep restriction, stimulus control), cognitive (e.g. putting the day to rest, thought re-structuring, mindfulness) strategies, relaxation strategies (e.g., progressive muscle relaxation) and advice on lifestyle and bedroom factors (sleep hygiene). Although the sessions can be completed at the persons own pace, the shortest interval between individual sessions is 7 days, thus participants can complete the course in 6 weeks, or take as long as 12 weeks. As part of the SLEEPIO program, participants will be required to enter their sleep/wake patterns using electronic sleep diaries. There is no face-to-face contact throughout the intervention and all treatment sessions, support and reminders are provided through the online platform."
46005526|NCT05244889|Behavioral|Sleep Hygiene Education|Sleep Hygiene Education (SHE) has successfully been used as a control condition in other trials evaluating dCBT-I42. SHE does not have any therapeutic benefits for individuals with insomnia alone, but is often part of usual care. Consequently it is a credible alternative to dCBT-I. The sleep hygiene education will be provided on a website with access to information about lifestyle changes (e.g., reducing exercise in the evening, light snack before bedtime, reducing caffeine) and changes to the bedroom environment (e.g., dark room, comfortable mattress, optimal room temperature). As with the dCBT-I group, participants will not be required to make any changes to their usual care.
46090882|NCT02640924|Radiation|Proton radiotherapy|
46090883|NCT02640924|Procedure|Radiofrequency Ablation|
46090884|NCT02535858|Device|Heart and respiratory rate and VE|To evaluate the effectiveness of the virtual environment (VE) as a biofeedback of chemically dependent's vulnerability front situations of risk, a total of 50 volunteers who were drug users, monitored by 10 therapists, were enrolled.
46090885|NCT02535858|Device|Heart and respiratory rate and video|Anxiety is characterized by the average variability from both heart and respiratory rate of 30 volunteers undergoing stress environment situations.
46090886|NCT02640846|Drug|Norepinephrine|Norepinephrine will be given to the patient due to septic shock. After the inclusion we will change the dose of Norepinephrine to achieve 3 different MAP-levels, 60 mmHg, 75 mmHg and 90 mmHg.
46090887|NCT02640846|Drug|Milrinone|Corotrope will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
46090888|NCT02640846|Drug|Levosimendan|Levosimendan will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
45678177|NCT04173559|Behavioral|Activity Intervention|After 1 week of baseline activity is obtained, participants will be contacted with personalized activity goals that are 10% higher than their previous weeks' activity levels. They will also receive feedback regarding sleep if they are not averaging at least 6 hours per night or if they are waking more than twice per night. Participants will also receive weekly text reminders and encouraging feedback, and will receive additional counseling in person at regularly scheduled prenatal visits until delivery.
46005527|NCT05244187|Device|OrthoCor Active System|The OrthoCor Active System is a portable (battery operated) non-invasive device that delivers Pulsed Electromagnetic Field (PEMF) therapy for General Use of temporary pain relief, utilizing wraps that position the therapy, such as on the ankle, back, knee, wrist, elbow, shoulder, foot, or neck.
46005528|NCT04589520|Behavioral|HeartBot App|HeartBot is an app designed to enable people 14 years and older to use relaxation tools offered by Heartfulness to deal with daily stress and anxiety in a healthy, productive manner.
46005529|NCT04622033|Biological|Brodalumab|brodalumab 210mg at week 0, 1, 2 and then every 2 weeks up to 24 weeks.
46005530|NCT01152580|Dietary Supplement|melatonin|3mg p.o. at bedtime daily
46005531|NCT01152580|Dietary Supplement|sugar pill|lactose p.o. at bedtime daily
46005532|NCT02884453|Drug|ibrutinib|Ibrutinib (PCI-32765) is a first-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton's tyrosine kinase (BTK) currently under development for the treatment of B-cell malignancies. Ibrutinib is being co-developed by Janssen Research & Development, LLC and Pharmacyclics Inc.
46090889|NCT00653640|Procedure|body weight supported treadmill training|BWSTT for 12 weeks, 3 times per week
45473945|NCT01285037|Drug|LY2801653|LY2801653 given orally once daily during 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
45678178|NCT01934894|Drug|cabazitaxel|
45678179|NCT01934894|Drug|lapatinib|
45678180|NCT01950169|Drug|Risedronate|The bisphosphonate group (B) receive 35 mg risedronate (Optinate® Septimum) once weekly for 12 months and calcium (1000 mg) and vitamin D3 (800 IU) (Calcichew-D3®) daily for 12 months.
46005533|NCT02884297|Drug|Contrast agent: SonoVue®.|SonoVue® Injection: will be done through the peripheral venous way already set up by the anesthetist for its injection. None venous dedicated way will be established. The injection will take place when the woman will be under general anesthesia, ventilated and under constant cardio-respiratory monitoring.
46005534|NCT04621799|Drug|Fibrin sealant|The intra-annular delivery of non-autologous fibrin into the annulus
46005535|NCT02884336|Other|No intervention|
46005536|NCT04621370|Drug|Durvalumab|Flat dose of 1500mg delivered intravenously over 30 minutes every 4 weeks.
46005537|NCT04621370|Drug|FOLFOX|"Oxaliplatin 85mg/m2 delivered intravenously as per institutional standard on Day 1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil bolus 400mg/m2 delivered intravenously as per institutional standard on D1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil infusion 2400mg/m2 delivered intravenously over 46 hours continuously as per institutional standard following bolus 5-fluorouracil."
46005538|NCT04621370|Radiation|Short Course Radiotherapy (Arm A)|25 Gray of photon radiation treatment delivered over 5 fractions.
46005539|NCT04621370|Radiation|Long course chemoradiation (Arm B)|50 Gray of photon radiation treatment delivered over 25 fractions.
46005540|NCT04621370|Drug|Capecitabine|Capecitabine is a non-cytotoxic pre-cursor of cytotoxic 5-fluorouracil and delivered in oral form. It is given concomitantly with long course radiation treatment on days of radiotherapy only. The dose is 825mg/m2 and this is delivered twice daily.
46005541|NCT01152385|Drug|AZD1656|Oral tablet administered twice daily during 4 months
46005542|NCT01152385|Drug|Placebo|administered twice daily during 4 months
46090890|NCT00653640|Procedure|traditional physical therapy|traditional PT for 12 weeks, 3 times per week
46090891|NCT03500640|Behavioral|DPP Intensive: 30-minute calls|Ongoing DPP intervention and behavioral progress review to prevent relapse and improve cardiometabolic and functional health targets as keys to healthy aging.
46090892|NCT03500640|Behavioral|DPP Support: 15-minute calls|No further behavioral intervention materials provided; phone-contacts for mutual social support and accountability
46090893|NCT00886769|Drug|Canakinumab|Canakinumab was supplied in individual 6 mL glass vials each containing 150 mg canakinumab powder as a lyophilized cake. Each reconstituted vial provided 150mg of canakinumab per 1 mL.
46090894|NCT00886769|Drug|Placebo|Placebo was provided in individual 6 mL glass vials each containing 150 mg placebo powder matching canakinumab as a lyophilized cake. Each reconstitued vial provided 150mg of placebo per 1 mL.
46090895|NCT03484884|Diagnostic Test|Cerenkov luminescence imaging.|Cerenkov luminescence imaging will be obtained from MSKCC patients who are scheduled for routine FDG PET scan or 131I therapy that emit a continuum of ultraviolet and visible light from the decay of certain radionuclides.
45678181|NCT01950169|Other|Nutritional supplement|The bisphosphonate and nutritional supplemented group (BN) receive 35 mg risedronate once weekly for 12 months plus nutritional supplement (Fresubin® protein energy drink) during the first six months following hip fracture and also calcium (1000 mg) and vitamin D3 (800 IU) daily for 12 months.
46090896|NCT02644044|Drug|Intrathecal methotrexate|12.5 mg of methotrexate diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle.
46090897|NCT00652860|Biological|aerosol sargramostim|
46090898|NCT00652860|Biological|sargramostim|
46005543|NCT04589130|Drug|Contrave 8Mg-90Mg Extended-Release Tablet|"Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day).~Participants randomized to the control arm for the first 6 months will crossover and be administered 4 Contrave tablets a day during the second 6 months (2 tablets taken twice a day). All participants will be in the treatment group (Contrave) during the second 6 month phase of the study."
46090899|NCT00652860|Drug|cisplatin|
46090900|NCT00652860|Drug|doxorubicin hydrochloride|
45678182|NCT01950169|Dietary Supplement|Calcium and vitamin D3|The patients in the control group (C) receive orally administered calcium 1000 mg and 800 IU vitamin D3 (Calcichew-D3®) daily for 12 months.
46090901|NCT00652860|Drug|ifosfamide|
45678183|NCT01934504|Procedure|Venipuncture for blood sample collection|Analysis samples from the blood sample collection at specific time points.
46005544|NCT04589130|Drug|Placebo|Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day (2 tablets, taken twice a day) during the first 6 months of the study. These participants will crossover to treatment with Contrave for the second 6 months of the study.
46090902|NCT00652860|Drug|mitomycin C|
46090903|NCT00652860|Other|flow cytometry|
45678184|NCT01950013|Behavioral|Auditory training program|Previous experiments performed under laboratory settings using a novel word-based auditory-training regimen have demonstrated substantial improvements in open-set recognition of words and sentences in noise. The current proposed study will investigate the effectiveness of the training regimen when used in a patient's home setting with their own hearing aids.
46005545|NCT04621487|Drug|Amoxicillin|14 days 1 gr bid
46005546|NCT04621487|Drug|Metronidazole|14 days 500 mg bid
46090904|NCT00652860|Other|immunological diagnostic method|
46090905|NCT00652860|Other|laboratory biomarker analysis|
46090906|NCT00652860|Procedure|adjuvant therapy|
46090907|NCT00652860|Procedure|multimodality therapy|
46090908|NCT00652860|Procedure|neoadjuvant therapy|
46005547|NCT04621487|Drug|Clarithromycin|14 days 500 mg bid
46005548|NCT04621487|Drug|Pantoprazole 40mg|40 mg bid 14 days
46005549|NCT04621487|Drug|according to antibiogram|according to antibiogram
46005550|NCT01152190|Drug|Tadalafil|Administered orally, once daily for 8 weeks
46005551|NCT01152190|Drug|Placebo|Administered orally, once daily for 8 weeks
46005552|NCT04649853|Other|Standardized nursing care|All patients will receive standardized evidence based nursing care
46005553|NCT04621565|Drug|Normal saline|No hydrocortisone or other steroids are given before, during, and after the surgery, except that patients develop postoperative adrenal insufficiency. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program.
46005554|NCT04621565|Drug|Hydrocortisone|"Hydrocortisone sodium succinate is given on the operation day (100mg at 0800 & 100mg at 2000), the postoperative day 1 (100mg at 0800 & 50mg at 2000), and the postoperative day 2 (25mg at 0800). Hydrocortisone (po.) is then given starting from the afternoon of postoperative day 2 (20mg at 1600 and 0800) to the end of the first postoperative week, and 20mg at 0800 during the second postoperative week. This is called the hydrocortisone taper program. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program."
46090909|NCT00652860|Procedure|therapeutic conventional surgery|
46090910|NCT00652860|Radiation|intraoperative radiation therapy|
46090911|NCT00652860|Radiation|selective external radiation therapy|
46090912|NCT04165980|Device|transcranial direct current stimulation|Transcranial direct current stimulation delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.
46090913|NCT04243187|Other|Chilean Native Beans|"In each visit the participant would have to:~Fill a survey of gastrointestinal symptoms and basal bowel movements (THE GASTROINTESTINAL SYMPTOM RATING SCALE (GSRS))~Fill a survey of food consumption~Bean plate intake~Expired hydrogen test, which consists of exhaling air in a syringe every 20 minutes for 12 times (4 hours in total). During this time the participant can do quiet activities (not physical activity).~Fill surveys of gastrointestinal symptoms (online or on paper), during the hydrogen test, at 12 and 24 hours (3 times). During this time (1 day before and 2 days later) the participant cannot eat other bloating foods (legumes, cauliflower, broccoli, lettuce, cabbage, artichokes, onions, topinambur and others described in the food survey)."
46090914|NCT02536014|Drug|Dexmedetomidine|Dexmedetomidine infusion (0.3㎍/kg/hr) from anesthetic induction to the end of pneumoperitoneum
46090915|NCT02536014|Drug|Saline|Saline infusion during the same time period
46090916|NCT02653014|Drug|KBP-5074|
46090917|NCT02643576|Behavioral|F&V Bonus|To examine the independent effect of offering an incentive (i.e. bonus dollars for fruit and vegetable purchases) to SNAP-like benefits to encourage the purchase of more healthful foods
46090918|NCT02643576|Behavioral|Restriction|To examine the independent effect of prohibiting the use of SNAP-like benefits to purchase foods high in discretionary calories (i.e.sugar-sweetened beverages, candy, or sweet baked goods) on food purchases and diet quality
46005555|NCT04650048|Device|Active HD-tDCS|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.
46005556|NCT04650048|Device|Sham HD-tDCS|"Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.~This sham-configuration is intended to mimic the sensory experience of active HD-tDCS."
46090919|NCT02643576|Behavioral|Bonus & Restriction|To examine the joint effects of prohibiting the use of SNAP benefits to purchase foods high in discretionary calories and offering an incentive to encourage the purchase of more healthful foods
46090920|NCT00886613|Biological|V212|Two doses of 0.65 mL V212 subcutaneous injection administered at Day 1 and Day 31
46090921|NCT00886613|Biological|Comparator: Zostavax™|Two doses of 0.65 mL Zostavax™ subcutaneous injection administered at Day 1 and Day 31
46090922|NCT00886613|Biological|Comparator: Placebo|Two doses of 0.65 mL subcutaneous injection of placebo administered at Day 1 and Day 31
46090923|NCT00886613|Other|VZV Skin Test|Three intradermal injections of the 0.1 ml varicella antigen (VZV Skin Test reagent) were administered, once at baseline before the first vaccination, a second time before the second vaccination, and a third time approximately 14 days after the second vaccination.
46090924|NCT00886613|Other|Saline|One intradermal injection of the 0.1 ml saline was administered at the time of the baseline VZV skin test prior to the first vaccination. Saline and VZV skin test reagents were administered on opposite arms.
46090925|NCT00653016|Drug|norelgestromin; ethinyl estradiol|
46090926|NCT02640768|Other|educational training|implementation of a structured educational program for physicians and nurses
46090927|NCT00886379|Dietary Supplement|Mongolian milk without vitamin D|710ml per day for 49 days
46090928|NCT00886379|Dietary Supplement|Mongolian milk with vitamin D|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
46090929|NCT00886379|Dietary Supplement|UHT milk|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
46090930|NCT00886379|Dietary Supplement|Milk Substitute|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
46090931|NCT00886379|Dietary Supplement|Seasonal D supplement|Deliver dosage of 13,700 IU vitamin D over 7 days
46090932|NCT00886379|Dietary Supplement|Daily D supplement|Deliver dosage of 13,700 IU vitamin D in vitamin capsules over 49 days.
46005557|NCT00562367|Drug|Cytomel (liothyronine)|Cytomel (liothyronine) 25-50 mcg/day for 4 weeks
46005558|NCT01151410|Drug|Aliskiren|"Low weight patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg~Mid weight patients: Starting dose 75 mg with optional titration to 150 and then 300 mg~High weight patients: Starting dose 150 mg with optional titration to 300 and then 600 mg"
46005559|NCT01151410|Drug|Enalapril|"Low weight patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg~Mid weight patients: Starting dose 5 mg with optional titration to 10 and then 20 mg~High weight patients: Starting dose 10 mg with optional titration to 20 and then 40 mg"
46005560|NCT04588896|Device|Continuous glucose monitoring|Abbott Freestyle Libre CGM for 8 weeks in adjunct to lifestyle modification programme
46005561|NCT04588896|Behavioral|Lifestyle modification programme|Lifestyle modification programme
46090933|NCT00633581|Dietary Supplement|Ascorbic acid (Vitamin C)|Single intravenous injection of vitamin C 10g(20ml) with 100ml of normal saline over 30 minutes
46090934|NCT00633581|Dietary Supplement|Normal saline|Single intravenous injection of 120ml of normal saline over 30 minutes
46090935|NCT02825147|Drug|Pegaspargase|
46090936|NCT02825147|Drug|Methotrexate|
46090937|NCT02825147|Drug|Dexamethasone|
46090938|NCT02825147|Drug|Etoposide|
46090939|NCT02825147|Radiation|radiotherapy|
46090940|NCT02825069|Other|Early introduction of solid foods|Early introduction of solid foods
46090941|NCT02825225|Other|20 core-biopsy fragments|Using the extended sextant fashion prostate biopsy, this randomized group was submitted to a 20-fragments core-biopsy to evaluate the diagnostic power, pain perception and complications comparative to institution's standard 12 cores.
46090942|NCT02825225|Procedure|Base and apex local anesthesia|Using the institution's standard local anesthesia protocol (base injection) as active comparator group, this randomized group was submitted to base and apex local anesthetic application to evaluate tolerability of the procedure, pain perception (with use of previous validated analogue pain scale) and complications.
45678185|NCT01950013|Behavioral|Sham Comparator: Active Control|This is a sham intervention in which the patient listens to audio books following the same regimen as the patients receiving the auditory training.
46090943|NCT02827097|Drug|denogan and rectus sheath block|administration of denogan and rectus sheath block with 0.375% ropivacaine
46090944|NCT02827097|Drug|denogan|administration of denogan
46090945|NCT04242407|Drug|DMTS|DMTS applied before surgery and worn for 96 hours
46090946|NCT04242407|Drug|Placebo|Matching patches that have no active drug applied before surgery and worn for 96 hours
46090947|NCT00637949|Device|lumiracoxib|400 mg once daily, oral over 6 weeks
46090948|NCT00637949|Drug|rofecoxib|25 mg, oral, daily over 6 weeks
46005562|NCT00562406|Drug|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8
46005563|NCT00562406|Procedure|Laser photocoagulation|laser photocoagulation to the retina at the area of edema
46005564|NCT04588974|Device|magnetic-assisted capsule endoscope system (InsightEyes EGD System) with or without 3D images|The patient will undergo both diagnostic tests within two days, a magnetic-assisted capsule endoscope system first and then conventional EGD will be carried on at least 4 hours afterward.
46005565|NCT04649658|Behavioral|Prone position|Prone position maintained at least 3 hours/day
46005566|NCT04621409|Biological|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, approximately 5 hours
46005567|NCT04621409|Biological|Placebo|IV infusion of saline, approximately 5 hours
46005568|NCT04588935|Drug|Bisoprolol; Perindopril;|based on the results of the patient study, different drug therapy regimens for cardiovascular complications during chemotherapy will be proposed
46090949|NCT02827019|Other|questionnaire|a questionnaire made puerperium the 2nd day of life during the interview with the parents on the basis of a semi-structured interview about the progress of the birth and the immediate postpartum period using the memories of parents
46090950|NCT04242017|Drug|Triptoreline|Comparison of the duration of ADT (Triptoreline)
46090951|NCT02825693|Procedure|Conventional cataract surgery (phacoemulsification)|
46005569|NCT04691258|Behavioral|Experimental: Complete Group|"The participants performed the squat and Stiff exercises with the maximum range of motion. In the squats, the knees were completely flirted, even if the participant could not perform the movement with neutral vertebral posture. The heels were also not supported to the ground in some participants due to lack of flexibility. It was instructed that the participants tried to perform the Squats and Stiff keeping the lumbar lordosis neutral, with the best posture they could in all training sessions, but all should perform the exercise with as much range of motion as possible.~The positioning of the feet was also carefully controlled, there was no hip rotation and the distance between the lateral edges of the heels was defined as the distance between the upper iliac spines (EIAS). The direction of the knees was oriented pointing in the direction of the tip of the feet parallel throughout the cycle of the movement."
46005570|NCT04691258|Behavioral|Active Comparator: Restricted Group|"The conventional movement technique of the squat exercise was used, in which the participants performed with the range of motion restricted to the neutral vertebral posture, approximately 90º of movement of the knee joint. may increase the range of motion if the lumbar posture did not rectify.~The positioning of the feet in this group was carefully controlled, the participants performed the exercise with the joints of the hips abducted and rotated laterally. Having markings on the ground as a reference, the feet went rotated at 21º and the lateral edge of the heels were moved away from each other, approximately with the biacromial distance. The direction of the knees was oriented pointing in the direction of the tip of the feet throughout the cycle of the movement, aligned to the lateral rotation of the hip. In the first training session, with the aid of a goniometer and metric tape, adhesive marks were placed on the floor to ensure this positioning of the support base."
46005571|NCT00562523|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400mg by mouth daily in combination with docetaxel 60mg/m2 IV once every 3 weeks
46005572|NCT04649541|Drug|MRX-8|novel semi-synthetic polymyxin B analog.
46090952|NCT02825693|Procedure|Femtosecond laser assisted cataract surgery|
46090953|NCT02824991|Procedure|detection of local twitch response intensities during dry needling|
46090954|NCT00599196|Drug|Rotigotine|"Rotigotine trans-dermal patches, once daily:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours); 50 cm2 (10 mg/24 hours); 60 cm2 (12 mg/24 hours); 70 cm2 (14 mg/24 hours); 80 cm2 (16 mg/24 hours);~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 8 mg/24 hours.~After the first year: allowed dose increase of rotigotine up to a maximum of 16 mg/24 hours."
46090955|NCT02825303|Other|Workplace consisting of two height-adjustable desks|Desk arrangements: self-determined by the participants Desk equipment: depending on pre-intervention condition - 1 or 2 screens per desk Build-up: one day prior to the intervention period at the location of the workplace Adjustment: together with the study leader
46090956|NCT04201145|Drug|Pembrolizumab|IV, predetermined dosage, twice per cycle
46090957|NCT04201145|Drug|Defactinib|Defactinib oral, twice daily, per predetermined dose and predetermined duration as defined by cohort
46090958|NCT02652702|Procedure|circular stapler-assisted colostomy|procedure:circular stapler-assisted colostomy device:circular stapler
46005573|NCT04649541|Drug|Placebo|5% dextrose in water
46005574|NCT00562562|Other|osteopathic manipulative treatment|Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
46090959|NCT02652702|Procedure|conventional hand-stitching colostomy|procedure:hand-stitching colostomy
46090960|NCT02824601|Device|Laser|1-visit-treatment (n=12): Chemomechanical preparation (CMP) - CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP
46005575|NCT04649424|Device|CanSwab|New nasopharyngeal swab design.
46090961|NCT02824601|Drug|Calcium hydroxide|2-visit-treatment (n=12): Chemomechanical preparation (CMP) + Ca(OH)2 + SSL medication for 14-days + PDT. CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after 14-days of intracanal medication
46005576|NCT00562640|Biological|filgrastim|Stem cell mobilization and harvest: Patients receive filgrastim (G-CSF) subcutaneously daily for five days. PBMC are collected by leukapheresis on the fifth day and then cryopreserved for subsequent reinfusion into the patient, in the event of prolonged cytopenia.
45459323|NCT04682678|Procedure|Implantation of electrodes for Spinal cord stimulation|The implantation of electrodes for SCS at the epidural thoracic level connected to a neurostimulator at the abdominal level will be performed under general anaesthesia (hospitalization for 3 days in the Neurosurgery Department, CHUGA) in a maximum delay of 1 month following the preoperative assessment. During the first postoperative month, the optimization of SCS parameters will be performed by an experienced movement disorders neurologist.
45678186|NCT04632524|Drug|MgSO4|Group (M) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery. Group (S) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse.
45459324|NCT03115294|Drug|Theophylline|iv injection
46005577|NCT00562640|Biological|therapeutic autologous lymphocytes|Autologous T-cell infusion with or without conditioning chemotherapy ( fludarabine treatment closed as of 12/01/2009): Approximately 4-6 weeks after T-cell sensitization, patients receive an infusion of autologous WT1-specific T cells over 5-10 minutes on day 0. Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2 and fludarabine phosphate IV over approximately 30 minutes on days -6 to -2. After a 48-hour rest period, patients receive autologous WT1-specific T cells. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after completion of therapy, may receive additional courses of autologous WT1-specific T cells every 14 days.
46005578|NCT00562640|Drug|cyclophosphamide|Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2
46005579|NCT00562640|Other|laboratory biomarker analysis|Obtained prior to adoptive therapy to quantitate baseline levels of WT1 reactive T cells, by quantitation of WT1 specific CTLp by LDA, T cells secreting IFNγ in response to peptide and, in HLA A0201+ patients, T cell binding WT1 peptide HLA A2 tetramers.
46005580|NCT00562679|Other|There is no intervention|
46005581|NCT04588779|Other|Graston|"Ultrasound for 10 mins/1 set/ (3 sessions/week), Graston for 5 mins/1 set/ (3 sessions/week), Piriformis stretching exercises/ 10 reps with 30 sec hold/ 1 set/(3 sessions/week), Hip abductor strengthening/10 reps/1 set/(3 weeks), Hip extensor strengthening/10 reps/1 set/(3 weeks),~A total of 9 sessions for 3 weeks (3 sessions/week) were given each consisting of 20 mins."
46005582|NCT04588779|Other|Manual myofascial release|"Ultrasound for 10 mins/1 set/ (3 sessions/week), Manual myofascial release for 5 mins/1 set/ (3 sessions/week), Piriformis stretching exercises/ 10 reps with 30 sec hold/ 1 set/(3 sessions/week), Hip abductor strengthening/10 reps/1 set/(3 weeks), Hip extensor strengthening/10 reps/1 set/(3 weeks),~A total of 9 sessions for 3 weeks (3 sessions/week) were given each consisting of 20 mins."
46090962|NCT02652858|Procedure|Non-invasive blood pressure oscillometer (NIBP) implementation|Implementation of two additional NIBP on humeral and femoral sites.
46005583|NCT04621214|Device|Audio-Visual Triage System (AVT)|Audio System was added to visual triage that resulted in an AVT. Protocols of AVT included, a medical personal sits on TRIAGE DESK (with glass barrier sheet on it) wearing personal protective equipment (PPE) at a distance of more than 6 feet from the PATIENT DESK. Both desks are connected with Non-touchable MIC SYSTEM for communication
46090963|NCT02643732|Drug|Methylphenidate (overencapsulated)|10mg (1 capsule) methylphenidate (standard release) twice daily, increased to 20mg (2 capsules) twice daily after 2 weeks. The drug can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
46090964|NCT02643732|Drug|Placebo (Over-encapsulated tablet)|Identical capsules (over-encapsulated placebo tablets), administered initially one capsule twice daily, increased to 2 capsules after 2 weeks. As with the methylphenidate arm, the dose can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
46090965|NCT04241939|Behavioral|Numberless BDS|Participants perform daily weighing using a numberless BDS with feedback from app (color codes, challenges), in conjunction with modified motivational interviewing (clinic visits and weekly telephone calls), and the standard adolescent weight loss program.
46090966|NCT04241939|Behavioral|Digital Scale|Participants perform daily weighing using a digital scale (number readout), in conjunction with standard adolescent weight loss program
45459325|NCT03115294|Procedure|Ventilator positive end expiratory pressure adjustment|Positive end-expiratory pressure variation
46090967|NCT04241939|Behavioral|Modified Motivational Interviewing|Modified motivational interviewing (clinic visits and weekly telephone calls), and the standard adolescent weight loss program.
46090968|NCT02643810|Other|Exercise training|Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
46090969|NCT04876937|Drug|Dexmedetomidine|Dexmedetomidine is infused at a rate of 0.1-0.2 μg/kg/h (0.025-0.05 ml/kg/h) from study recruitment in the ICU during mechanical ventilation, for no more than 7 days.
45459326|NCT03115294|Device|Videorecording|Myocardial movement videorecording
45473946|NCT01285037|Drug|Cetuximab|Cetuximab given via IV infusion once weekly, 400mg/m2 for first dose and 250mg /m2 for subsequent doses. If LY2801653 treatment is stopped due to toxicity after a minimum of 4 cycles, cetuximab may be continued until disease progression. In the event cetuximab treatment is stopped, participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
45678187|NCT01949155|Drug|OTO-201|Single, intratympanic injection
45678188|NCT01949155|Drug|Sham|Simulated single, intratympanic injection
46005584|NCT04649619|Procedure|GASTRIC BYPASS MODIFIED IN ROUX-EN-Y AS A THERAPEUTIC OPTION IN PATIENTS WITH INDICATION OF BARIATRIC AND / OR METABOLIC SURGERY|"Roux-en-Y gastric bypass:~Stapling and reduction of the gastric chamber of approximately 18 cm, followed by anastomosis with a deviated bowel, and another bowel anastomosis with a bowel in a lower portion, for deviation of biliopancreatic secretions. Maintenance of a gastro-gastric communication of approximately 1 cm between the functional gastric pouch and the excluded stomach for endoscopic access."
46005585|NCT04649697|Drug|Rebamipide|A mucosal protection drug developed in Japan for the treatment of gastritis and gastric ulcer.
46005586|NCT04649697|Drug|Nanoparticulated Rebamipide|A mucosal protection drug developed in Japan for the treatment of gastritis and gastric ulcer will be used in nanotechnology.
46005587|NCT04649697|Drug|Clobetasol Propionate|A corticosteroid drug used as a gold standard for treatment of methotrexate induced oral ulceration.
46005588|NCT04649502|Combination Product|Metformin|Metformin in combination with doxycycline
46005589|NCT04621097|Device|pulsed electromagnetic field|it is a device for magnetotherapy and it is one of the most recent noninvasive physical therapy modality which is used in multiple physical therapy fields . it consist of an appliance, motorized bed and solenoid . the appliance must be connected to electrical supplying 230 =10% at a frequency of 50 or 60 HZ with earth connection . the intensity and spatial lay out of the generated magnetic field depend on the type of solenoid used
46005590|NCT04621097|Other|treadmill training|supervised treadmill walking exercise. The exercise program consists of intermittent walking bouts to moderate claudication pain alternating with periods of rest in between for a total of 40-50 minutes .
46005591|NCT04621097|Drug|Medication|regular medications
46005592|NCT04588584|Other|Survey and Interviews|Survey and Interviews
46005593|NCT04621253|Drug|Novalgin|Single dose of 1000 mg metamizole, 1h after the last inhibitor or placebo intake
46005594|NCT04649463|Diagnostic Test|Open ABPM results|ABPM results were used in the decision making for adjustments in antihypertensive medication at follow up visit.
46005595|NCT04620902|Other|Tear sampling|Tear sampling using Schirmer's strips
46005596|NCT04588701|Procedure|surgical procedures commonly done for anal fistula|Surgical procedures performed, including fistulotomy; fistulotomy with sphincter repair; seton; advancement flap; fistula plug;
46005597|NCT00567762|Drug|FK506|Opthalmic suspension
46005598|NCT00567762|Drug|placebo|placebo eye drops
46005599|NCT04620785|Other|methylene blue / IPL|therapeutic
46005600|NCT04620785|Other|IPL|therapeutic
46005601|NCT04620785|Other|saline|placebo
46005602|NCT00567801|Procedure|conventional embolectomy/thrombectomy|
46005603|NCT00567801|Procedure|embolectomy/thrombectomy with controlled reperfusion|
46005604|NCT04620590|Drug|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin is a stable, reversible, highly selective, and orally active inhibitor of human renal sodium glucose co-transporter 2 (SGLT2), the major transporter responsible for glucose reabsorption in the kidney. Patients will receive one tablet dapagliflozin 10 mg per day for a total period of 14±1 days. This dose is the recommended dose for monotherapy and for add-on combination therapy with other glucose-lowering medicinal products including insulin to improve glycaemic control in T2DM.
46005605|NCT04649268|Device|Group B|The C2 CARE C2 Physio 2019.2 has been developed for physiotherapy rehabilitation purposes including vestibular disorders. Virtual reality environments will be provided via the VR Oculus Quest headset as part of the OKS exposure incorporated within a customised VRT programme. Participants will attend 45 minute individualised supervised sessions once weekly for 8 weeks. Participants in this rehabilitation group will also have a home-based exercise programme to practise on days not attending clinic. The home-based programme will incorporate customised VRT exercises with exposure to VR environments using the VR Oculus Quest headset.
46005606|NCT04649268|Other|Group A|Optokinetic stimulation treatment delivered through visual motion DVDs. Individualised 45 minute supervised sessions will occur for this group also once weekly for 8 weeks together with a home-based customised VRT programme incorporation the DVD to practise on days not attending clinic. Participants will have to use the OKS DVD for their exercises at home daily for 8 weeks as part of the prescribed home exercise programme.
46005607|NCT04691219|Dietary Supplement|Mulberry leaves powder|Dried powder of mulberry leaves crude extract containing 12 mg of DNJ will be packed in a sealed packet with light and moisture protection. Participants will be instructed to mix 1 packet of the powder with a half glass (approximately 120 mL) of plain water and ingest thrice daily before meals. Additionally, they will be informed to rinse the glass with more water and drink to ensure that all of the powder will be taken.
46090970|NCT04876937|Drug|Placebo (normal saline)|Placebo (normal saline) is infused at a rate of 0.025-0.05 ml/kg/h from study recruitment in the ICU during mechanical ventilation, for no more than 7 days.
46090971|NCT04165590|Other|Plasmodium immunotherapy|The patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.1-1.0 × 10^7 Plasmodium parasites.
46090972|NCT02826629|Device|Manual dexterity|Control of manual dexterity will be assessed by a force sensor (Power Grip Manipulandum, PGM)
46090973|NCT02826629|Device|Oculomotor movements|Oculomotor movements during behavioral task will be recorded using a video-oculography device
46090974|NCT02826629|Device|TMS coupled to EMG recording|The involvement of cortical inhibition in this volitional inhibition task will be studied by neuronavigation guided TMS coupled to EMG recording
46090975|NCT02826629|Other|Psychopathological evaluations|
46090976|NCT02826629|Other|Neuropsychological evaluations|
46005608|NCT04691219|Behavioral|Diet control|Participants will be requested for diet control. They will be asked for attending the diet control program, maintaining diet pattern throughout the study period, and recording a 3-day food record. Individual counseling and assessment of compliance will be performed by licensed dietitians every 4 weeks. Diet control is principally based on carbohydrate counting.
46005609|NCT04691063|Drug|SHR-1316; Carboplatin; Etoposide；Radiotherapy|SHR-1316; Carboplatin; Etoposide；Radiotherapy（Part 1 and Part 2）
45459327|NCT05154266|Behavioral|Taking it Further|This programme is offered to individuals who have already completed a Mindfulness-Based Cognitive Therapy (MBCT) or Mindfulness-Based Stress Reduction Programme (MBSR). In this programme, participants explore weekly themes (i.e. 'Responding not reacting' and 'Taking care of ourselves, taking care of others'). These themes reinforce the learning from the eight-week MBCT/MBSR courses whilst also providing new learning opportunities. The programme makes some of the dimensions that are implicit in MBCT/MBSR more explicit; for example, the cultivation of attitudes of mindfulness (such as equanimity, joy, and kindness). These attitudes of mindfulness require a foundational mindfulness practice and thus this is an additive learning theme from traditional MBCT/MBSR programmes.
45836336|NCT00142506|Drug|placebo tablets and questionaires|"Non-hormone therapy patients will be instructed to begin the study drug 3 days prior to start of radiotherapy. Patients beginning study drug anytime between 3 days before start of radiotherapy and 2 weeks after the first day of radiotherapy will also be acceptable. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.~In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand, open label, flexible dose fashion. Non-hormone patients will be offered on demand Sildenafil for approximately 12 months.~Assessments (IIEF, IPSS, QOL) will be completed by non-hormone therapy patients at baseline (within 4 weeks of start of study treatment) and at approximately months 3, 6, 9, 12, 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
45836337|NCT05266794|Drug|Alpha lipoic acid|20 patients who received Alpha Lipoic acid (ALA) (Thiotex fort®) 600mg once daily with their routine therapy just after the dialysis sessions for 3 months.
46005610|NCT04691063|Drug|Palcebo; Carboplatin; Etoposide；Radiotherapy|Palcebo; Carboplatin; Etoposide；Radiotherapy（Part 2）
46005611|NCT04588467|Other|Medical treatment|Pregnant women complaining thrombosed haemorrhoids will receive dietary modification (intake of at lest 3 liers of water), stool-softeners (a 25 ml solution containing: Macrogol 3350: 13.125 g Sodium chloride: 0.3508 g Sodium hydrogen carbonate: 0.1786 g Potassium chloride: 0.0502 g) and local anesthetics application
46005612|NCT04588467|Procedure|Surgical treatment|Pregnant women complaining thrombosed haemorrhoids will receive local excision or thrombectomy under local anesthesia
46005613|NCT04620395|Diagnostic Test|Punch biopsy|A standardized biopsy kit is used for a synovial fluid tap and subsequent acquisition of up to 7 Punch biopsies through an introducer (part of the kit)
45459328|NCT03485716|Other|running on a treadmill under normoxia or hypoxia|"30 min running (60% VO2max) on a treadmill under hypoxia (O2: 14%)~30 min running (60% VO2max) on a treadmill under normoxia (O2: 20%)"
45459329|NCT01367756|Drug|RO4995819|multiple oral doses, Days 10-16
45459330|NCT01367756|Drug|citalopram|multiple oral doses, Days 1-16
45459331|NCT01367756|Drug|placebo|multiple oral doses, Days 10-16
45459332|NCT04624958|Drug|Zanubrutinib and Rituximab|Zanubrutinb 160mg PO BID d1-28; Rituximab 375mg/m2 iv.drip d1.
45836338|NCT05266794|Drug|Selenium|23 patients who received Selenium 200µg once daily with their routine therapy just a
46005614|NCT04581993|Dietary Supplement|Super Cereal - wheat soya blend with sugar|Pregnant and lactating women will received Super Cereal during pregnancy and first six months of lactation.
46005615|NCT04581993|Dietary Supplement|Lipid-based nutrient supplement-medium quantity (LNS-MQ)|Children will receive LNS during 6-23 months of age.
46005616|NCT04581993|Behavioral|Social and behavior change communication (SBCC)|SBCC will be provided to improve care-givers knowledge, attitudes and practices related to infant and young child feeding.
46005617|NCT01151215|Drug|AZD8931|Tablet, oral, bd
46090977|NCT05660993|Drug|Nivolumab|"Drug: Nivolumab Schedule: Nivolumab 3 mg/kg on day 0 of the Nivo-BeGEV or a maximum of 4 cycles Drug: Bendamustine~Schedule:~Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles Other Name: Ribomustin~Drug: Gemcitabine Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles Other Name: Gemzar~Drug: Vinorelbine Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles Other Name: Navelbine"
46090978|NCT04243265|Procedure|MPFL reconstruction with fascia lata allograft|Reconstruction of MPFL using a fascia lata allograft. The rationale for this technique is to stabilize the patella and limit medium to long-term patellofemoral arthritic degeneration by restoring the MPFL in the most anatomical way possible, not using a tubular graft but an aponeurosis with biomechanical characteristics similar to the native MPFL. The MPFL reconstruction can be used alone or in association with the realignment of the extensor apparatus by transposition of the anterior tibial tuberosity, managing to correct most of the recurrent patellofemoral instabilities. Only in very serious particular cases is it necessary to perform more invasive additional procedures with a more uncertain clinical result (such as Trocleoplasty).
46090979|NCT02643654|Drug|MABp1|This is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal
46090980|NCT02643654|Drug|Placebo|The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
46090981|NCT00633659|Drug|Hemospan (MP4OX)|250 mL of Hemospan (MP4OX)
46005618|NCT01151215|Drug|anastrozole|Tablet, oral, od
46005619|NCT01151215|Drug|Placebo|Tablet, oral
45836339|NCT00142818|Drug|Naltrexone|150 mg daily for males; 100 mg daily for females
46090982|NCT00633659|Drug|Voluven (HES 130/0.4)|250 mL of Voluven (HES 130/0.4) solution
46090983|NCT02652936|Drug|AF-130|AF-130 oral capsules (50 mg) administered as a single dose or once daily for 7 days
46005620|NCT04588389|Drug|Ropivacaine injection Location 1|Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1
46090984|NCT02652936|Drug|Placebo comparator|AF-130 matching placebo capsule
46090985|NCT04241705|Other|Treatment of positive individuals per national treatment guidelines|"Treatment for everyone except children <6 months of age, pregnant women, women breastfeeding children <6 months of age, and women 12-49 years of age with an unknown pregnancy status:~P. falciparum cases: artemether-lumefantrine (AL) plus single dose primaquine (PQ) (0.25mg/kg daily)~P. vivax cases: chloroquine (CQ) plus 14 days of PQ (0.25mg/kg daily)~Mixed infections: AL plus 14 days of PQ (0.25mg/kg daily)~Treatment for pregnant women and women breastfeeding children <6 months of age:~P. falciparum cases or mixed infections: Quinine (1st trimester); AL (2nd & 3rd trimesters or breastfeeding)~P. vivax cases: Chloroquine (CQ)"
46090986|NCT04241705|Other|Presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ)|"Everyone who is eligible for the study except pregnant women and women breastfeeding children <6 months of age AND who are confirmed to have normal G6PD status will be treated presumptively with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ). Treatment will be given without RDT for malaria.~Women in the first trimester of pregnancy will be treated presumptively with quinine.~Women in the second and third trimesters or women who are breastfeeding will receive artemether-lumefantrine (AL).~Again, treatment will be given without RDT for malaria."
46090987|NCT04241705|Other|Optimized malaria control interventions|Optimized malaria control interventions that includes strengthened surveillance systems and commodities management, scale-up of vector control and case management services including follow-up, and social and behavior change communication to seek prompt treatment and use long lasting insecticidal nets (LLINs). Case management includes passive detection of malaria cases and treatment with artemether-lumefantrine (AL) plus single low dose primaquine (PQ) (0.25mg/kg once) for Plasmodium falciparum (Pf) cases and chloroquine (CQ) plus 14 days of PQ (0.25mg/kg daily) for Plasmodium vivax (Pv) cases, and AL plus 14 days of PQ (0.25mg/kg daily) for mixed infections as well as follow-up at the health post or health center on days 3, 7, and 13 for those receiving 14 days of PQ to assess for adverse events and adherence as per the national treatment guidelines.
46090988|NCT02643342|Device|Orthokeratology|
46090989|NCT04243109|Drug|Pomalidomide + Cyclophosphamide + Dexamethasone|"Treatment Phase: Combination of Pomalidomide, Cyclophosphamide and Dexamethasone, days 1-21 every 4 weeks (28 day cycles), up to a total of 8 cycles:~Pomalidomide: Treatment with Pomalidomide 4 mg / day 1-21 days in 28-day cycles is started. Dose reductions will be made based on the evaluation of hematological and non-hematological toxicity.~Cyclophosphamide: Cyclophosphamide will be administered 15 mg / day, days 1-28 in 28-day cycles.~Dexamethasone: Dexamethasone will be administered 40 mg / day, days 1, 8, 15 and 22 in 28-day cycles. In patients older than 75 years the dose will be reduced to 20 mg / day in the same previous schedule.~Maintenance Phase: Combination of Pomalidomide and Dexamethasone. The last doses prescribed in the previous cycle will be maintained."
45836340|NCT00142818|Drug|Modafinil|400 mg daily
45459333|NCT04624958|Drug|R-DHAOx|Rituximab 375mg/m2 iv.drip d1; Dexamethasone 20mg iv.drip d1-4; Cytarabine 2000mg/m2 (1000mg/m2 for patients aged over 65) iv.drip d2,3 Oxaliplatin 130mg/m2 iv.drip d1.
45459334|NCT04624958|Drug|Zanubrutinib Maintenance|Zanubrutinb 160mg PO BID.
45836341|NCT00142818|Drug|Placebo|400 mg and/or 100-150 mg placebo pills
46005621|NCT04588389|Drug|Ropivacaine injection Location 2|Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2
45459335|NCT03489226|Dietary Supplement|Capsimax|Capsimax
45836342|NCT05266716|Behavioral|Affect Methamphetamine Treatment Program|"Components of the treatment services include: contingency management (CM; monetary incentives for drug tests negative for stimulants), the digital behavioral therapy curriculum (based on CBT) delivered via the Affect app on smartphones, weekly one-on-one telemedicine (TM) with clinical personnel and group therapy, and referral to psychiatrist for medication support, as needed. The program incrementally builds skills and beliefs to develop personally meaningful strategies to combat cravings, using such techniques as regular app-promoted deep breathing exercises, daily exercise, and help in making and sticking to a relapse prevention plan. Counseling sessions are arranged via text sent by the Team Care advocate and also presented to the participant via the app as a reminder. Individual and group therapy sessions occur over Zoom, which is integrated into the app.~Contingency Management (CM). CM utilizes monetary incentives and rewards to promote behavior change."
46005622|NCT04588389|Drug|Multimodal Pharmacological Management|standard of care multimodal pharmacological management
46005623|NCT04620473|Drug|Anlotinib+Capeox|to use Anlotinib hydrochloride combined with Capeox in the neoadjuvant treatment of locally advanced rectal cancer
46005624|NCT04620473|Drug|Capeox|to use Capeox in the neoadjuvant treatment of locally advanced rectal cancer
46005625|NCT00637234|Drug|Oxcarbazepine|Oxcarbazepine (OXC), 300 mg tablets, up to 600 mg three times daily
46005626|NCT00637234|Drug|Placebo|Placebo, 300 mg tablets, up to 600 mg three times daily
46005627|NCT04581720|Device|Train-of-four (TOF)|Give 4 electrical stimulants on the ulnar nerve to see if the 4 responses (T1 ~ T4) of adductor pollicis fade or not. If there's no neuromuscular block, it shows no fade, or it fades. When an operation is over under general anesthesia, we use the ratio of the height of T4 to T1, and the ratio is over 90%, the neuromuscular block is recovered enough to extubation.
46005628|NCT02883985|Radiation|6 Gy/ fraction|"All patients will be treated with 6 Gy (measure of radiation dose) /fraction (each radiation session) delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.~In addition to routine care, patients may receive antihormonal drugs as part of your base line treatment."
46090990|NCT02824835|Procedure|biopsy during colonoscopy|sampling the lesion with forcept biopter
46005629|NCT02940665|Other|ERAS|Patients in the ERAS group received the ERAS protocol
45836343|NCT00147030|Procedure|Whole body mild induced hypothermia|Target rectal temperature 33-34°C for 72 hours, commencing by 6 hours of age; followed by re-warming at 0.5°C to normothermia
46005630|NCT04588194|Drug|Romiplostim|Romiplostim 2mcg/Kg subcutaneously weekly days 1, 7, 14, 21
45836344|NCT05266560|Drug|ciprofol|A new type of anesthetic drug, Ciprofol, which is newly listed and has national independent intellectual property rights, is an analogue of propofol. Its chemical name is 2-[(1R)-1-cyclopropylethyl]-6-isopropyl-phenol, and it acts on GABAA receptors like propofol. Compared with propofol, ciprofol is 4-5 times more potent, which can significantly reduce the amount of anesthetics.
46005631|NCT04588194|Drug|Rituximab|Rituximab 100 mg weekly days 1, 7, 14, 21
46005632|NCT04588194|Drug|Dexamethasone|40 mg IV/PO days 1-4
46005633|NCT04587921|Device|Digital oximeter monitoring|Digital oximeter and cardiac frequency monitoring.
46090991|NCT02640456|Biological|Bacteriology|Tonsillar surface swabs, tonsillar tissues, and pus aspirates.
46005634|NCT02940314|Drug|HIP1503|
46090992|NCT02640456|Procedure|Type of surgery|Surgical approach and complications.
46090993|NCT02640456|Biological|Biochemistry|Amylase concentration i pus aspirates.
46005635|NCT02940314|Drug|HGP1103|
46090994|NCT02640456|Biological|Serology|Levels of antibodies against selected bacteria (F. necrophorum, F. nucleatum, and Group A streptococci) in acute and convalescent sera.
45342468|NCT02574624|Procedure|Intraocular assistance|Intraocular assistance with help of surgical assistants during vitreous surgery (VISIA) in patients who require vitreous surgeries as part of standard of care procedure for conditions like retinal detachments, dislocated intraocular lens and glaucoma patients requiring endophotocoagulation.
45459336|NCT03489226|Dietary Supplement|Placebo|Placebo
45459337|NCT03489226|Other|Meal|Meal
46005636|NCT04581525|Device|transcranial direct current stimulation|
46090995|NCT04861181|Biological|Pharmacokinetics, Dosage of Niraparib|The biological samples collected during the NIRAPK study will be blood only. The complete biological work-up will be processed in the same way as the usual routine care procedure. Serum niraparib will be measured over 3 courses just prior to treatment (Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1). Close-up kinetic measurements will also be taken at 1 Hour, 2 Hours, 4 Hours, 6 Hours and 24 Hours at Cycle 1 Day 15.
46090996|NCT02640378|Other|NO intervention|This study was a cross-sectional study. It had no intervention.
45459338|NCT03067714|Other|Infant formula with added synbiotics|Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.
45459339|NCT03067714|Other|Standard infant formula|Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).
46005637|NCT04620083|Other|Integrative Learning Program for Old People with Dementia|The program included modalities for reality orientation, daily living skills training, reminiscence therapy, multisensory stimulation, fall prevention program, mindfulness activities, Meridian exercise, brain health program (Four Arts of the Chinese Scholar which referred to zither, go, calligraphy and painting) and health education. It was also agreed that case managers, caregivers, and participants were free to choose these treatments or could be assigned to a treatment regime on a 'mix and match' basis to suit their personality traits for improving their abilities to meet their own needs. This program was developed by the team using Delphi technique.
46005638|NCT04581564|Device|Rhythm-based speech therapy app (i.e., Speech Hero)|Patients with non-fluent aphasia will practice speech production during the intervention period.
46090997|NCT00603512|Drug|Placebo|0 mg BID, 3 blinded tablets administered BID for 12 weeks
45459340|NCT01374152|Other|cognitive sensory motor training therapy|training method that emphasis on cognition/ sensation/ and motor movement together train every working day 45 minutes per day for 4 weeks.
45459341|NCT03485560|Combination Product|ACE CSD|Topical application of the ACE CSD 4 times daily.
45459342|NCT03289702|Drug|CORETOX®|Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.
46090998|NCT00603512|Drug|CP-690,550|10 mg BID, 3 blinded tablets administered BID for 12 weeks
46090999|NCT00603512|Drug|CP-690,550|1 mg BID, 3 blinded tablets administered BID for 12 weeks
46091000|NCT00603512|Drug|CP-690,550|3 mg BID, 3 blinded tablets administered BID for 12 weeks
46091001|NCT00603512|Drug|CP-690,550|5 mg BID, 3 blinded tablets administered BID for 12 weeks
46091002|NCT04167774|Drug|Camrelizumab|Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg (3mg/kg for underweight patients).
46091003|NCT04167774|Drug|nb-Paclitaxel|nb-Paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 260mg/m2 for 4-6 cycles.
46091004|NCT02823509|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation-SR15-68_R84-089)
46091005|NCT02640300|Drug|Clozapine|Switching to clozapine with immediate or gradual antipsychotic discontinuation
46091006|NCT04241393|Drug|Tavapadon tablet|Participants will receive multiple dose titration of Tavapadon (0.25 mg once daily [QD] on Days 1 to 3, 0.5 mg QD on Days 4 to 6, 1.0 mg QD on Days 7 to 9, 1.5 mg QD on Days 10 to 12, and 2.5 mg QD on Days 13 to 15)
46091007|NCT04241393|Drug|Tavapadon [14C] suspension|Following 15-Day multiple dose titration of Tavapadon, participants will receive a single oral dose of Tavapadon 2.5 mg containing approximately 100 μCi of [14C] Tavapadon on Day 16
46091008|NCT02823587|Other|Pulmonary Rehabilitation|The exercise program will consist of an individual exercise prescription on the treadmill or bike, the initial intensity of 85% VO2max and active exercises or active-resistance for upper and lower limbs according to the capacity of each volunteer.
46091009|NCT02823587|Other|Control|No supervised exercise session, only will be informed at the beginning of the study to perform thirty minutes of physical activity of moderate intensity several days a week is associated with health benefits
46005639|NCT04620044|Other|Kaledo game|Before starting the study, the height and weight of the children in the play group were measured and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.Then the game sessions were started.Game sessions lasted 12 weeks. After 12 weeks, the height and weight measurements of the students were made and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.
46091010|NCT04838639|Drug|NO-13065|"Single ascending doses of NO-13065 in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065.~Single ascending dose of NO-13065 with food effect arm. Multiple ascending doses of NO-13065 for 10 or up to 28 days in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065."
46091011|NCT04838639|Drug|Placebo|Two subjects per cohort will take a matched placebo.
46091012|NCT02640144|Drug|Sodium Hyaluronate 1%|Intra articular knee injection following arthroscopy
46091013|NCT02640144|Drug|Placebo|Intra articular knee injection following knee arthroscopy. Serves as a placebo. This is the actual buffer of the ARTHREASE injection.
45678189|NCT01909466|Drug|Aripiprazole, OPC-14597|5 monthly applications of 400 mg of aripiprazole IM depot, where the first application is in the gluteal or deltoid muscle followed by 4 monthly administrations to the deltoid muscle
46005640|NCT04620044|Other|Education|Before starting the study, the height and weight of the children in the education group were measured and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.Then the education sessions were started.education sessions lasted 12 weeks. After 12 weeks, the height and weight measurements of the students were made and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.
46091014|NCT04242875|Diagnostic Test|Angle Kappa|Angle kappa will be measured using the OPD III scan.
46091015|NCT04242875|Other|Visual disturbance questionnaire.|Questionnaire evaluating visual disturbances.
45342469|NCT02575638|Drug|CZ48|CZ48 is an analog of the topoisomerase I inhibitor Camptothecin (CPT). CPT is a natural extract from the tree Camptotheca acuminata
46091016|NCT04165668|Other|Exposure: First on scene|To be first on scene for resuscitation at the suspected out-of hospital cardiac arrest, before EMS and first responders (fire and police services)
46091017|NCT05660837|Behavioral|T1: Mixed mode social support group|"This group will receive programs in both online and off-line setting. There will be one face-to-face group session to get to know participant's peer group members. After the in-person group meeting, participants will meet in WhatsApp group. In WhatsApp group, facilitator will provide the following program~In person get to know your group member activities~Nutrition information through WhatsApp~Tips and advice to maintain good mental health through WhatsApp~Motivational messages through WhatsApp~Reminder through WhatsApp~In-person baking class x 1 session"
45342470|NCT02573610|Drug|DE-108|Subjects will be assigned to receive DE-108 ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
45459343|NCT03289702|Drug|BOTOX®|Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.
45678190|NCT01977625|Drug|Lisdexamfetamine|The overall objective of this study is to assess the effects of LDX on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
45678191|NCT01977625|Other|Placebo|To assess the effects of a placebo pill on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
45678192|NCT01944631|Device|Placebo|Nasal spray saline
46091018|NCT05660837|Behavioral|T2: Online mode social support group|"This group will receive the same program as mixed mode social support group. The key differences would be delivery of all program components online.~Online get to know your group member activities~Nutrition information through WhatsApp~Tips and advice to maintain good mental health through WhatsApp~Motivational messages through WhatsApp~Reminder through WhatsApp~Online baking class x 1 session through WhatsApp"
46005641|NCT04620044|Other|No intervention|Body mass indexes were calculated by measuring the height and weight of the students.Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.The same measurements and scale applications were repeated after 12 weeks.
46091019|NCT02643264|Other|rTMS 10 Hz targeting the insula|Participants will receive a total of 15 sessions of rTMS targeting the insula bilaterally, Stimulation will be delivered at an intensity of 120% of the motor threshold (MT), with a frequency of 10 Hz, delivered as 50 trains of 30 pulses delivered in each train of 3 seconds duration, with a 20 seconds inter-train interval, for a total of 1500 pulses delivered over app. 20 min. On the very first two sessions stimulations will be given at lower strength for adaptation, starting at 100% for the first and 110% for the second session
46091020|NCT02643264|Other|Sham rTMS|Sham stimulation with the same regimen as active treatment
46091021|NCT05029661|Diagnostic Test|Carotid ultrasound|"Ultra-COMPASS measurements (longitudinal + cross-sectional) Shear wave elastography: plaque stiffness Strain elastrogaphy: plaque deformation B-mode visualization: geometry~Intima-media thickness~Pulse wave velocity"
46091022|NCT02643186|Drug|preoperative vaginal misoprostol|preoperative vaginal misoprostol 400 micrograms 1 hour before surgery
46091023|NCT02643186|Procedure|bilateral uterine artery ligation|bilateral ascending uterine artery ligation at the level of uterine isthmus with 2/0 vicryl sutures
46091024|NCT02826395|Drug|Carbon-11 Sodium Acetate|PET/CT Scans will be performed with or without oral and IV contrast. All investigational scans will be read by at least one board-certified nuclear medicine physician with established expertise in PET/CT of at least 5 years' experience. Fifteen minutes after injection of 11C-Sodium Acetate, we will acquire a scan Emission images will be acquired for 3-5min/bed position. Intravenous and oral contrast will be given for the CT portion of the study.
46091025|NCT02652312|Drug|Dexmedetomidine|A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour made to 20 mL with normal saline will be administered
46091026|NCT02652312|Drug|Placebo|A maintenance dose of 20 mL with normal saline will be administered at a rate similar to that of dexmedetomidine
46091027|NCT02652312|Procedure|Ondansetron|0.15 mg/kg intravenous (IV) will be given as a pre-medication
46091028|NCT02652312|Procedure|fentanyl|1.5 μg/kg intraoperative
46091029|NCT02652312|Procedure|propofol|10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia
46091030|NCT02652312|Procedure|Atracurium|0.5 mg/kg IV for endotracheal intubation
46091031|NCT02652312|Procedure|diclofenac sodium|1 mg/kg for postoperative analgesia
45678193|NCT01944631|Device|Iota-Carrageenan|Nasal spray containing 1.20 g/l Iota-Carrageenan in saline
46091032|NCT02652312|Procedure|desflurane|1 MAC concentration (expired fraction of 6.0 vol%) for maintenance of anesthesia
46091033|NCT02826317|Procedure|preoperative and postoperative setting|Preoperative assessment will consist on collecting demographic data as well as the presence preoperative chronic pain and its localization, preoperative opioid, gabapentin or pregabalin consumption. In postoperative, we will collect the following data: type of anesthesia, intra operative ketamine administration, type and total dose of opioid administered during surgery. Pain will be evaluated at least 2 hours after the surgery within the same day (D0) and then at day 2 (D2), 1 (M1) and 2 months (M2) after the surgery. Pain will be assessed using a 10-point NPS. If NPS >0, neuropathic pain will be diagnosed on the basis of DN4 questionnaire. NCPSP is defined by NPS >0 and positive DN4 (DN4 ≥ 4 /10) (11). APSNP and CPSNP are defined by D0/D2 DN4≥ 4/10 and M1/M2 DN4≥ 4/10, respectively.
46091034|NCT02826083|Dietary Supplement|XXS|
46091035|NCT02826083|Dietary Supplement|non-XXS|
46091036|NCT02643030|Behavioral|hypercapnia|Tidal volume (6 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 45mmHg
46091037|NCT02643030|Behavioral|normocapnia|Tidal volume (10 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 35mmHg
46091038|NCT05660759|Procedure|Portal vein embolization|Portal vein emboliazation with either NBCA or micro particles.
46005642|NCT04620122|Other|Progressive Muscle Relaxation Training and Music Therapy|Progressive Muscle Relaxation Training and Music Therapy have applied to the participants two sessions for a week during two months.
46005643|NCT04581213|Procedure|General anesthesia|Children under general anesthesia for an elective surgery, aged between 6 months and 5 years old, ASA 1-2.
45678194|NCT01948063|Drug|Ubiquinol|Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
45678195|NCT01948063|Dietary Supplement|Placebo|Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
46005644|NCT04581291|Other|Moderate Intensity Aerobic Exercises|Participants in the exercise group performed a two weeks aerobic exercise program. The exercise program consisted of walking/running on a treadmill or bicycling on a stationary bicycle. Each session is composed of five-minute warm-up slow walking or bicycling. Then the main intervention which composed of thirty-minutes of moderate-intensity aerobic exercises (walking/running or bicycling). Lastly, a five-minute of cool-down exercises (walking/running or bicycling). The exercise intensity was 60-75% of the predicted MHR (calculated as MHR=210-age).
45678196|NCT01995071|Drug|ABT-493|Tablet
45678197|NCT01995071|Drug|ABT-530|Tablet
45678198|NCT01995071|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
46005645|NCT04620317|Dietary Supplement|Synbiotic|10 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01, Bifidobacterium lactis BB12, and inulin oligofructose
45678199|NCT01995071|Drug|Ribavirin (RBV)|Tablet
45678200|NCT01994837|Drug|ABT-199|Tablet
45678201|NCT02010593|Drug|Dapivirine Vaginal Ring|Dapivirine, a non-nucleoside reverse-transcriptase inhibitor (NNRTI), is a substituted amino- pyrimidine (DAPY) derivative with potent antiviral activity against HIV-1. Dapivirine is chemically described as 4-[[4-[(2,4,6-trimethylphenyl)amino]-2- pyrimidinyl]amino]benzonitrile.6 The dapivirine matrix VR is a flexible ring containing 25 mg of drug substance dispersed in a platinum-catalyzed-cured silicone matrix. Dapivirine is known to be well-suited for delivery via VR
46005646|NCT04620317|Dietary Supplement|Placebo|Non-active ingredients - Maltodextrins
46091039|NCT04165512|Combination Product|bupivacaine and triamcinolone|a mixture of 4 mL 0.5% bupivacaine (marcaine) and 1 mL 40 mg triamcinolone (kenacort-a)
46091040|NCT02826473|Other|BRAINCHECK|Subjects of the Intervention-Group will undergo a brief cognitive assessment, using the BRAINCHECK, during hospital admission assessments. Subjects with positive results will then be referred to a Memory Clinic undergoing subsequent interdisciplinary comprehensive diagnostic examinations. Patients with established diagnosis will be invited to counselling services of the Alzheimer Association (providing social counselling).
46091041|NCT00653094|Device|Halevy kit|the use of Halevy kit in Crohn patients with Fistulas
45459344|NCT03126344|Device|King Vision video laryngoscope|nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
45459345|NCT03126344|Device|McGrath MAC video laryngoscope|nasal intubation using McGrath MAC video laryngoscope Device after general anesthesia induction
45459346|NCT03126344|Device|Macintosh laryngoscope|nasal intubation using Macintosh laryngoscope Device after general anesthesia induction
45459347|NCT03485482|Drug|Bisoprolol|bisoprolo 5 mg tablets
45459348|NCT03485482|Drug|Ivabradine|Ivabradine 10 mg tablet
45678202|NCT02010593|Drug|Placebo Vaginal Ring|The placebo VR is a flexible, platinum-catalyzed-cured silicone matrix ring, identical to dapivirine Ring-004, containing no active drug.
45678203|NCT01994291|Drug|Ranibizumab|"Intravitreal Injection supplied as:~10 mg/mL in a 0.2 mL vial with instructions on preparation and administration of the 0.5 mg (0.05 mL) dose.~6 mg/mL in a single use vial with instructions on preparation and administration of the 0.3 mg (0.05 mL) dose.~Adminstered once a month for 12 weeks"
45678204|NCT01994291|Drug|Placebo|"Oral Placebo is provided in tablet form to match the 50mg dose of PF-04634817.~Dose is 4 tablets each day for 12 weeks"
45678205|NCT01994291|Drug|PF-04634817|Four 50mg tablets PF-04634817 once a day for 12 weeks.
46091042|NCT02642874|Drug|Methocarbamol|Methocarbamol twice daily
46091043|NCT02642874|Drug|Calcium Carbonate|Calcium carbonate twice daily
46091044|NCT02824289|Behavioral|Sun Safe Workplaces Program|The intervention began by sending a Program Announcement Packet and requesting the first face-to-face meeting. At the first meeting, intervention staff covered: 1) Introduction to SSW; 2) Sun Safety Practices in the Workplace; 3) Sun Safety Policy for Outdoor Workers; 4) Sun Safety Policy Adoption; 5) Sun Safety Policy Reinforcement and Maintenance. They presented the SSW Website and a Sun Safety Tool Box. Following the first meeting, the manager scheduled Sun Safety Training by intervention staff with various employee groups. Workplace Sun Safety Materials were sent in four sets (twice a year over two years) for distribution to employees. Research staff made monthly Follow-up Contacts with managers.
45342471|NCT02573610|Drug|Levofloxacin 0.5%|Subjects will be assigned to receive Levofloxacin 0.5% ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
46091045|NCT02824289|Behavioral|Attention Control|Research staff sent printed materials on occupational sun safety to local government organizations twice. These included posters with personal protection messages and skin cancer rates, risk assessment brochures, worksite guides, total skin self-examination CD-Rom, the American Academy of Dermatology SPOT bookmark, and a sun safety tip card from the Occupational Safety and Health Administration (OSHA). Staff made presentations on general sun safety topics (not policy) at state professional conferences.
46091046|NCT03396510|Other|IMPROVED intervention|Patients randomized to IMPROVED will self-report their symptoms each day using a tablet computer. If any patient refuses or is unable to complete the symptom assessment on the computer, the investigators will permit them to use paper versions. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden. Patients randomized to IMPROVED will have their symptoms presented to their inpatient oncology team, but the investigators will not provide guidance about what actions to take in response to patients' symptoms.
46005647|NCT04620863|Other|t-DCS group|All the participants received daily stimulation sessions for 5 consecutive days, starting from the first Monday after hospital admission (Monday to Friday). The primary motor cortex (M1) was identified using the International 10-20 system for C3 (left M1) or C4 (right M1). For the stimulation, the anode was placed over the primary motor cortex (M1) ipsilateral to the side of trunk deviation, and the cathode was placed over the primary motor cortex (M1) contralateral to the side of trunk deviation (bi-hemispheric stimulation).
46005648|NCT04620863|Other|Sham group|The stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.
45459349|NCT03485482|Drug|combination of Ivabradine and bisoprolol|combination of 10 mg ivabradine and 5 mg bisoprolol
46005649|NCT04588155|Device|Functional assessment|Timed Up and Go Test administration with application of Inertial Measurement Unit for a temporal and kinematic assessment of movement performed during test esecution
45459350|NCT02946424|Drug|Placebo Oral Capsule|12 month course of daily placebo
46005650|NCT04588155|Other|Clinical assessment|"Roland Morris Disability Questionnaire (RMDQ) to assess the level of functional impairment and disability in the activity of daily living~Numerical Pain Rating System (NPRS) administration to quantify level of pain experienced just before the TUG test execution"
46005651|NCT01151137|Drug|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
46005652|NCT01151137|Drug|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
45342472|NCT02575560|Other|history data|history data of PFS after 1st line or second line theray
45836345|NCT05266560|Drug|Propofol|Propofol is a commonly used anesthetic in clinical practice and is often used before ECT.
46005653|NCT02940470|Other|Calorie restricted diet plus exercise|Daily meals plus exercise providing 1000 kcal restriction per day for 12 weeks.
46005654|NCT02940470|Other|Weight management classes|Weekly 1-hour weight management classes for 12 weeks.
46005655|NCT01151098|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear
46005656|NCT04619771|Behavioral|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
46005657|NCT04581252|Device|Non-invasive cardiac system|Non-invasive cardiac system
46005658|NCT04619888|Diagnostic Test|HeartLogic|In case of HeartLogic index ≥16, the investigator will contact the patient to assess the patient's clinical condition and possibly adjust the heart failure treatment. The management will be standardized across centers according to the Manage-HF protocol.
46091047|NCT02824055|Drug|Placebo|Participants will receive placebo matched to RO5545965 capsules orally daily in any of the three intervention period.
46091048|NCT02824055|Drug|RO5545965|Participants will receive RO5545965 5 mg capsules or RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily in any of the three intervention period.
46091049|NCT02640066|Other|acupuncture|
46091050|NCT04829591|Other|observational|Heart failure, non interventional
45459351|NCT02946424|Drug|Simvastatin|12 month course of daily simvastatin
45459352|NCT00783536|Drug|Etanercept + Methotrexate|
45459353|NCT00783536|Drug|DMARDS|
45459354|NCT01374230|Procedure|Total knee arthroplasty|Primary total knee arthroplasty surgery for the treatment of osteoarthritis.
45459355|NCT01367912|Drug|estradiol tablet|received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel
45459356|NCT01367912|Drug|estradiol tablet|received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel.
45459357|NCT00349466|Drug|CF101|Orally CF101 1mg
45459358|NCT00349466|Drug|Placebo|Orally matching Placebo
45459359|NCT04093466|Drug|CX1003|Oral dose A 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond) Dosage range: 25 mg, 50mg, 75mg, 100mg,125mg,150mg,175mg
45459360|NCT03115112|Drug|Bexagliflozin|tablets containing 20 mg bexagliflozin
46005659|NCT04587843|Drug|Contrave 8Mg-90Mg Extended-Release Tablet|"Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day)."
46005660|NCT04587843|Drug|Placebo|Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day for 1 year (2 tablets, taken twice a day).
45459361|NCT03115112|Drug|Sitagliptin|tablets containing 100 mg sitagliptin
46005661|NCT04619849|Diagnostic Test|EMG|Electromyography (EMG) is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles.
46005662|NCT04619849|Diagnostic Test|Palmaris Longus Test|Schaffer test will be done to understand the presence of palmaris longus. 4 different tests will be done to prove its absence.
46005663|NCT04587960|Procedure|Delayed primary closure of skin incision in Caesarean section in experimental group|Delayed closure of skin wound of emergency Caesarean section following wound dressing for 2-3 days in experimental group
46005664|NCT04587960|Procedure|Primary closure of skin incision in Caesarean section in active comparator group|Primary closure of skin wound (incisional) at the time of emergency Caesarean section in active comparator group
46005665|NCT04619576|Behavioral|Occupational health workers|Questionnaire online
46005666|NCT01151020|Device|Zenith® TX2® Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms/ulcers of the descending thoracic aorta having morphology suitable for endovascular repair
46005667|NCT04619810|Other|Nurse intervention program|Implementation of a specific care program for patients receiving immunotherapy for lung cancer
45459362|NCT03115112|Drug|Placebo for sitagliptin|inactive tablets to match the appearance of sitagliptin tablets
45459363|NCT03115112|Drug|Placebo for bexagliflozin|inactive tablets to match the appearance of bexagliflozin tablets
45459364|NCT03634280|Other|Kinesio taping|In patients in the splint group, 16-18 layers of cotton gauze (15-cm cast gauze) were applied from the tip of the toes to the beginning of the fibula. Following the gauze application, short leg splint application was performed in a neutral ankle position.
45459365|NCT01373528|Drug|Budesonide irrigation|A budesonide (1 mg) in saline (240 mL) irrigation solution is applied to the sinonasal cavities twice daily. 120 mL of the solution is applied via irrigation in the AM, and 120 mL again in the PM.
45678206|NCT01994291|Drug|Masked Sham Therapy|Empty, needle-less syringe is used by the unmasked team once a month.
46005668|NCT01150474|Drug|Belladonna and Opium Suppositories|Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
46005669|NCT01150474|Drug|Placebo Suppositories|Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
46005670|NCT05088044|Other|training porogram|training on modified early warning signs will be given to staff nurses and they will be asked to mark physiological parameters on MEWS chart and identify detrioration
46091051|NCT04165200|Diagnostic Test|Blood and feces samples|"Blood samples are going to be taken by puncturing peripheral vein extraction with 10 ml of venous blood for later biweekly to monitor in person and therefore monitor immune status with biomarkers T lymphocyte subclass CD4 and viral load. A total of four blood samples will be taken at weeks 4, 8, 12 and 24 of recruitment.~A total of four feces samples are going to be required during the study, to evaluate the changes on the microbiota of the patient. 1 week before the patients start their HAART, the same day the patients initiate their HAART, 8 weeks after they started HAART and 24 weeks after HAART."
46091052|NCT00603278|Drug|GW685698X|GW685698X
46091053|NCT00603278|Drug|placebo|placebo
46005671|NCT04587804|Device|rPMS+RF|The treatment administration phase will consist of three (3) treatments, delivered once a week. The applicator of the device will be applied over umbilicus and visible muscle contractions along with heating of the subcutaneous fat will be induced by the device.
45459366|NCT03634202|Combination Product|IMRT + oral chemotherapy|"It's a dose escalation of radiation (IMRT), during 5 to 7 weeks, 5 days per week.~Concomitantly, patient have oral chemotherapy (capecitabin)"
45459367|NCT05019560|Drug|Sevoflurane|IFT response, hemodynamics and BIS value were recorded during intubation period. Then the data acquisition was stopped and the isolated forearm cuff deflated. IFT values were noted by two independent observers
46091054|NCT02824211|Device|Right Dose System|Automated titration of oxygen system during exertion
46091055|NCT00653874|Device|BiliChek (jaundice assessment)|assessment of jaundice was done by either transcutaneous bilirubinometry (TcB) method or by clinical assessment of bilirubin (CaB)
46091056|NCT00653874|Procedure|Transcutaneous bilirubinometry (TcB)|transcutaneous bilirubinometry was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
46091057|NCT00653874|Other|Clinical asessment of bilirubin (CaB)|Clinical assessment of bilirubin (CaB) was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
46091058|NCT04224701|Biological|BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted|30 µg
46091059|NCT04224701|Biological|BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted|300 µg
46091060|NCT04224701|Biological|Placebo|Tris NaCl Diluent
46091061|NCT00653952|Drug|CAELYX|Dose of 50 mg/m2 by i.v. infusion over 1 hour every 28 days for up to 1 year
45459368|NCT05019560|Drug|TIVA|IFT response, hemodynamics and BIS value were recorded during intubation period. Then the data acquisition was stopped and the isolated forearm cuff deflated. IFT values were noted by two independent observers
45459369|NCT01373606|Drug|Terlipressin|
45459370|NCT03690284|Device|Conventional Double Lumen Tube|Patient will be intubated with Mallinckrodt Double Lumen endotracheal tube for single lung ventilation during thoracic surgery
46091062|NCT00653952|Drug|Paclitaxel HCl|Dose of 175 mg/m2 by i.v. infusion over 3 hours starting on Day 1 of a 21-day cy
45459371|NCT03690284|Device|VivaSight Double Lumen Tube|Patient will be intubated with the VivaSight double lumen endotracheal tube with an integrated camera for single lung ventilation during thoracic surgery
45459372|NCT03632252|Device|Powered ankle prosthesis|This device is a custom designed ankle prosthesis. Motors control force on the device through cables but are not worn by the person.
45459373|NCT03626012|Drug|BIIB078|Administered as specified in the treatment arm.
45459374|NCT03626012|Drug|Placebo|Administered as specified in the treatment arm.
45473947|NCT01285037|Drug|Cisplatin|Cisplatin given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, cisplatin may be continued as monotherapy until progression of disease. Participants discontinuing cisplatin therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
46005672|NCT04619459|Other|Kangaroo Mother Care (KMC)|Kangaroo mother care is a method of care of infants. The method involves infants being carried, usually by the mother, with skin-to-skin contact. Kangaroo mother care (KMC). early after delivery have better success at breastfeeding and achieve this success sooner. In this method The newborns' diapers were tied, their caps put on and then they were positioned on their mother's naked chest for KMC. The KMC session was continued for 3 hours.
46091063|NCT04241861|Other|Respiratory support (High-flow oxygen therapy)|Noninvasive respiratory support respiratory support
46091064|NCT04241861|Other|Respiratory support (Helmet PSV)|Noninvasive respiratory support respiratory support
46091065|NCT04241861|Other|Respiratory support (Helmet CPAP)|Noninvasive respiratory support respiratory support
46091066|NCT00650364|Drug|Midodrine HCl Tablets 5 mg|5mg, single dose fasting
46091067|NCT00650364|Drug|ProAmatine® Tablets 5 mg|5mg, single dose fasting
46091068|NCT02639832|Device|LiquidBiopsy®, NK VueTM|The LiquidBiopsy® device will test for cells with tumor cell markers in blood. The genetic sequence of DNA recovered samples will be studied. Using NK VueTM researchers will test for NK cell activity.
46091069|NCT04909697|Drug|Sivelestat sodium|4.8mg/kg sivelestat sodium was given in 50ml normal saline, and was continuously pumped in the dark for 24h, equivalent to 0.2mg/kg/h.Applied for 5 consecutive days
46091070|NCT04909697|Drug|Saline|50ml normal saline was continuously pumped in the dark for 24h. Applied for 5 consecutive days
45459375|NCT01367990|Drug|Norepinephrine|"The occipital scalp zone at risk for alopecia will be identified. The norepinephrine treatment site will be randomized to receive consistent treatment of one half of the scalp risk zone. Approximately 1.6 mL of a 400 mM norepinephrine solution will be applied topically to the norepinephrine site approximately 20 minutes prior to each radiation treatment, and placebo will be applied to the contralateral side (30-35 treatments)."
45459376|NCT03556358|Biological|TX05 (trastuzumab)|8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)
45459377|NCT03556358|Biological|Herceptin®|8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)
45836346|NCT05081934|Behavioral|A-CRA|12-14 weekly sessions of A-CRA, a behavioral treatment for youth suffering from substance use disorder and co-occurring problems. The average time for a placement within SiS is for boys 5,9 months and for girls 4,5 months. To further adjust A-CRA to the closed institutional care, frequency of sessions may be increased to twice a week. This is to facilitate maintaining of focus in treatment and closely follow treatment progress. Treatment consists of 18 procedures that aim to reduce problematic behaviors and increase constructive behaviors. Example of procedures are functional analysis of substance use behavior, functional analysis of prosocial behavior, increasing prosocial activities, drink/drug refusal, relapse prevention, anger management and caregiver sessions. Procedures are combined and tailored to youth individual goals and needs.
45459378|NCT03556358|Drug|Paclitaxel|175 mg/m^2, 60 min IV infusion, every 3 weeks (Cycles 5-8)
45459379|NCT03556358|Drug|Epirubicin|75 mg/m^2, IV bolus infusion, every 3 weeks (Cycles 1-4)
45678207|NCT02094677|Device|filcon II 3|Participants were randomized to wear filcon II 3 test lens.
45678208|NCT02094677|Device|etafilcon A|Participants were randomized to wear etafilcon A control lens.
45678209|NCT02094677|Device|nelfilcon A|Participants were randomized to wear nelfilcon A control lens.
45678210|NCT04667195|Other|Clinical assessment|"Within 4 hours of admission to the emergency department, clinical assessment will include:~Demographics,~comorbidity,~symptoms,~objective findings,~triage at admission,~blood test results,~urine test results"
45678211|NCT04674371|Other|central venous catheter insertion|Every operator should perform the CVC Insertion Procedure according to his common clinical practice.
46005673|NCT04580901|Behavioral|Group Interpersonal Psychotherapy|15 sessions over 12 weeks of group IPT taking place virtually via Zoom (2 sessions per week for the first 6 weeks (acute phase) then every other week for 6 weeks (maintenance phase)
45678212|NCT04667039|Biological|GNR-067|GNR-067 will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
45678213|NCT04667039|Biological|Lucentis®|Lucentis® will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
45678214|NCT01993823|Drug|G238|Five drops into the ear canal twice daily for 14 days
46091071|NCT00654108|Drug|Ciprofloxacin|500 milligrams(mg) will be administered orally twice daily for 5 days.
46091072|NCT00654108|Biological|Peru-15-pCTB|Live attenuated oral combined ETEC-cholera (Peru-15 pCTB) vaccine co-administered with bicarbonate buffer solution; vaccine dose levels 1 X 10^7; 1 X 10^8; 1 X 10^9; and 1 X 10^10.
46091073|NCT00654108|Other|Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer|Buffer solution: 2.5 grams (g) Sodium Bicarbonate powder, 1.65 g Ascorbic Acid and 25 mg Aspartame, in 100 milliliters (mL) water for injection.
46091074|NCT04165902|Drug|compare the effects of steroid plus hyaluronic acid and destrose plus hyaluronic acid on knee osteroarthritis|compare the immediate effect (one week after 3 times of injections), short-term effects (one month and three months after 3 times of injections), and midterm effect (6 months after 3 times of injections).
46091075|NCT02822339|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z12-030)
46091076|NCT04240847|Procedure|Skin incision|Skin incision on medial or lateral to tibial tubercle
46091077|NCT02687048|Behavioral|Otago Exercise program|The Otago exercise program (OEP) is an evidence-based falls prevention home-based program. The participants will be instructed by a physiotherapy to do muscle strengthening and balance exercises (to be done 3x/week). The physiotherapist will progress these exercises during 5 home visits to each participant.
45678215|NCT01993823|Drug|Clotrimazole|Five drops into the ear canal twice daily for 14 days
46091078|NCT02687048|Behavioral|Mindful meditation|Mindful meditation aims to reorient the individual to the present and broaden self awareness by promoting attention to internal experiences such as bodily sensations, thoughts, emotions, sights or sounds. The participants will be instructed in mindful meditation during 6 hour-long education sessions and will be expected to practice with audio meditations 30 minutes 5 times per week.
46091079|NCT02639598|Drug|Flunarizine|"as in arm descriptions"
45836347|NCT05081934|Behavioral|TAU|Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. This will be further specified and registered in the initial phase of the study, in collaboration with SiS.
46091080|NCT02639598|Drug|Topiramate|"as in arm descriptions"
46091081|NCT02823119|Device|Mini-hysteroscopy|Hysteroscopy will be performed with the use of the non-touch technique (vaginoscopic approach). The investigators will use a rigid 2.7-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 3.3 mm. All of the procedures will be diagnostic.
46005674|NCT04619303|Drug|Dexamethasone intravitreal implant|Intravitreal injection of 0.7mg dexamethasone implant
46005675|NCT04619303|Drug|Bevacizumab Injectable Product|Invtravitreal injection of 1.25mg/0.05mL bevacizumab
45836348|NCT00147966|Drug|rituximab|treatment with rituximab
46091082|NCT02823119|Device|Conventional Office Hysteroscopy|. Hysteroscopy will be performed with the use of the non-touch technique (vaginoscopic approach). The investigators will use a rigid 2.9-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 5 mm. All of the procedures will be diagnostic.
46091083|NCT02642796|Device|transcutaneous electric nerve stimulation|"The TENS device will be applied for treatment periods of 30-40 minutes. The electrodes will be connected to the TENS device are stimulated in modulation mode and the parameters will be adjusted as pulse width of 60 μs,frequency of 120 Hz and the stimulation intensity as high as the subject could tolerate.~Electrodes will be placed on either lumbar and sciatic nerve tracing unilaterally or on either side or parallel to the surgical wound."
46091084|NCT02320136|Behavioral|cognitive testing|patients perform simple tasks like watching a video or memorizing items
46091085|NCT04907279|Drug|Aripiprazole Once-Monthly (AOM)|Dosage and frequency of AOM administration individualized for each study participant in accordance with investigators' clinical judgment.
46091086|NCT02642718|Drug|Ketorolac Tromethamine|In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision (a single dose).
45836349|NCT04528212|Drug|Glimepiride Tablets|Glimepiride (4 mg) per Day
45836350|NCT04528212|Drug|glimepiride plus fenofibrate|Glimepiride (4 mg) plus Fenofibrate (160 mg) per Day
46091087|NCT02642718|Other|Placebo|In the operating room, the anesthesiologist administered 50 mL of 0.9 % saline intravenously to patients in the control group 30 minutes before surgical incision
45836351|NCT04528212|Drug|glimepiride plus curcumin|Glimepiride (4 mg) plus Curcumin (1100 mg) With 5mg Black Pepper per Day
46005676|NCT01150357|Drug|Aliskiren (6.25/12.5/25 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the low dose arm, participants used one or more of the 6.25 mg capsule (containing 2 minitablets) once daily to reach the body-weight stratified dose of aliskiren.
46005677|NCT01150357|Drug|Aliskiren (37.5/75/150 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the medium dose arm, participants used one or more of the 37.5 mg capsule (containing 12 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
46005678|NCT01150357|Drug|Aliskiren (150/300/600 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the high dose arm, participants used one or more of the 150 mg capsule (containing 48 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
46005679|NCT04580823|Dietary Supplement|Fasting with exogenous ketone salt supplement|Participants will have to take 2 doses of supplement, one 75 minutes before the scan and one 30 minutes before the scan.
46005680|NCT04580823|Dietary Supplement|Post-Prandial with exogenous ketone salt supplement|Participants will have to take 2 doses of supplement, one 75 minutes before the scan and one 30 minutes before the scan and they will have a liquid meal 20 minutes before the scan.
46091088|NCT00639314|Procedure|pylorus-preserving pancreaticoduodenectomy|pylorus-preserving resection is division of the duodenum 3-4cm distal to the pylorus
45836352|NCT04456140|Procedure|Biospecimen Collection|Undergo collection of blood samples
46091089|NCT00639314|Procedure|pylorus-resecting pancreaticoduodenectomy|In PrPD, the stomach is divided just above the pylorus ring. The nearly total stomach more than 95% was preserved.
46091090|NCT04240769|Device|Total or Partial Knee Arthroplasty|Reconstruction of part or all of the native articulation at the knee joint via implant.
46091091|NCT02642484|Drug|Gabapentin|Gapapentin twice daily
46091092|NCT02642484|Drug|Calcium Carbonate|calcium carbonate twice daily
46091093|NCT02537912|Dietary Supplement|Sugarlock®|Subjects ingested 2 capsules (Experimental group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
46091094|NCT02537912|Dietary Supplement|Placebo|Subjects ingested 2 capsules placebo in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
46091095|NCT02823275|Other|Functional mobilisation|functional mobilisation
46091096|NCT02823275|Other|Short term plaster cast fixation|2 weeks cast immobilisation
46091097|NCT00910884|Other|laboratory biomarker analysis|No supplements are given
46091098|NCT00910884|Procedure|therapeutic dietary intervention|Given orally daily for 12 months
46091099|NCT02007356|Biological|IFN-γ positive selected T-cells|
46091100|NCT04240613|Device|TVT-O|TVT-O is one of the most popular treatments for urinary incontinence (UI). Its efficacy is well established in patients with pure stress urinary incontinence (SUI). Data reporting long-term outcomes of TVT-O for the treatment of mixed urinary incontinence (MUI) or recurrent SUI is scarce. The objective of this study was to evaluate the efficacy and safety and overall patient satisfaction of TVT-O in different subgroups of UI in a long-term follow-up.
46091101|NCT04186754|Procedure|Comprehensive functional care plan|The treatment should be carried out INDIVIDUALIZED, in the hospital room or in a conditioned room, in sessions of approximately 30 minutes and on a daily basis. Carried out by professionals in the disciplines of nursing and occupational therapy.
46091102|NCT04186754|Procedure|Traditional intervention without rehabilitation|Clinical control by nursing professionals and exclusively pharmacological treatment
45836353|NCT04456140|Other|Genetic Counseling|Watch pre-test genetic counseling video
46005681|NCT04619264|Drug|Papacarie|First, tooth was cleaned with a wet cotton pellet. The gel was inserted using disposable syringe tip into the cavity and its color changed from clear to cloudy indicating the presence of infected tissues. After 40 seconds, the softened carious tissue was removed using excavator by gentle pressure. The remaining gel was removed with a cotton pellet. The procedure was repeated until there was no change in the gel color indicating that there was no more infected tissue.
46091103|NCT02686736|Behavioral|Internet-based educational intervention|The intervention will include four educational sessions about risky sexual behaviors and its prevention. The intervention will last one month (one session per week) followed by a three-month follow-up. Teens will be allowed to access to a weekly session at any time and as often as he/she likes.
46091104|NCT04241471|Procedure|incision and loop drainage|incision and loop drainage utilizing the rolled ring of a sterile glove technique
46005682|NCT04619264|Procedure|Atraumatic Restorative Treatment|The tooth was cleaned with a wet cotton pellet to remove debris and plaque and then isolated with cotton rolls to promote a dry environment. Caries was removed using a sharp excavator and the cavity was cleaned using a small wet cotton pellet and dried with a dry cotton pellet.
46091105|NCT04241471|Device|traditional incision and drainage (I&D)|traditional incision and drainage (I&D)
46091106|NCT00639392|Drug|Placebo|Patients will receive a single dose of placebo administered by vein over about 15 minutes. Placebo is mostly water without Zoledronic Acid.
46091107|NCT00639392|Drug|Zoledronic Acid|Patients will receive a single dose of Zolendronic Acid. Zoledronic Acid is administered by vein over about 15 minutes.
46091108|NCT04185506|Behavioral|DBT+BWL|DBT skills include a focus on emotion regulation, distress tolerance, and mindfulness techniques. BWL includes a focus on monitoring of food intake, calorie reduction, and dietary and physical activity education.
46091109|NCT02822261|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-66_R84-088)
46091110|NCT02642328|Other|HIIT Training|Circuit of high intensity interval training (HIIT) with Strength and Power Exercises for 4 minutes (20 sec of stimulus / 10 sec rest)
46091111|NCT02642328|Other|Control|Continuous aerobic exercise at 65% of VO2Max
46091112|NCT04185350|Drug|68Ga-NOTA-MAL-Cys39-exendin-4|After 68Ga-NOTA-MAL-Cys39-exendin-4 injection, the patient drank 300-500ml of water and urinated before the PET/CT scans.
46091113|NCT04241237|Procedure|Blood Draw|Blood will be drawn from each patient to check the concordance between liquid and tissue biopsy
46091114|NCT00653172|Drug|NXL103|600mg orally twice daily
45683809|NCT03082846|Radiation|hypofractionated radiation|The simultaneous integrated boost-intensity modulated technology is adopted to increase both the dose in the surgical cavity and residual tumor (PTV1).The dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1, until dose-limiting toxicity is present,the highest target single dose is 4 Gy/f. The planning target volume (PTV2) including the 2 cm region around surgical cavity and residual tumor remain unchanged, with 2.5 Gy each time and a total of 50 Gy/20f.
46091115|NCT00653172|Drug|comparator|comparator twice daily
46091116|NCT00653172|Drug|NXL103|500mg orally twice daily
46091117|NCT02821949|Biological|PCT dosage|When connecting chemotherapy products, a PCT dosage will be made. The results of dosage won't be communicated to the clinician responsible for the patient. Patient's care will then be identical to any other chemotherapy treated patient
46091118|NCT02822105|Biological|the H3N2 M2SR monovalent influenza vaccine|The H3N2 Bris10 M2SR influenza vaccine candidate (Bris10 M2SR) is formulated to contain different levels of an M2-deleted non-replicating influenza virus expressing the HA and NA genes of influenza strain A/Brisbane/10/2007.
46091119|NCT02822105|Other|Placebo|saline
46091120|NCT02639520|Drug|Canephron® N|2 tablets 3 times a day for 7 days
46091121|NCT02639520|Drug|Fosfomycin trometamol|1 sachet of 8 g of granules; one single dose on Day 1
46091122|NCT02639520|Drug|Canephron® N-placebo|2 tablets 3 times a day for 7 days
46091123|NCT02639520|Drug|Fosfomycin trometamol-placebo|1 sachet of 8 g of granules; one single dose on Day 1
46091124|NCT02823197|Other|Active transport lesson|
46091125|NCT02823197|Other|Active transport lesson and Facebook group|
46091126|NCT04164576|Genetic|Transplant patients|Study the specific immunity against Polyomavirus
46091127|NCT05659979|Other|Comprehensive geriatric assessment|A detailed comprehensive geriatric assessment will be given to all the participants randomized to this group, including the administration of multidimensional prognostic index (MPI), a tool derived from the CGA and consisting of eight different domains.
46005683|NCT04587765|Behavioral|Extra-curricular sports|The group follows the schedule of school teaching programme. Extra-curricular sports classes will be organized and provided in this group of schools in the afternoon after school until 6 p.m. (Monday to Friday).
46005684|NCT04619537|Drug|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
46005685|NCT04587414|Behavioral|eHealth +counselling contacts|The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. The eHealth intervention is complemented by face-to-face and telephone counselling on physical activity which comprises 4 to 6 contacts between a health care professional and the patient as well as at least 3 telephone contacts during 6 months.
46091128|NCT02639364|Device|Nellcor Puritan Bennett 840 ventilator system|Puritan Bennett 840 ventilator can provide the VCV,PCV,Bi-level Airway Pressure Ventilation-airway Pressure Release Ventilation(BILEVER-APRV) mode.
46091129|NCT02824133|Drug|AZD4547|80 mg bd (per os)
46091130|NCT02639130|Drug|Exendin [9-39]|Exendin [9-39] at 350 and 500 pmol/kg/min for infusion as challenge agent
46005686|NCT04587414|Behavioral|eHealth|The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. No telephone calls nor face-to-face counselling contacts on physical activity are taken.
46005687|NCT04587414|Behavioral|Usual care|Usual care and councelling given to type 2 diabetics within the primary health care setting.
46005688|NCT04580862|Other|Non-surgical endodontic retreatment in single visit|Full medical and dental history using a schematic dental chart, will be obtained from all patients treated during this study.
46091131|NCT02639130|Drug|Placebo|Placebo infusion as challenge agent
46005689|NCT04587609|Behavioral|Free Phone Mounts|Participants will receive free phone mounts
46005690|NCT04587609|Behavioral|Commitment Contract|Participants will develop and sign a personalized commitment contract where they will create their own weekly goals for phone use reduction, and plan potential future obstacles that may hinder them from reaching their goal and how and plan to overcome that obstacle.
46005691|NCT04587609|Behavioral|Personalized Habit Tips|Participants will receive weekly habit formation tips by text message. These messages will be tailored to encourage use of phone mounts, setting up do not disturb while driving, and include their personal obstacles and plans they developed to overcome.
46005692|NCT04587609|Behavioral|Social Gamification Feedback|"Each week of the intervention period, the participant will be notified whether they met their prior week's goal, stayed about the same, or backslid. Participants will all start with 100 points, and can gain/maintain/lose points each week in the intervention period. Levels are as follows:~Copper: 0-40 points Bronze: 50-80 points Silver: 90-120 points Gold: 130-160 points Platinum: 170-200 points~Social competition: participants will be placed in groups of 10 based on similarity of baseline phone use. Weekly leaderboard reports will be sent via email, with SMS reminder. In the leaderboard they'll see themselves as You."
46091132|NCT02822729|Drug|DE-117 ophthalmic solution|
46091133|NCT02822729|Drug|Timolol ophthalmic solution|
46005693|NCT04587609|Behavioral|"Contest Financial Incentives"|"Participants who finish in the platinum level will receive equal share of a prize, or a small amount will be awarded each week over the course of the intervention period to the weekly Safest Driver in each of the social competition cohorts."
46005694|NCT04619381|Behavioral|CORONARY ARTERY DISEASE AND CLOPIDOGREL: PATIENT SURVEY|Survey is a non-standardized assessment of demographics, medication compliance and reasons for non- compliance.
46005695|NCT00568464|Drug|VCR, CTX, ADM; IFO, VP-16|VCD: VCR 2 mg d1, CTX 1200 mg/m2 d1, Mesna 240 mg/m2 tid d1, ADM 75mg/m2 d1, G-CSF 300 ug/d d5-11; IE: IFO 1800mg/m2 d1-5,Mesna 360 mg/m2 tid d1-5,VP-16 100 mg/m2 d1-5,G-CSF 300 ug/d d6-12; q3w. Surgery or radiation will be done to the patients with local diseases after four cycles of VCD/IE.
45459380|NCT03556358|Drug|Cyclophosphamide|600 mg/m^2, 30 min IV infusion, every 3 weeks (Cycles 1-4)
45459381|NCT01374308|Biological|NASVAC|NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
46005696|NCT04618835|Diagnostic Test|40-Steps-test|40 steps performed on the spot
46005697|NCT04587063|Behavioral|Fear Appeals|Email
46005698|NCT04587063|Behavioral|Message about Future Healthcare Costs|Email
46005699|NCT04587063|Behavioral|Endorsement from a Doctor|Email
46091134|NCT05232240|Diagnostic Test|blood pressure variability measured by ambulatory 24-hour blood pressure monitoring|The ambulatory 24-hour blood pressure monitoring will be performed at baseline and one year after the enrollment. Various blood pressure variability characteristics will be obtained from these examinations.
46091135|NCT02690597|Other|Anxiety visual analog scale|Anxiety visual analog scale is a test of evaluation of anxiety done by the patient, this scale do not include number and the patient have to place a coloured marker at the level indicating his anxiety feeling
46091136|NCT04165434|Other|Concurrent Training|Strength training and interval aerobic training in the same training session
46091137|NCT04239677|Procedure|Conventional crystalloid solution-based priming|CPB circuit is also prepared with crystalloid solution-based priming in all participants (same as the RAP group). In this group (control group), CPB is initiated with antegrade priming (conventional priming).
46005700|NCT04587063|Behavioral|Comparison Table|Email
46091138|NCT04239677|Procedure|Retrograde autologous priming|CPB circuit is prepared with crystalloid solution-based priming in all participants. In RAP group, retrograde autologous priming is performed by displacing the crystalloid priming volume of arterial and venous lines via passive exsanguination of native blood prior to CPB initiation.
46005701|NCT04587063|Behavioral|Highlighting Cost Savings and Convenience|Email
46005702|NCT00568503|Drug|QAX028|
46091139|NCT02638038|Drug|INT131|INT- 131
46091140|NCT04241159|Biological|Allogeneic Young Plasma|"The experimental dosing will consist of once weekly administration of PF24 over a period of 8 consecutive weeks (8 total doses over 56 days). 250 mL single units of PF24 will be obtained from the South Texas Blood Bank and processed by the WFBH Blood Bank.~1 unit (250 mL) PF24, will be infused at 1 mL/kg/hr, once weekly for 8 consecutive weeks."
46091141|NCT02642250|Drug|Metronidazole|The data will be recorded for physical examination including gender , age, height, weight, temperature, heart rate ,respiratory rate and blood pressure of the subject, number of stool per day, stool with or without mucus or mixed with blood along with abdominal cramps, dehydration, nausea, vomiting and related clinical information will be carefully recorded. Statistical tools and tabulated results will be used to identify the similarities and differences in safety, efficacy and tolerability of treatment.
46091142|NCT02642250|Drug|Entoban|To evaluate the safety and efficacy of coded herbal formulation (Entoban) through randomized clinical study and compared with Metronidazole DS for treatment of gastrointestinal infections for improving the health of the community with due regard to the prevalence of disease and the feasibility of using alternative treatments.
46091143|NCT01284348|Drug|Sotatercept 15 mg|Sotatercept 15 mg SC injection every 42 days, up to 4 doses/cycles
46091144|NCT01284348|Drug|Sotatercept 30 mg|Sotatercept 30 mg subcutaneous injection Day 1 every 42 days, up to 4 doses/cycles
46091145|NCT02822183|Other|Online Survey|
46091146|NCT00653250|Drug|celecoxib|400 mg P.O. BID for five days prior to obtaining second serum/urine collection (starting after initial biopsy, serum and urine collection)
46091147|NCT00653250|Procedure|biopsy|in patients with newly diagnosed NSCLC, a pretreatment excision of a small amount of tumor tissue
46091148|NCT00653250|Procedure|therapeutic conventional surgery|surgery to remove the lung tumor
46091149|NCT02642172|Dietary Supplement|ITF (Inulin/OFS 75/25)|Participants will consume 16 g/day ITF
46005703|NCT00568503|Drug|Placebo|
46005704|NCT00568503|Drug|Tiotropium bromide|
46005705|NCT00568503|Drug|QAX028|
46005706|NCT00568503|Drug|QAX028|
46091150|NCT02642172|Dietary Supplement|Placebo|Participants will consume 16 g/day maltodextrin
45459382|NCT01374308|Drug|Pegylated interferon alpha 2b|Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
46091151|NCT02822651|Biological|Blood sampling|Patients will have a blood sampling at inclusion to measure vitamin D blood concentration.
46091152|NCT02822651|Other|self-administered questionnaire|Patients will fill a self-administered questionnaire the day of inclusion
46091153|NCT02639208|Other|PatientsLikeMe (PLM)|
46091154|NCT02686580|Biological|Collagen paste|Permacol cross-linked collagen paste, 2.5-3.5 mls to be injected into the MRI defined fistula tracts 7-10 days following drainage of the anorectal abscess.
46091155|NCT02824367|Behavioral|Completion of scales evaluation|Patient complete scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS), Hewitt Multidimensional Perfectionism Scale (HMPS), scores to depression scale (Beck Depression Inventory (BDI)) and anxiety scale (State Trait Anxiety Inventory (STAI))
46091156|NCT04185662|Dietary Supplement|sucralose|daily intake different dose of artificial sweeteners sucralose or placebo
46091157|NCT00654342|Procedure|Intraoperative injection (in vivo)|Intraoperative injection
46091158|NCT00654342|Procedure|Postoperative injection (ex vivo)|postoperative injection
45459383|NCT01368068|Drug|Tibolone|2.5mg/oral/daily
45459384|NCT01368068|Drug|Escitalopram|10mg/oral/daily
45459385|NCT01368068|Drug|Natvia|serving size: 0.09g per tablet
45459386|NCT03228680|Drug|Follitropin delta|Single daily subcutaneous administration through pre-filled injection pen
45459387|NCT03228680|Drug|Follitropin beta|Single daily subcutaneous injection in the abdomen
45459388|NCT01368146|Device|IV Clear™|Polyurethane film with a silicone adhesive dressing containing chlorhexidine and silver
45836354|NCT04456140|Other|Genetic Testing|Undergo genetic testing
46005707|NCT04619030|Other|Augmented Reality|The patient leaflet has an Augmented Reality model that appears out of the leaflet when viewed with a smartphone
46005708|NCT04619030|Other|Traditional leaflet|Traditional leaflet with no Augmented Reality capability
46005709|NCT00568542|Drug|erythropoetin beta|35 I.E. kg body weight subcutaneous once per week for 6 months
46005710|NCT00568542|Drug|placebo|35 I.E. kg body weight placebo to erythropoetin beta
46005711|NCT00568620|Procedure|Placement of nasogastric feeding tube|"Glucose tolerance test via nasogastric feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
46005712|NCT00568620|Procedure|Nasojejunal feeding tube|"Glucose tolerance test via nasojejunal feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
46005713|NCT04587102|Other|whole body viberation|vibration training in the form of whole body vibration for 20-30 minutes per session, 3 sessions per week for 8 weeks. The vibration training was performed on a whole body vibration platform
46005714|NCT04587102|Other|Traditional program(balance exercises and resisted exercises)|balance exercises and resisted exercises
46005715|NCT04619147|Other|No intervention|This is descriptive, retrospective study to evaluate the epidemiology of invasive fungal infections (IFI) in patients undergoing allogeneic haematopoiectic stem cell transplant in the era of antifungal prophylaxis with posaconazole delay-released tablets.
46005716|NCT00568659|Procedure|specific elastance|The investigators study the specific lung elastance in ALI/ARDS patients in supine and prone position.
46005717|NCT02940353|Device|TREFOIL concept|
46091159|NCT05659589|Other|blood sample|Blood sample withdrawal will be done and serum creatinine, IS, PCS, FGF-23, Angiopoietin-2, VCAM-1, E-Selectin and Troponin will be measured.
46091160|NCT02688920|Procedure|EUS and OCT imaging|Intraluminal imaging using endoscopic ultrasound and endoscopic optical coherence tomography
46091161|NCT00638534|Drug|Telithromycin (HMR3647)|
46091162|NCT04186910|Behavioral|Control group|The control group will carry the Fitbit for the entire period of the recovery but will receive no feedback and will not have the app downloaded onto the telephone.
46091163|NCT04186910|Behavioral|Feedback group|The feedback group will carry the Fitbit for the entire period of the recovery and will receive daily feedback on amount of physical activity carried out and percentage completed of target behavior at the end of the day from an app downloaded on their telephone. The feedback group will also participate in weekly one hour meetings focused on enhancing behavioral strategies to increase self-efficacy and motivation. They will also have their fitbit data analyzed and an agreed upon target of daily activity level increase.
46091164|NCT04240535|Drug|OnabotulinumtoxinA 50 UNT [Botox Cosmetic]|Injections to the Depressor Anguli Oris
45836355|NCT04456140|Other|Survey Administration|Ancillary studies
46005718|NCT04587258|Behavioral|Informational videos and social media campaigns encouraging cancer screening.|Informational videos will be made using community members and will be played in the Blackstone Valley Health Center, as well as posted on social media platforms, such as Facebook and Instagram. These videos will encourage at risk populations in the selected areas to visit their physicians to discuss the possibility of undergoing screening procedures for either breast or colorectal cancer. Data will then be collected about the rates of screening and will be compared to the screening rates from the time period of March 9th 2020 to May 31st 2020, with the goal of increasing screening rates by 25%.
46091165|NCT02638896|Drug|etanercept (Half-Dose)|AS patients who satisfied the criteria for disease remission (ASDAS<1.3) will be randomized to one of the three treatment arms. In the dose reduction arm, patients will receive etanercept 50 mg subcutaneous injections every other weeks .
46091166|NCT02638896|Drug|etanercept (Full-Dose)|AS patients who satisfied the criteria for disease remission (ASDAS<1.3) will be randomized to one of the three treatment arms. In the dose maintenance arm, patients will receive etanercept 50 mg subcutaneous injections every weeks.
46091167|NCT02638896|Drug|Sulfasalazine|AS patients who satisfied the criteria for disease remission (ASDAS<1.3) will take sulfasalazine (2g/d) from week12 to week48.
46091168|NCT02638896|Drug|Celecoxib|Celecoxib (0.4g/d) will be the background therapy.
45836356|NCT05265936|Procedure|Passing a guidewire through a double j stent|The previously placed double J stent is removed up to the urethral meatus with a cystoscope and forceps and kept fixed at the meatal level without further pulling. Then, after reaching the kidney by passing a guidewire through it, the double j stent is removed. Followed by the routine lithotripsy procedure.
45836357|NCT05265936|Procedure|Double J stent removal and guidewire insertion|The double j stent is completely removed with the cystoscope and forceps, and the guidwire is inserted into the ureter by visualizing it with the cystoscope. Followed by the routine lithotripsy procedure.
45836358|NCT05265858|Procedure|Total Hip Arthroplasty|Direct Anterior Approach (DAA) Total Hip Arthroplasty (THA)
46091169|NCT02688686|Biological|genetically modified dendritic cells + cytokine-induced killer|This Phase I/II Study to evaluate clinical efficacy, safety of genetically modified dendritic cells in combination with cytokine-induced killer cell treament in NSCLC with bone metastases.
46091170|NCT04240223|Drug|Brilacidin|Brilacidin
46005719|NCT00562835|Drug|Methylprednisolone|"Drug: Methylprednisolone Day 0 Loading dose 1 mg/kg IV bolus (30 min) followed by continuous infusion; Days 0 to 14*† ‡ 1 mg/kg/day mixed in 240cc Normal saline (NS) and infused at 10 cc/hr; Days 15 to 21*‡ 0.5 mg/kg/day mixed in 240cc NS and infused at 10 cc/hr; Days 22 to 25*‡ 0.25 mg/kg/day; Days 26 to 28*‡ 0.125 mg/kg/day~*Five days after the patient is able to ingest medications, methylprednisolone is given per os in one single daily equivalent dose.~†If between days 1 to 14 the patient is extubated, he is advanced to day 15 of drug therapy and tapered according to schedule.~‡ When leaving ICU, if the patient is still not tolerating p.o. intake for at least five days, he should receive the specified dosage as IV push every 6 hours until tolerating oral ingestion"
46005720|NCT00562835|Other|Normal saline intravenously and vitamin B1 per os|Patients in this group will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 25 cc [prednisolone + diluting fluid], then the patient will receive 25 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm. Five days after the patient is able to ingest medications, placebo is administered per os in one single daily equivalent dose. The placebo will be a Vitamin B1 (thiamine) 50-mg tablet. We will now designate each placebo tab as a 16-mg equivalent to each tablet of active drug. These tablets are scored and half tabs can be given if needed. Therefore if a patient is receiving 40 mg of study drug: 40/16 = 2.5 tabs x 50 mg = 125 mg actual dose of thiamine.
46091171|NCT04240223|Drug|Placebo|Placebo
46091172|NCT04240223|Radiation|4Mq 99mTc-DTPA|4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract
46091173|NCT00653406|Drug|Risperidone long acting injectable|
46091174|NCT01329926|Procedure|Harvesting of neural stem cells|During neurosurgical procedures, tissue samples are obtained along trajectory of implanted electrodes or removal of stimulators previously implanted.
46091175|NCT02821871|Drug|SP2086|
46091176|NCT02821871|Dietary Supplement|high fat diet|
46091177|NCT02637882|Other|Ear plug|The patients will receive the first intervention (ear plug) in the third night (N3) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale.
46091178|NCT02637882|Other|Eye mask|The patients will receive the second intervention (eye mask) in the second night (N2) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale
46091179|NCT02637882|Other|Mixed intervention (ear plug and eye mask)|The patients will receive the intervention (eye mask and ear plug) in the first night (N1) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale
46091180|NCT00633737|Behavioral|Stress reduction intervention|In addition to standard care, patients in the intervention group will receive a one-hour individually delivered programme administered once by a psychologist at least 3 days prior to surgery. This session aims to reduce stress and involves teaching relaxation and guided imagery exercises. Patients are provided a CD (or audiotape)of the relaxation instructions to take home and practice once a day.
46091181|NCT00638612|Biological|AdV-tk|Four dose levels of AdV-tk with a fixed dose level of valacyclovir are evaluated independently in the two arms of the study due to differences in the concomitant standard of care treatments. The first AdV-tk course is given prior to surgery or radiation by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery in Arm A or same as the first injection in Arm B again followed by 14 days of valacyclovir. The AdV-tk dose levels are: Level 1= 3x10e10 vector particles (vp), Level 2= 1x10e11 vp, Level 3= 3x10e11 vp, Level 4= 1x10e12 vp
46091182|NCT00638612|Drug|Valacyclovir|Valacyclovir caplets at a dose of 2 grams orally three times per day is administered for 14 days starting 1-3 days after each of the two AdV-tk injections in both arms.
46091183|NCT02535780|Procedure|Transcranial magnetic stimulation|TMS
45836359|NCT00148668|Drug|Herceptin|One dose given followed by an MRI, then weekly injections beginning week 3 and ending week 14.
45836360|NCT00148668|Drug|Navelbine|Weekly injections given starting week 3 and ending week 14
46091184|NCT02535780|Procedure|Transcranial direct current stimulation|tDCS
45459389|NCT01368146|Device|Tegaderm CHG™|Polyurethane film with a polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
45836361|NCT00148668|Drug|Taxotere|Given every three weeks starting week 3 and ending on week 14
46005721|NCT04587180|Procedure|Arthroscopic suture-bridge rotator cuff repair|Arthroscopic suture-bridge repair is a widely used and universal surgical method for symptomatic rotator cuff tear patients. It is arthroscopic surgery to reattach ruptured rotator cuff tendons to the original insertion (greater tuberosity) using medial and lateral row anchors.
46005722|NCT04587219|Biological|Gam-COVID-Vac|combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
46005723|NCT00568737|Drug|Drotrecogin alfa (activated)|Drotrecogin Alfa (activated)
46005724|NCT00568737|Drug|Placebo|0.9% sodium chloride
46091185|NCT04241081|Behavioral|Interrupting Prolonged Sitting with Periodic Interval Exercise: Effect on Postprandial Lipemia|This is a behavioral intervention designed to determine the effect of breaking up prolonged bouts of sitting every 2 hours and every 6 hours with 5 sets of 4 second bouts of maximum effort bicycle ergometer accelerations compared to sitting alone on the blood triglyceride response and whole body fat oxidation after a high fat meal.
46091186|NCT00655200|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46091187|NCT04239755|Drug|Doxycycline 100 MG Oral Tablet|doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 day
46005725|NCT00562874|Dietary Supplement|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
45459390|NCT01368146|Device|Silicone Vehicle Control Dressing|Polyurethane film with silicone adhesive dressing, without antimicrobials
45459391|NCT03144206|Drug|Hyperbaric oxygen|Patients with soft tissue sarcomas will receive HBOT treatment in the immediate postoperative period
45459392|NCT03097874|Behavioral|Family Based Treatment|Family Based Treatment of adolescent Anorexia Nervosa
45459393|NCT03097874|Behavioral|Family Based Treatment + Intensive Parental Coaching|Family Based Treatment of adolescent Anorexia Nervosa plus an Intensive Parental Coaching component.
45683810|NCT03082846|Drug|Temozolomide chemotherapy|Temozolomide(TMZ) is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
46005726|NCT00562874|Dietary Supplement|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy four as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
45683811|NCT03213418|Behavioral|Contingency management|Contingency management is an evidence-based psychotherapy program that promotes behavioral change with financial incentives.
45683812|NCT02929810|Behavioral|sleep extension|
46005727|NCT00562874|Dietary Supplement|Wheat Biscuit|75 women and one of their children will receive a biscuit containing only wheat lour as a source of protein as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 8 grams of protein per day and children will receive 350 calories and 5 grams of protein per day.
46005728|NCT04587141|Drug|Sucrosomial iron|This is an oral iron formulation commercially available as an integrator
46005729|NCT04587141|Drug|Ferric Gluconate|This is a commercially available iron formulation for parenteral administration
46005730|NCT04587141|Drug|Ferric carboxymaltose|This is a commercially available iron formulation for parenteral administration
46005731|NCT04619342|Device|GSMs-TACE|TACE using epirubicin (30-40mg/m2) and gelatin sponge microspheres (150-350μm or 350-560μm)
46005732|NCT04619342|Procedure|Surgical Resection|Surgical Resection of PVTT
46005733|NCT04586790|Drug|Midodrine Oral Tablet|midodrine group will receive midodrine 10 mg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral midodrine .
46005734|NCT04586790|Drug|Minirin oral tablet|Minirin group will receive minirin 60 µg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral minirin .
46091188|NCT04239755|Other|placebo|placebo in addition to the standard treatment.
46091189|NCT04185116|Device|3D Optic System (Olympus VISERA Elite II 3D)|"Use of the 3D Optic System Olympus VISERA Elite II 3D"
46091190|NCT02642016|Biological|CDX-0158 (formerly known as KTN-0158)|Single agent CDX-0158 until unacceptable toxicity or progressive disease
46091191|NCT02824445|Device|individualized Transcranial Magnetic Stimulation|
46091192|NCT00639470|Other|easy to read fact sheets|easy to read fact sheets with illustrations and without illustrations
46091193|NCT02638818|Procedure|minimally invasive pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
46091194|NCT02638818|Procedure|traditional pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
46091195|NCT04185194|Drug|Lidocaine|transmission of the drug molecules to the underlying muscles
46091196|NCT04185194|Device|pulsed ultrasound|using thermogenic and cavitation effect of ultrasound to reduce tight muscles and relieve pain
46091197|NCT04185194|Other|especially designed physical therapy program|by myofascial trigger point release, stretching and strengthening exercises of upper trapezius muscle and infrared radiation by tungsten lamp for upper trapezius
46091198|NCT02638662|Other|Observational|Questionnaires are completed such as self-evaluation questionnaire (STAI), Beck Depression Inventory, FertiQol International and Daily stress questionnaire
46091199|NCT02821793|Other|Consultation, evaluation questionnaire|Consultation, evaluation questionnaire
46091200|NCT02821793|Other|Geriatric consultation, evaluation questionnaire|Geriatric consultation, evaluation questionnaire
46091201|NCT00876447|Biological|Botulinum Toxin Type A 300U|Botulinum toxin Type A 300U injections into the detrusor > 12 weeks as needed for up to 3 years.
46091202|NCT00876447|Biological|Botulinum Toxin Type A 200U|Botulinum toxin Type A 200U injections into the detrusor > 12 weeks as needed for up to 3 years.
46091203|NCT04164420|Behavioral|Oral neuromuscular training and orofacial sensory-vibration|Oral neuromuscular training is performed by using an oral device. The device is placed pre-dentally behind closed lips, and the participant is sitting in an up-right position. The participant is the instructed to hold the device against a gradually-increasing horizontal pulling force for 5-10 s, whilst trying to resist the force by tightening the lips and pressing the head backward against a head rest.
46091204|NCT04164420|Behavioral|Orofacial sensory-vibration stimulation|All participants in the control group is given orofacial sensory-vibration stimulation by using an electrical toothbrush. Instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal.
46005735|NCT04586790|Drug|Nor-Adrenaline|control group will receive IV nor-adrenaline and is gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .
46005736|NCT00568815|Drug|Rituximab combined with ESHAP|Rituximab 375mg/m2 d1, VP-16 40mg/m2 d1-4, Ara-C 2g/m2 d5, DDP 25mg/m2 d1-4, Met 500mg/m2 d1-5
46091205|NCT04239833|Drug|SH-1028 tablets|"The initial dose of SH-1028 tablets is 200 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
46091206|NCT04239833|Drug|Placebo SH-1028 tablets|"The initial dose of Placebo SH-1028 tablets is 200 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
46091207|NCT04239833|Drug|Gefitinib|"The initial dose of Gefitinib is 250 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label SH-1028 tablets (crossover to active SH-1028 tablets)."
46091208|NCT04239833|Drug|Placebo Gefitinib|The initial dose of Gefitinib is 250 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.
46091209|NCT03513770|Other|Wrist-to-elbow (W-E) occlusion|"An IV will be inserted in the antecubital fossa of one arm. The arm will be fitted with occlusion cuffs arranged in a continuous fashion from the wrist to the elbow. A final cuff will be placed on the upper arm. The cuffs from the wrist to the elbow will be inflated to the same pressure of up to 300 mmHg using a pressurized air tank.~First, the subject?s arm will be elevated and the subject will make a fist to squeeze blood from the hand. Then the wrist cuff will be inflated. Once that cuff is fully inflated, the next cuff in the sequence will be inflated. Cuffs are inflated in sequence until the elbow cuff is inflated. After a 10-15 second period to allow blood to drain, the upper arm cuff will inflate (up to 250 mmHg) to keep any additional blood from entering the forearm. Next, the cuffs on the forearm will be removed but the upper arm cuff will remain inflated."
45683813|NCT02929810|Behavioral|sleep maintenance|
46005737|NCT00568893|Drug|drotrecogin alfa (activated)|
45836362|NCT00148668|Drug|Carboplatin|Given every three weeks starting week 3 and ending on week 14
45836363|NCT05265780|Procedure|kinesiotape|an elastic adhesive tape
45836364|NCT05265780|Procedure|sham taping|a sham taping without the tension
46005738|NCT00568971|Drug|Docetaxel, Cisplatin, 5-Fu|Docetaxel 33.3 mg/m2, Cisplatin 30 mg/m2 and 5-FU 1500 mg/m2 of 24-hour continuous intravenous infusion;d1,8,15 q4w.The treatment will not stopped until disease progression or unaccepted toxicities.
46091210|NCT03513770|Drug|ketorolac tromethamine|In the COX blockade trial, just after the Wrist-to-elbow occlusion, 6 mg ketorolac tromethamine in 10 ml saline will be infused into the forearm over 1 minute. After 10 minutes, a second infusion of ketorolac tromethamine (up to 3 mg) in 5% of the forearm volume of saline,( ~40-60 ml) will be infused into the occluded forearm at a rate of ~ 30 ml/min. Five minutes of data will then be collected before releasing the upper arm cuff. Infusion 1 is to block the COX pathway, while infusion 2 is to induce venous distension.
46091211|NCT03513770|Drug|saline control|In the saline control trial performed on a separate day, saline (without ketorolac) in identical volumes as those in the COX blockade trial, will be infused.
46005739|NCT04586322|Other|No intervention, (observational study).|"From every participant the following information was recorded for further analysis:~BEWE score- Basic erosive tooth wear examination (from 2 calibrated examiners) to diagnose the presence of erosive tooth wear.~Their answer to a validated questionnaire assessing the dietary habits based in the frequency of acidic diet.~2 Intra oral scans (IOS): Baseline and follow up (1 year after baseline) to perform a quantification of tissue loss (in Volume loss per mm3) using Wearcompare software."
46091212|NCT02638740|Procedure|SCALING AND ROOT PLANING (SRP)|Scaling and root planning done with ultrasonic scalar with reinforcement of oral hygiene measures and follow up for 90 days.
46091213|NCT02638740|Procedure|MUSTARD OIL AND SALT MASSAGE WITH SRP|Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
46091214|NCT04240067|Diagnostic Test|READ-MA Multimarker Approach|The presence or absence of ALSHF (gold standard used in the READ study) : diagnosis by 2 experts (cardiologist and emergency physician) based on data collected in the ED and during hospitalization (clinical examination, history, usual treatment, haemodynamic parameters, ECG, chest X-ray, emergency treatment, clinical and paraclinical results during hospitalization), biological assays (except NT-proBNP) and echocardiography (Left Ventricular Ejection Fraction, segmental kinetic, potential valvulopathy, transmitral flow, tissue doppler E' velocity) performed by a cardiologist within 24 hours of admission.
46091215|NCT03513614|Procedure|Tailored axillary surgery - both Arms|Axillary lymph node dissection - Arm A
45459394|NCT03077204|Biological|1 or 2-Level ACDF utilizing BIO4 with Bio AVS Cervical Allograft (with graft window).|The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.
46091216|NCT03513614|Radiation|Radiotherapy - Arm A|Regional nodal irradiation excluding the dissected axilla - Arm A
46091217|NCT03513614|Radiation|Radiotherapy - Arm B|Regional nodal irradiation including the full axilla - Arm B
46005740|NCT02277405|Device|Shikani Optical Stylet|Optical intubation
46005741|NCT02277405|Device|Endoeye Flexible Intubation (LF-V)|endoscopy intubation
46005742|NCT00562913|Drug|Nexavar (Sorafenib, BAY43-9006)|Cyclophosphamide plus 400 mg BID sorafenib and doxorubicin
46005743|NCT00569088|Drug|Chinese herbs formula|"The chinese herbs formula includes eight herbs,and they are Radix et Rhizoma Rhei Palmati(Rhubarb,10 grams),Cornu Bubali(Buffalo Horn,30 grams),Radix Paeoniae Bubra(Red Peony Root,15 grams),Cortex Moutan Radicis(Tree Peony Root-bark,10 grams),Radix Rehmanniae(Adhesive Rehmannia Root Tuber,20 grams),Pheretima Aspergillum(Earth-worm,10 grams),Radix Notoginseng(Sanchi,5 grams)and Rhizoma Acori Tarainowii(Tararinow Sweetflag Rhizome,10 grams).~Boiled together. 150ml of the juice,p.o.,twice a day,for 28 days"
46005744|NCT00569088|Drug|Mannitol|250 ml Mannitol Injection or Glycerin and Fructose Injection ,once a day, for 3-5 days
46005745|NCT02940158|Other|1/4 cup- Small red lentil|
46005746|NCT02940158|Other|1/4 cup- Small green lentil|
46091218|NCT02823977|Drug|Ketamine|Blinded study drug administered to experimental arm
46091219|NCT02823977|Drug|Dexmedetomidine|Open-label study drug administered to both arms
46091220|NCT02823977|Drug|Normal saline|Blinded comparator administered to control arm
46091221|NCT04164810|Other|Hydrotherapy|All sessions will be done by 3 physical therapists specialized in hydrotherapy under different modalities, and a pool equipped to perform this type of intervention. The most commonly used techniques in the institution are Bad Ragaz, for motor control, and the Watsu technique for relaxation and spasticity work.
46091222|NCT04164810|Other|Physical Therapy|All sessions will be done by 3 physical therapists expert in neurorehabilitation, following a physical therapy protocol, which includes stretching, aerobic excercise and muscle strengthening.
46091223|NCT04754243|Drug|Gonadotropin|Giving patients gonadotropins and antagonist cetrotide
46091224|NCT04754243|Drug|Standard protocol in IUI|Giving patients gonadotropins without antagonist cetrotide
46091225|NCT04032678|Device|Schiller Defigard Touch 7 - DGT7, Schiller Medical, France|Cardioversion with a pulsed biphasic waveform
46091226|NCT04032678|Device|LIFEPAK 15, Physio-Control Inc., Redmond, WA, USA|Cardioversion with a biphasic truncated exponential waveform
46091227|NCT05659433|Procedure|CEUS-guided percutaneous biopsy|A standard dose of SonoVue ultrasound contrast agent is injected prior to the biopsy, and the percutaneous biopsy is guided in real time, targeting the contrast-enhanced areas of the retroperitoneal tumors (viable, vascularized)
46091228|NCT05659433|Procedure|B-mode US-guided percutaneous biopsy|Standard of care (B-mode) ultrasound-guided percutaneous biopsy, without contrast enhancement
46091229|NCT00680511|Behavioral|Adolescent Methamphetamine Treament (AMT)|AMT Group Therapy plus Functional Family Therapy (FFT)
46091230|NCT00680511|Behavioral|Functional Family Therapy (FFT)|FFT
46091231|NCT00654576|Drug|Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole|patient will receive one of the seven study drugs (Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole) as the maintain treatment. the dose is flexible, is based on the study doctor's judgment.
46005747|NCT02940158|Other|1/4 cup- corn|
45836365|NCT00149838|Procedure|Prefrontal rTMS|Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.
45836366|NCT00149838|Drug|Antidepressant Regimen|Particpants who acheive remission with rTMS may start antidepressant medication in phase III.
46091232|NCT00654576|Behavioral|psychosocial intervention|the psychosocial interventions include psychoeducaiton, family intervention, skill training, and cognitive-behavioral therapy.
46005748|NCT02940158|Other|1/4 cup- macaroni|
46005749|NCT02940158|Other|1/4 cup- white potato|
46005750|NCT02940158|Other|1/4 cup- white rice|
45459395|NCT03077204|Device|Aviator Anterior Cervical Plating System|The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.
45459396|NCT03633890|Drug|DaZhu Rhodiola Rosea Capsule|Oral administration, 4 capsules, 3 times a day, for 8 weeks
45836367|NCT00149838|Procedure|Sham Stimulation|The sham stimulation will mimic the sensation of rTMS but will not induce an intracerebral current. Treatments will be administered daily for 3 weeks.
45836368|NCT01790646|Other|intubation|intubation using Glidescope videolaryngoscope
45836369|NCT04410822|Other|Clinical tests|Semi-qualitative interviews and questionnaire FITAS
45836370|NCT04046796|Genetic|NGS Diagnostic|Blood take for genetic diagnostic.
45836371|NCT00324870|Drug|vorinostat|Given orally
46005751|NCT02940158|Other|1/2 cup- small red lentil|
46005752|NCT02940158|Other|1/2 cup- small green lentil|
46005753|NCT02940158|Other|1/2 cup- corn|
46005754|NCT02940158|Other|1/2 cup- macaroni|
46005755|NCT02940158|Other|1/2 cup- white potato|
46005756|NCT02940158|Other|1/2 cup- white rice|
46091233|NCT00622622|Biological|VEGFR2-169 and gemcitabine|Escalating doses of VEGFR2-169 will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles(doses of 0.5,1.0,2.0mg/body are planned). Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on days 1,8 and 15. Repeated cycles of VEGFR2-169 and gemcitabine will be administered until patients develop progressive disease or unacceptable toxicity,or for maximum 2 cycles, whichever occurs first.
46091234|NCT02821481|Dietary Supplement|Beta-alanine|
46091235|NCT02821481|Dietary Supplement|Placebo|
46091236|NCT02821481|Behavioral|Muscular endurance exercise|
46091237|NCT00680589|Biological|injection of mouse TYRP2 DNA|Cohorts of three patients will receive injections with mouse TYRP2 DNA delivered intramuscularly at four different dose levels (500, 2000, 4000 or 8000 μg) every three weeks for six injections.
46091238|NCT04208282|Device|7 day infusion set|7 days survival of the sets
46005757|NCT02940041|Procedure|Pre-surgical diagnosis of uterine malignant tumors|All patientes who fit inclusion criteria will undergo a gynecologic sonography, pelvic MRI, determination of LDH, as in regular practice. No additional interventions will be done to any patient.
46091239|NCT00680667|Biological|Coriolus versicolor extract|Trametes versicolor (Tv) capsules at the assigned dose level (3 grams/day up to 24 grams/day) twice a day every day and continuing for weeks.
46091240|NCT00598650|Drug|E2020|Dosage and administration: Patients will receive oral administration of 1 tablet of 3 mg (E2020) from Day 1 to Day 14 of treatment period, 1 tablet of 5 mg (E2020) from Day 15 onwards once daily after breakfast.
45678216|NCT04673123|Other|Core stabilization exercises|"In our study, core stabilization exercises to be applied in the intervention group are arranged according to the patients with stroke and will be at three different difficulty levels. Exercises will be done on the back (hooked) and sitting positions where the risk of falling is low. First of all, activation of the transversus abdominis muscle, which is the basis of core stabilization, will be taught to patients. With this activation at the first level, the healthy side, at the second level the affected side, and at the third level, reciprocal upper and lower extremity movements will be requested. In addition to these, there will be exercises to bridge and curl up in supine position, and weight transfer in sitting position. In order to increase the difficulty level of the exercises, first of all, the number of exercises will be increased and then it will be asked to move on to the next level."
46005758|NCT00569244|Drug|Drug: YAZ flex (SH T00186D)|Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))
46091241|NCT02823899|Biological|HL-OCV|Pharmaceutical company in Bangladesh is now producing HL-OCV, with technological support from MSD wellcome trust Hilleman pt. ltd, which meets international Good manufacturing practice( GMP) standards and WHO production guidelines.
46091242|NCT02823899|Biological|Shanchol|The vaccine is manufactured by Shantha Biotechnics in hyderabad, India and is prequalified by the WHO. Shanchol is available in a single dose. This vaccine is used as two dose regimen.
46091243|NCT04150731|Radiation|16α-18F-fluor-17β-estradiol|16α-18F-fluor-17β-estradiol PET/CT scan
46091244|NCT02686190|Other|Luxtherapy|
46091245|NCT00680979|Behavioral|Interpersonal Psychotherapy|
46091246|NCT00680979|Behavioral|Health Education|
45836372|NCT00324870|Drug|bevacizumab|Given IV
46005759|NCT00569244|Drug|YAZ (SH T00186D)|YAZ (SH T 00186D) administered in the conventional regimen (24 days active + 4 days placebo) (Tablet p.o. (oral))
46005760|NCT03458156|Biological|SLE group|The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.
46005761|NCT03458156|Biological|LN group|The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.
46091247|NCT02641938|Drug|Dexmedetomidine|Dexmedetomidine group :1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery
46091248|NCT02641938|Drug|Normal Saline|Control group :IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
46091249|NCT04150185|Procedure|Donor hepatectomy|
46091250|NCT02821637|Other|Eurofit Tests of Physical Fitness (Eurofit)|Eurofit tests are a physical skills assessment. For the study, tests performed on the 1st and the 13th session of the program, then 3 more times : 2 months, 6 months and 12 months after the 13th weekly session.
46091251|NCT02821637|Behavioral|Child Health Questionnaire (CHQ)|The CHQ is a questionnaire about quality of life. The CHQ children form (CHQ-CF87) and the CHQ parent form (CHQ-PF50) are completed each time the Eurofit tests are performed : at the 1st and 13th weekly session then 2 months, 6 months and 12 months later.
45342473|NCT04070976|Radiation|Hypofractionated therapy|All patients will be treated with an external beam of 37.5 Gray in 15 fractions (2.5 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using the anterior/posterior field and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.
45459397|NCT03633890|Drug|DaZhu Rhodiola Rosea Simulation Capsule|Oral administration, 4 capsules, 3 times a day, for 8 weeks
45459398|NCT01374386|Behavioral|Exergaming|Participants will have access to Exergaming equipment (video games that require physical activity)
46005762|NCT03458156|Other|the control group|The patients will be assigned to the control group.
45459399|NCT01319708|Procedure|mild ovarian stimulation|100-150 mg of clomiphene citrate from day 2 till day 6 of the cycle and 150 mg of gonadotrophins as soon as 1 follicle is more than 14mm together with 1 fixed dose of GnRH antagonist until egg recovery
45459400|NCT01319708|Procedure|conventional ovarian stimulation|300-450 IU of FSH starting by day 2 of menstrual cycle together with a fixed dose of GnRH antagonist starting by day 6 till egg recovery, or same doses with GnRH agonist long protocol
45459401|NCT01373684|Drug|Peginterferon alfa-2a|180 μg per week s.c. for a total duration of 48 weeks.
46091252|NCT02821637|Other|Effort rehabilitation program|Part of the routine practice of the Pediatric Obesity and Pediatric Diabetes Organization of Mulhouse, the program consists in 13 sessions of 1hour30 of adapted physical activity. The physical activity in this program use cycles of games where rules are adapted to the overweight or obese children. The activities are performed in a playful atmosphere, for example using creative games like tchoukball or peteca, with each session aiming a specific objective each time.
46091253|NCT04249076|Drug|Clobetasol Propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05% is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)
46091254|NCT04249076|Drug|Vehicle|Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
46091255|NCT02641860|Biological|Mesenchymal progenitor cells|Biological: Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra-articular use
45459402|NCT01373684|Drug|Nucleos(t)ide analogue|All patients are all currently being treated with long-term NA treatment and will continue using these during the study. Dosage depends on which Nucleos(t)ide analogue they are using.
45459403|NCT04490018|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine)|Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular
45459404|NCT04490018|Biological|Meningococcal group A, C, W-135, and Y conjugate vaccine|Pharmaceutical form: Powder and solvent for solution for injection Route of administration: Intramuscular
45459405|NCT04490018|Biological|Human Papillomavirus 9-valent Vaccine (9vHPV)|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
45459406|NCT04490018|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine (Tdap-IPV)|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
45459407|NCT04485260|Drug|KRT-232|administered by mouth
45459408|NCT04485260|Drug|Ruxolitinib|administered by mouth
45459409|NCT02891798|Drug|Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)|Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements
46091256|NCT00681135|Device|sonic toothbrush (Philips Sonicare® FlexCare, Typ HX6942/04)|toothbrushing with a sonic toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
46005763|NCT04586361|Combination Product|RegenLab PRP|PRP preparations also improved functional outcome scores compared to hyaluronic acid and placebo in patients affected by knee osteoarthritis (OA). Based on previous studys, we can conclude that the PRP treatment is a safe and efficacious procedure which can provide functional benefit.
46005764|NCT04586361|Combination Product|hyaluronic acid|Few studies investigated the effects of HA+PRP combined treatment for knee osteoarthritis (OA). Numerous studies demonstrated the efficacy of HA injection therapy in knee OA for a clinical point of view, reducing the pain and improving the quality of life.
46005765|NCT04586361|Other|normal saline|In this study, we compare introperative PRP/PRP+HA/normal saline in ACL reconstruction patient.
46091257|NCT00681135|Device|manual toothbrush / interdental toothbrush (elmex® Inter X medium toothbrush / interdental brush Curaprox®)|toothbrushing with a manual toothbrush and interdental brush and sealant coating (ProSeal™) of the enemal surface around the brackets
45459410|NCT02891798|Drug|Bupivacaine Only (control arm)|Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements
46005766|NCT04618952|Drug|Calcium D|calcium D supplementation given to postmenopausal females
46005767|NCT04618952|Drug|Placebo|Placebo
46091258|NCT00681135|Device|manual toothbrush (elmex® Inter X medium toothbrush)|toothbrushing with a manual toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
46091259|NCT00681135|Device|manual toothbrush (elmex® Inter X medium toothbrush)|toothbrushing with a manual toothbrush without sealant coating of the enemal surface around the brackets
46091260|NCT02821559|Drug|TOMOX|
46091261|NCT02821559|Drug|Bevacizumab|Bevacizumab was allowed and used at 7,5 mg/kg or 5 mg/kg every 2 weeks.
46091262|NCT00681213|Drug|Tacrolimus/Sirolimus|
46091263|NCT00681213|Drug|Tacrolimus/MMF|
46091264|NCT00681213|Drug|Neoral/Sirolimus|
46091265|NCT04165356|Procedure|Mouth-rinse with 0.12% clorhexidine|mouthwash with 0.12% chlorhexidine twice daily compared to isotonic bicarbonated solution twice daily for the prevention of any infection associated with mechanical ventilation in patients requiring endotracheal intubation in the intensive care unit of a third level hospital.
46091266|NCT04165356|Procedure|Mouth-rinse with isotonic solution with 1.5% sodium bicarbonate|mouthwash with sotonic solution with 1.5% sodium bicarbonate twice daily for the prevention of any intection associated with mechanical ventilation
46005768|NCT00569283|Biological|therapeutic allogeneic lymphocytes|
46005769|NCT04619069|Radiation|SBRT|SBRT to all sites of metastatic disease as seen on PSMA PET scan
46005770|NCT04619069|Drug|Hormone therapy|Intermittent Hormone Therapy per physician discretion (Min. 8 months)
46005771|NCT00569322|Procedure|BG Test|
46091267|NCT04213274|Biological|80 mg RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
46091268|NCT04213274|Drug|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4 mL-glass vial
46091269|NCT02820701|Procedure|OMT|Osteopathic Manipulative Treatment to low back region
46091270|NCT02638506|Drug|Fentanyl|All patients will receive a 1.5 mcg⁄kg dose of fentanyl. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
45459411|NCT01368224|Dietary Supplement|Lactobacillus paracasei NCC 2461 and Bifidobacterium longum NCC3001|"1 treatment unit, in the form of a sachet of powder, to be reconstituted in a glass of water and taken once daily for 8 weeks (from D1 to D57), except if the last visit is bring forward or put back for no more than 3 days, in which case the subject will continue treatment until the final visit.~Oral route."
45459412|NCT01374464|Other|Interscalene brachial plexus block|"4 different administrations of levobupivicaine will be applied:~High Volume, High Concentration = 15mls of 0.75% levobupivicaine~High Volume, Low Concentration = 15mls of 0.5% levobupivicaine~Low Volume, High Concentration = 5mls of 0.75% levobupivicaine~Low Volume, Low Concentration = 5mls of 0.5% levobupivicaine"
46005772|NCT04618796|Other|vaccine|Effect of COVID-19 pandemic on vaccination compliance among children attending Assiut University Children Hospital and what is the degree of that.
46005773|NCT00569361|Procedure|Collection of nasal epithelial cells|Collection of nasal epithelial cells by brushing
46005774|NCT04580550|Other|Axial length variability|Biometry (axial length measurement)is performed using the IOL Master 700 (Carl Zeiss Meditec AG, Jena, Germany) and Heidelberg Anterion (Heidelberg Engineering, Germany) pre and postoperatively.
46005775|NCT04618640|Biological|DTaP-IPV combination vaccine|Dosage and administration: A single intramuscular injection of 0.5 mL will be given to healthy children aged 4 to 6 years
46005776|NCT04580706|Other|this is an observational study with none intervention|this is an observational study with none intervention
46005777|NCT04586439|Drug|JNJ-73763989|JNJ-73763989 will be administered (high or low dose) as single SC injection.
46005778|NCT02940197|Behavioral|MediterrAsian diet|no other description
46005779|NCT04585932|Drug|Apalutamide|Given PO
46005780|NCT04585932|Drug|Degarelix|Given SC
46091271|NCT02638506|Other|Salinex|All patients will receive an equivalent volume of similar looking placebo to fentanyl (1.5 mcg/kg dose). This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
46091272|NCT01124396|Drug|DSP-3025|
46091273|NCT01124396|Drug|Placebo|
46005781|NCT04585932|Drug|Leuprolide Acetate|Given IM
46005782|NCT04585932|Other|Quality-of-Life Assessment|Ancillary studies
46091274|NCT04745975|Drug|Personalized treatment guided by mini-PDX and RNA sequencing|Personalized treatment guided by mini-PDX and RNA sequencing
46091275|NCT04745975|Drug|Nab paclitaxel|Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8, 15, q4w
46091276|NCT04745975|Drug|Eribulin|Eribulin 1.4 mg/m2, d1,8 q3w
46091277|NCT04745975|Drug|Vinorelbine|Vinorelbine 25mg/m2 d1,8, q3w
46091278|NCT04745975|Drug|Gemcitabine|Gemcitabine 1000 mg/m2, d1,8, q3w
46091279|NCT04745975|Drug|Capecitabine|Capecitabine 1250 mg/m2 bid po
46091280|NCT04150107|Drug|ORMD-0801 Treatment A|Treatment A: 24 mg (16 mg capsule + 8 mg capsule) Once Daily (QD) at bedtime
46091281|NCT04150107|Drug|ORMD-0801 Treatment B|Treatment B: 8 mg (8 mg capsule) three times a day (TID) 45-90 minutes before meals
46091282|NCT04150107|Other|Placebo|Fish oil capsule
46091283|NCT02638428|Procedure|CancerSCAN™|Targeted deep sequencing
46091284|NCT02638428|Drug|Ifosfamide|
46091285|NCT02638428|Drug|Carboplatin|
46005783|NCT04585932|Other|Questionnaire Administration|Ancillary studies
46091286|NCT02638428|Drug|Etoposide|
46091287|NCT02638428|Drug|Fludarabine|
46091288|NCT02638428|Drug|Cytarabine|
46091289|NCT02638428|Drug|Pazopanib|
46091290|NCT02638428|Drug|Sorafenib|
46091291|NCT02638428|Drug|Axitinib|
46091292|NCT02638428|Drug|Crizotinib|
46091293|NCT02638428|Drug|Dasatinib|
46091294|NCT02638428|Drug|Erlotinib|
46005784|NCT04585932|Radiation|Radiation Therapy|Undergo RT
46005785|NCT02940119|Device|Multi Radiance Medical®|Volunteers received all procedures of the study with active or placebo phototherapy (PBMT) in 9 sites of the neck and shoulders, twice a week. The PBMT was applied in all sessions.
46005786|NCT00569400|Drug|human insulin|
46005787|NCT02939963|Procedure|ATC then pressure support 7 cm H2O PEP 4 cm H2O|spontaneous breathing through endotracheal tube with no ventilator support except for ATC, the patient is connected to the ventilator with pressure support 0 cm H2O and PEP 4 cm H2O during 30 minutes then 30 minutes of basal pressure support then 30 minutes with pressure support 7 cm H2O PEP 4 cm H2O
46005788|NCT02939963|Procedure|Pressure support 7 cm H2O PEP 4 cm H2O then ATC|30 minutes with pressure support 7 cm H2O PEP 4 cm H2O then 30 minutes of basal pressure support then 30 minutes with spontaneous breathing through endotracheal tube with no ventilator support except for ATC, the patient is connected to the ventilator with pressure support 0 cm H2O and PEP 4 cm H2O
46005789|NCT00569439|Drug|D5NS|5% Dextrose in Normal Saline (6.25 gr/hr) at 125 cc/hr
46091295|NCT02638428|Drug|Everolimus|
46091296|NCT02638428|Drug|Imatinib|
46091297|NCT02638428|Drug|Ruxolitinib|
46091298|NCT02638428|Drug|Vandetanib|
46091299|NCT02638428|Drug|Vemurafenib|
46091300|NCT02638428|Drug|Trastuzumab|
46091301|NCT01003964|Drug|IP|Irinotecan (65 mg/m2) IV on day1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks
46091302|NCT01003964|Drug|GP|Gemcitabine (1250 mg/m2) IV on D 1, 8. Cisplatin (75 mg/m2) IV on D1 every 3 weeks.
46091303|NCT02820779|Device|WILLIS|WILLIS® intracranial stent graft system is composed of the stent, delivery system, cobalt-based alloy stent and PTFE graft. It can effectively shunt the blood flow and keep it off of the aneurysm wall.
46091304|NCT02821325|Other|MRI|"Patients undergoing a total knee arthroplasty, will undergo additional MRI's. One MRI pre-operatively.~2nd MRI post-operatively on day 1. 3rd MRI post-operatively on day 2."
46091305|NCT00654810|Behavioral|Walking Exercise|Intermittent treadmill walking to near maximal claudication pain three days per week
46091306|NCT04149717|Dietary Supplement|Energy Drink Ingredients and Exercise|"Subject will ingest 500 mL of one of three test solutions:~A) sucrose (150g) B) sucrose (150g); caffeine (400 mg) C) sucrose (150g); caffeine (400 mg); taurine (4,000 mg); carnitine (400 mg) 3. 30 min later, subject will exercise on a treadmill using the Bruce Protocol maximum exercise test (https://www.aopa.org/go-fly/medical-resources/health-conditions/heart-and-circulatory-system/bru...). For one additional session, subjects will receive test solution C without exercise.~4. Each stage will last 3 minutes. Stage 1 = 1.7 mph at 2% Grade Stage 2 = 2.5 mph at 4% Grade Stage 3 = 3.4 mph at 6% Grade Stage 4 = 4.2 mph at 8% Grade Stage 5 = 5.0 mph at 10% Grade Stage 6 = 5.5 mph at 12% Grade Stage 7 = 6.0 mph at 14% Grade Stage 8 = 6.5 mph at 15% Grade Stage 9 = 7.0 mph at 15% Grade. The test will end when subjects reach exhaustion.~5. 1, 2, and 4 hrs following ingestion, HR, BP, and EKG will be recorded."
46091307|NCT02638350|Device|Strategy with lung ultrasound|"Each patient admitted for suspicion of acute lung edema will be treated according to the protocol of the emergency department.~Another doctor will independently do a lung ultrasound and measurement of the inferior vena cava. The ultrasound results are not made available to the doctor in charge of the patient.~At the end of the study, all the files will be analyzed by a independent committee, blinded ultrasound results for the final diagnosis of acute pulmonary edema."
46091308|NCT02627079|Other|Daily SMS text messaging|
46091309|NCT02820467|Device|fluorescence angiography|Injection of indocyanine grey in an antecubital vein at the posology of 0.05 mg/kg
46091310|NCT04031469|Other|There is no intervention in this study|There is no intervention in this study
46091311|NCT02823743|Drug|Aspirin|Daily medication
46091312|NCT02823743|Drug|Placebo|Daily intake
46091313|NCT00654888|Procedure|ALK (automated lamellar keratectomy)|ALK is performed with a microkeratome, to make a free cap.
46091314|NCT00654888|Drug|Mitomycin|mitomycin 0,02%, 30 seconds after ALK
46091315|NCT05299203|Drug|Sapropterin dihydrochloride tablets|dose escalation phase (BH4) aqueous solution is sprayed onto the skin of all radiotherapy areas, 3 times a day until two weeks after the end of radiotherapy.
46091316|NCT02818829|Other|Collection of biological samples|Collection of biological samples including whole blood, serum, plasma, saliva, DNA and RNA from tumor cells, tissue from tumor biopsies, tissue from tumor and adjacent tissue of pancreas
46091317|NCT00654966|Drug|Urotensine II|A few drops of the drug will be administered to the skin by iontophoresis.
46091318|NCT00654966|Drug|Soluble epoxide hydrolase|A few drops of the drug will be administered to the skin by iontophoresis.
45836373|NCT00151320|Drug|Bortezomib, CHOP, Rituximab|"Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)~VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the following dose escalation schedule:~Level Dose/Schedule (-2) 0.7 mg/m2 on day 1 of each cycle (-1) 0.7 mg/m2 on days 1 and 8 (0) 0.7 mg/m2 on days 1 and 4 (+1) 1.0 mg/m2 on days 1 and 4 (+2) 1.3 mg/m2 on days 1 and 4"
45836374|NCT00326196|Device|Percutaneous coronary intervention (PCI)|percutaneous coronary stenting with drug eluding stents
46091319|NCT02627313|Device|GammaPod Tumour Bed Boost|Single fraction Tumour Bed boost of 8Gy in 1 Fraction
46091320|NCT02685722|Biological|UC-MSCs Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,Observation of UC-MSCs Gel group patients efficacy, safety and tolerability of selective parameter.
46091321|NCT02685722|Other|Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,observed and compared Gel group patients may be no efficacy.
46091322|NCT02638584|Drug|Ilaprazole|Ilaprazole 10mg 2tablets once a day(1 times / day), before breakfast
46091323|NCT02638584|Drug|Rabeprazole|Rabeprazole 20mg 1tablets once a day(1 times / day), before breakfast
46091324|NCT02820545|Other|Sociological interview|A sociological interview will be performed with each patient by a sociologist, during their hospital stay
46091325|NCT02820545|Other|Self-administrated questionnaire|Self-administrated questionnaire will be performed by patients themselves at the end of hospital stay and one week after they left hospital
46091326|NCT02627235|Behavioral|DIAL|The physical activity intervention is based on Social Cognitive Theory and includes feedback on physical activity progress via IVR system and monthly graphic-based feedback letters delivered in the mail. Messages will encourage incremental increases until national PA guidelines are reached and provide specific information on cancer risk reduction.
45459413|NCT01374542|Procedure|Respiratory endoscopy|Bronchoscopy, thoracoscopy, endobronchial ultrasound
45836375|NCT00326196|Procedure|Coronary artery bypass graft (CABG)|coronary bypass
46005790|NCT00569439|Drug|D10NS|10% Dextrose Solution (12.5 gr/h) in Normal Saline at 125 cc/hr
46091327|NCT02627235|Behavioral|Wait List Control|Access to DIAL intervention 12 weeks following baseline assessment.
46091328|NCT02688452|Dietary Supplement|Control Unmodified Placebo Water|
46091329|NCT02688452|Dietary Supplement|Electrokinetically modified water (EMW)|
46005791|NCT00569439|Drug|NS|Normal Saline solution at 125 cc/hr
46091330|NCT02688452|Dietary Supplement|Electrokinetically modified water (EMW)|
46091331|NCT02688452|Dietary Supplement|Control Unmodified Placebo Water|
46091332|NCT04208516|Procedure|Continuous Erector Spinae Plane Nerve Block|To be administered to subjects in the active comparator group receiving primary unilateral thoracic surgery.
46091333|NCT04208516|Procedure|Continuous Quadratus Lumborum Nerve Block|To be administered to subjects in the active comparator group receiving primary major abdominal surgery.
46005792|NCT04618445|Behavioral|some risk factors that might be correlated with TMD|Fonesca questionnaire
46005793|NCT04585971|Diagnostic Test|Signal intensity gradient|"Signal intensity gradient:~In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A [Xa] along the arterial contour line) and at the inner point (Φb; signal intensity at position B [Xb]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
45836376|NCT04332198|Other|biological test|dyspnea evaluation, ventilatory evaluation and biological test before and after non invasive ventilation
45459414|NCT02562872|Drug|DSM265|DSM265 400 mg single oral dose
45459415|NCT02562872|Drug|Placebo|Placebo to match DSM265, single oral dose
45459416|NCT02562872|Biological|Sporozoites|Direct venous inoculation of 3200 cryopreserved Plasmodium falciparum (NF54 strain) sporozoites
45459417|NCT02562872|Biological|Infective mosquito bite|Five single bites by laboratory reared female Anopheles stephensi mosquitoes carrying Plasmodium falciparum
45836377|NCT00328614|Drug|Samarium-153|Samarium-153 will be administered as a single dose after one month of hormonal therapy. The dose level of Samarium-153 may change to determine maximum tolerated dose (MTD).
46005794|NCT04618367|Procedure|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 6 weeks
46005795|NCT04618367|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
46005796|NCT04618367|Drug|Sintilimab|200mg intravenously every 3 weeks
46005797|NCT00569478|Other|rehabilitation|Nursing consultations and physical training
46005798|NCT00569517|Behavioral|CBT|6-CBT based sesions
46005799|NCT00569517|Other|educational|subjects receive one hour of nutrition education and 5 weekly phone calls
46005800|NCT00562952|Drug|Telmisartan, Bisoprolol|Dosage will be given dependent on the NT-pro-BNP levels. Up-titration will be performed until values are decreased to 50% or below normal cut-point
46005801|NCT00562952|Drug|placebo|no intervention
46005802|NCT04585347|Drug|ALZ-801 170 mg Fasting|
46005803|NCT04585347|Drug|ALZ-801 205 mg Fasting|
46005804|NCT04585347|Drug|ALZ-801 205 mg After Food|
46091334|NCT04208516|Procedure|Single Erector Spinae Plane Nerve Block|To be administered to subjects in the experimental group receiving primary unilateral thoracic surgery.
46091335|NCT04208516|Procedure|Single Quadratus Lumborum Nerve Block|To be administered to subjects in the experimental group receiving primary major abdominal surgery.
46091336|NCT04208516|Drug|Lidocaine IV|To be given postoperatively as a continuous infusion at a dose of 50 mg/hr in the experimental group.
46091337|NCT04208516|Drug|Ropivacaine 0.5% Injectable Solution|To be used in both treatment arms as nerve block initial bolus injection.
46091338|NCT04208516|Drug|Dexamethasone|To be used in the experimental arm as a nerve block adjuvant to promote prolonged single block duration, as is standard of care in this institution.
46091339|NCT04208516|Drug|Dexmedetomidine|To be used in the experimental arm as a nerve block adjuvant to promote prolonged single block duration, as is standard of care in this institution.
46091340|NCT04208516|Drug|Lidocaine|To be used perineurally as a 0.25% solution in the active comparator group at a rate of 10 ml/hr per perineural catheter.
46091341|NCT00681447|Procedure|Lumbar Interlaminar Epidural|"Lumbar interlaminar epidural injections under fluoroscopy~Epidural tray and needle~Drugs:~0.5% Xylocaine and non-particulate Celestone"
46091342|NCT00681447|Procedure|Lumbar Interlaminar Epidural injection|"Lumbar interlaminar epidural injections under fluoroscopy~Epidural tray and needle~Drugs:~0.5% Xylocaine and non-particulate Celestone"
46091343|NCT02820389|Procedure|Optical colonoscopy|Patients with suspected colorectal cancer in this group will undergo Optical Colonoscopy as the initial imaging modality.
46091344|NCT02820389|Procedure|CTC|Patients with suspected colorectal cancer in this group will undergo Computed Tomography Colonography (CTC) as the initial imaging modality. Subsequent imaging might be required based on the findings from the CTC scan, i.e. patients with medium to large polyps or colorectal cancer will undergo Optical Colonoscopy as the second imaging test.
46091345|NCT00376844|Radiation|External Beam Radiation Therapy|
46091346|NCT00376844|Radiation|Vaginal Brachytherapy|
46091347|NCT02821091|Other|Interactive Dynamic Balance Training|
46005805|NCT04585347|Drug|ALZ-801 342 mg Fasting|
46091348|NCT04146987|Procedure|Rotator cuff repair surgery|Patients will undergo open rotator cuff repair or arthroscopic rotator cuff repair
46091349|NCT02688296|Device|Fibulock|Fibulock intramedullary implant will be used to repair fibula fractures
46091350|NCT02821169|Drug|ropivacaine|injection of 4mL of ropivacaine in the sphenopalatine area through an endoscopic approach
46091351|NCT02821169|Drug|saline solution 0.9%|injection of 4 mL of saline solution in the sphenopalatine area through an endoscopic approach
46091352|NCT02626767|Other|Novel high-intensity interval exercise training|Please see information already included in the 'intervention' arm description.
46091353|NCT02820935|Drug|CC-220|
46091354|NCT02820935|Drug|Rifampin|
46091355|NCT02820935|Drug|Itraconazole|
46091356|NCT02626845|Drug|Rituximab|Standard of care induction with Rituximab: 375mg/m2 weekly x 4 weeks. Once randomized, the rituximab dose will be 1000mg IV every 4 months x 2.
46091357|NCT02626845|Other|Placebo|Will be given at two time-points (week 16 and week 32) to subjects in the Placebo Arm.
46091358|NCT02821247|Drug|Aflibercept (Eylea, BAY86-5321)|Intravitreal injection; should comply with the recommendations written in the local Summary of Product Characteristics (SPC) of the product
45836378|NCT00328614|Drug|Total Androgen Suppression (TAS) with Bicalutamide|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
46005806|NCT05035316|Drug|acetylsalicylic acid|Oral tablet: acetylsalicylic acid,150 mg, 1 tablet/day
46005807|NCT05035316|Drug|Calcium|Oral tablet: calcium, 1 tablet/day
46005808|NCT00569556|Other|Case Management|Phone contact by specially trained nurse case managers; lifestyle recommendations and medication changes as needed
46005809|NCT00562991|Device|measurement of exhaled NO is used to guide treatment|exhaled NO
46005810|NCT00569595|Behavioral|Self-Care Stimulating Disease Prevention Program|The intervention is aimed at improving diet, increasing physical activity, and reducing sedentary behaviors among low-income patients, assuming that this will increase motivation and self-confidence to adhere to self-care regimens based on personal prioritizing and progressive goal setting.
46005811|NCT00569595|Behavioral|Fighting Cancer with Advice|"Patient health counseling program by lay health educators entitled Fighting Cancer with Advice."
46091359|NCT00681525|Drug|ABT-335|One ABT-335 135 mg capsule QD for 10 days
46091360|NCT00681525|Drug|Atorvastatin|One 80 mg tablet of atorvastatin QD for 10 days
46091361|NCT00681525|Drug|Ezetimibe|One ezetimibe 10 mg tablet QD for 10 days
46091362|NCT02818673|Radiation|labelled human serumalbumin (125-I, Séralb®CisBio)|Intra-veinous injection of 0,015 MBq/Kg ; 0,5 to 2 mL injected over less than a minute
46091363|NCT02818673|Radiation|labelled albumin (99m-Tc, Vasculocis®, Cisbio)|intra-peritoneal injection of 200 MBq of labelled albumin (99m-Tc, Vasculocis®, Cisbio) ; 5 ml injected over less than a minute
46091364|NCT04700969|Other|: A support program to facilitate implementation of evidence-based practice for postoperative urinary retention|A 12-month implementation support program for multi-professional internal facilitator teams
46091365|NCT00681603|Drug|subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)|subconjunctival injection of bevacizumab ( 1.25 to 2.50mg) according to the clinical judgment. Once per months for three times then reevaluate the drug effect, if the response was adequate, stop the trial; if no improvement, another three month intervention would be performed.
46091366|NCT04146597|Other|Neural mobilization|Neural mobilization (NM) is a physiotherapy method aimed at restoring the dynamic balance between the relative movement of neural tissues and surrounding mechanical interfaces, and different techniques are used for the treatment of various compression syndromes as well as other pain conditions, such as back and neck pain (Basson et al., 2017; Ellis and Hing, 2008). The main techniques used are neurodynamic sliders and neurodynamic tensioners, with the tensioning techniques being considered the more aggressive approach, in which the increase in nerve length occurs (Silva et al., 2014). The neurodynamic sliders techniques are gentle maneuvers as they involve nerve lengthening at one joint and simultaneous reduction in its length at an adjacent joint in order to produce sliding movements of neural structures relative to adjacent tissues (Efstathiou et al., 2015).
46091367|NCT04239443|Drug|PD-1 inhibitor|Intravenous administration of SHR1210 (200mg/2weeks or 200mg/3weeks)
46005812|NCT04618601|Drug|Spironolactone|Patients randomized to the high-dose spironolactone group will receive oral spironolactone (≥100 mg) on top of standard of care treatment for acute heart failure immediately after randomization and in the afternoon of each subsequent day unless the serum potassium level is >5 mmol/L. The exact dose will be determined based on a pre-specified algorithm provided.
46005813|NCT00567918|Drug|FK506|Ophthalmic suspension
46091368|NCT04239443|Drug|Apatinib|NSCLC and Uterine cancer will be given oral of Apatinib (250mg/d), soft tissue sarcoma will be given oral of Apatinib (500mg/d).
46091369|NCT02820155|Drug|RGN1016|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
46005814|NCT00569634|Procedure|Venous blood gas analysis|When an ABG is deemed to be necessary as part of ICU management, a central venous sample will also be obtained with minimum delay (always < 2 minutes) between the samples. The samples will be analyzed by a blood gas analyzer as quickly as possible.
46091370|NCT02820155|Drug|Placebo|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
46091371|NCT04200599|Other|duration of initiation of oxytocin|mode of delivery
46091372|NCT02820077|Device|Hemospray (Endoscopic treatment with hemostatic powder)|Malignant bleeding lesions will be treated with endoscopic powder and patients will receive optical clinical management afterwards
46005815|NCT00569712|Drug|budesonide/formoterol fumarate dihydrate inhalation aerosol|
46005816|NCT00569712|Genetic|DNA methylation analysis|
46091373|NCT00681915|Drug|AZD7325|Oral
46091374|NCT04651673|Other|This is a non interventional registry|All patients, at listed investigational sites, that get prescription for a knee orthosis indicated for Knee OA symptomatic treatment, get an invite to partake in the evaluation registry.
46091375|NCT00681993|Other|Standard Dose Dense Doxorubucin and Cyclophosphamide|4 cycles of Standard Dose-Dense Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
46005817|NCT00569712|Genetic|comparative genomic hybridization|
46005818|NCT00569712|Genetic|microarray analysis|
46091376|NCT00681993|Other|Standard Doxorubucin and Cyclophosphamide|4 cycles of Standard Dose Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
46091377|NCT00681993|Other|Standard Docetaxel, Carboplatin, and Herceptin|6 cycles of Standard Docetaxel, Carboplatin and Herceptin chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
46091378|NCT00681993|Other|Standard Docetaxel, Doxorubucin and Cyclophosphamide|3 cycles of Standard Docetaxel, Doxorubucin and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
46005819|NCT00569712|Other|bronchoalveolar lavage|
46005820|NCT00569712|Other|immunoenzyme technique|
46005821|NCT00569712|Other|laboratory biomarker analysis|
46005822|NCT00569712|Procedure|bronchoscopy|
46005823|NCT00569751|Device|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System|Drug Eluting Stent used to treat de novo coronary artery lesions.
46091379|NCT00681993|Other|Standard Docetaxel and Cyclophosphamide|4 cycles of Standard Docetaxel and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
46005824|NCT04618562|Other|Revival Active Program|Program comprised of physical activities, group play, mind games, reasoning and discussion on sleeted topics, breath work and relaxation techniques, 60 minutes all together.
46005825|NCT00569790|Drug|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 28-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).~Irinotecan 100 mg/m2 is administered by intravenous infusion on days 1 and 15. Bevacizumab 5 mg/kg (body weight)is administered by intravenous infusion on days 1 and 15."
46005826|NCT00567957|Drug|Remifentanil|1 microg/kg iv bolus before induction followed by 0.5 microg/kg/min infusion
46005827|NCT00567957|Drug|Saline|same volume iv bolus before induction followed by same volume infusion
46005828|NCT04618094|Other|bicycle ergometer training with different intensities|Following a 10-min warm-up phase at a constant work load below ventilatory threshold, participants of the high intensity interval group perform repeated high intensity exercise bouts, followed by an active recovery on a bicycle ergometer. The comparative group perform a constant moderate intensity with the same mean workload. The cool-down phase is 5 min with a constant work load for both groups.
46005829|NCT00569829|Behavioral|cognitive behavioral therapy|1 to 16 weekly sessions of modular cognitive behavioral therapy, each lasting 60-80 minutes
46091380|NCT05659043|Other|overnight fasting|All blood samples were taken on the day of cardiac catheterization after overnight fasting.
46091381|NCT02819999|Drug|Rovalpituzumab Tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
46091382|NCT02819999|Drug|Cisplatin|
46091383|NCT02819999|Drug|Etoposide|
46005830|NCT02940002|Drug|BAY1003803|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
46091384|NCT00633815|Other|Supine positioning|Subjects underwent exercise testing on a stationary bicycle in the supine position
46091385|NCT00633815|Other|Upright positioning|Subjects underwent exercise testing on a stationary bicycle in the upright position
46091386|NCT04173494|Drug|Momelotinib|Momelotinib tablets will be self-administered orally once daily
46091387|NCT04173494|Drug|Danazol|Danazol capsules will be self-administered orally twice daily
46005831|NCT02940002|Drug|Clobetasol propionate|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
46005832|NCT02940002|Drug|Betamethasone/calcipotriene|Simultaneous application of 10μl on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
46091388|NCT04173494|Drug|Placebo to match momelotinib|Momelotinib placebo tablets will be self-administered orally once daily
46091389|NCT04173494|Drug|Placebo to match danazol|Danazol placebo capsules will be self-administered orally twice daily
46091390|NCT02819921|Drug|Desvenlafaxine succinate 100mg|Pristiq 100mg
46091391|NCT02819921|Drug|Desvenlafaxine succinate 50mg|Pristiq 50mg
46091392|NCT02819921|Drug|Placebo|Placebo
46091393|NCT02819687|Drug|RDX5791|
46091394|NCT02819687|Drug|Placebo|
46091395|NCT04239209|Behavioral|Indirect - other patients|Video depicting an indirect response focusing on a comparison to other patients.
46091396|NCT04239209|Behavioral|Indirect - physiology|Video of an indirect response focusing on the physiology of the patient.
46091397|NCT04239209|Behavioral|Redirection|Video of a redirection towards discussing the patient's values and possible future decisions.
46091398|NCT04239209|Behavioral|Direct communication|Video of a direct response.
46091399|NCT02819609|Procedure|myomectomy|Myomectomy as part of routine clinical care
46091400|NCT02819609|Procedure|endometrial ablation|Endometrial ablation as part of routine clinical care
46091401|NCT02819609|Procedure|uterine artery embolization|Uterine artery embolization as part of routine clinical care
46091402|NCT02819609|Procedure|MRI-guided focused ultrasound ablation|MRI-guided focused ultrasound ablation as part of routine clinical care
45342474|NCT04070976|Radiation|Standard therapy|All patients will be treated with external beam radiotherapy with 50 Gray in 25 fractions (1.8-2 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using anterior/posterior fields and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.
46005833|NCT04580745|Drug|MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057."
46091403|NCT04184960|Diagnostic Test|Gastroscopy and gastric biopsies|Gastroscopy would be performed to assess the degree of atrophic gastritis and intestinal metaplasia. In addition, four random biopsies would be taken in the stomach for histological assessment of AG and IM
46091404|NCT02817035|Device|noninvasive mechanical ventilation|To examined the physiological signals of patients and healthy subjects during spontaneous breathing and noninvasive mechanical ventilation.
46091405|NCT00875979|Drug|Trastuzumab emtansine [Kadcyla] 3.0 mg/kg|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
46091406|NCT00875979|Drug|Trastuzumab emtansine [Kadcyla] 3.6 mg/kg|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
46091407|NCT00875979|Drug|Pertuzumab 420 mg|Pertuzumab was provided as a single-use formulation.
46091408|NCT02818751|Drug|Escitalopram|Patients being randomized to receive escitalopram.
46091409|NCT02818751|Other|Placebo|Patients being randomized to receive placebo.
46091410|NCT02697110|Behavioral|Edutainment based intervention|Edutainment intervention package
46091411|NCT04238975|Biological|GC3111 vaccine|0.5mL, Intramuscular
46091412|NCT04238975|Biological|Boostrix® vaccine|0.5mL, Intramuscular
46005834|NCT04580745|Drug|Placebo for MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo."
46091413|NCT00682149|Dietary Supplement|PomGT (500 mg pomegranate extracts, 300 mg green tea and 60mg vitamin C)|1 tablet/day for 3 months
46091414|NCT00639782|Device|On-X Heart valve replacement|On-X Heart valve replacement
46005835|NCT04618328|Drug|all trans retinoic acid|ATRA is given concomitantly at a daily dose of 10 mg twice daily orally for 12 weeks
46005836|NCT04585659|Other|Qigong|Mind-body movement art that includes specific movements, breath exercises, stretching and meditation.
46005837|NCT04617782|Combination Product|Donepezil TDS|Transdermal Delivery System
46005838|NCT04617782|Drug|Aricept|Oral
46005839|NCT04617704|Biological|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously.
46005840|NCT00569985|Biological|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
46005841|NCT00569985|Drug|carmustine|Given IV
46005842|NCT00569985|Drug|cyclophosphamide|Given IV
46005843|NCT00569985|Drug|etoposide|Given IV
46005844|NCT00569985|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
45678217|NCT04673123|Other|Multifactorial Education Program|The content of this program includes rehabilitation practices that are routinely applied in stroke rehabilitation and that patients will receive at the specified hospital. In the content of these applications; patient-specific upper and lower extremity stretching, and strengthening exercises; application of functional electrical stimulation (FES) to upper and lower extremity muscles; balance, coordination and gait training are included. he content of multifactorial fall prevention training includes the first brochure titled '' General Recommendations for the Prevention of Fall in Chronic Stroke Patients '', which will include general recommendations for preventing falling according to the fall risk factors specific to the stroke, and the recommendations to minimize the risk of falling in the home. A second brochure titled 'Suggestions for Making Your Home Safer' will be given. The information in these brochures will also be communicated to patients face to face verbally
46005845|NCT02939768|Other|High-intensity interval training (HIIT)|The HIIT sessions will be performed on cycle ergometers and will be consisted of 10 x 60-s cycling intervals interspersed with 60 s recovery. Individual workloads will be selected to elicit ~90% maximal heart rate attained in the cardiorespiratory fitness test (HRmax). A passive or active recovery will be given among high-intensity stimulus. Each training session will include 3-min warm-up and 2-min cool-down phase performed ~50% (HRmax), totalling 25 min. This intervention will last 10 weeks.
46005846|NCT02939768|Other|Strength training (ST)|ST protocol will consist of three sets performed at maximum weight that participants could move eight times with good technique in the following exercises: supine bench press (pectoralis major), leg press (quadriceps, biceps femoris, gluteus maximus), lat pulldown (latissimus dorsi), leg extension (quadriceps), shoulder press (deltoids), leg curl (biceps femoris) and abdominal crunch (abdominal muscles). It will be given 1-min rest between series, totalizing approximately 35 min of ST. This intervention will last 10 weeks.
46005847|NCT02939768|Other|ST combined with HIIT (ST+HIIT)|Participants in the ST+HIIT group will execute ST and HIIT (in this order) above described in the same training session, lasting approximately 60 min. This intervention will last 10 weeks.
46091415|NCT00639782|Device|SJM Heart valve replacement|SJM Heart valve replacement
46091416|NCT04238897|Device|soft contact lens|
46005848|NCT04585425|Behavioral|Sleep hygiene advice|Participants receive standard sleep hygiene advice.
46005849|NCT04585425|Behavioral|Bedtime music listening|Participants in the intervention group listen to their preferred sleep playlist daily at bedtime for minimum 30 minutes.
46091417|NCT04144881|Diagnostic Test|coronary computed tomography|patients randomized in this arm will perform computed coronary tomography 6 months after the index percutaneous revascularization on unprotected left main artery
46005850|NCT04617665|Other|One-handed mask ventilation|Using one-handed mask ventilation techniques during induction of general anesthesia
45678218|NCT01993667|Drug|Low Dose Acetazolamide|Administration of low dose acetazolamide
46005851|NCT04617665|Other|Two-handed mask ventilation|Using two-handed mask ventilation techniques during induction of general anesthesia
46005852|NCT00570024|Procedure|Traditional Acupuncture|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
46091418|NCT02685644|Procedure|Laparoscopic removal of cysts|Women with endometrioma lesions will undergo laparoscopic removal. Cysts will be enucleated with blunt dissection of the cyst capsule and following traction, counter traction maneuver. Bipolar coagulation will be used sparsely and suturing will be the predominant choice for achieving bleeding control.
46091419|NCT04239287|Diagnostic Test|Lung function + exercise tests|Lung function + exercise tests
46091420|NCT02626689|Other|Quality of Life (QOL) questionnaires|Monitoring of FACT-AN, SF-36V2, TransQol, and NTD PRO assessments,
46091421|NCT02626689|Other|Healthcare Resource Utilization|Monitoring and reviewing HealthCare Resource Utilization information.
46091422|NCT02818595|Device|electroencephalogram (HR-EEG)|
46005853|NCT00570024|Procedure|AA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
45678219|NCT01993667|Drug|Normal Dose Acetazolamide|Administration of normal dose acetazolamide
45678220|NCT01992107|Biological|QIVc|Novartis Investigational Quadrivalent Vaccine
45678221|NCT01992107|Biological|TIV1c|Licensed Influenza Vaccine
46091423|NCT02818595|Device|Near Infra Red Spectroscopy (NIRS)|
45678222|NCT01992107|Biological|TIV2c|Novartis Investigational Vaccine
46091424|NCT00602420|Drug|naproxen|Oral naproxen twice daily for 5-8 days.
46091425|NCT00602420|Other|placebo|Oral placebo twice daily for 5-8 days.
46091426|NCT02819531|Device|Rotational atherectomy|Pre-stenting lesion modification using the rotational atherectomy device using standard technique under intravenous infusion of heparin. Burr size will be selected by the operator according to vessel size. IVUS images will be obtained before lesion modification and after stenting.
45678223|NCT04673045|Device|Active Electrical stimulation|The intensity of stimulation will be set within the subject's tolerance level. The amplitude was adjusted to produce muscle contraction without affecting the patient's comfort. The cathode electrode will be placed over the common peroneal nerve as it passes over the head of the fibula and the anode will be placed on mid-muscle belly on one third of the line between fibular head and medial malleolus on paretic limb.
45678224|NCT04673045|Device|Sham Electrical Stimulation|For sham group, the current intensity will gradually decreased after few seconds to 0. Therefore, the participant will experience a passage of current on the muscle at the beginning but received no current for the rest of the stimulation period. The participants will be informed that the stimulation below the sensory level.
46005854|NCT00570102|Dietary Supplement|A highly hydrolyzed formula|Weaning to a highly hydrolyzed formula, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin up to the age of 6-8 months
46091427|NCT02819531|Device|Orbital atherectomy|Pre-stenting lesion modification using the orbital atherectomy device according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
46091428|NCT02819531|Device|Scoring balloon system|Pre-stenting lesion modification using the scoring balloon system according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
46091429|NCT00682227|Biological|TTK, LY6K, and IMP-3 peptides|Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
46091430|NCT04635605|Drug|Methylene Blue|Treatment Group. Methylene Blue 100 mg capsules, twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.
45678225|NCT01934192|Drug|GSK962040 50 mg|GSK962040 50 mg will be administered once daily enteral dose through NG tube up to 7 days.
46091431|NCT04635605|Drug|Control Test|Arm B: Control Group. Placebo capsules 100 mg twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.
45678226|NCT01934192|Drug|Metoclopramide 10 mg|Metoclopramide will be administered IV every 6 h
45678227|NCT01934192|Drug|Placebo NG|Matching placebo once daily enteral dose will be administered through NG tube up to 7 days
45678228|NCT01934192|Drug|Placebo IV|Placebo will be administered IV every 6 hours
45678229|NCT01933880|Drug|Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)|Osmotic release oral system methylphenidate hydrochloride (OROS-MPH) starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36mg/d up to a maximum dosage of 54mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18mg due to intolerance.
46091432|NCT00682305|Procedure|Hematopoietic stem cell transplantation|"conditioning regimen:~day -7: 12g/m^2 Treosulfan~day -6: 12g/m^2 Treosulfan~day -5: 12g/m^2 Treosulfan~day -4: 30mg/kg BW Etoposide~day -3: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide~day -2: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide~day -1: 20mg/kg ATG Fresenius (OPTIONAL)~day 0: SCT"
46091433|NCT02688374|Other|Treatment A: Nicorette 2 mg coated mint gum|Participants will be administered with 2 mg coated mint gum of Nicorette
46091434|NCT02688374|Other|Treatment B: Nicotinell 2 mg coated mint gum|Participants will be administered with 2 mg coated mint gum of Nicotinell
46091435|NCT02688374|Other|Treatment C: Nicotinell 2 mg coated fruit flavor gum|Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
46091436|NCT02819375|Drug|Propofol|1 mg/kg propofol
46091437|NCT02819375|Drug|Propofol+Remifentanil|0.5 mg/kg propofol+0.5 mg/kg remifentanil
46091438|NCT02819375|Drug|Propofol+Ketamine|0.5 mg/kg propofol and 0.5 mg/kg ketamine
46091439|NCT04144491|Dietary Supplement|Probiotic|"Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug.~100ml of yoghurt containing Lactobacillus rhamnosus yoba 2012 will be consumed 5 days per week, for 9 weeks."
46091440|NCT04144491|Dietary Supplement|Placebo|100ml of custard will be consumed 5 days per week, for 9 weeks.
46005855|NCT00570102|Dietary Supplement|A regular cow's milk based formula|Weaning to a regular cow's milk based formula supplemented with 20% of the highly hydrolyzed formula used in arm 1 to make the study formulas similar in smell and taste, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin
46005856|NCT04617626|Drug|Azithromycin|Single dose of azithromycin suspension
46005857|NCT04585230|Drug|CBD|CBD oil Roll-On Stick
46005858|NCT04585230|Drug|Mineral Oil|Mineral Oil- Roll on Stick
46005859|NCT04585230|Drug|Placebo|Roll- On stick with no CBD and no Mineral Oil
46005860|NCT04617899|Diagnostic Test|Intravascular imaging|Use of imaging catheter
46005861|NCT04584840|Procedure|Surgical treatment|"Same guidelines as group 1 (non-surgical) plus surgical treatment according to the following protocol:~Specific protocol for surgical treatment~Wide mucoperiosteal flaps and complete surgical excision of necrotic bone together with a mucosa margin of at least 2 mm.~Removal of dental pieces included in the diseased area and regularization of bony margins avoiding leaving sharp edges or spicules.~Secure a two layered waterproof closure without tension (simple or with local flaps).~Samples will be sent for Pathological and microbiological analysis.~Stitches removal after two weeks~Postoperative systemic antibiotic following the mentioned protocol until stitches removal."
46005862|NCT02939690|Device|UVC|UVC insertion depth calculated by [(3× birth weight (Kg) + 9)/2+1)]
46005863|NCT02939690|Device|UVC|UVC insertion depth calculated by umbilicus to nipple distance-1
46005864|NCT02939690|Device|Ultrasound|
46005865|NCT04580784|Radiation|Weekly hypofractionation for early breast cancer|Testing the feasibility of a hypofractionated adjuvant radiotherapy regimen after breast surgery on a-once-weekly basis for a total dose of 28.5Gy in 5 fractions over 5 weeks
46005866|NCT02939729|Other|Walking Programme|Walking programme measured by daily step count on pedometer provided to participant. Participants will be advised to increase daily step count from their baseline measure - realistic incremental rise according to individual ability and symptoms. Daily step count will be recorded in a participant study diary.
46091441|NCT00638768|Other|Physiotherapy|10 weekly individual sessions with the therapist each lasting approximately 45 minutes. Techniques included postural taping, massage, mobilisation, exercises. The patients also performed home exercises
46091442|NCT04144647|Other|Single testing session|"All participants that meet the inclusion criteria, will have to attend the research laboratory at Centre for Human and Applied Physiological Sciences, Shepherd's House, Guy's Campus, King's College London, SE1 1UL to be assessed in a single testing session.~The testing session will require them to complete some questionnaires regarding balance confidence, psychological state, sleep and physical function and to undertake some simple tests of cognitive function. They will also undertake a brief dynamic balance assessment and the dual-task gait test. The dual-task component involves two cognitive tasks (a numeracy and a literacy task) or auditory task. The gait test will be performed separately and then together with each of two cognitive tasks or auditory task.~On the day, after the testing, each participant will, also, be provided a physical activity monitor (accelerometer-AX3) to wear on their wrist for 24 hours a day, seven days a week without taking it off."
46091443|NCT04634747|Drug|PVX-410|PVX-410 in combination with pembrolizumab and chemotherapy
46005867|NCT02939729|Device|Incentive Spirometer|An incentive spirometer is a device used to measure lung tidal volumes. Participants will be asked to use the incentive spirometer to measure their tidal volume daily. Participants will record daily tidal volume measurement in the participant diary. A physiotherapist will teach participants how to use the incentive spirometer and provide an instruction sheet.
46005868|NCT02939729|Other|Deep Breathing Exercises|Participants will be taught deep breathing exercises - these are the same deep breathing exercises shown to all patients after cardiac surgery as part of chest physiotherapy treatment. Participants will be asked to carry out deep breathing exercises at home during the prehabilitation phase. An instruction sheet for the deep breathing exercises will be provided to participants.
46091444|NCT04187924|Other|Autogenic drainage|Autogenic drainage is an airway clearance technique characterised by breathing control using expiratory airflow to mobilise secretions from smaller to larger airways. The secretions will be collected during the physiotherapy session and during the 24 hours following the session.
46091445|NCT04187924|Device|SIMEOX + Autogenic drainage|SIMEOX is a device generating a succession of gentle depression at the mouth during the expiratory phase associated with autogenic drainage.
46091446|NCT04619927|Genetic|Direct CYP2C19 genotyping|CYP2C19 genotype will be determined by the Spartan RX CYP2C19 point-of-care system.
46091447|NCT04619927|Genetic|CYP2C19 genotyping at the end of the study|Blood-based CYP2C19 genotyping will be performed at the end of the study
46091448|NCT04619927|Drug|Poor metabolisers|Acetylsalicylic acid 100mg once daily plus rivaroxaban 2.5mg twice daily
46091449|NCT04619927|Drug|Intermediate metabolisers|Clopidogrel 75mg twice daily
46091450|NCT04619927|Drug|Normal metabolisers and unknown metaboliser state|Clopidogrel 75mg once daily
46091451|NCT02697266|Other|No intervention|This is an observational study.
46091452|NCT02626533|Procedure|Total Knee Arthroplasty|Patients will undergo total unilateral knee arthroplasty for osteoarthritis.
46091453|NCT05661656|Procedure|Intra-arterial chemoinfusion of breast cancer|Patients will be cannulated via the femoral artery. Then, a 4F fixed-curve catheter (Cobra catheter, Cook Corporation, Bloomington) was advanced to the ipsilateral subclavian artery. Digital subtraction angiography (DSA) was performed to determine tumor arterial blood supply. Super selection of the internal mammary artery done by micro-catheter. Chemo-infusion was decided by the major feeding artery. The intra-arterial chemoinfusion regimen consisted of docetaxel 75 mg/m2 and epirubicin 50 mg/m2 in 200 mL of normal saline and 5% glucose; the drugs were slowly infused via the catheter over at least 15 minutes. Intraarterial infusion was performed once every 3 weeks on average.
45342475|NCT00710190|Device|Rheos Baroreflex Hypertension Therapy System|This therapy uses implantable device-based electrical activation of the carotid sinus baroreflex to control blood pressure.
45342476|NCT00715182|Drug|TKI258|
46091454|NCT05658809|Procedure|thyroidectomy|Patients will be divided into 2 groups group will be treated with total thyroidectomy and the other group will be treated with hemithyroidectomy
46091455|NCT02688062|Biological|NeuroRegen Scaffold with BMMCs transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
46005869|NCT00570180|Drug|Bortezomib|21 day-cycle Induction therapy:bortezomib 1.3 mg/m2 (I.V. Days 1, 4, 8, and 11), then 10-day rest period. DOXIL 30 mg/m2 given after bortezomib (I.V. infusion Day 4 of each cycle). Dexamethasone 40 mg PO on days 1-4,8-11 and 15-18 during the first cycle. Subsequent 3 cycles, dexamethasone 40 mg PO given on days 1-4 and 11-14. Patients who don't progress may undergo elective stem cell mobilization, stem cell collection and cryopreservation. Patients will then receive post-induction therapy 1.5 mg/m2 bortezomib days 1, 8, and 15 I.V. + cyclophosphamide 300 mg/m2 PO weekly + prednisone 100 mg PO on alternate days for 8 monthly 28 day cycles.Maintenance therapy with weekly 40 mg dexamethasone (days 1, 8, 15 and 22) every month until disease progression occurs.
46005870|NCT02939807|Drug|ABC294640|"ABC294640 500 mg orally twice daily (approximately 12 hours apart) continuously.~ABC294640 will be dosed under fasting conditions (at least 1 hour before or 2 hours after eating). A cycle is defined as 28 days."
46005871|NCT04585074|Procedure|Robotic or endoscopic nipple sparing mastectomy|Cases or Patients who underwent robotic nipple-sparing mastectomy and immediate reconstruction are enrolled in this arm. Robotic nipple-sparing mastectomy should be performed using robotic surgical systems. Robotic surgical systems include da Vinci S,Si, X, Xi, and SP systems. Axillary or lateral incisions are used for this procedure. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases with robotic mastectomy without immediate reconstruction are excluded.
46005872|NCT04585074|Procedure|Conventional mastectomy (including nipple sparing mastectomy, skin sparing mastectomy)|Cases or Patients who underwent conventional mastectomy and immediate reconstruction are enrolled in this arm. Conventional mastectomy should not be performed using robotic or endoscopic surgical systems. Any incisions can be performed for this procedure. Conventional mastectomy includes also Nipple-sparing mastectomy and Skin sparing mastectomy. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases without immediate reconstruction are excluded.
46091456|NCT02688062|Procedure|Surgical intradural decompression and adhesiolysis|Patients with chronic SCI (ASIA grade A) will receive intradural decompression and adhesiolysis surgery and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
46091457|NCT04113044|Other|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics.|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics.
46091458|NCT02819219|Dietary Supplement|Supplemental|participants were provided with either placebo, placebo + ElevATP, or placebo + ElevATP + Caffeine + Vitamins.
46091459|NCT02819219|Other|Exercise Intervention|Concurrent with the supplemental intervention, all subjects participated in a resistance exercise intervention.
46091460|NCT04186364|Behavioral|Assigned Ambassador|If assigned to the intervention group, participants will be assigned a medical student ambassador on arrival to the Emergency Department. A brief discussion may take place to review the child's history and survey results, and a copy of the survey will be placed near the patient's bedside for healthcare personnel to review. The student ambassador will accompany the child and their family through key points of their visit and will be expected to make accommodations for the child as determined by the accommodation survey results. The family will be required to allow the ambassador to stay throughout the ED visit.
46091461|NCT00633971|Other|complex lymphedema therapy|Patients with established post thrombotic syndrome will be randomized to either compression stocking use or complex lymphedema therapy.
46091462|NCT02818985|Drug|Dexamethasone|patients will receive intra-articular 8 mg dexamethasone added to 18 mL 0.25% bupivacaine into the knee joint.
46091463|NCT02818985|Drug|Dexmedetomidine|patients will receive intra-articular 1ug/kg dexmedetomidine added to 18 mL 0.25% bupivacaine into the knee joint.
46091464|NCT02818985|Drug|Saline|patients will receive intra-articular 18 mL 0.25% bupivacaine and 2mL isotonic saline into the knee joint.
46091465|NCT02685410|Other|One Night Stan Prototype|The One Night Stan prototype, will be a social network game with the goal of risk reduction and HIV/STI prevention in young black women.
46091466|NCT03362060|Drug|Pembrolizumab|Pembrolizumab is a monoclonal antibody checkpoint inhibitor that blocks a protein in T-cells cells called PD-1, which then allows these cells and other parts of the immune system to attack tumors
46091467|NCT03362060|Biological|PVX-410|PVX-410 is a type of vaccine composed of 4 9-amino acid peptides that may help the immune system stimulate immunity against cancer cells
46091468|NCT02818361|Drug|Topical tripterygium gel|
45678230|NCT01933880|Other|No intervention|Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
46005873|NCT02939846|Drug|Trametinib|Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
46091469|NCT02818361|Drug|Placebo gel|
46091470|NCT02818907|Other|Additional biological samples|blood and tumor tissue samples
45342477|NCT04070586|Device|4DCBCT images|Images are acquired and assessed offline
45342478|NCT02574468|Drug|Dexamethasone applied on pulp or Dexamethasone did not applied on pulp|on half of cases we put dexamethasone on pulp on other half we did not put dexamethasone on pulp
45678231|NCT04647578|Device|GT3X Actigraph accelerometer.|GT3X Actigraph accelerometer during 7 days
46005874|NCT02939495|Drug|Dapoxetine/Sildenafil 30/50 mg film coated tablet|1 tablet before sexual intercourse
46005875|NCT04584879|Behavioral|Standard UP Treatment|Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).
45342479|NCT02574468|Procedure|DPC or MP|on half of cases we treat teeth with DPC(Direct Pulp Cap) on other half we treat teeth with MP(Miniature Pulpotomy)
46091471|NCT05649995|Other|Pain science education driven physiotherapy program|Pain science training will be carried out as described by Moseley and Butler. Topics covered within the scope of pain science education are planned to include: neurophysiology of pain, synapses, peripheral sensitization, central sensitization, plasticity of the nervous system. The aim of the training will be to teach participants that pain is a multifactorial experience rather than just tissue injury. Participants in this group will be told about the importance of physical activity integrated with pain science education (i.e., explaining that physical activity is the key to bioplasticity and causing changes in our system) and why sedentary behaviors should be reduced (reducing sedentary behaviors reduces the overprotectiveness of the pain system).
46091472|NCT05649995|Other|Biomedical education driven physiotherapy program|Participants in this group will be planned to increase their knowledge of knee anatomy, knowledge of knee OA and knee OA risk factors, and the importance of increasing physical activity and reducing sedentary behavior in reducing osteoarthritic pain and improving overall health. The importance of physical activity by integrating it with biomedical education (as physical activity can help strengthen muscles, protect joint function, and improve sleep and general health) and the necessity of reducing sedentary behaviors will be discussed within the framework of biomedical education.The main difference of standard education from pain science education will be that it does not contain information about pain mechanisms mentioned in pain science education.
46091473|NCT02683226|Drug|Vipdomet|
46091474|NCT02683226|Drug|Incresync|
46091475|NCT02818205|Other|Sensory Challenge Protocol|Measurement of electrodermal activity in response to sensation
46091476|NCT02815787|Drug|SP2086|In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.
46091477|NCT02815787|Drug|Glyburide|In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.
46091478|NCT00639938|Drug|Nevirapine|200 mg Nevirapine tablet
46091479|NCT00639938|Drug|HIV immune globulin solution|5% intravenous HIV immune globulin solution
45836379|NCT00328614|Drug|Total androgen suppression (TAS) with Goserelin Acetate|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
46091480|NCT02818439|Other|evaluation of frailty|
45836380|NCT00328614|Device|Radiation Therapy|Radiation therapy will begin 3 months following the initiation of hormone administration. Daily tumor doses will be given 5 days per week for 7-8 weeks.
46091481|NCT02685254|Behavioral|Structural skills training group|Weekly 2-hours sessions for 14 weeks follow the Norwegian translation of the Swedish version of the ADHD skills training manual/workbook (Hesslinger 2010; Hirvikoski 2011; Morgensterns 2015) which is based on an adaption of Marsha Linehan's dialectical behavior therapy (DBT) for borderline personality disorder into a group-based skills training program for adults with ADHD (Hesslinger 2002; Philipsen 2007). The groups embrace 7 - 10 participants, and two group leaders trained in group therapy, cognitive-behavioral treatment or DBT. Each session contains an initial short repetition and feedback on the previous session, followed by review of the homework during the first hour. After a break, a new topic with exercises and homework for the following week is introduced.
46091482|NCT02685254|Other|Treatment as usual|Treatment as usual includes clinical management and/or medication, and or supportive counselling by physician or nurse
45836381|NCT00328770|Drug|Sirolimus|Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l
46005876|NCT04584879|Behavioral|Capitalization UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.
46005877|NCT04584879|Behavioral|Compensation UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
46005878|NCT00570219|Drug|valproate|Valproate 20 mg/kg per day for 2 weeks, reduction during week 3. Conversion of benzodiazepines to an equivalent dose of diazepam (maximum 80 mg per day). Dosage reduced 10 mg daily until 40 mg per day. Reduction then continued 5 mg daily.
46091483|NCT02687750|Device|MRI|Investigational device is a dual tuned (fluorine/proton) MRI surface coil designed and produced by Clinical MR solutions
46005879|NCT04584957|Device|VAC therapy|Prophylactic ciNPWT therapy (Prevena® KCI) entails placement of the device over a closed incision immediately post-operatively. Prevena® KCI may be left in place with no additional intervention for up to 7 days.
46005880|NCT04610957|Drug|Rosafem (FEMININE FORMULA)|Rosafem is the only phytoestrogen product with the convenient dose which provides significant improvement of menopausal related symptoms premenstrual syndrome symptoms
46005881|NCT00570375|Drug|Erlotinib|150 mg, PO, QD beginning day 1 week 1. Patients will receive treatment for 16 weeks as long as there is no evidence of disease progression. In no response is noted after 16 weeks of treatment, patients will be taken off the study. Patients achieving response (HI, CR, or PR) will continue on treatment until evidence of disease progression or relapse.
46005882|NCT04617509|Drug|Formulation A GS-248|Formulation A of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
46005883|NCT04617509|Drug|Formulation B GS-248|Formulation B of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
46091484|NCT02815319|Drug|Dexamethasone|Steroid prophylaxis
45678232|NCT04620980|Diagnostic Test|targeted resequencing|The investigators will use a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID).
45678233|NCT02008877|Drug|ganetespib|Phase 1 Dose 1: 150 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 1 Dose 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour
46091485|NCT04039568|Behavioral|Health Enhancement Program (HEP)|This is the active control group of the study, where participants will be educated on health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation.
45678234|NCT02008877|Drug|Sirolimus|4mg taken orally once daily on a continuous dosing schedule; Loading dose 12 mg on cycle 1 day 1 only.
46091486|NCT04039568|Behavioral|Sahaj Samadhi Meditation (SSM)|This is the experimental arm of the study, where participants will be trained in a form of meditation that may improve depressive symptoms.
46091487|NCT02815475|Dietary Supplement|Placebo comparator|
46091488|NCT02815475|Dietary Supplement|Curcumin|
46091489|NCT02815475|Dietary Supplement|Turmeric powder|
46091490|NCT02815241|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z43-046)
46091491|NCT00640796|Procedure|Haploidentical donor derived natural killer cell infusion|Therapeutic cell infusion
46005884|NCT00570414|Device|Laryngeal mask airway|Airway management by the use of the flexible, reinforced laryngeal mask airway
46091492|NCT00640796|Drug|Chemotherapy|Cyclophosphamide, Fludarabine, Interleukin-2, Mesna
46091493|NCT00640796|Device|CliniMACS|Cell selection system based on magnetic-activated cell sorting
46091494|NCT05646641|Other|Strength exercise|The protocol consists of 8 weeks of training, consisting of 16 sessions of 50 minutes, twice a week on alternate days.
46005885|NCT00570414|Device|Endotracheal tube|Airway management by the use of endotracheal tube
46005886|NCT04617431|Behavioral|Mobile health application and social media|"The intervention involved reminding the intervention group to upload their dietary diary every day. The researchers were trained by a dietitian and provided suggestions about diet and exercise to the intervention group. LINE  is a mobile app operated by LINE Corporation. All users can use texts, images, video, and audio for contact at any time. A LINE group was created to deliver medical knowledge of diet and exercise. Each of the messages were guided by a diet manual for kidney disease (edited by Department of Dietetics, National Taiwan University Hospital Yunlin Branch). The intervention group also asked questions about CKD management, and a teleconsultation of health information was provided. A daily target of 7,500 steps was set and used to emphasize the correct concepts about exercise. Participants were inspired in the intervention group if someone achieved the target number of steps."
46005887|NCT00568035|Drug|QR-333|QR-333 or placebo will be applied three times a day for 12 weeks
46005888|NCT04611113|Dietary Supplement|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Impact®). The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
46091495|NCT02687984|Drug|RBP-7000|A single subcutaneous injection with doses of RBP-7000 containing 120 mg risperidone and either a low, high, or intermediate molecular weight PLGH polymer.
46091496|NCT05657873|Radiation|L-SABR|L-SABR will be delivered in a week during which the patient receives no chemotherapy. L-SABR can be on the same week or even day as anti-PD-(L)1 therapy.
46091497|NCT05657873|Biological|Anti-PD-(L)1 based immunotherapy|Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy
46091498|NCT05657873|Drug|Platinum based chemotherapy|Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy
45836382|NCT05105568|Behavioral|Process-based therapy|Process-based therapy (PBT) is a meta-theoretical model of evidence-based therapies that organizes adaptive and maladaptive processes of change using complex and dynamic networks based on an evolution science framework. Depending on the participant's presentation, PBT would be shaped by different evidence-based techniques. Examples of evidence-based procedures include: behavioral activation, exposures, mindfulness, self-compassion, values exploration, and contingency management.
46091499|NCT02327312|Device|Stents|Two Trabecular meshwork Micro-Bypass stents into the study eye
46091500|NCT02327312|Procedure|Laser|Laser Trabeculoplasty
45342480|NCT00710268|Drug|AZD2281|Oral Capsule, Dose Escalation 50, 100, 200, 400 mgContinuous twice daily dosing
45342481|NCT00710268|Drug|Bevacizumab|IV administration10 mg/kg every 14 days
46091501|NCT02327312|Device|Laser Trabeculoplasty|
46091502|NCT02815163|Other|Empowerment education|"admission (1 hour)~▪partnership~2 ds after THR (30-45min)~listening~dialogue~reflection~action~feedback~2 WKs after THR (30 min)~listening~dialogue~reflection~action~feedback~6 WKs after THR (30 min)~listening~dialogue~reflection~action~feedback~10 WKs after THR (30 min)~listening~dialogue~reflection~action~feedback"
46005889|NCT04611113|Dietary Supplement|Control Nutritional Support|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement. The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
46005890|NCT00568074|Drug|repaglinide|
46091503|NCT02683148|Drug|DHEA|
45459418|NCT04446182|Drug|Itacitinib|All eligible patients will begin study therapy with approximately a week lead-in of itacitinib monotherapy at scheduled dose. Itacitinib will be taken daily at scheduled dose for a total of six cycles. itacitinib may be tapered as deemed appropriate by the treating investigator. Patients will remain on study therapy as long as treatment discontinuation criteria are not met. Patients with PR or better may continue itacitinib for up to 1 year.
45678235|NCT01933334|Drug|Pirfenidone|Pirfenidone will be administered orally at a dose of 267 mg one oral capsule TID (801 mg/day) for 1 or 2 weeks followed by two 267 mg oral capsules TID (1602 mg/day) for 1 or 2 weeks (titration period) and then three 267 mg oral capsules TID (2403 mg/day) for 12 weeks (maintenance period).
45678236|NCT01908140|Drug|Aclidinium Bromide / Formoterol Fumarate|
46091504|NCT02683148|Other|FACT-67 validated survey|"Baseline, Cycle 1 Day 15, and Day 1 of each cycle beginning with Cycle 2~7 questions with answers ranging from 0=Not At All to 4 = Very Much."
46091505|NCT04238507|Device|Guedel airway|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a Guedel airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
46091506|NCT04238507|Device|USASK airway|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a USASK airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
46091507|NCT03992768|Device|Hamamatsu NanoZoomer S360MD Digital Slide Scanner System|Detection of pathology features using whole slide imaging
45678237|NCT01908140|Drug|Salmeterol / Fluticasone|
46091508|NCT02818127|Procedure|coronary angiography|Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.
45836383|NCT04281654|Other|Active Social Conversation|Active Social Conversation
45836384|NCT04952376|Behavioral|SMS delivery of information|Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. Links to information or phone for scheduling will be provided. Messages mimic the clinic's usual practice of information delivery to patients
45836385|NCT04952376|Behavioral|Personalized text message delivery of information|Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. The SMS message is personalized as a recommendation from the primary care clinician
45836386|NCT04952376|Behavioral|Interactive or 2-way SMS delivery of information|This intervention is same as in the Arm 2 using personalized messaging from the PCP. In addition, patients are given interactive or 2-way SMS options to obtain additional information about COVID vaccine and answers to frequently asked questions.
45836387|NCT04248192|Biological|DD HST-NEETs|HIV-infected individuals following Allogeneic Bone Marrow Transplantation (alloBMT) will be treated with DD HST-NEETS therapy. Participants and donors will be screened for eligibility. Eligible donors will undergo a blood draw of up to 300mL to allow production of allogeneic DD HST-NEETs. Participants, who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing, will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
45836388|NCT04177680|Drug|Omega 3 pentaenoic acid|Encapsulated omega-3 pentaenoic acid
45836389|NCT04177680|Drug|icosapent ethyl|Encapsulated omega-3 acid ethyl esters
45836390|NCT01790724|Behavioral|Walking exercise|
45836391|NCT00330876|Drug|Pitavastatin|
45836392|NCT01792206|Drug|Zemplar|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
46005891|NCT00568074|Drug|Glurenorm®|
46005892|NCT00568074|Drug|Glucobay®|
46005893|NCT00568113|Drug|acetylcysteine in arm 1|"Arm 2, control group: given hydroxyl progesterone caproate (150mgm) every 3 days starting from the 28th week of pregnancy till completed 36 weeks of gestation.~Arm 1 patients were given hydroxyl progesterone caproate (150mgm) weekly injections plus NAC 0.6 gm (Sedico, Egypt) orally daily starting from the 28th week of pregnancy till delivery or completed 36th week of pregnancy."
46005894|NCT04617392|Procedure|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy involves removing a part of the stomach, limiting the amount of food the patient can eat.
46091509|NCT02684786|Drug|reserpine|Patients with qualifying hemodynamics from prior right heart catheterization will receive open label reserpine, 0.05 mg by mouth daily for two weeks, then 0.10 mg by mouth daily for two weeks, and then have repeat non-invasive assessments of status
46091510|NCT02684786|Procedure|stellate ganglion block|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
45342482|NCT02575482|Drug|SUVN-D4010|
46005895|NCT04617392|Other|Strength endurance training|Patients included in the active cohort arm with physical activity will undergo three months of strength endurance training under the supervision of a professional physiotherapist
46005896|NCT00568152|Dietary Supplement|Low PA apple puree|Golden Delicious apple puree 230grams consumed daily for 14 days
46091511|NCT02684786|Drug|lidocaine|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
45836393|NCT01792206|Drug|Placebo|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
46005897|NCT00568152|Dietary Supplement|High PA apple puree|High PA apple puree (Mitchalin) consumed daily for 14 days
46005898|NCT00568152|Drug|Aspirin|75mg dispersable aspirin taken daily for 14 days
46005899|NCT04610879|Drug|Carbamazepine|Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
46091512|NCT04238273|Diagnostic Test|Functional Echocardiography|Imaging studies to assess Hemodynamics of both groups on and off non invasive ventilation
46091513|NCT02685020|Biological|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
46091514|NCT02685020|Biological|Clade C gp140|The Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
46091515|NCT02685020|Drug|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
46091516|NCT02815007|Drug|Chidamide with EGFR-TKI|Chidamide and EGFR-TKI, dosage described in arm description.
46091517|NCT02683070|Procedure|Bilateral pudendal nerve block|Bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) after the completion of surgery before extubation
46091518|NCT02683070|Drug|Intravenous tramadol|Intravenous tramadol of 1.5mg/kg after the completion of surgery before extubation
46091519|NCT05643599|Dietary Supplement|Mad Honey|mad honey (80 mg/kg); (n:6)
46091520|NCT05643599|Dietary Supplement|Normal Honey|normal honey (80 mg/kg),(n:6)
46091521|NCT05643599|Dietary Supplement|Control|Control
46005900|NCT04610879|Drug|Levetiracetam|Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
46005901|NCT04610879|Behavioral|Parent based sleep (PBS) intervention|The PBS intervention is an e-learning package for parents/primary carers and children with epilepsy. The PBS intervention offers parents education about normal sleep, advice about sleep-promoting practices and targeted strategies parents can employ to help their children to ''learn'' an appropriate set of sleep behaviours/habits and/or to unlearn inappropriate sleep behaviours.
45836394|NCT00333606|Behavioral|Acupuncture|Body acupuncture of 1 specific point per trial session
46091522|NCT04184414|Drug|CD19-CART|1-10x106 / kg CD19 CART cells
46091523|NCT02814851|Device|Transesophageal echocardiogram|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann. A transesophageal echocardiogram (TEE) will be performed and the TEE probe will stay continuously during the entire procedure, to allow all necessary measurements.
45836395|NCT04947852|Device|Investigation Mask|Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
46091524|NCT02814851|Device|Thermistor-tipped catheter|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a thermistor-tipped catheter (model 93A-131-7F, Edwards, Santa Ana, CA) will be inserted into the pulmonary artery to measure right atrial pressure (Pra), pulmonary arterial pressure (Ppa), Ppao and thermodilution cardiac output. Ringer's lactate will be infused to maintain an occluded pulmonary arterial pressure (Ppao) of 8-10 mmHg.
45836396|NCT04947852|Device|Comparator Mask|Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
45836397|NCT00334074|Drug|Clofarabine and Cytarabine|Phase II Trial of Clofarabine and Cytarabine in Relapsed Standard-Risk AML and Untreated High-Risk MDS in Adult Patients, and Untreated AML in selected Elderly Patients at high risk of anthracycline toxicity
45836398|NCT00335478|Drug|Daptomycin|daptomycin 6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is >500 cells/mm^3.
46005902|NCT04617236|Behavioral|Cultivando La Salud|"A lay health worker delivered educational intervention for breast and cervical cancer screening.~In total, the Intervention Group subject participation will take approx. up to four hours (1 hour for interview, 1 hour for the second interview, and 1-2 hours for the CLS intervention) and Control Group up to four hours (One hour for interview, one hour for the second interview, up to two hours for educational intervention after the second interview).~Follow-up data was collected 4-6 months post education session (intervention group) or post-baseline survey (control group)."
46005903|NCT04610801|Drug|Nasal Spray|Randomized to placebo and Xlear
46005904|NCT04584489|Other|iron stores assessment.|assessment of iron stores by measuring serum ferritin level (mandatory), serum iron and transferrin saturation.
46005905|NCT00570570|Procedure|Muscular Strengthening for paretic knee flexor and extensor|thrice a week during 6 weeks
46005906|NCT00570570|Other|conventional physiotherapy|trice a week during 6 weeks
45342483|NCT02575482|Drug|Placebo|
45342484|NCT02575326|Other|Standard Control|Teens in the control group will receive standard or usual care as provided by their physician.
45342485|NCT02575326|Behavioral|a provider administered, tailored discussion guide|Teens in the intervention group will receive a provider administered, tailored discussion guide based on motivational interviewing techniques.
45342486|NCT02575248|Drug|Dienogest 2mg|Dienogest 2mg is given daily for 3 months then followed by Clomiphene citrate 5 mg induction of ovulation for three months
45342487|NCT02575248|Drug|Clomiphene citrate 5 mg|Clomiphene citrate 5 mg for induction of ovulation for three months
46091525|NCT02814851|Device|Pressure/volume catheter|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a pressure/volume catheter (CD Leicom, Zoetermeer, Netherland) will be placed in the left ventricle through a left superior pulmonary vein purse string, in order to measure alternatively LV pressure/volume loops and LA pressure.
46091526|NCT02814851|Device|Transthoracic echocardiography|"A complete transthoracic echocardiography will be performed the day before the surgical procedure. It will establish the presence of the inclusion and exclusion criteria, as stipulated above. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).~During the surgical procedure, a transesophageal echocardiogram will be performed, using an Acuson Sequoia system (Siemens AG, Germany)."
46091527|NCT02685176|Device|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, B.C.)|A heater (STK Heatpac) will be used in the active warming arms of the study.
46091528|NCT02685176|Other|No heat|No active heating provided post cooling
45459419|NCT04446182|Device|Extracorporeal Photopheresis (ECP)|ECP will begin after itacitinib lead in period. At the end of 8 weeks of combination therapy, patients will start a standard ECP taper schedule. Patients achieving PR or better after 6 cycles of itacitinib may continue treatment with itacitinib for up to 1 year. Thereafter, itacitinib may be tapered at the treating investigator's discretion.
45459420|NCT01368302|Behavioral|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
45459421|NCT02507960|Device|The Gamma Pod|Immobilization of breast during radiation.
45459422|NCT02507960|Device|CT simulation|See arm description
45836399|NCT01790802|Device|2RT nanosecond laser|active laser therapy
45836400|NCT01790880|Behavioral|ORLA|Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system.
45836401|NCT01790880|Behavioral|ORLA + Writing|Treatment includes writing of sentences in combination with ORLA
46005907|NCT04617119|Device|Threshold IMT device|10 breaths X 3 sets, two times a day for 2 weeks. starting intensity 10 % of pre-measured maximal inspiratory pressure.
45836402|NCT02103816|Device|SmartLipo Triplex laser system along with the SideLaze800 hand piece|
46005908|NCT04617119|Other|Conventional physical therapy|daily
46005909|NCT00570609|Other|CPR Anytime education|After consent, participants will be asked to complete the 22 minute DVD CPR Anytime program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
46005910|NCT00570648|Drug|sodium hyaluronate|1% sodium hyaluronate applied at the end of corneal transplant surgery. The amount will be determined on how much is necessary to cover the ocular surface.
46005911|NCT00570726|Drug|Ranibizumab (Lucentis)|
46005912|NCT04584450|Other|Questionnaire|data collection using questionnaire
46005913|NCT00570804|Behavioral|Telephone Counseling|7 counseling calls where quit date set on first counseling call; then counseling calls on quit date, 3-5 days after quit date, 7-10 days after quit date, 15-30 days after quit date, 45-60 days after quit date, and 90 days after quit date, each taking about 15 to 30 minutes to complete.
46005914|NCT00570804|Behavioral|Telephone Assessments|4 assessment telephone calls at Weeks 12, 26 and 52 (interview by a research staff member), taking about 30 minutes each to complete.
46091529|NCT05656391|Dietary Supplement|Treatment vs control bread|Consumption of 200 grams per day of either treatment or control bread for eight weeks
46091530|NCT02684864|Other|Non-interventional|
46091531|NCT05656157|Device|Medical device|Clinical decision support system
45459423|NCT01374620|Drug|Paclitaxel dose escalation|"Paclitaxel will be administered intravenously over 60 minutes, at D1, D8 and D15, at a given dose.~The Paclitaxel dose (mg/infusion) levels are as follows:~40~60~70~75~80~85~90"
45459424|NCT01374620|Drug|Paclitaxel|Patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose in association with metronomic cyclophosphamide
45459425|NCT01374620|Drug|Cyclophosphamide|"D1 to D28: 50 mg x 2/day/cycle~1 cycle = 28 days"
45459426|NCT01374620|Biological|Blood collection|At D1, D8, D15 and D21 of cycle 1 and cycle 2:2 blood samples for the correlation between clinical response and biological parameters
45459427|NCT01368380|Behavioral|Psychological intervention|Couples in the intervention group attends six to eight couple-sessions performed by a psychologist.
45459428|NCT01374698|Drug|Aspirin|Aspirin 325 mg
45459429|NCT01373762|Behavioral|Exercise Videogame Bikes|The intervention group will receive an exercise videogame bike that will be linked into their Sony Playstation 2® (Sony Computer Entertainment America Inc, Foster City, California). The Active Cycle® system reads the participant's cycling cadence which, in combination with a handlebar-mounted game controller, allows each participant to play a variety of Sony Playstation 2 and 3® videogames while exercising. The control-distraction group will receive a traditional stationary bike (i.e., same bike as the Active Cycle, but without the videogame controllers), which will be placed in front of their television. The recommended exercise training regime for both conditions will be activity of moderate intensity exercise (i.e., 60 to 75% of heart rate reserve), 3 days/week for 30 minutes/day.
45836403|NCT04870164|Drug|Ensovibep|The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohorts. 3 IV infusion, 2 IV bolus, 4 subcutaneous and 4 intramuscular cohorts are planned. Subjects receive one or two administration(s) on day 1, depending on the cohort.
45836404|NCT04870164|Drug|Placebo|One administration at day 1 by infusion.
46091532|NCT04184024|Other|Massage|"Soft tissue massage known as Swedish massage technique was applied to the neck area for 20 minutes. This massage was carried out 3 days a week for 4 weeks (12 sessions) by the supervisor physiotherapist."
46091533|NCT04184024|Other|Kinesio tape|Patients were taped according to the Kenzo Kase's Kinesio Taping Method by an experienced physical therapist. The application was carried out in a relaxed sitting position. Y banding with extensor muscles on the back of the neck with muscle technique, I banding with the upper trapezius with muscle technique and I banding with ligament technique to the middle region of the neck were performed.
46091534|NCT04184024|Other|Neck stabilization exercise|Neck stabilization exercise was performed in stages with gradual progression according to the stages of motor learning and sensory-motor integration, namely, static, dynamic, and functional. The program started with postural training and then the cervical bracing technique with the activation of deep neck flexors for NSE was performed. The patients were asked to maintain a neutral spine during the exercises and throughout the day as much as possible. The difficulty and variety of exercises were increased weekly. It was carried out 3 days a week for 4 weeks (12 sessions) by the supervisor physiotherapist.
46005915|NCT04584606|Diagnostic Test|Lab workup (on admission and regularly during follow up).|"Complete blood count with differential leucocytic count. Absolute lymphocytic and neutrophilic count. Liver functions: Aspartate transaminase and Alanine transaminase . Renal functions: Blood urea nitrogen, serum Creatinine. HbA1C. C-reactive protein (quantitative). Serum ferritin level. D - dimer level (quantitative). Coagulation profile (Prothrombin time/ Partial thromboplastin time/ International normalized ratio).~Troponin level. Arterial blood gases when needed."
45459430|NCT01368458|Other|Conversion to Antipsychotic Monotherapy|Patients assigned to the antipsychotic monotherapy group will have the dosage of their secondary (i.e. one due to be reduced) antipsychotic reduced by decreased by approximately 1/3 every 3 weeks. Dosage of the primary antipsychotic will be left unchanged.
46091535|NCT02814773|Other|questionnaires|
45459431|NCT01374776|Drug|intravenous iron carboxymaltose|The patients will be randomized to one of the 2 treatment groups (12 patients in each group): Group I: intravenous iron carboxymaltose; Group II: intravenous placebo. Group I (intravenous iron): Ferinject will be applied via a short infusion. Patients will receive 15mg/kg of iron as iron carboxymaltose Ferinject® in 250 ml 0.9% NaCl intravenously (time of infusion 20 mins), in a single dose. The maximum dose is limited to 1000mg iron. Group II (intravenous placebo): Intravenous placebo (250 ml 0.9 % NaCl will be administrated in the same manner and time schedule than group I.
45459432|NCT04947332|Procedure|Auto-inoculation|A wart will be excised from the body, minced and will be inoculated in a subcutaneous pocket on forearm.
46091536|NCT02817971|Behavioral|Enhanced feedback|Hospital level feedback delivered every month through paediatrician on the level of adherence to revised pneumonia treatment recommendations.
45459433|NCT04035434|Biological|CTX110|CTX110 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components
45459434|NCT03118934|Device|Lotrafilcon B multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily wear basis and cared for with participant's habitual lens care solution
46005916|NCT00570843|Drug|New PEG based artificial tear|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
46005917|NCT00570843|Drug|Optive|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
45836405|NCT01791036|Procedure|Adductor Canal Block|Examination of the adductor canal using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin in the medial upper-thigh region. The ultrasound probe will be moved either cephalad or caudad from its initial position in order to visualize the femoral artery immediately deep to the middle of the sartorius muscle. This point will then be selected as the appropriate level for needle insertion. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
46005918|NCT00563069|Drug|Midazolam|
46091537|NCT02817971|Behavioral|Standard feedback|Hospital level feedback delivered every two months through paediatrician on the performance of multiple paediatric care indicators for managing severely ill children.
46091538|NCT05664152|Biological|MG1111|BARYCELA inj.
45459435|NCT03118934|Device|Nelfilcon A multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily disposable basis (removed every night and discarded) with a new pair of study lenses every morning
45678238|NCT02008565|Drug|Loperamide|Participants randomized to the loperamide group will begin with 2mg of loperamide/day. The participant will be administered the Patient Global Symptom Control rating scale (PGSC) to determine dose escalation. Participants who report inadequate control of stool leakage on the PGSC will be instructed to increase the daily dose of loperamide by 2 mg up to a maximum of 8 mg per day (1-4 capsules). Bothersome adverse events and resulting dose reduction will be based exclusively on the result of the Patient Global Tolerability Scale (PGTS). The daily dose will be decreased by 2mg to a minimum of 2mg every other day. If a PGSC score indicates inadequate control of stool leakage combined with a PGTS score indicating bothersome side effects, the participant will discontinue the study medication.
46005919|NCT04584411|Diagnostic Test|Cardiac Magnetic resonance imaging|"The following basic sequences will be conducted:~Cine imaging using SSFP sequence for cardiac structure and function.~Tissue characterization imaging, T1 and T2.~Myocardial perfusion imaging.~Late gadolinium enhancement.~Diagnosis of myocarditis will be based on the modified Lake Louise criteria:~T2-weighted: any of the following standard T2 sequences: regional high signal standard T2 sequences: global signal intensity ratio (myocardium/skeletal muscle) ≥2 T2 mapping: increased T2 relaxation times T1-weighted: any of the following late enhancement imaging: non-ischemic (subepicardial or mid myocardial) late enhancement native T1 mapping: increased T1 relaxation times or extracellular volume supportive criteria: signs of pericarditis: effusion or pericardial late enhancement regional or global wall motion abnormalities[5]"
46005920|NCT04580355|Procedure|One-Stage Full Mouth Debridement|Periodontal debridement
46005921|NCT04580355|Drug|Amoxicillin 500mg|Administration of Amoxicillin 500mg prescribed on the day of treatment tid for 7 days.
46005922|NCT04580355|Drug|Metronidazole 400mg|Administration of Metronidazole 400mg prescribed on the day of treatment tid for 7 days.
46005923|NCT04580355|Drug|Amoxicillin Placebo|Administration of Placebo on the day of treatment tid for 7 days.
45459436|NCT03118934|Device|Delefilcon A multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily disposable basis (removed every night and discarded) with a new pair of study lenses every morning
46005924|NCT04580355|Drug|Metronidazole Placebo|Administration of Placebo on the day of treatment tid for 7 days.
46005925|NCT00563108|Drug|Basiliximab|
46005926|NCT00563108|Drug|Placebo|
45678239|NCT02008565|Drug|Placebo|Participants randomized to the placebo arm will begin the a dose of one capsule per day and will be dose increased or dose decreased using the same algorithm described for the loperamide arm.
46005927|NCT00570882|Drug|Sunitinib 2/1|Sunitinib 50 mg PO 2 weeks followed by 1 week rest
46091539|NCT04364633|Other|Voice Handicap Questionnaire (VHI)|Voice Handicap Index (VHI) self-questionnaire
46091540|NCT05664074|Drug|Rectal indomethacin|"Dosage based on subject's weight:~>=50 kg, 100 mg; 30-49 kg, 50 mg; 10-29 kg, 25 mg"
46091541|NCT05664074|Drug|IV ketorolac|Dosage based on subject's weight: 0.5 mg/kg (maximum: 15 mg)
45342488|NCT02575170|Drug|Amino acid solution|a balanced mixture of 18 pure crystalline amino acids, eight of which are essential amino acids
45342489|NCT02575170|Drug|Ringer's lactate solution|200 ml of Ringer's lactate solution
45342490|NCT00710502|Procedure|Transvaginal NOTES cholecystectomy|Under general anesthesia, patients will undergo Transvaginal NOTES cholecystectomy
45342491|NCT00710502|Procedure|Laparoscopic cholecystectomy|Under general anesthesia, patients will undergo standard Laparoscopic cholecystectomy
45342492|NCT02573454|Behavioral|App assignment|Under-active undergraduates are assigned to use a GPS exercise app that is prosocial (i.e., allows the user to raise money for charities) or personal (does not allow the user to raise money for charities) in nature
45342493|NCT00710658|Behavioral|WebChoice|"Patients in the experimental group had over the study period access to the Internet support system WebChoice that allowed them to monitor symptoms over time, and provided access to evidence-based self-management options tailored to their reported symptoms as well as a communication area where patients could ask questions to a clinical nurse specialist in cancer care and exchange experiences with other cancer patients.~Patients in the control group received usual care"
45342494|NCT00710736|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
45342495|NCT00710736|Drug|Capecitabine, 5-fluorouracil prodrug; oral|multiple dose, single schedule
46091542|NCT00634205|Drug|Valproate plus doxorubicin|Valproate 20-30 mg/kg orally (in order to obtain serum concentration between 50-100 mcg/ml) Doxorubicin 60 mg/m² intravenously every 3 weeks
46005928|NCT00570882|Drug|Sunitinib 4/2|Sunitinib 50 mg PO 4 weeks followed by 2 week rest
46005929|NCT00563147|Drug|tivozanib (AV-951) plus temsirolimus|ascending doses of tivozanib (AV-951) capsules administered orally for 21 days with discontinuation for 7 days; ascending doses of temsirolimus administered intravenously every 7 days
46091543|NCT02681276|Procedure|Irrigation with 3% NaOCl|All the operators are informed to perform the endodontic treatment the way they normally do. The only variation during treatment was the concentration of the sodium hypochlorite solution for irrigation of the root canal.
46091544|NCT02681276|Procedure|Irrigation with 0.5% NaOCl|All the operators are informed to perform the endodontic treatment the way they normally do. The only variation during treatment was the concentration of the sodium hypochlorite solution for irrigation of the root canal.
45459437|NCT01374854|Biological|Umbilical mesenchymal stem cell (UC-MSCs) infusion|1×10^6/kg UC-MSCs is infused through pancreatic artery along with mononuclear cells by interventional therapy and another same dose of UC-MSCs is administered one week post-intervention.
46091545|NCT04238195|Drug|Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo|Treatment A: Subjects receive TBPM-PI-HBr + matching Placebo.
46091546|NCT04238195|Drug|Moxifloxacin 400mg|Treatment D: Subjects receive 1 400 mg tablet of moxifloxacin administered in an open label manner.
46091547|NCT04238195|Other|Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)|Treatment C: Subjects receive TBPM-PI-HBr matching placebo.
46005930|NCT00570999|Drug|Palifermin|60 mg/kg/day
46091548|NCT04238195|Drug|Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)|Treatment B: Subjects receive TBPM-PI-HBr.
46091549|NCT05639231|Behavioral|INTOMOB intervention|"The intervention will be multilevel, targeting the patients, healthcare professionals (HCPs) and environment:~PATIENTS:~Information booklet on the importance/benefits of mobility, consequences of low mobility, how to be more active (with concrete information).~Customizable diary to document mobility goals, results, difficulties and needs.~Exercise booklet with explanations & pictures of mobility exercises (supine, sitting, standing).~iPad 10.2'' with videos of the exercises.~HCPs (physicians & nursing staff):~E-learning on the consequences of low mobility, barriers/facilitators to hospital mobility; recommendations, documentation, communication & interdisciplinary collaboration regarding mobility; implementation.~Oral presentation on the intervention.~Checklist to remind HCPs to address mobility.~ENVIRONMENT:~Posters in the wards about mobility and other topics of interest to older adults.~Walking itineraries with quizzes in the wards."
46091550|NCT02815085|Other|RecoverLINK technology|HF patients will receive the RecoverLINK app upon study enrollment for 30-days. The Mount Sinai HF care team will interact with patients via the RecoverLINK cloud-based system during this period
46091551|NCT04238351|Device|Transnasal humidified rapid insufflation ventilator exchange|applying 40L of oxygen for 1min and afte that increase oxygen flow up to 70L for 1 min.
46091552|NCT04238351|Device|Conventional face mask|applying oxygen using usual face mask
46091553|NCT02818049|Procedure|Bronchoalveolar Lavage|BAL was performed in accordance with current practice. Patients are oxygenated with FiO2=1 at least 5 min before the start and 4 h after the procedure. Blood pressure, central venous pressure, heart rate and breathing are monitored by a monitor. O2 saturation (SpO2) is monitored continuously by pulse oximetry.
45459438|NCT01374854|Drug|traditional therapy|exogenous insulin injection daily
46005931|NCT00570999|Other|Placebo|1,2 mL once daily
46005932|NCT04616261|Behavioral|Training|6 weeks of training
46005933|NCT04616261|Drug|Formoterol|inhalation of 54 microg formoterol
46005934|NCT04616261|Drug|Placebo|inhalation of placebo
46005935|NCT04616222|Drug|CELSIOR® group|Patient who received Celsior® during their transposition of the great vessels surgery according to the routine care.
46005936|NCT04616222|Drug|Saint-Thomas group|Patient who received Saint-Thomas during their transposition of the great vessels surgery according to the routine care.
46005937|NCT04584177|Behavioral|Arm-hand BOOST program|The arm-hand boost program is provided 1 hour/day, 5x/week for 4 weeks, on top of their usual care program. The focus of the boost program is on scapula-setting, core-stability when reaching, movements with 30-60° flexion/abduction in shoulder, fine manipulation and integration in complex ADL tasks. Additionally, patients exercise 1 hour per week using the Armeo Power (Hocoma). Therefore, the additional arm-hand boost program consists of 24 one-hour sessions, provided over four weeks.
46091554|NCT02817425|Drug|SOX Sequential S-1|8 cycles SOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 ~14 (S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1.Every 21 days as a cycle.
45459439|NCT01368692|Procedure|position of shoulder retraction|position of shoulder retraction by placing a saline bag between the scapula
45459440|NCT01368692|Procedure|position of neutral shoulder|neutral shoulder position during subclavian vein catheterization
45459441|NCT01374932|Device|CPAP|Continuous positive airways pressure (CPAP)
46005938|NCT04584177|Behavioral|Control program|A dose-matched program of strengthening exercises for the lower limbs and general reconditioning
46091555|NCT02817425|Drug|SOX|S-1: 40 mg/m2 bid,po, day 1 ~14 (S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. Every 21 days as a cycle
46005939|NCT00563225|Drug|Insulin Glargine|Insulin glargine at the discretion of the investigator Subcutaneous, once daily injection (at bedtime)
46091556|NCT02817425|Drug|TEGAFOX Sequential S-1.|6 cycles TEGAFOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 ~14 (S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. TF 1000 mg/m2 with calcium folinate 300 mg/m2 IV infusion from Day 1 to Day 5 Every 28 days as a cycle.
46091557|NCT04237337|Other|Exposure to MS drugs|Exposure in ICSRs to MS drugs (dichotomous, exposed/not exposed), for each individual MS drug
46091558|NCT02684708|Drug|cyclophosphamide, vincristine, prednisone, dacarbazine|28-day chemotherapy cycle
46091559|NCT02684708|Drug|cyclo, vcr, pred, dacarb,etop and doxo|21-day chemotherapy cycle
46091560|NCT02817503|Drug|Standard BP control|Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
46091561|NCT02817503|Drug|Moderate BP control|Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
45459442|NCT03114488|Device|tDCS|Transcranial electrical stimulator
45459443|NCT05197478|Other|Mini Nutritional Assessment ,Pıtsburg Sleep Qualıty Scale, Short Physical Activity Survey|"To evaluate the lifestyle before being infected with COVID 19, physical activity, nutrition and sleep habits were questioned.~To evaluate sleep habits; Pitsburg Sleep Quality Scale (PSQS) Nutritional habits: Mini Nutritional Assessment(MNA) Scale For the evaluation of physical activity; International Brief Physical Activity Questionnaire"
45459444|NCT05197400|Diagnostic Test|preoperative airway ultrasonography|"Tongue thickness Median sagittal tongue cross-sectional area Tongue width~Tongue volume:~Lateral parapharyngeal wall thickness"
45459445|NCT05197400|Diagnostic Test|postoperative airway ultrasonography|"Tongue thickness Median sagittal tongue cross-sectional area Tongue width~Tongue volume:~Lateral parapharyngeal wall thickness"
45459446|NCT01368770|Other|Coronary CTA|Coronary CTA using standard protocols
45459447|NCT01368770|Other|Stress MPI SPECT|Stress MPI using standard protocols
45836406|NCT01791036|Procedure|Femoral Nerve Block|Examination of the femoral nerve using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin at the level of the femoral crease. The femoral artery will be identified and the femoral nerve will then be located immediately lateral to the artery, deep to the fascia iliaca and superficial to the iliopsoas muscle. The needle will be positioned next to the femoral nerve. Following this 20 ml of 0.25% bupivacaine with epinephrine will be injected incrementally over a 1 to 2 minute period. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
45836407|NCT04345926|Drug|Propofol|Stepped propofol concentration after 20 min of LOS
45836408|NCT04345926|Device|Electroencephalogram recording|Acquisition of EEG activity
46005940|NCT04580316|Behavioral|Parental active presence|The parents were allowed to stand close to their children, do handholding, eye contacting and help in explaining the dentist's instructions.
46091562|NCT02817503|Drug|Intensive BP control|Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
46091563|NCT04237415|Procedure|EMG biofeedback training|
46091564|NCT02814461|Drug|Axitinib|Axitinib (dose escalation): for total 8 weeks during and after RT, with starting dose of 1mg BID. According to the rule of traditional 3 + 3 design, 3-level axitinib dose escalation will be conducted: 1mg BID (level - I), 2mg BID (level - II) and 3mg BID (level - III).
46091565|NCT02814461|Radiation|Radiation|Radiotherapy (RT) dose (fixed strength for normal liver): 37.5 to 67.5 Gy in 15 fractions (2.5 to 4.5 Gy per fraction) to liver tumor(s) (e.g. portal vein thrombosis, tumors with size ≥3 cm, or recurrent/refractory tumors). The final prescribed dose is based on an upper limit of mean liver dose of 18 Gy for all plans. (Daily Entecavir 0.5-1mg or Telbivudine 600mg is recommended for patients with positive hepatitis B during and 3 months after RT.)
46091566|NCT02814617|Dietary Supplement|Cordyceps sinensis mycelium culture extract 1.68 g|Cordyceps sinensis mycelium culture extract 1.68 g
46091567|NCT02814617|Dietary Supplement|Placebo|
45459448|NCT05197088|Drug|Tamsulosin|1 week of tamsulosin
45459449|NCT01375088|Drug|propolis|15 ml mouth wash 3 times a day for the whole period of radiotherapy for 5 min swish and then swallow
45459450|NCT05197010|Other|Home based exercise program via a smartphone application|Daily home based exercise program (30min/day, 7days/week for 6 weeks).
45459451|NCT03631472|Device|RheOx|RheOx is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
46005941|NCT04580316|Behavioral|Parent passive presence|Parents were instructed to sit silently in the dental clinic behind the patient with no eye contact, and without a spoken word only to reassure their children
46005942|NCT04616495|Procedure|Liver transplantation|Chemotherapy and liver transplantation
46091568|NCT02814071|Other|Early enteral feeding|Early enteral feeding as per description
46091569|NCT04315415|Device|Silk Voice|Silk Voice comprised of silk protein and cross-linked hyaluronic acid (HA)
46005943|NCT00563264|Behavioral|KAN-DO|"The 10 month KAN-DO intervention includes eight mailed interactive activity modules involving both the preschooler and mother that include relevant printed materials emphasizing parenting skills, healthy eating habits and increased physical activity. Mailed kits will each be followed by a supportive telephone counseling session based on motivational interviewing techniques. Mailed modules and telephone calls will be supplemented with two in-person motivational and informational sessions (at the beginning and in the middle of the intervention period).~The Active Comparator group will receive monthly newsletters over the 10 month period related to boosting reading skills in their preschool children."
46005944|NCT03454490|Procedure|Postoperative pseudoaneurysm of the greater palatine artery|Patients had an autogenous connective tissue gingival graft.
46091570|NCT00875667|Drug|Lenalidomide|"For patients with a creatinine clearance of ≥ 60 mL/min: 25 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity.~For patients who have a moderate renal insufficiency (creatinine clearance is ≥ 30 mL/min but < 60mL/min: 10 mg daily x 21 days of a 28 day cycle (Cycles 1 and 2). After Cycle 2, if the patient remains free of Grade 3 or Grade 4 toxicity, the dose will be increased to 15 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity."
46091571|NCT00875667|Drug|Investigators choice single agent|Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine
46091572|NCT02814305|Behavioral|Financial|Patient receives information on a program that may offer a financial benefit for disposing of unused opioid analgesics at a pharmacy
46091573|NCT02814305|Behavioral|Educational|Patient watches a video featuring narrative vignettes of patients who developed opioid dependence or abuse after using opioids postoperatively
45836409|NCT03974646|Behavioral|Nurse-led self-management Program|Group-based sessions will be scheduled at week two, week four and week six. Participant will be given a printed booklet Participants will receive three individual follow-up phone calls of 20-30 minutes each at week three, week five and week seven.
46091574|NCT02811185|Drug|[F-18]-Fludeoxyglucose|Radiopharmaceutical imaging agent
46091575|NCT02814149|Procedure|Type 1 implant placement|Implant is placed immediately following tooth extraction in one surgical procedure
46091576|NCT02814149|Procedure|Type 3 implant placement|Implant is placed in the site which is left to heal for 3 months following tooth extraction
46091577|NCT02811341|Drug|Scopolamine Hydrobromide|
46091578|NCT02811341|Drug|normal saline|
46091579|NCT02811107|Other|Questionnaires|Completion of questionnaires on tablet computers in the preoperative area by 6 nurse anesthetists, 1 hospital physician and 1 resident physician.
45836410|NCT00337350|Drug|rosiglitazone|Rosiglitazone 4mg, one capsule per day for eight weeks
45836411|NCT00337350|Drug|placebo|matched placebo for rosiglitazone 4mg/day
45836412|NCT00338598|Drug|Glycine|Glycine, 0.8 gr per kg given in two daily doses
45836413|NCT00338598|Drug|placebo|
45836414|NCT00338988|Drug|Capecitabine|1500 mg/m^2 PO twice daily x 14 days.
45836415|NCT00338988|Drug|Oxaliplatin|130 mg/m^2 IV over 2 hours on day 1 of cycle.
46005945|NCT00571077|Device|Electrical Impedance Scanning (EIS) of the Thyroid gland|Patients will be examined in the supine position. A cylinder electrode conveying 2.5V electrical current will be held by the patient. The patient will be scanned by a probe (similar to an ultrasound probe. The examination takes 5 minutes and there is no risk or discomfort.
46091580|NCT02813993|Other|Health educational video|
46091581|NCT02811029|Behavioral|measurement of phonology|measurement of phonology will be assess using BILO-3, EDA, VS and VL tests
46091582|NCT00682383|Drug|Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta|"Cisplatin 75 mg/m2 day 1 and 22~Etoposide 80mg/m2 days 1-3, 22-24~Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days)~Filgrastim 5µg/kg* SQ injection days 4-13 and days 25-34~Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles~Pegfilgrastim 6 mg SQ injection day 2 of each cycle"
45836416|NCT00343044|Drug|Topotecan|Topotecan administered days 1, 8, and 15 of each 28 day cycle. Dose was 4 mg/m2 administered IV.
46091583|NCT02810717|Device|theta-burst stimulation using a MagPro X1000|TBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS over left DLPFC: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. Trains will be repeated 20 to reach a total number of 600 pulses per session. cTBS over right DLPFC: cTBS will comprise uninterrupted bursts to reach a total number of 600 pulses per session. Two sessions per day, separated by 60 minutes; 30 Sessions in total over 3 weeks.
45836417|NCT00343044|Drug|Bevacizumab|bevacizumab administered IV 10 mg/kg, days 1 and 15 of 28 day cycle.
46005946|NCT03454373|Behavioral|Incentive for linkage to care|"Participants who were found to have been lost to care will receive standard of care plus a one-time re-start incentive of 22,500 TZS to return to care"
45836418|NCT04724304|Diagnostic Test|Real-Time Myocardial Echocardiography (RTMPE)|Uses sound waves (ultrasound) to produce an images of the heart. During RTMPE a microbubble contrast agent is administered through an intravenous line (IV) to make the images of your heart clearer.
46091584|NCT02810717|Device|sham stimulation using a MagPro X1000|Sham TBS with the coil set at 45° against the skull will be performed over left and right dorsolateral prefrontal cortex for a period of three weeks
46005947|NCT04584216|Other|Steam Eye Mask with acupoints stimulation|A participant needs to use SEM with acupoints stimulation once a day for 10 days and use hands to massage the acupoints on the eyebrows for the first 3 minutes, total application time at least for 20 minutes.
46005948|NCT04584216|Other|Steam Eye Mask|A participant needs to use SEM once a day for 10 days, total application time at least for 20 minutes.
46005949|NCT04615793|Other|PILATES EXERCISES|The experimental group will receive Pilates exercises focusing on lower limb strength, flexibility and coordination in addition to exercises given to control group. Exercises or movements were done on a mat, on an exercise ball or in standing position while emphasizing on spinal and pelvic alignment, maintaining core contraction and the rhythm of respiration. All exercises were done for 10 repetitions with a rest period of two minutes before commencing the next exercise, and lasted for about 45 minutes. All the groups will receive the above mentioned interventions thrice in a week for a period of 10 week
46005950|NCT04584060|Combination Product|ERAS protocols|ERAS protocols including avoidance of prolonged pre-operative fasting and early removal of Ryle, surgical drains and urinary catheter
46005951|NCT04584060|Combination Product|Early oral feeding|Chewing gum, oral magnesium and alvimopan can be started early postoperatively, Initiation of feeding-Oral sips on day 1, step up day 2 onward
46005952|NCT04584060|Combination Product|Prophylaxis against DVT|Patient will wear well-fitting compression stockings and receive pharmacological prophylaxis with LMWH. Encourage to mobilize out of bed after effect of general anesthesia has weaned off.
46005953|NCT04615637|Device|MEG recordings|"Classical MEG recordings (patient at rest, normal subjects stimulated with visual, motor, somesthesic and auditory stimuli).~MEG recordings with our OPM He4 prototype (patient at rest, normal subjects stimulated with visual, motor, somesthesic and auditory stimuli)."
46005954|NCT04584021|Device|Xiaomi MiBand3|Recording of sleep, activity and heart rate data to study their association with stress.
46005955|NCT04584021|Other|Socio-demographic questionnaire|Self-made questionnaire to be filled by the participants at the beginning of the study with the following personal data: age, gender, marital status, residential environment, cohabitation unit, educational level, socio-economic level, contract, working hours, overtime or not, number of overtime hours in a day, overtime frequency and perceived stress level
46005956|NCT04584021|Other|EuroQol-5D-5L|Quality of life questionnaire to be filled by the participants at the beginning, mid-term and completion of the study with the following information: severity index, social value index for each health condition. Subjective evaluation of health status from 0 to 100.
46005957|NCT04584021|Other|Pittsburgh Sleep Quality Index (PSQI)|Questionnaire to be filled by the participants whose outcome is the perceived quality, quantity and efficient of sleep. To be given at the beginning, mid-term, and completion of the study.
46091585|NCT04049877|Other|None - Observational study|None - Observational study
46005958|NCT04584021|Other|State-Trait Anxiety Inventory (STAI)|Questionnaire to be filled by the participants which measures the anxiety level. To be given at the beginning, mid-term and completion of the study.
46005959|NCT04584021|Other|Perceived Stress Scale-10 (PSS-10)|Questionnaire to be filled by the participants which measures the stress level. To be given at the beginning, mid-term and completion of the study.
46005960|NCT04584021|Other|Stress questionnaire|Questionnaire designed by a work stress psychologist professional from the research group which is focused on stress and daily functioning. This questionnaire was given for the participants to fill. It is composed by 3 daily items and 4 weekly items.
46091586|NCT04237493|Drug|Metformin and Glimepiride (Low Dosage)|"Metformin (PO; 850 mg; BID [with Ifṭār and with Suḥūr])~Glimepiride (PO; 1.5 or 3 mg [75% of the pre-Ramadan dose]; OD [with Ifṭār])"
46091587|NCT04237493|Drug|Metformin and Vildagliptin (Low Dosage)|"Metformin (PO; 850 mg; BID [with Ifṭār and with Suḥūr])~Vildagliptin (PO; 50 mg; OD [with Ifṭār])"
46091588|NCT04237493|Drug|Metformin and Insulin Glargine U100 (Low Dosage)|"Metformin (PO; 850 mg; BID [with Ifṭār and with Suḥūr])~Insulin Glargine U100 (SC; 9-33 units [75% of the pre-Ramadan dose]; OD [at 10 P.M.])"
46091589|NCT04237493|Drug|Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage)|"Metformin (PO; 850 mg; BID [with Ifṭār and with Suḥūr])~Insulin Glargine U100 (SC; 6-39 units (75% of the pre-Ramadan dose); OD [at 10 P.M.])~Human Regular Insulin (SC; 15-33 units before Ifṭār and 6-18 units before Suḥūr [75% of the pre-Ramadan doses])"
45459452|NCT01368848|Drug|Bevacizumab|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -> Staging~-> further 3 cycles BCD Q3W -> Bevacizumab Q3W until progression"
45459453|NCT01368848|Drug|Cisplatin|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -> Staging~-> further 3 cycles BCD Q3W"
45459454|NCT01368848|Drug|Docetaxel|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -> Staging~-> further 3 cycles BCD Q3W"
46005961|NCT04615598|Behavioral|Action observation|The idea is to show some videos with the aim of improving patients' tongue strength.
46091590|NCT04237493|Drug|Metformin and Glimepiride (Regular Dosage)|"Metformin (PO; 850 mg; BID [with Ifṭār and with Suḥūr])~Glimepiride (PO; 2 or 4 mg [100% of the pre-Ramadan dose]; OD [with Ifṭār])"
46005962|NCT04615598|Behavioral|Placebo group|The idea is to show some videos of vegetation with the aim of having an intervention time but ineffective.
46091591|NCT04237493|Drug|Metformin and Vildagliptin (Regular Dosage)|"Metformin (PO; 850 mg; BID [with Ifṭār and with Suḥūr])~Vildagliptin (PO; 50 mg; BID [with Ifṭār and with Suḥūr]])"
46091592|NCT04237493|Drug|Metformin and Insulin Glargine U100 (Regular Dosage)|"Metformin (PO; 850 mg; BID [with Ifṭār and with Suḥūr])~Insulin Glargine U100 (SC; 11-44 units [100% of the pre-Ramadan dose]; OD [at 10 P.M.])"
46091593|NCT04237493|Drug|Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage)|"Metformin (PO; 850 mg; BID [with Ifṭār and with Suḥūr])~Insulin Glargine U100 (SC; 8-52 units (100% of the pre-Ramadan dose); OD [at 10 P.M.])~Human Regular Insulin (SC; 12-40 units before Ifṭār and 7-28 units before Suḥūr [100% of the pre-Ramadan doses])"
45836419|NCT04724304|Diagnostic Test|Magnetic resonance image (MRI)|Imaging that focuses on the heart or blood vessels to assess size and function of the heart's chambers, thickness and movement of the walls of the heart, and blood flow in the blood vessels.
46091594|NCT00682773|Other|SBAR|Educational intervention for nursing staff on effective communication regarding warfarin treatment/care; use of SBAR communication forms.
46091595|NCT04031625|Other|Metastatic Colorectal Cancer Database|Metastatic Colorectal Cancer Database
46091596|NCT02813759|Other|Sucralose|Subjects drank 200 mL of water with 14 mg sucralose, followed by a standard breakfast.
46091597|NCT02813759|Other|Placebo|Subjects drank 200 mL of water alone (placebo), followed by a standard breakfast.
46091598|NCT00683007|Other|Volume resuscitation (Crystalloid)|Crystalloid vs. Hypertonic Saline Solution
46091599|NCT00683007|Other|Volume resuscitation (Hypertonic Saline Solution)|Crystalloid vs. Hypertonic Saline Solution
45459455|NCT03604874|Drug|Oxytocin|intravenous infusion
45459456|NCT01368926|Drug|RO4917523|single oral doses
45459457|NCT01368926|Drug|RO4917523|multiple oral doses
45459458|NCT01368926|Drug|placebo|oral doses
45459459|NCT05196542|Procedure|patients with apical prolapse who will do Sacro hysteropexy using mersilene tape|comparison between standard poly prolene mesh and the poly ester mersilene tape in Sacro hysteropexy surgical procedure
45836420|NCT00344370|Drug|Pitavastatin|Pitavastatin 4 mg QD
45836421|NCT00344370|Drug|Atorvastatin|Atorvastatin 40 mg
45836422|NCT00344682|Drug|memantine|memantine 5mg - 20mg PO daily
46091600|NCT02810795|Other|Diagnostic detection of coronary artery disease|Myocardial perfusion defect on dynamic CT perfusion imaging, and diagnostic accuracy as compared invasive FFR.
46091601|NCT00683241|Biological|DCVac-L|Subjects will receive three doses of intradermal vaccination with ~5-10 x 106 dendritic cells (DCVax-L) on days 0, 14 and 28
46091602|NCT04237259|Other|Parent-administered TCM pediatric massage training|"Massage therapy is a kind of complementary and alternative therapy, which involves a number of techniques such as friction, pressing, rubbing, grasping, pinching, and kneading. TCM pediatric massage, also called pediatric tuina and pediatric anmo, is a special part of TCM massage system that usually use lines or surfaces rather than points as acupoints and the manipulations are different from those of TCM adult massage. From TCM perspective, the pathogenesis of ADHD is the abnormal exuberance of yang, which can be relieved by specific approaches of massage.~Participants in this group will receive two TCM pediatric massage training sessions (5 hours in total, one is 3 hours, and the other is 2 hours). The protocol will be tested for feasibility at the first feasibility stage (the first 8 subjects)."
46091603|NCT04237259|Other|Progressive Muscle Relaxation Exercise|The principle of progressive muscle relaxation exercise is to achieve a relaxation state through relaxing our muscles. With training, we become more familiarized with the sense of relaxation so that we can voluntarily induce this sensation in the face of a stressor.
46091604|NCT00683319|Drug|carboplatin|
46091605|NCT00683319|Drug|cisplatin|
45459460|NCT05196386|Behavioral|Admission conciliation interview|Previous treatment conciliation at hospital admission
45836423|NCT00344682|Drug|Placebo|5mg - 20mg PO daily over 8 weeks
45836424|NCT00345384|Drug|Dexmedetomidine|Dexmedetomidine titrated over 24 hours
45836425|NCT00345384|Other|Placebo (Normal Saline)|
45836426|NCT01791114|Other|Cold exposure|For the cold exposure trial, the subjects will follow an individualized cold exposure protocol maximize the elicited non-shivering thermogenesis. Subjects will be wearing liquid conditioned garments (Polar Products Inc, Stow, OH). The temperature will initially be set at 18°C, then decreased at 1 degree celsius intervals thought the air- conditioned temperature control bath until subjects report shivering. Electromyography (EMG; Delsys, Bagnoli 8, Boston, MA) will be performed continuously to verify shivering muscle activity. Upon shivering, the temperature will be increased by 1degree Celsius intervals until shivering resides. Subjects' core temperature will be measured at 10-second intervals with the use of a telemetric pill (Core Temp Inc., Palmetto, FL).
46005963|NCT00571116|Drug|Disulfiram|Given PO
46091606|NCT00683319|Drug|cyclophosphamide|
46091607|NCT00683319|Drug|methotrexate|
46091608|NCT00683319|Drug|vincristine sulfate|
46091609|NCT00683319|Procedure|adjuvant therapy|
46091610|NCT00683319|Procedure|cognitive assessment|
45459461|NCT05196386|Behavioral|Discharge conciliation interview|Allocated treatment during hospital stay
45459462|NCT05196386|Behavioral|Targeted pharmaceutical interview|Specific information about treatment delivered by pharmacist
46005964|NCT00571116|Drug|Arsenic trioxide|Given IV
46005965|NCT04615676|Other|Follow-up phone call|Follow-up phone call after month to detect which patient have been hospitalized
46005966|NCT00571155|Drug|levetiracetam|oral and intravenous dosing 2000-3000 mg per day
46005967|NCT04615481|Other|Elliptical Training Group|The training program will be consisted of total 30 minutes of elliptical cross training (5 minutes warm up + Progressive Training up to 20 minutes of elliptical cross training + 5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
46091611|NCT00683319|Procedure|magnetic resonance imaging|
46091612|NCT00683319|Procedure|magnetic resonance spectroscopic imaging|
46091613|NCT00683319|Procedure|quality-of-life assessment|
46005968|NCT04615481|Other|Ergo-metric Training Group|The training program will be consisted of total 30 minutes of ergometric training (5 minutes warm up + Progressive Training up to 10 minutes of upper limb ergometric training + Progressive Training up to 10 minutes of lower limb ergometric training+5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
46091614|NCT02813837|Biological|CD19CART|Patients will be given infusions of CD19CART cells into the vein over a period of 1 to 3 days. The target dose range administered in this study is 1x10e5-1x10e7 CD19CART cells/kg. Patients will be monitored for a response, toxic effects, and the expansion and persistence of circulating CD19CART cells.
46091615|NCT02813915|Device|NICOM|Use of NICOM and PLR to obtain patient fluid status
46091616|NCT00683397|Other|Blood sampling|Screening of thrombophilia
46005969|NCT04580433|Behavioral|Time-Restricted Feeding|"The trial consists of a 1-week baseline weight stabilization period followed by a 5-week TRF intervention period.~Participants will be instructed to eat freely from 8 a.m. to 4 p.m. daily and fast from 4 p.m. to 8 a.m. the next day."
46005970|NCT04584723|Other|Observation of flap survival and complications|We will report the flap survival and complications in this population group underwent to microsurgical procedures in a private practice setting
46005971|NCT04615169|Behavioral|Multi-component cognitive intervention with simulated everyday tasks (MCI-SET)|"2 hours per session: consisted primarily of modified everyday cognitive tasks, which were adjusted for individuals and for the group by the group leader to provide an error-reduction learning environment. Each session consisted of: (1) Warm-up: a 15-30 minute dual task of motor-cognitive exercises that increase arousal level and provide cognitive stimulation. For example, at the beginning of the group, the members would sing a song, mimic dance movement of the group leader, and clap hands when specific words occur in the song.~(2) 30-minutes guided and repetitive practices of contextually-relevant simulated everyday cognitive tasks with one 15 to 20- minute break in between; Cognitive tasks addressed complex attention, visual scanning, auditory attention, visual and motor memory, auditory memory, prospective memory, executive functioning, problem solving, etc."
45459463|NCT01369004|Behavioral|Daily Self-weighing + weekly feedback+ weekly lessons|Daily self-weighing as a form of self-monitoring of body weight using a smart scale that sends their weights directly to a website (www.bodytrace.com) via the cellular network. They will be able to review weight trends overtime on this website via a graph showing both changes in weight and BMI. They will also receive weekly emailed feedback on their weight loss progress and compliance to the daily self-weighing prescription from a registered dietitian, as well as weekly emailed lessons with content related to behavioral weight control (e.g, how to control portion sizes, how to develop and exercise routine).
46005972|NCT04615208|Diagnostic Test|suspected of COVID-19 infection|suspected of COVID-19 infection
45459464|NCT01319786|Other|Two portions of fruit and vegetables per day (excluding berries and dark chocolate)|Two portions of fruit and vegetables per day (excluding berries and dark chocolate)
45459465|NCT01319786|Other|Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.|Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.
45459466|NCT01369082|Drug|Maintenance Immunosuppressive Treatment|All immunosuppressive and immunomodulatory therapies are used presently to prevent rejection of transplanted islet cells. The agents listed are those used in the parent trials and continued in this trial, CIT08.
45459467|NCT03382730|Other|Chlorhexidine Mouth Rinse|Oral chlorhexidine gluconate oral rinse
46005973|NCT04614857|Other|Inclined treadmill gait|All subjects underwent measurements of muscle activity and respiratory metabolism energy during treadmill walking at a comfortable speed for 5 minutes and measured by three conditions (#0% inclined treadmill gait, #10% inclined treadmill gait, and #16% inclined treadmill gait)
46091617|NCT00634361|Drug|ethyl-eicosapentaenoic acid|2 mg per day
46005974|NCT04583865|Other|teleconsultation|In the pandemic period linked to COVID, pediatric pre-anesthesis consultations should preferably be carried out by teleconsultation. This is to assess the effectiveness of these teleconsultation and the satisfaction of parents.
46091618|NCT00683553|Drug|I5NP|Single IV injection of experimental drug given in escalated doses at 0.5, 1.5, 5.0 and 10 mg/kg doses to different patients
46091619|NCT00683553|Drug|Placebo|Single IV injection of saline
46005975|NCT04614818|Other|Non-intervention research|Non-intervention research
46005976|NCT04583826|Device|CAVA|CAVA is a medical device containing 5 face-mounted ECG electrodes which are used to record the movement of the eyes.
46005977|NCT04614623|Device|AHCL pump|Advanced Hybrid Closed Loop (AHCL) pump automatically adjusts insulin infusion rate of pump customized to patient's needs to reduce occurrence of hypo and hyperglycemia
46005978|NCT04614623|Other|Video conferencing Application|Video conferencing application will be used to enhance communication between participant and parent with the study certified diabetes educator (CDE) nurse coordinator. These individualized sessions will be designed to help the family with solving diabetes management problems to enhance glycemic control
46091620|NCT05298969|Procedure|Temporalis Myofascial flap|Improvement of speech and feeding quality in patients with palatal defects by temporalis myofascial flap
46005979|NCT00571350|Procedure|tvt-o operation|transvaginal tention free obturator tape
46005980|NCT00571350|Procedure|tvt o operation|transobturator vaginal tape insertion
46091621|NCT02813603|Procedure|EBUS|19G and 22G EBUS needles are compared in a randomized prospective way in lung cancer patients with enlarged mediastinal lymph nodes.
45459468|NCT03382730|Other|Chlorhexidine Mouth Rinse De-Adoption|Multifaceted education and audit/feedback.
45459469|NCT03135262|Drug|Idasanutlin|Induction Treatment: Idasanutlin tablets will be administered orally once daily at escalated doses (starting dose 100 milligrams [mg], maximum 600 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.
46005981|NCT04614584|Drug|Mirtazapine|Mirtazapine 30 mg PO daily x 4 days
46005982|NCT04614584|Drug|Methamphetamine|Methamphetamine 30 mg IV once
46005983|NCT04583631|Procedure|Adenoidectomy surgery|All patients underwent adenoidectomy under general anesthesia by routine curettage method and adenoid tissues were put in formaldehyde and sent to the genetics department for the exploration of ER stress and apoptosis markers.
46005984|NCT00571467|Drug|PRTX-100 (Staphylococcal protein A)|"4 weekly IV (in the vein) doses of 1 of the 3 following PRTX-100 dose levels:~Cohort 1: 0.075 mcg/kg~Cohort 2: 0.15 mcg/kg~Cohort 3: 0.30 mcg/kg"
46005985|NCT04614038|Diagnostic Test|DETEC® pH|DETEC® pH is a disposable diagnostic device that is used to indicate the alkalinity of the wound by testing wound exudate adsorbed onto wound dressing.
46005986|NCT04583553|Diagnostic Test|Vikor Scientific Urine-IDTM|Urine samples will be collected for both standard laboratory culture at KUMC Lab and expedited delivery to Vikor Scientific Lab for Urine-IDTM analysis. Vikor Scientific will cover all costs associated with sample delivery. If insufficient urine volume is collected for both standard laboratory culture at KUMC Lab and Vikor Scientific Urine-IDTM, urine will be preferentially used for standard laboratory culture at KUMC Lab.
45459470|NCT03135262|Drug|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg by intravenous (IV) infusion on Days 1, 8 and 15 of Cycle 1 and on Day 1 of each subsequent cycle (Cycles 2 to 6) (each cycle = 28 days) during induction treatment, and on Day 1 of every other month during maintenance treatment (eligible participants with FL only) or during consolidation treatment (eligible participants with DLBCL only).
45459471|NCT03135262|Drug|Venetoclax|Induction Treatment: Venetoclax tablets will be administered orally once daily at escalated doses (starting dose 200 mg, maximum 800 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.
45459472|NCT03135262|Drug|Rituximab|Rituximab will be administered by IV infusion at a dose of 375 milligrams per square meter (mg/m^2) on Day 1 of Cycles 1-6 during induction treatment and on Day 1 of every other month during consolidation treatment.
45459473|NCT01375244|Drug|Lisinopril|Tablets, 10 mg, single dose
45459474|NCT01375244|Drug|Zestril|Tablets, 10 mg, single dose
45459475|NCT01369160|Behavioral|Quality of Life measures|measuring QOL with different therapies
45459476|NCT01375322|Drug|Amlodipine+Benazepril|Amlodipine besylate 5 mg + Benazepril hydrochloride 10 mg, daily use and forced titrate till 16-week end
45459477|NCT01375322|Drug|Valsartan+Hydrochlorothiazide|Valsartan 80 mg + Hydrochlorothiazide 12.5 mg, daily use and forced titrate till 16-week end
45459478|NCT01369238|Device|Bee Venom Acupuncture Therapy|1:4000, SC 1cc/day, 2~3days/wk, for 1 month
45459479|NCT01369238|Drug|zaltoprofen|80mg/Tab, per os 1Tab tid, for 2 months
45459480|NCT03485404|Drug|methylcobalamin|methylcobalamin tablets, 0.5mg/tablet, 3 tablets/day.
46005987|NCT00563303|Drug|hydrocortisone|200mg/jour (solution of 48mL), Day 1 to Day 4 100mg/jour (solution of 48mL), Day 5 50mg/jour (solution of 48mL), Day 6
46005988|NCT00563303|Drug|NaCl|48mL from Day 1 to Day 6
46005989|NCT00571506|Drug|Rosiglitazone|Rosiglitazone 4 mg tablets by mouth daily for 3 months
46005990|NCT00571506|Drug|Pioglitazone|Pioglitazone 30 mg tablet by mouth once daily
46091622|NCT04141527|Procedure|Spinal analgesia|Spinal analgesia (SA) was provided by a resident or specialist anaesthesiologist with the patient in a sitting or a recumbent position. A pencil-point needle, primarily 27 G (0.4 mm), otherwise 25 G (0.5 mm), was used for transdermal intrathecal administration of 2.0 ml of sufentanil 5 µg/ml (Sufenta®, Janssen-Cilag AB, Solna, Sweden) at low-lumbar level. Blood pressure was recorded before, immediately after, and at five-minute intervals for 20 minutes after the block. Any decrease in systolic pressure to <100 mmHg or a decrease >20% from the baseline level despite infusion of crystalloid was defined to indicate maternal hypotension.
46091623|NCT00683709|Behavioral|Counselling as Usual|5 - 20 minutes, about the effects of clozapine on body weight, appetite, blood sugar and fats such as cholesterol and triglycerides in the blood, and how these might affect your health in the future.
46091624|NCT00683709|Behavioral|CBT|45 - 60 minutes individual treatment sessions focused on nutrition, exercise and weight control and will occur weekly for 4 weeks. After this, 10 group sessions focused on weight reduction will be held every 2 weeks. This will be followed by 6 group sessions focused on weight maintenance held every 2 weeks.
46091625|NCT04141293|Procedure|alveolar recruitment|Alveolar recruitment is a procedure to re-expand collapsed lung regions with the transient increment in transpulmonary pressure.
46091626|NCT02810249|Other|No intervention used|
45459481|NCT03485404|Drug|Folic Acid|folic acid tablets, 5mg/tablet, 1 tablet/day
46091627|NCT02810483|Drug|Topiramate|"Increase phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days."
45459482|NCT03485404|Other|Placebo for methylcobalamin|orange tablets that looks exactly like methylcobalamin
45459483|NCT03485404|Other|Placebo for folic acid|yellow tablets that looks exactly like folic acid
45459484|NCT03485404|Procedure|non-cardiac surgery|patients elective for non-cardiac surgery will undergo scheduled surgery after 7 days of intervention
45459485|NCT03485404|Behavioral|NPB test|participants will accept Mini-Mental State Examination (MMSE), Patient Health Questionnaire (PHQ-9), ADL, and NPB test before intervention, and NPB by discharge or similar time intermittent after the first assessment for non-surgical controls. Also ADL will be tested again through telephone interview at 3 months after discharge.
45342496|NCT00715416|Device|Nitinol stent|Interventions are performed percutaneously from either an antegrade or an over-the-bifurcation approach. After insertion of an 6 French sheath, 5000 IU of heparin are administered intra-arterially. After passage of the stenosis/occlusion with the guide wire, patients are randomized to either PTA or primary stent implantation. For standardized documentation of the lesion morphology and comparability during follow-up, a ruler is fixed at the patients thigh with the distal end exactly overlapping at the upper edge of the patella. As a bail-out procedure in the PTA group, stent placement is performed in cases with a residual stenosis of more than 30% in the worst view angiogram.
45342497|NCT00715416|Procedure|Nitinol Stent Placement|Balloon angioplasty compared to primary stent implantation for long segment superficial femoral artery lesions
45459486|NCT05195294|Biological|LioCyx-M|HBV antigen specific TCR redirected T cells
45459487|NCT05195294|Drug|Lenvatinib|12 mg once daily for patients ≥60 kg, 8 mg for patients <60kg by oral
45459488|NCT05195216|Behavioral|Survey Form, The Hospital Anxiety and Depression Scale, The Fear of COVID-19 Scale,World Health Organization Quality of Life Scale- Bref Form|Online questionnaires were administered to individuals.
45459489|NCT03072628|Other|e-cig with nicotine|use an e-cig with nicotine for 30 minutes
45459490|NCT03072628|Other|e-cig without nicotine|use an e-cig without nicotine for 30 minutes
45459491|NCT03072628|Other|nicotine inhaler|use a nicotine inhaler for 30 minutes
45459492|NCT03072628|Other|sham control|use an empty e-cigarette for 30 minutes
45459493|NCT05195060|Drug|casirivimab with imdevimab|Monoclonal antibody
45459494|NCT05195060|Drug|sotrovimab|Monoclonal antibody
45459495|NCT05195060|Drug|molnupiravir|antiviral agent
45459496|NCT03535194|Drug|Mirikizumab|Administered SC
46005991|NCT04614077|Other|ex vivo organ bath testing, preservation of vein sections without contact to patient|1 piece of vein is separated during surgical bypass procedure, then randomized and put ex vivo in two solutions: saline and specific solution, then tested in the organ bath
46005992|NCT00571545|Behavioral|Aerobic exercise|A supervised aerobic exercise program occurred weekly for 30 minutes with a 15 minute warm-up and a 15 minute cool down. A half hour educational session on aspects of exercise and overcoming barriers to exercise was also instituted.
45459497|NCT03535194|Drug|Placebo|Administered SC
45459498|NCT03535194|Drug|Secukinumab|Administered SC
45459499|NCT01369316|Procedure|Circumferential Submucosal Incision Resection|The patient is randomized, if in the active arm the procedure will continue as Circumferential Submucosal Incision Endoscopic Mucosal Resection.
45459500|NCT01369316|Procedure|Endoscopic Mucosal Resection|Patients randomised into this Intervention type will have Endoscopic Mucosal Resection performed
46005993|NCT00571545|Behavioral|No exercise|Controls were wait-listed for the exercise program during the 10 week study period.
46005994|NCT04583397|Other|radio frequency electromagnetic fields|Exposure system delivers emissions comparable to those from a WiFi access Point close to the bed or sham (no exposure)
46005995|NCT04614155|Other|Educational Intervention|Take part in health education session
46005996|NCT04614155|Procedure|HPV Self-Collection|Receive HPV self-collection kit
45459501|NCT03633812|Other|Observational study, Beta blocker medication history|Observational study, Beta blocker medication history
45459502|NCT05194904|Drug|Dexmedetomidine|This is a prospective randomised clinical study designed to assess the effect of intravenous ketorolac versus intravenous dexmedetomidin on postoperative pain after hypospadias repair in children
46091628|NCT02810483|Drug|Placebo Comparator|"ncrease phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days."
46091629|NCT00683865|Drug|Ofloxacin|Ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days
46091630|NCT00683865|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg po od for 14 days
46091631|NCT02813369|Drug|naloxegol|non-interventional study where patients are exposed to naloxegol during normal clinical practice
46091632|NCT02813369|Drug|non-PAMORA laxative|non-interventional study where patients are exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
46091633|NCT05582681|Diagnostic Test|Cepheid POC HCV Viremia (RNA) test|The Cepheid Xpert HCV Viral Load (VL) Fingerstick assay is a test designed for the quantitation (amount) of Hepatitis C Virus (HCV) DNA in human whole blood. The HCV RNA result will be compared to standardized laboratory assessment for HCV Viremia. The Cepheid test is for being conducted for research use only and will not be used for HCV diagnosis or treatment decisions.
46091634|NCT05582681|Other|HCV education from a health care provider|HCV education provided by health care provider. HCV Education will include HCV disease overview, HCV screening, treatment with G/P, and post treatment assessment and management
46005997|NCT04614155|Other|Questionnaire Administration|Complete questionnaires
46005998|NCT00571584|Drug|activated recombinant human factor VII|
46005999|NCT04614272|Behavioral|Prayer|Prayer is a non-pharmaceutical method of pain management and a form of alternative medicine.
46091635|NCT05582681|Drug|Glecaprevir and Pibrentasvir|G/P will be provided for 8 weeks.
46091636|NCT00683943|Drug|Lithium Carbonate|
46091637|NCT02813291|Device|tDCS|"All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:~- Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex."
46091638|NCT02813291|Device|sham tDCS|"All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:~- Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex."
46091639|NCT02813525|Other|ISI index on Doppler systolic flow in the aortic isthmus|Measure of the ISI index on Doppler systolic flow in the aortic isthmus in the follow-up by ultrasound of the fetus
46006000|NCT04614272|Behavioral|Reading a poem|Reading is a distraction tool for pain management
46006001|NCT04583436|Device|Endovascular recanalization|Recanalization with angioplasty and stenting: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Perform transluminal or subintimal recanalization of the occluded segment of the arteries with a hydrophilic guide wire. Next, balloon angoplasty of the recanalized segment is performed. After control angiography, a biomimetic braided nitinol stent is placed throughout the lesion.
46091640|NCT02810015|Drug|Botulinum Toxin Type A|BTX-A will be reconstituted as directed by the manufacturer. 2.5 mL of diluent (0.9% Saline) per 100 U vial will be used to reconstitute the solution while swirling. This creates a solution with a concentration of 4 U/0.1 mL. Patients will be seated and all usual precautions of sterility and skin preparation will be completed (i.e. alcohol wipes) Injections will be administered unilateral and/or bilaterally in accordance with the topography of the corresponding muscles (temporalis and masseter) into areas of maximal tenderness and pain. Plastic single use insulin syringes with 30 gauge needles will be used to inject 30 U intramuscularly into each masseter, divided evenly into 5 sites and 20 U will be injected into each temporalis, divided evenly over 5 sites. Injections will be completed by the principal investigator and supervisors who will be trained in botulinum toxin injections.
46091641|NCT02810093|Other|retrospective medical records analyze|Ten thousand medical records (between years 2000 and 2016) will be analyzed
46091642|NCT02809781|Biological|Intravenous infusion of MSCs|Intravenous infusion of MSCs:Human bone marrow-derived MSCs 1.0E+6 MSC/kg, IV drop
46091643|NCT02809781|Drug|Etanercept|50mg,hypodermic injection,once per week, for 12 weeks
46091644|NCT02809937|Drug|dexmedetomidine|low-dose dexmedetomidine infusion
46091645|NCT02809937|Drug|placebo|normal saline infusion
46091646|NCT02813213|Procedure|Skin micro Grafts|0.8 x 0.8 skin micro graft with graft to graft distance of 4 cm (1:50 expansion) bathed with keratinocyte growth factor solution ( 1.5 ml for each 14 square centimeters of wound)
45342498|NCT00715494|Behavioral|Cognitive, physical, and functional rehabilitation|A multicomponent program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients in their home environments over a focused 12 week period with the aid of tele-technology to utilize the expertise of physical therapy, occupational therapy, and neuropsychology.
46091647|NCT02813213|Procedure|Standard skin graft|Standard split thickness (0.3-0.5mm) skin graft
46091648|NCT02809703|Other|Survey Questions|Subjects will receive surveys via direct mail. They will be given the opportunity to opt in to receive a phone call regarding quality of life.
46091649|NCT02813057|Procedure|Stoppa inguinal hernia repair|Stoppa inguinal hernia repair
46091650|NCT02813057|Procedure|Total extraperitoneal inguinal hernia repair|Total extraperitoneal inguinal hernia repair
46091651|NCT02809547|Device|Dried Blood Spot device|
46091652|NCT02812901|Procedure|cardiac surgery scheduled in the morning|cardiac surgery scheduled in the morning
46091653|NCT02812901|Procedure|cardiac surgery scheduled in the afternoon|cardiac surgery scheduled in the afternoon
46091654|NCT02812979|Device|Airvo2 with Aerogen Solo|Nebulization of salbutamol with Airvo 2 and Aerogen solo
46091655|NCT02812979|Device|Mask|Usual nebulization of salbutamol with mask
46091656|NCT02812979|Device|arm control Airvo2 without nebulization of salbutamol|Airvo2 with Aerogen Solo. No nebulization of salbutamol
46091657|NCT02809313|Dietary Supplement|Treatment Gingivitis with Probiotic|gingivitis treatment (scaling and coronary polish) and one sachet containing Lactobacillus rhamnosus SP1 per day during 3 months
46006002|NCT04583436|Other|Open surgery|Femoropopliteal distal bypass with a synthetic ePTFE graft: Under general anesthesia, 2 standard open surgical approaches are performed: one to the common femoral artery, superficial femoral artery and deep femoral artery; the second - to the third portion of the popliteal artery, the tibioperoneal trunk and the anterior tibial artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the graft. Next, the graft is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Clamps are removed from arteries, blood flow is started, surgical hemostasis, wound drainage, layer-by-layer wound closure is performed.
46006003|NCT04613999|Drug|Ralinepag|"Ralinepag will be supplied as 50 mcg round, orange, XR tablets for oral administration.~It is planned that every subject will receive each of the following regimens in the fasted state:~Regimen A (50 mcg): 1 × 50 mcg ralinepag XR tablet~Regimen B (100 mcg): 2 × 50 mcg ralinepag XR tablets~Regimen C (150 mcg): 3 × 50 mcg ralinepag XR tablets Subjects will receive Regimens A, B and C in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose."
46091658|NCT02809313|Other|Treatment Gingivitis conventional|gingivitis treatment (scaling and coronary polish) and one sachet containing Placebo (talc powder) per day during 3 months
46091659|NCT02809391|Device|Orthotics alone|The sole thin sport orthotic will be heat moulded to participants footwear. A top cover will be used of similar cushioning thickness and durometer properties as the orthotics+texture intervention.
46006004|NCT04583202|Other|Exposure to placebo|Patients are exposed to a placebo for 4h in the Alyatec EEC
46091660|NCT02809391|Device|Orthotics+textured top cover|The sole thin sport orthotic will be heat moulded to participants footwear. A textured material will be used as the orthotic top cover in this intervention.
46091661|NCT02812823|Device|High-resolution anorectal manometry|Recording of conventional manometric parameters after insertion of the catheters.
46006005|NCT04583202|Other|Exposure to allergen|Patients are exposed to birch pollen allergens for 4h in the Alyatec EEC
46006006|NCT04613609|Device|Electronic Cigarette containing nicotine|Non-smokers used an electronic cigarette containing nicotine
46006007|NCT04613609|Device|Electronic Cigarette without nicotine|Non-smokers used an electronic cigarette without nicotine
46006008|NCT00571623|Other|Chest Physiotherapy|10-minutes of chest physiotherapy using programmed parameters that are components of the specialty beds used in ICU
46006009|NCT00571740|Biological|bevacizumab|Given IV
46006010|NCT00571740|Biological|cetuximab|Given IV
46006011|NCT00571740|Drug|fluorouracil|Given IV
46006012|NCT00571740|Drug|leucovorin calcium|Given IV
46006013|NCT00571740|Drug|oxaliplatin|Given IV
46006014|NCT04613687|Device|Compression bandage|Compression bandage URGO BD001 for the management of venous leg ulcers with ABPI (Ankle Brachial Pressure Index) ≥ 0.8, venous
46006015|NCT00571779|Device|AtriCure Bipolar System|
46006016|NCT00563342|Drug|Ethanol|Examine the risk of catheter dysfunction during the dialysis session that follows the instillation of ethanol 60% as lock solution in tunneled silicone catheters of end stage renal failure patients treated by hemodialysis
46006017|NCT00571818|Procedure|Oral glucose tolerance test|test done over 2 hours
46006018|NCT00571818|Procedure|IV Glucose Tolerance Test|Done over 4 hours
46006019|NCT00563420|Procedure|Bronchoscopy|
46006020|NCT04580082|Behavioral|Mindfulness lessons|14 lessons on mindfulness, each lasting approximately 20 minutes.
46091662|NCT04157465|Other|Treatment strategy trial|"Participants will be randomly allocated in a 1:1 ratio after meeting eligibility criteria to either early empiric or pre-emptive strategy of treatment with antifungals. The antifungal treatment initiation will be at the time of allocation in the empiric group. The treatment initiation rules in the pre-emptive group will include~Fungal Biomarkers positivity (Beta-D Glucan>150 pg/ml, Galactomannan index>1.0)~Mycological evidence of fungal infection on fungal cultures from a non-sterile site~Radiological evidence of fungal infection~Other Investigations suggestive of fungal infection viz. endophthalmitis, vegetations suspicious of fungal infection, Vegetations on echocardiography with negative blood cultures for bacteria that is non-responsive to appropriate antibiotics, refractory culture-negative spontaneous bacterial peritonitis~Treatment duration will be guided by serum biomarkers (BDG and GM) and fungal cultures."
46091663|NCT02812745|Device|recording of cardiac output|
46091664|NCT02812745|Device|other parameters|BIS (bispectral index ), PI (perfusion index ), etCO2 (end-tidal carbon dioxide ), and brain NIRS (near-infrared spectroscopy)
46091665|NCT02812511|Procedure|Biopsy|Skin biopsy is performed at the arm with a punch of 3 mm in diameter or a scalpel under local anesthesia, and then preserved in low glucose DMEM at room temperature.
46006021|NCT00563498|Drug|Glutamine|
46006022|NCT04583046|Drug|normal saline inhalation|When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply normal saline inhalation for control group and measure ABGA at the time of 20 min after normal saline inhalation has finished (T2).
46091666|NCT02809469|Drug|apixaban dose reduction|Participants taking apixaban 5mg BID will have their dose reduced to 2.5mg BID, and those taking 2.5mg BID will have their dose reduced to 2.5mg once daily (in the morning).
45459503|NCT05194826|Procedure|Test|immediate implant and VST with fascia lata membrane + xenogenic lamina membrane and particulate bone graft composed of autogenous cortical chips harvested from the surgical site
46091667|NCT02812589|Other|Diffusion tensor imaging (DTI) in Breast MRI|
46006023|NCT04583046|Drug|iloprost inhalation|When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply iloprost inhalation for iloprost group and measure ABGA at the time of 20 min after iloprost inhalation has finished (T2).
45459504|NCT05194826|Procedure|Control|immediate implant and VST with connective tissue graft + xenogenic lamina membrane and particulate bone graft composed of autogenous cortical chips harvested from the surgical site
46006024|NCT00563537|Radiation|18F-X PET SCAN|18F-X PET Scan : Injection of 7.8 mSv for 370 MBq of dose (0.021 mSv / MBq)
46006025|NCT04613765|Behavioral|Measure adherence behaviors|"Conducted in the ambulatory setting of two Brussels hospitals, the MADESIO mixed-method study design combine sequentially a first quantitative explorative questionnaire-based study with a second in depth qualitative approach.~The first 4 visits questionnaire-based survey prospectively measures adherence to OAMs and identify associated risk factors in the two sub-groups of ambulatory patients with various haematological malignancies. A combination of validated self-reported measures able to measure medication taking behaviours, assess both intentional and unintentional adherence, identify associated risk factors was selected.~The second qualitative phase, based on the McGill Illness narrative interview design, deeper address patients' therapeutic adherence and subjective meanings."
46091668|NCT02809079|Drug|Mycophenolate mofetil|Mycophenolate mofetil 500mg Bid
46091669|NCT02809079|Drug|Prednisone|prednisone 10mg Qd
46091670|NCT02812277|Other||This is a Non-Interventional Study, so there are no drug or devices included.
46091671|NCT02812199|Device|Composite Removable Sinus Stent|Post-FESS bilateral implantation of sinus stent into middle meatus. Nasal tampon will be placed to stop bleeding. Stent will be removed after 14 - 28-day implantation, during self-crimp procedure induced by cold saline flush and safely pulled out. During implantation period patients will be examined endoscopically for inflammation, adhesions and middle turbinate position.
46091672|NCT02812199|Drug|adrenaline-lidocaine|adrenaline - lidocaine administration to minimize bleeding prior to stent removal (group 1 and group 2)
46091673|NCT02812199|Procedure|cold saline wash|nasal wash with cold saline prior to stent removal, to induce stent self-crimping.
46091674|NCT02812121|Drug|umbilical cord blood mesenchymal stem cells|
46091675|NCT04237571|Behavioral|CANE Meal Program|Participants will be encouraged to pick up a healthy meal from the Community Agriculture Nutritional Experience (CANE) Kitchen in Whitesburg, Kentucky once a week for five weeks. The meals will consist of at least one serving of a fruit or a vegetable. At each meal, education materials will be distributed, including the recipe for the healthy meals and nutrition handouts that are linked to the recipes. Additional information about the ways the nutrients in the meal may help protect from the negative effects of environmental pollutants will be included.
46091676|NCT02808923|Other|Foam Rolling|"Participants will perform unilateral hamstring rolling for 2 repetitions of 1 minute with 15 second rest breaks on each leg with a 6x 36 foam roller."
46091677|NCT02808923|Other|Static Stretching|Participants will perform supine static hamstring stretch on a wall for 2 repetitions of 1 minute with 15 second rest breaks on each leg. When the position no longer causes a moderate stretching sensation to the hamstring, subjects will move their bodies closer to the wall to intensify the stretch.
46091678|NCT02808845|Other|microalbuminuria|
46091679|NCT02809001|Procedure|Fat grafting|In the experimental group, liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin.
46091680|NCT02812043|Device|1,064nm Long-pulsed Nd:YAG|Long-pulsed 1,064nm will be used for the treatment of onychomycosis which wll use 35-45 J/cm2 spot size 4, frequency 1 Hz for 2 passes on the infected nails
46091681|NCT02812043|Drug|Amorolfine|Amorolfine nail lacquer will be applied by the patient once a week on the infected nails
46091682|NCT02808767|Drug|Prasugrel|Prasugrel 60 mg loading dose and 10mg/5mg once daily maintenance dose
46091683|NCT02808767|Drug|Ticagrelor|Ticagrelor 180 mg loading dose and 90 mg twice daily maintenance dose
46091684|NCT02808689|Behavioral|Lifestyle Factors|Will look at nutrition and exercise that influence long-term health and chronic diseases.
46091685|NCT02808689|Other|Customized use of Dietary Supplements|Reduce ongoing biologic imbalances from deficiencies in dietary oxidants/ antioxidants via vitamin supplementation. Approach is customized based on results for laboratory testing.
46091686|NCT02808689|Other|Currently Accepted Asthma Care Guidelines|Use of asthma care guidelines set forth by the National Institutes of Health/National Heart, Lung and Blood Institute (NIH/NHLBI) and Global Initiative for Asthma
46091687|NCT02812355|Drug|Heparin|
46091688|NCT02811731|Drug|CKD-330 16/5mg - B|
46091689|NCT02811731|Drug|Candesartan 16mg and Amlodipine 5mg|
46091690|NCT02811809|Drug|Apalutamide|Apalutamide 240 mg (4 60mg tablets) daily
46091691|NCT02811809|Drug|IHT|Leuprolide 3-month depot 22.5 intramuscular dose
46091692|NCT05569421|Drug|Treatment A: BGF MDI HFO|Participants will receive 4 oral inhalations as a single dose - test formulation; administered during 1 treatment period.
45342499|NCT00620542|Drug|Rosuvastatin|capsule, oral, once daily
45342500|NCT00620542|Drug|Atorvastatin|capsule, oral, one daily
45342501|NCT00711048|Drug|AZD1386|oral, single dose
45342502|NCT00711048|Drug|Placebo|Oral solution, single dose
45342503|NCT04070742|Drug|FMX101|
45342504|NCT04269876|Dietary Supplement|Marine Lipid Oil Concentrate|Marine Lipid Oil Concentrate softgels
45342505|NCT04269876|Dietary Supplement|Dietary Supplement|Dietary Supplement capsules
45342506|NCT04269876|Dietary Supplement|Placebo|Placebo softgels
45342507|NCT04269876|Dietary Supplement|Placebo|Placebo capsules
46091693|NCT05569421|Drug|Treatment B: BGF MDI HFA|Participants will receive 4 oral inhalations as a single dose - reference formulation; administered during 2 treatment periods.
46091694|NCT02808611|Drug|propranolol|Reduction of the ANS response
46006026|NCT04582929|Drug|Neuronox ® Injection|Neuronox ® 50 or 100 unit intramuscular injection
46006027|NCT04613726|Drug|ondansetron|group consisted of receiving IV 8 mg ondansetron diluted in 10 ml of normal saline
46006028|NCT04613726|Drug|Granisetron|Another comparator group consisted of receivingIV 3 mg granisetron diluted in 10 ml of normal saline
46091695|NCT02808611|Drug|Placebo|
46091696|NCT02808455|Drug|Pacritinib 400 mg Capsule (Treatment A)|Four 100-mg capsules of pacritinib administered as a single oral dose
45459505|NCT01375400|Drug|Aspirin|Administration of 300 mg of aspirin, per os.
45678240|NCT02008565|Behavioral|Anal exercises with biofeedback|Participants will receive a formal anal exercises training program that can be easily applied in an office setting with minimal participant burden. Participants will attend six anal exercises with biofeedback sessions with trained personnel over a 12-week period for the 24-week study. Sessions will include introduction, standard patient education, and exercises using anal manometry-assisted biofeedback introducing concepts such as shaping, generalization and termination. The protocol uses strength and sensory training including urge resistance training. During the final twelve weeks, participants will perform anal exercises on their own. The sessions with interventionists will occur every other week for 12 weeks (total 6 supervised sessions).
46006029|NCT04613726|Drug|Saline|Control group consisted of patients receiving IV 10 ml normal saline
46006030|NCT00568230|Device|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein with placement of assessment and placement of PTMA Implant into the coronary sinus, great cardiac vein. Device remains accessible from a subclavicular pocket.
46091697|NCT02808455|Drug|Pacritinib 80 mg Solution (Treatment B)|A single 80-mg oral solution dose of pacritinib
46091698|NCT02808533|Drug|Topiramate|Topiramate capsules starting with 25 mg b.i.d with an incremental increase of 25 mg b.i.d weekly upto a maximum of 100 mg b.i.d.
45459506|NCT01375400|Biological|blood sample|2 blood samples will be performed
45459507|NCT05194670|Device|enhanced depth of focus IOL|Acunex Vario AN6V, enhanced depth of focus IOL
45459508|NCT05194670|Device|monofocal IOL|Acunex AN6, monofocal IOL
45459509|NCT03168386|Procedure|Intensive motor rehabilitation|Intensive motor rehabilitation during subacute stroke phase
46091699|NCT02808533|Other|Placebo|Placebo capsules visually identical to those containing topiramate will be administered.
46006031|NCT04613804|Drug|Toripalimab Injection|"Qualified subjects will be treated with toripalimab 240mg q21d as a treatment cycle."
46006032|NCT00568269|Procedure|Open repair|Open repair is according to the Lichtenstein technique
46006033|NCT00568269|Procedure|Laparoscopic repair|The TEP (Totally ExtraPeritoneal patch) repair is used as the laparoscopic repair
46091700|NCT04103177|Other|Chair based exercises in the dialysis environment|"Each participant will be given an educational / information booklet. It will include when the right time to engage in Physical Activity. The Chair-based Exercise Program will be the focus of the exercise intervention with written step- by-step instructions with demonstrative image of the exercises. Further details included in this booklet will include, information regarding the benefits of exercise including walking and safety measures in undertaking the exercises.~Sports Exercise Instructor led Chair-based Exercise Programme Patients will be given Sports Exercise Instructor led training on how to perform the chair-based exercises, for 6 weeks. This will be delivered during one of the patients' dialysis sessions. The Instructor will deliver a short 10 minute session to patients and deliver safety instruction.~Motivational interviewing Motivational interviewing will consist of discussion to encourage the participant without coercion and help them develop goals."
46091701|NCT05604365|Behavioral|FearLess Intervention|8-12 weekly telehealth sessions one hour in length.The intervention includes psychotherapy techniques varying from relaxation response to self-regulation targeted to the specific fears of patients with glioma.
46091702|NCT02811575|Other|Biopsy|Ileon and colon biopsy
46091703|NCT02811497|Drug|Azacitidine|
46091704|NCT02811497|Drug|Durvalumab|
46091705|NCT05567783|Biological|VIR-2482 (dose 1)|VIR-2482 given by intramuscular injection
46091706|NCT05567783|Biological|VIR-2482 (dose 2)|VIR-2482 given by intramuscular injection
46091707|NCT05567783|Biological|Placebo|Sterile 0.9% (w/v) sodium chloride solution given by intramuscular injection
46006034|NCT04613258|Dietary Supplement|SCAR Porridge|The treatment group was given SCAR porridge supplementation in the form of a soft porridge (a mixture of 50 g dry powder porridge added to 200 mL of hot water) along with nutritional counseling. The control group only received nutritional counseling and no SCAR porridge supplementation. A 50 g portion of SCAR porridge was provided once a day for 14 days. The SCAR porridge was monitored and administered by a researcher once a week to inquire about adherence to the supplementation consumption and perceived side effects. All research subjects went through a clearance period of one week and were requested not to consume any supplements.
46091708|NCT00634439|Drug|atomoxetine|
46091709|NCT00634439|Drug|Stimulants|Methylphenidate, amphetamines (including Adderall and mixed salts)
46091710|NCT00634439|Other|No intervention (general population)|
46091711|NCT02808299|Other|HBV infection history|HBV infection history or HBV carriers
46091712|NCT02807909|Drug|BMS-986177|
46006035|NCT04613258|Other|Counseling|21 subjects in the control group (C) who only received dietary counseling
46091713|NCT02807909|Drug|Itraconazole|
46091714|NCT02807909|Drug|Diltiazem ER|
46006036|NCT03453957|Other|Professional development program|Professional development program consists of training including workshops and consultation sessions to enhance therapists ability to detect and repair alliance ruptures in active community based psychotherapy.
46091715|NCT02808377|Other|Surgical Pelvic Organ Pessary|In participants randomized to intervention, the SPOP will be placed at the completion of surgery, following routine placement of IDC and prior to placement of vaginal pack. The SPOP is available in 4 sizes and the surgeon will select the appropriate size so that the SPOP rests snugly without undue tension inside the hymeneal remnant. The SPOP is sutured in place with 2/0 Vicryl to prevent dislodgement at the level of the hymen.
46091716|NCT05563181|Behavioral|Control bar code label|Viewing beverages that contain control labels (i.e., bar codes) on sugar-sweetened beverages
46091717|NCT05563181|Behavioral|Warning label|"Viewing beverages that contain an added-sugar warning label (icon-plus-text yellow label that says, WARNING: High in added sugar, on sugar-sweetened beverages"
46091718|NCT05563181|Behavioral|Informational campaign poster about added-sugar warning labels|Viewing an informational campaign about added-sugar warning labels. The poster will be shown in Spanish (instead of English) if the participant reports speaking and reading in Spanish better than English.
46091719|NCT02808065|Drug|Tacrolimus|Administered dose were individualized according to their own prescription
46091720|NCT02808065|Drug|Mycophenolate mofetil|Administered dose were individualized according to their own prescription
46091721|NCT02807987|Drug|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally
46091722|NCT02807753|Other|Ankle and Knee Ultrasound Joint Assessment|Ultrasound Examination of the ankles and knees
46091723|NCT02807753|Other|Ankle and Knee Magnetic Resonance Imaging|Ankle and Knee Magnetic Resonance Imaging
46091724|NCT02807831|Behavioral|Executive functions training|Daily training of executive functions via activities to develop auto-regulation, attention and memory.
46091725|NCT02807831|Behavioral|Language skills training|Daily training of language skills via activities to develop phonological awareness and vocabulary.
46091726|NCT02807831|Other|Regular school curriculum|Ministry of Education national school curriculum.
46091727|NCT04018469|Other|No Interventions|No Interventions
46091728|NCT00602030|Drug|Entinostat|Entinostat tablets on Days 1 and 15 of a 28-day cycle.
46091729|NCT00602030|Drug|Placebo|Placebo-matching entinostat tablets on Days 1 and 15 of a 28-day cycle.
46091730|NCT00602030|Drug|Erlotinib|Erlotinib 150 mg tablets once daily.
46091731|NCT02804867|Procedure|Online questionnaire and self-administered blood spot|
45342508|NCT04069806|Dietary Supplement|preoperative oral carbohydrate, preOp|Patients in the experimental arm will receive oral carbohydrate preparation at 2 hours prior to planned caesarian section.
45342509|NCT00851344|Drug|GSK835726 (10mg)|GSK835726 (10mg) tablet
45342510|NCT00851344|Drug|GSK835726 (50mg)|GSK835726 (50mg) tablet
45342511|NCT00851344|Drug|GSK835726 (100mg)|GSK835726 (100mg) tablet
45342512|NCT00851344|Drug|Cetirizine (10mg)|Cetirizine (10mg) tablet as positive control
46006037|NCT04613102|Drug|AVCN583601 (3% Cannabidiol cream)|Topical application twice daily for 4 weeks (phase 2) and for 8 weeks (phase 3).
46091732|NCT02807675|Drug|CVT-301, LIP|All subjects will receive 1 dose of CVT-301 and 1 dose of placebo inhalation powder, to be taken concomitantly with their standard oral medication in 2 dosing periods. The order of treatment will be randomized, with subjects assigned to 1 of 2 sequences CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)
46091733|NCT02807675|Other|Placebo|All subjects will receive 1 dose of CVT-301 and 1 dose of placebo inhalation powder, to be taken concomitantly with their standard oral medication in 2 dosing periods. The order of treatment will be randomized, with subjects assigned to 1 of 2 sequences CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)
46091734|NCT02804711|Biological|Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)|
46091735|NCT02804711|Biological|Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)|
46091736|NCT02804711|Biological|High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)|
46091737|NCT02804711|Biological|Placebo|
46091738|NCT00640094|Drug|melatonin|Patients will receive a total intravenous melatonin dose of 12 mg + intracoronary melatonin dose of 2 mg. The intravenous dose will be distributed in a volume of 50 ml of a isotonic and sterile solution and administered by intravenous infusion during 60 minutes. The intracoronary dose will be distributed in a volume of 10 ml of a isotonic and sterile solution and administered as a bolus.
46091739|NCT04186091|Procedure|correlation between baseline perfusion index and decrease in systolic blood pressure post spinal induction|correlation between baseline perfusion index and decrease in systolic blood pressure post spinal induction
46091740|NCT04183634|Drug|Rotigotine TTS (Test)|Transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24.
46091741|NCT04183634|Drug|Neupro (Reference)|Neupro®: transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24 h.
46091742|NCT00549757|Drug|Aliskiren|Aliskiren 150 mg film-coated tablets
46091743|NCT00549757|Drug|Placebo|Placebo to match aliskiren 150 mg film-coated tablets
46091744|NCT02804633|Drug|IV Acetaminophen|1 gram every 6 hours
46091745|NCT02804633|Drug|Placebo|100 ml of normal saline every 6 hours
46091746|NCT02807441|Drug|Acetylsalicylic acid|Patients will receive different doses of aspirin perioperatively to assess bleeding association.
46091747|NCT02684552|Device|Non invasive ventilation|Training on treadmill with Non invasive ventilation
45342513|NCT00851344|Other|Placebo|Placebo to match active
46091748|NCT02684552|Device|Oxygen|Training on treadmill with oxygen
46091749|NCT02807519|Genetic|collection of salivary cytokines|Collection of the saliva will be done following this procedure: The collection will be done prior to any other dental manipulation. The test person is sitting with its head tilted slightly forward. Initially, any saliva present in the mouth must be swallowed or spit out completely. Then, a paraffin gum is given to the test person. This paraffin gum must be chewed for minimally 2 and maximally up to 5 minutes. During the time period that the test person is chewing the paraffin gum, the saliva must be spitted into a cup repeatedly, or the saliva can also be let run passively into the cup. The amount of saliva is then weighted (1g equivalent to 1 ml) and a saliva flow rate (ml/min) is calculated and noted.
46091750|NCT02680886|Device|Novosyn® Quick|Skin closure
46091751|NCT02807285|Drug|Ocrelizumab|Participants will receive 600 mg ocrelizumab as two 300 mg infusions separated by 14 days, every 24 weeks.
46006038|NCT04582851|Other|some risk factors correlated with TMD|exposure factors causing TMD
46006039|NCT04613219|Drug|Tofacitinib 5 MG [Xeljanz]|Treatment with Tofacitinib
46091752|NCT05663996|Other|locally applied to the skin|Applying St John's wort oil locally on the knee three times a day for three weeks.
45342514|NCT00855478|Device|Cypher stent ™ or Cypher Select ™|Cypher drug-eluting stent
46091753|NCT05663996|Other|locally applied to the skin|Applying olive oil locally on the knee three times a day for three weeks.
46091754|NCT04182698|Drug|Simultaneous chemoradiotherapy for An Luo|"Experimental group: anlotinib(d1-14, d22-36), followed by 21 days period, 2 weeks medication, 1 week maintenance therapy.~. Group II: 10 mg po qd, Group III: 12 mg po qd;~Combined chemotherapy:~Cisplatin + etoposide Or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + cultured beauty (non squamous cell carcinoma). Synchrotron radiation: radiotherapy combined with radiotherapy (3D-CRT or IMRT) (60-66Gy / day).~The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD."
45342515|NCT04523922|Drug|40 IU Intranasal Oxytocin|40 IU Intranasal Oxytocin self administered 30 minutes prior to each COPE session.
45342516|NCT04523922|Drug|Placebo|Placebo (intranasal saline spray) self administered 30 minutes prior to each COPE session.
45459510|NCT01319864|Drug|Plerixafor Dose Escalation|"Plerixafor dose escalation Dose Level -1 = 3 mg/m2/dose Dose Level 1 = 6 mg/m2/dose Dose Level 2 = 9 mg/m2/dose Dose Level 3 = 12 mg/m2/dose Dose Level 4 = 15 mg/m2/dose~Doses administered 4 hours prior to chemotherapy, then at the same approximate time of day on subsequent days, through the end of that cycle of chemotherapy."
45459511|NCT04853654|Other|exercise|exercise training for 8 weeks
46091755|NCT02690051|Device|BeSmooth peripheral stent|patients treated with the BeSmooth Peripheral Stent System
45342517|NCT04523922|Behavioral|Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure|12 weekly sessions of COPE therapy for PTSD and AUD.
45459512|NCT05194280|Procedure|Robotic surgery|Robotic-assisted donornephrectomy
45459513|NCT05194046|Drug|JP-1366 20mg 1capsule|will be orally administered
45459514|NCT05194046|Drug|Amoxicillin 500Mg Cap|Amoxicilin 500Mg 2 capsules will be orally administered
46006040|NCT00563615|Drug|Tegaserod|
46006041|NCT04582656|Device|Targeted microwave ablation|Targeted ablation of the index tumor with microwaves, by using either a transperineal or a transrectal approach
46006042|NCT00563654|Drug|Alfuzosin GITS (Xatral XL)|
46006043|NCT04612985|Device|XACT Robotic System|CT-guided Minimally Invasive Procedures e.g., Biopsies
46091756|NCT03068390|Behavioral|RICHH Intervention|Whole health cardiovascular disease (CVD) self-care risk reduction intervention
46091757|NCT03068390|Behavioral|Usual care|Referral to primary care provider
46091758|NCT02804555|Other|Oxygen|Oxygen administration
46091759|NCT02682680|Drug|Colesevelam|Colesevelam 3.75 g daily for 24 weeks
46091760|NCT02682680|Drug|Ezetimibe|Ezetimibe 10 mg daily for 24 weeks
46091761|NCT02807207|Drug|A: 400 mg pacritinib|Treatment A
46091762|NCT02807207|Other|B: Placebo|Treatment B
46091763|NCT02807207|Drug|C: 400 mg moxifloxacin|Treatment C
46091764|NCT02682758|Drug|Xenon|Wash-in of xenon for maintenance of anaesthesia
46091765|NCT02682524|Drug|Pelubiprofen CR 45mg tab.|
46006044|NCT00571896|Drug|Senna+ docusate|Senna+Docusate: dose will be 8.6 mg senna concentrate with 50 mg docusate. The participants will take the medication as follows: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 & 3 (2 tabs at night and in the morning) until the first-postoperative visit.
46091766|NCT02682524|Drug|Aceclofenac 100mg tab.|
46091767|NCT05520983|Behavioral|Adapted Teens Achieving Mastery over Stress (TEAMS) Treatment|Teens Achieving Mastery over Stress (TEAMS) has been adapted for use with youth with I/DD. The intervention consists of virtual, manualized treatment groups for 10 weekly, 75-minute sessions plus 6 monthly, 60-minute sessions. Caregivers of participants will meet twice: weeks one and 16.
46006045|NCT00571896|Drug|placebo|Placebo pill: The participants will use the placebo pills in the following manner: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 & 3 (2 tabs at night and in the morning) until the first-postoperative visit.
46091768|NCT05520983|Behavioral|Adapted Teens Achieving Mastery over Stress (TEAMS) Prevention|Teens Achieving Mastery over Stress (TEAMS) has been adapted for youth with I/DD. TEAMS Prevention is a 10-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
46091769|NCT05520983|Behavioral|Adapted Competent Adulthood Transition with Cognitive-behavioral & Interpersonal Training (CATCH-IT)|Competent Adulthood Transition with Cognitive-behavioral & Interpersonal Training (CATCH-IT) has been adapted for youth with I/DD. CATCH-IT is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious. All adolescents will receive 8 engagement texts during their participation in the study - at 1-week, 1-month, 6-weeks, and 2-, 3-, 5-, and 5.5-months - to encourage participation in the online modules.
46091770|NCT05520983|Other|Strengthening Families|The Strengthening Families caregiving curriculum is an evidence-based, self-directed, virtual skills training for caregivers. Information and instructions on accessing the Strengthening Families parenting skills training curriculum will be included on the virtual resource website https://strengtheningfamilieslessons.org/.
46091771|NCT05520983|Other|Virtual psycho-educational discussion groups for caregivers and participants|The BEST project will host a total of 10 virtual psycho-educational workshops per year (5 for participants and 5 for caregivers) for the duration of the intervention period of the study. Workshops will be delivered remotely via Zoom and facilitated by graduate students in health/behavioral health. Simultaneous language interpreter services will be provided. Principles of universal design in learning will be applied to the content and delivery of workshops. Workshops are an optional resource available to all participants and families in the intervention condition. Topics for the virtual discussion groups will be determined based on pilot data and input from participants and caregivers.
46091772|NCT05520983|Other|Maternal Child Health Bureau (MCHB) Care Coordination|MCHB Care Coordination, funded through the Social Security Act of 1935 Title V Maternal and Child Health Services Block Grant Program, is the oldest and most universal care coordination model for children with I/DD. MCHB Care Coordination involves: comprehensive needs assessments, person-centered planning, and linkage to health care and social resources. MCHB care coordination has established efficacy, feasibility, and acceptability in improving child and family functioning, youth health, and health care access.
46091773|NCT04183556|Drug|Naproxen|use of naproxen twice a day orally in mens time
46091774|NCT04183556|Dietary Supplement|Turmeric|Use of turmeric orally (1 gram powder formula) in mens time
45459515|NCT05194046|Drug|Clarithromycin 500Mg Tab|Amoxicilin 500Mg 1 tablet will be orally administered
46091775|NCT02807129|Biological|blood withdrawn|
46091776|NCT02807129|Biological|urine collection|
46091777|NCT00640952|Drug|acamprosate|333 mg 2 tabs tid
46091778|NCT04236557|Behavioral|Music listening|Other than usual care, subjects will listen to a 30-min individualized playlists with preferred music genres sequenced by a registered music therapist according to the ISO-Principle when agitated.
46091779|NCT04236557|Behavioral|Audio Book Listening|Other than usual care, subjects will listen to to a 30-min audio-script of book reading in Cantonese (a common dialect in Hong Kong being spoken by most people) when agitated.
46091780|NCT02684240|Drug|Nitazoxanide|nitazoxanide 1000 mg orally twice daily with food for 14 days
46091781|NCT02684240|Other|Control|The control arm will receive WHO standard therapy for tuberculosis with isoniazid, rifampin, pyrazinamide, and ethambutol
46091782|NCT02807051|Drug|Pacritinib|Single 400-mg dose (four 100-mg capsules) administered in the morning on Days 1 and 12
46091783|NCT02807051|Drug|Clarithromycin|Twice-daily, 500-mg dose (one 500-mg tablet) administered every 8 to 12 hours on Day 8 through the morning of Day 12
45473948|NCT01285037|Drug|Gemcitabine|Gemcitabine given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, gemcitabine may be continued as monotherapy until progression of disease. Participants discontinuing gemcitabine therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
46006046|NCT04613180|Drug|Montelukast Sodium|Montelukast is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in adults and children 12 months of age and older. Montelukast is also used to prevent bronchospasm (breathing difficulties) during exercise in adults and children 6 years of age and older.
46091784|NCT02807051|Drug|Pacritinib and Clarithromycin|On Day 12, a single oral 400-mg dose of pacritinib was co-administered with the final 500-mg dose of clarithromycin
45836427|NCT01791114|Other|Cold exposure plus propranolol|For the cold exposure plus propanol trial, temperature will be titrated as previously described. The non-selective beta-adrenergic antagonist propranolol (0.5mg/kg and up to 40) will be given orally before the beginning of the study and again after 4-6 hours. In case participant's heart rate after propranolol administration decreases below 50 beats per min or systolic blood pressure below 90 mmHg second dose of propranolol will not be administered. Heart rate and blood pressure will be monitored continuously throughout the study. Propranolol doses up to 80 mg have been shown to significantly reduce fludeoxyglucose (FDG) uptake in brown fat in clinical patients.
45836428|NCT01791114|Other|Thermoneutral Conditions|Subjects will be exposed to thermoneutral conditions (26 - 28°C)
46091785|NCT02684084|Drug|Ozurdex|OZURDEX® (DEX implant; Allergan Inc. Irvine, CA, USA) is a sustained-release biodegradable implant approved for treatment of Macular Edema secondary to central retinal vein occlusion as well as noninfectious uveitis affecting the posterior segment
46091786|NCT02684084|Drug|Lucentis|LUCENTIS® (0.5 mg ranibizumab or RBZ, an anti-neovascular VEGF-A inhibitor, Novartis Pharmaceuticals Canada Inc.) was the first approved medical treatment for DME
46091787|NCT02806661|Procedure|Vagus nerve-preserving Robot-assisted Gastrectomy|
46091788|NCT02806661|Procedure|Conventional Robot-assisted Gastrectomy|
46091789|NCT02684318|Drug|PM01183 + olaparib|
46091790|NCT02806817|Drug|ME-344|ME-344 is a synthetic small molecule mitochondrial inhibitor based on the isoflavan ring structure. ME-344 is a chiral compound, and is manufactured predominantly as a single stereoisomer that is dextrorotatory. As a stereoisomeric drug with two chiral centers, ME-344 is one of four potential stereoisomers. The current manufacturing process produces a racemic mixture of two of those stereoisomers, which are enantiomers, and ME-344 is separated from the levorotatory enantiomer by chromatography in the final step.
46091791|NCT02806817|Drug|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
46091792|NCT02806817|Other|Normal saline|Use saline as placebo
46091793|NCT02683850|Dietary Supplement|Omega-3 SPM™ softgel|This four week, prospective, non-randomized, open-label study is assessing the impact on quality of life from taking an Omega-3 SPM™ softgel supplement in adults with pain symptoms at screening of 4 or higher on the PROMIS-43 Profile - Pain Intensity subscale.
46091794|NCT04182854|Drug|Furosemid hydrochlorothiazide|furosemide 100mg for one month;furosemide 200mg for one month;furosemide 100mg and hydrochlorothiazide 25mg for one month;
46091795|NCT02804243|Device|nasal high flow therapy|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
46091796|NCT02680808|Drug|Midazolam with F901318|Pharmacokinetics of midazolam with F901318
46091797|NCT02682446|Drug|H pylori eradication|The regimen of H. pylori eradication was like that: 1-week conventional proton pump inhibitor (PPI) based triple therapy (lansoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d. for a week) after confirmation of H. pylori infection. If the participants who initially failed to respond to the first eradication, they recommended to underwent second-line eradication therapy with the regimen of 7-day bismuth containing quadruple regimen [lansoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate (Denol; Greencross Co., Seoul, Korea) 300 mg q.i.d. (three tablets 30 min before meals and one tablet 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d. for 1 week]
46091798|NCT02806739|Dietary Supplement|Soy Group (Soy Protein + Isoflavones)|Women in the intervention group are asked to eat a combination of soy foods that contain about 25 grams of protein and 60-75 milligrams of isoflavones per day, from the 16th gestational week to birth. A registered dietitian will instruct them to incorporate the soy foods into their daily diet.
45836429|NCT01791114|Other|Cold water consumption|Subjects will be asked to consume cold water (4 °C,10 ml/ kg body weight within 10 minutes)
45836430|NCT01791114|Other|Tepid water consumption|Subjects will be asked to consume cold water (36 C,10 ml/ kg body weight within 10 minutes)
45836431|NCT01791114|Other|Exercise|Subject will be asked to complete four bouts of exercise for 10 min- at 85% of their maximal oxygen consumption (VO2max) with 15-min breaks between each bout
45836432|NCT01791114|Other|Meal consumption|Subjects will be asked to consume a high calorie meal (12 kcal/kg, 50% carbohydrates, 30% fat, and 20% protein) within 15 minutes.
45836433|NCT04271592|Drug|ABI-H3733 Liquid Oral Dosage Form|ABI-H3733 liquid oral dosage form
46091799|NCT02806739|Dietary Supplement|Control Group (Minimize Soy Intake)|Women in the control group will be instructed by the dietitian how to avoid soy supplements and minimize soy intake.
45473949|NCT01285037|Drug|Ramucirumab|Ramucirumab given via IV infusion every 2 weeks in a 28-day treatment cycle. Treatment with ramucirumab may continue until excessive toxicity or evidence of disease progression. In the absence of disease progression, treatment with LY2801653 may continue even if ramucirumab is discontinued provided no dose limiting toxicity related to LY2801653 is present. In the event that LY2801653 is discontinued, treatment with ramucirumab may be continued if there is no dose limiting toxicity related to ramucirumab.
45836434|NCT04271592|Drug|ABI-H3733 Solid Oral Dosage Form|ABI-H3733 solid oral dosage form
45836435|NCT04271592|Drug|Placebo to ABI-H3733 Liquid Oral Dosage Form|Placebo to ABI-H3733 liquid oral dosage form
45836436|NCT04271592|Drug|Placebo to ABI-H3733 Solid Oral Dosage Form|Placebo to ABI-H3733 solid oral dosage form
46006047|NCT04613180|Drug|Placebo|placebo containing no active substance
46006048|NCT00571935|Drug|insulin aspart|
46006049|NCT00571935|Drug|soluble human insulin|
46091800|NCT02680418|Drug|FDL169|
46006050|NCT04613063|Other|Diagnostic laparoscopy|A diagnostic laparoscopy was performed where a dilated jejunum was encountered with impaction of fecal content. Surgery was converted to open surgery, where a longitudinal enterotomy of 5 cm after the transition zone was created, evacuating manually the fecal material with mucous secretion.
46006051|NCT00572013|Drug|Rituxan|375mg/m2 IV on days -20 to -8. Infusion to begin at rate of 50mg/hour for 1st hour.If no toxicity rate may be increased. A second infusion 375mg/m2 given 30days post transplant and again at 60 days post transplant
46006052|NCT00572013|Drug|BEAM|BCNU(carmustine)on day -6 300mg/M2 IV, etoposide 100mg/M2 BID on days -5 through -2, cytarabine 100mg/m2 BID on days -5 through -2, melphalan 140mg/m2 IV on day -1
46091801|NCT02806583|Other|structured support groups|Telephone-based Support Groups, information booklet and telephone-based preparatory meeting prior to the telephone-based support groups
46091802|NCT02682368|Diagnostic Test|Point of Care Ultrasound by Surgeons (POCUSS)|"POCUSS-1. To identify the gallbladder and it's contents, complications and perform measurements, elicit sonographic Murphy.~POCUSS-2: To perform focused left lower quadrant sonography and identify bowel wall thickness, diverticulae, measure the colonic wall thickness, assess pericolic fat and detect possible complications; evaluate sensibility on graded compression."
46091803|NCT02682368|Diagnostic Test|Radiology report|Radiologist report compared to the point of care ultrasound impression.
46091804|NCT02682368|Procedure|Surgery-Intra-operative findings|Intra-operative findings compared to the previously performed point of care ultrasound.
46091805|NCT02806427|Other|Enteral Formula|
46091806|NCT05663684|Drug|Proparacaine Hydrochloride ophthalmic solution, USP 0.5%|One drop instilled in one eye, randomly chosen, as topical anesthetic
46091807|NCT05663684|Drug|Balanced salt solution|One drop instilled in one eye, randomly chosen, as control placebo
46091808|NCT04004819|Drug|Rituximab|A lower dosage of rituximab for HTLV-1-associated myelopathy
46091809|NCT02680340|Procedure|Total Hip Arthroplasty|Patients who had a primary THA between 2002 and 2005
46006053|NCT00572013|Procedure|Autologous stem cell transplant|following chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
46091810|NCT02806271|Behavioral|Worry Postponement|"In worry postponement, participants are instructed to learn to notice naturally occurring episodes of worry. When they notice they are worrying they are instructed to disengage from their worry and postpone it to a designated 30 minute worry period to be carried out at the same time and place daily during the two week intervention. Participants are to use their worry time to worry about problems that have come up during the day and to problem solve where appropriate."
46091811|NCT02806271|Behavioral|Worry Monitoring|For two weeks participants are instructed to monitor their worry using a smartphone based application. Participants are instructed to make a record each time they have a worry episode by briefly describing the content of their worry. Participants also complete two brief daily questionnaires about the duration of their worry, the intensity of their worry, their ability to disengage from their worry, and the occurrence of nighttime episodes of worry.
46091812|NCT00955435|Other|Non-interventional|Patients receive induction hormones* (bicalutimide and releasing-hormone agonist) for approximately 4 months prior to starting radiotherapy per standard treatment. Patients then receive radiotherapy consisting of 74 Gy up to a maximum of 81 Gy to the prostate gland per standard treatment.
46091813|NCT00955435|Genetic|Protein expression analysis|
46091814|NCT00955435|Genetic|Proteomic profiling|
46091815|NCT00955435|Other|Laboratory biomarker analysis|
46091816|NCT00641654|Drug|Pegylated interferon alfa-2a and ribavirin|Arm A: Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
46091817|NCT00641654|Drug|Pegylated interferon alfa-2a and ribavirin|Arm B:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
46091818|NCT00641654|Drug|Pegylated interferon alfa-2a and ribavirin|Arm C:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 24 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 24 weeks
46091819|NCT02804165|Genetic|Enterovirus vaccination|Enterovirus vaccination in genetically predisposed subjects having a high risk to develop type 1 diabetes.
46091820|NCT02826434|Biological|PVX-410|This is a Vaccine that will be injected intramuscularly as a mixture with an adjuvant.
46091821|NCT02826434|Biological|Durvalumab|This is an intravenous infusion of a monoclonal antibody.
45678241|NCT02008565|Behavioral|Usual Care|Usual care consists of patients receiving an educational pamphlet on fecal incontinence created by the National Institute of Diabetes and Digestive and Kidney Diseases.
46091822|NCT02826434|Drug|Hiltonol|This is an intramuscular injection of an adjuvant to enhance the immune response to vaccine.
46091823|NCT02803931|Device|Cardiogoniometry|Cardiogoniometry cardiologic explorer, Enverdis GmbH medical solutions, Germany
45836437|NCT04271514|Drug|RPT193|Antagonist of the CCR4 chemokine receptor
46006054|NCT04612634|Biological|Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun. 0.5ml per dose
46006055|NCT04612634|Biological|Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang. 0.5ml per dose.
46091824|NCT02803931|Device|12-lead ECG|
45678242|NCT01907906|Device|Mirasol System for Whole Blood|LR-pRBC units derived from WB will be treated with the Mirasol System. Treatment with the Mirasol System requires riboflavin to be mixed into the whole blood unit, which is then exposed to ultra violet (UV) light for a period of time; approximately an hour.
46006056|NCT04612634|Biological|Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, CAMS|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml per dose.
46091825|NCT00549601|Drug|Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)|Rivastigmine administered transdermally via patches at increasing doses (1 patch/day of 4.6 mg for the first month, changing to 1 patch/day of 9.5 mg for the remaining two months).
46091826|NCT00549601|Drug|Rivastigmine patch (9.5 mg/day)|Rivastigmine administered transdermally via patches at a constant dose (9.5 mg/day for the 3 months of treatment).
46091827|NCT00549601|Drug|Rivastigmine capsules (6 mg to 12 mg/day)|Rivastigmine administered orally, following the same regime as prior to randomization (doses between 6 mg and 12 mg/day), which remained unchanged throughout the 3 months of treatment.
46091828|NCT02683694|Device|iOCT|the number of subjects that can be peeled without dye are assessed
46091829|NCT02806349|Dietary Supplement|American Ginseng|herb
46091830|NCT02806349|Dietary Supplement|Konjac-glucomannan fiber blend|Blend of 2 viscous fibers: konjac mannan and xanthan
46091831|NCT02806349|Dietary Supplement|Control|Fiber matched control for intervention (corn starch and wheat bran)
46091832|NCT02682212|Other|Physiotherapy intervention|Compare the effect of early physiotherapy intervention (pelvic floor muscle training, PFMT) with standard care on pelvic floor dysfunction symptoms, quality of life (QoL) and (pelvic floor muscle (PFM) strength, for women who answered the questionnaire positively for 1) urinary incontinence, 2) other dysfunction of the pelvic floor.
46091833|NCT00957541|Device|Paradym CRT + Physiological Diagnosis (PhD)|All subjects will undergo CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
46091834|NCT02806193|Procedure|Cardiovascular Magnetic Resonance Imaging|"Cardiac magnetic resonance imaging (CMR) has emerged as both a remarkably powerful diagnostic and prognostic tool for the assessment of cardiovascular disease. The high spatial resolution of CMR and the ability to characterize soft tissue provides the opportunity for unique diagnostic assessment of a myriad of cardiac pathology, including ischemic heart disease (IHD), preoperative assessment, intra- cardiac mass and thrombus, pericardial disease, valvular heart disease, and cardiomyopathy evaluation.~Between individual CMR programs, GCMR will offer information useful in assessing the differences in protocol, performance, and clinical adaptation by varying geographic regions, institutional environments, and expertise. Such an assessment is critical for uncovering possible reasons for disparities in performance and obtaining opportunities for advancement."
46091835|NCT04184492|Drug|GP-40081|biphasic insulin aspart 30 in doses 0.4 IU/kg
46091836|NCT04184492|Drug|NovoMix® 30 Penfill®|biphasic insulin aspart 30 in doses 0.4 IU/kg
46091837|NCT02806115|Procedure|acetic acid-enhanced endoscopy|Acetic acid-enhanced endoscopy combines conventional endoscopy with the instillation of acetic acid.
46091838|NCT02806115|Drug|Acetic Acid|The concentration of acetic acid used in this study is 1.5%.
46091839|NCT02806115|Device|endoscope|This study using an EG-29-i10 endoscope (Pentax, Tokyo, Japan) and an EPK-i7010 processor (Pentax, Tokyo, Japan).
46091840|NCT02680496|Device|Lokomat|A single walking trial in which the patient walks in the Lokomat with 60% guidance force for 30 minutes at comfortable walking speed (body-weight supported if necessary)
46091841|NCT02680496|Other|Treadmill|A single walking trial in which the patient walks on a treadmill for 30 minutes at comfortable walking speed (body-weight supported if necessary)
46091842|NCT02680496|Other|Overground|A single walking trial in which the patient walks overground for 30 minutes at comfortable walking speed (body-weight supported if necessary)
46091843|NCT04010383|Diagnostic Test|virtual reality perimeter|Both groups will be examined with a standard automated perimeter as well as with the virtual reality perimeter.
45836438|NCT04271514|Drug|Placebo|Matching placebo
45836439|NCT01791192|Drug|FTY720|Fingolimod
45836440|NCT01791192|Drug|Oral Corticosteroid|Oral Corticosteroid
45836441|NCT01793766|Device|Brain modulation|Brain modulation using Eldith/Neuroconn transcranial Direct Current Stimulation device
46006057|NCT00572052|Device|NovoFine® needle 6 mm|
46006058|NCT00572052|Device|Ultra-Fine needle 12.7 mm|
46091844|NCT00955591|Other|Papanicolaou test|
46091845|NCT02682134|Drug|xylocaine|First group were given xylocaine
46091846|NCT02682134|Drug|Dexamethasone|Second group were given Dexamethasone
46091847|NCT02682134|Drug|Xylocaine and Dexamethasone|Third group were given both Xylocaine and Dexamethasone
46006059|NCT04612556|Drug|Mepolizumab 100 MG [Nucala]|subcutaneous injection once a month
46006060|NCT04579965|Drug|medical treatment of isthmocele|comparison between different drugs
46006061|NCT04612595|Other|serum urea nitrogen to creatinine ratio|According to sex and CKD stage , patients are divided into four groups,then evaluate whether the different mean sUCR and ΔsUCR can influent the survival of DKD patients.
46006062|NCT00568308|Drug|PI-88|160mg subcutaneous injection
46091848|NCT00957619|Drug|pentoxyfilline|The total dose of 1 mg/kg/h will be used. At the preoperative day half of the daily dose will be given as a 4-hour short-term infusion within 24 hours before surgery. Afterwards, a continuous intravenous infusion of PTX 1 mg/kg of body weight per hour will be started intra-operatively and will be continued for a total of 72 hours after surgery.
46091849|NCT00957619|Drug|Placebo|This group will be treated with saline solution at the same time points. The infusion volume and infusion rate of saline solution correspond to that of the PTF group.
46091850|NCT05550701|Other|lymph node yield|We recorded the number of lymph nodes dissected during surgery in patients with colorectal cancer
46091851|NCT05299489|Other|Direct restoration|Local anesthesia was achieved and the tooth were isolated using a rubber dam. Then, the entire caries and hypomineralized enamel were removed using diamond burs and removal the affected dentine caries by slow speed handpiece, the final preparation must be on intact enamel. The molars were wiped using 5.25% sodium hypochlorite followed by rinsing with water, etching using 37% phosphoric acid The surface of the restoration, bonding, applying composite and assessment of occlusion.
46091852|NCT05299489|Other|Indirect restoration|"Local anesthesia was achieved and the tooth were isolated using a rubber dam. Then, the entire caries and hypomineralized enamel were removed using diamond burs and removal the affected dentine caries by slow speed handpiece, the final preparation must be on intact enamel. Preparation walls were vertical according to the longitudinal axis of the tooth and the occlusal depth 2 mm. The impressions were taken for both jaws and the bite were recorded for the using red wax. The cavity in example were painted with insulating material. Indirect composite resin were applied, finishined and polished.~Cementation:~Tooth surface: The molars were wiped using 5.25% sodium hypochlorite followed by rinsing with water, etching using 37% phosphoric acid The surface of the restoration: application of silane coupling agent to enhance the formation of resin tags.~Dual cure resin cement was used for final cementation followed by an assessment of occlusion."
46091853|NCT04236401|Procedure|electrosurgery will be used for abdominal incision|electrosurgery will be used to open anterior abdominal wall and electrosurgery will be used for heamostasis also
46091854|NCT04236401|Procedure|scalpel will be used for abdominal incision|scalpel will be used for abdominal wall incision and thread will be used for haemostsis
46091855|NCT00640406|Device|Dynamic Renal Stent plus Best Medical Treatment|percutaneous transluminal angioplasty of the kidney artery at index procedure followed by best medical treatment for hypertension secondary to renal artery stenosis according to local standards
46091856|NCT00640406|Drug|Best Medical Treatment|best medical treatment for hypertension secondary to renal artery stenosis according to local standards
46091857|NCT04236323|Drug|Not used remifentanil infusion|Remifentanil is not used during operation
46091858|NCT04033796|Dietary Supplement|25,000 IU|Vitamin-D3 supplementation providing 25,000 IU administered orally every two months (equivalent to ~400 IU/d);
46091859|NCT04033796|Dietary Supplement|50,000 IU|Vitamin-D3 supplementation providing 50,000 IU administered orally every two months (equivalent to ~800 IU/d);
46091860|NCT04033796|Dietary Supplement|Placebo|A placebo (administered orally every two months) supplementation control group.
45678243|NCT01907828|Device|Renal Artery Ablation|Renal artery denervation using the EnligHTN™ Renal Denervation System
45678244|NCT01907828|Device|Cardiac Ablation|Safire BLU™ Duo or Therapy Cool Path Duo Irrigated Ablation Catheter or Therapy Cool Flex Irrigated Ablation Catheter EnSite Velocity System Agilis NxT Guiding Introducer
46006063|NCT00568308|Drug|placebo|matched placebo
46006064|NCT04580199|Procedure|thyroidectomy|to excise the thyroid gland
45836442|NCT01793766|Device|Sham modulation|
46006065|NCT04612673|Drug|Sintilimab|immune checkpoint inhibitor, 200mg, iv, d1,Q3W
46006066|NCT00572091|Device|PTMA Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein.
46006067|NCT04612829|Device|Medistus Antivirus Lozenges|A blend of Kistosyn Extract with Gum Arabic
46006068|NCT04612439|Device|VABB Elite 10G|If the biopsy device is a vacuum-assisted Elite 10G needle, insert the needle groove into the mass and rotate to cut the biopsy tissue one circle
46006069|NCT04612439|Device|BARD 14G CNB|If the biopsy device is a BARD 14G hollow core needle, insert the needle to the edge of the mass and pull the trigger in different directions to eject the needle to retrieve the material
46006070|NCT04612517|Drug|ZP7570|Each subject will be randomly allocated to multiple doses of ZP7570 at one of four dose levels in each cohort.
46006071|NCT04612517|Drug|Placebo|Placebo; corresponding volume
46091861|NCT00955669|Biological|Symptoms and Objective Examination|5.0*108~5.0*109 MSCs and MNCs were transplant into impaired lower limbs by intramuscular injection
46091862|NCT02805959|Device|MTS2|
46006072|NCT00568347|Drug|fluticasone 100mcg/ salmeterol 50mcg|inhaled fluticasone 100mcg/salmeterol 50mcg bid X 3 months
46006073|NCT00568347|Drug|fluticasone 250/salmeterol 50|inhaled fluticasone 250/salmeterol 50 X 3 months to evaluate effect on lung function and exhaled nitric oxide
46006074|NCT00568347|Drug|salmeterol|salmeterol 50 mcg by dry powder inhaler disk bid to evaluated effect on lung function and exhaled nitric oxide
46006075|NCT00568347|Drug|Salmeterol|salmeterol 50mcg bid X 3months
46006076|NCT00568347|Drug|salmeterol and fluticasone propionate|salmeterol 50mcg/fluticasone 250mcg by DPI bid
46006077|NCT04612127|Dietary Supplement|Dietary supplement consumption and physical exercise|"The consumption time of the experimental product was 90 days and the control consumption time was 90 days.~During this time, training should be done three times a week."
46006078|NCT04612361|Other|insommnia severity index questionnaire|insomnia severity index questionnaire and scoring system
46006079|NCT04582071|Behavioral|Psychotherapy|Psychotherapy is a term that we use to describe the use of the psychological method to understand and improve an individual's well-being and mental health. The Principal Investigator of this study, a clinical psychologist will be leading each of the sessions.
46006080|NCT04582110|Diagnostic Test|Optical coherence tomography angiography|Each subject underwent Optical coherence tomography angiography (a non-invasive, fast, diagnostic imaging technique)
46091863|NCT02680262|Behavioral|HPV self-sampling kit mailed directly|Women in intervention group 1 will be mailed a modified second reminder, a leaflet entitled Information about HPV self-sampling, and a self-sampling kit. The leaflet provides information about HPV and cervical cancer including benefits and harms about HPV self-sampling compared to regular screening. The kit includes a brush device (Evelyn Brush, Rovers Medical Devices B.V, Oss, Netherlands) to collect a cervico-vaginal sample for subsequent hrHPV testing, written and drawn instructions on how to obtain and mail the sample, and a pre-stamped return envelope addressed to the Department of Pathology, Randers Regional Hospital performing the hrHPV testing.
46091864|NCT02680262|Behavioral|HPV self-sampling kit on demand|"Women in intervention group 2 receive the same material as arm 1, except for the kit, which will only be mailed to the women on demand. Additionally, the leaflet for this group contains information on how to order the kit.~The modified second reminder in both intervention groups informs of the opportunity to collect a self-sample if wanted, but also about the opportunity to have a conventional specimen taken at a general practitioner (usual procedure)."
46091865|NCT02680262|Behavioral|Second reminder|The standard second reminder informs women about the ongoing opportunity to have a conventional cervical sample taken by a general practitioner. (control group)
46091866|NCT04206163|Diagnostic Test|68Ga-DOTA-TOC PET/CT|Somatostatin receptor imaging
45459516|NCT01369394|Other|Behavioral: Computer-based tailoring system|"Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will generate educational messages based on participants' responses to survey questions. The intervention group will receive tailored educational messages, whereas the control group will receive generic educational messages. The tailored and generic educational messages will be presented as to look like web pages. However, the messages will only exist on the study computer, and will not be linked to any live server or website."
46006081|NCT04612205|Device|TECAR followed by pelvic floor exercises|The signal generator was an INDIBA® 448 kHz RF device (vagina/rectum) (INDIBA SA, Barcelona, Spain).
46006082|NCT04612205|Other|pelvic floor exercises|The patients will instructed to contract their pelvic floor muscles without contracting adjacent muscles, such as the abdomen, glutei and hip adductors muscles twenty repletion consisted of contraction and squeezing of the muscle ten seconds followed by relaxation for twenty second then rested for two minutes. The exercises program lasted for lasting 45 min. divided into 5 min. warming up, 35 min. actual treatment and 5 min. cooling down, three times a week for eight consecutive weeks. The patient will teach to contract their pelvic floor muscles before coughing or sneezing thus to prevent leakage. Home exercises through continuing practicing these contractions as frequent as possible according to her ability, at early morning before getting from bed from crock lying position, at afternoon from sitting and standing positions, at evening from sitting and standing positions and finally at night at bed time from crock lying position.
46006083|NCT00572130|Genetic|Rexin-G Dose 1|Rexin-G i.v., 1 x 10e11 cfu, two times a week x 4 weeks, rest 2 weeks May be repeated if grade 1 or less toxicity
46091867|NCT04206163|Biological|Blood sample|Analysis of inflammatory biomarkers
46091868|NCT02803697|Other|Patients|
46091869|NCT00909974|Dietary Supplement|UNIMMAP - multiple micronutrients|"Daily supplementation of one UNIMMAP tablet~multiple micronutrient supplements (MMN): UNIMMAP: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg"
46091870|NCT00909974|Dietary Supplement|Food supplement enriched with multiple micronutrients|"One dose of 72g per day during whole pregnancy~Recipe of food supplement: 33% peanut butter, 32% soy flour, 15% vegetable oil, 20% sugar, UNIMMAP in powdered form Nutritional composition (per dose of 72g) Energy 1.56 MJ, protein 14.7 g, vitamin A 881 µg, vitamin E 13 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 21 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 461 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg"
46006084|NCT00572130|Genetic|Rexin-G Dose 2|Rexin-G i.v., 1 x 10e11 cfu, three times a week x 4 weeks; rest 2 weeks May repeated if grade 1 or less toxicity
46091871|NCT00957775|Behavioral|Usual care|Participants will receive the usual care (e.g., individual therapy, group therapy, family therapy, self-help groups) provided at the treatment site.
46091872|NCT00957775|Behavioral|Computer-delivered ACRA|Participants and willing caregivers will receive a computer-delivered intervention for 12 weeks, based on the Adolescent Community Reinforcement Approach to substance abuse treatment.
46091873|NCT02805881|Device|Neurolief system|Non-invasive cephalic neurostimulation device
46091874|NCT05300347|Diagnostic Test|adenosine deaminase enzyme deficiency test|adenosine deaminase enzyme deficiency
46091875|NCT04182152|Device|Indocyanine green (ICG)|Indocyanine green (ICG) was diluted with saline to 0.5mg/mL, and injected 0.6mL/site.
46091876|NCT04182152|Device|Electromagnetic navigation bronchoscopy|Electromagnetic navigation bronchoscopy (ENB) allows physicians to access peripheral lung nodules with high accuracy and provides a working channel for ICG injection.
46091877|NCT04182152|Device|Hook wire|Hook wire is a puncture locating needle with a hook head that is about 1 cm in length and 30 cm metal wire behind. Through the puncture path planned based on CT scan, hook wire puncture percutaneously into the chest cavity to reach the lesion for localization.
46091878|NCT05547191|Device|ChloraSolv|Debridement with ChloraSolv until the wound is visually assessed as clean.
46091879|NCT04011241|Drug|BI 1323495|Tablet
46091880|NCT04011241|Drug|Itraconazole|Oral solution
46091881|NCT02680028|Device|targon pft nail|220 mm vs 175mm nail
46091882|NCT05299411|Drug|iron (isomaltoside)|iron supplement through intravenous infusion
45836443|NCT04019418|Dietary Supplement|Maltodextrin (carbohydrate)|A drink containing 300ml of water and 75g of maltodextrin
46091883|NCT05299411|Drug|Dried Ferrous Sulfate|iron supplement through oral intake
46091884|NCT02683538|Device|Separable cluster electrode (Octopus®)|Patients undergo RFA under ultrasound guidance, and separable cluster electrodes are used for RFA in monopolar switching mode, using multiple overlapping technique to create larger ablative zones.
46091885|NCT00956059|Drug|prednisone, FK506, MMF|1.in the initial 3 months，prednisone dosage is 30mg per day；in the following 4~6 months，prednisone dose decreased to 20mg per day，then tapered gradually to 10mg per day；2.the initial dosage of FK506 is 0.2mg/kg/d, twice per day，the maintenance dosage is adjust to the serum concentration of FK506 (is maintained at the level of 6~10μg/L)；3. the initial dosage of MMF is 1.0g, twice per day，then reduce to 0.75 g, twice per day after 3 months
46091886|NCT00956059|Drug|prednisone|In the initial 16~24 weeks，prednisone is given at full dose of 1mg/kg/d，then prednisone is tapered gradually，the whole course of treatment is 52 weeks
46091887|NCT04158427|Procedure|Faecal transplantation|Faecal transplantation from a healthy donor via colonoscopy
45836444|NCT04019418|Other|Exercise|30 minutes on a cycle ergometer working at 75% VO2 max
45836445|NCT04019418|Other|Rest|30 minutes laying on a bed
45836446|NCT04019418|Other|Water|A drink containing 300ml of water
46006085|NCT04612088|Behavioral|Cognitive Dissonance|"A blood sample will be taken before the first take of the multivitamins and at the end of the intervention to measure: Hemoglobin, Calcium, Phosphorous, Iron, Copper, Zinc, Vitamin D, and Folate.~During the three months of the intervention, the intervention group will receive one psycho-educative session and five Cognitive Dissonance sessions.~Several tests will be applied to the patients at the beginning of the program and after the sessions to measure: patient knowledge and adherence to the multivitamin, self-efficacy, self-care, and Psycho-pathological symptoms.~The No intervention group on the wait list will receive the five Cognitive Dissonance sessions after the three months of the study."
46006086|NCT04611737|Behavioral|Interviewing|Self-Determination Theory within motivational interviewing
46091888|NCT04158427|Procedure|Placebo faecal transplantation|Placebo faecal transplantation containing patient's own feces via colonoscopy
46091889|NCT02683460|Procedure|Patella resurfacing|
46091890|NCT02683460|Procedure|Patella retention|
46091891|NCT00956137|Procedure|Ultrasound guidance|ultrasound imaging
46091892|NCT00956137|Procedure|Manual palpation|Manual Palpation of vertebra
45836447|NCT00347022|Drug|Xenetix|300 mg of iodine/ml
45836448|NCT00347022|Drug|Visipaque|270 mg of iodine/ml
45836449|NCT04714866|Behavioral|Cognitive behavioral therapy for ADHD|CBT is a time-limited and structured approach that influences change in thoughts, feelings and behavior, leading to symptom changes.
45836450|NCT00350142|Radiation|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy will be performed using Trilogy Linear Accelerator
45836451|NCT00350142|Drug|Gemcitabine|Weekly Gemcitabine will be administered at 1000mg/m2 over 100 minutes
46091893|NCT04183946|Behavioral|Online Cognitive Behavioural Therapy|"The Willkommen Mutterglück program is an 8-session, interactive web-based CBT intervention for prenatal and postpartum depression and anxiety. The sessions are administered online via audio and video images. Each weekly session has a duration of 40-50 minutes during which the participants are asked to actively participate through exercises and quizzes.~A SCID interview for screening will be conducted by a trained clinical psychologist and an experienced psychiatrist from our outpatient clinic will verify the diagnosis. Screened and consented participants will answer baseline questionnaires, provide sociodemographic information and receive a private login to access the program. After completing the 2nd, 4th and 8th intervention session participants will fill in psychological questionnaires.~During the intervention, participants will be contacted three times by telephone by coaches (psychotherapists in training) who follow a manualized script."
46091894|NCT05299333|Other|Exercise|High repetition muscle endurance and strengthening exercises Walking
46091895|NCT04184258|Biological|Pooled mesenchymal stem cell|Pooled allogenic mesenchymal stem cell derived from olfactory mucosa
46091896|NCT04184258|Other|Standard treatment according to the Clinical protocols|Standard SLE treatment according to the Clinical protocols approved by the Ministry of healthcare of Republic of Belarus
46091897|NCT02683304|Biological|Plasma S100B levels at inclusion|Patients will have blood drawn to measure plasma S100B levels at inclusion.
46091898|NCT02683304|Device|Magnetic resonance imaging|If not performed under emergency conditions, patients will have an MRI on days 2-4.
46006087|NCT04582461|Device|multislice computed tomography|All patients will undergo a preoperative multiphasic multidetector CT scan before surgery.The unenhanced scan will be used to generate a CT reconstruction of the upper abdomen (from the diaphragm to the kidneys) with a 5mm thickness. Two different radiologists (D.F. and D.I.), blinded to patient information, measured total fat volume (TFV), visceral fat volume (VFV), and analyzed pixels with densities in the - 190 hounsfield units (HU) to - 20 HU range. the ratio between the density of the pancreas over the density of the spleen will be calculated and the maximum diameter of the pancreatic duct will be measured using the arterial phase in order to better identify the entire length of the duct.
46006088|NCT04611971|Drug|Benlysta|Benlysta injection will be administered subcutaneously.
46091899|NCT04010929|Procedure|Partial pulpotomy with laser+MTA|After removing caries, laser+MTA was applied to the exposed area on the pulp following bleeding control with 5.25% NaOCl.
46091900|NCT04010929|Procedure|Partial pulpotomy with MTA|After removing caries, MTA was applied to the exposed area on the pulp following bleeding control with 5.25% NaOCl.
46091901|NCT02682290|Other|Expectoration and measurement of sputum rheological properties|
46091902|NCT02683382|Device|Moisturizing Eye Product in Liquid Formula|Moisturizing Eye Product in Liquid Formula for dry eyes and skin around the eyes
46091903|NCT00956215|Drug|Aprepitant|80 mg tablet of Aprepitant with 50 ml of water 30 minutes before surgery
46091904|NCT00956215|Drug|Aprepitant placebo|80 mg placebo tablet with 50 ml of water no later than 30 minutes before induction of anesthesia.
46091905|NCT00640640|Device|Pascal Dynamic Contour Tonometer|Pascal Dynamic Contour Tonometer is an ocular device that is able to safely measure the intraocular pressure and the ocular pulse amplitude
46091906|NCT00640640|Drug|Ranibizumab|measure the effect of intravitreal 0.5mg/0.05ml ranibizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
46091907|NCT00640640|Drug|Bevacizumab|measure the effect of intravitreal 1.25mg/0.05ml bevacizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
46091908|NCT00956371|Drug|ONO-7746|5mg, 10mg, 20mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg QD/1 day
46091909|NCT00956371|Drug|ONO-7746|5mg, 10mg, 20mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg QD/1 day
46091910|NCT03973177|Drug|Phenol Injection|6% aqueous phenol 2.5 mL will be mixed with 0.5 mL iopamidol 300 and will be injected at each target site with live, pulsed fluoroscopy (5-8 seconds at each location) to observe the contrast dye-tagged phenol covering the lateral margin of the femur or tibia respectively on AP and lateral views. The needles will then be removed and band-aids placed.
46006089|NCT04611971|Drug|Candin|Candin will be administered intradermally along with NaCl solution.
46091911|NCT03973177|Drug|Methylprednisolone Injection|Methylprednisolone acetate 10 mg with 2 mL preservative saline and 0.5 mL iopamidol 300 will be injected at each of the 3 target sites with live, pulsed fluoroscopy (5-8 seconds at each location) to observe the contrast dye-tagged steroid mixture covering the lateral margin of the femur or tibia respectively on AP and lateral views; the needles will be removed and band-aids placed.
46091912|NCT00136136|Procedure|Registration of the bispectral index and spectral edge frequency|Registration of the bispectral index and spectral edge frequency
45678245|NCT01907516|Device|Cell phone-internet home glucose reporting system|Glucose monitoring via cell phone and internet using the Confidant Diabetes Management Application and the Confidant Connector.
45678246|NCT01907516|Behavioral|Voicemail home blood glucose reporting|Glucose monitoring via standard telephone and fax reporting.
45678247|NCT01931462|Device|Microwave pre-coagulation|The Certus 140™ system is used for microwave pre-coagulation of the tissue around the part of the kidney to be removed. This is done in place of the standard clamping to stop blood loss.
45836452|NCT00350142|Other|4D pancreatic protocol CT scan|Patients will undergo this imaging procedure prior to treatment for planning purposes.
45678248|NCT01931150|Drug|Topical Dapsone 5% Gel|
45678249|NCT01931150|Other|Moisturizer|The moisturizer for the study will be Vanicream™ Lite Lotion.
45678250|NCT01931150|Drug|oral antibiotics|
45678251|NCT01930214|Device|Percutaneous Coronary Intervention|Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).
46091913|NCT03951493|Combination Product|Zoledronic Acid 4Mg Solution for Injection + Hypo-fractured radiotherapy in stereotactic conditions|"All patients receive radiotherapy i.e. treatment on D1, D3 and D5.~Several radiotherapy schemes are possible:~20 Gy in 1 fraction;~27 Gy in 3 fractions of 9 Gy~30 Gy in 5 fractions of 6 Gy. All patients in the experimental arm receive an intravenous injection of at least 15 minutes of 4 mg zoledronic acid every month for 12 months.~The first injection must be made no more than 3 weeks before the first day of radiotherapy. It can be performed up to J1 of radiotherapy.~The injections will be carried out either at the patient's home by the nurses or in the investigator centre."
46006090|NCT00572208|Drug|Gabapentin group|"Gabapentin group:~Preoperative (2 h before surgery): Tablet Gabapentin 1200 mg (blinded)~st Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~nd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~rd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)"
46091914|NCT03951493|Radiation|Hypo-fractured radiotherapy in stereotactic conditions|"All patients receive radiotherapy i.e. treatment on D1, D3 and D5.~Several radiotherapy schemes are possible:~20 Gy in 1 fraction;~27 Gy in 3 fractions of 9 Gy~30 Gy in 5 fractions of 6 Gy."
46091915|NCT04184102|Behavioral|education|The intervention group received pre-surgery education and training on therapeutic exercises in addition to the routine hospital care. The educational material was developed by the principal investigator (PI) and included a power point and a booklet with instructions on the exercises as well as information about the surgery and what to expect after the surgery. The educational material was based on previous research and adopted to our population after consultation with a panel of experts including two nurses and three physicians. Eligible women were approached while waiting for their appointment with their surgeon. If they showed interest in participating they signed a consent form. The PI explained the study and what is involved in participating including the weekly phone calls for women in the intervention group. Participants were told that they will visited at home by the PI to assess their ROM and to fill out a questionnaire.
46006091|NCT04611386|Drug|computerized tomography|Anti Factor Xa level
46006092|NCT00572247|Behavioral|Psychiatric Rehabilitation Approach to Weight Loss|The use of psychiatric rehabilitation as a way to lose weight
46091916|NCT00961909|Drug|RO5095932|cohorts receiving multiple ascending doses, sc once weekly for 4 weeks
46091917|NCT00961909|Drug|RO5095932|dose titration to target dose, sc once weekly for 6 weeks
45459517|NCT05193890|Genetic|retrospective analysis of a panel result|retrospective analysis of a exome clinical solution
46091918|NCT00961909|Drug|metformin|stable dose
46091919|NCT00961909|Drug|placebo|sc once weekly for 4 weeks
46091920|NCT04115189|Drug|Sunitinib|Patients to receive Sunitinib as first line therapy for mRCC
46006093|NCT04611620|Behavioral|Cognitive Dysfunction|To fully characterize factors associated with cognitive dysfunction in BCS and CRC survivors that have cognitive concerns and (2) to fully characterize factors associated with psychoneurological symptom cluster in BCS and CRC survivors.
46091921|NCT03940729|Drug|Chlorhexidine Topical|In the Malmö needle exchange program, people who inject drugs (PWID) are repeatedly screened for S aureus colonization during one year. Those colonized will repeatedly shower with chlorhexidine during the following year. The infection frequency will be compared between the two periods.
45836453|NCT00350142|Radiation|FDG PET scan|Patients will have this imaging procedure along with a CT scan to map the tumor and facilitate treatment planning.
46091922|NCT02678234|Drug|Paracetamol, phenylephrine HCl, and vitamin C|One sachet is provided for each participant randomized to the Theraflu Aktiv powder for oral solution
46091923|NCT03892759|Other|Osteopathic Manipulative Therapy|A set of hands-on techniques used by Osteopathic Physicians for the assessment and treatment of somatic dysfunction.
46091924|NCT02679950|Genetic|Next generation genome sequencing|DNA will be extracted from each sample and assayed.
46091925|NCT03773653|Behavioral|BMT to be combined with BAT|Specifically, the participants will first receive 40 to 45 minutes of bilateral robotic priming using the BMT. After the robotic priming, participants will receive another 40 to 45 minutes training in tasks focusing on bilateral symmetric movements of both ULs.
46091926|NCT03773653|Behavioral|BMT to be combined with MT|Similar to the RT+BAT group, the participants will first receive 40 to 45 minutes of bilateral robotic priming delivered by the BMT with the same priming protocol. After bilateral robotic priming, participants will receive 40 to 45 minutes of mirror therapy.
46091927|NCT03773653|Behavioral|BMT to be combined with IOT|Similar to the RT+BAT group, the participants will first receive 40 to 45 minutes of bilateral robotic priming delivered by the BMT with the same priming protocol. After bilateral robotic priming, participants will receive 40 to 45 minutes of impairment-oriented training.
45459518|NCT01369472|Drug|Dilatrend SR capsule|single oral administration in period 1 or 2, 3 for each sequential group.
45473950|NCT03743701|Diagnostic Test|The method of transrectal ultrasound in В-mode|A linear transrectal ultrasonic sensor with a frequency of 9 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. In real time, the rectal wall and anatomical structures of the anal canal are evaluated using linear sections. The localization of the internal fistula opening, the course of the fistula relative to the fibers of the external sphincter and the presence or absence of cellular and wall plug is determined.
46091928|NCT04236713|Other|Dietary intervention 1|Limiting dietary exposure to ethylenediaminetetraacetic acid, erythorbate, propionate and related food additives; limiting eating out to a maximum of 2 days per week.
46091929|NCT04236713|Other|Dietary intervention 2|Limiting dietary exposure to nitrites, sulfites and related food additives; limiting eating out to a maximum of 2 days per week; limiting drinking wine to a maximum of 2 days per week.
46091930|NCT00961987|Other|Collaborative model|Patients will be referred (if necessary) to an obstetrician who will be co-located in the Maternity Centre and who will be part of the collaborative model of maternity care.
45836454|NCT00350220|Other|transfusion strategy|For the High Hb group; transfusions will be given to keep the Hb >13.0 g/dl
45836455|NCT00350220|Other|Low Hb transfusion group|RBCs will not be transfused unless the Hb < 9.0 g/dl
45836456|NCT01791348|Other|d2 test of attention|
46006094|NCT04611659|Behavioral|Motivational Interviewing and Educational Training (MIET)|Women in the intervention arm will receive a motivational interviewing intervention coupled with education on contraception and the potential for neonatal abstinence syndrome.
46006095|NCT04581837|Diagnostic Test|2D-speckle tracking echocardiography|Two-dimensional speckle tracking echocardiography (2D-STE) allows for an angle-independent evaluation of myocardial strain, and provides comprehensive information on LV myocardial contractility. Thus, 2DSTE is superior in detecting subtle deteriorations of contractility. we will take 2D speckle tracking views for LV and RV strain (4ch, 2ch, 3ch, RV modified view).
45678252|NCT01958294|Device|MICHI Neuroprotection System|
45678253|NCT01906346|Drug|Cocaine|Three active doses of cocaine will be made available for self-administration during experimental sessions.
46006096|NCT00563693|Device|ASV|Adaptive servo ventilator
46091931|NCT00961987|Other|Usual care|At present, if Maternity Centre patients require the specialized services of an obstetrician, the current standard of care is to refer them to obstetricians located offsite with no professional ties to the Maternity Centre
46091932|NCT00601640|Drug|Diclofenac Na gel|Given topically twice daily on days 1-90
46091933|NCT00601640|Drug|Eflornithine HCL ointment|Given topically twice daily on days 1-90
46091934|NCT02803541|Behavioral|12 day mainstream summer camp experience|see arm description
46091935|NCT00962143|Device|Achilles repair with OrthADAPT augmentation|Achilles repair with OrthADAPT augmentation
46091936|NCT00962143|Procedure|Achilles repair without OrthADAPT Augmentation|Achilles repair without OrthADAPT Augmentation
46006097|NCT00563693|Other|without Autoset CS2|without Autoset CS2
45836457|NCT03962400|Procedure|Reinforcement Learning|New computer based procedure for determining dose using a decision support tool
46006098|NCT00563732|Drug|Lecozotan|
46091937|NCT02805725|Drug|Phase 1: Trabectedin|"Phase I trial based on a dose escalating study design (3+3 traditional design) assessing four dose levels of Trabectedin in combination with metronomic cyclophosphamide (CP).~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)"
46091938|NCT02805725|Drug|Phase 2: Trabectedin|"Patients will be included in a single-arm phase II trial. Administrated dose will be the RP2D defined in the dose escalation part of the trial. The design will follow a two-stage Simon's optimal design.~All patients will be treated at the RP2D of trabectedin defined in the preliminary phase I trial with the same schedule as in the phase I trial."
46091939|NCT02805725|Drug|Phase 1: Cyclophosphamide|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.
46091940|NCT02805725|Drug|Phase 2: Cyclophosphamide|All patients will be treated with metronomic cyclophosphamide with the same schedule as in the phase I trial.
46091941|NCT00962221|Procedure|laboratory analysis|laboratory analysis
45678254|NCT01906346|Drug|Placebo|Placebo cocaine will be made available for self-administration during experimental sessions.
46006099|NCT00572364|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
46006100|NCT00563771|Drug|Rasburicase|
46006101|NCT00563810|Drug|MYO-029|
46006102|NCT04582032|Drug|Dexketoprofen (KETAVEL 50 mg/2 ml)|intravenous dexketoprofen (KETAVEL 50 mg/2 ml)
46006103|NCT04582032|Drug|Saline (Isotonic Saline Solution 0.9% )|intravenous 2 ml of saline
46091942|NCT02805569|Device|articulating stylet|patient who intubated with articulating stylet
46091943|NCT02805569|Device|conventional stylet|patient who intubated with conventional stylet
46091944|NCT05300191|Diagnostic Test|Effluent dialysate|Effluent dialysate samples evaluated for evidence of peritonitis
46091945|NCT02805491|Other|meconium|to evaluate internal exposure to pesticide
46091946|NCT02805491|Other|self questionnaires to parents|to evaluate external exposure to pesticide
46091947|NCT04182308|Other|dissection|Dissection of lisfranc ligament from 30 aldult Vietnamese cadavers's foot
46091948|NCT03549715|Drug|Durvalumab|1500 mg IV D1 every 28 days (2 doses for each patient)
46091949|NCT03549715|Drug|Tremelimumab|75 mg IV D1 every 28 days ((2 doses for each patient)
46091950|NCT03549715|Drug|MVAC Protocol|"Methotrexate 30 mg/m2 IV D1~Vinblastine 3 mg/m2 IV D1~Adriamycin (doxorubicin) 30 mg/m2 IV D1~Cisplatin 70 mg/m2 IV D1"
46091951|NCT02803385|Other|Continous Epidural Analgesia|continuous epidural infusion at rate of 5-8 ml /hr based on maximum allowable safe dose as per body weight. The pump settings will be set at 0.1 ml per bolus with lockout interval of 20 minutes. Cross over to other group will occur after 36hours.
45678255|NCT01958060|Drug|BI 1034020|intravenous part
45678256|NCT01958060|Drug|Placebo to BI 1034020|intravenous part
45678257|NCT04618874|Diagnostic Test|Rapid on-site evaluation|Rapid on site evaluation performed with an MGG quick stain (Bio-Optica, Milano, Italy).
45678258|NCT04645004|Drug|Aspirin 81Mg Non-enteric coated Tab|one tab daily
45678259|NCT01929980|Drug|Bortezomib|
45678260|NCT04629950|Drug|Rimegepant|Active Agent
45678261|NCT04629950|Drug|Placebo|Placebo Comparator
45678262|NCT01363076|Drug|Ketorolac Tromethamine|Single IN dose of 15 mg ketorolac tromethamine for subjects weighing <50 kg.
45678263|NCT01363076|Drug|Ketorolac Tromethamine|Single IN dose of 30 mg ketorolac tromethamine for subjects weighing ≥50 kg.
45836458|NCT03962400|Procedure|Heath Care Provider|Warfarin dose will be determined by a qualified health care provider
45836459|NCT04588272|Device|DualGuard|DualGuard device (FlexiCare) which incorporate an endoscopy bite block with oxygen delivery and CO2 monitoring from both the mouth and nose simultaneously.
46006104|NCT00563849|Drug|Leflunomide|concomitantly leflunomide (no loading dose, 10 mg/day) and methotrexate (starting at 7.5 mg/week and titrating up to 15 mg/week) for 20 weeks.
46006105|NCT04581876|Drug|raltitrexed for injection|Patients receive raltitrexed 2mg/m2 (iv, 15min) on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
46006106|NCT04581876|Drug|nab-paclitaxel|Patients receive nab-paclitaxel at 125 mg/m2 on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
46006107|NCT00563888|Behavioral|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
46006108|NCT04579458|Procedure|Collection of tears and saliva.|Saliva and ocular tears will be collected.
46006109|NCT04611932|Drug|CKD-330 Tab. and D090 Tab.|1T
46006110|NCT04611932|Drug|CKD-333 Tab.|1T
46006111|NCT00563927|Procedure|Conventional RT|
46006112|NCT00563927|Drug|Cisplatin|
46006113|NCT00563927|Drug|5-fluorouracil|
46006114|NCT00572520|Behavioral|Weight loss treatment|Over 2 years, this treatment involves a total of 26 group visits and 10 individual visits with a health education counselor. Group visits, led by a registered dietitian and a licensed exercise physiologist, will target diet and physical activity.
46006115|NCT00572520|Behavioral|Behavior therapy for depression|Behavior therapy for depression will be delivered by a trained behavior therapist. Participants receiving behavioral counseling will learn about depression, links between activity and mood, and will be asked to keep a diary of moods and activities.
46006116|NCT00572520|Behavioral|Health education counseling|Health education counseling will be delivered by a trained health education counselor. Participants receiving health education will learn about women's health topics and receive tips on staying healthy and preventing disease.
46006117|NCT01150123|Biological|Group B streptococcus (GBS) vaccine- low dose|
46006118|NCT01150123|Biological|Group B streptococcus (GBS) vaccine- High dose|
46006119|NCT01150123|Biological|Placebo- Saline|
46006120|NCT00572559|Drug|Vancomycin|1 gram IV every 12 hours for 7 to 14 days
46006121|NCT00572559|Drug|Linezolid|600 mg every 12 hours (intravenously [IV] for a minimum of the first 4 days followed by a switch to oral if tolerated by patient) for a total duration of 7 to 14 days
46091952|NCT02803385|Other|Patient Controlled Epidural Analgesia|patient controlled epidural analgesia in form of Patient Controlled Analgesia pumps with continuous rate of 5-8ml/hour & demand dose of 2-3 ml p.r.n with a lock out interval of 20 minutes based on maximum allowable safe dose as per body weight .The group will have a cross over at 36 hours postop.
45459519|NCT01373996|Device|Wireless invasive blood pressure monitoring (Hybymed® Wireless IBPM System)|"The readings of invasive arterial pressure were obtained from 2 identical pressure transducers, connected to a common arterial line via a Y connector. Data was collected from one transducer via a direct cable connection and from the second transducer via wireless transmission of the signal to the patient's bedside monitor using the HMW 10 Wireless System.~A comparison of data received by patient's bedside monitor from the two transducers was done (standard connection vs. wireless connection), as well as a comparison of data collected by the transmitter and data received by the receiver of the HMW 10 Wireless System."
46006122|NCT04611464|Drug|Misoprostol|Misoprostol is a PGE1 analog
46091953|NCT00958321|Procedure|computed tomography|
46006123|NCT04611347|Drug|CBD|Topical CBD application for thumb basal joint osteoarthritis.
46091954|NCT00958321|Radiation|3-dimensional conformal radiation therapy|
46006124|NCT04611347|Drug|Shea Butter|Placebo Shae Butter for comparison
46091955|NCT00958321|Radiation|fludeoxyglucose F 18|
46091956|NCT00958321|Radiation|radiation therapy treatment planning/simulation|
46006125|NCT00572598|Drug|4- [F-18] fluoropaclitaxel|4- [F-18] fluoropaclitaxel, <84 micrograms, <10 mCi, IV followed by PET/CT imaging
46006126|NCT04611776|Drug|Atezolizumab|Atezolizumab will be administered intravenously during the induction phase and the maintenance phase.
46006127|NCT04611776|Drug|Placebo|Placebo will be administered intravenously during the induction phase and the maintenance phase.
46091957|NCT02679716|Other|MRI of the cerebral arteries|MRI of the cerebral arteries is performed
46091958|NCT02803463|Procedure|open appendectomy with peritoneal closure|open appendectomy with peritoneal closure under general anesthesia for acute appendicitis
46091959|NCT02803463|Procedure|open appendectomy without peritoneal closure|open appendectomy without peritoneal closure under general anesthesia for acute appendicitis
46006128|NCT04611776|Drug|Carboplatin|Carboplatin will be administered intravenously during the induction phase.
46006129|NCT04611776|Drug|Cisplatin|Cisplatin will be administered intravenously during the induction phase.
46006130|NCT04611776|Drug|Pemetrexed|Pemetrexed will be administered intravenously during the induction phase.
46006131|NCT04611776|Drug|Gemcitabine|Gemcitabine will be administered intravenously during the induction phase.
46091960|NCT00642434|Drug|carvedilol|variable
46091961|NCT00642434|Drug|metoprolol|variable
46091962|NCT00958399|Dietary Supplement|Placebo|Low fiber muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
46091963|NCT00958399|Dietary Supplement|Resistant Starch|25 g resistant starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
46091964|NCT00958399|Dietary Supplement|Resistant starch + soluble fiber|25 g fiber as resistant starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
45459520|NCT03057860|Other|No study intervention|
46091965|NCT00958399|Dietary Supplement|Fiber made from corn starch|25 g fiber made from corn starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
46091966|NCT00958399|Dietary Supplement|Fiber made from corn starch + soluble fiber|25 g fiber as a fiber made from corn starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
45459521|NCT01369550|Other|SDA soybean oil-containing foods|3 servings per day of foods containing 500 mg each SDA soybean oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day.
45459522|NCT01369550|Other|High-oleic sunflower oil containing foods|3 servings per day of foods containing 500 mg high-oleic sunflower oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day
45459523|NCT01369550|Other|Eicosapentaenoic acid|3 x 500 mg per day of Eicosapentaenoic acid as an ethyl ester in softgels plus 3 servings per day of high-oleic sunflower oil-containing foods
45678264|NCT01929044|Drug|654-II (anisodamine)|10mg injection
46006132|NCT04611776|Drug|Paclitaxel|Paclitaxel will be administered intravenously during the induction phase.
46006133|NCT00572637|Drug|CEP-18770|Administered as intravenous infusion on days 1, 4, 8, and 11 of a 21-day cycle up to 6 cycles. Starting dose 0,1 mg/sqm
46006134|NCT04611308|Other|C1q tumor necrosis factor-related protein 6 levels|C1q tumor necrosis factor-related protein 6 is a tumor marker
46006135|NCT01149655|Drug|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
46006136|NCT01149655|Drug|Aripiprazole|Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
46006137|NCT00575406|Drug|Rituximab|i.v., 375 mg/m2, d0 or d1 of each treatment cycle
46006138|NCT00575406|Drug|Cyclophosphamide|i.v., 750 mg/m2, d1 of each treatment cycle
46006139|NCT00575406|Drug|Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
46006140|NCT00575406|Drug|liposomal Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
46006141|NCT00575406|Drug|Vincristin|i.v., 2mg, d1 of each treatment cycle
46006142|NCT00575406|Drug|Prednisolone|p.o., 100mg, d1 - d5 of each treatment cycle
46006143|NCT00564005|Other|Constraint-induced therapy (CIT)|restraint of the unaffected arm and practice of the affected arm
46006144|NCT00564005|Other|Bilateral arm training (BAT)|bilateral symmetric, repetitive arm training
46006145|NCT00564005|Other|Combined therapy (CT)|combined different treatment approaches
46006146|NCT00564005|Behavioral|Control intervention|Conventional treatment program
46006147|NCT01149538|Drug|Choline bitartrate|Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix.
46006148|NCT01149538|Dietary Supplement|Placebo for choline bitartrate|Placebo for choline bitartrate, administered daily in fruit-flavored drink mix.
46006149|NCT02884063|Procedure|NGS reading for Media Free DNA|NGS reading for Media Free DNA instead of blstomer biopsy
46006150|NCT04601207|Drug|Cannabis Preparation|Dosed as a single oral dose
46006151|NCT04601207|Drug|Cannabis Preparation|Dosed as a single oral dose
46006152|NCT01149460|Drug|Valacyclovir|Test 1000 mg Tablet
46006153|NCT01149460|Drug|Valacyclovir|Reference Listed Valacyclovir 1000 mg Tablet
46091967|NCT02805413|Other|Détermination and comparison of blood pressure|Rebreathings will be performed every parabola (2, 4, 6, 8, 10…). Ultrasound measurements will be performed during the remaining parabolas (1, 3, 5, 7, 9…). The procedure consists of a fixed breathing frequency of 20 breaths per minute and an exact triggered start point for the measurements. . Central blood pressure measurements, finger blood pressure measurements, impedance cardiography, carotid plethysmography and phonocardiography will be performed continuously during the flights. The breaks between parabolas 10 and 11 and 20 and 21 will be used to change subjects, which takes approximately 5 minutes.
46091968|NCT04183478|Drug|K-001|K-001 is an antitumor active substance (peptidoglycan) which is prepared from the fermentation product of marine microorganism. K-001 is the Chinese first class new drug and get patent licensing in China, America and Japan.
46091969|NCT04183478|Other|placebo|Placebo which looks the same as K-001 in apparence
46091970|NCT05352373|Dietary Supplement|calcium|calcium carbonate
46091971|NCT05352373|Dietary Supplement|placebo|sodium bicarbonate
46091972|NCT04181528|Device|Total knee arthroplasty implant|In patients undergoing unilateral TKA, decide the implant of TKA (anatomically aligned or conventional TKA implant) will be decided using ramdon number table
46091973|NCT02805335|Device|KTFIX PLUS|
46091974|NCT02677610|Drug|MSRD-100|MSRD-100 is a topical gel.
46091975|NCT02677610|Drug|Vehicle|Vehicle is a topical gel without the active ingredient in MSRD-100
45459524|NCT03559530|Drug|Antimicrobial|Antimicrobial therapy according to A. baumannii susceptibility profile
45678265|NCT01929044|Drug|Buscopan® (hyoscine butylbromide)|20mg injection
45678266|NCT01903460|Drug|LUM001|
45678267|NCT01903460|Drug|Placebo|
46006154|NCT00575484|Drug|Hypertonic saline, then oral sodium chloride|2mL/kg hypertonic saline (4.4% NaCl if serum sodium </=135, else 2.8% NaCl) infused over 30min BID and dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) until patient is switched to oral loop diuretic. After switch to oral diuretic, subject will receive oral 0.75gm sodium (NaCL) capsule dosed BID with loop diuretic (latter dose per treating physician) until 60d after discharge.
46006155|NCT00575484|Drug|Normal saline, then oral placebo capsule|20mL normal saline infusion X 30min BID dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction. After switch to oral diuretic, begin oral placebo capsule BID, dosed with loop diuretic (dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction.
46006156|NCT00572754|Procedure|Circumcision|Circumcision by tying a ligature around the foreskin.
46006157|NCT04600739|Procedure|TAVI|Replacement of the aortic valve using a biological prosthesis that is inserted via a catheter.
46006158|NCT04579614|Behavioral|The Impact of Performance Feedback and Variable Goal Setting on Flu Vaccination Success Rates of Providers|"A given provider will be involved in the study for a maximum of 6 months. This will involve, at the most frequent, the delivery of weekly performance feedback.~The performance feedback will be delivered using standard approaches already in place in the organization and there will not be a period of seeking out participants for enrollment.~Providers will receive performance feedback bi-weekly for the duration of the study period."
46091976|NCT02803775|Device|CRT Algorithm|Programming based on Electrogram measurement
46091977|NCT02677532|Drug|Paracetamol|1 g every 8 hours
46091978|NCT02677532|Drug|Levobupivacaine wound infiltration|Wound infiltration with 10 ml levobupivacaine 0.5%
46091979|NCT02677532|Drug|Levobupivacaine epidural bolus|Epidural bolus of 10 ml 0.25% levobupivacaine
46091980|NCT02677532|Drug|Sufentanil epidural bolus|Epidural bolus of 0.15 mcg/kg sufentanil
46091981|NCT02677532|Drug|Morphine|Intravenous slow bolus of 10 mg morphine
46091982|NCT02677532|Device|Epidural catheter placement|Thoracic epidural catheter placement in the T7-T8 or T8-T9 intervertebral space
46091983|NCT02677532|Device|Wound infusion catheters placement|Pre-peritoneal placement of two catheters for wound infusion
46091984|NCT02677532|Drug|Levobupivacaine plus sufentanil epidural infusion|Epidural infusion of levobupivacaine 0.12% plus sufentanil 0.4 mcg/ml at 4 ml/h for 48 h
46091985|NCT02677532|Drug|Levobupivacaine wound infusion|Wound infusion with levobupivacaine 0.25% at 4 ml/h for 48 h
46091986|NCT02678078|Procedure|Analyzing biopsy samples|Analyzing biopsy samples that is preformed as part of the patient treatment.
46091987|NCT02804945|Biological|Mesenchymal Stem Cells (MSCs)|Participants receive a maximum dose of 3 x 10^6 cell/Kg by vein one time on Day 1.
46091988|NCT00641810|Behavioral|Caffeine reduction|Reduction in daily caffeine consumption from usual amounts to none.
46091989|NCT02803151|Radiation|Stereotactic ablative radiotherapy|SABR with 36 to 45 Gy in six fractions to the defined target volume with met organ-at-risk constraint criteria using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given once per day, 2-3 fractions per week with no more than 2 consecutive daily fractions, over 2 to 2.5 weeks.
46091990|NCT04033874|Other|kangaroo care|kangaroo care
46091991|NCT04033874|Other|holding on the mother's lap|holding on the mother's lap
46091992|NCT04033874|Other|white noise listening|white noise listening
46091993|NCT04033874|Other|ambient sound listening|ambient sound listening
46091994|NCT02805101|Drug|Biodentine|Biodentine is going to be used as the sealing agent for the perforation.
45459525|NCT05193734|Drug|Pertagen®|"Schedule:~Group Pertagen will receive two doses of Pertagen®. (one vaccination on Day 0 and 6 months later for each volunteer.)~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle."
45678268|NCT01957202|Drug|FF/levocabastine|FF/levocabastine (25mcg/50 mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
46091995|NCT02805101|Drug|MTA|MTA is going to be used as the sealing agent for the perforation.
46091996|NCT02802995|Drug|PRP/thrombin mixture|Mixture of platelet rich plasma and thrombin applied topically on the wound surface
46091997|NCT00910052|Device|Tisseelä fibrin sealant|Fibrin sealant applied intraoperatively
46006159|NCT04600778|Other|placebo|placebo
46006160|NCT04600778|Drug|Cavosonstat 5 mg|Cavosonstat (low dose)
46006161|NCT04600778|Drug|Cavosonstat 10 mg|Cavosonstat (medium dose)
46006162|NCT04600778|Drug|Cavosonstat 25 mg|Cavosonstat (high dose)
46091998|NCT03907319|Device|SIS System|Software technology for visualization of anatomical structures in the brain
46006163|NCT00572871|Other|plyometric exercise|single bout of plyometric exercise
46006164|NCT00572871|Other|resistance exercise|single bout of resistance exercise
46091999|NCT04181216|Device|Anatomically aligned total knee arthroplasty implant|In same patient, one total knee arthroplasty using anatomically aligned total knee arthroplasty implant Other total knee arthroplasty using conventional total knee arthroplasty implant
46092000|NCT04235933|Biological|Tai Ai(RC18) 80mg|The patient received one treatment of RC18 80mg in the test group
46092001|NCT04235933|Biological|Tai Ai(RC18) 160mg|The patient received one treatment of RC18 160mg in the test group
46092002|NCT04235933|Biological|RC18 240mg|The patient received one treatment of RC18 240mg in the test group
46092003|NCT02677454|Device|Flash Glucose Monitor|
46006165|NCT00572871|Other|No exercise|Will not do any exercise
46006166|NCT04600583|Device|Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA)|All patients, regardless of the alignment arm they are randomized to will undergo a primary total knee arthroplasty with the Triathlon® Total Knee System using Mako Robotic-Arm Assisted Technology. The surgical intervention will be administered by a physician wherein the expected duration of surgery is approximately 1.5 hours.
46006167|NCT04600700|Device|Clinical Decision support system (CDSS) for inotrope weaning|A Clinical Decision Support System informed by 6-hour rolling average IDO2, will be utilized during the intervention phase of the study. The CDSS tool will be introduced in a stepped-wedge pattern. Randomization will occur by center, with time of introduction being staggered, with each center ultimately receiving the CDSS intervention. Teams in the CICU make rounds twice per day. During each of the rounds (AM and PM), the team will refer to the CDSS and the 6-hour average IDO2 (as reported on the T3 platform at the bedside computer). The clinical team will consider the CDSS in decision making around inotrope weans. If the decision is made to not utilize IDO2, the bedside clinician will complete a brief survey with rationale.
46006168|NCT00575523|Drug|Atropine|Atropine 0,5mg is administered once intravenously immediately before starting percutaneous ethanol instillation.
46006169|NCT00575523|Drug|Placebo|1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
46006170|NCT04600661|Other|Traditional exercise therapy|Neuromuscular training
46006171|NCT04600349|Behavioral|Identity Oriented Psychotrauma Therapy|The method will be presented to the group at the beginning of the first group session. Then every person from the experimental group will set an Intention connected to the emotional or physical difficulties they experience in their lives. Then the person will choose for every word in their Intention, a representative from the support group who will resonate with that word. The focus of every Intention should be the current illness and the traumatic or stressful events which happened before the disease onset.
46006172|NCT04600349|Drug|Treatment as Usual|The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
46006173|NCT01149421|Drug|LY2189265|Administered as a subcutaneous injection once weekly for 26 weeks
46006174|NCT01149421|Drug|Placebo|Administered as a subcutaneous injection once weekly for 26 weeks
46092004|NCT02677376|Other|18F-Sodium Fluoride (NaF)|NaF is a tracer (dye) that will show changes to the cancer in bones. By using this tracer with PET/CT imaging, our ability to evaluate and measure changes in bone lesions could be greatly improved. Participants will have a NaF PET/CT scan within 14 days prior to starting enzalutamide. All subjects will undergo a second NaF PET/CT scan after taking enzalutamide for 12 weeks. The NaF PET/CT obtained at week 12 will be compared to the first NaF PET/CT to identify a bone tumor that is responding (shrinking) and a bone tumor that is not responding (not shrinking).
46092005|NCT02800889|Drug|Pixantrone|Pixantrone
46092006|NCT04183400|Behavioral|Safety Awareness For Empowerment (SAFE)|SAFE is a mindfulness-based cognitive-behavioral intervention that aims to build risk-related attention skills.
46092007|NCT02803073|Drug|Testosterone|Testosterone Cypionate Intramuscular injections will be administered weekly
46092008|NCT02803073|Drug|Normal Saline|Normal Saline Intramuscular injections will be administered weekly
46092009|NCT04181372|Drug|Anlotinib hydrochloride|Anlotinib hydrochloride was given 12mg once daily for two weeks, stop for one week, each 3-week cycle for 2 cycles.
46006175|NCT00575562|Drug|KRN330|Open-label, dose-escalation study of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer
46006176|NCT04600310|Device|ULTRAPREP|ULTRAPREP device for reducing OR prep times.
46092010|NCT04181372|Drug|platinum-based chemotherapy medicine|(1)Carboplatin was given dosed to an AUC of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m^2 ,i.v. on day 1, pemetrexed was given 500 mg/m^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m^2 i.v. on day 1; docetaxel was given 75 mg/m^2 i.v. on day 1 ,each 21-day cycle for 2 cycles.
46092011|NCT02800967|Dietary Supplement|Pure Aronia juice|Pure Aronia juice with appx. polyphenols content of 1000 mg gallic acid equivalents/100ml
46006177|NCT04600310|Device|No Intervention|Conventional skin preparation technique
46006178|NCT04600232|Diagnostic Test|Alere TB-LAM|Subjects also undergo clinical evaluation including CT, sputum smear, Gene Xpert and mycobacterial culture.
46092012|NCT02800967|Dietary Supplement|Aronia juice-based beverage|Aronia juice-based beverage with appx. polyphenols content of 250 mg gallic acid equivalents/100ml, obtained as a blend of ¼ vol. of pure Aronia juice and ¾ vol. of placebo beverage.
45459526|NCT05193734|Drug|Revaxis®|"Schedule:~Group Control will receive one dose of Revaxis® on Day 0 followed by 1 dose of Pertagen® 6 months later for each volunteer.~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle."
45459527|NCT05193656|Diagnostic Test|Al_bladder|Detection of bladder tumor with help of Artificial intelligence
45459528|NCT02740972|Drug|NS-065/NCNP-01|
46006179|NCT03453879|Other|no intervention|No intervention - only observation of teams delivering acute obstetric care
46006180|NCT04600193|Other|Diet containing organic phosphate|The patients will be receiving a 5 days diet containing organic phosphate
46006181|NCT04600193|Other|Diet containing inorganic phosphate|The patients will be receiving a 5 days diet containing inorganic phosphate
46092013|NCT02800967|Dietary Supplement|Placebo beverage|A polyphenol-free formulation with matched nutrient composition (sugars, vitamins, minerals) and similar sensory characteristics to active interventions
46092014|NCT00922532|Drug|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be administered continuously starting at 20ppm through an INOvent delivery system for up to 14 days.
46092015|NCT00922532|Drug|Placebo|Nitrogen gas will be administered in the same manor as the experimental drug
46092016|NCT02800577|Device|General Practitioner Emotional Test Battery (GP-ETB)|The GP-ETB (Class I Medical Device) comprises three computer tasks. In the first task, the 'Emotional Categorisation Task' patients are given forty words that might be used to describe them and indicate whether they would 'like' or 'dislike' to be described by a particular word. In the 'Facial Expression Recognition Task' patients are asked to judge whether a briefly displayed face is expressing one of six emotions. In the final task, the 'Emotional Recall Task', the patient should recall as many words as they can from the series of words that were presented in the first task. The patients perform these tasks once before antidepressant treatment and again seven days after treatment begins.
46092017|NCT04236089|Device|robotic hand|mirror therapy with robotic hand
46092018|NCT02681978|Drug|Ivabradine|Ivabradine 5 mg twice daily
46092019|NCT02681978|Drug|Standard medical therapy|Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
46092020|NCT05662904|Biological|Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion|CD33-deleted CD34+ hematopoietic stem cells derived from the initially matched family donor
46092021|NCT05662904|Drug|Gemtuzumab Ozogamicin|Intrapatient intra-individual dose escalation Level 0: GO day 1 Level 1: GO day 1, day 4 Level 2: GO day 1, day 4, day 7 with repetition after 21 to 28 days up to 84 days.
46092022|NCT02800733|Dietary Supplement|Saffron|20 patients with mild to moderate GAD, diagnosed by Diagnostic and Statistical Manual of Mental Disorders-IѴ (DSM-IѴ) who receive sertraline will randomly receive saffron (450 mg) as an add-on therapy on daily bases for 6 weeks. Hamilton Anxiety Rating Scale (HAM-A) will use to assess the effect of treatment.
46092023|NCT02800733|Dietary Supplement|placebo|20 patients with mild to moderate GAD who receive sertraline will receive placebo too
46092024|NCT00642512|Drug|dronabinol|10 - 20 mg
46092025|NCT00642512|Drug|ondansetron|8 - 16 mg
45459529|NCT02740972|Drug|Placebo|
45459530|NCT05193578|Drug|Semaglutide, 1.34 mg/mL|Semaglutide, 1.34 mg/mL
45459531|NCT05193578|Other|Placebo|Semaglutide-Placebo
45459532|NCT04834076|Diagnostic Test|ELISA|ELISA is is a test that detects and measures toxoplasma IgG and IgM antibodies in blood.
45459533|NCT04834076|Diagnostic Test|PCR|Polymerase chain reaction (PCR) is a method widely used to rapidly make millions to billions of copies of a specific DNA sample, allowing scientists to take a very small sample of DNA and amplify it to a large enough amount to study in detail.
45836460|NCT03860610|Diagnostic Test|Muscle strength test|Muscle strength in knee flexion and extension and hip abduction will be tested using using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA)
46006182|NCT00575601|Drug|SIMVASTATIN|20 mg/day,po,for two months until the day of hCG injection placebo pills as like as simvastatin will be used
46006183|NCT04600271|Drug|Crystalloid Solutions|exposure
46006184|NCT04600271|Drug|Colloid Blood Volume Expanders|exposure
46006185|NCT04600271|Other|blood replacement|exposure
46006186|NCT04600271|Drug|Diuretic|exposure
46006187|NCT04600271|Drug|noradrenaline|exposure
46006188|NCT04600271|Drug|Non-Steroidal Anti-Inflammatory Analgesics|exposure
46006189|NCT00575640|Drug|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
46006190|NCT00575679|Behavioral|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
46006191|NCT04600388|Device|Nerivio|Nerivio Remote Electrical Neuromodulation (REN) device
46006192|NCT04579887|Other|Brain changes triggered by PH induction in Parkinson's disease patients with presence hallucinations|Parkinsonian patients will undergo a two distinct experimental sessions, conducted in two separate days. In day 1, they will complete a series of validated and lab-tailored clinical evaluations, alongside with semi-structured interviews. These tests are designed to assess, the extent of the movement disorder, the predominance of positive symptoms and presence hallucination, potential cognitive impairment, amongst other relevant measures, for sleep assessment, loneliness, apathy and depression. In day 2 patients will perform the described robotic manipulation task in the MRI.
46006193|NCT04599959|Diagnostic Test|Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol|Kylt® for detection/confirmation of SARS-CoV-2 cobas® SARS-CoV-2 (PCR) test TaqPath™ COVID-19 CE-IVD RT-PCR kit
46092026|NCT00642512|Drug|dronabinol/ondansetron|10 - 20 mg/8 - 16 mg
46092027|NCT00642512|Drug|placebo|placebo
46092028|NCT03894059|Other|Educational Intervention|Additional training provided to ambulance telecommunicators in participating sites to help increase recognition of agonal breathing in the presence of out-of-hospital cardiac arrest.
46006194|NCT04579731|Drug|Lactitol Monohydrate|Patients with lower urinary tract dysfunction and assumed to have constipation were placed on lactitol monohydrate 10 g for 8 weeks, and had re-evaluated.
46092029|NCT02802683|Drug|Bupivacaine|spinal anesthesia with hyperbaric bupivacaine
46092030|NCT02802683|Drug|Levobupivacaine|spinal anesthesia with isobaric levobupivacaine
46092031|NCT02802683|Drug|Phenylephrine|continous infusion of phenylephrine
46092032|NCT02802683|Drug|normal saline|continous infusion of normal saline
46092033|NCT00641264|Drug|Omeprazole|
45459534|NCT04834076|Diagnostic Test|Sequencing|DNA sequencing is a laboratory technique used to determine the exact sequence of bases (A, C, G, and T) in a DNA molecule. The DNA base sequence carries the information a cell needs to assemble protein and RNA molecules. DNA sequence information is important to scientists investigating the functions of genes.
45678269|NCT01957202|Drug|FF|FF (25mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
45836461|NCT03860610|Diagnostic Test|Dynamic stability test during level and uphill walking|Instrumented gait analysis on an overground walkway with two embedded force plates (Kistler force plate 9260AA6, Kistler AG, Winterthur, Switzerland; sampling rate 2400 Hz) and on a treadmill with an embedded plantar pressure plate (h/p/cosmos, Zebris FDM-T, Isny, Germany)
46092034|NCT00641264|Behavioral|Quality of Life questionnaire|
46092035|NCT05664308|Other|Clinical follow-up (ECG)|Clinical follow-up with a consultation at the University Hospital at 3, 6, and 12 months, with an ECG at each visit.
46092036|NCT05664308|Other|Ongoing monitoring|"Once operated, patients will be monitored remotely via a computerized data transfer routine anonymized by the WITHINGS software, based on the data from the watch.~It's contractually agreed with WITHINGS that the transmissions will be scheduled and transmitted weekly to the center."
45836462|NCT03860610|Diagnostic Test|Postural stability test|The overall stability index (OSI) will be assessed using the Biodex Balance System SD (Biodex Medical Systems, Inc., Shirley, NY, USA) and is determined by the variance in platform displacement from the horizontal plane.
46006195|NCT00565487|Drug|Capecitabine, Tarceva|Capecitabine is a self-administered (oral) medication & will be dose escalated and administered in four dose levels: Level I - 600 mg/m2 bid; Level II - 700 mg/m2 bid; Level III - 825 mg/m2 bid; Level IV - 925 mg/m2 bid. Tarceva will be self-administered(orally) in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single agent Tarceva 100 mg/day. Treatment of Capecitabine & Tarceva is continued daily until the completeness of the radiation or toxicity.
45459535|NCT03486574|Diagnostic Test|Positive result from pathological test|Presence/absence of gastric cancer will be evaluated by upper gastroendoscopy or results of pathological test
46092037|NCT04181294|Behavioral|Family meetings using time limited trials as default ICU communication and care planning approach|Providers will be trained using didactics, focus groups, and simulations using actors as family members. A TLT protocol and checklist will be used to facilitate family meetings. A coordinator will schedule family meetings. Routine feedback sessions will be held with the local champions.
46092038|NCT04181294|Behavioral|Usual practice|Baseline practice of ICU communication and care planning
46092039|NCT05484167|Drug|Natesto Nasal Product|Nasal Gel used for 90 days then crossed over to placebo gel
46092040|NCT05484167|Drug|Placebo|A nasal gel with no active ingredients
46092041|NCT02800031|Device|Transvaginal ultrasonography|
45459536|NCT01375556|Drug|Ethanol|
45459537|NCT03486496|Drug|gefitinib|Patients will be treated with gefitinib, 250 mg p.o., daily
45459538|NCT03486496|Drug|Berberine|Patients will be treated with Berberine, 50 mg p.o., tid
45459539|NCT03124784|Device|RD Disposable Sensors|Noninvasive pulse oximeter sensor
45459540|NCT02410330|Procedure|Therapeutic ultrasound with 20 usec|A custom designed high mechanical index (MI) impulses at 4-20 usec and >1.0 mechanical index designed for the 1.7 MHz S5-1 transducer
46092042|NCT02679794|Behavioral|Egg consumption|Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil with 100g (2 large eggs) of whole eggs
46092043|NCT02679794|Behavioral|Control|Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil.
46006196|NCT03453801|Biological|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine): The pediatric dose (6-35 months) will be supplied in a prefilled, single dose syringe, 0.25 mL (no preservative). Each 0.5 mL dose of Fluzone® Quadrivalent (36 months-adult) will be supplied in a prefilled, single dose syringe, 0.5 mL (no preservative). Both formulations given IM.
46006197|NCT03453801|Biological|FluMist®|FluMist® Quadrivalent: live, attenuated influenza virus vaccine quadrivalent, given by intranasal spray
46092044|NCT02800187|Device|ESWT|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs).
46092045|NCT04183322|Biological|13-valent pneumococcal conjugate vaccine|
46092046|NCT02800343|Procedure|routine administration of 0.9% sodium chloride|0.9% sodium chloride is used as the wash and suspension solution for red blood cells during the Intraoperative red blood cell salvage (ICS) procedure.
46092047|NCT02679638|Other|Factors and perceptions questionnaire|A detailed questionnaire inquiring about demand factors, supply factors and perceptions affecting patients' treatment choices in 5 key decision points: participation role in the decision making process, hospital choice, treatment regimen choice, surgical extent and surgeon choice.
46092048|NCT02679638|Other|Qualitative interview|Depth interviews with 20 breast cancer patients, 2 spouses and 3 staff members.
46092049|NCT02799875|Other|Higher permissive hypercapnia|"pCO2 ≥ 60mmHg with an upper limit ≤ 75mmHg;~pH ≥ 7.20 from a capillary or arterial blood sample;"
46006198|NCT04600115|Drug|Adenosine|Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
45678270|NCT01957202|Drug|levocabastine|levocabastine (50mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
46092050|NCT02799875|Other|Lower Permissive Hypercapnia|"pCO2 ≥ 40mmHg with an upper limit ≤ 55mmHg;~pH ≥ 7.25 from a capillary or arterial blood sample;"
46092051|NCT04181918|Behavioral|AOT|During action observation, participants observe different daily actions (e.g. reading a newspaper; drinking an espresso) divided into up to four motor segments.
46006199|NCT04600115|Drug|Regadenoson|0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
46006200|NCT04600115|Drug|O-15 labeled radioactive water|O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
46092052|NCT04181918|Behavioral|MI|During motor imagery, participants imagine themselves performing the same daily actions as in AOT in the absence of motor output
46092053|NCT02802917|Drug|SPF 50 Y49 091 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
46092054|NCT02802917|Drug|SPF 50 X15 158 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
46092055|NCT02802917|Drug|SPF 50 X15 160 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
46092056|NCT02802917|Drug|SPF 50 X57 162 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
46092057|NCT02802917|Other|J & J baby shampoo, X46 046 (control)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
46092058|NCT00642044|Procedure|Corneal Collagen Crosslinking|UV light and Riboflavin eyedrops every 5 minutes for 30 minutes.
45678271|NCT01957202|Drug|Placebo|Placebo will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
45678272|NCT01616654|Drug|CD5789 25 µg/g cream|CD5789 25 µg/g cream applied once daily
45678273|NCT01616654|Drug|CD5789 50 µg/g cream|CD5789 50 µg/g cream applied once daily
45678274|NCT01616654|Drug|CD5789 100 µg/g cream|CD5789 100 µg/g cream applied once daily
45678275|NCT01616654|Drug|Tazarotene 0.1% gel|Tazarotene 0.1% gel applied once daily
46006201|NCT04600115|Device|MRI|Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
46006202|NCT04600115|Device|PET Imaging|Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day
46006203|NCT03453762|Procedure|recruitment maneuver|Recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.
46006204|NCT03453762|Procedure|ultrasonography-guided recruitment maneuver|Recruitment maneuver is guided by ultrasonography.
46006205|NCT04599998|Diagnostic Test|spirometry, thoracic CT, CPET, 6 minute walking test, SF-36 questionnaire|Participants will perform spirometry, lung diffusion capacity of carbon monoxide, 6-minute walk test (6MWT), Short form-36 (SF-36) questionnaire and cardiopulmonary exercise testing (CPET) after 6-12 months (Visit 1) of COVID-19. Clinical, laboratory and chest image data during the COVID-19 hospitalization will be obtained from medical records.
46006206|NCT04579419|Drug|Sodium Bicarbonate|Botulinum Toxin diluted in Sodium Bicarbonate
46006207|NCT04579419|Drug|Normal Saline|0.9 NaCl
46092059|NCT02802839|Device|Virtual Reality|
46092060|NCT04180982|Drug|SHR4640 dose1 plus Febuxostat dose1|Tablet,dose1,QD
46092061|NCT04180982|Drug|SHR4640 dose1 plus Febuxostat dose2|Tablet,dose1, dose2 QD
46092062|NCT04180982|Drug|SHR4640 dose2 plus Febuxostat dose3|Tablet,dose2, dose3 QD
46092063|NCT02799953|Device|Technology-based self-management model|Participants in the technology-augmented self-monitoring model (intervention group) will use a tablet-based, interactive touch screen self-monitoring system to monitor and manage their chronic conditions. The system is designed to augment patients' abilities to assess, record, and review their health signs while providing text-, audio-, and video-based resources supporting disease self-care.
46092064|NCT02681744|Behavioral|Resistance Training|24-weeks of progressive strength training
46006208|NCT04600037|Drug|Pregabalin 150mg|"Patients in group I received pregabalin at a dose of 75 mg twice daily during the first week that was increased to 150 mg twice daily thereafter and maintained at that level for 12 weeks.~Patients in two groups received exercise therapy (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months"
46092065|NCT02802605|Drug|Bemiparin|Bemiparin subcutaneus administration
45678276|NCT01616654|Drug|Vehicle cream|Vehicle cream applied once daily
46092066|NCT04183010|Behavioral|Physical activity coaching|"Interventions will be delivered via smartphone and will consist of physical activity coaching. Once randomized to the Coaching arm, individuals will be presented with seven broad categories of physical activity. They will receive a daily notification on their phone indicating that they have study activities to complete. They will then click on this notification and will be offered five options:~A low intensity activity from one of the categories they selected upon start of coaching~A moderate-to-vigorous endurance activity~The participant will be linked to video content with exercise tutorials/video coaching~Option to skip exercise that day~Option to fill in a different activity that the participant completed (free text entry)~The participant will then select one of these options and complete the chosen activity. They will be presented with the question Did you completed the exercise with three options:~Yes~No~Give me a different exercise"
45678277|NCT01902290|Biological|Placebo|Placebo administered subcutaneously
45678278|NCT01902290|Biological|Brodalumab|Brodalumab administered subcutaneously
45678279|NCT01927562|Device|Fractyl Duodenal Remodeling System|
45678280|NCT01467466|Drug|IV isotonic saline|The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic saline over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic saline (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
46092067|NCT02802371|Behavioral|Psychosocial intervention|Caregivers included in this group will benefit from a multi-component intervention with three collective sessions and individual interview in face-to-face or by phone according to the follow-up time.
46092068|NCT02802371|Other|Pharmaceutical care and psychosocial support|"Caregivers included in this group will benefit from the same multi-component intervention that group psychosocial intervention with the integration of pharmaceutical care by a clinical pharmacist. The clinical pharmacist will intervene in: 1) the pharmaceutical need assessment of the caregivers considering their medication management and the medication management of their relatives at the inclusion; 2) a collective session on medication management; and 3) personalized interviews to consider needs, medication problems and difficulties in the therapeutic optimization process."
46092069|NCT02677142|Behavioral|Structured social skills training program, SSIP|Detailed, session by session, in the manual written for this purpose. It addresses six major social skills, one per session, starting with easier skills (Social Initiation and Friendship Making, Cooperation) and moving towards more complex skills (Managing Teasing and Bullying, Conflict Resolution, Empathy, and Assertion).
45836463|NCT03860610|Diagnostic Test|EuroQol Group Health questionnaire (EQ-5D-5L)|Overall health will be assessed using the EQ-5D-5L health questionnaire
46006209|NCT04599842|Procedure|Erector Spinae Plane Block|Erector Spinae Plane block is performed by giving local anesthetic to the plan between the erector spinae muscle and the transverse process.
46006210|NCT04599881|Drug|PTR-01|IV recombinant collagen 7 at 3 mg/kg given weekly for 4 doses, followed by bi-weekly for 7 doses
46006211|NCT00575796|Drug|Vinblastine Sulphate|Vinblastine dose: 6 mg/m2 (10 mg maximum dose) route intravenous administration once a week.
46006212|NCT04599530|Device|Talaris Demonstrator|The Talaris Demonstrator will be evaluated during daily activities and compared to the current prosthesis
46006213|NCT04599452|Biological|Allogeneic NK cell regimen group|"10 patients with recurrent refractory elderly AML were treated with allogeneic NK cell regimen.~Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10^6/kg d13，d15."
46092070|NCT02677142|Behavioral|CG - social skills activities|Sessions will not be designed around a specific social skill and activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
46092071|NCT02800265|Dietary Supplement|Avmacol|Avmacol is an over-the-counter mixture of broccoli seed and sprout extracts in tablet form to promote detoxification. These tablets contain natural substances that stimulate the body's own defense mechanisms against toxic substances commonly encountered in the environment, such as air pollution and tobacco smoke.
45678281|NCT01467466|Drug|IV isotonic bicarbonate|The investigators will administer 3 ml/kg of isotonic bicarbonate over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic bicarbonate over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic bicarbonate (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
45678282|NCT01467466|Drug|N-acetylcysteine|NAC will be administered at a dose of 1200mg orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
46006214|NCT00573027|Procedure|noninvasive tests|clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory; Peripheral Artery Tonometry (PAT) testing; Cardiac Magnetic Resonance (CMR) imaging.
46006215|NCT00575835|Dietary Supplement|vitamin D twice daily|Kalsipos-D, vitamin D3 400 ID/tbl, 2 tbl/day for one year
46092072|NCT02676986|Drug|Enzalutamide|Anti-androgen
46092073|NCT02676986|Drug|Exemestane|Hormonal therapy (Licenced)
46092074|NCT02681588|Procedure|Obstetric management|Screening for gestational diabetes at 32 weeks of gestation, determination of fasting glucose during late pregnancy ; blood samples on arrival at the delivery room ; drawing blood from the umbilical cord after section; skinfold measurement of the newborn within 72 hours of life.
46092075|NCT02802215|Drug|metformin|Metformin group will receive 1500 mg of metformin per day orally ( 500 mg every 8hrs in the middle of meal) starting from 12th week of gestation till delivery.
46092076|NCT02802215|Drug|placebo (folic acid )|500 micro gram of folic acid every 8 hrs
45678283|NCT01467466|Drug|Placebo|A placebo study drug capsule will be administered orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
45678284|NCT01441180|Drug|GS7977|drug intervention
45678285|NCT01441180|Drug|RBV|drug intervention
46006216|NCT00575835|Dietary Supplement|Vitamin D3 oil three times in a year|Vigantol oil , D3 20000IU/ml, 4.9 ml every four months for one year
45678286|NCT01441102|Drug|Dextromethorphan hydrobromide|Participants instructed to take 60 mg dextromethorphan capsules orally two times a day for 24 months.
45678287|NCT04068922|Behavioral|Resilience Intervention|Resilience skills training including: pleasant activities, hope/goal-setting, pain acceptance, positive events/reappraisals, and self-efficacy.
45836464|NCT03860610|Diagnostic Test|HOOS/ KOOS|Site specific pain and function will be assessed with the Hip Osteoarthritis Outcome Score (HOOS) and Knee Injury and Osteoarthritis Outcome Score (KOOS) depending on the affected joint (hip or knee).
46006217|NCT04579185|Device|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
46006218|NCT00565565|Drug|BAY60-4552|Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg
46006219|NCT00573105|Procedure|Laparoscopic Ventral hernia repair by heavy weight mesh|Laparoscopic Ventral hernia repair by heavy weight mesh
46006220|NCT00573105|Procedure|Laparoscopic Ventral hernia repair by lighter weight mesh|Laparoscopic Ventral hernia repair by lighter weight mesh
46006221|NCT04599413|Other|SURVEY|Pain survey on pianists
46092077|NCT02799797|Procedure|ultrasound guided long axis placement of adductor canal catheter|The long axis of the ultrasound probe is placed parallel to the long axis of the adductor canal while scanning, and the catheter is placed along the long axis of the canal using an in-plane approach
46092078|NCT02799797|Procedure|ultrasound guided short axis placement of adductor canal catheter|The long axis of the ultrasound probe is placed vertical to the long axis of the adductor canal while scanning, and the catheter is placed along the short axis of the canal using an in-plane approach
46006222|NCT00573222|Drug|Symbicort|
46092079|NCT02799797|Device|Philip CX 50 Ultrasound Scanner|The linear (C5-12) probe of Philip CX 50 Ultrasound Scanner is used for scanning
46092080|NCT02799797|Device|PAJUNK Contiplex S Catheter|
46092081|NCT02799797|Drug|Ropivocaine|0.2% ropivacaine 10ml is given as loading dose. Following that, 0.2% ropivacaine 5ml/h is given as maintenance dose.
46006223|NCT04599374|Other|no intervention|This study collected data only without any intervention.
46006224|NCT04599179|Device|self-expandable metal stent|self-expandable metal stent endoscopic positioning
46092082|NCT02799797|Drug|rescue sulfentanil given postoperatively as PICA|bolus: 2mg, lock time: 10min, 1h limitation: 8mg
46092083|NCT05663372|Drug|Efez 50 mg eplerenone film-coated tablets|Oral, mineralocorticoid receptor antagonist, a blocker of aldosterone
46092084|NCT05663372|Drug|INSPRA® 50 mg eplerenone film-coated tablets|Oral, mineralocorticoid receptor antagonist, a blocker of aldosterone
46092085|NCT02799563|Other|Coach, Preselected number of cases|
46092086|NCT02799563|Other|Coach, Self-selected number of cases|
46092087|NCT02799563|Other|No coach, Preselected number of cases|
46092088|NCT02799563|Other|No coach, Self-selected number of cases|
46092089|NCT02638272|Procedure|no debridement|It is a spinal surgery performed with isolated posterior instrumentation without debridement.
46092090|NCT02799407|Other|ResearchKit Consent|Multi-tiered consent form using the Apple ResearchKit Platform.
46092091|NCT04164498|Other|music|exposure to music to investigate its effects on reducing noise adverse effects
46006225|NCT00575874|Drug|Rivoglitazone HCl|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
45678288|NCT04061980|Drug|Binimetinib|Given PO
46092092|NCT02802527|Procedure|Percutaneous Tracheostomy|
46092093|NCT02681900|Behavioral|Self-affirmation manipulation task|Participants in the self-affirmation condition indicate their most important value, give three examples of why this value is important to them and one example of something they had done to demonstrate its importance.
46092094|NCT02681900|Behavioral|Control task|People in the control condition indicate their least important value, three examples of why that value could be important to someone else, and describe something that person could do to show its importance.
46092095|NCT02638194|Other|Active smoking of Tobacco Hookah for 2 hours|
46092096|NCT02638194|Other|Exposure to tobacco hookah second hand smoke|
46092097|NCT02638194|Other|Visit a win bar|Participants will visit a wine bar for food and/or drinks
46092098|NCT02802137|Drug|tafluprost|
46092099|NCT02802137|Drug|tafluprost and dorzolamide/timolol|
46092100|NCT02679326|Device|Therapeutic ultrasound|
46092101|NCT02641704|Behavioral|Multidisciplinary program|Coordinated multidisciplinary program
46092102|NCT02799251|Other|Collection of plasma cell rate|Lymphocytes counts are obtained from patients undergoing pulmonary or digestive cancer surgery. The rates are assessed before surgery (day 0) and at days 1, 3, 5 and 8 after surgery. Anesthetic and surgical procedures are collected as well as risk factors for postoperative infections recognized in the literature. Clinical and biological signs of infection are collected.
46092103|NCT04033562|Drug|Lidocaine patch|Lidocaine patch will be applied at time of Cesarean delivery for post-operative pain control.
46092104|NCT04033562|Device|Ambu ACTion pump, 0.125% bupivacaine at 8cc/hr|Infusion pump will be placed at time of Cesarean delivery for post-operative pain control.
46092105|NCT02641626|Procedure|Urgent Coronary Angiography|Diagnostic test for the evaluation of the coronary vasculature.
45678289|NCT04061980|Drug|Encorafenib|Given PO
46006226|NCT00575874|Drug|rivoglitazone HCl|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
46006227|NCT00575874|Drug|rivoglitazone HCl|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
46006228|NCT00575874|Drug|pioglitazone HCl|30 mg capsules once daily for 12 weeks
46006229|NCT00575874|Drug|placebo|matching tablets or capsule once daily for 12 weeks
46006230|NCT03454217|Drug|Oxycodone|Postoperative pain treatment with oxycodone
46006231|NCT03454217|Drug|Tramadol|Postoperative pain treatment with tramadol
46006232|NCT00575913|Drug|Alfuzosin|Alfuzosin 10 mg One tablet per day after evening meal
46092106|NCT02641626|Procedure|Deferred Coronary Angiography|Diagnostic test for the evaluation of the coronary vasculature.
46092107|NCT02799173|Biological|RANKL/OPG ratio|
46092108|NCT02799173|Device|bone densitometry|
46092109|NCT02799173|Device|fan beam CT scan|
46092110|NCT02799173|Device|Doppler ultrasound|
46092111|NCT02681666|Dietary Supplement|Dietary intervention|Sessions will be spent with patients discussing the FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet and how to use this diet to treat their Irritable Bowel Syndrome.
46092112|NCT02681666|Behavioral|Irritable Bowel Syndrome eating awareness training|A type of meditation about their eating habits.
46092113|NCT04032834|Combination Product|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece|The VR647 Inhalation System consists of the AKITA JET control unit that has an inspiration flow rate of 12 L/min, an AKITA JET nebulizer handset, a mouthpiece and dose-specific VR647 Smart Cards designed specifically for this trial.
46092114|NCT04032834|Combination Product|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask|The VR647 Inhalation System consists of the AKITA JET control unit that has an inspiration flow rate of 12 L/min, an AKITA JET nebulizer handset, a facemask and dose-specific VR647 Smart Cards designed specifically for this trial.
46092115|NCT04032834|Combination Product|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece operated to sputtering.
46092116|NCT04032834|Combination Product|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.
46092117|NCT04032834|Combination Product|0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece|Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece operated to sputtering.
45459541|NCT02410330|Procedure|Repeated diagnostic high mechanical index|Repeated diagnostic high mechanical index impulses (all <2 usec pulse duration; MI=1.0) whenever very low mechanical index perfusion imaging detected microbubbles within the microvasculature
45459542|NCT05187416|Diagnostic Test|two-dimensional shear wave elastography|Preoperative ultrasound elastography examination
45678290|NCT04061980|Biological|Nivolumab|Given IV
46006233|NCT04598945|Other|Functionel MRI|During the activation fMRI sequences, the subject will perform target pointing tasks, that is to say that he will have to reach, by controlling a cursor using a non-magnetic joystick, targets projected onto a display screen. In each of the pointing tasks he will have to reach the target as quickly and as precisely as possible, and stay in the center of it for a long time times reached.
45678291|NCT01467076|Drug|Aerosolized Normal Saline|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 [150], IPGE1 [300], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. Placebo will be administered over a maximum duration of 72 hours.
46092118|NCT04032834|Combination Product|0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask|Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.
45678292|NCT01467076|Drug|Inhaled PGE1|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 [150], IPGE1 [300], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. In this Pilot RCT, two doses of IPGE1 (300 and 150 ng/kg/min) will be administered over a maximum duration of 72 hours to determine the optimal dose and duration of therapy.
46092119|NCT05654831|Drug|Placebo|Matching Placebo will be administered as oral tablet. Matching Placebo will be given orally during each dosing day.
46092120|NCT05654831|Drug|ECC5004|ECC5004 will be administered as oral tablet(s) during each dosing day.
46092121|NCT02817191|Drug|Hylo-Comod eye drop|The patients were administrated Hylo-Comod eye drop four times a day after Phaco+IOL
45459543|NCT05186480|Dietary Supplement|Neo Mune|"Neo-mune is a nutritional formula used in enteral feeding for critically ill patients. It's mainly indicated in cases of malnutrition, post surgeries and traumas and immunocompromisation.~Its composition:~Composition in approximate %w/w Maltodextrin 42.44% Sodium caseinate 18.25% MCT oil 6.28% Arginine 5.21% Polydextrose 4.00% Corn oil 3.48% Glutamine 2.61% Fish oil 2.32% Minerals 1.96% Vitamins 0.86% Artificial flavor (vanilla)"
45459544|NCT02091934|Procedure|Wavefront-guided PRK|Wavefront-guided PRK
45678293|NCT01466062|Drug|Palivizumab|
45678294|NCT04504864|Drug|low-dose aspirin|50mg aspirin is used to prevent recurrent stroke.
45678295|NCT04504864|Drug|conventional-does aspirin|100mg aspirin is used to prevent recurrent stroke.
46006234|NCT04579263|Other|Fecal microbiota|Transplantation of fecal microbiota of healthy donor with normal body mass index
46006235|NCT04598906|Behavioral|Virtual environment rehabilitation|The participants attended 10-15 computer sessions during 6-12 weeks. Each session lasted 30 minutes and consisted of the set of virtual environment tasks (Shooting Range,Virtual Supermarket Shopping Task and Objects). Shooting range demands differentiation of targets from non-targets and focuses on training of selective attention, psychomotor speed and inhibition control. Virtual Supermarket Shopping requires memorizing the shopping list and searching for products in the supermarket area. Objects requires memorizing of the spatial and temporal context while searching for objects.
46092122|NCT02817191|Drug|Tears Naturale Forte eye drop|The patients were administrated Tears Naturale Forte eye drop four times a day after Phaco+IOL
46092123|NCT02676830|Drug|K-312 100 mg|Single oral dose
46092124|NCT02676830|Drug|K-312 100 ug C14 IV|microtracer dose containing ≤37 kBq (1000 nCi) [14C] given as a 5-ml IV push over 2 minutes
46092125|NCT02636010|Drug|Pembrolizumab|
46092126|NCT02801981|Drug|GSK2230672|It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.
46092127|NCT02801981|Drug|Placebo|It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672
46092128|NCT02676908|Other|Compression socks for 2 weeks|Patients in the intervention group will be asked to wear compression stockings for two weeks post-operatively
46092129|NCT05474027|Other|Avoidance of Deliberate Hypotensive Anesthesia|The anesthesia team will be asked to avoid deliberate hypotensive anesthesia and maintain blood pressure closer to the patient's baseline throughout the surgery.
46092130|NCT05474027|Drug|TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION|1g of tranexamic acid will be given intravenously to patient undergoing orthognathic surgery as routinely performed about 5-15 minutes before first surgical incision.
46006236|NCT04598906|Behavioral|Paper-pencil rehabilitation|The participants in the paper-pencil rehabilitation attended 10-15 paper pencil sessions for 6-12 weeks. Each session lasted 45 minutes. Each paper-pencil session starts with a warm-up game. The session continues with a set of paper-pencil tasks focused on attention, fine motor skills, recall, short-term and long-term memory, verbal fluency, visual search, cognitive flexibility, abstraction and executive functions, numerical abilities. The tasks are adapted according to the participant´s abilities.
46006237|NCT04579302|Procedure|Serratus anterior block (SAB)|Patients will receive a sonar guided serratus anterior plane block with 20 ml of bupivacaine 0.5%
46006238|NCT04579302|Procedure|Erector spinae block|Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%
46092131|NCT02635854|Other|Septic choc group|Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood at the admission in intensive care unit and 48 hours later for leukocyte-platelet aggregates measurements.
46092132|NCT02635854|Other|Orthopedic surgery group|Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood during the orthopedic surgical anesthesia consultation.
46092133|NCT00642824|Drug|Standard chemotherapy|As prescribed--chemotherapy may be a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel.
46092134|NCT00642824|Drug|bevacizumab [Avastin]|15mg/kg iv or 7.5mg/kg on day 1, and subsequently once every 3 weeks
46092135|NCT02802059|Drug|EcN-Suspension|"Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day)."
46092136|NCT02802059|Drug|Placebo|"Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day)."
46092137|NCT02635698|Other|Optifast|medically-supervised weight management program
46092138|NCT02635698|Other|Food-Based|low-energy, low-fat diet
46092139|NCT02799017|Other|Intensive Phonology Treatment|Phonology based reading, writing, and naming therapy.
45459545|NCT02091934|Procedure|Wavefront-optimized PRK|Wavefront-optimized PRK
46006239|NCT04579302|Drug|Saline (as a placebo)|Patients will receive a sham block with 20 ml saline (as a placebo)
46006240|NCT04579302|Drug|Bupivacaine|bupivacaine
46006241|NCT04598867|Drug|CD-008-0045|CD-008-0045 20 mg capsules
46006242|NCT04598867|Drug|Placebo|Placebo capsules
46006243|NCT04598867|Drug|Afobazol|Afobazol 10 mg tabletes
46006244|NCT00573300|Procedure|Phlebotomy|Single blood draw
46006245|NCT04578795|Device|Single use flexible ureteroscopy (PUSEN-OLIMPUS)|single use flexible ureteroscopy
46006246|NCT00573339|Other|Cardiac MRI|up to 3 Cardiac MRI scans per participant in 1-4 months
46006247|NCT00565682|Drug|etoricoxib 120 mg|etoricoxib 120 mg, tablet, orally, OD
46006248|NCT00575952|Drug|Cisplatin|Given IV or IP
46006249|NCT00575952|Drug|Doxorubicin Hydrochloride|Given IV
46092140|NCT02799017|Other|Intensive SFA Treatment|Semantic based reading, writing, and naming therapy.
46092141|NCT05652920|Biological|Ori-C101|Hepatic arterial infusion
46092142|NCT04164108|Dietary Supplement|Intermittent Enteral Nutrition Protocol|Patients will receive total recommended nutrition divided into four equal meals, delivered at a rate of 400 cc/hr at 8:00, 12:00, 16:00, 20:00. Titration schedule will include administering 50% of volume for first two feeds, then 75%, and then 100%.
46092143|NCT02676596|Drug|K-312 10 mg QD|
46092144|NCT02676596|Drug|K-312 25 mg QD|
46092145|NCT02676596|Drug|K-312 50 mg QD|
46092146|NCT02676596|Drug|K-312 100 mg QD|
46006250|NCT00575952|Biological|Filgrastim|Given SC
46006251|NCT00575952|Drug|Paclitaxel|Given IV or IP
46006252|NCT00575952|Biological|Pegfilgrastim|Given SC
46006253|NCT00565799|Procedure|Omentectomy|Removing the omentum
46006254|NCT00565799|Other|No intervention|Only LAGB without Omentectomy
46006255|NCT00573417|Drug|modafinil|modafinil 100mg tablets. dose excalation up to 300mg
46006256|NCT00573417|Drug|Placebo|
46006257|NCT00565838|Procedure|AFS and TVT|Autologous Fascial Sling and Tension- Free Vaginal Tape
46006258|NCT00573456|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes per session.
46006259|NCT00565877|Other|Ultrasound inspection|post-PICC insertion Ultrasound inspection of the ipsilateral neck for PICC in a malposition (ipsilateral internal jugular vein)
46006260|NCT00573495|Biological|hTERT/Survivin Multi-Peptide Vaccine|100 mcg subcutaneous every 2 weeks four times, then monthly up to 28 vaccinations
46006261|NCT00565955|Drug|montelukast|"Standard case management will be carried out as per guidelines given by British Thoracic Society. All patients will receive montelukast or similar looking placebo tablets. The doses of montelukast will be as follows:~5-12 years: 5 mg chewable tablet of montelukast; > 12 years: 10 mg chewable tablet of montelukast. Study drug will be administered at time of administration of steroid."
46092147|NCT02676596|Drug|K-312 200 mg QD|
46092148|NCT02676596|Drug|K-312 400 mg QD|
46092149|NCT02676596|Other|Placebo|
46092150|NCT02801903|Drug|SB204 4%|Topically Once Daily (AM)
46092151|NCT02537756|Behavioral|Project Voice|A tablet-based intervention that directs participants through different activities related to adolescent HPV vaccination based on their assigned condition
46092152|NCT04238117|Procedure|Laser acupuncture treatment|Laser acupuncture therapy (LAT) is a noninvasive technique that involves stimulation of traditional acupoints with low intensity, non thermal laser irradiation.
46092153|NCT02679014|Drug|Placebo|With the exception of the mornings of Days 7 and 21, placebo capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, placebo will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
45459546|NCT01375634|Drug|Midazolam|2 mg intravenous over 2 minutes For patients >60 years of age or with history of pulmonary disease, 1 mg intravenous over 2 minutes
45678296|NCT04501276|Drug|ADG116|For monotherapy ADG116 (Part A), ADG116 will be administered IV over 60 90 minutes until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
46006262|NCT00565955|Drug|Placebo|The patients will receive placebo tablets.
46006263|NCT04598516|Diagnostic Test|serum creatinine assay|peak change in serum creatinine in a period of 5 days from baseline (day 0) will be determined
46092154|NCT02679014|Drug|RO5459072|With the exception of the mornings of Days 7 and 21, RO5459072 capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, RO5459072 will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
46006264|NCT04598594|Drug|Patch, Nicotine|Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
46006265|NCT04598594|Drug|Patch, Placebo|Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
46006266|NCT00575991|Dietary Supplement|Conjugated linoleic acid|3 grams per day of 80% CLA in safflower oil (2.4 grams active CLA isomers in triglyceride form)
46092155|NCT02801357|Drug|lofexidine administration in subjects seeking buprenorphine dose reduction|
46092156|NCT04180826|Other|Observational|"Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed, according to the usual care.~In a second step, the patient will be verticalized (from 0° to 90°). Intracranial hemodynamics parameters in supine position and during verticalization will be continuously recorded by attaching the ATYS TCD-X® transcranial Doppler helmet attached with glasses.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the ATYS TCD-X® helmet."
46006267|NCT04598243|Dietary Supplement|Smart Energy System|A nutritional /herbal combination
46006268|NCT04598438|Behavioral|Music behavioral early intervention program|The program consists of carefully designed play-based enhancement strategies implemented in the form of hybrid online/in-person playgroups. Following a teach-model-coach-review approach, parents will learn to implement various skills that are expected to enhance infant's language and communication skills through singing and engaging in musical play with their child at home.
46092157|NCT04183244|Procedure|Erector spinae block|A 5-cm needle prick in the back of the patient 3 cm lateral to mid-line under sterile conditions, with ultrasound guidance.
46092158|NCT04183244|Procedure|Infraclavicular subomohyoid (ISO) block|Under complete aseptic precaution, 12 cm needle will be inserted 2cm superior to the clavicle and advanced retroclavicular, with ultrasound guidance.
46092159|NCT02801591|Procedure|Conventional ovarian stimulation proctol without rhGH|
46092160|NCT04236011|Biological|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CART cells will be administered intravenously.
46092161|NCT02676674|Drug|Dose 1|Subjects with vitamin D deficiency will be given 100,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
46092162|NCT02676674|Drug|Dose 2|Subjects with vitamin D deficiency will be given 300,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
46092163|NCT02801513|Behavioral|Brief Mindfulness Training|Brief mindfulness training comprising of three weekly individual sessions and daily guided meditation home practice
46092164|NCT02801513|Behavioral|Resting Control Training|Brief resting control training comprising of three weekly individual sessions and daily home practice consisting of resting periods
46092165|NCT05279365|Biological|Pfizer/BioNTech (BNT162b2)|participants will receive a booster dose (1st booster or 2nd booster) of vaccine
45459547|NCT01987648|Procedure|Elective Craniotomy Patients|Patients who receive an elective craniotomy (no biopsy, no awake surgery, no re-operation)
45459548|NCT01369628|Drug|Atacicept|"Regimen 1: Atacicept 25 mg weekly for 12 weeks~Regimen 2: Atacicept 75 mg weekly for 12 weeks~Regimen 3: Atacicept 150 mg weekly for 12 weeks"
45678297|NCT04501276|Drug|ADG106|For the ADG116-ADG106 combination regimen, ADG116 and ADG106 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
45678298|NCT04501276|Drug|anti PD1 drug|For the ADG116-anti PD1 combination regimen, ADG116 and anti PD1 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
45678299|NCT04060342|Drug|GB1275|Oral
45678300|NCT04060342|Drug|nab-paclitaxel and gemcitabine|IV infusion
45836465|NCT03860610|Diagnostic Test|Muscle activity test|Surface electrodes (Ag/AgCl, Noraxon, U.S.A. Inc., Scottsdale, AZ, USA: 10 mm diameter, 22 mm inter-electrode distance) will be placed bilaterally on glutaeus medius, vastus medialis, semitendinosus, tibialis anterior, gastrocnemius medialis, and peroneus longus muscles. Periods of muscle activity will be defined as intensity above 2 Standard Deviation (SD) of the resting Electromyography (EMG) signal. Duration of overlapping muscle activity between agonists and antagonists normalized to one gait cycle or of a balance test, respectively, will be determined.
46006269|NCT04598438|Behavioral|Arts and crafts early enhancement program|The program follows the same general structure with the music intervention program. Parents will learn how to implement a series of arts and crafts activities at home, with an aim to enhance infant's visual-perceptual, motor, and sensory integration development.
46006270|NCT00576030|Other|hab cof with water|habitual coffee drinker provided with water
46006271|NCT00576030|Other|hab cof with dec espresso|habitual coffee drinkers given decaffeinated espresso
46006272|NCT00576030|Other|hab cof with caf espresso|habitual coffee drinkers given caffeinated espresso
45459549|NCT05388448|Drug|Sanfetrinem Cilexetil|"Sanfetrinem cilexetil powder, weighed for dose and administered as a suspension in water.~Amx/CA 250/125 mg tablets Rifampicin 150 mg, 300 mg and 600 mg tablets or capsules"
45459550|NCT05388448|Drug|Amoxicillin/clavulanic acid|Amx/CA will be administered orally as Amx/CA 250/125 mg, 1 tablet twice daily for 14 days alongside with sanfetrinem cilexetil.
45459551|NCT05388448|Drug|Rifampicin|Rifampicin will be administered at a dose of 35 mg/kg once daily for 14 days with or without sanfetrinem cilexetil.
45678301|NCT04060342|Drug|pembrolizumab|IV infusion
46006273|NCT00576030|Other|non-hab cof with water|non-habitual coffee drinkers given water
46006274|NCT00576030|Other|non-hab cof with dec espresso|non-habitual coffee drinkers given decaffeinated espresso
46006275|NCT00576030|Other|non-hab cof with caf espresso|non-habitual coffee drinkers given caffeinated espresso
46006276|NCT04579341|Dietary Supplement|probiotics|probiotics administration
46006277|NCT04598126|Other|Traditional physical therapy|Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/
46006278|NCT04598126|Other|patient education manual +traditional physical therapy|"Patient educational Manual~+ Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/"
46006279|NCT00576069|Drug|budesonide/formoterol|2 inhalations 2X/daily in treated arm/group. No placebo group
46006280|NCT00576069|Drug|fluticasone/salmeterol|fluticasone 100ug/salmeterol 50ug, 1 inhalation bid noplacebo fluticasone 250ug/salmeterol 50ug, 1 inhalations bid no placebo Spiriva handihaler daily or respihaler 2 inhalations daily no placebo group
46006281|NCT00576069|Drug|mometasone/formoterol|"200/5 mcg two puffs bid 100/5 mcg two puffs bid Breo Ellipta once daily Spiriva capsule handihaler once daily or Spiriva respihaler 2 in~no placebo group"
46006282|NCT00576069|Drug|Prednisone|0-15 mg daily as needed
46092166|NCT05279365|Biological|Moderna|participants will receive a booster dose (1st booster or 2nd booster) of vaccine
46092167|NCT02679248|Dietary Supplement|Neo40 Daily®|
45459552|NCT01375712|Dietary Supplement|Fermented milk containing Lactobacillus casei strain Shirota|A fermented milk containing Lactobacillus casei strain Shirota, 65 ml for oral administration, 1 bottle per day for 8 weeks (56 days). One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; 0.9 g of protein; and at least 6.5 x 10^9 colony-forming units of Lactobacillus casei strain Shirota.
45459553|NCT01375712|Dietary Supplement|Placebo|Non-fermented milk without Lactobacillus casei strain Shirota, 65 ml for oral administration, 1 bottle per day for 8 weeks (56 days). One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; and 0.9 g of protein.
46006283|NCT00573573|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
46006284|NCT00576108|Drug|KD7040 Topical Gel|KD7040 topical gel
46006285|NCT00576108|Drug|Placebo gel|Placebo gel
46006286|NCT00565994|Procedure|Blood Draw|For patients undergoing routine hemodialysis for chronic renal failure, 5-10 ml of blood will be removed from the dialysis tubing during vascular access. All other subjects will have 5-10 ml of blood drawn by routine venipuncture.
46006287|NCT00573612|Behavioral|Attention Control Counseling|Subjects will receive educational-based telephone counseling regarding fibromyalgia.
46006288|NCT00573612|Behavioral|Motivational Interviewing|Subjects will receive Motivational Interviewing telephone counseling.
46092168|NCT02679248|Dietary Supplement|Placebo|
46092169|NCT02798549|Other|blood draw|blood draw of 150ml, twice
46092170|NCT00962299|Drug|Beclomethasone|Beclometasone 100 ug b.i.d. by metered dose inhaler with spacer for 6 months
46092171|NCT00962299|Drug|Placebo|Placebo once a day by metered dose inhaler with spacer for 6 months
46006289|NCT00566033|Behavioral|Audit-driven intervention|Patients included in this arm will undergo to the multi-method quality improvement intervention (intensive intervention) that adds practice visits, telephone and e-mail contacts (for quality improvement facilitation) and audits to the approach of periodic guideline dissemination and feedback on demand used in the less intensive intervention.
46006290|NCT00573651|Other|Blood Draws for Serum Titers|All study subjects are receiving the Gardasil vaccine as part of their clinical care. The Gardasil vaccine is not given because of study participation. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers. Other study specific procedures performed include Questionnaires and observational data.
46006291|NCT00566072|Behavioral|instructions and coaching|instructions and coaching or no intervention on the use and intake of ganciclovir
46006292|NCT04597970|Drug|cTACE-HAIC|transarterial chemoembolization (TACE) plus Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona stage C hepatocellular carcinoma (HCC)
46006293|NCT00573690|Drug|carboplatin|Given IV
46006294|NCT00573690|Drug|cisplatin|Given IV
46006295|NCT00573690|Drug|etoposide|Given IV
46006296|NCT00573690|Drug|pemetrexed disodium|Given IV
46006297|NCT00573690|Drug|sorafenib tosylate|Given orally
46092172|NCT02678936|Biological|PRP|Application of platelet-rich plasma during surgery
46092173|NCT02798393|Other|Infrared Phototherapy|Subjects will wear a cuff on their extremities for a set period of time at set intervals over a period of several weeks. The cuff will emit the Infrared Phototherapy treatment (or sham if randomized to the non-treat group).
46092174|NCT02798393|Other|Sham|
46092175|NCT02679092|Drug|Misoprostol|400 mcg buccal 60-90 minutes prior to procedure
46092176|NCT02679092|Drug|Mifepristone|200 mg PO on the day prior to D&E
46092177|NCT02679092|Device|Hygroscopic cervical dilators|osmotic cervical dilators inserted through the internal os
46006298|NCT04597814|Other|No Intervention|No Intervention
46006299|NCT04597892|Diagnostic Test|serum creatinine assay|point-of-care and standard laboratory assay of serum creatinine
46006300|NCT00576225|Drug|CT-2103/carboplatin|CT-2103 (175 mg/m2 10 min IV infusion) and carboplatin (AUC 6, 30 min IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
46006301|NCT00576225|Drug|paclitaxel/carboplatin|Paclitaxel (175 mg/m2, 3 hr IV infusion) and carboplatin (AUC 6) (30 minute IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
46006302|NCT04597853|Diagnostic Test|Assessment of lung mechanics and heart-lung interactions|Impedance tomography, right-heart catheterization, oesophageal pressure measurements, indirect calorimetry and classic mechanical ventilation parameters
46092178|NCT03878147|Behavioral|Cognitive Games Training|Brain Powered Games (BPG) uses games for neurocognitive assessment and training, using images and sounds more familiar to African children. As a computerized cognitive rehabilitation training (CCRT) program designed for Sub-Saharan African school-age children, it can help children infected affected directly or indirectly by HIV. BPG consists of 5 core games evaluating different cognitive abilities (learning, memory, language, attention). Each game includes a visual tutorial, several adjustable settings on the administrative side (Admin), and records game play data for research purposes. Village Builder (VB) is a pro-social reasoning/planning world building strategy type game intended to evaluate frontal lobe executive functions in a culture-friendly and enjoyable game manner. It consists of many of the village artistic components as used in BPG but orchestrated into a village setting where children must gather resources and protect them in order to expand the capacity of the village.
46092179|NCT00962377|Procedure|Endomyocardial biopsy|Right ventricular endomyocardial biopsy in monitoring of asymptomatic heart transplant patients for acute cellular rejection
46092180|NCT00962377|Procedure|AlloMap Molecular Testing|Gene expression profiling in the monitoring of asymptomatic heart transplant patients for acute cellular rejection.
46092181|NCT04183088|Drug|Tislelizumab+regorafenib for part 1;Tislelizumab+regorafenib for group 1 of part 2; Regorafenib for group 2 of part 2.|"There will be no dose reduction for tislelizumab in this study. In the part 1(safety cohort), if the subjects do not experience grade 2 or greater regorafenib-related adverse events after 2 cycles (6 weeks) of treatment, the dosage of regorafenib may be escalated. For subjects who escalate the regorafenib dosage to Level 2, if the subjects do not experience grade 2 or greater regorafenib-related adverse events after 2 cycles of study drug treatment, the dosage of regorafenib may be further escalated to Level 3.~During study drug treatment, dose delay/ interruption of regorafenib will be done depending on the occurrence and severity of regorafenib-related adverse events. After dose reduction of regorafenib, if the subjects tolerate the reduced dose of regorafenib well, the investigators may consider re-escalation of regorafenib to the previous dose level, depending on the types and severity of adverse events that led to dose reduction."
46092182|NCT00962455|Other|e-learning & performance feedback|Initial e-learning by studying CD-Rom 'Spirometry Fundamentals', followed by repeated periodic performance feedback on spirometry test quality
46092183|NCT00962455|Other|usual practice|Usual practice regarding spirometry execution in family practice
46092184|NCT00642122|Drug|Budesonide|0.5mg once daily
46092185|NCT00642122|Drug|Budesonide|1mg once daily
46092186|NCT00642122|Drug|Budesonide|1mg twice daily
46006303|NCT00573807|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength)for 30 to 40 minutes per treatment session.
46006304|NCT04597931|Drug|Romosozumab|SC Romosozumab 210 mg/monthly
46006305|NCT04597931|Drug|Zoledronic Acid|IV Zoledronic acid 5 mg
46006306|NCT00576459|Drug|0.59 mg fluocinolone acetonide intravitreal implant|0.59 mg
45836466|NCT03860610|Diagnostic Test|Passive range of motion|Passive range of motion will be assessed for ankle plantar-/dorsiflexion, knee flexion/extension and hip flexion/extension, ab/adduction, internal/external rotation using goniometers and recorded in degrees. The range between two maxima will be recorded.
46092187|NCT00642122|Drug|Budesonide|2mg once daily
46092188|NCT00642122|Drug|Budesonide|4.00mcg twice daily
46006307|NCT00576459|Drug|2.1 mg fluocinolone acetonide intravitreal implant|2.1 mg
46006308|NCT00576459|Procedure|standard of care laser photocoagulation|standard of care laser photocoagulation
46092189|NCT02801435|Drug|0.5% Icotinib hydrochloride cream|Topical administration for twice daily
45836467|NCT01791426|Device|Artelac Rebalance|Instill 1 drop of the Artelac Rebalance eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment.
45836468|NCT01791426|Device|Vismed|Instill 1 drop of the Vismed eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment.
45836469|NCT03821844|Behavioral|Music and Memory|Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences.
46006309|NCT04597736|Biological|Biological collection with nasopharyngeal samples, saliva, blood, stool and urine|"Subjects with a COVID-19 infection and their contact cases (identification according to health insurance criteria, see Améli.fr) will be offered a clinical evaluation and the takin of biological samples, whether they are hospitalized or via the outpatient screening channel.~For the main objective: during the Day0 visit, the subjects who agreed to participate in the study will have a clinical evaluation according to a standardized questionnaire and a nasopharyngeal swab, saliva, blood, stool and urine.~For secondary objectives : longitudinal follow-up will be carried out for 21 days, for index cases and contact cases, whether they have a positive or negative RT-PCR test on D0. A final consultation will be carried out at M3. Nasopharyngeal samples, saliva, blood, stool and urine will be taken on D10 and D21. A blood test will be taken at M3 to carry out a COVID-19 serology."
45836470|NCT00350532|Drug|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
45836471|NCT00350532|Drug|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
45836472|NCT00351000|Drug|Ziprasidone|
45836473|NCT00351936|Drug|Aripiprazole|
45836474|NCT00351936|Drug|placebo|
46006310|NCT04597775|Drug|hydroxychloroquine|hydroxychloroquine
46006311|NCT00573885|Drug|defined green tea catechin extract|Given orally
46006312|NCT00573885|Other|placebo|Given orally
46006313|NCT04597424|Drug|Experimental: doxycycline|"2 tablets of doxycycline 100 mg (monohydrate form) will be taken orally after each risk sexual intercourse, ideally within 24 hours after sex and no more than 72 hours. PEP should not be taken more than 3 times over a 7 days' period.~If a participant has risk sexual intercourse for several consecutive days, PEP should be taken at least 48 hours apart and no more than 3 times 2 tablets over 7 days. A maximum of 3 intakes of 2 tablets will be allowed over a period of 7 days."
46006314|NCT04597424|Biological|Bexsero® vaccine|1st injection of Bexsero® vaccine at inclusion visit, 2nd injection at week 8.
46006315|NCT00573924|Drug|Proton pump inhibitor (lansoprazole)|"120 mg PO and then 30 mg PO q 3 h from 3 to 21 hrs~90 mg IV bolus followed 9 mg/hr infusion for 24 hrs"
46006316|NCT04597229|Dietary Supplement|Instant multigrain supplement|A twice daily instant multigrain supplementation for 12 weeks
45836475|NCT00352794|Drug|Lenalidomide|Oral 10 mg daily/days 1-21 of 28 day cycle
45836476|NCT00352794|Drug|Prednisone|Starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
45836477|NCT04421118|Other|a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient|a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient based on three-dimensional modeling and fluid dynamics simulation
45836478|NCT00353418|Drug|Peginterferon alfa-2a|180 µg subcutaneously weekly for 48 weeks
45836479|NCT00353418|Drug|Ribavirin|800 mg orally daily for 48 weeks
45836480|NCT00353418|Drug|Ribavirin|1000 mg or 1200 mg (based on patient weight of < 75 kg or ≥ 75 kg, respectively) orally daily for 48 weeks
46006317|NCT04579809|Procedure|4 strand technique|4 strand technique reapir of tendin flexor injury
46006318|NCT04579770|Dietary Supplement|Ketone ester|75g ketone ester in the form of a drink [96% (R)-3-hydroxybutyl (R)-3-hydroxybutyrate, Oxfordshire, UK)] will be provided.
46006319|NCT04579770|Other|Sodium bicarbonate|Sodium bicarbonate - widely accessible food ingredient will be provided.
45836481|NCT00353652|Drug|Study#1: chlorthalidone (CTD), titrated dose|Participants in study #1 will receive 3 months of chlorthalidone (12.5-25 mg/d) at the dose titrated to achieve 24-h ambulatory BP < 130/80 mmHg
45836482|NCT00353652|Drug|Study #1: spironolactone (SP), titrated dose|Participants in study #1 will receive 3 months spironolactone (25-75 mg/d), at the dose titrated to achieve 24-h ambulatory BP < 130/80 mmHg.
45836483|NCT00353652|Drug|Study# 2 chlorthalidone (CTD), fixed dose|Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.
45836484|NCT00353652|Drug|Study# 2 spironolactone (SP), fixed dose|Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.
45836485|NCT00353652|Drug|Study# 2 irbsesartan (IR), fixed dose|Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.
45836486|NCT01792362|Other|Weight loss diet|Control the patients diet to make them loosing weight
45836487|NCT03740880|Other|Dual trigger|dual trigger: 10.000 IU hCG i.m. and 0.3 mg Deca
45836488|NCT02982798|Drug|Metformin + Rosuvastatin|administration of Metformin + Rosuvastatin
45836489|NCT02982798|Drug|JLP-1310|administration of JLP-1310
45836490|NCT03709914|Drug|ZTI-01 100 mg/kg|ZTI-01 intravenous (IV)
45836491|NCT03709914|Drug|ZTI-01 75 mg/kg|ZTI-01 intravenous (IV)
46006320|NCT04579770|Other|Placebo|Placebo
46006321|NCT00576498|Other|NBI-AFI imaging|"Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.Target biopsies with standard biopsy forceps will be obtained from the different visualized patterns in separate jars.~Autofluorescence Imaging- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm).In this system, normal squamous and non-dysplastic BE appears green while the dysplastic areas appear magenta/purplish. Targeted biopsies will be obtained from the areas with abnormal fluorescence."
46006322|NCT00576498|Other|Standard Endoscopy|Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars.
46006323|NCT04597463|Procedure|Endometrial injury|Endometrial injury was performed hysteroscopically after freeze all cycles and during the cycle before the frozen embryo transfer
46006324|NCT04578990|Other|Walking intervention|"It will consist of performing the Treadmill training progression for 36-72 sessions. 3 sessions of 60 minutes, will be held weekly.~Depending on the data obtained in Visit 1, the speed will be determined for each patient and the degree of the initial slope that is comfortable when walking until it induces symptoms of moderate intermittent claudication. The progression of the intensity of the speed and incline of the slope will be increased progressively and individually for each patient."
46006325|NCT04578990|Other|Strength intervention|The training program consists of performing a training program with resistance exercises for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied. The same guidelines will be followed as in the walking exercise, but in this case, applying force stimuli. If symptoms of moderate intermittent claudication occur (3-4) based on the Claudication Symptom Rating Scale in 5-10 minutes, a period of rest (sitting or standing) will be performed until the pain disappears at the level of the lower limb. This sequence will be repeated until the strength training session is completed. The progression of force stimuli will be increased weekly depending on the subjective perception of the patient's effort and according to the guidelines set by our group of investigation.
46006326|NCT04578990|Other|Concurrent intervention|The training program consists of alternating strength and resistance stimuli in the same session for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied for 35 minutes and to complete the 60 minutes, the same guidelines will be followed as in the walking exercise, applying resistance stimuli. If claudication symptoms occur moderate intermittent (3-4) based on the Claudication Symptom Rating Scale in 5-10 minutes, a period of rest (sitting or standing) will be performed until the pain in the lower extremity disappears. This sequence will be repeated until the 20 minutes established to end the session are completed concurrent training. The progression of the strength and resistance stimuli will be increased weekly depending on the perception subjective effort of the patient and according to the guidelines established by our research group.
46006327|NCT04597385|Other|Long-term Follow-Up|No intervention
46006328|NCT00573963|Drug|ropivacaine|2 injections of 20mL 0.375% ropivacaine - one given on each side.
46006329|NCT00573963|Drug|saline solution|2 injections of 20mL plain saline solution - one on each side.
46006330|NCT04597034|Procedure|AN69-Oxiris|To demonstrate clinical efficacy of AN69-Oxiris membrane to reach a stable MAP, with less vasopressor dosing (at least 0.1 micrograms/kg/min) after 72h of treatment, compared to a conventional membrane (standard AN69) in critically ill patients with AKI, COVID-19 infection and requirement of continuous renal replacement therapy.
46006331|NCT04597034|Procedure|AN69-Standard|Standard treatment.
46006332|NCT00576615|Drug|Placebo solution|On the day of the study infusion into the vein of a solution containing no drug, Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion. Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks.
46092190|NCT02801435|Drug|1.0% Icotinib hydrochloride cream|Topical administration for twice daily
45459554|NCT01369862|Biological|GHB16L2|A/Brisbane/59/07(H1N1)-like delNS1, A/Brisbane/10/07(H3N2)-like delNS1, B/Florida/04/06-like delNS1 virus reassortants
45459555|NCT01369862|Biological|Placebo|SPGNH buffer
45459556|NCT05152498|Drug|Fu Zheng Jie Du Hua Yu therapy|Fu Zheng Jie Du Hua Yu is a Chinese herbal compound
45459557|NCT05185466|Behavioral|Nurse-Supported Self Management Programme|Training and incentives to improve nutrition habits and sleep health.
45459558|NCT05150470|Other|prevention|dental digital fingerprinting
45840086|NCT00597246|Drug|FACBC, Methionine|F-18 labeled FACBC is prepared stereo-specifically in a semi-automated, NCA procedure utilizing the General Electric FDG MicroLab, a system employing a quaternary 4-aminopyridinium resin to effect F-18 fluorination. The triflate species is displaced with F-18 fluoride in the MicroLab, and then the 1-t-butyl carbamate-3- trifluoromethane sulfonoxy-1-cyclobutane-1-carboxylic acid methyl ester is hydrolyzed with 1 N HCl. The final product is isotonic and sterile, and has been utilized in animal experiments. The product was obtained in 30% radiochemical yield after 65 minutes from EOB. The radiochemical purity was greater than 95% and no preparative HPLC was required. The procedure could be considered routine, and is performed on the FDG synthetic module without changes either to the programming or to the cassettes.
46092191|NCT02801435|Drug|2.0% Icotinib hydrochloride cream|Topical administration for twice daily
46006333|NCT00576615|Drug|propofol|"On the study day you will receive study drug propofol. Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion.~Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks."
46092192|NCT02801435|Drug|4.0% Icotinib hydrochloride cream|Topical administration for twice daily
46092193|NCT02801435|Drug|Placebo|Topical administration for twice daily
46092194|NCT00546871|Drug|Immune Globulin Intravenous (Human), 10%|Intravenous administration in Study Part 1, subcutaneous administration in Study Parts 2 and 3
46092195|NCT05597618|Other|Training Program to be Developed for Empowering New Graduated Nurses|"The training program, which will be prepared based on structural and psychological empowerment theories, will consist of two parts: face-to-face theoretical training and online training.~Theoretical Education Part In the theoretical part, empowerment based on structural and psychological empowerment theories, effective communication, problem-solving and decision-making, time management, stress management, and nursing legislation will occur. In addition, the subject related to the institution's promotion (organizational chart, vision, mission, values, etc.) will be included.~Online Education Part In the online part; Videos of theoretical education subjects, institutional information, and documents (institutional instructions and procedures, institution vision-mission-values, management chart, etc.), nursing-related legislation (nursing law, nursing regulation), nursing ethical codes and case studies of sample subjects are included."
46092196|NCT02817113|Drug|NC-6004|One cycle of treatment lasts for 3 weeks. NC-6004 will be administered over 1 hour on Day 1 (after the cetuximab infusion) every 3 weeks
46092197|NCT02817113|Drug|Cetuximab|One cycle of treatment lasts for 3 weeks. For each cycle, cetuximab will be administered at least 1 hour before the start of chemotherapy at a loading dose of 400 mg/m2 given over 2 hours initially (ie, on the first day of treatment), followed by a subsequent weekly doses of 250 mg/m2 over 1 hour.
46092198|NCT02817113|Drug|5-FU|One cycle of treatment lasts for 3 weeks. 5-FU will be administered at a dose of 1,000 mg/m2/day on Day 1- Day 4 as continuous infusion every 3 weeks.
46092199|NCT02676518|Other|serum|Serum for serum anti-Mullerian hormone, 2-hour 75 gram oral glucose tolerance test and lipid profiles
46092200|NCT04180592|Procedure|CT Fusion + Transrectal U/S Guided Prostate Biopsy|All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.
45840087|NCT00597246|Other|PET Scan|GE Advance PET scanner for sequential body imaging
45840088|NCT00597402|Drug|Avastin|Avastin will be administered 10 mg/kg every other week beginning a minimum of 28 days after last major surgical procedure, open biopsy, or significant traumatic injury. Following completion of XRT, patients will receive treatment that includes 6 cycles of Avastin, beginning a minimum of 14 days after last XRT.
45840089|NCT00597402|Drug|Temozolomide|Daily temozolomide 75 mg/m2/day for 6.5 weeks of radiation treatment. Following completion of XRT, patients will receive treatment including temozolomide 200 mg/m2/day on the 1st 5 days of each 28-day cycle.
45840090|NCT00597402|Radiation|Radiation Therapy (XRT)|Treatment with standard XRT (radiation) for 6.5 weeks.
46006334|NCT04596800|Other|Prehabilitation Program + Enhanced Recovery After Surgery|Prehabilitation Program (nutrition + exercise + psychological counseling) + ERAS protocol
46006335|NCT04596800|Other|Enhanced Recovery After Surgery|ERAS
46006336|NCT00576771|Procedure|PSV|Pressure Support Ventilation
46006337|NCT00576771|Procedure|NAVA|Neurally Adjusted Ventilatory Assist
46006338|NCT00576771|Procedure|patient-controlled|assisted controlled MV through a button
46006339|NCT04596761|Device|RF-utilizing powered toothbrush|RF-utilizing Powered toothbrush
45459559|NCT01375790|Device|Exercise with Whole-body vibration platform|The participants will perform static/dynamic exercises (balance and resistance training) on a vibratory platform (Frequency: 30-35 Hz; Amplitude: 2-4 mm).
46006340|NCT04596761|Device|Control placebo with no RF|Placebo control, toothbrush with no RF
45459560|NCT01375790|Other|Exercise|The participants will perform the same static/dynamic exercises (balance and resistance training) like WBV group but without the vibration stimuli.
45459561|NCT05150392|Biological|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.And the live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
45459562|NCT05108740|Drug|everolimus|Self-administered as a daily dose of 10mg orally
45459563|NCT01375868|Biological|Silgard|vaccination with tetravalent antiviral vaccine
46006341|NCT00574041|Drug|Interferon beta-1a|injected, once a week
46006342|NCT04596956|Drug|sodium bicarbonate Ringer injection|Used in surgery
46006343|NCT04596956|Drug|Lactated Ringer's solution|Used in surgery
46006344|NCT04597073|Procedure|Initial Periodontal Therapy|Oral hygiene education, including the use of toothbrushes and dental floss and/or interproximal brushes, was given to them. After one week Chronic Periodontitis group received nonsurgical periodontal therapy consisting of scaling and root planing (quadrant by quadrant) using manual scalers and curettes under local anesthesia. No antibiotics or any medications were prescribed during the treatment. Periodontal treatment was performed by the same investigator
46092201|NCT02801123|Behavioral|Mindfulness Based Cancer Recovery (MBCR)|Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools.
45459564|NCT05120180|Procedure|axillary lymph node dissection with vein branches reservation|Spare the vein branches when ALND being performed
45840091|NCT00597402|Drug|Irinotecan|Following completion of XRT, patients will receive 6 cycles of treatment that includes irinotecan. Beginning a minimum of 14 days after last XRT, the irinotecan dose will depend on whether the patient is on enzyme-inducing antiepileptic drugs (EIAED). (EIAED:340 mg/m2 every other week, non-EIAED: 125 mg/m2.)
45840092|NCT00597558|Drug|Egg white protein|Egg white protein powder
45459565|NCT05120180|Procedure|axillary lymph node dissection without vein branches reservation|Don't spare the vein branches when ALND being performed
45840093|NCT00598806|Drug|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
45840094|NCT00598806|Drug|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
45840095|NCT00598806|Procedure|TURBT|TransUrethral Resection of the Bladder Tumor
45840096|NCT00601146|Procedure|chest computed tomography scan|Once a year for three years
46006345|NCT04579107|Combination Product|Contrast Enhanced Mammography|A modality for examining breast conditions which is already approved and used but the evaluation of its role in a recalled screening population is limited. Intravenous iodine contrast is given prior to the mammogram.
46006346|NCT04596722|Dietary Supplement|Pomella|"Pomella® Pomegranate Whole Fruit Extract containing 75 mg punicalagin in white/white HPMC size 1 capsules packed in white color HDPE bottle of 30 counts"
46006347|NCT04596722|Other|Placebo|"White/white HPMC size 1 capsules each containing 97.67% Maltodextrin, 0.10% Tartrazine color, 0.22% Brown Color, 2.01% Aerosil packed in white color HDPE bottle of 30 counts"
46092202|NCT02801123|Behavioral|Tai Chi/Qigong (TCQ) for Cancer Patients|"TCQ involves a series of slow specific movements or forms done in a meditative fashion. It is purported that focusing the mind solely on the movements of the form helps to bring about a state of mental calm and clarity. The practice itself has been separated from its martial arts roots and is widely taught as a health behavior practice and exercise. Qigong exercises generally have three components: a posture (whether moving or stationary), breathing techniques, and mental focus on guiding qi through the body. Our program, developed specifically for a cancer patient population, incorporates simple Tai Chi elements within a healing framework stemming from Qigong principles."
46092203|NCT02681432|Drug|HIPEC|Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Paclitaxel (175 mg/m2) for 60 minutes at 42-43 degrees.
46092204|NCT02681432|Procedure|No HIPEC|Cytoreductive surgery without HIPEC
46092205|NCT02801201|Drug|Midazolam|
46092206|NCT02801201|Drug|Bupivacaine|
46092207|NCT04182932|Biological|CJ-40010 EV71 vaccine A dose|Inactivated vaccine against EV71, three doses, 28 days interval
46092208|NCT04182932|Biological|CJ-40010 EV71 vaccine B dose|Inactivated vaccine against EV71, three doses, 28 days interval
45836492|NCT03921840|Behavioral|ELDERFITNESS|"In person training: Participants will receive a 2-hour in person education session with the exercise trainer. Self-monitoring: Subjects will self-monitor subjects' level of physical activity (steps & minutes of moderate activity) using the smartwatch. The Google calendar and Fitbit apps will send messages and alerts to the subject's smartwatch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer.~Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans. Financial incentives: The intervention will include financial incentives. Specifically, when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects."
46006348|NCT00576849|Drug|Balanced HES 130/0.42|Volume is administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) was <60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is <10 mmHg
46006349|NCT00576849|Drug|Balanced HES 130/0.42|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is <60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is <10 mmHg
46006350|NCT00576849|Drug|6% HES 130/0.4 prepared in saline solution|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is <60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is <10 mmHg
46006351|NCT00566189|Procedure|Roux-en-Y Bypass Gastroplasty|Under open laparotomy, a stomach section separates a 80-ml proximal gastric pouch. A jejunum section below Treitz's Angle creates an excluded gastrobiliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the continuity between the gastric pouch and the jejunum and a silastic ring reduces the pouch outlet.The anastomosis of the excluded limb is done 100cm below the silastic ring.
46006352|NCT00576888|Other|no intervention|no intervention - observational only
46006353|NCT00566267|Drug|simvastatin 20 mg/ezetimibe|see protocol
46006354|NCT00574314|Other|No Intervention|Participants will be consented.
46006355|NCT00566306|Other|Polyhexamethyleneguanidine (PHMG)|6 months in 3 experimental wards
46006356|NCT00574353|Radiation|Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission|You will be scanned 2 to 3 times on the same day, but you will only be administered one dose of the FMISO tracer. The first scan will last about 30 minutes. Then you will have 1 to 3 hours to wait before you are scanned again. Some patients will undergo a second scan approximately one-and-a-half hours after the start of the first scan. This scan will last about 10 minutes. The final scan will occur between 2-4 hours after the start of the first scan. This final scan will also last about 10 minutes. During the PET scan, you may have a separate i.v. line put into your other arm so that we can take 2 to 3 blood samples. These samples will be less than half a teaspoon each. We are taking these blood samples to see how quickly FMISO leaves your blood stream. The first sample will be taken between 2 and 40 minutes after the FMISO is injected. The other two blood samples will be taken with each subsequent scan.
46092209|NCT04182932|Biological|CJ-40010 CVA16 vaccine C dose|Inactivated vaccine against CVA16, three doses, 28 days interval
45836493|NCT03921840|Other|Control|General education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life program book from the National Institute on Aging.
45836494|NCT01794078|Drug|Aminophylline 400 mg|Xanthine derivative
46006357|NCT04596839|Drug|Remdesivir|Remdesivir INN 100 mg lyophilized powder for infusion
46006358|NCT04596839|Other|Standard of Care|Standard of Care Treatment for COVID-19 Infection
46092210|NCT04182932|Biological|CJ-40010 CVA16 vaccine D dose|Inactivated vaccine against CVA16, three doses, 28 days interval
46092211|NCT04182932|Biological|CJ-40010 Bivalent vaccine E dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
46092212|NCT04182932|Biological|CJ-40010 Bivalent vaccine high dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
46092213|NCT04182932|Biological|Placebo|Placebo, three doses, 28 days interval
45836495|NCT01794078|Drug|Ambrisentan 5 mg|Endothelin receptor antagonist
46092214|NCT02798237|Other|Aerobic treadmill training|"Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of aerobic treadmill training at 60-80% of heart rate reserve). The training intensity progression will be individualized.~Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously during training. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program. Device: treadmill."
46006359|NCT00574392|Device|Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength)|Patients will be imaged with the Vivascope 1500m multiwavelength coherence microscope during a single patient visit. The lesion will be photographed with high resolution photography and surface epiluminescence microscopy. The clinically uninvolved site will be imaged in the same manner.
46006360|NCT04596371|Other|pure pulmonary ground glass nodules in women preparing for pregnancy|pure pulmonary ground glass nodules in women preparing for pregnancy
46006361|NCT00574431|Other|Data Collection|Collection of patient data before implementation of a nutritional management protocol
46092215|NCT02798237|Other|Control (overground walking)|Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of comfortable walking below 40% of heart rate reserve). Before and after the exercise, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program
45459566|NCT00708994|Drug|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
46006362|NCT00574431|Other|Nutritional management protocol|Collection of patient data after implementation of a nutritional management protocol
46092216|NCT03951805|Drug|Insulin icodec|Administered subcutaneously SC once weekly. Starting dose will be 70U.
46092217|NCT03951805|Drug|Insulin Glargine|Administered subcutaneously SC once daily.The starting dose will be 10U.
46092218|NCT02676362|Other|Gingival crevicular fluid collection with filter paper|Gingival Crevicular Fluid Dynamics
46006363|NCT04596683|Procedure|Same-day NSM or SSM|Discharge home same-day after nipple-sparing mastectomy (NSM), or skin-sparing mastectomy (SSM)
46006364|NCT00574470|Drug|daclizumab, infliximab|Daclizumab 1 mg/kg IV days 1, 4, 8, 15 and 22. Infliximab 10 mg/kg IV days 1, 8, 15 and 22.
46006365|NCT04596527|Drug|18F-FMPP|18F-FMPP were injected into the patients at rest (2.5 mCi) and during stress (6.0 mCi) for an individual subject before PET/CT scans.
46006366|NCT00577161|Drug|fludarabine and rituximab|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2
46006367|NCT00577161|Drug|fludarabine, rituximab, pixantrone|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2 pixantrone 120 mg/m2 day 2 only
46006368|NCT04596332|Other|no intervention measures|Because this study was a retrospective study, no intervention measures were implemented for the patients enrolled.
46006369|NCT00574509|Radiation|131Iodine-Anti-B1 Radioimmunotherapy|Dosimetric dose of 450 mg unlabeled Anti-B1 followed by 35 mg Anti-B1 which has been trace labeled with 5mCi of 131I-Anti-B1.
46092219|NCT02800811|Drug|FR104|GMP FR104 is provided to the site in extractable volume vials containing FR104. Appropriate Dilutions in Ringer's lactate solution is made on site.
46092220|NCT02800811|Drug|Placebo|The placebo injection contains the vehicle. For placebo dosing, vehicle is administered in accordance with the volume of study drug administered.
46092221|NCT02681198|Drug|Lofexidine|All subjects will receive two single doses of lofexidine HCl; one 0.4 mg dose taken alone on Day 1 and one 0.4 mg dose taken with 40 mg once daily paroxetine HCl at steady-state on Day 13.
46092222|NCT02681198|Drug|Paroxetine|All subjects will receive daily single doses of paroxetine HCl; one 20 mg dose taken Days 4-6, one 40 mg dose taken Days 7-19, one 20 mg dose taken Day 20, one 10 mg dose taken Days 21-22.
45459567|NCT00708994|Drug|Placebo|• Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
46006370|NCT04596410|Radiation|LLLT applied every other day|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day
46006371|NCT04596410|Radiation|LLLT applied daily|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied daily
46092223|NCT05597306|Drug|Bomedemstat|Bomedemstat will be administered orally once daily via capsule.
46092224|NCT05597306|Drug|Venetoclax|Venetoclax will be administered orally once daily via tablet.
46092225|NCT00962533|Drug|telbivudine|telbivudine, 600mg, oral, daily
46092226|NCT00962533|Drug|telbivudine|telbivudine, 600mg, oral, daily
45836496|NCT01794078|Other|Placebo|
46006372|NCT04579497|Other|38°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 38°C, followed by a ten-minute post-intervention rest period.
46006373|NCT04579497|Other|40°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 40°C, followed by a ten-minute post-intervention rest period.
45459568|NCT03485248|Dietary Supplement|Beetroot Juice|140ml of Beetroot Juice containing on avarege 9 mmol of nitrate
45459569|NCT03485248|Dietary Supplement|Placebo|140ml of Beetroot Juice (nitrate free)
45459570|NCT04732156|Biological|Blood sample|Measurement of PHI Index
45459571|NCT04732156|Other|Follow up questionnaire|3 years after inclusion
45459572|NCT04732156|Diagnostic Test|Human reading of prostate MR images (PI-RADSv2.1).|The PI-RADSv2.1 score will be compared to systematic and targeted biopsy findings (primary objective) and 3-year follow-up (secondary objective)
45459573|NCT05105750|Drug|aspirin 100 mg/d|100mg aspirin for at least 3 days followed by aspirin 100 mg/d
45459574|NCT05105750|Drug|indobufen 200 mg bid|100mg aspirin for at least 3 days followed by indobufen 200 mg bid
45459575|NCT03485170|Diagnostic Test|18F-FDG PET/CT|glucose analogue fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography scan
45836497|NCT03436680|Other|Best Practice|Receive standard of care
45836498|NCT03436680|Behavioral|Neurofeedback|Complete neurofeedback training sessions
46006374|NCT04579497|Other|42°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 42°C, followed by a ten-minute post-intervention rest period.
46006375|NCT04579497|Other|38-42°C rising temperature footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water. Water temperature starts at 38°C and is increased by 1°C every 6 minutes, resulting in 42°C after 30 minutes. The footbath is followed by a ten-minute post-intervention rest period.
46006376|NCT04596605|Other|T2309|Food for Special Medical Purpose / 4 capsules daily for 12 weeks
46006377|NCT04596605|Dietary Supplement|Nutrof Total|2 capsules daily for 12 weeks
46092227|NCT00642980|Drug|Clindamycin|300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: three times a month apart
45459576|NCT05152264|Device|Transcutaneous electrical nerve stimulation (TENS)|Treatment with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
45459577|NCT05152264|Other|Conventional analgesic treatment|Conventional analgesic treatment. Conventional analgesic treatment may include no pharmacological treatment if the patient does not use any analgesics.
45459578|NCT05759936|Dietary Supplement|500mg seaweed|4 week supplementation of 1 capsule per day of seaweed
45459579|NCT05759936|Other|Placebo|4 week placebo supplement of 1 capsule per day
45836499|NCT03436680|Other|Quality-of-Life Assessment|Ancillary studies
45836500|NCT03436680|Other|Questionnaire Administration|Ancillary studies
45836501|NCT01791504|Device|TissuGlu Surgical Adhesive|Standard Wound Closure Techniques Plus TissuGlu and no drains.
45459580|NCT02286154|Drug|Hydroxyurea|For New Cohort participants, PK/PD data will be used to predict the most effective maximum tolerated dose. Old Cohort participants will receive hydroxyurea escalated to MTD as per local clinical guidelines.
45678302|NCT01435018|Drug|Etoposide (ET)|"Beginning on day one of the chemotherapy cycle, ET was given orally in a dose of 50 mg twice daily for 7 consecutive days for the first cycle. If there was no Grade >= 2 toxicity attributable to ET after the first cycle, the dose was escalated to 150 mg daily for 7 days in divided doses of 100 mg/50 mg for the second cycle. After the second cycle, if there was no Grade >= 2 toxicity attributable to ET, the dose was escalated to 100 mg twice daily for 7 days for the third and subsequent cycles.~Treatment with ET was continued for six cycles at the maximum dose achieved or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first."
46092228|NCT00642980|Drug|Placebo|Double blinded capsules(per os) Intervention= 2 capsules/d during 4 days: three times a month apart
46092229|NCT00642980|Drug|Clindamycin|300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: one time and then, after one month placebo capsules 2 capsules/d during 4 days: two times a month apart
46092230|NCT02798081|Behavioral|Single arm study|In Step 1 the elderly will participate of eight conventional computer classes which they were spontaneously enrolled. In Step 2, 10 minutes of the next eight classes will be used to practice serious games using virtual reality, using physical interface (keyboard or mouse).
46092231|NCT04180748|Other|fluorescence imaging with 405nm light|Each group will have images taken with an Health Canada approved device to capture images under white light and 405nm fluorescence with an mCherry filter. These images will not be used for diagnostics and will be analyzed for features which correlate to identified microbes from 16S RNA analysis and traditional microbiological technique. Groups are self identified by participants in order to capture a diverse population.
46092232|NCT02798159|Drug|TD0025|
46092233|NCT02798159|Drug|Sildenafil Citrate 50mg|
46092234|NCT00962611|Drug|Copanlisib (Aliqopa, BAY80-6946)|BAY80-6946 given IV over 1 hour every week for three weeks with a one week break until progression or unacceptable toxicities develop.
46006378|NCT04578951|Device|FHK® total knee prosthesis|FHK® prosthesis are intended to be implanted in the tibial and femoral regions during total knee arthroplasty in order to restore joint function.
46092235|NCT04180280|Behavioral|Behavioral self-regulation Phone counseling to improve HIV care|Participants receive 5 sessions of behavioral counseling to improve HIV care. Counseling is delivered using phone calls by a trained adherence and care engagement counselor.
46092236|NCT04180280|Behavioral|Behavioral self-regulation Office counseling to improve HIV care|Participants receive 5 sessions of behavioral counseling to improve HIV care. Counseling is delivered in clinical care offices s by a trained adherence and care
45678303|NCT01435018|Drug|Bleomycin and Vincristine (BV)|"BV was administered on day one of each chemotherapy cycle.~Vincristine sulfate was administered at a dose of 2 mg (fixed dose) in a volume of 2 mL over 1 minute into the sidearm of a rapidly flowing intravenous infusion every 3 weeks. The vincristine infusion was followed by bleomycin as detailed below.~Bleomycin sulfate was administered at a dose of 15 units/m^2 over 10 minutes every 3 weeks.~Treatment with BV was continued for six cycles, or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first."
46006379|NCT04596488|Drug|Efavirenz 400mg|HIV-infected patients were treated with efavirenz 400mg combined with tenofovir 300mg and lamivudine 300mg.
46006380|NCT00574626|Procedure|PBSCT|Peripheral Blood Stem Cell Transplant
46006381|NCT00574626|Procedure|Bone Marrow Transplant|Bone Marrow Transplant
46092237|NCT04235621|Other|FSGS/TR-MCD|This is a non-interventional study
46092238|NCT04235621|Other|Diabetic Nephropathy (DN)|This is a non-interventional study
46092239|NCT00643058|Biological|LPS endotoxin|"Low challenge: saline (diluent), 5000EU, 10,000EU and 20,000EU LPS endotoxin as tolerated~High challenge: Saline (diluent), 40,000EU and 80,000EU as tolerated~Diluent Challenge: 3 X Sterile saline inhalation (2 ml)"
46092240|NCT02797925|Other|Training|Long slow strength training of the tendon for 3 months to improve function
46092241|NCT04180358|Behavioral|Native STAND|Native STAND is a comprehensive sexual health curriculum for Native high school students that focuses on sexually transmitted infections, HIV/AIDS, and teen pregnancy prevention, while also covering drug and alcohol use, suicide, and dating violence. Twenty-seven sessions support healthy decision-making through interactive discussions and activities that promote diversity, self-esteem, goals and values, team building, negotiation and refusal skills, and effective communication. Sessions will be conducted in regular Physical Education and/or Health Education classes during classroom/school hours.
46092242|NCT04180358|Behavioral|Regular Health/Physical Education Curriculum|General health and physical education curriculum provided by New Mexico's Public Education Department.
45459581|NCT04006418|Other||
45459582|NCT05152186|Drug|Topical Solution|Topical administration
45459583|NCT05152186|Drug|Topical Foam|Topical administration
45459584|NCT05152186|Other|Topical|Topical administration
45459585|NCT05759858|Other|None of intervention|None of the interventions was applied.
45459586|NCT03485092|Drug|Empagliflozin 10 MG|Empagliflozin 10mg tablets for oral self administration once a day
45459587|NCT03485092|Drug|Placebo Oral Tablet|placebo tablets for oral self administration once a day
46092243|NCT03868709|Drug|Penehyclidine inhalation|Penehyclidine inhalation is administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients
45459588|NCT03481582|Drug|Nitroglycerin|(nitrodermal®) 5 mg (patch)as a source of Nitric oxide from 2nd day of cycle till maturation of the follicles ≥ 18 mm just for one cycle.
45678304|NCT01435018|Drug|Paclitaxel (PTX)|Paclitaxel was administered by IV infusion in 200 mL, 250 mL, or 500 mL of 5% dextrose or 0.9%Sodium Chloride for injection at a dose of 100 mg/m^2 body surface area (BSA) every 3 weeks.
45678305|NCT01435018|Drug|Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)|"The following ART regimens were used:~EFV/FTC/TDF (Atripla) 200 mg/300 mg/600 mg orally once daily at bedtime or~FTC/TDF 200 mg/300 mg (Truvada) orally once daily at bedtime plus EFV (Stocrin) 600 mg orally once daily at bedtime or~FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus nevirapine (NVP) 200 mg orally twice daily or~FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus PI/r at standard dosing or~FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus integrase inhibitor at standard dosing"
45678306|NCT01419184|Drug|Daptomycin|
45836502|NCT03373968|Drug|Givinostat|suspension of givinostat (10 mg/mL)
46006382|NCT04596566|Other|Therapeutic diet Intervention|The CD-TDI will incorporate global principles of the Mediterranean Diet (MD) refined to inform specific food choices based on our pilot data results and published literature reported mechanisms of mitigating inflammation in IBD. Patient compliance will be measured in three ways: 1) Mediterranean diet score checklists completed every 3 weeks at the face-to-face visits; 2) goal attainment scores captured weekly to identify the goals set, and the goals attained 47; and 3) fatty acids profiled from red blood cells to identify if fat intake reflects CD-TDI fat recommendations: 35% total calories from fat, 15% from MUFA, 13% from SFA and 6% from PUFA with a 8 n6:n:3 ratio of 8:1
45678307|NCT01419184|Drug|Vancomycin|
45678308|NCT01417234|Device|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
45459589|NCT03481582|Device|Three dimensional power doppler|Once the follicle reached ≥18 mm 3D power Doppler will be used to assess the uterine and subendometrial blood flow
45459590|NCT01376102|Drug|BONVIVA(ibandronate) injection|Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
45678309|NCT01417156|Drug|Nintedanib|150 mg bid
45678310|NCT01417156|Drug|Pirfenidoneone|Existing treatment
45678311|NCT01417078|Drug|Diazepam|single-dose; dosage in mg, based on patient body weight
45678312|NCT01954394|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
45678313|NCT01954394|Drug|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
45678314|NCT01464424|Drug|Travoprost 0.004% ophthalmic solution|
45678315|NCT01464424|Drug|Bimatoprost 0.01% ophthalmic solution|
45678316|NCT01902134|Drug|Placebo|Placebo single oral dose (first 8 hours)
45836503|NCT00354978|Drug|5-Fluorouracil|"400 mg/m^2 injection by vein Day 1 of 14 day cycle immediately after completion of leucovorin infusion.~2.4 g/m^2 by vein over 46 hours over Days 1-3 of 14 day cycle immediately after completion of 400 mg/m^2 injection."
45836504|NCT00354978|Drug|Bevacizumab|"5 mg/kg over 90 minutes on Day 1 of first 14 day cycle as initial dose, administered alone without other drugs.~5 mg/kg by vein on Day 1 of 14 day cycle."
45836505|NCT00354978|Drug|Leucovorin|400 mg/m^2 over 2-4 minutes by vein on Day 1 of 14 day cycle.
46006383|NCT00574665|Other|Hyperinsulinemic Hyperglycemic Clamp|Glucose Clamp
45459591|NCT03109522|Procedure|axillary reverse mapping (ARM)|"ARM/SLNB: patient will be injected with technetium-99 radiolabelled colloid (Tc-99) into the subareolar area of breast, then 1-2 mls of blue dye (patent blue dye) injected subcutaneously into the medial ipsilateral arm, just proximal to the medial epicondyle of the elbow, at the start of the surgical procedure. the SLN(s) will be identified (hot node) and removed, and any blue lymph nodes and lymphatics will be preserved intact, and only removed or disrupted if there is 'crossover (i.e. the blue node is also the SLN) or if clinically suspicious for metastatic disease. ARM/ALND: 1-2 mls of blue dye will be injected subcutaneously into the medial ipsilateral arm at the start of the surgical procedure. Surgeons will perform a standard level I and II axillary dissection and any blue lymph nodes or lymphatics will be preserved intact, and only removed or disrupted if blue nodes are suspicious for metastatic disease."
46006384|NCT04578717|Procedure|Air-abrasion|A clinical air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 powder for 10 sec. The operating parameters were; air pressure, 20 psi; powder particles size, 20 µm; nozzle angle, 90◦; nozzle-lesion distance, 5 mm and the internal nozzle diameter, 900 µm
45459592|NCT03109522|Procedure|Standard axillary surgery (SLNB or ALND)|The control group will have standard SLNB or ALND surgery without identifying or sparing upper-limb lymphatics and nodes (blue dye is not injected).
45459593|NCT05064800|Drug|Dabigatran|A single dose of Dabigatran on Day 1
45459594|NCT05064800|Drug|PF-07321332/ritonavir + Dabigatran|PF-07321332/ritonavir twice daily (BID) for Days 1 and 2 Single dose of Dabigatran on Day 2
45459595|NCT05064800|Drug|Ritonavir + Dabigatran|Ritonavir BID on Days 1 and 2 Single dose of Dabigatran on Day 2
45459596|NCT05152030|Diagnostic Test|'TIB' Olfactory Test|A new smell identification test, 'TIB' Olfactory Test Device (Top International Biotech, Taipei) has been developed in Taiwan. It consists of 16 tests with an odorant embedded in fragrant microcapsules positioned on a strip. The examinee scratches the strip to release the odorant. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors. This process is then repeated with the next odorant on the strip.
46092244|NCT03868709|Drug|Placebo inhalation|Placebo inhalation is administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygendriven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
46092245|NCT04180514|Diagnostic Test|intradialytic hypotension episode|Intradialytic hypotension episode under regular hemodialysis
45678317|NCT01902134|Drug|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
45678318|NCT01902134|Drug|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
45678319|NCT01902134|Drug|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol oral single dose (first 8 hours)
45678320|NCT01902134|Drug|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
45678321|NCT01902134|Drug|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)
45678322|NCT01902134|Drug|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
45678323|NCT05110586|Other|Electrotherapy|Applications will be applied for 4 weeks, 5 days a week
45836506|NCT00354978|Drug|Irinotecan|180 mg/m^2 by vein over 90 minutes on Day 1 of 14 day cycle.
45836507|NCT01794156|Behavioral|Cognitive behavior therapy|
46006385|NCT04578717|Procedure|Adhesive application - Etch&rinse|Enamel and dentine were etched using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light. The light intensity of curing unit was calibrated daily using curing radiometer .
46006386|NCT04578717|Biological|Adhesive application - Self-etch|The bonding adhesive was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
45598971|NCT03202901|Dietary Supplement|B-turmactive|"The treatment consists of daily administration of B-TURMACTIVE®.~Treatment with B-TURMACTIVE® will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable"
45836508|NCT01794156|Behavioral|Mindfulness-based stress reduction|
45836509|NCT01794156|Behavioral|Inference-based therapy|
46006387|NCT04595942|Drug|Midodrine Hydrochloride Tablets|Patients will be started on 5 mg Midodrine three times a day and after one week the dosage will be up-titrated to 10 mg three times a day and continued for 12 months. They will receive the medication at four-hour intervals upon rising in the morning (the last dose should not be taken later than 6 PM). In case of intolerance, the dosage will be reduced to 2.5 mg three times a day. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting).
46006388|NCT04595942|Drug|Fludrocortisone Acetate Tablets|Patients will be started on 0.05 mg of fludrocortisone twice daily and after one week the dosage will be up-titrated to 0.1 mg fludrocortisone twice daily taken for 12 months. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting). In this arm, potassium levels will be checked 7-14 days after dose stabilization.
46006389|NCT04595942|Behavioral|Lifestyle modification|Patients will be recommended to drink 2 to 3 liters of fluid per day, consume 10 grams of salt per day, and practice counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting) for 12 months.
46006390|NCT00566384|Drug|Dehydroepiandrosterone, BAY86-5314|Treatment with daily oral intake of two capsules containing 50 mg DHEA each. Treatment duration will be 24 weeks
46006391|NCT00566384|Drug|Placebo|Treatment with daily oral intake of two capsules containing Placebo. Treatment duration will be 24 weeks
46006392|NCT00574743|Drug|Enteric-coated Mycophenolate Sodium|
45836510|NCT04194060|Combination Product|Enhanced Recovery after Surgery group|"Tracheal intubation and with General anesthesia~Short acting anesthetic agents,avoid opioid agents~Omental patch repair with placement of sub hepatic drain~Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.~Post operative nausea and vomiting prophylaxis.~Encourage to mobilize out of bed after effect of general anesthesia has weaned off.~Initiation of feeding-Oral sips on day 1, step up day 2 onward~Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.~Removal of urinary catheter-after weaning from the effect of general anesthesia.~Sub hepatic drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.~Avoid opiod analgesics."
45840097|NCT00601926|Biological|bevacizumab|15 mg/kg over 90 minutes every 3 weeks
45840098|NCT00603018|Drug|Fluoxetine|8 weeks of fluoxetine(2.5mg,5mg,10mg,20mg,30mg,40mg,40mg,40mg)each week per day.
45840099|NCT00603408|Drug|Cisplatin|
45840100|NCT00603408|Radiation|Radiation Therapy|
45840101|NCT00603408|Procedure|Mastectomy|(RECOMMENDED BUT NOT REQUIRED)
45840102|NCT00603564|Procedure|Castar Starmed (CPAP) delivered by a helmet|Continuous Positive Airway Pressure delivered by a helmet with PEEP valve of 10 cmH2O and FiO2 0.5
45840103|NCT00603720|Drug|L-NAME|nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging
45840104|NCT00603720|Drug|L-Arginine|aids in nitric oxide production
45840105|NCT00603720|Drug|Phenylephrine|alpha agonist; 10 μg/kg/min infusion during PET study
46092246|NCT02798003|Other|Functional magnetic resonance imaging (fMRI)|The food-cue elicited response in the reward-circuitry of the brain will be assessed by using fMRI. This technique is based on different magnetic properties of oxygenated and deoxygenated blood. Increased neuronal activity causes an increase in blood flow. Thereby, neuronal activity is indirectly reflected by changes in blood oxygenation level-dependent (BOLD) contrast.
46092247|NCT00962767|Drug|gemtuzumab ozogamicin|2 IV infusions 6 mg/m2 administered monthly
46006393|NCT04596020|Other|Blood Flow Restriction Group (exercise with blood flow restriction using a Delfi unit)|Each group performs the same 4 exercises The BFR group will utilize the Delfi BFR unit
46006394|NCT04578366|Device|Extracorporeal Shockwave Therapy|ESWT along with conventional therapy ESWT + hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
46006395|NCT04578366|Other|Conventional Treatment|hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
46006396|NCT04596059|Other|Frisolac Gold Intensive HA|Regular medical care
46006397|NCT04596176|Other|Program Supportive Housing Services|The existing statewide SH model that included routine access to housing (voucher) and case management
46092248|NCT00962767|Drug|ATRA plus 6-MP and MTX|6-MP 50 mg/m2/day PO; MTX 15 mg/m2/q week IM; ATRA 45 mg/m2/day PO
46092249|NCT02817269|Other|Manual palpation|The manual palpation level will kept constant by applying enough digital pressure to cause the finger nail bed to blanch. When the nail will be turn pale, the amount of pressure will be measured at approximately 3 4kg/cm2 and will be maintained for 5-10 seconds to evoke referred pain. A manual palpation referred pain will be present if the pain radiated far enough for the patient to feel more than just a local pain.
45459597|NCT05152030|Diagnostic Test|Traditional Chinese version of the University of Pennsylvania of Smell Identification Test (UPSIT-TC)|The University of Pennsylvania Smell Identification Test (UPSIT), which was developed at the University of Pennsylvania, is one of the most reliable and the most widely used olfactory test.The test consists of four 10-odorant booklets. Each odorant is embedded in 10 to 50 µm urea-formaldehyde polymer microencapsules fixed in a proprietary binder and positioned on a brown strip which is located at the bottom of each page of the test booklet.4 When the examinee takes the test, each of the 40 odorants is released by scratching the strip with a pencil tip. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors.
45459598|NCT01376180|Drug|Lamotrigine|Administered according to the prescribing information in the locally approved label by the authorities
45459599|NCT04460638|Biological|Saliva collection|Saliva samples are regularly collected over a period of up to 30 consecutive days.
45459600|NCT04460638|Other|Clinical assessment|The participant's clinical data will be collected regularly over a period of up to 30 consecutive days.
45840106|NCT00622518|Drug|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
45840107|NCT00625404|Drug|Truvada|Daily single oral tablet of Truvada - a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
45840108|NCT00625404|Other|Placebo|Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
46006398|NCT04596176|Other|Intensive Supportive Housing Services|an intensive treatment SH model with a higher dosage of case management, family teaming, and access to a vocational specialist
46092250|NCT02817269|Other|Deep dry needling|Intramuscular needling will be carried out via deep dry needling into myofascial trigger point (MTrP) area without the introduction any substances. The aim is to elicit a local twitch response upon inserting the needle into the MTrP area and perform a neurological stimulation (by rotating the needle 360 degrees) to more easily evoke referred pain, holding for 10 seconds and then extracting the needle gently. The procedure will be followed by one minute of haemostatic compression.
46092251|NCT04010149|Device|Active tDCS|For the first two weeks of the study, participants will receive 20 min of brain stimulation, concurrent with cognitive training. Electrodes will be placed over the dorsolateral prefrontal cortex (active electrode), and the contralateral supraorbital site (return electrode).
46006399|NCT04596137|Behavioral|İnfant pain management|Kangaroo mother care was applied to the infants during heel prick. With kangaroo mother care, the pain of infants was reduced.
46092252|NCT04010149|Device|SHAM tDCS|For the first two weeks of the study, participants will receive 20 min of SHAM brain stimulation, concurrent with cognitive training. Electrodes will be placed over the dorsolateral prefrontal cortex (active electrode), and the contralateral supraorbital site (return electrode).
45459601|NCT05048576|Behavioral|Negative Reinforcement|"Terms to be used in negative reinforcement:~You've got to walk faster than that. You're so slow! Why do you walk like that? Did you learn how to walk yesterday? You're doing terrible. Who walks like that? You have potential but you don't use it. You'll never amount to anything. You're not putting very much effort into this. This is the worst pace you've had yet."
46092253|NCT02816957|Drug|nigella sativ|nigella sativa powder (2 gm/day) for 3 consecutive months.
46092254|NCT00642200|Procedure|Lichtenstein hernioplasty|
46092255|NCT00642200|Procedure|Laparoscopic TEP|
45459602|NCT05048576|Behavioral|Positive Reinforcement|"Terms to be used in positive reinforcement:~Good job, you're doing awesome! Keep up the good work! You've got this! You're almost done, just a few more minutes! That's a great pace! You're going strong! Keep it up! Nice work. Great job! Good stuff. Keep it up. You're doing an amazing job."
45459603|NCT05048576|Behavioral|Silence|No recordings will be played during this condition.
45459604|NCT05048576|Behavioral|Music|Participant's can choose their own music to play during this condition.
46092256|NCT02816801|Other|Butler-Program 2.0|Internet based intervention for elderly, in which they learn how to use e-mail, video conferencing and a blog, in addition to virtual relaxation exercises.
46006400|NCT00574899|Other|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
46092257|NCT00962923|Biological|Allogeneic Mesenchymal Stem Cells (AlloMSC)|Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10^6 cells/kg body weight).
46092258|NCT04181840|Diagnostic Test|Blood and faeces tests|During V1 - Laboratory tests, particularly for calprotectin concentration assessment
46092259|NCT04181840|Device|Impedance spectroscopy test|During V1 - the electrical impedance of anal sphincter muscles will be measured
46092260|NCT04181840|Diagnostic Test|Full gynecological and proctological examination|During V1 and V2 - Examination with a gynecological speculum, Two-handed examination, Rectal examination, and Anoscopy
45459605|NCT03485014|Drug|Exparel|EXPAREL 4 mg/kg
45459606|NCT05044910|Dietary Supplement|Ready to Use supplementary food (RUSF)|Children with malnutrition will be given RUSF
45459607|NCT03484858|Other|High glycaemic index meal and exercise|
45840109|NCT00626340|Drug|MDD diagnosis and Estrogen treatment|Treatment for major depressive disorder occurring in the context of the menopause while participating in brain imaging sessions pre and post treatment. Women receiving treatment for depression will be compared to normal controls receiving estrogen only for physical symptoms of menopause.
45840110|NCT00626340|Drug|MDD diagnosis and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.
45840111|NCT00626340|Drug|MDD diagnosis with both Estrogen and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
46092261|NCT04181840|Diagnostic Test|Transanal ultrasonography|During V1 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
46092262|NCT04181840|Diagnostic Test|Anorectal manometry|During V1 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
46092263|NCT04181840|Other|Determining the degree of sphincter injury|During V2 - conducting the examination will finally determine the extent of sphincter damage, present the patient with therapeutic options and decide on the treatment or rehabilitation of sphincter.
45459608|NCT03484858|Other|High glycaemic index meal and rest|
46092264|NCT02797847|Drug|ALN-TTRSC02|Ascending doses of ALN-TTRSC02 by subcutaneous (SC) injection
46092265|NCT02797847|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
46006401|NCT00574899|Other|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
46006402|NCT04595825|Biological|Anti-human CCL24 monoclonal antibody (CM-101)|Anti-human CCL24 monoclonal antibody (CM-101) 100 mg Intravenous Infusion over 60 minutes (±5 minutes)
46006403|NCT04595825|Other|Placebo|Placebo (0.9% sodium chloride) intravenous infusion
46006404|NCT00574977|Biological|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be < 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
46006405|NCT00574977|Biological|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be < 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
46006406|NCT00574977|Biological|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 infusion of vvDD-CDSR.~Cohort 1: 3 x 10e8 p.f.u; Cohort 2: 1 x 10e9 p.f.u.; Cohort 3: 3 x 10e9 p.f.u."
46006407|NCT03453645|Procedure|ventricular tachycardia ablation|The usual organization of hospitalization of the patients addressed for ventricular tachycardia ablation and his follow-up are not modified by the protocol. .
46006408|NCT04595708|Behavioral|Phone Call|Calls were made by volunteers trained to engage with participants. Call structure was unscripted and call length was recommended to be between 5-10 min.
46092266|NCT02678780|Drug|Lenvatinib|
46092267|NCT02795741|Device|Cooling Bolero|a vest filled with a new material (not ice or a gel) that provides controlled cooling by absorbing heat
45459609|NCT03484858|Other|Low glycaemic index meal and exercise|
45459610|NCT03484858|Other|Low glycaemic index meal and rest|
46006409|NCT03453606|Other|Home respiratory rehabilitation|Home care is individual (often with the spouse or the carer), during 1h30, one visit per week for 8 weeks, after completion of the educational diagnosis, under direct supervision of a member of the team, with continued physical activities in autonomy the others days of the week, according to a personalized action plan. No visit is scheduled in the pulmonologist, the general practitioner or in the rehabilitation center. The team includes pulmonologist, nurses, dietician, socio-medical beautician and a administrative assistant.
46006410|NCT03453606|Other|Center respiratory rehabilitation|"In an outpatient setting, the course is performed in groups of 6 to 8 patients, during sessions from 3 to 7 am, under the direction of health professionals, 3 to 5 times a week, for 4 to 6 weeks, for a total of 20 to 24 sessions. Internally, patients come to complete hospitalization for 4 weeks. This duration can be modulated according to the evolution of the patients.~Supervision is carried out by the entire team including pulmonologists, nurses, physiotherapists, psychologists, activity professors adapted physicists, dietician"
46006411|NCT04595669|Behavioral|Personalised advise|personalised dietary advice in combination with feedback on dietary behaviour and health status (i.e. waist circumference, blood pressure, cholesterol, glucose and triglycerides)
46092268|NCT02795663|Device|NIRS EEG HR recording|NIRS EEG HR recording
46092269|NCT02678546|Other|Other|case review of diagnosed disease
46092270|NCT00963001|Drug|Treprostinil diethanolamine|Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth within 10 minutes of consuming each of four standardized meals on Study Days 1, 8, 15, and 22.
46092271|NCT00963001|Other|Standardized meals|Each subject will receive one of four different standardized meals of varying caloric and fat content in a randomized sequence such that all subjects will receive all four meals over the course of the study. Each subject will receive one standardized meal for breakfast on Study Days 1, 8, 15, and 22.
46006412|NCT04595552|Other|language therapy|auditory training and language therapy for 6 months up to 2 years in 2 session per week the duration of session 30 minuets
46006413|NCT03453411|Other|Non interventional study|Non interventional study
46092272|NCT04235153|Other|Evaluation of the 9 dimensions of the CANUT-QVA questionnaire|"Evaluation of the contribution of a new questionnaire by patients with solid or hematological cancer according to 9 dimensions:~Making food~Place where the meals are eaten~Eating and drinking: Nutrition~Eating and drinking: The pleasure of tasting, chewing~Eating and drinking: Satiated, well being~Food preparation: Supply, choice, presentation~Eating and drinking: Feelings~After eating: heaviness, discomfort, hunger~Taste/Odour Problems to confirm the number and structure of factors obtained at the end of the pre-study and to remove redundant questions."
46006414|NCT04595357|Procedure|Iris shelf technique|Removal of posterior segment intraocular foreign bodies through corneal incision combined with phaco-vitrectomy
46092273|NCT04182542|Device|Radiofrequency|The volunteers will receive radiofrequency (TECAR-BTL® device, with epidermal temperature above 40ºC) in the right infraumbilical abdominal region, with an application time of 10 minutes (2 minutes per applicator area) and the left region will be used as control. A single session will be held. After approximately 30 days of this application the material for histological analysis will be collected during the surgical act, at which point the skin and the subcutaneous tissue of the infraumbilical region are discarded by the surgeon.
46092274|NCT05290285|Dietary Supplement|Amino-Ther Pro|Food supplements
46092275|NCT05290285|Dietary Supplement|Placebo|Maltodextrin
46092276|NCT02797691|Other|CaCBT|Culturally Adapted Cognitive Behaviour Therapy
46092277|NCT02797691|Other|Medication/ Psychotherapy|Medication/ Psychotherapy used as usual
46092278|NCT00643136|Drug|Pregabalin|Pregabalin capsules 75 mg twice daily on Days 1-4, then 150 mg twice daily on Days 5-28
46092279|NCT00643136|Drug|Placebo|Matching placebo capsules twice daily for 28 days
46092280|NCT00963079|Procedure|Embryo cryopreservation|Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
46092281|NCT00963079|Procedure|Fresh blastocyst transfer|Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
46092282|NCT02797535|Procedure|Endoscopy procedures|GI fluids samples will be collected from: (i) fluids suctioned during standard endoscopy procedures / pouchoscopy, (ii) from ileostomy/colostomy bags removed for bag replacement and (iii) from stool samples collected by patients after pouch surgery.
46092283|NCT00641342|Device|onlay mesh|StomaMesh (Precut heavyweight polypropylene mesh) Vypro Mesh (lightweight Prolene and vicryl mesh)
46092284|NCT02795585|Other|QFR (observational)|QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
46092285|NCT02676128|Behavioral|Twine Collaborative Care Application|This application features a 24-hour medication clock that displays ART dosing schedule and allows participants to record the doses taken. It also features an interactive health coaching feature which will be used to provide support, encouragement, and resources to participants.
46092286|NCT02676128|Behavioral|Information-Motivation-Behavioral Skills Model of ART Adherence|Combines brief motivational interviewing, cognitive behavior therapy, and problem-solving skills to help participants formulate and follow ART adherence goals.
46092287|NCT03944707|Drug|LOU064 100 mg|LOU064 100 mg once daily orally administered as two 50 mg capsules
45836511|NCT04194060|Combination Product|Conventional|"Tracheal intubation~Short acting anesthetic agents, avoid opiod anesthesia agents.~Omental patch repair along with sub hepatic drain placement.~Post operative nausea and vomiting prophylaxis.~Ambulation-as per patients' own request.~Initiation of oral feed- after passage of 1st flatus.~Nasogastric tube removal-output <300ml/day with resolution of ileus.~Removal of urinary catheter- when patient sits on bed side/ambulate.~Removal of sub hepatic drain-when patient tolerates unrestricted amount of liquid diet and drain output is less than 200 ml /day.~Patient will receive opiod analgesics."
46092288|NCT03944707|Drug|Placebo|Placebo once daily administered orally as capsules
45836512|NCT00355914|Procedure|Lumbar Facet Joint Nerve Block|Lumbar Facet Joint Nerve Block
45836513|NCT01792596|Other|Pasta with protein|Pasta with Protein
46006415|NCT04595318|Drug|Standard clinical care and varenicline|Standard clinical care includes methadone clinic-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies. Varenicline therapy includes a one month's supply of the medication in standard doses: 0.5 mg for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 21 days.
46006416|NCT04595318|Other|Standard clinical care|Standard clinical care includes methadone clinic-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies
46006417|NCT04595201|Device|NIPT|Non-invasive pregnancy testing
46092289|NCT02795507|Device|Rehabit-Tec System|Device with visual and kinesthetic feedback
46092290|NCT02795507|Device|Rehabit-Tec System|Device without visual and kinesthetic feedback
46092291|NCT02795507|Behavioral|conventional exercises|
46092292|NCT00643214|Device|Tetrix|Twice daily topical application
46092293|NCT00643214|Device|Tetrix|Twice daily topical application
45836514|NCT01792596|Other|Pasta with Fiber|Pasta with Fiber
45836515|NCT01792596|Other|Pasta|Pasta
46092294|NCT05449301|Other|Rhythmic Auditory Stimulation|The participants will receive RAS on regular treadmill for balance and gait improvement. one session per day, 3 session per week for consecutively 12 weeks.
46092295|NCT05449301|Other|Treadmill Training|participants will be trained conventionally (bipedal) on regular treadmill. one session per day, 3 session per week for consecutively 12 weeks.
45836516|NCT00356304|Behavioral|Motivational interviewing|Participants assigned to motivational interviewing will attend two 1-hour sessions of motivational interviewing over 2 consecutive weeks, followed by a third session 8 weeks later. Motivational interviewing is a type of counselling. Each session is of approximately 1 hour duration.
46092296|NCT05449301|Other|Unilateral Step Training|Patients will be trained on regular treadmill for both paretic and non paretic lower extremity. Single session per day, 3 session per week for consecutively 12 weeks.
46092297|NCT05664230|Other|osteopathy|five osteopathy sessions
46092298|NCT05448755|Drug|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
46092299|NCT01563367|Drug|Iron isomaltoside 1000 (Monofer®)|All subjects randomised to this group will receive 1000 mg iron isomaltoside 1000 as a single dose infusion administered over 15 minutes
46092300|NCT01563367|Drug|Natriumklorid 9 mg/ml, Fresenius Kabi|All subjects randomised to this group will receive an infusion of 100 ml 0.9% sodium chlorid administered over 15 min.
46092301|NCT00641498|Behavioral|Psychotherapy|Individual supportive
46092302|NCT04101110|Other|Renal biopsy|Kidney biopsy will be done to understand the nature and degree of structural kidney damage
46092303|NCT02797223|Behavioral|Semi-structured interviews|Qualitative phenomenological study. Data collection will be done through semi-structured interviews. Each interview will last between 60 and 90 minutes. It will be the same researcher who interviewed and analyze them.
46092304|NCT02309593|Device|PROFEMUR® Xm Femoral Stems|THA using PROFEMUR® Xm Femoral Stems
46092305|NCT02795273|Drug|Grass-SPIRE|
46092306|NCT02795273|Drug|Placebo|
46092307|NCT04180124|Other|Walking|"Patients walk over ground on a mat with sensors and on a treadmill with sensors (in different conditions) to compare their movement pattern.~Also the movement pattern will be compared between walking at comfortable walking speed en fast walking.~Finally, the correlation between upper extremity impairment and arm swing will be investigated."
46092308|NCT00963313|Drug|Adalimumab (HUMIRA®)|Prefilled syringes containing 40 mg Adalimumab in 0.8 ml injection solution. Study drug will be subcutaneously self-administered every 2 weeks during 24 weeks.
46092309|NCT02797301|Other|synthetic test|The children performed the synthetic test with no time restriction.
46092310|NCT02797301|Other|computerised test|The children performed the computerised test with no time restriction.
46092311|NCT02676440|Other|Treatment|F13/T38
46092312|NCT02676440|Other|Comparator|M26
46092313|NCT00963391|Other|ABHS use|"Centers assigned to the intervention group were provided with ABHS dispensers with a gel solution with ethyl alcohol at 62% as active ingredient (Purell®, GOJO Industries, Dayton, Ohio). A total of 85 dispensers were installed, one dispenser was installed in each center of size less than 14 children, and one per classroom plus an additional one for common areas in centers with more than 28 children. Proper safety measures were followed.~Standardized ABHS training workshops for staff and children in centers allocated to the intervention were carried out simultaneously with dispenser installation. Thirty minute refresher sessions about ABHS technique were provided to staff and children on a monthly basis, for a total of 8 sessions per center."
46092314|NCT02797145|Drug|Digoxin dose-adjusted|Serum digoxin concentration : 0.5 to 0.9 nanogram/mL
46092315|NCT02797145|Drug|Standard dose|the dose of digoxin will be determined at the physician's discretion using traditional dosing methods.
46092316|NCT05663060|Drug|Probiotic Formula|Probiotic Formula
46092317|NCT04011007|Procedure|vitrectomy with or without inverted ILM flap technique|vitrectomy without ILM peeling versus vitrectomy with inverted ILM flap technique in cases of macular hole retinal detachment in high myopic eyes.
46092318|NCT02690129|Drug|Vaginal Progesteron|
46092319|NCT02681354|Other|Biorescue training|
46092320|NCT02797379|Other|Psychoeducation|The intervention is focused on psychoeducation. Four psychoeducation guides will be available: parent/caregiver, adult with ASD, adolescent with ASD, and child with ASD. The guides introduce the concept of anxiety and how it presents in individuals with ASD, different anxiety triggers, strategies that can be used to manage anxiety, and an introduction to specific anxiety disorders. Level of detail, language and presentation of content will vary across the guides to be appropriate for the functioning level of the readers.
46092321|NCT00549055|Drug|Macugen|Dosage form: solution for injection (intravitreal) Dosage: 0.3mg Frequency: every 6 weeks (9 injections/year)
45459611|NCT03633734|Drug|Sequential Treatment|One cycle of the treatment lasts for 56 days. Patients will receive chemotherapy based on Nab-paclitaxel Plus Gemcitabine and modified Folfirinox in sequence order. The cycle will repeat until progression or intolerance of toxicity.
45836517|NCT00356304|Behavioral|Treatment as usual|Participants will continue with their normal treatment regimen as usual.
46092322|NCT04237883|Behavioral|Standard communication email|This is the base communication that all physicians will receive.
45836518|NCT03138096|Biological|Pb(PfCS@UIS4)-infected mosquitoes|Pb(PfCS@UIS4)-infected mosquitoes
45836519|NCT03138096|Other|Challenge infection P. falciparum|Challenge infection with bites of five infected Pf mosquitoes
45836520|NCT02855892|Other|Placebo|
46092323|NCT04237883|Behavioral|Social comparison Intervention|The social comparison is added onto the standard communication email to provide some peer comparison between the physicians.
46092324|NCT04237883|Behavioral|Leadership Training|Clinic and Physician leads will be provided with a clinic leadership training seminars in leadership, quality improvement, and support from the Quality Improvement team at UCLA Health.
45459612|NCT03481504|Behavioral|Acceptance & Commitment Therapy-Exposure and Perspective Taking|To increase patients' participation by improving their level of coping with chronic pain.
45678324|NCT01954082|Drug|myo-Inositol 5% Injection|"Abbott Nutrition Division, Abbott Laboratories is supplying myo-Inositol 5% Injection to the clinical centers for the duration of the trial.~Inositol: myo-Inositol 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. It is administered via IV infusion using syringe pump over 15-30 minutes twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose)."
45836521|NCT02855892|Drug|GV1001|
46006418|NCT04595396|Procedure|Laparoscopic Gastric Bypass|The LGBP was performed using a classic Roux-en-Y procedure. Briefly, a gastric pouch of 30-50 cc was constructed with an antecolic calibrated gastro-jejunal anastomosis (mechanical anastomosis using a 2.5 mm load). The biliary and alimentary limbs measured ≈70 cm and ≈150 cm, respectively, and the jejuno-jejunal anastomosis was also performed in a latero-lateral fashion (mechanical anastomosis using a 2.5 mm load). Mesenteric defects were closed with running non-absorbable sutures and the omentum was divided in every case
46006419|NCT03453333|Procedure|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
46006420|NCT03453333|Procedure|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
46006421|NCT00566423|Other|Blood draw|Venous and Arterial Blood draw samples; 6 Minute Walk test
46006422|NCT01149343|Biological|Immunotherapeutic GSK2302025A, different formulations|Intramuscular administration
46006423|NCT04595240|Diagnostic Test|semen analysis|semen analysis
46006424|NCT04578561|Procedure|Prophylactic mesh use|After laparotomy sutured clousur the abdominal wall wound is reinforced using a suprafascial synthetic mesh.
46006425|NCT04595162|Biological|GC019F|GC019F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive one single infusion of GC019F.
46006426|NCT01149148|Device|INVOS Somanetics Cerebral Oximeter|"Sequence of Interventions To Increase Cerebral Oxygen Saturation~Check head and cannula position~Increase mean arterial pressure~Increase pump flow~Increase systemic oxygenation~Increase PaCO2 > 45~Increase anesthetic depth by increasing volatile anesthetic or by administering propofol boluses~Consider PRBC transfusion for Hct < 21%"
46006427|NCT01149148|Device|INVOS Somanetics Cerebral Oximeter|INVOS Cerebral Oximetry blinded monitoring with no deviation in surgical procedures or standard of care in anesthesia.
46092325|NCT05542706|Other|Accompanying caregivers by paramedical team|At each study visit (baseline, one week after hospital discharge, 4-8 weeks after surgery, 8-12 weeks after surgery and 16-20 weeks after surgery), the paramedical team have a dedicated meeting with the caregiver of the patient (at hospital or remote) and teach them the care procedures needed in accompanying the patient and the evaluate the learning progress. The training is adapted to each caregiver, according to his/her motivation and his/her ability. The goal is to have the training regarding the enteral nutrition, prevention of dehydration, pain management.
46092326|NCT00883116|Drug|Ixabepilone|
46092327|NCT00883116|Drug|Doxorubicin|
46092328|NCT00883116|Drug|Paclitaxel|
46092329|NCT02139397|Drug|DFMO|
46092330|NCT02139397|Drug|Bortezomib|
46092331|NCT02795429|Drug|PDR001|PDR001 will be administered intravenously
46092332|NCT02795429|Drug|INC280|INC280 will be administered orally
46092333|NCT00643292|Drug|amoxicillin/clavulanate postassium (Augmentin ES-600)|amoxicillin/clavulanate postassium 90/6.4 mg/kg/day, given in divided doses q12h, for 10 days
46092334|NCT00643292|Drug|azithromycin SR|azithromycin SR 60 mg/kg x 1 dose
46092335|NCT01969825|Behavioral|Massage|
45459613|NCT03633656|Device|Model predictive control|Computer aided dose selection for the treatment of iron deficient anemia.
45459614|NCT03633656|Device|Model Predictive Control of Iron Dosing|Model Predictive Control of Iron Dosing
45459615|NCT03481426|Other|Workplace intervention|The study contains normal services of occupational health. Both intervention groups are based on voluntary will, and the normal care and services are guaranteed. In the intervention group new working method which improve co-operation between occupational health services and workplaces.
45678325|NCT01954082|Drug|Placebo|% glucose(dextrose)
45678326|NCT01417000|Biological|GVAX Pancreas|
45836522|NCT02816580|Other|Blood collection|
45836523|NCT02713854|Procedure|endometrial biopsy|An endometrial biopsy taken 2-3 months prior to IVF cycle
45836524|NCT04182516|Drug|NMS-03305293|All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.
45836525|NCT02485860|Device|Melectis G|
45836526|NCT00357162|Drug|belinostat|Given IV
45836527|NCT04011072|Radiation|Far infrared radiation|The treatment group will receive FIR for 40 minutes on the skin above the fistula during each dialysis session for one year.
46092336|NCT02816645|Procedure|Magnetic Resonance Imaging (MRI)|
46092337|NCT00963625|Procedure|Embryo cryopreservation|Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
46092338|NCT00963625|Procedure|Fresh blastocyst transfer|Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
45459616|NCT03484780|Device|VisONE ADS|VisONE stimulator and leads for delivering continual Synchronized Diaphragmatic Stimulation
46006428|NCT04594967|Other|Patient-centred care home (PCMH)|New model of care defined by care provision by a team of people centered in the community that is both proactive and coordinated to improve the health and wellness of the people in that community.
46092339|NCT02675816|Device|Inspire® Upper Airway Stimulation (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System. This is a permanent, implantable therapy device, which consists of three implantable components: an implantable pulse generator (IPG), a stimulation lead, and a sensing lead. In addition, the patient receives a handheld remote to activate the therapy
45459617|NCT03481348|Device|Pharyngeal Electrical Stimulation|Pharyngeal Electrical Stimulation is applied at the pharynx via a nasogastral tube for 10 minutes per day on 3 consecutive days.
45459618|NCT01376258|Drug|5ARI|dutasteride or finasteride
45459619|NCT05151952|Radiation|Other: Registry|Registry of cancer patients who receive proton radiation therapy.
46092340|NCT04162392|Other|shared decision making|Patients can choose the intervention that they want. There are different physiotherapy interventions were the patients have to do physical activity during the hospital stay. The physiotherapist explains the advantages and disadvantages of each treatment before they choose.
46092341|NCT04162392|Other|control group|Patients receive a physiotherapy intervention but they do not have the opportunity to choose the treatment
46092342|NCT00641576|Device|ACE CONNECT Endosseous dental implant|"Subjects in this study receive ACE CONNECT Internal-Connection dental implants to: 1)replace a missing tooth in an edentulous area of the maxilla or mandible restored with a single-unit crown (may include up to two non-adjacent areas as study sites) or, 2)subjects with an edentulous mandible will receive two implants placed in the lower canine position and restored with an implant-retained removable over-denture.~Subjects will return for four follow-up evaluations scheduled at 6, 12, 18 and 24 months after delivery of the permanent restoration."
46092343|NCT02797067|Drug|indomethacin suppository|100mg rectal indomethacin 30min before ESWL
46092344|NCT02797067|Drug|Glycerin Suppository|30min before ESWL
46092345|NCT00655044|Drug|insulin detemir|Safety and effectiveness data collection in connection with the use of drug Levemir in daily clinical practice.
46006429|NCT00624988|Procedure|Vibration Therapy|Treatment will consist of 10 sessions of 60 seconds each with one minute intervals in between at 50 Hz frequency three times per week for three months.
46006430|NCT04313101|Other|withdrawl of blood samples for thyroid function testing|"Blood samples will be withdrawn from patients admitted to the intensive care for more than 7 days to measure Thyroid hormones (Free T3: Tri-iodothyronine and Free T4:thyroxine) and TSH ( Thyroid Stimulating Hormone) using ELISA kits. Reference ranges will be as follows: TSH 0.4-4mU/L, Free T3 2-4.4 mU/L, Free T4 0.8-1.9 mU/L. Patients will be then categorized into one of the following categories~Euthyroid ( Normal TSH, FT3 and FT4)~Hyperthyroid (Low TSH) either overt (increased FT3 and /or FT4) or subclinical (normal FT4 and FT3).~Hypothyroid (Elevated TSH) either overt (Low FT3 and FT4) or subclinical (Normal FT3 and FT4)~Non-thyroidal illness syndrome : normal or low TSH in addition to low FT3 ± Low FT4 levels."
46092346|NCT02676050|Other|Optical Imaging Agents (EMI-137, NAP)|Both optical imaging agents (NAP and EMI-137) will be administered to each patient during a bronchoscopy procedure. A novel delivery catheter (to deliver both agents), imaging fibre and endomicroscopy system with viewer software will be used to detect c-MET and activated neutrophil signal in the human lung.
46092347|NCT02676050|Device|Delivery Device Cathetar and Miniaturised imaging fibre|Both optical imaging agents (NAP and EMI-137) will be administered and imaged simultaneously during a bronchoscopy procedure using the devices mentioned above.
46092348|NCT02676050|Device|Optical endomicroscopy system|The signal emitted by both optical imaging agents (NAP and EMI-137) will be visualised using a novel endomicroscopy system.
46092349|NCT00963703|Drug|Rituximab|Rituximab 1000 mg Intravenously day 1 and day 15
46092350|NCT02796989|Dietary Supplement|Wheat bran|20 g each day
46092351|NCT02796989|Dietary Supplement|Placebo|20 g each day
45459620|NCT05151874|Drug|Abobotulinum toxin A|To measure ROM evolution in patients with post-stroke spasticity in the upper limb with spasticity pattern III.
45459621|NCT03531840|Drug|Olaparib|All subjects will take olaparib by mouth twice per day until disease progression or unacceptable toxicity
45459622|NCT03531840|Device|ClinOmics|Non-significant risk (NSR) device
45459623|NCT04915274|Other|uses of an application|Patients will be advised that they can still use their QuestOnco handset if they are hospitalized only for a treatment-related toxicity.
45459624|NCT05151796|Drug|Aspirin|Daily aspirin intake for cardiovascular prevention
45678327|NCT01417000|Biological|CRS-207|
45678328|NCT01417000|Drug|Cyclophosphamide|
45678329|NCT01416142|Device|PureVision2 HD contact lenses|Lenses to be worn through 1/2 of an HD movie. Following the movie, all subjects were to wear the dispensed contact lenses on a daily wear basis for approximately one week.
45678330|NCT01416142|Device|Spectacles|Spectacles to be worn throughout 1/2 of an HD movie.
46092352|NCT00655122|Drug|Dalteparin sodium|Dalteparin sodium was administered at a daily dosage of 5,000 UI anti-Xa by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
46092353|NCT00655122|Drug|Placebo|Placebo was administered with a daily injection of 0.2 mL by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
46092354|NCT05531630|Device|Nasal rinsing with saline 0.9%|"Nasal irrigations with saline (NaCl 0.9%) are considered golden standard in the treatment of chronic rhinosinusitis. Sachets consisting of mixtures for saline solutions, produced by DOS Medical®, consist of 1.875g sodium chloride and 0.625g sodium bicarbonate (figure 5). The content of the sachet has to be dissolved in 250mL heated water (lukewarm drinking water, max 37°C) in a NasoFree® nasal irrigator (Figure 4). Afterwards, the solution has to be mixed according to the instructions, the temperature has to be tested on the palm or forearm and afterwards, the product can be used. The patient will be asked to rinse their nose with the saline solution, once daily, for six weeks.~The sachet with rinsing salt is considered to be a class I medical device and has a CE-label (CNK number 3309028)."
46006431|NCT00577668|Drug|Melphalan, Velcade, Thalidomide, Dexamethasone|To assess, in patients with one or two prior auto transplants, the efficacy of a high-dose combination chemotherapy with MEL 300 (in 3 fractions of 100 mg/m2 on days -7, -4, -1) plus VTD (Velcade = bortezomib 1.3 mg/m2 on days -7, -4, -1; Thalidomide 200 mg/d on days -1 through -7; Dexamethasone 40 mg on days -7, -6, -4, -3, -1, 0) followed by autologous peripheral blood stem cell (PBSC) infusion of a minimum dose of 3 million CD34 cells/kg.
46006432|NCT04313179|Other|Music therapy|Mozart lullaby music
46006433|NCT04313179|Other|Sucrose|0.5 ml of 24% Sucrose
46092355|NCT05531630|Device|Nasal rinsing with Xylitol|"Xylitol is a sugar-alcohol that is already implemented in the treatment of patients with (difficult-to-treat) chronic rhinosinusitis. Some (pilot) studies have already showed a positive effect in CRS patients without cystic fibrosis. Xylitol nasal rinsing salt, produced by DOS Medical®, is a mixture of 4g Xylitol, 1.875g sodium chloride, 0.625g sodium bicarbonate and 0,03g mint (Figure 3). The content of the sachet has to be dissolved in 250mL heated water (lukewarm drinking water, max 37°C) in a NasoFree® nasal irrigator (Figure 4). Afterwards, the solution has to be mixed according to the instructions, the temperature has to be tested on the palm or forearm and afterwards, the product can be used. The patient will be asked to rinse their nose with the Xylitol solution, once daily, for six weeks.~The sachet with rinsing salt is considered to be a class I medical device, has a CE-label (CNK number 3309036) and is already commercially available in Belgium and The Netherlands."
45678331|NCT01415986|Drug|Temoporfin|A single dose of 0.15 mg of Temoporfin per kilogram of body weight will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes.
46092356|NCT05441579|Behavioral|Behavioral Economics (BE) recruitment strategies|Behavioral economics (BE), a method of economic analysis that applies psychological insights into human behavior to explain economic decision-making, has broad applicability and its techniques offer a novel way that may be applied to try to help enhance study recruitment and enrollment.
46092357|NCT05441579|Other|Biofeedback-based virtual reality (VR-BF)|Phase 1 will focus on patients that would be enrolled into a biofeedback-based virtual reality (VR-BF) arm.
45678332|NCT01415986|Device|Medical diode laser emitting light at a wavelength of 652 nm. (Ceralas PDT 652, CeramOptec GmbH)|Light dose of 20 J/cm, at a rate of 100 mW/cm, will be delivered to the target tumor and margins, within 200 seconds.
46092358|NCT05441579|Other|Manage My Pain|Commercially available and free app to track, analyze and monitor pain.
46092359|NCT02638116|Drug|Ibrutinib|Ibrutinib will be administered at a dose of 560 milligram (mg) orally (4 x 140 mg capsules) on Day 1 and Day 7.
46092360|NCT02638116|Drug|Omeprazole|Omeprazole will be administered at dose of 40 mg tablets orally once daily from Day 3 to Day 7.
46092361|NCT02681042|Procedure|Left atrial appendage closure|The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
45678333|NCT01415908|Device|INFUSE Bone Graft|Subjects enrolled in the investigational treatment group will receive surgical treatment with INFUSE® Bone Graft, the CAPSTONE® Spinal System, and posterior supplemental fixation (in this study the CD HORIZON® Spinal System). The investigational treatment will be implanted using a TLIF surgical approach.
46006434|NCT04595084|Behavioral|Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell|MBCT-R is designed to foster resilience and prevent new-onset anxiety and depression disorders or exacerbation of existing conditions. MBCT-R follows the MBCT structure of eight classes and one half-day retreat, with home practice and specific daily meditation, but is live-online and focuses on specific stressors (COVID-19, its economic and social consequences). Classes of 40-50 participants are led by 2 co-leaders. Participants have CHA MindWell Monitoring and telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a televisit with a clinician. If monitoring with CAT-MH interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
45836528|NCT00358332|Biological|FMP2.1/AS02A|FMP2.1 will be reconstituted in AS02A adjuvant. Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.
45836529|NCT00358332|Biological|Rabies vaccine (RabAvert)|RabAvert, white, freeze-dried vaccine for reconstitution with diluent. Dosage: 1.0 mL of rabies vaccine.
46092362|NCT02681042|Device|SentreHeart Lariat®|The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
46092363|NCT05351125|Procedure|cardiac catheterization|catheterization in critical congenital heart disease requiring atrial septostomy or balloon valvuloplastyor PDA stenting
46092364|NCT04164264|Drug|Propofol|At T0, a propofol infusion at a rate of 1.5 mg/kg/min will be started until apnea is achieved. Loss of consciousness will be defined clinically using loss of eyelash reflex (TLOER) and tolerance of nasal cannulae (TNC), tested every 10 sec., and by a BIS <60 for 30 sec. (TBIS). Apnea will be defined as absence of end-tidal CO2 for at least 20 seconds (TAPNEA). A saliva sample with be taken under anesthesia for genome-wide association study and principal component analysis.
46092365|NCT02795039|Drug|Fulvestrant|Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Fulvestrant into the right buttock (upper outer quadrant)
46092366|NCT02795039|Drug|Fulvestrant|Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Faslodex® (Fulvestrant) into the right buttock (upper outer quadrant)
46092367|NCT01633411|Device|Focal Cryoballoon Ablation System - 6 seconds|"Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
46092368|NCT01633411|Device|Focal Cryoballoon Ablation System - 8 seconds|"Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
46092369|NCT01633411|Device|CryoBalloon Focal Ablation System - 10 seconds|"Ablation of Barrett's Esophagus using the Focal CryoBalloon Ablation System. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
46092370|NCT02675894|Device|cooled-wet electrode|RFA is performed using three cooled-wet electrodes in switching bipolar mode. The electrode is anticipated to reduce tissue resistance by releasing small amount of saline during the procedure, which may lead larger ablative volume by delivering more RF energy.
46092371|NCT02675894|Device|separable clustered electrode|RFA is performed using separable clustered electrode in switching monopolar mode.
46092372|NCT02796833|Drug|SMOFlipid20%|
46092373|NCT04160364|Other|qualitative study|qualitative research via guided interview
46092374|NCT02678624|Other|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
46092375|NCT00963781|Device|Medtronic Endeavor Stent|The study population was to consist of 900 consecutive, eligible patients with ischemic heart disease scheduled to undergo elective percutaneous coronary revascularization and amenable to treatment with an Endeavor drug-eluting stent with reference vessel diameter between 2.5 and 4.0 mm. Patients will be assigned to 6 month duration of post-procedure thienopyridine treatment with indefinite aspirin (minimum 81 mg daily) according to protocol. Recruitment was terminated early due to difficulty recruiting patients and difficulty achieving patient compliance with the six month anti-platelet protocol.
46092376|NCT00963781|Drug|Reduced duration (6 months) DAPT|
46092377|NCT04578275|Other|diagnostic strategy using ECGI|"Procedure: Drug treatment, CVE, Pulmonary vein ablation isolation according to treatment guidelines and investigators discretion.~ECGI: customized body surface mapping (57 electrodes) at the inclusion in the study, after treatment assignment and prior to AF ablation procedure."
46092378|NCT02795195|Radiation|Carbon ion radiotherapy (CIRT)|Four dose levels (54GyE, 57GyE, 60GyE, 63GyE) are planned within the Phase I part. Daily fraction of 3 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., maximal tolerated dose, is determined or if the treatments to 63 GyE are safely delivered, the recommended dose (or 63 GyE) will be the prescribed dose in the Phase II part of the study. Ninety-five percent (95%) of the isodose line should cover the gross tumor volume plus 3~5mm.
46092379|NCT02673710|Other|No intervention|Besides participant reported outcomes and a muscle strength test no interventions are administered, all treatment decisions are at the discretion of the physician and will be in line with local clinical practice and labeling
46092380|NCT04009603|Drug|Probiotic Agent|"Probiotics are live microorganisms, which when administered in adequate amounts confer a health benefit effects on the host.~Many clinical trials have been done on probiotic which show its use as a single or as an adjuvant drug therapy for various diseases with no or rare side effects. It is now frequently used agent for various diseases.~Apart from this many studies have been published related to effects of probiotics on PCOS, which shows effectiveness of probiotics when used for 8 to 12 weeks with no adverse effects observed by these micro-organisms but none of the study have compare it with standarad drug"
45840112|NCT00626340|Drug|No depression and estrogen treatment|Control participants with no MDD diagnosis received estrogen only for the treatment of physical symptoms of menopause.
45840113|NCT00626574|Drug|Epoetin alfa|Intravenous administration of epoetin alfa (40,000 IU) immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
45840114|NCT00626574|Drug|Saline|3ml of saline will be administered via an IV push immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
45840115|NCT00626808|Drug|No Intervention|There were no interventions. No subjects were enrolled in this retrospective database study.
46092381|NCT04009603|Drug|Metformin|"Metformin, an insulin sensitizer, is an oral biguanide that is most commonly prescribed for the management of type II diabetes mellitus and various symptoms of PCOS. It is derived from the extract of Galega officinalis.~It remediates hyperglycemia through activation of AMPK which stimulates glucose uptake and its consumption; promote fatty acid oxidation along with suppression of hepatic glucose production. It is also involved in increase GLUT4 translocation in the muscle and fat leading to decrease hepatic lipid synthesis. Moreover, It is also reported that it decreases gut absorption of glucose by increasing the glucagon-like peptide-1 (GLP-1) in this way, it reduces the insulin requirement too.All of these actions of metformin decrease insulin resistance and thus improve the state of hyperinsulinemia associated with diabetes and PCOS"
46092382|NCT02635230|Drug|Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.|
46092383|NCT02673554|Drug|GIP Bolus|bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
46092384|NCT02673554|Drug|GIP Clamp|hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
46092385|NCT02673554|Procedure|Oral glucose tolerance test (OGTT)|an oral glucose challenge (75 g)
46092386|NCT02673554|Procedure|hyperglycemic clamp|a hyperglycemic clamp (capillary venous glucose concentration ~ 8.5 mmol/l)
46092387|NCT00964015|Drug|6% Hydroxyethyl Starch 130/0.4|
46092388|NCT00964015|Drug|0.9% Normal Saline|
46092389|NCT02673632|Drug|Merional ®|Using the long protocol of controlled ovarian hyperstimulation (COH). Down regulation by (Decapeptyl ®, Ferring) 0.1mg subcutaneously once daily starting from day 18 of the preceding cycle, human menopausal gonadotrophin (hMG) (Merional ®, IBSA) 75 IU starting from cycle day two after confirmation of down regulation (thin endometrium, number of follicular activity, E2 < 50 pg/mL). hMG dose is optimized according to age, BMI, antral follicles count (AFC), the local protocol, FSH level and previous response. Usually PCO patients start by 150 IU.
46092390|NCT04164030|Behavioral|Education and Exercise Program for Adults with Type 2 Diabetes|Eating Smart and Being Active program
46092391|NCT04164030|Behavioral|Nutrition Education plus Occupational Therapy plus Yoga|multimodal interdisciplinary approach
46092392|NCT04009525|Drug|Busulfan|Busulfan（4 mg/kg/day,4 days）
46092393|NCT04009525|Drug|Cyclophosphamide|Cyclophosphamide（50 mg/kg/day,4 days）
46092394|NCT04009525|Drug|Fludarabine|Fludarabine（50 mg/m2/day,3 days）
46092395|NCT04009525|Drug|Thymoglobulin|Thymoglobulin（2.5 mg/kg/day,4 days）
46092396|NCT04009525|Drug|cyclosporine A|cyclosporine A
46092397|NCT04009525|Drug|Mycophenolate mofetil|Mycophenolate mofetil（0.25g/day）
46092398|NCT04009525|Drug|Tacrolimus|Tacrolimus
46092399|NCT04009525|Drug|Methotrexate|Methotrexate
46092400|NCT04009525|Drug|Basiliximab|Basiliximab
46092401|NCT04009525|Drug|Ruxolitinib|Ruxolitinib
46092402|NCT02796911|Drug|Xenograft|group II will be treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);
45678334|NCT01415908|Other|Iliac Crest Bone Graft|Subjects enrolled in the control group will receive the same surgical treatment as the investigational group, including the CAPSTONE® Spinal System and posterior supplemental fixation system (CD HORIZON® Spinal System), except for the use of autogenous bone graft (from the iliac crest) instead of INFUSE® Bone Graft. A TLIF surgical approach will also be used for implanting the control treatment.
46092403|NCT02796911|Drug|Bioactive glass|group III will be treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).
46092404|NCT00643370|Other|CT scan of the chest under deep inspiration breath hold|computed tomography scan of the chest under dep inspiration breath hold conditions
45840116|NCT00626886|Drug|Bupivacaine Collagen Sponge|collagen; Bupivacaine hydrocholoride
46092405|NCT00594399|Behavioral|Physical Activity Counseling|Physical activity (PA) counseling program with the following components: a baseline in-person counseling session; telephone calls biweekly for 6 weeks then monthly; one physician endorsement of PA in a primary care clinic visit; monthly automated telephone calls from the primary care provider encouraging PA; and (5) quarterly mailed materials providing personalized feedback.
46092406|NCT04032366|Drug|inhaled nitric oxide|using of inhaled nitric oxide
46092407|NCT04032366|Device|PEEP|increasing PEEP or decreasing PEEP
46092408|NCT02796599|Device|Non invasive ventilation during exercise with facial or nasal mask.|Every patients will achieve 3 constant work load test (CWLT) at 75% Wpic. The first CWLT will be realized without any ventilatory support. The 2 others CWLT will be achieved with non-invasive ventilation support using facial or nasal interface in a randomized order.
46092409|NCT00964093|Device|Silver Alginate|(Algidex ™)
45840117|NCT00626886|Drug|placebo collagen sponge|collagen
45840118|NCT00627978|Drug|ixabepilone|ixabepilone 40 mg/m2 Q3w over 3 hours
45840119|NCT00628134|Drug|calfactant|single inhaled dose by nebulizer
45840120|NCT00628134|Drug|isotonic saline|single inhaled dose by nebulizer
45840121|NCT00632814|Drug|rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection once per week (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
45678335|NCT01415518|Drug|Drug: Budesonide/formoterol (Symbicort Turbuhaler|budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily)
46006435|NCT04595084|Behavioral|Internet Cognitive Behavioral Therapy plus CHAMindWell|MoodGYM is based on CBT and interpersonal therapy targeting depression, anxiety, stress, and general psychological distress. MoodGYM has 6 sessions with five curriculum modules and a review session that can be completed within an 8-week period. iCBT participants will also be enrolled in CHA MindWell Monitoring and Support (CHA-MW). Participants across arms will have CHA MindWell Monitoring and Technician telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a televisit with a clinician. If there are difficulties with accessing iCBT technology or if monitoring with CAT-MH or CAT-DI/ANX-CAT interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
46006436|NCT04595084|Behavioral|CHAMindWell|Participants across arms will have CHA MindWell Monitoring and Technician support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants across arms will have CHA MindWell Monitoring and Technician telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a televisit with a clinician. If monitoring with CAT-MH or CAT-DI/ANX-CAT interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
46006437|NCT00577785|Other|tissue procurement|No intervention. Tissue procurement study.
46006438|NCT01148017|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|
46006439|NCT04594928|Drug|GLPG3667|GLPG3667 capsules
46006440|NCT04594928|Drug|Placebo|Matching placebo capsules
46006441|NCT00577902|Other|Observation|Head and neck cancer patients receiving chemoradiation
46006442|NCT01147900|Biological|Boostrix™|Intramuscular, single dose
46006443|NCT01147900|Biological|Boostrix™-US formulation|Intramuscular, single dose
46006444|NCT04594850|Biological|Cellgram-ED|Patients will receive single injection of Cellgram-ED(mesenchymal stem cell) intracavernously.
46006445|NCT04313296|Device|Unique measurement (AutoSTRAIN) by a commercial software program (TOMTEC-ARENA)|The historic echocardiograms from patients who meet the study inclusion criteria will be uploaded into this software, which was newly acquired by the PBMC Cardiology Department. MaineHealth Information Services are currently working with study staff to assure appropriate security compliance within the network. LA GLS has not been routinely collected previously from echocardiograms performed at PBMC because of a lack of such technology.
46006446|NCT04594889|Procedure|angioplasty|Balloon releasing a drug inflated in the target vessel
46006447|NCT01147744|Drug|Fluticasone Propionate 100mcg via ACCUHALER/DISKUS|Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS
46006448|NCT01147744|Drug|GSK2190915 100mg|GSK2190915 100mg (1 x 100mg) once daily in the morning
46006449|NCT01147744|Drug|GSK2190915 10mg|GSK2190915 10mg (1 x 10mg) once daily in the morning
46006450|NCT01147744|Drug|GSK2190915 300mg|GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning
46006451|NCT01147744|Drug|GSK2190915 30mg|GSK2190915 30mg (1 x 30mg) once daily in the morning
46006452|NCT01147744|Drug|Montelukast 10mg|Montelukast 10mg (1 x 10mg capsule) once daily in the evening
46006453|NCT01147744|Drug|Placebo GSK2190915 one tablet|Placebo tablet, one tablet once daily in the morning
46006454|NCT01147744|Drug|Placebo montelukast|Placebo capsule once daily in the evening
46006455|NCT01147744|Drug|Placebo fluticasone propionate via ACCUHALER/DISKUS|Inhaled placebo twice daily via ACCUHALER/DISKUS
46006456|NCT01147744|Drug|Placebo GSK2190915 two tablets|Placebo tablet, two tablets once daily in the morning
46006457|NCT04594460|Device|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|the experimental arm will receive hydrogen-oxygen mixed gas inhalation (Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, output: 3 L/min (hydrogen concentration: 66.7%, oxygen concentration: 33.3%)) ,the treatment duration will be 8 hours per day, for 12 weeks.
46006458|NCT04594460|Device|OLO-1 Medical Molecular Sieve Oxygen Generator|the control arm will receive oxygen inhalation (OLO-1 Medical Molecular Sieve Oxygen Generator, output: 3 L/min (oxygen concentration: 33.3%), Shanghai Ouliang Medical Devices Co., Ltd.)the treatment duration will be 8 hours per day, for 12 weeks.
46006459|NCT04594655|Procedure|surgery|colectomy
46006460|NCT00625027|Other|Survey and Chart Review|After obtaining consent the survey will be completed. After a staff physician has assessed the patient, the chart will be consulted to retrieve the triage notes, diagnosis, treatment, and discharge recommendations. The physician will be asked to comment on the 'urgency' of the complaint and whether the patient would have been treated equally well at a walk-in clinic.
46092410|NCT02537600|Drug|Cobimetinib + Vemurafenib combination treatment|Patients will be treated from day 1 to day 28 with Vemurafenib and from day 1 to day 21 with Cobimetinib. Day 1 to Day 28 corresponds to one cycle of treatment.
46092411|NCT02796443|Procedure|Laparoscopic cholecystectomy (LC)|Removal of the gallbladder via a minimally invasive approach
46092412|NCT00657462|Other|Reminders|Users of the PAML Builder application will receive reminders about three application features (copy/paste, audit trail, sort medications by class) at the startup of the application
46092413|NCT00911196|Other|Retrospective analysis of already archived samples|Analysis using RNA extracted from tissue samples already archived; Analysis by Fluorescent in situ hybridization (FISH) using tissue samples already archived.
46092414|NCT02794961|Biological|CD22 CAR-T|Autologous CAR-T cells with average 1*10^6 cells/kg body weight
46092415|NCT00684099|Drug|Docetaxel|Docetaxel at starting dose of 65 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
46092416|NCT00684099|Drug|Pemetrexed|Pemetrexed at starting dose of 400 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
46092417|NCT02796365|Other|Exercise|Intervention will include 10 weeks of a standard cardiac rehabilitation program consisting of thrice a week aerobic exercise and 1-2 days per week resistance exercises.
46092418|NCT04235075|Device|ECG/PCG and ultrasound signal acquisition|"The ECG - PCG signals are acquired over a 20-minute monitoring phase with passive non invasive sensors (abdominal and thoracic). The volunteer's abdomen is photographed when the electrodes and sensors are installed. An ultrasonography is also performed for 10 minutes.~The session is filmed for 5 volunteers accepting the video. Any distinctive elements will be removed from photos and videos to prevent the identification of participants."
46006461|NCT04594577|Device|Fluispotter|Fluispotter automated blood sampling system applied for venous blood sampling of 20 10 μL samples in a 20 hours sampling session.
46092419|NCT02675738|Other|good clinical practice|
46006462|NCT04313374|Drug|Morphine PCA 1 mg|PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
46006463|NCT04313374|Drug|Morphine PCA 0,5 mg|PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
46006464|NCT04313374|Drug|Placebo|the PCA will contain placebo
46092420|NCT00684333|Device|painless subcutaneous injection by EZ-Ject Injector|EZ-Ject Injector device employee cutaneous local anesthesia on the injection site by an electronic anesthetic system
46092421|NCT04159896|Drug|Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981|Given PO
46006465|NCT04313335|Drug|Duloxetine|Oral Duloxetine (up to 60 mg per day) will be given, titrated, tapered in accordance with the pain intensity during the acute herpes zoster period.
46092422|NCT04159896|Biological|Nivolumab|Given IV
46092423|NCT00546715|Drug|Daclatasvir|Oral Solution, Oral, Single Dose
46092424|NCT00546715|Drug|Placebo|Oral Solution, Oral, Single Dose
46092425|NCT02816489|Device|Clarity SL MBT brackets; 3M Unitek, Monrovia, CA, USA|(passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner)
46092426|NCT02816489|Device|Gemini MBT brackets; 3M Unitek, Monrovia, CA, USA|(conventional stainless steel orthodontic brackets ligated with elastomeric ligature)
46092427|NCT02675660|Dietary Supplement|L-Homoarginine|125 mg L-homoarginine once daily
46092428|NCT02675660|Drug|Placebo|placebo capsules once daily
46006466|NCT04594148|Behavioral|Weight-shift training|Weight-shift training will consist of a single session of 10x 2.5min of mediolateral weight-shifting in the VR Wasp Game. Including breaks, the session will approximately take 45min.
46006467|NCT00577980|Drug|Testosterone|Initial dose of Testosterone 200 mg IM administered followed by 200 mg - 400 mg every 2 weeks.
46092429|NCT04031391|Other|Physical activity|"The intervention group: engaged in a therapeutic physical activity program involving low-intensity exercise, strength and balance work for 2 days a week over a 12-week period, with each session lasting 90 minutes. Both the intervention group and the control group separately completed the various baseline surveys which were part of the study. Once the intervention was over, they answered them again, also separately.~The classes were led by an experienced physiotherapist who followed the physical exercise guidelines established by the American College of Sports Medicine (ACSM), although the intensity of the exercises was adapted to the participants' tolerance levels"
46092430|NCT02635464|Biological|hUC-MSCs+Injectable collagen scaffold+CABG|Patients underwent Coronary Artery Bypass Surgery (CABG) with 10^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) in collagen scaffold injecting in the infarct region.
46092431|NCT02635464|Biological|hUC-MSCs+CABG|Patients underwent Coronary Artery Bypass Surgery (CABG) with 10^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) injecting in the infarct region.
46092432|NCT02635464|Procedure|CABG|Patients underwent CABG alone.
46092433|NCT02675504|Other|Placing a scale self-assessment of fear|Children spend a self-assessment scale of fear
45678336|NCT01415518|Drug|Drug: ipratropium (AtroventTM)|ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)
46092434|NCT05437211|Device|Virtual-reality (VR) Based Solution|VR-based solution comprises a mobile phone application including explanation on the different steps to be followed to perform infusions in satisfactory conditions, notably as regards safety, as well as VAS for pain and anxiety to be completed at each Factor VIII infusion between inclusion and the Week 4 visit. It also comprises a 3D mask (to be used before or during infusions) including simulation of the infusions themselves (before infusion) and a relaxing and distracting content (during and after infusions).
46092435|NCT00690261|Other||No intervention in this study
46092436|NCT02675582|Other|Herbal Beverage|Intervention involves consuming one beverage at the beginning of each visit during the incomplete block design sequence
46006468|NCT05219578|Drug|RTX-224|RTX-224 monotherapy
46006469|NCT01147471|Device|operative rib fixation|Randomized subjects will be operated upon within 72 hours of ventilation (early fixation)to stabilize the stove-in segment using a rib fixation system.
46006470|NCT01147471|Procedure|operative rib fixation surgery|
46006471|NCT04594343|Drug|Disulfiram|The subject will receive 500 mg of disulfiram orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
46006472|NCT04594343|Drug|Placebo|The subject will receive a matching placebo orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
46092437|NCT02635308|Behavioral|"Unilaterally Biased Resistance Training / MOVE"|High-intensity resistance training including: whole body movement patterns, unilaterally biased lower extremity strength training, task-oriented balance tasks
46092438|NCT02796521|Other|dietary counseling|Patients received individualized nutritional counseling encouraging them for enrichment
46092439|NCT02796521|Other|nutritional workshop with enrichment during a meal|Patients received in group nutritional informations for enrichment and are encouraged to try enrichment together during a meal.
46092440|NCT02625597|Device|Cotton Pellet|
46092441|NCT02625597|Device|Polytetrafluoroethylene Tape|
46092442|NCT02625597|Device|Synthetic Foam|
46092443|NCT02625597|Device|Polyvinylsiloxane|
46092444|NCT02635074|Drug|Cytarabine|Given IV
45678337|NCT01415518|Drug|theophylline SR|theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
46006473|NCT00578019|Procedure|IM Nailing|Patients randomized to Arm 1, A will be treated with a retrograde intramedullary nailing of the femur fracture utilizing the Smith & Nephew supracondylar nail.
46006474|NCT00578019|Procedure|LISS|Group B patients will have their fracture stabilized with the LISS plates (Synthes [USA], Paoli, PA, USA).
46092445|NCT02635074|Drug|Ibrutinib|Given PO
46092446|NCT02635074|Drug|Idarubicin|Given IV
46092447|NCT02796287|Procedure|achieving a neuropsychological examination in the acute amnesic phase|achieving a neuropsychological examination in the acute phase in addition to the normal protocole
46092448|NCT02796287|Procedure|Neurological consultation with neuropsychological evaluation|Neurological consultation with neuropsychological evaluation one year after the acute amnesic phase
45678338|NCT04058392|Biological|Camu Camu Capsules|Camu Camu powder encapsulated (500mg each). 2 capsules per day will be used for this study
45678339|NCT04057846|Device|EUS guided transgastric drainage|Whenever possible, randomisation and intervention shall be postponed until 4 weeks after onset of pancreatitis in line with international guidelines. All procedures in this study shall be performed by three experienced endoscopists (PNS, EFH, SN), who all have an extensive experience in endoscopic ultrasound (EUS-) guided drainage of pancreatic collections and the use of self-expanding stents. They have together performed more than 300 endoscopic, transmural drainage and debridement procedures in patients with WON since 2005. Endosonography-guided, transgastric drainage of the WONs shall be performed using a curve-linear echoendoscope (endoscope: Olympus GF-UCT180; ultrasound scanner: Hitachi Arietta 850 or Olympus EU-ME2). All collections shall be treated by single tract transmural cystogastrostomy (single-gate technique). T
45678340|NCT04767412|Device|aerobic exercise training, inspiratory muscle training|All participants received 30 min of aerobic exercise training thrice per week for a period of 12 weeks, whereas the group B received an additional 30 min of IMT before each aerobic exercise session.
46092449|NCT02796287|Radiation|MRI|Brain MRI with the same protocol or an acquisition time of 15 minutes without gadolinium, one year after the acute amesic phase
46092450|NCT02537366|Drug|Dexmedetomidine|
46092451|NCT02537366|Drug|Placebo|
46092452|NCT02796131|Drug|RDX5791|
46092453|NCT02796131|Drug|Placebo|Placebo
46092454|NCT00690417|Dietary Supplement|Cholecalciferol (vitamin D3)|low calorie (~60 calories) cookie-like disc containing 2,500 IU of vitamin D3, taken by mouth daily for 4 months
46092455|NCT05511584|Procedure|VO2 estimation|"st) VO2 (ml/min) will be estimated based on the formula: Inspired fraction of O2 (FiO2) - Expired fraction of O2 (FeO2) * minute volume (Volmin)~nd) Assuming the estimation of VDphys obtained with Fluxmed®, the investigators will calculate the VO2 corresponding to effective alveolar ventilation (VO2.alv), which will be the result of subtracting VDphys from Volmin.~rd) The investigators will calculate the O2 delivered fraction (DO2) (ml/min) corresponding to the estimated VO2.alv, and will supply it to the system while working in a closed-circuit mode."
46092456|NCT05511584|Procedure|SEVOup estimation|"st) SEVOup (ml/min) will be estimated based on the formula: Inspired fraction of sevoflurane (Fi.sevo) - Expired fraction of sevoflurane (Fe.sevo) * Volmin~nd) Assuming the estimation of VDphys obtained with Fluxmed®, the investigators will calculate the SEVOup corresponding to effective alveolar ventilation (SEVOup.alv), which will be the result of subtracting VDphys from Volmin.~rd) The investigators will calculate the sevoflurane delivered fraction (SEVOsuppl) (ml/min) corresponding to the estimated SEVOup.alv, and will supply it to the system while working in a closed-circuit mode."
46092457|NCT00690651|Procedure|Early mobilization|pt to get out of bed and mobilize with physiotherapist within 24 hours of surgery. they will be allowed toilet privileges and will go home when safe (as per medical staff and allied health)
46092458|NCT00690651|Procedure|Standard mobilization|this group will rest in bed with their leg elevated above their heart for 48 hours post surgery to ankle fracture and will then mobilize with physiotherapist with aim to discharge home.
46092459|NCT05434559|Drug|Insulin Degludec|Switch during standard routine care to Insulin Degludec.
46092460|NCT02635152|Behavioral|Interpretation Bias Modification|Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to appearance.
46092461|NCT02635152|Behavioral|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR).
46092462|NCT00690729|Behavioral|Cognitive Behavioral Bibliotherapy|Minimal therapist direction for self-guided bibliotherapy involving exposure and response prevention
46092463|NCT00690729|Behavioral|Cognitive Behavioral Therapy|Therapist-directed exposure and response prevention
46092464|NCT02796053|Drug|TAB08|The TAB08 will be administered intravenously, by infusion.
46092465|NCT02796053|Other|Placebo|The Placebo to TAB08 will be administered intravenously, by infusion.
46092466|NCT02671838|Behavioral|Musculoskeletal ultrasound program|Using a musculoskeletal ultrasound program to help improve medication adherence
46092467|NCT00655278|Drug|T2000|T2000 at previous most effective, well-tolerated dose (600-1000mg daily)
46092468|NCT00690807|Drug|PH-10|PH-10 will be applied daily for 28 days to skin areas affected by atopic dermatitis.
46092469|NCT04179656|Drug|Pyrotinib|400 mg administered orally, once daily, continuously in 21 day cycles
45678341|NCT01393600|Drug|NBI-98854|12.5 mg powder in bottle once daily for 14 days
46092470|NCT04237805|Drug|SAF-189s|20mg，40mg，80mg，120mg，160mg，210mg，once daily
46092471|NCT04163796|Device|UPnRIDE power wheelchair|The intervention will consist of approximately 3.5 hours per session, 3 times per week over 12 weeks. During each 3.5-hour session, subjects will be asked to stand at least 5 minutes during every 15 minutes or more as tolerated. One time each session, participants will be asked to perform the Activities of Daily Living course.
46092472|NCT04179578|Procedure|Crura plastic|Closure of hiatus with a running suture
46092473|NCT02634918|Other|ultrasound|ultrasound will be performed in hemophilia boys with a history of 20 joint bleeds- Group I, less than 2 joint bleeds into a joint -Group II and no joint bleeds- Group III
46092474|NCT00874029|Device|Halt Procedure|The Halt 2000 Electrosurgical Radiofrequency Ablation System is indicated for use in percutaneous, laparoscopic and intraoperative, coagulation and ablation of soft tissue.
45678342|NCT01393600|Drug|NBI-98854|50 mg powder in bottle once daily for 14 days
45678343|NCT01393600|Drug|Placebo|Solution containing no active substance
45836530|NCT01792908|Device|Kinesio tape|The KT used was Kinesiology Tape® of 5 cm and it was applied according to Kase protocol (Kase K). The first layer of tape consisted of a single strip placed over the anterior talofibular ligament from insertion to origin, with a 50% tension, except the two-centimetre proximal and distal ends, applied with no tension. The same procedure was repeated for the calcaneofibular ligament and posterior talofibular ligament
46092475|NCT02675348|Dietary Supplement|Dietary Supplement: Beef Protein|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of beef protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
46092476|NCT02675348|Dietary Supplement|Dietary Supplement: whey Protein|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of whey protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
45836531|NCT02442414|Drug|KBP-5209|Single oral dose beginning at 20 mg with daily dosing for 28 day cycles.
46092477|NCT02675348|Dietary Supplement|Dietary Supplement: CHO|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of maltdextrin after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
45836532|NCT01773486|Drug|Hesperidin|Citrus polyphenol, hesperidin
45836533|NCT01773486|Drug|Placebo|Placebo matching hesperidin
45678344|NCT01432756|Behavioral|Let's Talk Worksite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
45836534|NCT03549000|Other|NZV930|NZV930, Specified dose on specified days, intravenous (IV)
45836535|NCT03549000|Other|PDR001|PDR001, Specified dose on specified days, intravenous (IV)
46092478|NCT02675036|Procedure|Tooth extraction|
46092479|NCT00546637|Drug|Fesoterodine|Fesoterodine 4mg or 8mg
45459625|NCT03481192|Behavioral|Two visits for evaluation|"Visit 1:The first evaluation (E1) of cognitive functions will take place directly following the psychiatric interview (T1), in order to better reflect the cognitive abilities at the time of the proposal of the care project.~This will include the Memory Functioning Questionnaire (MFQ), the five words of DUBOIS, the TMT-A and B, the WAIS code test, and the BADDELEY door test. An intercurrent type ringing event of the phone will take place during this evaluation.~Visit 2: At 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place.~An episodic memory score will be determined by asking the patient to recall,as precisely as possible the evaluation E1. At first the reminder will be free,the data can be completed, if necessary, with an indication, a recognition."
46092480|NCT00546637|Drug|Placebo|Placebo
46092481|NCT04162236|Diagnostic Test|Ecocardiographyc ultrasound|"Epidemiological data: Maternal history risk factors. First trimester scan is performed on all patients.~Antropomethric measures~Systemic arterial stiffness: using applanation tonometry with pulse wave analysis and pulse wave velocity.~Carotid Intima Thickness~Echocardiography assessment: It will be performed by a cardiologist specialized in cardiac imaging according to the usual standard protocol. High resolution images will be acquired and post-processed with dedicated software for the speckle tracking analysis. 2D echocardiography parameters to be acquired, tissue Doppler and speckle tracking software~Markers in maternal blood: Angiogenic factor and cardiac function biomarkers: Blood samples will be collected without anticoagulant to obtain serum. sFLT-1, PlGF, High-sensitivity Troponin and NT-proBNP will be measured using automated electrochemiluminescence immunoassays."
46092482|NCT03841253|Procedure|Trans-epithelial PTK|The MEL 90 excimer laser will be used to ablate the corneal epithelium and stroma to a pre-defined depth, using the epithelium as a natural masking agent to smooth the stromal surface.
46092483|NCT03841253|Device|EpiMaster Application Software|The EpiMaster Application Software imports epithelial thickness data and corneal front surface topography data, and uses this to calculate the refractive change that would be induced by a trans-epithelial PTK treatment.
46092484|NCT00690885|Drug|interferon-alpha lozenges|150 IU natural human interferon-alpha lozenges for oral dissolution given 3 times per day for 4 weeks
45459626|NCT05199740|Other|in vitro analysis|in vitro analysis of mesoangioblasts from mtDNA mutation carriers
45459627|NCT04460092|Device|5-mm 32-gauge Insulin needles in the first three days of Intervention|32-gauge needles with a length of 5mm to inject insulin in first three days
45459628|NCT04460092|Device|8-mm 32-gauge Insulin needles in the first three days of Intervention|32-gauge needles with a length of 8mm to inject insulin in first three days
45459629|NCT04460092|Device|5-mm 32-gauge Insulin needles in the last three days of Intervention|32-gauge needles with a length of 5mm to inject insulin in second three days
45459630|NCT04460092|Device|8-mm 32-gauge Insulin needles in the last three days of Intervention|32-gauge needles with a length of 8mm to inject insulin in second three days
46092485|NCT00690885|Drug|placebo lozenges|matching placebo lozenges
45836536|NCT03549000|Drug|NIR178|NIR178 Specified dose on specified days, Orally
45836537|NCT03984240|Drug|Midazolam|Participant will be sedated by midazolam.
45836538|NCT03984240|Drug|Dexmedetomidine|Participant will be sedated by dexmedetomidine.
45836539|NCT00359736|Drug|sildenafil|Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.
45836540|NCT00360126|Drug|lamotrigine|
45836541|NCT00360360|Drug|paclitaxel|Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1
45836542|NCT00360360|Drug|carboplatin|Carboplatin AUC 6.0 IV Day 1
45836543|NCT00360360|Drug|bevacizumab|Bevacizumab 15mg/kg IV infusion,Day 1
45836544|NCT00360360|Drug|erlotinib|Erlotinib 150 mg by mouth daily
45836545|NCT01552590|Drug|Tolvaptan|
45836546|NCT01552590|Drug|Placebo|
46006475|NCT04594304|Behavioral|Behavioral: Usual care plus eToolkit|A baseline e-survey will be sent to participants prior to their scheduled appointment to collect baseline alcohol/tobacco use levels as well as a series of questions evaluating precursors to behaviour change. If randomized into the intervention group, patients will be sent a link to a tailored toolkit based on their behaviours, motivation to change and other pertinent factors. Patients who identify as non-smokers and meet the low-risk drinking guideline, will complete a third screening survey for physical activity. The cumulative patient profile (CPP) status for the patient for alcohol/smoking will be automatically updated post-baseline survey, and the PCP will receive a notification via EMR about the status update. For patients identifying with risky behaviours, the PCP will receive a prompt to update the CPP for the patient and will receive a link, embedded in the EMR, to a PCP-facing toolkit that facilitates evidence-based intervention.
45836547|NCT01496664|Procedure|Combined CABG and PCI|Coronary artery bypass grafting Percutaneous coronary intervention
46006476|NCT04578483|Other|PCA group|Patients receiving PCA are allocated in PCA group despite the route of administration. Intravenous PCA is commonly used with morphine or fentanyl while epidural PCA is used with ropivacaine and/or fentanyl frequently.
46006477|NCT04578483|Other|ERDS group|After anesthesia, extended-release dinalbuphine sebacate (ERDS) is injected into gluteus maximus with ultrasound guidance.
46006478|NCT01147393|Drug|90Y-epratuzumab tetraxetan|The 90Y-epratuzumab treatment will begin one week after the 4th veltuzumab injection. Patients will receive unlabeled, unconjugated epratuzumab (1.5 mg/kg) that will be infused over ~30 minutes. All patients will then receive a 90Y-epratuzumab dose. Dose will be escalated by patient cohort either at 15 mCi/m2 or 20 mCi/m2. The second 90Y-epratuzumab treatment will be given at the same dose, 1 week after the first 90Y-epratuzumab dose.
46006479|NCT01147393|Biological|veltuzumab|Veltuzumab is given in 4 weekly doses, each 200 mg/m2.
46006480|NCT05229718|Other|Diabetes Collaborative Care Model for Young Adults|We designed a diabetes collaborative care model for young adults that incorporates a mental health provider alongside a diabetes care provider during joint office visits to facilitate screening and treatment of psychosocial determinants of diabetes management. The Massachusetts General Hospital (MGH) Diabetes Center will be piloting this model with a multi-disciplinary team of diabetologists, nurse practitioners, diabetes nurse educators, and mental health provider. Patients scheduled to be seen in the diabetes collaborative care model will continue to follow in the diabetes collaborative care model, with follow up visits every 3-4 months. All patients will receive routine diabetes care with lab testing, medical interventions, therapies and referrals performed at the discretion of the patients' providers.
46006481|NCT05229718|Other|Usual Care Model|Patients enrolled in this arm will receive routine diabetes care per usual care at the Massachusetts General Hospital (MGH) Diabetes Center, with lab testing, medical interventions, therapies and referrals performed at the discretion of the patients' providers. In the usual care model, behavioral/mental health and social work services are available on a referral basis and are not integrated into a patients' routine appointment. Screening and treatment of psychosocial determinants of diabetes management are at done at the discretion of the patients' provider. Frequency of follow up visits is at the discretion of the patients' provider.
46006482|NCT00578058|Other|Counseling and Sound Therapy|Tinnitus counseling and sound therapy
46006483|NCT02884024|Other|no intervention|there is no intervention in this study
46006484|NCT00566774|Other|Full drug coverage|Patients randomized to first-dollar coverage will have their pharmacy benefits changed so that they have no out-of-pocket costs for any beta-blocker, angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) antagonist, or statin for every subsequent prescription after randomization. All co-pays and co-insurance will be waived at the point of care (i.e. pharmacy) as will any contribution that the cost of these drugs contributes to a patient's deductible
46006485|NCT00566774|Other|Usual coverage|Patients randomized to usual coverage will have no change in their existing benefits
46092486|NCT00643526|Device|Pre-filled Auto-injector Containing Placebo|Participants will self-inject placebo subcutaneously at thigh and abdomen.
46092487|NCT04159584|Other|Medical Music|Enrolled subjects will undergo 30 minutes of medical music listening
46092488|NCT05450237|Behavioral|Psychometric Evaluations|"The main evaluation scales we will use are the Beck Depression Inventory-II (BDI II), the State-Trait Anxiety Inventory (STAI), The twenty-item Toronto Alexithymia scale- I (TAS-20), The fatigue severity scale (FSS), Modified Fatigue Impact Scale (MFIS), The Multiple Sclerosis Impact Scale (MSIS-29), The Epworth Sleepiness Scale (ESS) (Johns MW. 1991), The Pittsburgh Sleep Quality Index (PSQ1), The Multiple Sclerosis quality of life Inventory (MSQOLI), The work productivity and activity impairment instrument (WPAI), Frailty Index.~These rating scales will be administered in person, by telephone and / or by sending them electronically."
45459631|NCT04894760|Diagnostic Test|Rapid Antigen Test (PanBio Ag test)|Rapid Antigen Test (PanBio Ag test)
45836548|NCT01105884|Procedure|Normal Saline|All the subjects in Group 1 will be treated with Normal Saline for healing of their diabetic foot ulcer
45836549|NCT01105884|Procedure|Biatin Ag (Foam)|All the subjects will be treated with Biatin Ag (Foam)
45836550|NCT01105884|Procedure|Hydrocolloid|All the subjects in this group will be treated with Hydrocolloid
45836551|NCT01105884|Procedure|Hydrogel|All the subjects in this group will be treated with Hydrogel
45836552|NCT01105884|Procedure|Ceredak|All the subjects in this group will be treated with Micro-porous Ceramic Wound Dressing
45836553|NCT00549978|Drug|Cilostazol|cilostazol, then cilostazol/probucol
45836554|NCT00549978|Drug|Probucol|Probucol probucol/ cilostazol
46006486|NCT00578097|Biological|Botulinum toxin type A|Single injection cycle, intradetrusor injection at baseline visit 2 of either 125 units (arm A), 250 units (arm B) or 500 units (arm C) in total.
45678345|NCT04767568|Diagnostic Test|Blood sample|"In cohort A: Blood sample n°1 (PBMC, plasma, ctDNA) previous colonoscopy. If no cancer lesions: STOP. If cancer lesion detected : Blood sample n°2 (PBMC, plasma, ctDNA) collected 1 month after surgery.~In cohort B: Blood sample n°1 (PBMC, plasma, ctDNA) collected before surgery. Blood sample n°2 (PBMC, plasma, ctDNA) collected 1 month after surgery"
46006487|NCT00578097|Drug|Placebo|Single injection cycle, intradetrusor injection at baseline (visit 2).
46092489|NCT04234685|Device|High Intensity Physio Light Therapy (HIPL Therapy™)|HIPL Therapy™ is an advanced phototherapy method that utilizes an emission wavelength spectrum that has been optimized for treatment of musculoskeletal disorders (MSD) such as OA.
45678346|NCT04767568|Other|Tumor tissue|In each cohort, tumor tissue will be collected from the surgical specimen.
46006488|NCT04593797|Diagnostic Test|carotid blood flow measurement with ultrasound|carotid blood flow measurement with ultrasound vs transpulmonary thermodilution calibrated continuous cardiac output measurements
46092490|NCT04234685|Behavioral|Education|Participants will take part in education on osteoarthritis, pain neurophysiology, and self-management strategies with the treating physiotherapist. The education will take place during the lab visits and will be brief (5-10 minutes at each session).
46092491|NCT04234685|Behavioral|Aerobic Exercise|Participants will develop an individualized walking program. The goal will be to walk 30 minutes 5 times/week if able. For all participants who are unable to achieve this walking, they will be provided with a progressive walking program that starts at their baseline (the distance they can walk without being sore an hour later; and without feeling like they will be unable to perform their usual activities of daily living because of the walk). They will be encouraged to then progress by 10-20% each week. Participants will be asked to use a provided walking log to keep track of their progress.
45678347|NCT04767178|Drug|Ibuprofen (Sanofi, Istanbul, Turkey)|Each enrolled infant received oral ibuprofen at a dose of 10 mg/kg 60 min before the onset of the eye examination.
45678348|NCT04767178|Drug|Paracetamol (GlaxoSmithKline, Istanbul, Turkey)|Each enrolled infant received oral paracetamol at a dose of 10 mg/kg 60 min before the onset of the eye examination.
45678349|NCT01432600|Drug|Pomalidomide|Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
45678350|NCT01432600|Drug|Dexamethasone|Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
45836555|NCT03983226|Procedure|Surgery|Tumor debulking surgery (surgery in recurrent ovarian disease)
46006489|NCT00578370|Drug|Ciclosporin 0.5% (Formulation 01B)|Cutaneous emulsion 200µl once a day (26 days)
46006490|NCT00578370|Drug|Ciclosporin 1.5% (Formulation 02B)|Cutaneous emulsion 200µl once a day (26 days)
46006491|NCT00578370|Drug|0.1% betamethasone|Solution 200µl once a day (26 days)
46006492|NCT00578370|Drug|0.005% calcipotriol|Solution 200µl once a day (26 days)
46006493|NCT00578370|Drug|Formulation 00B|Cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200µl once a day (26 days)
46006494|NCT04593719|Other|Experiment|The main components of the Lactation Management Model; breastfeeding training in the prenatal period (from the 30th week of pregnancy), early postpartum period (first 48 hours) skin to skin contact, early breastfeeding, relaxation using a dreaming technique, warm application to the breast, breast massage and for the first 48 hours after postpartum 6 months of continuous support (face to face, by phone, via social media).
46006495|NCT04593836|Drug|L-menthol|20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
46006496|NCT04593836|Drug|Placebo|20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
46006497|NCT04578405|Procedure|Intracorporeal anastomosis|Anastomosis performed totally laparoscopically
46006498|NCT04578405|Procedure|Extracorporeal anastomosis|Anastomosis performed through a minilaparotomy
46006499|NCT04593368|Other|FMT|oral dosing of fecal microbiome from allogeneic donor, 0.5-2 g/kg of recipients weight
46092492|NCT04234685|Behavioral|Resistance Exercise|Participants will also be instructed how to perform a series of six exercises: squat, step-up, lunge, single leg stance, knee flexion/extension, and resisted hamstring curl. The exercise technique and dosage will be tailored to the individual's current abilities. For example, if someone is unable to squat down to the level of a chair and return to standing, the chair height will be raised until the participant is able to perform the activity. The participants will begin by being asked to complete one set of 8-12 repetitions of each exercise, once daily, then progress to two or three sets daily as able. They will perform the exercises twice/week in the lab where they will receive support for problem solving and progression. Participants will be asked to use a provided exercise log to keep track of their progress.
46092493|NCT04234685|Device|Placebo Physio Light Therapy (HIPL Therapy™)|Phototherapy delivered at an intensity of 5 mW/cm2, a dosage at which there is no therapeutic benefit expected, but the light will still be visible to the participant.
46092494|NCT00690963|Procedure|Radiotherapy|Dose excalation based on normal tissue toxicity using 5 dose bins ranging from 56.8 Gy/ 27 fractions to 67.3 Gy in 27 fractions.
46092495|NCT02674724|Other|Gym Group|"Patients from Gym Group will perform a strengthening program of 45 minutes sessions, twice a week in a 12-week period.~The initial load is established as 60% of one-repetition maximum strength test (1RM) applied for each exercise at the beginning of program. Patients will be encouraged to perform 3 sets of 8 to 12 repetitions. All subjects will be instructed to rest for 30-60 second intervals between sets."
46092496|NCT02674724|Other|Free Weights Group|Patients from Free Weights Group will perform a strengthening program of 45 minutes sessions, twice a week in a 12-week period. The program aim to recruit the same muscles requested in Gym Group. Investigators will apply six different exercises with patients lying supine,standing in stance, sitting and in four points kneeling. All exercises aim to strengthen abdominal muscles, trunk extensors, gluteus, quadriceps and scapula adductors. Patients will perform 3 sets of 8 to 12 repetitions, the load will be offered with dumbbells, elastics with different resistances and anklets.
46092497|NCT02674724|Other|Control Group|All three groups will be instructed to perform stretching exercises of trunk, leg and shoulder muscles, according to an illustrated booklet. Only the Control Group patients will be instructed to perform stretching exercises at home in the same 12-week period.
45598972|NCT03202901|Dietary Supplement|Placebo|"The treatment consists of daily administration of placebo capsule with identical format and harmless thant B-turmactive product.~Treatment with placebo will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable"
46006500|NCT04593212|Diagnostic Test|Optical Coherence Tomography Angiography|Evaluation of microcirculatory dysfunction by assessment of retinal and choroidal microvasculature with optical coherence tomography angiography (OCTA)
46006501|NCT04593524|Dietary Supplement|vitamin D 1000 IU and A 6000 IU supplementation and nutritional counseling|24 participants, which are treatment group (I) which receives nutritional counseling, vitamin D 1000 IU, vitamin A 6000 IU
46092498|NCT02634840|Procedure|bilateral sagittal split osteotomy|surgical technique to split the mandibular ramus through three osteotomy lines on the medial-cranial, buccal-caudal and anterior surface to facilitate a split of the posterior border of the mandible without injury of the inferior alveolar nerve
46092499|NCT04138719|Drug|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles;
46092500|NCT04138719|Drug|Nab-paclitaxel + Epirubicin|nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and epirubicin given IV at 75 mg/m^2 on days 1 every 21 days x 6 cycles；
46092501|NCT02790359|Other|Air|Group of patients who would receive air insufflation
46092502|NCT02790359|Other|Carbon dioxide|Group of patients who would receive carbon dioxide insufflation
46092503|NCT02674646|Radiation|Radiotherapy|Radiation as indicated by the cancer diagnosis
46092504|NCT02674646|Device|Needle Acupuncture|Needle Acupuncture according to Traditional Chinese Medicine (TCM)
46006502|NCT04593524|Other|nutritional Counseling|control group (C) which only receives nutritional counseling for 28 days
46006503|NCT00578526|Drug|SU011248|50 mg capsule OD PO for 28 days followed by 14 days of rest until tumor progression
46006504|NCT00578526|Drug|Placebo|50 mg capsule OD PO for 28 days then 14 days rest until disease progression
46092505|NCT04162158|Biological|allogeneic NK cells therapy|PBMC was isolated from the peripheral blood of the donors and infused to the patient after 14 days incubation. In each cycle, patients will be infused 4.0-5.0×10'9 allogeneic NK cells. All patients in the experimental group received a total of three cycles of treatment with one month interval between each treatment.
46092506|NCT04138407|Other|seated Tai Chi|Seated Tai Chi is a redesigned short form of traditional Tai Chi, can be practiced in a chair or wheelchair
46092507|NCT04138407|Other|Usual rehabilitation exercise|Regular rehabilitation exercise used in participating hospital
46092508|NCT02790203|Drug|Celecoxib|NSAIDS
45459632|NCT04890938|Combination Product|Sputum-guided management and comprehensive care management|Those in the intervention group will have their treatment determined by the presence and type of airway inflammation whether during AECOPD or as part of clinic optimization. Corticosteroids are given for airway eosinophilia (sputum eosinophils >3%), and antibiotics for airway neutrophilia (sputum neutrophils ≥65% and total cells >10 million cells/gram) or a positive sputum culture. Specialized stains to identify aspiration (Oil Red O; (3)) and left ventricular dysfunction (Perl's Prussian blue; (4)) will guide swallowing assessment and cardiac work-up, respectively. If a sputum sample is not produced as an outpatient spontaneously, then sputum induction will be pursued 8 weeks after discharge. If there are no sputum samples to guide inhaler regimen, then it will be determined by the study physician guided by the Canadian Thoracic Society guidelines (2) if a sputum-guided regimen has not already been established.
45836556|NCT03983226|Drug|carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...|Salvage chemotherapy
45836557|NCT03983226|Drug|Niraparib|Niraparib maintenance therapy
46092509|NCT02790203|Drug|Placebo|Placebo
46092510|NCT05426096|Other|Best Practice Advisory|The BPA intervention will test the delivery of the insulin calculator (BPA) which automates the standard insulin dosing protocol guidelines through the electronic health record system.
46092511|NCT04138329|Procedure|Lichtenstein Technique|In this group was used the Lichtenstein technique for inguinal repair
46092512|NCT04138329|Procedure|Onstep Technique|In this group was used the Onstep technique for inguinal repair
46092513|NCT02790125|Drug|BMS-986166|
46092514|NCT02790125|Drug|Placebo matching BMS-986166|
46092515|NCT04179344|Other|Integrated e-healthcare services (IeHS) web-based app|Each participant is asked to complete study tasks using the IeHS web-based app as a part of IeHS simulation. This activity is followed by user experience survey, and an in-depth interview to explore user satisfaction on the IeHS web-based app
46092516|NCT00656760|Other|PET/CT|PET/CT is being performed on all patients in the study.
45836558|NCT04346082|Behavioral|online mindfulness group|Each weekly mindfulness session will last 45 to 60 minutes and will be held on an online platform (e.g. Zoom) via a livestream video. It will consist of short mindfulness exercise(s) of 10-30 minutes, including mindful tasting, mindful stretching, mindful walking, and body scan followed by group discussion to share, explore and make sense of the meditative experience. The intervention will be held in Cantonese.
45836559|NCT00360672|Drug|Revlimid|25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
45836560|NCT00360828|Drug|Irinotecan Hydrochloride (HCI) Treatment|Irinotecan injections. Irinotecan hydrochloride [CPT-11; CAMPTOSAR] is an antineoplastic agent of the topoisomerase I inhibitor class. The drug is supplied in amber vials and appears as a pale yellow transparent aqueous solution. Two vial sizes are available: 2 mL vials containing 40 mg of drug and 5 mL vials containing 100 mg of drug. A treatment cycle was 21 days. Patients were treated for a minimum of 3 cycles (doses) of CPT-11 or until their disease progressed.
45836561|NCT00360828|Drug|Continued Irinotecan Hydrochloride (HCI) Treatment|For patients responding to treatment, therapy could have continued beyond 18 cycles.
46092517|NCT00691041|Behavioral|Unity in Diversity|HIV/STI counseling and testing and a 7 session intervention to increase participants' level of knowledge and skills concerning HIV prevention (to decrease HIV acquisition or transmission) and to diffuse the information to their social network
46092518|NCT02816567|Drug|propofol|
46092519|NCT02816567|Drug|NMBA - cisatracurium|
46092520|NCT02816567|Drug|placebo - isotonic saline serum|
46092521|NCT02816567|Drug|sufentanil|
46092522|NCT02816567|Procedure|laparoscopic surgery|
46092523|NCT04162314|Drug|Beta-1,3/1,6-D-Glucan Ganoderma lucidum|Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
46092524|NCT04162314|Drug|Placebos|Placebos
46092525|NCT00691119|Behavioral|Relaxation and Visualization Therapy|Twenty minutes of facilitated relaxation and visualization therapy five days a week for six weeks. Self practice of 20 minutes per day for the next six weeks.
46092526|NCT00691119|Other|Health education|Facilitated health education sessions, twenty minutes, five times a week for six weeks.
46092527|NCT04234763|Behavioral|Strategies to lower postprandial hyperglycemia in T2D patients|T2D patients will undergo a 14-day chronic feeding trial intervention where the strategies to lower postprandial hyperglycemia will be educated. For example, to control portion of carbohydrate, incorporate low GI food and diabetes-specific formula, promote physical activity and practice consistent meal timing. After that, patients will undergo MCT again to evaluate the difference before and after the intervention.
46092528|NCT04234763|Behavioral|Control group|Assess nutritional status and no active intervention is conducted.
46092529|NCT00657774|Drug|FlutiForm 250/10 ug|SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
46092530|NCT00657774|Drug|FlutiForm 100/10 ug|SKP FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
46092531|NCT00657774|Drug|Oral Prednisone 10mg|2 x 5 mg oral prednisone tablets, over encapsulated, once a day for one week.
46092532|NCT00657774|Drug|Placebo|2 x 5 mg placebo tablets, over encapsulated, once a day for six weeks. SKP FlutiForm placebo HFA pMDI. Two actuations BID for six weeks.
46092533|NCT02674880|Drug|HMW-HA|Aerolized administration b.i.d.
46092534|NCT02674880|Other|Placebo|Standard therapy
46092535|NCT04138485|Biological|IgPro10|10% liquid formulation of human immunoglobulin for IVIG
46092536|NCT04138485|Biological|Placebo|0.5% human albumin solution stabilized with 250 mmol/L L-proline
46092537|NCT02789969|Drug|Hydromorphone|Hydromorphone 15mcg/kg IV
46092538|NCT02789969|Drug|Fentanyl|Fentanyl 1.5mcg/kg IV
46006505|NCT04593446|Drug|Oral Sulfate Tablet(ORA·FANGⓇ)|"Subjects who are randomized into experimental arm will receive 14 pills at 8 pm in the evening 2days before the surgery and another 14 pills on 6am in the morning 1day before the surgery~Subjects who are randomized into comparator will receive 170ml of solution with at 8 pm in the evening 2days before the surgery and another 170ml of solution on 6am in the morning 1day before the surgery"
46006506|NCT04593446|Drug|Sodium Picosulfate Solution(PicosolutionⓇ)|Sodium Picosulfate Solution(PicosolutionⓇ)
46006507|NCT00578604|Device|diffuse near infrared spectroscopy measurements|Measure blood flow to diabetic wounds
46006508|NCT00566891|Drug|tirofiban|tirofiban high dose bolus 25µ/Kg
46006509|NCT00566891|Drug|Clopidogrel|
46006510|NCT00578682|Biological|MEDI-557|Single IV dose of 3 mg/kg
46006511|NCT00578682|Biological|MEDI-557|Single IV dose of 15 mg/kg
46006512|NCT00578682|Biological|MEDI-557|Single IV dose of 30 mg/kg
46006513|NCT00578682|Biological|MEDI-557|Single IV dose of 0.3 mg/kg
45459633|NCT04890938|Other|Usual Care|As per previous, this group will receive three follow-up visits with study pulmonologist and clinic personnel interventions.
45459634|NCT03484624|Device|Treadmill walking|All subjects underwent measurements of muscle fatigue and respiratory metabolism energy during treadmill walking at a comfortable speed for 6 minutes and measured by three conditions (①NoGEMS-free gait, ②Torque off with GEMS, and ③Torque on with GEMS)
45459635|NCT01376336|Device|Safe storage device|This device is a specially designed water storage container that is intended to reduce the likelihood of re-contamination of household stored drinking water.
45459636|NCT04604158|Behavioral|Elly Mobile Phone Application|The Elly mobile phone application delivers daily audio recording aimed at reducing anxiety, stress, loneliness, and social isolation.
46006514|NCT04593485|Drug|Camrelizumab for injection|Carrelizumab will be administered at a fixed dose
46006515|NCT04592900|Other|balance exercising|selected physical therapy program strengthening the muscles of upper and lower limbs, balancing exercise, gait training in open environment,stretching for elbow flexors and forearms pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
46006516|NCT00578760|Drug|aspirin|325mg ASA OD for the duration of the cisplatin
46006517|NCT00578760|Drug|placebo|OD for course of cisplatin chemotherapy
46006518|NCT04592588|Behavioral|Common Elements Toolbox|COMET is an online unguided self-help intervention that lasts approximately 45-60 minutes.
46092539|NCT05407766|Biological|OSSM-001|Single injection of OSSM-001 at dose of 100M or 300M cells
46092540|NCT05407766|Other|Placebo|Single injection of placebo (saline)
46092541|NCT04159116|Other|Prophylactic suctioning when clinically indicated|Suctioned prophylactically when clinically indicated by copious secretions, coughing, choking or desaturatation
46006519|NCT04592588|Behavioral|Wait-list control|Participants in the control condition will receive access to the intervention after data collection for the study has been completed.
46006520|NCT00578799|Dietary Supplement|Kyo-Dophilus|5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening
46006521|NCT00578799|Dietary Supplement|placebo|placebo capsules (potato starch
46006522|NCT04592705|Device|Therapeutic plasma exchange|"TPE is the process of plasmapheresis, an invasive procedure separating plasma from red blood cells using centrifuge-based devices.~Filtration involves the insertion of a central venous catheter in the internal jugular, femoral or subclavian vein after which blood is drawn from the patient's circulation and transferred to a filter that separates the plasma from blood cells. Thereafter, the plasma extracted is substituted with human albumin and/or FFP."
46006523|NCT00578838|Other|Magnetic Resonance|Patients each will undergo 4 MR examinations as part of this research study.
46006524|NCT00578838|Other|Magnetic Resonance|You will have two MR exams on two different days. There will be no injection of contrast material. An MR exam requires about 1 hour. The second MR exam will take place 2-3 weeks after the first one. This second MR exam will take about 1 hour and will look at whether the results from the MR exams are reliable and repeatable.
46006525|NCT04592822|Drug|WD-1602|dabigatran etexilate mesylate granules for oral suspension
46006526|NCT04592822|Drug|Pradaxa®|dabigatran etexilate capsules
46006527|NCT00578916|Drug|EVRI (BMS-690514)|Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay
46006528|NCT00567047|Drug|vildagliptin|
46092542|NCT04009993|Device|A-BIRTHPERFORM digital tool|use of A-BIRTHPERFORM digital tool
46092543|NCT04178330|Radiation|tomotherapy|Whole brain radiation (WBRT) with 38-40Gy in 20 fractions and concurrent boost of 60-70Gy of the lesions. TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2*5d, q28d, up to 6cycles.
46092544|NCT02790047|Device|A non-re-breathing face mask with conical-PEP device|Participant will use a non-re-breathing face mask with conical-PEP device during an interval endurance spot marching exercise.
46006529|NCT00578994|Device|Oxford® Meniscal Unicompartmental Knee System|Oxford® Meniscal Unicompartmental Knee System is a medial, unicompartmental knee prosthesis containing three components: a femoral component, a tibial component, and a tibial meniscal bearing.
45459637|NCT03633578|Behavioral|walk test|"The patient will have to walk on a treadmill in four different conditions:~without distraction at preferential speed~with distraction at preferential speed~without distraction at the speed of 130% of the preferential speed~with distraction at the speed of 130% of the preferential speed"
46006530|NCT03454178|Diagnostic Test|WatchBP Office (BP measurement machine)|BP measurement: The nurse or assistant will leave the room after confirmed validity and the WatchBP will automatically measure BP for the participant at 1-minute intervals for 3 more readings; previous research showed that accurate BP readings could be obtained using 1-minute intervals. This is also the measuring method suggested by the manufacturer. The machine will automatically calculate the mean BP using the 3 readings. The mean BP value will be used for analysis. The diagnostic cutoff for diagnosing HT will be ≥135/85 for AOBP
46092545|NCT02790047|Other|A home-base exercise program|"Duration of the program is 8 weeks A frequency of exercise session is 3 to 5 sessions per week A content of each exercise session includes~Stretching exercise (shoulder, trunk and leg muscles) to warm up for 5 to 10 minutes~Interval endurance exercise using a spot marching movement for 30 to 40 minutes. In each phase of spot marching exercise, patients will perform the exercise from 0 to 3 or 4 score of 10 score of a modified dyspnea Borg scale, they will record exercise the exercise duration time. Then, they will be required to rest until a modified dyspnea Borg scale < 1 score. Next, they will perform the next interval of spot marching exercise with the same protocol.~Stretching exercise (shoulder, trunk and leg muscles) to cool down for 5 to 10 minutes"
46006531|NCT00579033|Other|Tactile training + sham rTMS|tactile training for 2.5/hr/day for 15 days - this plus the sham rTMS
46092546|NCT02790047|Other|Health education|"Health education include~Knowledge of COPD disease~Smoking status and smoking cessation~Medication correctly~Self dyspnea management~Basic nutrition for COPD"
46092547|NCT02790047|Other|ฺBreathing strategies for self secretion clearance|"Using a modified active cycle breathing technique (mACBT) include~Control breathing~Pursed lip breathing (PLB)~Slow inhale with sustain thoracic expansion for 3 sec and exhale with PLB technique~Force expiratory technique (FET) with low to medium lung volume~Huffing or coughing"
46092548|NCT02790047|Drug|The medication following the COPD GOLD guidelines (2015)|"Patients will receive medications following the COPD GOLD guidelines (2015). The medication names were listed below~Bata 2 agonist (short acting); Salbutamol (oral or inhaler), Terbutaline (oral)~Bata 2 agonist (long acting); Bambuterol (oral), Procaterol (oral), Salmeterol (inhaler), Formoterol (inhaler)~Xanthine derivative (sustained release theophylline)~Anticholinergic; Tiotropium(inhaler), Ipratropium bromide (inhaler)~Corticosteroids; Beclomethasone (inhaler), Budesonide(inhaler), Fluticasone(inhaler)~Combined anticholinergic+ Beta 2-agonist; Ipratropium+fenoterol (inhaler), Ipratropium+salbutamol (inhaler)~Combined Beta 2-agonist+ corticosteroids; Formoterol+ Budesonide(inhaler), Salmeterol+ Fluticasone(inhaler)"
46092549|NCT00657852|Drug|Disodium pamidronate|Single dose of 90 mg disodium pamidronate within days 7-12 and at 3 months after liver transplantation, diluted in 500 ml of 5% glucose serum and administered as a 4-hour continuous intravenous infusion
46092550|NCT00657852|Drug|Placebo|500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion
46092551|NCT02673164|Biological|CSCC_ASC|The stem cells will be injected directly into the myocardium using the NOGA XP system (BDS, US)
46092552|NCT00691275|Drug|Ondansetron|
46092553|NCT00691275|Drug|Saline|
46092554|NCT02794415|Other|Community-based exercise|"Intervention Phase (6 months): The HIV Community-Based Exercise (CBE) intervention is a 6-month exercise program at the Central Toronto YMCA. Participants will meet the fitness instructor to establish an individualized exercise program that will include a combination of aerobic, resistive, neuromotor and flexibility training. Participants will attend exercise sessions for ~1.5 hour, 3 times per week for 24 weeks. Sessions will be supervised weekly by a fitness instructor.~Post-Intervention Phase (8 months): At the end of the 24 week intervention, participants will be encouraged to continue to engage in unsupervised exercise 3 times per week. As per usual practice at the YMCA, a fitness instructor will be available to monitor participants monthly."
46092555|NCT00657930|Drug|insulin detemir|observational study - dose and frequency to be prescribed by the physician as a result of standard clinical practice.
46092556|NCT04178486|Behavioral|Hypnosis with amnesia suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
46092557|NCT04178486|Behavioral|Hypnosis with cognitive rehearsal suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
46092558|NCT04178486|Behavioral|Hypnosis with memory substitution suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
46092559|NCT04178486|Behavioral|Hypnosis with induction only|Participants received only hypnotic induction.
46092560|NCT02789891|Procedure|D2 lymphadenectomy including No. 14v|After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal with D2 lymphadenectomy including No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
46092561|NCT02789891|Procedure|lymphadenectomy excluding No. 14v|After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal gastrectomy with D2 lymphadenectomy excluding No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
46092562|NCT02673242|Device|Threshold IMT Philips Respironics|Inspiratory muscle training
46092563|NCT02632734|Device|CoreBone Cone device|coral derived devices in the form of Cones are placed in extraction sites for preservation of bone during 6month and more.
45459638|NCT03110900|Drug|Haloperidol + lorazepam|Haloperidol + lorazepam + placebo
45459639|NCT03110900|Drug|Loxapine|loxapine + placebo
46006532|NCT00579033|Other|Tactile training + rTMS|tactile training 2.5/hr/day for 15 days plus daily 5Hz rTMS
46006533|NCT04578171|Drug|Mepolizumab|100 mg subcutaneous injections every four weeks
45459640|NCT03934268|Genetic|KCNQ2|The researchers extracted DNA from the baby's serum and sent it to WES to get the baby's total exon sequence.
46092564|NCT02632734|Device|CoreBone 500 device|coral derived devices in the form of particulate (CoreBone 500) are placed in extraction sites for preservation of bone. Follow up during 6month and more.
46092565|NCT04233983|Procedure|Laparoscopic Endometriosis Surgery|Patient with ERROR(endometrioma related reduction in ovarian reserve), and endometrioma larger than 3 cm diameter will be operated after IVF&ICSI procedure. Operation will be done by senior surgeons of our department. Laparoscopic endometrioma operation procedure consists of excision of endometrioma cyst with its capsule from ovary without using any electric modality to prevent ovarian damage.
46092566|NCT02673086|Other|coracoid approach|Coracoid approach for ultrasound guided infraclavicular brachial plexus block
46006534|NCT03454139|Procedure|Subcostal transversus abdominis plane block|Ultrasound guided Subcostal transversus abdominis plane block is performed after anesthesia induction and endotracheal intubation , to the side where kidney stone is. A composition of 10 ml Lidocaine %1 plus 10 ml physiologic saline solution plus 10 ml Bupivacaine %0,5 , total of 30 ml of local anesthetic mixture is administered into the area between internal oblique muscle fascia and transversus abdominis muscle fascia.
46006535|NCT03454100|Behavioral|multisectoral package of activities|A multi-sectoral package of village level activities, including having a well dug, a shared latrine installed, training on handwashing and hygiene across the water chain, training on conservation agriculture techniques, care groups for pregnant and breastfeeding mothers, and training on market gardens.
46092567|NCT02673086|Other|retroclavicular approach|retroclavicular approach for ultrasound guided infraclavicular brachial plexus block
46092568|NCT00655512|Drug|pimecrolimus 1% cream|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
46092569|NCT00655512|Drug|hydrocortisonacetat 1% cream|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
46092570|NCT00655512|Drug|betamethasonvalerat 0,1% cream|twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
46092571|NCT00655512|Drug|clobetasol-17-propionat 0,05% cream|twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
45678351|NCT01432600|Drug|Cyclophosphamide|"The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study."
45678352|NCT01432444|Drug|Aripiprazole (Abilify®) IM Depot Injection|"400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Subjects have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2013."
45678353|NCT01432366|Other|SC anti-TNF|Subcutaneous (SC) anti-TNF
46006536|NCT03454061|Other|physical activity|Physical education program (PEP) of 16-week length
46092572|NCT00655512|Drug|Placebo|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
46092573|NCT02816177|Other|Telemedicine|
46092574|NCT02816177|Other|Usual Care|
46092575|NCT04138095|Device|Virtual Reality|Participants will have access to an Oculus Quest Virtual Reality Headset every second day as an alternative to opioids for pain management and benzodiazepines for anxiety management
46092576|NCT00644306|Drug|Thalidomide|100 mg/day continuously for 18 months
46092577|NCT00644306|Drug|melphalan, prednisone|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months
46006537|NCT00579267|Other|MINI-KID|Structured Diagnostic Interview for children and adolescent psychiatric disorders.
46092578|NCT00644306|Drug|melphalan, prednisone, thalidomide|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months
46092579|NCT04234841|Diagnostic Test|Blood test|Blood test
46092580|NCT00691431|Device|LASIK|
46092581|NCT02634528|Drug|Julphar Insulin N (human isophane insulin)|investigational insulin: Julphar N (human isophane insulin), biosimilar
46092582|NCT02634528|Drug|Huminsulin® Basal (NPH, human isophane insulin)|marketed reference product: Huminsulin® Basal (NPH, human isophane insulin)
46092583|NCT02672774|Procedure|Magnification endoscopy with narrow band imaging|Magnification endoscopy with narrow band imaging is an optically enhanced endoscopic imaging technique used for better characterization of lesions as compared to white light endoscopy alone. With only a push of a button optical filters are applied to reduce the illuminating light to 415 nm (blue) and 540 nm (green) wavelengths, which are selectively absorbed by haemoglobin. As a result the superficial vascular networks are highlighted and morphological changes in capillary patterns can be described for different gastrointestinal lesions.
46092584|NCT02672774|Device|Probe based confocal laser endomicroscopy|Confocal laser endomicroscopy enables in vivo microscopic analysis during ongoing endoscopy and has shown good accuracy for predicting the histopathological diagnosis in lesions of both the upper and lower GI tract. During the examination fluorescein is administered intravenously as a contrast agent, highlighting the vessels and surrounding epithelial structures. The probe based confocal laser endomicroscopy system can be easily integrated into the imaging protocol as it uses flexible catheter probes that can be passed through the working channels of the endoscopes once the area of interest has been identified.
46092585|NCT00656838|Behavioral|Patients receives letter, phone call, office visit, educational materials|Behavioral
46092586|NCT00691509|Genetic|gene expression analysis|
46092587|NCT00691509|Genetic|polymorphism analysis|
46006538|NCT03453983|Device|Transcrainial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a safe non-invasive form of brain stimulation, which modulates, through the application of weak direct current, cortical excitability. The applied subthreshold current passes through two externally placed electrodes, an anode and cathode.
46092588|NCT00691509|Other|high performance liquid chromatography|
46092589|NCT00691509|Other|laboratory biomarker analysis|
45459641|NCT04459858|Other|data analysis|"Data is extracted from the existing medical records and from the Rotator Cuff Repair Database (RCR_USB). The GTA (determined as the angle between a line parallel to the humerus diaphysis passing through the humeral head center of rotation and a line connecting the upper border of the humeral head to the most superolateral edge of the greater tuberosity) is determined."
45459642|NCT03896828|Dietary Supplement|Mixed-macronutrient meal|"Participants will be provided a mixed-macronutrient meal (liquid drink) at hours 0 and 3, mimicking the energy and macronutrient composition of breakfast and lunch in Western society (38). 20% of daily energy intake will be provided as breakfast and 30% at lunch. Macronutrient composition will reflect a diet providing 55% energy needs from carbohydrate (CHO) and 1.2g/kg/d protein. The remaining energy requirements, as determined by total energy intake, will be met with dietary fat (estimated to be ~0.2 and 0.3g/kg fat for breakfast and lunch, respectively), similar to previous liquid mixed-meal approaches."
45459643|NCT03486184|Diagnostic Test|Cystatin-C|"Laboratory values will be obtained, including level of preoperative serum creatinine, complete blood count, coagulation profile and Cystatin-C (5 ml. venous sample).~Serum creatinine and hemoglobin will be measured after operation, and thereafter at least once a day as a part of routine clinical care. Postoperative serum Cystatin-C will measured only once."
45678354|NCT01415440|Drug|Lisdexamfetamine|During the first 4 weeks of treatment, the dosage of Lisdexamfetamine will be adjusted based on the patient's response to the medication. The patient will then be maintained at the lowest effective dose for the remaining 8 weeks of treatment.
46006539|NCT04593017|Dietary Supplement|Active Probiotic|Lactobacillus Reuteri (DSM 17938 and ATCC PTA 4659
46092590|NCT00691509|Other|mass spectrometry|
45678355|NCT01415440|Drug|Placebo|Placebo dosing will parallel that of Lisdexamfetamine.
45678356|NCT04049890|Other|FAI-O|"Administration of Family Adjustment Inventory in the version Only-child"
45678357|NCT04049890|Other|FAI-S|"Administration of Family Adjustment Inventory in the version Sibling"
46006540|NCT04593017|Other|Placebo Probiotic|Placebo
45459644|NCT03109756|Drug|OV101|Single-dose 5 mg OV101
45459645|NCT03484546|Procedure|laparoscopic endometrioma cyst excision|laparoscopic resection of ovarian endometrioma
45678358|NCT04049890|Other|Personal Data Questionnaire|This form requires informations about child, respondent and partner (if any), and evaluates the presence of any distressful event happened during the last year
45678359|NCT02076412|Drug|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
45678360|NCT02076412|Drug|Placebo|Placebo tablet PO bid (morning and evening)
45678361|NCT04048252|Other|Focus group creation|Patients will join with researchers for a 2 hour recorded group discussion to highlight themes identified to require educational intervention
45836562|NCT00361140|Drug|Busulfan|"Bu IV (BusulfexR) over 3 hours on days -6, -5, -4, and -3. Day -6 and -5 doses for patients on Level 1 will be 170mg/m2. This dose is based on the dose used by DeLima (2004) adjusted proportionately to achieve an AUC of 6000uM-min. Subsequent daily doses for patients on Level 1 will be adjusted to achieve an average AUC of 6000uM-min.~Day -6 and -5 doses for patients on Level 2 will be based on the mean dose required on Level 1 to achieve target AUC then adjusted proportionally for new target AUC.~Subsequent daily doses will be adjusted to achieve target AUCs."
45836563|NCT00361140|Drug|Fludarabine|Fludarabine 40mg/m2 IV over 1 hour on days -6, -5, -4, and -3
46006541|NCT03453294|Device|Apnoeic oxygenation using THRIVE|Apnoeic oxygenation using THRIVE
46006542|NCT03453294|Device|Endotracheal intubation and mechanical ventilation|Endotracheal intubation and mechanical ventilation
46006543|NCT04578054|Other|Flying transport|Patient care who requires flying transport
46006544|NCT04592666|Drug|Almonertinib|the standard therapy of single agent almonertinib
46006545|NCT04592666|Drug|Pemetrexed|standard dose
46092591|NCT00691509|Other|questionnaire administration|
46092592|NCT02673008|Biological|donor lymphocyte infusion|DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10*8 mononuclear cells/kg.
46092593|NCT02794493|Drug|Traditional Chinese Medicine Formula LC09|
45678362|NCT04048252|Other|Workshop|Patients will attend 3-4 workshops on eg disease knowledge, medication management and side effects, adapted physical activity and nutrition
46006546|NCT04592666|Drug|Carboplatin|AUC=5
46092594|NCT02794493|Other|Placebo|
46092595|NCT04162002|Drug|Restylane® Lyft|Filler Injection
46006547|NCT04577937|Diagnostic Test|LAM patients underwent PSG|Patients with confirmed diagnosis of LAM underwent a whole-night polysomnography. The presence of either acute or chronic respiratory failure or the use of long-term oxygen therapy are considered exclusion criteria
46006548|NCT04593056|Drug|Warfarin|Warfarin dispensing claim is used as the reference
46006549|NCT04593056|Drug|Rivaroxaban|Rivaroxaban dispensing claim is used as the exposure
46006550|NCT00579423|Biological|QS21|"Treatment schedule and dose: Thirty patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administered at the standard dose of 100 ug.~Sites: The vaccine conjugate will be administered subcutaneously on a rotating basis to random sites on the upper arms and upper legs.~Dose modifications: If a patient experiences a Grade III or greater local or Grade II or greater systemic toxicity at any time a decrease by 50% in all components of future vaccinations will be administered for that patient. Any evidence of autoimmunity, however, will result in a cessation of immunization in that patient."
46092596|NCT02625363|Other|Glucose Ref - Std|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
46092597|NCT02625363|Other|Glucose Ref and 450 ml water|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes. Subjects given additional 150 ml water at 45, 75, and 105 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120
46092598|NCT02625363|Other|White Bread with 250 ml water|First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
46092599|NCT02625363|Other|White Bread and 700 ml water|"Sample consumed with 250 ml water immediately after meal consumption, and additional 150 ml water at 45, 75, and 105 minutes.~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'"
46092600|NCT02625363|Other|White Bread with 125 ml water (twice)|"Sample consumed with 125 ml water immediately after meal consumption, and additional 125 ml water after 60 minutes~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'"
46092601|NCT02816411|Dietary Supplement|Milk protein isolate|"Milk protein isolate in a powder form consisted of 80% casein and 20% whey protein. 20g were diluted into 500 ml water.~Placebo consisted of 365 ml water, 125 ml sugar-free cordial and 2g of low-calorie glucose/dextrose powder."
46092602|NCT02816411|Dietary Supplement|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 mL) and 2 g of low-calorie glucose/dextrose powder.
46092603|NCT02672930|Device|Electrocardiogram (ECG)|ECG and vital parameters were obtained before and after recommended standard calcium gluconate therapy for hyperkalemia
45459646|NCT03867734|Drug|Aztreonam|2g IM Aztreonam
45459647|NCT03131674|Other|Cervical physical therapy|Patients receive a multimodal cervical physical therapy treatment
45459648|NCT04965844|Device|Oxygen close-loop|The Automatic FiO2 option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the Oxygen setting to keep the patient's SpO2 in the target range.
45459649|NCT04965844|Device|No intervention|Manual FiO2 adjustment according to SpO2 values
46092604|NCT00655590|Drug|Levitra (Vardenafil, BAY38-9456)|20 mg daily dosing
46092605|NCT00655590|Drug|Sildenafil|100 mg daily dosing
46092606|NCT00655590|Drug|Placebo|Matching placebos
46092607|NCT02625129|Other|Pharmacist-provided travel care|Subjects will receive a pre-travel consultation from a pharmacist with specialty training in travel medicine, and with authorization to prescribe medications and vaccines and administer injections
46092608|NCT05408741|Other|The Intervention Group|Participants will complete a 20-minute guided imagery exercise (which includes deep breathing exercises) every day at home using the selected app and/or resource you downloaded at the beginning of this study.
46092609|NCT05408741|Other|The Control Group|Participants will continue to receive your current care, but will not receive guided imagery or deep breathing exercises from a social worker.
46092610|NCT02672696|Device|FluoroMap 3D|Use of the 3D reconstruction software developed by the manufacturer of the Gamma Nail (e.g. Stryker Inc.) along with the standard fluoroscopy
46092611|NCT02634372|Behavioral|EMDR therapy|EMDR: We designed a specific EMDR Bipolar Protocol which consists of a detailed interview with respect to traumatic events, the treatment of those with the EMDR standard protocol, and five new specific bipolar adapted EMDR protocols focusing on adherence, insight, de-idealisation of manic symptoms, prodromal symptoms and moodstabilization.
45678363|NCT01932788|Drug|Vitamin D3 4000 IU in gummy form|Subjects randomized to the Vitamin D3 4000 IU gummy vitamin arm, the investigational drug, will consume 4 gummies/day beginning at 10-14 weeks of your pregnancy. All subjects will consume a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of your pregnancy.
45836564|NCT01794468|Other|Dermal blood flow measurements|Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor (I.S. MedTech, Israel), which consists of a skin probe and a measuring and control feedback unit.
45836565|NCT00361374|Dietary Supplement|eicosapentaenoic acid|1 gram/day
46092612|NCT02634372|Behavioral|Supportive Therapy|Supportive therapy: Therapists adopt a client-centred focus, meaning that whatever problems the patient presents will be dealt with by providing emotional support and general advise. If no specific topic is mentioned by the patient, information about bipolar disorder and medication will be delivered by the therapist without referring to written or any other material.
46006551|NCT04592939|Procedure|immediate weight bearing after surgery|immediate weight bearing
45678364|NCT01932788|Drug|Placebo gummy vitamin|Subjects randomized to receive placebo, also in gummy form but manufactured without Vitamin D3, will consume 4 gummies/day beginning at 10-14 weeks of pregnancy. All subjects will take a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of pregnancy.
46006552|NCT04592939|Procedure|6 weeks of toe-touch weight bearing after surgery|6 weeks of toe-touch weight bearing
46006553|NCT00579462|Other|Blood and Tissue studies|Blood will be collected from participating patients at baseline, as close as possible to the date of their baseline radiologic assessment. Three follow-up blood collections will be drawn, each within 7-10 days of each follow-up radiologic evaluation.
46092613|NCT00691587|Biological|KB001|Single low-dose, administered intravenously
45678365|NCT01414738|Radiation|Radiotherapy|Hippocampal-Avoiding Whole Brain Irradiation with Simultaneous Integrated Boost
46092614|NCT00691587|Biological|KB001|Single high-dose, administered intravenously
46092615|NCT00691587|Biological|Placebo|Placebo single-dose, administered intravenously
46092616|NCT00643838|Drug|Kalinox 170 bar|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
46092617|NCT02794025|Drug|Esmolol|"patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava. The initial dose was 0.05 mg/kg/min and was adjusted based on heart rate (HR) (target HR: 70 bpm < HR < 100 bpm within 72 hours).~Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol."
46092618|NCT02794025|Drug|natural saline|Control group also received natural saline via a micro pump,
46092619|NCT00546481|Drug|methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]|0.6 micrograms/kg every 2 weeks
45836566|NCT00361374|Dietary Supplement|docosahexaenoic acid|1 gram/day
45836567|NCT00361374|Drug|Placebo|980 milligram/day
46092620|NCT00546481|Drug|Epoetin|As prescribed, iv, 3 times weekly
46092621|NCT04016480|Device|High Flow Nasal Cannula|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
45459650|NCT05759624|Drug|rhGH|Hormone replacement therapy with rhGH at a dose of 0.025-0.035 mg/kg of body weight per day (or 0.7-1.0 mg/m2 of body surface area per day).
45836568|NCT00362466|Drug|Dasatinib|Tablets, Oral, Once daily, 5-7 years
45836569|NCT00362466|Drug|Imatinib|Tablets, Oral, Once daily, 5-7 years
46006554|NCT00579540|Dietary Supplement|Flax Seed Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
46006555|NCT00579540|Dietary Supplement|Fish Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
46092622|NCT04016480|Device|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
45459651|NCT03484468|Device|anterior segment Ocular Coherence Tomography|anterior segment OCT (Ocular Coherence Tomography) a device shows imaging of anterior segment of the eye and able to show corneal layers and measures its thickness.
45459652|NCT03779126|Device|Electrical stimulation|1) Low frequency electrical stimulation (LF) ; High frequency (HF); Low and High frequency (LHF) ; and sham stimulation. Groups will receive bilaterally electrical stimulation, for 60 minutes, three times a week, during two months.
45836570|NCT00305682|Biological|anti-thymocyte globulin|Equine ATG dose is 15 mg/kg intravenously (IV) every 12 hours for 6 doses on days -6, - 5, and -4.
46092623|NCT04233905|Behavioral|Psychometric questionnaire study|Four groups participate in the psychometric questionnaire study. A group of mute children and their mothers (EG:A), as well as a normal, healthy control group (KG:A) with roughly the same age and sex characteristics fill out one-time questionnaires about current daily life experiences. In addition, another group of formerly mute adults (EG:B) as well as a comparable age/sex normal control group will be retrospectively questioned using the same specifically tailored questionnaire.
45459653|NCT03484390|Behavioral|Mindfulness-based stress reduction|
45836571|NCT00305682|Drug|cyclophosphamide|Cyclophosphamide 50mg/kg x 1 to be administered IV over 2 hours with high volume fluid flush on day -6.
45836572|NCT00305682|Drug|Fludarabine|Fludarabine 40 mg/m2/day or 30 mg/m2/day intravenously (IV) as one hour infusion x 5 days, on day -6 to -2.
45836573|NCT00305682|Drug|mycophenolate mofetil|Mycophenolate mofetil (MMF) 3 gram/day for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours.
46092624|NCT02535624|Procedure|PACKING|By retroperitoneal access the space in front of the pelvic fracture is compressed with surgical towels, which stops effectively venous bleeding
46092625|NCT02535624|Procedure|ANGIO|Using en endovascular approach, bleeding arteries are identified and clotted using embolizing agents, or coils.
46006556|NCT00579540|Dietary Supplement|Soybean Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
46006557|NCT00579618|Other|Saliva or Blood samples|Extracting sample of saliva or blood only once.
46006558|NCT04592315|Drug|Lipovirtide Injection|Single dosage of Lipovirtide Injection
46006559|NCT00579657|Other|control diet, supported by dietary supplement twice daily|control diet, see above
46006560|NCT00579657|Other|high cereal fiber diet, supported by dietary supplement twice daily|high cereal fiber diet, see above
46006561|NCT00579657|Other|high protein diet, supported by dietary supplement twice daily|high protein diet, see above
46092626|NCT02789813|Drug|Valproic Acid|Once oral administration of 500mg before exposure therapy.
46092627|NCT02789813|Drug|Placebo|Once oral administration of 500mg before exposure therapy.
46092628|NCT02789813|Behavioral|Fear reactivation|Fear reactivation before exposure therapy.
46006562|NCT00579657|Other|diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily|MIX diet, see above
46092629|NCT02789813|Behavioral|No fear reactivation|No fear reactivation before exposure therapy.
46092630|NCT05350735|Behavioral|Intervention arm: SMS text reminders and medical card|This study arm will assess compliance with anti-rabies vaccine regimen by participants in the presence of SMS text reminders as compared to without the SMS reminder.
46092631|NCT04137861|Other|Bioceramics|root repair material
46092632|NCT00958867|Behavioral|Exercise program (AT)|Six-month, twice-weekly aerobic training (AT) program
45678366|NCT01414114|Drug|Etelcalcetide|Administered 3 times a week by bolus injection into the venous line of the dialysis circuit after the end of hemodialysis.
46092633|NCT00958867|Behavioral|Exercise training (RT)|Six-month, twice-weekly resistance training (RT) program
46092634|NCT00958867|Behavioral|Exercise training (S & R; control)|Six-month, twice-weekly stretch & relax (S & R; control) program
46092635|NCT04179188|Procedure|Bariatric surgery|Classical Bariatric surgery (ring, Sleeve gastrectomy or Bypass)
45678367|NCT01393444|Device|Implantation of ECoG sensors on the brain surface|One ECoG sensor will be implanted over the motor cortex of study participants
46006563|NCT04592198|Drug|Palonosetron Hydrochloride Buccal Film 0.25 Mg|Dose equal to the iv control
46006564|NCT04592198|Drug|Palonosetron Hydrochloride Buccal Film 0.5 Mg|Dose twice that of iv control
46006565|NCT04592198|Drug|Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution|iv control
46006566|NCT04592432|Other|SIGN@L-A|Two prototypes of a serious game were developed as part of this study. The design of these prototypes is based on the conceptual model by Alexiou and Schippers (2018) linking the instructional design of a serious game to intrinsic motivation, engagement, and learning outcomes. The design of SIGN@L-A will include all elements of the serious game instructional design proposed by these authors which are game mechanics (i.e., objectives to meet, feedback, and rewards), a narrative (i.e., a protagonist, non-playable characters, and narrative events), and aesthetics (i.e., functional and hedonic aesthetics).
45459654|NCT03484390|Behavioral|Wellness Group|
45678368|NCT01431976|Drug|Lamictal|No comparison
45678369|NCT01413958|Drug|Phenylephrine|Phenylephrine hydrochloride 30-mg extended-release tablets, one tablet every 12 hours for 7 days
45678370|NCT01413958|Drug|Placebo|Placebo to phenylephrine hydrochloride 30-mg extended release tablets, one tablet every 12 hours for 7 days
46006567|NCT04592432|Other|SIGN@L-B|The design of SIGN@L-B will include only some of these elements which are some of the game mechanics (i.e., objectives to meet, limited feedback), and a functional aesthetic.
46006568|NCT00579774|Other|Low AGE Diet|Diet
46092636|NCT03780257|Drug|QR-421a|RNA antisense oligonucleotide for intravitreal injection
46092637|NCT03780257|Other|Sham-procedure (dose cohort 1&2 only)|Sham-procedure (no experimental drug administered)
46092638|NCT00691821|Other|Standard Dressings|Participants will receive standard dressings changes as needed. Different dressing types (e.g., silver, simple gauze, hydrogel, foam, creams, gels) will be used dependent on the type of the wound (e.g., dry, wet, and intermediate).
46092639|NCT00691821|Device|Negative Pressure Wound Therapy (Vacuum-Assisted Closure System [V.A.C.® Therapy™, KCI Medical Canada Inc., Mississauga, Ontario])|Participants will receive negative pressure wound therapy.
46092640|NCT02632578|Biological|2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)|Subjects received licensed influenza vaccine (Fluvax®), 1ml intramuscular injection.
46092641|NCT04138251|Drug|Empagliflozin|oral administration of Empagliflozin
46092642|NCT04176926|Diagnostic Test|Electrocardiogram|Diagnostic Test: Simultaneous assessment of heart rhythm by 12-lead ECG and wearable device characterization of heart rhythm.
46092643|NCT00964171|Drug|efavirenz|
46092644|NCT00964171|Procedure|quality-of-life assessment|
46092645|NCT02632500|Other|Quality of chest compressions|
46092646|NCT00691899|Drug|odanacatib|odanacatib; 5mg oral, once daily for Approximately 36 months.
46092647|NCT00691899|Drug|placebo (unspecified)|placebo; oral, once daily for Approximately 36 months
46092648|NCT00964249|Drug|GW642444|Long acting Beta 2 agonist
46092649|NCT00964249|Drug|Placebo|Matching placebo
46092650|NCT04016246|Drug|Propofol-Lipuro|sedation of babies < 32wGA with propofol / placebo before a LISA Procedure
46092651|NCT04016246|Drug|Placebos|injected to babies < 32wGA with propofol / placebo before a LISA Procedure
46092652|NCT00691977|Radiation|Radiation Therapy followed by prostatectomy|Radiation Therapy
46092653|NCT00658164|Other|Iron depletion treatment|Effect of iron depletion by phlebotomy plus lifestyle changes vs. lifestyle changes alone on liver damage in patients with nonalcoholic fatty liver disease with increased iron stores
46092654|NCT02794259|Device|tDCS|
46092655|NCT02794259|Device|sham-tDCS|
46092656|NCT04092218|Other|Questionnaire|"Data will be obtained through a written questionnaire to determine the type of parenting style of parents or caregivers.~The collected data will be saved and tabulated on computer and finally statistically analysed."
46092657|NCT05350579|Other|Yogurt Intervention|"Participants will be asked to consume one serving of yogurt per day.~Nutrient composition of yogurt provided to participants in the yogurt group:~Nutrients per serving Serving Size: 141 g Energy (kcal) 170 Total Fat (g) 8 Total Carbohydrate (g) 16 Sugars (g) 15 Protein (g) 5 Sodium (mg) 85 Calcium (%) 15 Vitamin A (%) 4 Ingredients: Pasteurized Grade A Milk, Cane Sugar, Yogurt Cultures (S. thermophilus, L. bulgaricus), Vanilla Extract."
46092658|NCT02789735|Device|Active laser therapy|Laser therapy at predetermined sites
45836574|NCT00305682|Procedure|umbilical cord blood transplantation|One or 2 UCB units may be infused to achieve the required cell dose.
45836575|NCT00305682|Radiation|total body irradiation|Administered Day -1, 200 cGy
45836576|NCT00305682|Drug|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL. Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
45836577|NCT00305760|Drug|Cetuximab|Cetuximab will be administered at an initial dose of 400 mg/m2, followed by weekly doses of 250 mg/m2 for a total of 6 cycles that last 3 weeks each.
45836578|NCT00305760|Biological|Pancreatic tumor vaccine|Vaccine will be administered one day after cyclophosphamide (day 1) every three weeks for 6 cycles.
46006569|NCT00579774|Other|Regular Diet|Diet
45459655|NCT05759546|Drug|Fluzoparib|Parp inhibitor
46006570|NCT04592354|Dietary Supplement|Oxaloacetate Medical Food/Dietary Supplement|500 mg Anhydrous Enol-Oxaloacetate BID
46006571|NCT04592081|Drug|Dextenza 0.4Mg Ophthalmic Insert|Dextenza 0.4Mg Ophthalmic Insert
46006572|NCT00579852|Procedure|CT Scan|Patients with NSCLC undergoing non-contrast CT scan of the chest will have a second, high resolution, non-contrast CT scan of the chest performed on the same day. The scans will be performed on the same CT scanner, generally within 30 minutes. Unidimensional, bi-dimensional, and volume measurements for the primary NSCLC lesion will be determined on both scans and the values compared. After completing the second scan, the patient will have completed participation in the protocol.
46092659|NCT02789735|Device|Sham laser therapy|Sham therapy at predetermined sites
46006573|NCT04591964|Combination Product|"mobile application M-Cardio based on android"|"Mobile apllication M-Cardio (android) for remote monitoring of patients with CHF developed on algorithms of clinical indicators, that's give us to evaluate current condition of patient, depends from quantity points of abnormals higher or lower threshold values, with automatically notification for doctor and patient for timely medical service."
46092660|NCT00959023|Other|laboratory biomarker analysis|
46092661|NCT00959023|Other|medical chart review|
46092662|NCT00959023|Other|questionnaire administration|
46092663|NCT04233437|Drug|MLC1501|MLC1501 capsules (4 capcules (2000 mg) twice a day)
46092664|NCT04233437|Drug|CYP Cocktail|Repaglinide 0.25 mg, caffeine 100 mg, warfarin 10 mg (with vitamin K), omeprazole 40 mg, dextromethorphan 30 mg, midazolam 2 mg
46092665|NCT04233437|Drug|Transporter Cocktail|Digoxin 0.25 mg, furosemide 1 mg, metformin 10 mg, rosuvastatin 10 mg
46092666|NCT02674256|Drug|CRH|100µg CRH powder for injection (CRH ferring®, Ferring, Aalst, Belgium) and 1 mL of NaCl 0.9% will be put together, then the solution will be injected intravenously over the course of 1 minute
46092667|NCT02674256|Other|Placebo|1 mL of NaCl 0.9% will be injected intravenously over the course of one minute
46092668|NCT02789501|Device|4% citrate lock solution regimen|(CitraFlow™ 4%, MedXL, Montreal, Canada) will be injected in each of the 2 lumens of the tunneled catheters after each dialysis session (2ml/lumen, 3x/week).
46092669|NCT02789501|Device|TauroLock lock solution regimen|After the first two dialysis sessions of the week (before the short intervals) 2 ml of TauroLock™-Hep500 containing 1% (cyclo)-taurolidine, 4% citrate and 500 IU/mL heparin will be injected into each of the two lumens of the tunneled catheter. After the third dialysis of the week, thus before the long interval, 2 ml of TauroLock™-U25.000 which contains 1% (cyclo)-taurolidine, 4% citrate and 25.000 IU urokinase will be applied into each lumen.
46092670|NCT02674022|Dietary Supplement|Prenatal supplement|Treatment with a standard and optimized prenatal supplement, dependent on laboratory evaluations of participants.
46092671|NCT02793713|Procedure|Endobronchial Ultrasound|Patients undergoing EBUS with TransBronchial Needle Aspiration will be invited to enroll on the day of their procedure. Once informed consent is obtained, the surgeon will assess the sonographic criteria, take pictures, and biopsy every lymph node of interest. All three elements of this assessment will need to be completed for a specimen to be included in the study. After the procedure, the operating surgeon will fill the Lymph Node Assessment questionnaire, assign an aggregate score to every lymph node specimen, and attach the pictures to the form. Pictures from every specimen will stored electronically to be reviewed and secondarily rated by a second blinded surgeon. Patient involvement in the study ends at the completion of the planned procedure.
46092672|NCT00644072|Drug|SNX-5422|
46092673|NCT04178876|Procedure|ethanol sclerotherapy|Endometrioma laparoscopic aspiration and sclerotherapy using 95% ethanol
46092674|NCT04178876|Procedure|stripping technique|Endometrioma laparoscopic cystectomy
46092675|NCT02789579|Drug|levofloxacin|There are 50 patients in the group,each patient receives levofloxacin 0.5g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
46092676|NCT02789579|Drug|Nitrofurantoin|There are 50 patients in the group,each patient receives nitrofurantoin 0.1g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
46006574|NCT04592042|Behavioral|Feel-Good- Group|Eight sessions of group intervention focussing on information on emotion regulation, training of emotion regulation techniques and mindfulness.
46092677|NCT02789579|Drug|cefuroxime|There are 150 patients in the group, 30 minutes before surgery, each patient is given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
46092678|NCT02674178|Procedure|Invitro fertilization|"All participants underwent long protocol. Daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG injection. Gn stimulation started in a starting dose of 150-300 IU/day depending on patients age and previous gonadotropin response. then the dose was adjusted according to ovarian response monitored by serum E2 and ultrasound evaluation. All patients were followed up by Transvaginal ultrasound scan daily or on alternate days~Triggering by HCG 10000 IU IM when at least 2 follicles reached a mean diameter of 18 mm [18]~Ovum pick-up (OPU) was done 34-36 hours after hCG injection Transfer of cleaving embryos was done on day 3 after oocyte retrieval"
46092679|NCT02793791|Procedure|minimally invasive ablation therapies|Including RFA (radiofrequency ablation);MWA (microwave ablation); PEI (percutaneous ethanol injection),etc.
46092680|NCT02672540|Drug|SANGUINATE 320 mg/kg|Two-hour infusion of SANGUINATE on Day 1 and Day 2
46092681|NCT02672540|Drug|Normal Saline|Two-hour infusion of Normal Saline and Day 1 and Day 2
46092682|NCT04233203|Drug|Insulin Faster Aspart|Currently receiving Faster Aspart during 3 or more months.
46006575|NCT04591769|Device|Different tracheal tube cuff design|Comparison of effect between 2 different designs of tracheal tube cuff
46092683|NCT04233203|Device|Insulin pump|Currently receiving CSII therapy during 6 or more months.
45678371|NCT01413958|Drug|Loratadine|Loratadine, 10 mg, once daily as rescue medication, only if needed for intolerable allergic rhinitis symptoms
45459656|NCT05759546|Drug|Dalpiciclib|CDK4/6 inhibitor
45678372|NCT02985502|Other|pancreatogenic diabetes|pancreatogenic diabetes
45459657|NCT05759546|Drug|Fulvestrant/AI|Endocrine therapy
45678373|NCT01413178|Drug|Busulfan|Test dose (32 mg/m^2) on day -9 then 130 mg/m^2 by vein or adjusted dose on Days -7, -6, -5, and -4.
46006576|NCT00579969|Drug|Latanoprost|dosage form:eye drops, dosage: One drop in each eye twice a day
46006577|NCT00579969|Drug|Timolol|dosage form:eye drops, dosage: One drop in each eye twice a day
46006578|NCT04591847|Drug|Vitamin D 2|Vitamin D2 20000IU 1 tab oral weekly
46006579|NCT04591847|Drug|Placebo drug|Placebo drugs 1 tab oral weekly
46092684|NCT00959101|Drug|repaglinide and metformin combination tablet|Combination tablet of repaglinide (1.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
46006580|NCT00580086|Other|MR spectroscopy|(1H MRS) on 1.5 Tesla (1.5T), using a software package from General Electric Medical Systems, Milwaukee, WI
46092685|NCT00959101|Drug|repaglinide and metformin combination tablet|Combination tablet of repaglinide (2.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
46092686|NCT00959101|Drug|repaglinide|Co-administration of metformin 500 mg tablet and repaglinide 2 mg tablet given just prior to a standard normal breakfast
46092687|NCT00959101|Drug|metformin|Concomitant administration: Metformin 500 mg tablet and Repaglinide 2 mg tablet
46092688|NCT00880698|Biological|RotaTeq|2 mL solution of live reassortant rotaviruses, containing G1, G2, G3, G4 and P1A which contains a minimum of 2.0 - 2.8 x 10^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10^6 IUs per aggregate dose
46092689|NCT00880698|Biological|Placebo|2 mL solution
46092690|NCT02672618|Other||The IRS system is capable of precisely measuring and storing real-time thermal images with a resolution of 320×240 pixels (IRS S6md Shanghai,China). The camera has Focal Plane Array (FPA), Uncooled microbolometer detector, with a thermal sensitivity of 0.05 ℃ at 20℃ to 30℃. The thermal images were captured at a distance of one meter from the various body regions namely face and the images were analyzed by thermal software（version 1.0）.
46092691|NCT04233359|Procedure|Local anesthetic thoracoscopy|Procedure to obtain histological biopsies of the parietal pleura on awake, fastening patients.
46092692|NCT04233359|Procedure|US-guided pleural biopsy|In local anesthesia, a closed needle biopsy is performed Ultrasound guided of the parietal pleura at the place of deepest fluid recess in the intrathoracic space. A pigtail catheter French 7-16 is placed afterwards for fluid drainage.
46092693|NCT00964327|Drug|TMC114|
46092694|NCT05252546|Drug|pyrotinib tablet|single oral dose of pyrotinib or co-administered with Montmorillonite Power or Loperamide
46006581|NCT04591535|Drug|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
46092695|NCT05252546|Drug|Montmorillonite Power|3 g or one pouch of montmorillonite power 2 hours after pyrotinib administration
46092696|NCT05252546|Drug|Loperamide|4 mg of loperamide with pyrotinib followed by 2mg every 2 hours for 2 times for a total of 8mg/day
46092697|NCT00964405|Drug|GSK233705|Inhaled Long acting muscarinic receptor antagonist
46092698|NCT00964405|Drug|Placebo|Matching placebo
45678374|NCT01413178|Drug|Melphalan|70 mg/m2 by vein over 30 minutes minutes on Days -2 and -1.
46092699|NCT00644384|Drug|acitretin|
45678375|NCT01413178|Other|Questionnaire|Quality of Life (QOL) questionnaire before starting the study drugs and then once every 4 weeks after the stem cell transplant, taking about 15 minutes to complete.
46006582|NCT00580242|Drug|Bortezomib|First cohort: Bortezomib 0.7mg/m2 IV on Days on Days 1, 4, 8, and 11. Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
45678376|NCT01413178|Drug|G-CSF|Approximately 5 mcg/kg/day subcutaneously beginning on Day +5.
45678377|NCT01413178|Drug|High Dose Melphalan|200 mg/m2 by vein over 30 minutes on Day -2.
45678378|NCT01413178|Procedure|Stem cell transplant|Stem cell infusion on Day 0.
46092700|NCT00644384|Genetic|gene expression analysis|
46006583|NCT00580242|Drug|Bortezomib|Second cohort: Bortezomib 1mg/m2 IV on Days 1, 4, 8, and 11 Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
46006584|NCT00580242|Drug|Bortezomib|Third Cohort: Bortezomib 1.3mg/m2 IV on Days 1, 4, 8, and 11 of each cycle Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
46006585|NCT00580242|Drug|Lenalidomide|Lenalidomide 10 mg PO QD on Days 1 -21 followed by a 7 day rest period
46092701|NCT00644384|Genetic|northern blotting|
46092702|NCT00644384|Genetic|polymerase chain reaction|
46092703|NCT00644384|Genetic|protein expression analysis|
46092704|NCT00644384|Other|laboratory biomarker analysis|
46092705|NCT04237961|Procedure|Botox and brow lift|Botox injection
46092706|NCT04237961|Procedure|Injection|Fat injection and botox
46092707|NCT04237961|Procedure|Suture|Suspension suture
46092708|NCT04177160|Behavioral|Music|Subjects sit still and listen to preferred music for 5 minutes.
46092709|NCT04177160|Behavioral|White noise|Subjects sit still and listen to white noise for 5 minutes.
46092710|NCT05653739|Behavioral|Mindfulness Based Stress Reduction Intervention|MBSR is Mindfulness based intervention designed by Kabat-Zinn (1990) in order to deal with the stress and other psychological issues among individuals. This has been very effective intervention across different cultures . In this 8 week intervention participants will be given some home tasks to practice for at least 40 minutes a day.
46092711|NCT02637648|Drug|Sodium Oxybate|parallel Group administration
46092712|NCT02637648|Drug|Placebo|parallel Group administration
46092713|NCT00964483|Behavioral|DASH diet|The intervention will consist of a 12-week pilot trial in which participants will be given intervention materials tailored to their community, focusing on DASH. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium. They will follow this diet for 12 weeks.
46092714|NCT00964483|Behavioral|Delayed Intervention|"The participants will receive a guide written by NHLBI entitled, Your Guide to Lowering Blood Pressure."
46092715|NCT02793635|Device|Indego Powered Exoskeleton|Subjects who have Spinal Cord Injury will wear the Indego device which will include being trained and evaluated for fifteen (15) sessions.
46092716|NCT02671526|Other|Computerized plasticity-based adaptive cognitive training|
46092717|NCT02815865|Device|Foley catheter and pitocin|Foley catheter will be inserted through the cervix and inflated with 80 ml saline, pitocin will be initiated 1 hour later in the delivery room
46006586|NCT04591496|Behavioral|Behavioral change intervention;|Behavioral change intervention: goal setting, regarding child's diet and parental feeding practices; self-monitoring, with observation and recording of the child's food intake and parental feeding practices; individualized feedback, based on preceding week monitoring and according to the defined objectives, regarding child's and parent's behaviors; modeling and direct suggestions by tailored parent figures; positive reinforcement associated to parents' accomplishment of the objectives; prompts, to remember the defined objectives and the main messages of the intervention.
46006587|NCT04591496|Behavioral|Health Education|Health education: provision of information about preschool children's nutrition guidelines, effective parental feeding practices, strategies to overcome food and feeding-related barriers, and steps to form healthy habits.
46092718|NCT02815865|Device|Foley catheter and Dinoprostone|Foley catheter will be inserted through the cervix and inflated with 80 ml saline Dinoprostone 3 mg will be inserted 1 hour later to the posterior fornix
46092719|NCT02815865|Drug|Dinoprostone|Dinoprostone 3 mg will be inserted to the posterior fornix
46092720|NCT02673866|Drug|DS-1971a|
46092721|NCT02673866|Drug|placebo|
46092722|NCT02673866|Drug|pregabalin|pregabalin
46092723|NCT00964561|Drug|Ciprofloxacin and Valortim|Days 1-3 400mg IV Ciprofloxacin BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
46092724|NCT00964561|Drug|Placebo Antibiotic and Valortim|Days 1-3 20mg/kg IV Normal Saline BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
46092725|NCT00964561|Other|Placebo Antibiotic and Placebo Valortim|Days 1-3 200mL IV Normal Saline for Placebo Antibiotic over 60 minutes. Day 4 200mL IV Normal Saline for Placebo Valortim over 60 minutes.
46092726|NCT02671682|Procedure|Immunoadsorption|
46092727|NCT02671682|Procedure|Plasmapheresis|
46092728|NCT02793323|Other|Superficial cervical nerve block|A nerve stimulator is used to guide superficial cervical blockade to relieve shoulder pain.
46092729|NCT02793323|Other|NSAID|100 mg (100 ml) intravenous NSAIDs (Profenid)
45836579|NCT00305760|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m2 will be administered one day prior to vaccination (day 0) every three weeks for 6 cycles.
46092730|NCT02793323|Other|General anesthesia|General anesthesia is induced with 1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen
46092731|NCT02793323|Other|IV placebo|100 ml IV saline
46092732|NCT02793323|Other|Placebo superficial cervical nerve block|Superficial cervical nerve block containing 5 ml saline
46092733|NCT00964639|Drug|Ropivacaine|During the surgery infiltration with Naropine 2 mg/ml. The dosage in the infiltration is 2 mg/kg. Thereafter bolus 3 times a day
46092734|NCT00964639|Drug|Saline|During the surgery infiltration with saline. Thereafter bolus 3 times a day
46092735|NCT02673788|Other|observation without intervention in this follow up study|observation without intervention in this follow up study
46092736|NCT04234373|Other|Low Carb diet|Low Carb diet (max. 130g carbohydrates/d) for 6 months
46092737|NCT00964717|Procedure|real chiropractic|real chiropractic manipulation
46092738|NCT00964717|Procedure|Sham Chiropractic|Placebo stimulation using 'activator' thumper
46092739|NCT02793401|Device|Hıgh İntensity Laser (HILT)|HILT was performed using a BTL-6000 High Intensity Laser, 12 W(watt), 1064 nm device was a hot laser with Nd: YAG LASER source. In HILT group, the investigators applied the device on the shoulder area in two phases: phase I - analgesia, and phase II - biostimulation.
46092740|NCT02793401|Device|Ultrasound|BTL 4710 US device was applied at 3 MHz frequency, and 1.5watt/cm2 intensity over 25 cm2 surface area. Headpiece area of the device was 5 cm2, and the application was performed as the head of device was positioned at 90º (perpendicular) at full contact for 5 minutes by using gel, and performing continuous circular motions.
46092741|NCT02793401|Device|Hotpack|All patients had the same physical therapy (PT) protocol including hot pack (HP) for 20 min/session,
46092742|NCT02793401|Device|Transcutaneous electrical nerve stimulation|All patients had the same physical therapy (PT) protocol includingTENS (Fizyotens 4000, Fizyomed Medical Devices Ltd,Turkey) (50-100 Hz) for 20 min/session,
45459658|NCT05151016|Drug|mifepristone|Mifepristone tablets, 10mg, 1 tablet daily, taken orally (beginning on the third day of Menstruation) for 24 weeks
46092743|NCT02793401|Other|Therapeutic exercises|All patients had the same physical therapy (PT) protocol including therapeutic exercises for shoulder muscles
46092744|NCT02793401|Other|Balneotherapy|All patients had the same physical therapy (PT) protocol including balneotherapy in 38-40 °C thermomineralized water for 20 minutes.
46092745|NCT05343715|Biological|Agalsidase beta from Biosidus 1 mg/kg|Patients received an infusion of 1 mg/kg of Agalsidase Beta from Biosidus. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg
46092746|NCT05343715|Biological|Fabrazyme (agalsidase beta) 1 mg/kg|Patients received an infusion of 1 mg/kg of Fabrazyme. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg
46092747|NCT00644150|Behavioral|Physician Ai Shi Zi training|This training uses a curriculum developed specifically for Project Ai Shi Zi and includes training in stigma; risk-reduction counseling; and quality HIV/STI diagnosis, treatment, and management. Physician training will consist of multiple components: an orientation workshop on fundamental knowledge and skills of HIV/STI treatment and prevention, a 3-month practice period, a 3-month post-practice seminar on preventive counseling, another 3-month practice period, and a 6-month post-practice seminar on clinical HIV and STI management. The practice periods will promote learning-by-doing to further enhance physicians' abilities to deliver high quality, integrated HIV/STI prevention and treatment. Post-practice seminars will allow participants to share experiences gained during the previous 3-month practice period.
46092748|NCT00644150|Drug|Standard care|If an STI is confirmed by a lab test, participants will receive standard of care treatment. Gonorrhea will be treated with a single dose of 250 mg of ceftriaxone sodium administered by intramuscular injection. If patients are allergic to ceftriaxone, they will be treated with azithromycin (2 g single oral dose). Chlamydia will be treated with azithromycin (1 g single oral dose).
46092749|NCT00644150|Behavioral|Patient risk-reduction counseling|On the initial visit, participants will receive HIV/STI risk-behavior counseling from the physician trained in Ai Shi Zi. The process is based on motivational interviewing techniques and will include discussing topics such as partner notification, HIV/STI prevention, and expected difficulties in changing behaviors. This risk-reduction model encourages the HIV/STI-infected or -uninfected person to develop a risk-reduction plan. The objective is to decrease the chance of infection for that individual and for others, too. Patients will develop a list of risk-reduction strategies to follow.
46092750|NCT05307913|Other|EIT-guided PEEP|PEEP setting according to EIT
46006588|NCT00580281|Other|blood test, urine test, and bone density x-ray.|start of the study (month 0), and at months 3, 6, 9, 12 (1 year), 15, 18, 21, and 24 (2 years)
46092751|NCT05307913|Other|Table-guided PEEP|PEEP setting according to the lower PEEP/FiO2 table
46006589|NCT04591457|Drug|Insulin Glargine Sansulin|Insulin Glargine (Sansulin Log-G) once daily at individually adjusted dose
46006590|NCT04591457|Drug|Insulin Glargine Pen Injector [Lantus]|Insulin Glargine (Lantus) once daily at individually adjusted dose
45678379|NCT01799889|Drug|Entospletinib MM|Entospletinib MM tablet administered orally
46092752|NCT02672384|Procedure|Dental examination and a point of care P. gingivalis test (Denka Seiken Co (Japan) )|Dental examination Study exams (oral and blood sample collection)
46092753|NCT02793557|Drug|FOL-005|Intradermal injection of 50 μl solution
46092754|NCT02793557|Other|Placebo|
46092755|NCT00880620|Drug|Placebo|Placebo
46092756|NCT00880620|Drug|IPX066 95 mg LD|IPX066 capsule containing 95 mg LD/23.75 mg CD
46092757|NCT00880620|Drug|IPX066 145 mg LD|IPX066 capsule containing 145 mg LD/36.25 mg CD
46092758|NCT00880620|Drug|IPX066 195 mg LD|IPX066 capsule containing 195 mg LD/48.75 mg CD
46092759|NCT00880620|Drug|IPX066 245 mg LD|IPX066 capsule containing 245 mg LD/61.25 mg CD
46092760|NCT00959335|Drug|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
46092761|NCT00959335|Drug|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
46092762|NCT02672462|Device|Radio frequency renal denervation system (Golden Leaf GL-06E15A)|
46092763|NCT00644618|Drug|gemcitabine|a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
46092764|NCT00644618|Other|125I brachytherapy PLUS gemcitabine|125I brachytherapy PLUS a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
46092765|NCT03967847|Drug|Ketorolac|Oral Ketorolac
45836580|NCT03839394|Behavioral|Telephone|A series of educational pamphlets on CVD risk reduction plus a telephone-based CVD risk reduction curriculum will be administered by Clinic-Based Case Managers (CCMs). Six modules will be given over 24 weeks in a rotating fashion on topics relevant to CVD risk. Subjects will be given the pamphlets every 2 weeks corresponding with the first time they receive the telephone - based module.
45678380|NCT01799889|Drug|Entospletinib SDD|Entospletinib SDD tablet administered orally
45678381|NCT01412944|Drug|secukinumab 150mg|secukinumab 150mg (2 injections per dose)
45678382|NCT01412944|Drug|secukinumab 10mg/kg i.v. regimen|secukinumab 10mg/kg i.v. regimen
45678383|NCT03025906|Drug|Phenobarbital|In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.
45678384|NCT03025906|Drug|Valproate|In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
45836581|NCT03839394|Other|Educational pamphlets|A series of 6 handouts will be given to controls once monthly over 6 months on the same topics presented in the telephone modules. Educational packets will be primarily drawn from free printed material available at www.learningaboutdiabetes.org and the American Heart Association website.
46006591|NCT00580320|Drug|Dacarbazine and bortezomib|Level 0: Dacarbazine 190 mg/m2 + Bortezomib 1.0 mg/m2; Level 1: Dacarbazine 250 mg/m2 + Bortezomib 1.0 mg/m2; Level 2: Dacarbazine 250 mg/m2 + Bortezomib 1.3 mg/m2; Level 3: Dacarbazine 250 mg/m2 + Bortezomib 1.6 mg/m2; Level 4: Dacarbazine 330 mg/m2 + Bortezomib 1.6 mg/m2; Level 5: Dacarbazine 440 mg/m2 + Bortezomib 1.6 mg/m2; Level 6: Dacarbazine 580 mg/m2 + Bortezomib 1.6 mg/m2
46006592|NCT00567086|Drug|TEZAMPANEL|Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)
46006593|NCT00580359|Drug|S-1, capecitabine|S-1 40mg/m2 orally twice daily on days 1(evening) - 15 (morning)every 3 weeks, until disease progression, Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)every 3 weeks, until disease progression
46006594|NCT00580437|Procedure|Dobutamine Stress Echocardiogram|stress echocardiograms involving the use of intravenous Optison or Definity contrast agents to improve endocardial definition
45459659|NCT05151016|Drug|Triptorelin Acetate|dafinil, 3.75 mg, first injection on the third day of menstruation, followed by intramuscular injection every 28 days for 24 weeks.
45678385|NCT04055272|Behavioral|Mobile text messaging intervention|Participants in the intervention arm will receive text messages to their mobile phones designed to communicate the risks of indoor tanning and motivate cessation. The intervention exposure lasts for 4 weeks with messages sent 2 days each week. It is an interactive intervention that engages participants by asking them to respond to prompts, and sending indoor tanning message content in return on message days.
45678386|NCT04054414|Drug|Normal Saline along with standard treatment|The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
45678387|NCT04054414|Drug|PMZ-1620 along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
45678388|NCT04053712|Drug|Glucagon|GlucaGen(R), Novo Nordisk, DK
46006595|NCT04591340|Dietary Supplement|dietary advice, oral nutritional supplement, supplementary parenteral nutrition or total parenteral nutrition|All HSCT(hematopoietic stem cell transplantation) patients should be accepted dietary advice or oral nutritional supplement, if their energy intake will not reach 60% of the goal level during the transplanting, then supplementary parenteral nutrition or total parenteral nutrition.
46006596|NCT04591418|Device|Rotary handpieces|Dental Caries removal
46006597|NCT04591418|Device|Er:YAG laser|Dental Caries removal
46006598|NCT00580593|Device|BiPAP® S/T System|The BiPAP® S/T System is a NIPPV device that provides intermittent ventilatory assistance to people with difficulty breathing secondary to respiratory muscle weakness.
46006599|NCT00580593|Other|sham-NIPPV|a sham-device
45678389|NCT04053712|Device|Closed-loop system|Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
45836582|NCT00309738|Drug|pitavastatin|
45836583|NCT00309738|Drug|simvastatin|
46006600|NCT04591145|Other|Observational group|Patient receive the standard bowel preparation strategy and routine colonoscopy
46092766|NCT02672306|Biological|UCMSCs|Biological: Human UCMSCs 20 million cells per subject (0.5×10^6 UCMSCs per kg) intravenous injection Infusion number: 8 (Once every two weeks)
45836584|NCT00310050|Drug|pemetrexed disodium|500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).
45836585|NCT00310050|Device|Radiotherapy|During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).
45836586|NCT00363168|Drug|Ranibizumab|0.3 mg/0.05 ml dose
46092767|NCT02672306|Biological|Placebo|Subjects with Alzheimer's Disease placebo comparator (normal saline) intravenous injection Infusion number: 8 (Once every two weeks)
46092768|NCT00658398|Behavioral|Interactive Computer Program to prevent alcohol misuse.|Interactive Computer Program with questionnaires, video and informations
46092769|NCT03755063|Other|Speech therapy apps|Speech therapy apps loaded on tablets
45459660|NCT04459312|Diagnostic Test|Antibody test (SARS-CoV2)|Antibody test
45459661|NCT01376414|Other|Urea Breath Test (UBT) for H. pylori infection|13C UBT to detect H. pylori infection. Single bedside test that determines infection in about ten minutes. Test machine is a product of Exalenz bioscience.
45678390|NCT01798485|Drug|Docetaxel|Docetaxel, 75 mg/m^2, was administered according to prevailing practice and Investigator decision, generally until disease progression, intolerability, or patient's withdrawal of consent.
45678391|NCT01798485|Drug|Ganetespib|Ganetespib, 150 mg/m^2, was administered with docetaxel. After docetaxel treatment ceased, participants whose disease has not progressed continued to receive ganetespib alone until disease progression, unacceptable toxicity, or patient's withdrawal of consent.
45678392|NCT01767597|Other|ELISA testing|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).
45836587|NCT00363168|Drug|Ranibizumab|0.5 mg/0.05 ml dose
46006601|NCT00580749|Procedure|Naso jejunal feeding tube insertion|Placement of feeding tube through nare and into jejunum for administration of enteral feeding.
46006602|NCT00580749|Procedure|NG feeding tube insertion|Placement of naso gastric feeding tube into stomach for purpose of enteral feedings.
46006603|NCT04591301|Drug|HEC113995 PA•H2O tablets|Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
46006604|NCT04591301|Drug|Placebo tablets|Placebo tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
46006605|NCT04577625|Dietary Supplement|Lactobacillus reuteri (L. reuteri)|L.reuteri high or low dose with vitamin D3 compared to vitamin D3 only
46006606|NCT00580827|Drug|Placebo|Matched placebo.
46006607|NCT00580827|Drug|Disulfiram|disulfiram at 62.5 mg/day for 12 weeks.
46006608|NCT00580827|Drug|Disulfiram|Disulfiram at 125 mg/day for 12 weeks.
46092770|NCT00910286|Other|Pulmonary Ventilator|The aim of the present study was to compare two different cycling off modes in PSV, a fixed and other automatic, about ventilatory mechanic variables, breathing comfort and patient-ventilator asynchrony patterns
46092771|NCT00658476|Dietary Supplement|Fish Oil|Omega-3 fatty acid supplements.
46092772|NCT00658476|Behavioral|Cognitive Behavior Therapy|Adolescents receive cognitive behavior therapy.
46092773|NCT00658476|Other|Placebo|
46092774|NCT04175990|Drug|Dydrogesterone Pill|started from day 1 of menses till trigger day
46092775|NCT00658554|Drug|ARQ 197|Treatment with ARQ 197
46092776|NCT05258227|Other|Conservational Physical Therapy and Proprioceptive Strength Training|The proprioceptive training cycle consist of squats, single leg stand, slide steps , forward and backward step, toe walking , heel walking , side sway etc.
46092777|NCT05258227|Other|Conservational Physical Therapy and Core Instability Strength Training|Core stability is essential part of lower limb rehabilitation; it is also known protocol which includes group of exercises in both standing and sitting improving biomechanics and functional performance of the body.
46092778|NCT03919877|Other|Dietary|Dietary counseling based on results of CGM analyses.
46092779|NCT00959569|Drug|Esmolol|esmolol (1-3 mg/kg) during cardiac surgery
46092780|NCT00959569|Drug|Placebo|normosaline (same ml of the study drug)
45836588|NCT03810456|Behavioral|Intensive Cognitive Behavior Therapy (iCBT)|Participants randomized to iCBT will receive 16 hours of cognitive behavioral therapy for anxiety over one weekend. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
45836589|NCT03810456|Behavioral|Standard Cognitive Behavior Therapy (sCBT)|Participants randomized to sCBT will receive 16 hours of cognitive behavioral therapy for anxiety weekly over a period of 12 weeks. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
46092781|NCT00881868|Drug|clobetasol propionate spray 0.05%|Apply enough product to cover affected areas topically twice daily at least 8 hours apart
46092782|NCT00881868|Drug|Vehicle spray|Apply enough product to cover affected areas topically twice daily at least 8 hours apart
46092783|NCT00964873|Drug|STA-9090 (ganetespib)|Chemotherapy agent
46092784|NCT04527419|Procedure|Systematically mediastinal lymph node dissection|Systematically mediastinal lymph node dissection will be performed.
46092785|NCT04527419|Procedure|No mediastinal lymph node dissection|No mediastinal lymph node dissection will be performed.
45836590|NCT03723798|Drug|SA001 Low dose|3 tablets b.i.d for 12 weeks
45836591|NCT03723798|Drug|SA001 Mid dose|3 tablets b.i.d for 12 weeks
46092786|NCT04176068|Combination Product|calcium hydroxylapatite (Radiesse) and IFUS (Ulthera)|Patients will receive IFUS to a randomly chosen side. Immediately after IFUS treatment, patients will receive the first CaHA injection. Injections will be given in the lower, anterior third of the thigh, above the knee. Only dermatology faculty will perform the filler injections. The patients will be instructed to return to the office in 6 weeks, 12 weeks, and 24 weeks (+/- 5 business days) for their next appointment for follow-up and injection of CaHA if deemed necessary by the investigator. At all visits (Visits 1-4) patients will have photographs and unblinded physician/patient questionnaires will be completed. At Visit 4 (24 weeks +/- 5 business days), patients will be given the option to receive treatment for skin laxity to the previously untreated side. If the patient chooses to receive treatment, patients will receive their second IFUS and CaHA combination treatment at this time. They will not receive further treatment after this visit.
45836592|NCT03723798|Drug|SA001 High dose|3 tablets b.i.d for 12 weeks
45836593|NCT03723798|Drug|Placebo|3 tablets b.i.d for 12 weeks
45840122|NCT00632814|Drug|rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection twice per week (30 IU/kg [day 1] + 40 IU/kg [day 4]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
45840123|NCT00632814|Drug|rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 75 IU/kg, dosing by injection three times per week (3 x 25 IU/kg [day 1, 3, 5]) for 9 months. No escalation opportunity for patients in this group
45840124|NCT00632970|Drug|Raltegravir|1, 400mg tablet twice a day, with Truvada 1 tablet once a day
46006609|NCT00580827|Drug|Disulfiram|disulfiram at 250 mg/day for 12 weeks.
46006610|NCT00580905|Drug|Adenosine|IV infusion of adenosine at a dose of 80 mcg/kg/min for 30 minutes.
46006611|NCT00580905|Drug|Sodium Nitroprusside|To compare the effects of adenosine on increasing cytokines, sodium nitroprusside will be infused at 5 mcg/kg/min (a dose expected to produce similar systemic effects to adenosine)
46092787|NCT00959725|Drug|Infliximab (intravitreal, 2.0mg/0.05ml)|One injection of intravitreal infliximab (2.0mg/0.05ml).
46092788|NCT04176146|Behavioral|Peer comparison and social norms messaging|This group will receive a letter noting that their organization has not implemented at least one common care delivery practice that a majority their peers have already implemented. The letter will also note the percentage of peer organizations that have implemented the practice. This is done using peer comparison data and social norms messaging.
46092789|NCT02793245|Other|Questionnaire|Questionnaire on their main characteristics : age, gender, height, weight, smoking
46092790|NCT02793245|Other|Simplified pulmonary function test|
46092791|NCT00656994|Drug|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 6 months.
46092792|NCT00656994|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 6 months
46092793|NCT02672228|Device|MalariaSense device|All participants enrolled in the study will be assessed for malaria using the intervention device called MalariaSense technology
46092794|NCT00964951|Biological|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg Inactivated H1N1 Vaccine.
46092795|NCT00964951|Biological|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
46092796|NCT03807713|Device|Minimally Invasive Ponto Surgery|Minimally Invasive Ponto surgery is used for hearing rehabilitation using Ponto Wide Implants in patients indicated and counselled for Bone Anchored Hearing Systems.
46092797|NCT04233281|Other|Kori tofu|16.5 gram Kori-tofu mixed in a high carbohydrate test meal
46092798|NCT04233281|Other|Whey protein|high carbohydrate test meal with whey protein, matched in macronutrient content
46092799|NCT02671994|Other|G8 screening|
46092800|NCT02671994|Other|Geriatric assessment|
45836594|NCT01794546|Behavioral|Telehealth|Telehealth visits will alternate between a dietitian and behavioral medicine provider for either 30 minutes or 1 hour. Over a 6-month period, 12 telehealth sessions will be scheduled for each participant. The dietitian will provide dietary and physical activity recommendations, and the behavioral medicine provider will counsel on strategies for achieving specific goals. Applying a Chronic Care Model, self-management support will be augmented by linkages to community resources.
46092801|NCT02789189|Drug|nedaplatin and gemcitabine|
46092802|NCT02670590|Behavioral|diet|diet
46092803|NCT00881712|Radiation|PET positive nodal disease measuring 15 mm or greater|Proton radiation at 2 cobalt gray equivalent per fraction to a total of 74 cobalt gray equivalent with concomitant weekly chemotherapy.
46092804|NCT00881712|Radiation|PET positive nodal disease measuring less than 15 mm|Proton radiation at 2 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent with concomitant weekly chemotherapy.
46092805|NCT00881712|Radiation|Patients considered resectable|Proton radiation at 2 cobalt gray per fraction. Re-evaluation performed between days 18-22 of treatment. If considered resectable after re-evaluation, radiotherapy will discontinue after a total of 50 cobalt gray equivalent and surgery will be performed.
45836595|NCT00365274|Drug|Cyclophosphamide|Given IV 750 mg/m^2 day 1
45836596|NCT00365274|Drug|Doxorubicin hydrochloride|Given 50 mg/m^2 IV day 1
45836597|NCT00365274|Drug|vincristine sulfate|Given 1.4 mg/m^2 IV
46092806|NCT00644930|Device|the application of NPPV|ARDS patients in the NPPV group showing no indications for urgent intubation received NPPV in addition to standard medical therapy, and those with indications were intubated. BIPAP Vision machine (Respironics, PA, USA) were used for NPPV.
46092807|NCT00644930|Device|invasive ventilation|Standard therapy group (invasive ventilation). Patients in need of endotracheal intubation were mechanically ventilated with Amadeus (Hamilton, Via Nova, Switzerland) and Esprit (Respironics, PA, USA) ventilators in the assist-control or synchronized intermittent mandatory ventilation (SIMV) mode.
46092808|NCT05407805|Other|Electronic Diary|Participants will be asked to complete a daily electronic patient reported outcome diary entry to report on their experience in the past 24 hours.
46092809|NCT02634450|Device|Alere q|
46092810|NCT03723239|Device|TricValve® System|The TricValve® Delivery System is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is unsheathed at the implantation site and positions itself as per the anatomy - self expanding frame.
46092811|NCT04176770|Procedure|ESP Block|ESP block: bilateral injection of 20 ml of isobaric Bupivacain 0,375% in the paraverebral space T5.
46092812|NCT04176770|Procedure|TAP Block|TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
46092813|NCT02634216|Dietary Supplement|Capros|250 mg BID
46092814|NCT04234607|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
46092815|NCT04234607|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
46092816|NCT04234607|Drug|Etoposide|Etoposide is a cell cycle-specific antitumor drug
46092817|NCT04234607|Drug|Carboplatin|Carboplatin is cell cycle nonspecific antitumor drug
46092818|NCT04234607|Drug|TQB2450（blank）|Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
46092819|NCT04234607|Drug|Anlotinib（blank)|Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
46092820|NCT03955471|Drug|Niraparib|Niraparib is a potent, orally active poly (adenosine diphosphate-ribose) polymerase (PARP)-1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
46092821|NCT03955471|Drug|Dostarlimab|TSR-042 is a humanized monoclonal antibody that binds with high affinity to programmed cell death-1 (PD-1) resulting in inhibition of binding to programmed cell-death receptor ligands 1 and 2 (PD-L1 and PD-L2).
46092822|NCT02637726|Drug|Propofol : TCI Schnider|Target controlled infusion using schnider model for propofol
46092823|NCT02637726|Drug|Propofol : TCI Kataria|Target controlled infusion using Kataria model for propofol
46092824|NCT02637726|Drug|Propofol : TIVA|Total intravenous anesthesia without use of a pharmokinetic model
45836598|NCT00365274|Drug|prednisone|100 mg orally daily days 1 - 5
45836599|NCT00365274|Drug|SGN-30|12 mg/kg weekly IV over 2 hours once weekly for 3 weeks.
46092825|NCT02637726|Device|EEG Monitoring|Maintaining a bispectral index between 45 and 55
45836600|NCT00310362|Behavioral|Use of Interactive Voice Response (IVR) system to improve adherence to GI appointments and prep procedures|Interactive voice response system (IVR) calls patients 7 or 3 days prior to their appointment. Information available in the IVR system is based on the same template nurses use in usual care and includes an appointment reminder, preparation instructions, basic information about the procedure, and answers to commonly asked questions.
45836601|NCT00311376|Biological|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at > 12 weeks interval
45836602|NCT00311376|Biological|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U (tx 1) followed by botulinum toxin Type A 300 U (tx 2); injections into detrusor, at > 12 weeks interval
45836603|NCT00311376|Other|Normal Saline (Placebo); botulinum toxin Type A (200U)|Placebo (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at > 12 weeks interval
45836604|NCT00311376|Other|Normal Saline (Placebo); botulinum toxin Type A (300U)|Placebo (tx 1) followed by botulinum toxin Type A 300 U (tx 2), injections into detrusor, at > 12 weeks interval
45836605|NCT03238170|Device|MRI scan|MRI scan using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan
45840125|NCT00632970|Drug|Lopinavir/Ritonavir|2 tablets twice a day, with Truvada 1 tablet once a day
46092826|NCT02637726|Drug|Remifentanil|Remifentanil at discretion of the anesthesiologist
46092827|NCT04161768|Drug|Norfloxacin|Norfloxacin 400 mg daily
46092828|NCT04161768|Drug|Itopride|Itopride 50 mg three times daily
46092829|NCT05300282|Drug|Atezolizumab|"In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): Atezolizumab will not be administered. In phase II b study - arm B (experimental): Atezolizumab will be administered at MTD determined in phase I study plus BEGEV regimen (at dosages performed by local practice)."
46092830|NCT05300282|Combination Product|BEGEV|"In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): only BEGEV will be administered. In phase II b study - arm B (experimental): BEGEV regimen will be administered in combination with Atezolizumab at MTD determined in phase I."
46092831|NCT02793089|Other|Analysis of Ectopic Pregnancy incidence|Collect retrospectively data. Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
46092832|NCT02634060|Device|Home Based Fecal Calprotectin|Home Based Fecal Calprotectin measurement at weeks 0, 4 and 8
46092833|NCT02789267|Other|Regular dietary support|Systematic and regular dietary support after radiotherapy
46092834|NCT00959803|Drug|PF-04447943|3 mg solution, oral single dose.
46092835|NCT00959803|Drug|PF-04447943|10 mg solution, oral single dose.
46092836|NCT00959803|Drug|PF-04447943|25 mg solution, oral single dose.
46092837|NCT00959803|Drug|Placebo|Solution, oral single dose.
46092838|NCT00959803|Drug|PF-04447943|25 mg solution, oral twice daily for 7 days.
46092839|NCT00959803|Drug|Placebo|Solution, oral twice daily for 7 days.
46092840|NCT02672150|Behavioral|Core|
46092841|NCT02672150|Behavioral|Enhanced|
46092842|NCT04161924|Diagnostic Test|X-ray imaging with physical grid using conventional processing|X-ray imaging with physical grid using conventional processing
45836606|NCT02104830|Biological|Empegfilrastim 6 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
45836607|NCT02104830|Biological|Filgrastim|Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
46006612|NCT00580905|Drug|Adenosine|"The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion."
46006613|NCT00581022|Procedure|Polysomnography|Overnight Sleep Study
46006614|NCT04577664|Procedure|total thyroidectomy|a total thyroidectomy (TT) in which the entire gland is removed
46006615|NCT04577664|Procedure|subtotal thyroidectomy|subtotal thyroidectomy (STT) , in which most of the gland is removed leaving a small unilateral or bilateral remnant in situ about 4-5 grams.
46006616|NCT04591262|Drug|14C-PF-06826647-LR 600 mg PO|14C-PF-06826647-LR 600 mg with 300 nCi orally as extemp prep
46006617|NCT04591262|Drug|PF-06826647 600 mg PO|Unlabeled PF-06826647 600 mg
46006618|NCT04591262|Drug|14C-PF-06826647 100 ug IV|14C-PF-06826647 100 ug IV
46006619|NCT00567203|Drug|PF-3463275|PF-3463275 10mg
45836608|NCT02104830|Biological|Placebo №1|Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.
46006620|NCT00567203|Drug|PF-3463275|PF-3463275 25mg
46006621|NCT00567203|Drug|Placebo|Placebo
45459662|NCT05150860|Behavioral|At-home COVID-19 testing|At-home over-the-counter (OTC) COVID-19 testing kits provided to middle school students and staff
45836609|NCT02104830|Biological|Placebo №2|Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.
46006622|NCT04590989|Other|Personalized Nutrition Plan|"Personalized breakfasts and dinners designed and cooked by Simplefeast, delivered twice a week (eaten 6 days per week) + access to Simplefeast's App for recipes of other meals not provided (i.e. lunches and Saturdays) which are designed to match the individual nutritional recommendations.~Personalized behavioral change program via electronic push notifications by ONMI"
46006623|NCT04590989|Other|Non-Personalized Nutrition Plan|"Standard meals of breakfasts and dinners designed and cooked by Simple feast, based on general dietary recommendations, and delivered to participants twice a week. In addition, they will also have access to Simple feast's recipe App for other meals not provided. The recipes presented are generic, not personalized.~Subjects in the control group will also be enrolled in the behavioral program by ONMI, but the program will not be personalized nor based on the same behavior change methodology as in the PP group. In other words, the control group will get information more than is triggered to take actual action (i.e. general guidelines that is available from the National Health Service and World Health Organization)."
46006624|NCT04590638|Other|tumescent with adrenaline|skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution containing adrenaline to see the bleeding control of donor site.
46092843|NCT04161924|Diagnostic Test|X-ray imaging without physical grid using conventional processing|X-ray imaging without physical grid using conventional processing
45459663|NCT05150860|Behavioral|Family-based model|Making the COVID-19 testing program available to household/family members to increase participation of students and staff in the school COVID-19 testing program
46092844|NCT04161924|Diagnostic Test|X-ray imaging without physical grid using experimental SimGrid offline processing|X-ray imaging without physical grid using experimental SimGrid offline processing
46092845|NCT02793011|Drug|Dexamethasone|Oral dexamethasone elixir (0.5mg/ml or 4 mg/ml) mixed with Ora-sweet or simple syrup to mask the taste. Or 1 mg or 4 mg dexamethasone capsules if age appropriate
46092846|NCT02793011|Drug|Placebo|Placebo liquid (Ora-sweet or simple syrup) or Placebo capsule
45836610|NCT02104830|Biological|Empegfilrastim 7.5 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
46092847|NCT04010617|Device|Pharyngeal Electrical Stimulation (PES)|PES will be delivered by a commercial device (Phagenyx, Phagenesis Ltd, Manchester, UK), which comprises a nasogastric feeding catheter that houses stimulation ring-electrodes and a computerised base station that delivers stimulation in the range 1-50 mA at 5 Hz.
46092848|NCT02671214|Other|Control|100 g high fibre flour
46092849|NCT02671214|Other|Active 2|98 g high fibre flour + 2 g guar gum
46092850|NCT02671214|Other|Active 3|88 g high fibre flour + 2 g guar gum + 10 g legume flour
46092851|NCT02671214|Other|Active 4|83 g high fibre flour + 2 g guar gum + 15 g legume flour
45836611|NCT00311766|Drug|Thymosin Beta 4|Topical administration, 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days
46092852|NCT02671214|Other|Active 5|96 g high fibre flour + 4 g guar gum
46006625|NCT04590638|Other|tumescent without adrenaline|skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution not containing adrenaline to see the bleeding control of donor site.
46092853|NCT02671214|Other|Active 6|86 g high fibre flour + 4 g guar gum + 10 g legume flour
46006626|NCT04590950|Other|Non interventional study|Non interventional study
46092854|NCT02671214|Other|Active 7|81 g high fibre flour + 4 g guar gum + 15 g legume flour
46092855|NCT02671214|Other|Active 8|94 g high fibre flour + 6 g guar gum
46092856|NCT02671214|Other|Active 9|98 g high fibre flour + 2 g konjac mannan
46092857|NCT02671214|Other|Active 10|96 g high fibre flour + 4 g konjac mannan
45459664|NCT05150860|Behavioral|Onsite COVID-19 testing|Onsite COVID-19 testing for middle school students and staff
45459665|NCT04881500|Other|Motivational interview|Patients will follow motivational interview (2 individual sessions by phone)
45836612|NCT00311766|Drug|Placebo|Topical administration, 0.00% Thymosin Beta 4 gel qd up to 56 days
45836613|NCT00313560|Drug|erlotinib hydrochloride|Erlotinib 100 mg PO QD (1 hour prior to Capecitabine) (both given daily without interruption)
46006627|NCT04590677|Other|Samples required from group 1 (procedure within observational study)|"Weekly maternal blood samples to be taken~Daily urine samples to be collected~One rectal swab at the initial visit only~Weekly vaginal swabs~Daily Heart rate monitoring (only applicable to a subset of women in group 1)"
46092858|NCT02671214|Other|Active 11|100 g low fibre flour
46092859|NCT02671214|Other|Active 1|85 g high fibre flour + 15 g legume flour
46092860|NCT04161612|Other|Demographic characteristics, duration of spinal cord injury, spinal cord injurylevel, etiology, number of intermittent bladder catheterization (IC), number of night time|Observational clinical study
46092861|NCT00965107|Drug|Thiopental|Thiopental given as a bolus dose of 2,5 mg/kg.
46092862|NCT00965107|Drug|Propofol|Propofol given as a bolus dose of 1 mg/kg.
46092863|NCT02788877|Drug|aflibercept|Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30 gauge needle-attached syringe.
46092864|NCT00959881|Drug|Donepezil plus placebo|5- and 10-mg tablets, single dose
46092865|NCT00959881|Drug|Donepezil|5- and 10-mg tablets, single dose
46092866|NCT00959881|Drug|Begacestat|6 x 50-mg capsules, single dose
46092867|NCT02671370|Other|Measurement of the range of motion of the cervical spine|There is no intervention. Only measurements and interviews are taken.
46092868|NCT00644462|Device|PulmoTrack® 2010 with WIM-PC™ Technologies|wheeze detection during dynamic bronchial situations in infants
46092869|NCT00959959|Drug|TOK-001|2 capsules (325 mg each), once per day
46092870|NCT00959959|Drug|TOK-001|4 capsules (325 mg each), once per day
46092871|NCT00959959|Drug|TOK-001|6 capsules (325 mg each), once per day
46092872|NCT00959959|Drug|TOK-001|3 capsules (325 mg each), once per day
46092873|NCT00959959|Drug|TOK-001|3 capsules (325 mg each), once per day with supplement
46092874|NCT00959959|Drug|TOK-001|6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
46092875|NCT00959959|Drug|TOK-001|8 capsules (325 mg each), once per day
45459666|NCT04881500|Other|Routine Care|Patients will follow routine care
45459667|NCT04459390|Diagnostic Test|realtime PCR|Detection of SARS-CoV-2 genes by realtime PCR
45459668|NCT01376492|Other|Functioning assessment|The functioning will be assessed with 2 scales, (Personal and Social Performance Scale (PSP) and Brief Psychiatric Rating Scale)
46092876|NCT00959959|Drug|TOK-001|8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
46006628|NCT04590677|Other|Samples required from group 2 (procedure within observational study)|"Weekly maternal blood samples to be taken~Daily urine samples to be collected~One rectal swab at the initial visit only~Weekly vaginal swabs"
46092877|NCT04234451|Procedure|SPA acupuncture|"For patients in the AA group, acupuncture was performed at a selected point in the SPG by inserting the needle from the lower border of the zygomatic arch, posterior to the suture protuberance between the zygomatic process and temporal process. The needle was directed obliquely anteriorly, until nearly the whole needle was beneath the skin, and then rotated until the patient felt de-qi sensations . The patients in the AA group received four courses of active acupuncture(visit 1,2,3 and 4), twice a week during weeks 1 and 2, and then followed-up for a further 2 weeks (visit 5 during week 3 and visit 6 during week 4)."
46092878|NCT04234451|Procedure|sham acupuncture|For patients in the SA group, the needle was inserted at the same acupuncture point as for patients in the AA group, but to a depth of only 2-3cm and the procedure of rotating, twirling and thrusting the needle was repeated. During the acupuncture process, the acupuncturist sat on the side of the participant, where the patient could neither see the acupuncturist's face nor the length of the needle. The patients in the SA group received four courses of active acupuncture(visit 1,2,3 and 4), twice a week during weeks 1 and 2, and then followed-up for a further 2 weeks (visit 5 during week 3 and visit 6 during week 4).
46006629|NCT04590755|Behavioral|Interactive father-child sessions and website|The Run Daddy Run intervention will consist of 5 (inter)active sessions for fathers and their children + 1 follow-up session, each session lasting 90 minutes. These sessions will be given to 8 groups of +- 13 families (fathers and their children), guided by 2 facilitators and will take place every 2 weeks, at a location in the neighborhood of fathers and children (e.g. school of the children). Additionally, a website will be available for the fathers and their children, with additional information about the project, tips and information about being active together (e.g. movement breaks, fundamental movement skills, etc.) and limiting screen time. In addition, fathers and their children will also log their goals on this website, and between two sessions (= a period of 2 weeks) they will be asked to keep track of their co-PA on this website, aiming to reach their goal.
46006630|NCT00567281|Device|Magstim Rapid 2 system triggering Magstim Super Rapid system|Week 1 treatment includes rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
45459669|NCT01376492|Other|Quality of sleep assessment|The quality of sleep will be assessed with 2 scales, (Pittsburgh Sleep Quality Index (PSQI) and Epworth scale)
46092879|NCT04033484|Procedure|Negative Pressure Wound Therapy|The perineal wound was reconstructed with biologic mesh after ELAPE. The subcutaneous adipose layer was closed with 2/0 vicryl sutures, and a suction drain was left in the deep layer. The subcuticular layer and skin were closed with 3/0 vicryl mattress sutures and the negative pressure system applied at 80 mmHg
46092880|NCT03651011|Drug|Aflibercept Injection [Eylea]|Intravitreal injection 2 mg Eylea every 4 weeks M0-M2 (loading phase). M3-M12: continue in a pro re nata treatment regimen.
46092881|NCT03651011|Procedure|Navigated laser photocoagulation|Navigated laser photocoagulation planned from flourscein angiography.
46092882|NCT00880542|Drug|sorafenib|Patients with sarcoma who have resectable disease will be treated with neoadjuvant sorafenib and ifosfamide. PET/CT will be used to assess the metabolic and radiographic response to therapy.
46092883|NCT00880542|Drug|Ifosfamide|Patients with sarcoma who have resectable disease will be treated with neoadjuvant ifosfamide and sorafenib. PET/CT will be used to assess the metabolic and radiographic response to therapy.
46092884|NCT05251597|Other|green exercise with aerobic exercise|Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. It is mostly applied in the form of brisk walking in the open air.
46092885|NCT02670668|Other|Mutation analysis|
46092886|NCT00960037|Dietary Supplement|Oral vitamin D3|Vitamin D3 50-100 mcg capsule(depending on baseline serum 25(OH)D concentration) daily for 8 weeks.
46092887|NCT00960037|Dietary Supplement|Placebo equivalent|One capsule daily for 8 weeks
45836614|NCT01791738|Procedure|Acetabular positioning system|Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
45836615|NCT00314106|Biological|Melanoma Reactive TIL|
45836616|NCT00314106|Drug|Cyclophosphamide|60 mg/kg/ day x 2 days intravenous
45836617|NCT00314106|Biological|IL-2|720,000 IU/kg/dose every 8 hours for up to 15 doses
45836618|NCT00314106|Drug|Fludarabine|25 mg/m^2/day intravenous x 5 days
45836619|NCT00314106|Radiation|1200 total body irradiation (TBI)|1200 cGY total body radiation
45836620|NCT00315120|Procedure|A. Active OMT and active UST|Active osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
45836621|NCT00315120|Procedure|B. Sham OMT and active UST|Sham osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
46092888|NCT02792933|Procedure|air in epidural space|The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be then withdrawn and the low resistance syringe filled with 3-5mL of air will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
46092889|NCT02792933|Procedure|saline in epidural space|The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be withdrawn and the low resistance syringe filled with 3-5mL of saline solution will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
46092890|NCT00658710|Behavioral|physical therapy sessions|two physical therapy sessions per week for two months
45836622|NCT00315120|Procedure|C. Active OMT and sham UST|Active osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
46006631|NCT00567281|Device|Magstim Rapid-2 system triggering Magstim Super Rapid system|Week 1 includes repetitive rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with sham rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, sham rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
46006632|NCT00567437|Other|NT-pro-BNP levels|pre- and post-exercise NT-pro-BNP levels
46006633|NCT00567515|Device|AtriCure LAA Exclusion System|Placement of clip of LAA.
46006634|NCT04577703|Drug|CT053PTSA|CT053PTSA will be administered daily in fasting state
46006635|NCT04577586|Other|oral contrast|negative oral contrast utilization in PET/CT studies
46006636|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel|
46006637|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel + bevacizumab|
46006638|NCT00567554|Drug|paclitaxel|
46092891|NCT04009369|Other|Direct access to a PT|Direct access to a PT in the ED immediately after triage and prior to physician assessment.
46092892|NCT05380661|Procedure|Self-catheterization|Participants will perform self-catheterization, following the same routine for intermittent catheterization at home
46092893|NCT05380661|Procedure|Catheterization performed by urology nurse, participant blinded to time of procedure|Participant will undergo procedure to completely empty bladder; Participant in supine position, and resting blood pressure and heart rate will be recorded for period of 5 minutes prior to catheterization; Perineum and genital areas will be draped and they will be not aware about exact timing of catheterization Catheterization will be conducted following standard clinic procedure by experience urology nurse.
46092894|NCT05380661|Procedure|Catheterization performed by urology nurse, participant aware of time of procedure|Participant will undergo procedure to completely empty bladder; Participant in supine position, and resting BP and HR will be recorded for period of 5 minutes prior to catheterization; Perineum and genital areas will be visible to participant and they will be fully aware about exact timing of catheterization Catheterization will be conducted following standard clinic procedure by experience urology nurse.
45836623|NCT00315120|Procedure|D. Sham OMT and sham UST|Sham osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
46092895|NCT04161690|Drug|Dexketoprofen Trometamol|intravenous dexketoprofen 50mg or intrathecal
46092896|NCT04161690|Drug|Ropivacaine Hydrochloride 7.5 MG/ML|Local Infiltration Analgesia
45836624|NCT00315588|Drug|Islet Transplantation|Islet Transplantation in subjects with a previous kidney transplant.
45836625|NCT01793064|Behavioral|Adaptive Intervention (AI)|Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
46006639|NCT00567554|Drug|paclitaxel + everolimus (RAD001)|
46006640|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel + trastuzumab|
46006641|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel + lapatinib|
46006642|NCT04577469|Drug|Maldox tablets|500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
46006643|NCT04577469|Drug|G-COSPE® tablets|500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
45836626|NCT01793064|Behavioral|Static Intervention (SI)|"Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website."
46006644|NCT04590911|Behavioral|Cognitive Enrichment Program (CEP)|Multimodal cognitive rehabilitation program for individuals having sustained a traumatic brain injury during older adulthood
46092897|NCT02671292|Behavioral|Interpersonal Psychotherapy|IPT-WG involves one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions. The IPT-WG group sessions follow 3 phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbated by LOC eating. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors for excessive weight gain and warning signs such as eating in response to negative affect as opposed to hunger, or feeling a sense of LOC while eating.
46092898|NCT02671292|Other|Health Education|"The HE group is based upon the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each session is 90 minutes). Additionally, individuals will attend a pre-group individual meeting with the group leaders to review family health history.The curriculum includes focus on various health topics, including alcohol, drug and tobacco use, depression and suicide, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence. Session content will be largely identical for boys and girls, with the exception of gender-specific videos and articles (e.g., on body image), which will be tailored for each sex."
46092899|NCT00960271|Procedure|EBUS|a minimally invasive technique of mediastinal lymph node staging using an integrated videoendoscopic device equipped with ultrasound for the localization and transbronchial sampling of lymph nodes in real time
46092900|NCT04233125|Procedure|Core Decompression|Core Decompression
46092901|NCT04233125|Procedure|PMMA augmentation|Polymethylmethacrylate (PMMA) augmentation
46092902|NCT02637414|Behavioral|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
46092903|NCT05377229|Device|MarginProbe2.0|The MarginProbe System is an adjunctive diagnostic tool for identification of cancerous tissue at the margins of the ex-vivo lumpectomy specimen following primary excision and is indicated for intraoperative use, in conjunction with standard methods (such as intraoperative imaging and palpation) in patients undergoing breast lumpectomy surgery for previously diagnosed breast cancer.
46092904|NCT00885534|Drug|Cisplatin, Vinblastine, Temozolomide|"Patients will receive CVT chemotherapy which consists of the following:~Cisplatin 25 mg/m2 given intravenously on days 2-5 Vinblastine 1.5 mg/m2 given as an intravenous push on days 2-5 Temozolomide 150 mg/m2 given orally on days 1-5. In patients who cannot receive temozolomide, dacarbazine can be used instead. Dacarbazine will be given at 800 mg/m2 IV on day 1."
46092905|NCT05376137|Device|continuous positive airway pressure (CPAP)|CPAP comfort settings will be modified in the active group to be personalized to each participant
46092906|NCT05277038|Drug|Clonidine 0.1mg pill|Routine prescription for insomnia
46092907|NCT05277038|Drug|Clonidine 0.2mg pill|Routine prescription for insomnia
46092908|NCT05277038|Drug|Zopiclone 3.75mg pill|Routine prescription for insomnia
45459670|NCT01376570|Behavioral|Abstinence-reinforcing contingency management intervention|The contingency management intervention consists of participants receiving vouchers exchangeable for goods and services contingent on achieving abstinence. When participants are abstinent (urine is free of cocaine, oxycodone and opiates), they will receive a voucher. If participants are not abstinent (cocaine or oxycodone or opiates are in the urine), they will not receive a voucher. The value of vouchers increases with continued evidence of abstinence. When participants have urines with opiates or cocaine, the value of the voucher is reset. The vouchers are part of the intervention, they are not participant compensation.
45836627|NCT00367380|Other|413ABM|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 413ABM
45459671|NCT01376570|Behavioral|Performance Feedback intervention|Participants will receive performance feedback about their drug use. The research team will provide informational slips of paper indicating results of urine tests and will congratulate participants when urines are drug-free or encourage participants to stop using cocaine and/or opiates when urines are not drug-free.
45459672|NCT05153512|Procedure|MRI|Pelvic MRI without injection of contrast product and WITHOUT rectal or vaginal opacification
45836628|NCT00367380|Other|414WRR|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 414WRR
45836629|NCT00367380|Other|418JAL|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 418JAL
45836630|NCT00368316|Biological|Shigella conjugate vaccines|Shigella sonnei-rEPA and Shigella flexneri2a rEPA vaccines
45840126|NCT00632970|Drug|Truvada|1 tablet, once a day, with either Raltegravir (Isentress) or Lopinavir/Ritonavir(Kaletra)
45840127|NCT00635232|Drug|irbesartan|300 mg (2 x 150 mg capsules) once daily for 12 weeks
45840128|NCT00635232|Drug|placebo|placebo capsules once daily for 12 weeks
45840129|NCT00635232|Drug|PS433540|200 mg (2 x 100 mg capsules) once daily for 12 weeks
45840130|NCT00635232|Drug|PS433540|400 mg (4 x 100 mg capsules) once daily for 12 weeks
45840131|NCT00635232|Drug|PS433540|800 mg (8 x 100 mg capsules) once daily for 12 weeks
45840132|NCT00637494|Drug|mifepristone|1200 mg (administered as four 300 mg tablets) once a day by mouth for the initial 7 days
46006645|NCT04577508|Behavioral|Functional Remediation|Functional Remediation is a manualized, group-based psychosocial intervention built on a neurocognitive-behavioural approach, involving modeling techniques, role-playing tasks, self-instruction, positive reinforcement and metacognitive cues (Vieta E et al, Cambridge University Press, 2014). It consists of 21 90-min weekly sessions, in which a trained therapist and co-therapist work with 10-12 patients: the first 3 sessions are dedicated to psychoeducation on neurocognitive deficits; then 13 sessions of neurocognitive training sequentially target attention, memory and executive functions domains, comprising exercises carried out individually, in pairs or in small groups; the last 5 sessions focus on skills training (communication, interpersonal relationships, autonomy, stress management). Content of the sessions involves ecological tasks adapted to real-world situations, and to-be-performed in two contexts (clinical and daily). Homework is assigned, collected and discussed each time.
46092909|NCT05277038|Drug|Zopiclone 7.5mg pill|Routine prescription for insomnia
46092910|NCT02634138|Device|Revitive IX|A foot plate Neuromuscular Electrical Stimulation Device
46092911|NCT02670824|Drug|CN-105|Single and multiple intravenous (IV) doses of CN-105
46092912|NCT02670824|Drug|Placebo|Normal Saline
46092913|NCT00960349|Drug|Cediranib|Given orally at a dose of 20mg/day everyday until the patient meets any discontinuation criterion.
46092914|NCT00960349|Drug|Cisplatin|Given as a intravenous infusion at a dose of 80mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
46092915|NCT00960349|Drug|S-1|Given orally at a dose of 80 - 120mg/day according to BSA for 3 weeks followed by a 2-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
46092916|NCT00960349|Drug|Cisplatin|60mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
46092917|NCT00960349|Drug|Capecitabine|Given orally at a dose of 1000mg/m2 twice daily for 2 weeks followed by a 1-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
46092918|NCT05375903|Drug|UGN-301|"Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment)."
46092919|NCT05375903|Drug|UGN-201|"Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment)."
46092920|NCT04161846|Behavioral|Virtual Training|The intervention involves a CHW training focused on raising awareness of diabetes prevention in the community. It is delivered remotely over 10 weeks using an internet based approach.
46092921|NCT04161846|Behavioral|In Person Training|The intervention involves a CHW training focused on raising awareness of diabetes prevention in the community. It is delivered in person over 10 weeks.
46092922|NCT00960427|Drug|systemic chemotherapy|
46092923|NCT00960427|Genetic|RNA analysis|
45840133|NCT00637494|Drug|placebo|Tablets of identical appearance to active drug, once a day by mouth for the initial 7 days
46092924|NCT00960427|Genetic|gene expression analysis|
46092925|NCT00960427|Genetic|reverse transcriptase-polymerase chain reaction|
46092926|NCT00960427|Other|immunohistochemistry staining method|
46092927|NCT00960427|Other|laboratory biomarker analysis|
46092928|NCT00960427|Procedure|endoscopic biopsy|
46092929|NCT00960427|Procedure|neoadjuvant therapy|
46092930|NCT00960427|Procedure|sigmoidoscopy|
46092931|NCT00960427|Radiation|radiation therapy|
46092932|NCT02670434|Drug|NK-104-CR|NK-104-CR 8 mg daily for 52 weeks
46092933|NCT02670434|Drug|Placebo|Placebo daily for 12 weeks
46092934|NCT02670434|Drug|Livalo|Livalo® IR daily from week 12 to week 52
45459673|NCT03484234|Device|Ultimaster stent|Percutaneous coronary intervention with Ultimaster stent for long lesion
46092935|NCT02788409|Other|Not applicable for study|Provide external perspective on background second primary cancer incidence rates for REASSURE study.
46092936|NCT05206344|Other|clowns|presence or absence of clowns during the performance of a painful act, on pain
46092937|NCT00960583|Other|Exercise program|24 group exercise sessions during 12 weeks
46092938|NCT00960583|Other|Routine follow-up|Advice to stay active
45840134|NCT00638274|Procedure|Air|3 mls used for identifying epidural space
45840135|NCT00638274|Procedure|Saline|3 mls of saline used to identify epidural space
45840136|NCT00638820|Procedure|Stem Cell or Umbilical Cord Blood Transplantation|Stem Cell (unrelated or matched related donor grafts (both peripheral blood and marrow) infusion on Day 0 and 42; Umbilical Cord Blood on Day 0 and 42
45840137|NCT00638820|Drug|Campath, Busulfan, Clofarabine|"12 Campath-1H 0.3 mg/kg intravenously (IV) over 2 hours~11 Campath-1H 0.3 mg/kg intravenously over 2 hours~10 Campath-1H 0.3 mg/kg intravenously over 2 hours~9 Busulfan <12 kg: 2.2 mg/kg/dose IV every 12 hours >12 kg: 1.6 mg/kg/dose IV every 12 hours~8 Busulfan <12 kg: 2.2 mg/kg/dose IV every 12 hours >12 kg: 1.6 mg/kg/dose IV every 12 hours~7 Rest~6 Clofarabine 40 mg/m2 intravenously over 2 hours~5 Clofarabine 40 mg/m2 intravenously over 2 hours~4 Clofarabine 40 mg/m2 intravenously over 2 hours~3 Clofarabine 40 mg/m2 intravenously over 2 hours~2 Clofarabine 40 mg/m2 intravenously over 2 hours"
46092939|NCT02787941|Behavioral|Pharmacist-delivered multifaceted intervention|"First counselling: A pharmacist performs a 30-minute in-person counselling within 1 week before discharge including: (1) assessment and giving advice on basic knowledge of acute coronary syndrome: definition, risk factors, possible cardiac events, and prevention; (2) assessment of past experiences of using medications, encouragement and tailored advice; (3) providing support with pill organiser and drug information leaflet; (4) teaching back and correcting misunderstanding.~Second counselling: A pharmacist performs a 30-minute telephone counselling within 1 week after discharge including: (1) assessment of general and medication-related issues patients concerning; (2) encouragement and tailored advice; (3) teaching back and correcting misunderstanding."
46092940|NCT00658866|Procedure|Microdialysis|PK measurements with microdialysis
46092941|NCT05129449|Device|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|Endoscopic Retrograde Cholangio-Pancreatography (ERCP) conducted with motorized PowerSpiral in subjects presenting with surgically altered GI anatomy indicated for ERCP with biliary indication.
46006646|NCT04577508|Other|Treatment as usual|Standard care for bipolar disorders according to good clinical practice, including drug therapy and individual case management.
46092942|NCT02670356|Dietary Supplement|Fish oil|two 750 mg/capsules/day
46092943|NCT02670356|Dietary Supplement|Krill oil|one 300 mg capsule/day
46092944|NCT02789423|Procedure|Direct Pulp Capping using Dycal and Biodentine|The operative procedure performed as follows: i)Administration of L.A and rubber dam isolation. ii)High-speed carious enamel removal. iii)Dentine mechanical curettage. iv)Manual final dentine curettage using a spoon excavator. v)Hemorrhage control by cotton pellet moistened with 2.5% sodium hypochlorite placed over the exposure for 1-2min. vi)The exposure site would then be dried with sterile cotton pellet.The operator shall apply the pulp capping agent(dycal/Biodentine)according to the manufacturer's instructions.And then another cover of glass ionomer is applied.This would be followed by permanent restoration.
46092945|NCT02672072|Other|Simulation during the study (5-day specific training with dedicated scenario done by an ICU expert simulation team)|
46092946|NCT02672072|Other|questionnaire to define the presence of job strain at 6 months|
46092947|NCT02672072|Other|questionnaire to define the presence of job strain at 12 months|
46092948|NCT00965653|Drug|folic acid|>/= 5 mg po weekly
46092949|NCT00965653|Drug|methotrexate|7.5 - 25 mg weekly (oral or parenteral)
46092950|NCT00965653|Drug|tocilizumab [RoActemra/Actemra]|162 mg sc weekly (QW)for 12 weeks
46092951|NCT00965653|Drug|tocilizumab [RoActemra/Actemra]|162 mg sc every other week (Q2W) for 12 weeks
46092952|NCT04158570|Procedure|Percutaneous Nephrolithotomy|"Application of different stone scoring systems :~Guy's scoring system (GSS).~Seoul renal stone complexity scoring system (S-ReSC).~S.T.O.N.E. nephrolithometry scoring system.~CROES Nomogram. These scoring systems will be applied on each patient and correlate the predictive values with the real results to know which one of the above scoring systems better predict the outcomes."
46092953|NCT02788799|Other|Standard 12-Lead ECG|Conventional record of Standard 12-lead ECG in every patient with suspect of acute coronary syndrome.
46092954|NCT02788799|Other|Posterior ECG Leads|Recording posterior ECG leads (V7, V8 and V9) in addition to standard 12-lead ECG for identifying STEMI involving left cirumflex coronary artery.
45459674|NCT03484234|Device|Xience alpine stent|Percutaneous coronary intervention with Xience alpine stent for long lesion
45459675|NCT03484156|Device|Installation of 3PEGASE Sensor|Volunteers will be equipped with the 3-PEGASE solution to monitor clinical indicators at home : By assessing older person's autonomy at home and detecting early infra-clinical indicators, the solution could provide relevant clinical parameters to the caregivers and healthcare professionals in order to support the patient's follow-up, and support the detection of preliminary signs of functional loss
45459676|NCT04871360|Dietary Supplement|L-Citrulline supplement|The intervention will consist of oral supplementation of six grams of pure l-citrulline for eight weeks.
46092955|NCT00644696|Drug|Irinotecan and Bortezomib|Dose level-1a: IV Irinotecan 30 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-1: IV Irinotecan 35 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-2: IV Irinotecan 40 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-3: IV Irinotecan 45 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-4: IV Irinotecan 50 mg/m2/day, IV bortezomib 1.2mg/m2/day
45459677|NCT04871360|Dietary Supplement|Carboxymethyl cellulose supplement|The intervention will consist of oral carboxymethyl cellulose supplementation as a placebo.
45459678|NCT05153200|Drug|Upadacitinib|15 mg po daily
46092956|NCT02788721|Drug|GLPG2451 single dose|GLPG2451 oral suspension, single ascending doses, daily
45459679|NCT05153200|Drug|Adalimumab|40 mg sc every other week
46006647|NCT04590716|Other|Data Collection|This is a non-interventional study conducted on the participant's smartphones to record MG related symptoms and conditions.
46006648|NCT04577742|Radiation|106 Ruthenium plaque brachytherapy|All patients, affected by uveal melanoma, were treated with 106 Ruthenium plaque brachytherapy to a total dose of 100 Gy to the tumor apex. The time of implant duration was calculated according to the conventional central-axis-point dose calculation
46092957|NCT02788721|Drug|Placebo|Placebo, oral suspension, daily
46092958|NCT02632266|Dietary Supplement|Powder HMF|powder human milk fortifier
46092959|NCT02632266|Dietary Supplement|Liquid HMF|Liquid human milk fortifier
46092960|NCT00960739|Drug|Topotecan hydrochloride|The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle)
46092961|NCT00960739|Procedure|Autologous hematopoietic stem cell transplantation|Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG
46092962|NCT00960739|Radiation|iobenguane I 131|444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity
46092963|NCT00960739|Radiation|total-body irradiation|the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled (131-iodine MIBG and Topotecan)
46092964|NCT02788487|Device|Tongue retaining device|Tongue retaining device is used for 3 weeks
46092965|NCT02788487|Device|CPAP|CPAP is used for 3 weeks
46092966|NCT00659022|Procedure|immediate surgery (resection of primary colorectal tumor)|no neo-adjuvant treatment, immediate surgery
46092967|NCT00659022|Drug|neo-adjuvant treatment with bevacizumab|neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary
46092968|NCT00659022|Drug|neoadjuvant treatment with capecitabine and oxaliplatin|neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
46092969|NCT00659022|Drug|neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin|neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary
46006649|NCT04590560|Diagnostic Test|screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice|women will be screened for breast cancer using tomosynthesis and synthetic 2D mammography with an interval defined according to their randomization arm for a follow-up period of 6 years;
45678393|NCT01767597|Other|Rapid testing|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.
46006650|NCT00581139|Behavioral|Preoperative Preparation Program (Child Life Specialist)|This group will receive the standard preoperative visit to the hospital with Child Life intervention
45598973|NCT03518593|Other|Cash and counselling|Additional 500 Ksh per child per month and household visits by Community health Volunteers (CHVs)
46006651|NCT00581139|Drug|Midazolam|0.5 mg/kg oral midazolam
46006652|NCT00581139|Behavioral|Parental Presence during Induction of Anesthesia|One parent will be present during induction of anesthesia of the child. The parent will be accompanied out of the OR by a nurse once the induction is completed. These parents will have completed a parent preparation program.
46092970|NCT05100667|Other|Hypoxia|altitude (3800m)
46092971|NCT05100667|Other|Normoxia|sea level
46092972|NCT02788643|Biological|biological fluids (serum, bronchoalveolar lavage and pulmonary aspiration) and bronchial biopsies collection|
46092973|NCT04175522|Drug|Immunoglobulin G|IGIV 10%(400mg/kg) QD for 5 consecutive days administrated intravenously.
46092974|NCT02637570|Dietary Supplement|Hibiscus tea|
46092975|NCT02637570|Dietary Supplement|green tea|
46092976|NCT02637570|Dietary Supplement|placebo (dextrose)|
46092977|NCT02788331|Other|No intervention|
46092978|NCT00960817|Drug|Statin, aspirin|
46092979|NCT00960817|Drug|Dipyridamole|
46092980|NCT02670200|Behavioral|cognitive behavior therapy|treatment technique to help people to overcome psychological distress and mental diseases
46092981|NCT04161222|Other|Experimental group|Experimental group will perform a typical warm-up of competitive football, added to a specific activation of gluteus medius and core.
46092982|NCT04161222|Other|Control group|Control group will perform a typical warm-up of competitive football
46092983|NCT03674021|Other|Chest Pain Choice visual aid|The Chest Pain Choice (CPC) decision aid is a visual aid that was developed to facilitate shared decision-making between physicians and patients who present to the emergency department with chest pain. The visual aid includes a brief description of what tests have been done thus far to assess the patient's risk of MACE, a graphic representation of the risk as calculated based on the HEART score, as well as the evaluation options available. The visual aid has been modified from its original form for the local context in terms of viable options for further evaluation.
46092984|NCT00965809|Drug|Tetrahydrocannabinol|Five mg. of THC in 6 drops of olive oil orally twice a day for 6 weeks.
46092985|NCT00965809|Other|Placebo|Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm
46092986|NCT04177784|Other|Online Educational Videos|The videos were developed by the researchers based on a prior study to test if specific information about obesity and weight control influence weight bias.
46092987|NCT02792387|Other|CVP measurement|CVP measurements had been performed with an electronic pressure transducer in spontaneously breathing non-ventilated patients. Central vein access was established trough the subclavian or internal jugular veins. Mean CVP was recorded for each patient, measured in mmHg.
45678394|NCT01767519|Biological|BOTOX®|BOTOX 100U injected at Day 1 (BOTOX/solifenacin placebo arm). After a minimum of 12 weeks, all patients could request/qualify for a BOTOX injection.
45678395|NCT01767519|Drug|solifenacin|Beginning on Day 1, one 5 mg solifenicin capsule, with optional dose increase to 10 mg at Week 6, (both overencapsulated for blinding purposes) taken orally once daily for up to 24 weeks.
45678396|NCT01767519|Drug|Botox placebo (normal saline)|Botox placebo (normal saline) intradetrusor injection at Day 1.
45678397|NCT01767519|Drug|solifenacin placebo|Beginning on Day 1, one capsule taken orally once daily for up to 24 weeks.
46006653|NCT00581139|Other|PPIA preparation program PLUS Midazolam premedication|Subjects in this group will receive both interventions 2 and 3.
46092988|NCT05247073|Procedure|patients of controlled group with routine closure of episiotomy|"Perineal trauma is traditionally repaired in three stages: a continuous locking stitch is inserted to close the vaginal trauma, commencing at the apex of the wound and finishing at the level of the fourchette with a loop knot. The perineal muscles are then re-approximated with three or four interrupted sutures and finally, the perineal skin is closed by inserting continuous subcutaneous or interrupted transcutaneous stitches.~The skin is then closed with inverted interrupted stitches placed in the subcutaneous tissue a few millimeters under the perineal skin edges (not transcutaneously)."
46006654|NCT04590482|Drug|letrozole|Letrozole 2.5 mg each 12 hours for 2 days followed by vaginal misoprostol 800 mcg for induction of abortion
46092989|NCT05247073|Procedure|The Mostafa Maged four-stitch technique fore closure of the episiotomy|"Identification of the apex of the episiotomy, then a simple suture is taken (0.5 cm) behind the apex of the episiotomy. First, the needle is inserted at the vaginal mucosa of the right edge of the episiotomy then extract the needle.~The second stitch is inserted on the deep muscle layer of the same side (Right side) of the episiotomy cutting edge then extracting the needle.~Then, insert the needle again on the left side of the episiotomy incision in the deep muscle layer on the left side of the episiotomy incision directing the tip of the needle upwards parallel to the second stitch taken.~The fourth step is inserting the needle in the vaginal mucosa of the left side parallel to the first stitch. Continue suturing the episiotomy incision continuously in the same way till reaching the remnant of the hymen.~Then suture the superficial perineal muscle in a continuous manner and the skin in a subcuticular manner as well."
46092990|NCT04085432|Other|Self administered questionnaire and Clinical evaluation|Self administered questionnaire and clinical evaluation
46092991|NCT04232891|Diagnostic Test|liquid biopsy|detection of tumor DNA alteration in cf-DNA
46092992|NCT00885378|Drug|Saxagliptin plus metformin IR|Tablets, Oral, 2.5 mg, Twice daily, 12 weeks
46006655|NCT04590482|Drug|placebo|placebo given twice daily for 2 days followed by 800mcg misoprostol vaginally to induce abortion
46006656|NCT00581217|Other|Aquacel Ag|Aquacel Ag will be applied to one donor site.
46092993|NCT00885378|Drug|Placebo plus metformin IR|Tablets, Oral, Placebo, Twice daily, 12 weeks
46092994|NCT04095494|Behavioral|Nitrous oxide use|In order to evaluate the perception of the Nantes health students we wish to place an anonymous survey concerning their training, their knowledge of the legislative framework governing the use of EMONO and their personal and professional experience around nitrous oxide.
46006657|NCT00581217|Other|Glucan II|Glucan II to be applied to a donor site on same patient for comparison
46006658|NCT04590170|Behavioral|Post-intensive Care unit syndrome|Post-intensive Care unit syndrome after an intensive care unit stay for the COVID19
46006659|NCT00581295|Device|Diffuse optical spectroscopy|Diffuse optical spectroscopy measurment
46006660|NCT04589858|Other|Supervised exercise protocol|Strengthening exercises:It included a sets/group of exercises such as a static quad set in knee extension, standing terminal knee extension, seated leg-press, partial squats weight-lessened with arm support as needed, and step-ups Stretching Exercises:A slow, sustained stretching was performed in different positions for different group of muscles with holding time 30-seconds, a gap of 1-minute between two repetitions, and repeated 3-times per session on alternate day for 2-weeks. The stretching performed for the calf muscle, hamstring muscle, and quadriceps femoris muscle in standing, supine, and prone positions respectively.
46092995|NCT02787161|Device|Hemodiafiltration|High volume online HDF
46092996|NCT02787161|Device|Hemodialysis|High-flux HD
46092997|NCT00965887|Drug|MK0974 Ethanolate formulation|Single dose MK0974 280 mg tablet in one of two treatment periods
45678398|NCT01797783|Device|Nelfilcon A multifocal contact lens with comfort additive|
46006661|NCT04589858|Other|Specified Manual Therapies|"Myofascial Mobilization: Patellar glide performed in all available ROM and direction such as superior-inferior and lateral-medial translation/glides of patella over patellar fossa.~Myofascial manipulation technique: Manipulation of knee joint. An impulse type thrust was delivered, directed in the caudal direction to mobilize the joint in a near-full extension position."
46092998|NCT00965887|Drug|Comparator: MK0974 Hydrate formulation|Single dose MK0974 280 mg tablet in one of two treatment periods
46092999|NCT02537210|Drug|Mesalazine|Patients will be prescribed Asacol 2g daily for 12 months
45678399|NCT01797783|Device|Nelfilcon A multifocal contact lens|
46006662|NCT00567671|Procedure|Corneal collagen|Corneal collagen cross-linking with riboflavin/UVA light
46006663|NCT00567671|Procedure|Sham comparator|Sham treatment
46006664|NCT00581451|Drug|bifeprunox|oral tablet once daily
46093000|NCT02537210|Drug|Placebo oral capsule|Patients will be prescribed placebo 5 capsules daily for 12 months
46093001|NCT01563289|Drug|Ibuprofen|3 times a day
46093002|NCT01563289|Drug|Placebo|3 times a day
45678400|NCT01766817|Drug|BMS-986020|
45678401|NCT01766817|Drug|Placebo matching with BMS-986020|
45678402|NCT01797705|Device|DeVilbiss AutoAdjust CPAP with revised algorithm|Subjects attended a one-night polysomnogram (PSG) titration study. DeVilbiss AutoAdjust CPAP with a revised algorithm was compared to hand-scored PSG to determine whether the machine results were equivalent to hand scores. Each subject acted as their own control for assessing accuracy of sleep event analysis and prescribed CPAP pressure.
45678403|NCT01797081|Biological|botulinum toxin Type A (24 U)|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
45678404|NCT01797081|Biological|botulinum toxin Type A (12 U)|12 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
46006665|NCT04589936|Procedure|Prone positioning|Patient will first lay supine for a given time period, followed by lateral position on either side, then prone position, lastly return to supine position. Participants are anticipated to stay in prone position for a minimum of 30min to a maximum of 2 hours depending on tolerability. Participants will be guided in how to independently position themselves and rotate through the cycle of positions.
46093003|NCT02786849|Other|neuromuscular electrical stimulation of high frequency and intensity|"Training with neuromuscular electrical stimulation isometric form in lateral and medial bilaterally vast, three times a week, lasting an hour, the first two hours of dialysis.~Will be applied using portable stimulators with 4 channels. The parameters are: frequency of 50 Hz, pulse width 400ms, rise time and 2s descent, stimulus mode on-off starting with a ratio of 1: 2 in the first week (stimulus time of 10 seconds and rest time of 20s, aiming at adaptation and mitigation of the effects of muscle fatigue), evolving from the second week to a ratio of 1:1 (stimulation time of 10 seconds and rest time of 10s).~The current intensity is adjusted individually for the first application and gradually increased as the tolerance of patients.~In each session there will be a warm-up period, training and slowdown. The intensity will be the maximum tolerated by the patient in order increments every session, this being monitored for further evolutionary calculating."
46093004|NCT02786849|Other|neuromuscular electrical stimulation of low frequency and intensity|"Training with neuromuscular electrical stimulation isometric form in lateral and medial bilaterally vast, three times a week, lasting an hour, the first two hours of dialysis.~Will be applied using portable stimulators with 4 channels. The parameters are: 5 Hz frequency, time on: off 1: 3 with a pulse duration of 100ms.~The current intensity is adjusted individually for the first application and it was the least noticeable by the patient.~In each session there will be a warm-up period, training and slowdown."
46006666|NCT04577196|Other|Trauma dashboard|A large dashboard available to all, providing a framework for synthesizing and displaying relevant information about the arriving critical patient, to be filled in by the trauma leader.
46093005|NCT00960973|Drug|Menatetrenone|Menatetrenone 30 mg, 3 times a day for 4 weeks
46093006|NCT00960973|Drug|Placebo|Placebo
46093007|NCT02633904|Procedure|Osteotomy|Femoral osteotomy are applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
46093008|NCT02633904|Procedure|Non-osteotomy|Femoral osteotomy are not applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
46093009|NCT05143892|Drug|Avatrombopag|Avatrombopag administered at the described frequency to achieve a target platelet count
46093010|NCT05143892|Other|Supportive care|Supportive care other than TPO-RAs or recombinant human thrombopoietin.
46006667|NCT04590053|Biological|Allocetra-OTS|Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
46093011|NCT04099849|Dietary Supplement|Diet-ZnBfR: Zinc biofortified rice-based diet|Diet-ZnBfR: Zinc biofortified rice-based diet
46006668|NCT00567710|Drug|BL - 1020|10 mg/day
46093012|NCT04099849|Dietary Supplement|Diet- CR: Conventional rice-based diet|Diet- CR: Conventional rice-based diet
46093013|NCT04099849|Dietary Supplement|CR + Zn: Conventional rice-based diet plus zinc fortificant (Diet-CR+Z).|CR + Zn: Conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
46093014|NCT00659100|Drug|Gabapentin|Gabapentin 50 mg oral capsule 30 minutes before bedtime
46093015|NCT05375357|Procedure|Application of L-PRF on the donor area|After implant uncovering procedure with apically positioned flap, the donor area is covered with a layer of L-PRF
46006669|NCT00567710|Drug|BL - 1020|BL 1020 20-30 mg/day
46006670|NCT00567710|Drug|Placebo|Capsules
46093016|NCT05375357|Procedure|Secondary intention healing of the donor area|After implant uncovering procedure with apically positioned flap, the donor area is left to heal by secondary intention
46006671|NCT00567710|Drug|Risperidone|Capsules
45459680|NCT01376726|Biological|Sub C gp140 Vaccine|"Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
45459681|NCT01376726|Biological|MF59C.1 Adjuvant|"Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
46093017|NCT02669966|Procedure|Kidney transplantation|Once the donor and recipient candidates have met inclusion criteria and cleared study-specific as well as standard of care screening, they will proceed to live-donor kidney transplantation and subsequent post-transplant monitoring
46093018|NCT00965965|Behavioral|New colorectal cancer screening patient education document|The newly developed educational document was created accounting for health behavioral models (such as the Expanded Health Behavior Model, Social Cognitive Theory, and the Transtheoretical Model) and related research studies indicating the factors that most strongly and positively influence patients' cognitions regarding colorectal cancer screening and are, in turn, predictive of actual colorectal cancer screening behavior.
46093019|NCT00965965|Behavioral|Traditional colorectal cancer screening education document|The traditional educational document is a slightly edited version of materials freely available on the National Cancer Institute (NCI) web site, used in this study with the permission of the NCI.
46006672|NCT04590131|Procedure|recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent, supplemented by fasciotomy in Hunter's canal.|Under local anesthesia, a standard endovascular approach is performed. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Immediately after the stenting procedure, under local anesthesia, access to the distal part of the SFA at the outlet of Hunter's canal and 1 portion of the popliteal artery is performed. The lamina vastoadductoria is dissected. The wound is sutured in layers. An aseptic bandage is applied. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
46093020|NCT02792543|Device|Entéromate™|Chyme reinfusion (the experimental treatment) consists of continuously reinfusing the chyme collected from the proximal small bowel segment via the enterostomy, and into the diverted distal small bowel segment. It implies the use of the Entéromate™ pump.
46093021|NCT02792543|Drug|parenteral nutrition|Parenteral nutrition (the gold standard treatment) consists of electrolyte supplementation, hydration, and nutrition through a central venous catheter.
46093022|NCT02669888|Drug|Indigo naturalis ointment|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
46093023|NCT02669888|Drug|Placebo|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
46093024|NCT05027347|Diagnostic Test|plasma circulating tumor DNA|A liquid biopsy assay for identification of tumor derived mutations in plasma of gastric cancer
46093025|NCT00659178|Drug|SB-485232 (interleukin 18), pegylated liposomal doxorubicin|SB-485232 (interleukin 18), pegylated liposomal doxorubicin
46093026|NCT02792621|Dietary Supplement|Acipimox|Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.
46093027|NCT02792621|Dietary Supplement|placebo|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
46093028|NCT04009759|Drug|Morphine|Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
46093029|NCT04009759|Drug|Ketamine Injectable Solution|Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
46093030|NCT04009759|Drug|Saline 0.9%|Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
46093031|NCT04158960|Behavioral|Equine-assisted activities|Participants performed riding-related activities on and off of a horse once per week for 8 weeks
46093032|NCT04158960|Behavioral|GaitWay program|Participants performed riding-related activities on and off of a horse, along with brain-building activities including balance tasks, swinging, spinning, music therapy, and sensory tasks, all once per week for 8 weeks
46093033|NCT02792309|Behavioral|MotherWise Program|Healthy Marriage or Relationship Education services for pregnant women.
46093034|NCT00645086|Drug|clarithromycin extended-release tablets|5-day course of clarithromycin extended-release tablets (2 x 500 mg QD)
45836631|NCT00368940|Behavioral|PATH|PATH utilizes a problem solving approach based on Problem Solving Therapy (PST) and identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies and environmental adaptations that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment. PATH also incorporates caregiver involvement to help patient reduce depression and improve functioning.
46093035|NCT00645086|Drug|clarithromycin immediate-release tablets|7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID)
46006673|NCT04590131|Procedure|recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.|Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
46006674|NCT04589975|Procedure|laparoscopic surgery|
46093036|NCT00655902|Dietary Supplement|Trans fat (soy bean oil)|Industrially produced trans fatty acid from soy bean oil (15 g/d for 16 weeks). The fat (a total of 25 g/d) will be baked into buns.
46093037|NCT00655902|Dietary Supplement|Control fat (sunflower oil)|Control fat from sunflower oil, with 60% oleic acid (in total 25 g/d for 16 weeks). The fat will be baked into buns.
46093038|NCT03312803|Procedure|Mini autogenous skin graft|mini-autogenous skin grafts and skin homograft versus autogenous skin grafts for covering post burn wounds in children.
46093039|NCT04009915|Procedure|VATS|Patients undergo a standard VATS operation for stage II-III lung cancer called a lobectomy.
46093040|NCT04009915|Procedure|Open surgery|Patients undergo a standard open operation for stage II-III lung cancer called a lobectomy.
46093041|NCT02633748|Behavioral|Mindfulness-Based Cancer Survivorship|Mindfulness-Based Cancer Survivorship (MBCS) is a four-week standardized mindfulness program, adapted for cancer survivors from Mindfulness-Based Stress Reduction (MBSR). MBCS teaches formal mindfulness practice (meditation) and informal mindfulness during daily activities. Mindfulness has been shown to help stress, fatigue, sleep complaints, and other symptoms but has not been extensively studied in cancer survivors.
46093042|NCT05350319|Radiation|A low-dose CT scan of the shoulder|Briefly, a conventional CT scan will be conducted, with scan images representing a reconstruction of simultaneous scans at two sensors. L-CT images will be derived from single source data (ie the scan data gathered by one of the emitters rather than a reconstruction from both).
45840138|NCT00638820|Procedure|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior (PA) fields (250 cGy AP and 250 cGy PA).
46093043|NCT05238649|Biological|Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
46093044|NCT05238649|Biological|Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
46093045|NCT05238649|Biological|SARS-Cov-2 Vaccine Inactivated|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
46093046|NCT02637336|Device|Acupuncture|Acupuncture in point 6 of the pericardium channel (neiguan) bilaterally
46093047|NCT02637336|Device|Aerobic exercise|aerobic exercise of moderate intensity
46093048|NCT02637336|Device|Aromatherapy|inhalation of eucalyptus essential oil
46093049|NCT02792153|Drug|Estradiol|AN participants will be prescribed 28 days of transdermal estradiol 0.1 mg/d (Days 1-28) plus 10 days (days 21-31) oral medroxyprogesterone 2.5 mg/d.
45459682|NCT03477214|Diagnostic Test|Biomechanical and electromyography mapping|The vaginal tactile imaging probe will acquire biomechanical and electromyography high definition measurements for anterior and posterior compartments along entire vagina.
45459683|NCT03726476|Behavioral|Patient centered pre-op education|To implement a patient centered education intervention to evaluate post-op narcotic use.
45459684|NCT03726476|Behavioral|routine preop education|To implement routine patient education intervention to evaluate post-op narcotic use.
45840139|NCT00641862|Dietary Supplement|Vitamin B12|Daily oral administration of 50 µg of Vitamin B12 taken from enrollment (at or before 14 weeks gestational age) until delivery
45459685|NCT03481036|Drug|Direct Acting Antivirals|Sofosbuvir and Daclatasvir
45840140|NCT00641862|Other|Placebo|Placebo taken daily from enrollment (at or before 14 weeks gestational age) until delivery
45840141|NCT00643578|Drug|formoterol|a single dose of 24 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
45840142|NCT00643578|Drug|formoterol|a single dose of 12 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
45840143|NCT00643578|Device|Dry Powder Inhaler (Twisthaler)|subjects inhaled deeply and forcefully and held their breath for 10 seconds for each dose
45840144|NCT00644592|Drug|Fenofibrate capsule daily for 4 weeks|Placebo capsule daily for 4 weeks
45840145|NCT00644592|Drug|Fenofibrate|160 mg/day orally for 4 weeks
46006675|NCT01580826|Other|pasteurization of mother's own milk|mother's milk heat treated at 62,5°C for 30 minutes with a Sterifeed® S75 TES pasteurizer.
46093050|NCT04161300|Other|Foam Rolling (FR)|FR auto-massage will place the foam roller between their ischial tuberosity and a hard surface (i.e., the floor) with their legs held in an extended position, keeping their ankles relaxed and oriented upward. For FR in the lumbar region, participants use their weight to slide the FR through the erector of the lumbar and thoracic spine. The total approximate duration will be about 10-15 minutes.
46093051|NCT04161300|Other|Control Group (CG)|The CG did not receive any intervention.
46093052|NCT04161300|Other|Orthopaedic Manual Physical Therapy Group (OMPT)|Based on the protocol used by Espí-López et al.: a) Unspecific and bilateral lumbar thrust (L5-S1), one of each side were performed; b) Hip joint decompression, performing 25 repetitions c) Hip rotator stretch with hip and knee flexion, 15 repetitions; d) Femorotibial decompression, 25 reps. e) Quadriceps femoral muscle compression and traction, 25 repetitions; f) Opening of the internal and external femorotibial interline, 15 repetition; g) Ankle decompression, 3 repetitions; h) Posteroanterior and anteroposterior mobilization of head and base of fibula, 25 repetitions. The total duration will be approximately 10-15 minutes.
46093053|NCT00644540|Biological|Influenza Trivalent Inactivated Vaccines|"This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.~Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.~Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm."
46093054|NCT00644540|Biological|Influenza Trivalent Inactivated Vaccines|"This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.~Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.~Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm."
46093055|NCT03275129|Diagnostic Test|Ultrasound assessment of heart and lungs|Patients will receive an ultrasound assessment of their heart and lungs.
45459686|NCT03481036|Drug|DAAs in Cirrhotics Genotype 2/3|Sofosbuvir and Daclatasvir with weight based ribavirin
46093056|NCT02669732|Drug|DS-8500a|tablets
46093057|NCT02669732|Drug|placebo|tablets
46093058|NCT05003245|Drug|HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection|0.05mL solution at a 4-week interval for intravitreal injection
46093059|NCT05003245|Drug|Lucentis|0.05mL solution at a 4-week interval for intravitreal injection
46093060|NCT05367089|Drug|Fluconazole|"Way of administration: oral capsules. One capsule at the same day of the week.~Dosage:~As treatment for active RVVC- in the first week on day 1 one capsule 150 mg Fluconazole, on day 4 one capsule 150 mg Fluconazole and on day 7 one capsule 150 mg Fluconazole.~As prophylaxis to prevent a new RVVC episode: one capsule Fluconazol 150 mg per week for a duration of 6 months."
46093061|NCT05367089|Device|L-Mesitran|"Way of administration: intra-vaginal application using an applicator.~Dosage:~As treatment for active RVVC - Single daily application (5 grams) for 1 month. As prophylaxis to prevent a new RVVC episode: Single weekly (5 grams) application for 5 months."
46093062|NCT02671058|Drug|Cortenema|Hydrocortisone Administered as a Liquid Enema
46093063|NCT02671058|Drug|Hydrocortisone Acetate|Hydrocortisone Acetate Administered as a Suppository with the Sephure® Rectal Suppository Applicator
46093064|NCT04158414|Diagnostic Test|PET/MR scan|500 cancer patients referred to PET-CT assessment will undergo PET/MR scan as well, and the net data will be compared. The overall data will be investigated in groups and subgroups of patients that share similar clinical characteristics and represent cancer patients in different time points during the natural history of their disease. Data analysis will be performed both visually and quantitatively using different MR and PET parameters according to the patient group. Specific populations will be detailed in the next sections per malignancy.
46093065|NCT02671916|Behavioral|questionnaire|Investigation on all study patients, no Intervention, no groups
46093066|NCT02791919|Drug|Cytarabine|Given IV or IT
45459687|NCT03481036|Drug|DAAs in Cirrhotics Genotye 1,4,5,6|Sofosbuvir and Ledipasvir with weight based ribavirin
46093067|NCT02791919|Biological|Filgrastim|Given IV or SC
46093068|NCT02791919|Drug|Fludarabine Phosphate|Given IV
45459688|NCT03477136|Diagnostic Test|ELISA to evaluate serum and seminal vitamin D level|Serum and semen samples will be collected from all participant males and ELISA method used to evaluate the level of vitamin D in serum and semen
46006676|NCT04589429|Drug|Morphine 10 MG/ML|intrathecal morphine 300 micrograms
46006677|NCT04589429|Drug|Nalbuphine Hydrochloride 10 MG/ML|intrathecal nalbuphine 2mg.
46006678|NCT04577118|Device|iotaSOFT Insertion System|Enrolled subjects undergoing cochlear implant surgery will have the iotaSOFT Insertion System used by the surgeon to assist with implantation of the implant electrode array during the procedure.
46006679|NCT04589390|Drug|Selexipag|treatment with selexipag
46006680|NCT04577040|Drug|Tadalafil 5mg|Drugs
46093069|NCT02791919|Other|Laboratory Biomarker Analysis|Correlative studies
46093070|NCT02791919|Other|Pharmacological Study|Correlative studies
46006681|NCT04589312|Biological|Standard of care vaccines|Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance)
46006682|NCT04589312|Biological|Boostagen, (BioNet-Asia)|Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance);
46093071|NCT02791919|Drug|WEE1 Inhibitor AZD1775|Given PO
46093072|NCT02637258|Other|Ultrasonographic Measurements of Optic Nerve Sheath Diameter|Bedside Ultrasonographic Measurements of Optic Nerve Sheath Diameter
46093073|NCT00961207|Drug|Aliskiren|Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
46093074|NCT00961207|Drug|Aliskiren|Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
46093075|NCT04177472|Behavioral|Obesity Prevention Group|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options.
46093076|NCT00966121|Procedure|endoscopic band ligation|"Perform EBL within 7 days after randomization~Apply 1-2 band/column/session to varices in the distal 5-7cm of the esophagus till they are eradicated (Disappearance or too small to apply band) with interval of 4weeks (at 4,8,12 weeks after initial treatment).~Acid suppression using proton pump inhibitor until eradicated.~After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months)."
46093077|NCT00966121|Procedure|EBL+Propranolol|"Start with 20 mg b.i.d~Adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min~After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
46093078|NCT02537288|Drug|Fedovapagon|
46093079|NCT02537288|Drug|Moxifloxacin|
46006683|NCT04577235|Other|severity of lung involvement with COVID-19.|transthoracic lung ultrasound and throcic CT
46093080|NCT02537288|Drug|Placebo (for fedovapagon)|
46093081|NCT05346263|Device|Intermittent Abdominal Pressure Ventilation|Patients of experimental group will use IAPV in daytime ventilation. Intermittent abdominal pressure ventilation (IAPV) is a portable ventilator with an internal battery and PneumoBelt corset as an interface.
46093082|NCT05346263|Device|Usual ventilation|NIV
46093083|NCT04032054|Device|mono-axial and poly-axial screws|types of pedicular screws for thoracolumbar fractures fixation
46093084|NCT02669654|Other|Day-care management of Severe Pneumonia|Day-care management of Severe Pneumonia
46093085|NCT03207191|Drug|F16IL2|F16IL2 dose escalation with provisional doses of 10, 20 and 30 Mio IU on Day 1, 8, 15 and 22 of each cycle through a rate-controlled intravenous infusion of 3 hours
46093086|NCT03207191|Drug|BI 836858|BI 836858 dose escalation with provisional doses of 10, 20, 40, 80 and 160 mg on days 3, 10, 17 and 24 of each cycle through a rate-controlled intravenous infusion up to 5 hours
46093087|NCT00659412|Drug|Alefacept|Intramuscular
46093088|NCT00659412|Drug|Methotrexate|Oral
46093089|NCT00659412|Drug|Placebo|Intramuscular
46093090|NCT04009135|Behavioral|internet delivered cognitive behavioural therapy (iCBT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) thoughts and feelings; 3) understanding stress and relaxation; 4) unhealthy and healthy thoughts; 5) layers of thinking; 6) core beliefs; and 7) relationship, lifestyle, problem solving, and relapse prevention. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
46093091|NCT04009135|Behavioral|online delivered acceptance and commitment therapy (iACT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) introduction to ACT; 3) cognitive fusion and defusion; 4) thinking mind versus observing mind & acceptance; 5) mindfulness; 6) values; and 7) taking action. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
46093092|NCT04009135|Other|Attention Control (AC)|1-module of psychoeducation about chronic pain and major depression. Weekly contact to complete measures of symptomatology and well-being.
46093093|NCT04176224|Drug|MT-1186|Suspension
45598974|NCT02350335|Drug|Nicotine (transdermal)|Application of transdermal nicotine replacement in smokers with acute aneurysmal hemorrhage
45598975|NCT03192995|Drug|lorcaserin|lorcaserin 20 mg tablet
46093094|NCT00966199|Drug|anti-hypertensive medication|8-12 weeks of anti-hypertensive treatment with 2 weekly titration using registered hypertensive medication
46093095|NCT03173729|Diagnostic Test|Biosensor Point of Care Device|This device is a point of care urine-based metabolomic diagnostic test that detects metabolite biomarkers for CRC and polyps.
46093096|NCT00910364|Other|Exercise|Exercise
46093097|NCT04158102|Drug|Bupivacaine liposome injectable suspension|Single dose of Bupivacaine liposome injectable suspension 266 mg in 20 mL
46093098|NCT00911352|Device|Frozen gel glove (Elasto-Gel Mitten)|Gel glove is frozen for > 3 hours at -5 to -30°C prior to use. Each patient wears a triple glove set (surgical glove overlaid with cotton glove, overlaid with gel glove) on their intervention hand. Gloves are worn for duration of infusion (15 mins pre, 60 minutes intratreatment and 15 mins post) to ensure the patients' peripheries are vasoconstricted on commencement of the infusion and for enough time afterwards to ensure circulating drug does not reach the target area. Because of the duration of the infusion, more than one gel glove will be used successively (for 45 minutes each) to maintain a consistently low temperature on the hand and nails.
46093099|NCT02689895|Other|modified directly administered anti-retroviral therapy (mDAART)|As described before
46093100|NCT04176536|Drug|BI 764198|Capsules
46093101|NCT02633592|Other|HRARM|Patients and healthy volunteers are investigated in the seated and lying position during HRAM
46093102|NCT02633592|Other|MRI Defecography|Patients and healthy volunteers are investigated in the supine and left lateral position in the MRI
46093103|NCT03161249|Behavioral|Experimental group|The experimental group receiving mobile treatment: treatment as usual plus a psychotherapy intervention by the telephone app (a total of 5 modules of psychotherapy: psychoeducation plus mindfulness plus alerts plus social wall plus problems solving)
46093104|NCT03161249|Other|Control group|Group that does not receive any treatment added to its usual treatment
46093105|NCT02668484|Device|repositionable valve prosthesis|repositionable valve prosthesis implanted via trans-femoral and trans-catheter route
46093106|NCT02668484|Device|balloon-expandable valve prosthesis|balloon-expandable valve prosthesis implanted via trans-femoral and trans-catheter route
46093107|NCT00961363|Drug|Sitagliptin|sitagliptin 100 mg per day
46093108|NCT00961363|Drug|Placebo|Placebo
46093109|NCT02668328|Behavioral|Social Cognitive Theory Tailored Behavioral Intervention|The intervention will enhance self-efficacy
46093110|NCT02633202|Radiation|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
46093111|NCT02633202|Drug|Cisplatin|concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
46093112|NCT04926415|Device|taVNS|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae. Electrical stimulation (30 Hz stimulation frequency, 300 μs pulse width) is applied for 30 min. The stimulation current is determined individually for each participant by slowly increasing the stimulation current until the participants feel a mild tingling sensation at the site of the electrode. Then the current is gradually reduced until the tingling sensation disappears. This current will then be used for taVNS. A TENS 7000 or EMS 7500 device (510(k): K080661) is used.
46093113|NCT04926415|Device|Sham taVNS|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae but no electrical current is applied to the electrode.
46093114|NCT02669420|Procedure|termination of second trimester pregnancy|Intra uterine extra amniotic (200 μg ) versus Vaginal (200 μg) Misoprostol for Second Trimester Pregnancy Termination. Randomized controlled trial
46093115|NCT02791841|Behavioral|Rhythmic Reading Training|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
45678405|NCT01797081|Other|Normal Saline|Normal saline (placebo) injected into bilateral Crow's Feet Line areas per treatment.
45836632|NCT00368940|Behavioral|ST-CI|Supportive therapy focuses on the use of nonspecific or common factors of therapy, including facilitation of affect, helping the person feel understood, empathy, the treatment ritual, success experiences, and therapeutic optimism. In working with the participant, the therapist creates a supportive relationship and encourages the participant to consider his/her strengths and abilities rather than focusing on negative aspects of his/her character.
45598976|NCT03192995|Drug|Placebo Oral Tablet|placebo 20 mg. tablet
45678406|NCT01794117|Drug|Anakinra|An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If active disease persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4 and 300mg/day at week 8.
45836633|NCT00369564|Drug|glutamic acid|Given orally 3 times daily
45836634|NCT00369564|Other|placebo|Given orally 3 times daily
45678407|NCT01766037|Device|Aspiration Therapy (AspireAssist)|Use of the AspireAssist device in aspiration therapy
45678408|NCT01766037|Behavioral|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
45836635|NCT00315822|Other|80% oxygen|Supplemental oxygen will be administered during surgery
45836636|NCT00315822|Other|30% oxygen|Subjects undergoing surgery will receive routine administration of oxygen
46093116|NCT02791841|Behavioral|Visual Hemispheric-Specific Stimulation + Action Video Games|"This training combines Visual Hemisphere-Specific Stimulation (VHSS) according to Bakker's Balance Model, and Action Video-Games (AVG). Hemispheric-specific stimulation is carried out by tachistoscopic presentation of words to a visual hemifield in order to selectively stimulate right-hemisphere perceptual analysis or left-hemisphere linguistic anticipation. A computerized program is used, in which the word is flashed and presented for less than 350 ms only if the child clicks on the mouse at the exact moment a dot is crossing a central target (control of eye position and fixation).~AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used."
46093117|NCT02791841|Behavioral|Action Video Games|AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used.
46093118|NCT00645242|Drug|fluconazole|Fluconazole oral suspension 6 mg/kg/day for 6 weeks followed by 4 weeks without treatment
46093119|NCT02786459|Device|ProxiScan|ProxiScan probe will be coupled with ProstaScint (a radioactive tracer) and used to perform imaging to detect small lesions in the pelvis that will otherwise be hard to detect with conventional imaging modalities.
46093120|NCT02786459|Device|Magnetic Resonance Imaging|Used as a comparative to ProxiScan.
46093121|NCT02786459|Device|SPECT-CT|Used as a comparative to ProxiScan.
46093122|NCT00966511|Procedure|Lung resection surgery|The study is designed in a way that will not alter the surgeon's decision based on routine assessment of candidates for resection (lobectomy or greater). Namely, the VRI data will be gathered prospectively; however, the analyses using VRI data will be performed retrospectively.
46093123|NCT00659568|Drug|metformin hydrochloride|
46093124|NCT00659568|Drug|temsirolimus|
45836637|NCT01794624|Behavioral|Cognitive Therapy for Catastrophizing|Cognitive Therapy for Catastrophizing will involve a standardized, 6-session cognitive intervention, focusing on cognitive restructuring techniques for managing pain and reducing catastrophic thinking and includes some general coping skills training. Cognitive restructuring includes identifying patterns of dysfunctional thinking which can give rise to emotional distress, physiological arousal, or maladaptive behaviors. Patients are taught to identify and replace distorted thinking with balanced, realistic thinking. Patients learn to identify these thoughts as they occur in daily life and challenge their own negative thoughts.
45840146|NCT00645450|Drug|Propranolol|Weekly doses of short and long acting propranolol (Inderal, Inderal LA, Hemangeol, Inderal XL) following recollection of traumatic memory
46093125|NCT02669342|Device|Radiance™ Clear Sharklet® Silicone Foley Catheter|
46093126|NCT02669342|Device|Silicone Foley Catheter|
46093127|NCT00961597|Procedure|Meniscus repair for red/white tears without PRP|Same operation as experimental, only without the use of platelet rich plasma.
46093128|NCT00961597|Procedure|Meniscus repair with PRP|Meniscus repair with platelet rich plasma using vertical divergent suture techniques.
46093129|NCT02637180|Drug|anti-osteoporotic medication|check previous information
45459689|NCT05759390|Diagnostic Test|Ultrasound elastography|Using an ultrasound scanner (Aloka Echo Camera SSD-3500; Aloka Prosound, Yokohama, Japan) for chest ultrasound examinations. If patients has multiple subpleural lung lesions, the largest and most approachable lesion to perform 2 Dimensions- shear wave elastography (2D-SWE) will be chosen.
45840147|NCT00645450|Drug|Placebo|Weekly doses of placebo (inactive pill) following recollection of traumatic memory
46093130|NCT02791529|Procedure|Electrocautery|Skin incision performed by electrocautery
46093131|NCT02791529|Procedure|Scalpel|Skin incision performed by scalpel
46093132|NCT00961753|Drug|optimized ibuprofen|day of life 0-3 - 10, 5, 5 mg/kg/dose at 24 hour intervals day of life 4-6 - 14, 7, 7 mg/kg/dose at 24 hour intervals day of life 7-29 - 20, 10, 10 mg/kg/dose at 24 hour intervals
46093133|NCT00961753|Drug|Standard Ibuprofen|day of life 0-29 - 10,5, 5 mg/kg/dose at 24 hour intervals
46093134|NCT02670980|Device|Intelligent Retinal Implant System|
46093135|NCT04232813|Drug|Estradiol 10 MCG Vaginal Tablet [VAGIFEM]|To insert the tablets the patient must use the applicator provided in the way explained in the prospectus.
46093136|NCT04232813|Drug|Promestriene Vaginal|To insert the cream the patient must use the applicator provided in the way explained in the prospectus.
46093137|NCT00966589|Procedure|laparoscopic hernioplasty (TEP)|Insertion of polypropylene mesh behind pubic bone
46093138|NCT02668406|Other|Venous blood sampling (2 timepoints) (Phase A and B)|8.5ml at Day 1 + 8.5ml at Day 5
46093139|NCT02668406|Other|Venous blood sampling (1 timepoint) (Phase A and B)|8.5ml at Day 1
46093140|NCT02668406|Other|Voided urine sampling (first sample) (Phase A)|At least 20ml upon confirmation of being part of one of the 3 study groups
45459690|NCT03477058|Other|WO 3308 cosmetic product for topical use|Application on the entire body at least once a day over two weeks
45459691|NCT03483922|Diagnostic Test|ctDNA methylation in and it's Correlation wth Development and prediction of HCC|Blood sample from patients with HCC, healthy individuals and individuals with hepatitis B will be collected, and DNA will extracted from PBMC and circulated tumor DNA will be subjected to bisulfite conversion. DNA from PBMC DNA will be analyzed with primers developed for the AHNAK-STAP1 genes. Plasma samples will be subjected to EZ direct DNA extraction and bisulfite conversion kit and will be amplified with primers developed to amplify the target regions. DNA will be used for the subsequent PCR amplification with specific primer to generate PCR amplicon for sequencing using a double PCR procedure. The product of PCR reaction will be subjected to indexed MiSeq Next-Generation sequencing that will allow us quantify DNA methylation level.
46093141|NCT02668406|Other|Voided urine sampling (second sample) (Phase A)|At least 20ml during routine hospital stay or routine follow-up visit
46093142|NCT02791295|Other|Diet and physical activity program|A personalized intervention focused on improving diet and increasing physical activity will be implemented at-home with a monthly support by a registered dietician and physical activity educator during 6 months
45459692|NCT03552068|Drug|placebo|"Treatment (placebo) will be taken during 8 weeks with one visit at 2, 4 and 8 weeks.~Medication: placebo twice a day (in the morning and evening)."
45459693|NCT03552068|Drug|Clonidine|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. Medication: 75 μg of clonidine twice a day (in the morning and evening).
46093143|NCT00659958|Drug|Zonisamide|300 mg tablet. Maintenance dosing period of 12 weeks, at the beginning of which, physicians will decide to keep the 300 mg dose from the titration period, lower it to 200 mg, or take it up to 400 mg.
46093144|NCT00644774|Drug|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
46093145|NCT00644774|Drug|azithromycin|2.5 ml of cherry flavored oral suspension 100 mg/5 ml
46093146|NCT00545779|Drug|Ibandronate|150 mg orally once monthly for 6 months
46093147|NCT02791451|Device|telemonitoring|To predict exacerbation of COPD with wireless telemonitoring
46093148|NCT00910442|Dietary Supplement|Glutathione precursors|HIV+ patients were assigned to 7 day diets containing either NAC or Gln
46093149|NCT00660036|Drug|Gemtuzumab ozogamicin|On Day 6 of an inpatient hospital stay: Based on the study design patients will be treated with one of three doses (3 mg/m^2, 6 mg/m^2 or 9 mg/m^2), administered intravenously in 100 ml of 0.9% sodium chloride over 2 hours.
46093150|NCT00660036|Drug|Mitoxantrone|On Days 1-3 of an inpatient hospital stay: 10 mg/m^2 administered via IVPB (intravenous piggy-back) in 50ml normal saline (NS) over 15 minutes
46093151|NCT00660036|Drug|Etoposide|On Days 1-5 of an inpatient hospital stay: 100 mg/m^2 administered intravenously in 500 ml of 0.9% sodium chloride over 2 hours
46093152|NCT02791373|Drug|Vinorelbine|Mobilisation Chemotherapy
46093153|NCT02791373|Drug|Gemcitabine|Mobilisation Chemotherapy
46093154|NCT02669108|Device|PET/ MRI of the Testis|PET/MRI of the testis will be performed upon the patient achieving azoospermia (following the vasectomy), or 25 ejaculations and following proven azoospermia (via standard of care semen analysis).
46093155|NCT00967681|Dietary Supplement|Oncoxin|(caplets 300 mg), three oral caplets per day for 24 weeks
46093156|NCT00967681|Dietary Supplement|Placebo|(caplets 300 mg), three oral caplets per day for 24 weeks
46093157|NCT02537132|Other|Adaptation and training to Non Invasive Ventilation (NIV)|Each person recruited after a respiratory evaluation (baseline spirometry and supine, maximal inspiratory and expiratory pressures (MIP / MEP) or sniff nasal inspiratory pressure (SNIP), 6 Minute Walking Test (6MWT) -if still ambulatory, arterial blood gas, nocturnal polygraphy) will be adapted to Non Invasive Ventilation (NIV). Moreover, the subject will be brought to the management of bronchial secretions (under the terms set out herein) during not less than five outpatient or house accesses, depending on who is randomly assigned to the experimental group or the control group. These accesses will take place weekly, for a period of two months, considering both the needs and the patient's clinical condition.
46093158|NCT02787707|Drug|Persumac|2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour
45459694|NCT03483844|Diagnostic Test|GE CT 750 HD|Low-dose dual-energy CT imaging
46093159|NCT02787707|Drug|lactose|2.7 grams Lactose every 8 hour
46093160|NCT04160754|Behavioral|Mindfulness Based Relapse Prevention|"Individuals assigned to the experimental group will receive interventions normally provided at the clinic and eight 1.5-hour group sessions of MBRP. Each sessions will occur once per week and will target a specific theme such as being aware of personal triggers, maintaining present focus, allowing or letting things be, responding to emotional and physical experiences in skillful ways, and recognizing intrusive thoughts. Each session will incorporate a mindfulness meditation technique (e.g.,SOBER breathing space and urge surfing). Participants will receive materials (e.g., recordings) with which to perform practices and meditation during the intervention phase."
46093161|NCT04160754|Behavioral|Control (CTL)|Individuals assigned to the CTL group will receive interventions provided at the clinic and up to eight CTL sessions. The CTL group will receive information (reading) and videos once per week on health behaviors (e.g., exercise, eating) and the neurobiology of addiction. This approach will reduce the possibility that intervention effects are solely due to the experimental group's receiving extra attention. In contrast to the active intervention, sessions will be educational in nature, with no motivational, cognitive, or behavioral components
46093162|NCT03102047|Drug|durvalumab|Within 3-7 days after completion of chemoradiation, patients will receive durvalumab (750 mg IV infusion) every 2 weeks for 4 doses on Day 1(Dose 1), Day 15 (Dose 2), Day 29 (Dose 3), and Day 43 (Dose 4)
46093163|NCT00966745|Drug|milrinone|
46006684|NCT04589000|Other|acupressure|"Throughout the study, acupressure will be applied to the acupressure group once on the post-op day 0, 2 times on the post-op 1st day, and once on the post-op 2nd day, 4 times in total for 15 minutes.~15 minutes after acupressure application, milk will be expressed for 15 minutes and the amount of milk expressed will be recorded in the milk measurement table."
46093164|NCT00966745|Drug|placebo|
46093165|NCT02633436|Other|SLC1A5 expression|To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.
46093166|NCT00967759|Drug|Bronpheniramine and fenilefrine (Decongex Plus)|Oral Solution: Bronpheniramine (2mg/ml) and fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
46093167|NCT00967759|Drug|Bronpheniramine isolated|Oral Solution: Bronpheniramine (2mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
46093168|NCT00967759|Drug|Fenilefrine isolated|Oral Solution: Fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
45459695|NCT05198570|Other|Pharmacokinetic analysis|Population pharmacokinetic analysis of plasma concentrations of aciclovir obtained during routine therapeutic drug monitoring
45459696|NCT00702988|Drug|Org 36286|single dose of 60, 120, or 180 μg Org 36286 (experimental group administered under protocol 38826)
45459697|NCT00702988|Drug|recFSH|150 IU recFSH daily (reference group administered under protocol 38826)
45459698|NCT05759312|Drug|Zimberelimab|Zimberelimab 240mg IV every 2 weeks
45459699|NCT05759312|Drug|Metformin Hydrochloride|Metformin 2000mg PO QD
45459700|NCT05152654|Device|Tacker|metallic staples used to fix the mesh
45840148|NCT00645762|Device|RS-Series Rhinosinusitis Treatment System|Single arm
46093169|NCT02669030|Drug|suvorexant|an FDA-approved sleep aid
46093170|NCT02669030|Drug|Placebo|control group
46093171|NCT02791139|Other|Cardiovascular Magnetic Resonance Imaging (MRI)|Cardiovascular MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create heart images.
46093172|NCT02791139|Other|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
46093173|NCT02791139|Other|Tonometry|Tonometry is a noninvasive method to obtain arterial pressure waveform
46093174|NCT02791139|Other|Genetic Testing (Blood)|The blood will be stored for genetic tests and development of cell lines to study genetic risks for aging related diseases and cardiovascular disease.
46093175|NCT02791139|Other|Hand-Grip Strength Measurement|We will measure your hand grip strength using a standard hand dynamometer which is a portable meter that you will use your hands to press on.
46006685|NCT04594668|Drug|Senicapoc|The intervention will consist of 50 mg enteral senicapoc administered as soon as possible after randomization and again after 24 hours
46006686|NCT00581568|Other|Cutaneous Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling
46093176|NCT02791139|Other|Body Fat Mass Analysis|Body composition will be analysed by a body composition analyser machine onto which you will have to stand on.
46006687|NCT04589234|Drug|Salmonella-IL2|Phase 2 study to determine the anti-tumor effectiveness of Salmonella-IL2 (Saltikva) with standard of care chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane) for metastatic pancreatic cancer
46093177|NCT02668796|Drug|Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
46006688|NCT04589234|Drug|FOLFIRINOX Alone (Historical Controls)|We will use historical data from the literature to compare FOLFIRINOX alone against the FOLFIRINOX with Salmonella-IL2 group
46006689|NCT04589234|Drug|Gemcitabine/Abraxane Alone (Historical Controls)|We will use historical data from the literature to compare Gemcitabine/Abraxane alone against the Gemcitabine/Abraxane with Salmonella-IL2 group
46006690|NCT03453177|Drug|Standard of Care + Fosfomycin|Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).
46093178|NCT02668796|Drug|Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)|apply using the given applicator
46093179|NCT02668796|Drug|Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
46093180|NCT02791061|Other|Cardiovascular Magnetic Resonance Imagine (MRI)|MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images.
46006691|NCT03453177|Procedure|PK|Two PK samples will be taken after each of the first IV and oral doses, with sampling times allocated within possible early (5, 10 or 60 minutes) and late (2, 4 or 8 hours) time-points after starting the IV and PO formulations; then again together with biochemistry after 7 days for those babies whom remain as inpatients.
46093181|NCT02791061|Other|Cardiopulmonary exercise testing (CPET)|Cardiopulmonary exercise testing (CPET) is non-invasive simultaneous measurement of the cardiovascular and respiratory system during exercise to assess a patient's exercise capacity.
46093182|NCT02791061|Other|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
46093183|NCT02668718|Radiation|Adjuvant radiotherapy|The radiation therapy will be given in 37 fractions of 1.8 Gy per day, five days per week. The total dose of radiation will be 66.6 Gy.
46093184|NCT04175366|Other|Shared Decision Making|Shared Decision Making including adapted decision aid.
46093185|NCT04198103|Device|Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting using EchoLaser system. The treatment consists of the trasmission of laser energy into the tissue through the percutaneous insertion of optical fiber under local anesthesia. Within each needle, an optic fiber of 300 µm will be inserted. Each ablation lasts 6 minutes and each fiber ablates 1800J at a power of 3W. At the end of the first ablation there is a pull-back of about 1 cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used for a total duration of about 30minutes. At the end of the treatment corticosteroid is given for anti-edema and anti-inflammatory effects and Antibiotic therapy and gastroprotective therapy is given. After an adequate amount of time for observation, the patient is dismissed.
45459701|NCT03446456|Drug|Arginine vasopressin|Intranasal vasopressin will be administered shortly before the fMRI experiment.
45459702|NCT03446456|Other|Saline|Intranasal saline will serve as a placebo for participants in the Saline Arm
45459703|NCT03446456|Behavioral|Observational learning|During the observational learning intervention, participants will learn the experience of analgesia in another person via a video. Participants will learn the analgesia nature of the placebo cream and the neutral nature of the control cream.
46006692|NCT03453177|Procedure|Analysis of Bacterial Isolates|For assessment of susceptibility patterns in bowel flora, we will systematically assess all admission and discharge nappy swabs.
46006693|NCT04588961|Procedure|Trapeziectomy with suspensionplasty|Surgical removal of trapezium bone and ligamentoplasty of first metacarpal bone using abductor pollicis tendon
46006694|NCT04588961|Procedure|Joint alloplasty|Surgical removal of degenerated joint surfaces nad replacement using modern designed prothesis
46006695|NCT04594629|Drug|Nitroglycerin|Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine ), its starting concentration was 200 mcg/ml with nitro glycerine was delivered at 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser connected to the inspiratory limb of the breathing circuit
46006696|NCT04594629|Drug|PGI2|Patients of PGI2 group received nebulized PGI2 (epoprostenol), 20000 ng/ml (Flolan; Glaxo Wellcome Inc, Research Triangle Park, NC) (60 ml syringe of PGI2 with concentration 20000 ng/ml was attached to an intravenous pump which delivers a titrating rate of 8 ml/h to the nebulizer compartment (MiniHEART nebulizer; Westmed, Tucson, Ariz) fixed to the inspiratory limb of the breathing circuit or to the face mask with venturi accessory for sprinkling. The nebulizer was filled with 15 ml PGI2 with nebulized oxygen flow rate 3 litres
46006697|NCT04589078|Device|GI Genius CADe system|Each patient will undergo standard white-light colonoscopy with the support of the latest version of the CE marked GI Genius CADe available.
46093186|NCT00597714|Drug|Non-myeloablative Stem Cell Transplantation|The preparative regimen is 4 days of daily fludarabine at 40 mg/m2/d infused over 30 minutes; melphalan 140 mg/m2/d for 1 day administered over 15 minutes; 4 days of Alemtuzumab at 20 mg/d in 250 ml of normal saline infused over 3 hours. Group B's prep regimen will begin on day -5 or day -4 and busulfan 130mg/m2/d for 2 days over 3 hours. The peripheral blood stem cells (PBSCs) will be infused over 2-4 days. Patient evaluations will occur 2 times per week by physical exam for toxicity through day 45.
46093187|NCT00645320|Drug|Ziprasidone|Oral ziprasidone tablets 40 or 80 mg twice daily with meals for 3 months. Doses were flexible based on investigator's discretion.
46006698|NCT04594161|Device|Percutaneous Nephrostomy|A Percutaneous Nephrostomy will be placed in patients with obstructive urolithiasis
46093188|NCT02790827|Behavioral|CETA|CETA first focuses on: 1) awareness of alcohol problems, violence, and the link between them; 2) gender norms. Skills taught include: changing drinking behaviors, coping with cravings, family dynamics that contribute and result from alcohol use, the role gender plays, and community norms around problem drinking, and cognitive/emotional/behavioral patterns connected with inter-personal violence. The intervention then addresses: 1) positive parenting, 2) positive family relationships, conflict management, and communication skills, 3) attitudes and beliefs about violence, 4) mental health problems and 5) reducing (further) traumatic experiences. The cognitive behavioral therapy (CBT) principles of CETA overlap with the CBT skills for alcohol reduction.
46093189|NCT02790827|Behavioral|Treatment as usual|The control condition is defined as 'treatment as usual'. In Zambia, there are no formal services or standard of care for alcohol use problems or domestic violence. There are, however, organizations (such as non-governmental organizations) operating in Lusaka that provide intermittent services for these types of problems. Some families receive informal counseling from parish priests or other leaders in their communities. In this study we are therefore defining these types of informal services as 'treatment-as-usual.' We will closely track the type, number, and degree of these kinds of services that all participants receive and access. Following the conclusion of the study, we will offer the CETA intervention to control families if it has been found to be safe and effective.
46006699|NCT04594161|Device|Double J catheter|A Double J catheter will be placed in patients with obstructive urolithiasis
46006700|NCT04588844|Drug|Polyethylene Glycol Recombinant Human Somatropin|Polyethylene glycol recombinant human somatropin will be injected weekly (3mg/per week) from the beginning of preceding menstruation cycle until the day of ovum pickup.
46006701|NCT04588532|Drug|BAM8-22|Bovine Adrenal Medulla will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
46093190|NCT04017312|Device|High Frequency Chest Wall Oscillation|High frequency chest wall oscillation (HFCWO) therapy (also known as high-frequency chest-wall compression or HFCWC) is commonly prescribed to provide routine airway clearance in patients with bronchiectasis as well as other patients with a need for regular airway clearance therapy. HFCWO generates high velocity expiratory airflow. This airflow is thought to mobilize secretions by the sheer force created, effecting changes in rheology and moving mucus in a cephalad direction during the oscillation. The Vest® Airway Clearance System, a commonly used device, generates HFCWO using an air pulse generator and an inflatable garment that delivers pressure pulses to the thorax. These pressure pulses within the garment create HFCWO.
46093191|NCT04017312|Device|Oscillating Positive Expiratory Pressure (OPEP)|Oscillating PEP is an airway clearance technique, where the person blows all the way out many times through a device. These types of oscillating PEP devices work in two ways. Firstly, they use resistance to make it more difficult during the breath out, like non-oscillating PEP devices. Oscillating PEP devices also create vibrations when breathing out. The vibrations move mucus from the surface of the airways. After blowing through the device several times, the person will huff and cough to clear the mucus from the lungs.
46093192|NCT02787629|Procedure|Simultaneous Intubation|Intubation with GlideScope and ETT inserted simultaneously
46093193|NCT02787629|Procedure|Standard Intubation|Intubation with GlideScope inserted first and ETT insertion after the GlideScope view is obtained
46093194|NCT02667860|Procedure|Intracorporeal anastomosis.|Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.
46093195|NCT02667860|Procedure|Extracorporeal anastomosis|A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.
46093196|NCT02667860|Device|Echelon Endopatch|Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis.
46093197|NCT02667860|Device|Proximate Linear Cutter|Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis.
46093198|NCT03938857|Drug|Fentanyl|Fentanyl standard of care
46093199|NCT03938857|Drug|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.2 mcg/kg/hr)
46093200|NCT03938857|Drug|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.5 mcg/kg/hr)
46093201|NCT03938857|Drug|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.7 mcg/kg/hr)
45459704|NCT03446456|Other|fMRI data aquisition|All participants from the intranasal vasopressin and intranasal saline groups will go through a fMRI data acquisition to obtain the brain structural, brain resting-states and functional MRI scans.
45459705|NCT03483688|Biological|CD19-directed CAR-T cells|CD19-directed CAR-T cells single infusion intravenously at a target dose of 0.5-5.0 x 10^6 anti-CD19 CAR+ T cells/kg
46006702|NCT04588532|Drug|Histamine|histamine will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
45840149|NCT00645762|Device|FinESS Balloon|
45840150|NCT00647400|Biological|adalimumab|Adalimumab 40 mg every other week, subcutaneous
45840151|NCT00647400|Biological|adalimumab|Adalimumab 80 mg every other week, subcutaneous
45840152|NCT00648648|Drug|MK-1775|MK-1775 administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.
45840153|NCT00648648|Drug|gemcitabine|Gemcitabine administered at 1000 mg/m^2 by IV infusion in a 28-day cycle.
45840154|NCT00648648|Drug|cisplatin|Cisplatin administered at 75 mg/m^2 by IV infusion in a 21-day cycle.
46006703|NCT04588532|Drug|Cowhage (Mucuna Pruriens)|cowhage spicules will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
45459706|NCT03412292|Drug|MAX-40279|"MAX-40279, is a multi-targeted kinase inhibitor inhibitor mainly target FLT3 and FGFR. It has a molecular weight of 496.56 Daltons, which has a formula of C24H25FN6O3S.~MAX-40279 is yellow powder. It is insoluble in water, methanol, ethanol, 0.1 mol/L hydrochloride solution or 0.1% saline; very slightly soluble in methylene dichloride and sparingly soluble in dimethylformamide. It is stable under strong acid, strong alkali, high temperatures and exposure to light.~MAX-40279 for clinical use is presented as a sterile yellow powder packaged in capsules at 5 mg, or 25 mg doses."
46006704|NCT04588532|Drug|Doxepin|Doxepin cream (antihistamine) will be applied in 4 areas on the volar forearm
45678409|NCT04413903|Procedure|The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations|The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations
46006705|NCT04594083|Device|Palm Stimulator|The Palm Stimulator, developed by the present researchers for the first time, is 1.6 cm in diameter, 4 cm in length, and has a cylindrical, non-slippery structure for an easy grip to ensure maximum contact with the palm The Palm Stimulator consists of blunt protrusions that will provide a tactile stimulus on the palm. The blunt protrusions do not penetrate into the skin. The simulator design is based on the gate-control theory, which allows for a reduction in the perceived amount of pain experienced during injection by closing the pain gate in the spinal cord in creating a stimulus on the skin.
46006706|NCT04594083|Device|ShotBlocker|ShotBlocker was placed in the ventrogluteal area properly 20 seconds before injection. It was fixed at the injection site until the injection process was completed.
46006707|NCT04588454|Other|18F-PSMA-1007 PET tracer|18F-PSMA-1007 PET/CT
46006708|NCT03453138|Device|LMA Protector|LMA Protector will be inserted by a blind researcher after standart anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale
45678410|NCT01765569|Drug|Digoxin|Participants received single oral dose of digoxin 0.25 mg tablet on Day 1 and Day 29.
45678411|NCT01765569|Drug|Vemurafenib|Participants received vemurafenib 960 mg tablet orally BID from Day 8 to Day 35.
46006709|NCT03453138|Device|Tracheal Intubation|tracheal intubation will be perform after standart anaesthetic induction and heamodynamic variables including blood pressure heart rate and possible complications will be observed
46006710|NCT03453099|Other|Preoperative Questionnaires|"The participants will be asked to complete 5 questionnaires:~An abbreviated version of the Caffeine Assessment Tool (CAT)~Sleep Questionnaire (SQ)~Surgical Fear Questionnaire (SFQ)~WHO Alcohol AUDIT Tool~WHO Smoking Questionnaire~They will also be asked to complete a demographics sheet~All participants will undergo standard anaesthetic induction, a research participant will observe the dose of propofol and time taken for loss of consciousness"
46093202|NCT05420129|Device|MAD Therapy|Participants will be treated with a Mandibular Advancement Device therapy
46006711|NCT03453099|Other|Postoperative Subjective Pain Scores|After the operation, participants will be provide with a scale from 1-10 in which to rate their pain at rest and whilst coughing. This will be undertaken at 1hr postoperatively.
46093203|NCT05420129|Device|CPAP Therapy|Participants will be treated with a Continuous Positive Airway Pressure therapy
46093204|NCT04163562|Drug|INP20|Part A: Oral INP20 administration at ascending doses once daily for 2 weeks. Part B: Two doses of oral INP20 derived from Part A once daily for 6 months.
46093205|NCT04163562|Drug|Placebo|Part A: Oral placebo administration onces daily for 2 weeks. Part B: Oral placebo administration onces daily for 6 months.
46093206|NCT00644852|Other|Retrospective chart review study|Retrospective study chart review long acting risperidone
46093207|NCT04032600|Procedure|Paracentesis|Full versus partial paracentesis (3 liters)
46093208|NCT02667938|Drug|HCP1303 capsule 5/0.2mg|
46093209|NCT02667938|Drug|HCP1303 capsule 5/0.4mg|
46093210|NCT02667938|Drug|HGP1201|
46093211|NCT02667938|Drug|HCP1303 capsule 5/0.2mg placebo|
46093212|NCT02667938|Drug|HCP1303 capsule 5/0.4mg placebo|
46093213|NCT02667938|Drug|HGP1201 placebo|
46093214|NCT04160598|Drug|IV infusion|Control group (Placebo Group): bolus 50 ml Nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
45459707|NCT03476902|Behavioral|Therapist assisted mobile intervention|Individuals will receive 4 introductory sessions with a therapist followed by weekly phone calls. Participants will utilize nOCD application to assist with treatment protocol adherence.
46093215|NCT04160598|Drug|intrathecal fentanyl|10-15mg hyperbaric bupivacaine and 30µg fentanyl intrathecally injected
46093216|NCT04174430|Biological|severe bronchiolitis|Prematurity (gestational age ≤36 weeks), Low birth weight, Age less than 12 weeks,Chronic pulmonary disease, particularly bronchopulmonary dysplasia (also known as chronic lung disease), Anatomic defects of the airways, Hemodynamically significant congenital heart disease, Immunodeficiency, Neurologic disease
46093217|NCT02633124|Device|Edelvaiss Multiline NEO|Use of Edelvaiss Multiline NEO to infuse the parenteral nutrition and drugs during the study period
45459708|NCT03396692|Procedure|Intravenous morphine patient-controlled analgesia (PCA)|"Group 1 control:~Morphine titration at 0.1 mg/kg~Establishment of PCA morphine:~concentration 1mg/ml~1ml bolus~refractory period of 7 minutes~no maximum dose per day. Premedication of the patient with Ketamine 0.15 mg/kg and Propofol 0.5 mg /kg"
45840155|NCT00648648|Drug|carboplatin|Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.
45840156|NCT00652080|Drug|API 31510|Topical Cream; 3% active; AM & PM application
45840157|NCT00652314|Device|Thrombi-Gel|Applicaton of Hemostatic product during surgery
45840158|NCT00654030|Drug|1650-G Vaccine|.6ml injection administered intradermally in the thigh at week 0 and week 4
45840159|NCT00654654|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of 3 mm biopsies~Two injection treatments of facial wrinkles and creases~Conduct of study assessments"
46093218|NCT02633124|Device|Standard Infusion Set|Use of Standard Infusion Set to infuse the parenteral nutrition and drugs during the study period
46093219|NCT00967837|Procedure|Pulsatile Intravenous Insulin Therapy|Diabetic pts that meet trial criteria referred by an endocrinologist are given Pulsatile intravenous insulin therapy on a weekly basis. Weekly orders for insulin dosage is based upon pt response to therapy monitored by RQ and insulin resistance.
46093220|NCT02668016|Drug|Atorvastatin|Atorvastatin 20mg tablets taken orally once daily for one month.
46093221|NCT02668016|Other|Placebo|Placebo tablets taken orally once daily for one month
46093222|NCT03012971|Drug|Dexmedetomidine supplemented morphine analgesia|Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.
46093223|NCT03012971|Drug|Morphine analgesia|Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.
46093224|NCT00966901|Drug|Nicotine Patch|25 mg nicotine patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.
46093225|NCT00966901|Drug|Placebo Patch|As a positive control, a placebo patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.
45840160|NCT00656448|Drug|Procrit|40,000 units sq every week starting within two weeks (before or after) from the start of induction chemotherapy.
45840161|NCT00659802|Drug|HMPL-004 low dose|HMPL-004, 400 mg (2 x 200 mg) t.i.d. (total of 1200 mg/day).
46093226|NCT00966901|Drug|No Patch Control|As a negative control, a marked site on the lower back or buttock was assigned as test area, but no patch was applied.
46093227|NCT00966901|Radiation|UVA and UVB irradiation|All three test sites exposed to UV radiation after patch removal. Induction: 10 J/cm2 UVA and 0.5 MED UVB, one treatment after first patch removal; and 3 MED UVB at the 5 following treatments. Challenge: 4 J/cm2 UVA and 0.5MED UVB, one treatment.( MED: Minimal Erythema Dose determined during screening)
46093228|NCT04157868|Drug|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
46006712|NCT04588415|Other|Bereavement Virtual Support Group|"Family members who experience loss will be invited to attend a virtual support group (VSG) led by Bereaved Families of Ontario- Ottawa (BFO). In pre-COVID-19 times, BFO presented monthly Support and Share nights with guest speakers, followed by breakout peer support groups for all different types of losses: loss of child, spouse, parent, loss by suicide, etc. These groups are facilitated by trained volunteers with a shared loss and include between 75 and 150 participants. These Support and Share Nights serve as intake sessions- interested participants from the breakout groups can attend Closed Groups where a smaller group of participants (up to 12) explore their grief more deeply. These run over 8-10 consecutive weeks with the same group of participants. They are led by trained facilitators who have experienced similar losses. Each week has a different theme, based on evidence-based components of bereavement support (e.g. writing a letter to the deceased)."
46093229|NCT04157868|Drug|Control|Saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.
46006713|NCT04594044|Behavioral|tics training including habit reversal training and exposure response prevention|In an open randomized controlled study, youth were randomized to either individualized, or group treatment. Both therapies included nine sessions, and the parents were offered one group-session.
45459709|NCT03396692|Procedure|Block of the posterior exo-thoracic fascia with Ropivacaine|"Group 2 PEF block:~Establishment of PCA morphine:~concentration 1mg / ml~1ml bolus~refractory period of 7 minutes~no maximum dose per day.~Realization of a block of the posterior exo-thoracic fascia (PEF block) at the median level of ribs fractures with ropivacaine 5mg / mL, 3 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of ropivacaine bolus 2mg / ml at 0.1ml/kg every 4 hours. Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia."
45678412|NCT04414605|Drug|Gu Ben Hua Yu Fang decoction (Chinese herbal medicine)|Chinese herbal formula (Gu Ben Hua Yu Fang) decoction will be orally administrated twice daily. One pack of Gu Ben Hua Yu Fang will be taken for each time. Chinese herbal medicine (Gu Ben Hua Yu Fang) will not be used on the day of receiving secukinumab injection.
45678413|NCT04414605|Drug|Secukinumab Auto-Injector [Cosentyx]|Secukinumab will be administered by subcutaneous injection. The required dose (300 mg) is divided into two doses of 150 mg (contained in two separate syringes), which are injected at the same time. The first five doses (each consisting of 2 injections of 150 mg) are given at weekly intervals, with subsequent treatment given monthly (2 injections of 150 mg).
45678414|NCT01609257|Biological|Norovirus Bivalent Vaccine|2 doses IM 28 days apart
45678415|NCT01609257|Biological|Saline Comparator|2 doses IM 28 days apart
46093230|NCT02668172|Drug|Pasireotide LAR 60 mg|as mono-therapy or in combination with pegvisomant
46093231|NCT02668172|Drug|Pegvisomant|only in combination with pasireotide LAR
46093232|NCT04844671|Device|da Vinci Surgical Systems|The da Vinci Surgical Systems enable surgeons to perform delicate and complex operations through a few small incisions with robotic assisted surgery.
46093233|NCT02790749|Procedure|Adjunctive hip arthroscopy to accompany PAO|This is the experimental group: those patients who undergo adjunctive hip arthroscopy in addition to periacetabular osteotomy (PAO).
45678416|NCT04569357|Drug|Prospecta|Oral administration.
46093234|NCT02790749|Procedure|PAO without adjunctive hip arthroscopy|This is the control group: those patients who undergo periacetabular osteotomy (PAO) alone, without adjunctive hip arthroscopy.
46093235|NCT04175132|Drug|foliglurax|Capsules of 20/80 mg foliglurax, orally. Single doses of 20-240 mg
46093236|NCT04175132|Drug|foliglurax|Capsules of 20/80 mg foliglurax, orally. Single doses of 20-160 mg
46093237|NCT04157946|Diagnostic Test|CT|"Patients with ARDS were included. We excluded patients with emphysema, asthma, pneumothorax, or serious conditions of instability: oxygen saturation ≤ 88%; severe shock, ventricular arrhythmia, or myocardial ischemia.~To allow comparison between groups, patients were ventilated in volume control under similar conditions of tidal volume (TV; 6 ml/kg-PBW), plateau pressure (PPlat 30 cmH2O), respiratory rate (18 bit/min) and constant flow. PEEP was adjusted to reach objective PPlat.~Transpulmonary pressures (TP) were measured and a chest CT scan performed during an expiratory and inspiratory pause. Global and regional volumes of lungs were measured using specific software (Volume Analysis Software,Toshiba, Japan). Three regions were identified: basal (from the diaphragm to the carina), middle (from the carina to the aortic arch) and apical (above the aortic arch)."
46006714|NCT04588493|Diagnostic Test|Lower extremity Lymphoscintigraphy|Study of lymphoscintigraphy (LCG) abnormalities in a group of patients with history of infiltration of modeling substances in buttocks and hips and complain about lower extremities edema. LCG was performed and evaluated by a single nuclear medicine specialist through injection of the sulfur nanocolloid Technetium 99m, injected intradermal and interdigital in bilateral toes. Dynamic studies were requested for all patients. Standardized acquisition times at 15, 30, 60 and 120 minutes after injection were taken. The following parameters were considered to obtain the transport index in each pelvic limb: transport kinematics, distribution pattern, index time for the appearance of regional lymph nodes, number and collection of colloids in lymph nodes and presence and quality of the colloid uptake by the lymphatic vessels. Summation of these five components resulted in the transport index, which could range from 0 to 45 points
46006715|NCT04577430|Drug|Dexmedetomidine|The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
46006716|NCT04577430|Drug|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
45459710|NCT03396692|Procedure|Block of paravertebral space with Ropivacaine|"Group 3 paravertebral block:~Establishment of PCA morphine:~concentration 1mg / ml~1ml bolus~refractory period of 7 minutes~no maximum dose per day.~Realization of a paravertebral block (BPV) at the median level of ribs fractures ropivacaine 5mg / mL, (0.3ml / kg) 1.5 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of bolus of ropivacaine 2mg / ml at 0.1ml / kg every 4 hours.~Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia.~In the case of failure of initial management with significant pain despite the iterative boli, epidural analgesia is used in recourse."
45459711|NCT04908904|Dietary Supplement|Cafestol|Capsule with 12 mg cafestol
45459712|NCT04908904|Dietary Supplement|Placebo|Placebo capsule without cafestol
45678417|NCT04569357|Drug|Placebo|Oral administration.
45459713|NCT05198336|Biological|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
45459714|NCT03476746|Drug|LEO 90100 foam|A foam formulation of the active comparator Dovobet® ointment
45459715|NCT03476746|Drug|Dovobet® ointment|Ointment formulation containing same active ingredients as LEO 90100 foam
45678418|NCT01609023|Drug|Rituximab|Rituximab will be administered in combination with chemotherapy according to SPC and routine clinical practice.
46006717|NCT04577430|Drug|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 1 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
46006718|NCT04577430|Drug|Normal saline|Normal saline is used to observe the effect on the electrophysiology of the patients' hearts
46006719|NCT00567788|Drug|Latanoprost-Bimatoprost|latanoprost 0.005% once daily followed by bimatoprost 0.03%
46006720|NCT00567788|Drug|Bimatoporost-Latanoprost|bimatoprost 0.03% once daily followed by latanoprost 0.005%
46093238|NCT04805047|Behavioral|education and monitoring|regular education programs supported by a dietician in combination with urine sodium monitoring as a feedback
46093239|NCT04175288|Other|Ultrasound, manual therapy and exercise|The experimental group will receive ultrasound (US) for 3 sessions a week for 4 weeks, with continuous US (1.8 w/cm2, 1 Mega Hz 8 minutes). Manual therapy will include posterior glides to talocrural joint, subtalar lateral glide, a 1st tarsometatarsal joint dorsal glide and extension mobilization to the 1st metatarsophalangeal joint. All participants in each group will be given specific exercises by the investgators targeting intrinsic and extrinsic muscles of the foot and ankle. Specific stretches for the plantar fascia and Achilles tendon, will be performed. Home exercises will be recorded using a log.
46093240|NCT00660270|Procedure|Pancreatic Surgery|
46006721|NCT04588766|Other|constipation group|Constipation symptoms of individuals with cerebral palsy who were randomly evaluated were questioned and recorded according to Rome IV criteria. The group with cerebral palsy constipation was included in this group.
46093241|NCT00660270|Radiation|Radiation therapy|
46093242|NCT00660270|Drug|Cisplatin|
45840162|NCT00659802|Drug|Placebo|Matching dose of Placebo
45840163|NCT00659802|Drug|HMPL-004 high dose|HMPL-004, 600 mg (3 x 200 mg) t.i.d. (total of 1800 mg/day).
46093243|NCT00660270|Drug|5-FU|
46093244|NCT00660270|Drug|Alpha-interferon|
46093245|NCT00660270|Drug|Gemcitabine|
45840164|NCT00660504|Drug|Amrubicin Hydrochloride|Amrubicin Hydrochloride combined with cisplatin
46093246|NCT02790593|Device|Juxta-Cures™|Juxta-CURES™ is an adjustable compression device, which may be used as a secondary dressing for the treatment of open venous stasis ulcers. It is an inelastic wrap around device with a Built-In-Pressure System™, which allows patients to easily and accurately apply pressure to their own leg and adjust it throughout the day.
46093247|NCT02790593|Device|Standard Compression|Compression bandaging
46093248|NCT02790593|Device|PicoPress®|Pressure monitoring to be done at time of bandage application and removal for both arms of the study.
46093249|NCT02790593|Device|Silhoutte® 3D wound imaging system|Photographic imaging system to measure wound surface area and depth. Picture to be taken at each appointment. This intervention is for both arms of the study.
46093250|NCT02666924|Dietary Supplement|Chinese-canadian specific cooking classes|Series of four, four-hour cooking classes, occurring monthly for four months. Each of the cooking classes in the series will have diabetes self-management learning objectives: food choices, meal planning and preparation, portion control, self-monitoring of blood glucose levels and physical activity.
45459716|NCT03633266|Procedure|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
45459717|NCT03633266|Procedure|PRP|vitreoretinal surgery combined with intraoperative PRP
45840165|NCT00660504|Drug|Etoposide-Cisplatin combined chemotherapy|combined chemotherapy
45840166|NCT00661674|Drug|Palonosetron|"Over 3 study visits, patients will receive one of the following treatment regimens:~Placebo saline IV and sugar pill~0.75 mg Palonosetron IV and sugar pill~0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
46006722|NCT04588766|Other|control group|Constipation symptoms of individuals with cerebral palsy who were evaluated randomly were questioned and recorded according to Rome IV criteria. The group with cerebral palsy without constipation was included in this group.
46006723|NCT00581607|Drug|Bosentan|62.5 mg bid for 4 weeks, then 125 mg bid
46006724|NCT00581607|Drug|Placebo|Placebo twice a day
46006725|NCT00581607|Drug|Bosentan|drug given for 16 weeks
46006726|NCT00581607|Drug|Placebo|placebo
46093251|NCT02666924|Other|Diabetes educational classes|Series of two, four-hour diabetes education classes, occurring weekly for two weeks. Each class is run by a registered dietitian and nurse, trained as clinical diabetes educators, as per standards of the canadian diabetes association. Classes include focused teaching of the background of diabetes, dietary recommendations for diabetes, lifestyle recommendations for diabetes, medications for diabetes, and general standard of living recommended for diabetes mellitus type 2.
46093252|NCT00967915|Procedure|Frentomy|Frenotomy will be performed. This procedure involves crushing frenulum tissue with straight hemostat for hemostasis and anesthesia while tongue is elevated with elevator. Frenulum then cut to desired length with iris scissors. Patient then returned to parents and immediately breastfeeds without parent observing infant's mouth.
46093253|NCT00967915|Other|Sham procedure|Infant taken into room away from parents and no frenotomy performed. Infant's mouth is examined but no interventions made.
46093254|NCT04032132|Drug|curcumin paste|curcumin is a herb used for medical purpose
46093255|NCT04032132|Procedure|curettage|open flab debridement surgery
46093256|NCT05342675|Procedure|Rapid Rollover|Repositioning of the participant post biopsy
46093257|NCT02668250|Procedure|OPTI-AGED|OPTI-AGED is composed of a multi-parametric optimization strategy.
46093258|NCT02668250|Procedure|Usual Care|Patients receive the usual care.
46093259|NCT00967057|Drug|asparaginase|Given intramuscularly
46093260|NCT00967057|Drug|dexamethasone|Given orally
46093261|NCT00967057|Drug|idarubicin|Given IV
46093262|NCT00967057|Drug|methotrexate|Given intrathecally
46093263|NCT00967057|Drug|mitoxantrone hydrochloride|Given IV
46093264|NCT00967057|Drug|pegaspargase|Given intramuscularly
46093265|NCT00967057|Drug|vincristine sulfate|Given IV
46093266|NCT02633514|Drug|Cisplatin|25mg/m2,iv gtt,d1-3
46093267|NCT02633514|Drug|Etoposide|75mg/m2,iv gtt,d1-3
45840167|NCT00661674|Drug|Hydroxyzine|"Over 3 study visits, patients will receive one of the following treatment regimens:~Placebo saline IV and sugar pill~0.75 mg Palonosetron IV and sugar pill~0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
46093268|NCT02633514|Radiation|radiotherapy|60Gy/30Fx
46093269|NCT04074902|Device|Ultrasonography|Mindray dp1100 plus.
46093270|NCT00656214|Drug|Lycopene|08 mg/day in two divided dosage
46093271|NCT00656214|Drug|Placebo|Two divided dosage
46093272|NCT02790671|Drug|DS-8500a|DS-8500a 25mg tablet
46093273|NCT02790671|Drug|Itraconazole|200mg itraconazole
46093274|NCT02668094|Drug|Lidocaine|
46093275|NCT02668094|Drug|Pregabalin|
46093276|NCT02668094|Drug|propofol|
46093277|NCT02785523|Drug|Ganoderma Spore Lipids|
46093278|NCT02785523|Drug|Placebo|
46093279|NCT02785523|Drug|Chemotherapy|
46093280|NCT00967135|Drug|Pregabalin|150 mg oral dose of pregabalin twice daily for 5 consecutive days.
46093281|NCT00967135|Drug|Placebo|Matching oral placebo twice daily for 5 consecutive days.
46093282|NCT02632968|Procedure|Pinhole surgery with and without buttons|
46093283|NCT02666768|Drug|Interferon gamma-1b|gamma interferon-1b dose escalation over first 4 weeks of study to 100 mcg SC 3 times weekly
46093284|NCT00967213|Drug|ranibizumab|Lucentis® (ranibizumab) 0.3mg (0.05ml volume) intravitreal injection. Eligible patients will be initially received three session of monthly injection of Lucentis® (week 0, 4, 8). After 4 weeks from third injection, a session of verteporfin PDT (week 12) and fourth injection of Lucentis® (week 16) will be added at intervals of 4 weeks. Two more combined treatment with verteporfin PDT and Lucentis® injection 4 weeks apart can be added at the treating physician's discretion in 3-month intervals (week 28, week 40).
46093285|NCT04160676|Drug|Hydrocortisone, Ascorbic acid, Thiamine|Combination of hydrocortisone, ascorbic acid, and thiamine
46093286|NCT04160676|Drug|Normal saline|Normal saline
46093287|NCT04175054|Other|Body-weight supported treadmill training in a room cooled to 16°C|Exercise will be performed on a treadmill using an overhead harness for safety in a temperature controlled-room at 16°C with 1:1 supervision. The high intensity group will maintain vigorous intensity with a target workload >60% of heart rate reserve for 30 min (plus 5min warm up and 5min cool down) while the low-intensity group will walk at mild intensity (<40% heart rate reserve) for the same duration. Heart rate, blood pressure, and rating of perceived exertion will be recorded throughout to monitor for potential adverse events and to ensure that target training zone heart rates are maintained. The intervention is 3 times per week for 12 weeks, with a 3-month run-in observational period to confirm disease stability, and 3-month follow-up to determine the sustainability of effects.
46093288|NCT02786225|Behavioral|Collaborative Care|Intervention Group: Women (n=118) will be seen one time, simultaneously by a VUMC perinatologist and a VUSN nurse-midwife (the CARE visit). During the CARE visit, the nurse-midwife and perinatologist will complete the CARE checklist The checklist will be signed by the woman and providers and scanned into the medical record. Following the CARE visit, women will return to midwifery care or be referred to perinatology depending on their needs, remaining in the study. Women returning to the midwifery practice will see a primary midwife for the remainder of care.
46093289|NCT02786225|Behavioral|Comparison Care- Usual Care + primary midwife|Comparison Group: Usual care enhanced with primary midwife. Women in the comparison group (n=118) will receive the standard individual consult visit with a perinatologist and then, if they return to midwifery care, have one consistent midwife (primary midwife) for the majority of remaining prenatal care.
46093290|NCT00660426|Drug|Oxaliplatin|
46093291|NCT00660426|Drug|Gemcitabine|
46093292|NCT00660426|Drug|Capecitabine|
46093293|NCT00967291|Drug|ifosfamide|2,500 mg/mq on days 1-3 every 28 days
46093294|NCT00967291|Drug|mitomycin C|8 mg/mq on day 1 every 28 days
46093295|NCT00645398|Drug|Pregabalin|Pregabalin 225 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
46093296|NCT00645398|Drug|Pregabalin|Pregabalin 150 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
46006727|NCT04588571|Procedure|Endovascular recanalization with angioplasty and stenting with the biomimetic interwoven nitinol stent|"Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion.~Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (100 mg per day) for a long time and clopidogrel (75 mg per day) for 3 months."
46006728|NCT04588571|Procedure|Femoropopliteal proximal bypass|"Under general anesthesia, 2 standard open surgical approaches are performed: first - to the common femoral artery, superficial femoral artery, and deep femoral artery; the second - to the first portion of the popliteal artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the shunt. Next, the shunt is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Surgical hemostasis wound drainage and layer-by-layer wound closure are performed.~Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (75-100 mg per day) for a long time."
46093297|NCT00645398|Drug|Pregabalin|Pregabalin 300 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
46093298|NCT00645398|Drug|Placebo|Matching placebo capsules taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
46093299|NCT02786303|Device|Whole-body diffusion- weighted MRI|
46006729|NCT04594122|Behavioral|Improve hygiene practice of pork sellers|includes 5 keys actions (Handbook) and provision of equipment incentive and training on good hygiene practices, branding, and certification
46006730|NCT00581646|Behavioral|survey instrument|Participants will be mailed or given a one time survey instrument and data will be collected either in person or by telephone. We expect the study survey to take approximately 35-45 minutes to complete. The domains assessed will include psychological functioning, reproductive knowledge, perception of third party reproduction and concerns, sexual functioning, and quality of life.
46006731|NCT04588376|Behavioral|Peer comparison feedback monthly|Monthly emailed data on performance for guideline-concordant use of antibiotics for three acute upper respiratory tract infections either at the clinician and clinic levels or at the clinic level only
46006732|NCT00581685|Drug|Pregabalin, Celecoxib|Pregabalin (75mg BID) and Celecoxib(100mg BID) two weeks prior to hip arthroplasty and 3 weeks postoperatively.
46006733|NCT04588220|Other|Obstetric ultrasound and fetal-maternal assessment|melatonin, soluble urokinase-type plasminogen activator receptor, and orosomucoid 2 measurements
46006734|NCT00581724|Behavioral|Telephone interview or self report survey.|We estimate that the completion time for the telephone interview or self-report survey will be 45-60 minutes.
46093300|NCT04197791|Device|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation(NMES) to core stabilization muscles will be applied using 8 electrodes. The application time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
46093301|NCT04197791|Other|Core Stabilization Exercises|Warm-up and cool-down exercises will be performed before and after core stabilization exercises. The exercise time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
46093302|NCT00884832|Drug|Clonidine|Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.
46093303|NCT00884832|Drug|Placebo|Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
46093304|NCT05299645|Behavioral|Interview|Pilot study with digital browsers
46093305|NCT02665130|Other|Tai-chi plus Indacaterol|Participants perform Tai-chi exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
46093306|NCT02665130|Other|Pulmonary rehabilitation plus Indacaterol|Participants perform conventional exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
46093307|NCT04232345|Drug|AZD4831|Subjects will be fasted for at least 10 hours before receiving the AZD4831 in the form of an oral suspension.
46093308|NCT04232345|Drug|Placebo|Subjects will be fasted for at least 10 hours before receiving the placebo in the form of an oral suspension.
46093309|NCT04681807|Behavioral|Emotion Recognition Training|Participants will undergo 2 fMRI scans, one before and one after the training sessions. There will be 4 visits consisting of an emotion recognition training exercise on iPad, lasting for a period of ~1 hour each. (More details about each condition will be added after study completion to protect the blinding of participants) .
46006735|NCT04588181|Behavioral|cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT) is a psycho-social intervention that aims to improve mental health. CBT focuses on challenging and changing unhelpful cognitive distortions (e.g. thoughts, beliefs, and attitudes) and behaviors, improving emotional regulation, and the development of personal coping strategies that target solving current problems.
46093310|NCT04681807|Behavioral|Active Control Training|Participants will undergo 2 fMRI scans, one before and one after the training sessions. There will be 4 visits consisting of a control training exercise on iPad, lasting for a period of ~1 hour each. (More details about each condition will be added after study completion to protect the blinding of participants) .
46006736|NCT00566787|Device|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
46093311|NCT00660582|Drug|Cetuximab (Erbitux)|500 mg/m² every second week, intravenous infusion, 8 cycles
46093312|NCT00660582|Drug|Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid|Given in combination day 1 and 2, every second week, 8 cycles
46093313|NCT00646724|Biological|cotransplantation of islet and mesenchymal stem cell|islet of allograft and MSCs of autograft
46093314|NCT00967525|Procedure|cord blood infusion|Receive two cord blood units. One administered by intraosseous infusion and the other by intravenous infusion. The second unit is being given as a safeguard, but will also allow the researchers to directly compare engraftment between intravenously and intraosseously infused cord blood units.
45459718|NCT03483610|Behavioral|Provider Referral|Participants will be asked if they are up-to-date on their cervical cancer screening. If not they will be referred to a provider. At the end of the study they will receive a 10 minute follow up telephone survey to collect data screening status and views on cervical cancer screening.
45459719|NCT03483610|Behavioral|Text Messaging|Participants will be asked if they are up-to-date on their cervical cancer screening. If not they will be referred to a provider. They will also receive a total of 3 text messages at 30-day intervals encouraging follow-up for cervical cancer screening. They will receive a 10 minute follow up telephone survey to collect data screening status and views on cervical cancer screening.
45459720|NCT04796948|Drug|Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)|irinotecan liposome in combination with oxaliplatin and 5-FU/LV
46006737|NCT04588064|Diagnostic Test|68Ga-FAPI PET/CT scan|Each subject receives a single intravenous injection of 68Ga-FAPI, and undergo PET/CT imaging within the specified time.
46006738|NCT00566826|Behavioral|Patient support sessions|Patient support sessions aim to enhance patient self-care for independent exercise and physical activity.
46093315|NCT04157712|Drug|ALZ-801 or matching placebo|
46093316|NCT00646802|Drug|Progesterone|1 vaginal capsule, 200 mg, once daily since gestation age 36 weeks and 6 days
46093317|NCT00646802|Drug|Placebo|1 vaginal capsule, once daily since gestational age of 36 weeks and 6 days
46093318|NCT00968383|Drug|Beta adrenergic blockers|Participants will receive beta adrenergic blockers.
46093319|NCT00968383|Drug|Platelet inhibitors|Participants will receive platelet inhibitors.
46093320|NCT00968383|Drug|Statins|Participants will receive statins.
46093321|NCT00968383|Drug|ACE inhibitors and/or ARB and/or AA|Participants will receive ACE inhibitors and/or ARB and/or AA
46093322|NCT00968383|Procedure|PCI with stenting|Participants will undergo percutaneous coronary intervention (PCI) and coronary stenting.
45459721|NCT03480958|Device|Intravenous morphine patient controlled device|24 hour morphine consumption will be recorded
45459722|NCT03480958|Other|Erector Spinae Plane Block|erector spinae plane block will be administered before the surgery
45459723|NCT03480958|Other|Thoracic Paravertebral Block|thoracic paravertebral block will be administered before the surgery
46006739|NCT00566826|Behavioral|Treatment as usual|Treatment as usual includes standard care for TKR surgery rehabilitation.
46006740|NCT04587986|Device|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
46006741|NCT04587401|Procedure|normotensive patients|patients who do not have high blood pressure diagnosis and actual blood pressure is within the normal range
45459724|NCT03476668|Other|MIRT|4-week multidisciplinary intensive rehabilitation treatment
45459725|NCT05759234|Drug|HS248 pieces|The overall safety and tolerability of PI3Kγ inhibitor monotherapy for solid tumors is good, and it has shown preliminary clinical benefits. The safety of PI3Kγ inhibitor combined with immune checkpoint inhibitor is good, and the efficacy of single drug is significantly improved. Based on the evaluation of the safety and efficacy results of HS248 preclinical and clinical studies of similar PI3Kγ inhibitors, the benefits of this product outweigh the risks for patients with advanced solid tumors who have progressed through standard treatment, have toxicity intolerance, or have no standard treatment regimen. Sufficient to support planned clinical studies.
46006742|NCT04587401|Procedure|patients with hypertension diagnosis|Patients who have high blood pressure diagnosis
46006743|NCT04587401|Procedure|patients who do not know they are hypertensive but actual blood pressure is high|patients with preoperative high blood pressure, who do not know they are hypertensive
46006744|NCT04587557|Behavioral|Storytelling with social contextual information|Four out of 100 stories from a storytelling app (SAHK, 2013) that incorporated social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.
46006745|NCT04587557|Behavioral|Storytelling without social contextual information|Four out of 100 stories from a storytelling app (SAHK, 2013) without social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.
46006746|NCT04587557|Other|Children with ASD|Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with ASD.
46006747|NCT04587557|Other|Children with TD|Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with TD.
46006748|NCT00581841|Other|Gait analysis, knee x-ray, and knee MRI|Gait analysis, knee x-rays, and knee MRIs will be done twice for each participant, 1 week apart.
46093323|NCT00657228|Drug|Intravenous heparin|"Intravenous heparin as an adjunct for the treatment of anaphylactic/anaphylactoid reactions in the Emergency Department.~To determine if a single bolus of intravenous unfractionated heparin (in conjunction with standard therapy) given to patients with anaphylactic/anaphylactoid reactions results in a faster time to recovery when compared to standard therapy alone."
46093324|NCT00657228|Drug|Saline|Standard treatment (epinephrine, corticosteroids, diphenhydramine, and H2 blockers) and saline.
46093325|NCT02666534|Drug|lidocaine-prilocaine 5% cream application|The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
46093326|NCT02666534|Device|2940-nm Er:YAG AFL pretreatment|After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
46093327|NCT02666534|Drug|methyl-aminolevulinate application|Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
45836638|NCT01794624|Behavioral|Behavioral Therapy for Sleep Continuity Disturbance|Behavioral Therapy for Sleep Continuity Disturbance (BT-SCD) will involve 6-sessions of standardized interventions on sleep restriction therapy (SRT), stimulus control therapy (SCT), and sleep hygiene education. Sleep Restriction curtails the amount of time in bed so that it matches the average baseline amount of total sleep time. Stimulus Control Therapy re-establishes the bed and bedroom as cues for sleep by insuring the patient does not spend significant time in bed awake and/or engaging in sleep-incompatible behaviors. Sleep Hygiene Education uses motivational interviewing to teach subjects about environmental and behavioral factors which may influence sleep. SRT and SCT alone or combined have demonstrated overwhelming efficacy and effectiveness.
46093328|NCT02666534|Device|Illuminating using red light-emitting diode lamps|Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
46006749|NCT04587362|Diagnostic Test|Musculoskeletal Ultrasound|High quality ultrasound scanners and high-resolution transducers, will be used to scan 16 joints sites for each subject. Ultrasound had excellent spatial resolution, making it an highly efficient, non-invasive tool for the assessment on enthesitis, which is an early feature of psoriatic arthritis. It is an affordable and accessible tool that is widely used in rheumatology practice.
46006750|NCT04594317|Device|low level laser therapy|buccal application of diode laser on non-contact mode
46093329|NCT02787473|Drug|pemetrexed|Pemetrexed 500mg/m2 IV on day 1 every 4 weeks for 2 cycles
46093330|NCT02787473|Drug|cisplatin|Cisplatin 25mg/m2 IV on day 1-3 every 4 weeks for 2 cycles
46093331|NCT02787473|Radiation|thoracic radiation therapy|Chemoradiotherapy, radiation 60Gy with 2 cycles of pemetrexed+ carboplatin/cisplatin
46093332|NCT02787473|Drug|docetaxel|Docetaxel 60 mg/m2 IV on day 57 every 3 weeks for 2 cycles
46093333|NCT00657306|Drug|hydrocortisone|50 mg/6 h per day
46093334|NCT00657306|Drug|dextrose solution 5%|dextrose solution 5% 100 ml/6 h per day
46093335|NCT00967603|Drug|sunitinib|oral sunitinib 37.5 mg daily
46093336|NCT02665442|Device|Esophageal Stylet - EsoSure|The Esophageal Stylet is a thin rigid tube, which will be inserted inside a commonly used nasogastric tube placed inside the esophagus during the ablation. We will use this stylet to move the esophagus away from the site of the ablation about 1-2 centimeters.
46006751|NCT04587596|Other|Pain education|70 minute lecture about chronic pain and one focus group afterwards
45836639|NCT00316524|Biological|MVA-BN® (IMVAMUNE)|1x 10E8_TCID50
46006752|NCT04587713|Drug|TD-1473 [Tablet A]|TD-1473 [Tablet A] (1 Tablet = Dose A) proposed commercial tablet formulation
46093337|NCT02785679|Dietary Supplement|cow's milk formula|addition of cow's milk formula in two different dosage - one only 20ml per day and one group a full meal per day
46093338|NCT00657384|Drug|acid tranexamic|10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention.
46093339|NCT00657384|Drug|Nacl 0.9%|10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention
46093340|NCT00973453|Drug|PURETHAL Mites 20,000 AUeq/ml|"Group 1: slow regimen (12+2 injections) Initial treatment: incremental weekly dose of 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1.0, 1.2*, 1.6* and 2.0* ml Additional maintenance: 2 two-weekly injections 2.0* ml~*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
45836640|NCT00316524|Biological|Placebo|Tris-Buffer
46093341|NCT00973453|Drug|PURETHAL Mites 20,000 AUeq/ml|"Group 2: intermediate regimen (9+2 injections) Initial treatment: incremental weekly dose of 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2*, 1.6* and 2.0* ml.~Additional maintenance: 2 two-weekly injections 2.0* ml~*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
46093342|NCT00973453|Drug|PURETHAL Mites 20,000 AUeq/ml|"Group 3: fast initial treatment (6+2 injections) Initial treatment: incremental weekly dose of 0.2, 0.4, 0.8, 1.2*, 1.6* and 2.0*ml.~Additional maintenance: 2 two-weekly injections 2.0* ml~*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
45836641|NCT02994498|Drug|DCB-BO1301|1, 2, or 3 capsules, three times a day, oral, at most 48 weeks
46006753|NCT04587713|Drug|TD-1473 [Tablet B]|TD-1473 [Tablet B] (2 Tablets = Dose A) current clinical tablet formulation
46006754|NCT04587011|Drug|Tegoprazan dose A or placebo|Tegoprazan A mg or placebo taken orally twice daily for 3 days.
46006755|NCT04587011|Drug|Tegoprazan dose B or placebo|Tegoprazan B mg or placebo taken orally twice daily for 3 days.
46093343|NCT00646880|Drug|propiverine|Two week washout period followed by propiverine 20 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to tolterodine PR 4 mg capsule daily for 1 week.
46093344|NCT00646880|Drug|tolterodine PR|Two week washout period followed by tolterodine PR 4 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to propiverine 20 mg capsule daily for 1 week.
46093345|NCT04232111|Device|Heat|Heat applied to hand
46093346|NCT04232111|Device|Vacuum|vacuum applied to hand
46006756|NCT04587011|Drug|Tegoprazan dose C or placebo|Tegoprazan C mg or placebo taken orally twice daily for 3 days.
46006757|NCT04587011|Drug|Tegoprazan dose D or placebo|Tegoprazan D mg or placebo taken orally twice daily for 3 days.
46093347|NCT04232111|Device|sham|neither heat nor vacuum
46093348|NCT04163250|Diagnostic Test|Urinary determination of TIMP-2/ IGFBP7|"Urinary determination of TIMP2-IGFBP7 in the an urine sample obtained within 12 hours prior to contrast administration. A single determination will be made, which will be sent to the laboratory. The doctor who treats the patient will not know the result of the test, and the treatment will not be influenced by the result.~According to the manufacturer, 10 ml of fresh urine should be collected in a sterile container and the laboratory should centrifuge them within the time of collection.~The result is reported as a single value calculated as the concentration of TIMP-2 (ng / mL) multiplied by the concentration of IGFBP7 (ng / mL) divided by 1000. The result is reported without units."
46006758|NCT04587206|Drug|CKD-348|QD, PO
46093349|NCT04064437|Diagnostic Test|Clinical tests|The investigators perform the following clinical tests: vibration threshold test, monofilament test, and height, weight and waist circumference measurement in every participant.
46093350|NCT04064437|Diagnostic Test|Clinical tests|The investigators perform the following clinical tests: height, weight and waist circumference measurement in every participant.
46093351|NCT04064437|Diagnostic Test|Biochemical tests|The investigators perform blood and urine tests in every participant.
45459726|NCT03480880|Device|Bispectral Index|Thiopentone was administered in 50 mg boluses during induction of anaesthesia, until reduction of Bispectral Index value to less than 50, and total dose of thiopentone recorded.
46093352|NCT04064437|Diagnostic Test|DXA scan|The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) in every participant.
46093353|NCT04064437|Diagnostic Test|AGE Reader|The investigators perform a skin AGE (advanced glycation end products) measurement with the AGE Reader machine in every participant.
46093354|NCT04033016|Behavioral|motivational interviewing|Motivational interviewing (MI) is a contemporary form of advisory support, which is often used for behavioral change. During the motivational interviewing educated health professional leads the counseling session by asking questions on lifestyle, attitude towards the behavioral change, and factors pro and against the change. During the MI the focus is on the patient/ client, his/her own perception of their health, understanding the reasons for current behavioral patterns, and encouragement to assess these patterns.
46093355|NCT04033016|Behavioral|online social media intervention|Facebook group was specially designed for purposes of intervention and was administered by the research team. It was used to motivate the participants to be more physically active. The intervention used hybrid approach, with health promotion campaign with motivational messages and pictures, journal articles, questions with the aim to spark a discussion on barriers or possibilities for physical activity and participatory approach (all members were allowed to post motivational messages or questions for their peers).
46093356|NCT02787395|Procedure|shoulder dislocation self reduction|shoulder dislocation self reduction using one of three methods in the study
46093357|NCT04157244|Behavioral|Tailored music listening intervention|The music intervention consists of listening to preferred soothing music at bedtime for 30 minutes every night for four weeks (28 sessions total). This theory based caregiver-assisted intervention builds on the evidence-based protocol of using individualized music to decrease agitation in nursing home residents. It also accounts for sleep-inducing properties of music.
45459727|NCT03495102|Drug|Dulaglutide|Administered SC
45459728|NCT04859608|Drug|Spacing of Eculizumab infusions|Personalized spacing of eculizumab infusions using a pharmacokinetic population model to estimate eculizumab concentration ( a one-week spacing of eculizumab infusion will be decide if predicted eculizumab concentration in the event of spacing is > 150 mg/L). Spacing of infusion can be decided every 3 months.
45459729|NCT03105362|Dietary Supplement|Enterade® oral rehydration solution|Commercially available amino acid based oral rehydration solution
45459730|NCT05120986|Other|IND/GLY/MF|Prospective observational cohort study. There is no treatment allocation. Patients will be invited to participate in the study when attending participating community pharmacies with a first prescription of IND/GLY/MF with sensor or IND/GLY/MF without sensor
45459731|NCT04754386|Behavioral|Acceptability of OraQuick Advance© Rapid HIV-1/2 Antibody screening Oral fluid-based HIV test|The project offers HIV oral test kits to index parents/caregivers with children eligible for index testing services at facility settings to expand access to HIV testing and treatment services for children, and to ensure that all children who screen positive with an oral fluid-based HIV screening kit are linked to confirmatory testing, and newly diagnosed children are initiated on ART.
45836642|NCT00317226|Drug|Ferric Carboxymaltose (FCM)|maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
46006759|NCT04587206|Drug|CKD-828, D097, D337|QD, PO
46006760|NCT00581880|Behavioral|questionnaires|A battery of questionnaires concerning your thoughts, opinions, and attitudes about your illness and outlook on life. In addition, we will ask to provide some background information about you and your illness. The questions will take approximately 30 to 45 minutes to complete. You fill out the questionnaire once only.
46006761|NCT00581958|Other|Blood Samples|blood (approximately two 4 ml; equivalent to less than 2 tablespoon) and urine (a cup of urine) samples or testing a total of three times. Blood will be drawn and urine will be collected once before radiation treatment and twice after first radiation treatment.
46006762|NCT04586816|Combination Product|1% red maple leaf extract in cream base|1% red maple leaf extract is combined in a cream base
46006763|NCT04586816|Combination Product|5% red maple leaf extract|5% red maple leaf extract is combined in a cream base
46006764|NCT04586816|Combination Product|vehicle|vehicle cream base only
45459732|NCT04762238|Other|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
45459733|NCT03483532|Dietary Supplement|Lit Control pH Up|dietary supplement based on citrate, saponins, magnesium, zinc and vitamin A
45836643|NCT05288010|Combination Product|Cannabis|The provision of whole flower cannabis via an inhalation device in addition to standard of care chronic pain treatment.
46093358|NCT00973531|Device|Autotitrating Positive Airway Pressure (APAP)|Then subjects will use Autotitrating Positive Airway Pressure machine for 90 days
46093359|NCT00973531|Device|Traditional Split Titration Polysomnogram|Then subjects will use Continuous Positive Airway Pressure (CPAP) machine for 90 days
45459734|NCT03483532|Dietary Supplement|dry cocoa extract|(Theobroma cacao, fruit), 2 capsules of 750 mg per individual, dosed at a rate of one during the breakfast and another during dinner.
45459735|NCT05198180|Drug|Topical 30%Potassium hydroxide solution|Patients will apply the solution every day under occlusion for 3 months
45459736|NCT05198180|Drug|Topical 45% hydrogen peroxide solution|Patients will apply the solution every day under occlusion
45459737|NCT04724564|Diagnostic Test|THE SURGICAL PLETH INDEX|CORRELATION OF DIFFERENT TIME MEASUREMENTS OF THE SURGICAL PLETH INDEX WITH POSTOPERATIVE PAIN
45459738|NCT03483454|Other|Exercise class|Same as above.
45459739|NCT03483454|Other|Home exercise|Same as above.
45459740|NCT03639402|Behavioral|Health education classes|Community empowerment through involvement of local mothers (peer mothers) for dissemination of education regarding health diet and physical activity to others eligible mothers in the community (fellow mothers).
45459741|NCT03253172|Dietary Supplement|Potassium Chloride|Two potassium supplements with varying anions.
45459742|NCT03253172|Dietary Supplement|Potassium Citrate|Potassium Citrate
45459743|NCT03253172|Dietary Supplement|Placebo|Placebo
45836644|NCT01793298|Drug|ASM-024|Ascending doses of ASM-024
45836645|NCT02973126|Procedure|FFRct and SPECT|enable the comparison of diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD after abnormal SPECT imaging who have no contraindications to coronary computed tomography angiography (CCTA).
46093360|NCT02786069|Drug|Propionyl L-carnitine Hydrochloride|500mg/ tablet; for oral administration, 1 dosage form is set for this trial: 1g, 2g and 4g.
46006765|NCT04593849|Other|Ru-Yih-Jin- Huang-Saan(RYJHS), Wan-Yin-Gao-Jia-Jean-Wey(WYGJJW), placebo ( topical agent without therapeutic effects)|We conduct a clinical trial using topical herbal medicine, including Ru-Yih-Jin- Huang-Saan(RYJHS) and Wan-Yin-Gao-Jia-Jean-Wey (WYGJJW) in treating post fracture pain and tissue swell. 24 eligible participants diagnosed of upper limb fracture with soft tissue injury grading of C1, C0 from Tscherne classification transferred from Orthopedic outpatient clinic and inpatient will be enrolled and randomly allocated to 4 groups, including experimental group A (RYJHS group), group B (WYGJJW group), placebo group( topical agent without therapeutic effects), and control group (only oral analgesics group), with 6 participants in each group.
46093361|NCT00910598|Drug|glatiramer acetate|20 mg daily s.c. for 1 year
46006766|NCT04586543|Drug|Selegiline|10 mg selegiline tablet per day
46006767|NCT04586543|Drug|Docetaxel|75mg/m2 docetaxel infusion every 3 weeks for maximum of 12 cycles
46093362|NCT04156932|Procedure|uterine artery closure|Interruption the uterine blood flow by closing the uterine artery at its cervical-isthmic part or at its origin.
46093363|NCT00968461|Drug|Phenethyl Isothiocyanate (PEITC)|Starting dose 40 mg capsules by mouth, 4 times a day, on Days 1-3 and 8-10 of each cycle.
46093364|NCT03564041|Behavioral|Sahaj Samadhi Meditation (SSM)|This is the experimental arm of the study, where participants will be trained in a form of meditation that may improve depressive symptoms.
46093365|NCT03564041|Behavioral|Health Enhancement Program (HEP)|This is the active control group of the study, where participants will be educated on health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation.
46093366|NCT00647114|Biological|V930|V930 - Over a 94 week duration, patients will receive a series of 5 injections (2.5 mg/injection), one every other week. Within 2 minutes of each injection of V930, each patient will be given an EP-IM injection consisting of two 60 msec pulses.
46093367|NCT00647114|Biological|V932|V932 - Over a 94 week duration, patients will receive a series of 5 injections, 6 patients will initially received intramuscular V932 vaccinations at a low dose (0.5x109 vg/injection),and following a safety assessment, up to an additional 35 patients will be treated with the high dose V932 (0.5x1011 vg/injection).
46093368|NCT00968695|Drug|Albumin|The pattern of administration of 20% human albumin is 1.5g/kg every week to be infused in 6 hours with a minimum of 90g up and a maximum of 150g in patients weighing less than 60 kg and more than 100 kg, respectively. Treatment duration is 12 weeks, which are 13 administrations of albumin.
45459744|NCT03483376|Procedure|Dental prophylaxis|Determining the effectiveness of dental prophylaxis alone in eliminating dental black stain.
46006768|NCT00582192|Other|Consult visit|Your appointment with your doctor will be audio taped. The research team will listen to the tape(s) and type them up. The team will then look for patterns in the discussions between patients and doctors. They will use this information to see if the discussions can be improved.
46093369|NCT04157010|Drug|Tocilizumab|
46093370|NCT04157010|Drug|Methotrexate|
45459745|NCT03483376|Device|Antimicrobial photodynamic therapy (aPDT)|Establishing the effectiveness of dental prophylaxis combined with antimicrobial photodynamic therapy using blue light and curcumin as the photosensitizing agent in eliminating dental black stain.
46006769|NCT04586777|Device|transvertebral direct current stimulation (tvDCS)|tvDCS is a painless, non-invasive form of spinal stimulation which delivers safe, low levels of electrical current to the spinal cord through the back. It is believed to be able to influence the excitability of the brain and spinal cord.
46006770|NCT04593576|Other|Physical activity protocol/out door sports|"Warm up exercise will be administered for 10 minutes, then one-to-five small group of instruction based activity will be administered for 15 minutes. After this whole group will be engaged in ball exercise and cooperative ball games for 20 minutes. At the end cool down and reward activity will be done with participants for 15v minutes.~Total 1 hour physical activity protocol will be administered twice a week."
45459746|NCT03726450|Dietary Supplement|Andrositol Plus|Myo-inositol
46093371|NCT02785211|Behavioral|Behavioral Activation Treatment|The modified model will be provided weekly to four groups for intervention, each group including about 10 participants with 1 facilitator for a period of 8 weeks after the baseline survey and general introduction. Each of the 8-week sessions will last for 2 hours. Groups 1 to 4 will have sessions on Mondays, Tuesdays, Wednesdays, and Thursdays respectively; four groups will meet on the same day of the week for all 8 weeks. The scheduling and timing of intervention provide consistency of scheduling for participants.
46093372|NCT04172792|Dietary Supplement|high-caloric fatty diet|see arm/group description
46093373|NCT04172792|Dietary Supplement|ultra-high-caloric fatty diet|see arm/group description
46093374|NCT04172792|Dietary Supplement|ultra-high-caloric carbohydrate-rich diet|see arm/group description
45459747|NCT03726450|Dietary Supplement|Andrositol Plus|N-Acetyl-Cysteine
45459748|NCT03726450|Dietary Supplement|Andrositol Plus|Folic Acid
46093375|NCT02632032|Drug|Insulin|"Monitoring insulin therapy of campers based on their usual regimen (one of the following):~premixed insulin in the morning and evening,~premixed insulin in the morning, regular insulin in the afternoon and premixed insulin in the evening,~regular insulin in the morning and afternoon, and premixed insulin in the evening.~Education of campers on different aspects of diabetes care:~monitoring of blood glucose~injection of insulin~adaptation of insulin doses according to blood glucose and during exercise~correction of hypoglycemia~dietary advice"
46093376|NCT00973609|Drug|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): No maintenance treatment."
46093377|NCT00973609|Drug|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): Fluoropyrimidine + Bevacizumab."
46093378|NCT00973609|Drug|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): Bevacizumab monotherapy."
46093379|NCT02786147|Other|Breast Cancer Genetics Referral Screening Tool 3.0|"The B-RST is a simple yet effective validated screening tool to quickly identify individuals who may be at risk for hereditary breast and ovarian cancer and should be referred for cancer genetic counseling to formally evaluate their family history and discuss the benefits and limitations of genetic testing for hereditary breast and ovarian cancer.~Clinic staff will give each patient arriving for a screening mammogram appointment a packet and briefly inform them about the opportunity to participate in a research study and that these materials can help them decide whether or not to participate.~Patients who indicate that they are interested in completing the B-RST screening while in the clinic will be provided with an electronic tablet that has a secure internet browser tab open to the web-based study version of the screening tool (the B-RST 3.0)."
46093380|NCT02786147|Other|Standard Handout|A document explaining the patient's positive test result indicating that they are at increased risk for HBOC (Hereditary Breast or Ovarian Cancer) which includes information on how to obtain cancer genetics services through Winship.
46093381|NCT02786147|Other|Physician Notification|Primary care physician or ordering physician will be notified vie EeMR that the patient screened positive on the B-RST. The note provides specific instructions on how to refer the patient for cancer genetic counseling services.
46093382|NCT02786147|Other|Automatic Follow-Up by Genetic Counseling Staff|Within 1-2 weeks after the mammogram appointment, patients will receive a phone call from a genetics counseling staff person to explain their screening result and to offer to set up a genetics counseling appointment.
46093383|NCT02537054|Drug|Aflibercept|Intravitreal injection
46006771|NCT04593576|Other|Intensive table teaching speech therapy|Control group participants will be given speech therapy session based on intensive table teaching for 30 minutes twice a week.
46006772|NCT04586738|Procedure|non-perforating deep sclerectomy surgery|Non-penetrating deep sclerectomy is a non-perforating filtration procedure used for the surgical treatment of medically uncontrolled open angle glaucoma.This surgery is performed to facilitate the outflow of aqueous humour from the anterior chamber to the subconjunctival space through a natural membrane (trabeculo-Descemet's window). This enables a more physiological reduction of intraocular pressure to be achieved.
46006773|NCT04593693|Device|Invia Motion Endure NPWT system|lightweight portable single patient use pump, that provides continous or intermittent operation and multiple negative pressure selection options
46006774|NCT04586582|Diagnostic Test|ST-segment resolution <40.15%|Forty-two STEMI patients with single-branch coronary artery stenosis or occlusion were enrolled. ST-segment elevations were measured at emergency admission and at 24 h after PCI. Late gadolinium-enhanced cardiac magnetic resonance imaging (CMR-LGE) was performed 7 days after PCI to evaluate myocardial scars.
46093384|NCT02636790|Procedure|Surgery wait time|VCH CRS patients need a waitlist system that promotes wellness and ensures care that focuses on quality - this can be achieved with a prioritized waitlist based on quality of life improvement and decreased healthcare expenditure.
46093385|NCT00973687|Drug|Ora Sweet|A pharmaceutical suspending vehicle and flavouring agent added to the dexamethasone. All arms received the same amount of dexamethasone based on the child's weight, only in different volumes.
46093386|NCT00973687|Drug|Dexamethasone|
46093387|NCT02785757|Other|Thrombin Generation Assay|
46093388|NCT04174898|Biological|human Mesenchymal Stem Cell (MSC) infusion therapy|Subjects will be infused with 100million human MSCs
46093389|NCT05279521|Behavioral|pulmonary rehabilitation exercise|The lung rehabilitation exercise is divided into three parts: upper and lower limb muscle strength, endurance training and breathing training skills. It lasts for eight weeks of exercise training, and the exercise frequency is: three times a week.
46093390|NCT04157634|Diagnostic Test|Prognostication model|In a prospective cohort of children hospitalized in a PICU, developement a model based on biomarkers, HRV, and a computerized classifier output, to predict long-term neurological outcome after a moderate or severe TBI in children aged 0 to 18 years.
46093391|NCT05318183|Other|Whole Wheat Bread|Standardized whole wheat bread (128 g daily)
46093392|NCT05318183|Other|White Bread (control)|Standardized white bread (128 g daily)
46093393|NCT00645554|Drug|Galantamine oral solution|
46093394|NCT04592185|Device|Fenestrated Anaconda™ Device|Treatment of complex abdominal aortic aneurysms
45459749|NCT03726450|Dietary Supplement|Andrositol Plus|Selenium
45459750|NCT03726450|Dietary Supplement|Andrositol Plus|L-arginine
45459751|NCT03726450|Dietary Supplement|Andrositol Plus|L-carnitine
45459752|NCT03726450|Dietary Supplement|Andrositol Plus|Vitamin E
46006775|NCT04586465|Drug|pembrolizumab, pemetrexed, gemcitabine, cisplatin, carboplatin|"Patients will receive 3 cycles pembrolizumab 200mg, fix dose, 60 minute IV infusion combination with chemotherapy.~Chemotherapy regimen: ① Eligible patients with non-squamous cell lung cancer, Pemetrexed 500mg/m2, IV infusion on day 1 and cisplatin 75mg/m2 or carboplatin area under the curve (AUC=5), on day 1 of a 3-week schedule for 3 cycles. ② Eligible patients with squamous cell lung cancer. Patients will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 or carboplatin AUC=5 on day 1 of a 3-week schedule for 3 cycles"
45836646|NCT05287854|Device|Virtual reality headset|Once the patient is on the operating table, the nurse proposes the different possible VR scenarios and installs the RV headset and an audio headset.
46093395|NCT02785601|Drug|Trazodone Hydrochloride prolonged-release tablets|strength 75mg, 150 mg. Oral administration with 200ml water
46093396|NCT02667548|Procedure|PCI|percutaneous coronary intervention
45836647|NCT05287776|Device|Narrow band UVB|Narrow band UVB emitting UVB at wavelength 311nm
45840168|NCT00661674|Other|Placebo|"Over 3 study visits, patients will receive one of the following treatment regimens:~Placebo saline IV and sugar pill~0.75 mg Palonosetron IV and sugar pill~0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
45840169|NCT00662298|Drug|prednisolone|40mg of prednisolone once a day for 14 days
45840170|NCT00666666|Drug|AT-101|AT101 will be administered orally 20 mg/day for 21 days of a 28 day cycle.
45840171|NCT00666666|Drug|Bicalutamide|Daily bicalutamide 50 mg po is encouraged for the first month of LHRH agonist therapy to prevent a flare. Continued bicalutamide use is optional. Bicalutamide will be administered orally at a dose of 50 mg po daily, Day 1 to 28 of each cycle.
45840172|NCT00666666|Other|LHRH agent|An LHRH agonist(Leuprolide Acetate or Goserelin)can be administered at standard dosing appropriate to the agent used.
46093397|NCT02667782|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Recruited subjects that are randomly allocated into the MBSR group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on stress reduction. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
46093398|NCT02667782|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|Recruited subjects that are randomly allocated into the MBCT group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on cognitive therapy. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
46093399|NCT05299567|Drug|Azithromycin|Placebo with the same color and size than azithromycin tree days a wek for 6 months
46093400|NCT02785133|Device|UVL1000 Treatment Station|"Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter"
46093401|NCT02785133|Drug|Normal Saline Solution|150 ml of 0.9% Sodium Chloride Solution
46093402|NCT02785133|Device|Peripheral Catheterization|"20-gauge 1.0 catheter"
46006776|NCT04593615|Procedure|ICG near-infrared imaging|Indocyanine green tracer is used to guide laparoscopic D2 lymph node dissection for gastric cancer
46093403|NCT00660894|Drug|folinate calcium|
46093404|NCT00660894|Drug|tegafur-uracil|
45459753|NCT03243656|Drug|Eltrombopag|An oral thrombopoietin receptor agonist
46093405|NCT00660894|Drug|tegafur-gimeracil-oteracil potassium|
46093406|NCT05062148|Other|Float-REST|Subjects receiving Float-REST will float for 60 minutes three times a week.
46093407|NCT05062148|Other|Photobiomodulation|Subjects receiving photobiomodulation will undergo a 20-minute therapy session three times a week.
46093408|NCT00660972|Drug|Raltegravir|400 mg tablet taken orally twice daily
46093409|NCT00660972|Drug|Emtricitabine/tenofovir disoproxil fumarate|Fixed dose tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate taken once daily. FTC/TDF will not be provided by the study and must be obtained by the particpant's health care provider.
46093410|NCT02667470|Drug|Solifenacin|Oral
46093411|NCT05327699|Drug|Ketamine|A single intravenous (IV) infusion of ketamine calculated at 0.5mg/kg through an indwelling catheter over a 40-100min period.
46093412|NCT05327699|Other|Placebo|A single intravenous (IV) infusion of saline through an indwelling catheter over a 40-100min period.
46093413|NCT04157556|Other|Yo-Yo Intermittent Recovery Test Level 1|"The test is a standard test battery with progressively increasing speeds. After every 40-m run (2x20 m), active rest is performed by walking or jogging at a distance of 10 m (2x5 m). for 10 seconds. Participants are trying to adjust their speed according to incoming audio signals.The test is terminated when the participants can not reach the signal twice. The test ends in 10-20 minutes depending on the level of participants.~Reference Bangsbo, J., Iaia, F. M., & Krustrup, P. (2008). The Yo-Yo intermittent recovery test. Sports medicine, 38(1), 37-51.~Krustrup, P., Mohr, M., Amstrup, T., Rysgaard, T., Johansen, J., Steensberg, A., ... & Bangsbo, J. (2003). The yo-yo intermittent recovery test: physiological response, reliability, and validity. Medicine & Science in Sports & Exercise, 35(4), 697-705."
45459754|NCT03480646|Drug|CPI-1205|Administered orally
45459755|NCT03480646|Drug|Enzalutamide|Administered orally
45459756|NCT03480646|Drug|Abiraterone/Prednisone|Administered orally
45459757|NCT03559218|Device|KeraStat(R) Cream|KeraStat Cream is a cream wound dressing that contains 5% keratin.
45459758|NCT03559218|Other|Standard of care|Patients will be instructed to follow institutional standard of care for radiation dermatitis
45459759|NCT05760872|Other|Placing esophageal probe|Placing an esophageal probe through the mouth
45459760|NCT03483142|Drug|Misoprostol|( 25 patient): who will receive 400 microgram (tablet 200mcg X 2) misoprostol rectally one hour before operation
45678419|NCT01765179|Drug|Oral testosterone undecanoate|Initial dose 200 mg T, BID; dose titration Days 42 and/or 84 based on serum T levels obtained 3-5 hours post AM dose on Days 30 and 72. Dosages increased or decreased in 50 mg increments.
45459761|NCT03483142|Drug|Placebos|( 25 patient): who will receive placebo . two rectal placebo tablet of the same size and shape as the misoprostol
45459762|NCT03726372|Drug|Rocuronium|rocuronium is a neuromuscular blocking agent with a duration of 40 minutes
45459763|NCT03726372|Other|continuous infusion|rocuronium is continuously infused
45678420|NCT04580667|Other|Collection of plasma samples|Collection of plasma samples - Plasma samples are collected at different times during the study for the RadTox test.
45678421|NCT04580043|Behavioral|Habit Override Practice|"Computerized brain training to provide practice in overriding avoidance habits."
45678422|NCT04580043|Device|Transcranial Magnetic Stimulation|Non-invasive method for temporary, focal stimulation of brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
45678423|NCT04580043|Behavioral|Sham Training|Computer-based task practice in a non-active/inert task.
45678424|NCT04580043|Device|Sham Transcranial Magnetic Stimulation|Sham stimulation of non-brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
46006777|NCT04586309|Behavioral|Transcendental meditation|"Instruction in the TM technique is taught over five sessions.~Introductory session-Review of previous scientific research on the TM program and a vision of possible benefits; Preparation- discussion of the mechanics and origin of the TM technique After the introductory session, a Personal Interview is conducted telephonically-with a teacher of the TM program.~Personal Instruction-individual one-on-one instruction in the TM technique. The student learns the mechanics of the TM technique. At the conclusion of this class the student is able to meditate properly.~First Day of Verification of Correct Practice and Further Instruction.~Second Day of Verification of Correct Practice-understanding the mechanics of the TM technique from personal experiences.~Third Day of Verification of Correct Practice-understanding the mechanics of the development of higher human potential and wellness."
45459764|NCT03726372|Other|intermittent injection|rocuronium is intermittently given
45459765|NCT03104816|Drug|Acetaminophen IV Soln 10 MG/ML|
45459766|NCT03104816|Drug|Acetaminophen|
45459767|NCT03104816|Drug|Hydromorphone|
45459768|NCT04306588|Other|Exercise|Participants are undergoing a 12 weeks tele-rehabilitation program.
45678425|NCT01764945|Drug|BI 201335 (Reference)|soft gelatine capsule, oral administration
45678426|NCT01764945|Drug|BI 201335 (Test)|oral solution 3
45678427|NCT01764945|Drug|BI 201335 (Test)|oral solution 3
45678428|NCT01764945|Drug|BI 201335 (Test)|oral solution 2
45678429|NCT01764945|Drug|BI 201335 (Reference)|soft gelatine capsule, oral administration
46093414|NCT02784197|Device|Phase Signal Recorder|The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal.
46093415|NCT04157478|Drug|Anlotinib Hydrochloride|Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
46093416|NCT04157478|Radiation|Radiation therapy|Radiation therapy will be delivered in daily fractions of 2 Gy given 5 days a week for a total of 60 Gy.
46093417|NCT04157478|Drug|Temozolomide|Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 150-200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
46093418|NCT04231019|Other|self-administered questionnaire|"Self-administered questionnaires with plain language statements and brief description of the clinical features and photographs of MIH were used to determine the knowledge, awareness and perception regarding the prevalence, severity, etiology and treatment modalities of molar-incisor hypomineralization (MIH) among Egyptian fifth year dental students, general dental practitioners and dental specialists.~There were two routes for delivering the questionnaire either as online questionnaire sent to the participants by email or as a hard copy that is hand delivered."
46093419|NCT00661050|Procedure|Alternative Medicine|
46093420|NCT00661050|Procedure|Tai Chi instruction and class participation or walking exercise and sitting meditation|
46093421|NCT04231175|Diagnostic Test|DWI MRI of the pelvis, abdomen and thorax|Patients in Arm A will receive a MRI scan of their pelvis, abdomen, and thorax before possible surgery. During the MRI standard Gadolinium contrast agent and Buscopan is intravenously administered, which is standard clinical practice in abdominal MR imaging. Total scan time is 35 minutes and includes T2 weighted, T1 weighted, Diffusion weighted and dynamic contrast enhanced imaging of the abdomen and the thorax. The findings of this scan will be used to determine whether to proceed with CRS/HIPEC, DLS and then possibly CRS-HIPEC, or palliative care.
46093422|NCT02666378|Other|Cardiac Magnetic Resonance Imaging (CMR)|Subjects will be recruited for observational cardiac magnetic resonance imaging.
46006778|NCT04586192|Other|Common Elements Toolbox- Adult version (COMET-A)|COMET includes four different modules that teach participants exercises designed to improve mental health and well-being. Participants are asked to complete exercises focused on behavioral activation, cognitive restructuring, gratitude and self-compassion. At the end of the intervention, participants are sent templates that they can you to complete the exercises on, and are encouraged to continue practicing their exercises in their daily life.
46093423|NCT02666378|Other|Echocardiogram (ECHO)|Subjects will undergo a research echocardiogram if a clinical echocardiogram has not already been ordered.
46006779|NCT04586192|Other|Self-awareness Control|A control condition in which participants learn about self-awareness through writing about memories, writing a short argumentative essay, and noticing objects in their surroundings.
45459769|NCT02523742|Device|IMRf|
46006780|NCT00582387|Genetic|specimen samples|blood, urine and tissue
46006781|NCT00582387|Behavioral|questionnaires|
46006782|NCT04586114|Drug|Corticosteroids and Derivatives|Any systemic corticosteroid treatment administrated during ICU stay
46006783|NCT00566865|Drug|placebo for gemfibrozil|mitiglinide + placebo for gemfibrozil 600 mg bid
46093424|NCT02632188|Procedure|Postoperative routine treatment|Postoperative routine treatment according to the hospitals local routines
45459770|NCT02523742|Other|language task and a reference task (rest and Tamil)|
45459771|NCT04720976|Drug|JAB-3312|JAB-3312 will be administered orally, variable dose.
45459772|NCT04720976|Drug|Binimetinib|Binimetinib will be administered orally.
45459773|NCT04720976|Drug|Pembrolizumab|Pembrolizumab will be administered as an intravenous infusion.
46006784|NCT00566865|Drug|gemfibrozil|Mitiglinide + 600 mg gemfibrozil bid
46006785|NCT04585997|Drug|Mepolizumab|Mepolizumab 100mg subcutaneous injection monthly for 6 months
46006786|NCT04585997|Drug|Omalizumab|Omalizumab subcutaneous injection every 2-4 weeks (dosage determined by the Omalizumab nomogram).
46006787|NCT04576845|Other|Survey|The children's eating behavior will be evaluated with Turkish validated Children's Eating Behavior Questionnaire - (CEBQ) by interviewing mothers face to face. The CEBQ is a Likert type, parent-report rating scale measuring the variation in eating behavior in children. The CEBQ consists of 35 items comprising eight subscales, each containing 3 to 6 items. Parents will be asked to rate their child's eating behavior on a five-point scale (never, rarely, sometimes, often, always; 1-5, respectively).
46006788|NCT04585880|Other|Virtual Collaborative Care Clinic|The vCCC will operate under a collaborative care agreement with the Primary Care Physicians as an extension (and not a replacement) of their care. Trained clinical pharmacists will monitor blood pressure and prescribe and adjust medications under the license of, and in communication with, the patient's Primary Care Physician. As part of the Primary Care Physician's team and per Primary Care Physician's directions, the pharmacists may coordinate blood pressure management with other clinicians such as cardiologists or nephrologists co-managing patients blood pressure.
45459774|NCT04720976|Drug|Sotorasib|Sotorasib will be administered orally.
45459775|NCT04720976|Drug|Osimertinib|Osimertinib will be administered orally.
45459776|NCT03480568|Drug|Alirocumab 150 MG/ML [Praluent]|Cholesterol-lowering therapy
45459777|NCT04707326|Drug|Dolutegravir / Lamivudine Pill|HIVRNA suppressed patients without documented M184V mutation in HIV RT and who are hepatitis B immune or have no risk factors for acquiring hepatitis B
46093425|NCT02632188|Biological|DC-PMAT treatment|Postoperative routine treatment according to the hospitals local routines; DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
46093426|NCT04174820|Other|Functional Magnetic Resonance Imaging (fMRI)|list of the tests: Box and Blocks test, Nine Hole Peg test, walkway GAITRite, EXALang tests, NEPSY II subtests, BRIEF, FEE, WISC 5 tests
46093427|NCT04157322|Diagnostic Test|prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study|Blood draw
46093428|NCT04073108|Diagnostic Test|tuberculin test|tuberclin test used to diagnose tuberculosis as cause of fever of unknown origin
46093429|NCT04156776|Other|Muscle Energy Technique|Muscle energy technique was repeated 4 times per session every day for 3 days a week for 4 weeks after the application of moist heating pad for 30 minutes before each session.
46093430|NCT04156776|Other|Active Isolated Stretching|"The patient was asked to sit in an upright seated position and flex his/her knees 12 to 18 inches. Patient was asked to tuck the chin, exhale, and firmly contract the abdominal muscles as he/she curls their body forward. He/she was also guided not to bounce or make rapid movements at the end range of the active motion. Then, he was asked to move back to the starting position and repeat the same procedure for 8 to 10 times. Stretch on the end range was not more than 2 seconds.~This technique was repeated 10 times per session every day for 3 days a week for 4 weeks after the application of moist heating pad for 30 minutes before each session."
46093431|NCT04156776|Other|Conventional Treatment|Conventional physical therapy treatment includes the application of moist heating pad for 30 minutes on lower back/ lumbar region prior to the intervention to both groups.
46093432|NCT00647192|Drug|Eplerenone|50 mg per day
46093433|NCT00647192|Drug|Placebo|50 mg per day
46093434|NCT03466697|Other|Glucose injection/Normal saline injection|Before each PET scan, subject will be injected either glucose or normal saline.
46093435|NCT02785367|Procedure|Cord blood samples|"After delivery, 8 cord blood samples will be taken from the umbilical cord in 8 syringes of about 3 ml, washed with Heparin (Designated syringes exist in the delivery room). 4 syringes will be stored in room temperature. Thermometer will be attached to any sample, and temperature values will be indicated before any measurement.~The samples will be measured in a gas measurement device, in 4 time points: at the birth, after 15 minutes, after 30 minutes and after 60 minutes from the birth."
46093436|NCT02631720|Procedure|Blood Draw|
46093437|NCT02631720|Procedure|Bronchoscopy|
46093438|NCT02666300|Other|TaperGuard ETT|tracheal intubation with TaperGuard ETT
46093439|NCT00661206|Drug|Clopidogrel|Patients on clopidogrel therapy at 6 months after implantation of a drug-eluting stent will be randomized to an additional 6 month period of clopidogrel 75mg per day
46093440|NCT00661206|Drug|Placebo|Patients randomized in this group will receive placebo for 6 months.
46093441|NCT04172870|Diagnostic Test|Molecular analysis|RT- PCR
46093442|NCT02689739|Procedure|venous duplex ultrasound|Venous duplex ultrasound
46006789|NCT04586036|Other|ankle joint brace 1|The influence of ankle joint brace 1 on gait biomechanics
46006790|NCT04586036|Other|ankle joint brace 2|The influence of ankle joint brace 2 on gait biomechanics
46006791|NCT04586036|Other|ankle joint brace 3|The influence of ankle joint brace 3 on gait biomechanics
46093443|NCT02664896|Other|Knee Osteoarthritis|Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, knee measurements, blood draw, and knee radiographs.
46093444|NCT02664896|Other|Healthy Control|Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, and knee measurements.
46093445|NCT04230629|Device|Vivinex XY1|Implantation of an intraocular lens Hoya Vivinex XY1
46093446|NCT04230629|Device|Vivinex XY1A|Implantation of an intraocular lens Hoya Vivinex XY1A
46093447|NCT03938545|Drug|RVT-1401 (Administered via subcutaneous injection)|RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
46093448|NCT03938545|Other|Placebo (Administered via subcutaneous injection)|Placebo
45459778|NCT03559062|Drug|TEZ/IVA|Participants weighing <40 kg received TEZ 50 mg/IVA 75 mg FDC tablet and those weighing ≥40 kg received TEZ 100 mg/IVA 150 mg FDC tablet.
45459779|NCT03559062|Drug|IVA|Participants weighing <40 kg IVA 75 mg tablet and those weighing ≥40 kg received IVA 150 mg tablet.
45459780|NCT03559062|Drug|Placebo|Placebo matched to TEZ/IVA FDC
45459781|NCT03559062|Drug|Placebo|Placebo matched to IVA
45459782|NCT03483064|Other|Interferential current|interferential currents of 4,000 Hz carrier frequency, 100 Hz of AMF, for 20 minutes and with an amplitude up to the motor threshold
46006792|NCT04586036|Other|ankle joint brace 4|The influence of ankle joint brace 4 on gait biomechanics
46006793|NCT04586036|Other|ankle joint brace 5|The influence of ankle joint brace 5 on gait biomechanics
46006794|NCT00582504|Biological|VEE TC-83|Subjects will receive a single 0.5 mL dose by subcutaneous route in the upper outer aspect of arm
46006795|NCT04585568|Other|Biosensors|Measures of blood flow and preassures
46006796|NCT04593108|Device|Letrozole misoprostol|Letrozole give pretreatment of abortion by misoprostol
46093449|NCT04156542|Behavioral|Basic School Lunchroom Nudges|"The intervention consists of three components: 1) serving fresh fruit in attractive bowls in at least two locations on the lunch line; 2) providing descriptive names for the vegetables; and 3) increasing amount of plain milk availability by 10% and placing it in front of the chocolate milk. For the vegetable naming intervention, researchers first developed, printed, and laminated descriptive vegetable name cards (2x4). Some examples included Savory Collard Greens, and [School Mascot] Salad. Cafeteria staff affixed name cards to the serving line sneeze-guards in front of the vegetables for the day. For the fruit intervention, we purchased and delivered two ceramic bowls to the intervention school. The cafeteria staff filled the bowls and put them in different locations on the lunch line. For the milk intervention, cafeteria staff increased the amount of plain milk available by 10% and placed plain in front of chocolate milk in the coolers."
46093450|NCT05276960|Drug|Cholecalciferol Pill|Dose increments according to serum levels determined every 2 months
46006797|NCT04593108|Drug|Misoprostol, placebo|Give placebo pretreatment of abortion by misoprostol
46006798|NCT04585334|Drug|Tricortin 1000|Tricortin 1000 [2 mL ampoules containing 12 mg of phospholipids and 1 mg of Vitamin B12 (Cyanocobalamin)] will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
46006799|NCT04585334|Drug|Itami|Diclofenac sodium 140 mg medicated plaster (Itami®) will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications plus Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2).
46093451|NCT04173884|Other|Coaching|Surgical coaching is based on a peer coaching model that has been proven to be highly effective in other disciplines and for surgeons in training. Surgical coaching can improve technical performance in one of two ways: 1) identifying new or alternative approaches to the procedure; or 2) improving surgeon technical skill, which can lead to improvements in patient outcomes. In this proposal, our primary objective is to evaluate the effectiveness of video-based collaborative learning for surgeons.
46093452|NCT04173884|Other|Constructive Feedback|Constructive feedback is critical for performance improvement. It is currently unknown, however, whether asynchronous constructive feedback alone, without interactive discussions with a coach, would be as acceptable and valued as formal in-person coaching. Furthermore, the effectiveness of either approach to collaborative learning in improving surgical performance and outcomes is not known.
46093453|NCT02787317|Drug|bivalirudin|Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention.
46093454|NCT02787317|Drug|Heparin|Heparin is used in patients undergoing percutaneous coronary intervention.
46093455|NCT00645632|Drug|cisplatin|
46093456|NCT00645632|Drug|doxorubicin hydrochloride|
46093457|NCT00645632|Drug|ifosfamide|
46093458|NCT00645632|Drug|methotrexate|
46093459|NCT00645632|Procedure|adjuvant therapy|
46093460|NCT00645632|Procedure|neoadjuvant therapy|
46093461|NCT00645632|Procedure|therapeutic conventional surgery|
46093462|NCT04156464|Drug|Phenobarbital|Phenobarbital loading dose followed by a taper will be given to control acute alcohol withdrawal syndrome
45678430|NCT01764945|Drug|BI 201335 (Test)|oral solution 1
46093463|NCT04156464|Drug|Lorazepam|Ativan will be given according to our institutional alcohol withdrawal protocol to control acute alcohol withdrawal syndrome
45678431|NCT01764945|Drug|BI 201335 (Test)|oral solution 1
45678432|NCT01764945|Drug|BI 201335 (Test)|oral solution 2
46093464|NCT02666456|Other|QST, Questionnaires|Assessment of sensory phenotype by QST and questionnaires
46093465|NCT00968773|Device|Rebound HRD|Laparoscopic TEP inguinal hernia repair using the Rebound HRD and no fixation
46093466|NCT00968773|Device|Standard hernia mesh (VitaMesh)|Laparoscopic TEP inguinal hernia repair using standard hernia mesh with fixation
46093467|NCT02607215|Drug|Vinorelbine|25 mg/m2, D1, D8
46093468|NCT02607215|Drug|DDP|75 mg/m2, D1
46093469|NCT04936724|Other|Pictorial Warning Labels|Participants will be randomized to one of two conditions and will view 4 pictorial warning labels from the assigned group for an eye-tracking task.
46093470|NCT00661440|Drug|Neramexane mesylate|2 double-blind, cross-over treatment periods of 7 weeks separated by a wash-out phase, up to 75 mg Neramexane mesylate per day
46093471|NCT00973999|Drug|Botulinum Toxin|"Each parotid salivary gland will be injected with 75MU of Botulinum Toxin type-A, 0.15mls in total, with 0.09mls into the mass of the gland and another 0.06mls into the adjacent part above the masseter muscle, using a 1ml syringe and a 30 gauge needle.~Each submandibular salivary gland will be injected with 15MU of Botulinum Toxin A, administering 0.03mls, using a 1ml syringe and a 30 gauge needle."
46093472|NCT04232579|Other|Therapeutic strategy|Therapeutic strategy compatible with the guidelines and development of predictive biomarkers of the response to treatment.
46093473|NCT04174664|Diagnostic Test|1-minute sit to stand test|Childrens will complete 1-minute sit to stand test and 3 minute step test and quality of life questionnaire.
46093474|NCT00968929|Drug|Recombinant Streptokinase|Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours
46093475|NCT00968929|Drug|Urokinase|Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours
46093476|NCT02785445|Device|Dip.io Home Based Dipstick Analyzer|"First intervention (assigned to the All participants arm)."
46093477|NCT02785445|Device|ACON U500 Mission® U500 Urine Analyzer|"Second intervention (assigned to the All participants arm)."
46093478|NCT04918940|Biological|Determination of COVID-19 vacciantion efficacy|Samples will be taken after each vaccine injection to perform Sars-Cov-2 serology and Elispot interferon gamma and 3 months after the first vaccine injection
46093479|NCT00661596|Drug|Levitra (Vardenafil, BAY38-9456)|5 mg, 10 mg and 20 mg one hour prior to sexual intercourse
46093480|NCT00661596|Drug|Placebo|Matching placebo
46006800|NCT04585334|Drug|Placebo|Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
46006801|NCT04577391|Other|Modified Constraint-Induced Movement Therapy|Children's less affected hand was restricted through a mitt with a material sewn shut on the palmar face to promote the involved side's use, and unimanual gross and fine motor activities were practiced with the more affected hand. Besides, if the participant attempted to use his/her less affected hand as an assistive, a bandage was also used to strap less affected upper limb to the trunk. Specific activities were selected according to the deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request (e.g., drawing, painting, and eating).
46006802|NCT04577391|Other|Bimanual Training|BIT was administrated without any restrictive material on the non-involved upper limb, but instead, children were engaged in age-appropriate gross and fine motor bimanual activities. All targeted deficits of interest were addressed within the context of the selected activity.
46006803|NCT04585412|Drug|Palonosetron|Pharmacokinetic study under fasting conditions
46006804|NCT04592796|Device|Xiaomi MiBand2|Recording of sleep and activity data to study their association with age.
46006805|NCT04592796|Other|Socio-demographic questionnaire|Self-made questionnaire to be administered at the beginning of the study with the following personal data: age, gender, marital status, residential environment, mobility aids, educational level, occupation, retirement type, socioeconomic status, medical records, treatment.
46006806|NCT04592796|Other|EuroQol-5D-5L|Quality of life questionnaire to be administered at the beginning and completion of the study with the following information: severity index, social value index for each health condition. Subjective evaluation of health status from 0 to 100.
46006807|NCT04592796|Other|Mini mental State Examination|Questionnaire to be administered at the beginning and completion of the study that measures cognitive impairment.
46006808|NCT04592796|Other|Tinetti Scale|Physical test to be administered at the beginning and completion of the study that measures gait and balance of the participants.
46006809|NCT04592796|Other|Barthel Index|Questionnaire to be administered at the beginning and completion that evaluates the level of independence in basic activities of life.
46006810|NCT04592796|Other|Pittsburgh Sleep Quality Assessment (PSQI)|Questionnaire to be administered whose outcome is the perceived quality, quantity and efficient of sleep. To be given at the beginning and completion of the study.
46006811|NCT00567866|Drug|Quetiapine|50 or 100 mg of quetiapine orally
46006812|NCT00567905|Dietary Supplement|Green tea extract|main content is epigallocatechin gallate (EGCG, 58%)
46006813|NCT04593030|Drug|Warfarin|Warfarin dispensing claim is used as the reference
46093481|NCT00969007|Behavioral|Lifestyle modification counselling|Patients meet individually every six weeks, a nurse or kinesiologist, and a dietitian (as well as a psychologist, if needed) and every three months an endocrinologist. A unique patient chart is shared by members of the interdisciplinary team, allowing sharing of the information and avoiding repetitions. Individualized behavioural intervention is proposed and focuses on attainable goals and progressive but sustained small changes in nutrition and physical activity. In addition, the participants have access to 24 weekly group seminars, on different aspects of excess weight and modification of lifestyle, to reinforce behaviour and commitment to lifestyle changes. Our approach meets all criteria suggested for clinical intervention in the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children.
46093482|NCT02221427|Other|Dynamic progression curve|Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes. This guideline is based on the labour progression curve by Zhang.
46093483|NCT02221427|Other|Static labour progression curve (F)|
46093484|NCT05008562|Other|COVID-19 RELATED MUSCLE MASS CHANGE IN THE INTENSIVE CARE UNIT|there is no interventions to the patients.
46093485|NCT02636634|Other|imaging|
46006814|NCT04593030|Drug|Apixaban|Apixaban dispensing claim is used as the exposure
46093486|NCT00974077|Behavioral|Mindfulness Based Cognitive Therapy|Group treatment over 8 weeks with training in meditation, stress regulation, shift attention, stay present, in addition with cognitive and behavioral strategies (following Williams et al. Manual 2002)
46093487|NCT00974077|Other|Waiting List Control|Patients receive MBCT with a delay of 6 months.
45678433|NCT04578249|Other|Blue light-blocking goggles|Participants will be randomly assigned to one of the two intervention groups.
46006815|NCT00582543|Other|eMRI/MRSI|Patients will undergo eMRI/MRSI examination. All subjects will be asked to administer a Fleet enema on the day of the study in order to reduce the potential for fecal residue to interfere with imaging acquisition and quality. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position. The entire eMRI/MRSI study will be performed within 55-60 minutes.
46093488|NCT02631642|Drug|HMPL-689|selective PI3Kδ inhibitor
46093489|NCT02631642|Drug|HMPL-689 placebo|placebo of HMPL-689
45678434|NCT04578249|Other|Clear goggles|Participants will be randomly assigned to one of the two intervention groups.
46006816|NCT00567944|Device|BrainPort Balance Device|The BrainPort balance device, is a non-invasive medical device that provides head and body position information to a person via their tongue.
46006817|NCT00567983|Drug|Restasis|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
46006818|NCT00567983|Drug|Endura|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
46093490|NCT00969085|Drug|Curcumin (Turmeric)|"Chew then swallow 2 sticks per day for up to 6 months.~2 sticks = 1 packet of curcumin = 8 grams"
46093491|NCT00969085|Behavioral|Questionnaires|Quality of life (QOL) questionnaires completed on Day 1, Weeks 2, 4, 8, 12, 16, 20, and at end of treatment visit.
46093492|NCT00969085|Other|Photos|Photos of up to 6 selected skin lesion(s) and half-body photos taken on Day 1, Weeks 2, 4, 12, and at end of treatment visit.
46093493|NCT04157166|Diagnostic Test|to record a whole body 3D of 25 minutes in camera VERITON-CT ™|The procedure of recording of 25 minutes in camera VERITON-CT ™ including the registration whole body 3D coupled to a scanner low dose (CT) will be added to conventional recording followed by complementary images SPECT/CT
46093494|NCT00974155|Drug|Escitalopram, venlafaxine, lithium|oral application, highest tolerable dose, once daily
46093495|NCT00974155|Drug|Escitalopram, venlafaxine|oral application, highest tolerable dose, once daily
45459783|NCT05759000|Drug|Dapagliflozin|Sodium-glucose cotransporter-2 (SGLT2) inhibitor is considered one of the four foundational therapies (ACE-I or ARNI, beta-blockers, MRA, and SGLT2 inhibitors) for HFrEF (6). However, guidelines do not specify the sequence and the timing of which therapy to be commenced. In particular, dapagliflozin has been shown in randomized controlled trials to reduce the combined risk of cardiovascular death or HF hospitalization and improve quality of life in HF patients with both reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), respectively, regardless of the presence or absence of diabetes in the DAPA-HF and DELIVER trials (
46006819|NCT00582582|Drug|Docetaxel plus doxercalciferol|Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day
46006820|NCT00582582|Drug|Docetaxel plus placebo|Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day
46093496|NCT04231955|Diagnostic Test|numerical rating scale|patients were asked to marked their pain intensity level on numerical rating scale between 0 and 10 and the result was recorded as pain intensity level.
45459784|NCT04979416|Behavioral|Video messages|video messages aimed at increasing vaccination
45459785|NCT03039296|Procedure|Endoscopic rhizotomy|Endoscopic rhizotomy (facet joint denervation) is carried out through the insertion of an endoscope to the medial spinal nerve area with the help of mobile C-arm x-ray guidance. The tissue surrounding the medial nerves is endoscopically visualized and dissected with a sterile grasper to expose the nerve structure. Finally, a radiofrequency probe is used to ablate the problematic medial branch nerve under direct endoscopic control. The procedure is concluded with the removal of the endoscope and the small incision is closed with 1-2 skin sutures.
46006821|NCT04585373|Other|kinesio-taping with conventional therapy 24 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
46093497|NCT04231955|Other|visual analogue scale|"Patients were asked to marked their pain intensity level on visual analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possible. Then the distance between no pain end and patients' mark was measured and recorded as pain intensity level."
46093498|NCT04231955|Other|color analogue scale|"Patients were asked to marked their pain intensity level on color analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possibleand color change towards to worst pain possible end. Then the distance between no pain end and patients' mark was measured and recorded as pain intensity level."
46093499|NCT04231955|Other|faces rating scale|"Patients were asked marked their pain on a faces rating scale which consisted of six different faces representing different levels of pain intensity with the first face indicating no pain whilst last face indicating worst pain possible. The result was recorded as pain intensity level."
46093500|NCT02664974|Dietary Supplement|Enteral nutrition|"Home Enteral Nutrition was planned to cover the basal energy requirement calculated with Harris Benedict Formula, it was administrated preferentially during nocturnal hours as an integration of oral diet.~Enteral Nutrition included any standard polymeric formula providing 1-1.5 Kcal/mL with carbohydrates 50%-60%, lipids 25%-35% and protein 12%-20%.~Home Enteral Nutrition can be withdrawn in the treated group, after 2 months from discharge, whenever a weight gain ≥ 5% is reported, and oral alimentation is regular and adequate."
46093501|NCT02664974|Other|Dietary counseling|"Specific nutritional advices including total energy and protein requirements were provided to patients and oral high-calorie supplements were prescribed whenever necessary.~Home Enteral Nutrition can be started in patients of the control group, not before two months from discharge, if a further weight loss ≥ than 5% is reported."
46093502|NCT00879996|Drug|Methadone|Oral, 10-60 mg per day, 2-4 times per day, 6 months
46093503|NCT00879996|Drug|Buprenorphine/naloxone|Sub-lingual, 4-16 mg per day, divided 2-4 times/day, 6 months
46093504|NCT00969163|Drug|testosterone gel|300 ug or 2.5 mg transdermal testosterone gel daily for 6 weeks
46093505|NCT00969163|Drug|Comparator: placebo|transdermal placebo gel for 6 weeks
46093506|NCT02784041|Drug|single adductor-canal-block|Single adductor-canal-block is performed before the surgery. A 12Hz linear ultrasound transducer is placed on the medial part of the thigh with the leg slightly externally rotated. The femoral artery was identified in short axis in the adductor canal, underneath the sartorius muscle. After skin disinfection , an 18-gauge needle (B.Braun Medical, Melsungen, Germany) is inserted in-plane from the lateral side of the transducer. The needle tip was placed underneath the sartorius muscle, just lateral to the artery and saphenous nerve, using 2-3 ml of saline to ensure correct placement. 25 ml of 0.35% ropivacaine is slowly injected with repeated aspiration.
46093507|NCT02784041|Drug|periarticular infiltration|The periarticular infiltration of multimodal agents will involve the preparation of a mixture of 100 ml solution. The mixture contains 30ml (300mg) ropivacaine, 0.5ml (5 mg) morphine, 2 ml (50 mg) flurbiprofen and 0.5 ml of 1:1000 epinephrine, and then is diluted with 0.9% normal saline to a total volume of 100ml. 50 ml of mixture will be injected into the anterior, medial and lateral soft tissues after the implantation of the joint prostheses. The remaining 50 ml of mixture will be injected into intraarticular space after the closure of articular capsule.
46093508|NCT04910048|Other|POPOP (preoperative patient optimization program)|A 2 month structured program focused on reduction of BMI, body weight, visceral fat, body fat and improvement of lean body mass and intracellular fluid.
46093509|NCT04910048|Other|SOC (standard of care)|Referral to a dietician for two months of self-directed weight loss
46093510|NCT00873093|Drug|L-asparaginase|Given IM 6000 IU/m2/dose Days 2 and 9
45678435|NCT01793883|Drug|40 mg Laninamivir Octanoate|
46093511|NCT00873093|Drug|doxorubicin hydrochloride|Given IV 60 mg/m2/dose on Day 1
46093512|NCT00873093|Drug|therapeutic hydrocortisone|Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 and 29 Block 2: Days 1 and 22
46093513|NCT00873093|Drug|vincristine sulfate|Given IV 1.5 mg/m2 (max 2 mg) on Days 1, 8, 15 and 22
46093514|NCT00873093|Drug|cytarabine|Given IT or IV 3,000 mg/m2/dose on Days 1, 2, 8 and 9
46093515|NCT00873093|Drug|prednisone|Given PO or IV 40 mg/m2/day on Days 1-28
46093516|NCT00873093|Drug|bortezomib|Given IV 1.3 mg/m2/dose Block 1: Days 1, 4, 8 and 11 Block 2: Days 1, 4 and 8
45459786|NCT03726216|Drug|Xydalba|Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration [e.g. hospital, ICU]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
45459787|NCT00204490|Dietary Supplement|isoflavones|soy isoflavones: Each tablet contains 246 mg Novasoy, 676 mg calcium, 15 mg riboflavin, and other innert materials to a total weight of 1000 mg. Subject takes two isoflavone tablets plus 1 multi-vitamin per day for five days per week for upto 2 years.
45678436|NCT01793883|Drug|80 mg Laninamivir Octanoate|
45678437|NCT01793883|Drug|Placebo|
45678438|NCT01792635|Drug|PF-05175157|PF-05175157 will be administered at 200 mg twice a day for 43 days.
45840173|NCT00666978|Behavioral|smoking cessation intervention|
46093517|NCT00873093|Drug|pegaspargase|Given IM or IV (over 2 hours) 2500 IU/m2/dose on days 2, 8,15 and 22
46093518|NCT00873093|Drug|methotrexate|Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 and 29 Block 2: Days 1 and 22
46093519|NCT00873093|Drug|etoposide phosphate|Given IV 100 mg/m2/dose on Days 1-5
46093520|NCT00873093|Drug|cyclophosphamide|Given IV 440 mg/m2/dose on Days 1-5
46093521|NCT00873093|Biological|filgrastim|Given IV or SC 5 micrograms/kg/dose Only on Day 6
46093522|NCT00873093|Drug|leucovorin calcium|Given PO or IV 15mg/m2/dose q6h x 3 doses
46093523|NCT00873093|Other|laboratory biomarker analysis|Correlative studies
46093524|NCT00873093|Drug|High Dose MTX|IV 5000 mg/m2/dose Block 2: Day 22
46093525|NCT00661752|Device|quarter-time stress scans reconstructed by WBR (4SPS) - Xpress3.Cardiac|Comparison of the diagnostic quality of quarter-time WBR stress with stress studies generated via FBP and half-time WBR
46093526|NCT00661752|Device|quarter-time rest scans reconstructed by WBR (6/8/10 SPS) - Xpress3.Cardiac|Comparison of the diagnostic quality of 6 SPS quarter-time rest acquisitions with FBP and half-time WBR rest studies; simulated 8 SPS and 10 SPS quarter-time rest acquisitions are also compared to FBP and half-time WBR rest studies.
46093527|NCT02664662|Other|tailored education|Tailored rehabilitated education is which fit for each breast cancer patients after surgery in clinic. We design three of tailored books for experimental group. Each patients will be tailored by three principles. First, the educated times and hours are depended on patients physical function and learning ability. Second, the material is depended on each patient's life experience. Finally, the educated content is depended on patient's operation method.
46093528|NCT02183987|Other|Active Knowledge Translation Intervention|"Access to CSN guidelines, & provider- & patient-directed infographics recommending an intent-to-defer dialysis initiation strategy will be displayed in prominent clinic wall space & disseminated to patients.~Educational whiteboard video will be made available as a resource for clinic staff & patients.~Each clinic will receive reports from the Canadian Organ Replacement Register (CORR) outlining the proportion of patients followed by a Nephrologist (>3 months) starting dialysis early (eGFR >10.5 ml/min), for all incident dialysis patients from the clinic, with provincial & national average comparisons. These reports, & the CSN guideline on timing of dialysis initiation recommendation, will be delivered to the medical lead for each CKD clinic.~Each clinic will receive an in-person visit from one of the study investigators/collaborators highlighting the clinical practice guidelines & evidence supporting an intent-to-defer strategy, & will receive follow-up."
46093529|NCT04008667|Other|Acupoint application|Acupoint application: The patients start using the acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
46093530|NCT04008667|Other|Fake acupoint application|Fake acupoint application: The patients start using the fake acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
46093531|NCT04174040|Behavioral|Gross's Process of Emotion Regulation Model Interventions|"Interventions were based on Gross's Process Model which include the basis concepts of cognitive-behavioral therapy and carried on with five semi-structured sessions. Cognitive-behavioral theories accept the existence of a thought process (attention-perception-interpretation) that appears in the mind about the event just before the anger emerges. Therefore, anger studies with cognitive-behavioral approach generally proceed with the steps of gaining awareness about this concealed thought, identifying behavioral response and avoidance attitudes and thus regulating emotion. It consists of five 90-minute group sessions structured in this context. While being an accredited cognitive behavioral therapist, investigator have qualified to manage these approach.~The effectiveness of these semi-structured sessions were evaluated by using:~Pretest application of STAXI~Taking feedback after each intervention session~Posttest application of STAXI~Follow-up test application of STAXI"
46093532|NCT04174040|Behavioral|Musical Rhythm Interventions|"This musical group rhythm intervention was continued with 90 minute long five sessions. The students participated in the practice together with a music expert and lead researcher. The lead researcher took on the role of observer in these sessions. Each session was continued with warming, improvisation and targeted semi-structured rhythm practices aiming anger regulation. The effectiveness of these semi-structured sessions were evaluated by using:~Pretest application of STAXI~Taking feedback after each intervention session~Posttest application of STAXI~Follow-up test application of STAXI"
45459788|NCT00204490|Dietary Supplement|carbohydrate|carbohydrate: 246 mg maltodextrin, 676 mg calcium, 15 mg riboflavin and other innert ingredients to a total weight of 1000 mg per tablet. subject takes two tablets plus one multivitamin per day for five days per week for upto 2 years.
45459789|NCT05198024|Behavioral|Nutrition knowledge|Nutrition knowledge either 'Usual care plus new education programme' or 'Usual care plus biggest loser'
45459790|NCT00089791|Drug|placebo|Placebo administered by subcutaneous injection
45459791|NCT00089791|Drug|Denosumab|Denosumab 60 mg administered by subcutaneous injection
45459792|NCT03558672|Device|Flexitouch system with Head and Neck Garments|Flexitouch system or Flexitouch Plus Head and Neck Treatment, as prescribed
45459793|NCT03476512|Other|Adherence Education|Patients were given adherence education to resolve the identified deficits
45459794|NCT03633188|Biological|Patients treated by antibiotherapy|"Biological samples (stool, blood, swabs) will be collected :~Blood sampling (12 ml) at baseline (week 0) at the end of treatment (W6/W24),and 15 days after antibiotherapy stop (optional) (W8/W26),~Feces collection at baseline (week 0) during antibiotic treatment (W2), at the end of treatment (W6/W24),15 days after antibiotherapy stop (W8/W26), and W26 after baseline~Swab samples (nasal and rectal) at baseline at week 0 and at the end of treatment (W6/W24),"
45459795|NCT04939870|Diagnostic Test|Biochemical parameters evaluation|selected biochemical parameters
45840174|NCT00666978|Drug|bupropion hydrochloride|
45840175|NCT00666978|Genetic|gene expression analysis|
45840176|NCT00666978|Genetic|polymerase chain reaction|
45840177|NCT00666978|Other|counseling intervention|
45840178|NCT00666978|Other|educational intervention|
45840179|NCT00666978|Procedure|psychosocial assessment and care|
45840180|NCT00668382|Biological|Alpha-Gal Glycosphingolipid|Intra-tumoral injection of Alpha-Gal Glycosphingolipid to evaluate toxicity
45840181|NCT00669552|Procedure|Percutaneous coronary intervention|PCI previously electively scheduled.
45840182|NCT00670956|Drug|Betamethasone|12 mg intramuscularly x 2 doses 24 hours apart
45840183|NCT00670956|Drug|Placebo|PLACEBO: IM x 2 doses 24 hours apart
45840184|NCT00671502|Drug|Carisoprodol SR|700 mg twice daily
46006822|NCT04585373|Other|kinesio-taping with conventional therapy 48 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
46093533|NCT04174040|Behavioral|Musical Rhythm Integrated Gross's Emotion Regulation Process Interventions|"The students participated in the practice together with a music expert and lead researcher. The lead researcher ensured the integration of rhythm applications into the Process Model through cognitive-behavioral semi-structured interventions. Five semi-structured 90-minute group sessions were performed. The effectiveness of the experiment was evaluated by using:~Pretest application of STAXI~Taking feedback after each intervention session~Posttest application of STAXI~Follow-up test application of STAXI"
46006823|NCT04585373|Other|kinesio-taping with conventional therapy 72 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
46093534|NCT02785289|Device|Vaginal swab|Vaginal cell collection will be performed with the two types of indicated swab.
46006824|NCT04592601|Procedure|S.L.I.M.M.S. Procedure|Combined Gastric Bypass with Vertical Sleeve Gastrectomy
46093535|NCT00969319|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
46093536|NCT02784899|Drug|iloprost|"20μg(2ml) of inhaled iloprost (Ventavis®)~When anesthesia induction finishes, change patients' position from supine to lateral position and measure arterial blood gas analysis (ABGA), venous blood gas analysis (VBGA) while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished."
46093537|NCT02784899|Drug|normal saline|"20μg(2ml) of inhaled normal saline~When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished."
46093538|NCT00647582|Procedure|adjuvant therapy|
46093539|NCT00647582|Procedure|therapeutic conventional surgery|
46093540|NCT00647582|Radiation|intraoperative radiation therapy|
46093541|NCT00647582|Radiation|radiation therapy|
46093542|NCT00974389|Biological|bevacizumab|
45459796|NCT05671094|Behavioral|Prehabilitation|Physical, mental, stress reducing and dietary prehabilitation programme, 4 to 2 weeks before surgery
45459797|NCT03482908|Behavioral|Early healthy lifestyles|Patient reported data to identify parenting practices and child behaviors associated with child's obesigenic risk in the future
45459798|NCT03482908|Behavioral|Responsive parenting curriculum|Information from the American Academy of Pediatrics Healthy Active Living for Families (HALF) program supplemented with messages from the INSIGHT study, that were written at the 5th grade reading level, with messages focused on 4 categories: 1) feeding the baby 2) soothing the baby 3) sleep health and 4) playing with the baby
45840185|NCT00671502|Drug|Carisoprodol SR|500 mg twice daily
45840186|NCT00671502|Drug|Placebo|Placebo tablet
45840187|NCT00671970|Drug|Bevacizumab and Erlotinib|"Bevacizumab administered intravenously at dose 10 mg/kg every 2 wks. Erlotinib administered orally, continuously once daily in fasting state for each 42-day cycle. Dose of erlotinib is based on prior erlotinib monotherapy trial in RMG. It will be 200 mg/day for pts not on cytochrome P450 3A4 (CYP3A4)-enzyme inducing anti-epileptic drugs & 500 mg/day for pts on EIAEDs.~It is possible that taking erlotinib w regular medications or supplements may change how erlotinib, subject's regular medications, or subject's regular supplements work. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent."
46093543|NCT00974389|Drug|tegafur-gimeracil-oteracil potassium|
46093544|NCT00646100|Procedure|transcatheter arterial chemoembolization|chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization.
46093545|NCT00969397|Drug|Topical Antiangiogenic|Topical Antiangiogenic
46093546|NCT00969397|Device|Pulsed Dye Laser|Pulsed Dye Laser
46006825|NCT04584944|Radiation|Dual energy X-ray absorptiometry|"Evaluation of the appendicular muscle mass of the limbs will be performed by Dual-Energy X-ray Absorptiometry, using a QDR 4500. Body composition analysis will also be evaluated with TANITA Body Composition Analyzer device,model BC-418MA. Bioelectrical Impedance Analysis measures the body composition using a constant power source (high frequency current 50kHz, 90 μA).~Muscle mass is also going to be measured by using ultrasound -U/S. It measures basic parameters such as muscle volume and spectrum length through the B-Mode imaging with Linear 7-12MHz frequency heads that can reliably determine the thickness and transverse incisions of the superficial muscular Groups."
46006826|NCT04592718|Behavioral|Slow deep breathing plus breath counting|Participants will perform a daily 5-min slow deep breathing exercise for 4 weeks. A breathing rate of 6 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
46006827|NCT04592718|Behavioral|Normal-paced breathing plus breath counting|Participants will perform a daily 5-min normal-paced breathing exercise for 4 weeks. A breathing rate of 15 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
46093547|NCT02783885|Drug|immunotherapy|
46093548|NCT00647660|Drug|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fasting
46093549|NCT00647660|Drug|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fasting
46093550|NCT00974467|Behavioral|After The Injury website|Parents participate in a web-based prevention intervention, which provides education and tips specific to coping with a child's injury.
45459799|NCT03482908|Behavioral|Data sharing/coordination|Data integration into child's electronic health record that is shared between settings (WIC and GHS PCPs) with display and documentation features that informs counseling.
46093551|NCT00974467|Other|Control|Usual hospital care provided.
46093552|NCT00634595|Drug|E10A|E10A 1*10(12)VP, intratumoral injection, d1 d8, repeat every 3 weeks for 4 cycles
46093553|NCT00634595|Drug|Cisplatin|25 mg/m2/d ivd d3 d4 d5, repeat every 3 weeks for 4 cycles.
46093554|NCT00634595|Drug|Paclitaxel|160 mg/m2 ivd d3, repeat every 3 weeks for 4 cycles.
46093555|NCT04899752|Behavioral|Motivational Interviewing|Participants will participate in three different communication styles to determine the effect of MI on cardiac rehab outcome measures.
46093556|NCT00969475|Device|Lumenis fractional carbon dioxide laser|intra-operative laser resurfacing at time of wound closure
46006828|NCT04584905|Dietary Supplement|dietary supplements for CKD patients|follow up and assessment of nutritional status of CKD patients
46006829|NCT00566904|Drug|Epikeia coatings with aspirin|Applied to affected skin area using a roll-on ball applicator
46006830|NCT00566904|Drug|Epikeia coatings with lidocaine|Applied to affected skin area using a roll-on ball applicator
46006831|NCT00566904|Other|Epikeia coatings alone|Applied to affected skin area using a roll-on ball applicator
46093557|NCT00647738|Drug|Baclofen|Single-dose 20 mg immediate-release oral tablets
45459800|NCT02881268|Other|blood sample|
45678439|NCT01792635|Drug|Placebo|Placebo tablets matched to PF-05175157 will be administered twice a day for 43 days.
46093558|NCT00647738|Drug|Baclofen|Single-dose 20 mg immediate-release oral tablet
46093559|NCT02783963|Device|OCT and CMR imaging|"OCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings."
46093560|NCT04008511|Drug|Regorafenib|Phase Ib Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX.
46093561|NCT04008511|Drug|Regorafenib|Phase II: Regorafenib MAD qd po for 14 days, every 3 weeks.
46093562|NCT04008511|Drug|Capecitabine|Capecitabine 1000 mg/m2 bid po for 14 days.
46093563|NCT04008511|Drug|Oxaliplatin|Oxaliplatin 130mg/m2, day 1, every 3 weeks
46093564|NCT02783807|Device|Eyenez Retinal Camera v200|
46093565|NCT02783807|Device|Volk Pictor Ret 1|
46093566|NCT00979537|Drug|Nisoldipine Extended-release Tablets, 40 mg|
46093567|NCT00979537|Drug|Sular Tablets, 40 mg|
46093568|NCT02667314|Behavioral|Jigsaw puzzles|"Intervention period 1: Participants are asked to solve jigsaw puzzles at home 6 times per week for at least 1 hour over a period of 5 weeks.~Intervention period 2 (voluntary): Participants receive the possibility to solve jigsaw puzzles free-of-charge at home for a period of at least 3 month before the 1.5-year follow-up."
46093569|NCT02667314|Behavioral|Cognitive health counseling|Cognitive health counseling regarding modifiable risk and protective factors of cognitive decline and dementia at baseline, and four telephone calls for expert monitoring (three calls during the 5-week period between pre- and posttest, and one call 12 month later)
46093570|NCT02783651|Other|Other|No intervention other than routine medical care
46093571|NCT00692055|Drug|PN400|naproxen 375 mg / esomeprazole 20 mg
46093572|NCT00692055|Drug|Naproxen|naproxen 375 mg
46093573|NCT04174976|Procedure|wall hernia repair|Wall hernia repair with mesh
46093574|NCT04232501|Device|Cirvo Compression device|Patients will wear Cirvo compression device during the surgery, after surgery and will be discharged to home with the device to wear at home as the per study protocol instructions.
46093575|NCT04072250|Procedure|hepatectomy|Hepatectomy for patients with recurrent intrahepatic cholanigocarcinoma
46093576|NCT02625051|Procedure|Ureteroscopy|Under general anesthesia, the patient is placed in the lithotomy position. All procedures are performed under direct videoscopic and fluoroscopic guidance. Fluoroscopic screening is utilized using a mobile multidirectional C-arm fluoroscopy unit. A safety guide-wire is then placed into renal pelvis, followed by a ureteral access sheath to maintain low intra-renal pressure, and to facilitate the procedures. Using flexible ureteroscope, renal or proximal ureteral stone is identified and fragmented with a holmium laser. Basket extraction of residual fragments is done until visual complete clearance of stone fragments is achieved.
46093577|NCT02625051|Procedure|Percutaneous nephrolithotomy|Under general anesthesia, an open-ended 5 french ureteral exchange catheter is placed into the ipsilateral ureter under cystoscopic guidance. The patient is then safely turned and secured in the prone position. Percutaneous renal access is obtained under ultrasonographic or fluoroscopic guidance. Either a 24 or 30 french sheath is advanced in the kidney and nephroscopy is performed with a rigid offset nephroscope. Stone fragmentation is accomplished using a dual CyberWand lithotripter or holmium laser lithotripsy. Flexible nephroscopy is performed to look for possible residual fragments and basket extraction is done for complete clearance of stone.
46006832|NCT04584983|Drug|usual prescribed intralipid (UL) regimen|Intralipid will be started at 1 g/kg/day and routinely advanced by 1 g/kg/day each day to a max of 3 g/kg/day as per usual clinical practice
46006833|NCT04584983|Drug|restricted prescribed intralipid (RL) regimen|Intralipid will be started at 0.5 g/kg/day and routinely advanced by 0.5 g/kg/day each day to a max of 1.5 g/kg/day (half rate of usual clinical practice).
46006834|NCT00568100|Procedure|PSV and NAVA|evaluated the effect of PSV and NAVA on breathing pattern, respiratory effort, gas exchange and level of breathing comfort in COPD patients
46006835|NCT04576611|Other|face-to-face protocol|The intervention is based on education (on pain neurophysiology and healthy lifestyle habits) and physical exercise (strength, flexibility, joint mobility and self-massage).
46006836|NCT04576611|Other|self-managed protocol|Subjects of this group receive the same intervention content as the other experimental group, but through a mobile application.
46006837|NCT04584515|Drug|IMP4297 40 mg|IMP4297 40 mg: IMP4297 alone, Itraconazole + IMP4297
46006838|NCT04584515|Drug|IMP4297 100 mg|IMP4297 100 mg: IMP4297 alone, Rifampin + IMP4297
46006839|NCT04592679|Device|FES-C|The participants were submitted to 20 sessions of FES-C three/five times per week. Each session lasted about 30'.
46006840|NCT04592679|Other|Standard Treatment|The participants were submitted to 20 sessions of standard rehabilitation for lower limbs with manual mobilization, three/five times per week. Each session lasted about 30'.
46006841|NCT04592757|Device|Virtual mirror therapy via VR headset|Participants will perform Activities of Daily Living (ADL) in a virtual environment through a VR headset. The application is based on mirror therapy. Participants will execute certain arm movements with their non-affected arm, while seeing their affected arm perform said movement in the virtual environment.
46093578|NCT04232267|Device|MEB-001|Software medical device used to aid in the screening of patients with potential depressive burden symptoms.
46093579|NCT04033250|Drug|Sodium Picosulfate / Magnesium Oxide / Citric Acid in two split doses + one dose of polyethylene glycol + two Bisacodyl tablets day before the procedure|Bowel preparation
46093580|NCT02624973|Drug|Neoadjuvant tamoxifen + goserelin (premenopausal women)|
46093581|NCT02624973|Drug|Neoadjuvant letrozole (postmenopausal women)|
46093582|NCT02624973|Drug|Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)|
46093583|NCT02624973|Drug|Neoadjuvant docetaxel + cyclophosphamide|
46093584|NCT02624973|Drug|Neoadjuvant docetaxel|
46093585|NCT02624973|Drug|Neoadjuvant docetaxel + trastuzumab + pertuzumab|
46006842|NCT04584476|Procedure|superior capsular reconstuction|these patients underwent arthroscopic superior capsular reconstuction
46006843|NCT04584476|Procedure|partial rotator cuff repair|these patients underwent arthroscopic partial rotator cuff repair
46093586|NCT02624973|Drug|Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab|
45678440|NCT01953692|Biological|Pembrolizumab|IV infusion
45678441|NCT01953692|Drug|Lenalidomide 20 mg|oral capsule
46006844|NCT00582699|Behavioral|assessment interview and blood draw|All subjects will be administered a battery of clinician rated and self report instruments including measures of depression, fatigue, and cognitive functioning. In addition, measures of pain, sleep, and anxiety will also be utilized to assess these important potential confounding variables. The SCIDIV will be used to ascertain the presence or absence of a current DSMIV diagnosis of Major Depressive Episode for all subjects. The interview should take approximately fortyfive minutes to complete. Patients will have their blood drawn once, in order to determine plasma levels of the cytokines IL1, IL6, TNFalpha, IL10, IL15 and IFNgamma.
46006845|NCT04584437|Other|Infrared Energy and Dietary Supplement|Infrared Energy with a wavelength of 5 - 20 microns. Multivitamins and minerals including Vitamin C Supplements.
46093587|NCT02624973|Drug|Neoadjuvant olaparib|
46093588|NCT02624973|Drug|Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone)|
46093589|NCT02624973|Procedure|Breast conserving surgery or mastectomy + SNB/axillary dissection|After response to neoadjuvant treatment
46093590|NCT02624973|Radiation|Postoperative radiotherapy breast/chest wall + regional lymph nodes|
46093591|NCT02624973|Drug|Adjuvant trastuzumab|
46093592|NCT02624973|Drug|Adjuvant letrozole (postmenopausal women)|
46093593|NCT02624973|Drug|Adjuvant tamoxifen + goserelin (premenopausal women)|
46093594|NCT02624973|Drug|Adjuvant palbociclib (if palbociclib given neoadjuvant)|
46093595|NCT02624973|Drug|Adjuvant Epirubicin+ Cyclophosphamide|
46093596|NCT05191823|Drug|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)|200 mg DHA+ 200 mg AA per day for 6 months
45678442|NCT01953692|Drug|Lenalidomide 25 mg|oral capsule
46093597|NCT05191823|Dietary Supplement|Placebo|400 mg corn oil per day for 6 months
46093598|NCT00647816|Drug|Propranolol Hydrochloride Extended-Release Capsules 160 mg|160mg, single dose fasting
46093599|NCT00647816|Drug|Inderal® LA Capsules 160 mg|160mg, single dose fasting
46093600|NCT04173806|Other|Facebook intervention|"The intervention consists of the content of the course on telemedicine through a closed group of Facebook according to the established syllabus whose educational material is video classes, discussion forums and online questionnaires. The duration of the course will be 5 weeks, each week two classes will be uploaded to the Facebook platform in succession until the course is completed. So that the student can visualize the content progressively and continuously."
46093601|NCT04173806|Other|Control Training:|In this group the participants are exposed to the same course content and perform similar activities as the intervention group on Facebook during the same period but on the Moodle educational platform. The Moodle platform was chosen because it has been widely used in several institutions, with a large user community worldwide, with approximately 50,000 registrations in more than 200 countries and due to the many easy-to-use educational tools it offers. So it is one of the educational platforms that has demonstrated its efficiency in the medical educational field.
46093602|NCT05182931|Drug|Dabrafenib 75 MG|Refer arm description
46093603|NCT05182931|Drug|Trametinib 2 MG|Refer arm description
46093604|NCT00647894|Drug|Alprazolam Extended-Release Tablets 1 mg|
46093605|NCT00647894|Drug|Xanax XR Tablets 1 mg|
46093606|NCT02782559|Drug|Sildenafil|
46093607|NCT02782559|Drug|Placebo|Color and size matched to active drug (sildenafil)
46093608|NCT00647972|Drug|Olanzapine Tablets 20 mg|20mg, single dose fasting
46093609|NCT00647972|Drug|Zyprexa® Tablets 20 mg|20mg, single dose fasting
46093610|NCT02782403|Drug|Axitinib|Given PO
46093611|NCT02782403|Drug|Bosutinib|Given PO
46093612|NCT02782403|Other|Laboratory Biomarker Analysis|Correlative studies
46093613|NCT00646178|Drug|adalimumab|40 mg adalimumab eow Week 0 - Week 12
46093614|NCT00646178|Drug|placebo for adalimumab|placebo eow Week 0 - Week 12
46093615|NCT02624817|Drug|Sulfonylurea|See Arm description.
46093616|NCT04172168|Diagnostic Test|Heart rupture|Left ventricular free-wall ruptrue after AMI
46006846|NCT04584593|Biological|Sample|Men will give semen, saliva, nasopharyngeal, urine and blood specimens
46093617|NCT02783417|Other|Strength Training|"G1: will be three series of repetitions to the concentric failure with occlusion pressure, with the two-second intervals for the concentric phase and two seconds for the eccentric phase (Moore et al., 2004;. LAURENTINO et al, 2012), with 30% of 1RM and intermittent vascular occlusion members. Will be provided one-minute intervals between sets and exercises (with the exception of the interval between the exercises of upper and lower; being provided at present a three-minute break for removal and installation of restrictive cuffs).~G2: will be three series of repetitions to the concentric failure, with cadence of movement and intervals similar to the G1. The intensity will be 80% of 1RM without occlusion."
46006847|NCT04584710|Drug|RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 2 weeks
46093618|NCT00692367|Behavioral|Physical Activity|1. Physical activity group: Subjects will be progressed to 4-5 days per week, 30-45 min per session (120-180 min per week) of moderate intensity exercise. 2. Control (educational) group: Subjects will receive their usual care following surgery that in addition to their weight loss.
46093619|NCT04230863|Behavioral|Neuroplasticity-based Computerized Cognitive Remediation|"The nCCR has two major components: Bottom up and Top down training. Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
46093620|NCT02666144|Device|Spectralis OCT|Measurement of structural parameters of the optic nerve head (ONH), in particular, the neuroretinal rim of the ONH, and the peripapillary retinal nerve fiber layer.
46093621|NCT04230551|Procedure|PTSMA|Alcohol Septal Ablation
46093622|NCT00692523|Other|Recreational therapy activities|Recreational therapy sessions will include leisure activities such as playing cards and/or doing arts and crafts.
46093623|NCT00692523|Other|Nintendo Wii|The Nintendo Wii gaming system, released in 2005, introduced a new style of virtual reality by using a wireless controller that interacts with the player through a motion detection system. Nintendo Wii involves the incorporation of 3-dimensional accelerometer technology that can respond to changes in direction, speed, and acceleration, down to the most delicate movements. Specifically, the controllers use embedded acceleration sensors to enable players' wrist, arm, and hand movements to interact with the games. Tilt measurements allow users to move characters, while the accurate three-axis acceleration sensing easily transforms the controller into a virtual sword, gearshift, or musical instrument
45459801|NCT03558516|Drug|Magnesium group|We will dilute magnesium 6 gram with 0.9% sodium chloride to 30 ml. The patient will receive magnesium sulfate 40 mg/kg infuse over 30 min started at skin incision and continuous drip 10 mg/kg/hr until the dura is closed. Anesthesia is standardized with propofol, fentanyl, cisatracurium and sevoflurane. Vasopressor or antihypertensive drug are used to control hemodynamics.
46006848|NCT04584710|Drug|Placebo|Oral matching placebo once daily for 2 weeks
46093624|NCT02664116|Drug|Diclofenac postassium powder for oral solution and placebo injection|Diclofenac postassium powder for oral solution 50 mg in 1 ounce water orally, single dose and placebo normal saline 2ml intramuscular injection, single dose
46093625|NCT02664116|Drug|Ketorolac intramuscular injection and placebo oral solution|ketorolac 60 mg in 2 ml intramuscular injection, single dose and placebo oral solution, 1 ounce, single dose
46093626|NCT00692601|Dietary Supplement|Acute consumption of Capsiate Natura|10 capsules = 3 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. 3 active capsules containing 1 mg capsiate each and 7 placebo capsules.
46093627|NCT00692601|Dietary Supplement|Acute consumption of Capsiate Natura|10 capsules = 10 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
46093628|NCT00692601|Dietary Supplement|Acute ingestion of identical placebo capsules|10 mg placebo = 0 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
46093629|NCT02664194|Device|Proteus® Cooling System|Intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters, using Proteus® Cooling System.
46093630|NCT02664194|Procedure|Primary Percutaneous Coronary Intervention|Primary percutaneous coronary intervention
46093631|NCT02785055|Procedure|Thoracic Epidural Placement|Thoracic Epidural Placement
46093632|NCT02785055|Drug|Bupivacaine 0.05%|Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution
46006849|NCT00582777|Behavioral|USUAL - take your BP Meds as you usually do|The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.
46006850|NCT00582777|Behavioral|HS DOSING|Take your usual BP meds at bed time
45678443|NCT01791153|Drug|Tocilizumab|Tocilizumab will be administered at a dose of 162 mg as SC injection qw or q2w for 52 weeks in Part 1 of the study and at a dose 162 mg as SC injection qw for 104 week at the discretion of the investigator in Part 2 of the study.
46006851|NCT00582777|Drug|ADD On Dosing|Take your usual BP meds but add one more med at bed time.
46006852|NCT04584398|Device|Respiratory muscle training with steam inhalation|
46093633|NCT02785055|Drug|Hydromorphone 0.01mg/mL|Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution
46093634|NCT02624661|Drug|Glycerol|
46093635|NCT02689817|Device|Patch|A bandage applied to the sacrum with pressure offloading characteristics and pressure monitoring components in a low-profile housing.
46093636|NCT00648050|Drug|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fasting
46093637|NCT00648050|Drug|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fasting
46093638|NCT00692757|Drug|Hypochlorous acid|Hypochlorous acid for preoperative scrubbing to prevent surgical site infection in spray
46093639|NCT00692757|Drug|Iodopovidone|Iodopovidone
46093640|NCT02783495|Behavioral|Device: iPad|All patients will receive baseline neurocognitive and quality of life testing, followed by 3 months of the iPad-based intervention. At the end of the baseline visit, subjects will be lent an iPad to take home (or will be assisted in the installation of the ReMind app on their personal iPad) and instructed in the use of the ReMind app (and more basic iPad skills, if necessary). Subjects will review the intervention schedule (approximately 3 hours per week). Testing will be repeated 3 months after the baseline visit (i.e., immediately after the intervention) and 9 months after the baseline visit (i.e., 6 months after completion of the intervention), both time-points including a new MRI.
46093641|NCT00646256|Behavioral|COGPACK training, psychoeducation|Bifocal psychoeducation group program (Munich Psychoses Information Program - PIP) with preceding computerbased cognitive training program (COGPACK)
45678444|NCT01791153|Drug|Prednisone|Prednisone will be administered at tapering oral doses as tablets daily for 26 or 52 weeks according to the protocol-defined schedule in Part 1 of the study. Prednisone will also be administered as escape therapy to treat disease flares in an open-label manner during Part 1 at a dose and duration selected by the investigator.
46093642|NCT00974623|Device|Bone graft substitute, autograft or allograft|spine fusion surgery utilizing any commercially available bone graft substitute(s), autograft or allograft
46093643|NCT02624505|Drug|90 mcg Reference Product|Drug: 90 mcg Reference Product
46093644|NCT02624505|Drug|180 mcg Reference Product|Drug: 180 mcg of Reference Product
46093645|NCT02624505|Drug|90 mcg Test Product|Drug: 90 mcg of Test Product
46093646|NCT02624505|Drug|Placebo|Placebo Product
46093647|NCT02664350|Genetic|CYP2D6|Gentic testing for CYP2D6 metabolic pathway will be performed at baseline.
46093648|NCT02664350|Behavioral|Brief Pain Inventory-Short Form (BPI-SF)|This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
46093649|NCT02664350|Behavioral|M.D. Anderson Symptom Inventory (MDASI)|This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
46093650|NCT02664350|Genetic|OPRM1|Genetic testing of the OPRM1 will be performed after week 8.
46093651|NCT00969631|Drug|metformin HCl (Cidophage®; CID,Cairo, Egypt), CC (Clomid®; Global Napi Pharmaceuticals,Cairo, Egypt),Cairo, Egypt)|metformin HCl 1500 daily for 6-8 weeks then 100 mg CC for 5 days starting from day 3 of menstruation up to 6 cycles.
46093652|NCT00969631|Procedure|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
46093653|NCT02783261|Other|CT volumetric measurement after Y90 radioembolization|Liver volume will be measure at 3 time points. All patients will undergo CT volumetry at baseline, 4-6 weeks and 8-12 weeks after SIRT. The images are then measured using a commercially available 3D software (Vital's Vitrea Advanced CT Liver Oncology package) and manually corrected, reviewed and resected by a single senior radiologist to ensure consistency in following the same anatomical landmarks.
46093654|NCT00912561|Behavioral|Intense aerobic exercise|3 Units (of at least 30 minutes) of intense aerobic exercise per week for 8 weeks
46093655|NCT00974701|Device|PillCam ESO2|The capsule to be tested in this proposed study, PillCam ESO 2 capsule Endoscopy, is an improved version with exactly the same dimensions as the current PillCam ESO capsule, both in length and diameter.
46093656|NCT02782481|Drug|ND0612|
46093657|NCT02782481|Drug|Placebo|
46093658|NCT04137081|Behavioral|App-based mindfulness training|Unwinding Anxiety is an app-based mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time.
46093659|NCT00884286|Drug|Aplidin®|Aplidin® will be administered at a starting dose of 3.2 mg/m2, as a 1-hour intravenous infusion, on days 1, 8 and 15, every 28 days cycle.
46093660|NCT02664428|Dietary Supplement|PreBIOil|A daily dose of about 90 gram will be given for 8 weeks
46093661|NCT02664428|Dietary Supplement|Control|A daily dose of about 90 gram will be given for 8 weeks
46093662|NCT00692835|Procedure|Total Thyroidectomy (Mini Video Assisted Thyroidectomy)|Immediate postoperative course of patients with Thyroidectomy
46093663|NCT00692835|Procedure|Total Thyroidectomy (Classic Thyroidectomy)|Immediate postoperative course of patients with Thyroidectomy
46006853|NCT03454113|Device|Ellipsys Vascular Access|The Ellipsys Vascular Access System comprises the Ellipsys Catheter, Ellipsys Crossing Needle and Ellipsys Power Controller. The Ellipsys Crossing Needle is used to facilitate access between the artery and the vein. The Ellipsys Catheter is placed percutaneously into the selected vein in close proximity to the selected artery. The Ellipsys Catheter is actuated at the selected anastomosis site, and the vein and artery are approximated. Once the vessels are in the appropriate relative positions the catheter is connected to the Ellipsys Power Controller to create the anastomosis after which the Ellipsys Catheter is removed, and the access site is closed using standard percutaneous closure techniques.
46093664|NCT04229927|Drug|BPDO-1603|"Arm1 : 1 tablet of the test drug, and 1 tablet of placebo reference drug~Arm2 : 1 tablet of the reference drug, and 1 tablet of placebo test drug"
46006854|NCT04584671|Diagnostic Test|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
46093665|NCT00648128|Drug|Clarithromycin|Single-dose 500 mg immediate-release oral tablet
45459802|NCT03558516|Drug|Normal saline group|The patient will receive 0.9% sodium chloride the same amount of magnesium sulphate infuse over 30 min started at skin incision and continuous drip until the dura is closed. Anesthesia is standardized with propofol, fentanyl, cisatracurium and sevoflurane. Vasopressor or antihypertensive drug are used to control hemodynamics.
45678445|NCT01791153|Drug|Tocilizumab Placebo|Tocilizumab placebo will be administered as SC injection qw or q2w for 52 weeks in Part 1 of the study.
46006855|NCT04584671|Diagnostic Test|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
46093666|NCT00648128|Drug|Clarithromycin|single-dose 500 mg immediate-release oral dose'
46093667|NCT00969787|Drug|DWP05195|tablets, oral administration, single and multiple administrations
46093668|NCT05342597|Drug|MT-1186|A crossover study in which Japanese healthy subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 3, 5, 7 and 24 according to their treatment sequence.
46006856|NCT04584671|Diagnostic Test|Pulmonary Function Tests (PFT)|Participants will have their lung function evaluated using PFT
46006857|NCT04584671|Diagnostic Test|Six Minute Walk Test (6MWT)|Participants will perform the six minute walk test as a measure of exercise capacity
46006858|NCT04584671|Diagnostic Test|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
46006859|NCT04584671|Diagnostic Test|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
46006860|NCT04584671|Other|Questionnaires|Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.
46006861|NCT00582855|Drug|AQW051|
46006862|NCT00582855|Drug|Placebo|
46006863|NCT04584359|Other|HVLA|High velocity, low amplitude manipulation for the sacroiliac joint and T10-L2. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 5 minutes.
46006864|NCT04584359|Other|global osteopathic protocol|Myofascial, visceral, and articular techniques. Complete treatment in order to restore and rebalance internal tensions and improve the visceral mobility: muscle inhibition techniques for the psoas muscle; deep massage in the obturator foramen; stretching for the greater omentum; lift of the uterus, ovary, and bladder ; abdominal maneuver; and thrust of sacroiliac joint and T12-L1. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 15 minutes.
46093669|NCT04137159|Other|Functional Electrical Stimulation rowing exercise|Full-body aerobic exercise
46093670|NCT00974779|Device|HCO1100 dialyzer|Thrice weekly dialysis using the HCO1100 dialyzer for 4.5h, 2 weeks
46093671|NCT00974779|Device|regular dialysis polyamide|Continuation of the regular hemodialysis using polyamide high-flux hemodialysers
46093672|NCT02667158|Other|Survey to Eval Relation between Shopping and Misuse, Abuse|A Survey Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion
46093673|NCT02784821|Drug|Antibiotic|Babies that are assigned to antibiotics receive therapy based on the clinical team's discretion.
46093674|NCT02784821|Other|Gastric fluid|Microbiome, metabolome, and inflammatory mediators will be evaluated using gastric aspirate.
46093675|NCT02784821|Other|Breast milk|Microbiome, metabolome, and inflammatory mediators will be evaluated using mother's breast milk.
46093676|NCT02784821|Other|Stool samples|Microbiome, metabolome, and inflammatory mediators will be evaluated using infant's stool.
46093677|NCT02784821|Drug|Antibiotics - pre-emptive|Babies that are randomized to antibiotics receive therapy based on the clinical team's discretion.
46093678|NCT00665730|Device|Sepraspray|
46093679|NCT00974857|Device|BCM|Overhydration (OH) in liters will be estimated with the BCM (Body Composition Monitor, Fresenius Medical Care, Deutschland GmbH) in order to determine dry weight at least once a month before a dialysis session.
46006865|NCT04584359|Other|pelvic floor muscle training|Pelvic floor muscle training for four weeks, with a weekly face-to-face visit lasting 10-20 minutes. In this intervention, participants were instructed to perform three sequences of exercises: contractions and relaxations (three seconds of sustained contractions and six seconds of rest), ten sustained contractions (ten seconds of sustained contractions and 20 seconds of rest), and five contractions associated with a cough. These exercises were performed in the standing, sitting, and lying positions
46093680|NCT00974857|Other|control group|BCM results obtained at the beginning, at the 6th, and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
46006866|NCT03454074|Behavioral|Problem-solving|Individualized goal-setting and group problem-solving to help older adults effectively integrate realistic, healthy behavioral changes into their everyday lives
46006867|NCT03454074|Behavioral|Education|Education about healthy brain aging behaviors provided.
46006868|NCT04584047|Procedure|Cell-based non-invasive prenatal testing|Blood sampling.
46006869|NCT04584242|Drug|gluconon tab 15mg|frosting and formulation : a round, convex tablet of white to gray. path of administration : once a day, two tabs, oral Amount of raw material medication (1 pill) : Pioglitazone hydrochloride 16.53mg storage method : Store 15 to 30°C to avoid light-tight containers and moisture manufacturing source : DONG-A ST
46006870|NCT04584242|Drug|suganon tab 5mg|frosting and formulation : pink circular film coating tablets path of administration : once a day, one tabs, oral Amount of raw material medication (1 pill) : Evogliptin tartrate 6.869mg(5mg as evogliptin) storage method : Confidential containers, stored at room temperature (1-30°C) manufacturing source : DONG-A ST
46006871|NCT04592835|Drug|DWRX2003|"Intramuscularly injection at predefined injection sites~Drug: Placebo Intramuscularly injection at predefined injection sites"
46006872|NCT04584008|Drug|FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.|According to the treatment dose approved by NMPA/FDA, evaluation will be conducted every 2 cycles until tumor progression or adverse events cannot be tolerated.
45678446|NCT01791153|Drug|Prednisone Placebo|Prednisone placebo will be administered as tablets orally daily according to the protocol-defined schedule (from Week 26 to Week 52) in Part 1 of the study.
46006873|NCT04584008|Drug|Other Therapy|Patients will receive other treatments, including cytotoxic drugs, antiangiogenic drugs, best supportive care, clinical trials of unmatched new drugs, etc..
46006874|NCT04583696|Dietary Supplement|The Investigation of effect on Blood Lipid parameters with walnut addition of Diet|Participants were asked to consume 30 g of walnuts daily for 21 days. Individuals have consumed walnuts on an empty stomach in the morning or with breakfast.
46006875|NCT04592211|Drug|olaparib+pembrolizumab+paclitaxel|olaparib, 100~200mg, PO, bid, continuous pembrolizumab 200mg, IV, q 3 weeks paclitaxel 175g/m2 IV, q 3 weeks
46006876|NCT04583813|Drug|Empagliflozin|Empagliflozin 10 mg oral tablet, once daily, for 24 months
46093681|NCT00646334|Device|Mesh Implantation|An elective incisional Hernia repair is performed by using Optilene® Mesh Elastic, a lightweight and large pore mesh, knitted from monofilament polypropylene. Due to the multidirectional elasticity the mesh is able to adapt to all movements taking place in the abdominal wall.
46093682|NCT00646334|Device|Mesh Implantation|Ultrapro® Mesh is a knitted, partly absorbable, lightweight mesh, consisting of equal parts of nonabsorbable polypropylene and absorbable polyglecaprone (Monocryl®). Polyglecaprone is fully absorbed in the body by hydrolysis. The addition of polyglecapron filament is only intended to reinforce the mesh to allow a convenient intraoperative handling and mesh placement, without additional function. Ultrapro® is an elastic mesh having enlarged elasticity cross to the blue strips.
46093683|NCT04137393|Combination Product|brushing|mechanical and chemical plaque removal
46093684|NCT04229537|Biological|SCT-I10A|200 mg intravenous (IV) on Day 1 of Q3W.
46006877|NCT04583813|Other|Placebo|Empagliflozin matching placebo, once daily, for 24 months
45598977|NCT02297191|Procedure|Thoracolumbar Interfascial Plane Block|"All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle.~Ultrasound images will be saved using the nomenclature TLIP Anatomy~Photos will only include surface anatomy of the low-to-mid back.~Participants will be assessed for evidence of adverse reaction to local anesthesia (tinnitus, disorientation, or perioral numbness) with each 5cc dose of local anesthetic. If any adverse reactions are noted the dosing will be stopped."
45598978|NCT02297191|Drug|Ropivicaine|
46006878|NCT04576143|Drug|Epirubicin|i.v. 90 mg/m2
46006879|NCT04576143|Drug|Cyclophosphamid|i.v. 600 mg/m2
46093685|NCT04229537|Biological|SCT200|6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W
46093686|NCT04229537|Other|Chemotherapy|Capecitabine and Oxaliplatin.
45678447|NCT01791153|Drug|Corticosteroids|Participants without sustained remission at Week 52 will receive corticosteroids at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
46093687|NCT04154592|Other|Humeral Head Depressor Muscle Co-Activation Training- Experimental Group|In addition to the conservative treatment, humeral head depressor muscle co-activation training will be applied for 14 weeks. Participants in the coactivation group will perform the glenohumeral exercises while recruiting the pectoralis major, latissimus dorsi, and teres major muscles. To achieve this, voluntary recruitment of the pectoralis major, latissimus dorsi, and teres major will be taught prior to the demonstration of the glenohumeral exercises using visual feedback provided by EMG Biofeedback. When recruitment is correctly executed (50% of the maximum voluntary contraction signal), it should be maintained while performing the glenohumeral exercises. This will be confirmed by visualizing EMG signals during the exercise training session. During each appointment with the therapist, participants will be evaluated on their capacity to achieve the exercises while performing co-activation.
46006880|NCT04576143|Drug|Docetaxel|i.v. 100 mg/m2
46006881|NCT04576143|Drug|Paclitaxel|i.v. 175 mg/m2
45678448|NCT01791153|Drug|Methotrexate|Participants without sustained remission at Week 52 will receive methotrexate at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
46006882|NCT04592367|Procedure|Patient age at time of procedure of reconstruction of ACL|Primary reconstruction of ACL with no other concomitant ligament reconstructions. Treatment of cartilage og meniscal injury may be a part of the procedure
46006883|NCT04576221|Device|stacked breathing exercise|"• Breath stacking was done using a bag which is a simple device used to give artificial breaths..~It is best done in a sitting position but can be done reclining or lying flat whichever position is used, try to avoid slouching. If sitting: rest against the back of a chair and keep the shoulders, arms and hands relaxed.~If using the mouthpiece, place the lips tightly around the mouthpiece to create a tight seal."
46006884|NCT04576221|Device|NIV by CPAP mask|provides pressurized air through a mask to help push air into your lungs and help you breathe
46006885|NCT04591899|Device|CAD/CAM splints|"Each of the maxillary and mandibular cast will scanned alone and then both scanned together in the centric relation using FREEDOM HD scanner1.~The CAD/ CAM splint will be designed using Exocad software; the design will be the same as the conventional one. The surveying will be done by the software and the under-cuts blocked.~The splints will be printed using Dent2 3D printer and then cured using Dentcure. The CAD/CAM splints material will be hard resin from PhotoCentric 3D."
46006886|NCT04583657|Other|Eggs|Consumption of two eggs (control or test) per day during three months
46006887|NCT04583267|Drug|tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration|Participants will take tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration for preventing HIV infection.
46006888|NCT04583111|Drug|Domperidone|Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
46093688|NCT04154592|Other|Control Group|"The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair will be used as guideline for rehabilitation of patients (Thigpen, C. A., Shaffer, M. A., Gaunt, B. W., Leggin, B. G., Williams, G. R., & Wilcox III, R. B. (2016). The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair. Journal of shoulder and elbow surgery, 25(4), 521-535.).~Individuals in the control group will use shoulder straps for 6 weeks after arthroscopic shoulder surgery. These patients will be referred to physiotherapy clinics 6th week. Patients between 6 and 20 weeks (a total of 14 weeks) will be admitted to the rehabilitation program according to the guideline mentioned above."
46093689|NCT00693069|Drug|Clopidogrel|clopidogrel 300 mg on the day prior to angiography
46093690|NCT00693069|Drug|Clopidogrel|clopidogrel 600 mg on the day prior to angiography
46093691|NCT00693069|Drug|Clopidogrel|clopidogrel 300 mg followed by 75 mg daily started one week prior to angiography
46006889|NCT04583111|Drug|sulpiride|Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
46006890|NCT04583345|Behavioral|Questionnaires|Questionnaires: Physical therapists ask questions these assess quality of life, anxiety and depression, physical activity level.
46006891|NCT04583228|Drug|HLX71|Single-dose, intravenous infusion
46006892|NCT04583228|Other|Placebo|Single-dose, intravenous infusion
46093692|NCT00693069|Drug|Clopidogrel|clopidogrel 300 mg followed by 150 mg daily started one week prior to angiography
46093693|NCT04949282|Drug|Lutetium [177Lu] oxodotreotide/dotatate|Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
46093694|NCT04949282|Device|Lutetium [177Lu] oxodotreotide/dotatate|Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
46093695|NCT00974935|Drug|Aluminum hydroxide|Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
46006893|NCT00583245|Other|Gait Training|Gait training with physical therapist 2/week for 3 months
46006894|NCT04583189|Diagnostic Test|Performance of the test antigenic and test RT-PCR|Each patient will have 1 test rapid antigenic Biosynex Covid-19 Ag-BSS with the results in 15-20 minutes and 1 reference test RT-PCR analyzed in microbiology laboratory of the hospital.
46006895|NCT01146652|Drug|SAR153191 (REGN88)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
46006896|NCT04582877|Device|FFR measurement|FFR is measured sequentially with the test article and the predicate device.
46006897|NCT04576026|Behavioral|mental fatiguing task|a 30-minute computerized Stroop test will be used to induce mental fatigue before exercise intervention
46006898|NCT04576026|Behavioral|45 - minute simulated soccer game|an intermittent running protocol using intensities and speeds seen in soccer will be used to simulate the physiological demands of the sport
46006899|NCT04576026|Behavioral|cognitive function|The Stroop test and a complex reaction time test will be used to assess cognitive function during exercise.
46093696|NCT00974935|Biological|STEBVax vaccine|Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
46093697|NCT00665808|Drug|insulin detemir|"Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany"
46093698|NCT00665808|Drug|isophane human insulin|"Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany"
46006900|NCT04582994|Behavioral|Beta tACS|participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Beta frequencies (22 Hz)
46006901|NCT04582994|Behavioral|Alfa tACS|participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Alfa frequencies (10 Hz)
46006902|NCT04582994|Behavioral|Sham|participants perform the Mental Time Travel task (duration 20 minutes), while Sham tACS stimulation is delivered
46006903|NCT04582955|Drug|Chidamide in combination with chemotherapy|Chidamide, orally,20mg at day 0,4,7,11,21,every 3 weeks; in combination with Docetaxel 75mg/m2,intravenous infusion，at day1 every 3 weeks，and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks
46006904|NCT04591938|Device|Fantom Encore Bioresorbable scaffold implantation|Fantom Encore Bioresorbable scaffold implantation
46006905|NCT01146613|Drug|Varenicline|0.5mg capsules x 2, 2x a day for 12 weeks
46093699|NCT05342207|Procedure|Endoscopic plantar fascia release in cases of chronic resistant plantar fasciopathy|A medial portal will be developed 1cm away from the plantar skin along a vertical line passing through the posterior border of the medial malleolus with the foot in neutral position. A 5 mm cannula will be then introduced through the lateral portal over the trocar. Irrigation fluid will be then connected. A 30-degree 4.0 mm endoscope will be inserted inside the cannula. A 4.5 motorized incisor blade will be then used to debride the subcutaneous tissue until full visualization of the shiny fibers of the plantar fascia will be possible. A needle was inserted vertically through the heel skin to act as a land mark for the middle of the plantar fascia. A scalpel blade will then introduced through the medial portal to divide the full thickness of the medial half of the plantar fascia into two leaflets under direct visualization . The posterior leaflet will be then totally debrided using a motorized incisor blade . The tunnel will then be irrigated and stitches will be done.
46093700|NCT04230317|Diagnostic Test|Chest CT|Low dose CT taken with three different protocols
46093701|NCT00873015|Drug|Sodium nitrite|14 day continuous infusion of one of 3 escalating doses of sodium nitrite: 32 nmol/min/kg, 48 nmol/min/kg, or 64 nmol/min/kg
46093702|NCT00873015|Drug|Saline|14 day continuous infusion of a vehicle control infusion
46093703|NCT03978325|Other|Control|The control group will receive standard pre-operative care. This involves standard pre-operative advice and a moderate intensity preoperative exercise programme.
46093704|NCT03978325|Other|Exercise - HIIT Intervention|"The HIIT intervention will take the form of a supervised programme, completed for at least two weeks, up to 5 days per week preoperatively. The HIIT intervention will be performed on a cycle ergometer. Exercise sessions will be individually supervised and scheduled at a time of convenience for each participant. Each exercise session will last 40 minutes and will include warm-up, exercise training and cool-down components. Lactate threshold, measured during the baseline CPT, will be used to determine the exercise intensity.~The training protocol will prescribe 15 second intervals of exercise and passive recovery. The highest resistance reached during the baseline CPET (measured in watts) will be recorded as the peak power output (PPO). During training, participants will undergo a 5-minute warm-up at 50% PPO, followed by up to 30 minutes of HIIT with intervals of 15 seconds at 100% PPO with 15 second recovery periods at 0 watts."
46006906|NCT01146613|Drug|Placebo|identical matched placebo x 2, 2xday, 13 weeks
46006907|NCT04591704|Other|hospitalisation, necessity of ICU, mortality rate, lung involvement|hospitalisation, necessity of ICU, mortality rate, lung involvement
46006908|NCT04582838|Diagnostic Test|Pulse oximeter|"In both groups, pulse oximeters provide continuous monitoring of oxygen saturation (SpO2).~Also, SpO2 curve can be recorded for off-line analysis."
46093705|NCT02667080|Other|2-7 days of Sexual abstinence|2-7 days of Sexual abstinence
46093706|NCT02667080|Other|2 hours of sexual abstinence|2 hours of sexual abstinence
46093707|NCT04230083|Drug|Dienogest 2.0 mg Test Drug|Bioequivalence
46093708|NCT04230083|Drug|Dienogest 2.0 mg Reference Product|Bioequivalence
46093709|NCT00645866|Drug|capecitabine|
46093710|NCT00645866|Drug|docetaxel|
46093711|NCT00645866|Drug|epirubicin hydrochloride|
46093712|NCT00645866|Other|laboratory biomarker analysis|
46093713|NCT00645866|Other|pharmacogenomic studies|
46093714|NCT00645866|Procedure|biopsy|
46093715|NCT00645866|Procedure|neoadjuvant therapy|
45598979|NCT02350413|Other|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
46006909|NCT04582838|Diagnostic Test|ECG|ECG signal is used to monitor respiratory rate (RR).
46006910|NCT01145755|Drug|AZD2066|18 mg once daily
46006911|NCT01145755|Drug|Placebo|
46006912|NCT01145755|Drug|Duloxetine|60 mg once daily
46006913|NCT02883946|Other|Data collection|
46006914|NCT04591743|Device|Active TCS|TCS active at 1 Hz on the right DLPFC for 6 weeks
46006915|NCT04591743|Device|Placebo TCS|Inactive TCS (placebo coil) at 1 Hz on right DLPFC for 6 weeks
46006916|NCT04591743|Drug|nicotine treatment|at least 21/14/7 mg/d + oral nicotine cp from 2 to 30 mg/d)
46006917|NCT04591743|Other|Questionnaires|"EVA on craving, TCQ, QSU, BDI-II, CO tester, IGT, BART"
46006918|NCT04583033|Behavioral|Cognitive Behavioral Therapy (CBT)|Treatment components include stimulus control, sleep restriction therapy, relaxation, and cognitive therapy. Each session will last approximately one hour and will be provided on line.
46006919|NCT00625105|Behavioral|Biofeedback|
46006920|NCT00567060|Drug|Piracetam|
46093716|NCT00645866|Procedure|therapeutic surgical procedure|
46093717|NCT00693147|Procedure|Total Thyroidectomy|Late postoperative course of patients with mini Video Assisted Thyroidectomy (miVAT) versus classic Thyroidectomy (T)
46093718|NCT05221151|Drug|Melatonin|In the night before surgery, 90 minutes before administering the intrathecal anesthesia and 12 hr after surgery
46006921|NCT00568217|Drug|Diclofenac, Paracetamol, Ibuprofen|Immediately if temperature > 38 degree Celsius, diclofenac suppository 1,5 mg/kg once or placebo suppository After eight hours, if temperature still < 38 degree Celsius, acetaminophen mixture 15 mg/kg up to four times a day, or ibuprofen mixture 10 mg/kg up to four times a day, or placebo mixture up to four times a day as long as temperature < 38 degree Celsius
46006922|NCT00568256|Behavioral|Mind/Body Courses|8-week Mind/Body course held once a week for 2 hours at a time.
46006923|NCT00583323|Drug|Lomotil|Orally 10ml of Lomotil
46006924|NCT00583323|Other|Normal saline|10 ml orally
46006925|NCT04582565|Combination Product|Decongestive lymphatic therapy (DLT)|Manual lymphatic drainage
46093719|NCT05221151|Drug|Pregabalin|In the night before surgery, 90 minutes before administering the intrathecal anesthesia and 12 hr after surgery
46006926|NCT04582565|Other|Standard Care|
46006927|NCT04575987|Other|Questionnaire|"Questionnaires will be sent by email or by post, in which questions about PFD, obstetrical history or dietetic follow-up will be asked.~Some obstetrical issues will be get from women medical files."
45459803|NCT03480490|Diagnostic Test|Pleural fluid C-reactive protein|"C-reactive protein is an acute phase protein that is synthesized by the liver in response to various stimuli.~The pleural fluid c-reactive protein levels are likely to reflect the serum levels because the presence of c-reactive protein in the pleural fluid may be due to increased diffusion from the blood as a result of inflamed capillary leakage.~Pleural c-reactive protein has been proposed as a specific biomarker for the differential diagnosis of pleural effusions and reportedly exhibits higher sensitivity and specificity than serum c-reactive protein.~c-reactive protein can be considered a good candidate due to its 1000-fold elevation in response to infection and the positive correlation between the serum and pleural c-reactive protein levels.~Pleural fluid c-reactive protein level was significantly higher in exudates than that in transudative effusion."
45459804|NCT02876510|Drug|Fludarabine|Fludarabine infusion
45459805|NCT02876510|Drug|Cyclophosphamide|Cyclophosphamide infusion
45459806|NCT02876510|Biological|IMA101 product|i.v. infusion of IMA101 product(s).
45459807|NCT02876510|Biological|Recombinant human interleukin-2|Low dose IL-2 Infusion for two weeks
45459808|NCT02876510|Diagnostic Test|IMADetect|IMADetect is a laboratory test that is part of screening used to determine the mRNA expression of ACTolog target source genes in tumor biopsies from solid tumors. IMADetect is intended for investigational use only.
45459809|NCT02876510|Drug|Atezolizumab|Atezolizumab infusion will be given no earlier than 3 weeks post IMA101 infusion and after hematologic recovery is achieved, thereafter every 3 weeks until 1 year after IMA101 infusion.
45678449|NCT01926782|Drug|Placebo (for alirocumab)|Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.
46006928|NCT04582604|Drug|modified By/Cy conditioning regimen intensified by Ruxolitinib and Decitabine|Day -15 to -14 ： Decitabine 20 mg/m2/day, Ruxolitinib 70mg bid; Day-10： Cytarabine 1.6 g/m2/day CI (only for Haploidentical and unrelated donor), Ruxolitinib 60mg bid; Day- 9： Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 to -7： Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 50mg bid; Day-6: Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5： Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid; Day-4： Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 20mg bid; Day-3： Carmustine 250mg/m2/day iv, Ruxolitinib 10mg bid; Day-2： Ruxolitinib 5mg bid; Day-1： Ruxolitinib 5mg qd;
46006929|NCT04582760|Other|early mobilization|In patients who require mechanical ventilation for acute respiratory failure or sepsis (non-malignant tumor patients), early mobilization will be performed in addition to conventional bedside physical therapy, for 30 mins per session, two sessions per day, 7 days per week until the patients are discharged from the ICU.
46006930|NCT00583401|Device|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
46093720|NCT05221151|Drug|Ondansetron 4 MG|before spinal anaesthesia
46093721|NCT02666690|Device|CEUS (Contrast-enhanced ultrasound)|Each patient will be performed 2 contrast echocardiography (a pre-prandial - a post-prandial) before the antiangiogenic treatment, at D15 and D30.
46093722|NCT04008043|Drug|Vicodin|In addition to taking one tablet of vicodin for pain every 4-6 hours up to 8 tablets, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
46093723|NCT04008043|Drug|Dexamethasone|In addition to taking one tablet of dexamethasone for pain beginning the day before surgery and on the day of surgery, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
46093724|NCT02783183|Drug|YHD1119|2 by 2
46093725|NCT02783183|Drug|Lyrica|2 by 2
46093726|NCT02666612|Procedure|Blood samples|
46093727|NCT00693381|Drug|Tacrolimus|oral
46093728|NCT00693381|Drug|Mycophenolate Mofetil|oral
46093729|NCT00693381|Drug|methylprednisolone and prednisone|IV and oral
46093730|NCT00979771|Drug|GSK706769|100 mg GSK706769 twice daily orally (BID) for 28 days
46093731|NCT00979771|Drug|Placebo|GSK706769 matched-placebo twice daily orally (BID) for 28 days
46093732|NCT05285891|Drug|Ocrelizumab|Two 300 mg intravenous (IV) OCR infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg OCR infusions every 6 months from Month 6 through Month 48.
46093733|NCT05285891|Drug|Placebo for Ocrelizumab|Placebo infusions every 6 months from Month 18 through Month 48.
46037795|NCT02780986|Behavioral|Female entertainment worker intervention group|"The following summarises the content of each session:~Session 1 (on-site): The peer educator will play 2 videos, demonstrating 5 sexy ways of putting on a condom in a pleasurable manner, and another one focusing on condom negotiation skills.~Session 2 (online): The peer educator will share an app game on condom usage and relevant online resources with the participants.~Session 3 (onsite): There will be discussion of common problems encountered in condom usage and condom negotiation by the participants. The peer educators will then conduct role plays with the participants to demonstrate the counter-strategies. In addition, the peer educators will get the participants who have been successful in condom negotiation to share their success stories.~Session 4 (online): The peer educator will share information about safe consumption of alcohol and tips to avoid getting drunk through the online platforms."
46093734|NCT00693537|Behavioral|Exercise training|4 weeks in-hospital exercise training (6x15 min bicycle/day, 5 days/week) followed by a 5 months ambulatory exercise program (30 min ergometer/day, 5 days/week, plus 1h group exercise/week)
46093735|NCT04007731|Dietary Supplement|DrRip - high protein, high fibre and creatine load|A protein bar or control bar consumption after training every day for 5 days, 5 days wash-out, 5 days second bar consumption
46093736|NCT04007731|Dietary Supplement|Voltage energy bar|A protein bar or control bar consumption after training every day for 5 days, 5 days wash-out, 5 days second bar consumption
46093737|NCT05278247|Diagnostic Test|NIRS|Performance of a NIRS to monitor abdominal tissue oxygen saturation in preterm infants
46093738|NCT00693615|Biological|MEDI-517 HPV-16/18 VLP AS04 vaccine|IM injection
46093739|NCT00693615|Biological|MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3|IM injection
46093740|NCT00693615|Biological|MEDI-517 HPV-16/18 VLP vaccine without adjuvant|IM injection
45459810|NCT03476434|Device|chromoendoscopy with indigo carmine|the lumen of the colon is sprayed in a segmental fashion using 0.4% indigo carmine delivered via a specially designed dye spray catheter (Olympus PW-5V1) or via the accessory channel with a 50cc syringe filled with indigo carmine and air.
45459811|NCT03482830|Procedure|Major emergency gastrointestinal surgery|"Open, laparoscopic, or laparoscopically-assisted procedures~Procedures involving the stomach, small or large bowel, or rectum for conditions such as perforation, ischaemia, abdominal abscess, bleeding or obstruction"
45459812|NCT03380455|Drug|Lucerastat|Single oral dose of 500 mg lucerastat under fasted conditions
45459813|NCT03380455|Drug|Cimetidine|Twice daily oral dose of 800 mg cimetidine under fasted conditions
45459814|NCT03557970|Drug|Edicotinib|Given PO
45459815|NCT03557970|Other|Pharmacokinetic Study|Correlative studies
45459816|NCT03339037|Device|Hyperbaric oxygen therapy|60 HBOT sessions at 2 ATA 100% oxygen
46093741|NCT00979849|Drug|AZD8683|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD8683 or placebo. Starting dose 1 ug (lung deposited dose) with up to 8 dose escalation not exceeding AstraZeneca pre-defined exposure limits.
46093742|NCT00979849|Drug|Placebo|Solution for nebulisation, inhaled
46093743|NCT02782793|Procedure|Endoscopic Mucosal Resection|
46093744|NCT02663960|Other|fixed citrate doses protocol|fixed doses of anticoagulant citrate dextrose solution to meet a circuit citrate concentration of 4 mmol/l.
46093745|NCT02663960|Other|adjusted citrate doses protocol|the starting infusion rate of anticoagulant citrate dextrose solution be set 2.5 % of blood flow and then be adjusted to obtain postfilter ionized calcium levels of less than 0.40 mmol/l.
46093746|NCT02624427|Device|Measurement of intraocular pressure (IOP)|Measurement of IOP with the following devices: (1) Goldmann tonometer, (2) Dynamic Contour tonometer, and (3) Corvis ST tonometer
46093747|NCT04229849|Drug|Anrotenib plus Toripalimab|Anrotenib: 10 mg on day 1-14 orally repeated every 21 days; Toripalimab: 240 mg on day 1 intravenously repeated every 21 days.
45459817|NCT03339037|Device|Normobaric air SHAM|60 sessions at 1 ATA 21% oxygen (air)
46093748|NCT04229849|Drug|Toripalimab|Toripalimab: 240 mg on day 1 intravenously repeated every 21 days.
46093749|NCT00693771|Drug|Insulin Glargine|Once daily and up-titrate accordingly
46093750|NCT02663804|Device|Total Knee Arthroplasty|
45459818|NCT04804228|Other|Electrical dry needling|The experimental group consisting of 40 subjects will perform electrostimulation on the active myofascial trigger points of the following muscles: quadratus lumbar, multifidus and iliocostalis. The electrostimulation of the PGM will be carried out using needle electrodes, the generated current will be produced by a TENS device with a frequency of 2 Hz and a pulse width of 250 μs, the application will be approximately 30 min. The therapeutic intervention will be 1 session per week for a total of 6 weeks.
46006931|NCT04582721|Other|Implantable Neurostimulator System (Spectra WaveWriter™ Spinal Cord Stimulator System), (Boston Scientific Neuromodulation Corporation, Valencia, California (CA), USA)|"the participants with chronic intractable back or back and leg pain will be implanted with the stimulation lead(s). The leads are initially connected to an external trial neurostimulator. Patients will be implanted with two epidural leads and two subcutaneous leads. A three weeks trial phase will follow. The first two days after the leads implant will be without stimulation and thereafter alternating stimulation every week will start, randomly ordering the treatments using a Williams design balanced for first-order carryover effects (i.e. incorporating 6 different treatment orders), from:~1) CON-SCS with Subcutaneous stimulation~2) HF-SCS~3) Combination Therapy A patient's favored SCS mode, providing that there is at least 50% reduction in pain intensity on the NRS in the trial phase, will then be implanted and patients will be followed up for 12 months."
46093751|NCT00970021|Dietary Supplement|Intake of 60 ml placebo daily in addition to chemotherapy|The patients will drink 60 ml of placebo daily from start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment is approximately 7 weeks.
46093752|NCT00970021|Dietary Supplement|Intake of 60 ml agaricus daily in addition to chemotherapy|The patients will drink 60 ml of agaricus extract from the start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment: Approximately 7 weeks
46006932|NCT00590928|Drug|esomeprazole|40mg once daily
46006933|NCT00590928|Drug|ranitidine|50mg every h hours
46093753|NCT00693849|Drug|Escitalopram|10 mg/day as a single dose, increased to max 20 mg/day
46093754|NCT00693849|Drug|Sertraline|50 mg/day as a single dose, increased to max of 200 mg/day
46093755|NCT00693849|Drug|Venlafaxine-XR|75 mg/day given once daily; increased to 150-225 mg/day
46093756|NCT00975247|Other|Receiving an educational booklet|Patients who receive an educational booklet will be considered to be receiving an intervention
46093757|NCT05342129|Other|exercise bike|exercise is to use an exercise bike, start pedaling on the first day, time setting: 20 minutes, speed: 2, and adopt passive mode. If you can complete the exercise on the first day, the time will be adjusted to 30 minutes on the second day. If you cannot complete the exercise on the first day, the time will still start from 20 minutes on the second day. The maximum time is 30 minutes. If you can complete 30 minutes of passive exercise for 3 consecutive days, the fourth day will be adjusted to active exercise. The entire exercise training is seven days a week, once a day, once a 30-minute, at least 5 days. Those who were discharged to the general ward continued to complete this exercise training for up to 28 days.
46093758|NCT04650932|Device|Deep brain stimulation|Patients with idiopathic Parkinson's disease who have previously been implanted with the Boston Scientific VerciseTM DBS system for at least 3 months. These patients will already be receiving high-frequency dorsal STN stimulation as part of the standard of care for PD. Once patients have provided consent and are enrolled in this study, they will receive simultaneous low-frequency stimulation of the ventral STN to examine if there are any effects on cognitive performance.
46093759|NCT00979927|Drug|SPC3649|5 weekly doses
46006934|NCT00583440|Behavioral|12-step facilitation|12 weekly individual 12-step facilitation sessions
46093760|NCT00979927|Drug|saline|5 weekly doses
46093761|NCT00693927|Procedure|Unmanipulated PBSC after nonmyeloablative conditioning|"Conditioning regimen with 2 Gy TBI with or without added fludarabine (90 mg/m2).~Unmanipulated PBSC from HLA-identical sibling or HLA-matched related or unrelated donor"
46093762|NCT00693927|Procedure|CD8-depleted PBSC after nonmyeloablative conditioning|
45678450|NCT01926782|Drug|Alirocumab|Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
46093763|NCT02510885|Device|AngioVue SD-OCT|OCT-A allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. SD-OCT units use the light source used in commercially available and FDA-cleared OCT units on a modified platform. Optovue, Inc. has developed a customized SD-OCT system that implements a novel algorithm, the amplitude-based method of split-spectrum amplitude-decorrelation angiography (SSADA) for OCT-A. This detects motion in the blood vessel lumen by measuring the variation in reflected OCT signal amplitude between consecutive cross-sectional scans. Optovue has integrated the novel SSADA algorithm into their commercially approved RTVue SD-OCT unit for their OCT-A unit, the AngioVue. This unit is being conducted under an abbreviated IDE.
46093764|NCT00648362|Drug|Glimepiride Tablets 1 mg|1mg, single dose fasting
46093765|NCT00648362|Drug|Amaryl® Tablets 1 mg|1mg, single dose fasting
46093766|NCT00970099|Behavioral|exercise|Patients exercise under supervision on either a treadmill, Stair Master, or LifeCycle apparatus. Exercise frequency, duration, and intensity will be incrementally increased to minimize the risk of injury. During weeks 1-3, you will exercise for 30 minutes 3 days per week at 70- 80 % of your maximum heart rate (MHR); weeks 4-7 will consist of exercising for 40 minutes 4 days per week at 70-80% of your MHR; and weeks 7-12 will consist of exercising for 45 minutes 4 days per week at 80-85% MHR
46093767|NCT00970099|Behavioral|Non exercise|subjects randomized to this group will not undergo exercise training for 12 weeks supervised by exercise specialist
45678451|NCT01926782|Drug|Statin|Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy
46006935|NCT00583440|Behavioral|Treatment as usual|Usual clinical treatment in a dual diagnosis treatment program
46006936|NCT04582526|Behavioral|BMS program|A BMS program with three components: relaxation exercises, healthy eating, expressive arts therapy
46006937|NCT01145560|Drug|AZD9773|A single loading dose following by up to 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
46093768|NCT00648440|Drug|Midodrine HCl Tablets 5 mg|5mg, single dose fed
46093769|NCT00648440|Drug|ProAmatine® Tablets 5 mg|5mg, single dose fed
46093770|NCT04137003|Other|Rouge et Or Program|It is a detailed, structured and precise training program. It is used from the third-month post ACL surgery to the sixth month.
46006938|NCT01145560|Drug|Placebo|Placebo
46006939|NCT04582175|Procedure|angioplasty|angioplasty of all non-culprit lesions
46006940|NCT00591045|Drug|mFOLFOX|oxaliplatin 100mg/m2, CF 400mg/m2, 5-FU 2400 mg/m2 46hr civ
46006941|NCT01145482|Drug|Insulin|20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle
46006942|NCT01145482|Other|Saline|200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle
46006943|NCT00583479|Other|one injection into the celiac ganglion|one injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
46006944|NCT00583479|Other|two injections into the celiac ganglion|two injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
46093771|NCT04137003|Other|CHU intervention guide|From the third month to the sixth month, it outlines the progression to have in the training without precise information on exercises, parameter or frequency.
46093772|NCT00980083|Drug|Saline|
46093773|NCT00980083|Drug|Exendin(9-39)amide|
46093774|NCT04172090|Other|Control|Normal physical activity and standard energy intake
46006945|NCT04313413|Other|Yoga|Yoga sessions includes sukshma vyayama (strengthening yoga expertise), stretching and relaxing postures (asana) on chair or standing, breathing and meditation practices.
46093775|NCT04172090|Other|SIT+E|Reduced physical activity and standard energy intake
46093776|NCT04172090|Other|SIT=E|Reduced physical activity and reduced energy intake
46093777|NCT05264363|Device|VIPUN Gastric Monitoring System prototype|The Investigational Medical Device (IMD) is used simultaneously with the reference device (solid state high-resolution manometry) to record gastric intraluminal pressure for approximately 2.5 hours.
46093778|NCT00694005|Procedure|kissing balloon|simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
46093779|NCT00694005|Procedure|"without kissing balloon angioplasty leave alone"|simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
46093780|NCT00975325|Drug|Yohimbine|yohimbine 5 mg, one tablet, single dose only
46093781|NCT00975325|Drug|Yohimbine|yohimbine 5 mg, one tablet, single dose only
46093782|NCT00910676|Drug|Diprosone|"Start of treatment: as soon as the EGF-R inhibitors treatment begins~Application: On the body area susceptible to be affected by folliculitis, once a day, in the evening~Dosage: Quantity corresponded to around 2 tubes of 30 grams a week on the face, the chest and upper side of the back. There is no maximum dosage.~Period of treatment: 8 weeks"
46093783|NCT00970177|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen & adjuvant, or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups.
46093784|NCT00634673|Other|sandwich|standard meal:sandwich (7.23 kcal/kg-total energy; 43.35% fat, 21.95% protein, and 34.70% carbohydrate)
46093785|NCT04136847|Device|SkinPen Precision|Surgical instrument motors and accessories/attachments/Hydrogel
46093786|NCT00648518|Drug|Metformin Hydrochloride ER Tablets 750 mg|750mg, single dose fasting
46093787|NCT00648518|Drug|Glucophage® XR Tablets 750 mg|750mg, single dose fasting
46093788|NCT04136691|Other|simulation training|Burn patient scenario was performed with the intervention group.
46093789|NCT04008589|Device|repetitive transorbital AC Stimulation|Repetitive transorbital ACS with max 30 Hz, 1,5 mA for 10 days, 20 min/day
45459819|NCT04804228|Other|Ischemic compression, analytical stretching and postural habits educational dossier|The control group G2, formed by 40 subjects, will perform an ischemic compression technique in active PGM with a time between 20 seconds and 1 minute until pain inhibition is achieved, and finally, analytical stretching will be carried out on the quadratus lumbar, multifidus and iliocostal muscles, 1 weekly session for 6 weeks, in addition to providing them with a training dossier on postural education in their activities of daily life.
45459820|NCT02815280|Drug|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
46006946|NCT05207605|Other|Rhythmic Stabilization (RS)|Group A includes rhythmic stabilization technique. The patient is in sitting position and faces the physical therapist. The RST program consisted of alternating (trunk flexion-extension) isometric contractions against resistance for 10 seconds, with no motion intended. Subjects performed 3 sets of 15 repetitions at maximal resistance provided by the same physical therapist. Rest intervals of 30 seconds and 60 seconds were provided after the completion of 15 repetitions for each pattern and between sets, respectively. The total duration of RS will be of approximately 33 minutes
46093790|NCT04008589|Device|combination of transcranial direct current stimulaton and rtACS|Sequential tDCS (anodal occipital stimulation with 2 mA for 20 min/day for 10 days) and rtACS
46093791|NCT04623632|Drug|Transversus abdominus plane block|transversus abdominus plane block using 40 ml of bupivacaine 0.25%
45459821|NCT02815280|Drug|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
45459822|NCT01241929|Behavioral|video decision aid|video of CPR
46093792|NCT04623632|Drug|Transversus abdominus plane placebo|injection of 40 ml of normal saline in the transversus abdominus plane
45678452|NCT01926626|Drug|Nicotine Patch|"Pre-Quit Period: 2 weeks of patch use (21mg/24hr)~Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)"
46093793|NCT00648596|Drug|sildenafil|sildenafil 50 mg tablet by mouth 1 hour before sexual activity for 12 weeks; the dose could be increased to 100 mg or decreased to 25 mg.
46093794|NCT00648596|Drug|placebo|placebo tablet by mouth 1 hour before sexual activity for 12 weeks
46093795|NCT03921151|Drug|Mirtazapine 15 MG Oral Tablet|The intervention will be a 15mg of mirtazapine oral tablet given to participants prior to their treatment scan and assessments. In order to ensure that biases or social desirability do not contaminate baseline assessments, all participants will also be given a tablet consisting of dextrose in gelatin prior to their baseline scan and assessment.
46093796|NCT02784665|Device|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the
46093797|NCT02784665|Device|577-TL|"All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-TL arm.~100 microns light spot size, 0.05 seconds duration, 80 ~ 200 milliwatts of power"
46093798|NCT00970255|Procedure|Lingual Frenulum frenotomy|Clipping the lingual frenulum with scissors
46093799|NCT00970255|Procedure|Sham frenotomy|Sham Clipping the lingual frenulum with scissors
46093800|NCT04570436|Drug|gabapentin 600 mg|participants will receive an oral dose of gabapentin 600 mg
46093801|NCT04570436|Drug|gabapentin 1200 mg|participants will receive an oral dose of gabapentin 1200 mg
46093802|NCT04570436|Drug|gabapentin 1800 mg|participants will receive an oral dose of gabapentin 1800 mg
46093803|NCT04570436|Drug|diazepam 20 mg|participants will receive an oral dose of 20 mg dose of diazepam
46093804|NCT04570436|Other|placebo|participants will receive an oral dose of placebo
46093805|NCT04007965|Procedure|Pneumatic Posterior Capsulorhexis|Pneumatic Posterior Capsulorhexis using air dose 0.1 ml and Healon dose 0.5 -1.0 ml.
46093806|NCT05195645|Drug|Abatacept 250 MG|Abatacept will be administered by intravenous injection over 1h15 to 2h30 on D1, D5+/-2 and D14+/-2 at 10mg/kg (arm A), or 20mg/kg (arm B) or 25mg/kg (arm C) depending on the randomization (max 3 000 mg per administration). Starting Day 21 (after evaluation of the primary outcome), other injection of abatacept may be given (D22 at D90) with dosage (10 or 20mg/kg max) decided by the treating physician (max 2 500 mg per administration) as a function of the relapse or not of the ICI myocarditis after immunosuppressant therapeutics tapering. After day 21, the administrations will be carried out in open but the blind administration 1 to 3 (D1 to D21) will be kept.
46006947|NCT05207605|Other|McKenzie technique|McKenzie technique will be guided to conduct four extension exercises and three flexion exercisesAll flexion exercises will be repeated for ten repetitions for two sets. There are three minutes for resting intervals in every set. The McKenzie treatment will lasted for 20-40 minutes.
46006948|NCT00568295|Drug|acetaminophen|Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
46093807|NCT00975403|Device|Dead space breathing|Chemical loading by adding a deadspace (600ml) to the breathing circuit during a single cycle exercise test
46093808|NCT00975403|Device|Room air breathing|Sham comparator (vs deadspace) during a single cycle exercise test will entail breathing room air on the same circuit without the rebreathe valves
46093809|NCT02665910|Drug|SHR0302|Oral tablets (1 mg, 5 mg, 10 mg)
46093810|NCT02665910|Drug|SHR0302 placebo comparator|Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
46093811|NCT00970333|Drug|[18F]-FEPPA|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not >10% of 5 mCi limit) of [18F]-FEPPA followed by serial PET imaging
46093812|NCT04171388|Drug|Azithromycin 500 mg|Azithromycin 500mg (Kern Pharma): 2g (4 tablets) at 2 time points during pregnancy: enrollment (<=24 weeks gestation), and follow-up ANC at least 4 weeks later
46093813|NCT04171388|Dietary Supplement|Multiple Micronutrient or Fortified Balanced Energy Protein Supplement|Daily multiple micronutrient (MMN) tablet (Contract Pharmacal Corp) for women with mid-upper arm circumference (MUAC) >=23 cm, OR Daily fortified balanced energy protein (BEP) supplement (DSM South Africa; Faffa Food Products): Fortified corn-soy blend (784 kcal/day) for women with MUAC <23 cm
46093814|NCT04171388|Drug|Placebo oral tablet 500 mg|Placebo 500mg (Idifarma): 2g (4 tablets) at 2 time points during pregnancy; enrollment (<24 weeks gestation), and follow up ANC at least 4 weeks later
46006949|NCT00568295|Drug|Rofecoxib|Rofecoxib: Capsules 12.5 mg, oral, C-904-1A - - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
46093815|NCT04171388|Other|Enhanced Infection Management Package (EIMP)|"ENROLLMENT VISIT: Screening for bacteriuria with urine culture, and antimicrobial susceptibility testing; Screening for chlamydia and gonorrhea with Cepheid GeneXpert; Presumptive deworming with albendazole 500mg.~FOLLOWUP TREATMENT VISIT: For women with identified urinary tract infection or asymptomatic bacteriuria, treatment with antibiotics based on antimicrobial susceptibility patterns. For women with identified chlamydia or gonorrhea, treatment of woman (and partner) with appropriate antibiotics. Test of cure sample and retreatment of infection.~Second deworming with albendazole at least 4 weeks after enrollment ANC visit."
46093816|NCT02782637|Other|survey and interview|"all participants: survey on prenatal counseling and treatment decisions at the limits of viability.~a selection of participants: individual interviews to further perform in-depth exploration of prenatal counseling preferences"
46093817|NCT00970411|Drug|KRN951|Orally once daily administration
46093818|NCT04229069|Dietary Supplement|alkaline salt mixture|blood and tissue alkalinisation
46093819|NCT04229069|Dietary Supplement|placebo|no blood and tissue alkalinisation
46093820|NCT00646412|Device|A-Part® Gel|10 - 20 ml of A-Part® Gel will be administered before abdominal wall closure in a standardised fashion
46093821|NCT05341193|Drug|Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab|"Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy."
46093822|NCT05341193|Drug|Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab|"Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy."
46093823|NCT00648674|Device|Apligraf|Applied at Day 0, possible re-application at Week 6
46093824|NCT00975793|Other|Early Goal Directed Therapy (EGDT)|Randomised allocation of early goal-directed therapy (EGDT). EGDT involves treatment with intravenous fluids, and medications to support the blood pressure and heart following a protocol. A special catheter is inserted to monitor central blood oxygen levels and the standard treatments are given according to the blood oxygen level reading. EGDT is given for 6 hours, then the patient receives standard care.
46093825|NCT04229459|Drug|Cisplatin|Cisplatin 100mg/m2 IV on day 1 of induction chemotherapy, 75mg/m2 IV on day 1 and 29 of chemoradiation
46093826|NCT04229459|Drug|5-FU|5-FU 1000mg/m2/d IV on days 1-5 of induction chemotherapy, 1000mg/m2/d IV on days 1-4 and days 29-32 of chemoradiation
46093827|NCT04229459|Radiation|Radiation therapy|1.8 Gy/fraction, 5 days a week for a total of 28 days
45678453|NCT01926626|Drug|Moclobemide|"Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)~Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)"
46006950|NCT00568295|Drug|Rofecoxib|Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
46093828|NCT04229459|Drug|Cetuximab|Cetuximab 400mg/m2 IV on day 1 followed by 250mg/m2 IV weekly on induction chemotherapy, 250mg/m2 IV weekly on chemoradiation, 500mg/m2 IV on day 1 of each treatment cycle, every two weeks during immunotherapy
46093829|NCT04229459|Drug|Nivolumab|Nivolumab 3mg/kg IV on day 1 of each treatment cycle, every two weeks during immunotherapy
46093830|NCT02663726|Other|Yoga|10 weekly 75-min sessions of specialised yoga
46093831|NCT02663726|Behavioral|Written advice|Written advice about physical activity
46093832|NCT04174586|Biological|microtransplantation|HLA mismatched donor cord blood infusion
46093833|NCT05341973|Behavioral|Education|Self-Management Program will increase Self-Efficacy, Self-Care Management in Hypertension Patients.
46093834|NCT04174274|Other|ventilator-associated pneumonia-developed group followed by mechanical ventilation|compliance with ventilator-associated pneumonia prevention methods and investigating the incidence of ventilator-associated pneumonia in intensive care units
46093835|NCT04174274|Other|not ventilator-associated pneumonia-developed group followed by mechanical ventilation|compliance with ventilator-associated pneumonia prevention methods and investigating the incidence of ventilator-associated pneumonia in intensive care units
46093836|NCT05279443|Other|yoga-based exercises therapy|Accompanied by a certified yoga instructor, and under the supervision of an PMR specialist and a Sports Medicine specialist, YBEs were administered to our patients included in the study for 8 weeks, 2 sessions a week, and with sessions of 60 minutes, using personal mats and equipment in a 2475 m3 (18mx25mx5.5m) gym area that belonged to our hospital, in the form of group therapy for 5 (five) people and in accordance with the social distancing rules. The exercises program was applied as a exercise program consisting of physical postures (asana) to improve the body's muscle strength and flexibility, breathing exercises (pranayama) to increase respiratory function, and relaxation and meditation (dhyana) techniques.
46093837|NCT04229225|Drug|UBX0101|Investigational drug intra-articular (IA) injection
46093838|NCT04229225|Other|Placebo|Placebo intra-articular (IA) injection
46093839|NCT00980239|Drug|Irinotecan|Starting dose of 35 mg/m^2 given through the catheter into your liver artery (hepatic artery infusion - HAI), continuously for 72 hours (Days 1 through 2 of each cycle).
46093840|NCT00980239|Drug|Bevacizumab|10 mg/Kg by vein on Days 1 and 15 of every 28 day cycle, over 90 minutes first cycle and over 30-60 minutes subsequent cycles.
46093841|NCT00980239|Drug|Oxaliplatin|Starting dose 60 mg/m^2 by vein over 2 hours on Days 1 and 15 of every cycle.
46093842|NCT00980239|Drug|Cetuximab|500 mg/m^2 by vein on Days 1 and 15 of every cycle. The first time given over 2 hours, all other cycles over 1 hour.
46093843|NCT05341895|Other|Kinesiotape|Taping
46093844|NCT00980317|Procedure|Restored Kidney Transplant Between Third Parties|Tumor part of the donor kidney is surgically removed and the kidney is restored and transplanted to a third party recipient
46093845|NCT02665832|Drug|DWJ1351|
45459823|NCT05665218|Diagnostic Test|right heart catheterization|Right heart catheterization (RHC) is an invasive hemodynamic procedure that allows direct measurement of right-sided cardiac pressures, calculation of cardiac output and pulmonary vascular resistance. It is the gold standard for the diagnosis of pulmonary arterial hypertension. Right heart catheterization is commonly performed by accessing the internal jugular vein (echo-guided access). Swan Ganz catheter with a dedicated thermistor is used to perform RHC; it is advanced through the right heart chambers to measure right atrial, right ventricle, pulmonary artery and pulmonary arterial wedge pressures. Cardiac output is measured using Fick direct, Fick indirect and thermodilution methods.
45459824|NCT03482752|Drug|Molgramostim|300 µg inhaled molgramostim in cycles of once daily administration for 7 days, then 7 days off treatment.
46006951|NCT00591084|Drug|ginsenoside-Rd 10 mg|infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days
46093846|NCT02665832|Drug|Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)|
46093847|NCT02781467|Biological|PNK-007|
46093848|NCT02781467|Drug|Cyclophosphamide|
46093849|NCT02781467|Drug|Fludarabine|
46093850|NCT02781467|Drug|Human recombinant Interleukin-2 (rhIL-2)|
46093851|NCT00648830|Procedure|Clarithromycin|Single-dose of Clarithromycin 250 mg oral immediate-release tablets
45459825|NCT04729543|Biological|Adoptive therapy with autologous MC2 TCR T cells|Adoptive therapy with autologous MC2 TCR T cells combined with AZA/VP
46093852|NCT00648830|Drug|Clarithromycin|single-dose 250 mg immediate-release oral tablets
46093853|NCT00970567|Behavioral|Different insulin therapy at different time points|different insulin therapy after positive blood ketones
46093854|NCT05341817|Drug|Letrozole|Letrozole priming before mTOP is used as an alternative to the use of mifepristone. Women randomly assigned (1:1) to the Letrozole arm will receive 10 mg letrozole daily for 3 days followed by 800 μg misoprostol.
46093855|NCT05341817|Drug|Mifepristone|Mifepristone priming before mTOP is the current standard of care. Women randomly assigned (1:1) to the Control arm will receive 200 mg mifepristone followed by 800 μg misoprostol 2 days later.
46093856|NCT02663570|Drug|Melatonin|
46093857|NCT04171544|Device|Streamline Occipito-Cervico-Thoracic Spinal Fixation System|Spinal Fixation
45459826|NCT03723330|Dietary Supplement|plant sterols|Consumption a healthy eating pattern diet with a plant sterols-enriched food product
45459827|NCT03723330|Other|healthy diet|Compliance with a healthy diet in accordance to the recommendation by the Singapore Health Promotion Board.
46006952|NCT00591084|Drug|placebo|infusion placebo (group B)once a day and continued for 14 days
46006953|NCT00591084|Drug|ginsenoside-Rd 20mg|infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days
46006954|NCT00591162|Drug|Tetracycline|Two courses of IV Tetracycline(10mg./kg./day for two days)separated by a two week interval.
46006955|NCT00591162|Radiation|Duel Energy X-Ray Absorptiometry (DEXA)|DEXA before discharge from acute admission and again one year post burn.
46006956|NCT00591162|Procedure|Bone Biopsy|Bone biopsy to be taken in the operation room at the last skin grafting operation at the site of the iliac crest. A second bone biopsy will be taken one year later post discharge from the acute admission.
46006957|NCT00568373|Device|Enterra Gastric Pacemaker|Gastric Pacemaker
46093858|NCT02781233|Other|Progressive resistance training|Progressive resistance training program
46093859|NCT02781233|Other|Normal daily activities|Usual daily activities
46093860|NCT00970645|Procedure|Mediastinoscopy/thoracoscopy|Mediastinoscopy used to detect/stage lung cancer.
46093861|NCT00970645|Procedure|EBUS/EUS|Minimal invasive technique to stage/detect lung cancer.
46093862|NCT02663492|Device|TEAS|The patients will be treated by their assigned acupuncture stimulation in 7 days. The surface electrical stimulation devices and application parameter are: G6805-II pulse acupuncture treatment instrument from Shanghai Medical Technology Company, Ltd (Shanghai, China); sparse-dense wave stimulation (sparse wave 30Hz; dense wave 100Hz) with an intensity of 6-15 V; and the corresponding parts of the body experienced a slight quiver, with a duration 20 minutes each time.
46093863|NCT02663492|Drug|Sanguisorba officinalis L.|Sanguisorba officinalis L., a Leukogenic medication, named Diyu Shengbai Pian (Chengdu Diao Tianfu Pharmaceutical Group Co., Ltd., China) will be taken 0.4g each time by 3 times per day.
46093864|NCT00980473|Procedure|Argon Laser Iridoplasty|
46093865|NCT00980473|Drug|Travatan/ Timolol/Azopt|
46093866|NCT02663414|Device|Atlas Knee System|The Atlas Knee System is an approved device (CE Marked) and is an extra-capsular knee implant specifically designed to treat patients with uni-compartmental, medial knee osteoarthritis (OA).
46093867|NCT05341739|Other|Pre-operative Stereotactic Radiosurgery|Pre-operative SRS will be performed prior to the surgical resection of the brain metastases.
46093868|NCT00649142|Procedure|Open sutured mesh repair|Open sutured mesh repair
46093869|NCT00649142|Procedure|Laparoscopic mesh glue fixation|Laparoscopic mesh glue fixation
46093870|NCT00970723|Behavioral|high blood pressure treatment|over one 14 month period: strongly recommended hygiene-dietetic measurements, complete assessment with ambulatory measurement of the blood pressure in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
46093871|NCT00970723|Behavioral|sleep apnea treatment|over one 14 month period: complete assessment with night polysomnography in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
46006958|NCT00583518|Drug|Parathyroid hormone (PTH)|Postmenopausal women with primary osteoporosis
46006959|NCT04582136|Drug|Sirolimus|In the double-blinded phase, sirolimus 1.5mg/day plus SOC is administered throughout 24 weeks; in the open-label extension period, patients who opt to participate continue on sirolimus 1.5mg/day plus SOC for an additional 24 weeks.
46006960|NCT04582136|Drug|Placebo|In the double-blinded phase, placebo plus SOC is administered throughout 24 weeks; in the open-label extension period, patients who opt to participate are switched to receive sirolimus 1.5mg/day plus SOC for an additional 24 weeks.
46006961|NCT04582331|Other|Smartphone-based voice and self-reported symptom collection|Voice samples and COVID-19 symptom inventories will be collected on participant smartphone devices. No outcomes or feedback is provided on acquired data during trial conduct but will be used for confirmatory data analysis post study
46093872|NCT00970723|Behavioral|diabetic macular edema treatment|over one 14 month period: control every 3 months, treatments by laser (focal or grid) are authorized until 9 months, treatments by injections are authorized until 6 months
46093873|NCT02784743|Drug|''albendazole'' and ''ivermectin''|annual single dose administration of albendazole 400mg and ivermectin 150ug/kg of weight (according to the height)
46093874|NCT00975949|Other|Survey|Parents of subjects were interviewed and two surveys were obtained, the Child Health Questionnaire and the Vineland-II.
46093875|NCT04173728|Dietary Supplement|Standard meal|Consumption a standard meal consisted of 75g glucose, 60g fat and 20 protein just for once.
46093876|NCT05341583|Drug|Ensartinib|Ensartinib 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
45459828|NCT03482674|Behavioral|DIMINI lifestyle intervention|DIMINI lifestyle intervention consists of the DIMINI-kit which contains health information, a list of food recommendations with additional information on calories, serving size and weight (traffic light rating system), a nutrition and an exercise diary. Participants in the intervention group can choose between a paper-based version or an app-based version of the DIMINI-kit. In addition, the kit includes an elastic exercise band with exercise poster, a measuring tape for self-control of the waist size and a pedometer.
46006962|NCT04582253|Diagnostic Test|Scheimpflug Camera Corneal Tomography|Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterior and posterior surfaces of the cornea to obtain corneal tomographic maps.
46093877|NCT05341583|Drug|Placebo|Placebo 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
46093878|NCT00980551|Drug|subtenon Carboplatin|Available in 50mg, 150mg, 450 mg, 600mg vials. It is provided as a premixed aqueous solution or lyophilized powder for injection given on day 1/week 10 (cycles 1-3).
46093879|NCT00980551|Drug|Topotecan Hydrochloride|Each vial contains topotecan hydrochloride equivalent to 4 mg of topotecan as free base. Given intravenously on days 1-5 of each week (cycles 1-6).
46093880|NCT00980551|Drug|Vincristine|Each vial contains vincristine sulfate, 1 mg; mannitol, 100 mg; sterile water for injection; Acetic acid and sodium acetate are added for pH control. Given intravenously on day 1/week 1 (cycles 1-6).
46093881|NCT00980551|Drug|Filgrastim|Supplied as a clear solution in 300 mcg/ml 1 ml or 1.6 ml vials and prefilled syringes containing 300mcg/0.5mL or 480mcg/0.8mL. Given intravenously on day 6 of each week (cycles 1-6).
46093882|NCT02660060|Drug|Pramipexole Dexa Medica|Pramipexole 0.25 tablets produced by PT Dexa Medica for PT Ferron Par Pharmaceuticals as the test drug.
46093883|NCT02660060|Drug|Pramipexole Boehringer Ingelheim Pharma|Pramipexole 0.25 tablets produced by Boehringer Ingelheim Pharma GmbH & Co.KG for Boehringer Ingelheim International GmbH as the reference drug.
46093884|NCT05340881|Behavioral|Bright Light Exposure|Research coordinator will follow-up with participant on Days 2 & 5, and weekly thereafter to assess for the presence of potential side effects. If side effects are present with bright light initiation and they do not resolve by Day 5, the intervention will be discontinued.
46093885|NCT05340881|Behavioral|Dim Light Exposure|A placebo pair of glasses that is identical in form to the bright light glasses with the exception of light intensity will be used in a manner identical to the bright light glasses.
46093886|NCT05340881|Other|Cognitive Assessment|Cognitive examinations will be completed in-person and remotely via an online platform; caregivers and participants will also be asked to complete questionnaires assessing fatigue, sleep, and mood. These outcomes will be completed at baseline (prior to intervention/placebo), Week 4, Week 6 (end of intervention/placebo), and Week 8 (2-weeks post intervention/placebo).
46093887|NCT04008979|Drug|Aspirin|Aspirin - lipid complex
46093888|NCT04171154|Behavioral|Expectation|writing task
46093889|NCT04171154|Behavioral|Acceptance|listening
46093890|NCT05263583|Drug|Sepantronium Bromide|continuous intravenous infusion
46006963|NCT00591201|Drug|infliximab|Infliximab 5mg/kg diluted in 250 ml of isotonic solution of sodium chloride will be administered by the intravenous route on weeks 0, 2, 6, 12, 18, 24, 30, 36, 42, and 48.
46006964|NCT00591201|Drug|Placebo|Placebo -powder diluted in 250 ml of isotonic solution of sodium chloride- will be administered on weeks 0, 2 and 6.
46006965|NCT04582058|Behavioral|Mobile Health of lifestyle|Mobile health of lifestyle with an orientation about daily activities and necessary care to patients with CEID, and protocol of exercise training with images and guidelines to execute five days per week, with a duration of 50 minutes, and space for doubts which patients could send message to researcher.
46006966|NCT04575831|Behavioral|Exercise, Nutrition, and Palliative Symptom Management|"Exercise: The exercise intervention is a 12-week group-based program, with 1 weekly 75 minute session focused on strength, balance, flexibility and aerobic capacity.~Palliative Symptom Management: Palliative symptom management will focus on symptoms that contribute to reduced QOL, limit ability to engage in exercise, or present barriers to oral intake.~Nutrition: A Registered Dietitian (RD) team will provide feedback and tailored nutrition advice based on a pre-study food recall evaluation, recommending interventions based on the nutrition assessment feedback form, such as oral nutritional supplementation or target daily protein and caloric intake."
46006967|NCT04575753|Other|Study group|"Blood samples will be taken from ICU patients on the day of ICU admission, day 2 and day 5 after ICU admission.~Similarly, patients will be subjected to cognitive testing (CAM-ICU) to determine the presence of delirium"
46006968|NCT04582097|Drug|Ramipril|angiotensin-converting enzyme inhibitor
46006969|NCT04582097|Drug|placebo|same odor, color and size as the drug but without the active ingredient
46006970|NCT04582019|Device|stent extraction|stent extraction using magnetic retriever or flexible cystoscope
45459829|NCT01237795|Other|Dentifrice|Dentifrices (4 formulations) used as auxiliary agents for brushing complete dentures.
46006971|NCT04575714|Other|Data record|Data record
45459830|NCT01310712|Drug|Oxybutynin|5 mg every 12 hours for 6 weeks
45459831|NCT01310712|Drug|placebo|placebo twice a day for 42 days.
45459832|NCT02737930|Drug|Fluoxetine|
46006972|NCT04581707|Device|Kyphoplasty Single Balloon Catheter Allevo|Vertebral compression fractures treated with Kyphoplasty Single Balloon Catheter Allevo (Joline®) and BonOs® Inject bone cement
46006973|NCT04581707|Device|Quattroplasty Double Balloon Catheter Stop'n GO|Vertebral compression fractures treated with Stop'n GO double balloon kyphoplasty system (Joline®) and BonOs® Inject bone cement
46006974|NCT00591357|Drug|loperamide|4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
46006975|NCT00591357|Drug|placebo|4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
46006976|NCT04581590|Other|Cognitive training|Both groups will undergo the motor training where only the type of received electric current is varied (active or simulated sham type) associated cognitive training. The twelve sessions will be performed in three sessions per week for 30 minutes.
46006977|NCT00591396|Drug|ZIO-101 (Darinaparsin)|Dose Escalation of ZIO-101 (Darinaparsin) given daily for five consecutive days to be repeated every 28 days for up to six months
46006978|NCT04575636|Diagnostic Test|Magnetic Resonance Lymphography|Magnetic Resonance Lymphography using Siemens 3T MRI unit and Gadobutrol as a contrast agent to visualize the lymphatic system
46006979|NCT04581278|Diagnostic Test|KTD Innov-2|"The main objective of the present study (KTD Innov-2) is to validate the feasibility of SDI within a limited time frame to ensure its clinically relevant use, with a high level of evidence to consider its labelling as a medical device by health authorities prior to routine transfer and/or future marketing.~300 kidney transplant patients will be included in the KTD Innov-2 study with data collection, blood, urine and graft biopsies for biomarker analysis and conversion to SDI (decisional algorithms) and interactive multi-dimensional presentation on a web interface for use of the tool by transplant physicians and their patients."
46006980|NCT00591435|Other|Comparison of performance of consultants versus residents|Anesthesia as well as surgical workflow will be analysed. Performance of consultants will be compared to residents
46006981|NCT04580966|Behavioral|Inquiry Based Stress Reduction (IBSR) workshop|The IBSR intervention workshop included weekly group meetings (3.5 hours/meeting) for 12 weeks. During the workshop, participants were encouraged to identify and inquire their stressful thoughts. Using self-inquiry practices participants were taught to increase awareness of their thoughts and feelings, to observe their emotional and physical responses during situations perceived by them as stressful, and allow their mind to return to its true, peaceful, creative nature. Through the process of self-inquiry, participants took an active role in investigating their stressful thoughts, and by this regulated their stress and managed symptoms and emotions, thus enabled them to cope better with the psycho-social consequences of the stuttering.
46006982|NCT04580849|Other|telerehabilitation with dance|Dance classes will be provided through a online platform. Each class will last 60 minutes, twice a week, during 8 weeks.
46006983|NCT00591474|Dietary Supplement|probiotics|100 gms of a yogurt drink containing probiotics will be given to pVRE positive patients for 4 weeks
46006984|NCT00591474|Dietary Supplement|yogurt|100 gms of pasteurized yogurt drinks with no live cultures will be given to VRE positive patients for 4 weeks
46006985|NCT04581239|Other|Active neural mobilization|"Active neural mobilization Base line treatment followed heating pad 10 minutes, lumber traction with 50 %of body weight in accordance with tolerance. 15 to 20 Lumber segmental mobilization.~Active oscillatory nerve mobilization was given in 3 sets of 10 repetition in each set with 20 sec rest time between set"
46006986|NCT04581239|Other|passive neural mobilization|"Base line treatment followed heating pad 10 minutes, lumber traction with 50 %of body weight in accordance with tolerance. 15 to 20 Lumber segmental mobilization~Passive neural mobilization This oscillatory nerve mobilization was given in 3 sets of 10 repetition in each set with 20 sec rest time between set. Both groups received total 18 session 3 session per week for consecutive 6 weeks"
46006987|NCT04581083|Diagnostic Test|RT-PCR|RT-PCR (Gold standard): Real-time PCR testing with reverse transcriptase (RT-PCR). The test consists of a polymerase chain reaction that has previously had a reverse transcription phase, RT. This test allows the cADN (complementary DNA) to be obtained from a RNA chain. This technique allows the detection and amplification of a sequence from a strand of RNA.
46006988|NCT04581083|Diagnostic Test|LAMP|LAMP: The LAMP technique, like PCR, has the ability to amplify specific DNA fragments (target sequence), allowing for highly sensitive detection of pathogens. Unlike pcr, LAMP requires between 4 and 6 feeders, external F3 and B3 feeders, which hybridte with the outer regions of the target sequence, while the internal FIP and BIP have sequences in both ways that allow the formation of a loop. The LAMP reaction is isothermal, i.e. it takes place at a single temperature. LAMP has been successfully used to detect viral diseases as well as viral pathogens such as West Nile virus, TMR-1, Norovirus, avian influenza, foot-and-mouth disease, classical swine fever, among others.
46006989|NCT04581083|Diagnostic Test|POOL RT-PCR|POOL RT-PCR: This test aims to mix in a single sample the extractions obtained from several people. The joint sample is evaluated and, if negative, it is understood that all are free of COVID-19; if it is positive, an array system is used to detect the affected person. That is, a single PCR (polymerase chain reaction), the diagnostic test used to detect the virus pathogen is applied to a group and repeated individually if positive.
46006990|NCT04581083|Diagnostic Test|POOL LAMP|POOL LAMP: Like the RT-PCR pool test. This test essentially involves mixing in a single sample the extractions obtained from several people. This joint sample is tested and, if it is negative, it is understood that everyone is free of COVID-19; if it is positive, an array system is used to detect the affected person. That is: a single LAMP applies to a group
46006991|NCT03452241|Other|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.BI refers to a standard 15-30 minute intervention that includes a series of standard models that stimulate knowledge, motivation and behavior that reduce substance abuse.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
46006992|NCT03452241|Other|Control Group|The participants only receive the materials about the harm of substance use.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
46006993|NCT04581005|Behavioral|Prehabilitation|Endurance and Resistance Exercise, Nutrition therapy, reducing intervention during the whole preoperative period
46006994|NCT04575675|Drug|Dapagliflozin|Dapagliflozin 10mg once daily
45459833|NCT02737930|Drug|Placebo|
45459834|NCT03723174|Behavioral|Oral Health Educational Program|proper introduction to brushing techniques, dietary recommendations and importance of visiting the dentist
46006995|NCT04575675|Drug|Sacubitril-Valsartan|Sacubitril-Valsartan, maximal tolerated dosage
46006996|NCT04575675|Drug|Beta blocker|Cardio-selective beta-blocker, including carvedilol, bisoprolol, metoprolol or nebivolol
46006997|NCT04575675|Drug|Mineralocorticoid Receptor Antagonist|Mineralocorticoid receptor antagonist, including spironolactone or eplerenone
46006998|NCT04575675|Device|Cardiac resynchronization therapy and/or implantable cardioverter defibrillator|CRT-P, CRT-D or ICD if clinically indicated
46006999|NCT00568412|Device|Zarzenda|Topical cream, applied twice daily for three weeks
46093891|NCT04171232|Other|Balance It|Each patient in group 1 i.e. Balance It group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to balance the objects falling from above on the imaginary bar (and an actual bar at later stages) held with their both hands, and not let those objects fall by opening their arms wide open and by staying or moving according to the target spot for the set time. This session would be repeated three times a week for two months (total 12 sessions/month).
46007000|NCT00568412|Drug|Elidel|1% cream, applied topically twice daily for three weeks
46093892|NCT04171232|Other|Bubble Pop|Each patient in group II i.e. Bubble Pop group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to reach for the balloons coming from random directions and pop them by moving their upper limbs and even their whole body if required. They would also be instructed to avoid a specific object that would result in deduction of their overall game score. This session would be repeated three times a week for two months (total 12 sessions/month).
46093893|NCT04171232|Other|Scoop'd|Each patient in group III i.e. Scoop'd group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to hold an imaginary ice cream cone (and an actual basket designed similar to an ice cream cone in later stages) with their both hands and move to catch the ice cream scoops falling at random spots from above, one spot at a time. They would also be instructed to avoid a specific object that would result in deduction of their overall game score. This session would be repeated three times a week for two months (total 12 sessions/month).
46093894|NCT00970879|Drug|cotrimoxazole|800 mg sulfamethoxazole and 160 mg trimethoprim daily, from 28 weeks of gestation until delivery
46093895|NCT00970879|Drug|mefloquine|mefloquine 15 mg/Kg three times, between 16 and 28 weeks, 24 and 32 weeks, then 28 and 36 weeks of pregnancy
45459835|NCT05664984|Behavioral|1-face-to-face|The cognitive rehabilitation intervention consists of 45-minute sessions, 2 days a week for 12 weeks. The same rehabilitation intervention program was applied to both groups by face-to-face or tele-rehabilitation method. The main purpose of the study is to see the effectiveness of cognitive rehabilitation intervention in the elderly with amnestic mild cognitive impairment and to compare the two methods.
46093896|NCT05340803|Radiation|Ultrasonograghic optic nerve sheath diameter US-ONSD|To compare effect of sedation in 3 groups by follow up of intracranial pressure by US-ONSD
46093897|NCT05340803|Drug|midazolam|midazolam
46093898|NCT05340803|Drug|dexmedetomidine|dexmedetomidine
46093899|NCT05340803|Drug|magnesium sulfate|magnesium sulfate
46093900|NCT02663258|Drug|Pembrolizumab|
46093901|NCT00980629|Drug|M516102|Twice a day
46093902|NCT00980629|Drug|placebo|Twice a day
46093903|NCT04033172|Drug|Pyrotinib Plus Fulvestrant|Pyrotinib: 400 mg/d, q.d., p.o. A course of treatment need 28 days. Fulvestrant: 500 mg/m2 q.d. i.m. A course of treatment need 28 day. First course needs extra dose of fulvestrant 500 mg/m2 q.d. i.m. on day 15.
46093904|NCT04231721|Device|High Resolution Colonic Manometry and 3D-Transit system|Measurement of colonic pressure changes and passage patterns in healthy.
46093905|NCT00980707|Drug|Inhaled corticosteroid (fluticasone)|inhaled fluticasone 220 ug/bid
46093906|NCT02665754|Biological|ILIT with extract of causal allergen|0.5 ml of allergen extract from D. farinae, D. pteronyssinus, cat, and/or dog for allergen specific immunotherapy (Tyrosine S, Allergy Therapeutic, UK) will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
46093907|NCT02665754|Biological|ILIT with normal saline|0.5 ml of normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
45459836|NCT05664984|Behavioral|2-tele rehabilitation|2-tele rehabilitation
45459837|NCT01242787|Drug|LB80380|Optimal dose of LB80380, by oral for 48 weeks (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)
46007001|NCT03452163|Device|PMD-200|"the patients will be monitored by PMD-200. The technology consists of measurements of a number of nociception-related physiological parameters that corresponds with the autonomic nervous system's response to noxious stimuli, and using the company's proprietary algorithms, 'translating' these measurements into an index that represents the nociceptive response, the NoL™ (Nociception Level) Index. The NoL index is a relative index from 0 to 100, while 0 is no pain/nociception and 100 is extreme pain/nociception."
46007002|NCT03452163|Device|EEG monitor|An EEG device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.
46007003|NCT00568529|Drug|Capecitabine and Oxaliplatin|Capecitabine 1000mg/m2 Bid d1-14 Oxaliplatin 130mg/m2 d1 q3w
46007004|NCT00568568|Drug|Growth hormone|GH infusion from 8.00 pm to 03.00 am (dose 10,2 ng/kg/min) c) GH infusion from 02.00 am to 09.00 am (dose 10,2 ng/kg/min).
46093908|NCT02665754|Drug|Rescue medication for allergic rhinitis|Subjects are requested to administer oral antihistamine (cetirizine) or nasal glucocorticosteroid (ciclesonide) as rescue medication for allergic rhinitis in accordance with severity and frequency of allergic rhinitis symptoms according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline.
46093909|NCT05340725|Drug|DEX-IV|patients will receive iv DEX 1µ/kg diluted in 100 ml saline and given slowly iv infusion over 10 min. 30 min. before induction of anesthesia.
46093910|NCT05340725|Drug|DEX-Rectal|Patients will receive rectal DEX suppository formulation at approximately 1µ/kg at 30 min. before induction of anesthesia
46093911|NCT05340725|Drug|DEX-Nano-Rectal|Patients will receive rectal DEX suppository in the Niosomes formulation at approximately 1µ/kg at 30 min. before induction of anesthesia
46007005|NCT04575558|Drug|Hydroxychloroquine and Azithromycin|Hydroxychloroquine 400mg PO BID 2 times a day + Azithromycin 500mg PO QD
45459838|NCT01242787|Drug|Entecavir 0.5 mg|Entecavir 0.5 mg, by oral for 48 weeks
46007006|NCT04581161|Device|Life2000® Ventilator|"POV support (Life2000) will be administered in six (6) to ten (ten) enrolled subjects based on clinical protocol flowchart (Appendix C). Specifically, if it is determined that a COVID-19 subject who would currently be considered for HFNC under current standard of treatment, will be eligible for POV treatment.~The prescribed therapy regimen, including duration of therapy will be documented and COVID-19 patients who fail therapy and require IMV will be recorded."
46007007|NCT03452124|Device|I quit ordinary smoking (IQOS)|I quit ordinary smoking (IQOS) assisted cessation program
46007008|NCT03452124|Other|Conventional cigarette|Conventional cigarette smoking continuation
46007009|NCT00568607|Drug|IFO, VP-16, DDP, DXM|DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 75 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
46007010|NCT03452085|Device|artificial saliva spray (AS)|cross over design
46007011|NCT03452085|Other|maritime throat spray (TT)|cross over design
46007012|NCT00568646|Drug|MKC-1|Oral MKC-1 capsules, administered twice daily, for 14 consecutive days, in a 28-day cycles
46007013|NCT03452046|Other|IVC diametres|
46007014|NCT00568763|Biological|sargramostim|
46007015|NCT00568763|Other|immunoenzyme technique|
46007016|NCT00568763|Other|immunohistochemistry staining method|
46007017|NCT00568763|Other|immunologic technique|
46007018|NCT00568763|Other|laboratory biomarker analysis|
46007019|NCT00568763|Procedure|biopsy|
46007020|NCT00568763|Procedure|cryosurgery|
46007021|NCT00568763|Procedure|radiofrequency ablation|
46007022|NCT04575480|Procedure|Shock Wave Lithotripsy for renal stone.|The following protocol will be applied for all patients in study groups. SWL will be performed using the Dornier Gemini lithotripter (Dornier MedTech, Wessling, Germany) . A total of 3 000 shocks will be delivered at 80 shocks/min. The patient will receive 1 mg/kg pethidine i.v. for analgesia. Treatment will begin at machine power step 1, which will deliver 49 MPa focal pressure and 0.35 mJ/mm2. Power will be gradually increased by one step for each 200 shocks up to step 4, which deliver 70 MPa and 0.7 mJ/mm2. The maximum session number will be 3 session. Patient treated with <2 sessions will be excluded from the analysis
46007023|NCT00568841|Drug|erlotinib|erlotinib p.o. (by mouth), 150 mg once daily for week 1-6 (day 1-42)
46007024|NCT00568841|Procedure|FDG-/FLT-PET|
46007025|NCT00583869|Drug|Placebo|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive a placebo PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (placebo PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
46007026|NCT00583869|Drug|Pregabalin|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 75mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 75mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
46007027|NCT00583869|Drug|Pregabalin|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 150mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 150mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
46007028|NCT00568880|Drug|bortezomib|bortezomib 1.0-1.3mg/m2 IV
46007029|NCT00568880|Drug|hydroxychloroquine|hydroxychloroquine 200 mg pill
46007030|NCT03451968|Other|amino acid tracer injection for metabolism analysis|"the intervention includes injecting stable amino acid tracers in order to evaluate differences in processing of amino acid in critically ill patients compared to a normal population.~after injection 5 ml of blood will be drawn at time 0, 2, 5, 10, 15, 20, 30, 40, 50, 60, 90, 120, 150, 180 minutes from the start of the study, a total of 14 blood samples (70 cc)."
46007031|NCT00569036|Drug|BMS-754807|Tablets, Oral, Dose Cohorts: 4mg, 10mg, 20mg, 30mg, 50mg, 70mg, 100mg, 130mg, 160mg, 200mg, Once Daily, Until disease progression, unacceptable toxicity or at the subject's request
46007032|NCT00569075|Other|collection of gingival crevicular fluid|GCF samples will be collected at 3 month intervals
46007033|NCT03453021|Drug|Mepolizumab|
46093912|NCT00970957|Drug|Avastin Intravitreal Injection|Intravitreal injection of 1.25mg Avastin (Bevacizumab) per month, during the first 3 months. Retreatments will be required if visual acuity or macular edema thickness worsen as defined per protocol
46093913|NCT00970957|Drug|Sham Avastin Intravitreal Injection|Intravitreal Injection simulation with a syringe without needle. The rest of the procedure remains the same as if intravitreal injection were to be performed (antibiotic prophylaxis, local anesthesia, ...).
45459839|NCT03476356|Drug|oral clomiphene citrate|oral clomiphene citrate 50 mg tablet, two times per day will be received from the third day of the cycle until the seventh day of the cycle.
45459840|NCT03476356|Drug|oral carnitine supplementation|oral carnitine supplementation 1g tablet, three times per day will be received from the third day of the cycle until the day of the pregnancy test.
45459841|NCT02611076|Behavioral|Stop Smoking for Good Intervention in Spanish (SS-SP)|Assessments will occur at six-month intervals, through 24 months.
45459842|NCT02611076|Behavioral|Usual care (UC)|Assessments will occur at six-month intervals, through 24 months.
45459843|NCT03723096|Drug|CC-4047|CC-4047 will be administered orally
46007034|NCT03453944|Device|VentFree prototype (VF03-K) active stimulation|Abdominal wall muscle stimulation synchronised with mechanical ventilation. Stimulation frequency: 30 Hz, pulse width: 352us, max. intensity: 100mA (threshold intensity determined using ultrasound)
45678454|NCT01953224|Behavioral|Game-based intervention|"Investigators will provide participants with a smartphone and required accessories (gift card for downloading the game application and music, headphones, armband). The game, Zombies, Run! encourages walking/jogging by playing music interspersed with a continuous narrative. Periodic zombie chases encourage brief interval training. Participants will set goals to increase their activity and receive weekly brief counseling phone calls to provide feedback."
45678455|NCT01953224|Device|Smartphone|
46007035|NCT03453944|Device|VentFree prototype (VF03-K) sham stimulation|Abdominal wall muscle sham-stimulation synchronised with mechanical ventilation. Stimulation frequency: 10 Hz, pulse width: 352us, intensity: 15 mA.
46007036|NCT03451890|Drug|E2730|oral capsule
46007037|NCT03451890|Drug|Placebo|oral capsule
45459844|NCT01237873|Drug|Ali/Amlo 150/2.5 mg|Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg
46007038|NCT02277392|Biological|Vaccine---primed, CD3/CD28---costimulated autologous peripheral blood T---cells|
46007039|NCT02277392|Biological|SB---485232 (Human recombinant Interleukin---18)|
46007040|NCT00569114|Drug|TG01|Drug:TG01tablets given orally QD Drug: erlotinib tablets 150mg QD
46007041|NCT03452904|Device|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
45459845|NCT03480412|Procedure|Follicular Phase|The follicular phase stimulation is conduced according to a standardized Antagonist protocol or Short protocol (with GnRH agonist) using recombinant or urinary gonadotropins (starting dose 300 or 450 UI) or a long lasting recombinant gonadotropin (Corifollitropin alfa 150 mcg) from the second day of the menstrual cycle. When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.
45678456|NCT01900730|Drug|Placebo|Patient takes placebo capsule 3 times a day by mouth for 10 weeks.
45678457|NCT01900730|Drug|Valproic Acid (VPA)|Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks.
45678458|NCT01900730|Behavioral|Questionnaires|Questionnaires completed at baseline, weeks 2, 6, and 10.
45678459|NCT01900730|Behavioral|Pill Diary|Patient given a pill diary to record the time each dose taken.
45678460|NCT01900730|Behavioral|Drainage Diary|Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
46007042|NCT03452904|Device|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting balloon
46007043|NCT00569426|Device|NovoFine® needle 6 mm|
46007044|NCT00569426|Device|NovoFine® needle 8 mm|
46007045|NCT03451695|Drug|Morphine|Morphine group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and 100 μg of preservative free morphine (0.1 ml).
45459846|NCT03480412|Procedure|Luteal Phase|Two - six days after the first oocyte retrieval a second gonadotropin stimulation will be started with a GnRH antagonist protocol (the stimulation will be started with 250 UI of human menopausal gonadotropin (hMG) and a GnRH antagonist (GnRH-an) 0,25 mg\die will be administered when the leading follicle is ≥ 14 mm until hCG criteria are met). When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.
46093914|NCT02659904|Other|Less than 2 mm remaining palatal tissue thickness|The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
46093915|NCT02659904|Other|2 mm or more remaining palatal tissue thickness|The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
46093916|NCT02780999|Device|Whale orthosis|Participants will be teach how to use the Whale orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain
46093917|NCT02780999|Device|Colditz orthosis|Participants will be teach how to use the Colditz orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain.
46093918|NCT02663180|Behavioral|Educational program|Educational strategies: 2 Lecture about depression 30 minutes supported by group discussion, brochures and display of posters with mental-health slogans on depression in the schools.
46093919|NCT02663180|Behavioral|Video contact|Contact strategies: Investigators will show a video of a young male who had been diagnosed with depression. The video presented information that was moderately disconfirming of prior stereotypes by balancing the individual's difficulties resulting from Depression, with his ability to live a normal life.
45459847|NCT02608346|Procedure|Blood sampling|"Patients will have a blood draw at each visit to the hospital,~with a maximum of 1 blood draw every 3 months, in absence of any abnormal clinical/radiological exam~with a maximum of 1 blood draw every week, in case of abnormal clinical/radiological exam that requires further investigation"
46093920|NCT00976105|Drug|Zolpidem or placebo - Hypnotic drug given for sleep disorders|The information gathered from Part A will be used as a benchmark against which any effects of GSK1521498 can be assessed in Part B.
45459848|NCT03723018|Behavioral|Meditation|10 minutes a day of meditation, done on your own time.
45459849|NCT03476200|Behavioral|Cognitive Behavioral Therapy|The intervention consist of 14 weekly group meetings lasting 1.5 or 2 h. Groups are made up of 10 patients. Each group session follow a structured format and consisted of the following elements: introduction to the session, discussion of homework, group discussion and the development of new coping skills. The sessions deal with the following: concept of stress, cognitive restructuring, alternative thought control strategies, relaxation techniques, training in social skills, training in social skills and humour and optimism as coping strategies.
45459850|NCT03913663|Other|vestibuloocular training|using vestibulo ocular training program for training neglect patient
46093921|NCT00976105|Drug|GSK1521498 or placebo|The first group will start at a low dose (10 mg GSK1521498 or placebo) for 10 days. The study team will then assess the data gathered from the first cohort and will select the dose that the next cohort will receive for 10 days. There will be up to 4 cohorts.
46093922|NCT02780921|Procedure|prehabilitation|
46093923|NCT02780921|Other|nutritional support|
46093924|NCT04865432|Device|UVB treatment|5 weeks of UVB titration to determine individual's UVB sensitivity followed by 4 weeks of UVB exposure intervention
46007046|NCT03451695|Drug|Placebo|Placebo group will receive 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1ml)
46007047|NCT00569465|Drug|Arginine|1200 mg, once a day
46007048|NCT00569465|Drug|Acetylcysteine|600 mg twice a day
46007049|NCT00569465|Drug|Placebo|3 vials a day
46007050|NCT00569543|Other|high performance liquid chromatography|urine analysis
46007051|NCT00569543|Other|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
46007052|NCT00569543|Other|mass spectrometry|The urine samples will be analyzed for 40 estrogen metabolites, conjugates and depurinating DNA adducts by UPLC with tandem mass spectrometric detection.
46093925|NCT00971113|Dietary Supplement|sc-FOS and Sideritis euboea extract|"dietary supplement: jelly with 5g sc-FOS and 0.3g Sideritis euboea extract per daily portion for 30 days~placebo food: jelly with no sc-FOS and Sideritis euboea"
46093926|NCT00976261|Drug|GSK1614235|Glucose lowering in Type 2 Diabetes Mellitus
46093927|NCT00976261|Drug|Sitagliptin|Glucose lowering in Type 2 Diabetes Mellitus
46093928|NCT00976261|Other|Placebo|Comparator
46093929|NCT02663024|Biological|idursulfase beta|IV, weekly infusion for 24 weeks
46093930|NCT02663024|Biological|idursulfase|0.5 mg/kg, iv, weekly infusion for 24 weeks
46093931|NCT02780843|Other|Computerized Tomography|Standard Operational Plan at admission: CT and CT-angiography
46093932|NCT02780843|Other|Magnetic Resonance Imaging|Standard Operational Plan at admission: Diffusion Weighted Imaging (DWI), T2-FLAIR, Gradient and arterial Time-of Flight (TOF)
46093933|NCT02659826|Device|anodal tsDCS|Transcutaneous spinal cord stimulation will be delivered through a direct current (DC) stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (anode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 milliampere (mA), fade in and fade out of 10 seconds, during 20 minutes.
46093934|NCT02659826|Device|cathodal tsDCS|Transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (cathode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during 20 minutes.
46093935|NCT02659826|Device|sham tsDCS|sham transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The electrode anode will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during only 30 seconds but the volunteers will continue with electrodes montage for 20 minutes.Thus, early sensations (eg. mild to moderate tingling or itch) on stimulation site will be experienced without inducing any modulatory effects.
45459851|NCT03913663|Other|regular exercise training for hemiplegic patients|Traditional gait training program.
45598980|NCT03189173|Device|Oral appliance|"An oral appliance (dental mouthpiece) will be used to improve upper airway patency. Patients who do not have their own custom dental oral appliance (various brands, commonly Herbst/Somnomed) will be provided with a device (BluePro, BlueSom) for the duration of the study.~Patients will also be administered sham (room air) at 4 L/min via nasal cannula."
45598981|NCT03189173|Drug|Oxygen|Supplemental oxygen will be delivered at 4 L/min via nasal cannula to improve ventilatory control stability.
45598982|NCT03189173|Other|Oral appliance plus oxygen|Both treatments will be administered simultaneously.
45678461|NCT01952834|Dietary Supplement|GoodBelly Probiotic|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
45678462|NCT01952834|Drug|Vancomycin|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
45678463|NCT04643912|Diagnostic Test|Vibration Device|Device which causes the bone to vibrate and records the spectrum of that vibration
45678464|NCT01952054|Drug|Denosumab|120 mg subcutaneously on Day 1 of every 28 day cycle.
46007053|NCT00569543|Other|medical chart review|Collection of information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease.
46007054|NCT00583986|Drug|Levalbuterol HFA MDI with top mounted actuation indicator|Levalbuterol HFA MDA with top mounted actuation indicator
46007055|NCT00569621|Drug|Moxaverine|intravenous administration
46007056|NCT00569621|Drug|physiological saline|intravenous administration
46007057|NCT03451617|Device|Stent delivery with Xpedition|Use of Xpedition stent delivery system to implant the XIENCE stent
46007058|NCT03451617|Device|Stent delivery with Alpine|Use of Alpine stent delivery system to implant the XIENCE stent
46007059|NCT00569699|Drug|S-1, Bevacizumab|"S-1 is administered orally on days 1 to 28 of a 42-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25 m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).~Bevacizumab 5 mg/kg (body weight) is administered by intravenous infusion on days 1, and 15."
46007060|NCT00569738|Procedure|PET scan with Ga68-DOTANOC|Imaging: PET scan with Ga68-DOTANOC
46007061|NCT00569816|Drug|Sevoflurane|1 MAC Sevoflurane will be given either continuously after induction of anesthesia until initiation of cardiopulmonary bypass or will be repetitively washed in and out twice before initiation of cardiopulmonary bypass.
46007062|NCT04580576|Procedure|Hematopoietic stem cell transplantation|Allogeneic or autologous bone marrow transplant
46007063|NCT00569894|Biological|FLuMist|One or two vaccinations with FluMist depending on prior vaccination status.
46007064|NCT00569894|Biological|TIV (Injection)|One or two injections of TIV depending on previous status.
46007065|NCT00569894|Other|Unvaccinated Control|no vaccine
46007066|NCT00584064|Device|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
45678465|NCT01925768|Drug|Apremilast 30 mg|30mg of Apremilast will be orally administered twice daily for 104 weeks
45678466|NCT01925768|Drug|Placebo|Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks
45678467|NCT01431274|Drug|tiotropium + olodaterol|fixed dose combination
45678468|NCT01431274|Drug|tiotropium|low dose
45678469|NCT01431274|Drug|olodaterol|one dose only
45678470|NCT01431274|Drug|tiotropium|high dose
45678471|NCT01431274|Drug|tiotropium + olodaterol|fixed dose combination
46007067|NCT00569933|Behavioral|Audio recording|Using audio recording to investigate if possitive affirmations help with pain management and other post of compllication.
46007068|NCT04574661|Other|Static Stretching|In Control group all the individuals will be asked to perform static stretching for 10 mints, 1 set . Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual.
45678472|NCT01431274|Device|Respimat|Respimat inhaler
46007069|NCT04574661|Other|Intermittent Occlusion|Individuals of Interventional group will be asked to lay down in supine position, apply proximal thigh cuff, 220mg for 12 minutes for intermittent occlusion. During this procedure discomfort will be checked on numeric pain rating scale, if we get 6 on scale, will stop the occlusion. Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual
46007070|NCT00570011|Drug|Somatropin|3 microg/kg/day for the first three months.The dose was then doubled (6 microg/kg/day) for the next three-months.
46007071|NCT00570011|Drug|Somatropin|6 microg/kg/day for the first three months. The dose was then doubled (12 microg/kg/day) for the next three-months.
46007072|NCT04574388|Other|open label placebo|open label placebo pill
45678473|NCT01991795|Drug|Ticagrelor 60 mg|Ticagrelor 60 mg bd taken orally as tablets
46007073|NCT04581122|Procedure|Lymphadenectomy|Patients with ground glass nodules smaller than 3cm and with more than 50%solid components would randomly assigned to selective lymphadenectomy group or systematic lymph node dissection group
45598983|NCT03189173|Other|No treatment|Subjects will not wear an oral appliance, and will be administered sham (room air) at 4 L/min via nasal cannula.
45598984|NCT03514615|Procedure|Incision|A skin incision will be made on the medial aspect of the upper arm.
45598985|NCT03514615|Drug|Active gel|The incision site on one arm will be dosed with the active gel.
45598986|NCT03514615|Drug|Placebo gel|The incision site on the other arm will be dosed with placebo gel.
45598987|NCT02293447|Drug|Lidocaine per-embolization|10mL of 1% lidocaine will be mixed with the embolization particles. Lidocaine will therefore be injected during the embolization.
45598988|NCT02293447|Drug|Lidocaine post-embolization|10mL of 1% lidocaine will be injected in both uterine arteries after the embolization endpoint is achieved.
45598989|NCT02353455|Procedure|Blood sampling|In each group a blood sample of approximately 50 mL will be obtained upon study inclusion.
45678474|NCT01991795|Drug|Ticagrelor placebo|Ticagrelor placebo bd taken orally as tablets
46007074|NCT00570050|Drug|Diluent / Insulin|Diluent (4 Weeks ) / Intranasal insulin (4 weeks)
46093936|NCT02659826|Device|Gait training|It consists of moderate gait training exercise for 20 minutes. To ensure that the exercise will be performed at moderate intensity will be used the 64% - 76% of maximum heart rate (HRmax = 220-age). Heart rate will be monitored every three minutes through a heart polar. In addition will be monitored perceived effort, gait speed and inclination of the treadmill. The Borg scale will be used to evaluate perceived effort. This is an analogue scale graded from 6 (light exercise) to 20 points (exhaustive exercise). Information about the exercise on the treadmill will be noted in the evolution record.
46093937|NCT02659826|Device|High frequency rTMS|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 20 hertz (Hz), 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28 seconds, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
46093938|NCT02659826|Device|Low frequency rTMS|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed.
46093939|NCT02659826|Device|sham rTMS|The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left primary motor area. After each rTMS session, presence of adverse effects will be computed.
46093940|NCT00980863|Behavioral|lifestyle intervention to increase physical activity|
46093941|NCT04196543|Other|écho-doppler with ultrasonar Sonovue® injection|"During this unique visit they will benefit from 2 imaging exams performed by two different operators:~Echo-doppler without standard method contrast injection (common practice)~An echo-doppler with Sonovue® ultrasound injection Ultra_evar method (2.5 ml bolus 2-3 seconds) During this examination, the endoprosthesis and the aneurysm sac will be scanned according to the 4 incidences described above in order to objective whether or not there is a endoleak.~The patient then performs the control CT-scan prior to discharge from hospital.~The results of the medical imaging exams will be communicated to them before the hospital discharge, once the CT-scan has been performed.~A cross-review of the studies will be performed later."
46093942|NCT00980941|Dietary Supplement|soup with or without starch|
46007075|NCT00570050|Drug|Insulin / Diluent|Intranasal Insulin (4 Weeks ) / Diluent (4 Weeks)
46007076|NCT00584103|Device|Alpha P Control|Subjects will be fitted with a terminal device with their current prosthesis and evaluated using the NYU trans-radial prosthesis checkout form.
46007077|NCT00584103|Device|Beta P Experimental|Subjects will be fitted with the inexpensive prosthesis model from Prestige Healthcare Technologies. Then the terminal device will be fitted and evaluated using the NYU trans-radial prosthesis checkout form.
46007078|NCT00570167|Procedure|Hip resurfacacing|Hip resurfacing with cementless acetabular cup and cemented femoral head
46007079|NCT00570167|Procedure|Cementless total hip arthroplasty with m-o-m bearings|Cementless monoblock acetabular cup and cementless femoral stem with modular large head and metal-on-metal bearings..
46007080|NCT00584142|Behavioral|Mindfulness-Based Stress Reduction|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program.
46007081|NCT00570206|Behavioral|Motivational Interviewing|Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
46007082|NCT00570245|Drug|Nitric oxide|inhalation, 10 ppm, for up to 48 hours
46007083|NCT00570245|Drug|Nitric oxide|inhalation; 10ppm; 3 hours (donor) up to 48 hours (recipient)
46007084|NCT04574544|Drug|Zinc Supplementation|The 25 supplemented children had received an oral zinc supplement per day for 14 days and had no dietary restrictions.
45678475|NCT02076100|Drug|Ruzasvir|Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
46007085|NCT04574544|Behavioral|Nutrition education of mothers|Nutritional information was delivered to each mother to facilitate a change in bad eating habits observed, improve knowledge, attitudes and skills of mothers on child nutrition. The anthropometric and biochemistry parameters of children were taken before and after the maternal nutrition education
46007086|NCT00570284|Drug|LBH589|orally administered panobinostat at 20 mg twice weekly (core phase); orally administered panobinostat 45 mg twice weekly if 20 mg twice weekly was tolerated in Cycle 1 (extension phase)
46007087|NCT00570440|Drug|Oral contraceptives--ethinyl estradiol, levonorgestrel|3 visits - screening/enrollment, 6-months and 12 months
46007088|NCT00584259|Other|Coffee|3 cups of coffee over a 24 hour period
45598990|NCT02345967|Device|Model 100 Sensor|One Model 100 Sensor to be implanted per subject.
45598991|NCT04464811|Diagnostic Test|Furosemide stress test|Furosemide stress test is performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have never received oral furosemide.
45598992|NCT03155451|Diagnostic Test|methylation markers screening|ctDNA extraction from plasma samples;bisulfite-treated DNA;DNA methylation levels by deep sequencing-Sequencing; data analysis
45598993|NCT02293525|Device|ReLeaf catheter|Continuous infusion rate 10ml/hr (5ml/side)
46093943|NCT04065464|Device|Ava Fertility Tracker|All women aged 18 to 40 years using Ava Fertility Tracker to track their cycles.
46093944|NCT02781155|Other|Moxibustion|Participants are taught to self administer moxibustion to acupuncture point Zusanli St-36 daily throughout the course of their chemotherapy
45598994|NCT02293525|Drug|Ropivacaine|
45840188|NCT00672204|Biological|Allogeneic islets of Langerhans transplant|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
46007089|NCT00570479|Drug|anecortave acetate|Patients will receive the specified dose of anecortave acetate every 4 months in an anterior juxtascleral depot injection
46007090|NCT04574622|Device|radial Extracorporeal Shockwave Therapy|rESWT was given on gastrocnemius muscles with the subject lying on prone position. No anesthesia was required.
46007091|NCT00584298|Drug|SMS995|
46007092|NCT00584298|Drug|Placebo|
46007093|NCT00570557|Other|TOR-BSST© Refresher Training|Web-based refresher training in dysphagia screening
46007094|NCT03451149|Device|Radiofrequency wire (Powerwire)|Using a radiofrequency wire in lieu of a needle for penetrating the liver during transjugular intrahepatic portosystemic shunt creation.
46007095|NCT00570791|Device|Tonometer|Tonometer devices used to measure IOP: Pascal Dynamic Contour Tonometer, Goldman Applanation Tonometer, Tono Pen, Reichart pneumatonometer, Langham Ocular Blood Flow, Schiotz Tonometer and ICare tonometer
46007096|NCT04580264|Behavioral|REINTERVENTION|This self-applied online program will take three months and comprise 9 behavioural modules developed gradually, achieving the changes needed on eating and physical activity habits, supported by audiovisual instructions given by an hypertension specialist doctor.
46007097|NCT00584376|Drug|Pregabalin|Gradually titrated dose ranging from 75mg po bid to 225mg po bid.
46007098|NCT00584376|Drug|Placebo|Placebo capsules which are identical in packaging, appearance and dosing as the active capsules.
46007099|NCT00570830|Device|Retisert (fluocinolone acetonide implant)|Patients with intermediate, posterior or pan-uveitis underwent simultaneous fluocinolone acetonide implantation (0.59 mg or 2.1 mg) and phacoemulsification and intraocular lens.
46007100|NCT04574349|Procedure|Decompressive craniectomy|Removing part of the skull (bone flap) to lower intracranial pressure
46007101|NCT00570869|Other|CPR Anytime|These participants will be consented, surveyed, asked to watch a 22-minute instructional Infant CPR DVD with an infant manikin.
46007102|NCT04574310|Other|Collect retrospectively data on embryo implantation rate|Collect retrospectively data on embryo implantation rate
46007103|NCT00570947|Other|CPR Anytime Kit|The study group will be asked to fill the CPR Anytime ™ prescription and complete the program. They will be encouraged to include other friends and family members in the program
46007104|NCT00584493|Drug|CP-675,206|"This is a single arm study. Patients will receive intravenous administration of CP-675,206 at a dose of 15 mg/kg on Day 1 of every 90-day cycle for up to 4 cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 (± 4 day) period. Patients who discontinue treatment after 4 doses of CP-675,206 without disease progression and who subsequently experience disease progression more than 3 months after the last dose may receive 2 additional doses of CP-675,206 provided that they have not received other systemic therapy for their melanoma~Survival in this study will be monitored on all patients for up to 5 years from the date of first dose of CP-675,206."
46007105|NCT00571025|Behavioral|APOE Disclosure|Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease and told their own APOE genotype.
46007106|NCT04573959|Device|SV-3 Capsule Endoscopy|The purpose of this study is to validate an updated version of the CapsoCam SV-3 Endoscopy System with respect to the reproducibility of the system to capture and download small bowel images in a manner consistent with the predicate CapsoCam SV-3 capsule endoscopy.
46093945|NCT02659748|Dietary Supplement|Milk Fat|Three daily servings of whole yogurt (3.25% fat).
46093946|NCT02659748|Dietary Supplement|Control Fat|Three daily servings of fat-free yogurt supplemented with a control fat.
46093947|NCT03075215|Device|Device Programming of the Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D)|The optimization during the standard of care visits in the first 12 months following implantation
45840189|NCT00672204|Drug|Raptiva|Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;
46093948|NCT00971191|Drug|PF-00299804|Brief exposure (5- 11 days) to study drug prior to surgical resection
46093949|NCT02659592|Procedure|transplantation of ovarian tissue|operation(mini laparotomy) for transplantation of frozen- thawed ovarian tissue
45598995|NCT02293525|Drug|Saline|
45598996|NCT02293525|Drug|Morphine|Patient-controlled analgesia (PCA) at 1mg every 6 minutes with a 4 hour lock out after 30mg
45598997|NCT02293525|Drug|Oxycodone|10mg every 4-6 hours
45840190|NCT00672204|Drug|Sirolimus|Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated
45840191|NCT00672204|Drug|anti-thymocyte globulin|2.0 mg/kg on days -2, and -1 IV
45840192|NCT00672438|Drug|Alfentanil|Target controlled intravenous infusion of alfentanil at a plasma concentration of 100ng/ml
45840193|NCT00672438|Other|Saline placebo infusion|Intravenous infusion of normal saline
45840194|NCT00672594|Drug|Sunitinib Malate|Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
45840195|NCT00673764|Other|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
45840196|NCT00673764|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
45840197|NCT00674466|Drug|1.5 mg or 2.0 mg CJC-1134-PC|twice-a-week
45840198|NCT00674466|Drug|Placebo|twice-a-week
45840199|NCT00674622|Drug|Prolotherapy|Injection of 15% dextrose with lidocaine at the lateral epicondyle
45840200|NCT00674622|Procedure|Placebo|Saline/lidocaine
46093950|NCT00971269|Device|Solesta (Nasha/Dx)|Gel (hyaluronic acid/dextranomer) for intersphincteric injection 4x2 ml and retreatment 4x2 ml after 4 weeks
46093951|NCT02662946|Procedure|ICG- angiography|Angiography with ICG prior to and after anastomosis. Extension of colon resection based on ICG angiography results
46093952|NCT02662946|Procedure|No angiography|Extension of resection based on subjective measures
46093953|NCT04007653|Other|Observation|No intervention
46093954|NCT02662790|Other|Doppler|
46007107|NCT04574037|Other|Clinical scores such as SAFE score, NIHSS; demographic data such as age and electrophysiological data (such as the absence/presence of Motor evoked potential)|Clinical scores such as SAFE score, NIHSS; demographic data such as age and electrophysiological data (such as the absence/presence of Motor evoked potential) will determine the predictive functional outcome of the upper limb deficit according to the PREP2 algorithm.
46007108|NCT04580342|Drug|oral Ivabradine|Ivabradine group will receive ivabradine 5mg PO in the evening and 1 hour before anesthetic induction
46007109|NCT04580342|Drug|oral Propranolol|propranolol group will receive propranolol 10 mg PO in the evening and 1 hour before anesthetic induction.
46007110|NCT00571142|Procedure|Bevacizumab + Pars plana vitrectomy|2.5 mg / 0.1 ml bevacizumab after pars plana vitrectomy. Limitorexis would be optional.
46007111|NCT00571142|Procedure|Bevacizumab + pars plana vitrectomy|2.5 mg /0.1 ml of bevacizumab after pars plana vitrectomy
46007112|NCT00584532|Drug|Placebo|10 Placebo Capsules taken orally every day.
46007113|NCT00584532|Drug|GCP - Genistein Combined Polysaccharide|Ten 500 mg capsules given orally per day. Total of 5 grams per day per patient.
46007114|NCT03453905|Diagnostic Test|CTFEA|CT scans are used to generate a finite element model of patient-specific long bones. The bone model is loaded in stance position. Load based on patient's weight and the mechanical response, including the risk of fracture, is computed.
46007115|NCT03453905|Other|Conventional decision algorithm|Decision on surgery vs follow-up will be based on expert opinion and Mirels' score
46007116|NCT00584571|Procedure|Sensory Adaptation Training|This study will last for approximately 3 months and will include 4-6 clinic visits with each visit lasting 2 hours every week or every 2 weeks. At the beginning of each visit we will ask you about your health status and level of satisfaction of your bowel habits. We will then place the pencil-thick probe and balloon inside your rectum and attach it to the barostat device and a computer. We will increase and decrease the volumes of the balloon until the most pressure you can tolerate or a certain level of pressure as measured by the machine is reached, whichever occurs first. You will continue to keep stool diaries and pain diaries for 7 days before and after each visit.
46007117|NCT00584571|Drug|Escitalopram Therapy|Escitalopram; 10 mg every day, orally.
46007118|NCT03451500|Drug|carbidopa-levodopa|See previous
46007119|NCT04573998|Procedure|LSG|bariatric surgery
46007120|NCT04574193|Device|digital therapeutic for substance use disorders|The Continuing Care application (app) is a HIPAA-compliant, mobile-friendly, software program designed to meet the recovery and personal support needs of probationers and parolees with SUDs who are at elevated risk of relapse, re-arrest, and incarceration.
46007121|NCT04574193|Other|Treatment As Usual|12-weeks of weekly group cognitive behavioral therapy
46007122|NCT00571181|Device|Closed-loop system|Automatic delivery of propofol and remifentanil
46007123|NCT00571181|Device|TCI (Infusion Toolbox)|TCI administration of propofol and remifentanil
46007124|NCT00584610|Device|Levonorgestrel-containing IUD (Mirena®)|Levonorgestrel-containing intrauterine device insertion
46007125|NCT00584610|Device|Copper-containing IUD (Paraguard®)|Copper-containing intrauterine device insertion
46093955|NCT00971347|Other|Extra sugar-free chewing gum sticks|90 minutes chewing per day after meals; mid-morning and mid-afternoon; 1 to 2 hours after dinner; and in response to hunger, cravings, preoccupation with eating, or negative feelings in general throughout the day.
46093956|NCT00971347|Behavioral|nutrition brochure|one-time at baseline visit
46093957|NCT02662712|Drug|JNJ-56136379|JNJ-56136379 oral tablets will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
46007126|NCT00571220|Procedure|gastric bypass surgery|weight loss bariatric surgery
46007127|NCT00571220|Other|Diet induced weight loss|low calorie diet with meal replacements. weekly outpatient visits with nutritionist.
46093958|NCT02662712|Drug|Placebo|Matching placebo to JNJ-56136379 will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
46093959|NCT05340569|Diagnostic Test|Whole-body diffusion-weighted magnetic resonance imaging|See arm description.
46093960|NCT00976651|Drug|human menopausal gonadotropin|200 IU per day in the late follicular phase
46007128|NCT00584649|Procedure|electrophysiology study and radiofrequency ablation|stimulation protocol searching for the neural inputs to the sinus node region and radiofrequency ablation of neural input to the heart
46007129|NCT00571298|Procedure|Extrapleural pneumonectomy (EPP)|Resection of the lung, the lining of the lung (pleura), the covering of the heart (pericardium), and the muscle that separates the chest and abdomen (diaphragm)
46007130|NCT00571298|Drug|Cisplatin|Given after the tumor is removed as a bath (perfusion) for one-hour
46007131|NCT00571298|Drug|gemcitabine|Given after the tumor is removed as a bath (perfusion) for one-hour
46007132|NCT00571298|Drug|amifostine|Given intravenously before perfusion chemotherapy and then 2 hours after the first dose
46007133|NCT00571298|Drug|sodium thiosulfate|Given intravenously immediately at the end of perfusion chemotherapy
46007134|NCT00571298|Procedure|Pleurectomy/Decortication|Resection of the lining of the lung (pleura), while the lung remains intact.
46007135|NCT04574271|Behavioral|Intensive dietary advice and exercise prescription|Personalized dietary advice and exercise prescription according to nutritional status.
46007136|NCT04574271|Behavioral|Usual dietary advice and exercise prescription|Generalized dietary advice and excercise prescription in elder patients.
46007137|NCT00571337|Drug|Infliximab|Stopping infliximab in patients having been treated with this drug for at least one year and in stable remission for at least 6 month.
46093961|NCT02780141|Drug|roxadustat|Oral
46093962|NCT04171076|Procedure|Transcutaneous spinal cord stimulation|Theta burst stimulation at thoracic level (T5) over 2 minutes
46093963|NCT00976729|Drug|NOX-E36|single ascending IV doses, ranging from 0.03 mg/kg to 2.0 mg/kg
46093964|NCT00976729|Drug|NOX-E36|single SC doses, at safe and tolerable dose level
46093965|NCT00976729|Drug|Placebo|
46007138|NCT04575519|Drug|Control group|placebo 2 months treatment: 2 tablets during 4 weeks + 1 tablet during 4 weeks
46093966|NCT00971503|Procedure|autologous bone marrow implantation|Filgrastim treatment before bone marrow aspiration that will then be implanted via pancreatic artery
46007139|NCT04575519|Drug|ASA group|Acetylsalicylic acid 2 months treatment: 2 tablets during 4 weeks (600 mg daily) + 1 tablet during 4 weeks (300 mg daily)
46093967|NCT00971503|Other|Saline injection|Injection of saline solution for 5 days
46093968|NCT05032703|Device|Arm ergometer|"The conventional physical therapy program included three sets of exercises as follows:~Flexibility exercises to restore joint mobility of soft tissues. Static and dynamic balance exercise. Functional walking exercises."
46093969|NCT02659436|Other|Verbal-linguistic CBT|Participants will receive 4 sessions of individual therapy focused on traditional cognitive restructuring and exposure therapy.
46007140|NCT04575519|Drug|IBU group|Ibuprofen 2 months treatment: 2 tablets during 4 weeks (800 mg daily) + 1 tablet during 4 weeks (400 mg daily)
46007141|NCT04575519|Drug|SoC TB|Standard of Care Tuberculosis treatment
46007142|NCT00571376|Other|Health information technology and exchange|Health information technology includes electronic health records, electronic prescribing, and electronic results notification and/or viewers. Health information exchange includes use of central repositories of data and peer-to-peer models.
46093970|NCT02659436|Other|Imagery-based CBT|Participants will receive 4 sessions of individual therapy focused on imagery-based cognitive work and behavioural experiments.
46093971|NCT00976807|Other|Pulmonary Rehabilitation|"Eight week programme of twice-weekly (sixteen sessions) supervised exercise and education sessions. Exercise will include aerobic cardiovascular and upper and lower limb strengthening exercises. Each session will comprise a warm-up period, followed by individualised exercises, and completed with a cool-down, and last approximately 40minutes.~Aerobic exercise will be prescribed based on the results of walking tests and include walking, step-ups, cycling, and strength prescription according to the repetition maximum principle. Patients will complete three sets using this weight.~Furthermore Borg scores will be used within each session to guide and direct exercise intensity. A home exercise programme will also be designed and accompanied by a manual detailing the individual warm-up, exercises and cool-down, and diary sections to record independent activity.~Each session will also include an education session where relevant."
46093972|NCT05341271|Other|Experimental: digital reminiscence group (DRG)|Experiment group A accepted the digital reminiscence group planned by the official account platform of line as the medium, the theme and content, it is planned to consider the development of the life cycle, and the experience of the thematic review will induce the motivation of the participants, since childhood life, study The design of eight unit themes such as stage, work and emotional family and festival life, and special life events; at the same time, it can adapt to the psychological adaptation behavior of the participants, review their life development stages according to the life development process, and pay attention to the interpersonal interaction carried out by the current group Negative emotional or symptomatic behavior with dialogue, and directing and dealing with life experiences
46093973|NCT05341271|Other|Experimental: general reminiscence group (GRG)|"Experiment group B participated in general reminiscence group (GRG)~, using actual nostalgic objects or utensils to carry out activities. The theme and content are intended to be considered in the context of life cycle development, and the experience of thematic retrospectives induces the motivation of participants, since childhood. The design of eight unit themes, including the stage of study, work and emotional family and festival life, and special events in life; at the same time, it can adapt to the psychological adaptation behavior of the participants, review their life development stages according to the life development process, and pay attention to the current group activities. Interpersonal interaction and dialogue, and negative emotional or symptomatic behaviors that guide and process life experiences"
45598998|NCT02346045|Procedure|Renal sympathetic denervation|"In the experimental arm, Intervention is renal sympathetic denervation using Symplicity® system (Medtronic Ardian Inc, Mountain View, CA, USA) and antihypertensive medications previously prescribed~After femoral puncture guiding catheter is engaged in renal artery~Symplicity radiofrequency ablation catheter is inserted into renal artery and by circular sequence, from distal to proximal portion, ablation energy is applied to the wall of renal artery~4-5 ablations are applied in each renal artery.~In the sham comparator, intervention is renal angiogram and continue antihypertensive medications previuosly decribed"
45598999|NCT02298517|Procedure|incentive spirometry|Incentive spirometry to flow and incentive spirometry to volume
46007143|NCT04573803|Drug|Phenytoin Sodium|Dosing will be as prescribed clinically by the treating physician. Phenytoin Sodium may be administered orally, intravenously or via nasogastric tube.
46007144|NCT04573803|Drug|Levetiracetam|Dosing will be as prescribed clinically by the treating physician.Levetiracetam may be administered orally, intravenously or via nasogastric tube.
46007145|NCT04575441|Other|Exercise with pilates ball|Pilates ball exercises are used to give various sensory stimulation and increase motor skills. Children usually enjoy these kind of exercises as there is ball in every movement.
46007146|NCT04573374|Procedure|Pulpotomy|Pulpotomy is the term for removal of the coronal pulp with the intent of maintaining the vitality of the remaining radicular pulp tissue.
46007147|NCT00571454|Behavioral|telephone depression care management|"1 call per week for first 4 weeks~1 call every other week for next 8 weeks"
46007148|NCT01144663|Biological|Nimenrix™|4- or 3-dose intramuscular injection
46007149|NCT01144663|Biological|Menjugate®|3-dose intramuscular injection
46007150|NCT01144663|Biological|NeisVac-CTM|3-dose intramuscular injection
46007151|NCT01144663|Biological|Infanrix™ hexa|4-dose intramuscular injection
46007152|NCT01144663|Biological|Synflorix™|4-dose intramuscular injection
46007153|NCT00571571|Behavioral|Psychotherapy|Individual psychotherapy with parent collateral/psychoeducation as necessary.
46007154|NCT00571571|Behavioral|Individual Psychotherapy|Individual psychotherapy and family interventions (as needed)
46007155|NCT00584688|Drug|quetiapine|quetiapine dosage will be titrated to subject tolerance beginning at 50 mg every 24 hours upwards to 400 mg every 24 hours.
45599000|NCT02298517|Procedure|inspiratory load equipment|Threshold and Power breathe
46007156|NCT00571610|Device|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein, diagnostic assessment, then placement of the PTMA implant in the coronary sinus, great cardiac vein.
46007157|NCT00584766|Procedure|High-dose chemotherapy|Cyclophosphamide 500 mg/m2 IV day 1; Doxorubicin 30 mg/m2 IV Day 1; Methotrexate 300 mg/m2 IV Day 8;5-FU 500 mg/m2 IV day 8; leucovorin 20 mg po q 6 h x 6 doses, day 9- cycles repeated q 21 days
46093974|NCT02662478|Procedure|Laparoscopic Surgery|Mid-point between the xiphoid and umbilicus was used to the entrance site of the telescope. Open trocar insertion was used in patients with history of open upper abdominal surgery; otherwise Veress needle established CO2 insufflations. The number, size and entry points of the other trocars were tailored according to the tumor location and size. In general, 2 to 4 additional trocars were used. All specimens were taken out of the abdomen through a suprapubic transverse incision in a sterile bag. Resection technique was determined by the size, number, location of the lesion, and surgical anatomy of the stomach. Lymph node dissection was not done as it is unnecessary.
46007158|NCT00571727|Drug|mecasermin|injections BID of rhIGF-1, mecasermin
46093975|NCT04170842|Other|Music intervention|Participants will work with the music therapist to make their selections. Music therapists will provide input on how best to synchronise type, tempo and genre of music to the wound dressing procedure. As musical preference is very personal, the choice of music provided will try to strike a balance of providing what is acceptable to patients while not exposing them to music with known stimulatory effects.
46093976|NCT00981097|Genetic|polymerase chain reaction|determination of elevated serum FLC and clonal Ig detection rates in plasma and tumor
46093977|NCT00981097|Other|laboratory biomarker analysis|determination of elevated serum FLC and clonal Ig detection rates in plasma and tumor
46093978|NCT04229693|Other|no intervention|no intervention, only observational.
46093979|NCT02665520|Procedure|liposuction for retrieval of own stem cells from fat cells|
46093980|NCT00971581|Drug|FDC KETOPROFEN+OMEPRAZOLE|Ketoprofen + Omeprazole FDC once daily for 4 weeks
46093981|NCT04228913|Other|Root Canal Obturation Technique|This study aims to compare the effects of three different obturation techniques(cold lateral condensation,thermoplasticized solid-core carrier method, cold free flow compaction technique) on postoperative pain following the endodontic therapy
46093982|NCT02662400|Biological|MNCs|200 - 300 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months
46093983|NCT00981331|Procedure|Subtalar joint manipulation|The intervention is defined as a toggle-recoil, high-velocity, low-amplitude subtalar joint manipulation.
45459852|NCT02534012|Drug|Paravertebral block|Bilateral nerve stimulator-guided PVB is performed while patients are in lateral decubitis position. An intervertebral line is drawn at the appropriate levels and the injection site is marked 2.5 cm lateral to the midline on both sides. After aseptic preparation of the skin, 0.3 mL 2% lidocaine is infiltrated at the injection sites. A 22-G nerve stimulation needle (Stimuplex, B.Braun, Melsungen, Germany) is advanced 1-2 cm perpendicularly to the skin using a nerve stimulating current of 2.5-5.0 mA, while closely watching for contractions of the abdominal muscles. The tip of the needle is adjusted to continue to produce muscle contractions while reducing the stimulating current to approximately 0.5-0.6 mA. Depending on patient weight, 3-5 mL of the local anaesthetic mixture is injected at each injection site.
45459853|NCT02534012|Drug|General anesthesia|Anesthesia is induced with 1 µg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg nimbex (cisatracurium). Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 µg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen.
46007159|NCT04573686|Drug|Erythropoietin|Erythropoietin will be given subcutenous to all patients
46007160|NCT05206708|Behavioral|Personalized psychotherapy|Strategy including personalized psychotherapy
46007161|NCT05206708|Behavioral|Standard of care|Strategy based standard intregrative psychodynamic therapy
46007162|NCT02883634|Other|Specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation according to the physical examination performed prior to the treatment allocation.
46007163|NCT02883634|Other|Non-specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation on the upper thoracic spine that will be not related to the physical examination performed prior to the treatment allocation.
46093984|NCT00981331|Procedure|Sham subtalar joint manipulation|The sham manipulation is conducted by placing the ankle in a non-manipulative position, and the operator simply engages the toggle board to simulate the audible noise of the toggle board dropping. No force or thrust is applied to the ankle.
46093985|NCT02662322|Other|Hypnotic communication|hypnotic communication during peripheral intravenous catheterization
46093986|NCT02662322|Other|negative connotation communication|negative connotation communication during peripheral intravenous catheterization
46093987|NCT02662322|Other|neutral connotation communication|neutral connotation communication during peripheral intravenous catheterization
45459854|NCT02534012|Procedure|Major abdominal surgery|
45459855|NCT05664906|Drug|Chinese Medicine Oral Rinse Formula-I (CMORF-I)|"Prescription of Chinese Medicine Oral Rinse Formula-I (CMORF-I)~Instruction to rinse:~The above amount of concentrated CM granules will be divided and packed in 4 bags per day.~Dissolve 1 bag of concentrated CM granules with 150ml 80'C boiled hot water, and wait for 20 mins to cool down.~Clean the mouth thoughtfully by rinsing with 150ml of distilled water for 2 minutes.~Rinse the mouth thoughtfully with one-third of the dissolved and cooled CM oral rinse, gargle, expel after 3 minutes, do not swallow and repeat twice.~To ensure better contact of the CM oral rinse in all parts and folds of the oral cavity, our research assistant and CMP will guide the patients to fully agitate the mouth, use the tongue to stir repeatedly among the teeth, cheeks and palate surface, and to raise the tip of the tongue for a moment and tilt the head back.~4 times a day (half an hour after every meal, half an hour before sleep), from baseline to 2 weeks after RT."
45459856|NCT05664906|Other|Standard Care|• Standard care including normal saline or medical mouthwash, optional analgesics and antibiotics will be offered by hospital.
45459857|NCT05664906|Other|Placebo|Placebo granules, instruction is the same as CMORF-I.
45459858|NCT03131284|Behavioral|Intensive education|"For each well visit within the first two years of their child's life, parents are provided with oral and written information on behaviors to adopt for their child to be protected from obesity: breast feeding, feeding on demand, responsive feeding, correct time of introduction of complementary feeding, portions shaped on the child's appetite, avoiding pressing the child to eat more and rewarding or punishing the child with food, avoiding added sugar and beverages other than milk and water, practicing active game with the child, alternating protein sources correctly and avoiding protein excess. Written menus examples and coloured photos of average portions are given for complementary feeding. Parents are also provided with information about health consequences of childhood obesity."
45459859|NCT01146847|Device|Space TGC|Space TGC with incorporated eMPC algorithm to establish tight glycaemic control with a blood glucose target range of 80-110 mg/dL (4.4-6.1 mM)
45459860|NCT05626387|Drug|Mycophenolate Mofetil plus prednisolone|Prednisolone is a glucocorticoid that suppresses inflammation by several mechanisms. Mycophenolate mofetil (MMF) is an immunosuppressive drug that acts by inhibiting the proliferation of T-lymphocytes and suppressing the recruitment of lymphocytes and monocytes into the sites of inflammation.
45459861|NCT05626387|Drug|Prednisolone|Prednisolone is a glucocorticoid that suppresses inflammation by several mechanisms.
45459862|NCT03480256|Drug|SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic gastric cancer
45459863|NCT03722940|Drug|Magnesium sulphate|Before induction of anesthesia; children in group M received an iv bolus dose of magnesium sulfate (Magnesium sulfate ampoule 1 gm/10 ml, Eipico, Egypt) 40 mg Kg-1 over 5 minutes followed by 15 mg Kg-1 h-1 ivi until the start of skin closure.
45459864|NCT03722940|Other|Na CL 0.9%|Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of magnesium sulphate.
46007164|NCT04573257|Other|Echocardiography and pulse wave velocity measurement|Echocardiography(Conventional ultrasonic imaging,tissue Doppler imaging and non invasive myocardial work) and pulse wave velocity measurement
46093988|NCT02662322|Other|peripheral intravenous catheterization|peripheral intravenous catheterization
46093989|NCT00971659|Drug|insulin glargine + exenatide + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, exenatide 5ug twice daily subcutaneously for 2 weeks, then 10ug twice daily for 2 weeks, continuation of preexisting metformin
46093990|NCT00971659|Drug|insulin glargine + sitagliptin + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, sitagliptin 100 mg once daily in the morning over 4 weeks, continuation of preexisting metformin
46093991|NCT00971659|Drug|insulin glargine + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, continuation of preexisting metformin
45459865|NCT01146925|Drug|CRMD-001-Deferiprone|CRMD-001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days
45459866|NCT01146925|Drug|Placebo|3 placebo tablets will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
45599001|NCT02293603|Biological|Allogeneic Cardiosphere-Derived Cells (CDCs)|Intracoronary delivery of CAP-1002 or placebo
46007165|NCT05205343|Other|Standard of Care|complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
46007166|NCT05205343|Other|Control Group|complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
46007167|NCT01143337|Drug|MP-435(dose1) + Methotrexate|MP-435 dose1 + stable weekly dose of Methotrexate
46007168|NCT01143337|Drug|Placebo + Methotrexate|Placebo + stable weekly dose of Methotrexate
46093992|NCT02662088|Procedure|laparoscopic-lavage|
46093993|NCT00977041|Behavioral|Neurofeedback|"Electrodes will be placed over the temporal lobes bilaterally and a ground electrode placed on the left earlobe. EEG activity will be amplified using a Procomp 2 or Nexus amplifier, and EEGer software will be used to provide subjects with feedback. Contingencies will be set such that alpha brain activity will be reinforced, and high beta and theta brain activity will be inhibited. Standard NF training procedures will be used, which involve simply asking subjects to relax while looking at the feedback screen and Do whatever is necessary to make and keep the bar wide. This protocol will be repeated for up to 40 60-minute sessions (that will include 30 minutes of NF training), scheduled at least weekly."
46093994|NCT00648986|Drug|Tazorac|All patients were to apply topical tazarotene (Tazorac) twice daily to all affected fingernails for 24 weeks.
45459867|NCT04635254|Other|Halophites-based cream 24 hours|The concentration of active aqueous extract will be in the range of 2% to 30% (v/v) by cold emulsification. A 2 gram amount of Halophytes-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
46007169|NCT04313023|Drug|PUL-042 Inhalation Solution|20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042) PUL-042 Inhalation Solution
46007170|NCT04313023|Drug|Placebo|Sterile saline for inhalation
46007171|NCT02883595|Drug|thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
46007172|NCT02883595|Other|Placebo|Subcutaneous injections of placebo (saline) twice per day for seven days
45459868|NCT04635254|Other|Halophites-based cream 48 hours|The concentration of active aqueous extract will be in the range of 2% to 30% (v/v) by cold emulsification. A 2 gram amount of Halophytes-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
45459869|NCT04635254|Other|Vehicle cream 24 hours|A 2 gram amount of vehicle cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
45459870|NCT04635254|Other|Vehicle cream 48 hours|A 2 gram amount of vehicle cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
45459871|NCT04635254|Other|Histamine 1%|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.
45459872|NCT04635254|Other|Cowhage|The insertion of cowhage spicule(s) rapidly and consistently produces itch with no or very little flare reaction. This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
46007173|NCT00571766|Drug|L-Arginine|Oral L-Arginine 2g, twice a day for 14 weeks
46007174|NCT00571766|Drug|Placebo|Placebo 2 g twice a day for 14 weeks
46007175|NCT01143259|Drug|Alvimopam|The treatment group will receive 12mg of Alvimopan by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.12 mg by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days.
46007176|NCT01143259|Drug|300 mg Polyethylene|The control group will receive 300mg of polyethylene glyco by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.
46007177|NCT04573608|Drug|Papacarie|Papacarie was introduced into the cavity using the applicator and left for 40 seconds. A blunt excavator was used to remove the softened dentin. The remaining gel was removed using a cotton pellet. When there was no change in gel color, the cavity was considered caries free. The cavity was then filled with high viscosity glass ionomer cement (GIC) in an encapsulated form (Riva Self-Cure, SDI Limited, Bayswater, VIC, Australia). A mechanical mixer was used to mix the capsule for 10 seconds, the capsule was placed into the applicator to apply the GIC into the cavity. For occluso-proximal cavities, a matrix strip with a wooden wedge was used to provide the appropriate contour of the restoration. A gloved finger was used to apply pressure on the GIC for one minute and occlusion was checked and excess material was removed
46093995|NCT00971815|Drug|Escitalopram|first week: 10mg/day. Then, treatment with 20mg/day is continued throughout a 3 months period of time.
46093996|NCT00971815|Drug|placebo|1/2 pill pr day first week, then 1 pill pr. day throughout a 3 months treatment period (90-118 ± 7days)
46093997|NCT02662166|Device|MR imaging|3 T MRI of the urinary bladder
46093998|NCT02781077|Procedure|Structured, Progressive, Task-oriented exercise program|The intervention is walking related task-oriented exercise program with three progressive steps at moderate to high intensity. Each step consists of 60 minutes last ten tasks to optimize walking function of stroke individuals.
46093999|NCT02659358|Device|Fitbit Charge HR®|A wrist worn biosensor, the Fitbit Charge HR® has sensor capability, good battery life, water resistant, Bluetooth capabilities, and provides accessible data.
46094000|NCT02659280|Other|Adjunct Therapy|"Store and Forward Tele-heath"
46094001|NCT02659280|Other|Standard of Care|Standard of Care Outpatient Physical Therapy
46094002|NCT05340101|Behavioral|ROGRESSIVE MUSCLE RELAXATION EXERCISE|"In the application, Relaxation Exercises CD Audio Recordings prepared by the Turkish Psychological Association were used. In the the second part of 30 minutes were explained with the sound of the PKGE stream and verbal instructions. Audio recordings in the second part were used in this study. In line with the PCGE sound recordings, each muscle group starting from the hands to the feet, and then the facial and whole body muscles were stretched for about 10 seconds. The exercise was applied by taking deep breaths while tensing each muscle group, and releasing this breath slowly during relaxation. The relaxation lasted 10-20 seconds before the next muscle group was stretched. In this way, the muscles groups in the hands, arms, neck, shoulders, chest, abdomen, hips, feet and fingers, face and whole body were voluntarily stretched and relaxed, respectively, and the students were relaxed."
45459873|NCT03476044|Drug|Placebo|40 patients will receive starch capsules orally with sips of water 2 hours before induction of anesthesia
46094003|NCT00977275|Radiation|Interstitial Implant Brachytherapy|Via tubes placed at the time of wide local excision delivered over 5 days
46094004|NCT05331755|Drug|Dupilumab|start medication in cohort
46094005|NCT00872001|Drug|Acadesine|Acadesine 42 mg/kg diluted in normal saline to a total of 500 mL, delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 0.1 mg/kg/min (translating into 1.2 mL/min for a 500 mL solution). In addition, a 5 µg/mL cardioplegia solution of acadesine will be administered, and acadesine will be added to the priming solution (5 µg/mL) in the heart lung machine during CPB.
46094006|NCT00872001|Drug|Normal Saline|Normal saline, 500 mL delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 1.2 mL/min for a 500 mL solution. In addition, standard cardioplegia solution with added normal saline will be administered, and placebo (normal saline) will also be added to the heart lung machine priming solution.
46094007|NCT00981487|Drug|Ondansetron|24 mg one time
46094008|NCT00981487|Drug|Ondansetron|24 mg, on time in the am
46094009|NCT04228835|Diagnostic Test|Fluorescence Cholangiography|Administration of ICG for fluorescence cholangiography
46094010|NCT00646568|Drug|s.c. human chorionic gonadotropin (Pregnyl)|S.C. Pregnyl 10000 IU once
46094011|NCT00971893|Drug|Oral Methylprednisolone Tablets|Oral Methylprednisolone tablets given as per locally approved prescribing information
46094012|NCT00694083|Drug|Ridaforolimus|Ridaforolimus (MK-8669), 20 or 40 mg administered orally on Day 1 followed by a washout of at least 6 days, then QD x5 (five consecutive days) followed by a 2-day holiday through Day 28 (Cycle 1), and QD x5 followed by a 2-day holiday for 21 days (Cycle 2 and subsequent cycles)
46094013|NCT02665208|Other|Treatment As Usual (TAU)|informational pamphlets and information from 1800 quit line + prescription for nicotine replacement therapy (NRT) based on on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
46094014|NCT02665208|Drug|Nicotine Replacement Therapies|a prescription for a nicotine replacement therapy (NRT) (i.e. nicotine replacement patches based on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
45459874|NCT03476044|Drug|Selenium|40 patients will receive Selenium (selenium NATURE'S BOUNTY, INC. Bohemia) 200 mcg orally with sips of water 2 hours before induction of general anesthesia
46007178|NCT04573608|Drug|Atraumatic Restorative Treatment|The tooth was cleaned with a wet cotton pellet to remove debris and plaque. Caries was removed using sharp spoon excavators (Darby-Perry #220/221, #17 DE, Hu-Friedy, Chicago, USA), followed by cleaning the cavity using a small wet cotton pellet and finally dried with a dry cotton pellet. The cavity was considered caries-free when a leather-hard texture was reached and the excavator did not stick anymore. GIC was used to restore the cavity using the same technique described for the other group.
46094015|NCT02665208|Behavioral|Text Message Intervention (TMI)|
46094016|NCT00977353|Drug|citalopram|20-60 mg/day, oral, for 6 weeks
46094017|NCT00977353|Drug|sarcosine|500-1500 mg/day, oral, for 6 weeks
46094018|NCT00871923|Drug|Tarceva (Erlotinib hydrochloride)|150 mg by mouth every day beginning Day 1.
46094019|NCT00871923|Radiation|Radiation Therapy|Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.
46094020|NCT00971971|Procedure|Dialysis|dialysate temperature (DT) reduction with Na and ultrafiltration (UF) profiling
46094021|NCT00971971|Procedure|Standard SLED|
46094022|NCT04170530|Drug|mFOLFOXIRI|irinotecan* 135 mg/m² + oxaliplatin 68 mg/m² + leucovorin 400 mg/m² + 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
46094023|NCT00981565|Procedure|open carpal tunnel release|surgery to release the carpal tunnel
46094024|NCT00981565|Other|Night-cast|individual night time splinting
45459875|NCT01250821|Drug|Menopur|"The medication used in this study is the follicle-stimulating hormone highly purified human menopausal gonadotrophin (HP-HMG), Menopur, (Ferring a/s).~Stimulation with HP-hMG (Menopur) is started on day 2-5 of menstrual bleeding.The HP-hMG starting dose is calculated based on the nomogram predicting the threshold dose. The dose-range is from 75 IU/day to 187.5 IU/day."
46007179|NCT00571805|Drug|varencline|2.0 mg/day varencline (1.0 mg BID)
46007180|NCT00571805|Drug|placebo|matching placebo
46094025|NCT02661854|Biological|MM09 Mannosylated 5.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 5.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
46007181|NCT02883556|Drug|Pembrolizumab|200 mg, administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
46007182|NCT04580069|Procedure|Lymphatic drainage|The interventions follow the validated techniques normally used in international rehabilitation
46094026|NCT02661854|Biological|MM09 Mannosylated 10.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 10.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
46094027|NCT02661854|Biological|MM09 Mannosylated 30.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 30.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
46007183|NCT00584961|Other|non-interventional|non-interventional
46094028|NCT02661854|Biological|MM09 Mannosylated 50.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 50.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
46094029|NCT02661854|Biological|MM09 Mannosylated 5.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 5.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
46094030|NCT02661854|Biological|MM09 Mannosylated 10.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 10.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
46094031|NCT02661854|Biological|MM09 Mannosylated 30.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 30.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
46094032|NCT02661854|Biological|MM09 Mannosylated 50.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 50.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
46094033|NCT02661854|Biological|Subcutaneous placebo|Comparison between placebo and active group
46094034|NCT02661854|Biological|Sublingual placebo|Comparison between placebo and active group
46094035|NCT00694239|Behavioral|Knowledge of Cardiovascular Risk Assessment|Knowledge of Cardiovascular Risk Assessment and risk reduction at target BP, reviewed every 3-6 months.
46094036|NCT02779517|Other|Mobile Service Robot Survey|The goal is to build a low-cost mobile service robot that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact).
46007184|NCT00571844|Behavioral|DASH diet|Participants in the DASH diet condition receive instruction in modifying the content of their diet to meet DASH guidelines. Participants are explicitly asked not to exercise or to attempt weight loss at this time, and to focus their attention on what they eat. Following the 2-week feeding period, participants will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 5 participants).
46007185|NCT00571844|Behavioral|DASH diet plus Weight loss|Participants in the DASH diet plus weight loss condition will receive the DASH dietary intervention as described in the DASH diet intervention and will participate in a program to promote weight loss consisting of 2 components: Supervised Aerobic Exercise and CBWL (Cognitive Behavioral Weight loss). During supervised exercise participants will exercise 3x/week under medical supervision at the Duke Center for Living. A trained exercise physiologist will supervise all exercise sessions, and will obtain exercise BP measurements to make sure that BP is not abnormally elevated. For the CBWL participants will meet in small groups of 3-5 patients for instruction in weight management techniques. CBWL will include Appetite Awareness Training (AAT), a self-monitoring strategy developed to provide more specific guidelines regarding how much to eat. Individuals learn to identify moderate hunger and fullness and use these internal cues to guide their eating.
45599002|NCT02345499|Procedure|Laparoscopic radical cystectomy with open urinary diversion|Laparoscopic surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
45599003|NCT02345499|Procedure|Open radical cystectomy with open urinary diversion|Open surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
45599004|NCT03137381|Drug|CTP-543|Administered as tablets.
45599005|NCT03137381|Drug|CTP-543 matching placebo|Administered as tablets.
45599006|NCT02298595|Drug|cisplatin|75 mg/m2 IV day 1 of each cycle
46094037|NCT02779517|Other|Mobile Service Robot Survey for Patients|The goal is to build a low-cost mobile service robot that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact). This survey differs in terms of design questions.
46094038|NCT05161897|Other|Individualized Nutrition Therapy|Explained in arm/group description.
46094039|NCT02617017|Drug|Buspirone|Capsules of buspirone will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
46094040|NCT02617017|Drug|Placebo|Capsules of placebo will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
46094041|NCT02780219|Other|stable amino acid infusion|stable isotopes Such as L-[ring-13C6]-Phenylalanine, L-[ring-D4]Tyrosine, L-[Methyl-D3]Tau-Methylhistidine, trans-[2,5,5-D3]4-Hydroxy-L-proline, L-[Guanido-15N2]-Arginine, L-[4,4,5,5-D4-5-13C]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-[1,2-13C2]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-[methyl-D3]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-[3,3,4,4-D4]Homocysteine, L-[1,2-13C2]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-[Dimethyl-13C2]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-[3,4-methyl-13C3]isovaleric acid, 13C3-glycerol is given IV simultaneously
46094042|NCT02780219|Other|acute exercise with amino acid infusion|resistance exercise of each limb (i.e., leg (right/left); arm (right/left) on an isokinetic exercise machine allowing control of velocity, force, etc. with stable isotopes such as L-[ring-13C6]-Phenylalanine, L-[ring-D4]Tyrosine, L-[Methyl-D3]Tau-Methylhistidine, trans-[2,5,5-D3]4-Hydroxy-L-proline, L-[Guanido-15N2]-Arginine, L-[4,4,5,5-D4-5-13C]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-[1,2-13C2]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-[methyl-D3]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-[3,3,4,4-D4]Homocysteine, L-[1,2-13C2]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-[Dimethyl-13C2]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-[3,4-methyl-13C3]isovaleric acid, 13C3-glycerol is given IV simultaneously
46094043|NCT02780219|Other|24-hour post exercise amino acid infusion|stable isotopes such as L-[ring-13C6]-Phenylalanine, L-[ring-D4]Tyrosine, L-[Methyl-D3]Tau-Methylhistidine, trans-[2,5,5-D3]4-Hydroxy-L-proline, L-[Guanido-15N2]-Arginine, L-[4,4,5,5-D4-5-13C]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-[1,2-13C2]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-[methyl-D3]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-[3,3,4,4-D4]Homocysteine, L-[1,2-13C2]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-[Dimethyl-13C2]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-[3,4-methyl-13C3]isovaleric acid, 13C3-glycerol is given IV simultaneously
46094044|NCT00981643|Behavioral|Meditation instruction and practice|Meditation techniques introduced and practiced, in a group setting, once weekly for 8 weeks
46094045|NCT05298111|Other|Formulation 3|Respondents were consumed 36 g of Formulation 3 containing 4.5 g of available carbohydrate dissolved in 180 ml water with study breakfast
46094046|NCT05298111|Other|Control|Respondents were consumed 4.5 g of control containing 4.5 g of available carbohydrate dissolved in 180 ml water with study breakfast
46094047|NCT02779439|Biological|Virus specific CTLs|Virus specific CTLs will be given to patients with persistent or recurrent viral reactivation after 2 weeks of standard anti-viral therapy
46094048|NCT02661698|Dietary Supplement|Omega-3 oil: DHA enriched|3 x 1 g capsules containing a SMEDDS formulation of an DHA-enriched oil: 50% DHA + 15% EPA totalling 900 mg DHA and 270 mg of EPA
46094049|NCT02661698|Dietary Supplement|Placebo|3 x 1 g capsules Placebo: olive oil
45599007|NCT02298595|Drug|Cetuximab|XXXX day 1, 8, and 15 of each cycle
45599008|NCT02298595|Drug|BYL719|200, 250, 300, or 350 mg/day by mouth every day
46094050|NCT02661698|Dietary Supplement|Omega-3 oil: EPA enriched|3 x 1 g capsules containing a SMEDDS formulation of an EPA-enriched oil: 50% EPA + 20% DHA totalling 900 mg EPA and 360 mg of DHA
46094051|NCT00977587|Drug|Saccharomyces Cerevisiae CNCM I-3856|Saccharomyces cerevisiae CNCM I-3856, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).subjects will take 1 capsule twice a day
46094052|NCT00977587|Drug|placebo|"Placebo: Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:~Calcium phosphate, Dibasic 472.0 mg~Maltodextrin DE14 112.1 mg~Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day"
46094053|NCT02616861|Drug|IW-1973|IW-1973 Tablet
46094054|NCT02616861|Drug|Matching Placebo Tablet|Matching placebo tablet
46094055|NCT02779595|Other|Perioperative pulmonary function tests|Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the the third, fifth and seventh postoperative day
46094056|NCT02658968|Drug|Betalutin|Dose finding study, starting on 10 MBq/kg b.w. Betalutin® (lutetium (177Lu)-lilotomab satetraxetan), single injection with lilotomab pre-dosing.
46094057|NCT00972049|Drug|AZD2516|Capsule administered once orally. Specific dose depends on dose panel.
46094058|NCT00972049|Drug|Placebo|Capsule administered once orally
45459876|NCT05760716|Other|practicing prone position|Wash your hands. Prepare the materials. Before starting the procedure, inform the patient and explain the procedure. Ensure patient privacy. Raise the guardrail opposite the work area. Take the proper posture. Pay attention to body mechanics. Lay the patient on their back in the middle of the bed. Place a pillow under the patient's head to cover their shoulders. Extend arms to side of body with elbows slightly bent inward (flexion). Place a pillow under your arms. Place roller in palm. Place a thin pillow or a thinly folded towel/sheet under the waist. Place a thin towel under the knees. Support the bottom of the ankles with a pillow. Support the soles of the feet with a foot board. Raise the guardrail on the working side. Inform the patient that they can stay in this position for a maximum of 2 hours.
45459877|NCT01253395|Behavioral|Strength training|Daily supervised strength training.
46007186|NCT00585000|Drug|CP-675,206|15 mg/kg. IV (in the vein) over 1 hour on Day 1 of each 90 day cycle. Number of cycles: maximum of 4 cycles unless progression of disease or unacceptable toxicity.
46007187|NCT00571883|Other|questionnaire administration|
46007188|NCT00571883|Procedure|psychosocial assessment and care|
46007189|NCT00571883|Procedure|quality-of-life assessment|
46007190|NCT00571883|Procedure|regional lymph node dissection|
46007191|NCT00571883|Procedure|therapeutic conventional surgery|
46007192|NCT00585117|Procedure|PET-imaging with CuATSM|imaging with CuATSM
46007193|NCT00585117|Procedure|PET Imaging|Imaging with CuATSM
46007194|NCT00585117|Procedure|PET CuATSM|Imaging with CuATSM
46007195|NCT00585117|Procedure|PET imaging|imaging with CuATSM
46007196|NCT00585117|Procedure|PET imaging with CuATSM|Imaging with CuATSM
46007197|NCT00585117|Procedure|PET imaging with CuATSM|Imaging with CuATSM
46094059|NCT02616939|Other|Cardiac CT scanning (with the SpotLight CT)|Cardiac CT scanning
46094060|NCT02656316|Device|Active tDCS|In this group subjects will receive 20 min of treatment.
46094061|NCT02656316|Device|Sham tDCS|In this group subjects will receive 20 min of sham stimulation.
46007198|NCT00572000|Biological|HPV-16/18 L1 VLP AS04 vaccine|Representation: 0.5ml monodose vials Administration: intramuscular Schedule: 0, 1, 6 month
46094062|NCT00981721|Drug|cediranib (RECENTIN TM, AZD2171)|20 mg or 30mg cediranib once on Days 1, then 20 mg or 30mg cediranib once daily from Days 8
46094063|NCT02617095|Device|T2762|One drop in each eye 3 to 6 times daily
46094064|NCT02617095|Device|Optive|One drop in each eye 3 to 6 times daily
46094065|NCT04133181|Device|3D guide|Use of a 3D guide in endodontic surgery
46094066|NCT04133181|Device|Mock guide|Use of a mock guide in endodontic surgery
46094067|NCT04007887|Other|Adult education program|A 10-hour program embodying major adult education principles, designed to achieve cognitive involvement of patients in their treatment
46094068|NCT05339867|Behavioral|Prevent Maternal Mortality using Mobile technology (PM3)|"PM3: The app will include:~integrated self-management and tailored health messaging feature~support center based on social support gaps which will also provide a centralized place for identifying healthcare providers and facilities~multimedia resource kit comprised of videos, current events, news feeds, podcasts, and support groups related to women's postpartum health and community resources~a feature that will update women on maternal and reproductive health policies that impact women."
46094069|NCT00649298|Procedure|haemodialysis|Comparison of different weekly duration of haemodialysis treatment
46094070|NCT00972127|Drug|Neramexane|25 mg or 2x25mg tablets
46094071|NCT04133337|Drug|Apatinib|Apatinib Mesylate Tablets
46094072|NCT04133337|Drug|SHR-1210|Camrelizumab for Injection
46007199|NCT01142908|Behavioral|Pharmacist CVD|clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
46094073|NCT02780453|Device|Negative pressure dressing|
46094074|NCT02780453|Device|Standard wound dressing|
46094075|NCT04133259|Drug|Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody|Treatment of CHB patient with HLX10
46094076|NCT04133259|Drug|Nucleoside/nucleotide analogues|Treatment NAs for chronic hepatitis B subject to achieve adequate HBV viral suppression
46094077|NCT04169984|Other|Myofunctional Therapy|Isometric, isokinetic and isotonic exercises for the upper airway muscles.
46094078|NCT04169984|Other|Placebo|Exercises that do not alter the function or morphology of the upper airway.
45459878|NCT01253395|Behavioral|Aerobic exercise|Daily supervised aerobic exercise.
45459879|NCT05181332|Other|Prediction model|Clinical models were developed and validated to predict liver-related complications and survival outcomes in pediatric patients with biopsy-proven with cirrhosis.
46094079|NCT00977821|Other|IVF|
46007200|NCT00572078|Drug|Sorafenib|Cohort 1 200 mg po BID D1-5; Cohort 2 200 mg po BID; Cohort 3 400 mg po BID D1-5 Cohort 4 400 mg po BID
45459880|NCT03475966|Other|Exercise|A kinesiologist will provide each patient wih an individualized home-based exercise program including aerobic, resistance and stretching exercises. Patients will also exercise at our clinic once per week under the supervision of the kinesiologist (prehabilitation arm only)
45599009|NCT03155139|Diagnostic Test|Aldosterone/renin ratio (ARR) testing|Plasma aldosterone concentration tests, Direct renin concentration tests
46007201|NCT01142791|Device|ExAblate|Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation
46007202|NCT04573218|Drug|Placebo|The placebo contains glucose
46007203|NCT04573218|Dietary Supplement|250 mg OPP|250 mg Oil Palm Phenolics
46007204|NCT00572312|Drug|atorvastatin (Sortis) 40 mg|In the 8-weeks run-in period angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 40 mg of atorvastatin in two active treatment periods lasting 8 weeks each
46094080|NCT00977821|Other|Oocyte Vitrification|
46094081|NCT02780063|Other|Lenstar Biometer|uses optical principles (laser interferometry) to measure axial length, measuring distance from the corneal apex to the retinal RPE. In addition to axial length, it also measures corneal thickness, anterior chamber depth, lens thickness, radii of curvature of flat and steep meridian, axis of flat meridian, white to white distance, and pupil diameter.
46094082|NCT02616471|Dietary Supplement|High-fat cheese|
46094083|NCT02616471|Dietary Supplement|Low-fat cheese|
46094084|NCT02616471|Dietary Supplement|No-cheese/carbohydrate|
46094085|NCT00977899|Biological|Malaria Transmission-Blocking Pfs25-Pfs25 Conjugate Vaccine|
46094086|NCT04169750|Behavioral|Exergames|"The training protocol will be delivered by the Nintendo ® Wii balance board and consists of repetitions of several games selected from the Wii Fit Plus package (http:// www.wiifit.com/training/balance-games.html). Each game starts at basic level, and when a certain score is reached, patients is automatically transferred to a more advanced level. Patients will be encouraged to play the next game if they have a level progress; otherwise, 10 minutes will be allocated for each game. During the first 4 weeks of training, patients will be allowed to play only Zazen (sitting position), Table Tilt and Ski Slalom; thereafter they will add the remaining games Penguin Slide, Tightrope Walk, Balance Bubble and Soccer Heading."
46094087|NCT04169750|Behavioral|Adaptive COGNI-TRAcK|"The training protocol will be delivered by a dedicated app for mobile devices (mobile phone or tablet). The app implements three different types of exercises (each one executed for about 10 min a session), consisting in a visuo-spatial working memory task, an operation N-back task and a dual N-back task.~The adaptive training is structured so that the exercises difficulty level will increase by one step every time the user will perform a correct exercise. On the other hand, the difficulty level will decrease by one step if the exercise is incorrect for three times in a row."
46094088|NCT04169750|Behavioral|Sham COGNI-TRAcK|The training protocol will be delivered by a dedicated app for mobile devices (mobile phone or tablet) as previously described for adaptive COGNI-TRAcK. However, the non-adaptive training (placebo-analogue intervention) consists in an algorithm implementing two low difficulty levels alternating every day regardless of the user's performance.
46094089|NCT04228133|Behavioral|Attention Control Training (ACT)|A home-delivered version of ACT will be administered in this study. ACT will be comprised of 8 sessions with a variation of the dot-probe task in which the target probe replaces the neutral and threat stimuli with an equal probability to reduce attention bias variability (ABV). In addition, sessions will include video conference with the experimenter. This condition has found to be more effective in PTSD symptom reduction compared to ABM.
46094090|NCT04228133|Behavioral|Attention Bias Modification (ABM)|A home-delivered version of ABM will be administered in this study. ABM will be comprised of 8 sessions with a variation of the dot-probe task in which the target probe always replaces the threat stimuli to induce diversion of attention away from threat. In addition, sessions will include video conference with the experimenter. This condition has found to be have an inferior effect on PTSD symptom reduction compared to ACT, and thus, this ABM condition has been chosen as a control condition.
46094091|NCT02616549|Behavioral|Sudarshan Kriya Yoga|A manual-based yoga program featuring a yoga-breathing meditation technique
46094092|NCT00972673|Drug|Placebo|comparator
46094093|NCT00972673|Drug|GW685698X|Inhaled steroid
46094094|NCT02661386|Device|Motility Procedure|The use of esophageal manometry device during general anesthesia
46094095|NCT04228055|Behavioral|CLIPP2|Diabetes Prevention Program and Comprehensive Lifestyle Improvement Program with emphasis on a low carbohydrate and Keto diet, physical activity, sleep optimization and stress management.
46094096|NCT02616315|Drug|Naltrexone HCl/Bupropion HCl Placebo|Naltrexone/bupropion placebo-matching tablets
46094097|NCT02616315|Drug|Naltrexone HCl/Bupropion HCl|Naltrexone HCl 8 mg/bupropion HCl 90 mg tablets
46094098|NCT00978055|Drug|1: Liothyronine Sodium Tablets|"Liothyronine Sodium Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting"
46094099|NCT00978055|Drug|2: Cytomel® Tablets|"Cytomel® Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting"
46094100|NCT02661230|Device|COGNIPLUS|"Run 1 Video game: Phasic Alertness (Alert S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 2 Video game: Intrinsic Alertness (Alert S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 3 Video game: Visual modality (Select S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 4 Video game: Acoustic / Stimulus Combinations (Select S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest."
46007205|NCT00585156|Drug|Celecoxib|Twelve hours prior to their first total knee surgery, patients will need to take an oral dose of Celebrex, 1 pill of 200mg. Following the patient's first total knee surgery, they will continue taking oral doses of Celebrex, 1 pill of 200 mg every twenty-four hours (200mg/day) for a two-week period.
46007206|NCT00572351|Other|Red Wine|8 ounces of assigned beverage (red wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
46094101|NCT02779283|Drug|Cyclophosphamide|Given IV
45599010|NCT03155139|Diagnostic Test|Confirmatory tests|Captopril challenge test, Saline infusion test
46094102|NCT02779283|Drug|Cytarabine|Given IV
46094103|NCT02779283|Drug|Dasatinib|Given PO
46094104|NCT02779283|Drug|Dexamethasone|Given PO
46007207|NCT00572351|Other|White Wine|8 ounces of assigned beverage (white wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
46007208|NCT01142596|Drug|Asenapine|Asenapine 5 mg sublingual tablet BID, Asenapine 10 mg sublingual tablet BID
46007209|NCT01142596|Drug|Placebo|Placebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only)
46007210|NCT00585234|Other|Digital Photography|Digital Photography
46007211|NCT00572390|Drug|oestrogen|Cyclic oestrogen substitution therapy
46007212|NCT01142128|Drug|Nexium (esomeprazole magnesium)|one 40 mg capsule per day for one month
46007213|NCT01142128|Drug|Placebo to Nexium|one capsule per day for one month
45599011|NCT02297269|Device|laparoscopic surgery|the method of surgery is conducted by laparoscope with proper pressure of pneumoperitoneum instead of opening the abdomen.
46007214|NCT01142128|Drug|Viokase 16 (pancrelipase) + Nexium|Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month
46007215|NCT01142128|Drug|Viokase 16 + placebo to Nexium|Viokase 16 pancrelipase tablets are given per day for one month with one capsule of placebo to esomeprazole magnesium, one per day for one month
46094105|NCT02779283|Drug|Doxorubicin Hydrochloride|Given IV
46094106|NCT02779283|Drug|Idarubicin|Given IV
46094107|NCT02779283|Drug|Idelalisib|Given PO
46094108|NCT02779283|Device|In Vitro Kinase Inhibitor Assay|Correlative studies
46094109|NCT02779283|Drug|Leucovorin Calcium|Given IV
46094110|NCT02779283|Drug|Methotrexate|Given IV
46094111|NCT02779283|Drug|Methylprednisolone Sodium Succinate|Given IV
46094112|NCT02779283|Drug|Ponatinib Hydrochloride|Given PO
46094113|NCT02779283|Biological|Rituximab|Given IV
46094114|NCT02779283|Drug|Ruxolitinib Phosphate|Given PO
46094115|NCT02779283|Drug|Sorafenib Tosylate|Given PO
46094116|NCT02779283|Drug|Sunitinib Malate|Given PO
46094117|NCT02779283|Drug|Vincristine Sulfate|Given IV
46094118|NCT04133103|Procedure|first ambulation at 4 hour after operation|Two groups were conducted for first ambulation at 4 or 24 hours aftër operation
46094119|NCT00978133|Procedure|Dermabond ProPen (2-octylcyanoacrylate)|Application of 2 layers of Dermabond to abdominal wounds after closure of deep layers
46094120|NCT00978133|Procedure|Skin closure with skin staples|Skin closure with skin staples
46094121|NCT02661308|Device|Litebook|
46094122|NCT02616003|Drug|Liraglutide|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
46094123|NCT02616003|Other|Aminosteril hepa 8%|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
46007216|NCT04572867|Device|Aquapheresis|The Aquadex FlexFlow® Fluid Removal System (from CHF Solutions™, Minneapolis, MN) is an FDA approved device that provides mechanical isosmotic fluid removal in volume-overloaded CHF patients via veno-venous ultrafiltration, and has been used in patients with congestive heart failure refractory to diuretics, it should be considered standard of care also. This study is using it in a randomized, controlled study in the Outpatient setting. The Aquadex FlexFlow® Fluid Removal System is a dual rotary pump device used with a sterile, single-use UF 500 Blood Circuit Set. Blood withdrawal is usually from a peripheral arm vein (such as the antecubital vein), using a 16 or 18- gauge, 3.5 cm catheter (similar to a standard IV catheter). A similar IV catheter is used for blood return via a second peripheral vein (typically in the forearm).
46094124|NCT02616003|Dietary Supplement|Caloric diet with 1000 kcal|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 1000 kcal from day 1 onwards till technical operability is achieved (about 21 days)
46094125|NCT02661152|Drug|Nimorazole|Hypoxia gene profile is expected to discriminate between HNSCC responders and non-responders to hypoxic modification with nimorazole during radiotherapy. In DAHANCA 30 expected non-responders are randomized to +/- nimorazole during radiotherapy (non-inferiority study). Thus, similar efficacy of radiotherapy is expected in these groups. More hypoxic tumours receive nimorazole after DAHANCA standards.
46094126|NCT00697671|Other|NK Cell Infusion|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued
46094127|NCT00697671|Biological|Immunotherapy|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
46094128|NCT00697671|Device|Miltenyi Biotec CliniMACS device|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
46094129|NCT00697671|Drug|Interleukin-2 (IL-2)|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
45836648|NCT05287698|Other|Cold vapor|Before surgery, socio-demographic data of the patients, ASA and Mallampati scores, sore throat level, and dysphagia level will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service.
45459881|NCT03475966|Other|Nutrition|Patients will be asked to fill in a 3-day food diary. A registered dietitian (RD) will review this diary, provide a full nutritional assessment, and ensure patients are following a high-protein diet (1.5 g of protein/kg/day). A whey-protein supplement may be provided to patients, should they require it. The RD will also ensure adequate calorie consumption for weight maintenance and will provided advice to help ease any GI issues the patients may be experiencing.
46007217|NCT04572867|Drug|IV Diuretics|Active Comparator: Intravenous Diuretics Per protocol (Fig 2), if randomized to IV diuretic therapy arm (IV), the patient will receive initial dose of IV diuretic based on base line renal function; then the dose will be doubled every 2 hrs if refractory, to a maximum of 8mg IV Bumex (or 320mg IV Lasix). Metolazone may be added at 2.5mg PO 30 minutes before loop diuretic if CR< 2.0, or 5mg PO if Cr > 2.0, if refractory to high dose loop diuretic. If the patient in IV arm is refractory to max 320 mg IV Lasix or 8 mg IV Bumex plus Metolazone then the patient may cross over to AQ arm.
46007218|NCT00572429|Dietary Supplement|l-carnitine|3 gram daily dose
46007219|NCT00572507|Device|MonoMax®|Abdominal wall closure with ultra-longterm absorbable monofilament suture after primary median laparotomy
46007220|NCT01142089|Drug|Placebo|Placebo (two matching tablets) orally twice daily for 3 days (72 hours).
46007221|NCT01142089|Drug|Rifamycin SV MMX|Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
46007222|NCT00585390|Dietary Supplement|Omega-3 Fatty Acids|"Essential omega-3 fatty acid replacement therapy with Eicosapentaenoic acid at 3.2 grams~Docosahexaenoic acid fish oil concentrate at 1.6 grams"
46094130|NCT00697671|Drug|Clofarabine|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
46094131|NCT00697671|Drug|Cyclophosphamide|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
46094132|NCT00697671|Drug|Etoposide|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
46094133|NCT03922945|Drug|VI-0521 oral capsule|Phentermine/Topiramate
46094134|NCT03922945|Drug|Placebo oral capsule|Inactive drug
46094135|NCT03922945|Behavioral|Lifestyle Modification|The lifestyle modification includes physical activity, behavior change, reduced calorie diet advice, and family support. This intervention is applied to all treatment groups.
46094136|NCT02616159|Other|Oatmeal|
45459882|NCT03475966|Behavioral|Relaxation techniques|Patients will see a psychologist who will provide relaxation techniques (eg. imagery, visualization, deep breathing exercises) to help patients manage anxiety prior to surgery.
46007223|NCT00585390|Other|Olive oil placebo|Olive oil capsules, 8 capsules per day
46007224|NCT00585390|Dietary Supplement|EPA fish oil concentrate; DHA fish oil concentrate|3.2 grams for EPA 1.6 grams for DHA
45599012|NCT02297269|Device|open surgery|the method of surgery is conducted by surgical instruments to open the abdomen.
46007225|NCT00585390|Drug|Placebo|Olive oil capsule
46007226|NCT01141660|Device|Endotracheal Tube|Patients randomized to either Laryngeal Mask Airway or Endotracheal tube prior to undergoing adenotonsillectomy.
46007227|NCT01141660|Device|Laryngeal mask airway|Randomized to either Laryngeal mask airway or endotracheal tube
46007228|NCT02883790|Dietary Supplement|Somnage|Melatonin 1mg, Zinc, Magnesium
46007229|NCT02883790|Other|Placebo|Placebo
46007230|NCT00572663|Drug|ACC (N-acetylcysteine) 1200 mg|N-acetylcysteine (ACC) 1200 mg In the 8-weeks run-in period angiotensin converting enzyme inhibitors and/or angiotensin II subtype 1 receptor antagonists were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 1200 mg N-acetylcysteine in two active treatment periods lasting 8 weeks each
46007231|NCT04572672|Other|Non-pharmacologic treatment; Pursed-Lip Breathing Combined with Number Counting|"Pursed-lip breathing and number counting one and two during inspiration, and then number counting, one, two, three, and four during exhalation. The nurse advised the patient to continue pursed-lip breathing with number counting for the first 15 minutes (min) of each hour to prevent the patient from being exhausted, total study time was 3 hours, or until the patient was discharged from the ER, or was withdrawn from the study."
46007232|NCT01140880|Drug|Truvada|Truvada At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
46007233|NCT00572702|Procedure|Vaginal fixation Amreich-Richter|Descending vaginal cuff will be treated with fixation of the cuff on sacrospinous ligament
46007234|NCT00572702|Procedure|Prolift total|Descending vaginal cuff will be treated with insertion of site-specific mesh into the vesico-vaginal and recto-vaginal space
46007235|NCT01140646|Drug|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given orally
46007236|NCT01140646|Other|questionnaire administration|Ancillary studies
46007237|NCT01140646|Procedure|quality-of-life assessment|Ancillary studies
46007238|NCT00572741|Dietary Supplement|B12|Methylcobalamin Dose: 75 μg/kg every 3 days
46007239|NCT00572741|Dietary Supplement|Placebo|cellulose
46007240|NCT00572741|Dietary Supplement|folate|Folinic acid: Dose: 400 µg twice a day (BID)
46007241|NCT00572741|Dietary Supplement|B complex|B-Complex: B-1 (3 mg); B-2 (3.4 mg); B-352 (20 mg); B-6 (4 mg;) Pantothenic Acid(10 mg); Biotin (300 mcg); pyridoxal (25mg)
46094137|NCT02616237|Behavioral|Lifestyle Intervention|East-meets-West Lifestyle Intervention elements include nutrition and exercise from the Western perspective, food therapy and acupressure from the Traditional Chinese Medicine perspective, self-monitoring, and motivational videos of successful stories from working colleagues. The group participants in the Facebook are encouraged to post their health behaviors and questions, self-monitor, pledge for weight loss, seek social support and interact with health partners and other participants.
46094138|NCT00697749|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection
45459883|NCT01147315|Procedure|Hybrid bone substitution|The patient will be treated by hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow after necrosis exeresis
46007242|NCT00572741|Dietary Supplement|vitamin C|Vitamin C 500 mg
46007243|NCT00572741|Dietary Supplement|cod liver oil|Cod liver oil 1/2 teaspoon
46094139|NCT00697749|Biological|Engerix™-B|3-dose intramuscular injection
46094140|NCT02615925|Other|Psychiatry Consultation|Psychiatry Consultation
46094141|NCT04973345|Drug|Terbutaline|management of asthma symptoms
46094142|NCT02615847|Drug|Memantinhydrochlorid|"Memantin Mepha® Lactabs (memantinehydrochlorid) will be provided as 5 mg, 10 mg, 15 mg and 20 mg tablets, packed in blister.~The study drug will be taken once a day per os, during 12 month."
46094143|NCT02779907|Other|No Intervention|No interventions planned for this observational study
46094144|NCT02615769|Behavioral|focused information of spirometry in the invitation|Focused information of spirometry in the invitation to the preventive health check compose the intervention in this trial.
46094145|NCT02615769|Behavioral|standard invitation|The active comparator will receive a standard invitation to the preventive health checks. The preventive health checks in the active comparator group and the intervention group are identical.
46094146|NCT05236985|Drug|Oxytocin bolus or oxytocin infusion|"On the day of surgery, the patients will be randomized to either bolus or infusion administration of oxytocin.~On the day of the procedure, periprocedural data and patient satisfaction (single question) will be recorded."
46094147|NCT02615613|Other|Low Acceptability Meal|
46094148|NCT02615613|Other|High acceptability meal|
46094149|NCT04196153|Procedure|Pedicle screws instrumentation|The screws are inserted in two or more consecutive levels to prevent motion at the segments that are being fused. It will be done using one of the two guidance technique depending on which arm the patient will be randomized to.
45459884|NCT04576442|Behavioral|Asthma-PASS|The investigator will collaborate with the student's primary care provider (PCP) by sending a letter via facsimile, and/or email to ensure appropriate medications are prescribed or adjusted and rescue medications are available at school. Community Health Workers (CHWs) will follow up with PCPs as needed to provide reminders about prescriptions for controlled medications and to ensure a MAF is provided to schools to allow rescue medication administration by nurses. CHWs will work with local pharmacies when possible to have prescribed medications delivered to schools and homes. For students without a PCP, we will refer families to one of Montefiore Medical Center's 20 practices throughout the Bronx. For students without medical insurance or who are unable to go to a Montefiore clinic, the NYC DOE physicians who routinely attend NYC schools will provide medical care and prescribe appropriate medications.
46007244|NCT00572741|Dietary Supplement|Mineral complex|Magnesium citrate (200 mg); Selenium (50 mcg); Zinc picolinate (25 mg); Molybdenum (50 mcg); Calcium citrate (400 mg)
46007245|NCT00572741|Dietary Supplement|carnitine|Acetyl L-Carnitine Dose: 250 mg
46007246|NCT01140568|Drug|nilotinib|400mg po (orally) BID (twice daily)
46007247|NCT04572945|Diagnostic Test|kidney function test|laboratory and imaging
46007248|NCT00572819|Drug|Misoprostol|1000 micrograms of self-administered vaginal misoprostol compared to placebo 12 hours before operative hysteroscopy after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
46007249|NCT00572819|Drug|Placebo|Vaginal lactosum monohydricum administered 24 hours in postmenopausal women, compared to misoprostol after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
46007250|NCT00572858|Procedure|Blood test|for cholesterol, glucose and insulin levels and levels of various hormones, including but not limited to estrogen
46007251|NCT00572858|Genetic|Blood test|Blood test for genetic testing
46094150|NCT04133025|Other|Vestibular Rehabilitation|Vestibular Exercises and Software in vestibular rehabilitation
46094151|NCT03922477|Drug|Atezolizumab|Atezolizumab will be administered to participants by IV infusion at a fixed dose starting on Day 22 of Cycle 1. In subsequent cycles (Cycles 2 and beyond), IV atezolizumab will be given every 2 weeks (Q2W) on Days 8 and 22 of each 28-day cycle.
46094152|NCT03922477|Drug|Hu5F9-G4|Two priming doses of 1 mg/kg of Hu5F9-G4 will be administered to participants by continuous IV infusion on Days 1 and 4 of Cycle 1, followed by loading doses of 15 mg/kg IV on Day 8 and 30 mg/kg IV on Day 11. Starting on Day 15 of Cycle 1, Hu5F9-G4 maintenance will be given by IV infusion at a dose of 30 mg/kg once a week (QW) of each 28-day cycle. Dosing for de-escalation, if needed: Hu5F9-G4 will be given as two priming doses of 1 mg/kg IV on Days 1 and 4, followed by loading doses of 10 mg/kg IV on Day 8 and 15 mg/kg on Day 11. Starting on Day 15, maintenance treatment with Hu5F9-G4 will be given by IV infusion at a dose of 15 mg/kg once a week (QW).
46007252|NCT00572858|Procedure|Ultrasound of neck arteries|Non-invasive test using ultrasound waves to measure the thickness of the arteries
46007253|NCT00572858|Procedure|Saliva test|Saliva test for cotisol levels
46007254|NCT00572975|Other|Pentadecanoic acid (PA) and Triheptadecanoin (THA)|"Two fats (Pentadecanoic acid and Triheptadecanoin) are administered in a breakfast shake for the purposes of determining malabsorption.~in breakfast shake x1"
46094153|NCT00978211|Drug|DOTA-TOC Treatment|"Intravenous injections of DOTA-TOC. Repeated treatment cycles for responders, except in case of~renal toxicity~loss of patient transferability or~denial of further treatment."
46094154|NCT05339711|Other|Robotic Pet Therapy/Robot Cat Group|"İn this study, the patients interacted with the robot cat Silver for 20 minutes during the hemodialysis session once a week for eight weeks (two months) under the supervision of the researcher."
46094155|NCT05339711|Other|Pet Therapy/Betta Fish Group|İn this study, two fish and the necessary materials (aquarium, fish food, plastic plant, aquarium stone, etc.) were given to the patients by the researcher to keep pets for eight weeks.
46094156|NCT02780375|Procedure|Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points before and during their radiotherapy
46094157|NCT00981877|Drug|GB (Florestor)|S. Boulardii preparation of 1 gram twice daily for 5 days
46094158|NCT00981877|Drug|GRALB|mixed probiotic preparation 1 gram twice daily for 5 days.
46094159|NCT00981877|Drug|GC (placebo)|Placebo 1 gram twice daily for 5 days.
46094160|NCT00867165|Drug|ezetimibe|oral tablets: ezetimibe 10 mg once daily for 12 weeks
46094161|NCT00867165|Drug|Placebo|oral tablets: placebo to match ezetimibe 10 mg; administered once daily during the 5-week, single-blind, placebo run-in and diet stabilization period and 12-week double-blind treatment period
46094162|NCT05071469|Other|Kinesiotaping|KT was applied.
46094163|NCT05071469|Other|Mulligan Mobilization Technique|MMT was applied
45459885|NCT04576442|Behavioral|Basic Asthma Management (AM)|PCPs and caregivers will be notified that children in the AM group have persistent/uncontrolled asthma that warrants use of guideline-based preventative medications.
45599013|NCT04047563|Drug|Normal Saline along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. In this arm normal saline along with standard treatment will be given for active comparison.
46007255|NCT00585624|Dietary Supplement|Impact Advanced Recovery|Nutritional supplement
46094164|NCT00981955|Dietary Supplement|Caffeine and L-theanine|Acute oral administration of 75mg of caffeine, 50mg l-theanine, 75mg caffeine and 50mg l-theanine in combination or placebo. One dosage administered on each of four separate study days.
46094165|NCT05013905|Drug|PRA023 IV|PRA023 administered at timepoints as directed by the protocol
46007256|NCT00585624|Dietary Supplement|No supplement|No supplement
46007257|NCT04580186|Procedure|bladder exstrophy repair|primary complete bladder exstrophy repair
46007258|NCT04572555|Other|Heat Treatment|Thermoforming was applied to the lower abdomen by the subjects themselves when the dysmenorrhea pain was at its peak.
46007259|NCT03451110|Drug|lemborexant|oral tablet
46007260|NCT03451110|Drug|Loestrin|oral tablet
46007261|NCT03451110|Drug|famotidine|oral tablet
46007262|NCT03451110|Drug|fluconazole|oral tablet
46007263|NCT03453827|Other|no intervention|no intervention
46007264|NCT03451032|Other|Non Interventional Study|Non Interventional Study
46007265|NCT03453788|Device|LETSGO app|LETSGO pilot test Group will test LETSGO app and partially nurseled follow-up
46007266|NCT03453749|Dietary Supplement|Salovum|Salovum is freeze dried egg yolk, highly enriched with anti-secretory factor. Salovum is registered as a medical food by the EU
46094166|NCT05013905|Device|Companion diagnostic (CDx)|CDx+ or CDx-
46094167|NCT00972829|Drug|Rosuvastatin|Rosuvastatin 10 or 20 milligrams once or twice a week
46094168|NCT00972829|Drug|Ezetimibe|Ezetimibe 5 or 10 milligrams
46094169|NCT05339165|Behavioral|Psychotherapy|
46094170|NCT05339009|Biological|BioADM determination in plasma|BioADM determination in plasma
46094171|NCT00978367|Drug|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
46094172|NCT00978367|Drug|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
46094173|NCT00978367|Drug|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
46094174|NCT00978367|Drug|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
46094175|NCT00978367|Drug|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
46094176|NCT00978367|Drug|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
46007267|NCT03450993|Other|SMART Program|This is an 8-week, multimodal resiliency program that targets stress with 4 main components: mind-body skills (participants learn a variety of meditation techniques, mini relaxations, walking meditation, and yoga), traditional stress management techniques, healthy lifestyle behaviors (sleep, exercise, nutrition, and social support), and cognitive reappraisal and adaptive coping skills (borrowed from cognitive behavioral therapy, acceptance and commitment therapy, and positive psychology)
46094177|NCT05037617|Drug|Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).|"At the intervention site (Foothills Medical Centre), for participants who consent to being part of the trial, once a patient is found to be >= 6 cm dilation, the study medication will be initiated. Pharmacy will make up identical vials of oxytocin or saline, which will be numbered according to the random allocation sequence created by the study statistician.~The intervention will be continued until delivery unless contractions decrease to less than 2 in 10 minutes or if no further cervical dilation is noted 4 hours after discontinuation."
46094178|NCT00972907|Drug|Nifedipine coated suppositories|12 mg Nifedipine coated suppositories BID
46094179|NCT02595593|Device|Rib Fixation System|This intervention involves a surgical procedure to affix rib plates to broken ribs
46094180|NCT02615457|Drug|Huaier Granule|Huaier Granule was given orally, 20 g tid for 5 years.
46094181|NCT04008433|Drug|Lidocaine|Advanced intravenous injection of lidocaine before the propofol injection
46094182|NCT00978523|Drug|AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)|Oral, dose-escalation
46094183|NCT04132479|Drug|Clarithromycin 500mg|1000mg taken orally every 12 hours for 5 days
46094184|NCT04132479|Drug|Amoxicillin 500mg|1000mg taken orally every 12 hours for 5 days
46094185|NCT04132479|Drug|Tinidazole 500mg|500mg taken orally every 12 hours for 5 days
46094186|NCT04132479|Drug|Rabeprazole 20mg|20mg taken orally every 12 hours for 5 days
45459886|NCT04576442|Behavioral|Child/Caregiver Education session|The investigator will provide in-school child asthma education sessions delivered by trained, bilingual (English-Spanish) Community Health Workers (CHWs) using an established manualized protocol from past and current studies designed to improve knowledge and self-efficacy. Each child will receive two 1-on 1, 20-minute developmentally appropriate educational sessions at school 3-4 weeks apart. Sessions will cover: 1) asthma basics, symptoms and triggers; and 2) medications and correct administration technique. Caregivers will be called after each child session to highlight key points reviewed with the child and answer questions.
45459887|NCT03493698|Drug|Midazolam|Midazolam
45459888|NCT03493698|Drug|Inarigivir|Inarigivir
45459889|NCT02737852|Device|"Trojan Chameleon Personal Lubricant"|silicone base with sensate
45459890|NCT05758844|Procedure|safe-line technique|Safe-line approach
45459891|NCT01148173|Drug|Combined systemic and intrathecal chemotherapy followed by HD-ASCT|Methotrexate Ifosfamide Cytarabine Thiotepa Liposomal cytarabine (intrathecal) Carmustine Etoposide Autologous stem cell transplantation
45836649|NCT01794858|Other|Therapeutic Hypothermia|Will receive medically-necessitated ventilator support under ICU monitoring with core temperatures ≥36°C and severe acute pancreatitis defined as either a Ranson Score ≥7, a CT indicating ≥50% pancreatic necrosis, or a significant deterioration in clinical status including dysfunction of two or more organ systems. All patients will receive current standard management for severe acute pancreatitis and a standardized protocol for application of therapeutic hypothermia and rewarming. Our primary endpoints are organ-specific cardiovascular, respiratory, hematological, renal, and metabolic dysfunction as measured at 28 days. Logistic Organ Dysfunction Scores will be compared before and after therapeutic hypothermia, establishing day 4 versus day 1 changes in LOD.
45836650|NCT00318708|Drug|clarithromycin|clarithromycin 500 mg twice daily (Biaxin)
46007268|NCT03450954|Procedure|Amniotic membrane transplant|Amniotic membrane graft was transplanted onto the bullous cornea by the inlay technique
46007269|NCT03453671|Behavioral|Mindfulness|Participants will use mindfulness techniques while exercising
46094187|NCT04132479|Drug|Clarithromycin 500mg|1000mg taken orally every 12 hours for 14 days
46094188|NCT04132479|Drug|Amoxicillin 500mg|1000mg taken orally every 12 hours for 14 days
46094189|NCT04132479|Drug|Tinidazole 500mg|500mg taken orally every 12 hours for 14 days
46094190|NCT04132479|Drug|Rabeprazole 20mg|20mg taken orally every 12 hours for 14 days
46094191|NCT00972985|Drug|modafinil|oral tablet, 100 mg, single acute dose
46094192|NCT00972985|Drug|methylphenidate|oral tablet, 20 mg, single acute dose
46094193|NCT00972985|Drug|lorazepam|oral tablet, 1 mg, single, acute dose
46094194|NCT00972985|Drug|placebo|oral tablet, single acute dose
46094195|NCT02779361|Dietary Supplement|Green tea|"Lipton pure green tea, 5 teas on the first 6 days, and 9 teas on the day 7. Teas will be ingested at 08:00 am, 10:30 am, 13:00 pm, 15:30 pm, 18:00 pm days 1-6, and 08:00 am (*), 10:30 am, 13:00 pm (*), 15:30 pm, 18:00 pm (*), 20:30 pm on day 7.~One bag of tea will be used to prepare the beverages with exception of some beverages on day 7 that will be prepared with two bags (*)."
46094196|NCT02779205|Procedure|adipose tissue sample|adipose tissue sample
46094197|NCT02779049|Other|Blood examination|blood sampling
46094198|NCT02779127|Other|Medical interrogatory|Cardiovascular risk, medical history, known pathologies and actual treatments are evaluated
46094199|NCT02779127|Other|Medical examination|Systolic blood pressure, diastolic blood pressure, cardiac frequency, pulse palpation, hearth and pulmonary auscultation
46094200|NCT02779127|Other|Specific bioassay|Exhaled carbon monoxide measure and nicotine in the urine are evaluated
46094201|NCT02779127|Other|Endothelial function evaluation|Endothelial function evaluation done by echotracking determining the basale flow mediated dilatation
46094202|NCT02779127|Other|General bioassay|Fasting bioassay evaluating total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, creatine, transaminases, gamma glutamyl transferases, fibrinogen, reactive protein C, blood count and sedimentation rate.
46007270|NCT03453671|Behavioral|Distraction|Participants will distract themselves while exercising
46094203|NCT00867087|Drug|inotuzumab ozogamicin (CMC-544)|1.8 mg/m^2 every 21 days by intravenous infusion, 3 to 6 doses
46094204|NCT00867087|Drug|rituximab|375 mg/m^2 two days before cycle 1 by intravenous infusion; 375 mg/m^2 every 21 days by intravenous infusion, 3 to 6 doses
46094205|NCT04227743|Device|cryobiopsy|. The cryobiopsy samples will be obtained by advancement of the cryoprobe into the working channel of the bronchoscope to touch the tip of the endobronchial tumor. The freezing time will be approximately 4 seconds. Then, flexible bronchoscope together with tissue sample attached to the tip of the frozen probe will be extracted outside the bronchial tree. The tissue sample will be released from the probe's tip by plunging it into saline at room temperature. FB will be reintroduced after cryobiopsy to evaluate and control the bleeding.
46094206|NCT02778425|Procedure|Endoscopic therapy+ beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (propranolol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.
46094207|NCT02778425|Procedure|Endoscopic therapy+ PSE+beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (propranolol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
46094208|NCT02778425|Procedure|beta blockers|A standard dose of NSBB (propranolol) was applied to the primary prevention patients according to the Baveno VI recommendations if there were no contraindications.
46094209|NCT02778425|Procedure|Endoscopic therapy|Endoscopic variceal ligation (EVL) is for the primary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
45836651|NCT00318708|Drug|fluticasone propionate|fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
46094210|NCT02778425|Procedure|Endoscopic therapy+ PSE|Endoscopic variceal ligation (EVL) is for the primary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
45836652|NCT00318708|Drug|placebo clarithromycin|placebo clarithromycin twice daily
46007271|NCT03453671|Behavioral|Self-monitoring|Participants will use associative attentional focus while exercising
46007272|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
46007273|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
46007274|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
46094211|NCT02778425|Procedure|Somatostatin+Endoscopic therapy|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
46094212|NCT02778425|Procedure|Somatostatin+Endoscopic therapy+PSE|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
45836653|NCT00319644|Device|Bronchoalveolar lavage|Using catheter to obtain respiratory sample
45836654|NCT02448420|Drug|Palbociclib|"Cohort A, B1 y B2: Palbociclib oral dose of 200 mg/day for 2 weeks, followed by 1 week off.~Cohort C1: Palbociclib oral dose 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles."
45836655|NCT02448420|Drug|Trastuzumab|Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.
46007275|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
46007276|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
46007277|NCT00573014|Other|Cervical Spine Clearance|All OBTPs with gross movement of all four extremities admitted to MetroHealth Medical Center who underwent a CT CS at MHMC between October 2006 and September 2008 will be included. Prospective data will be collected on these patients including age, gender, mechanism of injury, Glasgow Coma Scale (GCS) on admission, results of CT CS, GCS at the time of collar clearance, day of collar clearance, collar complications, date of reexamination, and results of reexamination. We will define an obtunded patient as a patient who was unable to reliably describe the presence or absence of CS symptoms in the opinion of the examining physician. Patients needed to have gross movement of all four extremities to be included in the study. We defined cervical collar complications as skin breakdown identified either by the skin care team during weekly rounds in the intensive care unit or by the treating physician at any time.
46094213|NCT04228757|Dietary Supplement|phytoestrogen herbal blend|phytoestrogen herbal blend
46094214|NCT04228757|Other|Placebo|Tablet without active ingredients
46007278|NCT00573053|Other|Oxygen saturation range|Maintain functional oxygen saturation range between 91 and 95%
46094215|NCT04227431|Other|Insulin degludec|Participants have been treated with Tresiba® (insulin degludec) for at least 20 weeks before entering the study. The study will be based on data already recorded in participants' medical records for approximately the last year and no new tests or procedures are required as part of the study.
46094216|NCT04993469|Diagnostic Test|Semmes-Weinstein monofilament testing and questionnaires|Semmes-Weinstein test for the assessment of genital sensation Battery of questionnaires assessing sexual function, voiding function, quality of life and patient satisfaction
46094217|NCT04227041|Drug|Pyrotinib in combination with capecitabine|Pyrotinib in combination with capecitabine
46007279|NCT00573053|Other|Oxygen saturation range|Maintain functional arterial oxygen saturations in the range of 85- 89%
46007280|NCT00585819|Procedure|reproduce breathing cycle utilizing spirometry|reproduce breathing cycle utilizing spirometry
46094218|NCT05074823|Drug|Ketamine 0.1 mg|Patients will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.1 mg/kg
46094219|NCT05074823|Drug|Ketamine 0.2 mg|will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.2 mg/kg
46094220|NCT05074823|Drug|Ketamine 0.3 mg|will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.3 mg/kg
46094221|NCT04226963|Drug|Ketamine|Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks) Ketamine will be given in intranasal spray twice weekly over a period of 4 weeks Ketamine will be given orally (solution 2.0mg/kg, 2.5mg/kg) twice weekly over a period of 4 weeks.
46007281|NCT00585819|Procedure|Freebreathing in Body fix mold|Freebreathing in Body fix mold
46007282|NCT03450876|Other|Non-Interventional|Non-Interventional
46007283|NCT00573209|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
46094222|NCT05058131|Dietary Supplement|Dietary fibre|Dietary fibre as a powder, 24 g per day for 6 weeks
46094223|NCT05058131|Dietary Supplement|Placebo compound|Maltodextrin powder, 24 g per day for 6 weeks
46094224|NCT02778737|Behavioral|ACT-based intervention|"Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. Although each session has specific objectives, therapists within the time frame, are encouraged to accommodate participants' discussion or other group dynamic issues that may arise.~Participants will receive their AP-ACT handbook including outlines of each session, activity plan assignments, and a CD with recorded mindfulness exercises.~Session highlights and AP-ACT activities relevant to each session will be given at each meeting, so that participants will follow along with the treatment protocol. Individuals missing more than two consecutive sessions will be considered as dropouts."
46094225|NCT02778737|Behavioral|CBT-based intervention|"Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. Although each session has specific objectives, therapists within the time frame, are encouraged to accommodate participants' discussion or other group dynamic issues that may arise.~Participants will receive their AP-CBT handbook including outlines of each session, activity plan assignments, and a CD with recorded relaxation exercises.~Session highlights and AP-CBT activities relevant to each session will be given at each meeting, so that participants will follow along with the treatment protocol. Individuals missing more than two consecutive sessions will be considered as dropouts."
46094226|NCT02778035|Device|Dorsomedial prefrontal rTMS|Dorsomedial prefrontal rTMS, bilateral, iTBS, 600 pulses per hemisphere, 120% RMT, 2 sessions at 0, 30, or 60 min inter-session interval
46094227|NCT00545233|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms subcutaneous weekly for 48 weeks
46094228|NCT00545233|Drug|ribavirin [Copegus]|1000-1600 mg day orally for 48 weeks.
46094229|NCT00545233|Drug|Pioglitazone|30 mg daily for 8 weeks increasing to 45 mg daily for 64 weeks.
46007284|NCT01140451|Drug|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
46094230|NCT02778815|Other|Kindness for Mums|
46094231|NCT05190731|Other|Osteopathic cranial manipulative medicine|Osteopathic cranial manipulative medicine technique using compression of 4th ventricle technique
46094232|NCT05190731|Other|Sham|Touch only, no osteopathic cranial manipulation
46094233|NCT02393248|Drug|Pemigatinib|
46094234|NCT02393248|Drug|Gemcitabine|
46094235|NCT02393248|Drug|Pembrolizumab|
46094236|NCT02393248|Drug|Docetaxel|
46094237|NCT02393248|Drug|Trastuzumab|
46094238|NCT02393248|Drug|Retifanlimab|
46094239|NCT02393248|Drug|Cisplatin|
46094240|NCT00601484|Drug|PF-04383119|PF-04383119 200 mcg/kg IV, single dose
46094241|NCT00601484|Drug|Placebo|placebo IV, single dose
46094242|NCT04228601|Drug|Fluzoparib|PARP
46094243|NCT04228601|Drug|Fluzoparib placebo|Placebo
46094244|NCT04228601|Drug|mFOLFIRINOX|mFOLFIRINOX
46094245|NCT00978601|Procedure|Multimodal analgesic protocol during minimally invasive myomectomy|Multimodal and preemptive analgesia using 8 mg of Dexamethasone iv,trocar ports infiltration with 5 mL of a local anesthetic, consisting of 0.26% ropivacaine HCL (7.5 mg/mL) and 0.74% of 0,9 % sodium chloride, before the skin incision. About 10 minutes before the surgery is completed, 4 mg Ondansetron iv and a mixture of 75 mg diclofenac and 600 mg of paracetamol intramuscularly (im) are administered.
46007285|NCT03450837|Diagnostic Test|Coronary Computed Tomography Angiography|To assess coronary artery plaque and calcification, all participants underwent coronary computed tomography angiography according to the guidelines of the Society of Cardiovascular Computed Tomography (SCCT). All CT scans were acquired in a 320-row detector scanner (AquillionOneTM - Toshiba Medical Systems Corporation, Otawara, Japan) with 0.5-mm thick slices. Acquisition protocol included coronary artery calcium scoring (CACS) and coronary CTA. CACS protocol utilized a 370-ms tube rotation, 120-kV tube voltage, 300-mA tube current, and 320x0.5-mm collimation with 3-mm slice thickness reconstructed images, one heart beat acquisition during diastole.
46094246|NCT00883896|Other|Placebo|Part 1: Placebo SC administration every 2 weeks X 10 weeks.
46094247|NCT00883896|Drug|ILV-094|Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.
46007286|NCT03450837|Diagnostic Test|Macrophage cholesterol efflux mediated by HDL|Macrophages were incubated with DMEM (Low Glucose, Gibco, Grand Island, New York, USA) containing 1 mg fatty acid free albumin (FAFA) (Sigma-Aldrich, Steinheim, Germany) plus 50 μg acetylated LDL/mL and 0.3 μCi 14C-cholesterol/mL (Amersham Biosciences, UK) for 48h. After washing with PBS/FAFA, cells were incubated in the presence or absence of HDL (50 µg/mL) for 8h. The amount of radioactivity present in the medium at the end of the HDL incubation period will indicate albumin-mediated cholesterol efflux with albumin alone and total efflux with albumin + HDL. Thus, specific HDL-mediated efflux will be calculated, subtracting the albumin-mediated efflux from total efflux
46007287|NCT04579913|Other|Review of medical history, administration of questionnaires, uroflowmetry and PVR as measured by ultrasound|Administration of questionnaires to assess patient LUTS, quality of life, sexual behavior and erectile function, in addition to performing PVR and uroflow tests.
46094248|NCT00883896|Drug|ILV-094|Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.
45836656|NCT02448420|Drug|Endocrine therapy|Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen
45836657|NCT02448420|Drug|Chemotherapy|Gemcitabine, vinorelbine, capecitabine, eribulin or a taxane
45836658|NCT02448420|Drug|Antibody-Drug Conjugates|3.6 mg/kg iv every 3 weeks
45836659|NCT02422446|Drug|Icosapent ethyl|icosapent ethyl is eicosapentaenoic acid, an omega-3 fatty acid that naturally occurs in fish
45836660|NCT05287386|Drug|Pemigatinib|The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0.
45836661|NCT02405676|Drug|Prednisone,Vincristine, Cyclophosphamide|Prednisone 45mg/m2, D1~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;
46094249|NCT00883896|Other|Placebo|Part 2: Placebo SC administration every 2 weeks X 10 weeks
46094250|NCT00883896|Drug|ILV-094|Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks
46094251|NCT00973063|Behavioral|Routine sterile gloving|routinely new sterile gloving just before sampling
46094252|NCT02778191|Drug|cisplatin|100 mg/m2 day 1, 22 and 43
46094253|NCT02778191|Drug|carboplatin|carboplatin 300-350 mg/m2 day 1, 22 and 43
46094254|NCT02778191|Drug|5-FU|5-FU 600 mg/m2 days 1-4, 22-25 and 43-46
46007288|NCT03450798|Device|SOFT block group|needle will be introduced medial to the femoral vein and 3 cm below the skin where 15 mL of bupivacaine 0.25% injected. the obturator nerve, the probe shifted medially, superior to the needle, and directed cranially to the pectineus muscle . Needle withdrawn to the subcutaneous tissue and redirected using out-of-plane toward the deep surface of pectineus, 10 mL of bupivacaine 0.25%will be injected. The sciatic nerve, we use the curvilinear probe, inferior to the needle, and tilted the probe to get the clearest image of the sciatic nerve.The needle will be inserted then withdrawn subcutaneously and directed by an in-plane toward the sciatic nerve deep to the inferior border of the quadratus femoris muscle.20 mL of bupivacaine 0.25% will be injected
46094255|NCT00982267|Drug|SU014813|Escalating doses of SU014813 from 50 to 250mg/day . Capsules administered daily either as continuous dosing or in cycles of 4 weeks on 1 week off
46094256|NCT02779829|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. Formulation number SR15-40-Z12-006.
46094257|NCT00978679|Device|Orthokeratology lenses|Nightly use of orthokeratology lenses to correct the refractive errors
46094258|NCT00978679|Device|Spectacles|Daily use of single vision lenses to correct refractive errors
46094259|NCT04007263|Drug|Placebo|Placebo via 30 minute infusion once daily for 5 days
46094260|NCT04007263|Drug|NP10679|NP10679 25 mg via 30 minute infusion once daily for 5 days
46094261|NCT02778269|Device|12-lead ECG T-shirt|The 12-lead ECG T-shirt system consists of three parts: the recording device, amplifier boards and the T-shirt.The T-shirt has 10 textile ECG electrode patches. The patches should be in contact with the patient's skin to record the electrical activity of the heart. The electrodes are made of electrically conductive textile. They are sewn into the inside of the T-shirt and are padded with foam. The cables to the device can be attached to snap fasteners on the outer side of the T-shirt on the ECG electrode patches.
46094262|NCT02778269|Device|Dexcom G4-System|Continuous Glucose Monitoring
46094263|NCT05170685|Biological|Nivolumab plus Relatlimab FDC|
46094264|NCT02778893|Drug|Conmana|125mg three times a day (TID) continuously
46094265|NCT02778893|Drug|Thalidomide|100mg one a day（QD）at night continuously,If can tolerance after 1 weeks to add to 200mg;
46094266|NCT05298059|Radiation|Laser of low frequncy|Apply the laser at three points on each tooth.
46007289|NCT03450798|Device|spinal anesthesia group|patients will receive spinal anesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg). This will be administered via a 25-G spinal needle at L4-L5 or L3-L4 with the patient in the sitting position under complete aseptic conditions.
46094267|NCT05298059|Drug|CPP-ACPF|Apply MI paste plus for five minutes, in the vestibular surface os teeth. During this time patientes should be with closed mounth ad should not talk or to split.
45836662|NCT02405676|Drug|Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1,8;
46007290|NCT00585897|Behavioral|discontinuation of sugar sweetened beverages|Individual sessions which utilize motivational interviewing to assist participants to eliminate sugar sweetened beverages from their diet.
46007291|NCT04579796|Other|ultrasound exam|An abdominal ultrasound exam to assess the placenta implantation site.
46007292|NCT04579796|Procedure|hysteroscopy diagnostic|Diagnostic hysteroscopy to asses the placenta implantation site.
46094268|NCT02778581|Dietary Supplement|Lipidic Blend 1|daily intake of the content of one 45 mL bottle containing the product
46094269|NCT02778581|Dietary Supplement|Lipidic Blend 2|daily intake of the content of one 45 mL bottle containing the product
46094270|NCT02778581|Dietary Supplement|Placebo|daily intake of the content of one 45 mL bottle containing olive oil
46094271|NCT00665886|Device|Open Intravenous System - Vasocan®|Vasocan® Safety catheter 18 G x 45 mm (Ref. 4248139S), 20 G x 33 mm (Ref. 4248112S) y 22 G x 25 mm (Ref. 4248090S)with wings and a passive safety mechanism. To the control catheters a three-way tap ('stopcock') with extension tubing 10 cm long (Connecta® Extra 3) from BD (ref 394995)will be added.
46094272|NCT00665886|Device|Closed Intravenous System - Nexiva®|BD Nexiva® Catheter (18G x 45 mm, 20 G x 32 mm, 22 G x 25 mm) (Ref. 383609,Ref. 383606,Ref. 383602) BD QSyte®, Ref. 385100 Catheter material is Vialon®. The entire system is Latex and PVC free.
46094273|NCT03920293|Biological|Ravulizumab|Concentrated sterile, preservative-free aqueous solution (10 milligrams [mg]/milliliter [mL]) in single-use, 30-mL vial for intravenous (IV) infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
46094274|NCT03920293|Drug|Placebo|Matching, sterile, preservative-free aqueous solution in single-use, 30-mL vial for IV infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
46094275|NCT02671864|Other|1: incretin-based therapy|
46094276|NCT02671864|Other|2: other antidiabetic|
46094277|NCT02661074|Other|Questionnaire|"A questionnaire will be completed in order to collect data on:~Potential allergic manifestations after fish contact: asthma, allergic rhinitis, conjunctivitis, chronic or acute urticaria, dermatitis/eczema, or severe allergic manifestations (angioedema, bronchospasm, anaphylaxis),~Occupational and/or domestic exposure to fish."
46094278|NCT00665964|Device|X-3 polyethylene|highly cross-linked polyethylene for knee arthroplasty
46094279|NCT00665964|Device|N2Vac polethylene|conventional polyethylene
46094280|NCT00867009|Drug|Pemetrexed|Induction therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles Maintenance therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation
46094281|NCT00867009|Drug|Cisplatin|Induction therapy: 75 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles
46094282|NCT00867009|Drug|Cetuximab|"Induction therapy: Loading dose of 400 mg/m², intravenous, on Day 1 of cycle 1, then 250 mg/m², intravenous, weekly for 4 to 6 cycles, 21 day cycles~Maintenance therapy: 250 mg/m², intravenous, weekly until progressive disease or treatment discontinuation"
46094283|NCT00666042|Drug|Vigamox - administration in spray form|Vigamox will be administered in a spray form
46094284|NCT00666042|Drug|Vigamox eye drops|Vigamox eye drops
46094285|NCT02660840|Drug|0.5 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
46094286|NCT02660840|Drug|1 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
46094287|NCT02660840|Drug|5 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
46094288|NCT02660840|Drug|0.5 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
46094289|NCT02660840|Drug|1 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
46094290|NCT02660840|Drug|5 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
46094291|NCT04902820|Other|PrEPTECH website|The intervention is a web site delivering access to PrEP telehealth. The platform provides access to laboratory testing for PrEP eligibility delivered to a participant's home, telehealth care and PrEP prescriptions for those eligible delivered asynchronously through an online form for all adult participants and through telephone appointments for adolescent participants, and an online pharmacy for PrEP. Additionally, free PrEP medication will be provided through the intervention. Transgender female and adolescent cisgender male participants will receive free PrEP medication (emtricitabine [200 mg]/tenofovir disoproxil fumarate [300 mg]) for the duration of their participation in the study, while adult cisgender male participants will receive a free 30-day supply of PrEP and subsequently have to pay for PrEP medication through insurance, patient assistance programs, or out of pocket.
46094292|NCT04902820|Other|Online PrEP resource list|Participants will receive access to an online list of web-based resources about PrEP and how to locate and pay for PrEP care and contact information for a professional PrEP navigator at a local community-based organization partnering with the study.
46094293|NCT02777801|Drug|Entecavir|anti-HBV
46094294|NCT04074694|Procedure|Sialoendoscopy|Sialoendoscopy
46094295|NCT00649064|Drug|Ziprasidone|Ziprasidone 40 mg capsules twice daily for the first 7 days followed by flexible dosing between 40 and 80 mg twice daily for the remaining 5 weeks.
46094296|NCT04132713|Drug|Capecitabine 150Mg Oral Tablet|Advanced breast cancer patients with first-line medication
45836663|NCT02405676|Drug|Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Ifosphamide 1.2g/m2, D1~5; Etoposide, 60mg/m2, D3~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1;
46007293|NCT00573326|Drug|Imatinib|200 mg p.o. once a day for 6 months
46007294|NCT01140061|Drug|MK-0873 Patch|MK-0873 skin patches containing 0.05%. 0.5%, or 2% MK-0873
46007295|NCT01140061|Drug|MK-0873 Cream|MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873
46007296|NCT01140061|Drug|Placebo Patch|Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches
46007297|NCT01140061|Drug|Placebo Cream|Placebo cream matching MK-0873 0.05%, 0.5%, or 2%
46007298|NCT01140061|Drug|Plain patch|Plain patch containing no MK-0873 or placebo
46007299|NCT04312750|Drug|Lidocaine topical system 1.8%|
46007300|NCT00573365|Device|Gentlewaves Select™ handheld high energy LED array|LED photomodulation within 5-10 minutes before and within 5-10 minutes after each radiation treatment
46007301|NCT00573365|Radiation|Radiation|Weekly radiation treatment
46007302|NCT00573365|Radiation|Radiation|Weekly radiation treatment
46007303|NCT00586014|Procedure|High-Dose Sequential Chemotherapy followed by ASCT|Patient will receive Cyclophosphamide(4 g/m2 over 2 hours) and blood progenitor cell collection (day -49). G-CSF (10 mcg/kg/d) will be administered SQ. A six hour leukapheresis will be performed,cells will undergo CD34+ cell selection, patients will receive high dose VP-16 (Etopophos)(day -28)(2 g/m2 over 4 hours)and G-CSF (5 mcg/kg/d) will be administered SQ two days following VP-16. The an IV of sulfamethoxazole-trimethoprim 1 ampule BID for 5 days (Day -5). BCNU 500 mg/m2 IV over 2 hours (Day -4). Melphalan (Day -2) will be administered IV (200 mg/m2 over 20 minutes). The frozen peripheral blood mononuclear cells will be transfused on Day 0. Day +1: G-CSF 5 mcg/kg/d SQ for 3 days.
46007304|NCT01139164|Drug|Regimen A|Chronic Lymphocytic Leukemia/ Chronic Prolymphocytic Leukemia, Multiple Myeloma.
46094297|NCT03343522|Behavioral|Exercise|A multimodal exercise training program (aerobic, strength and flexibility exercises) for 6 months (60-min sessions performed 3 times/week with moderate intensity).
46094298|NCT04007341|Drug|Dexmedetomidine|The study drug for each group was administered from the time immediately after induction of anesthesia until the end of the surgery.
46094299|NCT02656082|Drug|Etanercept|Treatment with etanercept is intended for remission induction of DLE only and not for maintenance purpose.
46094300|NCT02631486|Other|Physiotherapy|Passive exercises, active exercises, strengthening, stretching
46094301|NCT04132635|Device|artificial dermis|artificial dermis will be used after fully debridement of the wound
46094302|NCT04132635|Other|growth factor|growth factor
46007305|NCT01139164|Drug|Regimen B|Other malignancies not addressed in A or C
46007306|NCT01139164|Drug|Regimen C|B-Cell Lymphomas
46094303|NCT03335488|Drug|RAVICTI|RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose
46094304|NCT03335488|Drug|NaPBA|"NaPBA in patients weighing < 20 Kg - 600 mg/Kg, maximum total daily dose~NaPBA in patients weighing > 20 Kg - 13 g/m2, maximum total daily dose"
46094305|NCT04007185|Procedure|Maximal, safe resection of brain tumour|Standard surgical resection as part of routine care
46007307|NCT00573404|Drug|imatinib mesylate|will start at 200 mg daily and will be escalated up to 400 mg bid.If the 400 mg bid dose is tolerated, no further dose escalation will be performed. In the case of excessive toxicity on the starting dose, the option for de-escalation is provided. Sunitinib will start at 25 mg daily and if tolerated, will be escalated to 37.5 mg daily for subsequent dose levels.
46094306|NCT00982501|Drug|WS® 1442 900 mg/d|
46007308|NCT00573404|Drug|sunitinib malate|
46094307|NCT00982501|Drug|WS® 1442 1800 mg/d|
46094308|NCT00982501|Behavioral|Nordic walking training 2 x 30 min/week|
46094309|NCT00982501|Behavioral|Nordic walking training 4x45 min/week|
46094310|NCT04156308|Other|Osteopathic Manipulative Treatment (OMT) - Temp1|A total of 3 techniques selected from a list of 7 available techniques common to all centers will be applied in each session. The choice of techniques will be based on the results of the examination performed, the particularities of the patient and the clinical experience of the osteopath. In each session the techniques can change under the criteria of the osteopath. However, they will always be 3 and always within the list of available techniques.
46094311|NCT04156308|Other|Combined Exercises|A home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality
46094312|NCT02623504|Drug|Carbamazepine|200-1200 mg by mouth daily given in divided doses in the morning and the evening. Doses are titrated weekly in 200 mg increments based upon subject's response.
46094313|NCT02623504|Drug|Placebo|Dosage to match active treatment by mouth twice daily in the morning and in the evening.
45836664|NCT02405676|Drug|Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1,8;
46007309|NCT00573404|Other|pharmacological study|
46007310|NCT01139125|Drug|(Cystagon) Cysteamine Bitartrate|Cysteamine Bitartrate 300mg/day to 2100mg/day over a 4 month period. Number of cycles: until progression or unacceptable toxicity develops.
46007311|NCT03450759|Drug|AZD9977 Oral suspension (reference)|Randomized subjects will receive single oral dose of AZD9977 oral suspension 15 mg/mL on Days 1, 3, 5 and 7 in Part A.
46007312|NCT03450759|Drug|AZD9977 capsule|Randomized subjects will receive single oral dose of AZD9977 capsule 65 mg on Days 1, 3, 5 and 7 in Part A.
46007313|NCT03450759|Drug|AZD9977 ER capsule (fastvrate)|Randomized subjects will receive single oral dose of AZD9977 ER capsule (fast rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
46007314|NCT03450759|Drug|AZD9977 ER capsule (Int. rate)|Randomized subjects will receive single oral dose of AZD9977 ER capsule (Int rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
46007315|NCT01139047|Drug|metronidazole 1% gel|Apply topically once daily on one side of the face for three weeks
46007316|NCT01139047|Drug|azelaic acid 15% gel|Apply topically twice daily on the opposite side of the face for three weeks
46094314|NCT02777723|Drug|Xenobella|Hypotonic 0.3% Sodium Hyaluronate
46094315|NCT02777723|Drug|Isotonic 0.3% Sodium Hyaluronate|Isotonic 0.3% Sodium Hyaluronate
46094316|NCT00601250|Drug|linagliptin|Patients receive linagliptin 5 mg tablets once daily
46094317|NCT00601250|Drug|linagliptin|Patients receive linagliptin 5 mg tablets once daily
46094318|NCT04226885|Drug|fentanyl|nebulized fentanyl 2μg/kg body weigh
46094319|NCT04226885|Drug|midazolam|nebulized midazolam 0.2 mg/kg body weight 30 min before surgery.
46094320|NCT04226885|Drug|dexmedetomidine|nebulized dexmedetomidine 2 μg/kg body weight 30 min before surgery.
46094321|NCT00982579|Biological|MVA.HIVA|1 dose of 5 x 10^7 pfu of MVA.HIVA administered intramuscularly
46094322|NCT05673694|Drug|EG017|According to the dosage group of the program, once a day.
46094323|NCT04226651|Device|Virtual Reality Device|The Virtual Reality system (PlayStation 4 VR, Sony Inc.) is a simple and easy to use distraction device. The system consists of a screen mounted on a binocular headset connected to a console or personal computer. The head-mounted display provides a high-resolution visual display and unmutes the sound from the headphones using a soundproof mechanism that provides clear sound.
46094324|NCT04226651|Device|Protective glasses|Each patient was informed about the dental procedure and was provided with protective glasses. All patients were told that they were wearing these glasses to ensure a pain- and stress-free treatment, and that the dentist would devote additional attention to the treatment.
46094325|NCT04007419|Behavioral|Health Promoters and Organ Donation|Promotoras de Donación is a highly engaging and interactive online learning experience, that accommodates multiple learning styles by incorporating a variety of pedagogic approaches. The module consists of two components: a didactic educational component and a skills-based communication component. The didactic component provides basic information about organ donation and transplantation and the need for donors in the Hispanic community, and addresses concerns about donation commonly held by older Latina. The skills-based component provides instruction on the key communication skills needed to effectively engage small groups in discussions about organ donation. This component is intended to build communication self-efficacy or confidence opening the discussion about donation, addressing concerns raised by mature and older women participating in the small group sessions, and promoting the act of donor registration using persuasive, but non-coercive language.
46094326|NCT04694794|Other|Educational Brochure|Participants will be provided with Education Brochure developed by the study team to provide information to patients about managing side effects related to chemotherapy
46094327|NCT02779985|Dietary Supplement|Lycium Barbarum mixed meal|This mixed meal contains 25 grams of dried Lycium Barbarum (Goji berry, Wolfberry)
46007317|NCT00573482|Behavioral|REDE|"The intervention group received the education in REDE techniques.~The intervention in this study comprised four components:~Four group education sessions to introduce the REDE principles of eating;~Approximately 10 new lower energy-dense foods were introduced in the employee cafeteria daily at lunchtime;~Food labels for all foods sold in the employee cafeteria at lunch time, which provided the energy density, calories, and macronutrient content of the prepared cafeteria foods. Prior to the intervention almost no foods had food labels.~Price reductions for lower energy density items. Both groups were exposed to the food labels and the new lower ED foods, but only the intervention group received the education sessions about how to take advantage of the new labels and cafeteria foods and only they were eligible for the price reductions."
46094328|NCT02779985|Dietary Supplement|Control mixed meal|This mixed meal does not contain Lycium Barbarum, but is matched for energy and macronutrient content
46007318|NCT00573482|Behavioral|control|The control group received no REDE intervention at all. Both groups were exposed to the food labels and the new lower ED foods, but the control group did not receive the education sessions.
46094329|NCT00866775|Drug|Eslicarbazepine acetate|1600 mg QD
46094330|NCT00866775|Drug|Eslicarbazepine acetate|1200 mg QD
46094331|NCT02777411|Biological|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
46094332|NCT02777411|Biological|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
46094333|NCT02777411|Biological|EV71 vaccine ([2 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
46094334|NCT02777411|Biological|EV71 vaccine (2 μg total protein per dose)|Two vaccinations at 28 days apart
46094335|NCT02777411|Biological|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
45459892|NCT03482596|Behavioral|Reducing/breaking prolonged sitting|"The participants will be encouraged to reduce prolonged sitting by at least 60 minutes per day by introducing light upright movement breaks spread throughout their day. The frequency and duration of these breaks will be tailored to each participant to suit their individual circumstances.~The intervention will involve education regarding the health implications of prolonged sitting, personalised goal setting, behavioural feedback and self-monitoring of behaviour."
46094336|NCT02777411|Biological|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
46094337|NCT02777411|Biological|EV71 vaccine (1 μg total protein per dose)|Two vaccinations at 28 days apart
46094338|NCT05279287|Other|Video and kinematic data recording of minimally invasive surgical procedure|Analysis of video and kinematic data through validated methodology in order to analyse technical performance and errors enacted intraoperatively.
45459893|NCT03722862|Dietary Supplement|Low fiber|Partially hydrolyzed guar gum (PHGG) commercially available as Sunfiber in 3 gram doses
45836665|NCT02405676|Drug|Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone|Ifosphamide 1.2g/m2, D1~5; Etoposide, 100mg/m2, D3~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1,8;
45836666|NCT02405676|Drug|Rituximab|375mg/m2, 4 injections for patients in Risk group4; D0 of Protocol AA or BB;
45836667|NCT02056704|Device|Angiography with IVUS|The use of IVUS to evaluate dialysis access failure.
45836668|NCT05287230|Behavioral|CoSHA (Coping with childhood Sexual Abuse, HIV, and Aging)|Investigators will use concepts from the LIFT and REFLECT interventions.
45836669|NCT05287230|Behavioral|Control|Participants will watch HIV and health related videos and discuss how it is related to aging with HIV.
45836670|NCT05287152|Device|titanium tacks or pins|using tacks or pins made of titanium 2.5 mm diameter and 4mm length for free gingival graft fixation.
45836671|NCT05286840|Diagnostic Test|64Cu-SAR-bisPSMA|Diagnostic PET/CT imaging agent targeted for Prostate Specific Membrane Antigen (PSMA)
46094339|NCT02536820|Behavioral|psychoneuroimmune therapy|
46007319|NCT02883829|Behavioral|Peer-Based Web-Based Health Information|The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a peer-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
46007320|NCT02883829|Behavioral|Provider-Based Web-Based Health Information|The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a provider-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
46007321|NCT03450720|Drug|GLPG2737 single dose|GLPG2737 oral suspension, single dose
46094340|NCT02536820|Drug|Conventional treatment|Actual diabetes treatment in each participant
46094341|NCT02777489|Drug|Perindopril|Perindopril Bluepharma 8 mg tablets, daily, during approximately 12 weeks
46094342|NCT02660762|Drug|Vincristine|induction therapy I：1.4 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 1)：1.4 mg/m2 IV d1, 8, 15, 22； Maintenance therapy: 1.4 mg/m2 intravenously every 3 months for a total of 2.5 years
46094343|NCT02660762|Drug|Daunorubicin|induction therapy I：60 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 3)：25 mg/m2 IV d1, 8, 15, 22；
46094344|NCT02660762|Drug|Pegaspargase|induction therapy I: 2500U/m2,im,d8,22 Intensification therapy:2500U/m2 im, d2,23 consolidation therapy(Cycle 2，4)：2500U/m2 im, d1
46007322|NCT04310878|Other|Survey among perioperative nurses and surgeons|Online survey
46094345|NCT02660762|Drug|Prednisone|induction therapy I：60 mg/m2 PO d1-28; Maintenance therapy:prednisone 60 mg/m2 orally for 5 days every 3 months for a total of 2.5 years
46094346|NCT02660762|Drug|Intrathecal Methotrexate|induction therapy I：12.5 mg IT d15 induction therapy II：12.5 mg IT d1, 8, 15, 22
46094347|NCT02660762|Drug|Cyclophosphamide|induction therapy II:650 mg/m2 IV d1, 15, 29 consolidation therapy(Cycle 3)：650 mg/m2 IV，d29
46094348|NCT02660762|Drug|Cytarabine|induction therapy II:75 mg/m2 IV d1-4, 8-11, 15-18, 22-25 consolidation therapy(Cycle 1，2，4)：75 mg/m2 intravenously on days 1 to 5 consolidation therapy(Cycle 3):75 mg/m2 intravenously on days 31 to 34 and 38 to 41
46007323|NCT01139008|Drug|metronidazole 1% gel|Apply topically on one side of the face once daily for three weeks
46007324|NCT01139008|Drug|azelaic acid 15% gel|Apply topically on the opposite side of the face twice daily for three weeks
46007325|NCT03450681|Procedure|Pulsed radiofrequency of the saphenous nerve before knee replacement surgery|A trained anesthesiologist and pain clinician performs ultrasound guided pulsed radiofrequency on the saphenous nerve of a patient undergoing knee replacement surgery, prior to the beginning of the surgical act.
46094349|NCT02660762|Drug|6-Mercaptopurine|induction therapy II:60 mg/m2 PO d1-28 Maintenance therapy:75 mg/m2 orally each day for a total of 2.5 years
46094350|NCT02660762|Drug|Methotrexate|Intensification therapy:3 g/m2 intravenously given on days 1, 8, and 22 Maintenance therapy:20 mg/m2 orally or intravenously once a week for a total of 2.5 years.
46094351|NCT02660762|Drug|Etoposide|consolidation therapy(Cycle 1，2，4)：100 mg/m2 intravenously on days 1 to 5
46094352|NCT02660762|Drug|dexamethasone|consolidation therapy(Cycle 1)：10mg/m2 orally on days 1 to 28
46094353|NCT02660762|Drug|thioguanine|consolidation therapy(Cycle 3): 60 mg/m2 orally on days 29 to 42
46094354|NCT02660762|Drug|intrathecal cytarabine|50 mg intrathecal cytarabine was given on 4 occasions 3 months apart during maintenance therapy.
46094355|NCT05021471|Other|biofeedback|Twenty nine (29) patients will be treated stretching of hamstring with pressure biofeedback.
46094356|NCT05021471|Other|hamstrings stretching|Twenty nine (29) patients will be treated stretching of hamstring without pressure biofeedback.
46094357|NCT02552836|Behavioral|Interpersonal Psychotherapy|A 12-week intervention that focuses on resolving interpersonal stressors that are linked to the onset, maintenance or exacerbation of depressive symptoms
46094358|NCT02552836|Behavioral|Supportive Psychotherapy|A 12-week intervention that focuses on non-specific factors that contribute to therapy outcome
46094359|NCT00982813|Other|Periodontal screening|"Periodontal screening in all patients giving birth between 24 and 37 gestational weeks.~Bacteriological sampling in the periodontal pocketing. Search for specific cytokines in the periodontal pocketing. Professional prophylaxis and oral hygiene instruction."
45459894|NCT03722862|Dietary Supplement|Placebo|Participants will receive the placebo/dextrose.
46007326|NCT03450681|Procedure|Mock incision|A trained anesthesiologist and pain clinician performs a mock incision on the pulsed radiofrequency needle insertion site
46007327|NCT00573560|Device|VPD Implant System|Percutaneous introduction using standard catheterization techniques of the VPD Implant.
46094360|NCT04897906|Behavioral|Education Group|Mother care, newborn care and breastfeeding education will be provided to pregnant women in the third trimester of pregnancy.
46007328|NCT03450642|Other|Observational|Complement cascade components C3, C4, iC3b and TCC serum concentrations were measured over the time course from t= admission, 4,8,12,23,47,71 hours or until discharge.
46094361|NCT02660684|Drug|Prograf|Injection or oral
46094362|NCT02660684|Drug|Methotrexate|Injection
46094363|NCT02660684|Drug|Cyclosporine|Injection or oral
46094364|NCT00982891|Drug|Opioid (morphine sulphate) in low dose|individualized titration
46007329|NCT00573599|Drug|prochlorperazine and benadryl IV|prochlorperazine and benadryl IV, saline subQ
46094365|NCT05021003|Other|pressure biofeedback|: Core stabilization training with pressure biofeedback unit
46094366|NCT05021003|Other|core stabilization exercises|: Core stabilization training without pressure biofeedback unit
46094367|NCT02615223|Procedure|cryoablation|Cryoablation therapy
46094368|NCT02615223|Drug|Bicalutamide|bicalutamide
46094369|NCT02615223|Drug|luteinizing-hormone releasing-hormone (LHRH) agonist|luteinizing-hormone releasing-hormone (LHRH) agonist
46094370|NCT00978835|Behavioral|Tailored telephone-based case management|Telephone calls by a nurse every two months to assess adherence to diet, physical activity, and pill-taking regimens. The nurse will then identify barriers to adherence to these recommendations and use motivational interviewing approaches to offer solutions to the barriers identified. No changes to medication are made.
46007330|NCT00573599|Drug|Imitrex SubQ, saline IV|Imitrex SubQ, saline IV
46007331|NCT04572516|Drug|BTX A Topical|In group A (topical group) ,topical application in the form of merocel soaked with 20 units of BTX_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.
46007332|NCT04572516|Drug|BTX A Injection|In group B (injected group), 20 units of BTX_A(2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .
46007333|NCT00573638|Device|Xal-Ease device to be used with Xalatan eye drops|This intervention is a drop instillation guide to be used in conjunction with the FDA approved Xalatan eye drop.
46007334|NCT01138657|Biological|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by a 40 mg dose eow starting at Week 1.
46007335|NCT01138657|Drug|Prednisone|Administered orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all participants continuing in the study were to discontinue prednisone no later than Week 15.
46007336|NCT01138657|Drug|Placebo|Administered by subcutaneous injection
46007337|NCT04572282|Device|Mentora app|Remote monitoring mobile app
46007338|NCT01138501|Drug|turoctocog alfa|Subjects will be treated 3 times per week or every second day with intravenous injections of turoctocog alfa. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
46007339|NCT01138501|Drug|turoctocog alfa|Subjects will undergo half-life evaluation of their current factor VIII product and pharmacokinetic session with turoctocog alfa before entering preventive treatment (subjects with available evaluation of terminal half-life within the last year are to be excluded from receiving factor VIII). Intravenous injections. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
46094371|NCT00978835|Behavioral|Nurse Education|Didactic, non-interactive education by a nurse on general health topics. Calls are made every two months.
46094372|NCT05017805|Biological|COVID-19 Vaccines|One dose (0.5 mL) of coronavirus vaccine was inoculated on day 0 and day 25±3, respectively.
46094373|NCT04132557|Drug|Methylphenidate|Methylphenidate is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three United States (US) health care databases and one US electronic health record database.
46094374|NCT04132557|Drug|Lisdexamfetamine|Lisdexamfetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three US health care databases and one US electronic health record database.
46094375|NCT04132557|Drug|Atomoxetine|Atomoxetine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
46094376|NCT04132557|Drug|Amphetamine|Amphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
46007340|NCT02883361|Behavioral|Motivational enhancement therapy|Counseling meant to enhance motivation and decrease ambivalence about change, including asking open-ended questions, eliciting change-talk, and identifying discrepancies between current behaviour and valued behaviour
46007341|NCT02883361|Behavioral|Attention Control|Having participants come into the lab and fill out questionnaires with a researcher in-person
46094377|NCT04132557|Drug|Dextroamphetamine|Dextroamphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
46007342|NCT04579835|Other|External Cephalic Version|External Cephalic Version Twin A
46094378|NCT00978913|Biological|DC vaccine|DC vaccination, one vaccine biweekly
46007343|NCT04572360|Other|Cardiorespiratory Exercise|Each exercise session (40-60 minutes) will include warm-up, aerobic training, resistance training, cool-down, as well as inspiratory muscle training
46007344|NCT04572360|Other|Modified Bai He Gu Jin Tang|The Chinese herbal formula of Modified Bai He Gu Jin Tang will be prescribed in granules. A dose of 10g a day (5g, b.i.d) will be ingested. Patients will dissolve a sachet of granules (5.0g) in 200ml of hot water, twice a day after breakfast and dinner, seven days a week for three months.
46007345|NCT01138150|Drug|Treximet|One tablet of sumatriptan 85 mg and naproxen sodium 500 mg will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
46094379|NCT03265210|Behavioral|RELIEF|A 9-week behavioral intervention for primary care designed to reduce depression and pain-related disability.
45459895|NCT03722862|Dietary Supplement|High fiber|Partially hydrolyzed guar gum (PHGG) commercially available as Sunfiber in 6 gram doses
45459896|NCT05179850|Diagnostic Test|Radiomic Algorithm|Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.
45459897|NCT03131518|Behavioral|Access to an e-bicycle with trailer|Participants will be provided with an e-bike with trailer for 3 months.
45459898|NCT03131518|Behavioral|Access to a longtail bicycle|Participants will be provided with a longtail bike for 3 months.
45459899|NCT03131518|Behavioral|Access to a traditional bike with trailer|Participants will be provided with a traditional bicycle with trailer for 3 months.
45459900|NCT03720444|Other|MDT (mechanical diagnosis and therapy) method|The intervention consists of a first session to carry out an assessment, followed by 4 reassessment sessions
45459901|NCT01898312|Drug|Mifepristone|Randomised controlled trial of Mifepristone and placebo comparator Triobe
45459902|NCT03482518|Other|custom slippers with perforated synthetic leather cover.|the intervention group volunteers will receive a pair of custom slippers with perforated synthetic leather cover.
46007346|NCT01138150|Drug|Placebo|One tablet of a sugar pill will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
46007347|NCT00573911|Procedure|Endoscopy and pH study|endoscopy and PH study done one time
46007348|NCT01138111|Drug|Florbetaben (BAY94-9172)|single 300 megabecquerel (MBq) intravenous injection 2 mL to 10 mL, at baseline, at 12 and 24 months
46007349|NCT00586092|Drug|bevacizumab, ABT-510|"Stage 1 (Cohorts -1, 2, 2, 3) ABT-510: 25, 50, 50, 100 mg SC BID*, bevacizumab: 5, 5, 10, 10 mg/kg IV every 14 days*~Stage 2 (RPTD) ABT-510: X mg SC BID**, bevacizumab: Y mg/kg IV every 14 days**~Stage I is the dose escalation stage. Stage II will include an additional 20 patients (10 patients in each group) enrolled at the RPTD in two different schedules to better assess safety and biomarker correlates.~*Both agents begin on Day 1 of Cycle 1.~**At the RPTD, ½ the patients will begin ABT-510 (Dose X) on Day 1 and bevacizumab (Dose Y) on Day 15 and the other ½ of the patients will begin bevacizumab on Day 1 and ABT-510 on Day 15. This will allow for a collection of some preliminary data of wound angiogenesis effects of ABT-510 alone versus the combination and bevacizumab alone versus the combination."
46094380|NCT04227509|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
46094381|NCT04227509|Drug|placebo|normal saline will be administered as a 30 minute IV infusion every 3 weeks.
46094382|NCT00979225|Other|Medication Management report|Patients receive medication management reports delivered to their clinic-based caregivers for pharmacotherapy clinical decision support at point-of-care.
46094383|NCT00979225|Other|Care manager email notices|Community-based care managers receive email notices if the patient has not seen his/her primary care provider in the past 6 months, has low adherence to medications, and has no scheduled appointment.
46094384|NCT00979381|Biological|influenza vaccine|influenza vaccination
46094385|NCT03229876|Biological|CD19-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
46094386|NCT04915937|Other|Study Infant Formula|RTF milk-based infant formula with oligosaccharides
46094387|NCT03223090|Behavioral|Tool-use|Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)
46094388|NCT03223090|Behavioral|Hand|Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
46094389|NCT04832503|Behavioral|PROMPT- treatment|PROMPTs for Restructuring Oral Muscolar Phonetic Targets
46094390|NCT04832503|Behavioral|LNSOM-treatment|Language Non-Speech Oral Motor Treatment
46094391|NCT02778503|Other|High Cost|Surfaces allocated to this group will be treated with a high-cost glass ionomer cement restoration (Fuji IX, GC America, USA), according to the manufacturer's instructions.
46094392|NCT02778503|Other|Low Cost|Surfaces allocated to this group will be treated with a low-cost glass ionomer cement restoration (Maxxion R, FGM, BRA), according to the manufacturer's instructions.
46007350|NCT01137955|Drug|Rifaximin|Rifaximin 400mg orally three times a day for 10 days total
46007351|NCT01137955|Drug|Placebo|Placebo orally three times a day for 10 days total
46007352|NCT00573950|Drug|cilostazol|50 mg two times a day for 2 weeks and then 100mg two times a day for 6 weeks
46094393|NCT03219502|Other|Best Practice|Receive standard of care
46094394|NCT03219502|Other|Quality-of-Life Assessment|Ancillary studies
46094395|NCT03219502|Other|Questionnaire Administration|Ancillary studies
46094396|NCT03219502|Procedure|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
46007353|NCT00573950|Drug|Placebo|Placebo tablet comparable to 50mg cilostazol two times a day for 2 weeks and then placebo tablet comparable to 100mg cilostazol two times a day for 6 weeks
46007354|NCT03452748|Device|FTIR spectroscopy|FTIR spectroscopy examines collagen fibers in the excised membranes
46007355|NCT03452670|Behavioral|Active Group|Participants will be provided with a contemplative well-being application (CWA) which will facilitate meditation for 10 minutes daily during the 8 week study period.
46007356|NCT03452670|Other|Waitlist Group|The waitlist group will be maintained as a control group throughout all assessments and will be provided enrollment in CWA at the end of the 8 week study period.
46094397|NCT03219502|Procedure|Sham Intervention|Undergo sham rTMS
46094398|NCT00984607|Procedure|barium sulfate tablet|After a standard upper GI evaluation, oral administration of a standard 13 mm barium sulfate tablet was performed and swallowed with dilute liquid barium during fluoroscopic monitoring. A spot radiograph was obtained once the barium tablet was in the gastric pouch and the dilute liquid barium was passing through the gastric band stoma.
46094399|NCT02778659|Drug|Zolpidem|The hypnotic will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
46094400|NCT02778659|Drug|Placebo|The placebo will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
46094401|NCT04072900|Drug|Peptide|4 x 3 mg all the peptides given on days 84，87，91，98，105，133，and 161
46094402|NCT04072900|Drug|Anti-PD-1|3mg/kg, ivgtt, Q2w
46094403|NCT04072900|Drug|rhGM-CSF|3μg/kg given on Days 81，82，83，95，96，97，102，103，104，130，131，132，158，159，and 160
46094404|NCT04072900|Drug|Imiquimod 5% Topical Cream|topical application on the injection site 6 hours before each NeoAntigen peptides injection
46094405|NCT05092607|Diagnostic Test|Venous and Capillary blood sampling|"Venous sample at the bend of the elbow (7mL) taken immediately after the nasopharyngeal sample.~Capillary blood sampling, for patients included in participating centers"
46007357|NCT00574106|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength)
46037796|NCT02780986|Behavioral|Heterosexual men intervention group|"This will be delivered via 3 main activities:~Edutainment in the form of talk-shows based on 6 themes of sexual well-being and safe sex, held in the EE setting hosted by a famous female local comedian.~Web portal named THINK: This contains educational materials based on 6 themes of sexual health and safe sex, HIV risk profiling tool to calculate the risk of contracting HIV, videos on true life experiences of heterosexual men engaging in high risk sexual behaviour and another video on exit strategies to avoid casual or paid sex, online support for STI testing services and consultation with a clinical sexologist.~Public education event/photo booth: i. Distribution of pamphlets and brochures on sexual well-being and safe sex ii. Interactions with health promoters iii. Photo taking on safe sex messages iv. Free access to condoms and lubricants"
46007358|NCT03450564|Behavioral|Women Education|This intervention intends to provide health education message for women enhance FP utilization in pastoralist community. It was cognizant that, Ethiopia is the second most populous country in Africa. And there is a great discrepancy between contraceptive use, unmet need for FP and maternal and child morbidity and mortality between the pastoralist and agrarian community. Pastoralist community in the country expressed as low contraceptive users, a high unmet need for FP and highest maternal and child morbidity and mortality. The previous study indicates that only 5.4% of the women use contraceptive. The most common reason mentioned for not using of contraceptive are lack of awareness, demand for a large number of children and male dominance in all decision making power in general and FP in particular. In light of this, the study hypothesized that working with men and educating women towards the use of FP could enhance the use of family planning utilization.
46007359|NCT03450564|Behavioral|Male Involvement|Male involvement was a feature of intervention in this arm. Comprehensive health education about FP was given in addition to the video message about FP. In pastoralist community the most reason mentioned for not using of FP are husband objection and religion influence. And most of the decisions are in the palm of husband to seek care for reproductive, maternal and neonatal health in general and FP in particular. Besides, the pastoralist community manifested by high total fertility rate and maternal and child morbidity and mortality.
46007360|NCT03450564|Other|Control group|The third group in this community based intervention was following the community without provision of male iand married women education. In this group there was no intervention by the researchers. However, the activities performed by the government about family planning provision was maintained.
46007361|NCT00574223|Drug|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 8 visits
46007362|NCT00574223|Drug|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 8 visits
46007363|NCT03450525|Other|No intervention|No intervention
46094406|NCT04072666|Behavioral|Attempted Suicide Short Intervention Program (ASSIP)|The first session is based on a narrative interview with the consumer relating the personal story of how the point of attempting suicide was reached, videorecorded with consent. The second session involves the therapist and consumer watching the session together to reactivate the consumer's mental state during the crisis in a safe environment. Automatic thoughts, emotions, psychological pain and stress, and contingent behaviour are discussed. A psycho-educative handout is given to consumers. The third session involves discussing the handout. A credit card size leaflet is provided, with long term goals, individual warning signs and safety strategies listed, in addition to a card with crisis phone numbers. The sessions are followed by letters sent over 24 months (Michel, Valach & Gysin-Maillart, 2017).
46007364|NCT00586131|Drug|ammonium chloride or sodium citrate/citric acid|Dose dictated by changes in pH
46007365|NCT00586131|Drug|Sodium citrate/citratic acid|dictated by pH
46094407|NCT04072666|Behavioral|Cognitive Behavioural Therapy (CBT)|The intervention incorporates skills development and emphasises internal self-management. Therapy focuses on the identification of internal, external and/or thematic triggers for suicidal thinking and behaviours, as well as factors that maintain the desire to suicide, using thought records and/or chain analyses. Therapy aims to challenge distortions and misconceptions, including core beliefs that interfere with the motivation to initiate the process of problem solving and distress tolerance, by working on acceptance of emotional and/or physical pain. The final phase of treatment focuses on relapse prevention. CBT can challenge maladaptive beliefs, improve problem solving skills and social competence.
46094408|NCT04072666|Behavioral|Suicide Prevention Pathway (SPP)|The standardised care approach involves a Suicide Prevention Pathway (SPP) modelled on the Zero Suicide Framework, utilising comprehensive chronological assessment of suicide events (CASE) (Shea, 2009) to elicit suicidal intent, the prevention orientated risk formulation (Pisani, Murrie, & Silverman, 2016), brief interventions conducted with the consumer during their initial assessment prior to the treatment setting (Stanley et al., 2016), Safety Planning Intervention, Counselling on Access to Lethal Means (CALM), brief patient/carer information, rapid, structured follow up, safe transitions of care and caring contacts (Fleischmann et al., 2008). The SPP is supported by a blended learning course with online and face-to-face training for staff.
46094409|NCT04832113|Other|Adapted Physical Activity and Dietetic|session in addtion conventional management dietetic, hydratation and physical activity
46094410|NCT04832113|Other|conventional management|Dietary and hydratation advices according to the recommendations
46094411|NCT00984763|Biological|AMA1-C1/Alhydrogel® + CPG 7909|A 0.55 mL dose of AMA1-C1/Alhydrogel® + CPG 7909 (corresponds to 80 µg of AMA1-C1 and 564 µg of CPG 7909)
46094412|NCT03919474|Diagnostic Test|microvascular markers|follow up of microvascular biomarkers during patient follow up
46094413|NCT00984841|Other|Tailored letter|
46007366|NCT00574301|Procedure|Percutaneous Removal and Margin Ablation|Patients with a diagnosis of unicentric invasive breast cancer diagnosed by IVEB will then be assigned to the next available surgery date. On that day, the patient's axillary staging will be done, followed by ablation of the biopsy cavity using RFA. The breast surgery may include lumpectomy (which will be directed with US-guidance to assure more accurate removal of the en bloc IVEB site and the margin zone of ablation) or simple mastectomy with or without reconstruction. The tissue specimen will be sent immediately from the operating room to Pathology for routine processing.
46094414|NCT02578108|Procedure|genicular nerve diagnostic block with lidocaine (local anesthetic)|sensory denervation of the knee joint
46094415|NCT02578108|Procedure|genicular nerve radiofrequency ablation|Ablation of the genicular nerves of the knee by radiofrequency energy
46007367|NCT00574379|Drug|Bilastine|Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets
46007368|NCT00574379|Drug|Placebo|Placebo tablets twice daily for 14 days
46007369|NCT03450408|Procedure|Method of placement of Foley bulb transcervical dilator|This trial will assess two methods used to place a Foley bulb transcervical dilator.
46007370|NCT00574418|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes during each session.
46094416|NCT02776163|Drug|Cisplatin|Cisplatin 80mg/m^2，D1-3，2 cycles
46094417|NCT02776163|Drug|Docetaxel|Docetaxel 70mg/m^2，D1，2 cycles
46007371|NCT00574457|Other|Carotid Ultrasound|All subjects that meet the inclusion criteria at each certified site will be invited to participate and go through the same intervention (questionaire-scan-post scan questionaire and 1 month follow up questionaire)
46094418|NCT02776163|Radiation|Intensity-modulated radiotherapy|a total dose of 60-66Gy in 30-32 fractions over 6-7 weeks
46094419|NCT00984919|Other|high performance liquid chromatography|
46007372|NCT00586287|Other|Algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm A published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
46007373|NCT00586287|Other|algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm B published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
46007374|NCT00586287|Drug|Phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according to the discretion of the treating physician
46007375|NCT03450330|Drug|AZD4205|Daily dose of AZD4205, followed by daily dose of AZD4205 and Osimertinib 80 mg. Starting dose of AZD4205 at 75 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of AZD4205, and in combination with Osimertinib 80 mg.
46007376|NCT00574574|Dietary Supplement|anthocyanin|500mg/d of anthocyanin each day for 12 weeks (84days). Route of administration: oral capsules, 4 X 250mg capsules (125mg anthocyanin/ capsule). Dosage advice; 2 capsules to be taken with food, twice per day (n=4 in total).
46094420|NCT00984919|Other|laboratory biomarker analysis|
46094421|NCT00984919|Other|mass spectrometry|
46094422|NCT02578030|Drug|SHP465 12.5mg|
46094423|NCT02578030|Drug|SHP465 25mg|
46094424|NCT04177589|Other|Incidence of Delirium in Inpatient Elderly Patients|Study design: prospective cohort study.
46007377|NCT03450291|Other|Volatility task|Participants complete a volatility task, with pupillometry; and a Wisconsin Card Sort Task.
46007378|NCT04579562|Other|No intervention|This is observational, non-interventional study
46094425|NCT05325346|Drug|VLX-1005|Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
46094426|NCT05325346|Drug|Argatroban|Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
45459903|NCT02724319|Device|SpartanRX|A buccal swap genetic sample will be collected from eligible patients who provide written informed consent for CYP2C19 testing. Genotyping will be performed by the SpartanRX system as a clinical test at the UF Health Pathology Laboratory in Jacksonville.
45599014|NCT04047563|Drug|PMZ-1620 (sovateltide) along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
46094427|NCT00984997|Procedure|Surgery|Segmentectomy or lobectomy with en bloc resection of the involved chest.
46094428|NCT00984997|Radiation|Chest Irradiation|Radiation therapy consists of 60 Gy in 50 fractions for negative margins, or 64.8 Gy in 54 fractions for positive margins, at 1.2 Gy per fraction, 2 fractions per day, 5 days per week.
45599015|NCT02353143|Drug|MEN1112|"Intravenous infusion of MEN1112 pro/Kg body weight dose will be administered for two 21-day cycles; MEN1112 dose is administered as' one shot infusion' (first group of patients) and as a dose to be infused in 3 days for the first two doses in Cycle 1 (second group of patients).~Two treatment cycles will be followed by a 4-week End of Treatment Period and a Follow-up period. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration)."
45599016|NCT03518515|Other|White potato (french fries)|If randomized to this group, participants will be asked to consume 1 serving of French fries (~300 kcal) each day for 30 days as a part of their usual dietary intake. French fries will be portioned and provided to participants.
46094429|NCT00984997|Drug|Cisplatin|50 mg/M^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29.
46094430|NCT00984997|Drug|Etoposide|given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29.
46094431|NCT00984997|Radiation|Prophylactic Cranial Irradiation|25 Gy in 10 fractions of 2.5 Gy, 1 fraction per day, will be given at the completion of chest irradiation, and is optional.
46094432|NCT05673616|Other|Mckenzie Extension Exercises|"After two weeks of initial consultation, the patient will be taught to perform slouch-overcorrect on day 1 followed by flexion on day 2 in lying position and accompanied by flexion for 5 days in sitting position and finally flexion in standing will be performed.~The exercises will be repeated for 10 times and followed by extension in standing exercises."
46094433|NCT02777645|Other|Growth, feeding evaluation|Z-scores of the nutritional indicators were calculated. The dietary assessment was performed by using the 24-hour recall method. The Behavioural Paediatrics Feeding Assessment Scale (BPFAS) was used to assess both frequencies of negative feeding behaviours and parents' problematic perceptions
46094434|NCT00973219|Drug|Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate|Peg-Interferon alfa 2a 180ug/week + Adefovir dipivoxil 10mg/day, Peg-Interferon alfa 2a 180ug/week + Tenofovir disoproxil fumarate 245mg/day
45459904|NCT03528174|Device|Artificial Pancreas Control system (APC)|This intervention is a single hormone closed loop system including a Nexus 5 smart phone, two tslim insulin pumps, a Dexcom G5 CGM and two PDT glucose sensing cannulas that together make up a new experimental, investigational device system. The algorithm included in the APC is an automated version of the Fading Memory Proportional Derivative (FMPD) insulin and glucagon control algorithm.
46094435|NCT04226573|Other|Preoperative anxiety levels|"Serums were separated from blood samples taken from all patients in the study, Using the anti-human TNF-α and IL-6 enzyme-linked immunosorbent assay (ELISA) kits in the Elisa device, the TNF-α and IL-6 cytokines will be measured to determine their concentration.~No routine blood will be drawn during the procedures. Preoperative anxiety levels will be evaluated with STAI-Continuity and STAI-Statefulness scale."
46094436|NCT04194125|Drug|177Lu-DOTATOC|Four administrations of 5,55GBq up to 7,4 GBq 177Lu-DOTATOC will be administered at 8-week intervals.
45459905|NCT03528174|Device|Pacific Diabetes Technologies CGM Insulin Infusion system|An integrated combination CGM/insulin infusion system
46007379|NCT04575168|Diagnostic Test|Spartan COVID-19 Test|A nasopharyngeal sample analyzed on the Spartan COVID-19 System.
46094437|NCT00973297|Other|Multidisciplinary falls prevention|Group education on falls risk and mobility and transfers safety; Physical therapy at the subjects' bedside consisting of balance training; Medical assessment - medications use (anxiolytics/hypnotics, neuroleptics, antihypertensives, antiarrhythmics and other vasodilators) with effort to discontinue or reduce dose when possible; orthostatic hypotension - discontinue/reduce dose of related medications; urinary frequency/incontinence - evaluation and treatment; delirium - evaluation and treatment; visual pathology - evaluation and treatment
46094438|NCT04796311|Diagnostic Test|blood samples|T cells, B cells and cytokines testing
46007380|NCT00574613|Drug|P144|Cream 0,3 ml once a day (3 months)
46094439|NCT04973891|Drug|Canagliflozin combined with metformin|"Canagliflozin, a novel glucose-lowering medication, has been shown to have positive effects on reducing body weight, blood pressure and cardiovascular events.~Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS."
46094440|NCT04973891|Drug|metformin|Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS.
46094441|NCT00983047|Drug|Nimotuzumab and Docetaxel|"The chemotherapy treatment:Docetaxel was administered every 3 weeks 75 mg/m2, efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\PR\SD. No more than 4 cycles chemotherapy was given.~Nimotuzumab treatment: Dose of 200 mg intravenous infusion per week was continued after the end of chemotherapy until disease progression or unacceptable toxicity."
46094442|NCT05268575|Other|performing endoscopy|Hemorrhoids will be treated by endoscopic sclerotherapy or endoscopic rubber band ligation or endoscopic sclerotherapy combined with rubber band ligation
46094443|NCT04193969|Diagnostic Test|Pressure pain assessment using computer controlled cuff algometry|Pressure pain sensitivity is assessed. The pressure is gradually increased and pain is rated by the participant on an electronic visual analogue pain rating scale (VAS) which is connected to the equipment. The assessment is performed on the lower leg and the upper arm. The pain free leg and the left upper arm is used in the patient group. The leg used in the control group will be chosen in a balanced manner meaning that half will receive pressure on the left leg and the other half on the right leg. The pain detection threshold (PDT), pain pressure tolerance threshold (PPT) and pressure pain intensity perceived as 6 on the VAS (VAS6) at the leg site is registered. The PDT and PPT on the arm site is registered.
46094444|NCT04193969|Diagnostic Test|Temporal summation (TS)|10 repeated inflations on the lower leg with a 1 sec interval. The pressure used at each pressure is equivalent the PPT measured at baseline. Each inflation is rated on the VAS. TS is registered as the increase pain intensity.
46094445|NCT04193969|Diagnostic Test|Conditioned pain modulation (CPM)|The cuff on the upper arm is inflated until 70% of the PPT is reached. While the pressure on the arm is kept constant the cuff on the leg is inflated. PDT, PPT and VAS6 pressure at the leg site is registered during the tonic stimulation (pressure on the left arm). The procedure on the leg is repeated within 30 seconds after the pressure is released on the arm site.
46094446|NCT04193969|Diagnostic Test|Low back pain rating scale (LBPRS-pain)|A questionnaire measuring the intensities of low back pain and leg pain currently, on average the last two weeks and the worst pain within the same period.
46094447|NCT04193969|Diagnostic Test|Oswestry Disability Index|A questionnaire measuring the disability in relation to low back pain and leg pain.
46007381|NCT00574613|Drug|placebo|Cream 0,3 ml once a day (3 months)
46094448|NCT00983125|Drug|Clonidine|"Addition of a non-labeled drug (clonidine) in one of the two arm of the study, with randomisation.~To compare the effects of a systematic addition of clonidine (150 µg added in the solution bag) in the local anesthetic solution), versus no addition, on the quality of analgesia for labour."
46007382|NCT04575363|Other|Blood sample|Blood sample
45459906|NCT05756660|Drug|Sodium Thiosulfate|This goal of this study is to evaluate the efficacy of the proposed regimens in patients with relapsed/refractory platinum pre-treated patients with Hepatoblastoma, Wilms tumor, Germ Cell Tumor (GCT), and Neuroblastoma. The patients' initial cisplatin response (hepatoblastoma) and diagnosis will determine their treatment regimen on this study.
45459907|NCT03908671|Biological|Personalized mRNA Tumor Vaccine|subcutaneous injection with personalized mRNA tumor vaccine
46007383|NCT00586365|Drug|Naproxen|500 mg Naproxen twice a day for two weeks
45459908|NCT03844828|Device|IOL implantation experimental|Mono- or bilateral implantation of trifocal toric intraocular lenses POD FT. If both eyes of the same patient qualify for the implantation of a trifocal toric lens, a bilateral implantation will be performed. If only one eye qualifies for a trifocal toric lens, the contralateral eye will be implanted with the spherical trifocal IOL POD F (both lenses: (PhysIOL, Liège, Belgium).
46007384|NCT00574652|Drug|Proleukin|3 millions IU/day from day 1 to 5 every 21 days will be carried out at W1, W3, W6, and W9)
46007385|NCT00574691|Device|7F Ensure Medical Vascular Closure Device|Vascular Closure Device
46007386|NCT03450213|Device|Pentacam|Pentacam will be used to measure the magnitude and axis orientation of anterior and posterior corneal astigmatism.
46037797|NCT01199198|Drug|Tolvaptan|Starting dose 15 mg by mouth once a day for 14 days.
46007387|NCT00574730|Drug|CHOP/Rituximab|"Six cycles of CHOP/Rituximab therapy at 21-day intervals. CHOP chemo will be administered on day 1 after rituximab.~Cyclophosphamide750mg/m2 IV, Doxorubicin 50mg/m2 IV, Vincristine 1.4mg/m2 (max 2mg) IV, Prednisone 100mg PO daily x 5 days Rituximab 375mg/m2"
46094449|NCT02465398|Procedure|Fracture Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Fracture System
46094450|NCT00988039|Drug|Aluvia + 2NRTIs|"Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily~The choice of NRTIs will be at the discretion of the managing clinician and based on the local standard of care and drug availability, taking into account patient's previous drug exposure and side effects on first-line therapy."
46094451|NCT00988039|Drug|Aluvia + raltegravir|"Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily"
46094452|NCT00988039|Drug|Aluvia monotherapy|"Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily for the first 12 weeks only"
46094453|NCT02776241|Other|water|
46007388|NCT00574730|Drug|PEG INTRON|Pegylated Interferon-alpha 2mg/kg/week for 52 weeks
46094454|NCT04896268|Device|Radiofrequency|Rafaelo's technique consists of delivering a low-temperature 4 MHz radiofrequency wave current into the haemorrhoidal vascular tissue using a large single-use needle with microfibre electrodes at the end.
46094455|NCT04896268|Device|Arterial ligation then recto-anal repair with Doppler|"The aim of arterial ligation is to de-arterialise the haemorrhoids by reducing the arterial flow of the haemorrhoidal plexuses while avoiding obstructing the venous return."
46094456|NCT05258201|Other|Strain-counterstrain|Strain-counterstrain is also used for manual Trigger Point processing. This involves identifying active TRP and then applying pressure until a ridiculous reaction occurs. The area is then positioned to reduce tension in the injured muscle and later reduce tripod pain. When the pain subsides, the tissues that are most stressed feel relaxed and there is a local decrease in the ground
46094457|NCT05258201|Other|Muscle Energy Technique|Muscle Energy Technique is a common way to achieve muscle tension release (stop) before stretching other's adductor muscles
46094458|NCT04865809|Other|Peribioma Toothpaste and Mousse|Use of Peribioma Toothpaste and Mousse for home oral care.
46094459|NCT04865809|Other|Standard toothpaste|Use of Biorepair Plus Parodontgel for home oral care
46094460|NCT04934111|Drug|LNP-nCOV saRNA-02 Vaccine|a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19
46094461|NCT04855513|Drug|Metformin|Metformin is a medication used for treatment of diabetes. In this study it will be used to explore is potential role in prevention of preeclampsia. The drug will start before 12 week of pregnancy and continue till delivery
46007389|NCT03450174|Dietary Supplement|Placebo|In control group, participants will receive only a placebo product
45459909|NCT03913429|Procedure|Infiltration|"Infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla (blockage of terminal branches of the maxillary nerve) after intubation and previous to surgical incision.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 1amp Lidocaine 2% in physiological saline (SF) 100ml"
46007390|NCT03450174|Behavioral|Formative messgaes|In this group, participants will only receive daily formative messages
46007391|NCT03450174|Dietary Supplement|Fortified product|In this group, participants will receive fortified product on alternate day up till 8 months
46007392|NCT03450174|Combination Product|Fortified product plus|In this group participants will receive fortified product on alternate day and formative messages up till 8 months
45599017|NCT03518515|Other|White potato (French fries), +seasoning|If randomized to this group, participants will be asked to consume 1 serving of French fries (~300 kcal) with added potential glycemia modifying seasoning mix each day for 30 days as a part of their usual dietary intake. French fries and seasoning will be portioned and provided to participants.
46007393|NCT00574769|Drug|RAD001, Docetaxel, Bevacizumab|"RAD001 oral, 2.5 mg daily RAD001 oral, 5mg daily~Bevacizumab infusion (IV), 15 mg/kg every 21 days~Docetaxel infusion (IV), 75 mg/m^2 every 21 days"
46094462|NCT02776319|Device|Non-invasive brain stimulation (active)|Non-invasive brain stimulation (active)
46094463|NCT02776319|Device|Non-invasive brain stimulation (sham)|Non-invasive brain stimulation (sham)
46094464|NCT00543985|Procedure|Stress Echocardiography|Echocardiography was performs prior to and within 60 seconds of completing the standard Bruce treadmill protocol.
46094465|NCT04226183|Other|pregnancy workout|"Procedure of pregnancy workout has been legalized by the Ministry of Health of Indonesia act 2014 No.97.~100 ml fresh guava juice without sugar"
46094466|NCT02775773|Drug|Tranexamic Acid|2 vials ( =1 gram) of Tranexamic Acid slow intravenous infusion administered within 5 minutes from the delivery (third stage after labor)
46094467|NCT02775773|Drug|Oxytocin|2 vials (=10 IU/International Unit) of Oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
46094468|NCT04948073|Other|Dynamic neuromuscular stabilization approach|The experimental group will follow a DNS exercise protocol based on previous procedure for a whole period of 6 weeks (three 50-min sessions per week) in addition the conventional treatment.
45836672|NCT05286606|Behavioral|Exercise and Social Groups|"Participants in the exercise program, which will include a 2-3 time a week 30-45-minute group exercise programme over a 3-month period, 2 x three months. The intervention consists of a 30-45-minute exercise programme. The exercise programme is created by the Good Boost AI based on pre-registration questions or premade sessions, these are either generic sessions with options of strength, aerobic flexibility and balance/coordination exercise with intensity adjusted according to the user's feedback.~In this program the intervention content is standardised through the Good Boost exercise program. The standard program involves all users to be registered to a single group and to log on to the group, through, zoom, and the facilitator welcomes them. The group then performs the exercise programme they would like to do guided through the app, and afterwards they all meet on a group chat and get peer support."
46007394|NCT00586443|Drug|bevacizumab, everolimus, panitumumab|"Cohort # subjects Bevacizumab Everolimus Panitumumab~3 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 3.6 mg/kg IV Q2 weeks~2 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 4.8 mg/kg IV Q2 weeks~1 3-6 10 mg/kg IV Q2 weeks 5 mg PO QD 4.8 mg/kg IV Q2 weeks~3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 4.8 mg/kg IV Q2 weeks~3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 6 mg/kg IV Q2 weeks 3a 10 RPTD* RPTD* RPTD* 3b 10 RPTD** RPTD** RPTD**~Panitumumab and RAD001 started on Day 1, bevacizumab started on Day 15. **Bevacizumab and RAD001 started on Day 1, panitumumab started on Day 15."
46094469|NCT04948073|Other|Conventional treatment|Patients from both groups will receive a conventional 6-week treatment programme (18 treatment sessions, three a week, for 30-40min duration).
46094470|NCT00983203|Other|FID 114657 ORB Preserved Ocular Emulsion|1 drop OU
46094471|NCT00983203|Other|Soothe XP Lubricant Eye Drops|1 drop OU
46094472|NCT00988195|Biological|Pegylated Recombinant Human Arginase I|Week 1 (Single Dose); Weeks 3 - 11 (Weekly Dose x 8 weeks)in 8 escalation doses
45459910|NCT03913429|Procedure|Maxillary nerve blockade|"Bilateral ultrasound-guided maxillary nerve block by suprazygomatic route after intubation and previous to surgical incision performed by the anesthesiologist.~A total of 5ml of Ropivacaine 0.37% infiltrated on each side. Together with adrenaline infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 110ml SF."
46037798|NCT01199198|Drug|Placebo|Placebo by mouth once a day for 14 days.
46094473|NCT00988195|Drug|Doxorubicin|Weeks 13-24 (once every 3 weeks)
46094474|NCT04943393|Other|nointervention|Nointervention
46094475|NCT02777099|Procedure|remote ischemic postconditioning|Remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion.The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to 200 mmHg for 5 min,and then deflating it for 5 min.Each patients in the PIPostC group will have the treatment once a day for 30 days.
46094476|NCT02777099|Procedure|sham remote ischemic postconditioning|Sham remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion. The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to the patient's actual diastolic blood pressure for 5 min,and then deflating it for 5 min.Each patients in the sham PIPostC group will have the sham treatment once a day for 30 days.
46094477|NCT00988273|Device|Confocal endomicroscopy|Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the control group will be compared to the diseased group.
46094478|NCT00988273|Device|Confocal endomicroscopy|Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the diseased group will be compared to the control.
46094479|NCT00634985|Drug|eletriptan|40 mg oral tablet for migraine attack; additional 40 mg oral tablet >2 hours from first dose if migraine reoccurred within 24 hours of achieving response
45459911|NCT03482440|Drug|Salsalate Oral Tablet|1500mg twice daily for 5 days prior to experimental testing
46094480|NCT00985387|Drug|Solifenacin|oral
46094481|NCT02776943|Biological|umbilical cord mesenchymal stem cells|
46094482|NCT02776943|Device|Hyaluronic acid|
46094483|NCT02776709|Procedure|ERCP with cholangioscopy|
46094484|NCT04006327|Other|No intervention will be provided as this study is a cross-sectional observational study.|This item is not applicable because this study is a cross-sectional observational study and no intervention will be provided to participants.
46094485|NCT04005781|Drug|Hydroxychloroquine sulphate|After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
46094486|NCT04005781|Drug|Placebo|After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
46094487|NCT02779673|Other|Yoghurt drink containing plant stanol as esters|
46094488|NCT02779673|Other|Yoghurt drink without plant stanol as esters|
46094489|NCT04654351|Drug|TAK-667|TAK-667 single SC administration
46094490|NCT00635063|Drug|AD 923|
46094491|NCT00582556|Drug|Zometa|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given 7 days prior to beginning androgen deprivation therapy
46094492|NCT00582556|Drug|zometa|GnRH analogue 3-mo depot - q3 months for 1 yr andZometa 4 mg IV over 15 min x 1, given at mo 6
46094493|NCT00582556|Drug|Zometa|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min, given monthly x 6 months, beginning in month 6.
46094494|NCT04226417|Device|Transcranial direct current stimulation|Dual/ Sham tDCS will be applied in 2 mA, 20 mins before the home-based exercise program in 3 times per week for 4 weeks (12 sessions)
46094495|NCT00983593|Behavioral|Mind-Body Bridging|16 weeks of weekly Mind-Body Bridging group treatment lasting 60-90 minutes per session.
46094496|NCT02776397|Dietary Supplement|Vitamin E|Two hundred patients will be recruited to a pilot randomized controlled trial (RCT), stratified by Hp 2-2 phenotype status (100 Hp 2-2 and 100 non-Hp 2-2), and randomly allocated in a 1:1 ratio to either vitamin E 400 IU supplementation daily for 6 months or a placebo group. The trial will determine whether vitamin E improves the aforementioned surrogate markers in the Hp phenotype strata.
46094497|NCT02776397|Other|Placebo|Placebo arm
46094498|NCT03177616|Other|Chiropractic Treatment|"The treatment plan will be customized to the patient's needs. The chiropractic interventions are summarized as follows:~posture correction/spinal stabilization exercises~soft tissue relaxation techniques~spinal manipulation (i.e. chiropractic adjustment)/mobilization~breathing and relaxing techniques~stretches, self-care~ergonomic modifications~bracing and supports"
46094499|NCT04224857|Drug|AMT-101|Single or daily dosing at doses A, B, C, D, E, F
46007395|NCT00574808|Other|Outreach Facilitation implementing elements of the Chronic Care Model|"An outreach facilitator helps the practice identify areas for improvement, set goals and targets, and agree on the processes needed to reach them in order to improve the care delivery within the practices. Each facilitator will be assigned up to 12 practice sites. The first year of program implementation will involve frequent (once every 3-4 weeks) visits to the practices. Afterwards, the intervention will move into a sustainability mode, during which the frequency of visits will decrease to one every 6-8 weeks during the second year, and one every 12-15 weeks during the third year and thereafter. After the first year of program implementation, each facilitator will be able to take on 12 new practices during the second year, while still being able to sustain contact with the previous 12 practices. Similarly, in the third year, another set of 12 practices will begin the intense phase of program implementation."
45459912|NCT03482440|Drug|Placebo Oral Tablet|Placebo oral table twice daily for 5 days prior to experimental testing
46094500|NCT04224857|Drug|Placebos|Single or daily dosing at doses A, B, C, D, E, F
46094501|NCT03167554|Other|Sham comparator|The electrolysis technique was simulated to be delivered. The guide tube of the needle contacted with the skin, located on the painful area, and the device remained switched on to simulate its functioning.
46094502|NCT03167554|Other|Experimental group 1|Percutaneous Therapeutic Electrolysis (EPTE®) with monopolar needle, 330 microamps, 1 min 20 sec.
46094503|NCT03167554|Other|Experimental group 2|Percutaneous Therapeutic Electrolysis (EPTE®) with bipolar needle, 120 microamps, 1 min 20 sec.
46094504|NCT04225949|Other|survey 1|survey with one version of depiction
46094505|NCT04225949|Other|survey 2|survey with one version of depiction
46094506|NCT00985699|Genetic|polymorphism analysis|
46094507|NCT00985699|Other|laboratory biomarker analysis|
46094508|NCT00985699|Other|pharmacogenomic studies|
46094509|NCT04946032|Other|Epidural catheter|The epidural catheter length will vary, either 4 cm or 5 cm into the epidural space.
46094510|NCT02775929|Drug|FTC-TDF PrEP|FTC-TDF PrEP for HIV-1 uninfected partners
46094511|NCT02775929|Drug|ART|ART for HIV-1 infected partners
46094512|NCT00985777|Drug|Vitamin E δ-Tocotrienol|Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The investigator (or designee) will have records of the number of participants treated within a specific cohort and will determine which treatment cohort to assign newly enrolled participants.
46094513|NCT02773121|Behavioral|Physical Activity|Trainer-guided at-home behavioral intervention
46094514|NCT01563601|Drug|Obatoclax Mesylate, Carboplatine and Etoposide|"Obatoclax Mesylate:~30 mg fixed dose;administered IV on days 1-3 every 21 days for 6 cycles. Maintenance therapy (optional and only if documented CR or PR) with obatoclax mesylate is administered at the same IV dose on days 1-3 every 21 days until disease progression or death.~Carboplatin:~Dose targeted at AUC of 5; administered IV on Day 1 only every 21 days for 6 cycles~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21days for 6 cycles"
46094515|NCT01563601|Drug|Carboplatin and Etoposide|"Carboplatin:~Dose targeted at AUC of 5 administered IV on Day 1 only every 21 days for 6 cycles.~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21 days for 6 cycles"
46094516|NCT04225637|Device|Miniscrew-Supported Maxillary Expander- Slow activation|A maxillary expander is supported on 4 palatal miniscrews. The appliance is activated slowly by turning the expansion screw once every other day to correct the transverse maxillary deficiency.
46094517|NCT04225637|Device|Miniscrew-Supported Maxillary Expander- Rapid activation|A maxillary expander is supported on 4 palatal miniscrews. The appliance is activated rapidly by turning the expansion screw twice per day to correct the transverse maxillary deficiency.
45459913|NCT05660928|Other|Multidimensional intervention|Multidimensional intervention, with mutidisciplinary approach.
46094518|NCT05325268|Procedure|Osteosynthesis|Treatment of fracture with open reduction and osteosynthesis
46094519|NCT00988507|Drug|Ferroquine (SSR97193)|"Pharmaceutical form: capsule~Route of administration: oral"
46094520|NCT00988507|Drug|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
46094521|NCT00988507|Drug|artesunate|"Pharmaceutical form: tablets~Route of administration: oral"
46094522|NCT00985855|Drug|cisplatin, vinorlebine, cetuximab|patient will receive 2 cycles of cisplatine 80 mg/m² at day 29 and day 50 more vinorelbine 15 mg/m² at day 29, day 36 and day 50 and 57 associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
45459914|NCT04638634|Biological|CSL760|An Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin
46007396|NCT03450135|Behavioral|Trier Social Stress Test|Participants will perform an acute psychosocial stress manipulation (Trier Social Stress Test) involving a speech task and challenging mental arithmetic.
46007397|NCT03450135|Behavioral|Emotional go/no-go task|Participants will perform an emotional go/no-go paradigm to examine electrophysiological (EEG) correlates of cognitive and affective processing.
46007398|NCT00574886|Biological|Id-KLH|Idiotype vaccine - .5mg recombinant idiotype immunoglobulin protein given subcutaneously for a total of five administrations over 6 months.
46007399|NCT00574925|Drug|Esomeprazole|
46007400|NCT00586560|Drug|Kareniticin and cyclophosphamide|"An accelerated titration dose escalation design will be used in this study. Dose escalation will function independently for each stratum. Patients in both strata will receive Karenitecin and cyclophosphamide administered as an IV infusion each day for 5 consecutive days. In addition, patients in Stratum 1 will receive prophylactic G-CSF starting 24 hours after completion of the fifth dose of Karenitecin and cyclophosphamide (and continuing daily until the ANC is over 1500/mm3 after nadir). The regimen will be repeated every 21 days (1 treatment cycle).~Treatment may continue for up to 20 cycles, provided there is continued evidence of clinical benefit and absence of unacceptable toxicity."
46007401|NCT00574964|Other|Gliadel Wafer, Temodar and Radiotherapy|Given concurrently starting 10-30 days after surgery.
46007402|NCT03450057|Drug|Daratumumab|"Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs~Drug: Dexamethasone~Dexamethasone will be administered at 40 mg (20 mg for patients >75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle"
46007403|NCT00575003|Drug|CYT003-QbG10|6 subcutaneous injections
46007404|NCT00586599|Other|measurement of inflammatory markers|measuring inflammatory markers and comparing to controls.
46007405|NCT03453593|Other|No intervention|No intervention
46007406|NCT03453554|Other|Digital Notebook app|Training in use of Digital Memory Notebook app
46007407|NCT03453554|Other|Smart Home Prompting|Smart-home sensor based activity-aware prompting to support digital memory notebook app use
46007408|NCT00586638|Behavioral|Video game based training|36 one-hour sessions over 12 weeks
46007409|NCT00586677|Behavioral|Parent-Child Interaction Therapy|Sixteen one hour sessions done in-home for children ages 2-7. Proceed through protocol based on mastery of predefined skills.
46007410|NCT00586677|Behavioral|Health and Safety|Sixteen one hour sessions for children age 0-7 conducted in the home. Participants are quizzed on material to determine mastery.
46007411|NCT00586677|Behavioral|Early Relationships|Sixteen one-hour sessions for children age 0-2 provided in-home.
46007412|NCT03453476|Device|SRP and Fotosan 630|After isolating the test quadrants with cotton roll, toluidine blue was applied into the deep pockets (PD ≥ 4mm) at the test quadrants for 10 seconds, followed by inserting a perio tip (15 or 21 mm depending on the depth of the pocket) that connected to a LED emitting device, and light was emitted for 20 seconds. Toluidine blue in the deep pocket was removed by injecting normal saline into the pocket.
46007413|NCT01137682|Drug|Pasireotide|"Double-blind pasireotide LAR 40 mg i.m. injection once every 28 ± 2 days for 24 weeks or~Double-blind pasireotide LAR 60 mg i.m. injection once every 28 ± 2 days for 24 weeks"
46007414|NCT01137682|Drug|octreotide LAR 30mg|In an open-label, active control arm, continue on the same treatment with octreotide LAR 30 mg every 28 ± 2 days as received for at least 6 months prior to randomization
46007415|NCT01137682|Drug|lanreotide ATG 120mg|In an open-label, active control arm, continue on the same treatment with lanreotide ATG 120 mg every 28 ± 2 days as received for at least 6 months prior to randomization
46007416|NCT03453320|Drug|Albumin solution|Infusion rate and effects
46007417|NCT00586755|Procedure|Intensive Induction-BMT|Patients will undergo an induction regimen consisting of 1 cycle of cytarabine (3 gm/m2 intravenously over 1 hour every 12 hours for 8 total doses) and mitoxantrone (10 mg/m2/d intravenously over 30 minutes daily on days 1, 2, and 3). This will be combined with Alemtuzumab (anti-CD52 antibody) for 6-8 weeks. If, after this one cycle, subjects have not had progression of disease as noted on physical exam or radiographic scans, they will proceed to stem cell mobilization with cyclophosphamide. This will be immediately followed by high dose therapy with stem cell support. Following count recovery, rituximab will be used for 8 total doses as consolidation therapy. Involved field irradiation may be given post-transplant to those with localized bulky disease as well.
46007418|NCT00575120|Other|ischemia reperfusion|reperfusion after a 15 min. lasting cuff induced arm ischemia
45459915|NCT01253473|Drug|Budesonide|Inhaled budesonide twice daily plus inhaled ipratropium/albuterol combination four times daily and every 4 hours as needed
45459916|NCT01253473|Drug|budesonide/formoterol|Inhaled budesonide/formoterol (160/4.5 mcg Symbicort®) 2 puffs twice daily plus inhaled ipratropium/albuterol (Combivent®) 1 puff four times daily
46007419|NCT03458442|Other|Simulation-based surgical training|"Those in the intervention group will be introduced to a variety of simulation-based surgical training techniques. Specifically, this will involve breaking down the SICS cataract surgery procedure into stages, and practicing each stage repeatedly using simulation. This sustained deliberate practice will be integrated into the six-week course, as an enhancement to the course, and not as a replacement of any part of the educational content. Within the last three weeks of the course, 'intervention' arm participants will be introduced to the artificial eyes, the Simulation-OSSCAR rubric, and be provided with ongoing feedback.~All participants in both intervention and control arms will undertake the six-week Orbis-COS training course."
46094523|NCT00985855|Drug|cisplatine, etoposide, cetuximab|patient will receive 2 cycles of cisplatine 50 mg/m² at day 29, 36, 57, and 64 + étoposide 50mg/m² during day 29-33, day 57-61associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
45459917|NCT01253473|Drug|Ipratropium/albuterol|Inhaled ipratropium/albuterol combination 2 puffs four times daily
46007420|NCT03458442|Other|Standard surgical training|Standard surgical training (without bespoke training scheme using simulation and model eye). All participants in both intervention and control arms will undertake the existing six-week Orbis-COS training course, which includes 2-4 weeks of didactic lectures, surgical observation, and wet lab training with a minimum of 50 pig eye wet lab simulations per trainee. After observed mastery of wet lab pig eyes, trainees then perform hands-on training in county level hospitals. The hands-on training pairs a surgeon from the training centre to mentor the trainee through a minimum of 30 assisted surgeries and 50 independent surgeries under supervision.
46094524|NCT04226105|Drug|GP40081|1 ml of the GP40081 contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70. Insulin aspart 30 mix is self-administered drug by SC injection 1-3 times per day before meal intake.
46094525|NCT04226105|Drug|NovoMix 30|1 ml of the NovoMix 30 contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70. Insulin aspart 30 mix is self-administered drug by SC injection 1-3 times per day before meal intake.
46094526|NCT00988585|Dietary Supplement|EPA 600|EPA 600 mg/day for 6 weeks
46007421|NCT03457506|Diagnostic Test|Digital PET/CT scan|The digital PET/CT scan will be acquired before or after the conventional PET/CT scan.
46007422|NCT00575198|Other|No drainage threshold|Removal of the thoracostomy tube independently of the amount of fluid that drained from the tube in the prior 24 hours
46094527|NCT00988585|Dietary Supplement|EPA 1800|1800 mg/day for 6 weeks
46094528|NCT00988585|Dietary Supplement|Olive Oil|600 mg/day for 6 weeks
46094529|NCT00988585|Dietary Supplement|DHA|600 mg/day for 6 weeks
46094530|NCT02776865|Drug|suprascapular nerve block|4ml 2% xylocaine
46007423|NCT00575198|Other|Drainage <2 mL/kg|Removal of the thoracostomy tube only if the drainage from the tube in the prior 24 hours is less than 2 mL/kg of the patient's ideal body weight
46007424|NCT00586794|Drug|Sildenafil|3x per day 20 mg TID
46007425|NCT00586794|Drug|Placebo|3x per day, 20 mg TID
46007426|NCT00575237|Procedure|Recruitment manouver|In the intervention group, CO2 was removed by means of Trendelenburg position (> 30 degrees) with 5 manual pulmonary recruitment maneuvers.
46094531|NCT02776865|Other|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
46094532|NCT04072510|Behavioral|Self-esteem group|"The intervention will comprise of 6 sessions of group self-esteem therapy which uses a cognitive behavioural approach. The therapy has been manualised into a 76 page treatment protocol and will be administered by Assistant Psychologists employed at Newbridge House receiving weekly supervision from a Clinical Psychologist. The self-esteem group is based on Melanie Fennel's cognitive behavioural model of low self-esteem addressing thoughts, feeling and behaviours. The group aims to improve self-esteem and build positivity.~The sessions are structured and laid out in the following overview:~Week 1, Session 1: What is self-esteem and an introduction to CBT Week 2, Session 2: How might low self-esteem develop? Week 3, Session 3: Negative automatic thoughts Week 4, Session 4: Challenging negative automatic thoughts Week 5, Session 5: Creating new coping strategies Week 6, Session 6: Building positivity"
46094533|NCT04072510|Behavioral|Treatment as Usual|Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist.
46094534|NCT02772653|Other|Blood Lactate|Analyzed at the 1rst, 8th and 24th hour from hospital admission
46094535|NCT02772653|Other|Blood Base Excess|Analyzed at the 1rst, 8th and 24th hour from hospital admission
46007427|NCT00586833|Procedure|O2 consumption max bike test|Single visit exercise study
46007428|NCT03453255|Drug|Chemotherapy|chidamide, decitabine, homoharringtonine, cytarabine
46007429|NCT00575354|Drug|Sevoflurane|3-6% sevoflurane inhaled for anesthesia induction, and 2-3% sevoflurane was used to maintain the anesthesia till the end of the operation.
46007430|NCT00575354|Drug|Isoflurane|3-6% isoflurane inhaled for anesthesia induction, and 2-3% isoflurane was used to maintain the anesthesia till the end of the operation.
46007431|NCT00586911|Drug|Cystadane|Betaine 20 mg a day or identical placebo for 1 year.
46094536|NCT02772653|Other|Blood B-type Natriuretic Peptide|Analyzed at the 1rst, 8th and 24th hour from hospital admission
46094537|NCT02772653|Other|Blood Thromboelastometry (ROTEM)|Analyzed at the 1rst, 8th and 24th hour from hospital admission
45836673|NCT04271670|Other|Ginger powder footbaths|20-minute footbath with 12 liters of 40°C warm water and an additive of 80g dried ginger powder (reaching up to mid-calf level)
46094538|NCT02772653|Other|Near-infrared spectroscopy|Analyzed at the 1rst, 8th and 24th hour from hospital admission
46094539|NCT02772653|Other|Sublingual videomicroscopy|Analyzed at the 1rst, 8th and 24th hour from hospital admission
46094540|NCT00542269|Drug|Amlodipine|amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
45459918|NCT01883804|Drug|Methyldopa|6 weeks of Methyldopa administration; where the dose will be increased according to safety of efficacy.
45459919|NCT01247935|Other|Acupuncture|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
45459920|NCT01247935|Other|Transcutaneous electrical stimulation|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
45459921|NCT01247935|Other|Control|Patients are monitored for pain and discomfort
45836674|NCT04271670|Other|Mustard powder footbaths|20-minute footbath with 12 liters of 40° C warm water and an additive of 80g dried mustard powder (reaching up to mid-calf level)
46007432|NCT00586911|Drug|Identical Placebo|Placebo
46094541|NCT00542269|Drug|Aliskiren|aliskiren 150-300 mg tablets. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
46094542|NCT00542269|Drug|Ramipril|ramipril 5-10 mg capsules. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
46094543|NCT02776631|Device|Pinloc|Internal fixation device
46094544|NCT02776631|Device|Hansson Pins (LIH)|Internal fixation device
46094545|NCT02579434|Drug|Midazolam I.V.|Midazolam I.V. 1mg/ml
46007433|NCT00575393|Drug|gold sodium thiomalate|
46094546|NCT00866697|Drug|Pazopanib|Pazopanib 800 mg tablet daily for 104 weeks (24 months)
46094547|NCT00866697|Drug|Placebo|Matching placebo 800 mg tablet daily, for 104 weeks (24 months).
46094548|NCT00635141|Drug|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 1 will receive hypertonic saline (7 %) during the first phase of the study and will crossover to placebo (0.9% isotonic saline) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
46094549|NCT00635141|Drug|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 2 will receive placebo (0.9% isotonic saline) during the first phase of the study and will crossover to hypertonic saline (7 %) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
46094550|NCT00985933|Drug|AZD8529|6 capsules by mouth 1 time 12 to 24 prior to assessments
46094551|NCT00985933|Drug|Placebo to match AZD8529|6 capsules by mouth 1 time 12 to 24 hours prior to assessments
46094552|NCT02767739|Behavioral|Physical, social and cultural activities|This intervention included two 60-min aerobic exercise sessions per week. Each session was supervised by a physical activity specialist and walking and stretching exercises were performed after programmed exercise sessions. PHC nurses were prepared to advise patients about the health benefits of PA and used different strategies to encourage the adherence of participants to the program. In addition, social and cultural support activities were included in this intervention program. These activities were performed once a month and they included: visits to museums and libraries, cultural exhibitions, tourist attractions and dance lessons.
46094553|NCT04073914|Behavioral|Type 1 Teamwork Program|Psychoeducational web program
46094554|NCT02767817|Procedure|Stereotactic Hematoma Evacuation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas, and then the drainage tube was pulled out.
46094555|NCT02767817|Biological|MSCs Transplantation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas,and 10 million MSCs were transplanted into the hematoma cavity before the drainage tube was pulled out.
46094556|NCT02767817|Biological|Injectable Collagen Scaffold with MSCs Transplantation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas, and injectable collagen scaffold combined with 10 million MSCs were transplanted into the hematoma cavity before the drainage tube was pulled out.
46094557|NCT00542191|Drug|Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin|DOXORUBICIN 24mg/m2 IV plus CYCLOPHOSPHAMIDE 60mg/m2 PO weekly x 12 successive weeks followed by PACLITAXEL 80mg/m2 IV over 1 hour plus CARBOPLATIN AUC 2 IV weekly x 12 successive weeks
46094558|NCT00542191|Procedure|Definitive Surgery|Standard of care definitive surgery as determined by medical provider
46094559|NCT00542191|Radiation|Radiotherapy|Standard of care RADIATION THERAPY as indicated
45459922|NCT05259592|Behavioral|Psychotherapy|Modular Patient Centred CBT (MPC) for CPTSD (Folke, Friis, Thomsen & Roitmann, 2020) is a psychotherapy treatment manual consisting of up to 32 individual therapy sessions broken down by five treatment modules (each consisting of six sessions) that directly address the symptoms of CPTSD: 1) Affect dysregulation, 2) Disturbed relationships, 3) Negative self-concept, 4) PTSD symptoms, and 5) Insomnia and trauma-related nightmares.
45459923|NCT03475810|Device|Virtual Reality|Patients will wear virtual reality glasses and start watching 3 D video after confirmation of adequate motor and sensorial block.
45459924|NCT03475810|Drug|Midazolam|1-2 mg midazolam will be administered before spinal punction performed.
46094560|NCT00600938|Drug|Core Study: Deferasirox|20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day
46094561|NCT00600938|Drug|Core Study: Deferoxamine|50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week
45836675|NCT04271670|Other|Warm water only footbaths|20-minute footbath with 12 liters of 40° C warm water without any additive (reaching up to mid-calf level)
46007434|NCT00575393|Genetic|gene expression analysis|
46094562|NCT00600938|Drug|Extension: deferoxamine to deferasirox|40 mg/kg deferasirox once daily administered 30 minutes before taking food.
46094563|NCT00600938|Drug|Extension: deferasirox to deferoxamine|DFO at a target range of 50 mg/kg/day to 60 mg/kg/day via subcutaneous (sc) infusion lasting a period of 8 to 12 hrs administered for 5 to 7 days per week,
46094564|NCT00600938|Drug|Deferasirox|
46094565|NCT00600938|Drug|Deferoxamine|
46094566|NCT03069742|Other|RealRisks|RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
46007435|NCT00575393|Other|fluorine F 18 fluorothymidine|
46007436|NCT00575393|Other|mass spectrometry|
46007437|NCT00575393|Other|pharmacological study|
46007438|NCT00575471|Drug|Rivoglitazone HCl|0.5 mg tablets once daily for 12 weeks
46007439|NCT00575471|Drug|rivoglitazone HCl|1.0 mg tablets once daily for 12 weeks
46007440|NCT00575471|Drug|rivoglitazone HCl|1.5 mg tablets once daily for 12 weeks
46007441|NCT00575471|Drug|Placebo|Matching placebo tablets once daily for 12 weeks
46037799|NCT05089708|Drug|Trifarotene Cream|Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream on the face once daily, in the evening for 24 weeks
46007442|NCT03454308|Behavioral|SMASH|Auditory and visual reminders are active on Pill device will alert subject each time their medication dose is due. Pill device will transmit dose taken time stamps to researchers. Text message the following morning with tailored motivational messages that reflect the medication dose adherence from the preceding day. Subjects will monitor their BP at home at least every third day using Bluetooth monitor linked to smartphone to transmit encrypted readings to researchers.
46007443|NCT03454308|Behavioral|Enhanced SC|Auditory and visual reminders are inactive on Pill device. Pill device will transmit dose taken times to researchers. Healthy lifestyle test messages as attention control.
46007444|NCT04579601|Procedure|ERAS program|We designed our centre's ERAS program through different measures during the preoperative, intraoperative and postoperative period. This program incluided received comprehensive multidisciplinary information, daily goals and expected discharge date, explained the expansión exercises, the video-assisted thoracoscopic surgery (VATS) under general anaesthesia combined with regional techniques, leaving only one chest tube at the end of the surgery, maintain normothermia, extubation after the end of the surgery, and early removal of the urinary catheter. From the time of extubation, the patients began oral tolerance and respiratory physiotherapy exercises. Also, the patients were allowed to walk around early.
46094567|NCT03069742|Other|BNAV|Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
46094568|NCT02767583|Device|Exams|Patients the eligibility criteria will be proposed at the first consultation in central obesity, participate in a clinical study to assess the prevalence of subclinical damage peripheral nerves by simple and painless rapid measurement of skin conductance on the palm of the feet with the Sudoscan® device during the consultation and a Thermotest®, as well as monitoring during the various follow-up consultation after any bariatric surgery or not. This monitoring will be done by the same neurophysiological tests.
46094569|NCT03061474|Drug|Nicotinamide|Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.
46094570|NCT03061474|Drug|Placebo Comparator|Oral Tablet
46094571|NCT00988663|Drug|memantine|patient will receive 5mg daily for 7day then 10 mgm daily
46094572|NCT00988663|Drug|Placebo|will give placebo that looks like memantine
46094573|NCT04224389|Procedure|transoral resection|The technique of transoral surgery will be left to the choice of the surgeon according to the equipment and the experience of the team and will be gathered. The options are: transoral surgery robot-assisted, endoscopic laser transoral surgery, transoral laser surgery classical instruments. The exact description of the resected area will be collected. of the cross-sections will be made for extemporaneous analysis if necessary in lateral margins and deep until complete excision.
46094574|NCT04224389|Radiation|IMRT|Intensity modulation radiotherapy (RCMI or IMRT) will be performed using techniques static or rotational (arctherapy, tomotherapy). Restraint is recommended with thermoformed mask
46094575|NCT02579278|Other|Blood sample (mrEMVI positive patient)|Two blood samples are taken from each patient with mrEMVI positive tumours post chemoradiotherapy. One pre-surgery and one during surgery from a peripheral vein.
46094576|NCT02579278|Other|Blood sample (mrEMVI negative patient)|
46094577|NCT04671017|Biological|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide
46094578|NCT04072198|Drug|Nivolumab|240 mg every 2 weeks for 8 cycles followed by maintenance
46094579|NCT04072198|Drug|Bevacizumab|5 mg/kg every 2 weeks for 8 cycles followed by maintenance
46094580|NCT04072198|Drug|Irinotecan|165 mg/m2 every 2 weeks for 8 cycles
46094581|NCT04072198|Drug|Oxaliplatin|85 mg/m2 every 2 weeks for 8 cycles
46094582|NCT04072198|Drug|Leucovorin|200 mg/m2 every 2 weeks for 8 cycles
46094583|NCT04072198|Drug|fluoruracil|3200mg/m2 every 2 weeks for 8 cycles
46094584|NCT02772419|Drug|benralizumab|SC administration
46094585|NCT02772419|Drug|benralizumab|SC administration
46094586|NCT02772419|Drug|Placebo|SC administration
46094587|NCT00543439|Biological|Moroctocog alfa (AF-CC)|On-demand therapy for 6 months, followed by routine prophylaxis 25 IU/kg, administered every other day for 1 year.
46094588|NCT00543439|Biological|Moroctocog alfa (AF-CC)|"Routine prophylaxis crossover:~45 IU/kg, administered 2 times a week for 1 year followed by 25 IU/kg administered every other day for 1 year, or, 25 IU/kg, administered every other day for 1 year, followed by 45 IU/kg, administered 2 times a week for 1 year."
46094589|NCT04132323|Procedure|Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy according to the randomization group
46094590|NCT02772497|Drug|Ziv aflibercept|Intravitreal ziv aflibercept 1.25 mg (0,05ml) every 4 weeks
46094591|NCT04071886|Behavioral|Mindfulness-Based Training|Mindfulness-Based Training comprises of mindful walking, body scanning and raisin meditation exercise. Participants will receive a guided session of mindfulness meditation, and will be asked to finish at least 30 minutes of Mindfulness-Based Training every day as homework as well as keep a diary describing their experiences and reflections. An expert in mindfulness practice will offer feedback and answer any questions online.
46094592|NCT04071886|Behavioral|Relaxation Training|Participants will listen to a 15-minute Relaxation Training tape twice a day.
45599018|NCT03518515|Other|Almond|If randomized to this group, participants will be asked to consume 1 serving of almonds that is calorically-matched to the French fries (~300 kcal) serving in the other arms each day for 30 days as a part of their usual dietary intake. Almonds will be portioned and provided to participants.
46094593|NCT02615379|Device|EPIFLO|Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
46094594|NCT02767349|Drug|MNK-155|2 or 3 tablets initial dose, followed by two tablets every twelve hours
45599019|NCT02345343|Drug|Apixaban|
46007445|NCT03452397|Drug|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
46007446|NCT03452397|Drug|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
46007447|NCT03452397|Drug|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)
46007448|NCT03452397|Drug|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
46007449|NCT00575549|Other|Dobutamine: Perflutren Lipid Microsphere|Dobutamine with starting dose of 10 micrograms/kg/min and increased gradually to a maximum dose of 50 micrograms/kg/min Definity will be infused continuously at a rate of 4mL/min
46007450|NCT03453684|Drug|Administration of Vancomycin|Intravenous Vancomycin Administration
46007451|NCT00575627|Drug|Peg-Interferon alpha2a plus Ribavirin|Peg-Interferon alpha2a: 180 micrograms per week Ribavirin:100-1200 mg/daily
46007452|NCT04674878|Other|METs|The isometric contraction of 7 sec will be applied followed by a stretching of 30 sec in painless range. This treatment will be given to the both sides of the neck targeting the three major accessory muscles of respiration.
46007453|NCT04674878|Other|Breathing exercise group|Three exercises will be performed in a circuit, 2 circuits in every session. It will include diaphragmatic breathing exercise in which patient will be in supine position inhaling through nose and expiration through moth with half closed lips. Second exercise pursed lip breathing also in supine position with the hands on abdomen and then inspiration through nose and expiration through mouth with half closing of lips. Third exercise resisted diaphragmatic breathing also in same pattern as second exercise with an addition of 1 kg weight on abdomen.
46007454|NCT00586989|Procedure|Upper endoscopy with biopsy|Endoscopy with biopsy 6 weeks after the initial endoscopy
46007455|NCT04674839|Drug|MS-20|fermented soymilk product
46007456|NCT04674839|Other|Placebo|No active ingredient
46094595|NCT04132167|Procedure|perturbation training|exercises for body stability in different positions (bridge, sitting, quadrupedal, half- kneeling, kneeling, standing, monopodalic) performed with visual biofeedback; transfers training performed in front of a mirror; ambulation training with courses drawn on the ground in a straight line and with more complex tracks with visual controlin particular using the protocols seated balance/strength training, standing bal- ance/weight-bearing training, mobility training and closed-chain training;
46094596|NCT02767193|Biological|DCV3|"Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus.~Patients will receive three immunizations of dendritic cells during weeks 0, 2 and 4"
46094597|NCT02767193|Biological|DCV3 with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus with PEG_INF Patients will receive three immunizations of dendritic cells during weeks 0, 2 and 4 and INF during weeks 4,5 and 6
46094598|NCT02767193|Biological|Placebo|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded Patients will receive three immunizations saline + 1% albumin during weeks 0, 2 and 4
46007457|NCT03458130|Drug|AG10|TTR stabilizer
46007458|NCT03458130|Drug|Placebo Oral Tablet|Nonactive control
46007459|NCT04674488|Biological|TILs|a single center, single-arm, open label, interventional study
46007460|NCT03459690|Behavioral|Meditation|. IK is a meditation that can be learned quickly and requires approximately 12 minutes, twice a day of practice. This regimen was chosen because of its simplicity making it an excellent way to introduce meditation to beginners. IK does not incorporate a spiritual or religious focus
46007461|NCT03459690|Device|Enobio 32- EEG machine|The ENOBIO 32 EEG device is an investigational device under US federal law which is a 24-bit EEG data reader which is a wearable wireless device
46007462|NCT04674605|Device|biomarkers|biomarkers
46007463|NCT03456219|Other|Normal protein diet|The intervention with the control diet was composed of 65% of carbohydrates, 15% of proteins and 20% of lipids.
46007464|NCT03456219|Other|High-protein diet|The intervention with the higher-protein diet was composed of 45% of carbohydrates, 35% of proteins and 20% of lipids.
46007465|NCT02277483|Drug|LAIS®|10 X 1,000 / twice a week
46007466|NCT00555854|Behavioral|An individual motivational intervention program to promote and maintain self-care behaviour|5 individual interviews in an one year period
46007467|NCT04575129|Other|No intervention will be applied|No intervention will be applied
46007468|NCT00555932|Procedure|Ultrasound|All the studies will be performed with the portable ultrasound machine used on a regular basis in the neonatal care unit.
46007469|NCT04575402|Other|Wearable Activity Monitor|Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR4 or similar model)
46007470|NCT04674332|Drug|Long acting insulin|long acting insulin analogue once daily at bed time
46007471|NCT04674332|Drug|multiple dose regimen|intermediate and short acting insulin
46007472|NCT00587145|Drug|S-1,Docetaxel|"S-1 80 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)~Docetaxel 35 mg/m2 mixed in d5w 250 ml iv over 60-min on days 1 and 8"
46007473|NCT04674449|Diagnostic Test|Disclosure of IDP results|The results of the adjunctive IDP performed at time of invasive coronary angiography are made available to the catheter laboratory clinician, to aid in the diagnostic process.
46007474|NCT04674449|Other|IDP performed but results not disclosed|The results of the IDP performed at the time of invasive coronary angiography are concealed from the catheter laboratory clinician who will be blinded. The patient is managed according to standard of care.
46007475|NCT04674176|Drug|Rifaximin|550 mg of Rifaximin 3 times a day for 12 days at the start of the diet.
46007476|NCT00199875|Drug|Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)|Patients received a single infusion of ^90Y-DOTA-cG250, with escalating doses administered to sequentially enrolled cohorts until MTD determination.
46007477|NCT04674527|Drug|Elemene|Elemene injectable emulsion will be given for 80 mg/day in each 14-day cycle.
46007478|NCT04674527|Drug|Temozolomide|Maintenance chemotherapy with TMZ will be administered at 150 mg/m2/day for 5 days in each 28-day cycle.
46007479|NCT00199836|Biological|NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51|
46007480|NCT04674293|Drug|Revelisa|Thrombolytic therapy for patients with ischemic stroke
46007481|NCT00199797|Drug|Oxaliplatin|Oxaliplatin was administered at 85 mg/m2 on day 2 of every 2 week regimen.
46007482|NCT00199797|Drug|5-Fluorouracil|The dose of 5-FU was 400 mg/m2 IV bolus followed by continuous IV infusion at 600 mg/m2 over 22 hours on day 2 and day 3 of every 2 week regimen.
46007483|NCT00199797|Drug|Leucovorin|Leucovorin was administered at a dose of 200mg/m2 on day 2 and day 3 of every 2 week regimen.
46007484|NCT00199797|Drug|huA33|huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2.
46007485|NCT04674215|Behavioral|Turning in Bed|Preoperative Turning in Bed Training
45836676|NCT04750746|Other|Control group|Conventional Therapy Passive ROM and/or AROM exercises Muscle strengthening; Therapeutics stretching of the shoulder, the elbow, the wrist, and the fingers. Activities of daily living training, including eating, grooming, dressing, toileting, and transfer
46007486|NCT04674215|Behavioral|Mobilization|Preoperative Mobilization Training
46007487|NCT04674215|Other|information|Routine Clinical Care
46007488|NCT04572087|Other|Behavioral training and verum stimulation|Cognitive control training and verum tDCS
46007489|NCT04572087|Other|Behavioral training and sham stimulation|Cognitive control training and sham tDCS
46007490|NCT04673903|Other|Copenhagen adduction exercise|The Copenhagen Adduction exercise is a simple isolated eccentric partner exercise and doesn't require special equipment and can be performed as a warm up activity on the pitch.
46007491|NCT04673903|Other|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
45836677|NCT04750746|Other|Experimental Group|Interventional therapy Xbox Kinect (Xbox 360, Microsoft,) For training, programs such as Boxing and Bowling in the Kinect sports pack and Rally Ball, 20,000 Leaks, and Space Pop in the Kinect adventure pack, all of which required the use of the upper extremities, will be selected
45836678|NCT04750668|Other|Multisensory Balance Training|Multisensory Balance training includes 30 minutes per day, 5 days a week for 4 weeks, using visual, proprioceptive, and vestibular manipulations. The exercises involved movements of the eye, head, and body to stimulate the vestibular system, postural control exercises in different positions (feet together, tandem stance, and one leg stance), use of a soft surface to reduce the proprioceptive inputs, and exercises with closed eyes to deprive them of visual cues.
45836679|NCT04750590|Procedure|en bloc resection, morcellation|Laser en bloc resection with subsequent tumor morcellation will be performed. This tissue will be sent for histology in order to estimate the histological subtype and differentiation grade. Next stage laser resection of the tumor basis will be performed with subsequent histology to determine the depth of invasion and the status of surgical margin.
46007492|NCT01137604|Drug|Lenvatinib|24 mg lenvatinib capsules orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
46007493|NCT01137604|Drug|Bevacizumab|Bevacizumab 10 mg/kg administered intravenously every 2 weeks in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
46007494|NCT00637351|Procedure|Blood sample|One blood sample will be collected at the time of screening for subjects
46007495|NCT00637351|Procedure|Urine sample|One urine sample will be collected at the time of screening for subjects
46007496|NCT03454919|Drug|Palbociclib|"Drug: palbociclib; ibrance; Pfizer Inc，New York，NY Schedule: Recommended initial dosage 125mg/d，3 weeks on, 1 week off. If grade 3 or 4 adverse events occur during treatment，dosage could be reduced to 100mg/d, even 75mg/d.~Duration: till disease progression or drug intolerance."
46007497|NCT05218213|Other|No intervention|"Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~Dual-task walking with the auditory stroop task.~Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~Navigational and dual-task walking (condition 1 and 2 together)"
46007498|NCT00198822|Dietary Supplement|Vitamin A or Beta-Carotene Supplements|weekly dosage of either 7000 µg retinol equivalents as preformed vitamin A or 42 mg of beta-carotene from 1st trimester of pregnancy through 12 weeks after termination of pregnancy
46007499|NCT04674059|Other|patient survey|A questionnaire will be delivered by the health care providers at Ndera Hospital, Kigali, Rwanda or CHUK, Hospital, Kigali, Rwanda. The questions will explore the patient's clinical characteristics, the current treatment and their experience with the mental health care system.
46094599|NCT02767193|Biological|Placebo with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded with PEG_INF Patients will receive three immunizations saline + 1% albumin during weeks 0, 2 and 4 and INF during weeks 4,5 and 6.
46094600|NCT00986011|Other|questionnaire administration|
46094601|NCT00986011|Other|study of socioeconomic and demographic variables|
46094602|NCT00986011|Other|survey administration|
46094603|NCT00986011|Procedure|study of high risk factors|
46094604|NCT00582166|Drug|Ibritumomab Tiuxetan (Zevalin) + Rituximab|Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
46094605|NCT02775539|Drug|Mirabegron|Patients will receive 50 to 200 mg of mirabegron once a day during 16 weeks. Dose will be titrated during the first 8 weeks.
46094606|NCT02775539|Drug|Placebo|
46007500|NCT05214976|Drug|Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin Bound)|Firstly Dose Escalation of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) should be conducted. According to the DLT data in the dose escalation period, dosage of Famitinib malate capsule or Paclitaxel For Injection(Albumin Bound) would be adjusted. After dose escalation period, in order to evaluate the tolerance, study would choose the dosage regimen to complete the Dose Expansion period. The indication expansion would be conducted after that. The study would select specific indications based on the previous efficacy data with the RP2D of the combination therapy.
46007501|NCT05204134|Device|Automated Insulin Delivery Settings Initialization and Adaptation Algorithm|All participants wearing the t:slim X2 insulin pump with Control-IQ technology, and wearing the Dexcom G6 sensor, will have algorithm derived insulin delivery profile settings initialization and updates at regular intervals.
46007502|NCT05187832|Drug|AND019 PO QD|AND019 administrated as oral capsule once per day for 28 days for each cycle
46007503|NCT04673747|Procedure|Total Hip Arthroplasty|Total replacement of the head, femoral neck and acetabulum of the hip joint with specialized implants
46007504|NCT04673747|Procedure|Manual correction of the sacroiliac joint|Manual correction of the iliosacral displacement of the sacroiliac joint in total hip arthroplasty is performed in the operating room after anesthesia just before total hip arthroplasty. It is carried out according to the methodology developed by us.
46007505|NCT05181436|Diagnostic Test|measuring Total Haemoglobin (SpHb) using Masimo Rad-67.|To determine the prevalence of Malaysian children aged ≥ 6 to ≤ 36 months at risk of anaemia by measuring Total Haemoglobin (SpHb) using Masimo Rad-67.
46007506|NCT04674098|Device|The Beat Analytics System (BAS)|There are three subsystems to the BAS; data aggregation, data analysis and data presentation.
46037800|NCT05089708|Drug|Trifarotene Vehicle Cream|Participants will apply a thin a layer of trifarotene vehicle cream on the face once daily, in the evening for 24 weeks
46094607|NCT04840459|Biological|BAMLANIVIMAB|n. Bamlanivimab is a recombinant neutralizing human mIgG1? monoclonal antibody (mAb) to the spike protein of SARS-CoV-2, and is unmodified in the Fc region.
46094608|NCT04840459|Biological|CASIRIVIMAB|CASIRIVIMAB is a recombinant human mAbs which are unmodified in the Fc regions.
46094609|NCT04840459|Biological|IMDEVIMAB|IMDEVIMAB is a recombinant human mAbs which are unmodified in the Fc regions.
46094610|NCT02772575|Procedure|Hepatic trans-arterial embolization (TAE)|
46094611|NCT02772575|Device|MRI/CT scan|
46094612|NCT02772575|Procedure|biopsy|
46094613|NCT02772575|Other|blood draw|
46094614|NCT04666961|Drug|Tamoxifen 20 mg|Tamoxifen will be initiated in non menopausal patients orally for 6 months in a neoadjuvant situation.
46094615|NCT04666961|Drug|Anastrozole 1Mg Tab|Anastrozole will be initiated in menopausal patients orally for 6 months in a neoadjuvant situation.
46094616|NCT04618393|Biological|EMB-02|EMB-02 is a FIT-Ig® bispecific antibody against PD-1 and LAG-3.
46094617|NCT02772341|Device|Salt room with halogenerator|Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room with salt aerosol produced by a halogenerator (study group) or halotherapy without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values. The halogenerator is located outside the salt room.
46094618|NCT02772341|Other|Salt room without halogenerator|Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values.
46094619|NCT04006639|Procedure|Analgesic Technique|Patients undergoing tracheostomy procedure must be administered with analgesics, such Lidocaine 20% or Bupivacaine 0.5%
46094620|NCT00601172|Drug|Casopitant|Experimental NK-1 receptor antagonist
46094621|NCT00601172|Drug|Dexamethasone|Standard antiemetics
46094622|NCT00601172|Drug|Placebo|Placebo to match IV casopitant
46037801|NCT01095978|Drug|Clarithromycin (Klacid SR)|Klacid SR in a dose of 1000 mg once daily
46094623|NCT00601172|Drug|Ondansetron|Standard antiemetics
46094624|NCT02767115|Dietary Supplement|2% GSE mucoadhesive gel|2% GSE mucoadhesive gel administered in periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0
46094625|NCT02767115|Other|GSE free mucoadhesive gel|GSE free mucoadhesive gel administered in periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0
46094626|NCT04225793|Drug|Eziklen®|"The Eziclen solution should be taken in the one-time use regimen in morning before procedure.~Consumption of the full volume of the Eziklen® solution of the preparation and the additional amount of water or a clear liquid should be completed at least 2 hours and no later than 4 hours before the procedure."
46037802|NCT01134107|Drug|Insulin Lispro 6 Day (6D)|Administered by infusion pump for 12 week treatment period
46037803|NCT01134107|Drug|Insulin Aspart 6 Day (6D)|Administered by infusion pump for 12 week treatment period
46037804|NCT01199042|Device|BiPAP autoSV Advanced|The sleep apnea device will be set-up in automatic mode with the settings wide open for the entire night.
46037805|NCT02780674|Biological|MEDI7734|Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
46007507|NCT01137292|Drug|voriconazole (VFEND®)|The use and dosage recommendations for voriconazole (VFEND®) will take place on the basis of the Summary of Product Characteristics (SmPC) and will be adjusted solely according to medical and therapeutic necessity. The formulation and dose will be managed by the treating physician according to the SmPC, disease and clinical situation. According to the SmPC, in the adults the treatment should be started with the loading dose of 6 mg/kg of voriconazole iv. every 12 hours (during the first 24 hrs) followed by the maintenance dose of 4 mg/kg BID. For peroral formulations, the initial dose should be depending on the weight of the patient 400 mg or 200 mg BID during the first 24 hrs, followed by the maintenance dose of 200 mg or 100 mg of voriconazole BID respectively For paediatric population (<12 years of age), there is no initial dose necessary. Depending on the formulation, the daily dosage should be in children 7 mg/kg iv. BID or 200 mg of voriconazole orally BID.
46007508|NCT00197496|Procedure|Body weight supported treadmill training|hip fracture patients walk on a treadmill with body weight support
46007509|NCT04312477|Drug|Modified Gegen Qinlian Decoction|Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
46007510|NCT05367154|Procedure|Small incision lenticule extraction|Small incision lenticule extraction surgeries performed by two Refractive surgery experts (Refractive surgery expert 1: YYF, Associate Professor with 10 years of experience as a refractive surgeon; Refractive surgery expert 2: GF, Associate Professor with 5 years of experience as a refractive surgeon) and a Attending ophthalmologist (WNY, Attending ophthalmologist with 1 year of experience as a refractive surgeon).
46007511|NCT04673981|Diagnostic Test|diagnostic tes for neuropathic pain|Thermotest and hot water, cold water (for the oral cavity), Von frey filament and the brush
46007512|NCT05176795|Other|Stool sample|Comparaison of the gut microbiota composition
46007513|NCT02883478|Device|UV-X 1000 (3 mW/cm²)|Ultraviolet-A (UVA) irradiation for 30 minutes at 3 milliwatt/cm² (mW/cm²).
46007514|NCT02883478|Procedure|UV-X 2000 (9 mW/cm²)|Ultraviolet-A (UVA) irradiation for 10 minutes at 9 mW/cm².
46007515|NCT02883478|Drug|riboflavin with hydroxypropyl methylcellulose|Drops of riboflavin with hydroxypropyl methylcellulose will be applied in the eye for 20 minutes before ultraviolet-A(UVA) irradiation and every 2 minutes during UVA irradiation
46007516|NCT00197145|Drug|GW873140|400 mg twice daily
46007517|NCT04674137|Drug|XC8 100 mg|1 tablet of XC8 100 mg once daily in the morning during 12 weeks of treatment period.
46007518|NCT04674137|Drug|Placebo|1 tablet of placebo once daily in the morning during 12 weeks of treatment period.
46007519|NCT01136785|Device|active CPAP Therapy|7 days of active CPAP therapy
46007520|NCT01136785|Device|sham CPAP therapy|7 days of sham CPAP therapy
46007521|NCT04673864|Drug|CKD-386|QD, PO
46007522|NCT04673864|Drug|D012, D326, D337|QD, PO
46007523|NCT04312321|Device|Mandatory phone call consultation|Use of audio consultation (EMS crew smartphones, doctor smarphone) Smartphone (Xiaomi Redmi Note) and bluetooth handsfree headset (Jabra Talk)
46007524|NCT04312321|Device|Mandatory audiovisual consultation|Smartphone (Xiaomi Redmi Note) and bluetooth handsfree headset (Jabra Talk) with installed Android application (VSee messenger, USA, HIPAA compliant software) for paramedic crews; personal computer (Windows 10) with desktop version of application VSee messenger for Windows and eqipped with webcamera (Logitech C922 PRO) and headset (Jabra Evolve 20) for consulting doctor.
46094627|NCT04225793|Drug|MoviPrep|"The Moviprep® solution should be taken in the one-time use regimen in morning before procedure.~Consumption of the full volume of the Moviprep® solution should be completed at least 2 hours and no later than 4 hours before the procedure."
46094628|NCT02772107|Drug|Temozolomide|Temozolomide is a nonclassic oral alkylating agent. Temozolomide will be given alone as maintenance therapy in patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.
46094629|NCT02772107|Drug|first-line chemotherapy|first-line chemotherapy must be platinum-based: cisplatin(75mg/m2 for d1) or carboplatin（AUC 5 for d1) combined with etoposide（100mg/m2 for d1-d3）
46094630|NCT02772107|Radiation|Prophylactic cranial irradiation|Prophylactic cranial irradiation was allowed if necessary
46094631|NCT02772107|Radiation|thoracic radiotherapy|thoracic radiotherapy was allowed if necessary
46094632|NCT00986167|Drug|Quetiapine XR|The daily dose of oral Quetiapine XR at the start of therapy is 300 mg on Day 1, 600 mg on Day 2 and up to 800 mg after Day 2. The dose will be adjusted within the usual effective dose range of 400 to 800 mg/day, depending on the clinical response and tolerability of the individual patient.
46094633|NCT00988897|Drug|OXALIPLATIN (SR96669)|Pharmaceutical form: Lyophilized powder for injection (50mg/vial or 100mg/vial) or aqueous solution (50mg/10mL or 100mg/20mL) Route of administration: IV
46094634|NCT00988897|Drug|5-FLUOROURACIL (5-FU)|Pharmaceutical form: vials of 5g/100mL (50mg/mL) Route of administration: IV
46094635|NCT00988897|Drug|LEUCOVORIN (LV)|Pharmaceutical form: vials of 50mg/5mL or 500mg/50mL (10mg/mL) Route of administration: IV
46094636|NCT00988897|Drug|BEVACIZUMAB|Pharmaceutical form: vials of 100mg/4mL or 400mg/16mL (25mg/mL) Route of administration: IV
46007525|NCT04312438|Diagnostic Test|oral food challenge with cow's milk proteins|in children with diagnosed Cow's Milk Allergy open oral food challenge test with cow's milk protein (milk formula in children up to 3 yo, cow,s milk after 3 yo) will be carried out
46007526|NCT04312360|Drug|therapeutic endoscopy with metronidazole and fosfomycin disodium|therapeutic endoscopy where the two drugs: metronidazole and fosfomycin disodium are sprayed through out the right colon section (from caecum to right colon flexure). This intervention is going to be performed on patients in both track 1 and track 2a.
46007527|NCT04673474|Drug|Hemay022|Participants will receive a single oral dose of Hemay022 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
46007528|NCT04673474|Drug|Hemay022|Participants will receive a single oral dose of Hemay022 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
46007529|NCT00197106|Drug|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg|comparator
46007530|NCT00197106|Drug|fluticasone propionate 2 x 100 mcg|comparator
46007531|NCT01136746|Drug|Human regular insulin|Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization)
46007532|NCT01136746|Drug|Insulin lispro|Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
46007533|NCT01136746|Drug|Insulin glargine|Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
46007534|NCT02883751|Radiation|LED|A device with 36, rectangular, red LEDs, registered with the Brazilian National Health Surveillance Agency (ANVISA authorization nº 8.04554.6), λ = (650 ± 20) nm, with an output power of 324 mW and an output area of 2.54 cm2 (Cosmedical, Brazil), will be enveloped with sterile, disposable, plastic wrap (transparent in the red wavelength) to permit contact with the skin for ten minutes during each session. The plastic wrap will be changed after each use. The amount of energy delivered will be 194.4 J.
46007535|NCT02883751|Procedure|Control group|Conventional ulcer treatment with rayon® (Polar Fix, Polar Fix, Mauá, SP, Brazil) and essential fatty acids (Dersani®, Saniplan, Daudt, São Paulo, SP, Brazil) (composition: decanoic acid, caprylic acid, hexanoic acid, lauric acid, linoleic acid, lecithin, retinyl palmitate, tocopheryl acetate and alpha-tocopheryl).
46007536|NCT04673435|Device|PermeaDerm for temporary coverage|See above
46007537|NCT04673435|Device|FHCA for temporary coverage|See above
46007538|NCT04673435|Device|PermeaDerm over autograft|See above
46007539|NCT04673435|Device|FHCA over autograft|see above
46007540|NCT02883322|Other|Cross cultural adaptation of patient reported outcomes (PRO)|Process used to adapt a questionnaire from one cultural setting to another
46094637|NCT04225169|Other|Breathing exercises|The patient was taken to a quiet room and asked to lie on the bed. For the first 5 minutes, the researchers explained how the exercise is done with pictures and demonstrated it to the patient. The patient was asked to perform the exercise for 5 minutes under supervision by the researchers. If the patient performed DBE correctly, practice was discontinued. If not, the patient was asked to practice for another 5 minutes. If the patient still could not perform the exercise correctly at the end of this time, they were excluded from the sample. DBE was performed according to the Cleveland Clinic guideline as follows:
46007541|NCT01136356|Drug|buprenorphine|parenteral buprenorphine may be administered at multiple times each day
46094638|NCT00988975|Procedure|Insertion of pelvicol graft|Pelvicol graft
46007542|NCT01136356|Drug|morphine|parenteral morphine may be administered multiple times each day
46007543|NCT00587379|Drug|Atorvastatin|40 mg atorvastatin pill daily
46007544|NCT00587379|Drug|placebo|40 mg pill per day
46007545|NCT04673396|Drug|Norcantharidin Lipid Microsphere for Injection|"The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h.~This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen."
46007546|NCT04673396|Drug|Sodium Demethylcantharidate Injection|Dissolve the reference drug with appropriate amount of sterile water for injection, and add 250 mL of 5% glucose injection for slow dripping.
46094639|NCT02775227|Drug|Hydrocortisone|
46094640|NCT02775227|Drug|Pasireotide|
46094641|NCT04074382|Other|Online Questionnaires|We will use online questionnaires to complete research into functional outcomes after trauma
46094642|NCT04074382|Other|Qualitative Interviews|We will undertake qualitative interviews (remote or face to face) to shed more light on reasons for functional outcomes after trauma
46094643|NCT00986323|Device|Temperature controlled Laminar Airflow (TLA)|Nocturnal environmental control with Temperature controlled Laminar Airflow (TLA).
46007547|NCT00637390|Drug|Alemtuzumab|will be given Alemtuzumab therapy three times in your first week on the study and then once a week for six additional weeks
46007548|NCT00587418|Dietary Supplement|L-arginine|Arginaid (Novartis) 1 package (9.2g) bid for 7 days
46007549|NCT00587418|Dietary Supplement|Placebo|Placebo powder 9.2g bid for 7 days
46007550|NCT04673669|Diagnostic Test|Posterior tibial tendon strength mesure|Posterior tibial tendon strength is assessed with a hand-held dynamometer by two independent observer and with an isometric dynamometer by one observer.
46037806|NCT02780674|Biological|Placebo|One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
46007551|NCT00196326|Drug|DR-1011|Eighty-four orange, embossed tablets, each containing 100 μg levonorgestrel (LNG) / 20 μg ethinyl estradiol (EE) and 7 yellow, embossed tablets, each containing 10 μg of EE. One combination tablet was to be taken each day for 84 days followed by 7 days of EE tablets in 91-day cycles repeated consecutively for approximately one year (four 91-day cycles).
46007552|NCT04673318|Behavioral|heat therapy|leg heated garments with circulating water to conduct heat therapy at home
46094644|NCT00986323|Device|Placebo TLA|Placebo TLA (without filtration and TLA function)
46007553|NCT04673318|Behavioral|exercise training|A velocity based training program will be implemented at home using a mobile app allowing for the quantification the relative intensity.
46007554|NCT00587496|Drug|valacyclovir hydrochloride|500 mg capsule, one per day for 30 days
46007555|NCT00587496|Drug|placebo|lactose placebo capsule, six per day for 30 days
46007556|NCT00587496|Drug|valacyclovir plus aspirin|500 mg valacyclovir capsule, one per day for 30 days 325 mg acetyl salicylic acid (aspirin) capsule, three per day for 30 days placebo capsule, two per day for 30 days
46007557|NCT04610606|Behavioral|Multimodal intervention (MM)|"Exercise: Moderate intensity resistance and aerobic exercise, including one weekly supervised session and a home-based program. Participants were asked to 1) accumulate 30 min of aerobic exercise per day of their preferred type (ex. walking) and 2) perform 30 min of resistance exercise targeting major muscle groups, every second day for 2 sets of 8-12 reps.~Nutrition: Optimize diet with protein-rich foods to meet protein intake of >1.2 g/kg/d and energy of 25-30 kcal/kg/d. The supplement consists of whey protein isolate (with the goal of reaching 1.5 g/kg/d, providing 25 g/meal), 6g of leucine, fruit-flavored fish oil added with vitamin D.~Relaxation strategies: private consultations with psychology-trained personnel whereby techniques aimed at reducing anxiety are practiced. Participants are also provided with a compact disc with relaxation exercises to be used at home 2-3 times per week."
46007558|NCT00564044|Procedure|excision of the protruding mesh and its surrounding vaginal tissue|A piece of vaginal tissue 12mm*5mm*3mm in sized (for control group) and another piece of vaginal tissue combined with protruding mesh of the same size (for study group) will be obtained respectively for each of the two arms during intervention.
45836680|NCT04750590|Procedure|piecemeal resection, tissue removal by loop|Tumor piecemeal resection will be performed with electric loop. Then fragments of the tumor will be removed by the loop or Janet's syringe. Fragments from the base of the tumor will be sent separately in order to assess which stage the tumor is at and its surgical margin status.
46007559|NCT00564083|Procedure|sacral colpopexy|This surgery involves supporting the prolapsed vaginal wall with a piece of material (known as a graft) attached to a ligament along your backbone (or sacrum)
46007560|NCT00195663|Biological|Adalimumab|
46007561|NCT00195663|Drug|Methotrexate|
46007562|NCT00195663|Biological|Adalimumab placebo|
46007563|NCT00195663|Drug|Methotrexate placebo|
46007564|NCT00564122|Device|Artificially-Intelligent Stethoscope|After subjects' medical visits are complete, the heart sounds of all subjects will be recorded and assessed by an artificially-intelligent stethoscope. Attempts will be made to make satisfactory 20-second recordings from a total of eight positions on the chest with the patient in supine and upright positions.
46007565|NCT00564122|Other|Physical Examination|A Pediatric Cardiologist will examine each subject to the extent needed to make clinical assessments. This represents the ordinary standard-of-care.
46007566|NCT01135498|Drug|bevacizumab [Avastin]|Intravenous repeating dose
46007567|NCT01135498|Drug|eloxatin|Intravenous repeating dose
46007568|NCT01135498|Drug|capecitabine [Xeloda]|Oral repeating dose
46007569|NCT01135498|Drug|erlotinib [Tarceva]|Oral repeating dose
46007570|NCT04610567|Drug|Methotrexate-LDE phase 1|"3 patients will receive MTX-LDE at the dose of 15mg IV each 7 days during hospitalization, up to 3 times . After that, 9 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times .~All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE"
46007571|NCT04610567|Drug|Methotrexate-LDE phase 2|44 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE
46007572|NCT04610567|Drug|Placebo-LDE phase 2|44 patients will receive Placebo-LDE IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of Placebo-LDE
46007573|NCT02883439|Drug|MP29-02|local nasal application
46007574|NCT02883439|Drug|Fluticasone propionate|local nasal application
46007575|NCT02883283|Procedure|Epidural loading dose|Labor epidural analgesia loading dose
46007576|NCT02883283|Device|Epidural catheter|Epidural loading dose via epidural catheter
46094645|NCT02775305|Behavioral|Frail|"Slowness/weakness: Physical therapy(PT) strength and gait training. A standardized strengthening program will be prescribed, to be performed at home. Additional in-person PT training will be provided to those who are severely deconditioned .~Weight loss/malnutrition: A licensed nutritionist specializing in kidney disease will meet with participants for 3 one-hour one-on-one nutritional counseling.~Low physical activity: Participants will receive individualized walking recommendations using a pedometer. Walking activity will be assessed weekly, and new goals for increasing steps in the following week will be set.~Exhaustion: Those who meet criteria for severe depression using the center for epidemiologic studies depression (CES-D) scale will be immediately referred to psychiatry for counseling for patient safety. All others will participate in cognitive behavioral coping techniques."
46094646|NCT02875132|Drug|pembrolizumab|pembrolizumab at 200mg IV infusion every 3 weeks
45459925|NCT03109184|Behavioral|Project STRONG|The web-based program consists of a number of games, activities, and didactic information that teens move through with their parent. Didactic information introduces teens and parents to specific emotion management, communication, and problem solving strategies as well as sexual health and healthy relationship information. Games and activities allow parents and teens to practice and apply strategies to developmentally appropriate situations.
46007577|NCT02883283|Device|Epidural needle|Epidural loading dose via epidural needle
46094647|NCT02772185|Device|active tDCS|Duration: 30 minutes; Intensity: 2 mA; Placement:left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus
46094648|NCT02772185|Device|sham tDCS|The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham.
46094649|NCT02772185|Behavioral|real CT|Cognitive tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus).
45459926|NCT03480100|Drug|Xylometazoline Nasal Spray|Application of Xylometazoline Nasal Spray in accordance with the instructions for use
46007578|NCT04610255|Other|Assigned Interventions|"Hot pack for 10 minutes~TENS for 10 minutes~Trigger point release if any found.~Myofascial release~Home plan for stretching exercises will be prescribed to the patient. Receive two weeks intervention plan, three sessions per week."
45459927|NCT03480100|Device|Ectoin Nasal Douche|Application of Ectoin Nasal Douche (END01) in accordance with the instructions for use
45459928|NCT02348203|Drug|Aspirin|Given PO
45459929|NCT02348203|Other|Laboratory Biomarker Analysis|Correlative studies
45459930|NCT02348203|Other|Placebo Administration|Given aspirin placebo PO
45459931|NCT02348203|Other|Placebo Administration|Given zileuton placebo PO
45459932|NCT02348203|Drug|Zileuton|Given PO
45459933|NCT03493542|Biological|V501|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6
46007579|NCT04610255|Other|Dynamic myofascial release|"DMFR involves a manual application of low amplitude, long duration stretch to the fascia and muscle. Participants were instructed to relax as much as possible, and the therapist proceeded to smoothly move the joints in a diagonal or horizontal direction at a slow rate within the ROM. The therapist repeatedly pushed, pulled, or shook the joint area about three to five times for about 3 seconds with slight motion at the end of ROM.~Conventional therapy will includes~Hot pack for 10 minutes~TENS for 10 minutes~Trigger point release if any found.~Myofascial release~Home plan for stretching exercises will be prescribed to the patient. Receive two weeks intervention plan, three sessions per week."
46007580|NCT05161507|Procedure|Magseed|Patients with the non-palpable histologically confirmed breast cancer lesion - the tumor lesion will be labeled with Magseed and patient will undergo breast-conserving surgery and sentinel lymph node detection with Tc99.
46007581|NCT05161507|Procedure|Magtrace|Patients with the palpable histologically confirmed breast cancer lesion - The Magtrace will be injected preoperatively into the tumor and detected by Sentimag. Patient will undergo sentinel lymph node detection with Tc99 and Sentimag localization system with breast surgery.
46007582|NCT05161507|Procedure|Axillary lymph node metastasis - needle biopsy|Patients with the histologically confirmed breast cancer lesion with Axillary lymph node metastasis with pathologic confirmation by needle biopsy - the positive axillary lymph node lesion will be labeled with Magseed before the neoadjuvant systemic therapy, and later during target axillary dissection will be performed the biopsy of labeled lymph node during breast surgery.
46007583|NCT04610333|Behavioral|Modified MBSR programme|1 hour group session once a week in 10 weeks
46007584|NCT00195507|Drug|Etanercept|
46007585|NCT01134562|Drug|Placebo|Single IV injection.
46007586|NCT01134562|Drug|Etelcalcetide|Single IV injection. The initial dose was 5 mg and dose escalation proceeded with subsequent doses of 10 mg, 20 mg, 40 mg and 60 mg.
46007587|NCT04610216|Device|Naida CI M hearing device|speech intelligibility measurement with Naida CI M hearing device
46007588|NCT02883166|Drug|abiraterone|integested with a continental breakfast
46007589|NCT04610489|Diagnostic Test|Quidel Sofia SARS Antigen FIA|Obtained via bilateral mid-turbinate swab.
46007590|NCT00195429|Drug|Tacrolimus|
46007591|NCT00195429|Drug|Sirolimus|
46007592|NCT00195429|Drug|prednisone|
46007593|NCT04610021|Biological|i-FactorTM Bone graft|In the i-Factor ™ group it will be placed longitudinally in the intertransverse area. Likewise, in both groups, only autologous and bench bone will be placed in the intersomatic cages. The vertebrae where the i-Factor ™ is placed will be noted on the data collection sheet.
46007594|NCT00195351|Drug|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
46007595|NCT00195351|Drug|ceftriaxone sodium + metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
46007596|NCT04609982|Device|ear plugs|giving half of the patients ear plugs
46007597|NCT04609748|Drug|Cannabidiol Oil|Cannabidiol oil will be given twice a day, in a dose of 33,6mg, applied orally. The therapy will last 15 days.
46007598|NCT04609748|Drug|Nimesulide|Nimessulid will be given twice a day - 2x100mg, applied orally. The therapy will last 15 days.
46007599|NCT04574934|Other|aquatic therapy|Aquatic therapy refers to water-based treatments or exercises of therapeutic intent, in particular for relaxation, fitness, and physical rehabilitation. Treatments and exercises are performed while floating, partially submerged, or fully submerged in water. Many aquatic therapy procedures require constant attendance by a trained therapist and are performed in a specialized temperature-controlled pool. Rehabilitation commonly focuses on improving the physical function associated with illness, injury, or disability
46007600|NCT04609631|Behavioral|Tai Chi|24-form Tai Chi will be performed for 12 weeks. Each session contains a warm-up period (10 minutes), a Tai Chi period (40 minutes) and a cool-down period (10 minutes).
46007601|NCT04609631|Behavioral|CBT|CBT will be performed once a week for 12 weeks. Each session lasts for 1 hour.
46007602|NCT00195273|Drug|sirolimus|15 mg loading dose, followed by 5 mg/day to achieve target trough levels of 10-15 ng/mL at months 1-6, then 8-12 ng/mL at months 7-12
46007603|NCT00195273|Drug|cyclosporine|Initial dose of 10 mg/kg/day, then twice daily to achieve target trough levels of 300-400 ng/mL at weeks 0-4; 200-300 ng/mL at months 1-2; 150-250 ng/mL at months 2-3; 100-200 ng/mL at months 3-6; 75-150 ng/mL months 6-12
46007604|NCT00195273|Drug|mycophenolate mofetil|1 g twice daily; may be reduced to 750 mg BID for adverse events, or to 500 mg BID for persisting adverse events
46007605|NCT00195273|Drug|corticosteroids|As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day
46007606|NCT00195273|Drug|daclizumab|IV: 1 mg/kg to a maximum of 100 mg/dose. 5 doses at 2, 4, 6, and 8 weeks after transplantation
46007607|NCT00564200|Drug|Bortezomib|"PREACONDICIONAMIENTO:~2 cycles of 21 days : Velcade days: 1, 4, 8 and 11~1 cycle of 13 days : Velcade days 1, 4, 8 and 11~ACONDICIONAMIENTO:~- Day -2: Velcade~POSTRANSPLANTATION:~2 cycles of 21 days : Velcade days 1, 8 and 15~5 cycles of 56 days : Velcade days 1, 8 and 15"
46007608|NCT00564200|Drug|dexamethasone|"PREACONDICIONAMIENTO:~- 2 cycles of 21 days : Dexamethasone: days 1-4 and 8-11"
45459934|NCT03984916|Dietary Supplement|Hesperidin Pharma|Two capsules with 250 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R.
45459935|NCT03984916|Dietary Supplement|Hesperidin Pharma_M|Two capsules with 250 mg of sweet orange extract each with a mixture of hesperidin isomers -S and -R and micronized.
45459936|NCT03984916|Dietary Supplement|Cardiose|Two capsules with 250 mg of sweet orange extract each with more than 90% of hesperidin as isomer -S and micronized.
46007609|NCT00564200|Drug|Fludarabine|"ACONDICIONAMIENTO:~- Days -9 al -5: Fludarabine"
46007610|NCT00564200|Drug|Melphalan|"ACONDICIONAMIENTO:~- Days -4 and -3: Melphalan."
46007611|NCT00564239|Behavioral|Cognitive Behavioral Group Therapy|12 children group sessions, 8 parent group sessions
46007612|NCT00564239|Behavioral|Cognitive Behavioral Group Therapy|12 children group sessions
46007613|NCT00193479|Drug|Cyclophosphamide|Cyclophosphamide
46007614|NCT00193479|Drug|Mitoxantrone|Mitoxantrone
46007615|NCT00193479|Drug|Vincristine|Vincristine
46007616|NCT00193479|Drug|Prednisone|Prednisone
46007617|NCT00193479|Drug|Rituximab|Rituximab
46007618|NCT00564317|Behavioral|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
46007619|NCT00564317|Behavioral|Meditation/Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
46007620|NCT04609475|Procedure|Osseodensification technique|Implant bed preparation will be performed according to the manufacturer's guidelines, densifying burs (Densah® Burs) will be used sequentially in densifying mode (counterclockwise drill speed 800-1500 rpm with copious irrigation) to achieve the planned osteotomy diameter and desired ridge expansion. The implant will be then placed in the prepared osteotomy
46007621|NCT04609475|Procedure|Motor driven expanders' technique|The technique consisted of preparing the implant bed by progressively increasing the size of the osteotomes until the desired expansion will be achieved. At the planned implant site, a pilot drill 1000 rpm with irrigation until the desired length, then expansion with the series of ridge spreaders and finally using the final drill. The implant will be then placed in the prepared osteotomy.
46007622|NCT00193206|Drug|Gemcitabine|Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles
46007623|NCT00193206|Drug|Epirubicin|Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles
46007624|NCT00193206|Drug|Albumin-bound Paclitaxel|ABI-007 175 mg/m2 D1 q 14 days x 6 cycles
46007625|NCT00587691|Biological|Tovaxin Autologous T Cell Vaccine|"Primary Series (x1): 4 subcutaneous injections (wks 0, 4, 12 and 20 with 52 week evaluable period.~Retreatment Series (x3): 3 subcutaneous injections (wks 0, 4, and 8) with 26-week evaluable periods.~Retreatment Series (x3): 5 subcutaneous injections (wks 0, 8, 26, 24 and 32) with 52-week evaluable periods."
46094650|NCT02772185|Behavioral|placebo CT|Videos (short films) will be presented during the neurostimulation
46094651|NCT00984217|Radiation|Radiation|Radiation 64-70Gy (2.0 Gy/day, 5 days/week)
46007626|NCT04609358|Other|intervention group|When patients' hemodynamics was stable, start 1-2ml/kg/hr post-op 6-12 hours and increased 1-2ml/kg/hr each day if tolerating to reach the target energy supply When patients' hemodynamics wasn't stable, start post-op 6-12 hours 0.5-1ml/kg/hr and increased 0.5-1ml/kg/hr each day if tolerating to reach the target energy supply.
46007627|NCT00193050|Drug|Gemcitabine|Gemcitabine
46007628|NCT00193050|Drug|Epirubicin|Epirubicin
46007629|NCT00193050|Drug|Docetaxel|Docetaxel
46007630|NCT04609241|Drug|CD79b CAR-T Cells|Each subject receive CD79b CAR-Tcells by intravenous infusion
46007631|NCT00587730|Device|GE Attenuation Corrected Hawkeye Camera|GE Hawkeye AC system and 360˚ camera orbit
46007632|NCT04609163|Other|data collection|retrospective data collection
46007633|NCT04608734|Drug|Buccal midazolam|The drug was sprayed in the buccal vestibule across the area between the primary first and second molars in all four quadrants to maximize the absorption through wide area of the buccal mucosa.
46007634|NCT04608734|Drug|Intranasal midazolam|Half of the dose was sprayed in the right nostril and the other half in the left nostril to double the absorptive surface area by short and quick puffs.
46007635|NCT00192504|Biological|Motavizumab|Single dose of Motavizumab at a dose of 3 mg/kg administered intravenously (in the vein) on Day 0
46007636|NCT00192504|Biological|Motavizumab|Single dose of Motavizumab at a dose of 15 mg/kg administered intravenously (in the vein) on Day 0
46007637|NCT00192504|Biological|Motavizumab|Single dose of Motavizumab at a dose of 30 mg/kg administered intravenously (in the vein) on Day 0
46007638|NCT00192504|Other|Placebo|Single dose of placebo administered intravenously (in the vein) on Day 0
46007639|NCT00564356|Procedure|cataract surgery with phacoemulsification|removal of cataract with phacoemulsification technique
46007640|NCT00192114|Drug|Enzastaurin HCl|1200 milligrams (mg) loading dose orally, then 500 mg, orally, daily, up to six 28-day cycles.
46007641|NCT04608929|Behavioral|Kegel exercise-focused interventions|After the patients in the intervention group were interviewed on the telephone, the second home visit. During this visit, the patients were trained on Kegel exercises and they were administered the ICIQ-SF. Six weeks after the second visit, the third home visit was paid to determine whether the patients did the Kegel exercises and whether they did them accurately, to assess the perceived impact and to re-administer the ICIQ-SF. After the 2nd and 3rd visit, the patients were called once a week for 6 weeks to monitor if they kept up with doing the Kegel exercises as they were taught. Six weeks later, the 4th home visit were paid to the patients. During this visit, whether the patients did the Kegel exercises and whether they did them accurately was determined, the perceived impact was assessed and the ICIQ-SF was re-administered.
46007642|NCT04608929|Other|Home visit and scale evaluations|After the 1st visit, the patients included in the control group were called by phone and the 2nd home visit was planned. During the second home visit, the ICIQ-SF was administered to them. At the 3rd home visit paid 6 weeks after the 2nd visit, the ICIQ-SF was re-administered to the patients and the perceived impact assessment was performed. During the 4th home visit paid 6 weeks after the 3rd home visit, the ICIQ-SF was re-administered to the patients, assessment of the perceived impact was performed, and finally they were given training on Kegel exercises.
46007643|NCT00192075|Drug|Gemcitabine|900 mg/m2 IV over 90 minutes after Folinic Acid weekly for 6 weeks every 8 weeks until progression.
46007644|NCT00192075|Drug|avastin|5 milligrams per kilogram (mg/kg)
46094652|NCT00984217|Drug|Panitumumab|2.5 mg/Kg IV, weekly during RT. 6-7 weeks
46007645|NCT00192075|Drug|5FU/folinic acid|"Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG).~Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).~5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4)."
46007646|NCT00192075|Drug|oxaliplatin|85 mg/m2 as a 2-hour infusion on Day 1 of a 14 day cycle.
46007647|NCT00192036|Drug|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5)
46007648|NCT00192036|Drug|cisplatin|80 mg/m2, IV, every 21 days x 5 cycles
46007649|NCT00192036|Radiation|radiation|63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5
46007650|NCT04609007|Behavioral|Cognitive behavioral therapy (CBT)|A brief 4 sessions online CBT program with therapist support.
46007651|NCT04609007|Behavioral|Regular help-line telephone counselling|A single session of telephone counselling with a help-line counsellor
45459937|NCT04365088|Drug|Deflazacort 30 MG Oral Tablet|After the taken a deflazacort pill once preoperatively (one hour ago), local anesthesia was obtained using 2 ml articaine hydrochloride 40 mg/ml with epinephrine 0.01 mg/ml . The horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under sterile saline irrigation. Following the extraction, granulation tissues were removed, and bleeding was controlled. Finally, the mucoperiosteal flap was repositioned by 3.0 silk sutures.
45459938|NCT04365088|Drug|Sugar pill|Sugar pill
46007652|NCT04608461|Drug|Pumpkin seed extract containing cream|Pumpkin seeds extract, white wax, white petrolium, stearyl alcohol
46094653|NCT02346838|Dietary Supplement|Inulin|The treatment will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
46094654|NCT02346838|Dietary Supplement|Placebo|The placebo will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
46094655|NCT02656004|Other|Essential Eucalyptus Oil|Using a disposable face mask was inhale for ten minutes 0.25 ml of essential oil of eucalyptus measured through adjustable Pipettor 100/1000μl. Inhalation of the substance occurred immediately after the 20 minute rest period in the session Essential Oil of Eucalyptus.
46094656|NCT02656004|Other|Control Session|In the control session the procedure was the same. Using a disposable face mask was inhale for ten minutes fresh air. Inhalation of the fresh air occurred immediately after the 20 minute rest period in the session Control.
46094657|NCT00989053|Drug|escitalopram|10 mg/d for a duration of 8 weeks
46094658|NCT00989053|Drug|placebo|1 pill per day for 8 weeks
46094659|NCT02660450|Other|Prescription for Workload|Prescription from 65% VO2max for 5 min of exercise
46094660|NCT02660450|Other|Prescription for Heart Rate|Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise
46094661|NCT02660450|Other|Prescription Self Selected|Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise
46094662|NCT02862418|Other|UTE MRI|One MRI with UTE settings will be acquired.
45836681|NCT04750200|Procedure|Embolization of the Middle Meningeal Artery|EMMA is performed inside of the blood vessels where tiny catheters are used to deliver polymer embolic agents to block small blood vessels supplying the brain coverings. A particulate polymer embolic agent (also called polyvinyl acrylate, PVA) or a liquid embolic agents (polymers of ethynyl vinyl alcohol, EVOH) can be used.
46007653|NCT00191724|Drug|Drotrecogin Alfa (Activated)|6 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
46007654|NCT00191724|Drug|Enoxaparin|1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days
45459939|NCT04570904|Biological|Influenza vaccination at different time points|All HCWs will receive the seasonal influenza vaccine but at two different time points.
45599020|NCT01541345|Device|Autogenous bone graft|Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland)
45836682|NCT00321594|Drug|belinostat|Given IV
46007655|NCT00191724|Drug|Placebo|intravenous (IV), one infusion, over 12 hours
46007656|NCT00191724|Drug|Drotrecogin Alfa (Activated)|12 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
46007657|NCT00191724|Drug|Drotrecogin Alfa (Activated)|18 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
46007658|NCT00191724|Drug|Drotrecogin Alfa (Activated)|24 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
46007659|NCT00564473|Behavioral|questionnaire|"questionnaire of demographic and medical data, use of and attituded toward herbal medicine.~Beck Depression Inventory-Second Edition (BDI-II)- Hebrew Translation"
46007660|NCT04608422|Other|Electrical stimulation|A protocol of neuromuscular electrical stimulation will be applied on the quadriceps muscle (symmetric biphasic pulsed current, 80 Hz, 400 µs, 10 s contraction time, 50s/30s/20s rest time, the reciprocal mode, 20 min. After, a protocol of sensory stimulation will be applied on the anatomical region of the kidneys (First: 50 pps, 300 µs, continuous mode for 5 min; Second: 30 pps, 100 µs, continuous mode for 10 min; Third: 20 pps, 1000 µs for 30 min).
46007661|NCT00191646|Drug|Gemcitabine|"1000 mg/m^2, Intravenously (IV), day 1 and day 8 every (q) 21 days x 6 cycles~If anything other than complete response in Paclitaxel arm patients, 1000 mg/m^2, IV, day 1 and day 8 q 21 days until complete response, disease progression or unacceptable toxicity"
46007662|NCT00191646|Drug|Paclitaxel|"175 mg/m^2, IV, Day 1, q 21 days x 6 cycles~If complete response both Paclitaxel and Gemcitabine arms may elect to receive consolidation therapy, 135 mg/m^2, IV, 3 hours q 28 days x 12 cycles (1 year)~If no complete response, then Gemcitabine arm patients may receive 175 mg/m^2, IV, Day 1, q 21 days until complete response, disease progression or unacceptable toxicity"
46007663|NCT00191646|Drug|Carboplatin|"Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles~Paclitaxel/Carboplatin AUC 6, IV, Day 1, q 21 days x 6 cycles"
46007664|NCT04608656|Other|Provision of livestock feeds|Households will receive livestock feeds (ranch cubes) for the select lactating animals during the dry season
46007665|NCT04608656|Other|Nutrition counselling|Households will receive livestock feeds (ranch cubes) for the select lactating animals and will also be enrolled in to a nutrition counselling programme
46007666|NCT04608305|Biological|IIBR-100, low dose (prime)|Single administration of IIBR-100 1*10E5 pfu/ml
46007667|NCT04608305|Biological|IIBR-100 medium dose (prime)|Single administration of IIBR-100 1*10E6 pfu/ml
46007668|NCT04608305|Biological|IIBR-100 high-dose (prime)|Single administration of IIBR-100 1*10E7 pfu/ml
46007669|NCT04608305|Biological|IIBR-100 low-dose (prime-boost)|Two administrations of IIBR-100 1*10E5 pfu/ml, 28 days apart
46007670|NCT04608305|Other|Saline Placebo (single)|Single administration of saline placebo
46094663|NCT04170452|Procedure|liver biopsy|Pre-procedure assessment of the liver with ultrasound should be performed for planning positioning and needle entrance point. Supine, oblique, or total left lateral decubitus are the possible positioning of the patient - it is important to make sure that the patient is comfortable and can remain still in that position. Assessing if the procedure will be performed under breath held and practice this with the patient. Marking of the entrance point on the skin is advised to aid the skin cleaning and dressing. A time-out should be performed by this stage. Skin site is prepped and draped to ensure asepsis. Ocal anaesthesia is infiltrated under the skin abdominal wall/intercostal space until the liver capsule. Entrance point is created with a scalpel. Using the freehand technique the needle is advanced under ultrasound guidance during the entire course of the biopsy. The needle tip must always cross the capsule prior to deploying the cutting device.
45599021|NCT01541345|Drug|InductOs|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane). One time application at augmentation surgery.
46007671|NCT04608305|Other|Saline Placebo (double)|Two administrations of saline placebo, 28 days apart
46094664|NCT04614493|Device|SonoCloud-9 (SC9) device|"daily temozolomide (TMZ) during Radiation, followed by 6 months of adjuvant TMZ (5 days/months) with 6 concomitant Blood Brain Barrier opening sessions by ultrasound~+ 9 Blood Brain Barrier opening sessions by ultrasound without any associated drug"
46094665|NCT04614493|Drug|Temozolomide according Stupp protocol|daily temozolomide (TMZ) during Radiation, followed by 6 months of adjuvant TMZ (5 days/months)
46007672|NCT04608305|Biological|IIBR-100 medium-dose (prime-boost)|Two administrations of IIBR-100 1*10E6 pfu/ml, 28 days apart
46007673|NCT04608305|Biological|IIBR-100 high-dose (prime-boost)|Two administrations of IIBR-100 1*10E7 pfu/ml, 28 days apart
46007674|NCT04608305|Biological|IIBR-100 top-dose (prime-boost)|Two administrations of IIBR-100 1*10E8 pfu/ml, 28 days apart
45836683|NCT04751214|Procedure|APPENDICECTOMY|
46007675|NCT00191451|Drug|Gemcitabine|Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion)
46007676|NCT00191451|Drug|Carboplatin|Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion).
46094666|NCT02841748|Drug|Pembrolizumab|200mg, every three weeks, iv, x 1 year
46094667|NCT02841748|Drug|Placebo|iv, every three weeks, x 1 year
46094668|NCT04033094|Drug|MorphaBond ER|This was a retrospective, non-interventional study. Previous users of branded and generic products (tablets or capsules) with ER and immediate release (IR) release type formulations of oxycodone, oxymorphone, hydromorphone and morphine (except MorphaBond).
46094669|NCT04033094|Drug|Comparator Drug|This was a retrospective, non-interventional study. Previous users of the MorphaBond ER brand of ER morphine sulfate with A-D labeling, by prescription or non-prescription.
46094670|NCT04073758|Drug|Dexmedetomidine|Comparing effects of remifentanil versus dexmedetomidine
46094671|NCT03890497|Biological|IPV|The inactivated poliovirus vaccine (IPV) developed by Salk was the first available polio vaccine licensed in 1955 in the United States. The current formulation of IPV got licensed in 1987 and has a higher potency than the original Salk IPV. Almost 100% of children two months of age or older who receive 2-3 doses of intramuscular (IM) IPV achieve high antibody levels against the all three serotypes. IPV (.5mL) can be administered subcutaneously (SC) or IM and fractional (0.1 ml) doses of IPV are generally administered intradermally
46094672|NCT02655848|Procedure|Arthroscopic rotator cuff repair|Arthroscopic rotator cuff repair using suture anchors
46094673|NCT02655848|Procedure|LHB Tenodesis|Arthroscopic tenotomy and subsequent fixation of long head biceps proximal in the biceps groove
46094674|NCT02655848|Procedure|LHB Tenotomy|Arthroscopic tenotomy of long head biceps
45836684|NCT04751136|Drug|cerebrolysin|Infants of the treatment group were given Cerebrolysin in a dose of 0.1 ml / kg body weight once weekly intramuscular injection for 12 month (total of 48 injections).Each selected infant, in both treatment and control group, was assessed as regard: Socioeconomic status, Nutritional status and feeding practice, assessed for neurocognitive development
45836685|NCT04750980|Other|food allergy|food allergy
45836686|NCT04750980|Other|respiratory allergy|respiratory allergy
46007677|NCT00191451|Drug|Herceptin|"Day 1 of 14 day cycle (Cycle 1): 8 milligrams per kilogram (mg/kg) intravenous (IV) (90 minute infusion).~Day 1 of 14 day cycle (Cycles 2-9): 4 mg/kg IV (30 minute infusion). Day 1 of 21 day cycle (Cycles 10+): 6 mg/kg IV (30 minute infusion)."
46094675|NCT02576236|Other|Quadruple concomitant therapy treatment|"Quadruple concomitant therapy treatment:~high dose PPI (Esoméprazole 40 mg X 2 / d- amoxicillin 1gX2 / d - - clarithromycin 500mgX2 / d - metronidazole 500mgX2 / d for 14 days"
46094676|NCT02576236|Other|Triple therapy guided by the result of the molecular resistance test|"Triple therapy guided by the result of the molecular resistance test:~If clarithromycin S : high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d - clarithromycin 500mgX2 / d The total duration of treatment is 14 days.~If clarithromycin R: high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d- levofloxacin 500mg X2 / d The total duration of treatment is 14 days."
46094677|NCT00989131|Drug|Paclical®|"250 mg/m2 of Paclical® is given as a one-hour IV infusion, followed by carboplatin, on day 1 of each 21 day cycle.~Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments."
46094678|NCT00989131|Drug|Taxol®|"175 mg/m2 of Taxol® is given as 3 hour IV infusion, followed by carboplatin on day 1 of each 21 day cycle.~Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments."
45836687|NCT04750980|Other|healthy controls|healthy controls
45836688|NCT00390234|Drug|ziv-aflibercept|Given IV
46094679|NCT02660606|Other|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|
46094680|NCT02660372|Drug|Imonogas|Simethicone 120 mg in gel capsules
46094681|NCT02660372|Drug|Espumisan|Simethicone 40 mg in gel capsules
46094682|NCT00582010|Drug|inhaled nitric oxide|inhaled 80ppm for duration of surgery.
46007678|NCT04608383|Other|Additional and minimal collection of products of the human body carried out during a sample for standard of care|"Swab of the peritoneal fluid for traces of COVID19. The collection of peritoneal fluid is a standard care practice.~Swab from the laparoscopy filter"
45836689|NCT00391716|Drug|Gabapentin 900mg|900 mg gabapentin daily for 12 weeks
45836690|NCT00391716|Behavioral|behavioral counseling|The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.
45836691|NCT00391716|Drug|placebo|lactose capsule compounded to mimic gabapentin capsules
45836692|NCT00391716|Drug|gabapentin 1800mg|1800 mg gabapentin daily for 12 weeks
45836693|NCT00392496|Drug|sunitinib malate|Given orally
45836694|NCT01958190|Drug|Tacrolimus and Sirolimus|"Arm 1 once daily combination therapy of normal dosed extended-release tacrolimus and prednisone for 3 months and monotherapy once daily extended-release tacrolimus thereafter up to 3 years after liver transplantation.~Arm 2 once daily combination therapy of low doses sirolimus and extended-release tacrolimus and prednisone for 3 months and combination therapy of low dose sirolimus and extended-release tacrolimus thereafter for up to 3 years after liver transplantation Continue Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician Conversion to sirolimus (3-5 ng/ml) and decrease Advagraf (3-5 ng/ml); 7.5 mg prednisone and lower or discontinue steroids after day 180 at the discretion of the treating physician"
45836695|NCT01958190|Drug|Tacrolimus|Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
45836696|NCT01571778|Behavioral|Hand Hygiene before Donning Non-sterile Gloves|"In the No Intervention arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (usual practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens~In the Experimental arm, they will be instructed to don gloves without washing their hands as described."
45836697|NCT04388982|Biological|low dosage MSCs-Exos administrated for nasal drip|Dosage：5μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
45836698|NCT04388982|Biological|mild dosage MSCs-Exos administrated for nasal drip|Dosage：10μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
45836699|NCT04388982|Biological|high dosage MSCs-Exos administrated for nasal drip|Dosage：20μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
46007679|NCT04608071|Procedure|A modified method for blind bedside placement of post-pyloric feeding tube.|Modified post-pyloric feeding tube bedside catheterization as an optimized bedside blind post-pyloric tube placement, significantly shortened the time for passing pylorus without causing any severe adverse reactions.
46094683|NCT00582010|Drug|nitrogen gas|inhaled
46094684|NCT02660294|Biological|platlet rich plasma|Platelet-rich plasma (PRP) is prepared from fresh whole blood which is collected from a peripheral vein, stored in acid citrate dextrose solution A (ACD-A) anticoagulant and processed to increase platelets by separating various components of blood
46094685|NCT00989209|Drug|Botulinum Toxin Type A|All the patients received a one-time treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol,the total dose used per patient ranged from 15-69U, mean 37.9±5.4U.
46007680|NCT00191334|Drug|gemcitabine|1250 mg/m2, intravenous (IV) day 1 and day 8, every 21 days x 6 cycles or disease progression or unacceptable toxicity
46007681|NCT00191334|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles or disease progression or unacceptable toxicity
46007682|NCT04608032|Other|[Eco-Sz] Ecological Cognitive training program for schizophrenia spectrum disorder|The first group will have [Eco-Sz] Ecological Cognitive training program for schizophrenia spectrum disorder
45836700|NCT05286216|Behavioral|effectiveness of education|"The education program will be prepared using power point presentations within the relevant scientific literature. The education program is planned to be given to each group as 1 session on 2 different days, between 09:30 and 13:00. Day 1 module 1; Module 2 will be shared on the 2nd day and all patients in the experimental group will participate in the education program. During and after the education, individuals will be provided with the opportunity to ask questions. In addition, after the education, the researcher's phone will be given and counseling will be provided by phone. The duration and subject of the telephone conversations will be recorded by the researcher.~In order to evaluate the training, all patients will be invited to the hospital on the day of the control at the end of 12 and 24 weeks, and evaluations will be made again with data collection tools."
45836701|NCT00638898|Drug|busulfan|Given IV
45836702|NCT00638898|Drug|melphalan|Given IV
45836703|NCT00638898|Drug|topotecan hydrochloride|Given IV
45836704|NCT00638898|Other|laboratory biomarker analysis|Correlative studies
46007683|NCT04608032|Other|Recovery-Oriented Therapy|The second group will have [THoR] Recovery-Oriented Therapy
46007684|NCT00191139|Drug|gemcitabine|After induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In both treatment arms, gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles.
46007685|NCT00191139|Drug|docetaxel|Following cisplatin-etoposide induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In this treatment arm, docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine.
46007686|NCT00191139|Drug|cisplatin|As part of induction chemotherapy, cisplatin is given 50 mg/m2, IV, day 1, 8, 29 and 36 (spans 2 cycles)
46007687|NCT00191139|Drug|etoposide|As part of induction chemotherapy, etoposide is given 50 mg/m2, IV, days 1-5 and 29-33 (spans 2 cycles)
46007688|NCT00191139|Radiation|radiation therapy|In conjunction with induction chemotherapy, radiation therapy is administered at a dose of 200 centi Gray (cGy) per day, Monday through Friday for 6 weeks
46007689|NCT00564512|Biological|Campath|Fludarabine-Cyclophosphamide-Campath (FCCam)
46007690|NCT00564512|Biological|rituximab|Fludarabine-Cyclophosphamide-Rituximab (FCR)
46007691|NCT00564512|Drug|cyclophosphamide|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
46007692|NCT00564512|Drug|fludarabine|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
46094686|NCT00989209|Procedure|myofunctional therapy|All the patients were submitted to individual myofunctional therapy with the speech therapist, once a week, by four weeks.The myofunctional therapy began with isometric maneuvers for muscular elongation on the non paralyzed side, and on the paralyzed side when microsurgical reconstruction was present. It also included isotonic maneuvers to increase muscle tonus and isokinetic maneuvers to increase force on the paralyzed side.
46094687|NCT00649922|Biological|adalimumab|80 mg adalimumab (2 injections) day 1; 40 mg (1 injection) Day 15 and Day 29
45836705|NCT00638898|Biological|filgrastim|Given IV or subcutaneously
45836706|NCT00638898|Procedure|autologous hematopoietic stem cell transplantation|Undergo transplantation
45836707|NCT00638898|Other|pharmacological study|Correlative studies
45836708|NCT00638898|Procedure|autologous bone marrow transplantation|Undergo transplantation
45836709|NCT01793454|Other|Fraction of inspired oxygen 40%|
46094688|NCT00649922|Biological|placebo|2 injections Day 1, 1 injection Days 15 and 29
46094689|NCT00649922|Biological|adalimumab|40 mg adalimumab every other week
46007693|NCT04571853|Behavioral|PNE-explained group|There are 9 fact sheets overall. And each fact sheet incorporates two pages relating to one main concept. The first of two pages introduces the concept, and the second one quotes important ideas that emerge from the main concept. The 9 main concepts and consequent ideas presented in the fact sheets are based on current scientific research in pain science and have been selected and structured specifically for PNE education for chronic pain patients. The fact sheets have been fully developed and designed by Pain Revolution, a pain educator network founded by Professor Lorimer Moseley, group leader in Body in Mind Research Group from University of South Australia.
46007694|NCT04571853|Behavioral|PNE-read group|The PNE-read group will receive the fact sheets via email along with instructions regarding the content and the procedure to read the content. Instructions will suggest to read only two fact sheets per day during 4,5 days. It will be suggested to take 30 minutes at least for each fact sheet.
46007695|NCT04571853|Behavioral|TAU group|Participants allocated to this group will maintain treatment as usual (TAU) and will follow the recommendations by their usual health professiona
46007696|NCT00564551|Behavioral|High dairy and calcium intake|High intake of low-fat milk product intake (3-4 servings per day) plus one 350 mg calcium supplement per day during 500 kcal/day deficit diet.
46007697|NCT00564551|Behavioral|Usual intake|Usual intake of low milk product intake (1 serving/day) and low calcium intake with a placebo during a 500 kcal/day deficit diet
45599022|NCT01541345|Procedure|Augmentation surgery|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane)
45836710|NCT01793454|Other|Fraction of inspired oxygen 80%|
46007698|NCT00190983|Drug|Pemetrexed|Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.
46007699|NCT04607759|Dietary Supplement|nutraceutical|Subjects will consume two capsules for eight weeks
46007700|NCT04607798|Device|Radiofrequency and pulsed electro-magnetic fields treatment|Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.
46007701|NCT00190749|Drug|olanzapine|5-20 mg, oral, capsules, daily, 12 weeks.
46007702|NCT00190749|Drug|risperidone|2-6 mg, oral, capsules, twice daily (BID), 12 weeks.
46007703|NCT04607720|Procedure|artificial-EUS-FNA|The ultrasound endoscopists manually determined the region of interest (ROI) according to CH-EUS, and punctured 2 needles in the tumor area with a 22G needle, and each needle moved 15-20 times back and forth in the lesion. After puncture, insert the needle core, rinse the needle with 0.1ml sterile saline, and further apply air flushing to ensure that each tissue is sent to the slide.
46007704|NCT04607720|Procedure|AI-EUS-FNA|In the AI-assisted diagnosis system, the assisted targeting EUS-FNA unit is applied, and the ultrasound endoscopist selects the region of interest (ROI) according to the thermogram to perform targeted EUS-FNA puncture(2 needles in the same way).
46007705|NCT04607447|Behavioral|low intracranial pressure strategy treatment|"Supine position for 16h-18h daily, with head toward the affected side in most of the time, and 15-20 cm elevation of lower limbs.~Abdominal belt compression"
46007706|NCT04607447|Drug|Atorvastatin plus Dexamethasone|Atorvastatin plus Dexamethasone
46007707|NCT04607213|Procedure|Advancement-rotation approach based on Millard' for repairing lip defect.|"patients were treated using Millard technique is the downward rotation of the medial part of the flap, and lateral advancement of the flap to close and fill the defect. if more lip height is needed; cut- as- you-go by adding a back-cut incision at the end of his rotation incision down toward the philtral ridge of non-clefted side. Moreover; C-flap is used to close nasal sill."
46007708|NCT04607213|Procedure|Straight-line approach|"patients were treated using Straight-Line design based on Fisher modification. C-shaped flap extend from the proposed nasal sill to the origin of philtral column of medial flap as a straight incision to the planned top of the cupid's bow. In addition, to the previous mentioned incision, small inlate incision is needed to length the cleft side on the medial flap.~On the other hand, on the lateral flap; two connected triangular incisions are used; one on the vermillion border at Noordhoff's point. And the other one just above the cutaneous margin to improve aesthetic outcome and diminish formed scar."
46007709|NCT00190671|Drug|pemetrexed|Pemetrexed: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles
46007710|NCT00190671|Drug|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days x 8 cycles
45836711|NCT00393978|Drug|Quetiapine and placebo|placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).
45836712|NCT00393978|Drug|Quetiapine and Topiramate|topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).
45836713|NCT00396006|Biological|Alpha1-Proteinase Inhibitor|60 mg/kg, weekly, intravenous infusion
45836714|NCT00397020|Drug|divalproex ER|Dose: 30mg per kg, rounded to nearest 500mg, dosed PO QHS. Adjustments made through trial to obtain serum valproic acid levels of 85-125 mcg/ml
45599023|NCT02345577|Other|Stochastic whole body vibration (WBV) therapy - Physiotherapeutical intervention|Physiotherapeutical intervention
45599024|NCT02345577|Other|Stochastic whole body vibration (WBV) therapy - Sham physiotherapeutical intervention|Sham physiotherapeutical intervention
45836715|NCT00397020|Drug|quetiapine|Dose: 200mg PO QHS, titrated up to therapeutic dose of 600-800mg.
46094690|NCT00986557|Biological|adoptive immunotherapy|
46094691|NCT00986557|Biological|alemtuzumab|
45459940|NCT03913585|Behavioral|Lifestyle intervention|Upon inclusion and consent all patients receive a questionnaire to estimate risk of disease and risk behavior. Information about lifestyle is systematically registered and collated with existing Electronic Patient Record (EPR) data and the patients risk of developing a lifestyle-related disease is estimated based on validated algorithms for risk of type-2 diabetes, cardiovascular disease and COPD (Stratification). All patients receive digital feedback including a personal health profile and targeted advice. Patients at high risk of lifestyle-related disease(s) are offered targeted prevention activities at the GP including a health examination and if needed a health dialog. Patients with health risk behavior are offered behavior counselling in the municipality and community health services, if necessary. Patients diagnosed with a lifestyle related disease and patients with a healthy lifestyle are not offered any further services.
46007711|NCT00190671|Drug|pemetrexed|1800 mg/m2, intravenous (IV), every 21 days x 8 cycles
46007712|NCT00199914|Device|Shortwave diathermy|continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
46007713|NCT04607525|Drug|Dexmedetomidine|"On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group D: Patients received 0.5 µg/kg/h of Dexmedetomidine. Dexmedetomidine dosage was diluted in 50 ml syringe of normal saline Group C: Patients received equal volume and rate of normal saline as Group D.~This dosing regimen was in accordance with existing guidelines [5] [6] [7]."
46094692|NCT00986557|Biological|in vitro-treated peripheral blood lymphocyte therapy|
46094693|NCT00986557|Drug|foscarnet sodium|
46007714|NCT04607525|Drug|normal saline|"On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group C: Patients received equal volume and rate of normal saline as Group D."
46007715|NCT00198276|Combination Product|MedPulser Electroporation with bleomycin|The MedPulser device will be used in combination with Bleomycin Sulfate injection around the tumor area in a concentration of 1 U/ml per cm3 of tumor treatment area.
46007716|NCT04607642|Drug|BMX-001|BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates.
46094694|NCT00986557|Drug|ganciclovir|
46007717|NCT04607642|Radiation|Radiation Therapy|Treatment plan should include a continuous course of treatment delivered as single daily fractions of 2.0 to 2.1 Gy with a cumulative radiation dose between 60 Gy and 70 Gy. Planned radiation treatment volumes must include at least two oral mucosal sub-sites (buccal mucosa, retromolar trigone, floor of mouth, tongue, soft palate, hard palate) with a portion of each site receiving at least 50 Gy.
46007718|NCT04607642|Drug|Cisplatin|Cisplatin is an IV chemotherapeutic agent approved to treat head and neck cancers. Cisplatin will be administered per institution's standard of care practice. Common standard of care practice includes dosing cisplatin at 100mg/m2 IV q21 days starting on Day 1 of RT for 2-3 doses or dosing cisplatin at 40 mg/m2 IV each week of RT for 6-7 total doses. Cisplatin will be infused per institutional guidelines.
46007719|NCT04607642|Other|Placebo|The placebo to be used in this study is 0.9% Sodium Chloride Injection, USP.
46094695|NCT00986557|Genetic|polymerase chain reaction|
46094696|NCT00986557|Procedure|allogeneic hematopoietic stem cell transplantation|
46094697|NCT00986557|Procedure|infection prophylaxis and management|
46094698|NCT00986557|Procedure|peripheral blood stem cell transplantation|
46094699|NCT00986557|Procedure|standard follow-up care|
46094700|NCT00986557|Radiation|radiation therapy|
46094701|NCT00910754|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) administered orally once daily.
46094702|NCT00910754|Drug|Prednisone|Prednisone 5 mg tablets administered orally twice daily.
46094703|NCT02576002|Drug|Assigned pulmonary hypertension medication|As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators
46094704|NCT05712733|Other|Microbiological and histopathological investigation of bile and gallbladder wall specimens.|Bile and gallbladder wall specimens will be taken from all patients included in the study. The material will be sent for microbiological and histopathological investigation.
46094705|NCT02577484|Device|RXi System|"Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.~Measurement of FFR requires simultaneously monitoring the blood pressures proximal and distal to a lesion. The RXi system includes a single use catheter (Navvus) with a pressure sensor for acquisition of the distal pressure. The proximal pressure is acquired by the guide catheter via an interface to the hospital hemodynamic monitor.~The Navvus catheter interfaces to the RXi system console which includes embedded software, a user interface touch screen and associated electronics."
46094706|NCT02577484|Device|Pressure Wire|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.
46094707|NCT02536586|Drug|LY3023414|LY3023414 administered orally.
46094708|NCT00649376|Drug|Fexofenadine Tablets 180 mg|180mg, single dose fasting
46094709|NCT00649376|Drug|Allegra® Tablets 180 mg|180mg, single dose fasting
45836716|NCT00371436|Procedure|Progressive Audiologic Tinnitus Management|The five levels of progressive intervention are: (1) triage; (2) audiologic evaluation; (3) group education; (4) tinnitus evaluation; and (5) individual management.
46007720|NCT00587808|Procedure|RHC with VO2 consumption|All pressure-volume data is acquired at 250 Hz and stored on the Leycom system for offline analysis. Volume data will be calibrated using the most recent EF from echocardiogram and stroke volume from the Fick method. Measured O2 consumption will be utilized along with sampling of SVC and arterial blood oximetry to determine cardiac output at rest and during exercise
46007721|NCT00587925|Other|Bone Mineral Density|Clinic visits twice during the first 2 years of the study with medical care directed by your treating doctor.BMD is measured by an X-ray test. The most common type of BMD testing is by energy x-ray absorptiometry (DEXA). Usually BMD is measured every other year, but to closely monitor women on this study, the BMD will be evaluated more often. The BMD will be measured 3 times (baseline, 12 months and 24 months) on this study. Study blood work is obtained three times (baseline, 6 months, and 12 months). Blood (about 3 teaspoons).
46007722|NCT00588003|Drug|anastrozole|anastrozole 1mg/day 11 days before their surgery and to take the last dose of the oral endocrine agent (anastrozole) on the day before their surgery.
46007723|NCT00588003|Other|Placebo|No medication before surgery
46007724|NCT00588042|Device|Blood pressure cuff|Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
46007725|NCT00588042|Device|blood pressure cuff|3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
46007726|NCT00588081|Behavioral|QOL|Those women who chose to have an interview will be scheduled for a 45 to 60 minute open-ended interview with a trained research assistant and sign consent at the time of the interview.
46007727|NCT04607291|Other|Community Health Service|Receive Witness CARES services
46007728|NCT04607291|Other|Survey Administration|Ancillary studies
46007729|NCT00588120|Drug|C-13 labeled oxalate|"A single prescribed dose of C-13 labeled oxalate will be given orally in capsule form or in jello. Urine will be collected for 24 hours after the dose.~Take one capsule by mouth for one day."
46007730|NCT04574973|Device|transcranial direct current stimulation|This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.
46007731|NCT04574973|Behavioral|intensive upper extremity motor training|This training is administered one-on-one with an occupational therapist. Activities will be focused on skills to help the individual function better in daily life.
46094710|NCT02340676|Procedure|Extracorporeal Photopheresis (ECP)|Participants receive ECP treatment twice a week for 16 weeks
46007732|NCT04607057|Drug|Parenteral Nutrition Solutions|"Day0 : fasting(NPO) + crystalloid fluid~POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid~POD#2 : Semifluid diet (SFD) + crystalloid fluid~POD#3 : Semifluid diet (SFD) + PN~POD#4-7: Soft blended diet (SBD) + PN"
46007733|NCT04575012|Procedure|Deferred invasive strategy|PCI on 7 to 10 days after symptom onset
46007734|NCT04575012|Procedure|Early invasive strategy|Primary PCI
46007735|NCT00564590|Drug|Melatonin|4 mg of Melatonin once a day for 3 months
46094711|NCT02340676|Drug|Interleukin-2|Participants receive daily IL-2 injections starting Week 8 of study and ending at Week 16
46094712|NCT04167800|Other|Exercise|Orthosis, mobilization, strengthening, posture and segmental breathing exercises
45599025|NCT02297425|Drug|PF-06459988|The study will evaluate PF-06459988 PO (tablets) continuous daily dosing in 21 day cycles. The starting dose for PF-06459988 will be 50 mg PO daily. The escalation/de-escalation rules will follow the modified toxicity probability interval method with adjustments using the DLT rate and maximum size per dose level of 10 patients
45599026|NCT03949673|Drug|Fasinumab|Study drug will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
46007736|NCT00564590|Other|omeprazole|omeprazole 20 mg once a day
46007737|NCT00564590|Drug|Placebo|Placebo once a day
46007738|NCT00564668|Drug|biphasic insulin aspart|
46094713|NCT02655926|Procedure|Deep Brain Stimulation|Participants undergo implantation of bilateral electrodes at both the VS/VC and STN sites through a single burr hole under general anaesthesia. High-resolution MRI scans are used to calculate target coordinates and to verify accurate electrode location post-surgery. Each STN electrode have 4 electrical contacts at its distal tip (with a 0.5mm separation) and each VS/VC electrode have 4 electrical contacts at its distal tip (with a 1.5mm separation) to allow fine tuning of the exact site for stimulation delivery. Two non-rechargeable batteries (Activa PC) are connected to the electrodes and positioned under the skin of the right and left chest wall so that they correspond to the same set of electrodes for each patient: one for the 2 STN electrodes and one for the 2 VC/VS electrodes.
46007739|NCT04574817|Drug|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
46007740|NCT00564707|Behavioral|Biofeedback therapy|EMG guided biofeedback therapy using standard biofeedback computer software
46007741|NCT00564707|Procedure|Botulinum Toxin Type A Injection|Under EMG guidance Botox is injected directly into the painful levator ani muscle.
46007742|NCT04574778|Drug|Acetaminophen|1000 mg of oral acetaminophen preoperatively + IV placebo infusion intraoperatively 30 minutes prior to closure
46007743|NCT04607018|Device|PMA-zeolite|"subjects received boxes containing PMA-zeolite powder for supplementation for a total of 28 days.~Dosage for PMA-zeolite (100% zeolite; 1 ML - spoon for dosage = ca. 3 g zeolite):1 spoon of the powder stirred 2 times daily (morning and evening) in water (1 glass)."
46007744|NCT04606862|Device|Morley Medical Sepsis Software Device|The Morley Medical Sepsis (MMS) Software Device is a predictive analytics, stand-alone, cloud-based software system with no hardware components. The software acquires patient data from the electronic medical record, processes the data using unique artificial intelligence (AI) powered algorithms, and generates clinical decision support outputs that aid in the proactive delivery of customized and efficient care for patients. The software output is made available to the end users (trained medical professionals) via an intuitive user interface displayed on desktop computers or mobile communication devices such as laptops, smartphones or tablets.
46037807|NCT05339620|Procedure|implant driver facilitated micro-osteoperforations|"3 micro-osteoperforations(in a vertical pattern) are done on the randomly allocated experimental side , distal to canine under local anesthesia. the other side of the mouth is used as a control.~alginate impression is taken before the intervention ."
46007745|NCT00588276|Radiation|124I-Iodo-Azomycin Galacto-Pyranoside|You will receive the radioactive tracer through an injection in your vein. Blood (about 5 tablespoons in all) will be taken after the radioactive tracer has been given. Over the course of study day 1, bloods will be drawn 8 times and then 4 more times on study day 2. You will undergo three *IAZGP PET scans, one shortly after you receive the injection, one later the same day and one the following day. Each scan will take about an hour. This means you would be asked to come back 2 days in a row.
46007746|NCT04606667|Other|Exercise Program|Exercise program
46007747|NCT03452592|Drug|Alflutinib|Patients take Alflutinib orally once per day at dose of 80 mg or 160 mg
46007748|NCT04606511|Diagnostic Test|Circumference tape measurements|centimeter and volume criterias
46007749|NCT04606511|Diagnostic Test|Indocyanine green lymphangiography|Presence of dermal backflow
46007750|NCT04606511|Diagnostic Test|bioimpedance spectroscopy|7.5 and 10 L-DEX criterias
46007751|NCT04606511|Diagnostic Test|Symptom score|using lymph-icf, DASH and SF-36 questionnaires
45599027|NCT03949673|Drug|Naproxen|Naproxen will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
46007752|NCT00564746|Drug|A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323|"[14C] SB-681323 oral solution, is available as a powder which will be made into a solution of 0.1 milligram/milliliter (0.5 microcurie) [14C] SB-681323 in dextrose and water for injection on the day prior to dosing.~For a 10 milligram/50 microcurie oral dose of [14C]SB-681323, 100 milliliters of 0.1 milligram/milliliter (0.5 microcurie/milliliter [14C] SB-681323 oral solution will be dosed."
46007753|NCT04606277|Other|Smartphone addiction scale, physical activity scale and depression questionnaire|Telephone addiction of the subjects was measured. Then, physical activity levels were questioned, and finally depression scale was applied.
46007754|NCT00588393|Drug|FolateScan (Technetium Tc 99mEC20)|0.1 mg. of EC20 labeled with 20-25 mCi of technetium-99m followed by FolateScan
46007755|NCT04606043|Procedure|Sandblasting|Sandblasting will be applied onto the vestibular surfaces of the teeth before applying the etchant.
46007756|NCT04606043|Procedure|Acid Etching|Only acid etching will be applied onto the vestibular surfaces of the teeth before rebonding
46007757|NCT04606121|Combination Product|enhanced day care of TCM include acupuncture, massage, tai ji quan, TCM herbal medicine|acupuncture twice in enhanced day care of TCM massage twice in enhanced day care of TCM tai ji quan one time in enhanced day care of TCM TCM herbal powder three times a day
46007758|NCT00588510|Other|Blood draw|Peripheral blood samples (6-9 ml) will be collected in purple top tubes, when routine laboratory tests are being drawn. The blood will be drawn through central venous catheters, whenever possible. Blood will be drawn once from patients with malignant diagnoses other than osteosarcoma, neuroblastoma, Ewing's sarcoma or synovial sarcoma. In patients with osteosarcoma we will obtain blood when baseline laboratory tests are obtained, after every two cycles of treatment (approximately every six weeks), at the end of planned surgery and chemotherapy, every three months for the first year off therapy and yearly thereafter. We will also obtain blood if the patient relapses.
46007759|NCT04606082|Drug|Granulocyte Colony Stimulated Factor|GCSF was intrauterine injected once at ovum pick up day
46007760|NCT04606082|Drug|Human Chorionic Gonadotropins|500 IU of HCG was injected intrauterine once at ovum pick up day
46007761|NCT04605770|Drug|pemetrexed+cisplatin|"Pemetrexed 500 mg/m2 (Day 1) and cisplatin 75 mg/m2 (Day 1) will be given via intravenous (IV) infusion. Each cycle consists of 21 days, and this combination therapy will be continued until Cycle 6. Starting from Cycle 7, pemetrexed alone will be administered every 3 weeks (Q3W) as IV infusion until disease progression.~Vitamin B12 1000 mcg intramuscular (IM) injection will be given within 14 days prior to the first dose of pemetrexed, every 9 weeks (on the same day as study treatment) thereafter, and then 21 days after the last dose of pemetrexed. Folic acid 1 mg will be administered daily starting from 14 days before the first dose of pemetrexed and continued until 21 days after the last dose of pemetrexed. Study treatment will be continued until PD, unacceptable AE, or decision to discontinue by subject or physician."
46007762|NCT00588588|Procedure|Bronchoscopy|Bronchoscopy procedure
46007763|NCT00588588|Procedure|Clinical pulmonary infection score (CPIS)|Calculate CPIS
46007764|NCT04605887|Drug|Angiotensin 1-7|Ang 1-7 subcutaneously 500 mcg/kg /day
46007765|NCT00588705|Behavioral|focus group & questionaire|The focus group will last about 90 minutes. However, your involvement in this study will last from the time you join until you read over the summary of what happened during the focus group and return your comments. This should be approximately 2 months. Patient will complete a questionnaire and we estimate total time for completion to be approximately 7 minutes.
46007766|NCT04606004|Other|Stool application|Application of stool from the stoma bag 4 weeks prior, twice daily for 10 minutes at a time. However, with the stool application no barrier cream will be applied to the skin in order for the stool to achieve penetrance to the skin. Stool application will include removing any barrier creams gently, applying a thin layer of stool with a surface area shown in illustration to ensure consistent coverage, and placing a diaper on the subject. Depending on the type of the participant's ostomy, a medication cup, syringe, and/or tongue blade provided by the researchers, may be used to aid in the application of stool. After 10 minutes of application, the caregiver or inpatient healthcare provider will remove the entire thin layer of stool gently without excessive friction, just enough to remove the stool, a dabbing motion is preferred.
46007767|NCT04606004|Other|Standard of care skincare|"Standard of care for skin care pre-operatively: which is either no application of barrier cream, or an application of an over the counter (OTC) skin barrier such as Aquaphor, Desitin, or Vitamin A&D if the patient is experiencing skin redness from urine incontinence.~Standard of care skin creams post op: 3M no-sting immediately post op, once begin stooling- stoma powder, 3M no-sting, Critic-aid thick barrier paste will be applied to the skin."
46094714|NCT00649454|Drug|Glipizide and Metformin HCl Tablets 5 mg/500 mg|5/500mg, single dose fasting
46007768|NCT00588783|Device|I-beam design|This group will utilize tibial components with an I-beam design for total knee replacement.
46007769|NCT00588783|Device|Cruciate design|This group will utilize tibial components with cruciate designs for total knee replacement.
46007770|NCT04605926|Biological|EQ001|itolizumab [Bmab600]
46007771|NCT04605926|Biological|EQ001 Placebo|EQ001 Placebo
45459941|NCT03722706|Other|Educational handbook|The intervention being evaluated in this study is an educational handbook for parents of children with atopic dermatitis (AD). The handbook was developed and written by the interdisciplinary study team (psychologist, allergist, nurse practitioner, dermatologists, primary care physician, dietitian). Content was based on practice guidelines for AD management, consensus recommendations for therapeutic patient education for AD, and clinical experience of our study team. Content includes topics central to effective AD management, such as pathophysiology/course, elements of treatment plans, and strategies to improve quality of life, such as breaking the itch-scratch cycle, improving sleep, and coping with social-emotional issues.
46007772|NCT00588939|Device|Cell~vizio (Laser connfocal microscopy)|completed during endoscopy
46007773|NCT04605419|Procedure|Calcium electroporation|Areas with Barrett's esophagus high-grade dysplasia will get an injection of calcium chloride in submucosa through an endoscopic system before getting electroporation
46007774|NCT00588978|Behavioral|diet and/or exercise|Three arms are included: Diet Alone, Exercise Alone, and Combined Diet and Exercise
46007775|NCT04605536|Other|animation videos|watch animation videos about capsule endoscopy
46094715|NCT00649454|Drug|Metaglip® Tablets 5 mg/500 mg|5/500mg, single dose fasting
46007776|NCT04605536|Other|explanation about endoscopy endoscopy|Give general explanations about endoscopy endoscopy
46007777|NCT00589095|Other|dynamic contrast enhanced magnetic resonance imaging|dynamic contrast enhanced MRI using contrast agent gadodiamide
46007778|NCT04605575|Drug|Pyrotinib 320mg + Vinorelbine|pyrotinib 320mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
46094716|NCT03920215|Drug|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray
46094717|NCT03920215|Drug|OC-01 Mid Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray
46094718|NCT03920215|Drug|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray
46007779|NCT04605575|Drug|Pyrotinib 400mg + Vinorelbine|pyrotinib 400mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
46094719|NCT03920215|Drug|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
46094720|NCT02766959|Other|Observational study|
46094721|NCT02658578|Procedure|PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator. In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
46007780|NCT04605575|Drug|Pyrotinib plus Vinorelbine|pyrotinib administered daily by mouth（MTD）, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle, or vinorelbine(iv) 25 mg/m2 on day 1 and day 8 of 21 day cycle. Treatments will lasts until disease progression (as assessed by the investigator) or unmanageable toxicity.
46007781|NCT00589134|Dietary Supplement|Gatorade Endurance Formula|carbohydrate electrolyte beverage
46007782|NCT00589134|Other|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days.
46007783|NCT00589173|Behavioral|Interactive Preventive Health Record (IPHR)|Preventive health record designed to a) show patients the status of their preventive care recorded in their electronic record and b) make recommendations on what USPSTF endorsed preventive services that the user needs to receive.
46007784|NCT00589173|Behavioral|"Standard preventive care"|Existing mechanisim for receiving preventive care in primary care (i.e. patients not referred to the IPHR).
46007785|NCT04605146|Behavioral|Tele-monitoring|"The tele-monitoring will consist in filling in a specific questionnaire once a week in the first 6 months, every 2 weeks until 12 months, and on-demand (in case of upcoming toxicity, at any time). These questionnaires will be reviewed by a coordinating nurse. According to the result of the questionnaire, the coordinating nurse will adapt patients' management, either by giving them a phone call, or inviting them to directly contact their medical department, or even plan an emergency hospitalization if necessary. The coordinating nurse will closely work with the investigator to adapt patients' management.~Quality of life questionnaire (FACT-G) will also be filled in at inclusion, M3 and M12."
46007786|NCT00589212|Device|GliaSite Radiation Therapy System|GliaSite RTS is designed to deliver intracavitary radiation therapy for brain tumors. Following surgical resection, the balloon catheter is inflated to fill the cavity and Iotrex radiotherapy solution infused. It is a single applicator system that provides a uniform and conformal dose to the resection cavity.
46007787|NCT04605224|Behavioral|Culinary class|This hands-on, optional course teaches students how to measure and weigh ingredients, read and follow recipes, apply various food preparation, cooking and assembly techniques, as well as prepare meals, as per the provincial curriculum
46007788|NCT00589251|Other|penicillin skin test|"Prick skin tests will be performed on the volar surface of the forearm with each penicilloate and control reagents. The skin test sites will be examined at 15 minutes. A positive test result is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. Patients with negative prick test results to penicillin will undergo intradermal testing.~Intradermal skin tests will be performed on the volar surface of the forearm. The test reagents will be injected intradermally to produce an initial wheal of 2x2 mm. The skin test sites will be examined at 15 minutes. A positive intradermal test is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. In order to ensure patient safety, we will consider using an end point titration technique."
45459942|NCT03482362|Drug|Vinorelbine Tartrate|Intravenous administration of vinorelbine on day 1 and day 8 in a dose of 30 mg/m2. One treatment cycle is 21 days.
45459943|NCT03479866|Other|Dietary intervention|To carry out an interventional dietary study using standardised meals to predict for an individual their metabolic response to certain foods using the gut microbiome and their metabolic profile. Responses will include post-prandial appetite, levels of satiety, circulating glucose, insulin, ketone bodies and lipid levels.
46007789|NCT00589368|Behavioral|Transfer of grasp control across hands|transfer of planning and execution of grasp across hands in terms of its effect on fingertip forces, and the timing and magnitude of muscle contraction in patients with hemiparesis and healthy controls
46007790|NCT00564785|Drug|Synera(TM)|Synera(TM) patch applied 20 minutes prior to epidural
46007791|NCT00564785|Other|Placebo patch|placebo patch applied 20 minutes prior to epidural
46007792|NCT00564824|Drug|Caffeine|Caffeine 200 mg tablet
46007793|NCT00564824|Drug|Placebo|Placebo pills
46007794|NCT00589446|Device|Hysteroscope|An 8mm hysteroscope with irrigation channel and 30 degree view will be inserted into the uterus prior to curettage in cases of recurrent missed abortion
46007795|NCT00564863|Biological|CS19 expressing ETEC strain|Wild type ETEC strain expressing the colonization faction CS19, and LT and ST enterotoxins.
46007796|NCT00589485|Device|Simplex® Bone Cement|This arm will utilize Simplex® Bone Cement in total knee replacement.
46007797|NCT00589485|Device|Cobalt™ Bone Cement|This arm utilizes Cobalt™ Bone Cement in total knee replacement.
46007798|NCT00564941|Drug|deferasirox|
46007799|NCT00589524|Device|Computed tomography (CT)|Computed tomography (CT), as performed by Dual Source Computed Tomography (DSCT)(Siemens Medical Solutions Germany) to be conducted no sooner than 3 days before or after cardiac catheterization, but with 3 months of the cardiac cath.
46007800|NCT00589641|Behavioral|CBT-RP (relapse prevention) + Enhanced TAU|CBT-RP is an 20-week augmenting intervention. CBT-RP is based primarily on Alan Marlatt's cognitive behavioral relapse prevention model for substance abuse, but also includes motivational interviewing and mindfulness meditation approaches. Sessions are twice a week in first week, then weekly thereafter, with tapering to biweekly in the last 8 weeks depending on improvement. Participants also receive treatment as usual, and monthly check-ins regarding treatment use.
46007801|NCT00589641|Behavioral|Enhanced TAU Alone|Treatment as usual in the community, monthly check-ins regarding treatment use or needs, and monitoring
46007802|NCT04605068|Procedure|Transverse preputial island flap (Duckett's technique)|
46007803|NCT04605068|Procedure|Double-faced preputial flap (DFPF)|
46007804|NCT04605107|Drug|Epifasi: Human chorionic gonadotrophin|IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin
46007805|NCT04605107|Drug|Pregnyl: Human chorionic gonadotrophin|IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin
46007806|NCT04605341|Device|miniplate|comparison between k wires and miniplate in metacarpal fractures
46007807|NCT04605653|Behavioral|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
46007808|NCT00589758|Diagnostic Test|Echocardiography|2D and 3D echocardiography
46094722|NCT02772263|Other|CHAP-EMS|The CHAP-EMS program is a low cost community program that is designed to assess community dwelling seniors for lifestyle risk factors that may impact their health and well-being and to provide targeted education to address the pertinent risk factors. Each participant is guided through a structured health-risk assessment focused on diabetes, cardiovascular disease and other potential health issues. The assessment is conducted by a trained paramedic in a common area within the community housing building. Data gathered are used to develop individualized action plans concerning health-risk reduction, to direct participants to local health activities or resources, educate on promoting health and to transmit this information to a participants' family physician.
46094723|NCT02655770|Drug|Liraglutide|
46007809|NCT00589758|Other|Biomarker evaluation|Blood and urine collected
46007810|NCT00564980|Procedure|Wafer Procedure|A dorsal approach to the distal ulna is used dividing the extensor retinaculum between the 5th and 6th compartments. The ulnar head is exposed through a transverse capsulotomy. Cartilage and bone are resected to result in slight negative ulnar variance based on the preoperative pronated grip view. The ulnar styloid and TFCC attachments are preserved. The dorsal capsule and retinaculum are repaired in separate layers.
46007811|NCT00564980|Procedure|Ulnar shortening osteotomy|A longitudinal incision of approximately 8 cm is made at the distal third of the ulna along the ulnar border of the forearm. The interval between the flexor carpi ulnaris is used. The ulna is exposed at its distal third preserving the periosteum. Care is taken to protect the sensory branches of the lunar nerve. An oblique osteotomy is performed using a reciprocating saw, removing enough bone to result is slight negative ulnar variance. Fixation and compression at the osteotomy site is achieved using a 5 or 6 hole titanium LC-DCP plate.
46094724|NCT02655770|Drug|Placebo|
46094725|NCT00986713|Drug|Amphotericin B|Aerosolized Amphotericin B,2mg/day or 10mg/day
46094726|NCT02767037|Device|Sudoscan and clinical assessment|The primary variable will be electrochemical skin conductance (ESC), as assessed by the SudoScan (Impeto Medical, France). The clinical assessment will include a neurological evaluation (including MDS-UPDRS), evaluation of autonomic symptoms and signs, EKG, evaluation of possible neuropathy and evaluation of non-motor variables.
46094727|NCT02767037|Genetic|Skin biopsy|Evaluation of the denervation and synuclein deposition of skin biopsy
46094728|NCT02651870|Drug|Candesartan 16mg|
46094729|NCT02651870|Drug|Amlodipine 5mg|
46094730|NCT02651870|Drug|Amlodipine 10mg|
46094731|NCT00984451|Biological|Plasma collection following infection or vaccination with influenza A|High titer influenza A plasma collection for use as therapeutic plasma in influenza treatment studies.
46094732|NCT02766803|Drug|Simvastatin and micronized trans-resveratrol|
46094733|NCT04169516|Diagnostic Test|index of microcirculatory resistance|Physiological parameters of the culprit artery after PCI were determined with the restoration of Thrombolysis in Myocardial Infarction (TIMI) 3 flow. Aortic pressure (Pa), distal intracoronary pressure (Pd), fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) were measured using a 0.014 coronary temperature and pressure-sensing guidewire (PressureWireCertus, ST. Jude Medical, MN, USA).
46094734|NCT05712577|Other|Questionnaire|Rosenberg Self- Esteem; SF36; Cope NVI; OQ45.2
46007812|NCT00589953|Drug|Erythropoietin|"5 of first 10 subjects (Group 1): 400 units/kg/dose once daily for 7 days 5 of next 10 subjects (Group 2): 800 units/kg/dose once daily for 7 days 20 of next 30 subjects (Group 3): 1000 units/kg/dose once daily for 7 days administered i.v. over 1 hour.~The volume of the study drug will be 1 mL in a 1 mL Tuberculin syringe to be administered over 1 hour."
45836717|NCT00371436|Procedure|Usual Care|Typical audiologic care that would be received in a VA Audiology Clinic.
46094735|NCT02771951|Behavioral|"Lights of Change"|
46007813|NCT00589953|Drug|Saline placebo|Saline vehicle at a volume of 1 mL given over 1 hour intravenously once a day for the first seven days of life.
46007814|NCT00589992|Drug|Ibutilide fumarate|During scheduled radio frequency ablation for atrial fibrillation patients will be infused with 1mg of ibutilide over 10 minutes.
45836718|NCT00397878|Drug|saracatinib|Given orally
46007815|NCT00590070|Drug|adenosine|Adenosine (80 mcg as fast bolus followed by 2 mg given in 33cc of saline in 2 minutes as slow bolus)
46007816|NCT00590070|Drug|nitroprusside|Nitroprusside (60 mcg as fast bolus followed by 100 mcg given in 33cc of 5% glucose in 2 minutes as slow bolus)
45836719|NCT00397878|Other|laboratory biomarker analysis|Correlative studies
46007817|NCT00590070|Drug|placebo|33 cc of heparinized saline given in 2 minutes as slow bolus
46007818|NCT00565019|Drug|Triamcinolone Acetonide|"Triamcinolone acetonide will be administered into the cord following surgery with a tuberculin syringe and a 25-gauge needle.~Doses will range from 60-120 mg depending on extent of the disease.~Patients will receive injections at 6 weeks and 3 months for persisting nodules or cords.~PI will determine the dosages. Estimates will be made based on the following:~Size of nodule/cord: 1-2 cm2, dosage 20-40 mg~Size of nodule/cord: 2-6 cm2, dosage 40-80 mg~Size of nodule/cord: 6-10 cm2, dosage 80-100 mg~Size of nodule/cord: >10 cm2, dosage 100-120 mg"
46007819|NCT00565097|Drug|Placebo|
46094736|NCT02771951|Behavioral|Usual Care|
46094737|NCT00635297|Procedure|Percutaneous vertebroplasty|PMMA injection 3-10 milliliter in each treated vertebrae
46094738|NCT00650468|Drug|tacrolimus|Oral
46094739|NCT00650468|Drug|CellCept|IV or Oral
45836720|NCT00400686|Biological|epoetin alfa|Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.
45836721|NCT05220462|Drug|Remimazolam|As per Remimazolam arm
45836722|NCT05220462|Drug|Midazolam|As per Midazolam arm
46007820|NCT00565097|Drug|Lanreotide|
46007821|NCT04604756|Drug|Losartan|administration of losartan (50 mg) (oral)
46007822|NCT04604756|Drug|Placebo Oral Tablet|administration of placebo (oral)
46007823|NCT00590343|Drug|vatalanib|Subjects who meet all inclusion and exclusion criteria will receive an initial dose of PTK787/ZK222584 1,250mg once daily, and subjects will remain on the scheduled doses of Sandostatin LAR 30mg every 4 weeks.
46007824|NCT00590382|Device|AMPLATZER Muscular VSD Occluder|AMPLATZER Muscular VSD Occluder
46007825|NCT04604717|Other|Pulmonary rehabilitation|8 weeks of exercise training (twice weekly) of education and exercise
46037808|NCT01198574|Dietary Supplement|Iron group|Ferrous fumarate, 60 mg, weekly dose
46037809|NCT01198574|Dietary Supplement|Vitamin A group|Retinol, weekly dose, 15,000 IU
46037810|NCT01198574|Dietary Supplement|Iron and vitamin A group|Ferrous fumarate, Retinol combination group, weekly dose
46037811|NCT01198574|Dietary Supplement|Placebo group|folic acid only as placebo group
46037812|NCT05338294|Procedure|Laparoscopic splenectomy and azygoportal disconnection|Laparoscopic splenectomy and azygoportal disconnection is performed by the same surgical team.
46094740|NCT00650468|Drug|steroids (methylprednisone or prednisone)|IV or Oral
46094741|NCT02576080|Drug|Imatinib|
46094742|NCT02576080|Other|Surveillance|The Experimental Group will receive the same thoraco-abdominal and pelvic CT scan.
46007826|NCT04574700|Other|knee joint mobilization and traction|"Grade 3 traction (Kaltenborn)from knee fully flexed to end of available Range of motion(ROM). Traction 30 sec, 10 sec rest period, 4reps, total 2 min of traction.3 sets for a total of 6 min of traction mobilization.Grade3 keltonborn tibiofemoral and tibiofibular anterior, posterior mobilization 3 sets10glides/set, 3 times/week on alternative days for 4 weeks.~TENS for 20 mins in sitting and strengthening exercises i.e. Quadriceps Setting10 reps, air Cycling 2 min for a bout, straight leg raise (SLR) with weight , Full arc extension 10 reps of each exercise will be carried per session except for full-arc extension and air cycling. Air cycling cont. for 2 min for 1 bout of exercise. Measurement will be taken at base level, after first and last session. Treatment will be given for 3 times/week on alternative days for 4 weeks"
46007827|NCT04574700|Other|Post isometric relaxation|"Control group include Post isometric relaxation technique on hamstring muscle will be performed in supine lying, hip flexed to 90 degrees knee extended until the point of resistance 20% of maximum effort will be used by patient to create isometric contraction. Patient will be asked to breathe in and hold for 5 to 8 seconds and release both breath and effort then move to new barrier point and process was repeated three times per session~TENS and strengthening exercises as mentioned above.~This treatment regime will be given for 3 times/week on alternative days for 4 weeks."
46007828|NCT04604600|Drug|amyloid PET|Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB.
46007829|NCT04604678|Drug|Metformin|Metformin at 1500 mg/day
46094743|NCT04006483|Drug|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
46094744|NCT04006483|Drug|Positive control dentifrice|Positive control dentifrice containing (0.3%) triclosan.
46094745|NCT04006483|Drug|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
46094746|NCT04225247|Drug|Single Bond Universal|Single bond universal (by 3M ESPE) is a seventh generation bonding agents used as desensitizers in the present study.
46094747|NCT04225247|Drug|Bifluorid 12|it is a fluoride varnish by VOCO.
46094748|NCT04225247|Drug|Xeno V+|Xeno V+ (by Dentsply) is a seventh generation bonding agents used as desensitizers in the present study.
46094749|NCT02652026|Procedure|Nonsurgical periodontal treatment|Full mouth debridement, which consisted of scaling and root planing (SRP), was done in a single visit using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France) and Gracey curretes (Hu- Friedy, Chicago, USA).
46094750|NCT02652026|Procedure|Dental Prophylaxis|Removal superficial plaque using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France)
46094751|NCT02651792|Drug|ketamine- propofol|1 mg x kg(-1) ketamine + 1.2 mg x kg(-1) propofol.
46094752|NCT02651792|Drug|pethidine- propofol|1.1 mg x kg(-1) pethidine + 1.2 mg x kg(-1) propofol for sedation induction
45459944|NCT04500470|Drug|Ketoprofen + INH|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table 900 mg vaginal isonicotinic acid hydrazide by the patient 12 hours before the procedure
46007830|NCT04604678|Drug|Naltrexone|Naltrexone at 4.5 mg/day (LDN)
46007831|NCT04604483|Device|PTNS|Patients meeting the criteria are treated with PTNS and are evaluated at 3 months and 1 year after end of treatment.
46007832|NCT03452358|Procedure|Partial Ceramic Indirect restoration|Placement of an partial ceramic indirect restoration with the use of immediate dentin sealing as an adjunct to adhesive cementation.
46007833|NCT04604639|Diagnostic Test|NEWS2 score|Patients seen by ambulance crews within the preceeding 48 hrs of their cardiac arrest will have a NEWS2 score performed to assess the level of physiological deterioration at the time of thei intial assessment.
46007834|NCT04604327|Drug|Bemiparin sodium|Prophilactic vs full-dose for 10 days
46007835|NCT00590616|Procedure|transthoracic examination|observational transthoracic examination
46007836|NCT00590655|Behavioral|weight loss programme with maintenance programme|After usual weight loss treatment, there will be a one-year maintenance programme with monthly visits.
46007837|NCT00590655|Behavioral|weight loss programme|
46094753|NCT04754815|Drug|Pembrolizumab|PD-L1 inhibitor administered as an intravenous (IV) infusion.
46094754|NCT04754815|Drug|Pemetrexed|Folate analog metabolic inhibitor administered as an intravenous (IV) infusion single agent chemotherapy for advanced NSCLC
46094755|NCT04754815|Drug|Paclitaxel|A novel antimicrotubular agent administered as an intravenous (IV) infusion single agent chemotherapy for advanced NSCLC
46094756|NCT04754815|Drug|Nab-paclitaxel|Microtubule inhibitor administered as an intravenous (IV) infusion indicated for the treatment of locally advanced or metastatic NSCLC
46094757|NCT04754815|Other|Laboratory Biomarker Analysis|Correlative studies
46094758|NCT02775149|Other|Collection of saliva samples|Collection of saliva samples
46094759|NCT02775149|Other|Visual detection of BEWE-index|Visual detection of BEWE-index
46094760|NCT02658500|Dietary Supplement|Infant Formula|
46094761|NCT02658500|Dietary Supplement|breast milk|
46007838|NCT04604171|Behavioral|Action Observation Training|Action Observation Training (AOT) is composed, according to Franceschini et al. (2012), by 20 different videos of daily activities (actions) carried out with the upper limbs. Patients underwent only one task per day for 20 sessions, starting from the easiest. Each action (unimanual or bimanual) is observed from a first-person perspective. Actors in the videos are young non-disabled people, either men or women. Patients are asked to carefully observe the videos, in order to prepare themselves to imitate the presented actions, while the therapist consistently holds the patient's attention with verbal feedback. At the end of each sequence, the therapist prompts the patient to perform the same movement with the paretic upper limb over a time period of 2 minutes, providing verbal instructions or help, if needed. Each session lasts about 30 minutes (3 min of sequence observation and 2 min of action performance for 3 motor sequences repeated twice).
46007839|NCT04604171|Behavioral|Task Oriented Training|In Task Oriented Training patients performed functional activities with the upper limbs, using the same objects for AOT, in both unimanual and bimanual modalities, without watching the video beforehand. The therapist just provided for verbal instructions and feedback, avoiding demonstrative or imitative indications. The therapist could passively support the movement if patients were completely unable to perform the actions. When necessary, the therapists could also actively facilitate the upper limb movement if patients were unable to correctly perform the actions. Based on the patient's level of motor ability and progress, the levels of movement and task difficulty could be adjusted accordingly. Patients underwent one task per day for 20 sessions. Each session lasted about 30 minutes.
46007840|NCT04604171|Behavioral|Conventional Treatment|Conventional treatment consists of a range of different patient-tailored interventions, selected by the therapist on the basis of the functional level of the patient. Treatment sessions include training for transfers, mobility, walking up and down steps, balance tasks and tailored functional tasks for the upper limbs (unimanual and bimanual). Moreover, it is also provided for joint and soft tissue mobilization, specific sensory stimulation, exercises to increase strength, both for lower and upper limbs. Each session lasted about 60 minutes.
46007841|NCT00590694|Drug|ranibizumab|0.5mg injection monthly according to protocol for one year
46007842|NCT00565175|Drug|famotidine|Capsules containing 100 mg of famotidine p.o., twice daily for 4 weeks.
46007843|NCT00565175|Drug|Placebo (Microcrystallized cellulose)|Placebo administered in identical capsules as the experimental drug.
46007844|NCT04604249|Diagnostic Test|SARS-CoV-2 rapid diagnostic test (COVID-PRESTO® IgM/IgG, AAZ, Boulogne-Billancourt, France)|Presence of specific SARS-CoV-2 antibodies (IgM or IgG).
46007845|NCT00477165|Drug|Citalopram|20mg/day for 4 weeks, then 40 mg/day for 4 weeks
46094762|NCT05712499|Behavioral|mindfulness-based psychoeducation program|Mindful awareness is a mind and body practice that involves increasing attention to what is happening at the moment and accepting what is perceived without judgment. Mindfulness includes awareness and attention; Awareness is the mechanism that constantly controls the of the state of consciousness. Mindfulness-based cognitive therapies are evidence-based psychoeducation. Psychoeducation was organized in 2 consecutive sessions once a week for 8 weeks, and each session was 60 minutes, in total 16 sessions. The content of the psychoeducation program was explained in detail, and techniques such as presentation and question-answer narrative techniques, video, audio recording, mindfulness assignments for the next session were used in the training.
46094763|NCT05712499|Behavioral|ongoing life|The control group continued with their lives without any intervention. Only pre-test and post-test were applied. While the program was applied to the experimental group, no intervention was made to the control group.
46094764|NCT01660607|Biological|Conventional T cells (Tcon) and Regulatory T cells (Treg)|A baseline cell dose of conventional T cells of 1x10^6/kg will be used with escalation to the maximum tolerated dose up to 1x10^7/kg
46094765|NCT00986791|Other|GSP-A|6-week Gold Standard Programme (5 meetings in total) consisting a structured education programme, hotline, thiamine and B-vitamins (300 mg daily), Alcohol Withdrawal Prophylaxis and intervention (Benzodiazepines)and controlled Disulfiram support (200 mg x 2 weekly)
46094766|NCT00649532|Drug|Ondansetron Tablets 24 mg|24mg, single dose fasting
46094767|NCT00649532|Drug|Zofran® Tablets 24 mg|24mg, single dose fasting
46094768|NCT02655614|Drug|GDC-0134|GDC-0134 capsule will be administered orally at various doses, depending on the cohort and treatment period.
46094769|NCT02655614|Drug|Placebo|Placebo matching to GDC-0134
46094770|NCT02655614|Drug|Rabeprazole|Rabeprazole 20 mg twice daily orally
46094771|NCT02655614|Drug|Midazolam|2mg of liquid formulation of midazolam orally
46094772|NCT02655614|Drug|Caffeine|100 mg tablet or solution of caffeine orally
46094773|NCT02772029|Drug|Apatinib Mesylate Tablets|Apatinib 750 mg is administered orally daily, until disease progression or untolerable toxicity.
46094774|NCT00986869|Procedure|Doppler echocardiogram|All the patients will undergo a Doppler echocardiogram in the day of the bronchoscopy after the bronchoscopy
46094775|NCT02766725|Drug|preparation F12 sildenafil in situ gel|in situ vaginal gel
46094776|NCT02766725|Drug|preparation F2 sildenafil in situ gel|in situ vaginal gel
46094777|NCT02766725|Drug|placebo gel|vaginal gel
46094778|NCT02658422|Drug|Test Montelukast|Test Montelukast (GW483100) is available as round, biconvex, pink 10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water.
46094779|NCT02658422|Drug|Reference Montelukast|Reference Montelukast (innovator product) is available as pale beige, rounded square shaped,10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water. Singular is the innovator product used for this study, which is a trade name owned by Merck Sharp and Dohme Corporation.
46094780|NCT02766569|Device|ASD closure with the Occlutech Flex II ASD closure device|Monitoring of possible device related side effects with a minumum of 1 year follow-up.
46094781|NCT02658344|Biological|JOINTSTEM|Jointstem (Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml), 1 time injection
46094782|NCT02658344|Drug|Saline solution|Saline solution (Sodium chloride 9mg/ml), 1 time injection
46094783|NCT02771795|Drug|Herceptin (trastuzumab)|Intravenous administration
46094784|NCT02771795|Drug|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
46094785|NCT05577247|Other|functional magnetic resonance imaging|Patients treated with ketamine antidepressants will be tested with fMRI before or 24h after a single ketamine infusion administered in the clinical setting.
46094786|NCT02651558|Device|Experimental: OBPM 2015-MD-0022 - CHEST|"At the onset of general anesthesia:~continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~continuous estimates of optical blood pressure values at the chest (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
46094787|NCT02651558|Device|Experimental: OBPM 2015-MD-0022 - CHEST & FINGER|"At the onset of general anesthesia:~continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~continuous estimates of optical blood pressure values at the chest (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~continuous estimates of optical blood pressure values at the fingertip (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
46094788|NCT02651558|Device|Experimental: OBPM 2015-MD-0022 - FINGER|"At the onset of general anesthesia:~continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~continuous estimates of optical blood pressure values at the fingertip (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
46094789|NCT04224077|Diagnostic Test|Optimisation of DTI sequences|Optimisation of DTI sequences in the study of lumbar roots by MRI
46094790|NCT05560867|Device|robot-assisted training|These training platforms use gamified training tasks to improve motor control in the hemiparetic arm
46094791|NCT02655536|Drug|Bevacizumab plus erlotinib|Bevacizumab will be administered at a dose of 15 mg/kg on day 1 of every 3 weeks cycle by IV infusion erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
46094792|NCT02655536|Drug|Erlotinib|erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
46094793|NCT02766647|Biological|Filgrastim Hospira (US)|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
46094794|NCT02766647|Biological|US-approved Neupogen®|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
46094795|NCT02651636|Drug|myo-inositol,alpha-lipoic acid and folic acid|
45459945|NCT04500470|Drug|Ketoprofen + placebo|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table placebo by the patient 12 hours before the procedure
46094796|NCT04005937|Diagnostic Test|H-reflex|Electrical stimulation of Group Ia afferent of muscle spindle
46094797|NCT02774993|Drug|Doxycycline|
46094798|NCT02774993|Drug|placebo|
46007846|NCT00477165|Drug|Placebo|Identical to citalopram 20mg capsules; 1 capsule/day for 4 weeks, then 2 capsules/day for 4 weeks
46094799|NCT02651402|Behavioral|FRIENDS for Life|Friends for Life (FRIENDS): FRIENDS, a GCBT program, is an effective program for the prevention and treatment of anxiety disorders in children evidenced by a meta-analysis on school-based interventions for at-risk and clinically anxious youth. FRIENDS was developed based on the view that anxiety is a tripartite construct involving physiological, cognitive, and behavioral components. Core Intervention components: Experts in CBT for childhood anxiety disorders have identified 5 essential components: psychoeducation, somatic management skills training, cognitive restructuring, exposure methods, and contingency management. The FRIENDS protocol consists of 10 weekly sessions and two booster sessions. We included the booster sessions in the regular protocol for a total of 12 sessions.
46094800|NCT02651402|Behavioral|Adapted FRIENDS|Adapted Friends (aFRIENDS): We conducted planned adaptations to the FRIENDS protocol based on our collective experience with the protocol and qualitative data (focus group and interviews). We followed procedures developed by Lee and colleagues, including surveying service providers and trainers regarding the appropriateness of FRIENDS for the target population. Changes were made to the language (idioms, metaphors, words), cultural fit (cultural values), methods (session length, number of sessions), activities (in-session practices), which resulted in additions and substitutions in these areas while maintaining the 5 essential components of the treatment. aFRIENDS is a briefer (8-session) and more engaging and culturally-sensitive protocol than FRIENDS.
46094801|NCT02651402|Behavioral|Train-the-Trainer|Train the Trainer (TT): agency supervisors are trained to conduct effective supervision (one initial training and 2 booster sessions), and then go on to train intervention therapists.
45459946|NCT01960933|Procedure|Percutaneous coronary intervention|
45459947|NCT01960933|Procedure|FFR|
45459948|NCT03482284|Other|Dietary Intervention|Participants receive different monosaccharides for a defined number of days.
45459949|NCT05760638|Device|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
46007847|NCT04604054|Drug|Granulocyte Colony Stimulated Factor|GCSF was intrauterine injected once at ovum pick up day
46007848|NCT04604054|Drug|Human Chorionic Gonadotropins|500 IU of HCG was injected intrauterine once at ovum pick up day
46007849|NCT00476229|Drug|Thymoglobulin|1.5 mg/kg by vein on Days -11 to -7.
46007850|NCT00476229|Radiation|Total Lymphoid Irradiation|80 cGy daily on days -11 to -7 and -4 to 0.
46007851|NCT00476229|Procedure|Peripheral Blood Stem Cell Infusion|PBSC infusion administered on day 0.
46007852|NCT00476229|Drug|Rituximab|375 mg/m^2 by vein on days -13, -6, 1, & 8. Only those patients whose tumors express CD20 will receive Rituximab.
46094802|NCT02651402|Behavioral|Train-the-Trainer Plus|Train the Trainer Plus (TT+): a modified train-the-trainer approach by which supervisors receive training plus extended on-going consultation on conducting effective supervision with intervention therapists.
46007853|NCT04603976|Drug|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
46094803|NCT02774837|Drug|Tenofovir disoproxil|Tenofovir disoproxil 300mg once daily for 96 weeks
46007854|NCT00476151|Drug|EpiCept NP-1 (4% Amitriptyline/ 2% Ketamine) Topical Cream|topical cream applied daily for 4 weeks
46007855|NCT00476151|Drug|placebo cream|inactive placebo cream applied two times daily
46007856|NCT04603703|Other|HVLAT Manipulation|"Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week), HVLAT manipulation/ 1 rep/ 1set/ (3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins."
46007857|NCT04603703|Other|Conventional Physical Therapy|"Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins."
46007858|NCT00475644|Drug|Enzastaurin|Administered orally
46007859|NCT04603664|Diagnostic Test|serum NGAL and cystatin c|measuring serum NGAL and cystatin c on admission and after 48 hours in critically ill patients with covid 19 then compare results to serum creatinine and signs of acute kidney injury
46007860|NCT04603235|Behavioral|Manual-based Art Therapy|This is a manual-based treatment and consists of 10 one-hour weekly sessions. The treatment consist of detailed guidelines based on phenomenological art therapy. The sessions follow the same structure: Introduction, short relaxation, art-making, reflections about the image, and conclusions. Examples of comprised art tasks; lifeline, emotional scribbles, and different roles. The art tasks served as a prompt for painting.
46007861|NCT00474903|Drug|acetylsalicylic acid|Given orally
46007862|NCT00474903|Drug|esomeprazole magnesium|Given orally
46007863|NCT00474903|Other|placebo|Given orally
46007864|NCT01134055|Drug|pazopanib eye drops|A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.
46007865|NCT01134055|Drug|placebo|placebo eye drops
46007866|NCT01134055|Biological|ranibizumab intravitreal injection|Humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A
45459950|NCT03493386|Drug|Daprodustat 2 mg tablet|Daprodustat is available as 2 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 2 tablets of 2 mg daprodustat will be administered in a fasted state during Part 1 of the study.
45459951|NCT03493386|Drug|Daprodustat 4 mg tablet|Daprodustat is available as 4 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 4 mg daprodustat will be administered in a fasted state during Part 1 and in fed and fasted state in Part 2 of the study.
45459952|NCT03482206|Device|Automated extracranial internal carotid artery ultrasound sensor|The investigators' goal is to develop a wearable noninvasive, continuous, automated ultrasound sensor to accurately measure arterial blood flow volume outside of the head. Ultrasound uses sound waves to create a picture. In doing so, the investigators hope to detect CBF compromise early, preventing secondary injuries in TBI patients.
46007867|NCT00474708|Drug|Effexor|
46007868|NCT00474708|Drug|SSRI|
46007869|NCT04603040|Drug|Toripalimab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w), In a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
46007870|NCT04572048|Other|Single-day NRP Training|NRP training course completed in one single day of 8 hours
46007871|NCT04572048|Other|longitudinal NRP training|NRP training course completed over one year by attending nine 30-minute modules.
46007872|NCT05366959|Other|Trunk Muscle Endurance test|"Trunk flexors endurance test: Participants will be positioned with trunk flexed to 60º, knees and hips to 90º flexion. The evaluator fixes the feet on the ground by supporting them from the toes. When the 60º trunk flexion is broken, the test will be terminated and the time it maintains this position will be recorded in seconds.~Modified Biering-Sorensen test: With this test, the endurance of trunk extensors is evaluated. The subjects are positioned in the prone position with the pelvis, hips and knees on the bed. The subjects are asked to extend their upper body straight forward from the edge of the table and the time they maintain this position will be recorded in seconds.~Lateral bridge test: During the test, the subjects were asked to lie on their side, raise their bodies on their forearms and toes and maintain this position, and the time they held the position would be recorded in seconds. The test will be done on both sides."
46007873|NCT05366959|Other|Fatigue Severity Scale|"Fatigue Severity Scale was used to evaluate the fatigue level of the participants. This scale consists of a 7-point Likert scale. 1 point means strongly disagree, 7 means strongly agree. High scores are associated with increased fatigue. Evaluates the effects of fatigue on physical function, motivation, family and social life. Turkish validity and reliability was established."
46007874|NCT05366959|Other|Roland Moris Scale|"The Roland Moris Scale will be used to evaluate the participants for low back pain assessment. The Roland Morris Inquiry Form was designed to evaluate the functional disability of the patient. The total score ranges from 0 (no disability) to 24 (severe disability). The higher the total score, the lower the patient's functionality. It is a questionnaire filled by the patient, which evaluates the functionality of 24 items questioning the patient's mobility, self-care and sleep status. Each item marked as 'Yes' is given 1 point, and answers marked as 'No' are given 0 points. Turkish validity and reliability was established."
46007875|NCT05366959|Other|Physical Activity Levels|The physical activity level of the participants will be measured with the International Physical activity scale: MET values will be calculated according to this scale, which has Turkish validity and reliability.
46007876|NCT04603118|Procedure|Optic ultrasonography|
46094804|NCT02774837|Drug|Telbivudine|Telbivudine oral tablets 600mg once daily for 96 weeks
46094805|NCT00987025|Behavioral|Telehealth|Use of telehealth blood pressure station every week
46094806|NCT00987025|Behavioral|Educational materials|Control
46094807|NCT02658188|Drug|ASP8825|Oral
45836723|NCT05215938|Diagnostic Test|MRI examination|"The magnetic resonance imaging session will be performed in a clinical 3T MRI scanner (GE healthcare). A commercial human intent non-diagnostic RF coil (PulseTeq) will be used for 23Na MRI.~The scanner, coils and sequences are regularly used in research projects and validated for the same safety requirements as routinely used in the clinic. Nevertheless, the complete MRI session will be performed in research mode to use the advanced options (limits the usage to non-diagnostic purposes).~Participants will be placed in a supine position with coils covering the area of interest (AOF).~MRI examination will be performed by trained personnel."
46094808|NCT05712031|Procedure|Insertion of 1 Nucleoss T4 dental implants in posterior mandible|Nucleoss T4 dental implants is combined with first or second premolar to support 3 unit fixed partial dentures
46094809|NCT05712031|Procedure|Insertion of 1 Nucleoss T5 dental implants in posterior mandible|Nucleoss T5 dental implants is combined with first or second premolar to support 3 unit fixed partial dentures
46094810|NCT05712031|Procedure|Insertion of 2 Nucleoss T4 dental implants posterior mandible|2 freestanding Nucleoss T4 dental implants is used to support 3 unit fixed partial dentures
46007877|NCT04603118|Procedure|Lumbar puncture|
46007878|NCT02883127|Behavioral|Motivational interviewing|"The aim is to provide a one-to-one contact every second week of approximately 10 minutes duration. An action plan for improving dietary behavior will be made during the first session and evaluated in subsequent sessions. The following dietary objectives will be set for each participant to achieve or to maintain:~Watch portion size - to be conscious about the amount of carbohydrates in each meal.~Eat mainly carbohydrates of low glycaemic index.~Reduce the intake of carbohydrate of high glycaemic index.~Watch daily weight changes - aim for the recommended weekly changes.~In addition to the motivational intervention the women are given unchanged routine care."
46007879|NCT04603586|Radiation|SBRT|SBRT: in 5-6 fractions with CyberKnife
46007880|NCT04603586|Drug|Chemotherapy|1000 mg of Gemcitabine + albumin-bound paclitaxel per square meter of body surface area on days 1, 8 for 2 weeks, followed by 1 weeks of rest as one course
46007881|NCT00474240|Drug|Atorvastatin 20 mg|
46094811|NCT02771717|Drug|Budesonide (Pulmicort)|Budesonide (Pulmicort) - inhaled low dose inhaled steroid - I puff to be taken twice daily
46094812|NCT02771717|Drug|Placebo - dummy inhaler|Placebo - dummy inhaler to be taken 1 puff twice daily.
45459953|NCT04480658|Drug|Bryophyllum pinnatum 50 %, tablets into capsules (verum: 2x2capsules/day)|"Bryophyllum is administered for 3 weeks. Bryophyllum is given in form of capsules, 350mg per capsule, 0-0-2-2/d: 2 capsules 30min. before supper,2 capsules before going to bed.~Other Names:~Bryophyllum pinnatum/Kalanchoe"
45836724|NCT00373386|Drug|growth hormone|Growth Hormone treatment
46007882|NCT00474240|Drug|AEGR-733 5 mg|
46094813|NCT02655380|Drug|Ketamine 1|Anesthesia induction is performed with 1 mg ketamine.
46094814|NCT02655380|Drug|Ketamine 2|Anesthesia induction is performed with 2 mg ketamine.
46094815|NCT02655380|Drug|Remifentanil|After anesthesia induction with ketamine, predetermined remifentanil using Dixon's up and dowm method is administered.
46094816|NCT00580840|Drug|Certolizumab pegol|400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
46094817|NCT00580840|Drug|Certolizumab pegol|200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
46094818|NCT00580840|Other|Placebo|placebo (saline) administered as two injections every 2 weeks
46094819|NCT00987103|Drug|Tacrolimus|Oral: 0,1 mg/kg Rectal: 15 mg Sublingual: 0,04 mg/kg
46094820|NCT02655458|Drug|Elotuzumab|"The following must also be administered before any elotuzumab:~Dexamethasone 8 mg IV (on the day of elotuzumab infusion 45-90 mins prior to the start of infusion), the following 30 - 90 minutes prior to start of infusion: H1 blocker: diphenhydramine (25 - 50 mg po or IV) or equivalent, H2 blocker: ranitidine (50 mg IV) or equivalent (adjusted for renal failure as indicated), acetaminophen (650 - 1000 mg po)."
46007883|NCT00474240|Drug|AEGR-733 10 mg|
46007884|NCT00474240|Drug|Placebo|
46007885|NCT00474240|Drug|AEGR-733 5 mg + atorvastatin 20 mg|
46007886|NCT00474240|Drug|AEGR-733 10 mg + atorvastatin 20 mg|
46007887|NCT02277561|Procedure|diffusion tensor imaging|Undergo VB-DTI
46007888|NCT02277561|Radiation|whole-brain radiation therapy|Undergo WBRT
46007889|NCT02277561|Radiation|stereotactic radiosurgery|Undergo SRS
46007890|NCT02277561|Procedure|contrast-enhanced magnetic resonance imaging|Undergo contrast-enhanced MRI
45836725|NCT05154552|Other|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation (PNF) is a more advanced form of flexibility training, which involves both the stretching and contracting of the muscle group being targeted. PNF stretching is one of the most effective forms of stretching for improving flexibility and increasing range of motion.
46007891|NCT02277561|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW MRI
46007892|NCT00473889|Drug|vorinostat|vorinostat 400 mg capsules once daily. Up to 6 months of treatment
46007893|NCT00473889|Drug|Comparator: paclitaxel|intravenous (IV) paclitaxel 200 mg/m2. Up to 6 months of treatment
46007894|NCT00473889|Drug|Comparator: carboplatin|intravenous (IV) carboplatin AUC 6mg/min/ml. Up to 6 months of treatment.
46007895|NCT00473889|Drug|Comparator: placebo|vorinostat 400 mg placebo capsules once daily. Up to 6 months of treatment
46007896|NCT04602416|Behavioral|Training sessions|
46007897|NCT04602455|Behavioral|Self-Care Program through Heartfulness|A four-week Self-Care program through Heartfulness will be offered to participants in the Heartfulness group. This would include a daily practice of relaxation tools for 15 minutes a day using an app and once a week webinar for 30 minutes. Guided relaxation and meditation sessions will be offered to the participants during the intervention weeks. These virtual sessions were conducted by Heartfulness Champions and certified trainers from Heartfulness Institute.
46007898|NCT00565214|Dietary Supplement|Group 1|The treatment plan involves the administration of a combination of 3 vitamins (vitamin C 1000 mg, vitamin E 400 IU, selenomethionine 400 μg) to study volunteers in a 2:1 randomization, Vitamins are to be taken orally, once a day, for a duration of 30 days.
46007899|NCT00565214|Dietary Supplement|Group 2|The treatment plan involves the administration of a combination of 3 placebos to be taken orally, once daily for a duration of 30 days.
46007900|NCT00565253|Drug|Inhaled nitric oxide (NO)|20 ppm for 15 minutes
46007901|NCT04602689|Drug|Human fibrinogen concentrate|Spread the Human fibrinogen concentrate/Aprotinin/Thrombin/Calcium chloride hydrate mixture on iatrogenic ulcer after ESD
46007902|NCT02277600|Drug|BMS-663068|BMS-663068
46007903|NCT02277600|Drug|Darunavir|Darunavir
46007904|NCT02277600|Drug|Cobicistat|Cobicistat
46007905|NCT00575250|Behavioral|Osteoporosis Prevention and Self-Management Course|Four weekly education sessions of 2 1/2 hours duration, in a group session facilitated by a community nurse and trained lay leader.
46007906|NCT00575250|Behavioral|Introductory education session on osteoporosis|Introductory education session, 1 x 2 1/2 hours in a group session facilitated by a community nurse and trained lay person.
46007907|NCT04602143|Drug|Testosterone gel|Apply 12.5mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 4 or 6 weeks until next IVF treatment.
46007908|NCT02277678|Drug|Opioid administration oxycodone|Epidural administration single dose through epidural catheter
46007909|NCT02277678|Drug|Opioid administration morphine|
46007910|NCT04601636|Device|Active Prewarming|Active prewarming with Flex Warming Gown (Bair Paws, 3M) for at least 30 minutes before induction of anesthesia, with active warming intraoperatively with Bair Hugger (3M)
45599028|NCT03949673|Drug|Diclofenac|Diclofenac will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
46007911|NCT04601636|Other|Standard Care|Standard care with a passive prewarming (warm cotton blankets) before induction of anesthesia, with active warming intraoperatively with (Bair Hugger, 3M)
46007912|NCT04579536|Other|Light curable resin modified glass ionomer varnish|Light curing resin-modified glass ionomer varnish (ClinproTM XT Vanish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used to seal 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
46007913|NCT04579536|Other|Vanish White Varnish|5% Sodium Fluoride (NaF) with Tri-Calcium Phosphate topical varnish (Vanish White Varnish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used on 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
46007914|NCT04601519|Other|Cross-sectional observational study|Online questionnaire on the impact of type 1 diabetes on sleep quality
46007915|NCT02277717|Drug|SYD985 (trastuzumab vc-seco-DUBA)|IV (in the vein) infusion every three weeks. Number of Cycles: until cancer progression or unacceptable toxicity develops. Different doses.
46007916|NCT04601675|Drug|Ranibizumab Ophthalmic and Intravitreal Dexamethasone|Pro re nata patients with macula edema due to diabetes will receive Ranibizumab. Group A will continue to receive Ranibizumab depending on their clinical status of macular edema
46007917|NCT04601675|Drug|Ranibizumab Ophthalmic only|Group B will initially receive intravitreal Dexamethasone and Ranibizumab and then depending on their clinical status of macular edema, Ranibizumab will be injected.
46007918|NCT02277756|Device|thermode|thermal stimulation with test thermode
46007919|NCT00565292|Drug|MK0859|
46007920|NCT04601597|Device|Shu Bei Kang (China) Midline Catheters|The procedures ① evaluation and selection of blood vessels: select the puncture vein in the middle of the patient's upper arm, ② Skin disinfection and towel laying: take the supine position, extend the upper limb to be punctured 45 ~ 90 °, disinfect the pre punctured upper limb with 75% alcohol and 5% povidone iodine. ③ Puncture vein: tie a tourniquet to fill the vein. Before puncture, use 0.2 ~ 0.4 ml of 2% lidocaine for local anesthesia. Under the guidance of ultrasound, use the puncture needle in the improved sedinger assembly for puncture. After successful puncture, insert the guide wire. ④ Delivery and confirmation of catheter position: after successful puncture, insert the dilator catheter sheath assembly, withdraw the setinger guide wire, deliver the catheter, after catheter placement, flush and seal the catheter with normal saline, and fix the catheter with sterile dressing.
46007921|NCT01580865|Drug|Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis|Patients were randomly assigned to receive regimen I or II: TAC plus prednisolone (TAC group) or MMF plus prednisolone (MMF group). TAC was started at a dosage of 0.1 mg/kg/day divided into 2 daily doses at 12-hour intervals, and the dosage was titrated to achieve trough blood concentrations of 6-10 ng/mL in the first and second month and then 4-8 ng/mL., thereafter. MMF was initiated at a dose of 500 mg twice daily (for patients > 50 Kg and Estimated Glomerular Filtration rate (eGFR) > 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. Patients received concomitant prednisone at a dose of 0.5-0.7 mg/kg/d (maximum 60 mg/day), with tapering by 5-10 mg/day every 2 weeks until a dose of 5 mg/d has been achieved, and this dosage was maintained until the end of 24 weeks.
46007922|NCT04601441|Drug|Apalutamide|Apalutamide 240 mg administered orally once a day as four 60 mg tablets
46007923|NCT00473694|Drug|sugammadex|Administered as an intravenous (IV) infusion
46094821|NCT02655458|Drug|Lenalidomide|On the days of elotuzumab administration, the dose of lenalidomide is to be administered at least 2 hours after completion of elotuzumab dosing. Aspirin 81 mg PO daily will also be prescribed for DVT prophylaxis.
46094822|NCT02655458|Other|autologous PBMC reconstitution|Autologous peripheral blood mononuclear cell collection and reconstitution. PBMC will be collected from patients by standard apheresis procedures. Up to 25 ml of autologous plasma will also be recovered for dilution of cryopreserved products (if necessary). For reconstitution, Patients will be pre-medicated as per each institution's standard protocols prior to reinfusion of PBMC products. Patient ID will be checked and verified by nursing staff and the products will be re-infused by continuous intravenous infusion pump. Patient vital signs will be monitored every 15 minutes for the duration of the procedure as per standard reinfusion protocol.
46094823|NCT02655458|Other|ASCT|"Autologous peripheral blood stem cell transplantation. (stem cells from the patient's own marrow are harvested, stored and then returned to the body (engrafted). To be done as part of standard of care."
46094824|NCT04871243|Other|Qualitative Interview|Individual semi-structured interviews
46094825|NCT04006093|Drug|Apixaban Oral|one Tablet 5mg
46094826|NCT00879684|Biological|CVX-060|Weekly, intravenous dose
46094827|NCT02658266|Behavioral|Home based resistance training|The participants in the intervention group will receive an individualized resistance training program. The individual adjustments in load will will be made from the results of the muscle function and muscle strength tests. The resistance training will be home based and performed 3 times per week 10-12 reps 2 sets 12 weeks. Increment of load will be performed continuously according to rating of perceived exertion.
46007924|NCT00473694|Drug|neostigmine|Administered as an IV infusion
46007925|NCT00473694|Drug|vecuronium|Administered as an IV infusion
46007926|NCT00473694|Drug|rocuronium|Administered as an IV infusion
46007927|NCT00473694|Drug|glycopyrrolate|Administered as an IV infusion
46094828|NCT05556187|Other|Individualized automated oxygen titration|Automated oxygen titration based on the oxygen saturation during the entire day.
46094829|NCT02766491|Other|Strengthening and stretching|"Strengthening exercises will be performed 4 times a week for 10 weeks. Single leg heel raises will be the preferred exercise performed. The group of participants will have a wide range of strength and functional abilities, this will be accounted for with individualised programmes. The exercise load can be reduced by switching to bilateral heel raises, giving external support, reducing the range of motion or performing the heel raises while seated. Exercise load will be progressively increased by adding weight in the form of water bottles to a rucksack worn on the participant's back.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed."
46037813|NCT02580994|Drug|Pembrolizumab|IV infusion at the dose of 200 mg on day 1 every 3 weeks
46037814|NCT02580994|Drug|cis/carboplatin and etoposide|Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3
46094830|NCT02766491|Other|conventional stretching|"This group will perform seated biceps curls 4 times a week for 10 weeks, where extra load can be added progressively by holding water bottles in the hand.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed."
46094831|NCT02655302|Other|Sample collecting|Collect sputum, blood and nasopharyngeal swab during the exacerbation and at steady state 8 to 16 weeks later.
46094832|NCT02655302|Other|Lung function measure|Measure lung function and follow it during 4 years
46094833|NCT05545813|Dietary Supplement|Probiotic|Participants will be asked to take 1 capsule (3 billion CFU) daily for 8 weeks in the morning with their first meal.
46007928|NCT04601792|Drug|Individualized Decoction|Applied in the Tested Drug Observation Period. It is the highly individualized treatment of TCM, the modification of Bronchiectasis Stabilization Decoction (Rhizoma Fagopyri Cymosi 30g, Radix Lithospermi 15g, Radix Ophiopogonis 15g, Poria cocos 15g, Radix Astragali 20g, Rhizoma Bletillae 10g, Platycodon grandiflorum 10g, Semen Coicis 30g) based on syndrome differentiation. For example, for patients with qi and yin deficiency syndrome, the investigators added Adenophora Root, Radix Glehniae and Radix Rehmanniae Recens etc. For patients with phlegm-heat syndrome, the investigators added Radix Scutellariae and Viola Yedoensis etc. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
46007929|NCT04601792|Drug|placebo|Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc. and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
46094834|NCT05545813|Dietary Supplement|Placebo|Participants will be asked to take 1 capsule daily for 8 weeks in the morning with their first meal.
46094835|NCT02766179|Device|CPAP|CPAP is used for 6 weeks
46094836|NCT02766179|Device|Somnoguard|Somnoguard is used for 6 weeks
46094837|NCT05255120|Other|Intiensified structured perioperative information|The doctor takes a medical history and examines the patient according to regular routines, but uses the algorithm as support in deciding on the surgical method. After the doctor's visit, the patient must see a research nurse to receive the intensified preoperative information about hysterectomy. This information is designed according to a checklist. The patient can also download a mobile application. The study-specific mobile application (app) contains information about hysterectomy. The information is structured in three parts - Before the Operation, At the Hospital and After the Operation. A timeline describes the activities and events that occur before, around and after the operation. Within each section there are several information links, with eg checklists.
46094838|NCT04005547|Behavioral|Promoting Awareness through Live Movement and Sound for youth with Autism Spectrum Disorder|Session 1 - Let's Talk About Relationships Session 2 - Let's Talk About Intimate Relationships Session 3 - Let's Talk About Sex Session 4 - Let's Talk About Protection Session 5 - Let's Talk About Communication *Bring your Trusted Adult* Session 6 - Let's Talk About Growing Up
46094839|NCT00661986|Dietary Supplement|dark chocolate 6 g/day|dark chocolate 6 g/day
46094840|NCT00661986|Dietary Supplement|dark chocolate 25 g/day|dark chocolate 25 g/day
46094841|NCT04223921|Other|Comparison of patient's medicines|"Comparison of patient's medicines:~between patient's discharge from hospital and one month after this discharge (acute geriatric care unit)~between patient's admission and discharge from hospital (acute geriatric care unit"
46094842|NCT02658110|Dietary Supplement|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage
46094843|NCT02658110|Other|Mixed Macronutrient Breakfast Meal|A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kJ; 468 kcal total)
46094844|NCT02658110|Other|Mixed Macronutrient Lunch Meal|A standardised mixed-macronutrient lunch served to all participants. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat (3506 kJ; 838 kcal total)
46094845|NCT03917836|Diagnostic Test|endoscopy and histology|diagnostic evaluation of chronic gastritis
46094846|NCT02766257|Procedure|Anesthesia for ambulatory paediatric surgery|
45678476|NCT01411852|Drug|0.9% Sodium Chloride 250 mL bolus|Emergency Medicine Systems (EMS) agencies and in-hospital providers will be given the option to utilize either systolic blood pressure (SBP) or radial pulse as the endpoint for fluid resuscitation to patients randomized to the experimental group. Patients will receive a 250 ml bolus of normal saline (NS) only if the SBP is less than 70 mmHg or the radial pulse is not palpable. If the SBP is greater than or equal to 70 mmHg or the radial pulse is palpable, NS will be given to keep the vein open. The presence or absence of a radial pulse or the SBP will be documented before and after each bolus. The study will continue repeating the randomization procedure using only 250 ml bags of NS until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first.
46094847|NCT02577562|Device|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
46094848|NCT00662142|Dietary Supplement|docosahexaenoic acid|DHA 400 mg/day (200mg twice daily), vs DHA 1200 mg/day (400 mg three times daily), vs placebo; 1:1:1 ratio
46094849|NCT05711875|Other|Virtual Reality (VR) glasses|During the Non Stress Test (NST), the pregnant women in the experimental group watched a video of nature scenery with Virtual Reality (VR) glasses for 10 minutes
46094850|NCT02651714|Drug|Tradipitant|
46094851|NCT02651714|Drug|Placebo|
46094852|NCT04163172|Procedure|Surgical treatment of distal humeral fracture with elbow hemiarthroplasty|Latitude anatomical elbow hemiarthroplasty (WRIGHT -Memphis, Tennessee)
46094853|NCT04163172|Procedure|Surgical treatment of distal humeral fracture with double plating.|Double plating (Synthes - Switzerland and West Chester, Pennsylvania, United States)
46094854|NCT02576158|Procedure|TCT，HPV，colposcopic inspection|
46007930|NCT04601792|Drug|Tested drug minus heat-clearing herbs|It is the decoction of the Syndrome Differentiation Decoction (tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria Baicalensis, Rhizoma Coptidisor Herba Violae will be removed from the Syndrome Differentiation Decoction.
46007931|NCT04601324|Drug|Fluticasone Propionate|Participants will be required to use fluticasone propionate nasal spray twice daily.
46007932|NCT04601324|Drug|Azelastine hydrochloride and fluticasone propionate|Participants will be required to administer twice daily MP-AzeFlu nasal spray (formulation of 137 mg of azelastine hydrochloride/50 mg of fluticasone propionate) separated by 12 hours.
46007933|NCT04601324|Drug|Rupatadine|Rupatadine once daily for a total of 2 weeks.
46007934|NCT04601012|Diagnostic Test|Optical coherence tomography angiography|Each subject underwent optical coherence tomography angiography to evaluate the retinal vessel density.
46007935|NCT00565331|Drug|Rituximab|single dose of rituximab of 375 mg/m2 intravenously at the time of transplantation
46007936|NCT00565331|Drug|Placebo|saline solution
46007937|NCT00473655|Drug|rosuvastatin|10mg or 20mg
46007938|NCT04576481|Behavioral|Text Messaging|Text Messages will be sent to participants using Penn's Way to Health Platform. Participants will be asked to reply to daily text messages on daily shared reading activities including the titles of books and time spent reading.
46007939|NCT04576481|Behavioral|Coaching|Personalized coaching content will be made available to participants through links in the text messages and will provide comparisons of their reading frequency with that of other participants.
46007940|NCT04576481|Behavioral|Lottery|Participants who reply to a text message that they read on a particular day will be entered into daily and weekly drawings to receive cash payments.
45836726|NCT05154552|Other|Routine physical therapy|"Routine physiotherapy in Parkinson Disease will be administered according to the European Physiotherapy guidelines for Parkinson Disease and focused on the following areas based on the stage of the disease:Self-management support, prevention of inactivity and fear of falls, maintaining or improving global motor activities, improvement of physical performance, and improvement in the ability to perform transfer, balance, gait, and manual activities, reduce pain, and delay the onset of physical limitations.~Other exercises include:~Range of motion exercises~Stretching exercises~Upper and lower limb strengthening exercises"
46007941|NCT00582920|Radiation|Zometa™|Patients who will be receiving zoledronic acid therapy and are scheduled for an extent of disease evaluation with bone scan would undergo a second bone scan within 1 day of zoledronic acid therapy to assess changes in imaging.
46007942|NCT00473382|Drug|Ranibizumab|Sterile solution for intravitreal injection.
46007943|NCT00473382|Drug|Sham injection|
46007944|NCT00582959|Other|Cone Beam Imaging|Prototype, third generation EPID based portal imaging system utilizing the MV approach.
46007945|NCT04576364|Drug|Magnesium sulfate for 12 hour|drug used to prevent convulsions in patients having preeclampsia with severe features
46007946|NCT04576364|Drug|Magnesium sulfate for 24 hour|drug used to prevent convulsions in patients having preeclampsia with severe features
46007947|NCT02210325|Drug|solithromycin|
46007948|NCT02210325|Drug|ceftriaxone|
46007949|NCT02210325|Drug|azithromycin|
46007950|NCT00473265|Drug|PTH|
46007951|NCT00583037|Device|Neurally Adjusted Ventilatory Assist (NAVA)|Mechanical ventilation controlled by diaphragm electrical activity
46007952|NCT04576286|Procedure|Holmium versus Bipolar en bloc transurethral resection|"After obtaining informed consent, patients will be randomized with a 1:1 ratio using sealed envelopes that will be prepared by the department's ethical committee into 2 groups, group 1 represent the Holmium en bloc resection procedure while group 2 represents bipolar en bloc resection. Patients will be blinded to the type of intervention as well as the data collector and the statistician.~Intervention: all procedures will be done by an expert surgeon who performed over 50 cases of en bloc urinary bladder tumor resection with each energy source. In group A, Holmium en bloc resection procedure will be done under either general or spinal anesthesia, using a Holmium laser device (Cyber Ho, Quanta device, Milano, Italy). We will use a 30-40-watt power, 1-2 joules and 20-30 MHz frequency for Group A and bipolar en bloc resection for Group B. A 550 nm flexible laser fiber will be used in group A and a bipolar resection loop for group B."
46007953|NCT00472641|Drug|Ziprasidone/Geodon|Ziprasidone/Geodon
46007954|NCT04576208|Drug|TAK-788|TAK-788 capsules
46007955|NCT04576208|Drug|Antidiarrheal prophylaxis|Antidiarrheal prophylaxis includes loperamide tablet administered as per routine clinical practice.
46007956|NCT04571151|Drug|LEXETTE 0.05% Topical Foam|Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks.
46007957|NCT04571151|Drug|Sorilux 0.005 % Topical Foam|Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g.
46007958|NCT04571151|Other|Vehicle Foam|Vehicle Foam would be applied over the affected area twice daily for 6 weeks.
46007959|NCT04576169|Procedure|Arthroscopic Debridement|A central or radial TFCC tear found during wrist arthroscopy is debrided with a shaver. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Immediate mobilization of the wrist is allowed after operation. Instructions of home exercise are handed to the patient and patient is instructed to start the exercises two weeks from the operation.
46037815|NCT01198028|Drug|Erlotinib|Given PO
46037816|NCT02780362|Drug|Prodactariv|1 tablet contains 60 mg Daclatasvir
46037817|NCT02780362|Drug|Clatazev|1 tablet contains 60 mg Daclatasvir
46007960|NCT04576169|Procedure|Placebo surgery|Diagnostic arthroscopy only. A central or radial TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Immediate mobilization of the wrist is allowed after operation. Instructions of home exercise are handed to the patient and patient is instructed to start the exercises two weeks from the operation. The procedure is placebo surgery.
46007961|NCT04576169|Procedure|Arthroscopic or Open Repair|An ulnar TFCC tear found during wrist arthroscopy is sutured to the capsule or fovea with one of the separately defined methods choosed by the treating hand surgeon. The procedure is performed in general or regional anesthesia in operating room. Wounds are closed and standardized post-operative treatment is started after six weeks.
46007962|NCT04576169|Procedure|Physiotherapy|An ulnar TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Physiotherapy exercises of wrist and DRUJ stabilizers is started after two weeks.
46007963|NCT01133977|Drug|Lenvatinib|Lenvatinib tablets administered orally at doses of 16 mg, 20 mg, or 22 mg, once daily continuously over 3 weeks (21 days) during each 21-day cycle
46007964|NCT01133977|Drug|Lenvatinib|Lenvatinib 20 mg (MTD/recommended Phase 2 dose as determined in Phase 1b of the study) administered once daily continuously over 3 weeks (21 days) during each 21-day cycle
46007965|NCT01133977|Drug|Dacarbazine|Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.
46094855|NCT04005469|Drug|Treprostinil|Treprostinil (Remodulin) will be administered IV by a standard 3 + 3 dose-escalation approach. This dosing model will be followed until a target dose of 15 mg/kg/min is achieved or if it is medically determined that side effects prevent dose escalation. IV infusion will commence approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of surgery, unless hemodynamic changes or tolerability require discontinuation of treprostinil.
46094856|NCT02651324|Drug|Ketamine|
46094857|NCT02651324|Other|Placebo|
46094858|NCT02696603|Behavioral|Participant self-assessment surveys|At enrollment, participants are asked to complete a baseline health history and a participant-reported symptom inventory. Thereafter, participants are asked to respond to commonly used questions that assess Parkinson Disease symptoms and quality of life at regular intervals.
46094859|NCT02696603|Behavioral|Phonation|"Participants are asked to record themselves saying Aaah for 10 seconds using the iPhone microphone. This activity is designed to assess vocal features, including vocal tremor. The investigators extract features from the digital audio signals of these sustained phonations. The investigators apply feature selection and classifier algorithms and analyze these phonations using methods similar to those employed in the Parkinson Voice Initiative."
46094860|NCT02696603|Behavioral|Gait and balance|Participants are asked to walk back and forth for 30 seconds and then stand still for 30 seconds. Gait and balance are measured by gyroscope and accelerometer sensors. The investigators examine step-dependent and sequence-dependent features from these sensors. The investigators apply feature selection and classifier algorithms to analyze these data.
46094861|NCT02696603|Behavioral|Memory|Participants are asked to complete a visuospatial short-term memory game related to the Corsi block tapping test [Corsi, P.M. (1972)] as adapted by Kate Possin, PhD of the University of California San Francisco Memory and Aging Center (personal communication, 2015). In this activity, participants are presented with a grid of objects that change color in a set pattern. Participants are then asked to tap the objects in that same pattern. The investigators assess the sequence length completed.
46094862|NCT02696603|Behavioral|Dexterity|Participants are asked to tap on the phone screen with alternating fingers. This test can be done with either or both hands. The investigators record the rhythm, speed, and location of these taps using the touch sensors of the iPhone screen. The investigators assess participant dexterity through a combination of steadiness, speed, and tap precision.
46094863|NCT02696603|Behavioral|Participant open-response writing|Qualitative participant feedback is used to assess participant engagement with, understanding of, and acceptance of app-based research.
46094864|NCT02696603|Other|Parkinson mPower mobile application|Participants complete all described behavioral interventions via a dedicated iPhone app, Parkinson mPower.
46007966|NCT04570917|Behavioral|Online educational intervention to reduce ageism|Participants in this group will go over multiple short videos covering the following content:1). Myths about aging, 2). Ageism and its negative effects, 3). Distorted views about aging among young adults, 4). Ageism during the COVID-19 pandemic, and 5). importance of reducing ageism among healthcare professionals. These will be multiple videos posted on the LMS (Blackboard). At the end of the lesson, they will be asked to briefly write what they learned on Blackboard as an assignment.
46037818|NCT01197950|Device|Manual Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour.
45836727|NCT01796574|Dietary Supplement|Ketogenic diet|4:1 ratio fat: carbohydrates and protein ketogenic liquid via enteral feed
45836728|NCT01795404|Behavioral|Inquiry Based Stress Reduction (IBSR)|
45836729|NCT04271124|Other|exercise training|The patients are allocated to PR+ET group or PR Each group receive an exercise training
46007967|NCT04570917|Behavioral|Online educational intervention to enhance cultural competance|Participants in the control group will go over multiple short videos covering the following content: 1). Myths about cultural competence, 2) Cultural competence for health care professionals including dietitians, 3). Connecting culture and food, and 4). Importance of cultural competence in sports dietitians. At the end of the lesson, they will be asked to briefly write what they learned. These will be multiple videos posted on the LMS (Blackboard). At the end of the lesson, they will be asked to briefly write what they learned on Blackboard as an assignment.
46007968|NCT00583193|Drug|Duloxetine hydrochloride|Start 30 mg Q.D. for 7 days, then increased to 60 mg Q.D. @ the week 1 visit. Thereafter, dose may be increased or decreased by 30 mg increments based on tolerability and efficacy between a dosage range of 60 to 120 mg.
46007969|NCT01133821|Drug|IPSRT plus placebo (IPSRT-PLA)|"Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)"
46007970|NCT01133821|Drug|IPSRT plus quetiapine|"Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)"
46007971|NCT00472446|Drug|bilateral superficial cervical block|10 ml of 5% bupivacaine (Carbostesin®) was used for each side. Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side.
46007972|NCT00472446|Drug|placebo bilateral superficial cervical block|"10 ml of saline (the carrier of bupivacaine in the experimental treatment) was used for each side.~Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side."
46007973|NCT00583232|Drug|Stable isotope infusions|Stable isotope infusion will be given via an intravenous catheter. Subjects will receive a priming dose and a continuous dose.
46007974|NCT00583271|Drug|triamcinolone|80mg of triamcinolone injected into the celiac ganglion during the EUS-CB
46007975|NCT00583271|Drug|98% dehydrated alcohol|10ml of 98% dehydrated alcohol injected into the celiac ganglion during the EUS-CB
46007976|NCT04570995|Dietary Supplement|Fish Oil|Dietary supplement containing fish oil, encapsulated in soft gel capsules, given 5 days per week
46094865|NCT00662220|Drug|ribavirin|25-29 mg/kg/day
45678477|NCT01411852|Drug|0.9% Sodium Chloride 2000 mL bolus|Emergency Medicine Systems (EMS) personnel and in-hospital providers will utilize the systolic blood pressure SBP as the endpoint for delivering fluid resuscitation to patients randomized to the control group. If the SBP is equal to or less than 90 mmHg, the EMS personnel will start infusing a 1000 ml bolus of normal saline (NS) and will continue using only 1000 ml bags of NS as needed. If the total fluid resuscitation exceeds 2 liters, fluid will be stopped when the SBP exceeds 110 mmHg and restarted as necessary to maintain a goal SBP of 110 mmHg. The fluid will be given as rapidly as possible. This fluid resuscitation protocol will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first.
46094866|NCT00662220|Drug|ribavirin|12-15 mg/kg/day
46094867|NCT02651090|Drug|Sonazoid|Comparison of Sonazoid enhanced ultrasound to non enhanced CT
46094868|NCT02651246|Other|data collection|
46094869|NCT02575924|Drug|sequential medium|administration of Quinn's Advantage® Fertilization Medium on day0 administration of Quinn's Advantage® Cleavage Medium from day0 to day3 administration of Quinn's Advantage® Blastocyst Medium from day3 to day7
46094870|NCT02575924|Drug|1-step medium|administration of SAGE 1-Step™ with Human Albumin Solution, from day0 to day7
46094871|NCT02766101|Behavioral|Aerobic Exergaming PE Curriculum|Sustained aerobic exercise.
46094872|NCT02766101|Behavioral|Standard PE|Non-aerobic skill building.
45459954|NCT03908203|Procedure|Minimally invasive one-level lumbar deformity correction|The study treatment represents modified technique of MIS TLIF: one level screws fixation using Wiltse approach at one side, the other side - percutaneously, one level decompression, correction of segmental deformity by performing vertebrotomy and then intervertebral fusion.
45459955|NCT04937816|Drug|Placebo|Placebo
45459956|NCT04937816|Drug|Empagliflozin|Empagliflozin once daily
45459957|NCT03475732|Drug|XueBiJing injection|100mL XueBiJing injection (dissolved with 100 mL of 0.9% normal saline),intravenous infusion for 1.25 h, q12h for 5 days
45459958|NCT03908047|Other|magnetic resonance imaging|functional magnetic resonance imaging and diffusion tensor imaging after tibialis nerve stimulation
45459959|NCT02528149|Procedure|tissue of adjacent part and aneurysm of renal aneurysm|the samples are collected during surgery of renal artery aneurysms. Th tissue is cryopreserved in liquid nitrogen before analysis
46007977|NCT04570995|Dietary Supplement|Safflower Oil|Dietary supplement containing a placebo oil product (safflower oil), encapsulated in soft gel capsules, given 5 days per week
46007978|NCT04576013|Device|Peripheral nerve stimulation (PNS)|Non-invasive stimulation is applied to 3 nerves of the arm. The stimulation will be set at a level that is not painful or uncomfortable.
46007979|NCT04576013|Behavioral|Intensive upper extremity motor training|
46007980|NCT00472290|Drug|Romiplostim (formerly AMG 531)|"Subjects will begin the study at an initial dose of 750 µg.~Except for:~Subject whose doses were escalated to doses higher than 750 µg AMG 531 weekly, and maintained a response per IWG guidelines for platelet response.~Subjects who were stable at a lower dose of AMG 531 on the previous study. Doses will be adjusted throughout the study based on individual subject's platelet count."
45459960|NCT02528149|Other|blood sample|
46007981|NCT01133704|Biological|sipuleucel-T|
46094873|NCT02631096|Drug|ARB-001467|An IV infusion of ARB-001467
46094874|NCT02631096|Other|Placebo|An IV infusion of placebo
46094875|NCT02651168|Biological|aflibercept|EYLEA (aflibercept, solution for intravitreal injection) is a recombinant fusion protein consisting of portions of human Vascular Endothelial Growth Factor (VEGF) receptor 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.
46094876|NCT04073602|Drug|RC48-ADC|The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.0 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
45459961|NCT03475654|Behavioral|Technology-assisted rehabilitation|The Jintronix software platform, coupled with the Microsoft Kinect for movement capture, contains individualized exercise modules to increase ROM, endurance and strength. Within this PRCT, online monitoring of activity and actigraphy measurements through a wearable device and completion of an online diary will provide enhanced monitoring of home activities.
45459962|NCT03475654|Behavioral|Usual care|The control group will receive treatment as usual, which includes a personalized home exercise program prescribed by a burn therapist, prior to hospital discharge.
45459963|NCT04468412|Diagnostic Test|Carotid Artery Reactivity Testing|The carotid artery reactivity (CAR) test assesses macrovascular endothelial function by measuring the carotid artery diameter in response to sympathetic stimulation. Participants are in the supine position with the neck extended for assessment of the carotid artery. Left carotid artery diameter is recorded continuously during baseline (30 seconds) and during immersion of the right hand up to the wrist in icy water (4°C) for 3 minutes. CAR can either represent a dilatory response (normal endothelial function) or a constrictive response (endothelial dysfunction) of the carotid artery.
45836730|NCT00373698|Behavioral|Three Component Model of Collaborative Care|Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
46094877|NCT00650000|Drug|Modafinil Tablets 200 mg|200mg, single dose fasting
46094878|NCT00650000|Drug|Provigil® Tablets 200 mg|200mg, single dose fasting
46094879|NCT04162704|Device|EpiCheck|If the EpiCheck test is positive at the time of inclusion, the test is repeated prior to the fourth and sixth instillation with Mitomycin as well as prior to the subsequent two cystoscopies. If the EpiCheck test is negative at the time of inclusion, no further tests will be performed.
46094880|NCT02765945|Other|Supervised exercise program|Subjects were enrolled in a hospital-based wellness center where, after analysis of their medical history and previous levels of physical activity ands documentation of a normal exercise stress test, they chose individually tailored exercise programs
46094881|NCT02630862|Drug|Aspirin|Aspirin is a standard and guidelines supported therapy for patients undergoing carotid endoarterectomy as secondary prevention measure of cardiovascular risk
46007982|NCT01133704|Biological|APC-Placebo|
46007983|NCT02883088|Procedure|Frequency Domain - Optical Coherence Tomography (FD-OCT)|FD-OCT assessment of the native proximal-mid left descending artery during clinically indicated coronary angiography
46094882|NCT02630862|Drug|aspirin plus dipyridamole|the combination of aspirin plus dipyridamole is approved to lower the risk of stroke in people who have had a transient ischemic attack or stroke
45459964|NCT01253551|Drug|Treatment sequence AB|Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
46007984|NCT00583310|Behavioral|Telephone-based lifestyle counseling|Four 30-minute telephone sessions including education and behavioral counseling strategies that have been shown to be effective in promoting behavior change and reducing blood pressure.
46094883|NCT02536430|Drug|Ketorolac Tromethamine|One group received a buccal infiltration of Ketorolac Tromethamine
46094884|NCT02536430|Drug|Placebo|buccal infiltration of Normal Saline.
46007985|NCT05158582|Other|SPECIFIC MODIFIED EXERCISE PROGRAM GROUP|"The modified exercise program group will perform following exercises:~Resisted static Squats SLER Banded rows SL Banded Jumps Resisted explosive reverse lunges 5hurdle Jumps Elevated single leg Swiss ball Bosu Banded Stars RLE Barbell lunge Static shoulder Abd.with banded leg Add Ant.Banded static squat with medball press Bosu banded superman Sit ups"
46007986|NCT05158582|Other|CONVENTIONAL EXERCISES PROGRAM GROUP|The conventional exercise program group will perform the same exercises as they doing for their low back pain.
46094885|NCT00367666|Device|MRI, Digital Mammography, Ultrasound and Positron Emission Tomography (PET)|
45459965|NCT01253551|Drug|Treatment sequence BA|Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
45459966|NCT03633500|Other|Sterile water|Placebo Comparator: Sterile water: 0.2 ml of sterile water is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The liquid is given time to get absorbed, any pooled liquid is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
46007987|NCT00583349|Drug|Paclitaxel, nanoparticle albumin-bound|Intravesically administered, dose escalation, 6 weekly instillations
46007988|NCT04571073|Procedure|Fascial Distortion Model|"Using physical exam and manual manipulation skills informed by the FDM, he identified and treated locations of presumed fascial distortion about the plantar area of the foot; distortions could include any of the six reported fascial anomalies in the FDM: continuum distortions, trigger bands, herniated trigger points, folding distortions, cylinder distortions, and tectonic fixations. Each distortion is associated with a recommended reparative manipulation. The purported mechanism of action is that the distortion-specific manipulation restores normal fascial homogeneity."
46007989|NCT00583388|Dietary Supplement|L-arginine|Each subject will be exposed to three treatments, a) 5 g of L-arginine, b) 15 g of L-arginine, and c) placebo, the sequences will be randomly assigned to the 42 volunteers. The washout period between interventions will be from one to two days.L-arginine will be mixed in 60 cc of dextrose-based syrup to blind the taste and color of the L-arginine powder.
45599029|NCT03949673|Drug|Celecoxib|Celecoxib will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
46007990|NCT00583388|Device|Ultrasound|Ultrasound from the brachial artery will be done on 3 occasions: at 9 pm after 4hs of fasting, at 6 am and at 11 am. The brachial artery images will be acquired above the antecubital fossa in the longitudinal plane of the artery with an ultrasound machine using a 6-MHz linear transducer. Flow-mediated vasodilatation will be assessed by the reactive hyperemia method (inflation of a blood pressure cuff around the forearm to 200 mmHg for 5 minutes and then released). The diameter of the brachial artery will be assessed 60 to 90 s after deflation of the cuff. After a 10min period a second baseline image of the brachial artery will be obtained. Non-low-mediated vasodilatation will be measured by an administration of a sublingual dose of nitroglycerin (0.4 mg).
46007991|NCT01133665|Drug|Cetuximab and Lenalidomide|The treatment of Head and Neck Cancer with Cetuximab and Lenalidomide
46094886|NCT02765867|Drug|RBP-6000|A single injection of RBP-6000 containing a low dose of buprenorphine in the Atrigel delivery system
46094887|NCT02631174|Drug|Antithrombin III|We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume
46094888|NCT04167956|Device|ultrasound and CT|Experimental: ultrasound combined with CT guided Active Comparator: CT guided
46094889|NCT04687007|Behavioral|SMART-ALD|At the beginning of SMART-ALD, a multi-professional team evaluates participant's current health status and develops an individual treatment plan together with the participant. The SMART-ALD intervention offers medical, psychological, and social counseling, as well as a physical fitness and disease-specific nutritional program carried out via video consultation. Thus, scope and intensity of SMART-ALD intervention is initially tailored to individual needs and continuously adapted to changes during intervention.
46094890|NCT04687007|Behavioral|Waiting list|At the beginning of the study, patients of the waiting list (WL) control condition receive one medical consultation via video consultation, including recommendations to contact their local treating physician if necessary. Individuals are instructed not to seek any other medical or psychological treatment for X-ALD symptoms without informing the study staff. All WL patients are guaranteed 6 months of SMART-ALD intervention after a waiting period of 6 months.
46094891|NCT02630784|Procedure|Non-Invasive Ventilation with Homecare ventilator|
46094892|NCT02630784|Procedure|Non-Invasive Ventilation with ICU ventilator|
46094893|NCT04168034|Behavioral|iParent2Parent Program|In addition to standard care, parents in the experimental group will receive the iParent2Parent program. The iParent2Parent program is a tailored peer mentorship program that provides modeling and reinforcement by peers (trained parents of children with JIA) to parents of children diagnosed with JIA.
46094894|NCT04168034|Behavioral|Waitlist Control|The control group will receive standard care but without the iParent2Parent program
46094895|NCT04686929|Drug|Abatacept s.c.|subcutaneous abatacept: 250mg (d-1) , 125mg (d+5, +14, +21, +28, +35, +42, +49, +56) combined with CsA, MTX, MMF.
46094896|NCT02650934|Procedure|Percutanous coronary intervention|
46094897|NCT02765633|Drug|Cangrelor|
46094898|NCT00662376|Dietary Supplement|PreOP Booster (oral nutritional supplement, food for special medical purposes)|3 x 1 dosages of oral nutritional supplement / placebo are given prior to surgery: 2 the evening before the day of operation and 1 dosage 3-4 h before initiation of anaesthesia
46094899|NCT04167488|Device|Actigraphic measurement|Physical activity assessed with actigraphic device worn during 7 days
46094900|NCT00581776|Drug|Bortezomib|Administered by IV at 1.3 mg/m2 days 1 and 4 of each 21 day cycle.
46094901|NCT00581776|Drug|Rituximab|Administered by IV 375 mg/m2 IV day 1 of each cycle during induction chemotherapy, then weekly for four weeks during consolidation therapy; and then once every 12 weeks for up to 5 years (or until disease progression).
46094902|NCT00581776|Drug|Cyclophosphamide|Administered by IV at 300 mg/m2, 6 doses spaced 12 hours apart on days 1-3 of each cycle, to start after completion of rituximab infusion
46094903|NCT00581776|Drug|Doxorubicin|Given as a continuous infusion, 50 mg/m2 over 48 hours days 1-2 of each cycle, to start after completion of rituximab infusion.
46094904|NCT00581776|Drug|Vincristine|1 mg administered by IV on day 3 of each cycle.
46094905|NCT00581776|Drug|Dexamethasone|40 mg orally on days 1-4 of each cycle.
46094906|NCT02765243|Biological|Anti-GD2 CART|Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells
46094907|NCT04167410|Other|glycaemic management protocol implemented to clinic|Following the introduction of the glycaemic management protocol to the clinic, data on the patients in the intervention group was collected prospectively between June 2018 and December 2018. Data of the patients in the intervention group was collected after the patient applied to the hospital for surgery or just after the decision on surgery was taken. Patients in the intervention group whose HbA1C values exceeded 7% were referred to endocrinology specialists prior to surgery. Glycaemic management of these patients was evaluated at the department of endocrinology and medications or doses of insulin and oral antidiabetics were changed when necessary. Glycaemic management was conducted by nurses in line with the protocolConsequently, the glycaemic management of patients during the perioperative period was conducted by general surgery nurses according to the protocol.
46094908|NCT00662454|Drug|ethinyl estradiol / levonorgestrel|Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
46007992|NCT04571346|Procedure|trans-obturator procedure|TOT procedure will be done using silicon-coated polypropylene tape that will be inserted at the mid-urethral portion. In group 1, a classical vertical vaginal incision will be done proximal to the external urethral meatus with dissection along the axis of the urethra till the mid-urethral zone that is identified by palpating the urethral catheter balloon through the vaginal at the bladder neck, while in group 2, two paramedian incisions will be done 1cm long in the anterior vaginal wall 2 cm apart parallel to the urethra till identification of the mid-urethral portion, communication will be done between the two incisions 1 cm wide in this area creating a tunnel where the tape will be placed, this technique provides healthy tissues proximal and distal to the tape that allows more stabilization and less migration. The rest of the procedure is the same as the standard procedure of Trans-obturator outside-in tension-free technique.
46007993|NCT00583427|Drug|Sulodexide|200 mg per day in an oral gelcap form
46007994|NCT01133626|Drug|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 42 days of treatment
46007995|NCT01133626|Drug|Prednisone capsules|Prednisone 10 mg capsule taken each day on the last 7 days of treatment
46007996|NCT01133626|Drug|Placebo Prednisone Capsules|Placebo prednisone capsule taken each day on the last 7 days of treatment
46007997|NCT01133626|Drug|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 42 days.
46094909|NCT00662454|Drug|ethinyl estradiol / levonorgestrel|Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
46094910|NCT04073524|Other|Nature-Body-Mind-Community|The Nature-Body-Mind-Community (NBMC) approach has been developed in a pilot project over 2014-2018. The 'Wild man Programme' consists of the following main elements: 1. Nature environments and nature experiences, 2. Mind relaxation and meditation, 3. Body awareness and 4. Fire talks, storytelling and community spirit.
46007998|NCT04575974|Other|No intervention|No intervention
46007999|NCT01133392|Drug|Insulin lispro A|20 units (U) subcutaneously (SC).
46008000|NCT01133392|Drug|Insulin lispro B|20 U subcutaneously (SC).
46094911|NCT04073524|Other|Treatment as usual|Treatment as usual consist of the rehabilitation offered by the hospital or municipality for the specific condition e.i. cancer, diabetes, COPD, anxiety, depression and stress
46094912|NCT04156152|Other|DEENSIBILIZING TOOTHPASTE BASED ON NANOCRISTALS OF HYDROXIAPATITA / 5% POTASSIC NITRATE / SODIUM MONOFluORPHOSPHATE 1450 PARTS PER MILLION|The toothpastes will be delivered by the researchers and will be applied with a manual toothbrush, with soft bristles and straight handle, by the patient.The 2nd, 3rd, 4th session (2nd, 4th, 6th week of follow-up) will be the application of tests and reinforcement of oral hygiene instruction. In the 5th session (8th week of follow-up) the pastes will be requested to verify compliance.
45459967|NCT03633500|Biological|Breastmilk|Experimental: Breastmilk: 0.2 ml of mothers' own colostrum/ breast milk is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The colostrum is given time to get absorbed, any pooled milk is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours. independently sucks at breast, bottle or cup feed
46094913|NCT04156152|Other|5% POTASSIC NITRATE / SODIUM FLUORIDE 1426 PARTS PER MILLION TOOTHPASTE|The toothpastes will be delivered by the researchers and will be applied with a manual toothbrush, with soft bristles and straight handle, by the patient.The 2nd, 3rd, 4th session (2nd, 4th, 6th week of follow-up) will be the application of tests and reinforcement of oral hygiene instruction. In the 5th session (8th week of follow-up) the pastes will be requested to verify compliance.
46008001|NCT04575818|Drug|GLPG4059 oral suspension|GLPG4059 for oral administration
46094914|NCT02774603|Other|Aquatic Locomotor Training|
46008002|NCT04575818|Drug|Placebo|Placebo oral suspension
45599030|NCT03949673|Drug|Placebo|Matching Placebo will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
45599031|NCT02345109|Device|Transtek DUT|"Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie.~Measure each participants by Transtek DUT."
45678478|NCT01411774|Behavioral|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks using the evidence-based CBT protocol in POTS (2004). Sessions 1-4 will be held twice weekly; sessions 5-10 will be held on a weekly basis. Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-10 involve E/RP exercises specific to each youth.
46008003|NCT04575818|Drug|GLPG4059 tablet|GLPG4059 for oral administration
46094915|NCT02774603|Other|Land Locomotor Training|
46094916|NCT02575846|Dietary Supplement|Enteral Intake - Human Milk|Comparing formula and human milk
46094917|NCT02575846|Dietary Supplement|Enteral Intake - Formula|Comparing formula and human milk
46094918|NCT00662610|Drug|naproxcinod 375 mg -750 mg -1125 mg bid|naproxcinod 375 mg -750 mg -1125 mg bid
46094919|NCT00662610|Drug|naproxen 250 mg - 500mg -750 mg bid|naproxen 250 mg - 500mg -750 mg bid
46008004|NCT04570761|Device|Dreem headband|acoustic stimulation
46094920|NCT04225481|Other|isolation of waste material and culturing with different supplement culture media|isolation of waste material and culturing with different supplement culture media
46094921|NCT02657876|Biological|ExpressGraft-C9T1 Skin Tissue|ExpressGraft-C9T1 skin tissue is provided as a suturable, biologically-active, circular skin tissue with a fully-stratified epithelial compartment comprised of human keratinocytes (NIKSC9T1) and a dermal compartment containing fibroblasts
46094922|NCT04225325|Combination Product|SYMTUZA|DESCOVY+REZOLSTA
46094923|NCT04225325|Combination Product|DESCOVY+DOLUTEGRAVIR|DESCOVY+DOLUTEGRAVIR
46094924|NCT04225325|Combination Product|SYMTUZA+DOLUTEGRAVIR|DESCOVY+REZOLSTA+DTG
46094925|NCT00649610|Drug|valdecoxib|valdecoxib 40 mg QD for 7 days with a second dose of 40 mg the first day
46094926|NCT00649610|Drug|diclofenac|diclofenac 75 mg twice daily (BID) for 7 days
46008005|NCT04570761|Device|Dreem headband|acoustic stimulation
46008006|NCT02882815|Device|IrisFIT PFO Occluder|
46008007|NCT00583505|Device|Device closure with the AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
46008008|NCT00471354|Drug|Atomoxetine|atomoxetine 0.5 mg/kg/day once a day (QD), by mouth (PO) starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
45599032|NCT02345109|Device|Reference|Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie. Measure each participants by Reference.
46094927|NCT02631330|Other|Multicomponent physical activity|Balance, muscle strength and aerobic capacity will be increased in intensity according Training Intervention in a Controlled Population of Frail Elderly (EMTIFE) study NCT02331459
46094928|NCT02655146|Drug|triptorelin 0.1|a single dose of decapeptyl 0.1 s.c. on the 3rd day of embryo transfer with routine luteal phase support.
46094929|NCT02655146|Drug|E2|Patients will be on the Progynova tablets 4-10mg daily at least 14 days.
46094930|NCT02655146|Drug|Progesterone|After ultrasound and hormorne tests, progesterone 100mg intramuscular injection is allocated with Progynova.
46094931|NCT02655146|Drug|triptorelin 3.75mg|as a pretreatment of E2 in some subjects with a fail history of hormonal artificially endometrium preparing.
46094932|NCT00662688|Drug|daltéparine|
45599033|NCT03146169|Behavioral|Training group|"The training workshop includes four two-hour sessions:~Session one - a knowledge, self-efficacy, and motivation enhancement session at baseline; Session two - an interpersonal communication and leadership skills session at one week; Session three - a motivation enhancement session at one month Session four - an experience sharing session at three months"
45599034|NCT03515473|Device|cochlear implant|cochlear implant surgery
46094933|NCT00662688|Drug|Chemotherapy at the investigator's discretion|
46008009|NCT04575701|Other|TNF Alpha therapy|Retrospective analysis of outcome of first TNF Alpha therapy
46094934|NCT02774525|Behavioral|Reinforcement for drug & alcohol abstinence|
46008010|NCT02882893|Drug|Clostridium Botulinum A Toxin|
46008011|NCT02882893|Drug|Clostridium Botulinum A Toxin|
46008012|NCT00583544|Drug|TC-2216|Multiple ascending dose groups will be explored.
46008013|NCT02210364|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) 1 mg and 4 mg vials
46008014|NCT02210364|Drug|capecitabine|capecitabine 150 mg tablets
46094935|NCT02774525|Behavioral|Parenting intervention|
46094936|NCT02774525|Behavioral|Treatment as usual (TAU)|Outpatient substance-abuse therapy plus drug & alcohol screening plus support for personal goal setting
46094937|NCT00666120|Other|Enfamil LIPIL with iron|cow's milk based infant formula
46094938|NCT00666120|Other|Good Start Supreme with DHA and ARA|partially hydrolzed cow's milk protein
46008015|NCT00583583|Device|Device closure with the AMPLATZER Duct Occluder|Device closure with the AMPLATZER Duct Occluder
46008016|NCT00471315|Drug|Duloxetine|A preliminary, open-label single center study of duloxetine in patients with SOD
46008017|NCT00583739|Behavioral|Yoga|Gentle Yoga for breast cancer survivors, 1 time weekly, for 8 weeks.
46094939|NCT04169126|Drug|F-18 PMPBB3|The study will enroll 200 patients with prodromal AD and AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
46094940|NCT02774369|Behavioral|Physical exercise|Individualized aerobic intervention program
46094941|NCT02774369|Behavioral|Cognitive-behavioral therapy|Psychological intervention combining behavioral, cognitive, and educational strategies
46094942|NCT04169048|Behavioral|Group training for mothers with Borderline Personality Disorder|The group programme is designed to teach mothers with BPD parenting skills and to reduce dysfunctional parenting attitudes and strategies. The components are: childrens basics needs, mindfulness, stress and stress reduction, dealing with conflicts, dealing with emotions, dysfunctional attitudes, physical contact, parenting rules, self care.
46008018|NCT04575623|Diagnostic Test|Duration Pattern test (DPT) /Dichotic Digits Test (DDT) /Auditory fusion test-revised (ART-R)/|"Central auditory function evaluation including:~Duration Pattern test (DPT) designed to test temporal ordering abilities.~Dichotic Digits Test (DDT) it assesses binaural integration skills.~Auditory fusion test-revised (ART-R) to measure temporal resolution.~speech in test to assess central auditory function."
46008019|NCT04575623|Device|Dual band pure tone audiometer (Orbiter 992). -Impedance audiometer (AT 235h). -Sound treated booth (industrial acoustic company IAC model 1602-A-t) -Panasonic stereo CD player SA-AK 240.|"Cognitive function evaluation including:~-Recording of event-related potentials (ERPs) by using odd ball paradigm auditoryP300 wave in evaluating cerebral information processing.~Equipment:~Dual band pure tone audiometer (Orbiter 992).~Impedance audiometer (AT 235h).~Sound treated booth (industrial acoustic company IAC model 1602-A-t)~Panasonic stereo CD player SA-AK 240."
46008020|NCT00471237|Drug|Ronacaleret|100mg, 200mg, 300mg, 400mg
46094943|NCT04162626|Other|Supportive home visits to new families|The new families are offered home visits by a public health nurse from 28 weeks in pregnancy until the child is two years old. The number of home visits depends on the families needs and wishes. They also get the usual follow up from the Child health center.
46094944|NCT04162626|Other|Treatment as usual|Follow up at the Child health center according to national regulations
46008021|NCT00471237|Drug|Teriparatide|PTH (1-34)
46008022|NCT00471237|Drug|Alendronate|Bisphosphonate
46008023|NCT04575545|Diagnostic Test|Serology test for COVID-19|ELISA test
46008024|NCT00583895|Drug|10% ImCOOH cream|Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
46008025|NCT00583895|Drug|Placebo|Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
46008026|NCT04570683|Drug|Nivolumab 10 MG/ML|Se previously
46008027|NCT04570683|Device|Ablative fractionated laser|Se previously
46094945|NCT02774447|Procedure|ileostoma closure|The operation procedure is standardized as described above (see group description).The patients will be observed for 23 hours, and if there are no contraindications according to described criteria the patient can be discharged form the hospital, however all patients will have follow-up telephone contact on a daily basis with a nurse for the first week. Patients will meet the surgeon 3 days after discharge and after 4 weeks.
46094946|NCT04167566|Combination Product|Artemisinin Combination Therapy ACTs|All participants will be tested using RDTs and all confirmed cases will be treated with ACTs. The ACT regimen use at each time will be the one the National Malaria Control Programme will be using at that particular moment.
46094947|NCT02630550|Device|Cheetah NICOM|The Cheetah NICOM will be installed on all patients to evaluate the validity of its measurements.
46094948|NCT02630550|Device|Transesophageal echocardiography (TEE)|TEE will serve as gold standard measurements for the evaluation of the Cheetah NICOM.
46094949|NCT02636556|Radiation|concurrent chemoradiation|The patients receive chemotherapy concurrent with Radiotherapy. The prescription dose is 60Gy in 30 fractions in 6 weeks.The chemotherapy regimen is cisplatin (25mg/m2,iv drip,d1-3) and etoposide (75mg/m2,iv drip,d1-3),q4w*4.
46094950|NCT00650624|Drug|valdecoxib|valdecoxib 5 mg tablet by mouth once daily in the morning for 6 weeks
46094951|NCT00650624|Drug|valdecoxib|valdecoxib 10 mg tablet by mouth once daily in the morning for 6 weeks
46094952|NCT00650624|Drug|valdecoxib|valdecoxib 20 mg tablet by mouth once daily in the morning for 6 weeks
46094953|NCT00650624|Drug|placebo|placebo tablet by mouth once daily in the morning for 6 weeks
46094954|NCT04225403|Behavioral|Telephone-based motivational interviewing for smoking cessation|"The motivational brief intervention is known by the acronym 5 R and lasts about 5-10 minutes. It is an approach based on the principles of motivational interviewing and develops the intervention in five short steps:~Relevance. Help patients identify why personal reasons may be relevant to quitting smoking.~Risks. Help identify what negative consequences tobacco use has.~Rewards. Help identify potential benefits of quitting smoking.~Resistors. Help patients identify barriers to smoking cessation, which can often include fear of withdrawal symptoms, failure, wainweight, face social situations, etc.~Repeat. Repeat the intervention at 3 months if you do not advance at the stage of change."
46094955|NCT00666354|Drug|Methotrexate|0.01 gram of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin folds applied daily for three months.
46094956|NCT00666354|Drug|Methotrexate|0.01 gram of topical amphimatrix containing 0.25% methotrexate per affected nail and adjacent skin folds applied daily for three months.
46008028|NCT00471081|Biological|Meningococcal vaccine GSK134612|One or 2 intramuscular injections.
46094957|NCT00666354|Drug|Methotrexate|0.01 gram of topical amphimatrix containing 1.0% methotrexate per affected nail and adjacent skin folds applied daily for three months.
46094958|NCT02774291|Biological|Aldesleukin|Given IV
46094959|NCT02774291|Biological|Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes|Given IV
46094960|NCT02774291|Drug|Cyclophosphamide|Given IV
46094961|NCT02774291|Biological|Filgrastim|Given SC
46094962|NCT02774291|Drug|Fludarabine Phosphate|Given IVPB
46094963|NCT02774291|Other|Laboratory Biomarker Analysis|Correlative studies
46037819|NCT01197950|Device|Electro Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour. Eight needles in the painful area (local points) will be connected to an electro-stimulator and stimulated with high frequency (80 Hz) square wave pulses (0.18-ms duration) with alternating polarity. The woman will adjust the intensity of the electrical stimulation to be just under pain threshold.
46094964|NCT02655068|Other|PET/CT|"Patients who undergo primary radiotherapy will have their first study imaging surveillance at 6 months (+/- 30 days) post radiotherapy. The Positron Emission Tomography - Computed Tomography (PET/CT)surveillance will continue at 9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings."
46094965|NCT02655068|Other|Computed Tomography (CT)|"Patients who undergo primary surgery will have their first study imaging surveillance at 3 months (+/- 30 days) post-surgery. CT surveillance will continue at 6,9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings"
46094966|NCT00666432|Other|This is an observational study model that is family based|This is an observational study model that is family based
46094967|NCT02654912|Drug|Reactive Focal Drug Administration|This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).
46094968|NCT00662766|Dietary Supplement|black currant seed press residue|Black currant seed press residue, baked into bread
46094969|NCT00662766|Dietary Supplement|Bread without black currant seed press residues|Same bread but without seeds
46094970|NCT00662766|Dietary Supplement|Baseline data|No supplement was administered.
46094971|NCT02536352|Drug|Prenatal vitamin-mineral containing 3 mg fluoride|Prenatal vitamin-mineral containing 3 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
46094972|NCT02536352|Dietary Supplement|Prenatal vitamin-mineral containing 0 mg fluoride|Prenatal vitamin-mineral containing 0 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
46094973|NCT02774057|Drug|Captafer®|"2 pills daily. Contains~Vitamin C, known for its property to facilitate iron absorption by reducing iron to the reduced ferrous state necessary for uptake;~Vitamin E, an antioxidant, along with vitamin C it protects Fe++;~Folic acid, necessary to prevent megaloblastic anemia and abnormalities in the fetal nervous system, vital during pregnancy;~Zinc and Copper which act in different mitochondrial cytochromes-dependent systems and contribute to the use of iron by the biological systems"
46094974|NCT02774057|Drug|Iron Sulfate|195 mg Iron supplement
46094975|NCT02636400|Other|controlled ovarian stimulation with gonadotropins + intrauterine insemination|
46008029|NCT03453008|Other|elbow extension, electromyography|"Two evaluations before the toxin injection (T0 and T1), to quantify cocontractions and to determine the toxin injection pattern.~The first evaluation (T0) will be carried out within a period of between 1 month and 15 days before the injection. This evaluation makes it possible to pose the indication for the realization of injection of Botulinum Toxin A (TBA).~The second evaluation (T1) will be performed on the day of the injection to specify the muscle targets to be injected.~The first evaluation is a Clinical evaluation and second is Instrumental evaluation"
46094976|NCT02773979|Drug|Chloroquine|Administered as 600mg PO, day 1, 300mg PO days 8, 15, 22.
46094977|NCT02773979|Biological|PfSPZ (NF54) Challenge|Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
46094978|NCT02773979|Other|Placebo|Placebo
46094979|NCT00662844|Dietary Supplement|vitamin D3|Oral, one capsule daily of vitamin D3 (400IU, 800IU, 1600 IU, or 2400IU) plus calcium citrate (1-4 tablets) twice daily to reach a total calcium intake of 1000-1200 mg/day
46094980|NCT04168658|Combination Product|Physical activity and education intervention|"At least six staff from each nursing home that assigned to the intervention group will be invited to attend two educational workshops. Participants in the intervention group will receive the following interventions.~Face-to-face workshops: Five 1-hour educational workshops on physical activity will be delivered in months 1, 3, 5, 7 and 9 of the program held at each nursing home.~Booklet: At the first educational workshop, each participant will be provided with a pictorial booklet.~Exercise: The physical activity training consists of 50-60 min exercise sessions three times a week on non-consecutive days for 12 months.~Others (newsletters, phone calls, and reminders): The intervention group will also receive newsletters containing myth dispelling information on osteoporosis and physical activity, motivational phone calls and a total of 52 SMS via mobile phones (reminders to attend workshop sessions and physical activity motivating messages) over 12 months."
46094981|NCT04168658|Behavioral|Education intervention|Participants in the control group will only receive educational materials (i.e. face-to-face workshops and booklet) and will be wait listed to receive no other interventions of this study until after the post-intervention.
46008030|NCT03452969|Other|Implantation of multifocal intraocular lens|"Procedure/Surgery:~Bilateral implantation of a segmental refractive multifocal intraocular lens (MIOL) following cataract surgery."
46008031|NCT04570449|Drug|Fluoxetine|20 mg capsule
46094982|NCT04224935|Procedure|Leukocyte Platelet rich fibrin membrane|the use of Leukocyte Platelet rich fibrin as grafting materials for treatment of recession
46094983|NCT02650544|Drug|Mirtazapine|Patients in mirtazapine arm will be orally administered mirtazapine as an anti-depression therapy; along with palliative chemotherapy.
46094984|NCT02650544|Drug|Placebo|Patients in placebo arm will be orally administered placebo; along with palliative chemotherapy.
46094985|NCT02773745|Behavioral|Aquatic Prehab|Pool therapy
45678479|NCT01411774|Drug|d-cycloserine|D-cycloserine will be encapsulated into 25mg with identical placebo capsules. Youth will take (1 or 2) DCS or identical placebo capsule 1 hour before sessions 4-10. A 0.7mg/kg dosage corresponds with dosages found to be effective in adult studies (50mg/estimated average adult weight of 70kg=.71mg/kg). Accordingly, doses for this study will be about 0.7mg/kg. Two dosing levels will be used based upon weight ranges to ensure comparable mg/kg levels: children weighing 25-45kg will be given a dosage of 25mg (~0.56-1.0 mg/kg/day), and children ≥46kg will be given 50mg provided in two 25mg capsules (~0.50-1.08mg/kg/day). Doses will be given 1 hour before therapy sessions 4-10.
45678480|NCT01411774|Drug|Pill placebo|The pill placebo will be identical to the active study medication in every respect (e.g., size, shape, number of capsules, etc.).
46008032|NCT04570449|Drug|Placebo|fluoxetine placebo capsule
46008033|NCT00470847|Drug|Lapatinib|Orally twice daily
46008034|NCT00470847|Procedure|Whole Brain Radiation|15 treatments over a period of 3 weeks
46008035|NCT00470847|Drug|Herceptin|Herceptin 4mg/kg loading dose then 2 mg/kg IV once weekly, then once every three weeks after cycle 3.
45599035|NCT03122405|Device|RAM sensors|Noninvasive acoustic monitoring device
46008036|NCT00584090|Drug|Solifenacin Succinate (VESIcare)|5 - 10 mg po qd for 1 month
46008037|NCT00584090|Drug|Placebo|Placebo equivalent of 5-10 mg po qd for 1 month
46094986|NCT02774135|Other|direct occupational therapy intervention|Short term direct individual occupational therapy (9-12 weeks).Participants will receive occupational therapy intervention according to health law. The study will document the therapeutic intervention implemented in practice using the Documentation of Occupational Therapy Session during Intervention (DOTSI).
45599036|NCT02350491|Other|Collection of biological samples|collection of biologic samples ( blood and urine) befor and after woman pregnacy
46008038|NCT04570527|Procedure|PCI|percutaneous coronary intervention
46008039|NCT00584129|Other|Pre-treatment swallowing exercises|Swallowing exercises will be started pre-treatment with radiation.
46008040|NCT00584129|Other|Post-treatment swallowing exercises.|Patients to start swallowing exercises after completion of radiation therapy.
46008041|NCT04570566|Procedure|horizontal alveolar ridge augmentation|evaluate the potential application of resorbable pericardium membrane to augment localized alveolar ridge defects in esthetic zone, from histological, radiographical and clinical aspects in comparison with titanium mish for the subsequent placement of dental implants
46008042|NCT00584168|Drug|Dexamethasone|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
46008043|NCT00584168|Drug|Placebo|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
46008044|NCT00470535|Drug|erlotinib hydrochloride|Oral
46008045|NCT00470535|Other|immunohistochemistry staining method|Correlative Study
46008046|NCT00470535|Other|laboratory biomarker analysis|Correlative Study
46008047|NCT00584207|Procedure|radiofrequency ablation|Intraoperative RFA of uterine fibroids
46008048|NCT00584324|Combination Product|BIS 40|"Mini-mental state exam: For subjects > 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure."
45678481|NCT01411228|Drug|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 24 months
46008049|NCT00584324|Combination Product|BIS 60|"Mini-mental state exam: For subjects > 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure."
46094987|NCT02650388|Behavioral|Cognitive fuction, quality of life|To test the above score in patients undergoing TAVI
45678482|NCT01410604|Drug|Metformin|Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
45678483|NCT01410604|Drug|Placebo|Tablet of 500 mg oral placebo every 12 hours for 3 months.
46008050|NCT00470418|Drug|NIC5-15|a natural product, found in many foods and plants with mild insulin sensitizing effects
46008051|NCT00470418|Drug|Placebo|placebo comparator
46008052|NCT01133275|Drug|Prednisone|Prednisone therapy for 6 cycles (24 weeks).
46008053|NCT01133275|Drug|Lenalidomide|Lenalidomide therapy for 6 cycles (24 weeks).
46008054|NCT00470184|Drug|capecitabine|Oral
46008055|NCT00470184|Drug|oxaliplatin|IV
46008056|NCT00470184|Genetic|gene expression analysis|Correlative Study
46008057|NCT00470184|Genetic|microarray analysis|Correlative Study
46008058|NCT00470184|Genetic|reverse transcriptase-polymerase chain reaction|Correlative Study
46008059|NCT00470184|Procedure|adjuvant therapy|Metastatic growth control
46094988|NCT00883740|Drug|Pregabalin|Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks titrated to 300-450 mg/day
46094989|NCT00883740|Drug|Placebo|Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks
46094990|NCT02773823|Behavioral|Intervention group|Diet instruction for 3-4 times/semester,exercise 60min/day for 5d/week for 8 months.
46094991|NCT04830917|Other|Immobilization type for mallet injury|Method to hold the DIP joint in full extension to allow healing of terminal tendon injury/mallet injury
46094992|NCT04183712|Drug|gemcitabine and oxaliplatin.|GEMOX Conventional chemotherapy:gemcitabine and oxaliplatin.
46094993|NCT04183712|Drug|Afatinib|Target therapy Drug: afatinib
45599037|NCT02298751|Behavioral|Cue Exposure Treatment|
45599038|NCT02350257|Behavioral|Internet-based CBT|12 weeks of internet-based CBT
45599039|NCT05196295|Drug|Hydrogen|Participants take either 1 (n=5), 3 (n=5) or 6 (n=5) capsules every day for one month.
45599040|NCT02353065|Procedure|Ultrasound imaging|Point of care ultrasound of fracture site during and post-reduction
45599041|NCT02353065|Radiation|Bedside x-ray|Portable x-ray of fracture post-reduction
46008060|NCT00470184|Procedure|biopsy|Examination of tissue type
46008061|NCT00470184|Procedure|conventional surgery|Tissue removal
46008062|NCT00470184|Procedure|neoadjuvant therapy|Tumor shrinkage
46008063|NCT00470184|Procedure|quality-of-life assessment|Correlative Study
46008064|NCT00470184|Radiation|radiation therapy|Undergoing radiation therapy
46008065|NCT00584519|Other|non-interventional|non-interventional
46037820|NCT01092780|Drug|MK-7288|one or two 10 mg capsules, orally, single dose
46037821|NCT01092780|Drug|Placebo to MK-7288|one or two capsules, orally, single dose
46094994|NCT04225091|Dietary Supplement|Testing product|consume 1 bottle (50 mL) per day for 28 days
46094995|NCT04225091|Dietary Supplement|Blank|consume 1 bottle (50 mL) per day for 28 days
46094996|NCT04167644|Diagnostic Test|Modified Rankin Scale (mRS)|Modified Rankin Scale (mRS) is a profoundly valid and reliable measure of disability and is broadly utilized for assessing stroke outcomes and degree of disability. We characterized a favorable outcome as mRS ranging from zero up to two, while unfavorable outcome ranging for 3 up to six
46008066|NCT04570254|Drug|Vitamin C|Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours. Dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient. Protect from light at all times, as it is photosensitive.
46008067|NCT04570254|Drug|Vitamin E|Vitamin E. 800 mg tablet. 800 mg dose every 24 hours. Dissolve the capsule in 30 ml of hot water. The administration of vitamin E is recommended during or after meals since its absorption depends on pancreatic enzymes' presence.
46008068|NCT04570254|Drug|Melatonin|"Melatonin Tablet 5 mg. A dose of 50 mg every 24 hours. Grind the 10 5 mg melatonin tablets (50 mg), levitate with 50 mL of Ora-plus (Transferring to a beaker with a magnetic stirrer). Maintain gentle agitation. Rinse the mortar with 10 mL of Ora-sweet. Add 30 mL of Ora sweet to the glass where the mixture is being made. Makeup with Ora-sweet cbp 100 mL Place label FL02 with legend Melatonin 50 mg / 20 mL. Protected from light (Dispense in a black bag that covers the transparent bag of the preparation)'s primary packaging) Give after breakfast."
46008069|NCT04570254|Drug|N-acetyl cysteine|N-acetylcysteine. Tablets, 600 mg. 600 mg dose every 12 hours. Dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient.
46094997|NCT02773901|Device|HS-1000|
45678484|NCT01991483|Drug|LY2928057|Administered intravenously
45678485|NCT01991483|Drug|Placebo|Administered intravenously
46008070|NCT04570254|Drug|Pentoxifylline|Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours. The tablet is dissolved in 30 ml of water and is administered orally or nasogastric tube.
45678486|NCT01410448|Drug|Everolimus|Everolimus was provided in blisters containing 0.25 and 0.75 mg tablets and was taken orally.
45678487|NCT01410448|Drug|Mycophenolate sodium|Two 360 mg tablets were administered twice daily at 12-hour intervals. The tablets were swallowed whole in order to maintain the integrity of the enteric coating.
46008071|NCT00584597|Drug|Saline|Saline Control
46094998|NCT02650076|Drug|SK-1405|
46008072|NCT00584597|Drug|Traumeel S|Traumeel S 1 mL
46094999|NCT02771327|Device|CPAP plus Gas|
46095000|NCT02771327|Device|ventimask plus gas|
46008073|NCT00584597|Drug|Traumeel S|Traumeel S 2mL
46008074|NCT00584597|Drug|Traumeel S|Traumeel S 3mL
46008075|NCT00470067|Drug|carboplatin|IV
46008076|NCT00470067|Drug|pegylated liposomal doxorubicin hydrochloride|IV
46008077|NCT00584636|Drug|pulmicort respules|pulmicort respules 0.5 mg twice a day for 28 days versus placebo
46008078|NCT04570137|Dietary Supplement|Dietary fiber supplementation|"16g/day: mix of 70% wheat-bran arabinoxylan and 30% oat-derived fiber (ß-glucan)~16g/day: mix of 50% inulin and 50% oligofructose from chicory"
46008079|NCT00584675|Device|Dx-pH Measurement Probe|Dx-pH Measurement Probe measures gaseous pH values in the nasopharynx and oropharynx over a period of 24 hours.
46008080|NCT00479817|Drug|AMG 386|10mg/kg
46008081|NCT00479817|Drug|AMG 386|3 mg/kg
46008082|NCT00479817|Drug|Paclitaxel|Paclitaxel 80 mg/m2 IV QW (3 on/1 off)
46008083|NCT00479817|Drug|AMG 386 Placebo|AMG 386 Placebo
46008084|NCT04575506|Other|Multidisciplinary intervention program|The intervention program includes an educational program promoting healthy dietary habits and physical activity (nutritionist and exercise physiologist) (2 times/month, for children and parents), and supervised home-based exercise (from 3 to 5 times/week, 38-44 min) program for 12-weeks.
46008085|NCT04575194|Drug|Liraglutide 6 MG/ML [Saxenda]|3 mg of sc liraglutide daily plus lifestyle intervention
46008086|NCT04575194|Drug|Naltrexone-Bupropion Combination|32/360 mg of oral lnaltrexone-bupropion daily plus lifestyle intervention
46008087|NCT04570059|Behavioral|Counselling on textured food introduction between 8 and 15 months|"Intervention program : Advice and tips on the why and how introducing textured food during complementary feeding are grouped in a booklet and provided to participants. Monthly counselling via phone call by a dietician (at 9, 10, 11,12, 13, 14 months) and two baskets containing food preparation utensils and commercial textured foods provided at 8 and 12 months.~Usual care : reflects the standard information provided within French national guidelines (PNNS). Two phone calls at 9 and 13 months. If questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS. Two gift boxes containing presents for the child of same financial value as those provided to intervention group, provided at 8 and 12 months."
46008088|NCT00478179|Drug|Transdermal/Patch (Bupivacaine TTS [Eladur™])|
46095001|NCT02773589|Procedure|Peroral endoscopic myotomy|Peroral endoscopic myotomy
46095002|NCT02650310|Device|Thermostable device|Investigators place the catheter with the loaded embryos into a plastic device at 37ºC in order to maintain the temperature
46095003|NCT00666744|Other|Family Mediated Exercise Therapy|35 minutes of lower limb exercises to be completed by the person with stroke on a daily basis with the assistance of their family for a period of 8 weeks.
46095004|NCT02773199|Other|Preoperative Fasting for 8 hours|Patients will be exposed to preoperative fasting
46095005|NCT02773199|Other|Preoperative Fasting for more than 12 hours|Patients will be exposed to preoperative fasting
46095006|NCT02773199|Drug|Spinal Anesthesia with Bupivacaine|Spinal Anesthesia with heavy bupivacaine 0.5% is provided.
46095007|NCT02650232|Device|SOMNOtouch device (Somnomedics)|In each arm, we will evaluate the capacity of SOMNOtouch to measure the baroreflex sensitivity compared to Finapre Nova (reference)
45678488|NCT01410448|Drug|Cyclosporine|Cyclosporine was supplied as blisters containing 100 mg, 50 mg, 25 mg and 10 mg soft-gelatin capsules and was administered orally.
45678489|NCT01410448|Drug|Steroids|Steroids were administered according to local clinical practice.
45836731|NCT00374088|Drug|N-acetylcysteine|"Loading dose: Subjects randomized to IV NAC will receive a total loading dose of 100 mg/kg of 10% (100 mg/mL) solution. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the loading dose will be 1 mL/kg, anticipated to be 2.5-5 mL in our patient population. The loading dose will be administered over 1 hr beginning 1 hr prior to the patient's OR time. Subjects in the placebo group will receive 1 mL/kg of D5W over 1 hr.~Maintenance infusion: Subjects randomized to IV NAC will receive an infusion of 10 mg/kg/hr of 10% (100 mg/mL) solution for 24 hrs, starting in the OR after weaning from CPB. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the maintenance infusion will be 0.1 mL/kg/hr, anticipated to be 0.25-0.5 mL/hr in our patient population. Subjects in the placebo group will receive 0.1 mL/kg/hr of D5W for 24 hrs."
45678490|NCT04037176|Drug|Omalizumab|Subcutaneous administration every 2. week or every 4. week. Dose is depending of the patients weight and IgE
45836732|NCT00374088|Drug|Placebo|D5W bolus prior to surgery and D5W infusion after surgery in an equal volume to the drug arm.
46008089|NCT00584753|Radiation|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
46008090|NCT00584753|Radiation|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
46008091|NCT00584753|Radiation|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
46008092|NCT04569825|Drug|Ophtamesone|local application intranasally as drops
46008093|NCT00476931|Biological|SB-509|60 mg dose
46008094|NCT00476931|Other|Placebo|Saline
46008095|NCT00585026|Device|D-28 bifocal lenses and frame|
46008096|NCT00585026|Device|Progressive addition computer lenses and frame|
46008097|NCT04569669|Diagnostic Test|FFR and FFRCT|All the patients will undergo computed coronary tomography angiography to analysis FFRCT . Then FFR will be measured during invasive cardiac catheterization.
46008098|NCT00479427|Drug|GW842166|100 mg once daily
46008099|NCT00479427|Drug|Placebo|once daily
46008100|NCT00585143|Drug|ABT-335|45 mg once daily for 10 consecutive days
46008101|NCT00585143|Drug|Rosuvastatin|10 mg once daily for 10 days
46008102|NCT04569981|Other|Climbing|The patients in the Climbing Group (CG) followed a 12-weeks long climbing trainings course in small groups of 3-4 participants with a certified climbing instructor.
45678491|NCT04037176|Other|Placebo|Subcutaneous administration every 2. week or every 4. week. Dose is depending of the patients weight and IgE
45678492|NCT01943851|Drug|GSK525762|GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, amorphous free base and white to slightly colored crystalline besylate tablets, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.
45678493|NCT01430104|Drug|Teriparatide|Administered subcutaneously during the Treatment Period
45678494|NCT01430104|Drug|Aspara-CA 600 mg|Administered orally throughout the study
46008103|NCT04569981|Other|Unsupervised activity group|The patients in the unsupervised activity group (UAG) received education European physiotherapy guidelines for physical activity recommended by the WHO of recommended activity and followed their self-selected activities over 12 weeks.
46008104|NCT00585260|Drug|mannitol|indirect mannitol challenge
46008105|NCT04569474|Device|Transparent dressing|Use of sterile transparente dressing
46008106|NCT00585299|Other|Low-fat diet|20% calorie from fat diet followed for 8 weeks then maintenance diet for additional 8 weeks
46008107|NCT00585299|Other|Traditional diet|Traditional low-fat diet with dietitian follow-up in 16 weeks
46008108|NCT00585416|Drug|CGC-11047|CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)
46008109|NCT00475020|Drug|Busulfan|Test dose = 32 mg/m^2 by vein x 1 day; 100 mg/m^2 by vein daily over 3 hours x 4 days
46008110|NCT00475020|Drug|Fludarabine|40 mg/m^2 by vein daily over 1 hour x 4 days
46008111|NCT00475020|Drug|Thymoglobulin (ATG)|2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor
46008112|NCT00585455|Drug|sertraline|open label 25-50 mg daily as tolerated
46008113|NCT02484456|Drug|AV 101 (4-Chlorokynurenine)|L-4-chlorokynurenine (4-Cl-KYN) was developed as a prodrug that is rapidly converted in vivo to its active metabolite 7-chlorokynurenic acid (7-Cl-KYNA), a well-characterized N-Methyl-D-aspartate receptor (NMDAR) antagonist at the glycine site.
46008114|NCT02484456|Other|Placebo Comparator|Placebo
46008115|NCT00585728|Procedure|CT Virtual Proctoscopy (CTVP)|CTVP done prior to initiation of therapy and a couple of weeks before patient has surgery.
46008116|NCT01083966|Drug|Bevacizumab (Avastin)|"Super-Selective Intraarterial Intracranial Infusion of Bevacizumab in Vestibular Schwannoma~This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival and hearing function of patients with VS"
46008117|NCT01132807|Biological|Bleomycin Sulfate|Given IV
45678495|NCT01430104|Drug|Alfarol 1.0 µg|Administered orally throughout the study
46008118|NCT01132807|Drug|Doxorubicin Hydrochloride|Given IV
46095008|NCT02650232|Procedure|Orthostatic test|"For each arm we will proceed to an orthostatic test day one and day two with :~10 minutes in supine position~10 minutes in sitting position~5 minutes in standing position~5 minutes in supine position"
46008119|NCT01132807|Drug|Procarbazine Hydrochloride|Given PO
46095009|NCT02650232|Device|Finapres Nova device (FMS system)|
46008120|NCT01132807|Drug|Vinblastine Sulfate|Given IV
46095010|NCT00666822|Behavioral|compliance monitoring|To examine the relationship between adherence to endocrine therapy and variables from the Health Belief Model (i.e., perceived risk, barriers to and benefits of adherence, and cues to action such as physician recommendation) as well as measures of patient's perceptions of patient- and family-centered care in women with estrogen receptor-positive stage I-IIIA breast cancer.
45459968|NCT03475576|Other|Keuzewijzer|"The intervention, offered to the older civilians and their informal care groups will consist of a updated version of the 'Keuzewijzer'. This is a self-management tool which stimulates the communication within the informal care groups to make behaved choices concerning the care for the older civilian, taking into account the standards, values, concerns and needs of every informal caregiver and older civilian. The most important value of this intervention is the approachability and the structured, but adjusted manner of support, focused on the individual context of care with their specific needs.~The 'Keuzewijzer' is an online tool whereby, in conversation with the informal care group and older civilian, the following aspects will be discussed in the context of the care for the older civilian: 1) analyzing the problem, 2) detection of possibilities or alternatives, 3) clarifying of motives and feelings and 4) weighting between values."
46095011|NCT00666822|Other|medical chart review|Patient's medical records are reviewed for information about the time since diagnosis, tumor characteristics, treatment, and comorbidity.
46095012|NCT00666822|Other|questionnaire administration|Patients complete a 15 minute questionnaire on-line or by mail comprising questions of demographic and medical variables (i.e., age, race/ethnicity, marital and educational status, and medication side effects) as well as health beliefs and selected aspects of patient- and family-centered care. Data collected from the questionnaire will be stored in an Excel database.
46095013|NCT02773277|Other|head-impulse testing|all patients will receive quantitative head impulse testing using video goggles for all six semicircular canals.
46095014|NCT02657720|Device|Radical 7|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Radical 7 measures respiratory rate according to acoustic respiratory rate (RRa).
46095015|NCT02657720|Device|Capnostream20p|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream20p measures respiratory rate using capnography (RRetCO2).
45459969|NCT01251055|Drug|GlyT-1 inhibitor-1|GlyT-1 inhibitor-1(500) 4# BID
46008121|NCT01132807|Drug|Dacarbazine|Given IV
46008122|NCT01132807|Drug|Cyclophosphamide|Given IV
46095016|NCT02657720|Device|PTAF2|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. PTAF2 measures respiratory rate using flow pressure (RRflow).
46095017|NCT02765555|Drug|RBP-7000|Single dose
46095018|NCT02765321|Behavioral|Healthy lifestyle promotion|Healthy lifestyle changes (i.e., increase in physical activity levels and improvement in eating habits) will be promoted via population-based counselling through media (i.e., radio, newspapers, magazines, television, banners), cell phone applicative, workshops, specific programs at schools and companies, and community physical activity programs.
46095019|NCT02654834|Other|Exposure to nitrous oxide or other volatile anesthetics|No intervention, but routine work-place exposure to volatile anesthetics
46095020|NCT02764931|Other|Gluten free oats and gastrointestinal health|Subjects will be served 3 different test meals in a randomized order in the cross-over design
45459970|NCT01251055|Drug|Placebo|starch
45459971|NCT03482128|Device|Coagulation management guided by SONOCLOT|Application of blood products guided by SONOCLOT measurements
45459972|NCT03482128|Device|Standard coagulation management|Application of blood products based on clinical experience of the anesthesiologist in charge
45678496|NCT01990859|Biological|Ipilimumab|
46008123|NCT01132807|Drug|Etoposide phosphate|Given IV
46008124|NCT01132807|Drug|prednisone|Given PO
46008125|NCT01132807|Drug|Radiation Therapy|Undergo radiation therapy
46008126|NCT01132807|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
46008127|NCT01132807|Procedure|computed tomography|Undergo FDG PET/CT
45678497|NCT02093897|Biological|rVIII-SingleChain|
46008128|NCT01132807|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
46008129|NCT04569513|Biological|Thyroid and parathyroid disease|To analyze surgery or not, different surgical methods, timing of surgery, and alternative managements for patients of thyroid or parathyroid disease.
46008130|NCT00585845|Biological|CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin|2-hour IV infusion once every 21 days, up to 4 doses. Doses from 1x10^8 cfu to 1x10^10 cfu.
46037822|NCT01092780|Drug|Modafinil|two 100 mg tablets, orally, single dose
46008131|NCT01132651|Other|Current standard eczema treatment and standard pillow at night|Subjects will continue with their current eczema care and use their normal pillow at night.
46095021|NCT00656526|Drug|Lidocaine, perineural injection, intraoperatively|0.5 cc lidocaine, one single injection over the dorsal root.
46095022|NCT00656526|Drug|Lidocaine|0.5 cc %2 lidocaine,single injection
46095023|NCT02657330|Drug|SBP-101|Subcutaneous drug, escalating dose cohorts
46095024|NCT02765009|Drug|diuretics|Used to reduce fluid overload as evidenced by weight gain
46095025|NCT02765009|Drug|albumin|Used to reduce fluid overload in addition with diuretics in hypoalbuminemic patients
46095026|NCT02765009|Other|fluid restriction|Used to reduce fluid overload
46095027|NCT02765009|Device|renal replacement|Used to reduce fluid overload in patients with renal replacement
46008132|NCT01132651|Other|Chillow cooling pillow|Subjects will use the cooling pillow to sleep on in addition to their current eczema treatment for 2 weeks.
46008133|NCT01089543|Drug|Rabeprazole|Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.
46008134|NCT01089543|Drug|Rabeprazole|Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.
46008135|NCT01089543|Drug|Rabeprazole|Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.
45678498|NCT01990313|Device|Activa PC+S|The Model 37604 Activa PC+S is a multiprogrammable device that can deliver therapeutic electrical stimulation and record bioelectric signals from leads implanted in the brain.
46008136|NCT01089543|Drug|Placebo|Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.
46095028|NCT02636478|Other|questionnaire for travel habits|questionnaire has been used to collect information about travelling
46095029|NCT02649920|Device|Cervical ripening balloon|
46095030|NCT02649920|Drug|Dinoprostone|
46095031|NCT02765087|Other|Medical History|Oriented Survey and complete physical exam.
46095032|NCT02765087|Device|E-Nose|Patient will breath trough the device for 5 minutes, and during and after the intervention will be assessed for adverse effects related to the use of the e-Nose, according to the CTCEA
46095033|NCT02765087|Other|Chest CT|
46095034|NCT02765087|Other|Pleural Fluid Analysis|Cytomorphology Cytochemistry Adenosine Deaminase Value
46095035|NCT04167722|Procedure|Robotic Radical Prostatectomy|Routine NHS Radical Prostatectomy
46095036|NCT02764853|Behavioral|Experimental Intervention (STEP-AD)|This experimental intervention will consist of 10 sessions- 1 session of Lifesteps (problem solving for medication adherence) and 9 sessions of an intervention specifically tailored for Black women living with HIV to address trauma/abuse, racial discrimination, HIV stigma, and gender roles expectations in order to improve health outcomes (e.g., medication adherence, viral load), increase resiliency, and enhance adaptive coping strategies.
46095037|NCT02764853|Behavioral|Enhanced Treatment as Usual (E-TAU)|Participants assigned to the E-TAU condition will receive 1 session of Lifesteps (problem solving for medication adherence) and appropriate services and referrals as needed
46095038|NCT00663078|Behavioral|Brief CBT Group therapy|CBT based therapy also expert patient programme
46095039|NCT04137692|Other|Red Blood Cell Transfusion|The procedure will be performed as an outpatient according to protocols established for sickle cell anemia patients. Two IVs are placed for the purposes of transfusion, one for draw and one for return. Patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells.Total time of procedure: approximately 150 minutes.
46095040|NCT02771561|Procedure|Patent Foramen Ovale Closure|Transoesophageal guided percutaneous patent foramen ovale closure using Gore™ septal occluder device
46095041|NCT00649688|Drug|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg|100/50mg, single dose fasting
46095042|NCT00649688|Drug|Lopressor HCT® Tablets 100/50 mg|100/50mg, single dose fasting
46095043|NCT00597012|Procedure|Arthroscopic partial menisectomy|Arthroscopic partial meniscectomy is a surgical procedure that is performed to remove a piece of torn cartilage in the knee joint. Incisions for arthroscopy are quite small, usually about 1 centimeter each. The torn meniscus can be removed using a number of different instruments, including small shavers and scissors.
46095044|NCT00597012|Other|Standard physical therapy|Participants will undergo standard physical therapy that will include strengthening and stretching sessions one to three times a week for 8 weeks. This physical therapy regimen will have similar elements and goals as the postoperative intervention offered to Group 1 participants.
46095045|NCT00597012|Other|Postoperative rehabilitative physical therapy|This physical therapy is geared specifically toward rehabilitation after APM surgery.
46095046|NCT04631003|Diagnostic Test|dynamic functional testing|First, with an arthroCT of the wrist by intraarticular injection of contrast agent, a possible scaphulonary band lesion is detected. The surgeon does not yet know the findings of the possible ligament injury at this time, but he can assess the fracture in the CT. Subsequently, a dynamic functional test of the scapholunary distance is carried out intraoperatively under investigation with the modified Watson test before and after performing the osteosynthesis. For this purpose, the wrist is intraoperatively brought under pull on the thumb from a radial abduction into an ulnarabduction. In the presence of a scapholunary instability, a change in the distance of the scapholunary joint gap is shown here under illumination. Now the surgeon receives the finding of the Arthro-CT regarding an existing ligament injury. If necessary, this is treated in the same anaesthetic with a band seam and ossary transfixation.
46008137|NCT00585962|Radiation|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday), for 8 weeks.
45678499|NCT01947517|Device|Parasol Punctal Occluder|Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
46008138|NCT04569396|Diagnostic Test|Biochemistry analysis|Biochemistry analysis of liver parameters were analyzed among the study subjects before and after the surgery.
46008139|NCT04569396|Diagnostic Test|NAFLD fibrosis score|NAFLD fibrosis score was determined among the study subjects before and after the surgery.
46008140|NCT04569396|Other|BMI measurement|BMI was measured among the study subjects before and after the surgery.
46095047|NCT02773433|Other|Proportional Assist Ventilation|
46095048|NCT02773511|Procedure|Surgical treatment|Closed reduction and Kirschner wire fixation
46095049|NCT00667056|Drug|tacrolimus ointment|topical
45678500|NCT01947517|Device|Superflex Punctal Occluder|Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
45678501|NCT02006927|Device|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
46008141|NCT04569396|Diagnostic Test|Fibrosis 4 Index|Fibrosis 4 Index was determined among the study subjects before and after the surgery.
46095050|NCT00667056|Drug|placebo ointment|topical
46008142|NCT04569396|Diagnostic Test|Fatty Liver Index|Fatty Liver Index was determined among the study subjects before and after the surgery.
46008143|NCT00586040|Procedure|tissue bonding|application of rose bengal and treatment with green light
46095051|NCT02771639|Procedure|Hip arthroplasty|Treatment with a hip arthroplasty (semi- or total hip arthroplasty) for a displaced femoral neck fracture
46095052|NCT02772887|Dietary Supplement|L-Citrulline|amino acid supplement
46095053|NCT02772887|Other|Placebo|placebo
46095054|NCT02764619|Drug|Spironolactone|
46095055|NCT02764619|Drug|Placebo|
46008144|NCT00586040|Procedure|sutures|interrupted superficial sutures
46095056|NCT00663156|Procedure|breast implants|patients will have breast augmentation using implants
46095057|NCT00663156|Procedure|Liposuction, fat grafting|Autologous fat will be harvested from the body (typically the abdomen or thighs) using syringe aspiration techniques and then infiltrated into the subcutaneous tissue around the breast as well as between the breast and the underlying musculature using blunt cannulas. These procedures will be done in an outpatient surgery setting in the Georgetown University Hospital under general anesthesia and sterile conditions.
46095058|NCT04223375|Behavioral|Nutrition Training|Postpartum women were educated on postpartum healthy and regular nutrition.
46095059|NCT04162860|Device|Eso-SPONGE® device|Preemptive ENP therapy will be carried out with either an Eso-SPONGE® device system (Eso-SPONGE®, B. Braun Melsungen AG, Melsungen, Germany). Eso-SPONGE® consists of an open-pored polyurethane foam fitted to a gastric tube. Secretions are then continuously evacuated using a suction pump generating a negative pressure between 75 and 100 mmHg.
46095060|NCT04032210|Other|dual Zinc plus Arginine based toothpaste (Colgate total)|Regimen using dual Zinc plus Arginine based toothpaste (Colgate total)
46095061|NCT04032210|Other|Zinc based toothpaste (Crest complete)|Regimen using Zinc based toothpaste (Crest complete)
46095062|NCT04032210|Other|Fluoride based toothpaste (Signal)|Fluoride based toothpaste (Signal)
46095063|NCT04223219|Drug|Fentanyl|"Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxygen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~The patients will receive fentanyl infusion at a rate of 1 µg/kg/h and fentanyl bolus 20-40 µg according to patient hemodynamics. (tachycardia: increase of heart rate >20% of baseline or hypertension: increase of blood pressure >20% of baseline).~After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion."
45459973|NCT03478644|Device|Experimental Denture Wipe|Participants were instructed to use the experimental wipe to clean their dentures, external to their mouth, up to 4 times daily (once after completion of each of their three main meals and once at any other time) for 14 days. Participants were instructed to use one wipe per denture.
45678502|NCT01947283|Behavioral|DECIDE-PA|The DECIDE-PA intervention teaches patients strategies for asking questions and communicating more effectively with their behavioral health care provider in order to improve shared decision making.
46008145|NCT04569630|Other|Controlled hypoglycaemic state while driving|Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Driving data will be recorded in 4 subsequent glycemic states using an adapted hypoglycemic clamp protocol: euglycemia (d1, 5-8 mmol/l), progressive hypoglycaemia (d2, declining from 4.5 to 2.5 mmol/l), stable hypoglycemia (d3, 2.0-2.5 mmol/l), and again in euglycaemia (d4, 5-8 mmol/l). Patients will be blinded to their glucose levels.
45678503|NCT01947283|Behavioral|DECIDE-PC|The DECIDE-PC intervention trains providers in patient-centered communication techniques and encourages providers to be receptive to patients who take a more active role during the clinical encounter in order to improve shared decision making.
46008146|NCT00586079|Procedure|Deep brain stimulation surgery.|Deep brain stimulation surgery.
46008147|NCT04569318|Device|Treatment Beam|One of the subject's eyes will be treated with the 415 nm treatment beam (20mW) up to 8 times for 15 minutes.
46008148|NCT03452852|Device|PICO|NPWT with PICO (Smith and Nephew)
46095064|NCT04223219|Drug|Fentanyl, Propofol|"Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance of anesthesia will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxugen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~The patients will receive fentanyl bolus 20 µg/hr and propofol 20 mg at the time of surgical stimulation and according to patient hemodynamics (repeated as required).~After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion."
46095065|NCT04223219|Drug|Dexmedetomidine, Ketamine, Magnesium sulfate|"Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance of anesthesia will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxygen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~The patients will receive infusions of dexmedetomidine 0.2 µg/kg/h, ketamine 2 µg/kg/min, and magnesium sulfate 5 mg/kg/h.~After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion."
46095066|NCT02631252|Drug|Hydroxychloroquine|Doses ranging from 600-1400mg daily in divided twice daily doses and administered orally.
46095067|NCT02631252|Drug|Mitoxantrone|Dose: 10mg/m2 IVPB in 50ml NS
46095068|NCT02631252|Drug|Etoposide|Dose: 100 mg/m2 administered intravenously in 500 ml of 0.9% sodium chloride
46095069|NCT02764463|Device|Fiber Reinforced Composite Fixed Partial Dentures|All restorations were made indirectly on a plaster model using unidirectional E-glass fibers (Vectris- Ivoclar Vivadent, , liechtenstein) in combination with a laboratory resin composite (Signum, Heraeus-Kulzer)
46095070|NCT02631408|Drug|Vancomycin|Locally, intrawound applied vancomycin powder
46095071|NCT02773043|Device|CZT SPECT camera|
46095072|NCT00667212|Behavioral|Cognitive Behavioral Therapy|Twelve weekly therapy sessions, approximately one hour each in duration
46095073|NCT00667212|Behavioral|Supportive Psychotherapy|Twelve weekly therapy sessions, approximately one hour each in duration
46095074|NCT02762747|Procedure|preperitoneal suction drainage|preperitoneal suction drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
46095075|NCT00667290|Behavioral|Treadmill exercise|Graded treadmill walking 3 times per week for 3 months
46095076|NCT02762903|Procedure|TSA with tenotomy technique|Standard procedure: Utilization of tenotomy for mobilization of subscapularis during total shoulder arthroplasty (TSA). The subscapularis tendon is incised close to its attachment on the humerus. The Tendon is repaired with sutures.
46095077|NCT02762903|Procedure|TSA with lesser tuberosity osteotomy technique|Standard procedure: Utilization of the osteotomy to mobilize the subscapularis during TSA. A small fleck of bone is removed from humerus, the subscapularis tendon is still attached. The fleck of bone is reattached with sutures.
46095078|NCT02762903|Device|Shoulder prosthesis|"Standard procedure: Total shoulder arthroplasty replaces both components of the ball and socket joint with a metal device."
46095079|NCT02630394|Drug|Azithromycin|
46095080|NCT02771873|Behavioral|Integrated cardiovascular disease risk management.|Health promotion intervention
46095081|NCT04629443|Drug|S 64315 (also referred as MIK665) and azacitidine|"The combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) administered via intravenous (IV) infusion over at least 2 hours.~During the combination treatment period S64315 will be administered according to a dose escalation scheme starting at 50 mg up to 250 mg might be explored. The schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen of azacitidine administered at 75 mg/m² via subcutaneous (SC) injection for 7 days from D1 to D7 of each cycle followed by a rest period of 21 days."
46095082|NCT00667680|Device|Transcranial direct current stimulation (tDCS) - Eldith DC-Stimulator|real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system)
46095083|NCT02771405|Drug|Sofosbuvir|Sofosbuvir 400 mg orally once daily
45678504|NCT02006693|Device|XEN® Gel Stent|The XEN® Gel Stent (XEN45 implant) was placed in the study eye.
46095084|NCT02771405|Drug|Ribavirin|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
46095085|NCT02771405|Drug|Simeprevir|Simeprevir 150 mg orally once daily
46095086|NCT02771405|Drug|daclatasvir|Daclatasvir 60 mg orally once daily
46095087|NCT02771405|Drug|Ledipasvir|Ledipasvir 90 mg orally once daily
46095088|NCT00656604|Genetic|proteomic profiling|at the time of each procedure.
46095089|NCT00656604|Procedure|lumpectomy or mastectomy|removal of breast tumor or removal of the entire breast in which the tumor is located
46095090|NCT00656604|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Prior to initiation of treatment
46095091|NCT00656604|Procedure|histopathologic examination|After the breast tumor has been removed, examination of the tumor under a microscope to determine the type and grade of breast cancer
46095092|NCT00656604|Procedure|magnetic resonance spectroscopy|Prior to initiation of treatment
46095093|NCT02696447|Biological|Biomarkers assays|D-Dimer assays, C-reactive protein, blood platelets assays
46095094|NCT00667758|Drug|Cetrorelix|3-5 mg s.c. on days 1-5
46095095|NCT00667758|Drug|Placebo|3-5 ml NaCl s.c. on days 1-5
46095096|NCT02770937|Other|Virtual reality simulator|The virtual reality simulator group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on laparoscopic suturing.
46095097|NCT02770937|Other|Box trainer|The box trainer group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) on a box trainer.
46095098|NCT02770937|Device|Simbionix|
46095099|NCT02630238|Dietary Supplement|Branched-Chain Amino Acid Supplementation|All participants will partake in the same diet & exercise regime but this group will also be placed on a BCAA intake level of 0.342g/kg of BCAA per day
45678505|NCT02006693|Procedure|Cataract Surgery|Participants diagnosed with a cataract elected to have cataract surgery.
46008149|NCT03452852|Other|Coban 2 lite|Compression bandaging with Coban 2 lite
45459974|NCT03478644|Other|Tap Water|Participants were instructed to use running tap water to clean their dentures up to 4 times daily (once after completion of each of their three main meals and once at any other time) for 14 days.
46008150|NCT03452735|Other|Questionnaire about fertility|Sending a questionnaire about fertility that will have to be returned to us in order to be included in the study. The questionnaires, anonymous, will be numbered according to their order of return.
46008151|NCT01089504|Drug|phenobarbital|Phenobarbital, 4-5 mg/kg/d, by mouth, for 4 months
46008152|NCT01089504|Drug|placebo|Matched placebo, same volume as active drug, by mouth daily for 4 months
46008153|NCT03452696|Dietary Supplement|Calcium supplement|Calcium supplement for low contribution of elemental calcium in the daily diet
46008154|NCT01088997|Drug|Milrinone Lactate|Milrinone lactate will be given first as an IV bolus over one hour at the assigned dose level, followed by a 24 hour IV infusion at the assigned dose level.
46008155|NCT00586118|Drug|Sevoflurane|Sevoflurane sedation, 0.5-1 Vol%, continuously via syringe pump, up to 72 hours in ICU
46008156|NCT00586118|Drug|Propofol|Propofol, 1.5-3 mg/kgBW/h, continuously via syringe pump, up to 72 hours
46008157|NCT04569201|Procedure|Endoscope|The use of the neuro endoscope in excision of intraventricular lesions either alone or in assistance of the surgical microscope
46008158|NCT01088529|Drug|Abiraterone Acetate|1000 mg oral daily for 3 months followed by a prostatectomy.
46008159|NCT01088529|Drug|Prednisone|5 mg orally daily.
46008160|NCT01088529|Drug|LHRHa|LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3 months or 1 injection each month for 3 months.
46008161|NCT00586274|Procedure|CD34 selected haploidentical PBSCT|Infusion of CD34 selected haploidentical PBSCT
46008162|NCT00586274|Drug|Fludarabine|day -8 through day -4 Fludarabine 30 mg/m^2
45459975|NCT01366898|Drug|Dexamethasona, Idarubicine, ARA-C, Methotrexate|
46008163|NCT00586274|Biological|T cell infusion|"At least 30 days after the stem cell infusion, patients will be dosed with T cells. This study will begin with a dose of T cells known not to cause GvHD even in haploidentical recipients, even when the T cells administered have not first been allodepleted. Dose escalation will follow a traditional up and down method, but as results become available they will be used to determine subsequent dose levels by the continual reassessment method. Initially, 2 patients will be entered beginning at dose level 1. Each and every patient will receive up to three additional injections of T cells at the same dose, at monthly intervals, provided there is no evidence of grade 2 or higher GVHD, until total T cell numbers are > 1000/ul.~Dose level -1 (1 x 10^3 T cells/Kg); Dose level 1 (1 x 10^4 T cells/Kg); Dose level 2 (1 x 10^5 T cells/Kg); Dose level 3 (1 x 10^6 T cells/Kg); Dose level 4 (5 x 10^6 T cells/Kg)"
46008164|NCT00586274|Biological|Campath 1h|10 mg iv over 4 hours day-8 through day-6
46008165|NCT00586274|Biological|anti-CD45|anti-CD45 400 ug/kg over 6 hours day -5 through day -2
46008166|NCT00586352|Other|stable isotope infusions|Subjects receive stable isotope infusions through an IV for about 3 hours. The dosage is based on weight.
46008167|NCT01087944|Device|Autoinjector|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by autoinjector for 3 weeks.
46008168|NCT01087944|Device|Pre-filled syringe|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by pre-filled syringe for 3 weeks.
46008169|NCT00586430|Drug|lorazepam|single 2 mg dose of lorazepam
46008170|NCT00586430|Drug|placebo|single dose of placebo
46008171|NCT01132612|Drug|AIN457|AIN457A 150 mg powder for solution
46008172|NCT01132612|Drug|Placebo|Placebo to AIN457A 150 mg powder for solution
45678506|NCT01976845|Drug|Midazolam|Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication
45678507|NCT01976845|Drug|Propofol|Propofol (20mg) 2 ml IV, in the pre-op area as a premedication
45678508|NCT01976845|Drug|Saline|Saline 2 ml IV, in the pre-op area as a premedication
45678509|NCT01989689|Drug|Etanercept|Etanercept 50mg twice weekly
45678510|NCT01989689|Drug|Placebo|
46008173|NCT00586547|Biological|T-Cell Infusion Dose Level -1|(1 x 10^3 T cells/Kg)
46008174|NCT00586547|Biological|T-Cell Infusion Dose Level 1|(1 x 10^4 T cells/Kg)
46008175|NCT00586547|Biological|T-Cell Infusion Dose Level 2|(1 x 10^5 T cells/Kg)
46008176|NCT00586547|Biological|T-Cell Infusion Dose Level 3|(1 x 10^6 T cells/Kg)
46008177|NCT00586547|Biological|T-Cell Infusion- Dose Level 4|(5 x 10^6 T cells/Kg)
46037823|NCT01092780|Drug|Placebo to modafinil|two 100 mg tablets, orally, single dose
46008178|NCT04569279|Drug|Rivaroxaban|Rivaroxaban (Rovaltro®) is a novel oral anticoagulant that acts selectively, reversibly, and potently on activated Factor X (Factor Xa) inhibiting a critical point on the coagulation cascade. Rivaroxaban has excellent bioavailability, rapid onset of peak anticoagulation effect, and predictable pharmacokinetic and pharmacodynamic properties making routine laboratory monitoring and dose adjustments almost unnecessary (11). Rivaroxaban is an extensively studied drug and has received approvals for anticoagulation in several preventive and therapeutic indications (11). Now medical literature has some solid evidence that Rivaroxaban is comparable with other anticoagulants in terms of efficacy. Several studies imply that Rivaroxaban may have a lower risk of major bleeding (11). Several reports and small case-series (12,13) suggest that rivaroxaban may be beneficial as Warfarin in the treatment of cerebral venous thrombosis (CVT) with less or no major complications.
46008179|NCT04569279|Drug|Warfarin|Warfarin (Orfarin®) is the most popular vitamin K antagonist and is considered the standard of care in many venous and arterial anticoagulation indications with extensive clinical experience regarding its use. This inexpensive and effective drug has a narrow therapeutic window that is affected by diet changing and many drug interactions, making frequent monitoring with prothrombin time (PT)/international normalized ratio (INR) highly important.(14)
46008180|NCT01132495|Other|Stenting plus OMT|FFR guided PCI, plus OMT
46008181|NCT01132495|Other|OMT|OMT alone
46008182|NCT01132495|Other|Standard of care|FFR > 0.80; treatment according to local practice
46095100|NCT02630238|Other|Placebo|All participants will partake in the same diet & exercise regime but this group will receive an isocaloric placebo in form of carbohydrate solution
46095101|NCT02630238|Other|Exercise|Exercise will take place in a class based, circuit training setting run by a certified personal trainer composed of both aerobic and lifting exercises
46095102|NCT02630238|Other|Diet|Each participants will be placed on a daily energy deficit of 500 calories for the 8 week study period.
46095103|NCT02764307|Device|Constant jet nebulizer|A constant jet nebulizer (Neb-easy, Galemed Corp., Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
46095104|NCT02764307|Device|Breath enhanced nebulizer|A breath enhanced nebulizer (Pari LC plus, Pari Inc., Germany) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
46095105|NCT02764307|Device|Manual-actuated nebulizer|A manual-actuated nebulizer (A-T Neb, Atlantean Corporation, Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
45678511|NCT01943539|Device|Neuro-typical controls and ADHD will receive EVO game play.|EVO mobile video application
45678512|NCT04416373|Diagnostic Test|RT PCR SARS-CoV-2|Positive SARS-CoV-2 RT PCR in nasopharyngeal/oral swab tests or presence of IgM in blood samples
46095106|NCT02764307|Device|Breath-actuated nebulizer|A breath-actuated nebulizer (AeroElipes, Trudell Medical Inc, Canada) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
46095107|NCT00542815|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 40 weeks of flexible dose
46095108|NCT00542815|Drug|Another Phosphate binder (Sevelamer)|Current approved dosing recommendations for 12 weeks
46008183|NCT00586586|Behavioral|Cognitive behavioural therapy|The FRIENDS program developed by Paula Barrett, 10 weekly sessions of 60-90 minutes, with two additional parent meetings, and booster sessions 4 and 12 weeks after treatment.
46008184|NCT04312204|Drug|Sintilimab combined with Gemcitabine and Carboplatin|"The patients will received Gemcitabine1000mg/m2(d1,d8)(iv)+carboplatin AUC 5 (d1)(iv),4 cycles, Sintilimab 200 mg (3mg/kg when the weight <40kg ) (d1) (iv) in one cycle every 3 weeks, until PD or death.~Radiological examinations (according to the RECIST 1.1 criteria) at baseline will be repeated for tumor response evaluation following every two cycles of chemotherapy. Patients will be followed up to 30 days after the last dose of study chemotherapy, and then every 3 months."
46008185|NCT04312282|Drug|Tesetaxel|Tesetaxel orally on Day 1 of a 21-day cycle
46095109|NCT02764073|Device|Bioimpedance spectroscopy|The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM® measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. All calculations are automatically performed by the software of the BCM® device. Absolute fluid overload (AFO) is is defined as the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative fluid overload (RFO) is defined as the absolute fluid overload AFO to ECW ratio.
46095110|NCT02764073|Device|Lung Ultrasonography|Examinations will be performed in the supine position. Scanning of the anterior and lateral chest will be performed on both sides of the chest, from the second to the fourth (on the right side to the fifth) intercostal spaces, at parasternal to mid-axillary lines. B-lines will be recorded in each intercostal space and were defined as a hyperechoic, coherent US bundle at narrow basis going from the transducer to the limit of the screen. B-lines starting from the pleural line can be either localized or scattered to the whole lung and be present as isolated or multiple artifacts (with a distance 7 mm between 2 artifacts). The sum of B-lines produces a score reflecting the extent of lung water accumulation (0 being no detectable B-line).
46008186|NCT04312282|Drug|Tesetaxel|Tesetaxel orally on Day 1 of a 21-day cycle
46008187|NCT04312282|Drug|Itraconazole|Itraconazole orally once daily from Day -3 to Day 14 of a 21-day cycle
46008188|NCT04312282|Drug|Rifampin|Rifampin orally once daily from Day -6 to Day 14 of a 21-day cycle
46008189|NCT04311931|Other|Active Dance Program|All Creative Dance sessions comprised five phases: 1) opening ritual (5 min), in which participants will be welcomed and will be informed about the objectives and structure of the session; 2) warm-up (15 min), in which body muscle groups will be activated through the introduction of basics elements of movement; 3) main phase (30 min), will be proposed individual, pair and group activities, in order to achieve the objectives described above. This phase will end with a choreography composition; 4) cool-down (5 min) with stretching and physiological parameters normalization; and 5) ending ritual (5 min), in which the participants will be invented to share their sessions' experience and they will fill a sheet with attendance, exercise intensity perception (Borg Scale) and satisfaction's (Caregiver Treatment Satisfaction questionnaire).
46008190|NCT01087905|Drug|Nicotine patch|"If > 10 cigs/day: one 21 mg nicotine patch per day~If < or = 10 cigs/day: one 14 mg nicotine patch per day"
46008191|NCT01087905|Drug|Nicotine gum|"If < 25 cigs/day, 2 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
46008192|NCT01087905|Behavioral|CMAC|CMAC consists of tailored cessation counseling to improve medication adherence during the counseling calls. The CMAC protocol was developed by study investigators and involved: (1) pre-quit assessment of beliefs that might undermine NRT adherence; (2) on-going medication adherence assessment by quitline Quit Coaches; and (3) tailored coaching based on the ongoing assessments.
46008193|NCT00586742|Procedure|labral repair|labral repair with suture anchors
46008194|NCT00586742|Procedure|biceps tenodesis|biceps tenodesis with suture anchor
46008195|NCT00586742|Procedure|diagnostic arthroscopy|diagnostic arthroscopy
46095111|NCT02764073|Device|Echocardiography|All echocardiographic measurements will be carried out according to the recommendations of the American Society of Echocardiography by an observer unaware of the lung ultrasound and bioimpedance results. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).
46095112|NCT02762591|Drug|Pimavanserin tartrate|Pimavanserin tartrate 40 mg, tablet, taken as two 20 mg tablets, once daily by mouth
46095113|NCT00667914|Procedure|geriatric work-up|Pre- and postoperative treatment of hip-fracture patients in an orthogeriatric unit(geriatric evaluation and management)
46095114|NCT00667914|Procedure|Orthopedic care as usual|treatment in ordinary orthopedic unit
46095115|NCT02696369|Drug|2% lidocaine HCl with epinephrine 1:200,000|
46095116|NCT02696369|Drug|2% lidocaine HCl with epinephrine 1:80,000|
46095117|NCT00663312|Behavioral|e.g., Protein and calorie controlled diet; Self-hypnotic relaxation|Pilot description
46095118|NCT02771015|Device|Mepilex Border®|randomization
46095119|NCT02771015|Device|Cosmopor steril®|randomization
46095120|NCT02636244|Drug|SHAPE Gel|
45836733|NCT00401622|Behavioral|OneTouch® Ultra®2 System|Education and self-monitoring of blood glucose performed with OneTouch® Ultra®2 System that includes the Simple Start™ home-based education program
46095121|NCT04559633|Other|cognitive and behavioral therapy (CBT)|"The CBT program is delivered by a multidisciplinary team with 4 half day hospitalization that includes individual, group CBT and education time (2 hours per day delivered by the teacher). Participants have homework to do in their own time at home.~CBT is a manualized program with anxiety psychoeducation, stress management, cognitive restructuration, problem solving techniques, progressive exposure, assertiveness exercises and self-esteem work."
46008196|NCT04311892|Diagnostic Test|EMG of the hip abductor muscles|EMG will be carried out to examine the (superior gluteal nerve) SGN for all patients. The muscles will be evaluated according to the criteria of the American Academy of Electrophysiological Medicine for needle EMG. In order to exclude patients with polyneuropathy, radiculopathy, or plexopathy, nerve conduction studies of both lower extremities will be performed. Then, gluteus medius muscles will be assessed bilaterally to evaluate the SGN, the vastus medialis muscle for L4 root, tibialis anterior muscle for L5 root, and gastrocnemius muscle for S1 root.
46095122|NCT00663390|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
46095123|NCT02762357|Device|Novosyn® Quick|Episiotomy closure
46095124|NCT00668070|Drug|ASP9831|Oral
46095125|NCT00668070|Drug|Placebo|Oral
46095126|NCT04732013|Other|No clinical intervention is planned; study is observational|No intervention
46095127|NCT04154436|Other|Sodium Bicarbonate (NaHCO3) Plus Solution|Alkaline Solution
46008197|NCT04311736|Behavioral|Exergame|Cycling on a recumbent cycle ergometer + Virtual Reality Cognitive Training
46095128|NCT04154436|Other|Water (H2o)|Alkaline Solution
46095129|NCT02762435|Other|sham|light touch at established points on hand and wrist
45459976|NCT03916315|Behavioral|Transdiagnostic Treatment|"The Unified Transdiagnostic Protocol (PUT) is a cognitive-behavioral treatment focused on emotions. The PUT was developed to be applicable to anxiety disorders, mood disorders, as well as other disorders in which anxiety and emotional dysregulation play an important role, such as many somatoform and dissociative disorders.~The PUT proposal includes 8 modules, of which 5 are nuclear, it is recommended to give these modules between 11 to 17 sessions with a duration of one hour each."
46008198|NCT04311736|Behavioral|Cycling|Cycling on a recumbent cycle ergometer
46008199|NCT04311736|Behavioral|Stretching|Stretching exercises
46095130|NCT02762435|Other|control|no contact with the subject
46095131|NCT02762435|Other|acupressure|moderate pressure at established points on hand and wrist
46095132|NCT04154670|Biological|MGTA-145|MGTA-145 will be given intravenously
46095133|NCT02762279|Other|esophageal and pleural pressure measurement|Esophageal pressure will be monitored by a dedicated catheter and pleural pressure will be measured into the chest tube already in place
46095134|NCT00668226|Drug|Lactic acid (Dermacid)|
46095135|NCT02763995|Behavioral|Pharmaceutical care|This is a quasi-experimental study and the same group will be evaluated before and after the follow up.
46095136|NCT02636166|Other|Clearblue Investigational Pregnancy test|Clearblue Investigational Pregnancy test
46095137|NCT02636166|Other|Professional pregnancy test|Alere Professional use pregnancy test
46095138|NCT02636166|Other|Clearblue Marketed Pregnancy test|Clearblue Marketed Pregnancy test
46095139|NCT02763605|Other|no intervention|
46095140|NCT02636088|Drug|Cetuximab|
46095141|NCT04641143|Drug|Troriluzole|Troriluzole - 2 100mg capsules QD for the first two weeks.
46095142|NCT04641143|Drug|Placebo|Matching placebo - 2 140mg capsules QD from week two through week ten.
46095143|NCT02630160|Drug|Bupivacaine hydrochloride|Intraarticular infusion with bupivacaine
46095144|NCT02630160|Other|Physiological Saline|Intraarticular infusion physiological serum
46095145|NCT00668304|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg once orally daily
46095146|NCT00542425|Drug|teriparatide|teriparatide 20 µg subcutaneous daily
46095147|NCT00542425|Drug|Placebo|Placebo subcutaneous daily
46095148|NCT00542425|Drug|BA058 20 µg|BA058 20 µg subcutaneous daily
46095149|NCT00542425|Drug|BA058 40 µg|BA058 40 µg subcutaneous daily
46095150|NCT00542425|Drug|BA058 80 µg|BA058 80 µg subcutaneous daily
46095151|NCT00668460|Drug|Lactic acid (Dermacid)|
46095152|NCT00668538|Drug|Brentan (miconazole)|Vaginal suppository 1200 mg at day 6
46095153|NCT02770781|Other|Exercise regimen|Subjects will receive a personal exercise regimen based on their health history and individual capability.
46095154|NCT00668616|Drug|Cyclophosphamide, Epirubicin, Paclitaxel|4 cycles of 600 mg/m² cyclophosphamide i.v. and 90 mg/m2 Farmorubicin i.v. on day 1, q21d followed by 4 cycles of 175 mg/m² Taxol, day 1, q21d
46095155|NCT00668616|Drug|Epirubicin, Paclitaxel, Filgrastim|cycle 1-4: 120 mg/m² Epirubicin i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl) cycle 5-8: 175 mg/m² Paclitaxel i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl)
46095156|NCT02761889|Radiation|IGRT 45 Gy in 5 fractions of 9 Gy|Previously untreated patients with prostate cancer will be treated with 45 Gy in five fractions of 9 Gy over 5 consecutive days.
46008200|NCT00586781|Device|Scandinavian Total Ankle Replacement (STAR)|The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants.
46008201|NCT00586859|Device|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument. Additional sutures were placed in the same manner described above, with each additional implant placed incrementally closer to the GE junction in a linear configuration along the anterior gastric cardia. All plications were placed de novo, and re-treatment was not permitted.
46008202|NCT01087788|Biological|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
46008203|NCT01087788|Biological|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
46008204|NCT01087788|Other|Placebo|Matching Placebo to CZP injection.
46008205|NCT00586937|Behavioral|questionnaires or telephone interview|In the first phase, a random sample of lung cancer survivors will complete a comprehensive telephone interview or questionnaire by self-report focusing on assessment of quality of life and related covariates. We estimate the total time for completion of the survey by telephone interview or self-report to be 45-60 minutes. second phase of the study, a subset of telephone survey participants will take part in a focus group discussion that will explore their perceptions of barriers for delivery of post-treatment medical and psychosocial follow-up care.
46008206|NCT00586976|Drug|Ropivacaine|0.3% ropivacaine infusion at 4 ml/hr for 64 hours.
46008207|NCT00586976|Drug|Normal saline|Normal saline infusion at 4 ml/hour for 64 hours.
46008208|NCT00587015|Drug|CAT-8015|The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60…μg/kg until toxicity supervenes.
46008209|NCT01086969|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)|0.5 mL, Intramuscular
46008210|NCT00587093|Other|CA 125 and CT scan|Within 14 days prior to surgery serum for CA125 will be obtained. The patient will also undergo a CT scan of the abdomen and pelvis with oral and intravenous contrast within 35 days prior to the procedure.
46008211|NCT04568772|Drug|Atovaquone / Proguanil 250/100 mg|Atovaquone / Proguanil 250/100 mg tablet
46008212|NCT04568772|Drug|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
46008213|NCT04568772|Drug|Esomeprazole 40 mg|Esomeprazole 40 mg tablet
46008214|NCT04568772|Drug|Vonoprazan 20 mg|Vonoprazan 20 mg tablet
46008215|NCT04575272|Procedure|Ultrasound-guided continuous serratus anterior plane block|Local anesthetic infusion though a peripheral nerve catheter placed related to the serratus anterior muscle at the level of the 5th rib
46008216|NCT04575350|Genetic|reinterpretation of CNV|Reinterpretation of CNV of unknown significance
46008217|NCT01086423|Biological|Infanrix-IPV/Hib™|Intramuscular, three doses
46008218|NCT01086423|Biological|Infanrix Hib™|Intramuscular, three doses
46008219|NCT01086423|Biological|Poliorix™|Intramuscular, three doses
46008220|NCT04575389|Diagnostic Test|Serum uric acid levels ,HBA1C , fasting plasma glucose ,lipid profile , creatinine level|diagnostic tests
46008221|NCT04575116|Drug|Tafamidis free acid tablet|12.2 mg tafamidis free acid tablet
46008222|NCT04575116|Drug|Tafamidis meglumine capsule|20 mg tafamidis meglumine soft gelatin capsule
46008223|NCT01086150|Procedure|Skin biopsy|Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
46008224|NCT01086150|Drug|Lidocaine 5% patches|Subject will apply patches to affected area QD for 12 hours then remove.
46008225|NCT02278107|Device|Tidal Assist Ventilator System|Tidal volume augmentation with supplemental oxygen. Source gas options: cylinder, concentrator, wall.
46008226|NCT02278107|Device|Nasal Cannula Oxygen|Standard oxygen therapy delivered by nasal cannula at 2-5 lpm based on patient requirements. Source gas options: cylinder, concentrator, wall.
46008227|NCT00587249|Biological|Malaria ICC-1132|ICC-1132, a candidate malaria vaccine, with alhydrogel will be in 2 ml glass vials containing ICC-1132 at either 40 mcg/ml or 100 mcg/ml concentration formulated with alhydrogel at 1mg/ml. Each vial will contain approximately 0.8 ml solution to permit recovery of 0.5 ml for injection. When shaken, the solution is off-white to greyish-white turbid liquid free of foreign particulate matter.
46008228|NCT00587249|Biological|Alhydrogel|Aluminum hydroxide gel.
46008229|NCT00587327|Drug|Barusiban|Solution for IV treatment. Bolus and infusion for 4 hours
46008230|NCT00587327|Drug|Atosiban|Solution for IV administration. Bolus and infusion for 4 hours
46008231|NCT00587327|Drug|Placebo|Saline solution for IV administration. Bolus and infusion for 4 hours.
46008232|NCT00587405|Procedure|cryotherapy|"The Polar Wand device (GI Supply, Wayne, PA) is FDA 510(k) approved for endoscopic tissue ablation in the GI tract. It consists of a portable cryogen-containing unit and a single-use flexible cryogen spray catheter, designed for use with CO2 that is supplied in standard 20-lb cylinders. Controlled delivery of the cryogen is achieved by a foot pedal, and the tip of the catheter is maintained at about 1 cm from the mucosa. A cryogenic spray is applied to all vascular lesions until a whitened appearance of the mucosa is achieved within 3-5 seconds. Affected areas will be 'painted' by the spray catheter starting at the pylorus and sweeping proximally.~A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy."
46008233|NCT00587405|Procedure|Argon Plasma Coagulation|As per current clinical standard, the APC 300 device (ERBE Inc., Marietta, GA) will be used in this study. Targeted ablation of all vascular ectasias as best possible will be performed in standard fashion using an end-firing probe at a setting of 60 W and 2 L/min argon flow rate.A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy
46008234|NCT01085682|Behavioral|Lifestyle counseling|In intervention group, counseling sessions are conducted weekly for 3 months, once per two weeks for 3 months, monthly for 18 months, and then once every two months for the remainder of the study.
46008235|NCT01085682|Behavioral|Standard care|In standard care group, counseling sessions are conducted only 6 times for 4 years
46008236|NCT00587444|Drug|Heparin|300u/kg of heparin for CPB ACT performed. If ACT is < 480 seconds a bolus of 5000u heparin will be given. ACT will be repeated and bolus given until ACT is>480 seconds
46008237|NCT00587444|Drug|HH or high heparin|initial dose of 450u/kg for CPB ACT performed additional bolus given if result is <600 seconds anytime during CPB
46008238|NCT00587444|Drug|heparin concentration HC|"will have anticoagulation during CPB assessed with heparin concentration monitoring and heparin dose response (HDR) to determine the optimal dosage of heparin. This group will evaluate the possible benefit of the HDR to determine heparin dosing and monitoring to achieve maximal suppression of thrombin compared to a fixed dose of heparin as the other two groups. Additional heparin doses will be given to maintain a specific heparin concentration according to the HDR. This is a recognized way of managing heparin dosing and anticoagulation for CPB.~All three groups will have heparin neutralized by protamine. Adequacy of heparin neutralization will be based on a difference between the ACT and heparinase-treated ACT values of less than 10%"
46008239|NCT00587522|Device|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument.
46008240|NCT02278302|Drug|Aggrenox®|
46008241|NCT02278302|Drug|Placebo|
46008242|NCT02278302|Other|Ethanol|
46008243|NCT00587600|Procedure|Photodynamic therapy|Photofrin 2mg/kg Photoradiation The light dose delivered will be a total of 200 joules per centimeter fiber which has previously been shown to ablate Barrett's mucosa.
46008244|NCT00587600|Procedure|radiofrequency ablation of barrett's esophagus|radiofrequency ablation
46008245|NCT01085214|Other|Laboratory Biomarker Analysis|Correlative studies
46008246|NCT01085214|Drug|Selumetinib|AZD6244 (Selumetinib), 75 mg was administered orally, twice a day, continuously for 28-day cycles
46095157|NCT02761889|Procedure|Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)|Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.
46095158|NCT02761889|Device|Rectal balloon with air filling|A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.
46095159|NCT02761889|Device|Urethral catheter loaded with beacon transponders|A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.
46095160|NCT00668694|Behavioral|Stimulation|Stimulation given to the child by mother
46095161|NCT02763761|Drug|Infliximab + Prednisone|Prednisone dose will be decreased every 3 days for 18 days
46095162|NCT02763761|Drug|Methylprednisolone + Prednisone|Prednisone dose will be decreased every 4 days for 40 days
46095163|NCT04155918|Drug|Group 1: AR882 Alone and in Combination with Febuxostat (FBX)|AR882 + Febuxostat, AR882 alone, Febuxostat alone
46008247|NCT00587717|Drug|simvastatin|Two 80 mg pills simvastatin taken 24 hours prior to surgery
46008248|NCT00587717|Drug|placebo|take 2 80 mg pills placebo 24 hours prior to surgery
45459977|NCT03479632|Behavioral|Aerobic walking program|Participants will make 24 visits over an 8 week period, having 3 sessions per week. Each session will last about one hour.
46008249|NCT00587756|Procedure|One-stage ultrasound guided hepatectomy|Surgical strategy was based on tumor-vessel relationship at intraoperative ultrasonography (IOUS)and on findings at color-Doppler IOUS.
46008250|NCT01085136|Drug|Investigator´s choice of chemotherapy|BIBW 2992 in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
46008251|NCT01085136|Drug|BIBW 2992|BIBW 2992 will be given in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
46008252|NCT00587873|Drug|Methotrexate|MTX 6mg/m2 given IV bolus, followed by 24mg/m2 given in 24hrs continuous infusion
46008253|NCT00587873|Drug|Leucovorin calcium|5 mg orally at 12 hours after the end of MTX infusion then every 12 hrs for a total of 3 doses.
46008254|NCT00587873|Drug|6-Thioguanine|6-TG 300 mg/m2 PO as a single oral dose
46095164|NCT04155918|Drug|Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)|AR882 + Allopurinol, AR882 alone, Allopurinol alone
46095165|NCT02763839|Drug|BIA 3-202|"The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods."
46008255|NCT04574804|Other|Online training program in weight management for osteoarthritis|"An evidence based online education training program for physiotherapists in weight management for osteoarthritis. Training modules cover the following topic areas:~Overweight and obesity and osteoarthritis~Overview of weight regulation, overweight and obesity~Examining weight stigma in physiotherapy and personal beliefs about weight~Communication approach for addressing weight management~Interventions for weight management~Health behaviour change support~These 6 e-learning modules comprise the online training program, access to which comprises the study intervention."
46008256|NCT01084707|Drug|Oral Nicotine|Oral Nicotine either self-administered or provided by study personnel within 12 hours
45836734|NCT00401622|Behavioral|Standard care|Standard education and self-monitoring of blood glucose performed with traditional meter systems
46008257|NCT01084707|Drug|Nicotine Lozenge|Nicotine lozenge marketed as NiQuitin™ 4 mg hourly within 12 hours
46008258|NCT01084707|Drug|Nicotine gum|Nicotine gum marketed as Nicorette® 4 mg hourly within 12 hours
46008259|NCT00588107|Other|Web Intervention|Receives pharmacotherapy and access to an interactive Web site (Web condition). The Web site will offer tailored intervention messages and strategies in an interactive format that is much less labor-intensive and costly than the prior PFH peer telephone counseling intervention.
46008260|NCT00588107|Behavioral|print materials|tailored print materials designed to aid in smoking reduction and cessation
46008261|NCT02210520|Device|pulsatile ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
46008262|NCT02210520|Device|continuous ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
45836735|NCT04270890|Device|Abdominal compression belt system|"The abdominal compression belt system is provided free of charge from CDR systems, Canada.~The belt has specifically been chosen from other similar devices commercially available as it is independent of other immobilisation devices and can be used with the patient located within a full body vacbag as per current immobilisation position."
46008263|NCT02210520|Device|laser|1 W/cm², 2 minutes in 6 points around the back spine
46095166|NCT02763839|Drug|Placebo|Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route
46095167|NCT02763839|Drug|Sinemet 25/100|Levodopa 100 mg/carbidopa 25 mg (Sinemet 25/100, Merck Sharp & Dohme) tablets; oral route.
46095168|NCT00541099|Biological|bevacizumab|Avastin 10.0 mg/kg on days 1 and 15
46095169|NCT00541099|Drug|docetaxel|Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel.Docetaxel 35 mg/m2 on day 1, 8, 15
45459978|NCT03479632|Behavioral|Standard physical therapy|Participants will receive standard care they normally would after a stroke.
45836736|NCT00374244|Drug|Pimozide|half of the subjects are randomized to the active drug group
46008264|NCT04574726|Other|static balance|30-second right and left unipodal static balance test
46008265|NCT04574726|Other|dynamic balance|"for the unipodal dynamic balance test, 4 movements will be done by the volunteers in this order :~180° elevation of the arms~lowering of the arms on the side of the single-legged support to the horizontal position~180° horizontal translation of the arms~return from the horizontal to the starting point"
46008266|NCT02210598|Device|inpatient Foley balloon induction|The catheter will be left in place and IV oxytocin will be started per LAC+USC protocol. The foley catheter will be removed after 12 hours if not spontaneously extruded.
46095170|NCT00580606|Drug|Glycerinated peanut allergenic extract|Glycerinated peanut extract delivered sublingually.
45836737|NCT00374244|Drug|placebo|half of the subjects are randomized to placebo group
46037824|NCT05338138|Device|ultrasound guided central venous catheter insertion|Prospective comparative randomized controlled clinical study.
46095171|NCT00580606|Drug|Placebo for peanut extract (glycerin)|Placebo (glycerin) delivered sublingually.
46008267|NCT02210598|Device|outpatient Foley balloon induction|The catheter will be deflated and removed within 10 minutes of placement. The patient will then undergo a non-stress test (NST). If the patient has a reactive NST with no late or variable decelerations or uterine tachysystole, the patient will be discharged home with clear return precautions and instructions to return to the triage area in 24 hours.
46095172|NCT04155606|Device|microsurgery; endovascular interventions|microsurgery: surgical resection of the aneurysm endovascular interventions: coiling, stenting or both
46095173|NCT04637945|Dietary Supplement|ACRB|Product will be consumed once daily, preferably with breakfast.
46095174|NCT04637945|Other|Placebo|Product will be consumed once daily, preferably with breakfast.
46008268|NCT02210598|Drug|Oxytocin|"When a patient randomized to the outpatient Foley Balloon induction group returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.~Patients randomized to the inpatient Foley balloon induction group will have IV oxytocin initiated per LAC+USC protocol at the time of Foley balloon placement."
46008269|NCT04574960|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2, IV infusion on days 1 and 8 of each 3-week cycle
45459979|NCT03482050|Biological|AstroRx|Astrocytes derived from human embryonic stem cells
46095175|NCT04155762|Other|Pin Suspension System (a prosthetic suspension system)|Participants used the PSS for three months following fabrication and adjustment of the prosthesis, and a prosthetic training period.
46095176|NCT04155762|Other|Vacuum-Assisted Suspension System (a prosthetic suspension system)|After PSS, participants employed the VASS for three months after a similar training period.
46095177|NCT04634357|Drug|ET140203 T Cells|"Biological/Vaccine: ET140203 autologous T-cell product~Autologous T cells transduced with lentivirus encoding an ET140203 expression construct"
46095178|NCT02575768|Other|Adenosine-stress cardiac magnetic resonance imaging|undergoing adenosine-stress cardiac magnetic resonance imaging
45459980|NCT05754086|Behavioral|Clear Speech|"This behavioral modification asks participants to speak more clearly, as if they were speaking to someone with a hearing loss."
46095179|NCT00987493|Biological|rituximab|day 1 at a fixed dose of 375mg/m2
46095180|NCT00987493|Drug|bendamustine hydrochloride|Bendamustine at day 1 and 2 according to the dose escalation in phase I, and at the recommended dose in phase II: 70mg/m2.
46095181|NCT00987493|Drug|lenalidomide|Lenalidomide at days 1-21 according to the dose escalation in phase I, and at the recommended dose in phase II: 10mg
45459981|NCT05754086|Behavioral|Less Clear Speech|"This behavioral modification asks participants to speak less clearly, as if they were in a room with many people and they were mumbling something to the person next to them that they didn't want other people in the room to hear."
45459982|NCT03527550|Other|Cognitive Control Training|Cognitive Control Training involves daily practice with one of two computerized interventions. The first intervention is an adaptive Go/No-Go task to provide practice in the domain of response inhibition. Participants press a key as fast as possible in response to stimuli (letters of the alphabet), but must inhibit responses to a specific letter. The second intervention is an adaptive Paced Auditory Serial Addition Task (PASAT), designed to practice working memory. Participants are presented with single numbers presented aurally, and must add each number they hear to the previous number and click the correct sum on the screen.
45459983|NCT01248871|Drug|procedure:sevoflurane-remifentanil/sufentanil|Active Comparator
45459984|NCT01248871|Drug|volatile agent only during reperfusion|Active Comparator
46008270|NCT04574960|Drug|Cisplatin|Cisplatin 70 mg/m^2, IV infusion on day 1 of each 3-week cycle
46008271|NCT04574960|Drug|Carboplatin|Carboplatin AUC 5-6 calculated using the Calvert formula on day 1 of each cycle
46008272|NCT00588224|Other|3D ultrasound|measurement of stomach volume by 3D ultrasound
46095182|NCT02579356|Drug|Telmisartan|
46095183|NCT02579356|Drug|Atorvastatin|
46095184|NCT02763449|Behavioral|Self-monitoing|Participants will self-monitor their physical activity level via activity monitors
46095185|NCT02535390|Behavioral|Action based cognitive remediation|This is a novel form of cognitive remediation in which participants engage in simulated real world tasks in groups and receive therapist feedback in addition to receiving standard cognitive remediation.
45459985|NCT01248871|Drug|propofol-remifentanil/sufentanil|Active Comparator
46008273|NCT01084551|Drug|SPM 962|once a daily transdermal administration started at 2.25 mg/day to 4.5 mg/day for 13 weeks
46008274|NCT01084551|Drug|SPM 962|once a daily transdermal administration started at 2.25 mg/day to 6.75 mg/day for 13 weeks
45459986|NCT04458844|Other|Exercise|Intervention programmes were designed based on previous research (Duncan, et al., 2017; Faigenbaum, et al., 2011; Miller, et al., 2006) to ensure all exercises were developmentally appropriate for the age of the participants (an example session plan can be seen in the supplementary material). Each session consisted of five activities and lasted 50 - 60 minutes. Three out of the five activities were identical for the FMS and FMS+ groups, while two differed focusing on skill development for the FMS group and strength development for the FMS+ group. The FMS and FMS+ group received their sessions twice a week for 4 weeks. The sessions were delivered at least 48 hours apart to allow recovery and to reduce the risk of fatigue effecting performance (Faigenbaum, et al., 1996). All sessions were led by a researcher and a qualified sports coach.
45459987|NCT03479398|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is an evidence-based psychotherapy that treats a variety of disorders. In this study, clinicians will be enrolled who use types of CBT for anxiety disorders, depression and PTSD in their routine clinical practice. CBT is usually a 12-16 session treatment that focuses on intervening on disorders cognitively and behaviorally through the use of worksheets during session and outside of session.
46095186|NCT02535390|Behavioral|Cognitive remediation|Cognitive remediation engages participants in computerized exercises meant to improve cognitive functions and provides therapist feedback for how these improvements manifest in everyday life.
45459988|NCT01251133|Biological|LBVH0101 (Hib vaccine)|0.5mL
45459989|NCT01251133|Biological|Hiberix™ Vaccine|0.5mL
45459990|NCT03720288|Drug|Acetazolamide|Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
45459991|NCT03720288|Drug|Placebo|Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
45836738|NCT04270812|Behavioral|Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-C)|"TranS-C adopts a modular approach to reversing the psychosocial, behavioral, and cognitive processes maintaining sleep problems via 4 cross-cutting modules (introduced in the first session and included in every session thereafter), 4 core modules and 7 optional modules. TranS-C typically involves 6-8 individual, weekly 50-minute sessions."
45459992|NCT01147549|Drug|[C14]AZD9668|Oral Solution 60 mg Single Dose
46095187|NCT03914170|Drug|Folfirinox + cetuximab|Cetuximab 250 mg/m² iv infusion for 2h, Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h, Irinotecan 180 mg/m² iv infusion, 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles max)
45836739|NCT00377832|Drug|Acetaminophen 975 mg|Acetaminophen 975 mg by mouth once only
46095188|NCT04223063|Behavioral|Exercise program|As per the intervention arm
46095189|NCT04005313|Device|vibroacoustic device|the participants will receive the vibroacustic device or music therapy
46095190|NCT00663624|Drug|aspart insulin|subcutaneous aspart insulin every 2 hours
45836740|NCT00401778|Drug|RAD001|Patients will be assigned to one of three treatment arms with RAD001 doses of 5, and 10 mg/day for 21-28 days sequentially taken orally in tablet form.
46008275|NCT01084551|Drug|Placebo of SPM 962|once a daily transdermal administration for 13 weeks
46008276|NCT03452657|Drug|Ranibizumab|Participants in arm Ranibizumab will receive ranibizumab injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year
46008277|NCT03452657|Procedure|No drug|Participants in arm Sham-injection will receive sham injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year.
46008278|NCT02210676|Other|PROMIS Upper Extremity|
46008279|NCT02210676|Other|Likert Pain Scale|
46008280|NCT02210676|Other|Mallet Finger Extensor Lag Measurement|
46008281|NCT03452618|Diagnostic Test|diagnosis variables|"The study compare the diagnostic variables in patients who received Non invasive ventilation equipment one year after diagnosis with the patient who don't need it. For the independent variables, the present study determine a threshold at the diagnosis for which an early fitting risk appears~The diagnostic variable are :~Age of the patient~Sex~Presence of bulbar involvement or not~Time from onset of first symptoms to diagnosis of ALS~Score ALSFRS-R~Presence of another underlying respiratory pathology (COPD, asthma ...)~FVC measurement (Forced vital capacity)~PaCO2 measurement~Measure SNIP (Sniff nasal inspiratory pressure)~Measure of Pimax (Pressure inspiratory maximal)~Measurement of the nocturnal desaturation index (number of desaturation less than 90% per hour of sleep)"
46095191|NCT00663624|Drug|Usual care as prescribed by the ED physicians.|Usual care can be oral anti-diabetic agents, subcutaneous insulin therapy or a combination of both. Subcutaneous insulin used for usual care could include NPH, 70/30 insulin, aspart insulin, regular insulin or insulin glargine
46095192|NCT02762045|Biological|Ad5-gag|Ad5-gag is used as vaccine in all arms.
46008282|NCT03452501|Drug|Infliximab|A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg
46008283|NCT00588302|Drug|Moexipril|Moexipril was given at a starting dose of 7.5 mg daily for 1 week to all enrolled patients. If tolerated (no clinically significant hypotension or medication associated adverse event), the daily dosage was increased to 15 mg daily at the beginning of the 2nd treatment week. Patients took moexipril orally in the morning and 1 hour prior to food intake. The target dose was maintained for the 1-year period of the study unless the development of toxicities warranted dose reduction or discontinuation.
46008284|NCT00588419|Behavioral|breast exam and questionaire|A physical examination of your breast(s), we will ask you to complete a short questionnaire that asks questions regarding sensations in your reconstructed breast(s) and another short questionnaire that asks questions regarding your medical and surgical history. The physical examination and the questionnaires will be completed in the outpatient clinic. This should take about 30 minutes to complete.
46008285|NCT04568655|Device|noninvasive ventilation|noninvasive ventilation to support the COVID-19 patients with respiratory failure
46095193|NCT02762045|Biological|Placebo|Preservation Solution is used as control in all arms.
46095194|NCT00656682|Behavioral|Dietitian Counseling Alone|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian
46095195|NCT00656682|Behavioral|Dietitian Plus Community Group Lifestyle|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian, PLUS free-of-charge access to a group-based lifestyle intervention offered by the Community to prevent diabetes
46095196|NCT02577250|Drug|Ketamine|Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
46095197|NCT04193111|Diagnostic Test|TMD pain screener|The danish TMD pain screener is given to all participants
46095198|NCT00668850|Drug|Generex Oral-lyn™|Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
46095199|NCT00668850|Drug|Regular human insulin|Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
46095200|NCT05711563|Other|Observational study|Observational study
46095201|NCT02762201|Procedure|PASI|"Implant-secured removable partial denture will be delivered in 2 large steps: implant delivery followed by denture delivery.~Implant delivery will take 4 dental consultations : a pre-implant study at Day14 after inclusion, the surgical implant insertion at D28 after inclusion, stitches removal at D35 after inclusion, and finally functional implant delivery between 3 or 6 month after surgery (to allow implant osteointegration).~Denture delivery will take 6 weekly dental consultations between Week 3 and Week 8 after the functional implant delivery."
45459993|NCT03722628|Diagnostic Test|MMP1 genotypes polymorphism|Determination of MMP-1 gene polymorphism By PCR amplification followed by restriction Fragment length polymorphism (RFLP) and gel electrophoresis
46095202|NCT02762201|Procedure|PAC|Metalic standard removable partial denture, the standard treatment, will be delivered in 4 steps at Day 7, D14, D21, D28 after inclusion, as classically.
46095203|NCT05483335|Other|No intervention but assessing for burnout syndrome in all group|Using Maslach Burnout inventory to assess the presence of burnout and a self reporting questionnaire to identify possible stressors or associations
46095204|NCT02762123|Drug|BMS-986142 200mg|
46095205|NCT02762123|Drug|BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)|
46095206|NCT02762123|Drug|BMS-986142 350mg|
46095207|NCT05711485|Other|Whole blood transfusion|Whole blood is sourced from the Zambia National Blood Transfusion Service.
46095208|NCT02579200|Device|POWERbreathe®KHA (IMT group)|2 training sessions/day consisting of 30 breaths (~50% maximal inspiratory pressure; Pi,max), 7 days/week (once/week supervised at research center), for 8 weeks using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH2, HaB International Ltd., Southam, UK). Measurements of PImax will be performed every week and training loads will be increased continuously to maintain the actual ~50% Pimax values.
45459994|NCT03916393|Drug|PF-06651600 20 mg|PF-06651600 in four (4) different oral formulations will be administered in different periods.
45459995|NCT03916393|Other|Bitrex solution|Bitrex solution at 0.5 ppm will be included in the treatment sequence together with the four PF-06651600 formulations.
45459996|NCT03907813|Drug|Exparel|liposomal bupivacaine wound infiltration
45459997|NCT03907813|Other|Saline infiltration|saline wound infiltration
45459998|NCT03916705|Other|High Velocity Low amplitude spinal manipulation (HVLA-SM)|HVLA-SM is a commonly used spinal manipulation treatment for patients with chronic low back pain.
46095209|NCT02579200|Device|POWERbreathe®KH2 (sham group)|2 training sessions/day of 30 breaths at an inspiratory load of no more than 10% of their initial Pi,max (POWERbreathe®KH2, HaB International Ltd., Southam, UK). This training load will not be changed during the entire study period.
46008286|NCT00588458|Procedure|CT cholangiography|Cholografin 20ml will be diluted in 100 ml of normal saline and infused over 30 minute time interval. Following the infusion of the cholografin, morphine (0.04 mg/kg) will be administered to contract the sphincter of Oddi and improve bile duct distension and visualization. Thirty minutes following the administration of morphine a test scan (CT cholangiography) will be performed through the liver to determine if there is adequate biliary excretion. The test scan will consist of 10 mm thick image obtained through the mid liver. If there is evidence of biliary excretion, high-resolution images will be performed through the liver and bile ducts. The axial images will be reconstructed into maximum intensity projection models and volume rendered models that can be viewed in 3-dimension.
46008287|NCT01084005|Drug|linagliptin|patients receive linagliptin 5 mg tablets once daily
46008288|NCT01084005|Drug|placebo|patients receive placebo matching linagliptin 5 mg once daily
46095210|NCT00635375|Device|LED fiberoptic blanket phototherapy (BiliSoft blue LED fiberoptic blanket phototherapy)|35-50 mW/cm2/nm
46008289|NCT00588497|Procedure|Micro-insert hysteroscopic sterilization|Placement of micro-inserts transcervically with the aid of a hysteroscope
46008290|NCT00588497|Radiation|Plain abdominal Xray|Performed immediately after micro-inserts placement and at 3 months
46008291|NCT00588497|Procedure|Pelvic Ultrasound|Performed immediately after micro-inserts placement and at 3 months.
46008292|NCT00588497|Radiation|Hysterosalpingogram|Performed 3 months after micro-inserts placement
45836741|NCT00402714|Procedure|extracorporeal photopheresis|Extracorporeal photopheresis (ECP) is the ex vivo exposure of the leukocyte rich fraction to ultraviolet light in the presence of 8-methoxypsoralen.
46008293|NCT04568577|Other|Tape with tension|The elastic bandage will be applied with a voltage increase controlled weekly, for five weeks. Each week, 5% of tension will be added to the application. In the first week the application will be tension-free.
46008294|NCT04568577|Other|Tape without tension|Bandaging applications will be weekly, for five weeks, without tensioning the tape.
46008295|NCT00588653|Device|Capsule endoscopy, CT enterography, colonoscopy, small bowel follow-through|Each patient undergoes each of the 4 diagnostic modalities, but the readers are blinded to results of the other 3.
45836742|NCT00402714|Drug|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
46008296|NCT00588887|Device|Duracon®|This group utilizes the Duracon® prostheses for total knee replacement.
46008297|NCT00588887|Device|Vanguard™|This group will utilize the Vanguard™ prostheses for total knee replacement.
46008298|NCT01083810|Drug|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
46008299|NCT00588926|Drug|Remifentanil|After the mapping electrode is in situ, recording of baseline electrical activity is done for two-three minutes and an infusion of Remifentanil, 0.1 microgram per kilogram per minute is started. This procedure continues for a few minutes until the patient is sedated and then the infusion is stopped and the patient allowed to recover. The recordings continue during the whole procedure.
46008300|NCT01083771|Dietary Supplement|Olive Oil|Minimum of 3 tablespoon of olive oil per day
46008301|NCT00589082|Drug|DaunoXome|
46008302|NCT00589082|Drug|Daunorubicine|
46095211|NCT00635375|Device|Metal halide phototherapy (Spot PT metal halide phototherapy)|29.3-57.6 mW/cm2/nm
46095212|NCT00635375|Device|LED bank phototherapy (Natus neoBlue LED bank phototherapy)|12-35 mW/cm2/nm
46095213|NCT00635375|Device|Metal halide plus LED fiberoptic blanket phototherapy (BiliSoft and Spot PT)|29.3-57.6 mW/cm2/nm and 35-50 mW/cm2/nm
46095214|NCT04153734|Drug|Pembrolizumab|Pembrolizumab at 200 mg (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, Pembrolizumab at 200 mg (day 1) will be administered at 3-week intervals until disease progression or intolerable toxicity. Pembrolizumab administration should be continued for 2 years involving induction and maintenance therapies or until the 35th course.
46095215|NCT04153734|Drug|Cis Platinum|In patients with non-squamous histology, cisplatin (75 mg/m2) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.
46095216|NCT04153734|Drug|Carboplatin|In cisplatin-intolerable patients, carboplatin (AUC=6) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.
45836743|NCT00402714|Radiation|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
45836744|NCT00402714|Drug|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
45836745|NCT00402714|Radiation|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
45836746|NCT00405288|Drug|Proctofoam-HC®|Observational study of the exposure to Proctofoam-HC®
45836747|NCT00458406|Device|Bi-Flex|"Bi-Flex: Subjects in this arm undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.~Positive pressure used during sleep for 3 months"
45836748|NCT00458406|Device|CPAP|"CPAP: Subjects in this arm undergo standard continuous positive airway pressure (CPAP) therapy.~Positive pressure used during sleep for 3 months."
45836749|NCT00381810|Drug|Rituximab|Rituximab will be supplied as a liquid for intravenous infusion.
45836750|NCT00381810|Drug|Methylprednisolone|
45836751|NCT00381810|Drug|Acetaminophen|
46008303|NCT00589199|Procedure|Placement and use of the device|Surface electrodes currently used for peripheral muscle stimulation by other groups will be applied to the abdominal wall and over the posterior lower thoracic rib cage. Between two and three pairs (anodic and cathodic) of electrodes will be used in combination to activate the expiratory muscles. Electrodes will be positioned at various points over the abdominal wall and the posterior thoracic rib cage to ascertain optimal placement for airway pressure and expiratory airflow generation. The electrical stimulators to be used (EMPI and NeuroMedic) are powered by 9-volt batteries. These stimulators are currently in clinical use to stimulate other skeletal muscles and are known to be quite safe.
46008304|NCT00589238|Drug|carboplatin|
46095217|NCT04153734|Drug|Pemetrexed|In patients with non-squamous histology, pemetrexed (500 mg/m2) will be administered every 3 weeks until progression or 2 years after initiation (35 cycles) with pembrolizumab.
46095218|NCT04153734|Drug|nab paclitaxel|In patients with squamous histology, nab-paclitaxel (100 mg/m2, day 1, 8, 15, tri-weekly) will be administered until 4 cycles with pembrolizumab.
46008305|NCT00589238|Drug|cyclophosphamide|
46008306|NCT00589238|Drug|doxorubicin hydrochloride|
46095219|NCT02761655|Behavioral|Memory Strategies|Memory strategies on encoding retention, retrieval, execution and monitoring
46008307|NCT00589238|Drug|paclitaxel|
46095220|NCT05475769|Drug|Clinical evaluation|Patients will receive treatments under the criteria of the responsible physician and the response to these treatments will be prospectively collected.
46008308|NCT04568070|Diagnostic Test|mini-BESTest (Mini-Balance Evaluation Systems Test)|Balance evaluation test that has 14 tasks leading to a total possible score of 28 points requires only 10 to 15 minutes to conduct.
46008309|NCT04568070|Diagnostic Test|Berg Balance Scale|The scale is a 14-item objective measure designed to assess static balance and fall risk in adult populations.
46095221|NCT04073680|Drug|Serabelisib|Subjects will be dosed with Serabelisib on 3 consecutive days a week in a 28 day cycle until tumor progression. in combination with Canagliflozin 300mg, both are oral medications
46095222|NCT04073680|Drug|Canagliflozin 300mg|All subjects will be dosed with 300 mg canagliflozin in combination with serabelisib
45836752|NCT00381810|Drug|Diphenhydramine|
45836753|NCT00458952|Drug|Ultratrace Iobenguane (MIBG) I 131|Phase I: Dose escalation protocol Phase II: Treatment schedule at therapeutic dose
45836754|NCT00459732|Dietary Supplement|Zinc|25 mg of elemental zinc as zinc sulphate take once daily for 18 months
45836755|NCT00459732|Dietary Supplement|Placebo|Placebo capsule, identical to the zn capsule in size, shape and color, taken once daily for 18 months
46095223|NCT00668928|Other|Polyphenols (flavon-3-ol monomers and oligomers)|Flavanols
46095224|NCT02761577|Drug|Sodium bicarbonate|3 mL/kg/hour of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography
46095225|NCT02761577|Drug|N-acetylcysteine|N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure
46095226|NCT04154202|Other|Bone Scan|Bone Scan: three-phase planar Bone Scan and a SPECT/CT [perfusion, blood pool and SPECT/CT of the relevant region of interest (ROI), and a whole-body planar late bone scan].
46095227|NCT04006249|Diagnostic Test|dental probes|Measurement of the depth of the periodontal pockets and clinical loss
46095228|NCT02761421|Other|observation study|observation study
45836756|NCT00459810|Drug|transdermal estradiol|Transdermal estradiol given 0.2mg/day for duration of study.
45836757|NCT00459810|Drug|paclitaxel poliglumex|Paclitaxel poliglumex (PPX) is a macromolecular polymer-drug conjugate of paclitaxel. PPX was given every 28 days, at a dose of 150 mg/m2
46095229|NCT00987805|Dietary Supplement|Banhasasim-tang|Form : granules Contents : It consists of seven Herbs. It contains Rhizoma Pinelliae, Radix Scutellariae, Zingiberis Rhizoma, Panax ginseng, Glycyrrhiza uralensis Fisch, Zizyphi Fructus and Coptidis Rhizoma Dosage and frequency : 9g per day (three times a day) Route of administration : Oral Administration duration : 42 days in the study
46095230|NCT00987805|Dietary Supplement|Corn-starch granules|This placebo has the same form, color, and flavor as experimental intervention.The dosage, frequency and duration is also same as experimental intervention.
46095231|NCT00579982|Drug|Lamotrigine|Experimental formulation
46008310|NCT04568070|Diagnostic Test|Timed Up and Go Test|It is a simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.
46008311|NCT04568070|Diagnostic Test|Functional Reach Test|The Functional Reach Test is a single item test developed as a quick screen for balance problems in older adults. A score of 6 or less indicates a significant increased risk for falls. A score between 6-10 inches indicates a moderate risk for falls.
46095232|NCT05711329|Other|Accuracy|We will validate the accuracy of the method proposed by the SFAR to detect OSA patients via videoconference (in comparison with the results of the PSG).
46095233|NCT02763527|Behavioral|Smoking reduction|A brief intervention on smoking reduction plus a smoking reduction leaflet
46095234|NCT02763527|Behavioral|Smoking Cessation|A brief advice on quitting plus a leaflet on smoking cessation
46095235|NCT02630082|Procedure|Circumcision|
46095236|NCT02630082|Procedure|Flexible sigmoidoscopy|
46095237|NCT02763371|Other|Dietary: high GI lunch|High GI: High-GI rice lunch ad libitum on test day 1 and low GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
46095238|NCT02763371|Other|Dietary: low GI lunch|Low-GI: Low GI-rice lunch ad libitum on test day 1 and high GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
46095239|NCT00987961|Behavioral|Linkage|This intervention provides an outpatient appointment with a Suboxone provider for medically hospitalized opioid-dependent patients to attend post-discharge.
46095240|NCT02575612|Procedure|vacuum-assisted biopsy|Ultrasound guided VAB was used directly prior to breast conserving surgery or mastectomy. It was performed by experienced physicians (> 50 ultrasound guided minimal invasive biopsies per year, > 500 breast ultrasound examination of the breast per year). The needle was placed below or beside the target lesion according to physician's choice. At least six biopsies should be taken; up to 12 according to the physicians choice. After the VAB a clip marker was placed to highlight the position of the biopsy for specimen radiography and pathology.
46095241|NCT00596466|Drug|pregabalin|pregabalin
46095242|NCT02763293|Other|Manual Therapy|Non-manipulative treatment osteopathic techniques combined direct and indirect soft appropriate in patients with Crohn's disease
46008312|NCT00589394|Biological|pneumococcal vaccination (Pneumovax)|pneumovax was given
46008313|NCT01083576|Drug|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
46008314|NCT01083576|Drug|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
46095243|NCT02763059|Drug|Ibuprofen 600 mg|This group receives 1 hour before surgery 600 mg ibuprofen (and another 600 mg dose 6 hours after the first dose);
46008315|NCT04568265|Drug|APG-1387|Weekly intravenous infusion for 30 minutes
46008316|NCT04568265|Drug|Entecavir 0.5 mg|Taken daily by mouth
46095244|NCT02763059|Drug|Dexamethasone 4 mg|This group receives 1 hour before surgery 4 mg dexamethasone (and another 4 mg 6 hours after the first dose)
46095245|NCT02763059|Drug|Placebo|This group receives 1 hour before surgery placebo.
46095246|NCT02763059|Drug|Acetaminophen 1000 mg|A Rescue medication (1000 mg acetaminophen) was given to each patient who was instructed to take it if necessary.
46095247|NCT05708677|Biological|EB-101|This is non-interventional and follows patients treated with EB-101
45459999|NCT03475056|Biological|cAd3-Marburg vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, VRC-MARADC087-00-VP (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP).
46095248|NCT02758379|Device|Shockwave Coronary Lithoplasty System|Lithotripsy shockwaves are used to fracture calcified lesions in the coronary arteries
46095249|NCT04155372|Procedure|Different Fluid Ingestion Rate|The participants ingested sports drink in a volume equivalent to 150% of BW loss, in 30 min, 60 min, or 90min.
46008317|NCT00589589|Device|Endo Tool|Computer tool to help achieve glucose control
46008318|NCT04568343|Device|Capsule endoscopy|We use two capsule endoscopy for evaluation their diagnostic yield. Patient will recieve different capsule endoscopy:The Endocapsule (EC-10) and CapsoCam Plus (Capsovision) capsule
46008319|NCT00589706|Drug|MAb-425|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
46095250|NCT05449795|Device|Device: Contour Next and Contour Plus Elite BGMS testing of arterial blood|The purpose of the study is to extend the intended use of two BGMSs to include testing of arterial blood by Health Care Professionals (HCP) in a clinical setting.
46008320|NCT00589745|Other|Nasal potential difference measurement|Nasal potential difference measurement involves dripping small amounts of 5 test solutions into the anterior nostril. This is designed to test the ability of the cells to regulate the movement of salt and water in people with features of CF in whom the diagnosis is not entirely clear.
46008321|NCT04568304|Biological|Toripalimab Injection|Toripalimab Injection 240 mg iv infusion on Day 1 of each 3-week cycle. The cumulative duration of Toripalimab Injection is up to 2 years.
46008322|NCT04568304|Drug|Gemcitabine Hydrochloride for Injection|"Gemcitabine 1000mg/㎡ iv infusion, on Day 1 and Day 8 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles."
46008323|NCT04568304|Drug|Cisplatin for Injection / Carboplatin Injection|"Cisplatin 70mg/㎡ iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~Carboplatin AUC 4.5 iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles."
46008324|NCT04568304|Drug|Placebo|Placebo iv infusion on Day 1 of each 3-week cycle. The cumulative duration of placebo is up to 2 years.
46008325|NCT01082640|Drug|Febuxostat|Febuxostat capsules
46095251|NCT02771171|Radiation|CT Scan|CT imaging
46008326|NCT01082640|Drug|Placebo|Febuxostat placebo-matching capsules
46095252|NCT05446597|Procedure|Symptom-specific Headache Treatment|Greater Occipital Nerve Block
46095253|NCT05446597|Other|Symptom-specific Dizziness &/or Neck Pain Treatment|Cervicovestibular Physiotherapy Treatment
46095254|NCT05446597|Behavioral|Symptom-specific Sleep Disturbance Treatment|Cognitive Behavioral Therapy for Insomnia
46095255|NCT05446597|Behavioral|Generic Concussion Treatment|Lite combination of headache advice, general physiotherapy exercises, mindfulness, visualization, and relaxation
46095256|NCT02761343|Other|MRI scan|Following the clinically indicated cardiac ablation procedure, a post ablation MRI scan will be performed.
46095257|NCT00596934|Drug|metreleptin|0.1 mg/kg/day once a day via subcutaneous injections
46095258|NCT05428033|Drug|centanafadine capsule|capsule
46008327|NCT00589862|Drug|Plavix (Clopidogrel)|150 mg tablet of Plavix (Clopidogrel) per day for 12 months if resistance is identified
46008328|NCT00589901|Drug|capecitabine and cyclophosphamide|"capecitabine 1000 mg/m2 oral Bid d1-14~cyclophosphamide 65 mg/m2 oral Qd d1-14"
46008329|NCT04568187|Device|zeltiq|Zeltiq prototype device (Zeltiq Aesthetics, Pleasanton, CA) approved by FDA 2010
46008330|NCT04568187|Device|placebo|radiofrequency with 3000 Hz
46095259|NCT05428033|Other|placebo capsule|capsule
46008331|NCT00590174|Drug|Aspirin|stopping clopidogrel at 1 year after DES implantation
46095260|NCT04222517|Procedure|Incisional hernia repair by the mesh implant in sublay retromusuclar position|"Incisional hernia repair using mesh prolene implant in sublay retromuscular position. Dissect the posterior rectus sheets, suture them continuously, formed a retromuscular space in which the standard prolene mesh implant is installed. Perform hemostasis. Install the drainage tube into the retromuscular space.~After that, the anterior rectus sheets were sutured, hemostasis was performed, a drainage tube was installed in the subcutaneous tissue. Drainage tubes were connected to the UnoVac vacuum aspiration system (Unomedical, Denmark)."
46095261|NCT04222517|Procedure|Incisional hernia repair by the mesh implant in sublay retromusuclar position with using a local hemostatic Hemoblock|"Incisional hernia repair using mesh prolene implant in sublay retromuscular position. Dissect the posterior rectus sheets, suture them continuously, formed a retromuscular space in which the standard prolene mesh implant is installed. Perform hemostasis. Install the drainage tube into the retromuscular space. Used a local hemostatic Hemoblock 15 ml in this space.~After that, the anterior rectus sheets were sutured, hemostasis was performed, a drainage tube was installed in the subcutaneous tissue. Used a local hemostatic Hemoblock 15 ml in subcutaneus space. Drainage tubes were connected to the UnoVac vacuum aspiration system (Unomedical, Denmark)."
46095262|NCT02758145|Other|Flu vaccination information in 3 phases|"An oral information is given by the nurse during the recruitment visit at the occupational medicine unit. She initiates the discussion on flu and asks the employee if he usually receives the vaccine. Then she provides a brief standardized information on recommendations concerning flu vaccination, and the annual influenza vaccination campaign in CHUV and PMU. She responds to questions.~After the interview, she gives an informative document with key messages (information about the disease, benefits to be vaccinated, vaccine safety, etc.). The document includes frequently asked questions, website address, and the email address of the occupational medicine unit in case of questions.~The third phase consists of sending to the employee shortly after the start of the next campaign of flu vaccination (November 2016), a postal mail recalling the information provided during the recruitment examination and inviting them to get vaccinated."
46095263|NCT04155528|Other|Music therapy|The intervention is listening to selected prerecorded music, specific Raga, on the individual CD player.
46095264|NCT02761265|Procedure|Surgical intervention|Surgery to correct spinal deformity
46095265|NCT02761265|Other|None (Asymptomatic group)|Gait and balance testing performed, no treatment in this asymptomatic group
46095266|NCT00671112|Drug|Bortezomib|"Patients will be assigned to one of the following dose levels of Bortezomib: 0.7mg/m2, 1.0 mg/m2, or 1.3mg/m2 on days 1,4,8,11 of a 21 day cycle.~The appropriate amount of bortezomib will be drawn from the injection vial and administered as an intravenous (IV) push or sub-cutaneously over 3 to 5 seconds followed by a standard saline flush or through a running IV line."
46095267|NCT00671112|Drug|Everolimus|Everolimus 5 mg PO every other day, 5 mg by mouth (PO) daily, or 10 mg PO daily
46095268|NCT04154358|Diagnostic Test|HPV testing|will perform HPV testing with self-collected specimen
46008332|NCT00590174|Drug|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
46008333|NCT01082367|Drug|TOBI|TOBI (tobramycin inhaled solution)
46008334|NCT01082367|Drug|Placebo|Placebo
46008335|NCT00590213|Drug|Casodex 150mg|
46008336|NCT00590213|Procedure|Radiotherapy|
46008337|NCT00590213|Procedure|Haematology|
46095269|NCT02770469|Behavioral|Linguistically and Culturally Tailored Information|Participants received linguistically and culturally tailored information on diet and nutrition, physical activity, managing treatment side effects, follow-up care plans, complementary and alternative medicine, reducing environmental exposure to estrogen, navigating cancer-related financial issues, family history, body image, sexuality, and advances in breast cancer research.
46095270|NCT02770469|Behavioral|Cognitive-Behavioral Stress Management|Participants learned and practiced skills related to mindfulness, relaxation, stress reduction, rational thinking, improving coping, enhancing social support, anger management, and assertiveness training.
46008338|NCT04567797|Device|Laevo 2|The Laevo V2 is a wearable chest and back support exoskeleton. The Laevo transfers the from its chest pad to the thighs while bending forward. The passive exoskeleton (works with gas springs, not motors) transfers part of the load away from the back muscles, reducing the pressure on the spinal column. It provides a dampening effect on the back, reducing the risk of sudden back muscle contractions that needlessly overcompress the spine.
46008339|NCT04567797|Device|backX|"backX is a novel industrial exoskeleton that substantially augments its wearer and reduces the forces and torques on a wearer's lower back region (L5/S1 disc) by an average of 60% while the wearer is stooping, lifting objects, bending or reaching. backX augments the wearer's strength and can reduce the risk of back injuries among workers. It does not require external motors or power source. The mechanism of backX is similar to the first device Laevo 2."
46095271|NCT04857385|Device|Radial artery hemostasis|Each of the devices will be assessed for radial artery hemostasis.
46095272|NCT00671190|Drug|Ramelteon|Ramelteon 1 mg, tablets, orally once daily for up to 5 days
46095273|NCT00671190|Drug|Ramelteon|Ramelteon 2 mg, tablets, orally once daily for up to 5 days
46095274|NCT00671190|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally once daily for up to 5 days
46095275|NCT00671190|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally once daily for up to 5 days
46095276|NCT00671190|Drug|Placebo|Ramelteon placebo-matching tablets, orally once daily for up to 5 days
46095277|NCT02770235|Other|DE assessment|by a validated self-administered questionnaire: Index International erectile function (IIEF-15)
46008340|NCT04567797|Device|FLx ErgoSkeleton|The FLx ErgoSkeleton is a range limiting work vest for physical work use. The FLx naturally reminds the user of the correct posture and lifting techniques while on the job site.
46095278|NCT02770235|Other|AGE measurement|By AGE-ReaderTM
46095279|NCT00669474|Procedure|Suction curettage|Suction curettage
46095280|NCT00669474|Drug|Treatment with Botox|Treatment with Botox
46095281|NCT03911401|Drug|0.3% OPA-15406|Twice daily
46095282|NCT03911401|Drug|1% OPA-15406|Twice daily
46095283|NCT03911401|Drug|Placebos|Twice daily
46095284|NCT00664014|Drug|Tolvaptan|Tablet;15mg/tab;15/30/60mg/day for 7days Plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
46095285|NCT00664014|Drug|Placebo|placebo plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
46095286|NCT02770313|Behavioral|Intermittent Fasting|Subjects allocated to the fasting arm will undergo a fasting regimen of twice-per-week 24-hour fasting on non-consecutive days during the first 4 weeks of the study, then once-per-week 24-hour fasting during the rest of the study (22 weeks).
46095287|NCT00664092|Other|Residential|living in a democratic, resident-run setting
46095288|NCT00664092|Other|Residential|Professionally-run substance abuse recovery setting
46095289|NCT04825951|Other|CS 2000|treating growing Skeletal growing Class III patients
46095290|NCT02696915|Drug|Placebo|Patients received ultrasound guided fascial iliaca compartment blockade using normal saline 0.9%, 40 ml
46095291|NCT02696915|Drug|Bupivacaine|Patients received ultrasound guided fascial iliaca compartment blockade using bupivacaine 0.25%, 40 ml
46095292|NCT02696915|Device|Ultrasound guided fascia iliaca compartment block|Ultrasound guided fascia iliaca compartment block
46095293|NCT02696915|Drug|Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)|Intrathecal hyperbaric bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms
46095294|NCT00911664|Dietary Supplement|Vitamin D|Weekly dose of 5600 IU (800 IU per day)
46095295|NCT00911664|Drug|No supplementation|Control
46095296|NCT00911664|Dietary Supplement|Vitamin D|Weekly dose of 11,200 IU (1600 IU per day)
46095297|NCT04821817|Drug|Normal saline|peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 2 ml normal saline.
46095298|NCT04821817|Drug|Rocuronium|peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 0.06 mg/kg of rocuronium in 2 ml normal saline.
46095299|NCT00664170|Drug|ANX-514|75 mg/m^2
46095300|NCT00664170|Drug|docetaxel|75 mg/m^2
46095301|NCT02758067|Drug|brexpiprazole|2- 4 mg/day, tablets, oral, 28-weeks
46095302|NCT02758067|Drug|risperidone|4-6 mg/day, tablets, oral, 28-weeks
46095303|NCT02757677|Device|Optical Coherence Tomography based Angiography|A contrast-free, noninvasive technology to identify blood vessels in the eye
46095304|NCT00664248|Drug|IDP-110|Topical application for 12 weeks
46008341|NCT04567797|Device|V22 ErgoSkeleton|"Similar to the FLx ErgoSkeleton, the V22 ErgoSkeleton keeps the position of the human body as to always stay within a safe body posture while lifting or moving heavy objects. The V22 ErgoSkeleton applies pressure to remind the user both during improper lifts and over rotation.~In addition, the V22 ErgoSkeleton comes with two clutch controlled cables to assist in lifting and moving. The cables transfer part of the weight of the object being held directly to the V22 ErgoSkeleton vest, similar to other arm and shoulder support exoskeletons."
46008342|NCT01082211|Radiation|3D-Conformal External Beam|Radiation was to be delivered in 2 fractions per day, each of 1.5 Gy, separated by at least six hours, given in 15 consecutive working days to a total of 30 fractions and 45 Gy. Radiation was to be prescribed to the treatment unit isocenter, positioned at the approximate center of the planning target volume.
46008343|NCT04567758|Other|Telerehabilitation|"The home exercise program includes the following exercises:~Lumbar region and lower extremity stretching exercises;~Exercises to strengthen the abdominal muscles;~Exercises to strengthen the lumbar muscles;~Bridging, spine mobility exercise, McKenzie extension, and Williams flexion exercises~A web-based telerehabilitation platform (Fizyoweb) will be used to deliver the exercise program. Using the Fizyoweb web application, exercises will be presented to the patients in the form of audio-video and detailed instructions with explanations. The exercise program to be given will be prescribed specifically with slight changes according to the patient's condition. The exercise protocol will be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each."
46008344|NCT04567758|Other|Conventional Rehabilitation|"The home exercise program, which will be given with conventional rehabilitation, will be educated to the patient in the clinic on the first day. Exercise information form including explanation and picture of the exercises will be given to the patients. The exercise program to be given will be prescribed specifically with slight changes according to the patient's condition. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.~The home exercise program includes the following exercises:~Lumbar region and lower extremity stretching exercises;~Exercises to strengthen the abdominal muscles;~Exercises to strengthen the lumbar muscles;~Bridging, spine mobility exercise, McKenzie extension, and Williams flexion exercises"
46095305|NCT00664248|Drug|Clindamycin|Topical application for 12 weeks
46095306|NCT00664248|Drug|Benzoyl peroxide|Topical application for 12 weeks
46095307|NCT00664248|Drug|Vehicle|Topical application for 12 weeks
46095308|NCT02757755|Biological|AB-SA01 (10^8 PFU per phage)|Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
46095309|NCT02757755|Biological|AB-SA01 (10^9 PFU per phage)|Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
46095310|NCT02757755|Biological|Placebo (for Cohort 10^8)|Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
46095311|NCT02757755|Biological|Placebo (for Cohort 10^9)|Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
46095312|NCT04529239|Device|Abbott Freestyle Libre Pro|Continuous glucose monitoring device to analyze diabetes biomarkers.
46095313|NCT04221347|Other|blood sampling|blood samples will be taken in specified time points
46095314|NCT00669630|Behavioral|Lay Health Promoter (LHP) with maintenance|Lay Health Promoters (LHPs) and their congregations will join an existing social and organizational support network, comprised of LHPs and congregations who are part of an active community health improvement collaborative.
46095315|NCT04808167|Device|autoRIC®|The autoRIC device will be modified by the company from the standard cuff inflation of 200 mmHg to 180 mmHg for the purposes of this study. Three cuff sizes are available from the company: small, medium, and large, correlating to standard adult cuff sizes. The remote ischemic preconditioning cycles will be performed daily by trained research personnel during the preparative regimen through day 0 (see Figure 1), defined as transplantation of stem cells (last preconditioning cycle on day -1). A control group will undergo a similar procedure, however, the cuff will not be inflated.
46095316|NCT00579670|Drug|Ziprasidone|Ziprasidone 20mg, 40mg, 60mg, 80mg capsules, hard; Ziprasidone 10 mg/ml oral suspension Ziprasidone 20mg/ml powder and solvent for the reconstitution of solution for injection
46008345|NCT00590408|Dietary Supplement|coenzyme Q10|60mg capsule twice daily for 12 weeks
46095317|NCT04484519|Other|Functional Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging
46095318|NCT00669708|Device|cooling compound (ph5 Eucerin)|application twice daily to the skin
46008346|NCT00590408|Dietary Supplement|matching placebo|matching placebo capsule twice daily for 12 weeks
46008347|NCT04574648|Device|ActionADE|"ActionADE is a software application that allows healthcare providers to document standardized adverse drug event and non-adherence information in a user-friendly and standardized manner. We integrated ActionADE uni-directionally with PharmaNet, a secure province-wide network that links all pharmacies in British Columbia to a central data system. This allows care providers to pull in demographic information and visualize their patient's medication dispensing history.~In 2020, we enabled bi-directional integration with PharmaNet allowing clinicians to transmit standardized information back to the PharmaNet database. The three dominant community pharmacy systems in the geographic area of the trial will display non-adherence information in their systems."
46095319|NCT04005235|Device|Thorasys Tremoflo C-100 Airwave Oscillometry System (FOT)|Ultrasonography will be used to confirm hemidiaphragm dysfunction after brachial plexus nerve block. In subjects with U/S confirmed hemidiaphragm dysfunction, FOT measurements will be taken before and after nerve block and post-operatively after upper extremity surgery.
46095320|NCT04222439|Device|AI for the Diagnosis of Gastrointestinal Diseases|After receiving standard preparation regimen, patients go through colonoscopy or gastroscopy under the AI monitoring device. The whole procedure is monitored by AI associated recognition system. Gastrointestinal diseases will be detect and diagnosis in which the AI device will automatically captured relevant images and report the site of each segment on the screen. Histology analysis is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
46095321|NCT00669786|Drug|Human Menopausal Gonadotropin (HMG) & - Recombinant Follicle Stimulating Hormone (r-FSH)|
46095322|NCT04777435|Diagnostic Test|Therapeutic orientation test for TMA|Therapeutic orientation test for TMA performed on blood sample at inclusion, first visit at 1 month and last visit at 6 months.
46095323|NCT02760953|Procedure|Cryoablation|Using a novel cryoablation unit to perform transurethral cryoablation on the tumor base after transurethral resection
46095324|NCT02760953|Drug|Epirubicin|Epirubicin instillation should be give within 24 hours after initial TUR, this is accord with current guideline.
46095325|NCT00671268|Biological|AL0704rP|strict subcutaneous
46095326|NCT00671268|Biological|Placebo|strict subcutaneous
45460000|NCT03913507|Device|Macroduct® Advanced Model 3710 SYS, Wescor|for each subject, both methods will be tested in order to compare the efficacy of the new sweat collection method (Macroduct® Advanced Model 3710 SYS, Wescor) to the method currently used in clinical routine.
45460001|NCT00938912|Drug|Lacosamide|Lacosamide oral solution (syrup): Total daily dose between 2 mg/kg/day (1 mg/kg bid) to 12 mg/kg/day (6 mg/kg bid)
45460002|NCT00938912|Drug|Lacosamide|"Lacosamide tablets: Total daily dose between 100 mg (50mg bid) - 600mg (300 mg bid).~The maximum permissible dose of LCM will be 12 mg/kg/day or 600 mg/day."
46008348|NCT04567914|Diagnostic Test|Bilaterally abdominal muscle thickness with ultrasonography|AIS group was evaluated for localization of curvature and degree of curvature. Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness in the supine and standing positions in both groups. Spirometry evaluation was performed in both groups
45460003|NCT03473808|Behavioral|task-practice therapy|Standardized hand therapy program
46008349|NCT04567875|Other|No Intervention on patients|No Intervention on patients
46095327|NCT05691127|Diagnostic Test|Complete blood count (CBC), C reactive protein (CRP(., Chest x ray, ABG, Electrolytes, Random blood sugar, Creatinine|I will use these investigations in my study
46095328|NCT02760797|Drug|Emactuzumab|Emactuzumab will be administered IV every 3 weeks (every cycle) during Part I and every 3 or 6 weeks (every cycle or every other cycle) during Part II.
46095329|NCT02760797|Drug|RO7009789|RO7009789 will be administered IV every 3 weeks (every cycle).
46095330|NCT02630004|Drug|Melatonin oral gel 3%|
46095331|NCT02630004|Drug|Placebo oral gel|
46095332|NCT02760641|Other|Egg-based diet (EBD)|Participants will be asked to consume a carbohydrate-restricted diet including whole eggs for 8 weeks. Eggs will be provided.
46095333|NCT02760641|Other|Carbohydrate-based diet (CBD)|Participants will be asked to consume a low fat, carbohydrate-based diet for 8 weeks. Breakfast food items will be provided.
45460004|NCT03473808|Other|Vibration|Peripheral vibration applied to the wrist skin at an imperceptible level
45460005|NCT01148329|Device|Coronary stenting|The PROMUS™ Element™ Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. The treated lesion length should be less than the nominal stent length (8 mm, 12 mm, 16 mm, 20 mm, 24 mm, 28 mm, 32 mm, 38mm) with a reference vessel diameter of 2.25 mm - 4.0 mm.
46008350|NCT00590447|Drug|rituximab monotherapy|375 mg/m2, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between course 4 and 5 the patients directly enter R-CHOP chemotherapy (Arm B).
46008351|NCT00590447|Drug|sequential R-CHOP|"375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.~In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy."
46008352|NCT04567953|Other|Saliva collection|Use Spectrum Solutions SDNA1000 or Orasure collection kit or dry tube to collect 1-3 ml of saliva
46008353|NCT00590525|Procedure|Cardioversion|Baseline hsCRP will be drawn the morning of, prior to, cardioversion. An EKG to document the patient's rhythm will be obtained at the one-month mark
46008354|NCT01081626|Drug|Recombinant FSH (follitropin alpha)|A starting dose of 75 IU and a first adjustment on Day 14 or Day 7 of stimulation in Group I and II respectively, if no ovarian response is observed.
46008355|NCT03452423|Procedure|ACRFP|Arthroscopic cartilage regeneration facilitating procedure (ACRFP) is a set of surgical procedures that combines resection of medial plica, medial and lateral capsular release, synovectomy of focal synovitis, and chondroplasty of loosened cartilage flaps as a rationale for the deliberate arthroscopic management of osteoarthritic knee.
46008356|NCT03452384|Other|Acupuncture|For real acupuncture, disposable acupuncture needles (0.22 x 30-mm sterile stainless needles) were inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, the inserted needles were affixed with adhesive tapes so that real acupuncture procedure will be identical to control acupuncture procedure. For sham acupuncture procedure, Streitberger's noninvasive placebo acupuncture needles will be used. Its validity and credibility have been well demonstrated (Streitberger and Kleinhenz, 1998).
46008357|NCT01080768|Drug|Aliskiren/amlodipine|Aliskiren/amlodipine 150/5 mg/day
46008358|NCT01080768|Drug|Amlodipine|Amlodipine 5 mg/day.
46008359|NCT01080768|Drug|Placebo to Aliskiren/amlodipine|Placebo to Aliskiren/amlodipine 150/10 mg/day
46008360|NCT01080768|Drug|Placebo to Amlodipine|Placebo to Amlodipine 5 mg/day
46008361|NCT03452345|Drug|Meditoxin|Meditoxin (Botulinum toxin type A)
46008362|NCT03452345|Drug|Placebo|Placebo (Normal saline)
46008363|NCT03452306|Drug|Metformine|"First aIntervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fasting condition"
46008364|NCT03452306|Drug|Glucophage® Long|"Second Intervention Period:~Single administered dose of Glucophage® (750 mg tablet extended-release) in a fasting condition"
46008365|NCT03452306|Drug|Metformin|"Third Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
46008366|NCT03452306|Drug|Glucophage® Long|"Fourth Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
46008367|NCT04567641|Dietary Supplement|postoperative nutrition|Forty patients (50%) received enteral nutrition 6 hours after surgical procedures and 40 patients (50%) received parenteral nutrition 6 hours after surgical procedures.
46008368|NCT04568109|Behavioral|Cognitive-behavior therapy|The manualized protocol (Gloster et al., 2011) comprise of 12 weekly sessions of CBT focusing on therapist-guided interoceptive and in-situ exposure exercises.
46008369|NCT01080300|Drug|Gabapentin Extended Release|Gabapentin ER 1800mg daily
46008370|NCT01080300|Drug|Placebo|Sugar pill
46008371|NCT02210715|Drug|Isentress.|28 subjects will change from their normal cART treatment to Raltegravir, which will be given at the standard dose of 400 mg p.o. b.i.d. for 24 months.
46008372|NCT02210715|Other|Continue usual antiretroviral therapy|28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
46008373|NCT00590603|Drug|Arsenic Trioxide, Ascorbic Acid and Bortezomib|"Phase I/Cohort I~Loading:~Arsenic Trioxide (ATO): 0.25 mg/kg IV over 1-2 hr qd x 5 days (Monday-Friday)~Ascorbic Acid: 1000 mg by IV infusion over 15 minutes after each infusion of arsenic trioxide qd x 5 days~Maintenance cycles (21 days)~ATO: 0.25 mg/kg IV over 1-2 hr once a week x 2 weeks every 3 weeks (one cycle) for a total of 6 cycles.~Ascorbic Acid 1000mg IV will be given within 30 minutes of completion of ATO.~Bortezomib 1 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 8 of a 21-day cycle. ATO is given at least one hour prior to Bortezomib. The first cycle will start on week 2, after loading dose week.~Phase I/Cohort 1 is followed by Cohort 2. Phase II uses maximum tolerated dose from Phase I."
46095334|NCT04154280|Diagnostic Test|PET/MR scan|"The PET will be performed with 68Ga-PSMA tracer.~The 3 tesla magnet of the MRI will be used with sequence allowing MRS acquisition, additional sequences will include T2-weighted contrast and diffusion weighted contrast.~Images will be analyzed visually and quantitatively. Quantitative analysis will include MR parameters such as DWI apparent diffusion coefficient (ADC) and PET quantitative metabolic data such as standard uptake values (SUV) or Ki (in case dynamic PET protocol will be applied). In addition, content relationship between metabolic entities detected will be extracted.~Quantitative data will be correlated to clinical and pathological data to check accuracy, specificity and sensitivity."
46008374|NCT01085097|Drug|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
46008375|NCT01085097|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil (MMF) will be administered per dose and schedule specified in the arm description.
46095335|NCT00129922|Drug|paclitaxel|
46095336|NCT00129922|Drug|Fluorouracil|
46095337|NCT00129922|Drug|Epirubicin|
46008376|NCT01085097|Drug|Prednisolone/Prednisone|Prednisolone/Prednisone will be administered per dose and schedule specified in the arm description.
46008377|NCT01085097|Drug|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
46008378|NCT01085097|Drug|Methylprednisolone|Methylprednisolone (MP) will be administered per dose and schedule specified in the arm description.
46008379|NCT00590798|Behavioral|Walking|Patient will walk within 30 minutes of vascular closure system procedure
46095338|NCT00129922|Drug|Cyclophosphamide|
45460006|NCT03913351|Behavioral|Lifestyle modification|The program consists of education on glycemic index, balanced diet, interpretation of food labels, food exchanges, healthy eating out techniques and healthy cooking methods.
45678513|NCT04638595|Other|Observation|This project seeks to recruit 25 male and 25 female typically developing children between the ages of 3 and 18 years of age. Non-invasive measurements of movement patterns will be collected during common activities of daily living over a single data collection session.
46095339|NCT00664404|Other|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging (fMRI)of the Brain, one session while smoking, and one session while abstinent from smoking (not smoking).
46008380|NCT04567446|Other|Stool|collection at diagnosis, before initiating anticancer treatment, during treatment
46008381|NCT04567446|Other|Blood sample|40 mL collection before, 3 and 6 months of treatment cancer
46095340|NCT02760719|Drug|nebulized 3% hypertonic solution|already described
46095341|NCT02696213|Other|Systematic, Comprehensive, One to One Training (SCOOT)|An occupational therapist trained by the principal investigator will perform 1.5 hour SCOOT sessions with participants one to two times a week over a period of 6 weeks. SCOOT will provide instruction and practice for performing scooter skills (i.e., instruction on driving, basic and advanced scooter skills) that are embedded in self-selected activities that participants want to perform using their scooters.
46095342|NCT02696213|Other|Six Week Delay|Participants will begin the SCOOT intervention after a six week delay.
46095343|NCT03909295|Drug|LCZ696|Starting dose was either 50 mg b.i.d. or 100 mg b.i.d. largely depending on the last dose level taken by the patient at the time of completing PARAGON-HF and patient condition. The dose level was gradually up-titrated with the goal of reaching the target dose of 200 mg b.i.d. as soon as tolerated by the patient
46095344|NCT02696057|Other|manual technics|soft tissue technics, joint mobilization and muscle energy technics were applied three sessions per week, totally six week.
45836758|NCT00405522|Drug|Propofol 2.0 mg/kg + Remifentanil 1.5 ug/kg|Patients in this arm of the study will receive 2.0 mg/kg propofol + 1.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
46095345|NCT02696057|Other|Exercise|spinal stabilization exercise applied three sessions per week, totally six week.
46095346|NCT00664638|Device|Symplicty(TM) Catheter System|Renal denervation using the Symplicity Catheter System
46095347|NCT02757599|Other|Ultrasound training|Training on the transvaginal ultrasound simulator.
46095348|NCT04154124|Diagnostic Test|PET/MR scan|whole-body PET/CT scan and pelvic PET/MR scan (MR protocol will include three plane fast spin echo T2 weighted, DWI and dynamic contrast enhanced imaging). The ad interim assessment will use a pelvic PET/MR scan only (without PET/CT), to avoid the radiation associated with whole body CT. In the staging and post-nT assessment, the addition of PET/MR to the standard use of PET/CT adds no radiation exposure.
46095349|NCT01439776|Drug|Vit D|800IU/day
46095350|NCT02770157|Drug|DA-3002|
46095351|NCT02770157|Drug|Genotropin®|
46095352|NCT04153968|Dietary Supplement|β-cryptoxanthin|"Phase 1:~2.0mg of [13C14]β-cryptoxanthin, 1.0mg of [13C10]β-carotene and 0.4mg [2H6]retinyl acetate are given in sunflower oil at Time 0.~Phase 2:~1.5mg of [13C14]β-cryptoxanthin, 0.75mg of [13C10]β-carotene, 0.4mg [2H6]retinyl acetate are given in sunflower oil along with 0.25mg β-carotene and 0.5mg β-cryptoxanthin from maize are given at Time 0.~Then, 0.75mg of [13C14]β-cryptoxanthin, 1.5mg of [13C10]β-carotene, and 0.4mg [2H6]retinyl acetate are given in sunflower oil along with 0.5mg β-carotene and 0.25mg β-cryptoxanthin from maize are given on day 21."
45460007|NCT03907501|Dietary Supplement|Synbiotic|an herbal prebiotic plus probiotic
45460008|NCT03907501|Dietary Supplement|Probiotic|Triphala alone
46008382|NCT04567446|Other|Saliva|5 mL collection before initiation of treatment cancer
46008383|NCT00590837|Drug|Lomustine|"Induction: chemotherapy + lomustine (CCNU), 200 mg/m2 orally at day 1.~Consolidation: chemotherapy + lomustine (CCNU), 80 mg orally at day 1.~Reinductions: chemotherapy + lomustine (CCNU), 40 mg orally at day 1."
46008384|NCT01086267|Drug|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously
46008385|NCT01086267|Drug|BMS-908662|Capsules, Oral, (TBD) mg, Q 12 h, Continuously
46008386|NCT01086267|Drug|Cetuximab|Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously
46095353|NCT02577172|Behavioral|Exercise group|The intervention will be conducted during chemotherapy and tailored for each patient. The program will include 1) weight bearing aerobic exercises to maintain the oxygen transport and thereby reduce the decline in VO2max during chemotherapy and 2) strength training exercises to maintain muscle mass and muscle strength. The intervention will last for 9 or 12 weeks, depending on the number of BEP/EP cycles received. The program will consist of two-three one-hour exercise sessions per week, of which most supervised by a personal trainer. The intensity of each exercise sessions will varies from easy (warm-up: 60-70 % of peak heart rate) to moderate/high (between aerobic intervals 60-70% of peak heart rate and during aerobic intervals 85-95 %).
46095354|NCT02577172|Behavioral|Control group|The control group will receive one individual lifestyle counseling session during the first chemotherapy cycle and can perform all activities that they have planned to do during chemotherapy.
46095355|NCT00671424|Drug|Hydrochlorothiazide (HCTZ)|
46095356|NCT00671424|Drug|Remogliflozin etabonate (GSK189075)|
46095357|NCT00671424|Drug|Furosemide|
46008387|NCT04567563|Device|Remote Ischemic conditioning (RIC)|Intervention Group: Patients will self-administer RIC treatment with the LifeCuff device 3 times a week. Treatment will be delivered at the patient's home and compliance will be monitored by the LifeCuff device. Control Group: Patients undergo typical standard of care treatment. Assessment of Ulcer Closure: Ulcers will be assessed as completely closed by the Principal Investigator through clinical judgement and photographic support. Patients that completely heal their ulcer during the healing period will complete the study and no further blood or tissue measurements will be taken
46095358|NCT00599924|Drug|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
46095359|NCT00599924|Drug|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
46095360|NCT00599924|Drug|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 ( CRC, only Schedule 2/2)
46095361|NCT00599924|Drug|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
46008388|NCT04574687|Other|Neurodevelopmental Techniques|)Conventional treatment protocol including active and active-assissted ROM exercises. (b)Proprioceptive neuro-muscular facilitation techniques. (c)Neuromuscular Developmental Techniques.
46095362|NCT00599924|Drug|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
46095363|NCT00599924|Drug|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
45678514|NCT01942993|Drug|Vemurafenib|Vemurafenib will be administered at the FDA approved dose of 960 mg approximately 12 hours apart with or without a meal. Vemurafenib is provided at 240-mg film-coated tablets packed in bottles for oral administration. Vemurafenib should be swallowed whole with a glass of water and the medication should not be chewed or crushed. Management of symptomatic adverse events may require dose reductions, treatment interruptions, or treatment discontinuation. Dose reductions below 480 mg twice daily are not recommended.
45678515|NCT01989455|Drug|Deferiprone|"Deferiprone for infusion, 10mg/mL for intravenous infusion.~Oral dose of deferiprone: 80mg/mL oral solution. (Cohort 2)"
45678516|NCT01989455|Drug|Placebo|Placebo: normal saline solution.
45678517|NCT01942837|Drug|Enzalutamide|Enzalutamide, formerly known as MDV3100, is a rationally-designed second generation AR inhibitor which functions by blocking several steps in the AR signaling cascade. Enzalutamide competitively binds the AR with great potency. Additionally, enzalutamide inhibits nuclear translocation of activated AR and inhibits the association of activated AR with DNA.
46008389|NCT04574687|Other|Action observation Therapy|(a) active range of motion (AROM) exercises (10 min), (b) reaching movement or object manipulation (10 min), and (c) UE functional tasks (15 min). + Conventional treatment protocol as in group A
46008390|NCT02277873|Behavioral|pregnancy|Observational study in order to establish relationship between moon and births
46095364|NCT00599924|Drug|sunitinib + FOLFOX|25 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
45460009|NCT03907501|Dietary Supplement|Placebo|Inert capsule
46095365|NCT02760875|Behavioral|Early weight bearing|The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
46095366|NCT00670020|Procedure|supplemental perioperative oxygen|increased perioperative oxygen verses non-interventional oxygen
46008391|NCT00590915|Drug|Erwinia L-asparaginase|"Substitute Erwinia L-asparaginase 25,000 international units per meters squared, IM every other day (including weekends and holidays) x 6 doses for each dose of PEG-asparaginase that is replaced.~NOTE: Erwinia L-asparaginase dosing to replace native E.coli L-asparaginase varies; consult protocol for specifics."
46095367|NCT02757833|Other|A 3 Tesla MRI scanner (Siemens, Erlangen Germany), will be used to measure levels of GSH in the brain.|Using the MEGA-PRESS pulse sequence, high resolution T1-weighted sagittal anatomic images covering the brain using an inversion-prepared MP-RAGE pulse sequence to produce high grey/white matter contrast will be acquired. These will be used to localize the spectroscopy voxel in the vmPFC. Magnetic field homogeneity will be optimized in the voxel using an automated map shimming procedure. MEGA-PRESS spectra will be acquired to detect the glutathione cysteinyl ß-CH2 peak at 2.95 ppm with the editing pulse set at the j-coupled a-CH resonance at 4.95 ppm. A reference unsuppressed water spectrum will be acquired for absolute quantification. Metabolite spectra will be fitted in the time domain using a Levenberg-Marquardt least squares minimization routine. The contribution of each metabolite to the in-vivo spectrum can be scaled to the water signal intensity from within the voxel of interest to obtain an absolute measurement of metabolite concentration.
46095368|NCT00670098|Procedure|Bariatric surgery|patients receive either gastric bypass or lap-band
46008392|NCT04574570|Device|High Tibial Osteotomy|Personalised High Tibial Osteotomy (HTO) using a patient-specific fixation plate (TOKA®)
46008393|NCT04571892|Biological|Super circulating tumor infiltrating lymphocytes(ScTIL)|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and superamplification factor. The obtained ScTIL is used for one-time intravenous infusion."
46008394|NCT00590993|Other|MRI and MRSI|Compare treatment impact when using MRI and MRSI
46008395|NCT04567290|Drug|Chewed ticagrelor|Chewed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
46008396|NCT04567290|Drug|Swallowed ticagrelor|Swallowed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
46008397|NCT04567329|Drug|NOV03|100% perfluorohexyloctane
46095369|NCT00670098|Behavioral|lifestyle intervention (behavioral weight loss)|participants attend biweekly weight loss counseling group sessions
46008398|NCT04567329|Drug|Saline Solution|0.6% sodium chloride solution
46008399|NCT00591071|Other|Strict glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
46008400|NCT00591071|Other|Conventional glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
46008401|NCT01084161|Drug|N1539|5 mg IV once per day
45836759|NCT00405522|Drug|Propofol 4.0 mg/kg + Remifentanil 0.5 ug/kg|Patients in this arm of the study will receive 4.0 mg/kg propofol + 0.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
46095370|NCT02769923|Device|Westpharma ID adapter|device used for administering intradermal injection
46008402|NCT01084161|Drug|N1539|7.5 mg IV once per day
46008403|NCT01084161|Drug|N1539|15 mg IV once per day
46008404|NCT01084161|Drug|N1539|30 mg IV once per day
46008405|NCT01084161|Drug|placebo|IV placebo once per day
46008406|NCT01084161|Drug|Morphine|morphine 10-15 mg IV once per day
46008407|NCT01084161|Drug|N1539|60 mg IV once per day
46008408|NCT00591110|Behavioral|Eye care education|Participants will receive an educational intervention communicating practical information about vision, eye conditions and eye care pertinent to the older African American population
46008409|NCT00591110|Behavioral|Social-contact control|Participants receive an engaging informational session on a non-health related topic
46008410|NCT01083615|Drug|custirsen sodium|An antisense oligonucleotide that blocks production of clusterin
46008411|NCT01083615|Drug|isotonic, 0.9% sodium chloride|Placebo for custirsen sodium
46008412|NCT01083615|Drug|docetaxel|
46008413|NCT01083615|Drug|cabazitaxel|
46008414|NCT01083615|Drug|prednisone|
46008415|NCT00591188|Drug|capecitabine, interferon-alpha|Patients who meet inclusion/exclusion criteria will receive combination of study drugs.
46008416|NCT00591383|Drug|indibulin|indibulin, dose escalation, 200 mg - 600 mg. Taken twice every day.
46008417|NCT00591383|Drug|erlotinib|erlotinib taken at 150 mg every morning with food.
46008418|NCT01081782|Drug|ONO-4641|0.15 mg once per day for 26 weeks
45460010|NCT01251211|Drug|botulinum toxin type A|BTX A : 5 units/0.2 ml, maximum 300 units will be injected subcutaneous in the painful area ; this will be performed after randomization and within a minimum of 3 months interval depending on the duration of efficacy (maximum 6 months) Saline will be injected in the same volume in the painful area within the same frequency
45460011|NCT03473340|Drug|Pirfenidone Capsule|"Dosing:~Days 1 through 7, 267 mg three times daily; Days 8 through 14, 534 mg three times daily; Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks"
45460012|NCT03473340|Drug|Placebo Capsule|"Dosing:~Days 1 through 7, 267 mg three times daily;~Days 8 through 14, 534 mg three times daily;~Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks"
45460013|NCT03907267|Drug|Taurine Solution|Taurine Solution
45836760|NCT00381966|Device|robotic placement device|this device is a robotic arm that utilizes a template as a guidance system to precisely inplant radioactive brachytherapy seeds directly to the prostate.
46008419|NCT01081782|Drug|ONO-4641|0.1 mg once per day for 26 weeks
46008420|NCT01081782|Drug|ONO-4641|0.05 mg once per day for 26 weeks
46008421|NCT01081782|Drug|ONO-4641 placebo|Placebo once per day for 26 weeks
46008422|NCT00591422|Drug|ZIO-101-C (Darinaparsin)|Capsule, Dose escalation study from 100 mg to 1000 mg (or Maximum Tolerated Dose). 3 times weekly (>36 hours between doses) for 3 weeks with 1 week rest.
46008423|NCT04567212|Genetic|genetic evaluation|A sampe of blood (3 mL) and of oral mucosa will be take and analyzed using nCounter GX Human Inflammation Kit a comprehensive number of 8SNPs in 3 human genes known to be differentially expressed in allergic asthma.
46008424|NCT04567212|Other|MicroRNA evaluation|Using the sampe of blood (3 mL) using RT-PCR we will evaluate the expression of microRNA in enrolled patients
46008425|NCT01080222|Drug|telaprevir|tablet, 1125-mg, twice daily
46008426|NCT01080222|Drug|VX-222|capsule, 100-mg, twice daily
46008427|NCT01080222|Drug|ribavirin|tablet, 1000-mg for subjects weighing <75-kg or 1200-mg for subjects weighing ≥75-kg, twice daily
46008428|NCT01080222|Biological|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
46008429|NCT01080222|Drug|VX-222|capsule, 400-mg, twice daily
46008430|NCT03452267|Drug|Metformin|oral, 850 mg twice daily
46008431|NCT03452267|Drug|Pioglitazone|oral, 45 mg daily
46008432|NCT03452267|Drug|Placebo|oral, once daily
46008433|NCT03451994|Other|Breath test|Breath samples taken from all participants, analyzed with gas chromatography mass spectrometry (GC/MS), no treatment given.
46008434|NCT01088802|Radiation|IMRT|Dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks)
46008435|NCT01088802|Drug|Cisplatin|Cisplatin will be administered weekly for the first 3 weeks and the last 3 weeks of radiation. Patients will not receive chemotherapy during week 4 of treatment.
46008436|NCT01088802|Drug|Carboplatin|Carboplatin will be administered weekly during the 7 weeks of radiation. Carboplatin may be given as a substitution for cisplatin when cisplatin-related toxicities occur or when patients present with greater than grade 2 sensory or motor neuropathy, greater than 2 hearing loss, or less than 60 ml/min creatinine clearance.
46008437|NCT03451877|Genetic|TGFB1 AND LAMA1 GENE POLYMORPHISMS|we evaluated polymorphisms in the LAMA1 (rs2089760) and TGFB1 (rs4803455) genes in children younger than 13 years of age with ≥6 D myopia in an attempt to further elucidate the genetic basis of high myopia.
46008438|NCT04999683|Dietary Supplement|ITIS diet|anti-inflammatory diet for 14 days
46008439|NCT03451838|Diagnostic Test|Ultrasound|Ultrasound will be done to every pregnant lady
46008440|NCT03451838|Diagnostic Test|HbA1c level in blood|a blood sample will be taken to measure HbA1c level
46008441|NCT03451682|Dietary Supplement|procyanidine|Natural antioxidant
46008442|NCT04566822|Behavioral|High Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
45460014|NCT03907267|Dietary Supplement|Normal Saline|Normal Saline
45678518|NCT01987895|Drug|Cadazolid|Cadazolid 250 mg as oral suspension twice daily.
45678519|NCT01987895|Drug|Vancomycin|Vancomycin 125 mg as oral capsules 4 times daily.
46008443|NCT04566822|Behavioral|Medium Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
46008444|NCT04566822|Behavioral|Low Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
46008445|NCT04566822|Behavioral|Sleep Education Control|Participants in the sleep education control will not have access to a coach. Weekly sleep education will be accessible to the participant on a weekly basis. The sleep education content will be the same that is provided to the intervention participants.
46008446|NCT03451643|Procedure|ENDOSCOPIC PLACEMENT OF EXPANDABLE STENT|PLACEMENT OF AN ENDOSCOPIC SELF EXPANDABLE METAL STENT
46008447|NCT03451604|Other|preoperative assessement|All data concerning study, involved in normal care of patient for his anesthesia (non interventional study), where included in anonymous computerized database by anesthesiologist during pre operative clinic.
46095371|NCT02769923|Device|Star ID syringe|device used for administering intradermal injection
46008448|NCT04566744|Other|fRMI|The measurements performed will be the participant's brain activity, as well as behavioral measurements associated with the tasks performed (response time, correctness of the response). Brain activity measurements will be performed on the Siemens 3T system of the MRI department of CERMEP. The subject will perform the task under study while the level of brain activity is recorded. The functional examination will be subdivided into several parts according to its total length in order to spare the subject. The total duration of MRI acquisitions will be approximately 1 hour regardless of the axis.
46008449|NCT04574453|Device|Iracross|Administration of max 2ml of Iracross at first visit
46095372|NCT02769923|Device|BCG NS|syringe used for administering intradermal injection
46095373|NCT04004689|Other|2 times : 6-minute stepper test with a rest of 20min between each test.|"Patients will perform two 6-minute stepper tests separated by a rest period of at least 20 minutes. The second test will begin when the heart rate and the transcutaneous oxygen saturation values will be returned to baseline values. Standardization of the instructions for the test will be based on the actual guidelines for the 6-minute walk test.~The test will be performed in an isolated room in order to avoid noise or external stimuli which can affect performance. The stepper will be placed near a door and the patient was allowed to put a hand on it if out of balance or exhausted. The height of the step will be fixed to 20 cm. A step was defined as the rise and lowering of one foot. The patient was informed of the time each minute. No other encouragement was given. Heart rate and transcutaneous oxygen saturation will be continuously recorded by a pulse oximetry."
46095374|NCT00670176|Behavioral|REHAB (Pre- and postoperative cardiopulmonary rehabilitation)|
46095375|NCT02757209|Device|Spiromax (budesonide/formoterol)|"DuoResp Spiromax 160 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate), either one inhalation twice a day (morning and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup"
46095376|NCT02757209|Device|Turbohaler (budesonide/formoterol)|Turbohaler® (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate)- Symbicort® 160/4.5. Dose of one inhalation twice a day (mornig and evening) or two inhalations twice a day (morning and evening), for 1 week. Additional 8 weeks in one subgroup
46095377|NCT02757209|Device|Diskus(50mcg salmeterol &250/500 mcg fluticasone propionate)|Diskus® inhaler(50mcg salmeterol&250/500mcg fluticasone propionate)-Seretide Diskus 50/250mcg® or 50/500mcg.Dose of 1inhalation twice a day for1 week.Additional 8 weeks in1subgroup
46095378|NCT04004923|Procedure|Monopolar hysteroscopy|Unipolar resectoscopes are used in this group and the distention fluid is mannitol
46095379|NCT04004923|Procedure|Bipolar hysteroscopy|Bipolar resectoscopes are used in this group and the distention fluid is serum physiologic
46095380|NCT00670254|Drug|Placebo|Application is identical to experimental arm
46095381|NCT00670254|Drug|Hydrocortisone|50 mg loading dose, continuous infusion of 200 mg/d for 5 d, 100 mg/d for 2d, 50 mg/d for 2 d, and 25 mg/d for 2 d.
46095382|NCT00581542|Drug|moxifloxacin|1-2 drops three times a day for 8-10 days.
46095383|NCT00581542|Drug|polytrim|1-2 drops four times a day for 8-10 days.
46095384|NCT05338801|Other|Menthol-flavored e-cigarette|All participants will complete a lab visit where they will use menthol-flavored e-cigarette ad libitum for up to 60 minutes.
46095385|NCT05338801|Other|Tobacco-flavored e-cigarette|All participants will complete a lab visit where they will use tobacco-flavored e-cigarette ad libitum for up to 60 minutes.
46095386|NCT02757287|Drug|FSH-CTP + DESOGESTREL|"Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH and the day after the bolus ( estradiol, FSH, Progesterone, LH)~- Quality of Life questionnaire the day after the bolus"
46095387|NCT02649686|Drug|Durvalumab|
46095388|NCT02649686|Drug|Trastuzumab|
46095389|NCT04615390|Behavioral|Early rehabilitation|The intervention is primarily focused on the recovery of mobility and functional autonomy. The treatment sessions are dependent on the patient's exercise tolerance.
46095390|NCT04615390|Behavioral|Subacute rehabilitation|Comprehensive intensive rehabilitation in the hospital
45460015|NCT01147705|Drug|Allopurinol|Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks
45460016|NCT01147705|Drug|Placebo|Same appearance/dosing as active drug.
45460017|NCT03915847|Procedure|Single layer closure|Uterine incision will be approximated with continuous unlocked suture, including a narrow band of the endometrial layer, without trimming incision edges.
46095391|NCT04615390|Behavioral|Mindfulness training|The home mindfulness training consists of 2 parts: 1) explanation and reflection of the Mindfulness practice 2) formal and informal practice.
45460018|NCT03915847|Procedure|Double layer closure|The first layer suture penetrated the whole thickness of the uterine wall, including a narrow band of the endometrial layer. Second layer sture is acontinous sture performed in a lateral-to lateral position , imbricating first layer.
46095392|NCT04615390|Behavioral|Personalized ambulatory training|Low-intensity walking exercises at home
46095393|NCT02757365|Drug|aspirin|
46095394|NCT02757365|Drug|Levofloxacin|
46095395|NCT04808674|Behavioral|Cognitive remediation program|Evaluation of REmediation programs for patients suffering from mild cognitive deficits after Cancer
46095396|NCT02631018|Behavioral|Standard Weight Loss Intervention|18 session, group-based, 6-month, standard behavioral weight loss intervention
46095397|NCT02631018|Behavioral|Physical Activity Enhanced Weight Loss Intervention|18 session, group-based, 6-month, physical activity enhanced behavioral weight loss intervention
46008450|NCT04574453|Device|Iraline|Administration of maximum 2 ml of Iraline at visit 1 to visit 3, 4 and 5 depending of suject's need
46008451|NCT04566471|Other|prevalence/incidence|It is an observational study for prevalence/incidence, no intervention provided.
46095398|NCT02769767|Genetic|Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.|The frequencies of the polymorphic variants in subjects with MS and healthy subjects were evaluated. Also in subjects with MS, the response to treatment with the number of relapses and EDSS was assessed; to compare the allele frequencies of SNPs of Interleukins, Glypican, and Human Leukocyte Antigen Genes, between responders and no responders MS patients.
46095399|NCT02575690|Dietary Supplement|Spirulina|Individuals receive 2 g of spirulina daily, for 3 months.
46095400|NCT02575690|Other|Placebo|Individuals receive a placebo daily, for 3 months.
46095401|NCT02649530|Drug|WNT974|
46095402|NCT02575456|Biological|Ebola Vaccine|
46095403|NCT02575456|Biological|Placebo|control
46095404|NCT04005157|Procedure|MWA|Patients diagnosed with early-stage NSCLC and signing the informed consent will undergo MWA with the guidance of ENB.
46095405|NCT04005157|Device|ENB|ENB (LungCare Medical Technologies Ltd., Inc, Suzhou, China)will be used to guide bronchoscope into the accurate location of the lesion during MWA.
46095406|NCT00664794|Procedure|without acromioplasty|This group will not have their acromion shaved - instead they will receive a repair of their rotator cuff with the scope using sutures or suture anchors.
46095407|NCT00664794|Procedure|with acromioplasty|This group will have Their rotator cuff repaired with sutures or suture anchors and additionally will have the tip of their acromion bone shaved slightly.
46095408|NCT02760563|Drug|BAY 987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application (Formulation number V26-160)
45678520|NCT01987895|Drug|Cadazolid-matching placebo|Placebo matching cadazolid and administered orally twice daily
46095409|NCT02649296|Other|Skanlab bodywave|The intervention will be done twice a week
46095410|NCT02575534|Drug|Procainamide|the procainamide will be infused at 12mcg/kg up to a max of 1 gram at a rate of 20mg/min which will take up to 1 hour to infuse
45836761|NCT00461292|Biological|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U injection at Day 1 followed by botulinum toxin Type A 200 U injection > Week 12; injections into detrusor
46095411|NCT02696681|Behavioral|Cognitive Behavioral Therapy|Integrating CBT for mental health and substance issues concern with CBT for health behavior change
46095412|NCT00664872|Other|proactive psychosocial intervention by care managers|A case manager will be assigned to each of the participants in the intervention group. All case managers are psychologists. After discharge from the emergency department, the participants receive six sessions of proactive psychosocial intervention by their case manager over four months. Duration of each session is approximately 30 minutes. The intervention consists of telephone or face-to-face contacts with the case manager at scheduled intervals or when clinically necessary. If a patient declines medication therapy from the psychiatrist, case manager will provide psychotherapy using the model of cognitive-behavioural approach and problem-solving therapy. Case managers will receive backup and supervision by psychiatrist investigators and monthly supervision of therapy. Case managers will regularly monitor suicide risk, clinical status and provide follow-up.
46095413|NCT00664872|Behavioral|case management|
45678521|NCT01987895|Drug|Vancomycin-matching placebo|Placebo capsules matching vancomycin and administered orally 4 times per day
45678522|NCT02005445|Device|CPAP|Continuous positive airway pressure
45678523|NCT02005445|Behavioral|HLSE|Healthy living and sleep education
45836762|NCT00461292|Biological|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U injection on Day 1 followed by botulinum toxin Type A 300 U injection > Week 12; injections into detrusor
45836763|NCT00461292|Other|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 followed by botulinum toxin Type A 200 U injection > 12 weeks; injections into detrusor
46095414|NCT02649374|Behavioral|Dietary, Exercise and lifestyle modifications|Women without GDM will receive advise on diet, exercise and lifestyle modifications similar to what is advised to women with GDM
45678524|NCT01618669|Drug|Regadenoson|Administered as an intravenous (IV) bolus
45678525|NCT01618669|Procedure|Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)|
45678526|NCT01390948|Drug|Bevacizumab|10 milligrams per kilogram every 2 weeks during the study for up to 12 cycles, each cycle length of 28 days
45678527|NCT01390948|Radiation|Radiotherapy|Total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation phase.
45678528|NCT01390948|Drug|Temozolomide (TMZ)|75 milligrams per square meter (mg/m^2) daily continuous starting concomitantly with the first radiation fraction and ending with the last radiation fraction for a maximum number of treatment days = 49 days. During the TMZ adjuvant treatment phase and for participants from YPC: TMZ (150 to 200 mg/m^2/day) x 12 cycles, 1st cycle 150 mg/m^2/days 1-5, escalated to 200 mg/m^2 on Days 1-5 from Cycle 2 onwards depending on the tolerance during the 1st cycle. Cycle length = 28 days.
45678529|NCT02005211|Drug|AZD3293|Oral solution
46095415|NCT02757443|Drug|Phosphocreatine sodium tetrahydrate after anaesthesia induction|after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV)
46095416|NCT02757443|Drug|5% Glucose after anaesthesia induction|after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
46008452|NCT03451526|Procedure|Surgeries|Surgeries plus adjuvant chemotherapies or perioperative chemotherapies
45460019|NCT03915847|Procedure|Doble layer closure with trimming|Uterine incision will be trimmed and old scar tissue will be removed. The first layer suture penetrated the whole thickness of the uterine wall, including a narrow band of the endometrial layer. Second layer sture is acontinous sture performed in a lateral-to lateral position , imbricating first layer.
46095417|NCT02757443|Drug|Phosphocreatine sodium tetrahydrate added to cardioplegia|together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L)
46095418|NCT02757443|Drug|5% Glucose|together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany)
46008453|NCT04996602|Drug|2.0 GBq of 177Lu-EB-PSMA|Patients were intravenous administrated with the dose about 2.0 GBq (55 mCi) of 177Lu-EB-PSMA every 8 weeks (±1 week) for a maximum of 3 cycles.
46008454|NCT04997694|Procedure|Pre Heating|Before anesthesia was given, the participants were warmed for 20 minutes with prewarming techniques. Presence of postoperative hypothermia, vital signs and temperature comfort level were evaluated.
46095419|NCT02757443|Drug|Phosphocreatine sodium tetrahydrate after heart recovery|immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV
46095420|NCT02757443|Drug|5% Glucose after heart recovery|immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
46095421|NCT02757443|Drug|Phosphocreatine sodium tetrahydrate after ICU admission|immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV
46095422|NCT02757443|Drug|5% Glucose after ICU admission|immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes
46095423|NCT04646473|Behavioral|SweetGoals app|App offers goal setting and feedback
46095424|NCT04646473|Behavioral|Coaching|Web health coaching
46008455|NCT04574414|Diagnostic Test|Psychological testing and MRI imaging|"Every child will have three sessions with psychologists and be diagnosed as having or not having ADHD.~Every child will be invited to Krakow to undergo MRI measurements, including resting-state and event-related functional MRI, Diffusion Tensor Imaging (DTI), and T1/T2 structural MRI."
45460020|NCT05625451|Device|Elastic Tension Digital Neoprene Orthosis|The treatment consisted of an exercise program in conjunction with the use of an extension elastic tension digital neoprene orthosis to generate two different daily total end range time doses. Group A patients used a dose of twenty to twenty-two hours of daily total end range time while group B patients used the extension elastic tension digital neoprene orthosis to achieve a daily total end range time between eleven and thirteen hours for a mean of twenty hours a day. The exercise program was the same for both groups.
45678530|NCT02005211|Drug|Placebo|Oral solution
45678531|NCT03842722|Device|Protoporphyrin IX - Triplet State Lifetime Technique|Protoporphyrin IX - Triplet State Lifetime Technique is a way to measure mitochondrial oxygen tension in a non-invasive way at bedside.
45678532|NCT01429792|Drug|peginterferon alfa-2a [Pegasys]|standard treatment, subcutaneously weekly
45678533|NCT01429792|Drug|ribavirin [Copegus]|standard treatment, orally daily
46095425|NCT04646473|Behavioral|Incentives|Financial incentives for meeting goals
46095426|NCT00671580|Drug|PZ-601|750 mg
46095427|NCT00671580|Drug|PZ-601|1000 mg
45678534|NCT04034446|Biological|CD19-CD22 CAR-T cells|0.5 to 3.0 x 106 autologous CD19-CD22 CAR-T cells per kg body weight, with a maximum dose of 4 x 108 autologous CD19-CD22 CAR-T cells via intravenous infusion.
45678535|NCT01409434|Drug|Oral Glucose Tolerance Test|Administration of 75 gram oral glucose load and three plasma glucose measurements (including baseline).
46095428|NCT00671580|Drug|Standard of Care|as directed
46095429|NCT00649766|Behavioral|tailored newsletter|Tailored newsletter that addresses each person's stage of change, barriers to getting eye exams, and knowledge of eye exams and eye disease
46095430|NCT00649766|Behavioral|targeted newsletter|Targeted newsletter that contains messages about barriers to getting eye exams and presents facts about glaucoma and African-Americans.
46095431|NCT04071262|Drug|Abemaciclib|Administered orally
46095432|NCT04071262|Drug|Abiraterone Acetate|Administered orally
46095433|NCT04071262|Drug|Prednisolone|Administered orally
46095434|NCT05659225|Device|Electronic Stethoscope|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the control group and the electronic stethoscope group and complete their future onsite visits (V2-V5) at Shanghai Children's Medical Center. The patient's caregiver who was assigned to the electronic stethoscope group will be instructed to install the electronic stethoscope developed by our team and its accessories, then they will be trained by investigators on how to use the electronic stethoscope.
46008456|NCT04566549|Combination Product|Test group Probiotic Shampoo|Probiotic Shampoo
46008457|NCT04566549|Combination Product|Placebo group|Shampoo base
46008458|NCT04566705|Other|Risks factors, maternal and neonatal outcomes/complications|Risks factors, maternal and neonatal outcomes/complications
46095435|NCT05659225|Other|Standard treatment according to GINA(2019)|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the control group and the electronic stethoscope group and complete their future onsite visits (V2-V5) at Shanghai Children's Medical Center. The patient's caregiver who was assigned to the control group will receieve standard treatment according to GINA(2019).
46095436|NCT04224779|Biological|Biological collection|The biological collection will include samples of blood samples collected at different times but also tumoral biopsy before the surgery.
46095437|NCT02657174|Device|low level laser in auricular acupuncture points|40 third molars surgeries will be performed in a conventional manner. At the end of surgery, low level laser will be applied at auricular points for prevention of inflammation and pain in the immediate post-operative period (baseline).The operator will mark the points that will be irradiated on the outer atrium of the patient with red gel pen to avoid interference with red laser (λ = 660 nm). The low level laser points will be irradiated in the same operated side.
46095438|NCT02657174|Device|low level laser device off in auricular acupuncture points|40 surgeries will be performed in the conventional manner, identically to the G1. The patient will receive low level laser with a protection of lead in the laser nozzle, in order to block the passage of light, in the same auricular points used in G1.
46095439|NCT04154982|Drug|Acetyl cysteine|1200 mg of NAC are intravenously administrated 1 hour prior to carrying out CAP.
46095440|NCT02757131|Other|Ambulation|"Patients randomized to the intervention group will be asked to participate in the ambulation protocol outlined by the PT staff 3 times daily under the supervision of the dedicated ambulator PCNA. This protocol will involve four exercise levels (mobilization, standing, walking, stairs) that may be implemented depending on the current physical capacity of the patient. The cohort of patients randomized to ambulator protocol will also receive the usual care by primary nursing.~In an effort to best characterize mobility in these patients, the team will collect Braden Scale Activity data from the electronic health record, and provide each patient a mobility tracking device to directly record daily steps taken while the patient is in the hospital. Daily step counts will be collected on a weekly basis from each device. The Braden Scale is entered by nursing on each patient at least daily and measures current activity level on a 4-point scale."
46095441|NCT02656862|Other|No intervention|
46008459|NCT04566588|Procedure|EAR HoLEP|early apical release holmium enucleation of the prostate (EAR HoLEP), as a surgical treatment for benign prostatic hyperplasia
46095442|NCT00664950|Device|sliding hip screw|surgical repair of hip fracture using conventional sliding hip screw
46095443|NCT00664950|Device|IntertAn IM nail|interTAN IM nail
46008460|NCT04566588|Procedure|Classic HoLEP|classic holmium enucleation of the prostate as a surgical treatment for benign prostatic hyperplasia
45678536|NCT01940887|Drug|E10030|
46008461|NCT04566315|Procedure|Arteriography knee arteriography|arteriography and an injection of inert microparticles of 75 μm in neovessels
46008462|NCT04992858|Drug|CT053PTSA|CT053PTSA will be administered orally once a day
46008463|NCT04997382|Drug|Alectinib|Alectinib Cap 600 mg po bid
46008464|NCT02210754|Other|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
46008465|NCT02210754|Other|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle)|electronic cigarettes
46008466|NCT02210754|Other|blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
46008467|NCT02210754|Other|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)|electronic cigarettes
46008468|NCT02210754|Other|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)|electronic cigarettes
46095444|NCT02656784|Behavioral|Cognitive Therapy|Trial-Based Cognitive Therapy (TBCT) is a three-level, three-phase, case formulation approach. TBCT's foundation is in cognitive therapy (CT); however, it has a unique approach to conceptualization and techniques that make it a distinct intervention in modifying patients' core beliefs, especially those about the self. All the individuals will be submitted to MRI.
46095445|NCT02656784|Behavioral|Behavioral Therapy|The Behavioral therapy employs the technique of Exposure and Response Prevention ( ERP ).The technique involves directly exposing patients to recall stimulation of obsessive thoughts and prevent them from performing the compulsive rituals. All the individuals will be submitted to MRI.
46008469|NCT02210754|Other|Marlboro Cigarette|cigarettes
46095446|NCT02769377|Device|Breeze2 glucometer|Breeze2 glucometer for self-monitoring of blood glucose
46095447|NCT02769377|Device|Breeze2 glucometer and H2|Breeze2 glucometer and Health2Sync Mobile App for data transfer
46008470|NCT04996758|Drug|Toripalimab and Anlotinib|Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14.
46008471|NCT02210793|Procedure|transepithelial PRK|
46008472|NCT02210793|Procedure|LASIK|
46095448|NCT04154748|Device|Argon Plasma Coagulation 90W power|
46095449|NCT04154748|Device|Argon Plasma Coagulation 60W power|
46095450|NCT04154748|Drug|Omeprazole 120 mg|
46095451|NCT04154748|Drug|Omeprazole 40 mg|
46095452|NCT02657096|Procedure|Hybenx treatment (device)|In the maxillary quadrant assigned to SRP + hybenx treatment, hybenx was applied, after SRP, on the gingiva with a 30-second incubation period and then thoroughly rinsed away through abundant irrigation with a sterile saline solution.
46095453|NCT02657096|Procedure|Scaling and Root Planing (SRP)|The contra-lateral quadrants were treated as conventional Scaling and Root Planing (SRP) alone.
46095454|NCT03140371|Dietary Supplement|High energy high protein peptide feed study|"Each patient will receive the high energy, high protein peptide-based feed for a period of up to 4 weeks (28 days). The feed will be available as an enteral tube feed in a 500ml bottle, and as a Vanilla flavoured oral nutritional supplement in a 200ml plastic bottle. The appropriate feed presentation (tube feed or oral nutritional supplement) and prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management, based on the patient's clinical requirement and preference, and the Dietitian's clinical judgement.~The study feed is classed as a 'Dietary Food for Special Medical Purposes' (EC Directive 1999/21/EC, 1999) ."
46095455|NCT02756975|Device|coaxial prostate biopsy|In this method, a larger introducing needle is needed for the puncture. The introducing needle is placed over the perineum. The biopsy needle is inserted throughout the introducing needle.Then, the direction of the biopsy is changed by tilting the coaxial needle. The investigator needs to puncture the prostate capsule only once for sampling at each each side of the prostate (right and left sides).
46008473|NCT03451214|Other|Diet Zinc|4 mg zinc from zinc biofortified wheat, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period
46008474|NCT04996056|Drug|TNX-1300|TNX 1300 200 mg Intravenous injection
46008475|NCT04996056|Other|Usual Care|Usual Care per the Emergency Department protocol for Cocaine Intoxication
46008476|NCT04992078|Device|NAVIO/CORI Surgical System|Unicompartmental knee replacement with robotic assistance
46008477|NCT04992078|Procedure|Non-robotic conventional instrumentation|Unicompartmental knee replacement with non-robotic conventional instrumentation
46008478|NCT04998279|Drug|Granulocyte Colony-Stimulating Factor|Granulocyte-colony stimulating factors (G-CSF) is synthesized in the reproductive tract naturally, it is a hematopoietic lineage-specific cytokine which is known for its specific effects on the activation of intracellular signaling pathways that are associated with the cell proliferation, differentiation, and stimulation of hematopoietic cells of the neutrophilic granulocyte lineage; which act on macrophages of decidual cells and finally affect implantation
46008479|NCT04998279|Other|placebo|mock test without injection of G-CSF
46008480|NCT02210871|Drug|semaglutide|All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.
46008481|NCT04574141|Dietary Supplement|a prolonged release tablet and a spray containing melatonin|prolonged release tablet is dosed at 1.9mg and spray is dosed at 1mg for 2 oral sprays.
46008482|NCT04999605|Drug|AK112 low dose|AK112 injection low dose+ olaparib (Lynparza®) PARP inhibitor
46008483|NCT04999605|Drug|AK112 medium dose|AK112 injection medium dose+ olaparib (Lynparza®) PARP inhibitor
46008484|NCT04999605|Drug|AK112 high dose|AK112 injection high dose+ olaparib (Lynparza®) PARP inhibitor
45460021|NCT03906955|Behavioral|Efficacy for Lifestyle PA|The intervention group is asked to participate in three (10-minute) video chats during the first three weeks of six weeks of engaging in lifestyle physical activity. Participants in this group will receive information that addresses outcome expectations in week one (e.g. physical, social, and self-evaluative outcomes and intrinsic and extrinsic motives), self-efficacy in week two (e.g. the four efficacy sources: vicarious experiences, mastery experiences, social persuasion, and perceptions of physiological and affective responses to behavior), and self-regulatory strategies in week three (e.g. goal-setting, self-monitoring, and planning) for engaging in lifestyle physical activity.
46008485|NCT04573907|Drug|Drug Levothyroxine 100 mcg|Administration of a 600 mcg levothyroxine dose
46008486|NCT04573907|Drug|Drug Eutirox 100 mcg|Administration of a 600 mcg levothyroxine dose
46008487|NCT02277912|Device|navigated rTMS of motor cortex|Navigated repetitive transcranial magnetic stimulation of the motor cortex ( 10 Hz ) ,5 daily sessions per week for two weeks.
45460022|NCT03906955|Behavioral|Efficacy for Work-life Balance|The time-matched control group is asked to participate in three (10-minute) video chats during the first three weeks of six weeks of engaging in lifestyle physical activity. Participants in this group will receive information that addresses outcome expectations in week one (e.g. physical, social, and self-evaluative outcomes and intrinsic and extrinsic motives), self-efficacy in week two (e.g. the four efficacy sources: vicarious experiences, mastery experiences, social persuasion, and perceptions of physiological and affective responses to behavior), and self-regulatory strategies in week three (e.g. goal-setting, self-monitoring, and planning) for work-life balance.
46095456|NCT02756975|Device|noncoaxial prostate biopsy|"In this method, there is no introducing needle. Biopsy needle is inserted repeatedly for each tissue sampling (at least fourteen times). A smaller biopsy needle is used for the puncture in this method.~The main disadvantage of the coaxial technique is that a larger introducing needle is needed for the puncture (12). On the other whand, the advantage of noncoaxial method is that the needle is within the prostate for only a few seconds to document needle position with ultrasonography before firing"
45678537|NCT01940887|Drug|bevacizumab or aflibercept|Patients are randomized to receive either bevacizumab or aflibercept
45678538|NCT01940887|Drug|E10030 sham injection|Pressure on the eye with a syringe with no needle
46008488|NCT02277912|Device|navigated rTMS of somatosensory cortex 2|Navigated repetitive transcranial magnetic stimulation of the secondary somatosensory cortex ( 10 Hz ), 5 daily sessions per week for two weeks
46008489|NCT02277912|Device|SHAM rTMS with SHAM block|Repetitive SHAM transcranial magnetic stimulation of the motor cortex ( 10Hz) 5 daily sessions per week for two weeks.
46008490|NCT04573985|Behavioral|Serious game Eurekoi intervention|1 session in group using the serious game eurekoi
46008491|NCT02277951|Device|The Bonfils Intubation Fibrescope|Effectiveness and time to successful intubation will be measured.
46008492|NCT02277951|Device|The Video Rigid Flexing Laryngoscope|Effectiveness and time to successful intubation will be measured.
46008493|NCT02277951|Device|The C-MAC® S Video Laryngoscope|Effectiveness and time to successful intubation will be measured.
46095457|NCT02657018|Device|MOBIGAME|Mobile phone based game-like software application and platform (MOBIGAME) that includes individualized and structured exercise regimens (endurance, strength, balance and flexibility) that are based on the user's individual fitness evaluation (through established fitness tests) and incorporated into the story line of a gardening simulation game.
46095458|NCT02657018|Other|Control|One-time standard lifestyle counseling including the promotion of baseline activities of daily life as well as a structured exercise plan including strength and endurance exercises with moderately increasing intensity and duration that is to be implemented autonomously.
46095459|NCT04155138|Device|Naida Hearing Aid|hearing aid
46008494|NCT02277951|Device|The Macintosh Laryngoscope|Effectiveness and time to successful intubation will be measured.
46008495|NCT04573712|Other|Follow up and Assessment|each patient should wear an actigraph during a week and will be do some tests during 2hours (6min walk, apathy inventory, fatigue severity scale etc...)
46008496|NCT04573790|Procedure|eFONA|Surgical Tracheotomy
46008497|NCT02278068|Device|Metabolic Neuromodulation System (MNS)|Prospective, First-in-Human (FIH), multi-center, non-randomized trial to evaluate the initial safety and performance of hepatic sympathetic denervation to aid in glycemic control.
46008498|NCT04573595|Device|Blood Pressure Measurement|The purpose of this study is to provide supporting documentation for Noninvasive blood pressure measurement accuracy claims for Fresenius 5008S BPM Module and Cuffs on the intended population(s). The same arm sequential method with dual observer auscultation will be used to collect data.
46008499|NCT04566627|Behavioral|"Yo Sé Lo Que Quiero programl"|"Yo Sé Lo Que Quiero program is the cultural adaptation of the Unplugged program. This is a preventive intervention to reduce tobacco, alcohol, and marihuana use among adolescents. It consists of 12 sessions, delivered by a trained facilitator on a weekly basis."
46095460|NCT04155138|Device|Naida Contralateral Routing of Sound Device|This is a device that routes sound to the non-cochlear implanted ear.
46095461|NCT04559945|Device|Aveir VR Leadless Pacemaker System|Patients will undergo an attempted leadless pacemaker implant
46095462|NCT04489927|Device|Tcore|Temperature Measurement of standard care versus the Tcore measurement
45460023|NCT01147081|Biological|BEGRIVAC|126 healthy subjects enrolled to receive, in open-label manner, one dose of Begrivax (influenza vaccine)
45460024|NCT05623969|Diagnostic Test|Holter ,Echo , Speckle tracking echocardiography|A 24-h ambulatory Holter Echocardiography Speckle tracking echocardiography (STE)
45678539|NCT01925612|Drug|brentuximab vedotin|1.2 mg/kg by IV infusion every 3 weeks for up to 6 cycles
45678540|NCT01925612|Drug|brentuximab vedotin|1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles
45678541|NCT01925612|Drug|rituximab|375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
45678542|NCT01925612|Drug|vincristine|1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
45678543|NCT01925612|Drug|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
45678544|NCT01925612|Drug|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
46008500|NCT04573361|Other|Chiropractic care (one visit)|One visit to the chiropractor based on the use of spinal manipulative therapy, mobilization and other forms of manual therapy, exercise therapy, patient education, advice and reassurance
46008501|NCT04573361|Other|Chiropractic care (more than one visit)|More than one visit to the chiropractor based on the use of spinal manipulative therapy, mobilization and other forms of manual therapy, exercise therapy, patient education, advice and reassurance
46008502|NCT04566354|Other|Repeated 30-s sprint exercise|Analyze of Interleukin-6 concentration before and after repeated 30-s sprint exercise
46095463|NCT02536742|Drug|Palbociclib|125 mg, orally, daily for 3 weeks followed by 1 week off; repeated at every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
46008503|NCT04573400|Other|HADS|"The HADS is a 14-item self-report questionnaire assessing levels of anxiety (seven items) and depression (seven items) over the past week. Each question is assessed on a 4-point Likert Scale: I feel tense or 'wound up' (0= not at all 3= most of the time). Consistent with recommendations by Bjelland et al cut-off of 8 for each HADS subscale will be used to differentiate normal from mild to severe distress."
46095464|NCT02536742|Drug|Fulvestrant|500mg, intramuscularly on days 1 and 15 of cycle 1, then on day 1 (+/- 3 days) of every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
46095465|NCT00665106|Drug|"NOVA63035 Corticosteroid"|Single injection in the study eye
46095466|NCT04569487|Procedure|Biopsy|Muscle biopsy from vastus lateralis (100-200 mg from non-dominant leg)
46008504|NCT04998981|Drug|K-877 0.1 mg tablet|K-877 0.1 mg tablet x 2 twice daily
46008505|NCT04998981|Drug|Fenofibrate 200 mg capsule|Fenofibrate 200 mg capsule once daily
46008506|NCT04998981|Drug|Placebo tablet|Placebo tablet x 2 twice daily
46095467|NCT00670410|Procedure|Related donor transplant|Patients with a related donor will get reduced intensity transplant conditioning with busulfan and fludarabine.
46095468|NCT00670410|Procedure|Cord blood transplant|Patients with a matched cord blood donor will get reduced intensity conditioning with busulfan, fludarabine, and ATG.
46095469|NCT00670410|Drug|Busulfan|Busulfan (Busulfex) [4mg/kg/dose for patients < 4 years; 3.2 mg/kg/dose for patients > 4 years] will be given IV in 0.9% sodium chloride or D5W to a final concentration > 0.5 mg/mL solution for infusion equal to 10 times the volume of diluent to Busulfex, through a central venous access device over 3 hours once daily.
46095470|NCT00670410|Drug|Thymoglobulin|Patients with an umbilical cord blood donor will also receive Thymoglobulin (ATG-rabbit) during the preparative regimen.
46095471|NCT00670410|Drug|Fludarabine|Fludarabine 30 mg/m2 x 5 days, total dose = 150 mg/m2. Patients < 12 kg will receive Fludarabine 1 mg/kg x 5 days, total dose = 5 mg/kg. Fludarabine will be given IV in 100 ml (or to a concentration of 1 mg/mL) of D5W or 0.9% sodium chloride, and infused over 30 min on Days -6 to 2.
46095472|NCT02756663|Drug|panobinostat (capsules)|Panobinostat capsules, oral: 10mg, 15mg, 20mg dosing 3x a week, 1 week on / 1 week off, in a 4 week cycle (28 days). Treatment arm A: only capsules of 10mg will be used Treatment arm B: capsules of 10mg and 15mg are foreseen for dose reduction only.
46095473|NCT02756663|Drug|carfilzomib (infusion)|Carfilzomib infusion; 20 mg/m2 i.v. on C1D1 and C1D2; 56 mg/m2 i.v. on subsequent dosing days (2x a week; 3 weeks on/1 weeks off ); 4 week cycle (28 days)
46008507|NCT04998981|Drug|Placebo capsule|Placebo capsule once daily
46008508|NCT04998981|Drug|K-877 0.1 mg tablet|K-877 0.1 mg tablet twice daily
46095474|NCT02756663|Drug|dexamethasone (tablets)|Dexamethasone tablets p.o. 20 mg on days of carfilzomib infusion (2x week) and on D22 and D23 of each 4 week cycle (28 days)
45836764|NCT00461292|Other|Normal saline (Placebo); botulinum toxin Type A (300U)|Placebo injection on Day 1 followed by botulinum toxin Type A 300 U injection > Week 12; injections into detrusor
45836765|NCT00382590|Drug|5-Azacytidine|75 mg/m^2 daily for 7 days (days 1-7) via subcutaneous injection.
45460025|NCT03490032|Drug|[68Ga]-PSMA-R2|radio-labelled PSMA ligand
46008509|NCT04998981|Drug|Placebo tablet|Placebo tablet twice daily
46008510|NCT04573127|Other|descriptive study|Retrospective analysis of existing data collected as a part of the regular follow-up
46008511|NCT04566120|Drug|cinnamon extract mouthwash|cinnamon extract mouthwash
46008512|NCT04566120|Drug|chlorohexidine based mouthwash|chlorohexidine based mouthwash
46008513|NCT04573088|Behavioral|ACCEPTANCE-BASED INTERVENTION|24 hours prior to surgery the patients undergo acceptance-based intervention, incorporating questions about their subjective perception about the surgery, the domains of their lives that have been affected, and on their own expectations from surgery and its effects on their lives. They will be asked to express their fears and worries about their condition and they will be discussed about the likelihood of experiencing postoperative pain.
46008514|NCT04566198|Other|Questionnaire|The participants will have to filled out a questionnaire about their working conditions and their lifestyle habits.
46095475|NCT04244461|Behavioral|Personalized Normative Feedback|The personalized normative feedback (PNF) focuses on behavioral norms, where participants see (1) how their perceptions compare to other same-gender veterans' actual drinking and (2) how their actual drinking compares to other same-gender veterans' actual drinking. The format of the intervention highlights typical days per week, drinks per occasion, and binge drinking as per traditional PNF interventions. PNF will also contain a video description of theories of normative influence (e.g., how individuals are affected by perceptions) and a description of the normative data sample. Participants also see enhanced PNF content that will focus on sharing with participants treatment information that the investigators obtained from a pilot sample.
46095476|NCT02654678|Drug|Enalapril Orodispersible Minitablet|Weight-dependent long-term treatment scheme with enalapril ODMTs of 0.25 and/or 1 mg strength
46095477|NCT05288023|Drug|Azithromycin for Oral Suspension|"Azithromycin will be administered as a single dose in oral suspension form for children (up to the maximum adult dose of 1g).~Dosage will be calculated by age for children aged 1-5 months. For children 6-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program."
46008515|NCT04573049|Drug|Levosimendan|On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min levosimendan is given for 24 hours.
46008516|NCT04573049|Other|Placebo|On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min 5% glucose infusion is given for 24 hours.
46008517|NCT04572932|Drug|lactobacillus delbruekii|Comarsion between probiotics and one of the most widely used symptomatc treatment for IBS itopride hcl
46008518|NCT04572698|Drug|LY09004|LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
46008519|NCT04572698|Drug|Eylea|EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
46008520|NCT04994652|Device|Videolaryngoscopy|Indirect laryngoscopy using the C-MAC videolaryngoscope
45678545|NCT01925612|Drug|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
45678546|NCT02093663|Drug|MMX Mesalamine/Mesalazine (Low Dose)|Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (>) 23 kg to <= 35 kg; 1800 mg/day for participants weighing > 35 kg to <= 50 kg; 2400 mg/day for participants weighing > 50 kg to <= 90 kg.
45678547|NCT02093663|Drug|MMX Mesalamine/Mesalazine (High Dose)|Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to <= 23 kg; 2400 mg/day for participants weighing > 23 kg to <= 35 kg; 3600 mg/day for participants weighing > 35 kg to <= 50 kg; 4800 mg/day for participants weighing > 50 kg to <= 90 kg.
45678548|NCT01408888|Biological|LY2189265|Administered subcutaneously
45836766|NCT00382590|Drug|Ara-C|20 mg twice daily via subcutaneous injection for 10 days.
46008521|NCT04994652|Device|Direct laryngoscopy|Direct laryngoscopy with a standard laryngoscope
46008522|NCT02210910|Device|InSpace™ system over repair|
46008523|NCT02210910|Procedure|Best Repair of torn Rotator Cuff|
46008524|NCT04993404|Drug|Jaktinib Hydrochloride Tablets|A single oral dose of 100 mg Jaktinib Hydrochloride Tablets will be administered.
46095478|NCT04392401|Biological|Collection of blood samples in order to create a biocollection|Blood samples will be collected at admission in intensive care, at Day 3, Day 7, Day 12 and Day 20 during their hospitalization. Clinical data from routine care will be collected. Vital status will be assessed at Day 28 and Day 90.
45460026|NCT03915457|Other|Dry immersion Control Group|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
45678549|NCT01408888|Drug|Sitagliptin|Administered orally
45678550|NCT01918033|Drug|Desloratadine 5 mg|Desloratadine 5 mg tablets
45678551|NCT01918033|Drug|Placebo|Matching placebo to desloratadine 5 mg tablets
45678552|NCT01408732|Drug|Sclerotherapy|3% Sodium tetradecyl sulfate (STS) is mixed with air at a ratio of 4 parts air to 1 part STS for injection into the affected vessels in the nose. Topical anesthetic is applied to the nasal mucosa prior to injections. Once the mixture is ready for injection, the needle is placed into the vessel, in a submucosal fashion, penetrating 1-2 mm, and very small quantities of foam are injected The amount of foam injected into each lesion varies between 0.1 cc to 0.25 cc. Individual injection amounts vary between lesions, patients and treatment sessions. No more than a total of 3 ml of solution is used in each session. During each session, several lesions can be treated, but the total amount of STS used does not exceed 3 cc.
45836767|NCT00382590|Drug|Valproic Acid (VPA)|50 mg/m^2 orally daily days 1-7.
45836768|NCT00382824|Dietary Supplement|Coenzyme Q10|active drug
45836769|NCT00382824|Other|Placebo|Placebo
45836770|NCT00462072|Drug|Infliximab|Subjects will be on a stable dose of methotrexate 12.5 to 20 mg per week and will be started on infliximab 5 mg/kg.
46008525|NCT04572542|Drug|Camrelizumab|Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg
46008526|NCT04572542|Drug|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday
46008527|NCT04572542|Drug|nab-paclitaxel|nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2
46008528|NCT04565964|Other|change the health behaviors to clean indoor environment|Sheets and all covers should be wash weekly. Clean indoor environment with a vacuum cleaner twice a week
46008529|NCT04572386|Other|light cure 3m single bond universal bond|light -cure universal bond
46008530|NCT04572386|Other|Self-cure universal bond (Palfique, Tokuyama, Japan)|Self-cure universal bond with no light cure
46008531|NCT04991103|Drug|DaraVRD|"All patients with newly diagnosed multiple myeloma who was enrolled on the study will receive six cycles of combination quadruplet therapy (DaraVRD).~Six 28-day induction cycles of oral lenalidomide (25 mg daily on days 1-21), subcutaneous bortezomib (1.3 mg/m2 on days 1, 8, 15, 22), subcutaneous daratumumab (1800 mg on days 1, 8, 15, 22 of cycles 1-2 and days 1, 15 for cycles 3-6), and oral dexamethasone (40 mg on days 1, 8, 15, and 22)."
46095479|NCT04153656|Other|Reading and studying Spiritual Flow|The Wellbeing Inventory will be administered to subjects and they will be compensated upon completion of the survey. Two months after the first survey, the Wellbeing Inventory will be administered to subjects and they will be compensated upon completion of the survey.
46095480|NCT05253872|Other|The MelaCare intervention|"The primary principles applied will be:~Meta-cognitive strategies and normalization of emotions~Self efficacy related to SSE and knowledge on when to seek a doctor for clinical examination~The intervention will include 4 components:~An educational booklet~Doctor consultation to ensure correct SSE skills and compliance to the protocol~3-5 sessions with a experienced and specially trained melanoma nurse~Use of patients' answers from the Patient Reported Outcome 'Functional Assessment of Cancer Treatment - Melanoma' (FACT-M) at the nurse sessions to address current emotional and/or physical sequelae."
46095481|NCT03750175|Other|Plasma circulating DNA analysis|Clinical utility of ctDNA analysis for treatment decision
46095482|NCT02756741|Drug|ALBUMIN|Albumin in two different doses
46008532|NCT04572464|Other|Mindfulness Based Guided Meditation|Mindfulness Based Guided Meditation will be practiced by nurses under the supervision of researcher for 15 min thrice a week for two weeks
46095483|NCT02654522|Drug|Hylenex|1-3 hours post injection, the 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
46095484|NCT00670566|Drug|irbesartan/hydrochlorothiazide|50/12.5mg for 4 weeks follow 300/12.5mg for 4 weeks and proceed to 300/25mg for 4 weeks
46095485|NCT04595903|Device|Hemopurifier|Hemopurifier treatments will be one four to six hour treatment session daily for up to 4 days
46095486|NCT02654366|Behavioral|Risk Reduction Group|"The Risk Reduction and Treatment Readiness skills component includes six modules: 1) BNEP services and substance abuse treatment; 2) nature of chemical dependence (severity/chronicity and medical aspects); 3) infectious diseases (HIV and Hepatitis C virus (HCV) information); 4) injection drug use risk reduction (effective equipment cleaning and drug-splitting techniques); 5) sex risk reduction (reducing high-risk behaviors and effective condom use); and 6) overdose prevention.~The Community Outreach skills component is devoted to discussing the benefits of recovery-focused social support, and directing BNEP registrants and their CSPs to participate in activities together (as determined in the group session) at least 1 time per week to work toward expanding the scope of drug-free social support."
46008533|NCT04572620|Drug|Rituximab|375 mg/m2 as 4 weekly consecutive i.v. infusions with subsequent infusions of 375 mg/m2 performed every 3 months for 12 months.
46008534|NCT04572620|Drug|Abatacept|10 mg/kg i.v. every 2 weeks twice, then every 4 weeks for 12 months.
46008535|NCT04565808|Procedure|primary percutaneous coronary intervention|Primary Percutaneous Coronary Intervention (PPCI), also known as angioplasty or coronary angioplasty, is a procedure used to diagnose and treat the narrowed coronary arteries of the heart.
46008536|NCT03451097|Radiation|echocardiography|cardiac ultrasound
46095487|NCT02629848|Drug|Motesanib|Motesanib (AMG 706) 5 x 25 mg tablets
46095488|NCT02629848|Drug|Placebo|Motesanib placebo-matching tablets
46095489|NCT02629848|Drug|Paclitaxel|Paclitaxel IV
46095490|NCT02629848|Drug|Carboplatin|Carboplatin IV
46095491|NCT02760173|Other|perception of vertical after static roll-tilt over 5min|subjects will indicate perceived direction of vertical after 5min of static whole-body roll-tilt.
46008537|NCT04994691|Other|No Message|No messages are sent
46008538|NCT04994691|Other|Standard message|2 MyChart reminders that child is overdue for well child check visit
46008539|NCT04994691|Other|Tailored message|2 MyChart reminders that child is overdue for well child check visit with date of last WCC and age
46008540|NCT03451019|Drug|Sevelamer Hydrochloride|Single oral doses of lanthanum (1000 mg) or Sevelamer (2400 mg) were administered in random order 15 minutes after 5 g calcium carbonate with standardized meal
46008541|NCT03451019|Drug|Lanthanum Carbonate|Single oral doses of lanthanum (1000 mg)
46095492|NCT02656628|Device|Dynamic Locking Screw 3.7mm and 5.0mm|Treatment with DLS and locked plate constructs (small or large fragments)
46095493|NCT02629926|Other|GH Replacement (NutropinAq®)|GH Replacement continued.
46095494|NCT02629926|Other|No additional treatment|GH Replacement not continued.
46095495|NCT02769455|Other|Reference intakes|"FOP nutrition label which is already in use on a portion of food products in France: the 'Reference Intakes' (RIs). The RIs are a chain of rectangles presenting the contribution of a portion of the product to a reference balanced diet of an average person (2000kcal) for each of the following nutrients: energy, lipids, saturated fat, sugars and sodium.~The presentation of the products will always include the label affixed on it. Moreover, the product pages will include two pictures of the product: one with only the package (including the RI as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant. These elements ensure higher visibility, awareness and understanding of the label."
46095496|NCT02769455|Other|5-CNL|"The 5-CNL was developed as a colour-coded summary system nutrition label, following the elements pointed out in reviews.~The format includes five categories, ranging from green (Associated with the A grade) for foods of the highest nutritional quality to red (associated with the E grade), for products with lower nutritional quality. The format is presented in the form of a continuous chain of rectangles, each with its own letter/colour, the one corresponding to the product being enlarged.~The presentation of the products will always include the label affixed on it. Two pictures of the product will be included: one with only the package (including the 5-CNL as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant."
46095497|NCT03912337|Drug|Placebo|Placebo once every 4 weeks. SC injection.
46095498|NCT03912337|Drug|Erenumab|Erenumab once every 4 weeks. SC injection.
46095499|NCT00650156|Biological|adalimumab|40 mg single sc dose
46095500|NCT00650156|Biological|adalimumab|80 mg single sc dose
46095501|NCT04153266|Other|No intervention is planned for this study|No intervention was/is planned for this study. The study is questionnaire-based (observational).
46095502|NCT02576782|Drug|Perineural Dexamethasone and bupivacaine|
46095503|NCT02576782|Drug|Systemic Dexamethasone plus perineural bupivacaine|
46008542|NCT03450902|Combination Product|Chinese herb & acupuncture|Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
46095504|NCT02576782|Drug|intravenous saline plus perineural bupivacaine|
46095505|NCT02756585|Radiation|ct perfusion|computed tomography perfusion of the head
46095506|NCT04169360|Drug|ANS-6637|White, oblong 300 mg tablet
46095507|NCT04169360|Drug|Placebo oral tablet|White, oblong 300 mg tablet
46095508|NCT02629770|Drug|usual antibiotic treatment|pharmacological studies in patients treated with usual antibiotics, for different types of joint and bone infections
46095509|NCT04559243|Diagnostic Test|Transthoracic Echocardiography|After the surgey, the tests data will be collected during 8 visits when the subjects go back to the hospital.
46095510|NCT01372228|Biological|hematopoietic stem cell infusion|Enriched hematopoetic stem cell infusion
46095511|NCT02656940|Dietary Supplement|Group 1 - diet rich in n-3 and n-6 PUFA|In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
46095512|NCT02656940|Dietary Supplement|Group 2 - diet rich in MUFA|In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
46095513|NCT02656940|Dietary Supplement|Group 3 - Placebo group|Placebo group was instructed to keep their eating habits and consuming placebo for 60 days.
45678553|NCT01408732|Other|Standard Treatment|Normal standard of care followed by Drug interevention
45678554|NCT04033978|Behavioral|Cognitive remediation|10 sessions dealing with emotion recognition, jumping to conclusion, attributional style.program lasts 10 weeks
46008543|NCT03450902|Combination Product|Chinese herb & sham acupuncture|Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
46008544|NCT03450902|Combination Product|Placebo & acupuncture|Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
46008545|NCT03450902|Other|Placebo & sham acupuncture|Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
46008546|NCT04565652|Device|Device Wearers|The intervention arm will wear the LOIS ICD Smartband during routine ICD defibrillation following elective ICD implant.
46095514|NCT00665184|Behavioral|Resistance Exercise via Negative Eccentric Work|High intensity resistance training delivered 2-3 times per week for 12 weeks
46095515|NCT00665184|Behavioral|Standard care exercise training|Evidence based exercise training (resistance training, aerobic training, flexibility training) 2-3 times per week for 12 weeks.
46095516|NCT02577094|Drug|90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG|2 injections of 90Y-DOTA- hLL2 IgG- hLL2 IgG at day -21 and day -14. (The 2 drugs are mixted in the same infusion)
46095517|NCT02577094|Drug|Busulfan|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
46095518|NCT02577094|Biological|allogeneic stem cell transplantation.|At Day 0
46095519|NCT02577094|Drug|Fludarabine|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
46095520|NCT02577094|Biological|Thymoglobulines|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
46095521|NCT02760251|Drug|romiplostim|
46095522|NCT00665262|Drug|tramacet|2 tablets every 6 hours for 5 days
46095523|NCT00649844|Drug|Clozapine|Clozapine 25 or 100 mg tablets. Patients were initially titrated over the first 10 days to 300 mg/day and remained at this dose for 1 week. Thereafter, the dose could be varied between 250 and 600 mg/day based on response and tolerability for a total treatment duration of 18 weeks
46095524|NCT00649844|Drug|Ziprasidone|Ziprasidone 40, 60, or 80 mg capsules. Patients were initially titrated over the first 3 days to 80 mg/day, which could subsequently be increased to between 80 and 160 mg/day based on response and tolerability for a total treatment duration of 18 weeks
46095525|NCT03914560|Other|Burn injury|minor burn injury
46095526|NCT02769299|Radiation|Radiation Therapy|less than 1 Gy with protons to 4-8 Gy with photons
46095527|NCT02629614|Device|Cala ONE Device|The Cala ONE device is a wrist-worn stimulator which applies transcutaneous electrical stimulation non-invasively to the median and radial nerves of an individual through disposable hydrogel electrodes.
46095528|NCT03912259|Drug|Dupilumab|"Pharmaceutical form: solution,~Route of administration: SC"
46095529|NCT03912259|Drug|Placebo|"Pharmaceutical form: solution,~Route of administration: SC"
46095530|NCT03912259|Drug|Emollient (moisturizer)|"Pharmaceutical form: cream,~Route of administration: topical use"
46095531|NCT04222127|Other|EUS guided injection of gastric varices by CYA|EUS-guided injection of CYA will be done at entrance of of the varix or the perforator veins when identifiable using a mixture (1:1) of 2-octyl-cyanoacrylate & lipidol using 19G EUS-FNA needle
46095532|NCT04222127|Other|Direct endoscopic injection of gastric varices by CYA|Direct endoscopic injection of gastric varix by CYA
45678555|NCT04033978|Behavioral|psychosocial rehabilitation|10 sessions dealing psychosocial rehabilitation, neuropsychological evaluation, stigmatization, recovery process and severe mental disorders in general.
46095533|NCT02656472|Drug|Tranexamic acid|"TXA Loading dose: 31 mg/kg diluted to 2 ml/kg NS (in syringe)~31 x _______kg = _______ mg TXA (max: 930mg)~2 x _______ kg = _______ ml NS (max: 60 ml)~TXA infusion: 14 mg/kg hour = 1 ml/kg/hour (6 hour bag) (Max rate of infusion = 30ml/hr)~14 x ______ kg = _____mg x 6 = ______ mg TXA (max: 2,520mg)~1 x ______ kg = _______ml x 6 = ______ ml NS (max: 180ml)~TXA second bolus in 1 ml/kg NS~< 16 kg: TXA 45 mg in 1 ml/kg NS = _______ml NS~16-30 kg: TXA 90 mg in 1 ml/kg NS = _______ml NS~> 30 kg: TXA 120 mg 1 ml/kg NS = _______ml NS (max 30ml)"
46095534|NCT02656472|Drug|Epsilon Aminocaproic Acid|"Aminocaproic acid Loading dose: 75 mg/kg diluted to 2 ml/kg NS~75 x _______kg = _______ mg EACA (max: 2,250mg)~2x _______ kg = _______ ml NS (max 60ml)~Aminocaproic acid infusion: 75 mg/kg hour = 1 ml/kg/hour (6 hour bag)~75 x ______ kg = _____mg x 6 = ______ mg EACA (max: 13,500 mg)~1 x ______ kg = _______ml x 6 = ______ ml NS (max: 180ml)~Aminocaproic acid second bolus: 75 mg/kg in 1ml/kg NS~75 x _______kg = _______ mg EACA (max: 2,250mg)~1 x _______ kg = _______ ml NS (max 30 ml)"
46095535|NCT00665340|Drug|Placebo|Matching placebo
46095536|NCT00665340|Drug|Levitra (Vardenafil, BAY38-9456)|5m, 10 mg and 20 mg 1 h prior to sexual intercourse
46008547|NCT03450863|Drug|Fast-acting insulin aspart|Patients will be treated with commercially available fast-acting insulin aspart as bolus insulin (multiple daily injection [MDI]) or as insulin used in the insulin pumps (continuous subcutaneous insulin infusion [CSII]). Dosing of fast-acting insulin aspart is individual and determined by the treating physician in accordance with the needs of the patient.
45460027|NCT03915457|Other|Thigh cuffs intervention|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water. During the 5 days of dry immersion, the subjects will wear the thigh cuffs daily for 10 hours during the day (8 am to 6 pm). Thigh cuffs are strips of fabric with inserts of elastic fabric. Different sizes exist to adapt to different thighs. Each cuff has five tightening positions (from 1 to 5) and they will be tightened at the upper third of the thighs to create an occlusion pressure of about 30 mmHg.
45460028|NCT03912493|Device|Game Based Virtual Reality Exercises|A game-based virtual reality device named USE-IT will be added to the rehabilitation program. USE-IT is a technological rehabilitation system designed by the Department of Physiotherapy and Rehabilitation at Hacettepe University. It is a smart gaming device which has been used in patients who suffer from movement loss in their upper extremities due to various neurological and orthopedic reasons.
46008548|NCT02211027|Biological|Semi-allogenic human fibroblast (MRC-5) transfected with DNA|"Each vaccination consists of up to 1 x 10e7 (not less than 7 x 10e6) DNA-transfected irradiated fibroblasts. Each vaccination will be administered intradermally using a 1 mL syringe and a 25 gauge needle.The first immunization will be administered at least 12 weeks after surgery or completion of adjuvant chemotherapy and/or radiotherapy.Three additional vaccines will be administered once a week for a total of four vaccines.~Patients will have vaccinations administered at 4 different sites as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh. Approximately equal numbers of transfected fibroblasts will be administered at each site."
46008549|NCT03450824|Other|No intervention|The standardized standing whole-lower-extremity radiographs, the knee lateral view and skyline view of the participants will be taken.
46008550|NCT02211066|Drug|Clopidogrel|
46008551|NCT02211066|Drug|Ticagrelor|
46008552|NCT03450785|Other|ultrasound examination|Doppler ultrasound examinations from the thyroid cartilage level to the supraclavicular region were used after CVC placement and on each of the following days until the catheter was removed.
45460029|NCT03912493|Other|Conventional Physiotherapy and Rehabilitation|The conventional physiotherapy and rehabilitation program includes the application of Transcutaneous Electrical Nerve Stimulation (TENS), cold pack, therapeutic ultrasound, Codman Exercises, Wand exercises, shoulder wheel exercises, finger ladder exercises, strengthening exercises with elastic band and capsule stretching.
46095537|NCT00651092|Procedure|bilateral nasal inferior turbinectomy|the operation is performed endonasally under general or local anesthesia, the inferior turbinates are resected and removed
46095538|NCT00651092|Procedure|endoscopic submucosal resection of the inferior turbinates|surgery of the inferior turbinates- endonasally with endoscopic instruments and by performing submucosal resection of the nasal turbinates
46095539|NCT02756273|Device|bridge device|
46095540|NCT02756273|Device|no bridge device|
46095541|NCT02576704|Device|semi conductor gamma camera|we use a new mathematic technique from entropy analysis to provide precise, objective, automated quantification of perfusion heterogeneity at stress with camera SPECT. This method may be a non-invasive imaging to assess coronary microvascular dysfunction.
46095542|NCT00665418|Drug|sevoflurane|sevoflurane 2.5% versus 4.7% (inhaled concentration) 10min each
46095543|NCT02769143|Other|Whole-Body Vibration|Will be performed six months of WBV exercises
46008553|NCT04572113|Device|Cervical collar|Data will be recorded while patients are not wearing or wearing one of two cervical collars
46095544|NCT02769143|Other|Pilates|Will be performed six months of Pilates exercises
46095545|NCT00670644|Other|questionnaire administration|Completed self-report form
46095546|NCT00670644|Other|survey administration|Completed self-report form-other
46095547|NCT00670644|Procedure|quality-of-life assessment|Completed self-report form qol
46095548|NCT04488289|Other|Lifestyle|Cardiovascular risk and lifestyle
46008554|NCT04999059|Other|Safety and Efficacy Assessments|Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention.
46008555|NCT04572191|Diagnostic Test|CERAMIDE LEVEL IN BLOOD|BY ELISA ASSAY TO DETECT CERAMIDE LEVEL IN BLOOD IN ANTERIOR STEMI PATIENTS
46008556|NCT04998864|Device|Magnetic Resonance guided Focused ultrasound (MRgFUS)|FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.
46008557|NCT04995042|Drug|SHR7280|Drug: SHR7280 All participants receive SHR7280 alone.
46008558|NCT03450551|Device|Twin Block, Herbst, Frog distalising appliance|To study which of the three orthodontic appliances does achieve the best clinical progress, produce least discomfort to the patient, minimize the time taken for completion of treatment and maximize compliance.
46008559|NCT03450395|Other|Hot Cereal|Intervention involves consumption of one hot cereal in the beginning of each day
46008560|NCT03450317|Drug|Aspirin 80mg|No treatment
46008561|NCT04996563|Other|Video|A brief educational video, approximately 9 minutes in duration, on pelvic organ prolapse is sent electronically to patients to view prior to their initial visit in order to provide early access to information. The video was created to educate patients on the following key components of prolapse: the clinical condition, associated symptoms, common risk factors, evaluation and diagnosis, non-surgical treatment options, and surgical treatment options. Simple drawings and animations are included as visual aids to enhance the ability to conceptualize prolapse and its management options.
46095549|NCT02121652|Behavioral|Cognitive behavioral therapy for insomnia|Cognitive behavioral therapy for insomnia includes content on sleep restriction, stimulus control, relaxation, cognitive restructuring and sleep hygiene content delivered in a 90 minute group intervention with two follow up phone calls.
46095550|NCT02121652|Behavioral|Healthy eating control|Healthy eating control involves healthy eating content delivered in a 90 minute group session with two follow up phone calls.
46095551|NCT02756429|Other|blood samples|Patients with atrial fibrillation for whom electrophysiology exploration or ablation are programmed; All blood samples will be taken through the exploration catheter. For the peripheral blood sample, blood will be taken at the introduction of the catheter into the femoral vein. Then the blood samples in the coronary sinus and in the left atrium will be made at progressively exploration.
46095552|NCT04153812|Device|vagus nerve stimulation|Vagus nerve stimulation (VNS) is a new technique for stimulating the left cervical vagus nerve through implanted lead and a programmable pulse generator.
46095553|NCT04222049|Device|Vibro Tactile Gadget|The concept is to apply vibro tactile gadget to different nerve points which when applied transmit waves to the focused parts of brain which will result in blood flow and activation of dead cells. As a result some disabled part of the body because of those dead cells can show improvement.
46008562|NCT03450278|Procedure|micro-osteoperforation|Minor surgical procedure including performance of limited and shallow perforations of the cortical plate of bone to increase the expression of inflammatory cytokines, hence accelerating orthodontic tooth movement.
46008563|NCT04565496|Drug|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 3 cycles prior to RP and ePLND
46008564|NCT03450239|Other|MRI|MRI scan, including structural imaging, functional imaging (both task-related and structural), and Magnetic Resonance Spectroscopy.
46008565|NCT04992117|Other|NO INTERVENTION|NO INTERVENTION
46008566|NCT04572425|Other|Guided imagery|10 minutes of guided imagery experience delivered on tablet
46008567|NCT04572425|Other|Virtual reality|10 minutes of virtual reality experience delivered by Facebook Oculus Go VR device
46095554|NCT04058990|Device|Device: Paclitaxel-Coated PTCA Balloon Catheter|Percutaneous Transluminal Coronary Angioplasty
46095555|NCT04058990|Device|SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel|Percutaneous Transluminal Coronary Angioplasty
46095556|NCT03734107|Behavioral|Plan, Reflect, and Engage with Providers for Diabetes Care|Behavioral intervention designed to improve health communication skills and readiness for adult diabetes care
46095557|NCT00595920|Biological|Tovaxin|2 mL subcutaneous injections administered by a healthcare provider at weeks 0, 4, 8, 12, and 24 every year as required.
46095558|NCT02756117|Drug|L-Lysine|
46008568|NCT04565340|Other|Mode of delivery, maternal and neonatal outcomes/complications|Mode of delivery, maternal and neonatal outcomes/complications
46008569|NCT03450200|Other|exercises for diabetic peripheral neuropathy|Hands, fingers, and foot exercises for diabetic peripheral neuropathy to improve activities of daily living, and decreases the signs and symptoms of DPN
46095559|NCT02756117|Drug|Normal (0.9%) Saline|
46095560|NCT04070950|Other|Questionnaires|Two self-questionnaires
46095561|NCT02546713|Other|Abutment with concave subcritical contour|Implants will be restored with abutments with concave configuration of the subcritical contour
46095562|NCT02546713|Other|Abutment with convex subcritical contour|Implants will be restored with abutments with convex configuration of the subcritical contour
46008570|NCT03450200|Other|Health education for diabetic foot care|Health education for daily diabetic foot care to prevent diabetic foot ulcer was provided.
46008571|NCT04993287|Other|Non-invasive continuous remote monitoring with structured escalation pathway|Continuous patient monitoring through non-invasive biosensors coupled with machine learning algorithms, with a structured escalation and communication pathway for home health providers and HF care team
46008572|NCT04993287|Other|Affective Analysis of Participant Response to Continuous Remote Patient Monitoring|Surveys and interviews with enrolled participants
46008573|NCT03450161|Drug|Fentanyl dosing schemes|We routinely use fentanyl as the opioid of choice in CABG surgery. However, how much and whether or not to apply it in boli or continuously remain uncertain. We will apply 3 routinely used fentanyl dosing schemes in our hospital. To blind care-givers and patients, in each of the arms a bolus and a continous injection will occur, as delineated in the treatment arms.
46008574|NCT04996212|Procedure|Walking APP Group|"The participants of this group will be explained their treatment plan by a physiotherapist who will contact them through a video call. This treatment will consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of aerobic exercise: walking.~Participants will consult their treatment plan through an application that will be installed on their mobile phone. They will start with 25 minutes of walking and will increase progressively until they reach 45 minutes.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment.~Participants must perform the proposed exercises, 5 days a week, once a day In addition to the respiratory physiotherapy guideline, they will be given the health education manual."
46008575|NCT04996212|Procedure|Functional APP group|"The participants of this group will be explained their treatment regimen by a physiotherapist who will contact them through a video call. This treatment planwill consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of functional exercise which involve the activation and performance of large muscle groups. Participants will consult their treatment plan through an application that will be installed on their mobile phone.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment."
46095563|NCT04222361|Procedure|Preventive recommendations for kidney disease: guidelines for improving overall outcomes (KDIGO) for AKI|Patients assigned to the treatment group will receive the AKI preventive recommendations from the KDIGO guide: withdraw nephrotoxics, ensure volemia and renal perfusion pressure by means of advanced hemodynamic monitoring-optimization (minimum monitoring objective: Unit algorithm based on volume systolic (VS) by pulse wave analysis - Flotrac® / ClearSight® system - or transpulmonary thermodilution - VolumeView® system -), monitor plasma creatinine and urinary expenditure, avoid hyperglycemia (serum blood glucose target: 110-149 mg / dl), and consider alternatives to diagnostic-therapeutic radiocontrast procedures.
46095564|NCT02654288|Other|gemcitabine-based chemotherapy|
46095565|NCT02769221|Device|Rigid video stylet|
46095566|NCT02769221|Device|Video laryngoscope|
46095567|NCT00595764|Behavioral|Manual-guided Physician Management (PM)|Manual-guided Physician Management (PM) PM, consistent with federal regulations, is designed to reflect usual care by primary care physicians and includes referral to ancillary services.
46095568|NCT00595764|Behavioral|Physician Management (PM) combined with on-site manual-guided Cognitive Behavioral Therapy (CBT)|CBT is provided by skilled psychologists in weekly sessions for the first 12 weeks and focuses on reducing illicit drug use and increasing Buprenorphine adherence.
46095569|NCT04466215|Drug|Miricorilant|900 mg (6 x 150 mg) tablets taken orally once daily for two weeks
46008576|NCT03458039|Behavioral|In-person CETA|The Common Elements Treatment Approach (CETA) is a transdiagnostic, multi-problem intervention designed to address adult and youth trauma, depression, anxiety, safety, and substance use. It is comprised of a small set of common elements found to be efficacious and prevalent across a range of EBTs to treat common mental health problems. CETA was designed to be flexible in the elements utilized, their order, and their dose (number of sessions) to allow counselors to address heterogeneity, comorbidity, and symptom fluctuations in and across clients. Treatment typically consists of 6 to 12 weekly, approximately 60-minute sessions delivered by lay workers.
46037825|NCT04228744|Device|DBS system|"The DBS device utilized in the present study includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead contains four stimulating contacts. The length of each contact is 1.5 mm, and the spacing between contacts is 1.5 mm.~The participants will receive stepwise surgery. The electrodes will be implanted firstly which will be externalized for several days and then the IPG will be implanted. During externalization, the experimenters will record the local field potential and electroencephalography in resting or task-based state with conditions of sham-stimulation or active-stimulation."
46095570|NCT04466215|Drug|Placebo oral tablet|Six placebo tablets taken orally once daily for two weeks
46095571|NCT02578966|Behavioral|Motivational Interview|
46095572|NCT02578966|Other|Traditional health education|
46095573|NCT02649140|Dietary Supplement|Vinegar group|Each participant in vinegar group drink 15ml vinegar(Ninghuafu,Sanxi,China)after dinner at noon and evening respectively for a period of four weeks.
46095574|NCT02755961|Behavioral|Dietary education|
46095575|NCT02755961|Behavioral|Education on phosphate binder use|
46095576|NCT02578888|Other|Palliative Therapy|Palliative Therapy
46095577|NCT02578888|Other|Palliative Therapy + idiographic|Ancillary studies
46095578|NCT00665496|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg and 20 mg orally once a day as needed
46095579|NCT00665496|Drug|Placebo|Matching Placebo
46095580|NCT04440631|Other|no intervention, observational only|no intervention, observational only
46008577|NCT03458039|Behavioral|Telephone CETA|"For adaptation of the CETA manual for telephone delivery, the Applied Mental Health Research (AMHR) Group at Johns Hopkins University (JHU) reviewed evidence-based telehealth strategies and recommendations, telehealth ethical and legal guidelines, and clinical recommendations from telehealth providers. In addition, local TTTs in multiple contexts reviewed telehealth modifications and provided input that was incorporated into the final T-CETA manual used in this study. No changes were made to the structure, duration, and dose of CETA sessions, treatment components, or measurement-based clinical decision-making processes. Telehealth modifications, additions, and strategies were incorporated throughout the manual in delineated telehealth boxes. This way, the original manual was maintained outside of the telehealth boxes, allowing for clear identification and training of telehealth modifications for both new and existing CETA counselors."
46008578|NCT03458039|Behavioral|Treatment as Usual (TAU)|The control condition is defined as 'treatment as usual'. In Zambia, there are no formal services or standard of care treatments for mental and behavioral health problems among AYA. There are, however, organizations (such as non-governmental organizations) operating in Lusaka that provide intermittent services for these types of problems. Some AYA receive informal counseling from parish priests or other leaders in their communities. In this study we are therefore defining these types of informal services as 'treatment-as-usual.' We will closely track the type, number, and degree of these kinds of services that all participants receive and access. Following the conclusion of the study, we will offer the CETA intervention to control participants if it has been found to be safe and effective
46008579|NCT04565184|Drug|Artesunate-amodiaquine combination|Artesunate-amodiaquine (Coarsucam®: Sanofi-Aventis, France) is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
45460030|NCT03722472|Biological|ID93 + GLA-SE|The single-vial lyophilized vaccine will be reconstituted with WFI. For the two-vial presentation, the lyophilized ID93 will be reconstituted with WFI and mixed with liquid GLA-SE.
46095581|NCT02653898|Drug|DHA-PIP|Administered monthly (weight-based) on days 1-3, during months 1, 2, and 3 in the MMP arm and also as a first line agent for P.v malaria recurrence in both MMP and FSAT treatment arms
46008580|NCT04565184|Drug|Artemether, Lumefantrine Drug Combination|Artemether-lumefantrine (Coartem®: Novartis, Switzerland) is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child
46008581|NCT03455192|Drug|Synbiotic Supplement|
46008582|NCT03455192|Drug|Placebo Oral Tablet|
46008583|NCT04565262|Drug|NAs+IFN-α|NAs+IFN-α:(NAs +IFN)/96 weeks：NAs（when the CHB patients<2years old, the drug is LAM）combined with IFN-α（when the CHB patients<3years old, the drug is IFN-α）for 96 weeks。 NAs+(NAs+IFN-α) :NAs/48weeks+(NAs+ IFN)/96 weeks：NAs（when the CHB patients<2years old, the drug is LAM）for 48 weeks ，then combined with IFN-α（when the CHB patients<3years old, the drug is IFN-α）for 96weeks。 Response guided treatment（RGT） by HBsAg quantification： The course of interferon alpha was 24 weeks after HBsAg and HBeAg turned negative up to 96 weeks, and NAs was discontinued 12 months after HBsAg serological conversion.
46008584|NCT04564950|Other|Observation of serum and salivary Galectin-3 levels|Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices
46008585|NCT03454022|Behavioral|DART|A one-hour long web-based decision-aid program that explains treatment options for end-stage renal disease, including the benefits and risks of each treatment option.
46008586|NCT03454022|Behavioral|Choosing a Treatment for Kidney Failure|This is an educational pamphlet published by the National Kidney Foundation.
46008587|NCT03452579|Drug|Nivolumab|240mg
46008588|NCT03452579|Drug|Standard Dose Bevacizumab|10mg/kg
46095582|NCT02653898|Drug|Primaquine|22.5 mg weekly for 12 weeks in the MMP arm; low dose primaquine (15mg) for transmission blocking of P. falciparum or 14 days of primaquine (15mg) in G6PD normal volunteers or 8 weeks of low dose primaquine (45mg) in G6PD-deficient volunteers for radical cure of P. vivax
46095583|NCT02653898|Drug|Artesunate + Mefloquine|Weight based; first line agent for P.f malaria infection diagnosed at monthly follow ups, administered on days 1-3 in subjects with malaria recurrence
46008589|NCT03452579|Drug|Low Dose Bevacizumab|3mg/kg
46095584|NCT02653898|Drug|Permethrin (Insecticide treated uniform)|40% Permethrin IDA kit, applied once to the uniforms for volunteers assigned to ITU arm
46095585|NCT02768909|Device|E-Nose|1.They will be asked to perform a respiration for 5 minutes trough the E-Nose Device, with a nose clamp.
46095586|NCT02768909|Other|Survey & Physical Exam|2. Perform a oriented survey for risk factors and a complete physical exam.
46095587|NCT02768909|Other|Chest X-ray|Perform anteroposterior chest X-ray
46095588|NCT02768909|Other|Sputum Samples|Sputum samples for Ziehl Neelsen smear and Culture in L-J.
46095589|NCT02768909|Device|Follow Up 5 days after beginning of Tx.|"Patients will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
46095590|NCT02768909|Device|Follow Up 15 days after beginning of Tx.|"Patients will be asked to come 15 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
45460031|NCT01250041|Procedure|continuous femoral nerve block|ultrasound guided femoral nerve catheter insertion.
45460032|NCT01250041|Procedure|continuous saphenous nerve block|ultrasound guided saphenous nerve catheter insertion
45678556|NCT04626037|Behavioral|WECS Relational Toolkit|The Cuddle and Calm Book, The Mommy Baby Book, mother and child mutual narrative, the Bottle of Emotions, and the WECS for emotional connection, make up the WECS Relational Health toolkit.
46008590|NCT04565223|Behavioral|Cognitive behavioral therapy for insomnia|is a multicomponent intervention which focuses on cognitive and behavioral factors that contribute to sleep disorders , The CBT-i included sleep hygiene counseling, stimulus control, cognitive restructuring, relaxation techniques, and benzodiazepine therapy or withdrawal (when needed). To conduct the intervention, guidelines for GPs and nurses and graphic and written materials for patients (sleep diary, registry of behavior habits, and cognitive problems) were developed
46008591|NCT04997850|Drug|lenvatinib + sindilimab/carrelizumab|4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next treatment cycle was carried out. The trial was terminated if the drug was stopped for more than 28 days due to adverse drug reactions or other reasons. Patients with PD after 6 cycles of sindilimab/carrelizumab treatment were terminated. The follow-up treatment was based on the principle of individualization, multidisciplinary discussion and patients' willingness.
46008592|NCT04997850|Procedure|TACE|"TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor."
46008593|NCT03450629|Drug|Brimonidine Tartrate Ophthalmic Suspension|PDP-716
46008594|NCT03450629|Drug|Brimonidine Tartrate Ophthalmic Solution|Three Times Brimonidine Tartrate Ophthalmic Solution
46008595|NCT04565106|Device|Closed-loop control of oxygen supplementation by O2matic|Closed-loop control of oxygen supplementation to achieve a target SpO2 of 92 - 96 %
46008596|NCT04572347|Other|Observational|It is an observational study, and no intervention will be provided.
46008597|NCT04997772|Device|Digital Gaucher Platform|Digital platform specified for Gaucher patients.
45836771|NCT00462228|Drug|Memantine|After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
46008598|NCT03459014|Other|Stimulus rich VE|Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
45460033|NCT03489720|Behavioral|Prescribed Exercise Program|"Brief cardiovascular exercise training (>70% of maximum heart rate) for 15 minutes a day, 5 days a week for 8 weeks.~The exercise intervention will be a 15-minute per day of vigorous exercise that as monitored by a Fitbit Charge 2.~Examples of possible 15-minute exercise regimens to be used include:~Walking quickly or running up and down stairs~Plyometric exercises such as jumping jacks, high knees, squats, lunges, speed skaters, froggers, etc~Walking up an incline on a treadmill~Jogging or running on a treadmill or elliptical~Stationary cycling or rowing"
45460034|NCT03489720|Behavioral|Usual Exercise Program|Usual exercise activity for 8 weeks
45836772|NCT00462228|Drug|Placebo|After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
45460035|NCT03907111|Device|Chitosan Gauze|Gauze made by chitosan material
45836773|NCT00408564|Biological|cetuximab|
45836774|NCT00408564|Drug|capecitabine|
45836775|NCT00408564|Drug|oxaliplatin|
45836776|NCT00408564|Procedure|conventional surgery|
46095591|NCT02768909|Device|Follow Up 30 days after beginning of Tx.|"Patients will be asked to come 30 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
45460036|NCT03907111|Device|placebo|traditional gauze
46095592|NCT02768909|Device|Follow Up 60 days after beginning of Tx.|"Patients will be asked to come 60 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
46008599|NCT03459014|Other|Stimulus poor VE|Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
46095593|NCT02649452|Other|vibration|vibration will be given using whole body vibration machine. The subject will place both palms on top of the vibration platform with their knee supported on the ground. They need to apply as much pressure on the vibration platform by using their body weight. The whole body vibration machine will be set at the frequency of 30 Hz and the amplitude of 5 mm. They need to hold that position for 1 minute for 3 sets with 1 minute rest in between. The researcher will immediately stop this if the subjects feel dizziness and discomfort
46095594|NCT02755727|Procedure|Platelet Rich Plasma Injection|See Arms
45460037|NCT03722394|Behavioral|Pain Neuroscience Education|15 minute verbal one-on-one education session
45460038|NCT03906799|Drug|OMT-28|1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).
45460039|NCT03906799|Drug|Placebo|1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).
46008600|NCT03456947|Drug|Pregabalin|the patients receive 150mg or 300mg pregabalin 60 minutes prior to the surgery
46008601|NCT04999527|Drug|DISC-0974|DISC-0974 is administered (IV infusion or Subcutaneous Injection) as a single dose
46008602|NCT04999527|Drug|Placebo|Placebo is administered (IV infusion or Subcutaneous Injection) as a single dose
46008603|NCT04995861|Procedure|Adductor canal block and IPACK block|Peripheral nerve blocks
46008604|NCT03456791|Diagnostic Test|Human epididymis protein 4|Human epididymis protein will be quantitatively assayed using the enzyme immunometric assay (EIA) method
46095595|NCT02755727|Procedure|Open Surgical Release|See arms
46095596|NCT02629536|Drug|N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet|N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet
46095597|NCT04167098|Other|PRP injection|0.5 ml Platelet-rich Plasma around A1 tendon sheath
46095598|NCT04167098|Other|Corticosteroid injection|0.5 ml methylprednisolone around A1 tendon sheath
46008605|NCT04564638|Drug|Corticosteroid|
45460040|NCT03912571|Diagnostic Test|Structural 3T MRI|measures of global and hippocampal atrophy)
45460041|NCT03912571|Diagnostic Test|MRI Based Perfusion Imaging|brain blood flow
46095599|NCT04167098|Other|Placebo injection|0.5 ml 0.9% saline around A1 tendon sheath
46095600|NCT04153500|Other|Anatomy class with Pelvic+ methodology|Teaching of female pelvis anatomy using a interactive training model (Pelvic+ methodology)
46095601|NCT04071106|Drug|Turmeric Extract|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
46095602|NCT04071106|Drug|Turmeric Extract in Olive oil|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
46095603|NCT04071106|Drug|Petrolatum|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
45460042|NCT03912571|Diagnostic Test|VR-CO2 MRI Scans|reduced vaso reactivity to carbon dioxide
45460043|NCT05664828|Drug|SN132D|Novel manganese-based macromolecular MRI contrast agent
45460044|NCT03912727|Dietary Supplement|Alpha-Lipoic acid plus renal replacement therapy|Alpha lipoic acid (ALA) is a vitamin-like antioxidant
45460045|NCT03912727|Other|renal replacement therapy|standard renal replacement therapy
45460046|NCT01250197|Drug|AR-12286|Ophthalmic Solution
45460047|NCT03661567|Radiation|chest radiation|split-course chest radiation
45460048|NCT03661567|Drug|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
45460049|NCT03661567|Drug|Methylprednisolone|Methylprednisolone after the first course of radiation, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.
45460050|NCT01250275|Other|traditional canola oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from traditional canola oil.
46008606|NCT02277431|Dietary Supplement|Probiotic dietary supplement (Trenev Trio®)|"Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am & pm) offering a total daily serving of:~Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units [CFU])~Bifidobacterium bifidum Malyoth super strain (40 billion CFU)~Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)"
46095604|NCT04071106|Device|NB-UVB|Patients will receive 2 sessions of NB-UVB phototherapy and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
46008607|NCT02277431|Dietary Supplement|placebo|
46008608|NCT02277509|Behavioral|Chinese DPP|"The Chinese DPP intervention will include core curriculum, stress reduction, physical activity sessions, and self-monitor diet and physical activity.~."
46008609|NCT02277509|Behavioral|Minimal Intervention Control|Patients will receive printed diabetes prevention materials in Chinese. Materials will be from primary from the National Diabetes Education Program and from the New York City Department off Health and Mental Hygiene. Patients will receive an educational packet at randomization and quarterly thereafter.
46008610|NCT01580852|Procedure|Dead Sea water|Subjects will immerse in mineral (dead sea) waters for twenty minutes twice daily for a period of 10 days
46008611|NCT01580852|Procedure|Pool water|Subjects will immerse in sweet(pool)waters for twenty minutes twice daily for a period of 10 days
46008612|NCT04564326|Procedure|Pericapsular nerve Group block|Under ultrasound guidance a needle is inserted between the iliopectineal eminence and the iliopsoas muscle and tendon to block articular branches supplying the capsule of hip joint.
46008613|NCT04564326|Procedure|Facia Iliaca block|Under ultrasound guidance a needle is inserted between the fascia iliaca and Psoas muscle to block the femoral, obturator and lateral cutaneous nerves.
46008614|NCT04564326|Drug|Fentanyl|Intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between.
46095605|NCT04071106|Drug|calcipotriol/ Betamethasone|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
46095606|NCT04167254|Behavioral|Sit Down and Play|Brief health care-based program that aims to promote key parenting behaviors that promote early childhood development
45460051|NCT01250275|Other|high oleic canola oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high oleic canola oil.
45460052|NCT01250275|Other|soybean oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from soybean oil.
46008615|NCT03453164|Radiation|Radiotherapy + Nivolumab|Radiotherapy of 22.5 Gy/5 fractions/5 days will be given to a symptomatic lesion or the largest asymptomatic lesion suitable for irradiation from Day 1. Nivolumab will be administered intravenously starting on Day 15-22 at a dose of 3 mg/kg (body weight) every 2 weeks to a total of 6 courses of administration.
46095607|NCT00670722|Drug|insulin aspart|Intervention at the discretion of the physician
46095608|NCT00670722|Drug|insulin detemir|Intervention at the discretion of the physician
46095609|NCT00670722|Drug|biphasic insulin aspart 30|Intervention at the discretion of the physician
46095610|NCT04584892|Drug|Turoctocog alfa|Patients will be treated with commercially available NovoEight® (turoctocog alfa) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available NovoEight® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
46095611|NCT02755883|Behavioral|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and will receive the positive affect component.
46095612|NCT02755883|Behavioral|Physical activity plus education|Subjects will be randomized to a physical activity goal and will receive the educational component.
46095613|NCT02629458|Procedure|Treatment by Surgical resection|
46008616|NCT04571307|Procedure|cryotherapy|comparison between cryotherapy and surgery
46008617|NCT03450434|Drug|XC8 Oral Tablet|1 tablet of XC8 in a dose according to the treatment group + 2 tablets of placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
46008618|NCT03450434|Drug|Placebo Oral Tablet|Placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
46008619|NCT04564716|Biological|Gam-COVID-Vac|vaccine for intramuscular injection
46008620|NCT04564716|Other|Placebo|placebo comparator
46008621|NCT04994418|Dietary Supplement|Recommended sodium and low fructose diet|Upon completion of a 7 day dietary intervention of consuming the daily recommended sodium and low fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
46095614|NCT02629458|Procedure|Stereotactic Ablative Radiotherapy (SABR)|
46008622|NCT04994418|Dietary Supplement|High sodium and low fructose diet|Upon completion of a 7 day dietary intervention of consuming the daily high sodium and low fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
46095615|NCT02575378|Drug|Metronimic chemotherapy plus Chinese Traditional Medicine|Capecitabine 300mg/m2, twice a day, everyday plus Chinese Traditional Medicine
46095616|NCT02575378|Drug|Metronimic chemotherapy|Capecitabine 300mg/m2, twice a day, everyday
46095617|NCT02755415|Device|HIWIN Robotic Gait Training System|HIWIN Robotic Gait Training System is an automatic training system that combines weight-bearing standing, repetitive stepping and gait training
46095618|NCT02755415|Other|Static Standing Table|As part of the standard hospital rehabilitation, static standing table allows patient to be in a fully supported standing position
46095619|NCT02653820|Other|Reflexology|
46095620|NCT04427761|Behavioral|Measurement of Transitions in Cancer Scale (MOT-CA) Survey|These surveys will take 5-10 minutes to complete at two time-points, T0 (baseline) and T1 (four to six weeks after baseline visit) The patient will again complete the DT and MOT-CA at a chemotherapy treatment or clinic visit, if possible, or via a telephone call with the principal investigator in the event that there are no in-person visits scheduled (Time 1).
46095621|NCT04427761|Behavioral|Distress Thermometer Survey|These surveys will take 5-10 minutes to complete at two time-points, T0 (baseline) and T1 (four to six weeks after baseline visit).The patient will again complete the DT and MOT-CA at a chemotherapy treatment or clinic visit, if possible, or via a telephone call with the principal investigator in the event that there are no in-person visits scheduled (Time 1).
46095622|NCT00665574|Other|ActaVisc and ActaVisc Mx Intra-articular Injection|ActaVisc is a hyaluronan based device intended to alleviate the pain associated with osteoarthritis of the knee with a single injection and ActaVisc Mx is the same material combined with a corticosteroid.
46095623|NCT04071184|Drug|Alofanib|Five dose cohorts and expanded cohort will be included
45460053|NCT01250275|Other|high linoleic safflower oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high linoleic safflower oil.
45460054|NCT01250275|Other|coconut oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from coconut oil.
46008623|NCT04994418|Dietary Supplement|High sodium and high fructose diet|Upon completion of a 7 day dietary intervention of consuming the high sodium and high fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
46008624|NCT00198029|Device|Synvisc (hylan G-F20)|32 subjects in the pilot study have received 3 1ml injections of Synvisc intraarticular over the course of 3 weeks and then followed for 6 months post injection
46095624|NCT02648906|Drug|Choline alfoscerate|
46095625|NCT02648906|Drug|Placebo|
46095626|NCT05223205|Procedure|Air|Test if air is sufficient for macular hole closure.
46095627|NCT05223205|Procedure|10% SF6 and 90% air|Test if 10% SF6 and 90% air is sufficient for macular hole closure.
46095628|NCT04031898|Other|Non Interventional|This is a non interventional, observational, retrospective study including patients with EGFR-mutated advanced NSCLC, treated with 1st or 2nd generation EGFR TKI therapy in first line
46095629|NCT02755493|Behavioral|Sleep deprivation|
46095630|NCT02648828|Other|Clinical deterioration|Patients at risk of clinical deterioration
46095631|NCT00670878|Drug|3 x FEC 3 x DOC / Gemcitabine|3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 75 mg/m² body surface area i.v. (D), and Gemcitabine 1000 mg/m² i.v. (30 min infusion) (G), administered on day 1, followed by Gemcitabine 1000 mg/m² i.v. (30 min infusion) on day 8, repeated on day 22
46095632|NCT00670878|Drug|3 x FEC 3 x DOC|3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22
46095633|NCT02760017|Drug|B. forficata|
46095634|NCT02760017|Drug|Placebo|
46095635|NCT03652909|Device|Ascending Hearing Technologies device|Personal Sound Amplification Device
46095636|NCT02648984|Other|The intervention is performing an exercise test|Patients and controls will undergo a bicycle stress echocardiography and a cardiopulmonary exercise test
46095637|NCT00671736|Drug|Moli1901|2,5 ml inhalation solution, 8 weeks treatment period
46095638|NCT00671736|Drug|Moli1901 placebo|2,5 ml placebo solution, 8 weeks treatment period
46095639|NCT02760095|Drug|3 mg zinc sulfate supplement|
46095640|NCT02760095|Drug|0.5 mg of 13C10-retinyl-acetate|
46008625|NCT00197054|Biological|RTS, S/AS01B|0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
46008626|NCT00197054|Biological|RTS, S/AS02A|0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
45678557|NCT01390402|Drug|Fludarabine|40 mg/m2 intravenous over one (1) hour on each of four (4) consecutive days, Days -13 to -10.
46095641|NCT04071028|Procedure|warm-water footbath|"All the participants in the intervention group were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, the participants in the footbath group received legs soaking from the heel to the Sanyinjiao (SP6) acupoint (above the ankle) 24 in 42 ℃ water with air bubbles and vibration given to the soles for 20 minutes, whereas the participants in the control group kept on sitting quietly without legs soaking during the additional 20-minute period."
46008627|NCT00197054|Biological|Rabipur (Rabies) Vaccine|1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months
46008628|NCT04564131|Other|Reflexology|"Hands are washed.~The individual is provided to be in a comfortable position to lie down or to be in a semi-sitting position.~The toes of the patient are crossed and the patient's feet are placed at our chest level when we sit.~Depending on the size of the foot, a slightly moisturizing amount of non-allergenic petroleum jelly is taken, and it is spread to provide slipperiness.~Exercises to warm and relax the feet for five minutes.~General massage is applied to the whole foot for five minutes.~Reflexology massage is applied to the application areas for neuropathic pain.~The individual is helped to take a comfortable position.~Hands are washed."
46008629|NCT04564131|Other|Control|No intervention was performed to reduce pain in the control group
46008630|NCT04998435|Procedure|Erector Spinae Plain Block|"Using aseptic technique, ultrasound-guided ESPB will be performed with the patient in sitting position. The spinous process of the vertebra and a point 3 cm lateral to it will be marked before performing the block. The needle will be inserted and advanced under sono-visualization to contact the transverse process of the vertebra. After negative aspiration, LA will be deposited into the fascial plane deep to erector spinae muscle.~30 ml of Bupivacaine 0.25% will be used as LA, injected using a 22-gauge spinal needle at the level of T10 which will be identified by counting 3 spinous processes below T7 which is at the level of the inferior angle of the scapula and also rechecked by counting down from C7.~Patients will then receive general anesthesia. All patients will receive paracetamol (1gm/8hrs IV) as a regular analgesia. IV morphine (0.02mg/kg) will be given as a rescue analgesia if the Visual Analogue Scale for pain is ≥ 4."
45678558|NCT01390402|Drug|Busulfan|130 mg/ m2 by vein for 2 doses on Days -11 to -10.
46095642|NCT04168424|Other|no intervention|Completing the questionnaire for health-related resource use in the elderly population (FIMA) by the elderly people
46095643|NCT04418167|Drug|JSI-1187|JSI-1187 capsules for oral administration
46095644|NCT04418167|Drug|Dabrafenib|Dabrafenib capsules for oral administration
46095645|NCT00675870|Drug|NRX 195183 Soft Gelatin Capsule|Daily oral NRX 195183 administration for 90 days to assess CR rate. Patients with CR may continue maintenance therapy after a 2-week drug holiday. Maintenance therapy will consist of two 3-month daily oral NRX 195183 administration separated by a 2-week drug holiday.
46095646|NCT02648750|Behavioral|Bridges self-management programme|The Bridges self-management programme is based on self-efficacy principles. It includes a Bridges stroke workbook consisting of stroke survivors' experiences and strategies, with space to record and reflect on personal goals and achievements, which the practitioner will work through with the participant. The practitioner will also used strategies based on key principles of self-management during interactions with patients.
46095647|NCT02759783|Radiation|SBRT|Patients will receive a dose and fractionation regimen dependent on the metastatic site and proximity to normal tissues. If allocated to SBRT, SBRT will precede SOC. All patients should commence SOC therapy within 4 weeks of completing SBRT treatment.
45678559|NCT01390402|Procedure|NK cell infusion:|Natural killer cell infusion will be administered by vein on Day -8.
45678560|NCT01390402|Drug|Interleukin-2|0.5 million units subcutaneously daily for 5 days on Day -8 to day -4.
45678561|NCT01390402|Drug|Anti-Thymocyte Globulin|2.5 mg/kg by vein for 3 doses on Days -3 to -1.
45678562|NCT01390402|Procedure|Allogeneic related Stem Cell Transplant|Allogeneic related stem cell transplant by vein on day 0.
45460055|NCT01250275|Other|traditional canola oil|Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of food items prepared with traditional canola oil for eight weeks.
45678563|NCT01390402|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml.
45678564|NCT01390402|Drug|Methotrexate|5 mg/m2 by vein Days 1, 3 and 6 post transplant.
45678565|NCT01390402|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day + 7, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
45678566|NCT01976299|Device|AVERT|
45678567|NCT04661683|Other|e-hookah aerosol|Exposure to secondhand aerosol delivered by an e-hookah vaping machine for 60 mins
45678568|NCT04661683|Other|clean air|Exposure to clean air for 60 mins.
45836777|NCT00408564|Radiation|radiation therapy|
45678569|NCT04661683|Other|Charcoal-heated hookah smoke|Exposure to secondhand smoke delivered by a hookah vaping machine for 60 mins
46008631|NCT04998435|Procedure|Paravertebral Block|"Using sterile technique, ultrasound scanning of thoracic paravertebral space will be done in sitting position. The transverse process will be identified as hyperechoic structure while pleura will be identified as a mobile hypoechoic structure. The needle will be inserted cranio-caudal and advanced under sono-visualization to the identified thoracic paravertebral space. After negative aspiration, LA will be deposited displacing the pleura.~30 ml of Bupivacaine 0.25% will be used as LA, injected using a 22-gauge spinal needle at the level of T10 which will be identified by counting 3 spinous processes below T7 which is at the level of the inferior angle of the scapula and also rechecked by counting down from C7.~Patients will then receive general anesthesia. All patients will receive paracetamol (1gm/8hrs IV) as a regular analgesia. IV morphine (0.02mg/kg) will be given as a rescue analgesia if the Visual Analogue Scale for pain is ≥ 4."
46008632|NCT00197015|Biological|Havrix®|2 doses administered intramuscularly
46008633|NCT00197015|Biological|M-M-R®II|1 dose administered subcutaneously
46008634|NCT00197015|Biological|VARIVAX®|1 dose administered subcutaneously
46095648|NCT02759783|Other|Standard of Care|Choice of standard of care treatment at the discretion of the local oncologist. This may include: Chemotherapy, Endocrine therapy, surgery, palliative radiotherapy
46095649|NCT02645006|Behavioral|3 session workshop|The intervention group will attend a three session workshop, will learn to recognize their risk factors for fall, will be encouraged to adopt a healthy diet (vitamin D consumption), modify home hazards , and increase physical activity (a strength and balance program at home and a group walking route). After a monthly telephone follow-up they are invited to attend a recall session, were they realize the change in the strength and balance tests results.
46095650|NCT02645006|Behavioral|1 session workshop|The control group will attend a single workshop session summarizing the major points of prevention of falls ( risk factors of fall, healthy diet and vitamin D consumption, home hazards, physical activity). After a monthly telephone follow-up they are invited to attend the three session workshop for further prevention.
46008635|NCT04564248|Other|Website access|website access will be provide to families
46008636|NCT02215122|Drug|MGR001|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
46008637|NCT02215122|Drug|Advair® Diskus®|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
46008638|NCT02215122|Drug|Seretide™ Accuhaler™|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
46008639|NCT00196976|Biological|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
46095651|NCT00581308|Device|GORE® HELEX® Septal Occluder|Percutaneous transcatheter closure of ostium secundum atrial septal defects (ASDs)
46095652|NCT04407481|Drug|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
45678570|NCT01428076|Drug|Polidocanol Endovenous Microfoam (PEM)|Pharmacokinetic comparison of different doses of drug
46008640|NCT00196976|Biological|DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only
45678571|NCT01900652|Drug|Emibetuzumab|Administered IV
45678572|NCT01900652|Drug|Erlotinib|Administered Orally
45678573|NCT02093351|Drug|Olaparib|2 x 150mg tablets, twice daily Day 1-5, and Day 27 onwards (Cohort 1), Day 20 onwards (Cohort 2) or Day 39 onwards (Cohort 3)
45678574|NCT02093351|Drug|Tamoxifen|60mg Tamoxifen once daily, Day 10 - Day 13; 20mg Tamoxifen once daily, Day 14 - Day 31
45678575|NCT02093351|Drug|Anastrozole|1mg Anastrozole once daily Day 10 - Day 24
46008641|NCT00196976|Biological|DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only
46008642|NCT00196976|Biological|Meningitec™|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age
45460056|NCT01250275|Other|safflower oil|Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of foods prepared with an oil mixture representing the typical western diet
45678576|NCT02093351|Drug|Letrozole|2.5mg Letrozole once daily Day 10 - Day 43
45678577|NCT02093351|Procedure|Pharmacokinetic sampling|Blood sampling over 12-24 hour period for pharmacokinetic analysis
45678578|NCT02078284|Biological|CPP|One unit of frozen CPP contains approximately 3.4 x 10^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.
45678579|NCT02078284|Biological|LSP|
46095653|NCT04407481|Drug|Iohexol Inj 300 milligrams per milliliter (MG/ML)|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
46095654|NCT04407481|Radiation|PET/CT Scan|Imaging used to visualize the kidneys and quantify renal metabolic activity
46095655|NCT02645084|Other|Offering an online risk assessment questionnaire|Offering an online risk assessment questionnaire to CRC patients, to facilitate the detection of colorectal cancer patients with hereditary or familial colorectal cancer
46095656|NCT03536767|Drug|AG10|AG10 800mg twice daily, oral administration
46095657|NCT02576626|Drug|indacaterol/glycopyrronium 110/50 Breezhaler®|
46008643|NCT00196976|Biological|Mencevax™ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)
46008644|NCT04561167|Other|Cuspal reduction in MOD cavity in endodontically treated teeth|Not only the quality of endodontic treatment that affects the prognosis of the endodontically treated tooth, but the subsequent restorative treatment as well. Coverage, Endocrowns, Onlays, Inlays Restorations on Fracture Resistance of Endodontically Treated Molars, it was found that the worst results came to the inlay restorations and this was attributed to geometric form of preparation that exert a wedging force acting to split the tooth when under occlual stress however, onlay and full coverage direct the force along the long axis by overlaying the cusp tips and a portion of buccal and lingual surface thus opposing the wedging action created by internal design of restoration (Magne P and Belser C. et al 2003) That's why, choosing such a design as a comparator to the design of the cuspal reduction and further coverage (onlay) is crucial to show the importance of cuspal coverage for the indirect resin composite restoration in the endodontically treated teeth.
46008645|NCT04561167|Other|No cuspal reduction in MOD cavity in endodontically treated teeth|In an invitro study done by (Ahmed Hamdy 2015) investigating the effect of Full The amount of lost internal tooth structure as well as the coronal hard tissue in an endodontically treated tooth is considered the main factors that make the tooth susceptible to biomechanical failure when compared to a vital tooth. (Guo J et al 2016) .
46008646|NCT04563936|Drug|LY01005 3.6 mg|LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
46008647|NCT04563936|Drug|ZOLADEX® 3.6 mg|ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
45678580|NCT02092961|Drug|Fostamatinib|Fostamatinib 100mg twice daily.
45678581|NCT02092961|Drug|Adalimumab|Adalimumab 40 mg by subcutaneous injection every 2 weeks for 24 weeks.
46008648|NCT04572308|Biological|CD7 CAR-T|"Patients will be treated with CD7 CAR-T cells~Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;"
46008649|NCT04563975|Drug|Toripalimab|Toripalimab，240mg，d1，Intravenous Infusion，q3w
46008650|NCT04563975|Drug|Docetaxel|Docetaxel，60-75mg/m2，d8 and d15，Intravenous Infusion，q3w
46008651|NCT04563975|Drug|nab-paclitaxel|nab-paclitaxel，125mg/m2，d1 and d 8，Intravenous Infusion，q3w
46095658|NCT02576626|Device|Placebo by Breezhaler®|
45678582|NCT02092961|Drug|Placebo of Fostamatinib|Placebo bid for 6 weeks.
45678583|NCT02092961|Drug|Placebo of Adalimumab|Placebo injection once every two weeks.
46095659|NCT02576626|Drug|ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation|
46095660|NCT02576626|Device|Placebo by nebulisation|
45678584|NCT01898078|Drug|Alisertib|Alisertib ECT
45836778|NCT00408564|Drug|Gemcitabine|
46008652|NCT00196313|Drug|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily by mouth
46095661|NCT02759549|Behavioral|eSMART-MH|eSMART-MH (Electronic Self-Management Resource Training for Mental Health) is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programmed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. eSMART-MH will be used once a week throughout the duration of radiation treatment.
46095662|NCT02759549|Other|Mobile Mood Tracking (Mood 24/7)|Public social media data posted by participants will be accessed and downloaded to a computer program. Permission for the study team to access this data is optional.
46095663|NCT02759549|Behavioral|Theater Testing Workshop|The theater testing workshop consists of one to two one-on-one sessions with study staff during which participants will review a computer program for its content and usability, as well as discuss areas for improvement. Participants will also be asked to complete questionnaires and a attend a brief interview regarding any suggested improvements for the computer program.
46095664|NCT02648516|Combination Product|Conventional plus AAIT|Participants will receive ART and taken i.v., at a dose of 2-3*10E8 MNCs/kg body at baseline, week 1 and 2.
46095665|NCT00877890|Drug|exenatide once weekly|subcutaneous injection, 2.0mg, once a week
46095666|NCT00877890|Drug|exenatide twice daily|subcutaneous injection; 5mcg (4 weeks) and 10mcg (20 weeks); twice a day
46095667|NCT02648672|Drug|BPN14770|BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
46095668|NCT02648672|Drug|Placebo|
45678585|NCT01987817|Biological|AR101 powder provided in capsules|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
46095669|NCT02576470|Behavioral|Biofeedback|Motor learning is improvement in movement overtime, followed by retaining what was learned. To determine whether movements are improving, kinematics must be assessed over time, beginning with defining specific kinematic goals, then continually re-evaluating goals throughout rehabilitation while providing the participants with biofeedback. Biofeedback is fundamental in motor learning, because it increases guidance and motivation, supplements losses in intrinsic feedback (proprioception), and facilitates generalization and retention. Biofeedback enhances the training of novel movements and could be essential for training swallowing maneuvers. Biofeedback training will occur 3 times.
46095670|NCT02576470|Device|Transcranial Direct Current Stimulation|Weak direct currents can be applied non-invasively, transcranially and painlessly. Such application leads to transient changes in corticomotor excitability that are fully reversible. There are no known risks of tDCS of the brain, other than mild local discomfort at the electrode sites.The tDCS sessions will be separated by at least 24hrs, the electrode pads will not be used more than 4 times and they will be clean with a sterile saline solution.
45678586|NCT01987817|Biological|Placebo powder provided in capsules|Study product formulated to contain only inactive ingredients for use as defined in the protocol
45678587|NCT01940497|Drug|Doxorubicin|Participants will receive doxorubicin in doses according to the locally-approved regimen q3w (1 cycle), for 4 cycles prior to initiation of trastuzumab treatment.
45678588|NCT01940497|Drug|Docetaxel|Participants will receive docetaxel in doses according to the locally-approved regimen q3w for 12 weeks, in combination with trastuzumab.
45678589|NCT01940497|Drug|Paclitaxel|Participants will receive paclitaxel in doses according to the locally-approved regimen weekly for 12 weeks, in combination with trastuzumab.
45678590|NCT01940497|Drug|Trastuzumab|Participants will receive trastuzumab 600 mg SC (vial or SID) q3w for 18 cycles.
46008653|NCT00196313|Drug|Placebo tablet|1 tablet daily by mouth
46008654|NCT04563858|Diagnostic Test|Validation|Assessment of Polish version of the 4AT
46008655|NCT04563819|Genetic|Genom-wide association study (GWAS) and biological pathway analyses|
46008656|NCT04561440|Diagnostic Test|molecular karyotyping|performed by NGS or CMA chip
45460057|NCT03739138|Biological|MK-4621|"MK-4621 is delivered via the JetPEI™ in vivo linear polyethylenimine nucleic acid delivery system as follows:~For Arm 1: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle.~For Arm 2: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle according to randomization.~For Arm 3: administered intratumorally Q3W, on Day 1 of each 21-day cycle. Range administered will depend upon allocation and be based on emerging safety data."
46037826|NCT05338684|Device|Colour doppler,MSCT,MRI|ultrasound/color duplex at Jugular veins & carotid and vertebral arteries first ,then MSCT/CTA mainly with relation of neck & Bain arteries to the bone of the skull in 6 mm cuts and/or MRI/MRA/MRV by standardized multi-parametric MR protocol will be implemented for all patients. All sequences will be acquired on a 1.5T MR scanner.
46095671|NCT02576470|Behavioral|Financial Reward|Motor learning training can be enhanced by adjuvant techniques such as non-invasive neural stimulation and explicit reward. Both influence the primary motor cortex (M1), a key neural substrate of motor skill learning. Non-invasive neural stimulation reduces dysphagia after stroke as measured with subjective swallowing severity scales, however it is unknown whether it could also enhance swallowing maneuver training. Explicit reward (i.e. financial) incentivizes successful gains during motor training. Explicit reward has never been investigated in swallowing rehabilitation. However, it has been shown that increasing stress and financial penalty can reduce swallowing frequency in healthy adults.
46095672|NCT02576470|Behavioral|targeted dysphagia training maneuver|training swallowing maneuvers or compensatory techniques (referred to as targeted dysphagia training throughout this document) that might reduce their swallowing pathophysiology
46095673|NCT02576470|Radiation|Videofluoroscopy (VF) and Barium|The videofluoroscopy (VF) and barium will be used to record swallowing in all participant groups. This will capture full resolution VF images of all subjects in real time in the lateral view. From the digital recording, image sequencing will be exported to an image processing computer system and archived. The image intensifier will be focused on the lips, posterior pharyngeal wall, hard palate, and just below the upper esophageal sphincter (UES), providing a full view of the oral cavity and neck. A simultaneously recorded time-code will facilitate frame-by-frame data analysis. VF is the only option for visualizing swallowing kinematics during the pharyngeal swallow.
46095674|NCT02576470|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) will be used to provide a single-pulse to the brain.
46095675|NCT02576470|Device|Submental Electromyography|Submental Electromyography (sEMG) is used to train participants swallowing maneuvers.
46095676|NCT02759627|Other|Robotic-Assisted Gait Training|"There were three intervention arms in this study,~Robotic-Assisted Gait Training,~Conventional Training,~Combined Training."
46095677|NCT04355533|Biological|serology test|volume according to child weight
46095678|NCT04355533|Biological|nasopharyngeal swab|nasopharyngeal swab for PCR
46008657|NCT04561479|Other|Pulmonary Rehabilitation|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session. Training group will receive upper extremity aerobic exercise training using arm ergometer at 60-80% of maximal heart rate (dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale). Inspiratory muscle training (Powerbreathe® Wellness-Inspiratory Muscle Trainer) at 50-60% of maximal inspiratory pressure (MIP) and progressive resistance training at 30-60% of 1 RM (using proprioceptive neuromuscular facilitation techniques (flexion, abduction, external rotation/extension, adduction, internal rotation) for upper extremity resistance training; using sandback for knee extensors) will be performed during 24 sessions (3 day/week; 8 weeks)
45836779|NCT02110758|Other|Pilot of Patient-Centered Oncology Care|Patient-Centered Oncology Care addresses six domains: track & coordinate referrals, provide access and communication, identify and coordinate patient populations, plan and manage care, track & coordinate care, and measure and improve performance.
46008658|NCT04561479|Other|Alternative Exercises|Control group will receive alternative upper extremity exercises combined with breathing exercises. Control group will perform alternative upper extremity exercises combined with breathing exercises during 3 days/week, for 8 weeks
46095679|NCT04355533|Biological|rectal swab|rectal swab for PCR
46095680|NCT04355533|Biological|saliva sample|for biocollection
46095681|NCT02648594|Device|Hook wire CT guided|The intervention consist to place a CT-guided hook wire in lung patient
46095682|NCT04221971|Drug|chemotherapy combined with NK cells infusion|chemotherapy combined with NK cells infusion
45836780|NCT02111772|Biological|Rhinovirus|
46095683|NCT03495895|Behavioral|Minding the Baby|Visits are carried out on an alternating basis by a team made up of a nurse practitioner (NP) and social worker.
46095684|NCT03495895|Behavioral|Usual Care|Usual care condition
46095685|NCT02644694|Drug|Dexamethasone Phosphate Ophthalmic Solution|Experimental: Dexamethasone Phosphate Ophthalmic Solution (40 mg/mL) delivered via the EyeGate II Drug Delivery System
46095686|NCT02768987|Behavioral|Bright 1 Bodies|A 12-week intensive lifestyle program utilizing group exercise classes adapted for this population, supplemented with coping skills training and diabetes self-management education.
46095687|NCT02653742|Drug|Ketorolac|Ketorolac 1mg/kg sublingual is administered after induction of general anesthesia.
46095688|NCT02653742|Drug|Fentanyl|Fentanyl 2mg/kg intranasal is administered after induction of general anesthesia
46095689|NCT02755259|Drug|Acetazolamide|
45836781|NCT00383448|Drug|Clofarabine|days -7 through -3: 40 mg/m^2 intravenously over 2 hours
45836782|NCT00383448|Procedure|Total body Irradiation|Administration of TBI: The dose of TBI will be 200 cGy given in a single fraction on day -1. The dose rate will be between 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
45836783|NCT00383448|Drug|Melphalan|day -2: 140 mg/m^2 intravenously over 30 minutes
45836784|NCT00383448|Biological|Hematopoietic Stem Cell Transplantation|receives infusion of stem cells on day 0
46008659|NCT04563663|Procedure|Posteriorization of the talus.|Three sets of a 30-s grade IV anteroposterior mobilization.
46008660|NCT00196196|Device|Codman VPV System|Valve Positioning Verification (VPV) System
46095690|NCT02755259|Drug|Placebo|
46095691|NCT02575222|Drug|Nivolumab|3 mg/kg, IV (in the vein) on day 1 of each 2-week cycle, for a total of 3 doses prior to nephrectomy.
46095692|NCT00680394|Drug|mifepristone|200 mg mifepristone
46095693|NCT00680394|Drug|misoprostol|800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
46095694|NCT00680394|Drug|placebo|800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
46095695|NCT02768675|Device|LOADPRO|The Intellirod LOADPRO sensor is a single-use, disposable instrument for the intra-operative measurement of posterior instrumented, spine rod strain.
46095696|NCT04724044|Drug|Tablets|Oral tablets of similar appearance to active study drug
46095697|NCT04724044|Drug|Clarithromycin 500mg|Oral tablets of 500mg of clarithromycin
46095698|NCT04150848|Behavioral|Goal-Focused Emotion Regulation Therapy (GET)|Six sessions delivered individually over 8 weeks
46095699|NCT04150848|Behavioral|Individual Supportive Psychotherapy (ISP)|Six sessions delivered individually over 8 weeks
46008661|NCT02211885|Drug|14C-BIRB 796 BS|14C-radiolabeled BIRB 796 BS
46008662|NCT00195650|Biological|Adalimumab|Subcutaneous injection of 40 mg adalimumab every other week (eow) or monthly for up to 520 weeks (10 years)
46008663|NCT04563780|Device|99mTC pertechnetate thyroid scan|Thyroid scintigraphy was performed just before RIT. 20 min after intravenous injection 99mTc-pertechnetate, anterior images of the neck were acquired using a scintillation camera equipped with low-energy high resolution collimator. Energy discrimination was provided with a 20% window that was centered on the 140 keV peak of 99mTc .
46008664|NCT04560894|Drug|SCT-I10A|Participants receive SCT-I10A intravenously，200mg，d1，Q3w
46008665|NCT04560894|Drug|SCT510|Participants receive SCT510 intravenously，15mg/kg，d1，Q3w
46008666|NCT04560894|Drug|Sorafenib 200mg|Participants receive sorafenib orally，400mg bid
46008667|NCT04571957|Other|No Intervention|No Intervention
46095700|NCT02768519|Drug|OTS167IV|diluted to final concentration with cherry syrup
46095701|NCT02768519|Other|Cherry syrup|
46095702|NCT03530696|Drug|Palbociclib|Compare progression free survival of the combination arm (T-DM1 with palbociclib) to single agent T-DM1
46095703|NCT03530696|Drug|T-DM1|Compare progression free survival of the combination arm (T-DM1 with palbociclib) to single agent T-DM1
45460058|NCT03739138|Biological|Pembrolizumab|200 mg administered intravenously (IV) on Day 1 of each 21-day cycle beginning with Cycle 1 (Arm 2) or Cycle 2 (Arm 3).
45460059|NCT03472326|Drug|GS-9131|Tablet(s) administered orally once daily
45460060|NCT03472326|Drug|BIC|Tablet(s) administered orally once daily
45460061|NCT03472326|Drug|TAF|Tablet(s) administered orally once daily
45460062|NCT03472326|Drug|ARV regimen|ARV regimen may consist of the ARV agents containing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI)
45460063|NCT03472326|Drug|DRV|Tablet(s) administered orally once daily
46008668|NCT04560465|Drug|Tranexamic acid|intravenous perioperative tranexamic acid was added into infusion of normal saline for the cases while placebo of intravenous water for injection was added into normal saline perioperatively for control
46008669|NCT00195494|Drug|Etanercept|"Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 & 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2"
46008670|NCT00195494|Drug|Methotrexate|"Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 & 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2~Group 2b: Oral Methotrexate weekly for both Periods 1 and 2"
46008671|NCT00195494|Drug|Placebo|"Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2"
45460064|NCT03472326|Drug|RTV|Tablet(s) administered orally once daily
46008672|NCT02211144|Drug|BIBR 796 BS|
46008673|NCT02211144|Drug|Placebo|
46008674|NCT00194987|Drug|IVIG (Intravenous Immunoglobulin)|one gram per kg of IVIG per infusion given either once or twice
45460065|NCT03912649|Device|RemovAid|The RemovAid device is used for removal
45460066|NCT02737618|Device|"Trojan Chameleon Personal Lubricant"|silicone base with sensate
45460067|NCT03472014|Biological|IMVAMUNE®|IMVAMUNE® liquid -frozen, containing 1 x 10E8 TCID50 MVA-BN® per 0.5 mL dose
45460068|NCT03906487|Behavioral|Assessment measures MINI, PCL5 and BDI-II and definition of 5 SDM|"This group will have two visits:~the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms by completing assessment measures called MINI, PCL-5, BDI-II ;~the last to characterize the SDM by defining 5 personal memories"
45836785|NCT00383448|Drug|Alemtuzumab|0.3 mg/kg intravenously (IV) days -12 through -8
46008675|NCT00194987|Drug|prednisone|in arm with IVIG 1 gm/kg/wk will also receive prednisone 0.5 mg/kg/day
46095704|NCT04031664|Drug|Qianjin Capsule of Gynaecology|To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Qianjin Capsule of Gynaecology in reducing the use of antibiotics, reducing the risk of clinical use of drugs.
46095705|NCT02755181|Behavioral|Experimental|with functional imaging and behavioural measurements at baseline and 4 weeks
46095706|NCT00671814|Drug|TR-701|TR-701 will be given as single oral doses in Cohorts 1-5 and as once daily oral doses for 21 days in cohorts 6-8.
46095707|NCT00671814|Drug|linezolid|Linezolid will be given at 600 mg twice daily for 21 days in cohort 10.
46095708|NCT00671814|Drug|placebo|Placebo will be given once for cohorts 1-5, once daily for 21 days for cohorts 6-8, and twice daily for 21 days for cohort 10.
46095709|NCT04548869|Drug|CDX-0159|Administered intravenously
46095710|NCT03526562|Behavioral|Exercise|Exercise according to dose escalation
46095711|NCT01922440|Other|No intervention|This is a non-interventional study.
46095712|NCT02627430|Drug|Hsp90 Inhibitor AT13387|Given IV
46095713|NCT02627430|Other|Laboratory Biomarker Analysis|Correlative studies
46095714|NCT02627430|Other|Pharmacological Study|Correlative studies
46095715|NCT02627430|Drug|Talazoparib|Given PO
46008676|NCT04560855|Device|Connected devices measurements|The patient has to measure everyday several vital parameters like respiration and heart rate during the night with Withings Sleep, temperature with Withings Thermo, arterial pressure with Withings Tensiometer and physical activity with Withings smartwatch.
46008677|NCT00194792|Drug|exemestane|Given PO
46095716|NCT04348955|Behavioral|Women between 18 and 70 years old with an adjuvant breast cancer histologically characterized|"Quality of life and anxiety questionnaires before the course of chemotherapy (C1 and C4).~Touch-Massage during the course of chemotherapy (from C1 to C3) Anxiety questionnaire at the end of the course of chemotherapy (from C1 to C3)"
46095717|NCT02648360|Behavioral|Text Messaging|The content of the program will be delivered via 3 weekly text messages over a 4 month period of time.
46095718|NCT02627352|Procedure|Micropulse Transscleral Cyclophotocoagulation|In mTSCPC, a diode laser is used to damage tissue of the ciliary body, the tissue inside the eye that produces aqueous, the clear fluid in the eye that maintains intraocular pressure. This causes it to produce less aqueous.
46095719|NCT03945500|Device|Investigational Mobile Medical Software Application & IT Dashboard Application, FDA approved Bluetooth spirometer, FDA approved pulse oximeter|"Standardized Home Spirometry (SHS) Method consists of an Investigational Mobile Medical Application embedded into an Android Tablet, an FDA approved Bluetooth spirometer, an FDA approved pulse oximeter. HIPAA compliant data will be sent to an Investigational IT dashboard maintained at the Central Monitoring Institute Server.~Volunteers will train in-center or remotely & perform baseline testing with the SHS method along with a baseline laboratory-based spirometry test (if practicable).~Pre-Surveillance Phase: Daily home spirometry method testing for 4 to 10 weeks to enable normal range calibration.~Surveillance Phase: At least weekly home spirometry method testing for 2-10 months of participation. Volunteers will maintain a test log during study team directed SHS software pathway functionality testing."
46095720|NCT02759393|Drug|Dexlansoprazole|receiving 8-week PPI
46095721|NCT02759393|Drug|Lansoprazole|receiving 8-week PPI
46095722|NCT04150926|Other|Black currant|"The effect of black currant puree will be compared with black currant-quinoa product, quinoa base and with liquid with glucose, fructose and sucrose~Experimental: Black currant and quinoa product~Active Comparator: Quinoa base Meal study comparing the effect of black currant puree with liquid with glucose, fructose and sucrose, black currant and quinoa product and quinoa base"
46095723|NCT04150926|Other|Black currant-quinoa product|The effect of black currant puree will be compared with black currant-quinoa product
46095724|NCT04150926|Other|Quinoa base|The effect of black currant puree will be compared with quinoa base
46008678|NCT00194792|Drug|triptorelin pamoate|Given IM
46008679|NCT00194792|Drug|capecitabine|Given PO
46008680|NCT00194792|Drug|methotrexate|Given IV
46008681|NCT00194792|Drug|vinorelbine tartrate|Given IV
46008682|NCT00194792|Drug|paclitaxel|Given IV
46008683|NCT00194792|Procedure|therapeutic conventional surgery|Undergo lumpectomy or mastectomy
46008684|NCT00194792|Radiation|radiation therapy|Undergo radiation therapy
46008685|NCT00194792|Other|laboratory biomarker analysis|Correlative studies
46008686|NCT02486367|Drug|Clopidogrel|Standard ADP receptor blockade
46008687|NCT02486367|Drug|Ticagrelor|High potency ADP receptor blockade
46095725|NCT02759081|Device|cap-assisted water exchange|a transparent cap was mounted to the tip of colonoscopy when water exchange was performed.
46095726|NCT02759081|Procedure|water exchange|water was infused and suctioned at the same time during insertion of colonoscope
46095727|NCT02576548|Biological|MEDI4276|MEDI4276 is an investigational product
46095728|NCT02653976|Drug|SP-02L (darinaparsin for injection)|Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days
46095729|NCT02759003|Procedure|Nightime NIV initiation|In-hospital vs home
46095730|NCT02759237|Device|CoreValve System Family|"Bioprosthesis: Transcatheter Aortic Valve Implant (TAV - Heart Valve) -Different Models/Sizes of CoreValve/CoreValve Evolut R.~Delivery Catheter System: ACCUTRAK & EnVeo R - Used to facilitate the placement of the bioprosthesis within the annulus.~Loading System: Compression Loading System & EnVeo R Loading System - Used to load the TAV onto the delivery system"
46095731|NCT04565704|Device|Biopsy imaged by Optical imaging device.|
46095732|NCT00676104|Device|CoolSystems Discrete Cerebral Hypothermia System|The CoolSystems Discrete Cerebral Hypothermia System (DCHS) will be removed from the patients head after 48 hours.
46095733|NCT04325126|Other|Exposure factors|Exposure factors，such as diet，exercise，environment
46095734|NCT02758925|Drug|Rituximab|375mg/m2 IV day 1
46095735|NCT02758925|Drug|Bendamustine|90mg/m2 IV day 1-2
46095736|NCT02758925|Drug|Cytarabine|1000mg/m2 or 750mg/m2 at day 2 if patients aged more than 70 years or toxicity grade 3/4
46095737|NCT00676260|Drug|Pioglitazone|Pioglitazone 15 mg to 30 mg, tablets, orally, once daily for up to 10 weeks
46095738|NCT00676260|Drug|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 10 weeks
46095739|NCT00001258|Drug|Oxygen-15 Water|
46008688|NCT02211183|Procedure|Best Repair of torn Rotator Cuff|
46008689|NCT02211183|Device|InSpace™ system|
46008690|NCT00194675|Drug|Dutasteride|Dutasteride 0.5 mg orally daily
46008691|NCT00194675|Drug|Testosterone gel|Testosterone gel 7.5 g daily topical
46095740|NCT00652652|Drug|nesiritide, furosemide|
46095741|NCT02768441|Drug|Dexamphetamine|Participants will receive 60 mg Dexamphetamine SR daily for 5 consecutive days
46095742|NCT04152096|Drug|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
46095743|NCT04152096|Drug|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
46095744|NCT02644616|Drug|tolvaptan+torasemide|tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv
46008692|NCT00194675|Drug|Placebo dutasteride|placebo dutasteride orally daily
46008693|NCT04560387|Behavioral|Physician-lead complex program of weight-reducing interventions|A structured motivational and goal directed program will be used for weight reduction involving physicians, nutritionists, educators and physiotherapists. Initially, based on the input data provided by the patient an individual nutritional plan will be designed with the aim of reducing caloric intake by 10%. Low-intensity aerobic exercise for 30 min will be prescribed 3-times a week with the aim of increasing the frequency to 5-times a week and participants will be offered the possibility to participate in regular physiotherapist-lead group exercises. Patients will be required to maintain a diet and physical activity diary. Regular reviews will be scheduled every 3-6 months according to the actual weight loss.
46095745|NCT02644616|Drug|placebo+torasemide|placebo 15mg/d po(10 days) +torasemide 20mg/d iv
46095746|NCT02759159|Procedure|true acupuncture|"acupuncture at the four-gateacupoints, three times per week and last for 6 months"
46095747|NCT02759159|Procedure|sham acupuncture|"acupuncture at the places 1cm from the true four-gate acupoints,three times per week and last for 6 months"
46095748|NCT02648048|Drug|Pirfenidone|Pirfenidone will be administered as per the dosage schedule mentioned in arm description.
46095749|NCT02648048|Drug|Vismodegib|Vismodegib will be administered as per the dosage schedule mentioned in arm description.
45460069|NCT03906487|Behavioral|Assessment measures MINI and definition of 5 SDM|"This group will have two visits:~the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms by completing MINI questionary;~the last to characterize the SDM by and defining 5 personal memories"
46095750|NCT02578654|Other|Strategies to improve HIV care engagement|"Additional HIV care team daily inpatient round and three telephone calls to remind the upcoming clinic appointment. These interventions are specifically added on routine care during the post-intervention period. The routine care does not include the additional round and the three telephone calls and is assessed during the pre-intervention period."
46095751|NCT00671892|Biological|Lipopolysaccharide endotoxin|"Delivered in nebulized form expressed in activity units(endotoxin units -EU).~Subjects receive each dose 30 min after completing the previous dose, dose duration is approximately 10 minutes:~Challenge One first saline then 5000 EU 10,000 EU 20,000 EU~Challenge 1 and 2 must be at least 2 weeks apart.~Challenge 2 Saline 40,000 EU 80,000 EU"
46095752|NCT03474679|Drug|Ibrutinib|Participants will receive 420 mg (3 * 140 mg capsules) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.
46095753|NCT00676416|Drug|2,6-Diisopropylphenol|Propofol general anesthesia was performed in patients with asthma (1) and without asthma (2)
45460070|NCT03720132|Procedure|Extensive flushing of the port catheter|The port catheter will be flushed extensively with sodium chloride 0.9% before blood sampling. Blood sampling will occur through the central catheter and peripherally simultaneously.
45678591|NCT01924364|Device|Tissue Genesis Cell Isolation System™ (TGI CIS)|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101, NCT01345591) will be used for comparison.
46008694|NCT04560387|Procedure|Bariatric surgery - sleeve gastrectomy|Bariatric surgery will be performed based on actual medical indication and independently of patient's participation in the study. Sleeve gastrectomy was selected as the currently most frequent restrictive type of bariatric surgery with a proven efficacy on weight reduction, metabolic status and low-grade inflammation
46037827|NCT04306302|Biological|ExPEC10V|Participants will receive a single IM injection of ExPEC10V.
46095754|NCT04225013|Diagnostic Test|Early kidney damage biomarkers|In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured
46095755|NCT04225013|Diagnostic Test|Predisposition to kidney injury biomarkers|In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured
46095756|NCT02653430|Procedure|Sleeve gastrectomy|"After complete exams such as EKG，UCG，spirometry and other basic exams,estimate the condition of patient whether he(she) can tolerate a surgical operation.Then we operate theSleeve gastrectomy laparoscopically by a group of experienced surgeons."
46095757|NCT04153110|Device|Anodal cerebellar and cathodal spinal tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
46008695|NCT04560348|Other|adventure-based cognitive behavioral intervention|The adventure-based cognitive behavioral intervention is a combination of cognitive behavioral therapy and adventure training. The intervention program is delivered in a 39-hour general education course in a public university in Hong Kong. The program includes 6 lectures, 5 workshops, 5 adventure games and an adventure day camp. Students are divided into two groups in workshop to practise CBT skills to deal with their own issues.
46095758|NCT04153110|Device|Sham cerebellar and sham spinal tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
46095759|NCT00651326|Drug|bicalutamide|
46095760|NCT00651326|Drug|buserelin|
46095761|NCT00651326|Drug|flutamide|
46095762|NCT00651326|Drug|goserelin|
46095763|NCT00651326|Drug|leuprolide acetate|
46008696|NCT00194012|Drug|Aripiprazole|Addressed in arm description.
46008697|NCT00194012|Drug|Placebo|Addressed in arm description.
46008698|NCT04563351|Other|local anaesthetic techniques|The patients were anesthetized with two different local anaesthetic techniques.
46095764|NCT00651326|Procedure|neoadjuvant therapy|
46095765|NCT00651326|Procedure|quality-of-life assessment|
46095766|NCT00651326|Radiation|radiation therapy|"46 Gy in 23 fractions over < 5 weeks.~Boost:~24-28 Gy in 12-14 fractions over < 3 weeks"
46095767|NCT00651326|Drug|Docetaxel|
46095768|NCT02754791|Device|Steripath|A device that diverts the first 2 ml of blood drawn in order to reduce contamination
46095769|NCT02754791|Device|Soluprep|Wipes containing alcohol (70%) and chlorhexidine (2%) to achieve skin sterilization
46095770|NCT04150536|Drug|Lidocaine topical system 1.8%|
45678592|NCT01924364|Procedure|Standard of care fat grafting|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time.
46008699|NCT00192647|Drug|PEG-IFN alfa-2a|PEG-IFN alfa-2a will be administered once weekly for 48 weeks, at doses specified in respective arms.
46008700|NCT00192647|Drug|Ribavirin|Ribavirin 1000 or 1200 mg orally daily in divided doses, with the dose determined based on body weight, for 48 weeks.
46008701|NCT04563312|Procedure|Exercise|Nine different clubs and sport centers were screened and 18- to 35-year-old individuals regularly engaged in MT or BB for the last 6 months were invited to join the study.
46008702|NCT04560816|Drug|ALXN1840|ALXN1840 (120 milligrams) will be administered orally (supratherapeutic dose).
46008703|NCT04560816|Drug|Placebo|Placebo will be administered orally.
46008704|NCT04560816|Drug|Moxifloxacin|Moxifloxacin (400 milligrams) will be administered orally.
46008705|NCT00192296|Biological|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
45460071|NCT01148485|Other|Nasal, throat, inguinal and skin lesions swab samples will be performed|Nasal, throat, inguinal and skin lesions swab samples will be performed
45678593|NCT01987505|Drug|Rituximab|1400 mg will be injected subcutaneously (SC).
45678594|NCT01923896|Behavioral|Behavioral Intervention|Behavioral intervention targeting severe feeding disorders involves the combination of escape extinction and antecedent manipulation of food presentation to lessen the aversive quality of the meal. This allows treatment to address the consequences maintaining food refusal in the least restrictive environment while ameliorating possible side effects associated with extinction procedures.
45678595|NCT01923896|Drug|d-cycloserine (DCS)|
46008706|NCT00192296|Biological|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, IV dose
46008707|NCT00192296|Biological|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, IV dose
46008708|NCT00192296|Biological|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, IV dose
46008709|NCT04563429|Dietary Supplement|Oral Vitamin A|Oral administration of 5000 EU of Vitamin A during first 28 days of life
46095771|NCT05167123|Drug|Light cured tri-calcium silicate base material|TheraCal (LC) (BISCO Inc., Schamburg, IL, USA) was introduced in (2011), are available commercially as flowable cement applicable via syringe
46095772|NCT02644538|Drug|PegIFN alfa-2a|chronic hepatitis B patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir) arrived HBV DNA <1000copies/ml, and HBsAg<3000IU/ml, then change the treatment to original nucleot(s)ides add on PegIFN alfa-2a, the combined treatment is for 48 weeks, and follow up for 24 weeks
46095773|NCT02754635|Other|Induction of labour|Induction of labour
46095774|NCT02754635|Other|Expectant management|Expectant management
46095775|NCT04150302|Other|Exploratory interviews|Exploratory interviews to generate an interview guide
46095776|NCT04150302|Other|Semi-directive interviews|Semi-directive interviews to collect qualitative data that will be used for questionnaire item generation
46095777|NCT04150302|Other|Delphi Process|Cotation of newly developed items pertinence on a 4 points likert scale.
46095778|NCT04150302|Other|Think aloud interviews|Debriefing session for the newly developed items: final possibility to adjust the tool before validating the psychometric proprieties of the questionnaire.
46095779|NCT04150302|Other|Psychometric validation|Psychometric properties study
46095780|NCT02576314|Drug|sofosbuvir and daclatasvir|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60 mg tablet administered orally once daily.
46095781|NCT02576314|Drug|ledipasvir/sofosbuvir|"Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally.~once daily;"
46095782|NCT00650234|Drug|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fasting
46095783|NCT00650234|Drug|Glucophage® XR Tablets 500 mg|500mg, single dose fasting
46008710|NCT00192023|Drug|atomoxetine 0.5 mg/kg/day|atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO)
46095784|NCT00680940|Drug|Paclitaxel & Cisplatin|Chemotherapeutic agent
46095785|NCT00680940|Biological|Mycobacterium w.|Immunomodulator
46095786|NCT02755025|Other|Automated SOFA scoring calculator|Automated SOFA scoring will be activated within an existing electronic patient care dashboard for ICU patients.
46095787|NCT03472885|Drug|Danicopan|Participants received a daily oral dose of danicopan TID during the treatment period.
46095788|NCT03472885|Drug|Eculizumab|Participants received intravenous eculizumab administered at the participant's usual dose and schedule.
46095789|NCT02576392|Behavioral|Intervention|Intervention consisted of a mailing 2 weeks prior to surgery, another 2 weeks post surgery, and a pharmacist intervention if a refill of opioid medication was requested within 90 days of surgery.
46095790|NCT02644304|Drug|Clomiphene citrate|50 mg tablet twice daily from the second day of menses to the sixth day
46008711|NCT00192023|Drug|placebo|
46008712|NCT00192023|Drug|atomoxetine 1.2 mg/kg/day|atomoxetine 1.2 mg/kg/day QD, PO
46008713|NCT00192023|Drug|atomoxetine 1.2-1.4 mg/kg/day|atomoxetine 1.2 - 1.4 mg/kg/day QD, PO
46008714|NCT04563624|Drug|composite blocks|cad cam composite blocks
46008715|NCT04563624|Drug|ceramic cad cam blocks|ceramic cad cam blocks
46095791|NCT02644304|Drug|Cabergoline|Cabergoline 0.25 mg (half tablet) every 3 days (4 doses).
46095792|NCT02644304|Other|Placebo|placebo(half tablet) every 3 days (4 doses).
46095793|NCT00681018|Other|Liquid human milk fortifier|Liquid human milk fortifier added to human milk
45678596|NCT01923896|Drug|Placebo|lactose powder
46095794|NCT00681018|Other|Powder human milk fortifier|Powder human milk fortifier added to human milk
46095795|NCT02648126|Procedure|Pure Red Cell Aplasia diagnostic confirmation|"Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation by collecting 20 mL of blood in dialysis units.~The samples will be processed, aliquoted and transported to Bio-Manguinhos, where depart periodically (according to the volume of samples) to the reference laboratory Sce Immunologie et d'Hématologie biologiques Hôpital Saint Antoine, where the dosage of antibody will be held anti epoetin alfa"
46095796|NCT04316611|Drug|Potassium chloride|Direct intravenous injection (IVD) 20 mmol potassium chloride
46008716|NCT00191984|Drug|pemetrexed|400 mg/m^2, intravenous (IV), every 14 days x 12 cycles
46008717|NCT00191984|Drug|irinotecan|180 mg/m^2, intravenous (IV), every 14 days x 12 cycles
46008718|NCT04560426|Device|Intraoperative parathyroid gland auxiliary recognition system|The enrolled patients are grouped according to whether or not to use the intraoperative parathyroid auxiliary recognition system.
45678597|NCT04671797|Behavioral|Early dinner|Dinner at DLMO-3, sleep at DLMO+2
45678598|NCT04671797|Behavioral|Late Dinner|Dinner at DLMO+1, sleep at DLMO+2
45678599|NCT04671797|Behavioral|Late Dinner + Late Sleep|Dinner at DLMO+1, sleep at DLMO+6
45678600|NCT02004353|Device|Cochlear® Hearing Implants|Market approved hearing implants including: Nucleus Cochlear implants, Nucleus Auditory Brainstem Implants, Cochlear Baha implants, Cochlear Acoustic Implants
46008719|NCT04560270|Diagnostic Test|Blood samples|Blood samples to determine ctDNA levels during chemotherapy
46008720|NCT00191906|Drug|Atomoxetine Hydrochloride|Atomoxetine, 1.2 mg/kg/day, by mouth (PO)
46008721|NCT00191906|Drug|placebo|Placebo, every day (QD), by mouth (PO)
46008722|NCT04562922|Dietary Supplement|Lifemel|
46008723|NCT00191789|Drug|gemcitabine|1200 mg/m^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8)
46008724|NCT00191789|Drug|doxorubicin|60 mg/m^2, IV, every 21 days x 4 cycles (1-4)
46008725|NCT00191789|Drug|cisplatin|70 mg/m^2, IV, every 21 days x 4 cycles (5-8)
46008726|NCT00191789|Procedure|surgery|Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.
46008727|NCT04562883|Other|The way of Cumulus-oocyte complexes (COC) culture|Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM standard conditions: 24 hrs capacitation followed by 30h maturation. The first group will be culture in pools (group culture). The second group will be culture individually in 20µl droplets.
46008728|NCT00191282|Drug|Insulin lispro|Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study
46037828|NCT04306302|Biological|Placebo|Participants will receive single IM injection of matching placebo.
46095797|NCT04221113|Procedure|physiotherapy|Two protocols have been described for physiotherapy of post extensor tendon injuries. one is immobilization till 3 weeks and than gradual increase in active motion of hand. The second protocol is early active motion. this would be done under senior physiotherapist.
46008729|NCT00191282|Drug|Human insulin isophane suspension (NPH)|Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values >8.0%
45678601|NCT01938625|Drug|Simeprevir|Participants will receive 150 milligram capsule of simeprevir orally (by mouth) once daily with food for 24 weeks. In Part 1, if simeprevir pre-dose plasma concentration is greater than 7,300 nanogram per milliliter (ng/mL), participants will receive simeprevir 150 milligram capsule orally every other day to complete 24 weeks of treatment.
46008730|NCT00191282|Drug|Insulin glargine|Insulin glargine injected subcutaneous (SC) once daily in the evening until patient completes study.
45836786|NCT00383448|Drug|mycophenylate mofetil|Day -3 through Day 30: 1 gram three times daily (total daily dose 3 grams/day) if the recipient is >50 kg, or 15 mg/kg three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously. Consider dose modification if renal impairment (GFR<25 mL/minute corrected)
45836787|NCT00383448|Device|Cyclosporine A|"Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose intravenously (IV); if the recipient body weight is <40 kg, dosing will be 3 times daily, and if > 40 kg twice daily. An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2.5 x the current IV dose (maximum 12.5 mg/kg/day as initial oral dose).~CsA taper begins at day +100."
46008731|NCT00191282|Drug|Human insulin isophane suspension|Patient adjusted dose, twice daily, injected subcutaneous (SC) before morning and evening meals until patient completes study.
46095798|NCT00681174|Drug|Morphine|0.15 mg/kg i.v. bolus, 30 minutes before the expected end of anesthesia
46095799|NCT00681174|Drug|oxycodone|20 mg p.o. 1 h before the start of anesthesia
46095800|NCT00681174|Procedure|Paravertebral block|"Three injections of 0.5% ropivacaine, 5 ml each~Injections at the T5, T6 and T7 levels~A 22G spinal needle will be used to contact the ipsilateral transverse process; the needle will be walked off the process and the injection will be made 1 cm deeper."
46095801|NCT00681174|Drug|Propofol|"Plasma concentration target-controlled infusion based on bispectral index values~Acceptable range of concentrations: 2-4 µg/mL~Target bispectral index values: 40-60~Infusion starts at 4 µg/ml target, after pre-oxygenation (i.e., start of anesthesia)"
46095802|NCT00681174|Drug|Remifentanil|"50 µg/mL i.v. solution infused at 0.05-0.2 µg/kg/min~Infusion starts 7 min before propofol infusion (i.e., start of anesthesia)~Infusion rate adjusted to maintain mean arterial blood pressure within ±20% of baseline values.~Infusion stopped after end of surgery and after patients are brought back to the supine position (i.e., end of anesthesia)"
46095803|NCT00681174|Drug|Paracetamol|1 g i.v. bolus 30 min before the end of anesthesia; 1 g i.v. bolus q8h thereafter.
46095804|NCT00681174|Drug|Morphine|"Patient-controlled intravenous infusion pump (IV-PCA).~50 mg morphine in 50 ml saline solution (1 mg/ml)~Incremental dose: 1 mg~Lock-out time: 8 min~Limit: 40 mg in 4 h~Background infusion: none"
46095805|NCT02653352|Behavioral|Lifestyle modification|The centre of the campaign was to encourage the exchange of sugar-sweetened beverages for water. Ten one-hour sessions of activities facilitated by four trained research assistants were assigned for each class. The activities required 20-30 min and teachers were encouraged to reiterate the message during their lesson. Classroom quizzes and games using water v. sugar-sweetened carbonated beverages as the theme, as well as song and drawing competitions, were promoted. In addition, a musician using a tambourine helped each class to collectively develop songs related to drinking water and reducing the consumption of sugar-sweetened carbonated beverages. This musical activity was conducted during three one-hour sessions.
46008732|NCT00191282|Drug|Human insulin 30/70|Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values >8.0%.
45836788|NCT00383448|Drug|Hydroxyurea|hydroxyurea (HU) beginning day -28 and continuing through alemtuzumab administration
46008733|NCT04563156|Diagnostic Test|Lung Function Test|Lung Function Test at 1, 4, 6 and 12 months after discharge. Computerized tomography scan at 6 months after discharge. Cardiopulmonary Exercise Testing at 6 months after discharge
46095806|NCT02575066|Radiation|external beam radiotherapy|external beam radiotherapy 25 x 2 Gy / 18 x 2 Gy
46008734|NCT04559958|Diagnostic Test|tongue image|capture tongue images by Automatic Tongue Diagnosis System
46095807|NCT02575066|Drug|pazopanib|pazopanib QD 800 mg
46095808|NCT02647970|Behavioral|PUFA-Cys/Met diet|Provision of food and supplements that are rich in polyunsaturated fatty acids (PUFA, n-3 and n-6) and low in the amino acids cysteine (Cys) and methionine (Met).
46095809|NCT02647970|Behavioral|SFA+Cys/Met diet|Provision of food and supplements that are rich in saturated fatty acids (SFA) and the amino acids cysteine (Cys) and methionine (Met).
46095810|NCT02758769|Biological|ORENCIA Subcutaneous Injection|
45678602|NCT01938625|Drug|Daclatasvir|Participants will receive 60 milligram tablet of daclatasvir orally once daily for 24 weeks.
45678603|NCT01938625|Drug|Ribavirin|Participants will receive 5 or 6 tablets of 200 milligram of ribavirin orally twice a day with food for 24 weeks.
45678604|NCT01938625|Drug|Cyclosporine|Participants will receive cyclosporine as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Cyclosporine will be administered as per the manufacturer's prescribing information for 24 weeks.
45836789|NCT00383760|Drug|eribulin mesylate|Given IV
45836790|NCT00384774|Drug|Lasmiditan|Administered as intravenous infusion
45836791|NCT00384774|Drug|Placebo|Administered as intravenous infusion
45836792|NCT00410280|Biological|IMA-638 is a biologic|
46095811|NCT04272931|Procedure|Portal and Hepatic Vein Embolization|Procedure/Surgery: Combined portal vein embolization and hepatic vein embolization (PVE/HVE) • All techniques of PVE allowed (ipsi-lateral, contra-lateral, trans-splenic, all embolization agents except for ethanol alone) • All modifications of HVE allowed (venous occlusion umbrellas; trans-jugular, trans-hepatic, no use of vein glue to avoid lung embolization; staged approach allowed, but first PVE, then HVE and within 48 hours)
46095812|NCT04150146|Drug|Rebamipide SR 150mg after high-fat meal|Test Drug
46008735|NCT04559997|Other|Exercise+FU|6 years intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
46095813|NCT04150146|Drug|Rebamipide SR 150mg under fasting condition|Reference Drug
46095814|NCT00652730|Drug|Buspirone HCl|Tablets, 30 mg, single-dose, fasting conditions
46095815|NCT00652730|Drug|Buspirone HCl|Tablets, 30 mg, single-dose, fed conditions
46008736|NCT04559997|Other|Active Comparator group Exercise|After 3 weeks of intensive therapy, we withdrew treatment and monitored their condition for 6 years and received only hospital base treatment
46008737|NCT00191165|Drug|Somatropin|Doubled dosage with respect to the pre-enrollment (in-label) dosage
46008738|NCT00191165|Drug|Somatropin|In-label dosage
46008739|NCT04560231|Drug|Remdesivir|200 mg I/v Remdesivir will be given to moderate disease patients of COVID-19. It will be loading dose then 100 mg I/V dose will be given for 5 days. Customized decision for Remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of Ventilation and dose will be extended up to 10 days according to clinical condition of the patients.
46008740|NCT04560153|Other|karate kata|sessions of karate kata every week during 4 months
46008741|NCT00190775|Drug|Atomoxetine Hydrochloride|Atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
45836793|NCT00410826|Drug|erlotinib hydrochloride|Given orally
46008742|NCT00190775|Drug|Placebo|Placebo is administered QD, orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
46008743|NCT02211924|Drug|BI 44847|
46008744|NCT02211924|Drug|Placebo|
46008745|NCT00199901|Biological|NY-ESO-1 ISCOMATRIX®|"100 μg of NY-ESO-1 protein formulated with 120 μg of ISCOMATRIX® adjuvant.~Each patient will receive four intramuscular injections of NY-ESO-1 ISCOMATRIX® vaccine. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
46008746|NCT00199901|Biological|ISCOMATRIX® adjuvant|"120 μg of ISCOMATRIX® adjuvant~Each patient will receive four intramuscular injections of ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
46008747|NCT00198263|Combination Product|Medpulser Electroporation with Bleomycin|The MedPulser device will be used in conjunction with injection of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
46008748|NCT04562844|Other|sociale cognition|several social cognition test
46095816|NCT00652730|Drug|Buspar|Tablets, 30 mg, single-dose, fed conditions
46095817|NCT02758535|Device|coaxial renal biopsy|In this method, a larger introducing needle is used for the puncture. The introducing needle is advanced just to the outer cortex of the kidney, and the needle angle is adjusted so that the needle pathway became mostly in the renal cortex, then the biopsy needle is inserted throughout the introducing needle and at least 4 cores are obtained. In this technique, the skin surface is punctured only once during the procedure.
46095818|NCT02758535|Device|noncoaxial renal biopsy|In this method, introducing needle is not used. Biopsy needle punctures the skin surface and the needle is advanced to about 10-15 mm into the renal cortex, and tissue sampling is done. After each sampling, the needle is removed and then for the next biopsy, the whole procedure is repeated until four cores being taken.
45836794|NCT00410826|Drug|cisplatin|Given IV
45836795|NCT00410826|Radiation|3-dimensional conformal radiation therapy|35 fractions
46008749|NCT00198107|Drug|Aripiprazole|Participants will receive 8 weeks of initial treatment with aripiprazole. If responsive to treatment, participants may be assigned to an additional 16 weeks of aripiprazole and then an additional 8 more weeks of aripiprazole with D-cycloserine. Dosing schedule for participants less than 50 kg maximum dose will be 10 mg per day. Dosing schedule for participants greater than 50 kg maximum dose will be 15 mg.
46008750|NCT00198107|Drug|Placebo|Participants assigned to placebo will take a placebo pill for the initial 8 weeks of treatment.
46008751|NCT00198107|Drug|D-cycloserine|D-cycloserine will be dosed in the range of 25 to 200 mg daily for the final 8 weeks of treatment.
45678605|NCT01938625|Drug|Tacrolimus|Participants will receive tacrolimus as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Tacrolimus will be administered as per the manufacturer's prescribing information for 24 weeks.
45683814|NCT05249764|Other|Supervised Home Based Exercise Training|Exercise program was prepared based on WHO, American College of Sports Medicine (ACSM), Geriatrics Physiotherapists Association and Otago exercise program for the exercise group. The older adults are given individual supervised exercise training in their own homes for eight weeks, 3 days a week and 45 minutes a day, by a physiotherapist according to social distance rules. This exercise training consists of a program that includes strengthening, flexibility, aerobic and balance exercises. Each exercise is started with eight repetitions and each week will be increased by two repetitions. In case of fatigue, a rest is given. Brochures are also be prepared for the exercises. Before each session, individuals performed warm-up exercises for 5 minutes. At the end of the session, individuals performed cooling exercises.
46008752|NCT04563000|Drug|Vitamin C|Ascorbic acid 1,5 g intravenously every 12-hours for 4 consecutive days
46008753|NCT04563000|Drug|Placebo|0,9 % solution of sodium chloride 100 ml intravenously every 12-hours for 4 consecutive days
46008754|NCT04562961|Other|Schizophrenia caregivers qualitative interview|"The semi-structured qualitative interview will be carried out in a focus group or individually for a period of 1 hour. Focus groups are a group interview technique, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on a limited number of pre-defined questions. In this study we foresee groups of 4 to 5 subjects. Focus groups will be privileged because they allow a better elaboration of the participants and therefore a better collection of data. If the focus group is not possible, the visit will be done individually. This interview will be framework-guided and recorded in their entirety and anonymously using a dictaphone and then transcribed the objective verbatim on a computer using word processing software. These transcriptions will be called the verbatims. The source data recorded using a dictaphone will be stored in secure, locked cabinets located within the investigation center."
46008755|NCT00179660|Drug|Lenalidomide|Capsules for oral administration.
46008756|NCT04560114|Drug|Essential oils|"The patient will be invited to inhale the essential oils via the stick:~4 times a day before each meal and snack.~if necessary when nausea appears, as many times as he deems necessary."
46008757|NCT00178256|Drug|Paclitaxel|On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.
46008758|NCT00178256|Procedure|Radiation Therapy|Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible
46008759|NCT02211222|Drug|Lenvatinib|Lenvatinib at starting doses of 24-mg, 20-mg, or 14-mg will be administered as a combination of 10-mg capsules and 4-mg capsules to be taken once a day (QD) (recommended to be taken the same time each day). Subjects will receive one of three starting doses of lenvatinib, 24-mg/day, 20-mg/day, or 14-mg/day. Dose reductions occur in succession based on the previous dose level (24, 20, 14, and 10 mg/day). Any dose reduction below 10 mg/day must be discussed with the sponsor. Once the dose has been reduced, it cannot be increased at a later date.
46008760|NCT04560192|Behavioral|Mindfulness based Emotion regulation therapy (MBERT) - Treatment as usual (TAU)|"In each of 8 sessions (allocated over 4 weeks) the patient brings an (actual) topic that induces rumination. After identifying the underlying affect, the patients are instructed (1) to concentrate on it, (2) to accept and tolerate it (considering the personal situation and experiences), (3) to give it a new interpretation so the patient can look at it with a more generous view, and (4) to dissociate from it, so the patient can perceive it as one of many affects and as one that hasn't the power to influence one's thoughts and actions that much (as it does through rumination). These steps are gradually instructed and trained throughout 20 trials (à 40 seconds) in each session. After each trial there is room to talk about the trial, possible barriers and helpful strategies to overcome those. Between-sessions the patients are encouraged to train the strategies in their daily life and do some homework like a protocol of ruminative thoughts and meditation.~Waiting period with TAU."
46037829|NCT05338606|Drug|Bimatoprost Sustained Release Implant|Intraocular Implant
46037830|NCT01092702|Drug|Varenicline|During the first week varenicline will be started at a dose of 0.5 mg once daily for days 1-3; then 0.5 mg twice daily for days 4-7. Target quit date is set at day 8. Varenicline is then continued for weeks 2-12 at a dose of 1 mg twice daily.
46037831|NCT01092546|Drug|[18F]Flutemetamol|All subjects will receive an IV dose of [18F]flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of [18F]flutemetamol will be 185 MBq.
45836796|NCT00410826|Radiation|intensity-modulated radiation therapy|35 fractions
46037832|NCT02779348|Drug|BIA 3-202|Nebicapone tablets 200 mg
46037833|NCT02779348|Drug|warfarin|Varfine® 5 mg (warfarin 5 mg) tablets
46037834|NCT02877264|Drug|vapendavir 132 mg capsule|
46037835|NCT02877264|Drug|vapendavir 264 mg tablet|
46037836|NCT02877264|Drug|vapendavir 24 mg/mL oral suspension|
46008761|NCT04560192|Other|Treatment as usual (TAU) - Mindfulness based Emotion regulation therapy (MBERT)|"Waiting period with TAU.~In each of 8 sessions (allocated over 4 weeks) the patient brings an (actual) topic that induces rumination. After identifying the underlying affect, the patients are instructed (1) to concentrate on it, (2) to accept and tolerate it (considering the personal situation and experiences), (3) to give it a new interpretation so the patient can look at it with a more generous view, and (4) to dissociate from it, so the patient can perceive it as one of many affects and as one that hasn't the power to influence one's thoughts and actions that much (as it does through rumination). These steps are gradually instructed and trained throughout 20 trials (à 40 seconds) in each session. After each trial there is room to talk about the trial, possible barriers and helpful strategies to overcome those. Between-sessions the patients are encouraged to train the strategies in their daily life and do some homework like a protocol of ruminative thoughts and meditation."
46095819|NCT00681252|Biological|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
46008762|NCT00177164|Drug|Injectable Risperidone (Consta) or oral antipsychotic|"Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks~Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder"
46095820|NCT02653586|Other|"program In Favor of Resilience Self"|A prevention program aiming at improve self-resilience ,self-esteem and body image, contains nine interactive activities, based on a cognitive dissonance method.
46095821|NCT04271683|Procedure|Pressure controlled ventilation with PEEP|The intervention consists of starting ventilation after apnoea during induction of general anesthesia with pressure controlled ventilation with PEEP instead of manually without PEEP.
46095822|NCT04271683|Procedure|Manual ventilation without PEEP|The intervention consists of starting ventilation after apnoea during induction of general anesthesia manually instead of with pressure controlled ventilation with PEEP.
46095823|NCT04224467|Other|Intravenous ICG and Real-Time Near-infrared Imaging|Patients will be intravenously injected ICG (Yichuang Pharmaceutical Limited Liability Company, Dandong, China) at a dose of 2-5 mg per kg of body weight before surgery or 0.25-0.5 mg per kg of body weight during surgery. Then real-time near-infrared imaging will be conducted during surgery.
46095824|NCT02644148|Procedure|Conventional Roux-en-Y Gastrojejunostomy|Conventional Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
46095825|NCT02644148|Procedure|Uncut Roux-en-Y Gastrojejunostomy|Uncut Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
46095826|NCT00681330|Biological|URC10, TTK, KOC1|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg) and TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
46095827|NCT04070872|Procedure|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
46095828|NCT04070872|Procedure|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
46095829|NCT03437161|Radiation|Radiation Therapy (RT)|Undergo RT either in the supine position with DIBH or in the prone position.
46095830|NCT02768051|Procedure|AF Ablation|
46095831|NCT02627040|Device|InterTan Intertrochanteric Nail|Cephalomedullary fixation of intertrochanteric fracture with an InterTan Intertrochanteric Nail
46095832|NCT02627040|Device|Gamma 3 Intertrochanteric Nail|Cephalomedullary fixation of intertrochanteric fracture with an Gamma 3 Intertrochanteric Nail
46095833|NCT00652808|Drug|valdecoxib|valdecoxib 10 mg tablet by mouth once daily for 6 weeks
46095834|NCT00652808|Drug|naproxen|naproxen 500 mg capsule by mouth twice daily for 6 weeks
45678606|NCT04416815|Other|Integrating Health promotion with and for Older People - eHealth|The intervention will be delivered for 6 months on top of usual care. It will be provided by HCPs. If needed one home visit to install the digital platform will be conducted. A HCP will introduce how to use the digital platform and create a personal account. The intervention starts with a person-centred phone-call where a health plan is co-created and potential team members to support this are identified and invited. The health plan includes the older persons' goals, internal and external resources, and need of support from health and/or social-services. This plan will be the point of departure for the forthcoming dialogue. A digital platform will open up for extended and safe communication and visualize the health planning between the older person and team-members in different settings. The older person and the HCP and involved team members on the digital platform will regularly evaluate the health plan and commonly agreed goals.
45678607|NCT01975675|Drug|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
45678608|NCT01975675|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, > 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
45678609|NCT01975285|Drug|Dexamethasone|0.5% Bupivacaine with 1:200,000 epinephrine + Dexamethasone 4mg per 20cc
46095835|NCT04073212|Other|Dry Needling|Dry needling directly to the long head of the biceps tendon. The DN will be performed with disposable stainless-steel needles (.3 X 40mm; Seirin; Weymouth, MA) inserted into the skin over the most painful and/or thickened areas of the tendon, confirmed with palpation. Prior to insertion of the needle the overlying skin will be cleaned with alcohol. The needle will be inserted into the tendon. The technique will be a fast-in and fast-out technique described by Chiavaras et al.26 for 20-30 repetitions per session in up to 3 areas. An eccentric-concentric exercise program of the biceps muscle/tendon will follow each DN session and will be performed daily for the course of treatment and will be performed as described by McDevitt et al.
46095836|NCT04073212|Other|Heavy Slow Load Exercise|Eccentric exercise protocols have been found to be an effective treatment for tendinopathies of the upper and lower extremities and recent evidence supports heavy slow resistance training (including the addition of a concentric phase) as having better outcomes over eccentric exercise alone. Patients will use 1-5 pound weights to perform slow and controlled concentric and eccentric exercise to biceps muscle.
46095837|NCT04073212|Other|Rotator cuff and scapular stabilization exercise program|Both groups will be treated with a stretching and strengthening program. The rotator cuff and scapular stabilization strengthening and flexibility program used in this study has 3 phases and patients progress in phases based on their ability to perform a number of exercises using theraband or body weight resistance.
46095838|NCT04073212|Other|Soft tissue mobilization|Both groups will receive soft tissue mobilization to the anterior shoulder.
46095839|NCT00635531|Other|placebo|Placebo dosing same as alprazolam, except a placebo equivalent was substituted for alprazolam
46095840|NCT00635531|Drug|alprazolam XR|Oral treatment started at a daily dose of 1 mg tablets for the first 7 days; thereafter the daily dosage was titrated at a maximum rate of 1 mg every 7 days up to a maximum dosage of 6 mg for lack of response, and in the absence of dose-limiting adverse events; no further increases in daily dose were permitted after Day 36; dosage reductions were permitted if required for tolerability; subjects who were not eligible for entry into the 18-week continuation study, or who were eligible but elected not to participate, were tapered off study drug at a rate of 1 mg every 7 days for up to a 6-week taper period.
46008763|NCT04559841|Other|bone substitute; NanoBone®|surgical treatment of peri-implantitis using a regenerative surgical protocol utilizing NanoBone (NB) synthetic bone graft with or without simvastatin.
46008764|NCT02487251|Behavioral|Mealtime Supports|Participants will receive or engage in a variety of supports for family mealtimes in Phase 1 (e.g., receipt of prepared meals, receipt of cookware, informational supports, classes). In Phase 2 of the study participants received two prepared meals per week for 12 weeks and received a comprehensive set of cookware at the beginning of the intervention period.
46095841|NCT05137795|Drug|ZYESAMI™ (aviptadil acetate)|Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer
46095842|NCT05137795|Drug|Placebo|Normal Saline Inhalation
46095843|NCT05137795|Device|Nebulized administration of ZYESAMI™ or Placebo|Use of 510(k) cleared mesh nebulizer to deliver investigational product
46095844|NCT02535156|Drug|Risperidone|1 mg Risperidone
46095845|NCT02535156|Drug|Placebo|Lactose Placebo
46095846|NCT03855800|Diagnostic Test|Blood, stool, pancreatic juice and cyst fluid collection|Blood and stool will be collected at baseline from all study participants. Those in the Immediate Surgery group may undergo endoscopic pancreatic juice collection before surgery, either at the time of a clinically indicated endoscopic ultrasound (EUS) exam or during an optional pre-operative research endoscopy. Pancreatic cyst fluid will also be obtained from all participants in the Immediate Surgery group, either at the time of surgery, or during a clinically indicated preoperative EUS FNA procedure, or both. Pancreatic juice and cyst fluid will be collected opportunistically from participants in the Clinical Follow-up group who undergo a clinically indicated EUS, EUS FNA, or endoscopy exam.
46095847|NCT03855800|Procedure|Pancreatic Surgery|Surgical resection of pancreatic cyst
45678610|NCT01975285|Drug|Saline|0.5% Bupivacaine with 1:200,000epinephrine + Saline 1 ml per 20cc
45836797|NCT00410826|Procedure|quality-of-life assessment|Ancillary studies
46008765|NCT02487251|Behavioral|Usual Exposure|Participants receive no supplemental information on family mealtimes beyond what is already currently received
46008766|NCT02489942|Drug|Jardiance|Empagliflozin
46008767|NCT04562493|Procedure|Transforaminal Epidural injection|Transforaminal injection will be performed under fluoroscopy guidance. The patient will be placed in the prone position and draped in the sterile manner. A 22-gauge, 3.5-inch spinal needle will be used. The selected patients will receive transforaminal epidural injection of the drug
46008768|NCT04562571|Other|Charter & patient information leaflets|Public commitment charter, non-prescription pad, information leaflet in case of antibiotic prescription
46008769|NCT04559568|Drug|LY3522348|Administered orally.
46008770|NCT04559568|Drug|Placebo|Administered orally.
46008771|NCT04559568|Drug|Midazolam|Administered orally to some participants.
46008772|NCT02211300|Device|The OptiScanner|treatment of blood glucose per standard of care
46008773|NCT02211300|Device|YSI 2300 STAT Plus™|
46008774|NCT02211339|Behavioral|Peer facilitator training|Peer facilitation of a project-based activity without staff present
46008775|NCT02211339|Other|Usual care|Staff-led social activity
46095848|NCT03855800|Procedure|Endoscopy Exam|Clinically indicated endoscopic ultrasound
46095849|NCT03417895|Drug|SHR-1210|A humanized anti-PD-1 monoclonal antibody
46095850|NCT03417895|Drug|Apatinib|A tyrosine kinase inhibitor selectively targeting VEGFR-2
46008776|NCT00176462|Drug|aminopterin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
46008777|NCT00176462|Drug|L-asparaginase|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
46008778|NCT00176462|Drug|cyclophosphamide|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
46008779|NCT00176462|Drug|cytarabine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
46095851|NCT02754401|Other|16 Items|Patients took part in the questionnaire and were examined using the PSI (periodontal screening index).
46095852|NCT02754401|Other|PSI|The PSI scores (0 to 4) were recorded: score 0=healthy, score 1=bleeding, score 2=supra-/subgingival calculus, score 3=probing depths from 3.5mm to max. 5.5mm, score 4=probing depths greater than 5.5mm. Only the highest finding was noted for each sextant. Persons with findings of code 0 to code 2 were classified as non-periodontitis persons (group 1), whereby codes 3 and 4 were considered a probable periodontitis persons (group 2).
46095853|NCT05299164|Drug|Liposomal Mitoxantrone Hydrochloride dose level 1|Drug: Liposomal Mitoxantrone Hydrochloride 16 mg/m^2 (with a caret included) on day 1, every 3 weeks;
46095854|NCT05299164|Drug|Liposomal Mitoxantrone Hydrochloride dose level 2|Drug: Liposomal Mitoxantrone Hydrochloride 18 mg/m^2 (with a caret included) on day 1, every 3 weeks;
46095855|NCT05299164|Drug|Liposomal Mitoxantrone Hydrochloride dose level 3|Drug: Liposomal Mitoxantrone Hydrochloride 20 mg/m^2 (with a caret included) on day 1, every 3 weeks;
46095856|NCT05299164|Drug|Liposomal Mitoxantrone Hydrochloride dose level 4|Drug: Liposomal Mitoxantrone Hydrochloride 22 mg/m^2 (with a caret included) on day 1, every 3 weeks;
46095857|NCT05299164|Drug|Gemcitabine|Gemcitabine (800 mg/m^2) on day 1,8, every 3 weeks;
46095858|NCT05299164|Drug|Vinorelbine|Vinorelbine (25mg/m^2) on day 1,8, every 3 weeks;
46095859|NCT05299164|Drug|Rituximab|Rituximab (375mg/m^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
46095860|NCT02653508|Behavioral|Diet and Activity|During all the following meetings, before the initiation of the training sessions, 10 to 15 minutes were devoted to an interactive discussion with participants on food pyramid, food choices, food labels, food preparation and cooking, eating habits, regular meals, controlling environments that stimulate overeating. All adolescents participated in a three-day per week training programme (45 minutes per training session). Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills.
46095861|NCT02653508|Behavioral|Activity|All adolescents participated in a three-day per week training programme (45 minutes per training session). Training was directed by a professional teacher of physical education in a public training centre. The training program was designed according to the type and intensity of exercise that school children normally perform. Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills. In order to encourage adolescents' behaviour change, they were instructed to add an extra 30-45 minutes of walking or other sport activity of their preference at least once a week and to reduce inactivity
46095862|NCT02578420|Other|open-label placebo|"Placebo Cream, openly described as Placebo"
46095863|NCT02578420|Other|deceptive placebo|"Placebo Cream, described as Voltaren, containing Diclofenac"
46095864|NCT02754323|Device|Apparatus CODESNA|The inclusion period is evaluated at one month and the participation of each patient is two days. One day or the subject performs the evaluation of chronic stress by CODESNA and following through questionnaires and another day to 3 weeks / one month apart, to perform a second chronic stress measurement with tool CODESNA to evaluate its reproducibility and reliability.
46095865|NCT01563835|Drug|bupivacaine, fentanyl|10mL of 0.125% of bupivacaine plus 50 mcg fentanyl, injected through an epidural catheter.
46095866|NCT01563835|Drug|fentanyl|fentanyl IV PCA with boluses 25-50 mcg, 3-6 minute lockout.
46095867|NCT02768207|Drug|Cobimetinib|Participants will receive cobimetinib 60 mg tablets (three 20 mg tablet) orally OD for 21 consecutive days (Days 1 to 21), followed by a 7 day break (Days 22 to 28); in each 28-day cycle of treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.
46095868|NCT02768207|Drug|Vemurafenib|Participants will receive vemurafenib 960 mg tablets (four 240 mg tablet) orally BID from Day 1 to Day 28 of each 28-day cycle of the treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.
46095869|NCT00709462|Biological|CDX1307|
46008780|NCT00176462|Drug|daunomycin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
46008781|NCT00176462|Drug|dexamethasone|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
46095870|NCT02653196|Procedure|Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy|Allogeneic hematopoietic stem cell transplant (HSCT) following thiotepa-based marrow ablative chemotherapy (MAC) for children with high-grade and/or recurrent neuro-epithelial and other solid tumors.
46095871|NCT02653196|Drug|Keratinocyte Growth Factor|KGF 60 mcg/kg IV: 6 doses
46095872|NCT02653196|Drug|Alemtuzumab|Alemtuzumab 12 mg/m2 IV: 2 doses (not given if matched related donor is 10/10 HLA matched sibling donor)
46095873|NCT02653196|Drug|Thiotepa|Thiotepa 300 mg/m2 IV: 3 doses
46095874|NCT02653196|Drug|Etoposide|Etoposide 100 mg/m2 IV: 3 doses
46095875|NCT02653196|Drug|Fludarabine|Fludarabine 30 mg/m2 IV: 3 doses
46008782|NCT00176462|Drug|6-mercaptopurine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
46095876|NCT02653196|Drug|Melphalan|Melphalan 70 mg/m2 IV: Day 2 doses
45678611|NCT01974895|Biological|FluLaval® Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
46095877|NCT02653196|Drug|Tacrolimus|Tacrolimus 0.05 mg/kg/day IV (Cyclosporine may be substituted for Tacrolimus): Start Day -2, begin taper on Day +100, discontinue on Day +180
46095878|NCT02653196|Drug|Cyclosporine A|Cyclosporine A dosed as follows: Age ≤ 6 years: 6 mg/kg/day IV in divided doses (e.g. 2 mg/kg every 8 hours) OR Age > 6 years: 3 mg/kg/day IV in divided doses (1.5 mg/kg every 12 hours): Start Day -2, begin taper on Day +100, discontinue on Day +180
46095879|NCT02653196|Drug|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg every 8 hours oral or IV: Start Day 0 (4-6 hours post stem cell infusion) to Day +40, then taper weekly until discontinuation on Day +90
45678612|NCT01974895|Biological|Fluzone®|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
45678613|NCT01974817|Biological|13-valent conjugate pneumococcal vaccine|0.5ml IM for one dose
45678614|NCT04415749|Biological|NasoShield|NasoShield is an adenovirus-vectored anthrax vaccine
46095880|NCT00676728|Drug|JNJ-26481585|In Part 1, Initial dose of JNJ-26481585 4 mg oral capsule is administered once daily on each day of a 21-day cycle. Dose will be escalated or de-escalated until Maximum tolerated dose (MTD) of JNJ-26481585 is determined in Part 1. MTD of JNJ-26481585 will be the initial dose in Part 2.
46095881|NCT05135845|Drug|Capmatinib|Capmatinib 400mg BID for a maximum of 12 months or until progression, patient's refusal or unacceptable toxicity
46095882|NCT05135845|Drug|Spartalizumab|Spartalizumab 300mg Q3W for a maximum of 12 months or until progression, patient's refusal or unacceptable toxicity
46095883|NCT00709384|Procedure|Prophylactic surgical lesion|A prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy (surgical dissection plus cryoablation) and the atriotomy with the inferior caval vein (cryoablation alone).
46095884|NCT00676884|Drug|Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)|30 mgs s.c. b.i.d.
46095885|NCT00676884|Drug|placebo|1.5 mL s.c. b.i.d.
46095886|NCT02027155|Drug|AR09 solution|moderate levels of sedation
46095887|NCT02027155|Drug|placebo|Sterile Saline, USP
45678615|NCT04415749|Other|Placebo|Normal saline
45678616|NCT04624399|Drug|Atezolizumab|Patients receive 2 x 3-weekly cycles of Atezolizumab (one infusion on the first day of each cycle) prior to cystectomy surgery.
45678617|NCT01915849|Drug|LIK066|LIK066 15 mg, 50 mg and 150 mg
45678618|NCT01915849|Drug|Placebo|
46095888|NCT04479436|Drug|Patritumab Deruxtecan|U3-1402 will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.
46095889|NCT00676962|Behavioral|External facilitation|Study facilitator meets regularly with therapists to aid implementation of CBT
46095890|NCT02754167|Biological|PRS-080#022-DP|Hepcidin antagonism to mobilize iron and to treat anemia
46095891|NCT02754167|Biological|PRS-080-Placebo#001|Placebo comparator
46095892|NCT02653274|Other|Breakfast porridge|220 kcal breakfast porridge served with 240 mL glass of water
46095893|NCT00677118|Drug|Cisplatin,fluorouracil|Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy, then receive cisplatin (80mg/m2 on day 1) and fluorouracil (800mg/m2 on Day 1 to 5) every four weeks for three cycles after completion of radiotherapy.
46095894|NCT00677118|Drug|Cisplatin|Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy.
46095895|NCT02644226|Other|Sevoflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using sevoflurane as maintenance agents.
46095896|NCT02644226|Other|Desflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using desflurane as maintenance agents.
46095897|NCT04004377|Other|Scale of quality life|"The PANQOL scale (Penn Acoustic Neuroma Quality-of-Life) is a specific questionnaire containing 26 items Interviewing 7 areas: hearing, balance, facial expression, anxiety, vitality, pain, and 'general health. The score is encrypted from 0 to 100, and the highest score is a reflection of the best possible quality of life. This score has been translated from French into English and validated according to the reverse translation rules by usual Oddon et al.~Three questions for this score were added, evaluating quality of life parameters that seem particularly interesting: the first regarding the difficulties in driving, the second questioning the recovery of a normal life, and the third assessing difficulties in working life."
46095898|NCT02653118|Biological|V503|
46095899|NCT02653118|Biological|GARDASIL|
46095900|NCT02753855|Drug|Telavancin|A single dose of telavancin as a 1-hour intravenous infusion
46095901|NCT04151862|Device|tight eye bandage|sterile eye pad made of 100% cotton
46095902|NCT04151862|Device|Soflex Soft Contact Lens|Therapeutic contact lenses (TCL)
46095903|NCT02647814|Behavioral|Salud al Día|A pilot randomized controlled trial comparing the effectiveness of a parent support intervention consisting of periodic text messages and educational support (video, collateral materials),and usual care on the healthcare engagement of LEP Latino parents during their child's first year and to examine its impact on healthcare utilization and primary care quality.
46095904|NCT00714298|Other|Measure of Initial heart fatty acid binding protein and ischemia modified albumin|Initial heart fatty acid binding protein and ischemia modified albumin will be measured after patient's arrival in the emergency room. The aim of the study is to analyse the predictive value of association of heart fatty binding protein and ischemia modified albumin for non ST segment elevation acute coronary syndrome diagnosis in the first hour of management in the emergency room.Treating physicians, biologist physician will be blinded to the results of the markers.
46095905|NCT02758691|Drug|Intranasal Insulin|All participants in the devise testing portion of the study will self-administer a 20 IU dose of intranasal insulin. Half of the participants in the function Magnetic Resonance Imaging portion of the study will also self-administer a 20 IU dose of intranasal insulin.
46095906|NCT02758691|Drug|Intranasal Saline|All participants in the devise testing portion of the study will self-administer a 20 mL dose of intranasal saline. Half of the participants in the function Magnetic Resonance Imaging portion of the study will also self-administer a 20 mL dose of intranasal saline.
46095907|NCT00677196|Device|The stonebreaker arm (LMA Stonebreaker)|The interventional device name is the LMA Stonebreaker pneumatic handheld lithotriptor.
46095908|NCT00677196|Device|Pneumatic Lithotripsy (Swiss LithoClastR)|Pneumatic lithotripsy, the Swiss LithoClastR during percutaneous nephrolithotripsy (PNL)
46008783|NCT00176462|Drug|methotrexate|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
46095909|NCT04162951|Procedure|Ordinary approach paravertebral block|Ultrasound guided thoracic paravertebral block. At the appropriate dermatome, the needle (22-gauge, 8-10-cm, short bevelled spinal needle, or a Touhy needle if a catheter is to be placed) is inserted 2.5-3 cm lateral to the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process at a variable depth (2-4 cm) depending on the build of the individual. The needle is then walked above the transverse process and gradually advanced until a loss of resistance to air or saline, or a subtle 'click' is felt as the superior costotransverse ligament is penetrated, usually within 1-1.5 cm from the superior edge of the transverse process.
46095910|NCT04162951|Procedure|Retrolaminar paravertebral block|In the retrolaminar approach to TPVB or retrolaminar block (RB), local anesthetic (LA) is injected into the retrolaminar plane to achieve a truncal sensory block like that of traditional TPVB. It has been postulated that during RB, LA spreads from the injection plane to the thoracic paravertebral space (TPVS) through the superior costotransverse ligament (SCTL). Retrolaminar block will be performed under ultrasound guidance, as a single injection.
46095911|NCT02768285|Procedure|APICAL PATENCY|After determining the working length, a small and flexible size 10 K-file was inserted 1 mm beyond the WL.
46095912|NCT00714376|Drug|Docetaxel|75 mg/m2 iv every 3 weeks for 8 cycles
46095913|NCT04151784|Other|Pulmonary Group|Data collection will be obtained on the day an individual has an appointment at the pulmonary clinic. After patients meet with their pulmonary physicians, the physicians will inform them about the study and explain that participation is voluntary. If a patient agrees, the researcher will provide copies of the questionnaires and again clarify that participation is voluntary. The workflow of the clinic will not be interrupted while the researcher conducts the study, and he will only ask participants to fill out the questionnaires if they have enough time to participate.
46095914|NCT04151784|Other|Healthy Control|The second group will be recruited as a control group consisting of healthy adult participants through purposive convenience sampling at other collaborating UAB sites. The principal investigator will collect self-report responses through a questionnaire packet given to anyone willing to participate in the study
46095915|NCT02758457|Device|dental crowns|
46095916|NCT00714454|Other|APS Topical Lotion|
45678619|NCT01915771|Drug|lomitapide|20 mg dose
45678620|NCT01938391|Device|Stealth 360°® OAS|Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS) is used prior to adjunctive balloon angioplasty (BA)
46008784|NCT00176462|Drug|6-thioguanine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
46008785|NCT00176462|Drug|vincristine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
45836798|NCT00464646|Drug|Epirubicin|Both Cohorts: Epirubicin 90 mg/m2 IV every 21 days x 4 cycles
46008786|NCT00176462|Drug|Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)|
46008787|NCT00176462|Drug|Leucovorin|
46008788|NCT04559295|Biological|Bone Marrow Concentrate|The intradiscal delivery of bone marrow concentrate (BMC) into discs, facet , epidural space, and sacroiliac joints
46008789|NCT02211378|Other|Observer|Trainees are in the role of observers (not actively participating in simulation scenario) during first 2 simulation sessions, then placed in the role in the 'hotseat' actively participating during the third simulation session.
46095917|NCT00714454|Other|Placebo|
46008790|NCT02211378|Other|Hotseat|Trainees in the hotseat group are placed in the 'hotseat' to actively participate and manage the simulated medical crises in the simulation scenarios.
46008791|NCT00175019|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily.
45678621|NCT01915303|Drug|Pasireotide with or without cabergoline|The trial consisted of Pasireotide-untreated patients who started pasireotide 0.6mg twice a day for 8 weeks. If biochemical control was not achieved by the end of the 8 weeks, and the 0.6mg dose is well-tolerated, the dose was increased to 0.9mg twice a day for another 8 weeks. If biochemical control is not achieved, cabergoline was added and patients began combination treatment with cabergoline at the starting dose of 0.5mg once a day for 8 weeks. If biochemical control is still not achieved at the end of the third 8 week period, the dose of cabergoline was increased to 1.0mg once a day. Patients could also immediately start the combination treatment by adding cabergoline 0.5mg once a day at study entry to their current maximal tolerated dose of pasireotide. Patients continued with the combination treatment for 8 weeks. If biochemical control was not not achieved by the end of the 8 week period, the dose of cabergoline was increased to 1mg once a day.
45678622|NCT01987427|Drug|lorcaserin + phentermine placebo|lorcaserin 10 mg BID + phentermine placebo BID
45678623|NCT01987427|Drug|lorcaserin + phentermine-HCl + phentermine placebo|lorcaserin 10 mg BID + phentermine-HCl 15 mg QD + phentermine placebo QD
46008792|NCT00175019|Drug|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily.
46008793|NCT00175019|Drug|Allopurinol|Allopurinol 100 mg or 300 mg, tablets, orally, once daily.
46008794|NCT04559763|Device|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
46008795|NCT04559763|Other|Introduction of Motion conditions: tapping or rubbing|Standard motions include tapping or rubbing at periodic intervals with amplitudes of 1-2 cm and 1-4 Hz with a random variation in frequency will occur at each plateau. Each plateau will have both an interval of tapping and rubbing. Signals are recorded by a validated, computerized data acquisition system (CAS). The device values are sampled once per second and averaged over the time taken to draw the blood sample, taking into account circulation time delays and differences in device response times
46008796|NCT00174941|Drug|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.
46008797|NCT00174941|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.
46008798|NCT00174941|Drug|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.
46008799|NCT04558944|Device|Extracorporal Shock Wave Therapy|Acoustic high amplitude waves with Energy Flux Density of 0.15mJ/mm 2 and 512 pulses per session. A total of two sessions per week during a 4-week period.
46008800|NCT04562727|Drug|Chemotherapy|perioperative chemotherapy or postoperative chemotherapy
46095918|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the onset of regular uterine contraction
46095919|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 0.5cm
46095920|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 1.0cm
46095921|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 1.5cm
46095922|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 2.0cm
46008801|NCT00171704|Drug|Letrozole|2.5 mg tablets and supplied in bottles with 6-monthly supplies.
46008802|NCT00171704|Drug|Tamoxifen|20 mg tablets in bottles as 6-monthly supplies (supplied to Novartis as Tamofen from Schering Oy, Subsidiary of Schering AG, Pansiontie 47, FIN-2010 Turku, Finland)
46008803|NCT04559061|Device|Cardiac ablation procedure|Retrospective data will be collected from cases where successful ablation was completed.
46008804|NCT02211963|Drug|BI 44847|
46008805|NCT02211963|Drug|Placebo|
46008806|NCT00171314|Drug|Zoledronic acid|Zoledronic acid 4 mg Intravenous (IV)15 minute infusion every 6 months.
46008807|NCT00171314|Drug|Letrozole|Letrozole tablets 2.5 mg/day/taken orally for 5 years.
46008808|NCT04562259|Radiation|Verification of Kimmerle's anomaly by x-ray methods of research|In patients with Kimmerle's anomaly, using computed tomography of the brain with the capture of the upper cervical spine and cervical spine, it is planned to determine at what age this pathology is more common, localization of the anomaly (right, left), complete or incomplete form of the anomaly.
46008809|NCT04571918|Procedure|Biodegradable spacer|Implantation of a biodegradable balloon used as a subacromial spacer.
46008810|NCT04571918|Procedure|Debridement and biceps tenotomy|Surgery with arthroscopic debridement and biceps tenotomy
46008811|NCT04562454|Other|Specific diet|use a specific diet in different days with CGM to konw GI of different food in diabetes
46008812|NCT04562337|Drug|SHR1316|Anti-PD-L1 antibody
46008813|NCT04562337|Drug|Chemotherapy|Carboplatin
46008814|NCT04562337|Drug|Chemotherapy|etoposide
46008815|NCT04562337|Radiation|Radiation therapy|thoracic radiation therapy ,TRT
46008816|NCT00171158|Drug|imatinib mesylate|
46095923|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 3.0cm
46095924|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 4.0cm
46095925|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 5.0cm
46008817|NCT04562415|Device|Active Repetitive Transcranial Magnetic Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and inhibitor rTMS was applied with a frequency of 1 Hz consisting of 1200 pulses for 20 minutes. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
46008818|NCT04562415|Device|Active Continuous Theta Burst Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and cTBS was administered for a total of 600 pulses consisting of 3 burst stimulations of 50 Hz repeated every 200 milliseconds for 40 seconds. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
46008819|NCT04562415|Device|Sham Continuous Theta Burst Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and sham cTBS was administered for a total of 600 pulses consisting of 3 burst stimulations of 50 Hz repeated every 200 milliseconds for 40 seconds. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
45460072|NCT04182100|Drug|P1101|P1101 (ropeginterferon alfa-2b) will be administered subcutaneously every 2 weeks at the starting dose of 100 μg every two weeks (or 50 μg in patients under another cytoreductive therapy). The dose should be gradually increased by 50 μg every two weeks (in parallel, other cytoreductive therapy should be decreased gradually, as appropriate) until stabilization of the hematological parameters is achieved (hematocrit <45%, platelets <400 x 10^9/L and leukocytes <10 x 10^9/L). The maximum recommended single dose is 500 μg injected every two weeks. The dose will be maintained at the highest level which can be tolerated and delivers best possible disease response.
45460073|NCT04182100|Drug|Low-dose aspirin|Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.
45460074|NCT04182100|Procedure|Phlebotomy|Phlebotomy is performed aiming at a hematocrit < 45%. When the hematocrit value is 45% or higher, phlebotomy is performed. The volume of phlebotomy per procedure should be 200 to 400 mL while monitoring the circulatory dynamics such as blood pressure and pulse. In the elderly and patients with cardiovascular disorders, a small volume (100-200 mL) should be considered to avoid rapid changes in hemodynamics.
45678624|NCT01987427|Drug|lorcaserin + phentermine-HCl|lorcaserin 10 mg BID + phentermine-HCl 15 mg BID
45678625|NCT01937299|Drug|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
45836799|NCT00464646|Drug|Cyclophosphamide|Both Cohorts: Cyclophosphamide 600 mg/m2 IV every 21 days x 4 cycles
46008820|NCT04558788|Diagnostic Test|Immunohistochemistry on intestinal biopsies|Immunohistochemistry will be performed on human intestinal biopsies
46008821|NCT00170846|Drug|Everolimus (RAD001)|
46008822|NCT00170846|Drug|Calcineurin Inhibitors (CNI)|
46008823|NCT00170846|Drug|Mycophenolate acid (MPA)/Azathioprine (AZA)|
46008824|NCT00170846|Drug|Steroids|
46008825|NCT04562025|Drug|UC-MSCs|3 times of UC-MSCs (1*10E6 UC-MSCs/kg body weight/100mL saline containing 1% human albumin intravenously at week 1,week 2, week 3).
46008826|NCT04562025|Drug|Placebo|3 times of cell-free stem cell suspension (saline containing 1% human albumin/100mL intravenously at week 1, week 2, week 3).
46008827|NCT04562142|Device|CAD-det|CAD-det test will be done on participants with suspected CAD clinically referred for ICA at a participating clinical investigation site.
45678626|NCT01937299|Drug|Vehicle|Inactive ingredients used as a placebo comparator
45678627|NCT01937299|Drug|Travoprost 0.004% ophthalmic solution|
45836800|NCT00464646|Drug|Docetaxel|Both Cohorts: Docetaxel 100 mg/m2 IV on Day 1 every 21 days x 4 cycles
45836801|NCT00464646|Drug|Trastuzumab|"Cohort A: Pre-op therapy - 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly (16+ weeks) until 1-7 days prior to surgery. Post-operative therapy (beginning no sooner than 28 days after surgery and continuing every 3 weeks x 13 doses) - 8 mg/kg IV first post-op dose, then subsequent doses at 6 mg/kg IV~Cohort B: 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly on days 1, 8, and 15. Three (3) weeks after last dose of docetaxel, 6 mg/kg IV and continuing every 3 weeks x 13 doses"
46008828|NCT00476606|Drug|Zidovudine, Stavudine, Didanosine, Lamivudine|Refer to the Thai guideline for HIV management 2007
46008829|NCT00476606|Drug|Nevirapine, Efavirenz|Refer to the Thai guideline for HIV management 2007
46008830|NCT00476606|Drug|LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir|Refer to the Thai guideline for HIV management 2007
45460075|NCT01251523|Behavioral|PACE|The first intervention to be tested, Physician Asthma Care Education (PACE), is a rigorously evaluated intervention for physicians that has reached hundreds of clinicians across the U.S. and also has been implemented in the United Kingdom and Australia. The efficacy trial of PACE was supported by the National Heart, Lung and Blood Institute and the effectiveness trial by the Robert Wood Johnson Foundation. PACE is now widely available to clinicians, through, among other channels, the National Asthma Education and Prevention Program (NAEPP). It is designed to enhance physician communication, counseling and therapeutics for assisting the general population of children with asthma.
45460076|NCT01251523|Behavioral|PACE Plus|In the PACE PLUS intervention a cultural competence component will be added to the PACE curriculum. The cultural competence component uses mini-lecture, video demonstration (video to be developed as part of this proposal), case studies and self observation tools to present the principles of cultural competence derived from the study of the literature. The component integrates into the skills taught, specific content related to working with African American and Puerto Rican families where a child has asthma.
45460077|NCT04174222|Other|Moderate NMB|Neuromuscular block was maintained at train of four count 1-2.
45460078|NCT04174222|Other|Deep NMB|Neuromuscular block was maintained at train of four count 0 and post-tetanic count1-2.
45460079|NCT01253863|Other|exploration|exploration of wound for determining damaged tissue
45460080|NCT03479320|Drug|Lidocaine|Postoperative analgesic effects will be compared between lidocaine and normal saline group
45460081|NCT03479320|Drug|Placebo|Postoperative anlagesic requirements will be calculated and compared with experimental group
45460082|NCT01147159|Other|Extracts of allergens|Skin prick test of extracts of allergens in 4 tenfold dilutions. Assessment wheal size after 15 minutes
45460083|NCT04112524|Device|App|"Alleye® Test Alleye® Test is a mobile medical software application indicated for the detection and characterization of metamorphopsia. For the mean Alleye score (±standard deviation (SD) deviations of dots from an ideal line are calculated for each eye.~AMD-A Metamorphopsia Detector® Is based on the Amsler grid. The software uses the concept of a negative image: a distorted image can be straightened by moving the mouse. Degree and dimension of distorted lines or scotoma are transformed into indices."
45460084|NCT03915301|Procedure|Satisfaction assessed by the VAS [followed by its scale information in the Description]|Erector spinae plane block provided in thoracic part of spine, VAS scale 0-10
45460085|NCT01250353|Procedure|pterygium surgery|pterygium was removed surgically
45460086|NCT03526458|Device|Holmium:YAG laser|Treatment of urolithiasis is commonly done using the holmium:YAG laser as this has been shown to be a safe and effective method of treating a wide variety of stones and is currently considered the standard of care (AUA Guideline Panel on the Surgical Management of Stones)
45460087|NCT03914989|Other|olfactory enrichment (essential oils)|Participants will be exposed to either a higher or lower concentration of essential oils nightly for two hours as they are going to sleep, using a nebulizing fragrance diffuser, rotating through seven different scents, one per night.
45460088|NCT01253941|Other|Mud bath Therapy|patients will be randomized to Mud bath Therapy ( 12 sessions) or no treatment
45460089|NCT03488238|Device|ORi sensor|Noninvasive pulse oximeter sensor that is placed on the finger for measurement of ORi
45460090|NCT03912415|Biological|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
45460091|NCT03912415|Biological|Bevacizumab|IV infusion
46008831|NCT04562103|Drug|Epinephrine / Ropivacaine|In this group quadratus lomborum block was performed with 0.375% ropivacaine+100 mcg epinephrine.
45460092|NCT03912415|Drug|Paclitaxel|IV infusion
45460093|NCT03912415|Drug|Cisplatin (or Carboplatin)|IV infusion
45460094|NCT03912415|Other|Placebo|Placebo
45460095|NCT01147783|Other|CT, MRI|
46008832|NCT04562103|Drug|Ropivacaine|In this group quadratus lomborum block was performed with plane 0.375% ropivacaine.
46008833|NCT02278380|Other|Low GI Standard Breakfast|Low GI Standard Breakfast
46008834|NCT02278380|Other|Medium GI Standard Breakfast|Medium GI Standard Breakfast
46008835|NCT02278380|Other|Enfamama A+|Nutritional pregnant milk supplement
46008836|NCT02278380|Other|Glucerna Triple Care|Nutritional product for diabetics
46008837|NCT02278380|Other|Dumex Precima|Pregnant and lactation women milk powder
46008838|NCT02278380|Other|Diasip|Nutritional drinks for diabetics
45460096|NCT03525834|Drug|Everolimus|Everolimus 2.5 mg and 5 mg tablets with dosage regimen of 10 mg orally once daily.
45460097|NCT00925652|Drug|Bevacizumab|
45460098|NCT00925652|Drug|Cyclophosphamide|
45460099|NCT00925652|Drug|Methotrexate|
45460100|NCT00925652|Behavioral|Lifestyle: Diet|
45460101|NCT00925652|Behavioral|Lifestyle: Diet+Exercise|
45460102|NCT01251601|Other|Pharmacokinetics|Up to three 12 hour PK sampling sessions, one in the second trimester, one in the third trimester and one post partum
45460103|NCT03906097|Other|Play and Competition-Based Cognitive Therapy|The intervention group was received play and competition-based cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program
45460104|NCT03905785|Behavioral|Samarthan|Samarthan intervention was designed as group program, training parents in cognitive-behavioural techniques for managing child's difficult behaviour and issues. Program was focused on parent-child problem solving method and positive interaction.
45460105|NCT03915145|Other|Kinesio tape application|Kinesio tape application will be performed.Taping is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
45460106|NCT03915145|Other|Sham Kinesio tape application|Sham kinesio tape application will be performed. Sham taping is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
45460107|NCT03915145|Other|No intervention|The natural process will be followed from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
45460108|NCT03912025|Other|Relationship between positive mindset and exercise capacity|No intervention. Cross-sectional study looking at the relationships between questionnaire scores and outcomes
45460109|NCT05749874|Drug|Berberine plus lifestyle intervention|"berberine hydrochloride 500mg twice a day plus lifestyle intervention. Lifestyle intervention is based onChinese guideline on the primary prevention of cardiovascular diseases and Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition), including health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc."
46008839|NCT02278380|Other|Test product|Test product not patented yet
45460110|NCT05749874|Behavioral|Placebo plus lifestyle intervention|"Placebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention. Lifestyle intervention is based onChinese guideline on the primary prevention of cardiovascular diseases and Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition), including health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc."
45460111|NCT01250431|Behavioral|EFT (Emotional Freedom Techniques)|10 EFT sessions
45460112|NCT05748626|Device|Anti-snoring device|For group 1, the study team will aid the subject in molding and preparing the device in the pre-operative area. They will wear the device throughout the entirety of the case.
45460113|NCT05748626|Procedure|No anti -snoring device during their procedure.|For group 2 there will be no anti snoring device used during the case.
45460114|NCT01251679|Behavioral|Hand washing|hand washing education and material
45460115|NCT01251679|Device|Hand washing and surgical mask|hand washing education and material and paper surgical face masks
45460116|NCT00481052|Drug|Nilotinib|
45460117|NCT03912103|Other|Interdisciplinary Deprescribing and Medication Optimization Intervention|as current
45460118|NCT01147861|Drug|GSK256073|5mg in the AM and 5mg in the PM
45460119|NCT01147861|Drug|GSK256073|10mg in the AM
45460120|NCT01147861|Drug|GSK256073|50mg in the AM
45460121|NCT01147861|Drug|GSK256073|25mg in the AM and 25mg in the PM
45460122|NCT01147861|Other|Placebo|2 placebo tablets in the AM and 2 placebo tablets in the PM
45683815|NCT05249764|Other|Unsupervised stretching and breathing exercises|Individuals in the control group are performing stretching exercises for proximal extremity muscles for 15 minutes 3 times a week for eight weeks. The participants also perform breathing exercises for 5 minutes a day.
46008840|NCT04561635|Dietary Supplement|Multiple-micronutrients supplement|Multiple-micronutrients supplement with 15 micronutrients
46008841|NCT04561674|Other|Implementation of web-based patient education|Web-Based Patient Education on Colostomy and Ileostomy (WBPECI) was developed in accordance with the principles of the ADDIE instructional design. The web-based education was designed in line with these learning objectives determined. The content of the website was developed in light of the opinions sought from five subject experts. The WBPECI content includes a total of 7 videos, 1 animation with sound, 1 forum and 1 consultation page
45460123|NCT04872686|Drug|0.6% PVP-I oral and nasal spray to moderately ill COVID-19 positive patient|"Number of participants 768 COVID-19 positive, moderately ill admitted patient who will receive intervention~Step 1: Enrollment of the study populations by applying inclusion and exclusion criteria Step 2: Randomization to allocate experimental and controlled group by using table of random number Step 3: Application of 0.6% PVP-I spray to experimental group and distilled water to control group Step 4: Follow up (waiting for 2-5 minutes) Step 5: Collection of nasopharyngeal and oropharyngealsawab for RT-PCR test for both group Step 6: Observation of the patients for 30 minutes for possible early adverse effects (if any) and subsequent management (if needed).~Step 7: Analysis data collection, data processing and analysis by using SPSS software."
45460124|NCT04872686|Drug|0.6% PVP-I Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity|"Number of participants 20 asymptomatic to mild COVID -19 patients having multiple comorbidity who will receive intervention~Step 1: Selection of 20 patients randomly with no or mild symptoms and obtain their consent for the further tests.~Step 2: Collection of 2nd, 3rd and 4th sample from nasopharynx and oropharynx hourly Step 3: Data collection, data processing and analysis by using SPSS software"
45678628|NCT02003963|Behavioral|Klub Kinect|"Dance Central and Just Dance are a series of rhythm games developed by Harmonix Music Systems exclusively for the Xbox 360 Kinect. The Dance Central suite of games (Dance Central 1, 2, and 3) and Just Dance will be played on the Xbox 360+ Kinect gaming console, which employs whole body movement using an infrared sensor that tracks body movements such that an external controller device is not required. The player performs dance moves demonstrated by on-screen characters and set to popular music, with a choice of over 650 dance moves, 90 dance routines, and over 300 songs.~The exergaming condition will wear a pedometer to record total steps during game play, and they will participate in private weigh-ins at each session to track body weight over the 12-week intervention."
45678629|NCT01606761|Drug|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 22.
45678630|NCT01606761|Drug|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 52.
45678631|NCT01606761|Drug|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 23 through Week 52.
46008842|NCT04558671|Other|asthma exacerbations|to collect the number of asthma exacerbations between the 2 latent classes of patients within the year following bronchoscopy
46008843|NCT00479882|Drug|Comparator: simvastatin|
46008844|NCT00479882|Drug|MK-0524A|Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet
46008845|NCT00479882|Drug|Placebo|
46008846|NCT00479882|Drug|MK-0524B|
46095926|NCT04221659|Device|Transcranial Direct Current Stimulation|Participants will receive 16 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, on alternate days (3 times a week). The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². The cathode, reference electrode (5x7cm), will be positioned in the occipital region. These parameters are within the safe limits established in previous human studies.
46008847|NCT04558515|Diagnostic Test|Novel malaria diagnostics & tools|Next generation microscopy tools for malaria diagnosis and medical applications
46008848|NCT00479765|Drug|OncoGel (ReGel/Paclitaxel)|OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.
46008849|NCT04558242|Device|Genix|Low Level Light (LEDs)
46008850|NCT04558242|Device|Sham|Incandescent Bulbs Colored Red
46095927|NCT00718588|Drug|MTRX1011A|Subcutaneous and intravenous single and repeating dose
46008851|NCT00479687|Device|SUPARTZ®|Three Supartz injections over 2 weeks into the glenohumeral joint space.
46095928|NCT02753933|Other|MRI scan|MRI head scan to be performed as the first Secondary Care contact.
45678632|NCT01606761|Drug|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 52.
46095929|NCT02753933|Other|Neurology Appointment|Outpatient appointment with Neurologist as the first Secondary Care contact
46008852|NCT00479687|Device|Phosphate Buffered Saline|Three phosphate buffered saline injections over 2 weeks into the glenohumeral joint space.
46095930|NCT00709540|Biological|ACE-011 or placebo|multiple administrations of ACE-011 given subcutaneously once per month for 3 months (4 administrations total)
46095931|NCT04068766|Device|Paracervical block|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
46095932|NCT04068766|Drug|5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
46008853|NCT02212002|Drug|IAP|maternal IAP, consisting of intravenous ampicillin given every 4 hours until delivery (first dose 2 g, following doses 1 g each).
46008854|NCT02212080|Drug|BAY1214784|Escalating doses of 5, 20, 60, 150, 300, 600, 1000 mg of BAY1214784; single dose administration; liquid dosage form
46095933|NCT04068766|Drug|Normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
46095934|NCT02754089|Drug|Rhus Coriaria L.(Rhus)|500 mg twice daily after meals for 6 weeks
46095935|NCT02754089|Drug|Placebo|500 mg twice daily after meals for 6 weeks
46095936|NCT00912210|Dietary Supplement|Whey protein isolate|Loss of 10% baseline weight over 6 months, with whey protein isolate supplemented at 50g/day (two 25 g doses taken at breakfast and afternoon snack mixed with food or beverage)
46095937|NCT00912210|Dietary Supplement|Maltodextrin powder supplement|Loss of 10% baseline weight over 6 months, with whey protein isolate supplemented at 50 g / day (two 25 g doses at breakfast and afternoon snack mixed with food or beverage)
46095938|NCT00714532|Behavioral|Expert System Only|Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months
46095939|NCT00714532|Behavioral|Enhanced Expert System|"The intervention consists of 3 components:~Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months~scheduled smoking intervention, which includes a tailored-made 3-week smoking reduction schedule and a stage-matched tip guide to explain why and how to use the smoking reduction intervention~telephone check-in calls to provide brief counseling and technical support to motivate participants to use the intervention materials~a 2-week supply of nicotine gum or lozenge per participants' choice to use during smoking reduction"
46095940|NCT02753543|Drug|Chidamide|
46095941|NCT00677430|Behavioral|Questionnaire|A brief questionnaire packet will be completed.
46095942|NCT00677430|Procedure|Digital Imaging|Photographs of the breast(s) will be taken with two different types of digital cameras (2D and 3D). The photos will be used to develop automated methods for evaluating the appearance and shape of the breasts.
46095943|NCT02753621|Behavioral|Group singing|Weekly group singing classes led by professional choir instructor, lasting 90 minutes. 12 classes over 12 consecutive weeks.
46095944|NCT02753621|Behavioral|Facilitated Discussion Group|Weekly facilitated discussion group led by Parkinson Disease educator, lasting 90 minutes. 12 sessions over 12 consecutive weeks.
46095945|NCT03267199|Drug|Thrombolytic|Thrombolytic therapy
46095946|NCT03267199|Procedure|Primary PCI|Primary percutaneous coronary intervention
46095947|NCT03267199|Diagnostic Test|Complete blood count|Blood sample for complete blood count
46095948|NCT03267199|Diagnostic Test|Platelet function test|Blood sample for platelet function test
46095949|NCT03267199|Diagnostic Test|ECG|Electrocardiogram
46095950|NCT03983512|Device|PULSTA TPV System|PULSTA transcatheter pulmonary valve replacement.
45678633|NCT01606761|Drug|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 52.
46095951|NCT04725695|Drug|Viscous Lidocaine|The patients will be randomized to either viscous lidocaine or placebo
46095952|NCT04151472|Drug|Placebo|Placebo oral tablet, three times a day
45678634|NCT01790295|Drug|Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)|Ruxolitinib (INC424) tablets will be started 60 days (day -65) prior to start of conditioning chemotherapy. The starting dose of Ruxolitinib will be determined according to baseline platelet count and will be modified according to platelet count at follow-up. The drug will be given in the maximum tolerated dose as defined in the protocol for 56 days, followed by 4 days of taper, and will be stopped completely at the planned start of conditioning therapy (starting on day -5) i.e. 5 days prior to stem cell infusion. The drug will be supplied as 5 mg tablets.
46008855|NCT02212080|Drug|Placebo|Dose 1, 2,3, 4, 5, 6 and 7 of respective placebos; single dose administration; liquid dosage form
46008856|NCT00479336|Drug|OPC-41061 7.5mg|7.5mg, 1 tablet a day
46008857|NCT00479336|Drug|OPC-41061 placebo|placebo, 1 tablet a day
46008858|NCT00479336|Drug|OPC-41061 15mg|15mg, 1 tablet a day
46008859|NCT00479336|Drug|OPC-41601 30mg|30mg, 1 tablet a day
46095953|NCT04151472|Drug|90mg Idebenone|Idebenone 30 MG Oral Tablet, three times a day
46095954|NCT04151472|Drug|270mg Idebenone|Idebenone 90 MG Oral Tablet, three times a day
45460125|NCT04872686|Drug|0.6% PVP-I Oral and nasal spray to healthy volunteer|"Number of participants 10 healthy individual who accept intervention 0.6% PVP-I oronasal spray~Step 1: Selection of 10 healthy volunteers randomly who will be selected for using 0.6% PVP-I Oro-Nasal spray 2 puff inside both nostrils and mouth 3 to 4 times a day for one month.~Step 2: Collection of blood & urine of participants on day 0, 10, 20, 30 for determination of any change in biochemical marker (thyroid, kidney and liver functions will be done) Step 3: Data collection, data processing and analysis by using SPSS software"
46008860|NCT02212158|Behavioral|motivational interviewing group|Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies.
46008861|NCT00478244|Drug|busulfan|Day -9 through Day -6: 1.1 mg/kg if < 12 kg IV every 6 hours; 0.8 mg/kg if > 12 kg.
46008862|NCT00478244|Drug|cyclophosphamide|Day -5 through Day -2: 50 mg/kg IV over 120 min.
45460126|NCT04872686|Other|Oral and nasal spray by distilled water to control group|Placebo comparator: Distilled Water Oral and Nasal spray will be provided by Distilled water to control group
45460127|NCT03954106|Drug|Defibrotide|"Part 1: Defibrotide 2.5 mg/kg/dose or 6.25 mg/kg/dose once daily as a single dose on CAR-T Day -5, -4, and -3 before lymphodepletion, then every 6 hours daily for 8 days (CAR-T Day 0 to Day 7).~Part 2 Recommended Phase 2 Dose: Defibrotide 6.25 mg/kg/dose once daily as a single dose on CAR-T Day -5, -4, and -3 before lymphodepletion, then every 6 hours daily for 8 days (CAR-T Day 0 to Day 7)."
46095955|NCT04070794|Drug|Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fasting)|Fasting conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water after an overnight fasting for at least 8 hours.
45460128|NCT03525444|Drug|VX-445/TEZ/IVA|Participants received VX-445/TEZ/IVA orally once daily in the morning.
45460129|NCT03525444|Drug|IVA|Participants received IVA orally once daily in the evening
45460130|NCT03525444|Drug|Placebo|Participants received placebo matched VX-445/TEZ/IVA orally once daily in the morning and placebo matched to IVA orally once daily in the evening.
45460131|NCT01250587|Drug|PDC31|This study involves the sequential administration of PDC31 to 4 cohorts of patients. The dose will be escalated in the absence of dose-limiting toxicities. PDC31 is to be administered as a 3-hour continuous infusion.
45460132|NCT03924310|Device|FeetBack System Active|Commercially available hand prosthesis with feedback device turned on
45460133|NCT03924310|Device|FeetBack System Passive|Commercially available hand prosthesis with feedback device turned off
45460134|NCT01251835|Drug|Sitaxsentan alone|Days 1-5: Sitaxsentan tablet, 100 mg, q24 h (once a day)
45460135|NCT01251835|Drug|Sitaxsentan|Days 6-12: Sitaxsentan tablet, 100 mg, q24h (once a day)
45460136|NCT01251835|Drug|Rifampin|Days 6-12: Rifampin capsule, 600 mg, q24h (once a day)
46008863|NCT00478244|Drug|fludarabine phosphate|Day -5 through Day -3: 25 mg/m2 IV over 60 min.
46095956|NCT04070794|Drug|Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fed)|Fed conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water at 30 minutes after the start of standardized HFHC breakfast.
46095957|NCT02753465|Procedure|left colic artery|Laparoscopic D3 Lymph Node Dissection with preservation of left colic artery
46095958|NCT02753465|Procedure|High ligation|Laparoscopic D3 Lymph Node Dissection with ligation above the left colic artery
46095959|NCT00718744|Other|Standardization of allergenic extract (Ch. arcuatus)|Allergenic extract for cutaneous prick-test
46095960|NCT00672048|Other|Computer Tablet|A tablet computer based software application designed to collect structured clinical information from providers and patients at the point of care.
46095961|NCT00672048|Other|Continuing Education Course|Annual standard continuing education
45460137|NCT05200130|Other|Home Exercise Group|The home exercise program includes an educational training program and posture correction exercises. The program includes stretching and strengthening exercises of the neck and shoulder complex.
45460138|NCT05200130|Other|Manual Therapy Group|"Manual Therapy includes deep friction massage and myofascial relaxation techniques to shoulder and neck complex, active and resistant shoulder complex movements, shoulder complex mobilization, mobilization cervical joints.~The home exercise program includes an educational training program and posture correction exercises. The program includes stretching and strengthening exercises of the neck and shoulder complex."
45460139|NCT05200130|Other|Telerehabilitation Group|The telerehabilitation program applied to the same home exercise group. In addition, to the home exercises, these patients will apply active mobilization called self-mobilization. Self-myofascial release, active glenohumeral joint mobilization, thoracic mobilization, and active cervical mobilization.
45460140|NCT03914911|Device|Smart Biopsy Device|The radiologist will perform a routine ultrasonic guided biopsy procedure using the smart biopsy system, with the device readings not visible (i.e. the radiologist will be blinded to device readings)
45460141|NCT03632876|Dietary Supplement|retinyl palmitate|The intervention is a daily vitamin A supplement.
45460142|NCT03914755|Drug|Tucatinib|Administered via oral tablet
46008864|NCT00478244|Procedure|hematopoietic bone marrow transplantation|allogeneic bone marrow, peripheral stem cell or umbilical cord blood transplantation
46008865|NCT02212236|Other|Psychological preparation|Ninety-minute, group-based psychological preparation delivered prior to haematopoietic stem cell transplantation aiming at alleviating psychological distress during the procedure by enhancing perceptions of the procedure and fostering more helpful coping.
46008866|NCT04558437|Other|Questionnaire|"Questionnaire at M0 M3 M6:~PCL-5 (Post-Traumatic Stress Disorder Checklist Scale, version DSM-5) HAD (Hospital Anxiety and Depression Scale) SDS (Sheehan Disability Scales)"
46008867|NCT00478205|Drug|Aricept (donepezil SR 23 mg)|"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~23 mg donepezil SR concurrently with placebo identical in appearance to the 10 mg donepezil IR formulation."
46095962|NCT00672048|Other|Continuing education|Annual standard continuing education materials
46008868|NCT00478205|Drug|Aricept (donepezil IR 10 mg)|"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~10 mg donepezil IR concurrently with placebo identical in appearance to the 23 mg donepezil SR formulation."
46008869|NCT00477971|Biological|filgrastim|No administration information given
46008870|NCT00477971|Drug|dexamethasone|Given orally
46008871|NCT00477971|Drug|melphalan|Given IV or orally
46095963|NCT02572648|Other|Brain Imaging (Neuroimaging)|"Magnetic Resonance Imaging (MR) will be acquired on a research dedicated Siemens 3Tesla TIM TRIO MRI scanner with a 32-channel head coil.The MRI scanning protocol will have scans to measure voxelwise and whole-brain measures of grey matter (GM) volumes through a high resolution T1-weighted (T1W) multi-echo magnetization prepared gradient echo (MEMPRAGE) anatomic scan.~Total time in scanner will be approximately 53 minutes."
46008872|NCT00477971|Procedure|autologous hematopoietic stem cell transplantation|Given on day 0
46008873|NCT04558086|Device|Virtual reality|To develop the intervention strategies of hospitalized school-age children with IV placement, using interactive virtual reality(VR)as a guiding play and emotional catharsis play, to further examine the effectiveness of reducing IV pain and fear.
45460143|NCT03905317|Drug|Bevacizumab Injection|Bevacizumab maintenance therapy starts 1-2 months later after the chemotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, and the drug is given every 3 weeks until disease progression or intolerable toxicity occurs.
45460144|NCT03905317|Radiation|chest radiation|The patients receive SBRT radiotherapy for the primary (if any) and metastatic lesions or divided radiotherapy with or without concurrent chemotherapy.
45460145|NCT03905317|Drug|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
45460146|NCT03487848|Drug|Daclatasvir|Specified dose on specified days for specified duration
45460147|NCT03487848|Drug|Sofosbuvir|Specified dose on specified days for specified duration
45460148|NCT03914365|Procedure|Ultrasound-guided pudendal nerve block (PNB) and Ultrasound-guided penile nerve block (DPNB)|Our primary objective is to compare analgesia between the two blocks during and after pediatric circumcisions to minimize post-operative pain.
45460149|NCT05662878|Other|Assessment of Hand Strength and Spasticity|Assessment of Hand Strength and Spasticity
45460150|NCT03911635|Procedure|URAGPI technique|the Urethral Advancement, Glanuloplasty and Preputioplasty
46008874|NCT04558086|Device|Photo book|To develop the intervention strategies of hospitalized school-age children with IV placement, using Photo book to further examine the effectiveness of reducing IV pain and fear.
46008875|NCT00477464|Drug|Lapatinib|1250mg once daily
46008876|NCT00477464|Drug|capecitabine|2000mg/m^2 twice daily (14 days out of 21 days)
46095964|NCT02572648|Other|Cognitive Function Assessment|Cognitive function will be assessed using several batteries; the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Controlled Oral Word Association Test (COWA), the Color Trails 1 & 2, the WAIS-III Digit Span and Letter Number Sequence test, the Stroop Test, and the California Computerized Assessment Package Reaction Time test (CALCAP).
46095965|NCT02695901|Drug|Chlorhexidine gluconate 0.12% (PerioGard®)|At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%). Plaque indices will be recorded at baseline, day 4, and day 7.
46095966|NCT02695901|Drug|Nanoparticle solution of M. alternifolia oil (0.3%).|At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing a nanoparticle solution of M. alternifolia oil (0.3%). Plaque indices will be recorded at baseline, day 4, and day 7.
46095967|NCT00677664|Drug|Glatiramer acetate (Copaxone)|Drug was offered by subcutaneous administration one week prior and in the three sections of PRP, one per week.
45460151|NCT03719352|Procedure|Experimental: Deep dry needling|Deep dry needling until achieving twitch response of the muscle
45460152|NCT03719352|Procedure|Experimental: Superficial dry needling|Superficial dry needling to achieve sensitive pain with needle rotation
45460153|NCT03719352|Procedure|Placebo Comparator: Placebo Gastrocnemius dry needling|Simulate pain with de plastic needle guard in the gastrocnemius muscle
45460154|NCT01251991|Drug|Psyllium husks|Oral suspension, oral use, two daily dosages consisting of 5 grams each
45460155|NCT01251991|Dietary Supplement|Isolated soy protein|Oral suspension, oral use, 30 grams once per day
45460156|NCT01251991|Dietary Supplement|Isolated whey protein|Oral suspension, oral use, 30 grams once per day
45460157|NCT01251991|Other|Microcrystalline cellulose|Oral suspension, oral use, two daily dosages consisting of 5 grams each
45460158|NCT03719274|Dietary Supplement|vitamin c depigementation|locally injected vitamin c depigementation
46008877|NCT02212275|Drug|Dextromethophan|A single age and weight appropriate dose of over the counter Delsym Cough Syrup containing only DXM as an active ingredient.
46008878|NCT04558008|Behavioral|Online MBSR|Described previously
46008879|NCT04557774|Other|Cognitive function test|"Laboratory and imaging test~Biochemical serum test: total bilirubin, alanine aminotransferase (ALT), haptoglobin, aspartate aminotransferase (AST), gamma glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), albumin, blood urea nitrogen, creatinine, α-fetoprotein (AFP), prothrombin time, blood glucose, triglycerides, and total cholesterol.~Baseline evaluations: family and alcohol history, X-ray, electrocardiography, blood tests for electrolyte, liver function, and viral markers~Neuropsychological test~-Attention, Language, Visuospatial, Memory, Frontal/executive"
45460159|NCT04458454|Diagnostic Test|Relaxin ELISA Kit|Ovarian stimulation was carried out from day 3 of the menstrual cycle using a fixed protocol, with recombinant (Gonal-F, Pergoveris) or human menopausal gonadotropins (Meriofert), GnRH antagonist (ganirelix 0.25 mg). A recombinant human chorionic gonadotropin Ovitrel 250 μg or a GnRH agonist, Diferelin 0.2 mg, was used as an ovulation trigger.
46008880|NCT00477386|Drug|decitabine|"Decitabine dose will be escalated as follows.~Dose level 1: 10mg/m2 IV QD X 5 days Dose level 2: 20mg/m2 IV QD X 5 days Dose level -1: Carboplatin AUC 4."
46008881|NCT02212314|Behavioral|Response Inhibition Training|Computerized response inhibition training will be delivered via the Internet for 10 individual sessions.
46008882|NCT00477269|Drug|Imatinib mesylate|
46008883|NCT00477269|Drug|Placebo|
46008884|NCT04557852|Procedure|ATVM|Tailored anterior transvaginal mesh for pelvic organ prolapse
46008885|NCT00477152|Drug|hyaluronidase (human recombinant)/rehydration fluid|Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
46008886|NCT04557345|Diagnostic Test|Determination of cytokines|Subsequently, a blood sample will be taken from which the processing will be as follows: 6 ml of peripheral blood will be taken in tubes with a yellow cap and inert gel and clot retractor, immediately afterward it will be placed on ice, it will be transported to the laboratory where it will be centrifuged at 2500 rpm for 15 minutes at 4 degrees centigrade, immediately afterward 500 µl of serum will be aliquoted and stored at minus 75 ° C until later analysis. The general methodology for sandwich ELISA will be used.
46008887|NCT04557345|Diagnostic Test|Two-dimensional transthoracic echocardiogram|With prior informed consent, a two-dimensional transthoracic echocardiogram will be obtained by an echocardiographer certified by the Mexican Council of Cardiology (CMC) with a Phillips EPIC 7 echocardiography, 2D Arrary 3D Convex (1-6 Mhz) transducer.
46008888|NCT04557657|Drug|Active bio Activa|Cement that release fluoride
46008889|NCT04557657|Drug|Resin Cement|Resin Cement Convinonal
46008890|NCT00476996|Drug|Leflunomide|Oral repeating dose
46008891|NCT00476996|Drug|Methotrexate|Oral or parenteral repeating dose
46095968|NCT00677664|Drug|Mannitol|Drug was offered by subcutaneous administration one week prior and in the three sections of PRP, one per week.
46008892|NCT00476996|Drug|Ocrelizumab|Intravenous repeating dose (200mg)
46008893|NCT00476996|Drug|Ocrelizumab|Intravenous repeating dose (500mg)
46008894|NCT00476996|Drug|Placebo|Intravenous repeating dose
46008895|NCT04557267|Drug|low-dose|Dosage 1
46008896|NCT04557267|Drug|Middle-dose|Dosage 2
46008897|NCT04557267|Drug|Higher-dose|Dosage 3
46008898|NCT04557267|Drug|Placebo|Placebo
46037837|NCT02779582|Drug|Oral Micronized Progesterone|The dose of 300 mg of Progesterone is a physiological one that maintains the serum progesterone at or above the luteal (normal post-ovulatory) threshold for 24 hours. This duration of action is important because Progesterone is not safely taken during waking hours because of its soporific effects.
46037838|NCT02779582|Drug|Placebo|pill with no effect
46037839|NCT01197794|Drug|AZD1981|AZD1981 twice daily
46037840|NCT01197794|Drug|AZD1981|AZD1981 once daily
46037841|NCT01197794|Drug|Placebo|Placebo to match AZD1981
45460160|NCT03722316|Other|Immersive Nature Video|"An approximately 15-minute digital nature experience using work by filmmaker Louie Schwartzberg-Visual Healing by Moving Art. Time-lapse, high-speed, and macro cinematography are incorporated within each video. Audiovisual content include vivid imagery of a variety of ecosystems and climates accompanied by calming instrumental music.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention."
45460161|NCT03722316|Other|Neutral Video|"This video will include clips from relatively non-arousing educational documentaries. Fifteen minutes of documentary content will be selected from a longer video, ensuring that the content remains as neutral as possible. Video selections were modeled after the work from Eryilmaz, Van De Ville, Schwartz, and Vuilleumier (2011) who identified very brief movie clips (i.e., <1 minute) that were rated as neutral as opposed to frightful or enjoyable.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention."
45460162|NCT03914287|Other|Self-Myofascial release|The Self-Myofascial release protocol for the lower limbs using a Foam Roller will include: Self-Myofascial release of the plantar region using and Solid Ball Massage; release of the myofascial components of the back of the leg using a Foam Roller; release of the myofascial components of the anterior part of the leg using a Foam Roller; release of myofascial components of the hamstring region using a Foam Roller; release of the myofascial components of the adductor muscles using a Solid Ball Massage in a sitting position; release of the myofascial components of the abductor muscles using a Foam Roller in lateral decubitus; and release of the myofascial components of the pelvitrochanteric muscles using a Foam Roller in a sitting position.
45460163|NCT03479164|Other|Ultra Low-Dose CT|Ultra Low-Dose CT
45460164|NCT03911947|Device|Vibrolung|Device for vibroacoustic respiratory therapy
45460165|NCT03475030|Other|pre-filled medication trays|
45460166|NCT03475030|Other|automated medication reminders|
45460167|NCT03524664|Behavioral|Tuning In to kids intervention|"The Tuning Into Kids Program involves:~Meeting in a small group with other caregivers raising children with FASD.~8-week program that meets weekly for 2 hours at Mt. Hope Family Center or other community location.~Learn and practice an approach of responding to children's emotions and behavior."
45460168|NCT03914677|Drug|Mecamylamine Oral Tablet|nicotinic antagonist (ganglionic blocker)
45460169|NCT03474952|Procedure|remote ischemic preconditioning (RIPC)|remote ischemic preconditioning consists of 4 cycles of 5-min ischemia and subsequent 5-min reperfusion using pneumatic cuff applied to upper arm
46008899|NCT04557579|Procedure|Clear corneal phacoemulsification and IOL implantation|Clear corneal phacoemulsification and IOL implantation were performed by 2 surgeons (Chao-Kai Chang and Hung-Yuan Lin) by using an identical technique to minimize differences in surgically induced aberrations between groups. The surgical process involved topical anesthesia, a 3-step clear corneal incision (2.75 mm) at 180° (temporal in both eyes), a 5.0-mm continuous curvilinear capsulorhexis, phacoemulsification using the stop-and-chop technique, IOL implantation with an injector, IOL centration, and a sutureless incision. The study IOL models include EDOF Symfony IOL (AMO, Santa Ana, CA, USA), bifocal Restor +2.5D IOL (Alcon, Fort Worth, TX, USA), and monofocal Sensar AR40e IOL (AMO, Santa Ana, CA, USA).
46008900|NCT02212353|Other|Observational study, not interventional|
45460170|NCT03474952|Procedure|sham-RIPC|ischemia pressure less than 10 mmHg (sham-RIPC)
45460171|NCT03914131|Drug|Xinnaoning Capsule|Xinnaoning Capsule used in study group(treatment period) is the true drug that the investigators are to evaluate.
45460172|NCT03914131|Other|Xinnaoning Capsule Simulator|Xinnaoning Capsule Simulator used in control group and introduction period(both groups) is the placebo to reduce the risk of bias.
45460173|NCT03777826|Other|PKU Synergy|PKU Synergy is a citrus flavored, powdered amino-acid mixture (containing traces of Phe, 4,3mg per portion; and 20 gr. Protein Equivalent (PE)) with a tailored amino acid and micronutrient profile adapted for the special requirements of HPA/PKU (Hyperphenylalaninemia/Phenylketonuria) subjects over 10 years of age with an increased Phenylalanine-(Phe) tolerance/intake.
45460174|NCT03905551|Procedure|Cold Dialysis|Dialysate temperature reduced to 35oC for a period of 7 months.
45836802|NCT00464646|Drug|Bevacizumab|"Cohort A: Cycles 1-4, 15 mg/kg IV on day 1 of cycle 4 only; Cycles 5-7, 15 mg/kg IV on day 1 every 21 days x 3 cycles; post-operative therapy (beginning no sooner than 28 days after surgery), 15 mg/kg IV every 3 weeks x 13 doses~Cohort B: Cycles 5-8, 15 mg/kg IV on day 1 every 21 days x 4 cycles; beginning 3 weeks after last dose of docetaxel, 15 mg/kg IV every 3 weeks x 13 doses"
46008901|NCT04557306|Biological|CBT101 (2-6 x 10^9 cells), every 2 weeks|CBT101 (2-6 x 10^9 cells), every 4 weeks
46008902|NCT04557306|Biological|CBT101 (2-6 x 10^9 cells), every 4 weeks|CBT101 (2-6 x 10^9 cells), every 4 weeks
45460175|NCT03905551|Procedure|Typical Dialysis|Dialysate temperature is set at 37oC for a period of 7 months
45460176|NCT03905551|Procedure|Exercise|Aerobic Intradialytic exercise training
45836803|NCT00385008|Drug|Combination Product (sumatriptan succinate / naproxen sodium)|sumatriptan/naproxen sodium
45836804|NCT00385008|Drug|RELPAX(eletriptan) 40mg Tablet|eletriptan tablets
46008903|NCT00476957|Device|Stent|Stent implantation
46008904|NCT00476957|Device|Stent|Stent implantation
46008905|NCT04556955|Device|Graston technique|Experimental group included Graston technique :The protocol consist of Longitudinal stroking parallel to muscle fiber for 1min , spin over trigger points for 1 min using knob of instrument and fanning for 2 min.
46008906|NCT04556955|Other|post isometric relaxation|Post Isometric Relaxation, 5 rep , 20% isometric contraction 10 sec , 20 sec of stretch hold beyond resistance barrier
46008907|NCT00475865|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
45460177|NCT03479086|Drug|Topiramate|200mg/day 100mg b.i.d
45460178|NCT03479086|Drug|Naltrexone|50mg/day
46008908|NCT00475865|Drug|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
46008909|NCT00475865|Drug|Glatiramer Acetate (GA)|Solution in prefilled syringe for subcutaneous injection
46008910|NCT04556877|Procedure|Intraabdominal pressure and optic nerve diameters|Measuring Intraabdominal pressure with a Foley cathater and measuring optic nerve diameters with a USG
46008911|NCT00475709|Device|Trifecta Aortic Heart Valve|Surgical replacement of the aortic valve with the Trifecta Aortic Heart Valve.
46008912|NCT04556994|Other|Phase 1 Cardiac Rehabilitation|"Step 1:Breathing exercises, 3 sets of 10 repetitions. Active upper and lower extremity exercises, 3 sets of 10 repetitions; bed inclined at 45°.~Step 2:Active exercises as in step 1. Stay in the upright position and perform walking on the spot for three series of 1 min.~Step 3:Active exercises as in step 2. Ambulation within the inpatient wards (7 min). Transfer to an allocated chair beside the bed (at least 30 min).~Step 4:Same exercises as in step 3. Ambulation within the inpatient wards (10 min). Transfer to an allocated chair beside the bed (at least 1 h).~Step 5:Same exercises as in step 4. Ambulation within the inpatient wards (15 min). Transfer to an allocated chair beside the bed (at least 2 h).~Step 6:Active exercises from the previous day. Ambulation within the inpatient wards (20 min). Step training (3 times continuously, 20 cm standardized step).~Step 7:Exercises from the previous day. Step training (6 times continuously, 20 cm standardized step)."
46008913|NCT04556994|Other|Phase 1 Cardiac Rehabilitation with Lower Limb Paddling|Step 1 to step 6 of Phase 1 Cardiac Rehabilitation given to the patients along with Lower limb exercise on Paddler lasting 20 min (5-min warm-up, 10 min of low-intensity exercise, and 5-min recovery), 30 rpm ( rotation per minute)
46095969|NCT02572492|Drug|Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan|"All patients entering the study receive four series of CAR-CY-DEX (Cycle 1 with iv carfilzomib 20 mg/sqm on days 1 and 2, and iv carfilzomib 36 mg/sqm on days 8, 9, 15 and 16. Cycle 2 - 4 with iv carfilzomib 36 mg/sqm on days 1, 2, 8, 9, 15 and 16. P.o. cyclophosphamide 300 mg/sqm on days 1, 8 and 15 and p.o. dexamethasone 20 mg on days 1, 2, 8, 9, 15 and 16 in each 28-days series)~Subsequently all patients receive the conditioning regimen:~Iv carfilzomib 27 mg/sqm on day -2 and -1 Iv melphalan 200 mg/sqm on day -2 > 2.0 m CD34+ stem cells/kg body weight on day 0"
46095970|NCT02572492|Drug|Carfilzomib/dexamethasone maintenance|Maintenance therapy two months after salvage HDT with iv carfilzomib 27 mg/sqm every second week and p.o. dexamethasone 20 mg every second week. The maintenance dose of carfilzomib will be escalated to 56 mg/sqm after 4 weeks provided acceptable side effects.
46095971|NCT02572492|Drug|Observation without carfilzomib/dexamethasone maintenance|Observation without carfilzomib/dexamethasone maintenance
46095972|NCT03905863|Device|Natrox® Oxygen Wound Therapy|A battery-operated device which delivers pure humidified oxygen to the wound bed through water electrolysis via a sterile oxygen delivery system.
45460179|NCT03720054|Behavioral|MapTrek|Our objective is to report activity levels in our virtual environment to veterans, thereby encouraging them first, to walk more every day, and second, to maintain these new increased levels of physical activity. MapTrek will also motivate veterans to accumulate less sedentary time.
45460180|NCT03720054|Behavioral|Fitbit|Fitbit Only
45460181|NCT01254097|Dietary Supplement|Probiotic|Probiotic capsule, 2 capsules twice daily
45460182|NCT05662020|Biological|Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)|9-19 years group (3 doses) and 20-26 years group (3 doses) will be vaccinated at months 0, 2, 6. 9-14 years group (2 doses) will be vaccinated at months 0, 6.
45460183|NCT05662020|Biological|GARDASIL® 9|20-26 years possitive control group will be vaccinated at months 0, 2 and 6
45460184|NCT03905395|Behavioral|Meditation and mindfulness|Women in the intervention arm will 3 times receive a three hours work shop with introduction to meditation and mindfulness over a 7 week period from a certified meditation instructor. Questionnaires before and after the intervention.
45460185|NCT05259280|Other|Wellinks|Digital health and virtual care program for COPD management.
45460186|NCT03913897|Other|distraction methods|The children in the groups were distracted by virtual reality goggles and kaleidoscope 2 minutes before venipuncture, until the process was over
45460187|NCT03474796|Behavioral|Eye-tracking|Visualisation of 4 photographic scenarios (surgical situations), questionnaire, eye-tracking
45678635|NCT01597557|Drug|Magnesium Sulfate|2 grams intravenous drip over 30 minutes
45460188|NCT01252069|Drug|PGL4001, placebo, drug free period|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets) during 3 periods each ending with a drug free period until return of menses.
45460189|NCT01252069|Drug|PGL4001, progestin, drug free period|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets) during 3 periods each ending with a drug free period until return of menses.
45460190|NCT01252225|Drug|10 % Lidocaine|600 mg Nebulised Lidocaine ( 6 mls of 10 % Lidocaine) one-off dose
45678636|NCT01597557|Other|Placebo|Normal Saline 50 ml intravenous drip over 30 minutes
45678637|NCT01914757|Biological|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 52 inclusive.
45460191|NCT01252225|Drug|10 % Lidocaine|100 mg Lidocaine ( 1 ml of 10 % Lidocaine) given as one-off throat spray.
45678638|NCT01914757|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 52 inclusive.
46008914|NCT04556721|Drug|Sugammadex|On the day of surgery, after the establishment of general anesthesia, patients will be paralyzed via rocuronium. At the cessation of the case, an appropriate dose of Sugammadex will be utilized to reverse the rocuronium neuromuscular blockade.
46095973|NCT02628288|Device|Coronary Bifurcation PCI|In one group, the coronary bifurcation lesion will be treated (Coronary bifurcation PCI) with the Axxess device + Absorb BVS. In the other group, the coronary bifurcation lesions will be treated(Coronary bifurcation PCI) by modified T stenting using Absorb BVS.
46095974|NCT00718822|Other|oxygen concentration in the culture atmosphere|
46095975|NCT02626884|Drug|Ibrutinib|
46008915|NCT00475670|Drug|Trastuzumab|4 mg/kg i.v. loading dose on Day 1, followed by 2 mg/kg i.v. weekly; or 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks until disease progression, unacceptable toxicity, withdrawal or death.
46008916|NCT00475670|Drug|Taxane (docetaxel or paclitaxel)|Docetaxel 100 mg/m2 i.v. every 3 weeks, or paclitaxel administered in a dose of 75 mg/m2 i.v. weekly or 175 mg/m2 i.v. every 3 weeks for at least 18 weeks, or more at the discretion of the investigator. Choice of taxane at the discretion of the investigator. Taxane may be administered at the same time, or 24 hours after, administration of trastuzumab.
45460192|NCT01252225|Drug|0.9% saline|6 mls of 0.9% saline nebulised followed by 1 ml of 0.9% saline as throat spray
45460193|NCT04459780|Biological|Skin biopsies|3 biopsies on lesion skin (and one more for the first fifteen subjects in group 1)
45460194|NCT04459780|Biological|Blood sample|One blood sample for the group 1 only.
46095976|NCT02753387|Drug|Chlorhexidine|4 mouthwashes during 30 seconds with Eludril Perio 10 ml and 1 application after intubation with Eludril Perio
46095977|NCT02753387|Device|NaCl 0.9 %|4 mouthwashes during 30 seconds with NaCl 0.9 % 10 ml and 1 application after intubation with NaCl 0.9 %
46095978|NCT03968536|Behavioral|fall prevention|Training in physiotherapy sessions and ergonomic home development
46095979|NCT00672282|Drug|Bicalutamide|150mg p.o. daily
46095980|NCT00672282|Drug|Placebo|
46095981|NCT02753309|Drug|Sirolimus|
46095982|NCT00714766|Procedure|Intravascular volume administration|Infusion of colloid to reestablish CVP under heat stress
46095983|NCT05017129|Behavioral|Inmates Care|The single intervention is a computer-based learning program.
46095984|NCT02753231|Behavioral|Low physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
46095985|NCT02753231|Behavioral|High physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
46095986|NCT02753231|Behavioral|Low and High physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
46095987|NCT02753231|Behavioral|Conventional physical activity program|One Physical Education sessions / week
45678639|NCT02003573|Drug|decitabine iv|decitabine iv fixed dose
45678640|NCT02003573|Drug|volasertib iv infusion|volasertib iv infusion (Body Surface Area (BSA) based dosing)
46095988|NCT02573662|Biological|Blood and Urine sampling|Blood and Urine Sampling
46095989|NCT02573662|Radiation|DXA scan|Scan of Lumbar columna and neck of femur/hip Scan of visceral/subcutaneous fatty tissue
46095990|NCT02573662|Biological|OGTT|Oral Glucose Tolerance Test for Minimal Model analysis for insulin sensitivity and Lipid oxidation
46095991|NCT04330885|Other|Supervised abdominal exercises and stationary biking|Explain pain to the patients in order to minimize fear of movement
45678641|NCT01914679|Device|RINCE|The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.
45678642|NCT01789281|Drug|Everolimus|Everolimus was provided by the investigator in 2.5 mg, 5 mg or 10 mg tablets for daily oral administration. The starting dose of everolimus was the same as the last dose that was given in the parent study. Dose modification thereafter was done at the discretion of the Investigator based upon what is in the subject's best interest.
46008917|NCT04557072|Drug|Selective alpha-1-antagonist|Patients treated with selective alpha-blockade (prazosin, terazosin, doxazosin)
45678643|NCT01789281|Drug|Sandostatin LAR Depot|Sandostatin LAR Depot was provided by Novartis or by the investigational site considering local regulations. The dose and frequency of Sandostatin LAR Intramuscular injections was the same as the last dose that was given in the parent study.
45678644|NCT01923740|Device|XIENCE V EECSS|Subjects receiving XIENCE V
45678645|NCT01923740|Device|Absorb BVS System|Subjects receiving Absorb BVS System
45678646|NCT01789203|Drug|Ciprofloxacin|Patients will be randomized 2:1 active comparator, Cipro, to placebo comparator.
45678647|NCT01789203|Drug|placebo|Patients will be randomized 2:1 placebo comparator to active comparator, Cipro.
45678648|NCT01789047|Drug|Topiramate|Topiramate as adjunct to amantadine
46008918|NCT04557072|Drug|Non-selective alpha-1-antagonist|Patients treated with non-selective alpha-blockade (phenoxybenzamine)
46008919|NCT04556760|Drug|AZD9567|Participants will receive 72 mg/day (oral suspension) of AZD9567 for 3 consecutive days of each treatment period in Cohort 1 and 40 mg/day for 3 consecutive days of each treatment period in Cohort 2.
45678649|NCT01789047|Drug|Placebo|Placebo control
45678650|NCT01789047|Drug|Amantadine|Existing treatment for all participants
45678651|NCT01788423|Device|hearing aid|All subjects received hearing aids, some selected by audiologist, some selected by consumer, and some programmed as placebo devices.
45678652|NCT01617187|Drug|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually
45678653|NCT01617187|Drug|Placebo Asenapine|Fast dissolving placebo asenapine tablets (to match 2.5 mg and 5 mg active asenapine tablets) administered sublingually
46008920|NCT04556760|Drug|Prednisolone|Participants will receive 40 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 1, 20 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 2, and 5 mg/day prednisolone for 3 consecutive days of each treatment period in Cohort 3.
46008921|NCT04556760|Other|Placebo|Participants will receive placebo for 3 consecutive days of each treatment period in Cohort 3.
46008922|NCT00474968|Device|e2 Cell Collector [SoftPAP(R)]|Cervical cells collected using the e2 Cell Collector [SoftPAP(R)]
46008923|NCT00474968|Device|Spatula/Brush|Cervical cells collected using a combination of a cervical spatula and an endocervical brush
46008924|NCT04556799|Procedure|computer-assisted surgery|derotation osteotomy with the aid of 3D osteotomy template and computer-assisted simulated surgery
46008925|NCT04556799|Procedure|traditional osteotomy|traditional osteotomy without the aid of 3D osteotomy template
46095992|NCT00681408|Drug|Omega 3 Fish Oil supplements|Subjects in this arm will receive 3 grams daily Omega 3 fish oil supplements
46095993|NCT00681408|Drug|Placebo|Fish oil placebo pills
45460195|NCT03914209|Other|EHL clotting factor|This study shall not implement any intervention that might alter the normal development of the daily life activities of hemophilia patients included in the study. They will continue with the prophylactic regimen prescribed by their hematologist. Patients will also be asked to continue to develop their physical, work, entertainment and leisure activities in the same way as at baseline.
46008926|NCT00474929|Drug|RAD001|Phase I: Dose level 0: RAD001 5mg every other day; Dose level 1: RAD001 5mg every day; Dose level 2: RAD001 5mg every day; Dose level 3: RAD001 10mg every day; Phase II: RAD001 5mg every day;
46095994|NCT02753153|Procedure|Control surgical protocol|"A connective tissue graft will be harvested to the palate or posterior maxilla tuberosity. The dimension of the graft will be previously calculated according to the socket dimensions. The harvesting site will be made with a single edge incision and sutured with 4.0 silk (uninterrupted suture). The connective tissue graft will be reshaped if necessary to be 1-2mm thick and inserted into buccal pouch and sutured with 2 vertical interrupted sutures to be stabilized on the buccal aspect.~The connective tissue graft is then positioned to caver the socket and inserted and sutured in the palatal pouch also by the means of vertical interrupted sutures (polypropylen 6.0)."
46008927|NCT00474929|Drug|Sorafenib|Phase I: Dose level 0: Sorafenib 200 mg twice daily; Dose level 1: Sorafenib 200 mg twice daily; Dose level 2: Sorafenib 400 mg twice daily; Dose level 3: Sorafenib 400 mg twice daily; Phase II: Sorafenib 200 mg twice daily;
45460196|NCT04459702|Drug|hydroxychloroquine|Treatment with the drug hydroxychloroquine
45460197|NCT04459702|Drug|Azithromycin|Treatment with the drug azithromycin
46008928|NCT04556604|Behavioral|Educational meetings and visual prompts|Information was disseminated to trainees via informal meeting or dedicated audit meetings with the aid of visual prompts
46095995|NCT02753153|Procedure|Test surgical protocol|The filling biomaterial (Bio-Oss®, Geistlich), previously humidified with a saline solution containing doxycycline (1mg/ml) and inserted into the socket without heavy compaction.
45460198|NCT04459702|Drug|Ritonavir|Treatment with the drug ritonavir
45460199|NCT04459702|Drug|Lopinavir|Treatment with the drug lopinavir
46095996|NCT02753153|Procedure|Socket preservation|"An atraumatic extraction will be performed in order to preserve the socket bone wall as well as the cervical soft tissues.~Split- thickness pockets will be performed 5-6 mm deep buccally and 3-4 mm deep palatally preserving interproximal papillae. The filling biomaterial (Bio-Oss®, Geistlich), previously humidified with a saline solution containing doxycycline (1mg/ml) and inserted into the socket without heavy compaction. At this level of the surgery, the randomization envelope will be open and either the control or the test surgical protocol will be applied."
45460200|NCT01148641|Dietary Supplement|LNS|Infants and young children will receive 10 g of LNS for test trial during 3 consecutive days (crossover design) and thereafter, 20 g per day for 14 days.
45460201|NCT03911245|Other|Retrospective study. Analyze of data in medical records|Retrospective study. Analyze of data in medical records
45460202|NCT03478774|Drug|Oxygen 70l/min|HFNCT will be provided using OptiFlow by Fisher&Paykel.
45460203|NCT03478774|Drug|Oxygen 10 l/min|Medium flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.
45460204|NCT03478774|Drug|Oxygen 2l/min|Low flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.
45460205|NCT03478774|Procedure|Jaw thrust|Continuous
45460206|NCT03478774|Procedure|Videolaryngoscopy|Continuous
45460207|NCT03478774|Drug|oxygen 0.25l/min|0.25l/min of oxygen via an endotracheal tube
45460208|NCT03905005|Procedure|Mandibular reconstruction with free tissue transfer.|Mandibular reconstruction with free tissue transfer (free-flap bony reconstruction) requires the use of a titanium plate to secure bony segments until bony healing is complete. Plates are made of titanium but can be customised to the anatomical shape of the mandible by two different techniques: flexing (bending) of the plate before surgery, or printing of the plate from titanium alloy powder bed fusion techniques (additive manufacturing, such as selective laser melting).
46008929|NCT04556409|Device|low intensity pulsed ultrasound plus static abdominal and pelvic floor exercises.|Ultrasonic irradiation was employed with parameters of current use in clinical practice, including lower potency (0.16 W/cm2), which is more adequate for stimulation of nerve regeneration, according to results obtained in investigations in which the irradiation was applied at the lesion site 32, 33.
46008930|NCT04556409|Device|low level LASER plus static abdominal and pelvic floor exercises.|Application of laser irradiation (Ga-As laser) in the site of the anastomosis inhibits the degeneration process, accelerate remyelination, and nerve function recovery 27, 28
46008931|NCT04556409|Other|static abdominal and pelvic floor exercises only.|static abdominal and pelvic floor exercises., 3 times/week for 4 weeks.
46008932|NCT00474812|Drug|dasatinib|
46095997|NCT02573740|Drug|ABT-957|
46095998|NCT02573740|Other|Placebo|
46095999|NCT03113461|Device|CPAP|non-invasive positive airway pressure applied using an oronasal mask
45460209|NCT03574792|Drug|Gabapentin|Given PO
45460210|NCT03574792|Drug|Methadone|Given PO
45460211|NCT03574792|Drug|Oxycodone|Given PO
45460212|NCT03574792|Other|Quality-of-Life Assessment|Ancillary studies
45460213|NCT03574792|Other|Questionnaire Administration|Ancillary studies
45460214|NCT03574792|Drug|Venlafaxine|Given PO
45460215|NCT03574792|Drug|Venlafaxine Hydrochloride Extended Release|Given PO
45460216|NCT03904849|Drug|Cannabidiol|Cannabidiol oral solution
45460217|NCT03904849|Drug|Placebo|Placebo oral solution
45678654|NCT01617187|Drug|Olanzapine|5 and 10 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding
46008933|NCT00474812|Procedure|laboratory biomarker analysis|Correlative study
46008934|NCT00474812|Procedure|physiologic testing|Correlative study
46096000|NCT04147728|Drug|Anlotinib|Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.
46096001|NCT04147728|Radiation|Stereotactic Radiosurgery|Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases
46096002|NCT04174235|Device|Ultrasound scan|A full history taking was obtained according European surveillance of congenital anomalies EURO-CAT core data. All women underwent abdominal and transvaginal US (Toshiba Xario 200 unit)
46096003|NCT04004299|Diagnostic Test|HCV RNA self-test|Self-test set including instruction manual (video available as well), finger prick device, tube and envelope to safely transport biological material. Patient takes capillary blood sample, collects it in the tube and sends the sample to the lab by regular post mail.
45460218|NCT03471676|Other|Muscular oximetry|6 minutes walking test performed in the routine medical care with muscle oximetry recording
45460219|NCT01250743|Dietary Supplement|ascorbic acid (vitamin C)|intravenous vitamin C, 25 to 100 grams, once or twice a week, for five months
45678655|NCT01617187|Drug|Placebo Olanzapine|Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
45678656|NCT01759407|Drug|Ropivicaine|
45678657|NCT01759407|Drug|Epinephrine|
45678658|NCT01787331|Drug|Itraconazole|Given PO
45678659|NCT01787331|Other|Laboratory Biomarker Analysis|Correlative studies
45678660|NCT01787331|Other|Pharmacological Study|Correlative studies
46096004|NCT04147026|Device|SinnoTest®|"The selection of the biotherapy is carried out based on the recommendations of SinnoTest®. This test categorizes the bDMARDs based on the probability of response. It will allow to prescribe both original molecules, as well as biosimilars, in an equivalent way.~In the SinnoTest® arm, the investigator prescribes the treatment defined as the most effective by SinnoTest®, except in case of contraindication. If contraindicated, the investigator prescribes the second-choice treatment (if any) of SinnoTest® in terms of efficacy."
46008935|NCT04556643|Other|Breathing exercises|The main components of breathing exercises during training will be as follows (A) First, fill your stomach and then your lungs with air while breathing in; (B) Feel the expansion in the stomach; (C) Make sure the muscles from your stomach to your knee are relaxed, as if you are urinating while breathing out; (D) When there is pain, perform deep abdominal breathing exercises, and take a deep breath in and hold as much as you can; (E) Try to push the baby downward; (F) You can do it by holding your breath or breathing out quite slowly from your mouth; (G) The most important point in this stage is that you should not fill up the stomach with air, and you should push downward to deliver the baby; (H) You should continue the pushing until the pain is relieved
46008936|NCT00474383|Drug|Abiraterone acetate|Abiraterone acetate 1000 milligram (mg) capsule or tablet will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study.
46008937|NCT00474383|Drug|Glucocorticoid|Prednisone/prednisolone 5 mg tablet orally twice daily/dexamethasone 0.5 mg tablet orally once daily continuously in 28-day cycle up to disease progression, death, or end of study.
46008938|NCT04556448|Other|Aligners|Clear aligners
45678661|NCT01757847|Behavioral|Acceptance and Commitment Therapy (ACT)|The ACT group protocol consists of four 2-hour weekly sessions focusing on a) thoughts, feelings, and bodily sensations in the context of efforts to lose weight; b) limitations of efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness; and e) identification of personal values and goals to achieve improved quality of life.
46008939|NCT04556448|Other|Clear braces|Clear braces
46008940|NCT00474266|Biological|Meningococcal vaccine GSK134612 (Nimenrix)|Single dose intramuscular injection
46008941|NCT00474266|Biological|Priorix-Tetra|2-dose subcutaneous injection
46008942|NCT00474266|Biological|Meningitec|Single dose intramuscular injection
46096005|NCT04147026|Other|Biotherapy prescription without SinnoTest® software|The rheumatologist will use the current guidelines of rheumatoid arthritis to choose the more adapted biotherapy treatment to the patient
46096006|NCT04544189|Drug|Alpelisib|300mg (oral) once daily, in a 28-day cycle
46008943|NCT02277821|Device|Stendo pulsating suit System|The Stendo system, a multilayer pulsatile inflatable suit is applied to the lower limbs and the abdomen. This device induces a sequential compartmentalized compression synchronized with each diastolic phase of the cardiac cycle, each phase evolving centripetally (lower limbs to abdomen).
46008944|NCT00473564|Procedure|da Vinci® Robotic System|Head and Neck Surgery using the da Vinci® Robotic System
46008945|NCT00472199|Drug|Pramipexole|
46008946|NCT00472199|Drug|Placebo|
46008947|NCT04556331|Behavioral|Parenting programme (cognitive behavioural) aimed at reducing generational transmission of anxiety|'Psychoeducation' (psychologically informed information about the topic of transmitting anxiety) and cognitive-behavioural strategies aimed at reducing the transmission of anxiety from parent to young child. These will be shared with a group of maximum 8 remotely delivered, in a didactic format.
46008948|NCT00472082|Drug|efalizumab|Administration of a test dose of efalizumab 0.7mg/kg will be administered at enrollment. Weekly subcutaneous injections of efalizumab 1mg/kg will begin with study visit 2 and continue for 1 year for this pilot study.
46008949|NCT04556136|Device|Standing Phototherapy Kiosk|Benesol is a freestanding booth designed to deliver a small amount of targeted UVB with an interactive user interface and cloud-based software that enables patient self-care. The treatment delivery mechanism uses a metal halide lamp with a series of filters and a lens to optimize full-body exposure to the narrow spectrum (293 - 303nm) of UVB light most efficient at producing vitamin D3. The device uses software to identify patients, establish individual skin types and determine dosage. The system has been designed to manage exposure time and frequency and deliver 60% of a skin-type-adjusted Minimal Erythemal Dose (MED). The expected result for users is a rise in blood levels of 25(OH)D via the endogenous pathway.
46008950|NCT04556136|Dietary Supplement|D3 Oral supplement|Each subject assigned to the comparison group was instructed to take one vitamin D3 pill, dispensed by the research pharmacist, each day with a meal for 70 days. Subjects were instructed not to take any additional vitamin D supplementation during the study period. This dosing frequency is consistent with the RDA recommendation. Subjects were instructed to bring their pill bottle with them when returning for their follow up appointment.
46008951|NCT04556292|Drug|SC10914|SC10914 400mg tid
46096007|NCT04544189|Drug|Fulvestrant|Fulvestrant 500 mg (intramuscular, as two 250mg/5 mL injections) on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter
46008952|NCT00471887|Biological|CP-675,206|Patients will receive intravenous administration of CP-675,206 at a dose of 15mg/kg on Day 1 of an every 90 day cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 day period. Patients may receive up to 8 dose (8 cycles) in a 24-month period until progression of disease or intolerable toxicity.
45460220|NCT03481894|Drug|Kabiven®|"Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy."
45836805|NCT00466206|Device|Magnetic Mini-Mover Procedure (3MP)|"A rare earth magnet encased in FDA-approved titanium will be implanted securely on the outer surface of the lower end of the sternum in patients with pectus excavatum. This is accomplished as an outpatient procedure, under brief general anesthesia.~A 2-inch transverse skinline incision is made at the junction of the sternum and xyphoid and the space in front and behind the sternum is dissected bluntly. The titanium can containing the magnet is securely fixed to the sternum by screwing it into a titanium fixation disk in front of the sternum. The procedure takes 1/2-hour, and the patient can go home the same day.~In another outpatient procedure, the Magnimplant is explanted 18 months after implantation."
46008953|NCT04556058|Drug|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
46008954|NCT04556058|Drug|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
46008955|NCT00471536|Drug|pazopanib hydrochloride|800 mg Given orally
46008956|NCT04556019|Procedure|Hepatobiliopancreatic surgery|Different surgical techniques tailored to each patient´s pathology
46008957|NCT04556253|Drug|AK104|Subjects will receive AK104 by intravenous administration.
46008958|NCT00470834|Drug|dutasteride|0.5mg dutasteride (Investigation Product)
46008959|NCT00470834|Drug|placebo|making placebo
46008960|NCT00470834|Drug|bicalutamide|50 mg Casodex or generic equivalent
46008961|NCT04555746|Behavioral|Physical activity|Four PA experts (researchers (PhD) within the field of PA and health in children, and physical education teachers) in collaboration with two members of the ECEC staff and two members of the municipality health department (paediatric physiotherapists) developed a frame for the intervention based on COP elements to be further developed, concretized and implemented by the staff. The intervention lasted for four months and contained the following components (Table 1): pre-meetings and follow up meetings in each ECEC institution; start up seminar and two follow up courses with all the staff members; ongoing planning and collective reflections practice in the ECEC institutions; Facebook group; and an equipment-package.
46008962|NCT04555824|Drug|Recombinant Human Thymosin β4|Healthy subjects , were given a single intravenous dose of rh-Tβ4 in Day1.
45460221|NCT03481894|Drug|Compounded standard parenteral nutrition|"Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy."
45460222|NCT01147237|Device|Intracoronary stent implantation|Everolimus-eluting stent implantation in patients with long coronary artery disease
45460223|NCT03474562|Drug|Duowell®|Telmisartan/Rosuvastatin 40/20mg (increased to Telmisartan 80mg if SBP > 140mmHg or DBP > 90mmHg at week 12)
45460224|NCT03474562|Drug|Monorova® + Amlopin®|Rosuvastatin 20mg + Amlodipine 5mg (increased to Amlodipine 10mg if SBP > 140mmHg or DBP > 90mmHg at week 12)
45460225|NCT01254175|Biological|rHPIV3cp45 Vaccine|10^5 TCID^50 of rHPIV3cp45 vaccine, delivered as nose drops
45460226|NCT01254175|Biological|Placebo Vaccine|Placebo vaccine, delivered as nose drops
45460227|NCT03911479|Procedure|Bariatric Surgery|Bariatric Surgery - convencionals Roux-en-Y gastric bypass (RYGB) and vertical gastrectomy (Sleeve; SG)
45836806|NCT00466206|Device|Magnatract (external magnet in a removable external brace)|"An external orthotic device Magnatract which includes an external magnet in a removable brace is fitted specifically to the patient's chest wall deformity. A calibrated meter in the external device measures the force applied between the two magnets. When the patient and family are comfortable with the device and comfort and skin condition have been assessed, the patient will be allowed to take the Magnatract home and begin the process of gradually advancing the sternum forward as the abnormal costal cartilage is reformed."
46008963|NCT04555824|Other|Placebo|Five cohorts, with 10 healthy subjects , were given a single intravenous dose of Placebo. Cohorts received ascending doses of either 0.5, 2,5,12.5 or 25 ug/kg in Day1.
46008964|NCT00470366|Biological|pegfilgrastim|
46008965|NCT00470366|Drug|cisplatin|
46008966|NCT00470366|Drug|ifosfamide|
46008967|NCT00470366|Drug|paclitaxel|
46008968|NCT02212431|Drug|Cysteamine|Dose will be increased weekly from 450mg od to 450mg bd, to 450mg tds to 450mg qds, will remain on highest dose for 2 weeks
46008969|NCT00470093|Biological|recombinant interferon-α|
46008970|NCT00470093|Biological|recombinant interleukin-6|
46008971|NCT02212548|Device|PEG Hydrogel (SpaceOAR)|A single injection of PEG hydrogel (SpaceOAR) through the perineum under transrectal ultrasound guidance while under general anaesthetic.
46008972|NCT00470054|Drug|dasatinib|Given PO
45836807|NCT00466206|Procedure|3MP (Magnetic Mini-Mover Procedure)|"Subject has EKG performed to measure baseline cardiac activity.~Magnimplant is implanted.~After one week, Magnatract is fitted.~Chest x-ray and 2nd EKG performed 30 days post-implantation.~Patient and parents complete QoL questionnaire 30d post-implantation.~Patient seen weekly for first month post-implantation to assess comfort and skin condition. Thereafter, will be seen monthly.~At each monthly visit, patient will have lateral and anterior-posterior chest X-rays to monitor sternal correction.~At each visit data logger is downloaded to measure strength of pull since last visit and amount of wear-time.~Magnimplant explanted 18 months later as 1/2-hr outpatient procedure.~CT scan and third EKG performed after explanation.~Patient and parents complete QOL questionnaires after explantation and 1 yr post-explantation."
45678662|NCT01757847|Behavioral|Brief MOVE-II control group intervention|The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition to reinforcing the strategies taught during MOVE! and to provide support in implementing those strategies, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism.
45460228|NCT03478618|Drug|Lactated Ringer|"Patients will be divided into 2 groups according to the amount of fluids received during caesarian section under spinal anesthesia.~Group (R) 30 patients will receive 15ml/kg/h lactated Ringer (LR) intraoperative. Group (L) 30 patients will receive 30ml/kg/h lactated Ringer (LR) intraoperative. blood loss will be replaced if more than 500 ml in ratio 3 ml crystalloid : 1ml blood in both groups"
45460229|NCT03911323|Other|diabetic retinopathy|Patients with diabetes enrolled will undergo nonmydriatic fundus imaging and seven-field stereoscopic photography. The images will be run on an artificial intelligence (AI) algorithm. The diagnosis of the AI algorithm will be compared to the diagnosis of seven-field stereoscopic photography by ophthalmologist. Sensitivity and specificity will be calculated to evaluate the performance of AI algorithm.
45460230|NCT04377620|Drug|Placebo|Placebo administered BID approximately 12 hours apart
45460231|NCT04377620|Drug|Ruxolitinib|Ruxolitinb administered BID approximately 12 hours apart
45460232|NCT03478540|Drug|Anti-Retroviral Agents|First line antiretroviral therapy as recommended in China, e.g. tenofovir lamivudine and efavirenz
45678663|NCT01787097|Drug|Symbicort® total dose 400ug/12ug|Symbicort® is combination of formoterol 400ug and budesonide 12ug. Single dose
45678664|NCT01787097|Drug|Symbicort® total dose 800ug/24ug|Symbicort® is combination of formoterol 800ug and budesonide 24ug. Single dose
45836808|NCT00410904|Drug|cediranib maleate|
45836809|NCT00410904|Drug|pemetrexed disodium|
45460233|NCT01148095|Drug|AZD2516|Oral, single, daily, 11 days
45678665|NCT01787097|Drug|Formoterol 24ug|Turbuhaler
45836810|NCT00385788|Drug|Gemcitabine|800 mg/m^2 IV over 30 minutes on Day -7 (1 day)
45836811|NCT00385788|Drug|Fludarabine|33 mg/m^2 IV over 30 minutes Day -5 to Day -2 (4 days)
45836812|NCT00385788|Drug|Melphalan|70 mg/m^2 IV over 30 minutes on Day -3 to Day -2 (2 days)
45836813|NCT00385788|Drug|Antithymocyte Globulin|"2 mg/kg IV on Day -4 and Day -3 (2 days) before stem cell transplantation.~If receiving transplant from matched unrelated donor (not a blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant."
46008973|NCT04555668|Other|Global Postural Reeducation Program|Global Postural Reeducation Program with hamstring stretch The lying posture with flexion of the legs aimed to stretch the posterior chain (upper trapezius, levator scapulae, sub occipital, erector spinae, gluteus maximus, ischio-tibial, triceps surae, and foot intrinsic muscles). The initial position will lying with the hip flexed and progression consisted of increasing hip flexion, knee extension, and dorsiflexion of the ankle All above exercises will be given and to be held for 15 minutes each. 40 min/session, 3 times/week for 6 weeks
46008974|NCT04555668|Other|Hamstring Stretch Program|Hamstring Stretch Program 3 times for 30 seconds hold, subjects rested for 15 seconds between stretches. Knee -flexor eccentric training to prevent hamstring muscle strain 10-15 rep 40 min/session, 3 times/week for 6 weeks
46008975|NCT00478595|Drug|Rimonabant|Tablet, oral administration
45460234|NCT01148095|Drug|Placebo|
45460235|NCT03474328|Device|AlcoChange|Smartphone app and breathalyser
45678666|NCT01787097|Drug|BUD total dose 800ug|Turbuhaler
46008976|NCT00478595|Drug|Placebo (for Rimonabant)|Tablet, oral administration
45460236|NCT03903367|Drug|Fentanyl Citrate|standard GA and receive fentanyl infusion 2 mcg/kg/h after tracheal intubation and stopped at the end of the operation ,When HR or MBP increased ≥20% from base line readings, incremental dose of fentanyl will be given (2mcg /kg).
46096008|NCT04544189|Drug|Placebo|300 mg by mouth once daily, in a 28-day cycle
45460237|NCT03486834|Biological|V160|V160 was administered as a 0.5 mL (100 Units/0.5 mL dose with Merck aluminum phosphate adjuvant [MAPA], 4°C stable formulation) IM injection.
45678667|NCT04414371|Other|Yoga|Yoga Namaskar and Nadi Shuddhi
45678668|NCT01757691|Drug|Fingolimod 0.5mg/daily|
45678669|NCT01757691|Drug|Placebo|
45678670|NCT01786707|Biological|Autologous stem cells|Pancreatic artery infusion of Autologous Stem cells.
45836814|NCT00385788|Procedure|Allogeneic Stem Cell Infusion|Infusion of stem cells on Day 0.
45836815|NCT00385788|Drug|Tacrolimus|0.03 mg/kg beginning Day -2 by vein over 24 hours; when tolerable change to pill form given once daily for 3-4 months.
45836816|NCT00385788|Drug|Filgrastim (G-CSF)|Starting 1 week after transplant (Day +7) given as injection under the skin once daily until blood cell levels return to normal.
46008977|NCT00478595|Drug|Anti-diabetic monotherapy|Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period
45836817|NCT00385788|Drug|Methotrexate|5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.
45836818|NCT00411684|Drug|CDB-2914|
45836819|NCT00386256|Device|Health Buddy, Home telehealth technology|Exercise questions, educational messages, and clinical reminders have been programmed into the home telehealth technology and are administered daily via the Health Buddy(R) to evaluate the program's feasibility based on adherence rates, program completion rates, and safety.
46008978|NCT04555707|Drug|Apremilast 30mg|30mg PO BID started within 10 days of baseline
46008979|NCT04555707|Drug|calcipotriene and betamethasone dipropionate|1 application daily starting at baseline and continuing for 4 weeks; those achieving clear or almost clear PGA at week 4 will continue application twice weekly on Monday and Thursday in combination with Otezla. Enstilar application is discontinued at week 16 and study participation continues until week 20.
46008980|NCT04673279|Diagnostic Test|serology|An enzyme linked immunosorbent assay (ELISA) developed and validated in Argentina which detects antibodies against two viral antigens, trimeric spike and the receptor binding domain (RBD) of the spike protein.
45678671|NCT01786707|Other|Hyperbaric oxygen therapy|
45678672|NCT01786707|Drug|Insulin|Insulin dose as per clinical management
45678673|NCT01786707|Drug|Metformin|Metformin dose as tolerated
46008981|NCT04555980|Device|Warming patch|The warming patch can increase the temp of injection site, result in a blood vessels to dilate, which may have some contribute to decreasing injection pain.
46008982|NCT04555980|Device|Cotton patch|The Cotton patch will cover the injection site as placebo. It dose not have the function of heating comparing to Warming patch.
45678674|NCT01786629|Drug|SUPREP Bowel Prep Kit|solution for oral administration prior to colonoscopy
46096009|NCT04330690|Drug|Artesunate|2.4 mg/kg at 0 hours, 12 hours, 24 hours, and then daily for a total of 7 days plus standard of care
46008983|NCT04673084|Device|negative pleural suction|by comparing the effect of water seal alone of chest tube in one groups of trauma patients and the effect of both water seal and suction in other group
46008984|NCT02212626|Device|Rotarex S|
45460238|NCT03486834|Drug|Placebo|Saline solution administered as a 0.5 mL IM injection
45678675|NCT01786629|Drug|FDA approved bowel preparation containing electrolytes|solution for oral administration prior to colonoscopy
45678676|NCT01786551|Drug|Eplerenone|50 mg daily for 14 days
45678677|NCT01973569|Drug|denosumab|denosumab administered subcutaneously
45678678|NCT01973569|Drug|placebo|placebo administered subcutaneously to match denosumab
45678679|NCT01973491|Drug|ATX-MS-1467|Subjects will receive ATX-MS-1467 50 microgram (mcg), 200 mcg and 800 mcg on Day 1, Day 15 and Day 29 respectively during the titration period followed by biweekly dose of ATX-MS-1467 800 mcg for 16 weeks during the treatment period.
45678680|NCT01951586|Drug|Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
45678681|NCT01951586|Drug|Zoledronic acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
45836820|NCT00386256|Other|Telephone counseling|
45836821|NCT00412074|Drug|400 IU Vitamin D3 (cholecalciferol)|400 IU vitamin D3/day given to lactating mother and 400 IU vitamin D3/day given as oral supplement to her infant
46037842|NCT04307316|Other|ACBT group|"ACBT:~Breathing control 3 to 4 Thoracic Expansion Exercise A: 3 seconds hold B: Chest clapping C: Chest vibration Forced Expiratory Technique Breathing control A: 3 seconds hold B: Chest clapping C: Chest vibration 3 to 4 Thoracic Expansion Exercise Breathing control 1-2 Huff combine with breathing control Huff and cough~Chest Physical Therapy Early mobilization"
46096010|NCT04330690|Drug|Imatinib|400 mg enterally daily for 14 days plus standard of care
46096011|NCT04330690|Drug|Infliximab|5 mg/kg IV given one time, over 2 hours plus standard of care
45678682|NCT01951586|Drug|Placebo to Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
46096012|NCT04330690|Drug|Dexamethasone|6 mg IV/oral for a further five days, followed by a five day taper of 4 mg x 2 days and 2 mg x 3 days, for a total 20 day steroid course. If randomized to standard of care, discontinue the corticosteroid on day 10
45460239|NCT02523664|Drug|Hydrocortisone|effects of hydrocortisone on memory while fMRI
45836822|NCT00412074|Drug|2400 IU Vitamin D3 (cholecalciferol)|2400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
45836823|NCT00412074|Drug|6400 IU Vitamin D3 (cholecalciferol)|6400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
45836824|NCT00412464|Drug|Fondaparinux|Fondaparinux 0.1 mg/kg (up to 7.5 mg max initial dose) once daily for up to 21 days.
45836825|NCT00466752|Drug|sorafenib tosylate|Given PO
46037843|NCT04307316|Other|Conventional Physical therapy|Chest percussion, deep breathing, Huff and cough. Early mobilization
46037844|NCT02779426|Behavioral|Text messages|Daily text messages with information about atopic dermatitis and treatment reminders.
46096013|NCT04330690|Drug|LSALT Peptide|5 mg , 2 hour IV infusion once daily for up to 14 consecutive days
46096014|NCT03083041|Biological|SHR-1210|SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg
45460240|NCT02523664|Drug|Placebo|
45460241|NCT01252303|Behavioral|Nutrisystem|Nutrisystem meal replacements for 12 weeks
45460242|NCT04360772|Diagnostic Test|mHLA-DR|"Before treatment/ At inclusion/Day 0 : Collection of gender, date of birth, comorbidities, pathology implicating treatment by corticosteroids and other treatment administered at the time of inclusion.~At Day 0, Month 1, Month 3, Month 6 : Blood sampling (3mL) to proceed to mHLA-DR measurement. At those time-points, results from lymphocytes immunophenotyping, C-reactive protein and numeration will be collected.~At Month 24 : Collection from medical report of~any infectious events that would have occured during the follow-up~course of the disease with corticosteroids~survival or death at 24 months of follow-up."
45460243|NCT03177460|Biological|Daratumumab|Given IV
45460244|NCT03177460|Drug|FMS Inhibitor JNJ-40346527|Given PO
45460245|NCT03177460|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
45836826|NCT00466752|Genetic|microarray analysis|Correlative studies
46096015|NCT03083041|Drug|Apatinib|Apatinib tablet will be administered orally,once daily until progression
46096016|NCT00681486|Drug|Ghrelin|High dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
46037845|NCT04228198|Procedure|Radical cystectomy|Procedure/Surgery: Radical cystectomy. Removal of urinary bladder with three different approaches: i) Robotic-assisted, ii) Laparoscopic, and iii) Open Surgery
46096017|NCT00681486|Drug|Ghrelin|Low dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
45460246|NCT02528071|Other|Diaphragmatic endurance test|This consists of hyperventilation in a flask while maintaining the constant level of Carbon Dioxide (CO2). The patient will realize hyperventilation to increasing levels of Maximum Minute Ventilation (MMV), corresponding to increasing levels of respiratory rate, until exhaustion
45460247|NCT01254253|Device|Percutaneous coronary intervention, PCI|PCI was performed using standard techniques for CTO.
45460248|NCT05760404|Procedure|Surgery for colorectal cancer|Patients undergoing upfront surgery or surgery after neoadjuvant therapy for colorectal cancer with curative intention
45460249|NCT05760404|Other|in vitro study|on tissues from colorectal resections
45460250|NCT03905161|Other|6-minute walk test|The 6-minute walk test (6MWT) is widely used in the clinic to measure treatment efficacy and disease progression in patients with neuromuscular diseases and is found valid and reliable to measure decrease in walking speed for neuromuscular patients.
45460251|NCT01252381|Other|12 weeks Strength exercise training|Training 3 times a week, leg extensions and leg press
45460252|NCT05410184|Device|Virtual Reality Glasses group|Except for the preparation of the patient for the procedure, since the colonoscopy procedure takes approximately 30 minutes, 30-minute 360-degree VR video scenes will be watched using the phone and VR head device
45678683|NCT01951586|Drug|Standard Chemotherapy|Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.
45678684|NCT01951586|Drug|Placebo to Zoledronic Acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
45678685|NCT04643678|Drug|Anakinra|Patient will receive Anakinra 100 mg SC injection every 12 hours for 3 days, then 100 mg once daily from day 4 to day 7 plus Standard of Care
45836827|NCT00466752|Other|immunohistochemistry staining method|Correlative studies
45836828|NCT00466752|Genetic|gene expression analysis|Correlative studies
46037846|NCT04878432|Drug|MBG453|Solution for intravenous infusion
46037847|NCT04878432|Drug|Azacitidine|Solution for subcutaneous injection or intravenous infusion
46037848|NCT04878432|Drug|Decitabine|Solution for intravenous infusion
46037849|NCT04878432|Drug|INQOVI (oral decitabine)|Tablet for oral administration
46096018|NCT02767895|Behavioral|Prehabilitation|Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
45460253|NCT05410184|Other|mural curtain group|the mural curtain group; they will be asked to focusing the mural curtain with a nature view during the colonoscopy procedure.
45460254|NCT03522948|Behavioral|Brief intervention with text messaging to reduce sexual risk and heavy drinking among MSM|Combines a brief in-person motivational intervention with personalized cognitive counseling elements and 4 weeks of personalized text messaging to support goals related to sexual risk behavior and alcohol use
45678686|NCT04643678|Other|Standard of Care|Patients will receive the Standard of Care therapy as per the local treatment protocol
46096019|NCT05361265|Other|fetal movement counting|pregnant women were trained about fetal movements and fetal movement counting was taught. Pregnant women were asked to perform ten fetal movements by counting once a day. In the application of the study, it was ensured that the pregnant women in the experimental group performed fetal movement counting for at least four to six weeks. In this context, pregnant women were called every week to monitor and to motivate them to continue the counting.
46008985|NCT04673201|Procedure|"Viscotrabeculotomy Versus trabeculectomy with MMC"|Viscotrabeculotomy involved the creation of a partial thickness scleral flap, followed by localization of Schlemm's canal by radial incisions.High viscosity sodium hyaluronate was injected into Schlemm's canal.Trabeculotomy was completed using the standard metal Harm's trabeculotome.The scleral flap was then secured and conjunctival closure ensued.Trabeculectomy technique involved a creation of a limbal-based conjunctival flap, followed by creation of a half-thickness sclera flap. MMC was applied underneath the conjunctival flap.The procedure was completed with both sclera and conjunctiva closed by 10/0 nylon sutures.
46096020|NCT00677742|Other|enhanced initial supply of oral contraception|7 packs of pills, or 1 pack of pills and a prescription for 6 refills
46096021|NCT00677742|Other|conventional initial supply of oral contraception|3 packs of pills, or 1 pack of pills and a prescription for 2 refills
46096022|NCT02752919|Drug|Galunisertib|Administered orally
45678687|NCT04641728|Drug|Pembrolizumab|pembrolizumab 200 mg every three weeks (Q3W)
45678688|NCT04641728|Drug|Olaparib|olaparib 300 mg twice daily (BID)
45836829|NCT00466752|Procedure|needle biopsy|Correlative studies
46008986|NCT04555629|Other|Advanced Cognitive Stimulation Therapy Hong Kong|A modified version of Cognitive Stimulation Therapy for people with moderate to severe dementia translated and culturally adapted for the Hong Kong Chinese population.
46008987|NCT00478088|Device|NeoDisc|The NeoDisc is an artificial cervical intervertebral disc replacement intended for clinical use following a discectomy.
46037850|NCT04970368|Procedure|Sentinel node procedure|Excision of ALL mapped nodes and other suspicious nodes regardless of mapping and label by anatomic location
46096023|NCT00672360|Dietary Supplement|Folic acid|Compounded capsule, 7.6mg, taken orally, twice daily for 4 weeks.
46096024|NCT00672360|Dietary Supplement|Placebo|Compounded capsule of NaCl, taken orally, twice daily for 4 weeks.
46096025|NCT00714922|Procedure|PRK|Laser refractive surgery
46096026|NCT00714922|Procedure|SBK|Laser refractive surgery
46096027|NCT02752997|Other|Pharmacist discharge medication services|Included in arm descriptions
45678689|NCT01785849|Drug|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
45678690|NCT01785849|Drug|Placebo|Administered intravenously (IV) three times per week.
45678691|NCT01756833|Drug|Doxycycline|100 mg po bid
45678692|NCT01756833|Drug|Placebo|capsule identical to the doxycycline capsule
45836830|NCT00466752|Procedure|therapeutic conventional surgery|Undergo prostatectomy
46096028|NCT02628522|Other|ADRCs therapy|Patients with chronic anal fissures will receive one treatment of local injections of fat enriched with adipose derived regenerative cells starting from December 2014.
46008988|NCT00478088|Device|Instrumented Anterior Cervical Discectomy and Fusion (ACDF)|Surgical removal of the cervical disc, decompression, and anterior implantation of allograft bone with a cervical plate.
46008989|NCT00474188|Drug|CC-5013 (lenalidomide)|Lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle administerd in combination with dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle
46008990|NCT00474188|Drug|dexamethasone|Dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle administered in combination with lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle.
45460255|NCT05409014|Other|PFMT|The phase 1 of the protocol was awareness-raising, the athlete receives guidance from a physical therapist and learns the location of the PFM and the ability to contract them in isolation. The phase 2 is stabilization, consisting of 15 stabilization exercises, which are performed through pelvic floor contractions for 10 seconds and with the same relaxation time, repeating each group 10 times. The phase 3 is strength, the same exercises as the second phase are performed using 2 kg weights at the end of each leg and/or arm. There are eight groups of exercises and with changes in the time of slow contraction and relaxation. The phase 4 is power, in power exercises the training loads are increased and the sequence of movements is also increased. The phase 5 is to complement the power, this phase was the continuation of the previous one in the sense of potentiation of the results where ballistic movements, speed and impact fundamentally predominate.
45460256|NCT03911167|Procedure|open, laparoscopic, and robotic|Radical resection of rectal cancer in robotic, laparoscopic, and open approach
46008991|NCT04555473|Procedure|Tumor biopsy|"Both interventions performed at baseline upon study enrolment (pre- and post-NACT for NACT+IDS patients) and at the time of recurrence.~Part of each surgical specimen will be used to obtain organoids, whereas part will be frozen for direct comparative analysis of the original tumor (1-6 organoids from each patient).~Blood samples will be collected to purify extracellular circulating RNA (cRNAs)."
45678693|NCT01617967|Drug|Patisiran|Participants received a single dose of patisiran as an intravenous (IV) infusion on Day 0 and Day 28 (Q4W). Optional cohorts received an alternative dosing regimen (once every 3 weeks [Q3W]: Day 0 and Day 21) and an alternative premedication regimen.
45678694|NCT01785615|Drug|Atorvastatin|80mg
46008992|NCT04555395|Other|survival rates|survival rates
46008993|NCT00475982|Behavioral|Weight Loss|Subjects undergo a weight loss intervention prior to radical prostatectomy. The intervention includes weekly visits with the dietician, DEXA scanning, blood draws, and anthropometrics.
46008994|NCT00475982|Other|No Weight Loss Group|These subjects do not undergo a weight loss intervention prior to radical prostatectomy. This group does undergo DEXA scanning, blood draws, and anthropometrics prior to radical prostatectomy.
46008995|NCT01089647|Drug|budesonide and montelukast|budesonide aqua nasal spray 1 spray each nostril bid for 12 weeks Montelukast pill 10 mg po daily for 12 weeks
46008996|NCT01089647|Drug|Placebo|sugar pill po daily for 12 weeks salt water nasal spray 1 spray each nostril bid for 12 weeks
46008997|NCT04555434|Dietary Supplement|Probiotics|"Experimental group Main ingredients: P. pentosaceus KID7, L. lactis CKDB001 or L. helveticus CKDB001 (containing 9 × 10^9 CFU / day)~Control group Main ingredient: Crystalline cellulose"
46008998|NCT04673240|Drug|Botulinum toxin type A injection|"Adult patients with spasticity due to traumatic brain injury, spinal cord injury, or MS, treated with Botulinum Toxin type A.~As this is a non-interventional study, no diagnostic, therapeutic, or experimental intervention is involved. Subjects will receive clinical assessments, medications, and treatments solely as determined by their study physician."
46008999|NCT04555005|Other|Mindfulness based intervention|Mindfulness based intervention for frontline healthcare workers during COVID-19 outbreak
46009000|NCT01089608|Drug|Azithromycin|"Eye drops, Dosage : 1.5%~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times."
46009001|NCT01089608|Drug|Povidone|"Eye drops Single dose unit~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times."
45678695|NCT01785615|Other|Placebo|80mg
45460257|NCT03717168|Drug|Recombinant human growth hormone|All the patients received subcutaneous rHGH (0.3 IU/kg/ twice daily) for 10 days in addition to intensive care standard management.
45460258|NCT03717168|Other|Control|All patients will not receive growth hormone.
45460259|NCT04722926|Other|PJI|patients having had a PJI managed at the CRIOAc Lyon, with or without relapse
45460260|NCT03719196|Other|Reading glass|Participants from the experimental group have received reading glasses free of cost. Investigators hypothesize that a simple pair of eyeglasses could improve the lives of these people by enabling continued participation in the workforce, restoring productivity levels in both paid and unpaid work, and enhancing the ability to perform everyday tasks. Investigators also hypothesize that reading glasses will improve quality of life.
45460261|NCT03406078|Biological|Tezepelumab|Tezepelumab subcutaneous injection
45460262|NCT03406078|Other|Placebo|Placebo subcutaneous injection
45460263|NCT03719898|Drug|Brigatinib|Brigatininb is administered in tablet form. It is to be taken until disease progression, unacceptable toxicity or completion of 24 cycles. patients may continue to take brigatininb beyond 24 cycles if they are benefiting from the drug
46009002|NCT04554849|Other|Gender dysphoria psychosocial health|Retrospective analysis of medical records
45460264|NCT03719118|Genetic|genotyping for three genes (TPMT, NUDT15 and FTO)|Patients who carry any heterozygotic variants receive 50 mg AZA or 25 mg 6-mercaptopurine (6-MP), while those who have any homozygotic variants are recommended to take other alternative drugs instead of thiopurines
45460265|NCT03719118|Other|non-genotyping|Patients receive standard doses of thiopurines based on the conventional regimen without pretreatment genotyping. Conventional regimen starts with 50 mg of AZA, then the dose is increased by 25 mg in every 1-2 weeks to 2.0-2.5 mg/kg along with regular monitoring of general blood tests including WBC counts.
45460266|NCT04713020|Other|Intervention:APP educational programs|Use mobile device education programs to improve disease knowledge and self-efficacy of stroke patients, and reduce depression
45460267|NCT04713020|Other|No Intervention:general care|general care
45460268|NCT03717090|Other|No intervention|Sample collection study Sample collection and collection of laboratory values
45460269|NCT05648240|Other|Blood test|Venous blood samples taken at the moment of colonoscopy to test for biomarkers
45460270|NCT03634033|Behavioral|MiCAP with IF (Main Study)|"Sites will conduct MiCAP strategies described as follows. Relationship Building; Assess readiness to implement of the site; Internal Facilitator (IF) Champion Coalition Building, which will include IFs training in CAPABLE and facilitation and online IF coalition meetings; Facilitation by the IF, which will include training the clinicians, reviewing home visits with the clinician to assure CAPABLE was provided; IF developing a clinical team for implementation of CAPABLE and leading interdisciplinary coordination of individual beneficiary care; Intervention and implementation strategy fidelity data will be placed in a dashboard for audit and provided to IFs. IFs will use the data to provide feedback to clinicians; and develop action plans for improvement in training or care.~CAPABLE is a multi-component intervention used to enhance older adults ability to function at home independently."
45460271|NCT03634033|Behavioral|MiCAP with IF and EF (Main Study)|"Sites will conduct MiCAP strategies described above in MiCAP with IF with an addition of External Facilitation. Centralized Oversight will be conducted by External Facilitators. External Facilitators will train in facilitation. The work of the External Facilitators will be tailored (i.e., type of discipline) to each site's needs. Intervention and implementation strategy fidelity data will be placed in a dashboard and will be provided to External Facilitators. External Facilitators will use the data to provide feedback to Internal Facilitators; and develop action plans for improvement in site clinician training or beneficiary care as needed.~CAPABLE is a multi-component intervention used to enhance older adults ability to function at home independently."
45678696|NCT04172779|Drug|Erlotinib Hydrochloride|Oral administration of erlotinib 25mg tablet
45678697|NCT01756053|Drug|ABT-089|Selective neuronal nicotinic receptor agonist.
45678698|NCT01756053|Drug|Placebo|Matched placebo capsules supplied by study drug supplier.
45678699|NCT04576299|Other|Group 1|Survey about social networks, notification of adverse events, multidisciplinary teams, the doctor-patient relationship, the role of the ethics and patient safety committees, protocol compliance and suspension of outpatient procedures
45678700|NCT01785069|Device|Anatomically shaped, silicone-filled breast implants with low projection or extra-full projection|Surgical implant
46009003|NCT04672694|Procedure|Vagus nerve block|Ropivacine 0.75% 2mL will be injected two times around the vagus nerve (just below the bifurcation of recurrent laryngeal nerve); one before starting the surgical resection of lung including complete mediasitnal lymph node dissection and one at the end of operation.
46009004|NCT04672694|Procedure|No vagus nerve block|No vagus nerve block will be conducted during the surgery.
46009005|NCT04554654|Diagnostic Test|transvaginal ultrasound,|transvaginal ultrasound performed on day of the start of progesterone supplementation and on the day of frozen embryo transfer; serum progesterone level measurement on day of frozen embryo transfer
46009006|NCT04554615|Drug|Insulin|insulin infusion to control postoperative hyperglycemia
46009007|NCT01089413|Drug|bevacizumab [Avastin]|As prescribed by physician
46096029|NCT02628522|Device|Celution|Adipose derived regenerative cell isolation
46096030|NCT02628522|Device|Tulip cannulas|Lipoaspiration
45460272|NCT03634033|Behavioral|MiCAP with IF and Caregiver Engagement (Administrative Supplement)|A pilot study to examine use of informal caregiver engagement to provide CAPABLE to beneficiaries with Alzheimer's Disease or other Dementia using MiCAP with Internal Facilitation (implementation strategies from the (Main Study). External facilitator will be Champion, clinician, and an early adopters of CAPABLE.
45460273|NCT00708448|Radiation|PET Imaging|Patients will receive an FLT-PET scan, FDG-PET scan, a H215O-PET scan, and have a blood sample (15 cc, approximately 3 teaspoons) drawn for the genetic and protein studies. These studies will be done before patients begin taking erlotinib and bevacizumab.
45460274|NCT00708448|Drug|Erlotinib|150 mg/day
45460275|NCT00708448|Drug|Bevacizumab|15mg/kg q 21 days
45460276|NCT05597384|Procedure|Laparoscopic colorectal cancer resection|This is one of the routine procedures used for colorectal cancer resection.
45460277|NCT02892604|Device|insulin pump to inControl AP platform|Insulin from the pump is delivered according to the closed-loop algorithm fed by CGM data.
45460278|NCT05306912|Biological|Blood samples|Patients will be taken from an additional blood sample (2 tubes of 7.5 mL of blood = 15 mL) during the preoperative check-up on the day of the ultrasound-bronchoscopy in order to compare the sensitivity of the analysis of free circulating DNA present in the supernatant of pulmonary nodules less than 20 mm samples taken under ultrasound-bronchoscopy to that present in the plasma.
45460279|NCT03478306|Drug|Melatonin 4 mg Tablet|Participants are randomized into arm 1 or arm2, recieving melatonin or placebo, respectively, for 21 days, followed by 1 week of washout, and then swichting to the contralateral treatment arm.
45460280|NCT03103100|Drug|1% Lidocaine|10 mL of 1% lidocaine
45460281|NCT03103100|Drug|0.25% Bupivacaine|10 mL of 0.25% bupivacaine
45460282|NCT03103100|Drug|Bupivacaine plus Lidocaine|5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine
45460283|NCT03903601|Diagnostic Test|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) to diagnose ischemic changes in the brain.
45460284|NCT03903601|Diagnostic Test|Blood samples collection|Trimethylamine N-oxide (TMAO) concentration, oxidative stress markers and endothelial dysfunction markers will be determined in blood samples.
45460285|NCT03903601|Diagnostic Test|Neuropsychological tests|Cognitive functions assessment
45460286|NCT03474250|Diagnostic Test|Magnetic Resonance test for kidney|Magnetic Resonance test for kidney
45460287|NCT05233904|Diagnostic Test|Diagnostic-CT-enabled Planning|Diagnostic-CT-enabled planning for patient receiving palliative radiation treatment to bone, soft tissue and lung disease
45678701|NCT01784523|Drug|Hydroxychloroquine|
46009008|NCT04554810|Other|Medication Management Service|Medication review was delivered to the Syrian refugees by accredited pharmacists at the baseline visit. This followed by identifying the treatment-related problems (TRP) by the clinical pharmacist, and correction of the approved TRPs by the corresponding physicians and finally convey these changes in medications to the patients. In addition, counselling and education were delivered to the refugees' patients in the base line visit.
46009009|NCT02212665|Behavioral|High intense interval training|
46009010|NCT02212665|Behavioral|Increased daily activity detected by the pedometer|
45678702|NCT01784211|Drug|LY2605541|
45678703|NCT01784211|Drug|Insulin Glargine|
45678704|NCT01783821|Drug|Budesonide|Subjects will receive the standard aerosolized dose of budesonide (0.5 mg).
45678705|NCT01783821|Drug|Placebo|Aerosolized normal saline will be prepared to mimic the intervention arm, with the quantity, appearance and timing of the doses the being the same.
45678706|NCT01783821|Drug|Formoterol|Subjects will receive the standard aerosolized dose of formoterol (20 mcg) .
45678707|NCT01783743|Other|TT Training Program and TT Screening Card|The intervention is an additional half day training program on trichiasis recognition (TT Training Program) and a TT Screening card to assist community treatment assistants in recognizing TT cases and referring them to surgery.
45836831|NCT00466752|Other|laboratory biomarker analysis|Correlative studies
45460288|NCT05233904|Diagnostic Test|Standard of Care|Patients will be booked for CT simulation and treatment as per the local institution's standard practice
46009011|NCT02212665|Behavioral|Increased daily activity detected by the pedometer+HIIT|
46009012|NCT02212665|Behavioral|Increased daily activity detected by the pedometer+group intervention|
45460289|NCT02940496|Drug|Elbasvir/Grazoprevir|Given PO
45460290|NCT02940496|Other|Laboratory Biomarker Analysis|Correlative studies
45460291|NCT02940496|Biological|Pembrolizumab|Given IV
45678708|NCT01608321|Device|rTMS|Repetitive Transcranial Magnetic Stimulation
45678709|NCT01608321|Device|Sham device|Placebo Device that simulates active rTMS treatment
45678710|NCT01608087|Drug|BI 695502|BI 695502 single i.v. infusion
45678711|NCT01608087|Drug|bevacizumab|bevacizumab single i.v. infusion
45836832|NCT00466752|Genetic|western blotting|Correlative studies
45836833|NCT00466752|Genetic|RNA analysis|Correlative studies
45836834|NCT02115750|Drug|Etanercept|Head-to-head comparison
46009013|NCT01089023|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv infusion, every 4 weeks for a total of 6 infusions
46009014|NCT02212704|Other|Vestibular stimulation by use of the turntable (static roll-tilt while the head is roll-tilted relative to the trunk)|
45460292|NCT02940496|Drug|Ribavirin|Given PO
45460293|NCT01148719|Other|Index group|Diagnostic triage strategy includes; electrocardiography, echocardiography, spirometry and blood testing
45678712|NCT01608087|Drug|bevacizumab|bevacizumab single i.v. infusion
45678713|NCT01912963|Drug|Pertuzumab|
45678714|NCT01912963|Drug|Trastuzumab|
45678715|NCT01912963|Drug|eribulin|
45678716|NCT01912807|Drug|Dextrose (D5NS)|Solution Dextrose 5% in Normal Saline (D5NS) was used as a second antiemetic, at an intravenous maintenace rate (4 cc per Kg for first 10 Kg, 2 cc per Kg for next 10 Kg and 1 cc per Kg for the next Kg of weight) calculated based on the patient's weight
45678717|NCT01912807|Drug|Ondansetron (Control)|Ondansetron was used at a prophylactic dose (0,05 mg per Kg) based on patient's weight.
45678718|NCT01782885|Procedure|Intra-articular injection of PRP|Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks (6 weeks total).
45678719|NCT01782885|Drug|Acetaminophen|Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts (6 weeks total).
45678720|NCT01912729|Behavioral|Networked Peer Support with Peer Guide|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a peer guide. The peer guide will be another high school student around the same age as participants.
46009015|NCT02212704|Other|3D-video-head impulse testing|Evaluation of semicircular canal function. This intervention is part of the screening to determine suitability for this study
46009016|NCT02212704|Other|Vestibular-evoked myogenic potentials (VEMPs)|Evaluation of otolith function. This intervention is part of the screening to determine suitability for this study
46009017|NCT02212782|Drug|Linagliptin 5mg|Linagliptin 5mg once daily for 7 days
46009018|NCT02212782|Drug|DW1029M 1200mg and Linagliptin 5mg|Linagliptin 5mg 1 tablet once daily and DW1029M 300mg 2 tablets b.i.d for 7 days
46009019|NCT01088984|Drug|Bendamustine|
46096031|NCT02628522|Other|20mL Lidocaine 2% and Epinephrine 1:100 000|Infiltration prior to liposuction
45460294|NCT05182814|Dietary Supplement|Placebo drink|Blank
45460295|NCT05182814|Dietary Supplement|Collagen Juice Drink|Testing product
45460296|NCT03438006|Other|Safety data collection (following routine vaccination)|"This study assessed the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine when administered routinely according to the Prescribing Information in female Chinese subjects aged between 9 and 45 years.~The intervention consisted in the active surveillance of adverse events following immunization and pregnancy outcomes if the vaccine was administered inadvertently during pregnancy. Information of potential adverse events and pregnancy outcomes were collected at immunisation visits, telephone contacts and through spontaneous reporting by the patient/LAR/physician."
45678721|NCT01912729|Behavioral|Networked Peer Support with Clinician Coach|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a clinical psychologist.
45836835|NCT02115750|Drug|CHS-0214|
45836836|NCT02115828|Drug|Vismodegib|
45836837|NCT02115984|Drug|Panagen|
46009020|NCT02212821|Drug|Erythromycin|
46009021|NCT02212821|Drug|Placebo|physiological saline
46009022|NCT01088438|Behavioral|Contextualization workshop|A four-hour course on contextualization.
46009023|NCT04554537|Behavioral|SMART|A treatment program developed to address specific brain functions found to be crucial for the recovery following brain injury.
46009024|NCT04554537|Behavioral|Brain Health Workshop|A psychoeducation program designed to provide in depth information to participants about the neuroscience behind their TBI and PTSD and the symptoms and challenges they may experience.
46009025|NCT04554186|Procedure|Serratus anterior plane block|Injection of bupivacaine between serratus anterior plane and latissimus dorsi muscle using ultrasound
46009026|NCT04554186|Procedure|Thoracic Paravertebral block|Injection of bupivacaine in the thoracic Paravertebral space using ultrasound
46009027|NCT04554186|Procedure|Control|Place a fentanyl patch 50 microgram
46009028|NCT01088243|Drug|Mesalamine|Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
45678722|NCT01754493|Drug|Duloxetine|This study is a 12-week open trial to assess the efficacy of duloxetine (Cymbalta) for the treatment of Irritable Bowel Syndrome (IBS) symptoms and comorbid Major Depressive Disorder (MDD). Participants will visit the clinic 8 times to meet with the psychiatrist. They will receive duloxetine to see if it helps their major depression and Irritable Bowel symptoms.
45678723|NCT01972789|Drug|Ranibizumab|Ranibizumab solution for injection is commercially supplied in two presentations: as a pre-filled syringe (containing 1.65 mg of ranibizumab in 0.165 mL solution) and as a vial (containing 2.3 mg of ranibizumab in 0.23 mL solution) corresponding to a recommended dose of 0.5 mg (0.05 mL) given as a single intravitreal injection. It will be prescribed and administered by the investigator or designee
45678724|NCT01934335|Drug|Vandetanib|
45678725|NCT01934335|Other|Placebo|
45678726|NCT01912339|Device|Rezum System|"The Rezūm System uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of stored thermal energy directly to the transition zone of the prostate gland.~A narrow sheath, similar in shape and size to a cystoscope, is inserted transurethrally and positioned within the prostatic urethra between the bladder neck and the verumontanum.~A thin needle is deployed through the urethra into the transition zone, and a very short (8-10 second) treatment of water vapor is delivered directly into the hyperplastic tissue and immediately disperses through the tissue interstices.~Upon contact with the tissue, the vapor condenses, or phase shifts, into its liquid state, releasing the stored thermal energy contained within the vapor. This thermal energy is released directly against the walls of the tissue cells within the treatment zone, gently and immediately denaturing the cell membranes, thereby causing instantaneous cell death."
45678727|NCT01912339|Procedure|Rigid Cystoscopy|Endoscopy of the urinary bladder via the urethra.
46009029|NCT01088243|Drug|Placebo|Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
45836838|NCT02115984|Drug|Placebo|
45836839|NCT02115984|Procedure|Chemotherapy|Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.
45836840|NCT00413166|Drug|All-Trans Retinoic Acid (ATRA)|Induction: 45 mg/m2 daily by mouth in 2 divided doses beginning day 1
45836841|NCT00413166|Drug|Arsenic Trioxide (ATO)|Induction: 0.15 mg/kg daily IV beginning day 1
46009030|NCT04554342|Other|V01 candy|candy with sweetener (Isomalt) and apple flavour
46009031|NCT04554342|Other|V02 candy|candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid)
46009032|NCT04554342|Other|V03 candy|candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid) and Vitamin C
46009033|NCT04554342|Other|V04 candy|candy with sweetener (Isomalt) (control group 1)
46009034|NCT04554342|Other|V05 candy|candy with with sweetener (Isomalt) and acidifying agent (apple acid + citric acid) (control group 2)
46009035|NCT04672499|Drug|Miricorilant 300 mg tablets|Miricorilant 300 mg tablets for oral administration
46009036|NCT04672499|Drug|Miricorilant 150 mg tablets|Miricorilant 150 mg tablets for oral administration
46009037|NCT04672499|Drug|Placebo 150 mg tablets|Placebo to match miricorilant 150 mg tablets for oral administration
46009038|NCT04554108|Other|therapeutic strategy|Outpatient management strategy of acute non-severe osteomyelitis in children with oral antibiotic therapy compared to a standard strategy with conventional hospitalization and intravenous antibiotic therapy
46009039|NCT04554225|Drug|Oxygen gas|Oxygen administered to a patient using ambulatory oxygen
46009040|NCT04554303|Drug|S-amlodipine 2.5mg|Oral administration, 1 tablet per day
46009041|NCT04554303|Drug|Amlodipine 5mg|Oral administration, 1 tablet per day
46009042|NCT01088048|Drug|Idelalisib|Idelalisib tablet administered orally
46009043|NCT01088048|Drug|Rituximab|Rituximab administered intravenously
46009044|NCT01088048|Drug|Bendamustine|Bendamustine administered intravenously
45460297|NCT04233632|Device|FC2 Condom|FC2: FC2 is composed of a synthetic nitrile rubber latex and 170mm in length. It has a flexible inner ring as the internal retention mechanism and a circular ring as the outer retention mechanism at the open end of the condom. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is available in clear and other colors/scents. It is manufactured by Female Health Company, USA and has USFDA, World Health Organisation (WHO)/United Nations Populations Fund (UNFPA) and South African Bureau of Standards (SABS) approval
45460298|NCT04233632|Device|Cupid Condom|Cupid is composed of a Natural rubber latex and is 155mm in length. It has a Medical grade sponge as the internal retention mechanism and an octagonal outer frame as the outer retention mechanism. It is pre-lubricated with silicone oil. It has a shelf-life of 3 years and is available in clear and red color, vanilla scented variety. It is manufactured by Cupid Ltd, India and has WHO)/UNFPA, India Drug Control Authority, Conformitè Europëenne (CE) Mark of the European Union (EU) and SABS approval
45678728|NCT01911793|Device|Stoma Tube|Stoma tube will be inserted into stoma at the time of surgery for patients assigned to Stoma Tube group.
45678729|NCT04632511|Device|MetaSAMP|Rectal Sampler
45836842|NCT00413166|Drug|Idarubicin|"12 mg/m2 one dose only (may be given on day 1 to 5 of induction)~If either ATRA or ATO are discontinued due to toxicity, idarubicin 12 mg/m2 x 2 doses will be administered once every 4 to 5 weeks (depending on the recovery of counts) until 28 weeks has elapsed from the Complete Recovery date."
46009045|NCT01088048|Drug|Ofatumumab|Ofatumumab administered intravenously
46009046|NCT01088048|Drug|Fludarabine|Fludarabine administered orally
46009047|NCT01088048|Drug|Everolimus|Everolimus administered orally twice daily until disease progression
46009048|NCT01088048|Drug|Bortezomib|Bortezomib administered as a subcutaneous injection
46096032|NCT02572414|Behavioral|Health Promotion Intervention|Men Together Making a Difference Health Promotion Intervention, which included three, 3-hour weekly sessions, implemented in small groups by trained facilitators using scripted manuals, was designed to increase self-efficacy, outcome expectancy, and skills for behaviors tied to cardiovascular disease, diabetes, hypertension, and cancer. It encouraged men to adhere to guidelines for physical activity, 5-a-Day diet, and colon cancer screening. It encouraged at least 30 min of moderate-intensity aerobic activity on 5 days or at least 20 min of vigorous-intensity aerobic activity on 4 days and muscle-strengthening activity on at least 2 days each week. Participants identified their personal barriers to engaging in the recommended behaviors and strategies for surmounting those barriers.
46096033|NCT02572414|Behavioral|Health Awareness Control Intervention|Health Awareness Control Intervention consisted of one 1-hour small-group session led by a trained facilitator. Participants viewed and discussed video clips on physical activity, fruit and vegetable consumption, and colon cancer screening.
46009049|NCT01088048|Drug|Chlorambucil|Chlorambucil administered on Days 1-7 every 28 days to allow appropriate therapy for participants with CLL and to coordinate into a cycle period equivalent to other study treatment regimens.
46096034|NCT02751047|Other|manual ventilation|Facemask ventilation is performed by manual bagging with reservoir bag.
46009050|NCT01088048|Drug|Lenalidomide|Lenalidomide administered orally
46009051|NCT04554498|Device|1) high flux hemodiafiltration thrice -weekly during a 24 month follow-up|"the comparison of the effects of the two membranes on the serum levels of albumin, B2M, CRP, myoglobin, light chains, retinol binding protein, homocysteine, p-cresol, indoxyl sulfate, BPA, alpha-1-microglobulin (A1M), FGF23 (fibroblast growth factor 23), and inflammatory cytokines;~the evaluation of the changes induced by the two filters on lymphocyte subsets, monocyte activation and senescence, and apoptosis rate;~the definition of the impact of the two membranes on the accumulation of AGEs as an index of metabolic and oxidative stress, determined by a non-invasive method based on the measurement of skin autofluorescence through a dedicated device (AGE Reader, DiagnOptics Technologies BV, Groningen, Netherlands)."
46037851|NCT04970368|Procedure|Selective staging|Intraoperative consultation (IOC)
45460299|NCT04233632|Device|Cupid 2 Condom|Cupid2 is composed of a Natural rubber latex and is 125mm in length. It has a Medical grade sponge as the internal retention mechanism and an octagonal outer frame as the outer retention mechanism. It is pre-lubricated with silicone oil. It has a shelf-life of 3 years and is available in Clear and purple color, vanilla scented variety. It is manufactured by Cupid Ltd, India and has WHO)/UNFPA, India Drug Control Authority, CE Mark of the EU and SABS approval
45460300|NCT03131128|Behavioral|Mindfulness-based Intervention|"Keeping mindful when selecting food.~Be aware of hunger and satiety by the body clues.~Understanding how stress affect diet and life, and learn how to cope with stress in life.~Learning to identify overeating caused by mood, social stress and specific food."
45460301|NCT03131128|Behavioral|Health Education Intervention|"Identifying improper diet patterns and attitudes~Understanding the impact of irrational cognition and attitudes on dietary behavior~Training coping skills for stresses in real life and preventing the recurrence of bulimia."
45460302|NCT03910855|Behavioral|Mindfulness Based Intervention|The mindfulness-based intervention consists of four 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to stroke survivors and their family caregivers. Participants will be provided handouts for the information covered during these talks and discussions.
45460303|NCT03910855|Other|Health Education Program|The health education program consists of four 2-hour sessions covering various health topics (e.g. diet, nutrition and exercise) that pertain to stroke survivors. Participants will be provided handouts for the information covered during these talks and discussions.
45460304|NCT03130894|Other|Plasma TMAO concentration|Plasma TMAO concentration
45460305|NCT03639168|Drug|Chidamide combined with cisplatin|Chidamide combined with cisplatin
45460306|NCT01148797|Drug|Canakinumab|
45460307|NCT03131050|Drug|Scopolamine|Intramuscular injection with scopolamine (0.3 mg/1ml,QD or Bid) during the first three days;
45460308|NCT03131050|Drug|Escitalopram|Oral escitalopram 10 mg/d throughout the total of 4 weeks treatment
45460309|NCT03131050|Drug|Saline|Intramuscular injection with saline (1ml, QD or Bid) during the first three days;
45460310|NCT03719820|Drug|aggressive medical management|Aspirin (100 mg daily) and Clopidogrel (75 mg daily) for 3 months and Rosuvastatin (20mg daily) for at least 6 months as well as traditional risk factors management
45460311|NCT04206020|Drug|SkQ1 Vehicle Solution|SkQ1 Ophthalmic Solution Vehicle
45460312|NCT04206020|Drug|SkQ1 Ophthalmic Solution|SkQ1 Ophthalmic Solution
45460313|NCT03910699|Device|Three-row circular stapler|Para-aortic lymph node dissection, inferior mesenteric artery skeletonisation and ligation below left colic artery origin, nerve-preserving total mesorectal excision, rectum division with a linear stapler, sigmoid colon division and circular stapler envil fixation with a purse-string suture, end-to-end colorectal anastomosis creation with a three-row circular stapler, defunctioning colostomy is performed.
45460314|NCT03910699|Device|Two-row circular stapler|Para-aortic lymph node dissection, inferior mesenteric artery skeletonisation and ligation below left colic artery origin, nerve-preserving total mesorectal excision, rectum division with a linear stapler, sigmoid colon division and circular stapler envil fixation with a purse-string suture, end-to-end colorectal anastomosis creation with a two-row circular stapler, defunctioning colostomy is performed.
45460315|NCT03478228|Other|Multi-Sensory Training|
45460316|NCT01148875|Behavioral|Mammography appointment reminders; telephone counseling|Women randomly assigned to UCR, EAPR, ELR; repeated 4 times at yearly intervals. Using claims data, supplemented by self-report, verified if women had recent mammograms. Women who remained non-adherent after reminders received Barriers-Specific Telephone Counseling Call, or an enhanced call including focus on either positive or negative consequences of getting/not getting mammograms. Prior to calls, women in each of the three phone counseling groups received priming letters to prime them to process information in the call. Priming letters should prepare women to process information from subsequent counseling calls more deeply by focusing on the positive or negative consequences of getting/not getting mammograms or on identifying and overcoming their own barriers to being screened.
45460317|NCT03902899|Other|Educational intervention (oral presentation)|A brief oral presentation (30-45 minutes) which focused on making endoscopists aware of the significance and characteristics of serrated polyps.
45836843|NCT00413166|Drug|Gemtuzumab Ozogamicin|Induction: 9 mg/m2 on day 1 of induction
45836844|NCT00386880|Other|Sounds|
46096035|NCT02751047|Other|Pressure controlled mechanical ventilation|Facemask ventilation is performed with mechanical ventilator by pressure controlled mode.
46096036|NCT00709774|Device|Pacemaker Implantation|Implantation of right ventricular lead at septal or apex.
46096037|NCT04495751|Dietary Supplement|Muscadine grape extract|Four pills twice daily
46096038|NCT04495751|Drug|Placebo|Four pills twice daily.
45460318|NCT05019170|Behavioral|Smartphone-based Financial Incentives|Financial Incentives - Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples < 6 ppm will be considered negative and those > 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced, and incentives will be contingent on submitting a negative saliva cotinine test.
45460319|NCT05019170|Behavioral|Best Practices|Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at assessments that take place during pregnancy.
45460320|NCT03466086|Device|Test Eye Drops|blink® intensive TRIPLE ACTION 3 in 1 eye drops
46009052|NCT04554381|Biological|JL1 antigen|we hypothesis that JL1 can be used as an adjunctive marker for the initial diagnosis and the follow up of Acute Lymphoblastic Leukemia.
45460321|NCT03466086|Device|Control Eye Drops|Systane® BALANCE eye drops
45460322|NCT05632952|Device|Intraperitoneal Onlay Mesh positioning Plus|"Intraperitoneal Onlay Mesh (IPOM) Plus with closure of the hernia defect will be performed according to the common recommendations.~The closure of the wall defect will be decided according to the surgeon evaluations: hernia size and choice of technique will be recorded in the database. The mesh will have an overlap of at least 5 cm on all sides of the defect. Dimension of the mesh will be sized to overlap the hernia orifice by at least five centimetres and placed in the intraperitoneal position. Using non-articulating laparoscopic fixation devices, 5.1-mm non-absorbable or absorbable tacks will be then positioned around the circumference of the prosthesis in a 3-row manner or 2-row manner based on the intraoperative findings, the patient's specific situation and the operating surgeon's decision."
45460323|NCT01252459|Radiation|Radiation Therapy|Experimental intervention (Arm A): High-precision re-irradiation (stereotactic fractionated radiation therapy (SFRT) and/or image guided radiation therapy, (IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on AA-PET: GTV = AA uptake on PET, clinical target volume (CTV) = GTV+3mm, PTV = CTV+2mm
45460324|NCT01252459|Radiation|Radiation Therapy|Control intervention (Arm B): High-precision re-irradiation (SFRT and/or IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on T1Gd-MRI: GTV = contrast enhancement on T1Gd-MRI, CTV = GTV+3mm, PTV = CTV+2mm
45460325|NCT03719742|Other|Sponsor Test Products|Baby Bee Foaming Cleanser(at least once daily but not more than twice daily), BB Baby Ultra Gentle Lotion (Once immediately after cleansing and again approximately 10-12 hours after cleansing)
45460326|NCT04963010|Diagnostic Test|second forward view|second forward view examination of the proximal colon
46096039|NCT04495751|Other|Quality of Life Assessment|Ancillary studies
46096040|NCT04495751|Other|Questionnaires|Ancillary studies
46096041|NCT04495751|Other|Participant Feedback|Ancillary studies
45460327|NCT03718962|Device|Surrounding needling+ phototherapy|Surrounding needling+ phototherapy
45460328|NCT03718962|Device|phototherapy|phototherapy
46096042|NCT02572336|Drug|THR-18|THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
46096043|NCT02572336|Drug|Placebo|Placebo is a THR-18 lookalike, to be administered with tPA.
46096044|NCT02572336|Drug|Tissue Plasminogen Activator (tPA)|tPA is a thrombolytic agent. tPA is not an investigational drug.
45460329|NCT01254799|Drug|Doxycycline|100 mg Doxycycline capsules twice daily for 5 days
45460330|NCT01254799|Drug|Placebo|Placebo capsules twice daily for 5 days
45460331|NCT05553938|Drug|Empagliflozin 10 mg|Empagliflozin 10mg
45460332|NCT05553938|Drug|Placebo|Empagliflozin matched placebo tablet
46009053|NCT04553952|Other|Measurement of gingival display|"All individuals were instructed to sit on a dental chair and the measurements were made by using a millimetric ruler. Next, the patients were grouped according to Liebart's classification by gingival display at maximum smile as follows:~Class 1.Excessive gingival display (Gummy smile): ≥ 3mm gingival display Class 2.High smile line: 0-2 mm of gingival display Class 3. Average smile line: Dental papilla is visible. Class 4. Low smile line: Gingival margin, dental papilla is not visible at all."
46009054|NCT04672577|Other|Observational study|No intervention is planned
46037852|NCT05326204|Other|Home blood glucose monitoring|Self monitoring of capillary blood glucose
46096045|NCT00715000|Procedure|Oral rehydration therapy|oral rehydration solution
46096046|NCT00715000|Procedure|classical hydration via intravenous infusion|intravenous infusion
45460333|NCT03718884|Drug|Drug Cocktail|Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally
45460334|NCT03718884|Drug|Mirikizumab|Administered SC
45460335|NCT03903211|Drug|[18F]PI-2620|Imaging for evaluating the accumulation of abnormal tau protein in the brain
45460336|NCT05548010|Other|No intervention as this is an observational study|No intervention
45460337|NCT03718806|Drug|Zoliflodacin|oral suspension; oral administration
45460338|NCT03718806|Other|high calorie, high fat breakfast|fasted/fed conditions
45678730|NCT01933789|Behavioral|Communication Feedback Form for Patients with Serious Illness|"The intervention, based on self-efficacy theory, identifies patients' preferences for communication about end-of-life care (EOLC) and barriers and facilitators to this communication, and collates these data into a feedback form. The feedback forms are tailored to each recipient (clinician, patient, family) to support the communication tasks which that recipient will address. Feedback forms are sent to participants prior to the target clinic visit. The primary clinician's form suggests referral to palliative care if there are potentially unmet palliative-care communication needs. All forms include tips to help the recipient respond to communication preferences appropriately."
45678731|NCT01910389|Drug|Tadalafil|
45460339|NCT03911011|Other|Fresh air|Fresh air insufflation of 2 L/min toward mouth/nose.
45460340|NCT03903055|Diagnostic Test|MDS group|patients diagnosed as MDS with high risk，aged 18-80，men/wemen
45460341|NCT03716856|Genetic|CAR-BCMA T cells|"Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied."
45460342|NCT03716856|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
45460343|NCT03716856|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion
45678732|NCT01910389|Drug|Placebo for tadalafil|
45678733|NCT01970995|Other|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
45836845|NCT00413400|Drug|Etanercept|50 mg one syringe sc 2X per week for three months followed by 50 mg one syringe sc 1X per week for three months
46009055|NCT04553796|Device|fibroscan|Fibroscan is a non-invasive test that helps assess the health of your liver. Specifically, it uses ultrasound technology to determine the degree of fibrosis or scarring that may be present in your liver from various liver diseases or conditions
46009056|NCT01087970|Drug|Pemetrexed|Administered intravenously, for maximum of 6 cycles.
45460344|NCT05632640|Other|Standard of Care|Following the participants procedure, standard of care will be given in the recovery area.
45460345|NCT05632640|Device|Weighted blanket|Following the participants procedure once in the recovery area, the nursing staff will place a weighted blanket on the participants. Different weighted blanket sizes will be used based on participants weight.
45460346|NCT03910777|Diagnostic Test|Early Warning Score|National early warning score (NEWS) is another early warning scoring system recommended by the Royal College of Physicians in London to detect early clinical deterioration in hospitalized patients
45460347|NCT03902977|Procedure|quilting|After mastectomies or ALND dissections using standard technique for wound closure multiple sutures (monocryl 3.0) every 3 to 4 cm in the site of the mastectomy (1 or 2 rows) or in the dissected axilla.Placement of one drain into the breast and axilla or in the axillary cavity by a separate stab incision
45460348|NCT03902977|Procedure|conventional suture|After mastectomies or ALND dissections standard technique for wound closure. Placement of one drain into the breast and axilla or in the axillary cavity by a separate stab incision
45678734|NCT01970995|Other|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 85 days in an ambulatory setting
45678735|NCT01970995|Other|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
45678736|NCT01932697|Drug|Docetaxel|Given IV
45678737|NCT01932697|Radiation|Hyperfractionation|Undergo hyperfractionated IMRT
45678738|NCT01932697|Radiation|Intensity-Modulated Radiation Therapy|Undergo hyperfractionated IMRT
45678739|NCT01932697|Other|Laboratory Biomarker Analysis|Correlative studies
45678740|NCT01932697|Other|Quality-of-Life Assessment|Ancillary studies
45678741|NCT01970527|Biological|Ipilimumab|Given IV
45836846|NCT00413400|Drug|Placebo|50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months
45836847|NCT00413478|Drug|5-Azacytidine|Starting dose level: 75mg/m^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
45836848|NCT00413634|Drug|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide treatment regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
46009057|NCT01087970|Drug|Cetuximab|"Administered intravenously in combination therapy, for a maximum of 6 cycles.~After the completion of 6 cycles, participants who have not experienced disease progression will continue on cetuximab monotherapy until disease progression."
46009058|NCT01087970|Drug|Carboplatin|Administered intravenously, for a maximum of 6 cycles
45678742|NCT01970527|Other|Laboratory Biomarker Analysis|Correlative studies
46009059|NCT01087970|Drug|Cisplatin|Administered intravenously, for a maximum of 6 cycles
46009060|NCT04553874|Other||observational study without intervention
46009061|NCT01087814|Drug|Efavirenz|Subject will take efavirenz for 5 days.
46009062|NCT01087814|Drug|Over-encapsulated efavirenz|Subject will take efavirenz that has been over-encapsulated with a gel capsule for 5 days.
46009063|NCT02212938|Drug|BI 14332 CL|
46009064|NCT02212938|Other|high fat breakfast|
46009065|NCT04672421|Device|Medicurtain®|Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after laparoscopic surgery)
46009066|NCT04672421|Device|Placebo|No device after laparoscopic surgery
46009067|NCT04553991|Procedure|Ultrasound guided QL block|20 mL of 0.25% bupivacaine was applied bilaterally at the anterolateral border of the QL at its junction with transversalis fascia
45460349|NCT04024904|Device|OncomfortTM device|The VHRD (Virtual Reality Hypnosis Distraction) technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exist in 5,15 and 30 minutes
45460350|NCT03904459|Other|no intervention|
45460351|NCT03910543|Drug|Tofacitinib 5 mg twice daily|Tofacitinib will be administered at a dose of 5 mg twice daily
45460352|NCT01148953|Drug|ALN-TTR01|Dose levels between 0.01 and 1.0 mg/kg by intravenous (IV) infusion
45460353|NCT01148953|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
45460354|NCT03101462|Biological|Inactivated Influenza Vaccine|
45460355|NCT03101462|Biological|Live Attenuated Influenza Vaccine|
45678743|NCT01970527|Other|Pharmacological Study|Correlative studies
46009068|NCT04553991|Procedure|Ultrasound guided TAP block|20 mL of 0.25% bupivacaine was applied bilaterally in the TAP
46009069|NCT01087775|Behavioral|Cognitive Training|Plasticity Based Adaptive Cognitive Remediation (PACR)
46009070|NCT02213172|Dietary Supplement|Bifidobacterium longum R0175|
46009071|NCT02213172|Dietary Supplement|Lactobacillus paracasei HA-196|
45460356|NCT03902587|Device|Samsung's E-cervix technology|While patients are having their routine cervical ultrasound assessments which requires a 5 minute time period, we will use the built-in software to obtain additional E-cervix measurements to evaluate the consistency of the cervical os. This will be done within the standard 5 minute period which is typically done to observe for dynamic changes. The measurements will be obtained with the same sonogram machine, using updated software.
45460357|NCT01254955|Biological|H1N1 vaccine Pandemrix|
45460358|NCT05132335|Other|Imaging Biomarkers|"One arm: Subjects are studied under two consecutive conditions, after overnight fasting and after a liquid meal ingestion. During each condition they are examined for fatty acid uptake in subcutaneous fat and skeletal muscle by FTHA([18F]-FTHA) PET/MRI as well as adipose and skeletal muscle blood perfusion by radioactive water([15O]-H2O ) PET/MRI. This was done at two occasions, 2-14 days apart, to assess repeatability of the measurements.~Assigned interventions:~[18F]-FTHA tracer injections [15O]-H2O tracer injections~PET/MRI imaging~Overnight fasting Liquid meal ingestion"
45460359|NCT05531318|Other|Qualitative Interview|Participants will be interviewed about their experiences of substance use, post-traumatic stress and the way they regulate their emotions.
45460360|NCT03910309|Device|TLIF with Titan TT/TO interbody cage|fusion surgery
45678744|NCT01970527|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45678745|NCT01931995|Device|TMS positively correlated DLPFC|TMS, or transcranial magnetic stimulation, is a technique that is employed to non-invasively activate or suppress targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
45678746|NCT01931995|Procedure|TMS to negatively correlated DLPFC|TMS, or transcranial magnetic stimulation, is a way of non-invasively activating or suppressing targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
46009072|NCT02213172|Other|Placebo|
46009073|NCT04554030|Behavioral|Evaluate sperm count before and after immunotherapy|Evaluate sperm count before and after immunotherapy
46009074|NCT01087502|Drug|Glimepiride|1-4 mg daily after 12 weeks
46009075|NCT01087502|Drug|Placebo|Placebo mach to 5 mg linagliptin first 12 weeks of treatment once daily
46009076|NCT01087502|Drug|Placebo|Placebo maching Glimepiride 1-4 mg after 12 weeks of treatment
46009077|NCT01087502|Drug|Placebo|Placebo mach to 5 mg linagliptin once daily after 12 weeks
46009078|NCT01087502|Drug|Linagliptin|5 mg once daily
46009079|NCT02213211|Drug|Artemether lumefantrine|
46009080|NCT04672304|Other|Al-Husban University Naser|filling a questionnaire
46009081|NCT02213367|Drug|Bilastine|20mg (8 weeks)
46009082|NCT02213367|Drug|Bilastine|40mg
46009083|NCT02213367|Drug|Bilastin|80mg
46009084|NCT04553718|Other|experimental group|provide mHealth program, which has pregnant women using wearable device and app
46009085|NCT01086410|Drug|Placebo Inhalation Powder|Placebo Inhalation powder inhaled once daily for 6 weeks' treatment
46009086|NCT01086410|Drug|Fluticasone Furoate/GW642444 Inhalation Powder|Dose B inhaled once daily for 6 weeks' treatment
45460361|NCT03904537|Biological|anti-PD-1 antibody-activated TILs|Participants would received one dose anti-PD-1 antibody-activated TILs at the final cycle of XELOX regimen chemotherapy
45460362|NCT04505384|Procedure|left bundle branch pacing|left bundle branch pacing
45460363|NCT04505384|Procedure|biventricular pacing|biventricular pacing
45460364|NCT03904303|Drug|A 06 ad|Colonic cleansing before colonoscopy and CT colonografi
45460365|NCT05627336|Diagnostic Test|pregnant women in the 3rd trimester|Pregnant women who are in their third trimester and will give birth in the clinic will form the study group. These pregnant women will be measured by applying a set of questionnaires to measure their fear of childbirth.
45460366|NCT05526326|Device|Transplant with normothermic machine perfused (NMP) donor liver|The enrolled recipient will receive a DBD or DCD donor liver that underwent normothermic machine perfusion with the OrganOx metra®
45460367|NCT03902665|Drug|Up-front allogeneic hematopoietic stem cell transplantation (HSCT)|"Patients classified as fit/unfit are included in the HSCT program. There are two early approaches allowed. A) Patients will be left untreated until HSCT B) Patients will receive 1 short course of chemotherapy before HSCT (Ara-C and anthracycline).~Selection of strategy A or B, will be patient based on disease characteristics and dynamics or presence of high tumor load.~Conditioning for haplo-HSCT should be started as soon as possible, within day 45 after initial diagnosis. This is to avoid delayed transplantation. Two dosing levels of the Thiotepa-Busulfan-Fludarabine (TBF) based protocol are allowed based on the clinical condition of the patient: fit patients below 70 will receive the TBF with 2 days of Busulfan, whereas patients with poorer clinical condition or above the age of 70 will receive a dose-reduced TBF, in which Busulfan may be reduced to 1 day only."
45460368|NCT01149265|Behavioral|Online support group|Expressive writing involves people writing about their thoughts and feelings, often upsetting ones, for a short period of time.
45460369|NCT01149265|Behavioral|Expressive writing|Online support groups are internet forums where like-minded people give and receive both informational and emotional support.
45460370|NCT05513456|Behavioral|Randomization to a different factors in the case descriptions|The case descriptions will include factors like age, co-morbid status and acute physiological parameters; but the factor of sex/gender will be randomized. Moreover, randomization to case description of typical vs non-typical national name will be done.
45460371|NCT01252615|Behavioral|patient only|education, behavioral strategies, psychological interventions
45460372|NCT01252615|Behavioral|patient and partner intervention|education, psychological support, behavioral strategies
45460373|NCT03902275|Other|Quantra-Algorithm|Hemotherapy based on Quantra-Algorithm
45460374|NCT03902275|Other|ROTEM-Algorithm|Hemotherapy based on Basic-Algorithm
45460375|NCT03902743|Other|Anticipatory Care Plan group|The Anticipatory Care Plan will be delivered by a trained nurse. At the initial visit, the nurse will conduct a hollistic assessment using the EasyCare Assessment Tool. Following this visit, the nurse will draft a strucutred summary report of the home visit to include patient goals, preferences for care, identified problems and action list. The nurse will then consult with a pharmacist to identify any potential inappropriate prescribing. The nurse will then meet with the participants GP and review and provide feedback. The nurse will then re visit participants and discuss the report and agree a support plan and actions for follow up.
45460376|NCT03903913|Drug|S-1226|The drug product S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) nebulized with a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8% or 12% CO2.
46009087|NCT01086410|Drug|Fluticasone Furoate/GW642444 Inhalation Powder|Dose A inhaled once daily for 6 weeks' treatment
45460377|NCT03903991|Other|Temperature recording|Tympanic and oesophageal temperatures will be recorded during the procedure
45460378|NCT01252771|Other|PKM Algorithm|"The subject's serum calcium and phosphorus values will be input into PKM in order to determine the required PhosLo prescription. The prescription is determined as the number of gelcaps per day that must be taken by the subject.~If PKM determines the number of PhosLo gelcaps per day to be greater than or equal to the subject's current prescription, then PKM will calculate the current Ca++ and phosphate balance. Furthermore, the PKM algorithm will determine the additional number of PhosLo gelcaps needed to achieve neutral phosphate (P) balance with serum P reduced to 5.5 mg/dL.~The PKM algorithm also calculates the total P intake between dialyses and along with ePCR also calculates a Phosphorus/Protein Ratio (PPR). This ratio ranges from 8 to 14 in dialysis patients following a renal diet."
45460379|NCT03904225|Drug|Tegafur-Gimeracil-Oteracil|oral administration for 12 months
45460380|NCT01149031|Device|LOW LEVEL LASER SYSTEM|LASER DIODE CLASS 3B,OMEGA XP
45460381|NCT03910231|Drug|Tolvaptan Oral Tablet|Tolvaptan, to block V2R
46009088|NCT01086410|Drug|Placebo Oral Capsule|One placebo capsule taken each day on the last 7 days of the study
46009089|NCT01086410|Drug|Prednisolone Oral Capsule|Prednisolone 10mg oral capsule taken each day on the last 7 days of the study
46009090|NCT04553679|Behavioral|Mindfulness online intervention|A 3-week mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.
46009091|NCT04553601|Diagnostic Test|18F-FDG PET/CT and PET/CT-guide targeted biopsy in another group of participants|Each subject receive a single intravenous injection of 18F-FDG PET/CT and PET/CT-guide targeted biopsy within the specified time
46009092|NCT04553250|Procedure|Doubled-stapled colorectal anastomosis|Anastomosis performed between the colon an the rectal stump, using a double-stapled technique.
46096047|NCT02750969|Device|Lidoderm patch (Lidocaine 5% patch)|"The investigator will attach the patches on the patient's back for 12 consecutive hours.~tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch"
46009093|NCT04553328|Device|Us guided nerve blocks|The ILIH nerves were identified and located in the fascia compartment between the internal oblique and the transverse abdominis or external oblique muscles, a 20 G needle was advanced between the aponeurosis of the internal oblique and transverses abdominis muscles then 30 ml bupivacaine 0.25% was injected with intermittent aspiration,then 10 ml bupivacaine 0.25% was injected around the nerves.
46096048|NCT02750969|Other|Tegaderm patch. (neutral patch, containing no drug)|"The investigator will attach the patches on the patient's back for 12 consecutive hours.~tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch"
45678747|NCT01408576|Drug|Epratuzumab|600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles
45678748|NCT01408576|Drug|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over eight 12 week treatment cycles
45678749|NCT04033510|Other|Standard of Care Interventions to convert patient from atrial fibrillation to normal rhythm|Direct current cardioversion, PVAI-atrial fibrillation ablation, Minimally Invasive Surgical Maze procedure, Medications
45678750|NCT01427920|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin) using FlexPen® twice daily for 20 weeks. Directions for use were given to each subject at each dispensing visit. Subjects continued on their pre-trial metformin dose. Any previous basal insulin analogue and OAD (oral anti-diabetes drug) treatments (except for metformin) were discontinued.
46009094|NCT01085591|Drug|CB-183,315|
46009095|NCT01085591|Drug|Placebo|
46009096|NCT01085591|Drug|Vancomycin|
45460382|NCT03902353|Other|Screening of adult without diagnosis of PH carrying an heterozygous EIF2AK4 mutation.|will be performed : a clinical evaluation (dyspnea assessed by New York Heart Association functional class (I-IV), signs of right heart failure), a 6min walk test, a Computerized Tomography scan of the chest, an electrocardiogram, an echocardiography (measurement of the velocity of tricuspid regurgitation, measurement of Tricuspid Annular Plane Systolic Excursion (TAPSE) and Tei index, pericardial effusion, dilatation and hypertrophy of the right ventricle), an abdomina ulstrasound, a stress Test (ventilation oxygen peak and ventilation oxygen specific, minute ventilation, dead-space ventilation / dead space, ventilatory reserve, alveolar-arterial gradient, pulse oxygen, PaO2), a lung function tests and measurement of Diffusing capacity or transfer factor of the Lung for Carbon mOnoxide (DLCO) and Nitric Oxide (DLNO), and a blood sample.
45460383|NCT03902197|Biological|CD19 hsCAR-T|CD19 hsCAR-T will be administered by I.V. infusion
45460384|NCT03909919|Procedure|Standard Care or Usual Clinical Practice|The guidelines for the management according to the heart failure in primary care will be the treatment guidelines for the Standard Care.
45460385|NCT01255033|Device|Monitoring of tissular oxygenation|"Equanox: cerebral oxygenation by spectroscopy, near-infrared through forehead and noninvasive devices~Inspectra: tissular oxygenation by spectroscopy, near-infrared through thenar and noninvasive device"
45460386|NCT02527915|Other|Mental Health eConsults|Providers in primary care clinics who receive the intervention will be able to use electronic consultations (eConsults) with psychiatrists. If a primary care provider wishes to use eConsults, he/she will enter a specific question about a patient in the electronic medical record system and submit as an eConsult. A psychiatrist will review the question and the patient's record, and send a response back to the primary care provider within one business day.
45460387|NCT02527915|Other|Care as usual|Providers in primary care clinics will deliver care as usual to their patients.
45460388|NCT03902119|Device|INYBI tool|Patients will lie down in supine position so that the INYBI tool will contact the suboccipital muscles at the posterior arch of the atlas. The therapist will adapt the height of the tool for each individual. All patients will use the softest head of the device. A 50Hz vibration speed will be set sup during 5 minutes.
45460389|NCT03902119|Other|Manual suboccipital inhibition|Patients will lie down in supine position.The therapist will be seated at the head of the treatment table. The therapist will keep the metacarpophalangeal joints in a flexed position, while therapists fingertips of both hands will contact with the suboccipital muscles at the posterior arch of the atlas.
45460390|NCT03901885|Other|Female Sexual Function Index questionnaire|Assessment of FSFI (Female Sexual Function Index) questionnaires preoperatively and postoperatively (4 months).
45460391|NCT01149109|Drug|Temozolomide and lomustine|
45460392|NCT01149109|Drug|Temozolomide|
45460393|NCT03903757|Other|DNA methylome and total RNA sequencing|Epigenomics tools combined with bioinformatic analysis to correlate putative useful clinical biomarkers with clinical features
45460394|NCT03903679|Device|Laryngeal mask airway|Patients will be maintained with laryngeal mask airway during the septal surgery.
45460395|NCT03903679|Device|Endotracheal tube|Patients will be maintained with endotracheal tube during the septal surgery.
45460396|NCT03902041|Drug|Eltrombopag|The patients will receive Eltrombopag treatment after transplantation
45460397|NCT05667415|Drug|disulfiram and cisplatin|on the first day of treatment, patients were given intravenous drip of 80mg/m2 cisplatin, and 21 days was a course of treatment, lasting for 6 courses. Take 400mg disulfiram orally every day, and continue to use it until the end of chemotherapy. According to the patient's tolerance to disulfiram, the dose of disulfiram can be re-evaluated during the treatment, and the lowest dose is 125mg per day. The clinical symptoms, signs and adverse reactions of patients were observed, and the treatment effect of patients was evaluated after two consecutive cycles with 3 weeks as a cycle.
45460398|NCT05667415|Drug|cisplatin|on the first day of treatment, patients were given 80mg/m2 cisplatin intravenously, and 21 days was a course of treatment, lasting for 6 courses.
45460399|NCT03903445|Behavioral|Masayang Pamilya Para Sa Batang Pilipino Program (MaPa Kids)|"MaPa Kids is an 8-session parenting program delivered weekly to groups of parents (N=15 per group).~The program includes the following content: 1) spending one-on-one time with children; 2) describing actions and feelings for cognitive development and socio-emotional awareness; 3) using praise and rewards to encourage positive behavior; 4) establishing limits through effective instruction giving and consistent household rules; 5) nonviolent discipline such as ignoring negative attention seeking behavior, and consequences for noncompliance, rule-breaking, and aggressive behavior; 6) problem solving with children; and 7) mindfulness based stress reduction."
45678751|NCT01427608|Drug|Sertraline + Olanzapine|Olanzapine 15mg/day. Adjustment of dose to 5mg/day to a maximum of 20mg/day will be permitted if necessitated by significant side-effects or clinical worsening
46009097|NCT04672265|Other|Mother tongue and Norwegian|The screening invitation letter, the information leaflet, the reminder letter and the result letter will be sent in two languages; an official language in the country where the invitee is born, and Norwegian.
45678752|NCT01427608|Drug|Sertraline + Placebo|Taper from current dose of olanzapine to placebo over 4 weeks. Continue placebo for remainder of 36 week study.
45678753|NCT01408030|Drug|Sterile saline|0.9%, 0.1 ml spray in each nostril bid
46009098|NCT04553055|Other|online questionnaires|questionnaire (with detailed questions including how/when/which/for how long antibiotics are prescribed)
46009099|NCT02213406|Dietary Supplement|yogurt|Subjects will receive yogurt with varying fat concentrations
46009100|NCT04672070|Other|Selective Caries Removal|"Selective caries are removed only for secure sealing with a direct restoration, without removing deep caries next to the pulp.~If the pulp is exposed, pulpotomy will be performed instead and the tooth will be excluded from further analysis."
46009101|NCT04672070|Other|Pulpotomy|"Complete caries removal and excision of the coronal pulp to the level of the root canal orifices will be performed. After haemostasis, sealing with Biodentine® and restoration.~If the pulp is not exposed after complete caries removal, the tooth will be restored without further excavation and pulp exposure. If the pulp is assessed intra-operatively to be non-vital or not amenable to pulpotomy, root canal treatment will be performed instead. In both cases, the tooth will be excluded from further analyses."
45460400|NCT03903445|Behavioral|Masayang Pamilya Para Sa Tinedyer Pilipino Program (MaPa Teens)|"MaPa Teens is a 9-session parenting program delivered to groups of parents and children aged 10-17 (N=15 dyads per group).~The program includes the following content: 1) one-on-one time with parents and teens, 2) positive reinforcement of positive behavior, 3) managing anger and stress, 4) establishing rules and routines, 5) family budgeting, 6) accepting responsibility for actions, 7) resolving family conflicts, 8) keeping safe in the community and resolving conflicts, and 9) reflection and moving on."
45460401|NCT01586143|Drug|paracetamol|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
45460402|NCT01586143|Drug|Placebo|
45678754|NCT01408030|Drug|Bevacizumab|1% solution in saline, 0.1 ml spray in each nostril bid
45678755|NCT01408030|Drug|Estriol|0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid
46009102|NCT04552977|Drug|fluzoparil|a PARP1 inhibitor
46009103|NCT04552977|Drug|temozolomide|an alkylating chemotherapeutic agent
46009104|NCT04672343|Other|Data collection|from D0 to hospital discharge
46096049|NCT02750969|Procedure|blood test- serum lidocain levels|"each participant will undergo blood test. the participant's group that start the trial with the lidoderm patch and later will use the tegaderm patch will have 2 blood tests for werum lidocain level test. the group taht start the trial with the tegaderm patch and later the lidoderm patch will have only one blood test measuring lidocaine serum level.~the tubes containing the serum will be shipped abroad via an international medical cargo company for lidocaine levels tests."
46096050|NCT02750969|Other|Hearing tests|each participant that have not done hearing test in the last 1 year previous to the trial will have one in the first day of the trial.
45678756|NCT01408030|Drug|Tranexamic Acid|10% solution in saline, 0.1 ml spray in each nostril bid
46009105|NCT04672343|Other|Querying the INSEE database|Vital status at 3 months and 12 months
46096051|NCT04067011|Drug|Ciprofloxacin 500Mg Tablet|Ciprofloxacin 500mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 4-9, 22-24 and 31-37.
46009106|NCT04552860|Behavioral|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
46009107|NCT01085357|Procedure|Cataract Surgery|Cataract Surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
46096052|NCT04067011|Drug|Doxycycline 100Mg Tablet|Doxycycline 100mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 2-9, 22-24 and 32-38.
46096053|NCT04067011|Biological|AV7909|0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose.The vaccine will be administered intramuscularly on Study Days 8 and 23.
46096054|NCT00678054|Drug|GM-CSF|Each cycle will consist of 28 days. Patients will receive 250 ug/m2/day of GM-CSF administered subcutaneously on days 1-14.
46096055|NCT02751125|Drug|BCP with autologous mesenchymal stem cells (MSC).|Augmentation of narrow alveolar ridge with BCP and MSC
45678757|NCT04407832|Device|heat probe or hemoclip|for hemostasis
46009108|NCT01085357|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye after completion of cataract surgery.
46009109|NCT04552938|Other|pre-LVA|Venous serum samples were collected from patients before LVA.
46009110|NCT04552938|Other|post-LVA|Venous serum samples were collected from patients one-month after LVA.
46009111|NCT02277860|Behavioral|Exercise|Aerobic and strength training using the Wii Fit for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
46009112|NCT02213523|Dietary Supplement|Plant concentrate A|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
46096056|NCT00715234|Other|Reminder/recall notices for vaccines|"Receive a generic letter reminding them to make an appointment to get vaccines.~Receive a computer-generated telephone message at 1 week post initial letter.~Receive a computer-generated telephone message at 2 months post initial letter.~Receive a letter at 3 months post initial letter."
46096057|NCT00709930|Device|Magnetic field generator|dosage:Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF frequency:10min/day duration:1 month
46096058|NCT00709930|Device|Placebo magnetic field generator|Placebo device with no magnetic fields
46096059|NCT04990219|Drug|Lu AG06466|Lu AG06466 - capsule
46096060|NCT04990219|Drug|Placebo|Placebo - capsule
45460403|NCT03909841|Behavioral|Cambridge Neuropsychological Test Automated Battery (CANTAB)|Cognition using Cambridge Neuropsychological Test Automated Battery (CANTAB)
45460404|NCT03909841|Other|Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)|Quality of Life using Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)
45460405|NCT01252927|Other|ASIST|The gatekeeper training intervention group will receive the Applied Suicide Intervention Skills Training (ASIST) workshop in addition to training as usual. ASIST is a 2-day intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide.
46096061|NCT04488575|Drug|EDP1815|EDP1815 is an orally administered monoclonal microbe
46009113|NCT02213523|Dietary Supplement|Plant concentrate B|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
45460406|NCT01253005|Behavioral|Nutritional intervention|This study will investigate the effects of particle size of different triglyceride emulsions as well as the dynamics of intragastric structure formation and breakdown of the emulsions on GI function, the kinetics of the endocrine and the satiation response in healthy volunteers.
45460407|NCT01256359|Drug|Docetaxel and AZD6244|Docetaxel 75mg/m2 IV and AZD6244 75mg bd daily. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but AZD6244 may be continued beyond this, until disease progression.
45460408|NCT01256359|Drug|Docetaxel and placebo|Docetaxel 75mg/m2 IV and placebo given bd. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but placebo may be continued beyond this, until disease progression.
45460409|NCT01256437|Drug|Threolone ointment|ointment once daily for 1 month
45460410|NCT01256437|Drug|ointment Synthomycine|ointment once daily for 1 month
45460411|NCT01256437|Drug|Aqua cream|ointment once daily for 1 month
45460412|NCT02873936|Drug|Filgotinib|Tablet(s) administered orally once daily
45460413|NCT02873936|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
45460414|NCT02873936|Drug|csDMARDs|csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX is not allowed)
45460415|NCT03901651|Diagnostic Test|Colonoscopy with Retroview scope combing forward and retroflexed withdrawal technique|"Colonoscopy using a combined forward and retroflexed evaluation of the colonic mucosa. using the Retroview™ scope. The operator will be blind to the standard colonoscopy findings.~The operator will record the polyps and adenoma encountered, describing the size and location."
45460416|NCT03901651|Diagnostic Test|Colonoscopy with standard colonoscope and forward withdrawal technique|"A standard colonoscopy with forwarding viewing withdrawal technique. An HD colonoscope with I-scan technology will be used by one expert endoscopist.~Each polyp and adenoma will be recorded, including the size and location."
45678758|NCT04407832|Device|heat probe or hemoclip|for hemostasis
45460417|NCT01253083|Behavioral|mobility training with dynamic body weight support|
45460418|NCT02527993|Drug|Glucobay (acarbose)|Se arm description
45678759|NCT02985424|Other|18F-FDG PET/CT|18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
45678760|NCT01897532|Drug|Placebo|placebo matching tablets
45678761|NCT01897532|Drug|Linagliptin|
45678762|NCT04641026|Other|Broccoli sprouts|Subjects will consume one serving (about 1 cup) of broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
45678763|NCT04641026|Other|Deuterium oxide-labelled broccoli sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
46009114|NCT02213523|Dietary Supplement|Plant concentrate C|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
46009115|NCT02213523|Dietary Supplement|Plant concentrate D|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
46009116|NCT01085201|Drug|Lexiscan|Given as an infusion
46009117|NCT02213562|Dietary Supplement|200 mg of chrysanthemum flower oil|
46009118|NCT02213562|Dietary Supplement|300 mg of chrysanthemum flower oil|
46009119|NCT02213562|Dietary Supplement|400 mg of chrysanthemum flower oil|
45460419|NCT02527993|Drug|Januvia (sitagliptin)|Se arm description
45460420|NCT02527993|Drug|Verapamil HEXAL (verapamil)|Se arm description
45460421|NCT02527993|Drug|Victoza (liraglutide)|Se arm description
45460422|NCT02527993|Drug|Signifor (pasireotide)|Se arm description
45460423|NCT02527993|Device|Continuous glucose monitoring (CGM)|Continuous glucose monitoring will be performed during 6 days of the treatment period.
45460424|NCT02527993|Dietary Supplement|Meal tolerance test (MTT)|A meal tolerance test will be performed at the end of the treatment period. The subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
45460425|NCT03901417|Device|Fraxel Restore (Non-ablative Fractional Laser)|In the study, one side of the face will be treated with non-ablative fractional laser monthly for three months.
45460426|NCT03901417|Device|Fraxel Restore (Non-ablative fractional laser) and SkinPen (Microneedling Device)|In the study, one side of the face will be treated with a combination of non-ablative fractional laser and microneedling monthly for three months.
45678764|NCT04641026|Other|Alfalfa sprouts|Subjects will consume one serving (about 1 cup) of alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
45678765|NCT04641026|Other|Deuterium oxide-labelled alfalfa sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
45678766|NCT01923428|Drug|AZD1722|
45678767|NCT01923428|Drug|Placebo|
46009120|NCT04671992|Device|Out of-Plane Technique and In-Plane on|A comparison of out of-plane technique and in-plane
46096062|NCT04488575|Drug|Placebo|Placebo oral capsule
46096063|NCT00715312|Other|Novel Olein|A total of 70g of test oil is incorporated into cooked meal which accounts for 30-35% of calorie intake
46009121|NCT02213679|Dietary Supplement|Guanidinoacetic acid|Dietary supplement
46009122|NCT02213679|Other|Placebo|Placebo
46096064|NCT00715312|Other|Novel Olein|A total of 70g of test oil is incorporated into cooked meal which provides 30-35% of calorie
45460427|NCT03901495|Other|Diaana|"Diaana, the AMHTD used, functions as follows: on the basis of an interactive questionnaire completed by the patient before the consultation, it performs an exhaustive anamnesis focused on the problem and proposes a panel of DDs with a high sensitivity. The artificial reasoning system of Diaana mimics how a specialist physician would reason to establish a DD. The information transmitted is in an easy-to-use form for the physician that includes a summary of the anamnesis centered on relevant elements from the questionnaire and a list of possible diagnoses with their emergency level, potential contributing factors, and first-line management proposals."
45678768|NCT04627376|Other|Multimodal education and support program for cancer related cachexia prevention|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management related to anti cancer treatment.
46009123|NCT02213718|Drug|Desflurane|desflurane (7%-8% end-tidal concentration)
46009124|NCT02213718|Drug|propofol|propofol (TCI:3.5-4.0μg/min)
46009125|NCT02213718|Drug|sufentanil|TCI: 2-3 ng/ml during the duration of surgery, an expected average of 4 hours
45678769|NCT04618718|Device|cerebral embolic protection during TAVR|The ProtEmbo system is an adjunctive device placed in the central arterial system at the beginning of a TAVR procedure to deflect embolic particles during the procedure and removed following the completion of the procedure.
45678770|NCT04173416|Behavioral|Youth Opioid Recovery Support (YORS)|The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to treatment engagement in this vulnerable young adult population, especially difficulties with medication adherence. Its components include: (1) Home delivery of extended release naltrexone (XR-NTX) for OUD; (2) Engagement of families in collaborative treatment planning and monitoring focusing on medication adherence; (3) Assertive outreach from the treatment team including actively tracking and communicating with youth and families by text messaging and social media to promote engagement and adherence; and (4) Contingency management to provide incentives for medication adherence.
45678771|NCT01896128|Drug|Armodafinil|
46009126|NCT01085084|Drug|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
45678772|NCT01896128|Drug|Placebo|inactive pill manufactured to mimic Armodafinil 150 mg tablet
45678773|NCT01949870|Drug|Cisplatin|day1 and day8 at each cycle
46009127|NCT01085084|Drug|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
46096065|NCT02573506|Radiation|split-course radiotherapy|Patients are irradiation at a palliative dose in the initial course: 51Gy/17f to PTV-GTV. The disease is re-evaluated three weeks after the end of the initial course using CT. The patient without disease progression according to the RECIST criteria and had a recovery of lung function should get the additional boost. In the second course, the tumor is repositioned and scanned. The residual tumor is then treated with the second course of radiotherapy. A dose of 15-18 Gy/5-6f is delivered to the residue tumor.
46096066|NCT02573506|Drug|Concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
46096067|NCT04003831|Device|Device: P200TxE|The P200TxE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
45678774|NCT01949870|Drug|Gemcitabine|day1 and day8 at each cycle
45836849|NCT00413634|Drug|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
45836850|NCT00467298|Behavioral|Exercise adherence|The exercise program includes endurance and strength training and warm-up and cool-down strategies. Emphasis is placed upon implementing and adhering to the exercise program at home following intervention completion.
46009128|NCT04552548|Other|regional nerve block|Abdominal field blocks have been used in anesthesia for surgery involving the anterior abdominal wall with ultrasound-guided technique. TAP block is a regional anesthetic technique that blocks neural afferents of the anterolateral abdominal wall. Using anatomical landmark guidance or with the aid of ultrasound (US), local anesthetic is injected into the transversus abdominis fascial plane, where the nerves from T6 to L1 are located. Ultrasound-guided quadratus lumborum (QL) block is considered now as one of the novel truncal abdominal blocks, as it is effective in preventing somatic pain associated with upper and lower abdominal surgeries.
46009129|NCT01085045|Drug|PT003 MDI|Inhaled PT003 MDI administered as two puffs BID for 7 days
46009130|NCT01085045|Drug|PT005 MDI|Inhaled PT005 MDI administered as two puffs BID for 7 days
46009131|NCT01085045|Drug|Placebo MDI|Inhaled placebo administered as two puffs BID for 7 days
46009132|NCT01085045|Drug|Tiotropium bromide 18 μg (Spiriva Handihaler®)|Inhaled tiotropium bromide 18 μg (Spiriva Handihaler®) administered QD for 7 days
46009133|NCT01085045|Drug|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Inhaled formoterol fumarate 12 μg (Foradil® Aerolizer®) administered BID for 7 days
46009134|NCT01085045|Drug|PT001 MDI|Inhaled PT001 MDI administered as two puffs BID for 7 days
46009135|NCT02213796|Drug|Meropenem|
46009136|NCT04552392|Other|No intervention|No intervention
45460428|NCT01256515|Behavioral|Health Education|CDs, techniques, advice, and group training pertaining to a healthier lifestyle. Both groups will have this intervention, but the specific type of health education training will vary between groups.
45460429|NCT01256515|Behavioral|Health Education Training|8 weeks of group training regarding health education techniques.
45460430|NCT03909373|Other|PSFS|Patients will complete the patient specific functional scale. no intervention being administered
45460431|NCT01150513|Drug|EC-T|four cycles of EC (epirubicin: 90 mg/m2; cyclophosphamide :600 mg/m2, day 1) followed by four cycles of T (docetaxel : 75 mg/m2 or paclitaxel 175 mg/m2, day 1)
46009137|NCT04552626|Behavioral|Prolonged sitting (social breaks)|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a short social break. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
46096068|NCT04217759|Behavioral|Healthy lifestyle intervention|"The main goal was to provide knowledge and skills for targeted population in order for them to adapt healthy lifestyle throughout their life. At the end of intervention, participants were expected to be fully equipped with necessary knowledge and fundamental skills in adapting and maintaining healthy lifestyle throughout their life. Gradual improvements were emphasised and at least 5% loss of initial body weight was expected, aiming for at least 0.5% loss in the first month.~It was divided into three phases (preparation, implementation, maintenance) focusing on PA and diet, in which self-efficacy enhancement and self-regulatory skills were emphasised during the first month of intervention."
46096069|NCT05361187|Device|BOBBY™ Balloon Guide Catheter intended for use in neurovascular procedures, performing or as an adjunctive device|The BOBBY™ BGC used during a mechanical thrombectomy procedure (stent retriever alone, contact aspiration alone or stent retriever and contact aspiration) and according to the instruction for use (IFU).
45460432|NCT01150513|Drug|TP|six cycles of TP (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2 d1; carboplatin AUC=5, day 1)
45460433|NCT03908983|Device|Kalios Implant|KALIOS is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of KALIOS is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3
46009138|NCT04552626|Behavioral|Prolonged sitting with step-up exercise break|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform a simple moderate-intensity step-up exercise for three minutes at a predetermined pace. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
46096070|NCT02750891|Drug|DSP-7888|Phase1 portion: 1.75 or 3.5 mg/body, Id every 1-4 weeks Phase 2 portion: recommended phase 2 dose, Id every 1-4 weeks
46096071|NCT00718978|Procedure|CSS grafting|grafting of autologous three-cellular cultured skin substitutes (CSS) consisting of cultured keratinocytes, melanocytes and fibroblasts attached to a scaffold of hyaluronic acid (HYAFF11® and HYAFF11p80®) obtained from full-thickness skin biopsies to repair full-thickness loss of substance
46096072|NCT04044859|Genetic|Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 alone or in combination with either nivolumab 480 mg IV every four weeks or pembrolizumab 400mg IV every 6 weeks
46096073|NCT04481087|Device|Clearfil Universal Bond Quick|Adhesive systems
45460434|NCT03908827|Biological|Bone Mineral Aspirate Concentrate (BMAC)|A single BMAC injection will be performed into the arthritic joint
45460435|NCT05416502|Procedure|Ultrasound|Enrolled patients underwent ultrasound scan of kidneys, ureters, and the bladder.
45460436|NCT03898141|Other|Placebo (PL)|"Participants will get deceptive and receive an inert cream (=placebo intervention) that reduces pain."
45460437|NCT03898141|Other|Dog only (DO)|In the dog intervention a dog will be present during the second measurements. However, participants will only learn the true aims of the presence of the dog after the study (delayed informed consent).
45460438|NCT03898141|Other|Animal-assisted placebo (AAPL)|Participants receive the placebo intervention in the presence of a dog.
45460439|NCT04927052|Device|Revanesse Shape + with Lidocaine|Revanesse Shape + with Lidocaine. Participants had 1 cheek treated with Revanesse Shape + with Lidocaine
45460440|NCT04927052|Device|Juvederm Voluma with Lidocaine.|Juvederm Voluma with Lidocaine. Participants had 1 cheek treated with Juvederm Voluma with Lidocaine
45460441|NCT03901027|Behavioral|Therapeutic Conversation Interventions|Parents (N=31) at the Children's Hospital at the National University Hospital of Iceland, got two sessions of the FAM-SOTC intervention focusing on emotional support, evidence based information and recommendations and on the strengths of family members. The parents meet with the Advanced Practice Nurse at the Children´s Hospital without the child in both sessions, but each session lasted for 45 to 90 minutes. The sessions were offered with 4-8 weeks interval.
45678775|NCT01949870|Drug|Selumetinib|25mg/day, 50mg/day and 75mg/day
45678776|NCT01949480|Procedure|Thoracotomy|
45678777|NCT01949480|Procedure|Video-Assisted Thoracoscopic Surgery (VATS)|
46009139|NCT04552626|Behavioral|Prolonged sitting with simple resistance activity breaks|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
46009140|NCT01084772|Other|VISIONAIRE Total Knee Arthroplasty|TKA will be performed with VISIONAIRE instrumentation, depending on randomization assignment.
45678778|NCT01949090|Biological|Investigational H7N1 vaccine GSK2789869A|Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.
46009141|NCT01084772|Other|Standard Total Knee Arthroplasty|TKA will be performed with standard instrumentation, depending on randomization assignment.
46009142|NCT04552158|Dietary Supplement|Mediterranean diet|The Mediterranean diet (MedDiet) is a nutritional model inspired by the traditional dietary pattern of some of the countries of the Mediterranean basin. Mediterranean dietary pattern (MDP) gather the following characteristics: abundant consumption of olive oil and high consumption of fruits, vegetables, cereals (preferably as whole grain), legumes, nuts and seeds. The MDP also includes moderate consumption of fish and shellfish, white meat, eggs, and fermented dairy products (cheese and yogurt), as well as relatively small amounts of red meat, processed meats, and foods rich in sugars. Frequent but moderate intake of wine, especially red wine with meals is also recommended
46009143|NCT00179673|Drug|Lenalidomide|Lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed
46009144|NCT01084655|Drug|TAK-700|TAK-700 with docetaxel and prednisone on a continuous schedule.
46009145|NCT01084655|Drug|Docetaxel|TAK-700 with docetaxel and prednisone on a continuous schedule.
45460442|NCT05621876|Device|IgG deficiency rapid screening test|We will be testing patients who have already been diagnossed iwth primary immunodeficiency (PID) disease. there are 400 types of PID. We will test their blood before they receive antibody transfusion to evaluate the accuracy of our new screening test. We are trying to develop easy to use, low-cost screening tests for doctors to use with patients to detect those with low IgG levels before they are given the oral polio vaccine. These patients must be prioritized for intramuscular injections of a polio vaccine to prevent potential spread of wild type polio.
45678779|NCT01949090|Biological|Placebo|Two doses of placebo administered intramuscularly to the deltoid region at Day 0 and Day 21.
45678780|NCT01948076|Device|resident with GE vscan|resident with GE vscan
45678781|NCT01922258|Drug|Brexpiprazole, OPC-34712|Flexible dose of 0.5 to 2 mg/day or placebo tablets for up to 12 weeks
45678782|NCT01406938|Drug|AIN457 150mg|(1 injection per dose) and placebo to secukinumab 150 mg
45678783|NCT01406938|Drug|AIN457 300mg|secukinumab 150 mg (2 injections per dose)
45678784|NCT01405924|Drug|Fosaprepitant dimeglumine|Fosaprepitant 150 mg, IV on Day 1 of chemotherapy in Cycle 2
45460443|NCT01149499|Drug|Valacyclovir|1000 mg Tablet
45460444|NCT01149499|Drug|Valacyclovir|1000 mg Tablet
45460445|NCT04919798|Device|Non-invasive bladder emptying device|The NIBED is applied to the penis during urination to support bladder emptying in urinary retention patients. It is a battery-driven handheld device that is operated by the patient himself.
45460446|NCT04908644|Drug|MS-20 oral solution|Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans
45678785|NCT01405924|Drug|5-HT3 RA|5-HT3 RA will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
45678786|NCT01405924|Drug|Dexamethasone|Dexamethasone will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
46009146|NCT01084655|Drug|Prednisone|TAK-700 with docetaxel and prednisone on a continuous schedule.
46009147|NCT04552431|Drug|Ciprofloxacin|Ciprofloxacin, 500 mg twice daily
45460447|NCT04908644|Other|Placebo|Placebo
45460448|NCT03900871|Drug|Acetylsalicylic acid|Aspirin (aspirin), also known as acetylsalicylic acid (acetylsalicylic acid), is a salicylic acid drug commonly used as a painkiller, antipyretic and anti-inflammatory drug. There is growing evidence that aspirin has a preventive effect on certain cancers, especially gastrointestinal cancers, and that taking aspirin every day can reduce the risk of colon cancer, and in vitro experiments have also shown that aspirin inhibits the growth of a variety of cancer cells and induces apoptosis.
45460449|NCT03908905|Diagnostic Test|Polysomnography|Sleep screening, neurocognitive assessment, activity monitoring questionnaires, blood sample
45460450|NCT01149577|Drug|Olanzapine|06 weeks treatment with Olanzapine in a flexible dosage schedule.
45460451|NCT01150669|Other|laboratory biomarker analysis|Samples are analyzed in laboratory studies
45460452|NCT03894007|Drug|Docetaxel|75 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 4 courses preoperatively.
45460453|NCT03894007|Drug|Carboplatin|AUC 6 iv, day 1 every third week, 4 courses preoperatively.
45460454|NCT03894007|Drug|Trastuzumab|600 mg sc, day 1 every third week, 4 courses preoperatively. 14 courses postoperatively if complete response.
45460455|NCT03894007|Drug|Pertuzumab|840 mg iv starting dose, thereafter 420 mg, day 1 every third week. 14 courses postoperatively if complete response in patients with baseline high risk tumours.
45460456|NCT03894007|Drug|Epirubicin|90 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 3 courses preoperatively
45460457|NCT03894007|Drug|Cyclophosphamide|600 mg/m2 iv, day 1 every third week, 3 courses preoperatively
45460458|NCT03894007|Drug|Atezolizumab|840 mg iv, day 1 every third week, 3 courses preoperatively if randomised to arm A.
45460459|NCT03894007|Drug|Trastuzumab emtansine|3.6 mg/kg iv, day 1 every third week, 14 courses postoperatively if not complete response.
45460460|NCT03894007|Drug|Paclitaxel|80 mg/m2 iv, day 1 weekly, 12 weeks (4 cycles), in case of (anticipated) unmanageable toxicity related to docetaxel.
45460461|NCT01150747|Drug|ceftriaxone|250mg IM once
45678787|NCT01405924|Drug|Rescue medication|Rescue medication is defined as any medication used to relieve the symptoms of established nausea or vomiting. Multiple medications are permitted by the protocol and may be taken by the participant, including 5-HT3 antagonists, phenothiazines and benzodiazepines.
45678788|NCT01426438|Drug|Niacin|Extended-release niacin will be given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
46009148|NCT04552431|Drug|Tamsulosin Hydrochloride|Tamsulosin Hydrochloride, 0.4 mg once daily
45460462|NCT01150747|Drug|Azithromycin|1 gm once
45460463|NCT01255189|Device|Device: near infrared spectroscopy: INVOS 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
45460464|NCT01255189|Device|invos 5100|near infrared spectroscopy: invos 5100
45678789|NCT01426438|Drug|Aspirin|Aspirin 325 mg will be given by mouth in the evening with extended-release niacin through week 24.
46009149|NCT04552431|Drug|Tamsulosin Hydrochloride Placebo|Tamsulosin Hydrochloride Placebo (Placebo-TH) one tablet once daily
46009150|NCT04552431|Drug|Ciprofloxacin placebo|Ciprofloxacin placebo (Placebo-CF) one tablet twice daily
46009151|NCT01084538|Drug|Zemplar iv (paricalcitol iv)|Each patient will be treated at the physician's discretion. Zemplar (paricalcitol) will be prescribed in the usual manner in accordance with the approved Summary of Product Characteristics.
46009152|NCT00179517|Drug|Anastrozole 1mg|
46009153|NCT00179517|Drug|Placebo Oral Tablet|
46009154|NCT01083641|Drug|Estradiol|10mg oral three times daily
46009155|NCT00179010|Drug|Adenosine|Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each
46096074|NCT04481087|Device|Clearfil Universal Bond Quick|Adhesive systems
45460465|NCT03900481|Procedure|Vertical gastric plication|Vertical gastric plication ( without cutting gastric wall) is a novel surgical approach for reducing the stomach capacity. A transoral or endoluminal approach (i.e. a procedure that requires no incision, because access is granted through the mouth) offers some potential additional benefit to the patient, because the procedures continue to become more and more minimally invasive.
45460466|NCT05416034|Device|Use of the ATLAS 2025 exoskeleton at home|Each participant will use the ATLAS 2025 exoskeleton at their homes, 5 days a week during a period of two months, for walking with the device and performing motor activities in 60 minutes duration sessions..
46009156|NCT00179010|Drug|Adenosine Mono Phosphate (AMP)|Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)
45460467|NCT03900559|Behavioral|NO-FEAR Airlines|"NO-FEAR Airlines is an Internet-based self-applied treatment program that allows people with Flying Phobia the exposure to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.~NO-FEAR Airlines contains 6 scenarios related to the flight process: (1) flight preparation, (2) airport, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway, and landing, (6) sequences with images and auditory stimuli related to plane crashes."
45460468|NCT03893695|Drug|GT90001 and Nivolumab|Stage1:Dose de-escalation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.
45460469|NCT04811066|Device|Transcranial direct current stimulation|"Transcranial electrical stimulation device. A weak direct electrical current, up to 2 mA, is passed between two electrodes placed on the scalp. Electrodes are housed in 35 cm2 sponges saturated with 4 ml of saline solution (0.9 % NaCl) per side, per pad.~Stimulation is phased in with a 30-second ramp up of the electrical current to the specified stimulation parameters. Following the specified stimulation period, the current is phased-out with a ramp down of the current. For sham stimulation, the ramp-up and ramp-down periods are retained, but stimulation is switched off during the specified stimulation period."
45460470|NCT03900325|Drug|Nimacimab|2.5 mg/kg
45460471|NCT03900325|Drug|Placebo|0.9% sodium chloride
45460472|NCT05415956|Behavioral|Walking exercise therapy|Moderate-to-high intensity walking exercise therapy (7 weeks, 14 session) with progression in duration and intensity.
45460473|NCT02527759|Behavioral|Survey|
45678790|NCT01426438|Drug|Fenofibrate|Fenofibrate will be administered as 200 mg by mouth once daily for 24 weeks.
45678791|NCT04407910|Combination Product|AIRFLOW® Master device +Opalescence Xtra Boost.|Prophylaxis techniques for pre-bleaching treatment
45678792|NCT04407910|Combination Product|rubber-cup+Opalescence Xtra Boost.|Prophylaxis techniques for pre-bleaching treatment
45678793|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
45678794|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
46009157|NCT04552236|Device|Ultrasound ELastography|"A standardized liver Elastography is critical to obtain reliable and accurate results . The patient is imaged in supine or slight 30 degrees left lateral decubitus position, with the right arm elevated above the head to open the intercostal spaces and improve the acoustic window to the liver . it is recommended to sample measurements in the right lobe , which has shown the most reliable results. Transducer pressure on the skin should be similar to regular anatomical B-mode imaging.~When using SWE techniques, the acoustic radiation force push pulse should be applied perpendicular to the liver capsule, with measurements obtained 4-5 cm deep to the skin and within a minimum 1-2 cm of liver parenchyma to limit refraction of the pulse. The operator should verify that these areas are free of vascular and biliary structures and rib shadows."
45678795|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
46009158|NCT01083602|Drug|panobinostat|PAN 20 mg PO given TIW, weeks 1&2 of each 3-week cycle;• BTZ 1.3 mg/m2 IV push given BIW weeks 1&2 of each 3 week cycle (days 1,4,8 and 11);• Dex 20 mg PO given QIW, weeks 1&2 of each 3-week cycle (days 1,2,4,5,8,9,11 and 12)
45678796|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
46009159|NCT01083602|Drug|bortezomib|
46009160|NCT01083602|Drug|dexamethasone|
46009161|NCT04552002|Dietary Supplement|Synbiotic group|Probiotics and prebiotics
45678797|NCT01425814|Drug|Reference|Dry powder inhalation (capsule),single dose
46096075|NCT04481087|Device|Clearfil Universal Bond Quick|Adhesive systems
46096076|NCT04481087|Device|Clearfil SE Bond|Adhesive systems
46096077|NCT04481087|Device|Tetric N-Bond|Adhesive systems
45460474|NCT01258309|Drug|olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution|One drop of olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution administered to each eye, twice daily for 21 days.
45460475|NCT01258309|Drug|olopatadine hydrochloride 0.1% ophthalmic solution|One drop of olopatadine hydrochloride 0.1% ophthalmic solution administered to each eye, twice daily for 21 days.
45460476|NCT03893851|Behavioral|Interactions Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.
45460477|NCT01256905|Drug|Armodafinil|Armodafinil 150 mg
45678798|NCT01425814|Drug|Placebo|Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose
45460478|NCT03900091|Diagnostic Test|Multiplex PCR assay for meningitis|CSF from cases to be analysed with a FilmArray ME Panel
45460479|NCT03900091|Diagnostic Test|Multiplex vertical flow microarrray assay for meningitis|CSF from cases will also undergo analysis with a newly developed prototype for point-of-care diagnostic tool for CNS infections identification. The tool is a DNA-based vertical flow microarray technology printed on paper.
45460480|NCT03900091|Diagnostic Test|Profiling of blood proteins by multi-analyte Profiling technology|Blood from cases and controls to be analysed using Luminex technology to identify protein profiles associated with severe and non-severe infection. Myxovirus protein A (MxA) will also be analysed by the Luminex assay, to associate MxA levels with severe/non-severe infection.
45460481|NCT03900091|Other|Typing and whole genome sequencing|Pathogenic strains isolated from nasopharyngeal swabs from cases and controls will undergo whole genome sequencing (WGS) and typing .
45678799|NCT01782495|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
45836851|NCT00467298|Behavioral|Self-management- prevention of illness|Instruction is provided regarding key elements of managing heart failure and COPD with emphasis upon individual adaptations to prevent exacerbations, unscheduled provider visits, and hospital admissions as well as promotion of daily activity.
46009162|NCT00178464|Drug|aspirin|81 mg flavored chewable tablets. Subjects between the ages of 2.0 and 4.99 years will receive half of an 81 mg aspirin tablet each day. Those older than 5.0 years will receive a daily 81 mg aspirin tablet. The subject will receive the study drug for a period of 12 months.
46009163|NCT04671914|Drug|Hyaluronic Acid 20 MG/ML Injectable Solution|Application of hyaluronic acid gel into uterine cavity after After abortion in II trimester we do D&C
46009164|NCT04671914|Other|Dilation and curretage|After abortion in II trimester we do D&C.
46009165|NCT01083485|Drug|Oxycodone/Naloxone PR 20/10mg or 10/5mg tablets|Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)or Oxycodone 20mg
46009166|NCT01083485|Drug|Oxycodone|Oxycodone 20mg or 10mg BID for 2.5 days (total 5 dosages)
45460482|NCT05667337|Device|CLP-PEG-MPC|Implantation of a 500 um thick biosynthetic corneal implant utilizing DALK surgical technique
45460483|NCT05667337|Procedure|Human donor cornea penetrating keratoplasty|Implantation of a human donor cornea graft utilizing PKP surgical technique
45460484|NCT01151839|Procedure|Esophagectomy|Patient with squamous cell carcinoma of esophagus will be treated with surgery alone
45460485|NCT01151839|Procedure|Neoadjuvant chemoradiation followed by surgery|Patient with squamous cell carcinoma of esophagus will be treated by neoadjuvant chemoradiation followed by surgery
45460486|NCT03900013|Procedure|Injectable platelet rich fibrin combined with DFDBA|The i-PRF will be mixed with bone graft then will be placed into the intraosseous defect
45678800|NCT01782495|Drug|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
45678801|NCT01782495|Drug|ribavirin|tablet
45678802|NCT01922102|Drug|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections)
45678803|NCT01922102|Drug|Ranibizumab 0.5 mg|0.5 mg ranibizumab (intravitreal injections)
45678804|NCT01922102|Drug|Verteporfin PDT|Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application
45678805|NCT01405768|Drug|sodium bicarbonate buffered lidocaine|8.4% sodium bicarbonate will be mixed with lidocaine in a 1:10 ratio prior to mixing with epinephrine and injecting into the cervix.
45678806|NCT01405768|Drug|Non-buffered lidocaine|
46009167|NCT02213835|Other|Specific Carbohydrate diet (SCD)|
46009168|NCT04551924|Drug|HR18034|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
46009169|NCT04551924|Drug|Naropin|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg [0.5%, 5mg/mL] x 30mL
46096078|NCT00719056|Drug|Teicoplanin|The selected dose was 10mg/kg and it was given intravenously by a catheter inserted under aseptic conditions in a forearm vein within 15 minutes; it was diluted in one 5% glucose solution of a 50 ml final volume
45460487|NCT03900013|Procedure|Demineralized Freeze Dried Bone Allograft|Demineralized Freeze Dried Bone Allograft alone will be placed into the intraosseous defect
45460488|NCT03893227|Other|Questionnaire|Patients and healthy controls will fill out a questionnaire
46009170|NCT04671836|Drug|Lorazepam 1Mg Tablet|"1 mg, white, five-sided (shield shape) tablet with a raised A on one side and BPI and 64 impressed on scored reverse side. NDC 0187-0064-01 - Bottles of 100 tablets; NDC 0187-0064-50 - Bottles of 500 tablets; NDC 0187-0064-10 - Bottles of 1000 tablets.~The pharmacy at the Zucker Hillside Hospital will encapsulate both lorazepam 1 mg and placebo pills to make them look the same. On the day of the scan, the research coordinator or the PI will pick up the blinded study medication (lorazepam or placebo) and will administer it to the participant. One hour later, the participant will be placed in the scanner to complete the MRI."
46009171|NCT04671836|Drug|Placebo|Placebo will be purchased and encapsulated by the pharmacy at the Zucker Hillside Hospital.
45460489|NCT03899935|Procedure|Laparoscopy|Laparoscopy for endometriosis
45460490|NCT01586299|Drug|Ibuprofen|10 mg/kg every 8 hours until 24 hours after resolution of fever
45460491|NCT01586299|Drug|Acetaminophen|15 mg/kg every 6 hours until 24 hours after resolution of fever
45460492|NCT01257061|Drug|Group 1|Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g applied 2 times / day at lesion
45460493|NCT01257061|Drug|Group 2|Dexchlorpheniramine maleate 10 mg/g applied 2 times / day at lesion
45460494|NCT01149811|Drug|Fipamezole ODT|Subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks.
46009172|NCT04552353|Drug|Vaway|Drug: Voriconazole. Pharmacokinetic study under fasting conditions
46096079|NCT00719056|Drug|β-lactams or ciprofloxacin|Multiple doses for up to six consecutive days
45460495|NCT01149811|Drug|Fipamezole ODT Cohort 2|Subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week.
46096080|NCT00710008|Other|exercise training|3 bouts of exercise at 90%RCP during one week
45460496|NCT05099809|Other|Hyperthermia|Hyperthermia would be delivered once/twice a week for 60 to 90 minutes depending on patient's tolerance. A shortwave diathermy unit operating at 27.1 MHz would be used to deliver locoregional hyperthermia.
45460497|NCT02874794|Drug|LCZ696 (sacubitril/valsartan)|24/26mg, 49/51mg and 97/103mg oral, tablets.
45460498|NCT02874794|Drug|Enalapril|2.5mg, 5mg, and 10mg, oral, tablets
46096081|NCT02992951|Device|DACC-Coated Post Operative Dressing|Leukomed Sorbact is a non-active coated wound dressing, containing Dialkylcarbomoylchloride. This is a bacteria-binding compound that adheres bacteria via hydrophobic interaction and removes them from the wound bed at dressing change.
45460499|NCT02874794|Drug|Placebo of Enalapril|matching placebo (2.5mg, 5mg and 10mg) oral, tablets
45460500|NCT02874794|Drug|Placebo of LCZ696|matching placebo (24/26mg, 49/51mg and 97/103mg) oral, tablets
45460501|NCT01149889|Procedure|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively
45460502|NCT03897283|Drug|TQB2450|TQB2450 1200 mg administered IV on Day 1 of each 21-day cycle
45460503|NCT03897283|Drug|Anlotinib|Anlotinib capsules given orally in fasting conditions, dose ranging from 8 mg to 12 mg once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21). Initial dose is 10 mg. If there are no patients with DLT in first treatment cycle , begin to explore dose of 12 mg. If there are 2 or more patients in 3 patients with DLT, 8 mg dose is to explore.
46096082|NCT04217837|Device|Transcranial Magnetic Stimulator|Transcranial magnetic stimulation (TMS) uses a targeted pulsed magnetic field, similar to what is used in an MRI (magnetic resonance imaging) machine. While the patient is awake and alert, NeuroStar TMS Therapy stimulates areas of the brain that are underactive in depression.
46096083|NCT04004143|Other|No intervention|No intervention.
46096084|NCT04069546|Device|remote ischemic conditioning|RIC is a physical strategy performed by an electric device with cuffs placed on the unilateral arm and inflated to 180 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times.
45460504|NCT01258465|Behavioral|Pivotal Response Training|Naturalistic behavioral protocol designed to teach vocal communication.
45460505|NCT01258465|Behavioral|Picture Exchange Communication System|Pictorially-based behavioral protocol designed to teach communication to nonverbal children via pictures icons.
45460506|NCT03897517|Dietary Supplement|Proprietary Botanical Blend|Oral administration of capsules containing proprietary botanical blend 30 minutes prior to carbohydrate ingestion.
45460507|NCT03897517|Dietary Supplement|Placebo|Oral administration of capsules containing rice flour (placebo) 30 minutes prior to carbohydrate ingestion.
45460508|NCT04776902|Behavioral|Survey|Patients will fill a questionary with 8 questions.
45460509|NCT03900169|Genetic|Genetic|Lipid profile
45460510|NCT03899779|Other|Face-to-face hypnotherapy|12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)
45460511|NCT03899779|Other|Online hypnotherapy|12 weeks treatment with online hypnotherapy
46009173|NCT00556088|Drug|LBH589, Paclitaxel, Carboplatin, Bevacizumab|"LBH589 will be administered orally twice weekly. Paclitaxel and carboplatin will be administered intravenously every 21 days.~Once the MTD is established, drug dosages will be adjusted downward by one dose level and bevacizumab 15mg/kg intravenously every 3 weeks will be administered to a subset of patients with non-small cell lung cancer."
46009174|NCT00177294|Drug|Escitalopram|Escitalopram 10 mg daily for first 6 weeks, followed by escitalopram 20 mg daily for 16 additional weeks.
46009175|NCT00177294|Behavioral|Interpersonal Psychotherapy|16 sessions of interpersonal psychotherapy (IPT)
46009176|NCT00177294|Behavioral|Clinical Monitoring|16 weeks of depression care management(DCM). No psychotherapy will be provided.
46009177|NCT01082081|Drug|Paracetamol 1000 mg|Paracetamol 1000 mg
46009178|NCT01082081|Drug|Paracetamol 500 mg|Paracetamol 500 mg
46009179|NCT01082081|Drug|Placebo|Placebo
46096085|NCT04469699|Drug|Stereotactic biopsy followed by stereotactical photodynamic therapy with 5-aminolevulinic acid|5-ALA HCl orally (20 mg/kg bw) 3,5-4,5 hours prior to induction of anaesthesia for stereotactic biopsy followed by stereotactical photodynamic therapy. All patients will receive further treatment of recurrent glioblastoma at the investigator´s discretion (best possible care).
45460512|NCT03899779|Other|Online psychoeducation|12 weeks treatment with online psychoeducation
45460513|NCT03102710|Device|transcranial direct current stimulation (tDCS)|tCDS safely applies a weak electrical current to your scalp using two sponge electrodes that look like flat circular pads. The pads will be held in place on your head with a neoprene cap. The pads will be attached to a generator that will send a weak stimulus to your scalp. This current influences the way that your brain cells work. When the stimulus starts, you might feel a tingling sensation underneath the electrode pads. That sensation is not painful and goes away in seconds.
45460514|NCT03102710|Other|Lidocaine cream|Lidocaine cream will be applied on the arm to reduce pain sensitivity (analgesia).
46009180|NCT00177216|Drug|Zolpidem|The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or >). The dose was decreased to 5 mg if side effects occurred.
46009181|NCT00177216|Drug|Escitalopram|The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.
45460515|NCT03102710|Other|Capsaicin cream|Capsaicin cream will be applied on the arm to increase pain sensitivity (hyperalgesia).
45460516|NCT03102710|Other|Control cream|A neutral cream will be applied on the arm as a control.
45460517|NCT01149967|Drug|Citalopram Hydrobromide|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
45678807|NCT01913353|Biological|MVA BN®|0.5 ml MVA BN® with a nominal titer of 1x10E8 TCID50, administered as a subcutaneous injection
45678808|NCT01913353|Biological|ACAM2000®|0.0025 ml ACAM2000®, consisting of 2.5-12.5x10E5 plaque forming units of live vaccinia virus (VACV). Picked up with a bifurcated needle and administered by the percutaneous route (scarification) using 15 jabs of that bifurcated needle.
46009182|NCT00177216|Drug|Placebo|A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
46009183|NCT01081886|Device|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.
46009184|NCT01081886|Device|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
46009185|NCT02213952|Drug|Platelet-Rich Plasma|For obtaining autologous PRP, will be drawn from 9-30 ml of blood of the patient in sterile tubes containing 4.5 ml of 3.8% sodium citrate. The tubes will be centrifuged for 8 min at 580 Gs to separate the different blood components according to density gradient. After centrifugation, we will aspire the PRP. We will add CaCl2 to the PRP (50l per ml of liquid plasma). While the plasma will get gelified, we will cure the ulcer with saline cleaning and mechanical removal. Then the ulcer will be covered with gelified PRP and a secondary dressing. This cure will be done each 7 days.
46096086|NCT04469699|Procedure|Stereotactic biopsy|Stereotactic biopsy. All patients will receive further treatment of recurrent glioblastoma at the investigator´s discretion (best possible care).
46096087|NCT02574676|Other|non-interventional|
45460518|NCT05505409|Drug|Pirfenidone|Drug:pirfenidone CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease
45460519|NCT05505409|Drug|glucocorticoid and immunosuppressant|Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease
45460520|NCT04770740|Dietary Supplement|Vitamin K2 in the form of Menaquinone-7 (MK-7)|Patients will take three tablets of vitamin K2 menaquinone-7 (333mcg) per day. Patients taking vitamin K2 MK-7 will receive the total of 999mcg per day from day 1 until day 14 or discharge, whichever occurs earlier. All subjects can be treated with prophylactic or therapeutic heparin-based (heparin or any low-molecular weight heparin) anticoagulants, according to local hospital protocols. Provided by Kappa Bioscience.
45460521|NCT04770740|Dietary Supplement|Placebo|Patients will take three tablets of placebo containing only inactive ingredients per day, from day 1 until day 14 or until discharge, whichever occurs first. The placebo is provided by Kappa Bioscience.
45460522|NCT03360422|Other|Survey|Respondents meeting inclusion criteria will be informed they were selected for the longer survey and continue to the survey. Upon completion, the survey will generate a study identification (ID) that respondents will provide to study staff with additional contact information via phone, text or email to be compensated
45460523|NCT03360422|Other|Focus Group|After informed consent, participants will complete the web-based intervention component in development. Afterward, participants will be engaged by an experienced facilitator in a discussion of aspects of the intervention they liked and disliked and suggestions they have for enhancing its cultural appropriateness to young MSM.
45460524|NCT03360422|Other|Usability study|After informed consent, participants will utilize the mobile intervention in development for 30 days to establish usability, acceptability and correct any functionality issues.
46009186|NCT02213952|Other|Usual treatment|Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
46096088|NCT03475004|Drug|Pembrolizumab|An intravenous, potent and highly selective humanized monoclonal antibody of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
45460525|NCT01258543|Other|General Osteopathic Evaluation|2 general osteopathic evaluations of approximately 1 hour in duration done consecutively on the same day with a 15 minute break between evaluations
45460526|NCT05415878|Device|RCW design form|"Tall RCW= a knee high removable cast walker with an offloading insole~Short RCW= an ankle high (extending up the leg just past the ankle) removable cast walker with an offloading insole, paired with an external shoe lift to be used with a diabetic shoe on the contralateral limb"
45460527|NCT03896971|Drug|Combination of thrombopoietin mimetic and cyclosporin A|This is a controlled interventional study that will be carried out in the Clinical Hematology Unit, at the Department of Internal Medicine , Assiut University Hospital. Patients will be recruited among those who attending the outpatient clinic or admitted in the unit.
46009187|NCT01081769|Drug|paliperidone palmitate injection|injection with 150 mg equivalent on Day 1, 100 mg equivalent on Day 8, 75 mg equivalent on Day 38 and flexible dosing with 25, 50, 75, 100 or 150 mg equivalent once monthly thereafter
46009188|NCT01081769|Drug|oral antipsychotics|daily treatment according to local label for maximally 24 months
46009189|NCT04551768|Drug|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
46096089|NCT03475004|Drug|Bevacizumab|The pharmacokinetics of bevacizumab are characterized by a slow CL, long half-life, and a volume of distribution consistent with limited extravascular distribution.
46096090|NCT03475004|Drug|Binimetinib|Binimetinib (MEK162/ARRY-438162) is an orally bioavailable, small molecule selective and potent mitogen-activated protein kinase (MEK) 1 and MEK 2 inhibitor.
46096091|NCT04219397|Other|Medication take back|Patients will be provided with formal education about medication take back programs for left-over prescription medications. They will be provided with directions to the closest medication take back facility to their home, and directions to the closet medication take back facility near their post-operative clinic site, and instructed to dispose of any left-over oxycodone medication (at completion of analgesic therapy) through participating in medication take back.
46009190|NCT04551768|Drug|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
46009191|NCT04671407|Drug|Hypertonic Saline|Hypertonic Saline 3% and 0.9%
46096092|NCT04219397|Other|Medication home disposal|Patients and their families will be provided with formal education about how to use the medication home disposal kit: Dispose Rx, provided with a Dispose Rx home disposal kit, and instructed to dispose of any left-over oxycodone prescription medications with this kit following completion of analgesic therapy.
46009192|NCT02213991|Device|Intraoperative radiotherapy using Intrabeam®|"Operation day~Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity.~Purse string suture pulles up tissues and wraps up the applicator.~Intraoperative radiotherapy using Intrabeam® (20Gy) is followed.~After IORT, applicator was out of the operative field, and usual wound closure will be done.~Postoperative period~Chemotherapy WBRT (46 Gy) for 4~5 weeks~Endocrine therapy or target therapy"
46009193|NCT04671641|Device|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat varicose veins patients
46009194|NCT04551534|Drug|DNL201|Oral dose(s)
46096093|NCT05279209|Procedure|catheter-directed sclerotherapy|Ovarian endometrioma is targeted under transvaginal/transabdominal ultrasound. A guidewire is inserted to the lesion and is exchanged for a catheter. The cystic content is thoroughly aspirated and then sclerotherapy is performed by injecting 99% ethanol.
46096094|NCT05279209|Procedure|surgical resection|Surgical resection of the ovarian endometrioma is performed under general anesthesia. To preserve the residual ovarian function, enucleation is the primary surgical technique.
45460528|NCT05551429|Behavioral|Invitation to the CR|"Oral and written information emphasise the benefits of cardiac rehabilitation in terms of treatment of heart diseases, increasing functional capacity, reducing morbidity and mortality, and enhancing secondary prevention.~Introducing the scope and method of administration of CR to patients.~Setting up the appointment for the initial CR session four weeks later."
45460529|NCT01151059|Biological|Trivalent subunit inactivated flu vaccine, Formulation 2010-2011|This phase II is performed as a multicenter study site in non-elderly adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22).
45460530|NCT01255345|Other|Chronic pelvic pain|A physioterapeutic examination of abnormal muscular findings, i.e tonus, elasticitt and strength, in the pelvic area connected to female CPP.
45460531|NCT03899545|Other|Serratus Plane Block|0.5 ml /kg Bupivacaine/lidocaine mixture will be injected onto the serratus muscle
45460532|NCT03899545|Other|Serratus Plane Block plus Pectoral I Block|0.5 ml / kg %0.25 Bupivacaine/ %1 lidocaine mixture will be injected onto the serratus muscle and injected between the pectoralis minor/pectoralis major muscles.2/3 of the total drug will be applied for the serratus plane block and 1/3 of the total drug for the pectoral I block. If the total amount of the drug is less than 30 ml, it will be completed with isotonic saline to 30 ml.
45460533|NCT04540406|Drug|NBT-NM108|Taken in the form of drinks four times a day (before each main meal and 2 hours after dinner) for 28 days. Each drink is prepared by mixing one sachet (30 g) with 500 ml of water.
46096095|NCT02695745|Drug|V116517 aqueous suspension|300 mg (approximately 100 mL) aqueous suspension taken orally x 1 dose
46096096|NCT02695745|Drug|Celecoxib capsules|400 mg (2 capsules of 200 mg each) taken orally x 1 dose
46096097|NCT02695745|Drug|Placebo|Placebo for V116517 aqueous suspension taken orally x 1 dose and/or placebo for celecoxib, 2 capsules taken orally x 1 dose
45460534|NCT04540406|Other|Usual Care Only|Control group will also follow the same schedule except they will drink the same volume of water without NBT-NM108.
45460535|NCT05667259|Other|Surgical resection for cancer rectum|Curative resection for cancer recum
45460536|NCT01258621|Procedure|Laparoscopy|Laparoscopic distal pancreatectomy
45460537|NCT03893149|Behavioral|Active-Start intervention|Supervised exercise training. The intervention is a physical activity intervention that consist of 5 times per week before starting the first school-class (8:00-8:30 a.m.), 5 times per week. Each session was previously planned and described in a manual dedicated to the study. These sessions were designed by the research team and delivered by a graduate in Sport The intervention program included sports games adapted to the age of the participants, playground games, dance and other recreational activities. The intensity of the main part of the sessions was moderate-to-vigorous according to a previous study and this intensity was confirmed by accelerometry. Also, different activities favoring social interactions were designed to facilitate the interactions between the participants at the end of the sessions (cold-down).
45460538|NCT03893149|Behavioral|No Intervention|No-exercise
46009195|NCT04551534|Drug|Placebo|Oral dose(s)
46096098|NCT02695745|Drug|Capsaicin|1% administered topically
46009196|NCT04551456|Biological|Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS|Randomised, Double-blind, Placebo-controlled, Intravenous Infusion HumanWharton' Jelly-derived Mesenchymal Stem Cells in Patients With Coronary Artery Disease
46096099|NCT05361109|Drug|Baricitinib|The investigational medicinal product (IP) for this study is baricitinib 2mg. The dose will be administered as one 2mg tablet by mouth once daily for the first 8 weeks of study. If no unexpected serious adverse events related to baricitinib in the opinion of the investigator occur during the first 8 weeks of treatment, the dose will be increased to two 2mg tablets (4mg daily) for the remaining 16 weeks of study. All study participants will take baricitinib in combination with standard of care background therapy.
46096100|NCT00715546|Procedure|autologous transplantation of liposuction material enriched with adipose-derived stem cells|Lipoinjection enriched with adipose-derived stem-cells.
46009197|NCT01081301|Behavioral|Living with Hope Program|"The LWHP consists of the LWH film featuring caregivers of patients with advanced cancer describing their hope and a hope activity Stories of the Present. Following viewing of the video with trained research assistants (RAs), (without discussion) the RA's will instruct the subjects to take 5 minutes at the end of the day and write about their thoughts, challenges and what gave them hope over a 2 week time period. Subjects can choose to use a journal, a computer or audiotape their journals."
46009198|NCT00174954|Procedure|MRI|Subjects underwent MRI to evaluate tophi.
45460539|NCT04323020|Diagnostic Test|CT Perfusion|CT Perfusion
45460540|NCT03893071|Drug|Hydroxypropyl-β-cyclodextrin|HP-β-CD will be administered as Trappsol® Cyclo 25% (250mg/mL) by slow intravenous infusion over a period of 8 up to 9 hours.
45460541|NCT05412368|Other|Focus Groups|Focus Groups
45460542|NCT01258699|Drug|Thiocacid HR Tab 600mg|600mg for 1 day
45460543|NCT01258699|Drug|BK-C-0701 320mg|320mg for 1 day
45460544|NCT01258699|Drug|BK-C-0701 480mg|480mg for 1 day
45460545|NCT04298138|Biological|Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)|Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489 administered as a single injection.
46009199|NCT04671563|Drug|Tenofovir Disoproxil Fumarate 300 MG|One tablet of Viproof Film Coated Tablets or Viread Tablets will be orally administrated with 240 mL of water in the morning.
46009200|NCT04551573|Drug|Rifapentine daily|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed daily for four weeks (10mg/kg; 600 mg dose)
45460546|NCT01258777|Drug|400 mg golimumab or placebo|Single dose of 400 mg subcutaneously
46009201|NCT04551573|Drug|Rifapentine weekly|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed weekly for another four more weeks (15 mg/kg; 900mg dose)
46009202|NCT01081145|Drug|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on age and weight.
46009203|NCT01081145|Other|Placebo|Matching placebo will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on age and weight.
46009204|NCT00174915|Drug|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 28 weeks.
46009205|NCT00174915|Drug|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 28 weeks.
46009206|NCT00174915|Drug|Febuxostat|Febuxostat 240 mg, orally, once daily for up to 28 weeks.
46009207|NCT00174915|Drug|Allopurinol|Allopurinol, orally, once daily for up to 28 weeks. Dose of allopurinol received was based on renal status. Subjects with serum creatinine ≤1.5 mg/dL received 300 mg once daily; subjects with serum creatinine >1.5 mg/dL and ≤2.0 mg/dL received 100 mg once daily.
46009208|NCT00174915|Drug|Placebo|Placebo, orally, once daily for up to 28 weeks.
45460547|NCT01258777|Drug|200 mg golimumab or placebo|Single dose of 200 mg subcutaneously
45460548|NCT03899389|Diagnostic Test|plasma samples collection|Trimethylamine N-oxide (TMAO) concentration will be determined in plasma samples
45460549|NCT03632564|Device|REVIVIEW dichoptic audio-visual stimulation|REVIVIEW dichoptic audio-visual stimulation using video goggles
45460550|NCT01257295|Dietary Supplement|control: no fiber addition|liquid breakfast without addition of fiber
45460551|NCT01257295|Dietary Supplement|breakfast with low viscous, low gelling pectin|10g of low viscous, low gelling pectin dissolved in a liquid breakfast
45460552|NCT01257295|Dietary Supplement|high viscous, low gelling pectin|10g of high viscous, low gelling pectin dissolved in a liquid breakfast
45460553|NCT01257295|Dietary Supplement|low viscous, high gelling pectin|10g of low viscous, high gelling pectin dissolved in a liquid breakfast
45460554|NCT01257295|Dietary Supplement|high viscous, high gelling pectin|10g of high viscous, high gelling pectin dissolved in a liquid breakfast
45460555|NCT01257295|Dietary Supplement|pectin supplement|10g of high viscous, high gelling pectin provided as a dietary supplement, a liquid breakfast is served seperately
45460556|NCT03304028|Device|Connected Devices for 3 months|Inclusion will be proposed at a follow-up visit by the child's or adult's referring doctor. A written informed consent form will be obtained. Quality of Life and Anxiety-Depression will be collected. Then, each included patient will be equipped with CDs-spirometer, oxymeter, scale and watch during 3 months for base-line.
45836852|NCT00467298|Behavioral|Self-management of illness|This component of the intervention stresses the use of an action plan that is implemented to c-manage bouts of mild illness and to identify symptoms of more serious illness, including appropriate actions.
45460557|NCT03304028|Behavioral|Educationnal Intervention|After a first statistical analysis and interpretation (5 months), alert parameters for each patient are then fixed. An educational visit will be scheduled with patients and a personnalized action plan will be defined..
45678809|NCT01754259|Drug|Ranolazine|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
45836853|NCT00467844|Drug|GTx-024|1 mg GTx 024
45460558|NCT03304028|Device|Connected Devices for 12 months|Each included patient will be re-equipped with CDs-spirometer, oxymeter, scale and watch during 12 months. If alerts occur, patients will be informed by email or SMS, with data transmission to the medical team who will not interfere. Patients should apply the shared action plan they learned. Quality of Life and Anxiety-Depression will be collected.
45678810|NCT01754259|Drug|Placebo|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
45678811|NCT04574505|Dietary Supplement|Eufortyn Colesterolo Plus|Food supplement combination containing bergamot (Vazguard®) phytosomal polyphenolic fraction associated with standardized artichoke extract (Pycrinil®, Cynara Cardunculus L) and Cynara scolimus, associated with high coenzyme Q10 bioavailability(Q10 phytosome® Ubiqsome) and zinc.
46009209|NCT04671368|Diagnostic Test|Artificial Intelligence|The investigators will use the Artificial Intelligence Diagnostic System to review the H＆E stained slide of each patient and then report the classification of the tumor on a 10-type scale.
45678812|NCT04574505|Dietary Supplement|Placebo|Placebo
45678813|NCT04618406|Device|PICO VAC|PICO14 device from Smith and Nephew - Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager-sized) suction device/canister and provides a negative pressure of -80 mmHg for 14 days.
45678814|NCT04618406|Other|Standard care|Sterile surgical silicone foam dressing and soft dressing applied immediately postoperative and removed after 12 days
45678815|NCT01405456|Drug|Eplerenone and lifestyle|eplerenone 50mg by mouth daily as well as lifestyle counseling
45678816|NCT01405456|Other|placebo and lifestyle|placebo pill daily and lifestyle counseling
45678817|NCT04031794|Device|Extra Corporeal Membrane Oxygenator (ECMO)|Two cannular will be inserted via femoral vein or internal jugular vein and connect with blood pump and membrane oxygenation.
45678818|NCT01404988|Behavioral|Telephone-Delivered BI|Behavioral Intervention will be delivered over the phone.
45678819|NCT01404988|Behavioral|Telephone-Delivered BEI|Behavioral and Environmental Intervention will be delivered over the phone
45678820|NCT01404988|Other|Telephone-Delivered API|Attention Placebo Intervention will be delivered over the phone
45678821|NCT04043026|Drug|Statin|Any statin therapy
45678822|NCT01389232|Device|SeriScaffold® Surgical Scaffold|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
45678823|NCT01404208|Drug|D-Cycloserine|25mg dose for children weighing between 22.5kg and 45kg (dose = approx. .7mg/kg) 50mg dose for children weighing greater than 46kg (dose = approx. .7mg/kg) Dose given 7 times, every seven days, except for the third dose, which will be given three days after the second dose. All doses given 1 hour prior to therapy session.
45678824|NCT01404208|Drug|Placebo|Sugar pill
46009210|NCT04671368|Diagnostic Test|Practicing Pathologists|The ordinary pathologist will review the H＆E stained slide of each patient(without additional informations such as: Immunohistochemistry et al.) and then report the classification of the tumor on a 10-type scale only bases on the slide images
45460559|NCT03304028|Other|Interviews|At the end, semi-structured interviews will be completed to explore confidence on the CDs, impact on the doctor-patient relationship, change in the workload of medical team…etc.
45460560|NCT03304028|Behavioral|Refusal Questionnaires|Clinic staff will email all patients or parents (pediatric settings) to introduce the study. A qualitative interview with 10 patients who declined to participate in the study will be conducted to identify the reason of refusal
45678825|NCT01617668|Drug|LCL161|LCL161 was available as 300 mg, tablets, which was supplied in child-resistant bottles.
45678826|NCT01617668|Drug|paclitaxel|"Commercially available paclitaxel was sourced locally by each study site. Generic paclitaxel could be used for study treatment.~iv 80mg/m2"
45678827|NCT01425268|Device|AeroForm Tissue Expansion|The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
45678828|NCT01425268|Procedure|Saline Tissue Expansion|A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline.
45678829|NCT01425190|Drug|Boceprevir|Single dose of boceprevir powder prior to breakfast in a dosing vehicle of chocolate pudding (i.e., a mousse or custard), apple sauce, Nutella, fruit pudding such as strawberry, cherry, or raspberry pudding, or yogurt or a similar semi-solid product into which the boceprevir powder can be evenly stirred
46009211|NCT04671368|Diagnostic Test|Gold Standard|Firstly, the two expert pathologist(>=10 years of experience) will review the H＆E stained slide of each patient on their own (with additional informations such as: Immunohistochemistry et al.) and then report the classification of the tumor on a 10-type scale.If they report the same opinion, that opinion will perform as the ground truth; while if their opinion clash with each other, the expert pathologist(>=15 years of experience) will get involved and the agreement of three experts will perform as the ground truth
46009212|NCT01080716|Biological|Part 1/Arm 1 of Study: WRSS1 vaccine|Single, oral dose of WRSS1
46096101|NCT04308278|Drug|2LEBV® / 2LXFS®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
46096102|NCT04308278|Drug|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
46096103|NCT00990067|Drug|3,4-Methylenedioxymethamphetamine|125 mg, single dose
46096104|NCT00990067|Drug|Duloxetine|120 mg two doses 12h and 2h before MDMA
46096105|NCT00990067|Drug|Placebo|capsules identical to MDMA or duloxetine
45678830|NCT01388530|Device|EMS 7500 Digital Muscle Stimulator|A standard FDA approved transcutaneous electrical nerve stimulation (TENS) unit will be used to apply low intensity stimulation to the trigeminal nerves during sleep.
45678831|NCT01895270|Drug|Isradipine|Isradipine extended release formulation
45678832|NCT01895270|Drug|Placebo|Placebo will consist of microcrystalline cellulose.
45678833|NCT01424722|Device|Fortify® ST, Fortify Assura® ST, Ellipse® ST family of devices|Algorithm for detecting ST changes that may be indicative of an acute coronary syndrome.
45678834|NCT01424644|Biological|Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|"All three vaccines were administered concomitantly. Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine(Tdap) is Boostrix®."
45678835|NCT01424644|Biological|MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|"All three vaccines were administered concomitantly. MenACWY-CRM contains diphtheria-like toxoid as carrier for the capsular polysaccharides. Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid,Acellular Pertussis Vaccine(Tdap) is Boostrix®."
45678836|NCT01920854|Drug|soluble ferric pyrophosphate|
45678837|NCT01920854|Drug|Placebo|
45678838|NCT01403194|Device|CPAP/BiPAP|Subjects will be treated with either CPAP or Bi-PAP for three months.
45678839|NCT01403116|Drug|Oral testosterone undecanoate|Starting dose: 200 mg T (as TU) BID. Doses may be titrated up to a maximum dose of 300 mg T (as TU) BID or down to a minimum dose of 100 mg T (as TU) BID based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
45678840|NCT01403116|Drug|topical testosterone gel|Starting dose: 5 g T applied once daily. Doses may be titrated up to a maximum dose of 10 g daily or down to a minimum dose of 2.5 g daily based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
45460561|NCT01151995|Other|Remote source document verification|Remote access to electronic medical records of the 5 participating sites
45678841|NCT01402570|Dietary Supplement|Glutathione|glutathione is a dietary supplement and an antioxidant. Subjects will take 1000 mg per day for three month. Each capsule contains 500 mg glutathione.
45836854|NCT00467844|Drug|GTx-024|3 mg GTx-024
45836855|NCT00467844|Drug|Placebo|Matching Placebo
46009213|NCT01080716|Biological|Part 1/Arm 2 of Study: Placebo vaccine|Placebo vaccine
46009214|NCT01080716|Biological|Part 2/Arm 1 of Study: S. sonnei 53G|Subject from Part 1/Arm 1 of Study are given 53G S. sonnei
45460562|NCT01151995|Other|On-site source document verification|Study monitor will perform on-site source document verification during routine visit to the five participating sites
45836856|NCT00387036|Drug|Fluticasone|fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.
45836857|NCT00387036|Drug|Comparator: Placebo|Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.
45836858|NCT04388904|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)|Participants will receive Symtuza®. An oral tablet containing Darunavir 800 mg /Cobicistat 150 mg /Emtricitabine 200 mg /Tenofovir Alafenamide 10 mg FDC, once daily within 24 hours of the screening/ baseline visit.
46009215|NCT01080716|Biological|Part 2/Arm 2 of Study: S. sonnei 53G|10 naïve controls are given S. sonnei 53G
46009216|NCT04551339|Dietary Supplement|PreserVision AREDS formulation soft gels or tablets|Two tabs taken daily for three months
46009217|NCT04551339|Dietary Supplement|Multivitamin with 11mg of zinc|One tab taken daily for three months
45678842|NCT03025204|Biological|Enamel Matrix Proteins|EMD is composed of different proteins, 90% of which are amelogenins, which has the capacity to induce processes involved in the regeneration of periodontal tissues in a manner similar to normal tissue development (48). Several clinical and animal model studies have demonstrated the use of enamel matrix-derived proteins in regenerative periodontal procedures for the formation of a new periodontium.
45460563|NCT03896893|Other|Skin antisepsis|1% aqueous chlorhexidine gluconate
45460564|NCT03896893|Other|Emollient|Aquaphor skin cream
45678843|NCT03025204|Procedure|Open Flap Debridement|After administration of local anesthetics, full-thickness flaps will be raised in order to access all defect faces. Sulcular incisions will be performed extending to mesial and distal adjacent teeth, including the entire papilla in the flap. No relaxing incisions will be performed. All granulation tissue will then be carefully removed, and subsequently scaling and root planing will be performed. The surgical area will be irrigated with 0.9% saline and carefully inspected to ensure that all steps have been satisfactorily performed until then.
45678844|NCT01753401|Drug|Acthar|Acthar is given by subcutaneous (SC) injection (shot under the skin), at a dose of 40 units daily or 80 units every other day
45678845|NCT01753401|Drug|Placebo|Placebo contains the same inactive ingredients as Acthar, and is given by SC injection
45678846|NCT01753401|Drug|Steroid Drug|The patient's steroid regimen 7.5 to 30 mg/day of prednisone or equivalent, chronic/stable within the 4 weeks prior to screening.
45678847|NCT01618916|Drug|LY3015014|Administered SC
45678848|NCT01618916|Other|Placebo|Administered SC
45678849|NCT01753323|Drug|KAF156|KAF156 was supplied as tablets for oral use.
45678850|NCT04566939|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
45678851|NCT04566939|Procedure|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the shoulder at the physician's discretion.
45460565|NCT01257373|Device|Firebird 2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent|Firebird2 CoCr-alloyed sirolimus-eluting stent system is the 2nd generation of drug-eluting stent(DES). It was registered successfully on Jan. 16, 2009 in China. This stent is based with a CoCr alloyed metal platform. The length is from 13-33mm, the diameter is from 2.5mm-4.0mm.
45678852|NCT04566939|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Gyunwoo (LI15), Gyunryo(TE14), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
45678853|NCT04566939|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
45836859|NCT04388592|Other|Nurse Practitioner (NP) Led Care Arm|The NP will conduct baseline consultation visits with the participants and their caregivers (if applicable). They will then initiate treatment for the participant's symptoms as appropriate (ie: depression treatment for depressive symptoms, fatigue management strategies), connect to resources in the community as needed (ie: rehabilitation programs, home care support, psychologist support) to optimize functioning. There will be scheduled follow visits and/or phone calls with the NP at 3 and 6 months.
45460566|NCT02527837|Drug|Sodium nitrite|Sodium nitrite, 240 micrograms/kg/hour for 2 hours
45460567|NCT02527837|Drug|Sodium chloride|Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
45460568|NCT03899233|Device|Fractional CO2 laser|Low power fractional CO2 laser with a power of 12 watts, spacing 800 micrometer (7.3% density), and dwell time 300 microsecond
45460569|NCT03899233|Drug|Tranexamic acid intradermal microinjections|Tranexamic acid 500mg/5ml ampules
45460570|NCT03101150|Drug|400 IU Vitamin D3|Antenatal multivitamin
45460571|NCT03101150|Drug|4000 IU Vitamin D3|4000 IU Vitamin D3 (cholecalciferol) daily = 40 drops daily
45678854|NCT04566939|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
45678855|NCT04566939|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
45678856|NCT04566939|Procedure|Herbal hot pack|Herbal hot pack treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
45678857|NCT04566939|Procedure|Physical therapy|The participants in the control group will be receive one or more physical therapy according to the physician's decision.
45678858|NCT04566939|Procedure|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
46009218|NCT04671446|Diagnostic Test|Autoantibody ELISA|Serum will be tested for novel autoantibodies against eosinophil proteins by ELISA, such as those previously identified as of importance (e.g. eosinophil-peroxidase, EPX) and also novel candidate proteins specific to eosinophils (including ARFIP1, BCL2A1, PPCDC, SLC12A6 etc) as identified by FANTOM5 geneset analysis.
45460572|NCT03898999|Other|Overall status|An assessment is made of the participants measuring both the joint range of the ankle and the balance and risk of falls.
45460573|NCT03899077|Drug|Apalutamide|Apalutamide 240mg daily for 6 months (i.e. 6 28-day cycles); oral use
45460574|NCT03899077|Drug|Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial|Leuprorelin acetate 45mg for 6 months; subcutaneous use
45460575|NCT03899077|Drug|Goserelin Acetate 10.8 MG Subcutaneous Implant|Goserelin acetate 10.8mg for 6 months; subcutaneous use
45460576|NCT03899077|Drug|Triptorelin Pamoate|Triptorelin pamoate 22.5mg for 6 months; intramuscular use
45460577|NCT03899077|Drug|Degarelix acetate|Degarelix acetate 80mg for 6 months; subcutaneous use
45460578|NCT03899311|Other|protein-sparing modified fast diet|a PSMF diet follow the usual care format in the Center
45460579|NCT01255501|Drug|NI-0701|
45460580|NCT01255501|Drug|Placebo|
45460581|NCT01255579|Drug|Salmeterol Fluticasone|salmeterol 50 mcg and fluticasone 250 mcg (diskus) b.i.d.
45460582|NCT01255579|Drug|formoterol - beclometasone|formoterol 12 mcg and beclometasone 200 mcg HFA (by MDI) b.i.d.
45460583|NCT03898609|Other|Dietary intervention|3 weeks
45678859|NCT01894568|Drug|Insulin Peglispro|Administered SC using a prefilled pen.
45678860|NCT01894568|Drug|Insulin Glargine|Administered SC using a prefilled pen
45678861|NCT01894568|Drug|Oral Antihyperglycemic Medications (OAMs)|Administered orally
45678862|NCT01618838|Radiation|CyberKnife radiosurgery|"Treatment Planning:~Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the Planning Treatment Volume (PTV) and critical normal structures. The homogeneous CT model shall be used. Number of paths and beams used for each patient will vary and will be determined by the selected individual treatment plan. To reduce overall treatment time and total monitor units, 150-200 non-zero beams are recommended. No more than 250 beams shall be employed. Tuning structures shall be employed to minimize conformality index (CI) and new conformality index (nCI), preferably yielding values less than 1.20 and 1.25, respectively."
45460584|NCT03898921|Radiation|stereotactic body radiotherapy (SBRT)|Radiotherapy dose is 36-54 Gy, irradiated in 3 times, every other day, completed within 1 week.
45460585|NCT03898921|Procedure|Radiofrequency ablation (RFA)|RFA with a safe margin, RFA again if residual,no more than 3 times.
45460586|NCT03101930|Drug|Liraglutide|subcutaneous liraglutide daily
45460587|NCT03101930|Drug|Sitagliptin|oral sitagliptin daily
45460588|NCT03101930|Other|hypocaloric diet|Reduced calorie intake to achieve weight loss.
45460589|NCT03101930|Drug|Placebos|Subjects in the liraglutide arm will receive a placebo for sitagliptin. Those in the sitagliptin arm will receive a placebo for liraglutide. All subjects will receive a placebo for Exendin 9-39.
45460590|NCT03101930|Drug|Exendin (9-39)|All subjects will receive Exendin (9-39) or matching placebo in crossover fashion during study days on the first and third days of the second week after randomization and again on the 5th and 7th days of the 14th week of treatment.
45460591|NCT03898765|Diagnostic Test|Dry blood spot screening|Dry blood spot measurement of biomarker for screening biliary atresia
45460592|NCT03898687|Device|SLN Biopsy with Magtrace®/Sentimag®|Identification of SLN by means of Magtrace®/Sentimag® and SPIO-MRI
45460593|NCT04239950|Drug|Placebo|Placebo
45460594|NCT04239950|Drug|Ethyl Icosapentate|Ethyl Icosapentate
45460595|NCT01255657|Drug|ABT-806|ABT-806 will be administered by intravenous infusion.
45460596|NCT01255813|Device|Stimulation (Sub-perception)|Stimulation applied below the perception threshold
45460597|NCT01255813|Device|Stimulation (Full)|Stimulation applied above the perception threshold
45460598|NCT01255813|Other|Control|No stimulation applied
45460599|NCT05415254|Drug|Calcitriol|Calcitriol supplementation orally
45460600|NCT03898375|Other|Walking with different optic flow speeds|Patients will perform 4 sessions of 20 minutes treadmill walking: one control session without VR and 3 walking sessions with the VR. In each VR session, patients will walk with a different optic flow speed: the same as, faster than or slower than their walking speed.
45460601|NCT01255969|Other|Exercise|Personalized exercise program
45460602|NCT01256047|Dietary Supplement|Oral IMPACT|oral supplement for 5 days(1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
46009219|NCT04671134|Other|Biomimetic remineralizing agent|Self-assempling peptide
46009220|NCT04671134|Other|Resin Modified Glass Ionomer Varnish|Resin Modified Glass Ionomer Varnish
46009221|NCT04571489|Drug|Gimatecan|Patients will receive gimatecan orally at 0.8mg/m2 on day 1-5 every 4 weeks.
46096106|NCT02750423|Procedure|DHCA+RCP|During deep hypothermic circulatory arrest and retrograde cerebral perfusion (DHCA+RCP) the participant is placed on cardiopulmonary bypass (heart-lung machine) and their body temperature is lowered to a range of 14-18 °C. Once the goal temperature has been achieved, the circulation is stopped and aortic arch replacement is performed in a bloodless surgical field. Blood will be pushed to the brain through arterial vessels, much like the natural blood flow pattern. Once the aortic arch repair is complete, cardiopulmonary bypass is reinstituted, the participant is rewarmed, and separated from cardiopulmonary bypass.
45460603|NCT02928848|Device|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.
45460604|NCT01150201|Drug|Aliskiren|For CKD treatment
45460605|NCT01150201|Drug|Losartan|Control
45460606|NCT05269550|Radiation|High Intermediate Risk Patients|Patients will receive 35Gy/5 fractions to the whole prostate (25 Gy to proximal Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Six months of androgen deprivation therapy will commence with the start of radiotherapy (concurrent plus adjuvant)
45460607|NCT05269550|Radiation|High Risk or Very High-Risk Patients|Patients will receive 35Gy/5 fractions to the whole prostate (25Gy to whole Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Pelvic lymph nodes will receive 25Gy/5 fractions synchronous with prostate treatment with a simultaneous boost to imaging involved nodes to a maximum of 35Gy/5 fractions. Eighteen months of androgen deprivation therapy will commence with the start of radiotherapy (concurrent plus adjuvant)
45678863|NCT01920152|Biological|PRP|Each PRP preparation requires a total of 36 ml of peripheral blood. This will be obtained via venapuncture and collected in four 9 ml extraction tubes containing 3.8% sodium citrate. The tubes are then centrifuged at 640 rpm for 8 minutes at room temperature. The 1ml plasma fraction located above the buffy coat is aspirated from each tube and dispensed into the fractioning tube. The entire PRP process takes place under laminar airflow. Immediately prior to injection, calcium chloride is is drawn up from the activator ampoule with the activation syringe and is added to the PRP fractioning tube. The activated PRP is then injected in its entirety into the hip joint under strict aseptic technique.
45678864|NCT01920152|Device|Hyaluronic Acid|Hyaluronic acid is supplied as a non-pyrogenic solution in 2.5 ml pre-filled syringes and is administered by intra-articular injection using a 22-23 gauge needle. The full 2.5 ml is injected in one joint under strict aseptic administration.
45678865|NCT01752933|Drug|SGI-110|SGI-110 will be administered by subcutaneously (SC) on Days 1 - 5 every 28 days until disease progression or unacceptable toxicity
45678866|NCT01752855|Biological|New formulation adalimumab|New formulation adalimumab 40 mg every other week
45460608|NCT02928770|Device|Nastent|Use of the device while at home and in the sleep lab
45460609|NCT01256203|Drug|Solar Protection Formula SPF® 60|Solar Protection Formula SPF® 60 (2 mg/cm²) will be topically applied on a randomly predetermined specific skin area on the back of each subject on four separate occasions over 3 months. The same skin area will never be exposed more than once to the sunscreen.
45460610|NCT01256203|Procedure|Photobiological testing|Photobiological testing will consist of exposing a small area of the sunscreen-protected and unprotected (control) skin areas to visible light on four separate occasions over 3 months. Light will be applied 30 minutes after application of the sunscreen. The same skin area will never be exposed more than once to light.
45460611|NCT05087485|Other|education|digital education in skin cancer diagnostics
45678867|NCT01402492|Drug|Buprenorphine + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
45836860|NCT00470106|Behavioral|Cognitive remediation|Computer exercises in attention, memory, and speed of processing.
45460612|NCT03889327|Behavioral|Neuropsychological Feedback & Psychoeducation (Cognition)|The customary practice of providing feedback on neuropsychological test performance can address patient misperceptions of cognitive impairment by distinguishing between perceived and objective neuropsychological test performance. Explaining how normative data is derived by comparison to same age peers, patients are able to better understand their current cognitive functioning. The proposed intervention will employ both psychoeducation and neuropsychological feedback for participants assigned to the treatment group, and psychoeducation for participants assigned to the control group. Both groups will watch 3 brief videos (exactly the same length in time) and answer two qualitative questions following each video.
46096107|NCT02750423|Procedure|MHCA + SACP|During moderate hypothermic circulatory arrest and unilateral selective antegrade cerebral perfusion (MHCA + SACP) the participant is placed on cardiopulmonary bypass (heart-lung machine0 and the native blood flow to the brain is temporarily suspended. The body is cooled to temperatures of ≤28°C and blood is administered to the brain via an artery in the neck during the period of arch reconstruction. Once the aortic arch repair is complete, cardiopulmonary bypass is reinstituted, the participant is rewarmed, and separated from cardiopulmonary bypass.
46096108|NCT00719290|Procedure|Phacoemulsification (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)|Phacoemulsification of the lens with intraocular lens implant
45460613|NCT03889327|Behavioral|Psychoeducation (Health)|Information on importance of healthy eating habits and benefits of a healthy diet including medical outcomes such as reduced blood pressure, and decreased risk of stroke and cardiovascular disease. This intervention will also cover recommended serving sizes for daily helpings of fruits and vegetables, and ways to incorporate fruits and vegetables into meals throughout the day. The control intervention will include expert testimony from a nutritionist and expert dietician.
45460614|NCT01259947|Drug|Lippia alba (Mill.) N. E. Brown ethanolic extract|1-2 drops per kilogram per day, PO, twice a day
45460615|NCT01257451|Drug|Vildagliptin|vildagliptin 50mg bid
45460616|NCT01257451|Drug|Placebo|Placebo 50mg bid
45460617|NCT01257529|Drug|Pregabalin controlled release, 330 mg, low-fat|A single oral dose of 330 mg controlled release tablet administered following a low-fat evening meal
45678868|NCT01402492|Drug|Placebo + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
45678869|NCT01402102|Dietary Supplement|Aged garlic powder|Aged garlic powder(6.0g/day)
45678870|NCT01402102|Dietary Supplement|Placebo powder|Placebo powder(6.0g/day)
45836861|NCT00470106|Behavioral|Social Cognitive skills training|Group training on emotion perception, social perception, and understanding others' mental states.
46009222|NCT04571489|Drug|tegafur, gimeracil and oteracil potassium|Patients will receive tegafur, gimeracil and oteracil potassium orally at 40 or 60mg twice daily on days 1 to 14 every 3 weeks.
46009223|NCT04571489|Drug|gemcitabine|Patients will receive gemcitabine IV at 1000mg/m2 on days 1、8 every 3 weeks.
45460618|NCT01257529|Drug|Pregabalin controlled release, 330 mg, medium-fat|A single oral dose of 330 mg controlled release tablet administered following a medium-fat evening meal
45460619|NCT01257529|Drug|Pregabalin controlled release, 330 mg, high-fat|A single oral dose of 330 mg controlled release tablet administered following a high-fat evening meal
45460620|NCT01257529|Drug|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered following a medium-fat evening meal
45460621|NCT02972060|Drug|ODM-201|ODM-201 is a novel, oral, potent nonsteroidal AR inhibitor. ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) b.i.d. to a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food. Treatment should be initiated within 28 days from randomization.
45460622|NCT02972060|Drug|ADT|"ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.~This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician."
45460623|NCT03896113|Drug|Celecoxib 200mg capsule|Patient confirmed with endometrial cancer will received twice daily 200 mg Celecoxib, 15 days before the surgery.
45836862|NCT00470106|Behavioral|hybrid intervention|A combination of the two groups listed above.
45836863|NCT00470106|Behavioral|skills training|Skills training in how to identify symptoms of illness and medication side effects.
45836864|NCT00387660|Drug|carboplatin|Patients receive carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
46009224|NCT00172185|Drug|teduglutide 0.05 mg/kg/d|0.05 mg/kg/d subcutaneous injection
46009225|NCT00172185|Drug|teduglutide 0.10 mg/kg/d|0.10 mg/kg/d subcutaneous injection
46009226|NCT01080326|Device|Endoscopic Translumenal Omental Patch|The endoscope will be gently advanced through the ulcer. Irrigation with saline will proceed. Then a viable mobile piece of omentum will be identified and pulled into the ulcer. After the omentum is located in the stomach, clips will be used to fix it in place.
46009227|NCT00171951|Drug|Pasireotide|Pasireotide 600 μg or 900 μg was administered as an SC injection.
46009228|NCT01080131|Drug|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
46009229|NCT01080131|Drug|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
45678871|NCT04029220|Behavioral|Parent Peer Navigation|Parent Peer Navigation (PPN) is implemented by trained providers with lived experience, who are supported by training and coaching protocols. The role of PPN provider is to engage caregivers in necessary treatment for their children and prepare them to independently navigate the child serving system, community-based resources, and ongoing opportunities for support. PPN providers will support families who are just entering he child-serving systems for 6 months on a weekly basis during which they will: help link families with formal and informal supports; instill confidence and coping skills; assist in the development of goals and crisis plans; and serve as an advocate for resolution of issues. Also, the PPN provider helps the family to learn to navigate systems and advocate for their needs, prepares families for meetings and treatment sessions, helps identify ways for parents to practice self-care; and promotes family choice and shared decision making.
45678872|NCT01423084|Biological|Serogroup B meningococcal vaccine|"All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2.~A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination"
45678873|NCT04042168|Diagnostic Test|In Check Dial test|In Check Dial test will test the ability to actuate the inhaler.
46009230|NCT01080131|Drug|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
45460624|NCT03100838|Drug|Nifedipine 60 MG Extended Release Oral Tablet|Reference Drug (Brand)
45460625|NCT03100838|Drug|Nifedipine 60 MG Extended Release Oral Tablet|Test Drug (Generic)
46009231|NCT01080131|Drug|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
45460626|NCT03100838|Drug|omeprazole/sodium bicarbonate|Proton Pump Inhibitor/Antacid for drug-drug interaction
45460627|NCT03100838|Device|SmartPill (TM)|Gastric pH measurement using SmartPill (TM) Technology
45460628|NCT03895957|Behavioral|Virtual Reality Exposure Therapy VR Mind+|Virtual Reality Exposure Self-Therapy led by a participant
45460629|NCT03895957|Behavioral|Virtual Reality Exposure Therapy VR Mind|Treatment with Virtual Reality Exposure Therapy led by a therapist
45460630|NCT03895957|Behavioral|Cognitive Behavioral Therapy|Standard treatment for social phobia led by a therapist
45678874|NCT04026334|Device|V.A.C. VERAFLO CLEANSE CHOICE™ dressing with Normal Saline|-125mmHg, 10 minute soak time, 3.5 hours of negative pressure therapy
45678875|NCT01894256|Drug|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
45678876|NCT01780935|Drug|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
45836865|NCT00387660|Drug|irinotecan|Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
45836866|NCT00472056|Drug|Carmustine|300 mg/m^2 IV for 1 Day
46009232|NCT04551612|Radiation|Multislice computed tomography temporal bone|Patients with cholesteatoma will undergo multislice computed tomography (MSCT) temporal bone images. Then The Tegmen level will be determined and compared with the other normal ear at the same patient
45460631|NCT04118114|Drug|PRL3-zumab|IV administration every 2 weeks
45460632|NCT03892681|Other|hepatocyte-specific contrast agent, extracellular contrast agent|The type of contrast agent for the 1st MRI will be performed using hepatocyte-specific contrast agent (Primovist). The participant will undergo the 2nd MRI using extracellular contrast agent (Gadovist).
45460633|NCT03895879|Drug|Tocilizumab|Tocilizumab sc (162 mg) once every 2 weeks
45460634|NCT03895879|Drug|Tocilizumab|Tocilizumab sc (162 mg) once every week
45460635|NCT04031144|Procedure|Ultrafiltration|At the end of CPB procedure, free water is partly removed by ultrafiltration to increase relative mass of red blood cell and plasma components.
45460636|NCT01260025|Drug|PEDylated Recombinant Human Endostatin|The initial dose of PEDylated Recombinant Human Endostatin (M2ES) will be 7.5mg/m2.Dose Escalation to a next higher level will occur when 3 patients in the same dose level complete 28 days of continuous treatment without experiencing a dose-limiting toxicity.
45460637|NCT03984578|Drug|CAPEOX|Oral Capecitabine: 1000mg/m2 twice a day from Day 1 to 14 of a 3-week cycle, and IV Oxaliplatin: 130mg/m2 on Day 1
45460638|NCT03984578|Drug|Pembrolizumab|IV infusion of 200mg on Day 1 and Day 22
46009233|NCT00171873|Drug|Octreotide LAR (Long-acting release)|30 mg intramuscularly every 28 days
46009234|NCT00171873|Drug|Placebo|Sodium chloride intramuscularly every 28 days
46009235|NCT01087151|Drug|ABT-263|Oral repeating dose
46009236|NCT01087151|Drug|rituximab|Intravenous repeating dose
45460639|NCT03984578|Drug|Capecitabine/ 5-FU|Capecitabine: Oral dose of 825mg/m2/day twice a day on radiation days with concurrent radiation median 50.4 Gy/ 28 fractions; or 5-FU: 225mg/m2/day concurrent with radiation
45460640|NCT03984578|Drug|Pembrolizumab|IV infusion of 200mg on Day 1 of each cycle
46009237|NCT04551027|Behavioral|compensatory cognitive treatment|a brief group compensatory cognitive intervention including 12 meetings of 1 hour in a group of five and focuses on these cognitive domains: prospective memory, vigilance and attention, memory and learning and executive functions
46009238|NCT04571528|Behavioral|TAU + multicomponent treatment VIRTUAL FIBROWALK|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia.
46096109|NCT00719290|Procedure|Phacoemulsification and goniosynechialysis (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)|Phacoemulsification of the lens with intraocular lens implant and goniosynechialysis
46096110|NCT00635921|Drug|ziprasidone|Dose flexible from 40 to 200 mg/d during 12 weeks
46096111|NCT00635921|Drug|Placebo|flexible doses from 40 to 200 mg/d during 12 weeks
46096112|NCT00990145|Drug|EDP-322|
46096113|NCT02574442|Device|In Vivo Confocal Microscopy Probe|Participants will have 2 areas on their cervical imaged by the confocal probe.
45460641|NCT03984578|Procedure|Surgical resection|Performed after all medical intervention
45678877|NCT01894100|Device|Shoe lift correction for leg length inequality|Lift therapy will be administered by a physical therapist. Heel lifts and full length inserts used inside participants' shoes will be constructed on-site. If an external shoe lift is required for a participant, a local shoe repair shop will construct the lifts and add them to the outside of the shoe. Participants will be required to wear the lift in their shoes when they are walking or standing while enrolled in the study; participants will keep a daily diary to record their compliance (number of hours lift worn per day, amount of lift used, type of shoes worn, general symptoms experienced, and activities performed). They will be contacted weekly to be reminded to increase their lift height and identify when they have achieved their optimal lift height.
45678878|NCT02334982|Drug|TAK-137|TAK-137 tablets
45460642|NCT03892837|Procedure|PRP|PRP treatment following the conventional treatment for benign airway stenosis which contain a concentrate of platelet-rich plasma protein derived from whole blood.
45460643|NCT03892837|Procedure|Conventional treatment for benign airway stenosis|Including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
45678879|NCT02334982|Drug|Placebo|TAK-137 placebo-matching tablets
46009239|NCT04571528|Behavioral|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
46009240|NCT04571528|Behavioral|TAU + Physiotherapy part of VIRTUAL FIBROWALK|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients: - Pain neuroscience education (30 min.) - Physical exercise(30 min.) - Treatment as Usual (TAU). Standard pharmacological treatment usually provided to patients with fibromyalgia.
46009241|NCT04671095|Device|ERCP procedure with single use duodenoscope|ERCP is an endoscopic procedure done to relieve bile duct obstruction. It is done either under conscious sedation or deep sedation. The endoscope is inserted thorough the mouth and is taken to the second part of duodenum (small bowel). The ampulla is identified and the bile duct is cannulated. Biliary obstruction is relieved either by placing a stent or removing the stone/s
46096114|NCT04218305|Diagnostic Test|Serum Level Of Fetuin A|
46096115|NCT04166006|Biological|Autologous DC vaccine|7-14×106 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)
46096116|NCT04166006|Drug|Interleukin-2|Autologous DC vaccine is followed by IL-2, at a dose of 3 MU, given by subcutaneous injection daily for five days (days 3-7).
46096117|NCT03993691|Device|Tomo-E scan|High-resolution limited-angle tomography positioning and examination will vary depending on injury.
46096118|NCT03993691|Device|Radiograph|Standard of Care radiographic imaging of wrist.
46096119|NCT04069858|Drug|Switching to Generic Entecavir (Baracle®)|switching to Baracle® 1 mg (generic drug) in chronic hepatitis B patients taking Baraclude® 1 mg (brand drug)
46009242|NCT00171834|Drug|Patupilone|Patupilone (2.5 mg/mL) was supplied as a clear, colorless concentrate for solution for infusion in glass vials containing 5 mg/2 mL in Phase I and 10 mg/4 mL in Phase II part of the study. Patupilone was administered as a single intravenous (i.v.) infusion over 5 to 10 minutes (Amendment 1) till Amendment 2 and over 10 to 20 minutes (Amendment 2) till the completion of Phase I part of the study. Patupilone was administered as a single i.v. infusion over 20 minutes (Amendment 4), once every 3 weeks in Phase II part of the study.
45460644|NCT04363580|Other|Auditory processing disorder screening tool|"Screening tool : a questionnaire completed by the parents and the child's teacher and a mini-battery of tests composed of verbal and nonverbal assessments.~Questions for parents are grouped into four sections:~Reference pattern and portrait of the child.~Auditory history.~History of speech and language development.~School history.~The teacher questionnaire has seven sections:~Portrait of the child.~Reading and writing.~Speaking.~Mathematics.~Music.~Memory.~Listening skills and understanding:~Concentration and organization.~Environment.~Mini-battery of tests:~Dichotic Numeric Listening Test.~Identification test of 15 patterns of frequency-varying sounds at each ear.~Test of 10 monosyllables in noise per ear.~Auditory memory test by measuring the range of figures (instead of words in order to reduce the contribution of language processing)."
45460645|NCT03892525|Drug|Selicrelumab|escalated dose in intratumoral injection, every 3 weeks, for 3 cycles
45460646|NCT03892525|Drug|Atezolizumab|1200mg IV every 3 week until progression or relapse for maximum 1 year
45460647|NCT05418452|Drug|Metformin|metformin (MF), an antidiabetic agent, has been successfully used as a local drug delivery agent in periodontitis patients. Literature has suggested that MF possesses the osteogenic potential and induces the growth of osteoblast precursor cells. Therefore, several human studies have reported the use of MF alone or combined with PRF in the treatment of bony defects
45460648|NCT01257841|Drug|Leptin administration|Leptin 0.05 mg/kg sc daily in divided doses (0800, 1400, 2000, and 0200h) for four days.
45678880|NCT03025516|Device|Rapid Biosensor Systems (RBS) TB Breathalyser|Rapid Biosensor Systems (RBS) recently developed a portable, non-invasive, rapid TB diagnostic 'Breathalyser' capable of diagnosing TB in patient breath samples collected while patients cough (Figure 1). The TB Breathalyser comprises a disposable, single-use sample collection tube and a multi-use reader. At the bottom of the collection tube is a glass bio-sensor coated with a biochemical sensor that is formulated to react with TB bacilli. Patients cough into the collection tube after nebulization with 0.9% saline solution. Following sample collection, the tube is placed into the reader, where a diode laser interrogates the biochemical coating in the sample collection tube and reports the presence of TB bacilli. The entire process takes about two minutes.
45678881|NCT03025516|Device|eNose AeonoseTM|The eNose Company has also developed a hand-held, non-invasive rapid TB diagnostic 'electronic nose' (AeonoseTM) for TB detection based upon analysis of exhaled breath. After the device has been calibrated, the patient is instructed to breathe into the device through a mouthpiece for 5 minutes. Within the device is a micro-hotplate, metal-oxide sensor which behaves as a semiconductor at high temperature. Redox-reactions occurring at the sensor surface result in changes in resistance, with results read and interpreted by a phone application to confirm the presence of MTB.
45836867|NCT00472056|Drug|Etoposide|Arm 1 = 200 mg/m^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m^2 IV Every 12 Hours x 4 Days
45836868|NCT00472056|Drug|Cytarabine|Arm 1 = 200 mg/m^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m^2 IV Every 12 Hours x 4 Days
46009243|NCT02214030|Device|Assiut Femoral Compression Device|Assiut Femoral Compression Devices (AFCD) is a femoral compression system, The pressure dome is situated over the vessel puncture site in the groin and applies a mechanical pressure over the vessel puncture site to induce hemostasis.
46009244|NCT04571996|Drug|ODM-104|Capsule
45836869|NCT00472056|Drug|Melphalan|140 mg/m^2 IV x 1 Day
45836870|NCT00472056|Drug|Rituximab|Cohort 1, High-Dose Rituximab = 1000 mg/m^2 IV On Days +1 and +8 After Stem Cell Infusion; Cohort 2, Standard Dose Rituximab = 375 mg/m^2 IV On Days +1 and +8 After Stem Cell Infusion.
45836871|NCT00415506|Drug|Rituximab|Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.
45836872|NCT03531918|Drug|Cladribine|Given IV
46009245|NCT04571996|Drug|Paracetamol|Rapidly dissolving tablet
46009246|NCT00171249|Drug|STI571 400 mg|STI571 capsules and tablets
45836873|NCT03531918|Drug|Cytarabine|Given IV
45836874|NCT03531918|Drug|Gemtuzumab Ozogamicin|Given IV
45836875|NCT03531918|Biological|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
45836876|NCT03531918|Other|Laboratory Biomarker Analysis|Correlative studies
45836877|NCT03531918|Drug|Mitoxantrone Hydrochloride|Given IV
45836878|NCT00389532|Biological|Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)|Influenza vaccine
45836879|NCT00389532|Biological|Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)|Influenza vaccine
45836880|NCT03520686|Drug|N-803 + Pembrolizumab|"The treatment plan in the experimental arm will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~Pembrolizumab (200 mg intravenous infusion [IV])~N-803 (15 μg/kg subcutaneously [SC])"
46009247|NCT00171249|Drug|STI571 600 mg|STI571 capsules and tablets
46009248|NCT04671056|Drug|MGL-3196|MGL-3196 100 mg tablet administered orally in the morning for 13 days
46009249|NCT04671056|Drug|Pioglitazone 15mg|Pioglitazone 15 mg tablet administered orally on 2 separate days, initially on one day alone and again after MGL-3196 has been dosed to steady-state
46009250|NCT01082549|Drug|gemcitabine/carboplatin|i.v.
46009251|NCT01082549|Drug|gemcitabine/carboplatin plus Iniparib|i.v.
46009252|NCT02214069|Device|Record and transmit heart rhythm|The patient uses the AliveCor device to record and transmit heart rhythm two times a day. The patient, device software, and Electrophysiologist interpret the rhythm
46009253|NCT04550949|Drug|QL1206|The active ingredient of QL1206 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
46009254|NCT04550949|Drug|Xgeva|The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
45460649|NCT01257841|Behavioral|Fasting|Complete fasting, save for water and multivitamin, for four days.
45460650|NCT04346888|Drug|HBM9161 Injection (680mg and 340 mg)|HBM9161 Injection (680mg and 340mg)
45678882|NCT01422850|Biological|ALECSAT|Autologous activated CTL and NK-cells injected as three intravenous injections interspaced by 5 weeks.
45678883|NCT01422538|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin on the lower face.
45678884|NCT01422538|Drug|Sculptra®|Injectable filler reconstituted prior to use. Injections are administered to the lower face in a combination of cross-hatching and fanning techniques. The Sculptra is injected in two treatment sessions 6 weeks apart.
46009255|NCT01085630|Drug|pemetrexed disodium|Given IV
46009256|NCT01085630|Other|clinical observation|
46009257|NCT00171210|Drug|Deferasirox|Tablets taken orally once a day.
45678885|NCT01422538|Other|Sculptra® treatment followed by Ultherapy™ treatment|Sculptra® administered in 2 injection sessions 6 weeks apart, then Ultherapy™ treatment 4 months following Sculptra.
45678886|NCT04026256|Drug|Teriparatide|teriparatide daily subcutaneous injection
45678887|NCT04026256|Drug|Denosumab|denosumab subcutaneous injection
45678888|NCT04025866|Other|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for femur fracture
45678889|NCT04025866|Other|Aerobic exercise|30 min/day of aerobic exercise with arm cycle ergometer added to 1h/day for 5 days/week of conventional rehabilitation for femur fracture
45678890|NCT01422382|Drug|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
45678891|NCT01422382|Drug|Diltiazem (Cardizem LA) 240 mg QD|Diltiazem (Cardizem LA) 240 mg QD
45678892|NCT04025788|Device|Magmaris Resorbable Magnesium Scaffold (RMS)|Subjects will undergo a percutaneous coronary intervention for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of two single de novo lesions in two separate major epicardial vessels are allowed.
45678893|NCT01401322|Drug|Lenalidomide|50 mg; po
45678894|NCT01387594|Procedure|lumbar puncture|2 lumbar punctures prior to treatment; study drug 225mg SC once a month X 3 doses.
45678895|NCT01387594|Drug|lumbar puncture|1 lumbar puncture before and after 3 doses; study drug 225mg SC once a month X 3 doses.
45460651|NCT04346888|Drug|Placebos|Placebo, HBM9161 Injection (340mg)
45460652|NCT04346888|Drug|HBM9161 Injection (340 mg)|HBM9161 Injection (340 mg)
45460653|NCT05270798|Drug|triiodothyronine|Patients in septic shock who meet the diagnostic criteria for euthyroid sick syndrome will be divided into two groups; patients with low T3 levels and patients with low T3 and T4 levels. Both of these groups will be further randomly divided into patients receiving T3 hormone and patients receiving placebo.
45460654|NCT01260103|Drug|Temozolomide|Study subjects in a fasting state receive TMZ orally once a day for five consecutive days (days 1 through 5) at a starting dose of 200 mg/m2/day. Treatment cycles are repeated every 28 days following the first daily dose of TMZ from the previous cycle. In the absence of PD or unacceptable toxicity, subjects continue to receive TMZ for a maximum of 13 cycles.
45460655|NCT01260103|Drug|ANP Therapy|Escalating doses of ANP therapy are administered for 52 weeks. If the study subject has an OR or maintains SD, ANP therapy is continued.
46009258|NCT04670861|Procedure|Upper extremity Biodex balance training|"The person assumes the prone plank posture with both hands poisoned in the area assigned for foot placement on the tilting balance platform. Using the four keypads, the person's left hand, left wrist, right hand and right wrist positions are entered into the system using the midline of the hand and the platform grid as reference points. The dot that appears on the position patient screen represents the person's segmental center of gravity.~During each trial test, the person should shift his weight to move the cursor from the center along a target path and back as quickly and with a little deviation as possible. The same process is repeated for each of the targets. Target paths activate in a random order."
45460656|NCT03480750|Drug|trientine dihydrochloride|trientine dihydrochloride 300MG/CAPSUE PO daily (in different dose levels)
45460657|NCT03480750|Drug|pegylated liposomal doxorubicin|pegylated liposomal doxorubicin 40mg/m2 IV D1
45460658|NCT03480750|Drug|carboplatin|carboplatin AUC 4 IV D1
45678896|NCT01401010|Drug|Doripenem|500 mg every 8 hours
45678897|NCT01401010|Drug|doripenem|1000 mg every 8 hours
45678898|NCT01400932|Drug|GI148512|GI148512, Topical gel in 1 g containing benzoyl peroxide 30 mg
45678899|NCT01400932|Drug|vehicle gel|Matching vehicle gel of GI148512, not containing active ingredient (benzoyl peroxide)
45678900|NCT01400698|Drug|Saizen® A|Continuous or intermittent treatment with recombinant human Growth Hormone (r-hGH) 0.067 milligram/kilogram/day (mg/kg/day) subcutaneously (sc).
46096120|NCT02750579|Procedure|Percutaneous coronary intervention for revascularization|Percutaneous coronary intervention for revascularization with anticoagulant and antiplatelet therapy (routine care)
46096121|NCT02644382|Other|qualitative data collection|qualitative data collection
45460659|NCT05207384|Procedure|Ozone (O2-O3) injection|US-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. 3 sessions (1 session/week) of 5 mL of ozone (O2-O3) will be injected (with a concentration of 10 μg/mL in the first session, 15 μg/mL in the second session, and 20 μg/mL in the third session).
45678901|NCT01400698|Drug|Saizen® B|Observed until the first signs of puberty and then continuous treatment with r-hGH 0.067 mg/kg/day sc or observed without treatment.
45678902|NCT01400698|Other|Observation only|Subjects were only observed.
45678903|NCT04041622|Diagnostic Test|Endoscopy and biopsy|Participants with a positive celiac serology are assessed by endoscopy and duodenal biopsy
45678904|NCT01890746|Drug|Daunorubicin|For subjects between the ages of 18 and 60 years, 90 mg/m2/day by bolus IV injection through a freshly established free-flowing IV line for 10-15 minutes on days 1, 2, and 3. For subjects > 60 years: daunorubicin dose was adjusted to 60mg /m2.
46009259|NCT00171054|Drug|Valsartan 320 mg|Patients received 160 mg valsartan for 4 weeks. Patients were then up-titrated to receive either 320 mg valsartan for the following 8 weeks.
46009260|NCT00171054|Drug|Amlodipine 10 mg|Patients received 5 mg amlodipine for four weeks. Patients were then up-titrated to receive 10 mg amlodipine for the following 8 weeks.
46009261|NCT00171054|Drug|Hydrochlorothiazide|At Week 12, patients who did not meet target Blood Pressure for both Systolic Blood Pressure < 140 mmHg and Diastolic Blood Pressure < 90 mmHg were eligible to receive 12.5 mg open-label Hydrochlorothiazide for the following 26 weeks.
46009262|NCT00174837|Drug|Tirapazamine|in combination with cisplatin and concomitant radiation
46096122|NCT02644382|Other|survey|survey pre and post-surgical consult
46096123|NCT02644382|Other|decision aid|web-based decision aid post-surgical consult
46096124|NCT00710086|Drug|Hydromorphone|Intravenous administration of hydromorphone 1mg at the patient's request if they felt uterine contraction pain
45678905|NCT01890746|Drug|Cytarabine|100 mg/m2/day continuous IV infusion on Days 1 through 7.
46096125|NCT00710086|Drug|Remifentanil|Remifentanil intravenous PCA: 0.2μg/kg, lockout time interval 2 minutes, continuous infusion rate 0.2-0.8μg/kg/min.
46096126|NCT04424927|Biological|PRV-015|Fully human monoclonal antibody against interleukin 15 (IL-15)
46096127|NCT04424927|Other|Placebo|Placebo
46096128|NCT00652886|Drug|Oxandrolone|Tablets, 10mg, single-dose
46009263|NCT00174837|Drug|Cisplatin|with concomitant radiation
46009264|NCT04670705|Other|patients' characteristics|There was no intervention.
46009265|NCT00179400|Drug|Pioglitazone 45 mg|
46009266|NCT00179400|Drug|Placebo|
46009267|NCT04991090|Radiation|escalation dose of LLNs|The lymph nodes (SA ≥ 5 mm) existed at the internal iliac and obturator would be delineated, named as GTVnd, and received a radiation dose boost of 58Gy.
46009268|NCT04550793|Drug|Botulinum toxin injection|Botulinum toxin injection at affected brachialis and/or biceps brachials.
46096129|NCT00652886|Drug|Oxandrin|tablets, 10mg, single-dose
46096130|NCT00710164|Drug|XSCR capsule (Composed of Traditional Chinese Medicine Huangqi, Chuanxiong, Chishao, Danggui, Dilong, Taoren, Honghua.)|14 days of XSCR capsule
46096131|NCT00710164|Drug|Placebo|14 days of Placebo
46096132|NCT02647736|Other|Hypertonic saline infusion|
46096133|NCT01563991|Procedure|Normal fluid volume|Normal fluid group will receive lactated ringes at 8 cc / Kg/ hr total
46096134|NCT01563991|Procedure|Reduced fluid volume|Subject receives 80 cc/ hr LR during the peri-operative period
46096135|NCT02643992|Other|DOAC concentration measurement|
46096136|NCT03742999|Procedure|physical therapy program|this group received specially designed physical therapy program to facilitate eye-hand coordination and fine motor to improve VMI, VP and MC, which included: unbutton buttons, and button in all again; put the pellets in the bottle as fast as he/she can; place the shapes on its form board; build steps, wall, pyramid and a tower from cubes; cut out a line, square, triangle, and rectangular shapes on a paper by scissor; string squared cubes and lace the holes of strip. Children were trained for 60 minutes per session, three times a week for three consecutive months.
46009269|NCT04550910|Radiation|Hypofractionation Schedules for Breast Cancer patients after mastecomy|Two Radiotherapy HypoFractionation Schedules will be applied, after randomization, for female breast cancer patients after mastectomy.
46009270|NCT00479856|Drug|Lapatinib|Small molecule tyrosine kinase inhibitor
46009271|NCT00479856|Drug|Capecitabine|Chemotherapy
45460660|NCT05207384|Procedure|Corticosteroid injection|US-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. A mixture of 1 mL corticosteroid (betamethasone 3 mg/mL) and 1 mL lidocaine (20 mg) will be injected (1 session).
45460661|NCT03892447|Drug|Alprostadil|Alprostadil 0.2~0.3ug/kg.h,iv,1h/d,14d
45460662|NCT03892447|Drug|Sodium Ferulate|Sodium Ferulate 2~6mg/kg.d,iv,14d
45460663|NCT03892447|Drug|Dopamine|Dopamine3～5 ug/kg·min,iv,3 h/d,14d
45460664|NCT03718650|Drug|Pimonidazole|Patients will take a single dose of 0.5 g/m^2 (approximately 13 mg/kg) of oral pimonidazole HCI 16 to 24 hours prior to surgery.
45460665|NCT03718650|Procedure|Surgical Resection|Patients will undergo Pancreaticoduodenectomy or Whipple procedure, which involves the resection of the pancreatic head, duodenum, gallbladder, and a portion of the stomach, 16 to 24 hours after consuming oral pimonidazole.
46009272|NCT00479856|Drug|Docetaxel|Chemotherapy
46009273|NCT00479856|Drug|nab-Paclitaxel|Chemotherapy
45460668|NCT01152073|Dietary Supplement|Placebo|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
46009274|NCT04997759|Drug|Neostigmine and Sugammadex|Compare both groups efficacy of reverse the neuromuscular blocking agent
46009275|NCT04994600|Other|Reduces number of question items|The number of alarm fatigue questions are reduced to about 15 in the CFA_2nd_phase group.
46009276|NCT00479466|Drug|MK0893|MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
46009277|NCT00479466|Drug|Metformin|Metformin HCL 500 mg tablet twice daily titrating up to 1000 mg twice daily over 3 weeks.
46009278|NCT00479466|Drug|Placebo to MK0893|Dose-matched placebo tablets to MK0893; taken orally once daily.
46009279|NCT00479466|Drug|Placebo to Metformin|Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
46096137|NCT03742999|Device|E-Link Upper Limb Exerciser|The exercises in the E-Link Upper Limb Exerciser System are in the form of simple and exciting games such as soccer, hitting walls, space shooting, driving, arnd throwing balls into a bucket.Children were trained for 60 minutes per session, three times a week for three consecutive months
46096138|NCT03742999|Combination Product|physical therapy program and ELink Upper Limb Exerciser|physical therapy program and E-Link Upper Limb Exerciser. Children were trained for 60 minutes per session, three times a week for three months
46096139|NCT02653040|Other|Dynamic lighting|"Intervention is rooms with light settings imitating natural light conditions with white light at day and low-lux no-blue light at night:~07am-10am: white light, increasing intensity 10am-07pm: white light, full intensity 07pm-11pm: no blue wavelength, low intensity 11pm-07am: no blue wavelength, very low intensity"
46096140|NCT04218929|Other|Study Formula (SF)|New infant formula for term infants fed ad lib
46096141|NCT04218929|Other|Comparator Formula (CF)|Commercially available infant formula for term infants fed ad lib
45460669|NCT01152073|Dietary Supplement|Second Formulation|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
45460670|NCT01152073|Dietary Supplement|Third Formulation|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
45460671|NCT03716700|Biological|CUVITRU|CUVITRU
46096142|NCT02573272|Drug|eslicarbacepine|
45460672|NCT05250596|Drug|Colchicine|Colchicine 1 mg (0.5 mg for patients ≤ 70 Kg) on-admission followed by 0.5 mg/day until discharge.
45460673|NCT05250596|Drug|Atorvastatin|Atorvastatin 80 mg on admission followed by 80 mg/day until discharge.
45460674|NCT03719664|Drug|Albuvirtide|Intravenous infusion of Albuvirtide
45460675|NCT03719664|Drug|3BNC117|Intravenous infusion of 3BNC117
45460676|NCT03719664|Drug|Baseline ART|Subjects continuing on baseline ART
45460677|NCT04788914|Dietary Supplement|Active bamboo charcoal± probiotics|Active bamboo charcoal 2g, TID probiotics 0.8g
45460678|NCT03888859|Biological|ET1402L1-ARTEMIS™ T cells -IV|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct -intravenous (i.v.) arm
46009280|NCT04991948|Drug|CYAD-101|Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells
46009281|NCT04991948|Drug|FOLFOX|5-FU, leucovorin and oxaliplatin
46009282|NCT04991948|Drug|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
46037853|NCT04317638|Other|Lipid profile|3 ml of venous blood from the breastfed and infants and mothers of the breastfed and mixed fed infants will be taken under aseptic precautions for determination of triglycerides (TG), cholesterol, high density lipoprotein (HDL), very low density lipoprotein (LDL) at the age of 14 ± 2 weeks and the age of 6 months.
46037854|NCT04307472|Behavioral|Clinician Nudge|Active choice intervention in the electronic health record and peer comparison messaging on performance
46096143|NCT04166084|Other|Active ROM Exercises|Active ROM exercises programme will include hip flexion-extention, hip abduction-adduction, hip internal-external rotation, knee flexion-extention and ankle dorsi-plantar flextion exercises.
46096144|NCT04166084|Other|Trunk Stabilization Exercises Training|Trunk stabilization exercises training will be given under the supervision of a physiotherapist. This training exercises will include diphragmatic exrecises, posterior pelvic tilt exercises, abdominal streghtening exercises,
46096145|NCT00539305|Drug|testosterone gel|50-100mg applied topically daily for six months
46096146|NCT00539305|Drug|placebo gel|applied topically daily for six months
46009283|NCT04550286|Behavioral|Smartphone Use Reduction in Academic Context|"Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation). This refers to the behavior change techniques (BCT 4.1, instructions on how to perform the behavior; Michie et al.; 2013).~In the next step, participants in the intervention group complete planning sheets. Each student has to develop up to three action plans (BCT 1.4) including when, where, and for how long the smartphone will be put away during the daily exam preparation period (cf. Radtke et al., 2018). In addition, each participant should try to anticipate possible barriers to engaging in the planned behavior and plan what he or she could do to overcome these possible barriers (i.e., coping planning; BCT 1.2; Michie et al., 2013)."
45460679|NCT03888859|Biological|ET1402L1-ARTEMIS™ T cells -intra-hepatic artery|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct: intra-hepatic artery (i.a.) arm
46009284|NCT04550286|Behavioral|Control|Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation).
45460680|NCT03888859|Biological|ET1402L1-ARTEMIS™ T cells -Intratumoral Injections|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct: Intratumoral Injections (i.t.) arm
45460681|NCT03716622|Drug|Furazolidone|bismuth-furazolidone-containing quadruple regimens
45460682|NCT03716622|Drug|Clarithromycin|bismuth-clarithromycin-containing quadruple regimens
45460683|NCT03889015|Dietary Supplement|Probiotic yogurt|Probiotics are found in different dairy products including yoghurt, that are known as carriers of probiotics. These products can be easily integrated in daily meals to reduce cariogenic streptococcus mutans bacteria in dental biofilm
45460684|NCT03889015|Dietary Supplement|xylitol chewing gum|Xylitol is widely used as an added sweetener in sugar-free products. It has been found to prevent dental caries through reducing dental plaque and limiting salivary streptococcus mutans counts and their produced levels of lactic acid
45460685|NCT03714126|Device|Cordio Medical|Recording to an app, no interference to the regular care
45460686|NCT01152151|Device|Postal reminder letters|Postal reminder letters if adherence is not obtained (up to four)
45460687|NCT01152151|Device|Electronic reminder letters|Electronic reminder letters if adherence is not obtained (up to four)
46009285|NCT04990778|Drug|Eprenetapopt|Given IV
45460688|NCT01152151|Device|Reminder letters|up to four reminder letters in september - december 2010
45460689|NCT04926740|Other|Ringer's lactate|Ringer's lactate is the most commonly used balanced crystalloid. Compared to normal saline, balanced crystalloids have chloride concentrations similar to human plasma; therefore, treatment with balanced crystalloids may lead to faster DKA resolution.
45460690|NCT01153477|Behavioral|Telephone Monitoring and Counseling - Enhanced|Calls or in-person sessions, 1x weekly for first 8 weeks, then every other week up to a year. Step up session frequency if needed based on participants' ratio of protective and risk factors.
45678906|NCT01890746|Drug|Eltrombopag|200 mg orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose of the Investigational Product (IP) was to be increased to 300 mg if platelet counts were <100 Gi/L. IP continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage 100 mg orally once daily (a 50% dose reduction) was used and after 7 days, the dose of IP was increased to 150 mg if platelet counts were <100 Gi/L.
46009286|NCT04990778|Drug|Venetoclax|Given PO
45460691|NCT03462030|Drug|Baked non-fat cow's milk powder|Oral immunotherapy with increasing quantities of baked milk.
45460692|NCT03462030|Drug|Placebo: Tapioca Powder|Placebo control.
45460693|NCT05418374|Procedure|Continous Spinal Anestheisa|Continuous spinal anesthesia (CSA) describes subarachnoid blockade maintained by local anesthetics administered through an indwelling spinal catheter. CSA provides fewer episodes of hypotension and no severe hypotension versus single dose bupivacaine also it offers the ability to titrate the dose of local anesthetics needed while maintaining hemodynamic stability.
45460694|NCT02673320|Procedure|Early surgery within 48 hours|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, early surgery is then realised within 48 hours. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
46009287|NCT04993703|Other|Kinesiotaping|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound, kinesiotaping and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.times per day 3sets of ten repetitions) will be applied.
45460695|NCT02673320|Procedure|Delayed surgery at 15 days|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, delayed surgery is then realised at 15 days. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
45460696|NCT03639012|Dietary Supplement|Carbohydrate drink|Children randomised to this group will receive a preoperative carbohydrate drink 90-120mins prior to surgery
45460697|NCT03895723|Procedure|laparoscopic and robotic liver resection|laparoscopic and robotic procedure for liver resection
45460698|NCT03895723|Procedure|open surgery|using open surgery procedure for liver resection
45460699|NCT03892213|Drug|Benznidazole|Benznidazole single dose (2.5 mg/kg) at Day 1. Benznidazole single dose (2.5 mg/kg) at Day 9*. Benznidazole multiple dose (2.5 mg/kg twice daily) from Day 12* until Day 15.
45460700|NCT03892213|Drug|E1224|"E1224 multiple dose 400 mg loading dose once daily for 3 days (i.e. from Day 4 to Day 6 followed by maintenance dose 100mg once daily for 9 days (from Day 7 to Day15).~On Day 9 and from Day 12 to Day 15, E1224 and benznidazole will be given concomitantly."
45460701|NCT05237336|Behavioral|Mindfulness-based Cognitive Therapy|"MBCT is a relapse prevention program that is used to teach participants with chronic physical/mental ailment (used to their conditions):~to manage early signs of distresses with compassionate awareness, and respond more effectively to mood and cognitive changes.~To become aware of bodily sensations, feelings, and thoughts, from moment to moment.~To help participants learn different ways of relating to sensations, thoughts and feelings- through mindful acceptance and acknowledgement of unwanted feelings and thoughts, rather than habitual, automatic, preprogrammed routines that tend to perpetuate difficulties.~To help participants to be able to choose the most skilful response to any unpleasant thoughts, feelings or situations that they meet.~UK's NICE recommends MBCT for persons who are well and have had 3 or more episodes of depression. MBCT benefits persons whose distress is triggered by the way they process experiences."
45460702|NCT05237336|Behavioral|Counselling as usual|Control group, Counselling as usual
45460703|NCT03412734|Drug|Chlorhexidine|Chlorhexidine preparation solutions
45460704|NCT03412734|Drug|Iodine|Iodine-based preparation solutions
45460705|NCT04313114|Behavioral|health literacy appropriate education and demonstration|If a patient chooses the Fecal Immunochemical Test (FIT), the Screening Coordinator (SC) will give the FIT kit, emphasize the necessity of annual completion, and distribute an additional plain language, literacy appropriate, actionable handout with simplified illustrated instructions on how to complete the test and mail to the central lab. The SC will review the handout and instructions with the patient and use the 'teach back' method to confirm understanding.
45460706|NCT04313114|Behavioral|shared decision making|Screening Coordinator (SC) will give patients a plain language, literacy appropriate, actionable printed CRC screening handout emphasizing the benefits of CRC screening and screening options; using the low literacy handout as a teaching tool, the SC will briefly counsel patients on CRC screening options prior to seeing their healthcare provider, reviewing the benefits of each, as well as applicable costs. After reviewing the CRC screening pamphlets with a patient, the SC will use shared decision-making techniques using the study CRC materials to aid patients in selecting the test they prefer and that meets their needs - colonoscopy or FIT.
45678907|NCT01890746|Drug|Placebo|Orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose given was matching 300 mg Eltrombopag if platelet counts were <100 Gi/L. Placebo continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage placebo matching 100 mg Eltrombopag orally once daily was used and after 7 days, the placebo matching 150 mg Eltrombopag was given if platelet counts were <100 Gi/L.
45678908|NCT04614350|Biological|Markman Biologics Microsurfaced ADM|an ADM which has been scored (microsurfaced)
45678909|NCT04614350|Biological|AlloDerm|AlloDerm tissue matrix
45836881|NCT03520686|Drug|N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab|"The treatment plan in the experimental arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~Carboplatin (up to 900mg IV)~Nab-paclitaxel (100mg/m² IV)~Pembrolizumab (200mg IV)~N-803 (15 μg/kg SC)~Day 8:~Nab-paclitaxel (100mg/m² IV)~Day 15:~Nab-paclitaxel (100mg/m² IV)~Maintenance:~Day 1, every 3 weeks:~Pembrolizumab (200mg IV)~N-803 (15 μg/kg SC)"
45678910|NCT01422304|Drug|Sugammadex|Sugammadex 4 mg/kg intravenously
45678911|NCT01422304|Drug|neostigmine and glycopyrrolate or atropine|Neostigmine and glycopyrrolate or neostigmine and atropine administered intravenously per usual practice and per the product labels
45678912|NCT01422304|Drug|Placebo to neostigmine|Normal saline (NaCl 0.9%)
45460707|NCT04313114|Behavioral|automated call reminders or automated texts|"Colonoscopy year 1: Will receive an automated call recording by PCP 48 hours after the clinic visit to remind them of their choice of colonoscopy; then, one week before the test reminding them to pick up the preparation kit. Those who chose SMS will receive a text message from their PCP with content similar to the voice call. A 3rd reminder call/text will be sent 2 days prior to the test. If no colonoscopy with 3 months, the clinical manager (CCM) will call to determine if they want to switch screening options. The CCM will discuss barriers and option of choosing FIT for 3 years. If they opt to change, they will be mailed a FIT with simplified instructions and then follow the FIT follow-up protocol.~FIT year 1: Motivational reminders recorded by their PCP will be sent by automated call or text within 48 hours after the visit and again at 4, 8 and 12 weeks for those who have NOT completed the test. FIT will be mailed year 2 & 3 - follow-up will follow same procedure as year 1."
45460708|NCT03888781|Device|Echocardiography|An echocardiogram (also called an echo) is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of your heart. These echoes are turned into moving pictures of your heart that can be seen on a video screen.
45460709|NCT03888703|Device|Fractional ablative CO2 laser|Three treatments with a fractional ablative CO2 laser 8 weeks apart
45460710|NCT05082818|Combination Product|Chemotherapy, Radiotherapy and surgery|Trans urethral resection of the tumour or radical cystectomy
45460711|NCT01153789|Procedure|orthoptic rehabilitation|Orthoptic rehabilitation: 12 sessions (2 sessions per week) At the end of a series of 12 sessions of orthoptic, the child will be examined and will again perform an static and dynamic oculomotor evaluation and control of postural balance.
45460712|NCT01153789|Other|Orthoptic diagnostic|postural, oculomotor and orthoptics tests
45460713|NCT05000138|Diagnostic Test|FDG PET/CT|Patients with suspected giant cell arteritis, of which FDG PET/CT is indicated for diagnosis of large vessel involvement, will have the small cranial arteries analyzed for involvement.
45678913|NCT01422304|Drug|Placebo to sugammadex|Normal saline (NaCl 0.9%)
45678914|NCT01387516|Behavioral|Motivational Intervention|The MI session will be 60-90 minutes in length.The focus is on establishing rapport and building motivation. The counselor explores teen's reasons for entering treatment, prior treatment experience, previous attempts to change use, possible goals for treatment, substance effect expectancies, and perceptions of self-efficacy.A personalized feedback report outlines assessment results, highlights any problems or concerns related to cigarette use expressed by teen, and compares tobacco use levels with national norms for same age and gender peers.
45836882|NCT03520686|Drug|N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|"The treatment plan in the experimental arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)~Pembrolizumab (200mg IV)~Pemetrexed (500mg/m² IV)~N-803 (15 μg/kg SC)~Maintenance:~Day 1, every 3 weeks:~Pembrolizumab (200mg IV)~N-803 (15 μg/kg SC)"
46096147|NCT02573116|Procedure|scaling and root planing|full-mouth intensive removal of subgingival dental plaque biofilms with the use of scaling and root planing after the administration of local anesthesia
46096148|NCT02643914|Drug|Nicotine|
46096149|NCT02643914|Device|MR Compatible Nicotine Delivery Device|
46096150|NCT00715702|Drug|AZD5672|100 mg oral single dose
46096151|NCT04217213|Procedure|Intercostal nerve block|In the experimental group, the surgeons used 0.5% ropivacaine combined with mecobalamine (0.5mg) before the operation to perform intercostal nerve block in the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity, and injected 5ml in each intercostal nerve block.In the control group, surgeons used 0.5% ropivacaine alone before the operation to perform intercostal nerve block through the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity. 5ml was injected into each intercostal nerve block.
46096152|NCT02398747|Drug|AZD2014|50mg continuous dosing, 125mg intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
46096153|NCT02536274|Device|Lumbo Sensa® bandage|Patients have to wear it over 21-28 days for at least 8 hours a day
46096154|NCT02536274|Device|Dynaflex® flexion orthosis|Patients have to wear it over 21-28 days for at least 8 hours a day
46096155|NCT04808999|Drug|Pembrolizumab Injection|200 mg IV infusion
45836883|NCT03520686|Drug|Pembrolizumab|"Drug: Pembrolizumab~The reference treatment will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~• Pembrolizumab (200 mg IV)"
46037855|NCT04307472|Behavioral|Patient Nudge|Text message sent to patients to prompt awareness of statin eligibility before an appointment with their primary care physician
46096156|NCT00710242|Drug|DF01|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
46096157|NCT00710242|Drug|Placebo|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
46096158|NCT02643836|Device|PEMF|The PEMF device (Rio Grande Neurosciences - RGN) the investigators would be testing has been shown to have significant anti-inflammatory effects in animals and humans and an excellent safety profile in several clinical studies. Key findings demonstrated that PEMF-treated rodents with a closed-head TBI exhibited a 5-fold decrease in IL-1b in the cerebral spinal fluid, an outcome associated with decreased neuropathology and improved function.
46096159|NCT00990223|Drug|Eplerenone or Placebo|Eplerenone 100 mg or Placebo, daily for 10 days.
46096160|NCT04755725|Device|Epidural catheter|epidural catheter inserted pre induction
45460714|NCT04955210|Other|Not applicable（Cohort study）|This is a prospective observational study and does not include interventions.
45460715|NCT01260259|Procedure|RIPC|RIPC will be elicited in the operating room (OR) after anesthesia induction and before start of surgery. After placement of an arterial line, a tourniquet will be placed over a lower extremity. It will be inflated to 15 mmHg above systolic blood pressure for 5 minutes, and then deflated for 5 minutes. This cycle of inflation-deflation will be repeated another 3 times before surgery.
45460716|NCT01260259|Procedure|Control|In OR, after induction of general anesthesia and arterial line placement, a deflated tourniquet will be placed over the lower extremity for 40 minutes.
45460717|NCT01152463|Procedure|thoracic ultrasound|daily thoracic ultrasound evaluation of the chest
45460718|NCT03892135|Other|Interviews with parents of children with juvenile idiopathic arthritis|Interviews with parents of children with juvenile idiopathic arthritis
45460719|NCT03892135|Other|Interviews with children with juvenile idiopathic arthritis|Interviews with children with juvenile idiopathic arthritis
46009288|NCT04993703|Other|Night Splinting|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound, night splinting and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.
46009289|NCT04993703|Other|Control Group|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.
46009290|NCT00479388|Drug|Comparator: simvastatin|simvastatin (20mg to 40mg) for 12 weeks.
46096161|NCT04755725|Device|rectus sheath catheter|The surgeon will place one hand inside the abdomen and with the other hand inserted the Tuohy needle through the skin and fascia. The surgeon will feel when the needle tip is just superfacial to interface between the peritoneum and muscle layer and avoid penetration of inferior epigastric artery. The procedure will be repeated on the contralateral
46096162|NCT00715780|Drug|soluble human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46009291|NCT00479388|Drug|niacin (+) laropiprant|One tablet of ER niacin/ laropiprant (1g); titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
46009292|NCT00479388|Drug|Comparator: atorvastatin calcium|atorvastatin calcium (20mg to 40mg) for 12 weeks.
46009293|NCT04670939|Procedure|breath exercises|diaphragmatic breathing exercise that used during weaning is the respiratory physiotherapy
45460720|NCT03892135|Other|Interviews with Physicians|Interviews with Physicians
45460721|NCT04881032|Drug|Polysiloxane Gd-Chelates based nanoparticles (AGuIX)|Four intravenous injections of AGuIX will be delivered. Phase I : Three dose levels may be explored 50 mg/kg, 75 mg/kg and 100 mg/ kg. Phase II : recommended dose
45460722|NCT04881032|Radiation|radiotherapy|60 Gy in 6 weeks
45460723|NCT04881032|Drug|Temozolomide|"Concomitant chemotherapy consists of temozolomide (TMZ) at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy.~After a 4 week break after concomitant treatment, patient were then received up to 6 cycles of adjuvant TMZ according to the standard 5-day schedule every 28 days ."
45460724|NCT01260337|Behavioral|Portion controlled diet|Participants learn skills for changing nutritional and lifestyle habits and diabetes management follow a program that includes eating a pre-packaged, portion controlled meal for weight loss in addition to attending the behavior modification groups
46009294|NCT04670276|Procedure|injection of emulsified adipose tissue stromal vascular fraction|Endoscopic injection of 10 cc of autologous microfat into the fistula (through a 6-French catheter), until it was completely filled, and a total of 1-2 cc of tSVFem (through a 22G endoscopic needle) into the submucosa of the 4 quadrants of the fistula borders, to obliterate it completely.
46009295|NCT00479232|Drug|vorinostat|
46009296|NCT00479232|Drug|decitabine|
46009297|NCT04670315|Diagnostic Test|Telematic evaluation of motor function|Validation of the Telematic Spanish Version of the Fugl Meyer Assessment Scale
46009298|NCT04998305|Drug|TJ-68|For two periods (one period = 2 weeks) during the 11-week participation, participants will take 2.5 g of TJ-68 for three times per day before meals. It will be administered by dissolving 2.5 g of TJ-68 powder in 1 oz. of lukewarm water.
46096163|NCT00715780|Drug|biphasic human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46096164|NCT00715780|Drug|insulin NPH|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46096165|NCT00715780|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
45460725|NCT01260337|Other|Diabetes Support and Education|The DSE groups will consist of educational sessions offered for diabetes support and education which will include sessions on diet/nutrition, exercise, foot care and living with diabetes.
45460726|NCT03895177|Diagnostic Test|contrast enhanced computed tomography|pancreatic protocol CT with 80kVp tube voltage and more than 500mA tube current acquire late arterial phase and portal venous phase using volus tracking method
45460727|NCT03891979|Drug|Pembrolizumab|"Pembrolizumab will be given for two doses every 3 weeks starting on day 8 (ie days 8 and 29). Antibiotics will continue throughout the entire four week pre-operative period.~Ciprofloxacin 500mg PO BID days 1-29; Metronidazole 500mg PO TID days 1-29; Pembrolizumab 200mg IV days 8 and 29."
45460728|NCT03891979|Drug|Ciprofloxacin 500mg PO BID days 1-29|Antibiotics will continue throughout the entire four week pre-operative period.
45460729|NCT03891979|Drug|Metronidazole 500mg PO TID days 1-29|Antibiotics will continue throughout the entire four week pre-operative period.
45460730|NCT01257997|Biological|15N-Thymidine, 2H-Water|"Stable isotope 15N-thymidine, infused IV (15mg/hour) for 72 hours (phase 1 pilot).~Stable isotope 2H-water, ingested by mouth once per day for 3 days (phase 1 pilot) or 28 days (phase 2 pilot)."
45460731|NCT01260415|Drug|Panitumumab, Oxaliplatin, 5-FU|"Panitumumab 6 mg / kg, given over 60 minutes~Oxaliplatin 85 mg / m2 combined with leucovorin 400 mg / m2, given over 2 hours OR~Irinotecan 180 mg / m2 , given over 90 minutes, concurrent with leucovorin 400 mg / m2, given over 90 minutes~5FU 400 mg / m2, by bolus infusion~5FU 2400 mg / m2, given over 46 hours"
45460732|NCT02374814|Drug|Rabies vaccine|Compare dose schedule and route of administration
45460733|NCT02374814|Drug|Placebo|Placebo
45460734|NCT03892057|Behavioral|Internet-based Positive Psychological Intervention|"The investigator's culturally-tailored internet-based Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well- being, e.g., mindfulness/meditation. The current 5-week Internet-based intervention will be delivered via a secure website which participants will access at home (or in a public setting with Wi-Fi) using an assigned username and password. The on-line program includes didactic material and home practice with participants logging into the website 3-4 times per week for 15 to 20 minute sessions. In addition to weekly on-line instruction, participants are assigned homework as a means of incorporating skills learned into their day-to-day activities."
45678915|NCT01387516|Behavioral|Relaxation Therapy|The Relaxation Therapy intervention encompasses several techniques, including Progressive Muscle Relaxation and Visualization-Imagination, and meditation to reduce stress; which may lead to substance use.
45460735|NCT05194514|Device|SherpaPak™ Device|The SherpaPak™ Cardiac Transport System has been developed to provide a safe, consistent method for cold ischemic storage of donor hearts for transplantation. This device is FDA approved.
45460736|NCT05194514|Other|Cold Storage|FDA-approved method for organ procurement
45460737|NCT03891511|Device|MRI scann|MRI will be performed in the TMJ of participants affected with TMD
45460738|NCT04874012|Drug|Active comparator Taurine|Participants will receive 3 g taurine, twice a day, as a powder for oral suspension (3 g/packet) for 12 weeks. Participants will be recommended to take the taurine immediately before the breakfast and dinner.
45460739|NCT04874012|Other|Placebo Comparator|Participants will receive the same treatment regimen and intake recommendation, but packets with the same appearance and size from those taurine ones will contain a vehicle
45678916|NCT01387516|Behavioral|Cognitive Behavioral Therapy|The Cognitive-Behavioral Therapy (CBT) Intervention focuses on the interrelationship between thoughts, feelings, and behaviors. It addresses specific deficits, such as improving problem solving skills and developing social supports, and behaviors such as substance abuse and smoking.
45678917|NCT01387516|Behavioral|Self-Help Programming|"The Self-Help Programming intervention combines elements of Nicotine anonymous (NicA) to provide someone who uses nicotine but wants a nicotine-free life, with a community of people that has also experienced nicotine addiction and strives to be nicotine free. It incorporate the 12 Steps and the NicA tools (i.e., meetings, phone list, literature, sponsorship, and service) to facilitate and maintain abstinence from nicotine."
45678918|NCT03812146|Behavioral|PC-TIME|PC-TIME consists of five, 30-minute sessions delivered over 8 weeks. Intervention will be delivered by a behavioral health provider and will consist of brief Prolonged Exposure for PTSD integrated with aspects of the Motivational Interviewing counseling approach.
46009299|NCT04998305|Drug|Placebo|For two periods (one period = 2 weeks) during the 11-week participation, participants will take 2.5 g of placebo for three times per day before meals. It will be administered by dissolving 2.5 g of the placebo powder in 1 oz. of lukewarm water.
45460740|NCT05495815|Drug|6 months of SAT|6 months of oral suppressive antibiotic therapy
45460741|NCT05495815|Drug|12 months of SAT|12 months of oral suppressive antibiotic therapy
45460742|NCT03888625|Procedure|Conventional ILM Peeling|peeling with complete removal of the internal limiting membrane (ILM)
45460743|NCT03888625|Procedure|Inverted ILM Peeling|the inverted ILM peeling technique - the technique of Inverted flap described by Michalewska, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange
45460744|NCT04608344|Drug|Atorvastatin|Administered as single dose tablet orally.
45460745|NCT04608344|Drug|Pravastatin|Administered as single dose tablet orally.
45460746|NCT04608344|Drug|Rosuvastatin|Administered as single dose tablet orally.
45460747|NCT04608344|Drug|Filgotinib|Administered as tablet orally once daily for 11 days.
45460748|NCT01154023|Behavioral|stimulus control therapy, sleep restriction therapy, multi-component treatment (stimulus control therapy, sleep restriction therapy)|Treatment was given weekly for 6 weeks. Sessions 1 - 4 were in a group format. Session 5 & 6 were delivered individually by phone.
45460749|NCT05417984|Device|Restoris MCK|During this study the Restoris MCK will be placed using robotic-assisted surgery. At the time of surgery tantalum markers will be placed in the tibia and femur. With these markers migration of the prothesis can be measured over time using RSA radiographs.
45460750|NCT01153867|Behavioral|Schema Focused Therapy|SFT is a novel treatment approach to chronic, lifelong problems that incorporates cognitive, behavioral, experiential and psychodynamic elements and techniques. In the present study participants will receive up to 75 individual sessions of SFT depending on the individual progress in therapy.
45460751|NCT03895021|Behavioral|Pisando Fuerte|"Pisando Fuerte, a linguistically and culturally appropriate version for Spanish speakers of an evidence-based fall prevention program (Stepping On [SO])."
45460752|NCT03895255|Procedure|Paraaortic lymph node dissection, IMA high ligation, TME, routine splenic flexure mobilization|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta. Nerve-sparing total mesorectal excision is performed. Splenic flexure is mobilized. Side-to-end sigmoido-rectal anastomosis is created.
45460753|NCT03895255|Procedure|Paraaortic lymph node dissection, IMA low ligation, TME, selective splenic flexure mobilization|Nerve-sparing paraaortic lymph node dissection is performed. Then inferior mesenteric artery is skeletonized down to the origin of left colic artery and divided below it. Nerve-sparing total mesorectal excision is performed. Splenic flexure is mobilized only if sigmoid colon is unsuitable for anastomosis or doesn't reach the rectal stump. Then descending-rectal side-to-end anastomosis is created.
45460754|NCT03891433|Drug|Meropenem|Carbapenems group intervention.
45460755|NCT03891433|Drug|Ertapenem 1000 MG|Carbapenems group intervention.
45460756|NCT03891433|Drug|Piperacillin, Tazobactam 4-0.5G Solution for Injection|Piperacillin/Tazobactam group intervention.
46009300|NCT00478881|Drug|Vardenafil HCl (Levitra, BAY38-9456)|vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks
46009301|NCT00478881|Drug|Placebo|vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
46009302|NCT02214108|Other|Nintendo Wii|Tennis, box and bowling on Nintendo Wii, 3 hours per week.
46009303|NCT04571775|Device|Qi-Shield user group|real device Qi-Shield (treatment)
46009304|NCT04571775|Device|Sham Qi-Shield user group|sham device (placebo)
46009305|NCT04670120|Drug|Pyrifazimine (TBI-166)|"The new drug pyrifazimine (previous name: TBI-166) is obtained by retaining the key skeleton of the lead drug clofazimine which can exert its efficacy and modification by introducing moderate polar groups structural. While the drug has strong activity against tuberculosis-sensitive bacteria and drug-resistant bacteria in vivo and in vitro, its pharmacokinetic properties and skin staining side effects have been significantly improved compared with the lead drugs, so that the drug can achieve the goal that reducing fat solubility, accelerating metabolism in the body, reducing skin staining and reducing side effects.~In November 2016, the new anti-drug-resistant tuberculosis drug pyrifazimine and its tablets obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation."
46009306|NCT00556127|Drug|Rituximab|375 mg/m2 on day 1
46096166|NCT00715780|Drug|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46096167|NCT00715780|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46096168|NCT02652884|Drug|phosphate and betamethasone acetate, 2 mL.|single dose of intramuscular depot corticosteroid
45460757|NCT04240028|Other|Data Collection|The NuAge study has been designed to investigate nutrition as a determinant of successful aging in older men and women in Quebec. This study is based on a population-based observational cohort design that initially recruited healthy community-dwellers with age ranged from 67 to 82 years (51.8% women) between January 2004 and April 2005. All participants lived in the areas of Montreal, Laval, and Sherbrooke in the Province of Quebec, Canada. After recruitment, they have been followed for 3 years with one clinical follow-up assessment each year (i.e.; 4 data collection time). A previous analysis performed on the NuAge study database has shown a significant decline of physical and cognitive performances with time (respectively an average of 10% and 2%), participants with lower physical performance showing lower cognitive performance.
45460758|NCT03895333|Other|Audiological profiling and bone mineral densitometry measurement|bone mineral densitometry measurements and hearing test patients, osteoporosis according to whether the hearing test will be analyzed.
45460759|NCT03895411|Drug|sotalol|Oral sotalol 2.5mg/kg/time, per 12h
45460760|NCT03895411|Drug|Propafenone|Oral Propafenone 5mg/kg/time, pre 8h
45460761|NCT03895411|Drug|betaloc|Oral betaloc 0.5mg/kg/time ,pre 12h
46009307|NCT00556127|Drug|Epirubicin|110 mg/m2 on day 3
46009308|NCT00556127|Drug|Cyclophosphamide|1200 mg/m2 on day 3
46009309|NCT00556127|Drug|Vincristine|1.4 mg/m2 (maximum 2 mg) on day 3
46009310|NCT00556127|Drug|Prednisone|40 mg/m2 from day 1 to 5
46096169|NCT02652884|Drug|saline 0.9% NaCl|single dose of intramuscular placebo
46096170|NCT00990301|Drug|Moexipril HCl/ Hydrochlorothiazide 15mg/ 25mg Tablet, Paddock Laboratories, Inc.|test drug
46096171|NCT00990301|Drug|Uniretic® 15mg/25mg Tablets|reference drug
46096172|NCT04460027|Other|Woebot Substance Use Disorder|Woebot Substance Use Disorder is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
46096173|NCT00652964|Device|CPAP|CPAP treatment for patients with congenital central hypoventilation syndrome
45460762|NCT01568138|Device|PliCath HF System|To evaluate the safety and feasibility of the BioVentrix PliCath HF Epicardial Catheter-based Ventricular Reduction (ECVR) System for left ventricular (LV) volume reduction in heart failure (HF). The System utilizes anchors that are implanted into the scarred portion of the heart, rendering the ventricle smaller.
45460763|NCT01154179|Other|Hypocaloric feeding|This intervention group will be prescribed 60% of recommended (by Schofield) requirements.
45460764|NCT01152619|Drug|Placebo|Subcutaneous repeated dose
45460765|NCT01152619|Drug|RO4989991|Subcutaneous repeated dose
45460766|NCT03891589|Behavioral|Nutritional education program|These programs were a process of providing information or knowledge to mother of the children consisting of information on initiation of complementary feeding, variety, and frequency of food, nutrient requirements and diet pattern for children (the amount and types of food), and benefits of Taburia. All this information provided through class-based activities and group discussion by using leaflet and food model conducted by the researchers. Education materials developed based on CFR models from our previous study by applying the LP approach. There was also a demonstration on administering complementary feeding (demo and cooking class) to improve skills of the mother on food from selection, design, handling and preparing, based on requirements of the children. This activity conducted through training once per month for the first four months of the intervention. Components of complementary feeding promoted in this study are based on CFR using LP approach from our previous research.
45599042|NCT05629715|Device|ROSA Knee System|The Zimmer Biomet ROSA Knee System is a commercially available, FDA approved robotic assistant for performing TKA. It uses preoperative x-rays to create a three-dimensional image of the patient's knee anatomy which is used to create a preoperative template of the implants to be used and provides intraoperative guidance for bone cuts during the TKA. The robotic system also assesses the soft tissue envelope around the knee and can assist with the soft tissue balancing of the knee arthroplasty. Alternatively, it can also be used in an imageless mode where bone cuts are performed based on intra-operative mapping using anatomic landmarks.
45678919|NCT03812146|Behavioral|PC-TAU|PC-TAU consists of Brief Advice intervention from their PC medical provider that is built into the electronic medical record as a mandatory response to a positive screen. In addition, patients who score positive on the AUDIT-C or PC-PTSD are offered a referral to the PCMHI provider within the PC clinic. PCMHI in VA consists of licensed, independent providers (typically psychologists or clinical social workers) providing brief assessment and interventions to veterans and consultation to other members of the PC team. PCMHI sessions are typically focused on assessment, psycho-education, and supportive counseling.
45678920|NCT01421134|Drug|Lurasidone|20, 40, 60 mg, flexible dose, once daily PM 6 weeks
45678921|NCT01421134|Drug|Placebo|Placebo
45678922|NCT01894022|Drug|Ambrisentan 5 mg|Round, white, film-coated, immediate-release tablets, containing 5 mg ambrisentan. Subjects will be dosed orally once daily. Subjects may receive 5mg, or 10 mg of ambrisentan OD.
45678923|NCT01615328|Device|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
45678924|NCT01615328|Device|Bonion|The ACDF surgery will be carried out with Bonion after randomization procedure.
46096174|NCT00715858|Drug|doxycycline|capsule, 100 mg, b.i.d., 12 months
46096175|NCT00715858|Drug|rifampin|capsule, 300 mg, od, 12 months
46096176|NCT00715858|Drug|placebo|placebo matched to rifampin; placebo matched to doxycycline
45678925|NCT01387282|Drug|Anamorelin HCl|Anamorelin HCL 100 mg will be orally administered daily at least 1 hour prior to meal
45836884|NCT03520686|Drug|Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab|"The treatment plan in the control arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~Carboplatin (up to 900mg IV)~Nab-paclitaxel (100mg/m² IV) or Paclitaxel (200mg/m² IV)~Pembrolizumab (200mg IV)~Day 8:~Nab-paclitaxel (100mg/m² IV) -if assigned to receive~Day 15:~Nab-paclitaxel (100mg/m² IV) -if assigned to receive~Maintenance:~Day 1, every 3 weeks:~Pembrolizumab (200mg IV)"
46009311|NCT00556127|Drug|Granulocyte-colony-stimulating factor|(G-CSF 5 μg/Kg/day) from day 5 to day 11
46009312|NCT00556127|Drug|Mitoxantrone|8 mg/m2 for 3-day
46009313|NCT00556127|Drug|Cytarabine ARA-C|2 g/m2/12 hours for six doses in 3-hour infusion
46009314|NCT00556127|Drug|Dexamethasone|4 mg/m2/12 hours before ARA-C administration
46009315|NCT00556127|Drug|Carmustine BCNU|300 mg/m2 on day -7
46009316|NCT00556127|Drug|Etoposide|100 mg/m2/12 hours
46009317|NCT00556127|Drug|Melphalan|140 mg/m2 on day -2
46009318|NCT00556127|Radiation|Radiotherapy|Involved Field Radiotherapy (IF-RT)
46009319|NCT00556127|Procedure|PBSC reinfusion|ASCT
46009320|NCT00478647|Biological|GA-GCB (velaglucerase alfa)|15-60 U/kg, every other week via intravenous infusion
46009321|NCT04990934|Behavioral|Semistructured Interview|Patients with breast cancer (Stage I-III) will be interviewed about their experiences of telemedicine.
46009322|NCT04550325|Biological|Kamada Anti-SARS-CoV-2|Anti-SARS-CoV-2 is a preparation of immune gamma globulin manufactured from convalescent plasma of COVID-19 recovered patients, using Kamada's proprietary purification methods
45460767|NCT03891589|Dietary Supplement|Home fortification (Taburia)|Taburia is a multivitamin and mineral fortification to provide sufficient amount of nutrient for optimal growth and development of children aged 6-59 months. Every sachet of Taburia prepared to fulfill minimum nutrient requirements for children aged 6-59 months. Each sachet is one gram in weight and contains vitamin A (417 mcg), B1 (0.5 mg), B2 (0.5 mg), B3 (5.0 mg), B6 (0.5 mg), B12 (1 mcg), D3 (5 mcg), E (6 mg), K (20 mcg), C (30 mcg), folic acid (150 mcg), pantothenic acid (3 mcg), Iodium (50 mcg), Iron (10 mg), Zn (5 mg) and Selenium (20 mcg). One sachet of Taburia given to the subject by adding it to their breakfast and must be finished. The frequency of Taburia consumption per week follows the finding of the LP analysis from the previous study. Taburia intervention complemented by health education related to benefits, administration of Taburia, and its side effects. Compliance will be evaluated directly by the researcher based on empty Taburia sachet and conducted every month.
45460768|NCT01154257|Procedure|Cleaning of teeth with a toothbrush|This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a toothbrush. Cleaning will be twice daily from recruitment until day seven.
46009323|NCT00556205|Drug|Sunitinib|Sunitinib orally once daily
45460769|NCT01154257|Procedure|Cleaning of teeth with a foam swab|This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a foam swab. Cleaning will be twice daily from recruitment until day seven.
45460770|NCT03888313|Other|Pretreatment group consultation|A consultation in group with several patients and one surgeon
45599043|NCT05629715|Device|KneeAlign Computer Assisted Navigation System|The OrthAlign KneeAlign computer assisted navigation system is a commercially available device that uses gyroscopic limb position sensing technology mounted to intramedullary and extramedullary jigs to measure bone resection cuts in TKA that ultimately dictate implant position.
45599044|NCT02298829|Drug|Subjects Previously Treated with AA4500|no treatment to be administered - observational only
45836885|NCT03520686|Drug|Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|"The treatment plan in the control arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)~Pembrolizumab (200mg IV)~Pemetrexed (500mg/m² IV)~Maintenance:~Day 1, every 3 weeks:~Pembrolizumab (200mg IV)"
46009324|NCT00556205|Drug|Bevacizumab|Intravenously every 14 days
46009325|NCT00478608|Drug|Sirolimus (Rapamune®)|(1mg tablets): Initial loading dose of 6mg/day, followed by maintenance dose of 2mg/day, which was adjusted to specified trough level.
46009326|NCT00556244|Procedure|ILM peeling|ILM maculorhexis is initiated using scraper and completed using a 25-gauge Synergetics (St. Louis, MO) forceps.
46009327|NCT04550559|Procedure|Endoscopic ureterolitotripsy|Endoscopic ureterolithotripsy
46009328|NCT00556283|Device|STARR|Stapled Trans-Anal Rectal Resection for the treatment of ODS
46009329|NCT00556283|Behavioral|Biofeedback|electromyographic-based treatment sessions
46009330|NCT00478257|Device|bright white light|Intervention: Bright white light administered for 30 minutes each morning
46009331|NCT00478257|Device|comparator red light treatment|dim red light administered for 30 minutes every morning
46009332|NCT00478140|Biological|trastuzumab|For HER-2/neu positive biopsies, trastuzumab was administered intravenously, once every 3 weeks, at a loading first dose at 8 mg/kg over 90 minutes, and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose.
46009333|NCT00478140|Other|laboratory biomarker analysis|Correlative studies
46009334|NCT04990739|Drug|MTB-9655|"MTB-9655 is an orally available investigational product that is highly potent as it exhibits selectivity as an ACSS2 inhibitor when tested against a panel of related enzymes. MTB-9655 is formulated as a powder blend in a hydroxypropyl methylcellulose (HPMC) capsule and is presented as 25 mg and 100 mg strengths for oral administration.~Patients will receive MTB-9655, by mouth daily in 21-day treatment cycles,either 1 hour before mealtime or 2 hours after mealtime."
46009335|NCT00478023|Drug|Morphine|20 mg IR; 4 - 6 hourly; Total 72 hours
46096177|NCT04003909|Procedure|ultrasound-guided Erector spinae plane block|The patients will be in lateral position. A curvilinear array ultrasound probe will be placed in a transverse orientation at L4 level to identify the tip of the L4 transverse process. Local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle will be inserted inplane to the ultrasound beam in a cranial-to-caudal direction until contact made with the L4 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle will be confirmed by injecting 0.5-1ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total volume of 20ml bupivicaine 0.25% and 20 ml xylocaine 1% will be injected into the ESP on the affected side.
46096178|NCT04003909|Procedure|subarachonoid block|Local anesthesia 2ml of lidocaine 2% will be applied intradermally to the needle entrance point. A 22-G block needle will be inserted, free cerebrospinal fluid flow will be observed and 20mg of hyperbaric bupivacaine 0.5% and 10μg of fentanyl will be injected for 30 seconds.
45460771|NCT03888547|Other|Occupational Therapy Health & Wellness Education|The OT Health and Wellness Program will have four weeks of education and individual integration intervention modules. One of the investigators will lead each of these weekly modules under the direct supervision of the Principal Investigator. Investigators will be trained to provide the standardized educational module for each topic area and for using outcome measures. Each module will have an identified theme and information provided in each group will be education to topic, evidence based literature on intervention strategies, lifestyle, or environmental modifications that improve performance of daily activities that will last approximately 45 minutes. After, group sharing of ideas and individual identification of weekly goals for integration of 1-3 targeted interventions will occur and last approximately 30-45 minutes).
45460772|NCT02527525|Behavioral|Stepped Care|
45460773|NCT03894943|Diagnostic Test|PET/CT scan|Patient receive a PET/CT scan of their cerebrum and lumbar spine prior to surgery, 4-6 weeks after surgery and 6 months after surgery
45460774|NCT03894943|Diagnostic Test|Quantitative Sensory Testing|Patients undergo a battery of quantitative sensory tests prior to surgery, 4-6 weeks after surgery and 6 months after surgery
45836886|NCT01957956|Other|Laboratory Biomarker Analysis|Correlative studies
45836887|NCT01957956|Biological|Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Given ID
45836888|NCT01957956|Drug|Temozolomide|Given PO
45836889|NCT01795092|Other|Dermatology Consultation|A dermatology consultation will be conducted on patients randomized to this group.
46096179|NCT02643680|Device|The novel biocellulose wound dressing|The novel biocellulose dressing will used as a primary dressing at one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
46096180|NCT02643680|Device|Bactigras|Bactigras will used as a primary dressing at another one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
46096181|NCT05361031|Biological|Engensis (VM202)|Intramuscular injections
45836890|NCT00475878|Drug|escitalopram|10mg escitalopram/day for 3 months
46096182|NCT02573194|Dietary Supplement|Breakfasts varying in protein source content on appetite|In this randomized, within-subject study, subjects are asked to consume 4 iso-energetic and iso-volumetric puddings as breakfast (20% of estimated energy requirements) with varying distribution of protein sources. The objective is to identify the protein source and the distribution on suppressing appetite.
46096183|NCT04700033|Device|Somatic IVR (sIVR)|This intervention will consist of an IVR protocol that is focused on somatic interaction that encourages disassociation between pain and visualization and movement of the affected limbs. Subjects in this group will be exposed to an IVR environment that cycles them through a series of stretching and mobility exercises for the affected limbs bilaterally.
46096184|NCT04700033|Device|Distractive IVR (dIVR)|This intervention will consist of an IVR that is focused on distracting the subject from the pain. Subjects in this group will be exposed to a variety of engaging landscape IVR environments, without the ability to visualize their own body.
45836891|NCT00475878|Drug|placebo|placebo capsule/day for 3 months
45836892|NCT01795170|Dietary Supplement|Lysine Restricted Diet|Daily lysine intake will be managed to maintain a plasma lysine level of 50-80 µmol/L (normal range: 52-196 µmol/L). Diet prescriptions will be based on international guidelines for glutaricaciduria type I, another inborn error of lysine catabolism. In order to meet the recommended daily protein intake (DRI) [23,24], the diet may include commercially available lysine-free amino acid formulas approved for use in conditions affecting lysine metabolism, as well as commercially available low-protein products based on the participant's taste.
46009336|NCT00478023|Drug|CG5503 IR|50mg; 4 - 6 hourly; Total 72 hours
46009337|NCT00478023|Drug|CG5503 IR|75mg; 4 -6 hourly; Total 72 hours
46009338|NCT00478023|Drug|CG5503 IR|100mg, 4 - 6 hourly; Total 72 hours
46009339|NCT00478023|Drug|Placebo|4 - 6 hourly; Total 72 hours
45460775|NCT01259323|Biological|REGN668|Dose 1: REGN668 or placebo
45460776|NCT01259323|Biological|REGN668|Dose 2: REGN668 or placebo
45460777|NCT01259323|Biological|REGN668|Dose 3: REGN668 or placebo
45460778|NCT03891277|Drug|Ferrous succinate|"Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd,po during or after breakfast, Lasting for 12 weeks.~placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks."
45460779|NCT03888157|Drug|Liraglutide|Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. The physician's decision to initiate treatment with Victoza® is clearly separate from the opportunity to include the patient in the study.
45460780|NCT03890965|Other|Reflex locomoction therapy|"The intervention of the stimulation of the reflex locomotion is carried out in this study in a sitting position in a conventional chair, an unorthodox posture in the usual treatment of Vojta therapy.~The reflex stimulation is performed by the passive pressure exerted by the weight of the wrist (pisiform) on the rubber sphere. Simultaneously the patient has to exert a slight pressure with the heel towards the ground with his foot. This foot will be the opposite of the wrist that has the sphere under the pisiform.~Alternating each diagonal 4 times, 5 minutes each. Total session 20 minutes, 2 times x day, every day according to degree of affectation."
45460781|NCT03887923|Behavioral|Vestibular Physical Therapy|Balance, Gaze Stabilization, Habituation, and Walking exercises
45460782|NCT03887845|Procedure|Surgery|The respective surgical approach for any gastric and colorectal surgery
45460783|NCT01154413|Behavioral|Intensive education of the doctor/nursing team on the protocol|
45460784|NCT01154491|Drug|Ferric carboxymaltose|"Ferinject®: Ferric carboxymaltose: 2 vials of 10 mL containing each 500 mg iron, diluted in 250 mL normal saline for injection. Study drug to be administered by infusion immediately after preparation.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection."
45460785|NCT01154491|Drug|Erythropoietin|Erythropoetin: 40,000 units subcutaneous (unique dose).
45460786|NCT01154491|Drug|Placebo|"Placebo for ferric carboxymaltose: 250 mL normal saline for intravenous administration.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection."
45460787|NCT01260571|Drug|Benzoyl peroxide and sulfur|topical cream, 5% benzoyl peroxide and 2% sulfur Frequency once to day Duration 24 hours
45460788|NCT03887689|Behavioral|Modified prolonged exposure|Participants will receive three sessions of modified prolonged exposure therapy.
45460789|NCT03894865|Other|procedure1|The students will be asked to bend forward with his knees straight, feet together and hands freely and loosely hanged. if there was scoliosis the rib cage rotated and a hump appeared. Positive test indicated the presence of a rib hump and negative if there was any hump appeared
45460790|NCT03894865|Other|procedure2|Measurement of the angle of trunk rotation (ATR) by using a scoliometer HD smartphone application.
45460791|NCT03894709|Behavioral|family-centered care model|Teaching and training family caregivers to enhancing their skills for providing care for hip-fractured older persons The content of teaching material provided including management of wound, nutritional and balanced diet, rehabilitation exercises, home environment and behavioral problems after a hip surgery
45460792|NCT02527603|Procedure|Boss-Holzach-Matter method|The patient holds both his hands around his knees in a supine position until the dislocated shoulder is reduced
45460793|NCT02527603|Procedure|Spaso method|The physician holds the dislocated arm of the patient in a supine position and proceeds with gentle, soft movements of adduction, flexion and external rotation of the limb in this order until reduction is accomplished.
45460794|NCT02527603|Drug|Anti-Inflammatory Agents, Non-Steroidal|"All patients will be administered a dose of NSAI intra-muscular or orally (Dexketoprofen, Enantyum®) it is part of the normal treatment of these patients to cope with pain."
45460795|NCT01259479|Drug|Satraplatin|Orally, once daily for 5 days repeated every 28 days, dose-escalation
45678926|NCT01387282|Drug|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour prior to meal before the first meal of the day.
45678927|NCT01386970|Drug|zidovudine 300mg and lamivudine 150mg as Combivir|twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group
45678928|NCT01890434|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
45836893|NCT01795170|Drug|Pyridoxine|All participants will be on 15-30 mg/kg/day of pyridoxine therapy up to a maximum of 500mg/day divided in 2-3 doses enterally
45836894|NCT01796886|Other|pupillometry data|
46009340|NCT04993001|Other|Open lung extubation|Before starting emergence from anesthesia, the patient will be transferred to their hospital bed or stretcher and seated at 30 degrees. Secretions from the patients' oropharynx will be suctioned. To prevent the patient from coughing, the anesthetic gas or intravenous agent will be stopped after the transfer and suction procedure are completed. The FiO2 will be maintained at the same level or increased to 50% (minimum FiO2) with a fresh gas flow rate greater than or equal to 10 L.min-1. The ventilation mode will be changed to pressure support. The level of pressure support will be modified by the anesthesiologist to generate the same volumes as with controlled ventilation. The PEEP will be maintained at the same level. The minimum respiratory rate will be reduced by 4 min-1. The inspiratory flow for triggering will be 2 L.min-1.
46009341|NCT04993001|Other|Conventional extubation|Before starting emergence from anesthesia, the patient will be transferred to his hospital bed or stretcher and kept in the supine position. Secretions from the patients' oropharynx will be suctioned. To prevent the patient from coughing, the anesthetic gas or intravenous agent will be stopped after the transfer and suction procedure are completed. The FiO2 will be increased to 100% with a fresh gas flow rate greater than or equal to 10 L.min-1. The ventilator will be stopped with the APL valve open to atmosphere. The patient will be manually ventilated with the reservoir bag until spontaneous ventilation resumes. Then, the patient may be manually assisted if the treating anesthesiologist deems it necessary.
46009342|NCT04995107|Device|Electro Press needle|"Body acupoints will be stimulated by the press needles 0.25mm in diameter and 2mm in length and ear acupoints will be stimulated by the press needles 0.25mm in diameter and 0.9mm in length (all from ZhenXing Brand, Hangzhou Yuanli Medical Appliance Factory, China). After sterilization of the local skin, the needle will be pressed to the acupoints and the tape will be sticked to the skin. Then, the electric device (φ44×15.8mm Type ZXHPAMDZB-02C) together with the electrode patch will be sticked to the surface of skin (on top of the sticky tapes of the press needle) in the area of CV4 and bilateral EX-CA1, and bilateral SP6 respectively. The electric device will be switch to the mode of dense intermittent wave, and the current intensity will be increased gradually till the muscles around jumps slightly.All the needles on the body acupoints will be removed after each session, while those on the auricular acupoints can be kept for as long as 6 hours (removed before going to bed)."
45460796|NCT03894475|Device|AioCare|AioCare is an ultraportable, handheld hardware module that contains the MEMS-based flow sensor and electronics, with a dedicated mobile application that works on iOS and Android operating systems. The unit is used with a disposable mouthpiece fitted to the tip of the flow tube, and a nose clip. AioCare is connected to its dedicated mobile application, which contains software that will show flow-volume graphs and results in real time. The device encompasses all of the widely used spirometry parameters, including: peak expiratory flow (PEF), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, forced expiratory flow at 25% of expiration (FEF25), forced expiratory flow at 50% of expiration (FEF50), forced expiratory flow at 75% of expiration (FEF75), and forced expiratory volume in 6 second (FEV6).
45460797|NCT03894475|Device|Spirometer USB CPFS/D (MGC Diagnostics)|Spirometer USB CPFS/D (MGC Diagnostics) is a diagnostic desktop spirometer used in hospitals/clinics. CPFS/D USB spirometer is compatible with desktop and laptop computers.
45460798|NCT01260727|Biological|PENNVAX-G DNA Vaccine|PENNVAX-G DNA (HIV-1 env A, C, and D, and consensus gag plasmids) vaccine; 4 mg administered IM as a total volume of 1 mL
45460799|NCT01260727|Biological|MVA-CMDR Vaccine|MVA-CMDR live attenuated modified vaccinia ankara vector (HIV-1 CM235 env/CM240 gag/pol); 1 x 10^8 plaque-forming unit (pfu) administered IM by needle and syringe as a volume of 1 mL in either deltoid
46096185|NCT04700033|Device|Control IVR (cIVR)|This intervention will consist of an IVR exposure to a black screen for 20 minutes. No light, images or scenery will be present in the IVR and it will serve as a control condition for the trial.
46096186|NCT02643758|Device|Bifocal soft contact lenses|
45460800|NCT01260727|Biological|Placebo PENNVAX-G Vaccine|Sodium Chloride Injection USP, 0.9%
45460801|NCT01260727|Biological|Placebo MVA-CMDR Vaccine|Sodium Chloride Injection USP, 0.9%
45460802|NCT03887611|Device|Ultrasound diagnosis|Ultrasound diagnosis of lesions with Samsung S-Detect and ECI technology
45460803|NCT03890809|Drug|BMS-986165|Oral administration
45460804|NCT01151683|Dietary Supplement|magnesium|Magnesium chelate, 300mg (2 capsules of 150mg) twice a day, per oral Total of 600mg per day
45460805|NCT01151683|Dietary Supplement|placebo|Two capsules of placebo per oral twice a day
45678929|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous|One 0.65 mL injection subcutaneously on Day 1
45678930|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous|One approximately 0.22 mL injection subcutaneously on Day 1
45678931|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal|Two intradermal injections of approximately 0.15 mL each on Day 1
46096187|NCT04069780|Procedure|Intravitreal injection (4mg/0.1ml)|"Injection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Intravitreal injection (4mg/0.1ml) of triamicinolone acetonide will be done using a 30-31 gauge needle at a distance of 3.5 mm from the limbus in aphakic or pseudophakic patients, and 4 mm in phakic patients. The needle will be then removed with application of cotton tipped applicator over the entry site.~-IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups."
45678932|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal|One intradermal injection of approximately 0.1 mL on Day 1
45678933|NCT01385566|Biological|Full Dose Intradermal Placebo|Two intradermal placebo injections of approximately 0.15 mL each on Day 1
45836895|NCT00477204|Drug|Simvastatin|simvastatin 20 mg daily
45460806|NCT03891121|Device|Occlusal Splint|Occlusal splints are appliances that were usually applied to the upper jaw and covering all teeth and they are made of autopolymerizing acrylic resin. It is produced by using 2 mm thick hard acrylic between the maxilla and mandible as defined by the Okeson.
45460807|NCT03891121|Drug|Botulinum toxin type A|We diluted 100-U freeze-dried BTX-A with 1.0 milliliters of sodium chloride, resulting in a dose of 1.0 U per 0.1 mL. We administered all skin injections by using a 1-inch 30-gauge needle. Patients were placed with the Frankfurt horizontal plane parallel to the floor.
46096188|NCT04069780|Procedure|Superachoroidal injection (4 mg/0.1ml)|"Injection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Suprachoroidal injection (4mg/0.1ml) of triamcinolone acetonide will be done using a custom-made 30-31 gauge needle with a sleeve to prevent further penetration of the needle into the vitreous cavity. Injection will be done at approximately 4 mm from the limbus.~IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups.~UBM assessment will be done 24 hours following injection to confirm targeting of the suprachoroidal space."
45460808|NCT03891199|Procedure|Robotic-Arm Assisted THA|The study will examine the acetabular cup placement of THA patients and compare results for patients who undergo THA with robotic-arm assistance with those who undergo traditional THA.
45460809|NCT01154569|Drug|Azithromycin|500 mg single dose
46096189|NCT04069780|Procedure|Suprachoroidal injection (2mg/0.1ml)|"njection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Suprachoroidal injection (2mg/0.1ml) of triamcinolone acetonide will be done using a custom-made 30-31 gauge needle with a sleeve to prevent further penetration of the needle into the vitreous cavity. Injection will be done at approximately 4 mm from the limbus.~IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups.~UBM assessment will be done 24 hours following injection to confirm targeting of the suprachoroidal space."
46096190|NCT04696445|Drug|Morphine & Oxycodone|Morphine and Oxycodone are used in daily practice as part of standard care. Morphine and Oxycodone will be acquired through the clinical pharmacy of St Antonius and administered according to the standard postoperative pain protocol.
45460810|NCT03891043|Dietary Supplement|Selenium|A 100 micrograms of Selenium was given to be taken twice a day.
45460811|NCT03891043|Other|Placebo|Placebo pill of 100 micrograms of starch was given to be taken twice a day.
45460812|NCT03894397|Device|Electrical stimulation of the BNST|Electrical stimulation of the BNST
45460813|NCT01152775|Other|This group of patients will be exposed to multimedia|This group of patients will be exposed to multimedia
45460814|NCT01152775|Other|No Media|This group will not be exposed to multimedia
45678934|NCT01385566|Biological|Intradermal Placebo|One intradermal placebo injection of approximately 0.1 mL on Day 1
45678935|NCT05365984|Diagnostic Test|end tidal carbon monoxide corrected for ambient carbon monoxide （ETCOc）|The measurement of end tidal carbon monoxide corrected for ambient carbon monoxide （ETCOc）is conducted in the process of risk evaluation.
45678936|NCT05365984|Other|Internet Plus technology|The Internet Plus technology is applied in the process of follow-up management.
45678937|NCT01780545|Drug|OGX-427|"Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle. OGX-427 must be administered prior to docetaxel on day 1 of each cycle.~Following completion of 10 cycles of docetaxel, 600 mg OGX-427 will continue to be administered by IV weekly as maintenance therapy in Arm A participants who do not have disease progression (i.e., stable disease or better). Participants without documented disease progression who have discontinued from study treatment not due to toxicity related to OGX-427 can also continue to receive OGX-427 maintenance as long as they have completed disease assessments following at least 2 cycles of chemotherapy. Maintenance with OGX-427 will continue until disease progression or unacceptable toxicity."
45678938|NCT01780545|Drug|Docetaxel|"For Arm A Only: Docetaxel should be administered immediately following the completion of the OGX-427 infusion.~For Both Arms: Docetaxel (75 mg/M2) will be administered IV on Day 1 of each 21 day cycle for a maximum of 10 cycles."
45678939|NCT01780389|Drug|Open-label flexibly dosed milnacipran|
45836896|NCT00477204|Drug|Ezetimibe/Simvastatin|Ezetimibe (10mg)/Simvastatin (20mg)
45836897|NCT00528450|Drug|arsenic trioxide|
45460815|NCT03890341|Drug|Drospirenone/Ethinylestradiol|A single oral dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets will be administered on Days 1, 13 and 19.
45836898|NCT00528450|Drug|idarubicin|
45836899|NCT00528450|Drug|tretinoin|
45836900|NCT00478218|Drug|cyclophosphamide|300 mg/m2 administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles) OR 300 mg administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles)
45836901|NCT00478218|Drug|dexamethasone|40 mg administrated by PO (with food)on Days 1, 8, 15 & 22
45460816|NCT03890341|Drug|Midazolam|Midazolam 2 mg will be administered orally on Days 1, 13 and 19.
45460817|NCT03890341|Drug|JNJ-64530440|A single oral dose of JNJ-64530440 2,000 mg will be administered on Day 6 and once daily on Days 13 to 22.
45460818|NCT03890653|Behavioral|Performance-Based Financing|Incentive-based payments
45460819|NCT03890653|Behavioral|Decentralized Facility Financing|Financing not linked to service delivery.
45460820|NCT03894241|Behavioral|physical activity|"Participants will assist to the three different sessions at the same weekday (e.g., Monday) and at the same daytime to avoid differences in preceding school activities or circadian rhythms. Participants will undergo a Sedentary condition (SC), sitting and watching a documentary on TV as has been used previously, and two different PA protocols consisting in Moderate-Intensity Continuous Training (MICT), i.e., continuous outdoor walking, and Cooperative High-Intensity Interval Training (C-HIIT), composed of a circuit training with a partner (physical education teacher)"
45460821|NCT01260805|Drug|Reference Drug|Femiane® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
45460822|NCT01260805|Drug|Test Drug|Harmonet® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
45460823|NCT01259557|Drug|Botulinum Toxin Type A|2 times, Intra-muscular injection, Maximum dosage total 60U
45460824|NCT01152853|Drug|PF00299804|PF-00299804 will be given orally once daily at 45 mg daily. Patients will take study drug continuously, with cycles of 28 days.
45836902|NCT00478218|Drug|lenalidomide|25 mg administrated by PO (with food)on Days 1-21
46009343|NCT00477750|Drug|lenalidomide|"Phase I - dose escalating: 5mg level -1, 10mg level 0, 10mg level 1, 15mg level 2, 20mg level 3, 25mg level 4, orally days 1-21 every 28 days until progression~Phase II - 10 mg orally days 1-21 every 28 days until progression"
46096191|NCT02643524|Behavioral|Nutrition and Exercise Counseling|Patients are prescribed CAM boot and provided nutritional and upper body exercise counseling at the time the CAM boot is dispensed. Patients will be given a diary to complete their daily meal intake (optional), seated upper body physical exercise guidelines and asked to perform them three days per week and each exercise three times per session if able. They will be asked to record number of hours CAM boot is worn daily in the Patient Diary, if one is utilized. Albumin lab test will be drawn and their height and weight measured.
46096192|NCT02643524|Behavioral|Control|Patients are prescribed CAM boot. No nutritional or exercise guidelines will be provided. Patients will be given a diary to complete their daily meal intake and physician exercise (if any) and number of hours CAM boot is worn daily. Albumin lab test will be drawn and their height and weight measured.
46096193|NCT00715936|Behavioral|Control|
46096194|NCT00715936|Behavioral|ECD|
46096195|NCT00715936|Behavioral|Enhanced Nutrition|
45460825|NCT03894085|Drug|Paroxetine|Paroxetine treatment for 4 weeks usage:20-80mg Qd
45460826|NCT03890575|Procedure|Airway stent implantation|The airway stents modified with 3D printing were implanted to treat malignant stricture involving carina and bronchi distal to carina.
45460827|NCT05075707|Other|Electromagnetic therapy.|Electromagnetic therapy will be applied for 20 min/ session for (3 days/ week for two months) to the group intervention.
45460828|NCT05075707|Other|Low level laser therapy (LLLT)|Low level laser therapy (LLLT) will be applied for 20 min/session laser scanner for three days each week for two months to the group intervention.
45599045|NCT02350179|Drug|Tranexamic Acid|"This will be a prospective, randomized controlled trial that will be carried at Obstetrics and Gynecology Department, Ain Shams Maternity Hospital.~The study will include 100 pregnant women with singleton fetus 38 or more weeks gestation who will be divided in to two groups.~Study group will include 50 women and control group will include 50 women. Women assigned to the study group will receive 1 gr of TXA injection (Kapron, AMOUN Pharmaceutical co.) given slowly I.V over 10 minutes before the operation.~The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study."
45836903|NCT00479154|Drug|Botulinum Toxin A|Maximum dose of 90 units/leg was injected.
45836904|NCT04270656|Procedure|Insulin pump therapy|5-day hospitalization in case of randomization in the insulin pump group (insulin pump establishing in according to the recommendations of the HAS)
46009344|NCT00477750|Drug|melphalan|"Phase I - dose escalating: 5mg/m^2 dose level -1, 5 mg/m^2 dose level 0, 8 mg/m^2 dose level 1 - 4, daily x 4 orally days every 28 days until progression~Phase II - 5mg/m^2 orally days 1-4 every 28 days until progression"
46009345|NCT00477750|Drug|prednisone|60mg/m^2, orally days 1-4 every 28 days until progression
46009346|NCT04670003|Other|users|Data of users of the web-application
46009347|NCT00477672|Drug|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, 6 weeks
46009348|NCT00477672|Drug|Pimavanserin tartrate (ACP-103)|40 mg, tablet, once daily by mouth, 6 weeks
46009349|NCT00477672|Drug|Placebo|tablet, once daily by mouth, 6 weeks
46009350|NCT04549935|Drug|Dextenza|Dextenza 0.4mg
45460829|NCT03890263|Behavioral|Chronic Pain Self-Management Support|"Family physicians and nurse practitioners will participate in an academic detailing session with a pharmacist that focuses on safe, evidence-based opioid deprescribing. The pharmacist will provide pre-visit recommendations for each visit with a person on high doses of opioids. The pharmacist and healthcare providers will develop a patient centered, opioid taper schedule, with follow-up at 2 to 4 week intervals to assess for efficacy and safety.~The self-management intervention will be Chronic Pain Self-management Support with Pain Science Education and Exercise (COMMENCE), which consists of 2 visits per week over 6 weeks. One visit per week is 1.5 hours in a group format. with education about self-management and pain science as well as cognitive behavioural principles. The 2nd visit each week is 30 minutes in a one-to-one format and is individually tailored to support implementation of self-management plans and development of an exercise program."
46009351|NCT04549935|Drug|Topical Prednisolone|Standard of care topical drop treatment
45460830|NCT01155349|Behavioral|InSight|A cognitive intervention designed to enhance speed of visual processing.
45460831|NCT01155349|Other|No contact-control group|No contact-control group.
45460832|NCT01152931|Drug|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at Artesunate 100mg stat, 50mg 8hrs later and 50mg bd x 3days
45460833|NCT01152931|Drug|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisinin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at 100mg stat, 5omg 8hrs later and 50mg 12hrly for 3 days
45460834|NCT01152931|Drug|Lumefantrine + Artemether|Lumefantrine and artemether combination will be administered orally at a dose of 120/20mg daily for 3days
45460835|NCT01152931|Dietary Supplement|Artesunate + vitamin A|Artesunate will be administered orally at a dose of 100mg stat then 50 mg 8hrs later and 50mg 12hrly for 3days. vitamin A will be administered orally at a dose of 2000IU daily for 3 days
45678940|NCT04573569|Behavioral|Behavioral testing|Patients recruited for this study have already undergone surgical implantation of invasive electrodes for purpose of localizing and characterizing electrographic seizures as part of the second phase of surgical epilepsy evaluation. Patients who consent and complete enrollment will then be asked to complete cognitive and behavioral tasks on a portable computer or tablet PC while the invasive electrodes remain implanted. Tasks typically require the patient to think or act and then respond by interacting minimally with the portable computer. These tasks are performed at the will of each patient during their stay in the intensive care unit while surgical electrodes remain.
45460836|NCT01152931|Dietary Supplement|Artesunate + vitamin E|Artesunate will be administered orally at 100mg stat, then 50mg 8hrs after and 50mg 12hrly for 3 days. Vitamin E will be administered orally at 100mg dly for 3 days.
45460837|NCT01152931|Dietary Supplement|Artesunate + Zinc|Artesunate will be administered orally at a dose of 100mg stat then 50mg 8hrs after and 50mg 12mg 12hrly for 3 days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days
45460838|NCT01152931|Dietary Supplement|Artesunate + selenium|Artesunate will be administered orally at 100mg stat and 8hrs later 50mg. then 50mg 12hrly for 3 days. selenium will be administered orally at a dose of 100ug dly for 4 days
45678941|NCT01778985|Drug|Premarin|
45836905|NCT04270656|Procedure|Multi-injection treatment ( MDI ).|Corresponds to an outpatient visit if the patient is randomized into the multi-injection group
46009352|NCT00477633|Drug|Norethindrone/ethinyl estradiol|1 tablet per day
46009353|NCT04999787|Drug|HSK21542|HSK21542-0.3 μg/kg，HSK21542-0.6 μg/kg
45460839|NCT01152931|Dietary Supplement|Amodiaquine + vitamin A|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Vitamin A will be administered orally dly at a dose of 2000IU for 4 days
45460840|NCT01152931|Dietary Supplement|Amodiaquine + Vitamin E|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. vitamin E will be administered orally at a dose 100mg daily for 4 days
45460841|NCT01152931|Dietary Supplement|Amodiaquine + Zinc|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days.
45460842|NCT01152931|Dietary Supplement|Amodiaquine + Selenium|Amodiaquine will be administered orally at a dose of 10mg/kg daily for 3days. Selenium will be administered orally at a dose of 100ug daily for 4 days if > 1year. 50ug daily for 4 days if < 1 year.
45460843|NCT01152931|Dietary Supplement|Artesunate + vitamin A + vitamin E|Tab Artesunate 50mg orally daily for 4 days. Vitamin A, 5000IU orally daily for 4days if < 1 year. 10,000 IU orally daily for 4 days if > 1 year.
45460844|NCT01152931|Dietary Supplement|Artesunate + Vitamin A + Zinc|Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if < 1 year. 10,000IU daily for 4 days if > 1 year. All administered orally.
46009354|NCT04999787|Drug|Placebo|Placebo
46009355|NCT04996472|Behavioral|Sensitivity to phonological rules: Adults|Assess whether adults are sensitive to different phonological patterns that are predicted to align with development of morphosyntax or the lexicon.
46096196|NCT02749877|Behavioral|Working Memory Training|(Training Details already described above)
45460845|NCT01152931|Dietary Supplement|Artesunate + Vitamin A + Selenium|Tab Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if < 1 year. 10,000IU orally daily for 4 days if > 1 year.
45460846|NCT01152931|Dietary Supplement|Artesunate + Vitamin E + Selenium|Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if > 1 year. 50 ug orally daily for 4 days if < 1 year.
45460847|NCT01152931|Dietary Supplement|Artesunate + Vitamin E + Zinc|Tab Artesunate administered orally at 50 mg daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab Zinc 50 mg orally daily for 4 days if < 1 year. 25 mg orally daily for 4 days if > 1 year.
46009356|NCT04996472|Behavioral|Sensitivity to semantic category cues: Adults|Assess whether adults show improved learning of OR or family resemblance rules when a semantic category cue is used.
45460848|NCT01259635|Device|Biofeedback auditory stimulation|Whenever freezing episodes occures, a metronom sound will be heard.
45460849|NCT01261039|Radiation|UV radiation|Subjects in both groups will be exposed to light in a solar bed for approximately 10 minutes (depending on Fitzpatrick skin type test) on the first day, but only one of the solar beds wields ultraviolet rays. The other has a filter, which filters out the ultraviolet rays.
46009357|NCT04550091|Device|Detection of ascites using CT|Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites
45678942|NCT01778985|Other|Placebo|
45836906|NCT00422448|Genetic|To test the frequency of BRAF and NRAS mutations among nevi|Benign nevi excised for the study purpose where genetically analyzed for the presence/absence of BRAF and NRAS mutations
46009358|NCT04992767|Behavioral|Sunnyside|The Sunnyside intervention is an online intervention(an interactive website with didactic material and interactive tools) targeting skills to manage mood during and after pregnancy. The Sunnyside intervention will consist of 6 weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. Each lesson takes approximately 10 minutes to complete.
46009359|NCT04992767|Behavioral|SunnysideFlex|SunnysideFlex consists of 6 weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. SunnysideFlex has adapted the original Sunnyside intervention with revised, trauma-focused content that covers the impact of PTSD symptoms on the perinatal period and daily functioning, more broadly
46009360|NCT04992416|Procedure|immediate implant placement with ATBG and SMV|immediate implant placement using ATBG as a graft material, with SMV
46096197|NCT02749877|Behavioral|Physical Training|(Training Details already described above)
45460850|NCT01261117|Drug|oral ibuprofen|oral or iv ibuprofen in 10, 5 and 5 mg/kg/day with 24 hr intervals
46096198|NCT05360953|Drug|Clonidine|All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 0.375 clonidine. Using capsules of 0,075 mg clonidine.
46009361|NCT04992416|Procedure|immediate implant placement with ATBG|immediate implant placement using ATBG as a graft material without SMV
46009362|NCT04669847|Other|Trunk-oriented exercise program|The trunk-oriented exercise program was performed by a physiotherapist two days of the week for 8 weeks.Trunk-oriented exercises were specially adapted to the patient based on the patient's functional status and active participation in the exercises.
46096199|NCT05360953|Drug|Doxazosin|"All patients enrolled establish their individually tolerable dose by dose. Dosage up to a maximum of 10 mg doxazosin. Using capsules of 2 mg doxazosin.~Titration."
46009363|NCT04669847|Other|Conventional exercise program|Conventional exercise program was performed daily for 8 weeks, twice a day, on average 45 minutes, each exercise 5-10 repetitions. The program formed stretching exercises, and active or active-assisted strength exercises (upper extremity, lower extremity, abdominal muscles, back muscles).
46009364|NCT04541901|Other|Massage|12 minutes of effleurage and petrissage on the upper limbs
46009365|NCT04541901|Other|Cold water immersion|12 minutes of cold water immersion at the shoulder level with water temperature between 11 to 15°C
46009366|NCT04669730|Other|usual care|Routine care
46009367|NCT04669730|Behavioral|Walk|Walk 30mins
46096200|NCT05360953|Drug|Placebo|All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 5 capsules. Using capsules of placebo.
45460851|NCT03889717|Dietary Supplement|vitamin D|vitamin d drops will be given daily to the 2 groups of neonates ( 1st group will be given 400 iu /day and 2nd group will be given 1000 iu per day ) when they reach 100 cc per kg enteral feeding .. until they reach 40 weeks gestational age
45460852|NCT01262053|Other|Passive Intervention|When a user is about to place orders on a patient, a pop up alert will show the user the name, age, sex, room number and MR# of the patient who is currently activated. The point of the alert is to display identification information about the patient as a double check for the provider to make sure he is on the correct patient. This alert will only occur once at the onset of each order session (i.e. the provider will not be alerted for every single order, but if the provider leaves the order pad and then returns, the alert will reoccur).
45599046|NCT02350179|Drug|Glucose|The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
45678943|NCT01778751|Behavioral|Home Telehealth with Behavioral Education Component|The primary effectiveness outcome for this study will be hemoglobin A1c. Secondary effectiveness outcomes will include measures of diabetes self-care, self-reported medication adherence, and depressive symptoms.
45678944|NCT01865084|Drug|Tadalafil|Administered orally
45678945|NCT01865084|Drug|Placebo|
45678946|NCT01778127|Behavioral|Activity Monitor|Measurement of physical activity.
45836907|NCT00424554|Drug|temozolomide|"Temozolomide 75 mg/m^2 daily for 14 days prior to surgery.~As standard of care, it could also be given at the same dose for up to 28 days after surgery, per investigator discretion."
46096201|NCT04167020|Device|High definition surface electromyography (HD-sEMG)|HD-sEMG data will be collected by Mobita 32® (TMSi) device
46096202|NCT02750189|Other|Direct cost|Money spent to treat COPD in medical institute based on HIRA
46096203|NCT02750189|Other|Indirect cost|extra-expanses excluding hospital fees
46096204|NCT00719524|Drug|OMBRABULIN (AVE8062)|Dose escalation study with combination chemotherapy
46096205|NCT02647424|Drug|Letrozole|Letrozole 2.5 mg daily from Day 2 to 6
46096206|NCT02647424|Drug|Clomiphene|After one month of washout period, clomiphene 50 mg daily from day 2 to day 6 given
46009368|NCT04669730|Behavioral|Baduanjin|Baduanjin exercise is moderate in intensity and short in duration (a set of Baduanjin takes about 12 minutes). Baduanjin consists of the sitting and standing practicing form. The sitting Baduanjin exercise conforms to the aspects of low-intensity and long-term aerobic activity, which is suitable for the rehabilitation training of patients who are in stable condition during hospitalization. The standing Baduanjin is more suitable for patients with sequential rehabilitation after discharge and can be adjusted based on the patient's condition
45460853|NCT01262053|Other|Active Intervention|"The user will be required to enter the initials, age and sex of the activated patient prior to placing any orders. For example, for a patient named Donald Duck who is 76 years old and male, the user will be required to type dd76m to unlock the order pad. This step will NOT be required for every order, but WILL be required every time the user enters the order pad (i.e. if a user leaves the order pad and then returns, the system will require the initials, age and sex to be re-entered as above). This will be a forcing function."
45460854|NCT01262053|Other|Control|Parallel control with no intervention
45460855|NCT03889873|Behavioral|Narrative Writing|An writing task in which participants are given a description of a possible future self (that varies 3 factors: topic; drinking vs. smartphone; perspective: 1st vs. 3rd-person; and social network: specifically asked to be included vs. not specifically asked to be included). Participants are asked to imagine that future self vividly and to write about the thoughts and feeling describe themselves and their experiences, the characteristics they hope or wish they will ideally possess, the characteristics that they would need to have and the roles they will take on or things they will be doing. Participants are given 20 minutes to think and write. They will write and think about the same future on each of three lab-sessions (which occur at 1-week intervals).
45599047|NCT02843945|Device|Directional Brachytherapy Source Implant|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiaiton source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
45599048|NCT03515395|Behavioral|Instruction to a computer game and motivation to use it|Patients who are willing to use the computer game and who have given written informed consent shall have three instruction sessions by a physiotherapist instructor. They will then asked to use the platform at least 3 times per week at their own discretion. The platform will be installed in the patient room, alternatively in a defined training room. The patient will be free to choose the time and duration of the gaming. This allows the patients to select times that do not interfere with their usual therapy schedule or visits (e.g. evening or weekends). Prior to discharge compliance with the platform will be monitored by analyzing the gaming data of each patient.
45678947|NCT01778127|Behavioral|Interactive Website|Zamzee is a meter that measures activity and a website that makes moving fun. Parents of participants can set activity goals. Activity is uploaded to the website where participants track progress and earn rewards by increasing their level of activity. Participants can view leaderboards and check how other participants are doing.
45678948|NCT01778127|Behavioral|Educational Materials|All participants will receive educational handouts about physical activity. Participants will receive the educational handouts again via mail three and five months into the study to reinforce the importance of physical activity and maintain compliance.
45678949|NCT01892540|Diagnostic Test|positron emission tomography/computed tomography|Undergo PET/CT
45678950|NCT01892540|Diagnostic Test|PET/MRI|Undergo PET/MRI positron emission tomography/magnetic resonance imaging hybrid imaging
45678951|NCT01892540|Device|Position Device|
45678952|NCT01399372|Biological|Rituximab|One 28-day cycle = 500 mg/m^2 intravenously on day 1 and day 5.
45678953|NCT01399372|Drug|Cytarabine|One 28-day cycle = 3 g/m^2 intravenously on day 1 and day 2.
46009369|NCT04669730|Behavioral|Baduanjin plus walk|Walk 30mins then Baduanjin 12mins per day, 5 times per week.
45599049|NCT03146013|Diagnostic Test|MP Diagnostics HTLV Blot 2.4|HTLV I/II Confirmation and Differentiation
45678954|NCT01399372|Drug|Methotrexate|One 28-day cycle = 3.5 g/m^2 intravenously (standard hydration/leucovorin support) on day 2.
45678955|NCT01399372|Drug|Procarbazine|One 28-day cycle = 100 mg/m^2 orally on days 2-8.
45678956|NCT01399372|Drug|Vincristine|One 28-day cycle = 1.4 mg/m^2 intravenously, dose capped at 2.4mg, on day 2 and day 16.
45836908|NCT02117310|Drug|indocyanine green|ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery: during nasoseptal flap harvest and after final positioning of the nasoseptal flap to ensure its viability before ending the case.
45836909|NCT00425802|Biological|anti-thymocyte globulin|
45836910|NCT00425802|Biological|filgrastim|
45836911|NCT00425802|Biological|graft-versus-tumor induction therapy|
45836912|NCT00425802|Biological|rituximab|
45836913|NCT00425802|Drug|cyclophosphamide|
45836914|NCT00425802|Drug|cyclosporine|
45836915|NCT00425802|Drug|fludarabine phosphate|
46009370|NCT04541862|Other|Intensive care|intensive care for critically ill patients in the intensive care units
46096207|NCT02574754|Drug|warfarin|warfarin 10 mg PO x 1
46096208|NCT02647502|Other|Diet|Diet, standardized to the 50th percentile for macronutrients, will be provided at varied calorie levels as described.
46096209|NCT00719602|Drug|Lamivudine|Taken orally twice daily
45460856|NCT03886129|Diagnostic Test|Transcranial Doppler Ultrasound (TCD)|Participants will undergo an assessment of brain blood flow using TCD, with two small ultrasound probes held in place on the temples with a customised headframe. During the assessment, heart rate, breathing and blood pressure will also be monitored using a 3 lead ECG, nasal capnography and Finometer® respectively. The assessment will comprise three recordings. Firstly, participants will sit quietly for 5 minutes. Next, they will be asked to sit quietly for one minute before standing and remaining standing for 5 minutes. Lastly, they will be asked to stand and then complete a squat-stand manoeuvre in time with a computer sequence. A tilt sensor attached to the thigh will measure the efficiency and angle of the squatting motion. The squat-stand manoeuvre will consist of 15 squats and participants will be informed that they should try and complete all 15 squats if possible.
45460857|NCT03886207|Other|ginger powder footbath|38-40° C warm water footbath with an additive of dried ginger powder reaching up to mid-calf level, as practiced in anthroposophic medicine
45460858|NCT03886207|Other|warm water only footbath|38-40° C warm water footbath without any additive reaching up to mid-calf level
45460859|NCT03885895|Drug|Tranexamic Acid Injectable Product|Ampoules used for intradermal injection
45460860|NCT03885895|Device|Q switched KTP (532nm)|LASER
45460861|NCT01154647|Drug|citalopram|intravenous
45460862|NCT01154647|Drug|1 ml 0.9 % NaCl|intravenous
45460863|NCT03886051|Procedure|Connective Tissue Graft before Orthodontic treatment|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage will be done using sub - epithelial connective tissue graft. Orthodontic treatment will be 3 months following the grafting procedure.
46096210|NCT00719602|Drug|Lopinavir/Ritonavir|Taken orally twice daily
45460864|NCT03886051|Procedure|Orthodontic treatment only|Scaling and root planing will be performed and after resolution of periodontal inflammation, orthodontic treatment will be initiated.
46096211|NCT00719602|Drug|Nevirapine|Taken orally twice daily
45460865|NCT01153165|Drug|Citalopram|Participants will be commenced on Citalopram 20mgs daily. At week 4 participants will be assessed for response to treatment . If no response, dose of Citalopram will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
45460866|NCT01153165|Drug|Placebo|Participants in the control group will receive a matched placebo. At week 4 participants will be assessed for response to treatment. If no response, dose of placebo will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
45460867|NCT01155505|Drug|Lenalidomide (CC-5013)|CC-5013 given PO daily on D1-D14 every 21 days and Paclitaxel administered IV over 1 hour on d1 and 8 every 21 days until tumor progression or unacceptable toxicity
45460868|NCT03890185|Combination Product|Chemo + Low dose RT|Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1, Cisplatin 75mg/m2 IV D1.Radiathion therapy (LDFRT) using 50 cGy of radiation per fraction BID on the day of chemotherapy and the day after during induction i.e. 50 cGy x 4 times per cycle given for total of 2 cycles every 21 days.
45460869|NCT03890185|Drug|Chemo alone|Chemo alone: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1 and Cisplatin (CDDP) 75mg/m2 IV D1 given for 2 cycles every 21 days.
45460870|NCT03885973|Drug|Lactobacillus plantarum|Fermented milk containing probiotic Lactobacillus plantarum for three weeks
45460871|NCT03885973|Drug|Placebo|Fermented milk containing placebo for three weeks
45460872|NCT01154725|Behavioral|Patient education and rehabilitation|Patients in the experimental group will receive specialized and optimized care by stoma care nurses. This includes one-on-one guiding during the hospitalization, guidance by telephone after discharge and participation in patient education 3 times after discharge.
45460873|NCT01154725|Behavioral|habitual patient education|habitual patient education
46096212|NCT00719602|Drug|Zidovudine|Taken orally twice daily
45460874|NCT01153243|Drug|Ergocalciferol|"Active Comparator: Ergocalciferol~The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)"
45460875|NCT01153243|Drug|Placebo pill|The investigators will give control group 12 weeks of 1 placebo pill every week.
45460876|NCT01259791|Drug|Individual-specific statin causing myopathy|Individual-specific statin causing myopathy vs. placebo
45460877|NCT01259791|Drug|Placebo|Placebo
45460878|NCT03887065|Drug|JM-4|Novel small human peptide derived from erythropoietin
45460879|NCT03886987|Device|Blue Non Sterile Powder Free Nitrile Examination Gloves|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
45599050|NCT04464889|Drug|MDG1021 dose 1|3 patients to receive dose1: target dose of 0.3x10^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
45599051|NCT04464889|Drug|MDG1021 dose 2|3 patients to receive dose 2: target dose of 1x10^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
45678957|NCT01399372|Radiation|low-dose whole-brain radiation therapy|Total dose of 2340 cGy administered as 13 daily fractions of 180 cGy over 3 weeks. Participants with progressive disease on magnetic resonance imaging (MRI) do not receive WBRT.
45678958|NCT01385098|Dietary Supplement|Vitamin D3 and Calcium|1500 mg of calcium citrate plus 1000 IU of vitamin D3 and 1000 IU of vitamin D3 bariatric supplements per day
45678959|NCT01398514|Drug|Escitalopram|Escitalopram 10mg/day or matched pill placebo
45836916|NCT00425802|Drug|mycophenolate mofetil|
45836917|NCT00425802|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
45836918|NCT00425802|Radiation|total-body irradiation|
45836919|NCT00530634|Drug|cisplatin|
45836920|NCT00530634|Drug|gemcitabine hydrochloride|
45836921|NCT00530634|Genetic|gene expression analysis|
45836922|NCT00530634|Genetic|reverse transcriptase-polymerase chain reaction|
45836923|NCT00530634|Other|immunohistochemistry staining method|
46096213|NCT02652650|Drug|Ethinylestradiol|Participants will receive 35 microgram (mcg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
46096214|NCT02652650|Drug|Norethindrone|Participants will receive 1 milligram (mg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
46009371|NCT04992338|Device|Mobile app|The CarpeDiem application is a mobile application, designed in collaboration with the Health and Nutrition Technology Unit (UTNS, Eurecat) and the translational research group on respiratory medicine of the Institut de Recerca Biomèdica de Lleida. The application is available for devices with Android as the operative system and its advanced interface allows the user to monitor their physical activity, sleep and diet and motivate them to meet personalized goals through gamification. To do this, the user must answer the questionnaires that they will find on the main page of the application with a predetermined frequency, as well as perform missions that will help them acquire healthier habits. In addition, the user will receive motivational messages and recommendations through notifications that will help and guide them to achieve their missions and achieve their goals, and as a result of changing habits.
46009372|NCT04541823|Drug|Desﬂurane|Investigators administrated desflurane with target of BIS 40-60 during the maintenance of anesthesia
46009373|NCT04541823|Drug|Propofol|Investigators administrated propofol with target of BIS 40-60 during the maintenance of anesthesia
46009374|NCT04996043|Dietary Supplement|Collagen Peptide Drink|Testing product
46009375|NCT04996043|Dietary Supplement|Placebo drink|Blank
45678960|NCT01398358|Behavioral|Parents of Preschoolers Series|"The POPS-Parent intervention consists of eight 60-90 minute lessons about preventing childhood obesity followed by four 10-minute reinforcing telephone contacts. Each lesson includes opportunities for parents to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques, with an emphasis on building knowledge and self-efficacy.~The POPS-Child Intervention uses children's stories with embedded healthy nutrition themes. Five lessons (6 books) are delivered over 12 weeks. Activities include classroom cooking experiences, games/activities associated with the story's nutrition themes, and goal setting. Family Links and Parent Pages are sent home to reinforce content from school to home."
45678961|NCT01398358|Behavioral|Incredible Years Series|"The Parent component (BASIC) is a group-based program (12-14 weeks, 2 hours/week) focused on enhancing parenting skills such as using effective praise, incentives, and limit-setting, and handling misbehavior. Parents complete homework activities that will be reviewed in group sessions and receive follow-up reinforcement phone calls.~For the Child component (Dinosaur School), 60, 15-20 minute lessons are delivered during Circle Time in Head Start classrooms followed by small group activities. The curriculum focuses on teaching self-regulation skills, problem-solving strategies, and prosocial behaviors.~Teachers are trained in classroom management strategies."
45678962|NCT03025282|Drug|CD10367 3% Solution - Non-desquamated zone|Once daily application for 3 weeks
45678963|NCT03025282|Drug|CD10367 1% Solution - Non-desquamated zone|Once daily application for 3 weeks
45678964|NCT03025282|Drug|CD10367 solution placebo - Non-desquamated zone|Once daily application for 3 weeks
45678965|NCT03025282|Drug|Betneval ointment - Non-desquamated zone|Once daily application for 3 weeks
45678966|NCT03025282|Drug|CD10367 3% Solution - Desquamated zone|Once daily application for 3 weeks
45678967|NCT03025282|Drug|CD10367 solution placebo - Desquamated zone|Once daily application for 3 weeks
45678968|NCT01778049|Drug|BI 10773|Empagliflozin active
45460880|NCT03433482|Biological|MenACWY liquid|At visit 1 (day 1), each subject will receive a single dose of the investigational MenACWY liquid vaccine (GSK3536820A) aged for approximately 24 months in Phase 1 of the study (subjects randomized to study arm ACWY_Liq24) or vaccine aged for 30 months in Phase 2 of the study (subjects randomized to study arm ACWY_Liq30), administered by intramuscular injection in the deltoid of the non-dominant arm.
45460881|NCT03433482|Biological|MenACWY|At visit 1 (day 1), each subject will receive a single dose of the MenACWY vaccine in the Phase1 of the study (subjects randomized to study arm ACWY_1) or in phase 2 of the study (subjects randomized to study arm ACWY_2), administered by intramuscular injection in the deltoid of the non-dominant arm.
45460882|NCT03889483|Device|NeuroCatch™ Platform|The NeuroCatch™ Platform consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
45460883|NCT03713970|Procedure|celtra duo press|celtra duo press ingot
45460884|NCT03713970|Procedure|IPS e.max press|IPS e.max press ingot
45460885|NCT03432858|Drug|Vancomycin|Vancomycin - 1-gram dosing
45678969|NCT01778049|Drug|BI 10773 Placebo|Empagliflozin placebo
45678970|NCT01778049|Drug|BI 10773 / BI 1356|Empagliflozin / Linagliptin 25/5 mg Dose FDC active
45678971|NCT01778049|Drug|BI 10773|Empagliflozin active
45678972|NCT01778049|Drug|BI 10773 / BI 1356|Empagliflozin / Linagliptin 10/5 mg Dose FDC active
45460886|NCT03432858|Drug|Cefazolin|2-gram dosing for patients <120 kg 3-gram dosing for patients 120 kg or greater
45678973|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
45460887|NCT03432858|Drug|Saline Solution|Placebo
45460888|NCT01157143|Drug|XRP0038 (NV1FGF)|"Pharmaceutical form : solution~Route of administration : intramuscular"
45678974|NCT01778049|Drug|BI 10773|Empagliflozin active
45678975|NCT01778049|Drug|BI 10773|Empagliflozin active
45678976|NCT01778049|Drug|BI 10773|Empagliflozin active
45678977|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
45678978|NCT01778049|Drug|BI 10773 Placebo|Empagliflozin placebo
46009376|NCT04549584|Diagnostic Test|Vimentin/pan CK stain|Vimentin/pan CK stain positive/negative
45460889|NCT01261429|Drug|Tasigna|"The study drug is nilotinib (Tasigna®). All patients will be administered with nilotinib 400 mg twice a day for one year. The patient will begin the treatment the day of inclusion.~The prescribed dose should be swallowed whole with a glass of water. Doses of 400 mg should be administered twice daily approximately 12 hours apart. Patients should not eat within two hours before and one hour after taking nilotinib and need to avoid foods such as grapefruit juice which may inhibit CYP3A4 enzymes."
45460890|NCT03432390|Device|Continuous Positive Airway Pressure|A continuous positive airway pressure will be delivered to the patients during the induction of general anesthesia through the anesthesia work station
45460891|NCT03432390|Device|Open system ventilation|Facemask ventilation adapted to the anesthesia work station
45460892|NCT01157221|Other|a standardized physical therapy program|passive mobilization, stretching techniques, physical modalities (i.e., ultrasound, shortwave diathermy, and/or electrotherapy), and active exercises
45460893|NCT01157221|Other|EMSMTA|end-range mobilization/scapular mobilization treatment approach
45460894|NCT05659914|Drug|olaparib+durvalumab|olaparib: 300 mg tablets taken orally twice daily and durvalumab: 1500 mg via IV infusion q4w
45460895|NCT01154803|Dietary Supplement|Ready to Use Therapeutic Food (RUTF)|1 sachet/day, 500 kcal and multi micronutrients (fortified high quality food(RUTF),for 2 weeks after an illness (malaria, diarrhoea, pneumonia)
45460896|NCT01154803|Dietary Supplement|Micronutrient Powder (MNP)|2 sachets / day for 14 days after an illness (diarrheoea, malaria, pneumonia)
45460897|NCT03885427|Drug|Ketamine|evaluate sedative, and analgesic effects of oral or nebulized ketamine
45460898|NCT03881839|Other|emergency|The objective of this research will be to assess, in patients presenting in an emergency department, the prior consultation of medical information on a website, the impact on the emergency consultation decision and the relevance of this consultation.
45460899|NCT03881761|Biological|CD19/CD20 bispecific CAR-T cells|collecting blood for CAR-T cells culture three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CD19/CD20 bispecific CAR-T cell with a dose of 1-3x106/kg
45460900|NCT03456960|Drug|TAK-438ASA|TAK-438ASA tablet.
45460901|NCT03456960|Drug|TAK-438|TAK-438 tablet.
46009377|NCT04994093|Other|Collection of blood (PBMC), biopsy (FFPE) and stool samples.|Patients receiving routine treatment financed by the Polish National Health Fund (NFZ).
46096215|NCT02652650|Drug|JNJ-63623872|Participants will receive 600 mg twice daily (bid) for 5 days on Days 73 to 77 (Cycle III: OC plus JNJ-63623872, test) during third OC cycle under fed conditions.
45460902|NCT03456960|Drug|Aspirin|Aspirin enteric-coated tablet.
45460903|NCT01262209|Device|portable CCTV|This is a small handheld mini screen intended to improve reading.
46096216|NCT00716014|Drug|TD101|TD101 is injection into a callus on the bottom of one of the patient's feet
46096217|NCT00716014|Drug|Normal saline (placebo)|A normal saline solution (placebo) is injected into one of the patient's feet.
45460904|NCT01262209|Device|Telescopes, telemicroscopes and microscopes|These are either worn like glasses, or held in one's hand and are intended to improve distance vision (like details of a hockey game), intermediate vision (like reading a sign), or 'up-close' vision (like reading small print).
45460905|NCT01262209|Device|Absorptive filters|These are worn like glasses, and have tinted colour lenses. They are intended to improve contrast sensitivity, or being able to tell light from dark (like reading gray letters on a white background).
45460906|NCT03881605|Diagnostic Test|MRI screening|A standard contrast-enhanced MRI and Chemical Exchange Saturation Transfer (CEST) MRI of the brain will be performed at baseline, 4 months, 8 months and 12 months.
45460907|NCT01261663|Other|oral nutritional energy and protein enriched supplement (NOS)|
45460908|NCT03718572|Procedure|Laparoscopic cholecystectomy|Surgical removal of Gall bladder using laparoscopy
45599052|NCT04464889|Drug|MDG1021 dose 3|3 patients to receive dose 3: target dose of 3x10^6 HA-1H TCR transduced T cells/kg BW +20% in 100 mL
45836924|NCT00530634|Procedure|adjuvant therapy|
45836925|NCT00530634|Procedure|conventional surgery|
45836926|NCT00530634|Radiation|radiation therapy|
45836927|NCT02113410|Behavioral|Sit 'N' Fit Chair Yoga (SNFCY)|Experimental: Sit 'N' Fit Chair Yoga - a twice-weekly, 8-week yoga program of 45-minute sessions. Active Comparator: Health Education Program (HEP), a twice-weekly, 8-week program of 45-minute sessions
45836928|NCT02113410|Behavioral|Health Education Program (HEP)|Willing and eligible subjects randomized to the Health Education Program (HEP) attended twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
45836929|NCT00531882|Drug|Pioglitazone|30 mg once a day
45836930|NCT00531882|Drug|Simvastatin|40 mg once a day
45836931|NCT00531882|Drug|Ibuprofen|Ibuprofen 15-23 mg/kg twice daily, maximum 3200 mg/day
46096218|NCT02643602|Other|Hydration with bicarbonate in addition to theophylline|0.154-molar sodium bicarbonate; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
45460909|NCT03884959|Biological|HepaStem Infusion|HepaStem will be infused intravenously into the portal vein, either (1) via a permanent mesenteric PAC inserted surgically in an affluent of the portal vein; or (2) through a transient percutaneous transhepatic catheter inserted in to the portal vein under radio guidance.
46009378|NCT04669496|Drug|Neoadjuvant treatment|PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
46009379|NCT04669769|Other|interview|telephone interview
45460910|NCT03716388|Biological|Fecal Microbiota Transplantation|Freshly passed stools (80 g) will be diluted with normal saline (200 ml) and homogenized using a blender, filtered, filled into 4 syringes (50 ml each) and used within 1 hour of preparation or 6 hours of passage of stools. Polyethylene glycol lavage will be done for bowel preparation and the slurry administered into the ileum and/or caecum by colonoscopy. Post FMT, recipients will be encouraged to retain the slurry for 4-6 hours. FMT sessions will be scheduled at weeks 0,2,6,10,14.
45460911|NCT03716388|Drug|Mesalamine Granules|Mesalamine granules 4 grams a day
45460912|NCT03716388|Other|Placebo infusion|Water with food grade colour to resemble fecal slurry
46009380|NCT04571450|Behavioral|Reintervention|This self-applied online program will take three months and comprise 9 behavioural modules developed gradually, achieving the changes needed on eating and physical activity habits, supported by audiovisual instructions given by an hypertension specialist doctor.
46009381|NCT04571411|Other|CBC|The aim of this study is to investigate the relationship between severity of envenomation and hematological parameter by detectig initial mean platelet volume (MPV), neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in pediatric patients presenting with a scorpion sting.
46009382|NCT04541784|Other|WOMAN-PRO III|"Standardized care and three counselling sessions with a gynaecology-oncology nurse and the use of the mobile app WOMAN-PRO III."
46009383|NCT04541784|Other|Three counselling sessions with gynaecology-oncology nurses|Standardized care, three counselling sessions with a gynaecology-oncology nurse.
45460913|NCT03716388|Other|Placebo granules|Granules resembling mesalamine granules, 4 grams a day
45460914|NCT03565003|Drug|JAB-3068|25 mg,100 mg
45460915|NCT01311336|Drug|Loratadine|loratadine 10 mg capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
46009384|NCT04669262|Drug|BGB-DXP604|Administered as intravenous (IV) infusion over 30 to 60 minutes
46009385|NCT04669262|Drug|BGB-DXP593|Administered as intravenous (IV) infusion over 30 to 60 minutes
46009386|NCT04669262|Drug|Placebo|Placebo to match BGB-DXP593
46009387|NCT04669262|Drug|Placebo|Placebo to match BGB-DXP604
45460916|NCT01311336|Drug|placebo|placebo capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
45460917|NCT03886753|Other|Registry|Collect data on subjects
46009388|NCT04999319|Procedure|PVB|Paravertebral block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
45460918|NCT03886753|Other|PK microsampling of blood|Obtain 5 microsamples of blood from subjects via a fingerstick.
45460919|NCT03886597|Other|Table Olives|At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 60 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 5 minutes to ingest 60 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.
45599053|NCT04464889|Drug|MDG1021 optimal dose|20 patients to receive the selected optimal dose
46009389|NCT04999319|Procedure|ESPB|Erector spinae plane block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
46009390|NCT04993625|Procedure|avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy|Selective Omission of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy In HER-2 positive/Triple Negative Breast Cancer Patients with Excellent Radiologic Response to the Breast and Axilla
46009391|NCT04549818|Device|sacral neuromodulation|Sacral neuromodulation group, N=22 will be treated with Stimulation of the sacral nerve roots by placement of a lead and generator, typically using an implanted InterStim® device that provides constant electrical stimulation to the S 2, 3 and 4 nerve roots, for 2-week trial stimulation
46009392|NCT04541550|Drug|AMP-001 Low Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
46009393|NCT04541550|Drug|AMP-001 Medium Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
46009394|NCT04541550|Drug|AMP-001 High Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
46009395|NCT00556361|Drug|saline|2 mg/Kg IV saline within 5 minutes of initiation of Cardiopulmonary bypass
46009396|NCT00556361|Drug|ketamine|2 mg/Kg IV within 5 minutes of cardiopulmonary bypass
46009397|NCT04549350|Other|PSQI|Assessment of sleep quality using Pittsburgh Sleep Quality Index (PSQI): It is a simple tool which assess the sleep quality over one month period. It included seven components with a global PSQI score > 5 is indicative of poor sleep quality
46009398|NCT04671290|Other|Any intervention|No intervention
45460920|NCT03886597|Other|Table Olives|At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 120 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 10 minutes to ingest 120 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.
45460921|NCT03886597|Other|Table Olives|All the subjects will perform two experimental sessions of 30 days with 15 days of washout periods within experimental periods. In one experimental session subjects will ingest table olives and in the other session they will act as their own controls following their normal dietary habits. During all the experiment participants will avoid the consumption of products rich in phenolic and triterpenic compounds. Subjects will include the dose of 60 table olives within their normal dietary habits. Consequently, the olives will be consumed two times daily within each main meal; 30 olives before lunch and 30 olives before dinner. Blood samples will be collected at baseline and 15 and 30 days of each experimental session. Tolerability variables and blood pressure will also be measured.
45460922|NCT03885271|Other|Hall Technique|The Hall technique is a simplified method of utilizing stainless steel crowns in treatment of carious primary molars. The SSC is cemented onto the carious tooth using glass ionomer cement. Since there is no need for carious lesion removal, the use of local anesthesia is not mandate
45460923|NCT03885271|Other|Formecresol Pulpotomy|Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health .This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, Complete caries removal and then access to the pulp chamber using drills
45460924|NCT03430986|Device|JUVÉDERM® VOLUMA® with Lidocaine|Treatment with JUVÉDERM® VOLUMA® with Lidocaine injectable gel with optional treatment 8 weeks later.
45460925|NCT03430986|Other|No-treatment control|No treatment during the control period.
45460926|NCT01261741|Drug|Memantine|Each subject will receive memantine 10mg tablets once daily
45460927|NCT01261741|Drug|Placebo|Each subject will receive matching placebo tablets once daily
46009399|NCT04571606|Procedure|Single injection peripheral nerve block with liposomal bupivacaine (Exparel)|10 mL/133 mg liposomal bupivacaine and 10 mL 0.5% bupivacaine
45460928|NCT01157455|Procedure|Everolimus Drug Eluting Stent|Implantation
45678979|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
45678980|NCT01778049|Drug|BI 10773|Empagliflozin active
45678981|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
45678982|NCT01777581|Drug|Milnacipran|
45678983|NCT01777581|Drug|Placebo|
46009400|NCT04571606|Procedure|Single injection peripheral nerve block with 0.25% bupivacaine and subsequent peripheral nerve catheter with 0.2% bupivacaine infusion via onQ pain pump|20 mL 0.25% bupivacaine block and subsequent 10 mL/hr 0.2% bupivacaine infusion for 48 hours
46009401|NCT04669613|Other|CUDI|Analysis of the CEUS data by means of Contrast ultrasound dispersion imaging
46009402|NCT04541160|Diagnostic Test|CR|Lung imaging evaluation performed with CR
46009403|NCT04541160|Diagnostic Test|ULDCT|Lung imaging evaluation performed with ULDCT
46009404|NCT02210117|Biological|Bevacizumab|Given IV
46009405|NCT02210117|Procedure|Biopsy|Undergo biopsy
46009406|NCT02210117|Biological|Ipilimumab|Given IV
45678984|NCT01864148|Drug|BIIB033|
45678985|NCT01864148|Other|Placebo|
45678986|NCT01864148|Drug|Avonex|
46009407|NCT02210117|Other|Laboratory Biomarker Analysis|Correlative studies
45678987|NCT01751139|Procedure|Blood sample collection|Blood samples will be collected at each study visit (Day 0, Month 6, Month 12, Month 24, Month 36 and Month 48) and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue infection diagnosis.
45678988|NCT01751139|Other|Data collection|Diary logs will be issued to all subjects at every visit, except Month 48 (Day 0, Month 6, Month 12, Month 24, and Month 36), as required. Any completed diary logs will be verified, as applicable. Subjects will be given a diary log in the event of the occurrence of a symptom that may be associated with suspected dengue.
45678989|NCT04415138|Device|Robotic-assisted mitral valve repair|Mitral valve repair using robotic technology (DaVinci X platform)
45678990|NCT01890122|Drug|Alogliptin|Alogliptin tablets
45678991|NCT01890122|Drug|Metformin HCl|Metformin HCl capsules
46009408|NCT02210117|Procedure|Metastasectomy|Undergo metastasectomy
46009409|NCT02210117|Biological|Nivolumab|Given IV
46009410|NCT02210117|Procedure|Therapeutic Conventional Surgery|Undergo nephrectomy
46009411|NCT04541277|Drug|Tislelizumab|Tislelizumab combined with DNA demethylation agent +/- CAG regimen
46009412|NCT04541394|Device|MolecuLight|MolecuLight is a device that utilizes a special light which, when used on wounds, helps identify the regions which pathogenic bacterial counts are the highest. The device applies 405nm violet light which is harmless to the human tissue. When specific components in bacteria catches up the light, a photoluminescent reaction is triggered and the fluorescence light is caught by the camera on this device in real time.
46009413|NCT02210234|Dietary Supplement|50 grams of whole wheat bran cereal|This arm was randomized to eat 50 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
46009414|NCT02210234|Dietary Supplement|100 grams of whole wheat bran cereal|This arm was randomized to eat 100 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
46009415|NCT02214264|Behavioral|Loving-Kindness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided reflections and intentions related to feeling loving-kindness towards the self and others.
46009416|NCT02214264|Behavioral|Breath Awareness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided awareness focused on sensations of breathing.
46009417|NCT02214264|Behavioral|Gratitude|Participants undergo training for approximately 12 minutes. Training involves reflections of gratitude for people, events, and things in one's life.
46009418|NCT02214264|Behavioral|Control|Participants will write and then think about the physical space in which they live (i.e., their home) for approximately 12 minutes.
46009419|NCT04549740|Diagnostic Test|salivary alpha amylase level measurement|Saliva samples will be obtained to estimate salivary alpha amylase
45460929|NCT01157455|Drug|Aspirin|Orally take by 300mg per day at least within 24 hours before index procedure. Orally 100mg indefinitely after the procedure as a part of dual anti-platelet therapy
45460930|NCT01157455|Drug|Clopidogrel|"A loading dose of 300mg must be given at least 6 hours prior to index procedure, or a loading dose of 75mg/d 72 hours prior to index procedure.~75mg daily for at least 12 months after the procedure as a part of dual anti-platelet therapy."
45460931|NCT01157455|Drug|Heparin or Bivalirudin|During procedure or in-hospital, Heparin 100u/kg or Bivalirudin may be given,or follow up the standard practice of each site.
45460932|NCT03881527|Device|Aortic valve replacement using a nitinol blade|A circular nitinol blade will be inserted by to cut the aortic valve leaflets during conventional aortic valve replacement procedure
45460933|NCT03881527|Procedure|aortic valve replacement|Aortic valve replacement in a standard fashion
45460934|NCT03713892|Drug|CKD-504|orally administered once with investigational drug assigned on 1d morning with 240 mL of water
45460935|NCT03713892|Drug|Placebo|orally administered
45460936|NCT03884881|Diagnostic Test|metagenomic next generation sequencing|Pathogens in the NGS group will be tested by NGS，then according the NGS results, adjust antibiotics
45460937|NCT03884881|Diagnostic Test|Conventional pathogen detection|Morphological detection, microbial culture, nucleic acid amplification technology, serological pathogen antibody titer detection and specific pathogen PCR detection. Then, according to the pathogen results, adjust antibiotics
45460938|NCT03884881|Drug|Meropenem，Imipenem，Caspofene，Osstat|Meropenem，Imipenem，Caspofene，Osstat
46009420|NCT04571294|Procedure|removal of para-aortic lymphnodes (PALN)|During pancreaticoduodenectomy, para-aortic lymphnodes (PALN) will be removed for the surgeon
45460939|NCT03716310|Diagnostic Test|platelet responsiveness evaluation|Blood samples were anticoagulated with 0.129 mmol/L of sodium citrate and then centrifugated for 10 min at 200 rpm; platelets aggregation was assessed with an AggRAM Advanced Modular System light transmittance aggregometer (Helena Laboratories, Beaumont, Texas, USA). Low-molecular-weight heparin (LMWH) was given at least 8 hours before any blood aggregation sample. Agonist used to initiate aggregation test were: -Adenosine diphosphate (ADP) to assess P2Y12-dependent platelet aggregation; (20 ng) - Arachidonic acid (AA) to assess cyclooxygenase-dependent platelet Adenosine diphosphate aggregation (1 mcg) - thrombin receptor-activating peptide-6 (TRAP-6) to assess protease-activated receptor 1-dependent platelet aggregation. Max aggregation reached (Aggmax), the slope of the curve (slope) and the latency time (lat) were analyzed for each agonist.
46009421|NCT04541316|Device|ProFlor inguinal hernia device|Inguinal hernia repair
46009422|NCT04541238|Diagnostic Test|MRI|Magnetic resonance imaging
46009423|NCT04997408|Device|Customized exercise app|A Wearable Device-Based Assisted Post-Stroke Rehabilitation system
46009424|NCT04997408|Other|In-person therapist-supervised rehabilitation|In-person therapist-supervised rehabilitation
46009425|NCT04541199|Device|closed loop|RR and VT will be selected according to the respiratory mechanics by closed loop algorithm
46009426|NCT04541199|Device|conventional|RR, VT, Ti will be selected by the clinician according to the respiratory mechanics
45599054|NCT02233205|Device|ultrasonic microbubbles|inject 1ml once and five times in 20min, locate the probe on the lesion at the same time
46009427|NCT02210351|Device|MRI test|
46009428|NCT02214342|Other|Balance Training|"Experimental: Balance Training Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
45599055|NCT02233205|Drug|platinum and gemcitabine|Chemotherapy drug of pancreatic carcinoma is gemcitabine. Chemotherapy drug of liver metastases is oxaliplatin and taxol.
46009429|NCT04997369|Device|Rezum|The Rezum system is an ablative procedure for patients with benign prostatic hyperplasia (BPH).
46009430|NCT04549389|Device|Low intensity shockwave therapy|LiST will be applied in the perineum of the patients by using Dornier Aries 2 shockwave machine (5000shockwaves per session, energy level 7)
46009431|NCT04549623|Device|Novel end-tidal CO2 monitoring device|Apart from SpO2 and respiratory motion monitoring, the EtCO2 monitoring device is used to detect CO2 from nose and mouth simultaneously.
46009432|NCT04549623|Device|SpO2 and respiratory motion monitoring|Finger SpO2 and ECG-based respiratory motion monitoring are used during operation.
45460940|NCT01263847|Dietary Supplement|Galactooligosaccharide|Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.
45599056|NCT03145311|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|
46009433|NCT04995653|Drug|Vancomycin Pre-Treatment|Four times daily dosing with Vancomycin
46009434|NCT04995653|Drug|Vancomycin Placebo|Four times daily dosing with Vancomycin Placebo
46009435|NCT04995653|Drug|SER-155|Once daily dosing with SER-155
46009436|NCT04995653|Drug|SER-155 Placebo|Once daily dosing with SER-155 placebo
45678992|NCT01890122|Drug|Alogliptin and Metformin Fixed-Dose Combination (FDC)|Alogliptin and metformin FDC tablets
45678993|NCT01890122|Drug|Alogliptin Placebo|Alogliptin placebo-matching tablets
45678994|NCT01890122|Drug|Metformin Placebo|Metformin placebo-matching capsules
46096219|NCT02643602|Other|Hydration with sodium chloride in addition to theophylline|0.9% sodium chloride; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
46096220|NCT02652962|Device|Gelesis200|3 capsules each containing 0.70 g
46096221|NCT02652962|Other|Placebo|3 capsules each containing 0.57 g of a mixture of microcrystalline cellulose and maltodextrin in a ratio of approximately 50 ± 10%
46096222|NCT00710320|Procedure|Covered and uncovered anesthesia induction|"We hypothesize that the core temperatures of:~the covered group during induction of general anesthesia will be greater by 0.5ºC than the uncovered group during induction of general anesthesia.~both groups, covered and uncovered, will be equal during surgery and post-operatively. In other words, due to the active warming procedures during surgery and post-operatively in the PICU, core temperatures of the uncovered group will catch up to the covered group."
46096223|NCT04164316|Device|Kinesio Tape|Kinesio TexTM Tape which is the original elastic therapeutic adhesive tape which is a latex-free, hypoallergenic, waterproof, porous.
45678995|NCT01890122|Drug|Alogliptin and Metformin FDC Placebo|Alogliptin and metformin FDC placebo-matching tablets
46009437|NCT04541004|Biological|HDM SLIT-tablet|Sublingual allergy immunotherapy tablet, for daily administration (1 tablet per day)
46009438|NCT04570982|Biological|Convalescent Plasma|The objective of this protocol is to provide a coordinated approach for distribution and guidance for safe and effective administration of convalescent serum with antibodies against SAR CoV-2 for treatment of patients with COVID-19 infection who are most likely to benefit from this investigational treatment and monitor them.
46009439|NCT04548843|Procedure|Bone Marrow mobilization|"During four days before the apheresis, Neupogen (G-CSF) at a dose of 10 microgram per kilogram will be administered subcutaneously in the morning (days -6 to -3 of cell therapy). In addition, Mozobil (Plerixafor) at a dose of 0.24 milligram per kilogram will be administered subcutaneously approximately 4 hours before apheresis initiation.~A fifth dose of Neupogen (G-CSF) will be administered just prior to the apheresis"
46009440|NCT04548843|Procedure|Apheresis|Apheresis will be performed two days prior to MNV-BM-PLC infusion. During this procedure, patient's peripheral blood will be collected by apheresis
46096224|NCT02643446|Biological|IPV|IPV will be vaccinated at 2 months of age act as the first dose of poliovirus vaccine in the study group1 to group 4,group8 to group 11. IPV will be given at 3 month of age act as second vaccine in group 8,9,12
46096225|NCT02643446|Biological|OPV|"OPV will be vaccinated at 3 and 4 months of age, act as the second and third dose of poliovirus vaccine in the study group 1 to group 4,group 10 to group 11.~OPV will be vaccinated at 2, 3 and 4 months of age act as the full three primary immunization doses of polio virus vaccine in the study group 5 to group 7."
45599057|NCT02843633|Device|BioFreedom™ Drug Coated Coronary Stent System|a non-surgical procedure that uses a catheter to place a stent to open up coronary arteries that have been narrowed by atherosclerosis
45678996|NCT01397890|Drug|Budesonide/formoterol (Symbicort® Turbuhaler®)|Budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5μg/inhalation, 2 inhalations twice daily
45599058|NCT02843633|Drug|Antiplatelet Drug|Dual antiplatelet therapy for one month followed by single antiplatelet therapy indefinitely. Aspirin and clopidogrel (or other P2Y12 inhibitor) will be used and dosing is according to standard institutional practice
45599059|NCT02293681|Drug|Infliximab|This is an observational study. Participants receiving intravenous infusion of infliximab will be observed.
45599060|NCT02293681|Drug|NSAIDs|This is an observational study. Participants receiving aspirin, ibuprofen and naproxen as NSAIDs will be observed.
45599061|NCT02293681|Drug|DMARDs|This is an observational study. Participants receiving methotrexate (MTX), sulfasalazine, and thalidomide as DMRADs will be observed.
45460941|NCT03713814|Other|Exercise|"8-week exercise program, three times a week, during 45 minutes each section. Exercises for strength, endurance and mobility of the spine using pilates´ball and mat.~The researcher will explain, demonstrate and supervise the participants. It will start with 10 minutes of warming-up using a ergometer bicycle, followed by the mat exercises. Some of these will require motor control with mobility, others will require isometry, or concentric and eccentric phases with progression of eccentric phase timing."
45460942|NCT03884803|Behavioral|E-health website|Access to the e-health intervention (website)
45460943|NCT03884803|Other|Standard Care|Control group to continue with standard care
45460944|NCT03713736|Diagnostic Test|Cervical smear|Cervical smear will be obtained using an Ayre spatula and a cervical brush (Cervex-Brush®). HPV test will be performed using the CLART® HPV2 kit (Genomica).This kit enables the detection of 35 genotypes: HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43,44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73, 81, 82, 83, 84, 85 et 89.
45460945|NCT03713736|Diagnostic Test|Pregnancy test|Urinary pregnancy test
45460946|NCT03713736|Behavioral|Sexual activity questionnary|Sexual activity questionnary
46009441|NCT04548843|Biological|MNV-BM-PLC infusion|"The MNV-BM-PLC (autologous CD34+ cells enriched with placenta-derived allogeneic mitochondria) infusion will be performed by standard IV procedure.~The dosing interval between patients will be at minimum 2 weeks."
45460947|NCT01154881|Drug|insulin degludec|Insulin degludec (IDeg) injected s.c. (under the skin) once daily for 6 days in each treatment period. Each subject was randomly allocated to 2 out of 4 treatments.
45460948|NCT03886441|Drug|Beclomethasone propionate|Beclomethasone propionate inhaled twice daily during radiotherapy
45460949|NCT03713346|Other|Lactose free milk|Single dose of lactose free milk
45460950|NCT03713346|Other|Jersey milk|Single dose of jersey milk
45460951|NCT03713346|Other|High A1 β-casein milk|Single dose of high A1 β-casein milk (commercial milk)
45460952|NCT03713346|Other|High A2 β-casein milk|Single dose of A2 β-casein milk
45460953|NCT03716232|Device|Metallic stent|"All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 4-6cm fully covered expandable metallic stent (Kaffes stent, Taewoong medical, Seoul, Korea) will then be deployed at the level of the stricture. In cases close to the hepatic hilum where the deployment of the stent is expected to reach one duct and possibly block another duct, a 7 Fr stent will be inserted prior to deployment of the metallic stent in the contralateral duct..~- Stent will be extracted endoscopically after 6 months."
45460954|NCT03716232|Device|Multiple plastic stents|"Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 10 French plastic stent will be inserted bypassing the level of the stricture.~Stent replacement and the addition of further stents will be planned after 3 months from the initial procedure and every 3 months until stricture resolution occurs with a maximum of four procedures. Balloon dilatation with a 6-10 mm balloon will be used in each session before stent insertion."
45460955|NCT01154959|Drug|Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol|Moxifloxacin (400mg), Isoniazid (300mg daily, 600mg thrice weekly), Rifampicin (450mg, and 600mg for patients weighing 60kg or more), Pyrazinamide (1500mg), Ethambutol (800mg)
46009442|NCT04993586|Biological|AG0302-COVID19 for Intramuscular Injection|Vaccination 2 mg of AG0302-COVID19 three times at 2-week intervals
46009443|NCT04993586|Biological|AG0302-COVID19 for Intramuscular Injection|Vaccination 4 mg of AG0302-COVID19 twice at 4-week intervals
46009444|NCT04993586|Biological|AG0302-COVID19 for Intramuscular Injection|Vaccination 8 mg of AG0302-COVID19 twice at 4-week intervals
45460956|NCT04862754|Other|interval training exercise|interval training exercise
45460957|NCT03881293|Drug|lidocaine 2% gel|Transurethral instillation of 5 ml lidocaine 2% gel
45460958|NCT03881293|Drug|water soluble lubricant|Transurethral instillation of 5 ml water soluble lubricant
45460959|NCT01155037|Biological|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Patients infected with HIV will receive 3.75 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
45460960|NCT01155037|Biological|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Patients infected with HIV will receive 7.5 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
45460961|NCT01155037|Biological|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Control group will receive 3.75 µg of an adjuvanted A H1N1 vaccine in one single application.
45460962|NCT01261897|Procedure|Adductor-Canal-Blockade with Ropivacaine|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
45460963|NCT01261897|Procedure|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
45460964|NCT03448536|Drug|Naproxen Sodium, (Aleve, BAY117031)|220 mg *2 tablets, orally, single dose
45460965|NCT03448536|Drug|Acetaminophen (Tylenol Extra Strength)|500 mg *2 caplets, orally, single dose
45599062|NCT03145935|Diagnostic Test|Abdominal compression (AC)|An echocardiography with stroke volume measurement coupled with an abdominal compression will be performed before and after ta diuretics induced diuresis of 10ml/kg in pediatric patients hospitalized in a pediatric intensive care unit (PICU) diagnosed with fluid overload
45599063|NCT03145935|Diagnostic Test|blood sample|proteinemia and hematocrit will be measured before and after a diuretics induced diuresis of 10ml/kg
46009445|NCT04993586|Biological|AG0302-COVID19 for Intradermal Injection|Vaccination 1 mg of AG0302-COVID19 three times at 2-week intervals
45599064|NCT02297659|Procedure|Primary Fascial Closure|Abdominal wall closure following damage control laparotomy.
46009446|NCT04993586|Biological|AG0302-COVID19 for Intradermal Injection|Vaccination 1 mg of AG0302-COVID19 twice at 4-week intervals
46009447|NCT04992221|Procedure|arterial line|arterial line inserted for invasice mointroing and sampling
46009448|NCT04548765|Behavioral|Letter|Recipients receive a letter promoting CRC screening.
46096226|NCT00716170|Biological|Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)|"Day A: Oral glucose tolerance test (50g glucose)~Day B: Isoglycemic intravenous (iv) glucose infusion~Day C: Isoglycemic iv glucose infusion + iv GIP infusion (0-20 min: 4 pmol/kg body weight/min; 20-50 min: 2 pmol/kg body weight/min)~Day D: Isoglycemic iv glucose infusion + iv GLP-1 infusion (0-20 min: 0,6 pmol/kg body weight/min; 20-50 min: 0,3 pmol/kg body weight/min)~Day E: Isoglycemic iv glucose infusion + iv GLP-2 infusion (0-20 min: 1 pmol/kg body weight/min; 20-50 min: 0,5 pmol/kg body wight/min)~Day F: Isoglycemic iv glucose infusion + iv infusion of GIP, GLP-1 and GLP-2 in doses as Day C, D and E."
46096227|NCT02652806|Drug|FG-4592|
45678997|NCT01397890|Drug|Tiotropium (SpirivaTM)|Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily
45678998|NCT01777269|Drug|Dutasteride plus tamsulosin|Take 1 capsule daily
45678999|NCT01777269|Drug|Placebo|Take one capsule daily
45679000|NCT04616456|Drug|[F-18]PBR06|PET radiopharmaceutical
45679001|NCT04616456|Drug|Verdiperstat|verdiperstat targets microglial inflammation in the brain
45679002|NCT05365360|Device|LaserCap SD|LaserCap SD
45679003|NCT05365360|Device|Sham LaserCap|Sham LaserCap
45679004|NCT05365360|Device|LaserCap HD+|LaserCap HD+
45679005|NCT04016272|Device|Active tDCS|tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., NY) with headgear and saline-soaked surface sponge electrodes.
45599065|NCT02297659|Device|wound vac dressing application|temporary abdominal wall closure with this device after damage control laparotomy
45599066|NCT02259491|Other|Manuka Honey Dressing|After surgical resection and reconstruction the skin graft donor site (thigh) and the free flap donor site will be dressed with Medihoney surgical dressings. More specifically, a dressing of appropriate size will be applied to the anterior thigh and covered with tegaderm. For the STSG recipient site a Medihoney dressing will cover the skin graft, followed by dry gauze, kerlex and a cast.
45679006|NCT04016272|Device|Sham tDCS|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
45679007|NCT04371250|Other|Survey and Questionnaire|Resilience and Loneliness questionnaires
45679008|NCT01751061|Behavioral|Decision aid|A web-based decision aid to assist surrogate decision makers in prolonged mechanical ventilation decisions
45679009|NCT01751061|Other|Usual care|usual ICU care
45679010|NCT04024696|Drug|Abexinostat|Abexinostat Tosylate Tablets
45679011|NCT01777191|Drug|Ixekizumab Auto-Injector|Administered SC by auto-injector
46009449|NCT04548765|Behavioral|Loss Frame and Fear Appeals|The letter is enhanced with language that frames the situation in terms of losses. It also uses fear appeals by showing the risks of colorectal cancer, while also showing that screening is an achievable means to address those risks.
46009450|NCT04548765|Behavioral|Transparency|The letter explains why the kit was sent, which makes the purposes of the mailing clear to the recipient.
46009451|NCT04548765|Behavioral|Default Effect and Presentation of Alternatives|The pros and cons for screening with FIT kits and colonoscopy are presented. By showing an additional option, the table frames the FIT kit as the default option (since they are included in the mailer). In this situation, inaction is no longer the default option. Changing the default option increases the chance that the FIT kit is used. In addition, another viable alternative is provided (colonoscopy), which still contributes to the goal of the project (getting screened).
46009452|NCT04548765|Behavioral|Enhanced Fear Appeals and Decoy Effect|Comparisons of the mortality rates between screening with FIT kits, colonoscopy, and inaction (waiting for symptoms to appear) are displayed. Inaction is presented as a decoy, which has worse outcomes than either of the screening options. Due to this contrast, the inclusion of the decoy increases the appeal of the other screening options.
46096228|NCT02652806|Drug|Epoetin Alfa|
45679012|NCT01777191|Drug|Ixekizumab Prefilled Syringe|Administered SC by prefilled syringe
46009453|NCT04540926|Drug|Cyclosporin A|COVID-19 pneumonia patients treated with oral CsA at a dose of 1-2 mg /kg / day divided into two doses, for 7 days, since entering to hospitalization.
46009454|NCT04540809|Other|Assessment of strength, proprioception, skill and coordination of the hand|Disease Activity Score 28 was used to determine the disease activity of patients with PsA. Grip strength was measured with the help of Baseline Digital Hand Dynamometer®. Pinch strength was measured with Baseline Hydraulic Pinch Gauge®. Wrist proprioception was assessed by measuring the joint position sensation using a goniometer by actively repeating the target angle predetermined by the researcher (30 ° for flexion and extension, 15 ° for ulnar deviation, 10 ° for radial deviation. Finger skills were assessed using a mobile application called Ball Tap©. The application included the fastest contact of the participants to the balls coming from different parts of the screen for 30 seconds. Two hand coordination and skills were evaluated using the Purdue Pegboard test. The Michigan Hand Outcomes Questionnaire was used for functional evaluation of the hand, and the Health Assessment Questionnaire was used to assess the general functional condition and health-related quality of life.
46009455|NCT04540965|Drug|Telaglenastat|Glutaminase inhibitor
46096229|NCT04159714|Device|Air Optix contact lens|Contact lens will be placed on the surface of the patient's eye and is to be used as a bandage
46096230|NCT03785600|Device|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 90 minutes of waking up.
45679013|NCT01896050|Drug|anastrozole, letrozole, exemestane|Patients were treated with one of the listed anti-hormonal medications for up to one year
46009456|NCT04540965|Drug|Famotidine|Histamine-H2 Receptor Antagonist
46096231|NCT03785600|Device|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 90 minutes of waking up.
46096232|NCT04070716|Procedure|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
45679014|NCT01896050|Drug|Tamoxifen|Patients were treated with tamoxifen for up to one year
46096233|NCT04070716|Procedure|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
46096234|NCT04529135|Drug|Dexmedetomidine|The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.
46096235|NCT04529135|Drug|Remifentanil|The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.
45679015|NCT01775787|Drug|Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor|Subjects randomized to either Tobacco Flavor group for 7-10 days than crossed over to Tobacco & Menthol Flavor for 7-10 days or Tobacco & Menthol Flavor group for 7-10 days than crossed over to Tobacco Flavor for 7-10 days
46009457|NCT04540965|Drug|Placebo for famotidine|Placebo for Histamine-H2 Receptor Antagonist
46009458|NCT04548687|Procedure|carbon dioxide insufflation|Carbon dioxide insufflation at a rate of 5 l / min. through the Redon drainage during cardiac surgery (minimally invasive or repeated) during cardiopulmonary bypass
45679016|NCT01775553|Drug|Carfilzomib|During Cycle 1, patients will receive either 20 mg/m2 on days 1,2 (if the subject has not received carfilzomib as part another clinical trial within the last 4 weeks) or 56 mg/m2 (if the subject is enrolling in the present study after progression of disease on carfilzomib within the last month - for example subjects enrolled in CMAP compassionate use carfilzomib). Thereafter, all subjects will receive 56 mg/m2 for the remaining doses given Cycle 1 Day 8 onwards. Each cycle is 28 days.
45460966|NCT01155115|Procedure|Sputum Collection|Each study participant will be invited to expectorate sputum for culture, sensitivity, cytology and analysis of cytokine levels. Culture and sensitivity will be performed routinely at the beginning of a pulmonary exacerbation, as per standard of care, and will only be performed at subsequent visits if there is clinical indication. A volume of 5ml of sputum will be required at each visit for analysis. If the participant is unable to expectorate this volume of sputum, he/she will be invited to induce sputum instead as per standard protocols.
45460967|NCT01155115|Procedure|Pulmonary Function Testing|Participants will perform spirometry at each visit according to the American Thoracic Society and European Respiratory Society guidelines.
45460968|NCT01155115|Procedure|Exhaled Nitric Oxide|The investigators will measure exhaled Nitric Oxide (eNO) at each visit according to the American Thoracic Society and European Respiratory Society guidelines using a chemiluminescence analyzer. Briefly, single breath exhalation are performed in triplicate at flows of 30, 50, 100, 150, 200 and 250 ml/s and eNO is measured at the end of the exhalation. The higher the flow rate the more peripheral the airways that are being sampled.
45679017|NCT01775475|Drug|cyclophosphamide|Given IV
45679018|NCT01775475|Drug|doxorubicin hydrochloride|Given IV
45679019|NCT01775475|Drug|vincristine sulfate|Given IV
45679020|NCT01775475|Drug|prednisone|Given PO
45679021|NCT01775475|Drug|lomustine|Given PO
45679022|NCT01775475|Drug|etoposide|Given PO
45679023|NCT01775475|Drug|cyclophosphamide|Given PO
46009459|NCT04548687|Procedure|No carbon dioxide insufflation|standard methods of deaeration of cardiac cavities: manual method, change in body position, through the cannula of the ascending aorta, through the drainage of the left ventricle
45460969|NCT03885115|Behavioral|Intervention|Involves 12-weeks of education related to healthy behaviors, nutrition, and exercise from certified fitness instructors.
46009460|NCT02215356|Drug|Icotinib with concurrent radiotherapy|Icotinib: 125 mg is administered orally three times per day.
45460970|NCT03718338|Procedure|Evaluation|Undergo clinical evaluations
45460971|NCT03718338|Other|Quality-of-Life Assessment|Ancillary studies
45599067|NCT05255523|Drug|pyrotinib|After 4-6 cycles of taxane chemotherapeutics combined with trastuzumab±pertuzumab, the assessment result reaches CR or PR, and the subsequent sequential pyrrotinib plus capecitabine±trastuzumab to CNS Progress
45599068|NCT02297737|Behavioral|Tai Chi|
45599069|NCT02297737|Other|Health Education|
45599070|NCT02259335|Device|Extracorporeal CO2 removal device|A device able to remove CO2 using a dedicated device connected to the patient via a double lumen catheter inserted in the femoral vein
45599071|NCT03149679|Drug|Cyclophosphamide|Chemotherapy
45599072|NCT02298985|Drug|Curcumin|3 g/day (3 capsules/day) for 6 months
45599073|NCT02298985|Drug|placebo|3 g/day (3 capsules/day) for 6 months
45679024|NCT01775475|Drug|procarbazine hydrochloride|Given PO
45679025|NCT01775475|Other|laboratory biomarker analysis|Correlative studies
45679026|NCT01774929|Drug|TTS-fentanyl|TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
45679027|NCT01888874|Drug|GLPG0634|GLPG0634 capsules.
45679028|NCT01888874|Drug|Placebo|Placebo capsules.
45679029|NCT01749735|Device|Transcranial Direct Current Stimulation|Continuous mild transcranial direct current stimulation will be used while the participant plays video games using the Armeo Spring Robot to support the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
45679030|NCT01749735|Device|Sham Transcranial Direct Current Stimulation|Sham transcranial direct current stimulation will be used while the participant focuses on repetitive tasks using the Armeo device that incorporate multidirectional reaching, grasp and release action of the hand of the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
45679031|NCT01749735|Device|Armeo training|Upper extremity training with the use of a weight support device and virtual reality.
45679032|NCT01749033|Other|Group 1 Classic|"Active Comparator: Group 1 classic~Group 1 Using the classic inserting technique and completely deflated LMA recommended in the LMA manual."
45679033|NCT01749033|Other|Group 2 pre-inflated|Group 2 (pre-inflated): Using the recommended inserting technique with the pre-inflated volume that exists in a LMA (Laryngeal Mask Airway) from the manufacturer.
45679034|NCT01749033|Other|Group 3 ELL-PIC|Group 3 (ELL-PIC): Using the ELL-PIC technique
45679035|NCT01774305|Drug|Dexmedetomidine|We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously) at time of muscle layer closing.
46096236|NCT04168346|Drug|Ferric carboxymaltose|Ferric carboxymaltose iv infusion
45599074|NCT03926117|Biological|Ziltivekimab|human IgG1k anti-human IL-6 monoclonal antibody
46009461|NCT02215356|Drug|Chemoradiotherapy|Etoposide 50mg/m2, ivgtt, d1-d5; cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles
46009462|NCT04540653|Biological|Standard vaccination schedule|Administer a standard vaccination schedule (three doses of 20 μg of the hepatitis B vaccine, in months 0, 1, 6) at an age of ≥50 years and evaluate a production kinetics after each dose administered in the period of about 30 to 60 days.
45460972|NCT03884725|Drug|Fibrinogen Concentrate|Fibrinogen Concentrate is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given Fibrinogen Concentrate at an individually determined dose based on FIBTEM MCF and body weight as follows: (15 [mm] - MCF [mm]) * body weight [kg] / 140 [mm*kg/g] = gram fibrinogen to be dosed as Fibrinogen Concentrate. Fibrinogen Concentrate is to be infused over 1 to 2 minutes. After Fibrinogen Concentrate infusion, bleeding treatment will follow the predefined, standardized treatment regimen.
45460973|NCT03884725|Other|control|0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 0.9% saline (SF0,9%) prepared based on ROTEM measurement of maximum clot firmness (MCF). 0.9% saline is to be infused over 1 to 2 minutes. After 0.9% saline infusion, bleeding treatment will follow the predefined, standardized treatment regimen.
45679036|NCT01774305|Drug|Saline|We administrate the normal saline (single bolus, 0.25ml/kg) intravenously at time of muscle layer closing.
46009463|NCT04540653|Biological|Reinforced vaccination schedule|Administer an enhanced vaccination schedule (three doses of 40 μg of the hepatitis B vaccine, in months 0, 1, 6) in individuals aged ≥50 years and assess the kinetics of antibody production after each dose administered in the period of approximately 30 to 60 days.
45679037|NCT04571541|Device|Stenting|Effect of endoscopic stenting on healing of esophageal wall defects
46009464|NCT04999514|Behavioral|Mindful Parenting, Tuning in to Kids|The Mindful Parenting program consists of 8 weekly 2.5-hour group sessions and 3 weekly individual telephone interview sessions (each lasts for around 15-20 minutes). Program materials are translated into Chinese by local partners of the program developer. The Tuning in to Kids program consists of 8 weekly sessions, each lasting for 2.5 hours. Program materials are translated into Chinese.
46009465|NCT04548960|Other|cancer patients|Blood sample RNA_seq at time of diagnostic, best response and relapse ; Biopsy Exom_seq and RNA_seq at time of diagnostic and relapse Immulogical Profiling at time of diagnostic, best response and relapse
45460974|NCT01264003|Drug|sefazolin|In prophylaxis
45460975|NCT03448224|Other|Questionnaire Administration|Questionnaire
45460976|NCT03448224|Other|Internet-Based Intervention|Intervention
45460977|NCT03881371|Drug|Safinamide|At baseline (Day 1), eligible patients will be randomised to receive safinamide (initial 50 mg titrated to 100 mg the day after the Visit 3/week 2, ideally at day 15). The investigational medicinal product (IMP) will be taken in the morning at breakfast time, in addition to the morning dose of L-dopa and other (if any) PD medications.
45679038|NCT01737021|Other|Psycho-education|The information given to parents will cover expected reactions that follow a PICU admission; how parents can help their child cope with these reactions; how to recognise warning signs; and sign-posting of appropriate follow-up services (if relevant). There will also be a follow-up telephone call to reinforce the information and to support parents in putting it in to practice, if appropriate.
45679039|NCT04562649|Device|Wise App with medication adherence reminders|The Intervention group will receive the Wise App that delivers medication adherence reminders.
45679040|NCT04562649|Behavioral|CHW Sessions|The Intervention group will complete sessions with a community health worker (CHW).
45679041|NCT01397422|Drug|ADS-5102 (extended release amantadine HCl)|Oral capsules to be administered once daily at bedtime, for 8 weeks
45836932|NCT00428298|Drug|Valacyclovir|Subjects take two 500 mg capsules twice daily for 16 weeks.
45836933|NCT00428298|Drug|Placebo|Subjects take two 500 mg capsules twice daily for 16 weeks.
46096237|NCT04168346|Drug|Placebos|NaCl 0.9% infusion
46096238|NCT04469465|Drug|Danicopan|Oral tablet
45460978|NCT03881371|Other|Placebo|At baseline (Day 1), eligible patients will be randomised to receive matching placebo, orally OD. Placebo will be added to the standard stabilized treatment as a control of the safinamide group, hence patients on placebo will have benefit from other ongoing anti-PD medication
45460979|NCT03713190|Combination Product|Empagliflozin|Sodium-glucose co-transporter 2 (SGLT2), a low-affinity, high-capacity member of an increasingly numerous family of co-transporters, is highly expressed in the proximal renal tubule, and account for the majority of the reabsorption of filtered glucose.
45460980|NCT03713190|Drug|Placebo|A substance without specific pharmacology principles
45460981|NCT01262443|Procedure|Radiofrequency Ablation|Radiofrequency ablation by a standard 4mm irrigated flexible tip catheter
45460982|NCT05621850|Other|Blood sample|Based on supplementary blood sampled before embolization procedure and 6 hours and 24 hours after we will be analyzed cytokines concentration (Elisa test) and cortisol
45460983|NCT03886363|Behavioral|MBSR|Described previously
45460984|NCT03718182|Dietary Supplement|Cholecalciferol|vitamin D3 daily oral supplement
45460985|NCT01264159|Device|Lung impedence-guided therapy|
45460986|NCT01264159|Other|Usual treatment of patients with developing acute heart failure|
45460987|NCT03716154|Radiation|Diode laser|Diode laser 810nm, 2W, 20sec, 20 HZ
45460988|NCT01155271|Other|Rehabilitation|"12 weeks : 3 sessions per week (2 supervised sessions and 1 session at home)~1 technical visit and 1 nursing visit every two months at home for the CPAP"
45460989|NCT05637294|Device|splinting|neutral-positioned wrist orthosis
45460990|NCT03881449|Combination Product|ABILIFY MYCITE|Initiation of ABILIFY MYCITE will commence immediately, with subjects wearing the patch and using the smartphone app for a total of 3 months from baseline visit to the 3 month visit. Following the initial 90-days, the physician and patient may determine to use ABILIFY MYCITE anytime during the following 9 months. Following this period (up to 12 months), the subjects will not use ABILIFY MYCITE and return to standard care. A safety follow-up phone call will occur at 2 weeks after the 12 month/early termination (ET) visit. In addition, individuals in the ABILIFY MYCITE arm will evaluate satisfaction with the use of ABILIFY MYCITE.
45460991|NCT03713112|Other|Weekly MDT deprescribing rounds for certain drugs|"Weekly deprescribing round (from randomization to day of discharge)~Conducted by a multidisciplinary team (non-ward doctors, pharmacist, ward nurse)~Using the 5 steps of de-prescribing~De-prescribing targets:~Beer's list of potentially inappropriate medications (American Geriatric Society 2015 version)~Supplements of questionable benefits (glucosamine, chondroitin, vitamin B complex and multivitamins)~Symptomatic medications (laxatives, gastro-protectives, painkillers, anti-emetics and steroid creams) (Standardized verbal script to initiate de-prescribing by the team)~On top of usual care"
45460992|NCT01157611|Behavioral|Mentoring program|mentoring program group patients should register their SMBG, exercise, food intake and insulin dose on the website designed for this study and receive advices of mentors from peer group.
45460993|NCT01265329|Other|Negative selection|Sperm selection to continue the treatment with healthy sperm
45599075|NCT03149445|Drug|Tesofensine/Metoprolol|Study medication will be administered for 91 days.
45679042|NCT01888640|Device|TENS|"TENS Parameters: Active TENS and Placebo TENS~TENS Frequency - 2-125 Hz~TENS Pulse Width - 200 µs~TENS Intensity - Maximal tolerable intensity~Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.~Administration - Daily~TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.~Placebo TENS Unit Active TENS unit No TENS - Standard Care"
45679043|NCT01736475|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) evaluation of ADVATE
45679044|NCT01736475|Biological|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation of BAX 855
46009466|NCT04570865|Drug|Dapagliflozin|The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
45599076|NCT03149445|Drug|Placebos|Study medication will be administered for 91 days.
45599077|NCT03514537|Procedure|Microcannula harvest adipose stromal tissues|Use of disposable, closed syringe microcannula harvest autologous adipose stroma and stem/stromal cells
45599078|NCT03514537|Device|Centricyte 1000|Centricyte 1000, closed system digestion of stromal vascular fraction to isolate and concentrate stem/stromal cells associated with microvasculature
45599079|NCT03514537|Procedure|Sterile Normal Saline IV Deployment of cSVF|Sterile Normal Saline Suspension cSVF in 500 cc for Intravenous Delivery including 150 micron in-line filtration
46096239|NCT04469465|Drug|Placebo|Oral tablet
46096240|NCT04469465|Drug|C5 Inhibitor|Participants will continue to receive their ongoing C5 inhibitor (eculizumab or ravulizumab) therapy according to their usual dose and schedule.
46096241|NCT02647190|Drug|Erwinia Chrysanthemi asparaginase|
45460994|NCT03718026|Other|The timed 360° turn test|"The timed 360° turn test: Each participant turns around in place in a standing position for both sides.~Berg Balance Scale: It has 14 items, each of which is scored from 0 (i.e, severely impaired balance) to 4 (i.e., no balance impairment).~Timed Up and Go test: It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.~Functional Reach Test: It measures the maximum distance an individual is able to reach forward beyond arm's length in the standing position when maintaining a fixed base of support.~One-leg stance test: Individuals were asked to stand on either their left or right leg.~Four square step test: It requires an individual to step over obstacles in various directions including forward, backward, and sideways."
45460995|NCT03884491|Drug|Vortioxetine IV|an intravenous (IV) 10 mg dose (1 mg/mL) of vortioxetine infused over 2 hours
45460996|NCT03884491|Drug|Vortioxetine SLA|5-25 mg of sublingual formulation A of vortioxetine
45460997|NCT03884491|Drug|Vortioxetine SLB|5-25 mg of sublingual formulation B of vortioxetine
45460998|NCT03884491|Drug|Vortioxetine SLC|formulation SLC: solution of vortioxetine, concentrate (12.5 mg/mL-62,5 mg/mL) 200 uL or 400 uL, SL, 5-25 mg
45460999|NCT03712956|Drug|Caelyx®|Caelyx® every two weeks for 8 courses
45679045|NCT01736475|Biological|PEGylated Recombinant Factor VIII|Prophylaxis treatment
45679046|NCT01736475|Biological|PEGylated Recombinant Factor VIII|On-demand treatment
46096242|NCT02643368|Biological|mOPV2 at 6 and 7 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 7 weeks of age
45679047|NCT01863758|Biological|Human-cl rhFVIII|Human-cl rhFVIII was provided as a freeze-dried concentrate to be reconstituted in water for injection.
45679048|NCT01863680|Drug|COL-1620|The subjects will be administered with COL-1620 vaginal progesterone gel (1.125 grams of progesterone gel containing 90 milligram that is 8 percent [%] gel) vaginally once daily, from the day of ovum pick-up (OPU) until Week 12.
46096243|NCT02643368|Biological|mOPV2 at 6 and 8 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 8 weeks of age
46096244|NCT02643368|Biological|mOPV2 at 6 and 10 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 10 weeks of age
45679049|NCT01863680|Drug|Gonadotropin-releasing hormone (GnRH) analogue|Subjects will undergo conventional controlled ovarian stimulation (COS) therapy for in-vitro Fertilization and Embryo Transfer (IVF/ET) according to the Investigator's discretion using GnRH analogue (agonist or antagonist) preparation.
45679050|NCT01863680|Drug|Follicle-stimulating hormone (FSH)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using FSH containing preparation.
45679051|NCT01863680|Drug|Human Chorionic Gonadotropin (hCG)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using hCG preparation.
45679052|NCT01747629|Drug|Placebo MDPI|Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
45679053|NCT01747629|Drug|Albuterol MDPI|Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
45836934|NCT00486018|Drug|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
45836935|NCT00486018|Drug|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
45461000|NCT02527369|Device|XP1100RF|Treatment of adipose tissue within the fat layer with XP1100RF device.
45461001|NCT03717948|Other|BFR Exercise|Participants will exercise on a recumbent bike placed on a 45 degree incline (BFR).
45461002|NCT03717948|Other|CTL Exercise|Participants will exercise on a recumbent bike placed on flat ground (CTL).
45461003|NCT03717870|Procedure|Laparoscopic enucleation of ovarian endometrioma.|Laparoscopic enucleation of ovarian endometrioma (stripping of the peripheral capsule and coagulation using the lowest energy source available).
45461004|NCT03717870|Procedure|Prolonged pituitary downregulation|Treatment with GnRH-a (triptorelin, goserelin, and leuprolide), with add-back therapy (combined oral contraceptive) for 3-6 months.
45461005|NCT03717870|Procedure|Assisted Reproductive Technology (ART)|Fresh ART cycle: ovarian stimulation, oocyte retrieval, in vitro fertilization and embryo transfer.
45461006|NCT03881215|Procedure|Platelet Rich Plasma|Platelet Rich Plasma
45836936|NCT00486018|Drug|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
45836937|NCT00486642|Drug|Bicalutamide|Given PO
46096245|NCT02643368|Biological|IPV at 6 weeks of age|Participants assigned to this intervention will receive a dose of inactivated polio vaccine (IPV) 6 weeks of age
46096246|NCT02750033|Device|Multimodal Spectroscopy (MMS)|surgical margin assessment with multimodal optical spectroscopy (MMS) device
46009467|NCT04570865|Device|CardioMEMS|The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
46009468|NCT04540731|Other|This is an observational study without intervention|This is an observational study without intervention
46009469|NCT04570748|Procedure|Capsule repair|Direct anterior hip arthroplasty with or without capsule repair
46096247|NCT00653042|Drug|Nesiritide|
46096248|NCT04165538|Procedure|Thrombelastograph and surgical timing|Patients in the TEG group will undergo a Thrombelastograph test after admission, and the timing of operation will be determined according to the results of the test, that is, 1 day, 3 days and 5 days later respectively for patients with ADP-induced platelet-fibrin clot strength (MAADP) of > 50 mm, 30-50 mm and < 30 mm. For Non-TEG patients, the drug withdrawal time is determined by the doctor in charge according to the clinical routine, generally about one week.
46096249|NCT04165850|Drug|Fixed dose combination Ciprofloxacin/Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day
46096250|NCT02572258|Other|Nutritional cookie|
45679054|NCT04170920|Device|LifeExtend-AI|"LifeExtend-AI (LX-AI) will be piloted by adding AI- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating to-do lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added."
45679055|NCT01863368|Other|Preservative-free saline solution eyedrops|1 drop in each eye, 4 times a day, for up to two weeks as washout prior to Phase I and Phase II.
45679056|NCT01863368|Other|Systane® ULTRA lubricant eyedrops|
45679057|NCT01863368|Other|OPTIVE® lubricating eyedrops|
45679058|NCT01886690|Drug|carboxymethylcellulose sodium based new eye drop formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
45836938|NCT00486642|Other|Laboratory Biomarker Analysis|Correlative studies
46009470|NCT04570748|Procedure|capsulectomy|capsulectomy without repair
46096251|NCT02643290|Device|Peak Scoliosis Bracing System|Brace is fit to adult scoliosis patients for 2-4 hours a day and tracked for six months.
46096252|NCT00719758|Drug|TRK-100STP (BERASUS LA)|oral
46096253|NCT00719758|Drug|AST-120 (Kremezin®)|oral
46096254|NCT04167878|Device|3D printed biodegradable cervical fusion cage|ACDF with 3D printed biodegradable cervical interbody fusion cage for spinal fusion procedure at one level (C2 to T1) of the cervical spine.
46096255|NCT04167878|Device|PEEK cage|ACDF with PEEK cage for spinal fusion procedure at one level (C2 to T1) of the cervical spine.
46096256|NCT00719836|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
46096257|NCT04197167|Procedure|Hysteroscopy|Diagnostic procedure
46096258|NCT04197167|Device|Infrared Spectroscopy|This device uses spectral absorption of the tissue taken during hysteroscopy to determine immediate diagnosis of Chronic Endometritis
46096259|NCT02643134|Procedure|extracorporeal shockwave lithotripsy|Patients in Group 1 undergo extracorporeal shockwave lithotripsy(ESWL).
45461007|NCT03881215|Procedure|intra-uterine balloon|intra-uterine balloon
45461008|NCT01155817|Drug|Nilotinib|200, 400, 800, oral
45461009|NCT03880981|Drug|Ibuprofen 600 mg|ibuprofen 600mg Po q 6 hours prn pain
45461010|NCT03880981|Drug|Acetaminophen|acetaminophen 600mg po q6 hours prn pain
46096260|NCT02643134|Device|External Physical Vibration Lithecbole|Multi-dimensional physical harmonic vibration inertial guidance technology
46096261|NCT04000841|Behavioral|Mindful You mobile app|"The CRSR intervention consists of a native mobile application for Android and iOS devices. The mobile app includes:~Guided meditations of varying length designed to connect the user to the present moment and a place of calm through culturally aligned exercises grounded in spirituality, orality, self-empowerment, and resilience.~User-customized notifications prompting users to reflect and engage with the app, such as providing African American proverbs and quotes and asking simple questions like What are you grateful for today?~Scheduled messages on the importance mindfulness as a way increase control over physical and psychological health~User-customized reminders to do specific meditations and display personally selected images or messages."
46096262|NCT00710398|Behavioral|Exercise - Aerobic and Resistance|Subjects will perform exercise (aerobic and resistance) 7d/wk and will exercise supervised 5d/wk. Exercise will be carried out to expend 250 kcals/day. Supervised resistance training sessions will take place 2 days/wk and aerobic exercise will take place every day. During the resistance exercise sessions, subjects will engage in a circuit weightlifting routine using guided motion machines. During the aerobic sessions, subjects may choose whatever exercise modality they like (e.g. walking on track or treadmill, biking, elliptical, etc.). Subjects will wear devices that measure energy expenditure to get a better idea of the intensity and duration needed to expend 250 kcals with their exercise machine/modality of choice.
45599080|NCT03514537|Drug|Liberase|Liberase TM for use to enzymatically isolate cellular stromal vascular fraction
45599081|NCT03514537|Drug|Saline Solution|Sterile, Normal Saline 500 for Intravenous use
45599082|NCT05255289|Procedure|Urodynamic investigations before and after a trans-obturator tape protocol.|Urodynamic investigations (The urodynamic study included free uroflowmetry, postvoid residual, filling and voiding cystometry, and a urethral pressure profile. The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline similar to body temperature at an infusion rate of 80 ml/min.)
45599083|NCT02293759|Procedure|HoLEP|Holmium laser enucleation of the prsotate
46009471|NCT04548726|Device|Sapien 3 Transcather Aortic Valve Implant|Implant of a Ballon Expandable Aortic Valve Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) prosthesis via a transcatheter procedure.
46009472|NCT04548726|Device|Myval Transcather Aortic Valve Implant|Implant of a Ballon Expandable Aortic Valve Myval (Meril Life Sciences Pvt. Ltd., India) prosthesis via a transcatheter procedure.
46096263|NCT00710398|Behavioral|Dietary - Caloric Restriction|"Subjects will be counselled on their respective hypocaloric diets during the 16 wk period. Adherence to the prescribed diet will be assessed via collection of assigned food records (biweekly), frequent contact with subjects, and regular dietary counseling sessions. The daily dietary energy deficit will be 500 kcal per day based on the subjects' estimated daily caloric requirements (based on height, weight, age, sex), multiplied by a sedentary activity factor.~Additionally, subjects will consume 2 drinks per day that will differ depending on their randomization allocation. Subjects in the Dairy Protein and High Dairy Protein group will be provided with dairy products (e.g. milk, cheese, yogurt) to consume on a weekly basis to help facilitate their prescribed dairy and dietary protein intake."
45461011|NCT03424044|Device|Artificial Pancreas Controller in Dual Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The algorithm has 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to two Omnipod insulin pumps, one filled with insulin and one with glucagon.
45461012|NCT03424044|Device|Artificial Pancreas Controller in Single Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod pump filled with insulin.
45461013|NCT03424044|Device|Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod insulin pump filled with insulin.
45461014|NCT03424044|Drug|XeriSol glucagon|XeriSol glucagon is an investigational drug that is a stable, soluble liquid glucagon formulation that can be injected or administered through an insulin pump. XeriSol glucagon will be used to fill the Omnipod to deliver glucagon for the Artificial Pancreas Controller in Dual Hormone mode.
45461015|NCT03880903|Drug|normal saline and salbutamol|patients will recieve treatment with nebulized salbutamol and normal saline every 4 to 6 in hours
46096264|NCT02647268|Drug|Oxytocin|Oxytocin, 10-5M solution
46096265|NCT02647268|Drug|Magnesium Sulphate|Magnesium sulphate, 3.5mM solution
46096266|NCT04218149|Drug|Bupivacaine Injection|Block with bupivacaine
45679059|NCT01886690|Drug|carboxymethylcellulose sodium based eye drops|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
45679060|NCT01886378|Drug|UX007|
46096267|NCT00710476|Procedure|Insemination|Insemination with a lower concentration of spermatozoa: 150 000 spermatozoa/ml
46096268|NCT04032860|Drug|Tenofovir Disoproxil|patients with HBV-HCC would take TDF as antiviral therapy before curative treatment to see the prognosis after surgery
46096269|NCT04032860|Drug|Entecavir|patients with HBV-HCC would take ETV as antiviral therapy before curative treatment to see the prognosis after surgery
45461016|NCT03880903|Drug|hypertonic saline and salbutamol|patients will recieve treatment with nebulized salbutamol and hypertonic saline 3% in adose of 4ml every 4 to 6 hours
45679061|NCT04616378|Other|Phase 2 Prescribed Prosthesis|Everyday used prosthesis that was prescribed by their physician.
46009473|NCT04548492|Other|Survey|to assess and validate how healthcare professionals can trigger or inhibit the use of modern technology applications in home isolation
46009474|NCT02212886|Drug|GA Depot 80 mg|Recruitment completed
46009475|NCT02212886|Drug|GA Depot 40 mg|Recruitment completed
46009476|NCT04540419|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
46009477|NCT04540419|Biological|Placebo|Intramuscular administration
45461017|NCT03880903|Drug|Hypertonic saline|patients will recieve treatment with nebulized hypertonic saline 3% in adose of 4ml every 4 to 6 hours
45836939|NCT00486642|Drug|Pazopanib Hydrochloride|Given PO
46009478|NCT04570826|Other|Meditation.|The caregivers received eight sessions lasting each one two hours with the following sequence: before each practical exercises they always received 15 minutes about scientific theoretical evidence explaining the importance of doing them: to get a comfortable posture they received 25 minutes of mobility, flexibility, balance, strength and endurance exercises. To increase lung capacity, 25 minutes of costal, diaphragmatic and clavicular breathing exercises. Finally, to have an open attitude without distractions or judging they practiced 25 minutes of body awareness exercise observing sensations, thoughts and perceptions with gratitude and compassion.
46009479|NCT04570826|Other|Scientific descriptions about meditation.|The control group received scientific descriptions about meditation.
46009480|NCT04540614|Other|Strengthening exercises programme|Strengthening exercises for Deep Cervical Flexors, Shoulder external rotators, scapular adductors and thoracic erector muscles
46096270|NCT04217369|Device|Diabits Predictions|Participants will be able to view predictions of future blood glucose. These predictions will indicate where the participant's blood glucose will travel over the next hour given that the participant's state does not change. Based on this, the participant is expected, but not required to make decisions about their activity, food, and insulin, in order to maintain blood glucose in a healthy range. The intervention does not require a specific method of glucose management, or event that a participant takes any action after viewing a prediction, the intervention is simply to display the prediction.
46096271|NCT00716248|Drug|bucillamine|bucillamine 100 mg, twice a day
46096272|NCT00716248|Drug|methotrexate|methotrexate 6 mg or more per week
46096273|NCT02647034|Other|no intervention|no intervention
46096274|NCT04218383|Device|Transcranial Direct Current Stimulation|Anode placed over the OFC and cathode placed over the right primary motor cortex.
46096275|NCT00710632|Other|laboratory biomarker analysis|
46096276|NCT00710632|Other|physiologic testing|
46096277|NCT00710632|Other|questionnaire administration|
45461018|NCT03884257|Device|Passeo-18 Lux treatment group|Percutaneous endovascular angioplasty with the Passeo-18 lux
45679062|NCT04616378|Other|Phase 2 Robotic Prosthetic Leg|The RPL consists of a passive-dynamic ankle, powered knee, and an on-board inertial measurement sensors with an on-board kinetic and kinematic data collection system for analysis.
45679063|NCT04616378|Other|Phase 3 No Prosthesis|No prosthetic device is attached.
45679064|NCT04616378|Other|Phase 3 Robotic Prosthetic Leg|The RPL consists of a passive-dynamic ankle, powered knee, and an on-board inertial measurement sensors with an on-board kinetic and kinematic data collection system for analysis.
45461019|NCT03884257|Device|IN.PACT Admiral treatment group|Percutaneous endovascular angioplasty with the IN.PACT Admiral
45679065|NCT04616378|Other|Phase 3 Prescribed Prosthesis|Everyday used prosthesis that was prescribed by their physician.
45836940|NCT00486642|Other|Pharmacological Study|Correlative studies
46009481|NCT04561427|Other|Study of Sleep architecture in children with narcolepsy|Evaluate the cognitive performances, the effects of narcolepsy treatments on sleep architecture and the metabolic status of these children
46096278|NCT00710632|Procedure|management of therapy complications|
46096279|NCT00651638|Drug|Treatment with ARQ 197|Treatment with ARQ 197
46096280|NCT00716326|Device|Transcutaneous Nerve Stimulation (TENS)|Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises. The TENS will be used during 3-4 weeks of hospitalization. If patients want to continue the use of TENS/placebo-TENS at home, they will be offered to borrow equipment for 4 months.
46096281|NCT00716326|Device|Cefar Primo Pro TENS device|"Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises.~Active TENS: high-frequency modulated pulse duration stimulation Placebo TENS: manipulated device with impulses near sensory threshold."
46096282|NCT02643212|Drug|Rivaroxaban|
46096283|NCT02643212|Drug|Placebo|
46096284|NCT04218227|Behavioral|Self-hypnosis/self-care group|Self-hypnosis/self-care
46096285|NCT04218227|Behavioral|Music/self-care|Music-therapy/self-care
46096286|NCT04218227|Behavioral|Self-care|Self-care
46096287|NCT04218227|Behavioral|Psycho-education|Psycho-education
46096288|NCT04218227|Behavioral|Self-hypnosis/self-care motivation|Motivation to learn self-hypnosis/self-care
46096289|NCT00716404|Device|Targeted Renal Therapy|Patient diagnosis, treatment, and follow-up are left to the discretion of the participating investigator. There are no requisites as to how patients should be managed as this is intended to be an observational study. No procedures other than usage of the Benephit Infusion System per its Instructions for Use are specifically required for participation in this study.
45836941|NCT04388514|Procedure|Medical Ozone procedure|The systemic ozone treatment procedure was decided by the physician on duty and started preliminarily at the patient's bed with the drawing of autologous blood and, after proper O2/O3 mixing, with its re-infusion. After junction of an adequate venous patient's way with a dedicated latex free plastic bag containing 35 ml of sodium citrate, a blood amount of 200 ml is taken. At the end, the withdrawal line was washed and the re-infusion one was filled with saline solution. The blood, without any patient disconnection, was then mixed with a gas mixture of a 200 cc composed by 96% of Oxygen and 4% of Ozone with a therapeutic O3 range of 40 μg/mL of gas per mL of blood. In order to guarantee the O2/O3 homogeneous diffusion into the blood, the bag was gently mixed for about 10 minutes, therefore the blood was re-infused into the patients. The duration of ozone treatment lasted for 3 consecutive days.
45836942|NCT00428922|Drug|Trastuzumab|administered every three weeks on day 1, every 21 days. The dose given will be 6 mg/kg. The initial loading dose is 8mg/kg and is administered as a 90-minute infusion. Thereafter, the maintenance dose is 6mg/kg every three weeks administered as a 30 minute infusion (unless the treating physician indicates a longer infusion duration is warranted). Trastuzumab is given prior to bevacizumab. Trastuzumab is to be continued until disease progression or unacceptable toxicity.
46096290|NCT02642978|Procedure|RSRCLM|The Da Vinci Surgical System may help to overcome some of the difficulties of laparoscopy for complicated abdominal surgery. The aim of this study was to present an innovative technique that is robot-assisted, simultaneous radical resection of both colorectal cancer and liver metastasis (RSRCLM).
46096291|NCT02642978|Procedure|Open|Traditional open simultaneous radical resection of both colorectal cancer and liver metastasis
46096292|NCT00719992|Procedure|coronary angiography|effect of level of HS-CRP
46096293|NCT03723161|Device|Bone Achored Hearing surgery|This is a observational study of pediatric patients undergoing bone anchored hearing surgery. The collected data will be used to assess the implant stability development of the Ponto BHX implant during up tp 24 months after implantation in a pediatric population undergoing bone anchored hearing surgery.
46096294|NCT02642900|Procedure|Photodynamic Therapy|evaluate the effectiveness of photodynamic therapy (PDT) in the treatment of denture stomatitis in complete denture wearers.
46096295|NCT02642900|Drug|Nystatin 100.000 units|Control group treated with nystatin
46096296|NCT02749643|Device|Vibrotactile feedback system|
46096297|NCT04068532|Drug|Placebo|Administered as specified in the treatment arm.
46096298|NCT04068532|Drug|BIIB104|Administered as specified in the treatment arm.
46096299|NCT02652728|Drug|Enalapril Orodispersible Minitablet|Weight-dependent dose titration and long-term treatment scheme with enalapril ODMTs of 0.25 mg and 1 mg strength
46096300|NCT00720070|Procedure|positron emission tomography/computed tomography|Patients undergo PET/CT scan
46096301|NCT00720070|Procedure|therapeutic conventional surgery|Patients undergo neck dissection
46096302|NCT04216901|Diagnostic Test|Endoscopists refer to AI for diagnosis|The AI will provide a pathological prediction of the lesion during colonoscopy.
46096303|NCT00720148|Drug|Sunitinib and Bortezomib|50 mg/m2, IV (in the vein)on day 5 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops
46096304|NCT04165460|Other|Psychoeducation|Delivering systematic information about cancer, oncological treatment and efficient coping strategies.
46096305|NCT04165460|Other|Relaxation|Teaching the patient in diaphragmatic breathing retraining and passive relaxation with guided imagination.
46096306|NCT04165460|Other|Cognitive Restructuring|Teaching the patient to identify dysfunctional cognitions about cancer and oncological treatment that trigger maladaptive emotions and behavior. Then, focus in generating alternative thoughts through contrast with empirical reality based on the Beck Model.
46096307|NCT04165460|Other|Solving Problems|To generate alternative solutions to practical problems based on the model described by Nezu.
46096308|NCT04216979|Procedure|laparoscopy entry policy|"Patients will be randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site.~Group (B):- The umbilicus is the primary entry site."
46096309|NCT00710788|Drug|sevelamer phosphate-binders|1600 mg/day for 2 years
46096310|NCT00710788|Drug|Calcium Carbonate|Calcium carbonate 1 g/day for 2 years
46096311|NCT04068220|Other|intraoperative FVEPs monitoring|During the surgery, a pair of goggles (similar to the swimming goggles) will be placed on patient's closed eyes. The goggles equipped with red LEDs will apply no pressure or minimal pressure on patient's closed eyes. Patient's left eye then right eye will be stimulated with flashing red light emitted by the goggles. Two subdermal needle electrodes will be placed under the skin behind patient's ears, and one subdermal needle electrode will be placed under the skin above the bridge of patient's nose. The two electrodes placed behind patient's ears, will record intraoperative flash visual evoked potentials (FVEPs) resulted from red light stimulation of patient's visual pathway through the eyes and the electrode above the bridge of the nose will record, at the same time, the activity of each eye's retina.
46096312|NCT03530189|Drug|10% dextrose|After birth the intravenous 10% dextrose at 60-90 ml/kg/day will be started as soon as possible
46009482|NCT04548531|Behavioral|Shared Decision Making|"The decision aid is a paper information sheet presenting the pros and cons of three screening options (colonoscopy, stool-based tests, and postponing cancer screening until next year).~The decision coaching is a structured interview to help patients clarify their preference for screening test and to support them in implementation (whether scheduling colonoscopy, ordering stool test or seeking additional advice from specialist)."
45461020|NCT01155895|Drug|Amlodipine Besylate / Benazepril Hydrochloride|10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
45461021|NCT01265485|Drug|coated suppository|Dose escalating study
45461022|NCT01159483|Drug|PF-04958242|Administered as specified in the treatment arm
45679066|NCT04616144|Device|Fresh Corneal Lenticule Implantation using Relex-Smile VisuMax Femtosecond Laser|Fresh Corneal Lenticule Implantation using ReLex-Smile
46096313|NCT03530189|Drug|bolus of dextrose, reducing the glucose infusion, insulin|"Hypoglycemia will be treated with 2 mL/kg to 3 mL/kg (200-300 mg/kg) intravenous bolus of 10% dextrose.~Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion."
46096314|NCT02646800|Drug|Micafungin|Injection
46096315|NCT02749409|Drug|Parecoxib|
46096316|NCT02749409|Drug|Morphine|
45461023|NCT01159483|Drug|Placebo|Administered as specified in the treatment arm
45461024|NCT01157767|Other|standardized regimen of exercises, including a warm-up period, ROM arm exercises, and strength training exercises.|Module I is a group of arm movements. It consists of stretching exercises coordinated with breathing exercises to restore their physical mobility, range of motion and flexibility of shoulders. Module I is to be performed daily. In Module II the exercises are a series of copyrighted, sequential movements designed to put the body in proper alignment. It is a special series of muscle movements to help establish better body alignment, as well as increased strength and flexibility of one's arms, legs, and spine, each exercise is 4 repetitions. Module III is the walking and the resistance weight training program. The walking program is whole body exercise, multi-joint, weight-bearing, low impact and for beginners to advanced.
45461025|NCT03422250|Device|transcranial direct current stimulation (tDCS)|10 daily 25-minutes tDCS sessions over two weeks.
45679067|NCT04590404|Behavioral|Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach.|Automated calls to assess smoking status, medication use, and additional support for quit attempt.
45679068|NCT04590404|Drug|Nicotine Replacement Therapy|FDA-approved forms of nicotine replacement therapy for smoking cessation.
45679069|NCT04590404|Drug|Varenicline|FDA-approved smoking cessation medication.
46009483|NCT04570592|Drug|Granisetron 1 Mg/mL Intravenous Solution And Dexamethasone 4mg|Comparing PONV incidences in both arms
46009484|NCT04570592|Drug|Granisetron 1 Mg/mL Intravenous Solution|Comparing PONV incidences in both arms
46009485|NCT04540263|Diagnostic Test|Flow Cytometric analysis|Measuring the level of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokines in the serum
46009486|NCT04570514|Procedure|PCI|percutaneous coronary intervention (PCI)
46096317|NCT02647112|Other|Bladder EpiCheck|Urine test for the monitoring of bladder cancer recurrence
46096318|NCT03454529|Other|Laboratory Biomarker Analysis|Correlative studies
46096319|NCT03454529|Drug|Simvastatin|Given PO
46096320|NCT03449459|Dietary Supplement|oral probiotics|"Culturelle™ DIGESTIVE HEALTH 30 CT(VCAP)(10 Billion Claim) which consists of 100% Lactobacillus rhamnosus GG, 1 tablet, q.d., for 3 months.~Subjects will take conventional therapy at the same time."
46096321|NCT03449459|Drug|aerosol inhaled amikacin|"0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 5-7 days per month, for 3 months.~In order to observe and cope with adverse events timely, subjects will be admitted to the ward during the course of medication.~Subjects will take conventional therapy at the same time."
46096322|NCT03449459|Biological|combined vaccination|"Influenza Vaccine recommended by World Health Organization(WHO) in that year and imported 23-Valent Pneumococcal Polysaccharide Vaccine approved by China Food and Drug Administration(CFDA) are vaccinated at different body sites by professional nurses.~The interval between two vaccinations is 3-5 days to avoid the overlap of adverse events.~Subjects will take conventional therapy at the same time."
45461026|NCT01159561|Biological|Western Equine Encephalitis Vaccine|Subject will be vaccinated with 0.5 mL of reconstituted WEE vaccine, inactivated, TSI-GSD 210 (Lot 3-1-92) subcutaneously in the upper outer aspect of the deltoid region.
45461027|NCT01265641|Drug|AZD1981, 2000mg|Single oral dose, tablets
45679070|NCT04590404|Other|Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)|Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy. NMR is a blood test to measure how fast the body breaks down nicotine.
45679071|NCT01885208|Drug|semaglutide|One dose of 1.0 mg semaglutide administered subcutaneously (s.c., under the skin) once-weekly
46009487|NCT04548414|Other|No.|This is an observational study with no intervention.
46096323|NCT02646878|Device|Harmony 1 Sensor|Use of Harmony 1 Sensor for 10 days when inserted in the arm and abdomen and used with the Guardian Mobile in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 6 months.
46096324|NCT00653120|Drug|Propranolol|ER capsules, 160 mg, single-dose
46009488|NCT04560959|Device|tACS|tACS would be performed to epilepsy patients who have already received implantation of the SEEG electrodes
46009489|NCT04548336|Behavioral|Motor Imagery|Motor imagery group will have to imagine motor gestures of static and dynamic balance
46096325|NCT00653120|Drug|Inderal-LA|ER capsules, 160 mg, single-dose
46096326|NCT02695511|Other|Caloric restriction|25% caloric restriction below baseline energy requirement
46096327|NCT00877032|Biological|RN6G|intravenous, single dose, dose ranging from 0.3mg/kg up to a maximum of 40 mg/kg.
45461028|NCT01265641|Drug|AZD1981, 200mg|Single oral dose, tablets
45461029|NCT01265641|Drug|Moxifloxacin, 400mg|Single oral dose, capsule
45461030|NCT01265641|Drug|Placebo|Single oral dose, tablets
45679072|NCT01885208|Drug|exenatide|One dose of 2.0 mg exenatide ER administered subcutaneously (s.c., under the skin) once-weekly
45679073|NCT01859702|Drug|Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution|
46009490|NCT04548336|Behavioral|Action observation|Action observation group will have to observe static and dynamic equilibrium motor gestures
46009491|NCT04548336|Behavioral|Placebo group|This group will watch a video of nature without a human component.
46096328|NCT00877032|Biological|Placebo|intravenous, single dose with experimental dose.
46096329|NCT02652338|Dietary Supplement|MNC-01|twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
46096330|NCT02652338|Dietary Supplement|Placebo|twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
46096331|NCT03318809|Drug|AMG 986|tablets for oral administration
45461031|NCT03712800|Other|Rhythmical massage|Rhythmical Massage according to Dr Ita Wegman, derived from Swedish Massage in the 1920s. Applied for various indications in the context of Anthroposophic Medicine, aiming at a recovery of self-regulation and self-healing forces.
45461032|NCT03712800|Behavioral|HRV biofeedback|One of various biofeedback types, HRV biofeedback gives a visual feedback of the participant's heart rate variability as an indicator for general health, physical and cognitive performance, self-regulation and a decreased risk of illness.
45461033|NCT01589809|Drug|nicotinamide|dose-escalation, 2-8 grams, oral
46009492|NCT02211872|Drug|BI 2536 BS, intravenous|
46009493|NCT02214459|Behavioral|DASH Mobile mhealth enhanced coaching|Phone calls with a health coach that utilize the tracking data collected by the app and devices.
45461034|NCT02527135|Behavioral|Weekly HIV sensitization text messages|"Weekly HIV sensitization text messages with option to text back up to 3 times per week for additional messages. Message topics included pregnancy, condoms, sexually transmitted infections, contraceptives, anal sex and personal risk of HIV. All messages ended with the phrase Get tested for HIV."
45461035|NCT01264237|Drug|Etoricoxib|90mg Tablet QD at 10:00a.m.
45461036|NCT01264237|Drug|Placebo|One tablet QD at 10:00a.m.
45461037|NCT03884413|Other|questionnaires|Longitudinal observational study. Collection of health data using self-administered questionnaires online.
45836943|NCT00428922|Drug|Bevacizumab|administered every three weeks on day 1, every 21 days. The dose given will be 15 mg/kg. The initial dose is administered over 90 minutes. If the first infusion is well tolerated, the second dose is given over 60 minutes, and if that is well tolerated, then subsequent doses may be given over 30 minutes. Avastin is given after trastuzumab and prior to docetaxel.
46009494|NCT04561037|Device|Pulsed Electromagnetic Field therapy (PEMFT)|PEMFT was connected to electrical mains supplying 220v. Pair of applicators sized 16x10x3 cm was adjust to be over TMJ, on both sides of the face; the appliance was adjusted to the frequency of 50 HZ and intensity of 90 Gauss. Twelve PEMF treatment sessions of 30 min duration were provided 3 times per week TMJ mobilization techniques and isometric exercises against resistance for muscles of mastication
46009495|NCT04561037|Other|TMJ physical therapy program|TMJ manual physical therapy program (mobilization and gentle isometric exercises) for 30, 3 times a week, for 4 weeks.
46096332|NCT02642510|Other|Structured Education DVD + Verbal Teaching|"The structured education DVD is a 15-minute DVD presentation of information about unit routines and activities; leukemia/lymphoma; treatment modalities and procedures; treatment of side effects; and participant and family members activities of importance to prevent infection and promote well-being during cancer treatment.~Participants will also receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects."
46096333|NCT02642510|Other|Verbal Teaching|Participants will receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects.
46096334|NCT02642666|Behavioral|Children's Yoga|"Trained children's yoga instructors will guide the children through 30 minute yoga classes (in-person and on the yoga video), using a manualized curriculum from If I Was a Bird Yoga ™ with child centered themes. Each class will have a similar structure, set of poses, and breathing exercises, but the theme of the class will change every two weeks. The themes for the classes are ocean yoga adventure, jungle yoga adventure and outer space yoga adventure. The study participants will spend two weeks practicing the same theme at home and at school before moving on to the next theme."
46096335|NCT02628210|Other|map3® Cellular Allogeneic Bone Graft|Patients will receive map3® Cellular Allogeneic Bone Graft
45461038|NCT03880747|Procedure|Vagus nerve-preserving distal gastrectomy|Laparoscopic distal gastrectomy with the preservation of the celiac and hepatic branch of the vagus nerve.
45461039|NCT03880825|Drug|Metformin 500 mg Oral Tablet|single dose
46009496|NCT04548453|Device|uterine electromyography|Multichannel uterine electromyography will record uterine biosignals during labor.
46009497|NCT02215395|Drug|NES/EE CVR|Concurrent administration of vaginal antimycotic medication (Miconazole Nitrate) on the pharmacokinetics of Nestorone (NES) and ethinyl estradiol (EE) delivered by a contraceptive vaginal ring (CVR)
46009498|NCT04561310|Other|Post facilitation stretch|"Post facilitation stretch with maitland mobilization Grade I & II Maitland mobilization of shoulder joint in 1st and 2nd week progressing to Grade III oscillatory mobilization of shoulder joint in 3rd week. It will further progress to Grade IV Maitland oscillatory mobilizations in the 4th or 5th week.~Treatment will be provided 3 session/week for 6 weeks with 40 minutes/session"
45461040|NCT03880825|Drug|Levoketoconazole 150 - 600 mg (BID)|escalating dose from 150 mg to 600 mg (BID)
45461041|NCT01159639|Drug|Clopidogrel|patients with inappropriate response to aspirin 300 mg after CABG, assessed by multiple electrode aggregometry are randomized to receive clopidogrel 75 mg daily dose
45461042|NCT03880357|Drug|Betamethasone Scalp Suspension 0.064%;0.0005%|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
45461043|NCT03880357|Drug|Taclonex®|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
45461044|NCT03880357|Drug|Placebo topical suspension|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
45461045|NCT03884335|Procedure|laparoscopic radical prostatectomy|The surgery was carried out by laparoscopy. Intraoperative anesthetic maintenance was performed with TCI of propofol infusion for bispectral index between 40 and 60, restrictive administration of fluids or goal-directed parenteral fluid administration, normothermia, normotension and optimal intraoperative analgesia were maintained following the criteria of ERP. Afterwards, patients were awoken from general anaesthesia and transferred to the post-anaesthesia care unit (PACU) for a 6-hour follow-up prior to transfer to conventional ward.
46009499|NCT04561310|Other|Active release technique|"Active release technique with maitland mobilization Grade I & II Maitland mobilization of shoulder joint in 1st and 2nd week progressing to Grade III oscillatory mobilization of shoulder joint in 3rd week. It will further progress to Grade IV Maitland oscillatory mobilizations in the 4th or 5th week.~Treatment will be provided 3 session/week for 6 weeks with 40 minutes/session"
46009500|NCT02215434|Drug|Biolipid B2 (blanked/placebo)|the intervention will be the comparison effects of both emulsions
46096336|NCT00910832|Drug|Eductyl suppository|one suppository every morning during 21 days
45461046|NCT05470933|Drug|WJ01075|"Phase Ia: Dose Escalation Accelerated titration (the first two dose groups) and 3 + 3 combination (the subsequent dose group) were used for dose escalation.~Phase Ib: Dose Expansion and Cohort Expansion The actual dose, dosing schedule (including combination) and indication selection will be evaluated based on the results of existing trials."
45599084|NCT02293759|Procedure|Greenlight laser PVP|Greenlight laser (532nm) Photoslective vaporization of the prostate
45599085|NCT02345187|Dietary Supplement|Beverage powder fortified with Bacopa Monnieri Extract and Multiple Micronutrient supplementation|The study product (fortified beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
45679074|NCT04599686|Drug|ADT|On the day of enrollment, luteinizing hormone-releasing hormone agonist (LHRHa) was given for ADT.
45679075|NCT04599686|Radiation|SBRT|Evaluating men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT) (3-5 fractions).
45679076|NCT01835132|Device|Gevokizumab|Subcutaneous injection of 60 mg gevokizumab
45679077|NCT01747551|Drug|Oxaliplatin|
45679078|NCT01747551|Drug|Leucovorin|
45679079|NCT01747551|Drug|Fluorouracil|
45679080|NCT01747551|Drug|Ziv-aflibercept|
45679081|NCT01736397|Drug|Ferric Citrate|Dose depends on serum phosphorus levels collected at each study visit.
46009501|NCT02215434|Drug|Testosterone, Transdermal, Behavior|Transdermal 0.5% testosterone Biolipid/B2
45836944|NCT00428922|Drug|Docetaxel|administered every three weeks on day 1, every 21 days. The dose given will be 75 mg/M². All doses of docetaxel are administered over 60 minutes. Docetaxel is given after trastuzumab and bevacizumab.
45836945|NCT00533442|Drug|Rapamycin|Rapamycin was initiated on day 1 postoperatively, 4mg/day;levels were maintained 5-8ng/ml. Those patients randomized to receive mycophenolate mofetil were given 1gm twice/day starting on the first post-operative day.
45836946|NCT00533442|Drug|Mycophenolate Mofetil|MMF 1 gm BID beginning 1st day postoperative day
46009502|NCT04561076|Drug|HLX70|Single-dose, intravenous infusion
46009503|NCT04561076|Other|Placebo|Single-dose, intravenous infusion
46009504|NCT02215473|Drug|Chlorhexidine gluconate mouth rinse|Before local oral anesthesia and periodontal instrumentation individuals performed a single oral rinse (15mL of 0.12% chlorhexidine gluconate for 30 seconds). Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
45836947|NCT00533442|Drug|Tacrolimus|Part of standard maintenance.
45836948|NCT00533442|Drug|Steroids|Part of standard maintenance
45836949|NCT00533910|Drug|Rifaximin|550mg BID rifaximin for 8 weeks
45836950|NCT00533910|Drug|placebo|same as the experimental arm
45836951|NCT01954524|Drug|IV bolus injection of Sildenafil|"Dose escalation will be performed (in different participants). The doses will be as follows:~CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil."
45836952|NCT00535002|Drug|Yohimbine|Participants were pre-treated with either yohimbine or placebo.
45599086|NCT02345187|Dietary Supplement|Non-fortified isocaloric beverage powder|The study product (non-fortified isocaloric beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
45679082|NCT01736397|Drug|Placebo|
45679083|NCT01859390|Drug|AquADEKs-2|AquADEKs-2 contains standard amounts of fat-soluble vitamins (A, D, E, K) that are contained in typical CF multivitamin supplements plus several antioxidants including beta-carotene, mixed tocopherols (different forms of vitamin E), coenzyme Q10 (CoQ10), mixed carotenoids (lutein, lycopene and zeaxanthin), and the minerals zinc and selenium.
45836953|NCT00535002|Drug|Placebo|
45836954|NCT02117934|Biological|HEPLISAV|Intramuscular injections at Week 0 and Week 4, plus a placebo injection at Week 24
45836955|NCT02117934|Biological|Engerix-B|Intramuscular injections at Week 0, Week 4, and Week 24
45836956|NCT00429702|Drug|Decadron®|Given IV
45836957|NCT00429702|Drug|Benadryl®|Given IV
46009505|NCT02215473|Procedure|Periodontal instrumentation|Individuals only received local oral anesthesia before periodontal instrumentation. Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
45599087|NCT02299063|Drug|Dexmedetomidine|A bolus dose of 0.5 mcg/kg infused over 10 minutes will be administered, followed by a continuous infusion for the duration of the surgery at 0.6 mcg/kg/hr.
45599088|NCT02299063|Drug|0.9% NaCl|
45599089|NCT03149289|Drug|Antiviral drugs|sofosbuvir, ribavirin, daclatasvir, ledipasvir, simeprevir, paritaprevir, dasabuvir, ombitasvir
45679084|NCT01859390|Dietary Supplement|control multivitamin|The control multivitamin contains standard (standard for CF multivitamin supplements) amounts of vitamins A, B, D, E, and K without added antioxidants.
45679085|NCT01858766|Drug|SOF|400 mg tablet administered orally once daily
45461047|NCT03879031|Diagnostic Test|Cluster of Clinical tests to measure lumbar stability|"All subjects will be submitted to a cluster of clinical test before the starting of the first session, and at the ending of the last session of the physical therapy program. This cluster will include:~Aberrant Movements (AM) Test,~Active Straight Leg Raise Test (ASLR) Test,~Supine Bridge Test (SuBT),~Right Side Bridge Test (RBT),~Left Side Bridge Test (LBT),~Prone Bridge Test (PrBT),~Passive Lumbar Extension (PLE) Test,~Prone Instability Test (PIT)."
45461048|NCT01262521|Dietary Supplement|Dietary nitrate|150 ml tab water with 150 umol/kg sodium-nitrate
45461049|NCT01262521|Dietary Supplement|Water|150 ml Chapelle mineral water
45461050|NCT01264393|Behavioral|Shape Up Rhode Island + Online Resources|Participants will receive Shape Up Rhode Island, which is a 12-week statewide physical activity and weight loss campaign in addition to online weight loss resources
45461051|NCT01264393|Behavioral|Shape Up Rhode Island + Online Weight Loss Program|Participants will receive Shape Up Rhode Island, a 12-week statewide physical activity and weight loss campaign in addition to an online weight loss program
45461052|NCT01264393|Behavioral|Shape Up Rhode Island + Online Weight Loss Program + Group sessions|Participants will receive Shape Up Rhode Island, a 12-week statewide physical activity and weight loss campaign in addition to an online weight loss program and the option of attending group sessions
45461053|NCT01157923|Device|MD Logic Pump Advisor|Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
45679086|NCT01858766|Drug|VEL|Tablet administered orally once daily
45836958|NCT00429702|Drug|Ativan®|Given IV
46009506|NCT04560842|Device|A high flow oxygen device.|The HFNC group use high flow oxygen device for 48 hours
46009507|NCT04560842|Device|Conventional oxygen therapy|Conventional oxygen device
46009508|NCT04548102|Other|Fetal movement count|Pregnant women in the study group received verbal information regarding normal fetal movements (i.e. description of the changing pattern of movement as the fetus develops, normal sleep/wake cycles, and factors which may modify the mother's perception of movements such as maternal weight and placental position), and its importance to be followed during the third trimester. A chart for fetal movements counting provided and to ensure proper performance of this task, women telephoned once a week. They also asked to show the fetal movements chart to the researcher and the health care providers in each visit. Women followed according to her antenatal visits schedule till delivery.
46096337|NCT00910832|Drug|Placebo suppository|placebo suppository every morning during 21 days
46096338|NCT00678132|Drug|AZD 2281|
45461054|NCT01266031|Drug|vorinostat|Vorinostat 400mg/day will be administered on day 1 to 7 and day 15 to 21 orally on a 28 day cycle in the arm with combination of vorinostat and bevacizumab. Vorinostat will be administered orally. Vorinostat capsules should not be opened or crushed and must be administered whole.
45461055|NCT01266031|Drug|bevacizumab|Bevacizumab 10mg/kg will be administered on day 1 and 15 intravenously on a 28 day cycle in both arms.
45461056|NCT01264471|Procedure|Skin biopsy|A small skin sample will be obtained from the patients arm which is approximately the size of the top of a thumbtack (a small circle no more than a 1/4 inch across)
45461057|NCT01264471|Procedure|Blood Collection|Approximately 45ml or 3 tablespoons for blood will be drawn from a vein in the patient's forearm.
45461058|NCT03880045|Drug|Topical TA|A gauze soaked with 2 g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride0.9%
45461059|NCT03880045|Drug|vasopressin|intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy
45679087|NCT01858766|Drug|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45679088|NCT01734993|Drug|Tocilizumab|Participants will receive TCZ 162 milligrams (mg) SC injection once a week.
45679089|NCT01745367|Drug|Tivozanib Hydrochloride|
45679090|NCT01745367|Drug|paclitaxel|
45679091|NCT01745367|Drug|Placebo|
45679092|NCT01733121|Drug|NBI-98854|25 mg capsule
45679093|NCT01733121|Drug|NBI-98854|50 mg capsule
45836959|NCT00429702|Drug|ondansetron hydrochloride|Given IV
46096339|NCT00678132|Drug|Cisplatin|
46096340|NCT00678132|Drug|Gemcitabine|
46096341|NCT02789345|Drug|Ramucirumab|Administered IV
46096342|NCT02789345|Drug|Necitumumab|Administered IV
46096343|NCT02789345|Drug|Osimertinib|Administered orally
45679094|NCT01733121|Drug|Placebo|
45679095|NCT01744977|Behavioral|packaging|Intervention provides usual statin medication dispensed in pre-prepared adherence packaging (blister packaging) rather than the previously received prescription bottles
45679096|NCT01383928|Drug|Ixazomib|Ixazomib capsules
45679097|NCT01383928|Drug|Lenalidomide|Lenalidomide capsules
45679098|NCT01383928|Drug|Dexamethasone|Dexamethasone Tablets
45679099|NCT04023604|Other|Controlled diet with beef raised without antibiotics|The controlled diet with beef raised without antibiotics will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern. Beef included in this diet were raised without antibiotics.
46096344|NCT00651716|Other|flow cytometry|Lymphocyte Analysis: Lymphocyte subset studies will be performed on samples obtained from the patient, donor, or graft. Aliquots will be analyzed using standard flow cytometry.
46009509|NCT04560764|Device|Virtual Reality|"Participants in both groups will attend 10 sessions of approximately 30 minutes each three times a week. Each session contemplates the execution of a single repetition of two minutes of each of the four exercises.~There are four exercises:~Reaching: the participant is requested to reach a target in front of him with the paretic hand; the target will appear in a different place every time;~Reaching and grasping: the participant is requested to grab a wooden cube with the paretic hand and place it into a bowl positioned in front of him; the cube will appear in a different place every time;~Goalkeeper: the participant is requested to block a ball coming towards him with the paretic hand; the ball will appear in a different place every time;~Occupational task: the participant is requested to grab four cans, one at time, with the paretic hand and place them on four targets placed on a hemispherical arch.~Each exercise provides six levels of increasing difficulty."
45679100|NCT04023604|Other|Controlled diet with beef produced in conventional systems|The controlled diet with beef raised without antibiotics will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern. Beef included in this diet were raised with antibiotics.
45679101|NCT05365048|Other|Local Tailoring implementation strategy|"The local-tailored approach will be guided by a structured process involving the following: (1) convening a local HPV vaccine project team, (2) conducting a local diagnostic process to identify top barriers, (3) selecting from a menu of intervention options that will be offered in this study, categorized by core function (i.e., the forms and functions menu) that address top local barriers, and (4) deploying the selected interventions. The barrier assessment and intervention customization are key processes for the local-tailored strategy, which allow clinics to devote resources to respond to unique local barriers in addition to common barriers."
46009510|NCT04560764|Device|Action Observation Therapy|"Before the execution of the exercises described in the intervention Virtual Reality, the participants in the experimental group will see a video demonstrating the same exercise (according to the level of difficulty selected) he will be later asked to perform for two minutes."
46009511|NCT04560764|Device|Landscape video|"Before the execution of the exercises described in the intervention Virtual Reality, the participants in the sham comparator group will see a video of a natural landscape for two minutes."
46009512|NCT04560764|Other|Standard treatment|Participants in both groups will receive the standard treatment, one hour a day for three days a week.
45679102|NCT05365048|Other|Prescribed Strategy|"The prescribed strategy is the standard implementation approach used by most health systems. Our prescribed approach will be guided by the evidence-based, award-winning 4 Pillars™ Practice Transformation Program for improving vaccination rates in the outpatient setting. The 4 Pillars™ address 4 main functions, i.e., convenience, communication, office systems, and motivation to guide the selection of interventions. For adolescent HPV vaccination, the 4 Pillars has demonstrated moderate effectiveness."
45679103|NCT05368012|Drug|MIDCAB|Ultrasound-guided administration of the nerve block MIDCAB into mid-calf as analgesic intervention for patients.
45461060|NCT03880045|Other|placebo to TA|(120 ml of sodium chloride 0.9%) used to compress the myoma bed for 5 min.
45836960|NCT00535392|Drug|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose.~Dosage for subjects not on levetiracetam at study entry was based on weight: if <50 kg, the dose was 20 mg/kg/day (10 mg/kg/day twice daily); if weight ≥ 50 kg, the dose of levetiracetam intravenous (LEV IV) was 1000 mg/day (500 mg twice daily)."
46009513|NCT04548219|Drug|Mirikizumab|Administered SC.
46009514|NCT04570241|Behavioral|Malaria toolkit|Knowledge, attitude, and practice on malaria
46009515|NCT02215512|Drug|RRx-001 + WBRT|Subjects will receive a combination of RRx-001 and whole brain radiotherapy.
46009516|NCT04548258|Device|electric intraoral weilding|weilding metal framework to the implants in completely edentulous maxilla using electric weilding device intraorally
46009517|NCT04548258|Device|casting|casting metal framework
46009518|NCT04560803|Device|CelluTomeTM Epidermal Harvesting System|Autologous epidermal grafts that will be placed at the treatment site
46096345|NCT00651716|Other|laboratory biomarker analysis|Identification of gut-homing and skin-homing Treg subsets
45836961|NCT00535782|Drug|Tocilizumab|Administered by intravenous infusion, 8 mg/kg every 4 weeks.
45461061|NCT01159873|Drug|CEP-37251|up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of CEP-37251 (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) dose of 0.3 mg/kg will be studied.
45461062|NCT01159873|Drug|Placebo|up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of Placebo (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) placebo dose of 0.3 mg/kg will be studied.
45599090|NCT05624801|Drug|D3 VitaCaps®|Gelatine free soft capsules containing 24'000 IU cholecalciferol per capsule
45599091|NCT03515239|Procedure|lumbopelvic fixation for spinopelvic dissociation|unilateral and bilateral lumbopelvic fixation for spinopelvic dissociation
45599092|NCT04478097|Drug|CKD-330 Tab. and D086 Tab.|1T
45599093|NCT04478097|Drug|CKD-333 Tab.|1T
45599094|NCT01161641|Drug|ODSH at 0.125 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 1 of 0.125 mg/kg/h.
45679104|NCT05367388|Drug|APL-101|"APL-101 (Vebreltinib) is an orally available small molecule, which is a tyrosine kinase inhibitor (TKI) for the mesenchymal epithelial transition protein tyrosine kinase receptor (c-Met) with high selectivity and potency.~The treatments to be administered in this study include:~• Treatment A (reference): Two 100 mg APL-101 (Vebreltinib) capsules (200 mg dose), manufactured for Apollomics, Inc."
46009519|NCT02215590|Device|Re-Step|"Research Group:~Each session begins with a warm-up exercise, muscle stretching, and strengthening exercises: duration 10 minutes.~Afterwards, walking exercises for 40 minutes with Re-Step according to a program individually tailored and progressing with the training. Progress is shown by an increased range of tilting of the shoe and speed of changes, according to the individual ability of each patient.~At the end of the session 10 min of cool-down exercises~22 training sessions of 60 minutes each, twice a week."
46009520|NCT04547829|Drug|pegylated recombinant human granulocyte-colony stimulating factor|The dosage was determined according to the patient's weight, 100 UG / kg each time; The method of administration: subcutaneous injection; The time of administration: 24-48 hours after the end of chemotherapy, once in each chemotherapy cycle.
46009521|NCT04547634|Other|Therapeutic Exercise and Education|The intervention will consist of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualized based on the evaluations of muscular strength and endurance. Sessions lasted 1 hour, carried out twice a week, for 12 weeks. This intervention will be complemented by nutritional education.
45461063|NCT03880201|Procedure|ultrasound guided supraclavicular block|"The linear transducer will be applied firmly above the clavicle in the coronal oblique plane the 22-gauge needle will be inserted at the lateral side of the ultrasound probe using In-plane approach. The needle will be advanced towards the target nerves inferior, lateral and superficial to subclavian artery respectively. Local anesthetic solution is injected between 20 to 25 ml.~Motor block will be assessed as follow Radial nerve = Push the arm by extending the forearm at the elbow against the resistance, musculocutaneous nerve = Resisting the pull of the forearm at the elbow, median nerve = Thumb and second digit pinch, ulnar nerve = Thumb and fifth digit pinch.~Sensory block will be assessed by using piece of ice in the distribution of median, ulnar, radial and musculocutaneous nerves."
46009522|NCT02211911|Drug|Bisacodyl|
46009523|NCT02211911|Drug|Sodium picosulfate|
46096346|NCT00651716|Other|Data Collection|Patient samples will receive an alphanumeric code assigned by the principal investigator so that patient and donor identity will be known only to study investigators and research staff. Clinical records on each patient will be reviewed by participating investigators or research staff on a routine basis so that relevant clinical information including survival, malignancy relapse, and GVHD can be included in the patient database. Flow cytometry results will also be included in this database.
46096347|NCT02628054|Biological|Typhoid Vaccine|Typhoid Vaccine injection given 7 days apart
45679105|NCT05367388|Drug|PLB-1001|"PLB-1001 (Bozitinib) is a chemical drug category 1.1 innovative drug. It is a highly effective and highly selective c-Met tyrosine kinase inhibitor.~The treatments to be administered in this study include:~• Treatment P (test): Two 100 mg PLB-1001 (Bozitinib) capsules (200 mg dose), manufactured for Beijing Pearl Biotechnology Co., Ltd."
45679106|NCT01382602|Biological|AMDC-USR|AMDC-USR Treatment
46096348|NCT02628054|Biological|Placebo|Saline injection given 7 days apart
46096349|NCT02652572|Drug|Granexin|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
46096350|NCT02772965|Drug|Methotrexate|"Oral methotrexate (MTX): The weekly dose will be 15 mg for children ≥ 40kg, 12.5 mg for children 30 to <40 kg, and 10 mg for children 20 to <30 kg.~A twice per week, 4mg dose of ondansetron will be provided as pre-treatment to prevent nausea (study provider may opt-out of this component based on clinical judgement).~A 1 mg dose of folic acid per day will be provided. This will help to reduce the risk of side effects in the MTX group.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits."
46096351|NCT02772965|Other|Sugar pill (placebo)|"Placebo for methotrexate: The weekly dose will mimic that of methotrexate.~Placebo for ondansetron: The weekly dose will mimic that of ondansetron (study provider may opt-out of this component based on clinical judgement).~A 1 mg dose of folic acid per day will be provided to maintain blinding.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits."
46096352|NCT00681720|Drug|AZD7325|Single dose of oral solution or capsule. 3 times per subject.
46096353|NCT00681720|Drug|Radioligand (11C) flumazenil|Single dose of i.v solution. 4 times per subject. (3 times together with AZD7325)
45679107|NCT01382602|Biological|Placebo|Placebo treatment
45836962|NCT00535782|Drug|Placebo|Placebo to tocilizumab administered by intravenous infusion every 4 weeks.
45836963|NCT00535782|Drug|Methotrexate|Administered orally or parenterally, 7.5-25 mg weekly.
46009524|NCT04540146|Diagnostic Test|Flow-Cytometric analysis|IL-2, 4, 5, 6, 9, 10, 13, 17A, 17F, 22, IFN-γ and TNF-α levels in the intraabdominal ascites
46009525|NCT04560491|Diagnostic Test|Intraoperative examination of sentinel node|Intraoperative examination of sentinel node by either frozen section or scrape cytology to detect metastasis and decide for further lymphadenectomy.
46009526|NCT01131676|Drug|BI 10773 low dose|BI 10773 tablets once daily
46096354|NCT00650312|Drug|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fasting
46096355|NCT00650312|Drug|Glucophage® XR Tablets 500 mg|500mg, single dose fasting
46096356|NCT02749253|Other|Sudarshan Kriya Yoga Tauma Relief Program (SKY).|Sudarshan Kriya Yoga Trauma Relief Program (SKY) participants will undergo a 12-week training course in SKY conducted by certified instructors from the Art of Living Foundation
46096357|NCT02646956|Other|sweeteners|Participants tasted a variety of nutritive and nonnutritive sweeteners
46096358|NCT02106689|Device|Needle free system|Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
46009527|NCT01131676|Drug|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
46009528|NCT01131676|Drug|BI 10773 high dose|BI 10773 tablets once daily
45836964|NCT00431184|Drug|Pentazocine|see arms description
46009529|NCT01131676|Drug|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
46009530|NCT01131676|Drug|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
46009531|NCT01131676|Drug|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
46096359|NCT02106689|Device|Standard needle injection system|Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
46096360|NCT04165304|Dietary Supplement|sugar reduction|sugar reduction in the offered drinks
45683816|NCT02813668|Behavioral|Lifestyle Intervention Training Program|Participants will be placed into a peer-led classes of 10 to 12 people. The curriculum contains sixteen core sessions that occur weekly for four months followed by an eight month maintenance period. During lifestyle classes, participants will learn strategies for eating a healthy diet, increasing physical activity, overcoming barriers, building social support, reaching and maintaining a healthy wait, and maintaining healthy blood glucose levels. Participants will also be assigned goals to achieve; increasing physical activity and losing 5% of their baseline body weight. During maintenance, participants will receive biweekly SMS text messages providing lifestyle advice tips and encouragement.
45836965|NCT00431184|Drug|Lorazepam|see arms description
46009532|NCT04560569|Drug|Albuvirtide|Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
46009533|NCT04560569|Drug|3BNC117 Antibody|Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120
46009534|NCT04547322|Other|VR application group|During the transfer from the general surgery clinic to the operating room (3-5 minutes) and in the surgery waiting room, the VR aplication group were asked to wear a virtual reality headset (VR BOX 2) and headphones minimizing sound loss (Earpods with Apple Lightning Connector) that are compatible with mobile phones with IOS operating system. The VR headset and the headphones were controlled by a mobile phone (iPhone 7 Plus). The researchers had the patients watch three-dimensional videos (e.g. underwater world, museum trips, forest and park walks, beach trips, and space travel) for 10 minutes with their preferred background and relaxing music.
46096361|NCT00681798|Drug|Vandetanib|100mg/300mg
45836966|NCT00535938|Other|botulinum toxin type A|There will be no protocol-mandated intervention with regard to physician treatment choice or management of patient condition once the patient is enrolled in the project.
45836967|NCT00537576|Biological|Low dose LACTIN-V applicator|Low dose LACTIN-V applicator (150 mg LACTIN-V, 5.0 x 10^8 CFU), administered vaginally once a day for 5 consecutive days
45836968|NCT00537576|Biological|Medium dose LACTIN-V applicator|Medium dose LACTIN-V applicator (300 mg LACTIN-V, 1.0 x 10^9 CFU), administered vaginally once a day for 5 consecutive days
46009535|NCT04539990|Behavioral|Behavioral treatment for sleep difficulties|"This intervention is mediated by the parents. Parents are educated regarding sleep hygiene and instructed to follow simple rules which create a reliable evening routine and reduce exposure to stimulating factors that delay sleep onset (e.g., caffeine or exercise). In addition, parents are asked to initiate a fading behavioral protocol whereby they teach their child to fall asleep independently, with less parental attention. This requires parents to limit their interaction with their child after the children are put to bed so as not to interfere with sleep onset. This includes limiting conversations and lying in bed with the child. This behavioral approach is applied gradually and is expected to reduce the time it takes children to fall asleep."
46009536|NCT04560530|Radiation|Non-enhanced CT scan of the chest|Non-enhanced CT scan of the chest with multi-slice CT scan machine.
46009537|NCT04540029|Other|Maternal stress|Prenatal COVID-19-related stress retrospectively self-reported by mothers after delivery.
46009538|NCT04560374|Device|crochet octopus|Delivering crochet octopus to the hands of the neonates
46009539|NCT04539912|Device|angulated screw retained crown|ASC abutment was used in AG;
45461064|NCT03880201|Device|Masimo SET pulse oximetry (Masimo Corporation, Irvine, CA, USA)|Masimo reading of PI values will be recorded every minute (at both index and fifth digits) for 20 minutes then every 3 minutes for 30 minutes.
45461065|NCT03879889|Drug|Nicotine patch|Four weeks of nicotine patch will be provided at the first contact, which will be prescribed using the guidelines based on the subject's daily cigarette consumption. At week-4 visit, four more weeks of NRT will be provided.
46009540|NCT04539912|Device|cemented crown|prefabricated Ti abutment was used in CG
46009541|NCT04560257|Device|High flow nasal cannula HFNC|High flow nasal cannula HFNC is a device that delivered the warmed and humid air on high flow rate through nose. It is used to treat severe respiratory distress in COVID-19 patients, a non-invasive ventilatory approach which is relative comfortable by using humidified and pre-heated air containing large concentration of oxygen.
46009542|NCT04547361|Drug|E2511|E2511 tablets.
46009543|NCT04547361|Drug|E2511 Matched Placebo|Placebo tablets matching E2511 tablets.
46009544|NCT02882971|Behavioral|Pain Assessment|To create an objective observational pain scoring system and validate.
46009545|NCT02215629|Drug|VS-4718|
46096362|NCT02749487|Other|Neutrophil Lymphocyte Ratio|Neutrophil:lymphocyte ratio (NLR) is an emerging biomarker that is used to predict mortality and morbidity. The association of this biomarker with systemic illness and its usefulness in risk assessment of critically ill patients has not been fully elucidated.
45679108|NCT05893433|Device|Bedside cycling|"participants receive daily cycling once the patient is relatively stable by weaning off the ventilator and off the require inotropic support and continued to the discharge from the hospital.~Duration progression if the following conditions are reached:~Initially increase the duration by up to15 min of low exercise time and then increase the intensity after the patient can complete 15- 20 min.~Complete 15min with a medially stable condition gradually until reaching 20 minutes besides the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment."
45461066|NCT01159951|Other|Epidemiologic Surveillance System of the Ministry of Health of Panama|Systematic review of the databases of epidemiologic surveillance system, Ministry of health, Panama
45461067|NCT01158001|Behavioral|Prolonged exposure therapy|Twelve sessions (90 minutes each) of prolonged exposure therapy
45461068|NCT03883789|Diagnostic Test|FibroScan|FibroScan will be used to assess liver stiffness
45461069|NCT01158079|Drug|ALN-VSP02|The dose of ALN-VSP02 will be administered at the same dose level and schedule received at the completion of the previous study
45461070|NCT01155973|Behavioral|EDUCORE intervention|Direct exhibition of their cardiovascular risk with SCORE, visual images and documentation to the patients
45461071|NCT01155973|Other|Control group|SCORE oral information and counseling as standard practice care
45683817|NCT04276324|Other|Resistance training|Ten weeks of resistance training
45836969|NCT00537576|Biological|High dose LACTIN-V applicator|High dose LACTIN-V applicator (600 mg LACTIN-V, 2.0 x 10^9 CFU), administered vaginally once a day for 5 consecutive days
46009546|NCT01131520|Behavioral|Computerized brief intervention|This is a brief computerized intervention focused on drug use of patients receiving primary care treatment in an outpatient setting. The intervention is delivered in one session.
46009547|NCT01131520|Behavioral|Counselor delivered brief intervention|This is a one session brief intervention delivered in a primary care setting that is based on motivational interviewing.
46009548|NCT01131325|Drug|nilotinib|All patients will receive nilotinib 300mg bid po daily. Nilotinib dose is taken every 12 hours
46096363|NCT00538681|Drug|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral (po), daily (QD), until disease progression
46096364|NCT00538681|Drug|pemetrexed|500 milligrams/square meter (mg/m²), intravenously (IV), every 21 days, for each 21-day cycle
46096365|NCT00538681|Drug|cisplatin|75 mg/m², IV, every 21 days, for each 21-day cycle
46096366|NCT00538681|Drug|placebo|po, QD
46009549|NCT04547244|Other|echocardiographic optimization of CRTd|the patients after the implant of CRTd and during the follow-up will receive an echocardiography to optimize the atrio-ventricular and inter-ventricular delay, and to improve the effects of CRTd.
45461072|NCT03883555|Device|High flow nasal therapy (HFNT) : Optiflow™|"HFNT will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs.~Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance"
45461073|NCT03883555|Device|Non invasive ventilation (niv)|"NIV will be delivered through a face mask connected to a dedicated ventilator with pressure support applied in a noninvasive ventilation mode (Monnal T75, Airliquide Medical Systems, Antony, France).~The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort."
45461074|NCT01266109|Behavioral|Contingency Management-Family Engagement (CM-FAM)|Evidence-based outpatient intervention for adolescent substance use
45461075|NCT01266109|Other|Usual Services (US)|Typical community-based substance abuse treatment services
45461076|NCT03879187|Dietary Supplement|High-fat, high-energy diet|Participants consumed a diet that was high in fat and high in energy
45461077|NCT01266187|Procedure|adjuvant surgery + FOLFOX + cetuximab|surgery -> 4-8 weeks rest -> 24 weeks FOLFOX + cetuximab
46009550|NCT04560062|Other|Spontaneous changes in diabetes-related health care|The findings of a retrospective cohort analysis conducted in the initial phase of the study will be used in focus groups to identify observed weaknesses in local health systems and will promote possible solutions to strengthen diabetes-related health care. Every focus group will include community members, healthcare workers, decision-makers and diabetic patients and family members.
46009551|NCT01131130|Device|Investigational contact lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
45679109|NCT05893433|Other|control|the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment.
45679110|NCT05893420|Device|eCARTv5 clinical deterioration monitoring|eCART is a predictive analytic used for the identification of acute clinical deterioration built upon more than a decade of ongoing scientific research and chronicled in numerous peer-reviewed publications. eCART draws upon readily available patient data from the EHR, rapidly quantifies disease severity, and predicts the likelihood of critical illness onset.
45679111|NCT05893420|Other|Standard of care control|Standard of care is the health system's clinical best practices and workflows for identifying high-risk patients for clinical deterioration, including other tools already built into the electronic health record (EHR). Hospitals that do not implement eCARTv5 will be compared as a control against hospitals that do implement eCARTv5.
45679112|NCT05893407|Diagnostic Test|Measuring contrast-enhanced ultrasound perfusion with phase inversion harmonic imaging|Contrast-enhanced ultrasound perfusion imaging (PerCEUS) will be performed by a dedicated study team. The transcranial color duplex sonography will be performed with a 1-5 MHz dynamic sector array (S5-1) from a Philips Epiq 7 ultrasound machine (Philips Healthcare, Andover, MA). The field-of-view will be set to an imaging depth of 150 mm in a sector angle of 90°. The imaging plane will be then tilted to the diencephalic, in which the frontal horns of the side ventricles and the third ventricle serve as landmarks and where the anterior and posterior middle cerebral artery (MCA) territory and the basal ganglia (BG) as region of interest could be identified without artefacts from major vessels. High mechanical index bolus imaging will be performed from the sanest side of the head. Data acquisition of 45 seconds will be recorded immediately after the beginning of the contrast ultrasound imaging, using a mechanical index (MI) setting of 1.1 and a frame rate of 33 Hz.
45679113|NCT05893381|Drug|[177Lu]Lu-PSMA I&T|The radiopharmaceutical 177Lu-PSMA-I&T will be administered, by slow intravenous injection, in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 GBq.
45679114|NCT05893381|Radiation|Stereotactic Radiotherapy|Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen, depending on the target size and the surrounding normal tissue constraints,
45683818|NCT04276324|Other|Testing sessions|Testing sessions
45836970|NCT00537576|Other|Low dose Placebo applicator|Low dose Placebo applicator (150 mg Placebo), administered vaginally once a day for 5 consecutive days
45836971|NCT00537576|Other|Medium dose Placebo|Medium dose Placebo applicator (300 mg Placebo), administered vaginally once a day for 5 consecutive days
46009552|NCT01131130|Device|Acuvue Oasys Contact Lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
46009553|NCT01131130|Device|Air Optix Aqua|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
46009554|NCT04547478|Diagnostic Test|low dose chest CT(LDCT)|cross sectioned muscle area of the 1st vertebrae level obtained by LDCT
45461078|NCT01266187|Procedure|perioperative/Folfox + cetuximab|"12 weeks FOLFOX + cetuximab -> 4 weeks rest -> surgery~-> 4-8 weeks rest -> 12 weeks FOLFOX + cetuximab"
46009555|NCT01130974|Device|Bausch & Lomb contact lens|Bausch & Lomb daily disposable cosmetic tint contact lens
45461079|NCT01264627|Behavioral|Mindful Breathing (MB) Intervention|"The Mindful Breathing (MB)intervention is based on MBSR developed by Jon Kabat-Zinn. Participants will attend 8 individual weekly MB sessions. MB consists of closely following the breath, throughout inhalation and exhalation, sustaining moment-to-moment awareness on the breathing process, and passively observing thoughts, affective states, from a non-evaluative or judgmental perspective. As attention wanders to concerns or thoughts, participants will be instructed to acknowledge and accept these without evaluation and return the focus of attention back to breathing. Participants in MB will have their breathing rate and PetCO2 monitored during the 8 training sessions with a breathing monitor."
45599095|NCT01161641|Drug|ODSH at 0.375 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 3 of 0.375 mg/kg/h.
46009556|NCT01130974|Device|Marketed daily disposable contact lens|Marketed daily disposable cosmetic tint contact lens
46009557|NCT04560101|Drug|botulinum toxin A|Intramuscolar injection of botulinum toxin in affected muscles
46009558|NCT02214498|Drug|Enalapril/hydrochlorothiazide|The intervention implies that morning and evening administration of enalapril/hydrochlorothiazide will be compared
45599096|NCT01161641|Drug|ODSH at 0.250 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 2 of 0.250 mg/kg/h.
45599097|NCT03518281|Dietary Supplement|Whole Cell Euglena containing Beta Glucan|Whole Cell Euglena containing >50% Beta Glucan
45599098|NCT03518281|Dietary Supplement|Placebo|microcrystalline cellulose, hypromellose, titanium dioxide, water
46096367|NCT00650390|Biological|adalimumab|40 mg adalimumab every other week
45836972|NCT00537576|Other|High dose Placebo applicator|High dose Placebo applicator (600 mg Placebo), administered vaginally once a day for 5 consecutive days
45836973|NCT01795794|Drug|omeprazole|
45836974|NCT01795950|Drug|PLX-PAD|intravenous administration of a single dose of PLX-PAD cells
45836975|NCT01796028|Drug|METFORMIN|
46009559|NCT02214498|Drug|Placebo|
46009560|NCT04311775|Device|larengeal mask insertion with video laryngoscopy|it is a method of inserting a laryngeal mask into the airway with videolaryngoscopy
46009561|NCT04311775|Other|laryngeal mask insertion|laryngeal mask is a method of inserting atube into the upper airway
46009562|NCT04560218|Drug|sublingual Misoprostol|apply drug by Anesthesiologist
46009563|NCT04560218|Drug|Intrauterine Misoprostol|apply drug by surgeon at uterine cornu
46009564|NCT05135104|Drug|Palbociclib|"Palbociclib, an orally active pyridopyrimidine, is a potent and highly selective reversible inhibitor of CDK 4 and CDK6. The compound prevents cellular DNA synthesis by prohibiting progression of the cell cycle from G1 into the S phase. Specifically, Palbociclib inhibits CDK4/6-catalyzed phosphorylation of the retinoblastoma protein (Rb), which is required for cell division.~Palbociclib has selectivity for CDK4/6, with little or no activity against a large panel of 274 other protein kinases including other CDKs and a wide variety of tyrosine and serine/threonine kinases.~Therapeutic indications:~Palbociclib is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or MBC:~in combination with an aromatase inhibitor;~in combination with fulvestrant in women who have received prior endocrine therapy."
46009565|NCT04547517|Other|Evaluation of Counselling competencies|To complete a set of questionnaires
46009566|NCT04559828|Other|Experimental meal|Two dietary oils will be administrated as part of a single experimental meal, for the present is a postprandial phase study.
46009567|NCT04579718|Other|Zeus Cloud TPS V1.0|Zeus Cloud TPS V1.0 is used to design the radiotherapy plan for the subjects and the plan is evaluated.
46096368|NCT00681876|Drug|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
46096369|NCT00681876|Drug|Avastin|Avastin (IV) 10 mgr/Kgr on day 1 every 2 weeks until progression
46096370|NCT00681876|Drug|Erbitux|Erbitux (IV)500 mg/m2 on day 1 every two weeks until progression
46096371|NCT00653198|Other|No intervention|
46096372|NCT00533663|Procedure|Healing Touch|every other week (during their infusion)
46096373|NCT00533663|Other|Standard care|Adriamycin, cyclophosphamide, and paclitaxel administered as standard of care
46096374|NCT00533663|Procedure|guided relaxation|
45461080|NCT01264627|Behavioral|Usual Care (UC) Control Condition|"This control intervention is designed to account for the effects of nonspecific factors such as enrollment in a study to enhance health with the associated expectancy effects, staff attention, and measurement procedures including the monitoring of PetCO2 and (Blood Pressure) BP, and completion of questionnaires. Participants who are randomly assigned to the Usual Care condition will receive care as usual for the management of their prehypertensive condition. UC participants will receive their usual care and have access to all Kaiser Permanente (KP) health education resources, such as KP's interactive healthcare guide, and online Healthy Lifestyle Programs. We will assess the extent to which participants in both MB and UC used these resources."
45461081|NCT05666947|Other|Home-based exercise|Eight weeks of home-based exercise programs
45461082|NCT01586533|Drug|Zoenasa-1:4|Zoenasa Rectal Gel (4.0g mesalamine [5-ASA], 1.0g N-acetylcysteine [NAC]; 60ml)
45461083|NCT01586533|Drug|Mesalamine Enema|Mesalamine Rectal Suspension Enema (4.0g mesalamine [5-ASA], 60ml)
45461084|NCT03883321|Other|Cognitive behavioral stress management|Management of patients in 10 group sessions with cognitive and behavioral therapies associated with relaxation in order to learn how to manage stress
45461085|NCT03523039|Device|CytoSorb® Hemoadsorption|The therapy is initiated within 6 hours from randomization and maintained for a minimum of 12 consecutive hours to a maximum of 24 consecutive hours.
45461086|NCT01158235|Drug|LTX-109|1%, 2% and 3% Lytixar (gel formulation). TID for 3 days.
45461087|NCT03879265|Diagnostic Test|Noninvasive chromosome screening|Screening based on MALBAC-NGS technology
45679115|NCT05893368|Other|Sharing all key aspects associated with the quality of life in a single digital environment|"A digital platform called DNMLAB (DNMLAB) offers the possibility of sharing all key aspects associated with the quality of life in a single digital environment by activating:~a digital narrative diary in which the patient has the opportunity to share with the multidisciplinary team her needs, critical issues~report Patient-Reported Outcome Measures (PROMs) aimed at detecting health-related quality of life (i.e. QLQ-C30-B23 EORTC).~digital narrative diary focused on three main areas of health-related behavior-nutrition, physical activity, and sleep habits-aimed at personalizing and reshaping lifestyle, daily behaviors and, if required, the care pathway.~The patient will be guided by narrative prompts, but at the same time will always be free to share all aspects related to her lifestyle that she deems useful, in addition to those detected, to benefit from a personalized care approach."
46009568|NCT04579718|Other|Eclipse|Eclipse TPS of Varian company is used to design the radiotherapy plan for the subjects and the plan is evaluated.
46009569|NCT04540185|Biological|Biological: oral polio vaccine|Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
45461088|NCT01158313|Dietary Supplement|Thickened supplement|New thickener to be mixed to liquid to obtain different viscosities such as nectar viscosity, honey viscosity, conservative spoon-thick viscosity (CST) and extreme spoon-thick viscosity (EST
45461089|NCT03880123|Drug|Selinexor|"Selinexor will be taken orally on Days 1, 8, 15, and 22 of each cycle at the following dose levels (DLs):~DL 1: 40 mg; DL 2: 60 mg; DL 3: 80 mg; DL 4: 100 mg~The selinexor product is provided as 20 mg tablets in wallet-sized blister packs. Selinexor should be taken together with ixazomib."
45461090|NCT03880123|Drug|Ixazomib|"Ixazomib will be taken orally on Days 1, 8, and 15 of each cycle at the same dose level: 4 mg.~The ixazomib product is provided in strengths of 4.0, 3.0, and 2.3 mg capsules as the active boronic acid. Ixazomib should be taken on an empty stomach (no food or drink) at least 1 hour before or at least 2 hours after food."
46009570|NCT04540185|Biological|Comparable Placebo|Placebo of a vaccine 0.1 ml administered orally on a sugar lump
46009571|NCT04540185|Drug|NA-831|Drug: NA-831 30 mg of NA-831 in a capsule administered orally
46009572|NCT04540185|Drug|Comparable Placebo of drug|Placebo 30 mg in a capsule administered orally
46009573|NCT04540185|Combination Product|Combination of oral polio vaccine and NA-831|Combination of biological: Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump and drug NA-831 30 mg in a capsule administered orally
46009574|NCT04540185|Combination Product|Comparable Placebo of Oral Polio Vaccine and Placebo of drug|Combination of biological placebo 0.1 ml administered orally on a sugar lump and drug placebo 30 mg in a capsule administered orally
45461091|NCT01266499|Drug|Colistin (Polymyxin E) 100mg x 4/d|Colistin (Polymyxin E) 100mg x 4/d
45461092|NCT01266499|Drug|both medications|PO Garamycin 80mg x 4/d +PO Colistin (Polymyxin E) 100mg x 4/d
45461093|NCT01266499|Drug|will not receive PO treatment|will not receive PO treatment - will receive plecebo treatment
45461094|NCT01266499|Drug|PO Garamycin 80mg x 4/d|PO Garamycin 80mg x 4/d
45461095|NCT00075725|Drug|Cyclophosphamide|Given IV
45461096|NCT00075725|Drug|Cytarabine|Given IT, SC, or IV
45461097|NCT00075725|Drug|Daunorubicin Hydrochloride|Given IV
45461098|NCT00075725|Drug|Dexamethasone|Given PO or IV
45679116|NCT05893329|Drug|Mitoxantrone hydrochloride liposome injection|Intravenous infusion on day 1 in a 4-week treatment cycle.
46096375|NCT02642276|Other|Exercise training|Patients to be randomized to the 'maximal walking group' or 'submaximal group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
46096376|NCT00186095|Procedure|autologous followed by nonmyeloablative allogeneic transplant|
46009575|NCT00575744|Procedure|Sentinel Node Biopsy|Once the patient is asleep under anesthetic, they receive an intraoperative injection of 1.0 mCi of Technetium-99 sulfur colloid into normal breast tissue surrounding the primary cancer or biopsy cavity directed subareolar or around the tumor. This is followed by blue dye injected in the subareolar complex approximately 5 minutes prior to incision. The sentinel node biopsy is performed, followed by lumpectomy/mastectomy, and a completion axillary node dissection if the sentinel node(s) were positive.
46009576|NCT02214537|Other|MACS|
46009577|NCT01130272|Drug|Eluxadoline|Tablets, orally, twice daily.
45461099|NCT00075725|Drug|Doxorubicin Hydrochloride|Given IV
45461100|NCT00075725|Drug|Leucovorin Calcium|Given IV
45679117|NCT05893329|Drug|Cytarabine|Intravenous infusion
46009578|NCT01130272|Drug|Placebo|Matching placebo oral tablets twice daily.
46009579|NCT04559789|Behavioral|MindMate + Health Coaching|The MindMate app is a digital multi-domain lifestyle intervention designed to address modifiable risk factors for dementia. The app will be augmented with digital health coaching provided by Neurotrack.
46009580|NCT04559789|Other|Health Education|Health education materials delivered electronically
45461101|NCT00075725|Drug|Mercaptopurine|Given PO
45461102|NCT00075725|Drug|Methotrexate|Given IT or IV
45461103|NCT00075725|Drug|Pegaspargase|Given IM
45461104|NCT00075725|Drug|Prednisone|Given PO or IV
45461105|NCT00075725|Radiation|Radiation Therapy|Undergo radiation therapy
45461106|NCT00075725|Drug|Thioguanine|Given PO
45461107|NCT00075725|Drug|Vincristine Sulfate|Given IV
45461108|NCT03883399|Other|Survey|Survey among colorectal surgeons
45461109|NCT03879967|Device|Allograft block graft|The graft used is a mineralized, cortico-cancellous, delipidized, lyophilized allogenic block.
45461110|NCT02953782|Drug|Magrolimab|Administered intravenously
45461111|NCT02953782|Drug|Cetuximab|Administered intravenously
45679118|NCT05893329|Drug|Homoharringtonine|Intravenous infusion
45679119|NCT05893329|Drug|Venetoclax|Orally once a day
46096377|NCT02642120|Device|"Dental device Laboraide"|"After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.~Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire."
46096378|NCT05405647|Device|Shock wave Therapy|a program of 6 session of Shock wave Therapy on the affected wrist,5 minute per session and a frequency of 5 Hz., 1 sessions per week for 6 weeks.
46096379|NCT05405647|Device|kinesio tape|kinesio tape application on the affected wrist for 3 days and then one day off and then another 3 days each week for 6weeks.
46096380|NCT05358457|Behavioral|Familiar Metacognitive Training|The original metacognitive training program consist of 8 therapeutic units and 2 complementary. Seven of the therapeutic units address cognitive deviations and errors that are frequently seen in problem solving in schizophrenia, involved in the formation and maintenance of delusions. The other three units work with metacognition and the aims of the progra, as a psychoeducation session, so in total the MCTf will include 11 sessions.
45461112|NCT01158391|Device|NTrainer® Intervention|
45461113|NCT01158391|Device|Control Intervention|
45461114|NCT03883711|Other|Database|Create a database containing clinical characteristic, clinical presentation, flow indexes and treatment of consecutive incident patients with ACS or myocardial injury.
45461115|NCT01264783|Drug|RNS60|RNS60 for intravenous administration
45461116|NCT01264783|Drug|Placebo|0.9% normal saline for injection
45461117|NCT03712722|Other|Faecal microbiota transplantation (FMT)|FMT delivered by colonoscopy, nasojejunal tube, glycerol-based capsules, or freeze-dried encapsulated donor faeces
45461118|NCT01262911|Drug|SRT2379|SRT2379 will be supplied as hard gelatin capsules, with each containing 250mg.
45461119|NCT01262911|Drug|Placebo|Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
45461120|NCT03717792|Other|no intervention|no intervention
45461121|NCT01156129|Drug|stool softener|ducosate sodium, Milk of Magnesia, dulcolax
45679120|NCT05893316|Diagnostic Test|urine sample collection|The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN.
45836976|NCT01796028|Drug|Placebo|
45836977|NCT01796028|Drug|TAXOTERE®|
45836978|NCT00491244|Drug|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
46009581|NCT04559399|Procedure|smiley face shape rod|For treatment of isthmic spondylolithesis a transpedical screws for the same level and rod revolve around spinal process to stabilization of pars interarticularis of the same segment after removes bone at the margine of defects pars till reach to healthy bleed margine then put bone graft at the defect then stablizing pars and bone graft by rods.
46009582|NCT04539600|Drug|Camrelizumab|Camrelizumab is a type of anti-PD-1 antibody that could enhance the immune system of the patient to fight cancer.
46009583|NCT00575822|Device|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
45461122|NCT01156129|Device|Arm B: Acupressure bracelet|Bioband
46009584|NCT00575822|Device|Sham Control|The sham procedure was identical to the treatment procedure through the positioning of the retroflexed Plicator 1cm below the GE junction. The Plicator instrument remained in this position for 15 minutes, based on average procedure times established in previous studies. During the sham procedure, physician investigators were required to talk through the procedure steps to maintain the patient blind.
46009585|NCT04546815|Drug|Daptomycin|According to the severity of the disease, the site of infection and clinical response, the doctor makes a drug regimen of datoramycin.
45461123|NCT01156129|Dietary Supplement|sugar free gum|Orbit
45461124|NCT03712644|Device|FFR-guided coronary revascularization|Stenoses in range of 50-90% diameter stenosis in major coronary arteries will be assessed by FFR, and revascularized if FFR equal to or lower than 0.80. Lesions above 90% diameter stenosis in will be revascularized without further assessment.
45461125|NCT01160029|Drug|Nateglinide|Nateglinide Tablets 120 mg
45461126|NCT03717714|Dietary Supplement|Glucosamine 1500 mg|Patients in this group take 3 capsules, each capsule contains Placebo 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
45461127|NCT03717714|Dietary Supplement|Polycan 50mg + Glucosamine 750 mg|Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 250 mg, once a day for 12 weeks
46009586|NCT01129960|Drug|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
46009587|NCT01129960|Drug|Placebo|Tablets will be used.
45461128|NCT03717714|Dietary Supplement|Polycan 50mg + Glucosamine 1500 mg|Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
45461129|NCT01264861|Drug|Safinamide|"Safinamide 100 mg/day = two 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 200 mg/day = four 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 150 mg = three 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 300 mg/day = six 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 250 mg = five 50 mg tablets administered orally, once a day, in the morning, with or without food."
45461130|NCT03760081|Drug|ASP1650|Participants received ASP1650 dose level 1 or dose level 2 as intravenous infusion, Q2W starting on C1D1 for up to a maximum of 12 cycles or until study discontinuation criterion was met, whichever occurred earlier. Duration of each treatment cycle was 14 days.
45461131|NCT03422172|Drug|Oral CAB|CAB tablet will be formulated as white to almost white, oval shaped, film coated 30 mg tablets, administered orally once daily. The CAB tablets will be packaged in bottles containing 30 tablets each.
46009588|NCT04539756|Behavioral|positive psychological intervention|Participants will be asked to complete writing activities every other day. They will choose which activity they would like to complete each day, from a menu of six different activities. Each activity is a different positive psychology exercise.
46096381|NCT02751203|Behavioral|Make Safe Happen App|The Make Safe Happen app is a mobile app (available for free download android and iOS) developed by the safety experts in the Center for Injury Research and Policy. Parents and caregivers can use the app to learn how to make their homes safer with room-to-room safety checklists and links to recommended products. App users can also create to-do lists, set reminders and track their progress.
46096382|NCT02642198|Device|Surveyor S12 and S19 patient monitor|Non-invasive blood pressure measurement
45679121|NCT05893303|Other|1st Group|1st group is going to undergo scapula-oriented PNF techniques (diagonal) which are anterior elevation and posterior depression - posterior elevation and anterior depression with 20 repetitions with rhythmic initiation and repeated contractions facilitation techniques during all patterns. In addition to PNF techniques, gait training is going to be applied as standing with balance exercises (15 repetitions) as well as specific exercises for the stance and swing phases of the gait which are; stepping forward and sideways (15 repetitions), and gait education (walking 3 lapses within 2 meters parallel bar)
45679122|NCT05893303|Other|2nd Group|2nd group is going to undergo only gait training and balance exercises (15 repetitions) as well as specific exercises for the stance and swing phases of the gait which are; stepping forward and sideways (15 repetitions), and gait education (walking 3 lapses within 2 meters parallel bar)
46009589|NCT04539756|Behavioral|Active control condition|Participants will be asked to complete the same writing activity each day, which will ask them to list their daily activities. Participants will be encouraged to process their daily activities superficially by the receiving the following instructions: (1) list each activity in brief, incomplete sentences, (2) document only facts about performing the activities, and (3) to not provide any information about emotional responses to performing the activities. By following these instructions, participants are presumably deriving less meaning from their activities, which may minimize gains in positive affect in the active control condition
46009590|NCT01129921|Device|Percutaneous Lumbar Decompression|Fluoroscopic percutaneous lumbar decompression of the central spinal canal
46009591|NCT01129921|Device|Sham lumbar decompression|Sham fluoroscopic percutaneous lumbar decompression with no bone or tissue removal.
46009592|NCT04559672|Procedure|Cervical laminoplasty surgery|The posterior standard cervical laminoplasty procedure with ARCH mini-plate fixation
46009593|NCT04559672|Procedure|Cervical laminectomy and fusion surgery|The posterior standard cervical laminectomy and fusion surgery procedure with lateral mass screws fixation
46009594|NCT04312087|Procedure|Lateral neck sentinel lymph node biopsy|Lateral neck sentinel lymph node biopsy is performed in all patients in Arm B.
46009595|NCT04312087|Procedure|Modified lateral neck lymph node dissection|Modified lateral neck dissection (compartment II-V) is performed in all patients in Arm A, and some of the patients in Arm B (according to sentinel lymph node biopsy results).
46009596|NCT04312087|Procedure|Super selective lateral neck lymph node dissection|Super selective lateral neck lymph node dissection is performed in some of the patients in Arm B (according to sentinel lymph node biopsy results).
46009597|NCT04311814|Diagnostic Test|Maximum urethral closure pressure during Valsalva (v-MUCP)|v-MUCP measurement was performed for all patients referred for urodynamic exploration of the lower urinary tract
46009598|NCT04559165|Other|sericin and chitosan cream|sericin and chitosan cream
46009599|NCT04312048|Drug|Isosorbide mononitrate|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to copper IUD insertion
46009600|NCT04312048|Drug|placebo|one tablet of placebo vaginally 3 hours prior to copper IUD insertion
46096383|NCT05404243|Drug|phenolization|In case of phenolization group, an Abbocath catheter 18 G is introduced into the cystic cavity. Undiluted 88% phenol is instilled into the cavity, ensuring that the cystic cavity is filled. It is maintained for 5 min until complete coagulation of the cyst is achieved.
46096384|NCT05404243|Procedure|Conventional surgery|In case of conventional surgery, entire exeresis is performed by means of an electric scalpel
46096385|NCT04217681|Behavioral|Self-hypnosis/self-care|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
46096386|NCT04217681|Behavioral|Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
45461132|NCT03422172|Drug|CAB LA|CAB LA is a sterile white to slightly colored suspension containing 200 mg/mL of CAB as free acid for administration by IM injection in gluteus medius.
45836979|NCT00491244|Drug|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
46009601|NCT04547127|Biological|Convalescent anti-SARS-CoV-2 MBT Plasma|Intravenous infusion.
46009602|NCT04547127|Drug|Standard Medical Treatment|SMT
46009603|NCT00625222|Procedure|transcranial direct current stimulation|1mA, 15 Minutes, constant direct current
46009604|NCT04311697|Drug|Aviptadil by intravenous infusion + standard of care|Aviptadil by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.
46009605|NCT04311697|Drug|Normal Saline Infusion + standard of care|Saline by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.
46009606|NCT00575861|Drug|zileuton|zileuton (Zyflo) 600mg qid for 2hr and for 30 days
46009607|NCT04547088|Drug|Camrelizumab|Anti-PD-1 targeted immunotherapy
46009608|NCT04547088|Drug|Apatinib|A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor
46009609|NCT04559360|Device|PRESTOapp|The intervention group will be asked to use the app for a period of 2 months.
46009610|NCT01129882|Drug|Aripiprazole|Aripiprazole IM depot - 300 mg or 400 mg
46009611|NCT04546854|Behavioral|Appeals|Written text motivating participants to take up the seasonal influenza vaccination
46009612|NCT00575900|Behavioral|dietary intervention|12 weeks of dietary intervention
46096387|NCT04217681|Behavioral|Self-hypnosis/self-care motivation|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
46096388|NCT04217681|Behavioral|Self-hypnosis/self-care malignant pain|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
46096389|NCT02749097|Drug|SHR0534|
46009613|NCT02278419|Drug|Simeprevir|Simeprevir 150 mg capsule orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
46009614|NCT02278419|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
45461133|NCT00057863|Drug|Paclitaxel|Given IV
45461134|NCT00057863|Drug|Oxaliplatin|Given IV
45461135|NCT03960749|Device|Sprotte 25G needle, stylet reinserted|Lumbar puncture with small bore atraumatic needle, stylet reinserted before needle withdrawal
45836980|NCT00492336|Drug|rasagiline (Pharmacodynamics)|Rasagiline 1 mg/day for 12 weeks
45836981|NCT00492336|Drug|Placebo|Placebo 1 tablet each day
45461136|NCT03960749|Device|Sprotte 25G needle, stylet not reinserted|Lumbar puncture with small bore atraumatic needle, stylet not reinserted before needle withdrawal
45461137|NCT03960749|Device|Sprotte 22G needle, stylet reinserted|Lumbar puncture with larger bore atraumatic needle, stylet reinserted before needle withdrawal
45461138|NCT03960749|Device|Sprotte 22G needle, stylet not reinserted|Lumbar puncture with larger bore atraumatic needle, stylet not reinserted before needle withdrawal
45461139|NCT03960749|Device|Spinocan 25G needle, stylet reinserted|Lumbar puncture with small bore cutting needle, stylet reinserted before needle withdrawal
45461140|NCT03960749|Device|Spinocan 25G needle, stylet not reinserted|Lumbar puncture with small bore cutting needle, stylet not reinserted before needle withdrawal
45599099|NCT03897257|Drug|UHE-103A1 cream|Investigational mono-therapy cream (containing drug A [low dose]). Drug A is an antifungal agent.
45836982|NCT00538434|Biological|Reslizumab|
45836983|NCT00538434|Other|Saline|
45836984|NCT00538512|Biological|Fluzone|single dose licensed trivalent inactivated influenza vaccine (2007-08)
45836985|NCT00538512|Biological|Flumist|single dose licensed live-attenuated influenza vaccine Flumist (2007-08)
45836986|NCT00538512|Other|Physiologic saline|single dose placebo administered as an intranasal spray or intramuscular injection
46009615|NCT04559321|Procedure|Fragmentation of calculi with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization.|General anesthesia, Valdivia-Galdakao position, cystoscopy and ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization
46009616|NCT02882737|Drug|Glucagon before exercise|
46009617|NCT02882737|Drug|Glucagon after exercise|
46009618|NCT02882737|Drug|Glucagon after resting|
46009619|NCT04539171|Other|Pain Neuroscience Education and Physical Exercise|Patients assigned to the experimental group perform a PNE program consisting of seven sessions, with therapeutic PE. PNE is a health education intervention aims to provide up-to-date information on neuroscience advances in the field of chronic pain.
46009620|NCT02882698|Behavioral|Down Syndrome Group 1|Acquisition and retention phase on maze A, transfer on maze B and C.
46009621|NCT02882698|Behavioral|Down Syndrome Group 2|Acquisition and retention phase on maze C, transfer on maze A and B.
46096390|NCT02749097|Drug|Placebo|
45461141|NCT05451511|Other|Door-In-The-Face Technique|Sequential request strategies will be applied as an intervention. For the Door-In-The-Face Technique, participants first receive a large request they are unlikely to accept, followed by a smaller request that is the true behavior of interest.
45461142|NCT05451511|Other|Foot-In-The-Door Technique|Sequential request strategies will be applied as an intervention. For the Foot-In-The-Door Technique, participants are shown an easier first request that they are likely to accept, followed by a larger request that is not the behavior of interest.
45461143|NCT01266655|Drug|Baclofen|Baclofen will be administered orally for a maximum of 20 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams t.i.d.; subsequently, the daily dose of baclofen will be increased to a maximum of 90 milligrams t.i.d. within 4 weeks. In case of intolerance, dosage can be decreased to a minimum of 10 mg t.i.d.. Patients will receive maximum tolerated dosage of baclofen for 12 weeks. Medication will then gradually be tapered over a maximum of 4 weeks.
46009622|NCT02882698|Behavioral|Typical Development Group 1|Control group. Acquisition and retention phase on maze A, transfer on maze B and C.
46009623|NCT02882698|Behavioral|Typical Development Group 2|Control group. Acquisition and retention phase on maze C, transfer on maze A and B.
46009624|NCT02883010|Device|PICO Softport V1.6|PICO is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 2 weeks.
46096391|NCT05402215|Behavioral|The flipped classroom model was used to teach students' clinical practice skills.|Videos for clinical applications have been prepared by researchers. These prepared videos were shared with the students in the experimental group one week before the lesson day of each application for preliminary study and the students were asked to work on these videos. On the day of the lesson, group work, question-answer and discussion activities were held with the students in the classroom environment. At the end of the lesson, the students were asked to do the applications on the simulation models of the application and the checklists were filled.
46096392|NCT05402215|Behavioral|control group|To the students in the control group, the application was explained by the researcher (instructor conducting the course) using presentation and demonstration methods. Each application was made on different days. The prepared checklists were filled by the other researcher.
45461144|NCT01266655|Drug|Placebo|Placebo
45461145|NCT01099553|Other|Educational video|Instructions to view an educational video about preparing for a colonoscopy
45461146|NCT01099553|Other|Written instructions|Written instructions on preparing for a colonoscopy
45461147|NCT03878875|Diagnostic Test|Session One Test Battery|"Prior to noise exposure:~Test battery - High-frequency audiometry, Distortion Product Otoacoustic Emissions, Middle Ear Muscle Reflex, Speech-in-Noise test, Tinnitus Functional Index (Around 35 minutes with breaks if required)~Extended Frequency Audiometry (~ 8 min): Participants will be asked to press the button when they hear a sound through the headphones in a soundproof booth.~DPOAE (~ 5 min): A small tip will be placed in participants' ear and they will hear a sound. The tip measures a response from hair cells in the cochlea and they will not need to do anything.~MEMR (~ 8 min): A small tip placed in both ears and again a sound heard, however, this sound will gradually get louder until an involuntary muscle reflex is noted.~Speech-in-Noise Test (~ 5 min): Participants asked to repeat back a list of words as best as they can.~TFI (~ 8 min): Participants given a self-report sheet in which they have to fill out aspects of any tinnitus experienced."
45599100|NCT03897257|Drug|UHE-103A2 cream|Investigational mono-therapy cream (containing drug A [low dose]). Drug A is an antifungal agent.
45599101|NCT03897257|Drug|UHE-103B cream|Comparator mono-therapy cream (containing drug B). Drug B is a keratolytic agent.
45599102|NCT03897257|Drug|UHE-103A1B cream|Investigational combination-therapy cream (containing drug A [low dose antifungal] + drug B [keratolytic]).
46096393|NCT00876018|Other|Nutritional supplement|Fortified nutritional powder
46096394|NCT00876018|Other|Placebo|Un-fortified nutritional powder
46096395|NCT02749175|Device|Cricoid force sensor monitor system|Comprise of a sensor and a monitor system
46096396|NCT02749175|Device|Sham Cricoid force sensor monitor system|Comprise of a sensor and a sham monitor system
46096397|NCT02226367|Drug|prazosin hydrochloride|study drug arm prazosin
46096398|NCT02226367|Drug|placebo|study drug arm placebo
46009625|NCT02883010|Other|Standard Care|Care path normally used by the hospital
46009626|NCT02211950|Drug|BI 44847|
46009627|NCT02211950|Drug|Acarbose|
46009628|NCT02211950|Other|Japanese diet|
46009629|NCT02882776|Dietary Supplement|Ginger drink|Ginger powder dissolved in water
46009630|NCT04539210|Device|Electric Welded Metal Framework|Screw-retained Maxillary Complete Denture With Electric Welded Metal Framework
46096399|NCT02747147|Device|TIVA blood collection device|the device is attached to a peripheral IV catheter for use as a direct blood draw device into a vacuum tube or a syringe
45461148|NCT03878875|Diagnostic Test|Session Two Test Battery|"Exposure at single loud music event (Important that this is part of participants' normal recreational routine, and specifically require that attendance is not prompted by participation in this study): Participants to use sound level meter provided from the Audiology Department at Charing Cross Hospital to measure sound levels inside the loud event.~Morning after exposure: Repeat test battery from session one - Ideally as soon as event is over."
45461149|NCT03878875|Diagnostic Test|Session Three Test Battery|1 week later (recovery): Repeat test battery.
45461150|NCT03712488|Device|flowcytometry|four colour flowcytometry
46096400|NCT03885934|Biological|V114|V114 15-valent PCV containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL IM administration
46096401|NCT03885934|Biological|Prevnar 13®|Prevnar 13® 13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
46096402|NCT02159989|Drug|Sapanisertib|Given PO
45461151|NCT03715920|Device|Electrical currents|The training was planned as HVPG current for the the first group (n = 16), as Russian current for the second group (n = 15) and as isometric strengthening for the third group (n = 15). All treatments were performed under physiotherapist supervision for a total of 15 sessions for 3 days a week for 5 weeks.
45461152|NCT03883633|Behavioral|ReCODE Protocol|Functional medicine approach to address symptoms of Alzheimer's and cognitive decline
45461153|NCT00075023|Drug|Thalidomide Gel|
45461154|NCT00075023|Drug|Placebo Gel|
45599103|NCT03897257|Drug|UHE-103A2B cream|Investigational combination-therapy cream (containing drug A [high dose antifungal] + drug B [keratolytic]).
46009631|NCT02882659|Biological|Dendritic Killer Cell (DKC)|DKC is a hybrid cell type capable of dual functionality, i.e. cytotoxicity and antigen presentation, similar to NK cells and DCs, respectively.
46009632|NCT04579055|Other|1-min STS test: adjusted|Individually adjusted chair seat height of 90° knee joint flexion
46009633|NCT04579055|Other|1-min STS test: standardized|Standardized chair seat height of 46 cm
46009634|NCT04539288|Other||There is no intervention in this study.
46096403|NCT02159989|Biological|Ziv-Aflibercept|Given IV
46096404|NCT02746913|Device|Urodynamics|Urodynamics is performed with the Aquarius XT Laborie system and a fluoroscopic images are obtained with a GE OCE 9800 c-arm fluoroscopy unit. Urodynamic testing will be performed in a seated position with a pessary from the ambulatory pessary trial in place. Post residual void will be measured at the start of the urodynamics.
45461155|NCT03715842|Other|Tub shaped design|The tub-shaped inlay preparation design this consists of an occlusal proximal reduction featuring a 3.5-4 mm width bucco-lingually, 3-3.5mm depth occluso-gingivally and 7-7.5 mm length mesio distally for molars and 2.3-2.8mm width buccolingually, 3-3.5 mm depth occluso gingivally and 3.5-4mm length mesiodistally for premolars. when necessary, superficial extensions may also be made on the preparations so that the occlusal fossa included in the preparation area and then the susceptibility for plaque accumulation will be diminished.
45461156|NCT03715842|Other|Inlay shaped design|The occlusal inlay had a preparation depth that allowed a thickness of 2.0 mm for the ceramic. The occlusal preparation was 4 mm wide and extended 4 or 6 mm mesio-distally for the premolar or molar models, respectively. The proximal box was 1 mm wide and had approximately 5˚ divergence, extending 2 mm apical to the isthmus floor . The preparations corresponded to a proximal connector area of 3 mm × 3 mm for molars and premolars.
46009635|NCT04559087|Procedure|Laparoscopic Surgery|"NOSES:Natural orifice specimen extraction (NOSE) is the opening of a hollow viscus that already communicates with the outside world, such as the vagina or distal gastrointestinal tract, in order to remove a specimen. The premise of this technique is to reduce the trauma required to remove the specimen with the expectation that this may improve outcomes.~Conventional Laparoscopic Surgery:Surgical specimens were taken out through abdominal wall."
46009636|NCT04547010|Dietary Supplement|Soy Isoflavone supplement|Participants received 60 mg of soy-isoflavone supplement per day.
46009637|NCT04546893|Biological|CD19 CAR-T|Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
46009638|NCT04579289|Other|questionnaire|"A questionnaire was e-mailed to all identified institutions, with 3 reminders in one month. It included 39 questions concerning :~morbidity and mortality linked with COVID-19~structural features of the facility (location, architecture, residents characteristics)~human resources~crisis management (visits and circulation restrictions, personal protective equipment)"
46009639|NCT04539249|Drug|Magnesium sulphate|"1g of paracetamol as an I.V infusion and 4g of magnesium sulphate as an I.V. bolus preoperatively. Continuous infusion of 1g/hr of magnesium sulphate intraoperatively and for the first 2 hours post-operatively. Further post-operatively, 100 mg of suppository diclofenac 12 hourly, intravenous paracetamol 1g 6 hourly, both over 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is > 70 kg) will be used only as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite non-opioid analgesia) at least 4 hourly during the first 24 hours after caesarean section."
46009640|NCT04539249|Drug|Pentazocine|Post-operatively, suppository diclofenac 100mg 12 hourly, intramuscular pentazocine 30 mg (45 mg if patient is > 70 kg) 6 hourly, intravenous paracetamol 1g 6 hourly, all for 24 hours.
46009641|NCT04579328|Behavioral|Exposure to Growth Mats|see arm/group descriptions for description of intervention
46009642|NCT04546932|Procedure|Lung-protective mechanical ventilation|Patients were provided with a tidal volume of 7 ml/kg IBW and an intraoperative 10 cmH2O in PEEP. Simultaneously, the alveoli were recruited applying a stepwise increase in PEEP (from 4 to 10 cmH2O for 3 breaths, 10 to 15 cmH2O for 3 breaths, and 15 to 20 cmH2O for 10 breaths) with maximum PIP = 50 cmH2O [24]. The recruitment maneuvers were performed right after intubation, 30 minutes after CO2 insufflation, then every hour, and finally before extubation.
46009643|NCT04578860|Other|Music therapy with Music Care app|Listening to music with Music Care app, every day, for 20 minutes, sitting up or lying down, at bedtime, with a headset or earbuds.
46009644|NCT04578860|Other|Sound therapy with White Noise|Listening to white noise with an app, every day, for 20 minutes, sitting up or lying down, at bedtime, with a headset or earbuds.
46009645|NCT04578860|Other|Treatment as usual for sleep disorders|No intervention
46009646|NCT04546386|Procedure|Endoscopic endonasal pituitary surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter
46096405|NCT02746913|Device|Pessary|A pessary is a silicone disc that is used in to support the uterus and vagina of women with vaginal prolapse. During this study, the pessary that will be used is a ring with support. This is a disc shape with a membrane stretched across the center. It is a device used in standard practice and is safe to keep in place for up to 3 months at a time. The subjects will be fit with a pessary asked to wear the pessary for 3 days.
45599104|NCT05255211|Drug|Remimazolam tosilate|IV before procedure
45599105|NCT05255211|Drug|Propofol|IV before procedure
45599106|NCT05255211|Other|saline solution|IV before procedure
46096406|NCT02628132|Drug|Paclitaxel|Paclitaxel will be given weekly for 6 cycles
46096407|NCT02628132|Drug|Durvalumab|Durvalumab will be given q2 wks concurrently with paclitaxel.
46096408|NCT05387473|Behavioral|Cognitive behavioral therapy for insomnia (CBT-I) integrated in best-evidence usual care (CBTi-UC)|In the first two weeks, the participants will receive three sessions of education and advice based on current best-practice guidelines. In the following three weeks, the participants will be provided with once weekly exercise therapy and once weekly CBT-I. This is then spread out more over the next five weeks in which participants will receive once weekly sessions of either CBT-I or exercise therapy in alternating order. In the last four weeks of the intervention period, the participants will receive once weekly exercise therapy.
46009647|NCT04546503|Procedure|Continuous Regional analgesia|"Aseptic placement of one or two tunnelized CPNB at the level of the nerves or plexus of the traumatized limb (s), Nervestimulation and ultrasound guidance by trained operator.~Continuous infusion of ropivacaine 0.2% at 1mL/10 Kg /H~+ General anaesthesia"
46009648|NCT04546503|Procedure|Control Group|General anaesthesia without regional analgesia
46009649|NCT04558853|Drug|autologous NK cells|Autologous ex vivo expanded and activated NK cells
46009650|NCT04546659|Other|Retrowalking|Treatment of retro-walking including supervised 10 min retro-walking training with 5 min of warm-up and cool down on a flat surface at their comfortable speed
46009651|NCT04546659|Other|Conventional Therapy|Treatment of conventional therapy involve Isometric Quadriceps exercise, SLR, Isometric hip adduction exercises, Terminal knee extension exercise 1 set of 10 Reps twice a day.
46009652|NCT04558814|Diagnostic Test|Serum galectin-9 level|Determining level of galectin-9 in sera of patients of SLE with different disease activity and organ affection and Sera of control group
46096409|NCT05387473|Behavioral|Best-evidence usual care (UC) plus information sessions|In the first two weeks, the participants will receive three sessions of education and advice based on current best-practice guidelines. In the following three weeks, the participants will be provided with once weekly exercise therapy and once weekly general information sessions (general education sessions in line with recommendations from best-practice guidelines and recent evidence). This is then spread out more over the next five weeks in which participants will receive once weekly sessions of either CBT-I or exercise therapy in alternating order. In the last four weeks of the intervention period, the participants will receive once weekly exercise therapy.
46096410|NCT02695355|Drug|Methylphenidate (MPH)|Test 1: No medication. Registration of ERPs and behavioral data during an attention task. Test 2: Test repeated on a single dose of MPH. Outcome measure: Classification as responders or non-responders after a four weeks medication trial, based on rating scales from parents and Teachers.
45461157|NCT01263067|Behavioral|Lifespan Integration Therapy|LI treatment guides the client to imaginally visit past memories, and then leads her or him forward through time to the present using a concept referred to as the time line. Beginning with the individual's memories from the traumatic experience, the time line first follows memories from the days and weeks after the trauma, then season by season to the present, and is reviewed in ongoing sessions as increasing details of the traumatic event are uncovered.
46009653|NCT04546464|Behavioral|Therapeutic Recreation Program|"The experimental recreation program, which consisted of two sessions per week and lasted approximately~1 hour each session, lasted for 8 weeks between May 2019 and June 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions"
45461158|NCT01263067|Behavioral|Lifespan Integration- Control|Participants selected for the control group will be treated 4 weeks following initial contact. Treatment is the same as for the Experimental Group.
45461159|NCT03717636|Other|medical evaluation|return of medical evaluation after discharge
45461160|NCT01100801|Drug|TS-1 with cisplatin|
45461161|NCT01100801|Drug|TS-1 with oxaliplatin|
45461162|NCT01263145|Drug|Akt Inhibitor MK2206|Given PO
46009654|NCT01129102|Drug|NPC-01|Norethisterone 1mg, Ethinyl estradiol 0.02mg
46009655|NCT01129102|Drug|IKH-01|Norethisterone 1mg, Ethinyl estradiol 0.035mg
46009656|NCT01129102|Drug|Placebo|Placebo for NPC-01
46096411|NCT02627820|Drug|Isis 420915/GSK 299872|Open label study in comparison to historic control.
45679123|NCT05893290|Other|Therapeutic Exercise Group|Therapeutic exercise sessions will begin with a short educational talk that provides information on proper body mechanics, and the benefits of exercise, followed by simple warm-ups and three different stretching and five different strengthening exercises that emphasize hip, abdominal, and back muscles. The frequency of repetitions of each stretching and strength exercise will be 10 with a holding time of 10 sec. Each set of strengthening exercises will be followed by a different set of stretching exercises. Sessions will end with a short unguided period of deep slow breathing.
46096412|NCT05359549|Device|Two endosseous dental implants (NobelReplace Groovy®) were placed 10 years ago|All patients were 10 years ago referred to the Department of Oral and Maxillofacial Surgery (University of Groningen, University Medical Hospital) because of having two failing teeth in the maxillary aesthetic region and were treated with dental implant placement and implant-supported restorations. Patients will have a regular routine control visit (as part of regular follow-up of these patients)
46096413|NCT00672672|Biological|autologous platelet gel|Patients will receive APG to the surgical site in the operating room. The control site will receive no treatment.
46096414|NCT02749019|Drug|68Ga-NOTA-BBN-RGD|68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
45461163|NCT01263145|Other|Laboratory Biomarker Analysis|Correlative studies
46009657|NCT04539132|Behavioral|ABI Wellness Program|The ABI Wellness program includes a computerized task which will be completed by all participants remotely. The exercise is a sustained visual-spatial processing task of progressively increasing difficulty. Subjects are presented with an analog clock face, initially showing only one hand. The subject uses a keyboard to enter a value for the hour shown. Feedback on the computer screen indicates whether the response is correct or incorrect. If the response was incorrect, the subject continues to respond until the correct response is entered. After this, a new clock face is shown. Once subjects reach a criterion of 90% accuracy over a series of consecutive responses, an additional hand is added to the clock face. Participants will complete the program at home, online, and will be required to be present on a video call during the exercise with the other participants and research assistants. The program is 150 hours over 6 months, through twice weekly 3-hour sessions.
46096415|NCT00990457|Behavioral|Weight Loss Diets Plus Exercise|"The weight loss diet will be either a low-carbohydrate diet or a low-fat, low-calorie diet. All participants will also be enrolled in a supervised exercise program.~The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training."
46096416|NCT02748629|Device|Covidien Parietex ProGrip Self-Fixating Mesh|
46096417|NCT02748629|Device|Lightweight Polypropylene Mesh (<38g/m2 after absorption)|Serag Wiessner SERAMESH® PA 15x10 cm
45836987|NCT00538824|Drug|dexamethasone|"Cycles 1-4 • Dexamethasone (40mg ) will be given on days 1-4, 9-12, 17-20 of a 28-day cycle.~After completing 4 cycles:~Patients who demonstrate disease progression at any time will be taken off study.~Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.~Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Dexamethasone 20mg weekly days 1, 8, 15, 22 out of a 28 day cycle)"
46009658|NCT04559048|Drug|FK506|FK506 (tacrolimus), a calcineurin inhibitor, is widely used as an immunosuppressant to lower the risk of organ rejection after organ transplantation
46009659|NCT04538820|Drug|Dexamethasone 4 mg IV-control|dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to normal weight patients.
46096418|NCT02573038|Drug|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) followed by mandatory injections at week 4, week 8, week 20, week 32 and week 44. During the other visits, an injection can be performed in case of CNV activity (PRN regimen).Therefore, each patient receives between 6 and 13 injections in the whole study.
46096419|NCT02159755|Drug|Ibrutinib|Given PO
46096420|NCT02159755|Other|Laboratory Biomarker Analysis|Correlative studies
46096421|NCT02159755|Drug|Palbociclib|Given PO
46096422|NCT02159755|Other|Pharmacological Study|Correlative studies
46096423|NCT00678366|Procedure|addition of 4% oxygen|addition of 4% oxygen to the carbon dioxide pneumoperitoneum
46096424|NCT00678366|Procedure|carbon dioxde|classic pneumoperitoneum with 100 % carbon dioxide
46096425|NCT02746835|Other|Exercise program for fall prevention|"Set of exercises to improve the following parameters:~balance, endurance, muscle strength, flexibility."
46096426|NCT00716638|Behavioral|Trauma-focused Cognitive Behavior Therapy|This intervention comprises 10 sessions of trauma-focused cognitive behavior therapy for PTSD with the components (a) prolonged imaginal exposure, (b) in vivo exposure, and (c) cognitive restructuring.
46096427|NCT00716638|Behavioral|Eye Movement Desensitization and Reprocessing (EMDR)|This intervention comprises 10 sessions of EMDR according to the standard protocol.
46096428|NCT02627976|Device|Compression vest, Thuasne|Wearing a compression 4 days/weel with a minumum of 6 hours per day
46096429|NCT02746757|Other|Remote conditioning|
46096430|NCT02746757|Drug|Exendin 9-39|
46096431|NCT01822015|Drug|Sirolimus|Given PO
46096432|NCT01822015|Drug|Idarubicin|Given IV
46096433|NCT01822015|Drug|Cytarabine|Given IV
46009660|NCT04538820|Drug|Dexamethasone 4 mg IV|dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
46009661|NCT04538820|Drug|Dexamethasone 8 mg IV|dexamethasone 8 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
46096434|NCT04088734|Drug|ABO-102|Single dose of ABO-102 (scAAV9.U1a.hSGSH) administered by intravenous injection through a peripheral limb vein at a dose of 3 X 10^13 vg/kg
46096435|NCT02627898|Drug|green tea extract|Green tea extract capsules, 400mg 1 time daily with the first bite of eat meal
46096436|NCT02627898|Drug|placebo|Placebo capsules, 400mg 1 time daily with the first bite of eat meal
46009662|NCT00575978|Drug|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
46009663|NCT01129024|Drug|Lusutrombopag|tablet
46009664|NCT04546347|Radiation|[14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL)|Dose of [14C]AZD9833 Solution for Infusion
46009665|NCT04546347|Drug|AZD9833 film-coated tablet A Dose 1|Dose 1 AZD9833 film-coated tablet A Dose 1
46009666|NCT04546347|Drug|AZD9833 Oral Solution|AZD9833 Oral Solution
46009667|NCT04546347|Drug|AZD9833 film-coated tablet B Dose 1|AZD9833 film-coated tablet B Dose 1
46009668|NCT04546347|Drug|AZD9833 film-coated tablet A Dose 2|Dose 1 of AZD9833 film-coated tablet A Dose 2
46009669|NCT04546347|Drug|AZD9833 film-coated tablet B Dose 2|Dose 1 of film-coated tablet B Dose 2
46009670|NCT02882932|Procedure|Super Oxidized Solution in group I|Two groups were made as group I and group II. Peritoneal Lavage was given with SOS and normal saline in group I. in group II only normal saline wash was given.
46009671|NCT04559477|Other|Static extension endurance exercise|"Static extension endurance exercise were performed, 10 repetitions with 10 sec hold of each of exercises Heating pad:15 mins TENS: 15 mins~35 min/session, 3 sessions/week for 6 weeks"
46096437|NCT02746601|Behavioral|Risk Assessment, Counselling & Resources|A risk assessment tool is completed on a tablet. The results are scanned into the patient's electronic medical record. A healthcare provider gives behavioural counselling on identified risk factors. The patient is given a customized handout that includes health recommendations and resources based on the participant's identified risk factors.
46096438|NCT04417894|Drug|dupilumab|Solution for subcutaneous (SC) injection administration
46096439|NCT04417894|Drug|Placebo|Solution for SC injection administration
46096440|NCT04144686|Other|Physiotherapy Rehabilitation|Participants will be randomly allocated, using a random number generator, to a 12-week supervised customised exercise group incorporating VRT programme without (Group A) or with cognitive DT exercises (Group B).
46096441|NCT00990535|Drug|Octreotide-LAR|Octreotide-LAR 30 mg administered every 21 days until progression
46096442|NCT00716716|Drug|rFIXFc|As specified in the treatment arm
46096443|NCT00990613|Drug|Dimebon IR|A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.
46096444|NCT00990613|Drug|Dimebon Transdermal|A single, transdermal 5 mg dose of dimebon free base solution will be applied to the back over a 24 hour period. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
46096445|NCT00990613|Drug|Dimebon Transdermal|A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
46096446|NCT00990613|Drug|Dimebon IR|A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.
46009672|NCT04559477|Other|Dynamic extension endurance exercise|"Dynamic extension endurance exercise with 10 repetitions of each of exercises which has been performed Heating pad:15 mins TENS: 15 mins~35 min/session, 3 sessions/week for 6 weeks"
46009673|NCT04539054|Dietary Supplement|ENGN Shred|ENGN Shred is a multi-ingredient pre-workout supplement.
46009674|NCT04539054|Dietary Supplement|Nutricost caffeine powder|Caffeine powder.
46009675|NCT04539054|Dietary Supplement|Crystal Light|Non-caloric Crystal Light matched for the pre-workout in terms of flavor and consistency.
46009676|NCT00576017|Drug|Fentanyl-TTS|
46009677|NCT04558697|Drug|Shepherd's Purse extractum oleosum vagitories|Shepherd's Purse extractum oleosum vagitories will be administered once daily for 5 days
46009678|NCT04558697|Drug|Tea tree oil vagitories|Tea tree oil vagitories will be administered once daily for 5 days
46009679|NCT04558697|Drug|Hyperici extractum oleosum vagitories|Hyperici extractum oleosum vagitories will be administered once daily for 5 days
45461164|NCT01263145|Drug|Paclitaxel|Given IV
45461165|NCT01263145|Other|Pharmacological Study|Correlative studies
45461166|NCT03717558|Drug|ivermectin T1|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
45461167|NCT03717558|Drug|ivermectin T2|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
45461168|NCT03717558|Drug|ivermectin T3|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
45461169|NCT00074711|Drug|Calcium carbonate|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.
45461170|NCT00074711|Drug|Calcium Phosphate|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
45461171|NCT01156207|Drug|Aliskiren|300mg Aliskiren qd for 6 month
45461172|NCT05620524|Drug|Extra blood samples for determining exposure to 5-FU|Extra blood samples for determining exposure to 5-FU
45461173|NCT03639090|Diagnostic Test|mass spectrometry|mass spectrometry for bladder cancer cells
46009680|NCT04558697|Drug|Vagitories - Probiotic|Vagitories - Probiotic will be administered once daily for 5 days
46009681|NCT04546269|Procedure|Fully-guided vs. conventionally guided implant placement|Patients randomized to implant placement planned virtually based on a CBCT and a surface scan vs. implant placement based on a wax-up on gypsum casts
46009682|NCT04558658|Diagnostic Test|Complete Blood Count|neutrophil to lymphocyte ratio
46009683|NCT02215707|Biological|PfSPZ Vaccine|Suspension of metabolically active, non-replicating (live), radiation-attenuated, purified, cryopreserved, aseptic Plasmodium falciparum (Pf) sporozoites (SPZ)
46009684|NCT01128946|Drug|NaF|Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.
46009685|NCT01128946|Drug|SnF|Fluoride toothpaste containing stannous fluoride (1100 ppmF)
46009686|NCT01128946|Drug|NaMFP|Fluoride toothpaste containing sodium monofluorophosphate (1000 ppmF)
46009687|NCT04558580|Drug|Rufinamide|Rufinamide
46009688|NCT04546035|Device|radial Extracorporeal Shockwave Therapy|rESWT was given on hamstring muscles, with the subject lying on prone position. No anesthesia was required.
46009689|NCT02882620|Behavioral|High Intensity (Group 1)|The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
46009690|NCT02882620|Behavioral|Medium Intensity (Group 2)|The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
46009691|NCT02882620|Behavioral|Reference Group (Group 3)|The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
46096447|NCT00990613|Drug|Dimebon Transdermal|A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose in Cohort 1. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
45461174|NCT03878641|Behavioral|Children in Grade 1 to 5 with literacy and language needs|The investigators deliver a telepractice-based intervention targeting: (a) Word reading and phonics instruction, (b) applying a comprehension monitoring strategy to improve text reading accuracy, and (c) complex sentences use in written text. Participants receive 3 online 50-minute tutoring session weekly across 15 weeks.
45461175|NCT03960905|Other|Children with the usage of anti-infective drugs|According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
45461176|NCT05619120|Drug|Mexiletine|Mexiletine (150mg, bid, po) is given to patients who have been divided into Mexiletine group.
45461177|NCT05619120|Other|Conventional therapy|Treatment according to the guidelines for the management of ventricular arrhythmias (2017 AHA/ACC/HRS)
45461178|NCT01158625|Other|Change of time of administration|Change of time of administration
45461179|NCT03712332|Behavioral|Distress Tolerance Group|The intervention is a distress tolerance skills-based group informed by mindfulness and acceptance principles and dialectical behavioural therapy (DBT).
45461180|NCT01265017|Drug|Estradiol, medroxyprogesterone, hydrocortisone, GH|"Estradiol 1mg every 8 hours administered orally~Medroxyprogesterone 2.5 mg every 24 hours administered orally~Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally~Growth hormone 2 mg once a day administered by subcutaneous injection,"
45461181|NCT01265017|Drug|Matching placebo|matching placebo
45599107|NCT02297893|Behavioral|Dexterity training program (HOMEDEXT)|The dexterity training program contains 7 exercises which focus on improving fine motor skills.
45599108|NCT02297893|Behavioral|Theraband training program|The Theraband training program contains 7 exercises which focus on improving upper limb strength
46009692|NCT00625261|Other|Heidelberg Parent-based Language Intervention HPLI|The HPLI is a group program for parents of young children with language delay. This 12-14week program includes seven two-our sessions and one three-our session six months later. It is designed for 5 to 10 people and based of an interactive model of language intervention, wich presumes that optimized parental input will provide better language-learning opportunities.
45461182|NCT01266733|Behavioral|Interdisciplinary treatment|The Experimental Group received 6 weeks of interdisciplinary treatment of fibromyalgia combining coordinated psychological, medical, educational, and physiotherapeutic interventions delivered by a team that included a physician, a psychologist, and a physiotherapist.Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions. One session included 1 hour with the psychologist and 45 minutes of educational activities with the physician and psychologist, while the other session included 1 hour with the psychologist and 45 minutes with the physiotherapist.
45461183|NCT01266733|Behavioral|Interdisciplinary treatment of fibromyalgia|The Control Group received the usual standard of care, which included pharmacologic treatment with a tricyclic antidepressant (amitriptyline, maximum dose of 75 mg/24h), an analgesic (paracetamol, maximum dose of 4 grams/24h), and a non-opioid central analgesic (tramadol, maximum dose of 400 mg/24h). The Experimental Group (EG) received 6 weeks of interdisciplinary treatment combining coordinated PSYchological, Medical, Educational, and PHYsiotherapeutic interventions (PSYMEPHY) delivered by a team that included a physician, a psychologist, and a physiotherapist. Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions.
45461184|NCT03420300|Drug|EBR/GZR|Elbasvir/grazoprevir (EBR/GZR 50mg/100mg fixed dose combination [FDC]): 1 table per os per day for 12 weeks
45461185|NCT01099943|Other|Intervention: Education, Decision Support Tools|Clinic sites randomized to the intervention group will participate in an educational intervention comprised of lectures on antimicrobial resistance and implement decision support tools to guide primary care providers in appropriate antibiotic prescribing for common infectious conditions.
45461186|NCT03951155|Behavioral|Muscle Relaxation|"Ask the child to lie down in a comfortable position. Ask him/her to notice how their muscles feel in each part of the body. Taking one area of the body at a time (face, shoulders, arms, hands, fingers, abdomen, legs, feet, and toes).~Instruct the child to contract the muscles for 5 seconds, take a deep breath, and release.~Next, instruct the child to contract all muscles simultaneously, hold for 5 seconds, then release.~Finally, ask him/her to notice how his/her muscles feel after the exercise."
45461187|NCT03419598|Procedure|Opening wedge high tibial osteotomy|Realignment of knee by creating an opening wedge osteotomy in the upper part of the tibia. Since this is a virtual trial, the virtual patients were duplicated and enrolled into both arms
45461188|NCT03419598|Device|Personalised subject specific custom HTO plate|Subject specific custom plate for stabilizing an open wedge HTO
45461189|NCT03419598|Device|Generic HTO plate|Generic plate for stabilizing an open wedge HTO
46009693|NCT00625300|Device|repetitive transcranial stimulation (r-TMS)|Each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (active) over the motor cortex and the prefrontal cortex.
45461190|NCT01158781|Behavioral|Experimental: gait, balance, arm function, cognition|12 weeks of training for balance, gait, upper limb function, and cognition, including functional electrical stimulation with surface electrodes, robotics, and motor learning
45461191|NCT01584323|Dietary Supplement|Pomgranate pills|"Treatment arm will receive The POMx pomegranate 1,000 mg capsule a day for maximum of two weeks or until they deliver if occurs before~The POMx pomegranate 1,000 mg capsule contains at least 800 mg natural polyphenol using a pomegranate polyphenol standard and is comparable to mg/8 oz juice.(attached is confirmation Similarity of Pomegranate Juice and POMx Polyphenols)"
46009694|NCT00625300|Device|Repetitive transcranial stimulation|Sham treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of sham stimulation trains over the motor cortex and the prefrontal cortex.
46009695|NCT00576134|Device|Implantation of intralaryngeal prosthesis with a new double valve system, allowing tracheotomy closing|An artificial Larynx composed of a tracheobronxane ® Dumon ST prosthesis and a valves system will be implant under general anesthesia by endoscopy. The 3 first patients will be patients with tracheotomy, in order to allow breathing through this tracheotomy in case of valves dysfunction.
46009696|NCT02215746|Drug|BI 44370 powder for oral solution|
46009697|NCT02215746|Drug|BI 44370 tablet|
46009698|NCT02215746|Other|high fat breakfast|
46096448|NCT00875706|Behavioral|Educational Intervention|The intervention consists of two (2) different types of training, both to be delivered through a train-the-trainer approach. The first of these is coaching-supervision training for nurse managers and other supervisory personnel in the CLC units. The second component is a one-day training for DCWs on communication and managing problem behaviors associated with dementia. These two trainings build on validated training models that have been developed by PHINational, but will be adapted and customized to include VA-developed clinical content on the management of problem behaviors associated with dementia.
46096449|NCT00716794|Drug|HE3235|HE3235 will be administered orally in 28 day cycles.
46096450|NCT05590897|Procedure|Teeth Brushing|All 52 participants will be instructed to brush with toothpaste containing amine fluoride in its composition (Elmex®), 3 times a day after meals for 10 days.
46009699|NCT02278458|Drug|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
46009700|NCT02278458|Drug|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
46096451|NCT05590897|Procedure|Dental Flossing|All 52 participants will be instructed to floss, 3 times a day after meals for 10 days.
46096452|NCT05590897|Procedure|Tongue Scraping|Tongue scraping will be performed by the same operator on all participants. Posteroanterior movements will be performed with the scraper on the lingual dorsum, followed by cleaning the scraper with gauze. This procedure will be carried out ten times in each patient, with the aim of standardizing the mechanical removal of the tongue coating.
45461192|NCT01584323|Dietary Supplement|Placebo pills|The placebo group will receive placebo pills , for maximum of two weeks or until they deliver if occurs before The palecbo capsule contains gelatin and lactose. The capsuls are manufactured by the hospital pharmacy.All the components are medically approved fot use during pregnancy
45461193|NCT03878329|Behavioral|remote home monitoring|Will use telemedicine to guide behavior changes in outcomes
45461194|NCT03951623|Drug|HMPL-523|HMPL-523 will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.
45461195|NCT03951623|Drug|Placebo|HMPL-523 matching placebo will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.
45461196|NCT03879811|Drug|TMZ|Oral TMZ at 150mg/m2
46009701|NCT02215785|Other|Kiwifruit|Throughout the five-week study period the patient had to continue their normal eating habits and exercise regime.
46009702|NCT02215824|Drug|BIWH 3|
46009703|NCT02215824|Drug|Placebo|
46009704|NCT01128595|Drug|FF/GW642444M|
45461197|NCT03879811|Drug|Nivolumab|Nivolumab via IV infusion at 480 mg every four weeks (Q4W) starting 4 weeks after TMZ day 1
46096453|NCT05590897|Radiation|Antimicrobial Photodynamic Therapy (aPDT)|One session of aPDT will be conducted, with the photosensitizer (PS) annatto manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient amount to cover the middle third and dorsum of the tongue (5 sprays), for 2 minutes for incubation. Six points will be irradiated, with a distance of 1 cm between the points, considering the scattering halo of the light and effectiveness of aPDT. The device will be previously calibrated with a wavelength of 395-480 nm, for 20 seconds per point, energy of 9.6 J, and the light was radiated so that a halo of 2 cm in diameter per point is formed.
46096454|NCT05590897|Dietary Supplement|Probiotics|Pharmaceutical forms will be used (manipulated capsules or chewable gums) containing Lactobacillus salivarius WB21 strains (6.7 x 108 CFU) and xylitol (280mg). They will be delivered to each patient, who must ingest them, 3 times a day after the meals for 7 days.
46096455|NCT02572180|Behavioral|EMG-based biofeedback training|
46096456|NCT02572180|Behavioral|NIRS-based neurofeedback training|
45461198|NCT03951857|Other|Resistance exercise with a gym stick|Exercise intervention: The resistance exercise intervention is performed with a gym stick for 3 times a week for 12 weeks. Exercise load is gradually increased by the number of times the band is wound and the speed of motion by dividing into three stages in 1-4 weeks (1st stage), 5-8 weeks (2nd stage) and 9-12 weeks (3rd stage).
45461199|NCT01158859|Drug|Pregabalin|Preoperative administration of pregabalin vs placebo 1 hour before surgery
45461200|NCT01100021|Drug|Tamsulosin and avanafil|tamsulosin - 0.4mg daily for 18 days; avanafil - 200 mg 1 x 2 days
45461201|NCT01100021|Drug|Doxazosin and avanafil|doxazosin - 1 mg 1 x 1 day; 2 mg 1 x 2 days; 4 mg 1 x 4 days; 8 mg 1 x 11 days; avanafil - 200 mg 1 x 1 day
45461202|NCT03407430|Drug|Pregabalin|During the first chemotherapy cycle, the patient will receive pregabalin 75mg (1 capsule) BID x 4 days before pegfilgrastim 6mg subcutaneous (SC) x1; then pregabalin 150mg (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive placebo in the same dosing scheme.
45461203|NCT03407430|Drug|Placebo|During the first chemotherapy cycle, the patient will receive placebo (1 capsule) BID x 4 days before pegfilgrastim 6mg SC x1; then placebo (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive pregabalin in the same dosing scheme.
45461204|NCT01266811|Drug|Placebo, Velcade and dexamethasone|Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle
46009705|NCT01128595|Drug|GW642444M|
45461205|NCT01266811|Biological|Siltuximab, Velcade and dexamethasone|Given in 21-day treatment cycles
46009706|NCT01128595|Drug|Fluticasone Furoate|
46009707|NCT01128595|Drug|Placebo|
46009708|NCT01129336|Drug|Zoledronic acid|Patients with no bone metastasis (n=150) will receive Standard therapy plus Zoledronic acid administration 4 mg IV monthly during Months 1-18.
46009709|NCT01129336|Drug|Standard Therapy|Standard Therapy, including chemotherapy and hormonal therapy, was determined at the discretion of the investigator.
46009710|NCT02882386|Other|Strength Training|
46009711|NCT02882386|Dietary Supplement|Milk 1%|
46009712|NCT02882386|Dietary Supplement|Whey protein concentrate 80 (WPC-80)|
46009713|NCT02882386|Dietary Supplement|Microparticulated whey|
46009714|NCT02882386|Dietary Supplement|Hydrolyzed whey|
46009715|NCT02882386|Dietary Supplement|Native whey|
46096457|NCT04399889|Biological|Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.|Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University or University of Miami.
46096458|NCT04399889|Other|Placebo|Placebo will be comprised of 40-80 mL of Plasmalyte-A + 1% Human Serum Albumin (HAS) prepared in an identical container to the one used for cell administration. The placebo product will undergo the same process of sterility testing including release inspection, transport and product custodian.
46096459|NCT00682188|Behavioral|Counseling Intervention|Six 30-minute individual student-centered counseling sessions based on the 5A approach to assist adolescents in making changes in their diet and level of physical activity delivered by school nurses over 2 months (weekly in month 1, biweekly in month 2)
46096460|NCT00682188|Behavioral|Information Intervention|Six individual sessions with the school nurse over 2 months to check weight and behavioral changes and provide a series of six pamphlets on weight and weight management
45461206|NCT01584635|Procedure|Peroral Endoscopic Myotomy a less invasive treatment for Achalasia|In this study we will follow patients undergoing Peroral Endoscopic Myotomy at 1 and 6 months post surgery,1,2,3,4,and 5 years post surgery with esophageal high resolution Manometry and a Barium Esophagram when it is not standard of care. We will have you fill out a symptom questionnaire at each visit
45461207|NCT01100099|Dietary Supplement|Gluten challenge.|The study population consists of 50 HLA-DQ2+ patients on a gluten free diet, both celiacs and uncertain celiacs. The patients will undergo a oral gluten challenge with four slices of bread daily for three days. Before challenge blood samples will be drawn for tetramer staining of gluten-specific T-cells. The analysis is done at the Institute of Immunology at Rikshospitalet, using FACS analysis. Small intestinal biopsies will be examined for morhological changes and inflammatory gene expression. These procedures with blood samples and biopsies will be repeated after gluten challenge. Registration for clinical symptoms and personality traits will be done by standardised and validated forms. A dietist will perform an interview of the patients.
45461208|NCT01158937|Drug|Meropenem Infusion|Meropenem 2g infused intravenously over 30 mins (bolus infusion) Meropenem 2g infused intravenously over 3 hours (extended infusion)
45461209|NCT03407118|Drug|LY900014|Administered SC.
45461210|NCT03407118|Drug|Insulin Lispro|Administered SC.
45461211|NCT01100177|Drug|Sunitinib|Sunitinib 37.5mg/m2/d
45461212|NCT01100177|Radiation|Radiation|Radiation therapy (60Gy) 2 Gy per day during 30 days
45461213|NCT03883243|Device|Telecoaching|A telecoaching application linked to a step counter will be installed on a patients smartphone for 8 weeks. The application shows a daily goal (expressed as amount of steps per day) to the patient. This goal is weekly revised and patients themselves are able to increase the goal every week with 500 or 1000 steps/day. Every evening, they are able to check the daily feedback platform, which gives them insights in their physical activity pattern of the day and previous weeks. At a regular basis, 'tip of the day' messages appear as a pop-up, to keep patients motivated.
46009716|NCT01128361|Behavioral|Aerobic Exercise|Participants randomized to this group will perform 150 minutes a week of aerobic exercise over 3-5days. Participants will begin exercising 3 times the first week for 20 minutes, increasing to three bouts of 25 minutes the second week. Thereafter, weekly exercise duration will be increased until their target duration of 150 minutes is achieved in week 6. Exercise trainers will assist participants in adjusting exercise routines to achieve their weekly exercise duration goals. Use of equipment, achievement of target HR and safety will be closely monitored by the trainer through the course of the study. Each subject will wear a Polar F4 heart monitor (Polar USA) for recording heart rate during each exercise session. Subjects unable to exercise continuously on the treadmill will perform intermittent training until the target duration is reached. The majority of the exercise sessions will involve walking on a treadmill.
46009717|NCT01128361|Behavioral|Stretching|This groups intervention is designed to match the aerobic exercise intervention with respect to participation and socialization. Stretching and toning has been repeatedly used as control intervention for exercise studies.The schedule and format will be identical to the aerobic conditioning group to best balance confounding variables such as attention, social interactions, and other unknown variables that might influence the results. An experienced and trained exercise instructor will run the stretching sessions three days a week at the local YMCA. We will monitor changes in heart rate with Polar F4 heart monitors (Polar USA) during the sessions to assess, and minimize, potential aerobic benefits from the intervention.
46009718|NCT01128244|Dietary Supplement|Vitamin B6|Subjects will receive vitamin B6 supplementation.
46009719|NCT01128244|Procedure|Infusion of labeled serine, methionine and leucine|Subjects will be given an infusion of the stable isotope labeled amino acids, serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of B6 treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.
46009720|NCT05119660|Device|Intermittent Theta Burst Stimulation|iTBS
46096461|NCT05590663|Other|Physiotherapy|routine referral-based physiotherapy treatment for patients with knee osteoarthritis
45461214|NCT01100333|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant hFSH prescribed according to prescriber's judgement
45461215|NCT01327235|Drug|Endostar|intrapleural injection 45 mg; intraperitoneal injection 60 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
45461216|NCT01327235|Drug|Cisplatin|cisplatin 40 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
45461217|NCT03406962|Drug|MGTA-456|Hematopoietic stem cell transplantation will be done with the cell therapy product MGTA-456.
45461218|NCT03882931|Other|Theta Burst Transcranial Magnetic Stimulation|Theta Bursts are short bursts of stimulation at high frequencies, which are applied 5 times per second
45461219|NCT03882931|Other|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
45461220|NCT03882931|Other|Sham|The investigators will simulate theta bursts pulses similar to the Theta Burst Transcranial Magnetic Stimulation groups but without stimulation.
45461221|NCT03951701|Other|Evaluation of the supportive care|Evaluation of interest of a systematic screening for oncological supportive care needs
45461222|NCT02530307|Drug|HT-3951|
45461223|NCT02530307|Drug|Placebo|
46009721|NCT04545996|Other|Suboccipital Inhibition Technique|Suboccipital Inhibition Technique For 2min And Conventional Treatment Hot Pack For 10 To 15 Mints And Muscle Energy Technique(Post Facilitation Stretch) 5 Reps × 1 Set Sessions: 2 TIME A WEEK FOR 4 CONSECUTIVE WEEKS
46009722|NCT04545996|Other|Cranio Cervical Flexion Exercises.|Cranio cervical flexion exercises10 repetitions for 10 seconds and conventional treatment hot pack for 10 to 15 mints and muscle energy technique(post facilitation stretch) 5 reps × 1 set Sessions: 2 TIME A WEEK FOR 4 CONSECUTIVE WEEKS
45679124|NCT05893290|Other|Therapeutic Exercise+Basic Body Awareness Therapy Group|This group will receive BBAT as well as therapeutic exercises. Therapeutic exercises will include strengthening, stretching, and stabilization exercises. BBAT will include postural alignment, breathing, and cognitive exercises.
45679125|NCT05893277|Behavioral|Motivational Interviewing (MI) and Behavioral Couples Therapy (BCT)|Four Motivational Interviewing sessions with the husband (wife joins for last MI session) to reduce alcohol use dependency, followed by six Behavioral Couples Therapy session with the husband and wife together to improve their relation and communication and reduce intimate partner violence. Session 1: couple establishes daily trust contract and discusses strategies to cope with reduced alcohol use. Session 2: couple revisits these coping skills and builds on additional strategies, as necessary. Session 3: they shift to improving the relationship and communication. Session 4: activity to promote caring behavior between partners. Session 5: couple reviews communication strategies learned previously, learn active listening and address any ongoing communication challenges. Session 6: review session and plans to address challenges to create long-term change.
46009723|NCT01127893|Biological|Tanezumab|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
46009724|NCT01127893|Biological|Tanezumab|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
46009725|NCT01127893|Biological|Tanezumab|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
46009726|NCT00576173|Drug|tramadol hydrochloride; acetaminophen|
46009727|NCT00625339|Drug|Entecavir|entecavir 0.5 mg QD
46009728|NCT00625339|Drug|Lamivudine|lamivudine 100 mg QD
45461224|NCT03882853|Other|Conservative exercise group|The group will be thought exercise series which based on recommendations published on October 2016 by UK national osteoporosis foundation.Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed.
45461225|NCT03882853|Other|Tree pose added exercise group|"The group will be thought exercise series which will be based on recommendations which is published on October 2016 by UK national osteoporosis foundation, also be taught tree pose of yoga. Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed."
45461226|NCT03406260|Drug|Lasmiditan|Administered orally.
45461227|NCT03406260|Drug|Placebo|Administered orally.
46009729|NCT05114512|Other|RAPTOR protocol: hybrid in-person + telehealth physical therapy services|All participants will receive the RAPTOR intervention, which includes 2 in-person physical therapy visits and 8 telerehabilitation visits. Participants will attend an initial in-person PT evaluation to meet their provider, receive a hands-on assessment of their impairments and functional limitations, and receive instruction in an initial home exercise program. The remainder of their visits will be completed remotely, using a telerehabilitation platform. At the conclusion of care, the patient will return to the clinic for a follow-up assessment and training on their final home exercise program.
45461228|NCT01089179|Drug|Metformin|
45461229|NCT01156285|Other|Filling in a patient questionnaire|Filling in a patient questionnaire
45461230|NCT01583387|Other|1-Increased water intake regimen|Arm 1-Intervention
45461231|NCT01583387|Other|2-Non-modified water intake regimen|Arm 2-Control
45461232|NCT01160185|Drug|paclitaxel|paclitacel
45461233|NCT01160185|Drug|cisplatin|cisplatin monotherapy
45461234|NCT01160185|Drug|topotecan|topotecan
45461235|NCT03419364|Drug|nicotinamide|2.5 gm nicotinamide given orally in 3 divided doses: 1000 mg in morning and evening, 500 mg at noon/midday
45679126|NCT05893238|Procedure|Natural cycle In Vitro Fertilisation (IVF)|In Vitro Fertilisation (IVF) without hormonal stimulation
45679127|NCT05893238|Diagnostic Test|Blood samples for analysis|Test hormone levels in serum
46009730|NCT02215863|Biological|Fluad and Prevenar13|
46009731|NCT02215863|Biological|Fluad|
46009732|NCT02215863|Biological|Prevenar13|
46096462|NCT02629068|Behavioral|PURPOSE|"The first week of the intervention will focus on welcoming everyone to the facebook group and laying down the ground rules for participation. Each additional week of the intervention will focus on a specific topic to promote discussion and learning of each particular skill; however, questions and discussions on other relevant topics are always welcome and encouraged.~Week 1: Welcome Week Week 2: SUD Basics Week 3: Problem of Stigma Week 4: Communication Skills Week 5: Parental Monitoring Week 6: Stress Management Week 7: Family and Valued Directions Week 8: Putting It All Together"
46009733|NCT04558463|Drug|Favipiravir|"The favipiravir group received loading dose of 1600 mg twice a day (3200 mg/day) on the first day and continued with 600 mg twice a day (1200 mg/day) for the next 2nd - 7th day in addition to the standard therapy.~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug"
46009734|NCT04558463|Drug|Oseltamivir 75mg|"The oseltamivir group was given twice a day of 75 mg of oseltamivir (150 mg/day) for 7 days in addition to standard therapy~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug"
46096463|NCT00720304|Drug|docetaxel|Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
46096464|NCT00720304|Drug|erlotinib hydrochloride|oral erlotinib hydrochloride once daily for up to 2 years in the absence of disease progression or unacceptable toxicity
46096465|NCT00720304|Genetic|fluorescence in situ hybridization|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
46096466|NCT00720304|Genetic|polymerase chain reaction|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
46096467|NCT00720304|Other|immunoenzyme technique|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
46096468|NCT00720304|Other|immunohistochemistry staining method|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
45461236|NCT01089335|Procedure|Histological investigation of the SN|99m Tc- nanocolloid albumin, 10-15 MBq (volume 0.1-0.3 ml) is injected under ultrasound guidance in the thyroid tumour. Imaging (lymphoscintigraphy)with anterior and oblique projections is performed at 60 and 120 min after the injection. SN are mapped intraoperatively by a dedicated SN navigator and excised for final histology.
45461237|NCT01159093|Behavioral|Family Decision Support|Family-focused intervention includes informational vaccine reminder telephone calls prompted by an electronic health record.
45461238|NCT01159093|Behavioral|Clinician Decision Support|Clinician-focused intervention includes an electronic health record-based decision support mechanism including reminders, education, audit and feedback on vaccination success.
45461239|NCT01159093|Other|Family Decision Support and Clinician Decision Support|This will be a combination of the family-focused decision support (telephone reminder calls) and clinician-focused decision support (clinical alerts).
45461240|NCT01159093|Other|Control|Usual care
45599109|NCT03149367|Procedure|levator muscle resection with fixed sutures technique|The levator muscle is approached through skin incision and the muscle shortened and sutured directly to the tarsus then the skin crease reformed with interrupted sutures which pick up the underlying levator muscle
45679128|NCT05893238|Diagnostic Test|Follicular fluid for analysis|Test hormone levels in follicular fluid Test Oxidation-reduction potential
46009735|NCT04311385|Diagnostic Test|CT imaging|CT scan reported as 1-2 pericolic bubbles, but no free distant bubbles in the abdomen or abscess.
46009736|NCT01126879|Dietary Supplement|genistein|Given orally
46009737|NCT01126879|Other|placebo|Given orally
45679129|NCT05893238|Diagnostic Test|Sperm samples for analysis|Oxidation-reduction potential
45679130|NCT05893238|Procedure|Conventional In Vitro Fertilisation (IVF)|In Vitro Fertilisation (IVF) with conventional hormonal stimulation
45679131|NCT05893225|Drug|Metformin Hydrochloride 850 mg Oral Tablet|Metformin Hydrochloride oral tablets 850 mg t.i.d. or b.i.d.
45679132|NCT05893225|Drug|Placebo|Placebo matching Metformin Hydrochloride oral tablets t.i.d. or b.i.d.
45461241|NCT05593302|Behavioral|Trauma-Focused Art Therapy (TFAT)|"Individual Trauma Focused Art Therapy (TFAT) consisting of 10 sessions. Each session lasts 60 minutes. Sessions are aimed at trauma recovery using visual art therapy. The sessions cover an introduction, making pieces of artwork, and reflection. Three phases can be distinguished:~Phase 1: 'stabilization and symptom reduction', i.e. exploring traumatic and positive memories, imagining a lifecourse, and expressing a safe haven (4 sessions).~Phase 2:'uttering and expressing memories', i.e. expressing chosen memories by making 5 pieces of artwork. Materials that can be used include clay, paint, graphite pencil or crayons and if needed with support of imagination using relevant photographs or objects (5 sessions).~Phase 3: 'integration and meaning attribution', i.e. ordering and assembling of the 5 pieces of artwork. Patients are asked to appraise the memories in the here-and-now present (c.f. mindfulness-based cognitive therapy) (1 session)."
45461242|NCT01160263|Drug|SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM|"123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter.~123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter."
45461243|NCT01266889|Device|device:INVOS 5100|Continuous wave NIRS is a method for measurement of cerebral oxygenation and haemodynamics. This method is non-invasive, continuous, and can also be used as bedside monitoring. With continuous wave NIRS only changes in concentration of oxyhaemoglobin (O2Hb) and deoxyhaemoglobin (HHb) can be measured, not the absolute level of these parameters. It has been shown that changes in concentration of HbD (O2Hb - HHb) reflect changes in CBF. So, continuous monitoring of changes in concentration of HbD can be used as an indicator of changes in CBF, but changes in CBV will also influence the HbD signal, as will changes in arterial O2 saturation (saO2) and changes in cerebral metabolic rate for oxygen.
45461244|NCT01265173|Drug|Cefotaxime|3 g
45461245|NCT01265173|Drug|Ceftriaxone|2 g
45461246|NCT01265173|Drug|Ciprofloxacin|400 mg
46096469|NCT00720304|Other|laboratory biomarker analysis|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
45461247|NCT01159327|Drug|Sorafenib|Sorafenib 400mg, bid(800mg/day), daily, PO
45461248|NCT02527057|Device|DW-MRI|Participants will perform four DW-MRI scanning as follows,before chemoradiation , at 2 weeks , 4 weeks after the start of radiotherapy and before the surgery.If participants can not receive surgery,the last scanning time will replaced at the end of radiotherapy.
45461249|NCT01160341|Drug|Testosteron|Testosteron 250mg injection per 3-4 weeks for 6 months
45461250|NCT01263379|Biological|LZRSE-Col7A1 Engineered Autologous Epidermal Sheets|"This trial will create a graft, which we call LEAES, of the patient's own skin that has been genetically engineered in our lab to express this missing protein."
45461251|NCT01265251|Device|Computerized neuropsychological test|Computerized neuropsychological test battery.
45679133|NCT05893212|Behavioral|Nature based facilitated group intervention|The Nature-group programme included learning more about local outdoor areas and nature itself, the biotopes visited were chosen to provide a various nature experience, including forests, farmland, lakes, and seashore. Accompanied by nature guides the group practiced simple sensorial exercises that enhance the contact with nature and its microbiome.
45461252|NCT01265251|Other|Conventional neuropsychological test|Conventional neuropsychological test (paper and pen)
46009738|NCT01126879|Procedure|therapeutic conventional surgery|Radical prostatectomy for treatment of prostate cancer
45461253|NCT03882619|Behavioral|Calligraphy|Participants will (1) detect the emotion him or herself; (2) do the calligraphy activity by writing positive terms (e.g., peace, life); (3) detect emotion again; (4) share the experience with group members.
45461254|NCT03882775|Drug|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute STEMI during emergency PCI operation.
46009739|NCT00576212|Behavioral|supportive call|Each subject in the intervention group will receive a 10 minute (or longer) biweekly telephone call from a psychologist intended to provide non-judgemental support to TOPFA women with the aim of reducing depression, guilt, isolation, shame, marital discord, and other common psychological sequelae of termination for fetal anomalies.
46009740|NCT04311658|Drug|Isosorbide Mononitrate 40 MG|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to LNG- IUD insertion
46009741|NCT04311658|Drug|Placebo|one tablet of placebo vaginally 3 hours prior to LNG-IUD insertion
46009742|NCT02882308|Drug|Olaparib|50/25 mg BD split x 5 days
46009743|NCT02882308|Drug|Cisplatin|60 mg/m^2 d1-d5
46009744|NCT02882308|Drug|Olaparib|300 mg BD x 21-28 days.
46009745|NCT02882308|Drug|Durvalumab|1500 mg d1
46009746|NCT02278497|Other|ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR|
46009747|NCT02211989|Drug|BI 14332 CL|
46009748|NCT02211989|Drug|Placebo|
46009749|NCT04311619|Drug|[11C]UCB-J radiotracer|I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein per injection
46009750|NCT04311619|Device|PET-MR|Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
46009751|NCT00625456|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dosage from 1 x 10^5 pfu/kg to 3 x 10^7 pfu/kg Intravenous infusion is administered once over a 60 minute period
46009752|NCT04539444|Biological|CD19/22 CART|CD19/22 CART cells are administrated in a 3-day split-dose regimen at dose of 0.5- 2×10*107 CART cells per kilogram of body weight.
46009753|NCT04539444|Drug|Tislelizumab|Patients will receive Tislelizumab 200mg/dose every 3 weeks.
46009754|NCT00576329|Drug|Ketorolac|Topical use before surgery
46096470|NCT00720304|Other|pharmacological study|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
45679134|NCT05893212|Behavioral|Exercise in group|The Sports-group participated in an exercise programme and met weekly in community sports facilities. Exercise we define as a planned, structured, repetitive, and purposeful form of physical activity that aims for improvement or maintenance of one or more components of physical fitness. The sports programme was planned and executed by professional sports leaders in cooperation with health professionals and included both aerobic and anaerobic exercise as well as team sports, content was planned according to current best practice and considered the participants physical ability.
46096471|NCT00720304|Procedure|therapeutic conventional surgery|At 6-8 weeks after completion of chemoradiotherapy, patients with N2 or greater cervical lymph node involvement at baseline or with residual disease may undergo surgery.Patients with persistent disease during study therapy undergo salvage surgery 6-12 weeks after completion of chemoradiotherapy.
45679135|NCT05893199|Device|Clinical monitoring using the Ti.Care app (https://ti.care/es)|Clinical monitoring using the Ti.Care app (https://ti.care/es)
46096472|NCT00720304|Radiation|intensity-modulated radiation therapy|radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
46096473|NCT00720304|Radiation|radiation therapy|radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
45461255|NCT03882775|Drug|Heparin|heparin with or without gpi during emergency PCI.
46096474|NCT02746523|Other|Sensory Organization Test|Balance and proprioception test
46096475|NCT02746523|Genetic|Biomarkers|Blood, urine, and saliva biomarkers
45679136|NCT05893199|Other|Usual care|usual follow-up in primary care both arms
46096476|NCT02746523|Other|Conners' Adult ADHD Rating Scale (CAARS)|Adult ADHD rating scale
46096477|NCT02746523|Other|Depression Scale|Becks Depression Inventory and Patient Health Questionnaire 9 (PHQ-9)
46096478|NCT02746523|Other|Cognitive Assessment|Montreal Cognitive Assessment (MoCA)
46096479|NCT04152720|Device|Foley catheter|"If the subject is enrolled in this clinical trial, the test and control devices will be applied at baseline. All subjects will receive a urinary catheter at the site of the artificial bladder and the urethra after surgery, and temporary urinary replacement should be selected by the investigator at each institution in preparation for the possibility of postoperative blockage of the urinary catheter.~After surgery, urine analysis and culture are performed on the 4th and 7th day, and urine analysis and culture are performed before the urethral catheter removal on the 14th (2 weeks) and the urethral catheter is removed. At this time, the urethral catheter tip is cut about 5-8 cm and cultured."
46096480|NCT05360875|Procedure|Endometrial scratching|An intrauterine procedure that causes mild endometrial injury
46096481|NCT02746367|Other|Diagnostic test (LDT)|Proteomic assay
45679137|NCT05893186|Other|Deep Brain Stimulation, STN|DBS of the STN, within FDA-approved limits and labeling, for symptoms of PD
46009755|NCT02882464|Device|PC-02 Centrifuge device,2PRF+CAF|In 2PRF+CAF group two layers of stacked PRF membranes were positioned over the recession area at the level of cemento-enamel junction(CEJ). In CAF+2PRF group,two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ
46009756|NCT02882464|Device|PC-02 Centrifuge device, 4 PRF+CAF|Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. A split thickness flap was raised without vertical incision.18 The papillae were disepithelialized. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In test group-1, two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ. In test group-2, four layers of stacked PRF membranes were positioned over the recession area at the level of CEJ (Figure 2). Membranes were sutured to the recipient bed by a resorbable suture (polyglycolic acid 6/0, Doğsan, Turkey) at the level of CEJ.
46096482|NCT02574364|Radiation|The application of abdomen CT|A modified incision(MI)was designed based on abdomen CT.Using a MI compare traditional incision(TI) to the patient including cut extended, operating time,cut infection, false-positive rate,rehabilitation and return to work.
46096483|NCT02574364|Other|traditional incision|McBurney incision,Rectus incision,Appendix Transverse incision or Tenderness point incision,it was invaginated at the discretion of the surgeon.
46096484|NCT00682266|Behavioral|intensity controlled interval training (AIT)|4 x 4 min intervals at 90% of maximal heart rate, each interval separated by 3 min at 70%, twice a week for 3 months
46096485|NCT00682266|Behavioral|Multidisciplinary approach (MTG)|exercise, dietary and psychological advice, twice a month for 12 months
46096486|NCT02626728|Procedure|laparoscopic assisted transanal surgery (TAMIS)|all patients included recieve laparoscopic assisted transanal minimally invasive surgery
46096487|NCT02746445|Other|No intervention|No intervention. This is a longitudinal study looking at subjects who received MeRT treatment.
46096488|NCT01564147|Other|immediate therapeutic education|Access to the course of immediate therapeutic education
45461256|NCT01156441|Procedure|surgical mitral valve repair w/ mitral valve annuloplasty|"Mitral valve repair will be performed via median sternotomy, utilizing cardiopulmonary bypass and moderate hypothermia. The mitral valve will be approached through a left atrial incision. Following inspection of the valve, mitral valve annuloplasty will be accomplished with a complete semi-rigid annuloplasty ring. Additional techniques to address residual regurgitation will be at the discretion of the surgeon. The left atriotomy will then be closed and the patient weaned off and separated from the cardiopulmonary bypass.~Intraoperative transesophageal echocardiography will be performed on all study volunteers."
45679138|NCT05893186|Other|GP Deep Brain Stimulation|PD with GP DBS, within FDA-approved limits and labeling, for symptoms of PD.
45679139|NCT05893173|Behavioral|Sleep Deprivation|Ten individuals (aged 25-50) with a DSM-V diagnosis of MDD will undergo baseline GluCEST imaging and waking EEG prior to and following approximately 30 hours of total sleep deprivation.
45679140|NCT05893147|Other|De-escalation VS No De-escalation|"No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result)~De-escalation group: switched to narrower spectrum antibiotic."
45679141|NCT05893147|Other|Oral beta-lactams VS non beta-lactams|"Beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole.~Non beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime."
45679142|NCT05893147|Other|Central vascular catheter retention VS Central vascular catheter replacement|"Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 72 hours from blood culture finalization~Central vascular catheter retention: the catheter will not be changed and will be retained until it is no longer needed."
45679143|NCT05893147|Other|Cephalosporin VS Carbapenem for low risk AmpC organisms|"Cephalosporin (ceftriaxone) at standard doses~Carbapenem (like Meropenem, Ertapenem etc) at standard doses"
46096489|NCT01564147|Other|therapeutic education delayed|Group receiving therapeutic education 6 months later (control group)
45679144|NCT05893147|Other|Routine follow-up blood culture VS No routine follow-up blood culture|"Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria.~No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria"
45679145|NCT05893134|Other|Risk Assessment|A probabilistic risk model will be generated based on the variables of different natures used and maps will be built to identify the areas of greatest risk for dengue transmission in the study area
45679146|NCT05893108|Drug|Ethosomal gel bearing losartan 5%|A pharmaceutical company with a good manufacturing practice certificate is developing ethosomal gel bearing losartan 5%
45679147|NCT05893108|Drug|triamcinolone acetonide 10 mg/ml|intralesional injection
46096490|NCT00682344|Drug|Levobupivacaïne|1,75mg/kg
45461257|NCT03878563|Device|Cellvisio 100 Series (fibered confocal microscopic system)|"This system is intended to allow confocal laser imaging of the internal microstructure of tissues within or adjacent to anatomical tracts, i.e. Gastrointestinal accessed trough an endoscope.~An 488-nm wavelength laser system is used, images are steamed at a frame rate of 12 frames per second, obtaining real time videos of the mucosa. In this trial we will use the Confocal miniprobe ColoFlex UHD and GastroFlex UHD."
45679148|NCT05893082|Device|F2 Filter and Delivery System|Placement of F2 device in aorta to cover the great cerebral vessels.
45679149|NCT05893043|Drug|GSBR-1290|Participants will receive GSBR-1290 oral capsules.
45679150|NCT05893043|Other|Placebo|Participants will receive matching placebo oral capsules.
45679151|NCT05893004|Diagnostic Test|Headache Screening Questionnaire|The Dutch Headache Screening Questionnaire (HSQ) is the only screening questionnaire based on ICHD-3 which has at least moderate confidence in its criterion validity according to GRADE. The HSQ has already been translated into Portuguese and validated5. The HSQ has only 8 items and requires little time to complete. Due to its good sensitivity, the HSQ screening questionnaire is particularly well suited to exclude migraine.
45679152|NCT05892991|Other|interferential current|this intervention is a type of therapeutic electrical currents of medium frequency used commonly in physical therapy to relieve acute and chronic pain as well as stimulate muscle contraction.
45679153|NCT05892900|Device|Transcutaneous vagus nerve stimulation (tVNS)|The electrodes are placed at the left ear concha. The ear concha is principally innerved by the afferent branch of the vagus nerve
45679154|NCT05892900|Device|Sham transcutaneous vagus nerve stimulation (Sham tVNS)|The electrodes are attached to the center of the left ear lobe, which is known to be free of cutaneous vagal innervation
46096491|NCT00990691|Drug|Administration of a high dose of desipramine|"Administration of a daily dose of desipramine correlated with the patient's weight :~From 15 to 25 kg : 50 mg ;~From 26 to 35 kg : 75 mg ;~From 36 to 45 kg : 100 mg ;~> 46 kg : 150 mg."
46096492|NCT00990691|Drug|Administration of a low dose of desipramine|"Administration of a daily dose of desipramine correlated with the patient's weight :~From 15 to 25 kg : 25 mg ;~From 26 to 35 kg : 50 mg ;~From 36 to 45 kg : 75 mg ;~> 46 kg : 100 mg."
46096493|NCT00990691|Drug|Administration of a placebo|Administration of a daily dose of placebo
46096494|NCT02626650|Other|Symptom elicitiation|Survey procedure, people check or uncheck symptoms they have or haven't experienced. We randomly assign participants to only one of these symptom elicitation procedures.
46096495|NCT02748473|Other|Pilates Exercises program|"The volunteers were divided in two groups:~Group I: Pilates exercise program involving only the Pilates exercises protocol Group II: Pilates exercises program with voluntary pelvic floor muscle contraction.~The protocol of both groups consisted of 24 bi-weekly 1-h individual sessions of Pilates exercises program.~Both groups performed the same protocol . For the group PEP + PFMC the instructor asked for the maximum contraction muscle of the pelvic floor muscle, during expirations with 5 repetitions performed alternately, thus avoiding pelvic floor muscle exhaustion.~After the 24 sessions, both groups were retested with the same measured methods of the baseline."
45461258|NCT03877705|Drug|Listerine ready tabs|Technically, it's a rectangular-shaped, bilayer-compressed tablet that once chewed, creates just enough liquid to swish around your mouth to get a whole-mouth clean feeling.As manufacture claimed the tablet is easy to use just in three simple steps: chew (to activate), swish (to clean), then swallow as unlike mouthwashes which may contain alcohol and other ingredients not intended for ingestion, Listerine Ready Tabs are alcohol-free and safe to swallow which is highly suitable for bedridden patients.
45461259|NCT03879421|Procedure|Accelerated corneal collagen cross linking|This strategy is based on the underlying pathology of the disease. Corneal collagen cross linking (CXL) idea was based on the fact that a photosensitizer substance like riboflavin (vitamin B2) can interact with ultraviolet irradiation (Ultraviolet-A) to strengthen the corneal tissue inter and intrafibrillar collagen bonds thus preventing further thinning, corneal protrusion and reduces corneal irregular astigmatism.
45679155|NCT05892887|Drug|Bupivacaine 0.25% Injectable Solution|Bilateral ultrasound guided in erector spinae plane block by bupivacaine 0.25%
45679156|NCT05892848|Diagnostic Test|serum ostecalcin,serum sclerostin and parathroid profile|evaluation of bone turnover markers in blood
46009757|NCT02882464|Procedure|CTG+CAF|The connective tissue graft was sutured to the recipient bed by resorbable suture at the level of CEJ. Split thickness flap was coronally advanced and sutured by resorbable suture. Finally, periodontal dressing was fixed on the recipient surgical area.
46096496|NCT02748473|Other|Pelvic floor muscle strength|evaluated the pelvic floor strength by oxford scale and vaginal pressure before and after the 12 sessions with Pilates Exercises Program on sedentary nulliparous women
45679157|NCT05892835|Other|Educative|A 2-hour training workshop was held where a theoretical explanation was given to recognize a cardiorespiratory arrest, the correct technique of chest compressions, ventilations and DESA management, in addition a practical class was carried out with CPR training models (Manikin for CPR practices Little Anne QCPR). Laerdal and AED simulation for CPR training (AED Practi-Trainer - Bilingual. WNL). Both theoretical and practical training were given by a basic life support instructor from the Spanish Society of Intensive Medicine and Coronary Units (SEMICYUC), the participants were instructed under the guidelines of the 2021 CKD recommendations.
45679158|NCT05892822|Other|Amyotrophic Lateral Sclerosis|All ALS patients included in this group.
46009758|NCT02882581|Radiation|11C-metformin|400MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Position Emission Tomography.
46009759|NCT02882347|Drug|Somatostatin|
46009760|NCT00576368|Drug|INSULIN GLARGINE|The physician will be guided by the prescribing information outlined in the summary of product characteristics. The administration will be done by once daily subcutaneous injection.
46009761|NCT00637468|Drug|Intravenous injection of heparin|
46009762|NCT00637468|Drug|Intravenous injection of acetazolamide|
45461260|NCT01160419|Drug|Docetaxel 50 mg/m2, 1-hour-Infusion, day 1|50 mg/m2, 1-hour-Infusion, day 1
45461261|NCT01160419|Drug|Oxaliplatin 85 mg/m², 2-hour-Infusion, day 1|85 mg/m², 2-hour-Infusion, day 1
45461262|NCT01160419|Drug|Folinic acid 200 mg/m², 1-2-hour-Infusion, day 1|200 mg/m², 1-2-hour-Infusion, day 1
45461263|NCT01160419|Drug|5-FU 2600 mg/m², 24-hour-Infusion, day 1|2600 mg/m², 24-hour-Infusion, day 1
45679159|NCT05892809|Other|use an incubator cover|Vital signs of term and preterm newborns were measured separately and with and without an incubator cover.
45679160|NCT05892783|Other|manual treatment|soft tissue mobilization applied by the therapist on the plantar fascia of both legs and self massage and stretching using foam roller and self stretching.
45679161|NCT05892770|Drug|Zinc gluconate supplement|Subjects will take a 50 mg zinc gluconate supplement at breakfast for the five days leading up to their next injection appointment. They will also answer questionnaires and provide audio recordings at various time points of the two injection cycles, which is roughly six months.
45679162|NCT05892770|Drug|Botulinum toxin type A|This is the current standard of care for treatment of spasmodic dysphonia. Botox injection goes into the vocal cord muscle, and will be occur in both the control and experimental arms of the study.
46009763|NCT00637468|Procedure|Local intra-arterial fibrinolysis|
46009764|NCT00637468|Procedure|Globe massage|
46009765|NCT00637468|Drug|Topical use of beta-blocker|
46009766|NCT00637468|Drug|Isovolaemic haemodilution|
46009767|NCT00637468|Drug|Acetylsalicylic acid|
46009768|NCT00637507|Other|High-frequency Oscillation and Tracheal Gas Insufflation|Patients will receive daily sessions of High-frequency Oscillation and Tracheal Gas Insufflation (HFO-TGI), which will last at least 6 hours. These sessions will comprise a recruitment period of at least 90 min, a stabilization period of at least 4 hours, and a weaning period of at least 60 min. The HFO-TGI strategy will be aimed at initially maximizing PaO2/FiO2 without causing hemodynamic compromise (e.g., >10% reduction in cardiac output/index), and subsequently maintaining PaO2/FiO2 >150 mm Hg, while gradually reducing mPaw to 4-6 cm H2O below its initial setting. The weaning from TGI and HFO will be according to the reversal of the oxygenation criterion that mandated their use (see also Detailed Description).
46096497|NCT02748473|Other|3D perineal ultrasound|evaluated the pubovisceral muscle thickness and levator hiatus area by 3D perineal ultrasound before and after the 12 sessions with Pilates Exercises Program on sedentary nulliparous women
46096498|NCT00716872|Behavioral|Sleep Healthy Using the Internet (SHUTi)|"SHUTi is an Internet program based on cognitive-behavioral therapy for insomnia (CBT-I). Users complete daily online sleep diaries in addition to receiving weekly access to six interactive Cores of information. As they progress through the program, users receive tailored instructions for how to improve their sleep."
46096499|NCT00716872|Behavioral|Hypnosis recordings|Subjects listen to self-hypnosis recordings designed to improve their disturbed sleep.
46096500|NCT05359471|Device|Bone densitometry|It is the standard method for diagnosing osteoporosis. In the central DXA examination, which measures bone density of the hip and spine, the patient lies on a padded table.
46096501|NCT05359471|Other|Questionnaires|Smoking and drug related questionnaires will be used as variable to see dependence, how it impacts participants activities/health or determining whether they are light/moderate/heavy smoker
46096502|NCT05359471|Device|Review of medical chart|History of previous liver diseases including hepatitis B, C, and HIV
46096503|NCT00678522|Drug|Atorvastatin|80 mg atorvastatin daily on two following days
46009769|NCT00637546|Other|Physiotherapy|Gait and Balance training based on recommendations of Robertson et al. and Page et al. (different balance control exercises; progression in consecutive stages: Sensimotor training, a static phase, a dynamic phase combined with functional tasks. The treatment takes place twice a week over 12 weeks. Patients were encouraged to perform specific home exercises.
46009770|NCT02212067|Drug|semaglutide|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
46009771|NCT02212067|Drug|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
45461264|NCT03878017|Procedure|skin marking of clip axillary lymph node for localisation|to determine the feasibility of skin marking to localize clipped ln
45461265|NCT02954172|Drug|Bevacizumab in Combination With Paclitaxel/Carboplatin|Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
45461266|NCT02954172|Drug|IBI305 in Combination with Paclitaxel/Carboplatin|Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
45461267|NCT03879343|Other|Known diagnosis of attention deficit / hyperactivity disorder|Clinical group includes subjects with clinical diagnosis of attention deficit / hyperactivity disorder
46096504|NCT00678600|Other|Standard (static) Computer Alerts|Static Computer Alerts on Patient's EMR webpage.
45461268|NCT01156519|Other|Salivary Cortisol|"Day 1: 1st salivary cortisol at 23 hours~Day 2: 2nd salivary cortisol at 23 hours and administration of dexamethasone (for overnight 1-mg dexamethasone suppression test)~Day 3: serum cortisol at 8 am~Between Day 4 and Month 3: if serum cortisol at 8 am > 18ng/mL:~Cortisol for 24 hours~dexamethasone suppression test (2mg/j during 2 days)~Cortisol and ACTH cycle~Noriodocholesterol scintigraphy"
45461269|NCT01159405|Radiation|Radiolabeled (99mTc) GP (Glycopeptide)|one injection of Technetium Glycopeptide to yield a target activity of 20-25 mCi to be given by slow IV push (over 3-5 minutes) 5 mg, 10 mg & 20 mg of GP will be injected
45461270|NCT03877081|Biological|Probiotics|Administration of oral probiotics with 2 doses a day
45461271|NCT03877081|Other|Placebo|Administration of oral placebo with 2 doses a day
45461272|NCT01263457|Device|Easypod|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod
45461273|NCT03876925|Drug|CT053PTSA|Patients will received oral CT053PTSA once daily until disease progression or intolerable toxicity or subject's withdrawal from treatment ,each cycle is defined as 28 days
45461274|NCT02953938|Biological|Ranibizumab|"Ranibizumab is a biologic and known anti-VEGF (vascular endothelial growth factor) medication approved for treatment of ME (Macular Edema) due to RVO (Retinal Vein occlusion)~0.5 mg ranibizumab applied one + PRN as intravitreal injection of 0.05 mL, with or without laser treatment"
45461275|NCT02953938|Radiation|Grid&Direct short pulse laser photocoagulation|Grid&Direct short pulse laser photocoagulation is a kind of laser treatment to retina within vascular arcades and used to suppress macular edema
45461276|NCT01161667|Drug|naratriptan hydrochloride|2.5 mg tablet
46009772|NCT02278575|Drug|Atenativ|intravenous transfusion
45679163|NCT05892757|Drug|Atogepant|Oral Tablet
45679164|NCT05892757|Drug|Ubrogepant|Oral Tablet
46009773|NCT01126060|Drug|Usage of Fibrin sealant|Usage of 1 vial of fibrin sealant after hemostasis in total thyroidectomy with anterior compartment neck dissection
46009774|NCT01126060|Procedure|Thyroidectomy|surgical removal of bilateral thyroid glands
46009775|NCT02882542|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
46009776|NCT02212184|Other|Manual Diaphragm Release Technique|The therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. During inspiration, pulls the points of contact with both hands, in the direction of the head, accompanying the elevation movement of the ribs. During exhalation, deepens contact toward the inner costal, maintaining resistance. 2 sets x 10 breaths (1 min interval). Treatment will last two weeks (6 sessions) All patients will undertake four evaluations throughout treatment: Baseline Day 1 and post Day 1; Baseline Day 6 and post Day 6.
46096505|NCT00678600|Other|Enhanced Computer Alerts|Population level and asynchronous alerts with enhanced functionality
45679165|NCT05892744|Drug|Sertraline|50-200mg/day
46096506|NCT04391855|Drug|Tramadol with ropivacaine|A solution of tramadol 2mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
46096507|NCT04391855|Drug|Dexmedetomidine with ropivacaine|A solution of dexmedetomidine 1μg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
46096508|NCT04391855|Drug|Magnesium with ropivacaine|A solution of magnesium 10 mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
45461277|NCT03715608|Other|Psychological Intervention|The patients in the intervention group received psychological counseling and corresponding medication after the operation. Psychotherapy was based on the clinical expertise of the psychosocial specialist from Peking University Sixth Hospital, who selected the most appropriate plan for each patient.
45461278|NCT05582304|Device|Test Lens|ACUVUE OASYS MAX 1-Day with TearStable Technology and OptiBlue Light Filter
45461279|NCT05582304|Device|Control Lens|ACUVUE OASYS 1-Day with HydraLuxe Technology
45461280|NCT03877861|Device|Readiband Sleep Tracking|Once a patient has consented to study progression, a Readiband™ Sleep Tracker device will be provided to the patient, along with necessary instructions. Patients will return home with the device and fatigue data will be obtained from the device at subsequent standard care follow-up visits. In addition, surveys related to fatigue and quality of life will be administered via secure electronic survey to participants.
45461281|NCT02526979|Drug|mirabegron|oral
45461282|NCT01267123|Procedure|Trendelenburg position|The patient will be placed in the Trendelenburg position with a 15 degree angle of inclination
45461283|NCT01267123|Procedure|Standard care|The patient will be placed in the standard horizontal position
45461284|NCT03882541|Other|Music therapy|To evaluate the effect of music in patients anxiety and pain during perioperative process in surgical intervention with regional anaesthesia without sedatives or anxiolytics.
45679166|NCT05892731|Other|with depression|age-related hearing loss with depression
45679167|NCT05892731|Other|without depression|age-related hearing loss without depression
45679168|NCT05892718|Drug|HCB101|HCB101 administered via. intravenous (IV) infusion.
46009777|NCT02212184|Other|Manual Diaphragm release technique (sham)|Manual Diaphragm release technique (sham) In attempt to execute the sham protocol the therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib. The therapist will hold only light touch in the landmarks, without exerting pressure or traction. The maneuver will be performed in two sets of ten deep breaths, with an one minute interval between them.
46009778|NCT01125748|Drug|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
46009779|NCT01125748|Drug|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
45461285|NCT03882541|Drug|Sedation with midazolam|To evaluate the effect of sedation (in comparation with music group) in patients anxiety and pain durin perioperative process in surgical intervention with regional anesthesia without music
45461286|NCT01267903|Biological|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28,modern medicines
45461287|NCT01267903|Biological|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
46009780|NCT01125748|Drug|Asthma therapies|Participants could receive 1 or more of the following medications as concomitant asthma therapy: Inhaled corticosteroids; long acting beta-agonists; zafirlukast or other leukotriene receptor antagonist; zileuton or other 5-lipoxygenase enzyme inhibitors; oral, inhaled, and/or nasal anticholinergic therapy; mast-cell stabilizers; theophyllines; chronic oral corticosteroids, defined as a minimum dose of oral prednisone of 2 to 40 mg/day or 5 to 80 mg every other day.
46009781|NCT04558268|Drug|Prednisone|"Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.~Prednisone is used as an anti-inflammatory or an immunosuppressant medication. Prednisone treats many different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders."
45461288|NCT01267903|Biological|vaccine against EV71 of 160U/0.5ml|inactivated vaccine(vero cell) against EV71 of 160U/0.5ml on 0,28 day
45679169|NCT05892705|Drug|Dexmedetomidine Injection [Precedex]|intrathecal injection of 5 mcg dexmedetomidine
45679170|NCT05892692|Behavioral|Ecological Momentary Intervention|Participants will receive hypothetical and real-time behavioral feedback using a smartphone application which provides ecological momentary responses to their current behaviors. By providing safety tips and advice, the intervention may decrease incidences of sexual assault and risky sex compared to a control group.
45679171|NCT05892666|Other|On-site recruitment (information and consent) following a random sampling recruitment schedule|A trained research assistant in collaboration with local clerks at each site will screen eligible patients after on-site registration or online scheduling, but prior to assessment by a physician, based on included presenting complaints. The research assistant or member of the care team, depending on the local rules, will approach the potentially eligible participants and present them the research project and information consent form. If the patient agrees to participate and is eligible, they will sign the information and consent form and the research assistant will take their vital signs (for onsite participants only).
45461289|NCT01267903|Biological|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28
46009782|NCT04558268|Drug|Progesterone|"Progesterone is a female hormone important for the regulation of ovulation and menstruation.~Progesterone is used to cause menstrual periods in women who have not yet reached menopause but are not having periods due to a lack of progesterone in the body. It is also used to prevent overgrowth in the lining of the uterus in postmenopausal women who are receiving estrogen hormone replacement therapy."
45461290|NCT01267903|Biological|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
45461291|NCT01267981|Drug|Standard diet|"After the lunch the day before the exploration, drink only clear liquids and stop solid food.~From 10 pm, stay fasting, don't drink except the usual drugs taken with mouthful of water until the exploration by video-capsule endoscopy."
45461292|NCT01267981|Drug|Standard Diet + 500 ml of polyethyleneglycol|Apply the standard diet and drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
45461293|NCT01267981|Drug|Standard diet + 2 liters of polyethylene glycol the day before + 500ml of polyethylene glycol|apply the standard diet and drink 2 liters of polyethylene glycol between 19h and 21h the day before exploration. Then drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
45461294|NCT01161901|Procedure|blood sample|"This study's hypothesis is that patients with ARDS criteria and lobar morphology on CT scan present loss of aeration but no inflammatory pulmonary oedema, whereas patients with non lobar morphology on CT scan present both characteristics.~The primary purpose of our protocol is to show that the patients who respond to ARDS criteria and have a lobar morphology on CT scan do not have an elevation of the biomarkers specific to the pulmonary aggression of ARDS."
45461295|NCT03758443|Drug|TD-1473 Dose A|See Arm description
45461296|NCT03758443|Drug|TD-1473 Dose B|See Arm description
45461297|NCT03758443|Drug|TD-1473 Dose C|See Arm description
45461298|NCT03758443|Drug|Placebo|See Arm description
45461299|NCT03442764|Drug|mavacamten|MYK-461
45461300|NCT03442764|Drug|Placebo|Placebo
45461301|NCT03717324|Other|Procedure created in co-creation group|Interventions will be those obtained from the co-creation workshop with patients
45461302|NCT03877627|Procedure|Pelvic and Peritoneal Lymphadenectomy|Patients in arm 2 will be randomized to undergo pelvic and peritoneal lymphadenectomy to treat their endometrial carcinoma.
45461303|NCT05026957|Device|SharedHeart|A smartphone application
45461304|NCT03442296|Behavioral|Baltimore HEARS|Tailored aural rehabilitation for participant and communication partner (if applicable)
45461305|NCT03442296|Device|Baltimore HEARS|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
45461306|NCT03576313|Drug|dihydroartemisinin-piperaquine (DP)|DP will be available as tablets of 320/40mg and 160/20mg piperaquine/ dihydroartemisinin per tablet. Administration of a full course of DP will be done as per manufacturer's guidelines once daily for 3 days and according to body weight. DP will be taken orally with water and without food
45461307|NCT03576313|Drug|ivermectin (IVM)|IVM will be available as tablets of 3mg or 6mg strength. It will be given at 300-400μg/kg/day over 3 days (to the nearest whole tablet). IVM will also be taken on an empty stomach with water
45461308|NCT03576313|Other|standard malaria control interventions only|this is the standard malaria control interventions in the Gambia
45461309|NCT01161979|Drug|Zonisamide|Zonisamide capsules 100 mg
45461310|NCT01161979|Drug|Zonegran|Zonegran Capsules 100 mg of EISAI INC
45461311|NCT01263535|Device|SENSIMED Triggerfish|Contact lens-based device for the continuous recording of IOP fluctuations, with a portable recording system
45599110|NCT03149367|Procedure|Levator muscle resection with adjustable sutures technique|The adjustable sutures technique in which the sutures passes through the levator muscle into the tarsal plate and out through the skin edge .the skin crease is formed separately so that adjusting the suture doesn't open the wound, the suture can be adjusted according to the result up to 4 days post operative.
45599111|NCT02233283|Other|Clamp|Volunteers will be submitted to hyperinsulinemic, euglycemic clamp studies of 10 hours duration.
45461312|NCT03877783|Dietary Supplement|mediterranean diet|The recommended Mediterranean diet is based on lean meat, fish, eggs, vegetables, fruits, berries, and nuts. Extra-virgin olive oil is the recommended additional fat source for use in food preparation and dressings. Recommended exclusions or restrictions include dairy products, cereals, added salt, refined fats, and sugar. Participants in the intervention group will receive weekly deliveries of olive oil and mixed nuts, free of cost, and they will receive recipes for Mediterranean meals on a regular basis. During the study, the intervention group will receive written, personalized advice from a project dietician on how to improve their Mediterranean diets. This written personalized advice will be based on the reported food intake, its coherence with a Mediterranean diet, and its adherence to the recommended intakes of energy and nutrients for each participant.
45461313|NCT03877783|Behavioral|individualized fitness program|The exercise intervention will consist of individualized training programs designed to improve cardiovascular fitness (VO2). A personal trainer will distribute the training program instructions and monitor the training during the entire intervention. Support will be provided via text messages. The training intensity will be based on results from an extensive pre-test of individual physical fitness performance, and we will adjust the intensity over the study period, as fitness improves. The goal is to engage participants in training three times per week, for up to one hour per training session. The individualized training programs will consist of brisk walks, jogging, and cycling, tailored to each participant. To ensure that the training intensity is sufficient to improve cardiovascular fitness, heart rate will be monitored during each session.
45461314|NCT03877783|Other|recommended modified pharmacological treatment|"Hyperglycemia: first metformin till target level of HbA1c 1) 53-58 mmol/mol for patients with ≤2 coexisting chronic illnesses or 2) 59-64 mmol/mol for those with established cardiovascular disease (CVD). We will recommend a second glucose-lowering drug when HbA1c is not achieved and which reduce CVD even when the participant does not have a manifest CVD.~Hypertension: will be treated to achieve a target level according to European guidelines. Start with a combination of a renin-angiotensin system (RAS)-blocker and a thiazide in low dose or a combination of a RAS-blocker a calcium channel blocker in low dose. If the target is not reached within 12 weeks additional drugs should be added.~Dyslipidemia: Patients with a CVD risk of 2-8% within 5 years should receive treatment with atorvastatin 10mg +ezetimib 10mg; CVD risk 8-20%, atorvastatin 20mg + ezetimib 10mg and CVD risk > 20% atorvastatin 40-80mg +ezetimib 10mg."
45461315|NCT01160653|Device|FES-IM|implantable Functional Electrical Stimulation
45461316|NCT01160653|Other|Cognitive training|training of impaired cognitive processes
45461317|NCT01160731|Drug|cisplatin|
45461318|NCT01160731|Drug|etoposide phosphate|
45461319|NCT01160731|Drug|panobinostat|
45679172|NCT05892666|Other|First phone call 1-3 days after the initial visit|Once the patient has been discharged, a research assistant will call the patient within 72 hours following the initial visit. This phone call will allow to i) ensure that gender, ethnicity, comorbidities and disposition plans are fully documented; and ii) use our patient-reported experience measure tool and administer a questionnaire on motivation for choosing one care setting over the other. Motivation will be classified in the 6 domains of the Conceptual Model of Emergency Department Use (Uscher-Pines et al. 2019). Participants will be asked to specify whether their choice of care setting was based on accessibility, convenience, their perception of the severity of illness, their beliefs and knowledge regarding these care settings, referral/advice from a care professional or an acquaintance, or on costs.
46009783|NCT04558268|Dietary Supplement|vit D|Vitamin D acts on our bones, intestines, kidneys and parathyroid glands to keep calcium in balance throughout our body. Vitamin D receptors are also located within our cardiovascular system, lungs, pancreas, skeletal muscle, skin, and reproductive organs. In summary, vitamin D is a prohormone that is essential for good health.
46009784|NCT04558268|Dietary Supplement|Iron Supplement|Iron is one of the minerals in the human body. It is one of the components of hemoglobin, the substance in red blood cells that helps blood carry oxygen throughout the body.
46009785|NCT04558268|Dietary Supplement|Folic Acid|"Folic acid is a type of B vitamin that is normally found in foods such as dried beans, peas, lentils, oranges, whole-wheat products, liver, asparagus, beets, broccoli, brussels sprouts, and spinach.~Folic acid helps your body produce and maintain new cells, and also helps prevent changes to DNA that may lead to cancer."
45461320|NCT01160731|Other|laboratory biomarker analysis|
45461321|NCT01160731|Other|pharmacological study|
45461322|NCT01160809|Other|Mosquito repellent|Mosquito repellent (Buzz Off jelly) every evening applied to face, neck, hands and legs
46009786|NCT04545918|Device|Follicle Clarity|Mask Region-based Convolutional Neural Network in Ultrasound Follicle Identification
46009787|NCT01125514|Drug|Aliskiren 150 mg|Aliskiren 150 mg tablet
46009788|NCT01125514|Drug|Furosemide 60 mg|Furosemide 60 mg commercially-available tablets
46009789|NCT01125514|Drug|Placebo for Aliskiren|Matching placebo for aliskiren 150 mg and 300 mg
46009790|NCT01125514|Drug|Aliskiren 300 mg|Aliskiren 300 mg tablet
45461323|NCT03882151|Diagnostic Test|electrical source imaging|automated analysis of surface EEG with electrocal source imaging
45461324|NCT05010733|Device|Total hip arthroplasty using the Exeter V40 cemented femoral stem|Consists of applying a cement layer of at least 2 millimeters surrounding an undersized prosthetic stem, so that this layer of cement fits between the femoral medullary canal and the prosthetic's femoral stem.
45461325|NCT05010733|Device|Total hip arthroplasty using the Müller Straight Stem|Consists of applying a thin layer of cement, so that the prosthetic's femoral stem fills as much as possible the femoral medullary canal.
45461326|NCT01268137|Procedure|Deep Brain Stimulation|Surgical electrode implantation in the white matter adjacent to the Cg25 region and implantation of the DBS pulse generating device
45461327|NCT03876691|Other|Patients|Patients who are considered as terminally ill and would not benefit from aggressive treatment, who physicians suggest to family about a do-not-resuscitate.
46009791|NCT04538547|Radiation|Accelerated Radiotherapy|Accelerated Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 6 days per week from Monday to Saturday
45461328|NCT03876691|Other|Physician|The current emergency medical department departments within the preparation of the attending physician
45461329|NCT01162213|Dietary Supplement|Lychee Fruit Extract|placebo or 100, 200 and 600 mg of lychee fruit extract for 2 weeks with one week washout period between treatments 2000 mg of lychee fruit extract given at a single visit
46009792|NCT04538547|Radiation|Non Accelerated Radiotherapy|Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 5 days per week from Monday to Friday
46009793|NCT00576446|Biological|Dendritic cell Vaccine|Patients will receive three vaccines every two weeks
45461330|NCT01160965|Drug|0.5% levobupivacaine|15mls of a 5mg/ml solution of the local anaesthetic levobupivacaine given via the epidural catheter.
45461331|NCT01160965|Drug|0.75% Ropivacaine|15mls of a 7.5mg/ml solution of the local anaesthetic ropivacaine given via the epidural catheter.
45461332|NCT03441984|Drug|Treatment A|TRIUMEQ (Adult) administered as a, single dose, fixed dose combination (FDC) tablet - DTG 50 mg/ABC 600 mg/3TC 300 mg as 1 conventional tablet, orally as direct-to-mouth.
45461333|NCT03441984|Drug|Treatment B|TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/ 3TC 30 mg, orally as 10 dispersible tablets
45461334|NCT03441984|Drug|Treatment C|TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/3TC 30 mg, orally as direct-to-mouth.
45461335|NCT03441984|Drug|Treatment D|"DTG and 3TC (Adult), administered as a, single dose, Single dose, 1 tablet DTG (50 mg) and~1 tablet 3TC (300 mg), orally as direct-to-mouth."
46009794|NCT04545879|Dietary Supplement|Raw garlic juice containing allicin|Fresh garlic juice containing around 48mg allicin for 7 days
46009795|NCT04578782|Drug|OnabotulinumtoxinA|BOTOX contains onabotulinumtoxinA, an acetylcholine release inhibitor and a neuromuscular blocking agent available in the lyophilized form of purified clostridium botulinum toxin type A, suitable for injection, for intramuscular, intradetrusor, or intradermal use. The recommended dilution is 100 Units/2 mL, with a final concentration of 5 Units per 0.1 mL. The recommended dose for treating chronic migraine is 155 Units administered intramuscularly using a sterile 30-gauge, needle as 0.1 mL (5 Units) injections per each site.
46096509|NCT04391855|Drug|Ropivacaine plus normal saline|A solution of ropivacaine hydrochloride (10mg/ml) 100mg with 5ml of isotonic saline 0.9% mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
46096510|NCT00716950|Drug|valsartan/amlodpine|tablets; 160mg/5mg; od; 4 weeks
45461336|NCT03441984|Drug|Treatment E|DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as 10 dispersible tablets.
45461337|NCT03441984|Drug|Treatment F|DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as direct-to-mouth.
45461338|NCT01263613|Procedure|tumor biopsy and blood draw|tumor biopsy and blood draw during and after chemotherapy
46096511|NCT00716950|Drug|losartan/amlodpine|tablets; 100mg/5mg; od; 4 weeks
46096512|NCT00678678|Device|Incentive Spirometry - RESPIRON|Device that stimulates the deep breathing, flow-oriented
46096513|NCT00678678|Device|Kit Epap®:|Device that providing constant positive pressure during expiration, given by spring load (cmH2O), using a face mask as an interface
45461339|NCT01156909|Drug|Rituximab|"Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.~Approved amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period."
45461340|NCT01267357|Other|no intervention|
45461341|NCT01162525|Procedure|Percutaneous tibial nerve stimulation (pTNS)|A 34 gauge needle in placed close to the tibial nerve about 2-3 cm above the ankle. A self-adhesive surface electrode is placed on the skin. Needle and surface electrode are connected to an electric stimulator and the stimulating current (0 - 10 mA) is increased in 20 steps. When the patient feels a tingling sensation in the foot, stimulating current is set back for one step and the treatment is started (30 min stimulation).
46096514|NCT02748239|Behavioral|MEDIAS 2 CT|The MEDIAS 2 CT is a education program for the initiation of a conventional insulin therapy in type 2 diabetic patients. The program consists of 6 lessons and is conducted in group settings (4-8 participants).
45461342|NCT01162603|Device|Goldmann and Perkins applanation tonometry|IOP values will be assessed by the means of Goldmann or Perkins applanation tonometry at the following time-points: 10AM (± 1 hour), 2PM (± 1 hour), 6PM (± 1 hour), 10PM (± 1 hour), 2AM (± 1 hour) and 6AM (± 1 hour) after three months of treatment
45461343|NCT01162603|Drug|TAFLUPROST 0.0015% EYEDROPS|Tafluprost 0.0015% preservative-free ophthalmic solution
45461344|NCT01162603|Drug|LATANOPROST 0.005% EYEDROPS|Latanoprost 0.005% preservative-added ophthalmic solution
45461345|NCT01267435|Procedure|Anterior cruciate ligament reconstruction|reconstruct the anterior cruciate ligament rupturing
45461346|NCT03881995|Drug|IGlarLixi|Dose titration will be done based on the subjects fasting blood glucose
45461347|NCT03881995|Drug|Insulin Glargine 100 UNT/ML|Dose titration will be done based on the subjects fasting blood glucose
45461348|NCT01162759|Behavioral|Home Blood Pressure Monitoring|Home blood pressure readings are taken at least 3 times a week, uploaded to a Microsoft Health Vault account through American Heart Association Heart360 at least 1 time per week. Patients are followed by a clinical pharmacist, with physician oversight, who will make adjustments to antihypertensive medications or suggest additional medications using national JNC VII and KPCO hypertension guidelines.
45461349|NCT02527213|Drug|Sodium thiosulfate|Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
45461350|NCT02527213|Drug|Placebo|Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
45461351|NCT01161277|Drug|Aripiprazole|Dose: 5-10 mg depending on subject weight
45461352|NCT01161277|Drug|Haloperidol|Dose: 1-2 mg depending on subject weight
45461353|NCT01161277|Drug|Placebo sugar pill|Dose: 1-2 pills depending on subject weight
45461354|NCT01268215|Drug|Infasurf|Endotracheal instillation of Infasurf once per week for three weeks
45461355|NCT01268215|Drug|Pulmicort|Endotracheal instillation, once per week for three weeks
45461356|NCT01268215|Other|Sham|None instilled through the endotracheal tube
45461357|NCT01162837|Device|BEAM device|A red/blue LED device for the treatment of acne
45461358|NCT03877471|Genetic|Cell therapy|Ovary injection with MSC-like cells through transvaginal ultrasound,3 injection points for each ovary.
45461359|NCT01269307|Procedure|1:1 ketamine-propofol mixture sedation|"Prepare Ketamine and Propofol 10mg/cc of ketamine 10mg/cc of propofol mix 1:1 in 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus. Repeat dose 0.025 - 0.05 every 60-90 seconds as needed to reach and maintain target level of sedation.~May round to nearest 0.5-1 cc. Note - 1 cc = 5mg of propofol and 5mg of ketamine"
45679173|NCT05892666|Other|Second phone call 8-14 days after the initial visit|A follow-up phone call will be made to all participants 8 days after the initial visit to evaluate primary and secondary outcome metrics. Patient-reported outcome (primary) and cost measures will be completed by the participants at this moment.
46096515|NCT02748239|Behavioral|Current CT program|The Current CT program is currently used for the initiation of conventional insulin therapy in type 2 diabetic patients. The program consists of 6 lessons and is conducted in group settings (4-8 participants).
46096516|NCT00711178|Procedure|Photodynamic therapy with methyl aminolevulinate|daylight mediated photodynamic therapy
46096517|NCT00678756|Drug|Ketokonazol 2% cream|twice a day at 2 times,2 out of 5 areas have to be treated for 4 weeks/7 days a week
46096518|NCT00678756|Radiation|UVB-radiation 311nm|3 out of 5 areas are radiated for 4 weeks every MO/DI/DO/FR starting MED orientated, intensified everytime 0,03 J/qcm
45461360|NCT01269307|Procedure|Propofol Sedation|"Prepare Propofol 10mg/cc of propofol 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus over 30 seconds. Repeat dose 0.025 - 0.05 cc/kg every 30-60 seconds as needed to reach and maintain target level of sedation.~May round to nearest 0.5 cc Note - 1 cc = 10 mg of propofol"
45461361|NCT03874741|Drug|SCT200|"Anti-EGFR monoclonal antibody DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression~Other Names:~• SCT200"
45461362|NCT03874585|Behavioral|Group counseling and nicotine replacement|Participants will receive a 30-minute group smoking cessation counseling session and a supply of nicotine replacement.
45461363|NCT03874585|Behavioral|Group counseling, nicotine replacement, and text messaging support|Participants will receive a 30-minute group smoking cessation counseling session, a supply of nicotine replacement, and the 6-week text messaging intervention to provide ongoing support for quitting
45461364|NCT01268371|Device|Promus Element, Boston Scientific Corporation|Everolimus-eluting stent
45461365|NCT01268371|Device|Nobori, Terumo Corporation (Japan)|Biolimus-eluting stent with biodegradable polymer
45461366|NCT05016271|Behavioral|Air purifier and fresh air ventilation systems with high-efficiency particulate air (HEPA) filters|This group will receive an intervention of true air purifiers. The air purifiers in classroom (air purifiers and fresh air ventilation systems with HEPA filters) will operate during the school time and the air purifiers in bedrooms (air purifiers with HEPA filters) operate during the home time in the intervention period (4 months anticipated).
46096519|NCT02748395|Drug|Triamcinolone|
46096520|NCT02748395|Other|Placebo|
46096521|NCT02748395|Drug|Lidocaine|
46096522|NCT02745977|Other|Dairy Free Diet|Dairy Free Diet x 3 stool guaiacs. If positive, dairy is reintroduced to diet.
46096523|NCT02629224|Drug|ASP8825|Oral
45599112|NCT02233283|Other|Hypercaloric diet|Hypercaloric diet will be conducted during one month, and designed to provide 30% excess in calories compared to daily requirements. It will consist in a high fat, high carbohydrates diet.
46096524|NCT02572804|Device|Epidural|Patients in this group will have an epidural inserted in a standard fashion, prior to the induction of anesthesia. These will be infused with 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response. Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
45461367|NCT05016271|Behavioral|Air purifier and fresh air ventilation systems without high-efficiency particulate air (HEPA) filters|This group will receive an intervention of sham air purifiers. The air purifiers in classroom (air purifiers and fresh air ventilation systems without HEPA filters) will operate during the school time and the air purifiers in bedrooms (air purifiers without HEPA filters) operate during the home time in the intervention period (4 months anticipated).
45461368|NCT03876613|Behavioral|Different music types|the type of music that reduces anxiety best and most effectively.
45461369|NCT01161355|Drug|AZD9668|Tablets of AZD9668 and IV dose of [C14]AZD9668
45461370|NCT01161433|Behavioral|Virtually delivered spirometry quality improvement program|"Sites in the intervention arm receive the virtually delivered QI program.~The program includes:~Spirometry Fundamentals™ CD-ROM, a computer-based CD-ROM training program that teaches primary care providers and their staff techniques required to perform high-quality spirometry tests, and proper interpretation of spirometric data;~Case-based, interactive webinars; and~an Internet-based spirometry quality feedback reporting system."
45461371|NCT01161511|Biological|XmAb5574|Intravenous infusion of XmAb5574 administered weekly during two 28-day cycles with an additional dose being administered during the first week of Cycle 1. (Cycle 1 on Days 1, 4, 8, 15, 22; Cycle 2 on Days 1, 8, 15, 22)
45461372|NCT01162915|Biological|Autologous bone marrow-derived mesenchymal stem cells.|Intrathecal infusion of a single dose of ex vivo expanded MSC.
46009796|NCT04538703|Behavioral|acne vulgaris|Social media use of acne vulgaris patients, a questionnaire will be asked the patients and try to learn how they use social media for getting information about their disease.
46009797|NCT00576485|Procedure|Cataract surgery and intraocular lens implantation|Cataract surgery and implantation of an intraocular lens
45461373|NCT01267669|Drug|Somatostatin|Emergency EVL plus Somatostatin (250 mcg/hr) infusion for 5 days
45461374|NCT01267669|Drug|Placebo|Emergency EVL plus placebo infusion for 5 days
45461375|NCT05666869|Drug|Esketamine perfusion|Analgesic dose of ESKETAMINE via a 30 minutes.intravenous perfusion
45461376|NCT03874429|Device|T2259|HA and Trealose
46096525|NCT02572804|Device|Rectus Sheath Catheters|Patients in this group will have surgically inserted rectus sheath catheters (bilaterally), immediately prior to closure of the anterior abdominal wall. These will be infused with 0.125% Bupivicaine at 5mls an hour at a standard rate.Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
46009798|NCT04539015|Device|Prevena Plus|PREVENA Plus is a negative pressure wound therapy device intended for use on surgical incisions that continue to drain following sutured or stapled closures.
46009799|NCT00576563|Drug|FDG|contrast medium
46096526|NCT02746133|Other|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
46009800|NCT04538391|Drug|local ifiltration Bupivacaine, Meloxican and placebo|no other intervention done
46096527|NCT04152174|Procedure|Combined extracorporeal blood purification|Patients receive combined extracorporeal blood purification: CRRT in CVVHDF mode with AN 69 ST set (Baxter) and hemoadsorption with Cytosorbents Corp. CytoSorb adsorber.
46096528|NCT04152174|Procedure|CRRT|Patients receive CRRT in CVVHDF mode with AN 69 ST set (Baxter)
46096529|NCT02748551|Procedure|Laparoscopic procedures|Laparoscopic surgery
46096530|NCT02748551|Procedure|Open Surgery|Open surgery
46096531|NCT02626416|Device|LenZOC (mobile application)|The transparency of the visual axial at the anterior segment is observed through a dilated pupil. Image of the eye of a patient taken with LenZOC is calibrated with a standardized white and black bar adhered to the patient's eyelid. Calibrated images are dimmed as graysalegrayscale. The intensity and progress of visual axial opacification (VAO) is quantified as absolute area and relative area (calculated as: absolute area of VAO/ absolute area of dilated pupil).
46096532|NCT00711256|Other|sunscreen MATAS sunlotion SPF 8|
46096533|NCT00711256|Radiation|UVB light|duration 4 times 1 minute radiation on the trunk.
46096534|NCT04069234|Drug|Ticagrelor|ticagrelor 60 mg BID for 30 days
46096535|NCT04069234|Drug|Clopidogrel|clopidogrel 75mg OD for 30 Days
45461377|NCT03874429|Device|Vismed multi|HA
45461378|NCT01164943|Procedure|Stimulation with human FSH|Human FSH
45461379|NCT01164943|Procedure|Stimulation with recombinant FSH|Recombinant FSH
45461380|NCT01269541|Drug|Mupirocin|Topical in the nose 3 times daily for 5 days
45461381|NCT01269541|Drug|Rifampin+Clindamycine or Trimehoprimsulfa|Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2
45461382|NCT01162993|Procedure|Spinal Cord Stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (≥50% relief of pain intensity on a weighted numeric rating scale (NRS) or a score of ≥6 on a seven-point Likert scale (1=very much worse; 7=very much improved) of the PGIC scale for pain and sleep) a definite spinal cord system will be implanted.
45461383|NCT01269619|Device|Dynamic back support|A dynamic back support which provides pressure on the lumbar without pressure on the abdomen
45461384|NCT01269619|Device|Static back support|A standard wrap-around sacro lumbar support
45599113|NCT02233283|Other|Basal|Keeping the volunteers in the fasting state overnight and for the entire duration of the experiment (10 hours)
46009801|NCT04558307|Diagnostic Test|Pilot a rapid SARS-CoV-2 testing strategy|Rapid testing strategy at an FQHC using Mayo Clinic Laboratory (MCL) diagnostic processing with a real-time polymerase chain reaction assay for SARS-CoV-2 and a Mayo Clinic drive-through collection protocol.
46009802|NCT04558307|Other|Community-driven messages to promote COVID-19 testing|A one-time communication about the availability of COVID-19 testing at the FQHC to patients randomized to the intervention group using any available means of communication (text and/or mailed letter).
46009803|NCT04545801|Drug|0.25 mg/kg of Ketamine|patients will recieve 0.25mg/kg of ketamine intravenously 5 min after spinal anesthesia
46009804|NCT04545801|Drug|20ml of normal saline solution|20ml of normal saline solution intravenously 5 minutes after spinal anesthesia
46096536|NCT00672828|Behavioral|Non-tailored CRC screening brochure|Patients receive written educational material about colorectal cancer and prompting to talk to their doctor about getting tested.
46096537|NCT00672828|Behavioral|Interactive computer intervention|
45461385|NCT03874663|Device|Directly assisted oral HIV self-testing (HIVST)|"To determine the ability of participants with unknown HIV status to correctly perform oral HIVST;~To compare the results of the oral HIVST with confirmatory rapid finger prick HIV test.~To explore participants attitudes and preferences towards oral HIVST.~To explore the feasibility, acceptability and appropriateness of using a mobile photo verification app to verify HIV self-testing results."
45679174|NCT05892653|Drug|ABM-1310|"Dose Escalation Stage: Subjects will be given oral dosing of ABM-1310 twice daily (BID) for 28-day cycles of continuous administration until progressive disease (PD), unacceptable toxicity, or other withdrawal criteria are met as clinically observed.~Dose Expansion Stage: Subjects will begin to receive oral doses of ABM-1310, BID, for 28-day cycles at a fixed dose level (as determined at the dose escalation stage) until PD, unacceptable toxicity, or other withdrawal criteria are met as clinically observed."
46009805|NCT04558424|Dietary Supplement|zinc gluconate and ascorbic acid|This group will consist of 50 patients who will receive 220 mg zinc and 1gm ascorbic acid for 10 days in addition to their standard treatment.
46009806|NCT02214693|Drug|DA-1229|
46009807|NCT00576602|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose of 0.6 micrograms/kg sc every 2 weeks
46009808|NCT00576602|Drug|Supportive treatment|As prescribed
46009809|NCT01125358|Drug|LY2140023|Administered orally, twice daily for up to 7 weeks of treatment
46009810|NCT01125358|Drug|Placebo|Administered orally, twice daily for up to 7 weeks of treatment
46009811|NCT02214732|Behavioral|Mindfulness Based Cognitive Therapy|The modified MBCT program for pregnant women is an 8-session group intervention that aims to help women change their relationship to the thoughts, feelings, and bodily sensations that can lead to psychological distress. Participants are guided to recognize and disengage from unhelpful mind states characterized by self-perpetuating patterns of ruminative thought. The intervention was modified to address pregnant women's physical and emotional needs, as well as their risk of perinatal mood episodes.
46009812|NCT02212223|Dietary Supplement|Vitamin D3|
46009813|NCT05110924|Other|Standard of care|Patients in the treatment arm will receive standard care.
45461386|NCT01269697|Dietary Supplement|Nutrof Total|2 capsules 2 times per day during 6 month
45461387|NCT01269697|Dietary Supplement|Placebo Nutrof total|2 capsules 2 times per day during 6 month
45461388|NCT03877393|Combination Product|Probiotic supplementation + gluten-free diet|The probiotic and gluten-free diet group (PRO-GFD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of 3 × 10^9 colony forming units (CFU) per day divided in two equal doses, comprising two bacteria strains: Lactobacillus helveticusRosell®-52, Bifidobacterium longumRosell®-175, and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The participants will be asked to consume supplements before breakfast. The group will follow the elimination diet containing no gluten.
45461389|NCT03877393|Combination Product|Placebo supplementation + gluten-free diet|The placebo and gluten-free diet group (PLA-GFD) will receive one capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The participants will be asked to consume supplements before breakfast. The group will follow the elimination diet containing no gluten.
46096538|NCT04379063|Other|COVID-19 pandemic|Currently practicing during the COVID-19 pandemic
45599114|NCT02233283|Other|Isocaloric diet|Isocaloric diet will conducted for one month, and designed to provide the calculated daily energy needs
46096539|NCT03860740|Other|Exercise|Exercise intervention adapted to maximum rate of oxygen consumption measured during incremental exercise (VO2level) of each patient, working between 60% to 100% VO2level. The activity will be walk-run in a treadmill. 10 sessions minimum
46096540|NCT03860740|Other|Stretching|Stretching and relaxing exercise during 30 minutes. Same number of sessions as intervention group
46096541|NCT00678912|Device|Smartcare/PS|computer-driven protocol that adjusts pressure support level in pressure support mode to patient respiratory status
46009814|NCT05110924|Other|Monitoring|Patients in the non-treatment arm will be closely monitored: the tumor will be evaluated using non-invasive imaging devices based on multispectral dermoscopy, reflectance confocal microscopy to determine the exact histology and high definition optical coherence tomography for imaging and volume calculation of the BCC.
46009815|NCT00637585|Drug|Fexofenadine|
45599115|NCT02343471|Dietary Supplement|20 g whey protein|
45599116|NCT03514381|Drug|Patients starting a treatment with Doxorubicin and Ifosfamide|"9 blood samples will be collected at each Cycle:~Cycle 1 (Day 1-Day 2-Day 3)~Cycle 2 (Day 1-Day 2-Day 3)"
45679175|NCT05892627|Dietary Supplement|PoZibio|PoZibio (50 x 10^9 CFUs/ CAPSULE)
45679176|NCT05892627|Dietary Supplement|Placebo|Placebo
45679177|NCT05892614|Drug|efzofitimod 450 mg|IV infusion over approximately 60 minutes every 4 weeks
45679178|NCT05892614|Drug|efzofitimod 270 mg|IV infusion over approximately 60 minutes every 4 weeks
45679179|NCT05892614|Drug|Placebo|IV infusion over approximately 60 minutes every 4 weeks
46009816|NCT00576641|Biological|autologous dendritic cells|
46009817|NCT02214810|Drug|Bupivacaine/Exparel|The opaque envelope, which was selected by the treating physician, will accompany each of the study participants will be opened and the patient identified as belonging to either Group 1 or Group 2. It is important to note that randomization of the envelopes were computer-generated and placed by a co-investigator; the treating physician is completely unaware of the order of the opaque envelopes. Patients in Group 1 will receive a standardized medication regimen including non-liposomal bupivacaine by soft-tissue injection at the conclusion of their surgical procedure. Those in Group 2 will receive non-liposomal bupivacaine and ExparelTM by soft-tissue injection at the conclusion of their surgical procedure. Study participants will undergo injection in this manner until the conclusion of the study.
46096542|NCT04374773|Drug|Dronabinol|2.5 mg PO administered once prior to and once after 1 week of hormone therapy
46009818|NCT04558385|Diagnostic Test|IgG SARS CoV2|IgG SARS CoV 2 will be checked in serum of COVID 19 recovered population
45461390|NCT03877393|Combination Product|Probiotic supplementation + gluten-containing diet|The probiotic and gluten-containing diet group (PRO-GD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of 3 × 10^9 colony forming units (CFU) per day divided in two equal doses comprising two bacteria strains: Lactobacillus helveticusRosell®-52, Bifidobacterium longumRosell®-175 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The participants will be asked to consume supplements before breakfast. The group will stay with their current diet.
45461391|NCT03877393|Combination Product|Placebo supplementation + gluten-containing diet|The placebo and gluten-containing diet group (PLA-GD) will receive one capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The participants will be asked to consume supplements before breakfast. The group will stay with their current diet.
45461392|NCT03877159|Other|There is no intervention.|There is no intervention. This is a retrospective study analysing archived tumour samples.
46009819|NCT02214849|Behavioral|LATCH Intervention|
46096543|NCT00672906|Behavioral|Group Parent Training|Skills group for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
46096544|NCT00672906|Behavioral|Maudsley Family Therapy|Family therapy specifically adapted for the treatment of adolescent anorexia nervosa.
46096545|NCT00720538|Drug|Thalidomide|Thalidomide 1.5-2.5 mg/kg/die once a day, at evening.
46096546|NCT00720538|Drug|placebo|placebo capsules
46096547|NCT02746211|Biological|High Titre Influenza virus|High Titre Influenza virus
46096548|NCT02746211|Biological|Medium - High Influenza virus|Medium - High Influenza virus
46096549|NCT02746211|Biological|Medium Low Titre Influenza virus|Medium Low Titre Influenza virus
46096550|NCT02746211|Biological|Low titre|Low titre
45461393|NCT03877003|Other|Eggs|Eggs: Consume 3 eggs per day for 4 weeks Choline supplement: Consume 1.5 pills per day for 4 weeks
45461394|NCT01268449|Radiation|Low dose laser|5mv laser with a wavelength of 650nm
45461395|NCT01268449|Radiation|Placebo|The act of radiating laser to the ear is done while the set is off.
45461396|NCT01280149|Biological|substance P|injections of substance P and low dose allergen or placebo
45461397|NCT01280149|Biological|substance P injections|injections of substance P for 8 weeks
46009820|NCT02214888|Drug|BIRB 796 BS, low dose|
46009821|NCT02214888|Drug|BIRB 796 BS, high dose|
46009822|NCT02214888|Drug|Placebo|
46009823|NCT04558034|Other|cryotherapy|cryotherapy will be delivered
46009824|NCT04538508|Device|Diathermy|10 sessions of 12 minutes of radiofrequency diathermy at the anterior surface of the knee, in constant movement
46009825|NCT04538508|Other|Supervised knee exercises|Daily hamstrings exercises, quadriceps exercises and hip exercises, 20 minutes of duration.
46096551|NCT00678990|Procedure|Transplantation of islets with heparin coating|Transplantation of islets with heparin coating
46096552|NCT00679068|Drug|Bosentan|62.5 mg b.i.d. for 4 weeks, then 125 mg b.i.d.for the remaining 8 weeks (if tolerated)
46009826|NCT04545684|Behavioral|Motor imagery|The person will have to imagine different scenarios of manual gripping
46009827|NCT04545684|Behavioral|Placebo intervention|The placebo group will imagine a place without the presence of humans.
46009828|NCT00576719|Behavioral|Intensive panic control treatment without parent involvement|Intensive panic control treatment without parent involvement is an 8-day, intensive form of cognitive behavioral therapy (CBT) with exposure, including 15-20 hours of direct therapist contact. The basic treatment components are psychoeducation about anxiety, restructuring anxiety-provoking thoughts, exposure to bodily sensations that trigger panic, and in vivo exposures.
46096553|NCT02745899|Dietary Supplement|Cow milk|Ingestion of 240 ml cow milk
46096554|NCT02745899|Dietary Supplement|Soy milk|Ingestion of 240 ml soy milk
46096555|NCT02572102|Dietary Supplement|Energy Drink|Energy Drink, two 16oz containers consumed in 45 minutes
46096556|NCT02572102|Dietary Supplement|Panax Ginseng|Panax Ginseng, lime juice, water and cherry flavoring
46096557|NCT02572102|Other|Placebo|Lime juice, water and cherry flavoring
46096558|NCT00679146|Drug|Thiocolchicoside+Ketoprofen|1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
46096559|NCT00679146|Drug|Thiocolchicoside|2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d
46096560|NCT02748161|Procedure|DEB-TACE|Transarterial chemoembolization with doxorubicin-eluting beads.
46096561|NCT00679224|Drug|ambrisentan|ambrisentan
46096562|NCT02748083|Device|tDCS|Electrodes for tDCS will have the anode placed over the left DLPFC (F3) and the cathode over the contralateral (right) supraorbital ridge. The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tDCS sessions on consecutive days (weekends and holidays excluded). The tDCS group will have 10 active or sham tDCS sessions. The active group will be stimulated with a 2 mA current for 20 minutes.
46096563|NCT02748083|Device|Sham tDCS|Electrodes for tDCS will have the anode placed over the left DLPFC (F3) and the cathode over the contralateral (right) supraorbital ridge. The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tDCS sessions on consecutive days (weekends and holidays excluded). The sham tDCS group will have 10 active or sham tDCS sessions. The sham group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
46096564|NCT00837265|Biological|Balugrastim|Balugrastim (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) will be administered per dose and schedule specified in the arm description.
46096565|NCT00837265|Drug|Pegfilgrastim|Pegfilgrastim will be administered per dose and schedule specified in the arm description.
45461398|NCT01268605|Procedure|Restoration with a dentin bonding agent (DBA)|Restoration with a dentin bonding agent (DBA) and hybrid resin-based composite: Use of a self-etch DBA Clearfil SE Bond followed by Herculite Ultra resin-based composite (Sybron/Kerr), comprising a state-of-the-art bonding and restoration system for cervical lesions.
45683819|NCT05240482|Procedure|ST36 acupuncture|"ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed)."
46009829|NCT00576719|Behavioral|Intensive panic control treatment with parent involvement|Intensive panic control treatment with parent involvement involves the same form of intensive CBT, but with direct parent involvement. Parents will attend the last 30 minutes of didactic sessions, complete homework assignments, learn ways to coach their children, and participate in selected exposures.
46096566|NCT00837265|Drug|Chemotherapy Regimen|The chemotherapy regimen consisting of doxorubicin 60 mg/square meter (m^2) and docetaxel 75 mg/m^2 will be administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.
46096567|NCT02747771|Behavioral|Cognitive behavioral therapy|10 sessions Group therapy during 10-12 weeks. The first three sessions focus on habit reversal training, the fourth to sixth session on acceptance and commitment therapy and the last four sessions aims at integrating the two approaches.
46096568|NCT02748005|Dietary Supplement|Fenugreek seeds extract 500 mg|one cap once a day
46096569|NCT00990847|Drug|Procaterol, Salbultamol|
46096570|NCT02745743|Drug|BAY1251152|Weekly infusion of BAY1251152 in 21-day cycles.
46096571|NCT00594516|Drug|tapentadol (CG5503) Immediate Release IR|21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period
46096572|NCT00594516|Drug|tapentadol (CG5503) Extended Release (ER)|During 2 double blind periods: Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second
46009830|NCT00576719|Other|Waitlist control|Waitlist control participants will receive active treatment (treatment with or without family involvement) after 6 weeks of waitlist.
46096573|NCT00594516|Drug|tapentadol (CG5503) Immediate Release (IR)|Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second
46096574|NCT05629793|Other|Experimental tests|Walking for 6 minutes, sitting down and getting up from a chair for 1 minute and finally the cold test (Cold pressor) where the hand is introduced for 1 minute in water at 4ºC. The patient will be monitored by means of a Polar H10 chest strap, as used in sports, continuously and 02 saturation, TA and voice (exhalation while saying /a/ and dry cough) will be collected before and after the tests. Finally, skin conductance will be monitored by performing baseline tracing and then control while performing the cold test.
46096575|NCT02745665|Other|flow mediated dilation (endothelial function)|
46096576|NCT02745665|Other|ABPI|
46096577|NCT02745665|Other|Pulse wave velocity and augmentation index|
46096578|NCT02745665|Other|blood pressure|
46096579|NCT02745665|Other|ramp test|
46096580|NCT00682500|Drug|Calfactant|Intratracheal Instillation of 0.5 mL/cm of height of 60 mg/mL suspension in two aliquots at study entry. Repeat dosing 12 hours later if criteria are met.
46096581|NCT00682500|Drug|Room Air (placebo)|Administration of 0.5 ml/cm height of air at study entry into the trachea. Repeat dosing at 12 hours if criteria are met
46096582|NCT04410107|Diagnostic Test|Lung Function tests|Spirometry before and after bronchodilator, lung volumes by body plethysmography, lung diffusion capacity of carbon monoxide (DLCO), respiratory system resistance by impulse oscillometry (IOS)
46009831|NCT01125046|Biological|bevacizumab|Given IV
46009832|NCT04538937|Other|no intervention|no intervention
46009833|NCT04311346|Diagnostic Test|Cardiac MR|Cardiac MR diagnostic tool for detection of acute rejection, double blind comparison with invasive cardiac biopsy
46096583|NCT04410107|Diagnostic Test|Exercise capacity|6-minute walk test (6MWT distance)
46096584|NCT04410107|Diagnostic Test|Exercise physiology|Cardiopulmonary exercise test (CPET)
46096585|NCT04410107|Diagnostic Test|Health-related quality of life|Short-Form Health Survey Questionnaire (SF-36)
46096586|NCT04410107|Diagnostic Test|Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening|"Adapted translation American Thoracic Society respiratory symptoms questionnaire;~Beck Anxiety Inventory (BAI) and Beck's depression Inventory (BDI);~Questionnaire for screening for post-traumatic stress symptoms (PTSD)."
46096587|NCT00538291|Biological|cetuximab|
46096588|NCT00538291|Drug|capecitabine|
46096589|NCT00538291|Genetic|gene expression analysis|
46096590|NCT00538291|Genetic|microarray analysis|
46096591|NCT00538291|Genetic|polymorphism analysis|
46096592|NCT00538291|Genetic|reverse transcriptase-polymerase chain reaction|
46096593|NCT00538291|Other|immunohistochemistry staining method|
46009834|NCT04538313|Drug|Tumor infiltrating lymphocyte|Tumor infiltrating lymphocytes were isolated from tumor tissues from tumor biopsy or operation. These TILs were cultured in human IL-2 medium for 4 to 5 weeks. 10e9 to 10e10 TILs were yielded. The phenotype, function and sterile were detected before these TILs infused patients.
46009835|NCT04538469|Other|COVID visitation restrictions|Visitation to patients in hospitals in Scotland was ceased due to the COVID 19 pandemic. Slow reintroduction of visitors has been introduced, however not to the pre COVID 19 levels. This study will examine the effects of these restrictions on patients in the cardiothoracic critical care unit that do not suffer from COVID 19.
46009836|NCT04557878|Drug|Hypertonic Dextrose Solution|Patients in this group will receive an intra-articular injection of 12.5% hypertonic dextrose solution, once every month for three consecutive months, in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.The point of needle entry will be 1 cm below the apex of the zygomatic arch and guided by ultrasound to ensure intra-articular injection in the superior joint space.
46009837|NCT04557878|Biological|Liquid Phase Concentrated Growth Factor (LPCGFs)|Patients in this group will receive single intra-articular injection of LPCGF in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.
46096594|NCT04049526|Behavioral|The influence of different music genres on Heart Rate Variability (HRV) in preterm infants|Neonates undergo a daily randomized music listening program (25 minutes, every day, for 3 days) based on different music genres listening (soft pop-rap, pop-rock and classical music). Music programs is followed by 1 day of no music monitoring (25 minutes). An electrocardiogram is performed to evaluate HRV parameters in each neonate with and without music exposure
46096595|NCT02745509|Other|Extensive Intraoperative Peritoneal Lavage|Extensive Intraoperative Peritoneal Lavage
46096596|NCT00682578|Drug|Dihydroartemisinin + Piperaquine (Artekin)|An adult dose consists of four doses of two tablets, given at 0, 8, 24 and 48 h. The approximate total adult dose is 6/48 mg/kg (DHA/PPQ). For children, a dose of 1.6/12.8 mg/kg is given at the same time intervals; this dosage will be obtained by dissolving the tablets in 5 ml of water.
45461399|NCT01268605|Procedure|Restoration with a resin modified glass ionomer liner (RMGI)|Restoration with a resin modified glass ionomer liner (RMGI) (Vitrebond LC, placed on the pulpal floor at a thickness of approximately 0.5 mm) followed by application of a two step self etch DBA and nanofilled resin based composite (RBC).
45679180|NCT05892601|Other|Maternal kisses|"The parents of the children in the experimental group were informed about the process before the application. The parents were asked to approach their child immediately after the invasive procedure was over, call out Let me kiss it better and kiss the child from a point not close to the place where the invasive procedure was applied. Kisses were delivered by the mother, free of oral ulcers, with a standard 5-second pressing of both lips on the affected body part followed by an exaggerated puckering sound. Pain, fear, and anxiety scales were administered to the intervention group at the 1st and 5th minutes after the application. Invasive interventions have been applied by researchers who have been working as nurses in the emergency room for 4 years."
46009838|NCT01124734|Drug|Interleukin-2|Participants will receive IL-2 up to a maximum of 14 doses at 600,000 IU/kg
46096597|NCT00682578|Drug|artesunate-sulphadoxin/pyrimethamine, chloroquine|The standard treatment will be in accordance with that in Afghanistan
46096598|NCT05590429|Other|Blood transfusion|No intervention
46096599|NCT04351685|Biological|VPM1002|"The active ingredient of the recombinant BCG vaccine, VPM1002 is Mycobacterium bovis A dose of 0.05 ml will be administered intradermally.~Manufactured by the Serum Institute of India Pvt. Ltd., India~Diluent: 1 ml of Water for injection/vial"
46096600|NCT04351685|Biological|BCG SII|"Commercially available BCG vaccine from Serum Institute of India Pvt. Ltd. A dose of 0.05 ml will be administered intradermally.~Manufactured by the Serum Institute of India Pvt. Ltd., India~Diluent: 1 ml of Sodium Chloride for injection/vial Injection"
45461400|NCT01165099|Procedure|acupuncture|The description of the acupuncture, whether manual, electro or sham, is as described for each of the individual groups.
45461401|NCT01163071|Drug|ABI-011|ABI-011
46096601|NCT00594906|Drug|Teriparatide|Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
45461402|NCT01165255|Drug|3. Exposure to other antidepressants during the first trimester comparison cohort|"Exposure to other antidepressants during first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate dispensing of other antidepressants. Infants were classified according to maternal exposure to other antidepressants during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women who were exposed only to one type of an antidepressant (other antidepressant monotherapy), or more than one type of an antidepressant (other antidepressant mono or polytherapy) during the first trimester. A woman was considered exposed if there is at least one dispensing of another antidepressant during the first trimester of pregnancy."
45461403|NCT01165255|Drug|2. Exposure to bupropion outside the first trimester comparison cohort|"Exposure to bupropion outside the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. The comparison cohort (bupropion exposure outside the first trimester) included women whose bupropion exposure occurred at least one month before the estimated date of conception and women whose bupropion exposure occurred after the first trimester, but before delivery. This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy) during the period outside the first trimester."
46096602|NCT00594906|Drug|Placebo|Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
45461404|NCT01165255|Drug|1. Exposure to bupropion during the first trimester|"Exposure to bupropion during the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. Infants were classified according to maternal exposure to bupropion during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy). A woman was considered exposed in the first trimester if there was at least one dispensing of bupropion during the first trimester of pregnancy."
45461405|NCT01165333|Drug|Cilengitide dose escalation|"Cilengitide will be administered intravenously over 60 minutes, twice a week, at a given dose.~The Cilengitide dose (mg/m²/infusion)levels are as follows :~240~480~720~1200~1800"
45461406|NCT01165333|Drug|Cilengitide|Patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations
45461407|NCT01165333|Radiation|Concomitant radiotherapy|1.8 Gy per fraction for a total of 54 Gy over 6 weeks, from monday to friday of the first cycle. The radiation will imperatively begin between 3 and 7hours after the end of Cilengitide infusion.
45461408|NCT01165333|Biological|Pharmacokinetic|A pharmacokinetic assessment for Cilengitide will be carried for all patients. The pharmacokinetic (PK) samples will be drawn during day 1 and day 2 of the first cycle of treatment.
45461409|NCT01165333|Biological|Pharmacogenetic|For every patient 1 blood sample will be taken before study treatment. These blood samples can be made at any hour of the day, and does not require to be taken on an empty stomach. DNA will be extracted in the Laboratory of Pharmacology.Constitutional polymorphisms of genes will be measured before the treatment initiation.
45461410|NCT01165333|Biological|Exploratory investigation|Evaluate the metabolic impact of the treatment with dynamic MRI (diffusion, perfusion, spectro), and with FDG-PETand sestamibi SPECT.
45461411|NCT03872323|Procedure|Endovascular treatment|The arteries injuries are repaired by endovascular treatment.
46096603|NCT05590351|Behavioral|First diet: m-health coaching application|Intervention for the study would comprise of a culturally appropriate m-health application called first diet. This application will be developed considering the perceptions, barriers and facilitators identified through formative research. Content of the messages would focus on breastfeeding, its importance and early initiation within one hour of birth, significance of first feed i.e. colostrum, importance of EBF from birth till 6 months, introduction of complementary feeding to 6-8 months old infants and appropriate YCFP. These messages would be drafted in the local preferable language assessed during formative research. The content of the messages would be translated and then back translated to ensure validity. These messages will be short, contextual and tailored according to the women's stage of gestation, delivery and infant's age
46096604|NCT05590351|Behavioral|Face to Face counselling|Women randomly enrolled in the non-interventional group will receive face-face nutritional counseling instead of mobile application. Once enrolled in the group, Research Assistant (RA) will collect relevant details on the baseline questionnaire like intervention group but on a paper-based questionnaire. Women will be given first face-face counseling on the day of enrollment. The counseling sessions will coincide with the routine vaccination and growth monitoring schedule of the infant after women deliver
46096605|NCT02745431|Drug|Oxytocin|
46096606|NCT02745431|Drug|Placebo|
46096607|NCT04143360|Device|New Closed Drainage Device|For the first group, a new closed drainage device was adopted.
46096608|NCT04143360|Device|Traditional closed drainage device|For group 2, conventional closed drainage device was used.
46096609|NCT05360797|Other|Outpatient|After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is discharged and contacted daily for 4 consecutive days by the study investigators in each center.
46096610|NCT05360797|Other|Medical home care|After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is discharged and contacted daily for 4 consecutive days by the medical home care department in each center.
45461412|NCT03872323|Procedure|Open surgery|The arteries injuries are repaired by open surgical operation.
45461413|NCT03441360|Drug|Eribulin mesylate|Intravenous infusion
46009839|NCT01124734|Drug|Temozolomide|Participants receive temozolomide at 75 mg/m2 after completion of the second cycle of high dose IL-2. Participants take the medication at bedtime daily. Four weeks after Cycle 2 of a course, they would take it for 21 days.
46009840|NCT04538781|Device|VASCADE MVP VVCS|The VASCADE MVP Venous Vascular Closure System (VVCS) is indicated for the percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis, and time to discharge eligibility in patients who have undergone catheter-based procedures utilizing 6 - 12F inner diameter (maximum 15F OD) procedural sheaths, with single or multiple access sites in one or both limbs.
46009841|NCT04557839|Other|Traditional physical therapy balance exercise|"first phase : stepping forward, backward, and sideways on the exercise step stepping over blocks of various heights standing up from a chair, walking four steps forward,)A performing a range of motion and balance exercises (forward and backward rolling of the arms; bending the trunk forward and side to side);on a swiss ball. performed In a normal condition In first 20 m of each session 2nd phase Performing double-legged stance tandem walking forward and backward~• Dosage of exercise was twice a week for 6 week each session comprise of 60 mints. Each set consisted of 4 periods of 11 exercises and rest of 40 sec .many exercise over time will turn into circuit training"
45461414|NCT03872167|Device|BIPAP, Intelligent automatic mode defined by assured volume with pressure support|Correction of night ventilation through an automatic mode of ventilation with assured volume with pressure support
45461415|NCT03872167|Device|BIPAP, manual tritration.|Correction of night ventilation through a manual titration of non-invasive mechanical ventilation using polysomnography.
46009842|NCT04557839|Other|proprioception based balance training|"first phase : stepping forward, backward, and sideways on the exercise step stepping over blocks of various heights standing up from a chair, walking four steps forward,)A performing a range of motion and balance exercises (forward and backward rolling of the arms; bending the trunk forward and side to side);on a swiss ball. performed In a normal condition In first 20 m of each session 2nd phase Performing double-legged stance tandem walking forward and backward all exercise done under following condition.~eyes open firm surfaces~Eyes open soft surfaces~Eyes closed firm surfaces~Eyes closed soft surfaces (the soft surfaces will be a foam mate with 2.5 cm thick )~These exercise will perform with turning the head side to side ad up and down~Dosage of exercise was twice a week for 6 week each session comprise of 60 mints. Each set consisted of 4 periods of 11 exercises and rest of 40 sec .many exercise over time will turn into circuit training"
46009843|NCT04538976|Drug|Sildenafil|Sildenafil in standard dosage
46009844|NCT04545450|Drug|dutasteride 5 mg/day|Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
46009845|NCT04545450|Drug|Testosterone Undecanoate|Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
46009846|NCT04579133|Drug|Olaparib|300 mg BID OR 200 mg BID (if glomerular filtration rate [GFR] 31 to 50 mL/min)
46009847|NCT04579133|Drug|Durvalumab|Durvalumab 1500 mg IV
46096611|NCT05360797|Other|Hospitalization|After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is hospitalized with usual treatment (PADI_1) in each center.
45461416|NCT01167049|Drug|CAPECITABINE|Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; Repeat three cycles (approximately 3- months);
45461417|NCT03876145|Other|Minimal ovarian stimulation|After obtaining informed consent to participate in the study, the subjects will be randomly divided into the following 4 groups: The group of minimal ovarian stimulation with rec-FSH or HMG. The group of mild ovarian stimulation with rec-FSH or HMG. In all 4 experimental groups, after reaching at least three follicles the size of 12 millimeters (mm), daily administration of 0.25 milligram (mg) Cetrotide (antagonist GnRH) will be started and after reaching at least three follicles the size of 17 mm, 500 microgram Ovitrelle (recombinant Human curionic gonadotropin) will be prescribed. 36 hours later, ovulation process will be done. On the day of Ovitrelle administration, serum levels of estradiol and progesterone will be also evaluated. Based on the patient's condition and the quality of obtained oocytes and embryos, 2 embryos will be transferred.
45461418|NCT01311180|Drug|Sensoril®|Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
45461419|NCT01311180|Drug|Placebo|Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
46009848|NCT04545372|Other|aerobic exercise|
46096612|NCT02745041|Drug|Fibrinogen Concentrate|"Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM guided treatment algorithm [FIBTEM ≤ A5 10mm]~FIBTEM A5 0mm (Flat Line) = 6g FC FIBTEM A5 1 - 4mm = 5g FC FIBTEM A5 5 - 6mm = 4g FC FIBTEM A5 7 - 8mm = 3g FC FIBTEM A5 9 - 10mm = 2g FC"
46096613|NCT02745041|Other|Cryoprecipitate|"Fibrinogen replacement using Cryoprecipitate as per ROTEM guided treatment algorithm [FIBTEM A5 ≤ 10mm]~FIBTEM A5 0mm (Flat Line) = 20 Units Cryo FIBTEM A5 1- 4mm = 16 Units Cryo FIBTEM A5 5 - 6mm = 14 Units Cryo FIBTEM A5 7 - 8mm = 10 Units Cryo FIBTEM A5 9 - 10mm = 8 Units Cryo"
46096614|NCT00682656|Drug|Glucantime®|15mg Sb+5/Kg/day, during 20 days. Maximum dose:15ml/day
46009849|NCT00576914|Drug|recombinant human endostatin|recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
46096615|NCT00682656|Drug|Zithromax ®|Zithromax ®/ Pfizer, 500 mg - 1x day, during 20 days
46009850|NCT04545645|Behavioral|median nerve mobilization|The patient is placed in a supine position and his cervical spine with 25º of lateral flexion on the opposite side of the member in which we perform the test. First a passive scapular depression is performed, 90º of shoulder abduction combining external shoulder rotation. Next, a supination of the forearm is performed with wrist extension and finger extension. Finally, the elbow is extended to the limit of resistance or when the investigator observes the elevation of the shoulder girdle.
46096616|NCT05590117|Drug|Pentoxifylline|Pentoxifylline is a potent anti inflammatory may prevent chemotherapy induced neuropathy and mucositis and will be administered 400mg twice daily
45461420|NCT03871933|Other|Measurement of lung function, electrocardiography, echocardiography and autonomic function|Measurement of lung function, electrocardiography, echocardiography and autonomic function
45461421|NCT01311414|Drug|cafedrine/theodrenaline, urapidil|Increasing blood pressure using cafedrine/theodrenalin and decreasing blood pressure using urapidil during carotid endarterectomy.
45461422|NCT01280227|Behavioral|SiSom|SiSom is a symptom assessment tool designed to help the child report disease specific problems.The child also report the severity of their problems. After using the tool a report is printed and given to the clinician.
45679181|NCT05892575|Behavioral|improving quality of life, coping with urinary incontinence and kegel exercise training|Face-to-face training will be given to the elderly in the experimental group for a total of 5 weeks, once a week day (60 minutes). In the 4th week, reminder messages will be started over the phone. The 4th week kegel exercise chart and nutrition list will be given. In the 5th week, kegel exercise dance will be watched. Sending reminder messages from the phone will continue for 3 months.
45679182|NCT05892562|Other|No intervention|As this study is purely observational, no intervention is involved.
45679183|NCT05892536|Procedure|dental regenerative endodontics|regenerative procedures performed in necrotic mature permanent teeth
45679184|NCT05892523|Procedure|THA|positioning the acetabular cup regarding abduction and anteversion angles with or without concern to spinal deformity
45679185|NCT05892484|Device|Thermal Imaging|Thermal Imaging device used to evaluate fracture in those presenting with proposed wrist fracture in the emergency department.
45679186|NCT05892484|Diagnostic Test|X-RAY|Routine X-RAY
45679187|NCT05892471|Drug|ciprofol injection|Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia
46009851|NCT04545645|Behavioral|Neural stress provocation with cognitive auditory distraction|Neural provocation of the median nerve is performed but an auditory distraction is added with a metronome with a constant time of 50 beats per minute.
46009852|NCT04545645|Behavioral|Providing neural stress with a motor distraction|The neural provocation of the median nerve is performed and we add a motor distraction that consists of the patient intermittently squeezing a ball with the opposite hand.
45679188|NCT05892471|Drug|Propofol injection|Patients in propofol group received 1.5 mg/kg propofol for induction of anesthesia
46009853|NCT04545645|Behavioral|Neural stress provocation with auditory and motor cognitive distraction.|The neural provocation of the median nerve is performed, we add auditory distraction with the metronome with a constant time of 50 BPM and a motor distraction consisting of squeezing a ball to the rhythm that sounds the metronome.
46009854|NCT02212340|Drug|fresofol and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
46009855|NCT02212340|Drug|desflurane and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
46009856|NCT01124617|Drug|Tapentadol|Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.
46009857|NCT01124617|Drug|Placebo|Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
46096617|NCT05590117|Drug|Placebo|placebo tablets
46096618|NCT05590117|Drug|FOLFOX-6 regimen|12 cycles of FOLFOX-6 regimen
46096619|NCT00636311|Drug|Ifosfamide, Gemcitabine, Vinorelbine|Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
46096620|NCT00636311|Drug|Bortezomib + IGEV|Bortezomib 1,3 mg/sqm, day 1, 4, 8; Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
46096621|NCT02629302|Other|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
46096622|NCT02629302|Other|standard therapy|standard physiotherapy, speech therapy and occupational therapy
46096623|NCT03874715|Drug|Insulin Aspart SAR341402|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
46096624|NCT03874715|Drug|Insulin Aspart|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
46096625|NCT03874715|Drug|Insulin glargine U100|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
45461423|NCT03875989|Procedure|Anterior colporraphy|It will be delimitate a rectangular vaginal strip which will be isolated from the anterior colpocele. The superior edge of the strip is placed 2 cm from the urethral orifice. After lateral vesico-vaginal dissection, the paravesical fossae will be wide opened to repair the tendinous arches. The vaginal plastron will be fixed to the tendinous arch of the pelvic fascia by 3 lateral stitches (anterior/ lateral/ posterior) on each side of the plastron. After, the plastron will be tensioning and the cystocele will be suspended. The closure of the vaginal wall will end the procedure.
45461424|NCT03875989|Procedure|vaginal patch plastron|It will be make a midline incision of the anterior vaginal wall from the urethrovesical junction to the vaginal apex or anterior fornix. The vaginal epithelium will be separated from the underlying fibromuscular layer (Halban Fascia) after the midline incision. Midline plication of the fibromuscular layer will be obtained by interrupted horizontal stiches. The closure of the vaginal wall will end the procedure.
46009858|NCT04205890|Drug|Ketamine|The ketamine will be injected per the doctor's orders to achieve a dissociative state; dosage varies between 75mg - 1000mg depending on every individual's unique treatment plan.
45461425|NCT03715374|Procedure|Periodontal Surgery with PRF+ABB|Patients will be treated by periodontal surgical flaps with the addition of PRF+ Anorganic Bovine Bone filling material
45461426|NCT03715374|Procedure|Periodontal Surgery with Collagen Membrane +ABB|Patients will be treated by periodontal surgical flaps with the addition of Collagen Membrane + Anorganic Bovine Bone filling material
45461427|NCT01163305|Drug|Chemotherapy|The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
45461428|NCT03715296|Drug|Lenalidomide 25mg|Lenalidomide 25mg/d PO d1-10 Plus Rituximab 375 mg/m2 IV d1, Cyclophosphamide 750mg/m2 IV d2, Doxorubicin 50mg/m2 IV d2, Vincristine 1.4 mg/m2 IV d2, Prednisone 60 mg/m2 PO d2-6 OR Ifosfamide 1500mg/m2/d iv d1-3, Carboplatin 5*[GFR(ml/min)+25]mg/d iv d2, Etoposide 100mg/m2/d iv d1-3,
45461429|NCT01269775|Other|Teaching Methods|We carried out a randomized controlled trial comparing three methods of teaching. These three instructional methods consist of face to face lecture, interactive internet based teaching and computer based teaching (lecture synchronized with presentation) regarding medical students' knowledge achievement and satisfaction.
45461430|NCT03717246|Behavioral|Sleep Smart Latino|A culturally tailored group intervention aimed at improving sleep duration and quality for Latino middle school students.
45461431|NCT03717246|Behavioral|Basic Sleep Hygiene and Child Health|A group intervention providing sleep hygiene and child health topics education to Latino middle school students.
46009859|NCT00577070|Device|TMS|Transcranial Magnetic Stimulation (TMS) is a new tool in neuropsychiatry. This method is based on creating pre determined magnetic fields, which alternate rapidly. The magnetic fields are intended to cause electric induction in the brain cells and, as a consequence, generation of action potentials. The magnetic stimulation is delivered/ generated by a coil, positioned on the patient's scalp, inducing nerve stimulation within the brain. Therefore, when placed over the motor cortex, the magnetic stimulation creates Muscular Evoked potential, which can be measured by EMG.
46009860|NCT00577109|Drug|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
46009861|NCT00577109|Drug|Irinotecan|180mg/m2 iv on day 1 of each 2 week cycle
46009862|NCT00577109|Drug|Leucovorin|200mg/m2 iv on day 1 of each 2 week cycle
46009863|NCT00577109|Drug|5 FU|400mg/m2 iv on day 1 of each 2 week cycle
46096626|NCT04151238|Behavioral|Exercise intervention for cancer patients to increase physical activity during chemotherapy|The duration of the exercise intervention is eight (8) weeks. There will be guided endurance and muscle power training two (2) time weekly. The participants will also be provided with one training program per week for use at home.
46096627|NCT00990925|Behavioral|Nutritional Lifestyle Modification Group|Manualized group treatment to educate about basic nutritional concepts to help improve eating choices with the goal of losing weight.
46096628|NCT00990925|Other|Usual Care|Care as usual
46009864|NCT00577109|Drug|Cetuximab|Loading dose of 400mg/m2 iv followed by 250mg/m2 iv on day 3 of each 2 week cycle
46096629|NCT04151316|Procedure|crown preparation|includes tooth preparation
46096630|NCT04151316|Procedure|vertical preparation|type of vertical preparation on the tooth that accepts the crown
46096631|NCT04151316|Procedure|horizontal preparation|type of horizontal preparation on the tooth that accepts the crown
46096632|NCT00673140|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
46096633|NCT00673140|Radiation|Far infrared radiation|Far infrared radiation at a frequency of 5 microns to 20 microns for 30 to 40 minutes per session.
46096634|NCT02695199|Procedure|Laparoscopic varicocelectomy|Traditional laparoscopic varicocelectomy assisted by laparoscopic Doppler ultrasound
46009865|NCT04538001|Device|Balloon implantation|Subjects will undergo arthroscopic surgical intervention of debridement, long head of biceps tenotomy if deemed necessary with or without acromioplasty, and balloon implantation.
46096635|NCT02695199|Procedure|Microscopic Subinguinal varicocelectomy|Infertile patients with clinically palpable varicoceles were selected to receive microscopic Subinguinal varicocelectomy
45461432|NCT01347762|Drug|Nabilone|nabilone titrated to 1 mg by mouth twice daily
45461433|NCT01347762|Drug|Placebo|one placebo capsule by mouth twice daily
45461434|NCT03874273|Drug|Crizotinib|Crizotinib 280mg/m2 twice a day (for 24 months maximum)
45461435|NCT03874195|Behavioral|Access to PCforMe for review|Intervention Arm subjects will receive access to PCforMe.
45461436|NCT03874195|Behavioral|Access to three nationally-recognized Palliative Care websites for review|Subjects in the Active Control arm will receive a list of three nationally-recognized websites to receive information on palliative care
45461437|NCT05657652|Drug|cladribine, cytarabine,venetoclax|Cladribine 5 mg/m2/day, cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.
45461438|NCT01167127|Drug|Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release|OXN Tablet, oral, BID, flexible dose design
45461439|NCT01280305|Drug|raloxifene|raloxifene 60 mg bid
45461440|NCT01280305|Drug|placebo|Placebo bid
45461441|NCT03872011|Drug|Vitamin C,thiamine,hydrocortisone|"Vitamin C (2g) will be diluted in 100ml 0.9%NACL and administered ivd every 6 hours for 5 days or until participant is discharged from the ICU.~Thiamine(200mg) will be diluted in 100ml 0.9%NACL and administered ivd every 12 hours for 5 days or until participant is discharged from the ICU. Hydrocortisone was administered 200 mg/d as a continuous infusion for 5 days or until participant is discharged from the ICU."
45461442|NCT03872011|Drug|Placebo|Normal saline (0.9% NaCl solution) volume to match all components
45461443|NCT01163695|Behavioral|Children's development account|Children in the experimental condition (the SUUBI program) received, in addition to the usual care, an economic empowerment intervention aimed at promoting asset accumulation for families-and consisting of three major components: 1) workshops focused on asset-building and future planning; 2) a monthly mentorship program for adolescents with peer mentors on life options; and 3) a Child Development Account (CDA), dedicated to paying for secondary schooling, vocational training and/or a family small business. The CDAs were matched savings accounts, with a match rate of 2:1 as an incentive for participants to save, but with a limit on the maximum savings that could be matched (the match cap, in this case, was equivalent to $10 a month).
45461444|NCT01280383|Device|non-invasive neurally adjusted ventilatory assist|non-invasive neurally adjusted ventilatory assist in critically ill patients
45461445|NCT01163773|Other|MILK|"Consumption of the 2 experimental diets~Milk diet~Control diet"
45461446|NCT03438396|Drug|tisotumab vedotin|All patients will be treated with tisotumab vedotin once every three weeks until progression or toxicity
45461447|NCT01269931|Procedure|EBUS-TBNA|Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) is a revolutionary diagnostic pulmonary procedure that allows visualization and safe, accurate biopsies of intra-thoracic structures during bronchoscopy. Patients enrolled in this study at the University of Calgary would have undergone this procedure regardless of being enrolled in this study. The purpose of the study was to prospectively compare the EBUS-TBNA performance of 2 groups of learners, performing EBUS-TBNA on patients, who had received to different methods of EBUS-TBNA training. Patients were randomly assigned to undergo bronchoscopy with a trainee from Group 1 or Group 2.
45461448|NCT03876067|Drug|Ozone|"Our procedures for O3T application in CBP surgery conform to international guidelines of the ''Madrid Declaration on Ozone Therapy'' 32 . M-O3T will be carried out as follows:~50mL of blood drawn by vacuum from the patient central catheter into a sterile blood transfusion bag in which 10 mL of 3.8% Na citrate solution (Galenica Senese Industries, Siena, Italy) as an anticoagulant will be previously added so that the blood/citrate volume ratio was 9:1. After blood withdrawal, the bag will momentarily disconnected leaving the venous access open by a saline infusion 33 . A corresponding volume (50 mL) of gas was immediately added with an O3 concentration of 20-50 micrograms/mL gas. Ozone was produced by Medozon compact generator (Herrmann Apparatebau GmbH, Germany).~At this point, the hyper-oxygenated ozonated blood will be mixed with the cold cardioplegia (Thomsons cardioplegia) this amount of ozonated blood will be added to each 500 ml of cardioplegic solution"
45461449|NCT03876067|Drug|Cardioplegic Solutions|in which in which only cold blood cardioplegia
45461450|NCT03715218|Other|Mothers Touch Program|Mothers Touch Program with bed rest, Relaxation program to reduce stress, massage for mother and infant, gently physical exercise and special dietary program each week.
45461451|NCT03715218|Other|Usual Care Program|Usual care group had advice, support and educational program delivered by midwife, or physicians.
46009866|NCT04538001|Procedure|Rotator cuff repair|Subjects will undergo arthroscopic surgical intervention of debridement, long head of biceps tenotomy if deemed necessary with or without acromioplasty, and partial repair
46009867|NCT01124422|Drug|fluticasone propionate/salmeterol inhalation powder DISKUS 250/50|Experimental comparator consisting of inhaled corticosteroid plus long-acting beta agonist combination also known as ADVAIR DISKUS
46096636|NCT00991003|Procedure|Colon capsule endoscopy|The PillCam® Colon Capsule is 11mm x 31mm in size (Figure 1), is equipped with two cameras acquiring pictures from both ends of the capsule at a rate of 4 frames per second (2 pictures per second and camera). The PillCam® Colon Capsule is automatically activated when it is removed from the package. It enters sleeping mode after approximately 10 minutes and starts transmitting again 1 h 45 min later. It has a total operating time of 8 - 10 hours. During the examination the patient wears a sensor array which is attached to the abdominal skin and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the Given Imaging workstation and a video is generated.
46096637|NCT00991003|Procedure|Conventional Colonoscopy|
46096638|NCT02627742|Device|MetaNeb® System|The treatment protocol used for Respiratory Care during the CHANGE IN PRACTICE period of the Study will be that prescribed by the patient's health care team in the routine standard care of each patient. With the exception of standard airway clearance and lung expansion procedures, other components of the patients respiratory care regimen will remain the same as during the standard therapy period, however the CHANGE IN PRACTICE will incorporate the use/treatment with The MetaNeb® System as an alternative to usual airway clearance and lung expansion procedures. Use of The MetaNeb® System will follow the labeling of the device.
46096639|NCT05629559|Biological|4D-310|Single IV administration of 4D-310 Dose Level 1
46096640|NCT05629559|Biological|4D-310|Single IV administration of 4D-310 Dose Level 2
46096641|NCT05629559|Biological|4D-310|Single IV administration of 4D-310 at the selected dose
45461452|NCT01163929|Drug|paclitaxel|"Paclitaxel:~80mg/m2 IV TRO 3 hours every 28 days for 4 cycles~Trastuzumab:~4mg/kg IV load dose (TRO 90) minutes followed by 2 mg/kg TRO 60 minutes every week for 18 weeks~Everolimus: 10mg PO daily 16-18 weeks"
45461453|NCT03715140|Drug|Crucumin|Evaluation of the effect of Crucumin in patients with osteoarthritis
46096642|NCT05589961|Drug|TMZ|After enrollment, temozolomide 50mg/m2 was given orally for QD until progression, and radiotherapy and PF 0.2g/ time for TID were started one week later until progression. Pembrolizumab 200mg once every 3 weeks until progression; The radiotherapy regimen depends on the patient's recurrence and initial treatment.
46096643|NCT00679458|Drug|buprenorphine and low-dose naloxone|each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug, buprenorphine only, will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
46096644|NCT00679458|Drug|buprenorphine alone|each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
45461454|NCT03715140|Drug|Placebo|Placebo
45461455|NCT01280539|Device|Transcutaneous electrical nerve stimulation|3 weeks, 5 times a week, 60 minutes a day.
46096645|NCT02745197|Dietary Supplement|Nutritional Supplement|Participants will take 2 capsules, containing the nutritional supplement, 3 times per day.
46096646|NCT02745197|Dietary Supplement|Placebo|Participants will take 2 capsules, containing a placebo, 3 times per day.
46096647|NCT04003753|Other|VR App|Participants will be exposed in three different virtual height scenarios (rural mountain, urban town, cloudy weather). At the beginning of each exposure session participants will be standing on a virtual platform at ground level (level 0). From level 0 they will proceed to further levels according to a predefined exposure scheme based on SUDS ratings (scale 0=no fear to 10=extreme fear). Participants will have to stay at each level until their SUDS are 3 or below for two times consecutively (assessment via gaze selection). In each scenario there will be 15 different height levels available (corresponding to a range of heights between 1-75m). Each exposure session will be terminated by a time limit of 20 minutes (study phase 1) or 30 minutes (study phase 2) irrespective of achieved level.
45461456|NCT03871777|Other|Placebo mouthwash|Participants received placebo mouthwash (ultrapure unflavoured water) with which they rinsed their mouth for one minute, twice a day for 7 days. Resting metabolic rate and blood pressure were measured on day eight. Additionally, blood and saliva samples were taken from all the participants. Dietary records of seven days were also collected in order to confirm the foods and portion sizes consumed, preparation methods, recipes and any brand names.
45461457|NCT03871777|Other|Chlorhexidine mouthwash|After using placebo and complete all the physiological measurements, participants were given a further one-week supply of antibacterial mouthwash containing 0.2% chlorhexidine (Corsodyl, GlaxoSmithKline, UK), encouraged to rinse their mouth for one minute, twice a day for 7 more days. They returned to the laboratory in 7 days to repeat all measurements in the same order.
46009868|NCT01124422|Drug|tiotropium bromide inhalation powder HandiHaler|Open-label drug also known as Spiriva HandiHaler
46009869|NCT04544982|Other|Blue fenugreek kale extract|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
46009870|NCT04544982|Other|Placebo|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
45461458|NCT00073307|Drug|Sorafenib (Nexavar, BAY43-9006)|Multi Kinase Inhibitor
45461459|NCT00073307|Drug|Placebo|Placebo
45461460|NCT01167205|Dietary Supplement|astaxanthin|astaxanthin 20mg for 12 weeks
45461461|NCT03715062|Other|Dialogue tool|The intervention has two parts: an educational session and a dialogue tool. The educational session consists of 75 minutes of education in diagnosing urinary tract infection. The dialogue tool consists of 1) a checking box for the most important symptoms and observations for urinary tract infection 2) an algorithm to evaluate if urinary tract infection is likely based on the present symptoms and observations 3) a list of reflection points to evaluate with a collegue 4) a specialized ISBAR (communication tool) if long-term care facility staff finds it appropriate to contact the General Practicioner
46009871|NCT00577187|Device|EnSite NavX-Guided CRT implant|LV lead placement during CRT implant using EnSite NavX
46009872|NCT04309591|Device|CytoSorb haemoadsorption (HA) device|CytoSorb® cartridges contain biocompatible sorbent polystyrene divinylbenzene beads coated with polyvinylpyrrolidone, capable of removing inflammatory molecules (eg Interleukin). The cartridge is inserted in a cardio-pulmonary bypass circuit to remove inflammatory molecules during cardiac surgery .
45461462|NCT01270789|Drug|Liraglutide|Liraglutide administered as once daily sc injection
45461463|NCT01270789|Drug|placebo|placebo administered as once daily sc injection
45461464|NCT01164085|Drug|Intravitreal Ketorolac|4mg of intravitreal ketorolac
45461465|NCT05557656|Drug|Regorafenib 40 MG|participants who received the treatment of Regorafenib
45461466|NCT01271179|Procedure|sequential perfusion with ipv Ross solution and UW solution|Totally 6 L of ipv Ross solution were initially infused (aortic: portal=1:1), followed by 2 L of cold UW solution infusion (aortic: portal=1:1).
46009873|NCT05102929|Device|active intermittent Theta Burst Stimulation (iTBS)|iTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with patients with schizophrenia. This research study is using iTBS off label in SCZ patients to examine research questions.
46009874|NCT05102929|Device|sham intermittent Theta Burst Stimulation (iTBS)|"Sham TBS over the left DLPFC will be performed using a Cool-B65 A/P TMS coil, designed to support blinded clinical trials. Specifically, when the coil is placed in the P position (i.e. the placebo position), only a very small amount of current is induced in tissue, thus preventing the activation of cortical neurons."
45461467|NCT01271179|Procedure|sole perfusion with UW solution|Totally 6 L of cold UW solution were infused (aortic: portal =1:1)
46009875|NCT04538196|Other|Resident education on documentation and coding|Surgery residents will receive education on documentation and coding at the beginning of a particular surgical rotation vs the control group who will receive no education on documentation
46009876|NCT00625495|Drug|Esomeprazole|40mg Intravenous infusion over 3 minutes
46009877|NCT00625495|Drug|Esomeprazole|40mg Oral
46009878|NCT00625534|Procedure|Laparoscopic totally extraperitoneal inguinal hernia repair|3 trocars procedure. Blunt camera dissection without use of balloon dissector. Anatomical, preformed, polyester mesh passed around spermatic cord structures. No fixation of mesh.
46009879|NCT00625534|Procedure|Open tension free inguinal hernia mesh repair|Classical Lichtenstein repair. Polyester flat 14x8cm mesh
46009880|NCT02882425|Drug|Selexipag for intravenous use|Selexipag was reconstituted in sterile 0.9% w/v NaCl before infusion via an infusion pump at a rate of 2.5 µg/min.
46009881|NCT02882425|Drug|Selexipag for oral use|Tablet containing 200 µg of selexipag
46096648|NCT04216511|Diagnostic Test|Tumor autoantibody detection|Level of a set of autoantibodies potentially relative with lung cancer will be tested for each of the participants.
46009882|NCT04538235|Procedure|Thoracic Regional Analgesia|In the TEA group, a thoracic epidural was performed before VATS. In the Bi-block group, a SAP block associated with an ESP block were performed before surgical incision under general anesthesia.
46009883|NCT00577304|Drug|Nitroglycerin|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix with Nitroglycerin. Each dose contains 4.5mg of Nitroglycerin. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
46009884|NCT00577304|Drug|Topical AmphiMatrix|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
46009885|NCT01124149|Drug|MMX mesalamine/ mesalazine|4.8g/day given QD (four 1.2g tablets) for 8 weeks, 2.4g/day given QD (two 1.2g tablets) for 12 months
46009886|NCT04538118|Behavioral|Shoulder disability|"Shoulder disability was evaluated with Patient-specific functional scale, the disabilities of the shoulder, arm and hand questionnaire, and the upper extremity functional index.~First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
46009887|NCT04538118|Device|Shoulder Range of Motion|"Shoulder range of motion was evaluated with universal goniometer. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
46096649|NCT02627586|Other|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-60% of peak heart rate). The total duration of the HIIT training is 38 min.
46096650|NCT02627586|Other|MICE|MICE is also performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform MICE training three times per week.
46096651|NCT05589805|Device|Extracorporeal shock wave therapy|In addition to wrist splint, ESWT treatment (1.5 bar, 5Hz, 1000 beats) will be applied to the patients with Elmed Vibrolith Ortho brand ESWT device, which we routinely use in the treatment of carpal tunnel syndrome, for 3 weeks, once a week.
45461468|NCT05555940|Device|Transcranial magnetic stimulation|The stimulation sites of the true TMS group were mPFC-amygdala functional junction and SSRIs/SNRIs treatment, while the sham TMS group was treated with reversed magnetic head sham stimulation and SSRIs/SNRIs treatment.
45461469|NCT01167283|Device|Electrostimulation|Electrostimulation: 35 Hz, 0.4 ms, 1 h; 5 times/week
45461470|NCT01167283|Device|Sham stimulation|Sham stimulation: 1 h; 5 times/week
45461471|NCT03388164|Drug|Escitalopram + RT2CK17|Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
45461472|NCT03388164|Drug|Escitalopram + Placebo|Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
45461473|NCT03871699|Drug|Ferric carboxymaltose|Administration of Ferric Carboxymaltose intravenously, one dose only.
45679189|NCT05892445|Behavioral|Graphic Warning Labels|Based on a thorough review of the literature on e-cigarette risks and adverse effects, a graphic designer will be contracted to create ten experimental aversive health warnings related to e-cigarettes. These warnings will be exported as high-quality images and shown to participants in the intervention group prior to questions that obtain data on the primary endpoint.
45679190|NCT05892393|Drug|Zirconium Zr 89-DFO-YS5|Given IV
46096652|NCT05589805|Device|Laser therapy|In addition to the wrist splint, the patients will be treated with the BTL-4110 Laser Topline model low-intensity laser device, which we routinely use in the treatment of carpal tunnel syndrome in our hospital, 5 days a week for 15 sessions of laser treatment.
46096653|NCT05589805|Other|Control group|Patients will only be given a wrist splint to keep the wrist in neutral position.
46096654|NCT02745275|Behavioral|Peer-led Health Education|Peer-led health education
46096655|NCT02747537|Drug|Sorafenib|
46096656|NCT02747537|Drug|Irinotecan|
46096657|NCT00989365|Other|Aerobic training|Treadmill training
46009888|NCT04538118|Behavioral|Pain Intensity|"Pain intensity was evaluated with Numeric Pain Rating Scale. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
46096658|NCT04216745|Diagnostic Test|bile culture|Bile samples will be collected for microbial cultures and antimicrobial susceptibility testing using COMPACT-15 automated system (Bio Merieux, Marcy I'Etoile, France) for bacteria and saboroud's agar for fungal culture.
45461474|NCT01268761|Drug|GnRH antagonist (Cetrorelix)|•GnRH antagonist (Cetrorelix 0.25) during 7 days beginning administration the second day of oocyte retrieval
45461475|NCT01268761|Drug|Placebo (saline solution)|• Placebo (saline solution) 1 ampoule every 24 hours during 7 days beginning administration the second day of oocyte retrieval
45461476|NCT03714906|Procedure|Stellate ganglion block|Stellate ganglion block will consist of an injection of 0.25% bupivacaine placed under ultrasound guidance by a trained anesthesiologist in the pre-operative holding area prior to surgery.
45461477|NCT01268839|Drug|TMC278|25mg tablet once daily for 28 days
45461478|NCT01268839|Drug|TMC278|25mg tablet once daily for 14 days
45461479|NCT01268839|Drug|Efavirenz|600mg tablet once daily for 14 days
45461480|NCT03403374|Drug|evolocumab|Administered by SC injection via autoinjector (AI)/pen
46096659|NCT00912366|Procedure|Lobectomy|Assessment of VATS versus open surgery.
45461481|NCT01165567|Drug|sarpogrelate|sarpogrelate, 300mg/day,duration: 4 weeks
45461482|NCT01164163|Drug|ruxolitinib phosphate|
45461483|NCT01164163|Other|laboratory biomarker analysis|
45461484|NCT01164163|Other|pharmacological study|
45461485|NCT03387462|Drug|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open label daily emtricitabine/tenofovir disoproxil oral tablet
45461486|NCT03387462|Other|DOT Diary mobile app|DOT Diary mobile application for tracking medication adherence and sexual activities.
45461487|NCT03756883|Drug|Fluticasone Propionate and Salmeterol Inhalation Powder|100/50 mcg per actuation
46009889|NCT04545099|Drug|Sugammadex|Administration of Sugammadex for muscle relaxation reversal
46096660|NCT02747381|Dietary Supplement|Alfacalcidol|1-alpha hydroxy cholecalciferol 1 mcg
46096661|NCT00673218|Drug|Placebo|Placebo, Q2 or 4 weeks depending on Ige level and weight as appropriate for active treatment.
46096662|NCT00673218|Drug|Xolair|150 to 375 mg is administered SC every 2 or 4 weeks
46096663|NCT02747225|Device|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue.
46096664|NCT00673296|Drug|Intravitreal Bevacizumab|Intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
46096665|NCT04216355|Drug|Azacitidine|Low-dose AZA
45461488|NCT03756883|Drug|Fluticasone Propionate and Salmeterol Inhalation Powder|100/50 mcg per actuation
45461489|NCT03756883|Drug|Placebo Inhalation Powder|No active content
45461490|NCT01280773|Device|NAVA|Neurally adjusted ventilatory assist (NAVA) was delivered by a SVi ventilator. NAVA utilizes EAdi, a reflection of the neural respiratory output to diaphragm, as its primary source to trigger and cycle-off assist in synchrony with neural inspiratory efforts.
45461491|NCT03756571|Other|Ankle Foot Orthoses-Footwear Combination|This is a solid AFO with angle of ankle in AFO and shoe modifications per algorithm based on physical exam and visual observation of lower extremity kinematics through stance phase of walking.
45461492|NCT03756571|Other|Traditional Solid Ankle AFO (TSAFO)|This is a solid ankle AFO with angle of ankle in AFO at 90 degrees or neutral dorsiflexion/plantarflexion.
45679191|NCT05892393|Procedure|Positron Emission Tomography / Computed Tomography (PET/CT)|Positron emission tomography-computed tomography is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography scanner and an x-ray computed tomography scanner, to acquire sequential images from both devices in the same session, which are combined into a single superposed image
46009890|NCT04545099|Drug|Neostigmine|Administration of Neostigmine for muscle relaxation reversal
46096666|NCT04216355|Drug|CAG Protocol|Short term CAG derived regimen
46096667|NCT02744963|Other|Free and convenient medicine access|
46009891|NCT02882269|Drug|Postoperative chemotherapy|Locally advanced colon cancer patients will receive surgery first, followed by 6 months of chemotherapy. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
46009892|NCT02882269|Drug|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy will be given to locally advanced colon cancer patients for 3-4 cycles. Surgery will be performed between 3 to 4 weeks subsequent to the last cycle of chemotherapy. After surgery, additional chemotherapy will be given. Preoperative and postoperative chemotherapy will be given for a total of 6 months. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
46096668|NCT00683124|Drug|Losartan and nebivolol|"Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations.~Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations"
46009893|NCT05100082|Drug|Cabozantinib|Cabozantinib tablets
46009894|NCT04545294|Device|Theta tACS|See detail in arm/group descriptions regarding the intervention.
46009895|NCT04578899|Device|Transvertebral magnetic stimulation|Continuous theta-burst with a frequency of 5 Hz, lasting 20 minutes 3 times a week for 5 weeks, the total number of procedures is 15
46009896|NCT02882503|Device|endoscopic ultrasound - radiofrequency ablation (EUS-RFA)|Radiofrequency ablation will be applied with an innovative monopolar radiofrequency probe (1.2 mm Habib EUS-RFA catheter) placed through a 19 or 22 gauge fine needle aspiration (FNA) needle in patients with a tumor in the head of the pancreas.
46009897|NCT04578704|Other|Vacuum formed retainer, fixed bonded retainer, vacuum formed and fixed bonded retainer|"Patients will be instructed to wear the removable vacuum form retainer for 8 to 10 hours per day and only removed the retainers during tooth brushing. (Thickett 2010), (Gill 2007).~The vacuum formed retainer will be constructed using thermoplastic material that will be purchased from manufacturer at 1.0mm thickness.~Meanwhile, bonded retainer will be done using Ormco ® response deadsoft retainer wire size 0.190 round, made in USA by ORMCO Corporation, the fixed bonded wire will be extended distal to the extraction spaces that were previously closed by fixed appliances on both the upper and lower arches. The bonded retainer will be wearing by patients for 24 hours.~Double regime retainer that will be comprised of vacuum formed and bonded retainer will be constructed using the same properties as vacuum formed retainer and bonded retainer. A standard oral and written instruction will be given to patients regarding retainer's uses. (Shawesh M et.al, 2009)."
46009898|NCT01122862|Drug|0.12% chlorhexidine mouthrinse|commercially available 0.12% chlorhexidine mouthrinse
46009899|NCT01122862|Other|Cosmetic mouthrinse|Commerically available cosmetic mouthrinse
46009900|NCT01122862|Other|Sterile water|Sterile water
46009901|NCT04538274|Behavioral|peer-driven intervention|Trained patient researchers will conduct 3 motivational sessions, according to the principle of motivational enhancement and cognitive-behavioral therapies, by videoconference meetings of 45 to 60 minutes duration with 5 to 8 patients within 6 months after each patient's inclusion.
46009902|NCT04578977|Behavioral|Functional assessment of surgical treatment of terrible triade injury of the elbow|Functional assessment of surgical treatment of terrible triade injury of the elbow
46009903|NCT04537767|Drug|Esmolol|The protocol required a titrated esmolol infusion commenced at 25 mg/ h, with an upper dose limit of 2000 mg/h, to maintain the HR between 75 and 90 bpm in ES group. The control group were treated with placebo.
46096669|NCT00683124|Drug|Losartan|Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
46096670|NCT00683124|Drug|Nebivolol|Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
46096671|NCT02744807|Other|Chronic endometritis|with or without Chronic endometritis
46096672|NCT04141566|Procedure|Perineal pseudocontinent colostomy|"The procedure is performed in 2stages: as a usual APR starting by a laparoscopic approach esnsuring a complete mesorectal excision,then a perineal approach ensuring an extended excision of the entire internal and external sphincter complex, allowing the excision of the specimen.~8to10cm of tof the colon is resected and harvested as a free graft, stripped of its meso and epiploics , then from its mucosa and placed in an antibiotic solution for 10min. This graft is wrapped snugly around the end of the colon 2-3 cm from its distal end for 1 and a half round. Absorbable 3.0 Sutures are taken to hold it in place. The end of the colon is brought out as a stoma in the perineum.~Colonic irrigations are started from the third day according to the protocol previously reported. Patients and one of their family members are daily educated and assisted while performing colonic irrigations by specialized nurses."
46096673|NCT04141566|Procedure|Permanent left iliac colostomy|After a usual laparoscopic APR, the perineal wound is closed and a permanent left iliac colostomy is performed
46096674|NCT02744729|Drug|99mTc-3PRGD2|For patients in suspicion of esophagus cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
46009904|NCT04537767|Drug|Placebo|Placebo
46009905|NCT01122394|Behavioral|TI|Tailored intervention based on the transtheoretical model
46009906|NCT01122394|Behavioral|AP|Attention placebo
45461493|NCT01164319|Procedure|Circumferential PVI and subcutaneous cardiac monitor implantation|"The left atrium (LA) and PVs were explored through a transeptal approach. Real-time 3D LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in one lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. The endpoint of ablation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.~The ICM (Reveal XT, Medtronic Inc) was implanted the day of the ablation procedure or 1 week before.The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check."
46009907|NCT01121926|Drug|Trazodone HCl|"Dosage form:~Extended-release caplets containing 300 mg trazodone HCl and extended-release caplets containing 150 mg trazodone HCl (the 150 mg dosage form was only used for the up and down titration, and was not evaluated in the study).~Dose regimen:~75 mg trazodone HCl (½ x 150 mg extended-release caplet) on Days 1 and 11, 150 mg trazodone HCl (one extended-release caplet) on Days 2 and 10, 300 mg trazodone HCl (one extended-release caplet) on Days 3 to 9, each at 23:30 after a fast of at least 4 hours."
46009908|NCT01121926|Drug|Trazodone HCl|"Dosage form:~Immediate-release tablet containing 100 mg trazodone HCl~Dose regimen:~100 mg trazodone HCl (one immediate-release tablet) once (at 23:30) on Days 1 and 11, 100 mg trazodone HCl (one immediate-release tablet) twice (at 23:30 and 11:30) on Days 2 and 10, 100 mg trazodone HCl (one immediate-release tablet) three times daily (at 23:30, 07:30 and 15:30) on Days 3 to 9. Evening doses were administered after a fast of at least 4 hours."
46009909|NCT04578626|Device|dry needling|The use of filiform needles to stimulate muscles and connective tissues. The needle is inserted in a direction perpendicular to the skin, a local twitch response is looked for and, once found, the needle is kept in the muscle without moving for 10 seconds. No substances are injected.
46009910|NCT04544826|Drug|JNJ-77474462|JNJ-77474462 will be administered as SC injection.
46096675|NCT00683202|Drug|Acetylsalicylic acid|Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
46096676|NCT00683202|Drug|Placebo|Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
46009911|NCT04544826|Drug|Placebo|Matching placebo to JNJ-77474462 will be administered as SC injection.
46009912|NCT02216019|Other|Whole blood|preoparatoire whole blood and postoperative whole blood
46096677|NCT02744885|Dietary Supplement|Crave Crush|Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
46009913|NCT04578587|Device|MicroFET 2|Lumbar Flexor and Extensor Strength Measurement
46009914|NCT00577421|Drug|risedronate|5 mg tablet of risedronate once a day for 2 years
46009915|NCT04537611|Diagnostic Test|dHb contrast and gadolinium contrast imaging|see arm description
46009916|NCT04537494|Dietary Supplement|L. reuteri|Probiotic
46009917|NCT04545255|Device|Shockwave treatment|ED 1000 shockwave generator
46009918|NCT00577616|Procedure|Endovascular repair|Endovascular repair of the asymptomatic aneurysms of the abdominal aorta
46009919|NCT04537572|Diagnostic Test|comparison of sample collection methods|Samples will be collected via finger-stick, saliva collection, and traditional phlebotomy to determine effects on COVID-19 antibody test results.
46009920|NCT00577694|Drug|clofarabine|Intravenous, 20mg/m2, Days 1, 2, 3, 4 and 5; 2 cycles
46009921|NCT00577694|Drug|gemtuzumab ozogamicin|Intravenous, 3mg/m2, Day 1, one cycle
46009922|NCT04537533|Drug|Tranexamic acid|Intraoperative infusion
46009923|NCT04537533|Other|Normal saline|intravenous infusion
46009924|NCT02214927|Drug|BI 11634 tablet|
46009925|NCT02214927|Drug|BI 11634 drinking solution|
46096678|NCT02744885|Dietary Supplement|Placebo Comparator: Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
46009926|NCT04544553|Other|SMS reminder|The group receives reminder for the follow-up at 1 week and 2 days prior to their scheduled appointments.
46009927|NCT04544553|Other|No SMS reminder|The group did not receives any SMS regarding scheduled appoinments.
45461494|NCT01586611|Drug|5FU, leucovorin, oxaliplatin|Oxaliplatin 100 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1 5-FUl 400 mg/m2 IV day 1 5-FU 2400 mg/m2 IV continuous infusion over 46 hours starting day 1
45461495|NCT01586611|Drug|Gemcitabine|1000 mg/m2 IV weekly for 3 weeks then one week off
45461496|NCT03386448|Drug|Scopolamine and naltrexone|participants will receive scopolamine and naltrexone in buccal drops
45461497|NCT03386448|Drug|placebo arm|participants will receive placebo medications
46096679|NCT00679536|Drug|Busulfan|Patient will receive a Test Dose of Busulfan on either Day -10 or Day -9. Patient will receive their Regimen Dose of Busulfan on Day -5 to Day -2. The regimen dose of Busulfan will be based off of the findings from their Test Dose.
45461498|NCT01280851|Procedure|Magnetic Resonance Imaging|1 hour of MRI exam will be performed in addition to the standard of care procedures, using low dose of gadolinium-based contrast (not investigational drug).
45461499|NCT01280929|Procedure|Panretinal Photocoagulation (PRP)|
45461500|NCT01280929|Drug|Intravitreous injection of ranibizumab|
45461501|NCT03873961|Device|High-intensity laser therapy|tissue photobiostimulation for pain reduction and healing enhancement.
45461502|NCT03873961|Device|Low-level Laser therapy|tissue photobiostimulation for pain reduction and healing enhancement.
45461503|NCT02526823|Drug|R-CHOP/CHOPE or ABVD chemotherapy regimen|"R-CHOP:~Rituximab：375mg/m2，ivgtt，D0； Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CHOPE:~Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~ABVD:~Epirubicin：35 mg/m2，ivgtt，D1、15； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；"
45461504|NCT02526823|Drug|R-CDOP/CDOPE or DBVD chemotherapy regimen|"R-CDOP:~Rituximab：375mg/m2，ivgtt，D0； PLD 30-40 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CDOPE:~PLD 30-40 mg/m2，ivgtt，D1； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~DBVD:~PLD 15-20 mg/m2，ivgtt，D1； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；"
45461505|NCT05397535|Behavioral|Baduanjin|"Participants in these groups will receive health education on hypertension and attend a 4-hour class to learn Baduanjin before receiving the interventions after the randomization. Baduanjin exercise protocol is based on the Fitness Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Each Badaunjin exercise session will last at least 30 minutes and be conducted at least 5 days per week for 52 weeks. These participants will be required to practice Baduanjin regularly, and the researchers will monitor their adherence to practice and provide reminders if needed."
45461506|NCT05397535|Behavioral|Brisk walking|Participants in this group will receive health education on hypertension and practice brisk walking on their own for at least 30 minutes, at least 5 days per week for 52 weeks. These participants will be required to do brisk walking regularly, and the researcher will monitor their adherence to practice and provide reminders if needed.
46009928|NCT02216058|Device|NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System|
46009929|NCT00577850|Drug|risedronate|0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks followed by another 14C-labeled risedronate followed weekly by 35 mg risedronate for 3 weeks
45461507|NCT01586767|Radiation|Proton radiation therapy|Daily proton radiation therapy
45461508|NCT01586767|Radiation|Intensity-modulated radiotherapy|Daily intensity-modulated radiotherapy
45461509|NCT01586923|Biological|RBC transfusion|RBC transfusion of different storage age
46009930|NCT00577850|Drug|alendronate|0.45 mg 14C-labeled alendronate, followed 7 days later with oral 705 mg alendronate once a week for 52 weeks followed by another 14C-labeled alendronate followed weekly by 70 mg alendronate for 3 weeks
46009931|NCT04544631|Other|Virtual reality game as adjunctive pain management tool|A smart phone virtual reality-based pain alleviation tool (VR-PAT).
46009932|NCT04544514|Diagnostic Test|lung ultrasound|LUS was performed within first 20 to 30 minutes and repeated at 1, 2, 4 and 6 hours.
46009933|NCT00577967|Drug|Gabapentin|
46096680|NCT00679536|Drug|Fludarabine|Patient will receive Fludarabine from Day -6 to Day -2. The dose of Fludarabine will be 30 mg/m^2/day.
46096681|NCT00679536|Drug|Thymoglobulin|The patient will also receive Thymoglobulin (rabbitATG) on Day -4 to Day -2. Each dose of rabbitATG will be 1.5 mg/kg/day.
46096682|NCT00679536|Radiation|Total Body Irradiation|On Day -1 the patient will receive a total of 400 cGy of Total Body Irradiation.
46096683|NCT00537979|Drug|Paricalcitol injection|Most recent iPTH level in pg/mL divided by 100 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly
46009934|NCT04537338|Genetic|1. Characterize the immune response after infection with SARS-CoV-2|1. Characterize the immune response after infection with SARS-CoV-2 in terms of type of antibodies (IgM, IgG, IgA), seroconversion, maximum antibody levels, , and response to different viral proteins/antigens
46009935|NCT00578006|Behavioral|Questioners|The investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
46009936|NCT00578006|Behavioral|STAR website|You can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy.
46096684|NCT00537979|Drug|Paricalcitol capsules|Most recent iPTH level in pg/mL divided by 80 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly
46009937|NCT04537455|Diagnostic Test|Ultra-high frequency electrocardiography|Patients will have an ultra-high frequency electrocardiography performed.
46096685|NCT00679614|Drug|tramacet, naloxone|Group A: oral tramacet 2 tablets preoperatively, then 2 tablets every 6 hours for 5 days then 1-2 tablets of tramacet prn to a maximum of 8 tablets per day. A naloxone infusion will started preop at 0.25ug/kg/hr and will continue during patient's stay in hospital (an equivalent of 400ug over 24 hours in a 70 kg man). Infusion discontinued 1 hour before patient discharge. All the patients in groups A and B will be provided Morphine PCA for the duration of their hospital stay. Use of morphine PCA will be noted.Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice.
45461510|NCT03875677|Device|HD-tDCS group|5 sintered Ag/AgCl ring electrodes will be used at a radius of ~5cm. The electrodes will be placed inside plastic electrode holders which will be filled with gel to have better contact with the scalp.
45461511|NCT03875677|Device|Conventional tDCS group|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
45461512|NCT03875677|Device|Sham HD-tDCS group|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
45461513|NCT01587391|Drug|Placebo to BI 163538 XX|1 single dose per subject as oral solution
45461514|NCT01587391|Drug|BI 163538 XX|1 single dose per subject as oral solution
45461515|NCT01268917|Drug|aspirin|aspirin 100mg daily until the surgery day
45461516|NCT01268917|Drug|aspirin|aspirin is stopped 5-7 days before operation
45461517|NCT01164553|Biological|Trivalent Inactivated Influenza Vaccine|Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) (Fluzone®) administered intramuscularly (IM) in the thigh with a 25 gauge 1 inch needle. Naive cohort (enrolled over two influenza seasons (2010-11 and 2011-12)) will receive vaccine in two IM doses 28-42 days apart, Fully Primed cohort (enrolled in one influenza season (2010-11)) will receive vaccine in one IM dose.
45461518|NCT01281163|Drug|Akt Inhibitor MK2206|Given PO
46096686|NCT00679614|Drug|tramacet|Group B: oral tramacet 2 tablets preop,then 2 tablets every 6 hours for five days(or until discharge. Patient VAS after discontinuation of morphine PCA may dictate addition of oral narcotic oxycodone after discharge). Group also receives saline infusion at 4-6mls/hour during hospital stay.All patients in groups A and B will have Morphine PCA during hospital stay. Use of morphine PCA will be noted. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraopby the surgeon as per our standard practice.
46096687|NCT00679614|Drug|Acetaminophen|Group C will receive oral Acetaminophen tablets 1 gm preoperatively and subsequently 6 hourly plus an infusion of saline (placebo) at a rate of 4-6mls / hour for the duration of their stay. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice. The Visual Analogue Scale, the Ramsay Sedation Score and the Mini Mental State Exam will be used to assess the patients for pain, sedation and confusion every 6 hours while in hospital.
46096688|NCT02744417|Behavioral|Smoking cessation counseling|Multidisciplinary smoking cessation counseling, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures delivered by physicians, psychologist-assisted cognitive behavioural therapy, and counseling provided by dentists during the active phase of the treatment and maintenance session, using motivational interviewing techniques
46096689|NCT02744417|Procedure|Non-surgical periodontal therapy|Full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
46009938|NCT00578045|Procedure|Transfusion|Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
46009939|NCT04544397|Procedure|Catheter Ablation for AF|Pulmonary vein isolation (PVI) is the mainstay goal of atrial fibrillation (AF) ablation procedures, especially in paroxysmal AF (PAF), and is recommended during all AF ablation procedures. PVI can be obtained with different techniques, using 3D-mapping systems guiding point-by-point radiofrequency (RF) ablation procedures or balloon-based ablation systems (cryo- or laser balloon), introduced to simplify catheter ablation for AF. In particular, the 2nd generation of visually guided laser balloon ablation system (LB2) makes use of laser energy to achieve PVI, leading to better PV occlusion and isolation compared to the 1st generation.
46009940|NCT04537221|Biological|Blood transfusion|Transfusion of red blood cells peri-operatively
45461519|NCT01281163|Other|Laboratory Biomarker Analysis|Correlative studies
45461520|NCT01281163|Drug|Lapatinib Ditosylate|Given PO
45461521|NCT01281163|Other|Pharmacogenomic Study|Correlative studies
46009941|NCT00578162|Behavioral|we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENER|A cancer care facility or 'agency' is the study's unit of analysis. Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory
45461522|NCT01281163|Other|Pharmacological Study|Correlative studies
45461523|NCT02951988|Drug|Rapastinel|Rapastinel pre-filled syringes for IV injections.
45461524|NCT02951988|Drug|Placebo-matching Rapastinel|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
45461525|NCT01167439|Procedure|Upper esophageal sphincter myotomy|Upper esophageal sphincter release operation to allow better swallowing. The intervention is done under GA and by extra-mucosal approach.
45461526|NCT01587157|Procedure|capnography|
45461527|NCT01268995|Drug|Cyclosporine A|"Patients randomized into arm A will be switched from Tacrolimus to Cyclosporine A. Conversion will be done by a stop and go protocol. Patients will take their last dose Tacrolimus in the morning of the day of conversion and will start taking Cyclosporine A in the evening of the same day at a dose of 3mg/kg/d. The first measurement of Cyclosporine A trough levels will be performed 3 days after conversion and the dose will then be adjusted if necessary. Furthermore, treatment with NPH insulin once daily in the morning will be initiated."
45461528|NCT01268995|Drug|Tacrolimus|Patients in arm B will remain on their immunosuppressive therapy with Tacrolimus. Furthermore, treatment with NPH insulin once daily in the morning will be initiated.
45461529|NCT00009737|Drug|5-Fluorouracil|425mg/m2 iv daily from day 1 to day 5 every 28 days.
45461530|NCT00009737|Drug|Leucovorin|20mg/m2 iv daily from day 1 to day 5 every 28 days.
45461531|NCT00009737|Drug|Capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 every 21 days.
45461532|NCT01164631|Device|Bioajusta X Orthodontic treatment|Oral Appliance that promotes semi-rapid maxillary expansion, while corrects tongue positioning and jaws relationship
45461533|NCT03711240|Drug|bevacizumab|5mg/kg iv day 1 every 2 weeks
46009942|NCT00578201|Drug|radiochemotherapy,combination Cetuximab-FOLFOX|objective response rate at 12 weeks with radiochemotherapy then combination Cetuximab-FOLFOX
45461534|NCT03711240|Drug|Oxaliplatin|85mg/m2 2-hour iv infusion, day 1 every 2 weeks
45461535|NCT03711240|Drug|Irinotecan|150mg/m2 1.5-hour iv infusion, day 1 every 2 weeks
45461536|NCT03711240|Drug|Leucovorin|200mg/m2 2-hour iv infusion, day 1 every 2 weeks
45461537|NCT03711240|Drug|5-FU|2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
45461538|NCT01271881|Other|PTA alone without use of the GORE VIABAHN|PTA alone with no stent used
46009943|NCT04537104|Device|Coala Heart Monitor|ECG monitoring
45461539|NCT01271881|Device|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface|Covered stent produced by GORE VIABAHN
45461540|NCT05459844|Drug|Lutetium[177Lu] Oxodotreotide Injection|Four administrations of 7.4 GBq (200 mCi) Lutetium[177Lu] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
45461541|NCT05459844|Drug|Octreotide LAR|60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.
45461542|NCT02530853|Other|Laser acupuncture|Laser acupuncture
45461543|NCT03874975|Drug|oral vitamin D|vitamin D and UVB versus UVB alone in psoriatic patients and evaluate patients by PASI score before and after treatment and measure serum vitamin D before and after treatment
45461544|NCT01164709|Drug|bortezomib|Bortezomib i.v., day 8, 11, 15, 18; 1.3 mg/m2
45461545|NCT01164709|Drug|nelfinavir mesylate|p.o., days 1 to 21; dose level: (625), 1250, 1875, or 2500 mg, 2x/d
45461546|NCT01583465|Device|Aquamantys|Primary THA via the ASI approach will be performed using the Aquamantys Malleable Bipolar Sealer. The Aquamantys is a bipolar device that combines radio-frequency energy and saline to gently reach targeted tissue and provide a biomechanical seal. The saline acts as a conduit to allow the energy to penetrate the tissue from 1 to 2 mm where the collagen is transformed thus providing the seal. The saline also helps cool the tissue which allows for gentle handling of tissue, eliminating the black char that is a port for infection. The surgeon uses the Aquamantys to assist in tissue dissection, cauterize vessels, and to pre-treat fat pad in front of capsule prior to excision, to treat the entire anterior hip capsule prior to excision, treat oozing bone surfaces not covered by an implant.
46009944|NCT00578357|Behavioral|personalized feedback intervention|personalized feedback will be sent to participants after they complete and return self-help materials/questionnaires
46009945|NCT04544319|Drug|Zemiglo 50mg and Forxiga 10mg|Each component of Gemigliptin 50mg QD and Dapagliflozin 10mg QD
46009946|NCT04544319|Drug|Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg|Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg QD
46009947|NCT00578396|Dietary Supplement|grapes|1 pound of seedless red grapes
46009948|NCT00578396|Dietary Supplement|grapes|2/3 lb/day fresh red grapes
46096690|NCT02744417|Drug|Nicotine replacement therapy|Nicotine replacement therapy: chewing gum (Nicorette chewing gum 2-4mg) and patches (Nicorette patches 15-25mg)
46096691|NCT02744417|Drug|bupropion hydrochloride|bupropion hydrochloride 150mg
46096692|NCT02744417|Drug|Varenicline|Varenicline 0,5mg
46096693|NCT02627664|Other|observational study|natural history of non dopaminergic signs
46096694|NCT02629146|Drug|Midazolam|
46009949|NCT00578396|Dietary Supplement|grapes|1/3 lb/day fresh red grapes
46009950|NCT04544085|Behavioral|noise management|The intervention mainly includes the following three parts: control of noise source, control of noise transmission and personal protection of noise receiver.(1) control of noise source:equipment maintenance,alarm management,set quiet time,etc.;(2)control of noise transmission:improvement of architectural design;(3)personal protection of noise receiver:providing patients with earmuffs or earplugs.
46009951|NCT04557410|Drug|PolyMVA|"One-half teaspoon of PolyMVA contains the following:~Daily Value Thiamin (B-1) 23mg 1,533 Riboflavin (B-2) 0.45mg 26 Vitamin B-12 460mcg 7,666 Proprietary Blend 32mg - contains the following ingredients (no FDA value has been established on any of the following): Palladium, Alpha Lipoic Acid, Molybdenum, Rhodium, Ruthenium, Formyl Methionine, N-acetyl Cysteine.~For each ml of Poly-MVA, the exact dosages are as follows:~Palladium: 3.97mg Molybdenum: 0.044mg Ruthenium: 0.0014mg Rhodium: 0.014mg Lipoic Acid: 7.68mg Thiamine (B1): 9.26mg Riboflavin (B2): 0.174mg B12: 0.185mg Formyl Methionine: 0.026mg N-Acetyl cysteine: 0.185mg Vitamin A acetate 100 IU~Other Ingredients: Distilled water, purified water, thiamine hydrochloride, Vitamin B12 as cyanocobalamin."
46009952|NCT04537182|Procedure|Lung volume reduction surgery|Lung volume reduction by surgery
46009953|NCT04537182|Procedure|Bronchoscopic lung volume reduction with valves|Lung volume reduction with endobronchial valves.
46009954|NCT04578470|Drug|Vitamin D|Daily 2000 IU cholecalciferol(two tablets) for 13 weeks,and daily 1000 IUcholecalciferol(1 tablet) foranother 13 weeks.
46009955|NCT04578470|Drug|Placebo|two tablets daily for 13weeks then 1 tablet daily for13 weeks
46009956|NCT00578435|Procedure|Busulfan, Cyclophosphamide, BMD|Busulfan 0.8 or 1 mg/Kg/day Days 8-6 Cyclophosphamide 50 mg/Kg/day Days 2-5 BMT Day 0
46009957|NCT04537065|Other|cycloplegic refraction|"Cycloplegic refraction and the average corneal radius of curvature were performed using a handheld auto kerato-refractometer (Righton Retinomax K-plus2). Refraction was confirmed by retinoscopy and refractive errors were calculated as spherical equivalent and astigmatism in cylinder.~The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek)."
46009958|NCT04578821|Other|Educational intervention|Educational intervention
46009959|NCT04543929|Behavioral|exercise|partially supervised and home-based exercise activity
46009960|NCT04537260|Behavioral|Educational Video|Those in the intervention arm were asked to watch the 3-minute educational video prior to the knowledge questionnaire and meeting their provider (midwife or obstetrician). The video shown to these participants is linked here: https://youtu.be/Pc9tcIV4Dm8.
46009961|NCT04557332|Behavioral|On the Dot Mobile app|On the Dot is a mobile app to support HIV medication adherence. The mobile app is linked to a clinician portal through which participants can receive adherence support.
46009962|NCT04544163|Drug|Magnesium sulfate- Fentanyl|drug administration before intubation
46096695|NCT02629146|Drug|Fentanyl|
46096696|NCT02629146|Drug|Isotonic saline|
46096697|NCT02744339|Drug|Riociguat|Adempas up-titrated to max. 1.5mg TID
46096698|NCT02744339|Drug|Placebo|Placebo sham-titrated TID
46009963|NCT04544163|Drug|Fentanyl 4Mcg/kg|drug administration with induction of anesthesia
46009964|NCT04544163|Drug|Fentanyl 2Mcg/kg|drug administration with induction of anesthesia
46009965|NCT04544163|Drug|Lidocaine 1.5 mg/kg|drug administaration 90 sec before intubation
46009966|NCT04579016|Other|PAIGE2 lifestyle intervention|Education session during pregnancy. provision of fitness tracker, referral to commercial weight management organization, text and phone support
46096699|NCT05360563|Other|Home-based physical training|Patients allocated to this group will participate in a 16-week home-based physical training program, structured in three weekly sessions of aerobic and muscle strengthening exercises (which also have components that stimulate flexibility and balance). A third of the weekly physical training sessions will be supervised via telemedicine (with video call) by a clinical exercise specialist, but all patients will have illustrated exercise booklets and a full-time remote support service available for the remaining sessions (via text or voice messages).
46009967|NCT04579016|Other|Standard care|Care routinely provided to all pregnant women diagnosed with GDM
46009968|NCT04543851|Device|CARA - carbon fibre adjustable re-usable accessory for breast positioning|Breast positioning to alleviate infra-mammary fold and lateral breast sag
46009969|NCT00578591|Drug|Rituximab|"Rituximab 375 mg/m^2 is given weekly X 4. For patients with a partial response, an additional 4 doses will be permitted as needed (after 4 weeks from the last dose).~Diagnosis of grade II to IV aGVHD will be confirmed, whenever possible, by a biopsy taken from at least one of the following three sites: skin, gut, or liver."
46096700|NCT02747069|Device|NICU electronic stethoscope|Assessment of heart rate using the electronic stethoscope for up to 10 minutes compared to ECG and pulse oximetry devices used to monitor neonates whilst on NICU
46096701|NCT02747069|Device|Newborns <32 weeks and ECG|The three leads from the ECG device will be pre placed onto a plastic bag prior to delivery. The pre term infant (<32 weeks) placed into the bag at the time of delivery and heart rate will be assessed for up to 30 minutes
46096702|NCT00991159|Biological|RN316|Single, escalating doses of RN316 administered IV. Doses planned for testing = 0.3, 1.0, 3.0, 6.0, 12.0, and 18.0 mg/kg.
46096703|NCT00679770|Drug|AN2690, 2.5%|Once daily application for 90 days and 3 x weekly for 90 days
46096704|NCT00679770|Drug|AN2690, 5%|Once daily application for 90 days and 3 x weekly for 90 days
46096705|NCT00679770|Drug|AN2690, 7.5%|Once daily application for 90 days and 3 x weekly for 90 days
46096706|NCT00679770|Drug|Vehicle|Once daily application for 90 days and 3x weekly for 90 days
46096707|NCT05589493|Device|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis|A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by dental implants following the All-on-4 Concept arrangement.
46096708|NCT02744495|Drug|Betamethasone|Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
46096709|NCT02744495|Drug|Droperidol|Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
45461547|NCT01583465|Device|standard electrocautery (Bovie)|Primary total hip arthroplasty via an anterior supine intermuscular approach will be performed with the assistance of standard electrocautery. The electrocautery is used in tissue dissection and to cauterize bleeding vessels.
45461548|NCT03871387|Drug|Deep Group|"Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 0 & PTC= 1~2 (TOF = train-of-four. PTC = post-tetanic count)~TOF and PTC are assessed by acceleromyography (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme [MSD], Oss, the Netherlands) injection to reverse muscle relaxation.~Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF < 2"
46009970|NCT04536987|Device|HEXORR|The subject receives robotic assistance from the HEXORR robot during finger and thumb movements. Several different video games are used to provide feedback of performance and motivate the training. The assistance level is adjusted automatically in some games and manually in other games to enable a target success rate of 67% when playing the games.
46096710|NCT00679848|Device|RS2 (RESTORe Suturing System)|Suturing in stomach
46096711|NCT05589415|Device|High-definition Transcranial Direct Current Stimulation|"High-definition Transcranial Direct Current Stimulation (HD-tDCS) delivers current through five small electrodes (0.8 cm2) placed in an X-shaped configuration via a simple cap. This configuration leads to an 80% greater concentration or focusing of the electric field within the targeted region compared to conventional, non-focal Transcranial Direct Current Stimulation (tDCS). The participant will undergo 30 minutes of treatment at 2 milliamps."
45679192|NCT05892393|Procedure|Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI)|Positron emission tomography-magnetic resonance imaging is a hybrid imaging technology that incorporates magnetic resonance imaging soft tissue morphological imaging and positron emission tomography functional imaging.
45679193|NCT05892393|Other|Fludeoxyglucose F-18|Given IV
45679194|NCT05892367|Other|Transbrachial Access for Interventions|Adding a positioning splint in addition to compression bandage after intervention in order to guarantee immobilization of puncture site
45679195|NCT05892354|Dietary Supplement|Enteral immunonutrition|Enteral immunonutrition (Oral Impact®, Nestle), 250ml/ bottle, 2 bottles per day, from 5 days before radiotherapy to the end of radiotherapy.
45679196|NCT05892354|Dietary Supplement|Standard enteral nutrition|Isocaloric standard enteral nutrition formula (ENSURE®)， 250 mL per administration, 3 times per day. Preparation of the 250 mL dose involves adding 200 mL of potable water to a cup and slowly stirring in 52.7 g of ENSURE powder (approximately 6 scoops).
46096712|NCT05589415|Device|Conventional Transcranial Direct Current Stimulation|Surface electrodes will be placed in saline-soaked sponges (5 x 7 cm2) and applied to different regions of the scalp. The participant will undergo 30 minutes of treatment at 2 milliamps.
46096713|NCT02744027|Other|Dynamic Contrast Enhanced Magnetic Resonance Lymphangiography (DCMRL)|Following completion of the T2 lymphatic mapping, contrast agent administered will be calculated based on weight. Investigators will use dosage of 0.1cc/kg of contrast which will be injected by hand simultaneously into each lymphatic node (LN) at a rate of 0.5-1 cc per min. One minute after the injection, scanning will be initiated using high spatial and temporal resolution magnetic resonance angiography (syngo time-resolved angiography with stochastic trajectories [TWIST]) sequence. The sequence parameters will be adjusted with a time delay such that a complete volume will be acquired approximately every 20-60 seconds. This will be followed by additional scans with a high-resolution navigator gated 3-dimensional flash inversion recovery (IR) sequence. In all subjects the scan area covered the neck, chest, and abdomen as caudal as feasible.
46096714|NCT02744027|Other|Heavy Weighted T2 Imaging (T2W)|Magnetic Resonance imaging (MRI) will be performed and T2W MRI lymphatic mapping will be performed using a respiratory navigated and cardiac gated 3 dimensional turbo spin echo sequence with pre-set parameters. Scan time varies from 2-5 min depending upon the size of the subject.
45679197|NCT05892341|Device|AQUACEL® Ag+ Extra™|Wound treatment with AQUACEL® Ag+ Extra™ dressing
46096715|NCT02744027|Other|Lymph Node Access|"The procedure will be performed under sedation and anesthesia if participants are aged 16 or under. The procedure will be performed with local anesthesia for participants aged over 16 years old.~Using ultrasound guidance two inguinal lymph nodes (one each side) will be directly accessed with 25-gauge spinal needles attached to a short connector tubing. A shallow angle for puncture will be used to create a long subcutaneous tract to assist in stabilizing the needle. A small amount of an oil-based contrast or water soluble contrast will be injected under fluoroscopy guidance to confirm the correct position of the needles inside the lymph nodes. After stabilizing the needle, the subjects will be transferred into the MRI suite."
46096716|NCT02742155|Behavioral|Play2Sleep|Behavioral: Video self-modelling
46096717|NCT02742155|Behavioral|Comparison|Behavioral: Information only
45679198|NCT05892341|Device|Cutimed® Sorbact®|Wound treatment with Cutimed® Sorbact® dressing
46009971|NCT04536948|Other|Cooling Gel|Cooling gel (Nelsons Arnicare Arnica Cooling Gel) was applied to the lateral epicondyle region with sponge head 3 times a day. The cooling gel was applied to the painful area around the lateral epicondyle
46009972|NCT04536948|Other|Cold Pack|Cold pack was applied to the painful area for 15 minutes on a moist towel placed on the painful area around the lateral epicondyle.
45461549|NCT03871387|Drug|Control Group|"Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 1~2~TOF and PTC are assessed by acceleromyograph (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme [MSD], Oss, the Netherlands) injection to reverse muscle relaxation.~Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF < 2"
45461550|NCT03960671|Drug|Midazolam/diazepam/propofol|Therapeutic drug monitoring of anxiolytics
45461551|NCT01281553|Drug|Placebo|Suspension identical in appearance to cisapride q.i.d. for 8 weeks.
46096718|NCT05360407|Other|Using mobile information application about before and after surgery|"The mobile application had three sections: Information forum (I), Personal forum (notebook and reminder) (II) and Ask the Researcher (messaging) (III). The information forum (Figure 2) is a section that enables patients to access related articles, pictures, and videos. The personal forum is a section that allows patients to create their notes and use the necessary reminders. Ask the researcher section allows patients to communicate with the researcher via messages.~The participants could download the mobile application with the name Breast Cancer Surgery Information Guide from the Google Play Store and install it on their phones. Users who were authenticated by the researcher were able to access the content with an e-mail and password."
46009973|NCT04543890|Radiation|Hyperfractionated radiotherapy|Thoracic radiotherapy (45 Gy/30 fractions) for the Hyperfractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).
46009974|NCT04543890|Radiation|Hypofractionated radiotherapy|Thoracic radiotherapy (45 Gy/15 fractions) for the Hypofractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).
46009975|NCT04543890|Drug|Etoposide|Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
46009976|NCT04543890|Drug|Cisplatin|Cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
46009977|NCT04536870|Diagnostic Test|Echocardiography|Ultrasound of heart
46009978|NCT04536870|Diagnostic Test|ECG screening|Single lead ECG screening twice daily for two weeks
46009979|NCT04536870|Diagnostic Test|ECG Screening|12-lead ECG screening
46009980|NCT04536831|Drug|Vitamin D|Vitamin D will be given to group A selected by Lottery method
46009981|NCT04536831|Drug|Normal saline|Vitamin D will be given to group B slected by Lottery method
46009982|NCT02214966|Drug|Telmisartan/Ramipril, fixed dose combination tablet|
46096719|NCT00683280|Behavioral|contingency management|Prize-based contingency management, with the opportunity to earn prizes for expired carbon monoxide levels reading 6ppm or less and urinary cotinine levels reading 30ng/ml or less for 4 weeks.
46096720|NCT00683280|Other|Standard of Care|varenicline (smoking cessation medication) 0.5mg po daily Days 1-3, 0.5mg po twice daily Days 4-7, 1.0 mg po twice daily Days 8-84.
46096721|NCT00683280|Other|Standard of Care|Twice weekly brief counseling based on public health service guidelines for quitting smoking.
46096722|NCT05629403|Other|observe|no intervention
46096723|NCT05358223|Other|Music|A standard music determined by us for the 1st and 4th groups will be played during the process.
45461552|NCT01281553|Drug|Cisapride|0.2 mg/kg suspension q.i.d.for 8 weeks.
45461553|NCT03417102|Drug|fitusiran|solution for injection; by subcutaneous (SC) injection
46009983|NCT02214966|Other|high fat, high caloric meal|
46009984|NCT00578630|Other|buccal swabs and obtaining peripheral blood|will be the collection of normal cells and assessments of toxicity following chemotherapy at routine clinic visits.
46096724|NCT05358223|Device|TENS|TENS device will be connected to the 3rd and 5th groups during the process and the process will be done in this way.
46096725|NCT00683358|Biological|VEGFR1-A24-1084 (SYGVLLWEI)|HLA-A*2402-restricted VEGFR1-derived peptide (VEGFR1-A24-1084) 1mg emulsified with Montanide ISA51 will be subcutaneously injected 2 times weekly for total 16doses concurrently with conventional dose of gemcitabine 1,000mg/m2 BSA on 1st, 2nd, 3rd, 5th, 6th, 7th weeks for advanced/inoperable pancreatic cancer patients.
46096726|NCT02744105|Dietary Supplement|Spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
46096727|NCT00991237|Other|Pulsed Radiofrequency|Pulsed Radiofrequency
46096728|NCT00683436|Drug|Adipiplon|bilayer tablets 6 mg
45461554|NCT03417102|Drug|Bypassing agents|solution for injection; by intravenous (IV) injection
46009985|NCT04536558|Drug|olanzapine plus fosaprepitant-based triple regimen|olanzapine 5mg p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
46009986|NCT04536558|Drug|placebo plus fosaprepitant-based triple regimen|placebo p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
46009987|NCT00578708|Device|AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
46009988|NCT04543656|Behavioral|AI-Based Lifestyle Recommendations|The intervention provides participants with automated and personalized lifestyle recommendations involving a sophisticated analytics engine using advanced statistics and machine learning.
46009989|NCT04543656|Other|No Lifestyle Recommendations|The control group receives an identical activity tracker and BP monitor in order to objectively assess the effectiveness of the experimental group intervention.
46009990|NCT04557605|Other|Progressive cycling exercise test to exhaustion|Progressive step cycling exercise test to exhaustion
46096729|NCT00683436|Drug|Placebo|Placebo
45461555|NCT01164787|Drug|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
45461556|NCT01164787|Drug|Mavik|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
45461557|NCT01269151|Drug|Lucentis (Ranibizumab)|Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
45461558|NCT01165723|Biological|PF-04427429|Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
45461559|NCT01165723|Biological|PF-04427429|Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
45461560|NCT03417024|Device|Automated Breast Ultrasound|The ABUS system is designed to methodically scan a breast and capture multiple ultrasound images that can be rendered and reviewed in three dimensions.
45461561|NCT03417024|Device|Digital Breast Tomosynthesis|Digital Breast Tomosynthesis (DBT) systems are designed to collect 3-dimensional x-ray images of breast tissues.
45461562|NCT01269229|Drug|folfox|FOLFOX: Day1- Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, 5-FU 400mg/m2 IV bolus -> 2400mg/m2 46hrs continuous
46096730|NCT00683436|Drug|Ambien CR|Ambien CR 12.5 mg
46096731|NCT00683436|Drug|Adipiplon|bilayer tablets 9 mg
46009991|NCT04536753|Procedure|Induction of labour|Induction of labour using amniotomy, vaginal prostaglandin administration and syntocinon in combination as per protocol.
46096732|NCT00989443|Drug|Cidofovir gel|topical gel applied once a week for 3 weeks
46009992|NCT04557137|Drug|Somatostatin analog|120 mg ipstyl every 28 days
46009993|NCT04536675|Drug|Vilanterol and Umeclidinium Bromide|Perioperative inhaler therapy with VI/UME (Vilanterol 25mcg/Umeclidinium 62.5mcg) once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
46096733|NCT02743637|Drug|SDX-7320|SDX-7320 is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
46096734|NCT00683514|Drug|Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|"q 28 days :~50 mg/m2 oral vinorelbine d1, d8, d15~20 mg/m2/d cisplatin from d1 to d4"
46096735|NCT00683514|Drug|Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|"q 21 days :~60 mg/m2 oral vinorelbine d1,d8 for cycle 1 or 80 mg/m2 oral vinorelbine d1,d8 for cycle 2~80 mg/m2 cisplatin d1"
46096736|NCT05358145|Behavioral|Tinkering Activities|Tinkering activities are activities that comprise elements of science, art, and technology. Through a series of themes objectives, participants can involve interestingly, creatively, and flexibly in the activity when they fulfill the goal with the materials retrievable at the site. Participants will be trained as they involve in the elements hidden within the core of the training, such as problem exploration, active thinking and inference, trial and error, and problem-solving.
46096737|NCT05358145|Behavioral|Control Tinkering Activities|Controlled Tinkering Activities utilize the themes of Tinkering activities but eliminate the core of Tinkering training, hence implementing a new set of activities that emphasize participants strictly follow procedures to complete the similar objective of Tinkering activities. Each participant will end up with a similar piece of work as Tinkering Activities participants would without problem exploration, active thinking and inference, trial and error, and problem-solving.
46096738|NCT05358145|Behavioral|Board Games Activities|Board games are often constructed with concepts of different cognitive components, such as attention, working memory, planning, calculation; therefore serve as a commonly seen cognitive training, while more and more literature continues to support tabletop games being the medium of cognitive promotion.
46096739|NCT02743715|Device|Active tDCS (transcranial direct current stimulation)|An electrical current of 2mA is delivered to the cathode, positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks.
46096740|NCT02743715|Device|Sham tDCS|The cathode is positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in a 30-minute session, 5 days a week (Mondays through Fridays) for four consecutive weeks, without delivery of the electric current.
46096741|NCT00683670|Drug|cyclophosphamide|
45461563|NCT01269229|Radiation|short course Radiotherapy|After FOLFOX 4cycle, subject have short course RTx 5Gy at once this should be continuing for 5days so that subject should have 25Gy within 5days. Then, subjects have another 4 cycle of FOLFOX and evaluate cancer for resection.
45461564|NCT00028769|Drug|bicalutamide|
45461565|NCT00028769|Drug|estramustine|
45461566|NCT00028769|Drug|etoposide|
46009994|NCT04536675|Drug|Placebo|Perioperative inhaler therapy with placebo once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
46096742|NCT00683670|Biological|Mature dendritic cell vaccine|
46096743|NCT05629325|Drug|Buspirone Hydrochloride 10 MG|4 weeks of treatment with buspirone
45461567|NCT00028769|Drug|flutamide|
45461568|NCT00028769|Drug|goserelin|
45461569|NCT00028769|Drug|leuprolide|
45461570|NCT00028769|Drug|nilutamide|
45461571|NCT00028769|Drug|paclitaxel|
45461572|NCT01165801|Procedure|Cataract Surgery|Fifty-four patients with cataract and non-exudative age-related macular degeneration (AMD) were randomized into an early surgery group (ES=28) with immediate cataract surgery and a control group (CO=26) where surgery was performed after six months.
45461573|NCT01281787|Drug|Metoprolol|Metoprolol; 100 mg x 2 die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
46096744|NCT05629325|Drug|Placebo|4 weeks of treatment with placebo
46096745|NCT02743559|Device|Mechanical Stimulation using whole body vibration|All participants will undergo whole body vibration (WBV) by standing on the LivMD WBV platform on 5 consecutive mornings
46096746|NCT00989521|Drug|PUR003|PUR003 for inhalation
46096747|NCT00989521|Drug|Placebo|Normal saline for inhalation
45679199|NCT05892328|Other|Watermelon Flesh Dose 1|1 cup watermelon flesh, ~152g, 7 days/week over a 4-week period
45679200|NCT05892328|Other|Watermelon Flesh Dose 2|2 cups watermelon flesh, ~304 g, 7 days/week over a 4-week period
45679201|NCT05892328|Other|Control|304g italian ice, 0 g watermelon, 7 days/week over a 4-week period
45679202|NCT05892315|Procedure|Repeated subgingival instrumentation|Supragingival scaling will be performed at sites with plaque and subgingival scaling will be performed by the use of manual and ultrasonic instruments at pockets ≥ 4 mm with bleeding. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
45679203|NCT05892315|Procedure|Supragingival scaling|Supragingival scaling will be performed at sites with plaque. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
45679204|NCT05892289|Procedure|Robotic assisted proximal gastrectomy with double-flap technique|Patients in this group receive robotic assisted proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9，11p；D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9，11p and 11d).The double-flap technique is used for the digestive tract reconstruction.
46096748|NCT05589259|Procedure|Brachial Plexus Block plus Physiotherapy|"Participants will receive a single-shot axillary brachial plexus block. For the procedure, a 22g or larger peripheral intravenous cannula will be placed, and skin will be sterilized with chlorhexidine. Using aseptic technique, the anesthesiologist will anesthetize the skin and tract with 5cc of 1% lidocaine using a 25g 1.5 needle. After this, a 50mm or 100mm Pajunk needle will be guided under ultrasound with an in-plane technique to anesthetize the median, ulnar, radial, and musculocutaneous nerves. Identification of the axillary artery, vein and surrounding vessels will be done to ensure an intravascular injection is avoided. Once proper location is confirmed, the anesthesiologist will inject 1.5mg/kg (lean body weight) of 0.25% bupivacaine, in divided doses, after negative aspiration.~Participants in the EXP arm and the CON arm will complete the same physiotherapy program."
46096749|NCT05589259|Procedure|Physiotherapy Alone|Participants in the EXP arm and the CON arm will complete the same The physiotherapy program which will include manipulation under anesthesia (MUA) immediately following an initial visit (with or without block confirmation to break up adhesions, possibly overcoming microvascular dysfunction). After the MUA session, participants will take part in a specialized 6-week home exercise program (HEP). This 6-week program which will include graded motor imagery. During each session, the physiotherapist will work with the participants to increase ROM and limb function using manual therapy, stretching, and strengthening exercises specific to the affected joint(s)) and most importantly using GMI. At the end of each session, the physiotherapist will prescribe exercises to complete at home.
46096750|NCT00989599|Other|compress of Chamomilla recutita infusion|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy were treated with a compress of Chamomilla recutita infusion for 20 minutes three times per day
46096751|NCT00989599|Other|compress of lukewarm water|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy, in control group, were treated with a compress of lukewarm water for 20 minutes three times per day
46096752|NCT05629247|Diagnostic Test|Systematic screening of immune deficiency|Systematic screening of immune deficiency with blood tests
46096753|NCT02743325|Procedure|SVT ablation by ALARA protocol|Catheter ablation is a procedure that uses radiofrequency energy (similar to microwave heat) to destroy a small area of heart tissue that is causing arrhythmias. Destroying this tissue helps restore your heart's regular rhythm. The usage of CartoUnivuTM allows a seamless combination of a fluoro image and Carto® 3 System maps into a single view.
46096754|NCT02743325|Procedure|SVT ablation by conventional protocol|Catheter ablation is a procedure that uses radiofrequency energy (similar to microwave heat) to destroy a small area of heart tissue that is causing arrhythmias. Destroying this tissue helps restore your heart's regular rhythm. The convention Ablation procedure works without a 3D navigation System.
46009995|NCT04536363|Drug|Analogs, Prostaglandin E1|"Analog of PGE1:~Infusion starting dose: 0.05 -0.01 mcg per kilogram of weight per minute in infusion continues, maximum 7 days, until achieving the desired clinical response (increase in PaO2), at that time decrease the infusion rate to the lowest dose possible to keep answer. This can be accomplished by decreasing the dose from 0.1 to 0.05 to 0.025 to 0.01 mcg / kg / min.~If the response to 0.05 mcg / kg / min is inadequate, the dose can be increased to 0.4 mcg / kg / min, although in general high doses do not produce better effects. Maximum continuous infusion for up to 7 days"
46009996|NCT04536363|Drug|Standard therapeutic protocol|"Standard medical treatment is governed by current recommendations of national scientific societies and the Ministry of Health and Social Protection and may be modified throughout the course of the study according to the available evidence. In addition, the criteria of the treating physician are taken into account.~Among the alternatives proposed by the current clinical practice guidelines are:~Dexamethasone (4mg ampoule, intravenous) Dose: 6mg intravenous every day for a maximum of 10 days~Tocilizumab Dose: 8 mg / kg (maximum dose of 800 mg) IV, maximum 3 doses 8 to 12 hours apart~Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~Enoxaparin (40mg prefilled syringe) Dose: 40mg subcutaneously every 24 hours~Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe) Dose: 1mg / kg every 12 hours~Low molecular weight heparin (5000IU prefilled syringe) Dose: 5,000 IU subcutaneous every 12 hours"
46096755|NCT02629380|Biological|hyaluronic acid|A single injection of 3 ml hyaluronic acid to be performed under arthroscopic view at the end of meniscectomy
46096756|NCT02629380|Procedure|meniscectomy alone|The patients randomized in this group will receive arthroscopic meniscectomy alone
45461574|NCT01281787|Drug|Losartan|Losartan; 50 mg die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
46009997|NCT04556942|Diagnostic Test|Flow Mediated Dilation (FMD) measurement|FMD measurements will be performed by ultrasound using longitudinal images of the brachial artery using a high-frequency (10.0-MHz) ultrasound scanning probe (VividTM E9 with XDeclearTM; GE Healthcare, Chicago, Illinois, USA) proximal to the antecubital fossa. Two-dimensional images, acquired with electrocardiogram gating, will be obtained at baseline with Doppler ultrasound imaging to assess arterial diameter and flow velocity. Reactive hyperemia will then be induced by inflation of a pneumatic tourniquet around the forearm to at least 200 mm Hg (or > 50mmHg above systolic pressure) for 5 minutes. Post-deflation diameter and flow velocity will be monitored continuously from deflation for 210 seconds. To assess endothelial-independent vasodilation maximal brachial artery diameter will be measured continuously for 3 minutes after a single sublingual dose of nitroglycerin (NTG, 0.4 mg).
46009998|NCT04556942|Other|Blood pressure, pulse and blood oxygen saturation measurement|"Blood pressure measurement will be done with a pneumatic tourniquet on the upper arm, after at least 10 minutes rest of the patient.~Pulse measurement and oxygen saturation measurement will be done using a finger pulseoximeter, after at least 10 minutes rest of the patient."
46009999|NCT04556942|Other|ST George Respiratory Questionnaire|The is a validated and standardized Questionnaire designed to measure health impairment in COPD patients
46010000|NCT04556942|Other|Physical activity level (PAL) measurement|PAL will be assessed by the number of steps and kilometers per day using a triaxial accelerometer of a multisensory activity monitor (Fitbit Alta HR; Fitbit Inc., San Francisco, CA, USA). The device is worn like a watch on the wrist. The device is worn always, except while showering or swimming.
46010001|NCT04556942|Biological|Withdrawal of a blood sample|5ml of blood will be withdrawn and preserved after centrifugation at -50 degrees celsius for later analysis at a yet unknown time
46010002|NCT04556942|Procedure|Immediate Bronchoscopic Lung Volume Reduction|Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 2 weeks after T0
46010003|NCT04556942|Procedure|Delayed Bronchoscopic Lung Volume Reduction|Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 6-8 weeks after T0 and 3-4 days after T1
46096757|NCT02743403|Device|Neurodyn Portable activeTENS, IBRAMED®|Randomization and secret Allocation active TENS (GI / n = 27)
46096758|NCT02743403|Device|Neurodyn Portable placeboTENS, IBRAMED®|Randomization and secret Allocation placebo TENS (GII / n = 27)
46096759|NCT02743403|Device|Carboxyderm S20-1C|Randomization and secret Allocation control group (CG / n = 27).
46096760|NCT04141332|Diagnostic Test|EEG was recorded by EEG Machines|EEG was recorded by EEG Machines
46096761|NCT02743247|Drug|Tacrolimus|
46096762|NCT02743247|Drug|Mycophenolate mofetil|
46096763|NCT04190615|Diagnostic Test|thromboelastometry test (TEM test)|TEM test from the whole blood sample
45461575|NCT01167517|Other|Instructional digital video disc (DVD)|Breast milk expression instructions provided by digital video disc at the time of hospital discharge
46096764|NCT02743169|Other|Spatially-Optimized|Spatial analysis of retrospective data will be used to optimize the placement of ambulances to decrease response time from the time the call is received until the time the ambulance arrives at the patient's location.
45461576|NCT03951545|Procedure|First line total knee replacement for gonarthrosis .|Patients requiring 1st line total knee replacement for gonarthrosis with a Hip knee angle (HKA) between 170° and 183°. In the first group (Mechanical) the total knee replacement will be performed with a tibial cut by using extramedullary mechanical sighting and in the second group (Gyroscopic) by using gyroscopic and accelerometric navigation (I-Assist).
45461577|NCT03951467|Other|Interventional educational toolkit specific to low Health Literacy patients, designed with patients and health professionals.|"Two interviews between the patient and the nurse trained for the study: before discharge from hospital and a telephone reminder between 3 and 5 days after discharge.~First interview: the nurse will evolve using tools developed in the first phase of the study. The nurse will provide detailed personalized information on the patient's discharge order and illness and the action to be taken depending on the potential situations the patient may encounter.~Telephone interview: 3 to 5 days after discharge, the nurse will repeat the elements of the first interview with the patient to verify that the information has been properly understood and retained and that the patient is able to adopt appropriate behaviors in high-risk situations."
46010004|NCT04536441|Behavioral|Ultra Brief Online Mindfulness-based Intervention|We adapted and contextualized the original RAIN protocol to local pandemic-induced lockdown situation, with short journaling prompts that engage participants in self-reflection. Journaling is known to be a creative way to engage people in a therapeutic activity which promotes self-awareness (Utley & Garza, 2011). Creating a visual narration of thoughts, feelings and experiences help individuals make internal experiences more tangible and manageable, especially during these uncertain times.
46010005|NCT04536441|Behavioral|Control|The control group participants were asked to report preventive measures that they have taken to prevent COVID-19, ways that they obtained Movement Control Order news, and things that they wished to do once the Movement Control Order is lifted.
46010006|NCT04557293|Device|Continuous Positive Airway Pressure (CPAP) treatment|Treatment of Obstructive sleep apnoea syndrome with CPAP
46010007|NCT04536597|Other|Quince seed jelly group|Quince seed jelly, prepared by the researcher, was given to the mothers belonging to this group. Briefly, 3 g (2-3 pieces) of quince seeds are placed in 100 mL water and heated to boiling for 10 min. The prepared quince kernel was used for 3 days, immediately after cooling.14,15 On the 1st day postpartum, the researcher provided the mothers with practical training at the hospital, regarding the application of quince seed jelly to the nipple and areola and leaving it to dry. This training was repeated on the 3rd, 7th and 10th days, to ensure that the mothers followed it precisely. The training process was completed in 5-10 min, including questions and answers. Every 3-4 days (days 1, 3, 7 and 10), quince seed jelly prepared by the researcher was given to the mothers to continue applying, according to the procedure. The mothers were asked to apply it after every breastfeeding.
46010008|NCT04536597|Other|Breast milk group|Mothers in this group received practical training, conducted by the researcher on the 1st day postpartum at the hospital, on applying a few drops of their breast milk to the nipples and areola after each breastfeeding and leaving it to dry. This training lasted 5-10 min. Breast milk application of mothers in this group was recorded on the 1st, 3rd, 7th and 10th days, by the researcher.
46010009|NCT04536597|Other|Control group|Any kind of application that the mothers in the control group did for the nipple fissures were recorded on the 1st, 3rd, 7th and 10th days postpartum, by the researcher
46010010|NCT04556903|Combination Product|Bilateral Arm Training|First component of mCIMT will comprise one hour activity and a rest period of five minute given between each ten minutes of task practice. These activities will base on activities of daily living (ADL'S) and I
46010011|NCT04556903|Combination Product|modified constrained induce movement therapy|"BAT involves in four sessions, each session involve repetitive practice of bilateral tasks for one hour and a rest period of 5 minutes. The tasks are:~Block placement- 10minutes~Peg targeting- 10 minutes~Peg inversion-10miutes~Transferring objects- 10minutes"
46010012|NCT04536636|Drug|Docohexanoic acid|Patients received 650 mg DHA/3 times/wk/post-HD session
46010013|NCT04536636|Drug|Control-No drug|Patients received usual medical care with no DHA
46010014|NCT04556747|Other|VR - Distraction|Participants will be instructed to use any application.
46096765|NCT00673374|Device|radio-opaque adhesive skin markers|The examining physician will place a radio-opaque skin marker (Beekley Corporation, Ortho-SPOTS® Order Code 187; 6mm spherical markers) at the point of maximal tenderness to direct abdominal palpation indicated by the patient. Additional markers will be placed at the cephalad and caudad limits of the region of tenderness, defined as the point at which the patient no longer complains of direct tenderness to palpation.
46096766|NCT02743013|Drug|CHF 5993 100/6/12,5 pMDI|
46096767|NCT02743013|Drug|CHF 5993 100/6/12,5 DPI Test 1|
46096768|NCT02743013|Drug|CHF 5993 100/6/12,5 DPI Test 2|
46096769|NCT02743013|Drug|CHF 5993 100/6/12,5 pMDI replicate|
45461578|NCT02953314|Drug|TEZ|
45461579|NCT02953314|Drug|TEZ/IVA|
45461580|NCT02953314|Drug|IVA|
45461581|NCT01580761|Behavioral|Sleep restriction|14 days of sleep restriction, 4 hours of sleep per day.
45461582|NCT01100411|Device|Air Optix Aqua|Contact lens material: Lotrafilcon A
45461583|NCT01100411|Device|Biofinity|Contact lens material: Comfilcon A
46010015|NCT04556747|Other|VR - Biofeedback|Participants will be instructed to use the Mindful Aurora application.
46096770|NCT02743013|Drug|CHF 5993 100/6/12,5 pMDI with Valved Holding Chamber|
46096771|NCT00680160|Drug|AN2690|AN2690 7.5% Solution, once daily for 28 days
46096772|NCT02742857|Biological|BQ-A Peptide Extract|BQ-A Peptide Extract
45461584|NCT01100411|Device|Proclear|Contact lens material: Omafilcon A
45461585|NCT01100411|Device|Acuvue Oasys|Contact lens material: Senofilcon A
45461586|NCT01100411|Device|Acuvue 2|Contact lens material: Etafilcon A
45461587|NCT01100411|Device|Purevision|Contact lens material: Balafilcon A
46096773|NCT02742857|Biological|Mesenchymal Stem Cells|Mesenchymal Stem Cells
46096774|NCT02742857|Device|Transcranial Laser Therapy|Transcranial Laser Therapy
46096775|NCT02742857|Device|Median Nerve Stimulator|Median Nerve Stimulator
45461588|NCT01585285|Procedure|LIMA to SVG Bridge Technique|This surgical design use a composite-sequential venous graft to distribute left internal mammary artery (LIMA) inflow directly to the left anterior descending (LAD), but also to the other branches of the anterolateral territory thereby promoting a higher flow through the LIMA pedicle. It is constructed using a short saphenous vein graft (SVG) bridge interposed between the LAD and one (or more) other anterolateral targets, with the LIMA grafted on the hood of the SVG just above the LAD anastomosis.
46010016|NCT02278653|Other|Questionnaires for the evaluation of Quality of Life|"European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire, version 3.0, Global Quality of Life Score~Short Form (36) health survey~EORTC CR38~Vaizey score~Low Anterior Resection Syndrome (LARS) score~International Index of Erectile Function for men~International Prostate Symptom Score for men~Female Sexual Function Index for women"
46010017|NCT02278653|Other|Manometry|Manometry is a tool to measure the anal sphincter function. Patients do not need any bowel preparation before this procedure. During the examination a catheter tip will be positioned in the rectum above the sphincter and a small balloon will be inflated. This balloon is connected to a device that registers the measurements. Patients will receive instructions; e.g. squeeze, push, and cough. The procedure takes approximately 10 minutes and is not experienced as painful. Several parameters will be measured: the mean basal pressure, the maximum squeeze pressure, first sensation, first urge to defecate and the maximum tolerable volume. The manometric measurement will take place on the same day as the endoscopy and MRI (standard follow-up).
46010018|NCT00578825|Drug|Lopinavir / Ritonavir plus Ribavirin|
45461589|NCT01585285|Procedure|Conventional CABG|Conventional coronary artery bypass grafting (CABG) strategy with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
45461590|NCT03874819|Device|Medium cut-off dialyzer|Treatment using a Medium Cut-Off Dialyzer
45461591|NCT03874819|Device|High-flux dialyzer|Treatment using a high-flux dialyzer
45461592|NCT03402750|Behavioral|Meds to Beds|Medications will be delivered to patient bedside before discharge
45461593|NCT03402750|Behavioral|Electronic Prescription|Patient or surrogate can pick up medication from pharmacy
45461594|NCT03869671|Behavioral|PrEP uptake/adherence intervention|The interventionist will follow the manual to deliver informational and motivational strategies to participants to enhance their PrEP uptake (including completing clinical screening and obtaining/filling a PrEP prescription) and adherence (taking daily oral PrEP doses). The interventionist will assist participants in problem-solving around topics including limited transportation options, identifying local pharmacies, storing medications given complex living arrangements, coping with side effects, communicating with providers and pharmacists, and maintaining daily medication schedules with reminders and cues.
45461595|NCT03869671|Behavioral|Harm reduction standard of care|Participants will be provided with harm reduction supplies and health information and counseling according to routine practice at the community-based setting (harm reduction organization).
45461596|NCT00007475|Procedure|Plasma exchange|A course of plasma exchange of 5 treatments over 10 days, then administration of cyclophosphamide.
46010019|NCT04536129|Drug|Hydrocortisone (CORTIVIS ®)|Once enrolled all the patients had to instill topical low dose (1,005 mg) preservative-free hydrocortisone (CORTIVIS ®- Medivis, Catania, Italy) 2 times daily in each eye for two weeks.
46010020|NCT00578981|Behavioral|Osteoporosis Choice Decision Aid|The provider will introduce the patient to the choice of bisphosphonates using the decision aid.
46010021|NCT04556786|Behavioral|Transitions of care|The intervention was a pharmacist-led transitions of care program that include medication reconciliation, daily schedule for medication taking and medical condition monitoring, and follow-up phone calls from a pharmacist at 60- and 90-day post-discharge in addition to the usual care.
46010022|NCT04556825|Drug|PRP|After the arthroscopic operation was completed, a local PRP injection was performed
46010023|NCT04556825|Drug|normal saline|After the arthroscopic operation was completed, a local normal saline injection was performed
46096776|NCT00680238|Drug|Human derived FSH|Customized for each patient
46096777|NCT02742779|Drug|GDC-0310|Participants will receive single or multiple ascending doses of GDC-0310 orally in fasted or fed state.
46096778|NCT02742779|Drug|Placebo|Participants will receive placebo matched to GDC-0310 as single or multiple oral dose in fasted or fed state.
45461597|NCT00007475|Drug|Cyclophosphamide|For GFR > 50 ml/min/1.73 m2 received oral cyclophosphamide at a dose of 2 mg/kg/ day for 3 months. For GFR < 50 ml/min/1.73 m2 but > 10 ml/min/1.73 m2 will receive oral cyclophosphamide at a 25% reduced dose or 1.5 mg/kg/d for 3 months.
46010024|NCT04536246|Procedure|Bone Quadriceps Tendon (BQT) arthroscopic-assisted ACL reconstruction|New intervention method deployed in Indonesia to gain better clinical outcome for ACL--deficient patients requiring surgical treatment
46010025|NCT04536246|Procedure|Single-Bundle Hamstring Tendon (SBHT) arthroscopic-assisted ACL reconstruction|Comparator for New Reconstruction Technique
46010026|NCT04556708|Other|salin irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with saline was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
46010027|NCT04556708|Other|ozonated water irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with ozonated water was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
46010028|NCT04556708|Other|chlorhexidine irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with 0.12% chlorhexidine digluconate was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
46010029|NCT04535973|Diagnostic Test|unstimulated saliva sample for hormone analysis|hormone levels will be determined in frozen samples of unstimulated saliva
46010030|NCT04535973|Other|quality of life questionnaire|all participants will fill out self-perceived quality of life questionnaire
46010031|NCT04556513|Other|Paraclinical examination|Respiratory functional tests
46010032|NCT04556513|Other|Clinical Examination|Clinical Examination
46010033|NCT04556513|Other|Semi-directive interview|By phone
46010034|NCT04556513|Other|quality of life questionnaires|SF36, VSRQ, IESR, HADS
45461598|NCT01167673|Dietary Supplement|coltect|green tea 250 mg, selenium 100 micro gram, curcumin 500 mg
46010035|NCT04536090|Drug|Isoquercetin (IQC-950AN)|Isoquercetin will be administered by mouth twice daily for 28 days
46010036|NCT04536051|Biological|ChAdOx1 nCoV-19 single dose + paracetamol|Single dose of ChAdOx1nCOV19 vaccine, 5x10^10 vp + paracetamol
46010037|NCT04536051|Biological|MenACWY single dose + paracetamol|Single dose of MenACWY + paracetamol
46010038|NCT04536051|Biological|ChAdOx1 nCoV-19 two dose + paracetamol|Two dose of ChAdOx1 nCoV-19 vaccine, 5x10^10vp (prime) and 0.5mL boost (3.5 - 6.5 × 10^10 vp), 4-12 weeks apart + paracetamol
46010039|NCT04536051|Biological|MenACWY prime & saline placebo boost + paracetamol|MenACWY prime, and Saline Placebo boost (0.5mL) + paracetamol
46010040|NCT04543422|Dietary Supplement|Green tea|Green tea extract capsules
46010041|NCT04543422|Other|Placebo|Placebo containing inert material.
46010042|NCT00579215|Behavioral|Enhance Care|EC will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits
45461599|NCT01167673|Dietary Supplement|Placebo|placebo
45461600|NCT03714438|Drug|Medicago Sativa|Single oral doses of Medicago sativa (1,500 mg), 30 min before before the oral glucose tolerance test.
45461601|NCT03714438|Dietary Supplement|Placebo|Single oral doses of placebo (1,500 mg), 30 min before before the oral glucose tolerance test.
45461602|NCT01100489|Radiation|external beam radiation therapy|External beam breast radiation therapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.
46096779|NCT04141176|Device|Spiri+|CPAP Spiri+ will be weared during one night for each included patient.The validation of the CPAP Spiri+ algorithm will be in the first 10 patients and appreciation of overall clinical efficacy on the 10 last OSAS.
45461603|NCT01100489|Other|questionnaire administration|Ancillary studies: The patient will complete the Cosmesis /QOL form (Appendix II) and the treating physician will complete the Cosmetic Guidelines (skin assessment) form for baseline data (Appendix I).
45461604|NCT01100489|Procedure|therapeutic conventional surgery|Patients will undergo excisional biopsy or needle localization removal of the tumor. Patients with margins < 2 mm undergo re-excision of the biopsy cavity. Surgical clips should be placed at the time of tylectomy to define the excision cavities. Ideally, clips are to be placed marking the superficial, deep, right, left, inferior, and superior dimensions of the tylectomy or re-excision cavities.
45461605|NCT01273441|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 5 days: PPI and 1g amoxicillin every 12h. After dual therapy continue with a triple therapy for 5 days: PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
45461606|NCT01273441|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for ten days:PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
45461607|NCT03714360|Drug|Tranexamic Acid|patients with ASA(American Society of Anesthesiologists grades) 1 to 2, scheduled to undergo lumbar decompressive surgery at Middelfart Hospital. Patients were randomized, in blocks of 10, to two groups: TXA or placebo. Anticoagulation therapy was discontinued 2-7 days preoperatively. Prior to the incision, patients received either a bolus of TXA (10mg/kg), or an equivalent volume of saline solution (placebo).
46096780|NCT02742701|Other|diagnosis|Measurement of glycosuria
46010043|NCT00579215|Behavioral|Usual Care|As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.
46096781|NCT00683982|Drug|Nitazoxanide|Nitazoxanide 15mg/Kg/day twice day for 3 days
46096782|NCT00683982|Drug|Probiotic mix preparation|Probiotic preparation 1 gram twice a day for 5 days
46096783|NCT00683982|Other|Oral hydration solutions|Oral hydration solutions as needed
45461608|NCT03714360|Drug|Sodium Chloride 0,9%|Sodium Chloride 0,9%
45461609|NCT00025883|Drug|Metreleptin|Drug treatment
45461610|NCT01169857|Drug|Velcade|Velcade at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). The study will involve 3 cycles of Velcade therapy.
45461611|NCT01169935|Drug|Administration of intra-dermal Endorem|single dose, intradermal
45461612|NCT01169935|Biological|Mantoux test|single dose, intradermal
45461613|NCT01169935|Biological|Autologous Endorem-labelled mononuclear cells|single dose, intravenous
45461614|NCT01169935|Drug|Administration of Endorem|single dose, intravenous
46010044|NCT04536324|Procedure|Subcutaneous parenteral hydration|Patients will twice receive a subcutaneous infusion of 250 ml isotonic sodium chloride (NaCl) with 30 MBq Tc-99m pertechnetate mixed in. The patients will receive the first infusion during admission to our geriatric ward (when they are acutely ill) and the second infusion approximately 8 weeks after discharge when they are no longer acutely ill. The subcutaneous access will be placed on the abdomen in the lower left or right quadrant.
46010045|NCT04556669|Biological|Autologous aPD-L1 armored anti-CD22 CAR T cells|Autologous aPD-L1 armored CD22-targeting CAR T cells
46010046|NCT02215005|Drug|Telmisartan|
46010047|NCT02215005|Drug|Ramipril|
46010048|NCT04536714|Behavioral|Pythagorean Self-Awareness Intervention program|Stress management program of Pythagorean Self-Awareness Intervention (PSAI), which included eight sessions and lasted for eight weeks. On the first week, a personal session took place for measurements and training in the relaxation technique of diaphragmatic breathing. In the second week, patients attended a group session, in which they were adviced to follow specific directions for a healthy lifestyle, such as organized physical activity, adherence to the Mediterranean diet, creating a daily routine. In the third week, participants were introduced to the cognitive restructuring technique of (PSAI).In the following four group sessions, patients were trained on PSAI and the second relaxation technique, progressive muscular relaxation. In the last week, the final measurements were made. All sessions lasted for 120 minutes, except for the final one, which lasted for 60 minutes.
46010049|NCT02215044|Drug|BI 2536, intravenous|
46010050|NCT02215044|Drug|Gemcitabine, intravenous|
46096784|NCT04190381|Other|FR-Mask|"The investigational medical product of this study is a biomedical repair mask, FR-MASK, acting like moisturizing lotion applied on breasts.~The FR-Mask is applied to users' radiation-irritated breast skin for 15 to 20 minutes every 3 days."
46096785|NCT02742623|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Treatment with rivaroxaban for DVT and/ or PE and/ or prevention of recurrent DVT and PE according to local label
46096786|NCT00537823|Drug|Cetuximab|
46096787|NCT00537823|Drug|Bevacizumab|
46096788|NCT00537823|Drug|Leucovorin|
46096789|NCT00537823|Drug|Oxaliplatin|
46096790|NCT00537823|Drug|Fluorouracil|
45461615|NCT01273909|Procedure|Perforator Flap Breast Reconstruction|perforator flap breast reconstruction with or without vascularized lymph node transfer
45461616|NCT01273909|Procedure|Vascularized Lymph Node Transfer|perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction
45461617|NCT00072293|Procedure|Axillary lymph node dissection|Axillary lymph node dissection
45461618|NCT00072293|Procedure|No axillary lymph node dissection|Therapeutic conventional surgery
45461619|NCT03869827|Other|necrotizing enterocolitis|Collection of necrotizing enterocolitis diagnosis, as well as its severity, are based on the classification of Belle modified in 3 stages: 1) Suspected, 2) Proven, 3) Advanced
45461620|NCT01274065|Genetic|Genetic analysis|The research team will review data following DNA sample analysis and identify variants in genes that result in impaired drug metabolism
45461621|NCT01167751|Biological|MNC|Implantation of BM derived MNC
45461622|NCT01167751|Biological|AC 133|Implantation of BM derived AC133
45461623|NCT01167751|Biological|Control|Injection of cell carrier
45461624|NCT03869983|Other|Omnipaque™ (iohexol) Injection|755 mg/mL iohexol (350 mgI/mL), 80 mL infused intravenously over approximately 20 seconds
45461625|NCT03869983|Other|CE-Iohexol|755 mg/mL iohexol (350 mgI/mL)/50 mg CAPTISOL®/mL, 80 mL infused intravenously over approximately 20 seconds
45461626|NCT01167985|Device|IABN|Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
46096791|NCT04139928|Dietary Supplement|Picometer-ionic form of magnesium chloride|Single-dose (300 mg) of the picometer-ionic form of magnesium chloride
45461627|NCT01167985|Device|IABN|patients with molar teeth diagnosed with healthy pulp or irreversible pulpitis, and need root canal treatment, will be asked to participate in the study. After cleaning the teeth following a standard protocol, a sterile cotton wool will be placed in the pulp chamber. provisional restoration with and without nanoparticles will seal the teeth between apointments. After a month the cotton wool will be taken out and tansferred to the laboratory. The root canal treatment will continue following the standard protocol.
45461628|NCT01167985|Device|IABN|Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
45461629|NCT03870841|Drug|PC945|PC945, nebulized
45461630|NCT01274689|Other|individually tailored lead weight|patients were treated with an individually tailored lead weight to train M. orbicularis oculi during day time
45461631|NCT01283191|Behavioral|Behavioral Incentives|Vouchers for complying with target behavior of treadmill walking
45461632|NCT01283191|Behavioral|Education Control|Education class
46010051|NCT04556318|Device|Ion Mobility Spectrometry (IMS)|Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
46096792|NCT04139928|Dietary Supplement|Magnesium citrate or magnesium oxide|Single-dose (300 mg) of magnesium citrate or magnesium oxide
46096793|NCT04139928|Dietary Supplement|Placebo|Placebo
46096794|NCT00673530|Behavioral|evidence based clinical nutrition concept|The evidence based nutrition concept comprise a routine malnutrition screening for hospitalized patients, the implementation of an evidence based guideline for clinical nutrition in the participating hospital, education training of the clinical staff and thereby optimal clinical nutrition for malnourished hospitalized patients.
46096795|NCT00673530|Behavioral|care as usual|Unchanged treatment of hospital patients without interference by the study.
46096796|NCT00991393|Device|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
46096797|NCT02742389|Other|Preprocedure Telephone Call|The participants will receive a phone call from the investigators 1 week before their testing to talk about the procedure and answer any questions that patients may have . The investigator calling the participant will document the duration of the phone call and any questions asked by the participant
46010052|NCT02215083|Dietary Supplement|L-glutamine|10,000mg by mouth, twice daily for nine weeks (± 7 days) with one permitted dose escalation to a maximum of 10,000mg by mouth three times daily.
46010053|NCT04556279|Procedure|adrenalectomy|Surgical removal of an adrenal gland containing an aldosterone secreting adenoma.
46010054|NCT04556279|Drug|Aldosterone Antagonist|Medical treatment of primary hyperaldosteronism.
46010055|NCT04535856|Drug|allogeneic mesenchymal stem cell|"Assignment of Administration Group allogeneic mesenchymal stem cell:~Low-dose group (5 x 10^7cells)~High-dose group (1 x 10^8 cells)"
46010056|NCT04535856|Other|Placebo|Control group (placebo)
46010057|NCT00579332|Dietary Supplement|brassica intervention|diet and phyto-chemical intervention
46010058|NCT04535622|Behavioral|A structured exercise|Exercise training will be conducted by a physical therapist which will take about 10 to 15 minutes. Patient education will include how to keep face down in various postures, and how to actively exercise the related muscles and joints while maintaining face-down posture through video clip and brochure. Patients will go through three times of self-exercise sessions everyday according to the training provided to the patients. Active exercise for the FDP patients will include exercise in a hands and knees position, limb exercise in an FDP, and exercise in a standing position. The exercises were performed within the range of individual muscle strength and fitness.
46010059|NCT00579371|Drug|Islets of Langerhans|Subjects will receive islets isolated from one donor pancreas per transplantation event. Subjects will receive a cumulative dose of 8,000IE/kg. Islets will be infused intraportally. If necessary, additional transplantation events will be performed.
46010060|NCT02216253|Drug|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract tablet twice a day 7 days before and after surgery
46010061|NCT02216253|Other|Placebo|Placebo tablet twice a day 7 days before and after surgery
46010062|NCT04556240|Device|VitalConnect Platform|The VitalConnect Platform is a wireless remote monitoring system intended for use by healthcare professionals for continuous collection of physiological and irregular heart rhythm data in home and healthcare settings. This includes heart rate, electrocardiogram (ECG), heart rate variability (R-R interval), breathing rate, arrhythmia detection, body temperature, skin temperature, activity (including step count), and posture (body position relative to gravity including fall). Data is transmitted wirelessly to a central location where it is stored for analysis. The VitalConnect Platform can be configured by authorized persons to notify healthcare professionals when physiological data falls outside selected parameters
46096798|NCT02626572|Drug|S47445 5mg|S47445 5 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
46096799|NCT02626572|Drug|S47445 15mg|S47445 15 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
46096800|NCT02626572|Drug|S47445 50mg|S47445 50 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
46096801|NCT02626572|Drug|Placebo|Placebo tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
46096802|NCT05589025|Procedure|pulpotomy technique with formocresol|The pulpotomy procedure performed was a modification of that described by Pinkham et al; 2005 where pulp chamber was unroofed using a no. 330 sterile bur in a water-cooled high-speed handpiece. The entire roof of pulp chamber and overhanging dentinal remnants over the pulp horns were removed. After the completion of the access cavity, coronal pulp was extirpated using a sharp excavator. Any residual coronal pulpal tissue was removed using a sterile round bur in a slow-speed handpiece to a depth of few millimeters below the free gingival margin. Hemostasis was achieved with a water-dampened cotton pellet. If hemostasis was not achieved after the initial application of the cotton pellet, the case was eliminated from the study. Following hemostasis, a cotton pellet, moistened with formocresol was applied for 3 minutes and removed. A zinc- oxide and eugenol base was placed over the amputation site. Thereafter, a glass ionomer base was applied.
45461633|NCT03869359|Other|Gluten-free diet with gluten powder|The subjects will sprinkle gluten powder over their meals, twice a day. (14 g/day vital gluten: Real Foods, Edinburgh, United Kingdom). Plastic sachet marked with B (WePack, Derbyshire, United Kingdom). Free of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs).
45461634|NCT03869359|Other|Gluten-free diet with placebo powder|The subjects will sprinkle placebo powder over their meals, twice a day. (14 g/day rice starch: Doves Farm Foods Ltd., Berkshire, United Kingdom) Plastic sachets marked with A (WePack, Derbyshire, United Kingdom). Low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs).
45461635|NCT01168063|Drug|Molecular detection of antibiotic resistance|Helico DR®, triple therapy (Proton Pomp Inhibitor (PPI), amoxicillin, clarithromycin, metronidazole)
45836988|NCT00538824|Drug|thalidomide|"Cycles 1-4~• Thalidomide will be given 50mg daily on days 1-7, thereafter 100mg daily on days 8-28 of the first 28-day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 of each subsequent cycle.~After completing 4 cycles:~Patients who demonstrate disease progression at any time will be taken off study.~Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.~Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy."
45461636|NCT01168063|Drug|standard triple therapy (PPI, amoxicillin, clarithromycin, metronidazole)|"2 lines of treatments :~1) PPI + Amoxicillin + Clarithromycin for 7 days~1) PPI + Amoxicillin + Metronidazole for 14 days"
45461637|NCT03869593|Genetic|Sample analysis|Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia
45461638|NCT01168141|Drug|ZD4054|10mg ZD4054 daily in tablet form
45461639|NCT01283269|Behavioral|Memory Support System|Training in use of a memory notebook system
45461640|NCT01283269|Behavioral|Computer Training|Computer brain fitness training
45461641|NCT01283347|Drug|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG"
45461642|NCT01166035|Drug|Lenalidomide|"Lenalidomide will be supplied as 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules for oral administration.~Prior to Cycle 1, there will be a 21 day lead in treatment period with lenalidomide monotherapy (Days -21 to -1). Combination treatment will start at Day 1. Subjects will be enrolled in cohorts of three to receive a single, oral dose of lenalidomide administered on Days 1-28. For each cohort of subjects, the decision of whether or not to dose-escalate will be made after subjects have received the first treatment cycle of study drug. Treatment will continue until the occurrence of any of the following events.~Disease progression~Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.~Major violation of the study protocol.~Withdrawal of consent~Lost to follow up~Death~Suspected pregnancy"
45679205|NCT05892276|Behavioral|Trauma Memory Reactivation|Participants will be guided through the trauma memory reactivation paradigm by the study staff. The trauma memory reactivation paradigm entails two distinct procedures: (1) participants will watch a video clip related to their trauma; then (2) describe a verbal narrative of their traumatic event for approximately 5 minutes to a research team member.
46096803|NCT05589025|Procedure|pulpectomy technique with zinc oxide and eugenol|The pulpectomy procedure used herein was a modification of that described by Payne et al;1993 Pulp chamber was unroofed using a no. 330 sterile bur in a water-cooled high-speed handpiece. The entire roof of pulp chamber and overhanging dentinal remnants over the pulp horns were removed. An initial endodontic K-file fitting snugly in the canal was introduced inside it. In most cases, the pulp tissue was removed completely on the first attempt. If the first attempt was unsuccessful, the procedure was repeated and canals were generally enlarged three sizes past the initial file to eliminate the organic remnants. Copious irrigation with a light flow of sterile 0.9% NaCl-solution was used throughout the procedure. At the end, the canals were dried and filled with zinc-oxide & eugenol.
46010063|NCT02216292|Other|Control Group|Infants received preterm formula during their first days of life until breastmilk from their own mother was available
46010064|NCT02216292|Other|Preterm Single Donor Milk Group|Infants received preterm single donor milk during their first days of life until breastmilk from their own mother was available
46010065|NCT02216331|Drug|TMC207|"This is a two group, 2 period study design with both groups in the first period receiving TMC207 alone, followed by one group in the second period receiving TMC207 in the presence of dosing with rifapentine and the other group receiving TMC207 in the presence of dosing with rifampicin. All treatments details specified under Arms description."
46010066|NCT02216331|Drug|rifapentine|
46096804|NCT02742545|Behavioral|MayoExpertAdvisor|Access to MayoExpertAdvisor (MEA) in the electronic medical record (EMR). MEA will provide patient-specific knowledge and treatment suggestions for patients with hyperlipidemia, atrial fibrillation, and/or heart failure via a clickable tab in the Mayo Clinic EMR.
46096805|NCT00989755|Other|Fax to Quit (F2Q)|Clinics in this group receive electronic and hard copies of all materials necessary for implementing Fax to Quit within their clinics.
46096806|NCT02626494|Drug|N-Acetylcystein|n-AC will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of n-AC over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of n-AC 5 days after the screening assessment (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of n-AC capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
45679206|NCT05892276|Dietary Supplement|Cannabidiol (CBD) Broad-Spectrum Oil|300mg CBD broad-spectrum oil.
46096807|NCT02626494|Drug|Placebo|14 days before or after, placebo will be administered analogously as described with n-AC. Placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of placebo over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of placebo 1 day before scanning (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
45679207|NCT05892276|Dietary Supplement|Placebo Oil|3ml oral dose of medium-chain triglycerides (MCT) coconut oil.
45679208|NCT05892263|Other|early feeding|Enteral force feeding with 5% dextrose injection within 24 hours after operation
45679209|NCT05892250|Behavioral|Conventional physical therapy|Manual techniques and therapeutic exercise
46010067|NCT02216331|Drug|rifampicin|
46010068|NCT02212418|Other|Abdominal hypopressive technique|postural technique based on self-elongating, body axis anteriorization, shoulders extension, and maintenance of an expiratory apnea as long as possible
46010069|NCT04535817|Drug|Omalizumab Injection [Xolair]|300mg via 2 subcutaneous injections every 4 weeks
46010070|NCT04577924|Other|Interview|"Trained research assistants would abstract the data as per a preset proforma. The data would be collected from the patient (if coherent), pre-hospital care provider or primary care provider.~Data would was also obtained from patient records and the proforma filled by the attending doctors on duty.~Follow up of cases would be done until discharge from the hospital."
46010071|NCT04543149|Diagnostic Test|Flow cytometric immunophenotyping|To evaluate T cell subsets and monocyte
46010072|NCT04555889|Device|lung recruitment maneuver (LRM) with DrageerVN500|interventions involving device that may help to gradually lung development
46010073|NCT04543266|Procedure|Surgery|Resection of tumors
46010074|NCT02215239|Behavioral|Workplace intervention|WHO Healthy Workplace Framework and Model. The intervention plan is to implement a cyclic or iterative process recommended by WHO. The process includes eight steps: (1) Mobilize; (2) Assemble; (3) Assess; (4) Prioritize; (5) Plan; (6) Do; (7) Evaluate; (8) Improve. We focus on different phases of exercise and prescribe individualized physical activity program.
45461643|NCT01166035|Drug|Cetuximab|"Combination treatment will start at Day 1. Subjects meeting will be enrolled in cohorts of three to receive infusions of cetuximab (400 mg/m2 first infusion only, then 250 mg/m2 subsequently) administered on Days 1, 8, 15, and 22 of each 28-day cycle. Cetuximab will be supplied as Erbitux® 22 mg/ml Vial à 50 ml, Erbitux 5 mg/ml Vial à 10 ml and Erbitux 5 mg/ml Vial à 50 ml for intravenous administration.~Treatment will continue until the occurrence of any of the following events.~Disease progression~Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.~Major violation of the study protocol.~Withdrawal of consent~Lost to follow up~Death~Suspected pregnancy"
45461644|NCT01168375|Drug|conventional therapy plus umbilical cord serum eye drop|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours plus umbilical cord serum eye drop 20% every 4 hours
46010075|NCT04578236|Combination Product|Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg|Infected patients will receive aerosolized 13 cis retinoic acid in gradual one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Inhalation administration by nebulization captopril 25mg for 14 days
45461645|NCT01168375|Drug|conventional therapy|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
45461646|NCT03869281|Procedure|Pancreas transplantation alone|Pancreas transplantation
45461647|NCT01168453|Behavioral|head position change|AL-US distance measure using the ultrasound in two different head position
46010076|NCT04578236|Drug|Drug: Standard treatment Standard treatment|Drug: Standard treatment Standard treatment is according to the protocol of treatment of 2019-nCoV infection
46010077|NCT04555772|Other|factors evaluation|They investigated mortality and morbidity in patients who underwent emergency operation within 24 hours after traumatic brain injury.
45461648|NCT03869203|Other|Enhanced recovery after surgery (ERAS)|The patients in the ERAS group were given a pre-treatment drug [300 mg (gabapentin, Neurontin 300mg) and 10 mg oxycontin (oxycontin, Oxycontin CR 10mg) and 2 mg prednisolone (prednisolone 10 mg, Solondo 5mg)] on the evening before surgery. And pre-operative fasting should not exceed 6 hours, and clear liquid fasting should not exceed 2 hours. In addition, 400 ml of oral carbohydrate should be taken 2 to 4 hours before surgery to ensure adequate blood sugar and encourage regular diet (light meal) as soon as possible within a tolerable range after surgery. The initial pain after surgery is actively controlled by oral drugs such as celebrex and IR codon, and injections such as tramadol and demerol. On the first postoperative day, the urinary catheter is removed and CPM (continuous passive motion) rehabilitation is started.
45461649|NCT01170013|Behavioral|Family Check-up|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use
45461650|NCT01170013|Behavioral|Parent psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors. especially substance use
45461651|NCT01275391|Behavioral|Computer Screening, Brief Intervention, Referral toTreatment|A computerized screening for tobacco, alcohol and drug use accompanied by 10-15 pages of health information regarding the risks of tobacco, alcohol and drug use. This is followed by a brief conversation with the primary care provider regarding the health risks of tobacco, alcohol and drug use and a referral to treatment for those at high risk of substance use problems.
45461652|NCT01283425|Device|InsuPatch|Heaters for single use and a permanent control unit.
45461653|NCT01281943|Drug|Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2|"Temsirolimus 25mg IV on days 1, 8, 15 and 22 of each 28 day cycle~Pegylated liposomal doxorubicin 25mg/m2 IV on day 1 of each 28 day cycle"
45461654|NCT01283503|Drug|BKM120|
45461655|NCT01276249|Device|Fortevo Endograft|The Fortevo Endograft, Main Body and Iliac Lumen Delivery System are indicated for the endovascular treatments of patients with infrarenal abdominal aortic aneurysms or aortic-iliac aneurysms having suitable morphology for endovascular repair.
45461656|NCT01283659|Other|Standard Imaging|
46010078|NCT02215278|Dietary Supplement|10 x 55 g/ bean per arm|
46010079|NCT04578119|Procedure|Sliding Intubating Technique|Sliding technique' means that endotracheal intubation is performed by sliding the videolayngoscope blade under the epiglottis smoothly.
46010080|NCT04542954|Other|Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East|Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East
46010081|NCT04542876|Drug|Guduchi Ghan Vati|Guduchi Ghan Vati was orally administered 2 tablets (1000 mg) twice daily for 2 weeks.
46010082|NCT00579449|Behavioral|Healthy Families Durham|Implementation of Healthy Families America program plus Parents As Teachers curriculum
46010083|NCT00579449|Behavioral|Yearly Checkup|Mother and child are assessed annually and based on responses and stated needs, referrals to community resources are made.
46010084|NCT04542915|Other|No intervention|No intervention.
45461657|NCT01283659|Other|Advanced Imaging|
46010085|NCT04542759|Drug|Besifloxacin Ophthalmic|Prophylaxis for endophthalmitis
46010086|NCT04542759|Drug|Hydroxypropyl Methylcellulose Ophthalmic Ophthalmic Solution|Placebo
46096808|NCT02742233|Drug|saxagliptin|"Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive saxagliptin with regular treatment"
46096809|NCT02742233|Drug|placebo|"Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive placebo with regular treatment"
46096810|NCT00673608|Drug|deferasirox|Deferasirox up to 40mg/kg/day, PO, Dispersible tablets, taken once daily
46096811|NCT00537277|Drug|biphasic insulin aspart|Treat-to-target dose titration scheme (dose individually adjusted), injected s.c. (under the skin)
46010087|NCT04556006|Other|Patient education|"The data collection process of the study was carried out in two stages using data collection tools.~First stage: Personal Information Form and Compliance Questionnaire were applied to all patients in both groups. After anthropometric measurements, FR score was determined. The data collection forms were filled with the patients using face-to-face interview technique. The data collection process lasted for approximately 10-15 minutes. After the data collection, the patients in the intervention group were trained. No training was given to the patients in the control group but they received a Coronary Artery Disease Management Guide.~Second stage: 12 weeks after the first interview, the patients were interviewed again face-to-face interview technique and the forms and measurements applied initially were repeated."
46010088|NCT04542798|Device|Radiofrequency COSMAN|Radiofrequency ablation and neuromodulation
46010089|NCT04555850|Drug|Recombinant Human Thymosin β4|Healthy subjects , were given a dose of rh-Tβ4 for ten consecutive days.
46010090|NCT04555850|Other|Placebo|3 cohorts, with 6 healthy subjects , were given a dose of Placebo for ten consecutive days. Cohorts received ascending doses of either 0.5,2.0 or 5.0 ug/kg .
46010091|NCT04542447|Drug|Nuvastatic|Polymolecular botanical standardized extract Orthosiphon stamineus/Orthosiphon aristatas as an immunomodulator adjuvant therapy
46010092|NCT04542213|Drug|Linagliptin tablet|Linagliptin 5mg once daily plus a basal-bolus insulin scheme
46010093|NCT04542213|Drug|Insulin|Basal-bolus insulin scheme
46096812|NCT02742467|Drug|Perindopril plus Amlodipine|Group 1
46096813|NCT02742467|Drug|Perindopril plus Hydrochlorothiazide|Group 2
46096814|NCT02742467|Drug|Amlodipine plus Hydrochlorothiazide|Group 3
46096815|NCT00684216|Drug|capecitabine|200 mg, BID, PO, QD until progression of disease
46096816|NCT00684216|Drug|hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)|either tamoxifen or aromatase inhibitor (exemestane, anastrozole or letrozole), QD, until progression of disease
45461658|NCT03869047|Drug|Dexmedetomidine +bupivacaine|patients will receive combined general anesthesia and Quadratuslumborum block( transincisional ie before wound closure)with 19 mL of bupivacaine 0.20%plus 1 mic/kg of dexmedetomidine, total volume 20 ml
46096817|NCT02741921|Device|VivaSight DL|intubation using VivaSight DL tube
46096818|NCT02741921|Device|conventional double-lumen tube|intubation using conventional double-lumen tube
46096819|NCT00684294|Biological|TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine|Patients with solid tumors will receive TAG Vaccine 1 x 10^7 cells/ injection or TAG Vaccine 2.5 X 10^7 cells/injection once a month for up to 12 doses via intradermal injection as long as sufficient material is available. Selection of cohort is dependent on the amount of tumor cell yield following harvest and processing.
46096820|NCT05586997|Device|Bonded-Hyrax|The expansion screw of the bonded-hyrax will be activated until the palatal cusps of the permanent maxillary first molars are opposing the buccal cusps of the permanent mandibular first molars
46096821|NCT05586997|Combination Product|Bonded Rapid Maxillary Expansion and low-Level Laser therapy|Ten sessions of 0.5 watts for 20 seconds at 4 points along the mid-palatal suture
45461659|NCT03869047|Drug|Bupivacaine|patients will receive combined general anesthesia and quadratus lumborum block (transincisional) with 20 ml of bupivacaine 0.20% .
46010094|NCT02278406|Other|Deep brain stimulator|We will measure brain oxygen levels with a non-invasive near infrared spectroscopy device.
46010095|NCT00579605|Behavioral|Motivational Interviewing|Client-centered strategy that may decrease ambivalence in behavior performance with attention intervention (infant safety) on: a) breastfeeding self-efficacy, b) intended length of breastfeeding, and c) duration of breastfeeding.
46010096|NCT04542252|Drug|SyB V-1901|SyB V-1901 10 mg via IV infusion for 2 hours
45461660|NCT01283737|Device|DBX Putty|OCD of the knee will be treated with DBX Putty
45461661|NCT01283737|Procedure|Mosaicplasty|Mosaicplasty procedure performed to treat OCD of the knee
45461662|NCT03870685|Procedure|TAP Block|Transversus Plane block
46010097|NCT04542252|Drug|Cyclosporine|200 mg Capsule
46010098|NCT04555694|Drug|Cyclosporin|Used to increase tear production in patients who have dry eye caused by inflammation
46010099|NCT04555694|Drug|Loteprednol Etabonate|Used to treat inflammation of the eye
46010100|NCT04555694|Drug|Dexamethasone Ophthalmic 0.4 Mg Ophthalmic Insert|Used to treat inflammation of the eye
46010101|NCT04532775|Drug|magnesium|Preservative free magnesium which was used in the study was prepared in McGuff Pharmaceuticals, Inc. Laboratories and supplied in 50 ml vials containing magnesium (200 mg/ml).
46010102|NCT04532775|Drug|Methylprednisolone|Methylprednisolone which was used in this study was supplied from E.I.P.I.C.O pharmaceuticals -Egypt under license of UPJOHN s.a Puurs-Belgium (Depo-Medrol).
46010103|NCT04532775|Drug|Bupivacaine Hydrochloride|local anesthetic drug
46010104|NCT04532775|Drug|saline 0.9%|solution for intravenous and epidural injection
46096822|NCT02736851|Other|Home-based telemedicine group|"All patients referring to the rehabilitation service as out-patients underwent in-hospital a specific exercise program for the neck. Patients are instructed individually by a physical therapist to perform several types of exercises and, from the first rehabilitation session, are encouraged to exercise regularly at home. Written and illustrated material reporting home exercises is provided to all patients.~At the end of out-rehabilitation program, according to a randomization list, patients are randomized in 2 groups and those included in a Home-Based Telemedicine (HBT) program are followed up by a nurse tutor at home for a 6-month period."
46096823|NCT00684450|Procedure|Titration protamine|10. Study group: celite ACT will be performed every 3 minutes during protamine infusion until ACT values suggest reach of a plateau (defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds.), time at which infusion will be stopped. 2cc of blood is required per ACT test, for a maximum total of 10cc.
46096824|NCT00684450|Drug|Standard administration of protamine|1.3 mg of Protamine for 100u héparine
45461663|NCT03870685|Procedure|Surgical Site Infiltration|Surgical Site Infiltration
45461664|NCT03870685|Drug|Exparel|liposomal bupivacaine
45461665|NCT01166191|Radiation|Radiotherapy|Radiotherapy
45461666|NCT01276951|Dietary Supplement|Delivery and return of chocolate|At baseline and then every 2 weeks, each participant will receive different grams of chocolate, according to the group to which he is assigned.
46010105|NCT00579644|Drug|Combination of Minocycline and MTX or MTX alone|"Methotrexate Dosing:~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg"
46010106|NCT00579644|Drug|methotrexate|"Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.~2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.~4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.~6, 8 and 10 month evaluations:~If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.~If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 12 month evaluation: End of the blinded portion of the study."
46010107|NCT04532580|Device|Diagnosis of fracture on X-Ray Radiographs|Diagnosis of fracture on X-Ray Radiographs with and without the assistance of Boneview Software
45461667|NCT01276951|Procedure|Determination of blood pressure|Blood pressure will be determined at study entry, ninth and eighteenth week taking into account the protocols established in 2007 by the European Society of Cardiology and Hypertension. Because blood pressure has variations throughout the day and that measuring ambulatory health institutions can generate emotional changes that induce changes in this clinical setting, which for purposes of this study is the main outcome variable, there will be 24-hour monitoring of blood pressure at the beginning and end of the study.
46010108|NCT04578158|Drug|Standard COVID-19 care|Patients will receive standard covid-19 care as per the hospital/physician guidelines
46010109|NCT04578158|Dietary Supplement|Quercetin Phytosome|Patients will receive a daily dose of 400 mg of oral Quercetin Phytosome
46010110|NCT04532736|Drug|Emthexate|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
46010111|NCT04532736|Drug|Prednol|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
46010112|NCT04532736|Drug|Mometasone Furoate|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
46096825|NCT00991471|Behavioral|Interaction with MDRN STAT|Interaction with MDRNSTAT at triage to obtain orders for investigations and/or treatment
46096826|NCT00991471|Behavioral|No MDRNSTAT|Standard management of nurse-only triage for assignment of CTAS
46096827|NCT02736773|Other|xenograft material to slow resorption|xenograft material to slow resorption (Bio-Oss®)
46096828|NCT02741609|Device|Borrelia Diagnostic Test|The ALSI BDT is a high-yield in vitro cultivation method for Borrelia burgdorferi from venous whole blood samples.
46096829|NCT00684528|Drug|Metformin 1500 mg daily|500 mg thrice daily
46096830|NCT00684528|Drug|Metformin + Janufer (Janumet)|Titration up to 1500/150 mg daily
46096831|NCT05360251|Device|PDL(595nm)|One subject was treated with pulsed dye laser (Vbeam platinum, 595 nm, Candela Corporation): energy dosages of 9-11 J/cm2, pulse durations of 10/20 ms, and spot size of 7 mm.
46096832|NCT05360251|Device|IPL(DPL)|One subject was treated with IPL(delicate Pulsed Light, Dye-VL, Alma Lasers Corporation): energy dosages of 8.4-10.6 J/cm2, pulse durations of 10/12 ms, and spot size of 10×30 mm.
46096833|NCT05360251|Device|IPL(M22 590)|One subject was treated with IPL(M22 590, 590-1200nm, Lumenis Limited): energy dosages of 15-18 J/cm2, pulse durations of 3-4 ms, pulse delay of 30-40 ms, and spot size of 15×35 mm.
46096834|NCT05360251|Device|IPL(M22 vascular)|One subject was treated with IPL(M22 vascular, 530-650nm and 900-1200nm, Lumenis Limited): energy dosages of 9-17 J/cm2, pulse durations of 4-6 ms, pulse delay of 20-40 ms, and spot size of 15×35 mm.
46096835|NCT00684606|Drug|Oxytocin IV|5 miu/1000ml Glu/Saline
46096836|NCT00991549|Behavioral|interdisciplinary intervention or meeting-seminars|one-year individualized interdisciplinary weight loss program vs. small group seminars on healthy lifestyle
46096837|NCT00684372|Drug|leflunomide|"Screening: If BK viremia (BK PCR >10 000 copies/ml in serum) i. Reduced immunosuppression~MMF / AZA withdrawal~CNI reduction~Tacrolimus 5 ng/ml in serum~Cyclosporin 100 ng/ml in serum~Prednisolone to maintenance level~If effective => continue~Stable renal function (P-Krea)~>50% reduction in PCR (copies/ml) at 4 weeks after diagnosis~Negative PCR at > 3 months after diagnosis~If failure => add leflunomide~Deteriorating renal function (P-Krea) and positive PAD = BK nephropathy~<50% reduction in PCR at 4 weeks after diagnosis~Positive PCR at >3 months after diagnosis~Leflunomide dosing:~ii. Loading dose of 100 mgx1 PO daily for 5 days can be used or the patient can be directly started on iii. Maintenance dose (from day 1 or day 6)~Starting at 20 mgx1 PO daily~Thereafter adjusted between approximately 20-60 mgx1 PO daily according to serum levels of A77 1726 and the clinical situation a. Recommended level of A77 1726 >40 ug/ml"
46096838|NCT02736461|Procedure|Floor repair surgery|
46096839|NCT00684684|Device|Chartis System|Assessment of airway flow and pressure
46096840|NCT02736539|Drug|CBS 2004 (galacto-oligosaccharides)|CBS 2004 active treatment
45461668|NCT01276951|Procedure|Anthropometric Measurements|The study will be determined the body mass index (BMI) by the ratio of weight in kilograms over height in meters squared, for which anthropometric measurement will be made at first, ninth and the eighteenth week as follows: The weight will be taken with an electronic balance of 0.05 g sensitivity standing capacity of 150 kg. We will be rated based on BMI cut points given by WHO-PAHO (1993) and adopted by the Ministry of Health of Colombia (2000).
45461669|NCT01276951|Procedure|Food Anamnesis|With the aim of learning about the eating habits, it will be made based on a food intake recall the last 24 hours, taking into account that is not preceded by a special food day (sundays, holidays, celebrations). For more accurately calculate nutrient ingested food, modules will be used.
45461670|NCT01276951|Procedure|Samples: serological tests and culture of mononuclear cells|At admission and at the end of the study will be obtained after 12 hours of fasting, 8 mL of blood in a dry tube without anticoagulant and 30 mL of blood in heparin tubes, properly labeled with the code assigned to the participant. The sample will be used to determine the complete lipid profile (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol and VLDL cholesterol), State of oxidation of low density lipoprotein (oxLDL) and mononuclear cell culture. The remaining serum was kept at -20°C for use if is required repeat any study.
45461671|NCT01276951|Procedure|Analysis of cytokine production|We will be used the supernatant of mononuclears cell culture to quantify the production of interleukin one beta, interleukin two, tumor necrosis factor alpha by ELISA with commercially available kits for this purpose.
45461672|NCT01168531|Drug|Pregabalin|pregabalin: 300 mg/day, po, from operative day until third postoperative day.
45461673|NCT01168531|Drug|dexamethasone|Dexamethasone 16 mg, intravenous, before induction of anesthesia
45461674|NCT01168531|Drug|placebo|vitamin B complex formula
45461675|NCT03753763|Drug|Safinamide Methanesulfonate|100 mg (free base)
45461676|NCT03753763|Drug|Safinamide Methanesulfonate matching placebo|100 mg placebo
45461677|NCT03870373|Device|Pulse Oximeter|Aulisa's non-invasive pulse oximeter sensor is applied to a foot of the neonate; an adhesive patch secures the sensor to the neonate.
45461678|NCT01168609|Procedure|Primary percutaneous coronary intervention|Primary percutaneous coronary intervention (PCI) and stenting were performed for just the culprit lesion using standard techniques and bare-metal stents in all patients. Unfractionated heparin was used for 3 days after PCI, except in some cases with contraindications, and the dose of unfractionated heparin was selected to prolong the activated partial thromboplastin time by 2-3 times. The decision to use glycoprotein IIb/IIIa inhibitors was left to the discretion of the treating physician. The measurements of LVFP were performed via a fluid-filled pig-tail catheter placed into the LV after coronary angiography if PCI was not indicated or after primary PCI.
45461679|NCT01170169|Drug|Omeprazole|Omeprazole Delayed Release Capsules 40 mg
45461680|NCT01170169|Drug|Prilosec|Prilosec® 40 mg of Merck & Co.Inc.
45461681|NCT01166269|Biological|phleum pratense (grass-allergen)|6 injections of grass-allergen. Every dose will be 1000 SQ-U.
45461682|NCT01166269|Biological|phleum pratense (grass allergen)|3 injections of grass-allergen. Every dose will be 1000 SQ-U. Also 3 injections of placebo (physiological saline)
45461683|NCT01166269|Other|physiological saline|6 injections of placebo (physiological saline)in a lymph node.
45461684|NCT01283815|Procedure|Laparoscopic appendectomy|Laparoscopic appendectomy and laparoscopic drainage of the abscess. If appendectomy is not possible due to technical difficulties only laparoscopic drainage is performed. Patients are treated with the same antimicrobial therapy as the control group (intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day).
45679210|NCT05892250|Behavioral|Conventional physical therapy + Dynamic Humeral Centering exercises|Manual techniques and therapeutic exercise and active dynamic humeral centering exercises
45461685|NCT01283815|Procedure|Conservative management with percutaneous drainage|Patients are treated with intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day. If the abscess is at least 3 cm in diameter percutaneous ultrasound guided drainage is performed.
45461686|NCT01587313|Drug|Isosorbide dinitrate / hydralazine capsules|Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid
45679211|NCT05892237|Procedure|bronchial artery interventional therapy|After successful anesthesia, right femoral artery puncture was performed by Seldinger method. 5F-Yashrio catheter is chosen to locate the bronchial artery of the diseased side at the level of the thoracic aortotracheal bifurcation. Angiography was performed (Osu 300mg/ml, 3ml/s, total 8ml, 200Psi) to visualize tumor blood supply artery before infusion of chemo+PD-1 inhibitor and embolism.
46010113|NCT00579683|Other|Tumor core biopsy for RNA isolation|RNA isolation will be carried out using approximately 25 mg of gross tissue from these tumor specimens.
46096841|NCT02736539|Drug|Placebo|Placebo treatment
46096842|NCT00673686|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|SH T 00186 D in a 24-day regimen, i.e., 24 verum tablets, 4 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
45461687|NCT01282333|Drug|gemcitabine hydrochloride|Given IV
45461688|NCT01282333|Drug|veliparib|Given orally
45679212|NCT05892237|Drug|Chemotherapy drug|Nano-paclitaxel 260 mg/m2, d1, ivgtt, q3w+Cisplatin 75mg/m2, d1, ivgtt,q3w.
45679213|NCT05892237|Radiation|IMRT|60Gy/2Gy/30f
45679214|NCT05892237|Drug|Immunotherapy|PD-1 inhibitor (Tirelizumab) 200mg, d1, ivgtt, 30-60min, q3w.
45679215|NCT05892224|Procedure|Laparoscopic sleeve gastrectomy|Obese patients of different subtypes were all expected to undergo bariatric surgery
46010114|NCT04555733|Drug|Lemborexant|Lemborexant oral tablets.
46010115|NCT02216994|Drug|high dose lactulose|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
46096843|NCT00673686|Drug|Yasminelle (SH T 00186 D)|SH T 00186 D in a 21-day regimen, i.e., 21 verum tablets, 7 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
46096844|NCT02741843|Behavioral|Patient Education|
46096845|NCT05582941|Other|No intervention will be performed.|No intervention will be performed.
45461689|NCT01282333|Other|diagnostic laboratory biomarker analysis|Correlative studies
46010116|NCT02216994|Behavioral|conservative treatment|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
46010117|NCT02216994|Drug|paraffin oil|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
46010118|NCT04555928|Other|No intervention|This is a prospective cohort (survey) study. It has no intervention.
45461690|NCT01282333|Other|pharmacological study|Correlative studies
46096846|NCT00673842|Device|Implantable Cardioverter Defibrillator + Usual Care|Any Medtronic approved (in each geography) single chamber or dual chamber implantable cardioverter defibrillator (ICD)
46096847|NCT00673842|Other|Usual care|Usual post-MI care
46096848|NCT03820973|Behavioral|Brief CBT for Anxiety|All participants will receive psychoeducation on anxiety and bCBT treatment approach, work on setting goals, begin self-monitoring, and select skill sessions that fit his/her most pressing needs. Available skills: Relaxation-Diaphragmatic breathing is a simple relaxation technique that increases oxygen flow and reduces the unpleasant physiological sensations associated with anxiety; Exposure - designed to educate Veterans about the role of avoidance in maintaining anxiety problems, as well as information about how to reduce avoidance through exposure exercises; Cognitive - Veterans may opt to address anxiety and worry through modifying negative thinking patterns. Two available options - Increasing Helpful Thoughts and Managing Unhelpful Thoughts.
46096849|NCT04334915|Drug|Cenicriviroc Mesylate (CVC)|Administered orally
46096850|NCT04334915|Drug|Placebo|Administered orally
46096851|NCT03743077|Behavioral|Exercise training including inspiratory muscle training|Volunteers will participate in the the spinal mobility fitness training program for a frequency of one to 3 times a week with pre and post tests including four objective measures of function (timed t-shirt test, timed transfer test, four direction reach test and trunk test of strength) and a pre and post subjective interview. In addition to the program consenting volunteers will perform inspiratory muscle training as a home program and submit weekly diaries tracking their training. The inspiratory muscle trainer by Respironics provides specific pressure for inspiratory muscle strength and endurance, regardless of how quickly or slowly patients breathe. It exercises respiratory muscles and improves breathing. It Improves muscle strength and is easy to use.
46096852|NCT04888429|Drug|Camrelizumab|Patients received camrelizumab 200 mg every 3 weeks
46096853|NCT04888429|Drug|Famitinib|Patients received Famitinib 20 mg once per day
46096854|NCT02741765|Behavioral|Sham rTMS|Subjects will participate in daily sessions of sham-rTMS
46096855|NCT02741765|Other|Real rTMS|Subjects will participate in a combination of rTMS
45461691|NCT01282333|Drug|cisplatin|Given IV
45461692|NCT01283893|Procedure|Laparoscopic distal gastrectomy with D2 lymphadenectomy|The commonly practice laparoscopic surgery for gastric cancer involves a partial omentectomy+D1+b lymphadenectomy which includes the dissection of Lymph node stations 1, 3, 4, 5, 6, 7, 8a, 9; however, when performing a D2 lymph node dissection, a total omentectomy plus LN1, 3, 4, 5, 6, 7, 8a, 9, 12a retrieval will be completed. The same total omentectomy+D2 lymphadenectomy will also be performed by the open method.
45461693|NCT03870139|Device|Cerebral stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
45461694|NCT03870139|Device|Peripheral stimulation|Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia. Moreover, recent evidence has shown that PES can activate brain motor areas such as primary motor cortex.
45461695|NCT03384966|Drug|Selatogrel|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) or matching placebo will be reconstituted with 1 mL of water for injection. Further dilution with 1 mL sodium chloride (NaCl) 0.9% will be performed for preparation of the dose of 8 mg selatogrel.
45461696|NCT03384966|Drug|Placebo|Matching placebo for subcutaneous administration.
45679216|NCT05892198|Procedure|surgery|surgery with primary closure, Rhomboid flap , or Rotational flap
45679217|NCT05892185|Device|GELA|GELA glaucoma implant
46010119|NCT02217033|Other|'R' (Electro-kinetically altered beverage)|
46010120|NCT02217033|Other|Placebo (water)|
46010121|NCT04555538|Diagnostic Test|Cardiac MRI|These are routinely performed for many cardiac conditions, including atrial arrhythmias. The adverse effects are small but include claustrophobia and metallic objects. Therefore all patients will be counselled prior to the scans by an experienced MRI practitioner and standard measures will be taken to avoid distress during the scan. Furthermore, patients will be screened using routine clinical protocols in order to avoid any harm due to interaction of the MRI scanner with metallic objects.
46096856|NCT02741765|Behavioral|Supervised aerobic exercise|
46010122|NCT02217072|Behavioral|School intervention|A school-based intervention that builds on the promising Swedish programme SkolFam, but is adapted to a Danish school context. The two main components of the programme are a) comprehensive assessment of the child, involving testing of the child's cognitive and academic abilities and difficulties as well as an evaluation of the child's behaviour, school-related social relations and well-being, and b) a systematic and individually targeted intervention plan, made in collaboration between a psychologist, the teachers, and a special educational teacher at the school (e.g., the reading counsellor).
46010123|NCT02217072|Behavioral|Parents as Tutors|A home-based intervention, comprising a structured tutoring programme that allows foster parents to systematically support the foster child's school performance. Foster parents will attend an introductory tutor training seminar at which they will be introduced to relevant theory on learning and counselled on tutoring practice. The intervention itself is designed to provide approximately three hours per week of individual home-based tutoring for a period of 40 weeks.
46010124|NCT02217111|Behavioral|Adventures in Voice: Pediatric Voice Therapy|
46010125|NCT04532697|Other|Uncaria Rhynchophylla (Gou-Teng)|Uncaria Rhynchophylla (Gou-Teng) is a kind of Chinese Medicine. All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
46010126|NCT04532697|Other|Placebo|All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
46010127|NCT02212613|Drug|Brexpiprazole|Treatment (6 weeks) Up to 2 mg/day, once daily dose, tablets, orally
46096857|NCT03815591|Device|smokeSCREEN web-based game|smokeSCREEN tobacco use reduction/prevention web-based game. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
46096858|NCT00991627|Drug|Bupivacaine|10 mg of a 5 mg/ml hyperbaric solution, intrathecally
46096859|NCT00991627|Drug|Morphine|200 µg of a 100 µg/ml solution, intrathecally
45679218|NCT05892185|Device|XEN|XEN gel stent implant
46010128|NCT04532385|Dietary Supplement|Green tea extract|400 mg capsule
46096860|NCT00991627|Drug|Lactated Ringer's solution|25 ml/min intravenously
46096861|NCT00991627|Drug|Ephedrine, continuous infusion|37.5 mg/h intravenously
46010129|NCT04532385|Dietary Supplement|Placebo|400 mg capsule
46010130|NCT04555460|Procedure|Hemicraniectomy|Large hemicraniectomy and duraplasty
46096862|NCT00991627|Drug|Ephedrine, bolus|"6.25 mg IV bolus prn.~Hypotension defined according to study protocol for each arm."
45679219|NCT05892159|Behavioral|HRV biofeedback|An HRV biofeedback tool will be employed and utilized by individuals each day for the first 5 weeks during the intervention period.
45679220|NCT05892146|Drug|Prevention therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
45679221|NCT05892146|Drug|Rescue therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
45679222|NCT05892133|Behavioral|Maximal strength training|3 sessions/ week. leg press at ~85% of one repetition maximum for 8 weeks
45679223|NCT05892120|Behavioral|the MedAdhere app|The experimental group downloaded and used the MedAdhere app on their personal smartphones during this 8-week study
45679224|NCT05892107|Procedure|Toy Group|After meeting the children in the toy group, the toy will be given to the children to play 1 minute before the procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
46010131|NCT04555460|Other|Conservative medical therapy|Conservative medical therapy was based on published guidelines for the early management of patients with ischemic stroke
46010132|NCT04532229|Drug|Nimotuzumab+CRT(concurrent IMRT and TMZ)|"Drug: Nimotuzumab Concurrent radiochemotherapy period, 150mg/m2, weekly, for 6 weeks; Maintenance period, from the 7th to the 52nd week, 150mg/m2, every two weeks until disease progression or intolerable toxicity.~Other Names: h-R3~Drug: Temozolomide Concurrent radiochemotherapy period, 75mg/m2, daily, for 6 weeks; Maintenance period, rest from the 7th to 10th weeks, from the 11th week, 150-200mg/m2, day1 to day5, 21 days for a cycle, for 6 cycles.~Other Names: TMZ"
46096863|NCT00991627|Drug|Atropine|"0.1 mg/kg iv bolus prn~Bradycardia defined as 50% drop in heart rate from baseline values."
46096864|NCT02741375|Device|Somanetics 5100c (Invos oximeter cerebral/somatic Troy, MI, USA)|All patients underwent at least 6-h NIRS monitoring using a Somanetics 5100c (Invos oximeter cerebral/somatic Troy, MI, USA) cerebral oximeter in order to determined cerebral oximetry changes.
46096865|NCT02626260|Other|adhesive strip|Adhesive strip with a standard adhesive base
46010133|NCT00579800|Procedure|new software sequences, FIESTA and Vibrant-DE and IDEAL|Conventional images will be taken using the standard sequences consisting of T2-weighted imaging and T1-weighted imaging before and after contrast; these will be used for the diagnostic examination. FIESTA will be performed on 50 patients, while Vibrant-DE and IDEAL will be performed on the other 50 patients.
46010134|NCT04532268|Drug|Humanized CD19 CAR-T cells|Each subject receive humanized CD19 CAR T-cells by intravenous infusion
46010135|NCT00579839|Procedure|Delayed Cord Clamping|Delayed Cord Clamping: 30-35 seconds after birth
46096866|NCT05357209|Device|Avidhrt Sense Heart Monitor|Use of Avidhrt Sense Heart Monitor review ECG signals.
46096867|NCT03562871|Biological|IO102|test immunotherapy
46096868|NCT03562871|Biological|pembrolizumab (Keytruda)|anti-PD-1 immunotherapy
46096869|NCT03562871|Drug|Carboplatin (Carboplatin Kabi)|chemotherapy
46096870|NCT03562871|Drug|Pemetrexed (Pemetrexed Alvogen)|chemotherapy
46096871|NCT00685074|Behavioral|Computer-based Motivational Interviewing|The software includes three intervention components - pros and cons, feedback, and optional goal-setting in a fixed order.
46096872|NCT00685074|Behavioral|Time control|A series of therapeutically inactive videos and questions to (a) maintain RA blind, and (b) serve as a time control.
45461697|NCT03384966|Drug|Selatogrel|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
45461698|NCT01168765|Behavioral|Tu Salud Si Cuenta Behavioral Intervention|A behavioral intervention to assess the impact of the TSSC Media Campaign intervention outreach components with two study arms. The first arm is comprised of participants enrolled in the TSSC Media Campaign(control group) and the second arm(intervention group)consisting of participants exposed to media campaign who will be exposed to additional outreach efforts by monthly visits from lay health workers.
45461699|NCT03869125|Diagnostic Test|Blood pressure measurement|Blood pressure monitoring using automated office blood pressure measurement (AOBPM), office blood pressure measurement (OBPM), and 24-hour ambulatory blood pressure monitoring
45461700|NCT03402126|Other|TPD RAMWare|TPD RAMWare injected into enrolled subject's Implantable cardioverter-defibrillator (ICD) device for use
45461701|NCT01166425|Drug|Lithium Carbonate|Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID at visit 1 (total dose 900 mg). Participants weighing < 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID the day after visit 1 (total dose 600 mg). Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose. One mid-week dose increase will be scheduled in addition to the weekly increases at the scheduled in-clinic visits. On day 3 (+/- 2 days), a dose increase of 300 mg may occur based on the results of a telephone call placed by the study investigator to the participant's parent/guardian. During the telephone call, the prescribing clinician will assess medication adherence, adverse events, and overall improvement since baseline.
46010136|NCT00579839|Procedure|Immediate Cord Clamping|Immediate Cord Clamping: within 5 seconds of birth
46010137|NCT04532112|Device|Biocontainment Device For Aerosol Generating Procedures (Biobox)|The intervention consists of a biocontainment and aerosol evacuation device (Biobox) that will be placed around a patient prior to the airway procedure and remain in place throughout the airway procedure. The Biobox device is manufactured by National Flag and consists of a re-useable frame with a disposable, plastic torso drape. This is a new device that has not been used previously in a healthcare setting.
46010138|NCT04532112|Device|Control for aerosol generating procedures|There is no control device for the aerosol containment device. As such, intubation without a device will serve as the control/placebo arm for this trial.
46010139|NCT04555499|Other|Standardized neurological examination|
46096873|NCT00690222|Procedure|Intracameral injection of mydriatic agent|A mixture of 0.2 % tropicamide and 2% phenylephrine will be injected into the anterior chamber at the beginning of surgery
46096874|NCT02736071|Drug|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
46096875|NCT02736071|Drug|Tramadol|Women will receive oral Tramadol 100mg 2 hours before the procedure
46096876|NCT02736071|Drug|Placebo 1|Women will receive an oral placebo similar to Tramadol 2 hours before the procedure
46096877|NCT02736071|Drug|Placebo 2|Women will receive an oral placebo similar to Celecoxib 2 hours before the procedure
46096878|NCT00537199|Other|Visual Examination|Two (2) scheduled visits for visual examination of mouth for abnormal lesions and glands in the neck.
46096879|NCT00537199|Drug|OraTest|Two (2) scheduled visits for rinse staining: 2 teaspoons of OraTest for 20 seconds, then spit.
46096880|NCT00690300|Drug|Docetaxel|75 mg/m2 IV on day 1 of each 22 day cycle
46096881|NCT00690300|Drug|Oxaliplatin|80 mg/m2 IV on day 2 of each 22 day cycle
46096882|NCT03812627|Other|Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections|"All inpatient subjects: following samples will be collected during hospitalization:~Twice blood and urine collections:~at the beginning of hospitalization: 10 ml of blood + 5 ml of urine;~at the end of hospitalization: 5 ml of blood + 5 ml of urine. Synovial fluid collection: 1 ml Peri-prosthetic tissue collection: about 1 cm3 Hair collection: a single hair of 0.5 cm diameter"
46096883|NCT03812627|Other|Autopsy|Dead patients will be autopsied: hair, urine, blood, peri-prosthetic tissue and viscera (liver, kidney, spleen, brain, heart, lung) sampling for each autopsy.
46096884|NCT02628990|Other|1.6 g plant stanols|Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols
46096885|NCT02628990|Other|2 g plant stanols|Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols
46096886|NCT02628990|Other|1.6 g plant stanols and camelina oil|Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols and camelina oil
46010140|NCT04532073|Other|Eurythmy Therapy|A mindfulness-oriented movement therapy
46010141|NCT04532073|Other|Tai Chi|A martial art developed in China, which in recent times is often regarded as a system of movement theory or gymnastics
46096887|NCT02628990|Other|2 g plant stanols and camelina oil|Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols and camelina oil
46096888|NCT02628990|Other|Placebo|Lipid-lowering effect of Placebo Yoghurt Drink
46096889|NCT02741219|Drug|Normal saline|Control Group receives normal saline bolus after delivery
46096890|NCT02741219|Drug|Dexmedetomidine|Dex Group receives dexmedetomidine bolus 0.5mcg/kg after delivery
46096891|NCT02741219|Drug|Sufentanil|sufentanil PCA after surgery
46096892|NCT02741219|Drug|Sufentanil and dexmedetomidine|sufentanil combined with dexmedetomidine PCA after surgery
46096893|NCT00690534|Drug|Insulin Regular|insulin, 0.2 mU/kg/min for 3 hours
46096894|NCT00690534|Drug|L-NMMA|variable rate for 3 hours
46096895|NCT00690534|Drug|Sodium Nitroprusside|variable rate for 3 hours
46096896|NCT00690534|Other|mixed meal|mixed meal
45461702|NCT01166425|Drug|Placebo|Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
46010142|NCT04532073|Other|Standard Care|Treatment process that a clinician should follow for a certain type of patient
46010143|NCT00579917|Behavioral|Cognitive Behavioral Therapy: Questionnaires|CBT, we will interview you again after you have completed the 10 sessions. We call these follow-up interviews, and they include several phone calls and a questionnaire you would be asked to complete and then mail in. Each follow-up interview will take between 60 and 210 minutes. If you wish, these follow-up interviews can be done over different days. We will do the follow-up interviews three times; at approximately 4 months, 7 months, and 10 months after you complete the baseline interview.
45461703|NCT03868969|Drug|Fosfomycin Oral Suspension|Man with urinary tract infections with BLSE enterobacteriaceae will be treated by fosfomycin 1 packet by day for 21 days
45461704|NCT01311570|Drug|Buprenorphine|"In the first 2 weeks all subjects will enter into a dose titration phase, starting with minimum dosage of 1mg/day Buprenorphine gradually increasing to 4-8 mg/day according to tolerance and clinical benefit.~From week 3 to week 8, all subjects are prescribed Buprenorphine sublingually, OID in a stable dosage according to the decision of the treating physician."
45461705|NCT01168843|Other|computerized analysis of sonographic images|Evaluation of the Symmetry between the Primary Sulci of the Two Fetal Brain Hemispheres Using 3-dimensional Ultrasound Planes
45461706|NCT03714282|Device|Noninvasive spinal stimulation with gait training|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform locomotor activities.
46010144|NCT00579917|Behavioral|Usual Care: Questionnaires|If you receive Usual Care, you will not receive CBT while you are in the study. You will complete the questionnaires at the same time as participants who receive CBT. If you receive Usual Care you will be offered 10 sessions of CBT at no charge at the end of the study.
46096897|NCT00991705|Drug|Atorvastatin|
46096898|NCT00991705|Drug|Fimasartan|
46096899|NCT02735837|Drug|Doxycycline Group|Doxycycline 3% topical gel was put into the periodontal pocket using an insulin syringe
46096900|NCT02735837|Drug|placebo topical gel|placebo topical gel was put into the periodontal pocket using an insulin syringe
46096901|NCT04810429|Drug|Incobotulinumoxin A|"XEOMIN® (incobotulinumtoxinA) is an approved medication that inhibits the release of acetylcholine and muscle blockage. Xeomin is indicated for the symptomatic treatment of blepharospasm and hemifacial spasm, cervical dystonia of a predominantly rotational type (spasmodic torticollis), spasticity of the upper limbs and chronic sialorrhea due to neurological changes. Xeomin comes as a white powder for solution for injection. When dissolved Xeomin is a clear, colorless solution that does not contain particles. Xeomin is reconstituted before use with sterile sodium chloride 9 mg / ml (0.9%) solution, without preservatives, for injections.~The active substance is Clostridium botulinum type A neurotoxin (150 kD), without complexing proteins. The other components are human albumin and sucrose."
46096902|NCT04810429|Procedure|TMJ surgical arthroscopy|TMJ arthroscopy is a minimal invasive surgical technique for different types of temporomandibular joint (TMJ) internal derangements. Besides the acceptable outcomes of TMJ arthroscopy, the authors believe that adding to this treatment a single injection of BTXA into the temporalis and masseter muscles could reduce joint loading, improving TMJ arthroscopic results.
46010145|NCT02217189|Dietary Supplement|zinc sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
45461707|NCT03714282|Device|Conventional gait training|May receive up to 50 min of locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
45461708|NCT03714282|Other|Healthy control group|Participant in the Healthy Control Group will participate in up to 3 assessment sessions in order to obtain comparative data for Spinal Motor Evoked Potentials (MEPs), lower extremity MVC's, sidelying EMG data and overground EMG data
45461709|NCT01170325|Drug|Divalproex Sodium|
45461710|NCT01170325|Drug|Placebo Comparator|
46010146|NCT00579956|Drug|Meropenem|Meropenem 1gm, diluted with 50ml normal saline solution IV every 8 hours for at least 10 days. The dose will be adjusted according to the creatinine clearance.
46010147|NCT00579956|Drug|Ceftazidime|Ceftazidime 120mg/kg/day divided into 3 equal doses (maximum dose 2 gram/dose), diluted with 50ml normal saline solution IV every 8 hours for at least 10 days The dose will be adjusted according to the plasma creatinine level
46010148|NCT04555304|Drug|KH903 + Paclitaxel|KH903 4 mg/kg will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
46010149|NCT04555304|Drug|Placebo + Paclitaxel|Placebo will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
46096903|NCT02625558|Drug|Riociguat|Patients will initiated on 0.5 mg tid and titrated every 2 weeks to a maximum of 2.5 mg three times a day
46096904|NCT02625558|Drug|Placebo|Placebo given three times a day
46096905|NCT02741453|Procedure|Standard Practice|
46096906|NCT02741453|Procedure|Bilateral IJ Ultrasound Scanning|
46096907|NCT04809415|Other|Photobiomodulation|Photobiomodulation consists of irradiation by light in order to achieve photochemical and photophysical outcomes.
46096908|NCT04809415|Other|Sham|Simulation of the application of photobiomodulation therapy.
45461711|NCT05542446|Drug|Colistin|"Visit 1 - screening - Patient selection phase. Patients meeting the eligibility criteria will be screened if not meeting any of the exclusion criteria. A pregnancy test from a urine test will be performed on women of childbearing potential. The patient will be offered participation in the clinical trial and interviewed by the investigator.~Visit 2 (Visit 8, Visit 14 - optional, only if colistin is still indicated) - CMS administration The patient will be hospitalized at FNUSA. CMS will be given intravenously via the central vein catheter (a loading dose of 9 MIU intravenously over 30 minutes followed after 12 hours by a maintenance dose of 4,5 MIU intravenously over 30 minutes every 12 hours; only in patients requiring continuous renal replacement methods will the interval of the maintenance doses be 8 hours).~Visit 3 - Visit 7 (Visit 9-Visit 13, Visit 15-Visit 19 - optional, only if colistin is still indicated) - Pharmacokinetics blood samples collection."
45461712|NCT05513508|Procedure|Protocolized rotational use of interfaces|The NIV mask will be changed every 6 hours, alternating two different interfaces between the two most used in that center among those available i.e., oro-nasal, total face or hybrid mask.
45836989|NCT00538824|Drug|lenalidomide|"Cycles 1-4 • Lenalidomide will be given 25mg daily for days 1-21 of each 28 day cycle.~After completing 4 cycles:~Patients who demonstrate disease progression at any time will be taken off study.~Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.~Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Lenalidomide 25 mg/daily days 1 - 21 out of a 28 day cycle. 15mg/daily on days 1-21 of a 28 day cycle of lenalidomide will be given to patients with a creatinine clearance of < 40cc/min*"
46010150|NCT04531800|Procedure|Concentrated growth factor|In the concentrated growth factor (CGF) group, CGF was applied to the surgical area (n=14), and the area was primarily closed after additional releasing incisions.
46010151|NCT04531800|Procedure|Non-concentrated growth factor|In the non-CGF group, the surgical area was only primarily closed without any mobilization of the flap following sequestrectomy and bone curettage as a traditional surgical therapy.
46010152|NCT04531956|Other|Diagnostic decision aid s-decided|The intervention will consist of implementing a patient decision aid (PtDA) in general practice. The patient decision aid will be developed in line with the systematic development process specified by the International Patient Decision Aids Standards (IPDAS)
46010153|NCT00579995|Drug|Oral N-Acetylcysteine|600 mg
46010154|NCT00579995|Drug|Intravenous Sodium Bicarbonate|3mL/kg/hr for one hour pre-procedure and infused at 1mL/kg/hr for 6 hours post-procedure
46010155|NCT04531683|Other|electroacupuncture|same as described in experimental arm.
46010156|NCT04531683|Other|sham electroacupuncture|same as described in sham comparator.
46010157|NCT04531683|Behavioral|life style counselling|life style counselling to patients with mixed urinary incontinence contains advice on daily drinking, caffeine intake, diet, constipation, exercise, heavy lifting, lung disease, urinary track infection and etc.
45836990|NCT00539526|Drug|Bimatoprost 0.03%|bimatoprost 0.03%, 1 drop nightly for 3 months
45836991|NCT00539526|Drug|travoprost 0.004%|travoprost 0.004% eye drops, 1 drop nightly for 3 months
45836992|NCT00539526|Drug|latanoprost 0.005% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months
45836993|NCT00496860|Biological|ALT-801|Dose escalation (0.015 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.14 mg/kg, 0.16 mg/kg), intravenous infusions, two treatment cycle, each cycle with 4 daily on-dose infusion, 10 days rest between cycles.
46010158|NCT04555421|Device|Lumen|Subjects will use the Lumen device and mobile phone application, which will guide their diet, sleep, and routines according to their Lumen measurements. In addition, a Lumen coach will be assigned to the subjects, and they will have a 30 minutes video call with the coach during the familiarization stage, in order to acquaint them with Lumen and explain them about the application and the nutritional guidance.
46010159|NCT04531371|Drug|Dexmedetomidine injection|post surgical agitation prophylaxis
46010160|NCT04531605|Behavioral|YBank program|Adolescents participated in a 12-week peer-led life skills trainings at clinics and received financial incentives via mobile money upon clinic attendance and demonstration of suppressed viral load.
46010161|NCT04555382|Diagnostic Test|Blood and Urine|Blood and urine samples are collected every twelve hours when the patients are included in the study during observation period.
46010162|NCT04531722|Procedure|Intraoperative brain microdialysis|Our current standard practice is to use a lateral approach through the middle temporal gyrus to place 3 depth electrodes targeting the hippocampus for intraoperative verification of pathological epileptiform activity prior to resection. Our research protocol will add one FDA approved electrode that has a central cannula for insertion of a microdialysis probe.
45461713|NCT05513508|Procedure|Standard of care|Mask will be chosen according to the standard of care of the participating centers among the three types of masks available i.e., oro-nasal, total face or hybrid mask. Interface will be changed in case of discomfort judged by the patient as unbearable or in case of the presence of a pressure sore.
45461714|NCT03355326|Drug|Glycerin Suppository|Glycerin suppository is given once daily beginning after conditions described are met and continued until discontinue conditions are met.
46010163|NCT00580112|Drug|Dexamethasone|Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.
46010164|NCT00580112|Drug|Trabectedin|Trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks.
45461715|NCT01169077|Drug|Placebo|Injections of normal saline to be used as control; given at Days 0, 28, and 56. Administered via electroporation, using a DNA vaccine delivery device, in the deltoid.
45461716|NCT01169077|Biological|EP-1300|Single DNA plasmid dissolved in phosphate-buffered saline (PBS). Dose levels: 0.25, 1 and 4 mg based on DNA content, administered on Days 0, 28 and 56 via electroporation using a DNA vaccine delivery device, in the deltoid.
45461717|NCT03868813|Behavioral|Semi-structured Interview|One-on-one semi-structured interviews
45461718|NCT03353220|Drug|Belviq|Belviq is an oral drug
45461719|NCT03353220|Drug|Placebo|The placebo is made to mimic Belviq, but does not contain any active drug
45461720|NCT01169155|Other|Smoke Alarm Stimuli|See arm descriptions for information about the smoke alarm stimuli interventions.
45461721|NCT01166503|Procedure|mVEP Testing|Five small sensors are placed on the head which record the brain's response to moving stripes that are displayed on a computer screen. Each eye is tested while the other eye is patched. Each recording trial lasts about 10 seconds, and several trials are done for each eye.
45461722|NCT01166503|Procedure|Stereoacuity Testing|Subjects will have their 3D perception measured using standard clinical stereo tests (Randot, Lang, Titmus).
45461723|NCT01166503|Procedure|Optokinetic nystagmus testing|Subjects will be asked to view a screen with vertical stripes moving in both leftward and rightward directions while their eye movements are recorded using a remote video-based eye tracker.
45461724|NCT01166503|Procedure|Motion detection testing|Subjects will view a computer screen that has two panels of dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
46010165|NCT04531644|Procedure|double stimulation|the patients will be treated with two consecutive ovarian stimulations in one cycle
46010166|NCT04531644|Procedure|conventional ovarian stimulation|the patients will be treated with one conventional ovarian stimulation in one cycle
46010167|NCT04531332|Drug|Continuous infusion Linezolid|Linezolid 600 mg intravenous Loading dose followed by 1200 mg/ day by Continuous infusion ( 50 mg /hr )
46010168|NCT04531332|Drug|intermittent dosing linezolid|Linezolid 600 mg intravenous twice daily
46010169|NCT04530942|Device|Deep brain stimulation(Active)|Active DBS with the optiomal parameters
46096909|NCT00685152|Device|Repetitive Transcranial Magnetic Stimulation (rTMS) (MagPro, Medtronic)|6 weeks of either Active or Sham Repetitive Transcranial Magnetic Stimulation (rTMS). Active treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of Motor Threshold, 20 trains, 9 seconds per train, 51 seconds of intertrain interval that is applied over the Right Dorsolateral Prefrontal Cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6. Sham treatment will mimic active treatment; The rTMS machine used is MagPro and the company name is Medtronic.
46096910|NCT05629091|Device|FibDex|Nanofibrillar cellulose wound dressing
46096911|NCT05629091|Device|Epicite hydro|Wound dressing
46096912|NCT05629091|Device|Epiprotect|Wound dressing
45461725|NCT01166503|Procedure|Motion discrimination testing|Subjects will view a computer screen that has two panels of randomly moving dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
45836994|NCT01796106|Device|Icon|refer to instructions for use of Icon
45836995|NCT01796106|Device|fluoride varnish|The study clinician will provide oral hygiene instruction and topical fluoridation therapy (Duraphat fluoride varnish; Colgate Oral Pharmaceuticals, New York, NY, United States) to all study participants randomized to study arm 2 after the radiograph and visual exam. Topical fluoridation treatment will be provided is varnish (Duraphat) per manufacturer's instructions.
45836996|NCT03371004|Drug|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
46010170|NCT04530942|Device|Deep brain stimulation(sham)|Sham DBS with 0V Amplitude
46010171|NCT04555148|Biological|GC5131|COVID19 Hyper-Immunoglobulin
46010172|NCT04555148|Other|Placebo|Placebo
46010173|NCT04530864|Drug|Dextenza 0.4Mg Ophthalmic Insert|All patients will receive pre-surgical ocular surface treatment with intracanalicular sustained release dexamethasone, 0.4 mg
46010174|NCT04554875|Diagnostic Test|A scoring system|The scoring system was used to rate score patients.
46010175|NCT04531488|Procedure|Powered Mobility Training Simulator|Two groups of participants- 18 in each- were provided with either a simulator or powered wheelchair. Both groups were tested at baseline for powered mobility level. Both groups the practiced at home or school for 12 weeks, 4 times a week for at least 20 minutes. Both groups returned and underwent another evaluation to assess powered mobility level after 12 weeks of practice.
46010176|NCT04531488|Other|Training with Powered Wheel Chair|Training with Powered Wheel Chair
46010177|NCT00580190|Drug|alprazolam|tablet, 0.5 mg, single dose, only on Day 7 of the study
46010178|NCT00580190|Other|Placebo|solution, matching placebo to 500 mg PF-00572778, single dose, Days 1 and 7 of the study
46010179|NCT00580190|Drug|PF-00572778|solution, 500 mg, single dose, only on Day 7 of the study
45461726|NCT01170637|Drug|Ibuprofen|200 mg oral administration (RhinAdvil(R))
45461727|NCT01170637|Drug|Ibuprofen|200 mg oral administration (BI product)
45461728|NCT01170637|Drug|Pseudoephedrine-HCl|30 mg oral administration (BI product)
45461729|NCT01170637|Drug|Pseudoephedrine-HCl|30 mg oral administration (RhinAdvil(R))
45461730|NCT01169233|Device|Bright Light Box|Increased lighting used during night shifts to prevent sleepiness.
45461731|NCT01170793|Behavioral|educative telephone coaching (ETC)|a 30 to 45 minutes phone call, by appointment, by the nurse
45461732|NCT01282567|Other|Blood samples|The study will be proposed to four patients hospitalized in the Diabetes Unit for a glucidic fast test carried out during 24 hours (lunch, dinner and breakfast). Blood samples will be taken every 20 minutes during 6 hours and 40 minutes to measure plasma insulin concentration and blood glucose. T0 will correspond to the first modification of the insulin basal flow (in more or less) or to the first insulin bolus corrector, usually administered if capillary blood glucose reaches 1.8 g/l. The capillary blood glucose monitoring will be performed every two hours by the nurse.
45461733|NCT03873025|Combination Product|Pembrolizumab and CXD101|Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allow the immune system to destroy these cancer cells. CXD101 is a histone deacetylase (HDAC) inhibitor which kills cancer cells by blocking the vital functions of HDAC enzymes.
45461734|NCT02526745|Biological|the vaccine with high doses of virus content between 4.7～5.0 lgPFU|
45461735|NCT02526745|Biological|the vaccine with low doses of virus content between 4.7～5.0 lgPFU|
46010180|NCT04531137|Dietary Supplement|CLA-fortified milk powder|3.4 gram of CLA-fortified milk powder one a day for 12 weeks
46010181|NCT04531137|Other|Placebo|Placebo milk powder one a day for 12 weeks
45679225|NCT05892107|Procedure|Mask group with cartoon characters|The nurse who will open the vascular access with the children in the cartoon character mask group will meet the child 1 minute before the procedure with a cartoon character mask on his/her face.In all groups, the mother will be present with the child during the blood collection procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
46010182|NCT04531137|Other|Nutrition Counseling|Individualized nutrition counseling using nutrition module at week 0, 4, and 8 for 30-45 minutes each session
46010183|NCT04530903|Drug|Clonidine|75 µg (0.5mL) per injection site
45461736|NCT02526745|Biological|the vaccine with high doses of virus content between 4.3～5.0 lgPFU|
45461737|NCT02526745|Biological|the vaccine with middle doses of virus content between 4.3～5.0 lgPFU|
45461738|NCT02526745|Biological|the vaccine with low doses of virus content between 4.3～5.0 lgPFU|
45461739|NCT02526745|Biological|placebo|
45461740|NCT03868501|Behavioral|n-back task|All participants will be asked to finish the 3-back task and the 1-back task. The 3-back task and the 1-back task will be carried out at intervals to avoid the influence between different tasks. The sequence of the 3-back task and the 1-back task will be counterbalanced across participants.
45836997|NCT00541242|Drug|bimatoprost 0.03% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of bimatoprost 0.03% 1 drop every evening for 12 weeks
45836998|NCT00541242|Drug|latanoprost 0.005% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of latanoprost 0.005% 1 drop every evening for 12 weeks
45836999|NCT00438204|Biological|bevacizumab|Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days
45837000|NCT00438204|Drug|gemcitabine hydrochloride|Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed every 14 days
46010184|NCT04530903|Drug|Levobupivacaine|0.25% (10 ml) per injection site
46010185|NCT04530903|Drug|NaCl 0.9%|Nacl 0.9% (0.5ml) per injection site
46010186|NCT00580307|Procedure|Septoplasty|Surgical straightening of nasal septum
46010187|NCT00580307|Procedure|Septoplasty and endoscopic contact point correction|Septoplasty (as previously described). Contact point correction: structures of the lateral nasal wall that impinge on the nasal septum are mobilized to a more lateral position under endoscopic guidance.
46010188|NCT04530474|Drug|Ivermectin Pill|Ivermecin as a one-time dose
46010189|NCT04530474|Drug|Placebo|Inactive medication as a one time dose
46010190|NCT04554641|Other|Fasted breath samples|Participants will provide fasted breath samples pre and post Bio-Kult Advanced.
46010191|NCT04554641|Other|Daily Diary|Monitoring stool form, consistency and frequency on a daily basis.
46010192|NCT04554641|Other|Stool sample|Participants will provide stool sample pre and post Bio-kult Advanced.
46010193|NCT04530669|Device|High Tone Power Therapy|"High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort."
46010194|NCT04530669|Other|exercise program|physical therapy conventional selected exercise program inform of functional activities of daily living
46096913|NCT04002895|Drug|Foliglurax|Single oral dose of 80 mg [14C]-foliglurax(93µCi/3.44 MBq), 1mg/mL oral solution (prepared from [14C]-foliglurax powder for oral solution)
45461741|NCT01278199|Other|Medicals measures|"Rest in bed. Monitoring of respiratory frequency. Fixation of intravenous route. Administration of nasal oxygenotherapy in order to maintain SpO2 > 90%. Administration of antituberculosis treatment, in case with active pulmonary tuberculosis known at admission or diagnosed during the stay.~If necessary a bronchial wash out of will be realized by a bronchial fibroscopy with measures of use of cold serum, adrenalin xylocain or terlipressin.~The administration of antibiotherapy by general mode according to the clinician appreciation.~The administration of terlipressin according to the clinician appreciation. Against the cough treatment administration according to the clinician appreciation."
45461742|NCT01278199|Other|bronchial artery embolization|The bronchial artery embolization is practised within 48 hours which follow the hospital admission for non-severe acute hemoptysis.
45461743|NCT01169389|Procedure|Intraarticular injection|Durolane, one vial
45461744|NCT01169389|Procedure|Intra-articular injection of 0.5% Bupivacaine|
45461745|NCT01170871|Drug|Ixabepilone|
46010195|NCT04554680|Drug|dabrafenib and trametinib|"Participants will receive systemic therapy in the form of oral tablet dabrafenib 150mg twice a day & oral tablet trametinib 2mg once a day for 1 or 4 weeks.~Pre- & post-systemic therapy assessment of tumor iodine absorption is done using I-124 PET CT scan. Participants are prepared for this scan with intramuscular injection of thyrogen 0.9mg on 2 consequent days, followed by I-124 PET-CT scan over the next 3 days for tumoral lesional dosimetry.~Participants are then started on systemic therapy for 1 week, followed by I-124 PET-CT scan. If at least one tumor site can attain adequate dosimetry, RAI (I-131) treatment under thyrogen stimulation will be considered. Systemic therapy will be stopped 3 days after I-131.~If after 1 week of systemic therapy, tumors do not reach dosimetry criteria, participants will be continued on systemic therapy for a total of 4 weeks duration, followed by I-124 PET-CT scan. If tumor can attain adequate dosimetry, I-131 treatment will be considered."
46010196|NCT00580424|Drug|Norethindrone|Norethindrone 0.35 mg orally daily
46010197|NCT04530396|Biological|Gam-COVID-Vac|vaccine for intramuscular injection
46010198|NCT04530396|Other|placebo|placebo comparator
46010199|NCT04554992|Biological|COVID 19 Convalescent Plasma|COVID 19 convalescent plasma is a blood product collected from donors who have recovered from a previous COVID 19 infection
46010200|NCT04530786|Drug|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season, antigens measured for 3 years following vaccination in:~2004-2005: A/Wyoming H3N2; B/Shanghai~2006-2007: A/New Caledonia H1N1~2007-2008: A/Solomon Islands; A/Wisconsin H3N2; B/Malaysia"
46096914|NCT00685230|Biological|Antivenin Centruroides (scorpion) equine immune F(ab)2|3 vials of Alacramyn reconstitued in 50 ml of normal saline as a IV infusion over 10 minutes.
46096915|NCT00685230|Other|Placebo|Placebo reconstituted in 50 ml of normal saline administered over 10 min
46096916|NCT04286321|Other|Zero hard-boiled egg|No eggs will be consumed on test day
45461746|NCT01170871|Drug|Pemetrexed|
45837001|NCT00438204|Drug|pemetrexed disodium|Pemetrexed disodium 400 mg/m2 intravenously over 10 minutes every 14 days.
45837002|NCT00438750|Other|Independent Excercises|Subjects provided with wrist splint and instructions for independent exercises to perform at home on their own. Subjects were advised to perform exercises as often as possible, but at least three to four times a day for a minimum of thirty minutes. There was no formal strengthening program.
45837003|NCT00438750|Other|Occupational Therapy|Subjects were prescribed formal occupational therapy with supervised exercises to regain digit, wrist, and forearm motion and to strengthen the hand. The content, frequency, and duration of the rehabilitation program were at the discretion of the treating hand therapist.
46096917|NCT04286321|Other|Two egg whites|Two egg whites will be consumed on test day
46096918|NCT04286321|Other|Two hard-boiled eggs|Two eggs will be consumed on test day
46096919|NCT04286321|Other|Vegetable oil|Vegetable oil will be consumed on test day
46096920|NCT05472025|Other||
46096921|NCT02628756|Procedure|Endometrial injury|Office hysteroscopy (Karl Storz, Tuttlingen, Germany)
46096922|NCT05455879|Other|Impact of antenatal corticosteroid therapy on surfactants use postnatal|Intervention Description: Retrospective study on preterm infants to evaluate the impact of antenatal corticosteroid therapy on surfactants use postnatal
46096923|NCT00685308|Procedure|Stenting of atherosclerotic intracranial stenosis|"Patients will receive aspirin 300mg and clopidogrel 75mg per day for 3 days or more before stenting,and for at least 1 month after stenting. Modifiable risk factors will be controlled according to major international guidelines.~All stenting procedures will be performed in an elective setting, and under local or general anesthesia. The study will be terminated if stroke or death rate within 30 days of the stenting exceeds 15%."
46096924|NCT02740907|Procedure|premolar autotransplantation|Autogenous tooth transplantation of premolars to the anterior maxilla to stimulate bone and soft tissue growth.
46096925|NCT05357131|Behavioral|Hypnosis without VR (HYP)|"HYP will last for 15 minutes including an induction phase of 5 minutes. The hypnotic audio script Heaven of Peace developped/recorded by Pr. M-E. Faymonville will be used."
46096926|NCT05357131|Device|Hypnosis with VR (VRH)|The VRH intervention will use the Aqua video session developed by Oncomfort.
46096927|NCT00685386|Other|CO2 insufflation|The bowel lumen will be insufflated with CO2 during the endoscopy (as compared to room air).
46096928|NCT00685386|Other|Room air insufflation|During the ERCP, room air will be insufflated (current standard clinical practice) as a placebo comparator.
46096929|NCT04722055|Diagnostic Test|Multigene Methylation Detection Kit|Eligible participants are required to take stool samples for multigene methylation detection and gene sequencing, undergo colonoscopy examination, and have a biopsy when necessary (gold standard).
46096930|NCT00690690|Behavioral|Video (group-delivered video-based intervention)|group-delivered video-based intervention
46096931|NCT00690690|Behavioral|HCT|Offer of HIV counseling and testing
45461747|NCT01171027|Procedure|NOTES Cholecystectomy|The transvaginal NOTES approach is accomplished by performing a posterior colpotomy. Instead of a conventional laparoscope, a flexible endoscope is used in order to provide working channels and visualization. The gallbladder is removed through the vaginal incision. The transgastric cholecystectomy requires the flexible endoscope to be placed orally. A gastrotomy is made through the stomach wall allowing the flexible endoscope to pass into the abdominal cavity. The gallbladder is removed from the abdominal cavity into the stomach and ultimately out the mouth. The goal of NOTES is to develop further so either of these approaches will not require any incisions in the abdominal wall.
45461748|NCT01171027|Procedure|Laparoscopic Cholecystectomy|This technique utilizes the introduction of a laparoscope through a 1 cm incision in the fascia in or around umbilicus. Usually three additional 0.5- 1.0 cm incisions are employed for surgical instrumentation. Once separated from its attachments, the gallbladder is usually removed through the umbilical port. Sutures are used to close the larger port sites. The most devastating complication is injury to the major bile ducts which is avoided to the extent possible (incidence .2 to less than .01%)5 by careful visualization of the ductal structures.
45461749|NCT01282645|Device|PSI in PEEK|A Patient Specific Implant made of Polyether Ether Ketone to repair a cranial defect
45461750|NCT01278277|Dietary Supplement|Saffron supplementation|Saffron supplementation 20 mg
45461751|NCT01278277|Other|placebo|placebo supplementation
45461752|NCT03872869|Other|Hip school or Tai CHi for arthritis|Eighty-nine individuals were randomized to one of the three intervention groups 30 individuals to Tai Chi,30 individuals to Hip School and 29 individuals to the control group
45461753|NCT01171105|Drug|AZD5213|oral solution, multiple ascending doses
45461754|NCT01171105|Drug|Placebo to AZD5213|
45461755|NCT01169623|Other|Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance|55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model
45461756|NCT03868111|Drug|Sufentanil|The infusion rate of sufentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
45461757|NCT03868111|Drug|Remifentanil|The infusion rate of remifentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
45461758|NCT01282879|Drug|Itraconazole|200mg bid, oral solution, until a dose of prednisone was tapered to 10mg/day in case of prednisone alone therapy group, or until prednisone was stopped in case of CNIs plus prednisone, CNIs plus prednisone plus mycophenolate mofetil, or mycophenolate mofetil plus prednisone group, etc.
45461759|NCT03870061|Behavioral|All Babies Are Equal Initiative (conditional cash transfer program)|New Incentives, an NGO, offers cash incentives to caregivers for bringing their child to clinics for the first five visits of the Nigerian Routine Immunization schedule. These small cash transfers can provide some material benefit to new caregivers from poor communities. At a minimum, they help offset time and transport costs. The following vaccines are directly incentivized by the New Incentives' program: tuberculosis (BCG vaccine); diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae Type B (Pentavalent Vaccine), pneumococcal bacteria (PCV vaccine), measles vaccine.
45837004|NCT00439296|Drug|ABT-751|"Treatment Course 1:~Oral capsule to be given daily for 21 days at assigned dose.~Treatment Course 2:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.~Treatment Course 3:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest."
46096932|NCT02735759|Device|Photoacoustic flow cytometry device|The device for subjects enrolled on cohort 2 will be completed on day 0 (immediately after venous thromboembolism diagnosis and prior to anticoagulation therapy), day 7 ± 3 days after initiation of anticoagulation therapy, one week ± 3 days after completion of planned anticoagulation therapy and one month ± 3 days after completion of planned anticoagulation therapy. Anticoagulation therapy is part of the patient's normal standard of care and is not part of this study however data from what therapy was received may be captured. Patients will then be followed in hematology clinic to monitor the venous thromboembolism recurrence every 3 months for one year.
46010201|NCT04554602|Diagnostic Test|Fusion ultrasound|Fusion ultrasound is a technique that allows a volume acquired in MRI to be coupled to an ultrasound scan with real-time image synchronisation.
45837005|NCT00439296|Drug|Dexamethasone|"In Treatment Course 1 only:~10 mg/m2/day divided BID.~Take dexamethasone by mouth days 1-14."
45837006|NCT00439296|Drug|PEG-asparaginase|"In Treatment Course 1:~2500 IU's/m2/day.~Intramuscular injection (IM) on days 4, 11 and 18.~In Treatment Course 2:~2500 IU's/m2/day.~Intramuscular injection (IM) on day 15."
45837007|NCT00439296|Drug|Doxorubicin|"In Treatment Course 1 only:~• 60 mg/m2/day IV over 15 minutes on day 1."
46010202|NCT01121575|Drug|PF-02341066|Arm 1: The starting dose will be 200 mg by mouth, twice a day of PF 02341066 in tablet form The dose of each drug in the combination [PF-02341066 and PF-00299804] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
46010203|NCT01121575|Drug|PF-00299804|Arm 1: The starting dose will be 30 mg by mouth once a day of PF-0029804 in tablet form. The dose of each drug in the combination [PF-02341066 and PF-00299804] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
45461760|NCT01282957|Behavioral|Financial Incentive Group I|Lottery with 1 in 100 odds of $100 and 18 in 100 odds of $10. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
45461761|NCT01282957|Behavioral|Financial Incentive Group II|Lottery with 1 in 100 odds of $50 and 18 in 100 odds of $5. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
45461762|NCT02525887|Other|Observation|Observation and evaluation of care provided to patients that received DNA tests to determine metabolic pathways.
45461763|NCT01172587|Other|Behavioral Couples Therapy|Couples participate in 12 sessions of Behavioral Couples Therapy designed to reduce substance use and increase relationship functioning.
45461764|NCT03872635|Other|oral carbohydrate liquid|patients undergoing neoadjuvant chemotherapy and radical hysterectomy with bilateral pelvic lymph node dissection were randomized to receive 300mL of an oral carbohydrate liquid supplement 2 hour before surgery
46010204|NCT01121575|Drug|PF-02341066|Arm 2: With progressive disease the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
45837008|NCT00439296|Drug|Cytarabine|"Given Intrathecally on day 1 of course 1 at the dose defined by age below.~30 mg for patients age 1-1.99~50 mg for patients age 2-2.99~70 mg for patients >3 years of age~Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.~In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12."
46096933|NCT00991783|Drug|Digoxin + Fimasartan|Digoxin (7 days), Digoxin + Fimasartan (7 days)
46096934|NCT00690768|Drug|Bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 week after baseline; pars plana vitrectomy 3 weeks after baseline
46096935|NCT00690768|Procedure|pars plana vitrectomy|pars plana vitrectomy 3 weeks after baseline
46096936|NCT02735681|Procedure|meibomian gland probing|Investigator will do baseline (OSDI) questionnaires prior to probing as well as at 1 week (at home), 1 month, 3months, and 6 months at office visits.
46096937|NCT02735681|Procedure|Left eye Meibomian Gland Probing Control Group|There will be no probing in the left eye. This will be used as a control for the right eye.
46096938|NCT00673998|Device|Isokinetic Dynamometer (Biodex system III)|Biodex system III Isokinetic Dynamometer (Biodex Medical, Inc., Shirley, NY).
46096939|NCT03898063|Behavioral|90 DAYS film|the intervention conditions include exposure to a film, 90 DAYS (approx 20 minutes long), an entertainment film detailing a woman's decision to tell her romantic partner that she is HIV-positive.
46096940|NCT03898063|Behavioral|HIV pamphlet on disclosure|A standard-of-care brochure given to newly diagnosed HIV patients about the importance of status disclosure
46096941|NCT02735525|Device|Smartphone monitoring|Patients will be trained to use the smartphone and the wound surveillance app prior to discharge. Patients will use the app from home to take send digital images of their postoperative wounds and answer a short survey, all of which will be transmitted to a secure database maintained by the UW Department of Surgery and accessible only to UW-employed study personnel. These data will be evaluated by one of three vascular surgery service nurse practitioners (NPs) daily. Patients who have concerning findings either in their images or in their survey answers will be contacted for further evaluation.
46096942|NCT00690846|Drug|adalimumab|40 mg weekly adalimumab injection.
46096943|NCT04683679|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks for 3 doses
45837009|NCT00439296|Drug|Methotrexate|"In Treatment Course 1:~• Given Intrathecally on day 15 at the dose defined by age below.~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age~In Treatment Course 2:~• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age~In Treatment Course 3:~Intrathecally on day 1 at the age-defined dose"
46096944|NCT04683679|Drug|Olaparib|Olaparib will be administered twice daily continuously without breaks on a 21-day (3 week) cycle length, for a total of 2 cycles. Olaparib tablets will be administered bid (2 x 150 mg tablets twice daily; total 600 mg daily) on continuous days without interruption for 2 cycles. Each 3 week period constitutes one cycle.
45837010|NCT00439296|Drug|Cyclophosphamide|Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.
45837011|NCT00439296|Drug|6-thioguanine|Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.
46010205|NCT01121575|Drug|PF-00299804|Arm 2: The dose of 45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
46010206|NCT04554797|Other|Regional Hypothermia|Regional hypothermia was achieved by intraarteral perfusion of cold fluid into the ischemic area of the brain
46096945|NCT04683679|Radiation|Radiation|The dose of radiation will be 8-9 Gy x 3 fractions. Radiation therapy will begin on C1D2-7. For tumors that are too large for this schedule, an accomodation of 30 Gy in 6 Gy per fraction is allowed, a schedule commonly used at MSK.
46096946|NCT00685464|Drug|Abciximab|Intravenous.
46096947|NCT00685464|Drug|Abciximab|Intracoronary
46096948|NCT02740829|Drug|Intranasal glucagon|Glucagon will be administered via a nasal dispenser
46096949|NCT02740829|Drug|Intranasal placebo|Placebo
46096950|NCT00685542|Drug|diacerein|Diacerein 50mg bid
46096951|NCT00685542|Drug|placebo|placebo
45461765|NCT03872557|Dietary Supplement|Tyrosine (TYR) Supplementation|L-Tyrosine dietary supplement will be provided as 500 mg capsules and 4 (four) 500 mg capsules are to be given before OGTT. The capsules are formed from animal gelatin, and the contents are formulated with magnesium stearate as a flow agent, but without binders, coatings or colorings and also have no added flavorings, sugars, salt, artificial sweeteners, preservatives or salicylates. The capsules are to be administered with less than eight ounces of water to minimize dilution of gastric acidity.
45461766|NCT03868189|Other|Electroneuromyography with ultrasound|Patients whose electroneuromyography examination will be performed using an ultrasound
46096952|NCT05370781|Behavioral|Peer Led Diabetes Self-Management Support|While the effectiveness of peer-led interventions delivering diabetes-related education and support for short-term clinical, psychosocial, and behavioral improvements is well-established, older Black men in particular are less likely to participate and are at a higher risk of drop-out from these studies. This intervention aims to determine if using older Black men as peer leaders to other older Black men will improve retention rates for this population.
46010207|NCT04530591|Other|Survey|Participants will complete a survey about their opioid use history, its impact on their lives, their current strategies for preventing or reversing opioid overdoses, and their preferences for a device-based intervention.
46010208|NCT04530591|Other|Interview|"Participants will participate in a semi-structured interview, during which they will provide feedback on non-functional, looks-like prototypes of a naloxone delivery device."
46096953|NCT05370781|Behavioral|Diabetes Self-Management Education|Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom platform.
46096954|NCT02741063|Behavioral|screen low autistic subjects|screen subjects with low ASQ score
46096955|NCT02741063|Behavioral|screen high autistic subjects|screen subjects with high ASQ score
46096956|NCT02741063|Drug|oxytocin|intranasal administration of oxytocin (24 IU)
46096957|NCT02741063|Drug|placebo|intranasal administration of placebo (24 IU)
46096958|NCT05629013|Behavioral|After-Action Review|After-action reviews, or debriefs, are a relatively simple, inexpensive, and quick, tool to improve learning, performance, and the effectiveness of teams and individuals. After-action reviews are active self-learning processes wherein participants reflect on specific performance episode to actively engage in self-discovery and improve learning in a non-punitive/non-judgmental manner to result in enhanced performance. This proposal aims to apply the team effectiveness intervention of the after-action review (AAR) to the services intervention of the Child and Family Team (CFT) meetings currently used in the CWS.
46096959|NCT00685620|Behavioral|Reinforcement Based Treatment|3 group random assignment to receive standard care, recovery housing alone, or recovery housing plus behavioral treatment
46096960|NCT04138602|Device|BTL Emsella|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%.
45837012|NCT00542490|Radiation|Vaginal Cuff Brachytherapy|Clinical stage I-II endometrial cancer surgically staged. Stage I-II with any high-intermediate risk (H-IR) features OR Stage IIb any histology OR Stage I-II Papillary Serous or Clear Cell Histology Vaginal cuff brachytherapy Followed by Paclitaxel (175 mg/m2 over 3 hours) and carboplatin (AUC 6) Chemotherapy X 3 (high risk)
45837013|NCT03117660|Drug|Vitamin A|vitamin A daily X3-4 weeks
46096961|NCT04138602|Device|Sham BTL Emsella|Sham subjects will be seated on the device in the same manner as the active treatment group. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level ( < 10 % power).
46096962|NCT03480581|Behavioral|Forward First ICARE Training|Participants will engage in 12-sessions in forward direction, followed by 12-sessions in the reverse direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.
46010209|NCT04530708|Radiation|Thoracic radiotherapy|36 Gy to the primary lung tumor and present mediastinal node metastases after three months of medical treatment.
46010210|NCT00625573|Drug|Abraxane|100mg/m2 every week X's 3
46010211|NCT04205851|Drug|KIN-1901|KIN-1901 is a fully human monoclonal antibody (mAb).
46010212|NCT04205851|Drug|Placebo|Saline
46010213|NCT04530240|Procedure|Liver Transplantation|Use prospectively collected databases from each participate centre, register MELD score recorded at the time of drop-out, liver transplantation and end of the follow-up.
46010214|NCT04554758|Procedure|Sleeve gastrectomy|Bariatric operation will be done by laparoscopic sleeve gastrectomy procedure.
46010215|NCT04554758|Procedure|Roux-en-Y gastric bypass|Bariatric operation will be done by laparoscopic Roux-en-Y gastric bypass procedure.
46010216|NCT02882113|Drug|Advagraf|same dose as Tacrolimus bid der day in 24 weeks
46010217|NCT04311190|Other|Family engagement|Physical exercises and simple care tasks
46010218|NCT00580541|Behavioral|variety|variety and nonvariety
46010219|NCT04311229|Device|Negative-Pressure Wound Therapy group|The wounds were initially evaluated for any necrotic findings and debrided if needed, and then washed with an antiseptic solution. 3-DWM was used to measure the pressure sores by taking pictures.The length and width of wounds were measured with disposable paper rulers. Wound depth was determined in centimeters with a sterile cotton-tip applicator by measuring against a ruler. The wound was closed using a Wound Care Kit that includes foam dressing, film drape, TRAC pad with tubing and a drainage canister. Foam material was placed inside the wound and was attached to the canister through tubing.The canister was attached to the Vacuum-Assisted Closure device, which is a portable device that applies intermittent or continuous negative pressure.The device was operated at 125 mmHg pressure for 5 minutes with and 2 minutes without active vacuum.Wound dressings were changed every 48 hours.Wound area was measured after all three rounds of treatment.
46010220|NCT04311229|Other|contol group|Wounds were finally covered with gauze dressing soaked with saline. Wounds were treated three times a day, and measurements were repeated every 48 hours. Every wound was measured a total of four times: one pre-treatment (baseline) and three post-treatment measurements.
46096963|NCT03480581|Behavioral|Reverse First ICARE Training|Participants will engage in 12-sessions in reverse direction, followed by 12-sessions in the forward direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.
46010221|NCT04530357|Biological|QazCovid-in® - COVID-19 inactivated vaccine|QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
46010222|NCT04530357|Other|Placebo|Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)
46096964|NCT05409001|Diagnostic Test|tomography pan scan|This is a retrospective chart review
46096965|NCT04138836|Drug|BBT-877|BBT-877 oral capsule.
45461767|NCT03868189|Other|Electroneuromyography without ultrasound|Patients whose electroneuromyography examination will be performed without ultrasound (fake tracking)
45461768|NCT01171261|Behavioral|Health Games Field Trial|There were 4 arms to the intervention in the field trial of this study. Participants were randomized to one of 4 arms or exergame that were manufactured by SSD/Xavix (Shiseido Co. of Japan). Each exergame consisted of a game cartridge, the XavixPort, and game controllers (e.g., tennis racquets, boxing gloves, bowling ball, or floor mat). The XavixPort interfaces the exergame with the participant's television and contains the infrared sensors that track the movement of the game controllers. Each exergame cartridge includes multiple game modes. The four arms/exergames were: XaviX Tennis, The Jackie Chan Studio Fitness (J-MAT), XaviX Bowling, and XaviX Boxing.
45837014|NCT00439374|Drug|17 alpha-hydroxyprogesterone caproate|Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.
46096966|NCT04138836|Drug|Midazolam|Midazolam oral syrup.
45837015|NCT00439374|Other|Placebo Oil|Placebo oil is a 250 mg/mL solution of castor oil with benzyl benzoate and benzyl alcohol as a preservative
45837016|NCT00439608|Drug|Cetuximab,Paclitaxel, Carboplatin|IV treatment for 6 weeks
46010223|NCT04554563|Other|Core stability training|20 sessions of specific core stability exercise with no external loading.
46096967|NCT04138836|Drug|Itraconazole|Itraconazole oral capsule.
46096968|NCT04138836|Drug|Esomeprazole|Esomeprazole oral capsule.
46096969|NCT05558033|Other|Plyometric Exercise|Plyometric training consisting of ten different exercises [vertical unilateral and bilateral counter movement jump, horizontal unilateral and bilateral counter movement jump, drop jump (30 cm), squat jump, step-hop (20 cm), 180 degree rotation in transverse plane, frontal plane hurdle jump (20 cm) and sagittal plane hurdle jump (20 cm)] for 8 weeks, 3 sessions per week. Individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery)
46096970|NCT05558033|Other|Football Training|Routine football trainings
46096971|NCT02735369|Drug|2% OC-10X|2% OC-10X
46096972|NCT02735369|Drug|Placebo Comparator|Placebo
46096973|NCT00922584|Drug|sorafenib (Nexavar)|oral sorafenib 400 mg, twice daily, until disease progression or unacceptable toxicity
46096974|NCT04003597|Other|Usual-salt diet|Subjects followed their usual-salt diet but were asked to consume an equivalent in-house produced brown or white sliced pan bread equivalent in composition to the low-salt version but with its more typical salt content (1.2 g/100 g).
46010224|NCT04530045|Other|dosage of concentration of piperacillin and cefepim|Dosage of total plasma concentration of piperacillin and cefepim at different timepoints
46010225|NCT01121536|Drug|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
46010226|NCT02217423|Other|Chest physiotherapy chest wall expansion|chest physiotherapy The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression, Incentive Spirometry).
46010227|NCT02217423|Other|Chest physiotherapy airway clearance modality|The protocol will be consisted the breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest (vibration, compression) and active cough.
46010228|NCT00580580|Drug|Optison|0.1-0.4 mL through intravenous injection at the beginning of the study.
46096975|NCT04003597|Other|Reduced-salt diet|Subjects randomized to start on the reduced-salt diet were asked to restrict their consumption of dietary salt using a combination of pragmatic dietary advice as well as the replacement of bread and a limited number of other foods with equivalent foods which had lower salt content; these were provided to the participants. At the beginning of the salt restriction period, a research nutritionist provided the subjects with a list of the common salt-containing food (salted and naturally salty) and were asked to limit the consumption of such, as feasible. The subjects received in-house prepared 'low-salt (<0.3 g/100 g)' brown or white sliced pan bread as well as no-salt margarine/butter, and were given luncheon meats with no added salt if desired (optional).
46010229|NCT00580580|Drug|Definity|intravenous injection at 0.05-0.20 mL
45461769|NCT03872245|Biological|Probiotics|The patients will receive Adomelle 1caps/12h during 10 weeks
45461770|NCT03872245|Procedure|PENS T6|The patients will undergo percutaneous electrical neurostimulation of dermatome T6 weekle, during 10 weeks
45461771|NCT03867955|Other|Collection of datas|Collection of datas by videopupillometer results: pupil diameter and variation of the pupillary diameter.
45679226|NCT05892107|Procedure|Control group|In the control group, the nurse who will open the vascular access will meet the child 1 minute before the procedure with a white mask on her/his face. Children in the control group will be subjected to routine procedures before blood collection.In all groups, the mother will be present with the child during the blood collection procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
46010230|NCT00580580|Drug|PESDA|intravenous injections dosage 0.05-0.20 mL
46096976|NCT02740751|Dietary Supplement|Still-Tee|The mothers of the babies will receive Still-Tee galactogogue tea
46096977|NCT04139694|Dietary Supplement|Food plan with cinnamon supplementation|cinnamon twice daily plus follow Cardiometabolic diet
45461772|NCT03868033|Drug|Zoledronic Acid|Use Zoledronic acid as a sequential therapy after denosumab treatment for more than 2 years
45461773|NCT03868033|Drug|Denosumab|Continuous Denosumab treatment in arm 1 for two years or as a 2nd year treatment in arm 2 for one year
45837017|NCT01797042|Behavioral|Dietary Compliance|Incorporation of sugar sweetened milk into the usual diet. Instruction on how to account for additional calories provided by sugar sweetened milk Weekly compliance checks
46010231|NCT04311151|Procedure|own seizures visualization|At the hospital discharge, patients
46010232|NCT00580619|Other|Autonomic Function Testing|The autonomic function tests include asking the subject to breathe deeply for two minutes and breathing as fast and as hard as they can for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, placing one hand in ice water for 1 minute and an orthostatic test. All these tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the involuntary nervous system is working. In addition, a 24-hour blood pressure monitoring and exercise test may be also performed in some subjects.
46010233|NCT00580619|Other|Saline infusions|The effects of continuous IV infusion or pulse IV administration of saline in increasing total blood volume and fatigue score will be evaluated
46010234|NCT00580619|Drug|L-NMMA trimethaphan|Trimethaphan IV infusion for approximately 60 minutes at a dose of 4-6 mg/min L-NMMA IV infusion for approximately 45 minutes at 125, 250, and 500 mg/kg/min for 15 minutes each
46010235|NCT00580619|Drug|methyldopa|Aldomet oral twice a day for 12 weeks
46096978|NCT04139694|Behavioral|Food plan without cinnamon supplementation|Cardiometabolic diet only
46096979|NCT02735603|Drug|Naltrexone HCl/bupropion HCl|Naltrexone HCl/bupropion HCl extended-release tablet.
46096980|NCT02735603|Other|Placebo|Naltrexone/bupropion placebo-matching tablets.
46096981|NCT02735603|Drug|Moxifloxacin|Moxifloxacin tablet.
45461774|NCT01172899|Procedure|laparoscopic adjustable gastric band|Laparoscopic gastric band placement. Combined lifestyle interventions will continue after surgery.
45461775|NCT01172899|Behavioral|Combined life style interventions|Control group will receive standard therapy consisting of combined lifestyle interventions.
45461776|NCT01171339|Other|Optimization strategy (complex intervention)|"Healthcare assistant (HCA) and computer assisted optimization of multi-medication (complex intervention) in accordance with recommended standard#~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
45461777|NCT01166815|Dietary Supplement|Zinc sulphate|Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
45837018|NCT00500448|Device|Electrical Stimulation|Electrical Stimulation (NMES) will be delivered 3 times per week for 4 weeks
46010236|NCT02217579|Dietary Supplement|Protein|A food containing 5 grams/serving of supplemental protein.
46010237|NCT02217579|Dietary Supplement|Prebiotic fiber|A food containing 8 grams/serving of supplemental prebiotic fiber.
46010238|NCT02217579|Dietary Supplement|Protein plus prebiotic fiber|A food containing supplemental protein (5 grams/serving) and prebiotic fiber (8 grams/serving).
46096982|NCT04152798|Procedure|Laparoscopic hiatal hernia repair with ProGrip™ mesh|Suturing of the right and left diaphragmatic crura using 3 to 4 interrupted nonabsorbable stitches with additional reinforcement of crura repair with ProGrip™ mesh
46096983|NCT04152798|Procedure|Laparoscopic primary posterior crural repair|Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable sutures
46010239|NCT02217579|Dietary Supplement|Control|An isocaloric food not containing the test protein and fiber.
46096984|NCT00685776|Drug|anacetrapib|Participants will receive one tablet of anacetrapib 100 mg once daily for 76 weeks.
46096985|NCT00685776|Drug|Comparator: placebo|Participants will receive one placebo tablet once daily for 76 weeks.
46096986|NCT02735291|Biological|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
46010240|NCT04554524|Drug|Chemotherapy+Pembrolizumab.|Eligible subjects will receive 4 cycles carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab. Response rate assessed by the site investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). After 4 cycles treatment, complete response subjects continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab up to disease progression, some of partial disease and stable disease subjects can receive surgical treatment. And then continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab up to disease progression, other partial disease and stable disease subjects cannot be removed by surgery will continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab for 4 cycles and then pembrolizumab or Normal Saline up to disease progression.
45461778|NCT01166815|Other|Placebo|Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
46010241|NCT04530084|Device|OMNI Surgical System|Scheduled for canaloplasty and trabeculotomy with or without cataract extraction
46096987|NCT00685854|Drug|Ranibizumab|
45461779|NCT03751657|Drug|Insulin icodec|Insulin 287 once weekly subcutaneous (s.c.) injections at the starting dose of 70 units. Dose adjustment was done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL)
46010242|NCT02212652|Dietary Supplement|Vitamin D|10,000 IU of VitD3 daily (one gel daily)
45461780|NCT03751657|Drug|Placebo (insulin 287)|Participants will receive once weekly s.c. injections of placebo equivalent to insulin 287.
45461781|NCT03751657|Drug|Metformin|Metformin is considered as non investigational medicinal product. Subject will continue metformin at stable pre-trial dose.
45461782|NCT03751657|Drug|Dipeptidyl peptidase-4 inhibitors|Dipeptidyl peptidase-4 inhibitors are considered as non investigational medicinal products. Subject will continue dipeptidyl peptidase-4 inhibitor at stable pre-trial dose.
45461783|NCT03751657|Drug|Insulin glargine|Insulin glargine (100 U/mL) once daily s.c. injections at the starting dose of 10 units. Dose adjustment will be done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL).
45461784|NCT03751657|Drug|Placebo (insulin glargine)|Participants will receive once daily s.c. injections of placebo equivalent to insulin glargine.
46096988|NCT04138368|Behavioral|dyadic psychotherapeutic intervention|Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity, using the principles of Interaction Guidance Therapy (Sameroff et al., 2004). Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant.
45461785|NCT02525809|Device|Novae E®|
46096989|NCT04138368|Behavioral|supportive intervention|Supportive therapy: mothers will receive psychoeducational knowledge regarding the infants' development. The treatment will be administered one time a week during the 8-week trial period, at the subjects' home.
45461786|NCT02525809|Device|Sunfit®|
45461787|NCT02525809|Device|Quartz®|
46096990|NCT04138290|Device|Predictix Antidepressant Software tool|Predictix Antidepressant is a stand-alone software tool based on a patients' genetic panel, clinical, demographic and behavioral inputs, intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with Major Depressive Disorder.
46096991|NCT04003207|Drug|Recombinant human Growth hormone|Subcutaneous growth hormone injections given once daily at a dose between 0.15mg/kg/week to 0.47 mg/kg/week titrated based on IGF-1 levels in serum for a duration of 12 weeks.
46096992|NCT04138446|Other|Altitude exposure in climate chamber|Altitude exposure in a climate chamber will consist of hypobaric hypoxia similar to the conditions found at 3000m asl and 5000m asl.
45461788|NCT03873415|Drug|BMS-986165|Oral administration
45461789|NCT01171495|Dietary Supplement|Theragran-M; Ensure Plus|Theragran-M: One tablet daily for 6-months. Ensure Plus: One 8 fl.oz. bottle daily for 6-months. Nutritional counselling: at baseline, and at monthly follow-up visits.
45461790|NCT01171495|Dietary Supplement|Theragran-M|Theragran-M: One tablet daily for 6-months. Nutritional counselling: at baseline and at monthly follow-up visits.
46010243|NCT02212652|Other|Placebo|Gummy button placebo, which will appear very similar to the vitamin D supplement.
46010244|NCT02212652|Other|Standard of Care|Patients will receive the standard care provided to all patients undergoing bariatric surgery regardless of research study participation status.
46010245|NCT02217657|Device|Thermocool Smart Touch Catheter|Physician informed to contact force
46010246|NCT02212769|Drug|Losartan 50mg|Losartan 50mg once daily for 7 days
46010247|NCT02212769|Drug|DW1029M 1200mg and Losartan 50mg|Losartan 50mg 1 Tablet once daily and DW1029M 300mg 2 Tablets b.i.d. for 7days
45461791|NCT00025259|Biological|Bleomycin Sulfate|Given IV or SC
45461792|NCT00025259|Drug|Cisplatin|Given IV
45461793|NCT00025259|Drug|Cyclophosphamide|Given IV
45461794|NCT00025259|Drug|Cytarabine|Given IV
45461795|NCT00025259|Drug|Dexamethasone|Given IV
45461796|NCT00025259|Drug|Doxorubicin Hydrochloride|Given IV
45461797|NCT00025259|Drug|Etoposide|Given IV
45461798|NCT00025259|Biological|Filgrastim|Given SC
45461799|NCT00025259|Radiation|Involved-Field Radiation Therapy|Undergo IFRT
45461800|NCT00025259|Drug|Prednisone|Given orally
45461801|NCT00025259|Drug|Vincristine Sulfate Liposome|Given IV
45461802|NCT01279135|Radiation|Conventional Radiation|Standard Pelvic Radiation 50 Gy/ 25 fractions over 5 weeks
45461803|NCT01279135|Radiation|Tomotherapy based IGRT|Patients in this arm will received Tomotherapy based Image Guided Intensity Modulated Radiotherapy to a dose of 50 Gy/25 fractions/5 weeks
45461804|NCT03866863|Other|Intrauterine growth restriction (IUGR)|Collection of number of patient's diagnosed with IUGR as defined in accordance with the consensus-based definition for early and late IUGR : birthweight < 3rd centile using French AUDIPOG curves adjusted for term and sex or estimated fetal weight < 10th centile combined with umbilical artery pulsatility index > 95th centile or breakage of growth.
45837019|NCT04749888|Behavioral|Targeted nurse-led home visiting|The KECHI encompasses 25-29 home visits, group activities, and community service linkage by social workers from the prenatal period until the child reaches the age of 2 years; as such, it is a complex intervention involving various domains to address a wide range of outcomes. Pregnant women with two or more risk factors who are deemed to have difficulties in raising children are eligible for the targeted multiple nurse home visits. Each home visit is implemented based on families' needs, and individualized interventions are provided to improve parenting and the home environment in order to promote the child's health and development and maternal health. The program includes educational materials for parents, such as a booklet covering issues on prenatal care, child development, postnatal child care, parent-child attachment, play, communication, safety, and goal-setting.
46010248|NCT02217696|Other|Computerized reading training|
46010249|NCT00580658|Device|Medtronic Activa Gpi|Activa Therapy, Gpi
46010250|NCT02217735|Behavioral|Writing Intervention|Participants wrote for 20 minutes on three occasions about an emotional or traumatic topic (expressive writing intervention condition) or what they did the day before, while refraining from including emotional details.
46096993|NCT04582435|Drug|Insulin Icodec|Participants will receive 1 dose from a prefilled pen, administered subcutaneously (under the skin), once a week by designated study staff, for a total of at least 8 and a maximum of 16 doses which equals 8-16 weeks of treatment.
46096994|NCT02735213|Device|577-MPL|9 spots multispot micropulse mode(without spacing between the spots),160 um spot size, 0.2 second duration, 5% duty cycle(ON time 0.1ms + OFF time 1.9ms), and 250~400 milliWatts of power(50% threshold power),150~200 spots, the laser area is the corresponding leakage on mid-phase FA and around leakage.
46096995|NCT02735213|Device|TLT|contimuous wave,100um spot size, 0.05 seconds duration, 55~60 milliwatts of power, 18~27 spots,the laser area is the corresponding leakage on mid-phase FA.
46096996|NCT05295355|Drug|Tiotropium Bromide Combined With Odaterol|2 puffs once daily at the same time of the day for 52 week
46096997|NCT02740673|Device|Driving simulator|Patients are asked to use a driving simulator to test their driving skills
46096998|NCT00873912|Biological|Monovalent influenza virus vaccine|Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10^7 FFU (fluorescent focus units) of the cold-adapted, attenuated, 6:2 reassortant influenza strain B/Brisbane/60/2008 (Victoria lineage).
46096999|NCT00873912|Biological|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.
46097000|NCT05628935|Procedure|peripheral nerve block|local anesthetic application to the brachial plexus
46010251|NCT02212808|Other|Antimicrobial restriction|All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm. Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial. The pharmacist will then decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario. The pharmacist will document this interaction in the REDCap database.
46010252|NCT02212808|Other|Post-antimicrobial prescription review|All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations. The interaction will be documented in the REDCap database.
46010253|NCT02217774|Device|MGUIDE MORE|MGUIDE MORE System (MGS), consisting of MGUIDE MORE software, MGUIDE MORE surgical kit and MGUIDE MORE template, will be used for planning, drilling and inserting dental implants.
46097001|NCT05408689|Device|T1 TENS|The subjects in Group A will received TENS (Burst mode, 9 pulses per burst, pulse frequency =160Hz, burst frequency=2Hz, intensity was set to trigger visible muscular twitches). Two 2 x 3 cm electrodes was attached on T1 level with 2 cm from the spine. Previous study has shown that it was effective to improve the cognitive function in subjects with Alzheimer's disease.
46097002|NCT05408689|Device|Concha TENS|The subjects in Group B will received TENS (25Hz, 0.5mA) on the concha of left outer ear. The electrical stimulation was generated by the portable neurostimulator (Nemos®, Cerbomed, Erlangen, Germany) and was delivered by a titanium electrodes positioning on top of a silicon earplug. Previous study has shown that it was effective to improve the Accelerate extinction memory formation and retention in healthy young adults.
46097003|NCT05408689|Device|Control|The subjects in Group C will receive 30 min sham electrical stimulation on T1 by a placebo-TENS device. The Placebo-TENS was applied by an apparently identical TENS unit. The unit's power indicator light was illuminated, but the unit's electrical circuit had been manually disconnected inside. In order to shape the common mindset, all subjects (except those in the Control group) were informed that they might or might not feel an electrical current, as different stimulation parameters were being applied.
45461805|NCT01171651|Drug|JX-594 followed by sorafenib|Patients will receive a total dose of 1e9 per treatment starting with one IV dose on Day 1 and injected intratumorally in 1-5 intrahepatic tumors on Day 8 and 22. Starting on Day 25 (3 days after the final JX-594 dose) patients will initiate oral sorafenib therapy twice daily according to standard approved guidelines. An optional maintenance JX-594 dose may be given intratumorally at Week 12 (sorafenib briefly interrupted).
45837020|NCT04750122|Drug|neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning|The choice of chemotherapy is based on the PTC drug sensitivity results.
45837021|NCT04749576|Dietary Supplement|saffron supplement for IBD|anti inflammatory effect
46010254|NCT02217852|Drug|Nitrendipine|doses used range from 10-20mg po bid. Total duration would be until completion or study or medication intolerance.
46010255|NCT02217852|Drug|Hydrochlorothiazide|doses used range from 12.5-25mg po qd. Total duration would be until completion or study or medication intolerance.
46010256|NCT02217852|Drug|Captopril,Hydrochlorothiazide|doses used range from 25-50mg po tid for captopril and 12.5-25mg po qd for hydrochlorothiazide. Total duration would be until completion or study or medication intolerance.
46010257|NCT02217852|Drug|Beijing hypotensive No.0|1 pile po qd or less. Total duration would be until completion or study or medication intolerance.
46097004|NCT03436979|Device|NeuGuide™ System|The NeuGuide™ device is indicated for anchoring sutures to ligaments of the pelvic floor.
46097005|NCT02740439|Other|Avocado|The intervention meals will contain 1 large avocado.
46097006|NCT02740439|Other|Control|The control meals will be isocaloric to the intervention meals but will not contain avocado.
46097007|NCT01564303|Drug|Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine|to evaluate the effect of the above agents on Kidney functioning parameters
46097008|NCT00674232|Drug|600 mcg misoprostol|single dose of misoprostol taken orally
46097009|NCT00674232|Procedure|Surgical treatment|Either dilation and curettage or manual vacuum aspiration, as per local protocol
46097010|NCT02740283|Behavioral|glycemic monitoring|
46097011|NCT02740283|Dietary Supplement|dietary guide|
46097012|NCT05359159|Other|Data collection|Data collection
46097013|NCT04031274|Device|TAVI|Trascatheter aortic valve implantation
45461806|NCT03866629|Drug|Lifitegrast|Lifitegrast ophthalmic solution 5%
46097014|NCT04031274|Device|TMVR/r|Transcatheter mitral valve replacement/repair
46097015|NCT02735135|Device|AIRSOFT DUO for 1 day|The patient is placed on an AIRSOFT DUO mattress for 1 day.
46097016|NCT02735135|Device|SENTRY 1200 for 1 month|The patient is placed on a SENTRY 1200 mattress for 1 month.
46097017|NCT02735135|Device|SENTRY 1200 for 1 day|The patient is placed on a SENTRY 1200 mattress for 1 day.
46097018|NCT02735135|Device|AIRSOFT DUO for 1 month|The patient is placed on an AIRSOFT DUO mattress for 1 month.
46097019|NCT05274997|Drug|YY-20394|Linperlisib is a strong and selective small-molecule PI3K-δ (a protein involves in the survival of cells) inhibitor, which is able to interfere with the growth, migration and survival of T/NK lymphoma cells.
46097020|NCT00674310|Drug|Ropinirole Hydrochloride|Restless Leg Syndrome
46097021|NCT02740361|Behavioral|Deprexis, DeprexisPlus|Online program Deprexis, either as a stand-alone internet-based intervention (Deprexis) or with added standardized email support by a clinical psychologist (DeprexisPlus). In this trial, we will use a Version of Deprexis that has been adapted to MS-specific needs.
45461807|NCT01171729|Biological|Autologous dendritic cell|Autologous dendritic cells pulsed with prostate cancer antigen and KLH
46097022|NCT04494841|Device|Duotherm VibraCool Back Device|Low back plate belt with mechanicothermal and pressure intervention options.
46097023|NCT00912522|Device|TMS|TRANSCRANIAL MAGNETIC STIMULATION
46097024|NCT02734901|Dietary Supplement|400 g frozen raspberries|1x daily intake of 600 mL red raspberry beverage
45461808|NCT01280071|Drug|aminophylline|
45461809|NCT02526199|Drug|Bupivacaine|Sciatic nerve block
45461810|NCT02526199|Drug|Epinephrine|Adjuvant to perinerual block
45461811|NCT02526199|Drug|Dexamethasone|Adjuvant to perinerual block
46010258|NCT02217930|Drug|WCK 2349|
46010259|NCT02217930|Drug|Placebo|
46010260|NCT02217930|Drug|Moxifloxacin|
46010261|NCT01121185|Biological|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous
46010262|NCT01121185|Other|0.9% Sodium chloride Placebo|0.9% sodium chloride, intravenous
46097025|NCT02734901|Dietary Supplement|200 g frozen raspberries|1x daily intake of 600 mL red raspberry beverage
46097026|NCT02734901|Dietary Supplement|Placebo|1x daily intake of 600 mL raspberry deprived supplement
46097027|NCT00686010|Drug|Placebo|Placebo tablet, 3 tablets, oral, once daily after breakfast
46097028|NCT00686010|Drug|JTT-705 300mg|JTT-705 tablet, 1 tablet, oral, once daily, after breakfast. Placebo tablet, 2 tablets, oral, once daily, after breakfast.
46097029|NCT00686010|Drug|JTT-705 600mg|JTT-705 tablet, 2 tablets, oral, once daily, after breakfast. Placebo tablet, 1 tablet, oral, once daily, after breakfast
46097030|NCT00686010|Drug|JTT-705 900mg|JTT-705 tablet, 3 tablets, oral, once daily, after breakfast
45837022|NCT00441558|Drug|Flibanserin|flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
46010263|NCT01121146|Device|Total Hip Replacement|Comparison of Marathon and Enduron polyethylene
46010264|NCT04529733|Device|IB10 sphingotest PCT+|Whole blood in EDTA for procalcitonin POC testing on IB10 sphingotest PCT+ device
46010265|NCT01120756|Behavioral|Goal-oriented attentional self-regulation|This will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). In brief, the GBSM training protocol is designed to maximize the potential for improving attention regulation skills and the goal-directed functions they support, applying mindfulness-based attention regulation training to practice in redirecting attention to goal-relevant processes especially in the context of distractions is emphasized throughout training. Participants are asked to identify realistic functional goals as feasible individual and group projects, and are then trained in goal management strategies on the functional task(s) of their choice.
46097031|NCT02739971|Behavioral|Low AGEs diet|Oral and written instructions on how to reduce AGEs in diet, mainly by changing cooking methods in addition to standard of care dietary guidance for type 2 diabetes
46097032|NCT02739971|Behavioral|Standard of care dietary guidance for Type 2 diabetes|Oral and written instructions for standard of care dietary guidance for type 2 diabetes
45837023|NCT01797276|Drug|Dichloroacetate|Subjects are given DCA 25mg/kg in a divided dose twice a day.
45837024|NCT00443352|Drug|duloxetine|Duloxetine: 120 mg. daily or maximum tolerated dose (minimum: 60 mg per day)
45837025|NCT00445302|Drug|plerixafor|Single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection
45837026|NCT00502944|Behavioral|Counselor-based HIV screening|Participants will undergo oral HIV screening by HIV counselor and, if positive, further study visits for up to 6 months
45837027|NCT00502944|Behavioral|Emergency staff member-based HIV screening|Participants will undergo oral HIV screening by emergency staff member and, if positive, further study visits for up to 6 months
45837028|NCT00504504|Drug|Rituximab|375 mg/m^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.
46010266|NCT01120756|Behavioral|Brain Health Education|Brain Health Education (EDU) will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education in health and brain injury in a classroom format, with study materials for homework.
46010267|NCT01120717|Drug|QVA149|capsules for inhalation, delivered by an SDDPI
46010268|NCT01120717|Drug|Placebo|capsules for inhalation, delivered by an SDDPI
46097033|NCT00674544|Behavioral|Lifestyle intervention|Kindergarten and homebased increases in physical activity, healthy nutrition, sleep duration and decrease in media use: Involvement of parents and siblings
46097034|NCT05265247|Drug|Esomeprazole 20 mg Delayed-Release Capsules|Esomeprazole 20 mg delayed-release capsules will be given as one capsule once daily as oral administration.
46097035|NCT05265247|Drug|Esomeprazole 20 mg Delayed-Release Capsules (Nexium 24HR)|Esomeprazole 20 mg delayed-release capsules (Nexium 24HR) will be given as one capsule once daily as oral administration.
46097036|NCT00686088|Drug|PRX302|Determination of the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate.
46097037|NCT03823300|Drug|Faricimab|Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
46010269|NCT04577846|Drug|Cephalexin 500 MG|Cefalexin 500 mg PO q8 hours will be continued for the duration of the indwelling drains which usually is about 14 days.
46010270|NCT04577846|Drug|Placebo|A placebo capsule filled with inert material for the duration of the drains which usually is about 14 days.
46010271|NCT04529811|Drug|Rifaximin Novel Formulation|Rifaximin Novel Formulation
46097038|NCT03823300|Drug|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
46097039|NCT03823300|Procedure|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatment arms at applicable visits to maintain masking.
46097040|NCT00686244|Other|Combined 3-monthly endurance and strength training|"Combined 3-monthly endurance- (3x/week) and strength training (2x/week) with moderate beginning and continuous increase of volume, duration and intensity, orientated on metabolic equivalents (MET).~Main sport: walking, walk and cycling. Addition with other activities are possible up to once a week to achieve the basal metabolism"
46097041|NCT00537745|Drug|Vivitrol (Medication Therapy)|Vivitrol 380 mg/monthly
45837029|NCT00504504|Drug|Adriamycin|25 mg/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
45837030|NCT00504504|Drug|Bleomycin|10 U/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
45837031|NCT00504504|Drug|Vinblastine|6 mg/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
45837032|NCT00504504|Drug|Dacarbazine (DTIC)|375 mg/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
45837033|NCT00504660|Drug|Capecitabine|Arms 1,3 = 825 mg/m^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m^2 PO Every 12 Hours on Day 11-24.
45679227|NCT05892094|Other|Resistance and Aerobic Training|For aerobic exercise, participants will do brisk walking 30 minutes in the first two weeks, 3-6. weeks will be 35 minutes, 7th and 8th weeks will be 40 minutes.The first and last 10 minutes of each walk will be said to be done at a slow pace, for the warm-up and cool-down periods. Participants will be called regularly to monitor their participation in the aerobic exercise program, and their compliance with the exercise will be checked, and they will be motivated to continue the exercises by providing the necessary information. Resistance exercises sessions will include five minutes of warm-up, forty minutes of resistance training and five minutes of cool-down. The training load will be provided by progressively increasing the repetitions. The Borg Scale will be used to adjust the exercise intensity. Rest time between sets will be 60 seconds.
45679228|NCT05892081|Biological|Colloidal oatmeal|The colloid oatmeal had the following component: Colloidal Oat (5gm), stearic acid 5, cretoctryl alcohol 2.5, cetyl alcohol 2.5, koh 02, potassium sorbate 1gm, paraffin oil 5ml, and soft paraffin 10gm
45679229|NCT05892081|Biological|Cold cream|It is composed of stearic acid 5, cretoctryl alcohol 2.5, cetyl alcohol 2.5, koh 02, potassium sorbate 1gm, paraffin oil 5ml, and soft paraffin 10gm
46010272|NCT04529811|Drug|Placebo|Placebo
46010273|NCT04554407|Device|SOMAVAC® 100 Sustained Vacuum System|The SOMAVAC® 100 is a battery operated device that delivers 100mm/Hg of continuous suction.
46097042|NCT00537745|Other|Medication Management Therapy|Medication Management Therapy once a month.
46097043|NCT00686322|Drug|Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)|Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
46097044|NCT05243095|Other|Computer assited, game-based cognitive training|"After recording the demographic information of the participants, the Stroop Test was applied to evaluate attention. After the stages of the test were explained to the participants in detail, they were shown once in practice.~The training group received 20 minutes of cognitive training every day for 8 weeks. No training was applied to the control group. Groups were evaluated at baseline and after 8 weeks."
46097045|NCT00686400|Other|TAU = treatment as usual|medication and psychosocial interventions to be chosen by treating psychiatrist
46097046|NCT04494061|Procedure|blood collection|Blood samples will be collected as per protocol defined schedule. There is no investigation drug in this study.
46010274|NCT02217969|Behavioral|Electronic alert to SLUScore increase|Treat hypotension to minimize further progression of the SLUScore
45679230|NCT05892068|Drug|Tucatinib|Standard dose of 300mg orally twice daily for 4 days prior to surgery (day -4 to 0).
45461812|NCT03866941|Behavioral|causes of abuse synthetic cannibinoids|Epidemiological data (age, sex, residence, occupation, route of abuse, the cause of abuse and smoking) (2) Symptoms and signs (seizures, psychosis, hallucinations) (3) Injuries and their relation to violence (type of wound, type of instrument, number of injuries, external or internal injuries and assailant or victim).
46010275|NCT02218047|Drug|Pegylated-Proline-interferon alpha-2b|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit [Hct]<45%, platelets [PLTs]<400 x 109/L and leukocytes [WBCs]<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
46010276|NCT02218047|Drug|Best available therapy (BAT)|Best available therapy as selected by the investigator
46010277|NCT00580814|Drug|Methylphenidate|Methylphenidate
46010278|NCT01120600|Drug|Odanacatib|One 50 mg tablet once weekly
46010279|NCT01120600|Drug|Placebo for Odanacatib|One 50 mg tablet once weekly
46010280|NCT01120600|Dietary Supplement|Vitamin D3|5600 IU of open-label Vitamin D3 once weekly
46010281|NCT01120600|Dietary Supplement|Calcium carbonate|Sufficient amount of open-label calcium carbonate so that daily calcium intake from both dietary and supplementary sources in approximately 1200 mg
46010282|NCT04529694|Other|Psychotherapy|
46010283|NCT04577885|Drug|SHR2554 and Rifampin|Single-dose oral administration of SHR2554 and multiple-dose oral administration of Rifampin Capsules
46010284|NCT02218086|Device|Slackline|Slackbase PRO CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
45461813|NCT01100957|Procedure|tracheal intubation with a single use flexible videoscope|tracheal intubation with a single use flexible videoscope
45461814|NCT03351738|Drug|MEDI5884|Participants will receive SC dose of MEDI5884 50 mg or 100 mg or 200 mg or 350 mg or 500 mg on Days 1, 31, and 61.
45461815|NCT03351738|Drug|Placebo|Participants will receive SC dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.
45461816|NCT01284595|Drug|[14C] AZD8931|Single 160 mg oral dose administered on Day 1
45679231|NCT05892055|Other|Procedure|All children will receive a functional magnetic resonance imaging (fMRI) scan, where they will complete some preliminary scans while completing two cognitive tasks, and then be removed from the scanner to complete a water loading symptom provocation task (WL-SPT). After the WL-SPT task, they will resume the fMRI scan and complete additional cognitive tasks to assess for diminished attentional regulation. Measures of pain intensity, pain unpleasantness, and state anxiety will be obtained throughout.
45679232|NCT05892042|Drug|Rivaroxaban 15 MG [Xarelto]|Eligible subjects randomized into experimental group will receive rivaroxaban 15mg daily in addition to dual anti platelet therapy unless confirmed resolution of the left ventricular thrombus.
45679233|NCT05892016|Procedure|Alveolar ridge preservation|grafted with bone particle and covered with a subepithelial connective tissue graft
46010285|NCT02218086|Device|Wobbling Board|Wobbling Board CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
46010286|NCT02218086|Device|Pre-training|First investigation of the beginners with less than 1 hour experience with slacklining.
46010287|NCT02218086|Device|Fix visual anchor|Professionals have to gaze at a fixed visual anchor during the slacklining.
46010288|NCT02218086|Device|Moving visual anchor|Professionals have to gaze at a moving visual anchor during the slacklining.
46010289|NCT02218086|Device|Post-training|Second investigation of the beginners occurs after a training session of 9 times 30 minutes within a few weeks.
46010290|NCT02218086|Device|Slackline vs. standing-on-1-leg vs. control|beginners have to train 9 times ~15minutes within y few weeks.
46010291|NCT04554251|Other|Survey|invited questionnaire
46010292|NCT01120210|Drug|JNJ-39588146 5 ng/kg/min|1-hour infusion of JNJ-39588146 5 ng/kg/min on Day 1
46010293|NCT01120210|Drug|JNJ-39588146 15 ng/kg/min|1-hour infusion of JNJ-39588146 15 ng/kg/min on Day 1
46010294|NCT01120210|Drug|JNJ-39588146 30 ng/kg/min|1-hour infusion of JNJ-39588146 30 ng/kg/min on Day 1
46010295|NCT01120210|Drug|Placebo|1-hour infusion of matching placebo on Day 1
46010296|NCT01120210|Drug|JNJ-39588146 5, 15, or 30 ng/kg/min|18-hour infusion of JNJ-39588146 or matching placebo on Day 1 immediately folllowing the 3-hour infusion at a dose equal to the maximum dose tolerated by that patient during the 3-hour infusion in Part 1 of the study.
46010297|NCT04554329|Procedure|bandage contact lens|bandage contact lens
46097047|NCT02734745|Device|flash glucose monitoring|Patients will use Freestyle Libre for 14 days at home, during this period they will have to perform at least 7 measurements of capillary blood glucose per day . Patients also will go to our clinical center on two separate occasions , to run a test breakfast. In one of the two occasions it will be specifically induced a moderate initial hyperglycemia and subsequent hypoglycemia . During the test meal and in the subsequent hours for a total of 6 hours , will be carried out frequent blood sampling for measurement of blood glucose using the Yellow Springs glucose analyzer ( YSI system ) , simultaneous measurements with Freestyle Libre and with glucometer.
46097048|NCT02734511|Drug|sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
46097049|NCT04003441|Drug|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
46097050|NCT04003441|Drug|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
46097051|NCT02695043|Behavioral|RRTBIMS|TBI patients discharged from Bellevue inpatient rehabilitation and enrolled in the Rusk Rehabilitation Traumatic Brain Injury Model System (RRTBIMS)
46097052|NCT02695043|Behavioral|Multimedia Multicultural Educational Program for TBI (MMEPT)|
46097053|NCT04380805|Biological|AK104|All subjects will receive AK104 as a single agent at a dose of 6 mg/kg Q2W (Day 1 and Day 15 of each 28 day treatment cycle) via IV infusion.
45461817|NCT01284049|Drug|Intralipid 20%®|Administration of Intralipid 20%® at a dose ranging between 0.5 and 1 g/kg/infusion during 12 weeks.
45679234|NCT05892016|Procedure|Alveolar ridge preservation|grafted with bone particle and covered with vascularized interpositional periosteal connective tissue graft
46010298|NCT02218125|Biological|MVA Mosaic|0.5 mL (1x10E8 pfu) MVA Mosaic (comprised of MVA Mosaic 1 and MVA Mosaic 2 mixed in a 1:1 ratio before administration) will be administered by intramuscular (IM) injection.
46010299|NCT02218125|Biological|Placebo|0.5 mL Sodium Chloride Injection USP, 0.9%will be administered by intramuscular (IM) injection.
46010300|NCT00580931|Drug|Nicotinamide|1500 mg twice a day for 6 months
46010301|NCT00580931|Drug|Enduramide placebo|1 tab twice a day
46010302|NCT02218281|Behavioral|C2Q-Teen app|Commit to Quit (C2Q)-Teen app provides smoking cessation assistance incorporating mindfulness training.
46010303|NCT02218281|Behavioral|NCI's QuitSTART app|NCI's smoking cessation app
46010304|NCT02218281|Behavioral|Written smoking cessation materials only|Receipt of written smoking cessation materials
46010305|NCT01120093|Drug|Aclidinium bromide 100 μg bid|Aclidinium bromide 100 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
46010306|NCT01120093|Drug|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
46010307|NCT01120093|Drug|Aclidininum bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
46010308|NCT01120093|Drug|Placebo|Placebo via inhalation in the morning and evening for 7 days
46010309|NCT01120093|Drug|Formoterol 12 μg bid|Formoterol 12 μg twice-daily via inhalation by Aerolizer® dry powder inhaler: 1 puff in the morning and evening for 7 days
46010310|NCT00581009|Other|chronobiological augmentation|Sleep deprivation for one night, Chronobiological augmentation consists of partial sleep phase advance for three nights and Light therapy for two hours for three days
46010311|NCT00581009|Drug|sertraline, lithium|"Antidepressant, Subjects will be started on a serotonin specific reuptake inhibitor (SSRI), sertraline 100 mg (50mg hs x 2) daily or other SSRI's such as Paxil 20 mg or Prozac 20 mg daily and continue treatment for seven weeks.~Mood stabilizer, subjects will be treated with lithium 450 mg twice a day or another mood stabilizer such as depakote or valproate and continue treatment for seven weeks."
46010312|NCT00581009|Radiation|one night of sleep deprivation and two FDG PET scans|MDD Mechanism Only depressed subjects will have two FDG PET scans consisting of a baseline FDG PET scan and a sleep deprived FDG PET scan. One night of regular sleep,one night of sleep deprivation and one night of recovery sleep for a total of four nights at a sleep laboratory facility.
46010313|NCT02218359|Drug|Amikacin Fosfomycin Inhalation Solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the AFIS Inline System
46010314|NCT02218359|Drug|Aerosolized placebo|Placebo twice daily for Days 1 -5 to be administered by aerosol using the eFlow Inline System.
46010315|NCT02218359|Drug|Amikacin Fosfomycin Inhalation Solution|Open-label crossover for all patients Days 6-10
46010316|NCT05147584|Device|Dual fetal oxygen sensors|Placement of both internal and external fetal oxygen sensors
46010317|NCT02882191|Drug|LevoCept|placement of LevoCept IUD
46010318|NCT02882035|Other|OFA|
45461818|NCT01284049|Drug|OMEGAVEN 10%®|OMEGAVEN 10%® will be used as the sole lipid supplement at a dose of 0.5 to 1.0 g/kg/Infusion with a maximum dose per infusion of 40 grams, in view of formulation constraints during 12 weeks.
46097054|NCT02739893|Procedure|Scope Guide Assist|"Olympus has developed a new instrument which provides physicians a real-time, three dimensional visualization of position and configuration during colonoscopy. The Olympus ScopeGuide technology has received FDA clearance and can be used within the United States. The new technology called the 'scopeguide' has been developed that uses magnetic coils embedded into the scope to create a 3 D image of the shape of the entire scope inside the body that is projected onto the monitor to see. This acts as a GPS and shows the advancement of the scope through bends providing information on loops and thereby eliminating chances of loop formation, helping in loop reduction and also reducing the number of external maneuvers that may be required for the completion of colonoscopy."
46097055|NCT02739893|Procedure|Standard procedure for colonoscopy|
46097056|NCT05408299|Biological|Covid vaccines (Moderna - Pfizer- Astra Zeneca- Johnson and Johnson - Sinopahrm)|Vaccination
46097057|NCT02739815|Drug|Normal Saline containing a prophylactic Antibiotic 1 g|500 ml of normal saline containing a prophylactic Antibiotic 1 g.
46097058|NCT02739815|Drug|Tranexamic Acid|Tranexamic acid
46097059|NCT01564225|Drug|EDI200|Cohort 1 will be dosed at 3 mg/kg/dose. Cohort 2 will be dosed at 10 mg/kg/dose. Both cohorts will receive 2 doses/week for a total of 5 doses.
46097060|NCT00720616|Drug|Norditropin|Norditropin 0.1 mg/day self-administered once a day subcutaneously
46097061|NCT04002739|Diagnostic Test|Polygraphy|Patients will perform polygraphy during the CCU stay (baseline) and, if found to have a diagnosis of Obstructive Sleep Apnea (OSA) syndrome, will complete the study with a follow-up visit at 90-day (follow-up). Diagnosis of OSA syndrome will require an Apnea / Hypopnea Index (AHI) more than 5 events per hour.
46097062|NCT02734121|Behavioral|pre-consultation educational group intervention|"Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.~Surgeon (40 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities~Registered nurse (20 mins): preparing for surgery, postoperative recovery and how to navigate the health care system~Social worker (30 mins): values clarification exercise~Breast reconstruction patient volunteers (30 mins) questions and answers about their personal experience"
46097063|NCT00720694|Device|Duolith SD1|
46097064|NCT00720694|Device|Sham Duolith SD1|
46097065|NCT05188105|Device|Alpha tACS (12 Hz) over the occipital cortex|Single session of alpha tACS (12 Hz) over the occipital cortex
46097066|NCT02739737|Other|Blinded manuscript|Blinded version of sham manuscript
45679235|NCT05892016|Procedure|Alveolar ridge preservation|grafted with bone particle and covered with a collagen membrane
45679236|NCT05892016|Procedure|Alveolar ridge preservation|grafted with bone particle and covered with a Cytoplast
46097067|NCT02739737|Other|Unblinded manuscript|Unblinded version of sham manuscript
46097068|NCT00720772|Drug|25% intravenous (IV) sodium thiosulfate|50 ml IV drip twice/week post hemodialysis
46097069|NCT02739425|Device|Sentimag Device|The programme will compare the Sentimag with the conventional sentinel lymph node detection with radioactive tracer combined with blue dye (in centres using the combined technique) and thereby determine whether the new technique is equivalent to the standard technique for SLNB
46097070|NCT05177965|Other|Exposure to shift work|Detailed questionnaire adapted from the Standard Shiftwork Index, measured at inclusion
46010319|NCT02212847|Other|vestibular stimulation|
46010320|NCT02218398|Drug|Albuterol|
46010321|NCT04554368|Procedure|intra-arterial contrast enhanced Flat Detector CT|After femoral artery puncture, FDCT scan (if necessary) and IA-CEFDCT scan were performed on a single flat-detector angiography system (Allura Xper FD20, Philips Medical systems, Best, the Netherlands), respectively. FDCT was acquired with the following acquisition parameters: 20s rotation, 220° rotation, 617 single frames at a frame rate of 30/s, 48cm detector field of view, 1024 acquisition matrix. Images were reconstructed using a soft-tissue kernel with an isotropic voxel size of 0.9 × 0.9 × 0.9 mm on a dedicated workstation for FPCT data (XperCT Dual 3.2.0). For image analysis, these isotropic FDCT data were viewed in the axial plane with 5 mm slice thickness.
46097071|NCT05170633|Device|Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)|70 random infant will receive the packed red blood cell transfusion with the Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)
46097072|NCT00720850|Drug|lenalidomide|p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT
45461819|NCT01284673|Other|in vitro characterization of the cord blood stem cell|The quantitative and qualitative, functional characterization will insist on cell populations which could potentially participate to neuronal regeneration. and assessment such characteristics in conditions of cryo-preservation, compared to fresh cell preparation
45461820|NCT03711084|Dietary Supplement|Natural high potency sweetener from leaf extract|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
46010322|NCT02218437|Drug|MSC+ATG|MSC+ATG:Starting dose was 0.5-1.0 × 106 cells /kg; And the maximum tolerated dose was 1 ×107 cells /kg after ATG application.
46010323|NCT04577768|Device|HD-tDCS 2 mA|anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 2 mA
46010324|NCT04577768|Device|HD-tDCS 1.5 mA|anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1.5 mA
46010325|NCT04577768|Device|HD-tDCS sham|sham stimulation of the right primary motor cortex
46010326|NCT02218515|Procedure|Open Flap Debridement|Open Flap Debridement (Control Group)
45461821|NCT03711084|Dietary Supplement|Glucose|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
45461822|NCT03711084|Dietary Supplement|Sucrose|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
45679237|NCT05892003|Other|Phase 1 Control|Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d). Fed to energy balance (1.5 x Resting Metabolic Rate, RMR).
45837034|NCT00504660|Drug|Celecoxib (Celebrex)|Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.
45837035|NCT00504660|Drug|Temozolomide|Arms 1,3 = 150 mg/m^2 PO Daily On Day 4-8.
45837036|NCT00504660|Drug|Lomustine|Arms 2,3 = 100 mg/m^2 PO on Day 4.
46010327|NCT02218515|Biological|EmdogainⓇ(Enamel Matrix Derivative)|Open Flap Debridement+Enamel Matrix Derivative
46010328|NCT02218515|Biological|EmdogainⓇEnamel Matrix Derivative+Autogenous Bone|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)+Autogenous Bone
46010329|NCT02218554|Genetic|BRONJ|collection of the blood sample from the subject for evaluation of the Micromedic BRONJ Risk Assessment in vitro Diagnostic Assay
46010330|NCT02218593|Device|WREX orthosis|Upper extremity exoskleton used to assist movement
45837037|NCT00504660|Drug|6-Thioguanine|Arms 1,2,3 = 80 mg/m^2 PO Every 6 Hours on Day 1-3.
45837038|NCT00505362|Procedure|Rectus closure|Reapproximation of the rectus muscles with three-interrupted sutures
46010331|NCT04577612|Drug|CHI-554|hemp-derived CBD in MCT oil
46010332|NCT02218671|Drug|WE 941 OD tablets|
46010333|NCT01119937|Drug|NVA237|50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)
46010334|NCT01119937|Drug|Tiotropium|18µg capsules for inhalation, delivered via HandiHaler®
46010335|NCT04554290|Diagnostic Test|temporal artery biopsy|description of temporal artery biopsy features, and its correlation with diagnosis of giant cell arteritis or other differential diagnoses.
46010336|NCT02278731|Other|training program|Participants were randomly allocated to 1 of 3 groups: Pilates group (n=20), which underwent one-month (three times per week) training program with the Pilates method; PNF group (n=20), that underwent one-month (three times per week) training program using the PNF method; and Control group (n=18), that received no intervention during that one month and continued with their daily activities.
46010337|NCT01119898|Drug|PENNSAID Gel|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
46010338|NCT01119898|Drug|Vehicle|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
46010339|NCT04577534|Drug|iv Tocillizumab (TCZ)|Participants are randomized (2:1) to receive TCZ or Standard of Care
46010340|NCT02278809|Behavioral|Movie Models|"The intervention group got acces to a private website for 4 weeks on which the online videos were placed (Week 1: fruit + water, week 2: vegetables + breakfast + supermarket, week 3: PA, week 4: SB)~After each week, parents received a link for an online process evaluation questionnaire in which we asked how many times they watched each video, if they discussed the videos with other people, if they found them interesting, boring…"
45461823|NCT03711084|Dietary Supplement|Maltodextrin|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
45461824|NCT03711084|Dietary Supplement|Water|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
46010341|NCT04553900|Diagnostic Test|Transesophageal Echocardiography|Placement of a transesophageal probe and performance of a diagnostic Transesophageal echocardiography examination.
45461825|NCT03863977|Drug|Dexamethasone|After the surgery, dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
45461826|NCT03863977|Drug|Bupivacaine|After the surgery,1mg/kg of 0.5% bupivacaine in the TAP block.
45461827|NCT05511012|Other|motion control fault tests|Patients make 6 motion control fault tests, in the same order. Each test is performed three times
45461828|NCT01171807|Drug|Dexamethasone 21-phosphate|6 monthly infusions of dexamethasone 21-phosphate loaded into autologous erythrocytes
45461829|NCT03866551|Device|Reprieve Cardiovascular System|The Reprieve Cardiovascular System (RCS) shall be utilized to maximize fluid removal over a maximum duration of 72 hours.
45461830|NCT05445648|Drug|Tislelizumab Injection|After patient recruitment, every patient first receives a regimen of tislelizumab injection 200 mg every time , q3w, 4 times in total. Then all patients, if operable, undergo TURBT. The first day after TURBT, patients again start to receives a regimen of tislelizumab Injection 200 mg every time , q3w, 4 times in total. Meanwhile, on the eighth day after TURBT, patients start to receive radiotherapy. The total radiation dosage is 50.4 Gy (patients receive radiotherapy 28 times, dosage being 1.8 Gy every time), with the total radiation dosage on pelvis area being 45 Gy and total radiation dosage on bladder area being 50.4 Gy.
45461831|NCT05445648|Procedure|Transurethral resection of bladder tumor|After the initial tislelizumab injection regimen, patients undergo clinical assessment and receive transurethral resection of bladder tumor if operable.
45461832|NCT05445648|Radiation|Adjuvant radiotherapy|On the eighth day after TURBT, patients start to receive radiotherapy. The total radiation dosage is 50.4 Gy (patients receive radiotherapy 28 times, dosage being 1.8 Gy every time), with the total radiation dosage on pelvis area being 45 Gy and total radiation dosage on bladder area being 50.4 Gy.
45837039|NCT00505518|Drug|Psychotropic medication (at discretion of psychiatrist)|Antidepressant medication, prescribed at discretion of psychiatrist
46097073|NCT02733965|Other|Pharmaceutical Consultations|"The first part of the pharmaceutical consultation focuses on a complete clinical medication review, the effective use of drugs will be discussed with the patient.~Study of health behaviors Concerning self-medication and alternative medicine Addictions Drug adherence List and grade (NCI version 4) of clinical signs and laboratory abnormalities The biological data will be obtained Clinical signs will be obtained from patient questioning The second part of the consultation is to achieve firstly a pharmaco-therapeutic analysis of the treatment in order to detect problems with drugs as classified by the French Society of Clinical Pharmacy The third step consists on providing pharmaceutical interventions following the pharmaco-therapeutic analysis (18).~These pharmaceutical interventions might concern the prescribers, the other caregivers, or the patient himself. T"
46010342|NCT02278848|Other|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)
45461833|NCT01171885|Drug|0.9% saline|20 ml of 0.9% saline
46010343|NCT01119859|Drug|Tocilizumab|The maximum dose was 800 mg for patients weighing more than 100 kg. Tocilizumab was infused into an arm vein over a 1-hour period.
46010344|NCT01119859|Drug|Adalimumab|
46010345|NCT01119859|Drug|Placebo to tocilizumab|
46010346|NCT01119859|Drug|Placebo to adalimumab|
46010347|NCT02278926|Other|Ultrasound|Ultrasound measurements
46010348|NCT02278926|Other|Tapping and body inspection to define the area of insulin injection|Obese patients with a thickening fat subcutaneous tissue that could have interfered with the interpreting and analyzing of the data are left out of this first study. In the control group we manage to define the lypo-hypertrophic area by tapping and body inspection
46097074|NCT02733965|Other|No Pharmaceutical Consultations|
45461834|NCT01171885|Drug|Ropivacaine|20 ml of Ropivacaine 0.25%.
45461835|NCT01171885|Drug|Ropivacaine|20 ml of Ropivacaine 0.5%.
45461836|NCT03711006|Other|Fecal Microbiota Transplantation Capsules|25 daily multi-donor FMT Capsules for 50 days
45461837|NCT03866395|Drug|Ivabradine|Ivabradine 5 mg twice a day
45461838|NCT01284751|Other|MDI - self-rating inventory|MDI with 12 questions to be completed approximately 1 week before surgery
45837040|NCT00505518|Behavioral|Collaborative psychiatric and primary medical care|Regular care visits from health workers
45837041|NCT00544674|Drug|PR104|administered at a dose of 1100 mg/m^2 by intravenous infusion over 1 hour and repeated every three weeks
46010349|NCT01119703|Biological|Tetanus & Diphtheria booster vaccine (Td)|Tetanus & Diphtheria booster vaccine (Td), single intramuscular dose
45461839|NCT05499702|Behavioral|Caloric Restriction|"Subjects will be instructed to consume a diet of 900 kcal daily using meals derived from Nutritional Guidelines after Bariatric Surgery. Compliance will be monitored by weekly meetings with the dietician using an electronic record of food intake"
46097075|NCT05166499|Dietary Supplement|Hydroxy Methyl Butyrate|Hydroxy Methyl Butyrate
46010350|NCT01119703|Biological|TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine]|TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine], intramuscular, two doses of standard three dose regimen (opposite arms)
46010351|NCT01119703|Biological|Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)|Dukoral® Traveler's Diarrhea Vaccine, recombinant Cholera toxin B subunit (WC/rBS), standard two oral doses per treatment regimen
46010352|NCT04554446|Procedure|T-MSAT(Motion style acupuncture treatment using traction)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. T-MSAT(Motion style acupuncture treatment using traction) is a kind of MSATs, and a treatment that improves musculoskeletal problems by pulling the patient's body through the device and giving instructions for walking while being acupuncture.
46097076|NCT05166499|Dietary Supplement|Balanced Amino Acids|Balanced Amino Acids
46097077|NCT00720928|Drug|flucinolone acetonide|Intra-vitreal implantation of RETISERT on the study eye. The implant is a sustained-release delivery system containing 0.59 mg of flucinolone acetonide designed to deliver the drug for approximately 3 years.
46097078|NCT03785158|Other|Liquid Melatonin|Melatonin is a natural supplement.
46097079|NCT03785158|Other|Placebo|Similar looking/tasting placebo syrup
45461840|NCT05499702|Drug|Hyperglycemic clamp|Hyperglycemic clamp to measure the effect of glucagon on hepatic metabolism
46097080|NCT05486585|Other|Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders|The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
46097081|NCT05116891|Drug|CAN04 (nadunolimab)|FULLY HUMANISED MONOCLONAL ANTIBODY AGAINST IL1RAP
46097082|NCT05116891|Drug|mFOLFOX|mFOLFOX/CAN04
46097083|NCT05116891|Drug|DTX|DTX/CAN04
45461841|NCT01286233|Drug|Metformin|
45461842|NCT01286233|Drug|Placebo|
45461843|NCT03351114|Drug|Crisaborole|Apply Crisaborole 2% ointment to affected skin twice per day.
45837042|NCT00544674|Other|F-18-fluoromisonidazole|administered intravenously prior to PET scan
45837043|NCT00544908|Drug|dasatinib|
45837044|NCT00544908|Other|immunoenzyme technique|
45837045|NCT00544908|Other|immunohistochemistry staining method|
46010353|NCT04554446|Procedure|Korean medicine treatment|acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
46010354|NCT02882074|Drug|Human albumin|human albumin 5% during surgery
46010355|NCT02882074|Drug|Hydroxyethyl starch|6% Hydroxyethyl starch 130/0.4 during surgery
46010356|NCT02218749|Other|Initially triaged to physiotherapist|
46010357|NCT02218749|Other|Initially triaged to physician|
46010358|NCT02882230|Drug|prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir|chemical dosage ARV
46010359|NCT00581087|Drug|DHEA treatment|DHEA : 200 mg/day hard gelatine capsule
46010360|NCT00581087|Drug|Placebo|Treatment : 200 mg/day hard gelatine capsule
46010361|NCT01119625|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, one dose
46010362|NCT01119625|Biological|Infanrix-IPV/Hib|Intramuscular injection, one dose
46097084|NCT05116891|Drug|G/C|G/C/CAN04
46097085|NCT02571868|Device|Optimization CRT-D|
45461844|NCT03711942|Procedure|Intra orifice barrier|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.3mm GP in the orifice was removed and intraorifice barrier and 2mm thick base was given of GIC.
46097086|NCT02739581|Procedure|Endoscopic Variceal Ligation|
46097087|NCT02739581|Drug|Non selective beta blocker|
46097088|NCT02739581|Other|Placebo|
46097089|NCT00721006|Biological|MESENDO|40 subcutaneous injections of biological product
46010363|NCT02218827|Drug|Loteprednol Etabonate (FML)|a steroid topical treatment used for moderate dry eye symptoms. this drug causes less increase in intra ocular pressure
45461845|NCT03711942|Procedure|Base|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.2mm thick Base of GIC was applied over the orifice before composite restoration
46097090|NCT00721006|Biological|Placebo|40 subcutaneous injections of placebo
46097091|NCT05111587|Other|Questionnaire|Participant must complete a questionnaire about injury during climbing practice in an artificial structure
46097092|NCT02733809|Drug|Sorafenib|Liver lesion biopsy (HCC) and blood samples will be taken from the subjects before starting the treatment course, and another biopsy and blood samples when they devolve a resistance.
46097093|NCT05109715|Procedure|Continued ventilation|Ventilation is continued from going on CPB until clamping of the ascending aorta with tidal volume 3ml/kg ideal body weight, Fraction of inspired oxygen (FiO2) 50%, respiratory rate 5/min and Inspiratory:Expiratory (I/E) ratio 1/2.
46097094|NCT05109715|Procedure|Discontinued ventilation|Ventilation is discontinued after going on CPB and lungs are exposed to atmospheric pressure
45461846|NCT03711942|Procedure|Control|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.coronal accees upto orifice was restored with composite resin
45461847|NCT03350256|Device|Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.|BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.
45461848|NCT03863899|Procedure|Nerve block|drug mixture: 10-15 ml 0.5% ropivacaine plus 5 ml 1% lidocaine plus 1 mg dexamethasone plus 50 ug adrenaline
45461849|NCT03863899|Procedure|Local infiltration|15-20 ml of mixture of 0.5% bupivacaine and 1% lidocaine (1:1)
45461850|NCT03863899|Procedure|TAVI|Insertion of an aortic valve prothesis through the aorta accessed through femoral artery
46097095|NCT00717184|Drug|Interleukin, NK cells|
46097096|NCT00717262|Drug|HQK-1001|HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.
45461851|NCT03863899|Drug|Additional intraoperative analgesia|Administration of any analgesics during the operation
45461852|NCT03863899|Drug|Additional postoperative analgesia|Administration of any analgesics within first 24 hours after the operation
45461853|NCT02525965|Procedure|Wide resection margin >1cm|Surgical removal of lesions choosing the method of wide resection margin >1cm
45461854|NCT02525965|Procedure|Narrow resection margin <1cm|Surgical removal of lesions choosing the method of wide resection margin <1cm
46010364|NCT00581126|Drug|Recombinant Factor IX Coagulation|Benefix IV each 12 hours for 2 a 5 days
46010365|NCT04553978|Drug|WD-1603|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
46010366|NCT02881918|Other|Blood sample|Blood sample with 6 tube of blood (40 mL), after diagnosis and before any specific anticancer treatment
46010367|NCT02881762|Drug|Maraviroc|Participants will receive 4 weeks of maraviroc (dosing based on concomitant HIV antiretroviral regimen). Serial measurements of HCV viral load will be obtained before, during, and after maraviroc exposure. Study duration will be approximately 12 to 16 weeks.
46010368|NCT02218905|Behavioral|Sit to stand test|Subjects will be asked to sit to stand in 40 inches chair for 60 seconds.
46010369|NCT04554017|Other|Education/Training|It consisted of a brief overview of hypertension, risk factors, complications and much emphasis placed on the preventive measures (what they include and why it is necessary to practice them).
46097097|NCT00717262|Drug|placebo|Matching placebo capsules administered once a day, orally, for 14 days.
46097098|NCT02695433|Dietary Supplement|Active|Active Treatment Diet Plan
46097099|NCT02695433|Dietary Supplement|Control|Control Diet Plan
46097100|NCT00717340|Drug|tivozanib (AV-951) + paclitaxel|"Tivozanib (AV-951):~Subjects in the Phase 1b study will receive 1 dose of tivozanib (AV-951) on Day -5 (± 2 days) for PK sampling prior to Cycle 1 only.~Thereafter in the Phase 1b and 2a study, subjects will receive tivozanib (AV-951) once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment (1 cycle = 4 weeks). On days when paclitaxel and tivozanib (AV-951) are co-administered, AV-951 will be administered immediately following the end of the paclitaxel infusion.~Paclitaxel: Phase 1b study and Phase 2a study:~All subjects will receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off (1 cycle = 4 weeks)."
46097101|NCT04189991|Device|Free 02|"With the manual oxygen titration, the physiotherapist adjust manually the oxygen flow using the FreeO2 device during a titration 6 minutes walk test.~With the automated adjustment oxygen titration, the flow will be self adjusted by the FreeO2 device during a titration 6 minutes walk test. In that hase, the median flow rate and the 95th flow rate will be evaluated during the validation 6 minutes walk test."
46010370|NCT04307017|Other|StimaWell®EMS|The StimaWell®EMS device is a 12-channel medium-frequency device with modulated low frequency using a high-tech stimulation suit for the trunk and strap electrodes for the arms and legs allowing whole-body stimulation. The device has 70 preprogramed training programs based on goals (e.g., strengthening, endurance training, aerobic training).
46097102|NCT05357287|Device|PREVENA incision management system|We will apply Prevena on the surgical wound right after closure of the wound in the operating theater. Prevena will be used for 7 days, unless there is ongoing infection or much wound drainage that requires debridement.
46097103|NCT02733887|Device|magnetic resonance imaging|MRI was performed on a 3 Tesla system (GE Discovery 750W). A single-shot,echo-planar imaging-based, spectral adiabatic inversion recovery DWI sequence was obtained with b values of 0,30,50,80,100,150,200,400,600,800 and 1,000.
46097104|NCT02733887|Device|positron emission tomography/computed tomography|18F-FDG-PET/CT was performed using a multidetector PET/CT system (GE Discovery ST16). Patients fasted for 6 hours before imaging.
46097105|NCT02733887|Radiation|fludeoxyglucose F 18|Patients fasted for 6 h before receiving FDG intravenously. A dose of 5.18-7.4 MBq/kg was used.
46097106|NCT04961047|Behavioral|Digital neurotherapy (DNT) Treatment|The experimental group will have 8 weeks of DNT 4 times a week for 30 minutes in the participant's home. The computer-presented training will be done on the participants' tablets or personal computers with the Rejuvenate brain training program
46097107|NCT04961047|Behavioral|Wait list control group|Waiting-list control group participants will be offered 8 weeks of DNT training at the completion of the final outcome assessment.
46097108|NCT00874848|Biological|Imprime PGG Injection|4 mg/kg i.v. over 2 hrs, weekly, in three week cycles
46097109|NCT00874848|Biological|Cetuximab|initial loading dose of 400 mg/m^2 over 120 min and subsequent doses at 250 mg/m^2 over 60 min, weekly on Days 1, 8 and 15 of each 3-week treatment cycle
46097110|NCT00874848|Drug|Paclitaxel|200 mg/m^2 i.v. over 3 hr on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
46097111|NCT00874848|Drug|Carboplatin|dose equal to an AUC of 6 mg/mL · min based on the Calvert formula; i.v. over 30 min on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
46097112|NCT02733575|Other|Compassion Focused Therapy|Up to 26 sessions of Compassion Focused Therapy
46097113|NCT02739503|Device|Ultrasound|Patients will receive ultrasound in the ultrasound unit at Hillel Yaffe Medical Center within 10 days before onset of induced or spontaneous labors. The ultrasound team has been trained in FHC , Estimated Fetal Weight (EFW) and Biparietal Diameter (BPD) measurement .Optimal ultrasound measurements of FHC and BPD will be obtained. The average of 3 fetal head circumference measurements will be recorded. Investigators consider the FHC and BPD to be optimal when a clear outline of the entire fetal skull is measured, and the landmarks (the thalamus, cavum septum pellucidum and choroid plexus in the atrium of the lateral ventricles) are visualized. Subsequent information of labor outcome as well as normal head circumference ,post-delivery will be obtained from maternal and neonatal medical records.
45461855|NCT03867877|Other|Periodized training with motor practice|Exercises at 75-80% of the subject's maximum for strength exercise using contractions with 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day with high-speed concentric and 2 second eccentric contractions, and exercises that simulate activities of daily living for the motor practice day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
45461856|NCT03867877|Other|Simple Periodized Training|Exercises at 75-80% of the subject's maximum for strength using contractions with 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day, with high speed concentric and 2 second eccentric contractions, and for hypertrophy day at 60-75% of subjects' maximum strength. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes exercise using contractions warm-up, 50 minutes of training and five minutes of cool-down.
45461857|NCT01175161|Device|Copper T380A Intrauterine Device|the Copper T380A IUD will be placed either 10 minutes to 48 hours postpartum, or 4-6 weeks postpartum.
45461858|NCT03863743|Other|integrated care pathway|Incidence of POUR after undergoing total hip or knee replacement and integrated care pathway will be evaluated.
45461859|NCT03863743|Other|physician's standard of care|Incidence of POUR will be evaluated in standard of care treatment.
46097114|NCT00691236|Drug|Zoledronic acid|4mg IV 3 weekly for 6 doses
46097115|NCT00691236|Drug|Standard chemotherapy|Adriamycin + Cisplatinum and Ifosfamide
45599117|NCT05634005|Behavioral|Clinical Decision Support|In blood product order entry within the electronic health record, the ordering provider is required to select an indication for the blood product order. If the patient's laboratory values are not in line with the guideline indication selected, a clinical decision support alert will fire and be shown to the ordering provider. This alert will inform the provider that the order is outside institutional guidelines and the provider has the option to cancel the order (or bypass the order and select a reason for proceeding with the order).
46097116|NCT04837729|Other|Acupressure|acupressure is a non-pharmacological method originating from traditional Chinese medicine. According to the National Cancer Institute, acupressure is defined as pressure / massage applied to certain parts of the body to control symptoms such as pain or nausea. The main purpose of acupressure is to stimulate the regions associated with the specific organ by applying pressure with energy channels called meridians.
46097117|NCT02733731|Drug|Chinese Herbal Compound Ointment|
46097118|NCT02733731|Drug|Estriol|
45461860|NCT01173289|Radiation|External Beam Radiotherapy|"Definition of target volume:~Gross tumor volume (GTV) = gross tumor defined with intravenous bolus contrast administration given CT scan~Clinical target volume (CTV) = GTV + included volumes of clinical and suspected subclinical involvement (draining lymph nodes)~Planning target volume (PTV) = CTV + 5-10 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~Total dose 65 Gy for gross tumor, 62.4 Gy for microscopic involved area, 58.5 Gy for high risk lymph node area and 52 Gy for elective lymph node area in 26 fractions during 6 weeks~Dose prescription: 90% isodose volume of prescribed dose encompassed PTV~The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the esophagus, lung, contralateral normal thyroid, arytenoids, vocal cord and spinal cord, etc., was calculated."
45461861|NCT01172041|Device|Real time position management system|Device to monitor respiration by using optical monitoring of a marker block placed on the abdomen of the patient.
45461862|NCT01172041|Device|LS PET/CT|PET/CT scanner for acquiring CT and PET images (3D and 4D)
46010371|NCT04561947|Procedure|Tunnel technique|After local anesthesia, the exposed root surfaces were mechanically treated with curettes. A tunnelling knives were used to prepare a split-thickness flap and create a continuous tunnel in the buccal soft tissues, following the intrasulcular incision with a #69 microblade. Split-thickness flap preparation was performed to beyond the mucogingival junction with supraperiosteal dissection by placing the tunneling knives to the soft tissue. This process was repeated by entering through the sulcus of each tooth. After the elevation of the flap, a papilla elevator placed under the flap was entered through the sulcus to mobilize the papilla, the periosteum at the base of the papilla was cut, and the full-thickness flap was elevated.
46010372|NCT04561947|Procedure|Connective tissue graft|CTG was harvested using the de-epithelialized connective tissue graft technique. The epithelial tissue on the outer surface of the graft was removed with a 15 blade and a 1-mm-thick graft was obtained.
46010373|NCT04561947|Other|Concentrated growth factor membrane|Intravenous blood samples were collected in without anticoagulant 10-mL tubes and immediately centrifuged in a CGF centrifuge machine using a program with the following features: 30 ̋ acceleration, 2 min at 2700 rpm, 4 min at 2400 rpm, 4 min at 2700 rpm, 3 min at 3000 rpm, and 36 ̋ deceleration and stop. After centrifugation, four layers were formed in the tube: the serum layer at the top, the second buffy coat layer, the third CGF layer containing GF and unipotent stem cells, and the red blood cell layer at the bottom. The resulting CGF was removed from the tube and separated from the red blood cell layer using microsurgical scissors.
46010374|NCT01119118|Drug|ZD4054|All patients will be treated with ZD4054 at 10 mg PO daily, repeated in four week cycles (1 cycle = 28 days). All patients will initially undergo NaF and FDG PET/CT and MRI imaging at baseline (scan#1), and then again after 4 weeks (scan#2) of ZD4054 exposure. Subsequently, ZD4054 will be held for 2 weeks followed by the final NaF and FDG-PET/CT and MRI acquisition (scan#3). After the final PET/MRI is obtained, patients will resume ZD4054 and be assessed for safety prior to each new cycle of therapy. Standard disease evaluation assessments will be conducted after cycle#3, and repeated after every third cycle (sooner if clinically indicated). Therapy will continue until radiographical/clinical disease progression or unacceptable toxicity
45461863|NCT01172041|Drug|18-FDG|15mCi
45461864|NCT02526121|Procedure|Phlebotomy|Volume of 400 mL every 3 weeks, 3 times.
45461865|NCT02526121|Behavioral|Dietary and lifestyle counseling.|Dietary and lifestyle counseling.
45461866|NCT01172119|Device|Biofreedom Drug Eluting Stent|Biofreedom DES with a standard dose of Biolimus A9TM
45461867|NCT01172119|Device|Biofreedom Drug Eluting Stent|Biofreedom DES with a low dose of Biolimus A9TM
45461868|NCT01172119|Device|Tuxus Liberte Drug Eluting Stent|Standard paclitaxel dose Taxus Liberte DES
45837046|NCT00544908|Other|laboratory biomarker analysis|
45461869|NCT01175239|Genetic|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
45461870|NCT01284205|Biological|Mycobacterial Cell-Wall DNA Complex|8 mg/50 mL (sterile WFI) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
45461871|NCT01284205|Biological|Bacillus Calmette-Guerin|mg/50 mL (sterile saline) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
45837047|NCT00544908|Procedure|quality-of-life assessment|
45461872|NCT03863665|Device|A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci|Telemetric home monitoring is a promising strategy to facilitate home BP monitoring after stroke, which should improve adherence and optimize medication to better control BP. Telemetry allows patients with hypertension to monitor their own BP and automatically send the information to a secure website, available to their clinicians to monitor and adjust their treatment.
45461873|NCT00024167|Drug|Docetaxel|75 mg/m2 intravenous piggyback (IVPB) over 1 hour, Day 1, every 3 weeks.
46010375|NCT04577339|Procedure|Laparotomy or laparoscopy|"Laparotomy is the opening of the abdominal cavity usually through a midline incision.~Laparoscopy is using minimal access keyhole surgery to perform the surgery instead of laparotomy Interventional radiology is the use of imaging to perform a procedure on the abdomen without surgery, for example, using ultrasound to guide a needle to drain an abscess Best supportive care is usually end-of-life care concentration on relieving symptoms rather than treating the cause."
46097119|NCT00691314|Device|Stent implantation (Wingspan, Coroflex, and TiTAN2)|"Stent Implantation:~Wingspan intracranial stent with Gateway PTA balloon Catheter; Coroflex&reg - balloon expandable stent system and Coroflex Blue - Coronary Stent System; TiTAN2 Bio-active coating stent~Standard Medical Management:including antiplatelet agents(Aspirin 75~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .~Arms: 1"
45679238|NCT05892003|Other|Phase 2 High Fibre Weight Loss|High Fibre Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) will be fixed at 20g/day for all kcal levels with additional fibre coming from the diet provided. The FOS will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
46097120|NCT00691314|Drug|Standard medical treatment|Standard Medical Management:including antiplatelet agents(Aspirin 75~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide)
46097121|NCT02739191|Device|PICO, Smith & Nephew|Direct application of negative pressure wound therapy following Foot and Ankle surgery
46097122|NCT04137978|Drug|ADV7103|Patients receive ADV7103 twice a day at optimal dose.
46097123|NCT04137978|Drug|Standard of Care|Cohort of patients with cystinuria, matching-pair for age category to the patients of ADV7103 Cohort, will receive their own alkalinising treatment (SoC) taken at the usual dose and frequency and will follow their usual first intention treatment (hydration and diet) for a 2-year-period.
46097124|NCT00578812|Device|Anterior Cervical Discectomy and Fusion (ACDF)|Anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
46010376|NCT05095948|Procedure|Discussion|Undergo audio recording of clinic conversations
46010377|NCT05095948|Other|Electronic Health Record Review|Review of medical records
45461874|NCT00024167|Drug|Doxorubicin hydrochloride|20 mg/m2 IV, day 1 on Weeks 1, 3, 5
45837048|NCT00447330|Drug|capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)|"Capecitabine will be administered orally at a twice daily dose of 850 mg/m2 (equivalent to a total daily dose of 1700 mg/m2) given days 1-14 of the three week cycle.~Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2-hour intravenous infusion on day 1 of a three week cycle.~Bevacizumab will be administered at a dose of 15 mg/kg given as a 30-90 minute intravenous infusion on day 1 of a three week cycle following the administration of oxaliplatin."
45461875|NCT00024167|Drug|Estramustine phosphate sodium|140 mg orally 3 x day, Days 1 through 7 on Weeks 2, 4, 6
45461876|NCT00024167|Drug|Ketoconazole|400 mg orally (po) 3 x day, Days 1 through 7
46010378|NCT05095948|Other|Questionnaire Administration|Complete questionnaires
46010379|NCT01119001|Device|P300 Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
46010380|NCT02212925|Drug|BI 14332 CL|
46010381|NCT02212925|Drug|Placebo|
46097125|NCT00578812|Device|PCM Cervical Disc|PCM Cervical Disc replacement in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
46097126|NCT05358769|Dietary Supplement|Incoxil food supplement and pelvic floor muscle exercise|"Incoxil supplement group receives standardized written and verbal instructions on how to perform PFME and are asked to perform the pelvic floor muscle exercises 3 times per day, with 15 repetitions per set, daily for 6 weeks. Women perform PFME at an intensity of at least 65-75% of one repetition maximum. (Repetition maximum load is the maximum weight or force an individual can exert in a single lift.) In addition participants receive Incoxil food supplement and take the supplement once a day.~Incoxil composition: creatine, l-leucine, zinc, calcium and magnesium. Incoxil is specifically designed to contain ingredients that help strengthen muscles during regular resistance training of moderate intensity."
45461877|NCT00024167|Drug|Prednisone|5 mg orally 2 x daily, weeks 1-14
45837049|NCT04388280|Diagnostic Test|Echocardiography|Functional assessment of coronary artery disease
45461878|NCT00024167|Drug|Vinblastine|4 mg/m2 IVPB, Day 1 on Weeks 2, 4, 6
45461879|NCT00024167|Radiation|Strontium chloride Sr 89|One dose (4 mCi total dose) IV
45679239|NCT05892003|Other|Phase 3 High Fibre and Non-Nutritive Sweetener Weight Loss|High Fibre and Non-Nutritive Sweetener Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) and non-nutritive sweetener (sucralose) will be fixed at 20g/day and 30mg/day respectively for all kcal levels with additional fibre coming from the diet provided. The FOS and sucralose will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
45837050|NCT04388280|Diagnostic Test|CT angiography|Anatomical assessment of coronary artery disease
45837051|NCT02115048|Drug|Letrozole|
45837052|NCT02115048|Drug|Afatinib|
45461880|NCT00024167|Drug|Dexamethasone|4 mg is given orally at 12 and 1 hours before and 12 hours after docetaxel.
45461881|NCT01173367|Other|Aggressive Fever Treatment|Patients assigned to the aggressive fever treatment protocol will receive acetaminophen 650 mg enterally every 6 hours for fever ≥ 38.3°C and external cooling will be initiated for temperatures ≥ 39.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 38.3°C and 39.5°C respectively.
45461882|NCT01173367|Other|Permissive Fever Treatment|Patients assigned to the permissive treatment strategy will not receive anti-pyretic therapy until the temperature reaches 40.0°C at which point they will receive acetaminophen 650mg every 6 hours. External cooling will be initiated for temperatures ≥ 40.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 40.0°C and 40.5°C respectively.
46010382|NCT01118962|Drug|Lacosamide|Lacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949). At the beginning of SP0962, the dose may be maintained, or increased or decreased by 100 mg /day, as deemed clinically appropriate to optimize tolerability and seizure reduction. Dose increases should be no faster than 100 mg/ day per week up to a maximum of 800 mg/ day. Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses for up to a 56-week Treatment Phase. The Treatment Phase was followed by a 5-week End-of-Study Phase, during which subjects had to be tapered off Lacosamide at a recommended decrease rate of 200 mg/ day per week.
46010383|NCT04561830|Procedure|laparoscopic-assited excision of mesorectum with pelvic lymph nodes excision|"We performed laparoscopic dissection of the lateral pelvic lymph node for thirty patients while we performed open lateral pelvic lymph node dissection for the remaining thirty patients.~Performed surgical approaches were abdominoperineal resection, internal sphincter resection, and low anterior resection. All performed surgical procedures included lateral pelvic lymphadenectomy in addition to performing total mesorectal excision.~Choosing whether to perform unilateral or bilateral lymphadenectomy depends on lymph nodes invasion by cancer was on one side or both sides."
45461883|NCT03867565|Other|Nutritional intervention|Indirect calorimetry Weight development Nitrogen balance Food records Physical activity Nutritional risk screening and assessment Inflammatory response Wound healing as number of days from burn to no more need of dressing changes via health care facility Frequency of infections as the number, sort, dose, and length of antibiotic treatment(s) from burn to no more need of dressing changes via health care facility
46010384|NCT00581165|Drug|Etanercept|recommended dose of enbrel is 25mg administered twice weekly.
46010385|NCT05362006|Device|Exopulse Mollii Suit|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate 40 groups of muscles.~This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more."
46010386|NCT05362006|Device|Exopulse Mollii suit (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
46097127|NCT05358769|Other|Pelvic floor muscle exercise|Group receives standardized written and verbal instructions on how to perform PFME and are asked to perform the pelvic floor muscle exercises 3 times per day, with 15 repetitions per set, daily for 6 weeks. Women perform PFME at an intensity of at least 65-75% of one repetition maximum. (Repetition maximum load is the maximum weight or force an individual can exert in a single lift.) In addition participants receive placebo food supplement to take once a day.
46097128|NCT02733497|Procedure|Sympathectomy|Resection of ganglia at T3 level
46097129|NCT02733497|Procedure|Sympathicotomy|Cutting of symptahetic chain at T3 level without ganglia excision
46097130|NCT05408065|Drug|Triamcinolone Hexacetonide and hyaluronic acid|infiltration under fluoroscopy
46097131|NCT05408065|Drug|Triamcinolone Hexacetonide|infiltration under fluoroscopy
45461884|NCT03867721|Device|Ventilator|Comparison of two ventilators for mouthpiece ventilation
45461885|NCT03867097|Drug|Placebo IV infusion|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
45461886|NCT03867097|Drug|Iloprost Injection, for intravenous use|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
46097132|NCT00691392|Drug|Linezolid|Linezolid 600 mg po daily for 16 weeks (112 doses) - over-encapsulated
46097133|NCT00691392|Drug|Microcrystalline Methylcellulose - Placebo|The placebo will be over-encapsulated microcrystalline methylcellulose
45837053|NCT00546156|Drug|Doxorubicin|Standard chemotherapy regimen
46010387|NCT05092984|Drug|Spironolactone|"77 patients will be treated with spironolactone Mylan 25mg/day for the first 3 months of the study. Dosage adjustment can be performed according to the eGFR (estimated Glomerular Filtration Rate) concentration at baseline and the serum potassium variation.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation."
45461887|NCT01286389|Other|medical care|Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)
46010388|NCT05092984|Drug|Placebo|"77 patients will be treated with placebo 25mg/day for the first 3 months. At inclusion, a second randomization is automatically performed in the placebo arm to determine patients receiving a dose adjustment during the study to keep the double-blind.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation."
45679240|NCT05891990|Procedure|immediate implant augmented with sticky tooth|"Topical anesthesia will be administered using an infiltration technique.~Atraumatic extraction will be done with the aid of periotome and Luxators.~The extraction socket will be debrided to remove any residual debris or granulation tissue.~Full-thickness midcrestal incision and vertical releasing incision on the distal side will be made, and a vertical releasing incision on the mesial side will be made if necessary. The extraction socket and the labial bone defect will be exposed by buccal and palatal flap reflection.~Implant insertion will be performed according to the manufacturer's instruction, and then the implant will be inserted 2mm apical to the alveolar bone crest with adequate primary stability.~The gap between the implant and the defect of the facial bone will be filled with the sticky tooth to reach enough buccal bone supported and then will be covered with absorbable barrier collagen membranes.~Finally, the flap will be repositioned and sutured."
46010389|NCT02218944|Behavioral|Response Inhibition Training|The primary purpose of this research is to examine the feasibility and efficacy of a smoking specific response inhibition training program in the context of a quit attempt. The task is based on a modified stop-signal task. The study utilizes a one-way nested design with three conditions.
46010390|NCT01118728|Drug|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
46010391|NCT02218983|Device|Limited Transthoracic Echocardiogram (LTTE, SonoSite Ultrasound)|
46097134|NCT02738957|Behavioral|Prenatal Counseling Group|"Specific counseling on breastfeeding consisting of three different counseling sessions during prenatal visits given by one of the two midwives involved in the study. The information provided include the following: breastfeeding importance; how to prepare the nipples and breast for breastfeeding; the main complications and difficulties during the breastfeeding process and how to identify and overcome them; breastfeeding techniques and alternative positions for the simultaneous breastfeeding of twins, for example, double cradle, cradle-football or double-football, using illustrations and hands-on demonstration with doll models."
46010392|NCT02218983|Other|Usual care|
45461888|NCT01286389|Behavioral|caloric restriction|Nutritional guidance: through at least 2 individual assistance and group sessions, lasting 1 hour, weekly for 4 months, and biweekly for 2 months and monthly thereafter (26-28 meetings/1year).The diet plan will recommend a deficit from 500 to 750 kcal/day in order to promote loss of about 0.5kg/week, containing 1g/kg of protein per day (minimum 1200kcal/day), high in fiber, vegetables and whole foods. The goal of weight loss will be 10% of initial weight. Group activities consist of lectures on nutrition education, food composition and its importance to health, food preparation techniques, self-monitoring weight, eating behavior and count calories.
45461889|NCT03863275|Device|functional apparatus|The EMG activity will be recorded during different shots: T0. The activity of the muscles of the mastication in the position of clinical rest for a minute, in maximum intercuspidation. (It will be measured with a dynamometer to standardize the force), and with the use of the equipment. T1 The patient's citation is scheduled six months after the use of myofunctional device Sn1 and the test will be performed again measuring electrical activity of right and left masseter and right and left temporal muscle at clinical rest for one minute, in maximum intercuspation, and with the use of the equipment To avoid the effects of fatigue, a rest period of at least 5 minutes between each of the recordings will be allowed
45461890|NCT03863275|Other|Diagnosis and observation|Six months of observation in the control group: patients group the efforts are controlled. to obtain models and have an observation of the molar classification, and to verify if the terms of the inclusion in the study are taken into account, once it is confirmed that the activity is observed in the muscular activity of the chewing muscles, in two stages , at the beginning of the session and six months later. .
45461891|NCT00022763|Drug|Enfuvirtide|
46010393|NCT02219022|Other|Control group|
46010394|NCT02219022|Other|Experimental group|
46010395|NCT02213159|Drug|Dexmedetomidine|
46010396|NCT02213159|Drug|Morphine|
46010397|NCT00581282|Radiation|PET scan|positron emission tomography PET scan
46010398|NCT00581282|Other|fMRI|functional magnetic resonance imaging fMRI
46010399|NCT01118455|Device|Vagus Nerve Stimulation (VNS) Therapy|Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
46010400|NCT01118455|Drug|Anti-Epileptic Drug (AED)|Subject has tried at least 2 appropriate AEDs tested to tolerance or to blood levels at upper end of the target range of which at least 2 had been tolerated at normal doses.
46010401|NCT02219100|Drug|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone
46010402|NCT04553861|Device|Ambulatory blood pressure monitoring|Every 30 minutes from 7 AM to 10 PM and every 1 hour from 10 PM to 7 AM
45461892|NCT03867253|Drug|ORY-2001 Low dose|0.6mg ORY-2001 capsule
45461893|NCT03867253|Drug|ORY-2001 High dose|1.2mg ORY-2001 capsule
45461894|NCT03867253|Drug|Placebo|Placebo capsule
45461895|NCT03866317|Drug|Secukinumab|All subjects will receive secukinumab 300 mg injections subcutaneously at week 0, 1, 2, 3, 4, then every 4 weeks until week 12.
45461896|NCT03866005|Dietary Supplement|Diabetes Visual Function Study (DiVFuSS) softgels|The adjunctive nutritional supplement will be the multi-component formula used in the Diabetes Visual Function Supplement Study (Western IRB number 1129944 Olympia, WA), containing the macular carotenoids lutein and zeaxanthin, as well as antioxidants (vitamins B1, B12, C, D, E, lipoic acid, coenzyme Q10, resveratrol), omega3 fatty acids (EPA/DHA) and botanical extracts (Pycnogenol™ [patented extract of French maritime pine bark, Pinus pinaster], grape seed and green tea extracts, curcumin).
45461897|NCT03866005|Other|canola oil placebo softgels, 2 per day|Placebo containing canola oil, 2 softgels per day
45599118|NCT02233361|Behavioral|Counseling|A randomized controlled design will determine whether hearing aid users who are informed in advance of a follow-up appointment have a different pattern of hearing aid use than a control group that is not preinformed in advance.
46010403|NCT04553861|Device|Galaxy Watch Active2|Every 1 hour by subject (on-demand) from 7 AM to 10 PM and every 5 minutes (automatic) from 10 PM to 7 AM
46010404|NCT02219139|Device|ESTA abutment Roxolid|Enhanced Soft Tissue Attachment surface on Roxolid or machined surface on Roxolid abutment placement.
46010405|NCT04561752|Drug|ZN-c5|ZN-c5 is the study drug.
46010406|NCT01118377|Drug|Capecitabine|Capecitabine was supplied as film-coated tablets.
46010407|NCT01118377|Radiation|Radiation therapy|Local irradiation using conformal, volume-based delivery techniques. The nominal energy of the X-rays was ≥ 4 MV.
45683820|NCT04746118|Behavioral|DIET CHANGE|Nutritional supervision will be carried out individually based on the Food Guide for the Brazilian Population, ensuring an accessible, hygienic and contextualized diet according to the subject's culture and physiology. The protocol includes an initial assessment to define the meal plan and individual reassessments every four weeks. In the first evaluation participants will receive an eating plan with a 20% reduction in the total calories consumed or even the equivalent of their daily energy needs with a distribution of macronutrients comprised of 65% carbohydrate, 15% protein and 20% fat. The intention is to promote a reduction in weekly consumption by about 2000 kilocalories (Kcal). The prescription and diet control plan will include and be conducted by a team coordinated by a clinical nutritionist.
46010408|NCT04561323|Diagnostic Test|Dual-energy CT|"Patients suspected of acute bowel ischemia will be scanned in the dual-energy CT scanner.~The abdominal imaging protocols are predetermined by the Department of Diagnostic Radiology, Righospitalet, Denmark."
46010409|NCT05087875|Behavioral|TRAC: Tracking and Reducing Alcohol Consumption|The TRAC intervention focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. Participants set goals for reducing their drinking and learn strategies to help them achieve those goals. It requires four 30-minute sessions with a counselor using mobile phones.
46097135|NCT00717496|Other|Telephone Support Intervention to Improve Breastfeeding|The intervention will consist of outreach telephone calls daily by bilingual trained nursing staff for the first 2 weeks postpartum using the scripted protocols developed for this program. Both groups will receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream. The intervention nurse will ask the mothers on their initial intake call for the best time to call each day to minimize time needed to reach the mother.
46097136|NCT05407831|Genetic|Genetic|Calculate MODY probability
46097137|NCT05407831|Behavioral|Social habits|Alcohol vs Smoking vs Drug use
46010410|NCT05087875|Other|No intervention|The comparison group will be evaluated based on daily self-monitoring data.
46010411|NCT04577222|Procedure|Technical modification during radical prostatectomy|Covering the NVB with fat
46010412|NCT02219178|Drug|lenalidomide|25mg days 1 - 14 of 21 day schedule
46010413|NCT02219178|Drug|Subcutaneous bortezomib|1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule
46010414|NCT02219178|Drug|Dexamethasone|20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
46010415|NCT02213315|Drug|100mg Mavrilimumab|100mg Mavrilimumab
46010416|NCT02213315|Drug|150mg mavrilimumab|150mg mavrilmumab
46097138|NCT05407831|Other|Perinatal stress|Survey
46097139|NCT02625168|Drug|Afatinib|Afatinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
46097140|NCT02625168|Drug|Erlotinib|Erlotinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
46010417|NCT02213315|Other|Placebo|Placebo
45461898|NCT01285063|Other|Multidisciplinary intervention: physical activity, dietary instructions and behavioral treatment.|"3 months intervention. Nutritious plan: includes 6 meetings of the child and his or her parents with a dietician from the center.~Physical activity: physical trainings of 60 minutes each will be held twice a week.~behavioral treatment: all the participants will take part it a 45 minutes meeting of movement therapy once a week. The goal of such meeting is to strengthen nutritious and physical activity habits and to assimilate positive change in the participants' lifestyle."
45461899|NCT01285141|Biological|CN54gp140 glycoprotein-hsp70 conjugate vaccine|CN54gp140-hsp70 conjugate vaccine administered intravaginally 3 times over a 12-week period
46097141|NCT02738723|Radiation|SBRT|40 Gy for each patient. Patients receiving once-daily therapy ,4 Gy daily in 10 treatments over a period of two weeks.
46097142|NCT02738723|Radiation|IMRT|45 Gy for each patient，Accelerated twice-daily thoracic radiotherapy involved the administration of 1.5 Gy in 30 treatments over a period of three weeks.
46097143|NCT02738723|Drug|EP|Etoposide 75mg/m2/iv over 90min through day 1 to day 4 and cisplatin 25mg/m2/iv over 30min through day 1 to day 3, repeat Q 3weeks. Continuous administration to six cycles or to disease progression, unacceptable toxicity or patients' refusal.
46097144|NCT00717730|Dietary Supplement|Folic Acid|150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months.
46097145|NCT00717730|Dietary Supplement|Vitamin B12|1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
46097146|NCT00717730|Dietary Supplement|Placebo|Placebo with no active ingredients
46097147|NCT00717730|Dietary Supplement|Folic acid and vitamin B12|Folic acid 150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months vitamin B12 1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
46097148|NCT05407753|Dietary Supplement|Ketone ester|Subjects receive the ketone ester at the following timepoints: 25g before ultrarun, 12.5g every 30 min during race, 25g immediately after race, 25g before sleep, 3 x 25g on day after race.
46097149|NCT05407753|Dietary Supplement|Placebo|Subjects receive a non-caloric taste-matched placebo (water with sucrose octaacetate)
46097150|NCT00691470|Drug|ATI-5923|Dose Adjusted based on INR.
46097151|NCT00691470|Drug|Coumadin (warfarin)|Dose adjusted based on INR.
46097152|NCT05628701|Procedure|Ileorectal anastomosis (IRA)|After subtotal colectomy for ulcerative colitis the patients can either keep their end ileostomy or be reconstructed with an anastomosis (connection) between the ileum and the rectal remnant (Ileorectal anastomosis(IRA))
45461900|NCT01286467|Drug|PF-04449913|Escalating dose of PF-04449913 administered as tablets PO QD in 28-day cycles
45461901|NCT03867331|Biological|5 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
45461902|NCT03867331|Biological|15 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
45837054|NCT00546156|Drug|Cyclophosphamide|Standard chemotherapy regimen
46010418|NCT02219217|Drug|Dolutegravir, Elvitegravir and Cobicistat|
46097153|NCT05628701|Procedure|Ileal pouch anal anastomosis (IPAA)|The rectum is removed and a pouch constructed with the distal part opf the ileum which in subsequently anastomosed (connected) to the anus(Ileal pouch anal anastomosis (IPAA)).
46097154|NCT05628701|Procedure|ileostomy|no reconstruction is performed and the patient is left with his/her ileostomy
46097155|NCT05407597|Drug|Icatibant|"Solution for injection, 30mg (3mls) administered as a single subcutaneous injection~SARS CoV-2 patients will receive all supportive treatment and medications that are used as standard of care including but not limited to Dexamethasone, Remdesivir, Tocilizumab and antibiotics."
46097156|NCT05407597|Drug|0.9% Sodium Chloride Injection|"Solution for injection (3mls) administered as a single subcutaneous injection~SARS CoV-2 patients will receive all supportive treatment and medications that are used as standard of care including but not limited to Dexamethasone, Remdesivir, Tocilizumab and antibiotics."
46097157|NCT04069390|Device|CARDIOSKIN - Short record|A short record (max 2H15) is performed with Cardioskin
46097158|NCT04069390|Device|Cardioskin - long record|A long record (max 8H) is performed with Cardioskin
46097159|NCT04069390|Device|Neuronaute - long record|A long record (max 8H) is performed with Neuronaute
46097160|NCT04069390|Device|Neuronaute -short record|A short record (max 2H15) is performed with Neuronaute
45461903|NCT03867331|Biological|30 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
45461904|NCT03867331|Other|Plasmodium falciparum challenge|Expose forearms to five (5) Plasmodium falciparum (strain NF54; clone 3D7) bites
45837055|NCT00546156|Drug|Paclitaxel|Standard chemotherapy regimen
46010419|NCT02213393|Dietary Supplement|Protein enriched products|The intervention group receives CwC protein enriched products. After discharge the intervention group receives CwC products delivered at home for 12 weeks.
46010420|NCT02213393|Dietary Supplement|Usual menu|The control group receives the usual menu, which is energy and protein rich in this elderly patient group. After discharge the control group receives regular products, no protein enrichment, at home for 12 weeks.
45679241|NCT05891990|Procedure|immediate implant augmented with autogenous tooth graft|"Topical anesthesia will be administered using an infiltration technique.~Atraumatic extraction will be done with the aid of periotome and Luxators.~The extraction socket will be debrided to remove any residual debris or granulation tissue.~Full-thickness midcrestal incision and vertical releasing incision on the distal side will be made, and a vertical releasing incision on the mesial side will be made if necessary. The extraction socket and the labial bone defect will be exposed by buccal and palatal flap reflection.~Implant insertion will be performed according to the manufacturer's instruction, and then the implant will be inserted 2mm apical to the alveolar bone crest with adequate primary stability.~The gap between the implant and the defect of the facial bone will be filled with the autogenous demineralized dentin graft to reach enough buccal bone supported and then will be covered with collagen membranes.~Finally, the flap will be repositioned and sutured."
45679242|NCT05891977|Other|Intervention A - Tomato paste|Participants will consume a daily amount of 0.5 g of tomato paste / kg of body weight plus the regular diet
46097161|NCT05407207|Device|Tennant Biomodulator ®|Tennant Biomodulator ® (Avazzia, Inc., Texas, USA)(FDA Classification: 882.5890 Neurology, Biofeedback device) is FDA-cleared for symptomatic relief and management of chronic pain. The device is simply activated using device buttons and does not need to be adjusted or monitored once therapy begins, making it easy for the purpose of therapy under unsupervised conditions or for use in busy HD clinics. The device will be used with FDA-cleared TENS electrodes that will be connected to the device via wires, providing an electrically conductive interface between the device and the subject's skin.
46010421|NCT04577378|Drug|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole|After randomization, erosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Aerosolized Itraconazole 5mg per day for 14 days
45679243|NCT05891977|Other|Intervention B - Control|Participants will consume only their regular diet, avoiding the consumption of tomato or tomato-based products
46097162|NCT02738021|Behavioral|STRONG|A brief 3-session IPT-based preventive intervention, on maternal and child health outcomes.
46010422|NCT04577378|Drug|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid)|Drug: Aerosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
46097163|NCT02574208|Procedure|HIV testing by ELISA|HIV testing randomized between ELISA or rapid test
46097164|NCT02574208|Procedure|HIV testing by rapid test|HIV testing randomized between ELISA or rapid test
46097165|NCT05493995|Drug|Penpulimab|Penpulimab 200 mg administered intravenously every 3 weeks.
46010423|NCT02211573|Other|Exercise, Aerobic (Water based)|Patients of this group were submitted to an aerobic water based physical training
46097166|NCT05493995|Drug|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
45679244|NCT05891964|Drug|Secukinumab Injection|Injection Secukinumab 150mg subcutaneously will be administered at weeks 0, 1, 2, 3, 4, and then monthly for 5 months.
45679245|NCT05891938|Other|H2 gas inhalation|H2 gas inhalation treatment for 4 weeks in on community dwelling adults of various ages
45837056|NCT00546156|Drug|Bevacizumab|One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.
45837057|NCT00449046|Drug|GW815SF Salmeterol/Fluticasone propionate(HFA MDI)|
45837058|NCT00449748|Drug|RAD001 (Everolimus)|Oral RAD001 10 mg daily for 30 days
45837059|NCT00508716|Behavioral|Health Literacy-Tailored Education|Intervention group receives a visit from a nurse educator who, using the teach back method of educating patients, provides counseling on their disease methods of controlling their disease. A video is also viewed to reinforce the materials.
45837060|NCT00509496|Drug|fludarabine phosphate|25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days.
45837061|NCT00509496|Drug|cyclophosphamide|60 mg/kg/day x 2 days intravenous
45837062|NCT00509496|Biological|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
46097167|NCT05493995|Drug|Nab paclitaxel|125mg/m^2，administered intravenously on days 1 and 8 of every 21-day cycle.
46097168|NCT05493995|Drug|Gemcitabine|1.0g/m^2, administered intravenously on days 1 and 8 of every 21-day cycle.
46097169|NCT00717808|Drug|Tranilast|Tranilast (300mg twice a day) for a period of seven days whilst taking their weekly prescribed dose of methotrexate. Followed by a 7 day washout period before starting arm 2
46097170|NCT00717808|Drug|Placebo comparator|The patient will receive the placebo capsule twice a day whilst receiving their weekly dose of methotrexate
46097171|NCT02738177|Drug|Misoprostol|2 tablets of misoprostol (i.e. 400 ug) 4 hrs prior to surgical evacuation high up in the posterior fornix (misoprostol group)
46097172|NCT02738177|Drug|Isosorbide-5-mononitrate|2 tablets of Effox (i.e. 40 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (effox group)
45837063|NCT00509496|Biological|autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes|"Patients will receive a minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL .~The cells are infused intravenously over 20-30 minutes."
46010424|NCT04553627|Device|ZELTIQ thermoelectric device|This is a feasibility study to determine if cryolipolysis in this area produces a desirable lifted appearance to the buttocks. Typically, a lifted more youthful appearance is obtained through surgical means. Study participants will be recruited from the population of patients who have suitable, treatable subcutaneous fat on the medial infragluteal folds and desire a lifted appearance. Subjects will receive treatments with a cooled cup cryolipolysis applicator from the CoolAdvantage family of applicators (cooled cup vacuum applicator). Treatments will be performed with a treatment temperature of - 11°C for up to 35 minutes. Subjects will complete all study-required follow-up visits, including an 8-week follow-up which may include a second treatment session, as well as a 12-week post final treatment follow-up visit
46010425|NCT02219412|Drug|ticagrelor|90 mg bid for 2 weeks
46010426|NCT02219412|Drug|Aspirin|100mg Qd for 2 weeks.
46010427|NCT04577027|Drug|Topical travoprost 0.004% solution|30 Patches treated with Topical Travoprost 0.004% solution: Topical travoprost 0.004% solution once daily (1 drop for each 2.5 x 2.5 cm2) for 3 months.
46010428|NCT04577027|Device|Fractional CO2 laser|30 Patches treated with Fractional CO2 laser: Fractional CO2 laser sessions twice monthly for 3 months, parameters settings as follows: Energy\ dot 100mj, pulse duration 5ms, density level 17, pattern: array, depth level 1, 2 passes used
46010429|NCT04577027|Device|Excimer laser|30 Patches treated with Excimer laser: Excimer laser sessions will be repeated twice weekly on the selected patch only, The starting dose will be 200 mj /cm2, an increase of 100 mJ/cm2 in the following session if no erythema appears, an increase of 50 mJ/cm2 every session till the appearance of erythema that lasts 24 hours or more.
46010430|NCT04577027|Other|Combination therapy|30 Patches treated with Combination therapy: Fractional CO2 laser twice per month followed by application of topical travoprost 0,004% daily and excimer laser twice weekly .
46010431|NCT04577027|Other|Excimer laser and travoprost|30 Patches treated with Excimer laser twice weekly and topical travoprost once daily for 3 months
46010432|NCT04577027|Other|fractional CO2 laser and topical travoprost|30 Patches treated with fractional CO2 laser twice monthly and topical travoprost once daily for 3 months
46010433|NCT04553354|Procedure|cortical resections|is the removal of the epileptic focus either temporal or extra temporal area
46010434|NCT02211612|Dietary Supplement|PUFA-group|
46010435|NCT02211612|Dietary Supplement|SFA-group|
46010436|NCT04553315|Procedure|chest expansion exercises|Chest mobility exercises with Incentive spirometer and segmental breathing exercise ) and breath stacking technique e.
46010437|NCT02211690|Drug|dolutegravir 50 mg (one tablet daily)|
46010438|NCT02211690|Drug|emtricitabine-tenofovir 300/200 mg (one tablet daily)|
45837064|NCT00509496|Biological|autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes|"Patients will receive a minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered PBL.~The cells are infused intravenously over 20-30 minutes."
45837065|NCT00547638|Device|cyanoacrylate with pressure sensitive mesh|Topical Skin Adhesive
46010439|NCT04553393|Drug|Chidamide|Chidamide will be added 1 month after responding to CART cells infusion
46010440|NCT04553393|Drug|Decitabine|Decitabine will be added 1 month after responding to CART cells infusion
46010441|NCT04553393|Drug|Chidamide and Decitabine|Both chidamide and decitabine will be added 1 month after responding to CART cells infusion
46010442|NCT04553393|Biological|Decitabine-primed Tandem CAR19/20 engineered T cells|Tandem CAR19/20 engineered T cells
46010443|NCT02219451|Other|exercise training|exercise training
46010444|NCT04553588|Other|Disposal pouch|Medication Disposal Pouch
45837066|NCT00547638|Device|cyanoacrylate|Topical Skin Adhesive
46010445|NCT02211846|Drug|Mirabegron|oral
46010446|NCT02219568|Procedure|CT enterography|CT enterography is performed using 64-channel multi-detector row CT scanners (Siemens Sensation 64, Siemens Medical solution, Forchiem, Germany). Prior to the scan, 1500 cc of a neutral oral-enteric contrast material, polyethylene glycol (NIFLEC) is taken by the patient. During the scan, 2cc/kg of intravenous contrast (iohexol, Ominipaque Amersham GE-Health care, Princeton, NJ) is injected at the velocity 5 cc/sec.
46010447|NCT02219568|Device|video capsule endoscopy|Video capsule endoscopy is performed using PillCam SB (Given Imaging, Yokneam, Israel). Polyethylene glycol (NIFLEC) is used for bowel preparation.
46010448|NCT02219646|Drug|Vardenafil|Vardenafil 10 mg twice daily for six months
46010449|NCT02219646|Drug|Placebo|Placebo two tablets daily for 6 months
46010450|NCT04553510|Drug|Bevacizumab and steroid|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential prednisone 10mg / d orally, the total course of 12 weeks.
46010451|NCT04553510|Drug|Bevacizumab and placebo|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential placebo 2 pills per day orally, the total course of 12 weeks.
46010452|NCT02219724|Drug|MOXR0916|MOXR0916 will be administered as intravenous infusion on Day 1 of each 21-day cycle.
46010453|NCT04553549|Device|Transradial approach|"Patients who are undergoing endovascular intervention will be enrolled into the study. As the metrics analyzed in this study are already normally collected, this study can be considered as a secondary use of the data. The procedure will be done using standard criteria as per operator preference. All interventional cases at the study institution undergo a radial first approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr)."
45461905|NCT01285219|Drug|pegylated filgrastim and ﬁlgrastim|patients were administered pegylated filgrastim 100 ug/kg in cycle 1 and ﬁlgrastim 5 ug/kg/d in cycle 2
45461906|NCT01285219|Drug|ﬁlgrastim and pegylated filgrastim|patients received ﬁlgrastim 5 ug/kg/d in cycle 1 and pegylated filgrastim 100 ug/kg in cycle 2
46010454|NCT01642017|Drug|Pazopanib|Pazopanib will be administered orally at the starting dose of 400 mg/day in 28-days cycles ; barring limiting toxicities the dose of pazopanib will escalate in several steps (a maximum of 3 dose levels are defined : 400, 600 and 800 mg/day). The pazopanib will be administered at the same dosa until disease progression.
46097173|NCT02738177|Drug|misoprostol and Isosorbide-5-mononitrate|1tablets of misoprostol (i.e.200 ug) & 1 tablets of Effox (i.e. 20 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (combination therapy group)
46097174|NCT00711568|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|20 Hz rTMS delivered for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli (25 minutes)
46097175|NCT00711568|Procedure|Sham rTMS|20 Hz sham rTMS delivered to L or R frontal region for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli
46097176|NCT00711568|Device|Repetitive Transcranial Magnetic Stimulator|Repetitive Transcranial Magnetic Stimulator
46097177|NCT04043806|Drug|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration
45461907|NCT01173757|Drug|PF-04995274|Single dose of up to 5 mg PF-04995274, delivered in solution on study day 1
45461908|NCT03867409|Behavioral|message delivered via virtual technology|The intervention is precision messaging tailored to target audiences through development and evaluation of culturally sensitive, interactive messages about CRC screening delivered using VHT. The study will investigate whether interactive, tailored messages contribute to an overall enhancement of knowledge of CRC and screening options by eliciting positive attitudes and behaviors toward FIT screening.
45461909|NCT03867019|Diagnostic Test|Heart rate variability parameters monitoring|"No intervention- only additional monitoring of heart rate, physical tests and filling of questionnaires:~Heart rate variability parameters monitoring- by wearing a Polar watch (RS800CX).~Isometric grip test- by using a Jamar Hand Held Dynamometer.~Questionnaires:~Dizziness Handicap Inventory (DHI) - hebrew version.~Stait-Trait Anxiety Inventory (STAI)"
45461910|NCT01284439|Drug|hydroxypropylmethylcellulose|TearA: QID to every 2 hous , 1-2 drops per each time , duration 1 month
45461911|NCT01284439|Drug|sodium hyaluronate|QID to every 2 hous, 1-2 drops per each time, duration 1 month
46097178|NCT04043806|Drug|IVA|150-mg tablet for oral administration
46097179|NCT02737943|Drug|Moist Exposed Burn Ointment (MEBO)|is a registered USA patented formulation since 1995. MEBO is pure herbal, natural in origin, containing beta-sitosterol phellodendron amurense, scutellaria baicalensis, coptis chinensis, pheretima aspergillum, Beeswax and sesame oil. 15, 19 The pharmacological effects are attributable to: beta-sitosterol, isolated from phellodendron amurense, flavonoids mainly baicalin isolated from scutellaria baicalensis, alkaloids mainly berberine, isolated from coptis chinensis, Beeswax and sesame oil.
46097180|NCT02737943|Drug|Zagazig|Standard care is an antibiotic ointment in combination of analgesic for relief of pain.
45837067|NCT00510744|Drug|pancreatic enzyme supplement|4 caps with meals, 2 with snacks
45837068|NCT00548418|Drug|Topotecan|
46097181|NCT05290753|Drug|Prokinetic Motility Agents as primpiram and gastreg|Prospective cohort study to evaluate the effect of pro kinetic use in emergency intestinal anastomosis
46097182|NCT02737709|Drug|Paclitaxel and Carboplatin regimen|Chemotherapy regimen:Paclitaxel: 175mg/m2, d1; Intravenous drip injection with 500ml N.S；Carboplatin: AUC=5, d1; Intravenous drip injection with 500ml G.S Paclitaxel injection at first, followed with Carboplatin injection.
46097183|NCT05289739|Behavioral|Exercise training|Exercise training during intensive cancer treatment. Training mainly consists of age-appropriate and personalized endurance, strength, flexibility, balance/coordination and gait training. Three to five weekly training sessions lasting 30 to 60 minutes each for about eight to ten weeks (depending on the course of the cancer treatment).
46097184|NCT02572960|Drug|Valsartan|2 weeks of Valsartan 80 mg per day
46097185|NCT02572960|Drug|Placebo Valsartan|2 weeks of Placebo Valsartan, one tablet per day. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
46097186|NCT02572960|Dietary Supplement|Cholecalciferol|12 weeks of daily cholecalciferol treatment, 70 microgram per day
46097187|NCT02572960|Dietary Supplement|Placebo cholecalciferol|12 weeks of daily Placebo cholecalciferol treatment. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
45837069|NCT00548418|Drug|Cisplatin|
45837070|NCT00548418|Drug|Bevacizumab|
45837071|NCT00511914|Biological|cTIV|One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle
45837072|NCT00511992|Drug|Avastin|"Initial Treatment Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2)~Consolidation Treatment:~Avastin 15mg/kg IV every 21 days x 12 cycles"
45837073|NCT00511992|Drug|Paclitaxel|Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles
45837074|NCT00511992|Drug|Cisplatin|75mg/m2 IP day 2 every 21 days x 6 cycles
45837075|NCT00451698|Drug|acyanotic erythropoietin|Single dose IV push
45837076|NCT00451698|Drug|acyanotic placebo|Single dose IV push
45837077|NCT01796262|Dietary Supplement|docosahexaenoic acid|Supplementation with DHA Richoil 250mg pearl b.i.d. for six months
45837078|NCT01796262|Dietary Supplement|Wheat germ oil|Wheat germ oil 250 mg pearl b.i.d. for six months
46010455|NCT00581594|Procedure|Graft-augmented colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years for a pelvic exam for evaluation of posterior wall support and the questionnaires.
46010456|NCT00581594|Procedure|Traditional posterior colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 2 weeks for routine post-op care and evaluation of any post-op complications. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months, for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years to have a pelvic exam for evaluation of posterior wall support and the questionnaires.
45461917|NCT03863431|Other|High-fat diet|"Participants will consume a high fat diet for 14 days with approximately 65% of energy from fat. The diet will also provide an energy excess, at 130% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
45679246|NCT05891925|Other|Audiobook App|"The intervention will consist of the use of the audiobook application (with poems) for 4 weeks. Here, the application will record the following data autonomously:~older adult id,~date, hour and time that the older adult listened to each poem,~poems listened.~Initially, two questionnaires will be applied to the older adults: one to measure their digital skills (DIGCOMP), and another to assess their well-being prior to the experience with the audiobook application (Part A).~After two weeks of application use, a follow-up will be carried out, in order to answer any questions that may arise from the use of the application, and explain again the objectives of the research, if necessary. This follow-up will be initially done by telephone, and in person if required.~After four weeks, the older adult will be invited to a meeting at the Community Rehabilitation Center at Concepción, Chile, to answer the well-being questionnaire (Part B) and the usability questionnaire (SUS)."
46010457|NCT04553198|Behavioral|Backward Locomotion Treadmill Training (BLTT)|9-training sessions of reverse treadmill training (no bodyweight support)over three weeks.
45679247|NCT05891912|Other|Technological devices intervention (use of tablet and big screen with games oriented to training physical and cognitive function)|"The treatment will be performed in 30 min sessions, twice a week during 12 weeks. the weekly sessions will include the following games:~1 session per week: 15min small TABLET and 15min LIGHTS game.~1 session per week: 15min TABLE TABLET and 15min game of VINTAGE."
46010458|NCT01642095|Other|Laboratory Biomarker Analysis|Correlative studies
46010459|NCT03453281|Drug|Aflibercept Injection [Eylea]|Intravitreal Aflibercept injections were performed by vitreoretinal consultant at the place of study.
46010460|NCT02219841|Procedure|radiofrequency catheter ablation|
46097188|NCT04001959|Procedure|Silver Diamine Fluoride with Potassium Iodide|Dry the tooth for 30 seconds with air jet and apply one drop of Diamino 30% Silver Fluoride with a disposable applicator brush for 3 minutes and one drop of potassium iodide solution immediately on the treated surface, then wash.
46097189|NCT02737865|Drug|Sonazoid|Sonazoid: Commercially available contrast material for ultrasonography
46097190|NCT02737865|Device|Superb-Microvascular imaging|Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography
46097191|NCT04267159|Other|Acute cardioversion|Acute restoration of sinus rhythm by medical or electrical cardioversion in the emergency department
46097192|NCT04267159|Other|Delayed cardioversion|Delayed restoration of sinus rhythm by medical or electrical cardioversion in the out-patient clinic
46097193|NCT02738567|Procedure|patients undergoing surgery or medical procedure|
46097194|NCT00721240|Drug|montelukast|5mg montelukast once daily for 12 weeks
46097195|NCT02737319|Drug|Rosuvastatin|40 mg of rosuvastatin before angioplasty
46097196|NCT04001335|Diagnostic Test|Dental Broach|Dental broach, RDT and PCR
46097197|NCT02737241|Procedure|Low power Holmium laser enucleation of the prostate|HoLEP entails dissection of the whole median and lateral prostatic lobes off the surgical capsule via a retrograde approach starting at the apex. The enucleated lobes were pushed to the bladder followed by hemostasis of the prostate bed then intravesical morcellation of the enucleated adenoma. The procedure entails power setting of 50W holmium laser energy.
45679248|NCT05891899|Other|observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
45461918|NCT03863431|Other|High-carbohydrate diet|"Participants will consume a high fat diet for 14 days with approximately 70% of energy from carbohydrate. The diet will also provide an energy excess, at 130% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
45461919|NCT01172431|Drug|Indapamide|Indapamide SR 1.5mg qd
45461920|NCT01172431|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg qd
45679249|NCT05891886|Drug|Oxygen Therapy|Study subjects will be asked to breathe supplemental, or extra, oxygen during several time periods.
45461921|NCT03863197|Behavioral|Progressive strength training|Progressive Supervised Home-based Strength Training
45461922|NCT01173835|Behavioral|Incentives for being tobacco free|Students who join the program will be entered into regularly scheduled drawings throughout the school year to earn incentives for being tobacco free.
45461923|NCT01285297|Biological|Bone Marrow Aspirate Concentrate|Injection of up to 18 mL BMAC
45461924|NCT00071513|Behavioral|CAST-T/HSTS|Skills training small group.
45679250|NCT05891886|Device|Non-rebreather mask|Non-rebreather mask is a non-invasive oxygen supplementation device that is used to provide continuous oxygen flow, typically in a hospital setting.
45679251|NCT05891873|Diagnostic Test|CAM-ICU|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
46010461|NCT04553159|Biological|Autologous adipose derived stem cells|Once consented, tumescent liposuction will be performed and 100-300ml of lipoaspirate will be collected. The harvested lipoaspirate will be processed aseptically in theatre through centrifugation at 1200g, then the sediment will be washed with Phosphate buffered saline and then incubated at 37 degrees celsius in 0.075% Collagenase type 1a for 1 hour. This will then be washed in an equal volume of 10% Fetal Bovine Serum then filtered through a 100 micrometer cell strainer. Red cells lysed using the Red cell lysis buffer will be performed followed by washing in Phosphate buffered Saline and centrifugation and the stromal vascular fraction cell pellet collected and diluted into 5ml normal saline solution for immediate infiltration. cell counts and viability using Trypan blue will be perfomed prior to the infiltration
46010462|NCT01642134|Drug|aspirin+clopidogrel (Duoplavin)|100 mg aspirin ;75 mg clopidogrel 3º months
46010463|NCT04552964|Other|Single arm|Far Best Corrected Visual Acuity (BCVA) ; Intra-Ocular Pressure (IOP) assessment ; Fundus examination ; Automated visual field ; Slit lamp examination ; Pregnancy test ; Patient Satisfaction Questionnaire
46097198|NCT02737241|Procedure|High power Holmium laser enucleation of the prostate|HoLEP entails dissection of the whole median and lateral prostatic lobes off the surgical capsule via a retrograde approach starting at the apex. The enucleated lobes were pushed to the bladder followed by hemostasis of the prostate bed then intravesical morcellation of the enucleated adenoma. The procedure entails power setting of 100W holmium laser energy.
46097199|NCT04393558|Device|ADAM Sensor|ADAM sensor The data collected from this sensor contains a wide range of core and novel respiratory digital biomarkers as a home-based early identification system. The core measurements include: heart rate, heart rate variability, temperature, physical activity (including sleep quality) and respiratory rate. The novel respiratory digital biomarkers include: respiratory cadence (expiration / inspiration time), coughing, swallowing, throat clearing, and talk time.
45679252|NCT05891873|Diagnostic Test|ICDSC|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
45679253|NCT05891873|Diagnostic Test|4AT|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
45837079|NCT01796340|Behavioral|Food cue exposure|Participants will be exposed to several kinds of their favorite food. The aim of this exposure is to increase the food cravings as much as possible.
45461925|NCT00071513|Behavioral|Brief Intervention|Assessment of needs and referral to services as needed.
45461926|NCT03865849|Device|Cooled radiofrequent treatment|In the cooled radiofrequency group a treatment of 60°C measured at the tip and on average 80°C in the targeted tissue is applied during 150 seconds using the Coolief system.
45461927|NCT03865849|Device|Conventional radiofrequent treatment|In the conventional radiofrequency group a treatment of 80°C at the tip is applied during 90 seconds at each nerve.
45837080|NCT01796340|Behavioral|Psycho-education|General information about nutrients, calories, exercise and the energy balance will be provided. In addition, psychological problems that accompany overweight will be discussed.
45461928|NCT02530073|Device|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH and observed/expected length head ratio <25% (O/E LHR).
46010464|NCT03453086|Procedure|Thoracic paravertebral block(TPVB) group|"Thoracic paravertebral block group (TPVB) group: The midpoint of the transducer is to be placed in a longitudinal paramedian plane between two transverse processes.Tuohy needle will be introduced in a cephalad direction. The tip of the needle will be advanced under direct visualization until it pierces the superior costo-transverse ligament. When the needle tip is located immediately above the pleura, the needle is aspirated to confirm the absence of blood or air.~Serratus anterior plane block group (SAP) group: The US probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the 5th rib is identified in the midaxillary line. The latissimus dorsi, teres major and serratus muscles will be then easily identifiable by US overlying the fifth rib. The needle will be introduced in-plane with respect to the US probe from supero-anterior to postero-inferior"
46010465|NCT03453047|Diagnostic Test|S100β and Neuron specific enolase (NSE)|S100β is 10.4 kDa protein. Synthesized with end feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction.
46010466|NCT02219880|Dietary Supplement|Kava (240mg of kavalactones per day)|Kava 60 milligrams per tablet = 240mg of kavalactones per day
46097200|NCT05356819|Device|Smart Capnography™, Microstream®|patients monitored by capnograph
46097201|NCT02737085|Biological|Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells|Patients receive autologous-derived CD19-targeted CAR-T cells following CD20-targeted CAR-T cells after receiving lymphodepleting chemotherapy.
46097202|NCT00991861|Drug|LAS41007 o.d.|Once daily, topical application
46097203|NCT00991861|Drug|LAS41007 b.i.d.|Twice daily, topical application
46097204|NCT00991861|Drug|LAS106521|Twice daily, topical application
46097205|NCT02737007|Drug|[14C]-GSK3191607|[14C]-GSK3191607 is a solution to be administered intravenously as a single dose infusion over 15 minutes. It is a radio-labeled product; 100 mcg of [14C]-GSK3191607 contains approximately 7.4 kilobecquerel (kBq) of [14C] radioactivity.
46010467|NCT02219880|Dietary Supplement|Placebo|Inert tablets containing vegetable fibre matched for colour, size and consistency to active arm treatment.
46010468|NCT04553042|Drug|Seltorexant|Seltorexant will be administered orally as per assigned treatment sequence.
46097206|NCT00721474|Drug|Bosutinib|Bosutinib fasting
46097207|NCT00721474|Drug|Bosutinib|Bosutinib fed
46097208|NCT02736929|Behavioral|Cognitive Processing Therapy - Cognitive|CPT-C is a brief cognitive behavioral treatment for PTSD. It consists of 2 hours of therapy each week for 6 weeks (i.e., two sessions).
46097209|NCT05355727|Other|Clinical decision support tool recommended outcome|The PROSAIC-DS tool will take the variables and produce a suggested outcome. It will supply supporting evidence and best practice for its recommendations
46097210|NCT00721552|Drug|Sitagliptin 100 mg|28 days administration of 100 mg daily
46097211|NCT00721552|Drug|Prednisolone 30 mg|14 days administration of 30 mg daily
46097212|NCT00721552|Drug|Sitagliptin-placebo|28 days administration once daily
46097213|NCT00721552|Drug|Prednisolone-placebo|14 days administration once daily
46097214|NCT05483075|Behavioral|HCP-Guided Exercise Training Program|"Individually tailored exercise program consisting of aerobic training (5 days per week for a minimum of 30 minutes at moderate intensity) and strength training (2 days per week at moderate intensity).~Two days per week the participant will receive their exercise program at NYU Langone Health. When at NYU, the training will be supervised by a physical therapist and will consist of the following: warm-up of 5 minutes, 30 minutes of aerobic exercise on either a stationary bike or treadmill at 60-70% of maximum heart rate. Following aerobic training, strength training will be carried out. Strength training will consist of 1 exercise per major muscle group, 8-12 reps, 1-3 sets at moderate intensity.~The remaining three days a week the participant will perform aerobic training at home by exercising on a bicycle or by walking fast for a minimum of 30 mins at moderate intensity (60-70% of max HR)."
46097215|NCT04619485|Device|CO2 LASER|5 SESSIONS OF CO2 VAGINAL LASER
46097216|NCT04619485|Device|CO2 SHAM LASER|5 SESSIONS OF CO2 VAGINAL SHAM LASER
46097217|NCT04069078|Drug|Hyoscine Butylbromide 20 Mg/mL Solution for Injection Ampoule|Patients will receive IV study solution which is hyoscine butylbromide 20 mg in 1 ml one minute after spinal anaesthesia
46097218|NCT04069078|Other|Normal saline|Patients will receive 1 ml of IV normal saline as a placebo one minute after spinal anesthesia
46097219|NCT02732249|Drug|Esomeprazole|Given 30 min before morning and evening meals
45461929|NCT03866083|Drug|Extracorporeal Cytokine hemadsorption therapy|Hemoperfusion will be carried out for one session within 12 hours for all randomized patient using the adsorption columns for Jianfan Biotechnology Co., Zhuhai, China). The hemoperfusion apparatus will be connected in front of the hemodialyzer in series.
46097220|NCT02732249|Drug|Bismuth Potassium Citrate|Given 30 min before morning and evening meals
46097221|NCT02732249|Drug|Clarithromycin|Given 30 min after morning and evening meals
45461930|NCT03866083|Drug|Standard Medical Treatment|Standard Medical Treatment
46010469|NCT01642173|Device|Optical Coherence Tomography (C7 XR Dragonfly )|Evaluation of the coronary artery using Optical Coherence Tomography utilizing the Dragonfly OCT catheter following a clinically indicated angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLa2 inhibition or placebo.
46010470|NCT02213432|Biological|Different timing of influenza vaccination|The timing of Influenza vaccination for cancer patients receiving chemotherapy will be differently assigned to day 1 or day 11.
46010471|NCT02219919|Other|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
46010472|NCT02219919|Other|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
46010473|NCT01118299|Device|AMPLATZER Cardiac Plug|AMPLATZER Cardiac Plug is a percutaneous transcatheter device
46010474|NCT04552574|Dietary Supplement|HMR(Home meal replacement)-type omega-3-balanced diet|A diet of which omega-3 to omega-6 ratio is below 1:4 was developed by Agricultural entity Green Grass Co., Ltd.. A committee of experts that is composed of several university professors in authorities of IPET(Institute of Planning and Evaluation for Technology in food, agriculture and forestry) also participated in the development of this diet.
46097222|NCT02732249|Drug|Metronidazole|Given 30 min after meals or at bedtime
46097223|NCT04561063|Drug|Nitazoxanide|Nitozoxanide 1 tablet (500 mg) taken 12-hourly with food for the first week, followed by 2 tablets (1000 mg) taken 12-hourly with food thereafter. (Participants that fail to tolerated the 1000 mg 12-hourly dose may revert back to the lower dose.)
46097224|NCT04561063|Drug|Sofosbuvir/Daclatasvir|Sofosbuvir/daclatasvir 400mg/60 mg sofosbuvir/daclatasvir fixed dose combination 1 tablet daily
46097225|NCT02732093|Procedure|stellate block|
46097226|NCT02732093|Drug|Na.Cl 0.9% (placebo)|
46097227|NCT02732093|Drug|lidocaine 2%|
46097228|NCT00718276|Drug|25(OH)D|daily (20ug), weekly (140 ug), Bolus (140 ug)
46097229|NCT00718276|Dietary Supplement|vitamin D3|daily (800 IU), weekly (5600 IU), Bolus (5600 Iu)
45461931|NCT03960359|Other|Clinical, microbiological and inflammatory phenotype|Clinical phenotype: temporal pattern of wheeze (EVW, SIW, MTW), history and clinical data, allergy diagnosis work-up Microbiological phenotype: viral status (PCR in nasal swab sample), bacteriological status (culture of induced sputum) Inflammatory phenotype: profile of cytokines, phenotype of immune cells in the blood and the sputum, cytokine response to TLR ligands by peripheral blood mononuclear cells.
45837081|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
46097230|NCT00718354|Drug|Enoxaparin|Once daily dose of 1mg/Kg of body weight for 6 months
46097231|NCT00718354|Drug|Standard Chemotherapy|Investigator's discretion
45461932|NCT01172509|Drug|R-baclofen|oral R-baclofen at 0x2, 3, 10, and 25 mg
45679254|NCT05891873|Diagnostic Test|p(s)CAM-ICU|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
45837082|NCT00548652|Behavioral|medical crisis councelling|group counselling sessions
45837083|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
46010475|NCT01118143|Behavioral|Tailored oral health literacy instruction|The intervention includes oral hygiene instruction tailored to the level of oral health literacy, and will include information about the outcome of the clinical examination. Providing relevant information to the participant will be in focus, and there will be given a personalized demonstration as well as guidance on how to conduct proper oral hygiene practices at home. The aim of the intervention is to improve oral hygiene and attitudes towards dental care by taking the literacy level of the participant into consideration.
46010476|NCT00581711|Other|3-Part Intervention|A combination of training, an otitis media episode grouper, and clinical decision support.
46010477|NCT00581711|Other|4-Part Intervention|A combination of clinician training, an otitis media episode grouper, clinical decision support, and feedback.
46010478|NCT00581711|Other|1-part intervention|Provision of feedback on otitis media quality indicators
46010479|NCT00581750|Other|Tissue specimen|Human tissues taken after the clinically indicated removal of these tissues from patients as part of their routine care.
46097232|NCT02731937|Device|GE Healthcare Revolution CT Scanner (CT Scanner)|Raw CT Scan Data
46097233|NCT00718432|Behavioral|Exercise and nutritional integrated care|Besides the information sharing and the educational booklets, the ENIC group subjects are invited to take a structured exercise course at the participating hospital 3 times a week for 3 months. (twice a week for 24 weeks in 2009 study) The exercise program included warm up; a range of motion, stretching, and postural-correction activities; aerobic strengthening; balance; and cool down. The research team also inquired about the subjects' dietary compliance and responded to their dietary questions during the exercise sessions.
45461933|NCT03960593|Other|Evaluation of the influence of geriatric factors|Follow-up of patients> 70 years old with cancer pathologies to evaluate the influence of geriatric factors associated with a review of therapies on their care pathways and health conditions. We will be particularly interested in the main objective, the unplanned hospitalization rate at 3 months in patients> 70 years old with cancer treated in oncogeriatric HDJ before the initiation of oncological treatment such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or new generation hormone therapy.
45461934|NCT01173913|Drug|ModraDoc001 10mg capsules|Bi-daily administration. One cycle will last 7 days
45461935|NCT01173913|Drug|ModraDoc003 10mg tablets and ModraDoc004 10/50 mg|The patients will receive 40 mg docetaxel and 200 mg ritonavir once daily as different dosage forms (ModraDoc001 10 mg capsules, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets). Patients continue in Week 4 with 80 mg docetaxel (as ModraDoc001 10 mg capsules) in combination with 100 mg ritonavir once daily in a weekly schedule until progressive disease or adverse events, which require dose modifications or discontinuation of therapy, are observed.
45461936|NCT01173913|Drug|ModraDoc006 10 mg tablet|Bi-daily administration. One cycle will last 7 days
45461937|NCT01089959|Drug|Esomeprazole|40 mg daily for 7 days
45461938|NCT01089959|Drug|esomeprazole|40 mg. daily, oral medication, once daily for 7 days.
45679255|NCT05891873|Diagnostic Test|CAPD|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
46010480|NCT02212860|Radiation|Stereotactic Body Radiation Then Surgery|Stereotactic image-guided neoadjuvant ablative radiation (randomized to single dose of 21 Gy or three 10 Gy doses) followed by lumpectomy for early stage breast carcinoma
46010481|NCT00581789|Drug|erlotinib, sunitinib|erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
45461939|NCT01090037|Drug|TRK-100STP high dose|
45837084|NCT00548652|Drug|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
45837085|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
45837086|NCT00548652|Drug|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
46010482|NCT01642368|Other|The Optimum Omega-3 Fatty Acid Feeding Study|Assess whether swapping specific food ingredients in the diet can significantly improve polyunsaturated fatty acid blood profiles and improve a person's response to cognitive measures and physical fitness.
45461940|NCT01090037|Drug|TRK-100STP low dose|
46010483|NCT02213549|Dietary Supplement|Placebo|
45461941|NCT01090037|Drug|Placebo|
45461942|NCT01090193|Procedure|Whipple operation,Hepaticojejunostomy|Whipple operation, Hepaticojejunostomy
45461943|NCT01285375|Device|CDC solution|2 ml of CDC 12/mg/ml is added to 1 l of UW solution. 500 ml of of this solution is used for flushing the kidney allograft prior to transplantation
45461944|NCT01285375|Device|UW-solution|500 ml of UW solution is used for flushing the kidney allograft prior to transplantation
45461945|NCT03960437|Drug|Etelcalcetide|Administered intravenously at the end of each dialysis session. Dosing ranges from 5 mg to 15 mg set by the patient's physician.
45461946|NCT01288105|Device|Optical coherence tomography|Optical coherence tomography will be performed to determine the stent strut coverage. Patients in whom >95% of stent struts are covered will not receive perioperative bridging with a glycoprotein IIb/IIIa inhibitors, whereas those with <95% stent strut coverage will receive perioperative bridging.
45461947|NCT03960281|Other|Regular dental examination|Regular dental examination, and the patient will be asked to fill a questionnaire
45461948|NCT01100645|Drug|Sominex|Passiflora incarnata L.50 mg Valeriana officinalis L.40 mg Crataegus oxyacantha L.30 mg
45461949|NCT01100645|Drug|Placebo|Excipient
45461950|NCT03862885|Drug|Avapritinib|Avapritinib will be administered orally (PO) at a dose of 300 mg once daily (QD) in continuous 28-day cycles.
45679256|NCT05891873|Diagnostic Test|MASTcz (The Mississippi Aphasia Screening Test)|People with aphasia will be examined by a skilled speech therapist.
45679257|NCT05891873|Diagnostic Test|EEG|Patients with positive delirium will undergo EEG examination. 10-min native EEG.
45679258|NCT05891860|Other|Participation in virtual rounds|Virtual participation in daily ICU team rounds
45679259|NCT05891821|Drug|Balstilimab|An anti-programmed death (ligand) 1 [PD-(L)1] monoclonal antibody
45837087|NCT00548652|Behavioral|medical crisis councelling|group counselling sessions
45837088|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
45837089|NCT01797354|Behavioral|Cognitive-behavioral therapy and hypnosis group|
45837090|NCT01797354|Behavioral|Support group|
45837091|NCT00549042|Drug|OROS hydromorphone|hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
45837092|NCT00549042|Drug|Placebo|Placebo
45837093|NCT00452868|Drug|Donepezil|Donepezil 5 milligrams a day for 6 weeks
45837094|NCT00453336|Drug|Porfimer Sodium|Day 1 of Therapy. An IV access (of 20 gauge or larger) is started and 2 mg/kg of Porfimer Sodium (Photofrin®) is given intravenously. Once completed the patient puts on the light protective gear and is sent home.
45837095|NCT00453336|Procedure|Photodynamic Therapy|Laser Activation. The time of exposure and the power of the laser are computed based on the dosimetry in appendix A using a computed energy dose of 75 to 150 joules, depending on the depth of penetration desired.
46010484|NCT02213549|Dietary Supplement|Ume paste and ginger powder|
45461951|NCT03860389|Other|Exercise|An exercise programme will be delivered in the school for a period of up to 16 weeks. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
46010485|NCT01642446|Procedure|Precise hepatectomy|Precise hepatectomy
45461952|NCT05625971|Other|MRD Assessment|MRD assessment includes liquid biopsy and functional imaging. Liquid biopsy will be performed by the Adaptive ClonoSEQ® assay in peripheral blood. Functional imaging will be performed by whole body diffusion-weighted magnetic resonance imaging (WB-DWI).
45837096|NCT00549822|Drug|Letrozole|Treatment is intermittent with possible breaks between each 28 day treatment cycle if CA 15-3 or CA 27.29 level that has decreased by at least 50% of that individual patient's baseline or peak level on firstline letrozole or anastrozole therapy or has decreased into the normal reference range per institutional parameters. Letrozole or anastrozole therapy will be interrupted until CA 15-3 or CA 27.29 levels rise by at least 25% above trough CA 15-3 or CA 27.29 level. If the trough level is in the normal reference range then the CA 15-3 or CA 27.29 must rise into the normal reference range.
46010486|NCT01642446|Other|Combined intervention (chemoembolization/ablation)|transcatheter hepatic arterial chemoembolization and/or ablation
46010487|NCT02213588|Dietary Supplement|AOX blend|Antioxidant supplement
46010488|NCT02213588|Dietary Supplement|Placebo|
46010489|NCT01642524|Biological|hypertonic saline mixed Dextran|single dose administered intravenously
46010490|NCT01642524|Biological|Saline solution|placebo - saline solution
46010491|NCT02213705|Biological|INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS|
46010492|NCT02217228|Device|Sebacia microparticles and laser|
46010493|NCT02217228|Device|Vehicle suspension and laser|
46010494|NCT02217228|Device|Sebacia microparticles without laser|
46010495|NCT02213783|Drug|Imipenem|Each patient will receive 0.5 g of imipenem, 0.5 hr infusion every 6 hr at room temperature
46010496|NCT02213783|Drug|Imipenem|Each patient will receive 0.5 g of imipenem, 4 hr infusion every 6 hr of at room temperature
46010497|NCT01642563|Procedure|Platelet transfusion|One dose of pathogen reduced platelets
45461953|NCT01175863|Device|Grey scale intravascular ultrasound (Galaxy or Virtual histology-Intravascular Ultrasound)|minimal lumen area on Intravascular ultrasound
45461954|NCT01175863|Device|Pressure wire(Radi Medical Systems)|Fractional flow reserve measured by pressure wire
46010498|NCT01642563|Procedure|Platelet transfusion|One dose of standard platelets
46010499|NCT04552613|Drug|EGFR-TKI|(A) Standard programme group, EGFR-TKI targeted therapy;
46010500|NCT04552613|Drug|EGFR-TKI combined with chemotherapy (pemetrexed plus carboplatin)|(B) controlled programme group, EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )
46010501|NCT02213328|Drug|Truvada|Fixed-dose combination tablet containing 200 mg of FTC plus 300 mg of TDF, taken once daily by mouth.
46010502|NCT01642680|Other|A tailored physical activity program during chemotherapy|The early group will start the PA program during chemotherapy for 3 months, and after completion of chemotherapy for 3 months (total 6 months). The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
46010503|NCT01642680|Other|A tailored physical activity program after chemotherapy|The late group will start the PA program after completion of the chemotherapy for 6 months. The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
46010504|NCT00582101|Behavioral|Family-Based HIV Prevention for Latinos|7-hour one-day workshop with adolescents and parents in separate and joint sessions
46010505|NCT00582101|Behavioral|General Health Promotion|7 hour one-day workshop on general health promotion topics
45461955|NCT05625893|Radiation|PBT and atezolizumab/bevacizumab|"Atezolizumab 1200 mg and bevacizumab 15 mg/Kg is administered IV infusion every 3 weeks.~Proton beam therapy 30 - 50 Gy/5 fractions to portal vein tumor thrombosis with or without main primary tumor after 1 week (+/- 7 days) of 2nd cycle of atezolizumab and bevacizumab~The follow-up phase begins when the decision to discontinue study is made. The follow-up phase is defined as the day after the end of study treatment until the day the subject dies."
45461956|NCT01173991|Behavioral|Carbohydrate counting training|Carbohydrate counting was taught during 4-5 individual sessions with a dietician and a diabetologist.
45461957|NCT01102907|Other|Liquid Breakfast|The liquid breakfast meal will contain 370 calories and will consist of fruit juices and skim milk
45461958|NCT01102907|Other|Solid Breakfast Meal|The solid breakfast will contain 370 calories and will consist of oatmeal, golden delicious apples, blueberries, skim milk, and brown sugar.
45461959|NCT01174069|Procedure|NOTES assisted laparoscopic cholecystectomy|Surgical removal of the gallbladder using endoscopic instruments.
45461960|NCT01102985|Behavioral|aerobic resistance exercise|three times per week aerobic resistance exercise for 12 months
46097234|NCT00718432|Behavioral|Usual care with education|The study educational booklet (plus CD-ROM in 2009 study) on frailty, depression, osteoporosis, healthy diets, exercise protocols, and coping strategies are given to the participants. UC group subjects will receive a 2-hour education based on the content of study booklet including 1-hour demonstration of study exercise program in 2009 study. Subjects are contacted monthly (bimonthly in 2009 study ) for frequencies of reading this booklet and the compliance on the suggested diet and exercise protocols. Subjects are also encouraged to follow with their primary care physicians for abnormal results identified from our assessments.
46010506|NCT01642719|Behavioral|Sleep restriction|Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks.
46097235|NCT00718432|Behavioral|Problem solving therapy (PST) integrated care|Besides the information sharing and the educational booklets, the PSTIC group subjects will receive 6 sessions of PST (within 12 weeks in pilot study, within 24 weeks in 2009 study) aiming at solving the 'here-and-now' problems contributing to their mood-related condition and helps increase their self-efficacy. If major depressions are found, subjects are referred to their primary care physicians for further medical managements.
46097236|NCT02731781|Other|NONE . OBSERVATIONAL|OBSEVATION AND FOLLOW UP
46097237|NCT00536809|Drug|lapatinib|onced daily Days 1-21
45461961|NCT01102985|Behavioral|home based health promotion|education and support to adapt national guidelines for 30 minutes physical activity most days of the week
45679260|NCT05891782|Behavioral|HAPA-based multicomponent fall intervention|"According to the HAPA and the conceptual model of IC, this intervention consists of 3 phases: pre-intention phase → intention phase → action phase.~The pre-intention phase: Group lectures will be used, and the intervention is conducted from week 1 to week 3, with a frequency of 2 times per week and a duration of 30-45 minutes per intervention.~The intention phase: Individualized plans will be used, and the intervention is week 4, with an intervention length of 20-30 minutes. By designing action goals and plans in exercise, daily habits, and external improvements, the intention of the study subjects to manage fall risk is clarified.~The action phase: face-to-face interviews will be used, and the intervention keep from week 5 to week 16. It is supplemented with the text tool Tumbler: A Falls Risk Management Manual for Older Adults in Nursing Homes to assist participants in removing barriers to action and increasing their subjective motivation to change health behaviors."
45679261|NCT05891782|Behavioral|Regular health education lectures|Conduct regular health education lectures and distribute relevant materials in paper or electronic form. At the same time, follow-up visits is conducted once a month by phone, WeChat or face-to-face, with each visit lasting at least 25-30 minutes. We will understand the questions and needs of the study participants in multiple ways, and provide answers and support. Weekly bulletin board with information about falls.
46010507|NCT01642719|Behavioral|Non-sleep restriction|Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline.
46010508|NCT00582140|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
46010509|NCT00582140|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
45461962|NCT01178047|Drug|Rasagiline|Rasagiline: 1 mg/d p.o. or Placebo one tablet p.o. once daily
45461963|NCT01090271|Device|Isokinetic eccentric training|The eccentric training for the shoulder abductors was performed for 6 consecutive weeks, twice a week, on alternate days.
46010510|NCT00582140|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
45461964|NCT03960203|Diagnostic Test|InSight|Clinical decision support (CDS) system for severe sepsis detection and prediction
45461965|NCT01101113|Drug|cinacalcet|cinacalcet 25mg qd or 50 mg qd
45461966|NCT01101113|Drug|control|vit D + P binder
46010511|NCT01642758|Drug|Sodium 2,2 dimethylbutyrate|Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks
45461967|NCT01288183|Procedure|sham tDCS|"sham condition as delivered by the stimulator study mode (2mA during 40s and brief current pulses until the end of the stimulation) 20 minutes, 10 sessions, 2 per day"
45461968|NCT01288183|Procedure|active tDCS|anodal tDCS applied over the right DLPFC 2mA, 20minutes, 10 sessions, 2 per day
45461969|NCT03950999|Other|Placebo|Sugar pill
45461970|NCT01288261|Drug|paclitaxel|Given IV
46010512|NCT00582179|Procedure|Standard Pressure Dressing|If hematoma still draining at 5 days post surgery, patients who randomize to Group A will have a standard pressure dressing applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I&D.
46010513|NCT00582179|Device|VAC|If hematoma still draining at 5 days post surgery, patients who randomize to Group B will have a VAC negative pressure device applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I&D.
46010514|NCT01642797|Device|Confocal laser endomicroscopy (Pentax, EG3870K)|Confocal laser endomicroscopy with Targeted Biopsy
46010515|NCT01642797|Device|Standard White-light endoscopy (Pentax, 90i)|Standard White-light endoscopy with Standard Biopsy
46010516|NCT04552379|Biological|Peginterferon beta-1a|"Administration of trial drug: PLEGRIDY is given by an injection under the skin (subcutaneous injection). It will be administered to participants in accordance with product insert instructions by appropriately trained trial staff for whom administration of subcutaneous injections is within their normal scope of practice (e.g. RN or MD). They will wait for 20 mins after the last individual receives the interferon before leaving a residence. Administering staff will be supplied with appropriate PPE, trained in the use of this equipment and protocols for infection control, and will always attend in pairs.~PLEGRIDY will be administered in the home of the participants. Due to the heat-labile nature of the trial product (storage required at ~4oC) a verified English Spanish version of the product label will be printed by a GMP certified company and applied to the product and patient band just at the time of use."
46010517|NCT02215668|Procedure|Physical exercise|Exercise muscle stretching and body warming.
46010518|NCT01642836|Behavioral|MMM|"a theory-based community team sports program designed specifically for overweight and obese children,~a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and~a primary care provider behavioral counseling intervention linked to the community and home interventions."
46010519|NCT01642836|Behavioral|Health and Nutrition Education|"Enhanced standard care/health and nutrition education intervention:~notification of primary care providers about metabolic measures and blood pressure~state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and Family Fun Nights"
46097238|NCT00536809|Drug|oxaliplatin|Day one of each cycle
45461971|NCT01288261|Biological|bavituximab|Given IV
46097239|NCT00536809|Drug|capecitabine|given BID days 1-14
46097240|NCT02572726|Device|active repeated transcranial magnetic stimulation|ten daily sessions with active 10Hz 20 min-long stimulation over the primary motor cortex
46097241|NCT02572726|Device|'sham' repeated transcranial magnetic stimulation|ten daily sessions with 'sham' 10Hz 20 min-long stimulation over the primary motor cortex
45461972|NCT01288261|Other|laboratory biomarker analysis|Correlative studies
45461973|NCT01288261|Other|pharmacological study|Correlative study
46097242|NCT04189601|Diagnostic Test|Complement measurements|Blood and urine tests to assess the complement activation state
45461974|NCT03865693|Device|scarmbler therapy|Scrambler therapy is a patient-specific electrocutaneous nerve stimulation device.
45679262|NCT05891769|Drug|18Fluorocholine|18F Fluorocholine 5 mCi ± 20% administered intravenously.
45461975|NCT01174303|Drug|insulin degludec/insulin aspart|Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
45461976|NCT01174303|Drug|biphasic insulin aspart 30|Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
45461977|NCT01285453|Drug|vadimezan|
45461978|NCT01288339|Drug|Panitumumab + FOLFOX (DP)|Panitumumab and FOLFOX will be administered to patients with DP once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
45679263|NCT05891717|Other|Resistance training|Twice per week for 8 weeks. Total 16 sessions will given.
46010520|NCT01117987|Drug|Imatinib|Participants, who received imatinib 200 mg in the core study, CQTI571A2301 (NCT00902174), and completed the core study, received imatinib 200 mg every day (qd) in the extension. Participants, who were randomized to receive imatinib 400 mg in the core study and completed the core study, received imatinib 400 mg qd in the extension. Participants, who terminated early from the core study or who were randomized to placebo and completed the core study, started the extension with imatinib 200 mg qd. After 2 weeks, the dose was increased to 400 mg qd if tolerated.
46010521|NCT01117987|Drug|Placebo|To preserve the blind of the core study until the core study, CQTI571A2301 (NCT00902174), was completed, participants received a blinded study drug package containing a 70-tablet bottle of imatinib and a 70-tablet bottle of matching placebo.
46010522|NCT02215902|Device|Affinity plasmapheresis|Insert investigational affinity plasma filter into hemodialysis circuit during routine hemodialysis treatments.
46010523|NCT02213822|Other|Molecular Analysis of Cancer|The intervention performed in this study is the molecular analysis of cancer. Samples to be tested for genetic alterations will be collected during the course of a routine diagnostic procedure such as a surgery or tumor biopsy. Samples that have been stored from previous diagnostic procedures will be analyzed as well. This testing will be performed by the Department of Pathology at Rhode Island Hospital or an outside laboratory designated by Rhode Island Hospital. The extent of molecular testing will be different in each individual case. For example, in some cases, study of genetic alterations will start with whole genome or exome sequencing and will be confirmed by targeted Sanger resequencing, single nucleotide polymorphism, and transcriptome analysis. In other cases targeted multigene panel sequencing or targeted amplicon Sanger sequencing will be the initial and only step.
46097243|NCT03910426|Other|Blood sampling|Blood is sampled before a midweek dialysis session once every year with a maximum of 3 samples in total.
46097244|NCT03910426|Other|Nails collection|At the occasion of the blood sampling, finger nails are cut and collected.
46097245|NCT03910426|Other|Stool collection|At the occasion of the blood sampling, patients are asked to bring a stool sample.
46097246|NCT03910426|Other|Physical Functioning|A subgroup of patients are asked to perform some physical tests.
46097247|NCT03910426|Other|Sleep|A subgroup of patients are asked to sleep 2-3 nights with a Motionwatch (Actigraphy) to recording their arm movements.
45679264|NCT05891717|Other|Flexibility training|Twice per week for 8 weeks. Total 16 sessions will given.
45679265|NCT05891704|Procedure|Hand therapy Rehabilitation intervention program that incorporate cultural reference|The intervention will provide a conventional hand therapy rehabilitation intervention program that incorporates cultural reference based on Focused Acceptance and commitment Therapy ( FACT).
45679266|NCT05891704|Procedure|Conventional Hand therapy Rehabilitation intervention program|The intervention will provide a conventional hand therapy rehabilitation intervention program
46010524|NCT01117870|Other|Pulsed Radiofrequency|120 seconds at 42 degrees celsius
46010525|NCT01117870|Other|Placebo|Needle will be continuously stimulated at a low voltage to give a sensation of PRF application.
46010526|NCT01642875|Other|Enteral nutrition|Standard enteral diet is administered through a nasojejunal tube. Enteral nutrition is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.
46010527|NCT01642875|Other|Oral nutrition|Oral diet is started from the 2nd postoperative day and oral intake is advanced as tolerated
46010528|NCT01117792|Device|subcutaneous implantable defibrillator (S-ICD) system|implantable defibrillator system
46010529|NCT04552184|Other|GPOEM|gastric per oral endoscopic pyloromyotomy
46010530|NCT04552184|Other|SHAM Procedure|intrapyloric injection of saline solution
46010531|NCT02219490|Drug|ABT-450/r/ABT-267|Tablet for oral use
46010532|NCT02219490|Drug|ABT-333|Tablet for oral use
46097248|NCT02731859|Device|Insertion of EndoBarrier for approximately one year|Insertion of EndoBarrier for approximately one year then explantation and follow-up
46097249|NCT05274295|Device|Diabetic leg ulcer treatment with adipous SVF|The Celution® System isolates approximately maximum 30 million SVF cells per 100 mL of adipose tissue to be processed. Approximately 1-3 million cells per injection (total 8-30) will be administered locally, in the target ulcer.
46097250|NCT00721708|Dietary Supplement|pure carnosine|one time dose of pure carnosine (450 mg)
46097251|NCT00721708|Other|Beef|one time dose, 150 g of beef
46097252|NCT00721708|Other|Chicken|One time dose, 150g of chicken breast
46097253|NCT00721708|Other|Chicken broth|one time dose of chicken broth obtained from 150g of chicken breast
46097254|NCT04174963|Behavioral|eToke + TPsy|Combination of brief computerized intervention (eToke) with Information-Motivation-Behavior based text messages tailored to young adults in psychiatric treatment
46010533|NCT02219490|Drug|Ribavirin (RBV)|Ribavirin was provided as 200 mg tablets, and dosed based on weight,1000 to 1200 mg divided twice daily per local label. For example, for participants weighing < 75 kg, RBV may have been taken orally as 2 tablets in the morning and 3 tablets in the evening which corresponds to a 1000 mg total daily dose. For participants weighing ≥ 75 kg, RBV may have been taken orally as 3 tablets in the morning and 3 tablets in the evening which corresponds to a 1200 mg total daily dose.
46010534|NCT04310722|Other|None intervention. This is an observational study.|None intervention. This is an observational study.
46010535|NCT04310605|Behavioral|CBT 1|CBT for tinnitus (Step 1) comprised: individual audiometric assessment, and counselling about hearing and tinnitus (1hr) with an audiologist; a one-off educational group session (a max 10 participants and partners) (2hrs); an assessment session with a psychologists (1 hr).
46097255|NCT02731625|Other|Kettlebell training|Kettlebell training will be performed in 30 second work:rest intervals. Total training time will progress from 10 minutes at the beginning of the study to 20 minutes at the end.
46097256|NCT02731625|Other|Army Physical Readiness Training|Army Physical Readiness Training per Army Field Manual 7-22
46097257|NCT02731547|Behavioral|Education Against Tobacco School-Based Intervention|
46010536|NCT04310605|Behavioral|CBT 2|Step 2 group sessions were 2 hrs long over a 12-week period. Two therapists (a psychologist and physiotherapist) were present at any one time for Step 2 sessions. Step 2 included: psycho-education; exposure therapy; mindfulness exercises; cognitive restructuring; attention redirecting techniques; stress reduction; and, relaxation techniques. Evening sessions were also provided for participants to attend with family or partners.
46010537|NCT01117051|Drug|placebo|placebo
46010538|NCT01117051|Drug|prucalopride|1 or 2 mg prucalopride once daily before breakfast
46097258|NCT02731391|Procedure|Pelvic floor reconstruction（with or without mesh）|
46097259|NCT00721786|Behavioral|UCSF/SFGH Internet Stop Smoking Study site|Internet stop smoking site in Spanish and English
46010539|NCT01642953|Dietary Supplement|Early recovery|The patients are started on sips of water on the first postoperative day. If they are tolerable, a liquid diet is started on the second postoperative day, and a soft diet on a third postoperative day for them. We have a plan to discharge the patients on the fourth postoperative day if they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination.
46010540|NCT05360173|Behavioral|acupressure|The researcher use thumb and put about 3 kilogram on four acupoints where locating on the patient's arm and leg.
46010541|NCT05360173|Behavioral|sham acupressure|The researcher use thumb and put about 3 kilogram on four acupoints where locating at about 3 cm next to the acupoint on the patient's arm and leg.
46010542|NCT05359666|Device|Irrisept|"Irrisept® is a manual, self-contained irrigation device designed for wound cleansing and irrigation. The solution is 0.05% Chlorhexidine Gluconate (CHG) in sterile water for irrigation, USP (99.95%). Irrisept contents include the solution, a 450 mL bottle, and the Irriprobe applicator. Irrisept is a manual, self-contained irrigation device that can produce 7-8 psi of pressure for effective wound cleansing and irrigation. The user squeezes the bottle to create streams of solution and directs the fluid from the applicator onto a wound. The mechanical action of the streams of fluid being applied over a wound removes particulates and debris.~Subjects randomized to Irrisept on study protocol IRR-CT-901-2013-01 used the device, per the provided Instructions for Use. Those randomized to SoC received routine care, per the discretion of the investigator, and in accordance with the institution's guidelines."
46010543|NCT05359666|Device|Standard of Care|"Subjects randomized to SoC on study protocol IRR-CT-901-2013-01 used any SoC type, per the investigator's discretion. SoC types were not standardized. Sites recorded SoC information as free text. The following were recorded as SoC types: Saline (recorded as normal, warm and/or sterile saline or saline solution); Sodium Chloride (recorded as sodium chloride (NACL) or NACL 0.9%); SoC; Irrisept (recorded as normal saline & Irrisept and Irrisept); Chloroprep; Gentamicin & saline; unknown; and none."
46097260|NCT02731001|Radiation|Proton therapy|
46097261|NCT02731001|Radiation|Photon therapy|
46097262|NCT04510753|Device|Arterial catheterization kit|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform and blood pressure values.
46097263|NCT04510753|Device|GE Datex-Ohmeda Finger Clip Pulse Oximeter Sensor|PPG fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
46097264|NCT04510753|Device|NIBP Cuff (GE Healthcare)|A blood pressure cuff is used to measure blood pressure. The cuff has an inflatable rubber bladder that is typically fastened around the arm. A pressure meter indicates the cuff's pressure.
46097265|NCT04067986|Drug|Camrelizumab|"Camrelizumab One course will last 28 days.Intravenous injection at a dose of 200 mg, q2w~One course will last 28 days. Oral administration at a dose of 250 mg/d"
45461979|NCT01288339|Drug|Panitumumab + FOLFOX (no-DP)|Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
46097266|NCT04067986|Drug|Apatinib|Apatinib One course will last 28 days.Oral administration at a dose of 250 mg, qd
45461980|NCT00006389|Drug|bryostatin 1|Given IV
45461981|NCT00006389|Drug|cisplatin|Given IV
46097267|NCT02731079|Device|Covidien iDrive|Surgery performed with Covidien powered stapler
46010544|NCT04577105|Diagnostic Test|Simple chest tomography|The images were acquired with a Siemens 256-slice multidetector tomograph (SOMATOM DEFINITION FLASH 128x2) following the recommended parameters for low-dose simple chest tomography. The chest topogram was acquired using 35 mA, 100 Kv, and 6 mm slices, then the chest tomographic slices holding inspiration in a cephalocaudal direction with 80 mA, 100 Kv, a duration of 2.24 seconds, a pitch of 1, and slices 1 mm with a total of 110 DLP, which is calculated with the conversion factor for thorax a total of 1.5 mSv. Multiplanar reconstructions with Kernel filters B26f, B50f, and B70 for mediastinum and lung, respectively, at 1 mm slices.
46010545|NCT02211417|Drug|Oral DS107|
45461982|NCT00006389|Other|laboratory biomarker analysis|Correlative studies
45461983|NCT01285531|Device|Compass Lumbar Puncture Enhanced|Participants randomly assigned to this group will receive a lumbar puncture using the Compass device.
46097268|NCT02731079|Device|Ethicon Echilon|Surgery performed with Ethicon powered stapler
46097269|NCT02571946|Radiation|Proton beam therapy|
46097270|NCT00536731|Drug|Symbicort Turbuhaler|Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
46097271|NCT00536731|Drug|Symbicort pMDI|Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
46097272|NCT00536731|Drug|Pulmicort Turbuhaler|Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
46097273|NCT04189523|Other|SOC Pain Management|Study subjects will be compared to historical controls selected for same age +/- 5yrs, gender, fracture type who meet the inclusion criteria and do not have historical documentation of one of the exclusion criteria. Controls will be identified by the ICD-10 injury codes selected for use in this study. Clinical course and pain management data will be collected through the EMR only.
46097274|NCT04189523|Procedure|Early US Guided Nerve Block Administration|US-Guided regional anesthesia (fascia illiaca compartment block or brachial plexus block)
45461984|NCT02525497|Device|FM peritoneal dialysis machine|FM peritoneal dialysis machine APD 10L/10h
45461985|NCT02525497|Device|HOMECHOICE peritoneal dialysis machine|HOMECHOICE peritoneal dialysis machine APD 10L/10h
45461986|NCT04029077|Other|NA: intervention is not part of the study|NA: it is not an interventional study
45837097|NCT00550290|Drug|Cefazolin PostOperatively|Cefazolin 1 gram IV every 8 hours for a total of 3 doses. Patients in both arms will receive an initial pre-operative 2 gram dose of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV q 8 hrs will be used.
45461987|NCT01174381|Behavioral|lifestyle modification|Lifestyle modification for six months
46010546|NCT02211417|Drug|Placebo|
45461988|NCT04965311|Biological|Botulinum Toxin Type A|Given via endoscopic injection into intraduodenal sphincter of Oddi segment
46010547|NCT00582413|Behavioral|questionnaires|Patient will fill out questionnaires, initial clinic visit, first post-surgery clinic evaluation and 3, 6, 12, 18 and 24 months following completion of all therapy.
45461989|NCT01175941|Drug|NRL001|10 mg NRL001 in a 2 g suppository, administered once daily for 7 days
46010548|NCT00582452|Other|Telephone survey|Telephone survey
46010549|NCT02279121|Device|Taurolock|At the beginning of each course of IV anti-tumor treatment, a nurse removes the lock TauroLock ™ and makes rinsing the CVC. At the end of each course, she rinses again the CVC and instills TauroLock ™ solution. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
46010550|NCT02279121|Drug|saline solution|At the beginning of each course of IV anti-tumor treatment, a nurse makes rinsing the CVC. At the end of each course, she rinses again the CVC. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
46097275|NCT02571712|Drug|bimatoprost 0.03% plus timolol 0.5%|1 drop of bimatoprost 0.03% plus timolol 0.5% (GANFORT®) instilled in the affected eye once daily.
46097276|NCT02730845|Drug|Intra-articular dexmedetomidine|Patients will receive an intra-articular mixture of 19 ml bupivacaine 0.5% with epinephrine 1:200.000 added to 1ml (1 µg/kg) of dexmedetomidine (total volume 20 ml), and i.v. saline 20 ml infused over 10 min starting with local anesthesia
46097277|NCT02730845|Drug|Intravenous dexmedetomidine|Patients will be injected intra-articularly with mixture of 19 ml 0.5% bupivacaine with epinephrine 1:200.000 and 1 ml of isotonic saline (total volume 20 ml), in addition to i.v. 20 ml saline containing 1 µg/kg dexmedetomidine over 10 min infusion starting with local anesthesia.
46097278|NCT02730767|Behavioral|partially supervised exercise intervention|
46097279|NCT02730689|Drug|DP-R207|
46097280|NCT02730689|Drug|Rosuvastatin|
46097281|NCT02730689|Drug|Ezetimibe|
46097282|NCT03579316|Drug|Adavosertib|Given PO
46097283|NCT03579316|Drug|Olaparib|Given PO
46097284|NCT03579316|Drug|Ceralasertib|Given PO
46097285|NCT02730533|Drug|Esomeprazole|Proton pump inhibitor
46097286|NCT02730533|Drug|No PPI treatment|No PPI treatment before ESD procedure
46097287|NCT00712036|Behavioral|Interim|Methadone maintenance with emergency counseling only for up to 4 months
46097288|NCT00712036|Behavioral|Comprehensive|Methadone treatment with counseling as usual
46097289|NCT00712036|Behavioral|Restored|Methadone maintenance with counseling provided by a clinician with a lower than usual caseload
46097290|NCT04067362|Other|food containing dietary fiber|commercially available chicory root flour and chicory root fiber
45461990|NCT01175941|Drug|Placebo control|Matched placebo - administered as a 2 g suppository, once daily for 7 days
45461991|NCT01105481|Drug|Amisulpride add-on|At the beginning of the treatment phase (day 1), subjects in the combination treatment group will be started with adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. All of the add-on amisulpride will be provided to subjects at night. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
45679267|NCT05891691|Behavioral|Music Activities, Yoga, Massage|The program begins with music and dance movements using percussion instruments (rhythm stick, stone triangle, drum, cymbal, tambourine, maracas, etc.) and body percussion. In this phase, the children will follow the instructions of the researcher. The goal is to warm up the bodies and musically experience the beginning of the program After the warm-up, yoga postures are combined with breathing techniques that focus on developing awareness of body sensations and feelings.The daily program ends with massage. During the massage application, the children sit in a circle. The massage is performed by the children observing the movements of the researcher on their arms and legs and applying them on their own arms and legs.Yoga postures, breathing techniques, and massage practices are accompanied by stories to ensure children's active participation, encourage their development, and facilitate their acquisition of new approaches.
45679268|NCT05891678|Radiation|doppler study of central retinal artery|pulsed wave Doppler after decreasing the sample volume to fit inside the center of CRA. We will measure the peak systolic velocity (PSV), end diastolic velocity (EDV), and the resistivity index which equal PSV-EDV/PSV, we will measure 3 times and the expected normal value is less than 0.7.
45679269|NCT05891665|Procedure|Corticotomy|A corticotomy procedure will be applied with some osteoperforations during the surgical exposure of the impacted canine. Then this will be followed after 8 weeks with another surgical stimulation using piezosurgery.
45679270|NCT05891665|Procedure|Traditional traction of the impacted canine without corticotomy|In this group of patients, the traction of the impacted canine will be performed traditionally without the involvement of additional surgical intervention.
45679271|NCT05891652|Procedure|modified thoracoabdominal nerve block through perichondrial approach|Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
46010551|NCT04576520|Procedure|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
46010552|NCT04576520|Procedure|physical therapy|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions.
46097291|NCT00536575|Drug|Bortezomib|"Dose Level 1: Bortezomib 1.3mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.~Dose Level 2: Bortezomib 1.6 mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.~Dose Level 3: Bortezomib 1.6mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle."
45679274|NCT05891613|Drug|Bupivacaine Hydrochloride|20 ml of 0.25% Bupivacaine (50 mg) with 20 ml of injectable saline (total of 40 cc) as a subcutaneous infiltration along the inframammary fold incision on one breast
45679275|NCT05891613|Drug|Liposomal Bupivacaine|20 ml of Liposomal (Exparel) Bupivacaine (266 mg/20 ml) on the contralateral breast
45679276|NCT05891600|Device|Smartclic|The SmartClic® autoinjector is a reusable, electromechanical, and single-patient device for the administration of subcutaneously administered biologics.
45679277|NCT05891561|Drug|Pertuzumab|4 cycles of taxane, pertuzumab, trastuzumab
45679278|NCT05891535|Procedure|Robot assisted radical cystectomy without mono J ureteral stent placement|Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
45679279|NCT05891535|Procedure|Robot assisted radical cystectomy with mono J ureteral stent placement|Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
46097292|NCT00536575|Drug|Sorafenib|"Dose Levels 1 and 2: 200 mg by mouth twice daily~Dose Level 3: 400 mg by mouth twice daily"
46097293|NCT02730143|Other|Altitude exposure|Altitude exposure
46097294|NCT00712114|Drug|HE3286|HE3286 will be administered orally. Dosing will be 10 mg per day for 29 days.
45679280|NCT05891509|Procedure|Minimally Invasive Hematoma Evacuation|Procedure of minimally invasive hematoma evacuation PLUS best medical therapy
46010553|NCT02218164|Drug|Pegylated Interferon alpha-2b|Drug administration will occur on an outpatient basis at the infusion center at Moffitt Cancer Center. Dose will be weight-based. Starting treatment doses of 3 mcg/kg will be given subcutaneously (SC) injection in the thigh, abdominal wall, or upper arm every week for a total of 27 weeks as tolerated.
46010554|NCT02218164|Drug|Capecitabine|Drug administration will be on an outpatient basis. Capecitabine will be administered at an initial dose of 800 mg/m^2 by mouth twice daily on days 1-14 of a 21 day cycle with days 15-21 off. This cycle will be repeated every 21 days during the study for a maximum of 9 cycles as tolerated. Administration via feeding tube in patients unable to swallow is permitted.
46010555|NCT02218164|Drug|5-FU|If participants are not able to acquire oral capecitabine, then treating physicians will start participants on infusional 5-FU which can be delivered via standard of care. Participants will need to have a port placed for continuous infusion treatments. 5-FU pumps will be activated in the infusion center at Moffitt Cancer Center with a starting dose of 800 mg/m^2 days 1-4, with pump removal on day 5 at the infusion center. 5-FU pumps will be attached every 21 days (1 cycle) for a maximum of 9 cycles.
46097295|NCT00712114|Drug|HE3286|HE3286 will be administered orally. Dosing will be 20 mg per day for 29 days
46097296|NCT00712114|Drug|HE3286|HE3286 will be administered orally. Dosing will be 40 mg per day for 29 days
46097297|NCT02730065|Behavioral|Structured Aerobic Dance Training Group|Systematic physical activity
46010556|NCT01643109|Other|Casting & CIMT|"A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol (Hand2Hand developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies."
46010557|NCT04552106|Dietary Supplement|3 caps x3/day|3 capsules 3 times daily for 28 days
46010558|NCT04552106|Dietary Supplement|3 caps x2/day|3 capsules 2 times daily for 28 days
46010559|NCT04552106|Dietary Supplement|2 caps x3/day|2 capsules 3 times daily for 28 days
45679281|NCT05891509|Other|Best Medical Therapy|Best medical therapy
46010560|NCT04552106|Dietary Supplement|2 caps x2/day|2 capsules 2 times daily for 28 days
46010561|NCT04552106|Dietary Supplement|3 caps x1/day|3 capsules 1 times daily for 28 days
46010562|NCT04552067|Drug|Lovenox|patients given curative dose of Lovenox
46010563|NCT04552067|Drug|Enoxaparin|patients given curative dose of Enoxa
46010564|NCT01643187|Dietary Supplement|Beverage fortified with 21 vitamins and minerals|The serving contains 4 grs. of protein, 12 grs. of carbohydrate, 1 gr of fat 9 mg of zinc, 12.5 mg iron, 160 µg of folic acid, 90 µg of iodine, 250 mg of vitamin A, 40 mg of vitamin C, 0.5 mg of vitamin B6, 0.9 µg of vitamin B12, 6 mg of niacin, 0.5 mg of vitamin B2, 0.5 mg of vitamin B1, 0.3 mg of copper, 5 mg of vitamin D3, 5 mg of vitamin E, 200 mg ofcalcium, 150 mg of phosphorous, 40 mg of magnesium, 17 µg of selenium, 0.17 µg of manganese, 1.8 mg of pantothenic acid and 8 µg of biotin.
46097298|NCT02730065|Behavioral|Stretching plus education|Weekly group based stretching with psychoeducation and health education
45679282|NCT05891496|Drug|Semaglutide|Semagllutide will be administered once weekly subcutaneously.
45679283|NCT05891496|Drug|Placebo|Placebo matched to semaglutide will be administered once weekly subcutaneously.
46010565|NCT01643187|Dietary Supplement|Lactose-free milk|Serving contains 4 grs. of protein, 12 grs of carbohydrate and 1 gr of fat
46010566|NCT01643265|Dietary Supplement|Whey Milk Protein|20 grams of Whey Milk Protein
45837098|NCT00550290|Drug|Cefazolin Preoperatively|Patients in active comparator arm will receive an initial pre-operative 2 gram does of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV will be used.
46010567|NCT01643265|Dietary Supplement|Bovine Albumin Concentrate|20 grams of Bovine Albumin Concentrate
46010568|NCT04551833|Drug|Levobupivacaine|Tramadol versus Dexamethasone as adjuvant to Levobupvacain
46010569|NCT01643304|Behavioral|No drug|No drug intervention. The intervention is a questionnaire with quality of life and perception of menstrual bleedings. All subjects will complete both questionnaires.
46010570|NCT00582686|Procedure|ORIF of Calcaneus with bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) and Tricortical Iliac Crest bone grafting
46097299|NCT05355649|Device|PREGNOLIA SYSTEM|"The Pregnolia System is composed of two products: an active device (Pregnolia Control Unit) and a single-use sterile probe (Pregnolia Probe).~The intended use of the Pregnolia System is to provide information about the mechanical properties of the uterine cervix by assessing the tissue stiffness through a proxy parameter (the closing pressure, denominated CSI, or Cervical Stiffness Index, in mbar). The Pregnolia System is intended to be used in conjunction with the information obtained from the clinical evaluation of the patient and in addition to other standard examinations."
45837099|NCT03255408|Drug|Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep|The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Normoxia Exposure
46010571|NCT00582686|Procedure|ORIF of Calcaneus without bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) (no bone grafting)
46010572|NCT04551755|Drug|Ivermectin and Doxycycline|"Tab Ivermectin (6mg): 12mg first dose then one more dose of 12mgafter 12 hours~Cap. Doxycycline (100mg): 1+0+1 after meal for 10 days. To be taken with half glass of water and sit up for 20 minutes"
46010573|NCT04551755|Other|Placebo|Placebo (1) 2 tab stat then again 2 tab after 12 hours Placebo (2) will be given as 1+0+1 for 10 days
46010574|NCT01640106|Dietary Supplement|Omega-3|800 mg Omega 3 daily (600 mg DHA/200 mg EPA)
46010575|NCT01640106|Dietary Supplement|Placebo|Placebo is a combination of dietary plant-based oils in a paste containing no Omega-3 (EPA or DHA)
46010576|NCT01643421|Other|Deep inspiration and positive expiratory airway pressure|It was used a device the combines deep inspiration and positive expiratory airway pressure in asthmatic subjects, for 5 weeks, twice a day.
46010577|NCT04552028|Other|Non invasive oxygenation|To determine if the SpO2 / FIO2 ratio has a correlation with PaO2 / FIO2 ratio to identify respiratory compromise in acute pancreatitis.
46010578|NCT01643499|Drug|oxaliplatin|Given IV
46010579|NCT01643499|Drug|irinotecan hydrochloride|Given IV
46010580|NCT01643499|Drug|leucovorin calcium|Given IV
46010581|NCT01643499|Drug|fluorouracil|Given IV
46010582|NCT01643499|Other|laboratory biomarker analysis|Correlative studies
46010583|NCT00582725|Drug|R-CHOP+GM-CSF|addition of GM-CSF
46097300|NCT03214250|Drug|APX005M|Administer intravenously once every 28-day Cycle
46097301|NCT03214250|Drug|Nivolumab|Administer intravenously twice every 28-day cycle
46097302|NCT03214250|Drug|Nab-Paclitaxel|Administer intravenously on 3 times every 28-day cycle
46097303|NCT03214250|Drug|Gemcitabine|Administer intravenously 3 times every 28-day cycle
45679284|NCT05891483|Drug|SHR-1905 Injection|SHR-1905 Injection
45679285|NCT05891483|Drug|SHR-1905 Placebo Injection|SHR-1905 Placebo Injection
45679286|NCT05891470|Device|MonaLisa Touch device|sessions with intra-vaginal CO2 laster system
45679287|NCT05891470|Device|Vaginal dilatators|Home use of vaginal dilatators (at least twice a week for minimum 5 minutes)
45837100|NCT03255408|Drug|Drug Lowering CBF and Intermittent Hypoxia Sleep|The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Intermittent Hypoxia (IH) Exposure
45679288|NCT05891457|Combination Product|Nutritional Intervention|"Severe acute malnourished children were provided with appropriate nutritional therapy/treatment that include supplementation of a high-calorie diet; i.e., F-100 milk and khichuri-halwa for nutritional rehabilitation.~Egg milk and micronutrient supplementation for recovery from severe stunting following standard guidelines for facility based management and recently conducted community based nutrition intervention studies.~Wasted children were treated with suitable local nutritional management (NM), such as infant and young child feeding practices (IYCF), providing MNP and nutrition education."
46010584|NCT01643538|Behavioral|Financial incentive|Participants will receive a direct financial incentive in the amount of $20 for each week when their daily pedometer step count equals or exceeds their goal at least 5 out of 7 days.
46010585|NCT01643538|Behavioral|Social Goal|Participants will be asked to identify a charity to which they would like to donate the payment for reaching their walking goal. Each week they will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity.
46097304|NCT02729987|Behavioral|WorkGuru|A multi-modal stress management intervention accessed over 8 weeks, incorporates CBT, positive psychology and Mindfulness. Delivered via the internet.
45461992|NCT01105481|Drug|Placebo add-on|For subjects randomly allocated to the placebo treatment group, they will be added with one capsule of placebo from Day 1. On Day 8, Day 15 and Day 22, the placebo will be increased to 2, 3 and 4 capsules, respectively. and adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
45461993|NCT01178203|Drug|Placebo|Placebo
45461994|NCT01178203|Drug|Tramadol|Tab, 100mg in 6, 12 and 24 hours after root canal treatment
45461995|NCT01178203|Drug|Novafen|325 mg in 6, 12 and 24 hours after root canal treatment
45461996|NCT01178203|Drug|Naproxen|Tab, 500 mg in 6, 12, and 24 hours after root canal treatment
45461997|NCT01103219|Dietary Supplement|Nutrition|The control (placebo) group will be fed according to the routines of the participating institutions. The intervention (active) group will receive increased supply of energy, protein, vitamin A and long-chain unsaturated fatty acids.
45461998|NCT01176019|Device|Information about Prenatal Screening and Diagnosis|15-20 minute interactive video about prenatal screening and diagnosis given on day of recruitment.
45461999|NCT01178359|Drug|nitrite|
45462000|NCT01286701|Drug|Terbinafine Hydrochloride Tablets, 250 mg|Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
46010586|NCT01643538|Behavioral|Personal financial incentives & social goals|Participants will be able to allocate their reward for reaching their walking goal: the $20 reward can be divided between personal financial incentive and a charitable donation. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will be notified by email or mail (based on their preference), that a donation of the selected amount has been sent to the charity.
46097305|NCT00722098|Biological|DC Vaccine & Cyclophosphamide|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive either CPA 300mg/m2 for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
45462001|NCT00006305|Procedure|Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions|Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions
45462002|NCT00006305|Procedure|Coronary Artery Bypass|Coronary Artery Bypass
45462003|NCT00006305|Drug|Biguanides, thiazolidinediones|Biguanides, thiazolidinediones
45462004|NCT00006305|Drug|Insulin, sulfonylurea|Insulin, sulfonylurea
45462005|NCT00006305|Drug|ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers|ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers
45462006|NCT03862573|Device|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
45462007|NCT01176097|Drug|AZD5658|oral suspension, escalating single doses
45462008|NCT01176097|Drug|Placebo|oral suspension,single doses
45462009|NCT01284907|Dietary Supplement|Vitamin D3 (Cholecalciferol)|Vit D3 ( Cholecalciferol) 1200 IU oral daily for 6 months
45462010|NCT01284907|Dietary Supplement|Placebo Drops|
45462011|NCT01286857|Device|External Suction Interface and a Silicon Film|Evaluate the function of a new silicon cover film and an on-top suction device to be used in a NPWT system in the treatment of acute and chronic wounds.
45837101|NCT03255408|Drug|Placebo and Normoxia Sleep|The study participants will take Placebo and sleep under Normoxia Exposure
45837102|NCT03255408|Drug|Placebo and Intermittent Hypoxia Sleep|The study participants will take Placebo and sleep under Intermittent Hypoxia (IH) Exposure
45837103|NCT01797198|Drug|ASP3652|Oral
45462012|NCT01103297|Device|Variable Angle Distal Radius Plate ® (Surgery)|Fracture reduction with distal radius plate
45462013|NCT03865459|Other|Video group|Patients in the video group started to watch the relaxing video about 5-10 minutes before cystoscopy, and continued to watch video during the whole procedure.
45679289|NCT05891444|Device|High frequency transcranial random noise|High frequency tRNS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
46097306|NCT00722098|Biological|DC Vaccine & Placebo|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive saline for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
46010587|NCT01643538|Behavioral|daily pedometer use and weekly feedback|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.
46010588|NCT00582764|Other|perform dynamic contrast enhanced (DCE) MRI|With an IV catheter in place, the patient will lie prone on the MRI scanner table with the breasts positioned in the commercial breast coil and then be moved feet first to the center of the MRI scanner. The only difference introduced by the addition of DCE MRI is that before the patient is moved into the scanner for the first time, the IV catheter will be hooked up with a programmable power injector (Medrad, Indianola, PA) which is loaded with Gd contrast and saline. The contrast injection and saline flush will be delivered by the injector while the patient is inside the scanner and the DCE MRI data collection is in process. The Gd contrast dose used for DCE MRI is the same as for clinical MRI: 0.1 mmol/kg. The injection speed of 2 mL/sec is safe and similar to that of manual injection.
46010589|NCT01640145|Dietary Supplement|Protein|Whey protein intake
46010590|NCT01640145|Other|Exercise|Unilateral low intensity exercise
46097307|NCT03860857|Radiation|Amyloid PET scan|Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18
46097308|NCT03860857|Drug|Tau PET scan using MK-6240|Tau Positron Emission Tomography scan using radio tracer MK-6240
46097309|NCT03860857|Behavioral|Neurocognitive testing|A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.
46097310|NCT03860857|Other|MRI|High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.
45679290|NCT05891444|Device|Sham high frequency transcranial random noise|In the sham condition, tRNS was delivered only during the ramp-up and ramp-down periods (30s); no current was delivered during the 30-minute intervention.
46097311|NCT00712192|Procedure|coronary artery bypass grafting|patient with coroary artery diseases underwent coronary artery bypass grafting surgery
46097312|NCT04186871|Drug|branebrutinib|Specified dose on specified days
46097313|NCT04186871|Drug|abatacept|Specified dose on specified days
46097314|NCT04186871|Drug|branebrutinib placebo|Specified dose on specified days
46097315|NCT04067440|Diagnostic Test|Microbial Swab|Swabs will be taken from peritoneum and jejunum (intraoperatively), rectum, and stool
46097316|NCT05245591|Drug|Pentosan Polysulfate Sodium 100 MG Oral Capsule|Pentosan Polysulfate Sodium 100 mg three times daily (tid) for 0-8 weeks Pentosan Polysulfate Sodium 100 mg twice daily (bid) for 9-16 weeks
46097317|NCT05245591|Drug|Placebo|Placebo 100 mg three times daily (tid) for 0-8 weeks Placebo 100 mg twice daily (bid) for 9-16 weeks
46097318|NCT04067206|Other|RECORDED MOTHER'S VOICE|The mothers of the babies were given voice recorders and asked to record their voice in a comfortable room saying whatever they wanted to their baby. Each mother recorded her voice for 3-5 minutes. The voice recorder was placed at the baby's foot five minutes before the procedure and then played to the baby during the procedure.The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups.
46097319|NCT04067206|Other|White Noise|"The white noise was started five minutes before the heel lance and was played to the baby during the procedure. Dr. Harvery Karp's The Happiest Baby, which consists of only intrauterine sounds, was used. The speakers were placed at a distance of about 30 cm from the foot of the neonate. The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups."
46097320|NCT04067206|Other|MiniMuff|MiniMuffs placed on their ears five minutes before the procedure to reduce the environmental noise. Latus MiniMuffs - Neonatal Noise Attenuators have been developed for newborns and premature babies. MiniMuffs protect the sensitive ears of the premature and provide a safe environment for healthy development.
46097321|NCT00992095|Drug|buprenorphine hydrochloride|single dose 8 mg sublingual tablet
45679291|NCT05890963|Drug|ART|ART is a combination of three or more drugs from different classes of antiretroviral medication.
45679292|NCT05890963|Drug|10E8.4/iMab|10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.
45837104|NCT01797198|Drug|Gemfibrozil|Oral
45837105|NCT01797198|Drug|Repaglinide|Oral
46097322|NCT00653354|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by valdecoxib 20 mg tablet by mouth 1 to 12 hours after the first dose
45462014|NCT01101269|Drug|ACEI or ARB|Subjects will be asked to discontinue their usual ACE inhibitor or Angiotensin Receptor Blocker (ARB) for ten days, undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then resume their usual ACEI or ARB for ten days, then undergo another CEU using Definity as the contrast agent.
45462015|NCT01101269|Drug|Lisinopril|Subjects will be undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then take Lisinopril 10 mg every day for 7 days, after which they will undergo another CEU using Definity as the contrast agent.
45462016|NCT01174537|Biological|New Castle Disease Virus|Patients will receive IV 1*10^10 EID50 (50 percent Embryo Infectious Dose. One EID50 unit is the amount of virus that will infect 50 percent of inoculated eggs) on a daily basis for a minimum of 5 days a week until disease progression for a minimum duration of 1 year.
46010591|NCT05361577|Device|Exoplulse Mollii suit|Exopulse Mollii suits consists of a body Garments (Jacket and Pants) and a control unit. The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate 40 groups of muscles, conductive wires and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body. The control unit is a battery powered electrical device which sends low intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body.
45462017|NCT03529773|Biological|Formulation A|RSV vaccine
45462018|NCT03529773|Biological|Formulation B|RSV vaccine
45462019|NCT03529773|Biological|Placebo|Placebo
45462020|NCT01103375|Drug|erlotinib hydrochloride|Given PO
45679293|NCT05890963|Drug|VRC07-523LS|VRC07-523LS is an engineered variant of VRC01, a bNAb that targets the CD4 binding site of the HIV-1 envelope. VRC07-523LS will be administered IV at the 1200mg dose to participants in Step 1 per the SOE.
45837106|NCT00550368|Biological|Biological intervention: Enteropathogenic E. coli|5x10^8 or 1x10^9 organisms of EPEC were administered to all participants.
45837107|NCT00551070|Other|Laboratory Biomarker Analysis|Correlative studies
46097323|NCT00653354|Drug|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
46097324|NCT00653354|Drug|placebo|placebo within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
45837108|NCT00551070|Other|Pharmacological Study|Correlative studies
46097325|NCT04067128|Behavioral|Health coaching|Brief telephonic intervention consisting of up to three phone calls
45462021|NCT01103375|Drug|isotretinoin|Given PO
45837109|NCT00551070|Drug|Selumetinib|Given PO
45837110|NCT00551070|Drug|Selumetinib Sulfate|Given PO
45837111|NCT00552786|Drug|N-acetylcysteine (NAC)|600mg twice daily for 2 weeks
45837112|NCT00552786|Drug|glucose|1 gm glucose capsule
45837113|NCT04473378|Device|FreeStyle Libre Pro|The device uses patches that attach to the skin on the back of the arm to measure blood sugar changes for the duration of the chemotherapy course.
45837114|NCT01797744|Other|Vestibular rehabilitation|Usual rehabilitation and four different vestibular rehabilitation exercises, adapted to the individual patient
46010592|NCT05361577|Device|Exopulse Mollii suit (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
45462022|NCT01103375|Other|laboratory biomarker analysis|Correlative study
45462023|NCT01103375|Genetic|protein expression analysis|Correlative study
45462024|NCT03865537|Procedure|Cold snare EMR|Participants will have their large polyp removed without electrocautery
45462025|NCT03865537|Procedure|Hot snare EMR|Participants will have their large polyp removed with electrocautery
45462026|NCT03865537|Procedure|Eleview injection|Participants will have their polyp submucosally injected with Eleview
45462027|NCT03865537|Procedure|Placebo injection|Participants will have their polyp submucosally injected with placebo
45462028|NCT02525419|Behavioral|Weight Loss Phase|High Protein, Intermittent Fast, Low Calorie Diet
45462029|NCT02525419|Behavioral|HP-IF|High Protein, Intermittent Fast
45837115|NCT00517530|Drug|Obinutuzumab|Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.
45837116|NCT00518154|Drug|Pyridostigmine tablets|Patients will take 30mg tid PO for 12 weeks
45837117|NCT00553098|Biological|Alemtuzumab|Given IV
45837118|NCT00553098|Procedure|Allogeneic Bone Marrow Transplantation|Undergo HCT
46010593|NCT01640223|Device|Dexcom7|patients will wear 2 Dexcom sensors 3 days before hospitalization.
46010594|NCT01640223|Device|Dexcom7|patients will wear 2 Dexcom sensor one day before hospitalization
45462030|NCT02525419|Behavioral|HH|Heart Healthy
45462031|NCT03949049|Drug|Citicoline|Citacoline as neuroprotector
45462032|NCT03949049|Other|Placebo|placebo group
45462033|NCT03865225|Other|Biofeedback|9 x 10 minutes biofeedback sessions over period of three days
46010595|NCT04551794|Behavioral|Selfapy with therapeutic guidance|The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to talk about personal experiences with a therapeutic guide.
46010596|NCT04551794|Behavioral|Selfapy with additional peer support|The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to participate in exchange with peers via an internal closed forum.
45462034|NCT03865225|Other|Sham-Biofeedback|9 x 10 minutes sham-biofeedback sessions over period of three days
46010597|NCT01643577|Procedure|Acupuncture for gastroparesis|A series of acupuncture points selected for the treatment of gastroparesis will be used at each of the 10 acupuncture sessions
46010598|NCT01643577|Procedure|Acupuncture for musculoskeletal pain|Acupuncture points selected for the treatment of musculoskeletal pain will be used during each of the 10 acupuncture sessions
45462035|NCT01285687|Device|acupuncture|Sterile, disposable, FDA-approved acupuncture needles will be used. Acupuncture will be performed bilaterally. The needles will penetrate the skin to a depth of 5-10mm and will be kept in place for no more than 5 minutes. The acupuncture points will be: Li 4, Li 11, St 44, according to Chinese acupuncture mapping. Treatment will be repeated at least 3 times during the hospital stay. Treatment will start in the pediatrics department approximately two hours after discharge from the postoperative unit. The 2nd treatment will be given on the same evening, approximately 4-8 hours after the 1st treatment and the 3rd treatment will be given the following morning, approximately 12-18 hours after the 2nd treatment. Exact treatment times will be recorded in the patient's file.
45462036|NCT03949127|Other|Exercise Group|The group who will meet a physiotherapist who will show them strengthening and stretching muscles associated with pelvic tilt.
45462037|NCT03864991|Device|e-device for step count (fit-bit)|Patients in this group will receive fitbit device to count their daily steps and record it into their log books.
45462038|NCT03864991|Behavioral|e-messages for log book|Patients in this group will receive e-messages to maintain their log books as per instruction for blood sugar levels and send back weekly through snap shot.
45462039|NCT03864991|Behavioral|e-messages for log book & fit-bit|Patient in this group will receive e-messages to maintain their log books for blood sugar levels as well as use fitbit device and maintain their log book for daily step count and send back weekly through snap shot.
45462040|NCT01178437|Device|T-VNS® Stimulator cM02 (Transcutaneous Stimulation of the Vagus Nerve)|daily, transcutaneous, electrical stimulation of the vagus nerve by the t-VNS device for a period of 9 months
45679294|NCT05890378|Other|Testing water|Using existing secondary data available on the research communities as well as qualitative inquiry, we will purposefully select 40 water sources for the water analysis across from the communities selected for the implementation research (up to 30 communities with a maximum of 5 water sources per community). The selection of water sources will be stratified by type of water sourceand near the route for long-term animal migration. For each water source, we will aim to have a water sample collected at all water sources twice a day (morning and later afternoon) once a week for four weeks, varying the day of the week. Thus, we will collect a total of 320 water samples in the course of four weeks at the end of the dry season before the rains start.
46097326|NCT02729675|Other|Access Intervention|The 7 worksites in this arm received year-round, weekly mobile F&V markets (Fresh To You - FTY) selling local and non-local fresh produce at or below local supermarket prices. The markets carried 50 to 70 different produce items and were held both indoors and outdoors depending on the weather and worksite preference. When held indoors, F&V were sold in a cafeteria or other highly trafficked area. In good weather, the markets were held outside on the worksite property in a retrofitted a car trailer. Each market lasted two hours. On average, FTY prices were 15% to 25% lower than local retail supermarket prices. Signs, posters, email blasts and flyers advertised the markets. The FTY intervention at each worksite began with a Kick-Off event, which included the first FTY market. Each employee who attended the first market received a large, reusable shopping bag with the FTY logo on it and a freezer pack to keep F&V fresh.
46010599|NCT01117012|Drug|Ivacaftor|
45679295|NCT05890118|Drug|Stelara|A commercial formulation of ustekinumab for SC control (0.5mg)
45837119|NCT00553098|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
46010600|NCT01640262|Other|Multiparametric magnetic resonance imaging (mMRI)|A mMRI is performed before treatment of the patient and is compared to the standard diagnostic tools for evaluating the clinical stage and diagnose of prostate cancer
46010601|NCT04551209|Procedure|Maintaining apical patency|In apical patency group, a size 10 K file will be passed beyond the apical foramen between each instrument change to maintain apical patency while in Non apical patency group, K file will be carried up to the working length only. A final peri-apical radiograph will be taken in the group A with the 10 K patency file 01mm beyond the apical foramen to confirm patency.
46010602|NCT01640418|Device|Mepilex® Border Sacrum dressings|Mepilex® Border Sacrum dressings
46010603|NCT01116739|Device|Fluoride varnish|Fluoride varnish will be administered by the COHS quarterly for 2 years.
46010604|NCT01116739|Behavioral|Oral health education|Oral health education will be provided quarterly for 2 years. It will include information about how to mitigate the known risk factors for early childhood dental caries.
46010605|NCT01116739|Other|Dental services delivered by the Indian Health Service.|
45462041|NCT05625737|Drug|Fruquintinib|Fruquintinib will be administrated as 4mg orally, once daily for 2 weeks on/1 week off.
45679296|NCT05890118|Combination Product|RT-111 (0.5mg)|RaniPill capsule containing ustekinumab with a dose of 0.5mg
45837120|NCT00553098|Drug|Cyclosporine|Given PO or IV
45462042|NCT05625737|Drug|Sintilimab|Sintilimab will be administrated as 200mg once every 3 weeks.
45462043|NCT01288417|Drug|boceprevir|10 days of boceprevir 800mg TID
45679297|NCT05890118|Combination Product|RT-111 (0.75mg)|RaniPill capsule containing ustekinumab with a dose of 0.75mg
45679298|NCT05890066|Procedure|single-port laparoscopy|Compare the effectiveness and safety between single-port and multi-port laparoscopic surgery
46097327|NCT02729675|Behavioral|Enhanced Intervention|The 7 worksites in this arm received the Access intervention described above as well as set of educational/behavioral interventions. At the Kick-Off, employees received the first month's newsletter and an educational digital video disk (DVD) in the reusable shopping bag. They also received a chef-run cooking demonstration/taste-testing along with recipes and information about the upcoming intervention activities. Intervention activities included two 6-week campaigns (Just Add Two and Choose Color, Choose Health); a 90 minute DVD with cooking demonstrations about preparing quick, healthy inexpensive meals and unusual F&V; a two-page, full-color newsletter distributed monthly; Food demonstrations/tastings delivered once a month by chefs including an easy to prepare, F&V-based recipe; a total of 12 recipe handouts that correlated with the monthly cooking demonstration; a Good to Go website; and a project bulletin board.
46097328|NCT02729675|Behavioral|Comparison Behavioral Intervention|Brown University contracted with the Greater Providence Young Men's Christian Association (YMCA) to provide a physical activity and stress reduction intervention at the 7 worksites in the comparison group. Two, six-week campaigns were developed jointly by the Brown study team and YMCA staff. These campaigns followed the same format as the enhanced intervention group campaigns and were provided during the same time periods as those at the enhanced intervention sites. Everyone who participated in the campaigns also received a free, 6-week membership to the YMCA.
46097329|NCT02646488|Behavioral|Million Hearts ABCS 6 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
46010606|NCT01116544|Device|AMES Therapy (assisted movement and enhanced sensation)|Each subject will receive 30 sessions of AMES therapy in the clinic. Each session will consist of 10 min of functional testing (i.e., passive motion and strength tests) followed by 30 min of grasp therapy using the AMES device. One group of subjects will receive AMES therapy only with joint torque biofeedback (without EMG feedback), and the other group will receive AMES therapy with EMG biofeedback. While all test subjects should attempt to open the hand when the grasp mechanism is opening and close the hand when the mechanism is closing, the biofeedback information provided to aid a subject will differ for the 2 subject groups.
46010607|NCT01640496|Drug|Vitamin D3|3000 IU Vitamin D3 tablets (Cholecalciferol) will be used. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
46010608|NCT01640496|Other|Placebo|Placebo will be given to subjects. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
46010609|NCT04551443|Biological|Intravenous infusion placebo|Intravenous infusion placebo or WJMSCs in patients with AMI
46010610|NCT04551443|Biological|Intravenous infusion WJMSCs|Intravenous infusion WJMSCs or placebo in patients with AMI
46010611|NCT01643655|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Into the Femoral Head infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 cells/3mL
46010612|NCT04551248|Biological|10 or 13-valent pneumococcal conjugate vaccine|a four-dose series that is indicated for use at 2, 4, 6, and 12 to 15 months of age.
45679299|NCT05889949|Drug|Sorafenib|oral sorafenib
45462044|NCT01288417|Drug|raltegravir|raltegravir 400mg single dose
45462045|NCT03949205|Other|Leg Extension Isometric Training|The leg extension isometric exercise will be performed tree times a week , in four 2 min bouts of isometric contraction, at a intensity of 30% of maximal voluntary contraction and an interval of two minutes between bouts.
45462046|NCT02529917|Dietary Supplement|Hemp powder|Hemp powder supplement
45462047|NCT02529917|Dietary Supplement|Soy Powder|Soy powder supplement
45462048|NCT01285765|Drug|RCHOP21|Prednisone-60 mg/m2: D1 D2 D3 D4 D5;Rituximab-375 mg/m2 : D1; Doxorubicin-50 mg/m2 D1;Cyclophosphamide-750 mg/m2:D1 Vincristine-1.4 mg/m2 :D1; G-CSF SC -5 microg/kg/day: D6 to D13
45599119|NCT05613985|Other|Usual Care alone|"Usual Care is defined as the following procedures to apply to the foot ulcer, carried out in the order in which they are listed:~Sharp debridement (the debridement will be performed only if non-vital tissue is present), Mild washing of the whole ulcer with physiological solution, Treatment with topical antiseptic containing Iodopovidone, Covering with iodopovidone impregnated gauze while the ulcer is clinically infected (PEDIS ≥ 2) [If, during the study, PEDIS is < 2, the ulcer will be covered with nonadherent paraffin gauze].~Treatment 2 times a week (4 treatment weeks, 8 treatments)."
45599120|NCT05613985|Device|System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care|"System VULNOFAST® plus / VULNOLIGHT®: VULNOFAST® plus sterile solution, in combination with a red light source VULNOLIGHT®. VULNOFAST® plus and VULNOLIGHT® will be used in accordance with their Instructions for Use (IFU) and User Manual.~Treatments 2 times a week (4 treatment weeks, 8 treatments of Usual Care and 8 treatments of system VULNOFAST® plus / VULNOLIGHT®)."
45599121|NCT02343393|Drug|Hydralazine|
45599122|NCT02343393|Drug|Isosorbide Dinitrate|
45599123|NCT03896009|Drug|AXS-07 (MoSEIC meloxicam and rizatriptan)|AXS-07 taken once upon onset of a qualifying migraine.
45599124|NCT03896009|Drug|Meloxicam|Meloxicam taken once upon onset of a qualifying migraine.
45679300|NCT05889949|Drug|Lenvatinib|oral lenvatinib
45679301|NCT05889858|Other|Data collection|Data collection
45837121|NCT00553098|Drug|Fludarabine Phosphate|Given IV
45462049|NCT01103453|Behavioral|Virtual Action Planning Supermarket (VAP-S) Software|"The VAP-S simulates a supermarket with multiple aisles displaying items. Several obstacles are designed to hinder the progression of the shopper along the aisles. In addition, virtual humans populate the supermarket. The VAP-S is designed so that the user enters the supermarket behind the cart and navigates within the supermarket via the keyboard keys. He is thus able to experience the environment personally without any intermediate. The task is to purchase 7 items from a list, proceed to the cashier and pay for them.~We propose 9 sessions of 45 minutes. The results will be analyzed to develop goals for intervention, together with the client to study his awareness of his performance of IADL and Executive functions and to enhance his motivation to participate in the intervention."
45462050|NCT01103531|Behavioral|Aerobic and Resistance Exercise|Aerobic and resistance exercise for 24 exercise training sessions over an 8-week period (three times weekly).
45462051|NCT01103531|Behavioral|Educational information about health topics|A counselor will meet with participants for 24 sessions (3 times/week) over an 8-week period to present and discuss information that includes topics on health and wellness, and lifestyle topics such as healthy eating, meditation, sleep hygiene, and cancer screening.
45462052|NCT03864913|Drug|Testosterone injection|SQ or IM testosterone injections for pubertal induction of transgender male adolescents. Increasing doses per protocol at 3 month and 6 month follow up.
45462053|NCT03864913|Behavioral|PedsQL questionnarie|Validated Pediatric Quality of Life questionnaire completed by subjects at baseline, 3 month and 6 month study visits.
45462054|NCT03864913|Other|Masculinizing effects questionnaire|Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
45462055|NCT03864913|Other|Medication experience questionnaire|Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
45462056|NCT03865147|Drug|Tri-Solfen Gel (Lidocaine HCl, Bupivacaine HCl, Adrenaline Acid Tartrate /Cetrimide)|Investigational Drug
45462057|NCT03865147|Drug|EMLA cream|Active Comparator
45462058|NCT03865147|Drug|Post Operative Analgesia (Paracetamol, Ibuprofen)|Standard of Care
45462059|NCT05664867|Other|Mainstream Genetic Testing Model|Mainstream Genetic Testing Model of Cancer Genetics Service Delivery
45462060|NCT05664867|Other|Enhanced Standard of Care Model|Enhanced Standard of Care Model of Cancer Genetic Service Delivery
45462061|NCT03722823|Drug|Tucatinib|300mg oral single dose
45462062|NCT03862651|Drug|Cangrelor|Cangrelor is an intravenous analog of adenosine triphospate with a potent, selective and specific affinity for P2Y12 receptors.
45462063|NCT03799211|Behavioral|Motivational Interviewing|Phone call using motivational interviewing technique
45462064|NCT03799211|Behavioral|Treatment as Usual|will receive a regular study phone call after three months
45462065|NCT03722745|Behavioral|TARGET|TARGET is manualized cognitive-behavioral treatment designed to help adolescents and adults with symptoms of posttraumatic stress
45462066|NCT03722745|Behavioral|TAU|It involves referral to an offsite community mental health provider with no attempt to control the treatment modality-type-quality (i.e., evidence-based-treatment or not).
45462067|NCT03349710|Biological|Nivolumab|Specified dose on specified day
45462068|NCT03349710|Drug|Cetuximab|Specified dose on specified day
45837122|NCT00553098|Other|Laboratory Biomarker Analysis|Correlative study
45837123|NCT00553098|Drug|Mycophenolate Mofetil|Given PO or IV
46010613|NCT04551248|Biological|23-valent pneumococcal polysaccharide vaccine|Single 0.5-mL dose administered intramuscularly or subcutaneously only.
46010614|NCT04551248|Biological|Influenza vaccine|One dose of trivalent influenza vaccine in flu seasons.
45462069|NCT03349710|Drug|Cisplatin|Specified dose on specified day
45462070|NCT03349710|Radiation|Radiotherapy|Specified dose on specified day
45462071|NCT01286935|Drug|Safinamide|
45462072|NCT01286935|Drug|Safinamide|
45462073|NCT01286935|Drug|Placebo|
45462074|NCT01288495|Dietary Supplement|supplemental L-alanine|Subjects will consume l-alanine prior to eating fructose-containing foods.
45462075|NCT01288495|Dietary Supplement|Metamucil|Subjects will consume the placebo prior to eating fructose-containing foods.
45462076|NCT03946943|Drug|Anlotinib|Once a day dosing of anlotinib alone for the first 7 days, Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
45462077|NCT03946943|Drug|Toripalimab|Toripalimab 240mg shall be administered via intravenous (IV) infusion, once every 21 days, on day 8 and day 29 of the first cycle, and days 1 and 22 of the following cycles.
45462078|NCT03946943|Procedure|Blood Draw|Peripheral blood draws for correlative studies characterizing T-cells in peripheral blood will be performed at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
45599125|NCT03896009|Drug|Rizatriptan|Rizatriptan taken once upon onset of a qualifying migraine.
45599126|NCT03896009|Drug|Placebo|Placebo taken once upon onset of a qualifying migraine.
45837124|NCT00553098|Radiation|Total-Body Irradiation|Undergo low dose TBI
45837125|NCT00553410|Drug|Letrozole|Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously
46010615|NCT01643733|Device|Using Flow measurements to guide fistula angioplasty (Transonics)|Transonics flow measurements in the fistula would be used to guide the fistula intervention
46010616|NCT02214056|Other|Patient recruitment|Participating general practitioners (GPs) will inform and recruit participants from among regular patient consults. Using the provided web tools, GPs will organize a visit with the mobile team that fits the needs of the patient.
45462079|NCT03946943|Procedure|Tumor Specimen Collection|Tumor specimen collection via core needle biopsy for correlative studies characterizing T-cells in tumor tissue will occur at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
45462080|NCT03511053|Procedure|Epidural Steroid Injection with Lavage|All participants will receive a saline lavage prior to the epidural steroid injection.
45462081|NCT01178515|Other|Modification of the content of fat in milk|Comparison of three levels of fat content in cow´s milk
45462082|NCT01178515|Other|Modification of the content of cows milk|Comparison of three levels of fat content in cows' milk
45462083|NCT01178515|Other|Modification of the fat content of cows´ milk|Comparison of three levels of fat content in cow´milk
46010617|NCT02214056|Procedure|Mobile team exam|"Each patient enrolled will receive a standardized assessment in one locality, made in about two hours, and comprising:~questionnaire responses, a complete physical exam, a 12-lead ECG, spirometry before and after administration of β2-agonists, an arterial Doppler ultrasound (carotid and abdominal), ankle-brachial index (systolic pressure at the toe).~At the end of two hours, each patient will evaluate their satisfaction using a survey of acceptability and leave with a full report to the attention of their general practitioner (copy sent to Physician if needed) detailing the results of the different examinations."
46010618|NCT04529382|Diagnostic Test|Cognitive testing (Bayley III, WPPSI III and WISC V)|Parents and children will be invited to come for an outpatient clinic visit where cognitive testing and neurologic examination will be performed. In addition to this parents will be asked to fill in questionnaires, provide latest school results and medical files will be requested from treating physicians.
46010619|NCT04550819|Procedure|intraintestinal extended biliary stents|The test group will be placed intraintestinal extended biliary stents in intrahepatic bile duct in ERCP
46010620|NCT04550819|Procedure|ordinary plastic biliary stents|The test group will be placed ordinary plastic biliary stents in intrahepatic bile duct in ERCP
46010621|NCT01640535|Drug|Montelukast + Levocetirizine|Tablet, Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
46010622|NCT01640535|Drug|Levocetirizine|Tablet, Matching placebo of Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
46097330|NCT02646488|Behavioral|Million Hearts ABCS 9 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
45462084|NCT01105637|Behavioral|Augmented Exercise Program|12 week (3 x per week) exercise prescription
45462085|NCT03730155|Other|CCT intervention.|8-week course with 2 hours sessions weekly. Participants should meditate 25 min. pr. day during the 8 weeks.
45462086|NCT05666635|Biological|LTC004|"LTC004 Phase I:Participants will be allocated to one of the following dose groups: 3, 15, 45, 90, 180，270,360 and 450 ug/kg, and receive a treatment of LTC004 followed by 21 days of dose limited toxicity (DLT) observation period.~Phase Ib indication exploration~Other Name: LTC004 for Injection"
45462087|NCT03711864|Biological|IM21 CAR-T cells|fludarabine and cyclophosphamide Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
45462088|NCT03865069|Other|Mode of ventilation (Volume Guarantee)®|This is a volume-targeted mode of ventilation aimed at delivering the set tidal volume of gas by automatically adjusting the peak inspiratory pressure (PIP) on a breath-by-breath basis. Theoretically this should minimise variation in tidal volume delivery as lung compliance and the infant's condition changes. This function is achieved by an automated servo-controlled mechanism. The upper PIP limit can be set by the clinician as a safety mechanism.
45599127|NCT03514303|Diagnostic Test|Spiriplex Allergenex Microassay|A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.
45599128|NCT02344875|Drug|FYU-981, (Oral single dosing)|
45599129|NCT02293915|Drug|Sodium oligo-mannurarate 900mg|sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
45599130|NCT02293915|Drug|Placebo|simulant of sodium oligo-mannurarate capsule
45679302|NCT05888987|Biological|PCR multiplex by FilmArray|PCR multiplex by FilmArray system on corneal swabbing sample
46097331|NCT02646488|Behavioral|Million Hearts ABCS 12 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
45679303|NCT05888116|Device|Hidrante HA|Apply the 5 ml single dose three times a week, every other day, preferably at night before going to bed for 4 weeks.
45679304|NCT05888116|Device|Cumlaude Hidrante Interno®|Apply the 5 ml single dose three times a week, every other day, preferably at night before going to bed for 4 weeks.
45679305|NCT05887804|Biological|umbilical cord-derived mesenchymal stem cells (UC-MSC)|Group 1 was injected UC-MSC 2 million cells/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
45837126|NCT00553410|Drug|Letrozole|Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -> 36 mo) plus 1 x 12 mo in yr 5 -> 48 months
45462089|NCT03865069|Other|Mode of ventilation (Volume control Ventilation)|Volume-Controlled ventilation (VCV) is a type of 'volume targeted' mode. It aims to target be supported the desired tidal volume by delivering a set volume (chosen by the clinician) irrespective of the underlying lung mechanics. The ventilator will generate whatever peak inspiratory pressure is necessary to deliver this volume. There is constant inspiratory flow pattern (a square flow waveform) and peak volume and inspiratory pressure delivery are achieved at the end of inspiration. During the 'control period' of 12 hours without VG, infants will using VCV A/C (assist control) as is our current clinical standard.
46010623|NCT01640535|Drug|Montelukast|Tablet, Montelukast sodium 10 mg + matching placebo of Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
46097332|NCT02646488|Behavioral|Million Hearts ABCS 15 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
46097333|NCT02646488|Behavioral|Standard Care Regimen 9 Months|
46097334|NCT02646488|Behavioral|Standard Care Regimen 12 Months|
46097335|NCT02646488|Behavioral|Standard Care Regimen 15 Months|
46097336|NCT02646488|Behavioral|Standard Care Regimen 18 Months|
45462090|NCT01105793|Drug|Danazol|High dose FP1198 applied once daily to both breasts for 6 treatment cycles.
45462091|NCT04934579|Drug|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 375mg/m2 intravenous infusion d1, every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
45462092|NCT04934579|Drug|Lenalidomide|25mg orally d1-10 every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 25mg orally d1-14,d29-42 every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
45462093|NCT04934579|Drug|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
46097337|NCT02646488|Behavioral|Standard Care Regimen 21 Months|
46097338|NCT02646488|Behavioral|Standard Care Regimen 24 Months|
46097339|NCT02646488|Behavioral|Standard Care Regimen 27 Months|
46097340|NCT02646488|Behavioral|Follow Up Post Intervention 21 Months|
46097341|NCT02646488|Behavioral|Follow Up Post Intervention 24 Months|
46097342|NCT02646488|Behavioral|Follow Up Post Intervention 27 Months|
46097343|NCT02646488|Behavioral|Follow Up Post Intervention 30 Months|
45462094|NCT03134131|Drug|ONC201|ONC201 is an oral, small molecule selective antagonist of DRD2 that induces tumor cell death.
45599131|NCT03145623|Drug|Elbasvir and Grazoprevir|Elbasvir 50 mg and grazoprevir 100 mg during the French temporary authorization for use (ATU) program
45679306|NCT05887804|Biological|umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)|Group 2 was injected UC-CM 1 mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
45837127|NCT00554970|Drug|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol
45837128|NCT00554970|Drug|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol
45837129|NCT00554970|Drug|Budesonide inhalation suspension 0.25mg|a single dose of Pulmicort Respules® 0.25mg delivered by nebulization twice daily for 7 days as per protocol
46010624|NCT04550936|Drug|Isavuconazole|antifungal agent
46010625|NCT04529421|Behavioral|Online instruction|For some courses and groups of students, instruction is primarily offered digitally, so that the students can participate from outside campus.
46097344|NCT02646488|Behavioral|Follow Up Post Intervention 33 Months|
46097345|NCT02571322|Device|HyperVibe Whole Body Vibration training device|Standing on the HyperVibe platform during WBV training will cause repetitive upward movements of platform to be felt by participant.Thus the participant will feel a whole body vibration, as the name of training implies. Each session will last approximately fifteen minutes.
46097346|NCT02571322|Other|Aerobic Exercise|Aerobic exercise session will last approximately thirty minutes. Starting training intensity will be specific to each participant based on his/her baseline fitness level.
46010626|NCT04529421|Behavioral|In-person instruction|For some courses and groups of students, instruction is primarily offered in-person, on campus (or elsewhere).
46010627|NCT04550858|Drug|Rebamipide|rebamipide use for ttt of h.pylori infection
46010628|NCT01640574|Drug|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
46010629|NCT01640574|Drug|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
46010630|NCT01640574|Drug|Chloroquine|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
46097347|NCT03816319|Drug|UAE Inhibitor TAK-243|Given IV
46097348|NCT05402813|Other|Pure Tone Audiometry Assessment|Collection of Pure Tone Audiometry data performed in routine practice during study period
46010631|NCT01640574|Drug|Chloroquine|o Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
46010632|NCT04550975|Other|Advanced Cognitive Stimulation Therapy|An adapted version of Cognitive Stimulation Therapy for people with moderate to severe dementia.
46010633|NCT01643811|Procedure|gastrectomy|subtotal gastrectomy with gastroduodenostomy or loop gastrojejunostomy or Roux Y gastrojejunostomy total gastrectomy with Roux Y esophagojejunostomy
46010634|NCT01643811|Procedure|Endoscopic submucosal dissection|endoscopic submucosal dissection
46097349|NCT05402813|Other|Quality of Life Questionnaires|Collection of Quality of Life questionnaire's answers during study period
46097350|NCT00712504|Drug|sunitinib|25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in two different dosing regimens: schedule 2/1 (2 weeks on, 1 week off) and schedule 4/2 (4 weeks on, 2 weeks off)
46097351|NCT00712504|Drug|docetaxel|60, 75, and 100 mg/m2 docetaxel administered every 21 days as a 1-hr IV infusion
46097352|NCT02694497|Other|Chlamydia care as usual|
46097353|NCT02641574|Other|compare complication|
45462095|NCT03377634|Behavioral|MORPH|Participants will engage in 12 weekly group coaching sessions discussion behavioral approaches to pain management, weight loss, and daily physical activity. The first three sessions (i.e., weeks 1 - 3) will occur in-person, and the remaining 9 will take place via telephone. All intervention participants will receive access to an activity monitor, smart scale, and smartphone app that aims to provide support for daily physical activity and weight loss.
46010635|NCT01116427|Biological|abatacept|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52; Dosing: less than 60 kg, 500 mg; 60-100 kg, 750 mg; or greater than 100 kg, 1 gram
46010636|NCT01116427|Drug|Placebo|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52
45462096|NCT01103609|Drug|Warfarin|Oral tablet od on Day 4
45462097|NCT01103609|Drug|Placebo|Oral tablet bd, stepwise increased
46010637|NCT04550897|Drug|BM7PE|BM7PE immunotoxin is supplied as a liquid solution and is diluted in 0.9% saline to a total volume of 250 ml.
46097354|NCT03558022|Dietary Supplement|Salt Pills|7 days of a low sodium diet plus 4 salt pills (sodium chloride) taken 3 times daily with meals (approximately 7000 milligrams per day)
46097355|NCT03558022|Dietary Supplement|Placebo Pills|7 days of low sodium diet plus 4 placebo pills (microcrystalline cellulose) taken 3 times daily with meals
46097356|NCT03680755|Behavioral|Internet-based intervention for dental anxiety|Participants will complete the experimental dental anxiety management program, which will be facilitated by a person trained in psychological treatments or by dental staff. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
46097357|NCT00653510|Drug|Actrapid (human insulin)|On day one the patients will receive glucose and insulin in order to reach a blood sugar around 18 and 20 mmol/L and on day two the patients will receive glucose and insulin in order to have a blood sugar around 5 and 7 mmol/L. On both days amino acid, lipid and glucose metabolism will be assessed by means of whole body isotope dilution.
46097358|NCT05400317|Drug|AD-218|PO, Once daily(QD), 12weeks
46097359|NCT05400317|Drug|AD-218A|PO, Once daily(QD), 12weeks
46097360|NCT03480724|Other|Google Cardboard VRA|Intervention was randomized and shuffled.
46097361|NCT03480724|Other|Oculus Rift VRA|Intervention was randomized and shuffled.
45462098|NCT01103609|Drug|AZD1656|Oral tablet bd, stepwise increased
45462099|NCT03528369|Drug|CGS-200-1|CGS-200-1 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 1% for this study.
46097362|NCT05355493|Behavioral|Time to Exhaustion cycling test|After completing the MF/control task. Participants will be asked to take place on the cycle ergometer. Participants will perform a 3-min warm-up at 40% of peak power output followed by a rectangular workload at a power output corresponding to their predetermined respiratory compensation point (±80% PPO). RPM was freely chosen between 60 and 100 RPM and was recorded every minute. TTE was measured from the start until the pedal frequency was less than 60 RPM for more than 5s. This TTE task was chosen, based on a previous study of Marcora et al. (2009), who found that mental fatigue impairs physical performance. A researcher will sit behind the subject to ensure compliance with treatment. Subjects will be equipped with a heart rate monitor to continuously follow up heart rate. Subjective psychological assessment will take place with a M-VAS-scale, the NASA-TLX, the success motivation and intrinsic motivation scales, Karolinska Sleepiness Scale and visual analog scale for boredom.
45462100|NCT03528369|Drug|CGS-200-5|CGS-200-5 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 5% for this study.
45462101|NCT03528369|Drug|CGS-200 Vehicle|CGS-200 Vehicle contains all of the ingredients in CGS-200-1 and CGS-200-5 except for capsaicin.
45462102|NCT01288573|Drug|plerixafor|160 μg/kg subcutaneous (SC) injection
45462103|NCT01288573|Drug|plerixafor|240 μg/kg subcutaneous (SC) injection
45462104|NCT01288573|Drug|plerixafor|320 μg/kg subcutaneous (SC) injection
45462105|NCT03864835|Behavioral|Moderate intensity aerobic exercise|Subjects that meet requirements for the exercise arm (12 total) will be required to exercise 30 minutes, five days per week at a moderate intensity (HR target corresponding to 45-55% of their relative VO2max). Each session will be supervised in-person at the Penn State University Fitness Center with an ACSM certified exercise physiologist. This is feasible as Zhang et al.(87) found 66 out of 70 subjects (95%) completed the twelve-month supervised in-person moderate-intensity exercise protocol five-days a week.
45462106|NCT03859843|Combination Product|PRP|Ten mL of venous blood will be drawn in a syringe fill with 1.5 mL of anticoagulant solution (anticoagulant citrate dextrose solution formula A, Baxter, Deerfield, IL). The blood will be centrifuged at 160 g for 10 minutes. After the first spin, the lower red blood cell portion will be discarded, and the supernatant will be centrifuged at 400 g for 10 minutes. The resulting pellet of platelets will be mixed with 1.5 mL of supernatant, which make 1.5 mL of PRP. One mL of 3% calcium chloride will be added to the PRP to induce platelet activation.
45462107|NCT03859843|Other|Chemical peeling (Salycilic acid)|SA is a 2-hydroxybenzoic acid (from willow tree) used for superficial peeling due to its strong keratolytic and comedo- lytic properties. It promotes shedding of epidermal cells and due to its lipophilic properties can penetrate comedones and pores to prevent clogging and neutralize bacteria. It promotes desquamation of the upper lipophilic layers of the stratum corneum.19 These chemical properties explain its popularity and success in acne patients.It also has well- documented anti-inflammatory properties.
46010638|NCT04529226|Drug|Clozapine|Start treatment with 12.5 mg every 12 hours with the recommendation to increase dosage by 25-50 mg/day provided it is well tolerated up to a level of 300-450 mg/day at the end of the second week
46010639|NCT04529226|Drug|haloperidol, pimozide, olanzapine, risperidone, amisulpride|Treatment as usual using first-generation or second-generation antipsychotics
46010640|NCT04310683|Other|natural cycle for endometrium preparation|patients will not use oral contraceptive drugs
45462108|NCT03859843|Other|Chemical peeling (Jessener's solution)|is a superficial peeling agent used as adjuvant therapy for acne. it is generally proposed to break of the hydrogen bonds of keratin (keratolysis), disruption of cell membranes (cell death) and is bactericidal.
46010641|NCT04310683|Other|hormone replaced cycle for endometrium preparation|patients will receive oral contraceptive drugs for menstruation before embryo transfer
46010642|NCT04550702|Drug|Mirabegron 25mg|Mirabegron 25 mg per day
46010643|NCT01116232|Biological|anti-thymocyte globulin|Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter.
46010644|NCT01116232|Biological|rituximab|"The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour; if there is no reaction, increase the rate by 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Subsequent infusions: If patient did not tolerate initial infusion follow initial infusion guidelines. If patient tolerated initial infusion, start at 100 mg/hour; if there is no reaction, increase the rate by 100 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Note: If a reaction occurs, slow or stop the infusion. If the reaction abates, restart infusion at 50% of the previous rate.~In patients who tolerated the Rituximab well in the past, a rapid infusion rate can be used over 90 minutes with 20% of the dose administered in the first 30 minutes and the remaining 80% is given over 60 minutes."
46010645|NCT01116232|Drug|sirolimus|For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).
45462109|NCT01174693|Drug|Triflusal|Dose: 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014
45462110|NCT01174693|Drug|Clopidogrel|Dose: 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014
46097363|NCT05355493|Behavioral|Go/NoGo task|Participants are to react to different stimuli displayed on a computer screen, preceded by a screen with general instructions. Two different stimuli were present at the same time: a Go or NoGo stimulus, and a left or right stimulus (meaning that four combinations are possible: GoRight, GoLeft, NoGoRight and NoGoLeft). If a Go-stimulus is presented, participants are instructed to react to the left or right stimuli with the corresponding arrows. However, if a NoGo stimulus is presented, participants are instructed to refrain from reacting to the either the left or right stimuli. This proposed paradigm measures attention, response inhibition and working memory. Stimuli will be presented for 500 ms, with a varying interstimulus time between 1100 and 1700 ms. Outcomes for Go trials include reaction time and accuracy while the outcome for NoGo trials is only accuracy.
46097364|NCT03201848|Drug|Placebo|Placebo given to subject will be adjusted by body weight (<10kg, Placebo given to subject will be adjusted by body weight(<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day;) .
46010646|NCT01116232|Drug|tacrolimus|Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose.
46010647|NCT01116232|Other|laboratory biomarker analysis|laboratory biomarker analysis
46010648|NCT01116232|Procedure|allogeneic hematopoietic stem cell transplantation|allogeneic hematopoietic stem cell transplantation
46010649|NCT01116232|Procedure|management of therapy complications|management of therapy complications
45462111|NCT01285921|Other|vestibular test before and after hippocampal surgery|"Research of a spontaneous nystagmus with and without fixation(VIDEONYSTAGMOSCOPY) and segmentary deviations (Fukuda test)~HIT (testing semicircular canal function at high frequency).Results: Gain in %~VEMp (testing saccular function). Results: Amplitude in μV and latency in ms~ERI (testing lateral semicircular function at middle frequency). Results: Nystagmus during and after the rotations in frequency and slow phase velocity (SPV) in °/s~Caloric test (testing lateral semicircular function at low frequency). Results: Canal paresis in % and SPV in °/S"
45679307|NCT05887804|Drug|Triamcinolone Acetonide (TA)|Group 3 was injected TA 40 mg/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
46010650|NCT01116232|Procedure|peripheral blood stem cell transplantation|peripheral blood stem cell transplantation
46010651|NCT04310527|Drug|Enasidenib|Enasidenib
46097365|NCT03201848|Drug|Huaiqihuang Granule|Huaiqihuang Granule given to subject will be adjusted by body weight (<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day)
46097366|NCT02694653|Drug|Placebo|100 mL of normal saline IV given 30 minutes prior to elective c/section incision vs acetaminophen 1000 mg IV
46097367|NCT02694653|Drug|Acetaminophen|1000 mg acetaminophen in 100 mL normal saline IV given 30 minutes prior to elective c/section incision vs placebo
46010652|NCT04550663|Drug|KD-025 CAR-T cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
46097368|NCT00722956|Drug|AZD5672|100 mg once daily, 10 days
46097369|NCT00722956|Drug|atorvastatin|one single dose of 40 mg on day 10
46097370|NCT02694731|Behavioral|Mobile application intervention (Device: Smartphone)|Consists of the app described in the arm description.
45462112|NCT01288651|Drug|Ferricarboxymaltose|"Ferricarboxymaltose (Ferinject®, Vifor Pharma) is used for intravenous iron administration. This iron is administered in high dose iron infusion of 1000 mg iron (equals 20 ml Ferinject) in 250 ml saline in the vein (infusion site)within 2 hours. During infusion, patients will be observed and blood pressure and heart rate are monitored before and after administration.~Four weeks after iron administration, iron parameters are measured in the general practitioners setting. When iron parameters are still under normal values, a repeat infusion will be given of 500 mg iron (equals 10 ml Ferinject)."
45462113|NCT01178593|Other|Gut-focused hypnotherapy in group sessions|weekly session (45 min) of gut focused hypnotherapy (10 sessions within 12 weeks)
45462114|NCT00006011|Drug|Doxorubicin Hydrochloride|Given IV
45462115|NCT00006011|Drug|Cisplatin|Given IV
45462116|NCT00006011|Biological|Filgrastim|Given SC
45462117|NCT00006011|Biological|Pegfilgrastim|Given SC
45462118|NCT00006011|Drug|Paclitaxel|Given IV
45462119|NCT03864679|Other|Exercise|Subjects will perform a cycling test with 5 min incremental intensity exercise and 1 h cycling test exercising at a moderate-intensity (load will be selected in incremental intensity exercise).
45462120|NCT01105871|Drug|naloxone|4 mg naloxone in 10 ml saline given iv bolus
46010653|NCT05072977|Procedure|TransPRK|A Merocel sponge is soaked in a saline solution to expand before being gently applied to the corneal surface in three gestures similar to painting. This standardised procedure avoids inhomogeneous wetting of the cornea, which would result in uneven ablation. The laser ablation is then performed.
46010654|NCT05072977|Procedure|Alcohol PRK|A ring is placed in the centre of the cornea and filled with 20% alcohol. After 20 seconds of exposure, the alcohol is absorbed with a small sponge and the corneal epithelium is debrided with a polyvinyl alcohol expanding sponge (Merocel, Medtronic). The entire cornea is rinsed with balanced salt solution and the epithelium is peeled away from the corneal stroma. The corneal bed is then dried with a small sponge and laser ablation is performed.
46010655|NCT01115998|Other|Power wheelchair|Children used power wheelchairs for one year. They continued to receive their usual early intervention services.
46097371|NCT04165226|Device|Low level light therapy|Patients will be offered 8 sessions of photobiomodulation using HPL Pagani Diode 808/915nm LLLT 3.2W (Fimad Elettromedicali SRL®, Catanzaro, Italy) with the parameters adjusted individually according to the surface area to be treated. Optimum dose is 10 joules/cubic centimeters. The patients will take 2 to3 sessions / week.
45462121|NCT01105871|Drug|Placebo|10 ml of normal saline iv bolus
45462122|NCT03864757|Device|thyroplasty implant|Short-term implantation of thyroplasty implant, VOIS, and evaluation of voice quality and glottal closure. After evaluation, remove VOIS and perform medialization of vocal folds using conventional thyroplasty.
45462123|NCT03946787|Other|Eye Movement Desensitization and Reprocessing (EMDR) Therapy|The reprocessing and desensitization of each traumatic memory occurs in eight phases. In the first two phases, the therapist identifies targets and develops a treatment plan, enhances and develops personal resources, before working on traumatic memories. In stages 3 to 6, reprocessing and desensitization of memory is done. The patient focuses on the image of the event, negative beliefs and associated bodily sensations, while moving the eyes from side to side, following the therapist's fingers or other dual attention stimuli (eg, manual touch, auditory stimulation). Phases 7 and 8 are closing and reassessing, where the therapist determines if the memory has been processed properly.
45462124|NCT03946787|Other|Treatment as Usual|TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service.
45462125|NCT03377556|Other|Laboratory Biomarker Analysis|Correlative studies
45462126|NCT03377556|Other|Pharmacological Study|Correlative studies
45462127|NCT03377556|Drug|Talazoparib|Given PO
46097372|NCT04165226|Device|Fractional CO2|"Patients will be offered 2 sessions of fractional carbon dioxide laser on a 4 weeks interval. Topical anesthesia with pridocaine cream will be applied under occlusion for 30 - 60 minutes before the session.~Please update to the proper apparatus and parameters DEXA SmartXide DOT Fractional CO2 laser system 10600 nm (DEKA®, Florence, Italy) will be used with the following parameters adjusted individually to patients': power of 15-20 W, dwell time of 500-800 μs, spacing of 200-500 μm, and stack 2."
46010656|NCT01115998|Other|No power wheelchairs|Children in the control group did not use power wheelchairs. They continued to receive their usual early intervention services.
46010657|NCT04528914|Other|Low-FODMAP diet|The low-FODMAP diet will contain the amount of FODMAPs that will not exceed the cut-offs for each FODMAP sugar per serving of food per sitting. Diets will be individually tailored by dietitian and delivered by a catering company (five meals each day).
46010658|NCT02214095|Drug|glucosamine sulphate|group I (G1) patients received 500 mg glucosamine sulphate capsules (Glucosamine Compound) , three times daily for 3 months following initial cause related therapy. Group II patients were given placebo capsules( Lactose) for the same period following initial cause related therapy
46010659|NCT02214095|Drug|lactose capsules|
46010660|NCT04550351|Biological|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
45462128|NCT01285999|Device|PROMUS Element Coronary Stent System|Everolimus-eluting Coronary Stent
45462129|NCT01285999|Device|TAXUS Liberté Coronary Stent System|Paclitaxel-eluting Coronary Stent
45462130|NCT01105949|Device|Marketed nasal strip|Marketed nasal strip
45462131|NCT01105949|Device|NexGen AB 2R11|Nasal strip prototype
45462132|NCT01105949|Device|NexGen JB Organic PET/PE|Nasal strip
45462133|NCT05625581|Drug|tofacitinib|All subjects were treated immediately after non randomized enrollment. The treatment scheme of the experimental group: glucocorticoid+tropitib; the treatment scheme of the control group: glucocorticoid+cyclophosphamide.
45462134|NCT05625503|Drug|Verapamil|All patients routinely receive intra-arterial calcium channel blockers during transradial access for coronary angiography.
45462135|NCT05625503|Drug|Nicardipine|Calcium channel blocker
45462136|NCT03750955|Device|Plaque induced gingivitis|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene cessation utilizing localized stent-induced biofilm overgrowth model (SIBO), will manipulate the participants' oral environment by leading to reversible inflammation of the gingival tissues.
46010661|NCT04550351|Biological|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
46010662|NCT04550351|Biological|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
45462137|NCT03750955|Device|Oral hygiene maintenance|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene has been maintained by tooth brushing with fluoride toothpaste and flossing twice daily.
45462138|NCT03862105|Other|Mobile Health app tool - Twistle|The investigators propose to use radical cystectomy as a model to examine the utilization of an electronic, internet-based mobile health intervention that can prospectively collect Patient Reported Outcome data while providing timely feedback to patients and clinicians. This mobile health intervention will utilize a well-established platform (Twistle) that can be accessed through multiple technologies, including laptops, smartphones, and other computer-based systems.
45462139|NCT00005957|Radiation|Standard Breast Irradiation|Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.
45462140|NCT00005957|Radiation|Breast Radiation plus Regional Radiation|Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.
45462141|NCT01176175|Drug|Progesterone|Progesterone microspheres injectable suspension 50 mg, intramuscular weekly injection for a total of 7 doses.
45462142|NCT01176175|Drug|Progesterone|Progesterone microspheres injectable suspension 100 mg, intramuscular weekly injection for a total of 7 doses.
45462143|NCT01176175|Drug|Progesterone|Progesterone microspheres injectable suspension 200 mg, intramuscular weekly injection for a total of 7 doses.
45462144|NCT01176175|Drug|Progesterone|Progesterone microspheres injectable suspension 300 mg, intramuscular weekly injection for a total of 7 doses.
45462145|NCT01176253|Procedure|Blood draw|Blood draw for Type I DM patients will be taken every 4 weeks for 1 year post diagnosis/healthy volunteers will have 1 blood draw
46097373|NCT04165226|Device|Combined fractional CO2 laser and low level light therapy|Combined treatment of both modalities (fractionational CO2 laser and low level light therapy). Please describe more....
45679308|NCT05881252|Procedure|Clinical blood pressure threshold of SBP >= 160 mmHg for acute treatment of hypertension|Patients are treated for hypertension if SBP >= 160 mmHg.
46010663|NCT02214173|Dietary Supplement|rice bran arabinoxylan compound (RBAC)|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
46010664|NCT02214173|Dietary Supplement|Placebo|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
46010665|NCT01640652|Biological|MenPF-1.|A new vaccine against meningococcal disease.
46097374|NCT01682668|Procedure|Bilateral subthalamic stimulation|
46097375|NCT02729597|Other|medical history|The complete medical history (including cardiovascular risk factors and medication) will be assessed at baseline and follow-up.
46097376|NCT02729597|Other|neurological clinical examination|Neurological examination will be performed at baseline and follow-up.
46097377|NCT02729597|Other|neuropsychological testing|Neuropsychological testing using a 13 item test battery will be performed at baseline and follow-up.
45679309|NCT05881252|Procedure|Clinical blood pressure threshold of SBP >= 180 mmHg for acute treatment of hypertension|Patients are treated for hypertension if SBP >= 180 mmHg.
45837130|NCT00554970|Drug|Budesonide inhalation suspension 0.5mg|a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol
46010666|NCT01640691|Biological|Pandemic Influenza Vaccine (H5N1)|"Inactivated whole-virion vaccine~Administration route: Intramuscular Injection~Dosing schedule: 2 injections - at Day 1 and Day 22 separately~Dose(s): Each dose (0.5 mL) contains the 15 mcg hemagglutinin (HA) of influenza A (A/Vietnam/1194/2004)"
46010667|NCT01205230|Drug|pazopanib|Adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet derivative growth factor receptor (PDGFR)
46097378|NCT02729597|Other|brain MRI|Brain MRI ( 3.0 T) will be performed using the same hard- and software at baseline and follow-up.
45679310|NCT05880303|Procedure|Nonsurgical periodontal therapy|Oral Hygiene education, scaling and root surface debridement at baseline and 3 months
45462146|NCT05624177|Dietary Supplement|Streptococcus salivarius M18 probiotic 1 billion colony forming units chewing gum (chew 5 minutes)|Probiotic Streptococcus salivarius M18 products are commercially available in traditional formats such as a chewable tablet (lozenge) for local delivery to the oral cavity to provide health benefits. In this study, a chewing gum formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
45462147|NCT05624177|Dietary Supplement|Streptococcus salivarius M18 probiotic 1 billion colony forming units chewing gum (chew 10 minutes)|Probiotic Streptococcus salivarius M18 products are commercially available in traditional formats such as a chewable tablet (lozenge) for local delivery to the oral cavity to provide health benefits. In this study, a chewing gum formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
45462148|NCT01176331|Procedure|20 and 23 gauge pars plana vitrectomy|
45462149|NCT05624099|Drug|Camrelizumab|200mg i.v. d1 q3w
45462150|NCT05624099|Drug|Paclitaxel|150mg/m^2 d1 q3w
45462151|NCT05624099|Drug|Platinum|Carboplatin, cisplatin and other platinum
45462152|NCT05624099|Radiation|Radiotherapy|5000cGy/30f
46010668|NCT04550390|Diagnostic Test|Saliva collection|2 saliva samples are self-collected by participants
46010669|NCT04549961|Other|Nutrition|type and amount of food eaten or type and amount of oral nutritional supplements as well as enteral or parenteral nutrition
46010670|NCT01643889|Drug|Treatment A (domperidone 10 mg)|1 domperidone 10 mg capsule four times a day (q.i.d.) + 1 domperidone placebo capsule q.i.d. on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
45837131|NCT00520884|Drug|Ghrelin Infusion - Healthy|At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
45837132|NCT00520884|Drug|Ghrelin Infusion - Frail|At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min will be infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
45462153|NCT01178905|Procedure|ultrashort heat inactivation|
45462154|NCT03864601|Drug|14C-JNJ-56136379|14C-JNJ-56136379 25 mg dose formulated as a polyethylene glycol (PEG)-based oral solution containing 3,145 kilo Becquerel (kBq) of 14C labeled JNJ-56136379, with a maximal total radiation burden of 1,000 micro Sievert.
45462155|NCT03864523|Drug|Pioglitazone|
45462156|NCT00005879|Drug|arzoxifene|one tablet daily
45462157|NCT00005879|Drug|Placebo|matched tablet dialy
45462158|NCT01178983|Device|surface electromyography|Surface electromyography (SEMG) telebiofeedback
45462159|NCT01178983|Device|surface electromyography|conventional biofeedback
45462160|NCT03864367|Device|Device - Prism Medical FGA-700 Bariatric Floor Lift|This group will be using a Mobile Weight-Support Therapy (MWeST) device (the Prism Medical FGA-700 Bariatric Floor Lift) to determine if it improves mobilization of older patients with traumas of their legs.
45679311|NCT05879952|Behavioral|TAU + BTsN session|BTsN treatment session included exercises aimed at identifying, finding, chasing or moving objects, with the aim of improving the perceptual-cognitive skills of each patient, through audio-visual stimuli and feedback implementing visuo-spatial skills and spatial cognition, allowing at the same time motor coordination and balance improvement.
45679312|NCT05879952|Behavioral|TAU|neuro-psychomotor training promotes a better organization of global motor skills, improve hand-eye coordination, promote the development of language as communication, enriching representation and symbolization skills.
45462161|NCT05624021|Other|Scapular functional training|The scapular functional training consists of press up and push up plus. Press up was done in sitting position on the training bench, feet on the floor with straight arm and the palms on the edge of the bench fingers pointing forward and then lift off and dip down just in front of the seat by moving the shoulder girdle. Progression is done by placing weight on the thigh. Push-up plus exercise started from a push up position on the hand, feet or knees and keeping the torso rigid by bracing the abdominals followed by protracting the scapula as high as possible. Progression is done moving from knees to the feet or adding resistance on the upper back. The training continued for three sessions per week for four weeks.
45462162|NCT05624021|Other|Cervical isometric exercises|The isometric neck exercises taught to all the participants to perform in neutral sitting positions at home thrice a day for 15-days continuously. The sequences of exercises were shoulder circling in clockwise and anticlockwise direction, scapular retraction with cervical retraction, neck flexion, extension, either side of lateral bending/flexion, left and right rotation. Each exercise follows a set of 10 repetition of maximum voluntary contraction with a progressive hold time of 3, 5, 7, and 10 seconds depending on the severity of pain and tolerance of the participants.
46010671|NCT01643889|Drug|Treatment B (domperidone 20 mg)|2 domperidone 10 mg capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
45462163|NCT05624021|Other|Moist heating|A hydrocollator moist heat packs was applied over back of the neck in supine position to receive optimal heating. It was given for 20 minutes/day, five-day a week for four-week.
45462164|NCT01174849|Drug|Synflorix|The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
45462165|NCT01174849|Drug|Prevenar13|"The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg). CRM197 is a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197) grown in a casamino acids and yeast extract-based medium."
45462166|NCT01174849|Drug|COMBO|COMBINATION SCHEDULE of vaccine 1 and vaccine 2: Synflorix (PHiD-CV) at 1,2,4 months then Prevenar13 (PCV13) at 6 months of age.
45679313|NCT05877547|Drug|Efinopegdutide|Subcutaneous (SC) injection in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg
45679314|NCT05877547|Drug|Semaglutide|SC injection in a dose-escalation regimen of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg
45837133|NCT00520884|Other|Placebo Infusion -Healthy|At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
45837134|NCT00520884|Other|Placebo Infusion - Frail|At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
45837135|NCT00521352|Device|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic field (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) for 30min, five sessions a week for up to eight weeks.
45679315|NCT05877547|Drug|Placebo|SC injection of matching placebo
45679316|NCT05875896|Procedure|Total wrist fusion|Observation after implantation of Medartis Aptus Wrist Arthrodesis Plate
45679317|NCT05875493|Drug|JAB-21822|2 discrete single doses
45679318|NCT05875493|Drug|JAB-21822|2 discrete single doses
45837136|NCT00521352|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Generates a field with the same parameters as active rTMS (see active arm for parameters), however, the actual magnetic fields are blocked by an electromagnetic shield built into a sham coil. The field is impeded from stimulating the brain.
45837137|NCT00523302|Device|Active TMS|Active TMS uses the active TMS coil to stimulate the cortical area of interest. Active TMS involves 80 trains x 15 sec = 4000 pulses per session, 5 x per week= 20,000 pulses per week, x 2 weeks = 40,000 pulses.
46010672|NCT01643889|Drug|Treatment C (placebo)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
46010673|NCT01643889|Drug|Treatment D (moxifloxacin)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin 400 mg capsule in the morning of Day 1.
45462167|NCT03948815|Other|interventional birthing room|The design of the room is based on scientific evidence on the healthcare environment in general, and on a systematic review on the effect of birthing rooms published by the investigators, and interviews with women early after birth in Sweden. The room has a large birthing pool, several lighting options with dimming function, 40 mm suspended sound absorber in the ceiling, media installation covering two walls, which offers a choice of six different programmed nature scenes with light, sound effect and Music.
46010674|NCT04550078|Dietary Supplement|Calcium Carbonate|Subjects receive a single-dose of 800 mg calcium as calcium carbonate provided in 6 capsules with a standardized breakfast served in the morning.
45462168|NCT01103687|Biological|Ad26.ENVA.01 (rAd26)|5 x 10^10 virus particles (VP) vaccine delivered intramuscularly (IM)
45462169|NCT01103687|Biological|Placebo Vaccine|Placebo vaccine delivered IM
45462170|NCT03583359|Device|Radiesse (+)|Radiesse (+) for jawlines.
45462171|NCT01179061|Drug|Apelin|"Cardiac index will be assess in patients through the 6hr infusion, using thoracic cardiac bioimpedance. Prior to starting the infusion there will be a 30 minute run in period to achieve a stable cardiac index. Thereafter the infusion will be started, with cardiac index assess every five minutes during the first hour. For each subsequent hour participants will be free to mobilise for the thirty minute periods, with cardiac index and systemic haemodynmics assess for the following thirty minutes.~Additionally during the first hour pulmonary artery pressure will be estimated from pulmonary artery pressures assessed with echocardiography. This will be assessed at baseline with four further measurements during the first hour of infusion.~Participants will be asked to void prior to the study starting, thereafter all urine will be collected during the course of the study. Relevant biochemical/humoral factors will be assessed in the urine."
46010675|NCT04550078|Dietary Supplement|Calcium Permeate|Subjects receive a single-dose of 800 mg milk calcium as calcium permeate provided in 6 capsules with a standardized breakfast served in the morning.
46010676|NCT04550078|Dietary Supplement|Placebo|Subjects receive a single-dose of 0 mg calcium as placebo with maltodextrin provided in 6 capsules with a standardized breakfast served in the morning.
45462172|NCT01179061|Drug|Placebo|As per apelin arm, however we will use a saline placebo infusion. All other aspects will remain the same.
45462173|NCT05619887|Drug|Fentanyl|Fentanyl, when administered into the intrathecal (spinal) space suppresses feedback from the muscles below the site of action, i.e., the legs. It does not affect resting cardiorespiratory responses. We are using this to test what role the muscle reflex plays during exercise.
45462174|NCT05619887|Other|Saline|An equal volume (as above) of saline will be administered into the intrathecal (spinal) space. This has no effect of cardiorespiratory responses at rest or during exercise; it is to control for the invasiveness of the procedure required to suppress muscle feedback in the experimental condition.
46010677|NCT01640730|Drug|Kanglaite Injection|30gm IV infusion 5 days a week for 3 weeks every 28 days
45462175|NCT01174927|Drug|diacetylmorphine (DAM)|The heroin-dependent patients will administer either their individual dose of prescribed DAM dose or placebo (saline) through an indwelling intravenous line. Afterwards they will complete four experimental paradigms testing response inhibition, emotional processing and working memory while brain responses are measured with fMRI. Before and after the fMRI investigation cortisol samples, DAM blood levels, neurophysiological and psychological stress parameters, such as skin conductance, heart rate, anxiety, anger, and heroin craving will be measured.
45462176|NCT01174927|Other|Placebo|Saline
45462177|NCT05618483|Device|Nasal Spray|The nasal spray is made of xylitol and grapefruit seed extract. The spray is antiviral, but there is no data of its clinical efficacy against Covid-19.
45462178|NCT02525341|Other|Hatha yoga|A sequence of 8 - 10 core yoga poses, breathing and relaxation techniques were practiced in each yoga class, and 2 - 3 new poses were introduced progressively in each of the yoga session. Props such as blocks, blankets, belts, mats, and chairs were used during the session.
45462179|NCT02525341|Other|Aerobic and strengthening exercises|A 15 minute of gentle aerobic exercise and a 30 minute of strengthening program that includes both isometric (without moving the joints) and isotonic (moving the joints) exercises of the lower extremities were taught to the participants.
45462180|NCT02525341|Other|General education|One-time Arthritis Foundation educational brochures focusing on the disease process, diet and exercise and OA management education were given.
45462181|NCT03510663|Drug|OPC-61815 16mg|OPC-61815 16mg will be intravenously administered once a week.
46010678|NCT02214251|Device|PK-16CH EXG system|
46010679|NCT01643967|Other|sunflower oil|The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.
46010680|NCT01643967|Other|Ozone Therapy|The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
46010681|NCT04549805|Diagnostic Test|Computed Tomography Coronary Angiography|In order to optimise the quality of the Computed Tomography Coronary Angiography scan images, participants might be given tablets or an injection (e.g. beta-blockers, calcium channel antagonist, ivabradine) to slow their heart rate and glyceryl trinitrate (GTN) following local protocol guidance.
46010682|NCT01640769|Procedure|Image guided delivery of cardiac pacing leads.|Patients will be blindly randomized to image guided delivery of pacing leads during cardiac resynchronization therapy device implantation (study arm).
45462182|NCT03510663|Drug|OPC-61815 32mg|OPC-61815 32mg will be intravenously administered once a week.
45462183|NCT03510663|Drug|Moxifloxacin|400mg tablet will be administrated once a week.
45462184|NCT03510663|Drug|Placebos|Placebo will be intravenously administered once a week.
45462185|NCT05616845|Device|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
45462186|NCT01179139|Other|Biopsy|Percutaneous 2-3 mm biopsies of middle turbinate mucosae and nasal polyps will be obtained with 5 mm Thrucut® (Smith & Nephew, Memphis, TN) biopsy forceps. Generally, 2-3 specimens will be obtained from each side as in previous studies. Healthy controls and subjects with CRS without NP will have biopsies from both middle turbinates. Subjects with CRS with NP will have two nasal polyp biopsies and one middle turbinate biopsy.
45462187|NCT03948737|Drug|Alpha-Tocopherol|all of the subjects in the alpha-tocopherol group received alpha-tocopherol orally, doses adjusted by age for 4 weeks of treatment.
45462188|NCT03948737|Drug|Placebo oral tablet|
45462189|NCT01287247|Biological|Xeomin®|Xeomin® (incobotulinumtoxinA) at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.
45462190|NCT01101347|Device|Aneurysm-Embolization System|
45462191|NCT04905797|Diagnostic Test|Emotional Stop Signal Task|Emotional Stop Signal Task (modified version from CANTAB). Outcome Measure is commission and omission errors - higher score (percentage) indicate worse performance.
45462192|NCT04905797|Diagnostic Test|Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging (fMRI) Diffusion Tensor Imaging (DTI) Volumetry
45462193|NCT04905797|Other|World Health Organizations Disability Assessment Schedule (WHODAS 2.0)|Self-reported data on World Health Organizations Disability Assessment Schedule - 36 items self-administered (WHODAS 2.0). Assessing six domains of functional disability in daily life. Each item is rated on a Likert scale ranging from 0-4. Total range 0 - 144. High scores scores indicate more severe disability.
45462194|NCT04905797|Diagnostic Test|Personality Inventory for DSM-5 (PID-5)|Self-rated personality traits through Personality Inventory for DSM-5 (PID-5). Self-reported scores on domains of personality traits. Higher scores in one domain indicate more pronounced traits in this domain.
45462195|NCT04905797|Diagnostic Test|Stop Signal Task (CANTAB)|The estimate of time where an individual can successfully inhibit their responses 50% of the time.
45837138|NCT00523302|Device|Sham TMS|Sham TMS uses the same stimulation frequency as the Active TMS but uses the Sham TMS coil instead to prevent actual stimulation from occurring (chosen as a priori stimulation based on studies showing antidepressant and anti-nociceptive effects): 10 Hertz - Pulse train duration (on time) 5 seconds, Power (intensity) level 120% of stored motor threshold, Inter-train interval (off time) 10 seconds (15 second cycle time). Additionally, stimulation-train duration and inter-stimulus intervals were determined such that they are in compliance with current published rTMS safety guidelines.
46010683|NCT01640769|Procedure|Standard delivery of cardiac pacing leads.|Patients will be blindly randomized to standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
45837139|NCT00524472|Other|Hyperinsulinemic-normoglycemic clamp|Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
45462196|NCT04905797|Diagnostic Test|Intra-Extra Dimensional Set Shift (CANTAB)|"The number of trials for which the outcome was an incorrect response (subject pressed the incorrect button within the response window), calculated across all assessed trials.~The total number of times that the subject chose a wrong stimulus - i.e. one incompatible with the current rule, adjustment for every stage that was not reached."
45462197|NCT04905797|Diagnostic Test|Spatial Working Memory Test (CANTAB)|"The number of times the subject incorrectly revisits a box in which a token has previously been found. Calculated across all assessed four, six and eight token trials.~The number of times a subject begins a new search pattem from the same box they started with previously. If they always begin a search from the same starting point, we infer that the subject is employing a planned strategy for finding the tokens. Therefore, a low score indicates high strategy use (1 = they always begin the search from the same box), a high score indicates that they are beginning their searches from many different boxes. Calculated across assessed trials with 6 tokens or more."
45837140|NCT00524472|Other|insulin at the standard of care levels|Subjects will be administered insulin at the standard of care levels established by the participating institution.
45837141|NCT00524940|Biological|Inactivated, Split-Virion Influenza Virus|0.5 mL, Intramuscular
45837142|NCT00525174|Device|Bangerter filters|Bangerter filter worn on sound eye spectacle lens full time
46097379|NCT00992173|Drug|Ultratrace Iobenguane I 131|Subjects will receive an Imaging Dose of 0.1 mCi/kg [3.7 MBq/kg] (a minimum dose of 1.0 mCi [37 MBq] but not to exceed 5.0 mCi [185 MBq]) of Ultratrace iobenguane I 131 to have dosimetry performed and to confirm tumor uptake of the test article prior to receiving each of 2 planned Therapeutic Doses of Ultratrace iobeneguane I 131 . Within 28 days of screening, eligible subjects (as confirmed by the first Imaging dose study)will receive an Ultratrace iobenguane I 131 Therapeutic dose of of 15.0 - 18.0 mCi/kg (max. 666 MBq/kg) followed by imaging 7 days later or upon discharge from radiation isolation. A second Therapeutic Dose (preceded by a repeat Image Dose and dosimetry study)and imaging upon discharge from radiation isolation will be repeated approximately 8 weeks after the first dose.
46097380|NCT02729519|Procedure|TAVI|standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation) (ARM A) ou without pre dilatation (ARM B)
46097381|NCT02641886|Drug|Jian Pi Yi Shen Hua Tan Granules|Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
45462198|NCT04905797|Diagnostic Test|Multitasking Test (CANTAB)|"The number of trials for which the outcome was an incorrect response.~The median latency of response (from stimulus appearance to button press). Calculated across all correct, assessed trials.~The difference between the median latency of response on the trials that were congruent versus the trials that were incongruent. A positive score indicates that the subject is faster on congruent trials and a negative score indicates that the subject is faster on incongruent trials. A higher incongruency cost indicates that the subjects take longer to process conflicting information.~The difference between the median latency of response during assessed blocks in which both rules are used versus assessed blocks in which only a single rule is used. A positive score indicates that the subject responds more slowly during multitasking blocks and indicates a higher cost of managing multiple sources of information."
45679319|NCT05875272|Procedure|interchangeability of arterial or venous hemostasis|Paired arterial and venous blood sampling respectively on the radial arterial catheter and on the central venous catheter before the extracorporeal circulation, and on the sampling ramp during the extracorporeal circulation. Point of care biology exams are performed on two HSE devices simultaneously. Controls carried out, routinely, every 20 minutes according to the service protocol, before the CPB (starting ACT without heparin), during the CPB (ACT objective ≥400 seconds), after protamine reversal of heparin. On average, 10 samples are taken during heart surgery.
46097382|NCT02641886|Other|the placebo group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
45679320|NCT05875103|Diagnostic Test|linguistic processes|"Linguistic processes are assessed by performance score on the following tests:~naming tests : BNT 34 (Colombo & Assal, 1992) and semantic naming adapted from the BECS-GRECO (Merck et al., 2011)~vocabulary test (Mill Hill - Deltour, 1993),~repetition tests (Gremots - Bézy et al., 2016),~articulatory speed (Majerus, 2014 ; Roussel et al., 2012)~semantic matching task adapted from the PPT (Howard & Patterson, 1992) and from the BECS-GRECO (Merck et al., 2011),~semantic categorization and attributes adapted from the BECS-GRECO (Merck et al., 2011),~phonologic and semantic research tasks adapted from the color TMT (D'helia et al., 1996)"
45837143|NCT00525174|Device|Patching|2 hours daily patching of the sound eye
45837144|NCT00525174|Procedure|Near activities|one hour near visual activities
46010684|NCT04550273|Behavioral|aerobic treadmill exercise|The study group (n=20) received three sessions of aerobic exercise per week for 3 months. Every session was done on an electronic treadmill with no inclination started with 5 minutes warm-up then 30 minutes of moderate-intensity aerobic training with 60-75% of target heart rate then followed or ended by 5 minutes cool down.
46010685|NCT01644006|Procedure|Teleconsultation|Teleconsultation of an EMS physician to support the paramedics in acute coronary syndromes
46097383|NCT02729285|Drug|Ketorolac Tromethamine|On operation day, the patients were randomly assigned to receive intramuscular Ketorolac 60-mg 30 min before scleral buckle surgery.
46010686|NCT01205152|Biological|asfotase alfa|
46010687|NCT01640847|Drug|High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox|
46010688|NCT04549727|Other|Organoids creation|Organoids are created from discarded tissue
46010689|NCT01205035|Drug|ranibizumab 2.0mg|Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections
46010690|NCT01644045|Device|Teleconsultation|Teleconsultation for the EMS in acute respiratory emergencies
46010691|NCT04549844|Drug|Bupivacaine|"After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane.~Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery."
45462199|NCT04905797|Diagnostic Test|Cambridge Gambling Task Test|"The proportion (0 - 1) of all trials where the subject chose the majority box color. Calculated over all assessed trials from both the ascending and descending conditions in which the number of boxes of each color differed.~Risk adjustment is a measure of sensitivity to risk, based on the ability to modify choices in the light of information about the probability of different outcomes and to track the optimal outcome on eaeh trial. The measure is calculated from the average proportion of points that the subject ehose to bet with, taking into aeeount the number of colored boxes in the majority.~Allows for the dissociation between risk taking and impulsivity by determining whether subjects simply just place a bet at the first opportunity. Calculated as CGT Risk Taking for all trials from the descending condition minus CGT Risk Taking for all trials from the ascending condition."
45462200|NCT03722667|Behavioral|Technology-based Component|This intervention is comprised of three technology components: a) six weekly web-based modules focused on improving knowledge and skills to manage hypertension; (b) personalized medication adherence support (SMS reminder messages, adherence feedback, health and lifestyle tips) through Medisafe app; and (c) self-monitoring blood pressure to support self-managing hypertension.
45679321|NCT05874999|Other|Supramaximal High-Intensity Interval Training at 60% of MPO6|"Supramaximal HIIT is performed as 10×6 second intervals against a load of 60% of maximum mean power output for 6 seconds (MPO6) with a 54 second recovery between intervals. The MPO6 was estimated from the BCST.~Duration supramaximal HIIT: 10 minutes~Warm-up and cool-down: 5 minutes at 30% of maximum aerobic power (MAP) obtained during maximal incremental cardiopulmonary exercise test (CPET) on a stationary bicycle."
45679322|NCT05874999|Other|Moderate-Intensity Continuous Training|"MICT is performed against a load of 60% of MAP obtained during a maximal incremental CPET on a stationary bicycle.~Duration MICT: 20 minutes~Warm-up and cool-down: 5 minutes at 30% of MAP obtained during maximal incremental CPET on a stationary bicycle."
45837145|NCT04384848|Other|EMPATHY Pilot|The goal of this pilot is to develop and pilot a tailored monitoring intervention targeting symptomatic, Patient-reported adverse events (AEs) in chronic myeloid leukemia (CML) Patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy. The tailored monitoring intervention will draw primarily from the PRO-CTCAE Item Library, with additional items drawn from the FACIT and EORTC Item libraries as necessary. After identifying the full set of AEs to be monitored, we will load the Patient assessment and report program into tablets for electronic administration in the busy clinic setting. We will then pilot a six-month intervention aimed to monitor and manage emerging AEs, coupled with assessment of intervention feasibility, Patient acceptability and satisfaction, provider acceptability and clinical management utility, adherence to TKI therapy, and HRQoL. We expect that adherence to therapy, clinical response, and HRQoL will be enhanced by such an intervention.
45837146|NCT04166916|Other|Acoustic stimulation|Acoustic stimulation to modulate slow waves.
46010692|NCT01644084|Drug|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
46010693|NCT01644084|Drug|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
46097384|NCT02729285|Drug|placebo|On operation day, the patients were randomly assigned to receive placebo 30 min before scleral buckle surgery.
46097385|NCT02729285|Procedure|scleral buckle|Surgical procedure of scleral buckle under retrobulbar block anesthesia
46097386|NCT00722176|Drug|BL-1020|10 mg
46097387|NCT00722176|Drug|BL-1020 10-30 mg|BL-1020 10-30 mg
46097388|NCT00722176|Drug|risperidone|risperidone
45462201|NCT03722667|Behavioral|TechSupport|"The TechSupport intervention is the combination of both an behavioral and emotional intervention.~Technology-based Components: This intervention is comprised of three technology components: a) six weekly web-based modules focused on improving knowledge and skills to manage hypertension; (b) personalized medication adherence support (SMS reminder messages, adherence feedback, health and lifestyle tips) through Medisafe app; and (c) self-monitoring blood pressure to support self-managing hypertension.~Positive Psychological Training (PPT): This intervention will include a structured online training and skill building for PPT accessible by smartphone on techniques to promote optimism, resilience, well-being, and self-confidence."
45462202|NCT03510273|Device|Liger Medical Thermocoagulator|"Thermocoagulation treatment by Liger Medical device (US FDA 510K clearance received)"
45462203|NCT01327859|Drug|Prior Donepezil 5mg|Received 5 mg donepezil once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
45462204|NCT01327859|Drug|Prior Donzepezil 10mg|Received 10 mg donepezil once daily during the preceding double-blind study, E2020-G000-316 . Received open-label 5 or 10 mg donepezil during the present study.
45462205|NCT01327859|Drug|Prior Placebo|Received placebo once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
45462206|NCT01179295|Drug|BAY86-9766|BAY86-9766 30 mg twice a day (bid).
45462207|NCT01179295|Drug|BAY86-9766|BAY86-9766 50 mg twice a day (bid).
46097389|NCT04165382|Other|Interventions in the guideline to infants receiving NIV|"Interventions in the guideline involve six components as~choice of right nasal interfaces and bonnet~use of skin protective dressing~alternate the nasal interfaces every 6 hours;~positioning the infants at optimal developmental body position without prone every 4-6 hours, and well supporting the devices to prevent displacement and traction~supportive care with more new interventions~regular assessments on infants receiving NIV for pain level and skin integrity for the areas in contacting with the nasal interfaces and devices of NIV"
46097390|NCT04165382|Other|Usual care to infants receiving NIV|Usual care includes the choice of nasal interface for NIV; use of skin protective dressing; positioning of infants without specific frequency or types of position; supportive care as to provide humidification to the ventilator circuit, to remove water condensate in the ventilator circuit, to provide oral care every 3-4 hours and avoid unnecessary nasal suctioning.
46097391|NCT02729441|Drug|ramipril|Comparison of two renin angiotensin aldosterone inhibitors
46097392|NCT02729441|Drug|perindopril|Comparison of two renin angiotensin aldosterone inhibitors
46097393|NCT02729363|Behavioral|Guided Relaxation video clip|This intervention is a 12-minute guided audio-visual relaxation intervention.
46097394|NCT02729363|Behavioral|Sickle Cell Disease Experience Discussion|This intervention is a 12-minute computer-administered sickle cell disease experience discussion.
46097395|NCT00722332|Biological|HepaGam B|Hepatitis B Immunoglobulin
45462208|NCT01179295|Drug|BAY86-9766|BAY86-9766 100 mg once a day (od)
45462209|NCT01179295|Drug|BAY86-9766|BAY86-9766 60 mg once a day (od)
45462210|NCT01176409|Drug|Valacyclovir|Valacyclovir will be used at two different dosages (1g po BID and 500mg po BID) to be used for 12 weeks. Supplied as 500mg caplets.
45462211|NCT01176409|Drug|Placebo|Placebo, supplied as caplets identical in appearance, odour and taste to valacyclovir 500mg caplets.
45462212|NCT01287325|Drug|DNK333 100 mg twice daily|
45462213|NCT01287325|Drug|Placebo|
45462214|NCT03582813|Behavioral|Self-directed care|Traditional and non-traditional behavioral health services are chosen from within and outside the public mental health system
45462215|NCT03582813|Behavioral|Services as usual|Traditional behavioral health services are chosen from along those delivered at the patient's community mental health agency
45462216|NCT01176487|Other|questionnaire administration|
45462217|NCT01176487|Procedure|quality-of-life assessment|
45462218|NCT01176487|Radiation|3-dimensional conformal radiation therapy|
45462219|NCT01176487|Radiation|palliative radiation therapy|
45462220|NCT01176487|Radiation|whole-brain radiation therapy|
45462221|NCT03862183|Other|continuing medical education program|educating all the involved doctor the same medical knowledge on hypertension control
45462222|NCT03722433|Drug|Vigiis 101-LAB and sequential therapy|Vigiis 101-LAB is the probiotic containing Lactobacillus paracasei subsp. Paracasei, which is the isolate from Taiwanese by Prof. Pan. This strain is resistant to gastric acid and bile acid. Therefore, its survival rate in the gastrointestinal tract could be as high as 95%. Previous studies showed that Vigiis 101-LAB can modulate the gut microbiota, with 10% increase in Bifidobacterium species and 20% reduction in Clostridium difficile.
46010694|NCT01644084|Drug|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
46010695|NCT04549883|Other|Theoretical practical educational session|1 Theoretical practical educational session of 15 Min about the importance of low back control during hip extension. Includes anatomical issues and one practical exercise in quadruped position
46097396|NCT04181333|Drug|TRASTUZUMAB BS|"Regimen A or regimen B is used for HER2-overexpressing breast cancer.~RegimenB is used for HER2-overexpressing unresectable advanced or recurrent gastric cancer in combination with other anti tumor agent(s).~Regimen A: The recommended dose for trastuzumab (genetical recombination) [Trastuzumab Biosimilar 3] in adult patients is 4 mg/kg (weight) at initial dose and 2 mg/kg after the second dose, in both of them, by IV drip infusion over 90 minutes once daily every week.~Regimen B: The recommended dose for trastuzumab (genetical recombination) [Trastuzumab Biosimilar 3] in adult patients is 8 mg/kg (weight) at initial dose and 6 mg/kg after the second dose, in both of them, by IV drip infusion over 90 minutes once daily every 3 weeks.~If the initial dose is well tolerated, the dosing time after the second dose can be shortened up to 30 minutes."
46097397|NCT02646410|Other|FPD+NDOT|
45462223|NCT03722433|Drug|Placebo and sequential therapy|Placebo without Vigiis 101-LAB component
45462224|NCT03861949|Other|5 cmH2O CPAP|
45462225|NCT03861949|Other|head-up position|
45462226|NCT03864133|Drug|Omidria|Phenylephrine and Ketorolac infusion of 1%/0.3% during cataract surgery.
45462227|NCT03863821|Device|HHHFNC|"HHHFNC setting:~Flow rate: 40L/min~FiO2: 0.4~HHHFNC will use immediately before 6MWT and remove at the end of 6MWT"
45462228|NCT03480009|Drug|Dextromethorphan Hydrobromide|Dextromethorphan capsule
46097398|NCT02646410|Other|FPD+DOT|
46097399|NCT02646410|Other|DDD+NDOT|Door to door delivery + non directly observed treatment
46097400|NCT02646410|Other|DDD+DOT|Door to door delivery + directly observed treatment
45462229|NCT03480009|Drug|Avicel PH101 (Microcrystalline Cellulose NF) for Compounding|Placebo capsule
45837147|NCT04166916|Other|SHAM acoustic stimulation|This is the sham-control intervention; only the biosignal will be recorded but no acoustic stimulation will be played.
45837148|NCT00555048|Biological|alemtuzumab|
45837149|NCT00555048|Drug|busulfan|
46010696|NCT01204918|Drug|Riluzole|Riluzole 100mg PO
46010697|NCT01204918|Drug|placebo|placebo
46010698|NCT04528797|Drug|Levothyroxine|
46097401|NCT02729129|Other|Diesel exhaust exposure with filtered facemask|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise while wearing a filtered facemask.
46010699|NCT04528797|Drug|Methylprednisolone|
46010700|NCT00624481|Drug|Teriparatide|20ug subcutaneous injection daily for 24 weeks
45462230|NCT03480009|Drug|Oxycodone|Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.
45462231|NCT03864445|Drug|KHK7791|oral administration
45462232|NCT03864445|Drug|Placebp|oral administration
45462233|NCT01180855|Drug|Placebo|Placebo pill nightly for 42 nights.
45837150|NCT00555048|Drug|cyclophosphamide|
45837151|NCT00555048|Drug|methotrexate|
46010701|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
46010702|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
45462234|NCT01180855|Drug|Rozerem 8mg|Rozerem 8mg pill, nightly for 42 nights
46097402|NCT02729129|Other|Diesel exhaust exposure with sham mask|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise while wearing a sham facemask.
45462235|NCT01180855|Other|Rozerem 8mg in combination with Multi Component Behavior Therapy|Rozerem 8mg pill nightly for 42 nights with 4 sessions and 2 telephone calls of Multi Component Behavior Therapy.
45462236|NCT03721575|Procedure|Scarpa's preserving hernio-abdominoplasty|Scarpa's fascia is preserved during hernio-abdominoplasty
45462237|NCT03721575|Procedure|Classical hernio-abdominoplasty|Scarpa's fascia is removed during hernio-abdominoplasty
46010703|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
46010704|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
46010705|NCT04549766|Other|calculate PRECISE DAPT score using clinical data|calculate PRECISE DAPT score using clinical data in STEMI patients after PPCI
45462238|NCT03859375|Other|microbial skin counts in the disinfection area after paints of skin disinfectants|microbial skin counts in the disinfection area after 2 and 3 paints of skin disinfectants (chlorhexidine in alcohol [CHX] and povidone iodine in alcohol [PI])
45462239|NCT01310751|Drug|iloprost nebuliser solusion|50 ng/kg/min inhalation for 10 minutes, q2h for 2 days
45462240|NCT01310751|Drug|distilled water|2 ml per session
45462241|NCT01180933|Dietary Supplement|fish oil|400 mg of DHA and 150 mg of eicosapentaenoic acid per day
46097403|NCT00712660|Drug|antipsychotic dose increase|20% increase in the dose of current antipsychotic medication
46097404|NCT00712660|Other|no intervention|Treatment as usual
46097405|NCT02646644|Other|Metastasized intestinal NET|This is an observational study
46097406|NCT00636545|Drug|Oblimersen (Genasense)|Intravenous
45462242|NCT01180933|Dietary Supplement|folate|400 µg per day
45462243|NCT01180933|Dietary Supplement|fish oil + folate|500 mg DHA, 150 mg eicosapentaenoic acid, 400 µg MTHF per day
45462244|NCT01180933|Dietary Supplement|placebo|only vitamins and minerals as recommended, but no fish oil or folate
45462245|NCT01310829|Behavioral|Questionnaires|Questionnaires completed before and after viewing virtual reality scenes, taking about 30 minutes to complete.
45462246|NCT01310829|Behavioral|Physiological Measurements|Small sensors applied to skin will measure heart rate and sweat amounts while participants view a virtual reality scene.
45462247|NCT01310829|Behavioral|Virtual Reality Scene Viewing|Prototype virtual reality application that demonstrates a provider-patient communication scenario commonly encountered in genetic counseling for hereditary cancers.
45462248|NCT01287481|Behavioral|Stress and Emotions|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
45837152|NCT00555048|Drug|tacrolimus|
45837153|NCT00555048|Procedure|allogeneic hematopoietic stem cell transplantation|
46010706|NCT04318054|Other|Ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health.|fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
46010707|NCT01644162|Device|iVAPS ventilation|3 months of ventilation on iVAPS mode
46010708|NCT04549649|Other|Dual triggering|Adding GnRH agonist (0.2 mg Triptorelin (Decapeptyl; Ferring GmbH) to routine oocyte triggering (two ampoules of Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) is defined as dual triggering.
46010709|NCT01644201|Dietary Supplement|PolyGlycopleX® - PGX®|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
46097407|NCT00636545|Drug|Oblimersen (Genasense)|Intravenous
46097408|NCT00722410|Dietary Supplement|VSL#3|A probiotic preparation.
46097409|NCT00722410|Drug|Polyethylene glycol|Oral ingestion of 3 liters of polyethylene glycol solution.
46097410|NCT02641418|Other|Supervised exercise programme|supervised exercise programme
46097411|NCT02728973|Other|ERAS program|The main elements of this program were: preoperative advice, no colon preparation, provision of carbohydrate-rich drinks one day prior and on the morning of surgery, goal directed fluid administration, body temperature control during surgery, avoiding drainages and nasogastric tubes, early mobilization, and the taking of oral fluids in the early postoperative period.
46097412|NCT00722488|Drug|MLN4924|Intravenous dose 100 mg/m2 on a Days 1,4,8,11 schedule within a 21-day treatment cycle. Treatment may continue until disease progression or unacceptable toxicity develops.
46097413|NCT00652106|Drug|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
46097414|NCT00652106|Drug|Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution|Brimonidine 0.2% 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and concurrent timolol 0.5% ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
46097415|NCT00652106|Drug|Brimonidine 0.2% ophthalmic solution|Brimonidine 0.2% ophthalmic solution 1 drop instilled in each eye three times daily (morning, afternoon, and evening)
45837154|NCT00555048|Procedure|peripheral blood stem cell transplantation|
46097416|NCT02728817|Procedure|End-cephalic vein to side-radial artery fistula creation|"Circumferential dissection of the cephalic vein (4-5cm long)~Longitudinal arteriotomy (~10mm)~End-vein to side-artery anastomosis using 7-0 polypropylene continuous suture"
46010710|NCT01644201|Dietary Supplement|Rice Flour (placebo)|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
46010711|NCT02214329|Device|Sensor-based exercise training|Body-worn sensors are mounted on different body segments to acquire joint kinematic data and provide real-time joint feedback during exercise training.
46010712|NCT02214329|Other|In-home balance training|The control group performs similar exercise as intervention without sensors and with no visual feedback from sensors.
45837155|NCT04146714|Other|Substance use questionnaire|Screening questionnaire about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.
46010713|NCT04529187|Drug|Midazolam|To monitor the changes in heart function induced after midazolam sedation using cardiac MRI.
46010714|NCT04529187|Drug|Dexmedetomidine|To monitor the changes in heart function induced after dexmedetomidine sedation using cardiac MRI.
46097417|NCT02728817|Procedure|RADAR fistula creation|"Dissection of the anterior-medial aspect of the cephalic vein (~15mm) without grasping or clamping the venous wall~Circumferential dissection of the radial artery pedicle (5cm long) and ligation of collaterals with surgical microclips~Ligation and section of the radial artery (distal)~Longitudinal venotomy (~10mm)~End-artery to side-vein anastomosis using 7-0 polypropylene continuous suture"
45462249|NCT01287481|Behavioral|Thoughts and Behaviors|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
45837156|NCT04146714|Other|Physical activity questionnaire|Screening questionnaire about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
45837157|NCT00525798|Drug|SMC021 Oral calcitonin|0.8mg SMC021 - oral calcitonin, once daily
45837158|NCT00525798|Drug|SMC021 Placebo|SMC021 - Placebo, once daily
45837159|NCT00555360|Behavioral|HITCM+CP|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6-month and 12-month follow-up.
45462250|NCT01287481|Behavioral|Brain and Body|Focus on the empowering patients by providing the latest scientific information about fibromyalgia, including causes, the role of the nervous system, and various treatments.
45462251|NCT03721419|Device|High Flow High Humidity device|High Flow High Humidity device has a flow generator built into the body of unit and can deliver flows between 10 to 60 Liters per minute (LPM) with oxygen bled in as needed in order to deliver specified Fraction of inspired Oxygen (FiO2)
45462252|NCT03721419|Device|Low Flow High Humidity device|Standard high humidity trach collar utilizing venturi device bleed in
45837160|NCT00555360|Behavioral|HITCM only|Weekly automated assessment calls with follow-up by a care manager for 12 months. Baseline, 6-month and 12-month follow-up.
45462253|NCT01179373|Device|TMS, H coil|TMS, H Coil, High/ Low Frequency
46010715|NCT04549415|Drug|Metformin Hydrochloride|"patients were divided into 2 groups: 1st group was on lifestyle modification (LSM), 2nd group on regimen LSM+ metformin (1000 g b.i.d) during 12 months"
45462254|NCT03639363|Drug|4% chlorhexidine gluconate soap-like solution|"humidify the whole body surface with the exception of the face using water-impregnated washcloths~use 4% CHG-impregnated washcloths to bath the whole body surface with the exception of the face; use at least 30 ml of 4% CHG~wait for at least 30 seconds~rinse using water-impregnated washcloths"
45462255|NCT03639363|Other|standard soap|"humidify the whole body surface with the exception of the face using water-impregnated washcloths~use standard soap-impregnated washcloths to bath the whole body surface with the exception of the face~wait for at least 30 seconds~rinse using water-impregnated washcloths"
45462256|NCT03399786|Drug|evinacumab|IV administration of evinacumab
46010716|NCT04549415|Other|lifestyle modification|Lifestyle modification Standard Principles
46010717|NCT04549064|Diagnostic Test|diagnosis of pancreatic cancer|Diagnosis of pancreatic cancer based on the concentration of serum biomarkers
46010718|NCT01644357|Other|Pharmaceutical care|Pharmacist intervention, focused on the optimization of drug therapy, identification and resolution of drug related problems, resulting in best asthma control and quality of life. Pharmacists document their initial and monthly follow up encounters using a specified form. An action plan for self management of these patients was prepared and discussed aiming at early identification and treatment of an exacerbation episode. Meetings will be held weekly with intervention team to discuss action plan and measure of outcomes of all problems identified.
46010719|NCT02214368|Other|Early application of NIV|"Device:BiPAP Vision.~NIV bundle group : Early application of NIV(BiPAP Vision) in 1 h after randomization."
46010720|NCT02214368|Device|Fiberoptic bronchoscopy|Device:fiberoptic bronchoscopy. NIV bundle group :When patients were inability to spontaneously clear airways from excessive secretions during NIV, fiberoptic bronchoscopy (FBO) was used for suction of secretions.
46097418|NCT02641808|Other|follicular flushing|Depending on randomisation the follicle is not flushed (group A) or flushed adapted to follicule size (16mm 2ml, 18mm 3ml, and 20mm 4ml etc.) up to five times with (e.g.flushing media with heparin (SynVitro® Flush, Origio, Berlin, Germany). The flushings are collected each in a separate collecting tube (group B). The analysis of the collected oocytes is performed in the IVF lab.
46097419|NCT02641808|Other|no follicular flushing|
46097420|NCT02728739|Procedure|Transthoracic Echocardiogram (TTE) Assesment|Transthoracic Echocardiogram (TTE) will be carried out on all heart failure patients with elevated BNP level (>30 pg/ ml) for grading of MR severity within 7 days.
45837161|NCT00525876|Drug|Cyclophosphamide|"Matched Donors:~750 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~Unrelated or Mismatched Donors:~1000 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
46097421|NCT00723268|Drug|Prednisolone|5MG Prednisolone per day for 3 months
45837162|NCT00525876|Drug|Fludarabine|"30 mg/m^2 given intravenously on Days -5 and -3 before transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
45837163|NCT00525876|Drug|Rituximab|"Matched Donors:~375 mg/m^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.~Unrelated/Mismatched Donors:~375 mg/m^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)~For development of disease progression or no response, immunomanipulation with Rituximab 375 mg/m^2 given intravenously, then 1000 mg/m^2 given intravenously weekly for 3 weeks, and taper off Tacrolimus dose over 2 weeks.~DLI = Donor Lymphocyte Infusion/Immunomodulation Post Transplantation Immunomodulation for patients with lymphoid Malignancies:~375 mg/m^2 then 1000 mg/m^2 weekly x 3 if immunomanipulation is undertaken for persistent disease."
46097422|NCT00723268|Drug|Colchicine|0.5 MG Colchicine per day for 3 months
46097423|NCT02728583|Dietary Supplement|Margarine enriched with plant sterols and fish oil|
46097424|NCT02728583|Dietary Supplement|Placebo margarine|
45462257|NCT03399786|Drug|Placebo|IV administration of placebo
45462258|NCT03505593|Device|ENVUE System|The ENvizion Medical™ ENVUE™ System is designed to aid qualified operators in the placement of the ENvizion Medical™ Enteral Feeding Tube™ into the stomach or small intestine.
45462259|NCT03857971|Device|Coronary Optical Coherence tomography|Optical coherence tomography imaging is performed of non-obstructive, non-culprit coronary lesions to assess plaque morphology.
45462260|NCT03859141|Biological|Quadrivalent influenza vaccine|One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.
45679323|NCT05874999|Other|Supramaximal High-Intensity Interval Training at 80% of MPO6|"Supramaximal HIIT is performed as 10×6 second intervals against a load of 80% of MPO6 with a 54 second recovery between intervals. The MPO6 was estimated from the BCST.~Duration supramaximal HIIT: 10 minutes~Warm-up and cool-down: 5 minutes at 30% of MAP obtained during maximal incremental CPET on a stationary bicycle."
46010721|NCT02214368|Drug|Propofol|"Drug:propofol.continuous perfusion of propofol (0.50-2.00 mg/kg/h).~NIV bundle group :When patients showed intolerance or inadequate patient cooperation during the NIV session, they were sedated (Ramsay scale 2-3) by a continuous perfusion of propofol (0.50-2.00 mg/kg/h).~In the conventional treatment group: No intervention."
46097425|NCT00874770|Drug|Daclatasvir|Tablets, oral, 3 mg, Daily, 48 weeks
46097426|NCT00874770|Drug|Daclatasvir|Tablets, oral, 10 mg, Daily, 48 weeks
46097427|NCT00874770|Drug|Daclatasvir|Tablets, oral, 60 mg, Daily, 48 weeks
46097428|NCT00874770|Drug|Placebo|Tablet, oral, 0 mg, Daily 48 weeks
46097429|NCT00874770|Drug|Peginterferon alpha-2a|Syringe, subcutaneous, 180 µg, Weekly, 48 weeks
45679324|NCT05873608|Other|Educational video|Testing an educational video
45679325|NCT05873608|Other|Interview|Participate in interview
45679326|NCT05873608|Other|Observation|Undergo observation
45837164|NCT00525876|Drug|Alemtuzumab|"Unrelated/Mismatched Donors:~15 mg per day given intravenously days 1 through 3 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
46097430|NCT00874770|Drug|ribavirin|Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks
46097431|NCT00536263|Drug|pegylated interferon alpha-2b|1.0 mcg/kg subcutaneously (S.C.) QW for 24 weeks
46097432|NCT00536263|Drug|pegylated interferon alpha-2b|1.5 mcg/kg S.C. QW for 24 weeks
46097433|NCT00536263|Drug|pegylated interferon alpha-2b|1.5 mcg/kg S.C. QW for 48 weeks
46097434|NCT02728661|Behavioral|PACE|PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts up to 6 weeks prior to surgery.
45837165|NCT00525876|Procedure|Allogeneic Stem Cell Infusion|Infusion of stem cells.
45837166|NCT00555750|Drug|eszopiclone|3mg tablet, by mouth nightly 30 min before bed, for two months
46010722|NCT02214368|Other|Conventional application of NIV|Conventional treatment group:NIV(BiPAP Vision) was used, when patients failed the supplemental oxygen and met at least two of the following criteria:(1) severe respiratory distress with dyspnoea, respiratory rate>30breaths/min, and clinical signs suggestive of respiratory-muscle fatigue or increased respiratory effort (use of accessory respiratory muscles or paradoxical abdominal breathing, or intercostal indrawing), (2) respiratory acidosis (arterial pH of 7.35 or less with PaCO2 of 45 mm Hg or more) ;(3) arterial O2 saturation by pulse oximetry less than 90% or PaO2 less than 60 mm Hg at an FiO2> 0.5 or breathing at least 10 L/min oxygen.
46010723|NCT04529148|Drug|Ginkgo biloba dropping pills，best western medicine treatment|oral
46010724|NCT04529148|Drug|Mimetic drug of ginkgo biloba dropping pills，best western medicine treatment|oral
46010725|NCT04548908|Diagnostic Test|Serelogy testing, RT PCR|Serology testing for all the participants and RT PCR for participants with symptoms
46010726|NCT04548635|Device|VR-PAT|Smartphone-based Virtual Reality Pain Alleviation Tool (VR-PAT) via a lightweight, mobile VR headset
46010727|NCT01204294|Drug|Linagliptin|Linagliptin once daily
46010728|NCT01204294|Drug|Linagliptin|Linagliptin once daily
45679327|NCT05873075|Other|Intravascular laser irradiation of blood|Intravascular laser irradiation of blood via an intravenous catheter for irradiation of the blood under a period of 60 minutes daily for 20 days
45679328|NCT05867446|Behavioral|pecha kucha|pecha kucha training
45679329|NCT05865041|Drug|Farudodstat|Farudodstat tablets administered orally
45679330|NCT05865041|Drug|Placebo|Placebo tablets administered orally
45679331|NCT05863819|Other|No Intervention|As this is an observational study, no intervention will be administered in this study.
45679332|NCT05858541|Behavioral|Music Listening|The LUCID AI-based system for song selection responds to the collected measurement data (video and HRV) and music preference information (like/dislike button, music taste profile) to recommend the playlist for the listener. The songs are selected using 76 different musical features and raw audio information. The system uses these features to recommend and optimize recommendations for the listener
45837167|NCT00555750|Drug|placebo|inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months
45837168|NCT00526188|Drug|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
46010729|NCT01204294|Drug|Metformin|Metformin twice or three time per day
46010730|NCT01204294|Drug|Metformin|Metformin twice or three time per day
46010731|NCT01204294|Drug|Linagliptin|Linagliptin once daily
46010732|NCT01204294|Drug|Linagliptin|Linagliptin once daily
46097435|NCT02728661|Behavioral|Delayed PACE|Delayed PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts 12 weeks after surgery.
46097436|NCT00578344|Drug|Busulfan|Starting Day -9 / Busulfan 4.0 mg/kg/day IV divided into four doses daily for four days; total dose = 16 mg/kg.
46097437|NCT00578344|Biological|Campath 1H|Day -5 through Day -2; Campath-1H dosed as per institutional guidelines.
46097438|NCT00578344|Drug|Cyclophosphamide and MESNA|Day -5 through Day -2; Cyclophosphamide 50 mg/kg + MESNA.
46097439|NCT00653588|Drug|Rosuvastatin|40mg
46097440|NCT00653588|Drug|Atorvastatin|80mg
46097441|NCT02728505|Drug|SinuSurf irrigation twice daily|
46097442|NCT02728505|Drug|NeilMed Sinus rinse irrigation twice daily|
46097443|NCT00723346|Biological|GRASPA|50 UI/Kg
46097444|NCT00723346|Biological|GRASPA|100 UI/Kg
46097445|NCT00723346|Biological|GRASPA|150 UI/Kg
46097446|NCT00723346|Drug|native L asparaginase|10000UI/m2, 14 infusions during 4 chemotherapy cycle
46097447|NCT03301532|Drug|Triheptanoin|Dietary supplementation with triheptanoin
45462261|NCT03859141|Biological|Quadrivalent influenza vaccine|One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.
45462262|NCT03859141|Biological|Trivalent influenza vaccine (contains B/Victoria strain)|One dose of trivalent influenza vaccine (contains B/Victoria strain): 0.25 ml per dose containing 7.5μg antigen.
46010733|NCT01204294|Drug|Linagliptin|Linagliptin once daily
45679333|NCT05858541|Behavioral|Listening to Audiobooks|A selection of 40 audiobooks spanning 4 genres (10 each from Literary Classics, Fantasy, Mystery, Non-fiction) will be available. For each session, the participant and their caregiver will be given a prompt to make a genre selection. After making the genre selection, one of the ten stories associated with that genre will be selected at random. All stories were sampled from the Audible audiobook database. Stories had to be 30 minutes in length to align with the length of the music interventions and the selected stories had to have had a 4- or 5-star rating to ensure quality.
45679334|NCT05857020|Device|Auricular Acupressure|"Auricular Acupressure (AA) utilizing all-natural vaccaria ear seeds will be applied to 5 designated sites on each participant's ear (total of 10 seeds placed per patient).~Participants will be asked if they consent to having their ear placement photographed after placement (optional) and audio recorded during interventionist ear seed placement (optional) in collaboration with the BAApress training fidelity study."
45679335|NCT05854966|Drug|CPI 613|"For INDUCTION therapy (14 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 14-day cycles for cycles 1 and 2 only.~For MAINTENANCE therapy (21 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 21-day cycles until progression, intolerable toxicity or withdrawal of consent."
45679336|NCT05854966|Drug|Metformin|"For INDUCTION therapy (14 day cycles):~Metformin 500 mg daily (taken with meals), days 1-2 for cycle 1 only. Metformin 500 mg twice daily (taken with meals), days 3-14 for cycle 1 only. Metformin 1,000 mg daily (taken with meals), days 1-2 for cycle 2 only. Metformin 1,000 mg twice daily (taken with meals) days 3-4 for cycle 2 only.~For MAINTENANCE therapy (21 day cycles): Metformin 1,000 mg twice daily (taken with meals) days 1-21 until progression, intolerable toxicity or withdrawal of consent"
45679337|NCT05854966|Biological|Blood draws|In the first induction cycle ONLY, extra blood will be withdrawn on day 1 before and after treatment with CPI-613 research purposes. Additional blood draws on days 2-5 to test blood before receiving CPI-613 to make sure participants are healthy enough to receive CPI-613.
45462263|NCT03859141|Biological|Trivalent influenza vaccine (contains B/Yamagata strain)|One dose of trivalent influenza vaccine (contains B/Yamagata strain): 0.25 ml per dose containing 7.5μg antigen.
45462264|NCT03504189|Device|PregSense™|PregSense™ wearable device will be applied for maternal-fetal monitoring
45462265|NCT03504189|Device|Cardiotocopraphy (CTG)|Cardiotocopraphy (CTG) will be applied for maternal-fetal monitoring
45462266|NCT03859219|Drug|Rozanolixizumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous infusion"
46010734|NCT01641276|Device|Low intensity amplitude-moduled electromagnetic fields|Patients in each arm will be exposed to 30 min of amplitude-moduled low intensity electromagnetic fields only one time.
46010735|NCT05405218|Device|CTR-US|Carpal Tunnel Release with Ultrasound Guidance
46010736|NCT05405218|Procedure|mOCTR|Mini Open Carpal Tunnel Release
46010737|NCT01182181|Drug|Anastrozole (Teva Pharmaceuticals USA)|1 mg Tablets
46010738|NCT01182181|Drug|Anastrozole (Arimidex®)|1 mg Tablets
46010739|NCT04548674|Other|Whiteness HP 35%|Single application of 45 minutes on the buccal surfaces of third molars, with an average thickness of 1 mm
46010740|NCT04548674|Device|Whiteness HP 35% + LASER|A dose of LASER (60 J / cm2, for 16 seconds) was applied at two points, one point in the cervical region and another in the center of the buccal surface of the third molars, using visible infrared LASER therapy (Photon III / DMC, São Carlos, SP, Brazil), with a wavelength of 808 nm, and AsGaAl, as an active medium.
46010741|NCT04548674|Other|Whiteness HP 35% + CPP|Topical application of casein phosphopeptide amorphous calcium phosphate fluoride CPP-ACPF (My Paste Plus, Recaldent, GC, USA) with the aid of a microbrush (KG Sorensen, SP, Brazil) in a passive way for 5 minutes.
46010742|NCT04548674|Other|Whiteness HP 35% + NANO|A topical application of nanohydroxyapatite (Nano P FGM, SC, Brazil) was performed with the aid of a microbrush (KG Sorensen, SP, Brazil) in a passive way for 5 minutes after teeth whitening.
46010743|NCT01181986|Drug|Exenatide SC|Exenatide 5-10 ug sc BID/10 days
46010744|NCT01181986|Drug|Exenatide IV|50 ng/min intravenously for 45 minutes on 2 out of 3 study visits separated by 5-10 days
46010745|NCT01181986|Drug|Placebo SC|Placebo sc BID/10days
46010746|NCT01181986|Drug|Exendin-9|Primed (6,000 pM/kg), continuous (600 pM/kg) intravenous infusion for 75 minutes on 1 out of 3 study visits.
46010747|NCT01181986|Drug|Placebo IV|Intravenous infusion for 45 minutes on 1 out of 3 visits
46010748|NCT01644435|Biological|Autologous Human Platelet Lysate|Subjects will receive a single injection of Autologous Human Platelet Lysate for acne scarring
45462267|NCT03859219|Drug|Placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous infusion"
45462268|NCT03721263|Biological|ASLAN004|Single Dose
45462269|NCT03374358|Drug|Raltegravir|The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .
45462270|NCT01179451|Device|echocardiogram|echocardiogram
45462271|NCT05664633|Drug|Sugammadex|Sugammadex or G/N will be given at the end of the procedure once the surgeon communicates with the anesthesiologist. The surgeon will typically do this at the time of putting the closing sutures.
45462272|NCT01287637|Procedure|Early reversal of temporary ileostomy|Temporary ileostomy is reversed 8-13 days after the primary surgery
45462273|NCT01287637|Procedure|Standard reversal of temporary ileostomy|Patients in the control group will have the ileostomy reversed according to standard treatment, which is 12-26 weeks after primary operation
45462274|NCT03711708|Drug|Zoloft Oral Solution|Test Product: 50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water
45462275|NCT03711708|Drug|Zoloft tablets|Reference Product: 50 mg sertraline administered as 1x Zoloft 50 mg tablet
45462276|NCT01179529|Drug|Omalizumab (Xolair®)|
45679338|NCT05854966|Procedure|Bone marrow biopsy|After the second induction cycle participants will have a bone marrow biopsy. After this biopsy, participants will have other bone marrow biopsies every 3 months for the next year. After the first year, participants may have a bone marrow biopsy if the treating physician feels it is necessary.
45462277|NCT01181089|Biological|Placebo|
45679339|NCT05852756|Behavioral|pecha kucha|pecha kucha training
45462278|NCT01181089|Biological|Baminercept|
45462279|NCT03372096|Device|Prostatic Artery Embolization|LC Bead LUMI is a spherical polyvinyl alcohol embolic particle that incorporates radiopaque moieties. Once a catheter has been fluoroscopically guided into the target vessel, the beads are then injected, causing obstruction at the arteriole level until the desired degree of embolization has occurred.
45462280|NCT01179607|Drug|M0002|
45679340|NCT05848557|Behavioral|mSaada|mSaada is an integrated digital platform to support patients, community health volunteers (CHVs), providers and health systems in an HPV-based cervical cancer screening strategy. mSaada is hosted on an open-source platform (Dimagi, CommCare) as a mobile health application to support patient data collection, protocol support and counseling aids. mSaada will include an education module, patient and specimen tracking, screening reminders, and messaging functionality.
45679341|NCT05846594|Diagnostic Test|FoundationOne® Liquid CDx Assay|Participants will undergo liquid biopsy (FoundationOne® Liquid CDx) on blood samples collected once they have a clinical diagnosis of advanced cancer (as per label). Blood samples will be tested using the FoundationOne® Liquid CDx assay at a central laboratory. Results of the FoundationOne® Liquid CDx assay will be provided to the investigator to be used in accordance with professional guidelines in oncology for patients with malignant neoplasms.
45679342|NCT05846594|Diagnostic Test|Standard of Care Diagnostic Pathway|Participants will undergo the local standard of care diagnostic pathway including tissue biopsy/standard of care (if tissue not available), pathology workup, and molecular workup, according to ESMO guidelines or national guidelines for each tumor type included in this study.
45679343|NCT05845814|Biological|Coformulated favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg) IV infusion
45679344|NCT05845814|Biological|Coformulated vibostolimab/pembrolizumab|Coformulated vibostolimab/pembrolizumab (200 mg/200 mg) IV infusion
46010749|NCT01644435|Biological|Autologous Human Platelet Lysate|Subjects will receive two injections of Autologous Human Platelet Lysate at an interval of one month for acne scarring
46010750|NCT04315909|Drug|PRP-Fibrin Glue|Platelet-Rich Plasma-Fibrin Glue
46010751|NCT04315909|Dietary Supplement|Vitamin E and C|Vitamin E and vitamin C
46010752|NCT04315909|Other|Placebo|Placebo
46010753|NCT04548362|Other|Meat arm|Randomised sequence of pork, beef, chicken meat, and an egg white/pea combination
46010754|NCT04548362|Other|Starchy foods arm|Randomised sequence of boiled potato, fried potato, potato crisps, and boiled white rice
46010755|NCT01181167|Drug|edoxaban|
46010756|NCT01181167|Drug|enoxaparin sodium|
46097448|NCT02728427|Device|Suprapubic catheterization using central venous catheter(CVC-2 7F)|Suprapubic catheterization using central venous catheter(CVC-2 7F) will be performed for patients after laparoscopic surgery for rectal cancer.Suprapubic catheterization is inserted at the end of the procedure. It will be clamped depending on surgeon's specific instruction and removed if the urinary residual is less than 50 cc.
46097449|NCT02728427|Device|Transurethral catheterization using Foley catheter|Traditional transurethral catheterization using Foley catheter will be performed for patients.The catheterization is removed on day 5 in patients without complication.
45679345|NCT05845814|Combination Product|EV|1.25 mg/kg IV infusion
45679346|NCT05845814|Biological|Pembrolizumab|200 mg IV infusion
45679347|NCT05844527|Drug|MRG-001|MRG-001 is a novel fixed-dose drug combination administered subcutaneously to mobilize stem cells and immunomodulatory cells to the wound to accelerate healing.
45462281|NCT01179607|Drug|Placebo|
45462282|NCT00004859|Drug|carboplatin|Induction Chemotherapy dosing: AUC=6.0, 15-30 min IV infusion immediately following paclitaxel, Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing, AUC=2; 15- 30 minutes IV infusion immediately following paclitaxel; administered weekly during radiotherapy
45462283|NCT00004859|Drug|paclitaxel|Induction chemotherapy dosing: 225 mg/m² (3 hour infusion) Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing: 45 mg/m2; administered weekly during radiotherapy over one hour
45679348|NCT05844527|Drug|Saline|Sterile saline will serve as placebo treatment.
46010757|NCT04550507|Behavioral|Mindful sensory awareness intervention|The mindfulness sensory awareness exercise will be a brief (3-5 minutes), guided meditation focusing on sensory and interoceptive awareness developed by Co-I Price, modified slightly to meet the needs of this age group and targeted for attention to indicators of fatigue or a sense of overstimulation. Youth will be asked to use the exercise after ending media use but before trying to sleep. The meditation component will be delivered via an audio-guided MP3, along with illustrated instructions in both handout and video, and a guided workbook that coaches youth over the 8-week intervention period to practice their skills, reflect on their experiences, and maintain adherence.
46010758|NCT04550507|Behavioral|Mindful sensory awareness + mindful body awareness check-ins intervention|During the intervention period for Group B: Mindful Sensory & Body Awareness(the second 8 weeks), they will receive the same mindful sensory awareness intervention, and also learn the mindful body awareness check-ins to guide media use choices strategy (referred to here as the check-ins component). We will coach youth to pause briefly every 30 minutes during media use to discern if they detect physical, cognitive, or emotional signs of escalated state arousal, and to make an intentional and real-time choice about possible changes in media use content or duration to help decrease state arousal levels before bed.
45462284|NCT00004859|Drug|thalidomide|Induction Chemotherapy dosing: oral daily, starting Day 1 for 24 months or until disease progression. Concurrent Chemotherapy / Radiotherapy dosing: oral daily, begin with 200 mg thalidomide as a single dose at bedtime. The dose is then increased by 100 mg every week as tolerated up to a total dose of 1000 mg.
45462285|NCT00004859|Radiation|radiation therapy|Radiation therapy started between days 43-50 from day 1 of cycle 1. The primary tumor and areas of known nodal disease received 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks to the post chemotherapy tumor volume as seen on computed tomography (CT). The initial 50 Gy was delivered to target volume (TV). The final 10 Gy was delivered to a reduced volume targeting defined by TV
45462286|NCT01176643|Other|Standard care plus Yoga|Participants will be asked to complete two yoga classes weekly over a period of eight weeks.
45462287|NCT03710694|Device|DAV132|"DAV132:~Dosage: 15 g/day activated charcoal (22.5 g/day DAV132)~Route: Oral~Duration: duration of fluoroquinolone treatment + 2 days~DAV132 is regulated as a medical device in Europe and as a drug in the United States of America."
45462288|NCT03861715|Diagnostic Test|live birth rate|The blastulation rate and live birth rate according to the protocol of COS
45462289|NCT03500679|Biological|ExPEC4V|Participants will receive ExPEC4V vaccine as an IM injection on Days 1 and 181.
45462290|NCT03500679|Biological|Placebo|Participants will receive placebo as an IM injection on Days 1 and 181.
46097450|NCT02628834|Other|Fascial mobilization|The patient will lie on prone position with knee extension and therapist put the patient's plantar surface to her femoral region. Achilles, tibialis posterior, perenous longus and brevis distal tendons, gastrocnemius proximal tendons, hamstring's distal tendons will be mobilized at first stage. The second stage of fascia mobilization included the deep fascial mobilization of posterior crural muscle trunks. After that, the skin also will be gently mobilized. During fascial mobilization, once the spastic muscles relaxation will appeared, the ankle will move to dorsiflexion gradually. FM will carry out for 15 minutes for each foot.
45462291|NCT01179685|Procedure|pleural fluid tapping|Minimally invasive technique to detect malignant pleural effusion
45462292|NCT03861637|Other|ESA for correction of PTA to 12-13g/dl|To assess the impact of full correction of chronic PTA(to near normal values) on cardiovascular system and quality of life in renal transplant recipients with stable graft function using erythropoietin stimulating agents in comparison to partially treated PTA with HB level between 12-13g/dl.
45462293|NCT03348930|Drug|Tolcapone 200 MG|All eligible study subjects will go through a 2-week treatment phase during which they will begin tolcapone at 100mg twice a day.
45462294|NCT03857737|Procedure|endoscopic submucosal dissection|Endoscopic submucosal dissection is an endoscopic procedure which can achieve en bloc resection of GI tumor. ESD is characterized by three steps: injecting fluid into the submucosa to elevate the lesion from the muscle layer, circumferential cutting of the surrounding mucosa of the lesion, and subsequent dissection of the connective tissue of the submucosa beneath the lesion. The ESD procedure will be carried out by experienced endoscopists.
45462295|NCT03857737|Procedure|Surgery|Surgery for EGC include Distal, proximal, or total gastrectomy, which will be performed according to the location and macroscopic tumor type by experienced surgeons.
45462296|NCT03500211|Drug|Lidoderm 5 % Topical Patch|Lidocaine patch after cesarean section delivery.
45462297|NCT03500211|Other|Sham Topical Patch|Sham patch after cesarean section delivery.
45462298|NCT01181245|Drug|FG-3019|3mg/kg IV, 10mg/kg IV, 15mg/kg IV, 25mg/kg, 35mg/kg IV, 45mg/kg IV - Biweekly, 35/17.5mg/kg, 45/22.5 mg/kg - Weekly
45462299|NCT03709524|Device|Airtraq + fiberoptic|video laryngoscope with a monitor
45462300|NCT03709524|Device|Airtraq|video laryngoscope with a monitor
45462301|NCT03709524|Device|Nasotracheal Airtraq + styletted tube|video laryngoscope with a monitor
45462302|NCT03721185|Combination Product|Dr.K. Treatment|Overweight and obesity treatment response
45679349|NCT05842265|Other|Self acupressure|patients will do self acupressure
45679350|NCT05839847|Device|Low-intensity focused ultrasound|A noninvasive brain stimulation device using low-intensity focused ultrasound (LIFU) - ultrasound will be used to test whether noninvasive brain stimulation can reduce reactions to sensory stimuli.
45462303|NCT03947021|Radiation|Computed tomography (CT) scan|A CT scan of thorax and heart will be performed in the CT+BSPM group.
45462304|NCT03947021|Device|Body-surface potential mapping|Measurement of 256-lead body-surface electrocardiogram
45462305|NCT01176721|Device|t-VNS verum|Active stimulation of the left auricle by t-VNS
46097451|NCT02628834|Other|Stretching Exercise|Patients will receive also stretching exercises consisted of 30 s stretching and 10 s resting periods and will carry out for 15 minutes for each foot at second day after the first evaluation.
46097452|NCT02571400|Other|Continued use of opioid analgesics >90 days post-surgery|Exposure of interest: continued use of opioid analgesics >90 days post-surgery
46097453|NCT02641652|Drug|Sertraline|25 mg once daily for first 7 days, then 50 mg once daily for the rest of the trial
46010759|NCT01644630|Procedure|Cemented crowns|"The final lithium disilicate crowns will be cemented with an adhesive cement after tightening the abutments with the torque indicated by the manufacturer and closing the screw access hole with white guttapercha. The abutment will be cleaned with ethanol. A retraction cord will be placed for cementation if indicated. The crown will be etched with hydrofluoric acid and subsequently silanized. A sufficient amount of cement will be filled in the crown without creating major excesses. When the crown is seated correctly, the cement will be light-cured for a few seconds to facilitate the removal of the now hard excess cement.~- Excess cement will be meticulously removed with a carbon scaler. The removal of all excess cement will be checked with an X-ray and by visual and tactile inspection."
46097454|NCT02641652|Drug|Placebo|1/2 tablet once daily for first 7 days, then 1 tablet once daily for the rest of the trial
46097455|NCT02626104|Dietary Supplement|Bovine lactoferrin|The children will be randomly assigned to receive 100 mg of bovine lactoferrin twice a day orally for the whole period of antibiotic therapy.
46097456|NCT02626104|Dietary Supplement|Maltodextrin|The children will be randomly assigned to receive 100 mg of placebo - maltodextrin twice a day orally for the whole period of antibiotic therapy.
45462306|NCT01176721|Device|t-VNS placebo|Sham stimulation of the left auricle with the t-VNS device
46010760|NCT01644630|Procedure|Screw-retained crowns|The screw-retained crowns will be inserted and tightened with the torque indicated by the manufacturer. The screw access hole will to be closed with white guttapercha and a composite filling (Filtek, 3M ESPE).
46097457|NCT02728349|Drug|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
46097458|NCT02571166|Biological|HSV529|Live, Replication-defective HSV-2 virus
46097459|NCT02571166|Drug|Valacyclovir|500 mg orally, once daily for 4 weeks
46097460|NCT02646254|Other|blood cardioplegia|
46097461|NCT02646254|Other|del nido cardioplegia|
46097462|NCT02728193|Procedure|RFA|
46097463|NCT02728193|Procedure|MWV|
46097464|NCT02728193|Procedure|PEI|Percutaneous ethanol injection
46097465|NCT00686478|Drug|interferon alpha 2b|1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.
46097466|NCT00723424|Drug|AZD5672|50 mg, for 13 days
45462307|NCT01106183|Dietary Supplement|transfer factor|capsules, 2 per day by mouth for 7 weeks.
45679351|NCT05839847|Device|Low-intensity focused ultrasound - sham|A sham condition that will mimic the application of LIFU without actually administering any ultrasound to the brain.
46097467|NCT00723424|Drug|Digoxin|0.5mg dose
46097468|NCT02641340|Drug|Fentanyl Sublingual Spray|Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)
46097469|NCT02641340|Drug|Fentanyl Citrate IV|Fentanyl Citrate 50 mcg, delivered intravenously
46097470|NCT02728271|Biological|HPC cell infusion|"Administration of total lymphatic irradiation, antithymocyte globulins, and high dose cyclophosphamide, followed by the infusion of autologous stem cells.~Patients will not receive any cyclosporin A, rituximab, or azathioprine post transplant."
46097471|NCT03677947|Behavioral|Exposure and response prevention|ERP is a treatment developed to help people confront their fears based on the rationale that exposure to feared objects, activities, or situations in a safe environment helps reduce fear and decrease avoidance. During the treatment, participants will engage in these exposures to feared stimuli within and between sessions according to hierarchies developed during the initial evaluation sessions, and refrain from engaging in compulsive behaviour until their anxiety subsides (i.e. ritual prevention). Exercises will consist of both exposure in vivo (i.e. exposure in real life situations) and/or imaginal exposure according to recommendations.
45462308|NCT01106183|Dietary Supplement|Placebo|cornstarch, 2 capsules per day by mouth.
45462309|NCT01288885|Drug|ASP1941|Oral
45462310|NCT01288885|Drug|Placebo|Oral
45462311|NCT04760717|Drug|Spironolactone Pill|Participants randomized to the Spironolactone arm will be receiving Spironolactone in addition to their normal routine blood pressure treatment.
45679352|NCT05838209|Drug|test|Ozone oil used as an adjunctive of scaling and root planing and control,
45679353|NCT05838209|Drug|Control|saline solution 0.09% used as an adjunctive as scaling and root planing
45462312|NCT01289509|Drug|E5501|Lot P01010ZZA (test) single oral doses of 40 mg tablets.
46010761|NCT04548557|Biological|intravenous immunoglobulin therapy|It is passive immunization therapy. Plasma therapy is subjected to moderate to severe patients specially, while all effected individuals can take benefit of immunoglobulin therapy because dose of immunoglobulins can be controlled
45462313|NCT01289509|Drug|Drug: E5501|Lot P97001ZZB (reference) single oral doses of 40 mg tablets.
45462314|NCT03478683|Drug|budesonide/formoterol|Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
45462315|NCT03478683|Drug|albuterol/salbutamol|Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
45462316|NCT03478683|Drug|FF/UMEC/VI|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
45462317|NCT03478683|Drug|Placebo to match budesonide/formoterol|Subjects will be administered two inhalations of matching placebo twice daily via MDI
45462318|NCT03478683|Drug|tiotropium|Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
45462319|NCT03478683|Drug|Placebo to match FF/UMEC/VI|Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
45462320|NCT03478683|Drug|placebo to match tiotropium|Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
45462321|NCT03478683|Device|ELLIPTA|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
45462322|NCT03478683|Device|MDI|Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
46010762|NCT04548323|Behavioral|Motor imagery|Subjects will perform motor imagery tasks on the motor gestures of running and walking.
46010763|NCT01181128|Drug|Factor VIII (rFVIIIFc)|
46010764|NCT01181128|Drug|Advate®|
46010765|NCT04548401|Drug|Antiplatelet Drug|aspirin and/or clopidogrel or ticagrelor
45462323|NCT03478683|Device|HandiHaler|Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
45462324|NCT04744883|Other|Spinal Manipulation Therapy (SMT)|2 SMT techniques are administered each session, both of which are scripted interactions between the physical therapist (PT) providing the SMT and the subjects: 1) Participants will lie on the SMT table for 20 mins, while the PT sits approximately 6 ft away. As part of the script, the PT will review with subjects the inclusion/exclusion criteria ostensibly to ensure that nothing has changed. 2) The PT will perform the 2 SMT techniques during the next 20 mins. 3) Subjects will sit upright in a chair for the remaining 20 mins, while the PT sits approximately 6 feet away. The PT will review home exercises with participant.
45462325|NCT04744883|Drug|Naloxone|In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
46010766|NCT04548284|Drug|Glucocorticoids|Periorbital injection of glucocorticoid. Once every 3 weeks, the number of injections was determined according to the condition of the eyes during the follow-up.
46010767|NCT04548050|Other|Nurses training|"Presentation of the benefits of colostrum and manual expression technique on a slide show and practical workshops for learning the manual expression technique on a fictitious breast.~Presentation to all staff of a service protocol for early colostrum donation."
45462326|NCT04744883|Drug|Placebo|In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
45473951|NCT03743701|Diagnostic Test|The method of transrectal ultrasound examination using three-dimensional image reconstruction.|A mechanical circular transrectal ultrasonic sensor with a frequency of 13 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. Within 30 seconds with a scan interval of 2 mm with a length of 10 cm, a circular recording of the anatomical structures of the rectum, surrounding tissue and anal canal takes place, obtaining an array of images in the form of a cube. The study was completed. After, at a convenient time for the researcher is working with a three-dimensional array of images. The resulting cube can be rotated 360 degrees in a circle of its axis, work with the sagittal, frontal and axial plane. To obtain a more visual representation of the exact localization of the internal fistula orifice, the course of the fistula relative to the fibers of the outer sphincter and to design volumetric cellular and wall plug.
46010768|NCT04547894|Drug|ASC09F|ASC09F (300 mg ASC09 and 100 mg Ritonavir) one tablet at a time, once per day, up to 7 days.
45462327|NCT04744883|Behavioral|Mindfulness Based Stress Reduction Therapy (MT)|Each MT session consists of (a) body scan meditation accompanied by awareness of breathing and other bodily sensations while in a lying position, (b) sitting meditation, focusing on awareness of breathing, bodily sensations, thoughts, and emotions (c) gentle movement exercises intended to develop awareness (mindfulness) during movement. In-session activities include suggestions for application of mindfulness as a method for responding positively to stress; dealing with the challenges of pain; and exercises focusing on the challenges and achievements patients experience in integrating mindfulness into their lives and the stressful situations they encounter. Additional discussion will focus on stress reactivity and they will be taught problem-solving skills to develop solutions to meet MT goals. Finally, patients will develop a written maintenance plan that includes a list of short- and long-term goals for applying mindfulness methods and a plan for dealing with possible setbacks.
45462328|NCT01289587|Behavioral|Physical activity intervention|36 sessions of physical activity offered at different frequencies
46010769|NCT01641315|Biological|rabies vaccine|"Group 1: rabies vaccination was given to rabies exposed victims on day 0,3,7,14,28 with ERIG on day 0.~Group 2: rabies vaccination was given to healthy volunteers on day 0,3,7,14 with ERIG on day 0.~Group 3: rabies vaccination was given to healthy volunteers on day 0,3,7,28 with ERIG on day 0."
45462329|NCT02524873|Device|Geneticure Collection Kit for Pharmaocogenetics of Hypertension|Buccal (cheek) swab kit for DNA collection for analysis of genes for hypertension
45462330|NCT01176799|Drug|Arm A|Doxorubicin 60mg/m2 day 1 Cyclophosphamide 600mg/m2 day1, every 3 weeks x 4 cycles
45462331|NCT01176799|Drug|Arm B|Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
45462332|NCT03948659|Procedure|Arterio ventricular coupling|We analyse ventriculo arterial coupling (VAC) among cirrhotic patients admitted in intensive care unit, with non-invasive echography method
45462333|NCT03478371|Device|tampon D|regular absorbency tampon
45462334|NCT03478371|Device|tampon M|regular absorbency tampon
45462335|NCT03478371|Device|tampon T|regular absorbency tampon
45679354|NCT05834972|Device|Ultrasound-guided percutaneous dilatational tracheosyomy|All of the participants will be examined two times. First, the landmark-guided technique will be performed. Then, the ultrasound-guided technique will be performed.
45679355|NCT05834829|Device|Low-intensity focused ultrasound neuromodulation|ultrasound transducer applying low intensity waveforms to targeted brain regions for neuromodulation.
46097472|NCT03677947|Other|Inference-based cognitive therapy|The treatment primarily targets the dysfunctional reasoning that gives rise to obsessional doubts and overvalued ideas. IBCT does not include exposure in vivo, but instead, aims to bring resolution to the initial obsessional doubt or overvalued idea by showing the participant that the obsession is the result of incorrect reasoning.
45679356|NCT05828589|Drug|BGB-21447|BGB-21447 will be administered orally
46097473|NCT02625948|Drug|Tranexamic Acid|
46097474|NCT02571556|Drug|Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA|Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA
45462336|NCT03478371|Device|tampon V|regular absorbency tampon
45462337|NCT03858673|Procedure|VTH via the Tsuzi method with residual uterine ligament ligation|VTH via the Tsuzi method with residual uterine ligament ligation
45462338|NCT01103765|Procedure|post dilatation after stent deployment|Post-dilatation with a noncompliant balloon larger 0.25mm than stent balloon.
45462339|NCT01103765|Procedure|stent deployment without post-dilatation|stent deployment without systematic post dilatation
45462340|NCT03861403|Drug|TRX518|Administered by IV infusion
45462341|NCT03861403|Drug|Cyclophosphamide|Administered by IV infusion
45462342|NCT03861403|Drug|Avelumab|Administered by IV infusion
46010770|NCT04548011|Other|Acupuncture|The acupuncture treatment strategies in this study are based on traditional Chinese medicine theory and opinions from the acupuncture experts. The acupoints are bilateral Zhongwan（CV12）, Tianshu（ST25）, Neiguan（PC6）, Liangqiu（ST34）, Yanglinquan（GB34）, Zusanli（ST36）and Taichong（LR3）.All the acupoints will be localized according to the Nomenclature and Location of Acupuncture Points of the People's Republic of China. During the acupuncture treatment, the participants will be in supine position. After 75% alcohol pads sterilizing the skin around the acupoints routinely, the acupuncturists will use sterile disposable steel needles (0.3 mm×40 mm; Huatuo Brand, Suzhou Medical Appliance, China) to insert into the acupoints above. The acupoints will be inserted vertically at 13-40 mm with the manipulation of steady small lifting, thrusting, and twirling 3 times to induce a sensation of de qi (sourness, numbness, and heaviness).
45679357|NCT05825534|Other|EIT monitoring|EIT monitoring (PulmoVista 500, Dräger, Lübeck, Germany) will be applied using a dedicated silicon belt with 16 electrodes placed at the level of the fifth intercostal space. The EIT system will be connected to the ventilator and data of gas flow, volume, airway pressure, and impedance will be synchronously collected at 40 Hz. The investigators will perform one simple pressure-volume (PV) curve with a low-flow insufflation of 5 L/min starting from 0 cmH2O. During the low-flow insufflation, both ventilator and EIT-derived PV curves will be recorded. All PV curves will be analysed offline to detect complete and regional airway closures, and measure AOPs.
46010771|NCT01641393|Drug|EUR-1008 25,000 Units|EUR-1008 25,000 Units is a PEP with pancreas powder as the active ingredient.18 Pancreas powder contains various enzymes having proteolytic, lipolytic, and amylolytic activity. Each capsule contains approximately 25,000 Ph. Eur. lipase units. EUR-1008 25,000 consists of orally administered capsules containing enteric-coated beads.
46010772|NCT01641393|Drug|Kreon 25,000 Units|Kreon 25,000 is a PEP consisting of porcine-derived pancreatic enzymes.18 Each capsule contains approximately 25,000 Ph. Eur. lipase units. Kreon 25,000 consists of orally administered capsules containing enteric-coated spheres.
45473952|NCT03380884|Device|Low-magnitude high-frequency vibration (LMHFV)|Low-magnitude high-frequency vibration (LMHFV) is a biophysical intervention that provides non-invasive, systemic mechanical stimulation and has been reported to have no adverse effect.
46097475|NCT03635749|Drug|Intensive antiplatelet|"Day 1：clopidogrel 300mg/day+ aspirin100-300mg/ day~Day2 - 21: clopidogrel 75mg/day+ aspirin 100mg/day~Day22 - 90: clopidogrel 75mg/day+aspirin placebo"
45462343|NCT01101503|Drug|Intensive multifactorial group|"Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The intensive multifactorial therapy group:~For blood glucose control, target HbA1c >=5.5%and <=6.0%,fasting blood glucose >=5.0 mmol/L and <=6.0 mmol/L, postprandial 2 hour glucose >= 6.0 mmol/L and <= 7.8 mmol/L. The drugs include insulin, oral hypoglycemic agents.~For blood lipids control, target LDL-C < =1.9 mmol/L, triglyceride < =1.5 mmol/L. The drugs include statin and fibrate.~For blood pressure control, target >=120/70 mmHg and <= 130/80 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~Others, such as aspirin."
45462344|NCT01101503|Drug|conventional multifactorial therapy group|"Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The conventional multifactorial therapy group:~For blood glucose control, target HbA1c >6.5%and <=7.0%,fasting blood glucose >6.0 mmol/L and <=7.0 mmol/L, postprandial 2 hour glucose > 7.8 mmol/L and <= 10.0 mmol/L. The drugs include insulin, oral hypoglycemic agents.~For blood lipids control, target LDL-C > 1.9 mmol/L and < =2.5 mmol/L, triglyceride > 1.5 mmol/L and < = 2.5 mmol/L. The drugs include statin and fibrate.~For blood pressure control, target >130/80 mmHg and <= 140/90 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~Others, such as aspirin."
45462345|NCT03477903|Drug|TAK-954|TAK-954 infusion
46010773|NCT04547933|Diagnostic Test|Bladder diary|A 3-day bladder diary recording daily drinking fluid amount, daily urine amount, urgency and urinary incontinence episodes.
46010774|NCT01641432|Behavioral|Tonic and Phasic Attention Training|"The Tonic and Phasic Alertness treatment task (TAPAT) consist of two consecutive rounds of a 12-minute continuous performance task in which continually varying, rich visual (e.g., scenes, objects, faces) or auditory stimuli (tones or complex sounds) are briefly displayed and participants are required to respond via a button press when they see a non-target item (90% of trials) or withhold button-press responding when the item is a pre-determined target item (10% of trials). Presentation of the target item is non-predictive and infrequent, disallowing the development of an executive strategy. Participants simply sustain attention to the task over a prolonged period of time (tonic attention), ignoring distractions, and inhibiting the pre-potent motor response when they see a target item (phasic attention).~Following the 24 minutes of TAPAT treatment participants will undergo one additional computer-based cognitive exercise, Multiple Object Tracking (MOT), for an additional 12 minutes."
45462346|NCT03477903|Drug|Metoclopramide|Metoclopramide infusion
45462347|NCT03477903|Drug|Normal Saline|0.9% sodium chloride for injection
45462348|NCT04728425|Drug|subcutaneous immunoglobulin (SCIG)|20% subcutaneous immunoglobulin
45462349|NCT04728425|Drug|intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG)|10% intravenous immunoglobulin + 20% subcutaneous immunoglobulin
45462350|NCT01181401|Drug|TPF induction chemotherapy|Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 Cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
46010775|NCT01641432|Behavioral|Active Comparator|Computer games chosen from a list of progressive visual/audiovisual games from the top-100 game list: sporcle.com. Training duration will be similar to that of experimental training.
46097476|NCT03635749|Drug|Standard antiplatelet|"Day 1: Aspirin 100-300mg/day + clopidogrel placebo~Day 2 - 90: Aspirin 100mg/day+ clopidogrel placebo"
46010776|NCT04547972|Other|Higher-load resistance training|This intervention will have one arm and one leg of each participant training with ~80% of their one repetition maximum
46097477|NCT03635749|Drug|Immediate high-intensity statin|"Day 1 - 21：Atorvastatin calcium 80mg/day~Day 22 - 90：Atorvastatin calcium 40mg/day"
45462351|NCT01181401|Drug|TPF experimental|Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles 2. Antibody therapy with: cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
45462352|NCT01181401|Radiation|Standard Radiochemotherapy (HART)|Hyperfractionated accelerated radiotherapy with concurrent Cisplatin and 5-Fluorouracil chemotherapy
46010777|NCT04547972|Other|Lower-load resistance training|This intervention will have one arm and one leg of each participant training with ~30% of their one repetition maximum
46010778|NCT01644825|Drug|paclitaxel|80 mg/m2 IV days 1, 8, 15 every 28 days
46097478|NCT03635749|Drug|Delayed high-intensity statin|"Day 1 - 3：Atorvastatin calcium placebo~Day 4 - 21：Atorvastatin calcium 40mg/day + Atorvastatin calcium placebo~Day 22 - 90：Atorvastatin calcium 40mg/day"
45679358|NCT05821699|Behavioral|LCS (Life Care Specialist)|"The LCS will work with the patient to create a pain management plan focused on behavioral education. The LCS interventions can encompass all, but not limited to, the information included below:~Opioid Risk Education~Therapeutic Intervention~Clinical Pain Coordination"
46010779|NCT01644825|Drug|pazopanib|orally, 800 mg orally daily
46010780|NCT04547660|Biological|Convalescent Plasma|Fresh frozen plasma collected by apheresis from recovered COVID-19 patients added to best supportive care.
46010781|NCT04547660|Other|Best Supportive Care|Any form of ventilatory support, extracorporeal membrane oxygenation, steroids, antibiotics and other supportive measures except for investigational interventions.
46097479|NCT03752216|Drug|Niraparib|"Two different doses of Niraparib can be administrated:~For patient who had at baseline (T0) a body weight ≥ 77 kg and a platelet count ≥ 150 000/µL, Niraparib will be administrated at a dose of 300 mg daily. The planned dose of 300 mg daily will be made up of three 100 mg capsules.~For patient who had at baseline (T0) a body weight < 77 kg or a platelet count <150 000/µL, Niraparib will be administrated at a dose of 200 mg daily. The planned dose of 200 mg daily will be made up of two 100 mg capsules.~Patient should continue to receive study treatment until disease progression as per RECIST as assessed by the investigator or they do not meet any other discontinuation criteria."
46097480|NCT00691548|Drug|Cetuximab-Zr. 89|"Step 1: Determination of the toxicity of two low doses of 89Zr-cetuximab In three patients a standard loading dose of 400 mg/m2 of cetuximab will be administered, partly labelled with 89Zr (60 MBq, 2.5mg) on day 0.~On day 14, a second injection with dose of 250 mg/m2 of cetuximab, partly labelled with 89Zr (60 MBq, 2.5mg), will be given.~Step 2: Determination of the toxicity of one larger dose of 89Zr-cetuximab A standard loading dose of 400 mg/m2 of cetuximab will be administered in 3 patients, a part labelled with 89Zr (120MBq, 5mg)."
46097481|NCT00712738|Drug|Nifedipine|
46097482|NCT00712738|Procedure|Phlebotomy|
46097483|NCT00712738|Procedure|Urinalysis|
46097484|NCT00712738|Procedure|Echocardiogram|
46097485|NCT00712738|Procedure|Electrocardiogram|
46097486|NCT00691626|Behavioral|CBT for Insomnia plus Imagery Rehearsal|patients receive standard CBT for insomnia and psychoeducation combined with techniques of imagery rehearsal aimed at reducing posttraumatic nightmare frequency and distress
46097487|NCT00691626|Behavioral|CBT for Insomnia plus psychoeducation|patients receive standard CBT for insomnia combined with psychoeducation
46097488|NCT02571010|Other|Standard Medical treatment|Standard treatment with drugs and usual rehabilitation
46097489|NCT02571010|Device|Vibrotactile stimulation|Rehabilitation by vibrotactile stimulation at medical center
46097490|NCT02571010|Device|Sham Stimulation with Vibradol device switched off|Sham Rehabilitation at medical center but with Vibradol device switched off
46097491|NCT05340647|Procedure|Preserflo microshunt|Implantation of Preserflo microshunt (Santen) to lower intraocular pressure
46097492|NCT05340647|Procedure|Trabeculectomy|Trabeculectomy surgery to lower intraocular pressure
46097493|NCT05340647|Procedure|Other MIGS|Other MIGS than Preserflo microshunt (e.g., XEN gel stent, iStent inject) to lower intraocular pressure
46097494|NCT03720626|Drug|crizanlizumab|IV formulation with 30 min infusion, 5mg/kg dosage
46097495|NCT00686556|Drug|cyclophosphamide|60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg
46097496|NCT00686556|Drug|cyclosporine|Beginning on Day -3 pre-transplant maintaining a level of >200 ng/mL. CSA dosing will be monitored and altered as clinically appropriate by Pharm D or physician, and discontinue at approximately day + 180 post-transplant.
46097497|NCT00686556|Drug|Fludarabine|25 mg/m2/day intravenous as a 1 hour infusion for consecutive 3 days pre-transplant, total dose 75 mg/m2
46097498|NCT00686556|Drug|mycophenolate mofetil|Beginning on day -3, use intravenous route between days -3 and +5, followed by oral administration on Day +6 through +30, if tolerated. 15mg/kg/dose for patients <40 kg, 3 gm/day for patients >40 kg.
46097499|NCT00686556|Radiation|total marrow irradiation|Dose escalating schedule per Cohort (TMI: 300 cGy) once daily.
46097500|NCT00686556|Procedure|umbilical cord blood transplantation|product will be infused via intravenous drip on Day 0 according to current University of Minnesota guidelines for Umbilical Cord Blood Grafts
46097501|NCT00686556|Biological|Granulocyte colony-stimulating factor|5 mcg/kg/day intravenous or subcutaneous based on body weight beginning on Day +1 after umbilical cord blood infusion until absolute neutrophil count exceeds 2.5 x 10^9/L for 3 consecutive days.
46010782|NCT01644864|Drug|0.375% ROPIVACAINE|
46010783|NCT01644864|Drug|placebo|
46010784|NCT04547855|Drug|anlotinib combined with dose-dense temozolomide|Temozolomide Capsule 150mg, p.o., qd, d1-7,15-21,4 weeks one cycle; Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
46010785|NCT01641510|Drug|Prasugrel|Loading with prasugrel 30 mg followed by daily administration of prasugrel 5 mg
45462353|NCT03946865|Other|Reiki Therapy|Reiki is a healing practice that originated in Japan. Reiki practitioners place their hands lightly on or just above the person receiving treatment, with the goal of facilitating the person's own healing response.
46097502|NCT00686556|Biological|HLA-matched related donor bone marrow|Related donor bone marrow or mobilized stem cells will be collected (target cell dose 5x10^8 nucleated cells/kg recipient weight, minimum 3x10^8 nucleated cells/kg recipient weight) and infused without processing on day 0 according to University of Minnesota Blood and Marrow Transplant Program guidelines.
45462354|NCT03858829|Other|Psychometric analysis|Psychometric analysis
46010786|NCT01641510|Drug|Clopidogrel|Loading with clopidogrel 600 mg followed by daily administration of clopidogrel 75 mg
46010787|NCT01644942|Other|Lipid accumulation analysis|The lipid accumulation will be assessed with muscular biopsies.
46097503|NCT04070482|Other|Tenofovir exposure in utero and during breastfeeding|Exposed in utero and during breastfeeding to Tenofovir-containing antiretroviral drugs
45462355|NCT03475875|Device|senofilcon A TEST Lens|senofilcon A with new UV blocker investigational process
45462356|NCT03475875|Device|senofilcon A CONTROL Lens|senofilcon A with new UV blocker standard process
45462357|NCT02525107|Dietary Supplement|Omega-3 capsules|SCD patients on Hydroxyurea
45462358|NCT02525107|Dietary Supplement|Placebo|SCD patients on Hydroxyurea
45462359|NCT02525107|Dietary Supplement|Omega-3 capsules|SCD patients not on Hydroxyurea
45462360|NCT02525107|Dietary Supplement|Placebo|SCD patients not on Hydroxyurea
45462361|NCT01179763|Other|Optical coherence tomography|Spectral domain optical coherence tomography will be conducted once when patients are enrolled.
45462362|NCT01287715|Drug|etanercept|Discontinuation of etanercept (half of the dosis for 3 months and discontinuation thereafter)
46010788|NCT04547621|Device|Radiation|Intensity-modulated radiotherapy 20Gy/10fx
46097504|NCT04166786|Drug|Testosterone gel|Subjects receive a daily transdermal dose of 100 mg of testosterone (2 sachets of 5 g of gel) during 3 days.
46097505|NCT04166786|Drug|Ethanol Solution|Subjects receive a daily administration of 30 g of ethanol (94 mL of Vodka Absolut® diluted in 300 mL of lemon-flavoured water Fontvella®) during 3 days.
45462363|NCT01287715|Drug|etanercept|Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
46010789|NCT04547621|Device|Radiation|Hypofractionated Stereotactic Radiotherapy 30Gy/5fx
45462364|NCT03474081|Drug|FF/UMEC/VI|A single inhaler triple therapy of FF/UMEC/VI will be provided via ELLIPTA DPI. FF/UMEC/VI will be available as dry white powder with dosing strengths of 100/25/62.5 mcg per blister.
45462365|NCT03474081|Drug|Tiotropium|Tiotropium will be provided as a hard gelatin capsule for oral inhalation containing 18 mcg tiotropium bromide blended with lactose, administered via HANDIHALER DPI.
45462366|NCT03474081|Drug|Albuterol/salbutamol|Albuterol/salbutamol will be provided as an inhalation via MDI with a spacer or nebules and will be given as a rescue medication throughout the study.
45462367|NCT03474081|Drug|Placebo to match FF/UMEC/VI|Placebo matching FF/UMEC/VI will be available as a dry white powder of lactose or magnesium stearate, administered via ELLIPTA DPI.
45462368|NCT03474081|Drug|Placebo to match tiotropium|Placebo will be given as hard gelatin capsule for oral inhalation containing lactose, administered via HANDIHALER DPI.
46010790|NCT04547621|Drug|Temozolomide|Temozolomide 75 mg/m2 concurrently administered with RT.
46010791|NCT01644981|Other|blood sampling|blood sampling
45462369|NCT03474081|Device|ELLIPTA inhaler|ELLIPTA DPI will contain two individual blister strips with 30 blisters per strip. FF/UMEC/VI and placebo to match FF/UMEC/VI will be administered to the subjects using ELLIPTA DPI.
46010792|NCT01641549|Procedure|Emergency surgery|Emergency surgery (valve replacement or thrombectomy)
46010793|NCT01641549|Drug|Fibrinolytic therapy|Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent at standard doses
46010794|NCT04547348|Drug|Denosumab Injection|Injections made subcutaneously per standard description
46010795|NCT04547426|Other|Wine with or without alcohol and snuff with or without nicotine|Two by two factorial of wine and snuff with meals
46010796|NCT01641588|Behavioral|posture: sitting or standing|Intervention: postural position - whether seated or standing. The person carries out a battery of cognitive executive functioning assessments delivered via a laptop and carried out with the laptop keyboard while either seated or standing.
46010797|NCT04547387|Device|Trans-carotid access revascularization with MicroNET covered stent implantation|Implantation of the micronet covered self-expanding carotid stent during temporary cerebral flow reversal achieved with direct common carotid artery puncture
46010798|NCT01641627|Procedure|proprioceptive stimulation|tendon vibrations and plantar stimulation with a therapeuthic orthosis, 4x30 min/day during 14 days
46097506|NCT04166786|Drug|Testosterone placebo (vaseline)|Subjects receive a daily transdermal dose of 5 g of pure vaseline ointment during 3 days.
46097507|NCT04166786|Drug|Ethanol placebo (lemon-flavoured water)|Subjects receive a daily administration of 394 mL of lemon-flavored-water Fontvella® during 3 days.
46097508|NCT02727647|Drug|FVIII|FVIII concentration 35-40 U/kg/dose 1 time/week for 5 months
46097509|NCT02727647|Drug|FVIII|FVIII concentration 15-20 U/kg/dose 1 time/week for 5 months
45462370|NCT03474081|Device|HANDIHALER|Tiotropium and placebo to match tiotropium will be administered to the subjects using HANDIHALER DPI.
45462371|NCT03474081|Device|MDI|Albuterol/salbutamol will be provided as a rescue medication throughout the study using MDI.
45462372|NCT01179841|Behavioral|Playgroup|The playgroup will be conducted at our center and focuses on providing an invigorating learning environment in which emerging skills/knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children experiences that they would not otherwise have. Parent training sessions will focus on strategies aimed at improving child social engagement and communication. Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources.
46010799|NCT04547231|Diagnostic Test|Fractional flow reserve, Coronary CT angiography|"Coronary CT angiography (CCTA) and measurement of fractional flow reserve (FFR) will be performed as part of routine clinical practice. The decision to perform CCTA before invasive angiography was at the judgment of the physicians in charge.~Physiologic assessment includes delta FFR (lesion-specific) and FFR (vessel-specific) measurement. Delta FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).~Stenosis and plaque features on CCTA will be analyzed by an independent CCTA core laboratory (Severance Cardiovascular Hospital, Seoul, Korea), and pericoronary and epicardial fat metrics (fat attenuation index, epicardial fat attenuation index, epicardial fat volume, etc.) will be obtained by an independent cardiac CT fat core laboratory (Tsuchiura Kyodo general hospital, Ibaraki, Japan)."
46010800|NCT01641666|Drug|Boceprevir|Boceprevir will be dosed orally at a dose of 800 mg three times daily (TID) for a total daily dose of 2400 mg.
46097510|NCT00723502|Drug|Finafloxacin + Amoxicillin|Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Amoxicillin, tablet 1000 mg b.i.d. (1 X 1000 mg tablet), oral administration
46010801|NCT01641666|Drug|Peginterferon Alfa-2b 1.5 mcg/kg/week|Peginterferon alpha-2b will be administered subcutaneously at a dose of 1.5 mcg/kg each week.
46010802|NCT01641666|Drug|Ribavirin|Ribavirin will be administered orally at a dose of 800 mg/day to 1400 mg/day in two divided daily doses (BID).
46097511|NCT00723502|Drug|Finafloxacin + Esomeprazole|Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Esomeprazole, tablet, 40 mg b.i.d. (1 X 40 mg tablet), oral administration
46010803|NCT02214485|Behavioral|integrated care|Participants visit the study site with health education, social activities, warm up, stretch, and low intensity resistance exercise for about 1 hour per week. If any medical problems or functional decline suspected during the visit, the case manager refers participants to their primary care physicians for further managements.
46097512|NCT02727881|Drug|Squalamine lactate ophthalmic solution, 0.2%|Squalamine lactate ophthalmic solution, 0.2%
46010804|NCT02214485|Behavioral|lower extremity strength training|Participants receive 2 sessions of 30-minute lower extremity strength straining using isotonic strength training machines each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments.
46097513|NCT02727881|Drug|Placebo Ophthalmic solution|Placebo Ophthalmic solution
46097514|NCT02727881|Drug|ranibizumab|ranibizumab
46097515|NCT01298024|Other|Early Neuromuscular Exercise|30 patients are randomized to early neuromuscular exercise (n=15) or treatment as usual, i.e., late exercise (n=15). Both groups are given an orthosis and are instructed to wear this for eight weeks. The experimental group starts with a structured exercise program one week after the diagnosis. The patients attend one training session/week during eight weeks, guided by a physical therapist. The level of training is progressed during this time. The patients in the control group (treatment as usual) are given exercise instructions and information at one occasion; 2 weeks after diagnosis. Both groups are followed up, by a blinded assessor, with valid and reliable self-reported and physical function outcomes at 1, 4, 8 and 16 weeks after injury.
46097516|NCT04066972|Other|Body-weight supported treadmill training in a room cooled to 16°C|A total of 30 training sessions will be conducted in 10 weeks for 30 minutes per session and 3 times per week in a cool room (16⁰ C) on a treadmill that is equipped with safety straps to prevent falls. A pneumatic harness system will be used to provide 10% body-weight support during training sessions. The participants will start exercising on the treadmill at 80% of their self-selected walking speed with 1% incline and will increase as per their tolerance (will progress weekly based on 40-65% heart rate reserve). Heart rate, perceived fatigue and rating of perceived exertion will be monitored continuously during exercise sessions. Initial training will commence with intermittent rest periods [1 to 5 minutes] as requested by the participants and will be progressed to a maximum of 30-minute continuous treadmill walking.
46097517|NCT02628678|Dietary Supplement|FOS|
46097518|NCT01564381|Dietary Supplement|ResA|90mg of resveratrol conjugated with arginine.
46097519|NCT01564381|Dietary Supplement|Resveratrol|90mg of resveratrol.
46097520|NCT01564381|Dietary Supplement|Placebo|Made up of cellulose.
46097521|NCT04164524|Drug|Gentamycin|Gentamycin 160 mg spray applied over the mesh
46097522|NCT02570854|Biological|CSJ137|Starting dose is 0.010 mg/kg and dose escalation will proceed with semi-log increase steps to a maximum dose level 10 mg/kg. Subjects receive the treatment via up to 30 minutes intravenous infusion.
46097523|NCT02570854|Drug|Placebo|Subjects will be dosed with a matching placebo (vehicle control) via up to 30 minutes intravenous infusion.
46097524|NCT00691782|Other|Survey of exercise practices|detailed questionnaire regarding the subject's race, income level; type(s), frequency, intensity, and amount of exercise; attitudes about exercise; hair style; hair care practices; attitudes about hair; hair and scalp health; and attitudes about exercise with regards to hair
46097525|NCT04002427|Drug|Intravenous Infusion|30 µg [14C]AZD7594 containing 6.7 kBq (180 nCi) carbon-14 (14C) as a 1 hour infusion.
46097526|NCT04002427|Drug|Inhaled dose|A single inhalation on one occasion.
46097527|NCT04164446|Drug|Placebos|The placebo that will be used contains starch and glucose.
46097528|NCT04164446|Dietary Supplement|Oil Palm Phenolics|One capsule contains 250 mg OPP or 1 g OPP
46097529|NCT00674778|Procedure|Any percutaneous cardiovascular procedure|
46097530|NCT00723658|Biological|rituximab|
46097531|NCT00723658|Drug|bortezomib|
46097532|NCT00723658|Drug|carmustine|
46097533|NCT00723658|Drug|cisplatin|
45679359|NCT05821699|Behavioral|Standard of Care|Patients will receive the current standard-of-care for pain management in the aftermath of surgery: a standardized prescription protocol, hospital-system approved discharge instructions which provide written instruction on how to taper opioid use, links to written/online resources for opioid misuse, overdose prevention, and State-approved disposal options.
45679360|NCT05821049|Other|UPI65 (Low Dose)|Red colored Capsules
45679361|NCT05821049|Other|UP165 (High Dose)|Red colored Capsules
46010805|NCT01645215|Drug|Fruquintinib|Fruquintinib is a capsule in the form of 0.25mg , 1mg and 5mg, oral, once a day.
46097534|NCT00723658|Drug|cyclophosphamide|
46097535|NCT00723658|Drug|cytarabine|
46097536|NCT00723658|Drug|dexamethasone|
45462373|NCT01179841|Behavioral|Parent Training|The 1-2 hour individual therapeutic sessions with parent training in the home or clinic (1x every week over six months) are based on our own program which is in development. This program focuses on teaching parents how to encourage social and communication skills in their toddlers and also provides comprehensive information about development. Sessions will focus on knowledge of autism, current access to services, general knowledge of strategies used to facilitate child development, advocacy, knowledge of how to access services, and coping strategies.
46097537|NCT00723658|Drug|doxorubicin hydrochloride|
46010806|NCT04547270|Other|Ultrasound scan|Volunteers will have an ultrasound scanning of both sides of their neck lying in supine position. Sequentially the scanning will start from the base of the neck (supraclavicular fossa) to the upper part of the interscalene groove and then in the reverse direction to the supraclavicular fossa. Images will be recorded as video loops.
45679362|NCT05821049|Other|Placebo|Red colored Capsules
46010807|NCT01203787|Drug|Sorafenib Standard Dosing Regimen|Sorafenib 400 mg twice daily until wk 24 or end of treatment
46097538|NCT00723658|Drug|etoposide|
45679363|NCT05820737|Dietary Supplement|EF2001 (Low dose)|One capsule to be consumed once a day
45679364|NCT05820737|Dietary Supplement|EF2001 (High dose)|One capsule to be consumed once a day
46097539|NCT00723658|Drug|melphalan|
46010808|NCT01203787|Drug|Sorafenib Ramp-Up Regimen|200 mg daily, Day 0-Day 13 200 mg twice daily, Day 14-Day 20 600 mg daily, Day 21-Day 27 400 mg twice daily, Day 28 until end of treatment400 mg twice daily
46010809|NCT01641744|Behavioral|Systematic Training for Effective Parenting (STEP)|Parenting skills training class, 1x/week, 12 weeks
46010810|NCT01641744|Behavioral|Group Attachment Based Intervention (GABI)|Parent-child group, 3x/week, 26 weeks
46097540|NCT00723658|Drug|thalidomide|
46097541|NCT00723658|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|
46097542|NCT00723658|Procedure|peripheral blood stem cell transplantation|
45679365|NCT05820737|Dietary Supplement|beLP1 (Low dose)|One capsule to be consumed once a day
45679366|NCT05820737|Dietary Supplement|beLP1 (High dose)|One capsule to be consumed once a day
45679367|NCT05820737|Dietary Supplement|Placebo|One capsule to be consumed once a day
45679368|NCT05820022|Other|Research Barriers Scale|This scale was prepared after a detailed literature review and sent to five physiatrists for review and feedback. It consists of 21 items with Likert-type responses and two open-ended questions. It is designed to measure the barriers that individuals or groups face in conducting research. The scale includes a list of potential barriers and asks respondents to rate the extent to which they experience each barrier. Examples of barriers that may be included in such a scale could include lack of funding, limited access to resources or equipment, time constraints, difficulty finding participants or accessing data, institutional or administrative hurdles, and so on.
45679369|NCT05818293|Device|radiofrquency device|• The radiofrequency system has been used for treatment of subcutaneous fat layers.
46010811|NCT02887768|Device|Epicardial Infarct Repair with CorMatrix-ECM|CorMatrix-ECM-biomaterial will be surgically applied to the epicardial surface of the infarct myocardium at the time of coronary artery bypass surgery
46010812|NCT02887768|Procedure|Coronary Artery Bypass Grafting Surgery|All participants will undergo standard coronary artery bypass grafting surgery to treat coronary artery disease
46010813|NCT04547504|Drug|Pembrolizumab|Pembrolizumab 200 mg once every 3 weeks for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or the Investigator's or the patient's decision to stop.
46097543|NCT00691860|Device|Mesh (Ultrapro ®)|In the mesh group, the mesh was placed in the sublay position, above the peritoneum and the posterior rectus sheath of the rectus abdominis muscles, with a minimum of 5 cm of mesh around the colostomy
46097544|NCT00691860|Procedure|Conventional sigmoid end colostomy|Patients receiving conventional sigmoid end colostomy, without mesh
46097545|NCT05355415|Device|Adaptive optics imaging|Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
46097546|NCT02727725|Other|Traminer MRI Sequence|The Traminer MRI sequence will be added to the standard IR Turbo-Flash sequence and last 2-5 minutes.
46097547|NCT04139850|Drug|Discontinuation of antiviral treatment in chronic hepatitis B cohort patients|For the selective patients in the cohort with long-term antiviral therapy and with conditions such as HBeAg negative or loss more than one year, antiviral therapy is able to be discontinued with an intensive inspection who agreed to the process. If there are need of this intervention, another multicenter IRB approval will be taken.
46097548|NCT02638142|Drug|Continuous Furosemide Infusion|Intravenous continuous Furosemide infusion
46097549|NCT02638142|Drug|Intermittent Furosemide Infusion|Intravenous bolus intermittent Furosemide Infusion
46010814|NCT04547504|Drug|Pembrolizumab and Chemotherapy drugs|"An induction therapy followed by a maintenance therapy.~4 induction cycles every 3 weeks associating, on the first day of each cycle:~Cisplatin 75mg/m² or carboplatin AUC 5mg/mL/min, pemetrexed 500mg/m² and pembrolizumab 200mg for non squamous NSCLC.~Carboplatin AUC 6mg/mL/min, paclitaxel 200mg/m² and pembrolizumab 200mg for squamous NSCLC.~After the 4 induction cycles, a maintenance therapy will be possible for patients who are responding or stable:~Non squamous NSCLC: pembrolizumab and pemetrexed combination or either drug as monotherapy.~Squamous NSCLC: pembrolizumab monotherapy.~For pembrolizumab: treatment may be continued for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop.~For pemetrexed, treatment may be continued until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop."
46010815|NCT01645254|Drug|Argemone mexicana|30g, the powder decoction 2 times a day for 14 days
46010816|NCT01181011|Drug|amlodipine/telmisartan/combination|patient would take amlodipine(5mg)/telmisartan(80mg)/combination(T80+A5mg) single dose in random order, and each dosage will be separated in 21 days interval.
46010817|NCT04528602|Procedure|Control (Extended leg position) Group|"Common procedure steps -Legal representatives of the infants will sign an informed consent form. Materials (soap, napkin, non-sterile gloves, diaper, wet cotton towels for newborns, waste container, diaper change mat) will be prepared.~Hands will be washed and gloves will be worn. Tapes of the infant's dirty diaper will be opened.~For the Control Group~-The infant will be grasped on the legs, the legs will be given extension position and lifted up.~The dirty diaper will be folded in two and the perineum area will be wiped with a wet cotton towel from the front to the back.~The infant's feet will be freed. The dirty diaper will be removed and thrown into the general waste bin. The used gloves will be removed.~The infant's legs will be given in extension position and a clean diaper will be placed under them.~Tapes of the clean diaper will be fastened. Hands will be washed after the procedure Data will be collected before, during, after and 3 minutes after application."
45837169|NCT00556140|Drug|Aripiprazole|"Everyone in this study will receive aripiprazole and an antidepressant called a selective serotonin reuptake inhibitor (SSRI). There is only one arm for this study.~Aripiprazole is an antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.~You will receive aripiprazole (Abilify) and one of the following SSRI antidepressant medications that will be determined by the study doctor and you: sertraline (Zoloft), citalapram (Celexa), or escitalopram (Lexapro). The dose of aripiprazole (Abilify) will be 10 milligrams a day, and the starting doses for the SSRI anti-depressants will be: sertraline (Zoloft) 50 milligrams a day, citalopram (Celexa) 20 milligrams a day, and escitalopram (Lexapro) 10 milligrams a day."
46097550|NCT02727491|Drug|Dextromethorphan|Dextromethorphan is a drug of the morphinan class with sedative, dissociative, and stimulant properties (at higher doses). Dextromethorphan has been explored for a number other uses in medicine, including pain relief (as either the primary analgesic, or an opioid potentiator).
46097551|NCT02727491|Drug|Placebo|Placebo syrup identical to active comparator in taste, appearance and volume but is inactive. Placebo comparator will be used in the placebo arm of the trial.
46097552|NCT03562195|Drug|Mepolizumab 100 milligrams|Mepolizumab will be given as a lyophilized cake in sterile vials for individual use. The vial will be reconstituted with Sterile Water for Injection, just prior to use.
46097553|NCT03562195|Drug|Placebo|Placebo will be given as 0.9 percent sodium chloride solution.
46010818|NCT04528602|Procedure|Experimental (Legs are flexed toward abdomen) Group|"Procedure steps for the Experimental Group~Common procedure steps~The infant will be grasped on the legs; the legs will be kept in the flexion position and approached toward the abdomen.~The dirty diaper will be folded in two and the perineum area will be wiped with a wet cotton towel from the front to the back.~The infant's feet will be freed.~The dirty diaper will be removed and thrown into the general waste bin. The used gloves will be removed and thrown into the medical waste bin.~The infant's legs will be kept in the flexion position and a clean diaper will be placed under them. A bottom care plan will be applied in line with the treatment plan, if necessary.~Tapes of the clean diaper will be fastened.~Hands will be washed after the procedure.~Data will be collected immediately before, during, immediately after and 3 minutes after the end of application."
46010819|NCT04546997|Diagnostic Test|Optical Coherence Tomography Angiography|Patients underwent non-invasive, fast, diagnostic imaging technique (optical coherence tomography angiography)
46010820|NCT01180777|Device|etafilcon A (A)|Daily wear contact lens
46010821|NCT01180777|Device|etafilcon A (B)|Daily wear contact lens
45837170|NCT00527124|Drug|cediranib maleate|Given orally
45837171|NCT00527124|Drug|docetaxel|Given IV
46010822|NCT01180777|Device|etafilcon A (C)|Daily wear contact lens
46097554|NCT03562195|Drug|Salbutamol|Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
46010823|NCT01641783|Drug|nanoparticle Albumin-Bound paclitaxel|nanoparticle Albumin-Bound paclitaxel:125mg/m2 d1 iv
46010824|NCT02214524|Device|Bair Hugger forced air warming system|Bair Hugger Model 775 temperature management unit-offers two airflow settings, hose-end temperature sensing, and precise temperature delivery
46010825|NCT02214602|Drug|Epirubicin|"Experimental: Study group(Epirubicin)~in the arm -study group(Epirubicin)- : patients will receive immediate intravesical instillation of 50 mg of epirubicin in 50 ml of saline 0.9 % after 30 min after compete transurethral resection of bladder tumor"
46010826|NCT01646580|Drug|ciclopirox|Doses of 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with four weeks follow-up.
46097555|NCT00722644|Behavioral|Cognitive Behavioral Stress Management|
46097556|NCT00686868|Other|placebo|placebo
46097557|NCT00686868|Drug|ofatumumab|fully human anti-CD20 monoclonal antibody
46097558|NCT02641106|Other|Video Directly Observed Therapy|Video Directly Observed Therapy (VDOT) is a novel means of remotely observing patients ingesting medications using videos sent from a smartphone. VDOT was developed and found to be feasible and acceptable for monitoring daily treatment of active TB in San Diego, CA and Tijuana, B.C., Mexico (R21-AI088326; PI: R. Garfein). Patients are taught how to use the VDOT recording app, record medication ingestion, and contact their physician when side effects occur. Participants are trained at the time of their first LTBI treatment dose to ensure participants know how to record videos. All remaining 11 weekly doses are taken and recorded wherever the participant chooses. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken.
46097559|NCT02641106|Other|In-Person DOT|Clinic-based, in-person DOT is the standard of care for monitoring adherence for patients taking the 12-dose isoniazid/rifapentine treatment for LTBI. Participants visit the clinic once weekly until all 12 doses are taken or 16 weeks pass, whichever comes first.
46097560|NCT04169321|Drug|Single Arm|[68Ga]-NOTA-hGZP is a PET imaging agent.
46097561|NCT04067908|Other|2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling|The samples taken during this study are taken at the same time as those taken in routine during the diagnosis of threat of premature labor. There are added 2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling.
46097562|NCT00992329|Drug|ciprofloxacin|ciprofloxacin 200mg tablet (single dose)
46097563|NCT02727569|Device|New visual field algorithm with DLS|Mathematical model (software based) to derive retinal sensitivity.
46010827|NCT04546802|Drug|Elbasvir / Grazoprevir Oral Tablet|Elbasvir / Grazoprevir
46097564|NCT02727569|Device|SITA algorithm|Mathematical model (software based) to derive retinal sensitivity. Commercially available.
46097565|NCT02727569|Device|New visual field algorithm with MMDT|Mathematical model (software based) to derive retinal sensitivity.
46097566|NCT00712816|Device|Game Ready Injury Treatment System (CoolSystems Inc.)|Cold with intermittent compression postoperatively for 2 weeks
46010828|NCT04528875|Device|Ultrasound imaging|Imaging of low back with ultrasound
46010829|NCT04546880|Other|Breathing exercises|"Breathing exercises consist of the techniques of diaphragmatic and pursed-lip breathing. During the diaphragmatic breathing, attention is focused on the correct abdominal breathing.~The pursed-lip breathing is one step further to the diaphragmatic breathing and a technique designed to have control time and volume over breathing."
46097567|NCT00712816|Other|Ice with compressive bandages|Cold with static compression postoperatively for 2 weeks
45837172|NCT00527124|Drug|prednisone|Given orally
45837173|NCT00527124|Other|laboratory biomarker analysis|Correlative studies
45837174|NCT00527592|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as travoprost.
46010830|NCT04546880|Other|Stabilization exercises|"Training about the concepts of stabilization and abdominal bracing is given before starting to the study. The motor control tests for local muscles transversus abdominus and multifidi are performed after the training. The abdominal bracing test is performed in the quadruped position, in prone, and in hook lying position with the patient's spine supine with hips and knees flexed and knees in contact with the surface.~The second stage consists of closed-chain segmental control exercises. It is a series of weight-bearing exercises are performed on stable and unstable surfaces. The last stage of the stabilization program is an open kinetic chain exercise to promote distal stability."
45462374|NCT01179841|Behavioral|Parent Training|In the once-a-week 1 to 2 hour parent training/enrichment, we will ask parents to target specific play and care routines in which they may stimulate their child's development in the ways identified by the therapist. These stimulation times may be provided by the parents, other family members, friends, volunteers or hired assistants. Parents will be encouraged to have their child in direct skill-enhancing engagement for 1-2 hour per day. The therapist will work with the family to identify times during the day that best lend themselves to accomplishing this goal.
45462375|NCT01177033|Other|Best endovascular treatment or Best surgical treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
46010831|NCT01645293|Genetic|Genetically modified T cells # 1138|
46010832|NCT04546919|Other|sepsis|Body temperature higher than 38°C or lower than 36°C; Heart rate higher than 90/min; Hyperventilation evidenced by respiratory rate higher than 20/min or PaCO2 lower than 32 mmHg; White blood cell count higher than 12,000 cells/ µl or lower than 4,000/ µl.
45462376|NCT03346434|Drug|Dupilumab|Solution for injection, subcutaneous (SC)
45462377|NCT03346434|Drug|Matching placebo|Solution for injection, subcutaneous (SC)
45462378|NCT03857425|Drug|Clostridum Butyricum Capsule|Clostridum Butyricum Capsule 3*420mg,twice daily for 8 weeks
45837175|NCT00527592|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as latanoprost.
46010833|NCT01648023|Device|LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo|
46097568|NCT02727257|Procedure|MIRT|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The duration of each session, including recovery periods, is about one hour. The first session comprise cardiovascular warm-up activities, relaxation, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in day living activities. The last session includes one hour of speech therapy.
46097569|NCT03482089|Procedure|Cystoprostatectomy|Patients with bladder infiltrating T4 prostate cancer receive cystoprostatectomy with urinary diversion surgery and extended pelvic lymph node dissection
46097570|NCT03482089|Radiation|external beam radiotherapy|Patients with bladder infiltrating T4 prostate cancer are treated with adjuvant androgen deprivation therapy
45462379|NCT03857425|Drug|Bacillus Coagulans Tablets|Bacillus Coagulans Tablets 3*350mg, three times daily for 8 weeks
45462380|NCT03857425|Drug|Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets|Clostridum Butyricum Capsule 3*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3*350mg, three times daily for 8 weeks
45462381|NCT03857347|Other|Psychoeducation Group for FND|he intervention is a psychoeducation based group.
45462382|NCT01179997|Device|Interventricular pacing delay optimization by using Tissue Doppler-derived displacement curves|
46010834|NCT01648023|Drug|Gem-Cis or Gem-Carbo|
46010835|NCT04547114|Diagnostic Test|Multicapillary column coupled ion mobility spectrometry|sampling of nasal air via a foam cuffed oxygen catheter
45462383|NCT01179997|Device|Electrocardiographic optimization of the interventricular pacing delay according to QRS width|
46010836|NCT01580033|Biological|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered on one arm, intramuscularly, per 0.5ml dose
45462384|NCT01181635|Behavioral|Psychotherapy|Standard psychotherapy for psychiatric disorders.
45462385|NCT03393000|Drug|Trans Sodium Crocetinate plus SOC|Trans Sodium Crocetinate (TSC) plus the Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
45462386|NCT03393000|Other|Standard of Care (SOC)|Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
45462387|NCT01181791|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri DSM will be given at a dose of 1x108 colony forming units (CFU)/day
46097571|NCT02571478|Behavioral|Marriage Checkup|The MC adapted for primary care consists of three 30-minute appointments with the IBHC. Session 1 consists of discussing the of the couple's relationship history and each partner's primary strengths. Session 2 focuses on each partner's primary concern about the relationship. Session 3 is dedicated to providing feedback for the couple that identifies strengths, areas for possible improvement, and a menu of possible strategies or resources for the couple to consider pursuing.
45462388|NCT01181791|Other|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present.
45462389|NCT01177111|Other|Sunflower seed oil|Locally manufactured refined sunflower seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
45462390|NCT01177111|Other|Mustard seed oil|Locally manufactured mustard seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
46010837|NCT01580033|Biological|Placebo|Placebo will be administered intramuscularly on the other arm, intramuscularly, per 0.5ml dose
46010838|NCT01580033|Biological|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Yunnan Walvax Biotechnology Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
46010839|NCT01580033|Biological|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
46010840|NCT04547036|Device|XEN45|Up to 140 consecutive patients with preoperatively recorded endothelial cell counts will be summoned to a consecutive endothelial cell count record and measurement of central corneal thickness postoperatively.
46010841|NCT01645332|Drug|Placebo of DLBS3233|Placebo of DLBS3233 once daily for 12 weeks
45462391|NCT01311804|Procedure|parecoxib sodium|periarticular parecoxib sodium injection will be given during total knee arthroplasty
45462392|NCT01311804|Procedure|parecoxib sodium|intravenous parecoxib sodium during total knee arthroplasty
45837176|NCT02121912|Device|FPH Pilairo Q CPAP mask|CPAP nasal-pillow mask
46010842|NCT01645332|Drug|DLBS3233|100 mg DLBS3233 once daily for 12 weeks
46010843|NCT01645332|Other|Lifestyle modification|Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
46010844|NCT04546763|Device|Study Watch|The Study Watch is a miniaturized wearable device made with biocompatible contact materials containing various sensors capable of measuring physiological and environmental metrics.
46010845|NCT04546763|Device|Zio XT|The Zio XT Patch, the reference device, is a FDA-cleared single-patient use, continuously recording ECG monitor that can be worn up to 14 days.
46010846|NCT02757222|Radiation|Escalated Dose|"Boost Target Volume (BTV): The PET CT GTV (thresholding at 40% of SUV max) with a 3mm margin will form the BTV.~CTV1: A 3mm area around the BTV avid primary or 2mm area around the node will form the CTV1.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal metastatic disease and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~BTV receives 73.5Gy in 30 fractions. PTV 1 receives 63Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy."
46097572|NCT02727413|Procedure|Blood sample collection|Drawing of 10 ml blood at inclusion, at the time of CPB connection, 60 min under CPB, at the time of CPB disconnection, 6, 24 and 48 hours post-surgery
46097573|NCT02727413|Other|Assessment of signs of organ dysfunction|Assessment of signs of organ dysfunction based on medical data prior to surgery, 24 and 48 hours post-surgery, and at the time of ICU discharge
46097574|NCT05253313|Other|MRI scan|Patients will be randomized to a pre-operative scan or not. The MRI scan will evaluate the local extent of the tumor and especially focus on identifying possible liver metastases unseen on the CT-scan.
45462393|NCT03370770|Drug|Afatinib|GILOTRIF, GIOTRIF, XOVOLTIB
45462394|NCT03370770|Drug|Osimertinib|on T790M resistance mutation was developed
45462395|NCT01180075|Drug|tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
45462396|NCT01180075|Drug|tenofovir/emtricitabine (TDF/FTC)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
45462397|NCT01180075|Drug|Atazanavir (ATV)|Patients receiving this drug for clinical care at 300mg with 100mg ritonavir daily will be enrolled.
45462398|NCT01180075|Drug|Ritonavir|Patients receiving this drug for clinical care at 100mg daily with 300mg atazanavir will be enrolled.
45462399|NCT01180075|Procedure|Phlebotomy|Multiple blood draws will be performed in the study, and vary depending on the group.
45462400|NCT01311882|Drug|MK-4305 40 mg|4 x 10 mg MK-4305 tablets
45837177|NCT02121912|Device|Any other market released nasal or nasal-pillow CPAP mask|Any other market released nasal or nasal-pillow CPAP mask
46010847|NCT02757222|Radiation|Standard Dose|"CTV 1 includes 6mm isotropic margin around the entire PET-CT avid (thresholding at 40% of SUV max) larynx/ hypopharynx /oropharynx and 5mm isotropic margin around nodes.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal involvement, or at risk nodal areas, and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~PTV 1 receives 66Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy."
46010848|NCT04546490|Other|Pressure Release technique|Manual therapy technique used by the treatment of Myofsacial Trigger points. The therapist will apply it with the first and second finger on the previously marked Myofascial Trigger Point and increasing the pressure as he perceives a reduction in the resistance offered by the soft tissue under the finger
46010849|NCT04546490|Other|Ischemic pressure technique|Manual therapy technique by making pressure in Myofascial Trigger Point. The therapist will apply it with the first and second finger on the previously marked Myofascial Trigger Point. This is performed until the patient's tolerance, when he refers a decrease in pain or have a correct adaptation to the perceived pain increase the pressure to a new painful barrier.
46010850|NCT04546685|Other|Usual Care|Participants who are randomized in the waitlist or usual care do not receive the study intervention and will be instructed to continue with the care they would normally receive as part of their ongoing clinical care. Upon completion of the 3-month study, participants in the waitlist will be invited to enroll in the Empowered Relief class.
46010851|NCT04546685|Behavioral|Empowered Relief|The participants will attend the Empowered Relief class offered online via Zoom. The class is designed to treat pain catastrophizing in people with chronic pain. Class participants will learn self-management skills and develop a personalized plan to use the skills every day. Participants will receive an audio file (Relaxation Response) post-class. The class provides patients rapid access to actionable skills for symptom management and pain relief.
46010852|NCT02750865|Behavioral|Embodied Conversational Agent (ECA)|The ECA is a computer generated character who will interact with the subject on a daily basis via a touch-screen tablet. The system is designed to provide the following functions: (1) medication counseling; (2) physical activity promotion; (3) symptom management and continual screening for adverse events; and (4) alleviation of stress and anxiety. The investigators will augment the system to include: (5) spiritual needs assessment; and (6) advanced care planning.
46097575|NCT00687024|Procedure|Magnetoencephalography|MEG will be performed on a whole head Omega 151-channel gradiometer system. At least 15 2-minute periods of spontaneous data are recorded. The sampling rate for data acquisition is 625Hz, with a bandpass filter of 3 to 70 Hz and a notch filter of 60Hz.
45462401|NCT01311882|Drug|MK-4305 20 mg|2 x 10 mg MK-4305 tablets
46010853|NCT04546373|Drug|Niraparib|Patient's medical records will be screened by local clinical staff to assess for eligibility according to selection criteria. The study comprises a single study visit, in which the patient will give her informed consent to participate (when the patient is alive) and the physician will extract the study data from the patient's medical charts. All eligible deceased and consenting living patients at the participating centers will be included. Data will be directly retrieved from hospital medical records and reported in the electronic Case Report Form (eCRF).
46010854|NCT01645410|Drug|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
46097576|NCT00687024|Procedure|MR imaging|MR imaging will be performed on a GE 1.5T system using a variety of sequences, including sagittal T1, axial T2, axial FLAIR, coronal dual echo, coronal FLAIR, axial 3D T2 frFSE and axial SPGR.
46097577|NCT00687024|Procedure|Diffusion Tensor Imaging|Diffusion tensor imaging will be performed on the same scanner, using single shot diffusion-weighted echo planar imaging. Twenty-five 'xial contiguous slices are obtained aligned to the anterior commissure line to cover the whole brain, giving a total imaging time of 4min 40sec.
46097578|NCT02645864|Drug|Apatinib|250mg p.o. qd in first cohort (3 subjects). 250mg p.o. bid in second cohort (3 subjects) 250mg p.o. tid in third cohort (3 subjects)
45462402|NCT01311882|Drug|Zopiclone|1 x 7.5 mg Zopiclone tablet
46097579|NCT02645864|Drug|Irinotecan|150mg/m^2 i.v. q2w
45462403|NCT01311882|Drug|Grossly Matching Placebo for Zopiclone|Grossly Matching Placebo for Zopiclone
45462404|NCT01311882|Drug|Matching Placebo for MK-4305|Matching Placebo for MK-4305
45462405|NCT01287793|Drug|tigecycline|intravenous, 200 mg, single dose
45837178|NCT04062396|Device|Eurosets REMOWELL 2 oxygenator|The main characteristic of REMOWELL 2 oxygenator is the presence of a filtration system for extracavitary inlet. Multilayer cascade filtration and supernatant separator leads to lipid-leukocytes depletion
45837179|NCT04062396|Device|LivaNova INSPIRE oxygenator|INSPIRE oxygenator has no filtration system for extracavitary inlet
45837180|NCT04043598|Drug|0.9% Sodium-chloride|We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
45462406|NCT01287793|Drug|tigecycline|intravenous, 50 mg, single dose
45462407|NCT01287793|Drug|moxifloxacin|oral tablet, 400 mg, single dose
45462408|NCT01287793|Drug|100 mL 0.9% Sodium Chloride intravenous|intravenous fluid, 100 mL, single dose
45462409|NCT01287793|Drug|placebo|0.9% Sodium Chloride intravenous 100mL, single dose
45462410|NCT03709290|Radiation|mri|mri brain & spinal cord
46010855|NCT04546334|Drug|Medical treatment|routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol)
46097580|NCT02727101|Drug|perampanel|Each group of 6 patients will be followed for 12 weeks of baseline observation on baseline medication. Seizure frequency will be counted, using subjects' self-reported seizure diaries. Perampanel will be titrated to 8-12 mg/day, with the final dose determined by side effects and tolerability of Perampanel at 8-12 mg/day doses. Titration will occur at the rate of 2 mg/week or two weeks, as tolerated.
46097581|NCT03991351|Other|Exposure to images|Exposure to images
46097582|NCT02645942|Dietary Supplement|L-carnitine|L-carnitine 1400 mg daily for 8 weeks
46097583|NCT02645942|Dietary Supplement|Placebo|Placebo daily for 8 weeks
45837181|NCT04043598|Drug|Ringer's Lactate|We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
46097584|NCT03076385|Biological|VAL-506440|Escalating dose levels
46097585|NCT03076385|Other|Placebo|
46097586|NCT00992485|Drug|ADIPOPLUS|autologous adipose-derived stem cell
46097587|NCT00674856|Drug|naproxcinod|750mg
46097588|NCT02574130|Drug|Amikacin|400 mg, nebulizer, every 12 hours, 10 days
46097589|NCT02574130|Drug|Placebo|placebo 4 ml, nebulizer, every 12 hours, 10 days
46097590|NCT00652184|Drug|ARYS-01 (sorivudine) cream 3% or placebo cream|sorivudine cream 3% or placebo cream twice daily for 10 days
46097591|NCT00652184|Drug|placebo|placebo cream and placebo valaciclovir
46097592|NCT00652184|Drug|valaciclovir|active valaciclovir
46097593|NCT02727179|Procedure|Liver resection|The investigators perform an anatomical liver resections or wedge resections depending on tumour's location and tumour's characteristics
46097594|NCT05356663|Other|Mulligan Mobilization|Medial glide MWM for knee flexion (supine) Lateral glide MWM for knee flexion (supine) Medial glide MWM for knee flexion.( prone ) Lateral glide MWM for knee flexion (prone)
46097595|NCT05356663|Other|Hold Relax|Hold-relax technique of PNF included, the affected knee will be flexed passively to the end of range with the therapist's hand on the patient's lower leg. Patients then performed 5 s of quadriceps contraction against the resistance of the therapist. Patients will be asked not to let move. At the end of 5 s, the patients will be asked to totally relax for 10 s and the therapist pushed the knee into more flexion and hold at that newly acquired range
46097596|NCT02726867|Drug|levetiracetam|Treatment will consist of LEV 4000 mg i.v. over 10 minutes.
46097597|NCT02726867|Drug|lacosamide|Treatment will consist of LCM 600 mg i.v. over 10 minutes
46097598|NCT02726867|Drug|Ketamine|Treatment will consist of KET 2.5 mg/kg over 10 minutes
45462411|NCT03391284|Drug|acetominophen|INTRAVENOUS
45837182|NCT00556452|Drug|Clofarabine/Busulfan x 4|"Clofarabine IV (dose levels)~1st dose level: 20 mg/m2/day x 5 days~2nd dose level: 30 mg/m2/day x 5 days~3rd dose level: 40 mg/m2/day x 5 days~Busulfan IV 3.2 mg/kg daily x 4 days"
45837183|NCT00556452|Procedure|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
46010856|NCT04546334|Procedure|Real Erector Spinae block|Ultrasound guided Erector spinae plane block with injection of local anesthetic bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose)
46010857|NCT04546334|Procedure|Real Erector Spinae block with magnesium sulphate|Ultrasound guided Erector spinae plane block with injection of local anesthetic bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose with the addition of MgSO4 (equivalent to 100 mg))
46010858|NCT04546334|Procedure|Sham Erector Spinae block|Ultrasound guided Erector spinae plane block with injection ofnormal saline
46097599|NCT02726867|Drug|Phenobarbital|Treatment will consist of PHB 15 mg/kg mg i.v. at 100 mg/minute rate
46097600|NCT00687180|Drug|Treatment with mycophenolat mofetil|
46097601|NCT00687180|Drug|Treatment with azathioprin|
46097602|NCT00723970|Drug|Quetiapine Extended Release|Quetiapine XR, 150-300 mg QHS, for 8 weeks
46097603|NCT02637908|Behavioral|Mindfulness training|6-weeks of group-based mindfulness training for parents
46097604|NCT00636623|Other|Pilates exercises|15 FM patients participated in the PE programme three times a week during a 4-week period
46097605|NCT00636623|Other|Connective tissue massage|21 patients received CTM, three times a week during a 4-week period
46097606|NCT00873366|Drug|dextromethorphan hydrobromide|
46097607|NCT00873366|Drug|tamoxifen citrate|
46097608|NCT00873366|Other|high performance liquid chromatography|
46097609|NCT00873366|Other|laboratory biomarker analysis|
46097610|NCT00873366|Other|pharmacogenomic studies|
46097611|NCT00873366|Other|pharmacological study|
46097612|NCT00873366|Procedure|fluorescence imaging|
46097613|NCT02727023|Other|Osteopathic Manipulative Medicine|The procedures are picked for their generalized effect on the lymphatic system based on osteopathic literature and research. Our goal is to mobilize the lymphatic fluid to induce an increase of endocannabinoids. These procedures are similar to mechanical motion seen in exercise in regards to lymphatic movement. Each technique will be performed for a total of four minutes each
46097614|NCT00655226|Behavioral|Hepatitis C educational support groups|Hepatitis C educational support groups
46097615|NCT00655226|Behavioral|Cognitive Behavioral Therapy skills based group sessions|Eight CBT group sessions tailored for hepatitis C patients conducted by a clinical psychologist: 3 sessions conducted prior to IFN/ribavirin initiation, 1 session the day of IFN/ribavirin initiation, and 4 sessions during IFN/ribavirin treatment.
46097616|NCT00712894|Drug|Diltiazem|Intracoronary Infusion 400-2000ug
46097617|NCT00712894|Drug|Verapamil|Intracoronary Infusion 200-1000ug
45462412|NCT03391284|Drug|Acetaminophen|ORAL
45462413|NCT02524951|Drug|MSI-1436C|Dose escalation, single intravenous infusion twice a week for 3 weeks on a 4-week cycle.
46097618|NCT00712894|Drug|Nitroglycerin|Intracoronary Infusion 200-1000ug
46097619|NCT04164368|Drug|Lenalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Lenalidomide 25mg PO QD D2-11
46097620|NCT04070248|Other|No intervention|No intervention
45462414|NCT03709212|Other|interviews|20 participants will undergo individual semi-structured interviews, 60 will undergo one of 6 focus groups comprising of 10 participants of the same gender and ethnicity.
46097621|NCT02726477|Drug|Wuling San|Patients will be administrated with Wuling San at a dosage of 1g/kg twice a day after randomisation.
45462415|NCT05666557|Other|manual erector spinae myofascial realease|"The subjects first positioned the third, fourth, and fifth lumbar vertebrae in a relaxed lying position, about 2-3 cm away from the left and right sides (depending on the size of the subjects' muscles). And then in six postures (prone, prone with leg raise, sit straight , slouch sitting, stand straight and slouch standing), MyotonPRO was used to test the above-mentioned 8 points in these position.~Subjects will undergo a pre-mobilization assessment to see if MyotonPRO can detect changes in the erector spinae muscle properties, including changes in muscle tone, stiffness, and elasticity, under different test positions. After physical therapist manual mobilization, MyotonPRO's erector spinae muscle biomechanical data was collected again for data analysis to determine MyotonPRO could objectively quantify changes in erector spinae biomechanical characteristics."
45462416|NCT05666557|Other|self-myofascial release technique|"The subjects first positioned the third, fourth, and fifth lumbar vertebrae in a relaxed lying position, about 2-3 cm away from the left and right sides (depending on the size of the subjects' muscles). And then in six postures (prone, prone with leg raise, sit straight , slouch sitting, stand straight and slouch standing), MyotonPRO was used to test the above-mentioned 8 points in these position.~Subjects will undergo a pre-mobilization assessment to see if MyotonPRO can detect changes in the erector spinae muscle properties, including changes in muscle tone, stiffness, and elasticity, under different test positions. After self mobilization by roller, MyotonPRO's erector spinae muscle biomechanical data was collected again for data analysis to determine MyotonPRO could objectively quantify changes in erector spinae biomechanical characteristics."
45462417|NCT03473301|Biological|Infusion of allogeneic umbilical cord blood|Subjects will receive a single infusion of allogeneic umbilical cord blood at the baseline visit.
45462418|NCT03473301|Biological|Infusion of MSCs|Subjects will receive 3 infusions of MSCs (baseline, 3 months and 6 months).
46010859|NCT04546256|Drug|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test and Reference product in each study period
46010860|NCT04546256|Drug|ADVAIR DISKUS® 500/50|2 inhalations of Test and Reference product in each study period
45462419|NCT05433168|Procedure|SHIATSU|The patients will benefit from shiatsu treatments by a professional according to the shiatsu protocol developed by the Syndicate's evaluation commission Shiatsu Professionals (SPS).
45837184|NCT00556452|Radiation|Total Lymphoid Irradiation|Total Lymphoid Irradiation (TLI) of 4 Gy, if cord blood transplant
46010861|NCT01645449|Drug|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
46010862|NCT04546100|Other|Maternal-Infant Exercise Program|"Maternal-Infant Exercise Program can be divided into three videos stages. As time progresses during the three months, the parent-child exercise videos provided will have stronger intensity. The content includes general post-natal exercises (e.g., baby Lying on the mother's bed, raising legs or back of hands exercises, breast exercises; neck exercises; pelvic swinging exercises), aerobic exercises (e.g. walking with strollers, walking with baby on back), core exercises (e.g. kneeling balance, kneeling Push ups, stick exercises, modified side stick exercises) and hip and leg exercises (such as donkey kicks, side lifts), etc., with relaxing music during exercise."
46010863|NCT02755896|Radiation|Arm 1 600 cGY x 5 fractions|Patients who are randomized to Arm 1 will receive either 600 cGY x 5 fractions over 5 consecutive days
46097622|NCT02726477|Drug|placebo|Patients will be administrated with placebo powder at a dosage of 1g/kg twice a day after randomisation.
46097623|NCT02625246|Biological|hMSCs|intravenous infusion of bone marrow-derived allogeneic stem cells
46097624|NCT00724204|Dietary Supplement|follow on formula without probiotics|A follow on formula without probiotics
46097625|NCT00724204|Dietary Supplement|follow on formula with Lactobacillus salivarius CECT5713|follow on formula with Lactobacillus salivarius CECT5713 in a dose of 2x10E8 cfu/day
46097626|NCT02726555|Drug|Red yeast rice and atorvastatin|Participants will receive 2 capsules of 300mg red yeast rice and 2 capsules of 10mg atorvastatin for 24 weeks.
46097627|NCT02726555|Drug|Atorvastatin alone|Participants will receive 2 capsules of placebo and 2 capsules of 10mg atorvastatin for 24 weeks.
46097628|NCT00536107|Drug|Gefitinib|250 mg oral
46010864|NCT02755896|Radiation|Arm 2 800 cGY x 3 fractions|Patients who are randomized to Arm 2 will receive 800 cGY x 3 fractions given every other day
46010865|NCT01645761|Drug|Endonase|PPI- based triple therapy with endonase
46097629|NCT00536107|Procedure|CT or MRI|performed at screening and every 6 weeks
46097630|NCT00536107|Drug|Docetaxel|60mg/m2 intravenous infusion
46097631|NCT01022138|Biological|HER2Bi-armed activated T cells|Immediately after pheresis, the lymphocytes are activated with soluble monoclonal anti-CD3 antibody, which cross-links the CD3 receptors on T cells and activates them.
46097632|NCT01022138|Drug|Cyclophosphamide|After recovering from the last cycle of chemotherapy (approx. two-four weeks) patients will be re-staged. If there are no residual chemotherapy related toxicities, they will be given lymphodepleting chemotherapy consisting of one dose of Cyclophosphamide 1.0 gm/m2 on day -7. Appropriate anti-emetics will be given as pre-medications before the dose of Cyclophosphamide
45837185|NCT03158376|Drug|Gabapentin|
46097633|NCT01022138|Other|Laboratory biomarker analysis|The association between the [18F]-FDG PET/CT assessments (percent changes from baseline in SUVpeak) and immunologic biomarker changes as well as tumor response will be explored.
46097634|NCT00724360|Drug|Herceptin (trastuzumab)|Administered as a 4 mg/kg intravenous loading dose followed by 2 mg/kg weekly for at least 2 months and/or until progression
46097635|NCT02690519|Drug|GLPG1837 dose 1|one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
46010866|NCT04546646|Other|Elastic Band Exercises|Resistance exercise will be performed using theraband. The color of the band denotes the degree of elasticity and resistance level(yellow , red ,green ,blue, black or silver).Exercise load in terms of individual yielding elasticity (band color) in resistance training will set at a level that a patient perceived as somewhat hard, which is equivalent to a 13-grade rating (moderate intensity exercise) on the RPE, According to American College of Sports Medicine. For each exercise movement 3 sets of 10 repetitions of gentle concentric and eccentric contractions through the full range of motion will be slowly performed using a yellow Thera band initially. The exercise intensity will be increased when the patient is able to achieve a perceived yield strength corresponding to a 13- grade rating on the RPE scale.
46010867|NCT02759640|Drug|HS-10241|HS-10241 is administered orally starting at 100 mg/day.
46010868|NCT04546529|Device|Trans-spinal Magnetic Stimulation (TsMS)|Patients undergoing real TsMS with coil
46097636|NCT02690519|Drug|GLPG1837 dose 2|one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
46097637|NCT04139460|Device|CRT-D|After randomization, devices will be implanted as soon as possible (within 2 weeks). The ICD will be programmed with anti-tachycardia pacing and shock therapy as per common praxis.
46097638|NCT04139460|Device|CRT-P|After randomization, devices will be implanted as soon as possible (within 2 weeks).
46097639|NCT04164056|Device|deep brain stimulation|deep brain stimulation on the hippocampus or the anterior nucleus of the thalamus
46097640|NCT05374018|Diagnostic Test|urinary kit for pneumococcus antigen assay|urine test for detection of pneumococcus antigen
46097641|NCT02628912|Other|blood draw|
46097642|NCT02628912|Behavioral|study questionnaire|
46097643|NCT02628912|Other|cardiopulmonary exercise testing (CPET)|
46097644|NCT02628912|Other|DXA (dual-energy x-ray absorptiometry) scan|
46097645|NCT00653666|Other|Medically supervised fasting|Metabolic fasting studies will be conducted over an 18-hour period or until blood glucose is < 40 mg/dl. If the YSI reading is 40 mg/dl or less, at any time during the study, then a blood sample will be collected, and the fast terminated by giving D25W IV and then feeding orally.
46097646|NCT03385993|Device|Technology based guided meditation and relaxation|Subjects will be guided through a mediation and relaxation exercise on a tablet or virtual reality headset for up to an hour each day.
46097647|NCT02571088|Other|Training Program|Each training session will last 45 min. Exercise will start by a 5-min warm-up cycling period, followed by 30 min of cycling at the power output (W) individually determined before and corresponding to the first lactate threshold corresponding approximately to 2.5 mmol/l . Then patients will cool down for 5 min. Finally, the training sessions will end by 5 min of light stretching. All training sessions will take place at the hospital and will be under the supervision of a physician. Heart rate, oxygen saturation and blood lactate concentrations will be regularly measured. Work rate will be adjusted according to the obtained results. As a safety procedure, blood lactate concentration must not exceed 4 mmol/L during the training sessions. A particular attention will be paid to the hydration of patients. Pain and fatigue will be evaluated everyday by the patients using (100 mm) visual analog scales.
46097648|NCT02637830|Other|Application of fluoride varnish (22600 ppm F, Duraphat) at the begining of the study|
45462420|NCT05433168|Procedure|DUMMY SHIATSU|Exercising a fake shiatsu is a real problem as opinions differ. The consensus of the different schools and styles of the technique is that shiatsu pressure is weight transfer. We are therefore going to remove this aspect from the SFASPA shiatsu protocol. The professional will run the same sequence of points, without any weight transfer, being only in contact with the receiver
46010869|NCT04546529|Device|Sham Trans-spinal Magnetic Stimulation (TsMS)|Patients undergoing placebo TsMS with coil
45462421|NCT01180153|Drug|S-1 oxaliplatin|S-1 (20mg, 25mg); L-OHP (50 mg)
45462422|NCT03719625|Drug|Ephedrine|Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section
46010870|NCT04546022|Drug|Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.|
46010871|NCT01645800|Drug|Lysozyme hydrochloride|LYL 90mg capsule: Three times daily for 52 weeks.
46010872|NCT01645800|Drug|Placebo|Matching Placebo capsule: Three times daily for 52 weeks.
46097649|NCT02637830|Other|Application of fluoride toothpaste (1500 ppm F, Crest) twice a day for 3 days of the study|
46097650|NCT02637830|Other|Application of placebo toothpaste (0 ppm F, Ice Fresh) twice a day for 3 days of the study|
46097651|NCT00687258|Device|VitabranE ViE|Polysulfone dialyser with vitamin E alpha-tocopherol
46097652|NCT00687336|Other|Empirical Hp eradication|Empirical Helicobacter pylori treatment initiated immediately after oral intake is resumed
46097653|NCT00687336|Other|Eradication treatment guided by a positive test|Eradication treatment given if there is at least one positive diagnostic test (URT, histological test, breath test or serology) for Helicobacter pylori.
45462423|NCT03719625|Drug|Norepinephrine|Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section
45462424|NCT01289743|Drug|Etanercept|Etanercept 25 mg subcutaneously twice a week
46010873|NCT01645878|Behavioral|hands on|in hands on group it was instructed by direct help of instructor, mothers could ask questions and if necessary it was done again by researcher.
45462425|NCT03390426|Drug|Mepivacaine|An ultrasound guided injection of mepivacaine superomedially to the femoral artery.
45462426|NCT03390426|Procedure|Perifemoral Injection of Local Anesthetic|An ultrasound guided injection of mepivacaine superomedially to the formal artery in an effort to numb the nerves that contribute to tourniquet hypertension intraoperatively.
45462427|NCT03390426|Drug|Saline|An ultrasound guided injection using a medication that does NOT numb any nerves called saline, or salt water.
45462428|NCT03472521|Drug|Gabapentin|Treatment with analgesic adjutant commonly used for post-operative pain, titrated to effect by chronic pain specialist compared to placebo titration.
45462429|NCT03472521|Drug|Placebo|Placebo to match gabapentin
46010874|NCT01645878|Behavioral|hands off|In hands off group, was instructed by pictures, if mothers had questions, they could watch the pictures again
45462430|NCT02906020|Drug|venglustat GZ/SAR402671|Pharmaceutical form: capsule Route of administration: oral
46097654|NCT04001569|Drug|AZD8186 in combination with paclitaxel|"Phase 1b is planned for a 4-stage dose level and the traditional 3+3 design is applied. The RP2D will be determined based on the MTD and toxicity profiles.~In phase 2 part, RP2D from the phase 1b part will be applied.~AZD8186 ( )mg po bid, 5 days on, 2 days off~Paclitaxel ( )mg/m² on D1,8,15 every 4 weeks"
45462431|NCT02906020|Drug|Placebo|Pharmaceutical form: capsule Route of administration: oral
45462432|NCT01181869|Device|oxygen|oxygen therapy, ventilation for respiratory failure CPAP for sleep apnoea
46097655|NCT02694341|Procedure|Abdominal traction stitch|Abdominal traction stitch to prevent prolapse of the Bakri balloon. A suture is tied through the uterine end shaft hole of the Bakri balloon. The other end of the suture is placed through the uterine wall. The balloon is positioned in the lower segment.The abdominal traction stitch is held by forceps and fixed, with cephalad traction applied continuously to the balloon, preventing balloon prolapse.The abdominal traction stitch is fixed by an umbilical cord clamp on the abdominal wall, preventing the suture from receding into the abdominal cavity, and, thus, maintaining the correct position of the balloon and preventing prolapse. Removal of the balloon is easy, with no resistance; the suture does not hinder balloon removal. At the time of balloon removal, the suture that was placed through the abdominal wall will traverse the intra-abdominal and intrauterine cavities, and should be kept clean.
45462433|NCT03861247|Drug|Phosphate-binder intervention|Use phosphate-binders according to KDIGO Guidelines, Chinese Guidance for Diagnosis and Treatment of Mineral and Bone Disorder in Chronic Kidney Disease and drug specification .
45462434|NCT03861247|Dietary Supplement|Phosphorus-restricted dietary intervention|Use low phosphorus diet and prolong the time of hemodialysis according to the phosphorus balance evaluation if necessary
45462435|NCT01177423|Procedure|Dental anesthesia|Pulpal and periapical molar and premolar sedation is randomly managed among studied population and Pulp-tester measures anesthesia minute by minute.
45462436|NCT03861169|Device|Transluminal viscoelastic delivery and trabeculotomy|Ab-interno transluminal viscoelastic delivery and trabeculotomy using OMNI Surgical System
45462437|NCT03861013|Behavioral|Multidimensional stress prevention program (GeDStress)|The multidimensional stress prevention program (GeDStress) is composed of 8 session of 2-hour weekly sessions and integrated cognitive and behavioral strategies, mindfulness-based activities, emotional regulation and social skills exercises. Brief homework activities were given between sessions. The groups were composed by a maximum of 8 students and were led by two trained clinical psychologists.
45462438|NCT01180231|Drug|Moxonidine (Physiotens)|Subjects will be asked to take moxonidine, dosage to be determined prior to commencement by a medical doctor for 6 months duration.
45462439|NCT01180231|Other|Dietary intervention|Subjects will be asked to follow dietary plans designed by a qualified nutritionist for 6 months.
45837186|NCT03158376|Drug|Placebo|
45837187|NCT01797510|Behavioral|Web Based Health Coaching|
45837188|NCT04895670|Behavioral|Empowering Youth Aging out of Foster Care|App that allows storage of health information, and access to reputable health information and community resources.
45837189|NCT02126748|Other|inhalation 4ml hypertonic saline 3% 3x/day|
45837190|NCT02126748|Device|Intrapulmonary Percussive Ventilation|
45837191|NCT02126748|Procedure|Assisted Autogenic Drainage|
45837192|NCT05622630|Procedure|Four-cell bath|Four-cell bath:Treatment with direct current
45837193|NCT05622630|Procedure|Gravel bath|Gravel bath:In this procedure, the patients are given a footbath with heated stones (granules) of different sizes for a period of 20 minutes, during which the patients are encouraged to move their feet (and, if applicable, hands) evenly.
45837194|NCT01797900|Drug|Cisplatin|induction: Cisplatin: 80mg/m2, d1 and d22 concurrent: Cisplatin: 100mg/m2, d1, 22, 43 adjuvant: cisplatin: 75mg/m2, d1, d22, d43,d64
45837195|NCT01797900|Drug|Paclitaxel|induction: paclitaxel 175mg/m2 d1,d22 adjuvant: paclitaxel 175mg/m2 d1,d22, d43,d64
45837196|NCT01797900|Radiation|IMRT|69.96Gy-73.43Gy to gross tumor volume, 60Gy to high-risk clinincal target volume, 50Gy to lower risk clincial target volume
46097656|NCT02694341|Device|Bakri Balloon|uterine compression balloon
46097657|NCT00713050|Behavioral|Imitate Therapy|Imitation-based computer therapy
46097658|NCT04160507|Other|Biorepository|To collect and store biological samples (whole blood and urine), along with relevant medical information, from adult inpatients and outpatients. Buffy coats will also be received from H3Africa Kidney Disease Research Network.
45462440|NCT03474016|Diagnostic Test|Mammography-Histopathological examination of breast mass specimens- polymerase chain reaction|Mammography-Histopathological examination of breast mass specimens-Detection of long and short DNA fragments in serum using real-time quantitative polymerase chain reaction
45462441|NCT01177501|Drug|Topotecan|Six sequential doses established in the absence of limiting toxicity, as follows : 7.5 - 8.0 - 8.5 - 9.0 - 10.0 mg/m²
46010875|NCT01645878|Behavioral|routin breast feeding education|
46010876|NCT04546607|Other|Nuvastatic TM (C5OSEW5050ESA) 1000 mg|Nuvastatic TM is a patented polymolecular botanical medicine made from Lanctos 75TM which is a proprietary high potency herbal standardized extract.
45462442|NCT02983396|Device|Diagnostic accuracy of Mini Relf Device|Evaluation of the Mini Relf Device when it is applied on daily basis at home and during coronary angioplasty at 60 second acute coronary occlusion angioplasty
45462443|NCT01182025|Other|Western therapy|"Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.~Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;"
45462444|NCT01182025|Drug|Xiyanping Injection|"Dosage for child medication:~5-10mg/kg/d (0.2-0.4ml/kg/d) in 5% Glucose solution, IV, with speed of 20-30 drops per minute, each day; or as directed by doctor."
45837197|NCT03746808|Behavioral|EMA + App/Treatment Messages|"This study will develop and test a just-in-time adaptive intervention to reduce alcohol use among homeless adults. Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are enrolled in shelter-based treatment. Phase II will use this information to create a risk algorithm and tailored treatment messages that anticipate and intervene to prevent alcohol use."
45837198|NCT04747704|Behavioral|Three Principles Counseling|A 10-week insight-based program offered in prisons in a group setting for 2 hours each week. Approximately 15 - 20 adults or youth in custody participate at a time, led by two trained teachers. The curriculum is designed to teach an understanding of the mind and human experience for the purpose of reducing risk factors, uncovering resiliency and to promote emotional and psychological well-being for adults and youth in the criminal justice system. This is taught through a compilation of sessions that speak to the potential, ability and resilience inherent in every individual. Sessions include a mix of lessons, experiential learning, and group conversations.
46097659|NCT00674934|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
46010877|NCT01645917|Device|Arctic Front Advance Cardiac CryoAblation system|Standard of care ablation for indicated paroxysmal AF patients with Medtronic's Arctic Front Advance Cardiac CryoAblation system
46010878|NCT02278445|Radiation|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
46097660|NCT03352531|Biological|AK-105|Anti-PD-1 monoclonal antibody; Subjects will receive AK105 by intravenous administration.
46097661|NCT00692016|Drug|Naproxen sodium|Administered under fasting condition
45462445|NCT01182025|Drug|Xiyanping Injection with western medicine|"Symptomatic treatment using the same treatment methods in western therapy group;~Symptomatic treatment using the same treatment methods in Xiyanpin injection group."
46010879|NCT02278445|Device|Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel)|
46010880|NCT02278523|Device|Threshold IMT®|A device used to offer threshold load to inspiratory muscle
46010881|NCT02214680|Drug|Combigan (Combination of Brimonidine and Timolol)|On the first exam the subject will receive Combigan (Combination of Brimonidine and Timolol) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.
46010882|NCT02214680|Drug|Timolol|0.5% eye drop
46010883|NCT02214875|Other|CQI/BTS|Application of CQI/BTS interventions through employing rapid structured cycles of data collection, testing of solutions and review of changes will be implemented. At each site a Quality Improvement Team (QIT) will be established from among the facility staff. Local Government and State level QI teams will provide oversight function of the health facilities' QI initiatives. BTS as a collaborative learning approach will be conducted quarterly in each study state at a central location with participants from the intervention sites. The sessions will provide opportunity for teams to learn from each other and to adapt and implement changes using the Plan-Do-Study-Act (PDSA) model.
46010884|NCT02214875|Other|Control|Facilities in control will continue will routine unstructured, irregular continuous quality improvement. Break Through Collaborative will not be applied to the control facilities.
46097662|NCT00692016|Drug|Naproxen sodium|Administered under fed condition
46097663|NCT02733263|Dietary Supplement|15 g RMD|15 grams of resistant maltodextrin
46097664|NCT02733263|Dietary Supplement|25 g RMD|25 grams of resistant maltodextrin
46097665|NCT02733263|Dietary Supplement|0 g RMD|0 grams of resistant maltodextrin
46097666|NCT00724516|Device|Novel Breast Compression Paddle|Instead of using the regular wire localization mammography compression paddle, a new breast compression paddle will be used. The new breast compression paddle is similar to a tennis racquet. It consists of crossing plastic strings that are strung tightly in a frame. The needle/wire can be inserted anywhere between the strings.
46097667|NCT00655304|Device|Prometheus (R) liver support dialysis|6-8 hours of dialysis
45462446|NCT03478150|Other|zinc oxide nano-particles|The zinc oxide nano-powder will be mixed with ethanol
45462447|NCT03478150|Device|laser diode|The laser light is transferred through a 600µm flexible fiber optic tip by a special hand piece. the output power will be adjusted at 1.5W.
45462448|NCT03499353|Drug|TALAZOPARIB|Talazoparib 1mg/day
46010885|NCT02756208|Biological|300 ug FLSC vaccine|FLSC vaccine 300 ug (1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
46010886|NCT02756208|Biological|150 ug FLSC vaccine|FLSC vaccine 150 ug (0.5 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
46010887|NCT02756208|Biological|75 ug FLSC vaccine|FLSC vaccine 75 ug (0.25 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
45462449|NCT03473158|Device|Transvaginal ultrasound|using the 6.5mHz intra-cavitary probe (65EC10EA) of ultrasound machine DP-50 (Shenzhen Mindray Bio-Medical Electronics Co., Ltd., P.R.China) to determine the number, site, size and cardiac activity of the fetuses, and monitor the fetal reduction procedure
45462450|NCT03473158|Procedure|Mechanical fetal reduction|under transvaginal ultrasound guidance, fetal reduction will be achieved by mechanical disruption of the fetal heart till asystole is achieved, and may be aided by partial or total suction of the fetus, using suction device attached to the embryo reduction needle (Cook® Ireland Ltd., Limerick, Ireland)
46010888|NCT02756208|Biological|Placebo|Placebo sterile saline (0.25 - 1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
46010889|NCT04545788|Drug|Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.|AM is the traditional anti-TB drugs. Linezolid, bedaquiline and/or cycloserine, that might have potential efficacy of replacing injectable anti-TB drugs, are included into the total oral short-term therapy, and replace AM.
46010890|NCT02756013|Drug|Paclitaxel|80mg/m2 IV days 1,8, and 15 every 21 days x 6-9 cycles
46010891|NCT02756013|Drug|Carboplatin|area under the curve (AUC) 6 IV day 1 every 21 days x 6-9 cycles
46010892|NCT01680003|Drug|Hepar-P|
46010893|NCT01680003|Drug|Placebo for Hepar-P|
46097668|NCT00655304|Device|CVVHDF (Continuously Veno-Venous Hemodiafiltration)|6-8 hours of dialysis with the CVVHDF system PrismaFlex offered by Gambro (Sweden).
46097669|NCT03295981|Drug|Zoledronic Acid|4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement
45462451|NCT03473158|Procedure|Chemical fetal reduction|under transvaginal ultrasound guidance, fetal reduction will be achieved by injecting 0.5 mL of potassium chloride (Potassium Chloride® 15% , EIPICO, Egypt) into the cardiac region through the embryo reduction needle (Cook® Ireland Ltd., Limerick, Ireland)
45462452|NCT01289899|Drug|BR-A-657|120, 360mg or placebo 7days
45462453|NCT03473938|Device|Spatz3 AIGB|Implantation of Spatz3 AIGB balloon.
45462454|NCT03368664|Drug|Alemtuzumab GZ402673|Pharmaceutical form: solution, Route of administration: IV
45462455|NCT03368664|Drug|Glatiramer acetate|Pharmaceutical form: solution, Route of administration: subcutaneous (SC)
45462456|NCT03368664|Drug|Beta-Interferon|Pharmaceutical form: solution, Route of administration: SC / intramuscular (IM)
45462457|NCT03368664|Drug|Methylprednisolone|Pharmaceutical form: solution, Route of administration: IV
45462458|NCT03368664|Drug|Ranitidine|Pharmaceutical form: tablet, Route of administration: oral
45462459|NCT03368664|Drug|Ceterizine|Pharmaceutical form: tablet, Route of administration: oral
46010894|NCT01680042|Drug|Phenytoin paste|
46010895|NCT01680042|Drug|Placebo|
46010896|NCT04545710|Drug|Abemaciclib|Abemaciclib 150mg BID
46010897|NCT04545710|Drug|Osimertinib|Osimertinib 80mg daily
46010898|NCT01646229|Other|Polymyxin-B hemoperfusion|
46010899|NCT01646229|Other|Control|
46010900|NCT04545398|Other|Food. Beef, Pasture-raised|Pasture-raised beef
46010901|NCT04545398|Other|Food. Beef, Grain-fed|Grain-fed beef
46010902|NCT04545398|Other|Food. Meat alternative|Meat alternative
46010903|NCT04545398|Other|Food, Lamb|Lamb
46010904|NCT01680081|Other|Adenosine stress dynamic CT perfusion|
46010905|NCT04545203|Other|Slow-stroke back massage|Slow-stroke back massage was performed to the breast cancer patients in intervention group. The SSBM sessions were administered 10 minutes before and after chemotherapy treatment.The SSBM was applied for 20 minutes in total, on each cycle. The intervention group received 20-minute SSBM sessions 3 chemotherapy cycle in addition to the routine care.
46010906|NCT04545086|Behavioral|Video Based Education, Music Therapy|Video Based Education and Music Therapy was given as a part of Interventions to relieve anxiety of patients undergoing Magnetic Resonance Imaging
46010907|NCT01646307|Drug|Atorvastatin|
46010908|NCT01646307|Drug|Rosuvastatin|
46097670|NCT02570620|Device|Ultrasonography of the cervix|
46097671|NCT02733107|Drug|Apatinib|Apatinib, 250mg daily, po, continue until disease progression
46097672|NCT02733107|Drug|Etoposide|Etoposide, 50mg daily, po, day 1 to day 20, repeat Q 4 weeks until disease progression
46097673|NCT02645708|Procedure|Retrograde Intrarenal Surgery|Patients undergo Retrograde Intrarenal Surgery
46097674|NCT02645708|Procedure|EPVL after RIRS|Patients in Group 2 undergo EPVL after RIRS
46097675|NCT02726087|Procedure|ministernotomy|"Partial upper J hemisternotomy trough 4th right intercostal space)"
46097676|NCT02726087|Procedure|Full sternotomy|Conventional full median sternotomy
46010909|NCT04548089|Behavioral|Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC)|Each Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific intervention structure include: Week 1 - Empowering Self-Care: Introduction to the science of stress, self-care, burnout, as well as the arts and mindfulness to cultivate resilience; Week 2 - Reflective Caregiving: Reflection of caregiving experiences that demonstrates strengths and challenges; Week 3 - Understanding Loss: Introduction to the science of loss, how grief can impair hope and wellbeing, and how self-compassion can help transform suffering into blessings.; Week 4 - Meaning Reconstruction: Reflection on caregiver identities, to elicit the lessons and wisdoms learnt, and to create renewed meaning to sustain their caregiving journeys. Guided mindfulness mediation will also be professionally recorded to form a daily take-home mindfulness mediation exercise for participants, each exercise will last 10-20 minutes.
46097677|NCT00992641|Other|Experimental diet|Diet based on Nordic recommendations: rich in whole grain products, berries, fruits and vegetables, recommended fat quality. Realised based on eating habits of each Nordic country.
45462460|NCT03368664|Drug|Dexchlorpheniramine|Pharmaceutical form: tablet, Route of administration: oral
45462461|NCT03368664|Drug|Paracetamol|Pharmaceutical form: tablet, Route of administration: oral
45462462|NCT03368664|Drug|Acyclovir|Pharmaceutical form: tablet, Route of administration: oral
45462463|NCT03368664|Drug|Prednisolone|Pharmaceutical form: tablet, Route of administration: oral
45462464|NCT03368664|Drug|Diphenydramine|Pharmaceutical form: solution, Route of administration: IV
45679370|NCT05812703|Behavioral|Cognitive Behavioral Therapy|The participants will attend one of the behavioral group treatments programs offered by the Stanford Pain Management Center. This class may be held online via Zoom, or in person based at the Stanford Pain Management Center. The class may be recorded for training purposes. No names or images/faces will be recorded for privacy reasons. The behavioral groups are 3 types, with or without exercise/movement. Current Evidence Based treatments that are provided as standard practice include: Cognitive Behavioral Therapy Group, with movement, Acceptance and Commitment Therapy Group, with or without movement. Group participants will learn different skills in each group and develop a personalized plan to use the skills after group ends. At the end of group participants will be given an anonymous survey about the class to evaluate satisfaction of the treatment. Movement in this portion of class is designed to low impact and restorative/gentle, with no significant increases in HR > 50% HRmax.
45679371|NCT05812703|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT is a 6 week behavioral group program led by a psychologist to improve psychological flexibility and reduce pain interference in patients with chronic pain.
45679372|NCT05812703|Behavioral|Moderate to high Intensity Group Exercise|Group exercise led by supervised clinician with Cardiovascular focus to increase HR into zones to see adaptations to improve cardiovascular fitness.
46097678|NCT00992641|Other|Control diet|Diet based on the information of the current dietary intake and food consumption in Nordic countries.
46097679|NCT00675012|Drug|NGR-hTNF|iv 0.8 or 45 mcg/sqm q3W
46097680|NCT00675012|Drug|Oxaliplatin|iv q3W 100 mg/sqm 60 minutes after NGR-hTNF infusion
46097681|NCT00675012|Drug|capecitabine|orally 825 mg/sqm 2qDx14
46097682|NCT00652262|Drug|Levitra (Vardenafil, BAY38-9456)|Patients received BAY 38-9456 10 mg for the first 4 weeks of the treatment period, and then went on to receive 10 mg or 20 mg for the following 8 weeks.
45462465|NCT03368664|Drug|Other H1 antagonist|Pharmaceutical form: solution, Route of administration: IV
45462466|NCT03368664|Drug|Other H1 antagonist|Pharmaceutical form: tablet/pill, Route of administration: oral
45462467|NCT03860545|Diagnostic Test|urine and blood analysis|concentration of ischemia modified albumin assessed in blood before operation, immediately and one hour after cardiopulmonary bypass, 24 hours after operation; concentration of urinary excretion of brush-border enzymes of the proximal renal tubules assessed before operation, immediately and one hour after cardiopulmonary bypass, 24 hours after operation, serum creatinine levels will be evaluated on the day of the operation and 24 h and 48 h postoperatively
45462468|NCT02693938|Device|Follicular Euglycemic clamp|Follicular Euglycemic clamp during follicular phase
45462469|NCT02693938|Device|Luteal Euglycemic clamp|Luteal Euglycemic clamp during luteal phase
45462470|NCT01289197|Behavioral|Family Check Up|Families in the intervention condition will be contacted by the parent consultant following the T1 and T2 assessments and be invited to participate in the Family Check-Up (FCU). The FCU intervention involves at least three sessions in which we expect both mother and child to participate in. First is the in-home family assessment. The second session involves rapport-building via an initial interview with the caregiver(s), referred to as the Get-to-Know-You visit, or for families already enrolled in an ongoing study, a Check-Back-In visit. The third is a Feedback Session during which the results of the assessment and initial interview are discussed with the caregiver, with attention focused on the caregiver's and child's readiness to change and the delineation of specific change options.
45462471|NCT03711630|Behavioral|Meditation|Meditation practice will be through the InsightTimer smart device application. Participants will choose what types of meditation practices they will engage in and report their time spent meditating via REDCap.
45462472|NCT03638934|Other|Videos about ACP|Three videos about advanced care planning are provided for self-education.
46097683|NCT05373628|Diagnostic Test|Gradient and pulse imaging|A novel diffusion-based magnetic resonance imaging method
46097684|NCT05355103|Other|Educational tool about epidural analgesia|See arm description
45462473|NCT03638934|Other|Brochure about Life-Sustaining Treatment Act|Brochure about Life-Sustaining Treatment Act are provided for self-education.
46097685|NCT02640794|Drug|Clopidogrel|Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months.
45679373|NCT05809700|Drug|Freshly manufactured 35 kDa hyaluronan fragment|"This mixture of high molecular weight HA and hyaluronidase containing 100 mg of HA was locally injected at the pain point or where the nerve trunk innervates the pain point. Then, the pain scale (NPRS) was used to evaluate pain, and the pain relief of patients before and after treatment was recorded.~Each time, according to the amount of high molecular weight HA containing 100 mg HA and hyaluronidase mixture, the pain point area and pain point area of the nerve trunk innervation of the local multipoint injection. Then, the pain scale was used to evaluate pain, and the pain relief of patients before and after treatment was recorded."
45679374|NCT05809505|Diagnostic Test|360-degree Turn Test|The 360-degree turn test is a measure of dynamic balance. The person tested turns in a complete circle (360 degrees) while the time to complete and/or the number of steps to complete the turn is recorded.
45679375|NCT05809505|Other|Expanded Disability Status Scale|The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. It is widely used in clinical trials and in the assessment of people with multiple sclerosis. The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.
45679376|NCT05809505|Other|Perceived Exertion|The Borg Rating of Perceived Exertion (RPE) is a way of measuring physical activity intensity level. Perceived exertion is how hard you feel like your body is working. It is based on the physical sensations a person experiences during physical activity, including increased heart rate, increased respiration or breathing rate, increased sweating, and muscle fatigue. Although this is a subjective measure, your exertion rating based on a 6 to 20 rating scale, may provide a fairly good estimate of your actual heart rate during physical activity.
46097686|NCT02640794|Drug|Aspirin|Aspirin/acetylsalicylic acid (80-325 mg/d). Aspirin/acetylsalicylic acid therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
46097687|NCT00687570|Dietary Supplement|Fresubin Energy Drink|Fresubin energy drink 30 kcal/kg*dag-1, seven days before surgery
46097688|NCT00687570|Drug|Laxabon®|Laxabon® 4 litres starting the day before surgery
46097689|NCT00724672|Drug|etanercept|etanercept 50 mg subcutaneously once weekly
46097690|NCT00724672|Drug|infliximab|infliximab 3 mg/kg IV at Weeks 0, 2, and 6
46097691|NCT00724672|Drug|adalimumab|adalimumab 40 mg subcutaneously biweekly
46097692|NCT04159103|Biological|mRNA-3927|mRNA-3927 dispersion for IV infusion
46097693|NCT03113929|Radiation|MRI|Research MRI
46097694|NCT02570932|Biological|Autologous Mesenchymal Bone Marrow Cell|"Suspension in autologous plasma cell of Adult mesenchymal stem cells expanded autologous bone marrow.~Route of administration: Intrathecal in subarachnoid space by lumbar puncture.Total dose of 300 x 106 CME, divided in 3 injections of 100 x 106 CME, with intervals of three months between each administration"
46097695|NCT02624856|Drug|Liposomal bupivacaine|Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.
46097696|NCT02624856|Drug|Bupivacaine plus dexamethasone|Bupivacaine HCl 0.5% 10 mL plus dexamethasone 2 mg for quadriceps sparing femoral nerve block and bupivacaine HCl 0.25% plus dexamethasone 2 mg for posterior knee compartment periarticular injection
46097697|NCT02646020|Drug|Aprepitant|aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
45462474|NCT00004259|Drug|BCNU 80mg/m2|BCNU 80 mg/m2 will be administered as an intravenous infusion on days 1, 2, and 3 of the first week of radiotherapy and on days 56, 57, and 58, then every eight weeks for four more cycles for a total of 6 cycles (maximum BCNU dose 1440 mg/m2).
46097698|NCT02646020|Drug|Desloratadine|Desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
45462475|NCT00004259|Drug|TMZ 200mg/m2|200 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat every 28 days for a total of 12 cycles.
45462476|NCT00004259|Radiation|radiation therapy|1.8 Gy fractions (to isocenter), 1 fraction per day, 5 days per week to a dose of 59.4 Gy in 33 fractions.
46097699|NCT02646020|Drug|Placebo of aprepitant|Placebo of aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
46097700|NCT02646020|Drug|Placebo of desloratadine|Placebo of desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
46097701|NCT02733419|Drug|Enfuvirtide|Participants will receive 90 mg enfuvirtide subcutaneously (SC) b.i.d.
46097702|NCT02733419|Drug|Optimized background antiretroviral regimen (OB)|Participants will receive OB (nucleoside and or non-nucleoside reverse transcriptase inhibitor and protease inhibitor) as per investigator's discretion. Protocol does not specify any particular OB drugs.
46097703|NCT04163744|Device|Double balloon catheter|Induction of labour with double balloon catheter
46010910|NCT04545359|Behavioral|Alpha-based neurofeedback|"Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of auditory alpha-based neurofeedback with the Melomind device developed by myBrain Technologies (France). Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions."
46010911|NCT04545359|Behavioral|Sham neurofeedback|"Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of an auditory sham neurofeedback with the Melomind device developed by myBrain Technologies (France). Sham feedback is based on the real feedback of the participants in the Experimental arm. Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions."
46010912|NCT01680276|Behavioral|PBS based staff training|"Please see published study protocol for more information:~http://www.biomedcentral.com/1471-244X/14/219"
46010913|NCT01680276|Other|Treatment as Usual|http://www.biomedcentral.com/1471-244X/14/219
45679377|NCT05809427|Device|Periodontal probing|"Imaging/Scanning and recording : Ultrasonic periodontal probing per operator (10 teeth X 6 sites/teeth = 60 probing sites per operator). In addition, 2 teeth per patient will be probed with the ultrasonic probe a second time (2 teeth x 6 sites per tooth = 12 sites per patient) for intra-operator reproducibility purpose.~Manual probing per operator with the OMS probe (part of the routine of care)"
46010914|NCT02214914|Drug|BI 11634 drinking solution|
46010915|NCT02214914|Drug|BI 11634 tablet|
46010916|NCT02214914|Drug|Placebo|
46010917|NCT04544969|Drug|cisplatin-based chemotherapy|"GP: cisplatin 80 mg/m2 intravenous infusion on day1, gemcitabine 1000 mg/m2 intravenous infusion on day 1 and 8, both drugs are given every 3 weeks, recommended 6 cycles.~TP: cisplatin 75 mg/m2 intravenous infusion in day1, docetaxel 75 mg/m2 intravenous infusion in day 1, both drugs are given every 3 weeks, recommended 6 cycles.~PF: cisplatin 100 mg/m2 intravenous infusion in day1, fluorouracil 4000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~TPF: cisplatin 60 mg/m2 intravenous infusion in day1, docetaxel 60 mg/m2 intravenous infusion in day 1, fluorouracil 3000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~Choice of chemotherapy regimen is decided by patient's doctor in charge."
46010918|NCT01646463|Behavioral|CenteringPregnancy|CenteringPregnancy (CP) follows a standardized curriculum for group-based prenatal healthcare offered to groups of 10-12 women with similar due dates. In lieu of receiving a series of individually-delivered prenatal healthcare, participants meet 10 times over the course of pregnancy and early postpartum for 2 hour sessions, essentially pooling their minutes for each prenatal healthcare visit. The visit schedule adheres to the guidelines set forth by ACOG of monthly and then weekly visits close to birth. All sessions of CP include three core components of: (1) physical assessment (including blood pressure, weight, and fundal height assessment), (2) education and skills-building, and (3) support. Content topics for group discussion include nutrition, exercise, relaxation, understanding pregnancy problems, infant care and feeding, postpartum issues including contraception, comfort measures in pregnancy, sexuality and childbearing, abuse issues, parenting, and childbirth preparation.
46097704|NCT02624778|Biological|LY3002813|Administered IV
46097705|NCT02624778|Drug|Placebo|Administered IV
46097706|NCT00724906|Drug|123 I - ALTROPANE®|8.0 mCi (±1.0 mCi) will be administered intravenously to each subject.
46097707|NCT02725775|Dietary Supplement|100% Florida OJ|
45679378|NCT05808725|Drug|Amlodipine Freeze-Dried Powder for Oral Solution 5 mg|Amlodipine Oral Solution 5 mg is given to T1 Fasting and T2 Fed
46097708|NCT02725775|Dietary Supplement|Placebo Equicaloric Orange Drink|
46097709|NCT00675090|Drug|GSK239512|GSK239512 oral tablets once a day
46097710|NCT00675090|Drug|Placebo|Placebo tablets to match once a day
46097711|NCT02574052|Behavioral|participants' food choices|just recorded the participants' food choices in the school cafeteria
46097712|NCT02574052|Behavioral|menu labelling without nutrition education|The investigators provided every participant with a menu labeling without any interpretation and recorded their dietary selections
45679379|NCT05808725|Drug|Norvasc 5 mg tablets of Pfizer Labs|Norvasc 5 mg is given to R Fasting
45679380|NCT05803798|Device|IPL+LLLT|preventive treatment by IPL+LLLT (EYE-LIGHT) before laser refractive surgery
45679381|NCT05801939|Drug|Cevostamab|Cevostamab will be given as an IV infusion once every 3 weeks, starting on day +56 (+/- 4 days) post-CAR T cell infusion, with subjects planned to receive 8 cycles initially. Subjects receive a single step-up dose of 3.6 mg of cevostamab on cycle 1, day 1 (C1D1), followed by the target dose of 160 mg on C1D8. Myeloma responses are assessed every cycle, and a repeat bone marrow aspirate and biopsy (BMbx) is performed at the start of cycle 8. If subjects are not in an MRD-negative CR at this timepoint (or if the BM bx is inevaluable/indeterminate for CR or MRD testing), they continue with another 8 cycles (C9-16) of cevostamab. If they are in MRD-negative CR at start of C8, they stop therapy after receiving this cycle and are observed.
46097713|NCT02574052|Behavioral|menu labelling with nutrition education|The investigators not only sent a menu labeling to every participant, but also delivered nutrition education to participants by providing them with nutrition and health knowledge through WeChat daily.
46097714|NCT04163510|Behavioral|Behavioral: Parent/Child Reading Program|A 9-week parent/child reading program will help parents to identify strategies to establish literacy routines with their children, and to engage with them in enjoyable literacy activities that promote skill building while reducing negative feelings associated with reading. Three large-group sessions will be held in a central location, to build community and rapport among researchers and participants. Six individual sessions will take place in the participants' homes, to customize reading strategies and routines to each family's home setting and personal interests. Intervention sessions will be held once per week for 60-90 minute sessions.
46010919|NCT01646463|Behavioral|CenteringPregnancy with Mindfulness Skills|CenteringPregnancy with Mindfulness Skills contains the CenteringPregnancy (CP) content combined with training in mindfulness meditation and mindful movement/yoga. The mind-body methods have been adapted from those taught in the Mindfulness-Based Childbirth and Parenting (MBCP) course, which is a tailored version of the Mindfulness-Based Stress Reduction program delivered to pregnant women during the perinatal period. These practices include mindfulness meditation of the breath, body, feelings, thoughts, and emotions; body scan meditation; yoga postures practiced with mindful awareness of the body and the physical changes associated with pregnancy; and loving-kindness meditation. In addition, MBCP includes specific exercises in coping with stress, pain, and fear associated with pregnancy, childbirth, and early parenting with a focus on shifting the way participants relate to negative thoughts and emotions and cope with stress.
46010920|NCT01680354|Procedure|ReLEx|
46010921|NCT01680354|Procedure|LASIK|
46010922|NCT04544657|Other|no intervention|No intervention for enrolled patients
45462477|NCT00004259|Drug|CCNU|CCNU at 130 mg/m2 orally every 8 weeks for a total of 6 cycles. Administered on day 1 of the first week of radiotherapy and on day 56, then administered every 8 weeks for four more cycles for a total of 6 cycles.
45679382|NCT05797506|Drug|Sulforaphane (Avmacol Extra Strength)|4 Tablets of Sulforaphane (Avmacol Extra Strength) per day in patients with Chronic Kidney Disease, stages 3-4.
45679383|NCT05797506|Dietary Supplement|Placebo|These tablets will be matched placebos and will be provided by Avmacol.
45679384|NCT05794347|Other|Traction|Continuous mechanical traction will be applied to the lumbar area in 2 different positions.
46010923|NCT01646502|Biological|Esp protein|
46010924|NCT01646502|Other|Standard wound care|
46010925|NCT01680393|Device|Sequential compression device|a sequential compression device will be applied to the legs
46010926|NCT01680393|Other|TED stockings|TED stockings will be applied to the patients legs during surgery
46010927|NCT04544579|Device|Stent grafts anchored in different areas|Endovascular repair of ascending aortic dissection patients with stent grafts anchored in different areas
46010928|NCT04541732|Other|Thoracic epidural block|Patients who will be subjected to epidural block will be placed in the lateral position then, after sterilization of the skin, 21 G spinal needle will be inserted at T9-T11 intervertebral spaces. The epidural space will be located using the loss of resistance to air technique and a mixture of bupivacaine 0.25% + 50 μ fentanyl targeting T6 level will be injected following induction of general anaesthesia.
46010929|NCT04541732|Other|Ultrasound-guided bilateral quadratus lumborum block|Patients who will be subjected to major abdominal surgeries will be placed in a supine position with a pillow under their side to obtain an appropriate view of quadratus lumborum muscle. After sterilization of the skin and ultrasound-guided identification of the quadratus lumborum muscle, 20 ml bupivacaine 0.25% + 25μ fentanyl will be injected on each side following induction of general anaesthesia
46010930|NCT04541732|Drug|Induction of general anaesthesia with propofol|propofol: 1.5-2.5mg/Kg
45462478|NCT00004259|Drug|BCNU 150mg/m2|BCNU 150 mg/m2 will be administered as an intravenous infusion on day 5 of radiotherapy, and it will be repeated every eight weeks for a total of six cycles (maximum total BCNU dose 900 mg/m2).
46010931|NCT04541732|Drug|Muscle Relaxant|Atracurium : 0.5mg/Kg.
46010932|NCT04541732|Drug|Maintenance of general anaesthesia|Sevoflurane 0.7-1.5 MAC in 40% oxygen
45462479|NCT00004259|Drug|BCNU 200mg/m2|BCNU 200 mg/m2 will be administered as an intravenous infusion on day 1 of radiotherapy and will be repeated every six weeks for a total of 6 cycles (maximum BCNU dose 1200 mg/m2).
45462480|NCT00004259|Drug|TMZ 150mg/m2 six 6-week cycles|150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 6-week cycles
45462481|NCT00004259|Drug|TMZ 150mg/m2 six 8-week cycles|150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 8-week cycles
45679385|NCT05792540|Drug|Fluoxetine 20 mg|Fluoxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive-compulsive disorder and bulimia. It works by increasing the levels of serotonin in the brain
45679386|NCT05792540|Drug|Dapagliflozin 10mg Tab|Dapagliflozin (DAPA), a sodium-glucose co-transporter 2 inhibitor (SGLT2-I), has proven to be an effective hyperglycemic suppressor due to its role in inhibiting the reabsorption of 30-50% of the glucose filtered by the kidney, besides its role in the improvement of insulin resistance
45679387|NCT05792540|Drug|Atorvastatin 80mg|Atorvastatin is a synthetic and lipophilic statin, a class of drugs used in the treatment of hypercholesterolemia
46010933|NCT04544774|Drug|AIT|AIT for airborn allergens (SCIT/SLIT)
46010934|NCT04544774|Diagnostic Test|NAPT|NAPT test with airborn allergens ( HDM, Threes, Grasses)
46010935|NCT01680432|Dietary Supplement|Probiotic fresh cheese|Participants in the intervention group were instructed to drink 30 grams of fresh cheese enriched with probiotics daily for 30 consecutive days.
45462482|NCT02819050|Device|NCPAP|Nasal Continuous Positive Airway Pressure
45462483|NCT03711552|Other|ObsQoR-11|Quality of recovery questionnaire
45462484|NCT03711552|Other|QoR-15|Quality of recovery questionnaire
45462485|NCT01177579|Dietary Supplement|Copper gluconate|4 or 8 mg copper gluconate/day will be assessed for efficacy of copper repletion
45462486|NCT03722355|Radiation|Conventional RT|Radiation therapy
45462487|NCT03722355|Radiation|Hyperfractionated RT|Radiation therapy
45462488|NCT03722355|Drug|Carmustine|Chemotherapy
45462489|NCT01287949|Biological|Diphtheria, tetanus, polio and pertussis vaccination|1 dose of REPEVAX (0.5 mL) at Day 0, 1 dose of REVAXIS (0.5 mL) 1 month later and 1 dose of REVAXIS 6 month later
45462490|NCT03710616|Procedure|Surgeries|Surgical operations plus systematic lymphadenectomies
46097715|NCT00992797|Drug|Cholecalciferol|Cholecalciferol 200.000 IU pr ampoule, 400.000 IU given at randomization day, followed by additionally 200.000 IU at week 5 if serum 25(OH)D < 100 nmol/L. If serum 25(OH)D > 100 placebo will be given. The cholecalciferol will be given in orange juice.
45462491|NCT03478072|Device|trichoscopy|hair and scalp dermoscopy) is a non-invasive technique in which either a handheld dermoscope or a digital videodermoscope can be used to visualize hair and scalp structures
46010936|NCT01680432|Dietary Supplement|Regular Cheese|
46010937|NCT04541927|Genetic|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
46010938|NCT04542044|Other|management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia|Data collected with a cohorte of SARS-CoV-2 pneumonia in an outpatient basis
46010939|NCT02279277|Behavioral|Supervised physical therapy program prior to total knee replacement surgery|
46010940|NCT04544423|Other|Block group|Patients received lumbar erector spinae plane Block before operation
46010941|NCT01680471|Drug|Midazolam 0.03mg/kg|"This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
46097716|NCT00992797|Other|Orange juice|Orange juice at randomization day and at week 5.
45462492|NCT03473080|Behavioral|Internet CBT|The treatment consists of a standard cognitive behavior therapy for OCD with additional treatment components to make the treatment better suited for children and adolescents with Autism Spectrum Disorder.
45462493|NCT03857815|Radiation|anti-PD-1 antibody|"In patients with inoperable hepatocellular carcinoma or recurrence after local or regional therapy, stereotactic body radiation therapy will be combined with anti-PD-1 antibody.~Stereotactic body radiation therapy: SBRT is delivered to 1~5 Evaluable lesions of liver, lung, bone, brain or lymph nodes in limited fractions .~Anti-PD-1 treatment: anti-PD-1 antibody (IBI308) is injected intravenously 200mg every three weeks."
45462494|NCT03365934|Device|ADHESIVE BANDAGE #1|Bandage applied daily to wounded site for 14 days
46010942|NCT01680471|Drug|Midazolam 0.05mg/kg|"This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
46010943|NCT01680471|Drug|Placebo|"This group will be injected intravenous normal saline five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
46097717|NCT02725541|Drug|Trastuzumab emtansine|HER2-targeted antibody drug conjugate of trastuzumab and DM1
45462495|NCT03365934|Device|ADHESIVE BANDAGE #2|Bandage applied daily to wounded site for 14 days
45462496|NCT03365934|Device|ADHESIVE BANDAGE #3|Bandage applied daily to wounded site for 14 days
46097718|NCT00911066|Drug|MLN4924|"MLN4924 intravenous (IV) on a 21-day cycle on one of the following schedules:~Days 1, 3, and 5, followed by a rest period of 16 days (Schedule A)~Days 1, 4, 8, and 11, followed by a rest period of 10 days (Schedule B)~Continuous weekly dosing on Days 1, 8, and 15 (Schedule C)~Days 1, 4, 11, 15 for Cycle 1 only; Days 1, 4, 8, 11 for all subsequent cycles (Schedule D)~Dosing on Days 1, 3, and 5 in patients with high-grade MDS or AML (Schedule E)"
46097719|NCT00911066|Drug|Azacitidine|Azacitidine will be administered (IV or subcutaneous (SC)) on Days 8 to 12 and Days 15 and 16 in Cycle 1, and on Days 1 to 5 and Days 8 to 9 (Schedule D)
46097720|NCT00725062|Biological|CD4+CD25+ regulatory T cells|Cohort 1 will receive 3 x 10^6 CD4+CD25+ cells/kg, Cohort 2 will receive 1 x 10^7 CD4+CD25+ cells/kg, Cohort 3 will receive 3 x 10^7 CD4+CD25 cells/kg
46097721|NCT00725062|Procedure|allogeneic hematopoietic stem cell transplantation|Occurs on Day 0 of study - HLA-identical sibling donor peripheral blood progenitor cell (PBPC) transplantation
46097722|NCT02733341|Drug|Cangrelor|
46097723|NCT02733341|Drug|Ticagrelor|
46097724|NCT00692172|Drug|Alefacept|intramuscular injection (IM)
45462497|NCT03365934|Device|Antibacterial Bandage with 0.8% BZK|bandage with 0.8% Benzalkonium Chloride (BZK) applied daily to wounded site for 14 days
45462498|NCT03365934|Other|Intact and No Bandage|This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.
45462499|NCT03365934|Other|Wounded and No Bandage|This test site will be wounded but will not be treated with a bandage, serving as the positive control site.
45462500|NCT02494648|Device|POWERbreathe Fitness Plus, (POWERbreathe International Ltd, UK) [Inspiratory muscles strengthening]|CAD patients participated in a 6-week (20 sessions of training) resistive inspiratory muscle training (RIMT) program for 10 minutes twice daily at a training intensity of 70% of maximum inspiratory pressure (MIP).
45462501|NCT02494648|Other|Control|
45462502|NCT04682405|Drug|Uproleselan|Provided by study
45462503|NCT04682405|Drug|Placebo|Provided by study
45462504|NCT04682405|Drug|Melphalan|-Standard of care
45462505|NCT03477994|Drug|Dexmedetomidine|an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 ,if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.
45462506|NCT03477994|Drug|Clonidine|an infusion of 0.5μg/kg then 0.1-0.2 μg/kg/h if Richmond assessment sedation score from +1 to +4.
45462507|NCT03468855|Drug|ATI-50002 topical solution|Topical Solution administered twice daily
46010944|NCT02215304|Dietary Supplement|Bifidobacterium longum ssp infantis R0033|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
46010945|NCT02215304|Dietary Supplement|Lactobacillus helveticus R0052|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
46010946|NCT02215304|Dietary Supplement|Bifidobacterium bifidum R0071|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
46097725|NCT02645630|Other|Right Cervical Manipulation|We will use a high-velocity, mid-range, left rotational force to the right articular pillar of C3, on the right articular pillar of C4 with the patient in supine, with left rotation and right side-bending.
46097726|NCT02645630|Other|Left Cervical Manipulation|We will use a high-velocity, mid-range, left rotational force to the left articular pillar of C3, on the left articular pillar of C4 with the patient in supine, with right rotation and left side-bending.
45462508|NCT04668131|Drug|Sodium hyaluronate eye drops|eye drops, three times a day
46010947|NCT02215304|Dietary Supplement|Placebo|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
46097727|NCT02645630|Other|Sham Cervical Manipulation|The sham procedure will simulate C3/C4 manipulation in both sides without any therapeutic thrust
46097728|NCT03702127|Device|Transcranial magnetic stimulation|NIBS is applied to the brain.
45679388|NCT05788198|Other|Integrated care|"The intervention will be modelled based on the most frequently reported patient, family physician and specialist barriers in depression management. In this project, multiple interventions aiming to tackle these barriers will be set up, with the WHO Framework on Integrated People-Centred Health Services (IPCHS) serving as conceptual backbone to the study (Table 1). The IPCHS distinguishes five interdependent strategies supporting a shift in healthcare delivery, management and funding towards universal health coverage. These strategies are:~empowering and engaging people and communities;~strengthening governance and accountability;~reorienting the model of care;~coordinating services within and across sectors;~creating an enabling environment."
46010948|NCT02279316|Drug|Vi-De 3|All participants receive a dose of 800 IU vitamin D3 per day as a standard of care. 800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.
46010949|NCT02279316|Other|Jaques-Dalcroze eurhythmics|The Jaques-Dalcroze eurhythmics method includes different courses of motion (multi-task exercises) that are conducted to the rhythm of improvised piano music. A session starts with a short warm-up that includes simple exercises to get body and mind prepared for the rest of the exercise session. The complexity of the exercises increases gradually during the session: starting with single tasks and then combining them into a multi-task exercise gradually increasing complexity.
46010950|NCT02279316|Other|Home exercise program|The home exercise program is a strengthening program that will consist of five simple exercises.
46097729|NCT02725697|Other|TCM treatment|
46097730|NCT02640560|Other|Food allergy questionnaire|The Parents of the cases children will compile a questionnaire including questions about general information on the family, on life and food habits, on indoor environment, on health status, on clinical aspects of the allergy, on the access to diagnostic and treatment resources
46097731|NCT02640560|Other|Control Questionnaire|The Parents of the control children will compile a questionnaire including questions about general information on the family, on life and food habits and on indoor environment.
46097732|NCT02725931|Behavioral|Pulmonary rehabilitation (PR) plus PA-focused intervention|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychosocial support and education sessions (once a week). Patients will also have their PA levels monitored on weeks (W) 1, 7 and 12 and receive feedback in the following weeks.
46097733|NCT02640326|Other|No Foley Urinary Catheter|No Foley urinary catheter will be put in place during the operation
46097734|NCT02640326|Other|Standard of care Foley urinary catheter insertion|A Foley urinary catheter will be put in place during the operation
45462509|NCT04668131|Other|acupuncture|three times a week
46097735|NCT00692250|Drug|Colesevelam hydrochloride film-coated tablets (Cholestagel)|
46097736|NCT03675139|Drug|Medroxyprogesterone Acetate|At a dosage of 10mg/day
46097737|NCT03675139|Drug|Dydrogesterone 10 MG|At a dosage of 20 mg/day
46097738|NCT00636467|Other|No name|Injection of Nanocis® or Nanocoll® on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)
46097739|NCT02645552|Drug|Tranexamic Acid|Tranexamic acid 1 gram in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
46097740|NCT02645552|Other|Sodium chloride|Sodium Chloride solution (0.9%) 1 ml (gram) in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
46097741|NCT00692328|Behavioral|Levodopa or acupuncture|Comparison of subject expectancy of receiving levodopa or acupuncture.
45462510|NCT03857581|Drug|Clozapine|Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.
45462511|NCT03857581|Drug|Olanzapine|Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.
45679389|NCT05781750|Drug|zetomipzomib|Subcutaneous injection of zetomipzomib
45679390|NCT05781750|Drug|placebo|Subcutaneous injection of placebo
45679391|NCT05781711|Drug|levodopa-carbidopa|levodopa-carbidopa is the standard therapy used in Parkinson's disease
46097742|NCT03415828|Device|Ethanol gel|Intradiscal injection of ethanol gel
45462512|NCT01103843|Drug|Loading Dose Arm|Subjects who are thienopyridine naive will be randomized 1:1 to either clopidogrel 600 mg or prasugrel 60 mg loading dose at the time of PCI. A Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
45462513|NCT01103843|Drug|Maintenance Dose Arm|Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to a loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
45462514|NCT03738865|Drug|G-Pen|1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
46010951|NCT04544306|Other|Partial oral antimicrobial therapy|Switch intravenous antimicrobial therapy to oral after an initial period of 10 days to oral antimicrobial therapy. Antimicrobial choices will be guided by antimicrobial susceptibilities.
46010952|NCT01680588|Drug|[18F]NAV4694|
45679392|NCT05781711|Drug|Metformin|Metformin, a biguanide family member commonly used in treatment for type 2 diabetes, appears to increase liver and peripheral tissue sensitivity to insulin as well as reduce hepatic glucose production
46097743|NCT03415828|Drug|Prednisolone acetate|Intradiscal infiltration of steroids
46097744|NCT03650803|Device|3D MR Fingerprinting scan|"3D MR Fingerprinting technique is a non-contrast technique and generates quantitative information about MR-visible tumors without having to administer contrast.~MR Fingerprinting software is used in conjunction with a standard-of-care MRI scan."
46097745|NCT00652418|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)|Magnevist at a dose of 0.1 mmol/kg
45462515|NCT03738865|Drug|Novo Glucagon|1 mg subcutaneous injection of Novo Glucagon (glucagon injection)
45462516|NCT02524795|Dietary Supplement|Hiomega-3 supplement of Naturalis® company -|Patients (N=22) were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment, and were contacted by telephone in week 6 to check on compliance and any adverse events. Patients received, throughout 12 weeks, two tablets per day of omega-3 fatty acids (540mg of EPA and DHA of 100mg; Hiomega-3 supplement of Naturalis® company - registered in the National Health Department number 4.1480.0006.001-4). All participants were instructed not to take omega-3 rich foods during the study period.
45462517|NCT03524157|Drug|PRO-087|The intervention period consists of a therapy with PRO-087administered 4 times a day in the waking period for 10 days. with a security call to day 13.
45462518|NCT03524157|Drug|Systane Ultra|The intervention period with active comparator drug consists of a therapy with systane administered 4 times a day in the waking period for 10 days. with a security call to day 13.
45679393|NCT05780892|Behavioral|Emotional Wellbeing|Participants in this intervention will learn cognitive behavioral therapy tools to identify unhelpful beliefs and thought patterns, increase motivation through SMART goal making, and increase relaxation and stress management techniques through deep breathing, progressive muscle relaxation and pleasant activity scheduling. Additionally, participants will learn acceptance and commitment therapy tools to increase cognitive flexibility and resilience through acceptance and diffusion work, being present through contact with present moment and self as context and doing what matters through committed actions and value identification.
45679394|NCT05780892|Behavioral|EHR Skills Optimization|Participants in this intervention will learn how to better utilize the EHR by gaining knowledge and skills in the EHR. Session topics include, but are not limited to, understanding current usage patterns and behaviors in the EHR, optimization of the table of contents for easier chart navigation, integration of specialty-focused workflows with current EHR documentation and chart review tools, and recommendations to be more efficient and reduce amount of time spent in the EHR.
46010953|NCT04544228|Procedure|Serratus Anterior Plane Block Technique|The patient will be placed in Lateral Decubitus with a surgical side upwards with arm abduction. A linear ultrasound transducer (6-13 MHz) will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. The expecting depth for this block is 1-4 cm. After aspiration, injection 30ml local anesthetic mixture will be injected anteriorly to the rib and deep to the serratus anterior muscle.
46010954|NCT04544228|Procedure|General anesthesia|"Induction of general anaesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium.~Anaesthesia will be maintained with inhaled sevoflurane 2-2.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium 0.1 m\kg will be provided every 30 minutes.~The residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and extubation will be performed after complete recovery of the airway reflexes."
46010955|NCT04544228|Drug|bupivacaine +ketamine|30 ml bupivacaine 0.25% + 1 ml ketamine (50mg) in Serratus Anterior Plane Block.
46010956|NCT04544228|Drug|bupivacaine + neostigmine|30 ml bupivacaine 0.25% + 1 ml neostigmine (500 μg)in Serratus Anterior Plane Block.
46010957|NCT04544228|Drug|bupivacaine +saline|30 ml bupivacaine 0.25% + 1 ml normal saline in Serratus Anterior Plane Block.
46097746|NCT00652418|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)|Magnevist at a dose of 0.2 mmol/kg
46097747|NCT00687648|Drug|anastrozole|Given as previously prescribed
46097748|NCT00687648|Drug|cyclophosphamide|Given by mouth
46097749|NCT00687648|Drug|exemestane|Given as previously prescribed
46097750|NCT00687648|Drug|letrozole|Given as previously prescribed
45462519|NCT03524157|Drug|Xyel Ofteno|The intervention period with active comparator drug consists of a therapy with Xyel administered 4 times a day in the waking period for 10 days. with a security call to day 13.
46097751|NCT00687648|Drug|methotrexate|Given by mouth
46097752|NCT00687648|Drug|prednisolone|Given by mouth
45462520|NCT02750215|Drug|Capmatinib (INC280)|treatment with Capmatinib (INC280)
45462521|NCT01177657|Procedure|Stool sampling|Stool samples collected and checked for the presence of rotavirus
45462522|NCT03719469|Dietary Supplement|Green tea group|
45462523|NCT03857503|Diagnostic Test|iFR|"Patients will undergo standard of care diagnostic coronary angiography using established invasive physiological criteria for iFR and FFR to aid in clinical decision making for coronary revascularization.~Angiograms will be made in at least two projections, and the treating physician will record his/her estimation of stenosis severity.~Resting iFR and Pd/Pa measures will then be made distal to the target lesion; adenosine will be administered, and the FFR measures will be made without moving the wire. An iFR pullback will then be made after hyperemia as abated. Patients will be treated or deferred from treatment based on physician decision aided by the iFR measures."
45679395|NCT05780892|Behavioral|Performance Improvement|This intervention focuses on improving participants perception of Keck Medicine as a positive workplace environment by supporting participants in gaining basic performance improvement knowledge and skills through didactic training, group discussions based on sociocultural learning theory, and hands on practice leading a performance improvement project. Sessions will review performance improvement concepts such as Lean wastes, systems thinking, change management and sustainability. Participants in this intervention will then identify a project area of focus that they want to improve and develop a project charter. Once a project area has been identified, participants will be put into breakout rooms to discuss successes and challenges as well as receive feedback on their project from peers.
45837199|NCT05622552|Device|active group of tDCS|"Transcranial direct current stimulation(tDCS) is a neurostimulation that has aroused concern in psychiatry. As a non-invasive brain modulation that delivered a weak direct current (0.5-2 mA) via two scalp electrodes (an anode and a cathode) overlying targeted cortical areas. It can produce polarity-dependent effects, like inducing functional changes in resting membrane potential and cerebral blood flow. Specifically, a depolarization of the neurons membranes by anodal stimulation and thus invokes an increase of the spontaneous neuronal firing rate, whereas cathodal stimulation induces neuronal hyperpolarization.~In the active group, current stimulations were gradually ramped up to 2 mA (in 30 seconds) intensity for 20 minutes, once a day, for 10 days."
45462524|NCT03722277|Other|Variable load training|Based on symptoms/strength measured in an isometric maximum strength test at five different angles of knee flexion- and extension, participants will be training with variable load during both concentric and excentric phase of the dynamic movement. Initially participants will start at 40% of symptom limited isometric strength, this will increase to 50% during the training period.
45462525|NCT03722277|Other|Conventional strength training|Conventional strength training with rubber bands in knee flexion- and extension, additionally hip abduction- and adduction.
45462526|NCT03719391|Other|Virginia Tobacco flavored JUUL 5% ENDS|Treatment with Virginia Tobacco flavored JUUL 5% ENDS (10 puffs).
45462527|NCT03719391|Other|Cool Mint flavored JUUL 5% ENDS|Treatment with Cool Mint flavored JUUL 5% ENDS (10 puffs).
45462528|NCT03719391|Other|Mango flavored JUUL 5% ENDS|Treatment with Mango flavored JUUL 5% ENDS (10 puffs).
45462529|NCT03719391|Other|Creme Brulee flavored JUUL 5% ENDS|Treatment with Creme Brulee flavored JUUL 5% ENDS (10 puffs).
45462530|NCT03719391|Other|VUSE Solo e-cigarette|Treatment with VUSE Solo Original with 4.8% nicotine e-cigarette (10 puffs).
46010958|NCT04544540|Other|Units of transfusion|Participants will either receive 1-unit or 2-unit red blood cell outpatient transfusions
46010959|NCT02279433|Drug|DS6051b|DS-6051b 50 mg and 200 mg capsules for oral administration
46010960|NCT04544345|Device|His bundle pacing, AV optimized|A Select Secure 3830 (Medtronic, MN, USA) pacing lead will be placed on the bundle of His. In case of unsuccessful His capture, left bundle branch area pacing is going to be targeted. Pacemaker will be programmed to a low base rate and a high tracking rate to allow for intrinsic sinus rhythm. AV delay will be optimized with echocardiography to the shortest AV delay without truncation of the A wave on transmitral pulse wave doppler.
46010961|NCT04544345|Device|Backup VVI pacing|Pacemaker will be programmed to VVI (ventricular only) mode with low base rate as to allow for intrinsic sinus rhythm without AV optimization.
45462531|NCT03719391|Other|Nicorette White Ice Mint 4mg nicotine polacrilex gum|Treatment with Nicorette White Ice Mint 4mg Nicotine polacrilex gum (30 minutes Chew and Park method)
45462532|NCT03719391|Other|Usual Brand combustible cigarette|Treatment with usual brand cigarette (10 puffs).
46010962|NCT01680627|Behavioral|CASI|
46097753|NCT00725218|Drug|Saline|Saline 5 ml injection 10 min prior to propofol administration.
46097754|NCT00725218|Drug|Flurbiprofen Axetil|Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.
46097755|NCT02732795|Other|Morphine pharmacokinetic evaluation|Each group received morphine and blood drawn to evaluate morphine PK
46097756|NCT03638011|Drug|Exparel|Bilateral TAP Blocks with combination of regular Bupivacaine and EXPAREL
46097757|NCT00655460|Procedure|glucose control with computer generated recommendations|Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
46097758|NCT00687726|Behavioral|Standing balance exercise|Standing balance and mini squat exercise performed 30 times/day/side, 5 days/week, for 4 weeks.
46097759|NCT00687726|Behavioral|Isometric knee extension exercise|Isometric knee extension exercise performed 10 repetitions/set, 3 sets/day, 5 days/week for 4 weeks
46097760|NCT05373082|Other|questionnaire completion|Questionnaire to be completed by patients
46097761|NCT02732717|Other|ultrasound (observation)|"Important sonographic indices are to be collected from 11-14 weeks, 16-18 weeks, 22-24 weeks, 30-32 weeks and 37-39 weeks,including crown-rump length, nuchal translucency, amniotic fluid, umbilical artery flow, middle cerebral artery flow,ductus venous flow. It is observational.~Conditions as below are thought abnormal: discordance of crown-rump length more than 20%, discordance of nuchal translucency more than 20%, either of twin with abnormal amniotic fluid (polyhydramnios or oligoamnios), either of twin with abnormal umbilical artery flow (elevated resistance index, absent or reverse diastolic flow), either of twin with abnormal middle cerebral artery flow (more than 1.5Mom), either of twin with abnormal ductus venous flow (absent or reverse a-wave)."
46097762|NCT03623737|Drug|neoadjuvant chemoradiation|"Neoadjuvant chemoradiation:~Radiation: 180cGy/fraction, once daily, 5 days a week, to a total of 4,500cGy.~Chemotherapy: Arm A or Arm B Surgery: esophagectomy and 3-fields lymph node dissection"
46010963|NCT01680744|Other|Hypothermia|The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure > 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
45462533|NCT03858595|Device|Self monitoring of blood pressure using Health Gauge Device and monthly monitoring of weight gain|"Women in the intervention arm will be provided with the Health Gauge device. With this device, the women will be able to do self-monitoring of blood pressure as well as a few other things like heart rate, daily activities. We will also measure weight gain of the mothers at monthly basis."
45462534|NCT03857269|Other|Acupoint Massage|The operators is trained for two weeks. At 9 o'clock in the morning, the elderly are organized by Nursing home to perform acupressure.Intervention frequency will be monday to saturday per week for 6 months.
45462535|NCT03857269|Other|lavender essential oil|Modulated by an international aroma therapist,The cotton ball containing essential oil is replaced by the operator at 9 am.Intervention frequency will be monday to saturday per week for 6 months.
45462536|NCT03857269|Other|Acupoint Massage and lavender essential oil|At the same time as the acupressure, patients began to smell the essential oil.Intervention frequency will be monday to saturday per week for 6 months.
45462537|NCT03437733|Device|Radiofrequency Ablation|RF ablation using multi-electrode radiofrequency balloon catheter and multi-electrode circular diagnostic catheter
45462538|NCT03856957|Device|Endocuff colonoscopy|Colonoscopy performed with Endocuff for mucosal inspection and interventions (eg. polypectomy).
45462539|NCT03856957|Device|control|colonoscopy without endocuff
45462540|NCT01180543|Device|Oplon Active Patch|Patches are placed over acne lesion overnight. Treatment is a single treatment.
45462541|NCT01180543|Device|Placebo Patch|same as active patch
45462542|NCT03468543|Drug|Memantine Hydrochloride MR Prototype Capsule Formulation A|Memantine HCl MR capsule formulation will be administered orally in a single dose
45462543|NCT03468543|Drug|Memantine Hydrochloride MR Prototype Capsule Formulation B|Memantine HCl MR capsule formulation will be administered orally in a single dose
45462544|NCT03468543|Drug|Memantine Hydrochloride MR Prototype Capsule Formulation C|Memantine HCl MR capsule formulation will be administered orally in a single dose
45462545|NCT03468543|Drug|Memantine Hydrochloride MR Prototype Capsule Formulation D|Memantine HCl MR capsule formulation will be administered orally in a single dose
45462546|NCT03468543|Drug|Memantine Hydrochloride MR Prototype Capsule Formulation E|Memantine HCl MR capsule formulation will be administered orally in a single dose
45462547|NCT03468543|Procedure|Magnetic Resonance Imaging|MRI will be performed on specified days according to protocol
45462548|NCT03857113|Procedure|PSMA-radioguided surgery|PSMA-radioguided surgery
45462549|NCT03467763|Drug|Metformin Extended Release Oral Tablet|Metformin hydrochloride extended release tablets in dosages of 250 mg, 500 mg, 750 mg, and 1,000 mg. Individual encapsulations of metformin will contain dosages of 250 mg or 500 mg.
45462550|NCT03467763|Drug|Placebo oral capsule|Placebo capsule
45462551|NCT02524717|Drug|JNJ-56021927|Participants will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
45462552|NCT00004031|Biological|rituximab|375 mg/m2 IV every 21 days
46010964|NCT01646697|Other|cytology specimen collection procedure|Undergo cytopathologic sample collection
46010965|NCT04541771|Drug|Lactobacillus Reuteri DSM 17938|The trial group will receive their usual feeds plus daily probiotic addition 1 drop/kg/dose twice daily added in expressed breast milk/formula milk from the beginning of enteral feedings till the baby attain full feeds
46010966|NCT04541771|Drug|Placebo|expressed breast milk/formula milk plus normal saline drop from the beginning of enteral feedings till the baby attain full feeds
46097763|NCT02625714|Drug|Renexin®|Cilostazol 100mg/ginko biloba leaf extract 80mg, Immediate release, bid
45462553|NCT00004031|Drug|CHOP regimen|
45462554|NCT00004031|Drug|carmustine|
45462555|NCT00004031|Drug|cyclophosphamide|
45462556|NCT00004031|Drug|doxorubicin hydrochloride|
45462557|NCT00004031|Drug|etoposide|
45462558|NCT00004031|Drug|prednisone|
45462559|NCT00004031|Drug|vincristine sulfate|
46097764|NCT02625714|Drug|SID142|Cilostazol 200mg/ginko biloba leaf extract 160mg, Controlled release, qd
46097765|NCT02637752|Behavioral|Lifestyle counseling or nutrition/physical counselling|A brief (5-10 minute) counseling session for caregivers of the intervention group aimed to encourage an increase in the child's physical activity and decrease sugar-sweetened beverage consumption and screen time. Additionally, the caregivers of the intervention group were provided with the following handouts: five steps to a healthy body weight for teens; beverages; physical activity tips for children 5-11 years; Canadian physical activity guidelines for children 5-11; and Canadian sedentary behavior guidelines for children 5-11.
46010967|NCT01646736|Drug|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
46010968|NCT01646736|Drug|Cyclophosphamide|Cyclophosphamide 1.0 intravenous every month.
46097766|NCT05373004|Drug|Empagliflozin 25 MG|It is the experimental drug in this trial. this drug has an approved efficacy in delaying kidney deterioration based on the results of (the EMPA-REG OUTCOME) trial. it is also recommended based on the ADA/EASD 2019 consensus, as the SGLT2 inhibitors are recommended in patients with type 2 diabetes in patients with CKD to prevent the progression of CKD. However, the previous trials where always add it to a patient already on an ACE inhibitor (in most cases). In this trial, it will be compared head to head with the gold standard treatment of CKD which is Enalapril 20 mg (ACE inhibitor).
46097767|NCT05373004|Drug|Enalapril Maleate 20 mg|It is an ACE inhibitor, the active comparator in this trial, and is considered the gold standard for the treatment of diabetic kidney disease.
46097768|NCT02725307|Device|Noninvasive pulse wave analysis sensor, ECG-sensor|Noninvasive pulse wave sensors and ECG-sensors are attached
45462560|NCT00004031|Procedure|bone marrow ablation with stem cell support|
45462561|NCT00004031|Procedure|peripheral blood stem cell transplantation|
45462562|NCT00004031|Radiation|radiation therapy|
45462563|NCT03855397|Other|Microneedle|A microneedle patch (no drug) was applied in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa to access pain, discomfort and safety.
45837200|NCT05622552|Device|sham group of tDCS|"Transcranial direct current stimulation(tDCS) is a neurostimulation that has aroused concern in psychiatry. As a non-invasive brain modulation that delivered a weak direct current (0.5-2 mA) via two scalp electrodes (an anode and a cathode) overlying targeted cortical areas. It can produce polarity-dependent effects, like inducing functional changes in resting membrane potential and cerebral blood flow. Specifically, a depolarization of the neurons membranes by anodal stimulation and thus invokes an increase of the spontaneous neuronal firing rate, whereas cathodal stimulation induces neuronal hyperpolarization.~For sham stimulation, the procedure was identical, except that the current was gradually ramped up to 2mA and rapidly down to zero (in 30 seconds), thus leading to the same initial sensations of tDCS."
45837201|NCT03572790|Drug|Prucalopride|1mg prucalopride capsule, once daily for seven days
46097769|NCT00675168|Radiation|PET/CT (low-dose)|400 mBq 18F-flour-deoxyglucose given iv. 60 min. before PET/CT-scan
45462564|NCT03855397|Other|Hypodermic needle|30 gauge hypodermic needle was inserted in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa.
45462565|NCT03855397|Other|Flat patch|A flat patch was applied in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa.
45462566|NCT01184443|Drug|Olanzapine|Dosing regimen is in keeping with clinical practice. Patients will typically start oral olanzapine at 2.5mg (rarely 1.25mg) daily for 1 to 2 weeks, and if tolerated and clinically indicated, are increased to 5.0mg daily. The majority of patients will remain on a maintenance dose of 5.0mg, but more agitated patients may take 7.5mg (rarely 10.0mg) daily. Patients will be tapered off as they approach/attain their ideal body weight.
45462567|NCT03858127|Other|Collection of urine sample|Collection of urine sample for measurement of LH and FSH
45462568|NCT03858127|Other|Examination of genitalia|Examination of genitalia
46010969|NCT01646736|Drug|GC|Prednisone or equivalent 1 mg/kg/d(up to 60 mg), gradually tapering to 7.5mg/d in 24 weeks.
46010970|NCT04542005|Behavioral|q3h albuterol|Using q3h albuterol as discharge criteria from hospital
46010971|NCT01646775|Drug|epidural fentanyl|withold epidural fentanyl
46010972|NCT01680978|Drug|aleglitazar|150 mcg orally daily, 6 weeks
46010973|NCT01680978|Drug|placebo|orally daily, 6 weeks
46097770|NCT00992875|Behavioral|Mindfulness-Based Stress Reduction|Behavioral intervention, mindfulness meditation in form of yoga, sitting meditation, body scan and mindfulness to routine activities
45462569|NCT03858127|Other|Video messaging|Short video of infant recorded at home by the parents
45462570|NCT03857035|Other|Piezosurgery group|Piezosurgery technique will be examined about impacted third molar surgery.
45462571|NCT01180621|Biological|Fluviral|0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age
45462572|NCT01106417|Biological|NeoFuse|Single Dose NeoFuse Surgical Implantation
45462573|NCT01106417|Device|MasterGraft Granules|Single Dose MaterGraft Granules Surgical Implantation
45462574|NCT01103921|Other|Glucose|25% dose at 2-week intervention assigned to subjects.
45462575|NCT01103921|Other|Fructose|25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.
45462576|NCT01103921|Other|High-Fructose Corn Syrup|25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.
45462577|NCT01103921|Other|No sugar (Aspartame)|0% dose at 2-week intervention assigned to subjects.
45462578|NCT01290133|Drug|GW597599|Single dose IV infusion
45462579|NCT01290133|Drug|Placebo|Single dose IV infusion
45837202|NCT03572790|Other|Placebo|Lactose placebo capsule, once daily for seven days
46097771|NCT00655616|Drug|Montelukast Placebo|"Seretide 100 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Seretide 250 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Seretide 500 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily"
46010974|NCT04541576|Device|Merit WRAPSODY Endovascular Stent Graft|Target lesion treated with stent graft placement
46097772|NCT00655616|Drug|Salmeterol, Montelukast|"Flixotide Accuhaler 50 micrograms per blister, 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 100 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 250 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 500 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily"
46097773|NCT02725385|Other|Laboratory Biomarker Analysis|Correlative studies
46097774|NCT02725385|Other|Physiologic Testing|Undergo Trier Social Stress Test
46097775|NCT02725385|Other|Questionnaire Administration|Complete questionnaire
46010975|NCT01646853|Radiation|Megavoltage photon beam|initial dose:50Gy/2Gy/25f,5days/week escalation dose:4Gy/2Gy/2f
46097776|NCT00713362|Procedure|Video-assisted thoracoscopic surgery|VATS for bullectomy and mechanical pleurodesis
46097777|NCT00713362|Procedure|chest tube drainage|Chest tube drainage for pneumothroax
46097778|NCT00992953|Behavioral|Treatment as Usual|10 weeks of therapy and/or psychiatric medication as available
46097779|NCT00992953|Behavioral|Virtual Reality Exposure with Stimulus Control|10 weeks of therapy, up to twice a week, 90 min sessions involving Virtual Reality Exposure with Stimulus Control
46097780|NCT00687960|Dietary Supplement|Resistant starch type 4 - raw|Dose: 80g bar containing Resistant Starch Type 4 - raw
46097781|NCT00687960|Dietary Supplement|Resistant Starch Type 4 - Cooked|Dose: 80g bar containing Resistant Starch Type 4 - cooked
46097782|NCT00687960|Dietary Supplement|Dextrose|Dose: 7 oz of oral glucose tolerance beverage
46097783|NCT00687960|Dietary Supplement|Puffed Wheat|Dose: 80g bar containing puffed wheat cereal
46097784|NCT02637674|Procedure|Uterus Transplant|
46097785|NCT00713440|Other|Oral glucose test (OGTT); isoglycaemic iv. clamp; liquid meal test; Gastric Emptying Rate; Prednisolone; Paracetamol|"OGTT: The test is performed with 50 g of glucose deluded in 300 ml. of water. Isoglycaemic iv. clamp: Iv glucose infusion mimicking the glucose response curve of the OGTT.~Liquid Meal Test: The test is performed with 100g of formula milk in 300 ml. of water.~Gastric Emptying Rate: Paracetamol absorption test. Adrenocortical Steroids: Use of 37,5 mg./day of prednisolone during 10 days"
45462580|NCT03467217|Drug|Losartan potassium|Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype
46097786|NCT02732483|Drug|Endo-Clot(TM)|The patients agreed in this study, bleeding control will going to be done with Endo-Clot(TM)
46097787|NCT00922740|Drug|VA106483|Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
45462581|NCT03467217|Drug|Placebo losartan capsule|Matching placebo losartan oral capsule
45462582|NCT01184599|Drug|aliskiren|150 mg/day p.o.
45462583|NCT05227729|Diagnostic Test|Measurement of blood flow in descending aorta by suprasternal ultrasound Doppler technique|While study subjects are in general anesthesia the investigator will perform repeated measurements every 5 min.
45462584|NCT05227729|Diagnostic Test|Measurement of blood flow in descending aorta by transoesophageal ultrasound Doppler technique|While study subjects are in general anesthesia the investigator will perform repeated measurements every 5 min.
45462585|NCT00003875|Drug|busulfan|Given PO or IV
45462586|NCT00003875|Drug|etoposide|Given IV
45462587|NCT00003875|Biological|aldesleukin|Given SC
45462588|NCT00003875|Procedure|peripheral blood stem cell transplantation|Undergo autologous or syngeneic stem cell rescue
45462589|NCT01184677|Device|insertion of the ProSeal LMA (PLMA)|ProSeal LMA size 3 is inserted to the patients of Group size 3.
45462590|NCT01184677|Device|insertion of the PLMA|ProSeal LMA size 4 is inserted to the patients of Group size 4.
46010976|NCT01646853|Drug|cisplatin-fluorouracil chemotherapy|cisplatin 75 mg/m2 on day 1 with standard hydration fluorouracil 1000 mg/m2/day1 i.v. by continuous infusion from day 1 to day 4 of each cycle
46010977|NCT04541459|Device|new device against ambient electromagnetic radiation|New device provides protection against the radiations emitted by the smartphone and laptop devices. Device uses conductive fluids in a particular geometric arrangement intended to ameliorate the negative effects of EMW radiation.
46010978|NCT04541459|Device|sham device against ambient electromagnetic radiation|Sham device as as a control for new device, which provides protection against the radiations emitted by the smartphone and laptop devices. Device uses conductive fluids in a particular geometric arrangement intended to ameliorate the negative effects of EMW radiation.
46010979|NCT01647165|Drug|Bortezomib|Cycle 1-8: 1.0 mg/m2 SC at a concentration of 2.5 mg/ml or 1 mg/ml to the thighs or abdomen on days 1, 4, 8, 11 of a 21 day cycle for 8 cycles.
46097788|NCT00922740|Drug|Placebo|Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
46097789|NCT00655694|Procedure|sputum, blood, urine, exhaled breath, lung function|
45462591|NCT01180699|Biological|Influenza vaccine: Vaxigrip or Fluviral and Intanza|Patients will be randomized to receive either one intradermal dose of 0.1 mL or one intramuscular injection of 0.5 mL of the standard influenza vaccine in the deltoid muscle of the nondominant arm.
46010980|NCT01647165|Drug|Lenalidomide|Cycle 1: 15 mg oral daily on days 2-14 of 21 day cycle; Cycle 2-8: 15 mg oral daily on days 1-14 of a 21 day cycle
46010981|NCT01647165|Drug|Dexamethasone|Cycle 1: 10 mg oral or IV daily on days 2,4,5,8,9,11,12 of a 21 day cycle; Cycle 2-8: 10 mg oral or IV on days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle
46010982|NCT01681056|Behavioral|Autosuggestion for 30 days|
46010983|NCT01681134|Drug|Advagraf®|oral
46010984|NCT01681134|Drug|Prograf®|oral
45462592|NCT01327625|Drug|azithromycin + N-acetylcystein + inhaled corticosteroid|"Azithromycin 500mg qd x 1 week --> 250mg qod x 6 months~N-acetylcystein 200mg tid x 6 months~Fluticasone 250mcg puff x2/day x 6 months"
45462593|NCT03858439|Other|Dietary|Low sodium, low protein dietary recommendation
45462594|NCT03720951|Radiation|pudendal nerve|Fluoroscopic-guided pulsed R.F. to pudendal nerve bilaterally under image guidance
46010985|NCT04543916|Drug|Venetoclax 50 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
46010986|NCT04543916|Drug|Venetoclax 100 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
46010987|NCT04543916|Drug|Venetoclax 200 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
45462595|NCT03720951|Radiation|sacral n roots|Fluoroscopic-guided pulsed R.F. to nerve roots S 2, 3, 4 bilaterally under image guidance
45462596|NCT05329350|Device|muscular ventricular septal defects|intervention cardiology and structural heart disease, including transseptal puncture.
45462597|NCT01290211|Drug|Maraviroc|maraviroc 300 mg BID x 5 days
45462598|NCT01290211|Drug|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg BID x 10 days
46097790|NCT05372848|Diagnostic Test|Manual toothbrush|volunteers who used manual toothbrush for at least 2 years
46097791|NCT05372848|Diagnostic Test|Electric toothbrush|volunteers who used electric toothbrush for at least 2 years
45462599|NCT01290211|Drug|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
45462600|NCT01290211|Drug|Maraviroc|maraviroc 300 mg QD x 5 days
45679396|NCT05780892|Behavioral|control|Participants randomly assigned to the control condition will continue as usual care and will not complete any intervention during the duration of the study.
45462601|NCT01290211|Drug|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 1400/100 mg QD x 10 days
45462602|NCT01290211|Drug|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
45462603|NCT03720873|Drug|erlotinib or gefitinib or icotinib|Patients will be treated with erlotinib 150mgQD or gefitinib250mgQD or icotinib 125 mg TID
45462604|NCT03720873|Drug|Anlotinib|Patients will be treated with Anlotinib 12mg po d1-14 Q21d
45462605|NCT01187875|Dietary Supplement|Placebo- Fiber free control|Dextrin control administered in a muffin treatment.
45679397|NCT05780879|Drug|Venetoclax|Venetoclax administered orally once daily on days 3-16.
46010988|NCT04543916|Drug|Venetoclax 400|Escalating doses to determine recommended phase 2 dose (RP2D)
46010989|NCT04543916|Drug|Venetoclax 600|Escalating doses to determine recommended phase 2 dose (RP2D)
46010990|NCT04543916|Drug|Irinotecan 60 mg/m2|Intravenously (IV), days 1, 8, and 15
46010991|NCT04543916|Drug|Venetoclax (RP2D)|orally, once per day
46010992|NCT04541147|Drug|Dexamethasone|dexamethasone solution or tablet (depending on age of patient) at 0.5mg/kg/day max of 8mg/day, administered on post-operative days 1,3,5,7.
46010993|NCT04541147|Drug|Analgesics|"standardization of post-operative analgesics (narcotics and non-narcotic medication).~Oxycodone solution or tablet (depending on age of patient) at 0.05-0.1 mg/kg/dose every 6hrs; max 5mg (obese/OSA); prescribe 30 doses~Acetaminophen 10-15 mg/kg/dose every 6 hours; max 500mg per dose; prescribe 56 doses (over the counter medication)~Ibuprofen 5-10 mg/kg/dose every 6 hours; max 200 mg/dose; prescribe 56 doses (over the counter medication)"
46010994|NCT01681173|Dietary Supplement|Fiber|200ml drinks enriched with 7,5g of fiber (90% insoluble fiber, 10% soluble fiber), BID, over 24 months
46010995|NCT01681173|Dietary Supplement|Placebo|200ml Placebo, BID, over 24 months
46010996|NCT02214953|Drug|BI 11634 ER formulation A|
46010997|NCT02214953|Drug|BI 11634 ER formulation B|
46010998|NCT02214953|Drug|BI 11634 ER formulation M|
46010999|NCT02214953|Drug|BI 11634 ER formulation C|
46011000|NCT02214953|Drug|BI 11634 IR tablet|
46011001|NCT01647204|Other|trained volunteer mealtime assistance|trained volunteers helped inpatients at lunchtimes with dinner tray preparation, encouragement and feeding if required
46011002|NCT04541303|Drug|Tranexamic acid|tranexamic acid diluted to concentration of 25ml/mg
46097792|NCT00993109|Drug|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS/OROS 30 mg OM + Valsartan 80 mg OM
46097793|NCT00993109|Drug|Diovan (Valsartan)|Valsartan 160 mg OM (Two Valsartan 80mg tablets)
46097794|NCT02725229|Procedure|parasternal block|parasternal block and PCA for sternotomy pain
46097795|NCT02725229|Device|TENS group|TENS and PCA for sternotomy pain
46097796|NCT02725229|Device|control group|PCA for sternotomy pain
46011003|NCT04541303|Drug|normal saline|0.9% sodium chloride
46011004|NCT01647243|Other|Preoperative strength training|Progressive strength training on group basis (not more than 3 subjects) 3 sessions weekly starting 4 weeks before the operation, in total 12 sessions Strength training 3 sessions weekly 4 weeks postsurgery
46011005|NCT02214992|Drug|Telmisartan/Ramipril|Fixed dose combination tablet
46011006|NCT02214992|Drug|Telmisartan|
46097797|NCT00655772|Other|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®): 0.16% sodium chlorite (NaClO2) with an efficacy of 0.1% chlorine dioxide (ClO2),Placebo mouthwash: glycerin, mint oil and distilled water, contents are almost the same as those in the experimental mouthwash except ClO2.
45462606|NCT01187875|Dietary Supplement|Hi-maize resistant starch 9g|9g Hi-maize resistant starch administered in a muffin treatment.
45462607|NCT01187875|Dietary Supplement|Novalose 330 resistant starch 9g|9g Novalose 330 resistant starch administered in a muffin treatment.
45462608|NCT01187875|Dietary Supplement|4.5g Hi-maize resistant starch and 4.5g Novalose 330|4.5g Hi-maize and 4.5g Novalose 330 in a muffin treatment.
45462609|NCT01311960|Drug|bevacizumab eye drop 0.05%|bevacizumab eye drop 0.05% will apply 4 times a day for 3 months
45462610|NCT01311960|Drug|normal saline 0.9%|normal saline eye drop 0.9% will apply 4 times a day for 3 months.
46011007|NCT02214992|Drug|Ramipril capsule|
45462611|NCT03946709|Other|Action Observation|Strength, voluntary activation, and cortical responses to three conditions will be measured: 1) action observation of very strong, forceful contractions of the hand and wrist flexors 2) action observation of very weak, feeble contractions of the hand and wrist flexors 3) no action observation. Experimental conditions will be randomized and counterbalanced.
45462612|NCT03495453|Device|Percutaneous Revascularization of the Femoropopliteal Arteries using a DAS|"Diamondback 360 Peripheral Orbital Atherectomy System (OAS) is a small catheter with a diamond crown. The doctor inserts it at the groin and advances into the leg.The OAS works by spinning around inside the artery to sand down the buildup of material along the artery walls while leaving the healthy vessel behind."
45462613|NCT03495453|Device|Percutaneous Revascularization of the Femoropopliteal Arteries using a OAS device|HawkOne Directional Atherectomy System (DAS) also is the small catheter with cutting device. Doctor slowly and smoothly advances it across the blockage in your artery and shaves the plaque from the vessel wall and collects it in the reservoir.
45462614|NCT01587859|Procedure|laparoscopic surgery|Nissen fundoplication; Collis Gastroplasty.
46011008|NCT02214992|Drug|Ramipril tablet|
46011009|NCT01647321|Behavioral|Active cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to actively pedal while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
46011010|NCT01647321|Behavioral|Passive cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to sit passively on the stationary bile while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
46011011|NCT04544150|Other||
46011012|NCT01681290|Drug|CBX129801|
46097798|NCT00675246|Drug|Betamethasone|IM administration of 12mg of betamethasone each 24 hours (total dose=24mg)
46097799|NCT04357366|Drug|Anakinra|Treatment with 100mg Anakinra subcutaneously (sc) once daily for ten days
46097800|NCT02732405|Drug|MK5172 /MK8742|tablets of MK-5172 100 mg/MK-8742 50 mg will be administered orally, daily for 12 weeks without ribavirin
46097801|NCT02637596|Procedure|Radiofrequency ablation|After laparotomy, intraoperative IOUS quided RFA of primary tumor was performed.
46097802|NCT04001725|Drug|Dexamethasone|A minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day.
46011013|NCT04543721|Device|24-h-ABPM|24-h- blood pressure measurement and pulse wave analysis
46097803|NCT04001725|Drug|Metformin|A minimum daily dosage of Dexamethasone 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day and 2550 mg daily (maximum dose), oral administration (OS) of Metformin; starting dose will be 850 mg/day, to be progressively increased to 1700 mg/day on day 4 and 2550 mg/day on day 7, if well tolerated.
46097804|NCT04137744|Procedure|AXILLARY REVERSE MAPPING|subcutaneous injection of 1to 2 ml methylene blue 15 minutes before the procedure, identification of blue LN and lymphatic vessels
46097805|NCT03302273|Other|Corneal Epithelial Stem Cell Transplant|Self-administration of formulated topical eye drops containing cadaveric epithelial stem cell-derived biologic material.
45462615|NCT03709056|Drug|HSK3486|HSK3486 intravenous (iv) 0.4(0.5) mg/kg for induction, and 0.2 (0.15)mg/kg top-ups for maintenance. 0.3(0.375) mg/kg for induction and 0.15 (0.113)mg/kg for maintenance in adults of 65-70 years old
45462616|NCT03709056|Drug|Propofol|Propofol iv 2.0 mg/kg for induction, and 1.0 mg/kg top-ups for maintenance. 1.5 mg/kg for induction and 0.75mg/kg for maintenance in adults of 65-70 years old.
45462617|NCT03946475|Other|Intervention group|"Training of Trainers (ToT) was conducted among teacher who would deliver the messages. Remaja ASIK is Indonesian tagline meant girls who are active, healthy, smart, and creative. Nutrition education was performed in every Friday, at least 30 minutes during 20 weeks. In brief, this is the key messages of optimized food based recommendations: 1) 3 meals and 2 snack every day, 2) At least 2 portions of vegetables/day including at least 5 portions/week of green leafy vegetables, 3) At least 2 portions/day of animal protein including at least 2 portions/week of liver, 4) At least 1 portion/day of tempe or tofu, 5) At least 1 portion/day of fruit, 6) At least 3 portions/week of milk.Trained teachers delivered the messages accompanied by supervisor. The delivered topics were key messages, balance nutrition, anemia, menstruation, BMI, healthy and smart, strong bone, lunch box, safe snack, and food label."
45462618|NCT05663307|Drug|Ginkgo diterpene lactone meglumine injection|Intravenous injections of Ginkgo diterpene lactone meglumine injection at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.
45462619|NCT05663307|Drug|Ginkgo diterpene lactone meglumine injection simulation|Intravenous injections of Ginkgo diterpene lactone meglumine injection simulation at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.
45462620|NCT05663307|Drug|Aspirin|plus aspirin at a dose of 100 mg per day for 90 days.
45473953|NCT03441126|Other|Multicenter Quality Improvement program|Participating institutions will not participate in an intervention study. Sites will design and implement local QI programs to improve care within their unit. Local healthcare teams, who are interested in directly and immediately improving patient outcomes, will devise customized tools. The Bright STAR Team will assess the impact of these local QI initiatives on patient health outcomes, using data that are collected as part of the QI programs or through routine clinical care.
45679398|NCT05780879|Drug|FLAG Protocol|FLAG consists of daily infusions of Fludarabine (30mg/m2/day over 30 minutes) and Ara-C (2g/m2/day over 4 hours) for 5 days with daily subcutaneous injections of G-CSF until count recovery. Tbo-filgrastim will be administered as follows: WBC count >50,000 - 5mcg/kg; WBC count <50,000 - hold Tbo-filgrastim.
46097806|NCT05372692|Drug|mesothelin-specific chimeric antigen receptor T cell injection|Autologous T cell injection
46097807|NCT00692562|Procedure|simultaneous islet-kidney transplantation|
46097808|NCT02637518|Other|Assessment of frailty tools in elderly people|Assessment of the tools as screening/diagnosis instruments in older adults attended in Primary Care. To build the integration of tools in algorithms to be used in each setting of care and along the settings to permit an integrated care in different conditions (isolated assessment or sequential assessment)
46097809|NCT04137822|Biological|IMM-101|IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline. The treatment regimen with IMM-101 is one dose given every 2 weeks for three doses followed by 4 weeks rest, then one dose is given every 2 weeks for a further three doses. Subsequent doses are given every 4 weeks.
46011014|NCT04528095|Drug|Clozapine|Clozapine 400 ~ 600mg/d or plasma concentration >350ng/ml Amisulpride 200-800mg/d Gingke biloba 120-360mg/d
46011015|NCT04528095|Device|MECT|MECT:The treatment lasted for 4 months,16 times in total MST:The treatment lasted for 4 months,16 times in total
46011016|NCT04528095|Device|DBS|Two electrode emplacement groups (target nucleus accumbens and hippocampus respectively)
46011017|NCT04541264|Diagnostic Test|radiomic of chest CT|radiomics as a quantitative imaging method for early detection, risk assessment, and treatment decisions for early predicting sepsis induced acute respiratory distress syndrome.
46011018|NCT04543604|Behavioral|Leatlet + visual aid (pictogram)|The questionnaires were collected at baseline (at the end of the initial interview and once the patients assigned within the test groups declared to have read the leaflet) at 3- and 6-month follow-up. The questionnaire included demographic data such as age, gender, civil status, occupation (coded according to the CNO-11(2010), presence of systemic disorder, smoking and number of implants. Moreover, data concerning history of periodontal disease and type of prosthesis were further documented and added to demographics.
45462621|NCT01290289|Other|Epidura, CSE & IV|"Gp 1: received CSE analgesia: 25µg of fentanyl & a bolus dose of 10 ml of 0.5% lidocaine was injected epidurally. E top-ups of 5-10 ml of 0.5-0.8% lidocaine were then injected.~Gp 2: received CSE analgesia: 25µg of fentanyl & a bolus dose of 10 ml of 0.0625% bupivacaine was injected epidurally. E top-ups of 5-10 ml of 0.0625-0.25% bupivacaine were then injected.~Gp 3: received 50µg of E fentanyl analgesia & a bolus of 10 ml of 0.5% lidocaine was administered, followed by lidocaine E top-ups of 5-10 ml of 0.5-0.8%.~Gp 4: received analgesia: 50µg of E fentanyl & a bolus dose of 10 ml of 0.125% bupivacaine was administered, followed by E bupivacaine top-ups of 5-10 ml of 0.125-0.25%.~Gp 5: 50mg of IV pethidine was administered as loading dose, followed by 0.5 mg/kg."
45462622|NCT05481294|Other|Transpersonal Supportive Coaching|Coaching is given for four months (two times a month) with a 45-minute duration per coaching by a professional coach
45462623|NCT05481294|Other|Standard Support|Standard support is given for four months using a support system provided by Peer Support Foundation
45679399|NCT05780307|Drug|IMM2520|IMM2520 will be administered once a week intravenously at Day 1, Day8, Day 15 and Day 22 each cycle for up to 48 weeks.
45679400|NCT05776953|Drug|Ketorolac|IV Ketorolac for pain
45679401|NCT05776134|Biological|Brexucabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
46097810|NCT02573974|Other|Samples|Blood samples, muscle biopsy and sample of hair
46097811|NCT02637440|Procedure|FFR guided PCI|Patients undergo Fractional Flow measurement (FFR) followed by PCI, if the FFR is less than 0.8
45679402|NCT05775406|Drug|KT-253|KT-253 will be administered intravenously per the defined protocol frequency and dose level.
45679403|NCT05773573|Device|Experimental group|The experimental group will have a hyrax rapid maxillary expander anchored on the 2nd deciduous molars (V)
46011019|NCT04543604|Behavioral|Leaflet + no visual aid (no pictogram)|The questionnaires were collected at baseline (at the end of the initial interview and once the patients assigned within the test groups declared to have read the leaflet) at 3- and 6-month follow-up. The questionnaire included demographic data such as age, gender, civil status, occupation (coded according to the CNO-11(2010), presence of systemic disorder, smoking and number of implants. Moreover, data concerning history of periodontal disease and type of prosthesis were further documented and added to demographics.
46097812|NCT02637440|Procedure|Angio guided PCI|Patients receive PCI without FFR measurement
46097813|NCT02721563|Drug|Sodium Glycididazole|Sodium Glycididazole 700mg/m2.Three times a week (once every other one day),before radiation therapy, total 6 weeks.
46097814|NCT02721563|Drug|Placebo|Placebo:three times a week (once every other one day),before radiation therapy, total 6 weeks.
46011020|NCT04528056|Drug|Sulfasalazine|Sulfasalazine is an anti-inflammatory and immunosuppressive drug
46011021|NCT04528056|Drug|Ambrisentan|Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension
46011022|NCT04528056|Drug|Sulfasalazine's placebo|Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage
46011023|NCT04528056|Drug|Ambrisentan's placebo|Ambrisentan's placebo is similar to Ambrisentan in form and dosage
46097815|NCT03457129|Drug|Perampanel Oral Tablet|Perampanel is an AMPA receptor blockade, that has shown to be efficacious for seizure reduction in both partial onset seizures and generalized tonic-clonic seizures. Perampanel was approved by the FDA in October 2012 as adjunctive treatment in patients with partial onset seizures. Additionally, in June 2015, Fycompa was approved as adjunctive therapy in patients with primary generalized tonic clonic seizures.
46097816|NCT00688038|Procedure|Laser Ablation|Laser ablation procedure taking about 1-3 hours, depending on the size and location of the tumor.
45462624|NCT01106495|Device|Enhanced External Counterpulsation (EECP)|EECP one hour per day, 5 hours a week for a total of 35- 36 hours over a 7 week period
45462625|NCT01106495|Drug|Simvastatin|Simvastatin 40 mg/d for 7 weeks as the guideline- driven standard medical treatment
45462626|NCT01184833|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under the routine practice setting.
45473954|NCT01287767|Behavioral|A multidimensional support program|Counseling, education and problem-solving in support group, ad hoc counseling
46097817|NCT00688038|Procedure|Magnetic Resonance Thermal Imaging|MRTI will be used to monitor the temperature within the ablation zone during the laser ablation.
46097818|NCT00713674|Other|Theraworx|Theraworx swab intranasal BID for 5 days
45462627|NCT03720639|Device|Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM|Comparing reliability and timeliness in data transmission between two implantable cardiac monitors.
45462628|NCT05479968|Device|Spectrocor device|This feasibility study is intended to document the feasibility, safety, and usability of the Investigational device.
45462629|NCT01184911|Drug|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine tablets, once
45462630|NCT03716973|Device|High Density Programming|Patients implanted with Medtronic spinal cord stimulator will have high density programming.
45462631|NCT01185067|Drug|grape seed extract (MegaNatural BP, Polyphenolics, Inc.)|Subjects will be randomized in double-blind fashion to either grape seed extract (GSE) or maltodextrin placebo capsules for for 6 weeks. Patient will take 300 mg GSE/placebo twice a day for 6 weeks. Patient will have a 2 week washout period and then cross over to the opposite group for an additional 6 weeks.
45462632|NCT03364686|Biological|Biotin-Labeled Red Blood Cells|We will collect 500 mL of blood. The blood will be processed and split into two bags and labeled with a naturally occurring vitamin, biotin. The blood will then be re-infused back into the same participant at 2 time points (5-7 days and 35-42 days after storage).
45462633|NCT05663151|Behavioral|Prolonged Exposure Therapy for Posttraumatic Stress Disorder|Participation will occur throughout 17 weeks over 15 separate visits during which 10, 60-minute sessions of PE will take place. Session 1 of PE will focus on psychoeducation. Session 2 of PE will involve a continuation of psychoeducation and rationale for exposure as well as the collaborative construction of the in vivo exposure hierarchy. After session 2, participants will begin homework where they are instructed to confront situations on their hierarchy. Starting in session 3 of PE, participants will begin imaginal exposures to their worst trauma memory. This involves the participant recounting and visualizing the trauma memory aloud with the clinician in the room for 30-40 minutes. The session will end with 15-20 minutes of processing the imaginal exposure. Participants will continue in-session imaginal exposures until the end of treatment. Throughout the treatment, participants will listen to a recording of their imaginal exposure and engage in in vivo exposures daily.
45462634|NCT03853057|Other|body positions|positive pressure ventilation at different body positions
45462635|NCT03719235|Other|CBCT|ultra-low dose CBCT
45462636|NCT03856801|Other|Exercise|Whole-body vibration training in hypoxia and normoxia condition
45462637|NCT03437577|Drug|immediate-release tacrolimus|Standard of care for transplant patients
45462638|NCT03437577|Drug|extended release tacrolimus|Experimental care
45462639|NCT03853135|Diagnostic Test|measurement of serum endocan|measurement of serum levels of endocan
45473955|NCT03732391|Drug|Pembrolizumab 25 MG(milligram)/ML|Carboplatin AUC6 EV will be given every 3 weeks in combination with Pembrolizumab 200 mg EV every 3 weeks for 6 cycles. Afterwards, the Pembrolizumab will be continued with the same schedule until unacceptable toxicity or disease progression
46097819|NCT00713674|Drug|mupirocin antibiotic ointment|mupirocin antibiotic ointment swab intranasal BID for 5 days
46097820|NCT00885482|Drug|Lamiduvine (Epivir)|Epivir 300 mg
46097821|NCT00885482|Drug|Atazanavir (Reyataz)|Reyataz 300 mg
46097822|NCT00885482|Drug|Ritonavir (Norvir)|Norvir 100 mg
46097823|NCT05349799|Device|TEOSYAL RHA® 1|"During the first phase of the study, ubjects will be treated with TEOSYAL RHA® 1 at baseline (V1) and may receive an optional treatment at 1 month (V2).~In the exploratory phase of the study, subjects will not receive any additional treatment."
46097824|NCT05349799|Device|TEOSYAL RHA® 1 and TEOSYAL® PureSense Redensity 1 (needle)|"During the first phase of the study, ubjects will be treated with TEOSYAL RHA® 1 at baseline (V1) and may receive an optional treatment at 1 month (V2).~In the exploratory phase of the study, subjects will receive additional treatment with TEOSYAL® PureSense Redensity 1 using a needle. TEOSYAL® PureSense Redensity 1 will be administered over three sessions at 2, 3 and 4 months after baseline (respectively V3, V4 and V5)."
46011024|NCT04541342|Procedure|initial arthroscopy with medial opening-wedge high tibial osteotomy fixed by a plate system then second look arthroscopy with plate removal|It is a joint preserving procedure especially preferred in young patients for whom arthroplasty is not desirable. The procedure promotes regeneration by causing lateral shift of the weight-bearing axis, thus decreasing load on the medial compartment and widening the medial joint space.Many of the patients complains of irritation through the plate and wish metal removal after healing of the osteotomy.All patients will undergo initial arthroscopy before high tibial osteotomy (HTO). During arthroscopy, debridement of the degenerate tissues and meniscal tears if present will be performed. Then opening-wedge high tibial osteotomy (OWHTO) will be performed and fixed by a plate system. Second-look arthroscopy will be conducted at the time of plate removal after healing of the osteotomy. This will be after about 6 months up to one year.
45462640|NCT03336528|Drug|Degludec|Degludec is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner blood glucose (BG) between 100 mg/dL and 180 mg/dL.
45462641|NCT03336528|Drug|Glargine|Glargine is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner BG between 100 mg/dL and 180 mg/dL.
45462642|NCT03336528|Drug|Aspart|Aspart insulin will be given in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, aspart insulin dose will be held.
46011025|NCT04543565|Drug|Pradefovir Mesylate;Placebo of Tenofovir disoproxil fumarate tablet|Once daily
46011026|NCT04543565|Drug|Tenofovir disoproxil fumarate tablet;Placebo of Pradefovir Mesylate|Once daily
45473956|NCT03374722|Drug|Opioids|Mechanically ventilated critically ill patients who receive continuous opioid infusion for more than 24 hours will be observed for withdrawal symptoms when rate of opioid infusion is disrupted or decreased
45679404|NCT05773573|Device|Control group|The control group will have a hyrax rapid maxillary expander anchored on the 1st permanent molars (6)
45679405|NCT05768789|Dietary Supplement|Buoy Electrolyte|Buoy intervention amount is 4% of total body weight given in 16 divided doses over 4 hours.
45679406|NCT05768789|Dietary Supplement|Nuun|Nuun intervention given as 1L bolus and then free water in divided doses for a total of 4% total body weight.
45679407|NCT05768789|Other|Water|Water serves as a control
45679408|NCT05766943|Device|Smart Pass ON|Smart Pass filter will be programmed ON in the S-ICD while performing exercise testing.
45462643|NCT01291693|Behavioral|Personal Counseling|At three time-points, participants receive counseling by health professionals trained in Motivational Interviewing based counseling. To assure that both interventions do not differ in their content, individual manuals generated by a software program are used. Counseling will be face-to-face during the hospital stay, and by phone one and three months later.
45462644|NCT01291693|Behavioral|Computer-generated feedback letters|At three time points, participants receive feedback letters, tailored to the stages of change according to the TTM, and generated by a computer software program. The first letter is handed out during their hospital stay and includes normative feedback. One and three months later, participants receive ipsative feedback letters by mail.
45462645|NCT05660031|Procedure|LHB Tenotomy|Will be performed arthroscopically by cutting the LHB at its origin with arthroscopic scissors
45462646|NCT05660031|Procedure|LHB Tenodesis|"ill be performed arthroscopically with a tenodesis at the top of the articular margin using an onlay technique."
45462647|NCT01182649|Device|coronary stent|coronary angioplasty with stent implantation
45462648|NCT01182649|Device|stent|coronary angioplasty with stent implantation
45462649|NCT03364608|Drug|AS MDI 90 μg|AS MDI 90 μg (2 actuations of 45 μg/actuation)
45462650|NCT03364608|Drug|AS MDI 180 µg|AS MDI 180 μg (2 actuations of 90 μg/actuation)
46011027|NCT01681329|Behavioral|Cognitive-behavioral therapy|Cognitive-behavioral therapy addressing intolerance of uncertainty, positive beliefs about worry, negative problem orientation, and cognitive avoidance
45462651|NCT03364608|Other|Placebo MDI|Placebo MDI (2 actuations)
45837203|NCT05622474|Drug|Induction chemotherapy plus Concurrent chemotherapy|"Induction chemotherapy: TP( Docetaxel 75mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles) OR GP (Gemcitabine 1000mg/m2，D1,D8 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles）~Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation."
45462652|NCT03364608|Drug|Proventil 90 μg|Proventil 90 μg (1 actuation of 90 μg/actuation)
45462653|NCT03364608|Drug|Proventil 180 μg|Proventil 180 μg (2 actuations of 90 μg/actuation)
45462654|NCT03719157|Procedure|Unilateral ESP Block|USG guided ESP block will perform unilateral with Bupivacaine and Lidocain mixture
45462655|NCT03719157|Procedure|Unilateral OSTAP Block|USG guided OSTAP block will perform unilateral with Bupivacaine and Lidocain mixture
45462656|NCT03719157|Procedure|Injection of Local Anesthetic to Trocar Insertion|Bupivacaine infiltration will be performed at the end of the surgical procedure to trocar insertion sites.
45462657|NCT03719157|Drug|intravenous patient controlled analgesia|All patients were followed using a standardized postoperative analgesia protocol which includes tramadol PCA. Tramadol at a concentration of 5 mg/mL is included in our PCA protocol (total volume 100 mL.) PCAs were set to no basal infusion and 10 mg bolus doses with a 20 min lock time.
45837204|NCT05622474|Drug|Concurrent chemotherapy|Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation.
45837205|NCT05622474|Radiation|IMRT|Radical radiation: Intensity-modulated radiotherapy
45837206|NCT03428802|Other|Laboratory Biomarker Analysis|Correlative studies
45462658|NCT01185145|Radiation|Breast Brachytherapy with Mammosite RTS|Treatment will be performed using high dose rate brachytherapy, starting between 2-5 days of implant, 34 Gy at 1 cm in 3.4 Gy fractions BID for 5 treatment days with typical boost dose od 10 Gy given in 2 fractions at least 6 hours apart.
45462659|NCT01185145|Radiation|Intensity Modulated Radiotherapy|Accelerated Partial Breast Irradiation using intensity modulated radiotherapy, a novel planning and delivery technique for external beam radiation
45462660|NCT01185223|Drug|Valganciclovir|Valganciclovir 450mg tablet or Valganciclovir powder for oral solution 50mg/mL
45462661|NCT01185223|Drug|Ganciclovir|2x5mg/kg/d intravenous ganciclovir
45462662|NCT03852979|Drug|Paclitaxel|weekly paclitaxel 80 mg/m2 for 12 weeks
45462663|NCT03852979|Drug|Carboplatin|weekly carboplatin AUC=2 for 12 weeks
45462664|NCT03852979|Procedure|conisation|if tumor is reduced to <2 cm, patients will be treated with a conisation
45462665|NCT03852745|Behavioral|Cognitive Behavioral Therapy|cognitive behavioral therapy; focus on learning skills including acceptance and commitment
45837207|NCT03428802|Biological|Pembrolizumab|Given IV
46011028|NCT01681329|Other|Interpretation training|Computerized interpretation training using Word-Sentence Association Paradigm
46011029|NCT02215343|Dietary Supplement|Wheat bran extract|Patients will be provided with 15g of wheat bran extract (WBE) (Cargill R&D Centre Europe).
46011030|NCT02215343|Dietary Supplement|Fish oil|Patients will be provided with a fish oil supplement (capsules), containing 3-4g of N-3 fatty acids (Axellus A/S, Ishøj, Denmark).
46011031|NCT01647477|Behavioral|interview|25 minutes of semi directive interview
45462666|NCT01188031|Drug|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG|A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under fasting conditions
45462667|NCT01188031|Drug|NIRAVAM TM 2 mg orally disintegrating tablets, single dose|B: Active comparator Subjects received Schwarz Pharma Inc. formulated products under fasting conditions
45462668|NCT04926103|Other|Fecal Microbiota transplant (FMT)|Patients will come once a week for FMT for 8 weeks. FMT is the administration of the supernatant component of stool and water mixture from a healthy relative or an unrelated donor. The donor's stool and blood is rigorously screened to exclude known communicable diseases. Those that achieve remission with FMT will have the option of continuing FMT once per month for 3 years
45462669|NCT01290991|Device|Augment Bone Graft|Augment Bone Graft physically fills bone defects by providing a biocompatible scaffold for new bone formation.The material is comprised of a matrix of beta tricalcium phosphate and a highly purified recombinant human platelet-derived growth factor.
45462670|NCT03856489|Other|Richards-Campbell Sleeping Questionnaire (RCSQ)|This five-item visual analogue scale was designed as an outcome measure for assessing the perception of sleep in critically ill patients. The scale evaluates perceptions of depth of sleep, sleep onset latency, number of awakenings, time spent awake, and overall sleep quality.
45462671|NCT01182883|Drug|IMC-A12|
45462672|NCT01182883|Drug|Temsirolimus|
45462673|NCT01188265|Drug|Valproate|
45462674|NCT01188265|Drug|Dextromethorphan 60 mg per day|VPA plus dextromethorphan 60 mg per day
45462675|NCT01188265|Drug|Placebo|VPA plus placebo
45462676|NCT01188265|Drug|Dextromethorphan 30 mg|VPA & Dextromethorphan 30 mg per day
45462677|NCT01182961|Other|gait training|subjects will walk on a treadmill while virtual obstacles will be displayed using a head mounted device
45462678|NCT01182961|Other|gait training 2|subjects will walk on a treadmill under a progressive intensive gait protocol
45462679|NCT01182961|Other|exercise group|standard of care exercise group to improve strength and balance
45462680|NCT03856333|Other|Assigned Interventions|exercises, physical agents
45462681|NCT01183039|Other|Training|20 sessions of training
45462682|NCT01183117|Device|SM-01|SM-01 is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
45462683|NCT01183117|Device|PTA|balloon angioplasty
45462684|NCT01291069|Drug|Tadalafil Citrate|If allocated to the treatment arm, the patient will be given tadalfil citrate, 0.8-1 mg/kg/day in 1 daily dose. Maximum dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.
46011032|NCT01647477|Behavioral|questionnaires|questionnaires to answer at baseline 45 minutes
45462685|NCT01291069|Drug|Sugar pill|If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a mixture of Ora-Sweet® and Ora-Plus® in a 1:1 ratio. All patients will receive drug for 20 days
45462686|NCT00003869|Drug|carboxyamidotriazole|Given PO
45462687|NCT00003869|Other|placebo|Given PO
45462688|NCT00003869|Procedure|quality-of-life assessment|Ancillary studies
45462689|NCT00003869|Other|laboratory biomarker analysis|Correlative studies
45462690|NCT03855241|Behavioral|Informational Sheet|The informational sheet details how use opioid medicines safely, and lists ways to properly dispose of leftover opioids
45462691|NCT03855241|Behavioral|DisposeRx Drug Disposal kit|DisposeRx is a powder that is activated with water and traps leftover drugs (i.e. pills, capsules, caplets, liquids or tablets) in a semi-solid gel. The trapped drug cannot be retrieved from the resulting gel material for misuse, abuse or to leach into landfills. The participant can then throw away the biodegradable solid material in the prescription bottle into the trash, as it is safe for the environment.
45462692|NCT01185379|Dietary Supplement|Efalex active 50+|4 x 500 mg Efalax Active 50+, to be taken daily for 6 months.
45462693|NCT01185379|Dietary Supplement|DHA rich fish oil|4 x 500 mg DHA rich tuna oil to be taken daily for 6 months
45462694|NCT01185379|Dietary Supplement|Placebo|4 x 500 mg capsules to be taken daily for 6 months
45462695|NCT01327391|Procedure|On line Hemodiafiltration|3 sessions/week; 3-4 hours per session
45462696|NCT01327391|Procedure|Hemodialysis|3 sessions/week; 3-4 hours per session; high flux dialyzers
45462697|NCT01588639|Drug|Insulin (Scilin N, BAY81-9924)|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice.
46011033|NCT04540991|Procedure|implant placement|The implants are placed in accordance with each implant system manufacturer's instructions and the treatment were performed according to the patient's standards and indications. Surgical procedures on all patients are performed by the same operator with the same surgical approach, protocol and instrumentation.
46011034|NCT04540991|Procedure|gingiva former placement|Gingiva former are placed in accordance with each implant system manufacturer's instructions and the treatment were performed according to the patient's standards and indications. Surgical procedures of oppeninf implant cower and gingiva former placement on all patients are performed by the same operator with the same surgical approach, protocol and instrumentation.
46011035|NCT04540991|Diagnostic Test|Collecting gingival epithelial cellsusing the swab technique|Samples of gingival epithelial cells are collected from each participant's implementation site using the swab technique at three different time points: a control swab is taken just before the placement of the dental implant (T0); the second swab is taken 90 days after implantation meaning immediately before placement of the gingiva former (T1); and the third swab is taken 21 days after placement of the gingiva former (T2).
46097825|NCT05349799|Device|TEOSYAL RHA® 1 and TEOSYAL® PureSense Redensity 1 (cannula)|"During the first phase of the study, ubjects will be treated with TEOSYAL RHA® 1 at baseline (V1) and may receive an optional treatment at 1 month (V2).~In the exploratory phase of the study, subjects will receive additional treatment with TEOSYAL® PureSense Redensity 1 using a cannula. TEOSYAL® PureSense Redensity 1 will be administered over three sessions at 2, 3 and 4 months after baseline (respectively V3, V4 and V5)."
46097826|NCT04139226|Drug|CC-11050|CC-11050
46097827|NCT00688116|Drug|STA 9090 (ganetespib)|This is a dose-escalation study. The first cohort will consist of three patients who will receive 2 mg/m2 of STA 9090 (ganetespib) during a 1-hour infusion 2 times per week (e.g., [Monday, Thursday] or [Tuesday, Friday]) for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive 4, 7, 10, 14, 19, 25, 33, 40 and 48 mg/m2 provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Further dose increments will be approximately 20% over the previous dose level, until the maximum tolerated dose (MTD) is determined.
45837208|NCT03379194|Behavioral|Antibiotic stewardship program|Routine feedback on antibiotic prescriptions in addition to evidence based guidelines for the management of acute respiratory and urinary tract infection and patient leaflets for using antibiotics wisely
45837209|NCT02319486|Drug|carboplatin periocular injection|chemotherapy together with/without 20mg/2ml carboplatin periocular injection
45837210|NCT02319486|Drug|CEV chemotherapy|vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2
46011036|NCT01647555|Drug|Cetuximab|First cycle: 400 mg/m2 Next cycles: 250 mg/m2
46011037|NCT01647555|Radiation|Radiotherapy|Curative dose: 66 to 70 Gy
46011038|NCT04541615|Procedure|Online course with proficiency test|Participants will receive an online e-course with a proficiency test at the end. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
45462698|NCT01588639|Drug|Insulin (Scilin R _BAY81-9924|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
45462699|NCT01588639|Drug|Insulin(Scilin M30_BAY81-9924)|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
45473957|NCT03246672|Behavioral|maintenance intervention|Participants will receive calls at weeks 1, 2, 3, 4, 6, 8, 10, 12, and 14 that focus on satisfaction with outcomes of behavior change, self-monitoring, relapse planning, and social support.
45473958|NCT01285115|Drug|Placebo|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
45462700|NCT01291771|Procedure|Invasive FFR + CFR measurements are performed during coronary angiography using a pressure guide wire|The guide is placed in the distal segment of the coronary artery to measure instantaneously distal pressure and temperature with a tip sensor. Proximal pressure and temperature are being measured from the probe used to catheterize the coronary vessel and from the shaft of the guide. After basal measurement, intracoronary injection of 150µg of adenosine is performed to induce peripheral vasodilatation leading to hyperaemia in the vessel. Additional injection of 3mL 0.9% saline bolus at room temperature at the time of hyperaemia is performed to calculate CFR from transit mean time. FFR and CFR are being recorded at the time of hyperaemia. Subsequently IMR is being calculated from distal pressure and transit mean time. The measurements will be performed in the LAD, circumflex and right coronary arteries.
45462701|NCT02524639|Drug|Sirolimus|Subjects will receive 1 mg/m2/day orally for 6 weeks. Maintenance dose will be titrated up or down by 0.25-0.5 mg/m2/day every 4 days. Serum concentration will be checked on day 4 after initial therapy and 4 days after any dose adjustment. Levels will be checked at lease once a week during the duration of the study. Target serum concentration range is 5-10 ng/mL.
46011039|NCT04541615|Procedure|Online course|Participants will receive an online e-course but are not required to pass the proficiency test. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
46011040|NCT04541615|Procedure|Standard training group|After receiving a traditional lecture, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
46011041|NCT04541615|Procedure|Apprenticeship group|Participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end. Participants will only receive papers on how the task will be performed and clinicians will help them with completion of the task.
45462702|NCT03946319|Diagnostic Test|Introspect Health|Introspect Health is a software platform which has implemented both the monotopic and personalized, transdiagnostic assessment tools. The software is delivered via the internet using a mobile device or computer.
45462703|NCT03344640|Drug|secukinumab|AIN457 300 mg subcutaneously for 12 weeks
45837211|NCT03271554|Drug|Alectinib|According to local labeling the recommended dose of alectinib is 600 mg given orally, twice daily with food (total daily dose of 1200 mg).
45462704|NCT03344640|Other|Placebo|Placebo to match AIN457 subcutaneously for 12 weeks
45462705|NCT01104233|Device|LAP Protector|The LAP Protector is a device that consists of two flexible rings made of superelasticity alloys covered with polyurethane polyamide, and a thin silicone rubber membrane that is attached to the outer rim of the two rings
45462706|NCT01183273|Procedure|Microlaparoscopic gastric bypass|microlaparoscopic gastric bypass will be performed using standard of care procedure.
45462707|NCT01183273|Procedure|Laparoscopic Surgery|laparoscopic gastric bypass will be performed using standard of care procedure.
45837212|NCT03117972|Drug|FOLFOXIRI|12 cycles
45462708|NCT01291849|Drug|Dixon up-and-down method|The target Ce of remifentanil was determined by the response of the previous patient using Dixon's up-and-down method. If the patients did not cough throughout peri-extubation period, the extubation was defined as a smooth emergence, and the predetermined concentration of remifentanil for the subsequent patient was decreased by 0.5 ng ml-1. Similarly, if the patient cough anytime around extubation it was considered as failed smooth emergence and the predetermined concentration was increased by 0.5 ng ml-1 for the next patient. The patients were enrolled until getting at least six cross-over pairs in Dixon sequential allocation method.
45837213|NCT03117972|Drug|FOLFOX|12 cycles
45837214|NCT03117972|Drug|FOLFIRI|12 cycles
45462709|NCT03950843|Drug|CKD-825|"Dosage Form: capsule~Dosage: 3 types(low/medium/high dose)~Frequency: QD(once daily) administration"
45462710|NCT03950843|Drug|Placebo oral capsule|"Placebo of CKD-825~Dosage Form: capsule~Dosage: NA~Frequency: QD administration"
45473959|NCT01285115|Drug|KyungBangn-Gamisoyosan-x-gwarip|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
45837215|NCT03117972|Drug|Bevacizumab|12 cycles
45837216|NCT03117972|Drug|LV5FU2|Maintenance chemotherapy
45837217|NCT03117972|Drug|Capecitabine|Maintenance chemotherapy
45462711|NCT01183351|Behavioral|Psychosocial intervention|Multidisciplinary Intervention for challenging behavior in patients with Dementia (MID) is developed in clinical practice in nursing homes as an answer to the need of a systematic and simple tool for the nursing home health workers to meet agitation. The model is based on the theoretical framework of cognitive behavioural therapy (CBT) where human behaviour is understood as always acting under the influence of biological, social and psychological factors. The systematic and structured approach of CBT to problem solving is central and is transformed in the model to meet the specific characteristics of challenging behaviour in dementia.
45462712|NCT03344562|Device|CES|Patients will receive cranial electrical stimulation once a day for 20 minutes over 7 days. They will be allowed to increase the stimulation level on Day 2. A wrist worn actigraph will record sleep. Patients may elect to receive standard of care sleep medication if not satisfied with sleep.
45462713|NCT03344562|Device|CES|Patient will receive sham electrical stimulation once a day for 20 minutes over 7 days.
45462714|NCT01185535|Procedure|times of topical anesthesia for glottis|topical anesthesia with pressure nebulized 2% lidocaine for glottis either two times or three times or four times
45462715|NCT00003659|Biological|filgrastim|Filgrastim (300 μg for patients ≤ 70 kg or 480 μg for patients > 70 kg) will be administered beginning two days after each cyclophosphamide dose and given for a total of eight subcutaneous daily doses.
45462716|NCT00003659|Biological|rituximab|Approximately four weeks after the completion of the last cyclophosphamide dose, patients will receive rituximab 375mg/m2 as an intravenous infusion once weekly for four doses.
45462717|NCT00003659|Drug|cyclophosphamide|Cyclophosphamide 3000mg/m2 will be given intravenously q 2 - 3 weeks x 3 doses.
45462718|NCT00003659|Drug|fludarabine phosphate|Fludarabine will be administered intravenously at a dose of 25 mg/m2 per day x 5 days every 4 weeks.
45462719|NCT01185613|Device|Therapy™ Cool Flex Ablation Catheter|"The device under evaluation is the 4mm Therapy™ Cool Flex Ablation Catheter. The Therapy™ Cool Flex catheter is a flexible tip, insulated, 7F catheter constructed of thermoplastic elastomer material and noble metal electrodes.~The following CE Mark devices will be used in conjunction with the Therapy™ Cool Flex Ablation Catheter~IBI-1500T11 Cardiac Ablation Generator (RF ablation generator) with software version 3.0 or higher.~Cool Point™ Irrigation Pump~Cool Point™ Tubing set~Data Logger"
45462720|NCT01104389|Device|Fluorescence imaging|Intraoperatively acquire fluorescence images of renal tumors
45462721|NCT03852589|Device|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. PLMA will inserted by anesthesiologist with C-MAC videolaryngoscope.
45462722|NCT03852589|Device|Blind|PLMA will inserted by anesthesiologist with digital finger.
45462723|NCT01101581|Drug|Veltuzumab and 90Y-Epratuzumab Tetraxetan|Veltuzumab will be administered subcutaneously in phase 2. 90Y-Epratuzumab tetraxetan will be administered intravenously. Veltuzumab is given once weekly for 4 weeks. 90Y-Epratuzumab is also given at treatment weeks 2 & 3 (days 8 & 15).
45462724|NCT01101581|Drug|90Y-epratuzumab tetraxetan|
45462725|NCT01101581|Drug|veltuzumab|Veltuzumab will be administered subcutaneously on days 1, 8, 15 and 23
45462726|NCT01185691|Device|Impella 2.5|Impella 2.5 implant in patients with acute decompensated heart failure
45462727|NCT01183507|Behavioral|NIA intervention|The NIA physical activity intervention is of moderate intensity and will consist of aerobic, strength, flexibility, and balance training, with a target duration of 120 minutes per week.
46011042|NCT01647594|Behavioral|YWI|The YWI consists of print and web-based materials. Content for this group will include detailed information about issues facing young women with breast cancer, risks, discussion points and and resources. The following domains will be addressed: health/medical issues (i.e., side effects, breast cancer recurrence, long-term risks, genetic issues), psychosocial issues (coping, relationship and family concerns), beauty/body image, sexual functioning, fertility concerns, and work/school issues.
46011043|NCT01647594|Behavioral|Physical Activity|The PAI serves as the control group. This intervention consists of print and web-based materials, the content of which includes detailed information about the benefits of exercise in breast cancer survivors and discussion points, available options and resources to enhance physical activity after diagnosis.
46011044|NCT04543448|Other|Traditional Rehabilitation for multiple sclerosis|Traditional rehabilitation program include strengthening exercises for the muscles needed, balance and coordination exercises according to the individual's level, stretching for the lower limbs.
45462728|NCT01183507|Behavioral|TSE|The TSE intervention is also of moderate intensity and target duration of 120 minutes per week and will consist of exercises that closely mimic functional tasks, such as vacuuming, stair ascent and descent, and lifting a weighted laundry basket.
45462729|NCT05478005|Procedure|Femoral nerve block|Patients who receive a femoral nerve block during surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
45462730|NCT05478005|Procedure|Adductor canal block|Patients who receive an adductor canal block (saphenous nerve) at the time of surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
45462731|NCT05478005|Procedure|Intra-articular block|Patients who receive an intra-articular block at the time of surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
45462732|NCT03856021|Procedure|Microfracture with Bone Marrow Aspirate Concentrate|Bone Marrow Aspirate Concentrate harvested and prepared from the iliac crest
45462733|NCT03856021|Procedure|Microfracture|All surgeons will use a 2 mm microfracture pick to perform the microfracture procedure. Using the 2 mm pick, surgeons will make 5 holes per 10 cm2.
46011045|NCT04543448|Other|Cervical mobilization for multiple sclerosis|Cervical mobilization program include myofascial relaxation techniques and mobilization to cervical spine in addition to traditional program.
45462734|NCT03948425|Radiation|spectral CT|Head spectral CT
45462735|NCT01183585|Drug|RO4917838 and Rosuvastatin|multiple oral doses of RO4917838 and single oral dose of Rosuvastatin
46011046|NCT04543370|Drug|Edasalonexent 2000 mg TID|CAT-1004 capsules
45462736|NCT03494985|Device|Experimental Oralbalance Moisturizing Gel|Participants placed approximately a half inch length of the gel onto the tongue and spread thoroughly using their tongue. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
45462737|NCT03494985|Device|Biotene Original Oral Rinse|Participants rinsed their mouth with 15 milliliters (mL) of oral rinse for 30 seconds and spat out. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
45462738|NCT03494985|Device|Biotene Moisturizing Mouth Spray|Participants sprayed one jet directly into their mouth. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
45462739|NCT03494985|Other|Water|Participants were allowed to take only one measured sip of water (15 mL) 30 minutes before the supervised product use. After the supervised treatment at the site, participants assigned to the water only treatment were allowed to sip water as often as required.
45462740|NCT01185769|Dietary Supplement|Tocotrienol|500 mg of tocotrienol will be administered after consumption of high fat diet
46011047|NCT04543370|Drug|Midazolam 2 MG/ML|2 mg/ml syrup
45462741|NCT01185769|Dietary Supplement|Tocotrienol|500 mg of tocotrienol will be administered after consumption of low fat diet
45462742|NCT03852199|Other|Test protocol for proprioceptive force sense in case group|"The FS in the knee region was measured by the pressure, biofeedback device (Stabilizer ™, Chattanooga Group Inc., Chattanooga, TN).~Surface EMG device (Noraxon USA, Inc., Scottsdale, AZ) was used to measure activation levels of M. Vastus Medialis Obliquus (VMO), M. Vastus Lateralis (VL) and M. Rectus Femoris (RF) muscles. Due to the characteristics of the Bipolar Ag/AgCl surface electrodes, the distance between the electrodes was set to 1 cm and the electrode width to 2 cm. The electrode placement was determined according to the SENIAM (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles) criteria."
45462743|NCT01106729|Dietary Supplement|Cyanidin 3 glucoside|Ingestion of 500mg of Cyanidin 3 glucoside (a naturally occurring plant pigment)
46011048|NCT04543370|Drug|Deflazacort 36Mg Tab|36 mg tablets
46011049|NCT01681524|Drug|Flurpiridaz F18|Injection of Flurpiridaz F18 for the purposes of PET MPI analysis
45462744|NCT01185847|Drug|RO5083945|intravenously, until disease progression
45462745|NCT01185847|Drug|cisplatin|standard treatment, up to 6 cycles
45462746|NCT01185847|Drug|gemcitabine|standard treatment, up to 6 cycles
45462747|NCT01185847|Drug|pemetrexed|standard treatment, up to 6 cycles
45462748|NCT01327937|Device|Apligraf|Apligraf group - Applied at Day 0, Weeks 1-4 (maximum of 5 applications) Also cross-over at Week 4 for Control NPTH group - Apligraf applied at Week 4, Weeks 5-8 (maximum of 5 applications)
45462749|NCT01327937|Other|Standard of Care Dressing Group|Standard dressing regimen - Foam dressing (eg, Mepilex) and 4 layered compression system (eg, Profore)
45462750|NCT03720483|Drug|N-acetyl cysteine then Placebo|Subject will receive N-acetyl cysteine first followed by Placebo
45462751|NCT03720483|Drug|Placebo then N-acetyl cysteine|Subject will receive Placebo first followed by N-acetyl cysteine
45462752|NCT03437265|Drug|PLENVU powder for oral solution|PLENVU Dose 1 (1 sachet) and PLENVU Dose 2 (2 sachets)
45462753|NCT01183663|Drug|Lenalidomide|Starting dose 10 mg by mouth daily for 21 days of a 28 day cycle.
45462754|NCT01183663|Drug|Bevacizumab|Starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.
45462755|NCT01183663|Drug|Sorafenib|Starting dose: 200 mg by mouth daily for 28 a day cycle.
46011050|NCT04540874|Drug|BI 894416|BI 894416
46011051|NCT04540874|Drug|Placebo|Placebo
46011052|NCT04528485|Other|Sea swimming|8 sessions of swimming activities in the sea
46011053|NCT04543487|Other|Therapeutic touch|Therapeutic touch was applied twice to the women in the intervention group in addition to routine practices. The first application was performed in the active phase of the first stage of labour, and the second was done in the second stage of labour.
46011054|NCT01681563|Drug|Pentostatin|Lyophilized powder for intravenous administration.
46011055|NCT01681563|Drug|Cyclophosphamide|IV
46011056|NCT01681563|Drug|Ofatumumab|Liquid concentrate for solution for infusion.
46011057|NCT04543292|Device|MATFILL (PTFE)|Filling of the prosthetic chimney with the compressed material
46011058|NCT01681641|Other|A psycho-social intervention|
46011059|NCT04543214|Other|Enhanced recovery after surgery|Enhanced recovery after surgery (ERAS) protocols are multimodal perioperative care pathways designed to achieve early recovery after surgical procedures by maintaining preoperative organ function and reducing the profound stress response after surgery. It benefits patient by reducing complications and enhancing recovery and saves resources for the health care system. In this concept, surgeons work collaboratively with anesthesiologist, nurses, nutritionists and physical therapists to develop and manage the perioperative care.
46011060|NCT01681680|Drug|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
46011061|NCT04543175|Other|Taste disorder´s test|Each patient performed their own test placing three drops with a disposable dropper from each bottle into the center of the tongue for whole-mouth testing.
46011062|NCT01647633|Other|Calcium Glycerophosphate Nasal Spray Wash|Nasal wash two to six times per day
46011063|NCT04541069|Behavioral|Social Communication and Emotional Skill Development (SCESD) module|The intervention, Social Communication and Emotional Skill Development (SCESD) module, is based on the basics of the neuroscience of child development. The module has focused on these basic behaviors of infants, and has incorporated strategies to enhance the five basic behaviors i.e. eye contact, attention to others, joint attention, imitation and non-verbal communication.
45462756|NCT01183663|Drug|Temsirolimus|Starting dose: 15 mg by vein every week for a 28 day cycle.
45462757|NCT01183663|Drug|Lenalidomide|Starting dose: 5 mg by mouth daily for 14 days of a 21 day cycle.
45462758|NCT01183663|Drug|Oxaliplatin|Starting dose: 65 mg/m2 by vein on day 1 of a 21 day cycle.
45462759|NCT01183663|Drug|Leucovorin|400 mg/m2 by vein on day 1 of a 21 day cycle.
45462760|NCT01183663|Drug|5-fluorouracil|400 mg/m2 by vein through ambulatory pump on days 1-2 of a 21 day cycle.
45462761|NCT01291927|Procedure|Pancreas-sparing duodenectomy|Pancreas-sparing duodenectomy for periampullary carcinoma is defined as resection of the descending segment of duodenum; resection of papilla of Vater; reimplantation of bile and pancreatic ducts and reconstruction of duodenum.The Japan Pancreatic Society (JPS) system for numbering of lymph node stations was adopted for accurate description of the surgery and pathological assessment.The standard lymph node groups removed as part of PSD were the anterior pancreatoduodenal groups (JPS LN17), the posterior pancreatoduodenal groups (JPS LN13), the dextroinferior nodes of the hepatoduodenal ligament node groups (JPS LN12), the infrapyloric node (JPS LN6), the nodes around the anterior aspect of the common hepatic artery (JPS LN8) and the nodes on the right side of the SMA (JPS LN14).
45462762|NCT01291927|Procedure|Pancreaticoduodenectomy|The surgical technique used for standard PD has been described before. Standard PD included clearance of all soft tissues and lymphatics immediately to the left of the superior mesenteric artery, as well as removal of the lymphoareolar tissue along the proximal hepatic artery.
45462763|NCT00003509|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Melanoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
46011064|NCT01647672|Drug|Abraxane|Abraxane for neoadjuvant chemotherapy
45462764|NCT05655117|Other|AI based eye screening|The application of AI devices i.e Fundus Camera to detect diabetic retinopathy and macular Oedema in diabetics at the primary care centre
46011065|NCT04540562|Other|COPD app|The COPD app consisted of an 8 week self-management program. The app had three views: timeline, information page, and contact page. The timeline was classified in 8 weeks, and each week included the lung exacerbation plan, daily and extra medication, information and education and questionnaires. The first week also included a video of a pulmonologist explaining the purpose of the app and additional information about the functionalities of the COPD app. A video consultation was planned after after 4 weeks and a face-to-face consultation after 8 weeks.
46097828|NCT05366062|Drug|ERC1671|ERC1671 is an autologous and allogeneic cells and lysates suspension generated from human glioblastoma (GBM) tumors harvested from patients undergoing surgery for glioblastoma. For each patient the treatment is composed of three allogeneic cells vaccine and lysates vaccine (ERC1671 A, B, C) plus from one autologous cells and lysate (ERC1671D).
45462765|NCT03344172|Drug|Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab|Days 1, 8, 15 of Cycles 1 and 2: gemcitabine (1000mg/m^2) and nab-paclitaxel (125mg/m^2) Beginning on Day 8 of Cycle 1: hydroxychloroquine (600mg/BID) daily until day of surgery Day 1 of Cycle 3: avelumab (10mg/kg)
46097829|NCT05366062|Drug|GM-CSF|Sargramostim (Leukomax®, Leukine®); yeast-derived, recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF)
45462766|NCT03344172|Drug|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine|Days 1, 8, 15 of Cycles 1 and 2: gemcitabine (1000mg/m^2) and nab-paclitaxel (125mg/m^2) Beginning on Day 8 of Cycle 1: hydroxychloroquine (600mg/BID) daily until day of surgery
45462767|NCT03852355|Drug|Radiofrequency|), received bilateral 3rd occipital nerve RF under fluoroscopic guidance. Levobupivacaine (0.3 mL; 0.75%) and triamcilonone (1 mg) were injected at each level
46097830|NCT05366062|Drug|Cyclophosphamide|Cyclophosphamide is an alkylating agent, used for immunopotentiation. This drug is FDA approved and is being used off-label for the condition of hematopoietic stem cell transplant conditioning as an antineoplastic and immunosuppressant agent to modulate immunity.
46097831|NCT05366062|Drug|Pembrolizumab|A therapeutic antibody that binds to and blocks PD-1 located on lymphocytes. The receptor is generally responsible for preventing the immune system from attacking the body's own tissues - it is an immune checkpoint inhibitor.
46097832|NCT02645240|Drug|Heparin injection|Intravenous heparin injection in patients with acute mesenteric ischemia and evaluating their response within 24 hours
46097833|NCT02724917|Drug|APN1125|Oral solid dose form of APN1125
46097834|NCT02724917|Drug|Placebo|Placebo to match
46097835|NCT00688194|Drug|anastrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
46097836|NCT00688194|Drug|exemestane|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
45462768|NCT03852355|Drug|Steroids|received systemic steroids oral prednisolone tablet, 10 mg/day
45462769|NCT01106885|Behavioral|Medication Care Management (MCM)|"Basic physical activity counseling~Notify PCP and facilitate initiation of antidepressants~Medication monitoring calls at 1, 2, 4, 6, 8, 10, and 12 weeks*~1/mo monitoring in continuation phase (mos. 4-12)*~Report & recommendations to PCP after each patient call~Note: *average of 10 minutes of telephone time each (series is repeated if second antidepressant trial is needed)"
45462770|NCT01106885|Behavioral|Cognitive-Behavioral Therapy (CBT)|"Notify PCP~CBT Manual~Weekly CBT focused counseling for 12 weeks**~Monthly CBT in months 4-12**~Behavioral physical activity counseling~Report & recommendations to PCP after each patient call~Note: **average of 50 minutes of telephone time each"
45462771|NCT05654337|Other|Expert health counseling|Expert advice on dietary education, lifestyle change, and physical exercise schedule
45462772|NCT01188733|Drug|Long acting octreotide 10mg|Comparison of different doses
45462773|NCT01188733|Drug|Long acting Octreotide 30mg|Comparison of drug doses
45679409|NCT05766943|Device|Smart Pass OFF|Smart Pass filter will be programmed OFF in the S-ICD while performing exercise testing.
45679410|NCT05762432|Device|Wound Dressing|RTD Wound Dressing that is being investigated
46097837|NCT00688194|Drug|fulvestrant|Given intramuscularly
46097838|NCT00688194|Drug|lapatinib ditosylate|Given orally
46097839|NCT00688194|Drug|letrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
46097840|NCT00688194|Other|placebo|Given orally
46097841|NCT00653744|Drug|Rosuvastatin|
45462774|NCT01188733|Drug|Saline|Comparison of drug doses
45462775|NCT01101659|Drug|JNJ-40411813|500 mg as 20 mL of oral suspension
45462776|NCT01101659|Drug|normal saline|single dose
46097842|NCT00653744|Drug|Atorvastatin|
46097843|NCT04019158|Device|Virtual reality headset|All participants will walk in the three conditions described earlier in this form
45679411|NCT05762432|Device|NHS Standard Dressing|This is the standard dressing used by NHS staff when currently dealing with a diabetic foot ulcer
45679412|NCT05756010|Device|EMG|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretchings (cervical extensors and pectoral muscles) exercises
46097844|NCT03009227|Procedure|Colonic resection with D2 lymph node dissection|Appropriate to the tumor location colonic resection is performed with D2 lymph node dissection
46097845|NCT03009227|Procedure|Colonic resection with D3 lymph node dissection|Appropriate to the tumor location colonic resection is performed with D3 lymph node dissection
46097846|NCT03322267|Drug|Pembrolizumab|Cisplatin (30 mg/m2, QW, 2 cycles) and radiotherapy (18-26 Gy/10-13 fractions) as adjuvant chemoradiotherapy, followed by pembrolizumab (200mg, Q3W, 18 cycles)
46097847|NCT00652496|Drug|Bimatoprost 0.01% ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
46097848|NCT00652496|Drug|Bimatoprost 0.015% formulation 1 ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
46011066|NCT01681719|Device|WBV and Resistance|"use of WBV and resistance device during 03 months in elderly health people. The WBV used progressive increases of time and amplitude and the resistance training improves the weight.~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min."
46011067|NCT01681719|Device|resistance & sham WBV|"used only resistance~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK)off."
46011068|NCT01681719|Device|WBV & resistance sham|"used really the WBV, but sham for resistance training~For Resistance: performed similar movments in upper and lower limbs in weight machine Mega II Movement®, without using weights.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min."
45462777|NCT01101659|Drug|ketamine|20 mL of oral suspension
45462778|NCT01101659|Drug|Placebo|single dose
46011069|NCT04543058|Device|BeatPark Application|"The participant walks for 30 minutes a day, 5 day a week for 4 weeks. During the walking session, BeatPark Application delivers synchronized music adapted to the patient walking.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
46011070|NCT04543058|Other|BeatPark Application without synchronized music|"The participant walks for 30 minutes a day, 5 days a week for 4 weeks. During the walking session, BeatPark Application delivers random music at random tempo.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
45837218|NCT03093636|Device|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|"Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App and a study CGM at home for 12 weeks. The DSS contains a smart bolus advisor that adjusts the size of the correction insulin boluses based on short-term blood glucose predictions. It is able to complete this function by evaluating CGM values, insulin usage and carbohydrate intake record. It also contains an exercise advisor, a bedtime advisor, hypoglycemia risk and long-term tracker of HbA1c. Subjects will use study basal and bolus insulin during the study."
46097849|NCT00652496|Drug|Bimatoprost 0.015% formulation 2 ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
46097850|NCT00652496|Drug|Bimatoprost 0.02% ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
46097851|NCT00652496|Drug|Bimatoprost 0.03% ophthalmic solution|Bimatoprost 0.03% ophthalmic solution, one drop in one eye, once daily in the morning for 4 consecutive days, the other eye received one drop of any of the 4 study drugs
46097852|NCT00688272|Drug|Ciprofloxacin|Given 500mg BID x 6 days
46097853|NCT00688272|Drug|Eltrombopag|Given QD x 6 days
45837219|NCT03093636|Other|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use a study CGM at home for 12 weeks. Subjects will use study basal and bolus insulin during the study.
45837220|NCT05622162|Drug|Radiopharmaceutical 18F-JK-PSMA-7|"The Investigational product 18F-JK-PSMA-7 is a diagnostic radiopharmaceutical for use with positron emission tomography.~18F-JK-PSMA-7 is administered as direct intravenous injection. One single administration of 2-4 MBq/kg of 18F-JK-PSMA-7 is scheduled in each patient included in this study."
46097854|NCT00688272|Drug|Placebo|Given QD x 6 days
46097855|NCT00993343|Drug|Sirolimus/tacrolimus|Standard GVHD prophylaxis
46097856|NCT00993343|Drug|cyclosporine/methotrexate|Standard GVHD prophylaxis
45473960|NCT01285115|Drug|KyungBangn Gamisoyosan|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
45473961|NCT03983317|Device|Empower Neuromodulation System|Transcutaneous electrical nerve stimulation
45473962|NCT04732624|Drug|Oral Rehydration Solution|Feasibility study of Enteral-based resuscitation with Oral Rehydration Solution (ORS) vs standard-of-care Intravenous Fluid resuscitation for moderate-sized burn injuries in Nepal
45473963|NCT04732624|Drug|Lactated Ringer|Standard-of-care Intravenous Fluid resuscitation
45473964|NCT05571618|Drug|ADC|Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed).
45679413|NCT05748665|Drug|Remimazolam besylate|Using remimazolam for induction of general anesthesia
45679414|NCT05748665|Drug|etomidate|Using etomidate for induction of general anesthesia
45679415|NCT05746208|Drug|Lenvatinib|Given orally
45679416|NCT05746208|Drug|Pembrolizumab|Given IV
45679417|NCT05746208|Drug|Hyperpolarized 13C-Pyruvate|Given IV
45462779|NCT03708978|Diagnostic Test|mammography|When a woman comes to the clinic to receive mammography. Then a radiologist will give a BI-RADS classification after reviewing the images. If a BI-RADS 4/5 is obtained, the woman will receive pathological biopsy to ensure there is a benign or malignant lesion. If a BI-RADS 3 is obtained, the woman will be followed up by a half-year interval until two year after the first mammography. At each follow up, she will receive mammography. If a BI-RADS 4/5 is obtained at follow up, she will receive pathological biopsy; if a BI-RADS 1/2/3 is obtained at follow up, she will be followed up by a half-year interval until two year. If a BI-RADS 1/2 is obtained at the first mammography, the woman will receive a second mammography after two year. During the study period, breast examination and results will be recorded for every subject. Radiologists will give the diagnosis with and without AI support.
45462780|NCT03855865|Drug|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration).
45462781|NCT03855865|Drug|Vortioxetine|Vortixetine (10 mg with available dose increase to vortioxetine 20 mg oral daily after 3 weeks of administration).
45837221|NCT05622162|Drug|Radiopharmaceutical 18F-Fluorocholine|"The active substance of Comparator is 18F-Fluorocholine. The Comparator will be a 18F-Fluorocholine with a Marketing Authorisation in Italy that will be used in compliance with its Summary of Product Characteristics (SmPC).~18F-Fluorocholine is administrated as direct intravenous injection. One single administration of 18F-Fluorocholine is scheduled in each patient included in this study."
45837222|NCT00546390|Device|Blood Pressure Cuff|The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes. This will be done 4 times in a row.
46011071|NCT04543058|Other|BeatPark Application without music|The participant walks for 30 minutes a day, 5 days a week for 4 weeks. During the walking session, BeatPark Application does not deliver music. The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.
45837223|NCT00860652|Radiation|Adjuvant Radiotherapy|Adjuvant RT (ART) commenced within 4 months of Radical Prostatectomy. 64Gy in 32 fractions to the prostate bed.
45837224|NCT00860652|Radiation|Early Salvage Radiotherapy|Active surveillance with early Salvage RT (SRT). SRT - 64Gy in 32 fractions to the prostate bed. RT should commence no later than 4 months following the first PSA measurement ≥ 0.2ng/mL.
46011072|NCT01647789|Drug|CFG920|
46011073|NCT02215031|Drug|BI 44370|
46011074|NCT02215031|Drug|Placebo|
45837225|NCT04069572|Device|Vibrotactile Stimulation|Application of VCR stimulation to the belly and back of patients with pelvic pain, functional abdominal pain, or low back pain or to the temporal region for patients with migraine.
45837226|NCT04069572|Device|Sham Stimulation|Low-frequency sham of VCR stimulation
45837227|NCT04039074|Behavioral|Integrative Yoga|"A 12-week Integrative Yoga intervention which has meditative and psycho-educational components corresponding to traditional yoga practice."
45837228|NCT04039074|Behavioral|Iyengar Yoga|A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).
45837229|NCT04039074|Behavioral|Mindfulness|A 12-week mindfulness intervention designed for the healthy handling of stress.
46011075|NCT01681758|Other|IV fluid according to PPV|intravenous fluids
46011076|NCT01681758|Other|fluids according to standard care|
45462782|NCT03855865|Drug|Placebo|Placebo (prefilled syringe, weekly IV administration or oral daily).
45462783|NCT03719079|Device|SimpleSENSE|The Nanosense study is observational only. No interventions will be triggered by the SimpleSense device
45462784|NCT01106963|Procedure|Tibial intramedullary nailing|Patients' operations were performed using the peritendinous approach. A medial longitudinal incision was made, with care being taken not to damage the patellar tendon or its sheath. Standard proximal and distal locking screws were used. All patients were given postoperative instructions for thigh muscle rehabilitation and the same physiotherapy was performed after IM nailing during hospitalization. Nails were removed from some of the patients with the presence of knee pain or pain at the insertion points of the locking screws, however, no nails were removed earlier than one year postoperatively. Proof of the healed bone fracture was confirmed by radiologic examination.
45462785|NCT05195892|Drug|Treatment A|Single oral dose of alpelisib film-coated tablet at 50 mg in fed state
45462786|NCT05195892|Drug|Treatment B|Single oral dose of alpelisib granule at 50 mg in fed state
45837230|NCT05622084|Device|Inperia Advance|Patients with infra-popliteal artery stenosis implanted with at least one Inperia Advance device
45837231|NCT04005378|Other|CSC Step-down intervention|Web-based telemedicine and a smartphone app, to decrease disengagement likelihood
45837232|NCT04005378|Other|Usual Care|Usual Care provided by CSC center
46011077|NCT04540679|Other|VIP4SCI|Technology-enabled self-management & rehabilitation solution
46011078|NCT01647867|Other|Met analysis on tissue and blood|10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease
46011079|NCT04540367|Device|Blood flow restriction therapy|The study group underwent the same exercises as the control group modified by the use of a tourniquet for blood flow restriction during those exercises.
46011080|NCT01682070|Biological|SUBLIVAC FIX phleum prat.|Comparison of different dosages to placebo
46011081|NCT01682070|Biological|Placebo|
46011082|NCT04542941|Biological|COVID Convalescent Plasma|Plasma collected from recovered COVID 19 individuals
46011083|NCT01647984|Dietary Supplement|Ritmonutra|Ritmonutra ® contains: 720 mg of Fish Oil with Omega-3, including 480 mg of EPA and 40 mg of DHA, Hawthorn (extract from Crataegus mongyna) 300 mg equivalent to 5.4 mg of vitexin, 4 mg of Astaxanthin and 36 mg of Vitamin E
46011084|NCT01647984|Dietary Supplement|placebo|
46011085|NCT04540328|Other|Non-surgical periodontal treatment|
46011086|NCT01648062|Behavioral|Sleep Self-Regulation Using Mental Imagery|Comparison of two forms of mental imagery to instigate behaviors that assist in the sleeping process
46011087|NCT04540640|Device|Kidney perfusion pump|The pulsatile perfusion device will circulate room temperature oxygenated perfusion solution through the donor kidney ex vivo.
46011088|NCT01648179|Drug|GSK1322322 (mesylate salt) Powder for Injection|1500 mg (mesylate salt) as free base, dissolved in sterile water for injection to a concentration of 100 mg/mL free base equivalent and sterilized via filtration. 15 mL of solution, equivalent to 1500 mg GSK 1322322, is the diluted into 0.9% Sodium Chloride Injection prior to infusion
46011089|NCT01648179|Drug|GSK1322322 (freebase) tablets|500 mg tablets for a 1500 mg total single dose (3 tablets). Taken with 240 mL of water
45837233|NCT00556842|Device|Total hip arthroplasty|Proscribed approaches will include minimally invasive total hip arthroplasty (i.e., two incision approaches) and hinged prostheses or capture cups. Other surgical approach aspects, the use of cemented components, the implant manufacturer, and femoral head size will not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
45462787|NCT05195892|Drug|Treatment C|Single oral dose of alpelisib granule at 50 mg in fasted state
45462788|NCT01290367|Biological|Single Dose MPCs Injection|Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
45462789|NCT01290367|Procedure|Single injection of saline solution|Intradiscal control injection with saline solution
45462790|NCT01290367|Procedure|Single injection of hyaluronic acid|Intradiscal control injection with hyaluronic acid
45462791|NCT01290367|Biological|Single Dose MPCs Injection|Injection of HighDose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
45462792|NCT01107041|Behavioral|Mobilyze!|Mobilyze! delivers behavioral intervention for depression via a mobile phone, interactive website, and e-mail.
45462793|NCT03707730|Dietary Supplement|AGY|oral AGY taken prior to meals
45462794|NCT03707730|Other|placebo|oral placebo taken prior to meals
45837234|NCT00556842|Device|Hemi-arthroplasty|Surgeons will use modern implants for hemi-arthroplasty, excluding non-modular, non-canal filling unipolar implants such as Moore's and Thompson's prostheses. The choice of modular unipolar versus bipolar hemi-arthroplasty will not be standardized. Whether implants are inserted with cement or a press-fit design will also not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
45462795|NCT03946085|Dietary Supplement|Lumega-Z|A specially-formulated carotenoid supplement formula that utilizes a micronized, lipid-based liquid form of delivery.
45462796|NCT03946085|Dietary Supplement|AREDS2|A commercially-available multivitamin soft gel formula.
45837235|NCT00558012|Drug|Intravenous zoledronic acid|Intravenous zoledronic acid 5.0 mg once
46011090|NCT01648179|Drug|GSK1322322 (mesylate salt) Powder for Oral Solution|1500 mg as a free base, dissolved in purified water to a concentration of 100 mg/mL free base equivalent. 15 mL of solution, equivalent to1500 mg GSK1322322 is administered orally with 225 mL of water
46011091|NCT01648179|Drug|GSK1322322 (freebase) tablets FED|Drug 500 mg tablets for a 1500 mg total single dose (3 tablets) (FED moderate fat meal) Taken with 240 mL of water
45462797|NCT03639129|Device|Contrast-enhanced mammography|Contrast-enhanced mammography was FDA approved in 2012 and is currently being used in both clinical and research settings at breast imaging centers throughout the world
46011092|NCT02215382|Drug|sugammadex|sugammadex 2 mg/kg
46011093|NCT02215382|Drug|neostigmine+atropine|neostigmine 0,05 mg/kg + atropine 0,025 mg/kg
46097857|NCT02974049|Drug|Albendazole|"Subjects in Arms 1, 2, and 4 will receive 400mg of Albendazole~Subjects in Arm 3 will receive 800mg of Albendazole"
46097858|NCT02974049|Drug|Ivermectin|Subjects in Arms 1 and 4 will receive 200mg/kg body weight
45462798|NCT03639129|Procedure|Biopsy|Standard of care
45462799|NCT01183819|Behavioral|Space Fortress|Space Fortress sessions 3 times a week for 12 weeks
45462800|NCT01183819|Behavioral|Aerobic Exercise|Aerobic Exercise 4 times a week for 12 weeks
45462801|NCT01183819|Behavioral|Stretching|Stretching/Toning exercise 4 times a week for 12 weeks.
45462802|NCT01183819|Behavioral|Control Games|Control games session 3 times a week for 12 weeks
45462803|NCT05410002|Dietary Supplement|Dietary Supplement: N-111|Dietary supplement N-111
45462804|NCT05410002|Other|Placebo|Dietary placebo
45462805|NCT01107119|Other|integrated care pathway|communication and follow-up program for integrated care
45462806|NCT01107119|Other|usual care|
45462807|NCT01291147|Drug|Levobupivicaine|levobupivicaine 0.5% continous infusion for 48 hours
46011094|NCT04540601|Other|Continuation of antiresorptives in relation to tooth extraction (surgical tooth removal)|"We want to investigate the importance of an antiresorptive drug holiday (bisphosphonate, denosumab) in relation to tooth extraction. The experimental intervention in this trial is drug continuation starting before tooth extraction with primary closure.~We simply ask the participating cancer patients to continue their high dose antiresorptive treatment for 4 months (intervention-period: 1 month pre-operative, 3 months post-operative) instead of taking a drug holiday."
46011095|NCT01682109|Drug|Valacyclovir|
46011096|NCT02215148|Drug|Tolvaptan|
45462808|NCT01291147|Drug|0.9% Saline|0.9% saline continous infusion for 48 hours
45462809|NCT05195190|Other|Clinical test|The 2 minutes walking test, the time up and go test and the 30 second sit and stand test will be applied to the patients in order. Each test will be repeated 2 times after the familiarization test and the average of the tests will be taken. There will be a 10-minute rest period between tests. For the re-test, the tests will be repeated after the patients are given a rest period of 2 hour. Testing will be conducted by a single therapist with at least 5 years of experience blinded to the study.
45462810|NCT05413577|Behavioral|Mindfulness training|The intervention recordings taught the basic concepts of mindfulness through simple guided meditations with content supported by science. Each recording had the same format that included (1) a daily theme, (2) a meditation exercise echoing the theme, (3) a suggested exercise for practice, and (4) an invitation for participants to give a short response to their meditation experience at the end of the recording.
45462811|NCT01291303|Procedure|Optimized ventilation|Patients, ventilated in pressure support mode, were ventilated with initial setting PEEP and pressure support of 4 and as maximum tolerated cmH2O, inspiratory and expiratory trigger of 5 L/min and 50% of peak inspiratory flow, with changes driven by the analysis of flow and pressure curves; with a FiO2 to reach a SpO2 level between 88 and 92%.
45462812|NCT01291303|Procedure|Standard ventilation|"Patients, ventilated in pressure support mode, were ventilated with standard setting of ventilation:~-same initial setting, same time at the bedside (15 minutes at the beginning of NIV, and 5 minutes at each patients' new evaluation) same physician that optimized ventilation mode, while the ventilator screen was obscured (numerical data were, however, always available)."
45462813|NCT03465891|Drug|atezolizumab|1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year).
45462814|NCT03465891|Radiation|Low- Dose, Local Radiotherapy|4Gy will be administered in 2 fractions to a single nodal site amenable to radiation as identified by the radiation oncologist on day 2 and day 3 of Cycle 1 (over the two days following to the first dose of atezolizumab ).
45462815|NCT03948269|Behavioral|group behavioral cognitive therapy|First, we will establish a WeChat group containing the imGT group members and psychiatrists, in which everyone can talk instantly. The interactive treatments will be conducted every Friday evening for a duration of 1.5 hours via text, audio or video messaging. Table 1 summarizes the module topics and provides detailed information on the treatment program. All modules will be saved for repeated viewing after completion. Second, we will establish another WeChat program named Punched-in which participants report on aspects of their everyday life such as diet, sports, readings or mood, according to the plan made by psychiatrists, via text, audio, photo or video message. This program will only be visible to and able to be commented on by participants and psychiatrists.
45462816|NCT03363906|Drug|Dulaglutide (Reference)|Administered SC
45837236|NCT00558012|Dietary Supplement|Vitamin D 800 IU/daily|Daily divided dose
45837237|NCT00558012|Dietary Supplement|Calcium 1200 mg/daily|supplement plus diet
46011097|NCT01682265|Other|Stretta procedure|
46011098|NCT01682265|Other|Sham procedure|No radiofrequency delivered
46011099|NCT01682343|Dietary Supplement|Calcium|Milk-calcium supplement
46011100|NCT04542746|Procedure|Minimally invasive surgical technique|After local anesthesia , for the sites of test group , a minimally invasive surgical technique (MIST) will be performed. The defects associated inter-dental papilla will be surgically approached with a diagonal incision following the pattern of the simplified papilla preservation flap. Flap elevation was to the buccal and oral aspect in the interdental space, An enamel matrix derivative (EMD) was applied into the defect.f A primary closure of the interdental papillae will be achieved using a 5-0 monofilament non resorbable suturing material.
46011101|NCT01648257|Drug|GSK1265744 Na Salt Tablets|Each tablet contains 30 mg of GSK1265744 sodium salt and excipients.
46011102|NCT01648257|Drug|GSK1265744 Free Acid Nanomilled Capsules|Each capsule contains 30 mg of nanomilled and spray dried GSK1265744 free acid, blended with excipients.
45462817|NCT03363906|Drug|Dulaglutide (Test)|Administered SC
45473965|NCT01285193|Behavioral|Breath control|A music CD with sound cues is used to guide the subject to breathe in a regular and slower rate. This is practiced for at least 15 minutes a day over 2 months.
45837238|NCT00558246|Device|Dermabond Protape (Prineo)|cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
45837239|NCT00558246|Device|Suture|Topical Suturing
45837240|NCT00558792|Drug|Isovue 370, 70 mL|70 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
45837241|NCT00558792|Drug|Isovue 370, 80 mL|80 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
45837242|NCT00558792|Drug|Isovue 370, 90 mL|90 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
46011103|NCT01648257|Drug|GSK1265744 Free Acid Micronized Capsules|Each capsule contains 30 mg of micronized GSK1265744 free acid, blended with excipients.
45837243|NCT03884634|Device|Dabir Micropressure Overlay|"The study intervention is the use of the Dabir micropressure overlay on the operating room table during surgical operations. The device is positioned on top of a standard foam pad and gel heat exchanger. The overlay is already in use in some (but not all) adult cardiac operating rooms.~The overlay will be present on the operating room table for all adult cardiac operations. On odd calendar dates the device will be powered on, and on even calendar dates the device will be powered off."
45837244|NCT05621694|Behavioral|Tai Chi Easy|A meditative movement practice that includes simple qigong movement/breath practices and single, repeated tai chi movements taught to generate a meditative state and flow
45837245|NCT03718494|Combination Product|F-18 AV-1451 PET|Participants will receive an intravenous bolus injection of approximately 370 MBq (10 mCi) of 18F- AV-1451. PET/CT image acquisition will include a low dose CT and then a 20-minute PET acquisition starting at 80 minutes after injection of 18F-T807 and will be performed as 4, 5-minute frames that will then be summed into one static frame. Serial frames will allow for adjustment in the case of patient motion.
46011104|NCT04540250|Other|questionnaire|conventional intra-oral examination and questionnaire
46011105|NCT01648335|Device|Immobilization of the shoulder in external rotation in a soft dressing called universal shoulder immobilizer (USI)|
46011106|NCT01648335|Device|Immobilization of the shoulder in internal rotation in a soft dressing called universal shoulder immobilizer (USI)|
46011107|NCT02215460|Procedure|FMS full-mouth scaling|Participants received oral hygiene instructions and full-mouth scaling within 24 hours. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
45679418|NCT05742958|Drug|Intrathecal morphine|The study will be conducted in patients undergoing arthroscopic anterior cruciate ligament reconstruction surgery under spinal anesthesia. In this arm, 0.1 mg intrathecal morphine in addition to spinal anesthesia will be used for perioperative pain management. A placebo addctor canal block will also be performed for masking in these patients. The quality of recovery will be evaluated with a postoperative quality of recovery scale (QoR-40 questionnaire) at postoperative 24-hour and 14-day.
45837246|NCT03718494|Combination Product|F-18 Florbetapir|Each participant will be injected with 10 mCi of 18F-Florbetapir (target dose 370 MBq, range 296 - 444 MBq). After a 25-minute uptake period, the patient will be positioned on the scanner bed with instructions to remain motionless. A helical CT image will be obtained at 50 minutes after injection of 18F-Florbetapir, followed by a 10-minute PET acquisition consisting of two 5-minute dynamic frames.
45837247|NCT00561600|Device|ASR™-XL Modular Acetabular Cup System|The ASR™-XL Modular Acetabular Cup System treatment device is comprised of a metal acetabular cup, a unipolar femoral head and a taper sleeve adapter.
45679419|NCT05742958|Drug|Adductor canal block|After providing complete sensory block in the lower extremities with spinal anesthesia, the thigh where the surgery will be performed will be brought into slight abduction and external rotation while the patient is in the supine position. The blockage of the saphenous nerve in the adductor canal will be performed with 30 mL of local anesthetic (0.25% bupivacaine) solution with a 22 gauge 5-8 cm long block needle from the mid-medial part of the thigh under ultrasound guidance. The quality of recovery will be evaluated with QoR-40 questionnaire at postoperative 24-hour and 14-day.
45679420|NCT05742412|Device|Video streaming (smartphone camera)|Adding video streaming as a technical adjunct to the otherwise audio-based-only communication during emergency medical dispatch
45679421|NCT05742412|Device|Telephone (telephone microphone)|Usual care: Audio-based-only communication using telephone during emergency medical dispatch
46011108|NCT02215460|Procedure|QS quadrant scaling|Participants received oral hygiene instructions and quadrant scaling in 4 weekly sections. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
46011109|NCT02215460|Drug|FMS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
46011110|NCT02215460|Drug|FMS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of placebo mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
46011111|NCT02215460|Drug|FMS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
46097859|NCT02974049|Drug|Diethylcarbamazine|Participants in Arm 4 will receive 6mg/kg of Diethylcarbamazine per body weight
45837248|NCT00561600|Device|Pinnacle™ acetabular shell|The Pinnacle™ shells are cementless, titanium alloy cups with Porocoat® porous coating and HA DuoFix™ coating. There are various different liners available for use with the Pinnacle™ Acetabular Cup System. For the purpose of this investigation, the CoCrMo ULTAMET® 28mm or 36 mm metal liners will be used.
45837249|NCT00561834|Drug|ranibizumab|All patients (n=15) will be treated with open label 0.5mg ranibizumab given intravitreally monthly as needed for 6 months.
45837250|NCT04388202|Drug|Sertraline|FDA approved antidepressant
45837251|NCT04388202|Drug|Escitalopram|FDA approved antidepressant
45837252|NCT02128074|Drug|KRX-0502|1g tablets of KRX-0502
45837253|NCT02128230|Device|myPRS|Genome expression profiling used to identify high-risk and low-risk multiple myeloma
45679426|NCT05740033|Procedure|Split-Thickness Skin Graft for Radial Forearm Donor Site Closure|This method is performed by harvesting a 0.014-inch skin graft harvested from the anterolateral thigh on the side of the RFFF to reconstruct the forearm donor site. This skin graft is then used to cover the donor defect. The skin graft is sutured in place with 4-0 chromic suture, and a standard bolster dressing will be applied, and a partial splint will be left in place for five days post-operation.
45679427|NCT05740033|Procedure|Hatchet Flap for Radial Forearm Donor Site Closure|The hatchet flap closures will be performed based on prior description by Lane et al. (12), except no drain is placed in situ. A back cut of 3 to 4 cm is made to aid closure (Figure 1). Tension will be minimized by maintaining the wrist in flexion. A mepore dressing will be applied to the donor site post-operatively for two days.
46011112|NCT02215460|Drug|FMS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
46011113|NCT02215460|Drug|QS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
46011114|NCT02215460|Drug|QS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
46011115|NCT02215460|Drug|QS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
46011116|NCT02215460|Drug|QS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% placebo mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
46011117|NCT02215499|Drug|Placebo|
46011118|NCT02215499|Drug|Sodium Oxybate|
46011119|NCT02215499|Drug|JZP-386|
46011120|NCT01648608|Drug|Exemestane|Exemestane for neoadjuvant chemotherapy
46011121|NCT02215538|Drug|OROS methylphenidate|
45679428|NCT05740020|Device|virtual reality glasses|A specialized VR glasses will be used and VR games application in spider cage
45679429|NCT05740020|Other|The traditional exercise program|"The selected physical therapy program:~Neurodevelopmental approach: aims to facilitate typical motor development and function and to prevent secondary impairments (figure 4).~Approximation: aims to control spasticity and stimulate the joint mechanoreceptors (figure 5).~Stretching exercise: aims to maintain length and flexibility of shorten muscles (figure 6).~Strengthening exercise: aims to improve the functional ability (figure 7).~Spider suspension exercise for 30 minutes (figure 8).~5. Gait training activities: aims to improve balance (figure 9). 6. Balance training program: aims to improve balance (figure 10)."
46011122|NCT02215538|Drug|Placebo|Placebo medication appears identical to the active medication OROS methylphenidate
46011123|NCT01682421|Drug|Weak steroid (Flurolon, Allergan)|
46011124|NCT01682421|Drug|Potent steroid (Maxidex, Alcon)|
46011125|NCT04540172|Behavioral|Music Therapy|"Mahur tune, one of the nonverbal instruments of the Traditional Turkish Music Authorities, was selected for the study with the opinion of a music therapy specialist."
46011126|NCT04540172|Behavioral|Progressive Muscle Relaxation Exercise|"In this study, the steps of applying progressive muscle relaxation exercise were created with the guidance of the Relaxation Exercises  materials of the Turkish Psychological Association."
46011127|NCT01682499|Drug|calcium gluconate and magnesium sulfate|Intravenous calcium gluconate and magnesium sulfate, 1g each agent in 100 ml D5W over 30 minutes, immediately before and after each dose of paclitaxel
46011128|NCT04540055|Procedure|Paravertebral block|The subjects in this group received general anesthesia and USG-guided paravertebral block
46097860|NCT02645162|Behavioral|Community-based Preschool|"Preschool sessions in community-based preschool~Run by trained community youth leaders from the same village."
46097861|NCT00911976|Device|Xience V coronary stent|The Xience V stent will be implanted in aortocoronary saphenous vein bypass graft lesions
46097862|NCT05356429|Other|Small molecule LCDM|The cocktail of small molecules includes four chemical components of LCDM were added to GV oocyte culture medium.
46097863|NCT02637284|Drug|Bepecin|"Phase 1a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-02 containing 1 mg of Bepecin to study safety and pharmacokinetics.~Phase 1b: All subjects will take 3 tablets of PCO-02 containing 1 mg of Bepecin every 8 hours during two weeks, to study safety and pharmacokinetics."
45462818|NCT03852121|Behavioral|Bibliotherapy|"Bibliotherapy is the use of reading materials for therapeutic benefits. In this study, an evidence-based modified manual will be used as the reading material. The manual adopts the self-directed problem-solving approach to dementia caregiving, examples of how other caregivers solve the specific problem for each chapter is included in the corresponding chapter. Bibliotherapy also involves guided learning by reading written information, enabling caregivers to solve their caregiving problems step-by-step, so telephone coach is designed to figure out participants understanding, find out the unsolved problems and guide them for finding out the solution by themselves."
45462819|NCT03948191|Drug|Methylprednisolone|500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. once a week for 6 weeks.
45462820|NCT03948191|Drug|99Tc-MDP(99Technetium-Methylenediphosphonate Injection)|15mg i.v. infusion once a day for 10 days, 20 days apart, received 3 courses of infusions.
45462821|NCT03855319|Behavioral|SMR neurofeedback training to MCI|The intervention consisted to increase the synaptic strengths and sensitivity within this network. Electroencephalography signals for SMR/theta training was recorded at channel Cz according to the international 10-20 system. Theta rhythm was also recorded and, in this case, SMR was stimulated while theta waves were suppressed.A 32 channels system (EEGDigitrcak Biofeedback plus module, Inc Elmiko Medical) was used for the SMR/theta Neurofeedback training.
45462822|NCT05353127|Diagnostic Test|CPET/Cardiopulmonary Exercise Test|During CPET, a patient exercises against a progressively increasing work rate until volitional exhaustion, while breath-by-breath respiratory gasses are analyzed.
45462823|NCT01292083|Drug|azacitidine|Given IV
46011129|NCT04540055|Procedure|General Anesthesia|The subjects in this group underwent MRM under routine general anesthesia without peripheral nerve block supplementation.
45462824|NCT01292083|Other|laboratory biomarker analysis|Correlative studies
45462825|NCT01292083|Other|immunohistochemistry staining method|Correlative studies
45462826|NCT01292083|Genetic|polymerase chain reaction|Correlative studies
46011130|NCT02215655|Behavioral|Motivational interviewing|Motivational interviewing counselling sessions will be administered to the subjects.
46011131|NCT01202773|Drug|LY2127399|Administered Subcutaneously (SC)
46011132|NCT01202773|Drug|Placebo Q4W|Administered SC
46011133|NCT01202773|Drug|Placebo Q2W|Administered SC
46011134|NCT01648686|Procedure|Dental extraction|3 dental radiographies realised immediately, then 30 days, then 90 days after dental extraction
46011135|NCT02215694|Dietary Supplement|dual probiotics|2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
46011136|NCT02215694|Dietary Supplement|placebo|2g of powder daily without probiotics
45462827|NCT01292083|Genetic|western blotting|Correlative studies
45462828|NCT01292083|Genetic|nucleic acid sequencing|Correlative studies
45462829|NCT01292083|Procedure|therapeutic conventional surgery|Undergo definitive breast surgery
45462830|NCT01104467|Drug|Desmoteplase|1 bolus injection of desmoteplase 70 µg/kg intravenous (IV)
45462831|NCT01104467|Drug|Desmoteplase|1 bolus injection of desmoteplase 90 µg/kg (IV)
45462832|NCT01104467|Other|Placebo|1 bolus injection of placebo IV
45462833|NCT01184131|Other|Mentor Training|Four 2 hour sessions of Mentor Training
45462834|NCT05343143|Device|NeuraGen 3D Nerve Guide Matrix|Integra NeuraGen 3D Nerve Guide Matrix is a resorbable implant for the repair of peripheral nerve gaps.
45462835|NCT01292161|Drug|Silymarin|Tab 210 mg, 630 mg, daily, six months.
45462836|NCT03947879|Drug|L-glutamine|15 g of L-glutamine twice daily by mouth for 3 months.
45462837|NCT03947879|Other|No L-glutamine|The same patients will be given no L-glutamine for 3 months.
46011137|NCT01648725|Procedure|Hypnosis|A short preanesthetic hypnosis before induction of anesthesia
46011138|NCT01648725|Procedure|usual care|Standard care before induction of anesthesia
46097864|NCT02637284|Drug|Placebo|"Phase 1 a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-03 (placebo) as a control group.~Phase 1b: All subjects will take 3 tablets of PCO-03 (placebo) every 8 hours during two weeks, as a control group."
46097865|NCT02570464|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair
46097866|NCT02570464|Biological|Blood drawn|Blood drawn is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair
45462838|NCT03854851|Drug|Naldebain|In Naldebain group, patients will be injected with Naldebain (150 mg/2 ml, IM injection) between 12 and 24 hours prior to surgery.
46097867|NCT04138992|Drug|bevacizumab|bevacizumab will be used during neoadjuvant and concurrent chemoradiotherapy
46097868|NCT04138992|Drug|DDP|DDP will be used during neoadjuvant and concurrent chemoradiotherapy
45462839|NCT03854851|Drug|Morpine|In Morphine group, patients will receive morphine as needed after surgery.
45462840|NCT01101737|Other|Nurse-led blood pressure clinic|Blood pressure will be measured according to protocol.For patients with blood pressure above optimal targets, treatment changes will be discussed with the patient, a visiting consultant physician and the patient's GP. If they agree, the GP will intensify anti-hypertensive treatment with monthly follow up by the specialist nurse until BP targets are achieved.
45462841|NCT01185925|Drug|Sildenafil|Sildenafil, 50 mg 3 times/day
46011139|NCT04539782|Other|Physiotherapy intervention|Compare the effect of structured pelvic floor muscle training supported by physiotherapist post operation on POP on recurrence of symptoms or symptoms in a new compartment, quality of life and pelvic floor muscle function.
46097869|NCT04138992|Drug|Docetaxel|used in neoadjuvant chemotherapy
45462842|NCT01185925|Drug|Placebo|Placebo
45462843|NCT03947801|Other|Greek Yogurt|Female competitive soccer players (11-16y) will consume 0% plain Greek yogurt immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
45462844|NCT03947801|Other|Isoenergetic carbohydrate|Female competitive soccer players (11-16y) will consume an isoenergetic carbohydrate supplement immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
45462845|NCT01188889|Drug|RAD001|"Dosing schedule of RAD001 for the Phase I portion:~Regimen 1. 5.0 mg q72 hours (400 mg QD); Regimen 2. 5 mg q48 hours (400 mg QD); Regimen 3. 5.0 mg q day (400 mg QD); Regimen 4. 7.5 mg PO q day (400 mg QD."
45462846|NCT01188889|Drug|Imatinib|Imatinib will be given continuously at a fixed daily dose of 400 mg once daily.
45462847|NCT03947645|Device|Ipsilesional stimulation|Device: ipsilesional transcranial stimulation, neuromuscular Stimulation over target muscle
45679430|NCT05736367|Drug|U-13C-glucose|Discover new insights into the glucose, TCA cycle, amino acid, and lipid metabolic dependencies of HR+/Her2- breast cancer, via liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy analysis of in vivo U-13C-glucose-labeled biopsy of tumor and benign adjacent tissue
45679431|NCT05736107|Drug|CBL-514 Injection|Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
45679432|NCT05736107|Other|0.9% Sodium Chloride|Sodium Chloride (0.9% NaCl) placebo for injection
45679433|NCT05729412|Other|Mentioned|If prescription is properly filled for specific details than it is compliance
45679434|NCT05724615|Behavioral|Outreach + Bulk ordering|Participants will be sent an order for their lab screening and the recourse of the labs where they can schedule the screening.
45679435|NCT05724615|Behavioral|Outreach + Bulk ordering + Text Based Reminders and Scheduling assistance|Participants will be sent an order for their lab screening and the recourse of the labs where they can schedule the screening. They will also receive text messages to remind them to have their lab completed as well as a link to schedule the lab and inform them of walk-in hours.
46011140|NCT01180660|Drug|Lidocaine Infusion|1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hr throughout the intra operative period
46011141|NCT01180660|Drug|Normal Saline|Saline bolus equal to that of lidocaine in addition to continuous infusion of normal saline during the intra operative period
46011142|NCT04539860|Device|Transdermal Optical Imaging|Blood pressure measurements completed by standard assessment methods and Transdermal Optical Imaging
45679436|NCT05718323|Drug|Niraparib|200 mg orally once daily, until PD 300 mg once daily if body weight ≥77 kg and platelets ≥150 g/L, until PD
45679437|NCT05710666|Drug|trastuzumab deruxtecan (T-DXd) (IV)|Administered as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle for up to six cycles.
46097870|NCT04138992|Radiation|radiotherapy|standard treatment includes pelvic external beam radiation and brachytherapy
46097871|NCT02721485|Other|Ringer's Lactate|After a 1 week run in half of participating hospitals will be crossed over to using Ringer's Lactate as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the second 90-day test period.
46097872|NCT02721485|Other|Normal Saline|After a 1 week run in half of participating hospitals will be crossed over to using Normal Saline as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
46097873|NCT00585715|Device|1064 nm Nd:YAG laser|3 treatments at 3-5 week intervals Spot size: 10 - 18 mm diameter Fluence: 50 J/cm2 Laser pulse duration: 50 ms Rep. rate: Up to 2 Hz DCD cooling 0-50 ms
46097874|NCT02637362|Procedure|Ankle block|Ultrasound guided ankle block of the tibial, superficial peroneal and deep peroneal nerves will be performed using a standardised technique
46011143|NCT01648881|Radiation|TEP-18FDG for every patient after aortic dissection|"Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.~Example: 50 mg/m2, IV (in the vein) on day 5 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."
46011144|NCT01202227|Drug|pregabalin|Pregabalin capsules taken twice a daily (150-600mg/day)
45462848|NCT03947645|Device|Contralesional stimulation|Device: contralesional transcranial stimulation, neuromuscular stimulation over target muscle
46011145|NCT04539821|Other|VCPM|VCPM is a multi-component intervention consisting of already-established care processes and materials.
45679440|NCT05707949|Drug|Atogepant|Oral Tablet
45837254|NCT02128230|Drug|Induction 1 - MEL-10+CFZ-TD-PACE|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days 1, 5, & 6; MEL 10mg/m2 on day 3; T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 400 mg/m2/d, and E 40 mg/m2/d on days 5-8; G-CSF 10 mcg/kg/day from day 11 through end of Peripheral Blood Stem Cell (PBSC) collection.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until 1st transplant."
46011146|NCT01682694|Dietary Supplement|Glucosamine and Chondroitin|Glucosamine (1500 mg) and Chondroitin (1200 mg)
46011147|NCT01682694|Dietary Supplement|placebo|
46011148|NCT04539587|Other|Quality of life|"The patient will receive the following questionnaires to be completed :~EORTC QLQ-C30 EORTC QLQ-BR23 EORTC SHQ-C22"
46011149|NCT01682733|Drug|Botulinum toxin|In this study, Botulinum toxin will be injected in half of the subjects not as a primary treatment modality for obesity, but to retard the muscular grinding gastric activity arount the suture insertion sites to see if it improves the durability of the gastroplasty.
45462849|NCT01107275|Biological|rabies vaccine|intradermal vaccination
45462850|NCT03855553|Behavioral|Family Based Treatment|"10 families will be randomized to receive 10 - 16 weeks of Family Based Treatment (FBT), the gold standard in eating disorder treatment for adolescents. FBT is a highly structured behavioral intervention in which caregivers are charged with the primary task of re-feeding their child and normalizing his or her eating behaviors and weight status."
46011150|NCT01682733|Device|Overstitch Endoscopic Suturing System|The gastroplasty will be accomplished by a series of intralumenally placed full thickness interrupted sutures through the gastric wall, using the FDA-approved (510K) endoscopic suturing device, the Overstitch Endoscopic Suturing System.
46011151|NCT04539314|Drug|Bupivacain|We will carry out the TAP block using 0.5 ml/ kg bupivacaine 0.25%
45462851|NCT03855553|Behavioral|Enhanced Cognitive Behavioral Therapy|10 families will be randomized to receive 10 - 16 weeks of Enhanced Cognitive Behavioral Therapy (CBT-E), a clinically validated treatment for adolescent eating disorders. CBT-E is a short-term, individual treatment focused on normalizing eating behaviors and modifying underlying cognitions that contribute to the maintenance of eating disorder behaviors (e.g., over-importance of shape and weight in one's self-evaluation).
45462852|NCT03945851|Procedure|fMRI|All subjects will undergo 2 fMRI sessions. Each of these sessions will span two days, and subjects will spend 15 minutes in the MRI each day. fMRI tasks will consist of subjects grasping and releasing a handgrip. The control arm subjects will be offered a third fMRI session after unblinding and therapy with activation of the VNS.
45462853|NCT03851809|Drug|Wendan decoction combination in acute brain injury|In the intervention group, traditional Chinese medicine was given between 14 days of onset and TCM was used 1 month at least in intervention group.
45462854|NCT03855631|Genetic|Intervention on primary cultured cells|The intervention includes primary cultured cells, reprograming them into mesenchymal stem cells and CRISPR/Case9 gene therapy treatment on patients' cells
45462855|NCT01184287|Drug|Ranpirnase|Cycles 3 and until patient progression, on days 1,8 and 15 in a 21 day cycle
46011152|NCT04539314|Drug|Dexmedetomidine o.5 μg|We will carry out the TAP block using using 0.5 ml/ kg bupivacaine 0.25% with dexmedetomidine 0.5 μg / kg
46011153|NCT04539314|Drug|Dexmedetomidine 1 μg|We will carry out the TAP block using using 0.5 ml/ kg bupivacaine 0.25% with dexmedetomidine 1 μg / kg
46011154|NCT01682772|Drug|Olaparib|Until objective disease progression, unacceptable toxicity or patient withdrawal for whatever reason
46097875|NCT02637362|Procedure|Sham ankle block|In the supine position with the hip and knee flexed, and the hip externally rotated, the skin from medial malleolus to Achilles tendon will be prepared with chlorhexidine 0.5% solution and allowed to dry. An ultrasound probe (linear array HFL25, Sonosite, Hitchin, UK) will be placed on a line from medial malleolus to achilles tendon to identify the posterior tibial artery and tibial nerve. A Stimuplex A50 needle (B-Braun) will be placed against the skin at the point at which the practitioner would normally have performed insertion of the needle. It will remain there for a total of 30 seconds and then will be removed.
46097876|NCT02637362|Procedure|Metatarsal block|A metatarsal block will be performed using a standardised technique
46097877|NCT02637362|Procedure|Sham metatarsal block|In the supine position, after the surgical incision has been sutured, a 25G standard bevel needle will be placed against the skin at the points at which the practitioner would normally have performed insertions of the needle. It will remain there for a total of 30 seconds and then be removed.
45462856|NCT01184365|Behavioral|Energy Management Program|The program content over the four sessions is structured as follows: Session 1 is an introduction to the group, important concepts, and upcoming session topics; Session 2 further elaborates on the concepts introduced in session 1 and encourages self-reflection; Session 3 is the peer to peer contact by phone or in person to assist with problems and share tips that really worked; and Session 4 concludes the program and serves to consolidate information learned.
45462857|NCT01184365|Behavioral|Energy Management Program|The goal of the EnMP-2 is to control for group effects
45462858|NCT03851887|Combination Product|TAI combine SBRT|TAI combine SBRT
45462859|NCT01291381|Drug|Dermatophagoides pteronyssinus|Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol
45462860|NCT01291381|Drug|Pharmacotherapy|For patients randomized to non-SIT group, persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
45679441|NCT05701930|Behavioral|symptom management|pecha kucha training
45679442|NCT05701826|Drug|HRS3797|HRS3797 for injection, low dose
45679443|NCT05701826|Drug|HRS3797|HRS3797 for injection, medium dose
45679444|NCT05701826|Drug|HRS3797|HRS3797 for injection, high dose
45679445|NCT05701215|Drug|Venetoclax|Venetoclax will be taken orally once daily (400 mg) for 12 months
45679446|NCT05700214|Drug|Ropivacaine injection|30ml of 0.375% ropivacaine
45679447|NCT05700214|Drug|Lidocaine IV|Before induction bolus of 1% lidocaine 1,5mg/kg IBW i.v., continuous infusion of 1% lidocaine intraoperatively rate 1 mg/kg IBW i.v.
45679448|NCT05700045|Drug|Dexmedetomidine|each side dexmedetomidine 0.5ug/kg TAP block
45679449|NCT05695391|Biological|Coagulation Factor VIIa (Recombinant)|LR769
45462861|NCT00003473|Drug|Atengenal|Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
45462862|NCT00003473|Drug|Astugenal|Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
45462863|NCT01292317|Other|application of intravenous volume|weight based intravenous application of volume
45462864|NCT01292317|Other|oral fluid application|oral fluid application
46011155|NCT01682850|Behavioral|Mindfulness Based Pulmonary Rehabilitation|Participants in this group will under go 10 sessions of mindfulness based pulmonary rehabilitation prior to surgery. Each session is about 2 hours long and consists of upper /lower extremity training, breathing exercises, and education.
46011156|NCT01682850|Other|Usual Care|
46011157|NCT01649037|Drug|nor adrenaline and terlipressin|"IV bolus terlipressin at the dose of 0.5 to 1 mg every 6 hours with the maximum daily cumulative dose of 4 mg/day.~Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours in case of no response.[ No response defined as MAP < 10, or 4 hr Urine output < 200 ml] with maximum dose upto 3 mg/h."
46011158|NCT01649037|Drug|step up terlipressin therapy|IV bolus terlipressin starting at 1.5 mg every 6 hours with increase in dose by 0.5 mg/6 hours in case of no response [< 25% decrease in s.creatinine] after every 48 hours. Maximum daily cumulative dose of 12 mg/day.
46011159|NCT04539119|Drug|Tenofovir|Participants will be given tenofovir 300mg (1 capsule) qd po two weeks before the first cycle of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Tenofovir will be given until the copy count of HBV DNA drops below 1*10^3/L.
46011160|NCT04539119|Drug|Entecavir|Participants will be given entecavir 0.5 mg (1 capsule) qd po from two weeks before the first cycle of treatment until one year after the end of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Entecavir will be given until one year after the end of treatment.
46011161|NCT02279511|Drug|ADENOSINE TRIPHOSPHATE|Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)
46097878|NCT00725686|Drug|PF-04523655|This is a dose-escalation study (50, 100, 200, 400, 670, 1000, 1500, 2250, 3000 microgram) given at baseline and then the subject is followed up for 24 months
46097879|NCT04137588|Drug|Antiangiogenesis Agents|antiangiogenesis agents plus chemotherapy as first line treatment
46097880|NCT04137588|Drug|Immune checkpoint inhibitor|immune checkpoint inhibitor plus chemotherapy as first line treatment
46097881|NCT02721329|Device|APAP|Automatic Continuous Positive Airway Pressure
45462865|NCT01107431|Dietary Supplement|L-Arabinose and Chromium|Consumed 70 grams of sucrose simultaneously taking a dietary supplement
45679450|NCT05693935|Drug|TV-44749 - Dose level 1|In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections
45679451|NCT05693935|Drug|TV-44749 - Dose level 2|In Period 1, 2 monthly injections, In Period 2 up to 12 monthly injections
45679452|NCT05693935|Drug|TV-44749 - Dose level 3|In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections
45679453|NCT05693935|Drug|Placebo|In Period 1, 2 monthly injections (Period 1 only)
46097882|NCT02721329|Device|APAP with SensAwake|Automatic Continuous Positive Airway Pressure with SensAwake enabled. SensAwake is a pressure relief technology that detects the transition from sleep to wake, and promptly reduces the pressure during wakeful periods.
45683821|NCT04746118|Behavioral|PHYSICAL ACTIVITY|The physical activity program will consist of daily walking sessions performed outdoors and on a flat surface suitable for hiking. Each session will last 70 minutes and will be performed between 55% -60% of the maximum oxygen consumption (VO2), six times a week, for 24 weeks, with alternate on-site supervision on odd days and remote monitoring on even days. On-site supervision will be carried out by a team coordinated by a Physical Education teacher and implemented at two times in the morning and another two in the afternoon with meeting points previously defined. At the end of each supervised walking session, 20 minutes of exercise will be performed using the equipment available at the Senior Citizens Academy set up in public squares in the region so that the total expenditure of calories spent weekly with physical activities reach about 2000 kilocalories.
45462866|NCT01107431|Dietary Supplement|Sucrose without dietary Supplement|Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium
45462867|NCT01186081|Radiation|Preoperative chemoradiotherapy|Preoperative chemoradiation with conventional radiotherapy (46 Gy in 23 fractions to the whole pelvis followed by a boost dose of 4 Gy in 2 fractions) and oral fluoropyrimidine (capecitabine 825 mg/m2 twice per day without weekend breaks during whole radiotherapy period)
46011162|NCT02279511|Drug|PLACEBO|Infusion of 500 mL of saline solution. (IV)
46011163|NCT04538885|Biological|The pleiotropic factor derived from mesenchymal stem cells|The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2), and then the wound was covered with a foam dressing; the dressing was changed every 3 days to reach clinical healing as the end of the trial.
46011164|NCT01682889|Dietary Supplement|Arginine|L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours
46011165|NCT01682889|Dietary Supplement|Placebo|NaCl 0.9% intravenously for 24h
46011166|NCT04538963|Device|Orthodontic Band affixed with Glass Ionomer Cement|Glass ionomer cement utilized to affix a blank orthodontic band to the tooth; the mechanical retention of the band will also help retain cement in contact with the tooth- the hypothesis is that the fluoride release from the cement will aid in remineralization of tooth structure.
46011167|NCT04538807|Diagnostic Test|electromyography|Electromyography (EMG) is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles.
45462868|NCT01186081|Radiation|Postoperative chemoradiotherapy|Postoperative radiotherapy with conventional radiation schedule (50 Gy in 25 fractions to the whole pelvis) and oral fluoropyrimidine (capecitabine 825 mg/m2 twice per day without weekend breaks during whole radiotherapy period)
45462869|NCT01186159|Drug|Parecoxib Sodium|40 mg Parecoxib Sodium is give to the patients intravenously (diluted with 5 ml normal saline) at 30 minutes before surgery, 20 mg Parecoxib Sodium (diluted with 5 ml normal saline) at 8 hours,20 hours,32 hours,44 hours,56 hours after surgery respectively.
45462870|NCT03852043|Behavioral|High-intensity interval training|The intervals of high intensity are conducted between 90 and 95 % of heart rate maximum (HRmax) and resting between 50 and 60 % of the HRmax 15 loads of 30 seconds at high intensity, with 60 seconds of recovery at loads of moderate intensity.
45462871|NCT03852043|Behavioral|Moderate-intensity continuous training|The continuous training will be carried out at an intensity between 65 and 75% of the HRmax.
45462872|NCT01104857|Procedure|diaphragm muscle biopsy|Biopsy is obtained for biochemical analysis
45462873|NCT01104857|Procedure|Diaphragm muscle biopsy|Biopsy is obtained for biochemical analysis
45679454|NCT05693779|Behavioral|Home exercise training|"Participants will complete an Exercise Treadmill Test at baseline. The 12 weeks exercise program that will be assigned to each patient will be based on these results. The exercise will be three 20-minute exercise sessions per week for 6 weeks. This will increase to four 60-minute exercise sessions per week at increased intensity progressively over the course of the exercise program. The exercise program will involve walking/jogging, elliptical training, or biking 3-4 times per week for up to an hour each session. If participants don't have access to a bike or elliptical, they will be asked to exercise by walking/jogging.~Participants will also a phone call or video chat that takes about 15 minutes per week to discuss the exercise program and take 2 short surveys weekly on the MyDataHelps application and filling out a logbook recording exercise sessions. In addition, participants activity will be measured by using a smartwatch during the study."
45679455|NCT05684965|Drug|XTX301|XTX301 monotherapy
45837255|NCT02128230|Drug|First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days -5 & -4; MEL 20 mg/m2/d, T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 100 mg/m2/d, and E 80 mg/m2/d on days -5 & -2; PBSC transplant on day 0.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until inter-therapy."
46011168|NCT04542902|Biological|Dermatophagoides pteronyssinus allergen|Dermatophagoides pteronyssinus allergen is required to perform allergen bronchial challenge test.
46011169|NCT04542902|Procedure|Blood sampling|An amount of a person's blood taken from their body for use in medical.
46011170|NCT04542902|Procedure|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen. Measurements of differences in eosinophils activity after allergen challenge.
46011171|NCT02279628|Drug|Ropivacaine|Ropivicaine (0.2%) bolus of 10ml will be injected through the catheter after surgery and continuously infused during the postoperative period (8ml/H)
46011172|NCT02279628|Drug|Morphine|Morphine will be injected intrathecally (100µg) and oral morphine will be given during the postoperative period
46011173|NCT04538924|Other|extended clinical, laboratory and instrumental examination; treatment options comparison|Multimodality investigation and different treatment comparison
45462874|NCT01186237|Procedure|Early urinary catheter removal|All patients will have foley catheters removed between 0600 and midnight of post-operative day 3 (Day 0 being the day of operation).
46011174|NCT02279706|Other|questionnaire|Check the Korean version of rhinitis controlled assessment tests, the total non-symptom scores (total nasal symptoms score, TNSS), rhinitis-related quality of life (RQLQ), rhinitis controlled degree, severity, and after study enrollment and 4 weeks treatment.
45462875|NCT01107509|Drug|everolimus|10 mg/ day everolimus in the form of an oral tablet for 12 weeks leading up to nephrectomy (with a 1-week perioperative washout period) in patients with locally advanced disease and re-initiating the drug postoperatively in patients with metastatic disease for up to 24 months, or until disease progression. Dosage may be reduced at any point to 5 mg/ day in the event of any grade 3/ 4 toxicity.
45462876|NCT01186315|Behavioral|Prolonged Exposure Therapy|These treatments include repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories.
45462877|NCT01186315|Behavioral|Prolonged Exposure therapy + VR/ER|The therapy includes repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories and adding in virtual reality (VR)-based exposure to cues for marijuana, cocaine, heroin, cigarette, and/or alcohol use & CER used outside treatment sessions in response to VR exposure (available 24 hours per day/7 days per week) to high-risk contexts for drug use
45462878|NCT01101815|Drug|Oral Naltrexone|50 mg/day-oral
45462879|NCT01101815|Drug|Naltrexone Implant|monthly-implant
46097883|NCT02637128|Drug|artemether-lumefantrine (AL)|Dispersible formulation of artemether-lumefantrine (Coartem-D™; 20mg artemether/120mg lumefantrine per tablet, Novartis, Switzerland) administered twice a day for 3 days according to manufacturer recommended dosing for weight
45462880|NCT01101815|Behavioral|Group Drug Counseling Manual Driven|Given to both groups biweekly, weeks 2 - 48. Counseling will consist of three components: 1) giving advice, support and clinical management aimed to maintain abstinence; 2) adherence enhancement to encourage keeping appointments, taking ART medications as prescribed and getting treatment for associated problems; and 3) reviewing behaviors that are likely to spread HIV and other infectious diseases, and counseling on how to stop them.
45462881|NCT01186393|Behavioral|Control|Dietary manipulation in the free-living setting to include potatoes/potato products frequently in the diet (5-7 days / week). The control diet will be prescribed for weight maintenance.
46011175|NCT04538612|Device|measure capillary refill time|"Each time, capillary refill time will be evaluated three times consecutively by clinical method applying a firm pressure with the finger during 15s, then brutally releasing it, and estimating time of skin recoloration with a chronometer and by DiCART TM device~Three vascular occlusion tests will be successively performed with a cuff during less than 10 minutes:~Arterial vascular occlusion test (50mmHg above systolic arterial pressure of the healthy volunteers),~Veinous vascular occlusion test (30mmHg),~Control test without vascular occlusion test. Capillary refill time measurements will be repeated just before, during and just after vascular occlusion tests.~Randomization determine the order of the vascular occlusion tests. Investigators performing capillary refill time evaluation will be blinded from it. Vascular occlusion tests will be alternatively performed by one and the other limb. The whole protocol will be performed at the upper and then at the lower limb."
45462882|NCT01186393|Behavioral|Low Glycemic Index|Diets will be energy-restricted (~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
46097884|NCT02637128|Drug|artesunate-amodiaquine (ASAQ)|Co-formulated artesunate-amodiaquine (25mg artesunate/67.5mg amodiaquine and 50mg artesunate/135mg amodiaquine tablets) administered once a day for 3 days, according to manufacturer recommended dosing for weight
46097885|NCT02624622|Procedure|Chlorhexidine application to cord by mother|
45462883|NCT01186393|Behavioral|High Glycemic Index|Diets will be energy-restricted (~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
45462884|NCT01104935|Drug|trastuzumab monotherapy|
45462885|NCT01104935|Drug|trastuzumab and chemotherapy|
45462886|NCT01293643|Drug|100 mg clindamycin /800 mg ketoconazole vaginal ovule|1 vaginal ovule for 3 consecutive days
45462887|NCT01293643|Drug|100 mg tetracycline hydrochloride /50 mg amphotericin B cream|1 applicator (4 g) full of cream intravaginally for 7 to 10 days
45679456|NCT05684341|Combination Product|Connected Solution with H2S app which connects with blood glucose meter (BGM)|Combination of the Insultrate titration module software, the H2S app for participants, and the H2S platform for healthcare professionals
45679457|NCT05681039|Drug|Tiragolumab|Given by IV (vein)
46097886|NCT02624622|Procedure|Chlorhexidine application by CHW|
46097887|NCT05353660|Other|No intervention|No intervention
46097888|NCT02640092|Drug|[18F]GTP1|Participants will receive [18F]GTP1 as per the schedule specified in the arm description.
46097889|NCT00912054|Drug|DuoTrav APS|travoprost APS 40 micrograms/ml / timolol 5 mg/ml, Eye Drops, Solution, once daily
45462888|NCT03343626|Drug|Placebo|Placebo (normal saline (0.9% NaCl) IM injection.
45679458|NCT05681039|Drug|Atezolizumab|Given by IV (vein)
45679459|NCT05681039|Behavioral|Standard of Care|after care from surgery
45679460|NCT05681039|Behavioral|Questionnaires|Quality of life
45679461|NCT05681039|Radiation|Cisplatin|Given by IV (vein)
45679462|NCT05681039|Radiation|Carboplatin|Given by IV (vein)
45462889|NCT03343626|Biological|PIZV|Purified inactivated Zika virus vaccine with aluminum hydroxide adjuvant IM injection.
45462890|NCT01293721|Device|Low-magnitude high - frequency vibration treatment|stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 7 days/week
46011176|NCT04528524|Other|Questionnaire|QoR-15Dt
45462891|NCT01105013|Drug|Clotrimazole|Apply the product in sufficient quantity to cover the affected area 2 times daily (every 12 hours) for 60 days.
45462892|NCT01292395|Other|Dietary Protein Intake|Protein intakes within the current recommendation
45462893|NCT03851731|Drug|Naltrexone|Intranasal spray
45462894|NCT03851731|Drug|Naloxone|Intranasal spray
45462895|NCT03851731|Drug|Naltrexol|Intranasal spray
45462896|NCT03707652|Dietary Supplement|Oral supplement A|1, 2 or 4 capsules daily of oral supplement A for 3 days
45462897|NCT03707652|Dietary Supplement|Oral supplement B|4 capsules daily of oral supplement B for 3 days
45679463|NCT05678348|Drug|Pyrimethamine|Patients will be instructed to take their dose at approximately the same time each day.
45679464|NCT05676918|Behavioral|Positive Psychology Intervention|PPI includes 2 modules: hedonic well-being and eudaimonic well-being.
45462898|NCT03707652|Dietary Supplement|Oral supplement C|1,2 or 4 capsules daily of oral supplement C for 3 days
45462899|NCT03707652|Dietary Supplement|Oral supplement D|1 or 2 tablets daily of oral supplement D for 3 days
45462900|NCT03707652|Dietary Supplement|Oral Supplement D in combination with oral supplement C|1 or 2 tablets of oral supplement D in combination with 2 or 4 capsules of oral supplement C for 3 days
45679465|NCT05676918|Behavioral|Cognitive Behavior Therapy|CBT includes 3 modules: behavioral activation, cognitive restructuring, and interpersonal skills.
45837256|NCT02128230|Drug|Inter-Therapy - MEL-20+CFZ-TD-PACE (75%)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 27 mg/m2 on days 1-2; MEL 5 mg/m2/d, T 200 mg/d, D 20 mg/d, P 7.5 mg/m2/d, A 7.5 mg/m2/d, C 75 mg/m2/d, and E 60 mg/m2/d on days 1-4.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until 2nd transplant."
46011177|NCT04542629|Drug|RiTUXimab Injection [Rituxan]|375 MG/M2 /WEEK INFUSION
45462901|NCT03849859|Device|Single plastic stent|Deployment of single plastic stent
45462902|NCT03849859|Device|Multiple plastic stents|Deployment of multiple plastic stents
45462903|NCT01293799|Behavioral|Follow-up of PD patients´ theoretical and practical skills|Testing of patients knowledge and retraining if needed
45462904|NCT01588093|Drug|Increlex|Increlex 120 micrograms/kg body weight single subcutaneous injection
45462905|NCT01588093|Drug|0.9% Saline|Placebo (0,1 ml of 0.9% Saline) single subcutaneous injection
45462906|NCT01588249|Dietary Supplement|Pasteurized maple syrup|
45462907|NCT01588249|Dietary Supplement|Placebo|
45679466|NCT05676294|Drug|Olanzapine|5 mg of oral olanzapine one hour prior to ambulatory surgery
45679467|NCT05676294|Drug|Placebo|oral matched placebo one hour prior to ambulatory surgery
45679468|NCT05665608|Device|Implantable cardioverter-defibrillator (ICD)|"A transvenous ICD consists of an electronic medical device and electrode leads. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the transvenous ICD for the prevention of SCD, but in patients without an indication for bradycardia support, cardiac resynchronisation or antitachycardia pacing.~The extravascular implantable cardioverter-defibrillator (EV ICD) system with substernal lead placement is a novel nontransvenous alternative to current available transvenous and subcutaneous ICDs."
46011178|NCT01683006|Drug|Rocuronium|"Continuous application of Rocuronium (0.5 mg/kg body weight/hour).~Bolus application of placebo in case of shivering."
46011179|NCT01683006|Drug|Placebo|"Continuous application of placebo during therapeutic hypothermia.~Bolus application of Rocuronium (0.5 mg/kg body weight) in case of shivering."
46011180|NCT04542668|Other|Cycling then running|Ergometer cycling Treadmill running
46011181|NCT04542668|Other|Running then cycling|Treadmill running Ergometer cycling
46011182|NCT04542668|Other|Inotropy|Adrenaline induced inotropy
46097890|NCT00912054|Drug|Xalacom|XALACOM® (latanoprost 50 micrograms/ml / timolol 5 mg/ml) Eye Drops, Solution
45462908|NCT01186471|Other|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
45462909|NCT01186471|Other|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
45462910|NCT01186471|Drug|placebo|placebo - three times daily during each treatment period
45462911|NCT03854773|Other|Erector spinae plane block (Group ESPB)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
46011183|NCT04542668|Other|Resting|Subjects must be minimally physically active
46011184|NCT01683045|Device|The Estech COBRA® Surgical System|The Estech COBRA® Surgical System has been designed to create epicardial and endocardial lesions on the heart using temperature controlled radiofrequency (TCRF) ablation with the Estech COBRA surgical probes. Temperature control provides a meaningful endpoint, maintaining tissue at safe yet effective temperatures to produce the desired lesion set. Internal probe cooling and advanced suction helps to ensure reproducible transmural (full-thickness) endocardial or epicardial lesions.
45462912|NCT03854773|Other|Thoracal paravertebral block (Group TPVB)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
45462913|NCT03854773|Other|Control group (group C)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
45462914|NCT03854539|Other|Transdermal Vagus Nerve Stimulation|intermittent transdermal stimulation of the aurical vagus
46097891|NCT00585247|Drug|Imiquimod|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
46097892|NCT00585247|Other|Placebo|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
46011185|NCT04542356|Drug|PEG-rhG-CSF|During the concurrent chemoradiotherapy, a single subcutaneous injection of 6 mg PEG-rhG-CSF was given to the patient 2 hours after radiotherapy on the first day after the end of chemotherapy. Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
45679469|NCT05665608|Drug|Optimal Medical Therapy (OMT)|"Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure"
46011186|NCT04542356|Drug|rhG-CSF|Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
46011187|NCT01683162|Drug|ClinOleic|the lipid of all-in-one, 0.5-3.5g/kg.d
46011188|NCT01683162|Drug|Lipofundin|the lipid of all-in-one, 0.5-3.5g/kg.d
46011189|NCT01683162|Drug|Intralipid|the lipid of all-in-one, 0.5-3.5g/kg.d
46011190|NCT02215733|Drug|ARB|other than telmisartan
46011191|NCT02215733|Drug|ACEI|
46011192|NCT02215733|Drug|Beta-blockers|
46011193|NCT02215733|Drug|Diuretics|
46011194|NCT02215733|Drug|Telmisartan|
46011195|NCT01683201|Procedure|Functional exercise class|Functional exercise class running twice weekly for six weeks from week 12 to week 18
46011196|NCT01683201|Procedure|usual care group|Usual care group adhere to post operative instructions given on discharge from hospital
46011197|NCT02215772|Drug|BI 44370 BS|
46011198|NCT01202188|Drug|indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI.
46011199|NCT01202188|Drug|glycopyrronium (NVA237)|Capsules for inhalation delivered via SDDPI.
45462915|NCT03849781|Device|NeoBeat with a visible display|NeoBeat (Laerdal Medical) is a CE approved novel heart rate meter, able to detect heart rate in newborns within seconds of birth. The NeoBeat uses ECG dry-electrodes in a snug-fit abdomen-shaped buckle for rapid application around the newborn's abdomen or thorax. It allows healthcare providers to reliably assess heart rate of the newborn immediately after birth and continuously during resuscitation.
46097893|NCT02721407|Drug|Retroviral vector-transduced autologous T cells to express CD22-specific CARs|
45462916|NCT01292551|Drug|Bosentan|tablets Bosentan 62,5 mg x 2 daily for two weeks, then 125 mg x 2 daily for 12 weeks
45462917|NCT01292551|Drug|Placebo|Placebo tablets 2 x daily for 2 weeks, then change to different placebo tablets to match Bosentan group, 2 x daily for 12 weeks
46011200|NCT01202188|Drug|indacaterol (QAB149)|Capsules for inhalation delivered via SDDPI.
46011201|NCT01202188|Drug|tiotropium|Capsules for inhalation delivered via HandiHaler® device.
46097894|NCT00688350|Behavioral|Behavioral feedback|The medication adherence intervention consists of five components: medication feedback, hypertension feedback, medication-taking skills, habit adjustment, and succinct medication and disease information delivered over an 8-week period.
46097895|NCT02725073|Procedure|Photodynamic therapy|Photolon (Belmedpreparaty, Minsk, Republic of Belarus), was administered intravenously at a dose of 2.5 mg/kg at 3 hours before illumination. After advancing a catheter (7 F inner sheath of a plastic stent delivery catheter [MAJ-1419; Olympus America, Center Valley, Pa., USA]) across the biliary stricture using a 0.035-in guidewire, the cylindrical diffuser is inserted into a catheter at the level of the stricture to be treated. Photoactivation (660 nm with a light dose of 100-150J/cm2, and fluence of 0.8-1W/cm2; UPL- FDT; LEMT Research & Development Private Unitary Enterprise, Minsk, Republic of Belarus) is performed
46011202|NCT01202188|Drug|placebo|Placebo to match capsules for inhalation delivered via SDDPI.
46097896|NCT04002349|Drug|Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)|Detailed in arm descriptions
46097897|NCT04002349|Drug|Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)|Detailed in arm descriptions
45462918|NCT03854383|Drug|Isosorbide mononitrate|Administration of isosorbide mononitrate vaginaly together with misoprostol in induction of labor in postdate women
46097898|NCT04002349|Drug|0.9% natural saline|Detailed in arm descriptions
45462919|NCT03854383|Drug|Misoprostol|Used intravaginally to ripe the cevix in induction of labor
46097899|NCT04152408|Device|FiberSense System|FiberSense system, a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
45462920|NCT01189045|Behavioral|Aerobic Exercise Program|The AEROBIC PROGRAM will be the Experimental arm of this trial. It will be a structured, progressive aerobic training program that will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
45679470|NCT05659576|Drug|Sucralfate|"Sucralfate, 1 gram/10 mL oral suspension By mouth, take 10 mL twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime. Or~Sucralfate 1 gram tablets By mouth, take one (1) tablet mixed in 15-30 mL warm water twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime.~The frequency of sucralfate can be adjusted at anytime at the treating physician's discretion after the patient has started it at twice a day, and the patient may discontinue sucralfate at anytime after RT completion, per physician discretion."
45679471|NCT05659576|Other|Usual Care|Standard supportive care by using opioids.
45679472|NCT05659576|Other|One consent|Patient will sign one consent form.
46097900|NCT02950649|Device|invasive Hemodynamic monitoring via Clearsight/Nexfin Systems from Edwards Lifesciences|Experimental: Hemodynamic Monitored Guided Assesment This group will have the non-invasive hemodynamic monitoring device placed and its data will help guide (intervention) patient's management decisions (experimental).
46011203|NCT01649115|Other|Healthy Lifestyles Passport|The participants will be provided with the Healthy Lifestyles Passport, and with each corresponding page, there will be an activity. Each participant in the Healthy Lifestyles Passport arm will receive the same education.
46097901|NCT02950649|Device|No Hemodynamic Monitored Guided Assesment|Arm: Active Comparator: No Hemodynamic Monitored Guided Assesment This group will have the non-invasive hemodynamic monitoring device placed but its data will NOT be factored for intervention of the patient's management decisions.
45679473|NCT05659576|Other|Two consent|Patient will sign two consent forms.
46011204|NCT02215811|Biological|Mesenchymal stromal cells|
46011205|NCT01580046|Drug|iodixanol|"coronary angiography, 32gI/100ml, 40～60 ml once injection~left ventricular, aortic root and selective coronary angiography, 32gI/100ml, 30～60 ml once injection"
46011206|NCT01580046|Drug|iopromide|coronary angiography, 370mgI/ml(0.769gIopromide/ml),5～8 ml once injection
46097902|NCT05356351|Drug|RC48- ADC|RC48-ADC 2.0 mg/kg D1,Triplizumab 3mg/kg D2，Q2W
46097903|NCT00688428|Drug|Esomeprazole 40mg/ASA 325mg|combination capsule, administered as a single oral dose
46097904|NCT00688428|Drug|Esomeprazole|40mg capsule, administered as a single dose
46011207|NCT02215850|Drug|SLC-0111|
45462921|NCT01189045|Behavioral|Non-aerobic Exercise Program|The BALANCE AND FLEXIBILITY (non-aerobic) PROGRAM will be the Active Comparator arm of this trial. It will be comprised of upper and lower body stretching, or balance activities, yoga- or Tai Chi-style classes. This program will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
45462922|NCT01292707|Behavioral|Control|Standard national training
45462923|NCT01292707|Behavioral|HW|Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial
45462924|NCT01292707|Behavioral|HWC|The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.
45462925|NCT03334422|Drug|Baricitinib|Administered orally
45462926|NCT03334422|Drug|Placebo|Administered orally
45837257|NCT02128230|Drug|Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days -5 & -4; MEL 20 mg/m2/d, T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 100 mg/m2/d, and E 80 mg/m2/d on days -5 & -2; PBSC transplant on day 0.~Optional Bridging with T 50mg/d and D 20 mg on day 1-4 every 21 days until consolidation."
46011208|NCT01683318|Procedure|Thermal Pulsation therapy|
46011209|NCT01201915|Drug|Vismodegib|Vismodegib was supplied in gelatin capsules.
45837258|NCT02128230|Drug|Consolidation - CFZ-TD-PACE|"Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), adriamycin (A), cyclophosphamide (C) and etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter.~Regimen: CFZ 27 mg/m2 on days 1-2; T 200 mg/d, D 40 mg/d, P 7.5 mg/m2/d, A 7.5 mg/m2/d, C 300 mg/m2/d, and E 30 mg/m2/d on days 1-4."
45462927|NCT03854617|Drug|Oral NVB Metronomic|50mg three times weekly on Mondays (or Tuesdays), Wednesdays (or Thursdays) and Friday (or Saturdays). A cycle is a 3 weeks period.
46011210|NCT01649154|Procedure|Total Thyroidectomy with cut and tie technique vs Total Thyroidectomy with Ligasure Small-JAW vs Total Thyroidectomy with Harmonic Focus|
46097905|NCT00688428|Drug|ASA|325mg tablet, administered as a single oral dose
46097906|NCT02724761|Drug|Racemic Epinephrine|1 inhalation of 0.5 mL of 2.25% Nebulized Racemic Epinephrine every 8 hours for 24 hours after surgery
46011211|NCT04542122|Behavioral|Choices and judgements|In the intervention arm, the participant is asked to answer clinical cases in a reverse order from the control group (control has to make moral choices then judge somebody else's choices ; intervention has to judge moral choices first, then make his own)
45679474|NCT05654948|Other|computerised cognitive performance test : MindPulse|In practice, this tool measures the speed at which an individual reacts to the appearance of a simple image on a screen with instructions to react only to certain images. It thus makes it possible to measure the speed of information processing, attention, executive functions and reaction to difficulty
46097907|NCT02724761|Drug|Placebo (for racemic epinephrine)|0.5 mL of normal saline will be prepared in an identical amber syringe as the drug intervention (racemic epinephrine)
45462928|NCT03854617|Drug|Oral NVB Weekly|60mg/m2 weekly for cycle 1 and 80mg/m2 weekly for subsequent cycles in the absence of grade 3 or 4 toxicity. A cycle is a 3 weeks period
46097908|NCT05342311|Diagnostic Test|preoperative ultrasonographic evaluation of right common femoral vein diameter|preoperative ultrasonographic evaluation of right common femoral vein diameter to predict spinal anesthesia-induced hypotension in elderly patients
46097909|NCT00688506|Device|combined sono-electro-magnetic therapy (Sonodyn Medico Star)|twice a day for 10 minutes during 12 weeks
45462929|NCT01186549|Drug|Ephedrine 30microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
46097910|NCT00688506|Device|placebo therapy (Placebo Sonodyn Medico Star)|twice a day for 10 minutes during 12 weeks
45462930|NCT01186549|Drug|lidocaine0.5mg/kg -ephedrine30 micrograms/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
45679475|NCT05654922|Drug|ARINA-1|ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)
45679476|NCT05654922|Other|Standard of care only|Standard 3-therapy immunosuppression regimen and azithromycin
45679477|NCT05653843|Device|Endoscopic clip placement in the gastrointestinal tract.|The placement of a mechanical endoscopic clip in the gastrointestinal tract.
45679478|NCT05649072|Behavioral|Genetic Testing and Counseling|Participants will be asked to collect a saliva sample for hereditary cancer and genetic testing
45679479|NCT05649072|Behavioral|Screening Form|Participant will be answering demographic details
45679480|NCT05646303|Drug|Psilocybin|Psilocybin and psychotherapy
45679481|NCT05646303|Drug|Placebo|Placebo and psychotherapy
46097911|NCT02721095|Other|KCl plus 0.9%NaCl|comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia
46097912|NCT02721095|Other|KCl plus 0.45%NaCl|comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia
46097913|NCT04350190|Drug|Apatinib mesylate tablet|The dose of apatinib mesylate tablets is 250mg, oral, qd, continuous administration, 4 weeks (28 days) as an observation cycle.
45462931|NCT01186549|Drug|ephedrine 70 microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
45462932|NCT01186549|Drug|lidocaine 0.5mg/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
45462933|NCT01186549|Drug|normal saline 2ml|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
45837259|NCT02128230|Drug|Maintenance - CFZ-R(T)-D|"Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) and lenalidomide (R) are capsules and dexamethasone (D) is a pill; all will be taken by mouth.~Regimen: For Cycles 1-12 CFZ 27 mg/m2/wk and D 12 mg/wk on days 1, 8, 15, & 22; lenalidomide (R) 15 mg/d on days 1-21. For Cycles 13-24 CFZ 27 mg/m2/wk and D 12 mg/wk on days 1, 8, 15, & 22. T may be substituted for R at 100 mg/day at the treating physician's discretion."
45462934|NCT01293877|Procedure|Laparoscopy surgery for morbid obesity|The intervention will compare the 2 restrictive procedures one sleeve gastrectomy and gastric plication/
45679482|NCT05638867|Drug|Aspirin + Clopidogrel + Rivaroxaban|Triple antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily, and rivaroxaban 2.5 mg orally twice daily
45679483|NCT05638867|Drug|Aspirin + Clopidogrel|Dual antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily
45462935|NCT03851575|Other|Accelerated treatment of endocarditis|For the three main bacteria species we shorten the duration of antibiotic treatment
45462936|NCT03851575|Other|Usual guideline therapy|Usual guideline therapy
45462937|NCT03854305|Drug|PRV-6527|Treatment
45462938|NCT03854305|Drug|Placebo|Comparator
45679484|NCT05637502|Other|Graded Motor Imagery|Graded Motor Imagery programme consisting on three stages that will be gradually implemented. (i) Implicit Motor Imagery, that will be implemented through a developed app that resembles the Recognize app but adapted for Pelvic Floor disorders, (ii) Explicit Motor Imagery, applied through several sessions of motor imagery assisted through audio recordings and (iii) Graded Exposure, also guided through audio recordings and several practical tasks to perform.
45679485|NCT05637502|Other|Education|Participants will receive a therapeutic educational programme specifically developed for Genito-Pelvic Pain Penetration Disorder. The programme will include content involving Pelvic Floor anatomy, pain-processing and sexuality discussions.
45679486|NCT05634746|Drug|APT-1011|"APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.~Other Names:~fluticasone propionate"
45679487|NCT05634746|Drug|Placebo oral tablet|"Placebo orally disintegrating tablet.~Other Names:~PBO"
45462939|NCT03849703|Behavioral|Full Intervention #1|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Intervention group will receive the coparenting and then romantic relationship curricula. The lessons last between 45-60 minutes and are based on evidence based curricula.
46011212|NCT05401630|Other|Study Procedures|"All participants will answer a series of questionnaires that address a variety of factors such as patient medical history, family history, medication usage, health behaviors, psychological factors, etc. Questionnaires related to symptoms, psychological factors, depression, anxiety, and quality of life will be taken.~All participants will undergo 123I-MIBG SPECT imaging in the morning in a fasting state. Mental Stress Testing will be conducted in the Laboratory in the morning after fasting for at least 4 hours and withdrawal of all vasoactive medications, caffeine, and tobacco 24-48 hours prior to testing. In addition, participants will undergo 1-week of Home Monitoring using a single-use, noninvasive, water-resistant, 7-day ambulatory ECG monitoring, which offers the advantage of direct access to raw data that can be downloaded from the device after use."
46011213|NCT04124770|Other|Movement|Re-positioning of neck
46097914|NCT04350190|Drug|PD-1|The dose of PD - 1 is 200 mg/ time, intravenous injection, q2w, 4 weeks (28 days) for an observation period.
46097915|NCT02624466|Other|CKD progress|CKD progress
45462940|NCT03849703|Behavioral|Full Intervention #2|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Intervention group will receive the romantic relationship and then coparenting curricula. The lessons last between 45-60 minutes and are based on evidence based curricula.
45462941|NCT03849703|Behavioral|Partial Intervention #1|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Partial Intervention group will receive the romantic relationship curriculum and a control curriculum. The lessons last between 45-60 minutes and are based on evidence based curricula.
45462942|NCT03849703|Behavioral|Partial Intervention #2|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Partial Intervention group will receive the coparenting curriculum and a control curriculum. The lessons last between 45-60 minutes and are based on evidence based curricula.
45462943|NCT03851341|Combination Product|Janumet XR tablet 100/1000 mg|To administrate the Janumet XR tablet
45837260|NCT05621538|Behavioral|Realtime fMRI Neurofeedback - Active|fMRI aided reinforcement of craving regulation
45837261|NCT05621538|Device|TMS - Active|rTMS to right dorsolateral prefrontal cortex to reduce craving
46011214|NCT04532879|Device|HygiPrep (HyGIeaCare System)|Controlled gravity-based high-volume colon irrigation
46011215|NCT01649193|Other|Pulmonary rehabilitation|An eight week out-patient based programme consisting of twice weekly supervised exercise and educational sessions
45462944|NCT03851341|Combination Product|GLH1SM tablet 100/1000 mg|To administrate the GLH1SM tablet
45462945|NCT01293955|Drug|JOINS 200mg|1 tablet at each time, 3 times a day
45462946|NCT01293955|Drug|Placebo|placebo of Joins 200mg
45462947|NCT04788108|Drug|Dydrogesterone|Dydrogesterone tablet
45462948|NCT04788108|Drug|Placebo|Placebo tablet
46011216|NCT04318288|Other|Observational|Observational
46011217|NCT05332366|Drug|Delgocitinib cream|Cream for topical application
46011218|NCT05332366|Drug|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
46011219|NCT01179919|Drug|Oseltamivir|Capsule, 75 mg by mouth for 9 doses
46097916|NCT00993577|Other|Stretching exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
45462959|NCT04907695|Device|I View Video Laryngoscope https://www.intersurgical.com/content/files/108253/-1977057700|All intubations will be performed at the direction of the attending clinician. The decision to intubate is based purely on clinical factors by the primary team. The decision to use VL device will be at the direction of the clinical team. No patient will be recruited specific for this procedure.
45462960|NCT03851653|Behavioral|Lifestyle Intervention|Cognitive-behavioural intervention for weight loss and lifestyle change
45462961|NCT02524015|Other|Novel physical therapy|
45462962|NCT02524015|Other|Standard physical therapy|
45462963|NCT01294033|Other|Fractional inspired oxygen (FiO2) 0.21|
45462964|NCT01294033|Other|Fractional inspired oxygen 0.28|Supplemental oxygen
45837262|NCT05621538|Behavioral|Realtime fMRI Neurofeedback - Yoked Sham|Display of feedback from other participant's sessions to serve as a sham for fMRI aided reinforcement of craving regulation
45837263|NCT05621538|Device|TMS - Sham|rTMS using placebo coil (no brain stimulation, emulates other features of active TMS), placed over right dorsolateral prefrontal cortex
45837264|NCT03416244|Drug|Nivolumab|Nivolumab 240 mg IV fixed dose every two weeks
45837265|NCT03416244|Drug|Ipilimumab|Ipilimumab 1mg/kg IV every six weeks (starting in week 7 after safety assessment)
45837266|NCT05560776|Procedure|Endobronchial ultrasound|Two or three passes per lymph node
45837267|NCT05560620|Behavioral|Sleep Deprivation|Participants will be randomized into either the sleep deprivation group or the control group, who will sleep regularly.
45462965|NCT03851419|Diagnostic Test|Diagnosis of (Neuro)cysticercosis|"Serological tests for cysticercosis~Neurological examination and cerebral CT scan for the diagnosis of neurocysticercosis~Stool testing for T. solium"
46011220|NCT01649310|Other|whole body vibration|Exercises on the platform will be made in semi-squat position, static. In the first month training will be held for 10 minutes for the exercises on the platform, 30 seconds of vibration of low intensity, interspersed with rest 60 seconds while standing beside the platform. In the second month training will be held for 15 minutes, lasting 60 seconds of vibration and 30 seconds of rest in standing beside the platform. For the first two weeks training will have low intensity and the last two weeks training will have higher vibration. In the third month, training will be held for 20 minutes, 60 seconds of vibration and 30 seconds of rest while standing beside the platform. The intensity of the vibration will be high.
46097917|NCT00993577|Device|Stretching exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
46097918|NCT00993577|Device|Exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
45462966|NCT03849547|Other|App Balance training|"Training specially designed for balance ability of chronic ankle instability groups.~Guidance through smartphone application as home program."
46097919|NCT02721173|Drug|Tazarotene 0.1% gel plus clindamycin 1% gel|Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and tazarotene will be applied 5-10 minutes later.
46097920|NCT02721173|Drug|Adapalene 0.1% gel plus clindamycin 1% gel|Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and adapalene will be applied 5-10 minutes later.
45462967|NCT03849547|Other|Home Balance training|"Training specially designed for balance ability of chronic ankle instability groups.~Follow the usual home program provided in clinics."
45462968|NCT01191229|Device|Tecnis one-piece MF IOL|25 patients to be implanted after cataract surgery
45462969|NCT01191229|Device|Crystalens AO|25 patients that are previously implanted
45462970|NCT01294111|Behavioral|Tai Chi training|Three groups with 15 participants each will complete a 60 minutes tai chi training programme twice-weekly for 16 weeks. The programme is worked out by an expert in Chinese traditional medicine to suit elderly people with chronic heart failure, and the classes are led by experienced leaders.
45462971|NCT03362190|Drug|Zimura|Zimura in combination with Lucentis
45462972|NCT03362190|Drug|Lucentis|Zimura in combination with Lucentis
45679488|NCT05634746|Procedure|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus
45679489|NCT05630976|Drug|Isavuconazole|This is a single arm study, all enrolled participants will receive the study intervention.
45837268|NCT05560620|Other|Caffeine|On Day 2 morning, after the sleep deprivation or sleeping, participants will be randomized into receiving caffeinated or de-caffeinated coffee, which they will be blinded to.
46011221|NCT01201798|Drug|Difluprednate 0.05% ophthalmic emulsion|1 drop in study eye, 4 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
46011222|NCT01201798|Drug|Prednisolone acetate 1.0% ophthalmic suspension|1 drop in study eye, 8 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
45462973|NCT01186783|Drug|ivabradine|"Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or percutaneous endoscopic gastrostomy-probe) of ivabradine for 4 days.~Day 1 and 2:~5,0 mg ivabradine b.i.d. if heart rate ≥60bpm (acute renal failure: ≥70bpm)~Day 3 and 4:~5,0 mg ivabradine b.i.d. if 60bpm≥heart rate<90bpm (acute renal failure: 70bpm≥heart rate <90bpm~7,5 mg ivabradine b.i.d. if heart rate ≥90bpm"
45837269|NCT05560620|Other|No Caffeine|De-caffeinated coffee
46011223|NCT04539353|Other|Heart Rate Variability|Heart Rate Variability will be measured with a Polar device.
46011224|NCT04539353|Other|Pain intensity|Pain Intensity will be measured with a Numeric Rating Scale and Visual Analogue Scale
46011225|NCT02887456|Drug|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
45462974|NCT05193409|Drug|225 mg BNC210|225 mg BNC210
45462975|NCT05193409|Drug|675 mg BNC210|675 mg BNC210
45462976|NCT05193409|Drug|Placebo|Placebo
45462977|NCT03945929|Behavioral|Distraction|"Distraction-1 Group: Cards containing approximately six optical illusion pictures were shown to the patients and as a method of distraction during the PIC insertion procedure they were asked what they saw in these cards.~Distraction-2 Group: Underwater 3D audial videos were played with visual reality (VR) goggles during PIC insertion until the procedure was completed."
46011226|NCT02887456|Drug|Endodontic treatment using MTA paste|Endodontic treatment using MTA paste
46011227|NCT01201759|Drug|Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2
45462978|NCT03945695|Procedure|"Pneumatic Vitreolysis in combination with Drinking-Bird-Technique"|"Appropriate anesthesia and antiseptic preparation of the surgical field~Prophylactic paracentesis of the anterior chamber~One intravitreal injection of 0.2 to 0.3 ml of filtered sulfur hexafluoride gas (SF6) into the test eye Remark: Intraocular pressure of the examined eye is to be controlled before the intervention and kept at an appropriate level after paracentesis by manual application of pressure.~Patients are instructed to avoid supine position and to lie on one side or the abdomen during sleep until complete resorption of intraocular gas occured. In this period they should bend over several times during the day up to an angle of 90º or as much as possible, resembling the movement of a bird drinking water. (Hence the name drinking-bird-technique.)"
45473966|NCT03374644|Device|SentriTM ETCO2 adult nasal cannula|Sentri nasal cannula is the device which designed to sample exhaled ETCO2 in non-intubated patients during the administration of supplementary oxygen. By delivering oxygen through one prong and sampling exhaled gas from the other prong, the nasal cannula can provide end tidal values comparable to those achieved with intubated patients. It is fitted to the patients as same manner as conventional nasal cannula. Furthermore, it consists of curved prong to improve the anatomical fit.
45679490|NCT05623657|Other|Trunk Stabilization Exercise Training Group|The adolescents in this group who are involved in archery sports will be given 40 minutes of exercise training 2 days a week for 8 weeks. Exercise training will be applied as 5-10 minutes warm-up, 15-30 minutes trunk stabilization exercises, 5-10 minutes cooling down, and stretching exercises. The number of repetitions and difficulty levels of the exercises will gradually increase in the 3rd and 6th weeks.
45837270|NCT04388124|Drug|Bosentan|vascular assesment Clinical exam urinary analysis blood results natriuresis and measured glomerular filtration rate
45837271|NCT04388124|Drug|Placebo|Placebo
45837272|NCT05560386|Behavioral|Text messaging|text messaging content to support diabetes prevention.
45837273|NCT05560386|Behavioral|Virtual workshop|virtual workshop content to support diabetes prevention.
45837274|NCT05560152|Drug|Yiqihuayu Decotion|Per os, twice a day, for 7 days.
45837275|NCT02130258|Device|Quantitative Sensory Testing (QST)|Subjects will undergo hot and cold temperature testing using the QST device at two points: 1) Before ESI and 2) after ESI.
45837276|NCT02130258|Procedure|Epidural Steroid Injection (ESI)|Subjects will receive an ESI by their clinical physician as part of their clinical treatment. This procedure is not given as part of the research study.
45837277|NCT03172416|Drug|Oxaliplatin|This study started as a prospective, single arm phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC using oxaliplatin in patients with peritoneal carcinomatosis.
45837278|NCT03172416|Drug|Oxaliplatin & Nivolumab|PIPAC oxaliplatin 90mg/m2 has been well tolerated in our Cohort 1 study. Hence, we added a second cohort (Cohort 2) which combines PIPAC oxaliplatin at 90mg/m2 every 6 weeks with IV nivolumab at 240mg every 2 weeks to evaluate the safety and tolerability of combination therapy.
45837279|NCT03115788|Other|Heat induced pain|For the heat induced thermal pain, the research nurse will train the subject to estimate pain quantitatively using a 2 cm 2 Peltier controlled thermode (TSA®) applied to the skin of the arm. Typically, the subject is exposed to temperatures between 41° and 49° C using a random staircase method. After the volunteer learns to qualitatively estimate the thermal pain, pain will be established by heating the the leg with a 4 cm2 Peltier controlled thermode (TSA®) for 90 seconds with the probe clamped at a thermal intensity of 47°C.
45837280|NCT03115788|Other|Cold Induced Pain|Cold pain will be induced by placing a foot in a container of circulating water maintained at 10°C for 90 seconds (n=20). Half (n=20) of the subjects will have the foot placed in body temperature water of 38°C.
46097921|NCT00713986|Procedure|Water 2mL PO 2 minutes prior to intra-muscular injection|Sterile Water 2mL PO - single dose
45837281|NCT03115788|Device|iPad|
45837282|NCT03033420|Device|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
45837283|NCT01798212|Procedure|endoscopic full thickness plication|
45837284|NCT05560074|Device|Buzzy|In the Buzzy® group, 30 seconds before the blood collection procedure and during the procedure, the Buzzy® device ist placed 3-5 cm above the area from where the blood would be taken by the PhD qualified nurse researcher
46097922|NCT00713986|Procedure|skin-to-skin contact|neonates will receive skin-to-skin contact beginning 2 minutes before the intra-muscular injection and stopping 2 minutes afterwards.
45462979|NCT01292785|Drug|Hormones|"FtM will receive~1000mg testosterone undecanoate every 12 weeks (Nebido® 4ml i.m.), or alternatively 50mg testosterone transdermally (Testogel® 5g-bag per day) and~if menstruation still occurs, additionally either lynestrenol Orgametril® (2-3 tablets/day) or in some cases 0.075mg desogestrel (Cerazette®, 1 tablet/day).~MtF will receive~50mg cyproterone acetate daily (Androcur®)~estradiol 100µg transdermal therapeutic system (TTS) twice a week (Estradot®, Estramon®), especially if subjects age is > 40 years, or p.o. estradiol 2x2mg (Estrofem®) if subjects age is < 40 years; alternatively estradiol 0,75-1,5mg (1-2 hubs) transdermally (Estrogel-Gel®) and~2,5mg alpha-5-reductase-inhibitor every 2nd day (Finasterid Actavis/ Arcana/ Aurobindo®) in case of extensive hair loss."
45462980|NCT02323126|Drug|EGF816|EGF816 150 mg once daily (QD) administered orally as a capsule
45462981|NCT02323126|Drug|INC280|INC280 400 mg twice daily (BID) administered orally as a tablet
45462982|NCT02323126|Drug|Nivolumab|Nivolumab 3 mg/kg every 2 weeks (Q2W) administered by intravenous infusion
45462983|NCT01291459|Drug|MVC/RAL/FTC/TDF followed by Maraviroc/Raltegravir|MVC/RAL/FTC/TDF 24W followed by MVC/RAL until W48.
45679491|NCT05623657|Other|Game Based Exercise Program Group|At least 4 different games selected from Xbox 360 Kinect® games will be applied to adolescents practicing archery sports in this group for a total of 40 minutes with the physiotherapist. The games will be selected from games that include movement patterns similar to the exercises of the trunk stabilization exercise group. Game-based exercise training is planned to be performed twice a week for a total of 8 weeks.
45679492|NCT05622383|Other|aromatherapy|aromatherapy,
45679493|NCT05622383|Other|music concert|music concert
45679494|NCT05622383|Other|aromatherapy and music concert,|aromatherapy and music concert,
45837285|NCT05560074|Other|DistrACTION® Cards|In the DistrACTION® Cards group, picture cards containing various hidden pictures and patterns are used during blood collection by the PhD qualified nurse researcher
45837286|NCT05559996|Device|Injectable form of multifractional intercalated cross-linked hyaluronic acid (Armonia®, Regenyal, Italy)|2 mL of Armonia was injected into the vaginal wall with a standardized injection technique called Cannulated Intravaginal Injection Technique®. In this technique, Armonia® was injected as drops at 40 different points on the entire vaginal wall using 8 different entry points
45837287|NCT05559840|Device|S-Condom Uterine Tamponade|The condom catheter will be inflated with air
45837288|NCT05559840|Device|Traditional condom catheter|The condom catheter will be inflated with saline following national protocol
45837289|NCT02812212|Device|ultrasonography|bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.
45837290|NCT02812212|Device|diuretic renography|diuretic renography to measure the cortical transit time.
45837291|NCT02601378|Drug|LXS196|LXS196 as a single agent
45837292|NCT02601378|Drug|LXS196 and HDM201|LXS196 in combination with HDM201
46011228|NCT01201759|Drug|Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2.
46011229|NCT04315597|Drug|Laif® 900, BAY98-7108|1 x daily, 1 tablet, 900 mg
46011230|NCT04315597|Drug|Placebo|1 x daily, 1 tablet, 900 mg
46011231|NCT01683396|Drug|Placebo|Solution for subcutaneous injection
46011232|NCT01683396|Drug|gevokizumab|Solution for subcutaneous injection
46011233|NCT04532840|Device|cryotherapy (Gymna Cryoflow ICE-CT)|Cryotherapy (also called cryoablation) method was produced by James Arnot in England in 1945 to reduce the size of cancerous cells based on the theory that cold blood cells destroy the cells. Campbell White of New York City used cryotherapy as the first dermatological indication in early-stage epithelioma patients in 1890. Later in 1907, Whitehouse described the use of this method in diferent diseases such as pigmented nevus and lupus. In addition, he has published a case series of skin cancers in different face regions.
46097923|NCT00713986|Procedure|Glucose 25% 2 mL PO 2 minutes prior to injection|Glucose 25% 2mL PO - single dose
46097924|NCT00713986|Procedure|neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards.|neonates will receive 2 mL of glucose 25% PO (single dose) 2 minutes prior to the acute painful procedure. Skin-to-skin contact will start 2 minutes after the intra-muscular injection and will stop 2 minutes afterwards.
46097925|NCT00675324|Drug|Laxabon|Laxabon 4 litres, starting the day (e.m.) before the colonoscopy
46097926|NCT00675324|Dietary Supplement|Fresubin Energy drink|30 kcal/kg*day five days before colonoscopy
46097927|NCT05155813|Device|WatchPAT|FDA-approved portable home sleep testing device worn on the wrist.
46097928|NCT00993733|Procedure|Continuous veno-venous haemodiafiltration|Dialysis procedure administrated to the patients with acute renal failure
45462984|NCT01107587|Biological|GSK Biologicals' human rotavirus vaccine 444563|Oral, two doses.
45462985|NCT01107587|Biological|Placebo|Oral, two doses.
45473967|NCT03207243|Drug|GSK3772847|GSK3772847 10 mg/kg will be administered as IV infusion once every 4 weeks to randomized subjects.
45462986|NCT01191385|Drug|Any treatment for unresectable HCC as chosen by the physician|Only those patient are allowed to be enrolled that receive any HCC treatment for unresectable HCC as chosen by the physician except sorafenib. During the course of the study, each treatment is allowed.
46011234|NCT04532840|Other|Exercising, Positioning and splinting, Pressure Therapy and Massage|Exercising, Positioning and splinting, Pressure Therapy and Massage
46097929|NCT00692640|Drug|XL147 (SAR245408)|Gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing for 21 days/7 days off
45462987|NCT03473704|Behavioral|Treatment group (TG)|The Treatment group (TG) will receive the web treatment, which consists of 9 weekly sessions.
45462988|NCT03473704|Behavioral|Control group (CG)|For ethical reasons, the CG will receive the web treatment once the TG intervention has been completed (as long as it continues to meet the conditions of the study).
45462989|NCT02056054|Other|Pediatric transplant subject with d-AIH|30 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws will depend on the patient's pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.
45462990|NCT02056054|Other|Pediatric transplant subject with acute rejection|Recipients with acute rejection will have blood drawn at time of diagnosis before treatment for rejection is instituted.
45462991|NCT02056054|Other|Pediatric transplant subject with chronic rejection|Recipients with chronic rejection will have blood drawn either at diagnosis before treatment is instituted or for those with ongoing chronic rejection at the time of enrollment.
45473968|NCT03207243|Drug|Placebo|Placebo sterile normal saline will be administered as IV infusion once every 4 weeks to randomized subjects.
45473969|NCT03207243|Drug|Fluticasone propionate/salmeterol|FP/Sal 500/50 mcg will be administered via inhalation route twice daily to all subjects.
45473970|NCT03207243|Drug|Fluticasone propionate|FP 500, 250, 100 or 50 mcg will be administered via inhalation route twice daily to all subjects.
45679495|NCT05613387|Drug|ZP8396|"Part 1: Participants will receive 6 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort.~Part 2: Participants will receive 16 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort. Dose up-titration will be used."
45679496|NCT05613387|Drug|Drug: Placebo (ZP8396)|"Part 1: Participants will receive 6 once-weekly doses of placebo given subcutaneously (s.c., under the skin).~Part 2: Participants will receive 16 once-weekly doses of placebo given subcutaneously (s.c., under the skin)."
46011235|NCT01649349|Device|two-piece nasogastric tube|one week period
46011236|NCT04538846|Other|Culinary art therapy|Culinary art therapy is a novel approach which broadly perceives food and cooking as enabling participants to explore needs, patterns and relationships and facilitate therapeutic processes.
46011237|NCT01683435|Other|HBA binding assay|HBA binding assay will be preformed on the discarded portion of semen analysis used for IVF.
46011238|NCT04532684|Drug|Duloxetine|
46011239|NCT04532684|Drug|Pregabalin|
46011240|NCT01683474|Device|Venus MedTech Aortic Valve Prosthesis|Percutaneous implantation of aortic valve of Venus-A
46097930|NCT00692640|Drug|Erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
46097931|NCT05150717|Drug|[14C]-Jaktinib|Subjects will receive single dose of orally [14C]-Jaktinib on Day 1.
46097932|NCT04019080|Other|Anti-fibrostic drugs|The real-Life use of anti-fibrotic drugs in patients with idiopathic pulmonary fibrosis in Sweden
46097933|NCT00993811|Device|Shang Ring circumcision|novel device for adult male circumcision
46097934|NCT00692718|Drug|Epadel, Eicosapentaenoic acid|Epadel 900mg, 2 times a day, during hospitalization
46097935|NCT02724527|Drug|Cavosonstat|CFTR modulator that stabilizes CFTR
46097936|NCT02724527|Drug|Placebo|Matched Placebo capsule
46097937|NCT04137432|Drug|Oxytocin nasal spray|Intranasal administration of 24 international units oxytocin.
46097938|NCT04137432|Drug|Placebo|The placebo nasal sprays contains identical ingredients except for the peptide itself.
46097939|NCT00885170|Drug|Odanacatib|Odanacatib 50 mg tablets once weekly for 24 months
46097940|NCT00885170|Drug|Placebo|Placebo to odanacatib 50 mg tablets once weekly for 24 months
46011241|NCT04538768|Procedure|Mesh augmentation|P4HB retromuscular mesh placement for prevention of lateral incisional hernia after stomal closure
46011242|NCT04538768|Procedure|Direct suture|direct fascia suture
46097941|NCT00885170|Dietary Supplement|Vitamin D3|Vitamin D3, two 2800 IU tablets, taken once weekly for 24 months
46097942|NCT00885170|Dietary Supplement|Calcium|Participants will receive calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
46097943|NCT05342467|Drug|Gemeprost 1 Mg Vaginal Pessary|Intravaginal gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours
46097944|NCT05342467|Drug|Dinoprostone 3 mg|Intravaginal dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours
46011243|NCT01683513|Drug|GnRh agonist +1500E hCG|ovulation induction with GnRh agonist and 1500E hCG one hour after egg retrieval
46011244|NCT01649466|Drug|LAF237|Vildagliptin will be used as commercially available tablets of 50mg.
45837293|NCT02434848|Drug|Engerix B|"Engerix B 20 micrograms/1ml Licensee: GlaxoSmithKline UK Intra-muscular~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Shelf life and storage The product must be kept refrigerated (2°C - 8°C). Prescriptions will be written and dispensed from pharmacy on the day of consent, screening and vaccination. The shelf life is 3 years."
45679497|NCT05607407|Drug|Methimazole|Starting dose: Methimazole 15 mg/d. Six participants will receive this dose. If they achieve a 10% increase in peripheral blood H2S concentrations, an additional 13 participants will receive this dose to accrue a total of 19 participants for which a preliminary estimate of PFS6 can be calculated. If the first 6 participants do not achieve a 10% increase in peripheral blood H2S concentrations, the dose will be increased to the second and final dose level of 25 mg/d at which 19 participants will be treated.
46011245|NCT01649466|Drug|Protaphane|Protaphane will be used as commercially available injection pens
46011246|NCT01200589|Biological|Ofatumumab|liquid concentrate for solution for infusion in glass vials containing 50 mL of solution at a concentration of 20mg/ml to provide 1000 mg per vial.
45679498|NCT05607407|Procedure|Recurrent Glioblastoma Surgical Resection|The purpose of resection is to remove as much tumor as possible to alleviate mass effect and to obtain brain tissue for experimental analysis.
46011247|NCT01200589|Biological|Rituximab|sourced locally from commercial stock
46011248|NCT01200589|Biological|Ofatumumab|Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.
46011249|NCT01200589|Biological|Rituximab|Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.
46011250|NCT04532762|Device|nasal spray|Application of a nasal spray
46011251|NCT01683552|Drug|Aprepitant|125 mg on day 1; 80 mg on day 3; 80 mg on day 5
46011252|NCT01683552|Drug|Prednisone|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die),
45679499|NCT05607407|Diagnostic Test|Pharmacodynamic Assays|Pharmacodynamic assays are intended to investigate drug and downstream drug-induced effects.
45679500|NCT05603520|Other|Collection of Clinical Data|prospectively and systematically collection of clinical research data from apparently healthy volunteers and patients with aortic stenosis and aneurysms
45679501|NCT05603026|Device|Self-expanding valve (Medtronic Evolut FX)|Bioprothesis Medtronic Evolut FX supra-annular self-expanding valve
46011253|NCT01683552|Drug|Fexofenadine|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die)
46011254|NCT04532723|Device|ExoAtlet II|ExoAtlet II is the second version of an exoskeleton that ExoAtlet has manufactured
46011255|NCT01200511|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
46011256|NCT04532567|Drug|GLPG1205|GLPG1205 film-coated tablets
46011257|NCT04532567|Drug|Placebo|placebo film-coated tablets
46011258|NCT04532606|Drug|Remimazolam|Remimazolam is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.
45473971|NCT01285271|Drug|Xenon|gaseous anesthetic, dosage: 50% (v/v) in 50% oxygen, continuous application before the start and after the end of extracorporal circulation
45473972|NCT01285271|Drug|Sevoflurane|inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application before the start and after the end of extracorporal circulation
45679502|NCT05603026|Device|Balloon-expanding valve (Edwards Sapien 3 Ultra)|Bioprosthesis Edwards Sapien 3 Ultra valve
45679503|NCT05600686|Drug|Cyclophosphamide|Given IV
45679504|NCT05600686|Drug|Doxorubicin|Given IV
46011259|NCT04532606|Drug|Propofol|Propofol is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane is provided when considered necessary.
46011260|NCT04528368|Biological|Convalescent plasma|The intervention group will receive 400 mL of convalescent plasma with a SARS-CoV-2 antispike antibody titer with a dilution ≥ 1: 320.
46097945|NCT02720783|Drug|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary
46097946|NCT02720783|Drug|Placebo plus Econazole nitrate 150 mg vaginal pessary|
46097947|NCT02720783|Drug|Placebo plus Benzydamine HCl 6 mg vaginal pessary|
46097948|NCT02720783|Drug|Placebo vaginal pessary|
45679505|NCT05600686|Drug|Etoposide|Given IV
45679506|NCT05600686|Biological|Loncastuximab Tesirine|Given IV
45679507|NCT05600686|Drug|Prednisone|Given PO
45679508|NCT05600686|Biological|Rituximab|Given IV
46011261|NCT01683591|Procedure|High-resolution impedance manometry test|The test was performed as general guideline for high-resolution impedance manometry test. The parameter was obtained and analyzed using the Chicago classification for the liquid swallows with Takasaki's modification for pharyngeal function monitoring. Swallowing pattern and aspiration risk were defined using real-time assessment of high-resolution impedance manometry test.
46011262|NCT02216981|Behavioral|Cognitive Behavioural Therapy (CBT)|
46011263|NCT01683708|Dietary Supplement|Symbiotic therapy|Patients randomized into the Symbiotic group received Prebiotic® in a dose of one sachet twice a day for at least 1 week preoperatively. Postoperatively the medication was reintroduced as tolerated, and continued until discharge from hospital. One 4,5 gr sachet of Prebiotic® contains at least 1010 living Bifidobacterium bifidum, 1010 living Streptococcus Thermophilus, 1010 living Streptococcus Salivarius, 3 109 Lactobacillus Acidophilus, 1010 living Lactobacillus Casei, 1010 living Lactobacillus bulgaricus and galactooligosaccharides (4,5 gr).
46011264|NCT01649544|Device|EPICOR|Intraoperatively, in addition to the usual gesture, it will be conducted a systematic exclusion-ligation of the left atrium and the establishment of electrodes atrial and ventricular pacing. The right pulmonary veins are isolated by dissection of the inter-atrial groove and application of the probe by biting on the atrial tissue, the procedure is identical on the left after dissection of the area between the left pulmonary artery and pulmonary veins. The use of ultrasound application will require 10 minutes to around the pulmonary veins using a multi-electrode probe set to deliver an output pulse from 15 to 100 Watts at a frequency from 3.5 to 4.6 MHz. Using EPICOR extends the operating time of 15 minutes.
46011265|NCT01649544|Drug|Amiodarone|
46011266|NCT04538729|Behavioral|Acne Vulgaris|Alternative medicine and complementary therapies that acne vulgaris patients apply without informing the doctor, how they learn these techniques, what make them use these techniques for their illness
46011267|NCT04528290|Drug|Ozanimod|Ozanimod capsule formulation of 0.92mg
46011268|NCT04528290|Drug|Ozanimod|Ozanimod, granule formulation of 0.92mg
46011269|NCT04538690|Other|Shoulder Exercises|Exercises consist of shoulder range of motion, releasing exercises, strength training, stretching.
45837294|NCT02434848|Drug|Fendrix|"Fendrix suspension for injection GlaxoSmithKline UK~Route of Administration, dose regimen:~Intra-muscular Dose: 0.5ml (20mcg of Hepatitis B Surface Antigen) per vaccination at baseline and weeks 4, 8 and 24.~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Packaging and labeling The vaccine will have clinical trial labeling. Shelf-life and storage The product must be kept refrigerated (2°C - 8°C).~The shelf life is 3 years."
45473973|NCT03982069|Biological|FluMist live attenuated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.
45473974|NCT03982069|Biological|Flucelvax inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.
45679509|NCT05600686|Drug|Vincristine|Given IV
45679510|NCT05600309|Biological|favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
45679511|NCT05600309|Drug|regorafenib|Oral
45679512|NCT05600309|Drug|TAS-102|Oral
45679513|NCT05597345|Drug|Selinexor|Low-dose Selinexor for the Treatment of Intermediate to High-Risk Smoldering Multiple Myeloma
46011270|NCT04538690|Other|Electrotherapy|TENS, US
46011271|NCT01179334|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid oral for 12 weeks.
46011272|NCT01179334|Drug|Placebo|Placebo for 12 weeks
46011273|NCT01179334|Drug|Sildenafil|Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
46011274|NCT01649583|Device|Jaw Dynasplint System|Patients on the intervention arm will wear the Jaw Dynasplint® System for 30 minutes, 3 times per day each day during the cancer treatment period and for the first 3 months after primary or adjuvant based-radiation treatment (recovery period) is completed. Patients will maintain a daily patient log indicating the amount of time they used the Jaw Dynasplint® System.
46011275|NCT04532450|Device|Branched / fenestrated aortic stent graft|Endovascular repair of an aortic aneurysm with a branched/fenestrated stent graft to revascularise all visceral arteries together with exclusion of the aortic aneurysm.
46011276|NCT02886481|Device|perioperative monitoring|
46097949|NCT00688584|Behavioral|Pamphlet-based personalized alcohol feedback (PAF)|participants in this condition will be mailed their respective pamphlets
46097950|NCT00688584|Behavioral|control pamphlet condition|The goal is to test if it is the specific content of the pamphlet that leads to the change or just the receipt of any pamphlet.
46097951|NCT00714064|Biological|23vPPV, dTpa (Pneumovax, Boostrix)|Group A will receive 23vPPV during 3rd trimester and dTpa at delivery
45679514|NCT05585034|Biological|XmAb®808|Monoclonal bispecific antibody
45679515|NCT05585034|Biological|Keytruda® (pembrolizumab)|Monoclonal antibody
45679516|NCT05581108|Dietary Supplement|Juice PLUS+® OMEGA|Daily dose of total Omega blend: 925 mg (2 capsules)
45679517|NCT05581108|Dietary Supplement|Placebo|matched placebo (2 capsules)
45679518|NCT05581082|Other|Pragmatic, exploratory study of Precision Medicine|This pragmatic, exploratory study consists of individuals with frailty who are referred from routine care to a physical therapy-based strengthening intervention. This specific study will collect ancillary measures to evaluate our outcomes. The study staff will not be conducting any interventions themselves - the physical therapy program is as per usual care.
46011277|NCT02886520|Device|PVDF transobturator tape|
46011278|NCT02886520|Device|Polypropylene transobturator tape|
46011279|NCT01649622|Drug|Bendamustine|75 mg/m2 by vein twice daily for four days (Days 1-4). Cycles may be repeated every 3 to 10 weeks based on leukemia response for up to 12 courses.
46011280|NCT04538300|Diagnostic Test|Abramowitz Emesis Score|Postoperative vomiting was evaluated by Abramowitz emesis score in recovery room.
46011281|NCT04538300|Diagnostic Test|Degree of nausea|Degree of postoperative nausea was evaluated.
45462992|NCT02056054|Other|Adult non-transplant patients with auto-immune hepatitis|"75 ml of blood will be collected during periods of disease quiescence and activity in non transplanted subjects with AIH who are enrolled. Research blood draws will be drawn along with clinical blood draws.~The exact number of blood draws for each subject will depend on his or her pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.~Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.~In the event that any enrolled subject undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media."
46011282|NCT04538300|Diagnostic Test|Observer's Assessment of Alertness/Sedation Scale|Patients' sufficient wakefulness was evaluated by Observer's Assessment of Alertness/Sedation scale in the recovery unit.
46011283|NCT04538300|Diagnostic Test|Patient Satisfaction|Patient satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)
46011284|NCT04538300|Diagnostic Test|Surgeon Satisfaction|Surgeon satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)
46011285|NCT04538300|Other|Chewing Peppermint gum|Peppermint gum was chewed for 15 minutes in patients with sufficient wakefullness.
46097952|NCT00714064|Biological|23vPPV, dTpa (Pneumovax, Boostrix)|Group B will receive 23vPPV at delivery and dTpa 7 months following delivery
46011286|NCT02886676|Drug|Spirulina capsules|Spirulina capsules 2gm daily for 1 month
46011287|NCT04315753|Other|LDCT (Low Dose CT)|validate the role of non-invasive molecular and cellular biomarkers and combined radiomic signature, as complementary tools to assist early detection of lung cancer by LDCT using bioinformatic techniques for the integration of the results
46011288|NCT02886598|Drug|degarelix|
46011289|NCT01683747|Drug|Tranexamic Acid|
46011290|NCT01683747|Drug|Control Intervention (Carrier fluid only)|
46011291|NCT04532411|Other|Personal Protective Testing Booth|Health personnel who utilize the Hexapod will remain in the booth and utilize durable gloves attached to ports through a plexiglass wall in order to administer a nasal swab for SARS-CoV-2 (COVID-19) testing. Patient escorts and housekeeping/sanitation staff perform additional tasks outside of the booth such as escorting the patient to the correct testing bay and dropping off testing vials and printed information, collect samples and deposit in the appropriate location after testing is complete, and sanitizing the patient bay before a subsequent patient is tested there.
46011292|NCT04538027|Procedure|Lumbar Microdiscectomy at 6 weeks of symptoms|Microscope assisted lumbar discectomy done at 6 weeks of starting symptoms
46011293|NCT04538027|Procedure|Lumbar Microdiscectomy at 3 months of symptoms|Microscope assisted lumbar discectomy done at 3 months of starting symptoms
46011294|NCT04538027|Procedure|Lumbar Microdiscectomy at 6 months of symptoms|Microscope assisted lumbar discectomy done at 6 months of starting symptoms
46011295|NCT01178671|Drug|Mirtazapine|Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
46097953|NCT00714064|Biological|23vPPV, dTpa (Pneumovax, Boostrix)|Group C will receive dTpa at delivery and 23vPPV 7 months following delivery
46097954|NCT05339503|Other|enamel microabrasion|It is a non-restorative, conservative treatment that works both chemically and mechanically to remove up to 0.2 mm of affected enamel per application. Pumice either mixed with 18% hydrochloric acid or 5.25% sodium hypochlorite was used to remove fluorosis stains.
46097955|NCT02720705|Drug|Dexmedetomidine|oral dexmedetomidine
46011296|NCT01178671|Drug|Sertraline|Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
46011297|NCT01178671|Other|Sugar pill|Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks
46011298|NCT02886637|Other|None intervention|
46097956|NCT02720705|Drug|saline|2ml 0.9% saline administered orally half an hour before induction of anesthesia
46097957|NCT02625792|Drug|Endo-Clot(TM)|After patients treated with ESD, Hemostatic power was applied on the post-resection surface by Endo-Clot™ system. And treated with proton pump inhibitor as usual.
45462993|NCT02056054|Other|Adult non-transplant subjects with chronic hepatitis C virus|"For enrolled patients with chronic hepatitis C, 75 ml of blood will be collected before the start of treatment. This will be a onetime blood draw prior to treatment. Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.~In the event that any enrolled patient undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media."
45462994|NCT02056054|Other|Pediatric control subjects|2 tablespoons of blood (30 ml) will be collected at each blood draw over a 2-year period. . The maximum amount of blood draws will be 3 however there will be no more than 1 blood draw within an 8-week period.
46011299|NCT04532216|Procedure|Arthroscopic-Assisted Acromioclavicular Joint Reconstruction Using the TightRope Device|Arthroscopic-assisted AC joint reconstruction with the TightRope device with allograft augmentation and with the patient in the lateral decubitus position is a method of restoring joint stability
45679519|NCT05579990|Behavioral|Meal Delivery|10 home-delivered meals per week provided by a local meal delivery company supplemented by remote weekly behavioral support with study staff.
45679520|NCT05577754|Drug|Alpelisib (BYL719)|Administration during open label and double-blind period of group B: alpelisib will be taken once a day each day over 24 mois During open label period of group A: alpelisib will be taken once a day each day over 24 months
45679521|NCT05577754|Drug|Matching placebo|During double-blind period of group A: matching placebo will be taken once a day each day over 6 months
45837295|NCT05559684|Procedure|Erector spinae plane block|Under strict aseptic precautions, The T3 spinous process will be located. A high-frequency 12 MHz linear US transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process. Three muscles; trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process. Using in-plane approach a 25 G needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle. Correct needle tip location will be confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread (i.e., hydrodissection) in the fascial plane between the erector spinae muscle and the transverse process. Then, 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) will be injected and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process.
46011300|NCT04532216|Procedure|Traditional surgery|Tendon transfer
46097958|NCT04019236|Other|visual analogue scale (VAS),Respiratory distress observational scale (RDOS) and other Nursing care|Distressed patient will be assessed by visual analogue scale(VAS) or respiratory distress observational scale.Nursing interventions will be done according to its causes as giving supplemental O2 therapy, pharmacologic therapy ,initiating positive pressure ventilation or change Ventilator settings (TV, PEEP, Inspiratory pressure ), Improve inspiratory muscle function by Nutrition, positioning or by minimizing use of steroids , clearing airway by Suctioning, Check O2 saturation level frequently and maintain O2 saturation between 95-100%, ,Raising the HOB (Head of the Bed), high Fowler's ,Give pain medications as prescribed or diuretics as ordered and If thick secretions increase oral fluids intake
46097959|NCT02720861|Genetic|DNA sequencing|withdraw 3m blood from vein only once during the whole design to analyse on DNA sequencing on RNF213 rs112735431 Gene
46097960|NCT00692796|Other|Pulmonary rehabilitation|Pulmonary rehabilitation is a multi-disciplinary program that includes exercise training, disease education, psychosocial education (e.g., stress management, coping with chronic illness) and nutrition education.
45679522|NCT05577754|Procedure|Optional lumbar puncture|After 6 months or 24 months of treatment with Alpelisib
45679523|NCT05570955|Behavioral|Text reminder|weekly text to remind use of drug
46011301|NCT01649700|Biological|autologous adipose-derived mesenchymal stem cells|Patients will receive five infusions, one month apart, each comprising 5-7x10^7 cells of autologous adipose-derived mesenchymal stem cells.
46011302|NCT04532060|Drug|Nystatin|
46011303|NCT04532060|Procedure|Antimicrobial Photodynamic Therapy|
46097961|NCT00726076|Behavioral|WebEase|"Computer-based epilepsy self-management program~The Treatment Group received the WebEase Intervention immediately after completing the Baseline Assessment"
46097962|NCT00726076|Behavioral|WebEase|Control Group also received the WebEase Intervention. However, Control Group participants began the Intervention 6 weeks after completing the Baseline Assessment.
46097963|NCT05335759|Other|Coaching programme for improvement and development of teaching skills in preceptorship|Training program An intervention based on coaching. The strategies of this program consisted of three 6-hour sessions using case studies and role-playing for motivation towards the development of the teaching role in the preceptorship of undergraduate nursing students and debriefing and a 4-hour booster session seven months later.
46011304|NCT01649739|Drug|Levitra|There is 2 dosage:10mg Twice daily and 20mg Twice daily
46011305|NCT04532138|Device|VS-CMAC Rigid Fiberoptic Stylet|patients with severe predicted difficult airways scheduled for elective surgery randomized to this groups will receive awake endoscopic intubation using VS-CMAC Rigid Fiberoptic Stylet.
46011306|NCT04532138|Device|C-MAC Video laryngoscope awake intubation|patients with severe predicted difficult airways scheduled for elective surgery randomized to this groups will receive awake endoscopic intubation using C-MAC Video Laryngoscope intubation.
46097964|NCT02724605|Biological|Red blood cells unit age 14 days or less|30 Patients who will receive units of packed red blood cells stored stored for 14 days or less
46011307|NCT04527822|Other|Nurse led discharge planning program|a discharge planning program. It is a modified discharge planning program depends basically on the Re-Engineered Discharge program which is a program developed by Boston Medical Center in collaboration with AHRQ , 2013. The intervention consists of several components. The program components include making appointments for follow-up care (e.g., medical appointments and post discharge tests/labs). Plan for the follow-up of results from tests or labs that are pending at discharge. Identify the correct medicines and a plan for the patient to obtain them. Teach a written discharge plan the patient can understand. Educate the patient about his or her diagnosis and medicines. Review with the patient what to do if a problem arises. Assess the degree of the patient's understanding of the discharge plan and provide a telephone reinforcement of the discharge plan
45462995|NCT02056054|Other|Adult transplanted subjects with de novo autoimmune hepatitis|75 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws for each subject will depend on his or her pattern of disease activity. However, no more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2-year study period will be 8.
45462996|NCT01461304|Drug|triheptanoin|subjects will receive a modified diet containing triheptanoin (up to 2 grams/kg/24 hours; subjects who experience cardiomyopathy may receive doses up to 4 grams/kg/24 hours), or continued on their previously established triheptanoin dose; not to exceed RDA for fat, substituted for their MCT oil and/or natural fat. Study subjects will continue the triheptanoin-supplemented diet for a period of 12 months and then be able to continue into an indefinite extension phase in this compassionate use study. Laboratory evaluations will take place at two, six, and twelve months as well as every 12 months in the extension phase.
45462997|NCT05671627|Drug|DMARDs|Patients will be treated as per clinician's judgement with any kind or combination of DMARDs with or without corticosteroids (corticosteroid regimens do not exceed 15 mg/day), following EULAR recommendations for RA treatment.
45462998|NCT03491553|Drug|Selgantolimod|Tablet(s) administered orally once weekly
45462999|NCT03491553|Drug|Placebo|Placebo to match (PTM) selgantolimod tablet(s) administered orally once weekly
45837296|NCT05559684|Procedure|Transversus thoracis plane block|Under strict aseptic precautions, the T4-T5 intercostal space is identified under US using the US probe in the longitudinal plane 1 cm lateral to the sternal border. A high-frequency linear transducer is used. Next, a parasternal sagittal view of the intercostal muscle and the transverses thoracis muscle between the 4th and 5th rib is visualized above the pleura and a 22G, 5-10 cm needle is inserted in-plane (according to patient's body habitus and relevant anatomy) to the transducer with bevel up until the tip of the needle is located in the transverses thoracis muscles. After excluding intravascular and intrapleural placement, local anesthetic is adminstred bilaterally by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side.
46097965|NCT02724605|Biological|Red blood cells unit age more than 14 days|30 patients who will receive units of packed red blood cells stored for more than 14 days
46097966|NCT00675402|Other|supervised treadmill exercise program|Supervised treadmill therapy consists of a walking exercise on a treadmill under supervision of a physiotherapist, 2-3 times a week. This program is combined with individual walking every other day and the total duration of the program is 6 months. Guided by the painfree walking distance, every month the angle and/or speed of the treadmill will increase. A standardized protocol for this type of therapy is already in use by many physiotherapists in Limburg (Willigendael, 2005).
45463000|NCT03491553|Drug|Hepatitis B virus (HBV) OAV Therapy|"Commercially available HBV OAV therapy could include one of the following:~Tenofovir disoproxil fumarate (TDF; Viread®) Entecavir (Baraclude®) Adefovir (Hepsera®) Lamivudine (Epivir® ) Telbivudine (Tyzeka®) Tenofovir alafenamide (TAF; Vemlidy®)"
45837297|NCT05559450|Drug|Blinatumomab|Blinatumomab will be bridged to conventional BUCY conditioning regimen.
46011308|NCT01178125|Drug|DR-102|
46097967|NCT02640170|Other|Registry|
45463001|NCT03477760|Biological|rectal swab for Multi-Drug resistant bacteria|A rectal swab will be performed at admission of patients to look for intestinal carriage of Multi-Drug resistant bacteria
45463002|NCT00003377|Drug|cisplatin|
45463003|NCT00003377|Drug|paclitaxel|
45463004|NCT00003377|Radiation|brachytherapy|
45463005|NCT00003377|Radiation|radiation therapy|
45463006|NCT01189513|Drug|SCH 900105|10 mg/kg by vein every week on days 1, 8 and 15 of a 30 day cycle.
45679524|NCT05570916|Device|Zip-stitch(R)|Zip-stitch clips for vaginal cuff closure during laparoscopic hysterectomy
45679525|NCT05570916|Device|Reference suture|Standard suture for vaginal cuff closure during laparoscopic hysterectomy
45679526|NCT05565378|Drug|Pembrolizumab|Pembrolizumab will be administered as an IV infusion.
45679527|NCT05565378|Drug|Dostarlimab|Dostarlimab will be administered as an IV infusion.
45679528|NCT05565378|Drug|GSK4428859A|GSK4428859A will be administered as an IV infusion.
45679529|NCT05564338|Drug|Sitravatinib|Administered orally
45679530|NCT05564338|Drug|Tislelizumab|Administered intravenously
45679531|NCT05564338|Drug|sitravatinib-matching placebo|administered orally
45463007|NCT03950921|Behavioral|Patient Safety Display|Digital display of catheter and pressure injury information in patient hospital room
45463008|NCT01291537|Drug|Duodopa|
46011309|NCT01649778|Drug|Pazopanib|Prospective Observational study collecting real world data on Pazopanib in patients with advanced or metastatic Renal Cell Carcinoma. Study is considered non-interventional, no drug will be provided. No study visits or procedures are mandated per protocol.
45463009|NCT01291537|Drug|best médical treatment|
45463010|NCT03947567|Drug|Recombinant Human Coagulation FVIII|Participants received SCT800 for prophylaxis and/or on-demand treatment for 120 weeks.
45463011|NCT03849391|Dietary Supplement|Skate group|This group takes 500 mg/day Skate Skin extract for 12 weeks
45463012|NCT03849391|Dietary Supplement|Placebo group|This group takes 500 mg/day Placebo for 12 weeks
45463013|NCT03950765|Behavioral|Ecological momentary intervention|Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.
45463014|NCT00651742|Drug|S-1|All participants received S-1 orally at a dose of 30 mg/m2 BID for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial was planned to proceed to the second stage only if sufficient efficacy was demonstrated in Stage 1.
45463015|NCT01189591|Device|Slow-wave deprivation|Using acoustic tones to suppress slow-wave sleep
45679532|NCT05564338|Drug|tislelizumab-matching placebo|administered intravenously
46011310|NCT04532333|Drug|Bivalirudin 250 MG Injection|Bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until end of the procedure
46011311|NCT04532333|Drug|Heparin|Heparin should be administered each hour, 0.6mg/kg(75U/kg) as bolus dose, 0.3mg/kg 1h later, 10mg(1250U) every hour after.
46011312|NCT04538183|Other|WO 5000|WO 5000
45463017|NCT01191463|Other|Mung Bean Meal|50g mung beans will be cooked to a curry with oil, spices and small amounts of vegetables.
45463018|NCT01191463|Other|Guava|A fresh Guava fruit will be provided raw (approx 100g fresh weight)
45463019|NCT01105403|Drug|POL6326|IV infusion of POL6326 followed by apheresis to collect mobilized stem cells from peripheral blood
45463020|NCT01328015|Drug|Oxybutynin 5 mg pills|"½ pill oral 12/12h for 3 days~01 ½ pills oral morning and evening for 3 days Continue 1 pill oral 2x/day for three weeks."
45463021|NCT05155462|Other|One or two phone call|Phone call to collect patient data
45463022|NCT01294501|Other|Medication administration educational module|The Research Assistant (RA) will enter the subject's language (English or Spanish), the type of medicine (tablet/capsule, liquid, or ointment) from the antibiotic prescription, and the frequency (once a day, twice a day, three times a day, four times a day) from the antibiotic prescription into the web-based educational module on medication administration so that a tailored module will be setup for the subject. The subject will then view the educational interactive module. After the subject is done with the module, the RA will administer a verbal post-test. The post-test will include questions on medication administration as well as questions on fever assessment and management.
45463023|NCT05155228|Behavioral|Attachment Regulation and Competency|Trauma informed psychotherapy intervention for children with a history of exposure to trauma and their caregivers.
45463024|NCT05155228|Behavioral|Treatment as usual|Supportive psychotherapy
45463025|NCT03950687|Drug|Recombinant Human Erythropoiesis Injection (CHO cell)|rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
45463026|NCT03950687|Drug|Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)|rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
45837298|NCT05559450|Other|Conventional therapy|Control group will be given conventional BUCY conditioning regimen.
45837299|NCT01669200|Other|Medium Chain Triglyceride Oil|Differential changes will be compared in the test group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
46011313|NCT04538183|Other|WO 5001|WO 5001
46011314|NCT04538105|Other|Control|Saline Articular Nerve Branch Block
46011315|NCT04538105|Other|Articular Branch Block (ABB)|0.5% Bupivacaine with epinephrine 1:200,000 (Articular Branch Block)
46011316|NCT01649895|Drug|D-Cycloserine|Predicted to enhance the effects of exposure in internet-based cognitive-behaviour therapy
46011317|NCT01649895|Drug|Placebo|Placebo pills as adjunct to internet-based cognitive-behaviour therapy
46011318|NCT04527939|Procedure|three-dimensional endorectal ultrasonography|three-dimensional endorectal ultrasonography
46011319|NCT04527783|Other|experimental group|Each subject will undergo 10 rehabilitation sessions 2-3 times a week, lasting around 30'.
46011320|NCT04527783|Other|control group|Each subject will undergo 10 rehabilitation sessions 2-3 times a week, lasting around 30'.
46011321|NCT04537754|Device|bleaching device|activated bleaching
45463027|NCT01189669|Dietary Supplement|LC n-3 PUFA (fish oil) Supplement|4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
45463028|NCT01189669|Dietary Supplement|Placebo (olive oil) supplement|4 x 1g olive oil capsules were given daily for 6 weeks
45837300|NCT01669200|Other|Placebo Oil|Differential changes will be compared in the control group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
45463029|NCT01101893|Drug|Raltegravir|raltegravir 400mg q12h x 5 days (Reference Treatment)
45463030|NCT01101893|Drug|GSK2248761|GSK2248761 200mg q24h x 5 days (Reference Treatment)
45463031|NCT01101893|Drug|GSK2248761 + Raltegravir|GSK2248761 200mg q24h + raltegravir 400mg q12h x 5 days (Test Treatment)
45463032|NCT05155072|Drug|DW1903|DW1903
45463033|NCT05155072|Drug|DW1903-R1|DW1903-R1
45463034|NCT05155072|Drug|DW1903-R2|DW1903-R2
45463035|NCT01292863|Other|Active Comparator: Conventional peritoneal dialysis solution|Daily dialysis solution to be used for 3 months in crossover fashion.
45463036|NCT01292863|Other|Experimental: Novel biocompatible dialysis solution|Daily dialysis solution to be used for 3 months in crossover fashion.
45463037|NCT02523508|Behavioral|Experimental group|Subject will be put into lying position, small amplitude of passive movement on the lumbar spine of the subject. The procedure will last for 1 minute.
45463038|NCT02523508|Other|Control group|Passive limb mobilization which did not involve the spine
45463039|NCT02523430|Procedure|interventional therapy|nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
45463040|NCT01292941|Device|Intermittent catheterisation|Speedicath, Intermittent catheterisation
45463041|NCT01292941|Device|NonCE marked intermittent catheter/red|Paris, Intermittent catheterisation
45463042|NCT01292941|Device|NonCE marked intermittent catheter/green|Paris, Intermittent catheter
45837301|NCT05559294|Behavioral|Professional Development of Early Childhood Education and Care Staff for Science|A nine-month program consisting of three e-learning modules and three group workshops
45837302|NCT05559294|Behavioral|Education and care as Usual (ECAU)|Active control
45837303|NCT05559138|Other|no intervention|no intervention
45837304|NCT00564954|Drug|Dex-methylphenidate hydrochloride extended-release (Focalin XR)|20 mg capsule orally once a day for 7 days
45837305|NCT00564954|Drug|Placebo|orally once a day for 7 days
46097968|NCT02573818|Device|SEDASYS System|propofol sedation with the SEDASYS System
46097969|NCT05097313|Dietary Supplement|Yeast β-glucan fiber|The study is designed to determine if β-glucan is safe and if it presents an antioxidant and immunomodulatory response in healthy adults in Colombia.
45463043|NCT01292941|Device|NonCE marked intermittent catheter/blue|Paris, Intermittent catheter
45463044|NCT02523352|Procedure|Non-Invasive Ventilation|Progressive increase in airway pressure to open lungs atelectatic regions.
45463045|NCT02523352|Procedure|Esophageal catheter positioning|The esophageal tube (8 French diameter catheter) will be positioned in the larger nostril previous topical anesthesia
45463046|NCT03854071|Other|intravenous fluid challenge|Patients will undergo a receive a pre-load increasing stress test with intravenous fluids depending on tolerability
45463047|NCT03477682|Other|Early ambulation|Patients who are in the experimental arm will have a shorter duration of bedrest restriction following sartorius surgery (1 day) versus the standard group (5 days bedrest).
45463048|NCT00002651|Drug|bicalutamide|Given orally
45463049|NCT00002651|Drug|goserelin acetate|Given subcutaneously
45463050|NCT00002651|Other|clinical observation|Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease.
45463051|NCT03853993|Biological|Quadrivalent influenza vaccine|Received single dose QIV (15µg/0.5ml)
45463052|NCT03853993|Biological|Trivalent influenza vaccine (contains B/Victoria strain)|Received single dose TIV which contains B/Victoria strain (15µg/0.5ml)
45463053|NCT03853993|Biological|Trivalent influenza vaccine (contains B/Yamagata strain)|Received single dose TIV which contains B/Yamagata strain (15µg/0.5ml)
45463054|NCT03853681|Diagnostic Test|additional blood sampling|additional blood sampling
45679533|NCT05550818|Other|High Ultra Processed Food Diet|Participants will be provided and consume a diet emphasizing UPF (81% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, and overall diet quality, for 2 weeks.
45679534|NCT05550818|Other|No Ultra Processed Food Diet|Participants will be provided and consume a diet containing no UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, and overall diet quality, for 2 weeks.
46097970|NCT05097313|Other|Placebo|oral consumption of 200 mg (one capsule) or 400 mg (two capsules) of soy protein powder for 84 days.
46011322|NCT02217215|Device|CNDS Advanced Cervical Scan|"Subjects (approximately 500) will be initially enrolled from a general screening population in the first phase, and during the second phase from the colposcopy clinic population (approximately 300) based on their referral abnormal Pap cytology conducted within 120-days in order to achieve a statistically viable number of normal women, women with CIN1/2 and women with CIN3+, as described in Section 6.1, Cervical Cytology Enrollment Targets. After the CNDS test, a sample for Hybrid Capture 2 HPV testing and liquid cytology will be collected in addition to colposcopy and biopsy, if indicated."
46011323|NCT04537676|Other|No intervention, this is an observational study|No intervention
46097971|NCT02720471|Drug|Locoregional anesthesia|classical analgesia by ultrasound guidance by blocks of the femoral and cutaneous nerves side of the thigh
45463055|NCT03473626|Drug|Alicaforsen|Alicaforsen tablet
45463056|NCT03853603|Dietary Supplement|Santa herba|Santa herba dry extract; 400 mg/day. 2 capsules/day; 1 capsule twice daily with the main meals (lunch and dinner)
45463057|NCT03853603|Dietary Supplement|Placebo|Maltodextrin; 400 mg/day. 2 capsules/day; 1 capsule twice daily with the main meals (lunch and dinner)
46011324|NCT01649505|Drug|fibrin sealant (Beriplast P, TISSEEL VH)|Applied topically
46097972|NCT02720471|Drug|peroperative infiltration of local anesthetics|peroperative infiltration of local anesthetics
46011325|NCT01649505|Procedure|breast reconstruction|Undergo sharp dissection technique
46011326|NCT01649505|Procedure|breast reconstruction|Undergo electrocoagulation dissection technique
46011327|NCT02279784|Device|Freeway PTA|angioplasty with Freeway drug-eluting balloon
45463058|NCT05154682|Drug|OxyCODONE 5 mg Oral Tablet|Oxycodone will be given every 4 hours as needed for 2 weeks after surgery
45463059|NCT05154682|Drug|Acetaminophen 500Mg Tab|Acetaminophen will be taken every 4 hours for 2 weeks after surgery
46011328|NCT02279784|Device|Lutonix PTA|angioplasty with Lutonix drug-eluting balloon
46011329|NCT02217254|Procedure|Atrial fibrillation catheter ablation using the Medtronic Arctic Front Ablation System|
46011330|NCT01178086|Drug|Rituximab|Rituximab IV
46011331|NCT04531865|Drug|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 7
46097973|NCT00688818|Drug|Quetiapine|Patients will be initiated on 50 mg of Quetiapine XR and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
46097974|NCT00688818|Drug|Placebo|Patients will be initiated on 50 mg of Placebo and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
46097975|NCT00726154|Behavioral|IPSRT|Interpersonal and social rhythm therapy (IPSRT) focuses specifically on rhythmicity. IPSRT is based on the social zeitgeber hypothesis (Ehlers et al., 1988; 1993) and the conviction that regularity of social routines and stability of interpersonal relationships have a protective effect in recurrent mood disorders. In IPSRT, resolution of depressive symptoms is theorized to come about through the exploration of the links among mood symptoms, stability of social rhythms and quality of social relationships and social role performance, and the identification and management of potential precipitants of rhythm disruption.
45463060|NCT05154682|Drug|Naproxen 500 Mg|Naproxen will be taken every 12 hours for 2 weeks after surgery
45463061|NCT01107977|Behavioral|Iyengar yoga|Iyengar yoga twice/week for 6 weeks
45463062|NCT03477526|Procedure|Pulmonary rehabilitation program|3 weeks, ...
45463063|NCT01294657|Behavioral|Health Education|Counseling, referrals to available resources and self-help materials on Day 1, at 6 and 12 month visits, along with surveys at 6 and 12 months.
45463064|NCT01294657|Behavioral|MAPS|12 counseling phone calls over 1 year, lasting about 20-30 minutes.
45463065|NCT04312841|Drug|Letermovir|Given PO
45463066|NCT05154604|Drug|SHR-A1921|Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
46011332|NCT04531865|Drug|Mycophenolate Mofetil|Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards. Dose: 20~30mg/kg/day，BID. Total duration : 8 months.
46097976|NCT00726154|Behavioral|Collaborative Care|The collaborative care (CC) condition is a less intensive psychosocial intervention that was employed as the control condition in the STEP-BD study of psychosocial treatment (see Miklowitz et al., 2007). Participants assigned to this condition will receive a psychoeducational videotape and a workbook including information about: 1) the diagnosis, management, and treatment of bipolar illness; 2) the importance of medication adherence; 3) schedule management including daily mood charting; 4) typical biases in thinking relevant to mood states; 5) improving relationships through communication skills; and 6) developing a treatment contract geared toward preventing episodes.
46011333|NCT04531865|Drug|Placebo tablets matching Mycophenolate Mofetil|Addition of Maintenance Placebo tablets matching Mycophenolate Mofetil from 4 Month onwards. Dose: 20~30mg/kg/day，BID. Total duration : 8 months.
46011334|NCT01683981|Drug|L-Citrulline Malate|3 gr per day, oral, for 2 weeks
46097977|NCT00656006|Drug|Albuferon|
46097978|NCT00656006|Drug|Ribavirin|
45463067|NCT01294735|Drug|MK-4827|MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
46097979|NCT02720549|Procedure|remote ischemic postconditioning|Remote ischemic postconditioning post group will take a remote ischemic postconditioning with tourniquet in their lower extremity under thigh. The conditioning is 5 minutes of inflation, and 5 minutes of deflation, repeated 3 cycles.
46097980|NCT02720549|Procedure|valvular surgery with bypass|valvular surgery with bypass
46097981|NCT00993889|Behavioral|VR during Physical Therapy|Virtual Reality will be performed during a painful physical therapy procedure.
46097982|NCT00993889|Behavioral|VR Background Pain|Virtual Reality is used at anytime during the day for the background pain, not during physical therapy.
46097983|NCT00993889|Behavioral|NO VR|The subject will receive the usual standard treatment. At the end of the study, before being discharged from the hospital, the subject can experience the VR, not during a procedure.
46097984|NCT05143606|Other|3D-printed airway simulator|Two self-directed training on a standard fiberoptic bronchoscope and a custom-made 3D airway simulator.
46097985|NCT05143606|Other|virtual reality software, AirwayEx|Two self-directed training on AirwayEx. With additional training as necessary.
46097986|NCT00688896|Drug|JTT-705 600 mg and pravastatin 40 mg|"JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
46097987|NCT00688896|Drug|JTT-705 300 mg and pravastatin 40 mg|"JTT-705 300 mg tablets, 300 mg dose, 1 tablet, oral, once daily, immediately following breakfast and/or assessment~Placebo tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments~Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
46097988|NCT00688896|Drug|Placebo and pravastatin 40 mg|"Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
46097989|NCT02724215|Device|Sleep Apnea Screening (Out of Center Polysomnography Device)|
46097990|NCT00995137|Biological|NK Cell Infusion|Infusing genetically modified NK cells into research participants who have chemotherapy refractory or relapse B-lineage ALL.
46097991|NCT00688974|Procedure|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
46097992|NCT00688974|Procedure|Adjustable gastric band|Laparoscopic adjustable gastric band
45463068|NCT01294735|Drug|Temozolomide|MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
46011335|NCT01177969|Behavioral|Cognitive-Behavioral Therapy|The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
46011336|NCT01177969|Behavioral|Wait-list|A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
46097993|NCT05142280|Other|Decision-aid for cardiovascular disease risk|The active choice intervention aims to promote an active choice regarding coping with an increased risk of cardiovascular disease. This means that individuals should (a) become aware of a discrepancy between the current and desired situation; (b) understand what the CVD risk means, and what its causes and consequences are; (c) evaluate the pros and cons of the different options to cope with the risk; and (d) are clear about their values regarding the choice.
46097994|NCT05142280|Other|Control|The control condition contains information that resembles usual care by a GP regarding CVD prevention
46097995|NCT02720393|Other|No-carrageenan diet|Diet of food items that have no carrageenan as selected by study dietician.
46097996|NCT02720393|Other|Regular Diet|Diet of food items that have carrageenan as selected by study dietician
46097997|NCT05327725|Other|Fatigue Reduction Diet|Participants receive individualized nutrition counseling to adopt the fatigue reduction diet protocol.
46097998|NCT02640014|Dietary Supplement|Milk|Milk Oral immunotherapy
46097999|NCT02724293|Drug|pregabaline 300 mg once.|patients received pregabaline 300 mg 2 hours pre-operatively.
46098000|NCT02724293|Drug|pregabaline 300 mg twice.|patients received pregabaline 300 mg 2 hours pre-operatively, and 12 hours later.
46098001|NCT02724293|Drug|pregabaline 600 mg once.|patients received pregabaline 600 mg 2 hours pre-operatively.
46098002|NCT02724293|Drug|placebo|patients received placebo
46098003|NCT00675480|Procedure|Thrombectomy|Aspiration Thrombectomy prior to stent implantation in patients with ST segment elevation myocardial infarction
46098004|NCT00675480|Procedure|Primary angioplasty|Standard primary angioplasty with stent implantation
46098005|NCT05092828|Drug|Intrathecal Morphine Injection|In addition to standard post-operative pain management, Intratechal morphine will be given to patients in this group.
46011337|NCT01643070|Drug|Capecitabine, Oxaliplatin|Induction chemotherapy - Capecitabine (1250 mg/m2 PO twice daily on D1-14 and oxaliplatin 130 mg/m2 on D1, every 3 weeks for 2 cycles) Preoperative chemoradiotherapy - Capecitabine 825 mg/m2 PO twice daily during radiotherapy and oxaliplatin 50 mg/m2/day on weekly.
46098006|NCT05092828|Drug|Pain Relieving|Patient in this group will receive standard postoperative pain medications other than inthrathecal injection of morphine
46098007|NCT05327335|Device|Intelligent robotics for elderly assistance - sarcopenia|Participants will use the robotics system and integrated environment to perform daily self-care to uncover problems in functionality, usability, and acceptance of the robotic device prototype. The system, connected to mobile apps and the Internet, will serve as a platform to measure and record data on how the participants engage in pre-specified activities. The experiment will last six months, and the outcome will be assessed pre- and post-implementation for comparison and validation. The major testing criteria include the design specifications for functionalities and reliability, user experiences, system security and privacy.
46011338|NCT01643070|Radiation|Radiotherapy|Preoperative radiotherapy, 5040 cGy with 28 fractions
46011339|NCT02216006|Procedure|Control group, conventional ventilatory settings|"Handling of the airway during induction and intubation is performed in a conventional manner.~Initial ventilatory settings are also done in a conventional manner. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI >25) and a respiratory frequency of 10. The fresh gas flow is set to 1 Liter per minute with an oxygen mixture of 40%, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
46098008|NCT02720159|Device|Percutaneous Osseintegrated Prosthesis|
45473975|NCT04434586|Device|femoropopliteal revascularization for TASC C or TASC D lesion|Femoropopliteal revascularization: ATL or ATL/stenting for TASC C/D lesions. Control group: only angiography 2D final control. Experimental group: angiography + OCT control
46098009|NCT04137198|Drug|Sufentanil|intranasal administration of Sufentanil Forte 0,5mcg/kg as first dose and 0,3mcg/kg as titration doses
46098010|NCT02637206|Drug|GSK2894512 Cream|GSK2894512 cream supplied will be white to off-white cream packaged in 28-gram laminate tubes of 2 concentrations: 0.5% and 1%, to be applied topically.
46098011|NCT02637206|Drug|Vehicle Cream|Vehicle Cream (placebo cream without active ingredient) supplied will be white to off-white cream packaged in 28-gram laminate tubes, to be applied topically.
46098012|NCT02637206|Drug|Empty Patch|Empty patches without any ingredients will be used as negative control.
46098013|NCT00995293|Drug|DOCETAXEL|Intravenous
46098014|NCT00995293|Drug|CISPLATIN|Intravenous
46098015|NCT00995293|Drug|5-FLUOROURACIL|Intravenous
46098016|NCT02720315|Procedure|Intensive cryotherapy|Application of ice inside a plastic bag wrapped to the patient's site of pain, and held in place for 20min.
46098017|NCT02637050|Other|Standard of care|At the discretion of the attending physician.
46098018|NCT02720003|Device|LTX DCB|Treatment with a drug-coated balloon
46098019|NCT00726310|Device|SpineLink® , SpineLink® II|Spine plate system for lumbar spinal fusions
46098020|NCT00675636|Other|study of socioeconomic and demographic variables|database, no intervention
46098021|NCT00675636|Procedure|evaluation of cancer risk factors|database, no intervention
46098022|NCT00675636|Procedure|study of high risk factors|database, no intervention
46098023|NCT00714142|Drug|62Cu-ethylglyoxal bis(thiosemicarbazone)|15-25 mCi, IV
46098024|NCT00714142|Drug|15O-water|10-20 mCi, IV
46098025|NCT00714142|Procedure|Positron Emission Tomography|PET Scan
46098026|NCT02720237|Behavioral|Brief Intervention|In-person individual sessions (occurring one month apart) and booster phone sessions (occurring 2-3 weeks after each in-person session), delivered by a trained counselor.
46098027|NCT02720237|Behavioral|Motivational Enhancement Therapy (MET) Intervention|In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
46098028|NCT02720237|Behavioral|Cognitive Behavioral Therapy (CBT) Intervention|In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
46098029|NCT00692952|Drug|a novel Benzalkonium Chloride (BZK) contraceptive gel|insert 1 piece of the gel (containing 18mg BZK) into vagina before every coital act.
46098030|NCT00692952|Drug|LELEMI® contraceptive gel containing 50mg nonoxynol-9|insert 1 piece ofLELEMI® contraceptive gel within half an hour before every coital act
45463069|NCT05154292|Behavioral|Serious Game: Emotional Health Island (SAEM)|This intervention aims to aim to develop competencies for emotional regulation through exposure and acceptance strategies. This intervention is applied through a serious game developed for this purpose. the adolescent will complete a series of missions aimed at developing skills related to psychological flexibility, namely, greater psychological acceptance, mindfulness in the present moment, and committed actions in the direction of personal values. This serious game is guided by a therapist.
45463070|NCT03851263|Biological|Evolocumab|Subcutaneous injection, using a pre-filled auto-injector pen. Each pen contains 1.0 ml fluid (containing 140 mg evolocumab) which is injected in the abdomen, thigh or outer area of upper arm every 2 weeks (q2w).
45463071|NCT05105243|Drug|CVN766|highly selective orexin-1 receptor (Ox1R) antagonist
45463072|NCT05124106|Diagnostic Test|Raman Spectrometry|Bladder tumor is examined with Raman spectrometry during endoscopy
46011340|NCT02216006|Procedure|High fresh gas flow, high minute ventilation|"Handling of the airway during induction and intubation is performed in a conventional manner.~Immediately after confirming a successful intubation, the effect of preoxygenation is eliminated with a fresh gas flow of 10 L/min of air, delivered with volume controlled ventilation consisting of tidal volumes of approximately 15 ml/kg ideal body weight, a positive expiratory pressure of 10 cm H20 and a respiratory frequency of 10. As soon as the end tidal O2 reaches 25%, the ventilator settings are adjusted to normal values (same as in the control group), i.e. tidal volume 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI >25). The mixture of oxygen in the fresh gas is increased to 40% and the fresh gas flow is set to 1 Liter per minute, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
45463073|NCT02100397|Biological|Salmonella enterica serovar Paratyphi A (strain NVGH308)|Ingestion of 1-5x10³ to 1-5x10⁵ colony forming units (CFU) of the challenge strain after bicarbonate buffer solution.
45463074|NCT05086055|Behavioral|Kinematic movement analysis|moving arm/leg while registration with electromyography, electroencephalogram, accelerometers, functional near infrared spectroscopy and 3 dimensional video registration of hand, arm, foot and leg movements.
46011341|NCT04532021|Diagnostic Test|matrix metalloproteinase 14, neopterin, and orosomucoid 1 measurements|These three markers levels will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
46011342|NCT04531787|Drug|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly each season: 2004-2005, 2005-2006, 2006-2007, 2007-2008 for season specific A/H1N1, A/H3N2, and B antigens
46098031|NCT02724137|Behavioral|Fitbit®|Participants can read how many steps/day they walked on the Fitbit® daily. The treating physical therapist reviews Fitbit® recorded steps from the previous week and together with the patient sets a new step goal. The physical therapist discusses barriers to meeting step goals are discussed. Self-reward for meeting step/goal is set weekly. Participants in this group will also receive 1-month phone calls for 6-months after completing physical therapy rehabilitation to discuss physical activity, set monthly step count goal, barriers to overcoming goal and to continue to develop a reward system for when the participant achieves their step count goal.
46098032|NCT02724137|Other|Physical Therapy Rehab|Standard of care physical therapy after total knee replacement. The goals of physical therapy are to increase knee range of motion and strength, improve balance and agility, and increase daily walking. Physical therapy appointment times range from 45-60 minutes with appointments occurring 2 times a week for 6-8 weeks.
46098033|NCT02639858|Drug|Docetaxel-PM|Docetaxel PM 75mg/m2 IV infusion
46098034|NCT00689208|Drug|Atropine|10 ug/kg bolus, 4 ug/kg/h infusion
46098035|NCT00689208|Drug|Physostigmine|0,12ug/kg/min
45463075|NCT03473548|Device|Portable sleep monitor|Type III portable monitor obtaining greater than or equal to 6 hours of data adequate for polysomnography analysis and determination of an apnea hypopnea index (AHI), average SPO2, and SPO2 nadir.
45837306|NCT00565110|Behavioral|ADAPt-C intervention|Experimental Arm patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
45679535|NCT05545384|Drug|Immediate Azathioprine (1st attack)|"Patients randomized in Immediate Azathioprine group will benefit from immediate treatment with azathioprine. Treatment will be started at 2mg/kg or at 1mg/kg if the patient has a partial activity which would be increased slowly according the 6-TGN activity and clinical and biological tolerance at Week 2 for patient with partial activity or M1 for patient without TPMT activity deficit.~Only for patient with partial deficit and whose 6-TGN activity is low, azathioprine would be increased at 3mg/kg/d at Week 6 and without exceeding a total daily dose of 150 mg."
46098036|NCT00689208|Drug|Placebo Sodium|
46098037|NCT00726466|Drug|Efalizumab, Ranibizumab|
45837307|NCT00565266|Drug|tiotropium bromide|tiotropium bromide inhalation powder 18 mcg once daily
45837308|NCT00565266|Drug|salmeterol xinafoate|salmeterol xinafoate inhalation powder 50 mcg twice daily
45837309|NCT00565266|Drug|beclomethasone dipropionate|beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)
45463076|NCT01294813|Device|Electrical Impedance Tomography (EIT)|EIT measurements of 1-2 minutes are performed in patients who routinely undergo bronchoscopy (during 1.5 hours) before, directly after and 10, 30, 60 minutes after bronchoscopy. Therefore the rubber belt including 16 integrated electrographic electrodes is placed around the patient´s chest and connected with an EIT device. EIT data are generated by application of a small alternating current of 5mA and 50kHz and are stored and analyzed offline on a personal computer. Pseudonomyzed EIT data are evaluated descriptively.
46011343|NCT05140707|Other|Virtual Reality Distraction|The patients were administered to use the virtual reality device and they were free to choose the theme and video in the library to watch. Patients used the device during the port catheter implantation and untill the 4 hour after the implantation when they felt pain.
46011344|NCT01684059|Dietary Supplement|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
46011345|NCT04531748|Drug|Toremifene|Participants will be instructed to take 60mg of oral toremifene capsule daily, 30 minutes before bedtime.
46011346|NCT04531748|Drug|Melatonin|Participants will be instructed to take the pills orally around the same time in the morning and 30 minutes prior to bedtime in the evening.
46011347|NCT04531748|Other|Placebo|Oral placebo will be used with the same number and appearance to the pills as the interventions.
46011348|NCT01177813|Drug|Placebo identical to BI10773 high dose|placebo tablets once daily
46011349|NCT01177813|Drug|BI 10773|BI 10773 low dose tablet once daily
46011350|NCT01177813|Drug|BI 10773 open label|Patients receive BI 10773 high dose tablets open label once daily
46011351|NCT01177813|Drug|Placebo identical to BI10773 low dose|placebo tablets once daily
46011352|NCT01177813|Drug|Placebo identical to BI10773 low dose|placebo tablets once daily
45463077|NCT04562428|Drug|Xiang Sha Liu Jun Zi Decoction dry powder|the principles of Chinese medicine treatment areinvigorating Pi, regulating qi, dissipating dampness and appetizing wei
46011353|NCT01177813|Drug|Placebo identical to BI10773 high dose|placebo tablets once daily
46011354|NCT01177813|Drug|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
46011355|NCT01177813|Drug|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
45463078|NCT04562428|Drug|XSLJZ Placebo|XSLJZ Placebo
46011356|NCT01177813|Drug|BI10773|BI 10773 high dose tablets once daily
45463079|NCT03849235|Dietary Supplement|Standardised meal or glucagon|Standardised meal (Nutridrink, Nutricia, 300 kcal, 18.4 g carbohydrates, 5.8 g fat, 12 g protein) or 1mg glucagon
45463080|NCT04416958|Device|cardiac implantable electronic device (CIED) implantation|CIED Implantation according to the Guidelines aiming to avoid pacing induced dyssynchrony
45679536|NCT05545384|Drug|Immediate Rituximab (1st attack)|"Patients randomized in Immediate Rituximab group will benefit from immediate treatment with rituximab. Rituximab 375mg/m2 IV will be given at D1 and D15 and repeat every 6 months for 2 years.~Once the inclusion criteria are validated, the first injection will be performed according to the injection protocol (Annex 4). Fifteen day later, the second injection will be performed.~The next visit during a consultation with PI or his collaborators will be scheduled 1 week ± 2 days later, and patients will be advised to contact the PI if any neurologic symptoms or symptoms of adverse event occurs in the meantime."
46011357|NCT01177813|Drug|Sitagliptin|Sitagliptin tablets 100 mg once daily
46011358|NCT01177813|Drug|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
46011359|NCT01177813|Drug|Placebo identical to BI10773 low dose|placebo tablets once daily
45463081|NCT02524483|Behavioral|Therapeutic Challenge Program|The Therapeutic Challenge Program will consist of a 5 minute warm-up, 20 minutes of challenging balance training, and 20 minutes of challenging treadmill and overground walking.
45463082|NCT02524483|Behavioral|Therapeutic Exercise Program|The Therapeutic Exercise Program will consist of 15 minutes of strength training and flexibility exercises, 15 minutes of balance exercises, and 15 minutes of treadmill walking.
45679537|NCT05545384|Drug|Standard of care|Patients in this group will be treated according to standard care
46011360|NCT01177813|Drug|Placebo identical to BI10773 high dose|placebo tablets once daily
46011361|NCT04537481|Other|Lipid extraction|The sperm samples were used for lipid extraction. Lipids were analyzed using the UPLC-MS system.
46011362|NCT04531826|Other|5-strand hamstring graft preparation|Five-strand hamstring graft preparation
46011363|NCT01684137|Dietary Supplement|Joalis Bambi Analerg|
46011364|NCT01684137|Dietary Supplement|Joalis Bambi Bronchi|
46011365|NCT01684137|Dietary Supplement|Placebo|Sugar pill manufactured to mimic Joalis Bambi Analerg
46011366|NCT01684137|Dietary Supplement|Placebo|Sugar pill manufactured to mimic Joalis Bambi Bronchi
46011367|NCT04315831|Drug|Transdermal Buprenorphine|Intervention will be applied for patients with moderate to severe cancer pain
46011368|NCT04531436|Other|Brief mindful eating intervention|Over the 9-week intervention, participants will be introduced to various mindful eating and intuitive eating practices which are aimed at reducing overeating and facilitating weight loss. Each session will focus on one simple, evidence-based message, aimed at modifying a current weight-relevant eating behavior of the patient. The intervention will focus on two key elements: (1) the mindful awareness of body cues (intuitive eating) and (2) the mindful awareness of external cues (mindful eating).
45463083|NCT03473470|Device|forced air warming and warmed intravenous fluids|Use of warming system (forced air)
45463084|NCT03473470|Device|warmed intravenous fluids|Use of warming system to have warmed intravenous fluids
46011369|NCT01684176|Behavioral|Complex tailored intervention|
46011370|NCT01684176|Behavioral|Usual care|
46011371|NCT02216045|Drug|Peginterferon, Ribavirin, camel milk|"Peginterferon One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: < 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks .~camel milk 250 ml of raw camel milk will be consumed in 10 minutes orally twice daily for 12 weeks."
46011372|NCT02216045|Drug|Peginterferon, Ribavirin|"Peginterferon (PegIFNα-2a) One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: < 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks."
46011373|NCT04531358|Device|nasal spray|application of nasal spray
46011374|NCT04531358|Other|no treatment|no treatment
45837310|NCT05609526|Other|Compression Therapy|6, 8, 10 and 12 cm short tension bandages multi-layered and will be applied specifically to the extremity. Starting with the finger bandage, the pressure will be reduced as it goes distally.
45463085|NCT01189825|Behavioral|Exercise|Moderate to intense cardiovascular exercise on a treadmill for 20 minutes
46098038|NCT02694263|Drug|Canagliflozin|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide, Pioglitazone, Gliclazide or Glimepiride) for the treatment of Type 2 Diabetes.
45837311|NCT05609526|Other|Inspiratory muscle training|Maximum inspiratory intraoral pressure (MIP) and expiratory intraoral pressure (MEP) will be measured before patients begin IMT. Total training time per day will be 30 minutes.
46011375|NCT01684293|Behavioral|Occupational therapy-based cognitive rehabilitation|Occupational therapy-based cognitive rehabilitation
46011376|NCT01684293|Behavioral|Psychoeducation/games|Psychoeducation/games
46011377|NCT02216084|Drug|Recombinant ADAMTS13|"rADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a lyophilized formulation for intravenous injection. The lyophilized rADAMTS13 is reconstituted with sterile water for injection.~Subjects will receive an intravenous injection with rADAMTS13 at a dose of either 5 U/kg bodyweight (Cohort 1), or 20 U/kg bodyweight (Cohort 2), or 40 U/kg bodyweight (Cohort 3)."
46011378|NCT01684332|Other|Strawberry Jam|
46011379|NCT01684371|Other|Two oily solutions (Blue Dotted and Orange Dotted Elmore Oils)|Thirty participants received Blue Dotted Elmore Oil and another thirty received the Orange dotted Elmore Oil, they applied the oils three times daily on the affected knees for four weeks and stopped usage on the fifth week (flush out period) and on the 6 week, the two group switched to Orange and Blue Elmore Oil respectively. All throughout applications, they filled out their diaries to indicate changes in their mobility, moods, feeling of well being and ability to do their daily work at home or at work every week.
45463086|NCT03477448|Drug|Bleomycin|"an antibiotic derived from Streptomyces verticillus, has an antitumor, antibacterial, and antiviral activity that may be related to its ability to bind with DNA, causing bleomycin strand scission and elimination of pyrimidine and purine bases. The bleomycin hydrolase enzyme, which is known to inactivate bleomycin, is normally found in all body tissues but is present in very small amounts in skin .~Intra-lesional bleomycin injection (IBI) has been used for the treatment of warts."
45679538|NCT05536284|Drug|Bisoprolol Fumarate Tablets|Antihypertensive drug used for acute coronary syndrome patients
45679539|NCT05534386|Behavioral|Cancer survivorship care intervention|A one-off face-to-face assessment and personal advice by members of a multidisciplinary team
46011380|NCT04531397|Drug|ACEI treatment|ACEI, will be given once daily based on body weight (0.2mg/kg/d-0.6mg/kg/d，max 20mg/d), for 24 weeks
46011381|NCT04531397|Drug|Dapagliflozin+ACEI treatment|Dapagliflozin will be given 10 mg/day (weight>30kg) or 5mg/day (weight≤30kg), for 24 weeks ACEI, will be given based on body weight (max 20mg/d), for 24 weeks.
46011382|NCT04531475|Drug|X842|X842 capsules
45679540|NCT05534386|Behavioral|Step-up targeted personalized intervention|To provide a more personalized intervention to the participants, but focusing more on symptom management and weight control.
45679541|NCT05534386|Behavioral|First stage control intervention|A set of skill-based pamphlets will be given.
45837312|NCT05609526|Other|Calf muscle exercise training|A strengthening treatment program will be applied to the calf muscles.dorsiflexors and plantar flexors will consist of static stretching exercise, isotonic resistance exercise with elastic resistance bands, heel and toe raising in both feet, followed by toe raising and lowering without raising the heel.
46011383|NCT04531475|Drug|X842 Placebo|X842 placebo-matching capsules
46011384|NCT04531475|Drug|Lansoprazole|Lansoprazole capsules
46011385|NCT04531475|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
46011386|NCT01684449|Drug|Gemcitabine + Rapamycin|"Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).~Every three weeks until disease progression or unacceptable toxicity. The treatment will last for 6 cycles if there is not progression or intolerable toxicity.~Additionally, there will be a pharmacokinetic study in a minimum of 9 patients treated with the drug combination."
46011387|NCT01684527|Other|Respiratory secretions obtained|
46011388|NCT04537403|Drug|Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine)|Patients in Group 1, normal volunteers and patients with carotid and femoral artery disease who will be having surgery, will have a 1 day imaging session lasting approximately 60 minutes with an injection of 64CU-DOTA-ECL1i to visualize the carotid and femoral arteries. Patients with carotid and femoral artery disease will have their plaque specimens collected for further sutdy
45837313|NCT02124018|Procedure|Programmed ventricular stimulation|Programmed ventricular stimulation in high-risk patients based on non-invasive evaluation
46098039|NCT02694263|Drug|Repaglinide|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide) for the treatment of Type 2 Diabetes.
46011389|NCT04537403|Drug|Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine)|Patients in Group 2, who are patients with carotid and femoral artery disease who will not be having surgery will have two imaging sessions 7-14 days apart
45837314|NCT02124018|Device|ICD implantation|ICD implantation in patients with induced VT in programmed ventricular stimulation
45837315|NCT04346316|Drug|SHR0302|Oral tablets taken once daily (QD)
46011390|NCT01684605|Drug|NESP 60μg|Administrated NESP 60μg once intravenously
46098040|NCT02694263|Drug|Pioglitazone|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Pioglitazone) for the treatment of Type 2 Diabetes.
46011391|NCT01684605|Drug|CKD-11101 60μg|Administrated CKD-11101 60μg once intravenously
46011392|NCT04531319|Diagnostic Test|Flow cytometric analysis|Flow cytometric analysis of T helper, T cytotoxic cells, NK cells and monocytes
46011393|NCT01580085|Other|polysomnography|full night supervised laboratory polysomnography
46011394|NCT04537442|Drug|IM21 CAR-T cells|"IM21 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days~Other Names:~Fludarabine Cyclophosphamide"
46011395|NCT01684683|Drug|Theophylline|Theophylline 0.1 bid
45679542|NCT05534386|Behavioral|Second stage control intervention|Those in the survivorship clinic arm will be asked to follow the advice given by the multidisciplinary team in the initial visit and for those in the control arm will be asked to follow the advices printed in the skill-based self-management pamphlet
45679543|NCT05530343|Diagnostic Test|Seattle protocol|Participants undergo 4-quadrant biopsies with standard biopsy forceps taken at 2 cm intervals. For participants undergoing a confirmatory endoscopy for cases in which discordant results are noted (WATS3D positive for dysplasia/cancer and Seattle biopsy negative for dysplasia/cancer), repeat biopsies will be taken at 1 cm intervals along with target biopsies from any visible lesions.
45679544|NCT05530343|Diagnostic Test|WATS3D brushings|Participants undergo 2 WATS3D biopsies of every 5 cm segment of Barrett's esophagus, starting from the gastroesophageal junction and moving proximally through the entire segment of Barrett's.
46011396|NCT01684683|Drug|Placebo(for Theophylline)|Starch tablet manufactured to Theophylline 100mg (Theophylline Stained-Release Tablet)
46011397|NCT04537325|Device|RenalGuard system|Periprocedural intravenous hydration matched to urinary output.
46011398|NCT01684761|Biological|Tcelna|Autologous pool of myelin reactive T-cells (MRTC) expanded ex vivo with immunodominant epitopes selected from the three myelin antigens, MBP, PLP and MOG on a per subject basis. Attenuated by irradiation to prevent further proliferation before releasing product for administration.
46011399|NCT01684761|Biological|Placebo|2 ml of Tcelna excipients, prepared daily as individual doses and irradiated before releasing product for administration.
46011400|NCT04537091|Procedure|rESWT|rESWT was administered once per week for 3 weeks with 4 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses. Radial shock waves were transmitted to the greater trochanteric region with the maximum pain/tenderness that was identified with patients' reaction with small circular movements with an adequate amount of contact gel
46011401|NCT04537091|Procedure|PRP injection|PRP injection is performed with a high resolution 7-12-megahertz linear probe ultrasonography device. 15 ml of blood will be drawn from the patients and the blood will be centrifuged for 5 minutes. 4-5 ml PRP will be injected into the affected gluteal tendons accompanied by ultrasonography.
46011402|NCT01684800|Drug|A. Desmopressin 10 microgram|1 orally disintegrating tablet every night during study period
46011403|NCT01684800|Drug|B: Desmopressin 25 microgram|1 orally disintegrating tablet every night during study period
46098041|NCT02694263|Drug|Gliclazide|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Gliclazide) for the treatment of Type 2 Diabetes.
46098042|NCT02694263|Drug|Glimepiride|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Glimepiride) for the treatment of Type 2 Diabetes.
46098043|NCT03906760|Other|Magnetic resonance imaging (MRI)|MRI protocol associating sagittal and axial (+/- coronal) sequences in T2 + / - turbo spin T1 weighting with fat saturation.
46098044|NCT04162574|Other|Recovery Record|Observational data will be obtained through participants entering data on disordered eating episodes, mood, and food in Recovery Record, an app to assist people in managing their eating disorder during the 30 days of the trial. In addition, participants wear an Apple Watch from which passive data (e.g., heart rate, activity, and geolocation) are collected.
46098045|NCT04139070|Drug|Bleomycin|Electroporation in combination with systemically administered bleomycin
46098046|NCT00726544|Drug|ARC 1779 Placebo|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper.
45679545|NCT05527756|Other|Scar Cosmesis Assessment and Rating (SCAR) scale|The SCAR scale consists of two simple questions about symptoms (itch and pain) with yes/no response options that are responded to by the patient and six clinician-related items that are rated by observers through photos of the incisions. This scale includes both objective measurements and patient-reported symptoms
46011404|NCT01684800|Drug|C: Placebo|1 orally disintegrating tablet every night during study period
46011405|NCT04531163|Drug|N Acetylcysteine|(NAC) is a drug used in the experiment and participant are treated with it by 1200mg/day dose for two months.
46011406|NCT04537169|Procedure|Levator resection|Eyelid crease incision Dissection of the levator aponeurosis to the level of Whitnall ligament. Assessment of the structure of Whitnal ligament. Resection of a calculated part of the aponsurosis. re-attachment of the aponeurosis to the tarsus Incision closure with crease formation
46098047|NCT00726544|Drug|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 3μg/mL.
46098048|NCT00726544|Drug|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 6μg/mL.
45837316|NCT05567328|Device|Research FibroScan|"Once the inclusion and exclusion criteria are validated, the investigator can propose the study to the patient. After taking the time needed to consider the study, the patient will decide if he/she wants to participate in the study and to sign off the informed consent form.~The following examinations will be performed for each patient using the probe as per recommendations displayed on the screen. The same probe must be used for examinations.~Patients #1 to #70:~Exam 1: Exploratory exam with the Research FibroScan and the M+ or XL+ probe. Exam 2: Reference exam with the CE-marked FibroScan and the M+ or XL+ probe.~Patients #71 to #100:~Exams 1 and 2: Two consecutive exploratory exams with the Research FibroScan and the M+ or XL+ probe.~Exams 3 and 4: two consecutive reference exams with the CE-marked FibroScan and the M+ or XL+ probe."
46098049|NCT00726544|Drug|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 12μg/mL.
46098050|NCT02719925|Other|Mg(+)|"1,5 L per day during 30 days~No livestyle counseling"
46098051|NCT02719925|Other|Mg(-)|1,5 L water per day during 30 days No lifestyle counseling
46098052|NCT00693030|Device|sirolimus drug eluting coronary stent Cypher™ (Cordis Corp, Johnson & Johnson Co)|comparison of multiple drug eluting stents
46098053|NCT00693030|Device|paclitaxel polymer drug eluting stent Taxus Libertè™ (Boston Scientific, Natick MS)|comparison of multiple drug eluting coronary stents
46098054|NCT00693030|Device|zotarolimus drug eluting coronary stent Endeavor™ (Medtronic, Santa Rosa, CA)|comparison of multiple drug eluting coronary stents
46098055|NCT00693030|Device|Libertè bare metal coronary stent Libertè™ BMS(Boston Scientific, Natick, MS)|comparison of DES in overlap vs BMS in overlap
46098056|NCT00653822|Drug|alefacept|IC and SC
45837317|NCT00567840|Drug|PA-824|200 mg, 600 mg, 100 mg, 1200 mg qd
46098057|NCT00653822|Drug|placebo|IV and SC
46011407|NCT01684995|Behavioral|Brief physician advice|Brief physician advice to quit smoking
46011408|NCT01684995|Drug|nicotine patch|nicotine patch
46011409|NCT01684995|Behavioral|Individually Tailored Behavioral Skills training|Individually tailored behavioral skills training for smoking cessation
46011410|NCT04530851|Procedure|ERAS|"Counseling~H2- antagonist and metroclopramide for prevent aspiration~Drink clear liquid until 2 hour before surgery~First generation cephalosporin in 60 minute before surgery~Clorhexidine for skin cleansing and Povidine for vaginal cleansing~Regional anesthesia~Keep warming~Blunt expansion of uterine incision~Do not peritoneal suture and subcuticular suture if less than 2 cm~Local wound anesthesia.~Paracetamol and NSAIDs for for pain control~Early remove catheter and ambulation~5-HT3 antagonist for prevent nausea"
45473976|NCT03863015|Drug|Tocilizumab 20 Mg/mL Intravenous Solution|Tocilizumab is suspended in isotonic saline to a total volume of 100mL prior to infusion
45679546|NCT05527756|Other|Numerical rating scale (NRS)|The NRS scale, in which the patients score the cosmetic appearance of the scar from 0 to 10, is questioned.
45679547|NCT05524051|Drug|TIN816|TIN816
45679548|NCT05524051|Other|Placebo|Placebo
45679549|NCT05517668|Drug|Intravenous infusion of N-acetylcysteine|If randomized to Control, the participant will receive only N-acetylcysteine. The dose will be determined by the site investigator. Typical continued infusion rate is 6.25 mg/kg/hr. The control drug (D5W) will be administered using the same schedule as fomepizole.
45837318|NCT00568386|Other|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye once time
45837319|NCT00568386|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
45837320|NCT01798290|Behavioral|narrative medicine: reading workshop|
45463087|NCT03477448|Drug|Purified Protein Derivative|"is an extract of Mycobacterium tuberculosis and is used for testing exposure to tuberculin protein, either from a previous vaccination or from the environment. It contains live, attenuated Mycobacterium bovis.~Using this protein derivative for immunotherapy of warts is important for two major aspects. First, because the obligatory immunization program in many developing countries - with high prevalence of wart in many of them - includes BCG vaccination. PPD has a high prevalence of immunity in the general population. Second, although immunotherapy is generally an inexpensive method of treatment in wart patients, PPD, among conventionally used antigens, is the cheapest"
45463088|NCT01187485|Drug|Androderm® 2.5mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
45463089|NCT01187485|Drug|Androderm® 5.0mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
45463090|NCT01187485|Drug|Androderm® 7.5mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
45463091|NCT00002597|Drug|flutamide|Two 125 mg capsules (t.i.d., p.o.) beginning two months before RT and continuing until RT is completed.
45463092|NCT00002597|Drug|Zoladex|3.6 mg s.c. monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
46098058|NCT05021224|Behavioral|Rapidly prototype and test strategies|We will generate strategies for facilitating treatment initiation that address barriers and leverage facilitators, in partnership with a team of experts in behavioral science and implementation science. We will favor simple, established strategies with freely available resources (e.g., Caring Contacts templates) to promote scalability, but will also consider other potential strategies as indicated. We will explore both low- (e.g., manualized text messaging) and high-tech (e.g., electronic health record integrated patient messaging) strategies to maximize relevance across contexts. Next, prototype-strategy designs will be validated through rapid-cycle tests in this real world context and in a manner that is inexpensive and allows us to fail fast and learn quickly. After testing a given implementation strategy, the team will debrief and decide whether to refine or adjust it.
46098059|NCT04137276|Drug|vitamin C, vitamin B1|vitamin C 1,5 g/6 hours IV + thiamine 200 mg/12 hours for 3 days
46098060|NCT04137276|Drug|vitamin B1|thiamine 200 mg/12 hours for 3 days
45463093|NCT00002597|Drug|Lupron|7.5 mg IM (intramuscular) monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
46098061|NCT02724059|Procedure|EBUS with elastography followed by TBNA|Endo bronchial ultrasound (EBUS) with elastography followed by TBNA from mediastinal lesions or lymph nodes
45463094|NCT00002597|Radiation|radiation therapy|46.8 Gy (1.8 Gy/day four to five times a week [26 fx]) to regional lymphatics followed by 19.8 Gy (1.8 Gy/day x 11 fx) for a total of 66.6 Gy to the prostate. Prostate only may be treated in defined circumstances.
45679550|NCT05517668|Drug|Intravenous infusion of Fomepizole (4-MP)|"If randomized to fomepizole, the participant will receive fomepizole in a fixed dose relative to acetylcysteine. The fixed ratio is acetylcysteine 10 : 1 fomepizole. In the first 20-21 hours (2 vs. 3-bag regimen), a total of 30 mg/kg fomepizole is delivered. The investigator may continue the acetylcysteine infusion (and study drug) after the initial 20-21 hours. The dose will be determined by the site investigator. Typical continued infusion rate is 6.25 mg/kg/hr.~2 bag, 300 mg/kg, 20 hr regimen: The 2-bag regimen is provided as 200 mg/kg infusion over 4 h followed by 100 mg/kg infusion over 16 hours. 3 bag, 300 mg/kg, 21 hr regimen: The 3-bag regimen is provided as 150 mg/kg infusion over 1 h followed by a 50 mg/g infusion over 4 h, followed by 100 mg/kg infusion over 16 hours. The control drug will be administered using the same schedule. The dose of fomepizole will not be adjusted based on age, presence of liver injury or renal insufficiency."
45837321|NCT01798290|Behavioral|critical reading|
45837322|NCT03830970|Dietary Supplement|Canned beans of multiple varieties|Daily rotation of different varieties of canned beans including black, navy, pinto, red kidney and white kidney
45837323|NCT03830970|Dietary Supplement|White Rice|Minute Rice Long Grain White Rice
45837324|NCT01797978|Drug|Intravenous methylene blue administration|Initial history taking and physical examination --> enrollment --> 2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion of methylene blue for 6hrs
45837325|NCT01797978|Drug|Placebo|
45837326|NCT05508750|Other|New Infant Formula|New infant formula fed daily ad libitum
45837327|NCT05508750|Other|Commercial Infant Formula|Commercially available infant formula fed daily ad libitum
45837328|NCT05363202|Drug|Fluticasone propionate Inhalation Aerosol 44 mcg|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning & evening approximately. 12 h apart, Mode of Administration: Oral inhalation
46098062|NCT02636972|Drug|OCPs|"Participants in the contraceptive pill groups can use any one of the following contraceptive pills:~Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra"
45679551|NCT05516485|Other|Assessment|Undergo grading and recording of tumor consistency/stiffness
45463095|NCT03435081|Drug|Baricitinib|Administered orally
45463096|NCT03435081|Drug|Placebo|Administered orally
45463097|NCT03851029|Other|Tai chi|"Session:~• 3 times a week for 30-45 min.~Duration:~• For 6 weeks~Warm-up:~• 10-15 mints~Cool-down:~• 10-15 mints or stretching's~Exercises time:~• 20-30 mints"
45463098|NCT03851029|Other|Aerobic Training|"Session:~• 3 times a week for 30-45 min.~Duration:~• For 6 weeks~Warm-up:~• 10-15 mints~Cool-down:~• 10-15 mints or stretching's~Exercises time:~• 20-30 mints"
45679552|NCT05516485|Device|Magnetic Resonance Elastography|Undergo MRE
45463099|NCT04299100|Behavioral|Sleep Health Program for Participants with No/Mild Sleep Apnea|Participants randomized to the Sleep Health Program will receive the Self-Management for Sleep Care videos and digital materials.
45463100|NCT04299100|Behavioral|Sleep Health Program for Participants with Moderate/Severe Sleep Apnea|Participants randomized to the Sleep Health Program with suspected moderate/severe sleep apnea will receive the Self-Management for Sleep Care videos and digital materials, and be recommended for referral to a sleep clinic as part of standard of care.
45463101|NCT01294891|Other|Imaging|Contrast ultrasound perfusion imaging and complete echocardiography
45463102|NCT04458064|Other|LMA i gel|insertion of LMA for maintaining airway during anesthesia
45463103|NCT03850873|Drug|TQB3616|TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m，40mg，60mg，80mg，100mg，120mg once daily
45679553|NCT05514210|Behavioral|heart team meeting and discussion|When the patient is eligible for the study, the interventional cardiologist will invite a cardiac surgeon to conduct a heart team discussion. Both specialists will assess the patient comprehensively and make an optimal decision for the patient, with consideration patient's preference.
45679554|NCT05511519|Drug|ATI-450|Oral, small molecule MK2 inhibitor
45463104|NCT04458142|Other|Single buccal infiltration|painless technique for palatal anesthesia,single injection,single puncture given
45463105|NCT03853525|Drug|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one side of the inguinal region.
45463106|NCT03853525|Other|Semisolid vaseline|Product is applied to one side of the inguinal region.
45463107|NCT05133154|Biological|Blood samples|In total, about 20 ml of blood will be collected on EDTA tubes : collection of CTCs, TEPs and biobanking (V0, V1 and V2)
45463108|NCT01189903|Drug|Regorafenib|
45463109|NCT03849157|Procedure|pelvic floor reconstructive surgery|transvaginal mesh implantation for pelvic organ prolapse
45463110|NCT01189981|Behavioral|Lifestyle counseling|One health conversation at baseline
45463111|NCT01189981|Behavioral|eHealth intervention|SMS based encouragements to intensive exercise
45679555|NCT05511519|Drug|Placebo Oral Tablet|Placebo tablet manufactured to match ATI-450 in appearance
45463112|NCT03716583|Drug|Melatonin|25 mg
45679556|NCT05505565|Device|Abbott Freestyle Libre 2|Subjects will be educated on use of Abbott Freestyle Libre 2 and educated on how daily activities impact glucose.
45679557|NCT05505565|Other|Standard physical activity and nutritional counseling for prediabetes management|Subjects will be advised on recommendations for nutrition and activity goals for preventing progression of prediabetes.
45679558|NCT05503446|Other|Peanut in common foods or supermarket-sourced cow's milk (CM)|Participants will be given a set dose of peanut (e.g. peanut-containing cereal, whole peanuts) or cow's milk to take on a daily basis, as per protocol
45679559|NCT05503030|Drug|Nintedanib|Nintedanib
45463113|NCT03716583|Drug|Dimethyl Sulfoxide|150 mg
45463114|NCT03716583|Drug|Placebos|1 g
45463115|NCT02738008|Drug|ARC-520 Injection|IV injection
45463116|NCT02738008|Drug|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
45463117|NCT02738008|Drug|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
45463118|NCT02738008|Drug|antihistamine|All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
45473977|NCT03863015|Drug|isotonic saline|A one hour infusion of 100mL isotonic saline
45679560|NCT05497921|Device|handLITE LED device|handLITETM is a home use wearable LED phototherapy device. The device consists of a flexible silicone glove that contains red and near infrared light emitting diodes (LEDs) and a controller. The LEDs generate the light. The glove is worn on the hand and is held in place by an adjustable Velcro strap.
45679561|NCT05495243|Drug|ARINA-1|ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)
45679562|NCT05495243|Drug|Placebo|Isotonic saline (0.9%)
45463119|NCT01190059|Drug|Ex vivo lung perfusion with Steen Solution™|The circuit is primed with 2,000cc Steen Solution™. At one hour of EVLP, 500 cc of circulated perfusate was removed and replenished with 500 cc of fresh perfusate. After that, 250 cc of perfusate was exchanged every hour.
45463120|NCT03720249|Dietary Supplement|supplementation of compound nutrients|Betaine、 (6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc per day orally for 12 weeks.
45463121|NCT03720249|Dietary Supplement|placebo control|The placebo is an excipient and the color, flavor, shape, taste and weight are same with the tablet of supplement.
45463122|NCT01294969|Drug|AL-4943A|Once daily topical ocular allergy medication used for 7 days
46011411|NCT04536896|Other|Smartphone breastfeeding application|This intervention consists of a smartphone application which contains relevant information and topics regarding proper breastfeeding knowledge for medical students.
45463123|NCT05017090|Procedure|M-TAPA block|After tracheal intubation, a high-frequency linear probe will placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will inserted with in-plane technique and 25 ml 0.25 bupivacaine will be applied to the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side.
46098063|NCT02723981|Device|COMBO-Stent|The OrbusNeich COMBO Bio-engineered Sirolimus Eluting Stent (COMBO Stent) consists of a 316L stainless steel alloy abluminally coated with a biocompatible, biodegradable poly-mer containing sirolimus. Covalently attached to the surface of the stent is a layer of murine, monoclonal, anti-human CD34 antibody. The antibody specifically targets circulatory CD34+ cells (endothelial progenitor cells) thus favoring endothelialization.
46011412|NCT04536896|Other|Traditional face-to-face breastfeeding lecture|This intervention consists of the impartition of a face-to-face breastfeeding course
46011413|NCT01685190|Radiation|Prostate alone IMRT|Participants will receive standard prostate IMRT of 74Gy in 37 fractions delivered over 7.5 weeks.
46011414|NCT01685190|Radiation|Prostate and pelvis IMRT|Participants will receive prostate and pelvis IMRT with a dose of 74Gy in 37 fractions delivered over 7.5 weeks to the prostate and 60Gy in 37 fractions delivered over 7.5weeks to the pelvis.
46011415|NCT01685346|Behavioral|biofeedback-mediated stress management (BFSM)|Therapist and study assistant meet with patient, attach sensors, record physiologic variables and train the patient in relaxation techniques including deep breathing, guided imagery, progressive muscle relaxation, autogenics. Patient is given a handheld thermometer to take home and practice self-regulation between visits, along with a recording sheet to indicate how often practice occurs.
46011416|NCT04531124|Other|integrated management|establish an integrated management on cardio-metabolic risk factors including hypertension by updating and upgrading the daily practice of practitioners and screening patients
46011417|NCT01685385|Other|Patients who will receive the BNP test|Patients in Diagnostic Intervention Group A will receive the point-of-care BNP test, in addition to all other diagnostics they receive in addition
46011418|NCT04530968|Other|No intervention|No intervention
46011419|NCT01200394|Drug|PF-00489791|Tablet, 20 mg once daily for 12 weeks
46098064|NCT02723981|Drug|Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran|Anticoagulant medication after stent Implantation: (N)OAC and clopidogrel for 3 months followed by (N)OAC
46098065|NCT02723981|Device|Any drug eluting stent oder bare metal sent|Implantation of traditional bare metal stents and/or drug eluting stents (any device approved on the market, implanted according to CE marking and IFU) and medication regimen in accordance with ESC Guidelines
46098066|NCT02723981|Drug|ASA, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran|A combination of antiplatelet and anticoagulant therapy according to ESC guidelines (2014)
46011420|NCT01200394|Drug|Placebo|Tablet, placebo once daily for 12 weeks
46011421|NCT04527354|Drug|Treamid|Participants will receive Treamid 50 mg once a day during 4 weeks
46011422|NCT04527354|Drug|Placebo|Participants will receive Placebo once a day during 4 weeks
46011423|NCT04531280|Other|Home hospital care|Patients receive hospital-level care in their home.
46011424|NCT01685502|Drug|Glucobay ODT (Acarbose, BAYG5421)|Patients treated with Glucobay OD under practical manner
46098067|NCT00912444|Drug|Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 every 3 weeks for six cycles
45473978|NCT02937870|Device|Test Product 1|Test adhesive 1 with a thin nozzle
45473979|NCT02937870|Device|Test Product 2|Test adhesive 2 with a thin nozzle
45473980|NCT02937870|Device|Reference Product|Adhesive Cream
46011425|NCT04537130|Biological|IN01 vaccine|"INO1 vaccine is a biological compound comprising generated and purified from recombinant bacteria culture that contains a protein consisting of EGF-4-EGF portion and the Cholera Toxin B-Subunit Domain G33D sequence (CTB-G33D) separated by 4 amino acids and 14 amino acids respectively glycine/serine-rich linkers.~IN01 is a recombinant growth factor fusion molecule which, once injected into the patient, stimulates the immune system to produce polyclonal anti-Epidermal Growth Factor (anti-EGF) neutralizing antibodies. This vaccine-led active immunisation is a new approach to target the growth factor pathways allowing for combinations with other small molecule inhibitors in order to obtain a sustained efficacy with an acceptable toxicity.~The vaccine inhibits binding of circulating Epidermal Growth Factor (EGF) to its receptor, EGF-R to block downstream activation of cell signaling pathways contributing to tumor growth or other pathophysiologies such as fibrosis."
46011426|NCT04527276|Other|Oral care with 0,12% Chlorhexidine|0, 12 % CHX, and standard oral care with 0,9% NaCl were compared to assess VAP rates. Both solutions were applied to critically ill children who were intubated.
46098068|NCT00912444|Drug|Docetaxel, cyclophosphamide|Docetaxel 75mg/m2, cyclophosphamide 600mg/m2 every 3 weeks for six cycles
46011427|NCT04537052|Procedure|Ven Restoration Therapy|This is a novel and promising method, applied percutaneously, in the treatment of deep venous insufficiency . In this method, developed based on the effects of compression garments, a polymer consisting of cyanoacrylate and hyaluronic acid is injected, with ultrasound-guidance, percutaneously around the femoral vein. In this way, the diameter of the vein is reduced, and function is restored to the inadequately functioning valve. The procedure is also called percutaneous valvuloplasty. The underlying idea in the development of this product was that hyaluronic acid might cause an increase in connective tissue, while cyanoacrylate could serve as an exoskeleton by forming heavy tissue.
46011428|NCT01200355|Drug|micafungin|Micafungin 100 mg intravenously once daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
45679563|NCT05486078|Device|MD Tissue Collagen Medical Device|"The Experimental Group will be treated with 2-mL volume ultrasound-guided infiltration of: MD-Tissue (GUNA, Milan-Italy). Composition for 2 ml: collagen 100 micrograms Subjects will be treated with No.1 infiltration per week for 3 consecutive weeks. The infiltrations will be performed in an echoguided mode.~MD-Tissue Collagen Medical Device will be infiltrated into the trochanteric bursa and at the level of the tendons of the gluteus minimus and gluteus medius, particularly at the level of the most degenerated insertional areas."
45837329|NCT05363202|Drug|FLOVENT HFA 44 mcg|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning & evening approximately. 12 h apart, Mode of Administration: Oral inhalation
45837330|NCT05363202|Drug|Matching Placebo inhaler|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning & evening approximately. 12 h apart, Mode of Administration: Oral inhalation
46011429|NCT01200355|Drug|posaconazole|Posaconazole 400 mg orally twice daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
46098069|NCT02644525|Drug|Imatinib Mesylate|A single dose of imatinib 200mg PO is given
46011430|NCT04527705|Procedure|Non-surgical root canal retreatment|Non-surgical root canal retreatment
46011431|NCT04530929|Dietary Supplement|SANPROBI BARRIER|Competitors used probiotic for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).
46011432|NCT04530929|Dietary Supplement|PLACEBO|Competitors used placebo for three months at a dose of 2x2 capsules daily.
46011433|NCT01685541|Other|Maximum After Visit Summary Content|
46011434|NCT01685541|Other|Intermediate After Visit Summary Content|
46011435|NCT01685541|Other|Minimum After Visit Summary Content|
46011436|NCT01685541|Other|Usual AVS|
46011437|NCT04536818|Procedure|Laparotomy|Exploratory laparotomy.
46011438|NCT04527666|Drug|Anticoagulation Agents|Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.
46098070|NCT02644525|Drug|Imatinib Mesylate|A single dose of imatinib 400mg PO is given
46098071|NCT02644525|Drug|Imatinib Mesylate|A single dose of imatinib 600mg PO is given
46098072|NCT02644525|Drug|Placebo|A single dose of placebo pill is given
46098073|NCT02636894|Device|Restylane Silk|
46098074|NCT00726700|Biological|pegfilgrastim|Given subcutaneously
46098075|NCT00726700|Biological|rituximab|Given IV
46098076|NCT00726700|Drug|cyclophosphamide|Given IV
45473981|NCT02937870|Other|Negative Control|No adhesive
46098077|NCT00726700|Drug|doxorubicin hydrochloride|Given IV
46098078|NCT00726700|Drug|prednisone|Given orally
46098079|NCT00726700|Drug|vincristine sulfate|Given IV
46098080|NCT02535962|Biological|Lactobacillus acidophilus and Bifidobacterium lactis|study product will be freeze dried and put into foil sachets
46098081|NCT02535962|Other|Placebo|Placebo will look and taste like the investigational product. This also will be provided in a foil sachets
46098082|NCT02723903|Drug|Deanxit|we use Deanxit for the patient with anxiety
46098083|NCT02723903|Drug|Prozac|we use Prozac for the patient with depression
46098084|NCT02723903|Procedure|coronary artery disease treatment|including medication, coronary artery stent implantation according to the severity of stenosis of the coronary arteries
46098085|NCT00675714|Procedure|Stable Isotope Infusion Study|1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.
46098086|NCT00675714|Procedure|Collection of blood and tissues|Blood draw with each stable isotope infusion study and weekly Tissue biopsy: skin, fat, muscle at stable isotope infusion study
45679564|NCT05481411|Drug|Olpasiran|Subcutaneous injection
45679565|NCT05476926|Drug|Faricimab|Faricimab will be administered as per local clinical practice and local labeling.
45679566|NCT05476926|Combination Product|Port Delivery System with Ranibizumab|The port delivery system with ranibizumab will be administered as per local clinical practice and local labeling.
46098087|NCT00675714|Procedure|Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI|Testing to be done following every stable isotope infusion study to measure muscle, fat and bone tissues.
46098088|NCT00675714|Drug|Humatrope|Humatrope (Growth Hormone) dose:0.05mg - 0.2mg/kg/day SQ daily for up to 2 years post burn injury.
46098089|NCT00675714|Drug|Ketoconazole|Ketoconazole administration (or other glucocorticoid blocker--itraconazole or fluconazole) PO daily for up to 2 years post burn injury
46098090|NCT00675714|Drug|Oxandrolone|oxandrolone (or other anabolic steroid-testosterone or nandrolone) daily for up to 2 years post burn injury
46098091|NCT00675714|Drug|Propranolol|Propranolol (or other beta adrenergic blocker--metoprolol, inderol), PO administration daily for up to 2 years post burn injury.
46098092|NCT00675714|Drug|Oxandrolone and propranolol combined|Daily administration of oxandrolone and propranolol to be given for up to 2 years post burn injury.
46098093|NCT00675714|Drug|Humatrope and propranolol combined|Humatrope (growth hormone) and propranolol administration daily for up to 2 years post burn injury.
46098094|NCT00675714|Drug|Placebo|placebo to be given once a day for up to two years post burn injury.
45679567|NCT05468320|Drug|Caplacizumab|Lyophilized powder for solution for injection.
45837331|NCT05537064|Behavioral|Non-visit Based Intervention|At the beginning of the study period, PCPs will be sent an Inbasket message, a secure electronic messaging system included in EPIC, similar to an email. The message will notify them that pended orders for a referral to centralized pharmacy services for statin management will be entered for eligible patients unless the provider opts out. If no opt-out is received from the PCP within 7 days of receiving the message, their eligible patient panels will be referred to a centralized pharmacy team to begin pending referral orders to the PCP for eligible patients. Pharmacists affiliated with the centralized pharmacy service will then enter pended orders for referral to centralized pharmacy services that PCPs can sign either individually or in bulk. After the PCP signs the order for referral to centralized pharmacy services, a pharmacist from the centralized pharmacy team will then reach out to the patient on behalf of their PCP and discuss their indication for statin therapy.
46011439|NCT04530500|Genetic|COVID-19 Androgen Sensitivity Test (CoVAST)|The CoVAST Test is an in-vitro non diagnostic test. The test reports the genetic health risk of male patients in developing severe symptoms following COVID 19 infection. The genetic information provided by this test will help physicians evaluate the association of AR gene polymorphism with disease severity and mortality following COVID-19 infection. The CoVAST Test is indicated for reporting of the following variant associated with the following gene.
46011440|NCT01685580|Device|Manufacturer (VPAP ST)|non-invasive ventilation in two pressure levels 7 days before surgery
46098095|NCT00675714|Behavioral|Exercise--Hospital supervised intensive exercise program|intensive exercise program supervised by trained personnel in the hospital environment for six up to twelve week program.
45463124|NCT05017090|Other|Standard perioperative and postoperative multimodal analgesia|The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.
46011441|NCT01685658|Drug|Intravenous ketoprofen|Patients will recieve 100 mg of ketoprofen via slow intravenous perfusion. (100mg of ketoprofen powder for injection dissolved in 100 ml injectable isotonic solution)
46011442|NCT01685658|Drug|Intravenous paracetamol|Patients will receive 1g of paracetamol via slow intravenous perfusion. (100 ml of solution at 10mg/ml)
46011443|NCT04530578|Drug|Heparin sodium|Nebulized Heparin every 8 hours plus Subcutaneous Enoxaparin every 24hours
46011444|NCT04530578|Drug|Enoxaparin|Subcutaneous Enoxaparine every 24 hours
46011445|NCT01200238|Drug|STA-9090|
46098096|NCT00675714|Behavioral|Home exercise program|Home intensive exercise program: training occurs in hospital then patient sent home to continue exercise program for six weeks and up to 12 weeks at home.
45463125|NCT03720171|Device|e-OPRA Implant System|Implantation of e-OPRA Implant System in lower limb to be used with amputation limb prosthesis
45679568|NCT05468320|Drug|Corticosteroids|Solution for injection or Tablet
45679569|NCT05468320|Biological|anti-CD20 antibody|Solution for injection
45679570|NCT05465551|Combination Product|Stress Management Toolkit|The toolkit will be a home-based, dyadic tangible toolkit comprised of simple tools to help people living with dementia (PLWD) and their care partners manage stress at home. Potential tools for the toolkit includes low burden, high safety tools such as weighted blankets, robotic pets and baby dolls, guided journals, aromatherapy and bright light therapy devices, and massage and acupressure tools. The tookit will also include user-safety guidelines and directions on how to use each tool. Tools will be included for participants with dementia and care partners.
46011446|NCT01685853|Drug|Bisacodyl plus PEG-CS|"the day before colonoscopy: 3-4 bisacodyl tablets (according to patient bowel habit) at bedtime~the morning of colonoscopy: PEG-CS (2 litres) starting 5 hours before the exam"
46011447|NCT01685853|Drug|PEG 4 litres split|"the day before colonoscopy: 2 litres of PEG~the morning of colonoscopy: 2 litres of PEG starting 5 hours before the examination"
46011448|NCT04317976|Other|paralaryngeal pressure|cricoid pressure with paralaryngeal pressure by fingertips applied under ultrasound guidance
46011449|NCT04317976|Other|cricoid pressure|cricoid pressure by fingertips applied under ultrasound guidance
46098097|NCT03906214|Other|Web-based Survey|"Participants will be directed to online forms to report general information (ex. age, sex, test results, family history), suspected medication-related acute attacks, and uneventful use of possibly risky medication. If a patient has multiple medication-related acute attacks, the patient/caregiver will be able to submit multiple report forms that will be linked. In addition to the report forms, patients will be asked to review a list of Medications of Interest and report current or past use."
45679571|NCT05464498|Device|MD-Tissue Collagen Medical Device|"MD-Tissue (GUNA, Milan-Italy) Composition per 2 ml: collagen 100 micrograms Excipients: Ascorbic acid, Magnesium gluconate, Pyridoxine hydrochloride, Riboflavin, Thiamine hydrochloride, NaCl, Water for injection.~Subjects will be treated with No. 6 peri-tendon injections (2 infiltrations per week for three weeks)."
46011450|NCT04530422|Drug|Sofosbuvir plus Ledipasvir|"Sofosbuvir plus Ledipasvir, once daily for 15 to 21days~Oseltamivir 150 mg q 12 hours for 10 days ;~HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and~Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days."
45679572|NCT05464498|Other|eccentric strengthening protocol|Group B which, will implement only physiotherapy (eccentric strengthening protocol)
46011451|NCT02887573|Drug|Free-residue nutrients|This trial evaluated the efficiency of free-residue nutrients for the bowel prepartion of CCE.
46011452|NCT02887573|Drug|Low fiber diet|Low fiber diet often used in the bowel prepartion of CCE. In this study, it is the control group.
46011453|NCT02887573|Procedure|Colon capsule endoscopy|In the study,all patients should undergo two colonoscopies.The first is for examinations and the second for therapy.
45463126|NCT05140564|Behavioral|STEADY intervention|STEADY is a novel Cognitive Behavioural Therapy (CBT) based intervention for eating disorders in type 1 diabetes.
46011454|NCT02887573|Drug|2L PEG|2L PEG are laxatives for experiment group.
46011455|NCT02887573|Drug|4L PEG|4L PEG are laxatives in the control group.
45463127|NCT03850561|Dietary Supplement|Coenzyme Q10 200|Coenzyme Q10 200 mg/day
46098098|NCT00656240|Drug|DE-104 ophthalmic solution|
46011456|NCT02887573|Drug|PEG|These PEG are for boosters. All patients will take 0.75L and 0.5L PEG for two boosters.
46011457|NCT02887573|Drug|Mosapride citrate|5mg mosapride citrate are used to promote gastric motivity.
46011458|NCT01685892|Drug|Obinutuzumab|Participants will receive IV infusion of obinutuzumab 100 milligrams (mg) on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
45463128|NCT03850561|Dietary Supplement|Coenzyme Q10 400|Coenzyme Q10 400 mg/day
46011459|NCT01685892|Drug|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
46011460|NCT02887534|Drug|SPARC1401-low dose|SPARC1401- low dose
45679573|NCT05461170|Drug|VIR-2218|VIR-2218 given by subcutaneous injection
45679574|NCT05461170|Drug|VIR-3434|VIR-3434 given by subcutaneous injection
45679575|NCT05461170|Drug|NRTI|NRTI given orally.
45679576|NCT05459519|Drug|Dengzhanxixin Capsule plus Placebo Capsule|Dengzhanxixin Capsule, 0.54g (3 capsules) each time, twice daily; placebo, 1 capsule, twice daily
45679577|NCT05459519|Drug|Placebo|Placebo, 4 capsules each time, twice daily
46011461|NCT02887534|Drug|SPARC1401-mid dose|SPARC1401- mid dose
46011462|NCT02887534|Drug|SPARC1401-high dose|SPARC1401-high dose
46011463|NCT02887534|Drug|Reference1401 (Tizanidine)|Reference1401 (Tizanidine) three times a day
46011464|NCT02887534|Drug|Placebo1401|Placebo
46011465|NCT01685931|Drug|Paliperidone Palmitate|One intramuscular injection of paliperidone palmitate flexible dose will be administered on Day 1, Day 8, and monthly thereafter.
46011466|NCT04530461|Diagnostic Test|Serological test|Positive serological test of SARS Cov2
46011467|NCT01685970|Drug|High volume split-dose PEG|High volume split-dose PEG 2L/2L 2 times before the day and at the day of colonoscopy
46011468|NCT01685970|Drug|2 sachets of picosulfate|2 sachets of picosulfate 2 times for bowel preparation at the day of colonoscopy
46011469|NCT04530617|Drug|Camostat Mesilate|Tablets
46011470|NCT04530617|Drug|Artemisia Annua Leaf|Tea bags
46098099|NCT00656240|Drug|DE-104 vehicle|
46098100|NCT02611453|Other|"Air contrast cholangiography using carbon dioxide gas"|Carbon dioxide (CO2) will be injected into the biliary tree (which is already exposed to CO2 during routine ERCP) and images will be obtained by using fluoroscopy and digital subtraction imaging (a specific setting on certain fluoroscopy tables).
46098101|NCT00729976|Drug|Ibuprofen suppository|5-10mg/Kg of ibuprofen
46098102|NCT00729976|Drug|Ibuprofen Suspension|5-10mg/Kg
46098103|NCT00656318|Other|oral contraceptive pill (OCP; OCPs)|Daily administration of oral contraceptive pill for up to 3 months (2 months of daily administration required for the study).
46098104|NCT02451553|Drug|Afatinib Dimaleate|Given PO
46098105|NCT02451553|Drug|Capecitabine|Given PO
46098106|NCT02451553|Other|Laboratory Biomarker Analysis|Correlative studies
45473982|NCT03125434|Other|EOS full-spine, MRI, gait analysis|full-spine stereoradiography, high-resolution spine muscle MRI and 3D gait analysis will be performed
45473983|NCT03375970|Other|TCM|oral chinese herb, chinese topical ointment
46011471|NCT01686009|Drug|Intra-nasal ketamine|
46011472|NCT01686243|Other|epidural needle placement with echogenic 17G Tuohy needles (Pajunk TuohySono)|Anesthesiologist will place epidural with aid of ultrasound and placement with echogenic 17G Tuohy needles (Pajunk TuohySono)
46011473|NCT01686243|Other|standard epidural placement|Anesthesiologist will place epidural within standard practice, with standard needles.
46011474|NCT04530695|Other|Scaling and Root Planing|Periodontal treatment by scaling and root planing (SRP), deep cleaning
46011475|NCT01686282|Dietary Supplement|Freeze-dried Blueberry Powder|8 weeks of freeze-dried taken in two doses of 22g each per day.
45463131|NCT04971538|Diagnostic Test|OraQuick® HCV Self-Test|The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.
45463132|NCT01190137|Dietary Supplement|Cholecalciferol (D3) or ergocalciferol (D2)|400 IU administered as 1 drop daily for 3 months
45463133|NCT04180228|Other|self-administred questionnaire|On the occasion of a follow-up consultation with referent pediatrician, a self-administred questionnaire is distributed. It will take around ten minutes to the patient and her parents for completing the questionnaire. Questionnaire is anonymous. Participation is free and informed by an information notice. There is a list of items to complete by the patient and her parents. Most of questions are closed-ended. Clinical data are reported : age, level of education, principal disease (SLE or Juvenile arthritis), received treatments. In the questionnaire, it is asked if the patient is vaccinated or not for HPV, and reasons for it.
45463134|NCT02529839|Procedure|Autologous bone marrow transplantation|IMMUNOABLATIVE NONMYELOABLATIVE AUTOLOGOUS BONE MARROW TRANSPLANTATION on Day 0
45463135|NCT02529839|Drug|Fludarabine|30mg/m2 on days -6 through -3
45463136|NCT02529839|Drug|Cyclophosphamide|50mg/kg on days -5 through -4
45463137|NCT02529839|Drug|Alemtuzumab|3mg on day -3, 9mg on day -2, 12 mg on day -1
45463138|NCT03850639|Behavioral|Internet-based exposure therapy|The treatment is a three week long cognitive behavior therapy. It is based mainly on the principles of exposure; i.e. the participant is instructed to approach the memory of the traumatic event and situations they since the traumatic events are associated with fear and anxiety. Other interventions include psychoeducation, and breathing retraining to facilitate exposure.
46098107|NCT04065646|Other|Mobile|
45463139|NCT04458376|Behavioral|Internet-based self-help program|The program is divided into six short weekly lessons providing information about chronic dizziness and vestibular rehabilitation, and demonstrating the exercises by video. The program is freely available in the Norwegian electronic handbook for physicians (NEL). The participants in the study will receive the internet address after inclusion in the study.
45463140|NCT03473314|Drug|Nitric Oxide gas at 160ppm|Nitric oxide gas at 160 ppm inhaled three times daily for 50-80 min delivered with air as the carrier via inhalation for a maximum total of 90 days (extended 365 days twice). Total dose of 480 ppm hours per day.
45463141|NCT03945539|Drug|JNJ-56136379|Participants will receive JNJ-56136379 orally on Day 1 in Treatment Period 1 and on Day 38 in Treatment Period 2.
45463142|NCT03945539|Drug|Itraconazole|Participants will receive 200 mg of itraconazole once daily orally for 21 days starting on Day 34.
45463143|NCT01293019|Procedure|Osteopathic treatment|Real treatment of osteopathy
45463144|NCT01293019|Procedure|Sham Placebo|Sham treatment of osteopathy
45463145|NCT01293019|Procedure|Usual care|Classical treatment of pain in cystic fibrosis patients
45463146|NCT03796858|Drug|Guselkumab 100 mg|Participants will receive guselkumab 100mg as SC injection.
45463147|NCT03796858|Drug|Placebo|Participants will receive placebo as SC injection.
45463148|NCT01190293|Drug|Maraviroc|All patients (previously on an efavirenz-based therapy) will be administered maraviroc at 600mg twice-daily for 2 weeks.
45463149|NCT03950531|Other|No intervention|
45463150|NCT03945617|Behavioral|Unified Treatment Protocol|The Unified Treatment Protocol (UP) is a transdiagnostic psychotherapeutic treatment manual for emotional disorders, that is based on CBT principles and focuses on changing dysfunctional emotion regulation.
45463151|NCT03945149|Dietary Supplement|Turmipure Gold™|30 subjects will take 1000mg in 4 capsules (with 250ml water before breakfast , each day, during 5 weeks
45463152|NCT03945149|Dietary Supplement|Placebo|30 subjects will take 4 capsules with 250ml water before breakfast , each day, during 5 weeks
46098108|NCT02636816|Drug|carbetocin|drug used to increase the tone of uterine muscle to prevent post partum hemorrhage after cesarean delivery.
46098109|NCT02723825|Procedure|Closed reduction|Treated with Manipulatio, using plywood, gypsum or external fixation support to fixed
46098110|NCT02723825|Procedure|Open reduction|Open reduction and internal fixation
46098111|NCT00730054|Drug|Remifentanil+clonidine|iv Remifentanil+ iv clonidine
45463153|NCT03945227|Drug|standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001|drug: standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001 Arm A (consolidation only arm) will be treated with standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001 regimen. --For concurrent chemoradiation therapy, chemotherapeutic agents will follow the one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 D1, D8, D29, and D36; IV infusion - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 2 weeks after completion of radiation therapy (± 7 days), PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
45473984|NCT03375970|Other|Western medicine|oral steroid, oral antihistamine, topical steroid
45473985|NCT03862937|Dietary Supplement|Exercise training + whey protein|Whey protein (2x / day - 20g for breakfast and 20g for dinner).
46098112|NCT00866619|Biological|Malaria Vaccine 257049|administered intramuscularly into the left deltoid.
46098113|NCT00866619|Biological|Meningococcal C Conjugate Vaccine|administered intramuscularly into the left deltoid.
46098114|NCT00866619|Biological|Cell-culture rabies vaccine|administered intramuscularly into the left deltoid.
46011476|NCT01686282|Dietary Supplement|Placebo|8 weeks of freeze-dried taken in two doses of 22g each per day.
46011477|NCT04536389|Procedure|Office Hysteroscopy|"The hysteroscope with its light source and flowing fluid was gently introduced into the vagina allowing for gradual distention. Once this was accomplished, the anatomy was followed with delicate movements. The hysteroscope was advanced under vision to the level of the ectocervix, and guided into the endocervical canal. Once the endocervical canal was completely explored, the endoscope was advanced across the internal cervical os to allow evaluation of the panoramic view of the uterine cavity.~hysteroscopic correction of any detected lesion will be scheduled to the endoscopic operative list or the patient will receive the appropriate medical treatment."
46011478|NCT04536662|Drug|Hydrocortisone|The initial dose of hydrocortisone (20mg/tablet) was 15mg/m2/day to the maximum dose of 60mg, which was orally administered in three times, with the dose ratio of 2:1:3, and the administration time was 8:00-15:00-21:00.
45473986|NCT03862937|Other|Exercise training + placebo (maltodextrin)|Maltodextrin (2x / day - 20g for breakfast and 20g for dinner).
45473987|NCT03743623|Device|Neurocytotron|Neurocytotron utilizes a combination of instantaneous magnetic field and low-spectrum radiofrequency waves for therapeutic purpose. Its working principle is based on the theory of magnetic resonance.
45473988|NCT03743623|Device|Placebo|Same treatment procedures without being actually exposed to electromagnetic waves and magnetic field
45837332|NCT05537064|Behavioral|Visit-Based Intervention|"The study team will build an interruptive BestPractice advisory (BPA), a pop-up notification in the EHR that is delivered to the PCP when they open the patient's chart during a non-acute patient visit. The BestPractice Advisory will describe the guideline criteria for which the patient is eligible for statin therapy, and recommend referral to a centralized pharmacy service for statin initiation and management. It will also include a link to a menu for prescribing an appropriate-dose statin, should the PCP want to prescribe a statin without referral to pharmacy services. The option for ordering referral to centralized pharmacy services will be pre-selected, such that if the PCP simply clicks Accept on the BPA, an order for referral to centralized pharmacy services for statin initiation and management will be generated."
45837333|NCT05461092|Drug|Thoracolumbar Interfascial Plane (TLIP) Block of bupivacaine|Patient receives standard of care anesthesia with TLIP Block of bupivicaine (local anesthetic) intraoperatively after anesthesia administration and before spinal fusion.
46098115|NCT00866619|Biological|TritanrixHepB/Hib|administered intramuscularly into the left deltoid.
46098116|NCT00866619|Biological|Polio Sabin Oral Polio Vaccine (GSK)|administered orally.
46098117|NCT00693108|Drug|Transdermal testosterone|
46098118|NCT02913131|Drug|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
45463154|NCT03945227|Drug|PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001|drug:PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001 Arm B (concurrent arm) will be treated with PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001 regimen. -For concurrent chemoradiation therapy, chemotherapeutic agents will follow one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 days 1,8,29, and 36; IV infusion - Concurrent PDR001 400mg at D1, D29 - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 4 weeks after last dose of PDR001, PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
45463155|NCT01108133|Drug|10 mg HydrocortisoneHöchst|10 mg Hydrocortisone Höchst are administered one hour before fMRI scanning
45463156|NCT01108133|Drug|Dexamethasone|2 mg Dexamethasone are administered at 10 pm the day before the fMRI experiment.
45463157|NCT01108133|Drug|Placebo|Placebo
46098119|NCT02913131|Device|MRI|MRI scan following the pyruvate (13c) injection
46011479|NCT04536662|Drug|Prednisone|The initial dose of prednisone (5mg/tablet) was 3mg/m2/day to the maximum dose of 15mg. The dosage ratio was 1:2 and the administration time was 8:00 and 21:00.
46011480|NCT04536662|Drug|Dexamethasone|The initial dose of dexamethasone (0.75mg/tablet) was 0.3mg/m2/day to the maximum dose of 0.75mg and the administration time was 21:00.
46011481|NCT01686321|Drug|Bendamustine and subcutaneous rituximab|
46011482|NCT01199731|Drug|GSK2248761 100 mg once daily|1 100mg capsule OAD plus matching placebo
45463160|NCT01108211|Device|Vibration Platform|The patients receive treatment by standing on the Vibration Platform 20 minutes a day, five days a week. The platform will deliver a vibration of 0.3g with a vertical displacement of 0.085mm at 35 Hz.
45463161|NCT04587934|Device|iRes Warmer with ResusView|Rapid heart rate display utilizing optimized ECG algorithm in iRes Warmer in babies delivered between 23+0 and 32+6 weeks estimated gestational age
45679578|NCT05459519|Drug|Dengzhanxixin Capsule plus Placebo Capsule|Dengzhanxixin Capsule, 0.72g (4 capsules) each time, once daily; placebo, 4 capsules, once daily
45679579|NCT05456490|Drug|Liposomal Bupivacaine 13.3|Injection into the Intrathecal space
45679580|NCT05456490|Drug|Bupivacaine|Injection into the Intrathecal space
45679581|NCT05456490|Other|Placebo|Injection into the Intrathecal space
45679582|NCT05445674|Combination Product|Plasma Exchange Procedure|Plasma exchanges will be performed with 5% albumin as the replacement fluid. The typical schedule prescribed will be an exchange of 1 volemia. Blood will be separated into cells and plasma; the cells will be combined with reconstituted 5% human serum albumin and reinfused into the patient with normal saline
45837334|NCT05461092|Diagnostic Test|Blood Test|Blood Tests measuring inflammatory markers: IL-10, MCP-1, NfL
45837335|NCT05461092|Other|3D CAM Delirium Severity Scoring|Questionnaire that will rate each symptom of delirium
46011483|NCT01199731|Drug|GSK2248761 200 mg once daily|2 100mg capsules OAD
46011484|NCT01199731|Drug|Etravirine|2 100mg tablets twice daily
46011485|NCT01686360|Behavioral|Decision Aid|
45837336|NCT05461092|Other|Generalized Anxiety Disorder 7-item (GAD-7) scale|Questionnaire for screening and severity measurement of generalized anxiety disorder.
45837337|NCT05461092|Other|Numerical Rating Score (NRS)|Questionnaire assessing pain intensity
45837338|NCT05461092|Other|PROMIS-Pain Interference|Questionnaire measuring the effect of pain on patient physical, emotional, and social functioning.
45837339|NCT05461092|Other|Oswestry Disability Index (ODI)|Questionnaire assessing disability and quality of life impairment in adults with lower back pain.
46011486|NCT04530266|Diagnostic Test|Six minute walk test|Assessment of walking related performance fatigability using six minute walk test
46011487|NCT01686399|Behavioral|Nutritional and Activity Promotion|Multi disciplinary nutritional and behavioral messages to improve diet and activity levels
46011488|NCT01686555|Drug|ABT-199|Tablet
46011489|NCT01686555|Other|Placebo|Tablet
46011490|NCT04529993|Procedure|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
46011491|NCT01686672|Behavioral|Web Intervention|Behavioral
46011492|NCT02217371|Other|Neuropsychological tests|"The tests are :~Go/NoGo paradigm, Continuous Performance Test (CPT) II , Wisconsin Card Sorting Test (WCST), virtual CPT, Classic and virtual Stroop, PSG, MWT~These tests will be repeated during 32h each 4h (T0h, T4h, T8h, T12h, T16h, T20h, T24h, T28h et T32h)."
46011493|NCT05396053|Other|Physical therapy exercises|Three times a week for 8 weeks.
46011494|NCT05396053|Other|Mirror therapy|Three times a week for 8 weeks.
46011495|NCT01686711|Drug|AD-4833 15 mg|
46011496|NCT01686711|Drug|AD-4833 30 mg|
46011497|NCT01686711|Drug|Placebo|
46011498|NCT05393596|Behavioral|Virtual Reality Software Intervention|Virtual Reality Software Intervention
46011499|NCT02217488|Drug|DG3173|
46011500|NCT02217488|Drug|Placebo|
46098120|NCT00689286|Device|BION|"They will be divided into three groups. Two groups of experimental subjects will receive stimulation using BIONs. The first group will have a stimulation paradigm like that used in a previous feasibility study that preceded the proposed trial, using low-frequency (1-5 PPS) twitch stimulation. The second group will have a stimulation paradigm in which tetanic-frequency stimulation (25-50 PPS) is used to produce fused muscle contractions. A third group of experimental subjects will have a standardized program of voluntary exercise.~In Groups 1 and 2, the femoral nerve will be stimulated electrically according to the assigned protocol during the 12 week experimental period after implantation of the devices. Individuals assigned to Group 3, receiving conventional exercise therapy for 12 weeks, will be allowed to receive BIONs at the end of the trial, providing they request BION therapy and they have been at least minimally compliant with the exercises."
46098121|NCT03342274|Behavioral|Lifestyle Program|Participants will receive group weight loss sessions addressing healthy eating, exercise, and weight loss principles adapted from the Diabetes Prevention Program delivered by Community Health Workers.
46098122|NCT03342274|Other|Usual Care|Usual care consists of chronic disease management through medication delivery and monitoring of weight, blood pressure, and blood glucose by Community Health Workers.
46098123|NCT00884390|Drug|moroctocog alfa (AF-CC) (ReFacto AF)|Providing moroctocog alfa (AF-CC) as test article for use during this study.
46098124|NCT00884390|Procedure|Laboratory tests|Laboratory samples are collected during study visits, in order to collect safety and efficacy data related to the administration of test article.
45679583|NCT05445674|Other|Sham Plasma Exchange Procedure|For sham plasma exchange procedures, a sound behind the curtain will be performed imitating the sound of the cell processing platform. In these cases, only one infusion of 200 to 250ml of sterile saline solution 0.9% will be performed during the time stablished for all procedures. Albumin will not be necessary for those patients in the Sham plasma exchange arm
46098125|NCT02723669|Drug|AR10|effervescent tablet
45679584|NCT05441449|Device|Cooling Vest|"A self-regulating cooling vest for persons with SCI that can utilize both conductive and evaporative methods to dissipate body heat as a proof-of-concept to prevent an excessive rise in Tcore and thermal discomfort during a controlled exposure to a warm environment. The vest is an article of clothing, is made of commercially-available wicking material, which once saturated with water, uses evaporation to dissipate heat. Channels embedded in the vest supply cooled water to keep the wet vest cool. The cooling capacity of the vest is regulated by a microprocessor which continuously receives feedback from the user's skin and core temperature. The vest is non-invasive and supplies no energy to the user."
45679585|NCT05441137|Behavioral|Ride-On Cars Training with Different Postures|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 12-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual-effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
45837340|NCT05461092|Other|Saint Louis University Mental Status Examination (SLUMs)|Questionnaire assessing baseline cognition.
46011501|NCT04536740|Device|PDT treatment device|All patients will be treated under general anesthesia. After carefully covering the normal skin, hematoporphyrin monomethyl ether (HMME; Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Shanghai, China) was i.v. transfused at a dose of 5 mg/kg for 20 min at a constant rate. Five to 10 min after the onset of HMME transfusion, continuous irradiation at 532 nm (532-nm light-emitting diode green-light therapeutic apparatus; Wuhan Yage Optic and Electronic Technique, Wuhan, China) was applied with a power density of 80- 95 mW/cm2 for 20-30 min. Concomitant forced air cooling was applied during irradiation for epidermal protection. Post-treatment skin cooling was performed by intermittent application of ice packs over a 3-day period, to minimize pain and potential thermal damage. To prevent the effects of photosensitivity, patients were instructed to avoid exposure to strong light for at least 14 days after treatment.
46011502|NCT01686789|Drug|Pegylated interferon alpha-2a|
46011503|NCT02217605|Dietary Supplement|Fructose|Oral Fructose Challenge (75 g fructose in 500 ml water) following overnight fast
46098126|NCT02723669|Drug|acetylcysteine|oral solution
46098127|NCT04052646|Other|Medical condition: Subarachnoid hemorrhage|We identify patients with the condition of interest and retrospectively collect data on them.
46011504|NCT01686867|Device|Improved, ventilated cookstove|"An improved, ventilated cookstove incorporates the following key elements: burner openings customized to the size and shape of the cooking utensils; a flue designed to draw air into the fire box and pass it out through a chimney; a chimney, vented to the exterior, of adequate height to create a draft; an exterior port that has bidirectional openings to prevent the backflow of smoke and an access port for the chimney that permits cleaning.~The investigators piloted cookstoves prior to the trial and compared their ability to reduce indoor air pollution, the reliability between cookstoves of the same type, the functionality over time, preferences and cultural compatibility, and cost. The investigators selected the the Envirofit G-3300/3355, a modified Stovetec cookstove with a chimney and a locally-made improved, ventilated cookstove for use in the trial."
45463162|NCT04587934|Other|iRes Warmer without ResusView|Electrocardiogram monitoring using external ECG monitor in babies delivered between 23+0 and 32+6 weeks estimated gestational age
45463163|NCT01108289|Other|Oxytocin in Uniject|10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
45463164|NCT03471286|Drug|Epacadostat|Drug is taken orally two times per day for 14 days, prior to surgical resection of tumor.
46098128|NCT03269500|Other|use of nutrition education tools|"Use of different nutrition education tools :~General advice: feeding seniors~Oral supplementation: instructions for use~Information about enriched food~Food modified in texture: chopped masticatory disorders, chopped swallowing disorders, co-mingled~How should I drink? : With stimulus, texture syrup / nectar, velvety texture, texture compote / cream~Recipe booklets for people to easily eat (chewing disorders) or recipe with molded texture (swallowing disorders)"
45463165|NCT03489369|Drug|Sym022|Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
45463166|NCT03516838|Drug|ACTIVA™ BioACTIVE|Restorative Dental Material: Permanent resin containing filling dental material with bioactive properties to restore decayed teeth
46011505|NCT02217644|Drug|BI 653048 H3PO4 solution|
46011506|NCT02217644|Drug|BI 653048 H3PO4 low dose capsule|
46011507|NCT02217644|Drug|BI 653048 H3PO4 high dose capsule|
46011508|NCT02217644|Drug|Placebo|
46011509|NCT04536311|Procedure|internal fixation of mulitiple rib fracture|The dislocated rib fracture was anatomically reduced, and then fixed with appropriate equipment to prevent the fracture from being displaced again
46011510|NCT02217683|Drug|Nitric Oxide|Nitric oxide at 80 part per million will be administrated by inhalation for approximately 1 hour during the blood transfusion
46011511|NCT04536233|Biological|MSCs Derived Pleiotropic Factors|The pleiotropic factor derived from mesenchymal stem cells was injected on the wound
46011512|NCT04536233|Other|physiological saline|The physiological saline was injected on the wound
46011513|NCT02217722|Other|Ulcerative Colitis Diet|we have postulated that a diet that increases butyrate through fiber exposure, reduces intestinal sulfur exposure, and increases vitamin D levels could be beneficial for patients with Ulcerative Colitis. To date, no study has explored this possibility.
46011514|NCT02217722|Drug|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
46011515|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end dose of 20 mg. For oral administration.
45463167|NCT03516838|Drug|Compomer|Restorative Dental Material: Permanent resin containing filling dental material to restore decayed teeth
45463168|NCT03947489|Drug|Sarpogrelate HCL 300mg|a single oral dose administration in healthy volunteers under fasting condition
45463169|NCT03947411|Drug|Oseltamivir Phosphate|Take the dosage of Oseltamivir Phosphate recommended according to the instructions.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
45463170|NCT03947411|Drug|Xiyanping injection+Oseltamivir Phosphate|Take the dosage of Oseltamivir Phosphate recommended according to the instructions.Xiyanping injection intravenous administration of 0.4mL/kg/day ,QD for 7-10 days.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
45463171|NCT03257254|Drug|Varithena|Administration procedures and volume are per standard of care, full prescribing information, and instructions for use.
46011516|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg or 40 mg. For oral administration.
46011517|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg, 40 mg or 60 mg. For oral administration.
46011518|NCT01686945|Drug|placebo|Placebo semaglutide. For oral administration.
45463172|NCT04035239|Device|BGS goggles|BGS goggles use for 3-6 weeks
45463173|NCT03944837|Other|Oxygen gas|Transient maternal oxygen administration during echocardiographic and MRI imaging
45463174|NCT03944759|Procedure|serratus anterior plan block|serratus anterior plan block
45463175|NCT01327469|Drug|Albendazole, 2 x 400mg|Albendazole 2 x 400mg
45463176|NCT01327469|Drug|Albendazole 400mg|Albendazole 400mg
46011519|NCT01686945|Drug|placebo|Placebo semaglutide with carrier. For oral administration.
46011520|NCT04536506|Other|Bobath Therapy|Bobath group received 45 min of sessions three times weekly for 12 weeks. An individual program was scheduled for each case following pre-assessment. It was targeted to enable normal posture, facilitation of corrective balance and protective responses and development of normal movement patterns
46098129|NCT02719379|Biological|Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)|
46011521|NCT04536506|Other|Vojta technique|Vojta group received the following three times weekly for 12 weeks: 1. Reflex crawling, 2. First stage of reflex turning, 3. Second stage of reflex turning. Stimuli (pressure and stretch) for 30-60 sec were given by using the main stimulus points and auxiliary stimulus points together.
45463177|NCT01327469|Drug|Mebendazole 500mg|Mebendazole 500mg
45463178|NCT01327469|Drug|Mebendazole 2 x 500mg|Mebendazole 2 x 500mg
46011522|NCT01686984|Other|Altered breath|
46098130|NCT02719223|Device|NICaS|The NICaS is a non invasive device for measuring and calculating of hemodynamic parameters including mean arterial pressure (mm/Hg), cardiac index (l/min/m2) and total peripheral resistance (dynes/sec/cm5).
46011523|NCT02217839|Drug|DG3173|
46011524|NCT02217839|Drug|DG3173+Octreotide|
46011525|NCT02217839|Drug|Octreotide|
46011526|NCT02217839|Drug|DG3173 Placebo|
45463179|NCT01327469|Drug|Pyrantel-oxantel + mebendazole|Pyrantel-oxantel + mebendazole
45463180|NCT03945071|Device|Punctal plug|Punctal plug will be given to subjects after intravitreal injection in half of the study subjects
46011527|NCT02217839|Drug|DG3173 Placebo+Octreotide Placebo|
46011528|NCT02217839|Drug|Octreotide+DG3173 Placebo|
46011529|NCT02217917|Drug|Rivipansel|Rivipansel administered as a single dose subcutaneously with rHuPH20 in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of rivipansel). The planned dose levels are 350 mg, 1210 mg, and 4200 mg (these are subject to change based on emerging data).
45679586|NCT05441137|Behavioral|Conventional Therapy|The other independent OT will be responsible for providing conventional therapy based on the developmental and motor learning theories. The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve mobility, socialization and upper limb use in functional tasks.
46011530|NCT02217917|Drug|Placebo|Matched Placebo administered as single dose subcutaneously with rHuPH20.
46011531|NCT02217917|Drug|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 1400 mg loading and 700 mg maintenance for 12 doses (these are subject to change based on emerging data).
46011532|NCT02217917|Drug|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 2800 mg loading and 1400 mg maintenance for 12 doses (these are subject to change based on emerging data).
46011533|NCT02217917|Drug|Placebo|Matched Placebo administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20.
46011534|NCT01687062|Other|FeSO4|
46011535|NCT01687062|Other|reduction of phytate|
46011536|NCT01687062|Other|NaFeEDTA|
45463181|NCT01102049|Dietary Supplement|fish, beef, fruit|
45837341|NCT05461092|Other|Delirium Rating Scale-Revised-98 (DRS)|16 item clinician rated scale assessing delirium severity.
45837342|NCT05461092|Other|Telephone Interview for Cognitive Status - Modified (TICS-M)|Telephone interview questionnaire evaluating patient cognitive status.
46011537|NCT02217956|Drug|Cisplatin|
46011538|NCT02217956|Drug|Bevacizumab|
46011539|NCT01687140|Drug|D-Cycloserine|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
46011540|NCT01687140|Drug|Placebo|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
46098131|NCT04139148|Device|Ture Transcranial Direct Current Stimulation (tDCS)|Ture 1-2 mA current of tDCS intervention in patients' binary brain DLPFC areas(20 mm).
45463182|NCT03950141|Drug|Apatinib and S-1|Combined with Apatinib (250mg qd po) and S-1 (40-60mg bid d1-14) as maintenance therapy in advanced HER-2 negatived GC
45473989|NCT03862703|Device|mHealth intervention, PTSD Help app.|Experimental group will receive the app, PTSD Help.
45837343|NCT05461092|Other|Opioid Equivalents measured by Morphine Milligram Equivalents (MME)|The amount of opioids administered will be collected through patient self-report
45837344|NCT05461092|Other|Patient Health Questionnaire depression scale (PHQ-8)|Questionnaire used to diagnose and determine the severity measure for depressive disorders.
45837345|NCT05461092|Other|Pain Catastrophizing|Scale used to determine pain catastrophizing and it's severity.
46011541|NCT04535960|Drug|Empagliflozin 25 MG + Liraglutide 1.8 MG|Patients will be randomized to initial therapy with empagliflozin 25mg PO daily for 6 weeks. After that, patients in the empagliflozin group will also receive liraglutide 1.8mg SC daily for additional 6 weeks.
46011542|NCT04535960|Drug|Liraglutide 1.8 MG + Empagliflozin 25 MG|Patients will be randomized to initial therapy with liraglutide 1.8 mg SC daily, for 6 weeks. After that, patients will also receive empagliflozin 25mg PO daily for 6 weeks.
46011543|NCT02270463|Drug|SL-401|
46098132|NCT04139148|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Sham tDCS intervention in patients' binary brain DLPFC areas(20 mm).
45463183|NCT01108601|Drug|Ringer's Lactate (0.03% Ciprofloxacin)|For each patient, only one ear will receive the Ringer's Lactate solution. The other ear will act as a control. To ensure adequate delivery of the solution to the middle ear, a small pressure equalizing tube will be inserted under local anesthesia before commencement of chemotherapy treatment. The patient will be instructed to administer four drops of RL solution to the experimental ear twice a day during their chemotherapy treatment.
45837346|NCT05461092|Other|Fear Avoidance Beliefs Questionnaire (FABQ)|Questionnaire used to help predict patients that have a high pain avoidance behavior.
46011544|NCT04536428|Device|Endoscopic hemostasis with clip|"This intervention is performed as the following orders.~The tip of endoscope is accessed to a bleeding site.~The accurate visualization of bleeding site is done.~A sheath of delivery system of clip is inserted through a working channel of endoscope.~The end of clip is opened in front of the bleeding site. If needed, clip could be rotated to adjust to a bleeding target.~The both ends of clip are placed on both sides of a bleeding site.~If bleeding is still continued, additional placements of clip are tried until bleeding stops."
46011545|NCT01687374|Drug|1-84 parathyroid hormone|100 micrograms of 1-84 parathyroid hormone daily for 8 weeks, subcutaneous injection.
46098133|NCT04065412|Procedure|Conventional laryngeal handshake technique|The conventional laryngeal handshake technique is performed with the non-dominant hand, identifying the hyoid bone and thyroid laminae, stabilizing the larynx between thumb and middle finger, and moving down the neck to palpate the cricothyroid membrane with the index finger.
46098134|NCT04065412|Procedure|Modified laryngeal handshake technique|The modified laryngeal handshake is performed with the non-dominant hand, stabilizing the trachea between thumb and middle finger from the suprasternal notch and moving up the neck to palate the cricoid cartilage and cricothyroid membrane with the index finger.
46098135|NCT00689442|Drug|JTT-705 600 mg and atorvastatin 20 mg|"JTT-705 300 mg tablets, 600 mg dose, oral, once daily, immediately following breakfast and/or assessment~Atorvastatin 20 mg tablets, 20 mg dose, oral, once daily, immediately following breakfast and/or assessments"
46098136|NCT00689442|Drug|Placebo and atorvastatin 20 mg|"Placebo tablet, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~Atorvastatin 20 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments"
46098137|NCT02719457|Other|6 minute walk test (6 MWT)|6 minute walk test is the standard testing for COPD patients to evaluate their exercise capacity
45463184|NCT03738475|Drug|TIMP-GLIA|8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8.
45463185|NCT03738475|Drug|Placebo|Administered intravenously on days 1 and 8.
45463186|NCT03944369|Other|KB109|KB109 is a novel glycan
45463187|NCT03944369|Other|No intervention|No intervention
45473990|NCT02519920|Drug|fluorescein sodium 0.01ml/kg|fluorescein Sodium Dose of 0.01ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
45473991|NCT02519920|Drug|fluorescein sodium 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
45837347|NCT05461092|Other|Opioid Side Effects and Likeability Questionnaire|Survey determining adverse events related to opioid side effects and complications.
46011546|NCT01687374|Drug|Placebo|Saline injection daily for 8 weeks.
46011547|NCT04530188|Drug|Sevoflurane|Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)
46011548|NCT04530188|Drug|Propofol|Intravenous sedation with propofol, as already used in our ICU
46011549|NCT01687452|Biological|Blood samples|
46011550|NCT02216162|Other|Arm A: adapted physical activity + enhanced geriatric follow-up|"Patients have 3-monthly geriatric follow-up with biological tests, anti-aromatase agents blood dosing and a clinical assessment (M3 to M9, M15 to M22 and M27 to M33). Musculoskeletal adverse events and quality of life level will be reported and analgesic treatment adapted. Patients will be proposed weekly Taï-Chi exercises to improve joint flexibility, muscular tonus and balance and reduce fall risk.~A broader geriatric assessment including functionality, gait analysis and nutrition will be performed each year (M12, M24 and M36)."
46011551|NCT02216162|Other|No intervention|Usual clinical follow-up
46011552|NCT01687491|Drug|ENOXA®|enoxaparine 100 UI/Kg subcutaneous injection
46098138|NCT02719457|Other|Spot marching test (SMT)|Spot marching test is a new test that developed to evaluate their exercise capacity of COPD patients. This test is alternative method and practical to evaluate exercise capacity. The main benefit of this testing is use a small area to test and movement pattern involve both arm and leg. We expect that SMT may make COPD patient to more dyspnea in a short period of exercise.
45473992|NCT02519920|Drug|fluorescein sodium 0.05ml/kg|fluorescein Sodium Dose of 0.05ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
45473993|NCT02519920|Drug|fluorescein sodium 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
46011553|NCT01687491|Drug|LOVENOX®|enoxaparine 100 UI/Kg subcutaneous injection
45679587|NCT05440123|Other|screening for bronchopulmonary cancer|The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation
46011554|NCT04530071|Biological|CordSTEM-DD (0.7 x 10^7 cells)|CordSTEM-DD (0.7 x 10^7 cells)
46098139|NCT02570386|Procedure|Fresh embryo transfer|Women allocated to the control arm will either undergo embryo transfer at cleavage stage or extended culture and transfer at blastocyst stage according to local policy. A maximum of 2 embryos or blastocysts will be replaced according to the standard protocol under transabdominal ultrasound guidance. Luteal phase support is given according to local protocols.
46011555|NCT04530071|Biological|CordSTEM-DD (2.1 x 10^7 cells)|CordSTEM-DD (2.1 x 10^7 cells)
46011556|NCT04530071|Biological|Placebo|HA + saline + placebo comparator
46011557|NCT01687530|Procedure|AMCA Bone Membrane.|AMCA Bone Membrane, as a bone stimulating aid for orthopedic trauma applications.
46011558|NCT04530227|Drug|Biological: Camrelizumab|PD-1
46011559|NCT04530227|Drug|Pemetrexed|chemotherapy
46011560|NCT04530227|Drug|Nab-paclitaxel|chemotherapy
46011561|NCT01687569|Other|Control Cracker Snack|Base cracker snack
46011562|NCT01687569|Other|Experimental Cracker Snack 1|Cracker snack containing test ingredient 1
46011563|NCT01687569|Other|Experimental Cracker Snack 2|Cracker snack containing test ingredient 2
46098140|NCT02570386|Procedure|Frozen embryo transfer|Fresh embryo transfer will not be undertaken. Embryos will be frozen by vitrification or slow freezing at cleavage or blastocyst stage according to standard agreed local protocols. Women will be contacted after 4 weeks and arrangements made for frozen embryo transfer.
46098141|NCT02625636|Drug|SAR438544|"Pharmaceutical form: solution~Route of administration: subcutaneous"
46098142|NCT02625636|Drug|placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
46098143|NCT02625636|Drug|r-glucagon|"Pharmaceutical form: solution~Route of administration: subcutaneous"
46098144|NCT03012100|Drug|Cyclophosphamide|Given PO
46098145|NCT03012100|Other|Laboratory Biomarker Analysis|Correlative studies
46098146|NCT03012100|Biological|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
46098147|NCT03012100|Other|Placebo Administration|Given ID
45679588|NCT05437393|Device|Deep brain stimulation|Deep brain stimulation of the centromedian nucleus (bilateral)
46011564|NCT01199263|Other|Laboratory Biomarker Analysis|Correlative studies
46011565|NCT01199263|Drug|Paclitaxel|Given IV
46011566|NCT01199263|Biological|Pelareorep|Given IV
46011567|NCT04529837|Device|Dilapan-S|Use of dilapan-S for induction cervical ripening agent
46011568|NCT01687647|Other|low-dose CT-scan AND induced sputum sample AND blood test|All subjects will receive a low-dose CT-scan, a blood test (ancillary study) and provide an induced sputum
46011569|NCT02217995|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|"MBCT teaches patients to become more aware of, and to relate differently to, their thoughts, feelings, and bodily sensations. Through MBCT, patients will learn skills that allow them to disengage from habitual (automatic) dysfunctional cognitive routines, such as obsessional thinking. As an example, patients are encouraged to relate to thoughts and feelings as passing events in the mind, rather than to identify with them or treat them as accurate representations of reality. The MBCT protocol for OCD patients is adapted from Segal et al.'s original MBCT manual for depression (Segal, Williams & Teasdale, 2002)."
46011570|NCT01687725|Device|Renal denervation using Symplicity Catheter system|percutaneous selective renal sympathetic nerve ablation with the use of the Symplicity Catheter system
46011571|NCT02218034|Drug|AGN-190168 Formulation 1|AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
46011572|NCT02218034|Drug|AGN-190168 Formulation 2|AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
46011573|NCT02218034|Drug|tazarotene gel 0.1%|Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
46011574|NCT02218034|Drug|tazarotene cream 0.1%|Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
46098148|NCT03012100|Biological|Sargramostim|Given ID
46098149|NCT02379247|Drug|BYL-719 (alpelisib)|Oral PI3K inhibitor
46098150|NCT02379247|Drug|Nab-paclitaxel|IV taxane
46098151|NCT00689520|Drug|tinzaparin|tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
45463188|NCT03684629|Behavioral|the response of KPI and corresponding suggestion|Standardized templates of medical record, evidence-based clinical pathway, and written care protocols are applied in all hospitals.The KPI of the AIS patients who were admitted to a single hospital continuously at the time of hospitalization were studied. Feedback system of performance measures: the hospital included in the study upload the medical records of all AIS patients by medical records scanning system since that month into the group. Quality control platform of Cerebral apoplexy in Zhejiang province extracts and analyze the data through the computer and calculates the corresponding monthly KPI. The hospitals will receive their own monthly KPI and the monthly highest KPI of all hospitals included in the study. Expert online consultation: based on the compare of the monthly KPI of all hospitals, Quality control platform will give corresponding suggestions to all hospitals for the improve of next month.
45463189|NCT01108913|Drug|Bimosiamose|
45463190|NCT01108913|Drug|Placebo|
45463191|NCT03666845|Procedure|Sciatic nerve block|Sciatic nerve block will be performed using ropivacaine (2.5mg/kg) under ultrasound-guidance with nerve stimulator.
45463192|NCT03084718|Drug|CHF 718 pMDI|Dose Response: Test one of three different doses of CHF 718 pMDI
46098152|NCT00689520|Drug|acenocoumarol|tinzaparin subcutaneously 175 IU anti-Xa/kg of body weight once daily for 7 days followed by acenocoumarol for 6 months
45463193|NCT03084718|Drug|Placebo pMDI|Placebo Control
45463194|NCT03084718|Drug|Beclomethasone Dipropionate (BDP)|Active Control
45463195|NCT03950219|Other|Group course|Education and support
46011575|NCT01687764|Other|Attentional Bias Modification Treatment (ABMT) - Active|The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (< or >) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.
46011576|NCT01687764|Other|Attentional Bias Modification Treatment - Placebo|The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.
46011577|NCT01687764|Behavioral|Cognitive Behavioral Group Therapy|"FRIENDS for Life Australian protocol for the treatment of anxiety disorders in children"
46098153|NCT00693186|Biological|HBVaxPRO® 5 µg / 0.5 mL|5 µg / 0.5 mL
46098154|NCT00693186|Biological|Engerix B® 10 µg / 0.5 mL|10 µg
46098155|NCT05308615|Dietary Supplement|Rhea® Health Tone|Rhea® Health Tone
46098156|NCT00693264|Dietary Supplement|Hoodia Gordonii|750 mg capsule will be taken one time
45463196|NCT03944993|Device|Pulsed Electromagnetic Fields Therapy (Dominant leg)|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Fields on their dominant leg once a week for a total of 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.~The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak."
45463197|NCT03944993|Device|Pulsed Electromagnetic Fields Therapy (Non-dominant leg)|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Fields on their non-dominant leg once a week for a total of 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.~The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak."
45463198|NCT03944993|Device|Sham Therapy (Control)|Participants of this arm will be not be exposed to the fields. Sham treatment will utilise the same PEMF apparatus for 10 minutes, but in non-operational mode, which is indistinguishable from when the apparatus is in operation. Duration of intervention is 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.
45463199|NCT01102127|Device|Elastography|Performance of US, elastography and FNA.
45463200|NCT01208753|Drug|GLPG0555|two different aqueous formulations
45463201|NCT01208753|Drug|GLPG0555 aqueous|multiple dose, aqueous formulation, 13 days, 100 mg/day once daily, maximum dose to be determined
45463202|NCT01208753|Drug|placebo|multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
45463203|NCT01208831|Drug|LDE225|
45463204|NCT01111487|Device|Expiratory positive airway pressure (EPAP) by face mask.|Implementation of the EPAP as group pressure, 10 or 15 cmH2O, for 20 minutes then evaluated the electromyographic activity of muscles and sternocleidomastoid parasternal the tenth and twentieth minutes of your application.
45463205|NCT03488693|Radiation|Radiation|Radiotherapy given
45463206|NCT03488693|Other|No Radiation|No radiotherapy given
45837348|NCT05461092|Other|Daily Pain Trajectory|Questionnaire assessing pain location, severity, impact to quality of life, and medications used to alleviate.
46098157|NCT00693264|Dietary Supplement|Placebo|Placebo capsule to be taken one time
46098158|NCT02723279|Behavioral|EPNS|Electrical pudendal nerve stimulation Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
45463207|NCT03469882|Dietary Supplement|High protein nutrition|Patients in the HPE group will be submitted to nutritional support preferably through the enteral route. Energy expenditure will be determined by indirect calorimetry. They will receive 2.0 to 2.2 grams/kg/day of protein.
45463208|NCT03469882|Device|Cycle ergometry exercise|Patients will be submitted to two daily sessions of exercise (cycle ergometry) 15 minutes duration each, during the 7 days of the week. The intervention will be maintained exclusively duting the patient's stay in the ICU. The cycle ergometer will be the MotoMed Letto II (Reck Technik, Germany).
45463209|NCT03469882|Other|Usual care group|Participants randomized to the usual care group will receive usual care protein and exercise.
45463210|NCT02938624|Drug|Pembrolizumab 200 mg IV single dose|Pembrolizumab 200 mg IV single dose, 21 days later surgery
46011578|NCT01687764|Behavioral|Psychoeducational Control Intervention|Psychoeducational control intervention provides only brief psychoeducational information about anxiety associated with general educational activities
45463211|NCT02938624|Drug|Pembrolizumab 200 mg IV twice interval 21 days|Pembrolizumab 200 mg IV twice interval 21 days, 21 days later surgery
45463212|NCT02938624|Drug|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
45463213|NCT02938624|Drug|Pembrolizumab 100 mg I.V single dose|Pembrolizumab 100 mg I.V single dose, surgery after 21 days.
45463214|NCT02938624|Procedure|Surgical resection of tumor|Surgical resection of tumor by any of the acceptable procedures
46098159|NCT02723279|Drug|TT|Tolterodine tartrate (GSK， UK) 4mg per day is taken orally for six weeks
45463215|NCT03469804|Drug|Pembrolizumab|Route: intravenous infusion Dose regimen: 200 mg per infusion every 3 weeks Duration of treatment: 6 months (8 cycles)
45463216|NCT03944525|Device|High flow nasal cannula|Oxygen-therapy via HFNC
45463217|NCT03944525|Device|Continuous positive airway pressure|Non-invasive CPAP ventilation
46098160|NCT02615301|Dietary Supplement|Tailor-made salmon with high levels of vitamin D3 and K1|The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
45463218|NCT01108991|Behavioral|Physical activity self-management|This intervention includes a manual, telephone health coach calls, and automated telephone calls. The manual has 20 chapters for the active phase and 5 maintenance phase chapters. During the first 20 weeks the health coach will call patients every other week and the automated telephone calls will occur on the alternate weeks.
45463219|NCT01108991|Other|COPD education + Usual care|Six weeks of COPD self-management education plus usual care
45463220|NCT01102283|Device|Evolution(R) Colonic Stent|Palliative treatment of colonic obstruction or strictures caused by malignant neoplasms and to relieve acute large bowel obstruction prior to colectomy in patients with malignant strictures.
45463221|NCT03944291|Procedure|Pudendal Nerve Block|Pudendal Nerve Block
45463222|NCT03950297|Drug|609A|609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
45463223|NCT03265301|Procedure|Hysteroscopy|Includes Video set up, mini-hysteroscope system, continuous inflow and outflow, rod lens or fiber optic lens Zero to 30 degree angle and mechanical instruments (Scissors,Graspers , Cup biopsy forceps and bipolar instruments)
45463224|NCT03265301|Procedure|Office hysteroscopy|will be done in out patient clinic without anesthesia
45837349|NCT05461092|Other|Tampa Scale of Kinesiophobia|Questionnaire assessing Kinesiophobia
46011579|NCT04529759|Other|Control Infant Formula|Powdered partially hydrolyzed whey (WPH) based formula with an oligosaccharide
46011580|NCT04529759|Other|Experimental Infant Formula|Powdered partially hydrolyzed whey (WPH) based formula with oligosaccharides blend
46011581|NCT01687803|Behavioral|Physical Activity|Physical activity intervention that will consist of brisk walking or other aerobic-type activities (6 days per week), resistance exercise (using free weights, resistance bands or weight stacks for weight lifting, 3 days per week), and 'active lifestyle' activities such as gardening, dancing, participation in sporting activities. The total time spent in these activities will add up to ~60 min/day for 6 days/week (~360 minutes per week).
46098161|NCT02615301|Dietary Supplement|Tailor-made salmon with low levels of vitamin D3 and high K1|The aims were to investigate how intake of tailor-made salmon with low levels of vitamin D3 and high K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
46098162|NCT02615301|Dietary Supplement|Tailor-made salmon with high levels of vitamin D3 and low K1|The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and low K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
45463225|NCT03265301|Procedure|Conventional hysteroscopy|will be done in operative room under general anesthesia
45463226|NCT03165071|Drug|ACT-132577|Capsule
45463227|NCT03067571|Biological|Daratumumab|Given IV
46098163|NCT02615301|Dietary Supplement|Supplement with vitamin D and Calcium|The aims were to investigate how supplement with vitamin D and Calcium affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
46098164|NCT00994045|Biological|Fibrinogen concentrate|Fibrinogen concentrate will be administered initially at 2 grammes per hour by continuous infusion. This rate will be adjusted in response to the clinical picture and results of point of care coagulation tests. The infusion will be used intra-operatively.
46098165|NCT00994045|Biological|Fresh Frozen Plasma|
45463228|NCT03019367|Procedure|Umbilical cord milking UCM|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. This procedure infuses a placental transfusion of blood into the preterm neonate and can be done in 15-20 seconds.
45463229|NCT03019367|Procedure|Delayed cord clamping DCC|At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.
45463230|NCT05627609|Device|311 nm narrowband UVB irradiation|Participants will be irradiated with 311nm UVB for 5 days per week and 4 weeks in total.
45463231|NCT03944135|Other|Web platform: Neuronup|Neuronup is a web platform designed for neuropsychological rehabilitation that is focused on functional cognitive impairments resulting from normal aging and other causes. Neuronup emerged as a scientific, viable and accessible technological initiative.
45463232|NCT01109225|Biological|blood sample|
45463233|NCT01109225|Procedure|MRI|
45679589|NCT05436106|Behavioral|Adaptive Intervention Approach|"This is an adaptive intervention approach with 7 module-based sessions selected on the basis of post-session assessments of acceptability and satisfaction;~weekly group sessions will be co-led by a community member with expertise in working with transgender women and a public health nurse,~supplemental educational content will be available for individual consumption via an online portal or application (and tracked via participant click counts), and~additional social resources will be available through the online portal or app."
45679590|NCT05435612|Device|cochlear implant|Patients enrolled in the study undergo the cochlear implant surgery.
46011582|NCT01687803|Behavioral|Control|The control group will maintain their usual level of physical activity and participate in testing protocols, record keeping, and interviews.
46098166|NCT02570230|Other|NSS|NSS infusion
45837350|NCT05439174|Other|Intradialytic Parenteral Nutrition|"Intradialytic parenteral nutrition (IDPN) is compounded using a combination of dextrose (D70%) and amino acids (Prosol 20%, Clinisol 15%, or Plenamine 15%) with the option of adding lipids (Intralipid 20% prior to 8/2020, Clinolipid starting 8/2020 and after).~Each prescription is dosed based on patient height, weight, and other nutrition considerations including but not limited to presence of wounds, recent hospitalizations, electrolyte imbalance, etc. Adjustments to prescription are made on an as needed basis to increase or decrease goal infusion rate, adjust protein levels, and/or add or remove lipids."
45463234|NCT01109225|Procedure|echocardiography|
45463235|NCT01109225|Biological|urine sample|
45463236|NCT01109225|Procedure|pulmonary echography|
45463237|NCT01109225|Procedure|vascular check|
45463238|NCT01109225|Procedure|renal echography|
45463239|NCT03949751|Drug|Acne Crème Plus|The study specific intervention product is a combination of Benzoylperoxid and Miconazolnitrat (Widmer Acne Crème Plus, 47033 Swissmedic) to apply daily in the evening on the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae. The application should be done regularly for 7 days before shoulder surgery. The study specific intervention product is authorized by Swissmedic for use in the treatment of acne and is used standardly in clinical practice.
46011583|NCT04535843|Device|pheripheral biomarkers|Detect the pheripheral biomarkers,including lymphocytes and cytokines, in this prospective MG cohort.
46011584|NCT01687842|Other|Evaluation of 45,X Turner syndrome patients|Evaluation of 45,X Turner syndrome patients
46098167|NCT02570230|Drug|Ketamine|Ketamine 0.2 mg/kg/hr intravenous infusion
46098168|NCT00693342|Biological|immunological adjuvant OPT-821|Given subcutaneously
46098169|NCT00693342|Biological|polyvalent antigen-KLH conjugate vaccine|Given subcutaneously
46098170|NCT02718911|Drug|LY3022855|Administered IV
46098171|NCT02718911|Drug|Durvalumab|Administered IV
46098172|NCT02718911|Drug|Tremelimumab|Administered IV
45463240|NCT01109303|Procedure|TightRope System- Arthrex® / Dynamic Implant|Patients are operated on using a dynamic implant, the TightRope System by Arthrex®. The ankle is immobilized in a plaster boot for 6 weeks.
45463241|NCT01109303|Procedure|Screw fixation - Synthes® / Static Implant|Patients are operated on using a static implant, the rigid four-cortices 3,5 mm screw fixation by Synthes®. The ankle is immobilized in a plaster boot for 6 weeks.
45463242|NCT01102361|Procedure|Robotic Transperineal Biopsy|Saturation biopsy for previous negative patients
45463243|NCT03944213|Device|intermittent theta burst stimulation (iTBS)|20 sessions of iTBS
45463244|NCT01102439|Drug|Clopidogrel|300 mg loading dose, then 75 mg daily
45463245|NCT01102439|Drug|Clopidogrel|600 mg loading dose, 150 mg daily day 2-7, then 75 mg daily
45463246|NCT01102439|Drug|Aspirin|81 mg daily
46011585|NCT01687959|Other|tissue sampling from peritoneum of the gallbladder|tissue sampling from peritoneum of the gallbladder during laparoscopic cholecystectomy after an acute attack of acute biliary pancreatitis
46011586|NCT02216240|Other|Paramedic|
45463247|NCT01102439|Drug|Aspirin|325 mg daily
45463248|NCT03943979|Other|Cognitive Training|Cognitive Training (CT): 4 consecutive days, 30-45 min session involving 5 different tasks designed to train executive functions and attention, available at the Guttmann Neuropersonaltrainer platform (computerized cognitive training tool certified by the Spanish Agency for Medicines and Health Products as a Class I Health Product). The difficulty level of all the tasks was automatically adjusted on a trial-by-trial basis for both Active and Active Control conditions.
45463249|NCT03943979|Device|transcranial Direct-Current Stimulation (tDCS)|tDCS: 4 consecutive days, 20 min session, delivered through multichannel tDCS (Starstim, Neuroelectrics), with an excitatory target over the r-dlPFC, and an inhibitory target on the contralateral lobe (l-dlPFC). The positioning of the multichannel tCS (electrode location and currents) was solved using the Stimweaver (Ruffini 2013). The resulting tCS montage employed 8 gelled Ag/AgCl electrodes of π cm2 size (Pistim, Neuroelectrics) placed at AF3(-1093uA), AF4 (1178uA), F3 (-1161uA), F4 (1104uA), F7 (-414uA), F8 (530uA), FC5 (1189uA), FC6 (-1332uA).
45837351|NCT05421780|Dietary Supplement|autoclaved BSG-containing biscuits|Consumption of autoclaved BSG-containing biscuits as breakfast.
46011587|NCT02216240|Other|Standard care|
45463250|NCT01585181|Biological|PXVX0200|Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension
45463251|NCT01585181|Biological|Placebo|Approx 2 grams of lactose reconstituted in water
45463252|NCT01102517|Procedure|video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery
45463253|NCT01102517|Procedure|axillary thoracotomy|axillary thoracotomy lobectomy
45463254|NCT03949985|Other|Tests of biological hemostatic profile associated with contraceptives|Tests of biological hemostatic profile associated with contraceptives will be done before and after having stopped an estrogenic contraceptive (group 1) and during the non-use of an estrogenic contraceptive (group 2)
45837352|NCT05421780|Dietary Supplement|bio-transformed BSG-containing biscuits|Consumption of bio-transformed BSG-containing biscuits as breakfast.
45463255|NCT01109459|Other|Pediatric blood pressure screening|Website presenting case-based education with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.
45463256|NCT01109459|Other|Pediatric vision screening|Website presenting case-based education about amblyopia and strabismus with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.
45463257|NCT04321252|Drug|KAE609|"iv bolus administration over approximately 2 min for doses < 75 mg (Cohorts A1, A2 and B1)~iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)"
45463258|NCT04321252|Drug|Placebo|matching placeo for iv administration
45837353|NCT05421780|Dietary Supplement|control biscuits|Consumption of plain biscuits as breakfast.
45463259|NCT01584791|Drug|clopidogrel napadisilate + aspirin|clopidogrel napadisilate 75mg + aspirin 100mg
45463260|NCT01584791|Drug|clopidogrel bisulfate + aspirin|clopidogrel bisulfate 75mg + aspirin 100mg
45463261|NCT03471208|Device|Dynamic Navigation Assisted Implant Surgery|Implant surgery using dynamic navigation assistance
45837354|NCT05394012|Biological|RQ3013|Two doses of 30 μg/0.15 mL at an interval of 28 days, or two doses of 60 μg/0.3 mL at an interval of 28 days
45837355|NCT05394012|Biological|Comirnaty|Two doses of 30 μg/0.3 mL at an interval of 28 days
46011588|NCT01688115|Procedure|Video|The afternoon before the surgery session, a researcher will show to the child a video of the length of 6 minutes, using an I-pad. The video shows two clown doctors working constantly at Meyer Children's Hospital, which, through skits and gags, will tell the child how is an operating room and some devices and procedures used during the induction of anesthesia.
46011589|NCT01688115|Other|Standard care|In this arm orally information will be given by the nurse of the ward only to the parents of the child. Any additional information or explanation will be given to the child
46098173|NCT00697905|Drug|Gemcitabine|Intravenous administration on days 1, 8 of a 21-day cycle
46098174|NCT00697905|Drug|Carboplatin|Intravenous following Gemcitabine infusion on day 1
46011590|NCT04529486|Other|Kinesio taping|Before applying the tape, it was checked whether the children were allergic. Tape was first started from the distal part of the fingers and taped with 0% tension with Kinesio Taping Functional Correction Technique. Another I tape was applied from palmar area of the hand to spina scapula for supination of the forearm and external rotation of the shoulder with %0 tension to make functional correction (Figure 2). Kinesio Taping Functional Correction method is suggested to be done with 75% of tension but for children, we applied it with 0% tension to minimize the shear effects to the skin4. Kinesio Tex Light Touch Plus tape was used for taping application (Kinesio Co., USA).
45463262|NCT03471208|Procedure|Freehand Implant Surgery|Dental implant surgery via conventional freehand
45463263|NCT04285684|Drug|ketamine in lactation|2 dose IM by weight and assessing concentrations of ketamine in expressed milk at intervals
45463264|NCT03473002|Other|Placebo|0.9% Sodium Chloride
45463265|NCT03473002|Biological|SeVRSV Vaccine|Recombinant Sendai virus vectored respiratory syncytial virus (SeVRSV) vaccine. SeVRSV is a replication-competent Sendai virus that carries the RSV F gene produced by reverse genetics technology.
45463266|NCT03472924|Device|Kinesiotaping|The application of Kinesio Tape® (kinesiotaping) according to the guidelines provided by the Kinesio Taping Association (Kase, K. 2016). A 5 cm width strip of Kinesio Tape® (Kinesio TEX Products, NKT-050, Japan) will be applied from origin (the head of the fibula) to insertion (the medial cuneiform and first metatarsal) of the peroneus longus in a longitudinal direction. The proximal anchors will be applied without tension, and the Kinesio Tape® placed on approximately 50% stretch before being applied over the peroneus longus and the distal anchor point.
45463267|NCT03469726|Diagnostic Test|Contrast-enhanced Diffusion-weighted MRI|An MRI scan enhanced with intravenous contrast and with diffusion imaging at several B-values
45463268|NCT03469648|Procedure|Air-Test|The Air Test simply consisted in breathing room air for 5 min during anesthesia while measuring peripheral oxygen saturation by Pulse oximetry
45463269|NCT04760236|Biological|Oral Cholera Vaccine Simplified (OCV-S)|"Manufacturer: EuBiologics Co., Ltd.~Oral administration"
45463270|NCT04760236|Biological|Shanchol™|"Manufacturer: Shantha Biotechnics~Oral administration"
45463271|NCT04457128|Behavioral|Just-in-Time Adaptive Intervention|Randomized factorial design
45463272|NCT04103788|Dietary Supplement|95% Curcuminoid Powder|1200 mg curcuminoids
45463273|NCT04103788|Dietary Supplement|CurQ+|400 mg curcuminoids + coconut oil + polysorbate
45463274|NCT01598116|Procedure|Urine collection and ultrasonography|Bagged urine collection and ultrasound at each visit
46011591|NCT01688154|Dietary Supplement|35 mg/Kg of grape seed proanthocyanidins extract (2 capsules)|
46011592|NCT01688154|Other|2 empty capsules|
45463275|NCT01598116|Procedure|Urine collection|Bagged urine collection
45463276|NCT01310985|Drug|Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)|Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®)
45463277|NCT03433677|Drug|LY900014|Administered by CSII
45463278|NCT03433677|Drug|Insulin lispro|Administered by CSII
45463279|NCT02492711|Biological|Margetuximab|15 mg/kg via IV (intravenous) infusion on day 1 of each 21 day cycle,
45837356|NCT02129478|Drug|Olanzapine|"Patients will receive olanzapine once daily starting just before the first dose of chemotherapy within the study chemotherapy block and continuing until discharge from hospital or for a maximum of 4 doses after the last dose of chemotherapy.~Olanzapine will be dosed at 0.14mg/kg/dose (maximum 10mg/dose) as a single daily oral dose rounded to the nearest increment of a half-tablet (2.5mg)."
46011593|NCT02216279|Drug|PulmoBind|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
46098175|NCT00697905|Drug|Cisplatin|Intravenous on day 1 prior to 5-FU infusion on days 2 to 5 of a 28-day cycle
46098176|NCT00697905|Drug|5-fluorouracil (5-FU)|Intravenous infusion on day 2 to day 5
46098177|NCT04785898|Diagnostic Test|ID Now™ COVID-19 Screening Test|"Patients, meeting the eligibility criteria, are selected consecutively in the emergency room. The investigating doctor delivers the written information note, answers the patient's questions and obtains his free, informed and express consent. The patient has sufficient time to reflect to make the decision to participate in the study. His oral, free, informed and express consent will be traced in the computerized medical file on the day of its inclusion in the COVID-IDNow protocol. Each patient participating in the study retains the possibility of participating simultaneously in another research. No exclusion period is provided for in the protocol."
45463280|NCT02492711|Biological|Trastuzumab|8 mg/kg via IV (intravenous) infusion for the first dose and 6 mg/kg for all subsequent doses via IV infusion on day 1 of each 21 day cycle
45463281|NCT02492711|Drug|Physician's choice of chemotherapy.|Capecitabine (Xeloda®):1000 mg/m2 BID for 14 days in a 21-day cycle, or Eribulin (Halaven®): 1.4 mg/m2 on days 1 and 8 of a 21-day cycle, or Gemcitabine (Gemzar®): 1000 mg/m2 on days 1 and 8 of a 21-day cycle, or Vinorelbine (Navelbine®): 25-30 mg/m2 on days 1 and 8 of a 21-day cycle
45463282|NCT03718689|Device|Laser etching|Acid etching
45463283|NCT03716505|Device|gammaCore Sapphire active|GammaCore Sapphire™ is a handheld, non-invasive, low voltage electrical device which stimulates the vagus nerve by producing weak 120 second electrical stimulation cycles that may help reduce, ease, lessen or stop your migraine symptoms. GammaCore Sapphire™ has been approved for the treatment of headache, including migraine by the United States Food and Drug Administration (FDA).
45463284|NCT03716505|Device|gammaCore Sapphire Sham|The sham device is a hand-held portable device that appears identical to gammaCore Sapphire, in look, weight, visual and audible feedback, user application, and control. Like gammaCore Sapphire, the sham device is a multi-use device.
45463285|NCT03716427|Drug|CT1812|
45463286|NCT03716427|Drug|tolbutamide|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of tolbutamide
45463287|NCT03716427|Drug|dextromethorphan|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of dextromethorphan
45463288|NCT03716427|Drug|Omeprazole|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of omeprazole
45463289|NCT03716427|Drug|midazolam|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of midazolam
46011594|NCT04529681|Device|Stroke Riskometer Application|Mobile phone application uses to measure, monitor and manage, it mainly calculates the stroke risk probability within 5 year and 10 years by providing the absolute risk and relative risk which is compared to the normal healthy people with the same age and gender. Not only that, the application purposes to increase general awareness about stroke and its risk factors, and to improve stroke and heart attack prevention on an individual level.
46011595|NCT04529681|Other|Informational Leaflets|Informational leaflets consist of the stroke-related leaflet, CVDs-related leaflet and the healthy eating behaviors including; disease introduction, what are the risk factors, early symptoms and also the preventive measures. These materials were developed and published by health education and promotion division Ministry of Health, Malaysia in 2013 - 2016. Usually it will be distributed to public during health screening program and also can be found at all healthcare facilities. All materials were in Malay language only.
45837357|NCT02129556|Drug|MK-3475|The phase Ib trial will determine the recommended dose from three MK-3475 dose levels: 1mg/kg, 2 mg/kg or 10 mg/kg.
46011596|NCT04529642|Diagnostic Test|Inertial Measurement Unit evaluation|An IMU was worn by the subjects during the execution of the 6MWT, to assess the kinematic parameters of gait.
45837358|NCT05362500|Drug|Glycolic Acid 70%|Group A: contain 27 patients which had been treated every 2 weeks for 12 weeks with 70% glycolic acid to assess chemical peeling and cold water was used for washing
46011597|NCT01688349|Other|analyze the role of glucocorticoid in AT distribution.|"The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be~to compare the pattern of gene expression between visceral and subcutaneous adipose tissue in Cushing patients requiring an adrenalectomy as cortisol adenoma treatment;~to compare these patterns of gene expression with those of two control populations:1/ healthy metabolic subjects having a partial nephrectomy, 2/obese patients with similar degree of insulin resistance."
46011598|NCT02216318|Other|blue light|
46098178|NCT02718755|Drug|Fludarabine|"Induction Phase:~30 mg/m2 by vein over 15-30 minutes on Days 1 - 5 of a 28 day cycle.~Consolidation Phase:~30 mg/m2 by vein over 15-30 minutes on Days 1 - 4 of a 28 day cycle."
46098179|NCT02718755|Drug|Cytarabine|"Induction Phase:~2 grams/m2 by vein over approximately 2 hours on Days 1 - 5 of a 28 day cycle.~Consolidation Phase:~2 grams/m2 by vein over approximately 2 hours on Days 1 - 4 of a 28 day cycle."
46098180|NCT02718755|Drug|Erwinase|"Induction Phase:~25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes on Days 1 - 7 of a 28 day cycle.~Consolidation Phase:~25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes every other day on Days 1, 3, 5, 7, 9, 11, 13, 15 of a 28 day cycle."
46098181|NCT00730210|Drug|a: PTH (1-84)|preotact 100 microgram subcutaneous a day in 6 months
45463290|NCT02476487|Procedure|FDG PET CT|"FDG-PET CT will be performed on day 7-14 since the first positive blood culture. 1. Patients fulfilling current criteria for a short course (2 weeks) of antibiotic treatment: treatment will be prolonged if PET CT demonstrates a focus of residual infection.~2. Patients with risk factors mandating prolonged antibiotic treatment (4-6 weeks) according to current guidelines without IE: antibiotics will be stopped at 2 weeks if PET CT is normal."
46098182|NCT00730210|Drug|b:placebo|100 microgram placebo subcutaneous a day for 6 months
46098183|NCT02614989|Procedure|MRI guided focused ultrasound thalamotomy|MRI guided focused ultrasound thalamotomy
46098184|NCT04132089|Behavioral|capABILITY|All participants utilized the designed capABILITy application. The application consisted of education material and persuasive messaging. There were two types of messaging components named facilitators and sparks. This created three groups consisting of: control, facilitators and sparks. Participants spent 1 month in each group (total duration of the study was three months).
46098185|NCT00730288|Biological|Chimeric dengue serotype (1, 2, 3, 4)|0.5 mL, Subcutaneous, 1 dose
46098186|NCT00730288|Biological|Chimeric dengue serotype (1, 2, 3, 4)|0.5 mL, Subcutaneous, 1 dose
45837359|NCT05362500|Drug|Tranexamic acid injection|Group B: contain 27 patients treated with an intradermal injection of 0.05 mL of tranexamic acid solution in normal saline (4 mg/mL) into the melasma lesion at 1 cm distance using a sterile insulin syringe, weekly for 12 weeks
46098187|NCT00730288|Biological|Chimeric dengue serotype (1, 2, 3, 4)|0.5mL, Subcutaneous, 1 dose
46098188|NCT02718989|Device|Transcutaneous Electrical Stimulation|TENS transcutaneous electrical stimulation over the back the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
46098189|NCT02718989|Device|10Kilohertz (KHz)|10 KHz transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
46098190|NCT02718989|Device|Sham stimulation|Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
46098191|NCT02614911|Other|Biological sampling|Biological sampling including blood, feces, biopsies...
46098192|NCT00872898|Drug|Memantine - Extended Release (ER)|Memantine - 3mg and 6mg capsules, dose ranging 3 - 18 mg/day in 4 weight groups, administered orally.
46098193|NCT00872898|Drug|Placebo|Placebo capsules, once daily, oral administration.
46098194|NCT02723435|Drug|Midostaurin|Given PO
45837360|NCT05161806|Drug|SOK583A1 (40 mg/mL)|SOK583A1 provided in a Prefilled Syringe (PFS), which includes 2 mg aflibercept in 0.05 mL for IVT administration
45837361|NCT05161806|Device|Prefilled Syringe (PFS)|Prefilled Syringe (PFS)
45837362|NCT05362188|Drug|Nicotinamide Topical|"Patients with discoid lupus erythematosus (face & scalp) will be given topical nicotinamide in two concentrations (2&4%) to apply twice daily for 12 consecutive weeks and then follow up.~Topical nicotinamide will be prepared in different forms (cream & gel)."
45837363|NCT01798368|Device|PBASE system 2.0|
46098195|NCT02718677|Drug|Refacto AF|Observational - Non-Interventional Study
45463291|NCT03943433|Procedure|FiO2_1.0|Alveolar recruitment is performed with 100% oxygen concentration after general anesthesia induction, after position change to Trendelenburg, after position change to supine, and at the end of operation.
45463292|NCT03943433|Procedure|FiO2_0.4|Alveolar recruitment is performed with 40% oxygen concentration after general anesthesia induction, after position change to Trendelenburg, after position change to supine, and at the end of operation.
45463293|NCT01147822|Drug|Pazopanib|800 mg administered once daily orally continuous dosing
45463294|NCT01147822|Drug|Sunitinib|50 mg sunitinib to be administered in 6-week cycle: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment
45463295|NCT03431337|Drug|Amoxicillin 875 mg|Doubling the dose of amoxicillin by adding amoxicillin 875 to each dose of the standard treatment of amoxicillin/clavulanate 875/125
45463296|NCT03431337|Dietary Supplement|Placebo (lactase)|Placebo (in place of additional amoxicillin in experimental arm)
45463297|NCT01428791|Behavioral|Generations older adult membership program|"Rush Generations is a membership program for older adults emphasizing chronic disease prevention and management through a wide range of health and aging-related programs. Participants assigned to the Generations intervention are actively encouraged to participate in activities, including:~• RUSH-based lectures by experts in the fields of health and aging providing practical information and resources on physical and mental health, functional status, and social support. • Individual and family consultations with social work staff. • Health fairs with a variety of assessment services and information about community-based social service and health agencies. • Assistance with referral to community programs such as physical activity, driver safety events, and mind-body connection workshops."
45463298|NCT01428791|Behavioral|BRIGHTEN Heart Virtual Team intervention|"BRIGHTEN Heart provides an interdisciplinary team evaluation of physical and mental health and on-going support for mental health & health behavior change for 6 - 12 months, including:~• Comprehensive health risk assessment by a licensed social worker, including physical, mental, and functional status. • Virtual team case review and recommendations by interdisciplinary team including psychologist, social worker, occupational therapist, pharmacist, chaplain, dietitian, geriatric psychiatrist, and patient's primary care physician. • Development of Patient Centered Action Plan, in which the social worker assists the patient in prioritizing recommendations. • Monthly telephone calls by the social worker to support implementation of Action Plan and Case Management. • Evidence Based Psychotherapy, as needed, delivered by supervised geriatric psychology and social work fellows."
45463299|NCT01364363|Procedure|Allogeneic transplantation|Allogeneic transplantation with matched unrelated donors
45463300|NCT03738241|Biological|A/H7N9|Monovalent split 2017 A/H7N9 Inactivated Influenza Virus Vaccine containing the Hemagglutinin (HA) and Neuraminidase (NA) from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1). The HA content of the 2017 A/H7N9 vaccine formulations were determined by Single Radial Immunodiffusion (SRID) assay to be approximately two times higher (14.45 mcg of HA per 0.5 mL dose) than the targeted HA content on the label (7.5 mcg of HA per 0.5 mL dose).
45463301|NCT03738241|Drug|AS03|AS03 oil-in-water emulsion-based adjuvant system containing DL-alpha-tocopherol, squalene, polysorbate 80, and a buffer.
45463302|NCT03738241|Other|Phosphate Buffered Saline (PBS) diluent|0.006M PBS diluent for Influenza Virus Vaccine.
45463303|NCT03746704|Drug|89Zr˗DFO˗REGN3504|89Zr˗DFO˗REGN3504
45463304|NCT01111643|Device|Echocardiogram|An echocardiogram will be repeated at every step, from baseline to peak heart rate setting.
45463305|NCT03720015|Behavioral|Physical exercise|Physical exercise controlled program supervised by an accredited exercise specialist
46011599|NCT04822389|Device|Telerehablitation using heart rate monitor|Eligible participants will undergo 12 weeks of physical exercise using a heart rate monitor and internet platform at home. The participants will regularly (minimum once per week) upload the exercise data from the heart rate monitor into the internet platform. An exercise telerehabilitation session consists of the warm-up phase, aerobic phase (30 - 50 minutes gradually increasing exercise duration; heart rate zone based on baseline cardiopulmonary exercise test) and cool-down phase. The exercise training period is set to 3 times a week for 12 weeks. Study participants will receive user guides developed by research team with detailed instructions regarding equipment set-up, training protocol, and contact information. Also, participants will receive weekly phone calls from week 0 to week 12 to monitor adverse events, encourage compliance and adherence to the study protocol, address any subject questions or concerns, and collect information regarding participants' current symptomatology.
46098196|NCT04132011|Drug|Extended Release Opioid Formulation, Shortened Intervals|Extended release opioid, individualized total daily dose, dosing interval is less than every 12 hours
46011600|NCT02218073|Drug|JNJ-42756493 10 mg tablet|Participants will be administered with 10 milligram (mg) JNJ-42756493 tablet orally either on Day 1 of Period 1 or on Day 1 of Period 2.
46011601|NCT02218073|Drug|JNJ-42756493 10 mg Oral Solution|Participants will be administered with 10 mg JNJ-42756493 oral solution either on Day 1 of Period 1 or on Day 1 of Period 2.
46098197|NCT04132011|Drug|Extended Release Opioid Formulation, Standard intervals|Extended release opioid, individualized total daily dose, dosing interval is every 12 hours
46098198|NCT04132011|Drug|Placebo oral tablet|Lactose pill manufactured to mimic extended release opioid formulation
46011602|NCT02218073|Drug|JNJ-61818549|Participants will receive 100 mcg of JNJ-61818549 as intravenous injection on Day 1 of Period 2 or Day 1 of Period 1.
46011603|NCT05138523|Combination Product|Sofosdac®|Once daily fixed-dose combination of 400 mg Sofosbuvir and 60 mg Daclatasvir
45463306|NCT03720015|Dietary Supplement|Nutritional management|Nutritional management controlled by a PhD clinical and sport nutrition specialist
46011604|NCT02218112|Procedure|bariatric surgery (gastric bypass)|
46011605|NCT04535570|Other|Indirect Calorimetry|In the pre-transplant, before the conditioning regime, and also on the 10th and 17th post-transplant, the resting energy expenditure was measured by indirect calorimetry.
46011606|NCT05138484|Drug|experimental group 10% mouthwash of M. sylvestris extract|To each patient was delivering a 150 ml bottle with the corresponding mouthwash. The indications for posology were: rinse with 10 ml of mouthwash for 1 minute in the mouth, every 12 hours for 7 days. To the follow-up of the intervention, was made telephone calls at least once a day to remember the rinse.
46011607|NCT04535804|Drug|Aspirin/placebo|By using a random, double-blind research method, 1-550 digital computers are randomly divided into two groups, with two groups of digital coding placebo and aspirin. From 12 weeks of gestation, 100 mg of placebo or low-dose aspirin was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
46011608|NCT02218151|Other|Patient-Centered Medical Home (PCMH)|Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period at home. Advanced Practice Providers (APP) will travel to subjects' homes in the morning, where they will perform the same daily assessment as standard care. They will draw labs and bring them back to the hospital for processing. When results are available, a second home visit is made to deliver necessary interventions. Subjects will have internet access through cellular-networked iPads and have daily videoconferences with their physicians. Daily follow up at home will continue until discharge as per above criteria.
46011609|NCT02218151|Other|Standard Care|Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period inpatient or outpatient. Advanced practice providers (APPs) will perform histories and physical exams. Nurses will collect labs and inpatient rounds occur twice daily, or for outpatients receiving care through our outpatient clinics, a healthcare provider typically sees them daily for the first month following transplant or discharge from the day hospital.
46011610|NCT02273388|Drug|BI 6727|
46011611|NCT04535765|Other|early warm water sitz bath|The experimental group started the warm water sitz bath 6 hours after the end of the hemorrhoid surgery.
46011612|NCT04535765|Other|Regular time warm water sitz bath|According to the routine, the control group started the warm water sitz bath on the first day after the hemorrhoid surgery.
46011613|NCT05138445|Behavioral|FAME-W self-management intervention|FAME-W is an occupational therapy led, four-week group based self-management intervention. It focuses on providing people with IA skills and confidence to manage demands of their employment and daily life through education on IA, self-management techniques, managing symptoms of fatigue, pain and stress and managing physical and mental health.
46011614|NCT05138445|Behavioral|FAME-W Handbook|Individuals in this arm receive a self-guided FAME-W handbook containing the same information as that covered in the four week FAME-W program
46011615|NCT04529603|Device|LungBrella marker implantation and VATS partial lobe resection|The enrolled patients will receive a plain chest CT scan,then the data be loaded into JediVision software. The JediVision software can navigate the location of nodule and facilitate the implantation of LungBrella marker in the operating room after general anesthesia,then the patients will receive VATS partial lobe resection .
46011616|NCT04535739|Radiation|prophylactic cranial irradiation|25Gy/2.5Gy/10f were given for PCI patients
46011617|NCT04529525|Drug|Ivermectin|Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
45463307|NCT03942809|Device|Effectiveness|Effectiveness and Practicability in anesthetized patient under controlled conditions
45463308|NCT00481546|Genetic|rAAV2-CBSB-hRPE65|One or two, uniocular, subretinal injections; relative doses: 0.3X (Cohort 1), 0.6X (Cohort 2), 0.45X (Cohort 3), 0.9X (Cohorts 4 and 5)
45463309|NCT03718611|Drug|BR9001|BR9001 is a test drug as generic
45463310|NCT03718611|Drug|BR900A|BR900A is a reference drug
46011618|NCT04529525|Drug|Placebo|Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
45837364|NCT05355168|Procedure|neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery|neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
46011619|NCT02218346|Drug|AG221|AG221 in fed and fasted conditions
46011620|NCT04535427|Drug|L-arginine|Low (3g every time, 3 times a day)or high dose (5g every time, 3 times a day) of L-arginine will be administered to the experimental groups for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
46011621|NCT04535427|Drug|Placebo|Placebo will be administered to the control group for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
46011622|NCT05138367|Procedure|transplantation of human UCA-PSCs or WJ-MSCs into ovaries of POF patients|After vaginal sterilization, TVUS-guided transplantation was performed by the senior-level medical physician B Wang), using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcae Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The solution (a total number of 2×10^7cells, 1×10^7 /400 μL for unilateral ovarian injection) was injected into the ovary by using 21G PTC needles (Hakko Medical Co, Japan) under TVUS guiance. Each patent received up to three transplantations.
46011623|NCT02218385|Device|ForeCYTE Breast Aspirator|ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing
46098199|NCT02723357|Behavioral|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
46098200|NCT02723357|Behavioral|Access to Social Service Referrals|Access to referrals for common social needs.
46098201|NCT02723123|Other|Recording of cardio-respiratory signals|Biological signals: ECG, RIP, SpO2 and Pulse rate will be recorded during the interventions and analyzed offline.
46098202|NCT00693576|Drug|simvastatin|20 mg simvastatin daily
46098203|NCT00698061|Biological|HBV-MPL vaccine 208129|3-dose primary vaccination and booster vaccination by intramuscular injection
46098204|NCT00698061|Biological|Engerix™-B|3-dose primary vaccination and booster vaccination by intramuscular injection
45463311|NCT01111721|Behavioral|Project POWER HIV Risk-reduction Intervention|Nine session group-based behavioral intervention for incarcerated female adults.
45463312|NCT01111721|Behavioral|NC DOC Standard of Care for STIs|Standard North Carolina Department of Correction intake STI testing and counseling.
45837365|NCT05353374|Drug|Sodium Fusidate 2 % Topical Ointment|Sodium fusidate 2% topical ointment was applied twice daily on the wound after cauterization for 14 days.
45837366|NCT05353374|Drug|Petrolatum ointment|Petrolatum ointment was applied twice daily on the wound after cauterization for 14 days.
45837367|NCT05293236|Drug|ApTOLL|ApTOLL is an aptamer (DNA single strain) designed to block TLR4 (toll-like receptor 4)
46011624|NCT02216409|Drug|Hu5F9-G4|
46011625|NCT02218580|Other|Massage therapy|
46011626|NCT02218580|Other|Standard care|
46011627|NCT05127915|Device|Adient absorbable filter + best practice VTE prophylaxis|Adient absorbable filter helps prevent PE during an 8 week protection period then gradually breaks down into carbon dioxide and water within 6 to 8 months. The absorbable filter does not require removal.
46011628|NCT05127915|Device|best practice VTE prophylaxis|Best practice VTE prophylaxis includes sequential compression machines, compression stockings, and anticoagulants (blood thinners) when indicated.
46011629|NCT05126121|Drug|three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,levofloxacin,tinidazole,metronidazol|Three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,tinidazole,metronidazol
46011630|NCT02218658|Drug|WE941 OD tablets|
46011631|NCT02218658|Drug|Brotizolam|
46011632|NCT05125653|Procedure|Indocyanine Green Fluorescent Laparoscopic Cholangiography|Indocyanine Green Fluorescent Cholangiography
46011633|NCT05125653|Procedure|White Light|Performing the laparoscopic cholecystectomy and identifying the biliary structures under the conventional white light
46098205|NCT04116047|Drug|Cisplatin|
46098206|NCT04116047|Drug|Durvalumab|
46098207|NCT04116047|Procedure|Radiotherapy|
46098208|NCT00693732|Drug|Escitalopram treatment|On study inclusion at Visit 2, patients will be successively randomised using a computer generated randomisation list to either placebo or escitalopram (Lundbeck Export A/S, Singapore) 10mg given at bedtime in the first 2 weeks, followed by 20mg in the next 6 weeks. The treatments will be identical in appearance and will be administered in double-blind fashion. Treatment with any anticoagulants, antidiabetics, antimigraine drugs, antispasmodics, analgesics, psychoactive agents including antidepressants, Zelmac®, TCM or acupuncture for IBS and any drugs affecting nociception as judged by investigator are prohibited during the entire study.
45463313|NCT03469570|Device|EV1000 Clinical Platform with Assisted Fluid Management (AFM) Feature|Subjects enrolled in the validation study will have their fluid management decisions guided by the AFM Feature.
45463314|NCT03430245|Device|VelaShape III|The VelaShape III device combines controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with vacuum.
45463315|NCT03430245|Device|UltraShape Power|The UltraShape Power device uses focused ultrasound energy for lipolysis (breakdown of fat) via a non-thermal mechanism of action.
45463316|NCT01208909|Procedure|diagnostic 5-ALA and MRI for tumor resection|diagnostic 5-ALA and MRI for tumor resection
45463317|NCT05158660|Device|transcranial duplex sonography|it is an imaging device that will measure the intracerebral hematoma expansion
45463318|NCT01111799|Procedure|endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
45463319|NCT01111799|Procedure|endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
45837368|NCT05293236|Other|Saline|Saline for intravenous infusion
46011634|NCT02278679|Procedure|Digital Rectal Exam|The DRE digital rectal exam is an essential component of physical examination, but physicians enter their residency having neither been appropriately exposed nor trained in performing DREs. , the attending physician, resident physician(s), and medical student(s) will each perform a digital rectal exam on the subject, and independently document their examination on the DiRECT instrument.
46011635|NCT01199068|Drug|CS-7017|CS-7017 from 0.25 mg to 0.50 mg twice daily
46011636|NCT01199068|Drug|Erlotinib|Erlotinib 150 mg once daily
46011637|NCT05103891|Drug|Binimetinib Oral Tablet|two-period, crossover study
46011638|NCT04535375|Diagnostic Test|Doppler Ultrasound of venous cerebral circulation|No additional ultrasound examinations, specifically for the purpose of this study, will be performed. Instead, with each routine ultrasound examination, additional images on top of the routine frames will be collected. Those images will document the velocity and flow in the internal cerebral veins bilaterally using the standard Color Doppler tech-nique. Taking these additional images will prolong the time of ultrasound examination only minimally (with a few minutes).
45463320|NCT01111799|Procedure|natural cycle + IUI + endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
45463321|NCT01293097|Drug|Atorvastatin|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
45463322|NCT01293097|Drug|Statin|Usual care, but statin dose should not be higher than that described in exclusion criteria
45463323|NCT04362670|Drug|OTX-CSI|OTX-CSI intracanalicular insert
45463324|NCT04362670|Other|Placebo Vehicle|Hydrogel Vehicle intracanalicular insert
45837369|NCT05292300|Dietary Supplement|Cornelian Cherry (Cornus mas L.)|"Patients in Cornelian Cherry Group and Cornelian Cherry and Diet Group will receive 20 g/day freeze-dried powder Cornelian Cherry supplement."
45837370|NCT05292300|Behavioral|Diet|"Patient in Diet Group and Cornelian Cherry and Diet Group will be given a personalized diet and be followed up by a dietician."
46011639|NCT01198873|Drug|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
46011640|NCT01198873|Drug|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
46011641|NCT04535297|Other|exposure|Exposure to social distancing due to COVID-19
46011642|NCT04535388|Device|LK scleral lens|LK scleral lens fitting and application were done for 12 weeks.
46011643|NCT01198795|Drug|Escitalopram|Patients who meet eligibility criteria will receive open-label escitalopram. 10-20mg oral administration (10mg tablets) once daily for 24-weeks with a 2-week downtaper period.
46098209|NCT00693732|Behavioral|Quantitative sensory testing|Rectal Distention Stimulation
46098210|NCT04132245|Behavioral|behavioral intervention|Families were randomized to a 14-week family based obesity prevention intervention or a 14-week general health intervention
46098211|NCT04132245|Behavioral|Obesity prevention intervention trial|Families were randomized to a 14-week obesity prevention intervention or a 14-week general health intervention
46011644|NCT04535024|Radiation|Stereotactic Ablative Radiotherapy (SABR)|"We plan to irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate.~Target dose will be adjusted depending on site of the lesion and organs at risk (BED > 100Gy).~Treatment schedule is once per day and five days per week. Sequence of irradiation for multiple metastases is at the discretion of the investigators based on their experience."
46011645|NCT04535024|Drug|Sintilimab|Starts within one week upon SABR completion: 200mg, d1, q3w; Continued until disease progression, unacceptable toxicity or patient withdrawal.
46011646|NCT04535336|Other|Vitality acupunch (VA) exercise program|The VA had 3 phases and took 40 minutes to complete.
46098212|NCT00689598|Drug|Spironolactone|25 mg po qd 25 mg po bid
46098213|NCT00689598|Drug|Placebo|Spironolactone 25 mg po qd
45463325|NCT05626517|Diagnostic Test|Ocular Imaging|The retinal photography will be acquired from macula-centre and an optic-disc centre for both left and right eye after their cardiac assessment. Patient will be required to focus at a target inside the machine for approximately 5 to 10 seconds, with a flash followed at the end when eye image is captured. Based on patients' eye conditions, additional or less images may be taken. This allows a snapshot of both retinal and coronary vessels at a single point in time, no mydriatic drops will be used. Participants will be given the option to undergo mydriatic photographs of the retina at SNEC/SERI depending on participant eye condition. For mydriatic photograph, images will be obtained after pupil dilation and graded for presence and severity of diabetic retinopathy according to the modified ETDRS system and other retinal abnormalities by trained graders.
45463326|NCT05626517|Other|Questionnaires|3 to 4 questionnaires will be administered (i.e. EQ5D, International Index of Erectile Function, Pittsburgh Sleep Quality Index, General Questionnaire) to investigate the correlation between clinical characteristics, lifestyle (eg. exercise, sleep, erectile dysfunction) and diet to retinal and coronary vasculature and outcomes.Only male patients who are literate in English language will be invited to complete the International Index of Erectile Function (IIEF) questionnaire. Participants have the option to not complete the whole IIEF questionnaire or some of the questions if they are not comfortable with answering those questions.
45463327|NCT03853447|Diagnostic Test|Diagnostic imaging|MRI assessments including magnetic resonance cholangiopancreatography (MRCP) and diffusion weighted imaging (DWI) combined with gold standard EUS
45463328|NCT03516292|Diagnostic Test|Urinary Nerve Growth Factor|The subjective patient's discomfort regarding the vaginal prolapse problems and urinary incontinency symptoms will be assessed through the following questionnaires: (a) ICIQ-OAB (b) ICIQ FLUTS (c) ICIQ-VS. Determination of the bladder neck of urethra in midsagittal plane using a transvaginal two-dimensional ultrasound machine at lithotomy position in rest (point OA) and on Valsalva maneuver (point OB). Bladder Neck Mobility is defined as the difference from point OA to OB. BWT is determined and measured as the hypoechoic layer between two hyperechoic layers that is recognized as the urothelium and the perivesical tissue using a transvaginal two-dimensional ultrasound machine at lithotomy position. The measurement is performed with a bladder volume <30 ml and is taken place in 3 different bladder sites: (a) the thickest part of the bladder triangle, (b) the dome of the bladder in the midline, (c) the anterior wall of the bladder. NGF will be measured in urine sample.
46011647|NCT04535336|Other|Control|Participants maintained their daily activities.
46011648|NCT04535154|Other|No interventions|No interventions
46098214|NCT04131777|Device|Radiofrequency (RF) catheter|A catheter introduced into the lung lesion via a bronchoscope, used to deliver radiofrequency (RF) energy for the purpose of ablation
46098215|NCT00884312|Drug|Carfilzomib|Carfilzomib dose levels ranged from 11 to 27 mg/m² for 2- to 10-minute infusions and 36 to 56 mg/m² for 30-minute infusions. Carfilzomib doses were administered on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Dose level reduction to a minimum dose of 11 mg/m² for toxicity was permitted.
46098216|NCT02693873|Behavioral|GLA:D Canada (education and neuromuscular exercise program)|"EDUCATION: 2 sessions cover OA topics (e.g. diagnosis, causes, risk factors, symptoms, treatment). Education also aims to strengthen beliefs in the value of exercise to control and improve pain and encourage exercise adherence after the program.~EXERCISE: 12 sessions (twice weekly, each about 1-hour) are supervised by therapist(s) with individual progression of exercises when good neuromuscular functioning is demonstrated. Exercises are performed using both legs and focus on sensorimotor control, functional stability, and muscular strength. Exercises involve a 10-minute cycle warm-up followed by a 4-station circuit (i.e. 2 exercises per station with 3 progressive levels of difficulty performed in 2 to 3 sets with 10 to 15 repetitions)."
46098217|NCT04131699|Device|Cardiotronic ICON continuous non-invasive cardiac output monitor.|cardiac index, cardiac output & stroke volume measured and recorded with every change in intrathoracic pressure.
46098218|NCT00689754|Procedure|nasogastric tube placement|standard nasogastric tube placement, aspiration and lavage up to 1L of normal saline
46098219|NCT04131855|Other|Pumice prophylaxis|Pumicing the teeth is the recommended prophylaxis to be used prior to the application of the self etch primer by the manufacturer - 3M Unitek Transbond Plus Self Etch Primer which will be used in the experiment.
46098220|NCT04131855|Other|No pumice prophylaxis|Pumice prophylaxis will not be used as per manufacturers instructions.
45463329|NCT01291615|Drug|Gemcitabine|800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks
46011649|NCT04535180|Diagnostic Test|Dual-energy X-ray absorptiometry (DXA)|"Body composition will be measured using whole-body DXA (GE Lunar iDXA, GE Healthcare Lunar, Madison, Wisconsin, U.S.A.). Extremity skeletal muscle mass will be calculated using the values measured via the DXA; ASM will be calculated as the sum of skeletal muscle mass in the arms and legs, assuming that the mass of lean soft tissue is a skeletal muscle. Appendicular skeletal mass index (ASM/Ht2 ) will be determined as the sum of the arm and leg lean mass (kg)/height2 (m2~). BMD will be measured in lumbar spine and bilateral hip by the same DXA device (GE Lunar iDXA, GE Healthcare Lunar, Madison, Wisconsin, U.S.A.)"
46011650|NCT02216448|Other|Training knee simulator|Training in a lab on a virtual reality knee arthroscopy simulator
45463330|NCT01291615|Drug|S-1|S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks.
45463331|NCT03942965|Device|Double balloon accessory device|Double balloon accessory device is used during the endoscopic polypectomy procedure
45463332|NCT03849079|Other|Hyponut|Prick tests with hyponut
46011651|NCT02216448|Other|OR Training|Training on diagnostic knee arthroscopy in the OR
46011652|NCT02278757|Other|High protein diet|Group received a diet with higher protein content (1.34gr/kg body weight). Meal replacements (drinks and bars) and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. For both groups (intervention and control), the calorie density had a restriction of 500kcal/day calories less than the resting metabolic rate (RMR) and were equivalent in the type of carbohydrate. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week).
46011653|NCT02278757|Other|Low protein diet|Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
46098221|NCT04163354|Procedure|5% sodium fluoride varnish (NaF)|In the NaF varnish groups, 0.25mL (one drop) of the varnish is placed in a plastic dappen dish. A disposable microbrush is used to apply the varnish onto the second primary molars included in the study and all other teeth. The child is instructed not to eat or drink after the application of varnish for at least half an hour.
46098222|NCT04163354|Procedure|Glass ionomer sealant (GIS)|Glass ionomer sealants (GIS) is applied using the finger pressure technique described in the WHO manual for atraumatic restorative treatment (ART) (Frencken et al.; 1997). The primary second molars are cleaned by applying GC cavity conditioner with micro-applicator for 10-15 seconds, then clean with wet cotton pellets for several times. The surface will be dried with cotton pellets. GIS (GC Fuji VII) is mixed in standardized proportion with an amalgamator, then applied to the occlusal surface and slightly overfilled. A gloved finger with petroleum jelly will be used to push and rub the materials into the pits and fissures, and removing the excess. GIS will be covered and protected by a layer of petroleum jelly (Vaseline ®).
46098223|NCT04131621|Biological|Nivolumab/Ipilimumab|Immune checkpoint inhibitor combination
46098224|NCT02718365|Procedure|Wedge resection|A wedge resection is the surgical removal of the lung tumor with a small portion of the lung that surrounds the tumor. Hilar and mediastinal lymph nodes should be resected or sampled.
46011654|NCT05080179|Behavioral|Self-Benefit/Social Norm|"As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. and Over 650,000 Pennsylvanians have already downloaded the app!"
45463333|NCT01295047|Drug|Atenolol|
45463334|NCT01295047|Drug|VERAPAMIL|240 MG SR
45463335|NCT01295047|Drug|Perindopril|4 MG
45463336|NCT05158504|Other|Motivation|Motivational notifications were sent via SMS message to the nurses in the motivation group (n=30) at 07.00, 12.00 and 16.00 for 21 days.
45463337|NCT01207349|Behavioral|Secondary prevention intervention trial|Close follow-up by nurses, exercise physiologist and dieteticians
45463338|NCT01207349|Behavioral|standard follow up|
46011655|NCT05080179|Behavioral|Self-Benefit/No Social Norm|"As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. They will not read any information about the number of Pennsylvanians who downloaded the app."
46011656|NCT05080179|Behavioral|Other Benefit/Social Norm|"As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. and Over 650,000 Pennsylvanians have already downloaded the app!"
46011657|NCT05080179|Behavioral|Other Benefit/No Social Norm|"As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. They will not read any information about the number of Pennsylvanians who downloaded the app."
46011658|NCT04534946|Other|This is not an intervention study|This is not an intervention study
46011659|NCT02278913|Drug|Basal Bolus (Glargine and Glulisine)|Glargine daily + Glulisine before meals
46011660|NCT02278913|Drug|Human Insulin|NPH twice a day + Regular insulin before meals
46011661|NCT04846530|Device|RHA® 1, RHA® 2, RHA® 3, and RHA® 4|For each subject, two spaced boluses (0.2 mL each) of the product will be implanted on the same side (left or right side) in the post auricular area of the subject per treatment assignment. The assignment will specify one of the RHA® products to the left ear and another product to the right ear. Each subject will have a total of four boluses.
46011662|NCT02278991|Device|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
46011663|NCT02216474|Other|Transcranial direct current stimulation|
46011664|NCT02216513|Drug|desferrioxamine (DFO)|DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days
46011665|NCT02216513|Drug|placebo|normal saline IV for 4 hours for 5 consecutive days
46011666|NCT04534998|Procedure|Partial nephrectomy|Partial nephrectomy for localized kidney cancer as curative treatment.
46011667|NCT02218775|Drug|LY2456302|Mood and Anxiety Disorders
46011668|NCT02216552|Dietary Supplement|Resveratrol|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
46098225|NCT02718365|Procedure|Segmentectomy|A segmentectomy removes a segment of a lung lobe anatomically, or inclusion of a portion of adjacent segment, but does not remove the whole lung lobe. Hilar and mediastinal lymph nodes should be resected or sampled.
46098226|NCT04136808|Drug|enfortumab vedotin (EV)|Participants will receive an intravenously (IV) administered dose once weekly for the first 3 weeks of every 4-week cycle (i.e., on days 1, 8, and 15)
46098227|NCT00689832|Drug|Tacrolimus 0.03%|ointment
46098228|NCT00689832|Drug|Fluticasone 0.005%|ointment
46098229|NCT00653978|Procedure|ERCP plus one biliary stent|ERCP ＋ one biliary stent insertion
46098230|NCT00653978|Procedure|ERCP plus two biliary stents|ERCP ＋ two biliary stents insertion
46098231|NCT02718521|Procedure|Hydration Combined With Intravenous Infusion of Isosorbide Dinitrate|Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration conbined with isosorbide dinitrate in all patients 6 hours before angiography and 12 hours after angiography
46098232|NCT02718521|Drug|Visipaque|All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
46098233|NCT02718521|Drug|0.9% sodium chloride ﬂuid administration|
46011669|NCT02216552|Dietary Supplement|Placebo|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
46011670|NCT01198756|Biological|Quadrivalent seasonal influenza vaccine GSK2282512A|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 17 years of age, single intramuscular dose.
46011671|NCT01198756|Biological|Fluarix™ VB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose.
46011672|NCT01198756|Biological|Fluarix™ YB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose
46011673|NCT01198756|Biological|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose for primed subjects, two doses for unprimed subjects.
46011674|NCT04534647|Diagnostic Test|different serum and urine biomarkers|urine exosomes and serum biomarkers
46098234|NCT02718521|Drug|isosorbide dinitrate|
46011675|NCT04534868|Other|taking macroscopic and dermoscopic pictures of suspicious skin lesions|"If there is any diagnostic doubt about a skin lesion, teledermoscopy will be used, if the patient agrees.~A table containing the useful information about the patient for the lesion's analysis will be completed.~The pictures will be taken with a Fotofinder Handyscope. The photos will be integrated into the patient's electronic medical record (CareConnect program).~The photo is anonymized via a serial number assigned by the Handyscope application.~Sending photos and information via a secure email address to the dermatologists.~Response from the dermatologist (Prof. Tromme or Dr Harkemanne) in the following days also via email.~Contact (consultation or telephone call depending on the diagnosis) with the patient to communicate the results and the procedure to be followed.~This information (emails containing the dermatological report) will be saved in the patient's computerized medical file (CareConnect program) then deleted from the mailbox"
46011676|NCT02216487|Drug|HA-Irinotecan|HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan for treatment of mCRC.
46011677|NCT01198600|Device|Habitual contact lens|Hydrogel or silicone hydrogel contact lens per participant's habitual brand and prescription
46011678|NCT01198600|Device|Lotrafilcon B contact lens|Commercially marketed silicone hydrogel contact lens
46011679|NCT01198600|Device|Contact lens cleaning and disinfecting system (ClearCare)|Commercially marketed, hydrogen peroxide-based contact lens care system
46011680|NCT02218814|Procedure|Adductor Canal Block, Bupivacaine|"Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL (100 mg) of Bupivacaine is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration.~Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml of PF Normal Saline is deposited adjacent to the femoral artery at the level of inguinal crease."
45463339|NCT03461289|Biological|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).
45463340|NCT03472846|Drug|Prolia, 60 Mg/mL Subcutaneous Solution|antiresorptive treatment with Prolia
45463341|NCT03472846|Drug|Teriparatide|osteoanabolic treatment with Forsteo
46011681|NCT02218814|Procedure|Femoral Nerve Block, Bupivacaine|"Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml (100 mg) of Bupivacaine is deposited adjacent to the femoral artery at the level of inguinal crease.~Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL of PF Normal Saline is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration."
46011682|NCT04317898|Procedure|serratus plane block by ultra-sound|To perform Serratus block, patients will be placed in the lateral decubitus position with the affected side facing up, or in the prone position with the affected side facing the operator . After sterile preparation, a linear ultrasound probe will be utilized to identify the latissimusdorsi and serratus anterior muscles in a sagittal plane. The plane superficial to the serratus anterior muscle and below the latissimusdorsi muscle will be identified. The skin will be topicalized with 1 mL of 1% lidocaine using a 30-gauge needle. Using an in-plane approach, a 25-gauge 1.5-cm needle will be used to inject a total of 20-mL of 0.25% bupivacaine with 80 mg of triamcinlone under direct ultrasound visualization.
46011683|NCT04317898|Procedure|paravertebral block by ultra-sound|TPVB will be given using high frequency linear US transducer, place the probe parallel to the vertebral spine at T2 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of plura, transverse process and paravertebral space, the needle will be inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 10ml of 0.25% bubivacine and 80mg triamcinlone slowly; the pleura will be seen to be pushed downward.
46011684|NCT04341246|Device|LiverMultiscan|The Livermultiscan is a quick, 15 minute contrast free MRI scan that provided metrics to quantify liver health namely fat, iron and fibro-inflammation
46011685|NCT02216565|Other|Hospitalization in specialized neuro-vascular unit|
46011686|NCT02216565|Drug|Alteplase if patient is eligible|Alteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)
46011687|NCT02216565|Other|Supportive care|Drugs, procedures and techniques aimed at preventing/managing complications or aggravation of the patient's neurological condition
46011688|NCT02216565|Procedure|Endovascular treatment|Recanalization treatment (thrombectomy / intraarterial thrombolysis)
45463342|NCT01190371|Drug|Artesunate|Oral, once daily, 7-day regimen of artesunate 2mg/kg/day
45463343|NCT05158426|Drug|Propofol|anesthesia induction is initiated with intravenous infusion propofol at 1.5µg/ml, and increased 0.5µg/ml every 3min until OAA/S score 0.
45463344|NCT03853369|Drug|Nifekalant hydrochloride|Treatment is not limited. Patients who have used or will use Nifekalant hydrochloride.
45463345|NCT03949595|Other|Data collection|
45463346|NCT03428997|Device|Lotion|Formulated Lotion F# 13451-131 was applied on an occlusive patch and placed on a test site on each subjects back three times a week for four weeks.
45463347|NCT03428997|Other|Negative Control|Control. An undosed occlusive patch was placed on a test site on each subjects back three times a week for four weeks.
45463348|NCT01293175|Dietary Supplement|Whole grains|Subjects will consume whole grains at dose of 80 g/die, for two months
45463349|NCT01112111|Drug|mode of gonadotropin administration|Low dose step-up administration Step down administration sequential administration
45463350|NCT05158348|Drug|Dexmedetomidine Hydrochloride|Group A will receive post-operative nebulised dexametomidine and lidocaine.
45463351|NCT05158348|Drug|Nebulized lidocaine|Group B will receive post-operative will receive nebulised lidocaine
45463352|NCT05158348|Drug|Local infiltration of lidocaine|group C will receive intra-operative local infiltration of lidocaine
45463353|NCT03852823|Drug|SG001|Phase Ia: Subjects will receive intravenous infusion of SG001 following a sequential dose escalation design (1mg/kg, 3mg/kg and 10mg/kg). Dose limited toxicity (DLT) will be observed within 21 days after the first administration, then subjects can continuously receive SG001 every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal from the trial. Phase Ib: Subjects will receive intravenous infusion of SG001 at the dose of 240 mg every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal from the trial.
45463354|NCT03716271|Device|Visual Acuity Examination with a novel lens|Visual Acuity Examination with a novel lens set in an ophthalmic trial frame
45463355|NCT01112189|Procedure|Autologous transplant|Patients will be stimulated 3 days with Filgrastrim 300 micrograms per day. On the 4th day the autologous transplant of stem cells will be performed.
45463356|NCT01112189|Other|Compressed sleeve treatment|"Week 1-2: With compressed sleeve treatment.~Week 3 -4: Without treatment.~Week 5 - 6: With compressed sleeve treatment"
45463357|NCT05158192|Drug|Diosmin/Hesperidin (90/10) 500 mg Test Drug|Investigational Medicinal Product
45463358|NCT05158192|Drug|Diosmin/Hesperidin (90/10) 500 mg Reference Product|Daflon (Trademark)
45463359|NCT03716193|Other|Oxygen|Patients will be given oxygen via a facemask during the measurement session
45683822|NCT04746118|Other|INTEGRATIVE PRACTICES|The health integrative practices will includes Mind-Fullness, auriculotherapy and laying on of hands. A suitably qualified professional, using it use a practical manual so that the practice became uniform among the subjects, will apply the practice of Mind-Fullness in weekly 1-hour sessions to individuals. The practice of auriculotherapy will be applied to individuals by a professional qualified to perform the technique, which consists in the selection of auricular points according to the health problems presented and the therapeutic objectives that are to be achieved, followed by the insertion of the mustard seed at specific points in the ear over a six-month period. The laying on of hands will be carried out by properly trained individuals.
46011689|NCT02218931|Behavioral|Targeted ESTEEM diet|"The key components of the diet are:~High intake of vegetables, nuts, non-refined grains, legumes and fruits;Moderate to high consumption of fish;Small to moderate intake of poultry and dairy products such as yoghurt and cheese;Low consumption of red meat and processed meat and avoidance of sugary drinks, fast food and high fat food;High fibre;Intake of nuts including walnuts and almonds that are rich sources of monounsaturated and polyunsaturated fatty acids (30 g/day);Olive oil to cook and dress salads as the main source of fat (0.5 l/week)~The intervention will include structured meal plans and grocery lists, recipes for healthy diet and appropriate choices at restaurants"
46098235|NCT04131543|Drug|Cabozantinib 20 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.
45463360|NCT01187719|Drug|phenytoin|phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days
45463361|NCT01207505|Behavioral|Enhancing Emotion Regulation|12 week of group therapy 3 modules: 1) mindfulness, 2) emotion regulation, 3)distress tolerance
45463362|NCT03472690|Biological|QBECO-SSI|Subcutaneous injection
45463363|NCT03472690|Other|Placebo|Subcutaneous injection
45463364|NCT03718533|Drug|Eltrombopag|50mg Film-coated tablet and 25mg Film-coated tablet for oral use administration
45463365|NCT01102595|Drug|Temozolomide|"Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.~Temozolomide 75 mg/m2/d x 42-49 days~Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
45463366|NCT01102595|Drug|Bevacizumab|"2 cycles + bevacizumab 10 mg/kg every 15 days each two cycles.~Bevacizumab 10 mg/kg every 15 days, three dosis."
45463367|NCT01102595|Radiation|Standard radiation therapy|42-49 days with standard radiation therapy (60 Gy): 2 Gy per day.
45463368|NCT01187797|Other|Emotional stimulation|Increase of the physical correlates of an emotion
45463369|NCT05158036|Other|Classic massage group|Classic massage application will be given to the Classic massage group
45463370|NCT05158036|Other|Connective tissue masage|Connective tissue masage application will be given to the Connective tissue masage group
46011690|NCT02218931|Other|Non-randomised cohort|Non-randomised cohort of women with no metabolic risk factors will be followed up to delivery to collect outcome data
46011691|NCT04534790|Radiation|Low Dose Radiotherapy|anti-inflammatory effect with low-dose radiation to the lungs
46011692|NCT02216630|Drug|Adipose Derived Stem Cell (ADSC) Therapy|Patients undergo a liposuction where 100 cc of fat are extracted. The ADSCs are then isolated and injected intravenously.
46011693|NCT02218970|Behavioral|strength training|
46011694|NCT02218970|Behavioral|no training (control)|
46011695|NCT04534803|Drug|BCG Vaccine|.1 mL of reconstituted BCG vaccine given intradermally at baseline.
45463371|NCT03454893|Drug|AVR-RD-01|The subject will receive a one-time IV infusion of AVR-RD-01.
46011696|NCT04534803|Other|Placebo|.1 nL of diluent (saline) given intradermally at baseline
46011697|NCT02219126|Other|Dietary intervention|
46011698|NCT04534569|Other|Experts consensus|Consensus opinion using Delphi Methodology
46011699|NCT04534634|Combination Product|IFN-α combined with CAR-T cell therapy|"Adults: 14 daily intramuscular injections 300 million IU of Interferon-α for a 28-day cycle.~Children: 14 daily intramuscular injections 200mg/m^2 of Interferon-α for a 28-day cycle.~CAR T cell: (1-2)×10^7/kg, intravenously infusion."
46011700|NCT01198132|Dietary Supplement|Cholecalciferol (Vitamin D3)|Subjects receive Cholecalciferol 100,000 IU one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) for 96 weeks treatment period along with subcutaneous Rebif 44 mcg 3 times a week.
46011701|NCT01198132|Dietary Supplement|Placebo|Subjects receive matching placebo to Cholecalciferol once every two weeks orally along with subcutaneous injection of Rebif 44 mcg 3 times weekly.
45463372|NCT01191619|Procedure|McIvor retractor|The Mclvor blade- guided technique (McIvor group) involved the following steps. The PLMA was lubricated on the posterior aspect of the deflated mask with a water-based lubricant. The McIvor blade was fully inserted beneath the tongue of the patients. The tongue was lifted gently with the McIvor blade and PLMA was introduced into a space between the McIvor blade and maxillary incisors holding the bite block of the PLMA. The PLMA was advanced into the hypopharynx until definite resistance was felt and McIvor blade was removed.
46011702|NCT01198132|Drug|Rebif|Subjects receive subcutaneous injection of Rebif 44 mcg 3 times weekly.
46011703|NCT04534530|Other|Systematic screening for ischemic heart disease in type 2 diabetic patients|Systematic screening for ischemic heart disease in type 2 diabetic patients at very high cardiovascular risk, without known coronary heart disease.
46011704|NCT02219165|Drug|Intravenous human immunoglobulin|Single administration of IVIG 2 g/kg within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The bottles of IVIG used will contain 10 g of proteins in 100 ml of solution. Thus, to reach a concentration of 2 g/kg, will be administered 1 bottle per 5 kg of body weight (with a maximum of 14 bottles for 70 kg patients and over).
46011705|NCT02219165|Drug|Albumin|Single administration of albumin 4% within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The solution will be given at the same volume as IVIG (that is: 1 bottle / 5 kg of body weight).
46011706|NCT02887690|Device|Modular Prosthetic Limb|
46011707|NCT02216604|Behavioral|Multimodal Exercise Intervention|During their inpatient hospitalization the participants perform 3-5x weekly guided training sessions about 15-30min. The intervention includes: game console-based training using Nintendo Wii® (endurance, strength endurance and balance), age-specific resistance training and sessions of body awareness. During the outpatient phases the participants perform a home-based exercise training 3-5x weekly using a training manual. In addition, the patients obtain a movement diary and a pedometer for documenting their activity level.
46011708|NCT04534439|Drug|APX-115|oral administration of APX-115 400mg capsule once daily for 12 weeks
46011709|NCT04534439|Drug|Placebo|oral administration of APX-115-matching placebo 400mg capsule once daily for 12 weeks
46011710|NCT04534725|Drug|Interferon alfa|intranasal spray
46011711|NCT04534725|Drug|Selinexor|oral tablet
46011712|NCT04534725|Drug|Lenzilumab|intravenous infusion
46011713|NCT04534478|Drug|Prednisone|Patients will be randomized 1: 1 between the two arms of the study
45463373|NCT03949517|Drug|68-Ga RM2|Radioactive agent
45463374|NCT03949517|Drug|68-Ga PSMA11|Radioactive agent
46011714|NCT02216669|Drug|DTP348|Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
46011715|NCT03881748|Other|Manual acupuncture|"Manual acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes."
45463375|NCT03949517|Device|Investigational software and coils in PET/MR Scan|Investigational software and coils in PET/MR Scan by General Electric Healthcare
45463376|NCT03949517|Procedure|PET/MRI|Positron emission tomography (PET)/Magnetic resonance imaging (MRI) Scan
45683823|NCT02783716|Procedure|Subcutaneous adipose tissue collection|During standard of care device implantation procedure, a small piece of fat tissue will be removed from the device pocket inside the chest
46011716|NCT03881748|Other|Electro-acupuncture|"Electro-acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes.~Electrical stimulation will be applied to the needles concomitantly and continuously to acupuncture points by placing lead wires on the needles connected to an electro-acupuncture stimulator such as the Model IC-1107. The stimulator will be set on the Dense-Disperse wave setting with low frequency at 2-10 Hz and high frequency at 100-110 Hz. The needles will not be manually stimulated after electrical stimulation is applied."
46011717|NCT02219204|Procedure|Acupuncture|
46011718|NCT02219204|Other|Herbal treatment|
46011719|NCT03772158|Drug|Cetirizine 10mg|Chewable tablet
46011720|NCT03772158|Drug|Cetirizine 10 mg|Immediate Release Tablet
46011721|NCT03772158|Drug|Cetirizine 10 mg|Immediate Release Tablet
45463377|NCT03848611|Drug|CM082 plus JS001|CM082：150mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
45463378|NCT01584869|Device|capsule endoscopy|
45463379|NCT03469414|Other|Life Space Assessment Scale|This nine question survey asks participants where they have gone in the last week, frequency of those visits, and how independently they went there.
45463380|NCT03469414|Other|6-Minute Push Test|The 6 Minute Push Test is a measure of endurance, and requires that the participant wheel themselves around two pylons that are located 15 meters apart for 6 minutes.
45463381|NCT03469414|Other|Forward Push Test|This measure of wheelchair propulsion speed asks patients to propel themselves as fast as they can over 20 meters. This task is performed twice, and the average time is used for the score.
45463382|NCT03469414|Other|Wheelchair Slalom Test|In this measure, participants propel themselves through an 18 meter slalom course at their maximum self-selected speed, wheeling around seven cones, separated by three, two, or one meter.
46098236|NCT04131543|Drug|Cabozantinib 40 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.
46011722|NCT03653988|Procedure|PEC I/II blocks by anesthesiologist - pre-operative|PEC I/II blocks by anesthesiologist - pre-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II). Group I will have the PEC block administered by the anesthesiologist prior to surgical incision.
46098237|NCT04131543|Drug|Cabozantinib 60 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions and delays to manage toxicity. Cabozantinib should be taken in fasting condition with no food for at least 2 hours before and 1 hour after taking the tablets. A high fat meal significantly increased the median tmax to 6 hours from 4 hours (fasted). The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
45463383|NCT03469414|Other|Craig Handicap Assessment and Reporting Technique|A measure of social participation in individuals with SCI.
45463384|NCT03469414|Other|PART-O|The PART-O is a community participation measure.
46098238|NCT02718443|Drug|VXM01|Oral immunotherapy targeting VEGFR2
46098239|NCT00689988|Behavioral|speech-language therapy with AAC intervention|speech-language intervention in weekly 40-minutes sessions, without the presence of parents or caregivers, and 5 to 10-minutes to parents training and orientation
46098240|NCT02723045|Procedure|Open Lichtenstein Hernioplasty|
46098241|NCT02723045|Procedure|Laparoscopic TEP Hernioplasty|
46098242|NCT04131465|Diagnostic Test|Home HIV self-testing|Offer of 3 OraQuick HIV self-test kits
46098243|NCT04131465|Diagnostic Test|Home HIV rapid testing|Offer of HIV rapid testing with Alere Determine HIV-1/2
46098244|NCT04131465|Diagnostic Test|Home HIV self-testing and rapid testing|Offer of 3 OraQuick HIV self-test kits and HIV rapid testing with Alere Determine HIV-1/2
46011723|NCT03653988|Procedure|PEC I/II blocks by surgeon - intra-operative|PEC I/II blocks by surgeon - intra-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II).
46011724|NCT01197508|Drug|TC-5214|Twice daily for 8 weeks.
46011725|NCT01197508|Drug|Placebo|Twice daily for 8 weeks.
46011726|NCT02219243|Behavioral|Online Interpretation Training Condition 1|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
46011727|NCT02219243|Behavioral|Online Interpretation Training Condition 2|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
45463385|NCT03469414|Other|GPS Tracking|A GPS tracker will be attached to the wheelchairs of a subset of participants for one week. The GPS location is collected every minute, and mapped to Google Maps, which would allow calculation of speed of movement.
46011728|NCT04534764|Device|etafilcon A with cosmetic pattern|TEST
46011729|NCT04534764|Device|1-Day Acuvue DEFINE Vivid Style|CONTROL
46011730|NCT04534062|Other|PNF D2 technique|PNF D2 technique of bilateral upper limb will be performed
46011731|NCT02219399|Dietary Supplement|600 mg DHA|Pregnant women were given 600 mg DHA in the last trimester of pregnancy
46011732|NCT02219399|Dietary Supplement|300 mg DHA|Pregnant women were given 300 mg DHA in the last trimester of pregnancy and through the first 3 months of breastfeeding
46011733|NCT02219399|Dietary Supplement|Placebo|Pregnant women in the control group received placebo of either olive oil or high oleic acid sunflower oil during the study period
46011734|NCT02887378|Device|hot clamps|reusable hot biopsy forceps
46011735|NCT02887378|Device|normal clamps|
46011736|NCT04534244|Device|VBox Hybrid|Medical device intended to treat permanent venous insufficiency of saphenous veins and tributary veins in patients with superficial venous reflux
46011737|NCT04534140|Dietary Supplement|HBKB Capsule|The botanical dietary supplement 'Halo Beauty Kiwi Booster' (HBKB) taken daily orally.
46011738|NCT04534140|Other|HBKB Supplement Vehicle|Control group participants will take one capsule of the HBKB botanical dietary supplement vehicle orally, once daily
46011739|NCT03596697|Drug|CRV431|Single or multiple dose(s) of CRV431
46011740|NCT03596697|Drug|Placebo|Single Placebo dose
46011741|NCT03596697|Drug|TDF|Single or multiple dose(s) of TDF
45463386|NCT05671549|Procedure|Arthrocentesis of the temporomandibular joint|Arthrocentesis of the temporomandibular joint is a minimally invasive method performed under local anesthesia to irrigate the upper temporomandibular joint cavity with biocompatible substances. The procedure aims to wash out intra-articular inflammatory substances, reduce pain and restore the function of the related joint.
45463387|NCT03452943|Drug|TEV-50717|6, 9, 12, 15, and 18 mg oral tablets
46011742|NCT01196416|Drug|Cisplatin|Given IV
46011743|NCT01196416|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
46011744|NCT01196416|Other|Laboratory Biomarker Analysis|Correlative studies
46011745|NCT01196416|Other|Pharmacological Study|Correlative studies
46011746|NCT01196416|Drug|Temozolomide|Given PO
46011747|NCT01196416|Drug|Vinblastine Sulfate|Given IV
45463388|NCT03452943|Drug|Placebo|Placebo matched to TEV-50717 tablets will be taken BID for 12 weeks.
45463389|NCT01584947|Drug|Bupivacaine|Bupivacaine lozenge taken 3 times a day for two weeks
45463390|NCT01584947|Drug|Placebo|Placebo lozenge taken three times a day for two weeks
45463391|NCT03848767|Device|AID System|AID System
45463392|NCT03848767|Drug|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control except during meal challenges.
45463393|NCT04457908|Diagnostic Test|intelligent assessment|intelligent neurological function assessment
46011748|NCT02219555|Drug|Steroid Injection|volume and specific steroid drug will be based on the recommendation of the treating clinician
46011749|NCT02219555|Procedure|Carpel Tunnel surgery|Standard of care carpel tunnel surgery
46011750|NCT03272178|Device|Depuy total knee implant|patients from Dr Nunley's clinic will get a Depuy implant
46011751|NCT03272178|Device|Triathlon total knee implant|patients from Dr Barrack's clinic will get a Triathlon implant
46011752|NCT04534166|Other|Risk Prediction of Fracture in Diabetic Patients with Osteoporosis|Risk Prediction of Fracture in Diabetic Patients with Osteoporosis
46011753|NCT04534088|Behavioral|Standard Behavioral Weight Loss plus Non-Weight-Related VR app|Standard Behavioral Weight Loss Program
46011754|NCT04534088|Behavioral|Standard Behavioral Weight Loss plus Weight-Related VR app|Standard Behavioral Weight Loss plus Weight-Related VR app
46011755|NCT01196104|Drug|Technosphere® Insulin Inhalation Powder|
46011756|NCT01196104|Drug|Insulin Aspart|Usual Care
46011757|NCT01196104|Drug|Insulin Glargine|
46011758|NCT04534322|Drug|Melphalan Flufenamide|Melphalan flufenamide (melflufen) is an investigational peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.
46011759|NCT04534322|Drug|Dexamethasone|Dexamethasone, a synthetic adrenocortical steroid, is a white to practically white, odorless, crystalline powder. It is stable in air. It is practically insoluble in water.
46011760|NCT04534179|Procedure|Vacuum myofascial therapy and physical activity program.|"This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 30 minutes.~Then they carried out the physical activity program"
46011761|NCT04534179|Other|Physical activity program.|Active Comparator: Physical activity The exercise protocol would last 5 weeks, performing 3 exercise sessions per week, with an effective work time of 20 minutes per session. The exercises would be directly focused on activating the core stabilizing muscles.
45463394|NCT01109615|Drug|Pemetrexed|400 mg/m2 on day 1 of a 3 weeks cycle
45463395|NCT01109615|Drug|Gemcitabine|1000 mg/m2 intravenously on day 1 and 8 of a 3 weeks cycle
46098245|NCT02718599|Drug|terlipressin|Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
45463396|NCT01293253|Behavioral|Stair walking|Participants of the stair group is encouraged to use the stairs for 10 minutes a day at the workplace. Participants of the control group receive a health examination before and after the intervention period, and are advised to stay active
45679591|NCT05429099|Procedure|Virtual Surgical Planning (VSP)|The 3D reconstruction model, not requiring sterilization, will be sent directly to the SS. Prior to surgery, the SS will prebend a titanium fixation plate to the reconstruction model. Both the surgical cutting guides and titanium plate will be sterilized prior to use in surgery. If the planned resection cannot proceed (possibly due to tumour growth), the surgical team will note the reason for abandonment and conduct a standard FHS. Intraoperatively, the SS will apply the mandibular cutting guide to make the resection, remove the resected component and apply the pre-bent plate. Next, either the fibular or scapular cutting guide is applied to harvest the transplant which is then secured to the plate. The flap is re-vascularized by joining it to blood vessels in the neck.
46098246|NCT02718599|Drug|normal saline|Patients receive 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
46098247|NCT00693888|Behavioral|advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)|initial comprehensive assessment, stratified (city, suburbs) randomization into two groups: interventional group: individual comprehensive primary advice (medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives), control group: standard support, observation over a period of 6 months, possibility of completing the diagnostic after final assessment
46098248|NCT04016064|Procedure|Er:YAG LASER, Nd:YAG laser, elctrosurgery, conventional surgery|"Er: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) 200 mj, 10 Hz, 2 Watt and VLP (long pulse, 1000 μs); 1.3 mm diameter, 8 mm long cylindrical, a sapphire tip was used with air cooling and water irrigation.~Nd: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) was applied at 4 watts, 50 Hz, 300 μm microfiber tip and SP (short pulse: 180 μs) settings.~Electrosurgical (Servotome Classic System, High Frequency Surgical Equipment, Satelec, France).~Conventional surgical method was applied with hand instruments and gingivectomy knives."
46011762|NCT02219594|Device|CT image for patient with suspected in-stent restenosis|"Gemstone CT or 320-detector row spiral CT was assigned randomly to patient who was suspected in-stent restenosis.About after 10 days,they would accept the check of OCT which wold be the gold standard of in-stent restenosis."
46011763|NCT02219633|Drug|LEO 39652 cream|Applied for 21 days
46011764|NCT02219672|Drug|Triplitode|"Drug: Triptolide Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.~Other Name: Tripterygium Wilfordii Hook F (TwHF) Drug: cART Participants who will be enrolled in this Triplitode group would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir ."
46011765|NCT02219672|Drug|Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir|Participants who will be enrolled in this trial would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir.
45463397|NCT01209065|Drug|GSK1349572|GSK1349572 is an integrase inhibitor being developed for the treatment of human immunodeficiency virus -1 infection by ViiV Healthcare. This drug is experimental and has not been approved by the Food and Drug Administration (FDA).
45463398|NCT01209065|Drug|Fosamprenavir|Fosamprenavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
45463399|NCT01209065|Drug|Ritonavir|Ritonavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
45679592|NCT05429099|Procedure|Free-Hand Surgery|The SS will adopt their standard procedure for the mandibular resection and reconstruction. This typically involves bending a titanium fixation plate, harvesting of the bony flap, and shaping of the segments all intraoperatively based on the SS's judgement.
45679593|NCT05428267|Other|questionnaire|Completion of questionnaires (IIEF5/FSFI, SF 36, Fatigue Scale Score, Self Esteem Inventory, Hospital Anxiety and Depression Scale) during the pre-transplant consultation, then during a consultation 6 months after transplantation
46011766|NCT03113955|Device|Tandem Microsphere loaded with Epirubicin|The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)
46011767|NCT04533971|Other|Whole body cryotherapy|The WBC procedure consisted of 2-3 min walk in the cryogenic chamber at -110℃. Immediately before the WBC procedures, the patients were provided with a special treatment suit, they were instructed as to how to protect the parts of the body that are particularly vulnerable to frostbite, on the proper way of moving and breathing during the treatment. Excluding Saturdays and Sundays, the WBC treatments were performed daily for the next four weeks. Each time after the WBC the subjects participated in 15-minute kinesitherapy exercises conducted in groups of 5-6 people. The exercises were of general improvement nature and took into account the mobility of the subjects.
46011768|NCT02219750|Drug|switch twice-daily insulin|"compare two different insuiln regimen in basal insuln base and premixed insulin.~NovoMix 30, drug class:biphasic insulins Lantus, drug class: long-acting insuiln Levemir, durg class: long-acting insulin NovoRapid, drug class: rapid-acting insulin"
45463400|NCT01193803|Procedure|Microbiological cultures and Molecular biology|"Biological/Vaccine: Microbiological cultures and Molecular Biology Bacteriological procedures: All solid specimens will be crushed using a mechanic apparatus. Direct examination and cultures will be performed according to the guidelines applied for osteoarticular infections. Cultures and subcultures will be incubated for 15 days to 3 months for Mycobacteria.~Molecular procedures: DNA extraction will be based on Boom's method (QIAGEN kit and EZ1 BioRobot). Detections of bacteria will be performed by amplification and sequencing of the 16S rRNA gene. Some specific detections as the detection of Staphylococcus sp. and Mycobacterium tuberculosis will be added to this protocol."
45463401|NCT02782702|Drug|Botulism Toxin Treatment|Injection of 50 UI of botulism toxin for treated zone
45463402|NCT01102673|Drug|PF-04991532|The tentative dosing schedule is 30, 100, 300, 600, 1200, and 2000 mg. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as extemporaneously-prepared powder in capsule (PIC) formulation.
45463403|NCT01102673|Drug|Placebo|Placebo to match PF-04991532 will be provided
45463404|NCT03481725|Device|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio)|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electric current for 14 days
45463405|NCT03481725|Device|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable SHAM stimulator (SPR Therapeutics, Cleveland, Ohio)|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does not generate electric current for 14 days
45463406|NCT05388292|Other|Emergency triage decision support system|Evaluating the impact of the developed Emergency Triage Decision Support System on triage management
45463407|NCT01209221|Drug|Placebo - MAD|Once or twice daily doses of matching placebo to RO5271983 for 14 days
45463408|NCT01209221|Drug|Placebo - SAD|Single dose of matching placebo to RO5271983 for up to 3 periods
45463409|NCT01209221|Drug|RO5271983 - MAD|Once or twice daily doses of RO5271983 for 14 days
45463410|NCT01209221|Drug|RO5271983 - SAD|Single dose of RO5271983 at each period (for up to 3 periods)
45463411|NCT05157334|Device|Non-invasive auricular electrical transcutaneous vagus nerve stimulation|"A NEMOS ® stimulator (Cerbomed, Erlangen, Germany) is used for transcutaneous auricular vagus nerve stimulation. This is a handheld battery driven stimulator which stimulates conca in the outer ear. It stimulates in a serie of small electrical impulses with a pulse width at 250 us and a frequency at 25 Hz for 30 minutes in a cycle for 30 seconds on and 30 seconds off to avoid habituation. It is previously indicated that a stimulation intensity at 0,5 mA, 1 mA or 1,5 mA does not cause a significant chance in HRV, thus 0,5 mA is used in this study."
45463412|NCT05157334|Other|Deep breathing|The participant is first verbally introduced to the breathing exercises, and then to the visually cue (animation), which the participant have to follow throughout the session.
45463413|NCT01209299|Genetic|DNA methylation analysis|
45463414|NCT01209299|Genetic|gene expression analysis|
45463415|NCT01209299|Other|laboratory biomarker analysis|
45463416|NCT03719781|Diagnostic Test|standardized minimental testing|To diagnose postoperative cognitive dysfunction
46011769|NCT04534374|Behavioral|Resistance exercise|Barbell back squat, press, and deadlift for three sets of five repetitions with the weight closest to 75% of their estimated 1 repetition max. The participants were instructed to execute the movement with moderate speed (2s eccentric, 2s concentric, no pause in between). The rest period between sets and exercise movements was two to three minutes.
46011770|NCT04534374|Behavioral|Stretching exercise (sham exercise)|Participants completed a passive stretching exercise session for a similar duration of time as the resistance exercise (≈ 30 min) as sham intervention, which included 15-20 stretching movements twice, holding each for 30 seconds as recommended by ACSM.
45463417|NCT03850717|Device|acupuncture|insert in filiform needles into skin and other soft tissue to treat the illness or disorders
45463418|NCT03472456|Drug|Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne|Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne
45463419|NCT03472456|Drug|Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol|Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol
45463420|NCT01209377|Behavioral|standard|EMDR treatment with bilateral stimulation via eye movement
45463421|NCT01209377|Behavioral|fixed|EMDR treatment with fixed eyes
45463422|NCT01209377|Behavioral|no focus|trauma exposure without external focus
45463423|NCT01209377|Procedure|EMDR|Eye Movement Desensitization and Reprocessing (EMDR)
45463424|NCT01193881|Drug|Erlotinib Hydrochloride|Given PO
46011771|NCT04534452|Drug|Phenylephrine HCl (Sinus Comfort, BAY112476)|30 mg Extended Release Tablets, single oral dose
45463425|NCT01193881|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
45463426|NCT01193881|Other|Laboratory Biomarker Analysis|Correlative studies
46011772|NCT04533789|Other|selected physical therapy program|strengthening muscles of upper and lower limbs, balancing exercise, gait training in open environment, stretching for elbow flexors and forearm pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
46011773|NCT04533776|Behavioral|Celiac Disease Definition, Symptoms and Treatment|"Adolescents share their knowledge about the disease~Emphasizing the definition and symptoms of celiac disease~Discussion of the treatment of celıac disease Expression Question-Answer Discussion Summarizing"
46011774|NCT04533776|Behavioral|Difficulties Due to Celiac Disease|"Determining what experience living with celiac is fot the patient (What do I think about the disease, how do I feel about the disease,how do I perceive the disease, how does the disease affect me)~Determining the difficulties encountered in Daily life due to illness (How do I deal with difficulties)~Determining how the disease affects life Expression Question-Answer Discussion Summarizing"
46011775|NCT04533776|Behavioral|Gluten Free Diet in Celiac Disease|"Evaluating dietary information~Identifying the difficulties in diet therapy Expression Question-Answer Discussion Summarizing Case Study Presentation (Transfer of life experience of an individual who is 22 years old with celiac disease)"
45463427|NCT01193881|Other|Pharmacological Study|Correlative studies
46011776|NCT04533776|Behavioral|Difficulties Related to Disease in School and Social Life|"Assessment of difficulties encountered in school and social life~Evaluation of the solution suggestions fort he difficulties encountered Expression Question-Answer Discussion Summarizing Örnek Olay Sunumu (Transfer of life of experience of a 23 years old dietician with celiac disease)"
46011777|NCT04533776|Behavioral|Celiac Disease and Its Effects on Acamdemic Success Peer Relations|"Evaluation of the effects of the disease on academic success~Evaluation of the effects of the disease on peer relationships in the school enviroment~Difficulties experienced in peer relations and evaluation of relationships (exclusion) Expression Question-Answer Discussion Summarizing"
46098249|NCT04112381|Device|Exablate Model 4000 Type 1.0/1.1|Exablate thalamotomy of non tremor dominant side of the brain
46098250|NCT00693966|Biological|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1)|IM injection
45463428|NCT02529605|Dietary Supplement|Product B® IsaGenesis®|This will be a crossover comparison of a one time dose of the liquid-gel formulation contained in 2 capsules; 1280 mg/capsule.
45463429|NCT02529605|Dietary Supplement|IsaGenesis®|This will be a crossover comparison of a one time dose of the dried powder extract contained in 2 capsules; 1070 mg /capsule.
46011778|NCT04533776|Behavioral|Celiac Diseae anf Future Goals|"General summary of all sessions so far~Summarizing the topics discussed in the previous session~Evaluating the future goals of the participants Expression Question-Answer Discussion Summarizing"
46011779|NCT04533776|Other|No Intervention: routine health care- control group|Peer interactive group support was not provided to the control group. After all the sessions of the peer interactive group support of the study were completed, a separate training meeting was held for the control group.
46098251|NCT00693966|Biological|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2)|IM injection
45463430|NCT01194037|Drug|recombinant variant of interferon-alpha 2b|SC, Weekly
46011780|NCT04533828|Drug|68Ga-FAPI-04|Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
46011781|NCT03016338|Drug|Niraparib|200 or 300 mg daily PO, for 21 day cycle
46098252|NCT00693966|Biological|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3)|IM injection
46098253|NCT00693966|Biological|MEDI-517 HPV-16/18 VLP with Al(OH)3 (Formulation 4)|IM injection
46098254|NCT02718287|Behavioral|Home visiting intervention PCCSF (220 clusters)|Low income mothers of children 0-2.5 years of age in the randomized treatment micro-areas will receive home visits by community health workers trained in the PCCSF curriculum in addition to the basic health curriculum. The community health workers are supervised by trained and experienced nurses.
45463431|NCT01194037|Drug|Peginterferon alfa-2a|SC Weekly
45463432|NCT01295203|Behavioral|website assess|The internet intervention group were given assess to the intervention website which included a personal page with tailored physical activity advice and a personal profile together with Recommendations and general training programs.
45463433|NCT03480243|Drug|Padsevonil (UCB0942)|"Pharmaceutical Form: film-coated tablet~Route of Administration: Oral use"
45463434|NCT03480243|Drug|Erythromycin|"Pharmaceutical Form: film-coated tablet~Route of Administration: Oral use"
45463435|NCT01109693|Drug|Sertraline|Sertraline 50 mg/d or 100 mg/d for 6 more weeks
45463436|NCT01109693|Drug|Mirtazapine|Augment with or switch to mirtazapine 15-45 mg/d
46098255|NCT02718287|Behavioral|Home visiting without PCCSF (220 clusters)|Low income mothers of children 0-2.5 years of age in the randomized control micro-areas will receive home visits by community health workers trained in the standard basic health curriculum (no PCCSF).
46098256|NCT02655575|Behavioral|BI + VR + CBT|Brief intervention (information and advice) + group-based vestibular rehabilitation combined with cognitive behavioral therapy
46098257|NCT02655575|Behavioral|BI + phone calls|Brief intervention (information and advice). Patients are followed-up by phone calls
46098258|NCT00694044|Drug|varenicline|0.5 mg once daily for 7days followed by 0.5 mg twice daily for 7days followed by 1mg twice daily for 7 days
45463437|NCT03850405|Dietary Supplement|Dark Chocolate|20 patients (10 male, 10 female) will undergo a diet containing 25g of dark chocolate (70%), corresponding to ca. 145 kcal which will be detracted from the total caloric intake.
45463438|NCT01109771|Device|permanent mesh fixation|Permanent mesh fixation will be used.
45463439|NCT01109771|Device|absorbable mesh fixation|Absorbable mesh fixation will be used.
45463440|NCT01190683|Drug|Cholecalciferol|60,000 IU/week for ist eight weeks followed by 60,000 IU every 15 days for four months
45463441|NCT01190683|Drug|Calcium Carbonate|two tablets of calcium carbonate daily containing 1 gm of elemental calcium for six months
45679594|NCT05428267|Other|blood collection|Collection of a 5mL tube of blood during a scheduled blood draw in the patient's care pathway. This sample will also be taken after the transplant (6 months later)
45679595|NCT05424198|Procedure|Cervical Medial Branch Radiofrequency Ablation|The skin and superficial tissues will be anesthetized at each site with 1-2 mL of lidocaine. Prior to the ablation up to 2 mL of lidocaine may be used at each site to ensure adequate pain control during the ablation. Once in position, a radiofrequency ablation lesion will be made using a 30 second ramp-up time to a maximum temperature of 80 °C, followed by an additional 90 seconds at maximum temperature.
46011782|NCT03016338|Drug|TSR-042|500 mg once intravenously on day 1 of cycle (From cycle 1-4 followed by 1000 mg intravenously every 6 weeks for maximum of 2 yrs)
46011783|NCT02219789|Drug|Alisertib|Given PO
45463442|NCT01190683|Drug|cholecalciferol and calcium carbonate|60,000 IU of cholecalciferol for first eight weeks and then 60,000IU for next four months along with 1 gm of elemental calcium daily for six months
46011784|NCT02219789|Drug|Fulvestrant|Given IM
46011785|NCT02219789|Other|Laboratory Biomarker Analysis|Correlative studies
45463443|NCT01190683|Other|lactose placebo|similar number of granules and tablets as active group
46011786|NCT04533633|Procedure|Retrograde Percutaneous Coronary Intervention of Chronic Total Occlusion|Retrograde CTO-PCI using epicardial collateral connections
46098259|NCT00694044|Drug|varenicline|0.5 mg once daily for 14 days followed by 1 mg once daily for 7 days
46098260|NCT00694044|Drug|varenicline|0.5 mg once daily for 14 days followed by 0.5 mg twice daily for 7 days
45463444|NCT01190683|Other|lactose granules and tablets|one sachet every week for eight weeks followed by two sachets every month along with two lactose tablets daily
45679596|NCT05420740|Device|Aerobika OPEP|Subjects given Aerobika OEP to assess changes in small airway disease parameter , CAT Score , 6 minute walking test and exacerbation
45679597|NCT05416333|Drug|azelaic acid|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months
46011787|NCT04533932|Diagnostic Test|Elastography|Endosonographic shear wave elastography
46011788|NCT02219828|Drug|Anakinra|2mg/Kg daily sc up to 100mgday as maximum dose
45679598|NCT05416333|Other|usual medication for CCCA|Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months
45679599|NCT05409391|Device|Insulin Titration System|A noval insulin titration system, which is based on deep learning
46011789|NCT02219828|Drug|Placebo|Placebo
46011790|NCT04533867|Procedure|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy, also called a vertical sleeve gastrectomy, is a surgical weight-loss procedure. This procedure is typically performed laparoscopically, which involves inserting small instruments through multiple small incisions in the upper abdomen. During sleeve gastrectomy, about 80 percent of the stomach is removed, leaving a tube-shaped stomach about the size and shape
46011791|NCT04533867|Drug|Palonosetron 1mcg/kg|Injectable Palonosetron 1 mcg/kg diluted up to 5 mL with normal saline solution and injected intravenously at the end of the bariatric surgery.
46011792|NCT04533867|Drug|Ondansetron 1 mg/kg, max dose 8 mg|Injectable ondansetron 0.1 mg/kg, maximum of 8 mg was injected intravenously at the end of the bariatric surgery.
46011793|NCT01196026|Biological|Fluarix™|One or two intramuscular injections
46011794|NCT01196026|Biological|Havrix™ Junior|Two intramuscular injections
46011795|NCT02216708|Other|Rapid dehydration|
46011796|NCT02216708|Other|Slow rehydration|
46011797|NCT02219867|Drug|Ketamine|Drug (including placebo)
46011798|NCT04533906|Device|Coldamaris lozenges|sucking carageenan containing lozenge
46011799|NCT02219906|Dietary Supplement|Resveratrol|1000mg tid
46011800|NCT02219906|Dietary Supplement|Placebo|1000mg tid placebo
46098261|NCT00694044|Drug|Placebo|Placebo for 21 days
46098262|NCT02722811|Drug|Etanercept|etanercept of 50 mg/w, subcutaneous injection; treatment: 8 weeks
46098263|NCT02722811|Other|Health education, exercise and diet guidance|Health education, exercise and diet guidance in patient; treatment: 8 weeks
46098264|NCT04136886|Drug|Cisplatin|cisplatin is to give from the first Day of radiation therapy D1,D22 Q3W for 2 cycles Radiation: IMRT IMRT is to give 60Gy in 27 fraction
46011801|NCT04533893|Other|Medical simulator (3B Scientific Lilly Pro) and Platform combining simulator sensor data with OSCE scores|Hands-on training app combining OSCE scoring criteria with sensor data retrieved from the simulator's sensors was used for hands-on performance evaluation.
46098265|NCT04136886|Radiation|IMRT|Radiation: IMRT IMRT is to give 60Gy in 27 fraction
46098266|NCT02718209|Device|Mid-Infrared Spectroscopy with ATR|
46011802|NCT02335749|Device|The ZELTIQ System|The CoolSculpting System with a Small Area Applicator will be used to deliver treatments.
46098267|NCT00690144|Device|High-fidelity high-fidelity mannequin simulator (SimMan, Laerdal, Stavanger, Norway).|Critical care training using high-fidelity simulation. The case scenarios were simulated by a high-fidelity mannequin simulator (SimMan, Laerdal, Stavanger, Norway).
46098268|NCT02717975|Procedure|Use of catheter valve before 'trial removal of catheter'|The investigators are comparing two groups of patients (Group A) Trial removal of urinary catheter in patients with urinary retention after applying catheter valve and closing it 3-4 hours before catheter removal.
46098269|NCT02717975|Procedure|Trial removal of catheter in patients with urinary retention|The investigators are comparing two groups of patients (Group B) Trial removal of urinary catheter in patients with urinary retention without using catheter valve - 'Traditional method'
46011803|NCT02219945|Other|5 min exhaled breath sampling with soft nose clamp|study participants are requested to quietly sit and allow exhaled breath to be sampled through mouth piece breathing with nose clamp during 5 min while electronic data are collected in the device and later downloaded on a laptop pc
46011804|NCT01620918|Procedure|normal healing abutment|Patient receives the normal, uncoated healing abutment on 1 of his (minimal 2) dental implants.
46098270|NCT04136964|Other|Neck COMI|Patients will be asked to fill a questionnaire booklet consisting of five patient-reported outcome measures twice within 14 days.
46011805|NCT01620918|Procedure|nano-structured healing abutment|Patient receives the nano-structured healing abutment on 1 of his (minimal 2) dental implants.
46011806|NCT02214836|Device|Verasonics Data Acquisition System (VDAS)|Subjects will be imaged the Verasonics Data Acquisition System (VDAS) using conventional clinical outputs within FDA limits. The image processing has been modified. Stone location and size will be determined and compared to clinical determination of stone location and size.
46011807|NCT04533516|Other|Manual therapy technics|Manual therapy technics
46098271|NCT04103645|Drug|Vactosertib|This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
46098272|NCT02625870|Drug|Omega-3-Acid Ethyl Esters 90 Soft Capsules|Omega-3-Acid Ethyl Esters 90 Soft Capsules will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
46098273|NCT02625870|Drug|Corn Oil|Corn Oil will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
46098274|NCT02718053|Other|L-stiff|spasticity measurement with Lokomat
46098275|NCT02718053|Other|Ashworth|spasticity measurement with Ashworth scale
46098276|NCT05298852|Diagnostic Test|High resolution computed tomography of the chest|All participants were subjected to High resolution computed tomography of the chest.
46098277|NCT00534313|Drug|Abatacept|Solution, intravenous, monthly, short-term = 24 weeks (6 months)
46011808|NCT04533516|Other|Inspiratory Muscle Training|Inspiratory Muscle Training
46098278|NCT00534313|Drug|Placebo|Solution, intravenous, placebo (double dummy), monthly, short-term = 24 weeks (6 months)
46098279|NCT00694512|Dietary Supplement|Low fat diet|20% fat diet
46011809|NCT04533243|Drug|2.5ug/h transdermal fentanyl|2.5ug/h transdermal fentanyl administers for opioid-naive patients with moderate cancer pain very 3 days
45463445|NCT03949439|Procedure|Elective Cardiac Surgery|Surgical interventions (coronary artery bypass [CAB], valve replacement or valve repair).
45463446|NCT01293409|Other|Transcranial Brain-Targeted Bright Light Treatment|Transcranial Brain-Targeted Bright Light Treatment via Ear Canals
45463447|NCT03943199|Diagnostic Test|Visual Analogue Scale for pain|Will be assessed at 0´, 30´, 60´, 90 minutes and 18 hours after the application of the analgesic.
46098280|NCT00694512|Dietary Supplement|High fat diet|40% fat diet
46098281|NCT00694512|Dietary Supplement|MCT diet|Medium chain triglyceride diet
45463448|NCT01190761|Drug|Galantamine 4 mg Tablet, single dose|A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fed conditions
45463449|NCT01190761|Drug|Reminyl 4 mg Tablet, single dose|B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fed conditions
45463450|NCT01209455|Drug|Chlorphenamine and Ranitidine|We intend to use chlorphenamine (H1 antagonist) and ranitidine (H2 antagonist).Assuming NAC causes vasodilatation with an increase in forearm blood flow, we propose to administer 5 mcg/min to ensure maximal H1 blockade. In the presence of increased forearm blood flow, we propose to administer 37.5 mcg/min.
45463451|NCT01209455|Drug|Paracetamol|Therapeutic IV administration of 1g paracetamol results in a plasma concentration of ~12 mg/l. To achieve a desired concentration of ~25 mg/l, in the presence of a forearm blood blow of 50 ml/min, we would intend to administer an IA infusion of 1.25 mg/min. To account for the presence of increased forearm blood flow, we propose to administer 4 mg/min IA paracetamol.
45463452|NCT01209455|Drug|Paracetamol|To achieve a local paracetamol concentration of ~200 mg/l, a concentration comparable to potentially hepatotoxic concentrations following paracetamol overdose, we propose to administer 30 mg/min paracetamol.
45463453|NCT01295359|Other|Ground Walking Program|The patients will walk on a corridor, for 40min, once a day. The speed will be controlled through a metronome, that will be programed to a frequency of steps/min determinated as 80% of the mean frequency of steps performed in six minutes walk test of that day. The 40min will be divided in 3min of walk and 2min of rest, totalizing 24min of exercise and 16min of rest. Furthermore, these patients, in sitting position, will receive orientation to do calm and slow inspirations and expirations, associated with pursed lips expiration. They will try to maintain its Respiratory Rate in 6bpm, during four minutes.
45463454|NCT01328483|Procedure|Intrapartum Oropharyngeal Suctioning|After delivery of the head, the infant's mouth and nose were suctioned. Nose was suctioned after the mouth and throat. Oropharyngeal suctioning was performed using a 10 french suction catheter with suction pressure of 100mm Hg or De Lee's suction trap in event of electricity failure or non availability of suction machine
46011810|NCT04533243|Drug|Oral immediate-released morphine|5mg immediate-released morphine every 4 hours, double dose before sleep.
46011811|NCT04533620|Radiation|Standardized CIRT|CIRT with a dose of 63 GyE/21 fx
46011812|NCT04533620|Radiation|Individualized CIRT|A predictive model will be used to predict the chance of developing mucosal necrosis after salvage carbon-ion radiotherapy, and individualized dose prescription will be given. A dose of 60 GyE/20 fx, 63 GyE/21 fx and 66 GyE/22 fx will be given to patients with high, moderate and low risk of developing mucosal necrosis, respectively.
46011813|NCT02210585|Other|Rehabilitation|"12 weeks : 5 sessions per week (1 supervised session at home every month)~92 weeks : spontaneous training (supervised by phone every month)"
46011814|NCT04533321|Drug|Afatinib|Afatinib is approved therapy for SCC of the lung after progression with standard of care chemotherapy.
46011815|NCT04533191|Procedure|Bilateral implantation of light adjustable intraocular lens and subsequent adjustment to binocular custom vision|Subjects will receive bilateral implantation of a commercially available Light Adjustable Intraocular lens at the time of cataract surgery. Subsequently, they will undergo light adjustment of the lens to target binocular custom vision.
46011816|NCT01004367|Other|Experimental|Environmental- and individual based components carried out in the school.
46011817|NCT02211599|Other|15% protein|Meal to provide 15%en from protein.
46011818|NCT02211599|Other|30% protein|Meal to provide 30%en from protein.
46098282|NCT02651831|Other|Focus groups and individual interviews|Focus groups conducted to explore general experiences, insights and concerns of those receiving ICM therapies. Individual semi-structured interviews to provide in-depth data on the themes identified in the focus groups.
46098283|NCT02651831|Other|Questionnaire|Health related quality of life questionnaire (FACT-ICM) to be completed by patients
45463455|NCT03426345|Drug|Placebo|Placebo injected subcutaneously twice daily.
45463456|NCT03426345|Drug|Relamorelin|Relamorelin 10 μg injected twice daily for 12 weeks.
45463457|NCT01194115|Drug|cephalexin & metronidazole|cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
45463458|NCT01194115|Drug|placebo|placebo representing standard of care
45463459|NCT01194193|Drug|AZD8055|Oral tablet, single dose on Day 1, followed by a 48 hour - 7 day washout and then either twice daily alternate days dosing from multiple dose day 1 onwards or twice daily dosing for 21 days from multiple dose day 1 onwards followed by 7 days no treatment. Cycles of 28 days.
45463460|NCT01207661|Biological|Mesenchymal Injection|Intra Articular Injection of Mesenchymal cells to the knee joint
45463461|NCT03847597|Procedure|Explantation of the femoro-popliteal arterial segment from the amputed limb|Explantation of the femoro-popliteal arterial segment from the amputed limb
45679600|NCT05401110|Drug|Osimertinib|Osimertinib given by mouth daily at 40mg or 80mg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.
45679601|NCT05401110|Drug|Carotuximab|Carotuximab is administered intravenously weekly for the first 4 weeks, then every 2 weeks at 10mg/kg or 15 mg/kg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.
46098284|NCT00694200|Drug|Vinorelbine|Vinorelbine per os 50 mg 3 times a week
45463462|NCT01209533|Drug|Iloprost|Inhaled iloprost 2.5 or 5 micrograms four times daily for 14 days
46098285|NCT00694200|Drug|Bevacizumab|Bevacizumab 10 mg/kg IV every 14 days
46098286|NCT02722733|Drug|G-CSF (filgrastim)|
46098287|NCT02722733|Drug|Cytosine arabinoside with G-CSF (filgrastim)|
46011819|NCT02211599|Other|Sweetened beverage|Beverage sweetened with either sugar (sucrose) or sucralose (non-nutritive sweetener).
46011820|NCT00734019|Device|P.F.C. Sigma Knee|Orthopaedic implant for primary total knee replacement with a cobalt-chrome tibial tray and a moderately cross-linked polyethylene tibial insert
45679602|NCT05395819|Procedure|Reverse Total Shoulder Arthroplasty (RTSA)|"Patient will undergo a RTSA as per standard technique. It uses a stemmed metal humeral component attached to the glenoid and the shallow glenoid component attached to the humerus. Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric (high side) anterior reaming to within < 10 degrees of neutral glenoid version. Standard instruments including a spherical burr and power reamers will be used to achieve this."
46011821|NCT01195948|Drug|B27PD|
46098288|NCT02722421|Drug|Levonorgestrel|Increased dose levonorgestrel implant plus efavirenz-based antiretroviral therapy.
46098289|NCT02722421|Drug|Efavirenz|Participants will receive efavirenz-based ART as part of standard of care
46098290|NCT02617290|Drug|Ticagrelor|Ticagrelor Loading dose of 180mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 90mg bid.
46098291|NCT02617290|Drug|Clopidogrel|Clopidogrel Loading dose of 300 or 600mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 75mg per day.
46098292|NCT02717819|Dietary Supplement|Protein|Daily intake of supplement
46011822|NCT01195948|Drug|Placebo|Capsule with no active ingredients to mimic B27PD
46098293|NCT02717819|Dietary Supplement|Placebo|Daily intake of supplement
46011823|NCT02213354|Drug|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
46011824|NCT02213354|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent inactivated split influenza virus vaccine made with HA antigen derived from the influenza A/Shanghai/2/2013 virus. Monovalent influenza A/H7N9 virus vaccine. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
46011825|NCT04533048|Combination Product|MW33 injection|a recombinant fully human antibody to coronavirus
46011826|NCT04533048|Combination Product|MW33 injection placebo|Placebo
46011827|NCT01195831|Drug|Xamiol® gel|Once daily application
46011828|NCT01195831|Drug|Calcipotriol scalp solution|Twice daily application
46011829|NCT02210273|Device|Solace Bladder Control (Vesair) Balloon|Subjects may undergo treatment every 12 months until study completion.
46011830|NCT02210273|Device|Solace Sham Treatment|Sham treatment that resembles treatment with the Solace Bladder Control (Vesair) Balloon
46011831|NCT01195675|Drug|BI 10773 (low)|single oral dose
46011832|NCT01195675|Drug|Moxifloxacin|single oral dose
46011833|NCT01195675|Drug|BI 10773 Placebo|2 times single dose
46011834|NCT01195675|Drug|BI 10773 (high)|single oral dose
46011835|NCT04532931|Other|Standard of care (Paracetamol)|SOC - 2 tablets (1000 mg) to be taken 6-hourly as needed
46011836|NCT04532931|Drug|Artesunate-amodiaquine|SOC plus artesunate-amodiaquine (ASAQ) - 2 tablets (200/540 mg artesunate/amodiaquine) daily for 3 days
46098294|NCT02717819|Other|Resistance training|Resistance training (offered daily while hospitalized, and encouragement of 4 x/week as self-training after discharge)
46098295|NCT02717819|Dietary Supplement|Vitamin D|Aiming at a dose of 20 ug/day. 20 ug/day will be handed out to study participants who do not get vitamin D supplements from the hospital while admitted and to those who are not already taking vitamin D supplements themselfes e.g. as part of a combination tablet.
46098296|NCT00994201|Other|DCE-MRI, DW-MRI and MRS|"Patients will undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), Diffusion-weighted magnetic resonance imaging (DW-MRI), Magnetic resonance spectroscopy (MRS) prior to the initiation of chemoradiation and before their second cycle of chemotherapy.~Healthy volunteers will undergo DCE-MRI, DW-MRI and MRS."
46098297|NCT04134858|Other|The nurse-led health coaching program|The intervention was based on the customized nurse-led health-coaching program. The program consisted of an individual health-coaching nurse, health-coaching sessions and a written action plan according to each participant´s individual needs.
46011837|NCT04532931|Drug|Pyronaridine-artesunate|SOC plus pyronaridine-artesunate (PA) Weight 45 to <65 kg: 3 tablets (540/180 mg pyronaridine/artesunate) daily for 3 days Weight ≥65 kg: 4 tablets (720/240 mg pyronaridine/artesunate) daily for 3 days
46098298|NCT02007655|Drug|Eliquis|
45463463|NCT01190917|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT social skills curriculum is manualized and anchored in CBT strategies, such as problem identification, affective education, performance feedback, and weekly homework activities to facilitate generalization. The curriculum is a compilation of lessons targeting key social deficits in children with ASD, such as nonverbal communication, emotion recognition, and theory of mind. Structured teaching includes defining skills, breaking them down into simple, concrete steps, modeling the skill through role-play, and introducing a game or activity to practice the target skill. The approach to the parent group will be psychoeducational with a focus on reviewing target skills, rationale for teaching target skills, homework, progress or obstacles, and identifying strategies to promote generalization. Parent information handouts will be provided.
45463464|NCT01190917|Behavioral|Play Therapy|The social play group is manualized, led by a trained clinician and support staff, follows a specific routine, and contains a parent group component. Group leaders will follow participants' interests and suggestions for games. Group leaders utilize strategies such as reflective functioning statements on the child's behaviors to build emotion-focused play skills. The therapeutic setting incorporates play designed to encourage emotion-focused play including make-believe (dolls, houses), sensory (e.g. play-doh), and cooperative play (e.g. board games) toys. The approach to the parent group will be supportive rather than psychoeducational. Parents will set the agenda for discussion, facilitated by the group leader.
46098299|NCT02717741|Drug|tafetinib|
45463465|NCT05626283|Drug|transforaminal epidural injection.|transforaminal epidural steroid injection.
45463466|NCT05626283|Other|micro RNA-155 serum level|Estimation of miR-155 expression level:
45463467|NCT03847363|Procedure|epidural anesthesia|epidural anesthesia
46011838|NCT04532931|Drug|Favipiravir plus Nitazoxanide|SOC plus favipiravir plus nitazoxanide (FPV-NTZ) Favipiravir: 1600 mg 12-hourly for 1 day then 600 mg 12-hourly for 6 days Nitazoxanide: 2 tablets (1000 mg) 12-hourly for 7 days
46098300|NCT02611960|Biological|Pembrolizumab|IV infusion
46098301|NCT02611960|Drug|Capecitabine|oral tablet
46098302|NCT02611960|Drug|Gemcitabine|IV infusion
46098303|NCT02611960|Drug|Docetaxel|IV infusion
46098304|NCT00995605|Drug|AMAP102|AMAP102 or Placebo
46098305|NCT02717585|Device|Continuous Positive Airway Pressure Therapy (CPAP)|Continuous Positive Airway Pressure Therapy (CPAP) consists of a mask, fitted to the patient's face and hooked to a machine that generates positive pressure at the end of expiration to abolish obstructive apneic episodes during sleep.
45463468|NCT03847363|Procedure|nerve block|paravertebral or serratus anterior plane block
46011839|NCT04532931|Drug|Sofosbuvir/daclatasvir|"SOC plus sofosbuvir/daclatasvir (SOF/DCV)~1 tablet (400 mg/60 mg sofosbuvir/daclatasvir) daily for 7 days"
46011840|NCT02210975|Device|LES-Stimulation Device|
46011841|NCT01195636|Drug|XPF-002|Twice daily application of XPF-002 ointment which contains 8% of the XPF-002 active ingredient
46011842|NCT01195636|Drug|Placebo|Twice daily application of Placebo ointment
46011843|NCT04533009|Procedure|spine surgery|Tramadol-paracetamol 325mg/37,5mg two tablets twice daily
46011844|NCT04533113|Procedure|Carious tissue selective removal|Carious tissue selective removal in deep carious lesions in posterior teeth, using one of three materials as a liner under the final composite restoration
46098306|NCT05298462|Diagnostic Test|Livzon Rapid Antibody Test for COVID-19|Point-of-care Rapid Antibody Test for COVID-19
46011845|NCT01195363|Drug|quetiapine SR|quetiapine SR, dose range 200-600mg, each night QHS for 6mos
46011846|NCT01195363|Drug|quetiapine sr placebo|quetiapine sr placebo, dose range 200-600mg, each night QHS for 6mos
46098307|NCT00995683|Drug|half molar sodium lactate|intravenous infusion of 0.5 ml/kg during 48 hours
46098308|NCT00995683|Drug|isotonic sodium chloride|intravenous infusion of 0.5 ml/kg during 48 hours
46098309|NCT02717429|Behavioral|Mindfulness Meditation|The mindfulness meditation-training program is closely modeled after the 8-week mindfulness based stress reduction protocol developed by Dr. Jon Kabat-Zinn. The briefer four weeks of MMT involve the practice of concentrative attention, where different objects are used as the focus of meditative practices. For example, for the first two weeks, the investigators use breath as an anchor for attention. With repeated practices, the objects of sensations, emotions, and thought processes are introduced.
46011847|NCT04317625|Diagnostic Test|mpMRI scanning|The patients whose PSA levels are between 2.5 and 4.0ng/ml will be recommended to mpMRI scanning at first but not biopsy or active surveillance.
45463469|NCT01209611|Procedure|Autologous bone marrow mononuclear cells|Autologous bone marrow-derived mononuclear cells, after isolated by density gradient centrifugation from bone marrow aspiration and resuspended in saline, will be transplanted subcutaneously to expanded skin. The number of infused cells will be 1x10e6/cm2.
45463470|NCT01209611|Procedure|Placebo|Patients will have mimical bone marrow aspiration under local anesthesia following with saline injection to expanded skin.
46098310|NCT02717429|Behavioral|Computerized Cognitive Training|The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning of MS patients, will comprise of a cognitive training group, which will provide an attentional-training based approach. In this group, the focus will be to provide the individuals with cognitive training tasks to complete that have been shown to improve attentional ability. The investigators will also discuss relevant MS-related material on cognitive deficits during these courses.
46098311|NCT02621814|Dietary Supplement|Low glycation formula feeding|Formula feeding on demand for 3 months
46098312|NCT02621814|Dietary Supplement|Commercially common formula feeding|Formula feeding on demand for 3 months
46098313|NCT00998959|Behavioral|Mindfulness Based Stress Reduction and Psychoeducation|Participants will receive six individual weekly 50-minute sessions of mindfulness based stress reduction (MBSR) as well as problem solving therapy (PST. PST is a type of therapy that focuses on psychosocial problems and using your skills and resources to function better. MBSR uses exercises in mindfulness to reduce stress.
45463471|NCT03942575|Device|Negative pressure wound therapy|Wound dressing with negative pressure on closed incisions
45463472|NCT03714087|Device|T1 before aligner|The UDEA2 finishing protocol include: Training of the clinicians, evaluation of finishing records, checklist according OGS items, using of aligner with set-up)
45463473|NCT03714087|Other|T2 after the aligner|The UDEA2 finishing protocol include: Training of the clinicians, evaluation of finishing records, checklist according OGS items, using of aligner with set-up)
45463474|NCT03714087|Other|Historic control group|
45463475|NCT03850327|Device|BIOMONITOR III|Patients with ICM indication receive a third-generation implantable cardiac monitor
45679603|NCT05395819|Procedure|Total Shoulder Arthroplasty (TSA)|Patients will undergo standard glenoid preparation and implantation of a TSA. It uses a stemmed metal humeral component to replace the arthritic head of humerus and a shallow polyethylene glenoid component to replace the arthritic glenoid surface. The degree of anterior- reaming will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version.
46098314|NCT00998959|Behavioral|Psychoeducation|Participants will receive six individual weekly 50-minute sessions of psychoeducation. Psychoeducation consists of education on depression, its symptoms, its treatment, and recovery.
46011848|NCT04315870|Other|pregnant women with laboratory-confirmed 2019-n-CoV|Clinical records and compiled data of all consecutive hospitalized and outpatient pregnant women with laboratory-confirmed 2019-n-CoV were included in a merged database
46011849|NCT04533269|Other|Arnica montana, Ledum palustre|Homeopathic
46011850|NCT01195090|Drug|Sitagliptin|add sitagliptin100mg/d to pre-study OADs
46098315|NCT00730366|Drug|sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine given as intermittent therapy, at the dosage of 1500/75 mg per administration (3 tablets), Twice during pregnancy
46098316|NCT00730366|Drug|Chloroquine|Chloroquine tablets 100 mg. First administration of 1500 mg given over three days, followed by weekly doses of 300 mg/week
46098317|NCT02722343|Drug|Tenofovir intravaginal ring|The participant will wear the intravaginal ring consecutively for 14 days and nights. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)
45463476|NCT01207739|Drug|Doxycycline|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: oral Doxycycline 100 mg combined with a placebo b.i.d. for 12 weeks
45463477|NCT01207739|Drug|Clarithromycin and hydroxychloroquine|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: clarithromycin 500 mg combined with hydroxychloroquine 200 mg b.i.d. for 12 weeks
45463478|NCT01207739|Drug|Placebo|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: 12 weeks' course of double placebo b.i.d.
45463479|NCT01192009|Dietary Supplement|Leucine|7.2 g of leucine during 2 weeks
45679604|NCT05395364|Behavioral|Intervention program BeE-school|The intervention program will be co-developed and directed to school professionals. It will be based on the promotion of health literacy and lifestyles.
45679605|NCT05394493|Drug|avelumab|as provided in real world setting
45679606|NCT05394493|Drug|axitinib|as provided in real world settings
45679607|NCT05394116|Drug|Garetosmab|Garetosmab is supplied as a liquid drug product and will be administered IV.
45679608|NCT05394116|Drug|Placebo|Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.
46011851|NCT01195090|Drug|pioglitazone|add pioglitazone 30mg/d to pre-study OADs
46098318|NCT02722343|Drug|Truvada|The participant will take the tablet for 14 days. taking one tablet each morning. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)
46011852|NCT04533282|Diagnostic Test|Blood samples.|Peripheral blood samples (TEMPUS(TM) whole blood samples, EDTA plasma and heparin plasma, total volume 40ml) taken during (1) initial hospitalisation and (2) three month follow-up visit after hospital stay (follow-up samples are not taken from coronary CT healthy control patients).
46098319|NCT00694590|Drug|plerixafor|"Drug Course 1: plerixafor (20mg/mL). Dose escalation starting with 80 mcg/kg then 160, 240, 320, 420, and 540 mcg/kg, or to de-escalate to 40mcg/kg. Dosing 3 times/week for 3 weeks beginning at start of second week. Rituximab is also administered 3 times per week for 4 weeks using a fixed dose of 100 mg on Day 1 and a dose of 375 mg/m2 for all subsequent doses.~Drug Course 2: plerixafor (20 mg/m) same dose as course 1. Dosing 3 times/week for 4 weeks. Rituximab is also administered 3 times per week for 4 weeks using a dose of 375 mg/m2 for all doses."
46098320|NCT00730444|Drug|Iobenguane I 123 Injection|1-10 mCi administered intravenously
46098321|NCT00994357|Device|Real-time CGM|See previous description.
46098322|NCT00994357|Other|Standard care|See text.
46098323|NCT02717117|Other|Soup meal|Soup meal as above
46098324|NCT04018534|Behavioral|Standard Verbal/Written Education|This patients as control group received a standard printed educational material assisted with verbal information in accordance with British Orthodontics Society (BOS) educational goals.
45463480|NCT01192009|Dietary Supplement|Placebo|7.2 g of alanine during 2 weeks
45463481|NCT05626205|Device|PARO robot|PARO is an advanced interactive robot. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties. PARO has five kinds of sensors: tactile, light, audition, temperature, and posture sensors, with which it can perceive people and its environment. PARO can learn to behave in a way that the user prefers, and to respond to its new name.
45463482|NCT03426267|Drug|SDN-037|twice daily
45463483|NCT03426267|Drug|Placebo|twice daily
45463484|NCT05626127|Other|No interventions|As this is a observational study, there are no interventions.
45463485|NCT01194505|Other|Sciatic, femoral, obturator nerve blocks|Ultrasound guided blocks with ropivacaine
45463486|NCT01194505|Other|Sciatic nerve block, posterior lumbar plexus block|Ultrasound and neurostimulator nerve blocks with ropivacaine
45463487|NCT03412929|Device|Honey Impregnated Dressing|The investigational product being examined contains 100% Manuka honey and is ideal for difficult to dress wounds. The dressing provides a moist wound environment to help promote autolytic debridement. The dressing is ideal for partial or full thickness wounds with moderate-to-heavy drainage.
45463488|NCT03941951|Behavioral|Non-impositive Program for Optimizing the Use of Antimicrobials|Quasi-experimental intervention through the development of a Program for Optimizing the Use of Antimicrobials in the participating hospitals. The intervention will consist of the development of a consensus guide on the use of new antibiotics, its dissemination in Andalusian hospitals and an audit on the prescription of new antibiotics.
45463489|NCT01190995|Drug|24% Sucrose|The enrolled neonates will be administered either a sterile solution of 24 % sucrose or double distilled water orally for a period of 7 days from enrollment. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
46011853|NCT04533282|Diagnostic Test|Collection of right atrial appendage tissue sample.|Collection of the clinically insignificant small piece of heart's right atrial appendage tissue during either standard cannulation of the right atrium for the installation of the heart-lung machine in the beginning of the operation or additionally for routine surgical protocol.
46098325|NCT04018534|Behavioral|Video Assisted Education|The video training consisted of two separate sessions, each one lasting 5 minutes, one about the treatment materials and the other about the oral hygiene successively and in compliance with the British Orthodontics Society (BOS) educational obligations. All of the candidates were allowed to rewind and watch the video presentation until they reach all of the educational goals. The accomplishment of the educational goals was documented through a written examination form filled in by the candidates themselves. All of the candidates have rated fullscore in the written examinations on both topics.
46011854|NCT04533282|Diagnostic Test|Health Survey, Clinical symptom scaling|Patients in the study CABG and AVR cohorts are invited to both pre- and postoperative (3-month time-point), and in the case of PCI cohort only to postoperative, appointments led by experienced clinical cardiologists. The appointments will include clinical anamnesis, status and assessment of morbidity level with combined use of Canadian Cardiovascular Society grading of Angina Pectoris (CCS), New York Heart Association Classification for Heart Failure (NYHA) classification systems and Short Form 36 (SF36) Health Survey. The CT imaging control cohort is not invited to these appointments.
46098326|NCT04018534|Behavioral|Hands-on Training|The hands-on training consisting of two separate sessions was performed by one of the authors (E.A). The first is about the treatment materials and the second one is about the oral hygiene successively. They are in accordance with the British Orthodontics Society (BOS) educational obligations. All of the patients were allowed to ask questions freely until they reach all of the educational goals. The accomplishments of the educational goals were documented through a written examination form filled in by the candidates themselves. All of the candidates have rated fullscore in the written examinations on both topics. The time requirements for all three different educational interventions were recorded separately.
46098327|NCT02722187|Procedure|subinguinal microscopic varicocelectomy|
45463490|NCT01190995|Drug|Placebo|The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
45463491|NCT01293487|Biological|RN564|Intravenous, single dose with experimental dose
45463492|NCT03847207|Drug|HTL0030310|Solution for Subcutaneous injection
45463493|NCT03847207|Drug|Pasireotide|Pasireotide 600 μg for subcutaneous injection
45463494|NCT03847207|Drug|Placebo|Matching placebo Solution
45463495|NCT03942107|Procedure|Group 1: single-visit RCT|both root canal treatment and post and core restoration of the coronal part of the tooth is completed in single visit prior to postoperative pain evaluation at 24, 48 and 72-h and 7-day follow-up time
45463496|NCT03942107|Procedure|Group 2: two-visit RCT|after root canal treatment is completed, postoperative pain evaluation will be conducted in this group at 24, 48 and 72-h and 7-day follow-up time. post-core application will be completed at the seventh day after postoperative pain evaluation.
45463497|NCT01192087|Drug|Cetuximab|cetuximab initial dose (7 days prior to RT treatment start): 400 mg/m² body surface cetuximab weekly doses (from RT treatment start throughout radiation treatment): 250 mg/m² body surface
46011855|NCT04533282|Diagnostic Test|Transthoracic echocardiography (TTE)|In order to acquire comprehensive insight into the patients' functional heart status, all appointments are supplemented with echocardiographic evaluation for both functional as well as structural parameters. Detailed echocardiographic analysis criteria for the IHD-EPITRAN study are prespecified in the research plan.
46011856|NCT02211287|Other|'Comfort Care at the End of Life for Persons with Dementia'|A guide for caregivers to provide information on the trajectory of the disease, clinical issues, decision-making processes, and symptom management. The guide is written in a Q&A form and can help answer frequent family questions.
46011857|NCT02211287|Other|Project Nurse - ACP Facilitator|A nurse will receive training in the 'Respecting Choices Facilitator Curriculum' - an online program consisting of a series of six critical thinking modules designed for healthcare professionals who want to enhance their ACP facilitation skills. Local training resources in Northern Ireland will supplement.
46011858|NCT04524546|Diagnostic Test|Sterno-mental displacement test|While the patient is in sitting position, (SMD neutral) will be is measured using tape as the distance between upper borders of the manubrium sterni to the mentum with the head in a neutral position. The (SMD extension) will be then measured in the same way with the head extended on the neck. The difference between SMD extension and SMD neutral will be then calculated as sternomental displacement (SMDD).
46011859|NCT02213081|Drug|Ulipristal|Patients will take 15mg every other day, or every 4 days per week.
46011860|NCT02216760|Device|Ripple Mapping guided VT ablation|RM will be used to guide identification of conduction channels and hence substrate guided ablation
46011861|NCT02216760|Device|Conventional VT ablation|Substrate guided ablation using conventional methods (pace-mapping, LAVA/late potential abolition, scar border zone ablation)
46011862|NCT02213627|Drug|Corifollitropin alfa|
46098328|NCT02722187|Procedure|laparoscopic varicocelectomy|
45463498|NCT03942029|Drug|LY3154207 Capsule|Administered orally as capsule
45463499|NCT03942029|Drug|LY3154207 Tablet|Administered orally as tablet
45463500|NCT03942029|Drug|Placebo|Administered orally as tablet
45463501|NCT03942029|Drug|Fluconazole Tablet|Administered orally as tablet
45463502|NCT03846037|Other|Proprioceptive exercise on the vibratory platform|Unipodal support over the non-dominant lower limb with the contralateral limb in a knee flexion near 90ºon the vibratory platform
45463503|NCT03846037|Other|Proprioceptive exercise on the ground (stable surface)|Unipodal support over the non-dominant lower limb with the contralateral limb in a knee flexion near 90ºon the ground
45463504|NCT03740945|Drug|Placebo|Daily administration of one placebo vaginal ovule at bedtime
45463505|NCT03740945|Drug|Prasterone (DHEA)|Daily administration of one prasterone vaginal ovule at bedtime
45463506|NCT01192165|Drug|Trametinib (GSK1120212)|Investigational small molecule targeted therapy (MEK1/2 inhibitor)
45463507|NCT01192165|Drug|Docetaxel|Chemotherapy
45463508|NCT01192165|Drug|Erlotinib|Small molecule targeted therapy (EGFR inhibitor)
45463509|NCT01192165|Drug|Pemetrexed|Chemotherapy
45463510|NCT01192165|Drug|Carboplatin|Chemotherapy
45463511|NCT01192165|Drug|nab-Paclitaxel|Chemotherapy
45463512|NCT01192165|Drug|Cisplatin|Chemotherapy
45463513|NCT01192243|Drug|Gefitinib|250mg qd po d3-16
45463514|NCT01192243|Drug|Pemetrexed|500mg/m2 venous infusion,D1,q3w
45463515|NCT01192243|Drug|Cisplatin or carboplatin|Cisplatin:75mg/m2, venous infusion,D1,q3w or Carboplatin: AUC 5, venous infusion, D1,q3w
46011863|NCT02213627|Drug|Recombinant FSH|
46011864|NCT02213627|Drug|HP-hMG|
45463516|NCT01114295|Device|Capsule Endoscopy|Prior to the test, patients will be on a clear liquid diet for 24 hours and will have undergone an overnight fast. If a clear liquid diet is not possible, some patients may undergo a bowel preparation the day before the procedure. On the morning of the test, patients will swallow a video capsule with water. Clear liquids will be permitted after 2 hours, and a light meal permitted 4 hours after swallowing the capsule, if appropriate. No medications will be allowed 2 hours before the procedure and drugs that can delay gastric emptying will be avoided until the study is complete. At 8 hours after ingestion, the sensor array and recorder/battery belt pack will be disconnected and the data will be downloaded onto a computer equipped with software for image viewing. Images are sent through 8 skin electrodes to the recorder, stored and viewed on a RAPID workstation. At the end of the recording, the video is transferred to a computer for analysis.
45463517|NCT01114295|Radiation|CT Enterography|CT enterography at the Brigham and Women's hospital is performed by using intravenous iodinated contrast material (Ultravist 300) and a neutral oral-enteric contrast material containing methylcellulose (Volumen). During scanning, 150 mL of nonionic intravenous contrast medium will be administered at a rate of 3mL/sec and the imaging conducted 40 and 70 seconds after the administration of the intravenous contrast medium. All imaging will be performed on a Dual-Energy multi-detector row CT scanner, Somatom Definition (Siemens Healthcare, Forcheim, Germany). Two independent X-ray tube/detector system will be used for image acquisition. One tube operates at 140 kV and the other at 80 kV . Slice collimation will be 0.6 mm and images reconstructed at 3 mm thickness with 3 mm reconstruction intervals. Coronal and sagittal images will be reconstructed at 3 mm thickness with 3 mm increments. Images will be reviewed by a radiologist experienced in the interpretation of CT enterography.
45679609|NCT05385471|Biological|Matrix M with R78C and/or RH5.1|50 µg of Matrix-M adjuvant with R78C and/or RH5.1 at different doses and timepoints
46011865|NCT02216799|Drug|Glargine Insulin|80% of the insulin doses administrated via sliding scale will be administered every night as insulin glargine
46011866|NCT02216799|Drug|Regular insulin|80% of the Regular insulin administrated via sliding scale will be will be added to TPN bag to run over 24 hours
46011867|NCT04532996|Behavioral|Trauma-focused psychodynamic psychotherapy|"This psychotherapy addresses disruptions in narrative coherence and affective dysregulation by exploring the psychological meanings of symptoms and their relation to traumatic events. The therapist works to identify intrapsychic conflicts, intense negative affects, and defense mechanisms related to the PTSD syndrome using a psychodynamic formulation that provides a framework for intervention. The transference provides a forum for patients to address feelings of mistrust, difficulties with authority, fears of abuse, angry and guilty feelings, and fantasies.~This treatment will be provided in-person or over teletherapy as the public health situation demands."
46011868|NCT02216877|Drug|Mablet 360 mg|
46011869|NCT02216877|Drug|Placebo|
46098329|NCT03903406|Drug|ixazomib in combination with lenalidomide and dexamethasone|Patients with RRMM who have received at least one prior therapy will receive Ixazomib in combination with lenalidomide and dexamethasone within the routine clinical practice in accordance with prescription. Duration of therapy - until disease progression or unacceptable toxicity.
46011870|NCT02214563|Dietary Supplement|Cholecalciferol|Made for this trial by Molecular Physiological Chemistry Laboratory, Inc.
46098330|NCT02717351|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation- SR16-07)
45463518|NCT01296451|Biological|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
45463519|NCT01296451|Biological|AdCh3NSmut|genetic vaccine against Hepatitis virus infection
45463520|NCT01296451|Biological|AdCh3NSmut1|genetic vaccine against Hepatitis virus infection
45463521|NCT01209845|Drug|ketamine|intravenous ketamine(0.2 mg/kg) over 1-2 minutes IV
45679610|NCT05384587|Drug|asciminib|Supplied in 40 mg tablets for oral use to be taken daily. Dose may be increased at 6 and 12 months based on molecular response with BCR-ABL1 Polymerase Chain Reaction testing.
45679611|NCT05383911|Behavioral|Shared Decision Making Intervention|We are currently developing a shared decision making intervention for AYAs with SCD to provide decision supports for disease-modifying therapies. As the intervention is currently in development, additional details will be provided once development and usability testing phases have been completed.
45679612|NCT05382208|Drug|Doxycycline|Doxycycline 100 mg orally twice a day.
45679613|NCT05382208|Drug|Placebo|Matching placebo orally twice a day.
45679614|NCT05381454|Drug|Mitoquinone/mitoquinol mesylate|Mitoquinone/mitoquinol mesylate
46011871|NCT02214563|Dietary Supplement|Olive oil|
46011872|NCT01194973|Drug|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
46011873|NCT02218619|Drug|Tauroursodeoxycholic Acid (TUDCA)|TUDCA at 1750 mg/day x 12 months
46011874|NCT02218619|Drug|Sugar Pill (placebo)|Placebo
46011875|NCT04524234|Diagnostic Test|Echocardiography|Echocardiography for assessment of cardiac function
46098331|NCT03888391|Device|Active TNS|
46098332|NCT02745184|Biological|Lung stem cells|Patients will receive 10^6 (1 million) /Kg/person cells of clinical grade lung stem cells (LSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
46098333|NCT00594204|Drug|varenicline tartrate (CP-526, 555-18)|1 mg twice a day for 12 weeks, starting with a 1-week titration period.
46098334|NCT00594204|Drug|Placebo|matching placebo 1 tablet twice a day for 12 weeks
46011876|NCT02218697|Biological|Influsplit™ Tetra (Fluarix™ Tetra)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
46011877|NCT02218697|Biological|Pneumovax™ 23|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
46011878|NCT02218697|Biological|Placebo (Saline)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
46011879|NCT02216916|Drug|HM781-36B|
46011880|NCT02279069|Device|4-roll canne|
45463522|NCT01211717|Dietary Supplement|Branched Chained Amino Acids|Two doses of the Branched Chained Amino Acid supplement will be taken. The first dose will be taken 35 minutes before the intended exercise, and the other dose will be taken right after completing the exercise. The amount of the Branched Chained Amino Acid supplement administered to the subjects in the experimental group will vary from one person to the other but a total dose of 1 gram of BCAA per kilogram of lean body mass will be used. This dose will be divided in half and administered at the two specified occasions. The ratio of isoleucine, leucine, and valine will be 1:2.5:1 respectively
45679615|NCT05377008|Behavioral|OPTIMAL-SSI|The purpose of the intervention feedback session will be twofold: 1) to provide the results of the previous assessment, and 2) to provide general psychoeducation on psychological and neurocognitive functioning and tailored cognitive and behavioral interventions based on the results in order to reduce the impact of psychological and neurocognitive deficits.
46011881|NCT02216747|Drug|prednisone 60 mg/meter square Body Surface Area|treatment with prednisone 60 mg /meter square Body Surface Area to compare to other arms
46011882|NCT02216747|Drug|prednisone 45 mg|treatment with 45 mg prednisone to compare with other arms
46011883|NCT02216747|Drug|prednisone 30 mg|treatment with 30 mg prednisone to compare with other arms.
45679616|NCT05372367|Drug|BI 907828|BI 907828
45679617|NCT05372367|Drug|Rifampicin|Rifampicin
46011884|NCT04521933|Other|Survey|"Each participant completes a questionnaire. In the questionnaire, he performs a subjective qualitative evaluation of Point-of-Care ultrasound records of the heart.~Each participant will complete a questionnaire in which they perform a subjective qualitative evaluation of ultrasonographic recordings of the heart."
46011885|NCT02216786|Drug|AZD2014|Oral tablet
45679618|NCT05372367|Drug|Itraconazole|Itraconazole
45679619|NCT05372354|Drug|CC-92480|Specified dose on specified days
46011886|NCT02216786|Drug|Everolimus|Oral tablet
46011887|NCT02216786|Drug|Fulvestrant|Im injection
46011888|NCT02279147|Drug|neostigmine methylsulfate，raceanisodamine hydrochloride|The patients receive immediately raceanisodamine hydrochloride(10mg) by intramuscular injection after operation .From that date, for three consecutive days, the patients will be receive 50mg raceanisodamine hydrochloride and 0.15mg neostigmine methylsulfate in the 24h by slow injection of vein.
46011889|NCT02216825|Dietary Supplement|Delayed release capsule, L. reuteri NCIMB 30242, escalated dose|
46011890|NCT02216825|Dietary Supplement|Standard vegetarian capsule, L. reuteri NCIMB 30242, escalated dose|
46011891|NCT04518384|Procedure|colon or rectum resection|surgical procedure to resect the colon or rectum
46011892|NCT02279186|Drug|Tranexamic Acid|Intravenous Injection
46011893|NCT04471350|Device|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in spine surgery.
46011894|NCT04532957|Drug|KBP-7072|QD oral capsules
46011895|NCT04532957|Drug|Placebo|matching placebo capsules
45679620|NCT05372354|Drug|Tazemetostat|Specified dose on specified days
45679621|NCT05372354|Drug|BMS-986158|Specified dose on specified days
45679622|NCT05372354|Drug|Trametinib|Specified dose on specified days
45679623|NCT05372354|Drug|Dexamethasone|Specified dose on specified days
45679624|NCT05368428|Other|Transcutaneous Electrical Nerve Stimulation|Undergo TENS
45679625|NCT05367063|Drug|Canagliflozin 100mg or Sitagliptin 100mg|70 eligible type 2 diabetes patients at high risks of cardiovascular diseases will be randomly assigned by a 1:1 ratio to either Canagliflozin 100 mg once daily or Sitagliptin 100 mg once daily.
45679626|NCT05365581|Drug|ASP2138|intravenous
46011896|NCT01177540|Drug|Decitabine|5 day priming with decitabine followed by Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide).
45679627|NCT05364242|Biological|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide
45679628|NCT05360771|Device|SnowyTM PFO closure system|Percutaneously occlusion of PFO with SnowyTM PFO closure system
46011897|NCT01177540|Drug|Decitabine|Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide) only
46011898|NCT04516707|Other|clinical database|"The various clinicam database will be collected solely to meet the objectives of the study.~All data collected to create the database for this project will be anonymized"
46098335|NCT00730600|Procedure|Thai Traditional massage|Thai traditional massage for 2 hours by a single masseuse.
45679629|NCT05360771|Device|Cardi-o-fix PFO occluder|Percutaneously occlusion of PFO with Cardi-o-fix PFO occluder
45679630|NCT05359042|Other|Electronic Patient Reported Outcomes platform|The ePRO tool is developed by a third-party vendor, Conversa, and engages the patient in a chat-based interaction to assess patient symptoms and provide educational material.
45679631|NCT05359042|Other|Health Related Quality of Life Surveys|Surveys will be administered to participants
45679632|NCT05358548|Drug|Paclitaxel|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
45679633|NCT05358548|Drug|Pemetrexed|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
45679634|NCT05358548|Drug|5Fluorouracil|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
46011899|NCT04317469|Diagnostic Test|VWF measurement|Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).
46011900|NCT04468737|Behavioral|Bowel preparation|Observe patients who undergo bowel preparation by enema or irrigation
46011901|NCT01177384|Drug|Sitagliptin phosphate|Sitagliptin, 100 mg tablet once daily, orally for 24 weeks
46011902|NCT01177384|Drug|Comparator: Placebo|Placebo, to match sitagliptin tablet, once daily, orally for 24 weeks
46011903|NCT01177384|Drug|Acarbose|Acarbose 50 mg or 100 mg tablet, 3 times daily, orally (continuing on the stable dose established prior to screening) for 24 weeks
46011904|NCT01177384|Drug|Glimepiride|Participants not meeting specific glycemic goals during the study will use glimepiride as rescue therapy. For countries where glimepiride is not available, participants will receive a sulfonylurea marketed in that country as rescue therapy.
46011905|NCT04315714|Other|Yoga Program|Six-week, twice weekly, 60-minute private yoga program (delivered online/virtually via Zoom).
46098336|NCT02694419|Device|Doppler evaluation|Endometrial volume, endometrial and subendometrial vascularity indices are measured by 3D power Doppler
46098337|NCT00999115|Drug|Expanded allogenic adipose-derived adult stem cells|Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure)at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
45679635|NCT05358548|Drug|Carboplatin|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
45679636|NCT05358548|Drug|Pembrolizumab|It is a type of immunotherapy and works by helping your immune system to kill cancer cells
46098338|NCT02694107|Other|Proprioceptive exercises|
46098339|NCT02694107|Other|Control|
46098340|NCT02394964|Other|Sample Collection|Sample collection of blood, stool, and buccal and skin swab samples will be collected at baseline, week 4, and week 8
46098341|NCT00999193|Procedure|locking plate, ORIF|Open reduction of the fracture (and GH joint), internal fixation with a locking plate. Tuberculum fragments are sutured to the plate with thick non-absorbable suture.
45679637|NCT05358249|Drug|JDQ443|KRAS G12C inhibitor, oral
45679638|NCT05358249|Drug|trametinib|MEK inhibitor, oral
45679639|NCT05358249|Drug|Ribociclib|CDK4/6 inhibitor, oral
45679640|NCT05358249|Biological|cetuximab|EGFR inhibitor, intravenous
45679641|NCT05355805|Drug|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
45679642|NCT05355805|Drug|Placebo to izokibep|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
45679643|NCT05348564|Behavioral|Direct contact of family members for cascade screening of relevant variants|Study team members will directly contact potentially impacted family members to offer genetic testing of relevant variant.
45679644|NCT05346250|Behavioral|Non-exercise control|12 month lifestyle education
45679645|NCT05346250|Behavioral|Moderate intensity exercise|12 month moderate intensity exercise by brisk walk 30 min per day and more than 5 days per week.
46011906|NCT01640015|Other|dietary intervention|a low frequency diet (3 meals/day) a high frequency diet (9 meals/day)
46011907|NCT04315519|Other|Exercise|Aerobic Exercise
46011908|NCT01641887|Other|Decision Aid|Patients will use a decision aid administered on a computer.
46011909|NCT01640093|Drug|Abiraterone acetate, 250 mg (uncoated, current commercial tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
46011910|NCT01640093|Drug|Abiraterone acetate, 500 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
46011911|NCT01640093|Drug|Abiraterone acetate, 250 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
46011912|NCT01640093|Drug|Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
46011913|NCT04512807|Diagnostic Test|AMH|AMH & PREGNANCY
46011914|NCT01641965|Device|Home pressure ventilator model Vivo 40 (BREAS Medical AB)|Nocturnal non invasive ventilation (Vivo 40)with minimum pressure support of 10 cm H2O (IPAP 14, EPAP 4). Parameters will be adjusted according to tolerance and to achieve PaCO2 < 45 mmHg and improve symptoms.
46011915|NCT04466124|Radiation|Liver Cancer Patients Treated With Proton Beam Therapy|Proton Beam Therapy
46011916|NCT01642121|Other|laboratory biomarker analysis|Correlative studies
46011917|NCT01194154|Drug|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta 30 microgram (mcg) subcutaneous injection once monthly up to 24 months with sequential dose adjustments to 50 mcg or 75 mcg depending on change of hemoglobin values of more than 1.0 gram (g)/ deciliter (dL).
46011918|NCT01194154|Drug|Placebo|Placebo matching to Methoxy polyethylene glycol-epoetin beta subcutaneous injection once monthly up to 24 months.
46011919|NCT01640210|Device|JewelPUMP (insulin patch pump)|"The study will be proposed during the visit of selection.~Visit of inclusion:~This visit will take place after having received the consent of the patient. Women will be asked to achieve a pregnancy test. Patients will wear a JewelPUMP containing saline solution in parallel with their usual insulin pump. They will be trained to use JewelPUMP.~Patients treated with insulin pump will be instructed to reproduce the same programming between their usual pump and the JewelPUMP, they will use in parallel.~Volume infused will be evaluated during a period of basal and bolus with a precision scale.~Patient monitoring: Patient have to come back to the centre every 24 hours for 3 days. Study visit:~Patients will be asked to fill out a questionnaire of satisfaction to the JewelPUMPTM and Visual scales.~Volume infused will be evaluated with a precision scale, by comparison of weight of JewelPUMP and patients' usual pump"
46011920|NCT01642160|Behavioral|additional educational material|The internet-based intervention group would receive a weekly text or an email (based on the subject's preference). The content of the message asks about their approximate compliance over the past week. Based on their response, they will be directed to one of two internet web pages.
46011921|NCT01642160|Behavioral|Standard of care|participants will receive education from staff nurses as needed.
46011922|NCT01640405|Drug|modified FOLFOX6 + bevacizumab|"Bevacizumab 5 mg/kg iv, day 1, followed by~Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, day 1, followed by~5- Fluorouracil (FU)/Leucovorin (LV), day 1 and 2, as follow:~LV 400 mg/m2 iv administered over a period of 2 hours, followed by~5-FU 400 mg/m2 iv bolus, followed by~5-FU 2.400 mg/m2 over 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
46011923|NCT01640405|Drug|FOLFOXIRI + Bevacizumab|"Bevacizumab 5 mg/kg iv, followed by~Irinotecan 165 mg/m2 iv administered over a period of 30-90 minutes, followed by~Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, followed by~LV 400 mg/m2 iv administered over a period of 2 hours, followed by~5-FU 3,200 mg/m2 for 48 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
46011924|NCT04465929|Biological|Autologous Human Schwann Cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix
46011925|NCT02279225|Radiation|Group Phototherapy|
46098342|NCT00999193|Procedure|Hemiarthroplasty|Replacement of the humeral articular head with hemiprosthesis. Tubercles are sutured to the prosthesis with thick nonabsorbable sutures.
46098343|NCT00999193|Other|Conservative treatment|Immobilisation in a supporting brace for 3 weeks, then increasingly active rehabilitation program supported by a physiotherapist until 12 weeks of the injury.
46098344|NCT04998773|Device|Theta Burst Transcranial Magnetic Bilateral Stimulation|TMS protocol of 22 sessions of bilateral active 1800 pulses.
46098345|NCT04998773|Device|Theta Burst Transcranial Magnetic Sham Stimulation|TMS protocol of 22 sessions of sham bilateral 1800 pulses.
46011926|NCT02279225|Radiation|Phototherapy + Physical activity|
46011927|NCT02279225|Other|Physical activity|
46011928|NCT02279225|Other|Placebo|
46011929|NCT01640444|Drug|FOLFIRI + bevacizumab|"Bevacizumab 5 mg/kg iv, followed by~Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~5-FU 400 mg/m2 iv bolus, followed by~5-FU 2,400 mg/m2 for 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
46011930|NCT01640444|Drug|FOLFIRI + cetuximab|"Cetuximab in an initial 120-minute infusion on day 1 of 400 mg/m2, followed by 60-minute infusions of cetuximab at a dose of 250 mg/m2, once weekly~FOLFIRI:~Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~5-FU 400 mg/m2 iv bolus, followed by~5-FU 2,400 mg/m2 for 46 h continuous infusion FOLFIRI will be given after the cetuximab infusion on day 1 of each period (every 2 weeks: 1 cycle)."
46011931|NCT04464096|Other|non|non
46011932|NCT04529408|Device|EarSats Pulse Oximeter Probe|Off-the-shelf pulse oximeter embedded into a memory foam ear plug for measuring blood oxygen saturation (SpO2) from the ear canal; in-ear SpO2 measured at-rest and during 6 minute walk test
46098346|NCT04998773|Device|Theta Burst Transcranial Magnetic Unilateral Stimulation|TMS protocol of 22 sessions of left active 1800 pulses and right sham 1800 pulses.
46011933|NCT04509804|Other|non-interventional|non-interventional
46098347|NCT04733092|Drug|Lipiodol|Lipiodol in emulsion with contrast agent
46098348|NCT04000945|Device|BTL-899|Treatment with BTL-899 device, 3 therapies
46098349|NCT04000945|Device|Sham|Sham treatment with BTL-899 device, 3 visits
46098350|NCT02621658|Other|Clear Liquid Diet|Patients will be allowed to consume clear soft drinks like ginger ales, Sprite®, 7-Up®, Gatorade®, Kool Aid®. They can also have strained fruit juices like apple, white grape juice and lemonade, and water, tea and coffee without milk or non-dairy creamer. Patient in this arm will also be allowed to have low-sodium chicken or beef broth , in addition to non-red hard candies, Jell-O®, and popsicles.
46098351|NCT02621658|Other|Full Liquid Diet|Patients will be allowed to consume a Full Liquid Diet, including nutritional supplements(Ensure®, Boost®, Glucerna®), strained cereals(like cream of wheat or strained oatmeal) and vegetables, purred fruit without seeds or pulp, milk, plain ice cream or yogurt, sherbet, coffee with cream, and tea.
46011934|NCT01642199|Behavioral|Reduced Intensity Behavioral Weight Loss + Peer Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by peers (i.e., other members of their weight loss group).
46011935|NCT01642199|Behavioral|Reduced Intensity Behavioral Weight Loss + Mentor Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by a mentor (i.e., successful weight loser).
46011936|NCT01642199|Behavioral|Reduced Intensity Behavioral Weight Loss|Participants will receive 12 months of a reduced intensity group behavioral weight loss program.
46011937|NCT01642316|Other|washback|students received 8 specific related formative test for that lesson. plus a pre-test and post-test, Michigan English language proficiency test
46011938|NCT01642316|Other|routin intervention|students only received two tests, Michigan test of English language proficiency as pre-test and post-test.
46011939|NCT01642355|Behavioral|Prevention Consult|In addition to usual care, patients will receive a prevention consult by a prevention fellow and attending following their intervention. The consult will include guideline based medical recommendations for optimization of the patient's medical regimen targeting dyslipidemia, hypertension and diabetes. In addition, each patient will be educated on the cardiovascular disease process and given detailed lifestyle recommendations on physical activity, improved nutrition, smoking cessation and medication adherence.
46098352|NCT00999271|Other|Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)|"two different dosages:~0.8 pmol/kg/min~1.5 pmol/kg/min for 300 minutes"
46011940|NCT01642355|Behavioral|Consult & Behavioral Intervention|In addition to usual care and prevention consult (as detailed above), patients will receive a full motivational intervention program by a trained motivational coach and text messages over 6 months.
46098353|NCT02722265|Drug|CS-3150|CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks
46098354|NCT00912600|Other|Intensive Care Unit admission|Intensive Care Unit admission
46098355|NCT02717039|Procedure|Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
46011941|NCT04529330|Procedure|fasciotomy|if it was suspected with ACS, the fasciotomy was conducted. but if the blister observed, it means decreased conmpartment sydrome. therefore, the blister observed can avoid unnecessary fasciotomy to patients suspected with ACS
46011942|NCT04508556|Device|Breath Biopsy face masks with removable filters and fitted PVA strip|Device developed for collection of breath samples
46098356|NCT02621502|Dietary Supplement|Quinoa variety 1|"On the intervention day, the volunteers will consume the Quinoa Variety 1.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
46098357|NCT02621502|Dietary Supplement|Quinoa variety 2|"On the intervention day, the volunteers will consume the Quinoa Variety 2.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
46011943|NCT04508556|Diagnostic Test|Nasopharyngeal swab|Is a method for collecting a clinical test sample of nasal secretions from the back of the nose and throat.
46098358|NCT02621502|Dietary Supplement|Quinoa variety 3|"On the intervention day, the volunteers will consume the Quinoa Variety 3.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
46098359|NCT02621502|Dietary Supplement|Quinoa variety 4|"On the intervention day, the volunteers will consume the Quinoa Variety 4.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
46011944|NCT04508556|Diagnostic Test|oropharyngeal swabs|Is a method for collecting a clinical test sample from the back of the throat.
46011945|NCT01642433|Drug|Placebo|Placebo capsules, 3x daily
46011946|NCT01642433|Drug|Prazosin|Prazosin medication, 3x daily dosing, up to 15mg/day
46011947|NCT04529213|Procedure|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
46011948|NCT01642472|Drug|Ulipristal Acetate - open label|Ulipristal Acetate (PGL4001) tablets 10mg orally daily for 3 months (84 days) for each treatment course. There are four 3-month treatment courses in this study.
45463523|NCT01211717|Other|Cellulose Placebo mix|The control group will also take 2 doses, 1 before the exercise, and the other after completing the exercise. This dose will be divided in half and administered at the two specified occasions.
46011949|NCT04507191|Diagnostic Test|immunohistochemical staining|immunohistochemical staining of programmed death-ligand 1 (PDL1) marker
45463524|NCT01112813|Drug|Lithium Carbonate|0.4-0.8 mmol/L for 2 months
46011950|NCT04460196|Other|survey|Each admitted patient will complete a questionnaire
45463525|NCT01196767|Drug|Ropivacaine (in one arm); catheterization (in both).|"Parallel study with two groups:~ropivacaine (2 mg.mL-1), at the rate of 4 mL.hr-1 through two subcutaneous catheters lateral to the sternum, both alimented by an elastomeric pump.~same protocol, with normal saline instead of ropivacaine."
46011951|NCT01640639|Drug|Thalidomide|Thalidomide, pill, 50 mg, once p.d., 6 weeks
46098360|NCT02621502|Dietary Supplement|Anhydrous Glucose|"On the intervention day, the volunteers will consume the control product.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
46011952|NCT01640639|Drug|Placebo|Placebo, pill, once p.d., 6 weeks
46011953|NCT01640678|Procedure|ReCell epidermal cell suspension grafting|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser) after which the prepared ReCell cell suspension will be sprayed on.
46098361|NCT02716961|Drug|Gemcitabine, cisplatin|Patients who were pathologically confirmed as moderate-high risk NMIBC. Epirubicin was immediately instilled in 24h after TURBT and regularly conducted for a year. GC scheme systematic chemotherapy was underwent 5 days after TURBT, which contained gemcitabine 1000-1200mg/m2. Cisplatin (70mg/m2) was intravenous dripped in the first and 8th day after TURBT. Intravenous rehydration was conducted in the second day.
46011954|NCT01640678|Procedure|CO2 laser abrasion + UV-therapy|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
46011955|NCT01642628|Other|Mirror Education|Patients allocated to the experimental group will be given a small hand-held mirror and structured mirror viewing education verbally. In addition, they will receive a mirror viewing handout. This intervention will be given prior to mastectomy surgery. In addition, participants will receive all other standard care.
45463526|NCT03940781|Behavioral|comprehensive rehabilitation|oropharyngeal rehabilitation, cardiopulmonary rehabilitation, and therapeutic exercise
45463527|NCT01192321|Device|Toric T3 - T9|Bilateral implantation of Alcon AcrySof Toric Intraocular Lens (IOL) models SN60T3 through SN60T9 following cataract removal.
45463528|NCT01192321|Device|Monofocal|Bilateral implantation of any monofocal Intraocular Lens (IOL) following cataract removal.
45463529|NCT03940859|Device|intracranial stent, flow diverter and coils|Endovascular treatment was performed under general anesthesia. Patients were treated with internal trapping, stent-assisted coiling or flow diverter as appropriate. After the procedure, patients treated with conventional stent were given 75mg/d clopidogrel for 6 weeks and 100mg/d aspirin for 6months, while patients treated with flow diverter were given 75mg/d clopidogrel for 3 months and 100mg/d aspirin thereafter. All patients were recommended to undergo a 6-month angiographic follow-up.
46011956|NCT04459143|Behavioral|Advance directives|A workshop will take place during the third week of patient care to inform them about COPD, exacerbations, prognostic and advance directives. Then, a personal interview with patients who have participated to this workshop will take place at the end of their hospital stay, to collect their advance directives and their degree of satisfaction about this process.
46011957|NCT01642667|Drug|Prourokinase|a bolus of 1.2 million IU and an infusion of 4.8 million IU in 60 min.
46011958|NCT01642667|Drug|Placebo|
46011959|NCT04458012|Diagnostic Test|Oculus Keratograph. Schirmer test. Tear fluid sample.|Objective measurements of the ocular surface using Oculus 5 keratograph. Slit lamp examination and tear fluid sample using Schirmer strips.
46011960|NCT04456179|Device|GE Datex-Ohmeda Oxy-F Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
46011961|NCT04456179|Device|Arrow® arterial catheterization kit (Teleflex)|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
46011962|NCT01640912|Drug|RXI-109|Single intradermal injection of RXI-109 at incision sites
45463530|NCT05412121|Device|Acupressure|"The MeTime Acupressure app will be loaded onto computer tablets or smart phones by the participants. Participants will also receive an AcuWand to be used in association with the acupressure app to help participants apply the correct amount of pressure to acupoints. There are 9 acupressure points, totaling 27 minutes of stimulation per day. Participants will perform daily acupressure for a total of six weeks.~In addition all participants will complete a battery of validated questionnaires before, during and after completion of treatment intervention."
45463531|NCT03942185|Drug|Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy|Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 ~ 200ml each time for 8 weeks.
45463532|NCT03942185|Drug|Oral Chinese Herbal Medicine according with syndrome differentiation therapy|Oral Chinese Herbal Medicine according with syndrome differentiation therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 ~ 200ml each time for 8 weeks.
45463533|NCT03942185|Drug|Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy|Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 ~ 200ml each time for 8 weeks.
46011963|NCT01640912|Drug|Placebo|Single intradermal injection of placebo at incision sites
45463534|NCT03451773|Drug|M7824|1,200 or 500mg every 2 weeks by intravenous (IV) infusion
46011964|NCT01642745|Drug|Methacholine (Provocholine)|two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL
46011965|NCT01642745|Drug|Mannitol (Aridol)|single deep inhalation of dry powder per dose doses range from 0mg - 160mg (cumulative dose range 0mg-635mg).
46011966|NCT01642745|Drug|Methacholine (Provocholine)|two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL every 20 seconds a deep inhalation is performed
46011967|NCT01642784|Device|Primary PCI of culprit lesion in IRA with drug eluting stent (DES)|Primary PCI of culprit lesion in IRA with drug eluting stent (DES)
45463535|NCT03451773|Drug|Gemcitabine|Standard (1,000 mg/m^2) or reduced (600 mg/m^2 for 4 doses) intravenous (IV) once a week for first 4 weeks. Then, once weekly for 3 weeks with one week rest. Gemcitabine will be discontinued after 6 months of therapy
46011968|NCT01642784|Device|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
46011969|NCT04502238|Other|Fluid restriction|Study participants will refrain from drinking fluids overnight to facilitate 1-2% fluid loss from baseline
46011970|NCT01640990|Drug|Saline|30mins run-in period
46011971|NCT01640990|Drug|GW328267X (total dose of 12mcg)|8 mcg/h for 1.5 hours (total dose of 12mcg)
46011972|NCT01640990|Drug|GW328267X (total dose of 40mcg)|10 mcg/h for 4 hours (total dose of 40 mcg)
46098362|NCT03742843|Combination Product|A multi-omics analysis|A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics for eutopic and ectopic endometrium
46011973|NCT01641029|Other|No intervention|There is no intervention
46011974|NCT01641068|Other|Cognitive Intervention|Participate in memory and thinking skills workshop
46011975|NCT01641068|Other|Educational Intervention|Participate in workshops focusing on increasing knowledge and education on the brain and cognition
46011976|NCT01641068|Procedure|Functional Magnetic Resonance Imaging|Undergo functional neuroimaging
46098363|NCT05216627|Diagnostic Test|Self-administered saliva-based viral testing|Participants will be instructed on how to inactivate the virus and bring their sample to their laboratory's central PCR machine, where they will take an assay test. They will be instructed to collect saliva into a 1.5 milliliter (mL) collection tube containing inactivation buffer (TCEP and EDTA) using a small funnel and inactivate at 95°C for 10 minutes. Participants will then transfer 6ul of saliva into 2 PCR tubes containing amplification master mix and primers, put tubes in a heat block or PCR machine at 65°C for 45 minutes and assess fluorescence using a simple battery-powered fluorescence viewer. Once they assess their sample, they will be instructed to dispose of the saliva sample safely and in accordance with best laboratory practices. No saliva samples will be collected by the research team at any time as part of this study.
46098364|NCT02704156|Device|Cyberknife plus Pembrolizumab and Trametinib|Radiation therapy plus drug
46098365|NCT02704156|Device|Cyberknife plus Gemcitabine|Radiation therapy plus drug
46098366|NCT00912678|Drug|MMF (Cellcept) and Steroids|Prograf was withdrawn completely after randomization, MMF and steroids were given.
46098367|NCT00912678|Drug|Tacrolimus (Prograf)|After randomization CellCept was withdrawn completely, low-dose tacrolimus was given.
45463536|NCT01112891|Drug|Vitamin D|10 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
45463537|NCT01112891|Drug|Vitamin D3|25 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
45463538|NCT01112891|Drug|Vitamin D|50 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
45463539|NCT03847441|Drug|Calcipotriol|Calcipotriol ointment (0.005%)
45463540|NCT03847441|Device|Narrow Band UVB|NB-UVB (311nm) phototherapy
45463541|NCT03847441|Diagnostic Test|vitamin D3 level|vitamin D3 (ng/ml)
45463542|NCT02529683|Drug|Nuvaring|contraceptive vaginal ring with ethinyl estradiol and etonogestrel
46011977|NCT01641068|Other|Memory Intervention|Participate in memory and thinking skills workshop
46011978|NCT01641068|Other|Quality-of-Life Assessment|Ancillary studies
46011979|NCT01641068|Other|Questionnaire Administration|Ancillary studies
46011980|NCT04454385|Diagnostic Test|Patients with well controlled asthma|"Patients with well controlled asthma~The following parameters are to be evaluated:~Blood eosinophils FeNO Findings on lung function test"
45679646|NCT05346250|Behavioral|Vigorous intensity exercise|6 month vigorous intensity exercise on treadmill for 30 min per day and more than 5 days per week, and subsequent 6 month moderate exercise by brisk walk 30 min per day and more than 5 days per week.
45463543|NCT03847129|Other|Biofeedback training|Before the biofeedback training, the baseline pinch force detected from a pinch-holding-up activity is recorded to set the target level according to the baseline data. With the aim for improving the performance, a 94% peak force value detected at the baseline is set as the target threshold for the training. Each participant attends a 30-minute biofeedback protocol per session, two times a week for six to eight weeks. Once the pinch force value exceeds the target range, visual and auditory cues are provided to inform the subjects to modify the performance.
45463544|NCT03847129|Other|Home-based tendon gliding and resistance training|The participants receive similar doses of home-based tendon gliding exercises and resistance training with an anti-stress ball for 30 minutes at a frequency of 2 times a week for 6 to 8 weeks, also combined with the regular diabetic care treatment. Six to eight telephone visits are carried out to remind the patients to comply with the exercise program during the training period.
45679647|NCT05343364|Drug|Vonoprazan|Oral Tablet
46011981|NCT04529057|Procedure|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
46011982|NCT01642862|Drug|Simvastatin|Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
46011983|NCT04501263|Behavioral|DEMCoN Educational Intervention|Educational programme on constipation for Health care professionals in this clinical specialist palliative care
46011984|NCT04529369|Procedure|Middle lobe only Photoselective vaporization of the prostate (PVP)|Middle lobe only Photoselective vaporization of the prostate (PVP) without vaporization of the lateral lobes
46011985|NCT04529369|Procedure|Complete PVP|Traditional Photoselective vaporization of the prostate PVP
46011986|NCT01641146|Behavioral|Enhanced Sexual Health Intervention for Men (ES-HIM)|ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
46098368|NCT00995839|Drug|continuous infusion of terlipressin|Intravenous continuous infusion of terlipressin 1 µg•kg-1•h-1 for 6 hrs
46098369|NCT00995839|Drug|Arginine vasopressin|Intravenous continuous infusion of arginine vasopressin 0.04 UI•min-1 for 6 hrs
46098370|NCT00995839|Drug|terlipressin bolus administration|intravenous terlipressin bolus administration at the dose of 0.5 mg
46098371|NCT05214131|Device|gogoband|use of biometric alarm to wake patient prior to wetting
46098372|NCT05214131|Device|SNEA group|standard bedwetting alarm is used to treat patients, alarm sounds after wetting accident has occurred
46098373|NCT00994513|Dietary Supplement|Alpha Lipoic Acid|1200 mg/day
46098374|NCT00994513|Dietary Supplement|Placebo|1200 mg/day
46098375|NCT02616744|Drug|Ibandronic acid|150 mg per month oral ibandronate
45463545|NCT01112969|Behavioral|Internet-based supportive coaching OSCAR|The Internet-based supportive coaching (OSCAR) is an scientifically based multicomponent intervention
45679648|NCT05342038|Device|T-02|Stent retriever
46098376|NCT02616744|Drug|Placebo|1 oral capsule of placebo per month
45679649|NCT05334004|Drug|Lopinavir / Ritonavir|Human Immunodeficiency Virus (HIV) antiviral, given via suppository
45679650|NCT05329415|Diagnostic Test|TB Drug Levels|TB drug levels at 1-2 time points at weeks 2, 8 and 16
46098377|NCT00995917|Other|Vitamin K acupoint injection|Vitamin K will be injected into an acupuncture point within 2 days of the onset of painful menstrual cramps. Injections of 5 mg/0.5ml of vitamin K1 will be administered in bilateral acupuncture points. A single shot of vitamin K1 is 10mg/ml. Five mg/0.5ml will be drawn twice from one ampule and injected into each bilateral site, for a total dose of 10mg/ml of vitamin K.
45463546|NCT01112969|Other|Waiting-list control group (TAU)|Waiting-list control group (treatment as usual, TAU, no specific intervention)
45679651|NCT05329376|Device|Smart Speaker Echo Dot|"Participants will receive the Smart Speaker EchoDot (3rd Generation) system in a timely manner based on the day of study enrollment. In addition to the usual functionality of the system, all participants will receive the following interventions through voice commands:~1. Reminders of administration of antidiabetics at the time or period of the day informed in the medical prescription; 2. Check for confirmation of antidiabetic administration 1 hour after the moment of administration; 3. Capillary blood glucose monitoring reminder,when indicated by the attending physician and appropriate; 4. Invitation to perform balance and breathing exercises daily, at a time compatible with the daily schedule provided by the patient at the time of inclusion; 5. Reminder to maintain healthy food choices at times typically associated with meals; 6. Invitation to play activities (eg listening tomusic, dancing, meditating, etc.) daily,according to the daily schedule provided by the patient;"
45679652|NCT05329376|Other|Control group|Participants will maintain usual care during the study period
46011987|NCT01641146|Behavioral|Health Promotion (HP) Comparison Arm|Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
46011988|NCT01642940|Drug|Prasugrel|Prasugrel 10mg/day
46011989|NCT01642940|Drug|Ticagrelor|Ticagrelor 90mg twice a day
46011990|NCT01643018|Procedure|laparoscopic surgery|In laparoscopy group three trocars is used. The first is 10 mm and inserted within the umbilicus for telescop, the second is 10 mm and inserted just below the xiphoid process, and third is 5 mm and inserted at the right upper quadrant of the abdomen.
46011991|NCT01643018|Procedure|open surgery|-open surgery group describes the patients treated with traditional open surgery. In open surgery group a right subcostal incision is used.
46098378|NCT00995917|Other|Saline Injection|Injection of .5ml saline bilaterally into both legs within 2 days of the onset of painful menstrual cramps.
46011992|NCT01641185|Procedure|radiation|radiation with protons or carbon ions
46011993|NCT04497519|Drug|inhaled hydroxychloroquine|ascending dose of iHCQ
46011994|NCT01641224|Drug|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
46011995|NCT01641224|Device|Atractylodes|Atractylodes (~10-15g)
46098379|NCT02616822|Dietary Supplement|Trans-resveratrol|Used for trans-resveratrol substance 300 mg single dose
46098380|NCT02616822|Other|Placebo|Used for placebo substance single dose
46098381|NCT02722109|Other|No intervention|No intervention will be done
46098382|NCT00912756|Drug|cilostazol|200 mg/day BID
46098383|NCT02716883|Procedure|AMT|"The AM was trimmed in two layers to fit the corneal ulcer and was placed with its epithelium (basement membrane) side up, secured with 10/0 nylon sutures, supported by a therapeutic contact lens. The operated eye was patched for 2 h, and then administration of the medical treatment agents was resumed.~In patients in the case group AMT was performed during days 2-5 of antibiotic therapy when initial clinical response to the treatment was observed."
46098384|NCT02621346|Behavioral|Imagery|Prior to exercising participants will be given an imagery script. Afterwards, participants will imagine completing the leg press.
45679653|NCT05327764|Other|Work to rest cycles of 40:20 minutes|Walking in a hot environment for 2 hours with repeated 40 minutes of work and 20 minutes of rest
45679654|NCT05327764|Other|Work to rest cycles of 20:10 minutes|Walking in a hot environment for 2 hours with repeated 20 minutes of work and 10 minutes of rest
46011996|NCT01641224|Device|Paeonia Lactiflora|Paeonia Lactiflora (~15-30g)
46011997|NCT01641224|Device|Tangerine Peel|Tangerine Peel (~10g)
46011998|NCT01641224|Drug|Ledebouriella Root|Ledebouriella Root (~10g)
46011999|NCT01641224|Drug|Radix codonopsitis|Radix codonopsitis (~10-15g)
46012000|NCT01641224|Drug|Radix curcumae|Radix curcumae (~10g)
46012001|NCT01641224|Drug|Fingered citron|Fingered citron (~10g)
46012002|NCT01641224|Drug|Tuckahoe|Tuckahoe (15g)
46012003|NCT01641224|Drug|Placebo|Placebo is blindly given to patients.
45463547|NCT01296607|Drug|Urocortin 2|"Protocol 4a: Onset/Offset protocol: (Visits 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 in the presence of a saline washout between each dose.~Urocortin 2 will be infused at 3.6, 12, 36 and 120 pmol/min (15, 50, 150 and 498 nanograms/min) to achieve estimated end-organ concentrations of 0.6, 2, 6 and 20 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 2 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of urocortin 2 on repeated dosing. The doses used for this protocol will be identical to Protocol a."
45679655|NCT05326386|Behavioral|HTN and Medication Adherence|"Via the Way to Health platform, all patients will receive daily text messages asking about medication adherence for that day and twice weekly text messages asking if participants have measured blood pressure on that day.~Participants are entered into a game. Each week they receive 90 points. If they took their medications or checked their blood pressure the prior day, they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 70 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner. At the start of the intervention, the study team holds a 3-way phone call with the participant and support partner to discuss ways they can help the participant meet their goal. The support partner gets a weekly email with the participant's progress.~Primary care physicians will receive a monthly email noting patients' self-reported adherence and blood pressure."
45837371|NCT05249088|Other|Protocolised reduction of non-resuscitation fluids|"Maintenance fluids are discontinued in participants with positive cumulative fluid balance who are not dehydrated~Intravenous fluid and enteral water are given as needed to correct electrolyte disturbances~Enteral nutrition with energy density of at least 2 kcal/ml is administered according to local practice~Starting 72 hours after inclusion, glucose at a concentration of at least 20% and a maximal dose of 1g/kg/day may be used as nutrition if enteral feeding is not tolerated. Glucose at this dose or lower may be started earlier in patients with insulin dependent diabetes if enteral feeding is not tolerated and local protocol mandates this~Parenteral nutrition is administered according to local protocol~Intravenous medications are concentrated according to a predefined protocol~Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids such that total dose of fluids covers the daily need of water (about 1ml/kg/h)"
46012004|NCT01641263|Behavioral|Sleep Education Therapy|Each 2-hour session, held once a week for 8 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion
46012005|NCT01641263|Behavioral|Cognitve Behavioral Therapy for Insomnia|For each 2-hour session held once a week for 8 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
46012006|NCT04451733|Procedure|Endotracheal intubation|Perform the endotracheal intubation during CPR
46012007|NCT01643057|Device|Stochastic Resonance Mattress|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available, designed by engineers at the Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
46098385|NCT02621346|Behavioral|Muscle Maintenance|Participants complete the leg press exercises at an intensity that promotes muscle maintenance but not muscle growth
46098386|NCT02621346|Behavioral|Bicep Curls|Control group participants will complete a bicep exercise at a maintenance training intensity.
45679656|NCT05315258|Drug|Tebentafusp|Tebentafusp supplied as concentrate for solution for infusion and diluted prior to administration. 0.2 mg/mL drug product will be provided as a sterile, refrigerated solution in glass vials.
46012008|NCT01643096|Other|Zataria multiflora Boiss|Thermic effect of food of Zataria multiflora Boiss and comparison between hot and cold temperament people
46012009|NCT01643096|Other|Sumac|Thermic effect of food of Sumac and comparison between hot and cold temperament people
46012010|NCT01643135|Drug|tranexamic acid|Transamine acts as antifibrinolysis which looks alike 0.9% NaCl (placebo)
46012011|NCT01643135|Drug|0.9% NaCl|0.9% NaCL (NSS) is clear fluid which looks alike tranexamic acid
46012012|NCT01641419|Drug|Placebo|2 ml of saline added to 30 ml of ropivacaine 0.5% solution for nerve block
46012013|NCT01641419|Drug|Dexamethasone 4 mg|2 ml of dexamethasone 4 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
45837372|NCT05249088|Other|Usual care|"Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~Maintenance fluids (crystalloids and/or glucose and/or enteral water) are given at a dose of 1 ml/kg/h unless local protocol states otherwise~Glucose is used at maximal concentration of 10% unless local protocol states otherwise.~Medications are concentrated according to local protocol"
46012014|NCT01641419|Drug|Dexamethasone 8 mg|2 ml of dexamethasone 8 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
46012015|NCT04449081|Behavioral|Knowledge, Attitude, Practice, Awareness, Preference|KAP, Awareness level and Preference were assessed using questionnaires
46012016|NCT01643252|Drug|riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL system at 30mW/cm^2 for 4 minutes
46012017|NCT01643252|Drug|placebo: 0.0% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.0% riboflavin ophthalmic solution (placebo) followed by irradiation with the KXL system at 30mW/cm^2 for 4 minutes
46012018|NCT01641458|Other|5FU and capecitabine (Xeloda®) dosing based on DPYD genotype|Multiplex amplification of each sample is performed in an individual well of a 24-well plate using a Mastercycler platform. Template and Platinum Taq Polymerase (Life Technologies, Carlsbad, California) are added to an analyte-specific amplification mix (AutoGenomics Inc., Carlsbad, California). After amplification, the plate is transferred into the Infinity analyzer (AutoGenomics Inc.), followed by primer extension and hybridization of detection primers to individual oligonucleotides arrayed on the Bio-FilmChip. After hybridization, the BioFilmChips are washed and scanned in the Infiniti optics module. The Autogenomics DPYD assay is used to detect the presence of the four risk alleles (IVS14+G>A, c.1679T>G, HapB3/c.1129-5923C>G and c.2846A>T).
46012019|NCT01641458|Other|Therapeutic drug monitoring of 5FU|Repeated PK plasma sampling is done in all patients receiving 5FU. Blood is taken from venipuncture into one 5 ml heparin tube and into one 3 ml EDTA tube for the analysis of 5FU steady-state plasma concentrations in every (2-weekly) treatment cycle. Special attention has to be paid not to take PK blood from the site of drug infusion. For 5FU, PK sampling is done two hours before the calculated end of the 5FU pump on day 3 of every treatment cycle. The quantitative 5FU exposure expressed as the area-under-the concentration-time curve in mg•h/L is calculated from the measured steady-state plasma concentrations of 5FU and the duration of 5FU infusion. In all patients, 5FU doses for the second and subsequent administrations are adjusted to target a 5FU AUC between 20 and 30 mg•h/L
46012020|NCT01641497|Radiation|3D conformational radiation|25 * 1.8 Gy in 5 weeks (=45 Gy)
46012021|NCT01641497|Radiation|IMRT|25 * 1.8 Gy in 5 weeks (=45 Gy)
46012022|NCT01641536|Genetic|HB-110|Each patient will be administered HB-110 by Electroporation for 20 weeks based on the protocol and take one pill of Entecavir(0.5 mg) per day during the study period. The Dose of HB-110 will be determined by the classical 3+3 dose escalation schedule and dose levels are 1mg, 2mg, 4mg respectively. The number of patients will be ranged from 9 to 18.
46012023|NCT01641575|Drug|CO-1.01 and Cisplatin|CO-1.01 administered over 30 minutes followed by 75 mg/ml Cisplatin over 2 hours (both intravenous) on C1D1. CO-1.01 administered intravenously over 30 minutes on C1D8.
46012024|NCT01643369|Behavioral|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
45679657|NCT05308238|Behavioral|Occupational therapy intervention group|Participants will receive 6 telehealth coaching sessions and 8 brief email or text check-ins over the course of 4 months. Participants will also receive a Fitbit and Engage PD Workbook.
45679658|NCT05308238|Behavioral|Disease management education group|Participants will receive online educational videos that they can watch at their own convenience over the course of 4 months. There will be up to 6 hours of content, and the links to these online videos will be provided via email. Following completion of the study, individuals in this group will receive an Engage PD Workbook and one OT coaching session, if they choose to.
46012025|NCT01643369|Behavioral|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
46012026|NCT01643369|Behavioral|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
46012027|NCT01641731|Other|Cow's milk|"Group I: Increase 2 mL until 10 mL, 10 mL until 50 mL, 20 mL until 100 mL and 50 mL until 200 mL was reached.~Groups II and III: Doubling dose until 1 mL, increase 2 mL until 20 mL, 5 mL until 50 mL, 10 mL until 100 mL and 20 mL until 200 mL was reached."
46012028|NCT01643447|Drug|Ulinastatin|Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)
45463548|NCT01296607|Drug|Urocortin 3|"Protocol 4a: Onset/ Offset protocol: (Visit 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 or Urocortin 3 in the presence of a saline washout between each dose.~Urocortin 3 will be infused at 1200, 3600, 12000 and 36000 pmol/min (5, 15, 50 and 150 micrograms/min) to achieve estimated end organ concentrations of 199, 600, 2000 and 6000 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 3 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of 3 on repeated dosing. The doses used for this protocol will be identical to Protocol a."
45463549|NCT01210235|Behavioral|FLU-FIT Program|In the intervention, eligible patients aged 50-75 who come in for flu shots and are due for colorectal cancer screening will be offered FIT.
45463550|NCT05406895|Drug|2% Lidocaine with 1:100,000 epinephrine|2% Lidocaine with 1:100,000 epinephrine will be used for administering the lower jaw anesthesia (inferior alveolar nerve block).
45463551|NCT03425253|Drug|BELKYRA®|BELKYRA® was injected into preplatysma fat tissue in the submental area (at least 1 plus up to 5 optional treatments, for maximum of 6 treatments 8 weeks apart).
45463552|NCT03425253|Device|Juvéderm® VOLUMA™ with Lidocaine|Juvéderm® VOLUMA™ with Lidocaine VOLUMA™ was injected along the mandibular border.
45463553|NCT05406349|Behavioral|Self-navigation task|Participants will perform a self-navigation task with two experimental conditions: Either they will be asked to walk towards a visible wall-mounted sign, or they will be asked to find and learn a hidden target location within the experimental room.
45463554|NCT05406349|Behavioral|Observation task|Participants will sit on a chair in a corner of the room (RNS participants) or watch a video that was recorded from the corner of the room (EMU participants). They will be asked to keep track of another person's location who is walking around the room, and to press a button whenever the other person crosses a previously-learned target location.
45463555|NCT01211951|Drug|KCT-0809|
45463556|NCT01211951|Drug|KCT-0809|
45463557|NCT01211951|Drug|KCT-0809|
45679659|NCT05306340|Drug|Giredestrant|Participants will receive treatment with giredestrant 30 milligrams (mg) orally once a day (QD) on Days 1-28 of each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).
45679660|NCT05306340|Drug|Exemestane|If exemestane is chosen as the physician's choice of endocrine therapy, the participant will receive exemestane at a dose of 25 mg orally once a day (QD) on Days 1-28 of each 28-day cycle or as per local label, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
46012029|NCT01643447|Drug|Diammonium glycyrrhizinate|
46012030|NCT01643486|Other|iTouch phosphate counting program|After developing and pilot testing the iTouch phosphate counting program, the participants in the intervention arm will enter their meal into the program; the required number of phosphate binders will be calculated for the patient
46012031|NCT01643486|Other|Usual Care|The patients randomized to the usual care arm will continue to receive the usual dietary counselling and will input meal data into the iTouch program but no recommendations for the number of phosphate binders to be taken with the meal will be provided
46012032|NCT04491669|Diagnostic Test|GFR - Glomerular Filtration Rate|"Chronic Renal Failure staging according to GFR by Chronic Renal Failure EPI is:~Stage1 in which GFR>90 mil/min but evidence of kidney damage.~Stage 2 GFR 60-89 mil/min.~Stage 3 GFR 30-95 mil/min.~Stage 4 GFR 15-29 mil/min.~Stage 5 GFR<15 mil/min."
46012033|NCT01641770|Other|Nutritional beverage 10003RF|2 sachets per day
46012034|NCT01641770|Other|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
45463558|NCT01211951|Drug|Placebo|
46012035|NCT01641770|Other|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
46012036|NCT01600911|Other|Low phytochemical diet(LPD), high phytochemical diet(HPD)|LPD is a basal diet which low in soy,vegetable and fruit and other plant food to approach low phytochemical. HPD is the diet which add two serving test vegetable in the lunch of LPD.
46012037|NCT01643603|Drug|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
46012038|NCT01643603|Other|laboratory biomarker analysis|Correlative studies
46012039|NCT02279238|Procedure|cardiac rehabilitation|"It is a cross over study in which the participants are assigned for two test simultaneously with washout time of 6 hrs . 5th POD patients are randomly assigned to either 6 minute walk test or 3 minute ramp walk test as first test with 6 hours of rest [Washout time] in between the two test.~6 MWT : The patient is instructed to walk for a period of 6 minute on a 30 meters Hallway with its extent being demarcated by the placement of 2 cones at the extremes of the Hall.~3 MRWT : The patient is instructed to walk for a period of 3 minute on a Ramp with an elevation of 30 degree and length of 20 meters with its extent being demarcated by the placement of 2 cones at the extremes of the ramp.~The data of [HR, SPO2, PSG RPE scale, Distance walked, BP] the participants are collected before, during and after the completion of each lap [according to American Thoracic Society [ATS] protocol]."
46012040|NCT02754011|Drug|Combination of ribociclib + capecitabine|RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
46012041|NCT02488863|Other|MRI Neuroimaging|MRI scans utilized to measure the structural and functional integrity of the brain.
46012042|NCT02488863|Other|Quantitative Sensory Testing|Vibratory Detection Thresholds; Tactile Detection Thresholds; Thermal Detection Thresholds, Pain Thresholds, and Temporal Summation; Allodynia and Temporal Summation; Punctate Pain Testing and Temporal Summation; and Pressure Pain Thresholds.
46012043|NCT02488863|Other|Questionnaires|The Modified Mini-Mental State Examination (3MS), the Montreal Cognitive Assessment (MoCA), the Center for Epidemiologic Studies Depression Scale (CES-D), the Geriatric Depression Scale (GDS), the Edinburg Handedness Inventory, the Ten-Item Personality Inventory (TIPI), the Pittsburgh Sleep Quality Index (PSQI), the state and trait versions of the State-Trait Anxiety Inventory (STAI), the state and trait versions of the Positive and Negative Affect Schedule (PANAS), pain questionnaires (the Graded Chronic Pain Scale (GCPS), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Pain-Detect, the short-form McGill Pain Questionnaire (SF-MPQ-2), and the Coping Strategies Questionnaire-Revised (CSQ-R)), a standardized paper and pencil cognitive battery (Hopkins Verbal Learning Test (HVLT), Trail Making A&B, Boston Naming Test, Controlled Oral Word Association Test (COWAT), Stroop Interference Test, Ruff Figural Fluency Test, and Raven's Progressive Matrices Test).
46012044|NCT02488863|Other|Physical and Cognitive Function Testing|Upper Limb Isometric Strength, Short Physical Performance Battery (SPPB), GAITRite Instrumented Walking, Galvanic Skin Response, Knee Extension Isokinetic Strength, the Pepper Assessment Tool for Disability (PAT-D), and an electronic NIH Toolbox Cognitive Battery.
46012045|NCT02755844|Drug|Olaparib|"Olaparib tablet dose will be dose-escalated on 4 dose levels , guided by a continual reassessment method (CRM).~One cycle will be 28 days (4 weeks) in duration, except for cycle 1 which will be 6 weeks."
46012046|NCT02755844|Drug|metformin|From week 3 metformin will be gradually escalated from 500 mg/day to 1500 mg/day with weekly 500 mg dose escalation levels
46012047|NCT02755844|Drug|metronomic cyclophosphamide|from week 2 Metronomic cyclophosphamide will be given continuously on an oral daily basis at 50 mg qd
45463559|NCT03941561|Drug|S-1 for 9 months|S-1 for 9 months after D2 resection
45463560|NCT03941561|Drug|S-1 for 1 year|S-1 for 1 year after D2 resection
45463561|NCT05403229|Drug|Topiramate|The topiramate arm receives additional oral topiramate for 6 weeks. The dose of topiramate is started from 25mg orally daily with the weekly escalation of 25mg to a maximum of 100mg.
45463562|NCT05403229|Drug|Systemic Steroids|Both groups receive a systemic steroid with/without intratympanic steroids as the standard treatment of SSNHL.
45463563|NCT03424239|Drug|Zoledronic Acid|5mg zoledronic acid
45463564|NCT03424239|Dietary Supplement|Calcium citrate + vitamin D|Chewable 500mg calcium citrate with 500 International Units (IU) Vitamin D3
45463565|NCT03424239|Dietary Supplement|Vitamin D3|1000IU Vitamin D3 gummy
45679661|NCT05306340|Drug|Fulvestrant|If fulvestrant is chosen as the physician's choice of endocrine therapy, the participant will receive fulvestrant in the clinic at a dose of 500 mg intramuscularly on Day 1 and Day 15 of Cycle 1, then Day 1 of each cycle thereafter (1 cycle is 28 days) or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
46012048|NCT01643642|Other|Cognitive behavioral treatment/farmacotherapy intervention|Brief cognitive behavioral intervention/farmacotherapy; intake, treatment and ROM
45463566|NCT03941795|Biological|JS001(Toripalimab Injection)|"Test Group:~Toripalimab (240 mg, IV, Q3W) + axitinib (5 mg/tablet, one tablet, twice a day, orally); axitinib is started on the second day of administration of toripalimab until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death, with a maximum duration of toripalimab use of no more than 2 years."
45463567|NCT03941795|Drug|Axitinib 1 MG [Inlyta]|Axitinib (5 mg/tablet) one tablet, twice a day, orally until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death
45679662|NCT05306340|Drug|Tamoxifen|If tamoxifen is chosen as the physician's choice of endocrine therapy, the participant will receive tamoxifen at a dose of 20 mg orally QD on Days 1-28 of each 28-day cycle or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
45679663|NCT05306340|Drug|Everolimus|Participants will receive treatment with everolimus 10 mg orally QD during each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.
46012049|NCT01643642|Other|Treatment As Usual|Other: Treatment As Usual
46012050|NCT04490070|Behavioral|Cognitive Stimulation|The caregiver training program consisted of applying the cognitive stimulation model of the CUIDA-2 program. This application included theoretical training made up of three modules: 1) person-centered care, 2) communication strategies, and 3) mediated cognitive stimulation strategies. The training was given in two group sessions of two hours each, plus 50 hours of individual practice, either on the job (in the case of professional caregivers) or in the home (in the case of family caregivers), in both cases supervised by psychologists who were experts in the program. In these individual practice hours, the caregivers were required to keep a weekly log. Here they had to plan in advance the activities that they were going to carry out with the older adult, and once they had taken place, they had to record how they were done and how the older adult had responded.
46012051|NCT02756897|Drug|Ibrutinib|Given PO
45463568|NCT03941795|Other|JS001 and Axitinib|"Control Group:~Toripalimab (240 mg, IV, Q3W) is administered on the first day until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death, with a maximum duration of no more than 2 years"
46012052|NCT02756897|Other|Laboratory Biomarker Analysis|Correlative studies
46012053|NCT02756897|Drug|Venetoclax|Given PO
45463569|NCT03845959|Drug|TD0019 oral capsule|TD0019 are green, hard capsule with size 0, containing yellow herbal powder with special smell of herbal.
46012054|NCT01600989|Other|blood sampling|Blood samples will be taken at ICU admission, and 24h and 48h after admission, and at time of resolution of sepsis
46012055|NCT01600989|Other|blood sampling|Blood samples will be taken twice at a 7 day interval
45463570|NCT03845959|Drug|Placebo oral capsule|Placebo
45463571|NCT01197001|Drug|Amlodipine plus Losartan|Amlodipine/Losartan low dose
45463572|NCT01197001|Drug|Amlodipine, Losartan|Amlodipine, Losartan
46012056|NCT01643681|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Into lumbar intervertebral disc infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4x10e7 cells/1mL
46098387|NCT03888235|Procedure|Immediate corrective exercises|The sacroiliac forward flexion test (SIFFT) finds the position of each innominate bone. Subjects learn 1 of 3 exercises. To correct anterior rotation, flex the thigh hard against the ilium, pushing it backwards. To correct posterior rotation, hyperextend the thigh to pull the ilium forward. 1.Genuflect, anterior foot and posterior knee on the floor hands on the floor on either side of the foot, sliding the knee backwards to hyperextend the thigh. 2. Supine, anterior foot on an assistant's sternum, posterior thigh hyperextended. Assistant leans forward, forcing the anterior thigh against the ilium and pushing down on the posterior thigh. 3. For anterior rotation alone: anterior foot on a chair seat, pulling up hard with both hands, leaning back, forcing the thigh against the ilium. Hold position for 2 minutes. Use as needed for pain control. They are reassessed one month later when they receive the pelvic support belt. Both treatments used together will be assessed one month after.
45463573|NCT03940625|Diagnostic Test|Cardiac MRI and echocardiography, laboratory parameters|Cardiac MRI including cine imaging (volumetric determination of LV-EF), late gadolinium enhancement, strain analysis, T1 mapping and T2 mapping Echocardiography including 3D-EF, diastolic function and strain analysis Determination of laboratory parameters including cardiac enzymes (Troponin T and high sensitivity Troponin T) and cardiac markers (BNP and NT-pro BNP)
45463574|NCT03451071|Drug|Gardasil9|Gardasil 9
45463575|NCT01113047|Drug|Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ|Aliskiren 300 mg / Amlodipine 10 mg/HCTZ 12.5 mg
45463576|NCT01114451|Procedure|Removal of surgical skin staples|Skin staples will be removed using standard technique with subsequent placement of steri-trips
45463577|NCT01295437|Device|Vypro II mesh|partly absorbable mesh
45463578|NCT01295437|Device|Premilene LP|lightweight mesh
45463579|NCT01295437|Device|Premilene mesh|A conventional polypropylene mesh (82 g/m2)
45463580|NCT01114607|Drug|GSK1605786 ChemoCentryx: formulation A|ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.
46012057|NCT04489914|Device|High-Flow Oxygen Therapy|high-flow oxygen therapy after percutaneous transfemoral aortic valve replacement
46012058|NCT01601106|Drug|liposomal prednisolone|Two weekly dosages with 150 mg.
46012059|NCT01601106|Drug|Placebo|
45679664|NCT05306340|Drug|LHRH Agonist|Only premenopausal/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
46012060|NCT04529018|Combination Product|[18F]CETO|[18F]CETO is a PET radiotracer used to diagnose and visualise the cause(s) of primary aldosteronism
46012061|NCT01601145|Dietary Supplement|consumption of lozenges|Each subject two lozenges a day for 6 weeks
46012062|NCT02750540|Drug|Tenofovir enema|
46012063|NCT02750540|Other|Saline enema|
46012064|NCT04488588|Other|Kaplan Meier analysis|Kaplan Meier survival analysis was conducted to calculate the cumulative overall survival rates using Log Rank test for comparison between age groups
46012065|NCT01601184|Drug|vismodegib|Hedgehog pathway antagonist Dosage: 150 mg orally with or without food at the same time every day
46012066|NCT01601184|Drug|Temozolomide|alkylating agent Dosage: Dose in Cycle 1 is 150 mg/m2 orally once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200mg/m2 orally once daily for 5 days
46098388|NCT03888235|Device|Immediate use of pelvic support belt|"Participants will be given a pelvic support belt to stabilize their sacroiliac joints. The belt is fitted tightly around the pelvis, over the sacrum and below the anterior superior iliac spines (ASISs) to prevent opening the joint. (The upper part of the innominate bones flares out so pushing them inwards will move the lower part outwards, away from the sacrum, opening the sacroiliac joints, increasing their instability). They will use this belt for activities which have in the past precipitated back pain. They will be reassessed one month later.~At that time they will be given the exercises to correct their sacroiliac malrotation and the concurrent use of both treatments will be assessed at their last visit one month later."
45679665|NCT05306340|Drug|Dexamethasone Mouth Rinse|A compounded alcohol-free mouthwash of dexamethasone (0.5 mg in 5 mL) will be supplied, where feasible. It is strongly recommended for prophylaxis or treatment of stomatitis/mucositis. Participants should use the alcohol-free mouthwash of dexamethasone four times QD for 8 weeks started concurrently with study treatment, and use it reactively thereafter with the first appearance of symptoms.
46012067|NCT01643759|Drug|buprenorphine|The subjects will be randomized to receive either a single dose of BTDS 5, or BTDS 10, or BTDS 20 for 7 days. Plasma concentrations of buprenorphine and norbuprenorphine will be analyzed to determine the following pharmacokinetic parameters: AUC0-t:pg•hr/ml-Area under the plasma concentration-time curve frame: predose,6,12,24,36,48,60,72,96,120,144,168,169,170,171,172,174,180,192,216,240 hours post-dose.AUC0-inf:pg•hr/ml-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: pg/ml-Maximum observed plasma buprenorphine concentration. Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of buprenorphine elimination.
46012068|NCT04488237|Drug|Vitamin D|oral administration of Vitamin D in patients with acute leukemia treated with methotrexate
46012069|NCT02754557|Other|Breath-Focused Meditation|"Participants will attend two breath-focused meditation sessions per week for three weeks. During the breath focus task, participants are asked to alternatively focus their breathing (1.5 minutes of breathing and 15 seconds of rest). Participants will be asked to attend to the changing patterns of physical sensations as the breath moves in and out of your body. Focus your awareness on any sensations you may experience (e.g., your abdominal wall rising). Follow the sensations as you breathe in and all the way through until your breath leaves your body."
46012070|NCT02754557|Device|Physiological Feedback|Participants will receive breath feedback, via dynamic velocity estimates from a respiration belt, which allows an analog of breath to be felt as vibration on their wrist via a tactile transducer on a table. The transducer is tuned to produce low frequencies so there is more vibration and less of an audible component than a regular speaker would produce.
46012071|NCT04528979|Other|BioRoot RCS® root canal sealer|Root canal obturation with guttapercha and BioRoot RCS® root canal sealer
45679666|NCT05303428|Other|Neuromodulation with low-intensity focused ultrasound|application of LIFU to induce temporary neuromodulation, effects tested with resting state and task based fMRI scanning.
45463581|NCT01114607|Drug|GSK1605786 GSK: formulation B|GSK1605786 formulation B will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
45463582|NCT01114607|Drug|GSK1605786 GSK direct-fill: formulation C|GSK1605786 formulation C will be an opaque Swedish orange body capsule with size 1, administered 30 minutes after standard breakfast.
45679667|NCT05303051|Device|Application Validation|After creating accounts, participants in both groups will download the Azumio Instant Diabetes Test and provide a Photoplethysmography (PPG) waveforms by placing their index finger over their smartphone camera for 20 seconds to provide PPG waveform data for the study .
46012072|NCT04528979|Other|AH Plus® root canal sealer|Root canal obturation with guttapercha and AH Plus® root canal sealer
46012073|NCT01601262|Device|Low Intensity Extracorporeal Shock waves (Cardiospec 1000)|We will apply the cardiospec 1000 unit for LI-ESWL in the penile and inguinal areas, 300 shocks per area, total of 1500 shocks. Full description of treatment series can be seen in the detailed protocol.
46098389|NCT03888235|Other|Delayed treatment|Participants will continue the treatments they are currently using to relieve their low back pain for one month. At their one-month visit, they will be taught how to assess the direction of sacroiliac malrotation and how to do the corrective exercise. They will also be fitted for a pelvic stabilization belt.
46012074|NCT02279849|Other|Communications|Communication materials were used to promote healthier items to consumers in corner stores.
46098390|NCT04080245|Biological|Treatment Group Live Attenuated Flu Vaccine (LAIV)|We will administer LAIV once as a vaccine prime and IIV once as a vaccine boost with serial weekly blood draws for a month to validate a biomarker of LAIV efficacy.
45463583|NCT01114607|Drug|GSK1605786 GSK modified-process: formulation D|GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
45463584|NCT01114607|Drug|GSK1605786 GSK tablet: formulation E|GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.
45679668|NCT05299671|Behavioral|Video consultation|During the video visit, a pharmacist will speak with the patient about potential drug-drug interactions between the patient's cancer treatment and the other medications on the list, make recommendations about medication management (which will also be directly communicated to the oncologist), provide education about the patient's new OACD, and answer any questions. The virtual consultation will last about 30 minutes via an electronic device.
46098391|NCT04500028|Drug|INH|3 vaginal tablet of isonicotinic acid hydrazide (900mg) inserted by the study nurse 4 hours before IUD insertion.
45463585|NCT01192477|Other|Ozone|All subjects will have a 3-hour exposure to clean air, a 3-hour exposure to clean air with lower ozone (0.1 ppm), and a 3-hour exposure to clean air with higher ozone (0.2 ppm). Exposures will take place at least 3 weeks apart. Order of exposure will be randomized for each subject.
45679669|NCT05295433|Drug|mRNA-3705|A sterile liquid for injection
45679670|NCT05294731|Drug|BGB-16673|BGB-16673 will be orally administered as per dosage needs
46012075|NCT02279849|Other|Pricing|The pricing incentives were used to help promote sales of healthier food items.
46012076|NCT02279849|Other|Combined (Communications & Pricing)|Communications with Pricing incentives were used to promote the sale/consumption of healthier foods.
46012077|NCT04488549|Other|Survey|International E-survey
46012078|NCT01680029|Device|PBASE-system 2.0|
46012079|NCT04528628|Drug|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|Patients will be treated with one kind of selective serotonin reuptake inhibitors/ serotonin and norepinephrine reuptake inhibitors. Dose is titrated to the minimum effective dose within 2 weeks. Benzodiazepines can be used for a short period lasting no more than 2 weeks.
46012080|NCT04528628|Drug|Treatment as Usual|The research doctor discusses the treatment plan with the patient, and therapies and drugs are not limited.
46098392|NCT04500028|Drug|Placebo Comparator|3 tablet of placebo inserted by the study nurse 4 hours before IUD insertion.
45463586|NCT03449979|Device|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.
46098393|NCT00694668|Behavioral|Cognitive Behavioral treatment|Brief cognitive behavioral therapy (12 sessions)
45463587|NCT03449979|Device|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
45463588|NCT01197079|Other|Survey|Self administered anonymous survey
45463589|NCT01113125|Drug|Betamethason-17-valerate and fusidic acid|0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
45679671|NCT05293522|Combination Product|NTX-001|2 solutions plus a delivery device; one time use surgical product
45679672|NCT05288972|Device|Mattress 1|A mattress (M1) with the technical features suitable for scoliosis with supports the spine properly. The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
45463590|NCT01113125|Drug|Fusidic Acid|0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
45463591|NCT03714009|Behavioral|Fasting|"Periodic fasting last for 4weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet. Patients should take adequate water and non calorie beverages intake daily (2-3 liters)."
45463592|NCT03714009|Behavioral|No fasting|Patients will not fast . But they will take balanced food and drink 2 to 3 liters of water and non caloric drinks all the day for 4 weeks
45463593|NCT03846817|Other|Physiotherapist-led treatment|12-week of semi-standardized, progressive physiotherapist-led treatment aiming to increase hip muscle strength and load capacity.
45679673|NCT05288972|Device|Mattress 2|A mattress with standard technical features (M2). The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
46012081|NCT04528628|Combination Product|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors) Combined with Magnetic Stimulations|Drug therapies are the same as the SSRIs/SNRIs monotherapy group. Patients will randomly receive one kind of magnetic stimulations including repetitive transcranial magnetic stimulation (rTMS), continuous theta burst stimulation(cTBS) and intermittent theta burst stimulation (iTBS) at a ratio of 1:1:1.
46012082|NCT04528940|Diagnostic Test|PD-1/PDL-1 staining|Every endometrial or ovarian carcinoma will be stained for PD-1/PDL-1. The stage and grade of the tumor will be determined and correlation between tumor grade and stage and PD-1/PDL-1 staining will be made.
46012083|NCT01601340|Drug|HQK-1001|HQK-1001 tablets, twice daily for 48 weeks
46012084|NCT01601340|Drug|Placebo|Placebo tablets, twice daily for 48 weeks
46012085|NCT04528862|Behavioral|Nature slides|participants will view a presentation of nature slides
46012086|NCT04528862|Behavioral|Urban slides|participants will view a presentation of urban slides
46098394|NCT00694668|Behavioral|Mindfulness based cognitive therapy|9 sessions MBCT in a group-format (up to 8 persons)
46098395|NCT02716649|Other|No intervention|
46098396|NCT02621268|Drug|Indocyanine Green|Infusion of ICG 24 hours prior to surgery
46098397|NCT04487470|Other|Flavored filtered cigars|Flavored and unflavored Cheyenne filtered cigars that are currently available in the marketplace for purchase
45679674|NCT05287711|Behavioral|Motivational Enhancement Therapy|In Session 1, the therapist provides personalized feedback on a range of assessment variables, including alcohol consumption levels, negative consequences from alcohol use, and family risk of alcoholism. Sessions 2-4 are follow-through sessions in which the therapist attempts to help the Veteran participant establish or reaffirm a commitment to an action plan for addressing alcohol concerns.
46012087|NCT01600248|Behavioral|Online ABBT for Chronic Pain in Military|Participants will complete an 8-module, self-paced, online program for chronic pain using Acceptance-Based Behavioural Therapy (ABBT) as the therapeutic modality.
45679675|NCT05287711|Behavioral|Alcohol Education Control|Will consist of 4 weekly individual sessions, approximately 60 minutes each. AE therapists will explain that their job is to provide the Veteran participants with information and education about the effects of alcohol, and that it is up to the Veteran participant to use this information as he sees fit. In each session, the Veteran participant will watch an educational videotape in a comfortable consulting room and will be given an opportunity to discuss the videotape with the project therapist for approximately 10 minutes. Written educational materials will supplement the information provided in the videos, and the therapist will ask several structured questions to determine whether the Veteran participant understood the material presented in the video.
45679676|NCT05287711|Behavioral|Treatment as Usual|Supportive telephone monitoring sessions that ensure equal spacing between assessments across conditions and equal number of therapist contacts.
45837373|NCT05214222|Drug|Anlotinib/Penpulimab/Chemotherapy|"Initial treatment (4-6 cycles): Anlotinib, Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~Anlotinib: once a day, 1 capsule each time (10mg for body weight <60KG, 12mg for body weight ≥60KG), d1-d14, 3 weeks as a treatment cycle.~Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~Paclitaxel: According to 135-175mg/m2, intravenous infusion> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Anlotinib, Penpulimab~Anlotinib: once a day, 1 capsule each time (the same as the initial treatment dose), take the drug every cycle d1-d14, 3 weeks as a treatment cycle.~Penpulimab: 200mg, d1 per cycle, once every 3 weeks"
45837374|NCT05214222|Drug|Penpulimab/Chemotherapy|"Initial treatment (4-6 cycles): Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~Paclitaxel: According to 135-175mg/m2, intravenous infusion> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Penpulimab~• Penpulimab: 200mg, d1 per cycle, once every 3 weeks"
46012088|NCT01680068|Procedure|Pars plana vitrectomy and postoperative air tamponade|Pars plans vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
45463594|NCT01210391|Other|Extensively hydrolyzed whey infant formula|New hydrolyzed infant formula.
46012089|NCT01641341|Drug|Bifidobacterium infantis|once a day for seven to eight weeks
46098398|NCT04487470|Other|Unflavored filtered cigars|Flavored and unflavored Cheyenne filtered cigars that are currently available in the marketplace for purchase
46098399|NCT02621580|Device|Pan-Retinal Photocoagulation|"Diabetic retinopathy does not usually impair sight until the development of long-term complications, including proliferative retinopathy, a condition in which abnormal new blood vessels may rupture and bleed inside the eye. When this advanced stage of retinopathy occurs, pan-retinal photocoagulation is usually recommended.~During this procedure, a special laser is used to make tiny burns that seal the retina and stop vessels from growing and leaking. Hundreds of tiny spots of laser are placed in the retina to reduce the risk of vitreous haemorrhage and retinal detachment."
46098400|NCT02721953|Dietary Supplement|Butyrate|Butyrate
46098401|NCT02721953|Other|Placebo|Placebo
46098402|NCT04426240|Drug|Cyclosporine microemulsion|Intervention group receives topical cyclosporine dry eye treatment before cataract surgery
46098403|NCT00995995|Drug|Rosiglitazone|Rosiglitazone
46098404|NCT00694746|Drug|Omega-3-acid ethyl esters|Participants will receive 2 capsules of 1 gram of fish oil with meals twice a day for a period of six months (including a ramp up period of three weeks)
45463595|NCT01210391|Other|Extensively hydrolyzed casein infant formula|Commercially available infant formula.
45463596|NCT03846739|Drug|Oxytocin nasal spray|Intranasal administration, 6, 12, or 24 international units (IU) oxytocin.
45463597|NCT03846739|Drug|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself.
45463598|NCT03716115|Dietary Supplement|Colostrum high protein powder (Neovite)|Bovine colostrum provided as powder will be reconstituted and administered orally or via NG tube.
46012090|NCT01641341|Drug|Pancrelipase|Pancrelipase (one capsule prior to meals or snacks)
46012091|NCT01641341|Drug|Nitazoxanide|Nitazoxanide (500mg twice a day for 7 days)
46012092|NCT01641341|Drug|Placebo|Placebo capsule will not contain active treatment ingredients.
46098405|NCT00694746|Drug|Placebo|Participants will receive 2 capsules of 1 gram of placebo with meals twice a day for a period of six months (including a ramp up period of three weeks)
45463599|NCT03716115|Drug|N-Acetyl Glucosamine (GInNAC)|N-Acetyl glucosamine provided as powder will be reconstituted and administered orally or via NG tube.
45679677|NCT05287711|Behavioral|Strength at Home|IPV intervention which consists of 12 weekly, 2-hour cognitive-behavioral sessions offered in a closed group format and co-led by doctoral level male and female therapists. Strength at Home is based on a social information processing model of trauma and IPV and provides material covering psychoeducation regarding trauma and IPV, conflict and anger management skills, assertiveness training, and skills in stress management and communication.
46012093|NCT01601418|Drug|YF476|Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
46012094|NCT01601418|Drug|Placebo|Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
45463600|NCT03716115|Drug|Teduglutide|Teduglutide will be administered daily as subcutaneous injection
45463601|NCT03716115|Drug|Budesonide|Budesonide liquid (as marketed for nebulisation) will be administered orally or bia NG tube daily.
45463602|NCT01113203|Behavioral|Resistance training|Progressive high intensity resistance training performed twice a week for 16 weeks, and achieving in 7 exercises for the main muscles, the protocol of 4 sets of 6RM and 2 of 4RM.
45463603|NCT03421977|Biological|Onasemnogene Abeparvovec-xioi|Patients received treatment with onasemnogene abeparvovec-xioi in the parent study, AVXS-101-CL-101
45463604|NCT01113281|Biological|VPM1002 live vaccine|
45463605|NCT01113281|Biological|commercially available live vaccine BCG|
45463606|NCT03713931|Diagnostic Test|PUMA Score questionnaire|"Every patient who meet the criteria for active search (older than 40 years, smokers or ex-smokers of more than 10 pack-years who attend the usual care in the first level of care) will be scored with the PUMA´s questionnaire in an application and electronic database (RedCap) specially designed for the active search of cases.~Patients with PUMA´s score ≥ 5, and without exclusion criteria for spirometry will be referred to perform spirometry at the institution"
45463607|NCT01210469|Other|Strengthening and balance exercises|The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
45837375|NCT05211180|Behavioral|Vida Sana|Weekly group or individual education sessions with a health coach and fitness tracking with a fitbit.
46012095|NCT01680107|Drug|d-cycloserine|
46012096|NCT01680107|Drug|placebo|
46012097|NCT01680107|Behavioral|cognitive-behaviour therapy|
45463608|NCT01210469|Other|Stretching and balance exercises|The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
45463609|NCT01295593|Drug|valproic acid and 2-chlorodeoxyadenosine|VPA : daily, oral, starting dose 10mg/kg/day total dose, taken in 2 separate administrations of around 5 mg/kg/day each, for a maximum of 6 months CdA : 5.6 mg/m²/day IV during 3 days, every 28 days, for a maximum of 4 cycles
45463610|NCT03845881|Drug|Oxycodone|The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
45463611|NCT03845881|Drug|Placebo Oral Tablet|The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
46012098|NCT01680146|Dietary Supplement|PRO+FAT|
45463612|NCT03849001|Behavioral|Exercise Conditions|Light Exercise
45463613|NCT03849001|Behavioral|Exercise Conditions|Moderate Exercise
45837376|NCT05211180|Behavioral|Vida Sana y Completa|Weekly group or individual education sessions with a health coach, fitness tracking with a fitbit, and weekly food box delivery.
46012099|NCT01680146|Dietary Supplement|PRO|
46012100|NCT01643915|Behavioral|No distraction method|Patients with conventional treatment. No distraction method during the treatment visits.
45463614|NCT03849001|Behavioral|Exercise Conditions|Vigorous Exercise
45463615|NCT03849001|Behavioral|Exercise Conditions|Seated Rest
45463616|NCT01210937|Procedure|CEA and TCD monitoring|All patients will receive carotid endarterectomy. During the surgery, all of them will be monitored by TCD. Record the blood flow velocity and blood pressure on specified time.
45463617|NCT03846661|Device|Physiomesh|difference in risk for recurrence and postoperative complication
45463618|NCT01114685|Dietary Supplement|AlgaeCal-1|Daily consumption of 7 capsules containing bone health ingredients
46012101|NCT01643915|Behavioral|Distraction method|Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.
46012102|NCT01643915|Behavioral|Distraction method|Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
46012103|NCT01680185|Drug|Insulin lispro, Humalog (Eli Lilly) in insulin pump|all covered above
46012104|NCT01680185|Drug|Human insulin isophane, Humulin N (Eli Lilly)|all covered above
46012105|NCT01680185|Other|Standard of care|all covered above
46012106|NCT04486209|Device|transcutaneous spinal cord stimulation|electrical stimulation of the lumbosacral spinal cord through surface electrodes
46012107|NCT01643954|Procedure|robotic radical prostatectomy|robotic assisted surgery
46012108|NCT01680263|Device|Kinesiotaping|"Use of kinesiotaping on the painful area in the form of space correction. Kinesiotaping was repeated for 3 weeks with 1week interval"
46012109|NCT01680263|Procedure|NSAIDs/Physical therapy|Use of non-steroidal anti-inflammatory drugs and 10 sessions of daily physical therapy.
46012110|NCT01601574|Behavioral|Weight Watchers modified program|Weight Watchers: For people with Type 2 diabetes including (1) weekly standard in-person Weight Watchers meetings, (2) use of the standard Weight Watchers online program and tools, and (3) two scheduled telephone consultations with a Certified Diabetes Educator (CDE) who will assist the participant in tailoring the standard Weight Watchers program to accommodate the participant's diabetes-related status, with additional unlimited phone and email access to CDEs at the participant's request
46098406|NCT02387255|Device|Resoundant Driver System|This device is used to generate vibrations at the area of interest. The device has an active driver, a loud speaker sitting outside the scanner area, and a passive driver, which is shaped like a silicone paddle, which is secured with velcro straps to the area being imaged. Sound waves from the active driver travel through a tube attached to the passive driver and generate vibrations, images of which are captured by the MR scanner.
46098407|NCT00999349|Drug|Silymarin (LEGALON)|Study group: Silymarin Capsule, 140 mg, 3 times a day + desferrioxamine injection 50 mg/kg, Placebo group:Placebo capsules Similar to Silymarin +desferrioxamine injection 50 mg/kg
46098408|NCT00999349|Drug|Placebo|
46098409|NCT02621112|Biological|Intradermal HBVv with imiquimod|Intradermal hepatitis B vaccine with imiquimod pretreatment
46098410|NCT02621112|Biological|Intradermal HBVv with aqueous cream|Intradermal hepatitis B vaccine with aqueous cream pretreatment
46098411|NCT02621112|Biological|Intramuscular HBVv with aqueous cream|Intramuscular hepatitis B vaccine with aqueous cream pretreatment
46098412|NCT02693795|Other|Baduanjin exercise|"A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003."
46098413|NCT02693795|Other|aerobic exercise|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located on cardiac rehabilitation centre lasting 3 month. The program is consistent with the current recommended guidelines of moderate intensity exercises for MI.
46098414|NCT04000789|Drug|Sodium Hyaluronate, Vitamin A, Vitamin E|Eye drops consisting of combination of Sodium Hyaluronate, Vitamin A, Vitamin E will be . given to patients in control groups
46098415|NCT02621190|Drug|cabazitaxel|25mg/m2 q3w
46098416|NCT00730834|Device|Oasis|Digital sound player that provides customized acoustic stimulus based on subjects hearing thresholds
46098417|NCT02721797|Procedure|Orthopaedic & Gynaecology surgery|Patients will have the surgery they require for their treatment. During surgery, debrided tissues will be retained for research. No treatment plans will be altered for this research.
45463619|NCT01114685|Dietary Supplement|AlgaeCal-2|Taking 7 capsules a day for six months
45837377|NCT05195268|Procedure|Intracardiac Catheter Ablation|Both arms will receive intracardiac catheter ablation procedures as described.
46012111|NCT01601574|Other|Standard Care group|One session of in-person diabetic nutritional counseling with a registered dietitian, with follow-up written educational materials.
46098418|NCT00697554|Biological|HBV-MPL vaccine 208129|2-dose primary vaccination followed by 1 booster vaccination by intramuscular injection
46098419|NCT00697554|Biological|Engerix™-B|3-dose primary vaccination followed by 1 booster vaccination by intramuscular injection of double doses
46098420|NCT00730990|Other|Positron Emission tomography|Positron Emission tomography scans. Part 1of the study : 4 subjects will receive 2 scans a day for 1 day with PET ligand administered in tracer quantities.
46098421|NCT00730990|Drug|PET Scan with PF-03654746|If none of the data from Cohort 2 is informative, then: 2) an additional 3 subjects will receive 2 Scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746. Doses will be determined based upon the outcome of the first intervention.
46098422|NCT00730990|Drug|PET Scan with PF-03654746|If none of the data from the previous interventions are informative, then: 3) an additional 3 patients will receive 2 scans on Day 1 and 1 scan on Day 2 following three different doses of PF-0365476. Doses will be determined based upon the outcomes of the previous interventions.
46098423|NCT00730990|Drug|PET Scan with PF-03654746|"Part 2 of the study will have 3 possible interventions:~1) 3 subjects in Cohort 2 will receive 2 scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746 (0.5 mg, 1.5 mg, 4 mg)."
46098424|NCT02716571|Other|Leukapheresis or Plasmapheresis|"Leukapheresis: Donate 5x10^9 white blood cells and 400 ml of plasma. Plasmapheresis: Donate 400ml of plasma.~Donated white blood cell and plasma will be manufactured MG4101(allogeneic natural killer cell) to use for Hepatocellular carcinoma(HCC) patients after Transarterial Chemoembolization(TACE)."
46098425|NCT04133454|Drug|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV and IT administration
45463620|NCT01197157|Drug|Placebo|Group A: comprises 100 CHC patients who will receive placebo twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.
46012112|NCT01643993|Other|hCG at the Time of Embryo Transfer|hCG will be included in the 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
46012113|NCT01643993|Other|Control|Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
46098426|NCT00731068|Biological|PRGF|injection of 6cc into injured area of tendon
46098427|NCT00731068|Biological|placebo|injection of 6 cc of saline into injured area
46098428|NCT00866307|Drug|Cyclophosphamide|Given IV
46012114|NCT01601613|Drug|activated recombinant human factor VII|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
46012115|NCT01601613|Drug|placebo|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
46012116|NCT01601730|Drug|Modafinil and Escitalopram|Treatment 4: Modafinil 200 mg + Escitalopram 20 mg
46012117|NCT01601730|Drug|Placebo|Matching oral placebo capsules as control (Treatment 1: Modafinil 0 + Escitalopram 0).
46012118|NCT01601730|Drug|Modafinil|Treatment 2: Modafinil 200 mg + Escitalopram 0.
46012119|NCT01601730|Drug|Escitalopram|Treatment 3: Modafinil 0 + Escitalopram 20 mg.
46012120|NCT01644032|Other|Teleconsultation|Teleconsultation between paramedics and an EMS physician
46012121|NCT01644071|Drug|cipralex|one time 10 mg, tablet
46012122|NCT04528589|Other|prenatal psychotherapy|Prenatal psychotherapy to break intergenerational risk of adverse childhood events
45463621|NCT01197157|Drug|Nitazoxanide|• Group B: comprises 100 chronic hepatitis patients who will receive oral Nitazoxanide 500 mg twice daily with food for an average of 12 weeks followed by the standard of care treatment, peginterferon Alfa 2a once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses plus placebo twice daily for 48 weeks.
45679678|NCT05281666|Device|Absorbable Surgical Gut Suture material|Participants with lacerations below the level of the forearm that meet inclusion criteria and are consented and randomized to this group will undergo washout and laceration repair using absorbable surgical gut suture material. They will be sent home with antibiotics. They will be asked to return to the outpatient hand clinic at 2, 6, and 12 weeks follow-up. Their wound will be assessed by a single observer, utilizing the POSAS and VAS.
46012123|NCT01601769|Device|Vitom|Patients treated and diagnosed by vitom
46012124|NCT01601769|Device|Colposcopy|"a Carl Zeiss colposcope with a magnification power from 4x to 20x, with green filter.~Patients treated by colposcopy"
46012125|NCT01680536|Drug|maraviroc|
46012126|NCT01601808|Drug|Placebo|Orally once a day, continuously throughout the study
46012127|NCT01601808|Drug|Caprelsa (vandetanib)|Orally once a daily, continuously throughout the study.
46012128|NCT01680614|Behavioral|CASI|
46012129|NCT04482153|Device|fibroscan|The Controlled Attenuation Parameter (CAP) can using transient elastography (TE) (Fibroscan®) permits to efficiently separate different grades of severity of steatosis. CAP is based on the properties of ultrasonic signals acquired by the Fibroscan®. It allows to simultaneously measure liver stiffness and CAP in the same liver volume.
46012130|NCT01644383|Behavioral|logotherapy|Logotherapy is therapy during which the interaction between the therapist and the client centres on the topic of meaning. The problems that the clients experience are presented to the client as inseparable parts of his everyday life. The client is then challenged to discover his/her meaning and to take responsibility in facing up to his/her problem. This approach is aimed at helping the client to deal and understand what his /her existences entail.
45463622|NCT01194895|Other|protective ventilation|set tidal volume of 5ml/kg during one-lung ventilation
46012131|NCT01680692|Drug|Ropivicaine|Infusion of local anesthetic for post-operative analgesia.
46098429|NCT00866307|Drug|Cytarabine|Given IT and IV or SC
45463623|NCT01194895|Other|conventional ventilation|keep tidal volume at 8ml/kg during one-lung ventilation
46012132|NCT01680692|Device|Continuous Femoral Nerve Catheter|Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.
46012133|NCT01680692|Device|Continuous Tibial Nerve Catheter|Continuous infusion of local anesthetic delivered through a tibial nerve catheter post-operatively.
46012134|NCT01601925|Other|supine extended position of the neck|we measure the distances from cricoid cartilage to C6 or C7 transverse process in supine neutral and extended position of the neck
46012135|NCT04481880|Diagnostic Test|measuring IAP and respiratory parameters|Effect of IAP on respiratory parameters Correlation between IAP and Gastric and urinary bladder pressures
46012136|NCT01644422|Biological|Autologous Human Platelet Lysate|Study arm A subjects will receive hair follicles transplants that are dipped in HPL before transplant
46012137|NCT01644422|Biological|Autologous Human Platelet Lysate|Study arm B subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection
46012138|NCT01644422|Other|Standard hair follicle transplant|Control arm subject will receive Standard hair follicle transplant
46098430|NCT00866307|Drug|Daunorubicin Hydrochloride|Given IV
46098431|NCT00866307|Drug|Dexamethasone|Given IV
46098432|NCT00866307|Drug|Doxorubicin Hydrochloride|Given IV
46098433|NCT00866307|Other|Laboratory Biomarker Analysis|Correlative studies
46098434|NCT00866307|Drug|Mercaptopurine|Given PO
46098435|NCT00866307|Drug|Methotrexate|Given IT and PO
46098436|NCT00866307|Drug|Pegaspargase|Given IV
46012139|NCT01602003|Drug|LC15-0444 25mg bid|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
46012140|NCT01602003|Drug|LC15-0444 50mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
46012141|NCT01602003|Drug|Sitagliptin 100mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
46012142|NCT01680926|Dietary Supplement|Almased|During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.
46012143|NCT04481529|Other|Health Questionnaire|Completion of a short questionnaire noting the result of the serology and looking for elements in favor of exposure to the virus, whether professional or extra-professional.
46012144|NCT01644461|Other|Autologous Human Platelet Lysate|All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
46012145|NCT01681043|Behavioral|protocol 'Quiet in the room'|"Protocol 'Quite in the room' between 10 p.m. and 6 a.m.~nurse nearby~no visits after 10 p.m.~decreased alarm sound in ventilator and monitor~decreased light intensity~no unnecessary conversations around the patient~medication should be limited to max 1-2 times in this time period~no unnecessary therapeutic or diagnostic procedures in this time period~earplugs and sleep masks"
46012146|NCT01644539|Dietary Supplement|Water with guar gum - Non Caloric|Infusion 500 ml of water with 3 gram of guar gum through a naso-gastric tube directly into stomach during a fMRI scan.
45463624|NCT01211093|Procedure|High frequency whole body vibration|1 single session (10 minutes) of whole body vibration therapy at 30 Hz
45463625|NCT01211093|Procedure|Low frequency whole body vibration|1 single session of whole body vibration therapy at 20 Hz
45463626|NCT01211093|Procedure|control|1 single session of standing on the vibration platform, with no vibration signals delivered.
45679679|NCT05281666|Device|Non-absorbable Nylon Suture Material|Participants with lacerations below the level of the forearm that meet inclusion criteria and are consented and randomized to this group will undergo washout and laceration repair using non-absorbable nylon gut suture material. They will be sent home with antibiotics. They will be asked to return to the outpatient hand clinic at 2, 6, and 12 weeks follow-up. Their sutures will be removed at the 2-week follow-up visit. Their wound will be assessed by a single observer, utilizing the POSAS and VAS.
46012147|NCT01644539|Dietary Supplement|Chocolate milk - Oral Caloric|Ingestion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a tube in the mouth during a fmri scan.
46012148|NCT01644539|Dietary Supplement|Chocolate milk - Intra Gastric Caloric|Infusion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a naso-gastric tube directly into stomach during a fMRI scan.
46012149|NCT01602081|Device|reinforce soft tissue|reinforce soft tissue
46012150|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 20/20/20 μg|Subjects received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
46012151|NCT01193920|Other|Saline solution|Subjects received two injection of saline solution.
46098437|NCT00866307|Drug|Prednisone|Given IV or PO
46012152|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 μg|Subjects received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
46098438|NCT00866307|Radiation|Prophylactic Cranial Irradiation|Undergo radiation
46012153|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 μg|Subjects received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
46012154|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 5/5/5 μg|Subjects received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
46012155|NCT01193920|Other|saline solution|Subjects received one injection of saline solution.
46012156|NCT04480983|Device|Multidetector Computerized Tomography (MDCT)|To evaluate the role of MDCT in diagnosis of non traumatic causes of acute abdomen in pediatric patients with clinical and surgical correlation.
46012157|NCT01681082|Behavioral|Tai Chi training|24 form Yang style Tai Chi. 50 minute sessions, twice weekly.
46012158|NCT04315480|Drug|Tocilizumab|single intravenous administration 8mg/Kg
46012159|NCT01193686|Other|Peer Visitation|Trained Volunteers will visit OEF/OIF Veterans with Polytrauma Injuries to provide support.
46012160|NCT04480515|Other|in-hospital mortality rate|In-hospital mortality rate during pandemic of 2020 will be compared with the in-hospital mortality rate of the last year's same time period
45463627|NCT01296997|Dietary Supplement|calcium phosphate|the subjects consumed for 3 weeks a bread enriched with 1 g pentacalcium phosphate per day
45463628|NCT01296997|Other|placebo|the subjects consumed a bread without pentacalcium phosphate
45679680|NCT05280548|Drug|Venglustat (GZ402671)|Tablet; Oral
45679681|NCT05280548|Drug|Agalsidase alfa|Concentrate for solution for infusion; IV infusion
46012161|NCT01681160|Other|procedure:maggot therapy|each times in maggot therapy continued for three days.wound assessment was done before and after any intervention
46012162|NCT01681160|Other|conventional therapy|patients receive ordinary treatment for diabetic foot
46012163|NCT02886442|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
46012164|NCT02886442|Other|New adhesive strip|This is a newly developed adhesive strip
46098439|NCT00866307|Drug|Thioguanine|Given PO
46098440|NCT00866307|Drug|Vincristine Sulfate|Given IV
46098441|NCT04133298|Procedure|Tunneling with laser de-epithelized gingival graft|After the administration of local anesthesia, the dimension of the needed graft will be marked by a #15c blade and then diode laser de-epithelization will take place. The de-epithelized area will be then harvested using a # 15c blade. The donor site will be covered by cyanoacrylate tissue adhesive dressing .
46012165|NCT01644773|Drug|Crizotinib|"Starting dose level:~Initial Treatment Plan: 130 mg/m^2 per dose~Modified Treatment Plan per Amendment 1.0: 165 mg/m^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): once a day for 28 days~Cycles 2-26 (28 days each): once a day"
46012166|NCT01644773|Drug|Dasatinib|"Starting dose level: 50 mg/m^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): starting on day 3, once a day for 28 days~Cycles 2-26 (28 days each): once a day"
46012167|NCT01602159|Procedure|Open Bypass Surgery|Open Bypass Surgery with Autogenous vein or PTFE Graft
46012168|NCT01602159|Procedure|Angioplasty and Stenting|Angioplasty and Stenting of the superficial Femoral artery with Nitinol stent (Life Stent flexStar Stent System by Bard Inc. Tempe AZ).
46098442|NCT04133298|Procedure|Tunnelingwith subepithelial connective tissue graf|After administration of local anesthesia. A single incision will be made to the bone in a horizontal direction 3mm apical to the gingival margin of the maxillary teeth. The length of the incision will be determined by the dimensions of the graft required. A partial-thickness dissection will be then made within the single incision aiming to harvest an average thickness of two mm subepithelial connective tissue. Then, the graft will be carefully elevated from the palate with the use of the blade. Primary closure will be obtained using 4-0 polyglycolic acid
46098443|NCT00731146|Other|Ultrasound Minimum Effective Anesthetic Volume|Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
46098444|NCT00731146|Other|Nerve Stimulator Minimum Effective Anesthetic Volume|Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
45837378|NCT05118204|Drug|BUP microdose induction|"Participants will be started on a 5-day BUP microdose induction protocol (without stopping full agonists).~Day 1: participants will receive buprenorphine (Belbuca) 225 mcg mg every 12 hours Day 2: participants will receive buprenorphine (Belbuca) 450 mcg every 8 hours Day 3: participants will receive buprenorphine-naloxone 2-0.5 mg every 8 hours Day 4: participants will receive buprenorphine-naloxone 4-1 mg every 8 hours Day 5: participants will receive buprenorphine-naloxone 8-2 mg every 12 hours"
46098445|NCT02716415|Drug|Calmoseptine Ointment|"A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~regular diaper changing,~gentle cleansing~application of the trial ointment"
46098446|NCT02716415|Drug|Destin Maximum Strength 40% Zinc|"A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~regular diaper changing,~gentle cleansing~application of the trial ointment"
46098447|NCT02616354|Drug|Imipenem|Patients in group I received a dose of imipenem/cilastatin 1g each every 8 hours or 0.5g every 6 hours optimized two-step infusion therapy (rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours)
46098448|NCT02569372|Biological|GC1102|GC1102(Recombinant Hepatitis B Human Immunoglobulin)
46098449|NCT00731224|Drug|Rivastigmine transdermal patch|
46098450|NCT00531427|Drug|Buprenorphine|transdermal system 10 and 20 applied for 7-day wear
46098451|NCT00531427|Drug|Placebo|transdermal system (placebo) applied for 7-day wear
46098452|NCT04971551|Drug|Jaktinib Hydrochloride Tablets|Oral on an empty stomach
46098453|NCT00731302|Drug|aspirin and meloxicam|aspirin 81 mg daily then aspirin 81 mg plus meloxicam 7.5 mg daily
46098454|NCT00871728|Drug|Itraconazole|Itraconazole (ICZ) capsule will be administered in 3 cycles (Week 1, Week 5 and Week 9) and each cycle will consist of taking 2 capsules of 100 milligram (mg) each, orally twice daily, continuously for 1 week and then not taking medication for next 3 weeks. Total duration of treatment will be 49 weeks.
45837379|NCT05118204|Drug|TAU|2-day standard BUP induction protocol (with stopping full agonists) Day 1: hold all opioids Day 2: buprenorphine-naloxone 2-0.5 mg every 6 hours Day 3: buprenorphine-naloxone 8-2 mg every 12 hours
46012169|NCT01681199|Drug|Fluvastatin extended release tablet|
46012170|NCT04479345|Other|Questionnaire|Online questionnaire
45679682|NCT05280548|Drug|Agalsidase beta (GZ419828)|Powder for concentrate for solution for infusion; IV infusion
45679683|NCT05280548|Drug|Migalastat|Hard capsules; Oral
45679684|NCT05280366|Device|Streamline Surgical System|Completion of the Streamline Surgical System procedure
46098455|NCT00611273|Device|GFX|The GFX system employs minimally invasive technique utilizing Bi-polar (radio frequency) RF technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
45679685|NCT05280366|Device|iStent Inject W|Implantation of competitor device
45679686|NCT05277194|Behavioral|KeepCalm app|The KeepCalm app is designed to help manage stress and prevent challenging behaviors in children with autism.
45679687|NCT05276739|Behavioral|Bright Light|6.5-hour 10,000 lux light pulse (4100K fluorescent light) centered within the 16-hour wake episode (start 4.75 hour after wake and end 11.25 hour after wake).
46012171|NCT01681316|Drug|Danhong injection|A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
46098456|NCT00731380|Drug|ABI-007|Dose escalation beginning with ABI-007 75 mg/m2 day 1 + day 8, Cisplatin 100 mg/m2 day 1, 5-Fluorouracil (5-FU) 1000 mg/m2/d continuous infusion x 96 hours on day 1-4, for 3 weeks x 3 cycles. Followed by Concurrent weekly Carboplatin (AUC 1.5) with radiotherapy for 7 weeks. Carboplatin should be given on Monday or Tuesday of each week, if possible.
45679688|NCT05276739|Behavioral|Time-restricted eating|6.5-hour restricted meal window (4 meals at 4.75, 6.9, 9.1, 11.25 hours after waking) centered within the 16-hour wake episode.
45679689|NCT05276739|Behavioral|Dim light|dim light (<3 lux) throughout the 16-hour wake episode
45837380|NCT05118204|Behavioral|Linkage to outpatient BUP treatment|Participants will be given an expedited appointment (within 2 weeks) to continue BUP treatment at a Montefiore community health center
45837381|NCT04991454|Drug|129Xe Hyperpolarized|Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC), as is the case for all protocols currently carried out under IND 109,490.
45837382|NCT05108064|Diagnostic Test|Artificial intelligence model|Results of artificial intelligence model will be compared with the gold standard
45679690|NCT05276739|Behavioral|12-h meal window|12-hour restricted meal window (4 meals at 2, 6, 10, and 14 hours after waking) centered within the 16-hour wake episode.
45679691|NCT05275803|Dietary Supplement|Probiotics|The participant would receive non-surgical periodontal treatment, after which the participant uses probiotics (BioGaia Prodentis, L. reuteri DSM 17938+L. reuteri ATCC 5289, 0.8g, qn) for another 30 days.
45679692|NCT05275803|Dietary Supplement|Control|The participant does not use probiotics after non-surgical periodontal treatment.
45679693|NCT05274477|Drug|Fampridine SR|Fampridine SR is an inhibitor of voltage gated potassium channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
46012172|NCT01681316|Other|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
46012173|NCT01681316|Drug|Placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
46012174|NCT01602276|Procedure|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS
46012175|NCT04528394|Radiation|Photon|Photon combined with Carbon ion in Arm 1
46012176|NCT04528394|Radiation|Proton|Proton combined with Carbon ion in Arm 2
46098457|NCT00999427|Drug|Povidone-iodine|Povidone-iodine 10% solution. A piece of 10x10 cm gauze soaked in Povidone-iodine 10% solution wrapped around the index finger of the examiner is inserted into the rectum of the subject in arm A. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin of the prostate gland to the other. The examiner will allow at least 2 minutes to elapse between antisepsis and the insertion of the first needle into the prostate in order to allow the Povidone-iodine to dry.
46012177|NCT04528394|Radiation|Carbon ion|Same dose and fractionation will be used in both arms.
46098458|NCT04189211|Drug|BAT8001|IV infusions.
46098459|NCT00364780|Drug|XL647|XL647 will be administered orally as a single agent. XL647 will be supplied as 50 mg tablets. Subjects in the Intermittent 5 & 9 cohort will receive XL647 at a dose of 350 mg on a 5 days on and 9 days off cycle every 2 weeks for 8 weeks. Subjects in the Daily Dosing cohort will receive XL647 administered daily as a single oral dose of 300 mg. In the absence of progressive disease (PD) and unacceptable XL647-related toxicity, subjects may continue to receive XL647 treatment on their assigned dosing schedule for up to 1 year on this study. Subjects who reach 1 year of treatment with no evidence of disease progression may, with the concurrence of the investigator and the sponsor, continue to receive therapy.
46098460|NCT02716337|Dietary Supplement|Addition of human milk fortifiers according to human milk analysis|
46098461|NCT00994591|Drug|Pharmacokinetic dosing|Pharmacokinetic testing involves dosing with deuterated cotinine which has an associated IND#61329.
46098462|NCT00731458|Device|Optical coherance tomography ( Cirrus; Stratus)|Non-contact retinal thickness analyzer
46098463|NCT02716493|Behavioral|Telerehabilitation program|"The intervention was an 8-week home-based telerehabilitation program (three sessions of about 75 minutes per week) using the eChez-Soi telerehabilitation platform.~Through a unique software interface, the eChez-Soi allows for the following three technological aspects: 1- continuous data acquisition and recording from commercial biometric sensors; 2- continuous transmission of the collected data via the Internet to the clinician's computer, allowing the clinician to visualize the biomechanical and physiological parameters in real time; and 3- a challenging gaming environment with interactive exercises performed on musical rhythms.~In total, 15 supervised sessions and 9 unsupervised sessions were planned for a total of 24 exercise sessions"
46098464|NCT00868998|Drug|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 600 mg/m2/day (maximum dose 2000 mg/m2/day total divided into BID PO doses) Day 4 and 11: Gemcitabine 600 mg/m2 IV over 60 mins Day 4 and 11: Docetaxel 30 mg/m2 IV over 60 mins preceded by 12 mg dexamethasone IV or PO or 4 mg if diabetic
46098465|NCT04000711|Other|Outpatient oral treatment.|Participants allocated in oral outpatient group were discharged home with oral antibiotic to continue management. Participants were given Cefixime oral suspension (100 mg/5 mL). Antibiotic was given to the caretakers with written instructions about dosage and time of administration. Dosage indicated was 8 mg/kg/day to be given orally as a single dose (max dose 400 mg/day). Oral antibiotic treatment was given until documented ANC > 500, failure to treatment (restart of fever) or when 14 days of antibiotic were completed (whichever occurred first).
46098466|NCT04000711|Other|Inpatient intravenous treatment.|Participants allocated in the intravenous inpatient group continued receiving Cefepime 150 mg/kg/day every 8 hours (max dose 2 grams per dose or 6 grams per day) according to local standard of care guidelines. Intravenous antibiotic treatment was given until documented ANC > 500, failure to treatment (restart of fever) or when 14 days of antibiotic were completed (whichever occurred first).
46098467|NCT04131387|Device|LIPUS-1|After installing the disposable treatment head coat, the pelvic floor muscles, ligaments, etc. were treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Treated twice a week for 6 weeks.
46098468|NCT04131387|Device|LIPUS-2|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
46012178|NCT04479462|Procedure|total joint arthroplasty|The surgery includes primary, revision or partial joint arthroplasty.
46098469|NCT04065724|Other|Physical training as resistance and aerobic training.|
46098470|NCT02716181|Device|"Атопик Soothing Cream"|Topical application of a study cream to involved skin areas twice a day.
46098471|NCT02716181|Device|Placebo|Topical application of a study placebo cream to involved skin areas twice a day.
46098472|NCT04001023|Device|Imaging with 18F-EF5 PET/CT|Both 18F-FDG PET/CT and 18F-EF5 PET/CT imaging are performed in 1) preoperative work-up to clarify the disease distribution, 2) before IDS to evaluate treatment response to NACT (IDS arm); targeted samples from hypoxic and non-hypoxic tumors are collected during surgery
46098473|NCT04131153|Procedure|"three-step radiofrequency ablation"|"After destroying the main blood supply of the tumor, extracting the blood in the tumor, reducing the blood flow in the tumor and shrinking the tumor volume, the remaining tumor was then treated with radiofrequency ablation, namely the three-step radiofrequency ablation with one block, two inhalation and three damages."
46098474|NCT04131153|Procedure|radiofrequency ablation|Conventional radiofrequency ablation
46098475|NCT00731536|Other|No intervention|This is an observational study. Medical records of patients with the diagnosis of HSTCL in the PALGA database will be analyzed.
46012179|NCT04528316|Behavioral|Pilates Core Stability Exercises program|"Twenty patients will receive Pilates core stability exercises program ONLY. Total Period: 12 Weeks~Stages: Three stages:~Stage I: Warm-up: consists of four Pilates motions:~Breathing:~Rolling back:~Coccyx-curl:~Hundred breathing:~Stage II: Work-out: consists of twelve Pilates motions:~Single leg stretch:~Straight leg raise:~Basic bridge:~Bridging variation:~Quadruped:~Clap with seal motion~Mermaid twist:~Swimming:~Double leg stretch:~Shoulder bridge:~Swan dive:~Leg full front:~Stage III: Cool-down: consists of three Pilates motions:~Rest position:~Cat with arm/leg extension:~Breathing:"
46012180|NCT04528316|Behavioral|Balance Program|Total Period: 12 Weeks. The designed HUMAC program will work on the modified clinical test of sensory integration of balance (mCTSIB) with eyes open and with eyes closed, the center of pressure (COP) and the limit of stability test (LOS).
45463629|NCT01114841|Drug|Tazarotene Foam|"Patches containing Tazarotene Foam 0.1% will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required."
45463630|NCT01114841|Drug|Vehicle Foam|"Patches containing Vehicle Foam will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required."
45679694|NCT05274477|Drug|Placebo|no active component
45679695|NCT05274282|Other|Animation Therapy|Stop-motion movie shooting process designed for improving attention skill and regulating hyperactive and impulsive behaviours.
45679696|NCT05269498|Device|CORTEXPLORER MED|The CORTEXPLORER MED system is a platform that enables surgical navigation using real-time radiological images of patients. The application software formats patient-specific computed tomography or magnetic resonance images taken before surgery. These are displayed on the screen and through mixed reality from different perspectives (axial, sagittal, coronal, diagonal). Before surgery, the surgeon can then create, save and simulate the course along one or more surgical trajectories. As a visualization aid, the surgeon can also create and edit one or more 3D models of the anatomy. During surgery, the system tracks the position of specific surgical instruments in or on the patient's anatomy and continuously updates the position of the instruments on these images.
45679697|NCT05268016|Drug|ME3183|ME3183 capsule
46098476|NCT00996073|Biological|Lumbar Interbody Fusion with Autograft|Single Dose Autograft Surgical Implantation
46098477|NCT00996073|Biological|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
46098478|NCT00996073|Biological|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
46098479|NCT00996151|Drug|Testosterone MD-Lotion|Single dose Testosterone MD-Lotion 2%
46098480|NCT04131231|Drug|microparticles packaging methotrexate (MPs-MTX)|50ml, intrapleural infusion, day5,6,7,8
46098481|NCT04131231|Drug|recombinant human interleukin-2(rhIL-2)|50ml, intrapleural infusion, day5,8,11
45679698|NCT05268016|Drug|Placebo|Placebo capsule
45837383|NCT05198232|Behavioral|Zumba High Tempo|The Zumba high tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the high-tempo group will be played at full speed; the songs in the high-tempo group will be repeated to ensure an equal amount of time moving for both groups. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
46098482|NCT02716259|Procedure|Scaling and root planing|Two sessions of scaling and root planing under local anesthesia and clorhexidine rinse twice/day, 15 days
46098483|NCT02716259|Procedure|Supragingival prophylaxis|Two sessions of scaling and root planing under local anesthesia and sodium fluoride rinse, twice/day, 15 days
46098484|NCT04131075|Procedure|Coronary Angiography and Multimodal Coronary Physiology Study (FFR, CFR, HMR)|Coronary Angiography according to clinical indication and Multimodal Coronary Physiology Study (FFR, CFR, HMR) for functional assessment of intermediate coronary lesions
46098485|NCT00996229|Behavioral|Caloric restriction|20-30% CR for 6 months
46098486|NCT00996229|Dietary Supplement|Omega-3 (fish oil capsules)|2g/day DHA/EPA capsules for 6 months
46098487|NCT00996229|Dietary Supplement|Placebo|Daily corn oil capsules for 6 months
46098488|NCT00996229|Dietary Supplement|Resveratrol|daily resveratrol for 6 months
46098489|NCT02712671|Radiation|Chest radiograph|A chest radiograph involves the participant standing in front of a film and a low dose of radiation passes through the chest. This will be used to look for evidence of tuberculosis infection.
46098490|NCT02712671|Procedure|Blood interferon gamma release assay|Test of T-lymphocytes' response to exposure with tuberculosis antigens. This test is used for the diagnosis of latent tuberculosis infection and involves a blood sample in lithium heparin tube. It will be performed in an off site laboratory (Oxford Immunotec, Abingdon, Oxfordshire, United Kingdom).
46098491|NCT02712671|Procedure|Tuberculin skin testing (TST)|An intradermal test for latent tuberculosis infection that involves a small injection of purified protein derivative (PPD) from inactivated Mycobacterium tuberculosis. The reaction is interpreted at 48-72 hours by measuring the induration produced.
45463631|NCT01192633|Drug|GVP|"Drug: gemcitabine, vincristine,cisplatin~cisplatin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 vincristine 1.4mg/m2(less than 2 mg), iv, D1 repeat every 3 weeks"
45679699|NCT05267899|Drug|WGI-0301|WGI-0301 is a lipid nanoparticle preparation of Archexin® for the treatment of advanced solid tumors.
45679700|NCT05262556|Drug|NP-101 (TQ Formula)|Oral, five 600mg tabs daily every three weeks for four cycles (21-day cycle), then maintenance for an additional 12 weeks for a total of six cycles.
45679701|NCT05262556|Drug|Nivolumab (3mg/kg)|Intravenously on Day 1 every three weeks for four cycles (maximum dose 360mg once every 3 weeks), then 240mg maintenance every two weeks for six cycles for a total of six months of treatment.
46012181|NCT04528316|Behavioral|Coordination|"Total Period: 12 Weeks. Coordination will be assessed using BOT2, Bilateral coordination (Sub test No.4) composed of 7 items and Upper-Limb coordination (Sub test No.7) composed of 7 items too.~The raw scores are recorded first then it is converted into point scores, then subtest total point score is obtained by adding point scores."
45837384|NCT05198232|Behavioral|Zumba Low Tempo|The Zumba low tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the low-tempo group will be set to three-fourths speed. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
46012182|NCT01644812|Behavioral|Aerobic exercise|
46012183|NCT01644812|Behavioral|Stretching|
46012184|NCT01681355|Other|Infant Formula|Standard cow's milk based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition
46012185|NCT04477902|Other|none - observational|online survey
46012186|NCT01602588|Drug|Hydroxychloroquine|200mg bd from 14 days post surgery until clinical or radiological progression
46098492|NCT02712671|Procedure|Sputum induction for mycobacterial microscopy and culture|Participants will breathe in a nebuliser salt solution (3.5% normal saline) for 15 minutes and asked to cough up a sputum sample. This is undertaken in a negative pressure tent. The sample will be tested for mycobacteria under the microscope and then cultured for 42 days in liquid culture bottles the microbiology laboratory.
46098493|NCT02712671|Other|Mycobacterium tuberculosis polymerase chain reaction testing|Sputum from sputum induction will be tested using the GeneXpert system using polymerase chain reaction to identify genes present in Mycobacterium tuberculosis. This test is performed in a microbiology laboratory and tests for the presence of Mycobacterium tuberculosis in sputum, plus genes associated with drug resistance.
46098494|NCT02712671|Procedure|Spirometry|Participants will be asked to blow into a spirometer to measure how much air they can expel in one second and in a whole breath. This will be repeated six times (three times before inhaling 3.5% saline solution and three times five minutes after breathing 3.5% saline solution). The results will be used to identify those whose airways are sensitive to the solution and to look for the presence of airways disease (asthma or chronic obstructive pulmonary disease).
46012187|NCT01602588|Radiation|Radiotherapy|Short Course radiotherapy
46098495|NCT02614833|Biological|IMP321 (eftilagimod alpha)|In the placebo-controlled, double-blind randomisation stage, paclitaxel + IMP321 at the RPTD will be compared to paclitaxel + placebo
46098496|NCT02614833|Drug|Placebo|In the placebo-controlled, double-blind randomisation stage, paclitaxel + placebo will be compared to paclitaxel + IMP321 at the RPTD
46098497|NCT02614833|Drug|Paclitaxel|Paclitaxel will be given in both treatment arms (classified as Non IMP)
46012188|NCT01681394|Dietary Supplement|Polyphenol-rich cocoa extract|250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)
46098498|NCT05260957|Drug|Mosunetuzumab|"Induction Phase (Days -42 through -7):~1 mg of Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -42.~2 mg of Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -35.~60 mg of Mosunetuzumab administered via intravenous (IV) infusion on (given as per treatment guidelines) on Days -28 and -7.~Consolidation Phase (Day +1 through Day +90): 30 mg IV Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Days +14, +35, +56 and +77."
46012189|NCT01681394|Dietary Supplement|Chocolate cream|
45679702|NCT05262556|Drug|Ipilimumab (1mg/kg)|Intravenously on day 1 of each (21-day) cycle for a total of four cycles only.
45679703|NCT05261503|Other|HEP|The Homeostasis-Enrichment-Plasticity (HEP) intervention group will receive 45 minutes of face-to-face environmental enrichment-based intervention one day per week and online home support once a week for 12 weeks.
45679704|NCT05261503|Other|Traditional Phsical Therapy|The Traditional Physical Therapy group will receive a 45-minute intervention, two days a week for 12 weeks.
45679705|NCT05244070|Drug|BMS-986403|Specified dose on specified days
45679706|NCT05244070|Drug|Fludarabine|Specified dose on specified days
45679707|NCT05244070|Drug|Cyclophosphamide|Specified dose on specified days
45679708|NCT05236777|Drug|Natalizumab|Administered as specified in the treatment arm.
45679709|NCT05231473|Other|Nurse Enhanced Recovery After Surgery participation|Bellvitge University Hospital will include the NEC participation along Enhanced Recovery After Surgery program.
45679710|NCT05222607|Drug|IncobotulinumtoxinA|IncobotulinumtoxinA injections for aesthetic indications.
45463632|NCT01192711|Device|Diabetes Interactive Diary (DID)|DID is both a CHO/insulin bolus calculator, an information technology and a telemedicine system based on the communication between health care professional (physician or dietitian) and patient by SMS messages.
45463633|NCT01113437|Drug|Omalizumab|"Omalizumab or placebo by subcutaneous injections, at 4 weekly or 2 weekly intervals.~Dosage is according to manufacturer's guidance and calculated based on body weight and total serum IgE."
45463634|NCT01113437|Drug|Placebo|"Omalizumab or placebo by subcutaneous injections, at 4 weekly or 2 weekly intervals.~Dosage is according to manufacturer's guidance and calculated based on body weight and total serum IgE."
45463635|NCT01197235|Drug|darbepoetin-α|Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
45463636|NCT01197235|Drug|isotonic saline|Infusion of isotonic saline will be performed 1 hour before angiography
45463637|NCT01114919|Behavioral|Check Your Drinking (CYD)|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
45463638|NCT01114919|Behavioral|Alcohol Help Centre (AHC)|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
45463639|NCT01192789|Drug|Amoxicillin|LHWs treat severe pneumonia with oral amoxicillin at 90 mg/kg/day.
45463640|NCT01192789|Other|Referral to Health facility|LHWs refer the severe pneumonia case to local health facility or private practitioner. In case of refused referral , treat the case with oral cotrimoxazole for 7 days.
45463641|NCT01211171|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
45463642|NCT01211249|Drug|GLPG0259 oral capsule|Two capsules, each containing 25 mg of GLPG0259 (i.e. 50 mg/day), to be given once daily; in case of adverse events the dose may be split over two administrations, or reduced to 25 mg/day (one single capsule)
45463643|NCT01211249|Drug|Placebo|Placebo capsules; two capsules to be taken in the morning, in case of adverse events the dose may be split over two administrations, or reduced to one single capsule
45463644|NCT01211249|Drug|GLPG0259 (Part B)|Capsule, dosage to be established based on results of Part A
45463645|NCT01211249|Drug|Placebo (Part B)|Capsules, dosage to be established after Part A, and matching GLPG0259 (Part B)
45463646|NCT01297075|Behavioral|Outreach visits|The 16 facilitators in the project attend an educational programme designed to provide them with the necessary skills and tools for the task. The facilitators visit general practice clinics from March 2011 until the end of 2012. Each clinic is offered three visits. The facilitator is to act as a change agent who motivates and helps the clinic team in the process of defining common goals, and choosing the appropriate means for achieving them.
45463647|NCT03846973|Drug|Tranexamic Acid|intravenous infusion of 1 g infusion to be given and completed over 8 h in the hospital
45463648|NCT03846973|Other|Placebo|placebo (normal saline) infusion to be given and completed over 8 h in the hospital
45463649|NCT01328639|Other|TeamCare Depression Intervention|The TeamCare-PCN intervention involves a registered nurse Care Manager (CM), who coordinates collaborative team management for patients with diabetes and depression. The goal of the intervention is to reduce depressive symptoms, achieve targets for cardio-metabolic measures and improve lifestyle behaviours. The intervention includes three phases: (1) managing depression and improving depressive symptoms, (2) managing diabetes and controlling blood glucose, blood pressure and cholesterol, and (3) improving lifestyle behaviours such as healthy eating, physical activity and smoking cessation.
45463650|NCT01328639|Other|Usual diabetes and depression care|Usual care of diabetes and depression involves providing care by the family physician based on usual standards of care and available clinical practice guidelines. Usual care does not involve additional active support from the Care Manager.
45679711|NCT05219513|Drug|RO7443904|RO7443904 will be administered by subcutaneous (SC) or IV infusion on Cycle (C) 1 Day (D) 10, C2D3, and C2D8. From C3 onward, RO7443904 will be given every 3 weeks (Q3W), for up to 12 cycles (C = 21 days).
45679712|NCT05219513|Drug|Glofitamab|Glofitamab will be administered through IV infusion starting with step-up dosing (2.5 mg/10 mg/30 mg) on C1D1, C1D8, and C2D1. Starting in Cycle 3, glofitamab will be given in 30 mg doses every three weeks (Q3W) with RO7443904, for up to 12 cycles (Cycle = 21 days).
46012190|NCT04477824|Diagnostic Test|Diagnostic imaging|Ultrasonography, computerized tomography, magnetic resonance imaging
46012191|NCT01681550|Drug|Incretin-based therapy|
46012192|NCT01645085|Drug|MCC-based 13% drug loaded tablets|50mg tablets, dosed as 2 tablets (100mg total)
45463651|NCT01115075|Other|Dietary fat/intake of carbohydrate|Spontaneous intake of fat, carbohydrate, protein and alcohol each day for 17 days.
45463652|NCT01115075|Behavioral|Spontaneous oscillations of dietary fat/intake of carbohydrate in relation to energy intake.|Dietitians and senior level or graduate level dietetics students who are not restrained eaters to participate in food intake over 17 days. During this same time interval, integrated energy expenditure will be recorded using doubly-labeled water and day to day energy expenditure by accelerometer. Periodic blood sampling for leptin will be done completed at site intervals.
45463653|NCT01113515|Drug|Esmolol hydrochloride|
45463654|NCT01113515|Drug|Esmolol hydrochloride|
45679713|NCT05219513|Drug|Obinutuzumab|Obinutuzumab will be administered once through IV infusion, at a 1 g dose in Cycle 1, on either Day -7, -4, or -3 (C1D-7, C1D-4, C1D-3).
45679714|NCT05219513|Drug|Tocilizumab|Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
45679715|NCT05205486|Drug|Cefazolin 3gm for Injection USP and Dextrose Injection USP|Cefazolin 3gm for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur once as a 30 minute IV infusion prior to surgery in adult subjects weighing >/= 120 kg
45837385|NCT05175690|Diagnostic Test|Diagnostic Software as Medical Device|"AudibleHealth Dx is an investigational Dx SaMD consisting of an ensemble of software subroutines that interacts with a proprietary database of signal data signatures (SDS) using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. The intended use for the AudibleHealth Dx AI/ML-based Dx SaMD using FCV-SDS is for the diagnosis of acute and chronic illnesses.~The AudibleHealth Dx is a cloud-based AI/ML (locked ML) diagnostic software as medical device (Dx SaMD) with a mobile app based graphical user interface (GUI) designed to operate with COTS Android Operating System (OS) and Apple OS based mobile devices. The AudibleHealth Dx system uses a forced cough vocalization (FCV) signal data signature (SDS) to diagnose COVID-19 illness in ambulatory adults. Results are sent to ordering physicians, State Health Departments, and participants using Health Level 7 (HL7) compliant communication protocols."
45837386|NCT04961658|Biological|GEM00220|Cryopreserved allogeneic, enhanced MSCs administered as a single intravenous infusion
45463655|NCT01113515|Drug|Esmolol hydrochloride|
45463656|NCT01113515|Drug|Placebo gel|
45463657|NCT01195051|Other|Electronic medication reconciliation|A new, computer-based application will be used to document and prescribe outpatient medications in the inpatient setting.
45463658|NCT01195129|Device|MicroVention Hydrogel coil|Micro Vention Hydrogel Coils
45463659|NCT01195129|Device|Non-hydrogel coils|Cerecyte or bare platinum coils
45463660|NCT01211327|Drug|Cyclosporine A|Cyclosporine 2% eye drops
45463661|NCT01211327|Drug|Dexamethasone|Dexamethasone 0,1% eye drops
45463662|NCT05601895|Drug|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
45463663|NCT01113671|Drug|Vitamin E (d-alpha-tocopheryl acetate)|100% natural source d-alpha-tocopheryl acetate in a soft gel cap
45679716|NCT05202262|Drug|BFF MDI 320/9.6 μg|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 320/9.6 μg
45679717|NCT05202262|Drug|BFF MDI 160/9.6 μg|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg
45679718|NCT05202262|Drug|BD MDI 320 μg|Budesonide MDI (BD MDI), 320 μg
45679719|NCT05202262|Drug|Open-label Symbicort TBH 320/9 μg|Open-label Symbicort Turbuhaler 320/9 μg
45679720|NCT05201833|Behavioral|Telephone Outcome Assessment|Assessments will be administered over the telephone to evaluate participant outcome status
45679721|NCT05201833|Behavioral|In-Person Outcome Assessment|Assessments will be administered to evaluate participant outcome status
45679722|NCT05201833|Procedure|3T Magnetic Resonance Imaging (MRI)|Participants will be asked to complete a 3T MRI
45679723|NCT05201833|Procedure|Blood Draw|Blood Draw for Plasma, DNA, Serum, RNA
45679724|NCT05195138|Behavioral|Mindfulness-Based Diabetes Education|Mindfulness-Based Diabetes Education described in study arm.
45679725|NCT05195138|Behavioral|Standard Diabetes Self-Management Education (DSME)|Standard DSME described in study arm.
45679726|NCT05181618|Drug|Emicizumab|The emicizumab dosing regimen will be 3 milligrams per kilogram of body weight (mg/kg) subcutaneously (SC) once a week (QW) for 4 weeks followed by participant preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W) in agreement with the investigator.
45679727|NCT05177354|Device|Inceptiv|Implantable Neurostimulator with Neuro Sense
46012193|NCT01645085|Drug|Mannitol-based 38% drug-loaded tablet|One 100mg tablet
46012194|NCT01645085|Drug|MCC-based 13% drug loaded tablets|3 tablets (150mg total)
45463664|NCT01113671|Drug|Placebo|includes inactive Ingredients
45463665|NCT01113827|Dietary Supplement|Olive Extract|Capsule form ingested 1x/day for 6 weeks
45463666|NCT01113827|Dietary Supplement|Placebo|Placebo
45463667|NCT01207817|Other|Pupillometry|Pupillometry readings will be taken at low, intermediate and high ambient light
46012195|NCT01645085|Drug|Mannitol-based 38% drug-loaded tablet|One 150 mg tablet
46012196|NCT01602627|Drug|Hsp90 inhibitor AUY922|Given IV
46012197|NCT01602627|Other|pharmacological study|Correlative studies
46012198|NCT01602627|Other|laboratory biomarker analysis|Correlative studies
45463668|NCT01195207|Biological|CNTO 3157 or placebo|0.003 mg/kg CNTO 3157 or placebo infusion
45463669|NCT01195207|Biological|CNTO 3157 or placebo|0.03 mg/kg CNTO 3157 or placebo infusion
45463670|NCT01195207|Biological|CNTO 3157 or placebo|10 mg/kg CNTO 3157 or placebo infusion
45463671|NCT01195207|Biological|CNTO 3157 or placebo|0.01 mg/kg CNTO 3157 or placebo infusion
45463672|NCT01195207|Biological|CNTO 3157 or placebo|1 mg/kg CNTO 3157 or placebo infusion
45463673|NCT01195207|Biological|CNTO 3157 or placebo|3 mg/kg CNTO 3157 or placebo infusion
46012199|NCT01602783|Other|11C Acetate Imaging|Single scan
45463674|NCT01195207|Biological|CNTO 3157 or placebo|0.3 mg/kg CNTO 3157 or placebo infusion
45463675|NCT01195207|Biological|CNTO 3157 or placebo|0.1 mg/kg CNTO 3157 or placebo infusion
45679728|NCT05168813|Biological|Moderna mRNA-1273|COVID-19 vaccine (mRNA-1273) developed by Moderna, Inc. is a lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available).
45679729|NCT05168813|Biological|Vaccine 3 Dose|COVID-19 mRNA vaccine in 100 mcg dose given as IM injection into the deltoid muscle on Day 1, Day 29, and Day 169.
46012200|NCT01645124|Drug|Hydroxyurea|
46012201|NCT01645124|Procedure|Phlebotomy|
46012202|NCT01602861|Drug|Spironolactone|"One tablet per day (25 mg Spironolactone/placebo) for the first three months. Subsequently dosage is increased to two tablets per day (50 mg Spironolactone/placebo) for the rest of the study.~In case of hyperkaliemia (>5,5 mmol/L) or intolerable side effects dosage will be reduced to one tablet per day (25 mg Spironolactone/placebo)."
46012203|NCT01602861|Drug|placebo|
46012204|NCT01681667|Drug|Ibuprofen|ibuprofen liquid 400mg vs. ibuprofen tablet 400mg
46012205|NCT04474977|Other|Microvascular Decompressive Surgery|Microvascular decompression for hemifacial spasm
46012206|NCT01645163|Behavioral|Counselling using mobile phones|Feasibility and acceptability of using mobile phones to improve complementary feeding practices.
46012207|NCT01600365|Drug|Ophthalmic gel (placebo)|Ophthalmic gel (placebo): applied in affected eye 4 times daily for 10 days
46012208|NCT01600365|Drug|Ganciclovir|Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
46012209|NCT01602900|Drug|GSK356278|Investigational Medicinal Product
46012210|NCT01602900|Drug|Rolipram|Challenge Agent
46012211|NCT01645202|Procedure|Transcatheter Aortic Valve Implantation (TAVI)|Comparison of different types of valves
46012212|NCT01645241|Drug|gonadotropins plus GnRH antagonists|
46012213|NCT01645241|Drug|ganirelix|
46012214|NCT01602939|Drug|Cladribine and pegylated interpheron alpha-2a|"Cladribine (0.07 mg/Kg/day) s.c for 5 consecutive days each month for a total of 6 months.Cladribine daily doses could be increased up to 0.14 mg/Kg in the fourth, fifth and sixth cycles of therapy if no objetive response is achieved after the third cycle.~Pegylated Interpheron alpha-2a (1 mcgr/Kg) s.c weekly for a total of 6 months."
46012215|NCT04528745|Diagnostic Test|Bio Impedance Spectroscopy (BIS)|Determination of fat free mass by BIS
46012216|NCT04528823|Other|Strategy 2: Symptom screen, Genexpert and TST|Participants follow an algorithm similar to the standard care, however participants with positive symptom screen and/or positive TST will receive GX (i.e., GX replaces CXR in standard care algorithm). GX positive are considered to have active TB. TST positive and GX negative receive LTBI treatment. If an individual is not able to provide sputum, they will undergo a CXR.
46098499|NCT05260957|Drug|Polatuzumab|"Induction Phase (Days -42 through -7): 1.8mg/kg of Polatuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -28.~Consolidation Phase (Days +1 through +90): 1.8mg/kg of Polatuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Days +35, +56 and +77."
46098500|NCT05260957|Biological|CAR-T Cell Therapy|Participants will receive CAR-T Cell therapy via infusion on Day 0 (given as per treatment guidelines). Prior to CAR-T Cell Therapy, participants will begin receiving lymphodepleting chemotherapy on Days -5 through -3 (given as per treatment guidelines).
46098501|NCT00999505|Drug|Amantadine|Amantadine 200mg twice a day over 12 weeks
46012217|NCT04528823|Other|Strategy 3:Symptom screen, CXR but NO TST|Participants will receive symptom screening and CXR. No TST will be performed. If CXR abnormal or symptom positive, they undergo microbiological investigation. If the CXR is normal, and/or microbiological investigations negative - they receive LTBI treatment as per national guidelines. If microbiological investigation is positive they will be offered treatment for active TB.
46012218|NCT04528784|Device|Transcutaneous tibial nerve stimulation|Transcutaneous tibial nerve stimulation is a non-invasive electrical stimulation of the posterior tibial nerve, a branch of the sciatic nerve via sacral plexus. In our study the tibial nerve will be stimulated using Transcutaneous Electrical Nerve Stimulation (TENS) unit with two surface adhesive electrodes. The anode will be positioned between 5-10 cm above medial malleolus and posterior to the edge of the tibia and the cathode will be positioned distally on arch of the foot .
46098502|NCT00999505|Drug|Placebo|Placebo capsules twice a day over 12 weeks
46098503|NCT04920929|Device|Hydrophilic Biomaterial|PICC made out of a Hydrophilic Biomaterial
45679730|NCT05168813|Biological|Vaccine 2 Dose|COVID-19 mRNA vaccine is to be administered as IM injection into the deltoid muscle on Day 1 and Day 169.
45679731|NCT05167409|Drug|Evorpacept (ALX148)|IV QW
45679732|NCT05167409|Drug|Cetuximab|IV QW
46098504|NCT04920929|Device|Thermoplastic Polyurethane|PICC made out of a thermoplastic polyurethane material
46098505|NCT04130763|Biological|FMT capsule|FMT capsules administration starts in the first week of enrollment. Capsules are taken for three consecutive days in the first week. From week 2, anti-PD-1 therapy will be administrated in combination with the maintenance dose of FMT treatment once every two weeks for up to 6 times.
46098506|NCT00996385|Drug|Velcade (bortezomib) plus Eloxatin (oxaliplatin)|One cycle is defined as an interval of 28 days. A cycle is comprised of four treatments of Velcade (Bortezomib) 1.3 mg/m2 given on days 1, 14, 15, and 18 and two treatments of Eloxatin (Oxaliplatin) 85 mg/m2 on days 4 and 18.
46098507|NCT02616276|Other|Control breakfast|It consists of 350 ml of water at room temperature.
45679733|NCT05167409|Drug|Pembrolizumab|IV Q3W
45679734|NCT05161195|Drug|Ribociclib|Participants continue ribociclib as was administered in their parent study
46012219|NCT01600404|Drug|antimuscarinic treatment|
46012220|NCT01600443|Device|LoFric|Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.
46098508|NCT02616276|Other|High glycemic index breakfast|It consists of 350 ml of water at room temperature, 200 ml of grape juice (with 136.28 kcal), 40 g of white bread (2 slices of 52.2 kcal each) and 29 g of strawberry jam (with 127.52 kcal); providing a total of 368.2 kcal.
46098509|NCT02616276|Other|Low glycemic index breakfast|It consists of 350 ml of water at room temperature, a 150 g apple (with 81.12 kcal), a 125 g low-fat natural yogurt (with 56.10 kcal), 3 shelled walnuts (with 38.94 kcal per unit) and 17.5 g of 72% black chocolate (with 102 kcal); supplying a total of 356.04 kcal.
46098510|NCT04130841|Procedure|Internal Limiting Membrane Peeling|After removal of the epiretinal membrane, indocyanine green staining will be used to determine the internal limiting membrane (ILM) peeled off with the epiretinal membrane. (Group 1: spontaneous ILM peeling) If it is confirmed that the internal limiting membrane is not peeled together, the investigators determine whether the active Internal limiting membrane peeling is performed by 1:1 randomization immediately during surgery. (Group 2: Active ILM peeling, Group 3: no ILM peeling) The outcomes of the three groups will be compared.
46098511|NCT02716103|Other|blood collection|
46012221|NCT01600443|Device|SpeediCath|Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.
46012222|NCT01600443|Device|SpeediCath Compact Male|Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.
46012223|NCT01681823|Dietary Supplement|PectaSol-C Modified Citrus Pectin (MCP)|Oral administration of PectaSol-C MCP (4.8 grams in six capsules three times a day away from food).
46012224|NCT01603017|Device|MRI therapy|5 treatments with magnetic field delivered to knee (n=50)
46098512|NCT02716103|Other|bone marrow collection|
46012225|NCT01603017|Device|MRI therapy (off)|5 treatment where MRI therapy machine was switched off (both patient and therapist blinded to this by use of electronic 'prescription cards'). (n=50)
46098513|NCT00999583|Drug|EPOETINE ALPHA|5 injections of 40000 UI of EPO
46012226|NCT01681862|Behavioral|Personal Health Record|"Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications Your Guide to Lowering Blood Pressure and Facts about the DASH Eating Plan."
46012227|NCT04474782|Diagnostic Test|There is not an intervention|There is not an intervention
46012228|NCT01681901|Procedure|ultrasound imaging|Undergo ultrasound
46012229|NCT01681940|Drug|Lamazym|ERT, i.v. infusions weekly
46012230|NCT01603134|Drug|Allopurinol|300 mg tablet once a day
46012231|NCT01603134|Drug|Allopurinol|300 mg tablet once a day
46012232|NCT01603173|Drug|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
46012233|NCT01603173|Drug|Quetiapine Fumarate|25 mg tablet once a day
46098514|NCT00999583|Other|Control arm|Usual take care of cardiac arrest
46098515|NCT02614599|Drug|BP22042013|This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
45679735|NCT05161195|Drug|Letrozole|Participants continue ribociclib in combination with letrozole as was administered in their parent study
46012234|NCT01645358|Device|Helmet (Starmed)|The helmet is a kind of interface similar to a hood to deliver NIV
46012235|NCT01645358|Device|Total Face mask (Respironics)|"The total face mask is the classical interface for NIV delivery"
46012236|NCT01603212|Drug|Vemurafenib|"Phase I Starting dose: 720 mg by mouth twice a day for a 21 day cycle.~Phase II Starting dose: Maximum tolerated dose (MTD) from Phase I."
46012237|NCT01603212|Drug|IL-2|"Phase I Starting Dose: 7 million IU/m2 by vein on Days 2 - 5 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I."
46012238|NCT01603212|Drug|Interferon Alpha-2b|5 million U/m2 subcutaneously on Days 1 - 5 of a 21 day cycle.
46098516|NCT02614599|Dietary Supplement|Low carbohydrate diet|the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
46098517|NCT02716025|Procedure|Upper gastrointestinal endoscopy|Thorough examination of the esophagus, stomach and duodenum to the second part was done to all patients using Olympus CV-150 or Pentax EPM-3500.
46098518|NCT00533845|Drug|On-Q Pain Pump|Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally
46012239|NCT01645436|Other|exercise training|The intervention group will participate in combined inpatient physical training (aerobic + strength) over neoadjuvant chemotherapy. The intervention will include three weekly exercise sessions of 60-90 minutes, and will be held in child's room or in a pediatric gym specifically enabled on the aforementioned hospital, depending on the children's health status.
46012240|NCT01645748|Drug|S-1|S-1 is an oral fluoropyrimidine derivative, based on the concept of biochemical modulation. It consists in a molar ratio of 1:0.4:1: tegafur, a prodrug that is slowly metabolized to 5-fluorouracil; gimeracil, which reversibly inhibits dihydropyrimidine dehydrogenase. In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively.
46098519|NCT04295915|Device|Specimens that meet inclusion criteria|Specimens that have been de-identified and considered remnant by the laboratory (fresh specimens) or were contrived by the laboratory (using bacterial isolates with no identifying information) can be enrolled into the study.
45463676|NCT03943043|Drug|nab-paclitaxel|"Phase I dosing regimens:~The dose of treatment will be assigned at the time of enrolment in one of these 3 subsequent dose-levels:~- 1° level: gemcitabine 800 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 80 mg/m2 0° level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 100 mg/m2~level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 125 mg/m2~level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 150 mg/m2 each administered on day 1, every 14 day~Phase II:~Gemcitabine plus oxaliplatin plus nab-paclitaxel according to RP2D."
46012241|NCT01645748|Drug|S-1|Chemotherapy was comprised of docetaxel 30 mg/m2 on days 1 and 8, cisplatin 60 mg/m2 on day 1, and S-1 70 mg/m2 on days 1 to 14, with the regimen repeated every 21 days
46098520|NCT04000867|Device|Transcutaneous Magnetic Stimulation (TCMS)|The study will evaluate whether an experimental medical device that emits a series of brief, intense magnetic pulse called TCMS will relieve foot pain from Diabetic Neuropathy (DN) when compared to the same device giving a sham treatment without magnetic pulses. Participants will be blindly randomized into either the TCMS treatment group or the sham treatment group according to the number 1-20 that they draw. This is necessary to further investigate this TCMS treatment and to determine how to obtain statistically significant data as to whether this therapy reduces the foot pain caused by diabetic neuropathy.
46012242|NCT01645748|Drug|S-1|In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively. Another phase II study of TPS as induction chemotherapy for locally advanced HNSCC was determined to be 70/70/60 mg∙m2/d every 3 weeks. However, the rate of grade 3-4 neutropenia was 75% at this recommended dose. To reduce the hematologic toxicities, we used the docetaxel weekly. Therefore following regimen was evaluated in this study; docetaxel 30 mg/m2 (D1, D8), cisplatin 60mg/m2 (D1), S-1 70mg/m2 (D1-D14) every 3 weeks.
46012243|NCT02484924|Drug|Ticagrelor|No intervention- purely observational
46098521|NCT02752763|Drug|%40 diluted Autologous serum|Serum that obtained after centrifugation of blood sample
46098522|NCT02752763|Drug|Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)|Preservative free artificial tears is a group naming for drops commonly used for drye disease
46098523|NCT00857649|Drug|Memantine|20 mg Oral Tablets Once Daily
45463677|NCT01109927|Drug|Insulin|Insulin treatment in accordance to glucose values
46012244|NCT01645826|Drug|Diltiazem Hydrochloride|The study agent will be diltiazem and will start at 60 mg po BID then titrated up very two weeks until at a maximum maintenance dose of 180mg po BID for six weeks.
46098524|NCT00857649|Drug|Placebo|Oral Tablets Once Daily
46098525|NCT02712749|Device|Sound with Binaural Beats|Acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz generated by the special program Gnaural in stereo option
46098526|NCT02712749|Device|Sound without Binaural Beats|Acoustic frequencies of 256 Hz in both ears to perceive one tone without beats generated by the program Gnaural in mono option
46098527|NCT02752841|Dietary Supplement|Nutritional vitamin D repletion and maintenance|Ergocalciferol (50,000 IU weekly for 12 weeks) for vitamin D repletion, ergocalciferol (50,000 IU monthly) or cholecalciferol (1000 IU daily) for maintenance of vitamin D
46098528|NCT04119219|Procedure|Intravitreal injection|Intravitreal injection to the regimen pro re nata.
46098529|NCT03971669|Drug|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
46098530|NCT00857415|Drug|florbetapir F 18|Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
46098531|NCT00611429|Behavioral|Counseling sessions|The individual counseling sessions will last 60 minutes and will involve discussion about health care options and information on the latest advances in HIV treatment.
45463678|NCT01211795|Drug|topical intraoral ketoprofen gel|20% ketoprofen oral gel is applied once daily by cotton swab to a branch of the trigeminal nerve on the maxillary gingival mucosa above the 2nd and 3rd molars. The swab is held in place for 2 minutes at the same time once daily.
45679736|NCT05161195|Drug|Anastrozole|Participants continue ribociclib in combination with anastrozole as was administered in their parent study
46098532|NCT00611429|Behavioral|Group workshop|During the 3-hour group workshop, doctors, nurses, and case managers will talk to participants about HIV treatments and what it is like to undergo treatment. Participants will also hear from other people with HIV and their experiences with treatment.
46012245|NCT01645826|Drug|Sugar Pill|The placebo group of patients will be treated with sugar pill PO bid and return every two weeks for next titration dose (actually will be an unchanged concentration).
46012246|NCT01645865|Behavioral|Control|Health facilities where PMTCT services are available in the traditional clinical setting with HIV testing and counseling, PMTCT support, and enrollment in care and treatment.
46012247|NCT01645865|Behavioral|Intervention|In addition to the 'Standard of Care', HIV-infected pregnant women and male partners within the PMTCT program are engaged in multi-directional mobile communication for PMTCT promotion with health care providers.
46012248|NCT01645904|Behavioral|Audiotaped Focus Group|Participation in a focus group regarding web-based program designed to improve communication of health and health history information among family members affected by Lynch syndrome.
45463679|NCT01211795|Other|Placebo Gel|An identical oral gel, without ketoprofen, or 'placebo gel' is applied using a cotton swab, once daily to a branch of the trigeminal nerve on the maxillary gingival mucosa. It is held in place for 2 minutes, once daily.
46012249|NCT01645904|Behavioral|Demographic Questionnaire|Complete questions about demographics (age, race, marital status) and medical history. This visit should take about 1 hour to complete.
46012250|NCT01645904|Behavioral|Audiotaped Interview|"Group 2: Patients provide feedback regarding initial version of My Family Garden website.~Group 3: Patients provide feedback regarding final version of My Family Garden website."
46012251|NCT01645904|Behavioral|WAMMI Inventory|Patients complete Website Analysis and MeasureMent Inventory. This visit should take about 90 minutes to complete.
46012252|NCT01645943|Procedure|Coronary angiogram|Routine coronary angiogram and revascularization if indicated
46098533|NCT02715869|Drug|A pharmacologic cardiac preconditioning (Sevoflurane)|A Patients are anaesthetized by Sevoflurane more than 1 mac.
45679737|NCT05161195|Drug|Goserelin|Participants continue ribociclib in combination with goserelin as was administered in their parent study
45679738|NCT05161195|Drug|Tamoxifen|Participants continue ribociclib in combination with tamoxifen as was administered in their parent study
45679739|NCT05161195|Drug|Fulvestrant|All participants continue ribociclib in combination with fulvestrant as was administered in their parent study
45679740|NCT05156164|Device|Kinesio Tape Group|The application of the KT consists of 6 strips of I-shaped tape adhered to the skin areas of the shoulder
46012253|NCT01600521|Drug|A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs|The comparisons of the efficacy and safety of the following treatments for rheumatoid arthritis: paeoniflorin (PAE) + Cervus and Cucumis polypeptide injection (CCPI), methotrexate (MTX) + leflunomide (LEF), and MTX + LEF + CCPI.
46012254|NCT01646060|Device|CM-1500|Blood Volume Monitor
46012255|NCT01607034|Drug|Dexpramipexole|150 mg single dose
46012256|NCT01646099|Behavioral|Internet-based sun protection education|Prior to summer, KTRs who agree to participate will receive a text message with their access code to the Internet intervention to access from their homes on a personal device. After online completion of baseline assessments, participants will be randomized to receive the intervention or general skin care information (control). Following the initial use, the participants may revisit the Internet intervention on a personal device or at the doctor's office on a tablet PC. Over the next 6 weeks, sun protection text reminders will be sent to intervention KTRs' cell phones and they will respond that they read the message. Control participants will receive text messages about general skin care.
45463680|NCT01193023|Other|Pressure Support|Ventilation under pressure support
46012257|NCT01603251|Drug|Artemether-lumefantrine combination|Artemether-Lumefantrine (AL)combination; a placebo is given together with the first and fifth dose of AL
45463681|NCT01193023|Device|NAVA|Ventilation under NAVA
46012258|NCT01603251|Drug|Artemether-lumefantrine combination + single dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given once together with the first dose of AL. A placebo is given together with the fifth dose of AL.
45463682|NCT01207895|Device|PET imaging with [18F]-FLT|Up to three [18F]-FLT PET scans; one before beginning treatment, one at week three of treatment, and one at week 11, after completion of treatment but prior to surgery.
45463683|NCT01207895|Drug|[18F]-fluorodeoxythymidine|[18F]-fluorodeoxythymidine is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
45463684|NCT01193179|Drug|OPC-262|Oral administration of tablets for 52 weeks
46012259|NCT01603251|Drug|Artemether-lumefantrine combination + repeated dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given together with the first and fifth dose of AL.
46012260|NCT01646294|Drug|YM178 modified release (OCAS)|oral
46012261|NCT01646294|Drug|YM178 immediate release (IR)|oral
46012262|NCT01603329|Other|Increasing Medication Adherence through Physician Incentives and Messaging|"There are two treatments:~Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication.~Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes.~When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. For half of the arms, the investigators will make the patient sheets a bright, non-white, color, in order to further draw the physicians' attention to that specific paper in their chart."
46012263|NCT01193608|Drug|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
46012264|NCT01193608|Drug|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
46012265|NCT01193608|Drug|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
46012266|NCT01193608|Drug|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
46012267|NCT01193608|Drug|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
46012268|NCT01193608|Other|Placebo|Placebo, IV
46012269|NCT01646333|Behavioral|Memory and Problem-Solving Intervention|8 weekly 1 hour sessions of memory compensation and problem-solving strategies
46012270|NCT01646333|Behavioral|Supportive Therapy|8 weekly 1 hour sessions of non-directive supportive therapy.
46012271|NCT01603446|Drug|L-Arginine|NOW® L-Arginine powder
46012272|NCT01607151|Other|Normothermia|72 hours of targeted temperature management to achieve normothermia (36-37°C)
46098534|NCT02715869|Procedure|B ischeamic preconditioning|B ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
46098535|NCT00532441|Drug|Erlotinib|Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28
45463687|NCT01110083|Drug|EMD 1204831|Subjects will receive EMD 1204831 twice a day for 21 days during each treatment cycle
45463688|NCT03943355|Other|Patient before cohort (2005-2010)|The NOM protocol with AE was recognized and accepted after our previous study reported in 2004.
45463689|NCT03943355|Other|Patient after cohort (2011-2016)|The protocol of NOM became more aggressively and strictly adhered to since 2011.
45463690|NCT01110161|Device|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
45463691|NCT01193491|Drug|IPI-493|Capsules, ascending dose, multiple schedules
45463692|NCT01110317|Drug|paliperidone palmitate 100 mg|Patients will receive a single paliperidone palmitate 100 mg equivalent injection in the gluteal or deltoid muscle on Day 1, 8, 36, and 64.
46012273|NCT01607151|Other|Hypothermia|72 hours of targeted temperature management to achieve hypothermia (32-34°C)
46012274|NCT01646372|Other|Standard Simulation Based ACLS Refresher Teaching|45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by practice simulated megacodes
46012275|NCT01646372|Other|Cognitive Aid based ACLS Refresher training|45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by simulated ACLS megacode practice focused on the use of Cognitive Aids to guide management.
46098536|NCT00532441|Drug|Docetaxel|Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15
46098537|NCT04118985|Behavioral|Cognitive rehabilitation and health behavior change intervention|Cognitive rehabilitation and health behavior change intervention in a group-based program intervention compared to self-implementation of techniques without these interventions
46012276|NCT01603563|Behavioral|Stepped Care TF-CBT|Stepped Care TF-CBT patients will receive step one: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together), scheduled weekly phone meetings (15 minutes), and information from the National Child Traumatic Stress Network website (via web or paper for those without access). Children who do not meet responder status will receive step two: 9 (1 to 1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks.
46012277|NCT01603563|Behavioral|Standard TF-CBT|Standard TF-CBT patients will receive 12 (1 to 1.5 hr.) standard weekly in-office therapist-directed sessions over 12 to 14 weeks (Phase II only). The 2 additional weeks allow for scheduling difficulty. Standard TF-CBT includes child, parent and conjoint parent-child sessions addressing the core trauma treatment components discussed in section a.3 (e.g. stress management, skill building, gradual exposure, & trauma narrative etc.).
45463693|NCT01207973|Drug|BI 113823|5 dose-groups of multiple oral doses of BI 113823
45463694|NCT01197313|Other|Home-based exercise|
45463695|NCT03943121|Procedure|Steroid-eluting stent implant|After endoscopic bilateral sinus surgery, the Steroid-eluting stents were randomly implanted in one side of the sinus.
45463696|NCT03943121|Procedure|Without Steroid-eluting stent implant|After endoscopic bilateral sinus surgery, the Steroid-eluting stents were randomly implanted in one side of the sinus. And the side without the stent is defined as the control side.
45463697|NCT05600803|Procedure|Single-operator cholangioscopy|SpyGlass (Boston Scientific Co, Marlborough, USA) which enabled the direct visualization of the pancreaticobiliary system for the evaluation of intraductal lesions
45679741|NCT05156164|Device|Control Group|KT application on the deltoid but without support function
46012278|NCT01646450|Drug|Icotinib|Icotinib: 125mg, oral administration, three times per day.
45463698|NCT02529527|Behavioral|MyFamilyPlan|Web-based preconception health education tool (interactive self-assessment) - to be completed by patient
45463699|NCT01197391|Biological|REGN728|2 Subcutaneous Cohorts (dose 1, 2)
45463700|NCT01208285|Drug|VX-770|150 mg oral tablet
46098538|NCT04118985|Behavioral|Self-implementation|Self-implementation of cognitive rehabilitation and health behavior change recommendations
45463701|NCT01295749|Device|laryngeal tube ventilation and continuous chest compression|Comparison of no flow time between two strategies in out of hospital cardiac arrest
45463702|NCT01295749|Device|laryngeal tube ventilation and continuous chest compression|Comparison of no flow time between two strategies in out of hospital cardiac arrest
45463703|NCT01208363|Dietary Supplement|Cowpea fortified with NaFeEDTA, in form of Toubani.|66g raw Cowpea fortified with 10 mg Fe as NaFeEDTA, in form of Toubani, a cowpea snack. Ther snack will be given to the participants 3 times per week, for six month integrated in the school feeding trial.
45463704|NCT01208441|Drug|letrozole|
45463705|NCT01208441|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
45463706|NCT01208441|Procedure|therapeutic conventional surgery|
45463707|NCT01208441|Procedure|breast biopsy|
45463708|NCT01208441|Other|diagnostic laboratory biomarker analysis|
45463709|NCT01208441|Other|pharmacological study|
45463710|NCT03449199|Drug|TMX-049|A certain dose of TMX-049 to be taken orally, once daily
45679742|NCT05155761|Device|FeetMe® Monitor|"Each patient will be asked to go to 3 visits at the Cochin hospital, and to wear the soles after each of these visits during 3 days, at home, to record the data, so that it reflects walking patterns of the patient in his/her daily life and activities.~At each visit, clinical tests to assess fall risk will be performed (Timed Up and Go test, one foot stance, Short Physical Performance Battery and 6 minutes walking test ).~The patients will be supplied with a pair of FeetMe® Monitor insoles, return home and walking parameters will be recorded for 3 to 10 consecutive days."
45679743|NCT05145426|Device|Low Intensity Focused Ultrasound|Application of LIFU
45679744|NCT05130437|Biological|mRNA-3927|mRNA-3927 dispersion for IV infusion
45679745|NCT05130060|Biological|Colorectal Cancer Peptide Vaccine PolyPEPI1018|Given SC
46012279|NCT01607229|Other|observation|no intervention used, observed measurements from 3 test devices compared to reference criterion measurement for total body water and body composition
46012280|NCT01646489|Drug|Miravirsen sodium|Miravirsen 7 mg/kg to be administered as single subcutaneous injections for a total of 5 doses over a 5 week treatment period.
46098539|NCT02715791|Behavioral|TAP-HC-DM|"Patients randomized to the intervention group will complete the Healthy Lifestyle App modules. Their results will create a report with a suggested list of tip sheets that patients, volunteers, and clinics will see.~Patients will also be encouraged to access the McMaster PHR in order to track their health, and communicate with volunteers or the clinic.~Volunteer health connectors will connect with patients at least weekly, by phone, McMaster PHR message, or in person (depending on patient preference). They will be motivating, providing tip sheets or other education, doing tech support, providing community resources, and building a volunteer-patient relationship with the client.~Clinicians will see and triage the reports, and may follow up on various aspects identified."
46012281|NCT01646489|Drug|Telaprevir|Telaprevir 750 mg to be administered as single and multiple oral doses over two 7 day treatment periods.
46012282|NCT01603719|Dietary Supplement|new infant formula with prebiotics and beta-palmitate|experimental infant formula as sole source of nutrition over first 12 weeks of life
45463711|NCT03449199|Drug|Placebo|Matching placebo to be taken orally, once daily
45463712|NCT03845569|Other|Dietary protein intake reduction|Following two days of controlled diet at 2.2g/kg/d of dietary protein, intake was reduced to 1.2g/kg/d for five days, and protein metabolism was measured on days 1, 3, and 5.
46012283|NCT01646528|Procedure|CLE examination for upper gastrointestinal tract|Routine upper GI endoscopy plus targeted CLE examination
46012284|NCT01603758|Drug|Ezetimibe|Ezetimibe 10 mg/day or placebo will be given for 6 weeks
46098540|NCT02715791|Other|Usual Care|Patients randomized to the control group will receive usual care and upon the end of the intervention arm of the study will receive the TAPESTRY-HC-DM intervention as detailed in the intervention group.
46098541|NCT00699543|Device|Coroflex Please stent implantation|Use Coroflex Please stent in the treatment of coronary stenosis
46098542|NCT00699543|Device|Taxus stent implantation|Use Taxus stent in the treatment of coronary stenosis
46098543|NCT02712827|Procedure|Progrip|Self-fixating mesh
46098544|NCT02712827|Procedure|Non-Progrip|Non self-fixating mesh with the use of glue
46012285|NCT02279264|Device|RightSpot Infant pH Indicator|pH indicator
46012286|NCT01603797|Behavioral|Guided internet-delivered acceptance and commitment therapy|The treatment program consisted of seven sections and was based on ACT.The first part was about creative hopelessness and was followed in the next section by an introduction to willingness and to the process of acceptance of pain. Information and assignments about committed action and values were also part of the treatment program. Mindfulness exercises were a regular feature in the program. The last part was about how to maintain learned strategies but also an evaluation of the program.
46012287|NCT02279303|Behavioral|Dietary Intervention|Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
46012288|NCT02279303|Behavioral|Dietary Control|Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
46012289|NCT01177228|Drug|Vedolizumab|Vedolizumab for intravenous infusion
46012290|NCT01177228|Drug|Placebo|Placebo intravenous infusion
46012291|NCT01607268|Procedure|Magnetic Resonance Spectroscopy Imaging|Proton magnetic resonance spectroscopy [1H-MRS] is an emerging imaging tool that allows for non-invasive assessment of brain neurochemistry in human subjects. This technique allows for in vivo quantification of the concentration of neurotransmitters and metabolites in discrete brain regions through detection of hydrogen nuclei in these molecules. Autonomic failure patients will undergo a single imaging session lasting 30 to 90 minutes (0.5-1.5 hours) in the Vanderbilt Human Imaging Institute.
46012292|NCT02279342|Drug|Febuxostat|The starting dose of the febuxostat will be 10mg /day. The dose will be increased to 20 mg/day at week 4 and finally titrated to 40 mg/day at week 8.
46098545|NCT00999739|Biological|Prevenar and Pneumo23|Two vaccines: participants will receive via intramuscular in deltoid one dose of conjugated heptavalent vaccine at day 0 (Prevenar, Wyeth-lederle)and one dose of 23valent polysaccharide vaccine (Pneumo23, AventisPasteur)at week4 One vaccine:participants will receive only one dose of 23valent polysaccharide vaccine at day 0.
45463713|NCT03845569|Other|Three day Controlled Diet|Three days of a controlled diet providing 2.2g/kg/d of dietary protein with protein metabolism measured on day 3. This was used to model the habitual intake of this cohort.
45463714|NCT03845647|Procedure|contralateral central lymph node dissection|contralateral central lymph node dissection
45679746|NCT05130060|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
46012293|NCT01193530|Other|Bright Light Therapy|30 minutes every day for 14 days. After enrollment on day 0, blinded phase of study intervention (i.e. daily bright light or red light) from day 1 to day 14+/-3, then proceed to the open label phase and receive daily bright light between day 15+/-3 and day 28+/-3.
46012294|NCT01193530|Other|Dim Red Light Therapy|From day 1 to day 14+/-3, daily dim red light therapy for 30 minutes for 14 days where red light device accounts for placebo of the blinded phase of study intervention, then between day 15+/-3 and day 28+/-3 open label phase with daily bright light.
46012295|NCT01193530|Behavioral|Questionnaires|Weekly
46012296|NCT01193530|Behavioral|Study Diaries|Daily logs
46012297|NCT01193530|Device|Red Light Litebook|Control red light device produced by Litebook identical in appearance and dimensions to the bright light device, with the exception it emits at wavelength 680nm (i.e. red light) and at an intensity of 50 lux.
46098546|NCT00996463|Procedure|Electro-thermo-coagulation|Electro-thermo-coagulation
46098547|NCT00996463|Drug|Sodium Stibogluconate|Intralesional injection of sodium stibogluconate
46098548|NCT00996463|Drug|DAC N-055|Moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
46098549|NCT01886963|Device|SPY - Unblinded use of SPY Elite|Surgeon plans tissue advancement flaps with the aid of Spy Elite System imaging
45463715|NCT03941327|Device|AxoGuard Nerve Cuff|A porcine collagen implant will be used to make a protective sheath around the participant's exposed spinal accessory nerve during surgery. This will be performed by physically wrapping the exposed nerve with the implant and suturing the ends together. The goal is to protect nerve from adhesions and compression in the absence of normal protective lymphatic soft tissue.
46012298|NCT01193530|Device|Bright Light Litebook|Bright light device consists of 60 LEDs with spectral emission peak at approximately 464nm and fluorescent phosphors which provide a broader, secondary spectral peak near 564nm. Collectively the emitted light appears white.
46012299|NCT01607307|Drug|Oral/enteral TJ-100 solution|Oral TJ-100 solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent TJ-100 solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
45463716|NCT01195285|Procedure|Single-Incision Laparoscopic Surgery cholecystectomy|Laparoscopic Cholecystectomy
45679747|NCT05129891|Drug|Semaglutide D|Tablet given orally
46098550|NCT01886963|Device|Control - Blinded use of SPY Elite|Surgeon is blinded to Spy Elite imaging and plans tissue advancement flaps according to clinical judgment alone
46098551|NCT00999817|Drug|reference [dextromethorphan]|single 30 mg oral dose
45463717|NCT01195285|Procedure|Traditional Laparoscopic Cholecystectomy (TLC)|Laparoscopic Cholecystectomy
45679748|NCT05129891|Drug|Semaglutide G|Tablet given orally
45679749|NCT05129891|Drug|Semaglutide H|Tablet given orally
45463718|NCT01114061|Device|Insupatch|Applying heat to the infusion site using the insupatch device
46012300|NCT01607307|Drug|Oral/enteral placebo solution|Oral placebo solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent placebo solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
46012301|NCT02279381|Drug|Chlorhexidine|4% chlorhexidine will be applied to the umbilical stump from day 1 to day 10
45463719|NCT03845413|Behavioral|Control|Schedule an appointment to attend tobacco cessation at Basic Health Unit
45463720|NCT03845413|Behavioral|12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program|12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program
45463721|NCT03718377|Procedure|Serratus plane block|The subjects were received serratus plane block in the regional-anesthesia unit out of operation room before induction of general anesthesia. And, video-assisted thoracic surgery was performed under balanced general anesthesia.
45463722|NCT03718377|Procedure|General anesthesia only|Video-assisted thoracic surgery was performed under balanced general anesthesia without serratus plane block
45463723|NCT03941405|Drug|Albumin treatment|one dose per day of a 40g albumin g/l gram(s)/litre for 10 days. resolution of hyponatremia, defined as an increase in serum sodium of more than 5 mEq/L with a final value > 130 mEq/L, maintained for at least 48 consecutive hours during the 10-day treatment period
45679750|NCT05129891|Drug|Semaglutide I|Tablet given orally
45679751|NCT05129891|Drug|NNC0385-0434 B|Tablet given orally
45679752|NCT05129891|Drug|NNC0385-0434 C|Tablet given orally
45679753|NCT05129891|Drug|NNC0385-0434 D|Tablet given orally
45679754|NCT05129891|Drug|NNC0385-0434 E|Tablet given orally
46012302|NCT02279381|Other|Kangaroo Mother Care|Skin to Skin Care which is Kangaroo mother care will be carried out by mother from Day 1 till the study completion
46012303|NCT02279381|Other|Essential Neonatal Care|Essential Neonatal Care ensures delayed bathing, use of colostrum, exclusive breast feeding, skin to skin care for hypothermia, dry cord care, eye care and immunization for the newborn
46012304|NCT01607385|Drug|GSK2330672|BID, repeat doses
46098552|NCT00999817|Drug|test [PF-00299804 + dextromethorphan]|single 45 mg oral dose of PF-00299804 and a single 30 mg oral dose of dextromethorphan
46098553|NCT00857259|Drug|Everolimus|5 mg oral tablet
46098554|NCT00857259|Drug|Ranibizumab|0.5 mg administered by intravitreal injection
45679755|NCT05120466|Behavioral|AD IT UP media literacy intervention|AD IT UP was originally developed in 2006 as a classroom-based cigarette prevention program focused on traditional media influences, and was converted to a web-based program in 2011. In 2019, the AD IT UP program was updated substantially to include other forms of tobacco, such as e-cigarettes, and other forms of media, such as social media.
46012305|NCT01607385|Drug|Placebo|BID, repeat doses
46012306|NCT01607385|Drug|GSK1614235|BID, co-dosed BID with last dosing day of active/placebo repeat doses
46012307|NCT01646567|Drug|SHP-141C|Topical Cream
46012308|NCT01646567|Drug|Placebo to SHP-141C|Placebo Topical Cream
46012309|NCT01646567|Drug|Betamethasone Valerate|Topical cream, 0.02%
45463724|NCT01197469|Drug|Tadalafil|Tadalafil 10mg once daily for 3 months
45463725|NCT01197469|Drug|Placebo|
45463726|NCT03713775|Other|Meal Replacement Weight Loss Programme|The study intervention will be the referral to a commercial provider (CP) offering a Meal Replacement Programme. Briefly, participants will be referred to a nominated CP local counsellor who will set regular appointments during a period of 32-to-36 weeks to provide behavioural support, weight monitoring, and deliver formula meals. All counselors delivering the programme will receive, beyond their routine training and accreditation, specific information related to this study before being allocated patients.
45463727|NCT03713775|Other|Usual Care|Participants randomised to the control group will receive best usual care, consisting of a one-off face-to-face consultation on weight loss with a nurse at baseline (~15 min), together with supporting written information.
45463728|NCT01211561|Drug|Selenium, selenomethionine|Patients will receive one 200 ug pill of Selenomethionine
45679756|NCT05120466|Behavioral|Usual health education curriculum|The school's regular health education curriculum includes classroom lectures, hands on activities and group work.
46098555|NCT04871009|Behavioral|Neurofeedback Intervention|"InteraXon, Inc. produces the MUSE 2 wearable neurofeedback device and mobile application (heretofore referred to as the MUSE app), respectively comprising the electroencephalogram (EEG) hardware and interactive software components that will be used in this intervention. The MUSE 2 is an adjustable headband that is placed across the forehead and over and behind the ears. It contains EEG sensors for active sites across the forehead and behind the ears, and an additional reference site behind the ear. These sensors use EEG technology to passively record children's brainwaves. During a session, caregivers will help children place the MUSE 2 on their heads and connect it to the app on their personal device. Children's brain activity is recorded by the MUSE 2 and is represented on the app through audio-based feedback that children will listen to with earbuds, and use their volition to influence in real time, with the goal of gaining increased control over their own brain activity."
45463729|NCT01211561|Drug|placebo|Patients will be given one 200 ug placebo pill each day for 6 months
46098556|NCT04871009|Behavioral|standard of care|trauma focused cognitive behavioral therapy or other behavioral therapy at the discretion of therapist
46012310|NCT01646567|Drug|Calcipotriol|Topical cream, 0.005%
46098557|NCT00994747|Other|Nutramigen (Flavor and Type of Infant Formula)|Nutramigen, protein hydrolysate formula, fed to infants as sole formula source during specified times during the first 8.5 months of life
46098558|NCT00994747|Other|Enfamil, milk-based formula|Enfamil, milk-based formula, fed as formula source during first 8.5 months of life
46098559|NCT04044807|Diagnostic Test|Modified National Institutes of Health Stroke Scale|Clinical tool used in the diagnosis of acute stroke developed by the National Institutes of Health, and modified for simplicity.
46012311|NCT01607424|Behavioral|cognitive remediation|RECOS: cognitive remediation for schizophrenia CRT: cognitive remediation therapy
46012312|NCT01646606|Procedure|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. The nurse will attach the probe to the electrical cord which is connected to the monitor. For each measurement, the duration of monitoring will be until a steady wave form is present on the oxygen saturation monitor, indicating a reliable measurement (consistent with current standard of practice). The nurse will document the maximum and minimum reading during the period. The nurse will detach the probe from the electrical cord, leaving the probe attached to the child. Hence, the child's probe will be attached to the electrical cord intermittently as well.
45679757|NCT05113940|Drug|PF-07258669|PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days
45679758|NCT05113940|Drug|Placebo|Placebo will be administered as tablets; Q8H or Q12H over 14 days
45679759|NCT05113940|Drug|Midazolam|Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07258669
45679760|NCT05096117|Drug|ASP8062|ASP8062 is a novel compound with positive allosteric modulator (PAM) activity on the γ-aminobutyric acid type B (GABAB) receptor, 25 mg, 1 x per day for 6 weeks
45679761|NCT05096117|Drug|Placebo|1 x per day for 6 weeks
45679762|NCT05083130|Behavioral|a wake prone positioning|The team will give written and verbal advice and if necessary aid patients' positioning themselves in the prone position for at least 8 hours per day. The exact duration of prone sessions will be determined according to ward schedules to take account of nursing procedures, meal times and mitigation strategies. Other methods to encourage the maintenance of prone position includes phone calls to patients, carers or education of carers.
45463730|NCT05595967|Behavioral|Health education intervention|Both the two session contains modules focusing on heath related knowledge and pelvic floor muscle exercise. Both two session will be delivered by primary healthcare women workers in small groups (about 20 women per group). The local healthcare workers are responsible for making appointment with each participant through group activities. Each participant will receive a healthy calendar practice to record the number of exercises per day which will be supervised by primary healthcare workers. All healthcare workers are required to attend a full-day workshop organized base on the scheme and teaching materials developed by our research team. The contents of the workshop include: (1) introduction of pelvic floor dysfunction; (2) risk factors and prevention of pelvic floor dysfunction; (3) kegel movement; (4) methods of dealing with severe illness; (5) a standard procedure of group activities or one-on-one activities; (6) skills needed for the delivery of health education intervention.
45463731|NCT05358535|Drug|Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2)|"The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab."
45679763|NCT05081180|Drug|Avelumab|Participants with primary CNS malignancies who have received at least 1 prior therapy will be enrolled into Dose Escalation Part 1 and will receive intravenous infusion at a flat dose or weight based dose of Avelumab, every 2 weeks (Q2W) until progression, unacceptable toxicity, or withdrawal of consent. Enrollment into part 1 of the study will end when Maximum tolerated dose (MTD) and/or a safe Recommended Dose for Expansion (RDE) for the expansion cohort is determined. Participants with defined CNS tumors will be enrolled into Dose Expansion Part 2 and will receive RDE in Part 2 until progression, unacceptable toxicity, or withdrawal of consent.
45679764|NCT05081180|Drug|Lenvatinib|Participants with primary CNS malignancies who have received at least 1 prior therapy will be enrolled into Dose Escalation Part 1 and will receive daily oral escalated dose level of Lenvatinib until progression, unacceptable toxicity, or withdrawal of consent. Enrollment into part 1 of the study will end when MTD and/or a safe Recommended Dose for Expansion (RDE) for the expansion cohort is determined. Participants with defined CNS tumors will be enrolled into Dose Expansion Part 2 and will receive RDE of Lenvatinib in Part 2 until progression, unacceptable toxicity, or withdrawal of consent.
45679765|NCT05072093|Behavioral|PrEP discontinuation intervention|Men taking daily oral PrEP (Truvada) will receive a monthly screener through the mobile app. If answers to screener questions indicate a participant is at risk for PrEP discontinuation, then a peer navigator will deliver a motivational interviewing intervention and a clinician will consult with the participant. These efforts are intended to avert PrEP discontinuation.
45837387|NCT05048550|Device|Near vision spectacles|Near vision spectacles prescribed for full time wear (Add+3.00DS to the full cycloplegic refraction). These glasses will be changed to reflect changes in refractive error or frame fit as appropriate at follow up.
45837388|NCT04932018|Behavioral|Virtual Community of Support|The 6-month virtual community will consist of self-directed learning modules that will vary in content from worker and family relationships, collaboration and skill acquisition to self-care habits; problem-solving; monthly sessions will include a positive psychology exercise.
45679766|NCT05072093|Drug|Offering of on-demand oral PrEP|For men who are not interested in daily oral PrEP or plan to discontinue daily oral PrEP, the investigators will offer on-demand oral PrEP (Truvada) which will allow them to take it immediately before/after a sexual encounter. It is hoped that this will serve as an alternative to daily oral PrEP use that is desirable for some people.
45679767|NCT05072093|Drug|Offering of STI PEP|All men in the cohort will be offered STI PEP (doxycycline) to use after condomless sex with the goal of averting STI diagnoses. At a dosage of 200 mg to be taken in a single dose ideally within 24 hours of possible exposure (e.g. condomless anal sex) and no later than 72 hours after exposure. Participants will be dispensed enough pills to allow for up to 3 weekly doses of 200mg doxycycline (i.e. 6 pills/week) for 3 months (the interval between STI testing visits).
46012313|NCT01646606|Procedure|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Every 4 hours the nurse will complete and document a set of vital sign measurements, including oxygen saturation level, in keeping with current clinical practice. The reading will be displayed on the bedside monitor in the participants' room. At the completion of vital signs measurement, the nurse will not detach the electrical cord from the probe. Hence, the child's probe will be attached to the electrical cord continuously as well.
46012314|NCT01681979|Drug|Fluticasone propionate (with and without concurrent salmeterol)|"Fluticasone propionate is an inhaled corticosteroid used for the treatment of asthma, often in combination with the long-acting β-agonist salmeterol. For the primary endpoint, exposure status will be determined based on the individual receiving a prescription for the drug of interest (fluticasone propionate or another inhaled corticosteroid) in the 2 weeks immediately before the LMP date or during the first trimester of pregnancy.~Sensitivity analysis will be carried out categorising exposure based on mapping the duration of prescriptions based on the number of inhalers, number of puffs within an inhaler and the prescribed daily dose."
46012315|NCT01646684|Drug|SOM230|
46012316|NCT01607580|Drug|low-dose glucocorticoid Methylprednisolone|patients receive low-dose glucocorticoid from day 5 post transplant
46012317|NCT01646723|Behavioral|Volunteers Adding Life in Dementia (VALID) Program|"The VALID intervention will consist of 2 phases. First, volunteers will complete an assessment involving recording of a Life Story for each patient participant. This will include information on the patient's psychosocial history, occupational history, hobbies, interests and preferred activities using information from the LTC medical record and interviews with the patient and family members. Based on this information, a variety of potential psychosocial interventions will be developed for the individual with the assistance of the recreation therapist at the LTC. The second phase will involve implementation of the VALID intervention. Each individual with dementia will receive personalized pleasant activities for a minimum session of 30 minutes at a frequency of 3 times per week. One volunteer will complete the Life Story assessment and up to 3 volunteers may be involved with implementing the VALID program for each resident."
45679768|NCT05072093|Drug|Injectable PrEP|For men who are interested in injectable PrEP, they will be referred to local providers to access Apretude (Cabotegravir injection) every two months. In the study, their use of the medication will be monitored through monthly surveys during which they have the option to indicate interest in switching to oral PrEP.
45837389|NCT04932018|Behavioral|Mentorship Incubator|The 6-month incubator intervention will consist of monthly interactive time with an assigned study facilitator/farmer mentor.
45837390|NCT02829528|Behavioral|Little Flower Yoga For Kids|Little Flower Yoga for Kids is a promising yoga and mindfulness program for children developed by Jennifer Cohen Harper, MA, E-RCYT, which incorporates five elements (connect, breathe, move, focus, relax) to improve the child's ability to sustain attention and regulate emotions.
45837391|NCT04747236|Drug|Azacytidine|Azacytidine, 300 mg po daily on Days 1-14
46012318|NCT01607619|Dietary Supplement|Anatabine|1mg anatabine in a mint-flavored mannitol lozenge
46012319|NCT01646801|Device|NMB Balloon Catheter|patients treated by the NMB's Drug Ejecting Balloon
46012320|NCT01647152|Drug|Ustekinumab|
46012321|NCT01682018|Device|lung volume reduction using the Zephyr device|lung volume reduction using the Zephyr device
46012322|NCT01607697|Behavioral|Mindfulness Training|Mindfulness Training
46012323|NCT01682057|Device|ROX ANASTOMOTIC COUPLER SYSTEM (ACS)|The ROX Anastomic Coupler (ACS) will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
46012324|NCT01682057|Device|ROX Anastomotic Coupler System (ACS)|
46012325|NCT01604187|Drug|Fentanyl|Ten minutes before the procedure fentanyl sublingual tablet (Abstral ® 100 µg, ProStrakan) will be given to the patient.
46012326|NCT01604187|Drug|Placebo|Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
46012327|NCT01682096|Radiation|computed coronary angiography|Patients will be pre-medicated with atenolol 50 mg 1h prior to the scan.
46012328|NCT01682096|Procedure|Exercise stress echocardiography|Limited by symptoms
46012329|NCT01607736|Behavioral|Virtual Gait Training|The intervention consisted of 12-minute virtual gait training sessions once daily for a total of 14 weekdays within a three-week period. The intervention video showed walking legs of a 30-year-old woman for female and a 46-year-old man for male participants. The video screen was adjusted in height such that it corresponded to the legs of the standing participant, with a mirror placed above it. Participants began the training session with a circa one minute of concentration on the upcoming intervention. Afterwards, the video was started. Participants were instructed to stand (when necessary, to sit) and observe the video and mirror, and to imagine themselves walking. Training sessions were supervised by a physical therapist who gave additional instructions and comments regarding participants' visual/kinesthetic imagination of themselves performing the observed movement. Verbal and physical reactions during training sessions were documented in written form and sometimes videotaped.
46012330|NCT01682174|Other|Control Drink|
46012331|NCT01682174|Other|Experimental Drink|
45679769|NCT05065840|Behavioral|CDC 4 Pillars Program|The CDC's 4 Pillars Transformation Program (4 Pillars Program) is a robust and empirically supported strategic approach that promotes the uptake of adult vaccinations and addresses facilitators and barriers at the patient, provider, and clinic level. This multi-level, evidence-based intervention has been successfully utilized to increase HPV vaccination in the general population and is primed to be tested in the high-risk HIV population, particularly PLWH in the rural South. This proposal seeks to expand the success of the 4 Pillars Program and tailor, refine, and implement in the HIV positive population who are at extraordinarily high risk for HPV-related cancers and can obtain the most benefit from the vaccine.
45679770|NCT05062083|Drug|11C-MCI|Injected IV followed by PET scanning
45679771|NCT05062083|Drug|11C-PS13|Injected IV followed by PET Scanning
45679772|NCT05057273|Drug|BT-11|Oral once daily tablet
46012332|NCT01647191|Behavioral|intervention group|The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
46012333|NCT01647191|Behavioral|control group|The investigators will adopt previous treatment in the clinics to intervent the patients
46012334|NCT01604304|Procedure|flexible ureteroscopy|Flexible ureteroscopy will be use for 120 min max to treat renal stone. Laser, access sheath, baskets can be use to perform the technique.
46012335|NCT01604304|Procedure|extracorporeal shockwave lithotripsy|The lithotriptor is use with 1,1 Hz frequency and stop when patient get 1000 joules of energy or if there is a problem with tolerance of this treatment or if stone is broken
46012336|NCT01682291|Behavioral|Life-style modifications|Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)
46012337|NCT01682291|Dietary Supplement|Dietary supplements|combined pill (1 capsule/day containing Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
46012338|NCT01607931|Behavioral|Exercise|1 hour of cycling at 50% of maximum power output
46012339|NCT01604382|Drug|General Anesthesia|General Anesthesia as described above
46012340|NCT01604382|Drug|Neuraxial anesthesia|Neuraxial anesthesia as described above
46012341|NCT01604421|Procedure|Thermoregulation-standard care|Standard care without plastic bag. One hour after birth, a blanket will be wrapped around the infant and he/she will receive a wool hat, according to standard practices. The infant's axillary temperature will be monitored for 24 hours or until discharge, whichever comes first.
46012342|NCT01604421|Procedure|Thermoregulation with plastic bag|One hour after birth, the infant will be placed into a plastic bag up to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. A blanket will be wrapped around the infant, and he/she will receive a wool hat. The infant will remain in the bag, which will be changed when soiled, for 24 hours or until discharge, whichever occurs first.
46012343|NCT01647269|Procedure|Bilateral GPi Deep Brain Stimulation|Bilateral GPi Deep Brain Stimulation
46012344|NCT01682369|Biological|TIV (Aggripal)|
46012345|NCT01682369|Biological|ATIV (Fluad)|
46012346|NCT01604460|Procedure|Resuscitation with torso plastic bag|Infant will be placed within 10 minutes of his birth into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. After his/her head is dried, the infant will receive a cloth cap. Resuscitation will occur in the delivery room and the infant will be wrapped in a blanket and taken to the nursery where he/she will remain in the plastic bag until 1 hour after birth.
45679773|NCT05057273|Drug|Active comparator|Biologic
45679774|NCT05049733|Drug|CBD 1mg/Kg|Participants will ingest soft gel tablets containing CBD 1mg/Kg
45679775|NCT05049733|Drug|CBD 2mg/Kg|Participants will ingest soft gel tablets containing CBD 2mg/Kg
45679776|NCT05049733|Drug|CBD 4mg/Kg|Participants will ingest soft gel tablets containing CBD 4mg/Kg
46012347|NCT01604460|Procedure|Resuscitation-no plastic bag|Infant will be immediately dried and resuscitated in the delivery room per standard of care. The infant will be wrapped in a blanket and will receive a cloth hat before being taken to the nursery.
46012348|NCT01682408|Drug|Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
46012349|NCT01682408|Drug|Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed|3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
46012350|NCT01682408|Drug|Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)|1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
46012351|NCT01682408|Drug|Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)|1 x 150mg mannitol based 38% drug loaded tablet(batch variant B)
45679777|NCT05049733|Drug|Placebo CBD|Participants will ingest soft gel tablets containing placebo for CBD
45679778|NCT05047718|Biological|COVID-19 vaccine Pfizer (2 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
45679779|NCT05047718|Biological|COVID-19 vaccine Pfizer (1 dose)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
45837392|NCT04747236|Drug|Romidepsin|Romidepsin, 14 mg/m2 as an intravenous infusion over 4 hours on Days 8, 15, and 22 of a 35-day cycle
46012352|NCT01682408|Drug|Ranitidine|150 mg ranitidine
46012353|NCT01607970|Drug|Oxytocin|Oxytocin: 24 IU; 3 puffs per nostril, each with 4 IU OXT
45463732|NCT05358535|Drug|Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)|"The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab."
45463733|NCT01213355|Drug|Placebo|Capsule, single dose, oral, 1 day
45463734|NCT01213355|Drug|Scopolamine|injectable subcutaneous formulation, single dose, 1 day
45463735|NCT01213355|Drug|PF-05212377|5 mg, PF-05212377, capsule, single dose, 1 day
46012354|NCT01608009|Drug|Pazopanib and paclitaxel|Pazopanib 800mg od for 7 days, followed by 18 weeks of combination therapy (paclitaxel 80mg/m2 weekly and pazopanib 800mg od). Following the completion of combination therapy, patients will continue on maintenance pazopanib 800mg od until disease progression.
46012355|NCT01647347|Drug|Supra- and subgingival rinsing with 10% PVP-iodine|rinsing prior to and during subgingival ultrasonic debridement
46098560|NCT04220801|Drug|ZM-H1505R|Single oral doses of 300, 450, 600, 750, and 900 mg of ZM-H1505R or placebo and multiple oral doses of 450, 600, and 750 mg of ZM-H1505R or placebo will be administered in a fasted state, or in the case of Cohort 3 (Part 1), a second dose of 600 mg will be administered in the fed state. During each SAD and MAD dosing period, 2 subjects in each cohort will receive placebo instead of ZM-H1505R. The dose levels may be adjusted based on the safety and tolerability obtained from the previous cohort.
45463736|NCT01213355|Drug|Scopolamine|injectable subcutaneous formulation, single dose, 1 day
45463737|NCT01213355|Drug|PF-05212377|20 mg, capsule PF-05212377, single dose, 1 day
45463738|NCT01213355|Drug|scopolamine|injectable subcutaneous formulation, single dose, 1 day
45463739|NCT01213355|Drug|PF-05212377|60 mg PF-05212377, capsule, single dose, 1 day
45463740|NCT01213355|Drug|scopolamine|injectable sub cutaneous formulation, single dose, 1 day
46012356|NCT01647347|Other|Water|
46012357|NCT01604499|Behavioral|Feedback letters|"Subjects receive feedback letters about the proportion of green, yellow, and red purchases in the cafeteria per month with comparisons to all employees and to the healthiest employees eaters"
46012358|NCT01604499|Behavioral|Feedback plus incentives|Subjects receive feedback letters plus small incentives to increase healthy (green-labeled) purchases in the next month
46012359|NCT01682447|Other|Extensive Pulmonary Rehabilitation Program|Fulltime pulmonary rehabilitation program. Duration: 12 weeks
46012360|NCT01604577|Behavioral|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
46012361|NCT01607463|Procedure|Transcutaneous electrical nerve stimulation (Empi, USA)|In the active TENS group, TENS at 80 pulsed currents per second (PPS) with a pulse duration of 200 μs were delivered for 20 minutes. Current amplitude was slowly increased until a level was reached that participants reported was the maximum level they could tolerate below pain threshold without noticeable muscle contraction and maintained this intensity.
46098561|NCT00868608|Drug|Inotuzumab Ozogamicin (CMC-544)|Administered intravenously at 1.8 mg/m2 every 4 weeks for a planned 4 - 8 cycles
45463741|NCT01213355|Drug|Donepezil|Tablet, 10mg, single dose, 1 day
45679780|NCT05047718|Biological|COVID-19 mRNA Vaccine Moderna (2 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
46012362|NCT01607463|Procedure|Transcutaneous electrical nerve stimulation (Empi, USA)|"In the placebo group the TENS device had no current output although the power on indicator light remained active."
46012363|NCT01604031|Biological|B-CLL Vaccine|Patients will receive a fixed dose (2X10^7) of IL-2 secreting B-cells together with (2X10^7) of hCD40L expressing B-cells. Patients will receive doses of vaccine at 2 week intervals for 5 doses. Barring adverse events, an additional 11 doses of vaccine will be given, at 4 weekly intervals beginning on week 12 for a total period of one year or 16 vaccinations in total.
46012364|NCT01604031|Drug|Lenalidomide|Subjects will begin lenalidomide 5 mg orally daily on day zero and will continue daily dosing until week 60 (4 weeks after the final dose of vaccine).
46098562|NCT00699621|Biological|platelets|Four units of fresh platelets will be infused immediately
45463742|NCT01213355|Drug|Scopolamine|injectable sub cutaneous formulation, single dose, 1 day
45463743|NCT05594485|Device|Carebot AI CXR|Carebot AI CXR is a deep learning-based software that assists radiologists in the interpretation of chest radiographs in posterior-anterior (PA) or anterior-posterior (AP) projections. The solution with artificial intelligence automatically detects abnormality based on visual patterns for the following findings: atelectasis, consolidation, cardiomegaly, mediastinal widening, pneumoperitoneum, pneumothorax, pulmonary edema, pulmonary lesion, bone fracture, hilar enlargement, subcutaneous emphysema, and pleural effusion.
45463744|NCT05593705|Other|observation|photograph for maxillary labial frenum and measurements with a periodontal probe
45679781|NCT05047718|Biological|COVID-19 mRNA Vaccine Moderna (1 dose)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
46098563|NCT04295681|Drug|MMH-MAP|Oral administration.
46098564|NCT04295681|Drug|Placebo|Oral administration.
46098565|NCT04000633|Drug|Lidocaine 2%|the patients of this group will recieve nebulization of 5 ml of 2% lidocaine prior to induction of general anesthesia
46098566|NCT04000633|Drug|Normal saline|Normal saline
45837393|NCT04747236|Drug|Belinostat|Belinostat, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1-5 every 21 days.
45463745|NCT03938441|Other|Intermittent Fasting|"The version of 5:2 intermittent fasting to be applied in this study will be somewhat less intensive than implemented then what has been proposed in some recent, similar studies.~On fasting days, instead of limiting the subject to a specific calorie count, the subject will be instead instructed to skip either the first or last meal of the day in order to complete a 12 to 16 hour fast, during which time they are allowed drink water or any non-caloric beverage of their choice, but not consume any calories.~Furthermore, the patient will be instructed for their remaining 2 meals to consume no more than they would on a normal, non-fasting day."
45463746|NCT05578027|Procedure|Mild moxibustion with moxa stick|To conduct this intervention, we used moxa sticks which were 1.5 cm in diameter, 13 cm long, and weighed 12 gram to perform mild moxibustion manipulation at the control acupoint (the left side Pishu acupoint) or Mingmen acupoint in 2 trial phases. The main ingredient of the moxa was dried mugwort leaf, produced in Vietnam. All moxa materials were obtained from the Sai Gon TCS Co., Ho Chi Minh City, Vietnam.
45463747|NCT03938363|Other|Treadmill|Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups
45463748|NCT03938363|Drug|Botulinum Toxin injection|injection of Botulinum Toxin in the two groups of CD and BS
45463749|NCT03938363|Diagnostic Test|Severity scale of the disease|JRS for BS TWSTRS for CD
45679782|NCT05028816|Device|Side 1: Final layer closure with force modulating tissue bridges (FMTB)|Brijjit is a non-invasive wound closure device that reduces tension on scars and aids improving scar appearance.
46012365|NCT01682525|Other|Frozen ovarian tissue|Use of ovarian tissue cryopreserved and stored at Boston IVF
46012366|NCT02279927|Device|Ureteroscopy|Ureteroscopy with laser stone fragmentation
46012367|NCT01682564|Drug|Candemore tablet|"Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
46012368|NCT01682564|Drug|Atacand tablet|"Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
46012369|NCT01608048|Device|transcutaneous electrical acupoint stimulation (TEAS);EA|TEAS group (conventional IVF + TEAS), electro-acupuncture (EA) group (conventional IVF + electro-Acu.), and control group (only conventional IVF) Parameter of TEAS or EA: frequency of 2/100 Hz；moderate electrical current. Treatments start from the day 3 of menstruation，once every two days, 30 min for each for two continuous weeks.
45463750|NCT05283031|Diagnostic Test|Modified Diurnal Tension Curve|The modified diurnal tension curve (mDTC), an alternative that involves IOP measurements every 2 or 3 hours during office hours, is more feasible and may provide better information regarding the IOP profile than single IOP measurements.
45679783|NCT05028816|Other|Side 1: Final layer dermal closure with poliglecaprone 25 suture|Current method of wound closure
45679784|NCT05028816|Device|Side 2: Final layer closure with force modulating tissue bridges (FMTB)|Brijjit is a non-invasive wound closure device that reduces tension on scars and aids improving scar appearance.
46012370|NCT01647425|Behavioral|physician assessment|"Socio-economic conditions and general features: educational level, professional status...~Assessment of current and past use of tobacco: current smoking status reported by the patient; in lifelong non-smokers: previous history of passive smoking reported by the patient; breath carbon monoxide level; in past smokers: age of first cigarette, total reported duration of active smoking, breath carbon monoxide level...~in current smokers: age of first tobacco use, total reported duration of active smoking; Fagerström Nicotine Dependence Test...~Assessment of the current and past uses of alcohol: previous-year assessment using the CAGE questionnaire and the AUDIT Test; average weekly alcohol consumption over the last 12 months...~Assessment of current use of cannabis using the Cannabis Abuse Screening Test~Psychiatric assessment using the MINI 5.0"
45679785|NCT05028816|Other|Side 2: Final layer dermal closure with poliglecaprone 25 suture|Current method of wound closure
45679786|NCT05027633|Drug|Pembrolizumab|given by IV
45679787|NCT05027633|Drug|Docetaxel|given by IV
46012371|NCT01604655|Procedure|Coronary CT Angiography|CCTA
45463751|NCT01117493|Behavioral|Expert Patient Programme|Intervention was a disease specific Expert Patient Programme in addition to usual care. The disease specific Expert Patient Programme was delivered one session per week (lasting 2½ hours) for eight weeks and included 2 weeks disease specific education followed by 6 weeks standardised Expert Patient Programme.
46012372|NCT01604655|Procedure|Stress Test|Stress Test
46012373|NCT01604694|Procedure|TAP Block|An Ultra Sound-guided TAP block is performed after induction of general anesthesia prior to surgical incision. The syringes containing either saline 20 ml (placebo group) or levobupivacaine 20 ml are prepared by the hospital pharmacy under aseptic conditions.
45463752|NCT01117493|Behavioral|Usual care|Usual care included reviews at a specialist respiratory clinic on a three monthly basis to monitor spirometry, inflammatory blood markers and sputum microbiology. The patients were prescribed inhaled therapy and antibiotics if required, and treatment adjusted to the needs of the patient as necessary, including hospital admission.
45679788|NCT05027633|Drug|Cisplatin|given by IV
45679789|NCT05027633|Drug|Carboplatin|given by IV
46012374|NCT01682798|Dietary Supplement|Placebo yoghurt|100g of placebo yoghurt will be taken at 10:00 am and 4:00 pm, respectively; 2 times per day.
46012375|NCT01682798|Dietary Supplement|"Yili Chang Qing Pro-ABB yoghurt (Formula 1)"|"100g of Yili Chang Qing Pro-ABB yoghurt will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
46012376|NCT01682798|Dietary Supplement|"Yili Chang Qing Pro-ABB yoghurt (Formula 2)"|
45679790|NCT05015478|Device|Tailored Rhythmic Lighting Intervention|40 hertz (Hz) rhythmic lighting (RL) for a duration of 1 hour. The flicker frequency of the 40 Hz RL will be 40 Hz and the stimulation will be a square wave with a 50 % duty cycle (i.e., 12.5 milliseconds light- on and 12.5 milliseconds light-off). The RL will provide a 30 lux of red light on a vertical plane at the eye level.
46012377|NCT01608126|Procedure|cervical block|"In brief, the superficial block was performed using a 22G needle (07 x 40 mm). The mixture injected was 15 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine. Deep cervical plexus block was performed using a Stimuplex DR stimulating needle and the dose of anaesthetic used was 10 ml 0.5% bupivacaine + 5 ml 1% lidocaine applied in the vicinity of the C3 nerve root.~The MCPB performed using ultrasound-guidance aiming specifically for the interfascia space. Eighteen ml of 0.375% bupivacaine was injected into the interfascia space at the level of C3 vertebral body using a 22G needle (07 x 40 mm)."
46012378|NCT04528550|Biological|Autologous bone marrow-derived mononuclear cells|Intrathecal transplantation of autologous bone marrow-derived mononuclear cells through lumbar injection.
46012379|NCT04528550|Drug|Placebo|Included patients will receive the same amount of saline through lumbar injection.
46012380|NCT04528472|Other|Acupuncture Treatment|stimulate acupoints to accelerate recovery
46012381|NCT04528472|Other|Regular Treatment|Oral Medicine and Rehabilitation Treatment
46012382|NCT01647620|Drug|DPOC-4088|A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily.
46012383|NCT01647620|Drug|Placebo|A 10-day oral dosing of matching placebo prolonged release tablet.
46012384|NCT01608243|Biological|SLIT tablets of house dust mite allergen extracts|10 dosing days
46012385|NCT01608243|Biological|Matching placebo|10 dosing days
45463753|NCT05670769|Other|Education|The training module, which will be developed in line with the continuous midwifery care model, will include home care and counseling of pregnant women with gestational diabetes (glucose monitoring and control, diet, exercise, evaluation of fetal health, etc.).
45463754|NCT03421431|Drug|EDP-305 Dose 1|Two tablets daily for 12 weeks
45463755|NCT03421431|Drug|EDP-305 Dose 2|Two tablets daily for 12 weeks
45463756|NCT03421431|Drug|Placebo|Two tablets daily for 12 weeks
46012386|NCT04527692|Other|Questionnaire|semi-structured interviews on the quality of life
46012387|NCT01608282|Behavioral|OPEN website|The OPEN website includes interactive modules that allow users to prioritise their daily activities, set goals and find venues where they can participate in different types of activities according to their preferences and the local availability
46012388|NCT01608360|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
46012389|NCT01608360|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
46012390|NCT01647659|Drug|Trametinib tablet|2 mg, orally, on Day 1 of the dosing period
46012391|NCT01647659|Drug|Trametinib pediatric formulation|2 mg, orally, on Day 1 of the dosing period
46012392|NCT01608399|Behavioral|Metacognitive therapy|Metacognitive therapy, 10 weekly sessions of 45-60 minutes duration each
46012393|NCT01682993|Other|Topography guided Excimer Laser treatment and Corneal Cross Linking|A topography guided excimer laser treatment will be performed prior to CCL in one session.
46012394|NCT01682993|Other|Corneal Cross Linking|A standard corneal cross linking procedure will be performed in this arm.
46012395|NCT01604811|Drug|Permixon® 160 mg|Oral administration - 160 mg twice daily.
46012396|NCT01604811|Drug|Tamsulosine Arrow LP|Oral administration - 0.4 mg daily.
46012397|NCT01604811|Drug|Placebo matching Permixon® 160 mg|Oral administration - twice daily.
46012398|NCT01604811|Drug|Placebo matching Tamsulosine Arrow LP|Oral administration - daily.
46012399|NCT01683032|Drug|MPH|a capsule containing 20 mg
46098567|NCT04294355|Device|Artificial intelligence-Assisted colonoscopy|Artificial intelligence-Assisted colonoscopy for detection of colonic polyp
46012400|NCT01604928|Drug|YM178|Oral
46098568|NCT04294355|Procedure|Conventional colonoscopy|Conventional colonoscopy
46012401|NCT01604928|Drug|tolterodine|Oral
46012402|NCT01604928|Drug|Placebo|Oral
46012403|NCT01647776|Other|Stool DNA Test|Stool DNA test is done prior to the colonoscopy.
46012404|NCT01647776|Procedure|biopsies of rectal and colon mucosa|During the standard of care colonoscopy biopsies of rectal and colon mucosa will be taken for analysis of 15-PGDH pathway factors [levels of prostaglandin E2 (PG E2), and mRNA for 15-PGDH, COX-1 and COX-2 expression] as markers of risk of developing adenoma.
46012405|NCT01647776|Other|Questionnaires|A Food Frequency Questionnaire (FFQ), a Meat Preparation Questionnaire (MPQ), and a Physical Activity Questionnaire (PAQ), all developed at the University of Arizona Cancer Center will be used to collect dietary and physical activity data. Risk Factor Questionnaire (RFQ) developed by the University of Southern California will be used to collect general risk information. Stool (sDNA) test patient satisfaction survey.
46098569|NCT00994825|Drug|Levosimendan|
46098570|NCT00994825|Drug|placebo|"Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%"
45679791|NCT05015478|Device|Placebo Rhythmic Lighting Intervention|Placebo rhythmic light (RL) for a duration of 1 hour. In the placebo RL condition, the duty cycle will be delivered with a random interval determined by a Poisson process with an average interval of 40 hertz (Hz). The placebo RL conditions will provide a 30 lux of red light on a vertical plane at the eye level.
46012406|NCT01683110|Drug|cabozantinib|
46012407|NCT01608438|Device|Customizing the Body-Machine Interface|The intervention compares two ways of customizing the body-machine interface which will be used for subjects for 40 sessions (spread over 8 months). In one case (SCI static), the body-machine interface is static. In the other case (SCI Machine Learning), there is a machine learning algorithm that adapts to the movements made by the subject.
46098571|NCT02752529|Drug|Tacrolimus（FK506）|
46098572|NCT00856635|Drug|Glatiramer Acetate|20 mg injected daily subcutaneously
46098573|NCT00856635|Drug|placebo|injected daily subcutaneously
46098574|NCT02620956|Other|nebulizing with heliox and oxygen|Mesh Nebulizer with heliox and oxygen. In order to determine the sequence of the gas associated with the inhaled a randomization was performed, sequence 1- first oxygen and second heliox (80:20) or sequence 2- first heliox (80:20) and secondy oxygen.
46012408|NCT01647815|Procedure|Ultrasound measures|Ultrasound will be used to measure the surfaces of the axillary and subclavian veins with the arms in different positions. Our goal is to compare the vein surface area available among different vein-position combinations. Our goal does not include testing specific devices.
45679792|NCT05011188|Biological|FOR46|Given intravenously (IV)
46012409|NCT01605045|Other|Fluoroscopy-save group|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
46012410|NCT01605045|Other|Standard technique|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
46012411|NCT01683149|Drug|Topotecan|Topotecan will be given by mouth as outlined in treatment arm.
46012412|NCT01683149|Drug|Sorafenib|Sorafenib will be given by mouth as outlined in treatment arm.
46012413|NCT01608555|Drug|tobramycin|inhaled tobramycin 300 mg single dose OD for 28 days
46098575|NCT02712593|Dietary Supplement|Niagen™ 100|
46098576|NCT02712593|Dietary Supplement|Niagen™ 300|
46098577|NCT02712593|Dietary Supplement|Niagen™ 1000|
46098578|NCT02712593|Other|Placebo|
46098579|NCT02620800|Drug|5FU|5 fluorouracil (5-FU) (180 mg/m^2/day for 14 days) by CIVI via ambulatory pump
46098580|NCT02620800|Drug|nab-paclitaxel|nab-paclitaxel (75 mg/m^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15
46098581|NCT02620800|Drug|bevacizumab|bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15
46098582|NCT02620800|Drug|calcium leucovorin|calcium leucovorin (20 mg/m^2) IV bolus, on Days 1, 8, 15
45463757|NCT03938285|Other|Theranova 400 membrane|Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
45463758|NCT03938285|Other|FxCordiax 120 membrane|Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
45679793|NCT05011188|Biological|Enzalutamide|Given orally (PO)
46012414|NCT01647854|Procedure|Teleconsultation|Teleconsultation in prehospital emergencies
46012415|NCT01605084|Drug|Atazanavir|Capsule, Oral, 300 mg, Once daily (QD), 48 weeks
46098583|NCT02620800|Drug|oxaliplatin|oxaliplatin (40 mg/m^2) as a 60-min IV infusion on Days 1, 8, and 15
46098584|NCT04118907|Device|multiple sensory stimulation|The patients were recruited to record their medical history, and the hearing level, tinnitus indicators, vestibular function and tinnitus disability indicators were tested. Then the patients were randomly divided into six groups. They received the corresponding stimulation 20 minutes a day, 5 days a week for 3 weeks. After the last stimulation, the above tests were repeated immediately, one week later and three months later.
46098585|NCT02752451|Other|Non-Anatomic Arthroscopy Simulation|Knee arthroscopy training using Cigar Box Arthroscopy Trainer
46098586|NCT02752451|Other|Anatomic Arthroscopy Simulation|Knee arthroscopy training using Anatomic Knee Arthroscopy Trainer
46012416|NCT01605084|Drug|Darunavir|Oral, Two 400 mg Tablets, Once daily (QD), 48 weeks
46012417|NCT01605084|Drug|Ritonavir|Tablet, Oral, 100 mg, Once daily (QD), 48 weeks
46012418|NCT01605084|Drug|Optimized NRTI backbone|"tablet/capsule, Noninvestigational products i.e. NRTI backbone will be administered according to their respective package inserts for 48 weeks~NRTI backbone are:~- Abacavir (300 mg), Tenofovir (300 mg), Didanosine (250 mg or 400 mg), Stavudine (30 mg or 40 mg), Emtricitabine (200 mg), Lamivudine (300 mg), Zidovudine (300 mg), EPZICOM® (600 mg Ziagen® + 300 mg Lamivudine), COMBIVIR® (150 mg Lamivudine + 300 mg Zidovudine)~The following NRTI combinations are prohibited in this study:~Didanosine + Stavudine~Zidovudine + Stavudine~Lamivudine + Emtricitabine"
46098587|NCT02752451|Other|Pre-assesment education|Reading material and lecture with only still images about performing diagnostic knee arthroscopy
46098588|NCT04118829|Drug|Perampanel|"For group 1 the PER dose will be administered 2-14 hours prior to sample collection. They will be administered a single dose of PER (8 mg, 12 mg or 16 mg) followed by 4 mg/day for 14 days starting on postoperative day 1 (if continued prophylaxis with PER is needed).~It is anticipated that patients in group 2 will have the daily dose of PER in these individuals will range from 4 - 12 mg/day."
46098589|NCT04135014|Drug|Midazolam|oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
46098590|NCT04135014|Drug|Dexmedetomidine|intranasal dexmedetomidine 2µg.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
45463759|NCT03938051|Other|Experimental group|Multicomponent intervention for twice weekly 55-60 minutes 6 weeks
45463760|NCT03938051|Other|Control group|20 minutes treadmill walk thrice weekly, 5-7 /10 subjective rate of perceived exertion
46098591|NCT04135014|Drug|Midazolam and Dexmedetomidine|oral midazolam 0.5mg.kg-1 and intranasal dexmedetomidine 1ug.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
45463761|NCT03848065|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
45463762|NCT03848065|Biological|Pneumococcal 13-valent Conjugate Vaccine (PCV13)|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
45463763|NCT01115153|Other|prophylaxis|single doses of antibiotics before surgery in patients with gangrenous appendicitis Metronidazole 500 mg IV + amikacin 1 gr IV
45463764|NCT01115153|Other|therapy|antibiotic treatment (5 days) therapy in patients with gangrenous appendicitis metronidazole 500 mg IV three times a day + amikacin 1 gr IV per day
45679794|NCT05011188|Drug|Pegfilgrastim|6mg given subcutaneously (subQ)
45679795|NCT04993183|Behavioral|3-day PLUS Convention|Participants will participate in a 3-day PLUS Convention, comprising an inclusivity education workshop, a service-learning seminar, a disability simulation workshop, and two community contact sessions which will consist of a 60-minute interview with an older adult with a physical disability and an outdoor experience. Discussion sessions will be facilitated throughout to consolidate learning.
45463765|NCT01193725|Behavioral|Prolonged Exposure Therapy (PE)|Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
45463766|NCT01193725|Behavioral|Virtual Reality Exposure Therapy (VRET)|Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
45679796|NCT04987320|Drug|Olpasiran|Subcutaneous injection
45679797|NCT04983108|Other|No Intervention|No intervention. This is an observational Study
45679798|NCT04979052|Drug|Interferon Gamma-1B|100 microgram per day, three times a week, subcutaneous. The duration of the treatment is twelve days or until hospital discharge.
45679799|NCT04978584|Drug|Acalabrutinib|Given PO
46012419|NCT01647893|Drug|CTB-001|IV bolus or IV infusion
46098592|NCT02712437|Behavioral|PROSPECT|PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms, including insomnia, through non-pharmacologic approaches.
45463767|NCT01193725|Behavioral|Waitlist|This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
45463768|NCT01110473|Drug|ABT-348|An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
46098593|NCT00996619|Procedure|An optical fiber, inside the work channel of an endoscope, is added to the endoscopic examination|"An optical fiber, inside the work channel of an endoscope, connected to a spectroscope, enables measuring the spectrum of objects seen by the endoscope"
46098594|NCT02752295|Behavioral|stress-coping week|The multidisciplinary team will offer Mindfulness-Based Stress Reduction (MBSR), group psychotherapy (resilience, Cognitive Behavioral Analysis System of Psychotherapy CBASP, psychodynamic therapy), relaxation training, nutrition course, stress-coping and physical training in a group setting.
45463769|NCT01110473|Drug|ABT-348|An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
45463770|NCT01110473|Drug|ABT-348 and azacitidine|An oral dose of ABT-348 on Day 1, Day 8, and Day 15 of each 28 day cycle. An IV or injection of azacitidine on Days 1-7 of each 28 day cycle.
45463771|NCT01110473|Drug|ABT-348|An intravenous dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
45463772|NCT03942731|Other|Behavioral allergy testing protocol|skin tests followed by drug provocation test and skin retesting between 6 weeks and 6 months
45463773|NCT05558761|Drug|Pentoxifylline 400 MG|Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics. PTX exerts anti-inflammatory effects by inhibiting phosphodiesterase and activating the adenosine 2 receptor
45463774|NCT05547295|Other|Numeric prevention|Numeric information for prevention of pressure sores thgrough digital tool MEDIASCREEN
45463775|NCT05547295|Other|Paper prevention|Information for prevention of pressure sores in classic way with paper
46012420|NCT01608633|Other|Spray and stretch|Physiotherapeutic technique which consist in stretching the muscle while a cold spray is applied on the skin.
46012421|NCT01648010|Device|TC-3 gel|One intravesical instillation of 40 cc of TC-3 hydrogel is instilled using catheter.
46098595|NCT02752295|Behavioral|additional two days follow-up weekend|A two-days follow-up which recapitulates previous treatment elements.
46098596|NCT02620722|Device|Personalized Tourniquet Instrument|Measure the limb occlusion pressure in each patient using the new technique with the personalized tourniquet instrument.
45463776|NCT01117571|Device|iUni® Unicompartmental Knee Resurfacing Device|The iUni® Unicompartmental Resurfacing Device is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation
45463777|NCT05534425|Behavioral|GenX intergenerational mentoring program|GenX trains older adults to collaborate with K-3rd grade teachers in mentoring high-need elementary school students in core reading and math skills.
45463778|NCT03940391|Drug|Chlorpheniramine and midazolam|Administration of chlorpheniramine injection as an adjunctive sedative during sedative endoscopy.
45463779|NCT03940391|Drug|Midazolam|Administration of midazolam as a sedative during sedative endoscopy as routine clinical practice.
45463780|NCT03715881|Drug|Oral prednisolone administration 50 mg|50 mg oral prednisolone from the onset of the disease for 1 week, with the dose gradually reduced within 2 weeks and then discontinued
45463781|NCT03715881|Drug|Intravenous Erythropoietin injection|1000 units of erythropoietin every 12 hours for three days
45463782|NCT01197781|Drug|FOSTAMATIN|Oral tablets - single dose
45463783|NCT01197781|Drug|Verapamil|Oral tablets - administered 3 times daily over 4 days
45463784|NCT01117649|Drug|HES 10%|HES 10% dissolved in plasma adapted Ringer's solution (balanced solution).
45463785|NCT01117649|Drug|HES 6%|HES 6% dissolved in plasma adapted Ringer's solution (balanced solution)
45463786|NCT01117649|Drug|balanced electrolyte solution|plasma adapted Ringer's solution
45463787|NCT03713697|Behavioral|Pap testing|Un/underscreened women received a home visit by a Community Health Worker and were scheduled an appointment for a Pap testing at the Basic Health Unit
45463788|NCT03713697|Behavioral|Self-collection for HPV testing|Un/underscreened women received a home visit by a Community Health Worker and were given a kit to self-collect their own sampling for HPV testing at home
45463789|NCT03713697|Behavioral|Choice|Un/underscreened women received a home visit by a Community Health Worker and were given a choice between scheduling an appointment for a Pap testing at the Basic Health Unit or self-collect their own sampling for HPV testing at home
45463790|NCT01197859|Device|Definitive Contact Lens|Daily wear contact lens
45463791|NCT01197859|Device|Biofinity|Daily wear contact lens
46012422|NCT01648010|Device|TC-3 gel mixed with Mitomycin C (MMC)|One intravesical instillation of 40 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter
46098597|NCT02620722|Device|Handheld Doppler ultrasound|Measure the limb occlusion pressure in each patient using the gold-standard technique with the Doppler ultrasound.
46098598|NCT00856557|Behavioral|Seminar and Practicum|A 4 hour seminar and practicum for internal medicine residents designed to provide a systematic approach to identifying contextual factors essential to planning patient care.
46012423|NCT01605201|Biological|Tissue engineered cartilage graft|Autologous nasal chondrocytes expanded in vitro and cultured in a collagen type I//III scaffold
46098599|NCT00996697|Drug|Budesonide/formoterol and tiotropium|Symbicort 200/2, 2puff bid plus tiotropium 18mcg/day
46012424|NCT01683461|Behavioral|Enhanced Counseling|Women in the enhanced counseling arm receive the following intervention package: a video prior to their HIV pre-test counseling session that prepares them for decisions they will have to make regarding HIV testing and PMTCT participation, a pre-test counseling session and post-test counseling session with their nurse midwife/counselor, and two additional post-test counseling sessions with the same nurse midwife at 6 and 10 weeks postpartum. Women in the enhanced counseling arm also have access to ongoing support groups and legal support if needed at the clinic.
45463792|NCT01117805|Behavioral|Telephone counseling intervention|self-regulation telephone counseling program for African American women with asthma
45463793|NCT03713541|Other|No intervention|Survey during normal supply.
45463794|NCT01110551|Drug|Placebo (SC)|Phosphate buffered saline administered subcutaneously.
45463795|NCT01110551|Drug|Placebo (ID)|Phosphate buffered saline administered intradermally.
46012425|NCT01683461|Behavioral|Standard of Care|Women in the standard of care arm receive HIV pre and post-test counseling at their first antenatal visit. The counseling provided to them adheres to international guidelines for HIV counseling and testing developed by US CDC and the World Health Organization.
46012426|NCT01605318|Drug|IMMU-130|This is a Phase I/II, open-label study of IMMU-130 administered in 21-day treatment cycles, once or twice weekly for 2 consecutive weeks followed by one week of rest to patients with metastatic colorectal cancer who have been previously treated with at least one prior irinotecan-containing regimen.
46098600|NCT00996697|Drug|Budesonide/formoterol and placebo|Symbicort 200/6 2puff bid and placebo
46012427|NCT01608711|Biological|AGS-1C4D4|Intravenous Infusion
46012428|NCT01608711|Biological|gemcitabine|Intravenous Infusion
46012429|NCT01648049|Behavioral|Integrated Cognitive Behavioral Therapy (CBT)|CBT treatment is an abbreviated protocol based on manualized, evidence-based treatments for geriatric insomnia (Lichstein & Morin, 2000) and geriatric depression (Thompson, Gallagher-Thompson, & Dick, 1995).
46098601|NCT00999973|Drug|Mitomycin C 0.02%|
46098602|NCT00999973|Drug|Placebo|
46098603|NCT04118673|Behavioral|Lifestyle Prescription (LRx)|Standard care during consultations with the addition of a physical lifestyle prescription
46012430|NCT01648049|Behavioral|Treatment as usual|Standard Care - Treatment as usual
46098604|NCT00696852|Behavioral|Mindfulness Meditation|The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
46098605|NCT00696852|Behavioral|Yoga|The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
46098606|NCT00696852|Behavioral|Exercise, Relaxation, and Health Education|The Exercise, Relaxation and Health Education program will consist of a 90 min group session that will include simple relaxation (such as progressive muscle relaxation) and light stretching exercises, group support, and discussions of various health topics and on stress reduction.
46098607|NCT00996853|Other|Safety follow up|Collection of reactogenicity data from diary cards, reporting of medically-attended adverse events, reporting of serious adverse events and adverse events of special interest, reporting of pregnancy outcomes and fatalities.
46098608|NCT02715947|Drug|Methotrexate|During The first week: 7.5mg per week, oral; The second and third weeks: 10mg per week, oral; The fourth and fifth weeks: 12.5mg per week,oral; The sixth week:15mg per week, and maintain this dose, oral.
45463796|NCT01110551|Biological|Modified Live Tetravalent Chimeric Dengue Vaccine (SC)|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10^3, D2: 5 x 10^3, D3: 1 x 10^4, and D4: 2 x 10^5, total virus dose [plaque forming units (PFU)]: 2.2 x 10^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10^4, D2: 5 x 10^4, D3: 1 x 10^5, and D4: 3 x 10^5, total virus dose (PFU): 4.7 x 10^5. DENVax administered subcutaneously.
45463797|NCT01110551|Biological|Modified Live Tetravalent Chimeric Dengue Vaccine (ID)|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10^3, D2: 5 x 10^3, D3: 1 x 10^4, and D4: 2 x 10^5, total virus dose [plaque forming units (PFU)]: 2.2 x 10^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10^4, D2: 5 x 10^4, D3: 1 x 10^5, and D4: 3 x 10^5, total virus dose (PFU): 4.7 x 10^5. DENVax administered intradermally.
45463798|NCT01110629|Drug|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Daily dose: 750-2250mg 3 times a dayfor 8 weeks.
45463799|NCT01110629|Drug|Placebo|daily dose: 3 tablets TID for 8 weeks.
46098609|NCT00856323|Drug|Truvada|At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
46098610|NCT00856323|Behavioral|CM|Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.
46012431|NCT02482623|Behavioral|Dementia Symptom Management at Home Program|The DSM-H is a multi-modal interprofessional intervention that includes: 1. intensive training of clinician mentors; 2. disseminated online training for Registered Nurses, Physical Therapists, Occupational Therapists; 3. implementation of evidence-based care plans, assessment instruments, and teaching handouts.
46012432|NCT01683500|Device|shock wave therapy with Modulith SLK (Storz)|Three sessions with shock wave therapy, interval of one week.
46012433|NCT01605357|Drug|Induced, sustained hypernatremia using hypertonic saline|"Patients in the experimental arm will receive hypertonic saline to target a serum sodium goal of 150 - 160 mmol/L. All hypertonic saline will be administered intravenously.~Loading phase: Upon enrollment 23.4 % hypertonic saline (volume 20 cc) will be administered via a central venous catheter. A continuous infusion of 3% hypertonic saline will be administered at a rate of 30 cc per hour and titrated every six hours to target a serum sodium goal of 150-160 mmol/L.~Maintenance phase: Titrate serum sodium to 150-160 mmol/L using continuous 3% hypertonic saline infusion.~Discontinuation phase: After 5 days of completed therapy, begin to wean 3% hypertonic saline rate by 10cc every 6 hours. Discontinue hypertonic saline infusion after infusing at a rate of 20cc an hour for 6 hours.~Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines"
45463800|NCT01296139|Drug|Ferumoxytol|All subjects will undergo pre-injection, 24, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) MRI consisting of T1 weighted (W), T2W and T2*W MRI in a 3 Tesla magnet. Additionally, all subjects will undergo pre-injection, 24 hours, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) ultrasound.
45463801|NCT01296217|Procedure|lymph nod detection|
45463802|NCT03940469|Drug|Saline|2 ml normal saline
45463803|NCT03940469|Drug|Dexamethasone Injection|8 mg dexamethasone
45463804|NCT03940469|Drug|Dexmedetomidine Hydrochloride|100 microgram dexmedetomidine
45463805|NCT03847753|Other|Organic Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
45463806|NCT03847753|Other|Substance Use Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
45463807|NCT03847753|Other|Schizophrenia Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
45463808|NCT03847753|Other|Mood disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
45463809|NCT03847753|Other|Neurotic disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
45463810|NCT03847753|Other|Eating Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
45679800|NCT04978584|Drug|Cyclophosphamide|Given IV
45679801|NCT04978584|Drug|Doxorubicin Hydrochloride|Given IV
45463811|NCT03847753|Other|Personality Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
45463812|NCT03847753|Other|Intellectual Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
46012434|NCT01605357|Drug|Standard of care (hypertonic saline and mannitol; serum sodium)|Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines. Hyponatremia ( serum sodium < 135 mmol/L) is to be corrected at the discretion of the provider.
45463813|NCT03847753|Other|Developmental Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
45463814|NCT03847753|Other|Behavioral Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
45463815|NCT01110785|Biological|panitumumab|
45463816|NCT01110785|Drug|simvastatin|
45463817|NCT01110785|Other|laboratory biomarker analysis|
45463818|NCT01296295|Behavioral|Lifestyle counseling and spirometry|The patients of the intervention group will be given a brief structured smoking cessation advice by their primary care physician combined with a detailed and structured discussion of the spirometry results.
45463819|NCT01296295|Behavioral|Smoking cessation advice|Brief smoking cessation advice
45463820|NCT03846271|Drug|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
45837394|NCT04747236|Drug|Pralatrexate|Pralatrexate, 30 mg/m2 as an intravenous infusion over a 3-5 minute push once weekly for 6 weeks of a 7 week treatment cycle.
46012435|NCT01648127|Drug|Ceftaroline|A single dose of ceftaroline fosamil 600 mg as a 1-hour continuous intravenous infusion
45463821|NCT03846271|Drug|intranasal placebo|an identical amount of placebo nasal spray will be applied to each subject.
45463822|NCT01110941|Drug|S-1, leucovorin, oxaliplatin|S-1(20mg、25mg), capsule, 40~60mg, Bid,p.o., day1~7； LV (25 mg), tablet, 25mg,Bid,p.o., day1~7； L-OHP (50 mg),injection 85mg/m2, day1. repeated at every 2 weeks cycle till disease progression.
45463823|NCT03448419|Drug|Empagliflozin|Film-coated tablet
45463824|NCT03448419|Drug|Placebo|Film-coated tablet
45463825|NCT01117883|Other|Application of two different sternal weights|Two separate weights (first 10% of body weight, then 20% of body weight) will be placed on the sternum and changes in central hemodynamic measurements and intrathoracic pressure will be recorded and documented.
45837395|NCT04747236|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of a 28 day cycle.
45837396|NCT04742946|Other|Digital Physiotherapy Practice (Telerehabilitation)|Online Physiotherapy services
45837397|NCT01797666|Drug|Torrent's Pioglitazone Hydrochloride Tablets 45 mg|
45837398|NCT05017194|Drug|Emodepside|Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or albendazole (400 mg) or placebo.
46012436|NCT01605474|Other|Patient discharged home after foley bulb placement.|The patient will be discharged home after fetal status is evaluated and noted to be reassuring. A 16 French foley bulb insufflated with 30 cc of normal saline will be placed and secured to the patient's inner thigh.
46012437|NCT01605474|Other|Inpatient|The patients will not be discharged home after assessment and placement of the foley catheter.
46012438|NCT01683539|Behavioral|The Thinking Skills for Work Program|The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and work services.
46012439|NCT01683539|Behavioral|The Cognitive Skills for Work Program|The Cognitive Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, compensatory strategy training, and integration of cognitive and work services.
46012440|NCT01608750|Drug|Pantoprazol|40mg/day, oral, 28 days
45463826|NCT01117961|Behavioral|Lifestyle|Behavioral lifestyle intervention targeting diet and physical activity to reduce excessive gestational weight gain
46012441|NCT01608750|Drug|Folic Acid|5 mg/day, oral, 28 days
45463827|NCT05668273|Other|education with simulated patient|Students in the education with the simulated patient group will practice auscultation skills on the simulated patient with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination. A debriefing session will be held with the students by the educator right after the students have finished the application.
45463828|NCT05668273|Other|education with simulator|Students in the simulator group will practice auscultation skills on high fidelity simulator with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination. A debriefing session will be held with the students by the educator right after the students have finished the application.
45463829|NCT05668273|Other|control group|Students in the control group will practice auscultation skills on their peers with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination.
45463830|NCT01118039|Drug|sunitinib malate|
45463831|NCT01118039|Other|immunohistochemistry staining method|
45463832|NCT01118039|Other|laboratory biomarker analysis|
45463833|NCT01118039|Other|pharmacological study|
45463834|NCT01118039|Procedure|quality-of-life assessment|
45463835|NCT03844711|Other|Transcutaneous electrical diaphragmatic stimulation (TEDS)|"Stage I: In the first day (group 1) the parameters will be with 30 Hz frequency and the second day (group 2) will be with 80 Hz, with one-day interval between interventions. The TEDS will be applied with symmetrical biphasic pulsed current, pulse width 0.4 ms, rise time of 1 second (s), 1s lift, 2 s descent, maintaining respiratory rate of 15 rpm, intensity required to obtain visible muscle contraction, for 20 minutes or until muscle fatigue.~Stage II and III:The TEDS will be applied with symmetrical biphasic pulsed current, the parameters will be with 30 Hz frequency, pulse width 0.4 ms, rise time of 1 second (s), 1s lift, 2 s descent, maintaining respiratory rate of 15 rpm, intensity required to obtain visible muscle contraction, for 20 minutes or until muscle fatigue."
45463836|NCT03844711|Other|Inspiratory Muscle Training (IMT)|- Stage II and III: The training will start with a minimum load of 50% and will be progressed until reaching 60% of the PImax. Inspiratory muscle training will start with a minimum load of 50% and progress to 60% of the MIP. The patients will perform daily training, being two sets of 30 breaths, one in the morning and one in the afternoon.
45463837|NCT03844711|Other|Conventional physiotherapy|- Stage III: It consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resistance exercises.
45463838|NCT01213433|Drug|Artesunate-Amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008.It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
45463839|NCT01199419|Procedure|comparison of PCI vs. CABG in multivessel disease|invasive treatment of coronary artery disease
45679802|NCT04978584|Drug|Lenalidomide|Given PO
45679803|NCT04978584|Drug|Prednisone|Given PO
45679804|NCT04978584|Biological|Rituximab|Given IV
45679805|NCT04978584|Biological|Tafasitamab|Given IV
45679806|NCT04978584|Drug|Vincristine|Given IV
45679807|NCT04976634|Drug|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
45679808|NCT04976634|Drug|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
46012442|NCT01605513|Drug|interferon|PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.
46012443|NCT04528277|Drug|rifapentine plus isoniazid|receive the 1-month regimen of three times weekly rifapentine (450mg po) plus isoniazid (400mg po)
46012444|NCT01605591|Procedure|the DLT bending to the right|bending the bronchial lumen of DLT 60~90 degrees in the same side with the tracheal lumen
46012445|NCT01605591|Procedure|the DLT bending to the left|bending the bronchial lumen of DLT 60~90 degree opposed to the tracheal lumen
46012446|NCT01683617|Behavioral|Coping skills and relaxation training with new technologies|
46012447|NCT01683617|Behavioral|Traditional coping skills and relaxation training|
46012448|NCT01605630|Behavioral|Family-based family cancer literacy intervention|family based counseling and materials provided in navajo/english including digital stories
45463840|NCT03940079|Device|computer-based cognitive game (including 3 training tasks)|"First task was short-term memory training. Participants were instructed to memorize different colored circles with ordinal numbers which would disappear later. They triggered correct colored sensor in sequence according to their memory.~Second task was divided attention training. Different colored circles with ordinal numbers would not disappear this time.The participants should trigger correct colored sensor according to their sequence.~Third task was inhibitory function training. There were red and green lights, just like the traffic light, hung up at the upper left of the scene. Red light represented prohibition of triggering the colored sensor, while green light urged to trigger it. Yellow, red, blue and green circles showed up randomly and moved toward the beige region. When the circle came extremely closer to the beige region, the traffic light was randomized to lighten up red or green.The participants should judge and trigger the correct colored sensor."
45463841|NCT01213511|Procedure|Coronary artery bypass grafting with the use of minimal extracorporeal circulation|The MECC system (Maquet Cardiopulmonary, Hirlingen, Germany) consists of a pre-connected closed CPB circuit containing a RotaFlow centrifugal pump and a Quadrox D diffusion membrane oxygenator. A flow meter and a bubble sensor are integrated in the drive unit of the centrifugal pump. The system features a tip-to-tip heparin coating (Bioline Coating, Maquet Cardiopulmonary, Hirlingen, Germany). No arterial or venous line filters are included. Initial priming volume of the system is 500 mL, while using retrograde autologous priming (RAP) the circuit could be filled in with autologous blood, thus reducing hemodilution. Since no cardiotomy suction is used, shed blood is collected with a cell-saving device (Haemonetics Corp, Braintree, MA).
45463842|NCT01213511|Procedure|Coronary artery bypass grafting under conventional extracorporeal circulation|A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
45463843|NCT01195753|Biological|HHLivC|multiple infusion of liver cells
45463844|NCT01111097|Drug|Dichloroacetate|Subjects after passing the inclusion criteria are given a dose of dichloroacetate 4mg/kg bid for thirty days. While in the clinical research center they participate in a breath test where they exhale through a straw into a glass tube. This will measure CO2. They are monitored every two weeks for side effects and return to the clinical research center for evaluation in thirty days. They undergo another breath test and if all health parameters are within normal limits they are given a month's supply of dichloroacetate. The cycles continue unless a serious adverse event occurs or the PI judges the side effects preclude another 30 days of medication
45463845|NCT05299879|Diagnostic Test|Cardiopulmonary exercise test, NT-proBNP, Echocardiography, 6 minute walk test, Right heart catheterization|Screening for advanced HF with modified criteria from the Heart Failure Association of the European Society of Cardiology
45679809|NCT04976634|Drug|Lenvatinib|Lenvantinib dose for HCC is 8 mg QD for body weight <60 kg and 12 mg QD for body weight ≥ 60 kg administered via oral capsule. For all other tumors, the lenvatinib dose is 20 mg QD administered via oral capsule
45679810|NCT04975893|Biological|mRNA-1647|No investigational product will be administered in this extension study.
45679811|NCT04966559|Drug|Placebo treatment|Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
45679812|NCT04966559|Drug|Naldemedine 0.2 MG Oral Tablet|Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
46012449|NCT01605630|Behavioral|Control|standard of care
45679813|NCT04955808|Procedure|Biospecimen Collection|Undergo collection of tissue and blood samples
45679814|NCT04955808|Other|Laboratory Biomarker Analysis|Correlative studies
46012450|NCT01683656|Drug|niacin/laropiprant|
46012451|NCT01683656|Drug|Placebo|Procedures for the manufacturing and testing of the placebo are compiled in the IMP/study drug dossier and comply with local regulatory requirements (by GMP certified manufacturer).
46012452|NCT01605747|Dietary Supplement|Culturelle|one capsule 2x per day per feeding tube
46012453|NCT01605747|Dietary Supplement|Placebo|one placebo 2x per day per feeding tube
46098611|NCT02616588|Behavioral|Veteran Patient Navigator and Social Work Intervention|Each study participant will receive a veteran patient navigator intervention which consists of five study visits consisting of advance care planning, pain/symptom management, and education about hospice and palliative care. When clinically indicated, patients will be referred to a social work intervention providing psychosocial care and support.
46098612|NCT01666145|Device|Advanced Image Guidance|Patients with hepatocellular carcinoma will be treated through laparoscopic microwave ablation surgery, in which the surgeon will utilize a new guidance system for needle placement.
46098613|NCT02616510|Procedure|cardiovascular screening|cardiovascular screening: serum, urine, ECG, carotid intima media thickness (IMT), cardiac ultrasound
46098614|NCT00856245|Drug|Rituximab|375 MG/M2 (milligram per meter squared) given IV (intravenously) weekly x 4-8 doses.
46098615|NCT01193777|Drug|L-Carnitine|4 gram bolus followed by 8 gram in 1 L NS infused over 12 hours.
45679815|NCT04954820|Drug|Lutathera|2 additional infusions of Lutathera®
45679816|NCT04950608|Drug|Psilocybin|Oral, single administration, dosage 25 mg orally
45679817|NCT04950608|Behavioral|Psychotherapy|The treatment regimen consists of a single administration of psilocybin orally combined with a supportive psychotherapy including 2 preparation sessions and 2 integration sessions
45679818|NCT04940052|Drug|Dabrafenib|Dabrafenib will be administered orally twice daily
45679819|NCT04940052|Drug|Trametinib|Trametinib will be administered orally once daily
46012454|NCT01605786|Biological|Lyophilised PEBS synthetic protein (PfPEBS)|"PfPEBS, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131 aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 5μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval."
45463846|NCT03848533|Drug|melatonin|"The administration of melatonin will be indicated at night before bedtime to avoid alterations of the circadian cycle. It will be contained in bottles labeled Medication 2 to maintain the masking. This intervention will be indicated in two groups (Melatonin plus metformin and Melatonin plus placebo)"
45679820|NCT04940052|Drug|Trametinib placebo|Trametinib will be administered orally once daily
45679821|NCT04940052|Drug|Dabrafenib placebo|Dabrafenib placebo will be administered orally twice daily
46012455|NCT01605786|Biological|Lyophilised PEBS synthetic protein (PfPEBS)|"PfPEBS-LSP, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 30 μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval."
46012456|NCT01605786|Other|Rehydragel™ HPA|"Aluminium hydroxide adjuvant is being used as the adjuvant for the vaccine and will be used as the comparator in the control group. Vac4all is using Rehydragel™ (Manufacturer Reheis Inc.) which is a highly active protein adsorbent specially compounded for use as a fluid adjuvant. It has low oxide content and is carefully controlled for Al2O3 content and protein binding capacity. It has a lower viscosity than competing adjuvants, which makes it easier to process and handle.~Subjects in the control group will be administered a 0.5 ml injection in a 2-dose schedule at 28 days interval. Each injection will contain approximately 600 µg of Al(OH)3 per injected dose corresponding to 200 µg equivalent of Al3+, similar to the amount being administered in the vaccine group."
46012457|NCT01683695|Drug|AMG 557|AMG 557 will be administered as subcutaneous injections in the anterior abdomen of the subjects.
46012458|NCT01683695|Drug|Matching Placebo|Placebo will be administered as subcutaneous injections in the anterior abdomen of the subjects.
46012459|NCT01605864|Drug|Efficacy of ceftaroline|Determining the efficacy of ceftaroline compared to other cephalosporins
45463847|NCT03848533|Drug|metformin|"For the intervention with metformin, prolonged-release tablets will be used to reduce adverse effects and improve adherence to treatment. It will be contained in bottles labeled Medication 1 to maintain masking. This intervention will be indicated in two groups (Melatonin plus metformin and metformin plus placebo)"
45679822|NCT04936529|Dietary Supplement|β-glucan|"Group 1 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with ~2 weeks on, ~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14). This schedule includes annual booster vaccinations, with a 2-week cycle of β-glucan, administered at months 36 (3 years), 48 (4 years), and 60 (5 years).~Group 2 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with ~2 weeks on, ~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14).~Group 3 participants will be treated as in Group 1."
45679823|NCT04936529|Drug|GM-CSF|"Group 1 participants will not receive GM-CSF.~Group 2 participants will receive GM-CSF (250 mcg/m2/day) x3 days with vaccinations #1-#3; x7 days with vaccinations #4-#11; and x5 days with vaccinations #12-#14.~Group 3 participants will be treated as in Group 1."
45679824|NCT04936529|Biological|OPT-821|Vaccine injections must occur a minimum of 6 days apart. After the first four vaccine injections, vaccines can be administered up to two weeks earlier or later than indicated without representing a protocol violation.
46098616|NCT01193777|Drug|Normal Saline|Bolus followed by 1 L NS infusion over 12 hours.
46098617|NCT01000129|Other|Adaptive-Planning Organ Localisation (A-POLO) (Planning CT scan)|Planning CT scan performed by qualified planning radiographers
46098618|NCT01000129|Other|Cone beam CT acquisition|Cone beam CT acquisition performed by therapy radiographers who have training and experience of using cone beam CT.
46098619|NCT01000207|Biological|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
46098620|NCT00855933|Device|Experimental Floss|Experimental Glide® floss with cetylpyridinium chloride (~13% dry weight CPC)
46098621|NCT02715557|Behavioral|Relapse prevention program|The relapse prevention program is an innovative computer-based coping skills educational program for adolescent substance abuse treatment completers.
46098622|NCT00994903|Drug|Simvastatin|40mg orally, given 3-7 days pre-op and continued till 14 days post-op
45679825|NCT04932122|Procedure|Dorsal wrist ganglion alone (DWG)|Patients assigned to this arm will undergo dorsal wrist ganglion cyst excision alone.
45679826|NCT04932122|Procedure|DWG/PIN|Patients assigned to this arm will undergo dorsal wrist ganglion excision and the addition of a partial wrist denervation by resecting the common terminal sensory branch of the posterior interosseus nerve (PIN)..
46098623|NCT00994903|Drug|Placebo|Placebo (Inert calcium lactate) tablets 3-7 days pre-op to 14 days post-op (as per experimental arm)
46098624|NCT00699777|Drug|Risedronate|1 risedronate 150 mg tablet administered orally
46012460|NCT01648244|Other|Computer-Assisted Decision Support|"The CADS software makes a recommendation about what medication changes are appropriate with potential alternates. CADS providers will either accept or reject the recommendation by the software.Providers with their patients are block randomized into CADS or Usual Care for 1 year. Patients associated with a CADS provider will upload their blood glucose data weekly and perform a 7-point glucose profile once per month. They will report major hypoglycemic events and hospitalizations at the time of their quarterly visit. Those getting usual care will be seen quarterly and will do self-monitoring of blood glucose and have A1c tests as determined by the provider but no less than twice a year."
46098625|NCT00699777|Drug|Risedronate|2 risedronate 75 mg tablets administered as a single oral dose
46098626|NCT00997009|Drug|paclitaxel|175 mg/m2 IV day 1, every 21 days
46098627|NCT00997009|Drug|carboplatin|AUC 5 IV day 1 every 21 days
46098628|NCT00997009|Drug|cetuximab|400 mg/m2 IV, one week before starting carboplatin and paclitaxel; then 250 mg/m2 IV day 1, weekly
46098629|NCT02712125|Drug|isosorbide mononitrate|20 mg isosorbide mononitrate (IMN) tablet applied vaginally once daily until delivery .
46098630|NCT02712125|Drug|Placebo|placebo vaginal tablets once daily until delivery
45463848|NCT03848533|Drug|Placebo|"The placebo may be contained in bottles labeled Medication 1 or Medication 2 depending on the time of administration, and the group in which it is used. Placebo will be used in two groups (Melatonin plus placebo and Metformin plus placebo)"
45463849|NCT05129215|Other|Questionnaire|The LARS score is used for assessment of bowel dysfunction after rectal cancer resection.
45463850|NCT01115465|Device|Macroplastique|Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) primarily due to intrinsic sphincter deficiency (ISD).
46098631|NCT02752373|Device|Brain Sentinel Seizure Detection and Information System|The Brain Sentinel® GTC Seizure Detection and Information System is an ambulatory system designed to continuously monitor and perform real-time analysis of surface electromyography (sEMG) data to detect GTC seizures and to provide an alarm to alert caregivers within 30 seconds of bilateral, appendicular, tonic extension that a seizure is occurring. The System is for recording and storing sEMG data, which is subsequently reviewed by a trained healthcare professional in the outpatient clinical setting. The Brain Sentinel® GTC Seizure Detection and Information System is intended for real time monitoring of pediatric and adult patients who have an arm circumference ranging from at least 16 cm to no greater than 51 cm at the biceps. It may be used in the home or healthcare facilities for real-time monitoring during the day, night, or for continuous monitoring, including during the titration of, or the withdrawal from anti-epileptic drugs.
45463851|NCT01199497|Drug|Group 1|fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
45463852|NCT01199497|Drug|Group 2|placebo
46012461|NCT01608789|Device|Virtue® Male Sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD).
46012462|NCT01683773|Biological|AERAS-402|Intramuscular needle injection 1x10^11 vp
45463853|NCT05289817|Device|Transcutaneous Vagus Nerve Stimulation (t-VNS)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 10 Hz Number of channels: one Location and electrodes: cymba conchae at right ear (vagus branch nerve area); a clip electrode will be applied with its cathode on anterior cymba conchae, the anode placed behind.~Amplitude: from 2 times the perception threshold (individualized) at a comfortable, non-painful amplitude, and to a maximum of 9 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of tingling sensation On-Off times: trains of 30 s on, 5 s rump up, 1 s rump down, 24 s off Duration: 20 minutes"
45679827|NCT04929028|Drug|Capecitabine|Given PO
45679828|NCT04929028|Drug|Fluorouracil|Given IV
46012463|NCT01683773|Biological|MVA85A|Intradermal needle injection 1x10^8 pfu
46012464|NCT01608867|Biological|OMP-54F28|dose escalation of 0.5, 1, 2.5, 5, and 10 mg/kg administered IV once every 3 weeks
46012465|NCT01648478|Other|It is a hyperinsulinemic-euglycemic clamp.|"The hyperinsulinemic-euglycemic clamp includes three periods:~A basal period (from T-30 to T0)~The infusion of insulin at a constant rate (first level at 1 mUI.kg-1.min-1 and a second level at 2 mUI.kg-1.min-1) during 4 hours ( to obtain stable hyperinsulinemia)~The infusion of glucose at variable rate (so as to maintain euglycemia)"
46012466|NCT01608945|Drug|Hydrocortisone sodium succinate|100mg/day
45463854|NCT05289817|Device|Transcutaneous Sympathetic Ganglion Electrical Stimulation (t-SES)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 5 Hz Number of channels: two Location and electrodes: cervicothoracic area (stellate ganglion region); first channel: new 5 cm x 5 cm self-adhesive electrodes will be applied at 1-1.5 cm both sides of the vertebral spinous processes, approximately from C7 to T4, upper cathode on the left side of C7 and lower cathode on the right side.~Amplitude: 2 mA above the muscle contraction threshold (individualized) at a comfortable, non-painful amplitude and to a maximum of 25 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of muscle contraction On-Off times: no trains, continuously delivered Duration: 20 minutes"
45679829|NCT04929028|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45679830|NCT04929028|Drug|Mitomycin|Given IV
45679831|NCT04929028|Biological|Nivolumab|Given IV
45679832|NCT04925817|Other|Electronic Health Record Review|Medical record reviewed
45679833|NCT04925817|Procedure|Ultrasound Microvessel Imaging|Undergo 3D ultrasound microvessel imaging
45679834|NCT04924075|Drug|Belzutifan|Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.
45679835|NCT04920253|Device|Study Device Debridement|debritom+ water jet debridement
45679836|NCT04920253|Device|SOC Debridement|Sharp Scalpel
45679837|NCT04909450|Biological|CSB-001 Ophthalmic Solution 0.1%|CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
45463855|NCT05289817|Device|Sham Transcutaneous vagus nerve stimulation (Sham t-VNS)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 10 Hz Number of channels: one Location and electrodes: scapha at right ear (non vagus innervated region); a clip electrode will be applied with its cathode on anterior scapha, the anode placed behind.~Amplitude: from 2 times above the perception threshold (individualized) at a comfortable, non-painful amplitude, and to a maximum of 9 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of tingling sensation On-Off times: trains of 30 s on, 5 s rump up, 1 s rump down, 24 s off Duration: 20 minutes"
45463856|NCT01111253|Drug|Amoxicillin-clavulanate|"Amoxicillin-clavulanate: 4 times a day 1200 mg and switch to oral administration 3 times a day 625 mg after two days, for a total duration of 10 days.~In case of allergy to Amoxicillin-clavulanate: intravenous administration ciprofloxacin 2 times a day 400 mg and metronidazole 3 times a day 500 mg. In case of oral administration ciprofloxacin 2 times a day 500 mg and metronidazole 3 times a day 500 mg. For a total duration of 10 days."
46098632|NCT05192785|Procedure|Incentive Spirometry Group|"The inspiration and expiration applications of incentive spirometry (IS) involved 10-20 breaths every one to two hours, depending on the tolerance of the patients.~During the inspiration application of IS, the head of the bed was elevated to a 45° angle, and the patient was placed in a long sitting position. The patient was requested to surround and fix the IS mouthpiece well, ensuring no gap was left between the lips. The patient was told to breathe slowly and deeply, and was asked to hold their breath for 2-3 seconds, and then to breathe normally with the IS mouthpiece in his/her mouth. The patient was advised to repeat the exercise 5-10 times, and to try to cough after every 5 exercises.~For the applied IS expiration technique applied in the study, which had not been previously encountered in literature, the patient was requested to turn the IS upside down (clockwise,180°) and to place the mouthpiece in his/her mouth and expiration application it."
46012467|NCT01608984|Procedure|Remote ischemic preconditioning (RIPC)|"3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion.~The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. In the CABG-arms, during extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations."
46098633|NCT04118439|Other|Motor Imaginery and Action Observation|A set of tasks done with the shoulder, first with an Action Observation perspective and then asked to perform this tasks with motor imaginery
45463857|NCT05275387|Other|observational study, no intervention|observational study, no intervention
45463858|NCT01213667|Drug|Ranibizumab|upload (three monthly injections), re-treatment as needed
46012468|NCT01608984|Procedure|Coronary artery bypass grafting (CABG) without remote ischemic preconditioning protocol|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
46012469|NCT01608984|Procedure|Off-pump Coronary artery bypass surgery without remote ischemic preconditioning|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required.
45463859|NCT01212263|Drug|Step-up HP u FSH|HP u FSH (Fostimone 75 IU ,IBSA Institut Biochimique SA-CH 6903 Lugano) in doses of 37.5 IU (half ampole) im /day statrted from second day of the cycle for 7 days ,then increased to 75 IU for another 7 days ,then to 112.5 IU (one and half ampoule) untilleading follicle mean diameter reaches 18 mm
45679838|NCT04909450|Biological|Vehicle Control|Matching vehicle control without the drug substance
45463860|NCT01212263|Drug|Clomiphine citrate plus low dose uFSH|Clomiphene citrate 50 mg tab oral tablets(Clomid 50 mg tablets Global Napi , Egypt) two tablets(100 mg) /day are started from the 2nd day of cycle for 5 days togeteher with 37.5 IU HP uFSH (Fostimone 75 IU IBSA)/day for 8 days and may be extended to 10-12 days until leading follicle diameter reaches 18 mm
45463861|NCT01196065|Drug|RO5313534|single oral dose
45463862|NCT01196065|Drug|memantine|multiple doses to steady state
45463863|NCT01213745|Other|Intervention|
46098634|NCT04220411|Drug|AR100DP1|topical ointment
45679839|NCT04907643|Device|PICO G2 4k|Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
45679840|NCT04898621|Dietary Supplement|75g fructose solution|Subjects will drink a bottle of 350 ml solution containing 75g fructose per day for 4 weeks.
45679841|NCT04898621|Dietary Supplement|150g fructose solution|Subjects will drink a bottle of 700 ml solution containing 150g fructose per day for 4 weeks.
45679842|NCT04892446|Drug|Magrolimab|Administered IV
46098635|NCT02613429|Behavioral|identification of the airway by from the cranial end|The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the thyroid cartilage and from there moving distally
46012470|NCT01648517|Drug|chemotherapy|A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)
46012471|NCT01648517|Drug|chemotherapy|Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1
46012472|NCT01609101|Device|C-MAC ® videolaryngoscope|C-MAC ® videolaryngoscope
46098636|NCT02613429|Behavioral|identification of the airway from the distal end|The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the distal trachea and moving cranially
46012473|NCT01609101|Device|Coopdech® videolaryngoscope|Coopdech® videolaryngoscope
46012474|NCT01609101|Device|McGrath® Series 5 videolaryngoscope|McGrath® Series 5 videolaryngoscope
46012475|NCT01609101|Device|Glidescope® Cobalt videolaryngoscope|Glidescope® Cobalt videolaryngoscope
46098637|NCT00994981|Drug|magnesium|Thirty minutes after the beginning of the anhepatic phase, the patients were received a magnesium solution (MgSO4 25 mg•kg-1 mixed in 100 ml of normal saline) over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
45463864|NCT01213745|Other|Attention|
45463865|NCT01213745|Other|Control|
45463866|NCT05258773|Drug|SENS-401 (R-Azasetron Besylate)|Patients will receive SENS-401 ((R)-azasetron besylate) for 7 days B.I.D. before cochlear implant surgery and during 6 weeks after the surgery.
45463867|NCT01111409|Device|VFIX Device|Sterile, single-use instrument capable of delivering an absorbable PDS suture anchor
45463868|NCT03845179|Other|Placebo|Saline infusion
45463869|NCT03845179|Other|GIP receptor antagonist|Used for infusion on study days
45463870|NCT03845179|Drug|DPP-4 inhibitor|Oral administration of DPP-4 inhibitor in active treatment period
45463871|NCT03845179|Other|Placebo tablet|Oral administration of placebo tablet in placebo treatment period
45463872|NCT03936179|Radiation|high dose radiation therapy with concurrent chemotherapy|standard dose of 50 Gy concurrent weekly with paclitaxel (45 mg/m2) and carboplatin (area under curve 1.5 ), immediately followed by hyperfractionated radiotherapy boost of 36 Gy in 30 fractions of 1.2 Gy to residual metabolic disease as defined by PET/CT
45463873|NCT03936023|Drug|Saxagliptin|Saxagliptin dispensing claim is the exposure
45463874|NCT03936023|Drug|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
45679843|NCT04892446|Drug|Daratumumab|Administered either SC or IV
45679844|NCT04892446|Drug|Pomalidomide|Administered orally
46012476|NCT01609101|Device|King Vision® videolaryngoscope|King Vision® videolaryngoscope
46012477|NCT01609101|Device|Venner® videolaryngoscope|Venner® videolaryngoscope
46012478|NCT01609101|Device|McGrath® MAC|McGrath® MAC (Aircraft Medical, Edinburgh, UK)
45463875|NCT05235295|Procedure|Ultrasound-guided sacroiliac joint injection|Using ultrasound the sacral hiatus in transverse position was identified. Then, sliding laterally and cephalad in transverse position, the posterior superior iliac spine and the posterior sacroiliac joint were identified. The needle was advanced toward the posterior joint space from medial to lateral, using an in-plane technique.
45679845|NCT04892446|Drug|Dexamethasone|Administered orally
46012479|NCT01683929|Other|glucose|"The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing 75 gram glucose (oral glucose tolerance test (OGTT / GTT) All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR & BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire."
46098638|NCT00994981|Drug|normal saline|Thirty minutes after the beginning of the anhepatic phase, the patients were received 100 ml of normal saline over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
45463876|NCT05235295|Procedure|Flouroscopy-guided sacroiliac joint injection|Using anterior posterior and contralateral oblique view the posterior joint line and inferior joint margin were identified and a needle was advanced at the point the posterior inferior joint line was most clearly seen.
45463877|NCT01121627|Other|Computerized cognitive training|A 12 week computerized cognitive training at home with the Attengo™ software program.
46098639|NCT02715479|Drug|Dolutegravir|Dolutegravir
46098640|NCT02715479|Drug|BMS955176|BMS955176
45463878|NCT04806139|Behavioral|Remote Enhance Fitness|The Remote Enhance Fitness Intervention will include live-streamed exercise classes (1-hour long, 3 days per week, 16 weeks). Certified Enhanced Fitness trainers will lead the exercise classes per Enhance Fitness guidelines, including modifications and gradual progression. During weeks 8-12 participants will have the option to wear a Fitbit during classes for up to 6 class session (2 weeks) for collection of heart rate, steps, and physical activity intensity along with ratings of perceived exertion (RPE) during exercise classes.
45463879|NCT01212341|Biological|Allogeneic NK cells|
45463880|NCT01199653|Procedure|Operative treatment|Fracture stabilization with stainless steel reconstruction plate and screws. After the operation arm is immobilized to a sling for three weeks. Pendulum movements are allowed immediately.
46098641|NCT00699933|Other|CT-guided percutaneous drainage technique|Evaluation of different diagnostics and evaluation of outcome of patients who received percutaneous CT-guided drainage for necrotic debridement and analyze the further outcome
46098642|NCT01000441|Drug|infliximab, etanercept, adalimumab|
46098643|NCT01000441|Drug|abatacept, rituximab or tocilizumab|
45463881|NCT01199653|Procedure|Non-operative treatment with arm immobilised to a sling|Arm is immobilised to a sling for three weeks. Pendulum movements are allowed immediately.
45463882|NCT01121705|Drug|Peg Interferon alpha2b + Ribavirin|"B 1 I or II: Experimental~variable duration of treatment group according with RVR. In case of RVR present patients will be treated for 12 weeks. Patients without RVR will be treated for 24 (B1I) or 36 (B1II)weeks: different duration of treatment for patients without RVR"
45463883|NCT01198171|Other|Laboratory Biomarker Analysis|Correlative studies
45463884|NCT01198171|Other|Study of Socioeconomic and Demographic Variables|
46098644|NCT02752217|Other|Inspiratory Muscle Training|Inspiratory muscle training at 25%MIP with Slow breathing at 6 breath per min with BreatheMAX device for 8 weeks at home
45679846|NCT04892446|Drug|Bortezomib|Administered either SC or IV
45679847|NCT04892446|Drug|Carfilzomib|Administered IV
45679848|NCT04887116|Behavioral|Virtual Reality Exposure Therapy|Ten ninety minute sessions of Virtual Reality Exposure Therapy twice a week for five weeks
45679849|NCT04879641|Behavioral|Exposure|Participants are instructed to plan and track in vivo exposures using an exposure diary. Participants are also instructed to reduce safety behaviors, which are overt or covert acts such as avoiding eye contact or rehearsing sentences to prevent a feared outcome.
46098645|NCT02752217|Other|Control|Inspiratory muscle training at 2 cmH2O with Slow breathing at 6 breath per min with BreatheMAX device for 8 weeks at home
46098646|NCT04220567|Other|Experimental: Exercise and Patient-centred education|"An eight-week programme based on 24 sessions of exercise supervised by a physiotherapist. Exercise will be carried out three times a week. Once a week the exercise session is performed autonomously by patient at home (according to the physiotherapist's recommendations).~Patient-centred Education will follow the principles of transformative learning & incorporate patients' narratives. It will precede 9 of the 24 exercise sessions and be delivered by the same physiotherapist"
45463885|NCT03937739|Other|Nutritional and constipation questionnaire|Alcohol and smoking habits, daily activity, frequency of food consumption and the constipation scoring according to Agachan et all. were examined using questionnaire
45463886|NCT01196455|Drug|Capecitabine and Mitomycin C|"Capecitabine 1000 mg/m2 twice-daily, administered orally on day 1-14, every three weeks~Mitomycin C 8 mg/m2 i.v. bolus, on day 1, every three weeks"
45463887|NCT01215773|Drug|Placebo|Matching to HEA 200 mg tablet, oral administration
46012480|NCT01683929|Other|sweetner|"The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing artificial sweetened drink. All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR & BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire."
45463888|NCT01215773|Drug|BI 671800|High dose oral administration
46012481|NCT01609179|Drug|IPI-926|IPI-926 is administered orally as a capsule formulation, as a fixed dose in mg/day. Patients will be administered the same dose with same cycle length of IPI-926 and combination therapy that they were receiving in the original protocol at the time of transition into the extension study. The following are potential once-daily doses that patients are receiving in original protocols: 60 mg, 90 mg, 100 mg, 110 mg, 130 mg, or 160 mg.
45463889|NCT01215773|Drug|BI 671800|Medium dose oral administration
45463890|NCT03846583|Drug|Tucatinib|Tucatinib is a drug that inhibits human epidermal growth factor receptor 2 (HER-2) protein, which is a protein expressed in the cancer cells. By inhibiting this protein, tucatinib may help stop or reduce the growth of the tumor
45463891|NCT03846583|Drug|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
45463892|NCT03846583|Drug|Trastuzumab|"• Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When Trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system."
45463893|NCT03846583|Drug|Aromatase Inhibitor|These drugs act by lowering the amount of estrogen produced by the body by blocking an enzyme called aromatase
45463894|NCT01115543|Drug|alfacalcidol and calcitriol|The initial dose of alfacalcidol was twice that of calcitriol.Both were adjusted to control intact PTH within the ranges of 150-300 pg/ml.
45463895|NCT01115621|Other|Glutenfree diet during the first year of life|Glutenfree diet during the first year of life
45463896|NCT05670613|Other|CDSS Canceling|The use of Clinical Decision Support System in Parenteral Nutrition
45463897|NCT03937505|Drug|IS-001|intravenous injection of IS-001 investigational drug
45463898|NCT03937505|Drug|No treatment|no drug injection
45463899|NCT05502289|Device|TEST LENS|DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)
45463900|NCT05502289|Device|CONTROL LENS|PRECISION1™ for Astigmatism Contact Lenses (P1fA)
45463901|NCT03846349|Device|IOPI|IOPI is a portable device with a tongue bulb used to reinforce upper airway muscles.
45463902|NCT03846349|Device|EMT threshold|EMT threshold is a small portable device producing a positive expiratory pressure when the patient is exhaling.
45679850|NCT04879641|Behavioral|Attention Training|Participants are trained to reduce self-focused and biased attention. Various audio exercises are introduced in which participants learn to intentionally direct the attention away from themselves (i.e., less private self-consciousness), and to be less alert to potentially dangerous external social stimuli (i.e., less public self-consciousness).
46012482|NCT01648556|Other|Blood tests and bone marrow biopsy repeated|"Blood tests are realized for the dosage of the TPO, the dosage of the antiplatelet antibodies, to measure isotopic lifetime of platelet.~The test in corticoids by the prednisone per os is realized too. The bone marrow biopsy is realized at the inclusion and during follow-ups if the haemogram is abnormal."
46012483|NCT01605981|Drug|AMN107|
46012484|NCT01648595|Drug|Fentanyl|In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour after being diluted in 4 cc normal saline
46012485|NCT01606020|Other|sleep deprivation|Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.
46012486|NCT01606020|Other|No intervention|Overnight, the subjects stay in their homes. No intervention during this night
45463903|NCT01118585|Procedure|TIF Procedure|The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degrees around the esophagus.
45463904|NCT03844867|Dietary Supplement|Filippo Cea and Carmel|"Subjects will be given a subjective organoleptic assessment of both the almonds (Filippo Cea and Carmel) administered blindly and randomly.~Motility test: Each subject will be subjected to gastrointestinal motility study according to international guidelines, i.e. he will be evaluated in 3 different days. The test will be made in response to test-meal ('NutriDrink') or Filippo Cea almonds (12 gr. fat=24 gr. almonds) or Carmel almonds (12 gr. fat = 24 gr. almonds)."
45463905|NCT01216007|Drug|propofol|In the TIVA group, IV access will be obtained as per BCCH routine, with caregiver present. 2% lidocaine 1 mg/kg will be administered via IV to prevent venous pain before induction of anaesthesia with propofol, as per BCCH standard. Induction of anaesthesia will be achieved with an IV bolus of propofol 5 mg/kg and remifentanil 2.5 mcg/kg. Anaesthesia will be maintained with an infusion of propofol 200-400 mcg/kg/min and remifentanil 0.1-0.2 mcg/kg/min. Once the subject is under general anaesthesia, the anaesthesiologist will place a second IV cannula, specifically for the collection of blood samples. This cannula will not be in the same limb as the propofol infusion.
45463906|NCT01216007|Drug|sevoflurane|In the volatile anaesthesia group, induction of anaesthesia will be achieved with inhalation of sevoflurane (5-8% in O2/air). Maintenance of anaesthesia will continue with a volatile agent of the anaesthesiologist's choice.
45679851|NCT04879641|Behavioral|Cognitive Restructuring|Participants are instructed to identify and modify dysfunctional and negatively biased assumptions. It includes a thought diary to track negative beliefs in daily routine, alongside with exercises to formulate helpful and adaptive thoughts.
46012487|NCT01648634|Drug|Nebivolol|A 1.25mg-test dose will be administrated to assess the treatment tolerance before randomization. A forced titration of nebivolol will be performed with 2 weeks periods. Full dose of nebivolol is 5mg/day (7.5mg/day for patients whose weight is>60kg)
46012488|NCT01648634|Drug|Placebo|A 1.25mg-test dose of nebivolol will be administrated to assess the treatment tolerance before randomization. A forced titration of placebo will be performed with 2 weeks periods. Full dose of placebo is 5mg/day (7.5mg/day for patients whose weight is>60kg)
46012489|NCT04527848|Drug|small amount of undiluted C3F8|vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection
46012490|NCT01606059|Drug|DW-0920|Dosage form: Extended release tablet Dosage: 2 tablets
46012491|NCT01606059|Drug|DW-0919|Dosage form: Extended release tablet Dosage: 1 tablet
46012492|NCT04527731|Device|Accelerometry|Participants are asked to wear an accelerometer during the day for a period of seven days.
46012493|NCT01606293|Behavioral|Questionnaires|Completion of online surveys taking approximately 15 - 20 minutes.
46098647|NCT04220567|Other|Active Comparator: Exercise|An eight-week programme based on 24 sessions of exercise supervised by a physiotherapist. Exercise will be carried out three times a week. Once a week the exercise session is performed autonomously by patient at home (according to the physiotherapist's recommendations).
46098648|NCT00997087|Drug|Flumazenil|Sublingual daily
46098649|NCT02752061|Other|Potlako intervention|"Multicomponent intervention including:~provider training on early detection and diagnostic approaches to cancer~patient education on importance of obtaining timely cancer diagnosis~provision of a patient navigator to facilitate diagnosis and entry into care~provision of transportation support to vulnerable patients"
45463907|NCT05493553|Dietary Supplement|Dietary supplement regimen|"The powdered, soluble fiber-based supplement contains soluble fibers, phytosterols, plant-derived polysaccharides, flavor, maltodextrin, orange juice powder, citric acid, vitamin and mineral blend, and sweetener. This is prepared in water and consumed twice per day, prior to a meal.~The yerba mate-based supplement (containing green yerba mate leaf extract, sweeteners, and flavor) is a powdered supplement prepared in water and consumed in the morning."
46012494|NCT04527809|Device|tDCS-active|One session of active Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
46012495|NCT04527809|Device|tDCS-sham|One session of sham Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
46098650|NCT01000519|Other|Aerobic Training|18 sessions over 2 months period. Each session consist of 50 minutes of aerobic training at 65-70 % of maximum predicted heart rate
46098651|NCT01000519|Other|Progressive resistance training|18 sessions completed in 2 months. each session consists of 50 minutes of resistance training which is made up of 3 sets of 10 repetitions of nine resistive exercises using machines and free weights at 65-70% of 1-repetitive maximum.
46098652|NCT02751905|Drug|BIIB074|Administered orally as specified in treatment arm
45463908|NCT05493553|Other|Dietary supplement and intermittent fasting regimen|The dietary supplement regimen is the same as in Phase 1. The intermittent fasting protocol consists of a 16-hour fasting period and an 8-hour eating window.
45463909|NCT01198249|Drug|multiple dose, crossover study between single and concomitant administrations of amlodipine, losartan, and hydrochlorothiazide|amlodipine 10 mg for 9 days , losartan 100 mg for 9 days, hydrochlorothiazide (HCTZ) 25 mg for 9 days and combination of amlodipine 10 mg, losartan 100 mg and hydrochlorothiazide (HCTZ) 25 mg for 9 days, 4 way crossover study
45463910|NCT01212497|Behavioral|Mindfulness meditation coaching|Participants interact with virtual coach to obtain instruction in mindfulness meditation and coaching support.
45679852|NCT04879641|Behavioral|Psychoeducation|Participants are delivered detailed evidence-based information on SAD with a focus on maintaining processes (e.g., the vicious circle of negative thoughts and emotions, cognitions, and behaviors associated with the maintenance of SAD). Based on the information provided, participants are encouraged to develop an individual model of their social anxiety symptoms.
45679853|NCT04862260|Drug|Cholesterol metabolism disruption|Cholesterol metabolism disruption using a combination of atorvastatin, ezetimibe and evolocumab in metastatic pancreatic adenocarcinomas
46012496|NCT01606332|Procedure|Interscalene block with nerve catheter|Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
46012497|NCT01606371|Drug|Placebo|Administered orally
46012498|NCT01606371|Drug|LY2409021|Administered orally
46012499|NCT04527653|Device|Tixel|Non-invasive thermo-mechanical treatment
46012500|NCT01606410|Other|IPC|repeated cuff inflation (220 mmhg) around an upper limb for 5 minutes, followed by 5 minutes of reperfusion (repeated 4 times)
46012501|NCT01648712|Device|Balance surface, Carmeda heparin-coated surface|"This study compares the influence of a Balance - coated CPB system in pediatric use versus the Carmeda TM heparin-coated system in platelet function preservation and hemostatic activation.~Balance arm group recieved like intervention a Balance circuit"
46012502|NCT01648712|Device|non -heparin extracorporeal pediatric device for operation|The carmeda arm group received like intervention the Carmeda circuit
45463911|NCT04734301|Device|Intravaginal Electrical Stimulation (2 times/week)|IVES sessions were performed two times in a week, for 10 weeks. Every session lasted 20 minutes. The intervention comprised a 20-sessions treatment program of ES. The stimulation parameters were frequency at 10 Hz, a 5-10s work-rest cycle and 100 ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 0-100 mA. The intensity was controlled according to patients' discomfort level feedback.
46012503|NCT01606449|Procedure|Surgical Therapy|"Open Anti-reflux fundoplication according to Nissen-Rossetti, floppy Nissen, Belsey MK IV,Collis Nissen, Collis-Belsey.~Minimally-Invasive fundoplication according to floppy Nissen, left thoracoscopic Collis-laparoscopic Nissen."
46012504|NCT04527536|Diagnostic Test|Neonatal hyperbilirubinemia|Neonatal hyperbilirubinemia：The total serum bilirubin exceeds the 95th percentile of the Bhutani neonatal hourly bilirubin nomogram.
46012505|NCT05140629|Other|Baobab fruit aqueous extract|After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The intervention group ingested glucose solution followed by 250 ml of baobab aqueous extract (33.33 g FW). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
46012506|NCT05140629|Other|Placebo OGTT|After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
46012507|NCT01608165|Procedure|Surgical treatment for renal mass|Patients will be randomised to receive a partial nephrectomy as treatment for their renal cancer mass
46012508|NCT01608165|Procedure|Percutaneous Radiofrequency ablation|Patients may be randomised to undergo a radiofrequency ablation treatment for their renal cancer mass
46012509|NCT01608165|Procedure|Laparascopic or percutaneous cryoablation|Patients may be randomised to undergo cryoablation as treatment for their renal cancer mass
46012510|NCT01688544|Drug|Ilaprazole|Ilaprazole 10 mg for 7 days
46098653|NCT01000597|Drug|fluticasone furoate|"Seven inhaled doses of 200mcg FF given once daily in the morning (Part A; Days 1-7) followed by seven inhaled doses of 800mcg FF given once daily in the morning (Part B; Day 1 and Days 3-8, i.e. no dose on Day 2).~A single intravenous dose of 250mcg FF given over 20 minutes (Day 1)."
46098654|NCT02751593|Drug|Dexamethasone|dexamethasone 40mg/d for 4 days
46098655|NCT00997399|Drug|panobinostat (LBH589)|
46098656|NCT02751671|Procedure|POCUS|The use of Point-of-care ultrasound before urine sample procedure
45463912|NCT04734301|Device|Intravaginal Electrical Stimulation (5 times/week)|IVES performed in the same way as Group 1, except for frequency of treatment. IVES sessions were performed five times in a week, for 4 weeks. Every session lasted 20 minutes. The intervention comprised a 20-sessions treatment program of ES. Stimulation parameters were the same as Group 1.
45463913|NCT01121783|Other|Lactisole|A pre-infusion of lactisole solution (0.25mg/ml) is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
45463914|NCT01121783|Dietary Supplement|Lactisole|A pre-infusion of lactisole solution (0.25mg/ml)is administered as a bolus (1ml/kg body weight) via intragastric tube. After 15 minutes tap water will be administered as a bolus via the intragastric tube.
45463915|NCT01121783|Dietary Supplement|Lactisole|A pre-infusion of tap water(is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
45679854|NCT04860752|Device|Transcatheter Aortic Valve Implantation (TAVI)|Subjects will undergo TAVI
46098657|NCT02751671|Procedure|Standard|Urine sampling procedure without prior ultrasound
46098658|NCT01003873|Biological|Evaluation of the endocannabinoid system|The evaluation of the endocannabinoid system consist in the determination of plasma concentration of the 2 main endocannabinoids (2AG and AEA) before (5 blood samples) and after (5 blood samples) after consumption of a calibrated food. As a comparator, ghrelin will be measured at the same time.
46098659|NCT01003873|Procedure|Biopsy of visceral and peripheral adipose tissue|The endocannabinoids will be also determined in adipose tissue. Biopsy of visceral and peripheral adipose tissue will be done during surgery and peripheral adipose tissue will be done 6 months after surgery.
45679855|NCT04853576|Genetic|EDIT-301|Administered by IV infusion after myeloablative conditioning with busulfan.
46012511|NCT01688583|Drug|Fentanyl matrix|Dose will be adjusted in accordance with patient's degree of pain and treatment response in the investigator's judgment.
46012512|NCT01648829|Drug|Atorvastatin|Patients will receive randomly atorvastatin (20 mg day) for 30 days
46098660|NCT01003873|Biological|Evaluation of metabolic parameters|The evaluation of the metabolic status consist in evaluation of body composition (DEXA), determination of visceral adiposity (CT scan) and measurement of plasma lipids, glucose, insulin, leptin, adiponectin.
46012513|NCT01648829|Drug|Pitavastatin|Patients will receive randomly pitavastatin (4 mg day) for 30 days
46098661|NCT01003873|Behavioral|Evolution of behavioral parameters|The behavioral evaluation will de done with different questionnaires: ORWELL 97, HAD scale, Three Factor Eating Questionnaire, Beck Depression inventory, Questionnaire of personality TCI.
46098662|NCT01003873|Behavioral|Dietician consultation|The evaluation of the metabolic status will also be seen by a dietician.
46098663|NCT01003873|Behavioral|Psychologist consultation|The behavioural evaluation will de done with a psychologist consultation
46098664|NCT02751749|Behavioral|Unified Protocol|
46098665|NCT00997477|Drug|Foradil Combi (Formoterol-budesonide)|
46098666|NCT02751437|Dietary Supplement|Arginine|
45463916|NCT01121783|Dietary Supplement|Lactisole|A pre-infusion of tap water is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes tap water is administered as a bolus via intragastric tube.
46012514|NCT01688622|Behavioral|3months Exercise|training session consisting of a brief warm-up, followed by an approximately 45-min session of aerobic exercise at an intensity of 60-75% of the age-predicted maximum heart rate (approximately 300 kcal/day) and a 20-min muscle strength train- ing programme (approximately 100 kcal/day), followed by a brief cool-down period.
46012515|NCT01648868|Device|Transcranial Magnetic Stimulation (rTMS)|Excitatory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in patients with autism.
45463917|NCT03844009|Other|Computer integrated debriefing|At the end of each computer-based simulation, the participant had a computer integrated debriefing of his performance during the neonatal resuscitation simulation and a debriefing based on an auto-evaluation of his non-technical skills.
45463918|NCT02529761|Drug|Sorafenib|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
45463919|NCT02529761|Procedure|TACE|"The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response."
46012516|NCT01648868|Device|Transcranial Magnetic Stimulation (rTMS)|Inhibitory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in healthy controls
46012517|NCT01688700|Drug|Nimotuzumab combined with paclitaxel and cisplatin|"Nimotuzumab: 200mg, IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).~Cisplatin: 75mg/m2,IV on days 1，22~paclitaxel: 90mg/m2, IV on days 1,8,22,29.~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy."
46012518|NCT01684085|Behavioral|Explanation encouraging sleep|An explanation will be given about sleep, encouraging the patient to sleep - lorazepam 1mg will be offered to promote sleep.
46012519|NCT01684085|Behavioral|Explanation discouraging sleep|An explanation about sleep will be given, discouraging the patient from sleeping in the first night after the traumatic event.
46012520|NCT01684085|Drug|Lorazepam|Lorazepam 1 mg
46012521|NCT01648985|Other|Diabetes in stroke/TIA|Mostly no intervention. A small Group of the patients recieved Yoga
46012522|NCT01688817|Other|Physician's counseling|Colorectal cancer (CRC) screening was recommended to a patient personally by a PCP. The issue was discussed during a routine medical visit according to a standardized scheme. PCP provided a patient with a rationale for CRC screening in asymptomatic individuals and benefits of early treatment of the disease. A patient was told about colonoscopy-based screening program. A PCP provided patient with information on how colonoscopy is performed and how to prepare a bowel for the examination, and informed a patient about possible adverse events related to the procedure including post-polypectomy bleeding and bowel perforation. According to the scheme of the discussion screening modalities other than colonoscopy were not debated, unless a patient specifically asked about them.
45463920|NCT05219149|Behavioral|Qualitative Interviews|Conduct qualitative interviews with patients and families who are considering treatment options for new or recurrent CNS tumors to identify specific barriers to full participation in treatment and clinical trial enrollment (e.g., transportation, childcare, ancillary expenses). Qualitative interviews will be structured to comprehensively address potential barriers but also open-ended to give patients and families freedom to discuss a wide range of challenges.
45463921|NCT01118819|Biological|Clostridium novyi-NT spores|Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 X 10(5) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(5) spores/kg.
45679856|NCT04851613|Drug|Afuresertib|The starting doses of the combination therapy are afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1, 15 in the first cycle and afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1 Q4W in the subsequent cycles
45679857|NCT04847232|Drug|Sodium Zirconium Cyclosilicate (SZC)|Powder for oral suspension in a sachet. A dose is titrated in 5 g increments during a period of 4 weeks from 5 g up to 15 g qd on non-dialysis days. Afterward, the dose is adjusted monthly (or more frequent based on clinical judgment) depending on the current potassium value as measured after the long interdialytic interval (LIDI).
46012523|NCT01688817|Other|Information leaflet|Patients were given leaflet on primary colonoscopy colorectal cancer screening program. A leaflet provided rationale for colorectal cancer screening and information on colonoscopy-based colorectal cancer screening program.
46012524|NCT01684241|Biological|RBL001/RBL002|Each participant will receive 8 repeated intranodal administrations of RBL001 and RBL002 during a time frame of 43 to 51 days.
46012525|NCT01688934|Drug|V116517 50-mg tablets|Taken orally twice daily
46012526|NCT01688934|Drug|V116517 30-mg tablets|Taken orally twice daily
46012527|NCT01688934|Drug|Naproxen 500-mg capsules|Taken orally twice daily
46012528|NCT01688934|Drug|Placebo|Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily
46012529|NCT01684319|Dietary Supplement|Formula milk free of cow's milk protein|
46012530|NCT01684319|Dietary Supplement|Placebo|Infant formula milk
46098667|NCT01003951|Procedure|Acupuncture|"Acupuncture treatments will be given at the Integrative Medicine Outpatient Center, if needed in particular cases, at the MSKCC Breast Center. Each treatment is 30-40 minutes in duration. Each patient will receive two acupuncture treatments each week for four consecutive weeks.~Before and after each treatment, the circumference of the patient's upper arm, and forearm will be measured in both the affected and unaffected arms. The greater difference between affected and unaffected arms (either the forearm or the upper arm) for each patient will be used for outcome assessment. Photographs of the patient's affected and unaffected arms before and after each treatment will be taken to provide visual documentation of status. The patient's face will not appear in the photographs. Blood draws will be performed from the unaffected arm in serum collection tubes and will be performed within 1 week of starting acupuncture and within 1 week of completion of the 4 week protocol."
46012531|NCT02279576|Drug|Pazopanib|Pazopanib 800mg/day continuously administered.
46012532|NCT02279576|Drug|Paclitaxel|Paclitaxel 65 mg/m2 in weekly administration 3 administrations (D1, D8 and D15) every 4 weeks period.
46012533|NCT02279615|Drug|Mirabegron|50mg of mirabegron per day will be given.
46012534|NCT02279615|Drug|Tamsulosin|0.4mg of flomax per day.
45463922|NCT05670301|Diagnostic Test|cytokine and lipidomic profiling|"FEBRIS Cytokine Profile Assay (quantification of inflammatory cytokines)~Serum amyloid A~Biobanking of leftover sample for future analyses and specific immunofunctional assay in selected cases~Lipidomics"
45463923|NCT01115777|Other|Quality of Life surveys completed at specified timepoints|Quality of Life surveys (no treatment)
45463924|NCT03844243|Drug|NGF|Intramuscular injection
45463925|NCT03844243|Drug|Isotonic-saline|Intramuscular injection
46012535|NCT01689051|Other|human glucagon-like peptide 1 (7-36)amide|
46012536|NCT01689051|Other|human glucagon-like peptide 1 (9-36)amide|
46012537|NCT01684358|Device|Sino-implant (II)|Sino-implant (II) (Shanghai Dahua Pharmaceutical Co, Ltd.; Shanghai, China), a contraceptive implant with two rods each of which contain 75 mg of levonorgestrel.
46012538|NCT05140395|Diagnostic Test|ABTEST card|Pre transfusional control with the referent ABTEST card and the in study ABDTEST Card
46012539|NCT01684475|Drug|CJH1 (CLR4001)|
46012540|NCT05140356|Device|Applied high amplitude repeated transcranial magnetic stimulation|Each mode required 20 stimuli(100%RMT) for 20 minutes each time, 5 times a week
46012541|NCT05140356|Device|Applied low amplitude repeated transcranial magnetic stimulation|Each mode required 20 stimuli(15%RMT) for 20 minutes each time, 5 times a week
46012542|NCT04528121|Other|CoDuSe balance training and step square exercises|"The standardized intervention targeted visual, somatosensory, and vestibular aspects of balance and will be included with balance exercises~Examples of core stability exercises as follows: in supine position with knees bent, slowly slide one heel forward to straighten leg; and, in four-point kneeling position, slide one foot in a straight line away from the body and lift the leg off the floor.~Examples of dual-task exercises as walking while turning one's head and juggling a balloon.~Examples of sensory strategies as standing and walking on uneven surfaces and standing with eyes closed."
46012543|NCT04528121|Other|conventional balance training|static and dynamic balance training exercises from sitting, standing and ambulation activities
46012544|NCT01689090|Other|COX inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
46012545|NCT01689090|Other|L-NG-monomethyl arginine citrate|Intravenous administration of L-NMMA during recordings of diameter changes of retinal vessels
46012546|NCT01689090|Other|COX inhibitor + L-NG-monomethyl arginine citrate|Combination of interventions. Administration of an eye drop voltaren and 45 minutes later infusion with L-NMMA is started and recording of diameter changes of retinal vessels is performed
46012547|NCT01684553|Behavioral|Slow eating condition|The subjects were asked to eat their meal slowly during the slow eating condition
46012548|NCT01684553|Behavioral|Fast eating condition|The subjects were asked to eat their meal quickly during the fast eating condition
45679858|NCT04847232|Drug|SZC Placebo|Powder for oral suspension in a sachet. A dose is titrated in 5 g increments during a period of 4 weeks from 5 g up to 15 g qd on non-dialysis days. Afterward, the dose is adjusted monthly (or more frequent based on clinical judgment) depending on the current potassium value as measured after the LIDI.
46012549|NCT01689129|Drug|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
46012550|NCT01689129|Drug|Insulin glargine (HOE901) (Lantus)|Pharmaceutical form: solution Route of administration: subcutaneous
46012551|NCT01684631|Device|Total Hip arthroplasty|
46012552|NCT01689168|Behavioral|Counseling|Tobacco cessation counseling
46012553|NCT01689168|Procedure|Chiropractic adjustment|Full spine high velocity, low amplitude manipulation of the spine
46012554|NCT01689285|Drug|valacyclovir tablet|16 healthy adult volunteers (18-55 yr) will be exposed to one tablet
46012555|NCT01689285|Drug|valacyclovir oral solution|16 healthy adult volunteers (18-55 yr) will be exposed to 10 ml once
46012556|NCT01649102|Device|Tunneled Cuffed Catheter (Palindroom, Hemoglide Bard)|"A tunneled cuffed catheter is inserted, randomization between:~Palindroom~Hemoglide Bard"
46012557|NCT01606527|Drug|Ibuprofen 600mg orally three times daily|Ibuprofen is taken 600mg orally three times daily
46012558|NCT01684670|Behavioral|Speech sessions|Subjects will be instructed to use clear speech and increased effort when speaking.
46012559|NCT01609335|Drug|F-18 FDG|One time intravenous administration of 17 millicurie (mCi) +/- 10%
46012560|NCT01609335|Drug|C-11 PiB|One time intravenous administration of 10-20 mCi
46012561|NCT01609374|Device|M6-C Artificial Cervical Disc|Total disc replacement
46012562|NCT01609374|Device|Anterior plate system with corticocancellous allograft bone|Cervical fusion
46012563|NCT01684709|Behavioral|Telemonitoring + self-management support|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up
46012564|NCT01649141|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) is a structured, 12-16 session outpatient intervention originally developed to treat Posttraumatic Stress Disorder (PTSD) and related emotional and behavioral difficulties in youth with a history of child sexual abuse. TF-CBT's eight components are delivered in 90-minute weekly sessions split evenly between children and their parents. These components are summarized by the acronym PRACTICE including: psychoeducation and parenting skills (P), relaxation (R), affective expression and regulation (A), cognitive coping (C), trauma narrative development and processing (T), in vivo gradual exposure (I), conjoint parent/child sessions (C) and enhancing safety and future development (E).
46012565|NCT01609413|Dietary Supplement|AlgaeCal|One dose equals 3 times 180 mg of calcium, to be taken one time on the morning of the examination day.
46012566|NCT01609413|Dietary Supplement|Caltrate 600|One dose equals 1 capsule of 600 mg calcium, to be taken one time on the morning of the examination day.
46012567|NCT02279966|Drug|Vortioxetine 10 mg|
46012568|NCT02279966|Drug|Paroxetine 20 mg|
46012569|NCT02279966|Drug|Placebo|
46012570|NCT01606644|Procedure|Hyperbaric oxygen|Inhalation of 100% oxygen for 90 minutes
46012571|NCT01684787|Drug|Peginterferon alfa-2a + ribavirin in normal ALT|peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
46012572|NCT01684787|Drug|Peginterferon alfa-2a + ribavirin in elevated ALT|peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
46012573|NCT01606683|Other|Infant formula with GOS, beta-palmitate, acidified milk|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae."
46012574|NCT01606683|Other|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.
46012575|NCT01606683|Other|No intervention|
46012576|NCT01649219|Behavioral|Exercise|
46012577|NCT01609452|Biological|Blisibimod|
46012578|NCT01609452|Other|Placebo|
46012579|NCT01649258|Drug|granisetron transdermal system|Given granisetron transdermal system patch
46012580|NCT01649258|Drug|fosaprepitant dimeglumine|Given IV
46012581|NCT01649258|Other|laboratory biomarker analysis|Correlative studies
46012582|NCT01649336|Drug|MEK162, MEK inhibitor; oral|multiple dose, escalating
46012583|NCT01649336|Drug|Paclitaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
46012584|NCT01609491|Drug|phenylephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine or norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) of Norepinephrine (10 µg/ml) will be used in the syringes
46012585|NCT01609491|Drug|norepinephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
46012586|NCT01606878|Drug|Crizotinib|Given PO
46012587|NCT01606878|Drug|Cyclophosphamide|Given IV
46012588|NCT01606878|Drug|Dexrazoxane Hydrochloride|Given IV
46012589|NCT01606878|Drug|Doxorubicin Hydrochloride|Given IV
46012590|NCT01606878|Other|Laboratory Biomarker Analysis|Correlative studies
46012591|NCT01606878|Other|Pharmacological Study|Correlative studies
46012592|NCT01606878|Other|Questionnaire Administration|Ancillary studies
46012593|NCT01606878|Drug|Topotecan Hydrochloride|Given IV
46012594|NCT01606878|Drug|Vincristine Sulfate|Given IV
46012595|NCT01606917|Other|Intensive lifestyle counseling|Both dietary advice and individualized advice on increased regular physical activity
46012596|NCT01684865|Drug|Rituximab|Due to observational nature of the study protocol does not specify any dosing schedule for rituximab.
46012597|NCT01606956|Procedure|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
46012598|NCT01606956|Procedure|The cuff inflation by half the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
46012599|NCT01649453|Device|Pathwork® Tissue of Origin Test|
46012600|NCT01580163|Drug|JITAI Combined with psychological intervention|tablet，Each tablet weight 0.4g
46012601|NCT01580163|Drug|Methadone|Oral Solution，1mg/ml
46012602|NCT01580163|Drug|Traditional Chinese Medicine JITAI|tablet，Each tablet weight 0.4g
46012603|NCT01609647|Drug|Prasugrel|Reloading with prasugrel 20mg and followed by daily administration of prasugrel 5mg for 30 days
46012604|NCT01609647|Drug|Clopidogrel|Reloading with clopidogrel 300mg and followed by daily administration of clopidogrel 75mg for 30 days
45463926|NCT01118897|Radiation|Tomotherapy|"Radiotherapy 57-60 Gy in 25 fraction to PTV boost (SIBV - simultaneous integrated Boost volume) (2.3-2.4Gy/Fr)~Concurrent chemotherapy Weekly concurrent CT schedule: Inj Gemcitabine 300 mg/m2 weekly during RT.~Surgery: All patients will be evaluated for surgery in the joint clinic by surgeons and other treating physicians at 6-8 weeks post CT-RT. PET CT Scan will be used as the imaging modality. Patients suitable for R0 resection will be planned for surgery. Inoperable patients will be treated with palliative chemotherapy."
45463927|NCT01116011|Drug|AZD7268|Capsule, Oral, BID
45463928|NCT01116011|Drug|Placebo|Capsule, Oral, BID
45463929|NCT01196611|Behavioral|Voice Amplification|Behavioral: Voice Amplification. Patients use VA over a course of 6 weeks Control group. No treatment over a course of 6 weeks.
45463930|NCT01196611|Behavioral|Function Voice Exercises|Function Voice Exercises Patients will receive 6 sessions of therapy over a course of 6 weeks, with one session per week.
46012605|NCT01649492|Dietary Supplement|pineapple juice (Carrefour n°1) 500 ml/day 5 days|
46012606|NCT01580202|Drug|Entecavir|Entecavir 0.5mg daily per os
46012607|NCT01580202|Drug|Lamivudine|lamivudine 100mg daily per os
46012608|NCT01649570|Drug|insulin aspart|Administrated subcutaneously (s.c., under the skin) three times a day before each meal for 24 weeks
46098668|NCT04189289|Procedure|ESP block group|USG probe will be placed in a longitudinal parasagittal orientation 3 cm lateral to T7 spinous process. The erector spinae muscles will be identified hyperechoic transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 21-gauge 10-cm needle was inserted using an in-plane superior-to-inferior approach or an out-plane approach. Following confirmation of the correct position of the needle with 5 ml normal saline, a dose of 20 ml %0.25 bupivacaine will be administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine). Standard pain follow up and monitorization will be performed.
46098669|NCT04189289|Procedure|Control group|The patients in this group will be performed no block. Standard pain follow up and monitorization will be performed.
46098670|NCT01000831|Biological|adjuvanted Arepanrix|Two doses of adjuvanted Arepanrix vaccine given 3 weeks apart
46098671|NCT04189367|Drug|Traditional Chinese Medicine|"One bag of  Qingre Liangkou Ningxin Fang at a time, three times a day for 12 weeks."
46098672|NCT04189367|Drug|Western medicine|"Western medicine includes:~clonazepam 0.5mg every day before sleep or twice a day for 12 weeks~Nutritional supplement: vitamin B12, folic acid, iron, zinc, vitamin B complex depending on the hematic deficiency, for 12 weeks"
45463931|NCT03937271|Diagnostic Test|Traditional Chinese Medicine pattern|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine pattern.
45463932|NCT03937271|Diagnostic Test|Traditional Chinese Medicine tongue diagnosis|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine tongue diagnosis.
45679859|NCT04844866|Genetic|MB-CART2019.1|MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy® device.
46012609|NCT01685294|Behavioral|Group IPT for Depression + TAU|Interpersonal psychotherapy (IPT) will be administered in 20 group 90-minute sessions over 10 weeks and 4 individual sessions (before group starts, in the middle of the group, at the end of the group, and one month after the group ends). These sessions will focus on improving your relationships with others, building healthy relationships, setting goals, and increasing coping skills. Additionally, participants will receive standard prison mental health treatment, individual therapy, medication, etc.
46012610|NCT01685450|Device|Echodia® hand-held equipment|
46012611|NCT01609764|Behavioral|One year fitness training|Regular training schedule of moderate intensity, at 50% of heart rate reserve, as available for the specific age group in fitness centres
46012612|NCT01609803|Other|laboratory biomarker analysis|Correlative studies
46012613|NCT01649648|Biological|Autologous cord blood|Baby's own umbilical cord blood
46012614|NCT01609881|Drug|Acuvail|Dosing of drug 3 days prior to surgery
46012615|NCT01609881|Other|Placebo|Artificial tears qid for 3 days preoperatively
46012616|NCT01649687|Biological|Allogeneic adult adipose-derived mesenchymal stem cells|Patients will receive intravenously one dose of 5-7x10^7 cells of allogeneic adipose-derived mesenchymal stem cells
46012617|NCT01609920|Drug|Gadofosveset enhanced MRL of axillary lymph nodes|A MRL of the axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
46012618|NCT04527458|Other|Patient Characteristics|Characteristics of the patients
46012619|NCT04527458|Other|COVID-19 treatments|Specific treatments used on COVID-19 patients
46012620|NCT04527458|Other|Differences in triage|Triage criteria for treating COVID-19 patients
46012621|NCT04527458|Other|Surge capacity|Capacity of hospitals
45463933|NCT03937271|Diagnostic Test|Traditional Chinese Medicine pulse diagnosis|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine pulse diagnosis.
46012622|NCT01609959|Drug|Azilsartan|Azilsartan 20 mg or 40 mg (if blood pressure does not reach the target after 6 weeks) per day for 12 weeks
46012623|NCT01609959|Drug|Valsartan|Valsartan 160 mg per day
46012624|NCT01649726|Procedure|Apnea test - control|
45463934|NCT03937271|Diagnostic Test|Heart rate variability|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Heart rate variability.
45463935|NCT03937271|Diagnostic Test|Schirmer's test|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Schirmer's test.
45463936|NCT05210257|Other|Conventional physiotherapy|Group 1 was given conventinal physiotherapy Physiotherapy agents; 5 min ultrasound 1.5 watts/cm2 20 min conventional TENS 20 min heat agent application (hot pack) Exercise program; Stretching and relaxation exercises, Neck strengthening exercises that include concentric and isometric contractions Posture exercises 3 sets per day, 1 in the hospital with 10 repetitions
45679860|NCT04844866|Drug|R-GemOx or BR plus polatuzumab vedotin|Immunochemotherapy will be administered as per arm description.
45679861|NCT04843904|Drug|Venetoclax|Tablet, taken by mouth
45679862|NCT04843904|Drug|Obinutuzumab|Given as an infusion into the vein (intravenous, IV).
45679863|NCT04843904|Drug|Rituximab|Given as an infusion into the vein (intravenous, IV).
45679864|NCT04838613|Drug|[18F]CTT1057|Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan
45837399|NCT04993248|Other|Dialog Circle|"The intervention will offer participants the opportunity to share feelings and needs with people who are in a similar situation to their own.~Each intervention consists of 3 dialogue circles per group. Each group is composed of 10 participants and a facilitator, in all interventions the facilitator will be the principal investigator."
45837400|NCT04853394|Behavioral|MASLIHAT|peer educator intervention
45837401|NCT04853394|Behavioral|TANSIHAT|health education intervention
45837402|NCT04850820|Dietary Supplement|Novel essential amino acid supplementation|This intervention will determine the impact of EAA+ on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
45837403|NCT04850820|Dietary Supplement|Branched-chain amino acid supplementation (BCAA)|This intervention will determine the impact of the BCAA supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
46012625|NCT01649726|Procedure|Apnea test - CPAP|
46012626|NCT01609998|Biological|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 1 mg dosage is administered as 0.25 mL volume and the 4 mg dosage as a 1 mL volume.
46012627|NCT01609998|Biological|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
46012628|NCT04527263|Diagnostic Test|measurement of urinary 5-HIAA|urinary assessment of 5-HIAA
46012629|NCT01649882|Procedure|US ETT (ultrasound endotracheal tube)|Subjects will have a brief (< 15 minutes) ultrasound exam of the neck after intubation. The cuff of the endotracheal tube as well as the aortic arch will be identified. The distance between the two structures will be measured and recorded.
46012630|NCT01606098|Procedure|Surgery of the primary tumour|Surgical resection of the colon tumour
46012631|NCT01606098|Drug|Systemic treatment|"First line fluoropyrimidine-based chemotherapy with bevacizumab. The chemotherapy regimen is to the discretion of the local investigator, who may choose between:~5FU/LV or capecitabine or capecitabine + oxaliplatin(CAPOX)or 5FU + oxaliplatin(FOLFOX 4 or FOLFOX 7)or 5FU + irinotecan (FOLFIRI) or capecitabine + irinotecan(CAPIRI)"
46012632|NCT01685528|Behavioral|CBT|6-8 weekly sessions of CBT, 1 of which is in person with the rest being over the telephone
45679865|NCT04838613|Drug|[68Ga]Ga-PSMA-11|Single intravenous dose of approximately 150 MBq and subsequent PET/CT scan
46012633|NCT01600755|Biological|Autologous Muscle-Derived Cells (AMDC)|Cell Treatment
46012634|NCT01685645|Device|AlgiScan|The AlgiScan device will be used to monitor analgesia during surgery. The integrated nociceptive stimulator will be used on both legs.
46012635|NCT01608516|Radiation|68Ga-NODAGA-RGD PET/CT|200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images centred on the carotid area acquired
46012636|NCT01649921|Drug|Interferon-gamma, Recombinant|Interferon-gamma (Immukine, Boehringer-Ingelheim, Alkmaar, the Netherlands), 100mcg subcutaneously, on days 0-2-4-7-9-11. Interferon-gamma treatment will be initiated when the noradrenalin dose is reduced to 50% of maximum dose, ensuring that the sepsis-induced pro-inflammatory phase has passed
46012637|NCT01649921|Other|Saline 0.9%|subcutaneous administration on days 0, 2, 4, 7, 9, and 11.
46012638|NCT01606566|Drug|Amphinex induced PCI of bleomycin|Intravenous administration of 0.25 mg/kg Amphinex (day 0) followed by intravenous administration of bleomycin (15000 IU/m2, day 4) and laser light application (3 hours (+/- 1 hour) after bleomycin administration).
46012639|NCT01644968|Drug|Cohort 1 anti-OX40|0.1 mg/kg anti-OX40 on days 1, 3, and 5
46012640|NCT01644968|Drug|Cohort 2 anti-OX40|.4 mg/kg anti-OX40 on days 1, 3, and 5
46012641|NCT01644968|Drug|Cohort 3 anti-OX40|2.0 mg/kg anti-OX40 on days 1, 3, and 5
46012642|NCT01644968|Biological|Tetanus Day 29|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 29
46012643|NCT01644968|Biological|Tetanus Day 1|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 1.
46012644|NCT01644968|Biological|KLH Day 1|1 mg KLH in 1 cc diluent subcutaneously on Day 1.
46098673|NCT05170789|Drug|Elotuzumab, Selinexor, and Dexamethasone (ESd)|This is a single-arm, interventional, phase II clinical trial, in which the anticipated 18 enrolled patients will receive the trial drug, a combination of Elotuzumab, Selinexor, and Dexamethasone in monthly cycles. The study tests the theory of synergy between these drugs, as detailed in the study description above.
46012645|NCT01644968|Biological|KLH Day 29|1 mg KLC in 1 cc diluent by subcutaneous injection on Day 29.
46012646|NCT01605708|Drug|REGN846|Dose 1
46098674|NCT02715401|Drug|HCP1303|
46098675|NCT02715401|Drug|HGP1201|
46098676|NCT02715401|Drug|HIP1402|
45679866|NCT04837833|Diagnostic Test|ultrasound|Participants will undergo research ultrasound (rUS1) within three days of their routine CECT scan. A subset of participants will undergo a second research US (rUS2) at 3-4 weeks after rUS1 and at least one month prior to the next planned clinical CECT
45679867|NCT04837196|Drug|ASP7517|Intravenous (IV)
45679868|NCT04837196|Drug|Pembrolizumab|Intravenous (IV)
46098677|NCT01000909|Procedure|Ultrasound (venous pressure measurement)|increased venous pressure is predictive for chronic venous insufficiency
46098678|NCT02693951|Drug|Cefotiam|Prophylactic use of antibiotics group: Half an hour before endoscopic treatment, cefotiam 2.0g intravenous
45679869|NCT04835168|Drug|BT-11 low|Oral
46012647|NCT01685723|Behavioral|Counseling group|Subjects will receive brief advice based on risk communication by a nurse counselor. The brief advice will be based on a specifically-designed risk communication leaflet that warns about the risks of continued smoking for subjects' cancer treatment and prognosis. Subjects will receive a booster intervention via telephone at 1 week to assess the progress of and barriers to the subjects' action plans and identifying individual difficulties and facilitators towards quitting. They also receive a generic standard self-help smoking cessation booklet.
46012648|NCT01685723|Behavioral|General supporting|Subjects in this group will receive a generic self-help smoking cessation booklet and standard care without risk communication. They will have the same follow-up sections as the intervention group to receive diseases support.
45679870|NCT04835168|Drug|BT-11 high|Oral
45679871|NCT04835168|Drug|Placebo|Oral
45679872|NCT04820933|Drug|Doravirine 100 Mg|Doravirine 100 Mg orally dail
46012649|NCT01605162|Drug|TMZ|TMZ (at 150 mg/m2) will be administered orally according to the instructions on the product label, on Days 1 through 5 of the same 28-day cycle as E7016. TMZ capsules should be taken immediately after E7016. No food or drink intake, except water, will be allowed for 2 hours before or after administration.
46012650|NCT01605162|Drug|E7016|"E7016 capsules will be administered in the morning after at least a 2-hour fast. Subjects will be instructed not to eat or drink anything except water in the 2 hours prior and 2 hours after drug administration. Subjects will record the time at which they ate.~For the Single-Dose PK Period, 320 mg of E7016 will be administered once on Day -2. For the Multiple-Dose Treatment Cycle(s), 320 mg E7016 will be administered QD on Days 1 through 7 of each 28-day cycle."
46012651|NCT01649999|Drug|peficitinib|oral
45679873|NCT04816773|Device|EVOLUTION® NitrX™|EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert
45679874|NCT04812743|Behavioral|Colorectal Health Research Champions|"20 Colorectal Health Research Champions will be recruited from the VCU Massey Cancer Center Catchment Area (66 counties in Virginia) The Colorectal Health Research Champions will receive training in four specific areas during group educational sessions.~Colorectal Health Research Champions will be asked to disseminate the four defined messages on at least two occasions to small groups in their social network in a venue of their choice (house chats, faith-based, social gatherings, family gatherings, etc.). We ask that each CHRC participant host 2 chats with 5-10 people in attendance at each chat. We expect that at least 200 participants will be invited to chats through 10 CHRCs."
46012652|NCT01649999|Drug|Placebo|oral
46012653|NCT01604889|Drug|Epacadostat|
46012654|NCT01604889|Drug|Placebo|Placebo
46012655|NCT01604889|Drug|ipilimumab|ipilimumab 3 mg/kg IV
46012656|NCT01604889|Drug|ipilimumab|Doses to be determined following the completion of Phase I of the study
46012657|NCT01685762|Drug|Metformin|850 mg of metformin taken once daily by mouth for 4 weeks (weeks 1-4) and then twice daily by mouth for 8 weeks (weeks 5-12).
46012658|NCT01685879|Other|Rice|Rice portion containing 50 g total carbohydrate
46012659|NCT01685879|Other|Rice|Rice portion that provides 50 g total carbohydrate.
46012660|NCT01685879|Other|Rice|Rice portion that provides 50 g total carbohydrate.
46012661|NCT01685879|Other|Glucose Beverage|Glucose beverage that provides 50 g total carbohydrate.
46012662|NCT01602822|Drug|3 drug regimen: Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir|TDF 300mg and FTC 200mg fixed-dose combination tablet (TDF/FTC) once daily, and atazanavir, one 300mg tablet and one 100 mg ritonavir given once daily
46098679|NCT01001065|Procedure|Vascular ultrasound|RI ist predictive for arteriosclerosis
46098680|NCT02715089|Genetic|Precise treatment|During screening stage, all patients should accept next-generation sequencing (NGS) test.
45679875|NCT04810858|Device|Multimodal, multi-parametric MRI|The investigators will use multimodal, multi-parametric sequences to investigate neuroinflammatory and neurodegenerative processes in vivo. Participants will be assessed three times over 2 years.
46012663|NCT01602822|Drug|Ritonavir, Atazanavir, Truvada|
46012664|NCT01644344|Other|No-Xray|Treatment group: these patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks. After examining the patient, the surgeon or resident can order radiographs if required at any time. The decision will be made based on patient complaints of increased pain, appearance of abuse of the splint or cast suggesting lack of compliance or visible clinical deformity of the limb. The reason leading to radiographs will be documented by the ordering physician. If radiographs are ordered based on a wound complication, this will be specifically documented. Radiographic findings will be documented on a form identical to that used for the control group.
46012665|NCT01644344|Other|Xray|
46012666|NCT02273154|Drug|Buspirone|MDD patients with anxiety disorder take paroxetine (20-60mg/d), combining with buspirone (initial dose is 5mg tid, then increase the dose to 10mg tid on 4th day)
46012667|NCT02273154|Drug|Paroxetine|MDD patients with anxiety disorder take paroxetine (20-60mg/d)
46098681|NCT00871572|Drug|LY2409021|4 capsules by mouth taken once daily for 12 weeks
45679876|NCT04810858|Other|Immune and cytokine profiling|Blood samples will be collected for immune and cytokine profiling. Participants will be assessed three times over 2 years.
45679877|NCT04810858|Behavioral|Neuropsychological testing|Participants will have neuropsychological testing three times over 2 years.
46012668|NCT01644656|Device|ARFI ultrasound|ARFI imaging of the liver and spleen will be performed immediately before transjugular liver biopsy and HVPG procedures
46012669|NCT01607541|Behavioral|BCAP peer-driven intervention (PDI)|"The Brooklyn Community Action Project (BCAP) PDI entails structured sessions including the computerized CARE for Prevention tool, 3 peer education experiences, and 6 months of navigation for those HIV infected (if HIV-negative: total 3.5 hours of facilitated/computer intervention activities, plus peer education experiences; if HIV-positive: 5 hrs facilitated/computer activities, plus peer education experiences and navigation)."
46012670|NCT01607541|Behavioral|Control intervention|The control arm will receive a time- and attention-matched HIV counseling and testing intervention and for those found HIV-infected, an appointment with HIV services and reminders, the current standard of care.
46012671|NCT01644851|Behavioral|Executive function training|Computer-based training in executive functions, administered via www.lumosity.com website.
46098682|NCT00871572|Drug|Placebo|4 capsules by mouth once daily for 12 weeks
46098683|NCT00997711|Device|Cypher|Sirolimus-eluting stents
46098684|NCT02715245|Procedure|Home-based rehabilitation|Procedure/Surgery: Home-based rehabilitation In the patient's home, the primarily applied treatment has been physical therapy, seeking to achieve the highest possible functionality and gait training. In more than 25% of cases, health education is conducted for families and caregivers. Thus, consistent with the patient's condition and their tolerance to activity and to exercise their self-care independently, rehabilitation interventions are activated that prevent sequelae derived from functional limitations.
46098685|NCT01001143|Drug|Decitabine|
46098686|NCT01001143|Drug|Bexarotene|
46098687|NCT02715011|Drug|JNJ-63709178|Participants will receive JNJ-63709178 in Part 1 and Part 2.
45679878|NCT04801420|Biological|VLA15|a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
45679879|NCT04801420|Biological|Placebo|PBS (Phosphate Buffered Saline)
45679880|NCT04784715|Drug|Trastuzumab deruxtecan|Administered by intravenous infusion
46098688|NCT05248165|Device|PCI|Percutaneous coronary intervention
46098689|NCT02715167|Drug|Budesonide novolizer|
46098690|NCT02715167|Drug|Placebo|
46012672|NCT01603836|Biological|bone allogaft with bone marrow concentrate|In forty cases, the PLF was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
46012673|NCT01645046|Drug|Coenzyme A|Coenzyme A 200mg per day.
46098691|NCT00997789|Drug|Rebamide|Rebamipide 100 mg Tablet, three times a day
46098692|NCT02714933|Other|MRI sequence Advanced ZTE|Evaluation of the image quality in terms of visualization of anatomical structures of the lung parenchyma in safe zone by a new imaging method of the pulmonary parenchyma by MRI (Advanced ZTE sequence).
46098693|NCT03885661|Drug|Icosapent Ethyl 1000 MG [Vascepa]|Icosapent ethyl is an ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA). The empirical formula of icosapent ethyl is C22H34O2 and the molecular weight is 330.51. The chemical name for icosapent ethyl is ethyl all-cis-5,8,11,14,17-icosapentaenoate.
46098694|NCT00697632|Drug|MGCD265|Oral daily administration without interruption
46098695|NCT00997867|Procedure|Sciatic catheter left 0-1cm past needle tip vs. 5-6cm past needle tip|Patients undergoing orthopedic surgery who are getting a perineural catheter will be randomized to one of two groups: catheter tip placed 0-1cm past needle tip or catheter tip placed 5-6cm past needle tip. Patients will be called by research staff the day following surgery to assess their post-surgical pain using a numeric rating scale.
46098696|NCT00496613|Behavioral|Mini-Mental State Exam and Blood draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
46098697|NCT00496613|Behavioral|Mini-Mental State Exam and Blood Draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
46098698|NCT00496613|Behavioral|Mini-Mental State Exam and Blood Draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
46098699|NCT04034615|Biological|Mesenchyme Stem Cells low-dose group|Participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.
46098700|NCT04034615|Biological|Mesenchyme Stem Cells high-dose group|Participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
46098701|NCT04034615|Biological|Placebo|Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
45463937|NCT05210257|Other|Neuroscience education|"Conventional physiotherapy program and The neuroscience education trainings will be conducted in the form of face-to-face interviews and 45-50 minute one-to-one sessions.~In sessions ; neurons and nerve conduction in the session, the formation process of pain, peripheral neuropathic pain, pain spread during the session, neuroplasticity, peripheral and central sensitization, hyperalgesia and allodynia, acute-chronic pain, The effects of stress, fear, anxiety, false thoughts and beliefs about pain and other psychosocial factors on the pain process and determining possible psychosocial factors in the patient during the session, Strategies for controlling the pain process and coping with psychosocial factors in the session will be completed by explaining the effect mechanisms of exercise on pain."
45463938|NCT05479591|Drug|IDegLira|Participants will be treated with IDegLira at the treating physician's discretion according to the approved IDegLira label in Croatia and independent from the decision to include the participant in the study.
45463939|NCT01119209|Drug|Ropivacaine|Approved by the Danish Medicines Agency
45463940|NCT01119209|Drug|Saline|Approved by the Danish Medicines Agency
45463941|NCT05670535|Other|Visual analogue scale (VAS) for dyspareunia|Dyspareunia scores between 0 to 10 points
46012674|NCT01645046|Drug|Coenzyme A|Coenzyme A 400mg per day.
46012675|NCT01645046|Drug|Placebo|Capsule without coenzyme A.
46012676|NCT01605006|Device|NeuRx Diaphragm Pacing System (DPS)|The NeuRx DPS is a percutaneous, intramuscular, diaphragm stimulation system which is implanted using standard laparoscopic surgical techniques in an outpatient procedure. The implanted intramuscular diaphragm electrodes are connected to a four channel external stimulator at a percutaneous exit site. DPS is designed to help ALS patients breathe by providing conditioning stimulation of the diaphragm muscles. Recommended frequency of diaphragm conditioning is at least 3 times per day with each session lasting at least 30 minutes. Patients may find it helpful to use the DPS for longer periods to help with breathing. DPS may be used at the same time as non-invasive ventilation. Patents may also sleep with the DPS to assist with breathing difficulties at night.
45463942|NCT05670535|Other|Visual analogue scale (VAS) for vaginal dryness|Vaginal dryness scores between 0 to 10 points
46012677|NCT01606215|Drug|Mesenchymal stem cells|1.0-2.0 million cells/kg body weight
46012678|NCT01606215|Drug|Placebo|Placebo
46098702|NCT00868530|Biological|Xyntha|Xyntha for on-demand treatment of bleeding episodes were according to investigator prescription during the 6 months observation period. The recovery assessed by determining the Factor VIII (FVIII) concentration (FVIII:C) levels in individual subjects at the initial and final visits. The dose of Xyntha for recovery assessments is: single 50 IU/kg (±5 IU/kg) IV bolus infusion. All Xyntha administrations occurred in the clinic (hospital).
45463943|NCT05670535|Other|The European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)|Sjögren's Syndrome Disease Activity Index scores between 0 to 3 points
46012679|NCT01607775|Device|Implantation of a PEEK-cage|A commercially avaliable cuboid cervical cage will be implantet
45463944|NCT05670535|Other|The European League Against Rheumatism Sjögren's Syndrome Patient Reported Index (ESSPRI)|Sjögren's Syndrome Patient Reported Index scores between 0 to 10 points
45463945|NCT01116089|Drug|Bramitob® administered by PARI LC® PLUS nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
45463946|NCT01116089|Drug|Bramitob® administered by PARI eFlow® rapid electronic nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
46012680|NCT01607775|Device|PMMA-cage|The in-house produced cervical cage will be implanted
45463947|NCT05470777|Combination Product|"CD22/CD19 CAR T and auto-HSCT sandwich strategy"|The patients received sequential infusion of CD22 and CD19 CAR-T cells (co-stimulatory molecule was 4-1BB and infusion dose was 5*10^6/kg respectively) after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed 6-8 weeks after CAR-T infusion. Standard BuCy as conditioning regimen for Auto-HSCT was used 4 weeks after successful stem cell collection. CD22 and CD19 CAR-T cells were re-infused 2 days after Auto-HSCT. Patients were followed up and minimal residual diseases (MRD) was monitored by flow cytometry and second-generation gene sequencing of IgH rearrangement.
45837404|NCT04850820|Dietary Supplement|Isocaloric carbohydrate supplementation|This intervention will determine the impact of an isocaloric carbohydrate placebo supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
45837405|NCT04778748|Diagnostic Test|Under-mattress sleep monitor|Under-mattress sleep monitor for patients with a confirmed diagnosis of Obstructive Sleep Apnea.
45837406|NCT04520100|Behavioral|Clinical Hypnosis performed by the PI|The patient will receive clinical hypnosis by the PI prior to examination and listen to recorded session during their MRI.
46012681|NCT01685957|Behavioral|Standard dietary treatment (STD)|This group will receive 6 one-on-one sessions with a registered dietitian. Total time spent is 6½ hour. Dietary treatment is based national guidelines and counseling is individualized and tailored to the patient's needs and goals.
46012682|NCT01685957|Behavioral|"Ned i vaegt (NIV)"|"This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on the national dietary guidelines. Focus is to learn to make normal danish dishes in a more healthy way both ingredients, cooking, composition and quantity. They also learn about changing habits, making realistic goals and using their motivation."
46012683|NCT01685957|Behavioral|"Verdens bedste kur (VBK)"|"This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on new nordic diet and are a relative low-GI and high-protein diet. Focus is to learn to make new healthy dishes both ingredients, cooking and composition. They also learn about making realistic goals."
45463948|NCT01213901|Procedure|Lispro insulin|Each patient will receive 2 insulin injections in the abdomen: Once using a pinch method and once using a spread method.
45463949|NCT01116167|Drug|Letrozole -Berberine|"Letrozole~2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.~Berberine~1.5g daily for 6 month."
45679881|NCT04784715|Drug|Placebo|Administered by intravenous infusion
45463950|NCT01116167|Drug|Letrozole|"Letrozole~2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.~Berberine Placebo~5 tablet tds for 6 months"
45463951|NCT01116167|Drug|Berberine|"Berberine~1.5g daily for 6 month.~Letrozole placebo~1 tablet daily from day 5 of the menses for 5 days for month 1 to 3, 2 tablets daily from day 5 of the menses for 5 days for month 4 to 6."
45463952|NCT03844165|Behavioral|Diet change (red rice)|This interventions specifically aims to reduce liver inflammation, by replacing white rice in the diet with equal amounts of red rice and lentils. This will also enable for the research team to tests specific scientific hypotheses regarding the effects of diet on insulin resistance, liver pathology and the gut microbiome in NAFLD.
45679882|NCT04784715|Drug|Taxane|Investigator's choice of docetaxel or paclitaxel administered by intravenous infusion
46012684|NCT01602393|Drug|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 48 weeks
46012685|NCT01602393|Drug|CHF 5074 2x|oral tablet, 2x, once a day in the morning for 48 weeks
45679883|NCT04784715|Drug|Pertuzumab|Administered by intravenous infusion
45679884|NCT04784715|Drug|Trastuzumab|Administered by intravenous infusion
45679885|NCT04783272|Diagnostic Test|Photoacoustic Computed Tomography (PACT) Imaging|PACT will be completed prior surgery.
45679886|NCT04772456|Drug|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) [ 13C]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize [13C]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and [13C]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as [1- 13C]pyruvate, [2- 13C]pyruvate and [1,2- 13C]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body [Koletzko et al., 1997]."
46012686|NCT01602393|Drug|CHF 5074 3x|oral tablet, 3x, once a day in the morning for 48 weeks
46012687|NCT02273076|Device|Spatial Frequency Domain Imaging|Spatial Frequency Domain Imaging
46012688|NCT02271789|Other|problematic tooth|problematic tooth
46012689|NCT01645787|Drug|4-aminopyridine|10 mg/twice daily
45463953|NCT03844165|Behavioral|Yoga|All 84 study participants take part in the yoga intervention. This is an intensive programme organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute. This will evaluate whether physical activity alone improves metabolic health of the liver.
45679887|NCT04750226|Drug|ABBV-951|Solution for continuous subcutaneous infusion (CSCI).
45679888|NCT04746794|Behavioral|Population-level screening|"The study intervention involves having patients complete a familial cancer risk assessment survey. Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers. A previvor plan will be created to assist patients and their providers in completing the appropriate follow-up for those with a mutation identified."
45679889|NCT04740931|Drug|Faricimab|Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.
45679890|NCT04740931|Drug|Aflibercept|Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).
45679891|NCT04740931|Procedure|Sham Procedure|The sham is a procedure that mimics an IVT injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
46012690|NCT01645787|Drug|Placebo|Crossover study involving one trial with sugar pill (placebo)
46012691|NCT02270034|Drug|Crizotinib|Crizotinib is added to Stupp method
46012692|NCT01686113|Other|NEFA|
46012693|NCT01686113|Other|Sucrose|
46012694|NCT02270190|Device|Percutaneous Tibial Nerve Stimulation (PTNS)|
46012695|NCT01686230|Other|acupuncture|In each session, we treat bilaterally, 3 times a week and 2 days off a week, each patient in the acupuncture treatment groups will receive 12 sessions of acupuncture treatment over 4 weeks. The whole study period is 20 weeks including 4-week baseline period,4-week treatment period, and 12-week follow-up period. we will investigate at 0 day,4week,8week,12week,16week after randomization。
46012696|NCT01686230|Drug|Basic treatment|"Each group in the basic treatment，Foundation treatment including health education and basic drug therapy.~We recommend lifestyle modification for all patients. Modifications include increasing exercise; limiting alcohol consumption; and weight loss; quit smorking etc.~Basic medication： Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn."
45463954|NCT03843931|Behavioral|GLA:D|The GLA:D exercise and education program is an 8-week treatment program delivered by GLA:D certified physiotherapists. It consists of 2 educational sessions over 2 weeks (1/week in week 1 and 2) and 12 exercise sessions over 6 weeks (2/week in weeks 2 thru 8) The 2 educational sessions provide knowledge of OA, treatment and self-management, with a special focus on exercise and its benefits. The exercise part lasts for 6 weeks with 2 exercise sessions per week of approximately 1 hour (12 sessions total). The exercise sessions are group based at a facility supervised by a GLA:D certified physiotherapist. The goal is the obtain muscle control and stability in situations resembling daily life and/or more strenuous activities.
46098703|NCT02714777|Device|Autonomic nervous system activity|Autonomic nervous system activity (parasympathetic activity) will be measured by electrocardiogram (holter) during 24 hours postoperative
46098704|NCT01004341|Behavioral|Family-based behavioral weight control intervention|Standard behavioral weight control program for children ages 8-12 years old and their parents in a family-based intervention.
46098705|NCT02620566|Procedure|Bupivacain- Caudal|Bupivacain for caudal blocks, Group C received 1 ml kg of 0.25% (maximum volume 20 ml).
45679892|NCT04737616|Device|CO2 laser|Fractional CO2 vaginal laser for genitourinary syndrome of menopause
45679893|NCT04737616|Device|OCT|Optical coherence tomography endoscope
45679894|NCT04732130|Behavioral|Time-Restricted Feeding|Participants are instructed to limit food intake to maximum 8 hours per day.
45679895|NCT04732130|Behavioral|Alternate Day Fasting|Participants are instructed to fast every other day.
45679896|NCT04726462|Other|Functional exercises|The exercise program is planned as a function-oriented exercise program aimed at improving balance skills, increasing lower extremity muscle strength and functions.
46012697|NCT01686269|Procedure|blood collecting|
46012698|NCT02273271|Other|18F-FLT-PET/CT and DWI-MRI|Patients with NSCLC will undergo 18F-FLT-PET/CT and DWI-MRI scans on three separate occasions. Dedicated in-house developed software will be used to quantify 18F-FLT SUV and ADC to assess tumor characteristics and response to therapy.
46012699|NCT01688414|Procedure|photoacoustic imaging|Undergo PAI
45679897|NCT04726462|Other|Posture exercises|The exercise program was planned by focusing on posture exercises in order to increase the postural smoothness of the participants.
45679898|NCT04723264|Behavioral|Food protocols|"Participants will engage in several activities (i.e. offering a variety of foods and age appropriate games, etc.) regarding eating behaviors.~Participants will be asked to videotape interactions using a secure system. An alternative option may be provided if this videotaping is not acceptable."
45679899|NCT04721886|Procedure|Ultrasonsgraphy|Undergo ultrasonography
46012700|NCT01688414|Procedure|fluorescence imaging|Undergo fluorescence imaging
46012701|NCT01688414|Procedure|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic surgery
46012702|NCT02273349|Device|Lung Volume Reduction Coil (PneumrX Inc.)|Endoscopic Lung Volume Reduction
46012703|NCT01686308|Procedure|Yellow Intra Ocular Lens (IOL)|Standard operation with blue light filter Yellow IOL implantation
45679900|NCT04721886|Drug|Perflutren Lipid Microcpheres|Given IV
45679901|NCT04721886|Procedure|Contrast - Enhanced Ultrasound|Undergo CEUS
45837407|NCT04520100|Behavioral|Care by technician trained in empathic communication|The patient will be taken care of by an MRI technician who has been previously trained in empathic communication.
46098706|NCT02620566|Procedure|Bupivacaine- Local|Bupivacain for Local Wound Infiltration Group L received 0,2 ml kg 0,25% (maximum volume 4 ml).
46098707|NCT02714621|Device|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
46012704|NCT01686308|Procedure|Conventional Intra Ocular Lens (IOL)|Standard operation with conventional IOL implantation
46098708|NCT00855465|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid orally for 16 weeks.
46098709|NCT00855465|Drug|Placebo|Matching Placebo tid orally for 16 weeks
46098710|NCT01001611|Drug|CKD-501 0.5mg|0.5 mg/tablet, orally, 1 tablet once daily for 24 weeks or 52 weeks (If extension study)
46098711|NCT01001611|Drug|Placebo|Indistinguishable tablet from CKD-501, Orally, 1 tablet once daily for 24 weeks
46098712|NCT04134546|Procedure|CBD exoloration|Early versus late intervention after biliary tract injury post cholecystectomy
46012705|NCT02270268|Dietary Supplement|Pectin|Pectin （Andeli Ltd. Yantai, China）, 24g/d for six weeks
46012706|NCT02270268|Dietary Supplement|maltodextrin|
46012707|NCT01688531|Drug|CD0271 0.1%/CD1579 2.5% gel|one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
46012708|NCT01688531|Drug|CD0271 0.1%/CD1579 2.5% gel vehicle|one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
46012709|NCT02270307|Drug|Cyclophosphamide|Dose 50 mg/kg at day +3,+4 once daily
46012710|NCT02270307|Biological|Mesenchymal stromal cells|Dose 1 million per kg, at day of recovery once
46012711|NCT05140772|Drug|Dipeptiven|IV administration daily for 7 days
46012712|NCT05140772|Drug|normal Saline|IV administration daily for 7 days
46012713|NCT02270385|Behavioral|PU prevention programme|The PU prevention programme consists of two major components which are an intensive training course(a 2-hour lecture and two skill training sessions) and a PU prevention protocol.
46012714|NCT02270385|Behavioral|Usual PU prevention care|Usual PU prevention care that is a series of basic nursing care activities: repositioning of residents, moisturization , change of napkins to keep buttock dry.
46012715|NCT02270424|Drug|Salmeterol / fluticasone (Seretide®)|According to the revised 2013 GOLD, Salmeterol / fluticasone was used to severe and very severe COPD patients for 52weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
46012716|NCT02270424|Drug|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
46012717|NCT02270424|Drug|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
46012718|NCT02270424|Drug|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
46012719|NCT02270424|Drug|Placebo Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given placebo Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
45837408|NCT04504344|Device|Anodal transcranial direct current stimulation (tDCS) - Soterix Medical Inc, 1x1 tDCS (conventional)|We will compare the effects of active versus sham tDCS on quadriceps strength and corticospinal excitability in patients recovering from ACLR.
46012720|NCT02270424|Drug|Placebo Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given placebo Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
46012721|NCT02270424|Drug|Placebo Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given placebo Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
46012722|NCT01686347|Drug|ropivacaine|
46012723|NCT02270541|Other|Telemedicine|In-ambulance telemedicine
46012724|NCT01686425|Procedure|Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage|Percutaneous transhepatic cholangiography biliary drainage is compared tot endoscopic biliary drainage in the management of malignant biliary obstruction not amenable to ERCP
46012725|NCT02270580|Behavioral|PN+|"we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors"
46012726|NCT02270580|Behavioral|PN usual|participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
46012727|NCT05140655|Drug|Fulvestrant|Medicine for Advanced breast cancer
45463955|NCT03843931|Drug|Intra-articular saline injection|"Four [4] dosages of 5 ml intra-articular isotonic saline (0.9% (9 mg/mL) Sodium Chloride Injection (sterile, isotonic solution of sodium chloride and sterile water for injection)) every other week from baseline (week 1, 3, 5 and 7 = 4 injections).~The injections will be carried out with a 21 gauge (38 mm) needle and a Luer-lock syringe under ultrasound guidance to ensure that the needle is inserted into the study knee joint cavity and document correct deposition of the bolus in the joint cavity.~If the investigator detects presence of excessive joint fluid during the ultrasound guided preparation of the injection, this will be aspirated before injection of the saline - if possible."
45463956|NCT01119521|Biological|BCG strain Danish|Intradermal Bacillus Calmette-Guerin (BCG) live-attenuated vaccine prepared using the Danish 1331 BCG substrain; adult dose contains 2 to 8 x 10^5 colony forming units (CFU) BCG.
45463957|NCT01119521|Drug|Isoniazid|United States Pharmacopeia 100 mg or 300 mg oral tablets [5 mg/kilogram/day (rounded up to nearest 100 mg; maximum dose 300 mg/day)].
45463958|NCT05670457|Drug|Diosmin|diosmin 500 mg twice daily
45463959|NCT03939923|Drug|Rocuronium|Intubation with Rocuronium 1.0-1.2 mg/kg (vitals maintained within 20% of baseline. Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure.
45463960|NCT03939923|Drug|Neostigmine|Reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage)
46098713|NCT04784663|Behavioral|Messaging|Four brief video messages, each approximately 1.5 minutes in length, focused on facilitating treatment seeking by addressing barriers and improving attitudes. Intervention delivered to participant by study mobile app downloaded to participants' own smartphone.
46098714|NCT04784663|Other|Wait list control|one push notification each week thanking individuals for participation, informing them that they will receive messages in the near future or reminding them of the length of the study.
46098715|NCT00997945|Drug|ZD4054 (Zibotentan)|10 mg ZD4054 (Zibotentan) once daily on Day1, Day4 to Day15
46098716|NCT04134624|Other|Sepsis care bundle|Initiation of sepsis care bundle in prehospital setting, including collection of blood cultures, administration of antibiotics, and initiation of IV fluids
46098717|NCT02714699|Drug|diclofenac potassium|patients will take oral diclofenac potassium; two tablets (cataflam 25 mg) and one tablet placebo one hour before the procedure
45463961|NCT03939923|Drug|Glycopyrrolate|Reversal glycopyrrolate (0.07-0.015mg/kg up to 1 mg maximal dosage)
45463962|NCT03939923|Drug|Sugammadex|Reversal with Sugammadex (2mg/kg)
46098718|NCT02714699|Drug|hyoscine butyl bromide|patients will take oral hyoscine-N- butyl bromide; 2 tablets (buscopan 10 mg) one hour before the procedure
45683824|NCT02783716|Diagnostic Test|Peripheral arterial tonometry (PAT)|Non-invasive testing for blood vessel function. Specially designed finger probes placed on the middle finger of each hand. Pulsatile volume changes of the distal digit inducing pressure alterations in the finger cuff will be sensed by pressure transducers and recorded. Endothelial function will be measured via a reactive hyperemia (RH)-PAT index (RHI)
46098719|NCT02714699|Drug|placebo|patients will take oral placebo; 2 tablets one hour before the procedure
46098720|NCT01004419|Drug|ZD6474 (vandetanib)|vandetanib (100 mg or 200 mg or 300 mg) by mouth once daily for 28 days
46098721|NCT01004419|Drug|Faslodex (Fulvestrant)|Fulvestrant 500 mg intra-muscular injection on Day 1 and 250 mg Day 15 of cycle 1 Cycles 2 and beyond: Fulvestrant 500 mg intra-muscular injection on Day 1, every 28 days.
46098722|NCT02620644|Device|OCT Retinal GCC|measuring of the retinal ganglion cell complex (GCC) thickness and the central foveal thickness (CFT) using the RTVue® SD-OCT (Optovue, Inc.)
46098723|NCT02714855|Drug|Apixaban|
45463963|NCT01199809|Drug|Placebo|multiple doses
45463964|NCT01199809|Drug|RO5310074|multiple ascending doses
45463965|NCT01119599|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-D conformal radiation therapy
45463966|NCT01119599|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
45463967|NCT01119599|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45463968|NCT01119599|Other|Laboratory Biomarker Analysis|Correlative studies
45463969|NCT01119599|Other|Pharmacological Study|Correlative studies
45463970|NCT01119599|Drug|Temozolomide|Given PO
45463971|NCT01119599|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45463972|NCT03419403|Drug|Steroid eye drops|Solution, eye drop
45463973|NCT03419403|Drug|Vasoconstrictor eye drops|Solution, eye drop
45463974|NCT03419403|Other|Cold compress|Cold compress
45683825|NCT02738788|Other|Intubation|"The patient's airway will be visually assessed and photographed while the patient is resting comfortable in bed with the head up at 30-45 degrees and classified into one of 4 MMS categories. Digital photographs will be taken and the stored image prepared by the investigators in such a way that the patient cannot be individually identified (mouth only).~Neck circumference will be measured at the level of the thyroid cartilage using a tape measure, with temporary ink marks on the skin to allow for subsequent measurements at the same point.~After the patient has been extubated and recovered in the PACU for 30 minutes, their airway will be re-assessed and documented. These evaluations will be repeated at 2, 3, and 4 hours, as well as the next morning."
45837409|NCT04501380|Drug|AEMCOLO (Rifamycin SV MMX)|Participants will be issued a patient kit containing AEMCOLO (Rifamycin SV MMX) 194 mg tablets for the 1st or the 2nd treatment regimen in a random order.
45837410|NCT04465734|Drug|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
46012728|NCT02270619|Biological|Endotoxin|Low dose endotoxin (0.8 ng/kg of body weight) as IV bolus
46012729|NCT02270619|Behavioral|Partial sleep deprivation|Partial night sleep deprivation by staying awake from 23:00 to 03:00
46012730|NCT02270619|Other|Placebo|0.9% saline as IV bolus
46012731|NCT02270619|Other|Uninterrupted sleep|Uninterrupted sleep from 23:00 to 07:00
46098724|NCT00694902|Drug|GSK610677|GSK610677 Multi-Dose Powder Inhaler will be available in the strength of 10, 50, 100 and 25 microgram with dose levels of 10, 30, 50, 100, 250, 500 and 1000 microgram. Subjects will receive GSK610677 as single inhale dose.
45837411|NCT04465734|Drug|HLX04|HLX04 is an recombinant anti-VEGF humanized monoclonal antibody ，developed by Shanghai Henlius Biotech, Inc.
45837412|NCT04465734|Drug|Sorafenib|Sorafenib is a multi-target, multi-kinase inhibitor capable.The standard treatment of HCC.
46098725|NCT00694902|Drug|Placebo|Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.
46098726|NCT02712203|Biological|MMR vaccine / MMRV vaccine|Subcutaneous injection, two doses
46098727|NCT02620488|Behavioral|Guided Imagery|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
46098728|NCT00696930|Drug|90Y-SMT487|
45463975|NCT03419403|Drug|Ophthalmic steroid ointment|Ointment
45463976|NCT03419403|Drug|Depatuxizumab mafodotin|During the Chemoradiation Phase, participants were to receive depatuxizumab mafodotin at 2.0 mg/kg IV infusion over 30 - 40 minutes once every 2 weeks (Day 1 of Weeks 1, 3, and 5 of the 6-week regimen). During the Adjuvant Therapy Phase, participants were to receive depatuxizumab mafodotin at 1.25 mg/kg on Day 1 (± 2 days) and Day 15 (± 2 days) of each 28-day cycle as a 30 - 40 minute infusion for 12 cycles.
46012732|NCT05140616|Drug|Chidamide|After screening according to inclusion and exclusion criteria, patients meeting the criteria were enrolled. Treatment regimen: Chidamide 15mg biw po, lasted for 8 weeks. Pretransplant use of Chidamide for reasons other than cGVHD, such as for the treatment of leukemia or lymphoma, was permitted.All patients received systemic corticosteroid therapy for cGVHD prior to and during the study; concomitant use of other immunosuppressive therapies was also permitted, however, pre-existing corticosteroid and immunosuppressant doses must have been stable for 14 days before initiating Chidamide. Doses of concomitant corticosteroids and immunosuppressants could be tapered during the study as clinically indicated.
46012733|NCT01688570|Drug|duloxetine|Single dose, orally (pill), 30 mg, taken 6 hours prior to start of the testing session. Subjects will only take a single dose of duloxetine once.
46012734|NCT01688570|Drug|Cyproheptadine|Single dose, orally, 8 mg, 6 hours prior to the start of the respective testing session. Subjects will take a single dose of cyproheptadine once.
45463977|NCT03419403|Drug|Temozolomide|Temozolomide was to be administered according to the local standard of care. Duration of treatment was to be 6 - 12 cycles in the adjuvant phase and at the discretion of the investigator as supported by local standard of care.
45463978|NCT03419403|Radiation|Radiation|Radiation therapy treatment planning and administration was to be performed as per local institutional guidelines.
46012735|NCT01688570|Drug|Placebo|Single dose, orally, 6 hours prior to the start of the respective testing session. Subjects take a single dose once.
46098729|NCT00598442|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
46098730|NCT00598442|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
46098731|NCT00598442|Drug|Darbepoetin alfa|Participants received darbepoetin alfa by subcutaneous injection once every 2 weeks, as prescribed. The starting dose was 0.75 microgram per kilogram (mcg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
46012736|NCT02270697|Device|Array|Applications of oligonucleotide array in diagnosis.
46012737|NCT01686464|Drug|prednisone and valacyclovir treatments|patients were administered prednisone as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.while taking valacyclovir 400 mg in three doses daily for 10 days.
46012738|NCT01686464|Device|Magnetic and Oxygen Treatment|MOMC treatment was given as daily 20 min section for 10 days with 2~3 days of intermission between. Oxygen therapy was given simultaneously at a flow rate of 2~3.0 L / min for the same duration during all acupuncture sections.
46012739|NCT01686542|Procedure|CPVI plus renal sympathetic modification|CPVI plus renal denervation to reduce atrial arrhythmia recurrence.
46098732|NCT04132752|Other|Motivation|Families were called via phone weekly and all questions were answered. Parents were motivated through phone.
46098733|NCT02714543|Drug|aloevera juice|aloevera juice to drink twice daily for 3 months.
46098734|NCT02714543|Drug|Hydrocortisone|intralesional injection of hydrocortisone 100mg once a week for 6 weeks
46098735|NCT02714543|Drug|Hyaluronic Acid|injection hyaluronic acid 1500IU once a week for 6 weeks
46098736|NCT02714543|Drug|antioxidant|Capsules SM Fibro (antioxidants) once daily for 3 months.
46098737|NCT02714543|Drug|aloevera gel|aloevera gel one scoop to be applied 3-4 times daily for 3 months
46098738|NCT00593814|Device|GORE EXCLUDER® Bifurcated Endoprosthesis-Low Permeability|Implant
46098739|NCT02714231|Drug|diclofenac sodium (cataflam)|The patients in the study group will take one tablet of cataflam 50 mg 30 min before the scheduled time of the procedure
46098740|NCT02714231|Drug|hyoscine butyl bromide (buscopan)|The patients in the study group will take one tablet of buscopan 10 mg 30 min before the scheduled time of the procedure
46098741|NCT00855309|Drug|acyclovir sodium|Given IV
46098742|NCT00532129|Drug|Rituximab|375mg/m^2 IV on Day 1 of Cycle 1; 500mg/m^2 on Day 1 of Cycles 2-6.
46098743|NCT00532129|Drug|Chlorambucil|10 mg/m^2/day PO on Days 1 to 7 of each cycle for a maximum of 12 cycles.
45463979|NCT05456581|Behavioral|'Scotoma awareness' Training|In the 'scotoma awareness' training, patients will perform visual search and orientation discrimination tasks while an opaque occluder, custom-tailored to overlap each patient's retinal scotoma, is constantly presented on the computer screen.
45463980|NCT05456581|Behavioral|Control Training|The task will be performed in the control group without the visible scotoma.
45463981|NCT01116245|Biological|ADXS11-001 (Lm-LLO-E7)|ADXS11-001 at one of three dose levels given as 3 vaccinations separated by 4 weeks with an oral antibiotic regimen subsequent to dosing.
45463982|NCT01116245|Drug|Placebo Control|3 intravenous infusions of normal saline at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
46012740|NCT01686542|Procedure|CPVI|CPVI alone to reduce atrial arrhythmia recurrence.
46012741|NCT02270931|Device|CA 15-3 Assay|Physicians use the CA 15-3 test result to manage their patients
46012742|NCT02270970|Biological|belimumab|belimumab will be given at 10 mg/kg intravenously at Week 1, Week 2, Week 4 and monthly after that as was done in Phase III trials and approved in the FDA label
45837413|NCT04448808|Drug|BX-1|BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.
46012743|NCT05140733|Procedure|lumbar foraminal decompression|lumbar foraminal decompression with endoscopic instruments.
46012744|NCT05140733|Procedure|Fusion surgery|Fusion surgery for patients with foraminal stenosis
46098744|NCT02616120|Drug|SQJZ herbal mixtures|The SQJZ herbal mixtures is Chinese herb extracts. It contains Rehmannia glutinosa Libosch，Astragalus membranaceus (Fisch.) Bunge etc.( 29.375g, 2 times per day)
46012745|NCT01688648|Drug|Lidocaine infusion|a bolus dose of Lidocaine 1.5 mg/kg after anesthetic induction with following infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
45463983|NCT05156437|Drug|Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin|Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin
45463984|NCT05156437|Drug|Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline|Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
45463985|NCT01119677|Drug|Avonex|Group 1 subjects will receive weekly Avonex 30 mcg (full dose) IM injections from Week 1 to Week 8. Group 2 subjects will titrate in quarter dose increments every week up to a full dose of Avonex over a 3 week period from Week 1 to Week 3 and then continue on full dose from Week 4 to Week 8. Group 3 subjects will titrate in quarter dose increments every 2 weeks up to a full dose of Avonex over a 6 week period from Week 1 to Week 6 and continue on full dose from Week 7 to Week 8
46098745|NCT02616120|Drug|Placebo|placebo contains 5%SQJZ herbal mixtures and 95% dextrin,identified to SQJZ herbal formula (29.375g, 2 times per day)
46012746|NCT01688648|Drug|Dexmedetomidine infusion|Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 ~ 0.7 mcg/kg/hr during the surgery
46012747|NCT02271009|Drug|AllerT|Ultrafast immunotherapy
46098746|NCT02714309|Dietary Supplement|Whey protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage
46098747|NCT02714309|Other|Mixed macronutrient breakfast meal|A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kilojoules (kJ); 468 kcal total)
46098748|NCT02714309|Other|Ad libitum lunch meal|A mixed-macronutrient lunch served to all participants ad libitum. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat
45463986|NCT05436925|Device|Dexcom G6 sensor Continuous Glucose Monitor (CGM)|The device used as part of the study is to obtain results for glucose testing for research only and not for diagnostic purposes.
46012748|NCT02271009|Drug|Placebo|placebo control
46098749|NCT02714309|Other|Low/moderate intensity exercise|A 30 minute bout of treadmill walking is performed on a motorised treadmill at a low/moderate intensity (55% estimated VO2max)
45463987|NCT01196689|Drug|AZD1981 100 mg twice daily for 61/2 days|100 mg tablets
45837414|NCT04448808|Drug|Placebo|Placebo of BX-1, oral solution
45837415|NCT04388358|Drug|Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang by the weight of 9g+3g+3g/day|All patients were treated with mixed formula of Chinese medicine for one month
45837416|NCT04417296|Diagnostic Test|antepartum computerised cardiotocography analysis|A common obstetric methodical to evaluate the fetal well-being is the antepartum fetal heart rate (FHR) monitoring through cardiotocography (CTG)
46012749|NCT01686659|Device|Continuous Noninvasive Hemoglobin Monitoring|Availability of data from a continuous noninvasive hemoglobin monitoring device (total hemoglobin [SpHb] and Pleth Variability Index [PVI]) to the clinicians in the operating room
45837417|NCT04397874|Diagnostic Test|; Computerized cardiotocography (cCTG)|To estimate the correlation between the maternal perception of fetal movement and antepartum computerised cardiotocography parameters.
45837418|NCT04954872|Behavioral|Standard Problem Management Plus training (training as usual)|10-day training on Problem Management Plus.
45837419|NCT04954872|Behavioral|Equip-based Problem Management Plus training|Training and supervision for Problem Management Plus in which the trainers and supervisors use the EQUIP platform for competency assessment and feedback.
46012750|NCT02271048|Device|Remote ultrasonography interpretation using the smartphone|The reviewers interpreted the ultrasonography images on the smartphone transmitted from the ultrasound machine in real time
46012751|NCT01686698|Dietary Supplement|VSL#3 (Original De Simone formulation)|VSL#3 (Original De Simone formulation) is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus, bifidobacteria and lactobacilli.
46098750|NCT04163276|Diagnostic Test|18F FDG PET exam|All patients have received 18F-FDG PET/CT in nuclear medicine
46098751|NCT00854607|Other|No Intervention|Blood samples will be collected for 12 weeks to evaluate levels of fungal biomarkers.
46098752|NCT02616198|Other|EquiaFil G-coat|The old restorations or new caries were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing 10 sec. in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
45463988|NCT01119911|Other|Blood sampling from peripheral venous catheter.|Venipuncture is performed on the opposite limb of the peripheral venous catheter. Within 3 minutes, a second sample is taken from existing peripheral venous catheter used for fluid administration. Intravenous fluids are then stopped for 30 seconds and a tourniquet applied proximal to the device for another 30 seconds. A 2-mL syringe is attached and 0.5 mL of blood aspirated and discarded. Thereafter, 2 mL blood is slowly drawn during about 15 seconds, into a different 2-mL syringe, to allow a gentle pumping action that may reduce vacuum in the syringe and thus hemolysis rates. Afterwards, the intravenous device is flushed with 2 mL normal saline and infusion restarted.
46012752|NCT01686698|Other|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
45463989|NCT03715725|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Administration according to clinical practice
45463990|NCT03715725|Drug|Apixaban (Eliquis)|Administration according to clinical practice
46098753|NCT02616198|Other|EquiaFil Fuji Varnish|The old restorations or carious lesions were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers of Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
46098754|NCT02616198|Other|Riva SC G-coat|The old restorations or carious lesions were removed and a sectional matrix was applied for two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. The glass ionomer was packed with hand instruments in the cavities and 2min after the first setting the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat resin and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
45463991|NCT03715725|Drug|Dabigatran etexilate (Pradaxa)|Administration according to clinical practice
45463992|NCT03715725|Drug|Warfarin (Marevan)|Administration according to clinical practice
45463993|NCT01212653|Drug|Simponi|Golimumab 50mg monthly
45463994|NCT01212653|Other|0.9ml sodium chloride|0.9ml sodium chloride
45463995|NCT03843697|Device|An App for reminding patients to take their medication|Open-label, single-center study, up to 20 adults (>18) male and female with inflammatory bowel disease (chorn's disease, ulcerative colitis), unresponsive to biological drugs, will participate in a 4-week observation period during which no change in drugs is permitted. The patients will then begin 10-week treatment by taking their medications according to a semi-random schedule that is pre-set for them by the physician using the same drugs the patient is taking and only changing the dose and times of taking them each day while keeping the drugs within their therapeutic window.
45463996|NCT01119989|Dietary Supplement|Fructose+maltodextrin placebo|
45463997|NCT01119989|Dietary Supplement|amino-acid + fructose|
45463998|NCT01199887|Drug|IW001|IW001, 0.1 mg, 0.5 mg, 1.0 mg PO daily for 24 weeks.
45463999|NCT01213979|Drug|500 mg iron isomaltoside 1000|500 mg iron isomaltoside 1000 given as a bolus injection over 2 minutes
45464000|NCT01213979|Drug|1000 mg iron isomaltoside 1000|1000 mg iron isomaltoside 1000 given as a infusion over 15 minutes
45464001|NCT03937115|Device|Active tDCS|2 active tDCS sessions (20 min each, 2 mA) applied to the dlPFC and right motor cortex
45464002|NCT03937115|Device|Sham tDCS|1 sham tDCS session (20 min, 0 mA) applied to the dlPFC
45464003|NCT03937115|Device|Active tDCS|10 tDCS sessions (2 sessions/day for 5 days, 20 mA, 20 min each) applied to the dlPFC
45464004|NCT03937115|Device|Sham tDCS|10 tDCS sessions (2 sessions/day for 5 days, 0 mA, 20 min each) applied to the dlPFC
45464005|NCT03844555|Drug|Elafibranor|120mg oral single dose
45837420|NCT02132520|Device|rTMS|Low frequency rTMS (either real or sham) will be applied to the contralesional hemisphere at a rate of 1Hz for 10 minutes.
45837421|NCT02132520|Behavioral|BCI Training|BCI training will consist of a series of EEG-based motor-imagery tasks with virtual feedback presented on a computer screen.
46098755|NCT02616198|Other|Riva SC Fuji Varnish|The caries lesions were removed with diamond and stainless steel burs, a sectional matrix was applied for restoring two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. After the first setting of 2min, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers with Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
46012753|NCT01688687|Procedure|Endoscopic submucosal dissection|
46012754|NCT02271126|Device|TEG monitoring|anticoagulation monitoring during ECMO will be according to TEG
46012755|NCT02271126|Device|APTT monitoring|anticoagulation monitoring during ECMO will be according to aPTT
46012756|NCT02271126|Drug|Heparin|Anticoagulation provided to patients in ECMO
45464006|NCT05282719|Drug|venetoclax combined with azacitidine|On day 1 of each cycle, decitabine 75 mg/m2 will be given subcutaneously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 14 day cycle is finished.
45464007|NCT01118429|Drug|Oxybutynin|Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
45683826|NCT05241886|Other|anthoropometric measurement, SARC- F questionnare|SARC-F, CC, MUAC
45683827|NCT03145168|Other|High Target Mean Arterial Pressure|High target group (80-85 mm of Hg).
45683828|NCT03145168|Other|Low Target Mean Arterial Pressure|Low target MAP group (60-65mm Hg).
45683829|NCT02564848|Procedure|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
45464008|NCT01118429|Drug|Placebo|Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
45837422|NCT04020198|Other|Biomarker assay|Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in biofluid samples from patients with Parkinson's disease, multiple system atrophy, rapid eye movement sleep behavior disorder, normal pressure hydrocephalus and controls.
45837423|NCT03907644|Device|Transcranial Alternating Current Stimulation (tACS)|The tACS stimulator delivers very low (2mAmp) current with surface electrodes to the skull.
45837424|NCT03885336|Other|No Interventions|There are no interventions in this study. Participants are observed.
45837425|NCT03869814|Other|Blood Draw|Blood Draw
46098756|NCT00656396|Device|Coagucheck XS Plus (Point of care monitor of coagulation intraoperative)|Coagucheck XS Plus® is used for intraoperative measurement of Prothrombin time
46098757|NCT00656396|Procedure|Control Intervention|Standard care
46012757|NCT05140577|Other|Maximal voluntary isometric strengthening|The subject is asked to perform a maximum voluntary isometric force work against a wall during 5 seconds
46098758|NCT02751281|Procedure|Pneumatic percutaneous nephrolithotomy|Pneumatic percutaneous nephrolithotomy is type of surgery that we use pneumatic lithotripter to treat kidney stone
46098759|NCT02751281|Procedure|Ultra-sonic percutaneous nephrolithotomy|Ultra-sonic percutaneous nephrolithotomy is type of surgery that we use ultra-sonic lithotripter to treat kidney stone
45464009|NCT01200043|Other|fructose restriction diet|fruits and vegetables only
45464010|NCT01116479|Other|Blood transfusion|Blood transfusion with packed erythrocytes
45464011|NCT05121259|Other|ExerciseGuide Intervention Group|The single group which will be given access to the eight-week ExerciseGuide UK website containing a tailored physical activity programme and supportive and educational resources.
45837426|NCT03856632|Drug|Liraglutide|Liraglutide will be administered with a starting dose of 0.6 mg once daily and subsequent increments to 1.2 mg once daily (after at least one week) and to 1.8 mg once daily (after at least a week on 1.2 mg). This will be taken for 3 consecutive months in conjunction with RFM program prior to catheter ablation. Treatment will resume post ablation and will be continue for 6 months.
46012758|NCT02271165|Drug|Immunoglobulin (Hizentra)|
46012759|NCT01686737|Behavioral|Iyengar Yoga|"12 weeks of Iyengar yoga~2 weekly sessions of 60 minutes"
46012760|NCT01686737|Behavioral|Walking|"12 weeks of walking~2 weekly sessions of 60 minutes"
46012761|NCT02271204|Drug|Ibandronic acid|As prescribed by physician
46098760|NCT02616042|Other|Centella asiatica and bamboo salt|Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica and bamboo salt is compared with control dentifrice.
46098761|NCT02616042|Other|Centella asiatica|Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica is compared with control dentifrice.
46098762|NCT04163588|Drug|Metolazone|Study participants receive loop diuretics plus oral metolazone at a dose of 5/10 mg once daily
46098763|NCT04163588|Drug|Loop Diuretics|Study participants receive a standard diuretic strategy (intravenous loop diuretics as recommended by current guidelines plus placebo)
46098764|NCT05167513|Drug|Metformin / Sitagliptin Oral Tablet|"Metformin and sitagliptin are oral diabetes medicines that help control blood sugar levels.~Metformin works by decreasing glucose (sugar) production in the liver and decreasing absorption of glucose by the intestines. Sitagliptin works by regulating the levels of insulin your body produces after eating.~Metformin and sitagliptin is a combination medicine that is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. metformin and sitagliptin is not for treating type 1 diabetes."
46098765|NCT00635687|Device|Fibroscan|transient elastography measure - Liver stiffness
46098766|NCT04045704|Procedure|Cataract Surgery|Patients with bilateral Advanced Age-related macular degeneration and concurrent cataracts will be receiving bilateral cataract surgery
46098767|NCT02635568|Other|Cannabis Use|Observational Study
45464012|NCT03447249|Drug|VX-659/TEZ/IVA|Participants received VX-659/TEZ/IVA orally once daily in the morning.
45464013|NCT03447249|Drug|IVA|Participants received IVA orally once daily in the evening.
45683830|NCT02398786|Other|Patient-entered data|This registry provides patient-entered data for future clinical trial and study use.
45683831|NCT05249140|Device|Repetitive Transcranial Magnetic Stimulation|rTMS involves a safe, non-invasive, painless application of a magnetic field over the skull to a target brain area in order to change its activity and function.
45683832|NCT05249920|Drug|Edaravone Dexborneol Concentrated Solution for injection|Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.
45683833|NCT05249920|Drug|Edaravone Dexborneol placebo|Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.
45464014|NCT03447249|Drug|Placebo|Participants received placebo matched VX-659/TEZ/IVA orally once daily in the morning and placebo matched to IVA orally once daily in the evening.
45464015|NCT01120301|Device|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
45464016|NCT04166149|Diagnostic Test|dd-cfDNA Blood Test|The cfDNA measurement isolated from the peripheral blood contains small amounts from the graft. The blood sample is collected in Cell-Free DNA BCT (blood collection) tubes. These are measured by their difference in SNP (single nucleotide polymorphisms) genotype to determine the ratio of donor to recipient through shotgun sequencing. Higher levels of dd-cfDNA in a patient experiencing rejection is measured as a higher percentage of the total cf-DNA.
45464017|NCT04156555|Drug|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Oral amoxicillin-clavulanate 1 g twice a day for total of 6 doses
45464018|NCT01200121|Drug|Bevacizumab|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of 400 mg Bevacizumabafter paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
45464019|NCT01200121|Other|Placebo|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of Placebo after paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
45464020|NCT01214291|Drug|Toremifene|Toremifene 80mg daily
45464021|NCT01116557|Device|Radiofrequency Ablation procedure|Radiofrequency Ablation procedure Application of radiofrequency energy with the THERMOCOOL® catheter used in combination with the CARTO® 3 System and the LASSO® Circular Mapping Catheter to eliminate potentials arising from the pulmonary veins.
45837427|NCT03856632|Other|RFM|The program involves weight management and exercise regimen (30 minutes for 2 to 4 times a week), hyperlipidemia management (lifestyle measure changes and initiation of statins and fibrates if necessary), management of obstructive sleep apnea (initiation of Continuous Positive Airway Pressure (CPAP) if necessary), management of hypertension (reduction of salt intake, initiation of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor blockers (ARB) medications if necessary), diabetes management (lifestyle measure changes, endocrine review and initiation of metformin if necessary) and smoking cessation and alcohol abstinence or reduction. This program will be performed at start of study participation all throughout the follow up period.
45464022|NCT01116557|Device|Radiofrequency Ablation procedure|Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter® (PVAC®) to eliminate potentials arising from the pulmonary veins.
45464023|NCT01198405|Device|Enhanced external counterpulsation|Treatment of enhanced external counterpulsation (EECP) with a prespecified protocol on top of a guideline-driven standard medical therapy. EECP Protocol is defined as a standard session of a total of 36 hours of EECP treatment, given one hour per day, six days per week. The same session is thereafter repeated at least once every year.
45464024|NCT01198405|Drug|Guideline-driven standard medical therapy|Standard management, both pharmacological and non-pharmacological, given according to current practice guidelines at the discretion of clinicians
45464025|NCT03715647|Other|Sepsis|Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
45464026|NCT03715647|Other|HELLP Syndrome|Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
45464027|NCT03715647|Other|Respiratory Distress Syndrome Adult|Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
45464028|NCT01214369|Procedure|Type of Supplementary Injection|Patients will be selected from a group who were not anesthetized following 3.6 ml block injection. Half of the randomly selected patients will receive X-tip intraosseous injection and half will receive PDL injection as a supplementary for completing the anesthesia in selected hot mandibular molar teeth.
45464029|NCT03713151|Other|Dividat FIT|The study intervention is a blended therapy approach of face-to-face physiotherapy sessions with an interactive tablet-based home exercise program.
46098768|NCT04118127|Drug|2mg conventional tablet, once-weekly tablets|In each cohort, subjects will receive a brexpiprazole 2 mg conventional tablet on Day 1of Period 1, the QW formulation on Day 1 of Period 2 and 3, as single and multiple dose in a fasted state.
45464030|NCT01116635|Drug|doxorubicin, superabsorbent polymer microspheres, embolotherapy|varying doses of doxorubicin loaded onto SAP during embolization procedure. Pharmacokinetic analysis of elution profile through serum concentrations over 1 month period embolization of surgically resectable HCC with superabsorbent polymer microspheres loaded with doxorubicin from a single treatment. Phase I will follow a modified Fibonacci sequence (with pharmacokinetic analysis of serum doxorubicin) to determine mean tolerated dose (MTD), severe adverse reaction (SAE) and dose limiting toxicities (DLT) when microspheres are loaded with 25mg, 50mg, or 75mg of doxorubicin. Phase II will continue enrollment with the two highest tolerated doses. At least one month after treatment, all patients will undergo imaging and surgical resection of reference tumor, with assessment of degree of necrosis, microsphere distribution, and correlation with concentration of doxorubicin loaded onto microsphere.
45464031|NCT05670223|Other|Fit&Strong Exercise Program|The Fit and Strong! Program (F&S!) is an exercise program for older adults developed by a study consultant, Dr. Susan Hughes, with funding from the National Institute of Aging. It is tailored for the unique needs of older, underserved adults and targets modifiable factors depicted by the socioecological model is necessary. The F&S! exercise program assists older adults to improve strength and functioning.
45837428|NCT03856632|Drug|Anti Arrhythmics|The choice of antiarrhythmic drug will be at the discretion of the managing physician, but will generally include either a class IC or class III antiarrhythmic drug. If necessary, and clinically indicated, amiodarone may be used. Therapy will be initiated at the start of study participation and will be discontinued 6-12 weeks after the ablation, as deemed clinically appropriate by the managing electrophysiologist.
45464032|NCT01214447|Other|No intervention|Observational study - no intervention
45464033|NCT03936803|Behavioral|aerobic interval training exercise .|Its consisted of cycle ergometer training, 3 days a week for 6 weeks. Aerobic interval training consisted of ( 8 )minutes warm-up, followed by 4 times of 4-minute intervals with HR at 85% of sub maximum HR, with active pauses of 3 minutes of walking at 60% of sub maximum HR. The exercise session was terminated by 5 minutes cool-down
45837429|NCT03856632|Procedure|Afib Catheter Ablation|The procedure will be performed according to usual clinical practice. The primary approach will be antral pulmonary vein isolation (PVI), preferably performed by cryoballoon ablation, though radiofrequency may be used as deemed necessary by the operator for clinical reasons. This will be performed after 3 months of RFM or RFM + Liraglutide program.
45837430|NCT03821142|Device|Transvaginal mesh for anterior pelvic organ prolapse repair|synthetic mesh for anterior pelvic organ prolapse with or without apical vaginal wall involvement via the vaginal route in a highly selected patient population
45837431|NCT04286178|Dietary Supplement|creatine monohydrate|Creatine will be taken at a dose of 150mg/kg/day of creatine base divided into 2 daily doses up to 39.7kg in body weight, after which dosing will be based on body surface area (BSA) at 4.69g/m2/day. Creatine will be administered orally as a chewable tablet provided by BioTechUSA™. Tablets are 2g and contain 0.9g of creatine monohydrate which is equivalent to 0.8g of creatine base.
45837432|NCT04286178|Dietary Supplement|ubiquinol|Coenzyme Q10 (CoQ10, ubiquinol) will be taken at a dose of 10mg/kg/day divided into 2 daily doses with a daily maximum of 500mg. CoQ10 will be administered orally in 50mg softgels containing 50mg of ubiquinol (Active Q®), provided by Tishcon Corporation.
45837433|NCT04286178|Dietary Supplement|glucose tablet|Creatine placebo will be in the form of a glucose tablet with identical appearance and taste to the active supplement. The number of tablets/day will be determined based on the dose of creatine required for each patient.
46012762|NCT05140460|Behavioral|Cultural Pride Reinforcement for Early School Readiness (CPR4ESR)|The intervention entails distribution of a children's book with a cultural pride theme and the cultural pride parent book-sharing guide. Intervention participants select and receive a developmentally appropriate (baby, toddler, or preschool) book that features African American, Latino, Asian or diverse cultural pride perspectives.
45464034|NCT03936803|Device|electro acupuncture|"electroacupuncture (EA) of (2 Hz, 4 mA) was applied at points of:liver 3 LR3,liver 14 LR 14, gall bladder 34 (GB 34) and stomach 36 (ST36) .~Duration of the session was 15 min / each, three sessions per week for six weeks"
45464035|NCT01566799|Drug|Metformin|metformin 500 mg/day po for 24 weeks.
45464036|NCT03418545|Device|JUVÉDERM VOLBELLA® XC injectable gel|JUVÉDERM® VOLBELLA™ XC dermal filler injected into the infraorbital and adjacent area.
45464037|NCT03936959|Drug|LY3434172|Administered IV
45464038|NCT01198483|Procedure|Combined Micro- Surgery|Microincision Cataract Surgery combined with 23-gauge/25-gauge/27 gauge Vitrectomy
45464039|NCT01198483|Procedure|Combined Small-Surgery|Smallincision cataract surgery combined with 23 gauge vitrectomy
45464040|NCT01120457|Drug|BMS-936564 (Anti-CXCR4)|
45464041|NCT03842371|Other|Metabolic level of BCAAs in monocytes and macrophages|Metabolic level of BCAAs in monocytes and macrophages
46012763|NCT05140460|Behavioral|Reach Out and Read (ROR)|The control condition involves distribution of a standard ROR book and book-sharing advice. Distributed books are developmentally appropriate (baby, toddler, or preschool).
46012764|NCT02271282|Drug|Toremifene|
46012765|NCT02271282|Drug|Placebo|
45464042|NCT01121861|Procedure|Phacoemulsification with implantation of toric IOL|
45464043|NCT03409731|Device|ABSORB GT1 BVS|Patients receiving Absorb GT1 BVS
45464044|NCT04642807|Procedure|Long arm soft cast|Participants in group 2 will have a long arm soft cast applied without clinical or radiological follow up.
45464045|NCT04642807|Procedure|Long arm full cast|Participants in group 1 will have a long arm full cast applied.
45464046|NCT03939845|Radiation|RT|external- beam radiotherapy (EBRT)
45464047|NCT03939845|Procedure|TACE|transarterial chemoembolization (TACE)
45464048|NCT01216085|Drug|high-dose imatinib|Study patients will receive 400 mg twice daily oral administration in the morning and the evening.
45464049|NCT01198561|Device|repetitive Transcranial Magnetic Stimulation|10 times repetitive TMS, high frequency
45464050|NCT01122017|Procedure|Retro-Tubercle Opening-Wedge High Tibial Osteotomy|Retro-Tubercle Opening-Wedge High Tibial Osteotomy (ROWHTO) is among the latest approaches for the treatment of varus deformity of knee.
45464051|NCT01198639|Device|manual administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform|the anesthesiologists are instructed to maintain the BIS values between 40 and 60 throughout anesthesia using target controlled infusion method
45837434|NCT04286178|Dietary Supplement|gel capsule|Ubiquinol placebo will be in the form of a gel capsule with identical appearance to the active supplement. The number of capsules/day will be determined based on the dose of ubiquinol required for each patient.
46012766|NCT02271282|Drug|GHRH/Ghrelin combined Injection|
45464052|NCT01198639|Device|closed-loop administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform|an algorithm is used to maintain automatically the BIS values between 40 and 60
45464053|NCT03936725|Other|1 year phone call : data collection|"Included patients are contacted by telephone at 12 months after discharge. The investigators explain to the patient that this call is in the same context as a regular follow-up rehabilitation consultation and that the data collected will also be part of a study to evaluate and improve the program in which they participated. The interview will be transcribed in writing in their computerized and secure medical file. During this 20-minute telephone conversation, the patient answers a number of questions via a standardized questionnaire, in order to gather the various criteria for judgment.~If patients do not answer the first call, a phone message will be left and they will be contacted again up to 2 times. Patients who do not respond to 3 calls will be considered lost to follow-up."
45464054|NCT01200277|Procedure|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
45464055|NCT01200277|Procedure|sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
45464056|NCT01214681|Dietary Supplement|Maltodextrin and Amioca starch|12g Maltodextrin and 23g Amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
46012767|NCT02271321|Other|White noise|White noise is a simple, convenient, non-invasive and effective intervention. it sounds like the sound of running water, ocean or fan operation sounds. In this study, Subjects will receive 20 minute white noise of the ocean and the sound of running water at 16:00 to 17:00 for four weeks periods.
46012768|NCT01686893|Device|Nasal oxygen insufflation with a TNI 20 oxy device|Nasal oxygen insufflation with a TNI 20 oxy device
46012769|NCT01686893|Device|Standard Nasal Insufflation of oxygen|Standard Nasal Insufflation of oxygen
46012770|NCT01580111|Biological|Blood transfusion|The short storage arm; children were transfused with packed red cells of storage age 1-10 days; while for the Long storage arm; were transfused with packed red cells of 21- 35 days in storage.
46012771|NCT01688804|Behavioral|Behavioral intervention to reduce sedentary time delivered via mobile smartphone|The overall goals of the intervention are to decrease overall sedentary time and to increase the number of breaks in sedentary time. The intervention approach combines an advanced smartphone device with an on-board accelerometer and a sophisticated smartphone application to: 1) monitor participants sedentary behavior in real time in their natural environment; and 2) use monitored data to deliver immediate, individually-tailored, goal-driven prompts and feedback to encourage substitute of sedentary behaviors with physical activity.
46012772|NCT01688960|Drug|nesvacumab (REGN910/ SAR307746)|Dose level 1
46012773|NCT01688960|Drug|nesvacumab (REGN910/ SAR307746)|Dose level 2
46012774|NCT01688960|Drug|nesvacumab (REGN910/ SAR307746)|Dose level 3
46012775|NCT01688960|Drug|aflibercept (ziv-aflibercept)|Dose level 1
46012776|NCT01688960|Drug|aflibercept (ziv-aflibercept)|Dose level 2
45464057|NCT01214681|Dietary Supplement|Hi-maize 260|23g Hi-maize 260 and 12g Maltodextrin daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
45464058|NCT01214681|Dietary Supplement|Polydextrose|12g polydextrose and 23g amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
45464059|NCT01214681|Dietary Supplement|Hi-maize 260 and polydextrose|12g polydextrose and 23g Hi-maize 260 daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
45464060|NCT03842059|Device|Computer-aided detection|We developed an artificial intelligent computer system with a deep neural network (PX-1) to analyze real-time video signals from the endoscopy station
46012777|NCT02271360|Drug|Calcium Dobesilate|1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
46012778|NCT02271360|Drug|Cabergoline|1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
46012779|NCT01687049|Drug|Red yeast rice|
45837435|NCT04286178|Behavioral|Exercise|"Participants will be coached to hit 12,000 steps or 60 active minutes per day as logged by a FitBit (FitBit calculates active minutes as activities equivalent to moderate-to-vigorous physical activity (MVPA) done continuously for at least 10 minutes)"
46012780|NCT02271399|Drug|acetylsalicylic acid|300 mg aspirin(acetylsalicylic acid, AA, Bayer)/day was given orally for 10 days postoperatively.
46012781|NCT02271399|Drug|rivaroxaban|xarelto 10mg(rivaroxaban, AA, Bayer)/day was given orally for 10 days postoperatively
46012782|NCT01689038|Drug|F17464|Single dose
46012783|NCT02271438|Drug|Ibrutinib|Participants will receive a single oral dose of 12 capsules (12*140 mg capsules) of ibrutinib in Treatment A and 6 capsules (4 6*140 mg capsules) of ibrutinib in Treatment B.
46012784|NCT02271438|Drug|Moxifloxacin|Participants will receive a single oral dose of 1 moxifloxacin capsule (400 mg) in Treatment D.
46012785|NCT02271438|Drug|Ibrutinib-matching placebo|Participants will receive a single oral dose of 12 ibrutinib-matching placebo capsules in Treatment B and 6 ibrutinib-matching placebo capsules in Treatment C and D.
46012786|NCT02271438|Drug|Moxifloxacin-matching placebo|Participants will receive a single oral dose of 1 moxifloxacin-matching placebo capsule in Treatment A, B, and C.
45464061|NCT03842059|Device|Standard colonoscopy|Standard colonoscopy
45837436|NCT04655976|Biological|Cobolimab|Cobolimab will be administered
45837437|NCT04655976|Biological|Dostarlimab|Dostarlimab will be administered
45837438|NCT04655976|Drug|Docetaxel|Docetaxel will be administered
45837439|NCT04256460|Behavioral|Healthy diet, regular exercises and peer support|After assessing the exercise and nutritional status of the participants, health staff in community health centers implemented personalized healthy diet and regular exercises intervention, including coaching on healthy exercises and developing personalized dietary prescriptions for participants. Besides, peer support is implemented as a self management strategy in community health service centers or community self management groups to enhance the behavioral change support for these participants.
45837440|NCT03781128|Drug|Lysergic Acid Diethylamide|100 µg, per os, 3 times within 3 weeks
45837441|NCT03781128|Drug|Placebo|placebo in an identical-looking vial as LSD, per os, 3 times within 3 weeks
46012787|NCT01687127|Dietary Supplement|Folic acid|Supplement
46012788|NCT01687127|Dietary Supplement|5-methyltetrahydrofolate, calcium salt|Supplement
46012789|NCT02271516|Radiation|188Re-BMEDA-liposome|EKG at baseline and in 24hours after administration
46012790|NCT02272595|Other|Treatment Based on Genetic Mutation|Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
46012791|NCT02272595|Other|Treatment Based on No Genetic Mutation|Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
45464062|NCT01116713|Drug|intravenous dexamethasone|One dose of intravenous dexamethasone (8 mg) 60 minutes before skin incision.
45464063|NCT01116713|Drug|Homologated placebo.|Patients of the control group received homologated placebo 60 minutes before skin incision
45464064|NCT01202149|Device|Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)|
45464065|NCT03446781|Biological|EN3835|Collagenase clostridium histolyticum
45464066|NCT03446781|Biological|Placebo|Placebo
45464067|NCT01116791|Procedure|Cytoreductive Surgery (CRS) plus Hyperthermic Intraoperative Peritoneal Chemotherapy with Cisplatin (HIPC)|"CRS is defined as macroscopic tumour removal using surgical resection and/or local ablative therapy (LAT)~HIPC is administered immediately after CRS"
45464068|NCT03841903|Diagnostic Test|spinal cord MRI|high-resolution spinal cord MRI sequences on a 3Tesla magnet (Siemens Prisma) with high contrast between SC and CSF as well as high contrast within the SC (grey-white matter contrast)
45464069|NCT01120535|Device|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
45464070|NCT01585259|Drug|Anfibatide|Snake venom
45679902|NCT04706676|Behavioral|Integrative neuromuscular training (INT)|"Integrative neuromuscular training (INT), contains a multifaceted range of developmentally appropriate activities that incorporate general and specific strength and conditioning elements such as strength, power, motor skill training, dynamic stability, core-focused strength, plyometric and agility. INT can be camouflaged as games and play or performed as structured strength and conditioning program, depending on the participant's age, motor skill level and diagnosis. The intervention is designed to enhance health- and skill-related components of physical fitness.~Parents or guardians will receive education in conducting INT at home, alongside an exercise-kit consisting of training equipment corresponding to the child's age and fitness level (fitness ropes, medicine ball, dumbbells).~The INT group will receive usual standardized hospital care, including physiotherapy if needed."
46012792|NCT02271555|Drug|Sevoflurane|Anesthetic induction will be achieved via 8% sevoflurane
45464071|NCT01585259|Drug|Placebo|Saline
45464072|NCT03717909|Drug|Sodium Valproate 200Mg E/C Tablet|Treatment with twice-daily oral tablet(s)
45464073|NCT03717909|Drug|Sodium Valproate matched placebo|Treatment with twice-daily oral 200mg tablet(s)
45464074|NCT03940001|Biological|Sintilimab|Other Name: (IBI308)
46012793|NCT02271555|Drug|Remifentanil|After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
46012794|NCT02271555|Drug|Saline|After the loss of consciousness saline will be administered to Group sevoflurane-saline intravenous bolus.
45464075|NCT03940001|Drug|carboplatin/paclitaxel|carboplatin AUC 2/paclitaxel 50 mg/m2 weekly
46012795|NCT02271672|Device|XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
46012796|NCT02271672|Device|sham XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
45464076|NCT03940001|Radiation|Radiation|IMRT or VMAT
45464077|NCT04131907|Device|Optilume BPH Catheter System|The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.
46012797|NCT01687205|Drug|1% Tenofovir Gel|
46012798|NCT02271711|Other|Laboratory Biomarker Analysis|Correlative studies
46012799|NCT02271711|Biological|Natural Killer Cell Therapy|Given autologous ex-vivo expanded NK cells IV
46012800|NCT01689116|Drug|Bardoxolone Methyl 20mg|Oral
46012801|NCT01689116|Drug|Bardoxolone Methyl 80mg|Oral
46012802|NCT01689116|Drug|Bardoxolone Methyl Placebo|Oral
46012803|NCT01689116|Drug|Moxifloxacin 400mg|Oral
45464078|NCT04131907|Device|Optilume Sham Device|21 Fr sheathed Optilume™ BPH Prostatic Pre-dilation Catheter (modified to prevent inflation)
45464079|NCT01120613|Drug|Chronotherapy|"Patients identified with nocturnal hypertension while treated with blood pressure medications will have one medication switched from daytime to night time dosing in the following preference:~ACE or ARB~Calcium Channel Blockers~Alpha Blocker~Beta Blocker~If patient is on only one daytime BP medication, it will be switched to night time dosing. No dose adjustments will be made nor any new medications will be added. Only timing of BP medication will be changed."
45464080|NCT03715569|Diagnostic Test|Vestibular function|Vhit, Caloric test
45837442|NCT03725046|Other|Optimized information transmission|Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
45837443|NCT01798602|Drug|Rosuvastatin or identical placebo|Tablet crushed for administration via feeding tube
46012804|NCT01689116|Drug|Moxifloxacin Placebo|Oral
46012805|NCT01689194|Drug|genexolPM + cisplatin|
46012806|NCT02271750|Procedure|lumbar puncture|for spinal fluid
46012807|NCT01687361|Dietary Supplement|branched-chain amino acids (BCAA) supplementation|
46012808|NCT01687361|Drug|PLACEBO|
45464081|NCT03715569|Diagnostic Test|OAE/WBT|Oto acoustic emissions Wide Band Tympanometry
45464082|NCT03715569|Diagnostic Test|Biomarker|Biomarker examination
45837444|NCT01798602|Drug|Placebo|Identical placebo for rosuvastatin
46012809|NCT02271828|Procedure|Sentinel lymph node procedure|Sentinel lymph node procedure according to the Dutch breast cancer guideline
46012810|NCT01689272|Procedure|Kidney Transplantation from alive relative donor|Donor kidney sampling, preservation, transport and transplantation
46012811|NCT02271867|Procedure|Interscalene block|An ultrasound guided ISB was performed with injection aimed to block the C5-root
46012812|NCT01687439|Drug|Endostar|7.5mg/m2, D1-14
45464083|NCT03715569|Diagnostic Test|MOCA, eGOS|Cognitive tests
45464084|NCT03715569|Diagnostic Test|Audiometry|Hearing test
45464085|NCT04090177|Behavioral|TEAM Wheels|A 1-month, peer-led, eHealth training program (TEAM Wheels) for individuals transitioning to manual wheelchair use to improve satisfaction with activity participation and related rehabilitation outcomes.
45464086|NCT01120769|Drug|Acetaminophen|single dose
45464087|NCT01120769|Drug|Placebo|single dose
46012813|NCT01687439|Drug|Vinorelbine|25-30mg/m2, D1,8
46012814|NCT01687439|Drug|Cisplatin|25 mg/m2, D1-3
46012815|NCT01687439|Radiation|Radiotherapy|
46012816|NCT01588704|Drug|Neoadjuvant Bevacizumab|Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab followed by surgical resection
46012817|NCT01687634|Behavioral|In-home Mentor Mother visits|Pregnant women will receive twice-monthly in-home (or telephone) visits from a Mentor Mother who will provide information about pregnancy, breastfeeding, nutrition, and infant care.
46012818|NCT01687634|Behavioral|Health Information Mailings|Pregnant women will receive twice-monthly mailings that will provide information about pregnancy, breastfeeding, nutrition, and infant care.
46012819|NCT01588743|Drug|insulin aspart|Insulin Aspart will be administrated by insulin pump with an initial dose of 0.4-0.6u/kg body weight, of which 50% basal rate and the other 50% bolus dose. Time interval for administration will be as follows: 0-3Am-9Am-12Am-5Pm-9Pm-0Am. Specific adjustment will be made according to individual difference.
46012820|NCT01689311|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
46012821|NCT01689311|Drug|Ergonovine|Ergonovine, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
46012822|NCT01689311|Drug|Prostaglandin F2alpha|Prostaglandin F2alpha, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
46012823|NCT01689311|Drug|Misoprostol|Misoprostol, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
46012824|NCT01588782|Drug|Period 1: Abiraterone|1000 mg abiraterone acetate tablet administered orally on Day 1
46012825|NCT01588782|Drug|Period 2: Abiraterone/Ketoconazole|400 mg ketoconazole tablets administered orally on Days 11 to 16
46012826|NCT01588782|Drug|Period 2: Abiraterone/Ketoconazole|1000 mg abiraterone acetate tablet administered orally on Day 14
45679903|NCT04706676|Behavioral|Active control group: home-based training program|"The active control group is offered a home-based training program consisting of combined aerobic, strength and stretching exercises. Further, they will receive monthly motivational consultations, as described below, concerning the training program. The use of the home-based training program will be monitored through exercise journals.~The INT group will receive usual standardized hospital care, including physiotherapy if needed."
46012827|NCT02272062|Other|Decision-making tool for coronary artery disease treatment|A brief internet-based tool will provide education about coronary artery disease and assess patient preferences regarding treatment options (medical management, percutaneous coronary intervention, or coronary artery bypass graft). This information will be provided to the treating interventional cardiologist at the time of coronary angiography in the treatment group.
46012828|NCT02276456|Behavioral|Follow-up Appointment- early vs standard|Patient will undergo early follow-up (within 7 days of discharge) of discharge
45679904|NCT04706676|Behavioral|motivational counseling session|"Each child and their parents will participate in a monthly 30-minute motivational counseling session to adjust the intervention and training program according to the child's physical capacity and preferences. Further, the session will determine potential barriers towards performing physical exercise using the Self-efficacy for Exercise Scale.~The sessions are based on the principles in Self-Determination Theory that includes a spectrum of external and internal motivation factors for engaging in exercise. Each session will provide guidelines to increase the general activity levels and adjust the intervention according to the child's preferences and presence of symptoms."
46012829|NCT02273427|Drug|BIIL 284 BS|
46012830|NCT02273427|Other|high fat meal|
46012831|NCT02273427|Other|low fat meal|
45679905|NCT04702880|Biological|BMS-986012|Specified dose on specified days
46012832|NCT02272101|Dietary Supplement|Vitamin D versus placebo|Cross-over design
46012833|NCT01689467|Dietary Supplement|Fermented Velvet Antler extract|Fermented Velvet Antler extract (1g/day)
46012834|NCT01689467|Dietary Supplement|Placebo|Placebo (1g/day)
46012835|NCT02272218|Procedure|bariatric lap band surgery|The intervention in this study is laparoscopic gastric banding (LAGB) surgery as a treatment option for obese patients with pain from knee osteoarthritis (KOA) refractory to medical treatment
46012836|NCT02272335|Behavioral|Group Sessions|"10 weekly sessions:~CBSM - 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the CW condition as well.~CW/EE - roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain"
46012837|NCT02278133|Drug|WNT974|
46012838|NCT02278133|Drug|LGX818|
46012839|NCT02278133|Biological|Cetuximab|
46012840|NCT02277704|Drug|TNX-102 SL|
46012841|NCT02277704|Drug|Placebo|
46012842|NCT00107172|Procedure|surgery|
46012843|NCT00107172|Radiation|brachytherapy|
46012844|NCT01687868|Drug|Dexmedetomidine|dexmedetomidine 0.7mcg/kg/hr continuous infusion
46012845|NCT01687907|Behavioral|Music|
46012846|NCT02272374|Procedure|AVF creation|
46012847|NCT02272374|Procedure|TCC placement|
46012848|NCT02272374|Procedure|AVG creation|
46098769|NCT02751515|Other|Bain De Soliel - Solid|0.05gm/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
46098770|NCT02751515|Other|Untreated skin|One site is patched without treatment as control
46098771|NCT02615964|Radiation|Nova Flow Procedure|Evaluation of the diagnosis, and stratification of the severity of Raynaud's disorder in patients with scleroderma based on clinical and imaging data will allow creation of more precise diagnostic criteria as well as disease classification which may guide treatment practices. The study results will likely have no immediate benefit to the patients participating in the study, however may have a future impact diagnosis, stratification and ultimately treatment of patients with Raynaud's disorder. In addition, data collected in this study may provide insight into disease process and leading to future research endeavors.
46098772|NCT00654056|Drug|Actrapid (human insulin)|On day one: 0,5 IU/kg/min for 3 hours, 1,5 IU/kg/min for 3 hours, on day two: 3,0 IU/kg/min for 3 hours, 5,0 IU/kg/min for 3 hours
46098773|NCT02615886|Other|Observational Control|Participants will be observed and not provided any dietary supplementation.
46098774|NCT02615886|Dietary Supplement|Rice bran|Dietary rice bran consumed daily and amounts increase throughout the 6 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 2 g/day, 9 months: 3g/day, 10 months: 4g/day, 11 months: 5g/day).
46098775|NCT00854373|Drug|Bravelle(follicle stimulating hormone)|One dose of 6 amps of Bravelle given at the same time as HCG ovulation trigger.
45837445|NCT03722082|Behavioral|Enhancing Cognitive Reserve|The intervention is aimed at improving cognitive reserve in offsprings of patients diagnosed with schizophrenia or bipolar disorder. The program is composed of 12 sessions of 60 minutes and will be adapted according the three different age groups (6-12) (13-18) (18-25). Each group will include between 6-to-8 offsprings and conducted by 4 experienced neuropsychologists in both children and adults. The sessions are the following:
46098776|NCT00854373|Other|Saline ( placebo)|1 cc of Normal Saline (placebo) given at the same time as HCG ovulation trigger.
46098777|NCT00611507|Drug|Oxaliplatin, 5-Fluorouracil|5FU 500 mg/m² per week in IV bolus infusion during 30 min AF 20mg/m²/week in infusion, during 10-20 minutes prior 5FU infusion; Eloxatin 85 mg/m² as IV infusion 2-6 hours, every 2 weeks. Three weeks of treatment, one week rest.
46012849|NCT04058886|Behavioral|Telephone-delivered Mindfulness|The telephone-delivered mindfulness training intervention that will incorporate the following elements: 1) training for primary caregivers (CG) and their caregiving partner (CP) in a telephone-based mindfulness training intervention; 2) groups of up to eight participants (four CG-CP pairs) plus an instructor, on a shared telephone line; and 3) training in a 8-week, modified MBSR program, which places additional emphasis on training in the following: a) mindful experiencing, including mindfulness of feelings and body sensations; b) mindful communication, including non-verbal mindfulness, mindful listening, and mindful speaking; and c) mindful compassion for self and others. Additionally, homework assignments will involve listening to exercises on a dial-in telephone line; and assignments for CG-CP dyads (e.g. mindful listening and communication practices) as well as CG mindfulness practices in the presence of care recipients (e.g. mindful eating, and mindful listening).
46098778|NCT01001689|Behavioral|Nutritional counseling + exercise groups|Two telephone consultations on nutritional topics and twice weekly exercise groups. Access to a password-protected internet site with information on healthy lifestyle during pregnancy. Two evening meetings with information on healthy pregnancy lifestyle.
46012850|NCT01688024|Drug|Mitomycin C|
46012851|NCT01688024|Drug|Normal saline|
46012852|NCT01689506|Drug|Volulyte|6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution will be intravenously infused in order to achieve and maintain predefined hemodynamics goals and may be given up to a total daily dose of 50 mL/kg body weight/day.
46012853|NCT01689506|Drug|Human Serum Albumin|5% Human Serum Albumin will be intravenously infused in order to achieve and maintain predefined hemodynamics goals with no daily dose limit.
46012854|NCT02272452|Device|High-Resolution Magic-Angle Spinning Nuclear Magnetic Resonance spectroscopy|
46098779|NCT02635256|Radiation|Hypofractionated Radiosurgery|"Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife"
46098780|NCT04220333|Behavioral|Mandalas of Emotions|Application of mandalas during 15 minutes
46098781|NCT04220333|Behavioral|Control|"Participants were requested to lie down, relax and pay attention to your breath."
46098782|NCT01001845|Drug|Milk Thistle extract|1 tablet equivalent to 140 mg of silymarin, 3 times daily for 3 weeks
46098783|NCT01001845|Drug|vit E|200 mg twice daily for 3 weeks
46098784|NCT01001845|Drug|vit E + Milk Thistle extract|200 mg vit E twice daily + 1 tablet of Milk Thistle 3 times daily for 3 weeks
45464088|NCT03715413|Other|pulsed radiofrequency of 2nd , 3rd and 4th thoracic dorsal root ganglia.|Patients were lying prone. Firstly, T2, 3, 4 disc level was detected then the target 2nd, 3rd and 4th thoracic nerve roots were identified. After marking the entry points, adequate sterilization of the skin was achieved using bovidone iodine then the skin was anasthesied by 2 ml lidocaine 2% at each entry point. The Baileys radio frequency (RF) 22G, 10 cm, sharp needles with 10 mm active tip was introduced to face the 2nd, 3rd and 4th thoracic nerve roots.The PRF course was carried out at 42°C for 120 s twice at each level followed by injection of 1 ml lidocaine 2% and 1 ml dexamethasone 4 mg at each level.
45464089|NCT03715413|Drug|Tamoxifen|received Tamoxifen 10 mg daily
46012855|NCT01689545|Behavioral|Individual level|Index participants will participate in standard HIV VCT supplemented with 2 posttest counseling sessions, followed by 2 post-test skill-building support groups for HIV positive IDUs.
46012856|NCT01689545|Behavioral|Structural level|Community members will participate in 2 community-based HIV and IDU stigma videos combined with a series of visits with community outreach workers.
46012857|NCT01689545|Behavioral|Individual level standard of care|The education materials that are currently offered in Thai Nguyen will be delivered didactically by health workers on 1) the HIV situation in Vietnam; 2) consequences of drug use; 3) routes of HIV transmission; and 4) options for drug treatment.
45464090|NCT01120925|Biological|MNC|2-3 X 109 cells in 20ML suspension IPV in 4 min
45464091|NCT01120925|Biological|CD133|5-15 X 106 cells in 20ML suspension IPV
45464092|NCT01120925|Biological|Control|Injection of 20 ml Normal saline via IPV
46012858|NCT01689545|Behavioral|Structural level standard of care|Posters and billboards on HIV/AIDS transmission, leaflets on HIV/AIDS transmission available in health station, 15-minute monthly public broadcasts (via the village loudspeaker) on the consequences of HIV/AIDS and the number of HIV cases in the country and province will be delivered in communities.
46098785|NCT02712281|Behavioral|Autism MEAL Plan|"The Autism MEAL plan includes education on feeding issues and behavior management, and specific strategies to expand dietary diversity. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician. The first three sessions focus on understanding feeding problems and behavior management strategies in children with ASD.The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson.~The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson."
45464093|NCT04631419|Other|Flapless laser corticotomy|The flapless laser corticotomy will be done by Er, Cr: YSGG laser as a series of circular holes will be made along with the planned position. The depth of laser cutting will be measured and controlled continuously during the operation by the periodontal probe with stopper read to each 3mm depth in addition to a few parts of a millimetre depth into the medullary bone to enhance bleeding. Canine retraction will be started after this procedure.
45464094|NCT04631419|Other|Canine retraction|canine retraction will be done on 17x25 stst archwire using coil spring adjusted to 150 gm, and miniscrews will be used as an indirect method of anchorage reinforcement
45464095|NCT03935945|Behavioral|Personalized Feedback Intervention|Participants in the intervention group will receive a computerized personalized feedback intervention (PFI) lasting approximately 20-30 minutes. PFI highlights discrepancies between one's own drinking and typical drinking; reframes use in terms of personal, social, financial, and health consequences; and, offers strategies for reducing alcohol use. The feedback is non-confrontational in tone, seeks to increase motivation to reduce drinking and is based on the information provided during the baseline assessment
46012859|NCT04059861|Diagnostic Test|Ultrasound|enrolled patients will be investigated by ultrasound two times, awake in the clinic and in narcosis before the surgery. For those with tongue cancer ultrasound will be used during the surgery to visualise the deep margin of the tumour.
45464096|NCT05058469|Device|Tracheotomy|Tracheotomy in patients +/- antiplatelet therapy
46012860|NCT01689623|Drug|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral. TMC435 will be administered at a dose of 150 mg once daily from Day 4 until Day 15.
46012861|NCT01689623|Drug|Atorvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Atorvastatin will be administered as a single oral 40-mg dose on Day 1 and Day 13.
46012862|NCT01689623|Drug|Simvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Simvastatin will be administered as a single oral 40-mg on Day 1 and Day 13.
45464097|NCT01122251|Drug|Lercanidipine + Valsartan|L10/V80, L20/V80, L10/V160, L20/V160
46012863|NCT04055142|Procedure|electrocoagulation|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and electrocoagulation will be performed in 2-3 sessions (session every 2 weeks)
46012864|NCT04055142|Drug|cidofovir 1% topical ointment|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with cidofovir 1% ointment (3 times per week during 8 weeks)
46012865|NCT04055142|Drug|sinecatechins 10% topical ointment|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with sinecatechins 10% ointment (3 times per week during 8 weeks)
46098786|NCT02712281|Behavioral|Parent Education|"The Parent Education study arm includes 10 sessions focusing on the following topics: understanding Autism Spectrum Disorder (ASD), clinical assessments for ASD, development in children with ASD, medical and genetic comorbidities in ASD, family and sibling issues, treatment alternatives, and education and treatment planning. The Parent Education arm does not include topics related to feeding problems or feeding specific interventions. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician.~Children randomized to Parent Education will be offered the Autism MEAL Plan after completing the 10-week randomized trial."
46098787|NCT02635334|Drug|Montelukast 10 mg orally|
46012866|NCT02272569|Device|STARflo Glaucoma Implant|Implantation of the STARflo Glaucoma Implant following surgical technique described in European labelling. Procedure does not require the use of anti-fibrotic medications.
46098788|NCT02635334|Other|Placebo|
46098789|NCT00853905|Drug|Triesence|At end of standard glaucoma surgery and the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure, 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound.
46098790|NCT00853905|Drug|balanced salt solution BSS|At end of standard glaucoma surgery, the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure.
46098791|NCT04162496|Device|Restylane Refyne|Injection of Restylane Refyne with a cannula on one side of the neck and a 30 guage needle on the other side.
45464098|NCT01122251|Drug|Lercanidipine or Valsartan|L10, L20, V80, V160
46012867|NCT01688258|Procedure|Diagnostic swab|
46012868|NCT02272608|Other|Evaluation of Sleep Apnea Related Inflammation with CRP, ESR and Neutrophil toLymphocyte Ratio|CRP, ESR and Neutrophil toLymphocyte Ratio values of sleep apnea patients were evaluated with respect to apnea- hypopnea scores.
46098792|NCT05429801|Other|Ozone therapy|Rectal ozone treatment along with standard medical treatment was administered to the patients, in increasing doses for 5 sessions per week, 20 sessions in total for 4 weeks. First week: 25 mg/l, 100 ml; second week: 30 mg/l, 150 ml; third week: 35 mg/l, 200 ml; fourth week: 40 mg/l, 200 ml rectal ozone treatment was applied.
46098793|NCT00998101|Drug|cetuximab|400 mg/m2 Cycle 1 day 1 only over 120 minutes 250 mg/m2 Cycle 1 days 8,15 AND on all other cycles days 1,8,15 over 60 minutes
46098794|NCT00998101|Drug|carboplatin|AUC=6 Day 1 of treatment over 30 minutes every 21 days
46098795|NCT00998101|Drug|ixabepilone|30 mg/m2 , Day 1 over 3 hours every 21 days
46098796|NCT04163120|Other|Low calorie Mediterranean ketogenic diet with phytoextracts (KEMEPHY)|The KEMEPHY diet (24-29) is a Mediterranean low calories ketogenic protocol (about 1000/1100 Kcal/day) with the use of some phytoextracts. During this protocol subjects are allowed to eat with no limits green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants. The quantity of meat, eggs and fish was limited to once a day (120g of meat or 200g of fish or 1 egg) Table 1. Moreover, subjects daily consumed four food supplements and liquid herbal extracts. Food supplements are high proteins (19g/portion) and very low carbohydrate (3.5g/portion) formulas simulating the aspect and taste of common carbohydrate rich foods added with dry phytoextracts (30). Liquid herbal extracts were used for their draining /toning activity, useful to reduce some commonly reported light side effects of ketogenic diets as constipation, headache and halitosis.
46098797|NCT00998179|Device|Acu-TENS|Application of Acu-TENS (with electrical output from the machine)
46098798|NCT00998179|Device|Placebo-TENS|Application of Acu-TENS (without electrical output from the machine)
46098799|NCT04234217|Device|Continuous positive airway pressure|Continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA)
46098800|NCT04234217|Other|Niacin|Suppression of lipolysis by niacin infusion
46098801|NCT01002079|Drug|BMS-708163|Capsule, Oral, 125 mg, Once daily, 1 day
46098802|NCT01002079|Drug|Rifampin|Capsule, Oral, 600 mg, Once daily, 7 days
46098803|NCT01002079|Drug|Rifampin|Capsule, Oral, 600 mg, Once daily, 6 days
46098804|NCT02639624|Drug|Low bicarbonate dialysate First|
46098805|NCT02639624|Drug|Normal bicarbonate dialysate First|
46098806|NCT02639624|Drug|Normal bicarbonate dialysate|
46012869|NCT01688297|Biological|VXA-A1.1 Oral Vaccine|One or two doses of replication incompetent adenovirus oral tablet vaccine
45464099|NCT01122251|Drug|Placebo|Placebo of Lercanidipine and Valsartan
45679906|NCT04702880|Drug|Carboplatin|Specified dose on specified days
45679907|NCT04702880|Drug|Etoposide|Specified dose on specified days
45679908|NCT04702880|Biological|Nivolumab|Specified dose on specified days
45679909|NCT04699968|Drug|SHR-1701，Famitinib|SHR -1701, Intravenous ；Famitinib, oral
46012870|NCT01688297|Biological|VXA Placebo Tablet|Off-white tablets similarly formulated to the active drug product tablets.
46098807|NCT02639624|Drug|Low bicarbonate dialysate|
45679910|NCT04699968|Drug|SHR-1701|SHR -1701, Intravenous
45679911|NCT04677816|Drug|Standard of Care Neoadjuvant Chemotherapy|"Participants will receive standard of care neoadjuvant chemotherapy with doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles and paclitaxel (80 mg/m2) weekly for 12 cycles. Doxorubicin and cyclophosphamide (AC) may be administered on a classical every 3 week or dose dense every 2-week (with growth factor support) schedule at the treating physician's discretion. Routine incorporation of carboplatin is not required, however use of carboplatin (AUC 1.5 to 2 weekly or AUC 6 on week 1, 4, 7, and 10) with paclitaxel is allowed at the treating investigator's discretion.~Upon completion of neoadjuvant chemotherapy, all patients will undergo definitive surgery with either breast conservation or mastectomy with axillary lymph node staging. Type of surgery will be determined by the treating physician."
46012871|NCT04054323|Behavioral|Physical Activity Intervention|The physical activity intervention will include basic skill training during which the participant will be instructed on the use of (1) the activPAL physical activity device for the tracking of time spent sitting, standing, and walking, (2) tools to monitor exercise intensity, including ratings of perceived exertion, (3) an exercise calendar for setting a specific schedule for the completion of the home exercise program using the exercise videos posted on our website, (4) use of the exercise equipment that will be used in the home program (Therabands), and (5) strategies for reduction of sedentary behavior that target prolonged sitting and encourages frequent activity breaks. Duration of intervention is 6 months.
46012872|NCT05138354|Other|Low Level laser therapy|MLS® device (ASA Srl, Vicenza, Italy) IR laser with two synchronized sources (laser diodes) and a wavelength of 808 nm to deliver the intervention. The laser probe will be held vertically in contact with the skin to deliver the irradiation at three mandibular condyle points (front, behind and over) and one point at the external acoustic meatus. The irradiation will be applied with a laser bean of 3.14 cm² diameter for 14 seconds at each place using a pulse rate of 1500 Hz, pulse duration of 100ns, and energy density: 16 J/cm².
45464100|NCT04600999|Drug|Favipiravir|Name: AVIGAN Generic name: Favipiravir Content: T-705a tablets [200]
45464101|NCT01122329|Dietary Supplement|caprylidene|Axona® is dosed as a 40g packet mixed into 8 oz of liquid (Ensure) for 45 days
45679912|NCT04677816|Dietary Supplement|Vitamin D3|Participants with deficient levels of vitamin D will receive vitamin D supplementation at the initiation of chemotherapy with 50,000 IU of oral vitamin D3 (cholecalciferol) once a week to be continued for 20 weeks during neoadjuvant chemotherapy.
45679913|NCT04677816|Other|Drug Diary|Participants that will receive Vitamin D will be asked to fill out a drug diary on a daily basis. Compliance and feasibility will be assessed through a drug diary and pill counts at set time points.
45837446|NCT03722082|Behavioral|Support intervention|The support group will schedule meetings with the participants in order to talk about their daily life with the possibility to talk about the difficulties they encounter.
45837447|NCT00604890|Drug|API 31510 3% Topical Cream|Topical treatment 3% active cream applied to the lesion
46098808|NCT05429567|Drug|Fentanyl|All patients underwent combined spinal and epidural anesthesia (CSEA) with 2 ml of 0.5 % hyperbaric bupivacaine and 25 ug fentanyl administered using a 27-gauge Whitacre spinal needle and an 18-gauge Tuohy needle in the epidural space. The epidural space was identified utilizing the loss of resistance approach
45464102|NCT01122329|Dietary Supplement|Placebo|
45464103|NCT01216475|Procedure|Femtosecond LASIK|LASIK consists of two steps: the first step involves the formation of a corneal flap and the second one is when the excimer ablation is performed in the corneal stromal bed. Femtosecond lasers (FL) have been widely used in LASIK surgery to fashion the corneal flap. The laser will cut a lamellar followed by a vertical corneal incision. We are able to produce a vertical cut since the Femtosecond laser can deliver laser pulses of 1 micron diameter at a preselected depth in the cornea, which then expands to 2 to 3 microns with the formation of a cavitation bubble. These pulses create micro-photodisruption of the corneal tissue by the formation of an expanding bubble of carbon dioxide and water, which in turn cleaves the tissue and creates a plane of separation. The flap is then removed to expose the stroma and the refractive treatment is done by the excimer laser over the denuded stroma.
45837448|NCT00604890|Drug|API 31510 1.5% Topical Cream|Topical treatment 1.5% active cream applied to the lesion
45837449|NCT00604890|Other|Placebo|Topical treatment placebo applied to the lesion
46098809|NCT00868296|Drug|pantoprazole|
46098810|NCT01002157|Dietary Supplement|Menaquinone-7 (Vitamin K2)|Menaquinone-7 (Vitamin K2)
46098811|NCT01002157|Other|Placebo capsules|Capsules containing no Menaquinone-7
45837450|NCT03694704|Device|FineHearing strategy|Cochlear implant with FineHearing strategy
45837451|NCT03659448|Drug|SGM-101|A fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent.
45464104|NCT01216475|Procedure|Small incision lenticule extraction (SMILE)|Patient's eye will be centered and docked with the curved interface cone before application of suction fixation. First, the posterior surface of the refractive lenticule (spiral in), then the lenticule border is created. The anterior surface of the refractive lenticule (spiral out) is then formed which extended beyond the posterior lenticule diameter by 0.5mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the flap near the hinge before the flap is seperated and reflected. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula and removed through small incision.
45464105|NCT01199029|Drug|PF-04308515|10 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test(OGTT)
45679914|NCT04667455|Diagnostic Test|Biomarker analysis at enrolment|Controls will be compared to cases using biomarker analyses and non-invasive cardiac imaging techniques to improve risk stratification of cases
45679915|NCT04667455|Diagnostic Test|Biomarker analyses throughout the study|Controls will be compared to cases using biomarker analyses and non-invasive cardiac imaging techniques to improve risk stratification of cases
45464106|NCT01199029|Drug|PF-04308515|10 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test(OGTT)
45464107|NCT01199029|Drug|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
45464108|NCT01199029|Drug|PF-04308515|X mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
45464109|NCT01199029|Drug|PF-04308515|Y mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
45464110|NCT01199029|Drug|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
46098812|NCT02636738|Device|Vela XL thulium laser, laser fiber and accessories.|The VelaTM XL Laser is a continuous wave thulium laser that uses an optimized 1.94μm wavelength. This powerful, highly precise laser is designed for hemostatic cutting or ablation of soft and hard tissue
45837452|NCT02783430|Drug|Ketamine|One single perfusion of 0.5 mg/kg during 40 minutes at the beginning of the inclusion
46012873|NCT05138354|Other|Myofascial release|Patients will be positioned in supine in a treatment table. The therapist seated beside the patient at the side of affected temporomandibular joint to apply gross release technique for masseter, pterygoid and temporalis muscles. At each point, the therapist applied the technique for 90 seconds and repeated 5 times during the session (5 seconds of rest between each repetition).(15) The therapist worn gloves to deliver the intraoral myofascial release. In case the patient reported any latex allergies, the gloves were replaced by a latex free model.
46098813|NCT01004497|Drug|Dasatinib|After the completion of each induction and consolidation chemotherapy with recovery of leukocyte and platelet counts, dasatinib will be given as an alternative manner: 100 mg by mouth once daily for 4 weeks
46098814|NCT01004497|Drug|Cyclophosphamide|300 mg/m2, IV for 2 hours, every 12 hours x 6 doses, days 1-3
46098815|NCT01004497|Drug|Vincristine|1.4 mg/m2/day (maximum 2 mg/day), IV for 30 minutes, days 4 & 11
46098816|NCT01004497|Drug|Daunorubicin|45 mg/m2/day, IV for 1 hour, days 4 & 11
46098817|NCT01004497|Drug|Dexamethasone|40 mg/day, IV push, days 1-4 & days 11-14
46012874|NCT05138354|Other|Standard care|"Ultrasound Participants will receive an application of pulsed ultrasound at a frequency of 3 MHz and an intensity of 0.5 W/cm² with a 1:1 duty cycle over TMJ for six minutes.~Hot pack Participants will receive a warm water pack the TMJ and masticatory muscles for 10 minutes.~Exercise program:~Active exercises for mandibular muscles will be used to correct the mouth opening~Lateral movements of the jaw (3 sets of 10 repetitions).~Jaw relaxation exercise (3 sets of 10 repetitions).~Chin tuck (10 repetitions, holding 10s each).~Resisted opening of the mouth (3 sets of 10 repetitions).~Resisted closing of the mouth (3 sets of 10 repetitions).~Stretching exercise for mandibular muscles."
46012875|NCT02272647|Drug|IM Saline Placebo (0.25 ml)|
45464111|NCT01199029|Drug|Prednisone|20 mg (5 mg tablets) predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
45837453|NCT02783430|Drug|Milnacipran|One or two caps per day from the beginning of the inclusion. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
46012876|NCT02272647|Drug|IM Estradiol valerate (2.5 mg)|
46012877|NCT02272647|Drug|IM Saline Placebo (0.5 ml)|
46098818|NCT01004497|Drug|Cytarabine|2 g/m2, IV for 3 hours, every 12 hours x 10 doses, days 1-5
46012878|NCT02272647|Drug|IM Estradiol valerate (5.0 mg)|
46098819|NCT01004497|Drug|Mitoxantrone|12 mg/m2/day, IV for 30 minutes, days 1-2
46098820|NCT00654134|Biological|Clinical Center Reference Endotoxin|20,000 EU inhaled
46098821|NCT02713919|Behavioral|Adapted German PRO-SELF© Plus Pain Control Program|Two in-home visits (60 minutes) with at least weekly follow-up (visit or telephone call according to algorithm): Structured and tailored components; review of pain diary with participant, provision of information on pain medication, nurse coaching regarding pain self-management, detailed side-effect management plan, if distressing side-effects arise, re-evaluation together with participant at each subsequent visit.
46098822|NCT02713841|Drug|inhaled human insulin (INH)|recombinant human insulin administered with Adagio-01 inhaler device
46098823|NCT02713841|Drug|sc insulin lispro (LIS)|insulin lispro administered subcutaneously
46098824|NCT01004575|Device|implantation of Kaname Cobalt-Chromium coronary stent|implantation of Kaname Cobalt-Chromium coronary stent
45464112|NCT01121003|Behavioral|weight maintenance, low sugar diet|
45464113|NCT01121003|Behavioral|weight maintenance, high fructose diet|
45464114|NCT01121003|Behavioral|weight maintenance, high fructose diet+ exercise|
45679916|NCT04629521|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.
45679917|NCT04629248|Drug|Obinutuzumab|Open Label: An intravenous (IV) infusion of 1000 milligram (mg) of obinutuzumab will be administered at Week 0, Week 2, Week 24, and Week 26. Participants who relapse during the open-label treatment period may be eligible for further treatment.
46012879|NCT02272647|Drug|Oral Micronized Progesterone|
46012880|NCT02272647|Drug|Oral Placebo|
46012881|NCT02272647|Drug|Ghrelin (0.3 ug/kg)|
46012882|NCT02272647|Drug|Medroxyprogesterone - Acetate|
46012883|NCT02272647|Drug|Oral Placebo|(in lieu of Medroxyprogesterone)
46012884|NCT01689818|Other|exercise training|exercise training program which included aerobic exercise for 3 times per week.
46012885|NCT02272764|Drug|Itraconazole|Administered orally in a crossover design
46012886|NCT02272764|Drug|ALKS 5461|Administered sublingually in a crossover design
46012887|NCT01689896|Drug|Testosterone Gel|
46012888|NCT01689896|Drug|Placebo Gel|
45679918|NCT04629248|Drug|Tacrolimus|Open Label: Participants will receive tacrolimus at a starting oral dose (PO) of 0.05 mg/kilogram (kg) (participant dry weight) per day divided into two equal doses given at 12-hour intervals, titrated to serum trough level 5-7 Nanograms per millilitre (ng/mL). Optimized tacrolimus dose will be maintained for a maximum 52 weeks dependent on response and then tapered over 8 weeks. Participants who relapse during the open-label treatment period will have their dose of tacrolimus tapered over 8 weeks and may be eligible for further treatment.
46012889|NCT01316094|Drug|ASP1941|oral
46012890|NCT01316094|Drug|placebo|oral
46098825|NCT02615730|Drug|GSK2636771|Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily)
46012891|NCT01689935|Drug|20 % Aminolevulinic Acid|topical medication for ALA-PDT and i-PDT
46098826|NCT02615730|Drug|Paclitaxel|fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle)
46098827|NCT00656708|Other|Kerlix AMD gauze|Use Kerlix AMD gauze as the wound dressing for the entire burn unit
46098828|NCT00998257|Drug|EE20/DRSP (YAZ, BAY86-5300)|Patients under daily life treatment with YAZ according to local drug information.
46098829|NCT02713685|Procedure|Subarachnoid block|Subarachnoid block will be given using 2.5 ml of 0.5%Bupivacaine for lower limb anesthesia
46098830|NCT02713685|Procedure|combined Femoral and Sciatic nerve block|Femoral and Sciatic nerve blocks will be given using total 40 ml of 0.25%of Bupivacaine to anesthetise for lower limb surgery
45679919|NCT04629248|Drug|Methylprednisolone|Premedication: Methylprednisolone 80 mg IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
46012892|NCT01689935|Device|Red light only|Red Light therapy
46012893|NCT01689935|Device|Blue light only|Blue light only
46012894|NCT01316133|Drug|tacrolimus|oral
46012895|NCT01684826|Radiation|Angiographic run with new algorithm and low dose (50% dose)|Angiographic run with new algorithm and low dose (50% lower dose compared to Xper)
46012896|NCT01684826|Radiation|Angiographic run with predecessor algorithm and dose (100%)|Angiographic run with predecessor algorithm and dose (100% dose)
46012897|NCT01316172|Behavioral|5 Cs|education on consultation
46012898|NCT05140343|Diagnostic Test|Kardia Mobile ECG Monitoring (KMCM)|The KMCM will be introduced to the patient of the KMCM arm in the outpatient clinic. The activation and configuration will be done together with the physician in the outpatient clinic (installation of the ECG app, enabling heart rate rhythm notification). Patients are requested to acquired ECGs twice weekly plus additional ECGs if symptomatic. In case of symptoms the patient is asked to generate an ECG and communicate the event timely to the investigator and to the treating physician by sending an PDF through the ECG app. An e-mail account created for the study will be checked at least once a day. The arrhythmia diagnosis will be performed by the clinician based on the ECG information, independently of the arrhythmia classification automatically performed by the device. In case of stronger symptoms of any kind at any time the patient is asked to request medical help regardless of the KMCM notifications. Change of management will be collected.
46012899|NCT05654103|Device|endoAVF|The device will be used according to manufactures instructions and medical facilities standard of care. EndoAVF has a high likelihood of requiring additional procedures that would not have been required if they had undergone surgAVF.
46012900|NCT05654103|Procedure|surgAVF|The surgAAVF procedure will be done according to the medical facilities standard of care. SurgAVF can also require additional procedures to help with the fistula being useable.
46012901|NCT05654064|Drug|Remifentanil-dexmedetomidine|Compare adequacy of remifentanil-dexmedetomidine sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
46012902|NCT05654064|Drug|Dexmedetomidine-fentanyl|Compare adequacy of dexmedetomidine-fentanyl sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
46012903|NCT01689233|Drug|TRx0237 200 mg/day|TRx0237 100 mg tablets will be administered twice daily.
46098831|NCT02615808|Other|Oxygen saturation data visualization|The data visualization contains current and recent (over last 4, 8 or 12 hours) pulse oximetry readings and trends as well as the monitor alarm limits and most recently recorded supplemental oxygen content and flow.
45679920|NCT04629248|Drug|Acetaminophen|Premedication: Acetaminophen (650-1000 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
45679921|NCT04629248|Drug|Diphenhydramine|Premedication: Diphenhydramine (50 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
45837454|NCT02783430|Drug|Placebo|One single perfusion during 40 minutes at the beginning of the inclusion
46012904|NCT01689233|Drug|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
46098832|NCT01004653|Biological|H1N1 influenza A Vaccine (Split virion), Inactivated|100 elders were assigned to receive one dose of 15μg H1N1 influenza A Vaccine (Split virion), Inactivated
45837455|NCT03656328|Dietary Supplement|Lactobacillus Reuteri 4659|supplementation with L. reuteri 4659 twice a day for 10 days during the standard antibiotic therapy
46012905|NCT02272881|Procedure|surgical reconstruction|Patients randomized to surgical flap closure will undergo reconstructive plastic surgery to close an intended pressure ulcer at the earliest date after selection. Our group's co-investigator and staff plastic and reconstructive surgeon will decide on the optimal technical repair. Given the lack of retrospective evidence to support a superior surgical repair (myocutaneous, fasciocutaneous, local flap arrangement versus free microvascular tissue transfer) we will defer to our physician staff preference on a per patient basis. The time from enrollment to surgical intervention will be tracked, and no patient will be dropped from the study should this time exceed the two-week ideal.
46012906|NCT02272881|Procedure|wound management|Patients selected to the supportive wound care arm will be managed by the Center for Wound Care at Cottage Health System, a certified wound care center. They will receive standard of care conservative wound care including: debridement, dressing changes, wound checks, physical therapy, occupational therapy, antibiotic treatment, nutritional support and close follow-up over the study period.
46012907|NCT01687985|Drug|BLI801 laxative - low dose|BLI801 laxative - oral solution
46012908|NCT01687985|Drug|BLI801 laxative - high dose|BLI801 laxative - oral solution
46012909|NCT01686620|Drug|BIOD-123|
46012910|NCT01686620|Drug|Lispro (Humalog)|
46012911|NCT05653401|Drug|Magnesium sulfate|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 1 g of Magnesium Sulfate solution diluted in 10 ml of saline solution administered over 2 minutes
46012912|NCT05653401|Drug|Lidocain|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 10 ml of Lidocaine 1% solution administered over 2 minutes.
46012913|NCT05653401|Drug|Diclofenac|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution.
46098833|NCT02711891|Drug|Loperamide|Following lance one, 0.2 grams of loperamide 5% gel was applied from a sterile syringe to the participants previous lance site within an 8 mm diameter circular plastic mold. The loperamide gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The loperamide gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
46098834|NCT02711891|Drug|Drug, placebo gel|Following lance one, 0.2 grams of gel alone was applied to the participants previous lance site within an 8mm diameter circular plastic mold. The gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing left in place for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The placebo gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
46098835|NCT02615496|Behavioral|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Survey to measure physician awareness and understanding of the key messages in the educational materials: the prescriber guide and video.
45679922|NCT04628026|Drug|Venetoclax|Induction cycle 1: Venetoclax will be administered orally QD, daily dose: 100mg/200mg/300mg, days 1-12 (after a 1/2/3 day ramp-up phase) (as determined during run-in phase) Induction cycle 2: Venetoclax will be administered orally QD, daily dose: 100mg/200mg/300mg, patients not in CR/CRi: days 1-12 (after a 1/2/3 day ramp-up phase) or patients in CR/CRi: days 1-14 (without ramp-up) (as determined during run-in phase) Consolidation phase: Venetoclax will be administered orally QD, daily dose: 100mg/200mg/300mg, days 1-14 (as determined during run-in phase)
46098836|NCT02615496|Behavioral|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|"Survey to measure patient awareness and understanding of the key messages in the educational materials: the patient booklet Your guide to EYLEA, patient information leaflet, and audio CD."
46098837|NCT02639468|Device|Stroke Volume estimation using electrical impedance tomography|
45837456|NCT03656328|Dietary Supplement|Placebo|supplementation with a Placebo capsule twice a day for 10 days during the standard antibiotic therapy
46012914|NCT01685255|Drug|Epacadostat|
46012915|NCT01685255|Drug|tamoxifen|
46012916|NCT01684163|Drug|GLYX-13 5 mg/kg|Intravenous administration of 5 mg/kg into arm.
46012917|NCT01684163|Drug|GLYX-13 10 mg/kg|Intravenous administration of 10 mg/kg into arm.
46012918|NCT01684163|Drug|Placebo|Intravenous administration of normal saline into arm.
46012919|NCT05653284|Drug|AK130|IV infusion, specified dose on specified days.
46012920|NCT01680965|Drug|Ofatumumab|"Phase I: test an escalating dose of ofatumumab at cohorts of 300 mg, 700 mg, and 1000 mg given on day 0 and 14 of study.~Phase II: Ofatumumab MTD on day 0 and 14; patients will be followed for total of 24 months (months 1, 3, 6, 12 after therapy, then at 18 and 24 months following therapy)"
46012921|NCT02272920|Procedure|Renal denervation|Medtronic Symplicity Flex, Medtronic Symplicity Spyral, or St Jude EnligHTN.
45464115|NCT01200745|Drug|Capsaicin patch|Over an four-week period, the treatment group (n=30) uses capsaicin patch (100 mcg/3cc) at the tender point of neck for 12 hours a day; the control group (n=30) receives Hydrogel patch instead of capsaicin patch.
46012922|NCT02272959|Behavioral|Attention bias modification treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns using threat and neutral stimuli.
46012923|NCT02272959|Behavioral|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns using only neutral stimuli.
46012924|NCT05140304|Device|OCT angiography|OCT angiography of foveal avascular zone in diabetic retinopathy
46012925|NCT02272998|Drug|ponatinib hydrochloride|Given PO
46012926|NCT02272998|Other|laboratory biomarker analysis|Correlative studies
46012927|NCT01683188|Drug|vemurafenib + HD IL-2|
46012928|NCT01339923|Biological|rMenB + OMV NZ vaccine|3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)
46098838|NCT02714075|Other|Ferric Pyrophosphate and Zinc Oxide|Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO) and micronutrients
46098839|NCT02714075|Other|Ferric Pyrophosphate and Zinc Sulphate|Extruded rice fortified with Ferric Pyrophosphate, Zinc Sulphate (ZnSO4) and micronutrients
46012929|NCT01339923|Biological|rMenB + OMV NZ vaccine|2 doses (3.5, 5 months of age) plus booster (11 months of age)
46012930|NCT01339923|Biological|rMenB + OMV NZ vaccine|2 doses (6, 8 months of age) plus booster (11 months of age)
46012931|NCT01339923|Biological|rMenB + OMV NZ vaccine|2 doses 2 months apart
46012932|NCT01339923|Biological|Meningococcal C oligosaccharide conjugated vaccine|Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
46012933|NCT01339923|Biological|Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.|Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
46012934|NCT01339923|Biological|rMenB + OMV NZ vaccine|Schedule 3, 5, 12 rMenB + OMV vaccine
46012935|NCT01339923|Biological|rMenB + OMV NZ vaccine|Schedule 13,15 rMenB + OMV vaccine
46012936|NCT04615832|Device|Toffee Full Face Mask|Full face mask for PAP therapy applied in a home environment
46012937|NCT04417088|Drug|Carboplatin|Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
46012938|NCT04417088|Device|Exablate BBBD|BBB opening via Exablate Neuro Type 2 system with microbubble resonators.
46012939|NCT05652036|Biological|Intradetrusor Botox Injections|100 units of OnabotuliumtoxinA is injected into the detrusor muscle in 1 mL aliquots using a cystoscope.
46012940|NCT05651334|Device|Active repetitive Transcranial Magnetic Stimulation|Active stimulation
46012941|NCT05651334|Device|Sham repetitive Transcranial Magnetic Stimulation|Sham stimulation
46012942|NCT04412486|Biological|COVID Convalescent Plasma|One unit of COVID Convalescent Plasma transfused on Day 0
46012943|NCT05650905|Device|Dynamic Vessel Analyzer (DVA)|Retinal neurovascular coupling, Retinal vessel diameters and Retinal oxygen saturation will be assessed using the DVA
46012944|NCT05650905|Device|Fourier domain optical coherence tomography (FDOCT)|Retinal blood velocities and Retinal blood flow will be assessed using the FDOCT
46012945|NCT05650905|Device|Optical coherence tomography (OCT)|Retinal nerve fiber layer thickness, Central retinal thickness and Retinal vessel density will be assessed using the OCT
46012946|NCT05650905|Device|Laser Speckle Flowgraphy (LSFG)|Normalized blur and Relative flow volume will be assessed using the LSFG
46012947|NCT05650905|Diagnostic Test|Proteomics and Metabolites in Plasma, tear fluid and finger sweat|Proteomics and Metabolites in Plasma, tear fluid and finger sweat will be assessed using a Blooddraw, filter paper and Schirmer-test
46012948|NCT05140109|Other|Arm 1: Cognitive-dissonance based program|The first four sessions focus on body image and the last four sessions on eating behavior.
46012949|NCT05140109|Other|Arm 2: Mindfulness-based program|The sessions focus on different contents as body image, eating behavior and emotion regulation.
46012950|NCT05140109|Other|Arm 3: Person-centered program|The sessions are not structured. Participants can bring any subject they need to talk.
46012951|NCT04195919|Drug|Evogliptin 5mg|Participants receive Single oral administration of Evogliptin 5mg on day1
46098840|NCT02714075|Other|Ferric Pyrophosphate, ZnO, Citric Acid and Trisodium Citrate|Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO), Citric Acid (CA) and Trisodium Citrate (TSC) and micronutrients
46098841|NCT02714075|Other|Ferric Pyrophosphate, ZnSO4, CA/TSC|Extruded rice fortified with Ferric Pyrophosphate, ZnSO4, CA/TSC and micronutrients
46012952|NCT04195919|Drug|Evogliptin 5mg|"Period 1(1d,After hemodialysis) → Wash-out period → Period 2(15d,Before hemodialysis)~Hemodialysis patients receive Single oral administration of Evogliptin 5mg on day1 and day15 With a 14-day washout period"
46012953|NCT01380093|Drug|Placebo|Single-dose, 2 x microcrystalline cellulose (weighed to equal weights of average tablet/capsule of active comparator) mixed with 150 ml artificially sweetened, non-carbonated beverage
46012954|NCT01380093|Drug|MS Contin (morphine sulfate, controlled release)|Single-dose, 2 x 60 mg morphine sulfate whole tablets manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
46012955|NCT01380093|Drug|EMBEDA (morphine sulfate / naltrexone hydrochloride)|Single-dose, solution 2 x 60 mg morphine sulfate with sequestered 2.4 mg Naltrexone hydrochloride whole capsules manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
46012956|NCT01686854|Behavioral|Cognitive Behavioral (B)|a 12 months training program in small groups (max 10 persons) about problem solving strategies. Each 90 minute lesson will be given by clinicians, psicologist, dieticians, according cognitive behavioural approach and strategies.
45464116|NCT01121081|Drug|Alga Dunaliella Bardawil|4 capsules per day, 2 in the morning 2 in the evening for 3 month
46012957|NCT01686854|Other|Prescriptive Diet (A)|prescribed diet, with a reduction of 500 Kcal for overweight-1° degree obese, and of 800-1000 Kcal for 2° degree obese patients respect caloric requirement, in compliance with Italian guidelines (INRAN 2003).
46012958|NCT04099199|Diagnostic Test|Click Sexual Health Test|The Click Diagnostics device is a single-use (disposable), fully integrated, rapid, compact, device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for accurate, qualitative detection and differentiation of deoxyribonucleic acid (DNA) for Neisseria gonorrhea (NG), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT) organisms.
46012959|NCT04083326|Device|Digital Patient Journey Solution|Patients in the intervention arm are provided with a digital patient journey solution used on a mobile device. The application is intended to be used during the whole care path. The patient can familiarize him-/herself to the phases of care through visual timeline representation of the care path, get information on how to prepare for a surgery, receive reminders, fill in questionnaire forms, communicate with the care personnel via messaging functionality and video calls, and search information from frequently asked questions. The application contains information about the preparation, forms for anamnesis, anesthesia and treatment follow-up, information videos and pictures, and timely and individually-tailored reminders, e.g., on when to stop eating and drinking before the surgery. In addition, the application provides instructions on how to arrive to the treatment unit and comprehensive guidance for wound care and rehabilitation at home after the operation.
46012960|NCT04059926|Other|insert apossing lumen metal stent|insert apossing lumen metal stent
46012961|NCT04826705|Device|Drug-coated Balloon|To observe the effectiveness and safety of the drug-coated balloon in the treatment of lower extremity arteriosclerosis obliterans of the femoral popliteal artery segment.
46012962|NCT04829084|Behavioral|Pre-post educational intervention|To Increase the attendance of patients with Diabetes Mellitus, for retinal screening at REMEH by providing health education intervention to selected physicians and establishing a referral pathway
46012963|NCT03853616|Biological|MB-CART19.1|MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies
46098842|NCT02714075|Other|Ferric Pyrophosphate, ZnO, CA, EDTA|Extruded rice fortified with Ferric Pyrophosphate, ZnO, CA, EDTA and micronutrients
46098843|NCT02714075|Other|Ferrous Sulphate|Extruded rice fortified with micronutrients, Ferrous Sulphate solution will be added at consumption
46098844|NCT02635412|Other|Scheduled timing of delivery|
45679923|NCT04628026|Drug|Placebo|Induction cycle 1: Placebo will be administered orally QD, daily dose: 100mg/200mg/300mg, days 1-12 (after a 1/2/3 day ramp-up phase) (as determined during run-in phase) Induction cycle 2: Placebo will be administered orally QD, daily dose: 100mg/200mg/300mg, patients not in CR/CRi: days 1-12 (after a 1/2/3 day ramp-up phase) or patients in CR/CRi: days 1-14 (without ramp-up) (as determined during run-in phase) Consolidation phase: Placebo will be administered orally QD, daily dose: 100mg/200mg/300mg, days 1-14 (as determined during run-in phase)
45683834|NCT03181048|Procedure|Periacetabular osteotomy|The Bernese periacetabular osteotomy has become the osteotomy of choice in North America for correction of the dysplastic hip. The ability to position the acetabular component in a specifically desired position for each individual patient improves joint biomechanics, restores joint balance and stability, and offloads the structures at risk for damage such as the labrum and the adjacent articular cartilage.
46098845|NCT04132908|Dietary Supplement|Dietary Supplement: nutraceutical|Subjects will consume two capsules at breakfast and dinner for ten weeks.
46098846|NCT04132908|Dietary Supplement|Placebo|Subjects will consume two capsules at breakfast and dinner for ten weeks.
46098847|NCT05175157|Other|Gut Fellings questionnaire|Answer the Gut Fellings questionnaire
46098848|NCT02636426|Drug|sorafenib|In new dosing schedule of sorafenib is investigated in this study: high-dose, pulsatile sorafenib
46098849|NCT02713763|Drug|Sunitinib|Sunitinib 37.5 mg/day
46098850|NCT00867360|Drug|Mifepristone (RU-486)|
46098851|NCT00867360|Drug|Placebo|Placebo medication
46098852|NCT04219943|Procedure|Surgical Treatment for Impacted Femoral Neck Fracture|Surgical Treatment for Impacted Femoral Neck Fracture
46098853|NCT04000477|Device|Cytobrush|the brush would be inserted in full until the display of the brush in the endocervical canal disappears. A neck quadrant scan (= quarter turn) will be performed from front to back while simultaneously rotating the brush clockwise, for a total of 3 laps. This would represent 4 sweeps per turn, ie 12 sweeps in total
45464117|NCT01121081|Drug|Placebo|"Drug: Alga Dunaliella Bardawil~4 capsules per day, 2 in the morning 2 in the evening for 3 month"
45683835|NCT03181048|Procedure|Periacetabular osteotomy with hip arthroscopy|An intraarticular assessment with hip arthroscopy (HA) at the time of periacetabular osteotomy allows the surgeon to assess and treat the associated labral and chondral pathology and allows the surgeon to treat abnormalities of the femoral head junction.
46098854|NCT04000477|Device|Kevorkian curette|the colposcopist holds the curette horizontally and scrapes the endocervical canal all the way around. He realizes 1 small firm and linear movement by quarter turn or 4 movements to realize a complete turn. During this act, the curette must remain inside the canal, and during its extraction, care should be taken not to rotate it so as not to spill the collected tissue contained in the basket of the curette. The tissue material thus obtained must be rapidly immersed in formalin
46098855|NCT00656552|Drug|Escitalopram|Patient undergo a double- blind therapy of Escitalopram (10 mg) orally daily during breakfast (n=50) or placebo (n=50) for four weeks.
46012964|NCT01379937|Biological|Influenza vaccine GSK1562902A Formulation 1|Intramuscular injection, two doses each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group
46012965|NCT01379937|Biological|Influenza vaccine GSK1562902A Formulation 2|Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group
46012966|NCT01379937|Biological|Havrix™|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
46012967|NCT01379937|Biological|Havrix™ Junior|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
46012968|NCT03720392|Drug|FMT|FMT is a process utilizing microbial components which are the good, healthy bacteria that would otherwise naturally occur in the body.
46012969|NCT03720392|Drug|Placebo|a harmless pill, medicine, or procedure prescribed more for the psychological benefit to the patient than for any physiological effect.
46012970|NCT01379781|Behavioral|Behavioral Intervention for PPD|We will select a sample of pregnant women at risk for PPD, teach parenting skills to increase infant nocturnal sleep and reduce fuss/cry behavior to half of the sample during 3 perinatal visits.
46012971|NCT04820972|Drug|Antiplatelet Agents|using antiplatelet agents in 3 days after surgery
46012972|NCT03558854|Drug|Acetylsalicylic acid|Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
46012973|NCT03558854|Drug|Placebo oral capsule|Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
46012974|NCT03545126|Other|13C6 Leucine|Recruited participants will be given 13C6-labeled leucine through intravenous infusion (4mg/kg/hr for 16hrs)
46098856|NCT04132440|Other|Interview|Complete interview
46098857|NCT04132440|Other|Questionnaire Administration|Complete questionnaire
45464118|NCT01585415|Drug|Vemurafenib|Vemurafenib will administered orally twice a day at a dose of 960 mg from day -21 (+/- 7 days)until disease progression or patients are taken off protocol.
45464119|NCT01585415|Biological|Young TIL|Young TIL will be administered intravenously on day 0(1x10e9 to 2x10e11) in the Patient Care Unit over 20-30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping.
46012975|NCT01335477|Drug|placebo|placebo matching BIBF 1120 BID
46012976|NCT01335477|Drug|BIBF 1120|BIBF 1120 BID (twice daily)
46012977|NCT03389438|Biological|autologous Tcm cells immunotherapy|Autologous Tcm cells immunotherapy is to collect patient's own immune cells and infuse back into the patient's body after culture in vitro that can activate the anti-tumor immune response and achieve the purpose of cancer treatment.
46012978|NCT04829474|Other|Survey|It is a survey that the patient and doctor must complete.
46012979|NCT04828850|Procedure|Endobronchial ultrasound transbronchial needle aspiration lymph node staging|EBUS-TBNA in clinical N0 NSCLC patients
46012980|NCT01371825|Drug|Sebelipase alfa (SBC-102)|Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL Deficiency. Dosing occurred qw for up to 5 years.
46012981|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 8.4 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
46012982|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
46012983|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
46012984|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
46098858|NCT05429411|Other|Silicone gel|At the selected treatment sites the participants will wear the gels for 4 hours for the first 2 days, 8 hours for the second 2 days with a gradual increase of at least 2 hours/day until they reach >21 hours/day. Once the graduate progression has been completed the gel sheet will be applied daily by the subjects for as close to 21+ hours as possible. The gel will be removed for exercise and treatment interventions as well as personal hygiene
46098859|NCT01002391|Procedure|reduction mammaplasty|Dressing following reduction mammaplasty is removed on the first postoperative day
46098860|NCT01002391|Procedure|reduction mammaplasty|Dressing following reduction mammaplasty is removed on the sixth postoperative day
46098861|NCT04132518|Device|Sculptra|Initial injection and optional 3 injections with Sculptra in Midface.
45464120|NCT01585415|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
45464121|NCT01585415|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
45464122|NCT01585415|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)
45464123|NCT03841825|Behavioral|Oral hygiene instructions|Oral hygiene instructions and motivation
45679924|NCT04628026|Combination Product|Standard chemotherapy|"Induction cycle 1: Patients will receive cytarabine 200 mg/m2 continuous IV (days 1-7) and daunorubicin 60 mg/m2 IV (days 1-3). Induction cycle 2: Patients ≤ 60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-6, and daunorubicin 60 mg/m2 IV (days 1-3). Patients >60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-6 without daunorubicin.~Consolidation chemotherapy option 1 consists of one cycle of mitoxantrone (10mg/m2 IV) and etoposide (100mg/m2 IV) (ME) days 1-5 (patients ≤60 yrs) or days 1-3 (patients >60 yrs). Consolidation chemotherapy option 2 consists of intermediate doses of cytarabine. Patients ≤60 yrs will receive up to 3 cycles of IDAC (single dose 1500 mg/m2 every 12 hours, days 1-3). Patients who are >60 yrs will receive up to 3 cycles of IDAC with single doses of 1000 mg/m2, every 12 hours, days 1-3. In patients >60 yrs less than 3 cycles of IDAC or dose-reduced IDAC (500 mg/m2 per single dose) may be given based on an individual risk assessment."
45464124|NCT01212731|Radiation|Photon treatment plans|10 of the 30 subjects on Cohort 1 will receive photon treatment plans.
45679925|NCT04628026|Other|Autologous stem cell transplantation|Busulfan/Cyclophosphamide will be administered as conditioning regime. Patients may proceed to autologous HCT when they have reached CR/CRi/MLFS after at least two cycles of chemotherapy and performance status permits continuation with high-dose chemotherapy. Venetoclax will not be added to or given after the conditioning regimen.
45464125|NCT01212731|Radiation|Proton Treatment Plans|20 subjects from Cohort 1 will receive proton treatment plans with malignancies involving the base of skull.
46012985|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
46012986|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 33.6 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
46012987|NCT01371747|Drug|losartan|losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1)
46012988|NCT01371747|Drug|spironolactone|Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2)
46012989|NCT04825847|Device|BIS monitor|Information provided by the BIS (Medtronic, Canada) monitor will guide the volatile anesthetic administration in the EEG-guided group to maintain a BIS value between 40 and 60, a Suppression Ratio (SR; % of time with suppressed brain electrical activity) at 0% or the closest, a direct EEG display without any suppression time and a spectrogram (DSA or density spectral array) with most of the EEG wave frequency within the Alpha (8-12Hz), Theta (4-8Hz) and Delta (0.5-4Hz) frequencies.
46012990|NCT04825847|Other|Control group|In the standard care group, the age-adjusted Minimum Alveolar Concentration (MAC-age) of sevoflurane will be kept at [0.8-1.2] MAC.
45464126|NCT01212731|Behavioral|Neurocognitive evaluation|Verbal and Visual memory; immediate attention, working memory, and processing speed; executive functions and affect and depression.
45464127|NCT01212731|Device|Advanced MRI imaging|Anatomic Imaging, Blood volume measurements, Diffusion Tensor Imaging, DTI Image Processing
45464128|NCT01566643|Drug|RA5-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 5 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
45464129|NCT01566643|Drug|RA3-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 3 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
45464130|NCT01566643|Drug|RA7-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 7 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
45464131|NCT01121159|Procedure|orbital fracture repair|All patients will receive orbital fracture repair with one of the 4 specified implants
45464132|NCT03841747|Drug|Pembrolizumab|200 mg Pembrolizumab intravenously (IV) every 3 weeks (Q3W).
46012991|NCT03321617|Drug|Pomaglumetad methionil|metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist
46012992|NCT01371708|Drug|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35, or 50 mg/day as prescribed by the investigator
45464133|NCT03841747|Drug|Paclitaxel|80 mg/m2 paclitaxel intravenously (IV) on Days 1,8, and 15 of each 28 day cycle.
45464134|NCT01121237|Drug|Recombinant human erythropoietin alfa (biosimilar)|Recombinant human erythropoietin alfa (biosimilar) commercially available as prescribed per treating physician
46012993|NCT04828733|Procedure|Antireflux laparoscopic one anastomosis gastric bypass|Laparoscopic gastric bypass with suture cruroplasty and total wrapping of the fundus of gastric excluded part.
46012994|NCT04828733|Procedure|Standard laparoscopic one anastomosis gastric bypass|laparoscopic gastric bypass with only suture cruroplasty. Not used fundoplication.
46012995|NCT01335399|Drug|Lenalidomide|Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
46012996|NCT01335399|Drug|Dexamethasone|Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
46012997|NCT01335399|Drug|Dexamethasone|Tablets, Oral, 28 mg, once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
46012998|NCT01335399|Drug|Dexamethasone|Tablets, Oral, 40 mg, once daily, on Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
46012999|NCT01335399|Drug|Dexamethasone|Solution, Intravenous (IV), 8 mg, Once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
45683836|NCT05241808|Behavioral|Girls Can...Move!|Girls Can...Move! is an 8-week intervention designed to increase physical literacy and physical activity among middle school aged girls. One-hour, in-person sessions will be held twice per week for a total of 16 sessions. Each session involves: a brief educational lesson related to physical activity participation, a 30-minute group physical activity session, and a take-home challenge. The physical activities will prioritize enjoyment of physical activity and promote the development of movement competence. These activities may include: yoga; Zumba; Pilates; strength training; kick boxing; circuit training; etc.
46013000|NCT01335399|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug
46013001|NCT01335399|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
46013002|NCT03176615|Dietary Supplement|Experimental diet|The intervention will run concurrently with the gastric bypass treatment at the hospital. The first intervention is carried out before weight loss, and the intervention is repeated two times concurrently with two periods of weight loss (lifestyle and gastric bypass)
46013003|NCT01366521|Biological|Mepolizumab|Monoclonal antibody
46013004|NCT04825262|Drug|Tacrolimus|Starting dose based on CYP3A5 genotype
46013005|NCT04825145|Other|Pregnancy|Pregnancies complicated by preeclampsia
46013006|NCT01335009|Biological|MORAb-004 (monoclonal antibody)|Subjects will receive one cycle of treatment with MORAb-004, administered intravenously, on Days 1, 8, 15, and 22 (4 administrations per cycle). Additional cycles will continue without interruption until disease progression occurs or clinical or symptomatic progression as suggested by an investigator.
45464135|NCT04986241|Drug|Statin|Chronic use of statin prescribed previously by the assistant physician.
46013007|NCT04824365|Drug|Sodium Pyruvate|Subjects will use a sodium pyruvate nasal spray 3x daily for 14 days.
46013008|NCT04824365|Other|Saline|Subjects will use a saline nasal spray 3x daily for 14 days.
46013009|NCT01366443|Procedure|Sterile speculum exam|Sterile vaginal speculum exam to include Nitrazine, ferning and pooling observations
46013010|NCT01366443|Procedure|ROM Plus Exam|Vaginal swab exam for ROM Plus Test
46013011|NCT01366443|Procedure|Chart Reveiw|Post delivery blinded chart review by expereienced obstetrician
46013012|NCT01332630|Drug|TPI 287|"Starting dose Phase I: 160 mg/m2 by vein over 60 minutes on Days 1, 8, and 15 of every 28 day cycle.~Starting Dose Phase II: Maximum tolerated dose from Phase I."
46013013|NCT01332630|Drug|Dexamethasone|6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, dexamethasone 10 mg by vein may be given 30-60 minutes prior to treatment with TPI 287.
46098862|NCT04220177|Device|SETA LATECBA Stent Grafts|ABK model is a bifurcated polyester graft partially corrugated which is sutured at the proximal end (renal) to a balloon expandable 316 L stainless steel stent. The proximal half part of the stent is uncovered by polyester graft providing the anchoring to the healthy aorta wall when the device is implanted, as well as the perfusion of the renal arteries. The remaining half part is covered by polyester graft providing sealing of the aneurysm when it is expanded upon on the graft fabric and aneurysm neck. The distal end of each branch has the anchorage site for sealing after the connection with the iliac extensions RIK. The diameter of the anchorage site varies with the different ABK codes. The end of one branch is cone-shaped after the anchoring diameter with the purpose of promoting insertion of iliac extension RIK. The connection to iliac arteries is achieved by completing the aortic trunk ABK with 2 iliac extensions RIK.
46098863|NCT00998413|Behavioral|Multifaceted intervention|multifaceted family-based, physical exercise, nutrition, and behavioural intervention study for 18 month, in children aged 6-16 years with asthma and overweight/obesity.
46098864|NCT04220099|Procedure|Electroconvulsive therapy(ECT)|Patients recieve 8-sessions ECT treatments and those kinds of drugs they take since they were recruited remain unchanged during this study.
46098865|NCT01002469|Other|sodium [1-13C] acetate|
45464136|NCT04986241|Other|Physical activity|Physically active participants
45464137|NCT04986241|Other|Sedentary|Physically inactive or sedentary participants.
45464138|NCT03445065|Device|Eversense XL CGM System|The Eversense XL Continuous Glucose Monitoring (CGM) System consists of an implantable sensor inserted under the skin, an external transmitter, and a Mobile Medical Application (MMA) for display of glucose information that runs on a Handheld Device (HHD).
46013014|NCT01332630|Drug|Benadryl|12.5-25 mg intravenous (IV) push 30-60 minutes prior
46013015|NCT01332630|Drug|Ranitidine|As H2 blocker 1mg/kg IV 30-60 minutes prior
46013016|NCT04822961|Drug|Placebo|Senaparib-matched placebo capsules
46013017|NCT04822961|Drug|Senaparib|20 mg capsules
46013018|NCT01366209|Drug|Pirfenidone|Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.
46013019|NCT01366209|Drug|Placebo|Placebo equivalent given as 3 divided doses 3 times per day.
46013020|NCT01600001|Drug|KWA-0711|
46013021|NCT01600001|Drug|Placebo|
46013022|NCT01365546|Biological|human VWF/FVIII concentrate|intravenous infusion. Dose based on subject's individual invivo-recovery
46098866|NCT05429333|Other|Artificial intelligence-assisted personalized diet|"The AI-based nutritional recommendations system is based on the eating rates of the individual in a certain period, to ensure the homeostasis of the microbiome and increase the microbial diversity.~After the microbiome analysis reports of the study group are released, a 6-week diet was designed regarding AI-based food scores specific to constipated individuals in accordance with the individual's lifestyle and comorbidities. Diet lists are updated according to the individual's feedback, recovery level, and wishes with weekly meetings."
46098867|NCT01004809|Drug|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
46013023|NCT04828421|Dietary Supplement|Lactobacillus rhamnosus and Bifidobacterium lactis|Probiotics
46013024|NCT04828421|Dietary Supplement|Placebo|Placebo
45679926|NCT04628026|Other|Allogeneic stem cell transplantation|Generally, patients will proceed to allogeneic HCT upon completion of remission induction chemotherapy. It is however allowed, as per investigator's discretion, for a patient to receive 'bridging' consolidation chemotherapy in exceptional cases of delay towards transplantation. At baseline, HLA-compatible donor search must be initiated as soon as possible, first among siblings and second in the world donor bank for unrelated donors or cord blood. In order to avoid inappropriate delay in cases where no suitable sibling is present, high-resolution HLA typing should be performed immediately after registration, enabling a more rapid matched-unrelated donor search. In case no sibling or unrelated donor can be identified, haploidentical allogeneic HCT is allowed. Conditioning and GVHD prophylaxis will take place according to institutional guidelines. Patients who undergo allogeneic HCT will not receive venetoclax during conditioning, engraftment or after hematologic recovery.
45679927|NCT04614454|Device|High Frequency Impulse Therapy|The home TENS unit device is an at-home transcutaneous electrical nerve stimulation unit in that it provides non-invasive transcutaneous electrical impulses to reduce pain. It is a small, wearable device that utilizes both high and low frequencies to create a nerve-block effect based on the same gating theory.
45837457|NCT03642366|Other|Dornier Aries2 LiST Device + 5mg Tadalafil (1)|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
46098868|NCT02711813|Drug|TAB08|biologic
46098869|NCT02711813|Other|Placebo|
45837458|NCT03642366|Other|Dornier Aries2 LiST Device + 5mg Tadalafil (2)|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
46098870|NCT00998569|Behavioral|Neurocognitive Enhancement|Neurocognitive Enhancement Therapy (NET) uses behavioural treatment strategies that are designed to improve a range of cognitive skills. NET uses strategies such as coaching, repetition, practice, teaching, group discussion, and compensation for deficits by using cognitive strengths.
46098871|NCT00998569|Behavioral|Wait List|Participants will be wait listed for 10 weeks, following which time they will receive the intervention previously described.
46098872|NCT01004887|Other|diagnostic laboratory biomarker analysis|
46013025|NCT01600040|Radiation|Proton radiation therapy|5 days per week (Mon-Fri) for 5-6 weeks
46013026|NCT01365507|Drug|insulin degludec/insulin aspart|Insulin degludec/insulin aspart injected subcutaneously (under the skin) once daily. Dose individually adjusted.
45464139|NCT03445065|Device|Usual SMBG or FGM device used by participants|Commercially available products in France for self-monitoring of blood glucose (SMBG) or flash glucose monitoring (FGM) were considered as comparators for this study.
46013027|NCT02995694|Drug|Estradiol|Estradiol Vaginal Cream
46013028|NCT02995694|Drug|Placebos|Placebo with no active pharmaceutical ingredients. Topical vaginal cream
46013029|NCT02995694|Drug|Reference|Estrace Vaginal Cream
46013030|NCT01365468|Drug|Everolimus (RAD001)|oral daily dosing of tablet starting with 2.5 mg
46013031|NCT04827836|Procedure|Cooled eye drops and povidone-iodine|Cooled oxybuprocaine HCl 0.4% and lidocaine HCl 2% eye drops and cooled povidone-iodine (cul-de-sac 5% povidone-iodine and 10% povidone-iodine).
46098873|NCT04727255|Behavioral|Engaged and Resilient intervention|"Engaged and Resilient is a 3-phase program addressing the promotion of psychological resilience strategies for leaders.~To implement resilience training as a strategic and ethical intervention in the organization, stakeholders from Management/HR will be involved in the final design of the training program based on local institutional data, and the baseline measure result. Local training sessions will be selected from a bag-log of resilience skills structured by three general resilience factors.~To support ownership and internal sustainability, internal trainers will be educated on how to train the resilience skills in the program.~The Engaged and Resilient program consists of 20 short-term sessions for leaders based on cognitive and positive psychology."
46013032|NCT01357980|Biological|Botulinum toxin type A|750 U intra detrusor injection on Day 1 (single dose)
46013033|NCT01357980|Drug|Placebo|Intra detrusor injection on Day 1 (single dose)
46013034|NCT01332318|Drug|XP13512|XP13512 once daily for 16 days
46013035|NCT01332318|Drug|Diphenhydramine|one 50 mg dose of diphenhydramine (DPH) on day 16
46013036|NCT01332318|Drug|Placebo|XP13512 placebo once daily for 16 days
46013037|NCT04828226|Drug|Clonidine|Clonidine 2mcg/kg Body Weight diluted in 100ml sodium chloride 0.9% compared to placebo (sodium chloride 0.9% alone) given over 10 minutes, 10 minutes prior to electroconvulsive therapy.
46098874|NCT02711423|Drug|Gantenerumab|Gantenerumab will be supplied as a high-concentration liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
46098875|NCT02711423|Drug|Placebo|Placebo will be supplied as a matching liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
46098876|NCT00593736|Drug|Ramelteon|Ramelteon 1 mg, tablets, orally, once daily for up to two weeks.
45464140|NCT03841591|Drug|Insulin|Women with GDM will receive insulin and tailored according to their blood glucose levels to achieve glycemic control. Starting dose will be 30unit (20 unit intermediate dose + 10 unit rapid acting insulin) in the morning and before breakfast). In the 2nd trimester, we will start with half of the previous dose and if post dinner glucose level remain elevated additional injection of rapid acting insulin will be given just prior to dinner. If fasting glucose is elevated, intermediate acting insulin can be given along with the dinner dose of rapid acting insulin.
46013038|NCT04828226|Drug|Placebo|Sodium chloride 0.9% 100ml given over 10minutes, 10 minutes prior to electroconvulsive therapy.
46098877|NCT00593736|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to two weeks.
46098878|NCT00593736|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to two weeks.
46098879|NCT00593736|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to two weeks.
46098880|NCT03742765|Behavioral|Incentivizing planning|Participants receive bonus incentives for planning their workouts
46098881|NCT03742765|Behavioral|Incentivizing exercise|Participants receive bonus incentives for exercising
45679928|NCT04614454|Device|High Frequency Impulse Therapy - Sham|This device looks like the experimental device but does not provide the electrical current.
45683837|NCT03160612|Behavioral|Transfer Training|Transfer training interventions will take approximately 1 hour to complete and consist of an interactive web based module that participants interact with which includes text, pictures, videos and time to practice new skills. Additionally, participants will receive an educational handout summarizing the online module.
45683838|NCT01609790|Biological|Bevacizumab|Given IV
46098882|NCT02713451|Drug|Modulation of Inspired Fraction of Oxygen (FiO2)|"In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient."
46098883|NCT01002625|Drug|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
46098884|NCT01002625|Drug|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
46098885|NCT00883688|Drug|Bevacizumab|"10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week study cycle)."
46098886|NCT00883688|Drug|Lapatinib|Pills of 700 mg/m^2/dose given orally 2 times each day.
46013039|NCT04826861|Behavioral|SLIM intervention|Core components: 1) goal setting, 2) motivational interviewing, 3) feedback, 4) health technology
46013040|NCT02071901|Drug|eltrombopag olamine|Given PO
46013041|NCT01331109|Drug|Milnacipran|maximum tolerated dose (50, 75, or 100 mg/day tablets); for 52 weeks.
46013042|NCT01865396|Behavioral|Interventional palliative care|Palliative support team will meet the patient soon after diagnosis of incurable disease and will meet the patient at least once a month. The patient will also receive the standard oncologic care.
46098887|NCT04191863|Other|Clinical, EEG and laboratory assessment at presentation|"The patients' history, clinical, demographic, and laboratory data were acquired.~The following tests and imaging studies are routinely done for epilepsy patients receiving valproate treatment and developed nocturnal enuresis, blood urea nitrogen (BUN), serum creatinine (Cr), urinary pH (before and after valproate therapy beginning and at enuresis onset), serum levels and therapeutic doses of valproate.~Urinary tract ultrasonography (with full and void bladder).~CT brain and EEG."
45464141|NCT03841591|Drug|Metformin|Women with GDM will receive metformin and tailored according to their blood glucose levels to achieve glycemic control. They will receive an initial metformin dose of 500 mg once or twice daily (according to initial blood glucose level) with food and increased 500 mg every one or two weeks toward targets or up to a maximum daily dose of 2500 mg divided doses with each meal.
45679929|NCT04605861|Drug|Liraglutide|Liraglutide Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Liraglutide Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.
45683839|NCT01609790|Other|Laboratory Biomarker Analysis|Correlative studies
46098888|NCT04191863|Drug|Valproate|valproate monotherapy
45683840|NCT01609790|Other|Pharmacological Study|Correlative studies
46098889|NCT03883477|Device|Endoscopic Release|Retrograde endoscopic release of the A1 pulley for treatment of trigger finger will be performed using a commercially available device by A.M. Surgical, Inc. This device has been cleared for marketing, sale and use by the U.S. Food and Drug Administration (FDA) for use as an Orthopedic manual surgical instrument based on its similarity in structure and function to previously used devices.
46098890|NCT03883477|Procedure|Standard Open Release|Standard open surgical release of the A1 pulley for treatment of trigger finger.
46098891|NCT02711501|Procedure|Laser-assisted surgery.|laser-assisted surgery
46098892|NCT02711501|Procedure|conventional surgery by blade|conventional surgery
46098893|NCT04162730|Other|Pressure pain threshold and behavioural data|Pressure pain threshold level of the knee region will be collected and behavioural data will be measured
46098894|NCT02636348|Dietary Supplement|Calcium/Vitamin D|2000 mg calcium and 1000 IU vitamin D administered daily as 8 pills or 2 fortified snack bars.
46098895|NCT02636348|Dietary Supplement|Placebo|Administered daily as 8 placebo pills or 2 unfortified snack bars.
45464142|NCT03841591|Other|Assessment of weight gain|Body weight will be measured monthly from the start of treatment till delivery.
45683841|NCT01609790|Other|Placebo Administration|Given IV
45683842|NCT01609790|Biological|Trebananib|Given IV
46013043|NCT01865396|Behavioral|Standard oncologic care|Patients will receive standard oncologic care.
46013044|NCT01357551|Behavioral|Maintenance intervention|Theoretically-informed maintenance intervention that involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
46013045|NCT01640483|Other|psychodynamic techniques.|the patients go through a time-limited (50 sessions, 45 minutes, 2 sessions/week) experimental treatment which exists of a sequence of four A phases (control conditions), one B phase (supportive techniques only), one C phase (interpretative techniques only), and one BC phase (mixed supportive/interpretative techniques).
46013046|NCT01357239|Drug|AFQ056|
46098896|NCT05428631|Device|Implantation of the CARDIOMEMS™ HF device|The initial routine workup includes a nephrological evaluation: mGFR with Iohexol before fitting the CARDIOMEMS™ HF device, renal echo-Doppler, urinary sedimentation, etiological assessment of severe Chronic Kidney Disease, NT-ProBNP, impedancemetry, urinary ionogram, weight, anemia assessment, and correction of possible iron and/or vitamin deficiency and a cardiology evaluation: blood pressure, heart rate, clinical data, biology (Complete Blood Count, iono, urea, creatinine, total bilirubin, ferritin, CST), echocardiography (Left Ventricle Ejection Fraction, E/A, E/e', indexed volume of the left atrium, Tricuspid Annular Plane Systolic Excursion, Tissue Doppler S-wave, surface area of the right atrium, Systolic Pulmonary Artery Pressure, Right Atrial Pressure). The device will be implanted in the selected patients by Pr François Roubille at Montpellier University Hospital within 1 month of the pre-inclusion visit. It will monitor their pulmonary artery pressure.
46098897|NCT04162340|Biological|CD4 CAR T cells|CD4 CAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
46098898|NCT00998647|Device|modified ultrafiltration using Maquet haemoconcentrator, BC 20 plus|usage of modified ultrafiltration following extracorporeal circulation; filtration about 1,5 liters and re-fill with colloids
46098899|NCT05428553|Procedure|Endoscopic resection: CSP/p-CSP|Patients in the experimental arm will be assigned to receive CSP/p-CSP.
46013047|NCT01357239|Drug|Placebo|
46013048|NCT04820582|Other|Delphi Questionnaire|Evaluation of a list of PROMs and CROMs specific for endometriosis (previously selected from a litterature review) on a Likert scale of 1 to 9 for their relevance and feasibility
45464143|NCT01328795|Other|cardiogoniometry|In the course of the project a cardiogoniometry will be carried out during the ambulant or residential hospitalization before the coronary angiography.
46098900|NCT05428553|Procedure|Endoscopic resection: EMR/EPMR|Patients in the historical control arm have already finished EMR/EPMR
46013049|NCT00903500|Behavioral|Daily physical activity, pedometer and counseling|Individual counseling session, telephone counseling (7 calls), given by a psychologist and a pedometer, based on cognitive behavioral therapy, the Diabetes Prevention Program, the first Step Program and Motivational Interviewing
46013050|NCT01357161|Drug|MK-1775|MK-1775 capsules, orally, twice a day (BID) for a total of 5 doses starting on Day 1 of each 3-week cycle
46013051|NCT01357161|Drug|Placebo|placebo to MK-1775, capsule, orally, BID for a total of 5 doses, starting on Day 1 of each 3-week cycle
46013052|NCT01357161|Drug|paclitaxel|paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle
46013053|NCT01357161|Drug|carboplatin|carboplatin, IV infusion on Day 1 of each 3-week cycle
46013054|NCT00737321|Procedure|Samples will be collected|wound tissue biopsy, blood samples, saliva collection and wound VAC sponge (if applicable).
46013055|NCT01351350|Drug|MLN0128|MLN0128 capsules
46013056|NCT01351350|Drug|paclitaxel|paclitaxel intravenous infusion
45464144|NCT03841279|Diagnostic Test|MRI|Magnetic resonance imaging (MRI) produces detailed images of the body's internal structures without relying on radiation. It is used to diagnose and also gauge efficacy of treatment.
46013057|NCT01351350|Drug|trastuzumab|trastuzumab intravenous infusion
46013058|NCT02271503|Drug|CD-LD IR|CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
46013059|NCT02271503|Drug|IPX203 180 mg|IPX203 containing 45 mg carbidopa and180 mg levodopa
45464145|NCT01216553|Other|Oxygen Therapy|1 lt/min oxygen via nasal cannulae intermittently for 30 minuets 4 times daily for 7 days
45464146|NCT05667727|Drug|nebulized epinephrine|we are using 1:1000 epinephrine into nebulization form
45464147|NCT05667727|Drug|Normal saline|the control group will receive Normal saline (placebo) plus the standard treatment (salbutamol and ipratropium)
46013060|NCT02271503|Drug|IPX203 270 mg|IPX203 containing 67.5 mg carbidopa and 270 mg levodopa
46013061|NCT02271503|Drug|Rytary 195 mg|Rytary 48.75Mg-195Mg Extended-Release Capsule
46013062|NCT02271503|Drug|Rytary 145 mg|Rytary 36.25Mg-145Mg Extended-Release Capsule
45464148|NCT03939611|Other|Foot Reflexology|Reflexology is one of the complementary health approaches; it is based on systematic pressure and stimulation with fingers to energy points in feet and hands and is a topic nowadays studied. Reflexology argues that the reflex maps in the hands and feet with all of the parts of the body are in contact. The pressure applied to each point stimulates the circulation of blood and energy like a sensor, gives a sense of relaxation, provides homeostasis. With a touch that is a different way of communication with children, is supported to create physical awareness via reflexology techniques, and is provided healthy nutrition of the stimulated tissue.
45464149|NCT03939611|Other|Placebo Foot Reflexology|Placebo reflexology was performed by touch without pressure to the same rotation and to the same points as foot reflexology application. It was performed only to compare foot reflexology with a placebo effect.
45464150|NCT01200901|Drug|Quetiapine|quetiapine XR 100 - 300 mg (flexible dosing)
45464151|NCT03843385|Drug|encapsulated faecal microbiota filtrate|Multidonor stool mixed with sterile normal saline, homogenized, filtered, centrifuged, air pressure filtered, encapsulated in hypromellose capsules and frozen.
45464152|NCT03843385|Drug|encapsulated faecal microbiota|Multidonor stool mixed with sterile normal saline, homogenized, filtered, encapsulated in hypromellose capsules and frozen.
45464153|NCT03843385|Drug|Placebo|Sterile saline encapsulated in hypromellose capsules and frozen.
45683843|NCT01767116|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
45683844|NCT01767116|Drug|Ribavirin|Capsule
46013063|NCT04526405|Diagnostic Test|SARS-CoV-2 S1/S2 IgG|SARS-CoV-2 S1/S2 IgG analysis
46013064|NCT01350999|Drug|omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
46013065|NCT01350999|Drug|Eicosapentaenoic acid-ethyl (EPA)|EPA-E capsules
46013066|NCT02275559|Behavioral|Mindfulness Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.
46013067|NCT02275559|Behavioral|Healthy Living Course (HLC)|The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
46013068|NCT04526522|Other|No intervention|No intervention
46098901|NCT00654212|Procedure|endo-laparoscopic approach|endoluminal stenting followed by laparoscopic resection
46098902|NCT00654212|Procedure|open approach|emergency open surgery
46098903|NCT04219865|Drug|Group 1: Compound Edaravone/Placebo Injection|Compound Edaravone 30mg-600mg (containing edaravone 30 mg and 2-aminoethanesulfonic acid 600 mg) / placebo single intravenous infusion for 30min
46098904|NCT04219865|Drug|Group 2: Compound Edaravone/Placebo Injection|Compound Edaravone 60mg-1200mg (containing edaravone 60 mg and 2-aminoethanesulfonic acid 1200 mg) / placebo single intravenous infusion for 30min
45464154|NCT01212809|Device|Juvéderm Ultra|Split-face injection of Juvéderm Ultra into vertical lip rhytids and radial cheek lines on one side of face
45683845|NCT01767116|Drug|Placebo for ribavirin|Capsule
46013069|NCT02270021|Other|Provider Mobile Application (ProvAPP)|Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.
46013070|NCT02270021|Other|ProvAPP + Patient Educational Tool (Tab)|"Patient Educational Tool (Tab): A patient educational tool (mobile tablet) will educate women on cervical cancer screening and treatment. Patients' self-assessment using a tablet at the time of clinic check-in will help them to understand current guidelines and their choices for treatment if they have abnormal cytology. It will allow them to assess the risks and benefits of screening intervals and of treatment choices.~ProvAPP: Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition."
46013071|NCT01350804|Biological|AIN457|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
46013072|NCT01350804|Biological|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
46013073|NCT01350804|Biological|Abatacept|Abatacept (from 500 to 1000 mg i.v. based on weight) was given as i.v. at baseline, weeks 2 and 4, and then every 4 weeks starting at week 8.
46013074|NCT04526249|Device|rapid pulse confirmation device|device used to detect pulsatile blood blood during and after cardiac arrest
46013075|NCT02274818|Behavioral|Flexible Duty Hour Schedule|"IM programs randomized to intervention will be allowed to construct flexible duty hour schedules that comply with 3 rules:~No more than 80 hours of work per week (when averaged over 4 weeks)~1 day off in 7 (when averaged over 4 weeks)~In-house call no more frequently than every 3rd night (when averaged over 4 weeks)"
46013076|NCT04448418|Other|web based survey|Assess specific health care needs for the transpopulation during the COVID-19 outbreack using a newly created questionnaire and some validated questionnaries (Impact of Event Scale-Revised, BECK Depression Inventory and the Self-rated Health SF-12)
46098905|NCT04219865|Drug|Group 3: Compound Edaravone/Placebo Injection|Compound Edaravone 90mg-1800mg (containing edaravone 90 mg and 2-aminoethanesulfonic acid 1800 mg) / placebo single intravenous infusion for 30min
45464155|NCT01212809|Device|Cosmoderm 1|Split-face injection of Cosmoderm 1 into vertical lip rhytids and radial cheek lines on one side of face
45837459|NCT03642366|Other|Sham LiST Device + 5mg Tadalafil|Patients will receive sham shockwave treatment (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7)using a sham probe identical to active probes, three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks. The IIEF-ED domain will be evaluated at Visit 1 and, consequently, at baseline and all follow up visits together with the SEP diaries.
46013077|NCT01350492|Behavioral|Resistance Exercise Training|16 weeks of resistance exercise training for the treatment of chronic muscle pain compared to wait-list control
46098906|NCT04219865|Drug|Group 4: Compound Edaravone/Placebo Injection|Compound Edaravone 120mg-2400mg (containing edaravone 120 mg and 2-aminoethanesulfonic acid 2400 mg) / placebo single intravenous infusion for 30min
45464156|NCT01214993|Drug|GSK1349572|GSK1349572 is an experimental drug in the integrase inhibitor class of drugs to treat human immunodeficiency virus (HIV)
45464157|NCT01214993|Drug|Placebo|Placebo is a tablet with no drug in it.
45464158|NCT01214993|Drug|Iohexol Injection|Iohexol is an FDA approved radiologic contrast medium
45464159|NCT01214993|Drug|Para-aminohippurate infusion|Para-aminohippurate is an agent to measure effective renal plasma flow.
45837460|NCT05246592|Procedure|Branches Sparing|The patients will undergo axillary lymph node dissection with preserved axillary vein branches
45837461|NCT05246592|Procedure|None Branches Sparing|The patients will undergo axillary lymph node dissection without preserved axillary vein branches
46098907|NCT04219865|Drug|Group 5: Compound Edaravone/Placebo Injection|Maximum tolerated dose of drug / placebo for a single intravenous infusion for 30 minutes three times a day at an interval of 8 h until the last dose on the morning of Day 3, after which the sequential test drug 30 mg-600 mg / placebo will be administered daily from Day 3 night Intravenous infusion, 30 minutes at 12-hour intervals until morning on Day 7
46098908|NCT01002703|Drug|Lenalidomide, Bendamustine, Prednisone|During the study the first cohort of subjects receive a starting dose of lenalidomide 10mg/d d1-21, bendamustine 60mg/m²/d d1-2 and prednisone 100mg/d d1-4. Escalation steps will include 15, 20 and 25 mg of lenalidomide and 75mg/m² for bendamustine.
45464160|NCT03843229|Drug|Cinobufacini injection|The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
45464161|NCT03843229|Procedure|Transarterial Chemoembolization(TACE)|TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible.
45464162|NCT03843229|Drug|cinobufacini tablet|The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
45464163|NCT03717831|Other|Observational study of standard of care|Observational cohort study
45464164|NCT03939221|Behavioral|Infrared Lamp and Acupressure|Measure the ankle and wrist acupoints skin conductance to evaluate the basic condition of terminal hospice patients. Then investigators use the infrared lamp and acupressure(tender points, PC6 and ST36 for one minutes) for our patient for the cold limbs, pain control and constipation problems.
45837462|NCT05246436|Procedure|warming saline media|use warm saline as a distention media in office hysteroscopy
45837463|NCT05246436|Procedure|room temperature saline media|use room temperature saline as a distention media in office hysteroscopy
46013078|NCT02270957|Biological|Abatacept|
46013079|NCT02270957|Other|Placebo|
46098909|NCT04162886|Other|Exercise|Thrower's ten exercises will given for 8 weeks, 3 days in a week.
46098910|NCT01002781|Drug|Tocilizumab|Tocilizumab, IV, 8 mg/kg, every 2 weeks
46013080|NCT01350414|Device|Bronchial Thermoplasty with the Alair System|Bronchial Thermoplasty with the Alair System
46013081|NCT04523753|Procedure|emergency endoscopy|emergency endoscopy for gastrointestinal bleeding situation before or after surgery
46013082|NCT01350336|Device|Alair System|Treatment of airways with the Alair System
46013083|NCT04827290|Behavioral|Low-AGE diet|Low-AGE diet during 24 months
46013084|NCT04827290|Behavioral|High-AGE diet|High-AGE diet during 24 months
46013085|NCT04826315|Behavioral|COPE +|Six sixty minute sessions that teaches participants distress and communication coping skills.
46013086|NCT04823702|Biological|Aldafermin|Biological: Aldafermin (NGM282) Subcutaneous Injection
46013087|NCT01349049|Drug|PLX3397|Maximum Tolerated Dose of PLX3397 will be administered orally, twice daily.
46013088|NCT01349049|Drug|PLX3397|The drug product is available in capsule form, to be taken orally.
46013089|NCT04522700|Procedure|scapular free flap|use of scapular free flap to reconstruction post maxillectomy defect to provide bony support
46013090|NCT04829864|Behavioral|STEP|"The program is offered by two facilitators to groups of three to seven women, in-person or online. The program is divided in three phases entitles Becoming a mother; A look at my own history and Looking ahead. The first phase aims to explore and normalize the emotions experienced by the participants in the course of their pregnancy and to support the use of healthy emotion regulation strategies. The second phase aims to support mentalization of trauma, by discussing the nature of trauma and its impact; by validating participants' feelings as understandable responses to trauma; by supporting a reflection on positive and harsh experiences with significant others and the ways both types of experiences influenced participants' mental states; and identifying how participants coped with trauma. In the last phase, discussions focus on participants' needs and strengths, on available resources to support resilience and envision positive and challenging moments with the child."
46013091|NCT01348854|Device|iFS Femtosecond Laser System|arcuate incisions placed with the iFS femtosecond laser
46013092|NCT04522310|Other|MR-Pro-ADM|Dosage of MR-pro-ADM
46013093|NCT01348776|Device|Hair2Go (Mē)|Treatment with Hair2Go Device 7 times every week with maintenance treatments once a month for 3 months
46013094|NCT01348698|Procedure|Tumor tissue biopsy|Participants whose tumor does not secrete hormones will have a tumor biopsy to collect tissue for the study.
46013095|NCT01348698|Procedure|Surgery|Participants who have a large tumor or one that secretes hormones will have standard surgery to remove the tumor. Tissue will be collected for study.
46013096|NCT04520477|Diagnostic Test|Bio Impedance assesement (BIA)|BIA every 5 minutes od the test protocol. Patients stood up for 5 minutes, laid down for 70 minutes, followed by 5 minutes in a seated position and ending with 30 minutes standing. BIA was done every 5 minutes.
46013097|NCT04520477|Diagnostic Test|Blood and salava sample|Blood Samples were done at the initation of the protocol, and every 10 minutes after ingestion of the deutarated water
46098911|NCT02639234|Biological|Vigil™|Upon completion of nivolumab infusion, subjects will receive Vigil™, 1.0 x 10^7cells via intradermal injection on Day 1 every 14 days for a minimum of 4 and a maximum of 12 doses depending on quantity of Vigil™ manufactured from surgical specimens.
46098912|NCT02639234|Drug|Nivolumab|Prior to Vigil™, subjects will receive nivolumab 3 mg/kg by intravenous infusion over 60 minutes on Day 1 every 14 days. If nivolumab is administered beyond 12 months it will be administered off study.
46098913|NCT01002859|Drug|Sandimmum|Intravenous injection of cyclosporine
46098914|NCT01002859|Drug|Placebo|Intravenous Injection of NaCl solution
46098915|NCT00654290|Drug|Amiodarone + Propranolol|Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
45464165|NCT03712995|Procedure|'Cutler-Beard modified with graft'|A tarsoconjunctival graft was harvested from the contralateral upper eyelid, with an extra 3 mm of conjunctiva from the superior edge of tarsus and was attached to the upper eyelid defect, differently than previously described.
45464166|NCT03841435|Radiation|Hypofractionated Radiotherapy|Radiotherapy Treatment, totaling 15 Gy, will be given in 3 fractions over 2 weeks.
45464167|NCT03935477|Device|WellBeing catheter|Urethral catheterisation with integral Wellbeing Catheter to measure bladder tissue oxygen tension
45683846|NCT01574703|Drug|placebo|All dosing to have taken place per study A3051123
45683847|NCT01574703|Drug|varenicline tartrate|All dosing to have taken place per study A3051123
46013098|NCT04520477|Dietary Supplement|Ingestion of deuterated water|15 minutes after the intiation of the test protocol, participants drink an amount of deuterated water corresponding with 0.25% of their TBW calculated using the Watson Formula
46013099|NCT04520477|Diagnostic Test|Urine sample|A urine sample is taken at the initiation and after termination of the protocol.
46013100|NCT01348542|Drug|Trazodone|50 mg once a day, for 3 months
46013101|NCT01348542|Behavioral|Cognitive Behavioral Therapy|The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.
46013102|NCT04827758|Procedure|Screening and diagnostic tests for sarcopenia|"All of the following tests and questionnaires will be performed :~SARC-F questionnaire,~measurement of muscle strengh by a grip test,~measurement of muscle mass by impedancemetry (ASM/size2),~4-meter walking speed test,~Timed-Up and Go (TUG) test,~ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living) questionnaires."
46013103|NCT04447677|Other||
45683848|NCT01574703|Drug|bupropion hydrochloride|All dosing to have taken place per study A3051123
45683849|NCT01574703|Drug|Nicotine Replacement Therapy Patch|All dosing to have taken place per study A3051123
46013104|NCT04447638|Procedure|Tracheostomy with aerosol box in COVID-19 positive patients|Patients who underwent percutaneous tracheostomy with aerosol box in COVID-19 positive patients. The patients age, gender, hospitalization diagnosis, number of intubated days, anesthetic agents used during the procedure, neck ultrasonography data before and during the procedure, and complications were recorded.
46013105|NCT04826471|Device|DermoRelizema ecofoam|DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration
46013106|NCT04447248|Device|QDSP Protocol|Computerized expert system for fetal monitoring, based on cardiotocogrpaphy
46013107|NCT04519190|Diagnostic Test|Prolonged continuous single-lead ECG monitor|We use Smartpatch, a listed ambulatory electrocardiographic system that can continuously record and save patients' cardiac rhythm for up to 45 days.
45837464|NCT05246358|Device|ChoniSense Polso|"A range of stable respiratory rates was elicited from each volunteer test subject. The rates were 5, 10, 15, 20, 25, 30, 35, 40 and 45 breaths per minute; with some natural variation from these exact numbers.~Each subject was instrumented with an open system mask that allows for measurement of the end tidal carbon dioxide (EtCO2) respiratory rate and tidal volume. The EtCO2 monitor was used as the Accuracy Reference Device (Reference) in this study."
46013108|NCT04519190|Diagnostic Test|Intermittent ECG monitor|When using Smartpatch, we can set time markers by pressing the button on the device. We ask our subjects to press that button twice a day and also when they feel any discomfort. Analyzing the ECG 1 minute after those time markers can serve as a surrogate for intermittent ECG monitor.
45837465|NCT00604968|Drug|Caelyx (pegylated liposomal doxorubicin; SCH 200746)|Caelyx will be administered intravenously at a dose of 40 mg/m^2 on day one every 4 weeks until progression, or unacceptable toxicity, or other reason to discontinue the study treatment. The drug is diluted in 250 ml glucose 5% (500 ml for doses >=90 mg).
46098916|NCT00654290|Drug|Amiodarone|Amiodarone treated 7 days pre-operation to 5 days post CABG
46098917|NCT00654290|Drug|Propranolol|Propranolol from 7 days pre-operation to 5 days post CABG
46098918|NCT02713217|Other|Usual Care|This condition is defined as usual care occurring within Community Based Outpatient Clinics (CBOCs), which typically does not involve substantial integration of mental health care and primary care.
46098919|NCT02713217|Other|Blended Telemedicine-Based Integrated Care|"This condition involves exposure to a blended collaborative care model that includes care management for depression and alcohol disorders and virtual co-location of doctoral-level mental health providers with prompt access through tele-video or telephone communication."
46098920|NCT01005043|Radiation|heavy ion radiotherapy (C12)|"Desired target of Heavy ion radiotherapy is 60 to 66 Cobalt Gray Equivalent (GyE), whenever possible. It is applied through 1 - 3 isocenter treatment portals. Dose distributions are calculated and dose volume histograms (DVH) are generated. A α/β-ratio of 2 is used for biological plan optimization. Fractionation is planned to be equivalent to 6 x 3 GyE / week. Dosage to organs at risk is minimized. Treatment continues for 20 to 22 days or until one of the following criteria applies:~Other illness that prevents further administration of treatment, Patient or legal guardian decides to withdraw from the study, or changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator."
45679930|NCT04605861|Drug|Placebo|Placebo Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Placebo Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.
46098921|NCT02636192|Drug|No Intervention|This is an observational study and participants did not receive any intervention in this study.
46098922|NCT02713139|Drug|Clotrimazole + Metronidazole|Vaginal cream with Clotrimazole 200mg and Metronidazole 0,75%. Apply once per day, before bedtime, for 5 (five) days.
46098923|NCT02713139|Drug|Metronidazole|Vaginal gel with Metronifdazole 100mg/g. Apply once per day, before bedtime, for 10(ten) days.
46098924|NCT02713139|Drug|Clotrimazole|Vaginal cream with Clotrimazole 20mg/g. Apply once per day, before bedtime, for 3 (three) days.
46098925|NCT02634944|Diagnostic Test|Vestibular Ocular Motor Screening Tool (VOMS)|Vestibular Ocular Motor Screening Tool (VOMS)
46098926|NCT00853827|Drug|Placebo|Placebo
46098927|NCT00853827|Drug|Aliskiren|300 mg
45683850|NCT03028623|Procedure|Salpingectomy|Bilateral salpingectomy will be performed instead of standard tubal ligation as sterilization during cesarean section.
45683851|NCT03028623|Procedure|Tubal ligation|Standard tubal ligation by either Parkland or Pomeroy technique will be performed at cesarean section
46013109|NCT04519190|Diagnostic Test|Routine practice|Perform pulse palpation and also ECG if irregular rhythm is found.
46098928|NCT01005121|Drug|colchicine|2mg, per-os, once daily for six months
46098929|NCT02711579|Drug|Celecoxib|
46098930|NCT02711579|Drug|Placebo|
46098931|NCT02635178|Behavioral|Cognitive Anxiety Sensitivity Treatment|Cognitive Anxiety Sensitivity Treatment (CAST) is a computerized treatment designed to model the educational and behavioral techniques used in anxiety treatments. The psychoeducational component focuses on the nature of stress and its effects on the mind and body. CAST was designed to dispel myths concerning the immediate dangers of stress on cognitive processes. Individuals are taught that psychological arousal from stress is not dangerous and that they may have developed a conditioned fear to these sensations, as indicated by their elevated levels of AS cognitive concerns. In addition to psychoeducation, interoceptive exposure exercises will be introduced to correct the conditioned fear response. The program will demonstrate exercises that elicit sensations consistent with AS cognitive concerns.
46098932|NCT02635178|Behavioral|Physical Health Education Training|The Physical Health Education Training (PHET) control condition was designed to control for the effects of general education provided in the CAST condition. Participants will be presented with information regarding the importance and benefits of maintaining a healthy lifestyle. The program will discuss diet, alcohol and water consumption, exercise, sexual health, and sleep. PHET will instruct the participant how to monitor their daily health habits in order to achieve a healthy lifestyle. PHET will take approximately 45 minutes to complete. Based on the findings of Schmidt and colleagues (in press), this intervention does not appear to exert a strong effect on AS.
46098933|NCT00611195|Drug|propofol, remifentanil|propofol 3micrgr/ml (TCI plasma concentration Kataria model) versus propofol 3micrgr/ml and remifentanil 0.05microgr/kg/min
46098934|NCT02636114|Procedure|scaling and root planing|Scaling and root planing at baseline , checked clinical parameter and serum renal function markers at baseline and 1 month after therapy
46098935|NCT01003015|Drug|BAY73-4506|160 mg BAY73-4506
46098936|NCT02713061|Drug|TAK-850|TAK-850 injection
46013110|NCT04822766|Procedure|Hematopoietic stem cell transplantation|patients will undergo allo-HSCT after consolidation therapy (or completion of other appropriate non-palliative strategy) according to standard procedures of the transplant center (choice of donor, conditioning regimen, GVHD and infection prophylaxis). The use of novel therapies (such as sorafenib, midaustorine, venetoclax, etc.) will be allowed as post-transplantation maintenance strategy.
46013111|NCT04822766|Drug|Best chemotherapy treatment|patients will be treated according to the standard procedures of the treating center for this type of population. Patients will receive the best available treatments (including additional conventional chemotherapy or other non-palliative therapies such as 5-azacytidine, decitabine, venetoclax, midaustorine, enasidenib, etc.).
46013112|NCT05139953|Other|No intervention|No intervention
46013113|NCT04445961|Diagnostic Test|Respiratory mechanics measurement|Measurement of peak inspiratory pressure, plateau pressure, calculation of static compliance and driving pressure
46013114|NCT04445961|Diagnostic Test|Gas exchange measurement|Measurement of arterial oxygen and tension and arterial dioxide tension, calculation of arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio and alveolar dead space
45683852|NCT01686633|Drug|Fluticasone Furoate/ Vilanterol 200/25 mcg|Fluticasone furoate/ vilanterol will be available as 200/25 mcg Novel dry powder inhaler (NDPI) with 30 doses per device and 200/25 mcg per actuation
45837466|NCT00605202|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg a day for 14 days.
45837467|NCT00605202|Dietary Supplement|Licorice|Licorice candy 32 grams a day for 14 days.
45683853|NCT01686633|Drug|Fluticasone Furoate/ Vilanterol 100/25 mcg|Fluticasone furoate/ vilanterol will be available as 100/25 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
45837468|NCT03548454|Drug|Duloxetine|Open label prescription
45837469|NCT03548454|Drug|Desipramine|Open label prescription
45837470|NCT00605358|Behavioral|Open Door intervention|"Open Door intervention subjects will:~receive an evaluation~receive a referral to a local mental health provider~identify barriers, set goals and problem-solve to achieve a mental health evaluation using available resources."
46013115|NCT04828265|Biological|Aldafermin|Single dose of aldafermin
46013116|NCT01346592|Biological|Trivalent split influenza vaccine (TIV)|
46013117|NCT01346592|Biological|MF59-adjuvanted trivalent influenza vaccine (aTIV)|
46013118|NCT01346592|Biological|Licensed comparator trivalent split influenza vaccine (comparator TIV)|
46013119|NCT05139758|Diagnostic Test|Biodex Balane System|The Biodex balance system will be used for the assessment of static and dynamic balance of all children in the current study.
46013120|NCT04822610|Procedure|interscalene block|peripheral nerve block
46013121|NCT04822610|Procedure|suprascapular block + axillary block|peripheral nerve block
46013122|NCT04516928|Diagnostic Test|Anti-SARS-CoV2 Serology|The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.
46013123|NCT04516928|Other|Questionnaire|A questionnaire on socio-demographical status, health status and lifestyle habits during the pandemic will be filled by the participants at Day 0.
46013124|NCT01346514|Behavioral|Intensive Addiction/Housing Case Management|AHCM provided: 1) support in obtaining/maintaining housing through education about resources, coordination with VA and community housing program providers, assistance in establishing housing program eligibility, and problem-solving around threats to housing stability; 2) support for SUD and related issues that affect housing status through treatment engagement/re-engagement, referrals for needed services (e.g. psychiatric, medical, vocational), and addressing substance use issues proactively; 3) promotion of residential stability through Life Skills Training, which was designed to improve key skills (room and self-care, money management, and community participation).
46013125|NCT01346514|Behavioral|Housing Support Group|The HSG focused on gaining support from fellow study participants and learning from those who successfully obtained housing. Group facilitators provided education about housing resources and assistance with housing-related issues.
46013126|NCT01193335|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
46013127|NCT01193335|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
45464168|NCT01199107|Behavioral|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
45464169|NCT01199107|Behavioral|Exercise|30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
45837471|NCT05245578|Drug|KX01 ointment 1%|A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.
46013128|NCT02893995|Drug|Slow Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
46013129|NCT02893995|Drug|Rapid Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
46013130|NCT01342887|Drug|cyclosporine|Given IV
46013131|NCT01342887|Drug|pravastatin sodium|Given PO
46098937|NCT02635100|Other|CPAP machine with MNT algorithm|"The multinight (MNT) algorithm will be evaluated on patients with Obstructive Sleep Apnea (OSA) over multiple nights while using CPAP in the home for a total of 45 days. In particular the main goal is to assess the behavior of the two main stages of the algorithm:~Fast Track (FT) stage. Assesses if the algorithm reliably and timely reaches approximate therapeutic pressure levels.~Slow Titration (ST) stage.Assesses if data samples are appropriately collected in a pressure range so that the therapeutic pressure can be inferred according to the algorithm proposed.~Five days with standard auto titration.~MNT algorithm : 7 days (maximum) with Fast Track mode, 27 days (maximum) in Slow Titration mode. After PMNT is found, the device remains at PMNT for 5 sessions. Total approximately 45 days."
46098938|NCT02711657|Other|Fibrocyte measurement and lung function test.|
46098939|NCT01008709|Device|Teleflex HemoLock clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
46013132|NCT01342887|Drug|mitoxantrone hydrochloride|Given IV
46013133|NCT01342887|Drug|etoposide|Given IV
45464170|NCT01199107|Behavioral|Wellness Intervention|30 minutes of wellness education prior to Prolonged Exposure
45464171|NCT03939299|Procedure|OCT|Patients with coronary chronic total occlusion received successful stenting. Optimal coherence tomography imaged immediately and at 9-12 months after the index procedure to explore long-term vascular response and healing profile.
45464172|NCT01199185|Behavioral|Smoking Cessation|All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT).
45837472|NCT05245578|Drug|Placebo ointment|A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.
46013134|NCT01342887|Procedure|bone marrow aspiration|Correlative studies
46013135|NCT04445415|Diagnostic Test|COVID-19 antibodies testing|antibodies aganist COVID-19 detected in the serum of patients
46013136|NCT01342341|Drug|Parafon Forte|"Drug: Parafon Forte administered at study visit~Other: Placebo administered at study visit"
46013137|NCT01340664|Drug|Canagliflozin 50 mg|One canagliflozin 50-mg capsule taken orally twice daily with a meal for 18 weeks
46013138|NCT01340664|Drug|Placebo|1 placebo capsule taken orally twice daily with a meal for 18 weeks
46013139|NCT01340664|Drug|Canagliflozin 150 mg|1 canagliflozin 150-mg capsule taken orally twice daily with a meal for 18 weeks
46013140|NCT01340664|Drug|Metformin|The patient's stable daily dose of Metformin background therapy should be continued throughout the study.
46013141|NCT04824014|Diagnostic Test|4FMFES-PET|Intravenous 4FMFES injection, followed with PET imaging
46013142|NCT01340625|Drug|Norethindrone/Ethinyl Estradiol|0.4 mg/35 mcg Chewable Tablets
46013143|NCT01340625|Drug|Ovcon® 35 Fe|0.4 mg/35 mcg Chewable Tablets
46013144|NCT04823468|Dietary Supplement|Abbott®Ensure|Abbott®Ensure: 55.8 g each time, three times a day, from the beginning to the end of radiotherapy
46013145|NCT04823468|Radiation|Intensity Modulated Radiation Therapy|The prescribed dose was 68-76 Gy to Planning target volume of the primary tumor (PTVnx), 66-70 Gy to Planning target volume of the cervical lymph node (PTVnd), 60-64 Gy to planning target volume 1 (PTV1), and 50-54 Gy to planning target volume 2 (PTV2) in 30-33 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
46013146|NCT04823468|Drug|cisplatin|80-100 mg/m² cisplatin given intravenously every 3 weeks concurrently with radiotherapy.
46013147|NCT04511273|Drug|Follow up of female sexual function|Mirabegron 50mg once daily for treatment of overactive bladder symptoms
46013148|NCT01340196|Drug|tenofovir/BI 201335|tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through 22 with last dose on morning of day 22
45464173|NCT01199185|Behavioral|Smoking Cessation plus Weight Loss|All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT). Participants in the Intervention Group will also receive a Behavioral Weight Loss/ Weight Gain Prevention Intervention delivered via interactive technology. The Intervention group will receive 16 weekly webinar sessions beginning 7 weeks after randomization via Cisco WebEx. The webinar sessions will present the behavioral weight loss/ weight gain prevention program. After the 16 weekly sessions, the webinar sessions will then be scheduled monthly for the next 6 months then quarterly thereafter for 12 months.
46013149|NCT04827212|Behavioral|Companion|"Companion integrates wearable sensing with the smartphone to develop a behavior-aware, virtual system that uses a human-in-the-loop approach to enable meaningful two-way communication. Companion builds rich models of typical behavior using sensors and context sensitive ecological momentary assessment to deliver intervention components and behavior change strategies using socially engaging, contextually salient, and tailored text-message conversations in near-real-time."
46013150|NCT04826744|Other|Standard dermatology consultation|"with clinical examination, score filling such as SCORAD and DLQI~Standard Allergy consultation, with clinical examination, research of atopic or allergic personal and familial history~Allergy skin testing: patch tests with the Standard European Battery and with some products bring by the patient if necessary, skin prick tests with aero allergens. Two reading of the patch tests will be performed, at H48 and H72.~ophthalmologic consultation with slit lamp examination and OSDI (self questionnaire)"
46013151|NCT04137315|Device|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
46013152|NCT05139719|Drug|HEC585|HEC585 Tablets，once daily
46013153|NCT05139719|Drug|Placebo|Placebo，once daily
46013154|NCT02893332|Radiation|Radiation: SBRT|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL during a 1-week run-in period after which SBRT will be delivered to the all oligometastatic lesions concurrently with the TKI. The SBRT dose will be , ranging from at 25Gy (5 Gy per fraction) to 40 Gy (8 Gy per fraction).
46013155|NCT02893332|Drug|TKI (Gefitinib or Tarceva )|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL, no local therapy apply to oligo-metastatic sites.
46013156|NCT04443699|Behavioral|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
46013157|NCT04328493|Drug|Chloroquine phosphate|"Each chloroquine tablet contains 250mg chloroquine phosphate (or 150mg chloroquine base). Chloroquine treatment for patient is weight-based dosing.~Chloroquine will be administered orally, as tablets. For unconscious patients chloroquine can be crushed and administered as a suspension via a nasogastric tube.~The total duration of treatment with Chloroquine will be 10 days"
46013158|NCT02893449|Behavioral|Social adaptation|"Questionnaire to fill-in.~The structured program of preoperative cognitive remediation is divided in 3 parts: one interview with the patient to do a building of the subjective theories (difficulties due to the disease, hope relative to the intervention), a study meeting of the cognitive remediation possibilities and a cognitive remediation meeting with the patient. The spouse will be included in the program."
46098940|NCT01008709|Device|Aesculap U-clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
46098941|NCT02639156|Dietary Supplement|AYMES LONDON|AYMES LONDON is a powder, designed to be mixed with 75ml whole milk to make a dessert style ONS. When made-up, AYMES LONDON provides 303kcal (2.2kcal/ml) and 11.2g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
45837473|NCT00605826|Device|NASHA/Dx (Solesta) Gel|Injection of 4 x 1ml of NASHA/Dx Gel at the start of the blinded phase.
46013159|NCT02893449|Behavioral|Intensive care management|In this group, the structured program of the SICRPPD group will be replaced by 3 unstructured psychiatric interviews during which patients will be assessed for their perception of the disease and the upcoming surgery. This group will allow to control for the intrinsic effect of the preoperative management independently of the remediation itself.
46013160|NCT02893449|Procedure|Deep brain stimulation|
46013161|NCT04508270|Behavioral|Early mobilization|Mobilization as soon as patients can, which is not limited on walking
46013162|NCT04396587|Drug|Sufentanil|Sufentanil(0.1μg/kg), Hydromorphone(20μg/kg), or Oxycodone(60μg/kg) was administered before anesthesia induction.
46013163|NCT04396587|Drug|Hydromorphone|Sufentanil(0.1μg/kg), Hydromorphone(20μg/kg), or Oxycodone(60μg/kg) was administered before anesthesia induction.
46013164|NCT04396587|Drug|Oxycodone|Sufentanil(0.1μg/kg), Hydromorphone(20μg/kg), or Oxycodone(60μg/kg) was administered before anesthesia induction.
46013165|NCT05139641|Behavioral|Counseling to preserve fertility|Counseling to preserve fertility VS Control group
46013166|NCT04329156|Other|Digitally Flip Technique|A prefabricated shell will be made then after implant placement, the shell will be attached to a plastic abutment using flowable composite to make a customized healing abutment.
46013167|NCT04329156|Other|Stock Healing Abutment|After implant placement, a stock healing abutment will be placed onto the implant and screwed on. It will be selected to be 1-2 mm above the gingival margin and slightly smaller in diameter than the intended final restoration.
46013168|NCT04443231|Device|Optical Coherence Tomography Angiography|AngioVue (Optovue, Fremont, CA, USA) was used to capture the OCTA images before ICL surgery and at 3 months follow-up.
46098942|NCT04117893|Drug|Duloxetine|Participants will start on duloxetine 30 mg per day for one week and then titrated up to duloxetine 60mg per day for 23 weeks.
46098943|NCT04117893|Drug|intra-articular injection of corticosteroid and hyaluronic acid|Participants will receive a 3.5 ml intra-articular injection of 30mg of hyaluronic acid plus 10mg of triamcinolone acetonide.
46098944|NCT02615574|Biological|αDC1 vaccine|Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
46013169|NCT01600118|Device|Extracorporeal shockwave therapy|1000 impulses
46098945|NCT02615574|Drug|CKM|Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
46013170|NCT01600118|Device|No extracorporeal shockwave|0 impulses, acoustic effect
46098946|NCT04485767|Behavioral|Progressive Resistance Training Exercise|Progressive Resistance Training Exercise 2x weekly for 6 months.
46098947|NCT04485767|Behavioral|Flexibility and Balance Exercise|Flexibility and Balance Exercise Training Exercise 2x weekly for 6 months.
46098948|NCT01003093|Biological|50 microgram antigen (Ag85B + ESAT-6)|0.5 mL suspension for injection x 2 with 2 months interval
46013171|NCT04504799|Device|Body composition measurement with HAG-BIA scale|Bio-impendance analysis
46013172|NCT04395963|Device|Tobii Pro Glasses 50 Hz wearable wireless eye tracker|This system can measure eye movements using cameras integrated into the eyeglasses which record the corneal reflection of infrared lighting to track pupil position, mapping the subject's focus of attention on video recordings of the subject's field of vision (gaze).
46013173|NCT05139524|Other|Evidence of past or recent RVF exposure|Detection of RVF exposure.
46098949|NCT01003093|Biological|50 microgram antigen (Ag85B + ESAT-6) + 100 nmol KLK + 4 nmol ODN1a|0.5 mL suspension for injection x 2 with 2 months interval
46098950|NCT01003093|Biological|50 microgram antigen (Ag85B + ESAT-6) + 500 nmol KLK + 20 nmol ODN1a|0.5 mL suspension for injection x 2 with 2 months interval
46098951|NCT04032938|Procedure|extracorporeal circulation during cardiac surgery|We will observe the cardiopulmonary bypass status and time of patients undergoing cardiac surgery and extracorporeal circulation due to their medical needs.
46098952|NCT02615652|Other|no intervention|no intervention, observational study
46098953|NCT01003171|Drug|MCS-2 soft-gel capsule|MCS-2 30 mg/day
46013174|NCT04442217|Behavioral|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
46013175|NCT04395651|Device|PET/CT|It is a prospective clinical study that will include patients known to have lung cancer and referred to nuclear medicine unit to perform 18F-FDG PET/CT for staging and therapy planning as well as patients referred for assessment of response of therapy and restaging.
46013176|NCT01327599|Drug|Travoprost 0.004%+Timolol 0.5% ophthalmic solution|Fixed dose combination topical ocular agent preserved with polyquaternium-1 (POLYQUAD)
46013177|NCT05139407|Diagnostic Test|Teaching intervention|Different teaching methods are used to teach the experimental group and the control array in the classroom.
46013178|NCT04502147|Procedure|Laparoscopic Splenectomy|Laparoscopic splenectomy by ligating the splenic artery
46013179|NCT04328415|Radiation|Cerebral scintigraphy|Radioactive tracer 99mTc-DTPA
46013180|NCT04395534|Procedure|Complete mesocolic excision|
46013181|NCT04395066|Diagnostic Test|CD55|CD55 is an important complement regulatory protein that inhibits C3 and C5 activation by blocking the formation and accelerating the decay of new C3 and C5 convertases, both of which mediate downstream actions of all three complement activation pathways, and CD55 protects host cells from complement attack.
46013182|NCT04498871|Drug|Nilotinib|Nilotinib is recommended to be administered orally on a continuous schedule at a dose of 400 mg twice daily. The patient should be instructed to take each morning dose of nilotinib 2 hours after a light breakfast (e.g., toast and jam), with no oral intake other than water for 1 hour after dosing. It is recommended that the patient take nilotinib doses every 12 hours with a glass of water. The evening dose of nilotinib should be taken at least 2 hours after dinner with no oral intake other than water for 1 hour after dosing.
46013183|NCT02893215|Other|Screening for silent AF with Zenicor thumb-ECG|Each patient has a device for 14 days, which monitorizes their heart rhythm. They send the ecg four times daily.
46013184|NCT04439877|Behavioral|Peri-implant disease diagnosis|Diagnosis of peri-implant disease
45464174|NCT01215071|Procedure|limited lymphadenectomy|Field 5 (Group external iliac rigt) Field 7 (Group external iliac left) Field 9 (obturatorical Group right) Field 11 (obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
46013185|NCT04497896|Other|Repair of open globe injury|repair of corneal, corneoscleral, or scleral wounds
46098954|NCT05428241|Behavioral|Assigned Interventions|Behavioral: 6 sessions of Motivational Interviewing and 3-month follow-up. 6 sessions of Motivational Interview will be applied to the working group. All sessions will be in the form of face-to-face meetings. Each interview will take an average of 45-60 minutes. With this intervention, it was aimed to increase the levels of coping with motivational interviewing, functionality, adherence to treatment and quality of life in bipolar disorder patients. Study data consists of personal information form, Morisky Treatment Adherence Scale (MMAS), World Health Organization Quality of Life Scale, Short Form (WHOQOL-BREF), Assessment of Coping Attitudes Inventory (COPE), Bipolar Disorder Functioning Questionnaire (BDFQ). Data will be analyzed pre-intervention, post-intervention and 3 months post-intervention. A drug and device will not be administered to participants.
46098955|NCT02639000|Procedure|Embryo transfer|Embryo transfer of maximum of 2 embryos at cleavage or blastocyst stage
46098956|NCT05245513|Behavioral|Recovery Community Center Linkage (RCCL)|A certified recovery coach will meet with participants to educate them on recovery community centers and link them to one, with the aid of a facilitated connection to a volunteer recovery community center member (e.g., calling a standby peer, scheduling a meet-up at the center).
46098957|NCT05245513|Behavioral|Control Condition (CC)|A certified recovery coach will meet with participants to educate them on recovery support services more broadly, and will provide them with a list of resources.
46098958|NCT02708693|Drug|Triamcinolone Acetonide|ultrasound-guided injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort)
46098959|NCT02708693|Device|thermoplastic wrist splint|thermoplastic wrist splint with wrist placed in a neutral position
46098960|NCT02708693|Drug|lidocaine hydrochloride|ultrasound-guided injection using 1 ml of 2% lidocaine hydrochloride (Xylocaine)
46098961|NCT02638922|Drug|Estradiol|Estradiol containing compounds administered orally in a non-randomized manner.
46098962|NCT01005199|Drug|everolimus|Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily
46098963|NCT01005199|Drug|sorafenib tosylate|Sorafenib 2 x 400 mg daily
46098964|NCT02711189|Drug|Oxytocin|Oxytocin nasal spray given in dose 80
46098965|NCT02711189|Other|Placebo|
46098966|NCT02635802|Drug|Remifentanil|"a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time >1min,then 5μg/kg·h pumping if the operation can not be done in 5 minutes.~Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after the loading.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5 μg/kg·h every 2-5min."
45464175|NCT01215071|Procedure|extended lymphadenectomy|Field 1 (paracaval right) Field 2 (interaortocaval) Field 3 (paraaortal left) Field 4 (Group iliac artery right) Field 5 (Group external iliac rigt) Field 6 (Group iliac artery left) Field 7 (Group external iliac left) Field 8 (presacral) Field 9 (obturatorical Group right) Field 10 (deep obturatorical Group right) Field 11 (obturatorical Group left) Field 12 (deep obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
46098967|NCT02635802|Drug|Lidocaine|lidocaine 100-400mg,local anesthesia.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after local anesthesia.We should maintain the CPOT≤2 and RASS 0～2.
46098968|NCT02635802|Drug|Remifentanil+Lidocaine|a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time >1min,then 5μg/kg·h remifentanil pumping immediately if the operation can not be done in 5 minutes.then local anesthesia with lidocaine 100-400mg.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after anesthesia.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5μg/kg·h every 2-5min.
46098969|NCT02635802|Drug|Midazolam|midazolam is an adjuvant drug.we should maintain the CPOT≤2 and RASS 0～2,if lidocaine is already used up to 400mg or the pumping rate of remifentanil is already 7.5μg/kg·h,then we should use midazolam 3mg, intravenous injection slowly.
46098970|NCT00853749|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL intramuscular injection
46098971|NCT00853749|Procedure|Blood draw|Collection of 10 mL of blood
45464176|NCT01212887|Biological|MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes|
45464177|NCT01212887|Biological|aldesleukin|
45464178|NCT01212887|Drug|cyclophosphamide|
45464179|NCT01212887|Drug|fludarabine phosphate|
46013186|NCT05139329|Diagnostic Test|Imaging|To better understand the prevalance of further imaging for evaluation of myocarditis, all patients with negative workup will be included and see what number of patients undergo further CMRI, FGD-PET, or speckle tracking echocardiography. Patients will then be categorized as those with myocarditis with positive diagnosis, negative diagnosis or unknown.
46013187|NCT04497194|Other|not applicable (observational study)|not applicable (observational study)
46013188|NCT01193257|Drug|Orteronel|Orteronel tablets
46013189|NCT01193257|Drug|Prednisone|Prednisone tablets
46013190|NCT01193257|Drug|Orteronel Placebo|Orteronel placebo-matching tablets
45464180|NCT01212887|Other|laboratory biomarker analysis|
46013191|NCT02893371|Drug|Lithium Carbonate|Exposure to all dosages and delivery forms.
46013192|NCT02893371|Drug|Lamotrigine|Exposure to all dosages and delivery forms.
46013193|NCT02893371|Drug|Valproic Acid|Exposure to all dosages and delivery forms.
46013194|NCT02893371|Drug|Oxcarbazepine|Exposure to all dosages and delivery forms.
46013195|NCT02893371|Drug|Carbamazepine|Exposure to all dosages and delivery forms.
46013196|NCT02893371|Drug|Ziprasidone|Exposure to all dosages and delivery forms.
46013197|NCT02893371|Drug|Risperidone|Exposure to all dosages and delivery forms.
46013198|NCT02893371|Drug|Quetiapine|Exposure to all dosages and delivery forms.
45464181|NCT01212887|Other|pharmacological study|
45679931|NCT04600414|Other|Collaborative Care for Mental Health Disorders|CoCM is based on six key principles: 1) evidence-based, 2) measurement-based, 3) team-based, 4) population-based, 5) patient-centered, and 6) accountable. CoCM supports the delivery of evidence-based pharmacological and psychosocial treatments. CoCM is measurement-based with screening and monitoring of patient-reported outcomes over time to assess treatment response and facilitate treatment adjustments. CoCM is team-based led by a primary care provider with support from a care manager in consultation with a psychiatrist who provides treatment recommendations for patients who are not responding. CoCM is population-based whereby a registry is used to monitor treatment engagement and facilitate the identification of patients falling through the cracks. CoCM is patient-centered with proactive outreach to engage and activate patients. Collaborative care is accountable with continuous quality improvement to meet clinic performance benchmarks.
46098972|NCT02708771|Drug|Polyunsaturated fatty acids omega-3|4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.
46098973|NCT02708771|Drug|Placebo|4 daily capsules of similar appearance and flavor without active ingredient
46098974|NCT05093569|Device|K'watch|Patients
46098975|NCT02708615|Other|Type of speculum vaginal insertion method|Speculum insertion type will either be vertical rotation (as per common practice in Canada) or straight horizontal insertion
46098976|NCT01008865|Procedure|Studer Pouch orthotopic urinary diversion|
46098977|NCT01008865|Procedure|T-Pouch orthotopic urinary diversion|
46098978|NCT00657410|Drug|dexamethasone|
46013199|NCT02893371|Drug|Olanzapine|Exposure to all dosages and delivery forms.
46013200|NCT02893371|Drug|Aripiprazole|Exposure to all dosages and delivery forms.
46013201|NCT02893371|Drug|Fluoxetine / Olanzapine|Exposure to all dosages and delivery forms.
46013202|NCT02893371|Drug|Haloperidol|Exposure to all dosages and delivery forms.
46013203|NCT02893371|Drug|Perphenazine|Exposure to all dosages and delivery forms.
46013204|NCT02893371|Drug|Clozapine|Exposure to all dosages and delivery forms.
46098979|NCT00657410|Drug|prednisone|
46098980|NCT00657410|Procedure|quality-of-life assessment|
46013205|NCT02893371|Drug|Asenapine|Exposure to all dosages and delivery forms.
46098981|NCT01009021|Drug|potassium diclofenac|potassium diclofenac 50 mg, one tablet 45 minutes before laser treatment
46098982|NCT01005433|Drug|Dexmedetomidine|The dexmedetomidine groups (n = 20 for each) will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2, 4, and 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure, when their infusion rate will be decreased by 50% until 20 min after extubation.
46013206|NCT02893371|Drug|Lurasidone|Exposure to all dosages and delivery forms.
46013207|NCT02893371|Drug|Paliperidone|Exposure to all dosages and delivery forms.
46013208|NCT02893371|Drug|Mirtazapine|Exposure to all dosages and delivery forms.
46013209|NCT02893371|Drug|Bupropion|Exposure to all dosages and delivery forms.
46013210|NCT02893371|Drug|Desvenlafaxine|Exposure to all dosages and delivery forms.
46013211|NCT02893371|Drug|Duloxetine|Exposure to all dosages and delivery forms.
46013212|NCT02893371|Drug|Venlafaxine|Exposure to all dosages and delivery forms.
46013213|NCT02893371|Drug|Citalopram|Exposure to all dosages and delivery forms.
46013214|NCT02893371|Drug|Escitalopram|Exposure to all dosages and delivery forms.
46013215|NCT02893371|Drug|Fluoxetine|Exposure to all dosages and delivery forms.
46013216|NCT02893371|Drug|Fluvoxamine|Exposure to all dosages and delivery forms.
46013217|NCT02893371|Drug|Paroxetine|Exposure to all dosages and delivery forms.
45464182|NCT04522531|Other|Open cinetic chain shoulder exercise on unstabil ground|Open cinetic chain shoulder exercise will be performed on BOSU which provides an unstabil ground. This exercises will be include PNF (flexion-adduction-external rotation pattern), PNF (flexion-abduction-external rotation pattern), scapular plan abduction, external rotation while keeping shoulder in 45 degree abduction. The weight which used during exercise planned according to individuals body weight: 0-59 kg: 3 kg; 60-69 kg: 4 kg; 70-85 kg: 5Kg. Exercises will be carried out in 3 phases consisting of concantric, isometric and eccentric phases. Each phase will be lasted 3 seconds. The time will be checked by using a metronome.
45464183|NCT01215149|Biological|Ad35-ENV vaccine|Recombinant adenovirus serotype 35 vector vaccine 5x10^10 vp, delivered IM
46098983|NCT01005433|Drug|Placebo|The placebo group (n = 20) will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, at 30 min before induction of anesthesia. The placebo solution will be looked identical and their infusions will be continued until skin closure, when the infusion rate will be decreased by 50% until 20 min after extubation. The test solution will be prepared by one anesthesiologist before induction of anesthesia.
46098984|NCT01003327|Device|I-gel|intubation with I-gel airway
46098985|NCT01003327|Device|LMA-Unique|LMA-Unique airway is inserted first, then the I-gel
45464184|NCT01215149|Biological|Ad26.ENVA.01 vaccine|Recombinant adenovirus serotype 26 vector vaccine, 5x10^10 vp delivered IM
45464185|NCT01215149|Biological|Placebo Control|Colorless 10mm Tris/HCl buffer
45464186|NCT03843307|Device|Avazzia Tennant Biomodulator® PRO|High-voltage pulsed current (HVPC) electrical stimulation with Reactions and BEST™ (Bio-Electric Stimulation Technology) microcurrent that measure and change with tissue electrical characteristics.
45464187|NCT04961281|Drug|Dexmedetomidine|injection of Dexmedetomidine ( 10 microgram/kg) + 10 cc saline injection nearby median nerve as hydro-dissection
45464188|NCT04961281|Drug|Triamcinolone|injection of triamcinolone ( 40 mg) + 10 cc saline injection nearby median nerve as hydro-dissection
45464189|NCT03935789|Behavioral|BLAST|12-week self-guided intervention using a web-based platform
45464190|NCT03844477|Procedure|single-injection QLB(quadratus lumborum block)|"Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major without continuous local infusion~Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan~Device: PAJUNK StimuLong Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine given immediately after the correct position of the tip of the needle has been verified."
45464191|NCT03844477|Procedure|Placebo control|"Inject 0.4ml/kg saline between quadratus lumborum and psoas major without continuous local infusion~Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan~Device: PAJUNK StimuLong Drug: single dose 0.4ml/kg 0.9% NS. given immediately after the correct position of the tip of the needle has been verified."
45464192|NCT01212965|Drug|Selenium|400 μg once a day for 6 months by mouth
45464193|NCT03960697|Behavioral|walk out from operating room|After the surgery of laparoscopic total or partial nephrectomy， patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb
46013218|NCT02893371|Drug|Sertraline|Exposure to all dosages and delivery forms.
46013219|NCT02893371|Drug|Vilazodone|Exposure to all dosages and delivery forms.
46013220|NCT02893371|Drug|Doxepin|Exposure to all dosages and delivery forms.
46013221|NCT04495595|Other|No intervention|There is no intervention due to the observational, cross-sectional design of the study
46013222|NCT00591552|Device|Harmonic ACE23P Scalpel|Lymph node dissection
46013223|NCT00591552|Device|Electrocautery|
45464194|NCT02529449|Drug|Placebo|Oral
45464195|NCT02529449|Drug|ASP1941|Oral
45464196|NCT03939377|Other|Questionnaire and treatment|EVA questionnaire every day for 7 days. treatment (real or simulated) at J3 and J5
45464197|NCT03841123|Other|Dietary Counseling|"The intervention will consist of an individualized, face-to-face, 20 to 30 minute counseling session to mothers by trained health workers who will address healthy eating practices during the first two years of life. A printed, colorful and illustrated material will be used to assist mothers in appropriate food choices, mainly to avoid the introduction of sugar and ultra-processed foods. In addition, they will receive a booklet which addresses the Ten Steps of Healthy Feeding for children from Birth to Two years of life. The research team will focus on Step2: Do not give added sugar or foods with added sugar, and Step8:Do not offer ultra-processed foods as candies and soft drinks. To reinforce the intervention, mothers will receive telephone calls up to the infant reach six months."
46013224|NCT02886559|Drug|Chidamide plus DCAG regimen|chidamide, decitabine, aclarubicin, cytarabine and G-CSF
46013225|NCT05138978|Drug|Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer|Toothpaste
45464198|NCT01216709|Dietary Supplement|ferrous sulfate|6.3 mg iron from iron drops and 0.3 mg iron from infant formula with no added iron (0.5 mg iron/L) for 45 days
46013226|NCT05138978|Drug|Colgate Cavity Protection|Toothpaste
46013227|NCT04495049|Device|Alcon Vivity or Vivity Toric IOL|Patients who previously underwent cataract surgery with the Alcon Vivity or Vivity Toric IOL in both eyes.
46013228|NCT04391400|Diagnostic Test|nasal pharyngeal (NP) swab samples|These donors will be from a population of patients who are already providing nasal pharyngeal (NP) swab samples in universal transport media (UTM) for COVID-19 testing at LabPMM LLC.
46098986|NCT04162262|Other|Instrumental-assisted soft tissue mobilization (IASTM)|Instrumental-assisted soft tissue mobilization (IASTM) will consist of treatment focused on the plantar surfaces of foot, posterior heel, and lower leg. The IASTM will be implemented using Graston Technique Instruments by clinicians trained and certified in the technique. Each 10-minute treatment will consist of two phases: 1) six-minute static phase, which includes tissue status screening and soft tissue mobilization, and 2) four-minute dynamic tissue mobilization phase. The treatment will focus on the web spaces of each toe plantarly, the metatarsal heads, the spaces between metatarsals, the medial and lateral plantar fascia borders, plantar fascia proximal origin, the heel, and the lower leg muscle groups. The targeted soft tissues are the plantar fascia, ankle plantar flexors, heel fat pad, Achilles tendon, and the gastrocnemius-soleus complex.
46098987|NCT04162262|Other|High-Load Strength Training|Participants will perform a heel raise exercise used by Rathleff et al (2015). The exercise will be performed twice daily. While standing with the forefoot on a step, the toes will rest on a partially folded towel, placing them in a maximally dorsiflexed position. The exercise will consist of a maximum ankle plantar flexion followed by maximal dorsiflexion. The concentric plantar flexion and eccentric lowering phases will be 3 seconds, with a 2 second isometric pause in between. The exercise will be performed unilaterally if tolerated by the subject. Otherwise, a bilateral calf raise will be performed until the subject is able to perform the unilateral version. The exercise will be performed every other day and progressed throughout the trial as described by Rathleff and colleagues.
46098988|NCT04162262|Other|Plantar Flexor and Gastrocnemius Stretching|For the plantar flexor stretch (DiGiovanni et al, 2006), subjects will sit and cross the affected leg over the contralateral leg. Placing the affected side fingers on the plantar toes, distal to the metatarsophalangeal joints, they will passively dorsiflex the toes until they feel stretching in the arch of the foot. Subjects will be instructed to hold this stretch for 10 seconds and repeat it 10 times. The gastrocnemius stretch will be performed in supine with a towel placed around the distal foot and the foot actively inverted. With the knee extended, the subject will flex the hip while passively dorsiflexing the foot using the towel. This stretch will be held for 30 seconds and repeated 3 times. Subjects will be asked to perform both stretches three times each day.
46098989|NCT01003405|Drug|KUC-7483|
46098990|NCT00654446|Drug|Rosuvastatin|
46098991|NCT00654446|Drug|Simvastatin|
46098992|NCT01003483|Drug|orlistat|Tablet,120mg,three times a day,three months
46098993|NCT00592839|Drug|SCE-B|0.3 mg or 0.625 mg SCE-B tablets daily plus matching placebo
46098994|NCT00592839|Drug|Placebo|Matching placebo for 0.3 mg and 0.625 mg tablets
45464199|NCT01216709|Other|iron-fortified infant formula (12.4 mg iron/L)|6.6 mg iron from iron-fortified infant formula (12.4 mg iron/L) for 45 days
45464200|NCT01216709|Other|iron-fortified infant formula (2.3 mg iron/L)|1.2 mg iron from iron-fortified infant formula (2.3 mg iron/L) for 45 days
45464201|NCT01216787|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
45464202|NCT01216787|Other|pharmacological study|
45464203|NCT01216787|Procedure|therapeutic conventional surgery|
46098995|NCT00911222|Other|non-interventional|non-interventional
46098996|NCT01009177|Drug|Bosentan|Bosentan 500 mg bid
46098997|NCT01009177|Drug|Placebo|Placebo
46098998|NCT00598832|Drug|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
46098999|NCT00598832|Drug|Adapalene Lotion Vehicle|Adapalene Lotion Vehicle will be applied topically to the face, once a day, for 12 weeks
46099000|NCT01003561|Procedure|spinal anesthesia for surgery|spinal anesthesia (T10) for elective TURP surgery
46099001|NCT04219787|Procedure|Long BPL LRYGB|LRYGB with an 180 cm BPL and an AL of 80 cm.
45464204|NCT01216787|Other|laboratory biomarker analysis|Correlative studies
46013229|NCT04391400|Diagnostic Test|peripheral blood draw|"From patients suspected of SARS-CoV-2 viral infections.~At least 2mL to 5mL of peripheral blood.~Collected in EDTA tubes.~Shipped to ambient LabPMM, LLC within 2 days.~Specimen Collections:~Collected at the same time as the NP specimen sent for COVID-19 testing.~Collected two to three weeks post the original patient's COVID-19 testing."
46013230|NCT04391166|Other|Non invasive visual acuity testing|This will be visual acuity at home and visual acuity in clinic both using an ETDRS chart.
46099002|NCT04219787|Procedure|Short BPL LRYGB|The second group will receive a standard LRYGB with a 80 cm BPL and a 180 cm long AL.
45464205|NCT05282251|Drug|Bupivacain|Intrapleural Nebulization of local anaesthetic
45464206|NCT01202383|Behavioral|Household-based water treatment with NADCC tablets|Study participants will be supplied with tablets and encouraged to use them for treating their water daily
45464207|NCT01202383|Behavioral|Household-based water treatment with placebo tablets|Study participants will be supplied with tablets and encouraged to use them for treating their water daily
45464208|NCT01116947|Other|Meals during hemodialysis accompanied by lanthanum carbonate to control phosphorus|Based on the hypothesis that the efficacy and potency of Fosrenol enables increasing dietary protein intake and provision of meals during dialysis treatment for improving nutritional status in malnourished dialysis patients with a low serum albumin (<4.0 g/dL) while serum phosphorus can be effectively controlled with the target range of 3.5 to 5.5 mg/dL
46013231|NCT04436484|Diagnostic Test|Peripheral blood sampling|Non-interventional study
46013232|NCT05138861|Drug|TP-03 (Lotilaner Ophthalmic Solution), 0.25%|A single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 1 and then twice a day (in the morning and in the evening, approximately 12 hours apart) starting on Day 2 for 40 consecutive days (Days 2 to 41). Thereafter, a single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 42, for a total of 82 consecutive doses administered in each eye.
46013233|NCT05138744|Other|Behavioral activation using virtual reality|The investigators will encourage behavioral activation (increase in the number and time of conducted activities) situating the person in motivating situations using virtual reality
46013234|NCT04390659|Procedure|myomectomy|The myomectomy was done by conventional technique but timing of myomectomy either before or after delivery of the baby varied between different cases .Infusion of oxytocin during the operation and for 24 h later.
46013235|NCT04493294|Radiation|Low dose whole lung radiotherapy for older patients with COVID-19 pneumonitis|Low dose whole lung radiotherapy may decrease the cytokines storm related to the viral infection and may improve survival by decreasing the need for artificial ventilation
46013236|NCT02893176|Drug|macitentan|
46013237|NCT02893176|Drug|placebo (for macitentan)|
46013238|NCT05138627|Other|oral cryotherapy|Ice application protocol developed by the researcher by scanning the literature was prepared by taking the opinions of 5 faculty members who are experts in their fields. Also, the chamber of physics engineers and the chamber of chemical engineers' opinion was taken for the necessary corrections or improvements regarding the chemical/physical structure of the ice and the method applied. In the content of the protocol, materials, preparation before intraoral ice application (written and visual), steps of intraoral ice application (written and visual), termination of intraoral ice application, recording of intraoral ice application, and situations to be considered are explained in detail respectively.
46013239|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
46013240|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
46013241|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
46013242|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
46013243|NCT01193218|Drug|BI 10773|BI 10773 tablets low dose once a day
46013244|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
46013245|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
46013246|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
45464209|NCT01224106|Drug|Gantenerumab|Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.
45464210|NCT01224106|Drug|Placebo|Participants received Placebo SC injection Q4W.
45464211|NCT05282563|Procedure|double and a half layered esophagojejunal anastomosis|After the end of esophagojejunostomy, 3/0 barbed suture or absorbable suture was used. First, the anastomotic site was sutured continuously for one circle, with the suture spacing of 3-4 mm and the width of 4-5 mm. Then, the continuous horizontal mattress type seromuscular layer varus suture was used to embed the anastomotic stoma for one circle, and the suture width was 5~8 mm above and below the anastomotic stoma. After the completion of esophagojejunostomy, the full-thickness reinforcement of the anastomosis and the embedding of the seromuscular layer can ensure the complete anastomosis of the mucosal layer of the anastomosis. The embedding of the seromuscular layer can also improve the anti-pressure and anti-tension of the anastomosis, and provide a guarantee for the primary healing of the anastomosis.
46013247|NCT01193218|Drug|BI 10773|BI 10773 tablets mid-high dose once a day
46099003|NCT04117737|Other|Virtual reality combined with anti-gravity treadmill|"The system is composed of three major parts: the treadmill, the antigravity system and the virtual reality system.~The treadmill is the base of the device. It is a rounded and concave structure that permits to walk in all direction. For simulate anti-gravity, a harness and pulley system allow to regulate the weight. Finally, the virtual reality system enables participants to simulate an experience of daily life."
45837474|NCT00605826|Device|Sham Injection|Sham injection at the start of the blinded phase.
46099004|NCT01005511|Device|Grindcare|Active treatment
46013248|NCT01193218|Drug|BI 10773|BI 10773 tablets high dose once a day
46013249|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
46013250|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
46013251|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
46099005|NCT01005511|Device|Grindcare - inactive|Placebo treatment
46013252|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
46013253|NCT01193218|Drug|BI 10773|BI 10773 tablets mid-low dose once a day
46013254|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
46013255|NCT04389645|Diagnostic Test|IP-10 in CDS protocol|Dynamic IP-10 measurements in hospitalized COVID-19 positive patients
46013256|NCT00592098|Drug|Strontium chloride hexahydrate|Cutaneous solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
46013257|NCT00592098|Drug|Placebo|Cutaneous saline solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
46013258|NCT01193101|Drug|LCZ696|LCZ696
46099006|NCT02711267|Drug|5% Zovirax® cream|(manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)
46099007|NCT02711267|Drug|5% Aciclostad cream|(STADA Arzneimittel GmbH, Vienna, Austria)
46013259|NCT01193101|Drug|Placebo|matching placebo to LCZ696
46013260|NCT04472078|Diagnostic Test|Serological Assay or IgG for SARS-CoV-2|Serological Assay for detection of IgG for SARS-CoV-2
46013261|NCT02887846|Device|Heated Humidified High-Flow Nasal Cannula|Patients requiring mechanical ventilation for at least 6 hours on the first 7 postnatal days will be included in the study.When patients were Fi O2 < 0,40, Pa CO2 < 65 mmHg, pH> 7.20, MAP (mean airway pressure) <7 cm H2O, they will be extubated if statistically stable.Oxygen-air mixture of 4-6 l / min flow rate will be set in HHHFNC group, and pressure will be set to 5-8 cm H2O in NCPAP group. When flow is 2 l / min, FiO2 is<0.30 at 24 hours and above, free oxygen will be introduced. In NCPAP group, when pressure is 5 cm H2O and FiO2 < 0.30 at 24 hours and above, free oxygen will be introduced.
46013262|NCT04328805|Drug|Ibuprofen tablets|oral tablet
46013263|NCT02886364|Behavioral|Adapted Safe Childbirth Checklist|The World Health Organization has created and endorsed the WHO Safe Childbirth Checklist as a tool for improving quality of care around childbirth. This tool has been modified to the context in Mexico by another group of investigators at the National Institute of Public Health. Our team expanded the Mexican version of the WHO Safe Childbirth Checklist to include indicators around respectful maternity care.
46013264|NCT01192516|Behavioral|Tailored Activity Pacing|Therapeutic intervention will be based on a tailored approach using collected data on symptom and activity patterns of each participant.
46013265|NCT01192516|Behavioral|General Activity Pacing|Therapeutic intervention using generalized pacing instruction to manage symptoms
46013266|NCT04471883|Procedure|Percutaneous coronary interventions|Percutaneous coronary interventions in coronary bifurcation lesions
46013267|NCT04329000|Drug|Esomeprazole 40mg|On-demand Esomeprazole 40 mg QD
45464212|NCT01117025|Procedure|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
45464213|NCT01117025|Procedure|Circumferential PVI+renal denervation|"The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done."
45464214|NCT03842761|Drug|BI 685509|Tablet
45464215|NCT03842761|Drug|Placebo|Tablet
45464216|NCT03939455|Other|Mobile Augmented Screening tool|Tablet-based intervention
45464217|NCT01199341|Drug|AZD1981|100 mg per oral, twice daily for 14 days
45464218|NCT01199341|Drug|Warfarin|10 x 2.5 mg per oral, once daily at day 1 and day 15
45464219|NCT01199341|Drug|AZD1981|4 x 100 mg per oral, twice daily for 14 days
45464220|NCT01215539|Drug|panitumumab|Panitumumab will be administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg. Subjects with evidence of complete response, partial response or stable disease will continue to receive the combination of chemotherapy with panitumumab until disease progression, unacceptable toxicity or withdrawal of consent.
45464221|NCT01203709|Drug|low dose combination of MMF and Tac|mycophenolate mofetil 500mg BID + tacrolimus 2mg BID
45464222|NCT01122407|Drug|L-NMMA|L-NMMA 250 ug/Kg/min
46013268|NCT04329000|Drug|Esomeprazole|Continuous Esomeprazole 40 mg QD
46013269|NCT01192399|Biological|Eculizumab|
46013270|NCT04389294|Diagnostic Test|SARS-CoV2 serum antibody testing|Participants will have SARS-CoV2 serum antibody testing performed twice within 4 months of each other.
46013271|NCT01176916|Drug|Aromasin (exemestane)|the dosage, frequency and duration base on the LPD approved by SFDA.
46099008|NCT02711267|Drug|5% Aciclovir cream 1A Pharma|(1A Pharma GmbH, Vienna, Austria)
46099009|NCT02711267|Drug|5% Zovirax Cold Sore Cream|(GlaxoSmithKline Consumer Health Care, Brendfort, UK; Marketing authorization holder: Beeham Group PLC, Brendfort, UK)
46099010|NCT02711267|Drug|5% Zovirax® cream (Austria)|(GlaxoSmithKline Pharma GmbH, Vienna, Austria)
45464223|NCT01122407|Drug|Trimethaphan|Will infuse trimethaphan for until complete autonomic blockade is achieved.
45683854|NCT01686633|Drug|Fluticasone Furoate 100 mcg|Fluticasone furoate will be available as 100 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
46013272|NCT04328922|Other|Fecal microbial transplantation|Capsules of fecal matter solution (feces from healthy donor, glycerol and saline solution)/
45464224|NCT05670145|Other|PRECISE|"The target group is working pregnant women. Further, a smaller group of non-pregnant women from the same workplaces and with the same work tasks (colleagues) will be included. Around 95% of pregnant women in Denmark have a 1st trimester ultrasound scan.(17) To ensure a representative population, the recruitment to the project takes place at four obstetric departments. After giving informed written consent for participation, the pregnant women receive a baseline questionnaire followed by short weekly questionnaires by SMS until maternity leave.~Exposure to occupational standing/walking and bending are measured by use of triaxial accelerometers (Axivity sensors) worn on the back and thigh for 24 hours/day. Exposure to lifting is quantified through continuous observations during a workday with registration of number of lifts, weight of burdens, and number of person-liftings."
45464225|NCT03469180|Other|Treadmill training|Treadmill training Each season will be supervised and last 45 minutes. Treadmill speed will be adjusted to the child's maximal heart rate (MHR) (between 65 to 75 percent of the MHR).
45464226|NCT03469180|Other|Whole body vibration training|Whole body vibration training whole body vibration frequence will be 50 Hertz and childrens will be standing position on vibration platform .
46099011|NCT02711267|Procedure|OFM|Sampling method for interstitial fluid
45464227|NCT04411927|Other|assessment of postural stability|assessment of postural stability
46013273|NCT04328922|Other|Placebo capsuls|capsules of glycerol and saline (placebo).
46013274|NCT05382091|Drug|naltrexone implant|3.6 g per implant set each containing 60% naltrexone
46013275|NCT01192204|Drug|10% FBR containing bioadhesive gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
46013276|NCT01192204|Drug|placebo gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
46013277|NCT01192126|Device|Bausch & Lomb new daily disposable|Test lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
46013278|NCT01192126|Device|Johnson & Johnson Acuvue Moist|Control lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
46013279|NCT04433403|Other|pathogenic microorganism|Detection of pathogenic microorganisms in adult severe pneumonia by second generation sequencing
46099012|NCT02711267|Device|OFM Probe|Sampling probe used during OFM
45464228|NCT01213121|Drug|Quetiapine|oral tablet/25-600mg per day/once a day/six weeks
45464229|NCT05156086|Drug|COVID-19 vaccine, booster|Additional dose of COVID-19 vaccine (booster shot)
45464230|NCT01122485|Other|PG201|two tablets
45464231|NCT01122485|Other|Placebo|two tablets
45464232|NCT03409107|Drug|Daprodustat (GSK1278863)|Daprodustat will be available as 9 millimeter (mm) or 7 mm film-coated tablets. Daprodustat will be administered once daily via oral route and can be taken without regard to food.
45464233|NCT03409107|Drug|Placebo|Daprodustat matching placebo will be available as 9 mm or 7 mm film coated tablets. Placebo will be administered once daily via oral route and can be taken without regard to food.
45464234|NCT03409107|Drug|Iron therapy|Iron therapy will be administered if ferritin is <50 Nano gram per milliliter and/or TSAT is <15 percent.
45464235|NCT01216865|Biological|umbilical cord mesenchymal stem cells|5*10/7 per ischemic limb
46099013|NCT02711267|Device|OFM Pump|Pump used to operate OFM probes
45683855|NCT02511106|Drug|AZD9291 80 mg/40 mg|The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.
45683856|NCT02511106|Drug|Placebo AZD9291 80 mg/40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.
45837475|NCT05216562|Drug|Exosome-MSC Intravenous injection|Intravenous injection of Exosome-MSC
46013280|NCT04433286|Other|Questionnaire|"This is a cross-sectional survey which will be distributed online between surgeons. The survey was proposed by a consensus of consultants of surgery and revised by an improvement consultant. It consists of a semi-structured questionnaire that is provided in English language. A subsequent translation in different Language will provided based on geographical distribution. The survey will be conducted online through an online survey development cloud-based software (SurveyMonkey®; San Mateo, CA, USA). Participants will be aware of the nature of the survey and informed that they will be listed as co-authors. Collected data will be confidential and anonymous.~The first sector of the questionnaire includes trainee demographics and baseline characteristics. Then the questionnaire aims to compare the trainee experience before and after the pandemic with focus on research activities, clinical, and surgical practice."
46013281|NCT04468802|Other|Case fatality rate|Mortality rate caused by SARS CoV-2
46013282|NCT02894268|Drug|Doxycycline|Doxycycline 100g po bid
46013283|NCT02894268|Drug|Furazolidone|Furazolidone 100mg po bid
46099014|NCT00700089|Behavioral|Assertive intervention|8-20 assertive contacts after suicide attempt
46099015|NCT00700089|Other|Standard treatment|In standard treatment there is no procedure for ensuring that the patient will actually receive the recommended treatment. Patients are often referred to available treatment modalities such as general practitioner, psychological treatment, treatment for alcohol abuse, and most often, the patients are themselves responsible for getting into contact with the treatment to which they are referred.
46099016|NCT03999619|Behavioral|Move 2 Learn|10-week (1 hour/week) program designed to target fundamental movement and pre-literacy skills with active parent involvement.
46099017|NCT00700167|Biological|dendritic cell vaccine|"The vaccine will be split between as many as 10 injections, more or less. Each shot will be about 1/25th to 1/50th of a teaspoon (100 to 200 microliters). Each vaccine will be injected with a tiny needle just under your skin. This will usually cause a very small area of swelling at the injection site that may last for a few minutes to an hour or so. You will receive two additional booster doses of the same vaccine every 4-6 weeks. This would mean that you receive a total of three vaccines over about 2-3 months."
45464236|NCT01216865|Drug|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
46099018|NCT04219553|Behavioral|Antimicrobial stewardship|The multifaceted AMS intervention includes pharmacist education, a clinical decision support tool, a parent/guardian questionnaire, and individualized monthly audit and feedback with each pharmacist.
46099019|NCT04219553|Other|Comparator (no intervention)|No active intervention
45464237|NCT01121471|Dietary Supplement|Conjugated Linoleic Acid (CLA)|6.4 g CLA/day, capsule form, for 16 week arms
45464238|NCT01121471|Dietary Supplement|Safflower OIl|8.0g/day safflower oil
46099020|NCT05383469|Other|Exercise Training|Endurance training with a resistance-free bicycle ergometer Strength training with bodyweight Non-resistance ankle pumping exercises
45464239|NCT03921073|Drug|T-VEC|Participants will receive intralesional injections of T-VEC of up to 4cc. Dosing of T-VEC is dependent of the size of the lesion.
45464240|NCT01215617|Behavioral|Aerobic Interval training|Treadmill walking or running - 3 times per week for 3 months. The interval training session consists of 10 minutes warm up and continues with 4 x 4 minutes high intensity intervals at 90-95% of maximal heart rate. Training intensity will be supervised through the use of Polar pulse monitors and the BORG scale of subjective perceived exhaustion.
45464241|NCT01215617|Behavioral|Control|Standard medical treatment
45464242|NCT01202461|Procedure|Triple therapy of vitrectomy, IVTA and grid/focal laser photocoagulation|"all pars plana vitrectomy were accompanied with removal of retinal Internal limiting membrane (ILM) around fovea in round fashion with a dimension of approximately 2 disc diameters.~IVTA was introduced at the end of surgery or on the next day (4mg in 0.1cc). Two weeks afterward, fluorescein angiography guided macular laser photocoagulation which consisted of direct photocoagulation on leaking microaneurysms and application of grid pattern laser was undertaken."
45683857|NCT02511106|Drug|Open-label AZD9291 80 mg/40 mg|Eligible patients will be offered open-label osimertinib upon recurrence and in the absence of intervening systemic anti-cancer therapy.
46099021|NCT05383469|Other|Massage|Classical massage including superficial and deep stroking and friction methods for the lower extremity.
45837476|NCT05216562|Drug|Placebo Intravenous Injection|Intravenous injection of Placebo
46099022|NCT05383469|Other|Neuromuscular Electrical Stimulation|Symmetrical biphasic current at a frequency of 30-85 Hz
46099023|NCT05383469|Other|Compression Therapy|Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.
46099024|NCT01009255|Drug|GSK239512|Histamine H3 Antagonist
46099025|NCT01009255|Drug|Placebo|Placebo to match GSK239512
46099026|NCT00638261|Radiation|UVB-311nm|UVB-311nm radiation given 3 times a week to one randomized body-half
45683858|NCT04545723|Device|FibriCheck|FibriCheck is a smartphone application that measures hearth rhythm using the phone's built-in camera. It is able to detect aberrant rhythms, such as atrial fibrillation.
45683859|NCT04413669|Procedure|white light bronchoscopy & autofluorescence bronchoscopy|White light bronchoscopy and autofluorescence bronchoscopy were carried out，and Take a biopsy for abnormal bronchial mucosa
45837477|NCT05216562|Drug|COVID-19 Standard Treatment|Specific drugs considered standard treatment for COVID-10 by each location may vary
45837478|NCT03381300|Procedure|Ovarian tissue cryopreservation|Laparoscopic unilateral oophorectomy followed by cryopreservation of ovarian cortex tissue
45837479|NCT05216094|Other|smart phone App|stroke subjects completed tasks-oriented program demoed in the smart phone app with affected upper limb or bilateral arm movement for 12 weeks
46013284|NCT02894268|Drug|Esomeprazole|Esomeprazole 20mg po bid
46013285|NCT02894268|Drug|Colloidal Bismuth Subcitrate|Bismuth 20mg po bid
45464243|NCT02529371|Device|UriCap-RM|UriCap-RM is comprised of a reusable part and a single use adhesive tape. The reusable part is applied over the urethral meatus and is held in position by a stabilizer and adhesive tape. It is connected to a standard urine collection bag. The UriCap-RM is used on male patients who would otherwise use diapers, a condom-type urine collection device or an indwelling catheter for urine collection.
46013286|NCT02894268|Drug|Sensitivity antibiotics|Two antibiotics based on antibiotic sensitivity of H.pylori culture, including amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline and furazolidone.
46013287|NCT02893683|Other|Paris Visual Learning Test|
46013288|NCT01600625|Drug|oral minocycline hydrochloride treatment|Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment
46013289|NCT04386954|Procedure|observational study|observation study
46013290|NCT01600664|Behavioral|Interactive computer game|Participants will use the interactive computer game installed on a convertible PC
46013291|NCT01600664|Behavioral|Convertible PC|Participants will be using the convertible PC without the interactive computer game
45464244|NCT03920683|Other|Data collection|Retrospective : data from medical record Prospective : vital statuts from follow-up phone call
45679932|NCT04600414|Other|Collaborative Care for Opioid Use Disorder|"Pharmacologic treatment of OUD will rely mainly on transmucosal buprenorphine/naloxone prescribed by primary care providers with DATA 2000 waivers. Measurement-based care and treat to target are fundamental principles of CoCM and will be incorporated into the intervention. Care managers will ask four yes/no questions about: 1) opioid withdrawal symptoms, 2) illicit opioid craving, 3) illicit opioid use, 4) medication side effects. If necessary, consulting psychiatrists will then recommend a change to the treatment plan to the primary care provider. In the case of buprenorphine/naloxone, options for changing the treatment plan include: 1) increasing the dosage (max dose 32mg), 2) augmenting with clonidine, 3) switching to injectable buprenorphine, and/or 4) intensifying psychosocial interventions. If the patient is experiencing medication side effects, but not opioid withdrawal symptoms or illicit opioid craving, consideration will be given to lowering the medication dosage."
45679933|NCT04575220|Other|12 weeks of bicycle exercise|Subjects will conduct monitored exercise, three sessions per week for 12 weeks.
45679934|NCT04572906|Combination Product|NTX-001|One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy. An isolation chamber medical device (device) is utilized to focus the application of PEG (Solution #2) on the coapted nerve for the required amount of exposure time.
45464245|NCT03939143|Drug|DA-1229_01(A), Sugamet SR Tab 5/1000mg®|"Period 1: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar."
45837480|NCT05216094|Other|conventional rehabilitation|stroke subjects receive conventional rehabilitation home program with smart phone app ,without task-oriented program demoed function, for 12 weeks
45837481|NCT02132598|Drug|cabozantinib|
45837482|NCT00605904|Drug|Acamprosate|orally administered tablet, 333mg, three times daily for a minimum of 2 weeks (14 days)
46013292|NCT02893839|Other|Prick to prick test|
46099027|NCT02708225|Behavioral|medical clown|a medical clown will assist the child during the performance of pulmonary function test
45464246|NCT03939143|Drug|Sugamet SR Tab 5/1000mg®, DA-1229_01(A)|"Period 1: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar."
45837483|NCT00605904|Drug|Yohimbine|Intravenous infusion of yohimbine (0.4 mg/kg) administered once over 10 minutes
45837484|NCT00605904|Drug|mCPP|Intravenous infusion of mCPP (0.05 mg/kg) over 10 minutes, two times, for a total of 0.1 mg/kg
45837485|NCT00605904|Drug|Saline|"Intravenous infusion of 0.9% sodium chloride solution over 10 minutes, three times during the study (2 times for the Saline Infusion milestone, and one time immediately following the Yohimbine Infusion milestone)"
45837486|NCT01798914|Drug|Technosphere Insulin Inhalation Powder|Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
46013293|NCT01600742|Drug|Vorinostat|"Run-in phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat: 400 mg/day during WBRT, day 1 through day 7 every week till one day after WBRT.~Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
46013294|NCT01600742|Drug|Placebo|"Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
46013295|NCT04431804|Other|silver nanoparticle|fungicidal effect of silver nanoparticles on aspergillus isolates
46013296|NCT04430829|Diagnostic Test|Weight-Bearing CT arthrography|A 20ml mixture of 5ml 0.5% ropivacaine, 5ml preservative-free sterile saline, and 10ml of non-ionic iodinated contrast media (e.g. iohexol 240) will be instilled into the knee joint of each patient prior to WBCTa imaging of the knee (LineUp, CurveBeam, LLC).
46013297|NCT04430829|Diagnostic Test|Knee MRI|MRI will be acquired (in-plane 0.25mm x 0.25mm, and 1.00mm slab thickness/separation and In-plane 0.25mm x 0.25mm, and 2.00mm slab thickness/separation)
46013298|NCT01327482|Drug|Raltegravir|Dosage: 400mg/PO (by mouth) Frequency: Twice daily Duration: During course of menstrual cycle (28 days)
46099028|NCT04459871|Biological|recombinant human Thrombin(CHO cell)|2 rhThrombin, dissolved in 5mL sterile saline and mixed, the final solution contains 1000IU/mL rhThrombin solution (clear and transparent liquid).
46099029|NCT04459871|Biological|placebo|placebo, dissolved in 5mL sterile saline and mixed, the final solution contains 1000IU/mL rhThrombin solution (clear and transparent liquid).
45464247|NCT03938753|Device|Audéo M90-T|Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
45464248|NCT01124435|Drug|Carboplatin plus Celecoxib|celecoxib (200 mg tablets by mouth twice daily, day 1 to 28), associated to intravenous carboplatin (area under the curve (AUC) 5 over 30 to 60 minutes, every 28 days).
45464249|NCT03840655|Procedure|Near-Infrared Imaging Thoracoscopy|Sympathicotomy performed by near-infrared imaging thoracoscopy
45464250|NCT01219049|Drug|Tyrosine|1000 mg / day
45464251|NCT01219049|Drug|Tyrosine|2000 mg / day
45464252|NCT01219049|Drug|Placebo|Placebo daily
45464253|NCT03294304|Drug|Nivolumab|Nivolumab will be given at a fixed dose of 360 mg IV over 30 minutes on Day 8 every 21 days for 4 cycles.
45464254|NCT03294304|Drug|Cisplatin|Cisplatin will be given at 70 mg/m2 IV over 30 minutes on Day 1 every 21 days, and based on treating physician's discretion, split-dose cisplatin can be given at 35 mg/m2 IV Day 1 and Day 8 every 21 days for 4 cycles.
45464255|NCT03294304|Drug|Gemcitabine|Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1, 8, and every 21 days for 4 cycles.
45464256|NCT03712761|Dietary Supplement|Enriched Protein®|This product contains high quality bovine milk proteins enriched with additional leucine.
45464257|NCT01204021|Behavioral|Tai Chi Chih|12 weeks of weekly classes of Tai Chi Chih
45464258|NCT01204021|Behavioral|Stress Education Control|Weekly meetings, for 2 hours for 12 weeks discussing issues related to stress education.
45679935|NCT04569266|Other|Specific exercise rehabilitation treatment|"Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment)."
45683860|NCT01685697|Procedure|Mask ventilation with a Laerdal face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the intervention group.
45837487|NCT00607620|Behavioral|Brief Intervention|Training in brief interventions for alcohol use disorders, with a focus on motivational interviewing
45837488|NCT05194488|Device|Low level laser therapy|Patients will receive low-level laser therapy on the temporomandibular joint disc
46099030|NCT01005667|Device|BirthTrack|Measurement of cervical dilation and head station
46099031|NCT02708459|Device|surgically inserted Transversus abdominus plane catheter|at end of surgery, a surgeon will insert catheter in Transversus abdominus plane (TAP) between internal oblique muscle and Transversus abdominus muscle
45464259|NCT01201213|Drug|local anaesthetic injection|Single bolus of drug for pain relief in early labour
45464260|NCT03715257|Device|14F staged extubation set guidewire|"14F staged extubation set guidewire is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts.~Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
45837489|NCT05194488|Drug|Botulinum toxin type A|Patients will receive Botulinum toxin type A injection into the lateral pterygoid muscle under Electromyography (EMG) guidance.
45837490|NCT05194488|Device|Anterior repositioning appliance|Patients will receive hard maxillary anterior repositioning appliance.
45837491|NCT05175768|Other|Nicotinamide Mononucleotide|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
45837492|NCT05175768|Other|Nicotinamide Mononucleotide with L-Leucine|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
45837493|NCT05175768|Other|Placebo|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
45464261|NCT03715257|Device|Tube changing catheter|"Tube changing catheter Tube changing catheter is an alternative extubation device. Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
45464262|NCT01124513|Procedure|Induced Erythema|Study personnel will induce erythema by sequentially applying ice for approximately 2 minutes to the 2 cm^2 target region of the upper volar arm. This erythema is a reaction to the vasoconstriction caused by skin cooling. The vasoconstriction is visually monitored to determine the onset of the vascular dilation that occurs after cessation of cooling. Images with the Digital Camera, Spectrophotometer and Videodermoscope are re-taken.
45464263|NCT01201291|Other|Normobaric oxygen|Fraction of inspired oxygen
45464264|NCT03195322|Procedure|Pre-pectoral Tissue Expander|All participants in the study will undergo bilateral mastectomy followed by Immediate, bilateral pre-pectoral tissue expander breast reconstruction with complete AlloDerm® coverage.
46099032|NCT02708459|Drug|Intravenous morphine|Boluses of intravenous morphine (2 mg) will be given to patients if Visual analogue scale (VAS) more than 3
46099033|NCT02708459|Drug|Bupevecaine|
46099034|NCT02708459|Drug|Dexmedetomedine|
45464265|NCT03712683|Drug|Thyroxine|Thyroxine was prescribed with the diagnosis of SCH and continued when pregnancy was confirmed
45464266|NCT03933839|Behavioral|PainCOACH|PainCOACH is an eight-week, automated, internet-based training in specific pain coping skills (such as progressive muscle relaxation, pleasant imagery and activity pacing), and guided practice with each skill.
45464267|NCT03839173|Other|Human milk based human milk fortifier|A human milk fortifier with added minerals made from donor human milk
45464268|NCT03472378|Drug|DFN-15|Oral Solution of 4.8 mL containing 120 mg of DFN-15
45464269|NCT03472378|Other|Placebo|Oral Solution of 4.8 mL containing 0 mg of DFN-15
45464270|NCT01219127|Other|Derma-PACE|ESWT group received derma-PACE shockwave treatment 2 x 1 wk for 3 wks for a total of 6 treatment using derma-PACE dervice (Alpharetta, GA). HBO groups received HBOT daily 5 days a week for 8 weeks or a total of 40 treatments.
45464271|NCT03842605|Other|Strength training|
45464272|NCT03408873|Drug|Abilify Maintena|Drug is in an injectable form and will be administered approximately every four weeks through Week 24 of the study. Dosage is per package insert or at the discretion of the psychiatrist.
45464273|NCT03408873|Behavioral|Customized Adherence Enhancement (CAE)|CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
46099035|NCT02711033|Procedure|Laparoscopic-assisted total gastrectomy|When patients with advanced proximal gastric cancer are randomized in the laparoscopic-assisted total gastrectomy (LATG) group, they will received LATG with spleen-preserving splenic hilum lymph nodes dissection.
46099036|NCT02711033|Procedure|Open total gastrectomy|When patients with advanced proximal gastric cancer are randomized in the open total gastrectomy (OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
46099037|NCT00853593|Device|Pacing Lead|implant and follow-up of study device
46099038|NCT05610241|Device|Compression Therapy System Prototype|A device designed to deliver compression therapy at a pre-set level to the lower leg for legs with a circumference between 30-50 cm. The device provides compression through a series of three air bladders and is controlled by a battery-powered electronic module that controls compression levels by monitoring bladder pressure.
46099039|NCT05610241|Device|Standard Compression|Coban 2 represents the standard of care 2-layer compression wrap used to treat venous leg ulcers. The device consists of a comfort layer and a compression layer. A clinician applies the device to establish compression therapy.
45464274|NCT01124591|Behavioral|Brief motivational intervention|two session delivered two weeks apart
45464275|NCT01201369|Device|Coronary Stent Cypher|The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols.
45837494|NCT05128500|Procedure|Total Shoulder Arthroplasty with Permedica's MIRAI|Total Shoulder Arthroplasty with Permedica's MIRAI Modular Shoulder Prosthesis System
45837495|NCT05097846|Drug|Group1 Vonoprazan Fumarate + amoxicillin + doxycycline|Vonoprazan Fumarate + amoxicillin + doxycycline
45837496|NCT05097846|Drug|Group2 Vonoprazan Fumarate + furazolidone + doxycycline|Vonoprazan Fumarate + furazolidone + doxycycline
45837497|NCT05097846|Drug|Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline|esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
45837498|NCT05097846|Drug|Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline|esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
45464276|NCT01201369|Device|Coronary stent Xience|The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols
45464277|NCT03471052|Procedure|Radiofrequency ablation (RFA)|"Ablation using the Barrx RFA System is a new technique for field ablation in the oesophagus. It has been used for eradication of diseased epithelium of all three subclasses of Barrett's oesophagus (non-dysplastic Intestinal metaplasia (IM), Low grade dysplasia (LGD) and High grade dysplasia (HGD). The BarrxTM RFA System uses ultra short pulse RF energy delivering 40Watts/cm2 power density and 12Joule/cm2 energy density, and affects the mucosa whilst preserving the submucosa.~Clinical trials have suggested that it is safe and effective for treating non-dysplastic IM, LGD and HGD in Barrett's oesophagus . Long term data show the effect to be durable over 5 years."
45464278|NCT05282095|Other|Follow up|Participants will be followed up at baseline, 6th and 12th months with HPV viral integration tests, HPV genotyping tests, thinprep cytologic tests (TCT) for cervix and vaginal secretion tests. Colposcopy and biopsy will be conducted for participants if necessary.
45679936|NCT04569266|Other|No specific exercise rehabilitation treatment|"Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment)."
45679937|NCT04564443|Other|Medaxis Debritom+|Advanced micro fluid jet therapy to clean and stimulate wound
45679938|NCT04564443|Other|Sharp Surgical Debridement|Scalpel or Curette to clean and debride wound
45679939|NCT04564443|Other|Additional Outer Dressing Application|Application of moisture retentive dressing, and a multi layer compression dressing
46099040|NCT02708069|Other|e-Unstuck|An e-learning software that delivers the evidence-based Executive Functioning intervention to parents of children with Autism Spectrum Disorder without Intellectual Disability (ASDwoID) with personalized training and feedback on the evidence-based Unstuck and On Target (UOT) curriculum. Through video modeling, intelligent games, adaptive interactive exercises, and personalized feedback, e-Unstuck will provide parents with new tools for applying UOT principles to real world settings, above and beyond learning UOT principles.
46099041|NCT02708069|Other|Unstuck and On Target|An executive functioning intervention specifically targeted to the needs of the Autism Spectrum Disorder without Intellectual Disability (ASDwoID) population.
46099042|NCT01005823|Drug|LEO 29102 cream|Twice daily application for 7 days
46099043|NCT01005823|Drug|LEO 29102 placebo cream|LEO 29102 placebo cream
45464279|NCT02937142|Behavioral|cognitive behavior group therapy|1,5 hours weekly session during 12 weeks, 8 participants, 2 therapists.
45464280|NCT02937142|Other|Treatment as usual|Education on ADHD, and ADHD medication if indicated
45464281|NCT03715101|Drug|Rosuvastatin|Open-label, one-sequence, multiple administration
45464282|NCT04457830|Drug|F520|3mg/kg every 3 weeks
45837499|NCT04388046|Device|Herbst fixed functional appliance|Herbst appliance could be considered as an artificial joint working between maxilla and mandible. The appliance consists of a bilateral telescope mechanism attached to upper and lower jaws keeping the mandible in an anterior jumped position.
45837500|NCT00608634|Drug|perillyl alcohol|Applied as topical cream
45464283|NCT03780959|Drug|Etanercept|Administered twice weekly by subcutaneous injection
45464284|NCT03780959|Drug|Placebo|Administered twice weekly by subcutaneous injection
45679940|NCT04564443|Other|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
45679941|NCT04564443|Other|Fibracol Wound Dressing|Application of a collagen alginate dressing
45679942|NCT04560595|Behavioral|Caffeine Reduction Manual|We will provide participants with a Guide to Caffeine Reduction and Cessation in order to help the reduce their caffeine use and determine their ratings of treatment acceptability.
45837501|NCT00608634|Other|placebo|Applied as topical cream
46099044|NCT04445363|Drug|Jacatinib hydrochloride cream|Jacatinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks
46099045|NCT04445363|Drug|Placebo|Dose extension: Placebo
46099046|NCT05734261|Procedure|Airway Oscillation System|After each methacholine dose administred, respiratory function will be measured by forced oscillation
46099047|NCT02707835|Other|self massage|self massage, skin care education, manual lymph drainage exercise, compression garment
46099048|NCT02707835|Other|manual lymph drainage|manual lymph drainage by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
46099049|NCT02707835|Other|epidermis fascia taping|epidermis fascia taping by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
46099050|NCT00700245|Behavioral|Exercise-only (EXO-12 weeks of regular supervised exercise without diet restriction)|The exercise intervention for subjects in the EXO consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session. The subjects could choose between different modes of exercise; stationary bicycling, jogging on a treadmill or stair stepping.
46099051|NCT00700245|Behavioral|Diet-only (DIO-8 weeks of very low energy diet (VLED 600 kcal/d) followed by 4 weeks weight maintenance diet|Subjects in the DIO group were prescribed a liquid VLED(Nupo, Copenhagen) of respectively 600 and 800 kcal pr. day (proteins 41 g, carbohydrates 29 g, fat 5.6 g. pr 100 gram) for eight weeks followed by a weight maintenance diet for four weeks.
46013299|NCT04430205|Procedure|Adhesive restoration protocol|"The canal walls were etched with 37% orthophosphoric acid for 30 seconds with use of a microbrush.~The primer was applied on the wet canal walls, with a microbrush several times, after checking by drying the canal, that the appearance of the dentine was shiny and not opaque or chalky.~The next step was the application of bonding with a microbrush, blowing in the fracture line to make sure it is not loaded with bonding.~Flow composite was used to make it penetrate the fracture line with the help of a 0.06 mm k-file.~The canals were filled with dual composite parts more deeply, light cured at the canal entrance and pulp chamber; the following phase was the coronal restoration with a sandwich technique, covering the cusp with composite."
46099052|NCT00700245|Behavioral|Diet+exercise (DEX-8 weeks VLED 800 kcal/d + a four weeks weight maintenance diet combined with regular supervised exercise throughout the 12 weeks).|The exercise intervention for subjects in the DEX group consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session
45679943|NCT04560140|Behavioral|Narrative and Skills-building Intervention|The intervention is grounded in Narrative Theory and Bandura's principles of Self-efficacy and Outcome Expectation. It will consist of eight individual sessions over six months delivered by a facilitator. Participants will be facilitated to narrate their survival experiences and rebuild core life skills.
45679944|NCT04558840|Procedure|Macromastia|Patients with macromastia seeing the principle investigator (PI) (JMK) at his office at the Outpatient Building, which includes the Outpatient Surgery Center (OSC), in the Department of Plastic Surgery clinic at UT-Southwestern for their initial operative consultation for reduction mammaplasty will be offered enrollment in the trial if they are deemed appropriate surgical candidates, based on the PI's clinical judgement and expertise.
45679945|NCT04553822|Other|Assisted autogenous drainage group (DAA)|DAA, is used when the patient is not able to perform this technique autonomously and is assisted by the physiotherapist. Its greatest utility is in infants and preschoolers. The technique consists of positioning the patient in a supine position with the head slightly elevated on the supporting plane and then placing both hands around the rib cage and applying bimanual expiratory compression on both hemithoraxes. The physiotherapist must ensure that the child takes 2 to 3 controlled breaths, close to the residual level, with the objective that the expiratory flow displaces the secretions, located distally, towards the central airways.
45837502|NCT03088566|Procedure|The D-Foot method|The D-Foot method is a standardised routine of foot screening. The D-Foot i web program aimed to be used on a surf plate.
45837503|NCT03088566|Procedure|Conventional foot screening|The foot screening is performed with clinical conventional methods.
46013300|NCT04490291|Other|chronic pain team|enrollment in chronic pain team at study site
46099053|NCT00635765|Drug|C2L-OCT-01 PR 30 mg|Administered by deep IM (gluteus) on Day 1. Beginning on Day 42, drug injection frequency (6, 5 or 4 weeks) and dose modification/adjustment will be allowed for every 3 drug injections based on the mean serum GH and clinical symptoms obtained at the last visit of study C2L-OCT-01 PR-301 and during the course of this study.
46099054|NCT01005979|Drug|Lenalidomide, Rituximab, and Cyclophosphamide|"COHORT 1: Cyclophosphamide 250 mg/m2 day 1, 2 and 3, Rituximab 500 mg/m2 i.v. day 1, Lenalidomide 2.5 mg/day starting day 8-28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 2: Cyclophosphamide 250mg/m2 day 1, 2 and 3. Rituximab 500 mg.m2 i.v. daY Lenalidomide 5 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 3: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 10 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 4: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 15 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~Patients will receive a total of 6-8 cycles."
46099055|NCT00913029|Device|iStent|iStent
46099056|NCT00913029|Drug|latanoprost/timolol|Combination latanoprost/timolol
46099057|NCT00635843|Device|MAVERICK™ Disc|The MAVERICK™ disc is a spinal arthroplasty system and is intended to replace a damaged disc in the lumbar spine. It is a permanent implant used to maintain motion at the treated level and is inserted using an anterior surgical approach.
46099058|NCT00635843|Device|LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft|The control is the treatment with LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft. It is commercially available for anterior lumbar spine interbody fusion procedures.
46099059|NCT05734183|Other|MIME|Multisensorial IMmersive Experiences
46099060|NCT05734183|Other|MIME + tDCS|Multisensorial IMmersive Experiences plus transcranial direct current stimulation
46099061|NCT00700323|Dietary Supplement|PS-Omega3 conjugate supplementation|
46099062|NCT00700323|Dietary Supplement|placebo|
45464285|NCT03838783|Drug|Insulin Degludec|50% of the patient's daily basal insulin dose delivered through once daily insulin degludec injected in the morning; 50% of the basal insulin to be delivered through previously established CSII
45464286|NCT03935165|Drug|Indocyanine Green|"0.25 mg /(kg BW) Indocyanine Green PULSION®/ VERDYE Diagnostic Green®~- Indocyanine Green is administered Intravenously"
45464287|NCT03408639|Drug|CinnaPoietin®|The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
45679946|NCT04553822|Other|Group prolonged slow expiration (ELPr)|Passive expiratory aid technique applied to the baby by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
46013301|NCT04490291|Other|chiropractic team|enrollment in chiropractic team/intervention at study site
46013302|NCT04385823|Device|patients receiving nasal high flow|patients admitted to the ICU for Covid-19-related acute hypoxemic respiratory failure treated with nasal high flow
46013303|NCT04429386|Procedure|Bariatric surgery|Laparoscopic bariatric surgery including gastric bypass and sleeve gastrectomy
46013304|NCT02893488|Drug|DTG/ABC/3TC FDC DISPERSIBLE TABLET|DTG/ABC/3TC FDC dispersible tablet
46013305|NCT02893488|Drug|EPZICOM (ABC/3TC)|"EPZICOM will be available as orange, film coated, modified capsule shaped tablets, debossed with GS FC2 on one side."
46099063|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with end stage renal disease
46099064|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with mild renal impairment
46099065|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with moderate renal impairment
46099066|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in healthy volunteers
46099067|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with severe renal impairment
45679947|NCT04553822|Other|Control group (CG)|Nebulization with 4 ml Muconeb® 3% hypertonic serum, for 8 minutes in a Philips® vibrating mesh nebulizer. Once the nebulization is finished, you will wait 30 minutes in a closed room.
46013306|NCT02893488|Drug|TIVICAY (DTG)|TIVICAY will be available as white, round, biconvex tablets
46099068|NCT00853125|Biological|therapeutic allogeneic lymphocytes|Patients with a partially HLA-matched family member who can serve as a hematopoietic stem cell transplant donor will receive partially HLA-matched irradiated donor lymphocytes approximately every 8 weeks depending upon response
46099069|NCT00853125|Drug|sunitinib malate|Sunitinib will be administered orally at a dose of 50 mg qd for 4 consecutive weeks followed by 2 weeks off for every cycle.
46099070|NCT02707913|Drug|BF-Amlodipine Tablet 10mg|BF-Amlodipine Tablet 10mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
46013307|NCT04328883|Drug|Aspirin|Oral and inhaled ASA formulations
46013308|NCT04464356|Device|mechanical circulatory support|mechanical circulatory support: cardiopulmonary bypass, extracorporeal membrane oxygenation(ECMO), left ventricular assist device
46013309|NCT04385472|Radiation|3T MRI|The main method used will be 3 Tesla MRI, which is a high resolution imaging technique. The participants will be asked to undergo musculoskeletal MRI scanning (pelvis and lumbar spine).MRI is a non-invasive procedure which excludes the risk of radiation (in comparison to other imaging modalities: X-ray, CT
46013310|NCT01600196|Procedure|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
46013311|NCT00591669|Other|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
46099071|NCT02707913|Drug|Norvasc Tablet 10mg|Norvasc Tablet 10mg will be used as a comparator drug for the BE study
46099072|NCT05734027|Device|Sectional matrix|The sectional matrix is the best way to achieve a strong contact point in Class II restorations with composite resin in the posterior dental sector. The pre-wedging is essential to get a separation between teeth which avoid the matrix deformation during its insertion
46099073|NCT05734027|Device|Circumferential matrix|Circumferential matrix (thickness 0.038mm) ,the band encircle the tooth and secured by retainer on the buccal and lingual aspect
46099074|NCT02711111|Device|Face mask|to apply for on the upper jaw (12 - 14 hrs / day) via extra-oral elastics to the face mask
45679948|NCT04550260|Drug|Durvalumab|Durvalumab intravenous infusion
45679949|NCT04550260|Drug|Placebo|Durvalumab matching placebo for intravenous infusion
45679950|NCT04550260|Drug|cisplatin + fluorouracil|cisplatin + fluorouracil, as per Standard of Care
45679951|NCT04550260|Drug|cisplatin + capecitabine|cisplatin + capecitabine, as per Standard of Care
45679952|NCT04550260|Radiation|Radiation|50-64Gy in total
45683861|NCT01685697|Procedure|Mask ventilation with a F&P face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the control group.
45679953|NCT04549532|Behavioral|Targeted Multidomain|Participants in the T-MD intervention group will be prescribed targeted interventions to address each individual's symptoms, impairments, and functional limitations in the areas of anxiety/mood, cognitive, migraine/headache, ocular, vestibular, sleep, autonomic. The length of the intervention period will be 4 weeks or until RTA, whichever comes first.
45679954|NCT04549532|Behavioral|Behavioral Management|1.3. Usual Care (Controls) Group Participants randomized to the usual care (control) group will receive standardized (i.e., all participants in this group will receive the same interventions) behavioral management strategies that include activity, hydration, nutrition, sleep, and stress management strategies.
45679955|NCT04538742|Drug|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
46013312|NCT00591669|Other|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
46013313|NCT04464083|Diagnostic Test|IOP Measurment|To determine IOP readings before and after accelerated corneal collagen crosslinking (CXL)
46013314|NCT01600235|Drug|Phenylephrine|Phenylephrine (0.12mg/mL) Starting dose: 10cc/hr Titration: increase 10cc/hr every 30-60min, maximum 160cc/hr rate: increase systolic blood pressure (SBP) 10-25mmHg /hr Target: initially 20% increase of initial SBP, up to improving NIHSS score or SBP 200mmHg
46013315|NCT02893254|Drug|IBI303|12 cycles. IBI303: 40 mg, iH
46013316|NCT02893254|Drug|Adalimumab|12 cycles. Adalimumab: 40mg, iH
46013317|NCT02893137|Device|Optune|For further information see www.optune.com
46013318|NCT02893137|Procedure|Craniectomy|A small hole is placed in the skull between the tumor and the closest Optune electrode. The position and geometry of the craniotomy is determined by computersimulation of the electric field induced by Optune therapy. Craniotomy is a surgical procedure, which is carried out under general anaesthesia.
46013319|NCT04429581|Other|Anthropometry|
46013320|NCT04462991|Diagnostic Test|corneal topography|In all patients, TCT will be measured first by WaveLight® Oculyzer™II Pentacam HR and second by The Optovue AS-OCT .
46013321|NCT04383171|Device|Motomed cycle ergometer (MOTOmed letto2 - Reck, Reckstr 1-5, Betzenweiler 88422, Germany).|
46013322|NCT04382508|Other|Questionnaire|A weekly questionnaire will be filled in
46013323|NCT04460339|Other|Swimming participants in the 25-km|The 25-km race was the French national Open Championship event and participants were the swimmers registered for the race who volunteered to participate in this study
46013324|NCT04425954|Procedure|Endoscopic Endonasal Pituitary Surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter.
46013325|NCT04482491|Procedure|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection
46099075|NCT02711111|Device|orthodontic bone anchor|to apply force on the upper jaw (24 / 7) via intra-oral elastics on the bone-anchor
46099076|NCT02707679|Other|Mulligan's Straight leg-raise with traction|Mulligan's Straight leg raise technique was performed on patients with patellofemoral pain syndrome. The extremity on which the practice would be performed in supine position was grasped from the ankle level and was, then, subjected to traction longitudinally. Afterwards, the knee was lifted up passively while in extension and was kept for waiting for a few seconds at the point where tension was felt and was, then, returned to its initial position. The practice was repeated 10 times, and 3 sets of practice at 1-minute-intervals were performed.
45679956|NCT04538742|Drug|Durvalumab|Durvalumab: administered as an IV infusion
46013326|NCT04379622|Other|Dietary intake, body composition, lifestyle, and CVD risk factors|Dietary intake, body composition, lifestyle, and CVD risk factors
46013327|NCT04458701|Device|Hemodynamic monitoring|This is a comprehensive hemodynamic management strategy that would-be initiated in the operating room post-bypass and then continued for the first 12 hours in the intensive care unit
46013328|NCT04328220|Diagnostic Test|chest ultrasound|"A point-of-care lung ultrasound exam will be performed within 24h of admission to PICU and serial follow up according to each case.~chest x-ray will be performed for comparison with ultrasound findings."
45679957|NCT04538742|Drug|Paclitaxel|Paclitaxel: administered as an IV infusion
46013329|NCT04379232|Biological|Screening test for covid ( RT PCR and CT Chest)|Each patient was screened before surgery with RT PCR and CT Chest. Post operatively, if symptoms, patients are tested with RT PCR and CT Chest
46013330|NCT04424277|Other|diaphragm ultrasound|respiratory loading
46013331|NCT04378491|Other|Collection of clinical measurements|"Collection of clinical measurements:~Active and passive range of motion (ROM) of the knee, hip and ankle Joint bilaterally.~Passive patellar translation in 30° of flexion billaterally in quadrants of translation.~Patellar apprehension test (Fairbank's Test) and the Moving Patellar Apprehension (MPAT) test for the diagnosis of patellar instability. The Fairbank's Test is performed in 30° of Flexion while the MPAT is performed while flexing the knee from 0° to 90°."
45679958|NCT04538742|Drug|Pertuzumab|Pertuzumab: administered as an IV infusion
45679959|NCT04538742|Drug|Tucatinib|Tucatinib administered orally (tablet) twice daily
45679960|NCT04530799|Other|Identification of biomarkers for IAPA via patient sampling|Blood, BAL, microbiome
45679961|NCT04530630|Drug|BIKTARVY 50Mg-200Mg-25Mg Tablet|A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide.
45679962|NCT04528511|Device|Continuous Electronic Monitor|All patients with NOAF complicating AMI will receive at least 5 days electronic monitoring for the evaluation of NOAF burden
45679963|NCT04506606|Procedure|Afferent block|Block sensory feedback to evaluate hemodynamic and fatigue consequence of group III/IV muscle afferents
45464288|NCT03408639|Drug|Eprex®|The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
45464289|NCT03408639|Drug|Nephrovit|Nephrovit tablet is daily administered to all the patients.
45679964|NCT04482062|Device|Edwards EVOQUE System|Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with OMT
46013332|NCT04378491|Other|Collection of data for muscle strength|"Collection of data for muscle strength:~Muscle strength will be measured bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). For the knee, maximum isokinetic Flexion and extension torques will be collected between full extension and full flexion at a movement speed of 60°/s (3 x 5 repetitions) Maximum joint torques in each movement direction will be recorded for each joint and normalized to body weight"
46013333|NCT04378491|Other|Collection of EMG Data|"Collection of EMG Data:~Surface electrodes will be placed bilaterally on the vastus medialis and lateralis rectus femoris, biceps femoris and semitendinosus muscles following the guidelines of the SENIAM project (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles). Simultaneously with the muscle strength measurements, EMG data will be collected using a 12-channel EMG system (myon AG, Schwarzenberg, Switzerland, sampling rate 2400 Hz)."
46013334|NCT04378491|Other|Collection of Clinical Scores|"Collection of Clinical Scores:~patient's pain, range of motion and ability to perform daily living activities will be assessed using the Kujala Anterior Knee Pain Scale, Lysholm Knee Score, visual analog scale score (VAS) and the Tegner Activity Score"
46013335|NCT04378491|Other|Collection of Imaging Data - Radiological measurements|Collection of Imaging Data - Radiological measurements: Xrays and MRIs which were already performed as part of the original diagnostic and follow-up procedures pre- and postoperative will be reviewed and analysed.
46013336|NCT04457024|Other|classification statistics|Without any intervention
46099077|NCT02707679|Other|Mulligan's Mobilization with Movement|Mulligan's Mobilization with Movement technique was performed on patients with patellofemoral pain syndrome. Each patient was tested in every direction in the course of the active knee flexion-extension movement so as to find out the best pain-free tibial gliding direction (medial-lateral part of the tibia, anterior-posterior, internal-external rotation). At the time of the active movement of the knee, the tibial gliding direction where pain was felt at the least was selected as the treatment direction of mobilization technique along with movement. The practice was performed by doing 10 repetitions for 3 sets and by providing 1-minute-resting time between the sets.
46099078|NCT02707679|Other|Kinesiotaping|Kinesiotaping was applied on patient with patellofemoral pain syndrome. To maintain proprioceptive stimulation in the quadriceps (from origo towards insertio) and to alleviate the tension of hamstring muscle, a 'Y''-shaped kinesiotape was applied by using the muscle technique.
45464290|NCT03408639|Drug|Vitamin B12 Injection|Vitamin B12 is monthly injected to all the patients.
45464291|NCT03838237|Diagnostic Test|Cardiological evaluation|"Baseline evaluation~FAbry STabilization indEX (FASTEX)~12 leads ECG~Blood samples for microRNA, TnT HS and NT-proBNP dosages~2D echocardiogram~Cardio-pulmonary test~Contrast-enhanced CMR including:~Cine images~T2 mapping sequences~T1 mapping sequences before and 15' after contrast medium administration~Late Gadolinium Enhancement (LGE) imaging~Phase contrast images (LVOT, aortic flow)~Follow up evaluation~•After 18 months, the same procedures will be repeated"
45464292|NCT01217021|Drug|[18F] MNI-558|Subjects will be injected with 5mCi, not to exceed >10% of 5mCI, of [18F]MNI-558, followed by PET imaging.
45679965|NCT04482062|Drug|Optimal Medical Therapy|Optimal Medical Therapy
45679966|NCT04479696|Other|Educational Intervention|Receive standard of care verbal and written education materials
45679967|NCT04479696|Other|Questionnaire Administration|Ancillary studies
46013337|NCT04328454|Other|retrospective analysis|The investigators retrospectively analyzed the hospitalized patients with COVID-19
46013338|NCT04423497|Other|Balance Evaluation Systems Test|Balance Evaluation Systems Test application
46013339|NCT00592137|Dietary Supplement|C (smoothies based on soy protein containing no additional calcium)|Two smoothies per day based on soy protein containing no additional calcium
46013340|NCT00592137|Dietary Supplement|B (smoothies based on soy protein containing calcium)|Two smoothies daily based on soy protein containing 650 mg calcium as calcium carbonate
46013341|NCT00592137|Dietary Supplement|A (smoothies based on dairy protein containing calcium)|Two smoothies daily based on dairy protein containing 650 mg calcium
46099079|NCT02707679|Other|Exercise|All the patients were provided with several exercises within the scope of the home exercise program, such as hamstring muscle stretching, quadriceps isometric exercises, 4-way-strengthening with exercise elastic bands for the muscles of the hip, knee locking on foot and mini-squatting exercises. They were asked to do these exercises in 3 sets a day along with 10 repetitions for a period of 6 weeks.
45679968|NCT04479696|Other|Survey Administration|Complete optional survey
45679969|NCT04479696|Other|Video|Watch NIRS video
45683862|NCT03028233|Behavioral|Healthy Lifestyle|A Community Health Worker coaches families regarding healthy eating, physical activity, and obesity prevention, and promotes the use of existing built environment resources.
45683863|NCT03028233|Behavioral|Positive Parenting|A Community Health Worker coaches parents on improving positive parenting skills and promotes the use of relevant community resources.
45683864|NCT02395120|Behavioral|Standard letter|Standard referral letter according to Ohio Department of Health Bureau guidelines. This letter is consistent with others used across the country.
45837504|NCT02897700|Drug|Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate|Procedure: Routine chemotherapeutic regimens using one out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as single agent was performed 30~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agent was given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
46013342|NCT04455776|Drug|Propofol|Sedation by propofol
46013343|NCT04135092|Biological|Individual Patient TCR Transduced PBL|Day 0: Cells will be infused at a dose not to exceed .5e11 in 400 mL IV on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
46013344|NCT04135092|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
46013345|NCT04135092|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2 /day IVPB daily over 30 minutes for 5 days.
46013346|NCT04135092|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
46013347|NCT04135092|Drug|Pembrolizumab|Pembrolizumab 2 mg /kg IV over approximately 30 minutes on Day -2 and then every 3 weeks until time of disease progression.
46013348|NCT00592215|Drug|Experimental (mifepristone and misoprostol)|Mifepristone 200mg followed by labor induction with misoprostol after 6-8 hours
46013349|NCT04479137|Diagnostic Test|PCR for COVID-19|Novel Coronavirus 2019 DNA will be analyzed by PCR in nasopharyngeal swab
46013350|NCT00592332|Drug|Alprazolam|1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)
46013351|NCT00592332|Other|control group|control group is two hyperinsulinemic glucose clamps on day 1 with no drug given.
46013352|NCT04422444|Diagnostic Test|Questionnaires|Participants will answer questionnaires in three areas: physical/functional, emotional status and cognitive status
46013353|NCT04477382|Dietary Supplement|holo-BLG (beta-lactoglobulin) - a major component of the protein fraction of raw milk, is loaded with ligands such as retinoic acid, zinc and polyphenol-iron complexes.|Subjects suffering from house dust mite (HDM) allergic rhinoconjunctivitis who are reacting positively to chamber exposure with HDM are reevaluated in the exposure chamber 3 months after taking food supplements.
46013354|NCT04375644|Other|Questionnaires on psychological quality of life|Assessement of evolution of the psychological quality of life of health professionals during the confinement period linked to the COVID-19 pandemic by two questionnaires (one during the confinement period and the second one month after the end of the confinement period)
46013355|NCT04422015|Other|No intervention|No intervention
46013356|NCT04454021|Procedure|hip arthroscopy|hip arthroscopy was performed when symptoms were not alleviated by nonsurgical treatment
46013357|NCT04453592|Other|No intervention assigned as part of this study.|"The intervention included in this study is part of routine medical care, and not assigned as a result of study participation. This study includes only the addition of a measurement; the bent knee fall out test. Therefore, we believe this study design is observational, and in line with the provided observation study design definition: Observational: studies in human beings in which biomedical and/or health outcomes are assessed in predefined groups of individuals. Participants in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the study participants. This includes when participants receive interventions as part of routine medical care, and a researcher studies the effect of the intervention.~See uploaded study protocol for further details."
46013358|NCT04477226|Diagnostic Test|Transvaginal ultrasound scan|Transvaginal ultrasound is done to measure the cervical length, as per Fetal Medicine Foundation guidelines
46013359|NCT04453397|Drug|TNB-383B|TNB-383B is a bispecific antibody targeting BCMA on tumor cells and CD3 on T-cells.
45464293|NCT01219205|Procedure|intravitreal bevacizumab|Intravitreal injections of bevacizumab were performed under sterile conditions in the operating room. a 27-gauge needle was inserted through the corneal limbus to withdraw 0.05 ml of aqueous humor and soften the globe. Then, 1.25 mg (0.05 ㎖) of bevacizumab was injected into the vitreous in the superior temporal quadrant with a 30-gauge needle that was inserted into the eye 3.5 mm from the limbus. The postoperative medications included topical antibiotics.
45464294|NCT03810235|Drug|Transdermal Lidocaine Patch|Transdermal Lidocaine Patch
45464295|NCT03810235|Drug|Transdermal Hydrocolloid Placebo Patch|hydrocolloid placebo patches
46013360|NCT01600274|Drug|Dienogest-Ethinyl Estradiol (test product)|One tablet of Test
46099080|NCT05148247|Behavioral|The Perceive, Recall, Plan and Perform System of Intervention|The aim of the PRPP intervention is to enhance mastery in performance of needed or desired occupations, and extend traditional task training. Systematic instructions to support the clients' cognitive capacity to think about doing in different tasks and contexts are given by the OT, based on the results of PRPP Assessment stage 2. Further, the OT uses graded verbal, visual or physical prompts and cues directly during the participants task performance, progressing from content-free meta-prompts 'Stop' to alert the participant to process information required for the task, and for errorless learning. Then the OT prompt 'sense/attend, think and do', to more specific behavioural prompts selected by the therapist based on the components from the PRPP Assessment stage 2. At best the skills are generalized throughout all everyday activities, and the OTs' role as a cognitive mediator fades as the person internalize the strategies.
45464296|NCT01213277|Other|Fast Glycator|The subjects enrolled in this study will have a fructosamine test and blood drawn to see whether they are fast glycators
46013361|NCT01600274|Drug|Dienogest-Ethinyl Estradiol (reference product)|One tablet of Reference
46013362|NCT01176565|Drug|Intravenous nicardipine hydrochloride|"IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range.~Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present."
46013363|NCT04374123|Diagnostic Test|Serological screening for IgG and IgM antibodies against COVID-19|Serum evaluation for IgG and IgM antibodies against COVID-19 in patients in the endoscopy unit during the COVID 19 pandemic
45464297|NCT01213277|Other|Control|These patients will have their blood drawn to know what the normal glycation rate is in diabetic patients
46013364|NCT01600313|Dietary Supplement|rice bran oil|Treatment group received the low - calorie diet with(30g/day) rice bran oil
46013365|NCT01176292|Device|Rotating Platform High-Flex Cruciate Substituting TKA|
46013366|NCT01176292|Device|Rotating Platform Cruciate Substituting TKA|
46013367|NCT04310410|Combination Product|combined radiotherapy and MR-HIFU|Following standard EBRT (single or multiple fraction), patients will receive one MR-HIFU treatment with the Profound Sonalleve MR-HIFU device on the most painful of their bone metastases. This treatment will take place in a short time frame of 3 hours to maximum 4 days. Patients will be followed up until 4 weeks after treatment. During follow-up they will be phoned around day 3, 7, 14, 21 and 28 to retrieve pain scores, pain medication and (serious) adverse events. At day 3 the patient's experience with the combined treatment will also be inquired.
46013368|NCT04315675|Behavioral|Guided Imagery Intervention|The participant listens to a selected Guided Imagery for 21 consecutive days.
46013369|NCT04315675|Behavioral|Cognitive Power Intervention|The participant develops a plan to achieve healthy outcomes and reviews plan for 21 consecutive days.
46013370|NCT04315675|Behavioral|Combined Guided Imagery and Cognitive Power Intervention|The participant completes 21 days of selected Guided Imagery in combination with the development of a plan to achieve healthy outcomes and reviews the plan for 21 days.
46013371|NCT01600469|Drug|DAOI-B|250-1500 mg/day, oral, for 24 weeks
46013372|NCT01600469|Other|Placebo|placebo, oral, for 24 weeks
46013373|NCT01113541|Drug|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40-160 mg total daily dose) for up to 1 year.
46013374|NCT04417608|Procedure|Infraclavicular brachial plexus block|Ultrasound-guided infraclavicular brachial plexus block
46013375|NCT04451252|Procedure|Fluoroscopically guided lumbar medial branch nerve radiofrequency denervation.|"While in prone position, lumbar facet joints are identified by fluoroscopy. 18 gauge needles are then advanced aiming to the medial branch of lumbar facet joints. Correct positioning is confirmed by anteroposterior and lateral fluoroscopy. Then, the needles are attached to the radiofrequency device. Correct positioning of the needles is confirmed also by sensitive stimulation (paresthesia evocation) with the following settings: 50 Hz (hertz), 1ms, 0,6V (volts). In order to avoid motor lesion, it is confirmed that no motor response is produced with 2Hz, 2ms (millisecond) and twice the voltage that produced sensitive response. After correct positioning and repositioning the needles if needed, conventional radiofrequency ablation of medial branch nerves is performed using the following settings: 90 seconds, 80º Celsius degrees.~The selection of target facet joints is made based on clinical findings. Some patients receive bilateral while other unilateral facet joint denervation."
46013376|NCT04451252|Procedure|Fluoroscopically guided lumbar facet joint injection.|With the patient in prone position and guided by fluoroscopy, lumbar facet joints are identified. The 22 french needles are then advanced aiming to the lumbar facet joints. Correct positioning is confirmed with anteroposterior and lateral fluoroscopy. A mixture of 3 ml of ropivacaine 0,2% + 1 ml (40 mg) of triamcinolone (trigon depot) is prepared. 1 ml of the mixture is injected in each lumbar facet joint through the needles. Four facet joints are selected for therapy. Some patients receive bilateral and other unilateral but contiguous facet joint infiltration. The selection of target facet joints is made based on clinical and radiological findings.
46013377|NCT04451252|Procedure|Fluoroscopically guided lumbar epidural corticosteroid injection.|With the patient in prone position and guided by fluoroscopy, an epidural needle attached to a syringe filled with saline serum is advanced through the interlaminar approach using a loss of resistance technique for the identification of the lumbar epidural space. When loss of resistance is encountered, 1 ml of iodinated contrast is injected. After fluoroscopical confirmation of epidural spilling, a mixture of 4 ml of ropivacaine 0,1%, 2 ml (12 mg) of betamethasone and 2 ml of saline serum is injected in the epidural space. The lumbar level to which it infiltrates depends on each patient.
46099081|NCT02710877|Device|Programmed Intermittent bolus|Programmed epidural bolus of 10 ml mixture every 75 minutes, plus patient controlled bolus of 5 ml same mixture; lock-out 15 minutes.
46099082|NCT02710877|Other|Manual epidural bolus|Epidural bolus of 15 ml levobupivacaine and sufentanyl 10 mcg or 5 mcg administered by anesthesist on maternal request.
45464298|NCT03408483|Drug|Quadratus Lumborum Block (QLB)|Under ultrasound guidance, the needle will be advanced to the posterior border of the quadratus lumborum muscle. After negative aspiration, a bolus of 40 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots, ensuring proper placement of needle tip and appropriate spread of local anesthetic.
45464299|NCT03408483|Drug|Standard of Care|This is currently the standard of care, no local anesthetic will be injected. Pain will be managed with parenteral and oral medication.
45683865|NCT02395120|Behavioral|Intervention letter|Referral letter based on the Common Sense Model of Self-Regulation (CSM). The letter includes the cognitive dimensions of the CSM (identity, cause, timeline, consequences and control).
45683866|NCT02395120|Behavioral|Reduced intervention letter|"Reduced (removing text corresponding to timeline) CSM theory-based referral letter. The letter includes the remaining cognitive dimensions of the CSM (identity, cause, consequences and control)."
46013378|NCT04451252|Procedure|Fluoroscopically guided caudal epidural corticosteroid injection.|With the patient in prone position and guided by fluoroscopy, an epidural needle attached to a syringe filled with saline serum is advanced through the sacral hiatus using a loss of resistance technique for the identification of the epidural space. When loss of resistance is encountered, 2 ml of iodinated contrast is injected. After fluoroscopical confirmation of epidural spilling, a mixture of 7 ml of ropivacaine 0,2%, 2 ml (12 mg) of betamethasone and 7 ml of saline serum is injected in the epidural space.
46013379|NCT04451252|Procedure|Fluoroscopically guided pulsed radiofrequency of the lumbar dorsal root ganglion.|With the patient in prone position and guided by fluoroscopy, a 18 gauge needle is advanced aiming to the intervertebral foramen. Patient is cautioned about the paresthesia which will be felt. A lateral view was taken occasionally to confirm position. 0.5 ml of iodinated contrast is injected to confirm the position of the needle. Then 1 ml of the combination of 12mg of betamethasone and 1ml of ropivacaine 0.2% is injected over the affected root. Then, the needle is attached to the radiofrequency device. Correct positioning of the needles is confirmed also by sensitive stimulation (paresthesia evocation) with the following settings: 50 Hz, 1ms, 0,6V. In order to avoid motor lesion, it is confirmed that no motor response is produced with 2Hz, 2ms and twice the voltage that produced sensitive response. After correct positioning is confirmed, pulsed radiofrequency ablation of lumbar dorsal root ganglion is performed using the following settings: 4 minutes, 42ºC (degrees Celsius).
46013380|NCT04451252|Procedure|Fluoroscopically guided transforaminal epidural corticosteroid injection or lumbar selective root block.|With the patient in prone position and guided by fluoroscopy, a 22 french needle is then advanced aiming to the intervertebral foramen. Patient is cautioned about the paresthesia which will be felt along the course of the lumbar root when the needle touches the nerve. A lateral view was taken occasionally to confirm position. 0.5 ml of iodinated contrast is injected to confirm the position of the needle. Then 1 ml of the combination of 12mg of betamethasone and 1ml of ropivacaine 0.2% is injected over the affected root.
46013381|NCT04450823|Other|no intervention|no intervention study, survey amongst health workers
46013382|NCT04372368|Biological|COVID-19 Convalescent Plasma|1-2 units of COVID-19 convalescent plasma will be administered over 1 to 2 hours (rate of 100 to 200 mL/hr)
46013383|NCT04417413|Device|Fotona ProlapLase|Non-ablative SMOOTH mode intravaginal Er:YAG teratment for pelvic organ prolapse
46013384|NCT04372173|Diagnostic Test|analysis of the concentration of the clotting factors in patients who underwent primary hip arthroplasty|"Blood samples were taken before surgery, 6 hours, two, four, and six days after the procedure. Venous blood samples were taken from peripheral veins.~All analyzed parameters (fibrinogen, factor II, factor VIII, factor X, D-dimer) were determined using an ACL TOP 500 CTS automated coagulation analyzer.~All patients were operated on by a single surgical team, with cementless hip replacements implanted, and without tranexamic acid administered in the perioperative period. All patients underwent venous thromboembolic complications prophylaxis.~The following data were collected: age, body mass index, gender, perioperative risk assessment scale according to the American Society of Anesthesiologists score, blood transfusions, hemoglobin levels before surgery and two days post-surgery, instances of thromboembolic complications. Because of the observational nature of this study no changes in the treatment of patients were made."
46013385|NCT04450277|Procedure|Emergency surgery|Emergency surgery vs conservative management
46013386|NCT01113502|Drug|Eltrombopag|Oral formulation taken daily
46013387|NCT04474652|Other|Single Blood Draw from each participant|Health Professionals will seek informed consent and take a single blood collection from the participant. This will take place during the patient's visit to the breast one stop clinic as part of their routine urgent breast referral pathway.
46013388|NCT04416789|Other|Exercise programme|1 session of trampolining/dry sports (1.5 hours) and 1 session of supervised swimming (1.5 hours) per week for 10 weeks.
46013389|NCT01113463|Drug|TPI 287|Starting dose of 160 mg/m^2 as a 60-minute (± 10 minutes) IV infusion once every 3 weeks, (i.e., 1 cycle = 21 days).
46013390|NCT02886403|Other|Standard adhesive strip|A standard adhesive strip (hydrocolloid)
45679970|NCT04479475|Behavioral|Supportive care through community support persons|The adapted B-SBNT involves families and the wider social networks of people receiving MMT to support recovery. Key components of the intervention include: mapping the social networks of clients; inviting others identified through the mapping to participate in the intervention; building communication strategies with network members; and developing joint activities with network members, e.g., income-generating activities. MMT client participants attend seven sessions over the course of six weeks: (1) Introduction, (2) Working in a social network-based setting, (3) Setting drinking and drug use goals, (4) Coping skills 1, (5), Coping Skills 2, (6) Making lifestyle changes, (7) Generating income. Social support persons attend up to five sessions over the course of six weeks.
46013391|NCT02886403|Other|New adhesive strip|A newly developed adhesive strip
46099083|NCT02710877|Drug|Levobupivacaine|Levobupivacaine 0,0625% through peridural catheter
46099084|NCT02710877|Drug|Sufentanil 4 mcg|Sufentanil 0,4 mcg/ml through peridural catheter
46099085|NCT02710877|Drug|Sufentanil 5 mcg|Sufentanil 5 mcg through peridural catheter
45679971|NCT04475146|Other|video vizualisation|video vizualisation
45679972|NCT04469764|Drug|Abemaciclib|Given PO
46013392|NCT01112917|Device|VenaTech Convertible Vena Cava Filter|Prevention of Pulmonary Embolism
45464300|NCT03777917|Device|Belotero Balance®|Belotero® Balance for infraorbital hollows. Mode of application: subdermal injection.
45464301|NCT03787693|Behavioral|VR - Virtual Reality|Subjects in the experimental group will perform the split-belt task in a VR environment
45464302|NCT04830423|Procedure|Medical ozone injection|Patients in the ozone (O2-O3) injection group will be given intraarticular and periarticular knee injections 3 times as the first dose of 10 μg / ml, the second dose is 15 μg / ml, and the third dose is 20 μg / ml, each session in a volume of 10 ml. Patients will be evaluated according to the study criteria at the beginning, 4 and 12 weeks later by a blinded investigator.
46013393|NCT01112917|Procedure|Vena Cava Filter Conversion|Conversion of VenaTech Convertible filter to open configuration.
46013394|NCT00591708|Dietary Supplement|Beverage containing calcium citrate malate|Beverages containing a lower amount of calcium (0-400 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
46013395|NCT00591708|Dietary Supplement|Beverage fortified with calcium citrate malate|Beverages containing a higher amount of calcium (500-1300 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
45464303|NCT04830423|Procedure|steroid injection group|In the steroid injection group, 1 ml of betamethasone (6 mg / ml) will be injected once intraarticular knee injection. Patients will be evaluated according to the study criteria at the beginning, 4 and 12 weeks later by a blinded investigator.
45464304|NCT01202695|Drug|AVP-21D9|intravenously, single dose
45464305|NCT01202695|Drug|Placebo|Placebo comparator
45464306|NCT03717675|Device|NovaCross™ Chronic Total Occlusion micro-catheter|The NovaCross™ micro catheter is a guidewire positioning and support micro catheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment. Investigators will use the NovaCross Micro catheter during a standard of care catheterization of patients diagnosed with coronary total occlusion.
45464307|NCT03840889|Other|Data collection|"he different modes of active data collection:~Data collection by telephone~Data collection by mail~Collection from discharge database summaries (PMSI)"
45464308|NCT03715023|Drug|PC786|PC786 suspension for inhalation
45464309|NCT03715023|Drug|Placebo|Placebo solution for inhalation
45464310|NCT03715023|Drug|SOC|Standard treatment for RSV infection at study site
45464311|NCT03842527|Device|Ultrasound|Gastric ultrasound of the stomach antrum to assess contents 1 hour prior to C-section surgery. Scans will be completed in both supine (lying on back) and right lateral decubitus (positions) positions. The completion of both scans will take 5-10 minutes total
46013396|NCT01176058|Drug|Anidulafungin/Fluconazole|Anidulafungin:IV,100 mg daily preceded by an initial 200 mg dose on Day 1, 14 - 42 days Fluconazole: IV/Oral, 400mg,QD,14 - 42 days
46013397|NCT01606982|Drug|MDV3100|oral
45464312|NCT01311375|Dietary Supplement|w3 supplement in SCI|"supplements(Mor DHA and Ca 500 mg -D200 micro g )( will be given in this group"
45464313|NCT01311375|Other|placebo|placebo+ capsule CA-D
46013398|NCT04328766|Drug|DWC202005, alone|DWC202005, as a single dose
45464314|NCT03777059|Drug|Atogepant|Atogepant tablet
45464315|NCT03777059|Drug|Placebo|Placebo-matching atogepant tablets
45464316|NCT03638973|Procedure|Biopsy|Removal of specimen biopsies in patients with leukoplakic or lichenoid mucosal lesions using Er: YAG laser or scalpel under previous local anesthesia.
46013399|NCT04328766|Drug|DWP14012 + DWC202005|DWP14012 and DWC202005, as a single dose
46013400|NCT04328766|Drug|DWP14012 + DWC202005, after multiple doses of DWP14012|DWP14012 and DWC202005, after multiple oral doses of DWP14012 once daily for 12 days
46099086|NCT04219631|Device|expiration mouthpiece used during breathing exercises to ensure a constant ventilatory flowrate.|women enrolled in WINNER-FLOW-URO-MG group will freely use the expiratory mouthpiece device during all their childbirth process.
45464317|NCT01201525|Procedure|Pulsed dye laser treatment|Part 1 of the surgical scar will be treated with 4 595nm Pulsed dye laser treatments.
45464318|NCT01201525|Procedure|Control|Part 2 of the surgical scar will serve as a within patient control.
45464319|NCT03714945|Other|No intervention|No intervention is required as this study is observational.
45464320|NCT02913001|Other|Low Glycemic Load Diet|Participants received a diet education on a low glycemic load diet.
46013401|NCT01600781|Dietary Supplement|NutriniDrink/Fortini MF unflavoured (1.5kcal/ml)|During the 6-week Intervention period children allocated to group 1 will consume 2 bottles of study product per day (400ml in total).
46013402|NCT01600820|Other|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1 = Intervention 1 (1 test product/day)
46013403|NCT01600820|Other|2- Low fat drinkable fermented dairy product enriched with 2.0g of plant sterol (as free equivalent) per unit|2 = Intervention 2 (1 test product/day)
46013404|NCT01600820|Other|3- Low fat drinkable fermented dairy product without plant sterols(control)|3 = Intervention 3 (1 control product/day)
45464321|NCT02913001|Other|Usual Eating Plan|Participants received a diet education to continue with their usual eating plan.
45679973|NCT04469764|Drug|Anastrozole|Given PO
46099087|NCT02695823|Device|Ultrasound|"Ultrasound measurements of the optic nerve sheath diameter and intracranial Doppler, at 4 time points during surgery (incision, anhepatic phase + 30 min, declamping + 5 min, declamping + 30 min), and at day 1 and day 5 after surgery, to detect presence of intracranial hypertension.~Search of any neurological complication during the 5 postoperative days."
46099088|NCT00636857|Procedure|Fluid administration|Preoperative: bolus of 10 ml/kg body weight. During operation: 5 ml/kg body weight/hr. Postoperative: 3 ml/kg body weight/hr
46099089|NCT00636857|Procedure|Perioperative fluid management based on Lean Body Mass|Preoperative: bolus of 12 ml/kg LBM. During operation: 6 ml/kg LBM/hr. Postoperative: 3.5 ml/kg LBM/hr
46099090|NCT00530023|Device|MiniMed Paradigm REAL-Time System|MiniMed Paradigm 722 insulin pump The transmitter The sensor Paradigm Link Glucose Meter The ComLink
46099091|NCT02707367|Behavioral|Recovery Roadmap (RR) Wave 1|"A web-based tool that provides guidance for implementing Person-Centered Recovery Planning. There are 3 components:~Online module for service providers: A self-paced online module with interactive exercises, audio/video case studies, self-assessment, handouts, and collaborative materials designed for use with clients.~Online module for people in recovery: A self-paced online module with interactive exercises, case studies, self-assessment, informational handouts, and collaborative materials to be completed with providers.~Coaching & Support Center: A multimedia resource for providers with online coaching, a community of practice, and a resource library."
45679974|NCT04469764|Drug|Letrozole|Given PO
46013405|NCT01600859|Drug|E2609|"E2609 capsules: 5 mg, 25 mg, 50 mg, and 200 mg~E2609 doses: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, and 400 mg~According to the randomized study design, participants who are assigned to receive E2609 will each receive a single assigned dose consisting of two capsules of E2609 or in some cases one capsule of E2609 and one of placebo"
46013406|NCT01600859|Drug|Placebo for E2609|"Placebo capsules~According to the randomized study design, participants who are assigned to receive placebo will each receive a single dose consisting of two capsules of placebo"
46013407|NCT04328142|Other|Qigong group|Traditional Chinese Medicine exercise programme
46013408|NCT04328142|Other|Physiotherapy|Physiotherapy exercise programme
45464322|NCT01202851|Other|Relaxation Program|3 times a week, 60 minute sessions for 6 weeks.
46013409|NCT01607099|Procedure|Compatibility|Patients asses the compatibility of the bowel cleansing procedure
46013410|NCT02273765|Drug|Tenofovir + lamivudine + raltegravir|"In this arm, patients will receive the following medications :~Tenofovir disoproxil fumarate (TDF) 300 mg / Lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~Raltegravir (RAL) 400 mg (Isentress®): twice daily (1 tablet bid), with food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~Lamivudine (3TC) : 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~Raltegravir (RAL) 400 mg (Insentress®): twice daily (1 tablet bid), with food"
45464323|NCT01202851|Behavioral|Questionnaires|Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study.
45679975|NCT04460794|Behavioral|Ballet-inspired workouts|8 weeks, delivered by volunteers with a self-directed resource package
45679976|NCT04460794|Other|Usual care|Usual care and general recommendations on basic stretching and leg exercises for stroke survivors
45679977|NCT04457895|Behavioral|educational yoga program|"Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yog (the first on site and by videoconference for the others)"
45679978|NCT04457895|Other|no intervention|no yoga session at home and no yoga -therapeutic educatuion session
45679979|NCT04457310|Drug|CVL-562 (PF-06412562) 1 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
46013411|NCT02273765|Drug|Tenofovir + lamivudine + efavirenz|"In this arm, patients will receive the following medications, in accordance with treatment guidelines in all countries:~Tenofovir disoproxil fumarate (TDF) 300 mg / lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd)~OR:~• Tenofovir disoproxil fumarate (TDF) 245 300 mg / lamivudine (3TC) 300 mg / efavirenz (EFV) 600 mg: once a day (1 tablet qd), at night, if possible without food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~Lamivudine (3TC): 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd), if possible without food. The dose will not be adapted to the patient's body weight."
46013412|NCT04370184|Procedure|Ultrasound guided Costoclavicular Brachial Plexus Block|Ultrasound images from patients scheduled for upper limb surgery under costoclavicular brachial plexus block (one kind of regional anesthesia) have been routinely collected at our institute. These images will be reviewed.
46013413|NCT00591747|Behavioral|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
46013414|NCT00591747|Behavioral|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
45679980|NCT04457310|Drug|CVL-562 (PF-06412562) 4 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
46099092|NCT02707367|Behavioral|Recovery Roadmap (RR) Wave 2|"A web-based tool that provides guidance for implementing Person-Centered Recovery Planning. There are 3 components:~Online module for service providers: A self-paced online module with interactive exercises, audio/video case studies, self-assessment, handouts, and collaborative materials designed for use with clients.~Online module for people in recovery: A self-paced online module with interactive exercises, case studies, self-assessment, informational handouts, and collaborative materials to be completed with providers.~Coaching & Support Center: A multimedia resource for providers with online coaching, a community of practice, and a resource library."
46013415|NCT01607177|Behavioral|Daily text message reminders|Daily text message reminders to motivate patients to exercise in conjunction with an exercise information sheet.
46013416|NCT02279888|Device|CardioMEMS HF System|Pulmonary artery pressure sensor
46013417|NCT04414332|Other|Data collection only|This registry is to capture high quality patient safety and effectiveness data on use of the Angiovac device for 3 separate, but overlapping conditions; a) Iliofemoral and Caval DVT, b) Right heart masses, and c) PE. The goal will be achieved by capturing a concise set of immediate and short-term functional and clinical outcome data for all patients who have the angiovac catheter deployed into the vascular system.
46013418|NCT02489591|Device|Oral appliance|Patients will bring their prescribed oral appliance.
46099093|NCT05733949|Procedure|Biospecimen Collection|Undergo collection of blood samples
46099094|NCT05733949|Procedure|Computed Tomography|Undergo CT
45464324|NCT01202851|Other|Saliva Testing|4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
45679981|NCT04457310|Drug|CVL-562 (PF-06412562) 15 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
45679982|NCT04457310|Drug|CVL-562 (PF-06412562) 25 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
45679983|NCT04457310|Other|Placebo|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
46013419|NCT02489591|Device|BluePro oral appliance|Patients without a prescribed oral appliance will have a device provided for the duration of the study (BluePro, BlueSom; used for investigational purposes only). The device provided is a prefabricated thermoplastic customizable mandibular advancement splint.
46013420|NCT01607333|Drug|Lamotrigine use|Lamotrigine prescription during the study period
46013421|NCT02892981|Other|cardiopulmonary exercise test,hypoxia and hypercapnia test|class I and IV Pulmonary hypertension patients in stable haemodynamic status and optimized medical therapy underwent cardiopulmonary test and hypoxia and hypercapnia tests to evaluate the chemoreceptor sensitivity
46099095|NCT05733949|Radiation|Stereotactic Body Radiation Therapy|Undergo ST-SBRT
46099096|NCT02710799|Other|Teleconsultation|The teleconsultations will be performed by medical doctors, mostly family physicians, but also internists and endocrinologists. The teleconsultations will follow a structured format to discuss some topics on the disease and access the relevant information (based on the state's protocols). The doubts from the primary care physician will be addressed.
46013422|NCT01601015|Other|Manual Therapy|Manual therapy of Suboccipital soft tissue Inhibition is performed with patient in supine position. The patient's head leans against the physiotherapist's hands, which palpate suboccipital muscles by sliding fingertips until contacting posterior arch of atlas. At this point, a deep and progressive gliding pressure is applied, for 10 minutes. The purpose of this technique is to release suboccipital muscle spasm, which can be responsible for the mobility dysfunction of the occiput-atlas-axis joint.
46099097|NCT02710799|Other|Protocol|The informations provided in the referral list will be evaluated through the state's referrals protocols.
46013423|NCT01601015|Other|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
46013424|NCT01601015|Other|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
46013425|NCT01601015|Other|placebo treatment|"The physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
46013426|NCT02893098|Drug|Humia inj.|"Single injection of 3mL Humia inj.~Dummy: Single injection 2ml Normal Saline inj. given weekly for 2 weeks"
46013427|NCT02893098|Drug|High hyal Plus inj.|Single Injection of 2mL High hyal Plus inj. given weekly for 3 weeks
46013428|NCT01601054|Device|Tantalum cage from Zimmer|A tantalum cage will be inserted through a left sided retroperitoneal approach
46013429|NCT01607528|Dietary Supplement|Winclove-849|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
46013430|NCT01607528|Dietary Supplement|Placebo|A similar looking and tasting powder with no active substances
46013431|NCT01601093|Drug|High dose|Ceftazidime 3g, iv, bid and Sulbactam Sodium 1.5g, iv, bid for 5-14days.
46013432|NCT01601093|Drug|Low dose|Ceftazidime 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
46013433|NCT01601093|Drug|Cefoperazone and Sulbactam Sodium (CFP/SUB)|Cefoperazone 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
46013434|NCT04328571|Dietary Supplement|OLE enzymatically treated|OLE (Olive leaf extract ) enzymatically treated + maltodextrin
46013435|NCT04328571|Dietary Supplement|OLE + probiotic|OLE (Olive leaf extract) co-administered with probiotic
46013436|NCT04328571|Dietary Supplement|OLE|OLE (Olive leaf extract) + maltodextrin
46013437|NCT04367688|Drug|Tenofovir Disoproxil Fumarate 300 mg / emtricitabine 200 mg|daily use for PrEP
46099098|NCT01006213|Behavioral|Motivational intervention|Two groups will be established in geographically separate areas, one of which will receive the group motivational intervention (intervention group) and the other will receive standard follow-up (control group)
46013438|NCT02485418|Drug|Propofol|Intravenous propofol infusion at 20 mcg/kg/min for 10 minutes, followed by an increase to 30 mcg/kg/min for 10 minutes and then by an increase to 40 mcg/kg/min for 40 minutes.
46013439|NCT04366830|Drug|Remestemcel-L|Participants will receive remestemcel-L in two infusions of 2 x 10^6 mesenchymal stromal cells per kilogram (MSC/kg), administered intravenously (IV).
46013440|NCT01175824|Drug|Insulin Lispro Low Mixture (LM)|Participant-dependent dose, administered subcutaneously for 24 weeks
46099099|NCT02707445|Drug|Clopidogrel|Administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months after percutaneous coronary intervention
46099100|NCT05733871|Dietary Supplement|meal replacement product- STANDARD PRODUCT|standard product line contains common ingredients and this type of product already exists on world markets
46013441|NCT01175824|Drug|Insulin Glargine|Participant-dependent dose, administered subcutaneously for 24 weeks
46013442|NCT01175824|Drug|Prandial Insulin Lispro|Participant-dependent dose, administered subcutaneously for 24 weeks
46099101|NCT05733871|Dietary Supplement|Meal replacement product- INNOVATIVE PRODUCT|innovative product line contains raw materials that are considered better sources of potentially bioactive components
46099102|NCT02710955|Dietary Supplement|Thickened infant formula|
46099103|NCT05060887|Biological|OVX836-003|One single administration intramuscularly at Day 1.
46013443|NCT02482532|Biological|tvs-CTL Vaccine|autologous, 14g2a.zeta chimeric receptor transduced, activated T-cells, enriched for vaccine specific cytotoxic T-lymphocytes (tvs-CTL)
46013444|NCT01607684|Device|Magnetic Marker Imaging (MMI) with Magma 3D system|Magnetic Marker Imaging (MMI). It comprises of a high-resolution three-dimensional detector system, that detects passively and continuously the magnetic field of a magnetic marker capsule (1g, 6x12mm), which is taken orally by the subject. Changes in frequency, intensity and duration of oscillating marker movements allow us to delineate migrating gastric motor complexes. The Magnetic Marker Imaging takes up to 4 h in which the patient lies in a bed. Short interruptions (e.g. to visit the restroom) during this 4 h period are possible.
46013445|NCT01601210|Drug|Creatine monohydrate or placebo|Placebo, 2g, 4g, and 10g of creatine monohydrate
46013446|NCT01175707|Drug|Daptomycin|
46013447|NCT01175707|Drug|Vancomycin|
46013448|NCT01601249|Procedure|Embryo selection based on polscope grading or morphology|In the experimental arm embryo grading will be performed by polscope rather than conventional morphology, and the best embryo/s for transfer will be selected by this method.
46099104|NCT05060887|Biological|Saline solution|One single administration intramuscularly at Day 1.
45464325|NCT03717519|Diagnostic Test|Measurement of platelet count at diagnosis|Blood samples were drawn by expert phlebotomists in vacuum blood tubes containing K2-EDTA (Terumo Europe NV, Leuven, Belgium). The complete blood cell count (CBC) was performed using Advia 2120 (Siemens Healthcare Diagnostics, Tarrytown NY, USA). The local reference range for platelets was 150-400 x 109/L. The same analyser was used throughout the study period, and the quality and reproducibility of test results was validated by data of both internal quality control and external quality assessment
45464326|NCT03842449|Diagnostic Test|BabyCO|An expired CO measurement will be performed by BabyCO and the result will be returned to the smoking pregnant woman by the consultant.
45464327|NCT03842449|Other|Biological samples|"The nature of the samples taken during the delivery are:~maternal blood,~cord blood~placenta fragment"
46099105|NCT03999697|Drug|Autologous chimeric antigen receptor T cell transfusing agent targeting CD22|The enrolled patients will receive autologous-derived CD22-targeted CAR-T cells in 1 day with 100% of the total expected dosage after receiving lymphodepleting chemotherapy
46099106|NCT03999775|Dietary Supplement|Calcium, vitamin D and bioactive collagen peptides supplement|
46013449|NCT02892903|Device|Routine Measurement of FFR|FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow <3 will not be examined but will be 'awarded' an FFR value of 0.5
46013450|NCT01112059|Drug|Doxycycline|100 mg twice a day for 8 days
46099107|NCT03999775|Dietary Supplement|Calcium and vitamin D supplement|
45464328|NCT03714867|Drug|Pregabalin 150mg|150 mg concealed pregabalin capsule
45464329|NCT03714867|Other|Placebo|Concealed placebo capsule
46013451|NCT01112059|Other|placebo|placebo
46099108|NCT02706977|Drug|Low Dose Sinemet CR|Sinemet CR (25 mg carbidopa/100 mg levodopa) will be taken by mouth twice daily for two weeks.
46013452|NCT01175668|Drug|Clonidine|This group of infants undergoing NAS will be treated with neonatal morphine sulfate and Clonidine as an adjunct medication to control the symptoms. Once stable Finnegan scores <8 for 24h, NMS will be weaned by 10% daily till off, then Clonidine will be weaned off in a stepwise manner. Infant will not go home on any medication for NAS. NMS will be dosed as mg/kd/day divided q3h and Clonidine will be dosed as microgm/kg/day divided q6h based upon the initial Finnegan scores.
46013453|NCT01175668|Drug|Phenobarbital|"Infants in this arm will be treated as current standard practice with NMS and Phenobarbital. NMS will be weaned by 10% daily to completely off during the hospital stay. Infants will be discharged home on Phenobarbital.~NMS will be dosed as mg/kg/day divided q3h and Phenobarbital will be dosed as mg/kg/day divided q8h based on the Finnegan scores."
46013454|NCT01601327|Drug|Testosterone enanthate (Sustanon 250 mg)|Twenty-eight patients were treated with testosterone enanthate (TE),
46099109|NCT02706977|Drug|High Dose Sinemet CR|Sinemet CR (50 mg carbidopa/200 mg levodopa) will be taken by mouth twice daily for two weeks.
45464330|NCT01204177|Drug|BAY86-9766 MEK Inhibitor + Sorafenib|All patients who meet the entry criteria will receive BAY86-9766 50mg (2x20mg + 1x10mg capsules) twice daily in combination with sorafenib 800 mg (2x200 mg tablets bid). During the first 3 weeks they will receive a reduced dose of sorafenib: 600 mg / daily (1x200mg tablet in the morning + 2x200mg tablets in the evening) daily. This dose will be increased to the standard dose of 800 mg (400 mg bid) if no major side effects occur. Treatment until PD or until one of the withdrawal criteria for this study is met as described in the protocol (e.g. radiological progression or clinical progression)
45464331|NCT01217099|Drug|methylprednisolone|treatment patients were iv methylprednisolone pulse azithromycin for 5 days.
45464332|NCT01217099|Drug|azithromycin|control patients were iv azithromycin for 5 days.
45837505|NCT02897700|Drug|cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM)|Procedure: Routine chemotherapeutic regimens using two agents from cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as combinatorial treatment was performed 30~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agents were given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
45837506|NCT02897700|Drug|Placebo|Procedure: Routine placebo standardized in clinical oncology was provided to patients to replace any chemotherapeutic agent.
46099110|NCT02706977|Device|RETeval Electroretinogram (ERG) Testing|ERG testing consists of sitting in the dark for 15 minutes. During the procedure, participants will have a single-use adhesive sensor strip placed on the skin near the eye. A hand-held device, called the RETeval, will be placed in front of the eye and a series of flashes and flickering lights presented. The light intensity level is typically not uncomfortable. When right eye imaging is complete, the procedure will be repeated on the left eye. Both eyes will be evaluated in less than 5 minutes for most participants. Electroretinogram (ERG) testing will be completed at baseline, day 1, week 2, and week 4.
46099111|NCT02706977|Other|Contrast Sensitivity Testing|Contrast sensitivity testing consists of looking at a series of moving lines on a tablet device. The lines will change from white to grey to black. Participants will be asked to determine when they can no longer distinguish between the lines. Contrast sensitivity testing will be completed at baseline, day 1, week 2, and week 4.
46099112|NCT02706977|Other|Visual Acuity Testing|Participants will be asked to look at an eye chart with letters or symbols that become smaller as they move from top to bottom of the chart. Visual acuity testing will be completed at baseline, day 1, week 2, and week 4.
46099113|NCT02707133|Other|No intervention|
46013455|NCT01601327|Drug|Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU)|twenty-five patients were treated with human chorionic gonadotropin (hCG)
46013456|NCT01601327|Drug|Testosteron gel (Testojel 50 mg)|Twenty-four patients were treated with testosterone gel (TG).
46013457|NCT01607723|Other|NAVA ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
46013458|NCT01607723|Other|PAV+ ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
46013459|NCT01601366|Device|LNG-IUS|"The study includes 2 treatment groups: Group I the LNG-IUS group where they will have a LNG IUS inserted for them"
46099114|NCT02707211|Biological|Anti-oxLDL IgM antibody|Immunization
45679984|NCT04456920|Other|phone consultation|At D1, D2 and D3, patients in the experimental group 1 will receive a call from a neuro-psychologist during which pain, anxiety and esthetical biopsy impact will be assessed using numeric or visual analog scales during a semi-direct interview. During this call, any adverse events related to the breast biopsy will also be noted, as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken linked to the biopsy. If detected, pain or significative distress would be specifically managed.
45679985|NCT04456920|Other|e-PRO self-completed via connected objects (tablet/phone)|Patients in the experimental group 2 will be asked by SMS or notification to connect to the application in order to complete online the numeric and visual anog scales of pain, anxiety and esthetical impact. Any adverse events related to the breast biopsy will also be noted online, as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy. If detected, pain or significative distress would be specifically managed
45679986|NCT04456920|Other|phone consultation|At D4 post biopsy, all patients (of the 3 groups) will receive a phone call from a neuro-psychologist to assess pain, anxiety and esthetical impact, using numeric scales, and to collect adverse events. If detected, pain or significative distress would be specifically managed.
46013460|NCT01601366|Drug|Combined oral contraceptives|Group II: will recite combined oral contraceptives for 6 months
46013461|NCT04412226|Device|aerosol box|The aerosol box is a barrier that protects the staff against the aerosols during the aerosol generating procedures like endotracheal intubation. It is a transparent cube that covers the patient's head during the endotracheal intubation. Operator can intubate the patient through the two holes for arms.
46013462|NCT04412226|Device|transparent sheet|The transparent sheet is a barrier that protects the staff against the aerosols during the aerosol generating procedures like endotracheal intubation. It is a transparent cover that covers the patient's head and body during the endotracheal intubation. Operator can intubate the patient through the space under the cover
46013463|NCT01607762|Drug|Aripiprazole|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg aripiprazole tablet will be administered after an overnight fast.
46013464|NCT01607762|Drug|Quetiapine|Type= exact number, unit= mg, number= 100, form= tablet, route= oral administration. A single oral dose of two 50-mg quetiapine tablets will be administered after an overnight fast.
46013465|NCT01607762|Drug|Olanzapine|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg olanzapine tablet will be administered after an overnight fast.
46013466|NCT01607762|Drug|Risperidone|Type= exact number, unit= mg, number= 1, form= tablet, route= oral administration. A single oral dose of a 1-mg risperidone tablet will be administered after an overnight fast.
46013467|NCT01607762|Drug|Paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral administration. A single oral dose of a 3-mg paliperidone tablet will be administered after an overnight fast.
46013468|NCT04412031|Other|non applicable|non applicable
46013469|NCT04327869|Device|Magnetically controlled capsule endoscopy|The subjects swallowed the capsule with water in the left lateral position. When capsule enter stomach cavity, subject was asked to sit up and ingested 4 g aerogenic powder with 5 ml water to distend the stomach, and performed gastric baseline examinations to identify the lesions. After baseline examination, subjects ingested dyed sucralfate gel and performed the first-time examination. The examination was repeated at 30 min intervals, until dyed sucralfate gel disappeared completely.
46099115|NCT01006447|Behavioral|Instructor contact|
46013470|NCT01601405|Drug|YF476|Each subject took one capsule of YF476 100 mg twice daily on Days 1-6 and once on Day 7. Each capsule taken with water 150 mL.
46013471|NCT01601405|Drug|Placebo|On Days 0 and 14, each subject took a placebo capsule. Each capsule taken with water 150 mL.
46013472|NCT01607840|Procedure|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham for 20 to 60 minutes
46013473|NCT04327947|Other|Hyaluronic acid - Research product 1|Health care product (intimate gel)
46099116|NCT01006447|Behavioral|Instructor contact|
46099117|NCT02710487|Behavioral|REMSA|Awakening from REM sleep during the last hour of the sleep period
46099118|NCT02710487|Behavioral|NREMSA|Awakening from N2 (NREM) sleep during the last hour of the sleep period
46099119|NCT01006525|Drug|zolpidem|placebo or zolpidem (10mg)daily for one year
46099120|NCT05476393|Other|Postoperative management|1 g paracetamol will be administered 3 x 1. If the NRS score is ≥ 4, 1 mg kg-1 iv tramadol will be administrated.
46013474|NCT04327947|Other|Hyaluronic acid - Research product 2|Health care product (intimate gel)
46013475|NCT04327947|Other|Hyaluronic acid - Comparator product|Health care product (intimate gel)
46013476|NCT01601444|Device|Pletysmograph|Pletysmograph electrodes are applied to the thoracic wall
46013477|NCT01601483|Drug|MC-1101|1% Ophthalmic Solution TID
46013478|NCT01601483|Drug|MC-1101 Vehicle|Ophthalmic solution, TID
46013479|NCT01607879|Drug|Standard of care ADT + (HMB + arginine + glutamine)|"1 packet of HMB+arginine+glutamine contains 1.5 g of the amino acid metabolite HMB + 7 g arginine and 7 g glutamine.~Take one packet twice daily for 3 months"
46013480|NCT01607879|Other|Standard of care ADT|Patient will receive standard of care androgen deprivation therapy (ADT) alone
46013481|NCT01607918|Drug|D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole)|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
46013482|NCT01607918|Drug|D1-D14: (lansoprazole + clarithromycin + amoxicillin)|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
45679987|NCT04456920|Other|visit|And at D10 (+/- 2 days), all patients will physically come to the Cancer center in the consultation of biopsy results announcement. At the beginning of this consultation, pain, anxiety and esthetical impact will be assessed using numeric scales. . The adverse events related to the breast biopsy will be collected as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy and its findings. Insomnia will be evaluated by the Insomnia Severity Index. If detected, pain or significative distress would be managed as usually in the center.
46013483|NCT04363125|Diagnostic Test|Pathology result|Pathology result of rectal biopsy
46099121|NCT05733559|Device|QIAstat-Dx® Respiratory Panel Plus (RPP)|An observational prospective performance evaluation study of QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 target against a marketed comparator, using NPS collected per the manufacturer's instructions and eluted in Universal Transport Media (UTM) from subjects with signs and symptoms of respiratory infection
46099122|NCT04219241|Biological|Cellavita-HD|The participants will receive a total of 12 intravenous administrations of 2x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 180 days (total of 4 cycles).
46099123|NCT01006681|Biological|Focetria (Monovalent MF59-Adjuvanted vaccine)|"7.5 mcg Hemagglutinin H1/InfluezaA/California/7/2009 ,9.75 mg squalene MF59, 1.175 mg polysort80, 1.175 mg sorbitan trioleate~Intra muscular"
46099124|NCT01006681|Biological|Focetria (Monovalent MF59-Adjuvanted vaccine)|"7.5 mg Hemagglutinin H1/InfluezaA/California/7/2009, 9.75 mg squalene MF59, 1.175 mg polysirate 80, 1.175 mg sorbitan trioleate~Intramuscular injection"
46013484|NCT04362774|Device|ORBERA365|Behavioral modification program in conjunction with endoscopic placement of a single ORBERA365 Intragastric Balloon, filled with saline to an inflation volume between 400cc and 700cc with 2mL of Methylene blue (10mg/mL)
46013485|NCT01607996|Procedure|Epidural anesthesia|Epidural will be performed using carbostesin (0.1%), fentanyl (2 microg/ml) administered continuously at a rate of 6 to 15 ml/hour
46013486|NCT01607996|Drug|Patient controlled intravenous analgesia|Fentanyl 10 microg/ml at continuous flow of 10 to 20 microg/hour
46013487|NCT01601561|Drug|Regular human insulin injection|"Hyperinsulinemic normoglycemic clamp from beginning of surgery until 8 hours after surgery.~Humulin R 5 mU/kg/min and a variable infusion of glucose."
46013488|NCT04361682|Procedure|Surgical Drain Management|
46013489|NCT01601717|Drug|RTI-336|Four medication dosage groups (0 mg, 1 mg, 12 mg, 20 mg) administered in the form of a pill once per day for 10 days.
46013490|NCT01601717|Drug|Placebo|Matching placebo pill administered once per day for 10 days.
46013491|NCT01601756|Device|navigated revision knee arthroplasty|revision knee arthroplasty with the aid of a navigation system the navigation system is the Orthopilot System with a software specifically dedicated for revision operations (TKR 1.0). The system is from Aesculap AG (Tuttlingen).
46013492|NCT01601756|Device|conventional revision knee arthroplasty|revision knee arthroplasty using conventional instruments
46099125|NCT01006681|Biological|Focetria (Monovalent MF59-Adjuvanted vaccine)|Monovalent MF59-Adjuvanted vaccine
46099126|NCT05189561|Other|near-infrared scanner|"Tests to be administered: Near Infra-Red Scanning of the head at the bedside.~Time taken for testing: Two minutes~Biological samples collected: None~Frequency of testing/collection: Once~Risks for the participants while being tested: None"
46099127|NCT05733403|Drug|isotonic solution|Isotonic solutions are IV fluids that have a similar concentration of dissolved particles as blood.
46099128|NCT05733403|Drug|Noradrenaline|Noradrenaline itself is classified as a sympathomimetic drug: its effects when given by intravenous injection of increasing heart rate and force and constricting blood vessels make it very useful for treating medical emergencies that involve critically low blood pressure.
46099129|NCT05186909|Drug|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
46099130|NCT05186909|Other|Placebo|Placebo
45679988|NCT04450173|Drug|Ibrutinib|Given PO
45679989|NCT04450173|Biological|Obinutuzumab|Given IV
45679990|NCT04450173|Drug|Venetoclax|Given PO
46013493|NCT04327830|Other|Decisional needs assessment|Assessment of decision-making needs
46013494|NCT01601795|Drug|Sevoflurane|volatile Anaesthetic, duration during cardiopulmonary bypass
46013495|NCT01601795|Drug|Isoflurane|volatile anesthetic, duration during cardiopulmonary bypass time
46013496|NCT04360590|Device|pressure support ventilation versus neurally adjusted ventilatory assist|All patients underwent three mechanical ventilation modes, lasting 1 hour each: pressure support mode, neurally adjusted ventilatory assist and again pressure support ventilation
46013497|NCT01608035|Procedure|Sciatic catheter|presurgical sciatic catheter insertion
46013498|NCT01608035|Procedure|Stump catheter|intraoperative placed stump catheter
46013499|NCT01601912|Drug|Atomoxetine|40 mg, 1 application
46013500|NCT01601912|Drug|Citalopram|20 mg, 1 application
46013501|NCT02489201|Drug|donafenib tosilate tablets|200mg,bid
46013502|NCT04410939|Diagnostic Test|Reverse transcription polymerase chain reaction|PCR test is performed from the oropharyngeal and nasal swab samples taken before admission to each pregnant to prevent contamination from the pregnant women hospitalized in this clinic. In addition, the same test is done before each operation and before the operation. The aim of the study is to scan these tests retrospectively and to determine the rate of positive COVID-19 cases in asymptomatic pregnant women. The results will determine the importance of the measures to be taken in the pregnant and undergoing pregnant women.
46013503|NCT01601951|Other|Procedural, Bone Marrow concentrate injection|This is strictly data collection and outcomes based. The procedure is not part of this study
46013504|NCT01111825|Drug|Temsirolimus|"28 day treatment cycle Phase 1~Weekly intravenously (IV) on days 1, 8, 15, and 22~Starting dose 8 mg IV weekly (dose level 1). Three patients initially enrolled in each cohort~Phase 2~Dose escalation cohort - 8 mg IV weekly on Days 1, 8, 15, and 22, and then 15 mg IV weekly starting on Day 29~HER2-amplified and Triple negative - 8 mg IV weekly on Days 1, 8, 15, and 22"
46013505|NCT01111825|Drug|Neratinib|"28 day treatment cycle~• 240 mg orally daily"
46013506|NCT01608191|Behavioral|CBT follow up|11 weeks programme conducted via internet. CBT with focus on weight stability.
46013507|NCT01175590|Drug|Besivance|Ocular administration to affected eye for 7 days
46013508|NCT01175590|Drug|Vehicle|Vehicle of Besivance administered to affected eye for 7 days
46013509|NCT01601990|Drug|Placebo group(once daily)|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks.
46013510|NCT01601990|Drug|LC15-0444 50mg qd|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks
46013511|NCT01175473|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
46013512|NCT01175473|Device|Pen auto-injector|
46013513|NCT01175473|Drug|Liraglutide|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
46013514|NCT01175473|Device|Pre-filled pen injector|
46099131|NCT03893903|Drug|IDH1R132H peptide vaccine|"The vaccine is applied by s.c. injection with 300 μg IDH1R132H peptide emulsified in 0.5 ml 33% DMSO / 0.5 ml Montanide® per dose.~Patients receive 3 doses in two week intervals for 6 weeks, followed by re-resection. 4 weeks after surgery, treatment will be resumed consisting of 5 additional vaccinations in 4 week intervals, followed by maintenance vaccines until progression in three months intervals after a pause of 16 weeks."
46099132|NCT03893903|Drug|Avelumab|"Avelumab is a humanized anti-PD-L1 antibody approved for patients with Merkel cell carcinoma and urothelial cancer. It is applied by i.v. infusion with 10 mg/kg per dose.~Patients receive 3 doses of Avelumab in 2week intervals for 6 weeks, followed by re-resection. Avelumab will be administered in monthly intervals starting 4 weeks after the surgery until progression."
46099133|NCT01006759|Other|exercise and orientation|guidances for prevention of disability in leprosy with focus on hands, eyes and feet.
46099134|NCT02706587|Device|Neuromuscular electrical stimulation|NEMS is delivered bilaterally to the quadriceps femoris muscle using a portable battery-powered stimulator (Rehab 400, Cefar Compex, France). The electrodes are placed on the motor points of vastus medialis and vastus lateralis muscles. Electrical stimuli of 45Hz (pulse width: 380 µseconds; 6 seconds on with 1.5 second rise time; and 0.75 seconds fall time.; 5 seconds off). The current is adjusted to ensure maximum tolerable muscle contraction The protocol is applied twice daily for 25 minutes, five days a week.
46099135|NCT02706587|Device|Sham control|No electrostimulation
46099136|NCT02706821|Dietary Supplement|Persimmon leaf extract|Persimmon leaf extract (PLE), crossover design
46099137|NCT02706821|Dietary Supplement|Placebo|Placebo, crossover design
46013515|NCT01175473|Drug|Metformin|Metformin to be continued at stable dose (1.5 gram per day) up to Week 4.
46099138|NCT02706665|Other|SEDline monitor|The SEDline monitor gives us the Patient State Index (PSI), a dimensionless number within a range of 0 to100.
46099139|NCT02706509|Drug|Tramadol|patient will receive oral Tramadol 50 mg an hour before IUD insertion
46099140|NCT02706509|Behavioral|Verbal anesthesia|patient will receive full explanation about the procedure for five minutes before IUD insertion
46099141|NCT02706509|Device|Jaydess|Patient will go through an insertion of Jaydess intrauterine device.
46099142|NCT02706431|Procedure|Hyperventilation|
46099143|NCT02706275|Other|External warming|External warming via forced air warming to a goal body temperature 1.5°C greater than the baseline minimum temperature (within previous 24 hours) for 48 hours
46099144|NCT02710565|Other|Cohort|Obtaining additional EBUS TBNA samples for cell culture
46099145|NCT02710409|Biological|Quadrivalent influenza vaccine|0.5 ml/vial, one dose, intramuscular injection on day 0
46099146|NCT02710409|Biological|Trivalent influenza vaccine A|0.5 ml/vial, one dose, intramuscular injection on day 0
46099147|NCT02710409|Biological|Trivalent influenza vaccine B|0.5 ml/vial, one dose, intramuscular injection on day 0
46099148|NCT05265455|Dietary Supplement|Plant sterols 2.5 g/day|Daily consumption of one stick (2.5 g of plant sterols) during lunch or dinner for 3 weeks
46013516|NCT01602107|Other|Pelvic Floor muscle strengthening exercises|Participants will attend regular physical therapy visits (weekly X 2 weeks, bi-weekly X 4 weeks, and continuing monthly) until the time of their surgery. they will then see the physical therapist for assessment, exercise and advice at 2 and 4 weeks after their surgery. During physical therapy visits, patients will receive two sessions of biofeedback training, and at each visit will work on strength and motor control exercises for their pelvic floor muscles.
46013517|NCT01602146|Other|ultramarathon running|"blood samples before and after ultramarathon~urinary samples before and after ultramarathon~voluntary ant electrically muscular forces measuring before and after ultramarathon~Broadband ultrasound Attenuation before and after ultramarathon"
46013518|NCT01111552|Drug|Escitalopram|Escitalopram oral capsules.
46013519|NCT01111552|Drug|Aripiprazole|Aripiprazole oral capsules.
46013520|NCT01111552|Drug|Placebo|Study drug matching placebo capsule.
46099149|NCT05265455|Dietary Supplement|Placebo|Daily consumption of one stick (the same matrix without plant sterols) during lunch or dinner for 3 weeks
46099150|NCT03879239|Device|Vibrating capsule|Vibrating Capsule administered 5 times per week
46099151|NCT04605185|Drug|Donafenib Tosilate Tablets|100mg Qd/150mg Qd/100mg Bid, po
46099152|NCT04605185|Biological|Toripalimab Injection|240 mg, iv drip,q3w
46013521|NCT01602185|Drug|Dextromethorphan (drug used like antitussive)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
46013522|NCT01602185|Drug|Memantine (drug used in Alzheimer's disease)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
46013523|NCT01602185|Drug|Placebo (lactose)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
46013524|NCT02886208|Behavioral|Measurement|The intervention consists of diabetes prevention education sessions focusing on increasing physical activity and decreasing the intake of sugared drinks while increasing intake of fruits and vegetables. The 2-hr sessions occur weekly for 6 weeks. Height and weight is measured for each consenting participant at baseline and after 6 weeks. Participants are also asked to complete a short questionnaire to collect demographic and knowledge data. Outcome measures include: BMI, knowledge of physical activity and dietary habits conducive to diabetes prevention, and feelings of food insecurity.
46013525|NCT05062720|Radiation|Local consolidative therapy|Local Consolidative Therapy (LCT) will be defined as surgical resection or stereotactic body radiotherapy (SBRT) or a combination of both strategies
46013526|NCT01602302|Drug|bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)|bDMARDS (etanercept, adalimumab, infliximab, certolizumab, golimumab, tocilizumab, abatacept) will be discontinued after baseline visit in all participants
46013527|NCT05098171|Biological|Signal Switch Receptor Modified TIL|Adoptive transfer of 2x10^8-1x10^10 autologous signal switch receptor modified TILs to patients i.v. in 30-120 minutes.
46013528|NCT02893956|Procedure|echocardiography with postural support|
46013529|NCT02893956|Procedure|echocardiography with standard condition (usual)|
45464333|NCT04305457|Drug|Nitric Oxide|Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted No inhaled concentration will be maintained between 140 and 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the subject.
45464334|NCT01122563|Drug|Solifenacin|oral
46013530|NCT01602458|Procedure|Silicone Only Therapy (SOT)|SOT group will be instructed to wear the silicone for 23 hours/day, removing only for bathing. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. Compression free medical tape will be used to secure the silicone in place. Patients will be provided with 6 months of topical silicone therapy. If optimal results are achieved prior to 6 months of therapy, the treatment will be discontinued. Patients will also be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone.
46013531|NCT01602458|Procedure|Silicone Pressure Garment Therapy (SPGT)|"SPGT group will be instructed to use the Mepiform™ silicone only for 2 weeks during the interim before final fitting with the custom compression garment. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. The patients will be instructed to wear the silicone for 23 hours/day, removing only for bathing.~The patient will continue to use the Mepiform™ silicone under the compression garment for the entire length of the study. The garment will be replaced after 3 months of wear, in order to ensure that optimal pressure and silicone management is applied to the area. Patients will be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone and Compression Garment."
46013532|NCT02893722|Drug|atosiban|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion in total dose of 37.5 mg is set in certain infusion rate, and complete the infusion in 3 hours.
46013533|NCT02893722|Drug|0.9% saline|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion is set in the same rate with experimental group, complete the infusion in 3 hours.
46013534|NCT01602497|Device|rTMS|Patients undergone 10 session of high-frequency rTMS therapy over their left DLPFC
46013535|NCT01602497|Device|sham rTMS|Patients will undergo ten session of sham rTMS.
46013536|NCT01608269|Drug|Abacavir/Lamivudine|one tablet once a day
46013537|NCT04407156|Other|acute kidney injury|AKI in COVID positive cases
46099153|NCT05265143|Other|bolus/intermittant feeding|sequential randomization
45679991|NCT04449874|Drug|GDC-6036|The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).
45837507|NCT02889666|Drug|Cisplatin|Procedure: Preoperative chemotherapy using Cisplatin (60mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
45837508|NCT02889666|Drug|Carboplatin|Procedure: Preoperative chemotherapy using Carboplatin (400mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
45837509|NCT02889666|Drug|Docetaxel|Procedure: Preoperative chemotherapy using Docetaxel (120mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
46013538|NCT01602536|Behavioral|smoking cessation aides|All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.
46013539|NCT01602536|Behavioral|Twitter|Twitter quit-smoking group
46013540|NCT04407117|Behavioral|Lock-down and social distancing|Lock-down and social distancing during COVID-19 pandemic
46013541|NCT01602575|Behavioral|Mindfulness based Stress Reduction Training (MBSR)|8 (2 hr) classes weekly of MBSR and required homework of MBSR practice approximately 30 minutes per day.
46013542|NCT01608347|Drug|LMWH+Folic acid|Patients will receive a fixed dose of 40 mg of enoxaparin subcutaneous daily. Treatment will start once positive pregnancy test and will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tablet once daily will be started once positive pregnancy test and continues until 13 weeks' of gestation.
46013543|NCT01608347|Drug|Folic Acid|Folic acid 500 micrograms daily once positive pregnancy test until the 13th week of pregnancy or abortion
46013544|NCT04404933|Other|Treatment algorithm for OIC|Treatment Algorithm for OIC
46013545|NCT01608386|Procedure|IVC clamping|in right hepatectomy,use anterior approach and infrahepatic Inferior Vena Cava clamping.
46013546|NCT01602653|Device|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.20mJ/mm2, 2400 pulses once a week for 4 weeks.
46013547|NCT01602653|Device|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.10mJ/mm2, 2400 pulses once a week for 4 weeks.
46013548|NCT01602770|Drug|EV/DNG (Qlaira, BAY86-5027)|Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
46099154|NCT05264987|Other|intensive care follow-up|The need for the mechanical ventilator, the length of stay in the intensive care unit, and outcomes of mothers were recorded. Deceased patients were evaluated in detail.
46099155|NCT05119361|Other|Early Dry protocol|"After meeting eligibility criteria, patients have a net ultrafiltration of 2mL/kg/h with systematic perfusion monitoring (lactate concentration, central venous saturation, mottling score and capillary refill time) and restrictive input.~If the patient presents hypoperfusion (at least to sign), net ultrafiltration is stopped and haemodynamic optimized.~If the patient presents pulmonary oedema or right ventricular failure, with venous congestion, ultrafiltration is set at 3mL/kg/h.~Ultrafiltration is set between 0.5 and 1mL/kg/h when the following criteria are fulfilled: weight inferior to the admission weight; central venous pressure inferior to 5mmHg; absence of clinical oedema.~The haemodynamic status is reevaluated all six hours."
45837510|NCT02889666|Drug|Gemcitabine/Carboplatin|Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
45837511|NCT02889666|Drug|Gemcitabine/Cisplatin|Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Cisplatin (60mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
45837512|NCT02889666|Drug|Docetaxel/Oxaliplatin|Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Oxaliplatin (200mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
46013549|NCT04405284|Other|use and exposure to disinfectants during the coronavirus pandemic|The use of disinfecting products in deep house cleaning by women during the coronavirus lockdown.
46013550|NCT01603004|Other|MRI|Patients will be treated with either sunitinib, everolimus, or traditional chemotherapy according to standard of care. Follow-up with imaging (either MRI or CT) will be performed approximately every 3 months. Unidimensional tumor measurement on standard CT and MRI sequences will be performed, according to guidelines from RECIST v1.1, which will be used to assess for progression of disease. Patients will be followed for up to 5 years. Upon evidence of disease progression, patients will be asked to undergo a post-treatment biopsy. If medically possible and safe, they will stay on the drug until the time of biopsy.
46013551|NCT04328610|Procedure|LYMPHA(LYmphatic Microsurgical Preventive Healing Approach) technique|Patients will receive a lymphatic-venous anastomosis at time of their required Axillary Dissection
46013552|NCT01608464|Drug|irinotecan and docetaxel|combination of irinotecan and docetaxel regimen for 2 cycles, recycling every 21 days Irinotecan 100 mg/m2 by intra venous infusion over 2 hours in day1 and docetaxel 40 mg/m2 over one hour will be given on day 1 Assessment by PET scan and CT chest and abdomen will be done 2-3 weeks after end of 2nd cycle of irinotecan and docetaxel
45464335|NCT01217177|Drug|everolimus|
45679992|NCT04449874|Drug|Atezolizumab|A 1200 milligram (mg) intravenous (IV) infusion of atezolizumab will be administered on Day 1 of 21 day cycles.
46013553|NCT01608464|Drug|Cisplatin, fluorouracil and concurrent radiation therapy|Cisplatin, fluorouracil and concurrent radiation therapy 50 Gy in 25 fractions over 5 weeks with cisplatin 75 mg/m2 on first day of week 1 and week 5 and fluorouracil 750 mg/m2 daily by continuous intra venous infusion at Day 1 and Day 29 of Radiation therapy for 4 days.
46013554|NCT01603160|Behavioral|Quality Improvement|"There are no interventions for the individual patient. The changes in processes developed by the quality improvement team will be made for all adults with sickle cell disease, not just adults who consent to interviews.~A proactive risk assessment methodology, Failure Modes, Effects, and Criticality Analysis (FMECA), will be used in two EDs to identify the vulnerabilities, risks, and weak points (failures) in the systems and processes involved in four key decisions of the ED-SCANS. Based on the aggregated results of the FMECA's, generalizable quality improvement interventions (QII's) will be developed and implemented with the purpose of changing the way emergency care for adults with SCD is delivered and organized."
46013555|NCT04404699|Diagnostic Test|Stimulation TcPO2 test|"During measurement of TcPO2 in various angiosomes the stimulation test will be performed. We modify the Ratschow test (elevation of the lower limbs, rhythmic flexion and extension in talocrural joints for 2 minutes, then return to horizontal position). TcPO2 is measured continuously. Depending on the type of detected flows by DUS in the evaluated arteries supplying the relevant angiosome, in which TcPO2 values are measured, the patients and their angiosomes will be divided into 2 baseline groups - group M with monophasic flows or arterial obliterations and group T with triphasic flows.~We will compare macrocirculation parameters-systolic pressure on dorsalis pedis artery (DPA), posterior tibial artery (PTA) and their doppler indexes. The resting TcPO2, the minimal TcPO2 found during the stimulation test, their delta (resting TcPO2 - minimal TcPO2) and the percentage decrease in TcPO2 will be compared between the study groups, as well as the duration of TcPO2 recovery."
45837513|NCT02889666|Drug|Docetaxel/Carboplatin|Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
46013556|NCT01608503|Procedure|lung deflation|lung was deflated during respiration cycle
45464336|NCT05281939|Diagnostic Test|Artificial intelligence diagnosis|Participants were divided into the intervention group and the control group using a random number table. The intervention group participants' cervical colposcopic image data and non-image data as follow：age, the infection of high-risk human papillomavirus (HR-HPV),the type of HR-HPV infection,the duration of HR-HPV infection, cervical cytology (TCT) results, HIV/sexually transmitted infection history, marriage and childbearing history,first sexual life history, sexual partner history, smoking history,oral contraceptives history,the use of immune drug and possible clinical symptoms of cervical lesions such as postcoital bleeding, abnormal vaginal secretions, vaginal bleeding symptoms, etc.
45464337|NCT03933527|Behavioral|making staining beverage rinse during in-office tooth bleaching|the subjects in experimental group should make staining beverage(coffee or tea) rinse for 30 second, four times daily.
45679993|NCT04449874|Drug|Cetuximab|Cetuximab will be administered at an initial dose of 400 milligram per square meter (mg/m^2) IV infusion followed by 250 mg/m^2 IV infusion weekly in 21 day cycles.
45679994|NCT04449874|Drug|Bevacizumab|A 15 milligram per kilogram (mg/kg) IV infusion of bevacizumab will be administered on Day 1 of 21 day cycles.
45679995|NCT04449874|Drug|Erlotinib|150 mg of erlotinib will be administered PO QD in 21 day cycles.
45679996|NCT04449874|Drug|GDC-1971|The starting dose of GDC-1971 will be determined from its single-agent dose escalation.
45679997|NCT04449874|Drug|Inavolisib|The starting dose of inavolisib will be determined from its single-agent dose escalation.
45837514|NCT02889666|Drug|Placebo|Regular placebo in replacement of agent-specific chemotherapy was supplied to these patients.
46013557|NCT01608503|Procedure|lung inflation|lung was inflated during respiratory cycle
45679998|NCT04439331|Drug|Defactinib Hydrochloride|Given PO
45679999|NCT04439292|Drug|Dabrafenib Mesylate|Given PO
45680000|NCT04439292|Drug|Trametinib Dimethyl Sulfoxide|Given PO
45680001|NCT04439227|Drug|Adavosertib|Given PO
45680002|NCT04439188|Drug|PI3K-beta Inhibitor GSK2636771|Given PO
46013558|NCT04404270|Diagnostic Test|Anti-SARS-CoV2 Serology|The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.
46099156|NCT00529087|Drug|N-methylnaltrexone bromide (MOA-728)|Subcutaneous
46099157|NCT00529087|Other|placebo|placebo
46099158|NCT02710175|Other|serum TSH level|
45680003|NCT04439149|Drug|PI3K-beta Inhibitor GSK2636771|Given PO
45680004|NCT04432922|Other|Hospitalized Patients for COVID-19 Infection|Face to face semi-directed interviews about perceptions, representations and experiences of septic isolation, including nine opened-questions.
45680005|NCT04421963|Drug|Olaparib|300 mg olaparib (2×150 mg tablets) twice daily
45837515|NCT02737566|Behavioral|Standard Care + Financial Incentives|Tobacco cessation counseling plus pharmacotherapy and financial incentives for quitting.
45837516|NCT02737566|Other|Standard Care|Tobacco cessation counseling plus pharmacotherapy.
45837517|NCT04955340|Drug|[14C]-resminostat|1 single dose of 400 mg [14C]-resminostat
45837518|NCT04887324|Other|no intervention|no intervention
46013559|NCT04404270|Behavioral|Questionnaire|"Epidemiological data will be collected in a questionnaire that will be filled by participants at Day 0 (Visit 1), after 3 months (Visit 2) and after 9 months (Visit 3).~The questionnaire includes:~medical data (height, weight, smoking, history of intense stress);~socio-demographic data (age, gender, civil/military status, function/occupation, rank category, army, family status/home composition, housing conditions, etc.);~clinical data : history of symptoms suggestive of COVID-19 in the last 3 months, current symptoms suggestive of COVID-19;~use of care, hospitalization, work stoppage in the last 3 months;~contact with people who are symptomatic or proven COVID-19."
46013560|NCT04404270|Diagnostic Test|Anti-SARS-CoV2 serological controls and serum neutralization|Serological controls and a serum neutralization test will be performed on blood samples collected 3 months (Visit 2) and 9 months (Visit 3) after Day 0, respectively.
46013561|NCT01608542|Drug|Fostamatinib 100mg|oral tablet
45837519|NCT04815330|Other|increment sweep gas flow|If a sweep gas flow through the membrane lung increment has been decided upon to relieve dyspnea, a new recording will be made after each scan increment and the patient will be asked at each step.
46013562|NCT01608542|Drug|Fostamatinib 200mg|oral tablet
46013563|NCT01608698|Drug|30 mcg ethinylestradiol/2 mg chlormadinone acetate|By orally 1 tablet before bedtime for 21 days and withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
46099159|NCT02224924|Other|ABPI|If the patient was assigned to the ABPI group, a blood patch will be administered using the clotted blood in the syringe obtained at the beginning of the procedure. The guiding needle will be retracted up to 1.5-2 cm from the pleural surface, and the blood will be injected steadily and gently as the needle is pulled back out of the pleura. Injection will stop when the operator feels the needle is in subcutaneous tissues.
46013564|NCT01608698|Drug|30 mcg ethinylestradiol/3 mg drospirenone|By orally 1 tablet before bedtime for 21 days then withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
46013565|NCT04133805|Dietary Supplement|viscous fiber|ex. barley b-glucan, oat b-glucan, konjac glucomannan, psyllium, guar gum, and pectin
46013566|NCT01603199|Dietary Supplement|High protein high fiber diet|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
46013567|NCT01603238|Drug|[14C]-LC15-0444|A single oral administration of [14C]-LC15-0444 50 mg, containing 4.9 MBq [14C]. Subjects in the fasted state will receive the drug as a capsule, with 240 ml of water.
46013568|NCT01175083|Biological|GSK1024850A (Synflorix)|2, 3 or 4 intramuscular injection
46013569|NCT01175083|Biological|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
46013570|NCT01175083|Biological|Polio Sabin|4 oral doses
46013571|NCT02489708|Behavioral|Cessation Counseling|Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
46099160|NCT02224924|Device|BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug|If the patient is assigned to BioSentry group, using the manufacturer's deployment device the introducer needle is positioned so that the tip is at least 1.5 cm deep to the visceral pleura. The coaxial introducer needle hub will be prehydrated with a drop of saline, the BioSentry plug housing will be mated and locked to the hub and the plug will be deployed.
46099161|NCT00731848|Dietary Supplement|pomegranate liquid extract|Pomegranate liquid extract, 8 oz per day, for 52 weeks
46099162|NCT04318210|Drug|Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg|
46099163|NCT03999385|Behavioral|Mindful Self-Compassion (MSC)|The MSC program was developed by Christopher K. Germer, PhD and Kristin Neff, PhD.
45680006|NCT04416737|Other|Ultra-rapid insulin|Following 0.5-3 hours of insulin suspension from insulin pump, participants will receive insulin injection in respective locations (separated by at least 1 week) and then have serial lab measurements (YSI glucose, insulin and glucagon) taken during induced hypoglycemia.
45680007|NCT04414202|Procedure|tumorectomy with axillary dissection (sentinel lymph node)|All patients will have local excision of the primary tumor following appropriate clinical work-up. Surgery will be done according to usual local practice with a complete excision of the tumor. The aim of the local excision should be to achieve a minimum free margin of 2 mm whilst maintaining a good cosmetic outcome.
46099164|NCT04158323|Device|Airway Management in patients with a anticipated difficult airway|survey of anesthesists and intensive care physician of the perfomans with the flexible endoscope in patients with a anticipated difficult airway
46099165|NCT04066582|Device|ApolloVue™ S100 image system, Viper1-S003|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
46099166|NCT05465395|Procedure|Upper Cervical Adjustemnt|Upper cervical adjustement
46099167|NCT05465395|Procedure|Thoracic Adjustemnt|Thoracic adjustment
46099168|NCT05733247|Other|Copenhagen adductor exercise|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise.
45464338|NCT03674593|Procedure|Mitral valve chordae prosthesis|"The method consists of five stages:~Measure the required length of the chords~Forming loops~Fixation of the loop group to the papillary muscles~Fixation of chordal loops to the free edge of the valve~Annuloplasty with a support ring and a hydraulic test to confirm the absence of prolapse"
46099169|NCT05733247|Other|The adduction and abduction partner exercise|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise.
46099170|NCT00611663|Biological|Prevenar® and Pneumo23®|Vaccination with conjugate vaccine Prevenar® (WYETH-LEDERLE)at week 0 and Poly Saccharidic vaccine Pneumo23® (Sanofi Pasteur MSD) after 6 months (W24)versus2)
45680008|NCT04414202|Radiation|per-operative partial irradiation|20 Gy of per-operative partial irradiation at the tumor site during the surgery
46013572|NCT04403061|Diagnostic Test|Cytokines measurement|Quantification of plasma cytokine levels of human GM-CSF, IFN-α, IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-17A, and TNF-α using multiplex technol-ogy (quantitative measure).
45680009|NCT04384341|Radiation|Bone densitometry (BMD)|"Recruitment of haemophilic patients during a routine visit at the haemophilia centre.~Information of the subjects that the study requires a BMD measure for all and a blood sampling for patients only.~After inclusion and exclusion criteria have been checked, the subject can sign the consent.~For all subjects, an appointment will be made for BMD measure.~For patients and controls: BMD will be measured by Dual Energy X-ray Absorptiometry (DXA) technology, on femoral and lumbar spine (L2-L4) sites.~Recruitment of healthy volunteers through registers (Clinical Investigation Centers) and advertisements."
45680010|NCT04384341|Biological|Blood sampling for patients only|For patients, fVIII/fIX activity and antigen, thrombin generation potential and plasmatic markers of bone remodelling will be measured centrally.
45680011|NCT04381468|Drug|Pepinemab|Pepinemab is a humanized IgG4 monoclonal antibody. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
46013573|NCT04403061|Diagnostic Test|Cellular response|SARS-CoV-2 peptides (Prot-S, Pros-N and Port-M) will be used to activate CD4 and CD8 T cells. Cytokines released, such as IFNg, TNFa, IL4, IL17A, and IL2, from each cell subset will be measured by flow cytometry (quantitative measure).
46013574|NCT04403061|Diagnostic Test|TLRs activation measurement|After specific cell activation through TLR7/8 receptors, such as resiquimod, ORN R-0002, ORN R-0006, ORN R-1263, ORN R-2336, and controls as Poly (I:C), the release of IFNa, IFNg, TNFa, IL12, and IL6 will be analyzed (quantitative measure).
46013575|NCT04403061|Diagnostic Test|KIR phenotype evaluation|Characterization of the presence of 14 genes plus 2 pseudogenes of KIR gene family (qualitative genotyping) by PCR, mRNA expression profiling (quantitative measures) by RT-PCR, and phenotyping of human NK cells analyzing different KIR receptors (quantitative measure) by flow cytometry, will be analyzed.
46013576|NCT02881333|Genetic|Blood samples|
46013577|NCT04310254|Procedure|EDTA and CHX Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with Qmix 2in1 solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
46013578|NCT04310254|Procedure|EDTA Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with EDTA solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
46099171|NCT00611663|Biological|Placebo, Pneumo23®|Vaccination with placebo at W0 and Poly Saccharidic vaccine Pneumo23® at W24
46099172|NCT05448235|Other|conventional treatment|the patient will be asked to make pursed lip breathing (Breathe in for 2 seconds through his nose and Breathe out for 4 seconds through pursed lips)for 5-10 min ,3-4 times , 8-10 rep each cycle then asked to make diaphragmatic breathing exercise (Lie on his/her back and Inhale deeply through his/her nose for a count of three)for 5-10 min , 3-4 times , 8-10 repetition then postural drainage , furthermore the patient takes different position (prone to make percussion on lower lobes, side lying on anterior basal segment then sitting position on the upper lobe). After that a vibration on the chest (place a flat hand firmly atop the lung segment to be drained., and should apply light pressure and create a rapid, shaking movement) 1 min inhale and 5 time of repetition at the exhale and finally asked the patient to make productive cough for 5 times to get out the sputum.
45464339|NCT03674593|Procedure|Mitral valve chordae translocation|"The method consists essentially of three stages:~Selection of the secondary chord.~Fixation of secondary chords to the free edge of the valve.~Annuloplasty support ring and hydraulic test to confirm the absence of prolapse."
45464340|NCT01204333|Drug|Endovascular thrombolysis|Endovascular thrombolysis consists of local application of alteplase or urokinase within the thrombosed sinuses. Standard endovascular techniques to mechanically remove clot material, such as thrombosuction, are allowed, but not mandatory.
45464341|NCT01204333|Drug|Heparin|The patients randomized to standard care will receive (or continue) either intravenous adjusted dose unfractionated heparin (aPTT value kept within 1.5 to 2.5 times the normal value), or any type of body-weight adjusted low molecular weight heparin in therapeutic dose, according to local custom and international guidelines
45464342|NCT02529059|Drug|Eviplera|A single-pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily for 24 weeks.
45464343|NCT03932669|Drug|Nilotinib|150-300mg daily dose of nilotinib
45464344|NCT04257175|Biological|CAR-T CD19|The CAR-T infusion will be given in IV infusion. The target dose is 1 X 106 positive CAR / kg T cells (range: 0.5-1.5X 106 CAR / kg positive T cells).
46099173|NCT05448235|Other|thoracic mobilization|we will use A SNAG to mobilization using type 3 oscillatory and sustain for 90 second, at first put the patient in 3 position (side lying to make mobilization of upper 6 ribs in downward direction then make on lower 6 ribs ,furthermore flexion of the thoracic and next rotation toward the midline then ask the patient to transfer to supine lying position and mobilize the sternum in downward direction the next mobilize the clavicle and ask the patient to take sitting position and put his hand on his head in adduction position and make extension on the thoracic vertebrae with inward mobilize with the investigator knees ,take each 4 vertebrae along the 12 thoracic vertebrae.
46013579|NCT04310254|Procedure|CHX Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with CHX solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
46013580|NCT02480972|Procedure|magnetic resonance imaging|"multiparametric MRI as follows:~diffusion weighted imaging using multiple b-values~Fat quantification sequence~perfusion MRI using ECCM agent~MR elastography~------------------------------------~routine MRI using hepatocyte specific agent (optional in patients with focal liver lesion)"
46013581|NCT01608737|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
46013582|NCT01608737|Drug|BI 201335|BI 201335 once daily high dose for 12 weeks
46013583|NCT01608737|Drug|BI 201335|BI 201335 once daily high dose for 12 weeks
46013584|NCT01608737|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
46013585|NCT01608737|Drug|BI 201335|BI 201335 once daily low dose for 24 weeks
46013586|NCT02886130|Dietary Supplement|Placebo|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
46099174|NCT04524533|Behavioral|Experimental smoking cessation video|Participants who are randomized to the intervention group will watch an educational video that includes tips on quitting smoking during a dental cleaning. The video is approximately 10 minutes long and tailored to readiness to quit at the time of the dental visit.
46013587|NCT02886130|Dietary Supplement|Experimental|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
46013588|NCT02881606|Device|Naso-alveolar molding (NAM)|
46099175|NCT04524533|Behavioral|Control video|Participants randomized to the control group will watch a 10 minute video.
46099176|NCT04524533|Other|Brochure of smoking cessation EBTs|All participants will receive identical print materials on EBTs consistent with smoking cessation standard clinical care.
46099177|NCT04524533|Behavioral|Tailored text message program|Participants randomized to the intervention group will be enrolled in a 4-week tailored text message program which includes assessment questions in addition to text messages geared towards motivating and facilitating EBT utilization for individuals ready to quit smoking and individuals who are not ready to quit smoking.
46099178|NCT04524533|Other|Assessment text messages|Participants randomized to the control group will be enrolled in a different 4-week text message program that includes only assessment questions.
46099179|NCT05264519|Other|foot bath intervention|Students in this group will have their feet soaked in water with a temperature of 38-42 degrees for 20 minutes, half an hour before bedtime.
45464345|NCT01217333|Behavioral|In-person CP|CP is a structured interview in which a lay health worker prompts a patient to articulate questions and concerns about decision issues in preparation for a treatment discussion with a provider. The Consultation Planner (CPer) then completes and prints out a word-processed template, paraphrasing and summarizing the patient's questions and concerns. The patient takes away the printed Consultation Plan to serve as a visual aid and agenda during the meeting with the doctor. CPers are trained to avoid providing medical advice or information. Arrangements will be made for participants who do not have transportation to the CRCMC.
45464346|NCT01217333|Behavioral|Tele-CP|Participants in the Tele-CP arm will receive CP by telephone. Arrangements will be made for participants who do not have access to a telephone.
45464347|NCT01567189|Behavioral|Cardiac rehabilitation|"Training sessions: 8 weeks of supervised physical training sessions. Stress intensity will be calculated from the peak heart rate reached during stress test: 60-70% during the first month and 70-85% during the second one. Patients will be advised to do at least 1 hour of outdoor exercise with the same intensity on the days when they do not attend hospital.~Health education sessions and relaxation sessions: one per week.~Smoking and diet checking: as recommended by doctor."
46099180|NCT05060029|Drug|Lactobacillus Species|Lactobacilli containing suppositories have been successfully used in the past to maintain the vaginal environment and for treatment of infections like BV. Some of the Lactobacilli species that have been used include Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus gasseri and Lactobacillus plantarum, none of which demonstrated any safety concerns. The investigational product, which contains a Lactobacilli complex as its main component, has already been marketed as a tool to maintain vaginal microbial balance, pH and the prevention of microbial infection, thus there are no additional safety concerns or risks involved in this clinical trial design.
46099181|NCT05060029|Other|Placebo|Coconut Oil Fatty Acids
45837520|NCT04815330|Other|non-invasive ventilation|In ventilated or non-ventilated patients in whom the decision to implement non-invasive ventilation has been made, an increase in PEEP in 2 cmH2O steps without exceeding a plateau pressure of 25 cmH2O and a VT of 10ml/kg of the patient's theoretical weight will be achieved.
46099182|NCT00612209|Drug|ARQ 197|Treatment with ARQ 197
45837521|NCT02740374|Device|ROTEM|ROTEM coagulation assessment and guided transfusion management.
45464348|NCT01567189|Behavioral|Cardiac rehabilitation|The only difference in the hospital's program is that training sessions will be out of hospital with the same target heart rate that in this case will be controlled with pulsometer or Borg scale. The recommended frequency of sessions will be: at least 5 days a week with a minimum of 1 hour / day.
46099183|NCT01006915|Procedure|Surgery|Surgical decompression of the common peroneal, tibial, and deep peroneal nerves
46099184|NCT03809117|Diagnostic Test|Biofire Film Array Gastrointestinal Panel|The 22-target FilmArray® GI Panel allows a syndromic approach to the diagnosis of infectious diarrhea as it includes bacteria, viruses and parasites in one test. Results are typically available within two hours of collection.
46099185|NCT05733169|Other|Frequency lowering intervention|Modified parametrization of the current frequency lowering parametrization.
46099186|NCT05733169|Other|Frequency lowering reference|Current frequency lowering parametrization
46099187|NCT00870870|Drug|Gemcitabine|"1000 milligrams per square meter (mg/m^2) on Days 1 and 8 of each cycle~[First 6 cycles (18 weeks)]"
46013589|NCT02881606|Device|Computer aided design NAM (CAD/NAM)|
46013590|NCT01608776|Device|MIST Therapy|The MIST Therapy System is used as a non-contact method of delivering ultrasound to treat chronic wounds.
46099188|NCT00870870|Drug|Cisplatin|"75 mg/m^2 on Day 1 of each cycle~[First 6 cycles (18 weeks)]"
46099189|NCT00870870|Biological|IMC-A12 (cixutumumab)|"6 milligrams per kilogram (mg/kg) intravenous (IV) infusion, administered once per week (on Days 1, 8, and 15 of each cycle)~[First 6 cycles (18 weeks)]"
45464349|NCT01124669|Genetic|DNA analysis|
45464350|NCT01124669|Genetic|mutation analysis|
46099190|NCT00870870|Biological|Cetuximab|"400 mg/m^2 IV infusion, administered on Day 1 of Cycle 1, 250 mg/m^2 once per week thereafter~[First 6 cycles (18 weeks)]"
45464351|NCT01124669|Other|laboratory biomarker analysis|
45464352|NCT03100058|Drug|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally.
45464353|NCT03100058|Drug|Placebo|Placebo
45464354|NCT01201603|Dietary Supplement|orange juice|250ml of orange juice or a sugars matched orange drink
45680012|NCT04381468|Drug|Placebo|Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
45680013|NCT04376333|Behavioral|Cognitive-Behavioral Treatment|Cognitive-behavioral coping skills training
45680014|NCT04376333|Behavioral|Individualized Assessment and Treatment Program|Experience-sampling based cognitive behavioral coping skills assessment and training
45837522|NCT02740374|Other|Standard of Care|Standard Coagulation Tests assessment and guided transfusion management
45837523|NCT00609804|Drug|Sorafenib|Sorafenib 400 mg twice daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.
45837524|NCT00609804|Drug|Erlotinib|Erlotinib 150 mg once daily by mouth
45837525|NCT00610116|Device|Electronic Repositioning|Change of pacing vectors for CRT pacing
45837526|NCT00610428|Drug|Staccato Placebo|Inhaled Staccato Placebo
45837527|NCT00610428|Drug|Staccato Prochlorperazine 5 mg|Inhaled Prochlorperazine 5 mg
45837528|NCT00610428|Drug|Staccato Prochlorperazine 10 mg|Inhaled Prochlorperazine10 mg
45837529|NCT02446236|Drug|Lenalidomide|Dose escalation of lenalidomide. Patients will receive 10, 15, 20, or 25 mg PO days 1-21
45837530|NCT02446236|Drug|Ibrutinib|560 mg PO daily
46013591|NCT01608776|Other|SOC - Standard of Care|Standard of Care includes wound cleansing and debridement as needed, moist wound healing dressings, and offloading
46099191|NCT00870870|Biological|IMC-A12 (cixutumumab)|"10 mg/kg IV infusion, administered once every 2 weeks~(Maintenance therapy)"
45680015|NCT04376333|Other|Standard Conservative Care|Standard conservative dental care for orofacial pain
45680016|NCT04364607|Drug|Neostigmine|Participants will receive 0.5 mg IM neostigmine
45464355|NCT03933683|Device|Pudendal nerve terminal motor latency assessment|After a specialized coloproctology evaluation, each patient with pelviperineal dysfunction was addressed to dynamic transperineal ultrasound to determine anterior and posterior displacement of puborectalis muscle, and subsequently a blinded neurophysiologist performed pudendal nerve terminal motor latency assessment to identify pudendal neuropathy.
45680017|NCT04364607|Drug|NaCl 0.9%|Participants will receive IM NaCl 0.9% as a placebo
45837531|NCT02446236|Drug|Rituximab|375 mg/m2 IV Day 1
46099192|NCT00870870|Biological|Cetuximab|"500 mg/m^2 IV infusion, administered once every 2 weeks~(Maintenance therapy)"
46099193|NCT00870870|Drug|Carboplatin|"Area under the curve (AUC) = 5, Day 1 of each cycle~[First 6 cycles (18 weeks)]~*Carboplatin will be replaced by Cisplatin"
46099194|NCT02569840|Dietary Supplement|Amino Acid Feed|Each child will receive the amino acid based feed for a period of up to 4 weeks (28 days). The feed prescription will be determined on an individual basis by the Dietitian responsible for the child's nutritional management. The child will take the feed orally or via a pre-existing naso-gastric, gastrostomy or jejunostomy tube.
46099195|NCT04000321|Other|Windmill at 30 Minutes|The so-called windmill technique of placenta development for the management of the retained placenta involves the application of a continuous 360-degree umbilical traction force with centripetal rotation in such a way that it runs at the level of the introitus perpendicular to the direction of the birth canal. This rotation around a 360-degree traction plane is repeated slowly and continuously with a motion that resembles the motion of the wings of a windmill until the placenta can be safely delivered.
45464356|NCT03840577|Device|Monitorization of sedation by Bispectral Index|"The BIS value of the patient will be evaluated twice per nursing shift (every 4 hours) and will be recorded in the electronic medical record. The objective of BIS will be between 40 and 60.~According to the BIS of the patient at the time of the evaluation, the dose of sedative administered in a continuous infusion pump will be increased or reduced in order to reach the target BIS, with 20% modifications of the current dose at the time of evaluation.~The dose of sedative used will be recorded in the electronic medical record. The BIS values will be saved in the equipment and downloaded every 72 hours."
46099196|NCT04000321|Other|Windmill at 45 Minutes|The so-called windmill technique of placenta development for the management of the retained placenta involves the application of a continuous 360-degree umbilical traction force with centripetal rotation in such a way that it runs at the level of the introitus perpendicular to the direction of the birth canal. This rotation around a 360-degree traction plane is repeated slowly and continuously with a motion that resembles the motion of the wings of a windmill until the placenta can be safely delivered.
46099197|NCT00566878|Biological|alglucosidase alfa|At least one infusion of alglucosidase alfa post partum
46099198|NCT01006993|Device|NeuroFlo catheter|NeuroFlo™ catheter 45 minute treatment
45680018|NCT04354012|Combination Product|methylene blue, gentian violet, and ovine forestomach wound dressings|"Hydrofera Blue is an antibacterial foam dressing that contains methylene blue and gentian violet to manage wounds. This is a safe, non-cytotoxic product that can be worn for 7 days while not inhibiting growth factors. This products wicks bacteria into the foam and away from the wound surface using natural negative pressure through capillary flow.~Endoform (ovine forestomach) is a natural dermal template used in all phases of wound healing. This product helps to stabilize, build, and organize tissue in acute and chronic wounds.~Hypafix tape aids in stabilization of wound dressings. This productIt is easy to apply, skin friendly, and comfortable to use."
45680019|NCT04348383|Drug|Defibrotide|6.25 mg/kg every 6 hours in 2 hours infusion for 7 or 15 days
45680020|NCT04348383|Drug|Placebo|Placebo 250 cc every 6 hours for 7 or15 days
45680021|NCT04332926|Other|Tobacco product administration and assessment|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
46099199|NCT05264441|Device|In-Check DIAL G16|Patients will inspire into an In-Check DIAL G16 device.
45680022|NCT04323202|Drug|Pembrolizumab|Post Fine-cut CT: 4 doses of pembrolizumab (200mg) IV q 3 weeks. Post standard resection and reconstruction: 1 year of pembrolizumab (200mg) q 3 weeks (another 13 doses, thus 17 doses total)
45837532|NCT00610740|Drug|topical gemcitabine hydrochloride|Gemcitabine 100 mg/m2 will be administered as a single dose, directly to the cervix via the CerviPrep™ device.
45837533|NCT00610740|Procedure|therapeutic conventional surgery|hysterectomy
45837534|NCT02444676|Other|Stratification and outcomes|No necessary
45837535|NCT04470180|Behavioral|Virtual Teach to Goal|Participants will complete inhaler education on a tablet device.
45837536|NCT04470180|Behavioral|Brief Instruction|Participants will be read out loud instruction on how to use their inhaler.
45837537|NCT00611442|Drug|lubiprostone|lubiprostone 24mcg gelcap, 1 gelcap taken at noon the day prior to the colonoscopy
45837538|NCT00611442|Drug|placebo|placebo gelcap, taken at noon the day prior to the colonoscopy
45837539|NCT02136420|Drug|Promethazine|Subject receives promethazine
46099200|NCT04120636|Drug|Episcleral Celecoxib|Sustained Release Transscleral Celecoxib
46099201|NCT04969003|Behavioral|Short videos|Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.
46099202|NCT04160585|Other|There is no intervention.|There is no intervention.
46099203|NCT00731926|Dietary Supplement|Oligomerized litchi fruit extract|100mg at once twice a day for 1 month
46099204|NCT00731926|Dietary Supplement|VItamin C + Vitamin E mixture|Vitamin C 400mg + Vitamin E 160IU at once twice a day for 1 month
46013592|NCT04402554|Behavioral|Cannabis questionnaire|The effectiveness and use of cannabis in the management of chronic pain has been well known for many years, but has so far been illegal and therefore largely unacknowledged. We hypothesize that the use of cannabis in this population of patients with chronic joint or spinal pain is not anecdotal and responds to a need to further improve the overall management of patients. The objective of our anonymous questionnaire is to estimate the prevalence of cannabis use in patients with chronic inflammatory rheumatism.
46013593|NCT01111474|Other|Cyanoacrylate|3 applications of cyanoacrylate (48 hours interval) at the cervical region of the sensitive tooth
46099205|NCT00731926|Other|placebo|twice a day for 1 month
46099206|NCT02709941|Other|Inspiratory muscle strength training|Breathing training designed to augment inspiratory muscle strength, and thus targeted muscle groups may benefit from improved force generating capability result in improved breathing.
46099207|NCT02709941|Other|Placebo|
46099208|NCT02620176|Device|Transcutaneous vagal nerve stimulation|Trans-auricular vagal nerve stimulation
46099209|NCT04134702|Other|Acupuncture|Acupuncture and ear acupuncture using indwelling fixed needles, that will remained in situ several days after surgery until the patients will experience pain
46099210|NCT05733091|Behavioral|Standard of Care|Standard of care assessment of their function including pituitary hormone lab draws, audiogram hearing test, eye exam, teeth and jaw exam (in trismus clinic) and speech and swallowing evaluation
45680023|NCT04323202|Other|Tissue collection|Non-marginal tissue as well as pre-op biopsy tissue to be stored
46099211|NCT05038631|Drug|Ribociclib|50 mg and 200 mg hard gelatin capsules o tablets as individual patient supply packaged in bottles
46099212|NCT00732004|Device|Silicone Hydrogel Contact Lenses|
46099213|NCT00732004|Device|1x PMBH preserved MPS|
46099214|NCT00732004|Device|1x Polyquad/Aldox MPS|
46099215|NCT02710019|Other|Back to Reality Series Video Games|Back to Reality Series are a psycho-educational video games that provide information about psychosis and marijuana use from the perspective of 'Harry': a character who experiences problems with both issues. The aim is for players to learn how to detect some signs of psychosis and where to seek help for mental health and addictions problems.
46099216|NCT02710019|Other|Control Video Game|The control video game consists of digital puzzles and spelling game about pop culture. The control games does not have any content related to mental health and addictions problems
46099217|NCT00732082|Drug|Gemcitabine|
46099218|NCT00732082|Biological|LAG-3|
46099219|NCT05221177|Behavioral|TR-30|Suspension training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
45680024|NCT04316286|Procedure|Tele-multidisciplinary care|Scheduled televisit by sleep medicine specialists, endocrinologists, legal-medicine specialists
46099220|NCT05221177|Behavioral|TR-45|Suspension training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
46099221|NCT02620098|Other|Size Matters Handwriting Program|The Size Matters Handwriting Program (Moskowitz, 2009) (SMHP) program incorporates principles grounded in motor learning theory, cognitive theory, and motivation theory. Children learn the importance of letter size by learning size 1 (capital and tall letters), size 2 (small letters) and size 3 letters (those that dive below the baseline) at different stages (Moskowitz, 2009). The intervention group received a total of 30 sessions of the SMHP, completed twice weekly over a 16 week period. Sessions lasted 30 minutes, and were led by an occupational therapist with training in the Size Matters Handwriting Program. All interventions were provided within the existing support classrooms. Each child had their own SMHP workbook.
46099222|NCT05004155|Diagnostic Test|24 hour pH & impedance monitoring|24 hour pH impedance monitoring will be done on healthy subjects so that normative data specific to indian population can be generated.
45680025|NCT04316286|Other|Standard care|Scheduled in-office visit by sleep medicine specialists, endocrinologists, legal-medicine specialists
45680026|NCT04314401|Procedure|Biospecimen Collection|Undergo collection of blood, tissue, bone marrow, and cerebral spinal fluid samples
45680027|NCT04314401|Other|Medical Chart Review|Medical charts are reviewed and data is collected
45680028|NCT04305691|Drug|Ixazomib Citrate|Given PO
45680029|NCT04305691|Other|Quality-of-Life Assessment|Ancillary studies
46013594|NCT01111474|Radiation|Laser|This process was conducted three times with an interval of 48 hours between applications, according to laser's manufacturer advice Clean Line Easy Laser - LILT®, Clean Line Easy Laser Doctor Dental Products Industry LTDA, BRA). For dentin hypersensitivity, the application of 1Joule/cm^2 is recommended for eight seconds at three points along the dental neck, using the infrared wavelength (795nm).
46013595|NCT01608932|Procedure|Telemonitoring for frail patients with chronic diseases|"Patients are equipped with a telemonitoring kit that can be composed by a portable wrist clinic device, a digital weight scale and a glucometer for clinical parameters measuring, according to the pathologies of the patient. The equipment is completed by a gateway device for data transmission.~The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG, body weight and glycemia with a frequency set by the clinician in the personalized treatment plan. In the same protocol the clinician includes also the alarm thresholds that determine when the clinical measures are out-of-range. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the general practitioner in case of worsening of symptoms."
46013596|NCT01603433|Device|Sapheon™ Closure System|Sapheon™ Closure System for the treatment of incompetent saphenous veins.
46013597|NCT01603511|Device|Rewarming modality|A commercial charcoal heater will be applied to the torso or the head in two of the trials. The control trial involves shivering only.
46013598|NCT04400955|Diagnostic Test|Audiometry tablet diagnostic tool and web-based test|as above
45464357|NCT03840577|Other|Monitorization of sedation by clinical scales|"The BIS monitor will be placed on the patient but it will be left blind to the nursing team, the BIS values will be stored in the equipment and downloaded every 72 hours.~The RASS of the patient will be evaluated twice per nursing shift (every 4 hours) and will be recorded in the electronic medical record. The RASS will be evaluated by a research team member.~According to the patient's RASS at the time of evaluation, the dose of sedative administered in a continuous infusion pump will be increased or reduced in order to reach the target RASS. The modification of infusion speed will be done by the nurse in charge of the patient. The dose of sedative applied will be recorded in the electronic medical record."
45680030|NCT04305691|Other|Questionnaire Administration|Ancillary studies
46099223|NCT05397145|Other|Postoperative analgesia management|Intravenous 0.5 mg/kg tramodol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. Patients in all groups will be attached to IV PCA containing 10 mcg/ml fentanyl, 10 mcg bolus without infusion dose, 10 min lock time protocol. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
46099224|NCT00611741|Drug|furosemide, Na supplements|furosemide 20 mg, Na supplements 8g in divided doses/day for 5 days
46099225|NCT02022982|Drug|Palbociclib|Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 75 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered without food with patients fasting for 1 hour prior and 2 hours post drug administration.
45680031|NCT04301622|Device|Primary Knee implants|Primary knee arthroplasty
45837540|NCT02136420|Behavioral|Hyper gravity training|Subject receives hypergravity training before testing
45837541|NCT02136420|Drug|Placebo|Placebo
46099226|NCT02022982|Drug|PD-0325901|PD-0325901 will be administered orally twice daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 2 mg twice daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. PD-0325901 will be administered using a flat-dosing plan. No premedications are required. As the effect of food on PD-0325901 is uncertain, patients will be permitted to dose either fasting or after food.
46099227|NCT02620332|Drug|MultiPepT1De injection|A mix of peptides
45837542|NCT02136420|Behavioral|No hypergravity training|Subjects do not receive normal Earth gravity
45837543|NCT02136498|Drug|Varenicline|Standard 12 week course of varenicline, provided in both arms
45837544|NCT02136498|Behavioral|Cognitive-behavioral self-help|Standard self-help education for smoking cessation, delivered via mobile-optimized website accessible via smartphone.
45837545|NCT02136498|Behavioral|MyMAP (My Mobile Advice Program)|Same standard self-help intervention as in control arm + automatically-tailored support and advice for managing nicotine withdrawal symptoms + secure messaging with cessation counselor
46013599|NCT01603550|Other|Sleep Deprivation|Sleep Deprivation
45464358|NCT03933761|Drug|Pamiparib|60 mg of pamiparib (3 capsules of 20mg) will be administered orally twice a day, once in the morning and once in the evening continuously in 28 day cycles.
46013600|NCT01603550|Other|Energy Restriction|Energy Restriction
45464359|NCT01202929|Procedure|High Resolution Manometry|High Resolution Manometry which uses 36 solid state sensors spaced at 1-cm intervals, positioned from the hypopharynx to the stomach.
45464360|NCT03932123|Drug|Piperacillin and tazobactam, azlocillin, latamoxef, meropenem, vancomycin，cefotaxime|Efficacy and safety of antibiotics
45464361|NCT01124747|Drug|ASP1585|Oral
45464362|NCT01124747|Drug|14C-Labeled ASP1585|Oral
45464363|NCT02866279|Device|Etonogestrel Contraceptive Implant|Women will be randomized to the TIMING of implant placement
45464364|NCT01222169|Drug|NaCl 0,9%|Propofol 3micrgr/ml (TCI plasma concentration) and NaCl 0,9% 2min. and 10min. application
45464365|NCT02871778|Drug|VX-371|
45464366|NCT02871778|Drug|Hypertonic Saline|
45464367|NCT02871778|Drug|Placebo (0.17% saline)|
45464368|NCT02871778|Drug|VX-371 + HS|
45464369|NCT02871778|Drug|Ivacaftor|
45464370|NCT01217489|Procedure|Breast scan - Electrical Impedance Mammography|Scanning of the breast on a non-invasive device, using harmless minute electrical currents
45464371|NCT01203007|Dietary Supplement|Tailored diet|Tailored diet according to demonstrated food sensitivity, 6 months
45464372|NCT01203007|Dietary Supplement|Low antigen content diet|Low-antigen content diet for one month
45464373|NCT01222325|Procedure|extracorporeal shockwave lithotripsy (SWL)|patients were submitted to one session SWL at a Dornier Compact Delta lithotripter under general anesthesia under supervision of an anesthesiologist and an urologist.
45464374|NCT04226911|Behavioral|S&SEs|"S&SEs:~As many sugar-containing products in the diet as possible should be replaced with S&SE-containing products.~To ensure that a certain amount of S&SE products is consumed every day, a fixed minimum amount of units for each individual is planned."
45464375|NCT04226911|Behavioral|Sugar|"Sugar group:~In the sugar group it is allowed to consume up to a certain number of units of sugar-containing products each day, corresponding to < 10 E% added sugar.~The sugar group is not allowed to consume any S&SE products."
45464376|NCT01217567|Procedure|Staples left, subcuticular suture right|Closure of the skin after cesarean section with staples on the left side of the wound and subcuticular suture on the right side.
45464377|NCT01217567|Procedure|Subcuticular suture left side and staples right|Closure of the skin after cesarean section with staples on the right side of the wound and subcuticular suture on the left side.
45464378|NCT02860975|Other|Inhaled Nitrogen|"To create the correct gas mixture, nitrogen tanks or membrane technology nitrogen generators will be utilized.~Humidified, high flow, hypoxic gas by nasal cannula will allow the participant to walk short distances, eat, execute basic personal needs (e.g., use of toilette, washing, bathing etc.), or take breaks from wearing the mask."
45464379|NCT02855242|Behavioral|Lifestyle Counseling|Participation in weekly group sessions over a period of 10 weeks, with information on healthy nutrition and exercises promoting weight loss
45464380|NCT02855242|Other|Controls Group|Subjects not participating in any lifestyle counseling
45464381|NCT01124825|Device|IGEL|iGEL(TM) airway will be used for induction and maintenance of positive pressure ventilation
45464382|NCT01124825|Device|King airway|KING-LTS-D(TM) airway will be used for induction and maintenance of positive pressure ventilation
46013601|NCT04399590|Other|Interficial Intelligence|Interficial Intelligence
46099228|NCT02620332|Other|Placebo|Water for injection
46099229|NCT00726934|Other|Food Safety Guidelines|Participants will be randomized to the food safety guidelines will receive information and recommendations regarding Food Shopping, Food Storage, Food Preparation, Safe Cooking, and Safe Serving of Food.
45464383|NCT01124903|Procedure|Dehydration|Subjects were dehydrated by 2 - 7% of body mass over 3-5 hours using exercise-heat stress and fluid restriction.
45464384|NCT04947592|Drug|Fluconazole 150 mg|fluconazole 150 MG once daily for 14 days
45464385|NCT02735473|Drug|Choline bitartrate|
45464386|NCT02735473|Drug|Placebo|
45464387|NCT01124981|Drug|Haemocomplettan® P|Dosing of study medication will be individually determined based on plasma fibrinogen concentrations (measured with Clauss method during the reperfusion period on CPB) and body weight. Intravenous infusion within 10 minutes.
45464388|NCT01124981|Drug|Human albumin (Placebo)|Human albumin with concentration 200g/L. The study bottles of 50 mL will be diluted with saline and will contain 2g in total. This concentration resembles the total protein load in the bottles with Haemocomplettan® P.
45464389|NCT05156788|Drug|PD-1+Lenvatinib+GEMOX|Tilelizumab 200mg, add 0.9% NS 100mL, d1 Q3W, Lenvatinib 8mg, po, qd Gemox chemotherapy: Gemcitabine 1000mg/m2 with 0.9% NS 100mL, 30 minutes, d1, 8, Q3W, + oxaliplatin 85mg/m2 with 5%GS 500mL, 2 hours, d1, Q3W
45464390|NCT03931733|Other|Music Therapy|Single thirty minute receptive music therapy intervention.
45464391|NCT04457986|Drug|Erector spina plane block (ESP)|Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol
45464392|NCT04457986|Drug|Modified thoracolumbar interfacial plane block (MTI)|Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol
45464393|NCT04457986|Drug|Intravenous patient controlled analgesia (IV-PCA)|Patient will receive intravenous patient controlled analgesia with tramadol
45464394|NCT01219517|Other|Polar body and embryo biopsy|2 polar bodies and all embryos will be biopsied prior to embryo transfer.
46013602|NCT01603667|Drug|PG2|"STUDY DRUG DOSAGE:IV infusion of PG2 Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg PG2 Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5~3.5 hrs. The same dose of PG2 Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
46013603|NCT01603667|Drug|placebo|"STUDY DRUG DOSAGE: IV infusion of Placebo Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg Placebo Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5~3.5 hrs. The same dose of Placebo Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
45464395|NCT04201405|Drug|Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene|Autologous CD34+ haematopoietic stem cells from MPS IIIA patients will be genetically modified ex vivo using CD11b.SGSH Lentiviral vector (LV), a self-inactivating LV expressing the SGSH gene codon optimized for human use and regulated by a human CD11b myeloid-specific promoter. Cells will be cryopreserved prior to patient administration.
46013604|NCT01603745|Drug|Zoely|1 pill every day
45464396|NCT04199767|Drug|20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)|Participants will be assigned to receive regular insulin either 20 or 40 IU administered through an intranasal nebulizer-like device.
45464397|NCT04199767|Drug|40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)|Participants will be assigned to receive regular insulin either 40 or 20 IU administered through an intranasal nebulizer-like device.
46013605|NCT01603745|Drug|Yasmin|1 pill every day
45464398|NCT03740633|Behavioral|passive ankle pump motions on the day of surgery|Passive ankle pump motions include flexion and extension, circumduction, which will be conducted by caregiver on the day of surgery.
45464399|NCT03740633|Behavioral|active ankle pump motions and abdominal breathing training on the 1-3 day after the surgery|Active ankle pump motions include flexion and extension, circumduction, which will be conducted by patient on the 1-3 day after the surgery. On the same time, the patient is given abdominal breathing training.
45464400|NCT03740633|Combination Product|Regular care|Regular post-operative care consists of compression stockings, anticoagulant and instructions of early mobilization
45464401|NCT01566877|Drug|AVI-7288|"Cohort 1: AVI-7288 at 1 mg/kg IV; Cohort 2: AVI-7288 at 4 mg/kg IV;Cohort 3: AVI-7288 at 8 mg/kg IV; Cohort 4: AVI-7288 at 12 mg/kg IV~The amount of AVI-7288 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day."
45464402|NCT01566877|Other|Placebo|Normal Saline Solution (NSS)
45464403|NCT01125059|Drug|Methadone|0.2 mg/kg methadone IV bolus
45464404|NCT01125059|Drug|Saline|3 mL saline IV bolus
45464405|NCT01204411|Drug|Artesunate-amodiaquine fixed-dose combination|"artesunate 25 mg / amodiaquine 67.5 mg: 1 tablet / day for 3 days for children with a weight of 5 kg to less than 9 kg;~artesunate 50 mg / amodiaquine 135 mg: 1 tablet / day for 3 days for children with a weight of 9 kg to less than 18 kg;~artesunate 100 mg / amodiaquine 270 mg: 1 tablet / day for 3 days for children with a weight of 18 kg to less than 36 kg;"
45464406|NCT01566955|Procedure|transgastric adnexectomy|adnexectomy transgastrically with transvaginal support
46013606|NCT02691585|Other|Music Intervention|A raga will be played for 10 minutes & data collected.
45464407|NCT01125137|Procedure|Removal of Keloid|Keloid will be excised by Henry Ford Hospital Dermatologist, Dermatosurgeon or Plastic Surgeon.
45464408|NCT01471444|Drug|Fludarabine|"Flu + Bu Group: 40 mg/m2 by vein on Days -6 through -3.~Flu +Clo + Bu Group: 10 mg/m2 by vein on Days -6 through -3."
45680032|NCT04299828|Other|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the role of immune cells in coagulopathy.
46013607|NCT01174264|Other|Pharmacological Study|Correlative studies
46013608|NCT01174264|Drug|Vismodegib|Given PO
46013609|NCT01603784|Behavioral|Intensive Exercise|"Standardized aerobic training program that is individualized to each participant's fitness level, and supervised by a certified exercise specialist. Participants attend 3 training sessions per week for 6 months. The session begins with a 10-15 minute warm-up. Participants then exercise on a treadmill or stationary bike, followed by cool-down activities. Heart rate and rating of perceived exertion are used to evaluate exercise intensity. Participants begin at ~30 min/day 60-70% of HR max and/or an equivalent level of RPE, and progress to 45-50 minutes at 75-85% for HR max."
46013610|NCT01603784|Behavioral|Home Exercise|Exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. Each participant has a 60-minute sessions with an exercise trainer to teach them how to perform the exercises correctly. They are also given diagrams illustrating the exercises, along with written instructions. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes. They also go to the recreational center monthly to meet with an exercise trainer to ensure that they are doing the exercises correctly. Participants record their exercise activities on a calendar for the 6 months.
46013611|NCT01603784|Behavioral|Cognitive Training|Computer-based training that is is administered 3 days per week for 8 weeks during months 5 and 6. The training program focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. One day of the week is devoted to each of the three cognitive processes. Some training sessions include a homework assignment for application and practice of the target cognitive processes in everyday activities.
45464409|NCT01471444|Drug|Clofarabine|30 mg/m2 diluted in normal saline to produce a final concentration of 0.4 mg/mL, and infused on Days -6 through -3.
46099230|NCT00726934|Other|Neutropenic Diet|"The Neutropenic Diet Guideline includes all information contained in the FDA Food Safety Guidelines with the addition of the following recommendations:~Avoid raw vegetables and fruit (Oranges and bananas are okay.)~Avoid take-out foods and fast foods and fountain drinks.~Avoid aged cheese (blue, Roquefort, Brie).~Cook all produce to well done. Eggs must be hard-boiled.~Avoid deli meats.~No raw nuts, nuts roasted in shell, or freshly ground nut butters from a health food store.~No well water~No yogurt"
45464410|NCT01471444|Drug|Busulfan|Busulfan systemic exposure dose of 6000 µMol-min in normal saline over three (3) hours by vein every twenty-four (24) hours for four (4) consecutive days (days -6 to -3), starting immediately after the completion of Clofarabine. The dose on day -6 to -3 based on pharmacokinetic analysis of target AUC of 4,000 µMol-min ± 5% for 61-70 years of age (without Pharmacokinetics alternate dose 130 mg/m2).
45464411|NCT01471444|Drug|Thymoglobulin|"Both groups who receive a graft from an unrelated donor:~0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.0 mg/kg on day -1. On day -3, administered after the chemotherapy is complete."
45464412|NCT01471444|Procedure|Stem Cell Infusion|Cryopreserved bone marrow or peripheral blood progenitor cells infused on day 0.
45464413|NCT01471444|Drug|Tacrolimus|Starting dose: 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
46099231|NCT04134468|Drug|Pegvorhyaluronidase alfa|IV infusion
46099232|NCT04134468|Drug|Abraxane|IV infusion
45464414|NCT01471444|Drug|Methotrexate|5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
45464415|NCT05282407|Drug|Tenofovir disoproxil 245mg|1 tablet q.d. for 48 weeks
45464416|NCT05282407|Drug|Tenofovir disoproxil fumarate 300mg|1 tablet q.d. for 48 weeks
45680033|NCT04294472|Drug|MAU868|MAU868 is a human monoclonal antibody (IgG1) that binds the viral capsid protein, VP1, that is responsible for binding to the surface of host cells
46099233|NCT04134468|Drug|Gemcitabine|IV infusion
46013612|NCT01603784|Behavioral|Health Education|"Weekly educational sessions are administered during months 5 and 6, conducted at the recreational center by research staff. Sessions last 1 hour, and cover health and other topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and saving energy in one's home. At the completion of each session, participants are given a homework assignment."
46099234|NCT02709863|Drug|Sevoflurane|1-1.5 MAC, inhalation route, during operation
46099235|NCT02709863|Drug|Desflurane|1-1.5 MAC, inhalation route, during operation
46099236|NCT02709863|Drug|Propofol|6-10 mg/kg/h, iv infusion, during operation
46099237|NCT02619942|Procedure|D2 radical operation|In D2 radical operation group(D2), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue.
45464417|NCT01222559|Drug|co.don chondrosphere®|co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.
46099238|NCT02619942|Procedure|Complete mesocolic excision (CME)|In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
46099239|NCT04065490|Device|Valeda PBM treatment|The Valeda Light Delivery System
46099240|NCT04065490|Device|Valeda Sham treatment|The sham mode of the Valeda Light Delivery System.
46099241|NCT03877237|Drug|Dapagliflozin|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
46099242|NCT03877237|Other|Placebo|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
45464418|NCT01222559|Procedure|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form new tissue.
45464419|NCT04209686|Drug|Paclitaxel|"Patients will receive treatment on Day 1 and 8 starting with cycle 2.~Paclitaxel (80 mg) will be administered IV on days 1 and 8 starting with cycle 2 (every 21 days).~Drug - Paclitaxel - 80mg IV"
45464420|NCT04209686|Drug|Olaparib|"Olaparib will be taken by mouth daily for 3 weeks (every 21 days).~Drug - 100 mg or 300mg"
45464421|NCT04209686|Drug|Pembrolizumab|"Patients will receive treatment every 21 days.~Pembrolizumab (200 mg) will be administered IV on day 1 (every 21 days).~Drug - 200mg IV"
45464422|NCT01125215|Drug|0.75% capsaicin nanoparticle cream|0.75% capsaicin nanoparticle cream apply to area with neuropathic pain twice daily for 12 weeks
46099243|NCT02619786|Drug|Inhaled colistin|75 mg of colistin activity, inhaled per dose, every 12 hours
45464423|NCT01125215|Drug|Placebo|Identical cream base of nanoparticle apply to area with neuropathic pain twice daily for 12 weeks
45680034|NCT04294472|Other|Placebo|250 mL D5W placebo IV to be labeled to match that of MAU868
45837546|NCT00612222|Biological|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10^7 CCID50 (with a range of approximately 10^6,4 to 10^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2 mL). This will be repeated on day 14.
45837547|NCT00612222|Biological|ALVAC MART-1 Vaccine|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10^7 CCID50 (with a range of approximately 10^6,4 to 10^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2 mL). This will be repeated on day 14.
46013613|NCT01174186|Drug|Adalimumab|Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given
46013614|NCT01609049|Drug|Peginterferon alfa-2a|Administration of treatment will be according to local recommendation under local labeling.
46013615|NCT01609049|Drug|Ribavirin|Ribavirin tablets twice daily orally will be administered depending on body weight, according summary product characteristics and prescribing of ribavirin in real clinical practice.
45464424|NCT01141816|Other|Contrast-Enhanced Ultrasound|Contrast-enhanced ultrasounds of the kidney will be performed within 7 days of routine CTs or MRIs at 3, 6, 12, 18, and 24 months post-radiofrequency ablation, with Perflutren Lipid Microsphere Injectible Suspension ('Definity') as the contrast agent.
45464425|NCT04943614|Other|Biodex balance system|BIODEX stability system (BIODEX Medical Systems Inc; Shirley, New York) offers a system that can deliver particular hip and ankle postural training strategy with external biofeedback as a monitor to enhance the reduced subclinical limitations of patients with diabetic neuropathy
45464426|NCT04943614|Other|conventional exercises|balance board exercises, walking on different surfaces, Wobble board exercise and parallel bars for ambulatory training, range of motion exercises, foot care as a home program. Same duration treatment
45464427|NCT02644135|Drug|Halo Oral Spray|Three sprays per use, total = 9 sprays per day
45464428|NCT02644135|Drug|Halo Placebo|Three sprays per use, total = 9 sprays per day
45464429|NCT01217723|Biological|Anti-Thymocyte Globulin (Rabbit)|Thymoglobulin 0.5 mg/kg on Day -2 prior to the Transplant, 2.5 mg/kg on Day -1, and 2.5 mg/kg on the day of transplant.
45464430|NCT01217723|Other|Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)|The standard preparative regimen can be myeloablative or reduced intensity.
46013616|NCT02893566|Behavioral|Mi Band Step Challenge|
45464431|NCT05162872|Drug|Niraparib，Sintilimab|Niraparib 200 mg QD D1-21 Sintilimab 200 mg IV q3W
45464432|NCT01222637|Drug|CetuGEX™|
46013617|NCT02893527|Behavioral|personalized coaching|personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
46013618|NCT01609088|Dietary Supplement|Erythritol-containing beverage|Orange flavored beverage containing erythritol
46013619|NCT01173718|Device|GORE® ACUSEAL Vascular Graft|Surgical implantation of the GORE® ACUSEAL Vascular Graft for Hemodialysis per the Investigator's standard of practice.
46013620|NCT01603862|Procedure|ThinkingFit programme|Combined physical, cognitive and social stimulation activties.
46013621|NCT01609127|Drug|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each 21-day cycle
46013622|NCT01609127|Drug|Tesetaxel|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 of each 28-day cycle
46013623|NCT01609127|Drug|Capecitabine|Capecitabine 1250 mg/m2 orally twice daily (in the morning and evening after a meal; equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 of each 21-day cycle
46013624|NCT01603901|Device|Regulated Negative Pressure-Assisted Wound Therapy Device|Negative pressure will be applied in the usual way that is normally applied in our Medical Center
46013625|NCT01603979|Biological|AV-203|The antibody AV-203 is a humanized immunoglobulin G1/kappa (IgG1/κ) monoclonal antibody that targets the receptor tyrosine kinase (RTK) ERBB3 and inhibits ERBB3 activities. AV-203 will be administered as a 60 to 75-minute IV infusion once every 2 weeks until disease progression or unacceptable toxicity.
46013626|NCT00592020|Procedure|Short Transverse Incision|Short Transverse Incision for kidney transplantation
46013627|NCT00592020|Procedure|Hockey Stick Incision|Hockey Stick Incision for kidney transplantation
46013628|NCT01609166|Drug|Allopurinol|Allopurinol 3% cream application in one side of the body, twice a day for 6 months
46013629|NCT01609166|Drug|Placebo|Placebo cream application in the other side of the body, twice a day for 6 months
46013630|NCT01609205|Biological|Adalimumab|Adalimumab 40 mg eow (totally 27 doses/patient) manufactured by Abbott will be distributed as add-on therapy to DMARD
46013631|NCT01604057|Drug|ZT-034 Low Dose Nasal Spray|Nasal Spray
46013632|NCT01604057|Drug|ZT-034 Mid Dose Nasal Spray|Nasal Spray
46013633|NCT01604057|Drug|ZT-034 High Dose Nasal Spray|Nasal Spray
46013634|NCT01604057|Drug|Teriparatide|20 mcg subcutaneous daily
46013635|NCT01604057|Drug|Placebo|Nasal Spray
46013636|NCT04331223|Other|Observation|observational
45464433|NCT03842215|Device|smart physical exam|Use smart physical exam to collect functional performance
45464434|NCT05156554|Drug|PEG-rhG-CSF|PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 6mg.
45464435|NCT05156554|Drug|rhG-CSF|rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 5μg/kg once per day until the count of neutrophil>0.5×10^9 /L.
45464436|NCT03931967|Diagnostic Test|MR-proADM|to evaluate the plasmatic level of MR-proADM and endothelin-1 in the first five days of ICU stay.
45464437|NCT01567111|Procedure|11C-Metomidate Positron Emission Tomography|Dose of intravenous 11C-Metomidate injection is 440MBq and emission scanning of upper abdomen. PET/CT imaging will be done using the Discovery PET/CT VCT or 690 scanner (General Electric Medical Systems, Milwaukee, WI, USA)
45680035|NCT04285476|Diagnostic Test|Signature of microRNA for patients with bethesda classification 3, 4 or 5|If the cytology results are Bethesda 3, 4 or 5, then a miRNA analysis will be performed.
45680036|NCT04284787|Drug|Azacitidine|Given IV or SC
46013637|NCT01604096|Other|Multifaceted information campaign|"Following is the description of the multifaceted intervention:~brochures targeted at the general population and available in general practices, pharmacies, local health services and on the web (also translated in eight languages)~posters (same distribution as brochures)~short videos transmitted in local TVs, websites of Local Health Authorities and in video terminals in some pharmacies~radio-spots transmitted in local radio stations~advertisements in local newspapers~banners on websites of local newspapers~newsletter on antibiotic resistance in Emilia- Romagna, available to physicians and pharmacists~training courses in counselling strategies, directed to a subgroup of GPs and paediatricians"
46013638|NCT01604174|Other|Interactive Virtual Telerehabilitation (IVT)|Rehabilitation after arthroplasty of knee using IVT
46013639|NCT01604174|Other|Standard care rehabilitation|Standard care rehabilitation after total knee arthroplasty
46013640|NCT04330014|Behavioral|vaccine|affect vaccination on children
46013641|NCT01609244|Device|Bilevel therapy (somnovent ST 22, Weinmann, Hamburg, Germany)|nighttime positive airway therapy for 6 weeks
46013642|NCT01609244|Device|servoventilation (Somnovent CR, Weinmann, Hamburg, Germany)|nighttime positive airway therapy for 6 weeks
46013643|NCT01609283|Biological|autologous mesenchymal stem cells|"There will be five treatment groups of up to five patients each. Groups 1, 2 and 4 will receive a single dose of cells. Groups 3 and 5 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:~Group 1: single intrathecal dose of 1 x 107 cells~Group 2: single intrathecal dose of 5 x 107 cells~Group 3: one intrathecal dose of 5 x 107 cells followed one month later by a second intrathecal dose of 5 x 107 cells~Group 4: single intrathecal dose of 1 x 108 cells~Group 5: one intrathecal dose of 1 x 108 cells followed one month later by a second intrathecal dose of 1 x 108 cells"
46013644|NCT00592566|Drug|Dexamethasone, desmopressin|200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion
46013645|NCT01111123|Drug|Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%)|Steroid on weekends only group
46013646|NCT01111123|Drug|Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment|Placebo on weekends only group
46013647|NCT01609322|Behavioral|Activity, Balance, Learning, and Exposure|An in-home intervention that integrates exposure therapy with cognitive restructuring, exercise, and a home safety evaluation.
46013648|NCT01609322|Behavioral|Fall prevention education|In-home, individual sessions with a health educator regarding fall prevention
46013649|NCT04310800|Procedure|LIFT-plug technique|Small-intestine submucosa extracellular matrix plug was soaked in saline for 5-10 min, then placed into the intersphincteric groove and pulled through the curetted tract to the external opening. The plug was secured with a figure-of-eight 3/0 absorbable suture to the fistula opening in the external sphincter and ligated. Excess plug protruding from the external opening was trimmed flush with the skin without fixation. The wound was loosely closed with 2-3 interrupted 3/0 absorbable sutures
46013650|NCT00592644|Procedure|Pulse Dye laser (PDL)|one-time PDL, in 10 subjects
46013651|NCT00592644|Procedure|CO2 laser or other traditional surgeries|once-time CO2 laser or other conventional surgeries, in other 10 subjects
46013652|NCT01604330|Drug|Baclofen|Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
46013653|NCT01604330|Drug|Placebo|Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
45464438|NCT03443427|Biological|NTHi Mcat investigational vaccine (GSK3277511A)|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm and a third dose administered at either Day 181 or Day 361, according to each vaccination scheduling defined per protocol.
46013654|NCT00622830|Drug|SB-480848 (Darapladib)|
46013655|NCT01609361|Other|Rehabilitation program|Rehabilitation program including specific anesthetic drugs, post operative fast track recovery (early diet, mobilisation, antalgics)
46013656|NCT01173679|Drug|dasatinib|Taken orally once a day on days 1-14 of each 28-day cycle
46013657|NCT01173679|Drug|Rituximab|Given intravenously, 375 mg/m2 each cycle (dose split, given on Days 3+4 of cycle 1, variable after that).
46013658|NCT01173679|Drug|fludarabine|Given intravenously, 25 mg/m2/day, for 3 doses per cycle (Days 3-5 in cycle 1, Days 1-3 after that)
46013659|NCT02881528|Drug|Metformin Hydrochloride|Liquid formula metformin administered by oral syringe in a dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
46013660|NCT02881528|Drug|Placebo|Liquid formula of placebo administered by oral syringe in an equivalent volume to a metformin dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
46013661|NCT01609439|Drug|Vitamin D|Vitamin D 800 units for 4 weeks preoperatively
45464439|NCT03443427|Biological|Placebo|One dose administered intramuscularly at either Day 181 or Day 361 in the deltoid region of the non-dominant arm.
45464440|NCT04744636|Drug|Other|"Healthy volunteers will be selected within 3 weeks before inclusion (Day 0). The investigations will be performed on 2 days (Day 1 (D1) and Day 2 (D2)): vascular endothelial function assessment and blood collection for biomarker investigation on Day 1 and Case Report Form (CFR) on Day 2.~Then, subjects will be discharged at the end of the last investigation day (Day 2).~All the participants have received two pharmacological agents (NIMP) :~Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function.~Adenosine : administered intravenously during MRI for the measurement of CFR."
45680037|NCT04284787|Procedure|Biopsy|Undergo biopsy
45680038|NCT04284787|Procedure|Biospecimen Collection|Undergo blood specimen collection
45680039|NCT04284787|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspiration
45680040|NCT04284787|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
46013662|NCT01609439|Drug|Placebo|Placebo
46013663|NCT01110382|Drug|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route-intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after meropenem placebo for up to 14 days
46013664|NCT01110382|Drug|Meropenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days.
46099244|NCT00732316|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|administration of conditioning therapy including immunosuppressive agents plus alkylating agents and infusing hematopoietic progenitor cells collected from the donor
46099245|NCT00732316|Procedure|peripheral blood stem cell transplantation|infusion of donor hematopoietic cells collected by leukapheresis after mobilization with growth factor
45464441|NCT04744636|Drug|Other|"Type 2 diabetic patients will be selected within 3 weeks before inclusion (Day 0).~The investigations will be performed on 2 days (Day 1 (D1) and Day 2 (D2)): vascular endothelial function assessment and blood collection for biomarker investigation on Day 1 and CFR on Day 2.~Then, subjects will be discharged at the end of the last investigation day (Day 2).~All the participants have received two pharmacological agents (NIMP):~Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function.~Adenosine : administered intravenously during MRI for the measurement of CFR."
45464442|NCT03955211|Drug|HTX-011|300 mg
45464443|NCT03955211|Drug|HTX-011|400 mg
45464444|NCT03955211|Device|Luer Lock Applicator|Applicator for instillation.
45464445|NCT03955211|Drug|Ibuprofen|400 mg
45680041|NCT04284787|Biological|Pembrolizumab|Given IV
46099246|NCT02619864|Drug|AZD2014|
45464446|NCT03955211|Drug|Acetaminophen|975 mg to 1 g
45464447|NCT02632669|Radiation|Hemigland focal LDR brachytherapy|The treatment is limited to the hemigland that has been diagnosed with unilateral low to intermediate risk prostate cancer by means of pre-treatment staging with mpMRI and transperineal template biopsy. The affected hemigland will be treated with iodine-125 to a prescription dose of 145Gy. Patients will be assessed at baseline and subsequently at 6 weeks, 3, 6, 9, 12,18, 24 months after treatment with PSA and EN2 measurements and validated questionnaires relating to erectile, urinary, and bowel function and general health related quality of life. mpMRI and transperineal template biopsy will be performed 24 months after treatment.
45464448|NCT03472222|Behavioral|Arsha Vidya program|Integrated intervention program includes counselling and supportive care with the support of Arsha Vidya program
45464449|NCT03933605|Drug|midazolam and palonosetron group|intravenous midazolam and palonosetron administraion as prevention of postoperative nausea and vomiting
45464450|NCT03933605|Drug|palonosetron group|intravenous palonosetron administraion as prevention of postoperative nausea and vomiting
45464451|NCT03931811|Device|Short wave diathermy|SWD group took short wave diathermy with specifications of 400 watt power output, 27.12 MHz frequency, 11.06m wave length, using condensators and electrodes of 12 cm diameter parallel to the knee for 20 minutes(Enraf-Nonius, Curapuls 970 Short wave diathermy device).
45464452|NCT03931811|Other|Prolotherapy|Prolotherapy solutions were injected to the knee by a blinded physician in the group, using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular. Injection points wwere defined as medial collateral ligaments, adhesion points of quadriceps tendon, adhesion points of patellar tendon, tuberositas tibia, pes anserinus, lateral collateral ligaments, coronal ligaments, medial and lateral tibia plateaus. Patients were blinded to their treatment groups
45464453|NCT03714789|Other|Blood and spent dialysate collection|A certain amount of blood and spent dialysate are collected during and after dialysis for quantification of drug concentration.
45680042|NCT04284787|Drug|Venetoclax|Given PO
45680043|NCT04283409|Other|Graded activity|Exercise therapy using principles of cognitive behavioral therapy and education
45680044|NCT04283409|Other|Motor Control Exercises|Exercise therapy using principles of motor control and motor learning and education
45680045|NCT04278781|Drug|AG-120|AG-120 500 mg orally once daily days 1-28 of a 28-day cycle
46013665|NCT01110382|Drug|Meropenem|Type=once every 8 hours infused over 30 minutes, Unit=mg, Number=20 mg/kg to 1 gram per dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv meropenem administered every 8 hours immediately before doripenem placebo for up to 14 days
46013666|NCT01110382|Drug|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately after each iv infusion of meropenem for up to 14 days
46013667|NCT01110382|Drug|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or meropenem.
46013668|NCT01604369|Procedure|Medtronic Freezor Max Cardiac Cryoablation Catheter|Cryoablation is performed using a sequential application technique point-by-point from the tricuspid annulus to the inferior vena cava. Ablation is performed at a target temperature of -80 ºC. Each application will last for 240 seconds.
46099247|NCT00727012|Device|mitral valve repair (SJM® Rigid Saddle Ring)|mitral valve repair due to mitral degenerative or functional disease
46099248|NCT00697086|Drug|Dronedarone (SR33589)|
46099249|NCT00697086|Drug|Placebo|
46013669|NCT00592917|Dietary Supplement|calcium carbonate and cholecalciferol|one tablet (calcium carbonate resembling 500 mg of calcium and 400 IU or 5 micrograms of vitamin-D3, cholecalciferol) twice daily for the whole duration of the study
46013670|NCT01609517|Drug|Spinal anesthesia (heavy bupivacaine)|Spinal anesthesia with heavy bupivacaine of 6, 7, 8, 9, 10, 11 mg
46013671|NCT04309903|Other|Manual therapy|Both groups received for 3 sessions per week, a total of 5 weeks. Home exercises were performed by the patient for 30 minutes at home.In home exercises active ROM for warm-up (5 min), passive stretchening (5 min), strengthening exercises (10 min), proprioceptive and balance exercises (10 min). In manual therapy group, myofascial release techniques (MRT) and Kalternborn mobilization techniques lasted about one hour. In MRT, each manuever was applied for 2 mins and 3 times. The superficial strokes were performed, assisted by slight movements of joints. MRT to posterior capsule of the knee, ligaments, iliotibial tractus, plantar fascia, metatarsal, tarsals, and toes. Kalterborb mobilization tecnqiues; posterior gliding for restricted knee flexion, anterior gliding for restricted knee extension,talocrural posteior gliding for dorsal flexion, talocrural anterior gliding for plantar flexion.3 * 10 repetitions, 20 sec of per reps and 10 sec of interval.
46013672|NCT02881489|Other|Biological: Cell-based therapy|Human autologous bone marrow-derived mesenchymal stem cell transplantation in ALS patients.
46013673|NCT05265325|Drug|AND017|Orally, 3 times per week in Period 1 and dose adjustment in Period 2 at 4 mg and 2-weeks interval according to Hb levels
45464454|NCT03542383|Device|High Definition Transcranial Direct Current Stimulation|Administer 1 ma anodal HD tDCS over the preSMA for 20 minutes a session for 10 sessions over a two week period
45464455|NCT03542383|Device|Sham High Definition Transcranial Direct Current Stimulation|Administer sham HD tDCS over the preSMA for 20 minutes a session for 10 sessions over a two week period
45464456|NCT01217645|Radiation|150 mg [14C] AZD6765|
46013674|NCT05265325|Drug|AND017|Orally, once per week in Period 1 and dose adjustment in Period 2 at 4 mg and 2-weeks interval according to Hb levels
46013675|NCT05265325|Drug|Epoetin Alfa|Dose regimen and adjustment rules according to the USPI or SmPC or local practice
45464457|NCT04828473|Device|Allay Lamp|"The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10lux)narrow band (20nm) green light (peak wavelength 520nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k). However, we believe that light likely also has benefits for sleep. To better understand its effects,we are planning to conduct the proposed study. In that context, the Allay Lamp would be considered an investigational medical device because it has not been cleared or approved by FDA for the intended purpose of treating sleep. No FDA submission should be necessary for this study using 21 C.F.R. 812.3, because the Allay Lamp is a non-significant risk (NSR) device:~It is not an implant~It is not intended for use in supporting or sustaining human life The Allay Lamp provides a very low risk light-based therapy. The light provides no more risk than any other table lamp available on the market today."
45464458|NCT01127477|Drug|1: Hydroxyethyl starch 130/0.4, 6 %|1: Up to 50 ml 6 % hydroxyethyl starch 130/0.4/kg body weight administered intravenously from start of surgery (skin incision) until two hours after end of surgery.
45464459|NCT00701974|Biological|collagenase (IRUXOL)|patients will be treated with collagenase one time per day.
46099250|NCT03804905|Other|No-cost Medications|Patients will be connected to Trillium Health Partners outpatient pharmacy, and they will be given an information sheet with further details. The patients will get free access to diabetes, blood pressure and cholesterol medications and for glucose test strips. They can attend the pharmacy in person or arrange for home delivery.
46099251|NCT04066660|Dietary Supplement|Oligo Fucoidan|4.4 g oligo fucoidan powder, oral, BID
45464460|NCT00701974|Biological|collagenase (Kollagenase)|patients will be treated with collagenase one time per day.
45464461|NCT05281861|Other|Zirconia reinforced Lithium disilicate (Vita Ambria) ceramic onlay restoration|In experimental group, Participants will be restored with onlay ceramic restorations constructed from zirconia reinforced Lithium disilicate (Vita Ambria) glass ceramic
45464462|NCT05281861|Other|Lithium disilicate (IPS e-max press) ceramic onlay restoration|In control group, Participants will be restored with onlay ceramic restorations constructed from Lithium disilicate (IPS e-max press) glass ceramic
45464463|NCT03717363|Procedure|Training programme|Training program in the primary care center supervised by a physiotherapist. The duration is two months and the frequency of sessions 3 times / week. Each session lasts 60 minutes.(30 minutes of aerobic exercise and 15 minutes of strength exercise).
45464464|NCT03717363|Behavioral|Educational talk|An educational talk given by the nurse and the physiotherapist about the components of a cardiosaluble lifestyle.
46099252|NCT04066660|Dietary Supplement|Placebo|4.4 g placebo powder, oral, BID
46099253|NCT02709707|Device|Blood glucose monitor|
46099254|NCT05372029|Behavioral|Approach Avoidance Training|"AAT condition, participants use a joystick to respond to the color of the border surrounding the stimulus images presented (i.e., pull for green, push for blue). The stimuli used are alcohol-related images and neutral beverage images. To experimentally manipulate automatic action tendencies, a contingency is set between alcohol stimuli and avoidance behaviors"
46099255|NCT05372029|Behavioral|Sham Training|In the Sham participants use a joystick to respond to the color of the border surrounding stimulus images presented. There is no contingency between instruction type and pictures (i.e., non-training version of the task)
46099256|NCT00697164|Drug|Placebo|Saline Admission, day 1, day 2 3 days
46099257|NCT00697164|Drug|Erythropoietin|Erythropoietin, 1500 U/kg/day Admission, day 1, day 2 3 days
46099258|NCT00732394|Other|MSDR|"The MSDR® questionnaire establishes an individual's musculoskeletal functional status using information gathered from 1) a questionnaire the patient fills out regarding medical history, chronic medical conditions, and health risk factors; 2) anatomic pain survey completed by the patient; and 3) evaluation by a trained researcher of various patient biometric parameters related to range of motion. Stratifying an individual into a risk category with this evidence-based assessment tool then permits an assessment of which patients respond long term to therapy.~MSDR® demonstrates the ability to benchmark specific musculoskeletal findings (both clinical and sub-clinical) to ICD-9 Diagnoses supported by diagnostic, radiographic and/or MRI findings where clinically indicated."
46099259|NCT04986917|Device|Hernia repair surgery using the Su2ura® approximation device|. The hernia defect will be measured and the Su2ura® approximation device will then be used to close the defect, placing stainless steel implantable anchors threaded on a Polyethylene braided surgical suture.
46099260|NCT04986917|Diagnostic Test|Physical Examination|All subjects will undergo a standard physical examination by an authorized physician. The physician's evaluation will include diagnosis and documentation of any significant clinical abnormalities or diseases.
46099261|NCT04986917|Diagnostic Test|Vital Signs|Vital signs include blood pressure, pulse, temperature, body weight and height, body mass index (BMI).
46099262|NCT04986917|Diagnostic Test|Blood Tests|"All subjects will undergo Hematology and Biochemistry blood tests. Blood Hematology test will include a complete CBC. Blood Biochemistry test will include the following measures: Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL, LDL, Triglycerides).~5 ml of blood (equals to 1 spoon) will be taken for each test."
46099263|NCT04986917|Diagnostic Test|Urine Pregnancy Test|Urine pregnancy test will be performed during the screening visit (for WOCBP).
46099264|NCT04986917|Diagnostic Test|Abdominal Ultrasound imaging|All subjects will undergo an abdominal ultrasound (US) imaging at 12 Months visit. The US will be performed to verify an absence of hernia recurrence.
46099265|NCT04986917|Other|EuraHS-QoL|patients will be asked to fill a questionnaire assessing patient-reported satisfaction and function. questionnaire score range: 0-180; higher score indicates higher pain and discomfort
46013676|NCT01604447|Procedure|Hypothermia prevention with plastic bag|Upon removal from the incubator, infant will be placed into a plastic bag to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket and receive a cloth hat. The bag will be changed when soiled and the infant will remain in the bag for 72 hours or until discharge, whichever comes first. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
46099266|NCT04986917|Other|Visual Analouge Scale (VAS)|A validated, subjective measure measuring acute and chronic pain. questionnaire score range: 0-10; higher score indicates higher pain level.
46099267|NCT04986917|Diagnostic Test|Clinical evaluation for hernia recurrence and clinical bulging|"The procedure includes:~Clinical examination to determine the presence of hernia recurrence and clinical bulging, in an inconclusive physical exam a radiological imaging will be performed such as US or CT.~SAE's and SADE's evaluation of the seroma.~Taking a photograph of the surgery area without disclosing the subject's identity."
46099268|NCT01007227|Other|Lifestyle instruction|Instruction dietetic and exercise therapy
46013677|NCT01604447|Procedure|Hypothermia prevention without plastic bag|Upon removal from incubator, the infant will be wrapped in a blanket and receive a cloth hat, according to standard bundling practices. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
46013678|NCT00593073|Behavioral|Electronic tailored messaging|Tailored CRC message based on patient screening barriers, preferences and attitudes and reminder to get screened.
46013679|NCT00593073|Behavioral|General Reminder Message|General CRC health education message and reminder to get screened.
45464465|NCT05162716|Device|Single-chamber pacemaker implantation with left bundle branch area pacing|A prepectoral single-chamber pacemaker is implanted with a 3830 (Medtronic) IS-1 pacing lead screwed via the right ventricle in the deep interventricular septum in order to capture the left Purkinje system on the left ventricular endocardial side.
45464466|NCT03935243|Behavioral|equine assisted therapy|The equine assisted group therapy is carried out by a riding therapist (nurse psychiatry HF, certified riding therapist SG-TR). There is a detailed plan for the PT.
45464467|NCT03935243|Behavioral|activating control phase|The control phase includes a generally activating employment offer, such as board games, light physical activations, roundtables and artistic design.
46013680|NCT02892669|Other|non interventional study|non interventional study
45464468|NCT03837223|Drug|GnRH agonist|In High Responder patients (HR) (more than 18 follicles with diameter ≥ 12mm at ovulation induction), the trigger was obtained with triptorelin 0.2 mg sc. In this cohort if less of 18 oocytes were retrieved, patients were considered at intermediate risk of OHSS and fresh transfer was performed. An adequate support of the luteal phase was initiated: HCG 1500 IU / sc the day of the pick up + estradiol 4 mg + vaginal progesterone 400 mg daily (Rescue protocol).
45464469|NCT05624541|Diagnostic Test|Measurements|All infants at high risk of cp will be assessed by Specific Test of Early Infant Motor Performance (STEP) Version 3.0 at term age and at corrected age 3 months, by Hammersmith Infant Neurological Examination (HINE) a corrected age 3 and 6 months, also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) at corrected 6 months.
46013681|NCT01609595|Drug|sodium 2,2 dimethylbutyrate|Oral capsule, dose 20 mg/kg/day, daily, for 26 weeks
46013682|NCT00593151|Other|Locteron (controlled-release interferon alpha 2b)|biological+device, bi-weekly subcutaneous injections for 4-12 weeks, 160 mcg per injection
46013683|NCT00593151|Biological|pegylated IFNa2b|biological, weekly subcutaneous injections for 4-12 weeks, 1.5 mcg/kg
46013684|NCT01609634|Other|Test Product|Standard infant formula/follow-on formula with added scGOS/lcFOS and Nuturis®
46013685|NCT01609634|Other|Control Product 1|Control group 1: Standard infant formula/follow-on formula with added scGOS/lcFOS
46013686|NCT01609634|Other|Control Product 2|Control group: Standard infant formula/follow-on formula with standard fat droplets and without specific prebiotic oligosaccharides.
46013687|NCT00593190|Drug|Gas SF6 (Sulfur Hexafluoride)|ONCE
46013688|NCT01604525|Behavioral|Tailored Web|The tailored website included 6 weeks of content about making healthy lifestyle choices, eating breakfast, exercising, reducing drinking and quitting smoking. Each week, participants were asked to check in with their past week's behavior, and to set goals for the next week's check-in.
46013689|NCT01604525|Behavioral|Peer Coaching|Participants chose a peer coach, who reviewed the participant's check-in data and goals, and provided personalized feedback to help the participant reach those goals. Interaction took place via personalized videos recorded each week and uploaded to a participant's web profile, and through pro-active phone calls to the participants each week.
46013690|NCT01604525|Other|Untailored Web|Content about lifestyle issues (music, travel, dating) was created for participants assigned to the control group. There was new web content each week for 6 weeks.
46013691|NCT04327128|Device|LifePod|The intervention group is testing LifePod on a digital communication platform between patient and healthcare provider
46013692|NCT02485496|Device|Endovascular abdominal repair|
46013693|NCT04327167|Behavioral|Video and questionnaire|Potential donors would be shown a video and asked to complete a questionnaire to capture change in attitude towards donation.
46099269|NCT00694980|Drug|placebo|Intravenous and subcutaneous escalating doses
46099270|NCT00694980|Drug|rhuMAb Beta7|Intravenous and subcutaneous escalating doses
46013694|NCT00593307|Other|high GI|high GI and high carb breakfast
46013695|NCT00593307|Other|Low GI|low GI, high carb breakfast
46013696|NCT00593307|Other|Low GI Low Carb|low GI low carb breakfast
46013697|NCT00593307|Other|High GI Low carb|high GI low carb breakfast
46013698|NCT02489006|Drug|Olaparib|
46013699|NCT02489006|Drug|Platinum-based Chemotherapy|Chosen by the study doctor, per standard of care.
46013700|NCT01173601|Drug|LY2216684|
46013701|NCT01173601|Drug|Placebo|
46013702|NCT01173601|Drug|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
46013703|NCT01609673|Drug|Everolimus|"On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."
46013704|NCT01604642|Other|blood tests and muscular biopsies|blood tests and muscular biopsies
46013705|NCT01604681|Dietary Supplement|Placebo|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
46013706|NCT01604681|Dietary Supplement|Flaxseed Oil|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
46013707|NCT01173523|Drug|STA-9090|
46099271|NCT00732550|Procedure|Single trocar cholecystectomy|Patients with symptomatic cholelithiasis will be operated using the single trocar surgery approach
46099272|NCT00732550|Procedure|Standard laparoscopic cholecystectomy|Patients with symptomatic cholelithiasis will undergo a standard laparoscopic cholecystectomy
46099273|NCT01007305|Procedure|Bilateral salpingo-oophorectomy|Removal of both ovaries and fallopian tubes at the time of hysterectomy
46013708|NCT01609712|Procedure|Radiofrequency Kyphoplasty|"Radiofrequency kyphoplasty is a new form of surgical treatment. It injects an ultrahigh viscosity cement into the fractured vertebral body, using radiofrequency to achieve the proper consistency of the cement. This ultrahigh viscosity cement is designed to first restore proper height and alignment to the fractured vertebra and then to stabilize the fracture, thereby preventing further intravertebral motion and reducing pain.~The RF-Kyphoplasty is standard of care in our hospital. It is FDA and CE approved."
46013709|NCT00593424|Other|Low Fat/High Carbohydrate|Low Fat/High Carbohydrate for 6 week period
46013710|NCT00593424|Other|High Monounsaturated Fat/Low Carbohydrate|High Monounsaturated Fat/Low Carbohydrate for 6 week period
46099274|NCT01007305|Procedure|Ovarian conservation|Both ovaries and fallopian tubes not removed at the time of hysterectomy
46099275|NCT00612755|Drug|Peginterferon alfa-2a + ribavirin|Peginterferon alfa-2a 180 mcg/week ribavirin 1000-1200 mg/day during 24 weeks
46013711|NCT01173055|Drug|milnacipran|Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
46013712|NCT01173055|Drug|Placebo|Placebo will be given orally twice daily in tablet form at different times during the course of the study.
46099276|NCT05298228|Drug|Remimazolam bolus does administration|The beginning dose of remimazolam is 0.3 mg/kg, and when LMA insertion is successful, the dose will be decreased by 0.05 mg/kg in the next patient. When LMA insertion is unsuccessful (failed), the dose will be increased by 0.05 mg/kg in the next patient.
46013713|NCT04327440|Biological|RTS,S/AS01 malaria vaccine|Malaria vaccine: RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen combined with an adjuvant. The Phase 3 trial of three doses administered to 5-17-month-olds confirmed moderate protection, with overall efficacy estimates of 50.4% against clinical malaria and 34.8% against severe malaria after three doses. Efficacy, which waned over time, was marginally improved by boosting at 18 months. The European Medicines Agency adopted a positive scientific opinion of the vaccine for use outside of the European Union. The World Health Organization has created the Malaria Vaccine Implementation Program (MVIP) and selected Malawi as one of the sites to explore the feasibility, efficacy and safety of RTS,S vaccination in the context of routine use.
46013714|NCT04327440|Other|PBO bed nets|PBO nets: The PBO nets represent a new formulation of insecticide-treated bed nets with a chemical synergist, piperonyl butoxide (PBO), designed to enhance the insecticidal effect of pyrethroids. They seem to be helpful in areas like Malawi where insecticide-resistance is increasing. PBO inhibits the enzyme that detoxifies the pyrethroid, allowing the pyrethroid to act on the mosquito. The impact of PBO net use was also detectable in key entomological measures including Anopheles density, sporozoite rate and entomological inoculation rates. Following these promising preliminary results in Tanzania, Malawi's National Malaria Control Program (NMCP) is piloting the use of PBO-nets iin one of our two study sites, presenting us with the opportunity to study the effectiveness of these nets in the context of real-world program setting
46099277|NCT01007383|Drug|LEO 27847|First in man
46099278|NCT00727324|Drug|bovine intestinal alkaline phosphatase (BIAP)|30,000U/24h for 7 consecutive days via a duodenal catheter
46099279|NCT00697242|Biological|Engerix™-B|Intramuscular injection, 3 doses
46099280|NCT00697242|Biological|Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL|Intramuscular injection, 3 doses
46099281|NCT05263817|Biological|CD19/BCMA CAR T-cells|Each subject receive CD19/BCMA CAR T-cells by intravenous infusion
46099282|NCT05732857|Device|valveless trocar|the valveless trocar will be used instead of the standard trocar - these trocars are used for insufflation of carbon dioxide into the abdomen
46099283|NCT05732857|Device|standard trocar|standard trocar, usually camera port for robotic surgery
46099284|NCT00732628|Device|Boomerang closure device|Use of percutaneous of Boomerang closure device. Follow up outcomes evaluated after the use of Boomerang closure device.
46099285|NCT04132674|Drug|Bictegravir/emtricitabine/tenofovir alafenamide|Taking one oral tablet of B/F/TAF once-daily for 72 weeks
46013715|NCT01609829|Procedure|SAFE (situation, all together, fly on, evaluate)|Video-assisted, structured debriefing after simulated critical airway-events.
46099286|NCT00612287|Drug|buprenorphine|Sublingual buprenorphine; product name Suboxone® (buprenorphine/naloxone). Dosing is informed by a clinical guideline which permits flexibility dependent up physician's clinical judgment. During the induction period (Day 1, at the physician's office) the first dose is 2 mg and can be brought up to 20 mg depending on patient's response. On Day 2 going forward dose can range from 2 mg q8h to 12 mg q8h. Rescue doses with buprenorphine are also permitted.
45464470|NCT03535831|Diagnostic Test|18F-DCFPyL|The purpose of this study is to determine if use of 18F-DCFPyL would increase the detection of lesions and to better inform your oncologist on the best method of treatment for your disease.
45464471|NCT04456738|Behavioral|Parent Training|16 weeks of of parent training led by a trained group facilitator
45464472|NCT01311141|Drug|doripenem|doripenem once i.v.500mg
45464473|NCT01204489|Behavioral|Intensified dietary counseling at child wellfare clinics.|The intervention is completed by public health nurses who receive updating education in nutrition. A special training in a family-centred lifestyle counseling method in implemented. The nutrition intervention consists of tailored dietary counseling, information leaflets and self-evaluation card given to the families in the intervention arm. In the control clinics, public health nurses continue their usual dietary counseling.
45464474|NCT04456660|Procedure|sFlt-1 measurement & placental Doppler|Measurement of sFlt-1 levels in maternal blood as a potential inflammation indicator. Investigating the levels of placental circulation.
45464475|NCT01122641|Drug|Vildagliptin|Vildagliptin 50mg bid
46013716|NCT00593502|Drug|oseltamivir|Body weight: ≤ 15 kg, 30 mg twice daily; 15 - ≤ 23 kg, 45 mg twice daily; 23 - ≤ 40 kg, 60 mg twice daily; > 40 kg, 75 mg twice daily, for 5 days
46099287|NCT03999541|Other|Freeze-all policy|A policy of freezing all the embryos followed by subsequent thawed frozen embryo transfer
46099288|NCT00732706|Procedure|Sartorius Muscle Twitch|Stimulation of the femoral nerve branch responsible for activating the Sartorius Muscle fascia with the lowest possible current.
46099289|NCT00732706|Procedure|Quadriceps Muscle Twitch|Stimulation of the femoral nerve branch responsible for activating the Quadriceps Muscle fascia with the lowest possible current.
46099290|NCT00732784|Drug|Imatinib mesylate|Dosage form: tablets Dosage: 400 mg Frequency & duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
46099291|NCT00732784|Dietary Supplement|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
46099292|NCT00528931|Biological|collagenase clostridium histolyticum|Single dose of AA4500 0.58 mg into the cord
46099293|NCT04496219|Device|Acupuncture Therapy|Undergo acupuncture therapy
46099294|NCT04496219|Biological|BCG Solution|Given by intravesical injection
46099295|NCT04496219|Other|Best Practice|Receive standard of care symptom management
46099296|NCT04496219|Other|Quality-of-Life Assessment|Ancillary studies
46099297|NCT04496219|Other|Questionnaire Administration|Ancillary studies
45464476|NCT01122641|Drug|Placebo|Matched tablets
45464477|NCT03417219|Behavioral|Education and Skill Building Rehabilitation-mobile (ESBR-m)|Participants randomized to the ESBR-m group will participate in four, 90-minute group ( 5 participants) sessions. These four sessions are supplemented with a booster session one month following the last intervention session.
45464478|NCT03417219|Behavioral|Usual Care (UC)|"Participants randomized to the UC group will receive supplemental educational materials (e.g., VA Caregiver Support Program; Veterans Crisis Line; National Institute on Aging's Understanding Memory Loss)."
45683867|NCT02395120|Behavioral|DIG|Dental information guide (DIG) to reinforce/change illness perception, knowledge about dental caries, and resources to seek care. DIG is a brochure with illustrations which provides myths and facts about dental caries, hints for getting dental care, making appointments and Medicaid access, transportation and dentist availability resources.
46013717|NCT00593502|Drug|placebo|The dosage of placebo will be similar to the active drug
46013718|NCT01609868|Dietary Supplement|Powder protein modular|Infants will receive powder protein modular to achieve 4 grm/kg/day
46013719|NCT01609868|Dietary Supplement|Liquid protein modular|Infants will receive a commerically avaliable liquid protein modular to provide 4 grm/kg/day
46013720|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 1)|Period 1(A) Period 2(B) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
46013721|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 2)|Period 1(C) Period 2(A) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
46013722|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 3)|Period 1(B) Period 2(C) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
45464479|NCT03520855|Other|Serious game|DIVE software will be accessible via internet, children and parents will have to their disposition a room at the hospital specifically to work on the software. The DIVE software is organized in chapters, each matches an item of the therapeutic education process and ends with a knowledge assessment. The child has to end every chapter and succeed every evaluation to pursue on the next chapter. Measures will be taken in order to avoid contamination bias between groups. Children will have to connect to DIVE 2 times per week for a time duration of at last 1 hour.
46099298|NCT00866814|Device|Bard Ventrio Hernia Patch|The Ventrio Hernia Patch is a self-expanding, non-absorbable, sterile prosthesis for use in the reconstruction of soft tissue deficiencies, such as for the repair of hernias.
46013723|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 4)|Period 1(C) Period 2(B) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
46013724|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 5)|Period 1(B) Period 2(A) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
46099299|NCT02947126|Drug|Hypertonic Saline|Inhaled 7% Hypertonic saline
46099300|NCT02947126|Drug|Isotonic Saline|Inhaled 0.9% Isotonic saline
46099301|NCT02947126|Drug|Indium-DTPA|Inhaled Indium 111 DTPA
46099302|NCT02947126|Drug|Technetium Sulfur Colloid|Inhaled Technetium99m sulfur colloid
45464480|NCT03520855|Behavioral|ETP|"Initial therapeutic education only will be applied in this group, with the help of doctors and nurses, based on theoretical educational lessons, reported on the AJD book.~Health education sessions will also be taught by nurses."
46013725|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 6)|Period 1(A) Period 2(C) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
46013726|NCT00593580|Drug|placebo|placebo
46013727|NCT00593580|Drug|alendronate/cholecalciferol|FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
46013728|NCT01604759|Device|Polarized Reflectance Spectroscopy System|Fiber optic probe designed to measure polarized reflectance spectroscopy will be used to gather data from all study participants.
46013729|NCT01609946|Device|Realtime-Elastography, linear ultrasound probe, Hitachi EUB-900, Japan|
46099303|NCT05732779|Other|DOT intervention|A mobile health application developed by eMocha Health Inc. facilitates asynchronous mobile video directly observed therapy (DOT) intervention, empowering users to track dose-by-dose medication adherence
46099304|NCT04492553|Drug|AndroGel|Treatment indication: hypogonadism after cancer treatment. Dosage: 1-2 sachets a day. Follows standard treatment.
46099305|NCT04136106|Drug|IL-2|IL-2 is a medicine which can use in autoimmune disease, infection or cancer with different dose. Low-dose IL-2 preferentially used in autoimmune disease, such as SLE. Our enrolled SLE patients will divided into two groups depend on whether use IL-2 or not, combined with corticosteroid and immunosuppressor.
46099306|NCT00727480|Procedure|Ultrasound|Ultrasound scanning of fingertips for assessment of possible imaging modes with Gray scale ultrasound, color flow vascularity imaging, and color flow vascularity imaging before and after exercise.
46099307|NCT02619708|Behavioral|Immersive Preoperative Experience|The video will include a simulated patient encounter (with actors not real patients) showcasing the preoperative experience of the patient, including getting checked in, meeting the nurses, surgeons, and the anesthesiologists. The technology used will allow the immersion of the patient in the preoperative environment. Patients will be able to look around and explore the spaces they will visit on the day of their operation.
45464481|NCT01219595|Other|Sweetened, dried cranberries|Women in Arm 1 will consume one serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for two weeks.
46099308|NCT05364229|Radiation|MR-guided Radiotherapy Boost|IMRT/VMAT prostate whole gland SBRT to 30 Gy in 5 fractions. MRL focal boost of 15 Gy in 1 fraction will be delivered either before or after whole gland SBRT.
46013730|NCT01609946|Procedure|Cytology (FNAB) or Surgery|
46013731|NCT04327011|Biological|Toca 511 vector|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
46013732|NCT04327011|Drug|Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine|Toca FC is an extended-release formulation of flucytosine.
45683868|NCT02395120|Behavioral|Reduced DIG|"Text and illustrations related to the timeline construct of the CSM have been removed in the reduced dental information guide."
46013733|NCT00593619|Drug|Iron dextran|300mg in 250cc normal saline given over 2 hours
46013734|NCT00593619|Drug|Iron sucrose|300mg in 250cc normal saline given over 2 hours
46013735|NCT01604915|Procedure|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered to Group R.
46013736|NCT01604915|Procedure|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
46013737|NCT00593658|Drug|pentoxifylline|pentoxifylline extended release 800mg PO TID for 8 weeks
46013738|NCT00593697|Drug|trastuzumab (9 weeks) + docetaxel|"Patients diagnosed with early breast cancer with a high risk of disease recurrence will be randomly allocated to one of the following 2 arms in a 1:1 ratio:~A. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) (HT x3 ->FE75C x3) B. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)"
46013739|NCT00593697|Drug|trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)
46013740|NCT02892747|Behavioral|Educational Program|
46099309|NCT00732862|Procedure|glucose clamp|Hyperinsulinemic Hypoglycemic clamp
46099310|NCT00732862|Procedure|glucose clamp|Hyperinsulinemic Hypoglycemic clamp
46099311|NCT02709551|Behavioral|HRV_Bfb|
46099312|NCT02709551|Behavioral|MBI|
46099313|NCT02709551|Behavioral|MBI_HRV_Bfb|
46099314|NCT01007461|Drug|Sodium Sulfide (Na2S) for Injection|IK-1001 is Na2S administered as an isotonic solution for intravenous (IV) injection or continuous infusion. IK-1001 will be administered as a 3-hour continuous IV infusion started > 5 minutes but < 20 minutes (approximately) prior to coronary artery reperfusion.
46099315|NCT01007461|Drug|Placebo|0.9% Sodium Chloride (NaCl) will be administered in the same manner as the experimental drug.
46099316|NCT00733018|Behavioral|"Western versus balanced macro nutrient diet composition"|Randomized crossover diet intervention. 6 days on solely one of two isocaloric diets, 8 days washout, and then the other diet for 6 days. Fasting blood sampling before and after each diet intervention period.
46099317|NCT05261243|Diagnostic Test|EEG / questionnaires / working memory task|EEG resting state measurements and analysis of frequency bands (gamma, beta, alpha, theta), peak frequencies and connectivity measures / questionnaires for depression, anxiety, social activities, cognition, pain, sleep, fatigue / digitalized block-tapping task
45464482|NCT01219595|Other|Strawberry Fruit Pieces|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
45683869|NCT03180034|Biological|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
45683870|NCT03180034|Other|Questionnaire Administration|Ancillary studies
45683871|NCT03180034|Biological|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
45683872|NCT03180034|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
46013741|NCT01604954|Behavioral|Nutrient-label|A label indicating that the lunch they will eat is low in saturated fat and free from trans fat will be posted on the containers.
46013742|NCT01604954|Behavioral|Calorie-label|"A label indicating the amount of calories for a fixed serving plus information about daily caloric requirement (The recommended daily caloric intake for an average adult is 2000 calories) will be posted on the containers."
46013743|NCT01604954|Behavioral|No label|Lunches will be free from labels, so that no nutritional information will be provided to the participants(control group).
46013744|NCT04327050|Procedure|Magnetic anchored guided endoscopic submucosal dissection|Using magnetic anchoring technology, the magnetic pulling unit is anchored to the abdominal wall, and micro surgical tweezers are used. The tumor tissue is pulled indirectly, so that the mucosa is lifted up, which is beneficial to the peeling of the submucosa.
46013745|NCT01608074|Procedure|Radical fimbriectomy|"Laparoscopic bilateral radical fimbriectomy :~Complete resection of the tubes, from the uterine tube (up against the uterus) to the fimbriae, with resection of the part of the ovary adjacent to the ovarian fimbriae (adhering to the ovary)"
46013746|NCT01608074|Other|Histopathology SEE-FIM|Anatomopathological study of surgical specimens
46013747|NCT02892786|Other|Circulating Tumor Cells|"Patients with stage III and IV head and neck squamous cell carcinoma undergoing surgery were enrolled in this study~5 and 7.5 ml of peripheral venous blood will be taken before the surgery, just at the end of surgery and one week after surgery~Analysis was performed by RT-PCR and the CellSearch™ method using immunomagnetic and fluorescence approaches.~Patients will be followed every 3 months for two years."
46013748|NCT01601522|Procedure|Peanut protein|500 mg
46013749|NCT01601522|Procedure|Oat flour|500 mg Oat flour
46013750|NCT01601522|Drug|Antihistamine|Desloratidine 5 ml po od (0.5mg/ml = 2.5 mg) Ranitidine 5ml (15mg/ml=75 mg) po bid
46013751|NCT02892552|Radiation|Cone Beam Computed Tomography (CBCT)|Patients had an additional Cone Beam Computed Tomography, after the usual MDCT
46099318|NCT00871494|Drug|Azithromycin|The patients will receive 500 mg intravenous azithromycin QD for 1 to 2 days. The period of administration of intravenous dosing is judged by investigators according to patient status. Following intravenous administration, the patients will be received the 250 mg oral azithromycin (tablet formulation) QD to complete a total of 7 days therapy.
46099319|NCT01007539|Dietary Supplement|CDP-choline|The subjects will be given 1g citicoline twice daily for a total of 8 weeks.
46013752|NCT02892552|Radiation|Multiple Detector Computed Tomography (MDCT)|Patients had a usual MDCT, before having an additional Cone Beam Computed Tomography
46099320|NCT01007539|Dietary Supplement|Placebo (fructose)|The Subjects will be given 2 tablets of placebo twice daily for 8 weeks. They will be taking the same quantity as the CDP-choline group.
46099321|NCT02569216|Device|Electrical Inhibition (EI)|constant direct current 1-20mA transvaginal 10 second bursts only when needed
46099322|NCT05261165|Procedure|hysterectomy|Hysterectomy as primary surgical treatment of endometrial cancer. Abdominal laparotomy approach was performed without intrauterine manipulator (NonManip). Endoscopic - total laparoscopic hysterectomy, laparoscopic assisted vaginal hysterectomy or robotic hysterectomy was performed with use of intrauterine manipulator (Manip). It was Hegar dilatator (ManipHe) or Koh-Rumi device (ManipKoRu).
46099323|NCT02569918|Device|Surface electrical stimulation|"Surface electrical stimulation using the following experimental devices. 1) The CE-approved HASOMED electrical isolated stimulator (Rehastim). 2) Two hand prosthesis: the robotic hand Azzurra (Prensilia, Italy) and the robotic hand Multi-sensory Prosthetic Hand (Wessling robotics, Germany) 3) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject."
46013753|NCT00593775|Procedure|assisted hatching|assisted hatching with laser
46013754|NCT01604993|Other|Spinach soup|556 g of high Nitrate spinach soup that is orally consumed as a single dose for 7 days
45464483|NCT01219595|Other|Sweetened, dried cranberries|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
46013755|NCT01604993|Other|Asparagus soup|556 grams of low nitrate asparagus soup that is orally consumed for a period of 7 days as a single does
46013756|NCT04329507|Diagnostic Test|Breath test|collection of an exhaled breath sample
46099324|NCT04967027|Device|ASCLU-300 TTF|BM treated by continuous TTFields treatment (ASCLU-300, approved by Chinese FDA)
46099325|NCT02619630|Drug|nelarabine|"Nelarabine 1500 mg/m2/d (IV 2h) : D1, D3, D5 Cyclophosphamide 150 mg/m2/d (IV 3h) : D1, D3 etoposide (VP-16) 75 mg/m2/d (IV 1h) : D1, D3 granulocyte-colony stimulating factor 5 µg/kg/d (SC) : D7 until neutrophil >1 Giga/Liter~for a maximum of 5 blocks"
46099326|NCT04953689|Behavioral|Conscientiousness Coach|Participants will use the Conscientiousness Coach app to organize their goals and assist them in engaging in more conscientious behaviors. The participant will also be educated about Conscientiousness as it relates to healthy living and accomplishing life goals and values. Participants will receive brief phone calls during weeks 1, 2, 6, and 10 from the research assistant, tracking progress, answering queries, and return visits to the clinic/teleconference will be scheduled for further assistance during week 4 and week 8. These mid-study visits (or 'Booster Sessions') will last approximately 50 minutes and will involve a brief discussion of goal and value progress and app usage; at this in-person meeting/teleconference, similar questions and topics will be covered as in the bi-monthly phone calls. At week 12, there is a treatment termination visit with the principal investigator and research assistant.
46099327|NCT02615418|Device|NIBS system for evaluation and treatment utilizing non invasive brain stimulation|
46099328|NCT02569762|Dietary Supplement|Sucralose-Aspartame|Sucralose or aspartame
46099329|NCT02569762|Dietary Supplement|Aspartame-Sucralose|Aspartame or sucralose
46099330|NCT04951817|Drug|Ga-68 PSMA ligand|For PET/CT PSMA scan, the subject will have catheter(s) placed for intravenous administration of [68Ga]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi [68Ga]PSMA-11 and received PET/CT scan 60 minutes later.PSMA PET-CT scan was performed on a GE Discovery MI PET/CT system.
46099331|NCT00695058|Device|Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)|"A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum in women and the perineum or the frenulum in men.~In the women the stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz. In the men the vibration parameter/location will be determined by the results of the new pressure profile studies (aim 3).~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks in both the women with stress incontinence and overactive bladder syndrome.~In the 3 groups of patients the subjects will be randomized to either active treatment or placebo treatment. The placebo treatment will be done with a vibration device with an amplitude of 0 mm. Subjects will be randomized by a draw."
46099332|NCT00733876|Biological|Multipotent Stromal Cells|Post-operative administration of MSC
46099333|NCT00733876|Biological|Administration of MSC|Dose escalation protocol
45464484|NCT01219595|Other|Sweetened, dried cranberries|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for one 4-week period.
45464485|NCT01219595|Other|Strawberry Fruit Pieces|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for one 4-week period.
45464486|NCT01219595|Other|Observation|Subjects in the non-UTI susceptible group will have one visit where one vaginal and one rectal swab will be collected.
45464487|NCT05162248|Diagnostic Test|Microsatellite instability analysis|Molecular analysis for Microsatellite Instability (MSI) status was performed using immunohistochemistry (IHC). IHC now recognized as an approved method to highly precision predict MSI in colorectal cancer.
46013757|NCT00593853|Drug|Methylphenidate Hydrochloride|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
46013758|NCT00593853|Drug|Matched Placebo|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
46099334|NCT04137185|Drug|Recombinant Human Thyroid Stimulating Hormone for Injection|rhTSH was dissolved in 1.2 mL of sterile water for injection to obtain a solution containing 0.9 mg/mL rhTSH.
46013759|NCT01607294|Drug|ETC-1002|ETC-1002 Daily for 4 weeks
46013760|NCT01607294|Drug|Placebo|Placebo Daily for 4 weeks
46013761|NCT01601600|Drug|BYM338|BYM338
46099335|NCT02619474|Other|Whiteboard|"On morning rounds, the child's management will be discussed with the family and the day's plan for treatment and investigations will be written on the whiteboard.~The second step will be to review and update the whiteboard at the end of the day. Anything that has been left out or uncompleted will be highlighted and brought up on the following morning's rounds. Next, the nurse will ask the family to write down any questions.~Lastly, on the afternoon before a child's discharge, the nurse will take particular care to make sure the parents write down all of their concerns prior to going home. These specific questions concerning discharge planning will be addressed in detail at rounds the following morning."
46099336|NCT04948931|Other|Lavender aromatherapy|The application will be once a day, every day for four weeks. Each session will take five minutes.
46099337|NCT04948931|Other|Rosemary aromatherapy|The application will be once a day, every day for four weeks. Each session will take five minutes.
46099338|NCT04948931|Other|Control|The application will be once a day, every day for four weeks. Each session will take five minutes.
46099339|NCT00733174|Drug|Rosiglitazone|tablet
46099340|NCT00733174|Drug|Placebo|
46013762|NCT01601600|Drug|Placebo|BYM338 Placebo
46099341|NCT00529789|Drug|duloxetine|20 - 120 milligrams (mg) every day, once-daily (QD), by mouth (PO) for 30 weeks; If patient is ≤40 kilograms (kg), initial dose is 20 mg, then titrated up. If patient is >40 kg, initial dose is 30 mg, then titrated up.
46099342|NCT04136028|Drug|Kineret|Kineret at a dose of 8 mg/kg per day subcutaneously daily, every day at the same time
46099343|NCT00611819|Drug|Peg interferon + Ribavirin|Peg interferon 180 mcg/weekly Ribavirin 800 mg/daily during 24 weeks
46099344|NCT00611819|Drug|Peg interferon + Ribavirin|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
46099345|NCT00577642|Drug|Zoledronic acid|4mg IV over at least 15 minutes or corrected for creatinine clearance x 1
46099346|NCT02619240|Procedure|bronchoscopy|performance of bronchoscopy with BAL
46099347|NCT02709629|Behavioral|Individualized and adaptive computerized cognitive training|
46099348|NCT02709629|Behavioral|Active control|
46099349|NCT00733252|Procedure|bronchoscopic and lung imaging studies|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
46013763|NCT00593931|Other|fMRI|Functional Magnetic Resonance Imaging without contrast
46013764|NCT01605110|Drug|Hyperbaric oxygen treatment|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of 100% oxygen at 2.0 atmospheres absolute (ATA) inside mono-place chambers for 90 minutes (at depth).
46013765|NCT01605110|Drug|Air sham|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of medical grade air (21%oxygen; sham) at 1.2 ATA inside mono-place chambers for 90 minutes.
46013766|NCT00594048|Device|Resperate|Use of the device 15 minutes a day for 9 weeks
46013767|NCT00594048|Device|discman with freely chosen music|Use the discman 15 minutes a day for 9 weeks
46013768|NCT00594087|Drug|eszopiclone|eszopiclone 2mg or 3mg at bedtime
46013769|NCT00594087|Other|placebo|2 mg or 3 mg at bedtime
46013770|NCT01605305|Drug|FOLFOX6|OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h
46013771|NCT00594126|Drug|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
46013772|NCT00594243|Behavioral|Mindfulness based stress reduction program|8-week mindfulness based stress reduction program
46013773|NCT00594243|Other|Wait-list control|No treatment given.
46013774|NCT01605344|Drug|FOLFIRI.|All patients will receive FOLFIRI infusion on day 1 and day 15.
46013775|NCT01605344|Drug|Atorvastatin|A subjects will receive atorvastatin 20 mg orally once daily given for two weeks starting on Day -14 during PERIOD ONE. ARM A will then receive no statin during PERIOD TWO. ARM B subjects will receive no atorvastatin during PERIOD ONE. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks during PERIOD TWO (starting on Day 2). One cycle = 28 days.
46099350|NCT00733252|Procedure|diagnostic bronchoscopy|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
46099351|NCT00733252|Procedure|histopathologic examination|All imaged areas are marked. The marked areas are then excised and fixed in formalin for histopathologic analysis.
46013776|NCT04358211|Biological|Biological: COVID-19 convalescent plasma|One unit of ABO compatible COVID-19 convalescent plasma
46099352|NCT00733252|Procedure|optical coherence tomography|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
45464488|NCT03423979|Device|Optilume™ BPH Prostatic DCB Dilation Catheter|BPH Prostatic DCB treatment - The Optilume BPH Prostatic DCB Dilation Catheter System should be prepared per the Instructions for Use (IFU).
46013777|NCT01605383|Biological|XCEL-MT-OSTEO-ALPHA|Core decompression plus XCEL-MT-OSTEO-ALPHA
46099353|NCT02619162|Drug|Nintedanib|Tablets of 100 mg. or 150 mg.
46099354|NCT02619162|Drug|Letrozole|Tablet of 2.5 mg.
46099355|NCT01007617|Device|LLLT :low level laser therapy|"The patients will be randomized in 2 groups according to the delivered dose: 2 J/cm2/d or 8 J/cm2/d.~Main evaluation criteria: mucositis maximal intensity (WHO scale).~Secondary evaluation criteria: mucositis duration, mucositis survival free, pain, opioid treatment, hospitalization, fever and infection, nutrition."
46099356|NCT04018690|Behavioral|Patients will be submitted to needle lavage, followed by the injection of 3mL of hylan and 1 mL of ropivacaine|"Patients with K&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 3mL of hylan, 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.~Answer: WOMAC, Lequesne, VAS, EQ-5D-5L at inclusion, one week prior to surgery, 1st, 3rd, 6th and 12th months postoperatively.~Submitted to evaluaton in the isokinetic dynamometer (Cybex 6000, Ronkokoma Lumex Inc.) where de amplitudes of movement of hip flexion, extension, abduction and adduction will be measures. Hip flexion, extension, abduction and adduction force will be assessed isokinetically at 60 degrees/second.~Costs will be evaluated for cost-effectiveness and cost-utility analysis."
46099357|NCT04018690|Behavioral|Patients will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine,|"Patients with K&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.~Answer: WOMAC, Lequesne, VAS, EQ-5D-5L at inclusion, one week prior to surgery, 1st, 3rd, 6th and 12th months postoperatively.~Submitted to evaluaton in the isokinetic dynamometer (Cybex 6000, Ronkokoma Lumex Inc.) where de amplitudes of movement of hip flexion, extension, abduction and adduction will be measures. Hip flexion, extension, abduction and adduction force will be assessed isokinetically at 60 degrees/second.~Costs will be evaluated for cost-effectiveness and cost-utility analysis."
45464489|NCT03423979|Drug|Paclitaxel|paclitaxel will release to adjacent tissue after the balloon inflated in the urethra
45464490|NCT03714555|Diagnostic Test|Safety Laboratories|CBC w Differential, CMP, PT/INR, aPTT, Urinalysis
46013778|NCT01605383|Procedure|Standard treatment|Isolated core decompression
45464491|NCT03714555|Other|AE Assessment|Assessment of Adverse Events
45464492|NCT03714555|Other|Physical Exam|Physical Exam, Weight, Vital Signs, ECOG Performance Status
46013779|NCT00594282|Device|Radiolucent cushion|MammoPad radiolucent breast plate cushion used during mammogram
46013780|NCT00594321|Device|SPACE CpsXL Bone Cement and SPACE 360 Delivery System|SPACE CpsXL Bone Cement and SPACE 360 Delivery System
46099358|NCT02619318|Behavioral|Balancing Everyday Life (BEL)|
46099359|NCT02619318|Behavioral|Care as usual (generally standard occupational therapy)|
46099360|NCT00697866|Biological|HBV-MPL vaccine 208129|3 consecutive lots; 3-dose intramuscular injection
46099361|NCT00697866|Biological|Engerix™-B|3-dose intramuscular injection
46099362|NCT00733486|Device|L.C.S. APG Knee Anterior Posterior Glide knee|Orthopaedic implant for primary knee replacement
46099363|NCT05215717|Behavioral|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
46099364|NCT05215717|Behavioral|Self-Administered White Noise Hypnosis|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
46099365|NCT00727792|Procedure|MRI -Clinical|MRI done is standard of care
46099366|NCT00727792|Procedure|MRI-Research|MRI includes extra sequences
46099367|NCT04935385|Other|Collecting blood specimens|Blood samples will be collected from all study participants at different required timelines
46099368|NCT00733564|Drug|Lidocaine|Paracervical injection of 2% Lidocaine to block associated nociception input
45464493|NCT03714555|Other|Concomitant Medication Review|Prior and Concomitant Medication Review
45464494|NCT03714555|Diagnostic Test|Tumor Imaging|Tumor CT or MRI
46013781|NCT00594321|Device|standard vertebroplasty|standard vertebroplasty
45837548|NCT00612222|Biological|aldesleukin|Aldesleukin - 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)
46099369|NCT00733564|Drug|Propofol|Propofol 3mg/kg will be injected intravenously; 1 mg/kg will be added additionally for incomplete anesthesia
46099370|NCT00733564|Drug|Sevoflurane|Sevoflurane 8% for anesthesia induction, 2-3% as the maintenance
46099371|NCT05732623|Behavioral|Semi Quantitative Food Frequency Questionnaire (SQFFQ)|"The SQFFQ quantifies the frequency of consumption of each food and drink and the following list of variables:~date of birth~sex~ethnicity~weight (kg)~height (m)~BMI (kg/m2) at the time of eoCRC diagnosis and at 18 years old~country where they live permanently~tobacco smoking at the time of eoCRC diagnosis and at 18 years old~sitting time~TV-viewing time~moderate-to-vigorous physical activity (MVPA)~waist circumference (cm)~home blood pressure levels (mmHg)~fasting blood glucose (mg/dl)~regular consumption of aspirin/NSAID and years of consumptions~calcium and folate supplements and years of consumptions~oral contraceptive agents and years of consumptions~post-menopausal hormones and years of consumptions"
46099372|NCT04065178|Behavioral|Level of activity|"Inpatients will be asked if they are willing to wear a heart rate tracking fitness watch during their stay. They will be asked quality of life questions on a questionnaire that will take approximately 30 minutes to answer at admission and discharge. At the end of the study they will return the Fitbit Charge 2 to the study coordinator or their nurse.~Your rehabilitation plan of care will not change in any other way."
46099373|NCT00727870|Device|Shapes by PolyMem dressing|Shapes by PolyMem dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site
46099374|NCT00727870|Device|Shapes by PolyMem Silver Dressing|Shapes by PolyMem Silver dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site
46099375|NCT00727870|Device|Shapes by PolyMem on one site and Shapes by PolyMem Silver dressing on second site|Shapes by PolyMem dressing on one site. Shapes by PolyMem Silver dressing on other site.
46099376|NCT01007695|Drug|Valproic Acid|Valproic Acid is FDA approved and indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures.
46013782|NCT01605422|Other|Dietary pulses|beans, peas, chickpeas, lentils in whole or flour form
46099377|NCT02709473|Drug|Propofol|Propofol will be used in either two arms. The injection sequence will be changed. In propofol arm of the study, general anesthesia will be started with 2 mg/kg propofol administered within 15 seconds. And, then remifentanil will be given. In remifentanil arm of the study, 2 mg/kg propofol will be applied within 15 seconds following remifentanil injection.
46099378|NCT02709473|Drug|Remifentanil|Remifentanil will be used in either two arms. The injection sequence will be changed. In remifentanil arm, general anesthesia will be started with 2 μg/kg remifentanil administered within 30 seconds. And then propofol will be given. In propofol arm of the study the same dose will be applied within 30 seconds following propofol administration.
45837549|NCT00612222|Drug|cyclophosphamide|60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
46013783|NCT01607372|Drug|GSK2245035|GSK2245035 nasal spray solution. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate
46013784|NCT01607372|Device|Type 1 amber glass bottle|fitted with a metered Valios VP7 pump
45837550|NCT00612222|Drug|fludarabine phosphate|25 mg/m^2 day intravenous piggy back over 30 minutes for 5 days
45837551|NCT01931436|Drug|Qing'E pill|Qing'E pill is composed of eucommia, psoralen, walnuts and garlic.
45837552|NCT01842360|Biological|Placebo|The subjects will receive daily dose of placebo during 12 months
45837553|NCT01842360|Biological|MV130|The subjects will receive daily dose of MV130 during 12 months
46013785|NCT01607372|Other|Placebo|As for GSK2245035 nasal spray solution except for omission of the active ingredient
46013786|NCT01608581|Other|multimedia burn awareness campaign|Television commercials x4 delivered 86 times over 10 days plus logo in print media daily in two papers in two cities
46013787|NCT04130568|Diagnostic Test|INO survey|Garvin's Learning organisation tool
46013788|NCT00594360|Behavioral|Exercise on Prescription|Exercise two times a week for two months at a physiotherapist. Afterwards exercise one time a week at a physiotherapist and self-contained training one time a week for 2 months.
46013789|NCT01605578|Procedure|Biopsies|Abdominal and gluteo-femoral subcutaneous adipose tissue biopsies
46013790|NCT00593463|Drug|Cycloserine|Cycloserine: 500, 675, 750 mg oral capsule may possibly be given
46013791|NCT00593463|Drug|Diltiazem|Diltiazem: 30, 60, 120 mg oral capsule may possibly be
46013792|NCT00593463|Drug|Gabapentin|Gabapentin: 100, 200, 400 mg oral capsule may possibly be given
46013793|NCT00593463|Drug|Isradipine|Isradipine: 5, 10 mg oral capsule may possibly be given
45680046|NCT04263792|Drug|[18F]fluoropropyl-trimethoprim|[18F]Fluoropropyl-Trimethoprim, also known as [18F]F-TMP, is a radiolabeled imaging agent for positron emission tomography (PET/CT).The use most relevant to this protocol is for imaging bacterial infection in human subjects. The parent compound, trimethoprim (TMP) is a well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder. An immediate clinical use for TMP radiotracers is imaging of pathologic bacteria that are the cause of human infection.
46099379|NCT02709473|Drug|Rocuronium|Rocuronium will be used for either two study arms. Rocuronium will be given in a 0.8 mg/kg dosage in the first study subject. And then, if the intubation condition is acceptable, the dose of the rocuronium will be decreased by 0.1 mg/kg for the next patient. Otherwise, if the intubation condition is not acceptable, the rocuronium dosage will be increased by 0.1 mg/kg for the next patient. This will be continue for ten crossover points (the point that turn from unsuccessful intubation to successful intubation).
46013794|NCT00593463|Drug|Naloxone|Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given
46099380|NCT00734110|Device|P.F.C. Sigma Total Knee System|An orthopaedic implant for total knee replacement
46099381|NCT00866658|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
46099382|NCT00866658|Drug|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
46099383|NCT00866658|Device|Pen auto-injector|
45680047|NCT04261361|Behavioral|CBCBT intervention|8 group CBT sessions and 4 weekly follow-up calls
45680048|NCT04261361|Behavioral|Adherence counseling|All participants in both CBCBT and ETAU groups will have one session of Life-Steps, a stand-alone CBCBT intervention designed to improve adherence to medical recommendations and individualized DM self-management goals.
45680049|NCT04261361|Behavioral|Psycho-education package|Printed materials of a DM self-management education program will be delivered to both the CBCBT and ETAU groups.
46013795|NCT00593463|Drug|Nifedipine|Nifedipine: 5, 10, 20 mg oral capsule may possibly be given
46099384|NCT00866658|Drug|Sulfonylurea|Sulfonylurea if given, to be continued at a stable dose.
46099385|NCT00866658|Drug|Basal Insulin|To be continued at a stable dose.
46099386|NCT04064866|Device|High yield pure PRP|"The investigational product is hemocyte autograft derived from the subject's own blood. Subjects with a clinical diagnosis of discogenic pain had a discogram with ¼ cc to ½ cc of contrast injected by hand (leaving up to ½ cc contrast in the needle lumen and connecting tube); any concordant pain will be noted. Subjects received the injectant delineated by coordinator-provided randomization. Subjects were awake for the entirety of study treatment procedure.~All subjects had blood drawn (50 cc) from any access site and double-centrifuged using the EmCyte Hemocyte Autograft system; the first spin separated the buffy coat, the second spin and subsequent siphoning separated a purified platelet sample."
46099387|NCT04064866|Other|Placebo|Placebo injections will have saline placed in centrifuges and run for the duration required for PRP preparation. 3cc of saline will be placed in 3 cc syringes with opaque tape around the barrel to cover the fluid chamber. 1-2 cc of saline will be injected into the nucleus pulposus of each treatment level disc under fluoroscopy for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.
45683873|NCT01685229|Device|Balloon sinus dilation|Subjects electing continued medical therapy group will not have balloon sinus dilation intervention. Subjects electing balloon sinus dilation group will have balloon sinus dilation intervention.
45683874|NCT01685229|Drug|Medical Management|Subjects who select to continue on medical management rather than have a BSD procedure.
46013796|NCT00593463|Drug|Placebo|Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given
46013797|NCT00593463|Device|Saline|Saline: I.M. injection may possibly be given
46013798|NCT00593463|Drug|Verapamil|Verapamil: 30, 60, 120 mg oral capsule may possibly be given
46013799|NCT00594438|Device|Synthes Reamer-Irrigator-Aspirator (RIA)|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram (TEE) will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using the RIA device.
46099388|NCT04064866|Device|ProPlaz PPC|Trademarked name of an FDA-cleared product
46013800|NCT00594438|Device|Zimmer Sentinel Reamer|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram TEE will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using either a conventional reaming technique or the RIA device.
46013801|NCT02270138|Behavioral|Movement-to-music video program|Three separate movement-to-music video programs will be utilized. Genres of the songs are Children's rock, latin and folk. Range of the tempo is 64-124 beats per minute. The use of movement-to-music video program will be instructed 10-30 minutes every other day.
46013802|NCT02270216|Procedure|static hand grip exercise|The static exercise pressor response will be tested using isometric handgrip of the left hand. The forearm will be supported on an arm rest with elbow flexed. The maximum voluntary contraction force will be measured as the best of three attempts. After 2 minute rest, subjects will perform 2 minute of isometric hand grip contraction at 30% MVC. Circulatory occlusion(50 mmHg supra-systolic pressure) will start at 1.30 min and continued for 2 minute after the end of the isometric handgrip exercise. Following release of the cuff there will be a further 2 minutes recovery. The blood pressure and heart rate will be measured at the end of each minute during rest, isometric handgrip, circulatory occlusion and recovery. Subjects will be instructed to breathe normally during the test and avoid any Valsalva maneuver; breathing frequency will be monitored during the handgrip pressor test using capnography.
46099389|NCT04942067|Drug|APG-2575+ Pd|APG-2575 + Pomalidomide 4mg QD x 21 days + dexamethasone (40 mg for patients ≤ 75 years old or 20 mg for patients > 75 years old) on Days 1, 8, 15, and 22 of a repeated 28-day cycle
46013803|NCT02270216|Procedure|cycling exercise|"The dynamic exercise will be with the subject sitting on a cycle ergometer (Monark 828 E). Resting heart rate will be measured for 2 minutes before the start of exercise. The exercise level will be limited to 50% of the estimated maximum heart rate reserve. Maximum heart rate will be estimated as 207-0.7*age and heart rate reserve (HRR) as maximum minus resting heart rate. Subjects will pedal at 50 rpm for 1 min with no load and then 3 minutes against a load of 0.5 Kp (25W) increasing to a load of 1 Kp for the next 3 minutes and to 1.5 Kp, if necessary, for a further 3 minutes until the target heart rate of 50% HRR is reached.~Subjects will be asked about their level of perception of dyspnea using a visual analog scale every 3 minutes at the end of each load. At the end of the exercise, the subjects will sit for ten minutes."
46099390|NCT04942067|Drug|APG-2575 + DRd|APG-2575+ Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone will be administered at a dose of 40 mg (or 20 mg for patients > 75 years old) once weekly, and daratumumab will be administered intravenously at a dose of 16 mg/kg (or 1800 mg administered subcutaneously if commercially available) weekly in cycles 1 and 2 and then every 2 weeks in cycles 3 to 6 and every 4 weeks thereafter.
46099391|NCT05732467|Device|visual function training software|Experimental group: If there is a refractive problem, first correct the refraction, wear corrective glasses, and then use visual function training therapy software (model: SJ-JRS2021) for treatment.
45464495|NCT03714555|Drug|nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate|nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
45464496|NCT03714555|Drug|FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate|FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing
45464497|NCT03714555|Drug|Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate|Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
45464498|NCT01125449|Drug|Ascorbic acid (vitamin C)|Intravenous administration of up to 1.5gm/kg of ascorbic acid, twice weekly for up to 12-weeks.
46013804|NCT00592410|Drug|human regular insulin|administration of a primed continuous infusion of human regular insulin at a rate of 2.0 mU/kg/min while maintaining the plasma glucose level at 100 mg/dl via adjusting a variable infusion of 50% dextrose (i.e., a hyperinsulinemic euglycemic blood glucose clamp); duration of 3 hours; performed concomitantly with amino acid supplementation
46013805|NCT01605656|Behavioral|Cognitive Interview|A research staff member will use a questionnaire to ask about many different health and social topics. The cognitive interview should take up to 45 minutes to complete.
46099392|NCT05732467|Other|occlusion therapy|Control group: If there is a refractive problem, correct the refraction first, wear corrective glasses combined with occlusion therapy, and cover the fellow eye for 2 hours a day.
45464499|NCT04741126|Other|Manually assisted cough technique|Manually assisted cough technique will be given for four weeks. 10 to 12 repetitions of manually assisted cough technique with rest will be given in one minute 3 to 4 time of repetition in a 1 set. The result of the peak cough flow meter and incentive spirometer will be check pre and post only.3 sets will be given in one session and 2-time session will be recommended per day. The session will be given three days in a week. The Result of the Peak Cough flow meter and incentive spirometer will be check pre and post only.
45683875|NCT03141424|Drug|Tapering of inhaled corticosteroid (ICS) treatment|Tapering of ICS treatment over 8 weeks. Follow-up over 52 weeks in total. Dosis reduction of 50% in ICS treatment for 8 weeks, followed by total ICS removal. Other inhaled asthma medication remains unchanged during the entire study period.
45683876|NCT03028389|Procedure|limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
46099393|NCT05732467|Other|corrective glasses|corrective glasses
45683877|NCT03614494|Drug|Piroxicam 40 mg|Additional co-treatment
46013806|NCT01605656|Behavioral|Questionnaires|"Phase I: Completion of a questionnaire about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~Phase II: Completion of 2 questionnaires. The first questionnaire will ask about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~The second questionnaire will ask about many different health and social topics. This questionnaire should take up to 45 minutes to complete."
46013807|NCT01605656|Behavioral|Focus Groups|"Phase I: There will be up to 8 women in each of the 5 focus groups.~Participants asked questions about personal and clinic-related factors that might make it more difficult to receive pap smear screenings. Participants also asked to discuss what might make it easier or encourage women to receive pap smear screenings. The focus group discussion should last 60-90 minutes."
46013808|NCT00594477|Radiation|IMRT|
45464500|NCT05669443|Device|conventional PEEP|Maintain positive end expiratory pressure at 5 cmH2O throughout the surgery.
45464501|NCT05669443|Device|optimized PEEP|Immediately after induction of anesthesia, the patient remains unapplied to PEEP. After pneumoperitoneum + Trendelenburg posture, an appropriate PEEP value is derived using electrical impedance tomography (airtom®). And then derived value ( = optimized PEEP value) is applied until the end of the operation.
45464502|NCT03714477|Procedure|Extracorporeal shock wave lithotripsy|A minimally invasive treatment for renal stone which was first introduced in early 1980's. It tries to fragment the renal stones by high-energy shockwave at the kidney from the outside.
45464503|NCT01206049|Drug|Gemcitabine|1,000 mg/m2 on day 1 of a 2 weeks cycle
46013809|NCT02270294|Other|Thai traditional massage|Thai traditional massage treatment based on original Thai traditional massage at Wat Po was use in this study. The participants will be assigned to receive one time of Thai traditional massage one time. Thai traditional massage techniques consists of petrissage, friction, and passive stretching on head, neck, shoulders, arms, back and legs for 60 minutes.
46013810|NCT02270294|Other|No massage|The participants will be asked to lie down in relaxant position on bed without sleep for 60 minutes.
46013811|NCT00592449|Behavioral|Cognitive behavioral therapy (CBT) for insomnia|During CBT, participants will learn how to change their sleeping habits and reduce arousal and alertness while trying to sleep. Participants will attend 8 weekly CBT sessions with a psychologist.
46013812|NCT00592449|Behavioral|Behavioral desensitization treatment for insomnia|The behavioral desensitization treatment is designed to decondition states of arousal that interfere with sleep. Participants will attend 8 weekly behavioral desensitization treatment sessions with a psychologist.
46013813|NCT04328064|Drug|Rosuvastatin calcium 40mg|Active drug -Rosuvastatin
46013814|NCT04328064|Drug|Placebo oral tablet|40 mg placebo for 12 months
45464504|NCT01206049|Drug|Oxaliplatin|60 mg/m2 on day 1 of a 2 weeks cycle
45464505|NCT01206049|Drug|Capecitabine|1,000 mg/m2 x 2 daily on days 1-7 of a 2 weeks cycle
45464506|NCT01206049|Drug|Panitumumab|6 mg/kg on day 1 of a 2 weeks cycle
45464507|NCT01206049|Drug|Bevacizumab|10 mg/kg on day 1 of a 2 weeks cycle
45683878|NCT03614494|Drug|Levonorgestrel 1.5mg|Standard treatment
46013815|NCT01605734|Procedure|TACE|After obtaining arterial access,a diagnostic visceral arteriogram will be performed to demonstrate arterial supply to the tumor and the presence of variant arterial anatomy.After having positioned the catheter within the artery feeding tumor,the chemoembolization mixture will be infused into th e artery until stagnant flow is observed.
45464508|NCT05162092|Other|Conventional physiotherapy|Participants will be given Conventional Physiotherapy. It included Passive Soft tissue elongation of tight muscles, Lower limb resistance exercises, Movement transitions, balance board and foam board standing, walking and stair climbing.
45464509|NCT05162092|Other|Vestibular stimulation with conventional physiotherapy|Participants in group B will be given conventional physiotherapy and vestibular stimulation exercises. It included conventional is same as given to the conventional and Vestibular Stimulation
45464510|NCT03931889|Dietary Supplement|Vitamin D3|Cap. Cholecalciferol 40,000 IU
45464511|NCT05417672|Diagnostic Test|Nutritional Risk Screening-2002|Nutritional Risk Screening-2002
45683879|NCT03028155|Drug|Oxaliplatin: BSA-based HIPEC|oxaliplatin: 460 mg/m2 volume: dependent on the capacity of the peritoneal cavity of the patient
46013816|NCT01605734|Drug|sorafenib combined with TACE|All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study
45464512|NCT05417672|Diagnostic Test|Nutritional Risk Index|Nutritional Risk Index
45464513|NCT05417672|Diagnostic Test|Mini Nutritional Assessment|Mini Nutritional Assessment
45683880|NCT03028155|Drug|Oxaliplatin: Concentration-based HIPEC|oxaliplatin: 230 mg/L
46013817|NCT02270372|Biological|ONT-10, Varlilumab combination|"ONT-10 a liposomal synthetic glycopolypeptide MUC1 targeted antigen formulated with PET Lipid A adjuvant.~Varlilumab is a recombinant, fully human mAb of the IgG1κ isotype that specifically binds human CD27."
46099394|NCT00612833|Procedure|Vasectomy occlusion techniques|Cautery and excision with fascial interposition Cautery and excision without fascial interposition Ligation and excision with fascial interposition
46099395|NCT00734188|Drug|PTI-6D2|monoclonal antibody
45464514|NCT05417672|Diagnostic Test|Glasgow Prognostic Score|Glasgow Prognostic Score
45464515|NCT05417672|Diagnostic Test|Prognostic Nutritional Index|Prognostic Nutritional Index
45464516|NCT05417672|Diagnostic Test|Anthropometric measurements|middle arm circumference
46099396|NCT01007773|Drug|Precedex|Once this patient is deemed stable on the propofol infusion, the patient will be started on a dexmedetomidine infusion at 0.4 mcg/kg/hr. The dexmedetomidine infusion will be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -1 (maximum rate of 1.5 mcg/kg/hr). In the meantime, once sustained ICP control has been achieved, the initial sedative agent (usually propofol) will be weaned. Dexmedetomidine will be infused for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued. When the patient is ready to come off sedation, the dexmedetomidine will be weaned by 50% every hour over a 4-hour period to off.
45464517|NCT05417672|Device|Handgrip strength test|Handgrip strength test
46099397|NCT01007773|Drug|Propofol|Propofol will be initiated at 25 mcg/kg/min and titrated to achieve an ICP < 20 mm Hg (up to a maximum of 75 mcg/kg/min). Propofol will be continued for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued.
46099398|NCT01007773|Drug|Fentanyl|Fentanyl will be initiated and titrated to achieve adequate pain control.
45464518|NCT03931421|Biological|CAR-T treatment|a novel method for treatment of multiple myeloma, in which patients' T cells are engineered into B Cell Maturation Antigen（BMCA）-Targeted CAR-T cells to eliminate myeloma cells.
45464519|NCT01206127|Other|Postoperative positioning: Bed rest|Patients in this group should be lying down facing up 2 hours postoperatively
46013818|NCT01605773|Drug|repaglinide|Dose individually adjusted and conducted according to labeling
45464520|NCT01206127|Other|Postoperative positioning: Sitting up|Patients in this group should be sitting up in a chair 2 hours postoperative
46013819|NCT01605773|Drug|glyburide|Dose individually adjusted and conducted according to labeling
46013820|NCT00592527|Drug|insulin detemir|
46013821|NCT01605851|Device|Closure, Foramen Ovale|
46099399|NCT01007773|Drug|Propofol|Propofol will be titrated to an ICP < 20 mm Hg until achievement of sustained ICP control.
46099400|NCT02615340|Drug|Melatonin|Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
46099401|NCT02615340|Drug|Placebo|Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
46099402|NCT04899791|Other|Wheat bread enriched with hydroxytyrosol|Wheat bread enriched with hydroxytyrosol
46099403|NCT04899791|Other|Wheat bread|Wheat bread
46099404|NCT02615028|Other|Closed eyes double-leg stance|Closed eyes double-leg stance: Body relaxed with both arms naturally placed beside thighs, eyes closed for 40 seconds.
46099405|NCT00733642|Biological|PF-04360365 1 mg/kg|PF-04360365 1 mg/kg infused as a single dose
46099406|NCT00733642|Biological|PF-04360365 3 mg/kg|PF-04360365 3 mg/kg infused as a single dose
46099407|NCT00733642|Biological|PF-04360365 5 mg/kg|PF-04360365 5 mg/kg infused as a single dose
46099408|NCT00733642|Biological|PF-04360365 10 mg/kg|PF-04360365 10 mg/kg infused as a single dose
45464521|NCT04739020|Diagnostic Test|Resp-Aer-Meter|Measurement of respiratory aerosols (particle size and concentration) through breathing into the Resp-Aer-Meter for 3-6 Minutes and comparison between groups.
45464522|NCT04739020|Diagnostic Test|Spirometry|Comparison of peak expiratory flow (PEF) and forced expiratory volume in one second (FEV1) between groups.
45464523|NCT04739020|Diagnostic Test|Qualitative and quantitative virus PCR of respiratory secretions in patients with high aerosol concentrations|Comparison between result of aerosol measurement and quantitative and qualitative virus PCR of respiratory secretions that are caught in a filter in which the patient breathes for 10 minutes. Test will be conducted on patients with high aerosol concentrations (>5000/L).
45464524|NCT01122719|Device|Drug Eluting Stent|
45464525|NCT02953821|Drug|Acthar Gel|1 mL (80 Units) given by a shot under the skin (via subcutaneous injection)
45464526|NCT02953821|Drug|Placebo Gel|1 mL (0 Units) given by a shot under the skin (via subcutaneous injection)
45464527|NCT01206205|Drug|Lenalidomide, Bortezomib|"Induction:~3 cycles of 21 days of Dexamethasone : 40 mg/j, days 1, 8 et 14 Bortezomib (Velcade®) : 1,3 mg/m2/d, days 1, 4, 8, et 11 Lenalidomide (Revlimid®) :25 mg/d, days 1 to 14~Consolidation (2 months After ASCT):~2 cycles of 21 days of Lenalidomide (Revlimid®) 25 mg/j, days 1 à 14 Bortezomib (Velcade®) 1,3 mg/m2/d, days 1, 4, 8, et 11 Dexamethasone 40 mg/j, days 1, 8 et 14~Maintenance Phase:~3 to 8 weeks after consolidation. Cycle length: 28 days Lenalidomide (Revlimid®) 10 mg/d until 12 months"
45464528|NCT04673734|Diagnostic Test|myelin sensitive MRI scan|"Acquisition of 3 myelin sensitive MRI scans as follows: 1. Two MRI during 1 day; the second after 30 min interval and a repositioning.~2. One MRI within one week after the first one.~The total scan time will be ~ 1 hour. T1 maps will be calculated after magnetization-prepared 2 rapid acquisition gradient echoes (MP2RAGE6) acquisition based on a product sequence. Magnetization Transfer (MT) sat maps will be calculated. Quantitative susceptibility mapping (QSM) maps will be reconstructed using an in-house implementation of the structural feature based collaborative reconstruction algorithm (SFCR). For the reconstruction of multi-shell diffusion data, AMICO10 Accelerated Microstructure Imaging via Convex Optimization (AMICO) from diffusion MRI data will be used. Myelin Water Fraction maps will be fitted voxel-wise using a Non-Negative Least Squares fitting."
46013822|NCT02270528|Behavioral|Exercise|10 seconds of sprinting on a bicycle ergometer against a resistance equivalent to 5.5% of a participant's body weight, followed by 20 seconds of rest, repeated 10 times. (~5 minutes)
46013823|NCT02270528|Behavioral|Cognitive Task|The Wisconsin Card Sorting Task (WCST) is a measure of Executive Function.
46099409|NCT04899557|Procedure|Single Port Robotic Splenectomy|Pediatric patient with splenomegaly underwent a single port robotic splenectomy.
46099410|NCT02615106|Drug|Endostar|7.5 mg/m2/day, day 1-14
45464529|NCT05155930|Behavioral|Internal Family Systems (IFS)|Weekly individual psychotherapy
45464530|NCT03783923|Drug|Deflazacort|Deflazacort tablet will be administered as per the dose and schedule specified in the arm.
45464531|NCT03470974|Behavioral|Self-titration strategy|The self-titration strategy allows patients or medical professionals to adjust their medicine (additional, maintain, or decrease dose) depending on a bespoke plan. The bespoke plan for hypertensive patients involves setting target blood pressure, self-monitoring blood pressure, recording blood pressure readings and constructing a medication titration schedule. Each medication titration step is conducted based on the average home BP measurement readings.
45464532|NCT05588271|Other|Exposures|This study is an observational study.Exposure factors is patients with pressure injury.
46013824|NCT00594555|Drug|Imatinib Mesylate|Imatinib Mesylate: 400mg po BID every day. Imatinib Mesylate will be administered Day 2 to Day 15
46013825|NCT00594555|Drug|CLAG|"Cladribine: 5mg/m2 administered through a 2 hour intravenous infusion daily for 5 consecutive days starting on Day 2~Cytarabine: 2gm/m2 administered through a 4 hour intravenous infusion starting 2 hours after the ignition of Cladribine for 5 days starting on Day 2~G-CSF: 300mcg sc for 6 days starting at 24 hours (Day 1) before the first dose of Cladribine; administration starting on Day 1 for 6 days"
46099411|NCT02615106|Radiation|21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor|21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
46099412|NCT04893239|Biological|LMN-201|Components of LMN-201
45464533|NCT03472144|Drug|gel loaded with steroids (momentasone)|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local corticosteroids (momentasone) after balloon sinuplasty for chronic sinusitis patients.
46013826|NCT01605929|Procedure|Retroclavicular Brachial Plexus Block and Catheter Insertion|A Sonosite ultrasound machine will be used to visualize the nerve and needle simultaneously. A Braun 18 g 4 inch Touhy needle with markings will be inserted into the skin and advanced toward the nerve. Once the optimal location is determined under ultrasound visualization, the local anesthetic, mepivacaine, will be injected beside the nerves. The dose of drug will be mepivacaine 1.5%, 0.5 cc/kg (with a minimum 30 cc and maximum of 50 cc.) A Braun 20 g closed tip polyamide catheter will be inserted next to the nerve and left in place to allow for additional medication to be given postoperatively.
45464534|NCT03472144|Drug|gel loaded with antibiotic (Levofloxacin)|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local antibiotic(levofloxacin) after balloon sinuplasty for chronic sinusitis patients.
45464535|NCT03472144|Drug|gel loaded with both steroids and antibiotic|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local both steroids (momentasone)and antibiotic(levofloxacin) after balloon sinuplasty for chronic sinusitis patients.
45464536|NCT03840499|Drug|Optimal medical therapy|Optimal medical therapy
45464537|NCT03417141|Drug|Mechlorethamine 0.016% Top Gel|Valchlor, a 0.016% gel formulation of mechlorethamine. Once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris.
46099413|NCT02569138|Device|Modified Insole|hard and thin shoe insert between the foot sole and base of the footwear
46099414|NCT02569138|Device|Non-Modified Insole|regular shoe insert between the foot sole and base of the footwear
46099415|NCT04930237|Drug|Relistor Injectable Product|12-mg RELISTOR to be administered as once-daily subcutaneous injections for 4 to 7 days
45464538|NCT03840265|Procedure|carotid endarterectomy|In this project the following parameters will be assessed both in asymptomatic and symptomatic patients underwent carotid endarterectomy: 1) hemodynamic modeling of effect of the supraaortic arteries anatomic variations and pathologies 2, preoperative stroke risk prediction based on comparative analysis of CTA results of plaque morphology and ultrasound-based plaque elastography analysis, 3) cerebral flow measurement by transcranial Doppler sonography(TCD), 4) presence recent of silent brain ischemia on DWI-MRI, 5) OCT angiography could be a useful non-invasive method for evaluation of the outcome of carotid interventions
45464539|NCT01222949|Drug|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 3 Tablets a Day for body weight comprised between 36 and 75 kg, 4 tablets for body weight above 75 kg.
45464540|NCT04536688|Drug|RGLS4326|Solution for subcutaneous injection
45464541|NCT01219751|Drug|Sunitinib|Sunitinib 50 mg D1-D28 every 6 weeks
45464542|NCT03714321|Device|Mechanical insufflation-exsufflation (MIE)|Randomization of 30 patients, 15 in each arm, to receive either CPAP or MIE.
46013827|NCT00594594|Other|Probiotic Lactobacillus GR-1 and RC-14|Two capsules of Lactobacillus GR-1 and RC-14 daily for 12 months
46013828|NCT02270606|Radiation|intensity-modulated radiation therapy|Undergo IMRT
46013829|NCT02270606|Drug|fluorouracil|Given IV
46013830|NCT02270606|Drug|oxaliplatin|Given IV
46013831|NCT02270606|Drug|leucovorin calcium|Given IV
46013832|NCT02270606|Procedure|therapeutic conventional surgery|Undergo total mesorectal excision
45683881|NCT04276480|Drug|Piperacillin-tazobactam|"At the time of ventilator-associated pneumonia diagnosis, patients will receive an initial 4g loading dose of piperacillin-tazobactam with a continuous maintenance dose of 16g per day the first day of treatment. The dose of the piperacillin-tazobactam administered the following days will be adjusted to the renal function.~The antimicrobial treatment will be adjusted to the narrower-spectrum agent after the antimicrobial susceptibility determination for a total length of treatment of seven days."
46013833|NCT00594633|Other|donepezil and questionaires|Patients will undergo a brief cognitive evaluation prior to (baseline/Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 2) ,Cognitive Re-Evaluation (about 6 months after discontinuation of Donepezil). Then pt will be tx with donepezil, an acetylcholinesterase inhibitor. They will undergo a four-week dose titration (i.e., 5mg QD during weeks 1-4) to reach a final dose of 10mg QD of oral donepezil there after for a maximum of 24 weeks.
46013834|NCT02270762|Other|Rest in bed|
46013835|NCT02270762|Other|Passive verticalization|
46013836|NCT02270762|Other|Rest in bed|
46013837|NCT01605968|Device|BCT Silver Bandage|Activated carbon fiber impregnated with silver particles
46013838|NCT01605968|Device|Aquacel® Ag. Dressing|Antimicrobial primary dressing incorporating the unique gelling action of Hydrofiber® Technology with ionic silver for wounds that are infected or at risk of infection.
46013839|NCT04355013|Device|Core emperature monitoring|Monitoring core temperatures with probes placed in the arterial outlet and venous inlet of extracorporeal pump, pulmonary artery, bladder, nasopharinx and forehead using a doublé-sensor probe
46013840|NCT01606046|Device|vapocoolant spray|spray for 5 seconds from a distance of 30 cm just before the needle EMG
46013841|NCT01606046|Drug|topical anesthetic cream|application of EMLA cream on the needle electrode insertion site 60 minutes before the needle EMG
46013842|NCT02892630|Other|No intervention|
45464543|NCT05161702|Other|MAG-SPM treatment on isolated PBMC cells|Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.
45464544|NCT05161702|Other|Isolated PBMC cells without treatment.|Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.
45683882|NCT01551693|Drug|STA-9090|
45683883|NCT01922518|Procedure|Septal pacing|Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
46013843|NCT01606085|Behavioral|HF DM self care|Education in monitoring signs and symptoms of Heart Failure and Diabetes as well as self care instruction
46013844|NCT01606085|Behavioral|Usual Care|Educational materials on Heart Failure and diabetes at study enrollment. Full educational binder delivered at end of study.
46013845|NCT00594828|Device|CoaguChek (Patient self testing)|Patients will test their INR at home either biweekly, weekly or every 2 weeks using a CoaguChek point of care meter and communicate with the healthcare provider via an internet based expert system
46013846|NCT00594828|Device|Anticoagulation Management Service (AMS)|Patients will attend the AMS for six months and have their INR checked every 4-6 weeks or more frequently, at the discretion of the clinician
46013847|NCT02270801|Drug|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
46013848|NCT04327713|Dietary Supplement|fish oil supplement|daily fish oil supplement vs. placebo
46099416|NCT04930237|Drug|Docusate Calcium|Standard of care
46013849|NCT01606163|Biological|GC1102|"Description: GC1102 IV bolus injection during 10~ 30 seconds.~Amount: group1-3ml, group2-5ml, group3-8ml~Subject number: group1-8, group2-8, group3-8~Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
46013850|NCT01606163|Other|JW normal saline|"Description: Normal saline IV bolus injection through 10~ 30 seconds.~Each 3 subjects of this placebo comparator group will match with group 1,2,3 respectively. Placebo comparator subjects in each group will be treated with same condition of each group(group 1, group 2, group 3) except being administered JW normal saline.~Subject number: 9~Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
46013851|NCT02892942|Drug|Gonal-F®|225 to 450 IU/d; from day 2 of menstrual cycle onward
46013852|NCT02892942|Drug|Cetrotide®|0.25 mg/day, starting on day 6 of Gonal-F®.
45464545|NCT01223105|Procedure|slow freeze|Eggs will be placed in a cryo-protected solution and frozen slowly in a programable freezer
45680050|NCT04247620|Behavioral|DiaBetter Together|Following an intervention manual, the Peer Mentor will teach behavioral strategies and offer support to the young adult, including (a) teaching and modeling strengths-based skills for goal-setting, problem-solving, and stress management; (b) guiding participants in obtaining support from their social support network (e.g., family, friends); (c) developing a plan for accountability around diabetes management and follow-up in adult care; (d) sharing his/her transition experiences and strategies for successfully navigating the adult healthcare system; (e) discussing how to prioritize diabetes self-care; and (f) assisting them in accessing diabetes-related resources (e.g., local diabetes groups, apps, social media). Contact will be in-person, by phone, email, text message, and/or video, approximately weekly for first 3 mos, approximately biweekly for next 3 mos, and approximately monthly for last 6 mos (while COVID-19 safety recommendations are in place, in-person meetings will not occur).
45683884|NCT01922518|Procedure|Apex pacing|Put RV lead around the apex
46099417|NCT04930237|Drug|Bisacodyl|Standard of Care
46099418|NCT04930237|Drug|Milk of magnesia|Standard of Care
46099419|NCT04930237|Drug|Magnesium citrate|Standard of Care
46099420|NCT04930237|Drug|Senna|Standard of Care
46099421|NCT04930237|Drug|Enema|Standard of Care
46013853|NCT02892942|Drug|Cetrotide®|1.5 mg/day (6 ampoules of 0.25 mg), starting on day 1 (S1) of Gonal-F® treatment until dhCG
46013854|NCT02270879|Procedure|Phacoemulsification cataract surgery|Phacoemulsification of cataract (opacified lens) using clear corneal approach. Implantation of a intra-ocular lens in the capsular bag
46099422|NCT02615262|Drug|Dexamethasone|
46099423|NCT02615262|Drug|Placebo|0.9% Sodium Chloride
46099424|NCT00733720|Drug|Suboxone|4/1mg, 8/2mg 16/4mg
46099425|NCT05262829|Biological|Human Umbilical Cord Mesenchymal Stem Cells|MSCs treatment by intestinal submucosal injection/MSCs treatment by intravenous drip + MSCs treatment by intestinal submucosal injection
46013855|NCT00594867|Drug|Acetaminophen - 4 grams per day + Placebo|Acetaminophen - 4 grams per day + Placebo
46013856|NCT00594867|Drug|Aspirin - 325 mg per day + Placebo|Aspirin - 325 mg per day + Placebo
46099426|NCT04134312|Biological|MVA-BN-Brachyury|MVA-BN-Brachyury will be administered intravenously every three weeks with three administrations in total at the dose indicated by the enrolled cohort.
46099427|NCT03872453|Drug|Zavegepant|A single dose of zavegepant
46099428|NCT03872453|Drug|Zavegepant matching placebo|A single dose of placebo matched to zavegepant
45464546|NCT01223105|Procedure|Vitrification|Eggs will be placed in a high concentration of cryo-protectant and frozen very quickly by plunging in liquid nitrogen
46099429|NCT03872453|Device|Intranasal Aptar Pharma Unit Dose System|A single-dose intranasal device
46099430|NCT05732389|Drug|Nivolumab|Nivolumab is a highly selective fully humanized, IgG4 monoclonal antibody inhibitor of programmed death-1 (PD-1) (17). PD-1 is an inhibitory receptor expressed on the surface of T-cells, B cells, macrophages, and NK cells. Endogenous binding of PD-1 with one of its two ligands PD-L1 and PD-L2 results in production of an inhibitory signal which results in reduction of T-cell proliferation, cytokine production, and cytotoxic activity. This results in significant dampening of the immune response. Nivolumab acts to selectively block the receptor activation of PD-L1 and PD-L2, resulting in a release of PD-1 mediated inhibition of the immune response.
46099431|NCT05732389|Drug|Ipilimumab|Ipilimumab is a fully humanized monoclonal anti-CTLA-4 antibody that acts as an antineoplastic ICI by selectively binding to cytotoxic T-lymphocyte-associated antigen 4, a molecule located on the surface of cytotoxic T-cells, suppressing the immune response (17). Ipilimumab blocks CTLA-4, leading to a continuously active immune response in malignant cells.
46099432|NCT02624388|Drug|Genistein|Estrogen-like compound (isoflavone) derived from soybeans
46099433|NCT02624388|Drug|Placebo|Pill that contains no medicine
45464547|NCT02453113|Other|low power laser|Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
45464548|NCT05161624|Diagnostic Test|Accuracy evaluation|The design of the diagnostic trial will include 160 cases of liver tumors with indications for microwave ablation after a multidisciplinary consultation with clinicians (Multiple Disciplinary Team, MDT), including primary liver cancer and metastatic liver tumors, and the tumor diameter is less than 3 cm. The test subjects consist of three groups: a. path planning model, b. junior ablation specialists, c. senior ablation specialists. The three groups will perform microwave ablation path planning on 160 selected cases of liver tumors. The attending professor of the clinical medical group of the department is responsible for scoring, evaluating whether the design of the plan is reasonable, and then comparing the scoring results by using statistical methods to evaluate the accuracy and effectiveness of the path planning model established in this study.
45464549|NCT05584917|Behavioral|tegner acticity scale|phone call to complete the tegner activity scale after surgery
45464550|NCT03470896|Procedure|preanesthesia teleconsultation|According to his allocated group, patient will have a teleconsultation at home/at work with an anaesthesiologist.
45464551|NCT03470896|Procedure|preanesthesia traditional consultation|According to his allocated group, patient will have a traditional consultation with an anaesthesiologist in the surgical center Emile Galle.
45464552|NCT01203241|Procedure|Pulmonary vein encircling|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum
45464553|NCT01203241|Procedure|Pulmonary vein encircling plus roof ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum plus creation of a radiofrequency line joining contralateral superior pulmonary veins throughout the left atrial roof.
45464554|NCT04823091|Drug|Fludarabine + Cyclophosphamide + CAR7-T Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 250 mg/kg on day -5, -4, and -3; CAR7-T Cells on day 0.
46013857|NCT00594867|Drug|Acetaminophen 4 gram per day + Aspirin 325 mg per day|Acetaminophen 4 gram per day + Aspirin 325 mg per day
46013858|NCT01606241|Drug|Cyclophosphamide|Given PO
46013859|NCT01606241|Other|Laboratory Biomarker Analysis|Correlative studies
46013860|NCT01606241|Biological|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
46013861|NCT04353453|Device|Study Procedure for Participants That Were Not in the Driving Group|"Subjects were fitted with One lead Holter monitor and the CardiacSense1 watch simultaneously and were tested in the following condition:~Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 28 ±3 degree Celsius.~Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 22 ±3 degree Celsius.~Sitting down for 10 minutes,outdoor walking for one minute and repeat this sequence four times At the end the devices were removed from the subject by the medical staff.The recorded data was downloaded for analysis by the Sponsor"
46013862|NCT04353453|Device|Study Procedure for Participants That Were Included in the Driving Group|"Subjects were fitted with One lead Holter monitor and the CardiacSense1 watch simultaneously and were tested in the following condition:~Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 28 ±3 degree Celsius.~Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 22 ±3 degree Celsius.~Going from the indoor facility to the car and driving for 30 minutes at least. Subject drove the car in city streets under light traffic conditions. At the end the devices were removed from the subject by the medical staff.The recorded data was downloaded for analysis by the Sponsor"
46013863|NCT00595023|Device|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
46013864|NCT04352985|Device|Toraymyxin PMX-20R (PMX Cartridge)|The intervention is two (2) treatment sessions of PMX cartridge administration within approximately 24 hours of each other. Each treatment session will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute). In cases where the clinical status of the subject is improving, or if the subject suffers from a relapse and the treating physician believes an additional PMX treatment may improve the clinical outcome of the subject, they may administer an additional PMX treatment session (for a total of 3 treatment sessions) at their discretion. All subjects will continue to receive standard medical care for COVID 19 and septic shock.
46099434|NCT00733798|Drug|131I-TM601|After a single 20mCi/0.4 mg Imaging Dose of 131I-TM601, patients in the Dose Escalation Phase will be administered between 2-5 weekly doses of 131I-TM601 at 1.2 mCi/kg of lean body mass (specific activity of 131I-TM601 will be maintained at 50 mCi 131I/mg TM601 for all doses administered in this study.) Patients in the Efficacy Phase of the study will be treated at the Maximum Tolerated Dose established in the Dose Escalation Phase.
45464555|NCT01125527|Biological|Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib)|a single dose was administered
45683885|NCT04276402|Procedure|Irradiation of implants with 808nm laser|Irradiation of implants with 808nm laser
46013865|NCT02270918|Drug|Kcentra|IV infusion
46013866|NCT02270918|Drug|Apixaban|
46013867|NCT02270918|Drug|Placebo|
46013868|NCT02270996|Other|Antimicrobial Stewardship Program|Twice weekly meeting with Infectious Disease and Pediatric Surgery team members to audit antibiotics prescribed and suggest role for discontinuation.
46013869|NCT00595062|Radiation|Intra Operative Radiation Therapy (IORT)|Quadrant High Dose Rate Intra Operative Radiation Therapy (IORT)
46013870|NCT01580189|Dietary Supplement|Whey protein|18g protein, immediately after training, 9 weeks
46013871|NCT01580189|Dietary Supplement|Chocolate milk|500ml chocolate milk, immediately after training, 9 weeks
46013872|NCT01580189|Dietary Supplement|Sugar|55-65g maltodextrin solution, immediately after training, 9 weeks
46013873|NCT00595140|Drug|pegvisomant|growth hormone receptor antagonist pegvisomant in patients´ individual dose
46013874|NCT00595140|Drug|combination with somatostatin analogue octreotide|s.c., 100µg, one time
45464556|NCT01125527|Biological|Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)|a single dose was administered
45464557|NCT03934853|Device|Dynamic Dental Navigation|Aid in dental implant placement in humans
46013875|NCT00595140|Drug|combination with dopamine agonist cabergoline|oral, 0.5mg, one time
46013876|NCT02271035|Drug|Deflux|Deflux will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one ureteral orifice and Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
46099435|NCT05731453|Genetic|Polygenetic risk score|Polygenetic risk score assessment for breast cancer
46099436|NCT04134156|Procedure|sleeve gastrectomy|5-port sleeve gastrectomy
46099437|NCT04134156|Procedure|one anastomosis gastric bypass|5-port one anastomosis gastric bypass
46099438|NCT00727948|Drug|Aspirin|325 mg tablets, once daily for 45 days
46099439|NCT01007851|Drug|triptorelin acetate|single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
46099440|NCT01007851|Drug|NaCl %0.9|0.1 ml sterile saline sc injection 3 days after embryo transfer
45464558|NCT01206283|Procedure|Modified Lund concept|"After surgical evacuation of intracranial mass lesion and clipping of aneurysm the objectives were achieved:~Reduction of cerebral energy metabolism with fentanyl (2-5 µg/kg/h) and thiopenthal (0.5-3 mg/kg/h);~Maintenance of colloid osmotic pressure with administration of red cell and albumin/plasma transfusions to maintain Hb/s 125-140 g/L and Alb/s ≈40 g/L;~Reduction of capillary hydrostatic pressure with α2-agonist clonidine (0.4-0.8 µg/kg, 1 x 4-6 iv.) and maintaining normovolaemia;~Reduction of mean arterial pressure and neuroprotection with Nimodipine infusion 5 ml per hour for 21 days and Urapidil 200 mg /200 ml, 7-10 ml/h.~Control of ICP, which can be in majority of patients, kept at values below 15 mmHg."
45464559|NCT01206283|Procedure|Cerebral perfusion pressure-targeted therapy|"ICP monitoring using an external ventricular drain and CSF drainage as a first measure if ICP was increased (over 15-20 mmHg);~Maintenance of CPP over 70-80 mmHg (Triple 'H' therapy = 3L/24 hours including 1L of colloids - 5% albumin; drugs = dopamine, dobutamine);~No hyperventilation if ICP was under 20-25 mmHg and hyperventilation as a third measure if ICP was increased;~Osmotherapy (20% manitol, bolus 150-350 ml or 10% manitol, 50 ml/h for 10 hours and standard electrolytes [Na, Cl and K]);"
45464560|NCT05577195|Device|Impella|To provide active left ventricular unloading in the experimental arm
46013877|NCT02271035|Drug|Vantris|vantris will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
46013878|NCT01606358|Drug|Carboplatin and / or taxol chemotherapy|Patient with proven epithelial ovarian cancer and receiving carboplatin and / or taxol chemotherapy (usual care).
46013879|NCT04352517|Other|Online Survey|Online survey completion through google app.
46013880|NCT02271074|Other|Point of care CD4 testing|Participants in this arm will receive POC CD4 testing using the PIMA™ CD4 test system. Results will be made available to the participant within 20 to 25 minutes, before the participant leaves the HCT room. Participants will be given a copy of their results, which will be affixed to their referral letter, and they will be educated on the meaning of the CD4 results in relation to their health. This session will only be performed once at the time of issuing POC CD4 results.
46099441|NCT00697320|Drug|eptacog alfa (activated)|"A NON INTERVENTIONAL OBSERVATIONAL STUDY:~Doses and frequency of injections to be prescribed by the physician as a result of the normal clinical evaluation"
46099442|NCT05580016|Diagnostic Test|Soluble Urokinase Plasminogen Activation Receptor measurement|In addition to the standard of care, Soluble Urokinase Plasminogen Activation Receptor levels will be measured in patients.
46099443|NCT05730673|Drug|700mg leronlimab weekly dose|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5
46099444|NCT05730673|Drug|80mg Regorafenib at week 1|Regorafenib is a small-molecule multiple kinase inhibitor
46099445|NCT05730673|Drug|120mg Regorafenib at week2|Regorafenib is a small-molecule multiple kinase inhibitor
46099446|NCT05730673|Drug|160 mg Regorafenib at week 3|Regorafenib is a small-molecule multiple kinase inhibitor
46099447|NCT01701388|Device|Ekso exoskeleton|The participants will receive 1 - 40 training sessions. The sessions will be 1 hour of device use including balance training, gait training and sit to and from stand training with rolling walker and/ or forearm crutches.
46099448|NCT04134078|Drug|inhaled nitric oxide|Inhaled nitric oxide at 40 ppm will be administered upto 24 hours post ROSC in patient who developed in hospital cardiac arrest
46099449|NCT01007929|Drug|14C-AZD1236|Oral solution 1mg/mL
46099450|NCT05260931|Diagnostic Test|Fetal echocardiography|Two-dimensional, M mode, and Doppler echocardiographic examination performed to rule out cardiac defects and to evaluate cardiac morphometry and function. Cardiac, thoracic, and ventricular areas and diameters measured on 2-dimensional images from an apical or basal four-chamber (4 ChV) view at end diastole. Ventricular sphericity indices calculated by dividing the longitudinal by basal-transverse ventricular diameters. Atrial areas at maximum distension at end of systole. Atria and ventricle to-heart ratios calculated. Myocardial wall thicknesses and ventricular shortening/ejection fractions obtained from M-mode transverse 4 ChV. MAPSE/TAPSE assessed by M-mode from an apical or basal 4 ChV. Mitral and tricuspid early and late ventricular filling obtained by Doppler, and E/A ratios calculated. Left and right myocardial performance indices obtained from Doppler spectrum in a cross-sectional image of the thorax.
46099451|NCT00695370|Drug|Pegfilgrastim (drug)|
46013881|NCT02271074|Behavioral|Care Facilitation|The goal of this intervention is to provide on-going counselling using a combination of motivational and strengths-based counselling approaches.This is a time limited intervention with a maximum of 5 client sessions over a 90-day period. Participants will also be transitioned out of the intervention upon successful entry into HIV care. Sessions will be done using both face-to-face and telephonic approaches, although the former is more preferred.
46013882|NCT02271074|Other|Transport support|The goal of this intervention is to address one of the most frequently noted structural barrier to entry-into-care in resource constrained settings: prohibitive distance or transport cost to reach a health facility.This is a time limited intervention with a maximum of 3 transport assists for healthcare visits over a 90-day period. Transport assistance is provided in the form of reimbursements to claims submitted by the participant after a self-reported HIV care clinic visits. Participants in this arm, receive their transport support through in-person collection or via cell phone transfer. Transport support amounts are standardised according to geographical area.
46013883|NCT00595218|Behavioral|Physician behavior related to Patient Preference Survey|Access to initial Patient preference survey results
46013884|NCT00595218|Other|Patient Preference Results|Knowledge of Patient Preference Results
46013885|NCT01606397|Drug|Placebo|Administered orally (capsule)
46013886|NCT01606397|Drug|LY2409021|Administered orally (capsule)
46013887|NCT00595257|Device|centrifuge, laboratory, tabletop (SmartPReP2 BMAC System)|autologous bone marrow aspirate will be concentrated using the SmartPRep2 BMAC system and then injected/infused into ischemic limbs
46099452|NCT05729815|Other|Relaxation|Sessions focused on relaxations activities (Jacques Choque Method).
46099453|NCT05729815|Other|Loose parts play|Loose parts play-based sessions, with open-ended materials.
46099454|NCT05729815|Other|Combined|Sessions focused on loose parts play and relaxation activities.
46013888|NCT02271113|Drug|GMI-1271|
46099455|NCT03871829|Drug|Carfilzomib 20 mg/m^2|Carfilzomib 20 mg/m^2 will be administered intravenously (IV).
46099456|NCT03871829|Drug|Carfilzomib 70 mg/m^2|Carfilzomib 70 mg/m^2 will be administered IV.
46099457|NCT03871829|Drug|Dexamethasone 40 mg|Dexamethasone 40 mg will be administered as IV infusion or orally.
45837554|NCT00612768|Biological|TRUE Test allergens Fragrance Mix and Thimerosol|"Thimerosal, 0.008 mg/cm2 in hydroxypropylcellulose~Thimerosal, 0.008 mg/cm2 in polyvinylpyrrolidone~Fragrance mix, 0.43 mg/cm2 in hydroxypropylcellulose with β-cyclodextrin~Fragrance mix, 0.43 mg/cm2 in polyvinylpyrrolidone with β-cyclodextrin~Patches are placed at day one and removed 48 hours. The duration of the study lasts 21 days. However, the subject is only exposed the the study allergen for 48 hours."
45837555|NCT01711242|Drug|Capecitabine|
46013889|NCT02271113|Drug|Placebo|
46013890|NCT02271113|Drug|Enoxaparin Sodium (Lovenox®)|
46013891|NCT04349904|Diagnostic Test|Near-Focus Narrow Band Imaging|High Definition White Light Endoscopic Imaging followed by Near-Focus Narrow Band Imaging and target biopsy of 6 areas of the duodenum (2 from the first part and 4 from the second part of the duodenum)
46013892|NCT02271152|Procedure|FAST mapping and ablation|
46013893|NCT02271152|Procedure|PVI|
46099458|NCT03871829|Drug|Dara-SC 1800 mg|Dara-SC 1800 mg will be administered by SC injection.
46099459|NCT03871829|Drug|Dexamethasone 20 mg|Dexamethasone 20 mg will be administered as IV infusion or orally.
45464561|NCT05577195|Device|VA-ECMO|To provide circulatory support in both arms
46013894|NCT01606514|Behavioral|Bounce Back Now Website|Bounce Back Now is a web-based psychoeducation and self-help website
46013895|NCT00595296|Device|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
46013896|NCT02271191|Drug|Nicardipine|nicardipine 1-5 ug/kg/min and remifentanil 0.05 ug/kg/min during deliberate hypotension in spine surgery
45837556|NCT01711242|Drug|Oxaliplatin|
45837557|NCT01711242|Radiation|Radiotherapy|
45837558|NCT04405908|Biological|SCB-2019|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22).
45837559|NCT04405908|Biological|SCB-2019 with AS03 adjuvant|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
45837560|NCT04405908|Biological|SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
46013897|NCT02271269|Behavioral|Value Pricing Subsidies|"Usual care for glaucoma~Subsidies granted to adherent patients for their glaucoma medications and physician visits, lowering the costs of treatment and providing a financial incentive for patients to take their medicines as prescribed.~Subsidy (25 / 50%) granted based on meeting dose-rate adherence percentage targets (75 / 90%) at the month 3 and 6 assessment points."
46013898|NCT00595374|Drug|insulin detemir|
46013899|NCT00595374|Drug|insulin NPH|
46013900|NCT00595374|Drug|insulin aspart|
46099460|NCT00738478|Device|nasogastric tube|insertion of nasogastric tube for 2 days after operation
46099461|NCT00738478|Device|without nasogastric tube|without nasogastric tube after operation
46099462|NCT02619084|Procedure|STN DBS|Bilateral STN DBS
46099463|NCT05729659|Dietary Supplement|Sideritis Scardica (SidTea+) extract supplementation|1500 mg of Sideritis Scardica (SidTea+) extract per day, divided into 3 equal doses of 500 mg (every 8 hours) for a total duration of 1 month
46099464|NCT05729659|Dietary Supplement|Placebo supplementation|1500 mg of placebo per day, divided into 3 equal doses of 500 mg (every 8 hours) for a total duration of 1 month
46099465|NCT00738556|Device|Drug-eluting stents (Cypher and Taxus)|Spot or full length stenting of a coronary lesion
46099466|NCT01008007|Dietary Supplement|Viusid|One Viusid bag (4 grams, orally administered) every 8 hours, for 6 days in combination with the conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
46013901|NCT01606553|Device|High-intensity IMT|High intensity short duration respiratory muscle training with a valve prototype
46013902|NCT01606553|Device|Sham High-intensity IMT|High intensity short duration respiratory muscle training using a sham valve prototype
46013903|NCT04328025|Other|Peer-delivered HIV self-testing, STI self-sampling and PrEP|Peer delivery of combination HIV prevention interventions to transgender women.
46013904|NCT02271308|Behavioral|Low-resistance elastic band training|The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
46013905|NCT04349670|Procedure|GPOEM - gastric per-oral endoscopic myotomy|Endoscopic section of the pyloric muscle with submucosal tunnel technique.
46013906|NCT01606592|Behavioral|Panic Control Treatment (PCT)|Manualized, 13 sessions (60 min, sometimes extended to 90-120) completed in 12-16 weeks. Total duration 840-1080 min.
46013907|NCT01606592|Behavioral|Panic-Focused Psychodynamic Psychotherapy (PFPP)|Manualized, 19-24 sessions (45 min) completed in 12-16 weeks. Total duration 855-1080 min.
46013908|NCT01606592|Other|Waiting-list|Sparse telephone contact during 12 weeks, then re-randomization
46013909|NCT00595569|Behavioral|Flexible insulin therapy (FIT)|Flexible insulin therapy (FIT) courses consisting in 7 weekly ambulatory sessions lasting 90 minutes each
46013910|NCT02271347|Drug|CMX001|CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
46013911|NCT04348734|Diagnostic Test|pleural ultrasound|Patients will benefit from a daily pleural ultrasound for 96 hours, D1 being the day of hospitalization. The therapeutic course of action will depend on the presence or not, and on the type of pleural effusion according to a pre-established algorithm
46013912|NCT01172938|Drug|Apremilast 20mg|Apremilast 20 mg twice daily, orally
45837561|NCT04405908|Biological|SCB-2019 with Alum adjuvant|SCB-2019 intramuscular vaccinations at 9 µg twice (on Day 1 and Day 22), and administered with Alum adjuvant.
46013913|NCT01172938|Drug|Apremilast 30mg|Apremilast 30 mg twice daily, orally
46013914|NCT01172938|Drug|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
46013915|NCT01172938|Drug|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
46013916|NCT02271464|Drug|Maintenance:BEVACIZUMAB|"Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~IRINOTECAN 165 mg/sqm IV over 1-h, day 1~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~- BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks)"
46013917|NCT02271464|Drug|Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE|"Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~IRINOTECAN 165 mg/sqm IV over 1-h, day 1~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks),~CAPECITABINE 500 mg/tid orally, continuously,~CYCLOPHOSPHAMIDE 50 mg/day orally, continuously."
46013918|NCT00595608|Drug|Sterimar Spray|Post-op nasal spray, three times a day
46099467|NCT01008007|Drug|Conventional treatment|Conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
45837562|NCT04333368|Biological|Umbilical cord Wharton's jelly-derived human|Umbilical cord Wharton's jelly-derived human MSC (at the dose of 1 Million / kg) will be administered via a peripheral or central venous line over 60 minutes, using tubing with a 200-μm filter. Cells, in a 150 mL volume, will be delivered at D1 - D3 - D5.
45837563|NCT04333368|Other|NaCl 0.9%|NaCl 0.9% (150 mL) given via an intravenous route at D1 - D3 - D5
46013919|NCT00595608|Drug|Generic homemade nasal saline spray (salt and water)|post op nasal saline spray in syringe, three times a day
46013920|NCT04326894|Drug|25 mg/week oral methotrexate tablets|
46013921|NCT04326894|Drug|25mg/week oral placebo tablets|
46013922|NCT02271542|Drug|propofol|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
46013923|NCT00595647|Device|Drug eluting stent|Implantation of stent
46013924|NCT00595647|Device|Bare metal stent|Implantation of stent
46013925|NCT04315402|Other|prospective, descriptive study via survey|"Survey administered at check out.~Patient's rate of follow-up data gathered via chart review."
46013926|NCT01109992|Drug|Exercise plus Regadenoson (Lexercise)|Standard Bruce exercise stress test with regadenoson injection at maximal stress with Rubidium-82 Positron Emission Tomography
46099468|NCT00597584|Drug|peginesatide|"Participants received peginesatide by intravenous (IV) or subcutaneous (SC) injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa or beta dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa or beta dose. Participants who received epoetin alfa or beta IV at the time of screening received peginesatide IV during the study, and participants who received epoetin alfa or beta SC at the time of screening received peginesatide SC during the study.~The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period."
46013927|NCT01109992|Drug|Regadenoson (Lexiscan)|Regadenoson Rubidium-82 Positron Emission Tomography
46013928|NCT02892357|Drug|Treatment group|Jianpi Qinghua granules:twice a day,1 bag a time;10mg omeprazole and 10mg sham ,once a day,all for 4 weeks.
46013929|NCT02892357|Drug|Control group|sham Jianpi Qinghua granules:twice a day,1 bag a time; 20mg omeprazole once a day ,all for 4 weeks.
46013930|NCT00595686|Drug|SNX-5422|dose escalated; tablets every other day; undetermined duration until disease progression
46013931|NCT02271620|Procedure|nasal allergen provocation test|nasal allergen provocation test
46013932|NCT00595725|Other|Lymphatic Mapping|Intra-Operative Lymphatic Mapping
46013933|NCT02271659|Radiation|Brachytherapy boost with external beam radiotherapy|Bras A: External beam radiotherapy of 46 Gy delivered with a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds from Bard (110Gy) or high dose rate (14Gy) with a iridium-192 source) only to the prostate. Each center will choose the appropriate brachytherapy technique. The number of seeds or needles will depend on the prostate's volume.
46013934|NCT02271659|Radiation|Exclusive external beam radiotherapy|Bras B: External beam radiotherapy of 46 Gy delivered with photons and a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.
46013935|NCT01109524|Drug|Cetuximab|Vial, Intravenous, 400mg/m², week 1, then 250mg/m², Weekly, Until Progressive Disease (PD)/ Toxicity/Pt-PI Decision
46013936|NCT01109524|Drug|Cisplatin|Vial, Intravenous, 80mg/m², Day 1 of each 21 day cycle, Maximum 6 cycles
46013937|NCT01109524|Drug|Vinorelbine|Vial, Intravenous, 25 mg/m², Day 1 and 8 of each 21 day cycle, Maximum 6 cycles
46013938|NCT02271737|Behavioral|Training HC/VHSG, Health Education, and Supportive Supervision|1. Improve infection control Practice at health centers; 2) improve knowledge on newborn danger signs among HC staff, VHSG, and the mothers; 3) improve care coordination between community and health facilities, e.g. improve referral of sick newborns
46013939|NCT01109173|Drug|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
46013940|NCT01109173|Drug|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, for 16 days
46013941|NCT01109173|Other|Nepafenac Ophthalmic Suspension 0.3% Vehicle|Nepafenac 0.3% vehicle, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
46013942|NCT01109173|Other|NEVANAC Vehicle|Nepafenac vehicle, one drop in affected eye three times daily, for 16 days
46013943|NCT02271776|Dietary Supplement|Galactooligosaccharide|The dietary fiber GOS will be supplemented in powder form to regular daily food intake three times per day for 12 weeks
46013944|NCT02271776|Dietary Supplement|maltodextrin|
46013945|NCT04327596|Procedure|RF ablation of AF using CARTO 3 and a Thermocool ST SF ablation catheter|Ablation of AF is standard of care in the management of patients with paroxysmal or persistent AF. The most common triggers initiating AF arise from pulmonary veins (PV) and successful electrical isolation of PV's can significantly reduce the burden of AF. Therefore, the main objective in patients undergoing ablation of AF is to achieve PV isolation.
46099469|NCT00597584|Drug|Epoetin alfa or Epoetin beta|"Participants continued to receive commercially available epoetin alfa or beta by intravenous or subcutaneous injection, at the same starting dose, frequency and route of administration as received during the last week of the Screening Period, with the first study dose of epoetin alfa or beta administered after randomization at Week 0.~The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period."
46099470|NCT02614950|Other|Treatment interruption|
46099471|NCT00734422|Behavioral|Virtual Reality Exposure Therapy|Standard virtual reality exposure therapy for fear of flying will be combined with the administration of either yohimbine hydrochloride or an inactive placebo pill.
45464562|NCT05161312|Behavioral|iACT-BC: Oncovox|A guided internet-delivered ACT intervention to improve psychosocial outcomes in BCP diagnosed in the past two years
45464563|NCT01298401|Biological|ganitumab|
45464564|NCT01298401|Drug|capecitabine|
45464565|NCT01298401|Drug|gemcitabine hydrochloride|
45464566|NCT01298401|Radiation|3-dimensional conformal radiation therapy|
45837564|NCT04331496|Other|Hypertonic solution|Hypertonic serum 4 ml 3%, administered for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow: passive technique of expiratory aid applied to the participant by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through assisted cough or stimulation of the trachea achieves expectoration of sputum.
46013946|NCT02271971|Dietary Supplement|Vitamin D3|A daily 5.000 IU vitamin D3 capsule during 6 weeks.
46013947|NCT02271971|Dietary Supplement|Placebo|A daily placebo capsule during 6 weeks.
46099472|NCT03999307|Radiation|Low-Level Laser Therapy (LLLT)|LLLT will be applied in this group
46099473|NCT03999307|Procedure|Flapless Corticopunture|Small holes in the cortical bone will be achieved using 1-mm diameter round surgical Tungsten bur
46099474|NCT03999307|Other|Control|Typical orthodontic treatment with no LLLT or flapless corticopuncture
46099475|NCT05260853|Other|Weaning Board|structured care concept
46099476|NCT00695448|Drug|GSK1059615|GSK1059615 is dosed orally once daily for 21 days of a 28-day cycle. Patients continue treatment for subsequent cycles as long as eligible and receiving benefit.
46099477|NCT05260775|Other|Evaluation test: cataract surgery steps|The development datasets were used to train the deep learning model. The validation and test group were used to optimize hyperparameters
46099478|NCT00529633|Drug|Thalidomide|Thalidomide by mouth at night for a total of 24 weeks
46099479|NCT00529633|Other|Sugar pill|Placebo by mouth at night for a total of 24 weeks
46099480|NCT01366144|Drug|Carboplatin|Given IV
46099481|NCT01366144|Other|Laboratory Biomarker Analysis|Correlative studies
45464567|NCT03931343|Procedure|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance|Thoracolumbar interfascial plane block: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance
45464568|NCT03931343|Procedure|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance|Erector spinae plane block: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance
46013948|NCT04344639|Other|the incidence, risk factors, treatment, prognosis of necrotizing enterocolitis in newborn infants born in newborn intensive care units in our country|With this project, which is planned as a national multicenter prospective study, the incidence of necrotizing enterocolitis in newborn infants born in newborn intensive care units in our country and the risk factors associated with the disease, especially the detailed feeding history of the patient (when the first feeding is nourished, antibiotics and other treatments that are being used). Most epidemiological data such as the most common stage of the disease, treatment, prognosis, comparison with the data of other countries will provide important information for the neonatal health of our country.
45464569|NCT03840109|Behavioral|Questionnaire 1a|Participants will be randomly shown two versions of messages in which the last 20% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
46099482|NCT01366144|Drug|Paclitaxel|Given IV
46099483|NCT01366144|Other|Pharmacological Study|Correlative studies
46099484|NCT01366144|Drug|Veliparib|Given PO
46099485|NCT00697944|Drug|Amphotericine in liposome (Ambisome®)|2 IV infusions separated by one week 10 mg/kg per injection
46099486|NCT05260697|Other|sexual counselling with plissit model|sexual counselling
46099487|NCT02619006|Other|Delayed Cord Clamping or Cord Milking|Healthy term infants who were previously randomized or assigned at birth to the intervention group known as delayed cord clamping. The cord was clamped and cut at or beyond 300 seconds (5 mins). Cord milking (cord milked x 5) was used as a proxy for delayed cord clamping when there was a clinical situation of concern.
46099488|NCT04160234|Other|web-based questionnaires|Patients will be asked to complete web-based questionnaires on a tablet computer
46099489|NCT00657488|Drug|Thalidomide|Thalidomide 100mg/day or 400 mg/day at bed time during one year
46013949|NCT02273024|Behavioral|Exercise|
45464570|NCT03840109|Behavioral|Questionnaire 1b|Participants will be randomly shown two versions of messages in which the first 20% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
46013950|NCT02272088|Behavioral|physical activity-moderate|cross -over of moderate and intense physical activity
46013951|NCT02272088|Behavioral|Intense physical activity|cross -over of moderate and intense physical activity
46013952|NCT01172821|Drug|placebo|Placebo that represents BI drug
46099490|NCT00530335|Drug|Atomoxetine|40 mg/day every day (QD), by mouth (PO), for 1 week; 80 mg/day every day, by mouth, for 1 week; 105 mg/day every day, by mouth, for 2 weeks; 120 mg/day every day, by mouth, for 4 weeks
46099491|NCT00712270|Drug|Aripiprazole|Target dose = 15mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
46013953|NCT01172821|Drug|placebo|Placebo that represents comparator
46013954|NCT01172821|Drug|placebo|Placebo that represents comparator
46013955|NCT01172821|Drug|tiotropium Respimat® low dose|IMP
45464571|NCT03840109|Behavioral|Questionnaire 2a|Participants will be randomly shown two versions of messages in which the last 40% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
46099492|NCT00712270|Drug|Risperidone|Target Dose = 2mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
46099493|NCT04188821|Procedure|breast drain removal|"Investigators remove the drains when the suction drain flow was less than 30 ml/day for at least 2 days or at discharge, with no further signs of infection, fluid collection or impaired wound healing (complicated, see below). Ultimately, we removed drains 3 weeks postoperatively (21 days post op) even if the flow was higher than 30 ml/day. However, leakage or severe patient discomfort led to immediate drain removal at any time during postoperative care."
45464572|NCT03840109|Behavioral|Questionnaire 2b|Participants will be randomly shown two versions of messages in which the first 40% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
45464573|NCT03840109|Behavioral|Questionnaire 3a|Participants will be randomly shown two versions of messages in which the last 60% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
46013956|NCT01172821|Drug|placebo|Placebo that represents BI drug
46013957|NCT01172821|Drug|tiotropium Respimat® high dose|IMP
46013958|NCT01172821|Drug|50 mcg salmeterol HFA MDI|Active comparator
46013959|NCT01172821|Drug|placebo|Placebo that represents comparator
46013960|NCT02272127|Drug|icotinib|
46099494|NCT04131816|Behavioral|HeartHome|The HeartHome program is an expanded home-based cardiac rehabilitation program that combines nurse home visits with telephone and electronic supports for participants that allows them to engage in cardiac rehabilitation activities at home.
46013961|NCT02272205|Other|Retrospective analysis of records|
46099495|NCT00738634|Behavioral|Self-motivated physical activity|"Components:~Physical activity education in the form of a brief booklet (double sided A4 page).~Physical activity motivation tips (one sided A4 page).~Pedometer~Monitoring chart~Online presentation of common obstacles and ways to overcome these obstacles"
46013962|NCT05328973|Other|ELEQUIL|patch placed on skin
46099496|NCT00738634|Behavioral|Nutrition|"Components:~Nutrition education booklet (Double-sided A4 page)~Nutrition motivation tips (single-sided A4 page)~Nutrition monitoring chart~Online presentation of common obstacles and ways to overcome these obstacles"
46013963|NCT01172275|Drug|N-Acetylcysteine|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
46013964|NCT01172275|Other|Placebo|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
46013965|NCT02272283|Device|Percutaneous coronary intervention with Nobori biolimus-eluting stent implantation|The third-generation biodegradable polymer Nobori biolimus-eluting stent is implanted in all patients
46013966|NCT05036356|Other|Headspace App|"A mobile-application (app) focusing on teaching and sustaining mental well-being."
46013967|NCT05034952|Drug|VX-548|Tablets for oral administration.
46013968|NCT05034952|Drug|HB/APAP|Capsules for oral administration.
46013969|NCT05034952|Drug|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
46013970|NCT05034952|Drug|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
46013971|NCT00596037|Drug|Growth hormone - LB03002|
46013972|NCT02272322|Device|cystocele repair with biomesh soft prolaps and endofast reliant|
45464574|NCT03840109|Behavioral|Questionnaire 3b|Participants will be randomly shown two versions of messages in which the first 60% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
45464575|NCT03840109|Behavioral|Questionnaire 4a|Participants will be randomly shown two versions of messages in which the last 80% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
45464576|NCT03840109|Behavioral|Questionnaire 4b|Participants will be randomly shown two versions of messages in which the first 80% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
46013973|NCT04310371|Behavioral|3-month lifestyle intervention|"Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.~There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only."
46099497|NCT00738634|Behavioral|Physical activity researcher contact|"Behavioral: Self-motivated physical activity~Components:~Physical activity education in the form of a brief booklet (double sided A4 page).~Physical activity motivation tips (one sided A4 page).~Pedometer~Monitoring chart~Online presentation of common obstacles and ways to overcome these obstacles"
46099498|NCT00695526|Dietary Supplement|cranberry|cranberry extractive in powder product (by Triarco Industries, Inc. NJ, USA) and encapsulated in dose of 500mg/capsule (by Topo digital tech co., Taiwan). By one capsule after each of three meals per day.
46099499|NCT03860597|Drug|Memantine|To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
45464577|NCT03472066|Other|Previous conization|a group of women who have been conized,
45464578|NCT03472066|Other|no previous conization|group with asymptomatic patients on routine second trimester echography
45464579|NCT01122875|Drug|MFGR1877S|Intravenous repeating dose
46013974|NCT02881372|Other|Oral food desensitization|The child's specific food antigen will be diluted in a 50% glycerin/water solution containing ascorbic acid (Vitamin C). This oral spray solution will need to be administered twice a day, every day for a total of 4 months
46099500|NCT03860597|Drug|Placebos|To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
46099501|NCT04159844|Device|URGOBD001|Application with 50% overlapping
46099502|NCT04159844|Device|URGOBD001 associated with wading|Application with 50% overlapping in association with wading
46099503|NCT02614872|Drug|GLASSIA® and Institution standard of care (SOC)|Alpha-1 Antitrypsin (AAT) [GLASSIA®] add-on pharmacotherapy and Institution standard of care (SOC)
46099504|NCT04064320|Behavioral|Lullaby intervention|Listening to lullabies, and accompanied by lullabies touching their abdomen and think about their babies of hospitalized women with high-risk pregnancy
46099505|NCT04162106|Device|Smoke management during laparoscopic cholecystectomy using the Ultravision™ System|The Ultravision™ System will be used during the procedure to manage smoke generated as a result of the use of diathermy.
46099506|NCT04162106|Device|Smoke management during laparoscopic cholecystectomy using the Airseal® iFS|The Airseal® iFS will be used during the procedure to manage smoke generated as a result of the use of diathermy.
46099507|NCT01008085|Device|Stentys coronary stent|Self-expanding Nitinol stent
46099508|NCT01008085|Device|Balloon-expandable stent|VISION/Driver
46099509|NCT00695604|Drug|Placebo|Placebo via MDI.
46099510|NCT00695604|Drug|Fluticasone|Fluticasone MDI.
45464580|NCT01298479|Other|Uniject|single use container
45464581|NCT03935087|Diagnostic Test|two-dimensional echocardiogram|two-dimensional echocardiogram with evaluation of left ventricle volumes and of left ventricular ejection fraction
45464582|NCT02146885|Other|Weight Control|Weight Control
46099511|NCT00612443|Behavioral|Sham treatment|The sham/placebo treatment will consist of the RN graduate assistant standing near the table, slowly walking around from each side and to the foot of the table stopping periodically. The RN graduate assistant will be instructed to not focus on the patient in thought. While providing the placebo treatment the RN graduate assistant will mentally do multiplication equations. This serves as a distracter to keep the RN graduate assistant from setting intention or thoughts on the participant. At no time will the RN performing the placebo treatment move hands or arms over or around the participant or come in physical contact with the participant. The placebo treatment will be a minimum of 20 minutes but no greater than 30 minutes in length. A timer will be set in the treatment room to notify the practitioner of the time limit.
45464583|NCT05281315|Other|Patients were retrospectively enrolled. This was a retrospective study and no intervention was performed.|Patients were retrospectively enrolled. This was a retrospective study and no intervention was performed.
45464584|NCT05012176|Behavioral|Behavioral Intervention|Participate in EFT
45464585|NCT05012176|Behavioral|Behavioral Intervention|Participate in ERT
46013975|NCT04326855|Other|Incremental shuttle walking protocol (ISWT)|Patients will perform an incremental shuttle walk test to the limit of tolerance to establish peak walking speed. The test will be developed in a 10-m course corridor, and it will be externally-paced via a recorded metronome that gives a signal for each stride. The walking pace will be increased every minute and the test will be terminated when the individual is no longer able to keep up the pace. Pulmonary variables will be recorded breath-by-breath. Cardiac output will be assessed every min. Arterial oxygen saturation will be measured by a pulse oximeter. Patients will score the intensity of their breathlessness and leg discomfort using the 1-10 Borg's scale every minute.
45464586|NCT05012176|Other|Quality-of-Life Assessment|Ancillary studies
45464587|NCT05012176|Other|Questionnaire Administration|Ancillary studies
45464588|NCT03931499|Diagnostic Test|Metabolomic analysis|Blood will be collected in all patients blood before surgery and after surgery (postoperative day 1). Our study is based on a polar metabolomics profiling of plasma and/or serum using hybrid triple quadrupole mass spectrometer coupled with chromatographic system.
45837565|NCT04331496|Other|Physiological solution|Single-dose physiological saline serum (5 ml 0.9% NaCl), administered for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow: passive technique of expiratory aid applied to the participant by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through assisted cough or stimulation of the trachea achieves expectoration of sputum.
45464589|NCT01206361|Drug|XALACOM|Xalacom eye drops
45464590|NCT01206361|Drug|Duotrav|Duotrav eye drops
45464591|NCT01206361|Drug|Ganfort|Ganfort eye drops
45464592|NCT04867798|Drug|Lamivudine-Tenofovir 300 Mg-300 Mg Oral Tablet|PrEP eligible participants will be asked to follow up monthly for 12 months. PrEP will be prescribed for once-daily use and discontinued if HIV tests are positive. At quarterly visits, participants will receive Integrated Next Steps Counseling (iNSC) for PrEP adherence with point-of-care drug level feedback. Participants will receive iNSC Support Level 1 to address PrEP adherence and sexual health needs. Those with urine tenofovir levels <1500 ng/mL will receive iNSC Support Level 2, in which participant responses to two 7-item questionnaires on PrEP adherence and sexual health will guide problem solving on improved dosing. Medication refills will consist of 3-month supplies.
45464593|NCT01122953|Drug|Phenytoin|Single dose of Phenytoin 125 mg/5 ml suspension made by Laboratorios Pfizer, S.A. de C.V.
45464594|NCT01122953|Drug|Epamin|Single dose Epamin 125 mg/5 ml suspension made by McNeil LA LLC
45464595|NCT01298635|Procedure|combined phacotrabeculectomy|trabeculectomy plus phacoemulsification with intraocular lens implantation
45464596|NCT01298635|Procedure|trabeculectomy|
45464597|NCT01125683|Drug|AZD1446|Capsule, oral single and multiple dose
45464598|NCT01125683|Drug|Donepezil|Capsule, oral and single dose
45464599|NCT01125683|Drug|Placebo|Capsule, oral and single dose
45464600|NCT04682704|Device|Parasym|Tragus stimulation
45464601|NCT01127555|Drug|5-fluorouracil, leucovorin, oxaliplatin|D1 Oxaliplatin 85mg/m2 D1, 2 LV 30mg/m2 IV push D1, 2 5-FU 1500mg/m2 CIV over 24hrs Every 2 weeks
45680051|NCT04247620|Behavioral|Peer Mentor Delivery|Peer Mentors deliver the intervention to multiple young adult participants, each for 12 months. Peer Mentors may take on one or more participants at a time, and Peer Mentors may stay in their role in the study (delivering the intervention) for 1-3 years.
46013976|NCT04326855|Other|Endurance shuttle walking (ESW) protocol|Subsequently, during the second visit all patients will perform the continuous endurance shuttle walk (ESW) protocol to the limit of tolerance at a walking speed corresponding to 85% of VO2 peak derived by the ISWT (visit 1). During the ESW protocol patients will receive standardized instructions to walk for as long as possible although there will be a predetermined 6 minute maximum point. No further encouragement will be provided during the exercise performance. The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
46013977|NCT04326855|Other|First Intermittent shuttle walking protocol|All patients will perform an intermittent shuttle walking protocols to the limit of tolerance (visit 3) by alternating 1-min walking bouts sustained at a walking speed equivalent to 85% peak (equivalent to the continuous ESW protocol) with 1-min rest periods.The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point.Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
46013978|NCT04326855|Other|Second Intermittent shuttle walking protocol|To obtain test re-test reliability in terms of distance walked, of cardiorespiratory and symptoms responses this intermittent shuttle walking protocol will be repeated on a different day (visit 4). The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
45464602|NCT03840031|Other|High Fe OFSP meal labelled with Fe-58|400 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days
45464603|NCT03840031|Other|Control OFSP meal labelled with Fe-57|400 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days
45464604|NCT03470662|Other|Care bundle|Care bundle
45464605|NCT01219907|Biological|HER-2/neu peptide vaccine|Given intradermally
45464606|NCT01219907|Drug|cyclophosphamide|Given IV
45464607|NCT01219907|Biological|ex vivo-expanded HER2-specific T cells|Given IV
45464608|NCT01219907|Other|laboratory biomarker analysis|Correlative studies
45464609|NCT01219907|Other|flow cytometry|Correlative studies
45464610|NCT01219907|Other|immunoenzyme technique|Correlative studies
45464611|NCT01203397|Drug|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G|APLIED 4 TIMES/DAY AT LESION
45680052|NCT04246671|Biological|TAEK-VAC-HerBy|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose defined in stage 1. During stage 2, it may also be administered concurrently with a HER2 antibody(ies) (trastuzumab, pertuzumab).
45680053|NCT04235777|Drug|M7824|1200 mg administered IV every two weeks while on M9241 and with or without SBRT
45680054|NCT04235777|Drug|M9241|An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks while on M7824 and with or without SBRT
45680055|NCT04235777|Radiation|Stereotactic body radiation therapy (SBRT)|A fixed dose of 8 Gy x 3 fractions sequential or concurrent with M7824 and M9241
45680056|NCT04233918|Drug|Evinacumab|Part A: Single IV dose Part B & C: IV dose Q4W
45680057|NCT04230564|Drug|azacitidine|Patients taking azacitidine
45680058|NCT04230564|Drug|venetoclax|patients taking venetoclax
46013979|NCT04326855|Other|Focus group study|Semi-structured interviews to explore patients' preferences of undertaking the intermittent or continuous ESW protocols and healthcare professionals' perceived factors affecting the implementation of these protocols in the PR setting. These semi-structured interviews consist of questions in some degree predetermined order but still ensures flexibility in the way issues are addressed to the patients. Conversation is sustained in an informal tone and lasts for about an hour. Participants are allowed for an open response in their own words.
46013980|NCT02272400|Other|IGRT for prone partial breast irradiation (PBI)|IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy. Simulation and treatment will be started within 50 days from surgery in order to maximize the chances of optimal lumpectomy cavity visualization on the planning and cone beam CT scans. All patients will be followed monthly for the first 90 days then q3 months for the first year, then yearly for the next 10 years.
45464612|NCT04672876|Drug|Telotristat Ethyl Oral Tablet|XERMELO is a prescription pill, used along with somatostatin analog (SSA) therapy, for Carcinoid Syndrome diarrhea in adults who are not adequately controlled by SSA therapy. The drug is currently FDA-approved for this use but this study has received special approval from the FDA (under an Investigational Drug Application) to study telotristat ethyl in individuals with carcinoid tumors who plan to undergo surgery.
45464613|NCT03935009|Behavioral|Manual toothbrush Curaprox 5460 ultra soft|Soft manual toothbrush (Curaprox 5460 ultra soft) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chumswill will be used to brush teeth.
46013981|NCT02273102|Drug|Tranylcypromine|Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each.
46013982|NCT02273102|Drug|Tretinoin|45 mg/m2 of ATRA to be administered orally twice a day (12 hours apart), beginning on day 4 for up to 16 cycles of 21 days each.
46013983|NCT02272478|Drug|Arm A Mylotarg plus DA Versus CPX-351|Patients not known to have adverse risk cytogenetics will enter a randomisation comparing DA with Mylotarg (GO) delivered at 3mg/m2 on day 1 of chemotherapy, with CPX-351 on days 1, 3 and 5.
46013984|NCT02272478|Drug|Arm B Vosaroxin and Decitabine|If a patient is known to have adverse risk Cytogenetics at diagnosis they will enter a registration to receive up to 5 courses of Vosaroxin and Decitabine.
45464614|NCT03935009|Behavioral|Electric toothbrush Play Smart Brush N°1|Electric toothbrush (Play Smart Brush N°1) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App will be used to brush teeth.
45464615|NCT03935009|Behavioral|Electric toothbrush Play Smart Brush N°2|Electric toothbrush (Play Smart Brush N°2) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia will be used to brush teeth.
45464616|NCT03471988|Drug|AK1820|"Only a switch from IV infusion (vial) to oral administration (capsule) will be permitted; a switch from oral administration to IV infusion will not be possible.~372.6 mg of AK1820 (isavuconazonium sulfate) is equivalent to 200 mg of isavuconazole.~Other Names: Cresemba, BAL8557"
45464617|NCT03471988|Drug|Voriconazole|"Only a switch from IV infusion (vial) to oral administration (tablet) will be permitted; a switch from oral administration to IV infusion will not be possible.~Other Name : VFend"
45464618|NCT03724981|Drug|Dulaglutide Pen|Injected on a practice pad.
45464619|NCT03724981|Drug|Semaglutide Pen|Injected on a practice pad.
45464620|NCT03442569|Drug|Panitumumab|6 mg/kg via IV every 2 weeks in combination with nivolumab and ipilimumab
45680059|NCT04230564|Drug|glasdegib|patients taking glasdegib
45680060|NCT04230421|Device|The Monsenso system with feedback|See description under intervention
45680061|NCT04230421|Device|The Monsenso system without feedback|See description under intervention
45680062|NCT04230421|Device|CAG Bipola and mood monitoring only|See description under intervention
46013985|NCT02272478|Drug|Arm D Small molecule or Not|The randomisation to AC220 or not will take place immediately before course 2 of treatment for patients who have received DA induction +/- Mylotarg, irrespective of residual disease status. Patients allocated to receive AC220 will be randomised in a 1:1 fashion to AC220 or no small molecule with a 1:1 randomisation in patients drawing AC220 between short and long therapy.
46013986|NCT02272478|Drug|Arm C DA V FLAG-Ida V DAC|If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1:1 fashion between DA, FLAG-Ida (or mini FLAG-Ida if 70 years or older) and DAC.
46013987|NCT02272478|Drug|Arm E CPX-351 (200 V 300)|If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1 fashion between CPX given on days 1, 3 and 5 (3 doses) and CPX given on days 1 and 3 (2 doses).
45680063|NCT04218409|Drug|OxyCODONE 5 mg Oral Tablet|Oral oxycodone 5 mg orally
45680064|NCT04218409|Drug|Oxytocin nasal spray|Intranasal oxytocin administration (48 IU)
45464621|NCT03442569|Drug|Nivolumab|240 mg via IV every 2 weeks in combination with panitumumab and ipilimumab
45464622|NCT03442569|Drug|Ipilimumab|1 mg/kg via IV every 6 weeks in combination with nivolumab and panitumumab
45464623|NCT04849988|Drug|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
45464624|NCT04849988|Drug|Placebo|0.9% sodium chloride, sterile, unpreserved, USP/Ph.Eur.
46013988|NCT02272478|Drug|Arm F DA V IDAC|Following recovery from course 2, patients in the MRD-ve arm will be randomised between a further 5-day cycle of DA or a cycle of intermediate dose cytarabine (IDAC) as the third chemotherapy course.
46013989|NCT02272517|Drug|Vortioxetine 10-20 mg|
46013990|NCT02272517|Drug|Escitalopram 10-20 mg|
46013991|NCT02272673|Dietary Supplement|Honey|The subjects in the I/C group consumed 2 ml (2.5 g) honey/kg body weight/dose twice weekly in the first 12-week period (period 1), while the subjects in the C/I group did not receive honey as a control in the period 1. After period 1, the subjects of each group exchanged their protocol for the following 12-week period (period 2).
46013992|NCT02272712|Behavioral|Cognitive Behavioural Therapy|psychoeducation about insomnia, relaxation training, sleep restriction, stimulus control, hypnotic tapering under direction of a physician, cognitive therapy, sleep hygiene
45464625|NCT04648306|Device|Prophylactic Impella support for a non-emergent PCI|Impella percutaneous mechanical circulatory support is placed via the femoral or axillary artery prior to a non-emergent PCI in patients at high risk for periprocedural complications including hemodynamic collapse.
46013993|NCT02272751|Behavioral|Exercise|The Exercise intervention will consist of aerobic activity followed by upper and lower limb resistance training using Therabands and some core exercises.
45464626|NCT03931577|Diagnostic Test|C-reactive protein rapid testing|Continuous (workshop and monthly web-based training) disease-focused intervention with the provision of CRP rapid testing in the primary care practices.
45464627|NCT03931577|Procedure|Communication skill enhancement|Continuous (on-site and monthly online training) illness-focused intervention (enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets) in the primary care practices.
45464628|NCT03834181|Device|"Monitoring evaluation by connected devices: Wristband activity tracker Garmin Vivosmart® 3, Fora® Scale 550, Terraillon® Tensioscreen, Pulse oximeter Nonin® 3230, thermometer Fora® IR20b"|"All patients will be monitored before and after the bariatric surgery:~During the preoperative preparation phase: weight, exercise, blood pressure and heart rate~In the immediate post operative period: continuous monitoring of the heart rate with a telemetry system~Prolonged follow-up: weight, exercise, blood pressure and heart rate"
45680065|NCT04218409|Other|Placebo Oxycodone|Oxycodone 0 mg orally
45680066|NCT04218409|Other|Placebo oxytocin|Intranasal placebo administration
46013994|NCT02272751|Behavioral|Relaxation|The Relaxation intervention will consist of a chair-based program incorporating breathing exercises, meditation, visualisation and progressive muscle relaxation.
46013995|NCT04344132|Procedure|Scalp Block|standard practice of controll the pain after surgery. Block of the nerve emergences.
46013996|NCT00596076|Behavioral|Back School|"All the workers undergo a clinical examination for low back pain, by two trained practitioner. Those workers who are diagnosed for mechanical low back pain during the last six months fulfill a self report Quality of Life Questionnaire (SF36). The objective level of low back pain will obtain by a visual analogue scale. Then a back school training course will be held in 6 sessions, in 6 consecutive weeks. Two previously trained physiotherapists are responsible for the training course. Each series will have 10 participants. They will learn vertebral column anatomy and its function at the first session. The proper posture and exercises to reduce or inhibit low back pain are taught in the next 4 sessions. The 6th session is arranged for answering questions and checking how exercises are performed.~A visual analogue scale and quality of life assessment will be held at the end of the last session and the end of the sixth month."
45464629|NCT01123031|Drug|lansoprazole|lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months
45464630|NCT01123031|Drug|esomeprazole|esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
45464631|NCT04637932|Procedure|Percutaneous Dilatation Tracheostomy|pro-seal laryngeal mask or intubation tube in bronchoscopy-guided percutaneous dilation tracheostomy procedure.
45464632|NCT04354454|Other|Fitbit|Participants will select a daily step goal and track their steps every day for 4.5 months.
45464633|NCT04354454|Other|Fitbit + Game + Support from a Teammate|"Daily Fitbit tracking for 4.5 months, divided into 2 parts.~3 months on active intervention with Fitbit, a Game, and Support from a self-selected Teammate and pre-designed game.~1.5 month follow-up period with Fitbit and social support teammate only"
45680067|NCT04218409|Drug|OxyCODONE 2.5 mg Oral Tablet|Oral oxycodone 2.5 mg orally
46013997|NCT02272829|Behavioral|Choacot: Behavioral Intervention for Chronic Opioid Use|This is an intervention for individuals who use opioid medication for chronic pain, and targets the collaboration between the participant and his/her PCP.
46013998|NCT02272829|Other|Health Education|
46013999|NCT00596115|Drug|R(+) pramipexole dihydrochloride monohydrate|20 mg tid per day orally
46014000|NCT02273219|Drug|AEB071|Oral, 100-400 mg twice daily A potent, oral, selective inhibitor of the classical Protein Kinase C (PKC)
45683886|NCT01574157|Drug|Sodium bicarbonate|Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.
46014001|NCT02273219|Drug|BYL719|Oral, 200-350 mg daily An oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds
45464634|NCT03714243|Device|ExAblate BBBD|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in patients with Her-2 positive breast cancer and brain metastases
45464635|NCT01204567|Other|Aerobic training|Group-based Aerobic Interval Training twice a week in 12 weeks, based on the Ulleval model. The Norwegian Ulleval Model is a group-based aerobic interval training program which is widely used in Scandinavian hospitals for patients with coronary disease. It is designed to improve physical capacity, body awareness and emotional well-being.
46014002|NCT02272868|Biological|Fecal Microbial transplant|Pretransplant regimen(rifaxamin+omeprazole+miralax) + Donor feces transplant
46014003|NCT02272868|Drug|Normal Saline|Pretransplant regimen(rifaximin+omeprazole+miralax) +Normal Saline
46014004|NCT02272868|Drug|rifaximin+omeprazole+miralax|
46014005|NCT02892864|Other|Neuromuscular Retraining and Virtual therapy|Neuromuscular retraining is a problem solving approach to treatment using selective motor training to facilitate symmetrical movement and control undesired gross motor activity (synkinesis). Treatment consists to accomplish daily massages and facial exercises. Motivation on the part of the patient is a crucial element in the success of treatment
46014006|NCT02892864|Other|Oro-myo-functional classical rehabilitation|"Patients taken care in external consultation who receive oro-myo-functional rehabilitation through a virtual rehabilitation program targeted at the smile, in their place of living in virtual conditions.~Patients taken care in consultation within the ENT service which provides oro-myo-functional classical rehabilitation."
46099512|NCT00612443|Behavioral|Healing Touch|Behavioral: Healing Touch The Healing Touch intervention will consist of a brief meditative state in which the practitioners sets the intention of healing for the session. A hand scan to assess the biofield; consists of a technique of where the practitioner slowly moves her hands three to six inches above the body going from head to toe, to assess for any disturbances in the biofield; a non-contact Healing Touch treatment which will follow, to include a connection of the chakras. The chakras are connected by placing the hands above the body over each chakra, starting at the feet and progressing to the head. This will be followed by smoothing the biofield, achieved by the Practitioner slowly moving her hands above the body from the head and moving towards the feet (Hover-Kramer et al., 1996). At no time will the Practitioner make physical contact with the participant during the treatment. The treatment will be 20 minutes to 30 minutes in length.
46099513|NCT02638688|Other|ultrasound|
45680068|NCT04210089|Device|Total Contact Soft Cast|"The total contact soft cast will consist of wound dressing of choice to the ulcer and a plantar foot accommodative offloading felt pad for all foot ulcers, with 4x4 gauze pads added to the arch to create a rocker bottom for metarsophalangeal joint (MPJj) and plantar heel ulcers. The next layers will be:~Unna boot from MPJs to just below the knee,~Sterile Kerlix from MPJs to just below the knee~Sterile 4 inch Kling wrap from the MPJs to just below the knee,~Four inch coban from MPJs to just below the knee, and~Ace wraps from MPJs to just below the knee"
46099514|NCT01008163|Drug|YY-351/Placebo|comparison of different dosages of drug
46099515|NCT01008163|Drug|YY-351/Placebo|comparison of different dosages of drug
45680069|NCT04210089|Device|Cam Boot|Removable Diabetic cam boot will be used in patients willing and capable of using it. If patient does not want to use Diabetic cam boot then surgical shoe or regular shoe would be options.
45680070|NCT04191590|Procedure|nasal brushing and bacteriological sample|A nasal brushing as well as a bacteriological sample using a swab under general anesthesia at the beginning of the endonasal surgery procedure
45680071|NCT04190862|Drug|E-CEL UVEC|Injection of E-CEL UVEC
45680072|NCT04187040|Procedure|Study intervention: 3-step hand hygiene technique|"3-step hand hygiene technique:~Covering all surfaces of the hands (based on own judgement)~Rotational rubbing of fingertips in the palm of the alternate hand~Rotational rubbing of both thumbs"
46014007|NCT02272907|Other|Injection of saline solution into specimen to test bursting pressure.|A 1 cm gastrotomy will be made with a purse-string suture placed around the defect. A fluid-instillation catheter will be inserted into the specimen via the gastrotomy. The purse-string suture will then be secured around the catheter. The catheter will be fenestrated with a flange to prevent leakage from the gastrotomy site. The catheter will be attached to a Biopac pressure-monitoring device to monitor pressure within the lumen of the specimen. The specimen will then be suspended in a water bath and methylene blue saline solution will be injected into the specimen to a pressure reading of 0. This will be time zero for our experiment. Methylene blue saline solution will then be injected steadily in incremental levels. During this process, the study team will observe for any obvious blue dye leaks at the staple line or drop in pressure on the monitor.
46099516|NCT01008163|Drug|YY-351|comparison of different dosages of drug
46099517|NCT01008163|Drug|Placebo|comparison of different dosages of drug
46099518|NCT00738712|Procedure|MRI Magnetic Resonance Imaging|MRI
46099519|NCT02708927|Other|Clinical evaluation|• Clinical assessment : Expanded Disability Status Scale (EDSS), ambulation test. Medications will be recorded.
46099520|NCT02708927|Other|Cognitive evaluation|• Neuropsychological, psychological, social and social cognitive evaluation
46099521|NCT00654524|Drug|gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin|The patient will be managed with GnRH-a injection (Goserelin 3.6mg) every 4 weeks for 6 months plus add-back therapy (Caltrate With Vitamin D 600mg p.o. q.d.& Livial 1.25-2.5mg p.o. q.d.) if needed.
46099522|NCT04064554|Device|BCG vaccination with MicronJet600|BCG vaccination with MicronJet600
46099523|NCT04064554|Device|BCG vaccination with conventional needle|BCG vaccination with conventional needle
46099524|NCT02618460|Device|Non contrast-enhanced magnetic resonance imaging|
46099525|NCT05260619|Drug|lenalidomide|Patients with MRI documented response CR or PR after induction chemotherapy will enter the study protocol of lenalidomide maintenance (at a dose of 15 mg per day, on days 1 to 21 of each 28-day cycle) for up to 12 cycles or until the patients withdrew consent, the disease progressed, or unacceptable toxic effects occurred.
46099526|NCT04160156|Device|Long term sensor|Observational study including subjects using long term sensor according to local guidelines and patients preferences
46099527|NCT04000087|Other|AI-enabled ECG-based Screening Tool|A novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.
45683887|NCT01574157|Drug|Placebo|Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.
46099528|NCT00695682|Drug|intravitreal injection of infliximab|All subjects will receive 0.5 mg/ 0.05 mL of infliximab by intravitreal injection at their first treatment visit or the 6 weeks visit if eligible for a repeat injection.
46099529|NCT05260463|Device|Implantation|Fractures of the distal fibula (AO4F3) are treated with a trauma implant.
45464636|NCT04353050|Procedure|Non-invasive adhesive system (patch)|The already registered on the market adhesive skin patch will be applied and removed for several times on the pigmented skin (or mucosal) lesion just before the preplanned excisional biopsy after local anaesthesia have been already administered. Excisional biopsy and local anaesthesia are not the part of this study and will be carried out according to local practice
46014008|NCT02892825|Other|Music|headphones with music
46099530|NCT00657566|Other|duration of antibiotics|4 +/- 1 days of antibiotics
46099531|NCT00657566|Other|duration of antibiotics|active comparator antibiotics given until 2 days after resolution of fever, elevated white blood cell count, and gastrointestinal dysfunction.
46099532|NCT03998995|Device|Immersive Virtual Reality|"An Oculus Rift VR Headset and a set of Oculus Touch Controllers was used as interactivity device. Two scenarios of IVR rehabilitation game were offered to the patients: 1) Archery based on behind-the-neck overhead press, using a quiver on the user back to encourage bending their arm and firing the arrow to help with stretching exercises and 2) Climbing based on an overhead arm raise exercise.~Each child will took part in a single IVR trial during their rehabilitation care with the physiotherapist, supported by IP, the games expert/researcher. Timing of participation was approximately 15 minutes of trial with each scenario of game. A short interview was conducted with each child and their parent (together) after each trial, and a focus group was conducted with the clinical staff."
46099533|NCT00738790|Radiation|Short course of radiotherapy|5 x 5 Gy plus boost 4 Gy
46014009|NCT02892825|Other|No Music|headphones without music
46014010|NCT02273453|Drug|Songha® Night|
46014011|NCT02273453|Drug|Oxazepam|
46014012|NCT02273453|Drug|Placebo|
46014013|NCT01108510|Drug|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
46014014|NCT01108510|Drug|RTV|Ritonavir (RTV) 100 mg tablet administered orally once daily
46099534|NCT00738790|Radiation|Radiochemotherapy|28 x 1,8Gy plus boost 3 x 1,8 Gy with three 2-days cycles of chemotherapy during weeks 1, 3 and 5 of irradiation (the each cycle consisted of leukovorin 20 mg/m2 per day and 10-20 minutes later of 5-fluorouracil 400 mg/m2 per day, both administrated as rapid intravenous infusion)
45464637|NCT05575557|Procedure|Right heart catheterization|All groups were detected with SW catheter by the internal jugular vein before the procedure. After the measurement, the catheter was indwelled, and the pacemaker implantation procedure was started. After ventricular pacing for 5 minutes, the SW catheter measurement was performed again. After the measurement, the SW catheter was withdrawn.
45683888|NCT04276246|Device|dental implants and retentive implant components|retentive components (Group A Test), which are connected to the implants to retain the RPD
45683889|NCT04276246|Device|dental implants and supportive implant components|supportive components (Group B Control), which are connected to the implants to support the RPD
46014015|NCT01108510|Drug|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
46014016|NCT01108510|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
46014017|NCT01108510|Drug|COBI placebo|Placebo to match COBI administered orally once daily
46014018|NCT01108510|Drug|RTV placebo|Placebo to match RTV administered orally once daily
46014019|NCT04343781|Other|observation|observation of clinical symptoms related to COVID-19 disease
46014020|NCT02273258|Drug|SAR342434|Pharmaceutical form:solution Route of administration: subcutaneous
46014021|NCT02273258|Drug|Insulin Lispro|Pharmaceutical form:solution Route of administration: subcutaneous
46014022|NCT02273258|Drug|Insulin Lispro|Pharmaceutical form:solution Route of administration: subcutaneous
46014023|NCT02273414|Drug|BIIL 284 BS - rising dose|
46014024|NCT02273414|Drug|Placebo|
46014025|NCT01108237|Other|TruMatch™ Personalized Solutions|TruMatch™ Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation. TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon.
46014026|NCT01108237|Device|Total Knee Arthroplasty with Conventional Instrumentation.|Total Knee Arthroplasty (PFC Sigma System) implanted using conventional instruments, not TruMatch™ instrumentation.
45464638|NCT02051101|Other|Biopsy sample from Port Wine Stain Birthmark|Biopsy sample from Port Wine Stain Birthmark
45464639|NCT01220063|Radiation|Radiation|10 Gy for 4 times (total 40 Gy)
45464640|NCT01220063|Drug|Irinotecan|40 mg/m² : Day 1 and day 8
45464641|NCT03109366|Behavioral|Online patient-provider communication service|
45464642|NCT04834622|Behavioral|Melodies for Mums|Melodies for Mums (M4M) is an intervention that was developed and tested as part of a collaboration between the Royal College of Music, Imperial College London and University College London from 2015-2017. The programme involved weekly singing classes for mothers and their babies delivered in groups of 8-12 in Children's Centres for 10 weeks. A trained artist delivers 1-hour long singing sessions to mothers with postnatal depression (and their babies) for a period of 10-weeks. The sessions are aimed at the mothers, with songs ranging from sound baths to folk songs and songs created by the mothers themselves. Mothers randomised to the intervention will be prompted via text message, each week before the session, to attend these singing sessions.
45464643|NCT04834622|Behavioral|Control Community Sessions|Group mother-baby interventions in the community (i.e. baby play, baby reading sessions, baby massage, etc). A list of these activities will be collected from the activities on offer in the community. All the mothers randomised to the control group will be pointed towards these activities, prompted by text messages in line with the prompts received by the mothers in the intervention group. Mothers will be encouraged to attend these non-music based community activities once a week with their babies.
45464644|NCT01298713|Drug|Tamoxifen|20mg daily (1 cap) until unbearable toxicity or progression
45464645|NCT01298713|Drug|Everolimus|10mg daily (2 caps of 5mg) until unbearable toxicity or progression
45464646|NCT01223339|Drug|Ertugliflozin|Dose escalation of 1, 5, and 25 mg Ertugliflozin administered in the fasted state
45464647|NCT01223339|Drug|Placebo|Placebo tablets to Ertugliflozin administered in the fasted state
45464648|NCT01223339|Drug|Ertugliflozin|Ertugliflozin 25 mg tablets administered once daily in the fed state for 7 days
45683890|NCT05247892|Procedure|Ultrasound-guided S1 Radiofrequency stimulation|Pulsed radiofrequency stimulation of the S1 dorsal root ganglia under ultrasound-guidance
45683891|NCT05247892|Procedure|Fluoroscopic-guided S1 Radiofrequency stimulation|Pulsed radiofrequency stimulation of the S1 dorsal root ganglia under fluoroscopy-guidance
46014027|NCT02881411|Other|Self-soft tissue therapy|Manual therapy for the muscles in the upper or lower limbs.
46014028|NCT02881411|Other|Fibromyalgia coping skills programme|Exercise, education programme
46014029|NCT01588691|Device|Eon-mini IPG (implantable pulse generator)|programming parameters set at low frequency. Patients will receive this therapy dose for 3 weeks.
46014030|NCT01588691|Device|Eon-mini IPG (implantable pulse generator)|programming parameters set at high frequency. Patients will receive this therapy dose for 3 weeks.
46014031|NCT01588691|Device|Eon-mini IPG (implantable pulse generator)|programming parameters set at lowest settings to deliver minimal power. Patients will receive this therapy dose for 3 weeks.
46014032|NCT05018494|Other|experimental treatment|This group will receive the common treatment and will be discharged with complete manual on life style modifications comprising education, exercise and diet with telerehabilitation monitoring.
46014033|NCT05018494|Other|common treatment|This group will receive the common treatment and will be discharged with home exercise plan without telerehabilitation monitoring.
46014034|NCT05015686|Biological|Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd|live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
46014035|NCT05015686|Biological|Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd|live varicella-zoster virus in trehalose,human serum albumin,sodium glutamate,sucrose,glucose,carbamide,arginine and injection water per injection
45464649|NCT01223339|Drug|Placebo|Placebo tablets administered once daily in the fed state for 7 days
45464650|NCT03585478|Drug|Latiglutenase|Latiglutenase administered orally (daily)
45464651|NCT03585478|Other|Placebo|Placebo administered orally (daily)
45464652|NCT01298791|Behavioral|Sitting|Providers will sit during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain seated while communicating with the patient and caregiver.
45464653|NCT01298791|Behavioral|Standing|Providers will stand during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain standing while communicating with the patient and caregiver.
45464654|NCT01220141|Drug|activated recombinant human factor VII|Administration of room temperature stable NovoSeven® (activated recombinant human factor VII) in dosages prescribed by the treating physician according to the product labelling text approved in his country.
46014036|NCT05015686|Biological|Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd|live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
46014037|NCT05015686|Biological|Placebo|Sodium chloride and distilled water
46014038|NCT02881645|Behavioral|Best practices|Nurses in intensive care units will be trained to the best practices protocol for a period of two-month preceding the trial
46014039|NCT04327245|Other|Intervention ingest a 5000 mg of D-tagatose|"Woman with resistance insulin who ingest a 5000 mg of D-tagatose. D-tagatose is a sweetener of natural origin, low in calories (1.5 kcal / g) and with a sweetness power of 0.9.~About 20 to 25% of the ingested D-tagatose is absorbed and metabolized in the liver, the rest is fermented by the microbiota producing short chain fatty acids."
46099535|NCT03828773|Drug|Posaconazole|Posaconazole is a triazole with broad-spectrum activity, to include Candida species, Aspergillus species, and other fungal pathogens, including the Zygomycetes. Posaconazole is available as slow release tablets (300mg/day) and as intravenous (IV) formulation (300mg/day) and is licensed and approved in Switzerland for the prevention of IFI, including mold and yeast infections, in patients >18 years who are at high risk of developing these types of infection (patients with long-term neutropenia or HCT recipients). Furthermore, international guidelines recommend posaconazole for primary antifungal prophylaxis in high-risk patients, such as AML patients with prolonged neutropenia. Posaconazole is available in Switzerland under the name of Noxafil® in capsules of 100mg, suspension of 40mg/mL and intravenous formulation of 300mg/16.7 mL.
45464655|NCT01347879|Drug|Visonac PDT|cream application prior to illumination with red light
46099536|NCT03828773|Drug|Fluconazole|Fluconazole is an antifungal with activity against most Candida species. Fluconazole is licensed and approved in Switzerland for prophylaxis of IC in patients with neutropenia induced by chemotherapy or radiotherapy at a daily dose of 200 to 400 mg once daily. Fluconazole (200 mg or 400 mg once daily) is still currently used as primary antifungal prophylaxis (standard of care) in all 7 centers participating in this trial. Fluconazole is available in Switzerland under the name of Diflucan® in capsules of 50 mg, 150 mg and 200 mg and in powder for preparation of suspension (50 mg/5 ml and 200 mg/5 ml (forte)) or perfusion (2 mg/1 ml). Several generics of Diflucan® are authorized in Switzerland. Prescribing Diflucan® or any of its generics will remain at the discretion of and based on the standard operating procedures (SOP) at each institution.
45464656|NCT01347879|Drug|Vehicle cream with PDT|placebo/vehicle cream application prior to illumination with red light
45464657|NCT01217879|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
45464658|NCT01218035|Drug|zoledronic acid|The patients in the active-treatment group will receive a single 5 mg dose of zoledronic acid intravenously just prior to release from the hospital (about 5th day post-surgery) as an adjunct therapy. The control group will receive a placebo (saline) infusion. All infusions will be given 100 ml in volume and infused over a period of 15 minutes with a pre- and post-infusion flush with normal saline.
45464659|NCT03470584|Other|Diet Exposure|Vegetarian diet vs nonvegetarian diet
45464660|NCT04249310|Drug|Tiotropium/Olodaterol|Soft Mist Inhaler product
45464661|NCT04249310|Drug|Tiotropium|Soft Mist Inhaler product
45464662|NCT05665075|Drug|QN-023a|NK cell therapy
45464663|NCT05665075|Drug|Cyclophosphamid|Lympho-conditioning Agent
45464664|NCT05665075|Drug|Fludarabine|Lympho-conditioning Agent
45464665|NCT05665075|Drug|Cytarabine|Lympho-conditioning Agent
45464666|NCT05665075|Drug|VP-16|Lympho-conditioning Agent
45464667|NCT03714165|Diagnostic Test|Alpha defensin and 16SrRNA gene|Alpha defensin 16S rRNA gene CBC: Complete blood count CRP: C reactive protein ESR: Erythrocyte sedimentation rate Culture and antibiotic sensitivity of synovial fluid
45680073|NCT04187040|Procedure|Control intervention: 6-step hand hygiene technique|"6-step hand hygiene technique (according to the WHO Guidelines on Hand Hygiene in Health Care, First Global Patient Safety Challenge):~Rubbing hands palm to palm~Palm to palm with fingers interlaced~Right palm over left dorsum with interlaced fingers and vice versa~Back of fingers to opposing palms with fingers interlocked~Rotational rubbing of left thumb clasped in right palm and vice versa~Rotational rubbing backwards and forwards with clasped fingers of right hand in left palm and vice versa"
45837566|NCT04304274|Procedure|Paravertebral block-ropivacaine|Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)
45464668|NCT04294420|Behavioral|Patient education program|The education program provides information and guidance concerning aetiology, diagnostics and treatment of pain-predominant functional gastrointestinal disorders. The patient education program will be provided in a group setting and the children will participate along with one of their parents. The participants (n=20) will be divided into two groups consisting of ten child-parent pairs. Two lectures will be held, two weeks apart, two hours per lecture. Represented teachers are physician, psychologist and dietician.
45464669|NCT01123109|Procedure|3-D Endoanal Ultrasound|The subject will be placed in the supine position with their feet in the stirrups and a drape will be used, exposing only the anus and perineum in order to introduce the probe. In order to prevent and minimize any potential discomfort, the lubricated ultrasound probe will be gently inserted into the anal canal up to the anal verge, with minimal manipulation of the probe once inserted. The scan lasts approximately two minutes and the entire exam will take no more than five minutes.
45464670|NCT04117646|Other|Sinus and nasal quality of life survey questionnaire (SN-5)|Subjects respond to the translated questionnaire twice at 15 days apart.
46014040|NCT04327245|Other|Intervention ingest a 15,3 mg of stevia|"Woman with resistance insulin who ingest a 15,3 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)"
46014041|NCT01588769|Biological|ALECSAT cell based immunotherapy|I.V. injected Cell Based Medicinal Product, containing between 10 million and one billion autologous Cytotoxic T cells and Natural Killer cells.
46099537|NCT04164992|Device|EUSRA electrode needle connected to a radiofrequency generator (VIVA RF generator; STARmed, Seoul, S. Korea)|The operative needle (EUSRA-STARMED) is a novel monopolar 18 gauge radiofrequency ablation (RFA) electrode that is placed in the echoendoscope operative channel. It is 140 cm long with a sharp conical 1 cm tip for energy delivery. The needle is associated with an internal cooling system connected via a pump to an external cold saline solution source (0 °C) that prevents the charring of the tip and improves the ablation accuracy.
46014042|NCT00596310|Other|CT|Screening CT
46099538|NCT00728338|Dietary Supplement|Docosahexenoic acid (DHA)|The DHA group received 7.5 g/d DHA oil (DHA 3.0 g/d) which is produced in the microalga Crypthecodinium cohinii.
46099539|NCT00728338|Dietary Supplement|Olive oil|7.5 g olive oil/day
46014043|NCT04327401|Drug|Dexamethasone|Dexamethasone administration for 10 consecutive days after randomization.
46099540|NCT03827291|Drug|Exparel|Bilateral administration on each side of 30 ml aliquot containing 10 ml of liposomal bupivacaine (133 mg) and 20 ml of 0.25% bupivacaine (50 mg) in the fascial plane between the QL and psoas major muscles.
46099541|NCT03827291|Other|Thoracic epidural analgesia|Historical cohort that received thoracic epidural analgesia
46099542|NCT00530257|Drug|Placebo|Placebo (sugar pill)
46014044|NCT01340027|Drug|Mirabegron|oral
46099543|NCT00530257|Drug|OROS-methylphenidate|18 mg to 54 mg once a day for 1 week
45683892|NCT05245708|Drug|Intranasal oxytocin|Each subject will be assigned to intranasal administration of oxytocin (24 IU).
46014045|NCT01340027|Drug|Solifenacin succinate|oral
46014046|NCT01340027|Drug|Placebo|oral
46014047|NCT01327053|Drug|LDE225|LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
46099544|NCT00738868|Biological|cetuximab|
46099545|NCT00738868|Radiation|stereotactic body radiation therapy|
46099546|NCT04159766|Drug|NLY01|NLY01, a PEGylated form of the anti-diabetic peptide exenatide
46099547|NCT04159766|Drug|Placebo|normal saline
46099548|NCT00738946|Drug|Intermittent preventive treatment with AQ+ SP|Amodiaquine (10 mg/kg over 3 days) and Sulfadoxine Pyrimethamine (25 mg of sulfadoxine + 1.25 mg of pyrimethamine per kg in a single dose) or placebo administered over 3 rounds of one month interval
46099549|NCT00657644|Drug|Levitra (Vardenafil, BAY38-9456)|4 weeks treatment with 10 mg vardenafil followed by a flexible titration phase for 8 weeks
46099550|NCT00869778|Biological|εPA-44|subcutaneously injection of εPA-44 at week 0, 4, 8, 12, 20, 28.
46099551|NCT00869778|Other|Placebo|subcutaneously injection of Placebo at week 0, 4, 8, 12, 20, 28.
46014048|NCT00596349|Behavioral|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
46099552|NCT00739180|Other|Control|Standard care control (no exercise)
46099553|NCT00739180|Other|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
46099554|NCT00739180|Other|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
46099555|NCT04159610|Drug|WO3970|Application of cream to each axilla
46099556|NCT04159610|Drug|Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use|Qbrexza should be applied to the clean, dry, intact skin, of your underarm areas only
45464671|NCT04230928|Other|Very low carbohydrate diet|Participants will learn to follow a very low carbohydrate diet in modified versions of GLB modules 2,3,5 & 10. Participants will learn to track carbohydrate intake
45464672|NCT04230928|Other|Standard DPP-GLB diet|Participants will learn to follow a very low fat, calorie-restricted diet and track fat grams and caloric intake in standard GLB modules 2,3,5, & 10
46099557|NCT04162028|Drug|Nebutlized Ketamine|The PK-BAN package will be opened and weight -based dose of ketamine will be administered to the patient via BAN. The medication will be delivered with a minimum time of 5 min and maximum time of 15 min.
46099558|NCT00549172|Procedure|Operative (partial arthroscopy)|Partial arthroscopic resection of degenerative rupture of the medial meniscus
46099559|NCT00549172|Procedure|Conservative (diagnostic arthroscopy)|Diagnostic arthroscopy
46099560|NCT00656786|Drug|Menadione Topical Lotion|Menadione Lotion will be applied topically twice a day; beginning when the rash appears during EGFRi therapy.
46099561|NCT00656786|Drug|Menadione Topical Lotion|Menadione Lotion will be applied topically twice a day, starting 1 day before EGFRi therapy.
46099562|NCT05259761|Other|Unmanned ariel vehicle|Use of an Unmanned ariel vehicle for medical delivery (drugs and samples)
46099563|NCT01008397|Drug|AHIST NDC#58407-012-01|Oral tablet containing chlorpheniramine tannate 12mg.
46099564|NCT02618226|Device|Optic nerve ultrasound|Measurement of ONSD with concomitant invasive ICP measurement will be performed at enrollment and at least daily for a total of 7 days. Additional measurements of ONSD may be performed at any time following any decline in Glasgow Coma Scale (GCS) score by 2+ points during the 7 day period.
46099565|NCT00734812|Procedure|Laparoscopic supracervical hysterectomy|Patients will be randomized to LSH (retaining the cervix) and TLH (cervix removal)
46099566|NCT00734812|Procedure|Total laparoscopic hysterectomy|Patients will be randomized to either removal or retention of cervix
46099567|NCT01008631|Drug|Sodium thiosulfate|6g of Sodium Thiosulfate are applicated in a short infusion over a time of 5 min
46099568|NCT04852211|Procedure|Open or laparoscopic surgery|"Patients, with their consent, will be recruited to participate by investigators after considering the inclusion and exclusion criteria. Treatment allocation to the eligible patients will follow a randomization schedule. A total of 212 subjects will be randomized 1:1 to one of the two treatment arms:~Laparoscopic group: LMH~Open group: OMH"
46099569|NCT04131894|Biological|autogenous dentin graft|
46099570|NCT04131894|Biological|platelet rich fibrin (PRF)|
46099571|NCT00734890|Biological|bevacizumab|
45464673|NCT04230928|Behavioral|Standard DPP-GLB program modules|Participants will learn standard DPP-GLB modules for other lifestyle modifications for stress, physical activity, etc. in sessions 1,4,6-9, 11-22
45680074|NCT04182022|Behavioral|Contingency management: Contingent incentives|Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions and verified abstinence from alcohol.
46099572|NCT00734890|Drug|vandetanib|
46099573|NCT00734890|Other|laboratory biomarker analysis|
46099574|NCT00734890|Other|pharmacological study|
45680075|NCT04182022|Behavioral|Contingency management: Noncontingent incentives|Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions only with no contingency on alcohol use.
46099575|NCT04857073|Other|Glucose Monitoring|Glucose monitoring consists of finger stick fasting and 2 hours post prandial
46099576|NCT04131660|Device|AVAPS-AE mode during NIV|NIV will be setup in AVAPS-AE mode, with a Trilogy ventilation device (Respironics, Murrysville, PA). The range of positive expiratory pressure will be set between 4 and 14 cmH2O. The range of inspiratory pressure support will be set between 14 and 24 cmH2. The target tidal volume will be set to achieve 8 to 10 mL/kg of ideal body weight (Size (m) * Size (m) * 23).
46099577|NCT04131660|Device|S/T mode during NIV|"NIV will be setup in ST mode, with a Trilogy ventilation device (Respironics, Murrysville, PA).~The physician will decide the level of positive expiratory pressure and of pressure support."
46099578|NCT04817735|Procedure|TAVI|TAVI sizing with dedicated algorithm
46099579|NCT04933825|Biological|ET-02|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before ET-02 injection.
46099580|NCT05325190|Drug|Granisetron Transdermal Patch System|Granisetron transdermal patch 3.1mg was given 48 hours before the first day of chemotherapy, Dexamethasone 12mg was taken orally on the first day of chemotherapy and dexamethasone 8mg was taken orally on the second and third days of chemotherapy,3.1mg granisetron transdermal patch was replaced on the 5th day of chemotherapy. Granisetron transdermal patch was removed and discarded on the 12th day of chemotherapy.
46014049|NCT00596349|Behavioral|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
46014050|NCT00596349|Behavioral|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL- Cancer Survivor, FACT-Ovarian, SF-36, CES-D, IES, FACT-GOG-NTX, FSFI, Cognition Testing, Perception of disease chronicity/acuity, Report of surveillance type, frequency, utility, Health behaviors, Self-report of co-morbidities, Self-report of potential unmet needs, Background information form, List of current medications,Patient-defined QoL domains
45680076|NCT04170660|Diagnostic Test|Diagnostic test|During a vascular check-up usually prescribed, an additional blood sample is taken to allow the determination of the sFlt1/PlGf ratio.
46014051|NCT04342767|Device|EZ Debride®|EZ Debride ® is intended for the mechanical debridement of topical wounds including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, surgical wounds (donor sites/grafts, post Mohs' surgery, post-laser surgery, podiatric, wound dehiscence) trauma wounds (abrasions, lacerations, second-degree burns and skin tears), draining wounds and tunnelled /undermined wounds.
46014052|NCT01588808|Behavioral|Immobilization|Immobilization with protein (elderlY), immobilization without protein (elderly and young)
46014053|NCT01107925|Drug|prasugrel|Administered orally, daily for 12 days
46014054|NCT01107925|Drug|clopidogrel|Administered orally, daily for 12 days
46014055|NCT04310293|Other|Femara,Grotwth hormone,HMG|NOVEL THERAPY
46099581|NCT02624310|Drug|Droxidopa (L-DOPS)|Patients will be given their initial 100 mg of L-DOPS (visit 2a). The dose of L-DOPS will be increased in escalation in the following visits. Each day the dose will be increased 100 mg. The escalating doses of L-DOPS will be 200 mg (visit 2b), 300 mg (visit 2c), 400 mg (visit 2d), 500 mg (visit 2e) and 600 mg (visit 2f). Following this titration step, L-DOPS will be withdrawn from the subjects for a minimum of two weeks, when the subject will return for visit 3.Visit 3a,b,c,d,e,f: Carbidopa open-label dose titration. This titration step will be similar than L-DOPS titration. Carbidopa starting dose will be 100 mg (visit 3a) and will be increased 100 mg each visit up to a maximum of 600 mg (visit 3f). Following carbidopa titration step, patients will be withdrawn from the drug for minimum of two weeks, then the subject will return for the next titration step (visit 4).
46099582|NCT02624310|Drug|Placebo|
46099583|NCT04800185|Drug|Crisaborole 2% Top Oint|To analyze the skin microbiome of patients with atopic dermatitis before, during, and after treatment with crisaborole 2% ointment
45680077|NCT04162678|Procedure|Biospecimen Collection|Undergo collection of blood via HD-SCA fluid biopsy
45680078|NCT04162678|Other|Laboratory Biomarker Analysis|Correlative studies
45837567|NCT04304274|Procedure|Paravertebral block-saline|Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% saline infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)
45464674|NCT03828955|Dietary Supplement|Soybean peptides|Subjects receive two bags soybean peptides per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), body weight, body fat, waistline, hipline and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every four weeks.
45464675|NCT03828955|Dietary Supplement|Placebo|Subjects receive two bags of starch placebo of similar appearance per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), body weight, body fat, waistline, hipline, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.
45464676|NCT03442101|Drug|Patients with psychosis will be treated with known antipsychotic medication|Subjects with first episode psychosis will be treated with risperidone, the most frequently used antipsychotic drug (APD) for 32 weeks. The study will follow a rigorous longitudinal design to capture treatment response whereby those without an adequate response after 16 weeks of treatment will be switched to aripiprazole, another APD for 16 weeks. All patients will be scanned four times: at baseline and after 6, 16, and 32 weeks of treatment.
45680079|NCT04162678|Procedure|Liquid Biopsy|Undergo collection of blood via HD-SCA fluid biopsy
46014056|NCT01339559|Drug|Brivaracetam|"Tablet, Flexible dosing up to 200 mg/day, twice daily.~The study will continue until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures or until the Sponsor decides to close the study, or until the investigational product development is stopped by the Sponsor."
46014057|NCT00596544|Behavioral|questionnaires|will be offered referral to the Sexual Health Clinic (SHC) at MSKCC for evaluation and possible treatment. The effectiveness and compliance of the intervention offered at the SHC will be assessed at approximately 3, 6 and 12 months using the FSFI, SAQ, CES-D, MSC and IES. At each evaluation they will complete a Health Surveillance Form (HSF). They will have completed the study at 12 months after entering the study or at the time they have evidence of recurrent disease requiring treatment
46014058|NCT00596544|Behavioral|questionnaires|Those women who have a FSFI score > 26 will be reassessed at approximately 3, 6 and 12 months. They will complete the FSFI, SAQ, CES-D, IES, MSC and HSF at each assessment. They will be followed out until 12 months after entering the study or until they have evidence of recurrent disease.
45680080|NCT04162678|Other|Medical Chart Review|Review of medical chart
45680081|NCT04161781|Drug|18F-BMS-986229 Injection|Single injection prior to scan
45837568|NCT04304274|Drug|patient controlled analgesia with morphine|Morphine was given as intravenous patient-controlled analgesia bolus: 1-2mg, lock time: 5min, 1h limitation: 8mg
46014059|NCT01588847|Procedure|Spinal anesthesia with Bupivacaine hyperbar 0.5 %|Spinal anesthesia with Bupivacaine hyperbar 0.5 %
46014060|NCT01588847|Procedure|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane
46014061|NCT04339530|Other|Normal weight and overweight adults|Association between vitamin D levels and insulin resistance
46099584|NCT04800185|Genetic|Skin Microbiome Swabs|At the baseline visit the investigator will identify sites for swabbing the skin including one affected distinct crisaborole-treated AD lesion, and one untreated AD lesion. The lesions will both be sampled at baseline, 14 days into treatment, 28 days into treatment, 3 months into treatment, and 4 weeks after treatment completion. Photographs of each lesion will be taken for reference. Skin swabs will be obtained in a sterile fashion using a BD Culture SwabsTM EZ Collection and Transport System (or equivalent) and soaked with sterilized 0.15 M NaCl and 0.1% Tween-20. The samples will be frozen at -80 C, kept at this temperature, and stored until analysis may be completed.
46099585|NCT05192317|Device|Sollievo Fisiolax|Class IIb Medical Device
46099586|NCT05192317|Other|Sollievo Fisiolax Placebo|Placebo
46014062|NCT00107900|Drug|DU-176b|
46099587|NCT00735046|Behavioral|Cognitive behavioral therapy for early Alzheimer's disease|12 weekly individual sessions, total duration 3 months, regular involvement of patient's proxy ever second session. Intervention is manualized but is flexible with regard to individual resources and needs.
46099588|NCT00735046|Other|Control|Patients and proxies who are assigned to treatment as usual
46099589|NCT04135872|Other|strengthened nuitritional treatment|improving nutritional status by nasal feeding for dysphagia or iv. albumin when serum albumin level lower than 35g/L
46099590|NCT00612521|Drug|Adenosine|For lesions in the left coronary system the patient will receive either 120 micrograms of adenosine in 20 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis. For lesions in the right coronary system the patient will receive either 60 micrograms of adenosine in 10 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis.
45464677|NCT01123187|Procedure|islet transplantation|Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
45464678|NCT05130866|Drug|REC-2282|Participants will receive REC-2282 3 times per week orally for 3 weeks followed by 1 week off for a 4-week cycle.
46014063|NCT00596583|Drug|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
46014064|NCT00596583|Drug|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
46014065|NCT01339052|Drug|BKM120|
45464679|NCT05130866|Drug|Placebo|Participants will receive placebo orally 3 times per week for 3 weeks followed by 1 week off for a 4-week cycle.
46014066|NCT01339052|Procedure|Surgery|Surgery
46014067|NCT04327323|Device|CCM device implantation|CCM implantation involves the introduction of two active fixation stimulation leads, fixed on the interventricular septum, and connected to the CCM generator (Optimizer Smart IV, Impulse Dynamic, and any subsequent versions of the same device) inserted in the subcutaneous or submuscular pocket. The implantation is ususally performed using vascular access via right or left cephalic or subclavian vein. The CCM signal consists of 2-3 biphasic pulses lasting 10 msec (total duration of about 20 ms) with an amplitude between 4.0 and 7.5 V, delivered during the absolute refractory period of the ventricle, at a distance of 40 msec from ventricular sensing. The CCM device is compatible with other pacing and defibrillation devices already implanted in the patient; at the time of the implantation, the devices are checked in order to confirm the absence of interference between the devices. The patient is instructed to charge the device battery weekly.
46014068|NCT04338360|Biological|COVID-19 convalescent plasma|COVID-19 convalescent plasma
46099591|NCT00735124|Drug|Gabapentin|1200 mg single dose gabapentin
46099592|NCT00735124|Other|placebo|Injection of placebo/sham
46099593|NCT04131348|Procedure|botulinum toxin type A|From to December 2016 to December 2018, a single-center prospective comparative study was performed in 80 patients with LMIH at our tertiary center.
46099594|NCT00698100|Biological|human tyrosinase|Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
46099595|NCT00698100|Biological|mouse tyrosinase|Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
45464680|NCT04201444|Diagnostic Test|Patient group|Patients with Cushing Disease (CD) receiving a medical treatment: n = 30 Plasmatic cortisol UFC Urine biocollection Salive biocollection
45464681|NCT04201444|Diagnostic Test|Remission control group|Patients in remission of CD and having recovered a normal pituitary function for at least 12 months following pituitary surgery (normal UFC associated to: cortisol suppression following dexamethasone suppression test, or normal LNSC, or midnight serum cortisol < 200 nmol/L) n = 15 Plasmatic cortisol UFC Urine biocollection Salive biocollection Haircortisol
45464682|NCT04201444|Diagnostic Test|Bilateral surrenalectomy control group|Patients with previous CD, treated with bilateral adrenalectomy and receiving weight adjusted doses of hydrocortisone for at least 6 months. Last daily dose of Hydrocortisone should be administered no later than 5 pm. n = 15 Plasmatic cortisol UFC Urine biocollection Salive biocollection Haircortisol
45464683|NCT05664451|Behavioral|UI-Assist|"To support primary care in implementing guideline-based care, it is helpful to distill interventions to their key components, such as the five major intervention steps for tobacco use and dependence (the 5 A's). The 5 A's (Ask, Advise, Assess, Assist, Arrange) has been shown to help primary care providers implement clinical practice guidelines with minimal additional burden. The 5 A's can be similarly simplified for urinary incontinence (UI) screening and treatment to Ask (screen for UI); Advise (inform that effective nonsurgical treatments exist); and Assist (help patient get treatment with pharmacotherapy, referral to community classes, physiotherapy or urology / urogynecology)."
45464684|NCT05664451|Other|Partnership Building|In addition to the strategies described above, those practices allocated to streamlined practice facilitation and partnership building will have facilitation and configurable solutions that engage community resources and enable coalition building. In addition to a practice facilitator, a partnership facilitator from the Wisconsin Institute for Healthy Aging (WIHA) will identify existing local community resources with which the practice may choose to partner. After initiating academic detailing, these practices will have further access to Drs. Brown and Neuner for ongoing consultation. An online learning community will also be created where information can be shared and exchanged throughout the duration of the project and beyond the maintenance phase.
46014069|NCT00107315|Biological|bevacizumab|
46099596|NCT04246541|Drug|Ketorolac|Patients will receive IV ketorolac during surgery followed by 3 days of oral ketorolac (10 mg every 6 hours) for pain control. Patients will also be given oxycodone-acetaminophen (5mg-325mg) PRN for pain not controlled with ketorolac.
46099597|NCT04246541|Drug|Oxycodone-Acetaminophen|Patients will be discharged with oxycodone-acetaminophen (5mg-325mg) PRN for pain control after surgery.
46099598|NCT02618304|Drug|Treatment of Meibomian gland dysfunction|artificial tears, 3% Diquafosol Tetrasodium eye drops, steroid eye drops, squeezing of meibomian glands, cleansing of eyelids.
46099599|NCT04778423|Other|Avatar Therapy|In the first session (assessment), participants will create a computerised representation of the eating disorder voice (avatar) on a computer. They will be able to manipulate the facial and voice characteristics of the avatar and will be asked to provide examples of the critical eating disorder comments most often spoken by the avatar. In the following sessions (6-8 therapy sessions), participants will interact with the avatar displayed on the computer screen for 5-10 minutes.The main goal during the interaction with the avatar is for participants to stand up to the critical comments made by the avatar and build a sense of power, control and self-awareness in the context of the eating disorder voice. The sessions will be conducted remotely, using a personal laptop or computer. This will provide patients with the opportunity to practise answering back to the eating disorder voice during a meal, a time at which the eating disorder voice is loudest.
46099600|NCT05153395|Other|Carbon dioxide breathing|Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure.
46099601|NCT05153395|Other|Neurovascular Coupling|Participants will be asked to repeatedly open and close their eyes. With eyes open, participants will focus on a visual image. This will be done before and after intra-nasal insulin exposure.
45464685|NCT03932825|Drug|Nitrous Oxide|An 1-hour session of inhaled nitrous oxide at concentrations of 50%.
45464686|NCT03932825|Drug|Placebo|An 1-hour session of mixed oxygen-air gas(inspired oxygen concentration ~50%)
45680082|NCT04161781|Drug|IV 18F-BMS-986229|370 MBq administered intravenously prior to scan
45680083|NCT04161781|Diagnostic Test|PET/CT Scan|Whole-body PET/CT (80 mA)
45683893|NCT05245708|Drug|intranasal placebo|Each subject will be assigned to intranasal placebo.
46014070|NCT00107315|Drug|capecitabine|
46014071|NCT01335971|Drug|Sulforaphane 25|25 micromoles (4.4 mg) sulforaphane daily by mouth
46014072|NCT01335971|Dietary Supplement|Sulforaphane 150|150 micromoles (26.6 mg) sulforaphane daily by mouth
46014073|NCT01335971|Other|Placebo|Microcrystalline cellulose once daily by mouth
46014074|NCT00596661|Device|TriMaxx Coronary Stent placement|Angioplasty with coronary artery stent placement
46099602|NCT05153395|Drug|Human insulin|Participants will be administered human insulin (160 IU) as a bolus using an intra-nasal device.
46014075|NCT04337892|Device|Standard of Care4|The current standard of care for surgical planning for the participating investigator surgeon is to use Zeiss Veracity Surgical, so this same method will be used for the surgery actually performed on participating patients.
46014076|NCT00107276|Drug|capecitabine|
46014077|NCT00107276|Drug|cyclophosphamide|
46099603|NCT02618694|Procedure|Posterior retroperitoneoscopic adrenalectomy|Patient is in prone, half Jack-knife position, and hips and knees are fixed in 75-90°. A 15 mm trocar incision just below the tip 12th rib. Prepare a small retroperitoneal space with finger and insert two 5 mm trocars about 5 cm lateral and medial to the first trocar with digital guidance. Medial trocar will be inserted upward. Lateral one will be lateral and below the 11th rib. Dissect inferior to diaphragm and retraction of the kidney downward. Mobilize the adrenal gland. At right side, start medial and caudally. Control the adrenl arteries crossing the IVC posteriorly. Prepare adrenal vein posterolaterally. Control between two clips. Continue gland dissection laterally and cranially. At left side, prepare the adrenal vein between the gland and diaphragm medial to the upper pole of the kidney. Dissect medial, lateral and cranially. Retrieve the mass through middle incision. Insert a drain and close skin incisions (Walz M. K., 2005).
46099604|NCT02618694|Procedure|Transperitoneal laparoscopic adrenalectomy|On right side, patient is on supine position. Put a trocar at umbilicus for the camera. Put 4 trocars 1-2 cm subcostal from subxiphoid (10-12 mm) for liver retractor, to far lateral (5 mm) and two 10 mm trocars inbetween. Retract liver, incise the retroperitoneum, and identify right adrenal gland between upper pole of the kidney and IVC. Dissect gland from the kidney than laterally and posteriorly from the diaphragm. Expose, apply clips to, and divide the adrenal vein. On left side, patient is on lateral decubitus. Put a trocar at umbilicus for the camera, 4 trocars 1-2 cm subcostal from the midline to the far most lateral possible (the last is 5 mm the rest are 10 mm). Mobilize colon flexure and expose the kidney. Separate kidney from the pancreas and spleen. Mobilize the tumor, starting by posterior surface, superior border then from the renal surface. Divide the adrenal vein. Retrieve the mass (Suzuki, Tsuru, & Ihara, 2012; Linos, 2005; George & Kavoussi, 2010).
45464687|NCT01298869|Biological|HPV-6/11/16/18 vaccine|HPV-6/11/16/18 vaccination 3 doses at day 1, month 2, and month 6
46099605|NCT03999073|Other|Ultrasound measurement|Ultrasound measurement
45464688|NCT03471910|Drug|Diosmin|Diosmin 600mg tablet, once daily
45464689|NCT03471910|Drug|Diosmin / Hesperidin|Diosmin 900 mg / Hesperidin 100mg tablet, once daily
45464690|NCT03932981|Drug|Temozolomide|Temozolomide at a monthly standard dose of 150-200 mg/m2/day at day 1 to day 5 for a duration of treatment of 12 months
45464691|NCT03470506|Other|Stool Samples|Stool samples will be collected at baseline and 3 months to assess differences in microbiome composition between groups
45464692|NCT01220219|Drug|Pregabalin controlled release, 82.5 mg|Two tablets of 82.5 mg controlled release (administered concurrently) once daily for four days.
45464693|NCT01220219|Drug|Pregabalin controlled release, 165 mg|165 mg controlled release tablet administered once daily for four days.
45464694|NCT01220219|Drug|Pregabalin immediate release, 75mg|75 mg immediate release capsule administered every 12 hours for four days
45464695|NCT03441789|Drug|Enstilar|Enstilar foam applied to affected areas daily
45464696|NCT03441789|Drug|Vehicle|vehicle foam applied to affected areas once daily
45464697|NCT03441789|Drug|Otezla|Otezla 30mg
45464698|NCT03359005|Drug|Vincristine|vincristine 1.5mg/m2 iv D1,D8
45464699|NCT03359005|Drug|Temozolomide|Temozolomide 100mg/m2/d iv on days 1-5.
45599132|NCT02343315|Device|TENS|"Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.~Equipment- TENS (CEFAR Basic TENS Machine)~Electrodes- Four channel electrode to cover the site of pain~Site of electrode placement- will be decided by the physical therapist to best suit or cover the area of pain based on complaints of patient based on the body chart.~Intensity- the intensity will be increased progressively until maximum tolerable intensity is reached. This stimulation may cause visible muscle contraction. This type of current is also referred to as Motor-level TENS, which is effective for chronic pain. The intensity will not be increased beyond 25 milli Amperes if no sensation is perceived by the patient.~Frequency- 5 Hertz~Duration- 30 minutes"
46014078|NCT04326777|Procedure|Ballon pulmonary angioplasty|Percutaneous vascular access for BPA is via the femoral vein using Seldinger technique. A 5Fr sheath is inserted into the vein, through which a 6Fr long introducer sheath is advanced into the pulmonary artery. Subsequently, a 6Fr guiding catheter is advanced into the pulmonary artery being treated. Generally, selective pulmonary angiography should be performed to evaluate lesion feature before BPA. Then a 0.014-inch guidewire is used to cross the lesion, a balloon catheter of an appropriate diameter is selected to dilate the lesion.
46099606|NCT00612911|Other|Cell therapy|bone marrow mononuclear cell
45599154|NCT03514147|Other|Control|"Profile of participants: an anamnesis file was used to collect personal data;~To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;"
46099607|NCT04902859|Drug|Clonidine Oral Liquid Product|Clonidine prepared from pharmacy with 20 mcg/ml concentration.
46099608|NCT04902859|Drug|Sterile water|Sterile water used as placebo
46099609|NCT04215809|Drug|APG2575|APG2575 investigation drug in ramp up dosing
45599155|NCT02342925|Other|Omnipaque 300|647 mg/mL of iohexol, equivalent to 300 mg/mL of iodine, used for assessment of glomerular function and other measure of renal function
45837569|NCT04290780|Other|nosocomial infection/hospital acquired infection|"When there is suspicion of a community-acquired case (admission of an infected patient) or nosocomial case (infection of a patient already hospitalized), a case report form including demographic data, medical history, and clinical and biological data on the infectious episode will be completed for each case, either patient, caregivers or health care professionals, presenting clinical signs or symptoms compatible with SARS-CoV-2 infection. The suspected cases will undergo nasopharyngeal swab collection and detection of SARS-CoV-2 in nasopharyngeal swabs will be done by real-time RT-PCR assay.~Hygiene measures applied by the service will be collected using a questionnaire as well as recommendations of the learned societies within the country regarding the risk of infection by coronavirus. In addition, data characterizing the service and hospital will also be collected (specialty, number of beds, number of nurses, doctors, etc.)."
45837570|NCT04253496|Other|Tumor samples and MRI|We will use DNA and RNA tumor samples. We will not use germline or blood DNA. These data will be combined with their magnetic resonance imaging (MRI) at different times: at diagnosis, at the end of treatment and at the progression of the disease.
46014079|NCT01335698|Drug|Atazanavir Sulphate|
46014080|NCT01335698|Drug|Ritonavir|
46014081|NCT00596700|Device|Given® Diagnostic System including PillCamTM SB Capsules|"Device for detection of pathologies as a tool in the diagnosis of gastrointestinal disorders.~An ingestible,disposable video camera that transmits high quality images of the small intestinal mucosa"
46099610|NCT05227313|Dietary Supplement|Eefooton oral solution|Eefooton is extracted from Rhodiola, Huang Qi, American Ginseng, Dang Ginseng, and Ligustrum lucidum by biotechnology. It has immunomodulatory effects, anti-oxidation and anti-inflammatory effects, and regulates calcium metabolism.
46099611|NCT05227313|Dietary Supplement|Placebo oral solution|oral solution matched placebo
46099612|NCT05128513|Device|DELP|The blood was pumped into the PCS2 plasma separator through one side of the forearm vein. The plasma was separated by pump and then sent to the DELP system (Shanghai Jiangxia Blood Technology Co.). After purification, the plasma was returned to the patient via another forearm vein. The total treatment plasma volume was 800-1,000 mL; the anticoagulant 4% sodium citrate dehydrate solution with a ratio of 1:16 to plasma, was dropped before pumping. To prevent hypocalcemia, 500 mg CaCl2 diluted with 250 mL physiological saline was infused at a rate of 150 mL/h, in the first cycle of the returning blood transfusion.
46099613|NCT05127967|Other|Skin biopsy|A skin biopsy involves taking a piece of skin to obtain cells (fibroblasts). Skin biopsy is a minimally invasive examination and a technically simple procedure performed with a 3mm diameter punch, or with a scalpel under local anesthesia (Lidocaine patch). The procedure can be done in a consultation office with strict asepsis. It lasts 15 minutes in total + the time to reach between putting on the lidocaine patch and performing the procedure. This biopsy will usually be done on the inside of the arm. In the majority of cases, it is not helpful to close the scar with stitches.
46099614|NCT05217095|Device|Convergence Dialyzer|The Convergence dialyzer with design changes made to FX Coral 600 dialyzer will be tested together with Sidecar. In the dialyzer is integrated centrifugal-flow blood pump.The centrifugal-flow blood pump replaces the peristaltic roller pump of the extracorporeal circuit which pumps blood from patient to the dialyzer and from dialyzer to the patient. The centrifugal-flow blood pump is designed to transport blood from the patient to the dialyzer, and after purification, return the blood to patient.
46099615|NCT00711958|Drug|HX575, solution for injection (s.c.)|1000, 2000, 4000, 8000 and 10.000 IU of rh erythropoiethin
46099616|NCT00711958|Drug|ERYPO®, Janssen-Cilag, solution for injection (s.c.)|1000, 2000, 4000, 8000 and 10.000 IU of epoetin alfa
46099617|NCT04180943|Drug|interscalene nerve block|intra and post-operative analgesia
46099618|NCT03769415|Device|Intrinsic Subtyping of Primary Breast Cancer|Primary breast tissue will be sent for Nanostring PAM50 Testing to determine intrinsic subtype
45464700|NCT01223651|Procedure|two step hyperinsulinaemic glucose clamp study.|Study participants will have their blood glucose stabilized between 5 - 6 mmol/L by the delivering of a controlled rate insulin/glucose infusion. Participants will have their blood glucose level reduced by conducting a controlled two step hyperinsulinaemic glucose clamp. The clamp procedure will take a total of 120 minutes and will reduce the blood glucose level to below 3 mmol/L. During this time blood tests will be obtained for analysis, physical observations recorded and cognitive function tests performed at regular intervals. Participants will have been fitted at least 12 hours prior to the intervention with 2 real time continuous glucose monitoring systems which will remain in place for the duration of the clamp procedure, however participants will be blinded to their glucose readings.
45464701|NCT04321174|Drug|Lopinavir/ritonavir|The intervention is a 14-day course of LPV/r 400/100 mg orally twice daily, or equivalent weight-based dosing, to be initiated as soon as possible (within 1-7 days) after the last exposure.
45464702|NCT03711513|Behavioral|Cognitive behavioral therapy|All conditions start with a psycho-education session (PE). Subsequently, participants in condition A follow four exposure sessions (EX). Participants in condition B follow two cognitive restructuring (CR) followed by two exposure sessions. Participants in condition C follow two relaxation exercises sessions (RE) followed by two exposure sessions. All sessions will take place at their school in a group of five to eight adolescents (week 9,10,11,12,13,14). The sessions will be provided by a psychologist who receives training and supervision by a certified CBT therapist. The psychologist is assisted by a master student in psychology.
45464703|NCT05281783|Device|percutaneous radiofrequency ablation (RFA)|We aim to evaluate the percutaneous radiofrequency ablation (RFA) efficacy as monotherapy in intermediate versus early-stage hepatocellular carcinoma (HCC).
45464704|NCT01123265|Drug|Methotrexate|Subjects will start Methotrexate which will be escalated from 7.5 mg weekly to 15 mg/weekly over a 3 week period.
45464705|NCT01123265|Drug|Anti-TNF|Anti-TNF to be administered per standard of care within the practice.
45464706|NCT04231162|Dietary Supplement|Active product|Bifidobacterium lactis HN019 (probiotic powder). One capsule to consume orally with still water (not sparkling) at room temperature once a day at least 15 minutes before breakfast time.
45464707|NCT04231162|Dietary Supplement|Control product|Placebo. One capsule to consume orally with still water (not sparkling) at room temperature once a day at least 15 minutes before breakfast time.
45464708|NCT01204723|Drug|Placebo Aprepitant|Placebo Aprepitant 0 mg once daily for 5 days
45464709|NCT01204723|Drug|Active Aprepitant|Active Aprepitant 160 mg once daily for 5 days
45837571|NCT01285362|Drug|Fish Oil Supplementation|Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of DHA.
46014082|NCT04327362|Device|Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 min. of either sham or active tDCS prior to PE sessions using a 1 x 1 tDCS device with a ring electrode configuration that allows relatively excitatory and focal stimulation of the dorsomedial prefrontal cortex (dmPFC). Electrodes consist of sponges in a silicone rubber holder with a metal mesh conductor saturated with normal saline. A center anode (2.5 cm diameter) and a ring-shaped cathode (diameter inner/outer: 9.2/11.50 cm) will be centered over the dmPFC, with the anode placed the midline at 15% of the Fz to FPz distance. Active stimulation will commence with a 15 sec. ramping up period to target current (1.5 mA), followed by constant current for 20 min., and a 15 sec. ramping down period. For all sham sessions, stimulation will be immediately ramped down over a 15 sec. period following the initial ramping up period, and subsequently ramped up over 15 sec. prior to the final ramping down period.
46014083|NCT04327362|Behavioral|Prolonged Exposure Therapy|All participants will receive 10 weekly sessions of standard Prolonged Exposure Therapy, or PE, which is a gold standard trauma-focused cognitive behavioral treatment for PTSD. The first sessions (1-2) predominately consist of psychoeducation about PTSD and the rationale for treatment, whereas subsequent sessions (3-10) consist of imaginal and in vivo exposure, involving repeated, prolonged, systematic, and deliberate practice approaching trauma reminders, as well as cognitive and emotional processing reactions to an index trauma memory.
46014084|NCT02892474|Procedure|Hybrid Coronary Revascularization (HCR)|Hybrid coronary revascularization (HCR) is a combination of surgery and catheter procedures to open up clogged heart arteries. HCR is the intentional combination of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). The HCR strategy combines grafting of the left anterior descending artery (LAD) coronary artery using the left internal mammary artery (LIMA) with PCI of non-LAD coronary stenoses. Drug-eluting stents are substituted for saphenous vein grafts (SVG) for non-LAD coronary targets, and the surgical LIMA to LAD bypass is performed, ideally through a minimally invasive, limited access, sternal-sparing approach.
45464710|NCT03717285|Procedure|Insert the UAS under direct vision|Patients in this group，we use rigid ureteroscopy to insert the UAS under direct vision.
45464711|NCT03717285|Procedure|Insert the UAS under non direct vision|Patients in this group，we insert the UAS by the experience of the surgeon and under non direct vision .
45837572|NCT01285362|Drug|Placebo Supplementation|Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
45837573|NCT00612924|Device|Anaconda Stent Graft System|Endovascular device
45464712|NCT01127789|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation
45464713|NCT03130816|Biological|allogeneic cord blood transplantation|UCB with total nucleated cell count ≤ 7x108/kg will be used for this clinical trial. Suitable UCB (i.e., containing total nucleated cell count ≥2x107/kg with three or less mismatch among HLA-A, -B, and -DR) will be selected. This criterion was selected upon the rationale that even though minimal HLA mismatch is preferred, prior studies indicate significant effects of UCB therapy for patients with 3 HLA mismatches.
45464714|NCT01204801|Device|Focused Microwave Thermotherapy|Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs + Thermotherapy. Thermotherapy at first 3 chemotherapy treatments for Anthracycline chemotherapy nominally every 21±7 days plus Standard of Care chemotherapy. (A targeted tumor temperature of 44ºC (plus or minus 1.5ºC) and a targeted thermal dose of 80 equivalent treatment minutes (plus or minus 20 treatment minutes)). In the event that the targeted minimum cumulative thermal dose of 180 equivalent treatment minutes is not achieved in the first three treatments, an optional fourth thermotherapy treatment may be administered in combination with the fourth course of Anthracycline and standard of care chemotherapy. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
45464715|NCT01204801|Drug|Chemotherapy (control)|Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs. Anthracycline chemotherapy nominally every 21±7 days. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
45464716|NCT04194814|Drug|crisaborole (2%) ointment|twice daily application on one forearm for 4 weeks (randomised site allocation)
45464717|NCT04194814|Drug|betamethasone valerate 0.1% cream|twice daily application on one forearm for 4 weeks (randomised site allocation)
45464718|NCT03832621|Drug|Temozolomide|temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks
45464719|NCT03832621|Drug|Nivolumab|nivolumab 480 mg i.v. every 4 weeks
46014085|NCT02892474|Procedure|Coronary Artery Bypass Grafting (CABG)|Coronary artery bypass grafting (CABG) is a surgery to create a new path for blood flow to the heart. A healthy section of vein or artery from elsewhere in the patient's body will be attached to the coronary artery just above and below the area of concern, to create a way for blood to bypass the blocked part of the coronary artery.
46014086|NCT00107198|Procedure|Conventional Surgery|Undergo surgery
46014087|NCT00107198|Drug|Cyclophosphamide|Given IV
46014088|NCT00107198|Drug|Doxorubicin Hydrochloride|Given IV
46014089|NCT00107198|Drug|Prednisone|Given IV or PO
46014090|NCT00107198|Radiation|Radiation Therapy|Undergo IFRT
46014091|NCT00107198|Drug|Vincristine Sulfate|Given IV
46014092|NCT04336839|Procedure|Portal vein resection / reconstruction|Portal vein resection and reconstruction, with or without concommitant arterial resection
46014093|NCT00107120|Drug|Escitalopram|Escitalopram 10mg per day for three weeks, 10-20mg per day for up to the remaining 5 weeks
46014094|NCT00107120|Drug|Placebo|Placebo once daily for up to 8 weeks
46014095|NCT00596778|Other|chest physiotherapy|The protocol consisted of breathing exercises during 30 minutes and included: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion.
46014096|NCT00596856|Behavioral|Development and dissemination of priority oral health risk assessment and referral guidelines - PORRT|The RCT will compare passive distribution of guidelines by mail to an in-office intervention consisting of guideline distribution combined with educational outreach providing training in guideline use and patient mediated information provided by the risk and referral assessment tool (PORRT). The three-arm trial will consist of 25 medical practices that have never participated in IMB and 25 practices that are currently participating, both of which will receive the guidelines through the mail, and 25 practices currently participating in IMB that will receive the more intense in-office training intervention.
46014097|NCT01335464|Drug|placebo|placebo matching BIBF1120, BID
46014098|NCT01335464|Drug|BIBF 1120|BIBF1120 BID (twice daily)
45464720|NCT03832621|Drug|Ipilimumab|low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks
45599156|NCT02342925|Drug|RG1662|Oral administration twice daily
45599157|NCT02342925|Drug|metformin|Single 850 mg dose of metformin
45599158|NCT03518047|Drug|risankizumab|rizankizumab subcutaneous (SC) infusion
45464721|NCT01220375|Drug|Vinorelbine, G-CSF, & Plerixafor|Patients 1-10 receive 35 mg/m2 vinorelbine i.v. on day 1, G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
45464722|NCT01220375|Drug|Vinorelbine and Plerixafor|Patients 11-20 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No G-CSF will be administered. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
45599159|NCT03518047|Drug|placebo for rizankizumab|placebo for rizankizumab subcutaneous (SC) infusion
46014099|NCT00622947|Procedure|right temporal low frequency (1 hz) rTMS|Right temporal low frequency (1 hz) rTMS.
46014100|NCT00622947|Procedure|Sham-rTMS|The coil is angled 90 degrees away from the scalp
46014101|NCT04333056|Other|Biometric measurement agreement|Patients scheduled for cataract surgery were measured with both ss-OCT devices. The following biometry parameters were compared: anterior keratometry, central corneal thickness (CCT), anterior chamber depth (ACD), lens thickness (LT) and axial length (AL).
46014102|NCT00107042|Biological|Recombivax|Participants receive doses of Recombivax at weeks 0 and 24.
46014103|NCT00107042|Biological|Twinrix|Participants receive doses of Twinrix at weeks 0 and 24.
46014104|NCT00596895|Dietary Supplement|Isoflavone|Ingested 47 mg of isoflavone in three 8 oz servings per day
46014105|NCT00596973|Procedure|Surgical Treatment|Ileal transposition with sleeve gastrectomy
46014106|NCT02891772|Procedure|ultrasonographic measurement of corrected flow time(FTc) in carotid artery|Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time). The blood pressure was taken before anesthetic induction and every two minutes after anesthetic induction till ten minutes after endotracheal intubation.
46014107|NCT00106964|Biological|Engerix-B 20 mcg|A single dose of 1 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Weeks 4 and 24.
46014108|NCT00106964|Biological|Engerix-B 40 mcg|A single dose of 2 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Week 4 and 24.
46014109|NCT00106964|Biological|Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg|"Arm 3: 720 EIA HAV Ag, 20 mcg HBsAg/ml:~A single dose of 1 mL will be administered in the deltoid muscle."
46014110|NCT02892435|Device|incisional negative pressure wound therapy|positioning incisional negative pressure therapy over closed wound.
46014111|NCT02892435|Device|conventional dressing|positioning conventional dressing
46014112|NCT00106184|Drug|Rituximab|Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9
46014113|NCT00106184|Drug|Placebo|"Treatment Group A: placebo infusion at Weeks 8 and 9~Treatment Group B: placebo infusion at Weeks 0 and 1"
45837574|NCT00612924|Device|Anaconda ONE-LOK Stent Graft System|Endovascular device
46014114|NCT00598923|Drug|topiramate|100 mg twice per day for 3 months
46014115|NCT00598923|Drug|topiramate|100 twice per day for 6 days after loading dose of phenytoin
46014116|NCT00598923|Drug|phenytoin|loading dose of 20 mg/kg and then 300 mg/day for total of 7 days
46014117|NCT02892318|Drug|Atezolizumab|Atezolizumab 840 mg administered by IV infusion on Days 8 and 22 of each 28-day cycle.
46014118|NCT02892318|Drug|Guadecitabine|Guadecitabine 60 mg/m^2 SC on Days 1-5 of every 28-day cycle.
46014119|NCT01334918|Drug|regadenoson|Administered by intravenous bolus.
46014120|NCT01334918|Radiation|technetium Tc99m sestamibi /technetium Tc99m tetrafosmin|Administered by intravenous infusion
46014121|NCT01334918|Radiation|Contrast|Administered by intravenous infusion.
46014122|NCT01334918|Procedure|Single Photon Emission Computed Tomography|Procedure/Surgery
46014123|NCT01334918|Procedure|Multidetector Computed Tomography|Procedure/Surgery
46099619|NCT04694261|Behavioral|SM-ART|Intervention is a group based training delivered by midwives on SM-ART module. These training will consist of 6 sessions, one per week for 90 to 120 minutes each.
46099620|NCT02693327|Other|Biological Sample|A one time sample will be collected.
45464723|NCT01220375|Drug|G-CSF and Plerixafor|Patients 21-30 receive G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No chemotherapy with vinorelbine will be gine on day 1. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
45464724|NCT01220375|Drug|Vinorelbine & Plerixafor on day when CD34 count is at least 15'000 CD34+ cells/ml of peripheral blood|Patients 31-40 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application at 08:00 AM, on the first day on which the CD34 count has risen to at least 15'000 CD34+ cells/ml of peripheral blood. Stem cell collection is initiated 4 hours later (at 12:00 PM) on this day. No G-CSF will be administered.
45464725|NCT03998878|Behavioral|Low-Carbohydrate Diet|Participants will be instructed to follow a low-carbohydrate diet.
45464726|NCT03998878|Behavioral|Intermittent Energy Restriction|Participants will be instructed to follow intermittent energy restriction.
45464727|NCT03998878|Behavioral|Hunger Training|Participants will be instructed to follow Hunger Training.
45464728|NCT01125995|Radiation|early CCRT|"patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 & Cisplatin 70mg/m2 D1.~radiotherapy start from day 1 of 1st chemotherapy cycle and complete 5250cGy/25fraction (daily one fraction, 210cGy)."
45464729|NCT01125995|Radiation|late CCRT|"patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 & Cisplatin 70mg/m2 D1.~radiotherapy start from day 1 of the third cycle of EP chemotherapy and complete 5250cGy/25fraction (daily one fraction, 210cGy)."
45464730|NCT04456582|Procedure|Shear wave elastography|The elastographic technique by ultrasound (USE), shear waves or shear wave elastography (SWE), quantitatively evaluates tissue stiffness by mapping the propagation of acoustic waves (shear waves), in a non-invasive manner and without emission of ionizing radiation. Their speeds are tracked by the ultrasound equipment after tissue deformation occurs, generated by pulses of acoustic radiation (ARFI) of the transducer itself. Assuming the correlation between tissue stiffness and increased acoustic propagation speeds, it is possible to describe mathematically the elasticity of tissues by measuring specific acoustic waves.
45464731|NCT01203553|Procedure|Abdominal surgery|Intraoperative mesh implantation
45464732|NCT01223729|Drug|Acetyl-L-Carnitine|2 g acetyl-L carnitine twice a day
45464733|NCT01223729|Other|placebo|placebo twice per day
46014124|NCT04059185|Other|Triple P-Level 2|Triple P-Level 2 (TPL2) consists of a brief, 30 minute, one-on-one consultation with a parenting professional followed by a phone call from that professional roughly 2 weeks later. TPL2 will be delivered on an individual level and consist of a brief, 20 to 40 minute, one-on-one parenting consultation. Parents will receive a positive parenting booklet. They also will be offered parenting tip sheets that are designed to provide basic information on the prevention and management of common behavioral, emotional and developmental problems. All materials are: 1) written in simple English; 2) understandable at a sixth grade reading level; 3) gender-sensitive; and 4) avoid technical and colloquial expression that may pose barriers from non-English speaking backgrounds. Participants will receive a follow-up phone call to check on the family's progress and offer any additional needed advice.
46099621|NCT02693327|Other|Blood Sample|A one time blood sample will be collected.
45464734|NCT04456348|Other|there is no intervention|There is no intervention
45464735|NCT05669521|Drug|TK-112690|TK112690 treatment Post 5-FU chemotherapy
45464736|NCT05669521|Drug|Placebo|Placebo treatment Post 5-FU chemotherapy
45464737|NCT01223807|Other|Diaphragmatic breathing training|The training group will participate in a diaphragmatic breathing program which will consist of three 45-min sessions each week (12 sessions totally). The program training will be individualized and supervised by the same physiotherapist. In each session, the patients will be initially instructed to perform 3 series of 10 maximally inspirations, predominantly with abdominal motion, while reducing upper rib cage motion in a supine position.
45464738|NCT03712293|Device|BBB Disruption with Chemotherapy Arm|The ExAblate BBB disruption of targets associated with enhancing post-resection MRI imaging procedure will be performed with ExAblate 4000 type 2.0 system and will coincide with on one of three first days of each planned TMZ adjuvant therapy cycle as one procedure per cycle.
45464739|NCT01126073|Drug|Niacin/laropiprant|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, willer receive ER niacin/laropiprant in addition to the statin therapy. Patients will receive ER niacin/laropiprant 1000mg/20 mg tablet for 4 weeks, after that the dose will be increased to 2000mg/40mg tablet. The intention is that all patients receive 2000 mg/40mg dose for the rest of the study period, but should they be intolerant to the higher dose, the maximum tolerated dose will be used.
45464740|NCT01126073|Drug|Placebo|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will receive placebo in addition to the statin therapy. Patients will receive 1 tablet for 4 weeks, after that the dose will be increased to 2 tablets for the rest of the study period.
45464741|NCT03827707|Behavioral|Noise|Noise applied via headphones during 60 min after meal ingestion
45464742|NCT03827707|Behavioral|Silence|Headphones without sound applied during 60 min after meal ingestion
45464743|NCT01206673|Other|Blood sampling|One blood sampling is required for the research
46014125|NCT04059185|Other|Play Nicely|"Play Nicely is a brief, multimedia, computer-based educational program. The online program uses narrated modules to enhance parenting skills and promote effective parental responses to normal aggressive behavior in young children. The parent educational module presents a hypothetical situation of one child harming another. As the module progresses the viewer is given 20 different discipline options from which to choose. Participants are encouraged to click on all the options they wish to learn more about. The different options provide ways to respond to the situation and explain that there are discipline choices that are considered Great options, Good options after others have been tried, or There are better options. The length of the program is dependent on how many of the 20 discipline options the participant chooses to learn about, but generally it can be finished in 20-40 minutes."
46014126|NCT04059185|Other|Usual care|"Our usual care control group participants receive a resource and referral list for local social services"
46014127|NCT00598962|Drug|Azithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
45464744|NCT01298947|Device|Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems|comparing the use of a Paclitaxel-eluting angioplasty balloon (PTX PTA) with initial photoablation to the use of PTX PTA alone in the treatment of instent lesions in femoropopliteal arteries
46014128|NCT00598962|Drug|Rifabutin/rifampin|
46014129|NCT04059302|Behavioral|Internet-delivered Cognitive Behavioral Therapy for Insomnia|The therapy consists of 6 modules or 'cores' that are introduced on a weekly basis. The cores are designed to decrease sleep-inhibiting cognitions and behaviors, and to alter sleep-wake schedules.
46014130|NCT00599001|Drug|SD-101|Single subcutaneous escalating dose
46014131|NCT00599001|Drug|placebo|placebo
46014132|NCT04052516|Drug|Icosabutate|Icosabutate oral capsule once daily
46014133|NCT04052516|Drug|Placebo|Matching placebo oral capsule
46014134|NCT00597051|Drug|ARD-0403|
46014135|NCT00599040|Behavioral|The DASH diet with weight loss|A reduced calorie diet is provided to participants based on the DASH diet.
46014136|NCT00599040|Behavioral|The DASH diet without weight loss|participants are given a weight maintainenance diet based on the DASH diet
46014137|NCT00599040|Behavioral|Dairy diet|participants are given a high dairy, reduced calorie diet
45464745|NCT01567748|Procedure|BP Measurements at aorta, radial and femoral locations|The following additional research related procedures will be performed in patients recruited into the study: 1) a small cuff will be placed on one the finger of each subject to measure the pulse in the finger (Finapres); 2) a cannula will be placed in the femoral artery by the surgeon to measure femoral artery pressure; 3) for a period of two minutes immediately before and after the cardiopulmonary bypass a small cannula (the size of a pencil tip) will be inserted by the surgeon under direct vision into the aorta and 4) the information from each of these cannula will be recorded on a computer for later study.
45464746|NCT03287050|Drug|Pembrolizumab|200 mg IV q 21 days
45599160|NCT03879863|Drug|Reproxalap Ophthalmic Solution (0.25%) QID|Reproxalap Ophthalmic Solution (0.25%) administered QID for twelve weeks
46014138|NCT01332968|Drug|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion will be administered on Day 1, 8, and 15 of Cycle 1 and then on Day 1 of each subsequent cycle during induction period and obinutuzumab 1000 mg IV infusion every 2 months during maintenance period.
46014139|NCT01332968|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m^2 IV will be administered on Day 1 of each cycle during induction period.
46014140|NCT01332968|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 IV will be administered on Day 1 of each cycle during induction period.
46014141|NCT01332968|Drug|Vincristine|Vincristine 1.4 mg/m^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.
46014142|NCT01332968|Drug|Prednisone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.
46014143|NCT01332968|Drug|Bendamustine|Bendamustine 90 mg/m^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.
46014144|NCT01332968|Drug|Rituximab|Rituximab 375 milligrams per square meter (mg/m^2) IV infusion will be administered on Day 1 of each cycle during induction period and rituximab 375 mg/m^2 every 2 months during maintenance period.
46014145|NCT00599079|Drug|Azithromycin|Azithromycin Daily Dosage dependent on clinical factos such as age, weight and patient specific health descriptors
46014146|NCT04326816|Procedure|Rehabilitation of severely worn dentitions using minimally invasive composite restorations (Estenia C&B or Clearfil AP-X, Kuraray, Osaka, Japan)|
46014147|NCT00597129|Biological|90Y-hPAM4|Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks.
46014148|NCT01332851|Behavioral|Promoting First Relationships (PFR)|PFR is a parenting intervention based on attachment theory and is strengths based. It is a 10 week intervention that is delivered in the home of the family.
46014149|NCT01332851|Behavioral|Resource and Referral|Needs assessment, followed with a resource packet sent by mail
46014150|NCT00599235|Drug|sildenafil|50mg 3 times daily for 7 days
46014151|NCT00599235|Drug|hydralazine|25mg 3 times daily for 7 days
46014152|NCT00599235|Drug|placebo|3 times daily for 7 days
46099622|NCT05011357|Drug|Phenylephrine|Phenylephrine will be administered as an infusion
46099623|NCT05011357|Drug|Saline Control|Saline infusion
46099624|NCT02693405|Other|Executive functions|measures of executive functioning with tasks
46099625|NCT02693405|Other|social cognition|measures of socio-cognitive functioning with tasks
46099626|NCT02693405|Other|quality of life|measures of quality of life with questionnaires
45464747|NCT03287050|Radiation|SBRT|Stereotactic body radiation therapy (SBRT) that will commence not later than the initiation of the second cycle of pembrolizumab. SBRT dose and fractionation will be at the discretion of the treating radiation oncologist, and will be selected to respect the normal tissue tolerance of adjacent organs at risk.
46014153|NCT04058834|Drug|NNC0385-0434|Healthy volunteers and patients will receive one injection s.c. (subcutaneously, under the skin)
46014154|NCT04058834|Drug|Placebo (NNC0385-0434)|Healthy volunteers will receive one injection s.c.
46014155|NCT04055168|Drug|AZD6615|AZD6615 (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
45464748|NCT01204879|Behavioral|Contingency Management|Participants earn the chance to win prizes for the targeted behavior.
45464749|NCT03712215|Other|Rehabilitation|diaphragmatic electrical stimulation
45464750|NCT01206751|Other|Chest imaging technique and case presentation|
46014156|NCT04055168|Drug|Placebo|Placebo (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
46014157|NCT01332305|Drug|GEn (XP13512/GSK1838262)|Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91
46014158|NCT01332305|Drug|Placebo|Placebo orally once daily
46014159|NCT00599274|Drug|Interferon beta-1a|injection once a week
46099627|NCT00711880|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
46014160|NCT00599274|Drug|Interferon beta-1a|injection three times a week
46014161|NCT01332227|Drug|Atazanavir|Capsules, Oral, 300mg, Once daily, 48 weeks
46014162|NCT01332227|Drug|Ritonavir (heat-stable)|Tablets, Oral, 100 mg, Once daily, 48 weeks
46014163|NCT01332227|Drug|Raltegravir|Tablets, Oral, 400 mg, Twice daily, 48 weeks
46014164|NCT01332227|Drug|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, Once daily, 48 weeks
46014165|NCT00599352|Dietary Supplement|magnesium|Single infusion of elemental magnesium given over 4 hours, 0.2mEq/kg (2.4 mg/kg)
46099628|NCT00711880|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
45464751|NCT05470881|Drug|Atropine Sulfate|Administration of one drop QD on both eyes for 14 days.
46099629|NCT00528775|Drug|HPPH|4 mg/m2 IV
46099630|NCT00528775|Procedure|endoscopic procedure|Treatment with 150 joules from laser
46099631|NCT02693483|Drug|10% povidone iodine|Vaginal cleansing will be done with 3 gauze pieces soaked with 10% povidone iodine in a sterilized bowl and the scrub will be done from the vaginal apex to introitus with attention to the anterior, posterior and lateral vaginal wall
46099632|NCT04873063|Drug|Beclomethasone dipropionate|BDP 3 mg bid (R product) BDP 6 mg qd (T product)
45464752|NCT03130504|Drug|17α hydroxy progesterone caproate|where patients will have a 17α hydroxy progesterone caproate intramuscular injection every week starting from 24 weeks of gestation till completed 37 weeks
45464753|NCT01206829|Behavioral|8-session CBTcourse|Hearing impaired workers voluntarily sign up for an 8 session cognitive therapy course. The study has a waiting list control group design. Participants will be randomized assigned to either an experiment group that will be offered to start on an immediate course, or a control group that will be offered the same course 12 months later.
45464754|NCT01206829|Behavioral|8 session cognitive behavioral therapy|8 sessions cognitive behavioral therapy in group
45464755|NCT01126151|Behavioral|parent handbook|parent handbook
45464756|NCT03439683|Other|Survey about patient-ventilator asynchrony|Participants will fill an online survey that asks multiple-choice questions related to knowledge, attitudes and practice related to patient-ventilator asynchrony and also have images of ventilator waveforms wth asynchrony, where they need to identify the type of asynchrony
45464757|NCT01993082|Behavioral|Aerobic Training Intervention|"For 24 weeks, subjects randomized into the aerobic training group will be asked to increase their physical activity level to meet the Centers for Disease Control and Prevention recommendations for physical activity of 150 minutes per week of moderate activity.~A first visit with a fitness coach support provider, followed by weekly coaching texts and phone calls, will provide the framework for the activities in which participants should engage."
46014166|NCT00599391|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation for 30 to 40 minutes per session.
46014167|NCT01332149|Drug|Pregabalin|"Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn.~At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day."
46014168|NCT01332149|Drug|Placebo matched with pregabalin|Subject will take placebo matched with pregabalin twice a day.
46014169|NCT00599430|Dietary Supplement|Placebo|Inert excipient
46099633|NCT05198687|Procedure|Long implant and partial overdentures|insertion of long implants anterior to the maxillary sinus to retain partial overdentures
46099634|NCT05198687|Procedure|Sinus lift and long implant|performing sinus lift surgical procedure with simultaneous placement of long implants to support screw-retained prosthesis
46099635|NCT05198687|Procedure|short implant without sinus lift|placement of short implants in the remaining bone above maxillary sinus to support screw-retained prosthesis without performing sinus lift
46014170|NCT00599430|Dietary Supplement|Lactobacillus acidophilus NCFM|1e10 CFU/day
46099636|NCT05198687|Device|Partial overdentures|Distal extension metallic partial dentures retained by attachments to the implants
46099637|NCT05198687|Device|Metal ceramic prosthesis on long implants|porcelain fused to metal fixed screw-retained prosthesis supported by long implants
46099638|NCT05198687|Device|Metal ceramic prosthesis on short implants|porcelain fused to metal fixed screw-retained prosthesis supported by short implants
46014171|NCT00599430|Dietary Supplement|Combination of Lactobacillus acidophilus and Bifidobacterium lactis|1x10e10 CFU/day
46014172|NCT02892240|Other|No intervention. Observational study|
46014173|NCT04326270|Device|Nasal interface|Randomized to initial interface of nCPAP prongs or infant cannula
46014174|NCT04054427|Device|IOL implantation experimental|Implantation of trifocal IOL POD L GF consisting of hydrophobic material
46014175|NCT00599469|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared radiation for 30 to 40 minutes per treatment session.
46014176|NCT04054505|Dietary Supplement|EZPAK|One packet with breakfast for three months
46014177|NCT04054505|Dietary Supplement|Placebo|One packet with breakfast for three months
46099639|NCT05197361|Diagnostic Test|Invasive coronary physiology|Estimation of guide-wire coronary physiology parameters
46099640|NCT00739414|Drug|LBH589|10, 15, 20 mg/m2, i.v. on day 1 and 8 of each 21 day cycle
46099641|NCT02693561|Behavioral|Deep Breathing Exercises|Technical Deep Breathing: Deep breathing is to deep breath and slowly through the nostrils until total lung capacity. At the end of inspiration is kept a few seconds of apnea and started after the expiration slowly. End-expiratory apnea will remain a few seconds to start new inspiration cycle. With this process the individual breathe about 6 times per minute. Breath learning occurs through visual feedback. In the intervention group will be held deep breathing for 10 minutes. Subjects will be instructed to deep breath for 10 minutes 2 times a day for 15 days beyond the period in which they cleft, which is one of the symptoms of withdrawal syndrome. Control and frequency of deep breathing will be obtained weekly through specific daily fill, which will be provided weekly.
45464758|NCT04106986|Combination Product|Pulsed electromagnetic field and Progressives resistance exercise|"The pulsed electromagnetic field treatment consist of 30 minutes pulsed electromagnetic field with 50 Hz pulses~The progressive resistance exercise training consist of 45 minutes of progressive resistance exercise protocol as the following:~The PRE session begun with warm-up exercises that included riding a stationary ergometer for 5 minutes followed by stretching exercises for the hamstrings, quadriceps and gastrocnemius muscles. After this, subjects performed non-weight bearing (open chain) and weight bearing (closed chain) quadriceps exercises.~The amount of resistance and number of repetitions for each exercise are based on a modification of the daily adjustable progressive resistance exercise (DAPRE) program that was described by Knight eta al."
46014178|NCT01316120|Other|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
46099642|NCT02693561|Behavioral|Self-Help Book|Reading the self-help book.
46099643|NCT02569684|Dietary Supplement|Prebiotic fibers: oligofructose and inulin|
46099644|NCT02569684|Dietary Supplement|Maltodextrin|
46014179|NCT01316120|Other|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
46099645|NCT01564615|Device|Umbilical catheterization (AgION )|Infants received a AgION impregnated catheter (4.0-5.0 F Lifecath PICC ExpertTM, Vygon, Ecouen, France).
46099646|NCT01564615|Device|Umbilical catheterization (ArgyleTM)|Infants received a polyurethane non-impregnated catheter (3.5-5.0 F ArgyleTM, Kendall, Tullamore, Iceland)
46099647|NCT00612599|Drug|biphasic insulin aspart|
46099648|NCT00735280|Drug|unfractionated heparin|bolus of 100 U/kg of unfractionated heparin
46099649|NCT04172909|Other|LEGO Bricks MRI|LEGO Bricks model MRI (A model of the MRI machine and adjacent control room made out of LEGO bricks) will be used by the child life specialist to prepare the child for MRI
45464759|NCT04106986|Other|PRE|"The progressive resistance exercise training consist of 45 minutes of progressive resistance exercise protocol as the following:~The PRE session begun with warm-up exercises that included riding a stationary ergometer for 5 minutes followed by stretching exercises for the hamstrings, quadriceps and gastrocnemius muscles. After this, subjects performed non-weight bearing (open chain) and weight bearing (closed chain) quadriceps exercises.~The amount of resistance and number of repetitions for each exercise are based on a modification of the daily adjustable progressive resistance exercise (DAPRE) program that was described by Knight eta al."
45464760|NCT03819127|Drug|Vildagliptin 50 MG Oral Tablet|
45464761|NCT03819127|Drug|Metformin Pill|
45464762|NCT01218269|Device|nitinol u-clip|The U-clip is comprised of nitinol, an alloy of nickel and titanium.
46099650|NCT04172909|Other|Mock MRI tube|Mock MRI tube will be used by the child life specialist to prepare the child for MRI
46099651|NCT00728572|Procedure|Logan Basic Technique and Surface EMG|Participant will receive a brief Basic Technique and Surface EMG examination and Basic Technique treatment.
46099652|NCT00728572|Other|Surface EMG|Surface EMG only, no intervention
46099653|NCT00728572|Procedure|Logan Basic Technique Sham|Participants will receive a sham Basic Technique treatment, not indicated by examination.
46099654|NCT01564927|Device|Electroacupuncture to right LI4 and LI11 (ITO, EX-160)|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
46099655|NCT01564927|Device|Sham Electroacupuncture to knee caps|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
46099656|NCT01564927|Device|Sham electroacupuncture to LI4 and LI11|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
45464763|NCT05107310|Procedure|Pedicle screws insertion by free hand technique|Spinal deformity correction. Pedicle screws are inserted using free hand technique with the help of intraoperative fluoroscopy if needed.
45599161|NCT03879863|Drug|Vehicle Ophthalmic Solution QID|Vehicle Ophthalmic Solution administered QID for twelve weeks
45464764|NCT05107310|Procedure|Pedicle screws insertion using ARSN|Spinal deformity correction. Pedicle screws are inserted using augmented reality surgical navigation (ARSN) with the ClarifEye navigation system and the Philips Allura 2D/3D imaging system.
45464765|NCT05107310|Procedure|Pedicle screws insertion using IRSN|Spinal deformity correction. Pedicle screws are inserted using infra-red surgical navigation (IRSN) with the Brainlab Curve 1.2 navigation system combined with the Medtronic O-arm 2D/3D imaging system.
45464766|NCT03387735|Other|Treatment as usual (TAU) + Internet|Patients in this group will receive TAU+internet and links to helpful websites.
45464767|NCT03387735|Behavioral|TAU + ElderTree|"For the patient, ElderTree provides tools, motivation, and social support to help them manage their specific set of chronic conditions and communicate with peers and their primary care physician.~For the clinic, ElderTree has a Clinician Report (CR), a visual dashboard of health-tracking data that can be customized based on the needs of the clinic. The CR provides alerts to the clinician when a patient passes a certain threshold. The dashboard is intended to help clinicians prepare for patient office visits."
45464768|NCT04086082|Device|Markerless Image Guidance|Single arm trial using implanted markers to determine the feasibility of Markerless Image Guidance using Intrafraction Kilovoltage X-ray Imaging
45464769|NCT05622799|Behavioral|Mind-Body Medicine Training Program|A mind-body medicine training program that teaches mind-body skills including meditation, autogenics and biofeedback, guided imagery, body awareness, genograms, and self-expression through writing and drawings. The first 4 day training consists of lectures and small groups where the mind-body techniques are practiced. The second 4 day training allows participants to lead a mind-body skills group and teach the techniques under supervision.
46014180|NCT00597324|Procedure|coronary catheterisation|Coronary angiography which may be followed by ad hoc percutaneous intervention if indicated clinically
46014181|NCT01330628|Device|Turbo Elite Laser and Turbo Tandem Laser Guide Catheters|application of laser energy to remove blockage followed by standard balloon angioplasty
46014182|NCT01330628|Procedure|Balloon angioplasty|standard balloon catheters for PTA
46014183|NCT02892279|Other|Diesel exhaust exposure|Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute diesel exhaust via mask.
46014184|NCT02892162|Procedure|Additional LAAW linear ablation|Additional linear ablation on LAAW using ThermoCool SmartTouch ablation catheter.
46014185|NCT01330433|Device|CoSeal Surgical Spray Group|"A patient randomized to the CoSeal treatment group will have CoSeal Surgical Spray applied at the end of their first staged procedure.~The dose regimen is as follows:~Patients weighing < 3kg will receive 1ml of CoSeal~Patients weighing 3-10kg will receive 1-2ml of CoSeal~Patients weighing >10kg will receive 2-4ml of CoSeal"
46014186|NCT00597363|Device|Neptune P.A.D. (R)|The Neptune Pad ® (Biotronik GmbH & Co. KG, Berlin, Germany) is a soft and hydrophilic wound dressing, which has been developed to accelerate local hemostasis, reduce compression times, enable early ambulation and minimize the risk for bleeding complications. Neptune Pad ® consists of calcium alginate, which is cationically charged and exerts potent procoagulant properties.
46014187|NCT00597363|Other|conventional manual compression|The most common technique for puncture site management is manual compression. This technique requires an extended pressure on the puncture site, and after achievement of hemostasis a pressure bandage is applied for several hours at bed rest.
45464770|NCT03931031|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
45464771|NCT04177394|Device|MitraClip G4 System|Percutaneous mitral valve repair using the MitraClip G4 system.
45599162|NCT03879863|Drug|Reproxalap Ophthalmic Solution (0.25%) QID to BID|Reproxalap Ophthalmic Solution (0.25%) administered QID for four weeks, followed by BID administration for eight weeks
46014188|NCT00599508|Dietary Supplement|Concord grape juice|Several ounces Concord grape juice administered 3 times a day for 12 or 16 weeks. Specific dosage determined by participant's weight.
46014189|NCT00599508|Dietary Supplement|placebo juice|several ounces placebo juice consumed three times a day for 12 or 16 weeks; dosage determined according to participant's weight
45464772|NCT02908789|Radiation|Antimicrobial photodynamic therapy (aPDT)|Selective caries removal + Antimicrobial photodynamic therapy (aPDT) is an effective low potency laser that involves the activation of a photosensitizer( 0.01% methylene blue ) by a visible light source that creates chemical reactions, producing cytotoxic reactive oxygen species and causing oxidative stress and inactivation of pathogenic microorganisms + tooth restauration
45464773|NCT02908789|Other|Without Antimicrobial phothodynamic therapy|Selective caries removal + tooth restauration
45464774|NCT05607550|Drug|furmonertinib 240 mg oral, daily|furmonertinib tablet
45464775|NCT05607550|Drug|furmonertinib 160 mg oral, daily|furmonertinib tablet
45464776|NCT05607550|Drug|platinum-based chemotherapy|(carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV)
46014190|NCT00599508|Dietary Supplement|blueberry juice|wild blueberry juice administered daily for 12 weeks, dosage determined according to participant's weight
46014191|NCT00599508|Dietary Supplement|whole fruit blueberry powder|whole fruit, freeze dried blueberry powder derived from a blend of cultivated blueberries administered daily for 16 weeks
46014192|NCT00599508|Dietary Supplement|berry placebo powder|berry placebo powder administered daily for 16 weeks
46014193|NCT01330316|Drug|BI 201335|BI 201335 for 24 weeks
45464777|NCT01127867|Dietary Supplement|dietary intervention|dietary intervention
45464778|NCT01498393|Device|Laser treatment|Laser treatment to Improve the Appearance of Onychomycosis
45464779|NCT01123343|Device|TrueVision 3D Visualization and Guidance System for MicroSurgery|Adjunct imaging tool (to the microscope oculars) that provides onscreen video guidance for alignment, orientation, and sizing during eye surgery, based on a surgeon's defined nomogram
45464780|NCT03632174|Other|Topical Ointment with L. reuteri|Topical Ointment containing live Lactobacillus reuteri DSM17938 applied twice daily in dry areas of the entire body
45464781|NCT03632174|Other|Topical Ointment without L. reuteri|Topical Ointment that does not contain Lactobacillus reuteri DSM17938 applied twice daily in dry areas of the entire body
45464782|NCT01204957|Dietary Supplement|Seaweed and Soy Protein|5 g/d Seaweed for 6 wks, followed by 5 g/d Seaweed + Soy Protein for 1 wk
45464783|NCT01204957|Dietary Supplement|Placebo and Soy Protein|5 g/d Placebo for 6 wks, followed by 5 g/d Placebo + Soy Protein for 1 wk
46014194|NCT01330316|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
46014195|NCT00599547|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation after dose-reduced Conditioning for Myelofibrosis Patients
46014196|NCT01316198|Dietary Supplement|Verum|10 subjects consume for 4 weeks a beverage containing 10 mg lutein and 3 mg zeaxanthin per day
46014197|NCT01316198|Dietary Supplement|Placebo|10 subjects consume for 4 weeks a placebo beverage without any lutein and zeaxanthin
46014198|NCT00599586|Other|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
46014199|NCT01316237|Drug|GS-6620|GS-6620 tablet, 50 mg QD
45464784|NCT04084574|Behavioral|DASH diet counseling|Culturally-appropriate, disease-sensitive counseling intervention to enhance DASH diet adherence in Blacks with CKD compared to standard of care condition
46014200|NCT01316237|Drug|GS-6620|GS-6620 tablet, 100 mg QD
46014201|NCT01316237|Drug|GS-6620|GS-6620 tablet, 300 mg QD
46014202|NCT01316237|Drug|GS-6620|GS-6620 tablet, 100 mg QD, Fasted
46014203|NCT01316237|Drug|GS-6620|GS-6620 tablet, 300 mg QD, Fasted
46014204|NCT01316237|Drug|GS-6620|GS-6620 tablet, 900 mg QD, Fasted
45464785|NCT01223885|Dietary Supplement|Camel's milk|Patients with proved cow's milk allergy who have negative prick skin tests to came's milk will be administered gradually increased doses of pasteurized camel's milk at 30 minute intervals
45464786|NCT01299181|Drug|Atorvastatin|80mg once daily orally
45464787|NCT01123577|Other|Home Blood Pressure Monitor Group|Participants receive home monitors, modems, educational materials and training. Participants will send home BP readings to research database monthly and receive usual care by providers for 9 months.
45464788|NCT03960892|Behavioral|Problem Management Plus (PM+)|This intervention is based on the WHO treatment guidelines for conditions related to stress (WHO, 2013). It is a 5-session intervention that is delivered by trained non-specialists, and is available in individual and group delivery formats for both children and adults. PM+ includes evidence-based techniques such as; problem solving, stress management, behavioral activation, and accessing social support. It has proved to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan (Bryant, Dawson, Schafer, Sijbrandij, & van Ommeren, 2016; Rahman, Hamdani, Awan, Bryant, Dawson, Khan, Mukhtar-ul-Haq Azeemi, et al., 2016).
46014205|NCT01316237|Drug|GS-6620 tablet, 450 mg BID|GS-6620 tablet, 450 mg BID
46014206|NCT01316237|Drug|GS-6620 tablet|GS-6620 tablet, 900mg , BID
46014207|NCT01316237|Drug|GS-6620 tablet|GS-6620 tablet, 900 mg
46014208|NCT02892084|Device|tDCS|Constant non-invasive, low intensity, direct electrical current utilized to stimulate specific areas of the brain. Evaluating immediate effects of anodal/cathodal stimulation during 20 minutes of treadmill walking.
45464789|NCT01483495|Device|Diffuse optical spectroscopy|Diffuse Optical Spectroscopy Imaging Cerebrovascular Reactivity
45464790|NCT03930875|Other|Aspirin Resistance testing|Aspirin resistance will be measured using platelet aggregometry (VerifyNow assay)
45464791|NCT03932968|Procedure|pH-metry during 24 hours|For patients with gastric symptoms such as retrosternal burning, regurgitations, and epigastric pain, a pH-metry will be performed
46099657|NCT05342909|Other|5x a week BFR training group|This group will perform the two exercises 5x a week with blood flow restriction, set to 80% of limb occlusion pressure, applied to the dominant thigh.
46099658|NCT05342909|Other|2x a week BFR training group|This group will perform the two exercises 2x a week with blood flow restriction, set to 80% of limb occlusion pressure, applied to the dominant thigh.
45464792|NCT01206907|Drug|oxymorphone IR|oxymorphone IR liquid
45464793|NCT03831997|Drug|Dextrose 5% W/ Sodium Chloride 0.225%|D5 1/4NS is comprised of 5% dextrose in a 0.225% sodium chloride (NaCl) solution. D5 1/4NS is initially slightly hypertonic to plasma, with an osmolarity of 321 mOSm/L. As the glucose component is rapidly metabolized, 0.225% NaCl solution remains and is hypotonic to plasma at an osmolarity of 77 mOsm/L. Because of the hypotonicity of the 1/4NS, it shifts into the intracellular compartments, followed by free water, and allows for volume expansion.
45464794|NCT03925246|Drug|Nivolumab|"Nivolumab (Opdivo) is a potent human monoclonal antibody (mAb) of the IgG4 isotype designed to directly block the interaction between Programmed Cell Death 1 (PD-1) and its ligands, Programmed Death Ligand 1 (PD-L1) and PD-L2.~Nivolumab is administered by a 30 minutes intravenous infusion at dose of 240 mg every 2 (+/- 2 days) weeks for 8 cycles (4 months), followed by a dose of 480 mg administered by a 60 minutes intravenous infusion every 4 weeks (+/-3 days) (beginning at cycle 9) for a total therapy duration of 1 year (maximum 16 cycles of treatment) or until progression, death, unacceptable toxicity."
45464795|NCT01218347|Drug|Rosuvastatin|20 mg once daily for 21 days
45464796|NCT01220765|Device|Capnography|In the capnography arm, respiratory monitoring is performed with pulse oximetry and capnography. If the capnogram indicates sub-optimal ventilation and/or apnea, denoted as a flat line on the capnometer for ≥ 15 seconds, a respiratory rate ≤ 6, or a end-tidal CO2 > 50 mmHg, medical staff will intervene by arousing the patient, performing chinlift or jawthrust, abandon from giving additional propofol, or provision of oxygen. The nurse qualified in sedation management will assess capnography him/ herself.
45599163|NCT03879863|Drug|Vehicle Ophthalmic Solution QID to BID|Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
46014209|NCT02892084|Device|Sham tDCS|"Per published protocols, tDCS will be administered for 30 secs allowing for sensory adaptation to occur and then turned off, so that the remaining sham stimulation will include zero current. Evaluating immediate effects during 20 minutes walking on a treadmill."
46014210|NCT00597480|Drug|rhGH (Norditropine SimpleXx®)|the recommended dose in the EU of rhGH (Norditropine SimpleXx®
46014211|NCT00597480|Drug|rhGH norditropine simple Xx|"the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)"
46014212|NCT01326702|Drug|Bendamustine Hydrochloride|Given IV
46014213|NCT01326702|Other|Pharmacological Study|Correlative studies
46014214|NCT01326702|Biological|Rituximab|Given IV
46014215|NCT01326702|Drug|Veliparib|Given PO
46014216|NCT05654129|Other|saliva samples|saliva samples (non-invasive, in the sites evaluated during the partial survey) will be perform by one of the investigators .
46014217|NCT05654129|Other|medical questionnaire|a complete medical questionnaire will be carried out (general, lifestyle and quality of life) will be perform by one of the investigators .
46014218|NCT00599625|Drug|Pravastatin|80mg administered daily for 6 consecutive weeks
46014219|NCT05661474|Drug|Fitostimoline ® hydrogel group|Treatment of DFUs with Fitostimoline® hydrogel every day for 12 weeks.
46014220|NCT05661474|Drug|Saline gauze group|Treatment of DFUs with saline gauze every day for 12 weeks.
46014221|NCT00599664|Drug|OMS201|OMS201 irrigation solution during surgery
46014222|NCT00599664|Drug|Vehicle|Vehicle irrigation solution during surgery
46099659|NCT04764487|Device|KidneyPRO|Web-application for symptoms assessment
46099660|NCT04764487|Other|standard follow-up|usual follow-up
46099661|NCT00612989|Drug|Temodar and O6-Benzylguanine|"O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30 mg/m2/day for 5 consecutive days. Every 48 hrs repeat dose of 120 mg/m2 over 1 hr administered for total of 3 doses.~Temodar administered orally, in fasting state within 60 minutes of end of 1st 1-hr infusion of O6-BG & then every 24 hrs during continuous infusion of O6-BG. Temodar administered on day 1 of treatment cycle & every 24 hrs thereafter for 5 days with treatment cycles repeated every 28 days.~Pts must fast for minimum of 1 hr prior to administration of each dose of Temodar & continue fasting 2 hrs after administration of each Temodar dose."
45464797|NCT03831685|Other|Blood sample|Patients meeting the inclusion criteria and none of the non-inclusion criteria will benefit from 2 venous blood samples in order to precise the initial blood lactate level, e.g. at the first medical contact, and the final blood lactate level, e.g. at the hospital admission.
46014223|NCT04326699|Procedure|Bilateral SIJ injection|under US guidance a 22G spinal needle, where 1 mL 2 % lidocaine hydrochloride (xylocaine, AstraZeneca) mixed with triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) will be injected in each SIJ
46014224|NCT02891655|Other|immuno-histo-chemical analysis|in vitro immuno-histo-chemical analysis of corneal epithelium
45464798|NCT03916978|Biological|Autologous PRP intra ovarian infusion|Autologous PRP intra ovarian infusion
45464799|NCT03916978|Biological|Autologous PFP intra ovarian infusion|Autologous PFP intra ovarian infusion
46014225|NCT05653310|Drug|Tradipitant|Tradipitant Capsule
46014226|NCT05653310|Drug|Placebo|Placebo Capsule
45464800|NCT01126229|Dietary Supplement|Placebo|2 capsules of placebo daily for 12 weeks
46014227|NCT05653037|Drug|RBD4059|Subcutaneously Administered RBD4059 in Healthy Subjects.
46014228|NCT05653037|Drug|Placebo|Subcutaneously Administered Placebo in Healthys Subject.
46014229|NCT05650697|Biological|Group 1 cannabidiol (CBD) oil with silicone ointment|CBD oil with silicone ointment will be used on either the top half of a forehead scar. Specific placement instructions will be given to the participant. They will treat the scar the same way for 7 months.
45464801|NCT01126229|Drug|Low dose Resveratrol|2 capsules daily for 12 weeks containing 300 mg/d (combined) of resveratrol active ingredient
45464802|NCT01126229|Drug|High dose Resveratrol|2 capsules daily for 12 weeks containing 1000 mg/d (combined) of resveratrol active ingredient
45464803|NCT03831841|Behavioral|Multicomponent exercise programe|An intervention consisting of training by a multicomponent program 3 times a week, working on aerobic capacity, flexibility, balance and strength.
46014230|NCT05650697|Biological|Group 2 cannabidiol (CBD) oil with silicone ointment|CBD oil with silicone ointment will be used on either the bottom half of a forehead scar. Specific placement instructions will be given to the participant. They will treat the scar the same way for 7 months.
46014231|NCT05649878|Drug|Evaluation of bioavailability of methylprednisolone succinate administered intravenously|Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intravenously. The nominal doses were similar, volunteers were randomly assigned to receive a single dose of MEP by IV bolus of 1.5 mL. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
46014232|NCT05649878|Drug|Evaluation of bioavailability of methylprednisolone succinate administered intranasally|Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intranasally. Volunteers were randomly assigned to receive a single dose of MEP intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
46014233|NCT01327703|Drug|Panzytrat® 25,000|Panzytrat® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 European Pharmacopoeia (Ph.Eur.) units lipase/kilogram (kg) body weight/day in either first treatment period or second treatment period.
46099662|NCT00735358|Procedure|Cyanoacrylate|Cyanoacrylate 0.5 ml, endoscopic injection of gastric varix at each shot
45464804|NCT03471754|Device|TESA-HB Transcranial Electronic Stimulation Device|Duration of treatment: 50 Minute Therapy sessions administered one time each day, for two 5-day cycles
45464805|NCT01127945|Drug|statin|"adding atorvastatin 80mg, po on day (1 to 3) acute heart failure therapy~acute heart failure therapy"
45464806|NCT03827005|Dietary Supplement|L-arginine|NOW Foods, Bloomingdale, IL
45464807|NCT03827005|Dietary Supplement|Placebo|InHealth Specialty Pharmacy, Fargo, ND
45464808|NCT03474640|Biological|Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody|Toripalimab is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
45464809|NCT03973996|Dietary Supplement|Green Tea Extract|A gummy confection with catechin-rich green tea extract (1 g/d)
45464810|NCT03973996|Dietary Supplement|Placebo|A matched gummy confection formulated without green tea extract
45464811|NCT01126307|Drug|Verapamil|80 mg tid
45464812|NCT01126307|Drug|placebo|placebo tid
45464813|NCT03831061|Other|Cognitive stimulation|
45464814|NCT03439137|Drug|MT-6548|Oral tablet
45464815|NCT03439137|Drug|Darbepoetin alfa|Intravenous administration
45464816|NCT03439137|Drug|MT-6548-matching placebo|Oral tablet
45464817|NCT03439137|Drug|Darbepoetin alfa-matching placebo|Intravenous administration
45599164|NCT02344641|Drug|Exenatide|
45599165|NCT03513991|Other|Infant formula|
45599166|NCT03853343|Dietary Supplement|Seaweed extract|1 capsule 3 times per day
46099663|NCT00735358|Procedure|Cyanoacrylate|Cyanoacrylate 1 ml, endoscopic injection for gastric varices at each shot
46014234|NCT01327703|Drug|Kreon® 25,000|Kreon® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 Ph.Eur. units lipase/kg body weight/day in either first treatment period or second treatment period.
45464818|NCT03469024|Other|Home Rehabilitation Program|It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
45464819|NCT03469024|Other|e-Health program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
45599167|NCT03853343|Dietary Supplement|Placebo|1 capsule 3 times per day
46014235|NCT01380080|Drug|Atripla (r)|Patients are administered one tablet of Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EFV/FTC/TDF, Atripla) to taken be taken orally once daily at bedtime without food.
46014236|NCT01380080|Drug|Efavirenz|Participants will take one 600 mg tablet administered orally once daily without food.
46014237|NCT01380080|Drug|Truvada|Participants will take one tablet of Emtricitabine 200mg/tenofovir disoproxil fumarate 300mg (FTC/TDF, Truvada) administered orally once daily with or without food.
46014238|NCT01380080|Drug|Rifampin/isoniazid/pyrazinamide/ethambutol FDC|Participants will be administered Rifampin/isoniazid/pyrazinamide/ethambutol FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 of the protocol, for the first 8 weeks.
46014239|NCT01380080|Drug|Rifampin/isoniazid FDC|Participants will be administered rifampin/isoniazid FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 in the protocol, for 16 weeks following the first 8 weeks.
46014240|NCT01380080|Drug|Isoniazid|INH 300 mg orally once daily
46014241|NCT01379768|Device|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily and extended (overnight) wear for up to 30 nights.
45599168|NCT02344719|Drug|Taurin 6g per day per oral for 28 days|Taurin 6g per day per oral for 28 days
46014242|NCT01379768|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily or extended (overnight) wear up to 6 nights.
45680084|NCT04143269|Device|Non-invasive transcutaneous vagus nerve stimulation|Bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period.
45680085|NCT04143269|Device|Sham vagus nerve stimulation|"Bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period.~The sham device produces a slight vibrating sensation, but do not provide any vagal nerve activation"
46014243|NCT01379768|Device|Clear Care Cleaning and Disinfection Solution|Hydrogen peroxide-based contact lens care system for nightly cleaning and disinfection of study lenses
46014244|NCT04444505|Other|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
46014245|NCT04444739|Other|radiographic data collection|From existing radiological Images (upright standing X-ray and supine MRI of the lumbar spine), specific radiographic parameters will be extracted
46014246|NCT02894333|Behavioral|behavioral observation|
46014247|NCT01379573|Drug|Hydroxychloroquine|Nineteen women meeting eligibility criteria will receive 400mg per day of HCQ beginning as soon as pregnancy is established and informed consent obtained. Mothers already on HCQ will remain on 400mg, or escalate to 400mg if on 200mg. Hydroxychloroquine is taken in 200mg pill form - 400mg = 2 200mg pills.
46014248|NCT01379534|Drug|TKI258|
46014249|NCT01371851|Drug|Doxazosin extended release|initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.
46099664|NCT00735514|Behavioral|compliance monitoring|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
45464820|NCT01128023|Other|Myocardial perfusion imaging using Rb-82 PET or Tc-99m or Tl SPECT|Patients will undergo a clinically indicated PET Rb-82 myocardial perfusion scan for diagnosis or risk stratification of CAD. This cohort will be matched to the SPECT perfusion database.
46099665|NCT00735514|Other|questionnaire administration|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
46014250|NCT01371734|Drug|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 25, 35, or 50 mg/day based on subject weight at the Baseline visit.
45464821|NCT04055090|Genetic|Long-Term Follow-Up of Patients who Received Engensis (VM202)|No study drug is administered in this study. Patients who received Engensis (VM202) in the previous trial (VMDN-003) will remain blinded and were evaluated in this trial for long-term safety and efficacy.
45464822|NCT04055090|Drug|Long-Term Follow-Up of Patients who Received Placebo|No study drug is administered in this study. Patients who received Placebo in the previous trial (VMDN-003) will remain blinded and were evaluated in this trial for long-term safety and efficacy.
45464823|NCT03818893|Drug|Combination of GEN0101 and Pembrolizmub|New Combination immunotherapy GEN0101 and Pembrolizmub
45683894|NCT01574079|Other|Traditional Physical Therapy|Traditional physical therapy includes, but is not limited to, therapeutic exercise, functional mobility training, pre-gait and gait activities, electrotherapeutic modalities, and education.
46014251|NCT01371734|Drug|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 20, 25, or 35 mg/day based on subject weight at the Baseline visit.
46014252|NCT01371734|Drug|Placebo|Subjects randomized to the Placebo treatment arm will receive placebo tablets
45464824|NCT01126385|Device|DensiProbe Spine|Intraoperative DensiProbe Spine measurements
45464825|NCT03666754|Procedure|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with the deferred treatment of superficial reflux (usually once the ulcer has healed)
45464826|NCT03666754|Procedure|Early endovenous glue embolization arm|Early endovenous glue embolization of superficial venous reflux within 2 weeks in addition to standard compression therapy
45464827|NCT05562141|Biological|Blood sample|Blood sample before induction, 1h after induction and 24h after the start of procedure
45464828|NCT01206985|Other|Von Frey electronic|Change in pain threshold testing mechanical stimulation (von Frey electronic)
45464829|NCT04173338|Drug|Cabozantinib|start at 20mg then increase by 20mg every cycle or until there's a dose-limiting toxicity.
45464830|NCT04173338|Drug|Pemetrexed|Start with 400mg/m2, then increase and maintain 500mg/m2 unless dose-limiting toxicity.
46014253|NCT01365494|Biological|Purified Chick Embryo Cell Inactivated Rabies Vaccine|Two group (Zagreb and Essen) will receive Rabipur vaccine IM according to either Zagreb or Essen schedules.
46014254|NCT00637169|Other|Titration of oxygen therapy|Supplemental oxygen to maintain functional arterial oxygen saturations in one of two saturation target ranges.
46014255|NCT04443218|Device|Edwards PASCAL Transcatheter Valve Repair System|The Edwards PASCAL Valve Repair System is indicated for the percutaneous reconstruction of an insufficient mitral valve.
46014256|NCT04443140|Diagnostic Test|PCR, lung ultrasound|PCR for Covid-19
46014257|NCT04442360|Behavioral|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
46014258|NCT04442204|Other|Prospective study across two time-points examining the impact of viral mitigation protocols on mental health|Prospective study across two time-points examining the impact of viral mitigation protocols on mental health
46014259|NCT04441268|Procedure|primary IOL implantation|implant IOL in capsular bag after cataract extraction
46014260|NCT04328870|Other|oxytocin and spinal anesthesia|start oxytocin 10 IU/200 ml saline at the insertion of the spinal anesthesia
46014261|NCT04328870|Other|General anesthsia|General anesthesia alone.
46014262|NCT04329026|Device|Smart glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
45464831|NCT03933137|Other|Portsmouth Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity (P-POSSUM) score|P-POSSUM score's variables are divided into physiological parameters (age, cardiac, respiratory, ECG, systolic blood pressure, pulse rate, haemoglobin, leukocyte count, urea, sodium plasma, potassium plasma, and GCS) and operative parameters (operation type, number of procedures, operative blood loss, peritoneal contamination, malignancy status, CEPOD).
45464832|NCT01311531|Procedure|Open reduction and fixation with TriMed fragment-specific system|Anatomical reduction, achieved by the open technique.
45464833|NCT01311531|Procedure|Open reduction and fixation with TriMed volar locking plate|Anatomical reduction, achieved by the open technique.
45464834|NCT01207063|Other|Radiotherapy and concurrent chemo-therapy|Radiotherapy and concurrent chemo-therapy
45464835|NCT03531112|Behavioral|Appetite Awareness Treatment + Lifestyle Modification|The AAT + LM intervention includes 16 60-90 minute group sessions to enable participants to be able to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. All sessions involve didactic training, review of self-monitoring of eating episodes, interactive activities, and homework assignments to enable participants to practice learned skills. Participants will be provided a workbook, which will include session content, and self-monitoring forms.
46014263|NCT04329026|Device|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
46014264|NCT00591539|Procedure|Carotid Ultrasound|Bilateral carotid ultrasound measurements: A test that uses sound waves to look at the blood vessels in the neck.
45464836|NCT04796168|Procedure|Splinting (plaster of paris)|Placing stockinette followed by cotton rolls and 10-12 layer of posterior ankle splint made of plaster of paris
45464837|NCT03936491|Drug|Methylphenidate|Methylphenidate is a central nervous system stimulant used for the therapy of attention deficit disorder and narcolepsy.
46014265|NCT00591617|Other|Psychosocial treatment plus Suboxone pharmacotherapy|Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)
46014266|NCT04328987|Procedure|cold snare polypectomy|Resection of colorectal polyp using cold snare polypectomy method. The polyp will be resected by mechanical force of snare without electrical cautery.
46014267|NCT04432844|Procedure|Biplanar Ultrasound guided Internal Jugular Vein Cannulation|Using Philips EPIQ elite ultrasound system with a high-frequency 3D and 4D volume linear array transducer (USG XL 14-3) to obtain the biplanar imaging of Internal jugular vein cannulation.
46099666|NCT00735514|Procedure|assessment of therapy complications|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
46099667|NCT00735514|Procedure|management of therapy complications|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
46014268|NCT01357889|Biological|albiglutide (GSK716155)|subcutaneous injection administered once a week
46014269|NCT01357889|Biological|albiglutide (GSK716155)|subcutaneous injection administered once a week
46014270|NCT02893748|Device|HyGIeaCare Prep|Patients will receive the HyGIeaCare Prep, which is an open colon lavage system using warm water by gravity drip to evacuate the colon by stimulating peristalsis to cleanse the colon prior to colonoscopy.
46014271|NCT02893748|Procedure|Colonoscopy|Screening colonoscopy as per standard of care.
46014272|NCT02893748|Drug|polyethylene glycol (PEG)|PEG preparation to be delivered in two doses - 1/2 the night before and 1/2 the morning of the colonoscopy
46014273|NCT04429256|Other|data collection|retrospective analysis of perioperative data collected from patient medical charts and from a telephone enquiry
46014274|NCT01357850|Drug|GSK716155|GSK716155
46014275|NCT01357850|Drug|Placebo|Placebo
46099668|NCT00735514|Procedure|psychosocial assessment and care|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
46099669|NCT05342831|Other|Biological Nutrition Technique|Biological nutrition technique woman trying Biological feeding technique was applied after each breastfeeding. Breastfeeding self-efficacy and breastfeeding success were assessed at regular intervals.
45464838|NCT03936491|Drug|Atomoxetine|Atomoxetine is a medication used to treat attention deficit hyperactivity disorder (ADHD).[6] Use is only recommended in those who are at least six years old.[6] It is taken by mouth.[6]
46014276|NCT01357655|Drug|Dasatinib|Tablets, Oral, 100 mg, Once daily, approximately 5 years depending on response
46014277|NCT01357655|Drug|BMS-833923|Capsules, Oral, dose to be determined, Once daily, approximately 2 years depending on response
46014278|NCT01357616|Drug|Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension|
46014279|NCT01357616|Drug|Brinzolamide 1% ophthalmic suspension|
46014280|NCT01357616|Drug|Timolol 0.5% ophthalmic solution|
46099670|NCT04763941|Diagnostic Test|CDR assessment face-to-face|The assessment of the CDR is administered once by a psychologist with the patient and his caregiver.
46099671|NCT00739492|Behavioral|financial incentives|financial incentives based on attaining weight loss goals
46014281|NCT01357577|Behavioral|Cognitive behavioral therapy for PTSD|The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.
46014282|NCT01351025|Drug|atorvastatin|10 mg daily for 4 weeks, if no symptoms or lab findings suggestive of atorvastatin toxicity, dose increase to 20 mg daily from week 4- week 20
46014283|NCT01351025|Drug|atorvastatin|Starting at week 24, 10 mg daily for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, 20 mg daily from week 28- week 44.
46014284|NCT01351025|Drug|placebo for atorvastin|One tablet once daily for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, then increase the dose to two tablets once daily.
45464839|NCT05555511|Other|Control Group|Patients will not receive N-Acetylcystiene and will receive standard care according to our institutional protocol
46099672|NCT04141865|Device|Xen|Xen microstent implantation
46099673|NCT04141865|Device|Aqueous shunt|Aqueous shunt implantation
45464840|NCT00890617|Procedure|Cryotherapy (PTC)|CT-guided PTC with the intent to eradicate the entire tumor(s).
45464841|NCT00890617|Drug|Prednisone|"Prednisone taken:~20mg BID on the day of the cryotherapy procedure 20mg BID on the day after the procedure 20mg BID two days after the procedure 20mg AM and 10mg PM three days after the procedure 10mg AM and 10mg PM four days after the procedure 10mg five days after the procedure 5mg six days after the procedure"
45464842|NCT05101382|Other|Observation|Retrospective Observation of standard clinical practice
46099674|NCT04929067|Drug|immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma|immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma
46014285|NCT01349036|Drug|PLX3397|Capsules administered once or twice daily, continuous dosing
45464843|NCT03514498|Procedure|Dental surgery|All types of dental surgery
45464844|NCT03934385|Behavioral|Mental Rehearsal|After each exposure session, participants complete three rehearsal/retrieval exercises that involve viewing images of spiders and completing multiple-choice and free-response questions. Exercises involve retrieving information specific to the spider exposures, reflecting on the experience, and highlighting expectancy violation (i.e., that the participant's feared outcome did not occur).
45464845|NCT03934385|Behavioral|Exposure|All participants complete two exposure sessions. The first set of exposures consists of ten 30-second trials hovering one's hand 3 inches over a live tarantula. The second set of exposures consists of ten 30-second trials placing one's hand inside the spider's terrarium with all five fingertips touching the bottom.
45464846|NCT03711357|Radiation|980 nm diode laser|980 nm high power diode laser device.
45464847|NCT03711357|Other|placebo|the diode laser fiber optic tip will be inserted in root canals, but will not be activated.
46014286|NCT01348763|Drug|Maraviroc|Maraviroc 150 mg daily
45464848|NCT03468946|Other|salty taste perception|"salty taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate salty taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors(high caries risk, medium caries risk, low risk )."
46014287|NCT01348763|Drug|Truvada|daily until 10. day then stop
46014288|NCT01348763|Drug|Darunavir|daily until 10. day then stop
46014289|NCT01346969|Drug|EXC 001|Single-dose administered by injection four different times
46014290|NCT01346969|Drug|EXC 001|Single reduced dose compared to Group 1 administered by injection at the same four time periods as Group 1
46014291|NCT01346969|Drug|EXC 001|Single reduced dose compared to Groups 1 and 2 administered by injection at the same four time periods as Groups 1 and 2
46014292|NCT01346969|Drug|EXC 001|Same sinlge dose as Group 1 administered by injection at the same four time periods as Groups 1, 2, and 3
46014293|NCT04424498|Procedure|Absorbable Rods and Kirschner Wires|A Boyd incision was applied in all patients; olecranon fractures were reduced first and fixed with Kirschner wires. Then, the displaced radial neck fractures were reduced and fixed using absorbable rods.
46099675|NCT03742609|Other|ii) the reminder|Participants assigned to the prompt group were received instruction to use their hearing aid box as a physical prompt to remind participants to use their hearing aid(s)
46099676|NCT03742609|Other|ii) written behavioural plan|Participants assigned to this group were received instruction to create at least one written plan for hearing aid use. Specifically, participants were asked to plan where and when to use their hearing aid(s).
46099677|NCT03742609|Other|iv) all materials|i) provision of written information regarding consequences of using a hearing aid and not using a hearing aid, ii) the provision of a physical prompt for the purpose of prompting or cueing the behavior (hearing aid use) development, and iii) creation of a written behavioural plan for hearing aid use.
46099678|NCT00614003|Behavioral|Decision support skills building Intervention|Decision support skills
46014294|NCT04424342|Other|Pre-test procedure|The Turkish version of CPQ8-10 was subjected to a preliminary test on a group of 20 children, who were not included in the final study, in order to discuss the intelligibility of the items and to determine comprehension problems for children of this age group
46014295|NCT04424342|Other|Test re-test|The Turkish version of CPQ8-10 was administered to 50 children who were asked to complete the questionnaire on their own without any assistance. These 50 children were interviewed for a second time within two weeks to measure the reliability of the test-retest
46014296|NCT01346774|Drug|Cranberry powder capsules|2 cranberry powder capsules twice a day
46099679|NCT04188587|Drug|177 Lu-PSMA-I&T|All patients were intravenous injected with single dose 2.0-8.0 GBq. The time of the next treatment cycle is determined according to the patient's condition, and it is recommended to treat once every 8-12 weeks.
46099680|NCT05300321|Device|frame lens|The subjects were randomized to allocate in Single Vision (SV) lens or Defocus Incorporated Multiple Segments (DIMS) Lens group.
46099681|NCT05215405|Drug|Venetoclax|"Venetoclax will be administered orally once daily (QD), continuously. Each dose of venetoclax should be taken with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast.~Day 1 (200 mg equivalent):~Patients 20 < 30 kg will take 70 mg~Patients 30 < 35 kg will take120 mg~Patients 35 to 45 kg will take 200 mg~Day 2 onwards (400 mg equivalent):~Patients 20 < 30 kg will take 170 mg~Patients 30 < 35 kg will take 250 mg~Patients 35 to 45 kg will take 400 mg"
46099682|NCT05215405|Drug|Navitoclax|"Navitoclax will be administered orally once daily, starting on day 3 of cycle 1 and then may start on day 1 for subsequent cycles. Navitoclax should be taken at the same time each day approximately 24 hours apart. Dosing will be based on the recommended phase II dosing as per the phase I data and subsequent dose recommendations.~Patients 20 < 45 kg will take 25 mg~Patients 45 kg or more will take 50 mg"
46099683|NCT04875247|Device|IOLMaster 700 with central topography|The time needed to perform the measurement using the IOLMaster700 equipment with central topography will be recorded.
46014297|NCT01346774|Drug|Placebo powder capsules|2 placebo capsules twice a day
46099684|NCT04875247|Device|IOLMaster 700 without central topography plus Cassini|The time needed to perform the measurement using the IOLMaster700 equipment without central topography plus the Cassini equipment will be recorded.
46099685|NCT04875247|Device|IOLMaster 700 without central topography plus Pentacam|The time needed to perform the measurement using the IOLMaster700 equipment without central topography plus the Pentacam equipment will be recorded.
46099686|NCT05273411|Dietary Supplement|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone monoester|Single-dose pharmacokinetic study over 4 hours.
46014298|NCT01346696|Device|OsseoSpeed™ TX implant (Ø 4.0 mm, length 6 mm)|
46099687|NCT05273411|Dietary Supplement|Beta-hydroxybutyric acid|Beta-hydroxybutyric acid
46099688|NCT05273411|Dietary Supplement|1,3-Butanediol|1,3-Butanediol
46099689|NCT00613067|Drug|escitalopram|"Start with escitalopram 10mg~According to patient's symptoms, stay on 10mg or increase up to 20mg~Concomitant therapy : up to Xanax 0.5mg, or Ativan 1mg, not allowed above these dosages~Length of washout period will be at least 2 weeks for any psychotropic drugs"
46099690|NCT04652219|Biological|gucy2c cart cells|Patients with advanced malignant gastrointestinal tumors were injected with CART cells
46099691|NCT04649489|Drug|Atezolizumab|atezolizumab 1200mg and bevacizumab 15mg/kg
46099692|NCT04649489|Procedure|Surgery|hepatic resection with post-operative atezolizumab 1200mg and bevacizumab 15mg/kg
46099693|NCT00613145|Drug|Capecitabine and Sorafenib|"During Cycle 1, patients will receive capecitabine alone for the first 7 days (Cohort A will receive 750 mg/m2 of capecitabine twice daily). For Days 8-14 of Cycle 1, patients will receive capecitabine (750 mg/m2 twice daily for Cohort A) combined with sorafenib (400 mg twice daily); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows:~Cohort A will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 750 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle."
45599169|NCT02344719|Procedure|HVPG Measurement baseline|On day 1 (baseline) and day 28 HVPG measurement will be performed
46014299|NCT01346540|Drug|BIBF 1120|VEGF inhibitor
46014300|NCT01346540|Drug|Placebo|BIBF 1120 placebo
46014301|NCT01342913|Drug|Fluticasone Furoate 100mcg/Vilanterol 25mcg|Inhalation Powder
46014302|NCT01342913|Drug|Fluticaosne Propionate 500mcg/Salmeterol 50mcg|Inhalation Powder
46014303|NCT04423250|Other|impact of the intervention of a clinical pharmacist with expertise in sterile medical devices on non-compliances related to the use of sterile medical devices|- Failure to trace, Lack of product information, absence of product in the operating room
46099694|NCT00613145|Drug|Capecitabine and Sorafenib|During Cycle 1, patients will receive capecitabine alone for the first 7 days Cohort B will receive 1000 mg/m2 of capecitabine twice daily for the first 7 days of Cycle 1). For Days 8-14 of Cycle 1, patients will receive capecitabine (1000 mg/m2 twice daily for Cohort B) combined with sorafenib (400 mg twice daily for both cohorts); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows: Cohort B will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 1000 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle.
45837575|NCT02132832|Drug|Buspirone|Buspirone is an anxiolytic compound marked by modulation of both 5-HT1A and D3 receptors. Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
45837576|NCT02132832|Drug|Placebo|Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
45464849|NCT03468946|Other|bitter taste perception|"bitter taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate bitter taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk )."
45464850|NCT03468946|Other|sour taste perception|sour taste perception in high caries risk, medium caries risk, low caries risk. The aim of this study was to evaluate sour taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk ).
45599170|NCT02344719|Procedure|HVPG Measurement day 28|On day 1 (baseline) and day 28 HVPG measurement will be performed
45680086|NCT04133168|Device|Boston Scientific Cardiac Cryoablation System|"The Boston Scientific Cardiac Cryoablation System is intended for ablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF).The main devices and components of the system consists of the following:~POLARx™ or POLARx™ FIT Cryoablation Catheter~POLARMAP™ Catheter~POLARSHEATH™~SMARTFREEZE™ Console~Diaphragm Movement Sensor (DMS)~Related Accessories"
45680087|NCT04104529|Other|Biological collection|The biological collection will also include samples of blood samples collected before and during treatment.
45837577|NCT00614406|Drug|Celebrex|One 400mg tablet daily.
45837578|NCT00614406|Drug|Placebo|One tablet daily.
46099695|NCT03964571|Diagnostic Test|WOUNDCHEK|fluid swab of wound and measurement of wound onto film
45837579|NCT02132910|Other|RESTORE Intervention|
45837580|NCT02133066|Procedure|Bedside Ultrasound-Assisted Site Marking|Patient will receive a bedside ultrasound-assisted site marking of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap using Mindray M7 Ultrasound.
45837581|NCT02133066|Device|Mindray M7 Ultrasound|Patient will receive a bedside ultrasound exam of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap
45837582|NCT02133066|Procedure|Routine lumbar puncture|Lumbar puncture will be performed per routine standard of care
45680088|NCT04104529|Other|tumor collection|Tumor collection (diagnosis) will be done for thyroid cancer and neuroencrine
45837583|NCT00614484|Radiation|Proton Radiation Therapy|A five week coarse of proton radiotherapy begins on day 28 and is given once daily for the first two weeks and twice daily for the final 3 weeks. The total dose given with proton beam is 76 Gy. Weekly chemotherapy with carboplatin and taxol is given during proton therapy.
45837584|NCT00614484|Drug|Taxol|200 mg/m2, IV, for 2 cycles followed by 50 mg/m2 weekly for 5 weeks during radiotherapy.
45837585|NCT00614484|Drug|Carboplatin|AUC 6, IV, for two cycles followed by AUC 2 weekly for 5 weeks during radiotherapy.
45837586|NCT04159974|Drug|Durvalumab 50 MG/ML|IV Infusion
46099696|NCT04593095|Other|NeuroN-QI|SSC session lasting 2-hr during the day 4 times/wk including a 15-min of auditory stimulation with maternal voice and controlled levels of NICU light and noise followed by a 1-hr quiet period where infants will rest in their incubator/crib with olfactory stimulation and where the control of light and noise levels will be continued.
45837587|NCT04159974|Drug|Tremelimumab|IV Infusion, Combination with Durvalumab
46014304|NCT01342796|Biological|MF59C.1-adjuvanted subunit influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
46014305|NCT01342796|Biological|Sub unit, Inactivated, Influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
46014306|NCT01342640|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose 1.2 micrograms/kg subcutaneously every 4 weeks (depending on patient's weight). Dose adjustment may be required in the event of inadequate or excessive treatment response.
46014307|NCT01342484|Drug|placebo|comparison of different dosages of drug (low vs high) vs placebo
46014308|NCT01342484|Drug|BI1356 low dose|comparison of different dosages of drug (low vs high) vs placebo
46014309|NCT01342484|Drug|BI1356 high dose|comparison of different dosages of drug (low vs high) vs placebo
46099697|NCT04578743|Device|Graded Exercise Therapy: ClearPlay(TM)|ClearPlayTM; a novel therapeutic intervention, downloadable to an Apple i-touch or i-phone device, that provides a telemetry-based graded exercise program that enables remote monitoring of symptoms.
46099698|NCT04570085|Drug|Caffeine|100mg caffeine capsule treatment, beginning after caffeine diet during 6 weeks, titrate in 3 weeks (by 100mg stages) until 400mg aim dose per day in 2 doses during 27 weeks, and finally interrupt according to the same negative titration.
45599171|NCT02344719|Drug|Placebo 6g per day per oral for 28 days|Placebo to Taurin 6g per day per oral for 28 days
45599172|NCT03515005|Behavioral|Lay Health Advisor|Patients will meet regularly Lay Health Advisors who will address the social context of their hypertension.
45837588|NCT04142502|Drug|Propofol|Propofol as a sedation drug
45837589|NCT04142502|Drug|Dexmedetomidin|Dexmedetomidine as a sedation drug
45837590|NCT00615420|Dietary Supplement|manuka honey|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
46014310|NCT01342445|Drug|lisdexamfetamine dimesylate|30-mg, 50-mg, 70-mg administered for one week in context of double-blind, placebo-controlled crossover design
46014311|NCT01342445|Drug|Placebo|
46014312|NCT01342211|Biological|Placebo|Intravenous placebo monthly during treatment phase.
46014313|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
46014314|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
46014315|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
46014316|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
46014317|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
46014318|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
46014319|NCT01342211|Drug|Satin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
46014320|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
46014321|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
46014322|NCT01342094|Drug|DE-111 ophthalmic solution|
46014323|NCT01342094|Drug|Timolol ophthalmic solution 0.5%|
45599173|NCT03798743|Drug|Sintilimab Combined With Docetaxel|Sintilimab 200mgi.v q3w Docetaxel 75mg/m2 i.v q3w
46014324|NCT01342094|Drug|Placebo ophthalmic solution|
46014325|NCT01340768|Drug|Sitagliptin|One 100 mg tablet taken orally once daily
45599174|NCT04083183|Biological|Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10|Given IV
45599175|NCT04083183|Drug|Fludarabine|Given IV
45599176|NCT04083183|Drug|Cyclophosphamide|Given IV
45599177|NCT04083183|Biological|Lapine T-Lymphocyte Immune Globulin|Given IV
46014326|NCT01340768|Drug|Sulfonylurea|Participant continued pre-study sulfonylurea therapy (dose as prescribed by the physician). Pre-study sulfonylurea therapy consisted of either glibenclamide, glimepiride or gliclazide.
46014327|NCT01340768|Drug|Metformin|Participants receiving metformin at enrollment, continued pre-study doses of metformin. If necessary, the physician could either discontinue or adjust the dose of metformin during Ramadan.
46014328|NCT01340651|Drug|Ruxolitinib|Ruxolitinib was supplied as SR and IR formulated tablets.
46014329|NCT04423016|Device|Near Infrared Spectroscopy monitoring|Non-invasive continuous monitoring of cerebral oxygenation
46099699|NCT04570085|Drug|Placebo|Placebo capsule treatment, beginning after caffeine diet during 6 weeks, titrate in 3 weeks until 2 doses aim dose per day during 27 weeks, and finally interrupt according to the same negative titration.
46099700|NCT00529399|Drug|GAD-Alum|Participants will receive 3 injections of 20 micrograms GAD-Alum subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
46099701|NCT00529399|Drug|GAD-Alum and Aluminum hydroxide|Participants will receive 3 injections subcutaneously. The first two will contain 20 micrograms GAD-Alum vaccine and are given 4 weeks apart. The third injection will be Aluminum hydroxide alone and will be given 8 weeks after the second injection.
46099702|NCT00529399|Drug|Aluminum hydroxide|Participants will receive 3 injections of Aluminum hydroxide alone, subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
45680089|NCT04085536|Procedure|Dental and medical treatment|If the dental cause of sinusitis is objective, if necessary, dental treatment combined with medical treatment will be carried out.
46014330|NCT04423016|Device|Electrical velocimetry and pulse oximetry|Non-invasive continuous monitoring of cerebral oxygenation
45464851|NCT03468946|Other|sweet taste perception|"sweet taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate sweet taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk )."
46014331|NCT01340495|Radiation|Proton Radiation|45-50.4 Gy(RBE) to the chest wall and 45-50.5 Gy(RBE) once daily, 5 days per week, for approximately 5 1/2 weeks
46099703|NCT00614081|Device|Contrast-enhanced dynamic MRI|
45464852|NCT03403413|Device|muscle vibration during walking|Baseline assessment of gait followed by 12 sessions (3/week for a month) of gait training with cyclic muscle vibration during walking emulating normal muscle activity of lower extremities in treatment group. Gait assessment both with and without muscle vibration were collected at follow-up after 12 sessions of gait training with muscle vibration.
45464853|NCT01299259|Behavioral|Text Message Reminders|Patients in the intervention group will receive text messages on their cell phones following discharge from the emergency department reminding them to make an appointment with their primary care provider. Text messages will be sent daily for 4 days after discharge from the ED.
45464854|NCT01218425|Drug|Methylphenidate 40 mg|Oral dose 40 mg
45464855|NCT01218425|Drug|Levodopa/carbidopa 125 mg|oral dose, 100 mg levodopa, 25 mg carbidopa in one capsule
45464856|NCT01218425|Drug|Domperidon 10 mg|Domperidon 10 mg
45464857|NCT04096586|Other|Red juice|To determine the effects of red juice on satiety and gut health
45464858|NCT04096586|Other|Watermelon juice|To determine the effects of watermelon juice on satiety and gut health
45464859|NCT03443908|Device|CPAP|CPAP therapy 3-4 weeks
45599178|NCT04083183|Radiation|Total-Body Irradiation|Undergo TBI
45599179|NCT04083183|Procedure|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
45599180|NCT04083183|Drug|Mycophenolate Mofetil|Given PO or IV
45680090|NCT04085172|Drug|Guanfacine hydrochloride (TAK-503)|In both Part A and Part B of the study participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg TAK-503 oral tablets once daily for 52 weeks.
46014332|NCT01340300|Behavioral|Exercise training|Two supervised exercise sessions per week
46014333|NCT01340300|Drug|Metformin|Oral metformin QD for two weeks, then BID
45599181|NCT04083183|Drug|Sirolimus|Given PO
46014334|NCT01340300|Other|Educational information|educational information
46014335|NCT01340066|Drug|UISH001|sublingual dosing, 1 drop 3 times a day
46014336|NCT01340066|Drug|matching placebo|sublingual dosing,1 drop 3 times a day
46014337|NCT02893904|Device|EEG monitoring|Steady state concentrations periods of Propofol for EEG data analyzes. Remifentanil was administrated at constant rate in all patients.
46014338|NCT02893904|Device|Target Controlled Infusion|Steady state effect site concentrations of remifentanil administrated to all patients.
46014339|NCT04397627|Procedure|Colorectal resection|All patients undergoing elective colorectal surgery with anastomosis will be included in a prospective database after written informed consent.
46099704|NCT00700479|Drug|aldosterone|4 hour infusion
46099705|NCT00700479|Dietary Supplement|low or high sodium diet|
46099706|NCT00700479|Drug|placebo|placebo
46099707|NCT02624076|Other|Acupuncture|semi-fixed protocol will be used including four local core points; conception vessel (CV) 3, CV 6, and stomach (ST) 29 bilaterally and four in the leg/feet; spleen (SP) 6, and SP 9 bilaterally. The core points CV 3, CV 6, ST 29, SP 6, and SP 9 are thereafter connected to electrical stimulator (Hwoto, China) and stimulated with low-frequency, 2Hz, 0.5 ms
46099708|NCT02624076|Other|expectant management|one initial counselling session, an information leaflet on timed intercourse, access to a telephone helpline for queries and ad hoc support on demand from the fertility clinic over a period of 4 months post randomization.
46099709|NCT05268419|Drug|Ethanol|Inhalation of 35%-ethanol spray
46014340|NCT04309825|Procedure|transgastrostomal endoscopy|Placement the endoscope through the g-tube port and not through the mouth of a patient undergoing an upper gi endoscopy
46014341|NCT05010850|Device|Colovac|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
46014342|NCT05010850|Procedure|Stoma Creation|Protective ileostomy
46014343|NCT05010655|Device|Use of Eko DUO Electronic Stethoscope|Auscultation of heart sounds using electronic stethoscope
46099710|NCT05268419|Drug|Water Distilled|Inhalation of water distilled spray
46099711|NCT00852969|Drug|Niacin|1000 mg tablets once per day
45464860|NCT05621005|Drug|Rifaximin 550 milligram Oral Tablet [XIFAXAN]|Rifaximin was given on dose of 550 milligram every 12 hours orally for at least 3 months
45837591|NCT00615420|Dietary Supplement|placebo gel|Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
46014344|NCT01107535|Biological|Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice.|Synagis (palivizumab) administered according to usual clinical practice. After the enrollment visit, subjects will have monthly visits until they have received the complete Synagis immunization regimen of their hospital, then they will have 2 follow up visits, one of them 30 days after the fifth dose of Synagis and the other visit at one year of age.
45837592|NCT00568854|Biological|BCG|Both arms: diabetics and nondiabetics will receive vaccination in the upper arm with a 0.1-mg intradermal dose of a single strain of BCG (Mycobax, Sanofi-Aventis), which is FDA approved for this indication.
46099712|NCT00852969|Drug|Active Placebo|100 mg Niacin tablets once per day
46099713|NCT04555265|Device|Radiofrequency ablation or microwave ablation|Hepatocellular carcinoma treated by either radiofrequency ablation or microwave ablation
46099714|NCT02618070|Other|Yogurt|
46099715|NCT03870997|Behavioral|Diabetes Digital Intervention|The Diabetes Digital Intervention is a digital campaign that provides interactive ways (e.g., videos, infographics, quizzes) for individuals to learn about influenza and related complications, and the importance of influenza vaccination. It is tailored to people living with diabetes and highlights the importance of influenza vaccination for this specific patient population.
46099716|NCT03870997|Behavioral|Generic Digital Intervention|The Generic Digital Intervention is a digital campaign that provides interactive ways (e.g., videos, infographics, quizzes) for individuals to learn about influenza and related complications, and the importance of influenza vaccination. It provides generic influenza vaccination interventions that can be applicable to any adult who should receive influenza vaccination.
45837593|NCT00569010|Drug|Azacitidine|Group 1 and 3 at Level 0 = 37.5 mg/m^2 IV Over 20-30 minutes Daily for 7 Days Group 2 and 4 at Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days
45837594|NCT00569010|Drug|Ara-C|"Group 1 and 2 at Low-Dose = 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days~Arms 3 and 4 at High-dose = 1 g/m^2 Daily CIV for 4 days (age<65 years) or 3 days (age>=65 years)"
45837595|NCT00616122|Drug|cyclophosphamide|
45837596|NCT00616122|Drug|methotrexate|
45837597|NCT00616122|Drug|sunitinib malate|
46014345|NCT02881294|Drug|SUVN-G3031|
46014346|NCT04420988|Biological|COVID-19 Convalescent Plasma|COVID-19 Convalescent Plasma from recovered COVID-19 patients transfusion into severely or life-threateningly ill COVID-19 infected patients
46014347|NCT02881216|Device|Synergy Stent|Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.
46014348|NCT02881216|Device|Currently common drug-eluting stent (DES)|Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus)
46014349|NCT05010070|Behavioral|diet and lifestyle program|See description of main arm.
46099717|NCT00613457|Drug|dexamethasone|10 mg/sqm/day from for 21 days
46099718|NCT00613457|Drug|asparaginase|native E-coli Asparaginase 5,000 IU/sqm x 8 doses
46099719|NCT00613457|Drug|Asparaginase|native E-Coli Asparaginase 10,000 IU/sqm x 4 doses
46099720|NCT00613457|Drug|cyclophosphamide|1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III
46099721|NCT00613457|Drug|cytarabine|75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III
46099722|NCT00613457|Drug|daunorubicin|30 mg/sqm i.v. 4 doses in Induction phase
46099723|NCT00613457|Drug|doxorubicin|30 mg/sqm i.v. x 4 doses in Protocol II and III
45837598|NCT00616122|Other|laboratory biomarker analysis|
45837599|NCT00616200|Other|Very low carbohydrate diet|4 weeks on strictly controlled low carbohydrate diet
46014350|NCT04309747|Procedure|nanosecond knife liver cancer ablation|This trial is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.
46014351|NCT02881060|Dietary Supplement|Alcohol|
46014352|NCT02881060|Dietary Supplement|Placebo|
46014353|NCT00592085|Behavioral|Questionnaires|Participants will use a computer to complete a series of questionnaires.
46014354|NCT00592085|Behavioral|Motivational Relapse Prevention Counseling|Total of 6 counseling calls for Smoking Relapse: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
46014355|NCT00592085|Behavioral|Relapse Plus Alcohol Risk Reduction Counseling|Total of 6 counseling calls for both Smoking Relapse and Alcohol Risk: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
45837600|NCT00617058|Drug|metformin|open dosed, randomly assigned flexible dose treatment with 250-2000mg/day divided BID or TID
45837601|NCT00617058|Behavioral|healthy lifestyle intervention|additional component to regular psychiatric visits that includes monitoring of lifestyle and eating behaviors.
45837602|NCT00618540|Biological|alemtuzumab|Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
45837603|NCT00618540|Drug|fludarabine phosphate|Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3. (dose adjust if age <12 months)
46014356|NCT04328168|Procedure|ROM exercises, stretching, positioning, gait training|
46014357|NCT04328168|Procedure|by two physiotherapist under the supervision of a doctor|
46014358|NCT02880943|Drug|XOFIGO|"XOFIGO® will be administered intravenously as a bolus injection every 4 weeks with a maximum of 6 administrations per patient.~Four dose levels are available for evaluation : 27.5 kBq/kg, 55 kBq/kg, 88 kBq/kg and 110 kBq/kg.~Starting dose for phase I will be 55 kBq/kg."
46014359|NCT02881021|Other|Rehabilitation program|Standardized conventional evidence-based physiotherapy for treating rotator cuff tendinopathy.
45837604|NCT00618540|Drug|melphalan|Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age <12 months)
45837605|NCT00618540|Procedure|stem cell transplantation|Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation
45837606|NCT00570960|Drug|Dextran 70|dextran 70, 1.0 g/kg on days one, two and three
45837607|NCT00570960|Biological|human albumin|human albumin 1.5 g/kg on day one and 1.0 g/kg on day three
45837608|NCT00571428|Drug|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 15 microgram twice a day (BID)
46014360|NCT02881021|Device|Kinesiotaping|Combined Kinesiotaping techniques (3 strips) for rotator cuff tendinopathy, following the principles of Kenzo Kase et al. (2003).
46014361|NCT04328519|Other|observation|observation
46099724|NCT00613457|Drug|Etoposide|100 mg/sqm i.v. for 3 doses in HR block 3
46099725|NCT00613457|Drug|Ifosfamide|800 mg/sqm i.v.q12h x 5 in HR block 2
46014362|NCT02893202|Other|Therapeutic Horseback riding|An 8-week equine-assisted program designed to especially for veterans. The curriculum consists of eight 90-minute sessions designed to teach basic horse care and riding skills along with communication skills.
46014363|NCT02893982|Radiation|brachytherapy|image-guided navigation of catheter placement for high dose rate (HDR) brachytherapy treatment of patients with primary liver lesions
46014364|NCT04417010|Procedure|Radiofrequency ablation|Both groups of patients underwent radiofrequency ablation
46014365|NCT04425941|Other|artificial intelligence diagnosis|artificial intelligence prediction of colorectal polyp histology
46014366|NCT00597792|Device|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
45837609|NCT00571428|Drug|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 30 microgram once a day (QD)
45837610|NCT00571428|Drug|Placebo|Placebo inhalation solution (citrate buffered 0.9% saline solution) once a day
46014367|NCT00597948|Behavioral|Healthy Lifestyles Curriculum|Three consecutive days of six hours of training comprised of instruction and participant interaction.
46014368|NCT02892006|Behavioral|Improvisational Comedy|6 week curriculum in improvisational comedy. Each class meets for 1.5 hours for 6 consecutive weeks.
46099726|NCT00613457|Drug|mercaptopurine|60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase
45837611|NCT00571974|Device|PDL-585, ScleroPLUS laser|PDT Treatment; emits light with 585 nm wavelength in pulses of 1.5 milliseconds in sections of 5 mm diameter to target the lesion and surrounding tissue
46099727|NCT00613457|Drug|Methotrexate|by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
45837612|NCT00571974|Drug|5-Aminolevulinic Acid (Levulan KerastickTM)|Topically administered; incubation time 60-180 minutes; single dose (345 mg of active 5-ALA in 1.5 ml solution); soaked onto white gauze and applied to lesion, covered with sterile Xeroform gauze
46014369|NCT00598104|Drug|QAX576|
46014370|NCT00598104|Drug|Placebo|
45464861|NCT05657535|Device|Low-intensity continuous ultrasound stimulator|Stimulation 5 minutes, 3 times a day for 4 weeks on the knee
45464862|NCT04770038|Behavioral|Dialectical Behavior Therapy (DBT)|Evidence-based psychotherapy for the treatment of Borderline Personality Disorder
45464863|NCT01224041|Drug|Tacrolimus|oral
45464864|NCT03181828|Drug|Acetohydroxamic Acid Oral Tablet|A single oral dose of 60 mg/kg acetohydroxamic acid rounded to the nearest 250 mg tablet.
45464865|NCT03181828|Other|No treatment|No treatment
45837613|NCT00571974|Procedure|Fluorescence Diagnosis Imaging|FD Image taken prior to PDL-585 usage
45837614|NCT00621348|Drug|Isotonic fluid|0.9% saline with 5% dextrose at standard maintenance rate
46014371|NCT02891928|Device|Rocker sole shoes|Measure of walk testing Measure of standing position
46014372|NCT02891928|Device|Normal shoes|Measure of walk testing Measure of standing position
46099728|NCT00613457|Drug|prednisone|60 mg/sqm daily p.o. for 28 days then tapered in Induction phase
46099729|NCT00613457|Drug|thioguanine|60 mg/sqm p.o. x 14 days in Protocol II and Protocol III
46099730|NCT00613457|Drug|Vincristine|1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1
46099731|NCT00613457|Drug|Vindesine|3 mg/sqm i.v. x 2 doses in HR block 2
46014373|NCT04207632|Drug|Botulinum toxin type A injection|Ultrasound-guided BoNT-A injection in biceps brachii or brachialis
46014374|NCT00598260|Procedure|induction of labor|study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
46014375|NCT00598338|Drug|Prucalopride|4 mg o.d.
46014376|NCT00598338|Other|Placebo|o.d.
46014377|NCT04326348|Drug|TQ05105|TQ05105 is a JAK2 inhibitor.
46099732|NCT04131582|Combination Product|Linagliptin + metformin and Empagliflozin + metformin|Linagliptin-Metformin 2.5/850mg once daily, Empagliflozin-Metformin 12.5/850mg one daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
45464866|NCT01297153|Device|Intraocular Lens (Acrysof IOL)|IOL fixation, material and size are important determinants of immediate and long-term outcome. In-the-bag fixation is the most preferred site of IOL implantation.
45464867|NCT01297153|Device|No IOL|No IOL will be implanted in these eyes
45680091|NCT04085172|Drug|Atomoxetine hydrochloride|Participants in Part A of the study will receive Atomoxetine hydrochloride oral capsule once daily for 52 weeks.
45680092|NCT04085172|Other|Placebo|In Part A participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg placebo matched to TAK 503 oral tablets once daily for 18 weeks and placebo matched to atomoxetine hydrochloride oral capsules at once daily for 18 weeks.
45680093|NCT04081545|Drug|Opioid Anesthetics|see arm/group description
45680094|NCT04081545|Drug|Non Opioid Analgesics|see arm/group description
45680095|NCT04076527|Drug|UDCA|Routine data is collected for UDCA therapy.
46014378|NCT00598416|Behavioral|Family-Responsive Psychoeducation Program (PERF)|Group psychoeducation for HCV patients and their primary caregiver.
46014379|NCT00598572|Drug|Deferoxamine Mesylate|Various dose-regimens ranging from 7 mg/kg to 125 mg/kg (with a maximum allowable total daily dose of 6000 mg at any of the tested dose tiers, regardless of patient's weight), administered daily by IV infusion for three consecutive days.
45680096|NCT04076527|Drug|Ocaliva|Routine data is collected for OCA therapy.
45680097|NCT04073628|Device|Lighting Intervention|Lighting Intervention consisting of a cool or warm light source.
45680098|NCT04064697|Drug|Valganciclovir|The experimental intervention consists of taking the treatment Valganciclovir 900 mg morning and evening for 3 weeks
45680099|NCT04064242|Drug|CMK389|single i.v. dose every 4 weeks
45680100|NCT04064242|Drug|Placebo|single i.v. dose every 4 weeks
45680101|NCT04063215|Biological|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
46014380|NCT04326426|Drug|Tradipitant|Neurokinin-1 antagonist
46014381|NCT04326426|Drug|Placebo|Matching placebo
46014382|NCT00598728|Behavioral|Quality of Life Questionaires|A patient questionnaire, which includes questions on medical morbidities and QOL, will be mailed to participants.
46014383|NCT00598884|Behavioral|Internet-Based Self-Management for Prolonged Grief Symptoms|The treatment consists of empirically derived cognitive behavioral therapy strategies to promote stable and active routines, self-care, accommodation of loss, enhanced self-efficacy, re-engagement in pleasurable activities, and reattachment with significant others. Treatment sessions will be Internet-based and will occur three times per week for 6 weeks.
46014384|NCT00622986|Drug|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
46014385|NCT00622986|Drug|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
46014386|NCT00622986|Drug|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
46014387|NCT00622986|Drug|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
46014388|NCT00599742|Behavioral|Balance training|Physical exercise of balance. The training will last 7 weeks, twice per week, 1 hour per session.
46014389|NCT00599742|Behavioral|Motor training|Motor exercise of power and flexibility. The training will last 7 weeks, twice per week, 1 hour per session.
46099733|NCT04131582|Drug|Metformin|Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
46014390|NCT00599820|Drug|Intravitreal Bevacizumab|
46014391|NCT00599898|Drug|Atosiban|Atosiban group will receive an atosiban bolus (6.75 mg) over 1 min then an intravenous infusion of 300mcg/min for 3 h followed by 100mcg/min for another 45h. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, atosiban will be stopped and the women will receive nifedipine as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
46014392|NCT00599898|Drug|Nifedipine|Nifedipine group: the initial dose will be 20 mg (one tab) orally every 20 min for 3 doses. If the contractions is inhibited, a maintenance dose of 20 - 40 mg every 6 h up to 48 h will be followed. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, nifedipine will be stopped and the women will receive atosiban as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
46099734|NCT05632939|Drug|ASKB589 +CAPOX+Sintilimab|"Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 6 cycles; Capecitabine: oral administration, 1000mg/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Sintilimab was administered intravenously at 200mg. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years.~ASKB589 is administered intravenously at a fixed dose. the drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years."
46099735|NCT00700557|Dietary Supplement|Probiotics - Lactobacillus casei and Bifidobacterium breve|Experimental group:This group received enteral tube feeding or oral diet plus a juice containing 1 sachet (1g) of probiotics (Lactobacillus casei and Bifidobacterium breve - 6x 108 UFC/g) three times a day.
46014393|NCT00599976|Procedure|Pulmonary vein isolation|Pulmonary vein isolation
46014394|NCT00600054|Biological|nimotuzumab (anti EGFR humanized monoclonal antibody)|150 mg/m2 I.V. Induction phase: infusions once a week for 8 weeks. Consolidation phase: infusions once every 2 weeks for 10 weeks. Patients may then continue on the consolidation regimen of nimotuzumab, until disease progression or the occurrence of unacceptable toxicity.
46099736|NCT00700557|Dietary Supplement|Maize starch|Placebo group: This groups received enteral tube feeding or oral diet plus a juice containing,approximately, 725mg of placebo three times a day.
45464868|NCT05449743|Other|Spa therapy|Thermal treatments among the following: pool, Kneipp pool, high pressure shower under immersion in a swimming pool, general jet shower, cataplasm in multiple local application, compress, massage under water or with thermal derivatives, walking corridor
46099737|NCT00695916|Procedure|Breast MRI|
46014395|NCT00600210|Drug|Bevacizumab|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
46014396|NCT00600210|Drug|Carboplatin|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
46014397|NCT00600210|Radiation|Radiation Therapy|"Whole pelvis will be treated to a total dose of 45 Gy in 5 weeks.~Cesium will be used with standard intracavitary systems preferably in two intracavitary applications. An effort should be made to deliver a minimum cumulative external and intracavitary dose to Point A of 85 Gy in 2 insertions."
46014398|NCT00600366|Drug|biphasic insulin aspart|
46014399|NCT00600444|Procedure|Venae sectio|surgical preparation of the cephalic vene to insert a totally implantable access port.
46014400|NCT00600444|Procedure|Punction of V. subclavia|radiological punction of the v. subclavia with Seldinger technique to implant a totally implantable access port
46014401|NCT04326114|Device|Inspiratory training device|Inspiratory training by a Power-breath device
46014402|NCT04326114|Device|Expiratory training device|Expiratory training a Winner-flow device
46099738|NCT04116957|Device|RTLS current tag|Validate location system performance against manual observation of nursing activity
46099739|NCT04116957|Device|RTLS tag revised|Test a next-generation RTLS tag for healthcare process validation
46014403|NCT01326546|Biological|Therapeutic HBV vaccine|Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
46014404|NCT01326546|Drug|entecavir|0.5mg,per day,oral intake.
46014405|NCT01326546|Other|placebo|Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
46014406|NCT00600522|Procedure|Ultrasound-guided hepatectomy|"After laparotomy and staging by intraoperative ultrasound (IOUS), anterior surface of the hepatocaval confluence is exposed. Than, compression by means of the surgeon's finger-tip is applied at the MHV caval confluence verifying at color-Doppler IOUS the disappearance of the blood flow in the MHV or its inversion. Then, MHV clamping itself is carried out, and parenchymal sparing resection would be selected if at least one of these 3 findings is confirmed:~Reversal color-Doppler IOUS flow direction in the peripheral portion of the MHV, which suggests the drainage through collateral circulation in the RHV/LHV depending on the side of the MHV branch with reversal flow.~Detectable shunting collaterals at color-Doppler IOUS with RHV or LHV.~Hepatopetal flow in P5-8 and/or P4inf portal branches. If none of these finding is confirmed and in particular hepatofugal flow direction in the P5-8 and/or P4 inf is detected the hepatectomy has to be extended."
46014407|NCT00600600|Drug|Tigecycline|Tigecycline dosage based on age and clinical status of patient.
46014408|NCT00600678|Dietary Supplement|ProvideXtra DRINK (oral nutritional supplement, food for special medical purposes)|Single, oral administration of nutritional supplement under fasting condition within 2 minutes.
46014409|NCT00623064|Drug|cisplatin|
46014410|NCT00623064|Drug|gemcitabine hydrochloride|
46014411|NCT00623064|Drug|lapatinib ditosylate|
46014412|NCT00623064|Other|pharmacological study|
46014413|NCT00623142|Drug|Hyperbaric Oxygen|100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG
46014414|NCT00623220|Other|N2O|EMONO
46014415|NCT00623220|Other|oxygen|oxygen
45464869|NCT01123811|Drug|Cetuximab IF|Cetuximab loading dose 400 mg/m² weekly dose 250 mg/m² Irinotecan 80 mg/m2 i.v. over 2 hours day 1, 8, 15, 22, 29, 36 Folinic acid 200 mg/m2 over 24 hours day 1, 8, 15, 22, 29, 36 FA will be given as sodium folinate 5-FU 1500 mg/m2 continuous infusion over 24 hours day 1, 8, 15, 22, 29, 36
45464870|NCT05068687|Diagnostic Test|high-resolution PET-CT specimen imaging.|"Included patients are given a single weight-dependent activity of 18F-FDG at the department of Nuclear Medicine. After administration, patients are brought to the operating room where standard of care surgical removal of the malignancy is performed.~The resected specimen(s) are brought to the imaging lab and scanned using a preclinical and/or a dedicated specimen PET/CT device. Following PET/CT imaging, the specimen is brought to the department of pathology, where it is sliced. Some of these slices are then rescanned using the preclinical PET/CT device. Moreover, frozen sections are made from one of these slices with macroscopically visible malignant tissue and placed on an autoradiograph overnight. Finally, the imaging results are then correlated to the results found during histopathological analysis of the specimens."
45464871|NCT03165526|Device|AMPLATZER™ Post-infarct Muscular VSD Occluder|The AMPLATZER™ PIVSD Occluder is intended for percutaneous transcatheter closure of post-myocardial infarct muscular VSDs in patients who are not satisfactory surgical candidates.
45464872|NCT01128101|Drug|Spironolactone|The group who receive spironolactone, the dose employed will be 25 mg each other day and titrated to 25 mg daily according to potassium.
46014416|NCT00600912|Drug|SMOFlipid®|continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
46014417|NCT00600912|Drug|2-ClinOleic 20%®|continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
45464873|NCT01299337|Drug|T3|Given each day of ECT treatment 25 mg for the first 5 days increasing to 50 mg for the duration of treatment.
45464874|NCT03138226|Procedure|uterus transplantation|
45464875|NCT01299415|Drug|Vadimezan™|
45464876|NCT01123967|Other|proactive outreach (PRO)|a mailed invitation letter followed by telephone outreach
45464877|NCT01123967|Other|telephone counseling (TC)|free telephone counseling
45464878|NCT01123967|Other|Nicotine replacement therapy (NRT)|free nicotine replacement therapy (NRT)
45464879|NCT01123967|Other|Usual care (UC)|nicotine replacement products (patch, gum, lozenge, inhaler, and nasal spray)
45464880|NCT03354663|Device|TactiCath SE|Ablation to achieve pulmonary vein isolation.
45464881|NCT01126463|Drug|188Re-SSS Lipiodol|Hepatic Intra-Arterial Administration of radio-active lipiodol.
46014418|NCT00600990|Drug|GW597599|
46014419|NCT00601068|Other|Observational|Group of patients with osteochemonecrosis related to oral bisphosphonate use
46014420|NCT00601224|Behavioral|Social cognition and interaction training (SCIT)|SCIT is a group-based treatment that has the goal of improving social cognition and social functioning for individuals with psychotic disorders. SCIT is composed of three phases: emotion training, figuring out situations, and integration. SCIT will be delivered by two therapists in 20 weekly sessions over 5 months.
46014421|NCT00601224|Behavioral|Treatment as usual (TAU)|TAU will involve routine care and meeting with case-managers and healthcare providers on an as-needed basis.
46014422|NCT00601302|Drug|Amlodipine|
46014423|NCT00601536|Drug|Lithium|
45464882|NCT01299493|Other|Systems-level intervention to promote colon cancer screening|Intervention practices will receive access to, and assistance in implementing, evidence-based strategies for increasing colorectal cancer screening rates.
45464883|NCT03201640|Behavioral|slideshow|Participants will be shown a slideshow showing a child being prepared for surgery
45464884|NCT03201640|Behavioral|virtual|Participants will be shown an immersive virtual reality preparation for surgery
45464885|NCT01224119|Device|Amplex|225 micrograms of B2A per cc of ceramic granules
45464886|NCT01224119|Procedure|Autograft bone|Bone is collected through a separate incision at the iliac crest or tibia.
45837615|NCT00621348|Drug|Hypotonic fluid|Reduced volume (two thirds of standard maintenance rate) of N/5 saline in 5% dextrose
46014424|NCT02891460|Device|40 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
46014425|NCT02891460|Device|80 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
46014426|NCT02891694|Other|in vitro immuno-histo-chemical analysis of corneal epithelium|
46014427|NCT00601614|Drug|temozolomide|
46014428|NCT00601614|Drug|vandetanib|
46014429|NCT00601614|Other|immunoenzyme technique|
46014430|NCT00601614|Other|laboratory biomarker analysis|
46014431|NCT00601692|Drug|cisplatin|Given IV
46014432|NCT00601692|Drug|docetaxel|Given IV
46014433|NCT00601692|Drug|irinotecan hydrochloride|Given IV
46014434|NCT00601692|Radiation|radiation therapy|Given 5 days a week for 3 weeks
46014435|NCT04208022|Other|Respiratory evaluation|Hypermobility and Respiratory evaluation
46014436|NCT00601770|Biological|IC41|injection
46014437|NCT00602004|Drug|losartan|losartan 50 mg a day
46014438|NCT00602082|Drug|capecitabine|
46014439|NCT00602082|Drug|cisplatin|
46014440|NCT00602082|Drug|streptozocin|
46014441|NCT00602082|Genetic|DNA analysis|
46014442|NCT00602082|Genetic|RNA analysis|
45464887|NCT01126697|Drug|Coenzyme Q10 and Lisinopril|Arm 1. Coenzyme Q10: taken once a day each morning by mouth OR Arm 2. Lisinopril: taken once a day each morning by mouth OR Arm 3. Coenzyme Q10 and lisinopril: each taken once a day in the morning by mouth OR Arm 4. Enhanced Standard Care (more doctor visits, muscle and breathing testing, and x-rays for monitoring, but no study medication).
46014443|NCT00602082|Genetic|protein analysis|
45464888|NCT04456114|Device|Acid etched brackets|The brackets will be bonded to the teeth with composite on the same patient in a split mouth design and observed for bracket debonding for 18 months
46014444|NCT00602082|Genetic|proteomic profiling|
46014445|NCT00602082|Other|laboratory biomarker analysis|
46014446|NCT01325532|Device|Active CES|CES current
45464889|NCT04456114|Device|Sandblasted brackets|The brackets will be bonded to the teeth with composite on the same patient in a split mouth design and observed for bracket debonding for 18 months
45464890|NCT05620147|Other|Root canal instrumentation EdgeFile X7 to size #35/0.06|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
45464891|NCT05620147|Other|Root canal instrumentation EdgeFile X7 to size #45/0.04|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
45464892|NCT05620147|Other|Root canal instrumentation EdgeFile X7 to size #45/0.06|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
45464893|NCT05620147|Other|Root canal instrumentation EdgeFile X7 to size #35/0.04|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
46014447|NCT01325532|Device|Sham CES|Sham CES (device off) for 20-minutes each day 5 days/week for 3 weeks.
46014448|NCT04327752|Other|dermatological consultation|Dermatological consultation will be done on every children treated by biotherapy for chronic inflammatory disease in the Amiens hospital.
46014449|NCT04126356|Procedure|mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression.
46014450|NCT05063695|Other|Multimodal Erector spinae catheter protocol|Patients either received multimodal epidural or ESP protocol
46014451|NCT01171963|Biological|GSK Biologicals' liquid human rotavirus vaccine 444563|Oral administration
46014452|NCT01171963|Biological|Placebo|Oral administration
46014453|NCT01171963|Biological|Infanrix™|Intramuscular administration
46014454|NCT01171963|Biological|Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV)|Oral administration
46014455|NCT04315207|Behavioral|Telephone call|"All patients are informed that they will receive a telephone call between 08 AM and 5 PM on workdays, as soon as the results of invasive workup are available. This is expectedly 3 to 5 days after invasive workup. At the telephone call, patients are free to ask for a later call, to summon relatives, to turn on the loud speaker, and/or ask the physician to call one relative of choice to share the information.~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter."
46014456|NCT04315207|Behavioral|In-person meeting|"All patients are provided a written and verbal appointment date 5 workdays after invasive workup, and that they will receive a telephone call if 1) results are not available at the time of the meeting, and/or 2) if results need urgent action (such as small-cell lung cancer).~At the in-person meeting, patients are free to invite family and relatives (up to 4 persons, restriction due to space available).~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter."
46014457|NCT01171183|Drug|controlled release carvedilol|carvedilol (Coreg CR) 80 mg/day in once daily dosing for 12 weeks followed by a 2-week taper
46014458|NCT01171183|Drug|Placebo|Placebo
46014459|NCT04315441|Diagnostic Test|STEPS and AUDIT questionnaires|assessment was done according to World Health Organization STEPS manual for surveillance of risk factors of Non-communicable chronic diseases; and the Alcohol Use Disorders Identification Test. Five cardiovascular risk factors were assessed, smoking, harmful alcohol consumption, obesity/overweight, hypertension and diabetes. Cardiovascular risk was considered high in subjects with three or more cardiovascular risk factors.
46099740|NCT00521365|Drug|Quetiapine 600mg|"300 mg quetiapine fumarate tablets for oral use.~Day 1: One 300 mg tablet in the evening Day 2: Two 300 mg tablet in the evening Day 3 and onwards: Two 300 mg tablets in the evening, efforts must be done to maintain a daily dose of 600 mg/day."
46099741|NCT00695994|Drug|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m2 given as a 1-hour intravenous infusion on day 1 of a 21-day cycle. Docetaxel is re-constituted in 500 mL of normal saline and infused through a peripheral or central venous line. Docetaxel (Taxotere®, Sanofi-Aventis Inc.) is available in 80 mg and 20 mg in 2 mL polysorbate 80, 13% (w/w) ethanol in Water for Injection.
45464894|NCT01220843|Drug|Placebo|dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks
45464895|NCT01220843|Drug|Sevelamer carbonate|dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks ( each tablet :800mg sevelamer carbonate
45464896|NCT02918890|Other|Constraint-induced Movement Therapy|
45464897|NCT02918890|Other|Hand-arm Bimanual Intensive Therapy|
45464898|NCT03933995|Other|no Intervention|no Intervention
45464899|NCT02804932|Dietary Supplement|Super Beets|Nitrate rich beetroot powder (10g/day) for 8 weeks
45464900|NCT02804932|Other|Super Beets Placebo|Nitrate deficient beetroot powder (10g/day) for 8 weeks
45464901|NCT02529215|Behavioral|Just-in-time training (JITT)|The JITT training is a 20 minute simulation-based teaching session targeting: (1) CPR quality and (2) medication administration.
46014460|NCT04315051|Drug|Cohort 1 J. Lividum|Subject to apply DBI-001 Gel on each foot covering all web spaces, the plantar and lateral aspects, toes and toenails
46014461|NCT04315051|Other|Placebo Gel|Subject to apply Placebo Gel daily on each foot covering all web spaces, the plantar and lateral aspects, toes and toenails.
46014462|NCT04315129|Diagnostic Test|Smart Catheter Biosensor|A novel biosensor in-built into the catheter drainage system that monitors the chemical composition of the urine, with the intention of providing early diagnosis of developing infection
46014463|NCT01169779|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
46014464|NCT01169779|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
46014465|NCT01169779|Device|Pen auto-injector|
46014466|NCT01169779|Drug|Metformin|Metformin to be continued at stable dose (at least 1.0 gram per day and not more than 1.5 gram per day) up to Week 24.
46099742|NCT00695994|Drug|gemcitabine and carboplatin|"Gemcitabine (Gemzar®, Lily Inc.) is available in vials containing 1000 mg or 200 mg of active drug formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder.~Carboplatin (Spectrum Pharmaceuticals, Inc.) is supplied as a 10 mg/mL aqueous solution. Unopened vials of gemcitabine are stable when stored at controlled room temperature at 25°C, protected from bright light. It can be diluted in normal saline or 5% dextrose. The solution remains stable for 8 hours at 25°C after reconstitution.~Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. It will be given before gemcitabine at the dose to achieve an AUC of 5 using the Calvert formula.~Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion."
46099743|NCT00711802|Drug|Daptomycin|
45464902|NCT01205191|Behavioral|Cell-phone supported CBT|Cognitive behavioural therapy provided with all-time (ubiquitous) support by cell phone applications
45464903|NCT01205191|Behavioral|CBT with digital audio player support|Cognitive behavioural therapy provided with access to a digital audio player with self-administered materials for stress management and relaxation.
45464904|NCT01205191|Behavioral|CBT|CBT for anxiety disorders
45464905|NCT03468790|Drug|CMAB007|the study drug
45464906|NCT03468790|Drug|Symbicort|asthma-controlled drug
45464907|NCT03468790|Drug|Seretide|asthma-controlled drug
45464908|NCT03468790|Drug|Ventolin|asthma rescue drug
45464909|NCT03468790|Drug|placebo|No active components
45464910|NCT01224197|Drug|TMC435|100 or 200 mg capsule, one single dose
45464911|NCT01224197|Drug|TMC435|100 or 200 mg capsule, once daily for 5 days
45837616|NCT00621348|Drug|Hypotonic fluid|N/5 saline in 5% dextrose at standard maintenance rate
46014467|NCT01169779|Drug|Sulfonylurea|Sulfonylurea if given at screening, to be continued up to Week 24. In patients with a screening HbA1c <8% the dose is decreased by 25% to 50% at randomization and then increased up to the screening dose between Week 4 and 12 as per fasting self-monitored plasma glucose (SMPG) values. In patients with a screening HbA1c >=8%, the dose is not to be changed at randomization. In any case, after Week 12, sulfonylurea is to be continued at a stable dose.
46014468|NCT01169701|Drug|Everolimus|Everolimus was supplied in boxes with 60 tablets. Available tablets: 1.0 mg, 0.5 mg and 0.25 mg.
46099744|NCT00711802|Drug|Standard of Care (SOC)|
46099745|NCT00851877|Biological|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor
46099746|NCT00851877|Drug|Cisplatin|Cisplatin is an anti-cancer chemotherapy drug
45464912|NCT05281237|Device|AveCure 16 Gauge Flexible Microwave Ablation Probe|Microwave ablation of the solitary pulmonary nodule will be performed through a bronchoscopic approach using the AveCure Flexible Microwave Ablation Probe before surgery
46099747|NCT00851877|Drug|Nab-Paclitaxel|paclitaxel albumin-stabilized nanoparticle formulation
46099748|NCT00851877|Radiation|intensity-modulated radiation therapy|intensity-modulated radiation therapy
45837617|NCT00574236|Drug|PS-341, doxorubicin|bortezomib:1.3 mg/m2 IVP over 3-5 sec. days 1, 4, 8, 11 of 21 day cycle doxorubicin: 20 mg/m2 IV over 3-5 min. days 1,8 (one hour after bortezomib) of 21 day cycle
46014469|NCT01169701|Drug|Tacrolimus|Tacrolimus was administrated as Prograf® or Advagraf®, but could not be changed during study.
45837618|NCT00574548|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
46014470|NCT01169701|Drug|Mycophenolic acid (MPA)|Myfortic® (MFS) was given as 720-1440 mg/day or 360-1440 mg/day. Cell-Cept® (MMF) was given as 1000-2000 mg/day or 500-2000 mg/day.
46014471|NCT01168999|Other|spinal manipulation|Spinal manipulation commonly used in the treatment of low back pain and known to be effective for some individuals experiencing low back pain
46099749|NCT00698178|Other|Anthropometric measurements|All patients undergo anthropometric measurements to record body weight, body height and waist circumference on the day of enrollment
45464913|NCT01844362|Procedure|uterine transplantation|Transplantation of the uterus from live donor and IVF treatment.
45464914|NCT01218503|Behavioral|CHOICES - obese|Standard group behavioral weight loss treatment
45837619|NCT00574548|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
45837620|NCT00574548|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
45837621|NCT00574548|Biological|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
45837622|NCT00574548|Biological|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
45837623|NCT00574704|Drug|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 6 visits
45837624|NCT00574704|Drug|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 6 visits
46014472|NCT01168999|Other|sham spinal manipulation|Sham spinal manipulation intended to mimic the studied spinal manipulation
46014473|NCT01168999|Other|Enhanced sham spinal manipulation|"Sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people"
46014474|NCT01167907|Device|0.2% ropivacaine|0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
46014475|NCT01167907|Drug|saline|saline (control) by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
46014476|NCT01166659|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye.
46014477|NCT02886169|Other|High fat meal with Sacha Inchi|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) added with 15ml of Sacha Inchi oil and 125ml of coffee with 10g of sugar
46014478|NCT02886169|Other|high saturated fat meal|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) and 125ml of coffee with 10g of sugar
46014479|NCT01115491|Drug|bevacizumab [Avastin]|Bevacizumab 10 mg/kg body weight will be administered intravenously every two weeks
46099750|NCT03663257|Device|AneurysmFlow|AneurysmFlow R1.0 is an approved (CE labeled, cleared in US, Canada and Argentina), software tool intended to provide relevant information on the blood flow in a cerebral aneurysm and its parent artery based on angiography. It provides color coded and vector field representation of a digital subtraction angiography (DSA). It can quantify blood flow rates in the artery based on DSA and 3-D Rotational Angiogram (3DRA) data. It can visualize blood flow patterns in an aneurysm based on DSA data. Specifically, it calculates the Mean Aneurysm Flow Amplitude (MAFA) ratio to measure the volumetric flow rate quotient before and after Flow Diverter Stent (FDS) implantation in the region of interest. It is manufactured by Philips Medical Systems B.V., a Philips Healthcare company.
46099751|NCT00613223|Drug|Vandetanib and Etoposide|Vandetanib will be given orally once day. Swallow tablet with 240 ml of non-carbonated water. Initial dose is 100 mg/day for stratum 1 & 200 mg/day for stratum 2. Etoposide will be taken by mouth in capsule form at a flat dose of 50 mg/day for 1st 21 days of 28-day cycle. You will not take etoposide for following 7 days of the cycle.
46099752|NCT02617914|Procedure|individualized PEEP treatment, Invasive mechanical ventilation, ECMO,|
46099753|NCT00882908|Drug|TMC435|TMC435 will be administered as one or two 75 mg capsules orally, once daily, for 12 or 24 weeks.
46099754|NCT00882908|Drug|Ribavirin (R)|Ribavirin (R) will be administered as 200 mg tablets (5 to 6 tablets) orally, twice daily, for 48 weeks.
46099755|NCT00882908|Drug|PegIFNα-2a (P)|PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.
46099756|NCT00882908|Drug|Placebo|Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.
46099757|NCT00739570|Device|AAI signature IV AMCT|Chiropractic adjustments of the lumbar spine following the activator basic scan protocol
45680102|NCT04060251|Device|CyMedica e-vive™ System; CY-1000|"All the patients in Group 2 will be given the CyMedica Orthopedics e-vive system 3 weeks before the surgery. The patients will begin using the unit after their first pre-intervention measurements are taken.~Patients will be instructed to apply the e-vive NMES Strength therapy twice a day, 5 days a week. The NMES Strength program is 20 minutes in length. Treatment intensity (adjustable from 1 to 100 in NMES programs) is required to be set at the highest tolerable limit for the patients.~Stimulation from the garment will have the following parameters: frequency of 50 Hz; pulse duration of 5 ms; time on: 12.8 seconds; and time off: 10 seconds. The total contraction time in a 20-minute treatment will be 11 minutes. The waveform will be pulsed and asymmetrical."
45680103|NCT04060251|Other|iGetBetter telemedicine physical therapy|Group 1 patients will only use a Post-Op program from iGetBetter for the first 3 weeks after surgery. After those 3 weeks have elapsed, Group 1 patients will receive outpatient physical therapy in addition to iGetBetter, approximately twice per week for the next 6-8 weeks as all other groups.
46014480|NCT01115491|Drug|temozolomide|Daily by the oral route (dose, 150 mg/m2) on days 1 to 7 and 15 to 21 of each cycle
46014481|NCT01113931|Drug|Doxycyline Hyclate tablet|200 mg tablet, once daily for 7 days
46014482|NCT01113931|Drug|Vibramycin (doxycyline hyclate) capsule|100 mg capsule, twice daily for 7 days, over-encapsulated
46099758|NCT03580967|Drug|Vortioxetine|Oral pill to be taken daily for 8 weeks, 10 or 20 mg dosage. Participants who cannot tolerate this dose may be reduced to 5mg dose.
45680104|NCT04048876|Drug|CC-90001|oral
45464915|NCT03064750|Behavioral|pelvic floor exercises|In preparation for surgery, patients receive individual information by a physiotherapist on pelvic floor anatomy and correct pelvic floor contraction. Patients are told to do the following pelvic floor exercises 3 times a day: 8-12 maximal contractions, hold contractions during 10 seconds, and 3 fast contractions after each long contraction. In addition exercise in groups with skilled physical therapists once a week during 12 weeks.
45464916|NCT03064750|Other|Waiting list|patients wait as usual until surgery without special treatment.
45680105|NCT04048876|Drug|Placebo|oral
45680106|NCT04036279|Procedure|Total Hip Arthroplasty|
46014483|NCT04310761|Procedure|one single blastocyst transfer, both fresh and warmed|Ultrasound guided transvaginal embryo transfer.
46014484|NCT02881879|Biological|Allergovac depot DPT/DF (50:50)|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
45680107|NCT04023591|Procedure|Surgery/Occupational Therapy|Surgery based on function and injury/ Occupational therapy for 48 months post-surgery
46014485|NCT02881177|Drug|Oxytocin|40 IU
46014486|NCT02881177|Drug|Placebo|40 IU
46014487|NCT04187677|Procedure|Sensory Training|The sensory training group includes sensory-oriented interventions and exercises unlike the other classical hand therapy group.
46014488|NCT04187677|Other|classical hand therapy|classical hand therapy
46099759|NCT02624154|Procedure|pancreatectomy|Remove the pancreatic neuroendocrine tumor by surgery
46099760|NCT00851799|Drug|Emtricitabine/tenofovir disoproxil fumarate|"200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).~Other Name: TDF/FTC"
46099761|NCT00851799|Drug|Ritonavir|"100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV"
46099762|NCT00851799|Drug|Atazanavir|"300 mg taken orally once daily. A protease inhibitor (PI).~Other Name: ATV"
45837625|NCT00574704|Drug|CYT003-AllQbG10 in combination with house dust mite allergen extract placebo|subcutaneous injections at 6 visits
46014489|NCT02881723|Procedure|Surgery|
46014490|NCT02881723|Radiation|Radio- chemotherapy|
46014491|NCT04187599|Device|Paragon CRT®100 Contact Lens|Paragon CRT® 100 Contact Lenses for Corneal Refractive Therapy are indicated for use in the reduction of myopic refractive error in nondiseased eyes.
46099763|NCT00851799|Drug|Raltegravir|"400 mg taken orally twice daily. An integrase inhibitor (INI).~Other Name: RAL"
46099764|NCT00851799|Drug|Darunavir|"100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV"
46099765|NCT00521053|Drug|PV-10 (10% rose bengal disodium)|Intralesional injection for chemoablation
46099766|NCT04508777|Behavioral|Saliva-based testing|Participants will take part in a voluntary COVID-19 screening program that includes bi-weekly saliva-based testing.
45464917|NCT01224275|Other|group based care|Midwives is randomized and allocated to group based antenatal care. The midwives have a manual for the model of care.
45464918|NCT03740555|Drug|HNC042 single dose|HNC042,freeze-dried powder,single ascending doses Single dose, Intravenous route,starting dose of 100mg escalating up to 1200mg
45464919|NCT03740555|Drug|Placebo single dose|Placebo single ascending doses , Intravenous route Single dose, matching placebo
45464920|NCT03740555|Drug|HNC042 multiple ascending doses|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, anticipated doses: 300mg to 1200mg
45464921|NCT03740555|Drug|Placebo multiple ascending doses|Placebo, multiple ascending doses, Intravenous route, Multiple doses, daily for 7 days, matching placebo
45464922|NCT02944006|Procedure|multi-parametric MRI|multiparametric MRI is performed in all patients, and the sequence includes dynamic contrast enhanced (DCE) MRI, diffusion weighted imaging (DWI), tissue maps, and MR cholangiography.
45464923|NCT01124123|Drug|Bilastine|20 mg oral tablet
45464924|NCT01124123|Drug|Bilastine|10 mg endovenous bilastine
45464925|NCT03721705|Device|Renew NCP-5|Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.
45464926|NCT01224353|Drug|lipoic acid|Tablet, 600mg, for oral use, 30 min before breakfast, once daily for 6 weeks
45464927|NCT01224353|Other|Placebo|Tablet, placebo, 1-week single-blind placebo treatment then, 30 min before breakfast, once daily for 6 weeks
45464928|NCT05663047|Other|Prevent It 2.0|A free, anonymous, internet-delivered, therapist assisted, cognitive behavioral therapy (CBT) intervention
45464929|NCT05663047|Other|Waitlist|Participants in the waitlist control will wait thirteen weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing problematic sexual behavior.
45837626|NCT00574704|Drug|CYT003-QbG10-placebo in combination with house dust mite allergen extract placebo|subcutaneous injections at 6 visits
46014492|NCT02880787|Drug|Rocuronium|Anesthesia induction with Propofol and maintaining with desflurane. For adult patients, the curare is rocuronium (0.6 mg/kg) For pediatric patients, the curare can be rocuronium (0.6 mg/kg), cisatracurium (0.1 mg/kg) or atracurium (0.5 mg/kg)
46014493|NCT02880787|Device|Neuromuscular monitoring with TOFScan® and TOF-Watch SX®|Each monitor on one arm
45837627|NCT04309630|Procedure|intercostal block|pain control by intercostal block
45837628|NCT04309630|Procedure|erector spina plane block|pain control by erector spina plane block
45837629|NCT01168219|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
46099767|NCT05215769|Behavioral|Health Education|Participate in a video intervention
46099768|NCT05215769|Other|Questionnaire Administration|Complete questionnaires
46014494|NCT04309669|Drug|TOT'HEMA|three ampoules per day during 12 weeks
46014495|NCT02880709|Dietary Supplement|Special diet|Tate and energy content adjusted with spices to obtain maximal intake
46014496|NCT04992637|Behavioral|ClockWork|ClockWork is a behavioral weight loss intervention comprised of coaching sessions as well as digital monitoring and feedback tools. It addresses 4 key behaviors related to the CTS, weight, and health and their Amount, Regularity & Timing-the ART of ClockWork. Women will receive 12 tailored coaching sessions to review their digital monitoring of each key behavior, learn intervention content, and set goals, which are delivered in-person, by phone, or web to fit women's needs postpartum. Coaches will use women's baseline responses to tailor sessions around the key behaviors. The investigators will protocolize real-time monitoring to increase engagement and adherence, and to facilitate just-in-time adaptive reminders, recommendations, and coaching sessions.
46099769|NCT00853047|Drug|Telotristat etiprate|Telotristat etiprate capsules; orally 3 times daily.
46099770|NCT00853047|Drug|Octreotide LAR Depot|A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.
46099771|NCT00853047|Drug|Placebo|Placebo-matching telotristat etiprate capsules; orally 3 times daily.
46099772|NCT04164914|Dietary Supplement|Prebiotic|Soluble prebiotic fiber (resistant dextrin 14 g/d x 4 weeks)
46099773|NCT02613351|Device|scooting|three-wheeled scooter (Monark 662, Monark Exercise AB Sweden) comprised of a single front wheel that provides steering and two rear wheels that create a wide base of support.
46099774|NCT00657722|Other|Angiography and Computed Tomography|Preoperative angiography and Computed Tomography
46014497|NCT04992637|Other|Usual Care|Usual Care consists of an e-newsletter on maternal health, postpartum weight loss, and general calorie guidelines for lactating/nonlactating women.
46014498|NCT04309435|Behavioral|Self-esteem intervention|See relevant study arm for description
46014499|NCT04309435|Behavioral|Self-stigma intervention|See relevant study arm for description
45464930|NCT01207297|Drug|Tacrolimus|"The calcineurin inhibitor is widely administered for organ transplantation，which establish the current method for lupus nephritis (LN).~20 patients with LN were self-assigned the therapy of TAC and prednisone for 12 months. The dosage was adjusted to achieve a whole blood TAC 12 h trough concentration."
45464931|NCT01207297|Drug|cyclophosphamide|20 patients with LN were self-assigned the protolcol of intravenous cyclophosphamide (750mg/m2 per month)/prednisone for six months followed by azathioprine(100mg/day)/prednisone for six months.
45464932|NCT03934151|Procedure|intracorporeal ileocolic anastomosis|laparoscopic bowel transection and ileocolic anastomosis performed inside the abdomen with specimen retrieval in plastic bag
45464933|NCT03934151|Procedure|extracorporeal ileocolic anastomosis|ileocolic anastomosis is carried out by exteriorizing the bowel through a limited laparotomy
45680108|NCT04001751|Behavioral|educational yoga program|"Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yoga."
45680109|NCT03980561|Drug|Varenicline|Active medication
45680110|NCT03980561|Drug|Placebo|Inactive medication
45680111|NCT03976011|Device|Transcutaneous Laryngeal Ultrasonography|"TLU will be performed during the same time period of The gold standard NF (who is performed as usually after endocrine surgeries) by an investigator blind to the NF results, between D1 and D15.~The subject will be his own control, NF and TLU being compared. When facing VF immobility, the subject will benefit from the usual clinical follow up: consultation with NF at 6 weeks and 6 months. TLU will be added to these appointments."
45680112|NCT03975959|Other|QMRP questionnaire|a single consultation for test and questionnaires for a duration of 20 minutes
46014500|NCT04309435|Behavioral|Jumping to conclusions intervention|See relevant study arm for description
46014501|NCT04309435|Behavioral|Control procedure (assessment only)|See relevant study arms for description
46014502|NCT01107379|Device|Relieva Balloon Sinuplasty System|Sinuplasty balloon tools for dilation of sinuses in patients with chronic rhinosinusitis
46014503|NCT01106911|Device|tomosynthesis and screening mammography|All eligible subjects will undergo both full field digital mammography and digital breast tomosynthesis.
46014504|NCT01106677|Drug|Placebo|One matching placebo capsule orally (by mouth) once daily for 26 weeks with protocol-specified doses of metformin immediate release.
45680113|NCT03971409|Biological|Anti-OX40 Antibody PF-04518600|Given IV
45680114|NCT03971409|Drug|Avelumab|Given IV
45680115|NCT03971409|Drug|Binimetinib|Given PO
46014505|NCT01106677|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with protocol-specified doses of metformin immediate release.
46099775|NCT04102475|Other|Eatline|"After discharge from a first hospitalization:~Phone calls at 15 days, 1, 2, 4 and 9 months by a trained psychologist. The phone interview will be guided by the same standardized frame, which was developed by a group of experts and tested with a group of patients. The purpose of this intervention is to provide a therapeutic and motivational approach, with positive reinforcement and reassurance.~Added to treatment as usual (TAU): outpatient visits (at least monthly consultations) or scheduled hospitalizations~6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition"
46014506|NCT01106677|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily for 52 weeks (sitagliptin 100 mg arm) or once daily beginning at Week 26 until Week 52 (placebo/sitagliptin arm). Sitagliptin will be given with protocol-specified doses of metformin immediate release.
45464934|NCT01300897|Procedure|Cortical Evoked Potentials|A probe with 2 ring electrodes is placed in the anorectum. A small amount of electric current is passed separately through the anal and rectal electrodes.. The cortical evoked potentials from the anal and rectal sites are measured.
45464935|NCT01300897|Procedure|Transcranial motor evoked potentials|A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the scalp at the anorectal site on each side, and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.
45464936|NCT01300897|Procedure|Translumbosacral motor evoked potentials|A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the back at the lumbar plexus and sacral plexus levels and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.
46014507|NCT01106677|Drug|Metformin immediate release|The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.
45464937|NCT03818347|Device|oxyhydrogen generator (AMS-H-03)|Rated gas output (L) : 3L/min, concentration of hydrogen and the oxygen was 66.6% and 33.3%, respectively. The patients inhale 3 hours each day through a cannula or mask, and persist for long term
45464938|NCT03818347|Device|analogue machine|This machine has the same apperance and gas condition
45680116|NCT03971409|Biological|Utomilumab|Given IV
46014508|NCT04309045|Behavioral|DBT|Today, the most well-known and established treatment for borderline personality disorder is Dialectical Behavior Therapy (DBT) that developed by Marsha Linhan in the 1990s. DBT is currently used in other disorders such as: eating disorders, addictions, impulse control problems and bipolar disorder. Various studies have found a beneficial effect for this treatment in various areas: decreased suicidal thoughts and attempts and self-harm behaviors, improvements in suicide attempts, anger levels, impulsive behaviors, depressive symptoms, The use of drugs, the percentage of dropouts from treatment, number Hospitalization and general function.
45464939|NCT01220921|Procedure|Lumbar Discectomy|Microsurgical removal of disc that is compressing a nerve root
45464940|NCT01220921|Procedure|Single-level lumbar fusion|pedicle screws with arthrodesis as directed by surgeon. Fusion can be posterolateral, interbody, or both.
45464941|NCT03932435|Drug|Fisrt period TWLO_C|"First Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)"
45680117|NCT03971409|Drug|Liposomal Doxorubicin|Given IV
45464942|NCT03932435|Drug|Fisrt period TWLO|"First Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)"
45464943|NCT03932435|Other|Washout period|7 days
45464944|NCT03932435|Drug|Second period TWLO_C|"Second Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)"
45464945|NCT03932435|Drug|Second period TWLO|"Second Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)"
45680118|NCT03971409|Drug|Sacituzumab Govitecan|Given IV
45680119|NCT03967990|Other|Refined cornmeal flour|48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
45680120|NCT03967990|Other|50/50 refined cornmeal-bran mix|48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins
45680121|NCT03967990|Other|Whole grain cornmeal flour|48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
45680122|NCT03955510|Other|Right time eating|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Each subject will be required to do this intervention twice during the study period. One time they will have right time eating with alcohol , the second time the will have this intervention without alcohol."
45837630|NCT01168219|Biological|Anti-Thymocyte Globulin|Given IV
45837631|NCT01168219|Drug|Azacitidine|Given SC or IV
45837632|NCT01168219|Drug|Busulfan|Given IV
45837633|NCT01168219|Drug|Fludarabine Phosphate|Given IV
45837634|NCT01168219|Other|Laboratory Biomarker Analysis|Correlative studies
45837635|NCT01168219|Drug|Methotrexate|Given IV
46099776|NCT04102475|Other|Control|"After discharge from the first hospitalization:~No specific phone calls~TAU: outpatient visits (at least monthly consultations) or scheduled hospitalizations~6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition"
46099777|NCT00501826|Drug|Cyclophosphamide|Given IV
46099778|NCT00501826|Drug|Cytarabine|Given IV
45464946|NCT03720847|Drug|Estradiol Transdermal Patch 0.1 mg/24 hrs|Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
45464947|NCT03720847|Drug|Oral Micronized Progesterone|100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation
45464948|NCT03720847|Drug|Inactive Clear Patch|Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
45464949|NCT03720847|Drug|Placebo capsule|Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
45464950|NCT01128257|Drug|alendronate|As prescribed by physician
45464951|NCT01128257|Drug|ibandronate [Bonviva/Boniva]|As prescribed by physician
45464952|NCT01205347|Drug|Simvastatin 80mg|Simvastatin 80mg once a day
45464953|NCT01205347|Drug|Simvastatin 10mg|Simvastatin 10mg once a day
45680123|NCT03955510|Other|Delayed time eating|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Each subject will be required to do this intervention twice during the study period. One time they will have delayed time eating with alcohol , the second time the will have this intervention without alcohol."
46014509|NCT04309045|Behavioral|DDP|DDP treatment is part of a trend of dynamic therapies to treat borderline personality disorder. The DDP focuses on deficiencies in the emotional experience processing and is performed in the form of weekly, individual sessions with a trained therapist over a 12-18 month period. Treatment is based on the need to correct three neurocognitive functions responsible for adaptive processing of emotional experiences: association (the ability to recognize, understand their existence, and experience a sequence of emotional experiences), attribution (the ability to make complex attributions about the self and others), and the ability to make realistic attribution, about the self and the other. Interventions that activate these three functions are the basis for DDP treatment.
46014510|NCT04309045|Other|control group|Patients on the waiting list for treatment, or patients in the hospital under routine care.
46014511|NCT04309357|Drug|Alteplase|Alteplase in dose 0.9 mg/kg in acute ischemic patient with indications of thrombolytic therapy
46099779|NCT00501826|Drug|Dexamethasone|Given IV or PO
46099780|NCT00501826|Drug|Doxorubicin Hydrochloride|Given IV
45464954|NCT01218737|Drug|0.3% gatifloxacin and 1.0% prednisolone acetate association|"Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the association and another with placebo. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.~This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15."
45464955|NCT01218737|Drug|isolated 0.3% gatifloxacin and 1.0% prednisolone acetate|"Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the 0.3% gatifloxacin eye drops and another with 1.0% prednisolone acetate eye drops. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.~This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15."
45464956|NCT03818113|Other|cardioplegia with HTK-Bretschneider cardioplegic solution|cardioplegia with HTK-Bretschneider cardioplegic solution
45464957|NCT03818113|Other|cardioplegia with St. Thomas cardioplegic solution|cardioplegia with St. Thomas cardioplegic solution
45464958|NCT03933917|Procedure|Acute Normovolemic Hemodilution|Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
45464959|NCT03818269|Procedure|Subcutaneous pressure measurement|Subcutaneous interstitial measurement at D1 and D2
45464960|NCT01224509|Drug|Mifepristone|Administration of 200 mg of mifepristone orally 48 hours prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
45464961|NCT01224509|Other|Non-treatment|Non-treatment prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
45464962|NCT01329107|Behavioral|Multimodal Intervention|"Patients in the intervention group will be taught to manage their new urinary diversion BEFORE operation. Traing kit will be provided so they can train the procedure forehanded. Second they will get a personally physical training program to optimize the total body function before operation. Nutritional status will be meassured and appropriate advices will be given BEFORE operation.~After operation the intervention group will be mobilised in a fast speed compared to standard care."
45464963|NCT01297231|Other|MRI|"Baseline Breast-MRI within 1 year before starting tamoxifen (allows for surgery, chemotherapy and radiation before the start of tamoxifen).~During Tamoxifen Treatment:~Blood will be drawn for CYP2D6 genotype testing. Analysis of samples will be performed internally at MSKCC.~Follow-up breast MRI after 9-12 months of tamoxifen therapy. In patients whom further breast MRI screening and/or follow-up is clinically indicated, follow-up breast MRIs may be performed within 3 months (before or after) the 2, 3, and 4 year time points during tamoxifen treatment. All breast MRIs will be performed using the same technique.~Follow-up for all patients during and after tamoxifen should include routine standard clinical assessment and imaging such as mammography and breast MRI when clinically indicated."
45464964|NCT03932513|Drug|inarigivir soproxil|Inarigivir 200mg and 400mg oral tablets, once daily
45464965|NCT01300975|Drug|pentavalent antimony|3 intralesional injections of antimony at D1, D3 and D7
45464966|NCT01300975|Procedure|cryotherapy|Frozing of lesions with liquid nitrogen ad D1 and D14
46014512|NCT04985929|Drug|Sildenafil 50 mg|Sildenafil is a phosphodiesterase type-5 inhibitor, which augments/prolongs the naturally occurring nitric oxide mediated vasodilatory pathway. Sildenafil pill is over-encapsulated to be identical in appearance to the placebo intervention.
46014513|NCT04985929|Drug|Placebo|Medical-grade placebo pill, over-encapsulated to be identical in appearance to the sildenafil intervention.
46099781|NCT00501826|Drug|Mercaptopurine|Given PO
46099782|NCT00501826|Drug|Methotrexate|Given IV and PO
46014514|NCT04309279|Behavioral|Zentangle|Zentangle is a mindful doodling process in which participants draw repetitive, structured patterns on small pieces of paper. The patterns consist of combinations of dots, lines, and curves.
46014515|NCT02880397|Drug|Garcinia mangostana|The properties of mangostana includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
46014516|NCT02880397|Drug|Placebo gel|The properties of placebo includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
46099783|NCT00501826|Drug|Nelarabine|Given IV
45464967|NCT01300975|Drug|placebo cream|topical emollient crean 3 times a day during 21 days
45464968|NCT05623813|Other|Postoperative education|provide patients with the understanding and confidence to safely engage in their daily activities whilst following post-sternotomy precautionary guidelines throughout their recovery
45464969|NCT01221467|Device|Overnight closed-loop|The closed-loop system is purpose-built and comprises a hand-held computer containing the algorithm and communicating with the CGM device and the insulin pump.
45464970|NCT01297387|Other|PTA BPG procedure,|Surgery PTA or BPG Procedure, according usual local clinical practice
45837636|NCT01168219|Other|Pharmacological Study|Correlative studies
45837637|NCT01168219|Drug|Tacrolimus|Given PO or IV
45837638|NCT01115803|Drug|LY2584702|Supplied as 25 milligrams (mg) and 100 mg capsules, administered orally for two 28-day cycles.
45837639|NCT01115803|Drug|Erlotinib|"Supplied as 25 mg, 100 mg, or 150 mg tablets, administered orally, daily for two 28-day cycles.~Starting dose is 150mg. Doses may be decreased in 50mg increments if necessary due to toxicity."
45837640|NCT01115803|Drug|Everolimus|Supplied as 5 mg or 10 mg tablets, administered orally, daily for two 28-day cycles.
45837641|NCT01115569|Drug|Hydrocodone Bitartrate|Open-Label, Capsule Strengths 10 mg, 20 mg, 30 mg, 40 mg, 50 mg; by mouth (PO) twice a day (BID) for up to 48 weeks
45837642|NCT01107886|Drug|Saxagliptin|5 mg or 2.5 mg once daily
45837643|NCT01107886|Drug|Placebo|
45837644|NCT01107457|Biological|Ixekizumab|Administered subcutaneously
45837645|NCT01107457|Drug|Placebo|Administered subcutaneously
46014517|NCT01106287|Drug|MK-0941|A single 60, 80, 100, 120 or 140 mg oral dose of MK-0941 will be administered in each period
46099784|NCT00501826|Drug|Pegaspargase|Given IV
46099785|NCT00501826|Drug|Prednisone|Given PO
46099786|NCT00501826|Drug|Venetoclax|Given PO
46099787|NCT00501826|Drug|Vincristine Sulfate|Given IV
46099788|NCT04117191|Dietary Supplement|Doctor's Best L-Tryptophan|2g tryptophan loading once
46099789|NCT02632604|Behavioral|Computerized cognitive training|40 hours of a computerized cognitive training, given 1 hour daily
46099790|NCT02632604|Behavioral|Computer games|
46099791|NCT05171699|Other|electroacupuncture|The patients in Group EA received electroacupuncture at Zusanli (ST36) (located 5 mm below the head of the inferior fibula and 2 mm lateral to the anterior tibial tuberosity) and Baihui (DU20) (located in the midpoint of the parietal bone) acupoints, the stainless steel acupuncture needles were connected to a Hans acupoint nerve stimulator and inserted into the acupoints.
46014518|NCT01106287|Drug|Comparator: Placebo|a single oral placebo will be administered in the designated period (Periods 1-5)
46014519|NCT04309123|Device|TransAeris System|The TransAeris System is a temporary percutaneous intramuscular diaphragm stimulator intended for patients at risk of or on prolonged positive pressure mechanical ventilation. TransAeris is indicated for use in the prevention and treatment of ventilator-induced diaphragm dysfunction (VIDD).
45464971|NCT01124201|Other|Stabilization , strengthening and stretching|Interventions were conducted over 6 weeks, twice per week, lasting 30 minutes each. Sessions were supervised by the investigator, and participants were instructed to report any adverse event. Groups were instructed not to participate in any other physical program during the study. Forty-five patients were randomized into three groups namely: Segmental stabilization group (ES)(transversus abdominis and lumbar multifidus), superficial strengthening group (FS)(rectus abdominis, oblique abdominal muscles and erector spinae muscles) and stretching group (AL) (erector spinae, posterior connective tissues and ischiotibials muscles). Patients were evaluated for pain , functional disability,and ability to contract the TrA before and after the treatment.
45837646|NCT05767008|Other|Sunscreen -R43|Long wear metal oxide particles
46014520|NCT04308343|Drug|Methotrexate|Drugs to treat undisturbed ectopic pregnancies
46014521|NCT04308343|Drug|Letrozole|Drugs to treat undisturbed ectopic pregnancies
46099792|NCT05171699|Other|shame electroacupuncture|The patients in Group SEA received electroacupuncture at a shallow depth and 1 mm lateral to Zusanli (ST36) (located 5 mm below the head of the inferior fibula and 2 mm lateral to the anterior tibial tuberosity) and Baihui (DU20) (located in the midpoint of the parietal bone) acupoints, the stainless steel acupuncture needles were connected to a Hans acupoint nerve stimulator and inserted into the acupoints.
46014522|NCT04308343|Drug|cetrotide|Drugs to treat undisturbed ectopic pregnancies
46014523|NCT01104493|Biological|Monovalent Frozen FluMist®|Single dose of monovalent vaccine (240 subjects) by intranasal spray on Study Day 1.
46014524|NCT01104493|Other|Placebo|Single dose of placebo (60 subjects) by intranasal spray on Study Day 1
46099793|NCT02638610|Device|Cochet-Bonnet aesthesiometer|"The eyelid's sensation will be assessed at 6 points of the eyelid using the Cochet-Bonnet aesthesiometer (Luneau Ophtalmologie, Paris, France). Measurements will take place before surgery, and two weeks, three months and six months after surgery.~This instrument contains a 6 centimeters long, retractable, flexible monofilament. For any given length, when applied perpendicularly to a test surface, the filament will exert a precise pressure before visibly bending. The filament's length inversely corresponds to the pressure exerted by the aesthesiometer such that the shorter the filament length, the more pressure it exerts on the test surface."
46099794|NCT05115227|Behavioral|Education|The team will educate the patient about low back pain and how this can be self-managed.
45464972|NCT01301053|Other|Current UVA intensive care insulin protocol|Current UVA intensive care insulin protocol used for insulin management for 12 hours
45464973|NCT01301053|Other|"Current UVA intensive care insulin protocol with brakes"|"Current UVA intensive care insulin protocol for insulin management with the addition of brakes which reduces insulin administration based on continuous glucose monitoring data between hourly reference glucose data to reduce episodes of hypoglycemia (blood glucose <70 mg/dl)and severe hypoglycemia (blood glucose<50 mg/dl)."
45464974|NCT03932747|Other|pre- Hydratión skin|Measurement of hydration of the skin.
45464975|NCT03932747|Other|post- Hydratión skin|Measurement of hydration of the skin.
45837647|NCT05766969|Drug|CBD/PEA|A water-soluble sublingual tablet containing 10/50 mg of CBD/PEA.
45837648|NCT05766969|Drug|Placebo|An inactive compound.
46014525|NCT01104415|Drug|Telotristat etiprate|Telotristat etiprate capsules orally three times daily.
46014526|NCT01099579|Drug|Atazanavir powder|Powder, oral, dosed by weight. Participants who weighed 5 to <10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg; those who weighed 10 to <15 kg received ATV, 200 mg, and RTV, 80 mg; and those who weighed 15 to <25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
46014527|NCT01099579|Drug|Ritonavir oral solution|Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
46014528|NCT01099579|Drug|Atazanavir capsules|Capsules, oral, dosed by weight in Stage 2. Patients who reached the age of 6 years or a weight of ≥25 kg transitioned from the powder to the capsule formulation of atazanavir (ATV). Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
46014529|NCT01099579|Drug|Ritonavir capsules|Oral, capsules, 100 mg, administered in Stage 2 with atazanavir capsules, dosed by weight.
46014530|NCT01103713|Drug|Azithromycin plus chloroquine|Study drug is a fixed dose tablet of AZCQ containing 250 mg AZ and 155 mg CQ base. All subjects will be administered a 3 day course of AZCQ IPTp regimen: a single dose of 1000 mg AZ/620 mg CQ base (4 fixed dose combination tablets of AZCQ: 250mg/155mg) administered per os (PO, orally) once daily for 3 days (Days 0, 1, 2).
46099795|NCT05115227|Behavioral|Exercise|The team will advice the patient to conduct relevant exercises and to stay physical active.
45464976|NCT01297621|Procedure|reduction mammaplasty|conventional reduction mammaplasty
46099796|NCT00520975|Biological|Bevacizumab|Given IV
46099797|NCT00520975|Drug|Carboplatin|Given IV
45464977|NCT01297621|Other|control|follow up, questionnaire responses
46099798|NCT00520975|Drug|Paclitaxel|Given IV
46099799|NCT00520975|Other|Placebo|Given IV
46014531|NCT01103479|Behavioral|Physician Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training
45837649|NCT05766891|Behavioral|Group 1|Participants will receive hypnosedation will be restarted after arriving in the operating room and will continue for the whole time of surgery
46014532|NCT01103479|Behavioral|Physician and Patient Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training; patients in this condition will also view an educational DVD on CRC and CRC screening
46014533|NCT01103323|Drug|Regorafenib (Stivarga, BAY73-4506)|160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
46014534|NCT01103323|Drug|Placebo|matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
46014535|NCT01103323|Other|Best Supportive Care (BSC)|BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
46014536|NCT01103245|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 12.5mg daily
46014537|NCT01103245|Drug|Aliskiren 150 mg (ALI 150)|Aliskiren 150mg daily
46014538|NCT01103245|Drug|Spironolactone (SPL 25)|spironolactone 25mg daily
46014539|NCT01103245|Drug|Aliskiren 300 mg (ALI 300)|Aliskiren 300mg daily
46014540|NCT01103245|Drug|Spironolactone 50 mg (SPL 50)|Spironolactone 50 mg daily
46014541|NCT04307875|Diagnostic Test|Blood pressure measurement (sphygmomanometer)|measuring blood pressure with standard sphygmomanometer
46014542|NCT04307875|Diagnostic Test|Blood glucose measurement|measuring blood glucose using standard measurement devices
46014543|NCT04307875|Other|psychometric tests|WHODAS 2.0, PHQ-9, CAPS-5
46014544|NCT02878837|Drug|Dexmedetomidine|
46099800|NCT00520975|Biological|Trastuzumab|Given IV
46099801|NCT03886415|Drug|Jaktinib hydrochloride tablets|Jaktinib hydrochloride tablets 100mg bid dose group and Jaktinib hydrochloride tablets 200mg qd dose group
45464978|NCT01224587|Drug|D1000078|Oral, one single dose
45464979|NCT01224587|Drug|D1000082|Oral, one single dose
45464980|NCT01224587|Drug|D1000083|Oral, one single dose
45464981|NCT01224587|Drug|D1000085|Oral, one single dose
45837650|NCT05766891|Behavioral|Group 2|Participants will receive standard general anesthesia and medications to control your pain after arriving in the operating room
46014545|NCT02878837|Drug|Midazolam|
46014546|NCT02880007|Radiation|External Beam Radiation Therapy|45 Gy pelvis / 25 fr
46014547|NCT02880007|Radiation|PDR Brachytherapy|1 puls/hour ; 12 Gy / day
46099802|NCT04159298|Device|Top Spin 360|The TopSpin360 is a dynamic multi-planar neuromuscular training device that has been shown to improve static and dynamic multi-planar neck strength in a healthy athletic population
46099803|NCT04451681|Other|Cardiopulmonary exercise test|Data such as oxygen consumption, cardiac parameters and speed of the patient are analyzed numerically on the treadmill in the KPET; Objective performance values such as maximum oxygen use (VO2max), maximum heart rate, respiratory capacity, and maximum rate will be obtained.
46099804|NCT02638532|Procedure|Foot Fat Pad Grafting|Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.
45464982|NCT01301131|Other|Probiotics|80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily
46099805|NCT03575429|Behavioral|Engagement Intervention|"Family navigators will use MI to engage families to decrease resistance and build motivation and commitment to challenging behavior changes by eliciting and reflecting broader goals and values, linking those values to specific behavior change, and negotiating a menu of options for change based on individual preferences. PSE will be used by the Family Navigators to guide families in selecting an objective, measurable problem, then proceed through a series of steps that involve goal setting, brainstorming and evaluating solutions, choosing a solution, and action planning."
45464983|NCT01301131|Other|control|usual oral care
46014548|NCT02880007|Drug|Cisplatin|increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy
46099806|NCT03575429|Behavioral|Engagement + Coaching Intervention|ESI program planning entails identifying goals and objectives for the child and teaching strategies and supports for parents. Each session includes the following components: 1) setting the stage to develop that visit's agenda and gather updates; 2) intervention implementation that must include the following steps to coach the parent: a) review the objective, b) use modeling, guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to the parent, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and 3) summarize plans for parent implementation between sessions. Families are invited to Autism Navigator How-To Guide for Families, a self-guided web-based course, with an online weekly group meeting.
46099807|NCT00657800|Behavioral|Intensified inpatient diabetes education program (IDEP)|Assessment of educational needs and coordination of inpatient unit based education program by Certified Diabetes Educator (CDE)
46099808|NCT00614159|Drug|Ketamine|Weight based dosage for Peds subjects, used for duration of the endoscopy.
46099809|NCT00614159|Drug|Propofol|Weight based dosage for Peds subjects, used for duration of the endoscopy.
46099810|NCT04159532|Dietary Supplement|MAG-EPA/MAG-DHA|monoglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
46099811|NCT04159532|Dietary Supplement|TG-EPA/TG-DHA|Triglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
46099812|NCT04159532|Dietary Supplement|EE-EPA/EE-DHA|Ethyl ester of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
46099813|NCT03548675|Drug|TCA treatment|All patients fulfilling inclusion criteria will be genotyped for CYP2C19 and CYP2D6 genes. Based on the genetic test results patients will be classified into a metabolisation phenotype (UM, EM, IM or PM).
46099814|NCT00735592|Other|Observational|Retrospective data obtained from electronic files
46099815|NCT04159064|Diagnostic Test|Thromboelastometry, Impedance Aggregometry|Study of coagulation changes after cardiac surgery on CPB using Minimal Extracorporeal Circulation
46099816|NCT00613535|Device|Mechanical debridement|Mechanical shaver will be used to remove large chondral flaps and loose fragments
45464984|NCT01221545|Drug|AZD1656|3 escalating dose levels are planned. Administration of the escalating doses of AZD1656 will be based on review of available safety from the previous dose.
45464985|NCT01221545|Drug|Placebo|Placebo
45464986|NCT01218581|Drug|received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)|
45464987|NCT01124279|Drug|AMG 853|Single dose administration of AMG 853 in tablet form to healthy adult subjects
45464988|NCT01205425|Other|PCI on the basis of coronary angiography|Interventional cardiologist will be blinded to the images obtained by CT. The PCI procedure will be planned and performed solely on the basis of invasive coronary angiography
45464989|NCT01205425|Procedure|CT guided PCI|The results of the CT scan will be analysed by the interventional cardiologist that is to perform angiography and PCI. Based on this analysis preliminary procedural strategy is planned (stent diameters, decision on direct stenting vs. predilatation, decision on postdilation)
46014549|NCT04982029|Drug|Cannabidiol 100 MG/ML [Epidiolex]|600mg
46014550|NCT04982029|Drug|Placebo|Matching placebo
46014551|NCT01098487|Drug|Eltrombopag olamine|Thrombopoietin receptor agonist
46014552|NCT02880085|Drug|Local anesthetic|local injection
46014553|NCT00591890|Drug|indibulin|dose escalation of indibulin given twice daily for 21 days, to be repeated every 28 days.
46014554|NCT02878993|Device|Recording of diaphragm EMG|Recording of diaphragm EMG prior to extubation using surface diaphragm electromyography
46014555|NCT01098097|Biological|Peginterferon alpha|Peginterferon alpha given in combination with ribavirin according to local labeling guidelines
46014556|NCT01098097|Drug|Ribavirin|Ribavirin given in combination with peginterferon alpha according to local labeling guidelines
46014557|NCT01097863|Device|nelfilcon A contact lens, modified inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with modified inversion indicator
46099817|NCT00613535|Device|Paragon T2|Use Paragon device to debride after removal of larger chondral lesion flaps with mechanical shaver.
46099818|NCT00613535|Procedure|Lavage debridement|Remove loose chondral fragments
46099819|NCT00613535|Device|Mechanical Debridement|Use of a mechanical device such as a shaver, punch, or biter to remove large chondral flaps and loose fragments
46099820|NCT00613535|Device|RF- based Debridement|Use of debridement device to remove large fragments followed by use of RF-based debridement to smooth the base of the shoulder of the tear.
46099821|NCT04064398|Procedure|Aspiration of gastric residuals|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
46099822|NCT00729040|Behavioral|Stepping Up to Health|Internet-mediated walking program with pedometers, goal-setting and tailored messaging
46014558|NCT01097863|Device|nelfilcon A contact lens, no inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with no inversion indicator
46099823|NCT05042531|Drug|Azacitidine|Azacitidine, 75mg/m2,d1-7;Treatment cycles every 28 days
46099824|NCT05042531|Drug|Dasatinib|dasatinib,20mg,po,qd,treatment cycles every 28 days
46099825|NCT00851721|Biological|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period
46099826|NCT00851721|Biological|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|FEIBA NF dose and dosing interval as prescribed by the treating physician
46014559|NCT01097863|Device|nelfilcon A contact lens, inversion indicator|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear, with inversion indicator
46014560|NCT04407572|Other|Serum zinc, vitamin d vitamin b12 levels .|Serum zinc, vitamin d vitamin b12 levels of 45 patients will be measured and evaluated together with the information of the patients.
46014561|NCT04406090|Other|Mechanical Trombectomy|Stent retriever for treatment of cerebral arterial occlusions
46014562|NCT04404920|Other|Questionnaire|"Novel questionnaire about oral symptoms (Oral symptom assessment scale / OSAS), and validated questionnaire about physical and psychological symptoms (Memorial Symptom Assessment Scale / MSAS)."
46099827|NCT00657956|Device|Advance Biofoam porous metal backed tibial component with or without screw augmentation|total knee arthroplasty tibial component that has a backing of porous titanium metal to facilitate bone in-growth
46099828|NCT04409093|Procedure|Nail bed repair with eponychial sent|The nail bed repair will be performed with 6-0 chromic suture material. After the nail bed repair, an eponychial stent will be secured under the eponychial fold with suture. The stent can be the native nail plate, suture container foil, or nonadherent gauze (i.e. Xeroform). If the injury avulsed the nail plate and the patient presents without it, either the foil from the suture wrapper/container or a piece of nonadherent gauze (i.e. Xeroform) will be used as a stent. A nonadherent sterile dressing will be applied to the digit, and each patient will be discharged with a 5-day course of cephalexin for prophylaxis against infection.
46099829|NCT04409093|Procedure|Nail bed repair without eponychial stent|The nail bed repair will be performed with 6-0 chromic suture material. After the nail bed repair, an eponychial stent will not be secured under the eponychial fold. A nonadherent sterile dressing will be applied to the digit, and each patient will be discharged with a 5-day course of cephalexin for prophylaxis against infection.
46099830|NCT02634632|Behavioral|Choosing to write advance directives|
46014563|NCT04405232|Other|Non-interventional|Observational study
46099831|NCT05563714|Behavioral|Clinician Notification with Nurse Facilitation (CNNF)|An anticoagulation clinic nurse sends a templated message to the patient's target clinician that identifies the patient as high risk for upper GI bleeding, summarizes guidelines on appropriate antiplatelet medication use and PPI gastroprotection, and recommends that the clinician consider either discontinuing the patient's antiplatelet medication(s) or initiating a PPI for gastroprotection. The nurse will also offer to pend the order for a PPI if the clinician wants to initiate a PPI and will provide education to the patient on any medication changes recommended by the clinician.
45464990|NCT03930719|Diagnostic Test|Stroke screening tools|"Patients are evaluated for the presence of PSD using DSM-5 criteria (gold standard). Established delirium detection tools are evaluated for their diagnostic accuracy compared to the gold standard."
46099832|NCT05563714|Behavioral|Wait list control|The anticoagulation clinic will not send the clinician notification letter or other project-specific materials to the clinician or patient, and the patient will be included on a list of patients who will receive the intervention at the conclusion of the trial.
46099833|NCT04071119|Drug|Oxytocin nasal spray|Participants administer the oxytocin (40 IU) twice a day for 5 - 7 days
45464991|NCT01126853|Biological|Twinrix|Up to three intramuscular doses of 1cc of Twinrix (combined hepatitis A/B vaccine) at 0, 1, and 6 months post-enrollment
45464992|NCT03824821|Other|No intervention|No intervention
45464993|NCT03825133|Procedure|Bone Marrow Aspirate Concentrate|Bone marrow ( 100 ml) is aspirated from proximal tibia, concentrated in Arthrex Angel Centrifuge, and after concentration 6 ml of BMAC is injected in the knee
45464994|NCT03825133|Procedure|Leukocyte Rich Platelet Rich Plasma|Blood sample is taken ( 100 ml), centrifuged in Arthrex Angel Centrifuge and after double spinning process about 6 ml of PRP is injected in the knee
46099834|NCT04071119|Drug|Placebo|Participants administer the placebo (40 IU) twice a day for 5 - 7 days
46099835|NCT00740038|Behavioral|Stress Management training|Self-administered stress management training comprising 10 minute introduction by staff, & provision of DVD, CD,brochure, and workbook. Materials provide overview of sources of stress during chemotherapy, and instruction in cognitive-behavioral stress management techniques (paced abdominal breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements). Daily use is encouraged over 13-14 weeks of the study.
45464995|NCT03825133|Drug|Hyaluronic Acid|Three injections of Cartinorm (1% Sodium Hyaluronat (20mg/2 ml) by Goodwill Pharma) is injected in the knee weekly
45464996|NCT01224743|Dietary Supplement|Blend 1|Blend 1 consists of a combination of Juice Plus+® Orchard (Fruit), Garden (Vegetable), and Vineyard (Berry) blends
45464997|NCT01224743|Dietary Supplement|Blend 2|Blend 2 consists of a combination of Juice Plus+® Orchard (Fruit) and Garden (Vegetable) blends
45464998|NCT01224743|Dietary Supplement|Placebo|Placebo capsules are provided by the study sponsor and are identical in appearance to active treatments to ensure blinding.
46014564|NCT04404452|Device|Use of Eko CORE and Eko DUO electronic stethoscopes|Auscultation of heart and lung sounds using electronic stethoscopes
46014565|NCT04328636|Drug|Nebulized Magnesium Sulfate|Nebulized magnesium sulfate (isotonic solution) 256 mg every 15 minutes
46014566|NCT04328636|Drug|Intravenous Magnesium Sulfate|Intravenous magnesium sulfate 200 mg/kg over 30 minutes, followed by a continuous infusion at a rate of 50 mg/kg/hour
46014567|NCT04403828|Other|Survey|a cross-sectional, online survey-based study administered to Dentist in Egypt. A 20-item questionnaire developed and distributed using Google Forms.
46014568|NCT02893826|Drug|EG-1962 (nimodipine microparticles)|
46014569|NCT02893826|Drug|Enteral Nimodipine|
46099836|NCT00740038|Behavioral|Exercise Training|Home-based exercise (walking) program: brief introduction by staff (10 minutes) and provision of packet with DVD, brochure, workbook, pedometer (electronic step counter) along with instructions on initiating and maintaining a walking program. Dose Recommendations: 3-5 exercise session per week for at least 20-30 minutes at maximum intensity of 50 to 75% of their estimated heart rate reserve (RPE of 11-13) which is calculated based on their age and resting pulse.
45464999|NCT03817567|Drug|recombinant anti-EGFR monoclonal antibody|Experimental: Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
45465000|NCT03932591|Procedure|kinesio taping method|Kinesio tape is an elastic, adhesive, hypo-allergenic, latex-free tape. Kinesio taping method is rehabilitative taping technique. One of the purposes of this technique is to facilitate or inhibit the muscles.
45465001|NCT03932591|Procedure|Sham kinesio taping|Sham kinesio tape will be used for controlled group. 2,5 cm width, 5 cm length, skin color 2 pieces kinesio tape will be applied on medial and lateral head of gastrocnemius muscle without stretch. 5 cm length, 5 cm width, skin color 1 piece kinesio tape will be a
45465002|NCT01127009|Drug|bortezomib|Given IV
45465003|NCT01127009|Drug|mitoxantrone hydrochloride|Given IV
46099837|NCT00740038|Behavioral|Usual care|Usual psychosocial care and provision of NCI booklet, Chemotherapy and You (NCI, 1999) which gives general feedback about fitness testing, exercise and stress management during chemotherapy. Recommended to read booklet at least once.
46014570|NCT00591968|Device|SonoSite Titan portable ultrasound coupled with email telediagnosis|"Sonographic exam will be performed by principal investigator. A first-look diagnosis, correlated with patient symptomology and laboratory analysis, will be made at the point of care. Using a store-and-forward framework, properly formatted non-compressed sonographic images and Request for Interpretation (RFI) forms will be transmitted to participating radiologists. RFI forms will be used to record diagnostic findings and rate the quality of the images and/or diagnostic value using a five-point Likert scale. RFI forms will also include a five-digit patient number, age, sex, and symptomology / reason for sonographic exam. Completed RFI forms will be transmitted back to the clinic at the radiologist's earliest convenience."
46099838|NCT00740038|Behavioral|Combined stress management and exercise training|Home-based, self-administered stress management and exercise (walking) program: brief introduction by staff and provision of DVD, CD, brochure, pedometer, workbook. Dose Recommendations: walking/exercise program (3-5 times per week for at least 20-30 minutes) and use of CD (progressive muscle relaxation with guided imagery) and coping statements once per day.
46099839|NCT02634476|Behavioral|Alcohol approach/avoidance task|The approach-bias modification is a computerised alcohol approach/avoidance task (alcohol-AAT) in which participants are instructed to respond with an approach movement (pulling a joystick) to pictures in landscape orientation and an avoidance movement (pushing a joystick) to pictures in portrait orientation. The size of the image is increased and decreased by pulling and pushing the joystick respectively, generating a sensation of approach or avoidance. Pictures include images of 20 alcoholic and 20 non-alcoholic drinks presented in a fixed orientation such that participants are in effect instructed to respond to pictures of alcohol by making an avoidance movement (pushing the joystick) and to pictures of non-alcoholic soft drinks by making an approach movement (pulling the joystick).
46099840|NCT02634476|Behavioral|Sham approach/avoidance task|The computerised training for the sham condition is the same as for the experimental condition, except that in the sham approach/avoidance task, both landscape and portrait pictures all contain neutral (non-alcohol related).
45465004|NCT01127009|Drug|etoposide|Given IV
45465005|NCT01127009|Drug|cytarabine|Given IV
46099841|NCT04385303|Drug|Lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 m vehicle
46099842|NCT04385303|Drug|Placebo|One intra-articular injection of 0 mg lorecivivint in 2 m vehicle
46099843|NCT00654602|Drug|Rosuvastatin|
45465006|NCT01127009|Other|flow cytometry|Correlative studies
45465007|NCT03817411|Drug|Telatinib|300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.
45465008|NCT03817411|Drug|Capecitabine|1000 mg/m²,twice daily for 14 days followed by a 7-day rest period (14 days on/7 days off schedule).
45465009|NCT03817411|Drug|Oxaliplatin|130 mg/m2, administered intravenously over 2 hours, on Day 1 every 3 weeks (one administration per cycle) for a maximum of 6 cycles.
45465010|NCT03817411|Drug|Placebos|300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.
45680124|NCT03955510|Procedure|Sigmoidoscopy|Subjects will undergo unprepped sigmoidoscopy to collect tissue and stool sample at each intervention visits (visit 2, 3, 4, and 5). Flexible sigmoidoscopy will not require any colon cleansing and it will be very limited to the most distal (closest to the end of the anus) 20 centimeters (approximately 8 inches) of the colon and thus will be far less uncomfortable than the routine flexible sigmoidoscopy.
46014571|NCT00592046|Drug|ZIO-101 (Darinaparsin)|ZIO-101 (Darinaparsin) given for five consecutive days to be repeated every 28 days for up to six months. This is a dose escalation study.
46014572|NCT02893280|Drug|aspirin, clopidogrel, statin, enoxaparin, streptokinase|Acute coronary syndrome treatment
45465011|NCT03817645|Other|Zeolite|The natural zeolite clinoptilolite is of volcanic origin. The mineral belongs to the group of zeolite minerals. Zeolites are silicates with a microporous structure. This results in a stable structure with nanometer-sized cavities that pass through the natural zeolite clinoptilolite - comparable to a mineral sponge. Due to the numerous pores and channels, the mineral has a large internal surface and it can absorb molecules that are smaller in diameter than the pore openings. Since zeolite clinoptilolite has an anionic charge, there are cations such as Na +, K +, Ca 2+, Mg 2+ which can be exchanged for other ions (e.g., Pb^2+) in the cavities for electrical charge balance. In particular, the ion exchange capacity is essential for the effect and is used in many areas.
45465012|NCT01218815|Procedure|IRA stenting in culprit lesion only|stenting
45465013|NCT01218815|Procedure|IRA stenting|Complete IRA revascularization
46014573|NCT02893436|Procedure|Surgery with tracheal intubation curarisation|
46014574|NCT02893358|Drug|Allisartan Isoproxil|Allisartan Isoproxil 80mg once daily taken in the morning during 8:00-9:00. To achieve the target blood pressure allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan isoproxil. Duration: 12 months.
46014575|NCT02893358|Drug|Placebo|Corresponding placebo once daily taken in the morning during 8:00-9:00. Duration: 12 months.
46014576|NCT04390802|Drug|5-aminolevulinic acid|Study participants who are deemed surgical candidates for management of their pituitary lesion will drink 20mg/kg 5-ALA 2-4 hours preoperatively. They will then be taken to the operation room and undergo general anesthesia. Intraoperative blood draw may occur from lines places for anesthesia purposes at any time during the operation. In alignment with the neurosurgeon's practice and discretion, the sella will be accessed and opened. During the surgical exploration of the sella, the surgeon will attempt to identify the pituitary mass. The location of the tumor will be assessed using the blue-light filtered microscope or endoscope. These steps will be documented photographically during the operation. A biopsy of the fluorescent region will be taken to confirm pituitary adenoma histopathology. The tumor will then be maximally resected. The tumor sample will be used for further clinical testing as part of the patient's routine care.
46014577|NCT04328480|Drug|Colchicine|"The colchicine dosage schedule will vary according to the following scenarios:~In patients not receiving Lopinavir/Ritonavir~Loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)~The next day 0.5 mg bid for 14 days or until discharge.~In patients receiving Lopinavir/Ritonavir~Loading dose of 0.5 mg (day 1)~After 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.~Patients under treatment with Colchicine that are starting with Lopinavir/Ritonavir~Dose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir.~Continue with 0.5 mg every 72 hours for 14 days or until discharge.~Only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube."
45465014|NCT01205737|Biological|TL011|375 mg/m2 iv every 3 weeks for 8 cycles
45465015|NCT01205737|Biological|Rituximab|375 mg/m2 iv every 3 weeks for 8 cycles
45465016|NCT01124357|Device|NovaSure|Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
46014578|NCT04328480|Other|Local standard of care|Local standard of care for COVID-19 SARS moderate /high-risk patients
46014579|NCT04382222|Procedure|prenatal ultrasound|prenatal cardiac ultrasound
46099844|NCT00654602|Behavioral|Maintenance of specific diet|
45465017|NCT01124357|Device|thermachoice|ThermachoiceTM III thermal balloon ablation
45465018|NCT03934073|Other|DEXTRAIN|12 sessions of 1 hour of rehabilitation (3 sessions / 4 weeks) for the DexTrain group will consist of 20 minutes of conventional training followed by 40 minutes of exercises using the DexTrain targeting the dexterity components.
45465019|NCT03934073|Other|CONVENTIONNELLE|12 sessions of 1 hour of rehabilitation (3 sessions / 4 weeks) Conventional will be constituted of conventional training consisting of stretching of the spastic muscles as well as exercises used classically in the protocols of rehabilitation post-stroke
45465020|NCT03934073|Other|CONTROLE|Only one assessment will be provided for the control group which will include, Box & Blocks Test (BBT), FFM Dexterity Assessment, Moberg Pick-Up Test (MPUT), Maximal Finger Tapping Rate, Proprioception, SMT, fMRI, Spontaneous hand activity (accelerometry / portable electromyography)
45465021|NCT03817723|Radiation|c-arm cholangiography|
45465022|NCT01218893|Drug|Chloroquine prophylaxis|The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
46099845|NCT00740194|Drug|Aromatase inhibition|Letrozole
46099846|NCT00740194|Drug|Estradiol|Dermestril
46099847|NCT00658034|Procedure|Acupuncture|Subjects will receive acupuncture weekly for six weeks. Subjects will complete a Brief Fatigue Inventory (BFI) questionnaire, a Functional Assessment of Cancer Treatment scale (FACT-G), and a Hospital Anxiety and Depression Scale(HADS) at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why.
45465023|NCT01218893|Biological|Immunization|All groups will be immunised with mosquitobites. The number of infected mosquitoes differs per group, as clarified in group description.
45465024|NCT01218893|Biological|Plasmodium falciparum challenge|Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
45465025|NCT01218893|Drug|Malarone treatment|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
45465026|NCT01297699|Drug|Tocilizumab (RoActemra®)|Single intravenous infusion of tocilizumab (8 mg/kg); every 4 weeks during 16 weeks.
45465027|NCT01297699|Drug|Sterile 0.9% Sodium Chloride|Single intravenous dip infusion of a sterile 0.9% sodium chloride, every four weeks during 16 weeks.
46014580|NCT00592202|Device|Placement of an adjustable gastric band|Laparoscopic placement of an adjustable gastric band around the upper portion of the stomach and subsequent adjustments of the band via a subcutaneous port as needed to maintain appropriate restriction.
45465028|NCT03930407|Procedure|The Hayman uterine compression suture.|Hayman suture is a common technique for uterine compression to stop bleeding due to uterine atony. Hayman described placement of two to four vertical compression sutures from the anterior to posterior uterine wall without hysterectomy. It is usually employed to overcome uterine atony during cesarean section.
46014581|NCT00592280|Device|Two-Layer Method pancreas preservation system|Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
46014582|NCT04375358|Biological|Blood and urine samples|To measure the clearance of creatinine, urea, potassium, magnesium, sodium, chlorine...
46014583|NCT04374266|Diagnostic Test|physical examination, and computerized tomography|physical examination, and computerized tomography was performed during routine follow-up
46014584|NCT02893124|Drug|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
46014585|NCT04370678|Behavioral|Change in preference to surgery under COVID-19 pandemic.|Under the COVID-19 pandemic all arthroscopic procedures were cancelled. We wished to describe if patients experienced a change in preference to surgery under this period.
46014586|NCT04369508|Radiation|permanent brachytherapy|"Briefly, the patient had a general anesthesia and PPB was performed by using the real-time intraoperative planning method guided by TRUS. The radioactive seeds were inserted transperineally according to a modified peripherally loaded Seattle technique 17. I-125 was used for all implants with a mean seed activity of 0.45 mCi per seed. All procedures were completed by a single surgeon."
46014587|NCT04327778|Procedure|Music Therapy|Automate music therapy every two weeks
46014588|NCT02892968|Procedure|Fascia-Iliaca Block(FIB)|The target of the FIB is the potential space between the fascia iliaca and the iliacus muscle, at least 4 cm lateral to the Femoral artery. This is neither a drug nor a device.
46014589|NCT02892968|Procedure|Femoral Nerve Block(FNB)|The target of the FNB technique is the intersection of the fascia iliaca and the femoral nerve. This is neither a drug nor a device.
46014590|NCT04368338|Diagnostic Test|COVID-19 RT-PCR|Polymerase chain reaction tests after reverse transcription for the detection of viral Covid-19 RNA (RT-PCR)
46014591|NCT04368338|Procedure|lung ultrasound|lung ultrasound is standard practice to diagnose acute respiratory failure in Emergency room
46014592|NCT02893046|Other|No intervention|
46014593|NCT04359992|Other|Extra blood sample|3 extra blood samples at day 0, 2 and 7
45465029|NCT01301287|Drug|Chlorella|
45465030|NCT01224899|Procedure|Left cervico-thoracic sympathetic blockade|Left cervico-thoracic sympathetic blockade by videothoracoscopic clipping under general anesthesia and single-lumen orotracheal intubation in semi-sitting position.
45465031|NCT03824119|Drug|Ibuprofen 600 mg|Standard postpartum care (including administration of NSAIDs)
45465032|NCT03824119|Other|Standard Postpartum Care without NSAIDs|NSAID administration will be withheld from this group.
45465033|NCT01221701|Behavioral|In-Home Cognitive Behavioral Psychology|Adapted form of CBT that is delivered in the home setting, uniquely designed for young, low income new mothers, and is explicitly integrated with home visitation. IH-CBT is delivered by a masters level therapist. It consists of 15 weekly sessions and 1 booster session provided 1 month after the 15th session.
45465034|NCT03824509|Other|Chart Review|"Study staff at PBMC (Cardiologist and two clinical researchers) will be responsible for maintaining all data related to this study in REDCap. Patient data to be included in this secondary data analysis will originate from MMC and PBMC.~Case-patient data to be included from MMC will be identified by an EPIC data request from Enterprise Reporting. The elements of the data request will be patients who have had a stroke or TIA, atrial fibrillation, and a transthoracic echocardiogram at MMC from 2014-2017."
45465035|NCT03930563|Dietary Supplement|Pre-beetroot juice supplementation|Before administering beetroot juice to subjects.
45465036|NCT03930563|Dietary Supplement|Post-beetroot juice supplementation|After administering beetroot juice to subjects.
45465037|NCT03823417|Drug|Tranexamic Acid|Intravenous TXA given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
46099848|NCT00658034|Procedure|Placebo Acupuncture|"Subjects will receive placebo acupuncture weekly for six weeks. During the placebo phase, placebo acupuncture needles will be applied a few mm away from the required points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. When it is pressed against the skin, the subject feels a slight prick and sees the handle of the needle moving towards the skin as if the needle has been inserted.~Subjects will complete a BFI, a FACT-G, and a HADS at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why. Subjects in the placebo group will be given the option to receive true acupuncture."
45465038|NCT03823417|Drug|Normal saline|Normal saline infusion
46014594|NCT04358042|Other|Brief Psychiatric Rating Scale|The Abbreviated Psychiatric Rating Scale is a clinical scale for measuring symptomatic change in psychiatric inpatients for various conditions. It includes an accurate and complete description of the major characteristic symptoms. It is based both on patient responses and on observations made during the interview by the clinician. The usual reference period is the last two weeks.
45680125|NCT03955510|Procedure|Optional 24h circadian assessment in the Biological Rhythms lab|"Subjects may choose to participate in the 24 hour circadian assessment in the Biological Rhythms Research Lab. During this assessment, a saliva sample will be taken every hour, a mouth swab will be done every 2 hours, and rectal swab will be done twice (every 12 hours). Subjects will be kept awake in dim light on a recliner chair. Subjects can watch a television with dimmed light. Subjects will be provided with food and drink during the assessment.~If subjects choose this intervention they will be asked to complete 4 assessment during the course of the study period."
45465039|NCT01129037|Other|Goal directed fluid management based on continuous monitoring of stroke volume|Baseline SV measurement, repeated volume loading (VL) with aliquots of 250 ml HES until SV increased < 10% in response to receding VL: SV is optimized, no further VL required.
45465040|NCT01297777|Drug|Imatinib Mesylate|"In patients without B or C findings and without biological progression: 300 mg/24 h p.o during one year or until progression/unacceptable toxicity.~In patients with B or C findings or biological progression: 300 mg/24 h p.o for two weeks and then 400 mg/24 h p.o for a total of one year of therapy, or until progression/unacceptable toxicity."
46014595|NCT04358042|Other|Depression, Anxiety and Stress Scale|"evaluation of 3 dimensions of psychological distress: depression, anxiety and stress. The scale consists of 21 items and the patient is instructed to choose for each item the one that best corresponds to his or her experience over the past week, on a scale of 0 (does not apply to me at all) to 3 (applies entirely to me, or the vast majority of the time). A score is calculated for each dimension according to a predefined rating."
45680126|NCT03955510|Other|Alcohol|Moderate alcohol drinking means 0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 2 alcohol intervention weeks. The order of conditions will be random.
45465041|NCT01225913|Drug|fluticasone/salmeterol in all asthmatics|budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days
45465042|NCT01225913|Drug|budesonide/formoterol or fluticasone/salmeterol in all asthmatics|budesonide 160ug/formoterol 4.5ug, 2 inhalations bid or fluticasone 250ug/salmeterol 50ug, 1 inhalations bid
45465043|NCT03817489|Behavioral|Baduanjin qigong|The intervention consists of eight sequential forms of movements which is practiced with guidance on rhythmic breathing and mindful awareness. Each cycle of the eight movements requires 10 to 15 minutes for completion. Four cycles will be practiced in each session with short breaks arranged between them.
45465044|NCT03817489|Behavioral|Mindfulness meditation|The intervention is developed based on the core components of the established Mindfulness-Based Stress Reduction and the Mindful Self-Compassion program with adaptation for local practice. The focus of the group is to nurture mindful awareness, acceptance, and self-compassion. The group sessions are composed of a combination of mindfulness-based practice, relaxation, and yoga exercise. The basic philosophy of this intervention is the emphasis of the nurturing of self-kindness attitude, and non-attachment attitude towards inter-personal connectedness and letting go of self-criticism, need for control, and defensive separation in times of adversity. Short breaks will be arranged between each practice.
45465045|NCT01224977|Drug|azithromycin|azithromycin 500 mg 3/week for 3 months
45465046|NCT03830437|Other|Evaluation of newborn stress|Newborn stress will be evaluated by salivary cortisol levels at 48 hr of life. Saliva sample of the newborns will be collected in oral cavity at 48 hr of life. Samples collected will be storage at -80 C for up to 4 months and analysed by analysis laboratory of Poliambulanza Foundation.
45680127|NCT03952598|Device|3T MRI scanner|Research proton MRS (1H-MRS)followed by DW-MRI
45837651|NCT05766891|Behavioral|Group 3|Participants will receive standard general anesthesia and medications during surgery to control your pain.
45837652|NCT05766865|Procedure|Emergency neurosurgery|Surgical evacuation for intracerebral hemorrhage
45837653|NCT05766865|Procedure|Conservative treatment|Standard treatment for intracerebral hemorrhage
46014596|NCT04358042|Other|Impact of Event Scale-Revised|is a 22-item self-questionnaire that measures perceived stress in reference to a traumatic event during the previous 7 days. Each item is rated on a scale ranging from 0 (not at all) to 4 (extremely) and 3 sub-scores of post-traumatic symptoms are calculated: Revivification, Avoidance, Psychophysiological Activation, as well as a total score of severity of the state of stress. Acute Stress Disorder (ASD) and Post-Traumatic Stress Disorder (PTSD) share the same symptoms, the former lasting between 3 days and one month, while the latter is diagnosed when symptoms persist beyond one month. Since the exposure to the stressful event will have occurred less than a month ago, this questionnaire here will help identify a state of acute stress. A total R-ESI score equal to or greater than 33 suggests a significant level of symptoms
46014597|NCT04358042|Other|Connor-Davidson Resilience Scale 10 items (CD-RISC 10)|"Self-questionnaire composed of 10 items, evaluating the resilience capacities of patients. Resilience may act as a moderator against the symptoms of PTSD. This instrument uses a 5-point Likert-type response scale ranging from 0 Not true at all to 4 True most of the time."
46014598|NCT04327856|Procedure|Cataract Surgery|The cataract will be removed from patient's eye and artificial intraocular lens will be implanted
46014599|NCT04352426|Other|Exercise Test|Tests were conducted to evaluate exercise capacity.
46014600|NCT04349540|Other|no intervention|no intervention
46014601|NCT04348682|Diagnostic Test|Positron Emission Tomography (PET) Imaging|A single dose activity of 5 mCi (accepted range of 3-7 mCi) of 68Ga-PSMA-11 will be intravenously administered to patient as a bolus injection. After 50-100 minutes of uptake time, the patient will undergo a whole body (skull to mid-thighs) PET/CT imaging.
45837654|NCT05766826|Other|Coupons for safe water program: Treatment|Randomly selected women in the treatment group will receive coupons for free chlorine solutions to be redeemed at the health facility each month.
46014602|NCT04348448|Drug|Canakinumab 150 MG/ML [Ilaris]|COVID-19
46014603|NCT05661500|Other|Creative Darama Group|Postmortem care training given by creative drama method
46014604|NCT05661500|Other|Classical Education Group|Postmortem care training given by classical education method
46099849|NCT00740272|Procedure|AF ablation + pacemaker implantation|regular pacemaker implantation and concomitant AF ablation procedure (PV isolation)
46099850|NCT00740272|Procedure|Pacemaker implantation|regular pacemaker implantation
46099851|NCT04159376|Diagnostic Test|PET/MR|"All patients will have a PET/CT and PET/MR study performed at the same clinical setting using a single dose of tracer administration.~The study cohort includes 150 patients 18 years or older, having metastatic skeletal involvement on baseline PET/CT prior to treatment. Baseline studies and follow up studies of the patients referred post treatment, will be reviewed.~The tracers will be FDG, labelled PSMA labelled Somatostatin and F-DOPA in order to assess skeletal lesions detection of all tumor types.~Skeletal lesions will be divided into marrow-based lesions, lytic, blastic and scleroric lesions. Tracer uptake will be measured at baseline and after treatment. Metabolic PET parameters, CT appearance and MR parameters will be assessed.~The best MR-based attenuation algorithm for detection of lesions and monitoring response will be derived."
45465047|NCT03830437|Other|Evaluation of body weight trend|Body weight trend between newborns subjected to double weighing or to body weight control will be carried out at 36 hr and 48 hr of life
46014605|NCT04343456|Procedure|Salvage surgery with massive debulking|For patients with regorafenib treatment and facing local progression, we remove the tumor with progression and achieve cytoreduction.
46014606|NCT04340648|Device|Vital GlucoseDetect|11 time points for blood glucose measurements over 210 min including the ingestion of a standardized meal 30 min after the first blood glucose measurement.
46014607|NCT04340726|Procedure|One time abutment|
45465048|NCT03930329|Behavioral|MBRP group|same as arm description
45837655|NCT05766826|Other|Coupons for safe water program: Control|Randomly selected women in the treatment group will not receive coupons for free chlorine solutions after enrollment.
46014608|NCT04336280|Other|Symptom questionnaire|Arabic version of the International Prostate Symptom Score: Known and validated questionnaire to quantify and qualify the severity of symptoms of the lower urinary tract
45465049|NCT01205893|Device|Neovasc Reducer|Implantation of the Reducer
45465050|NCT01205893|Device|Control|Control - No device implanted
45837656|NCT05766813|Drug|Lenrispodun|Lenrispodun 30 mg tablets administered orally, once daily.
45837657|NCT05766813|Drug|Placebo|Matching tablets administered orally, once daily.
46014609|NCT04336280|Diagnostic Test|Urodynamics|Urodynamics: the standard diagnostic tool, it includes invasive recording of the pressure that is produced when the bladder muscle contracts via pressure sensors introduced in the urinary bladder through special types of urethral catheters.
46014610|NCT04334252|Other|Questionnaire|Questionnaire
46014611|NCT02892812|Biological|Pneumococcal conjugate vaccine|
46014612|NCT00592670|Drug|Fluoxetine|20 mg fluoxetine orally one per day for 1 week, 40 mg fluoxetine orally once per day for one week, 80 mg Fluoxetine orally for remaining 4 weeks of treatment
46014613|NCT00592670|Drug|Placebo|20 mg placebo pill taken orally once per day for one week, 40 mg placebo pill taken orally one per day for one week, 80 mg placebo pill taken orally once per day for remaining 4 weeks.
46014614|NCT00622856|Behavioral|psychological intervention|Psychological intervention
46014615|NCT00622856|Behavioral|Diabetes education|5 sessions with diabetes nurse
46014616|NCT00592748|Radiation|Charged Particle Radiation Therapy|Radiation doses will be determined by planning CT
46014617|NCT04327232|Drug|Spironolactone 25mg|Mineralocorticoid Receptor Antagonists
46014618|NCT04327232|Drug|Placebo oral tablet|Placebo
46014619|NCT00593138|Drug|dex-methylphenidate|The drug is administered as a capsule by mouth. Participants are assigned to receive either 20, 30 or 40 mg doses before each scan visit.
46099852|NCT04064944|Device|blood purification equipment|The subjects enrolled in this study will undergo blood purification treatment, and will be randomized into either immunoadsorption group or plasma exchange group, and the following indicators will be evaluated: (1) changes in EDSS scores and visual acuity before and after treatment; (2) changes in AQP4-IgG levels; (3) the safety of immunoadsorption treatment.
46099853|NCT04969055|Other|Not|Not
46099854|NCT04159142|Drug|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles；
46014620|NCT00593216|Device|Functional MRI imaging|The functional MRI imaging of whole brain will be obtained before, during and after the vestibular response which is induced by the designated caloric stimulation. Post-imaging analysis will reveal which region or neural pathways in the central nervous system may attributed to the development of vertigo.
46014621|NCT04326998|Procedure|solvent|using solvent (GuttaClear) in procedure
46014622|NCT04326998|Procedure|non-solvent|non-solvent
46014623|NCT00593294|Behavioral|Physical exercise|45 minutes each day for three times/week for 6 months
46014624|NCT00593294|Drug|OC - Drospirenone plus Ethynylestradiol|1 cp for 21 days each month for 6 months of OC (Drospirenone 3 mg plus Ethynylestradiol 30 microgram = Yasmin, Schering, Milan, Italy)
46014625|NCT00593294|Dietary Supplement|Vitamin, polyvitamins tablets|Tablet of vitamin 1cp for 21 days each month for 6 months
46014626|NCT00593528|Device|Naked Stents: Wallstent® (Boston Scientific), Luminexx® (Bard), Zilver® (Cook), Palmaz Genesis® and Smart Control® (Cordis)|Vascular Stents
45465051|NCT01226069|Drug|Glycerine Magnesium sulphate paste|Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
45465052|NCT01226069|Drug|Mucopolysaccharide polysulphate|Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
45465053|NCT01226069|Other|No application|No application
45465054|NCT01205971|Behavioral|Motivational Interviewing|Motivational interviewing is delivered by trained public housing residents, every 3 months for a total of 8 sessions over 24 months.
46014627|NCT00593528|Device|PTFE Covered Stents: Fluency® (Bard), Advanta V12® (Atrium) and Viatorr® (Gore)|Vascular Stents
46014628|NCT00593528|Procedure|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt (TIPS)
46014629|NCT04327076|Device|Using robot system of endotracheal intubation and airway cleaning|"Using the control screen to control the machine, the device first extends the intubation guide rail to the mouth of the patient's oropharyngeal ventilation tube, first sends the magnetic guide strip into the epigarynx, and at the same time, extends the magnetic anchoring unit to the patient's neck. The external magnetic anchoring unit can sense and attract the magnet on the magnetic guide strip. At this point, the machine can send the guide strip into the respiratory tract.~Then, the control machine sends the tracheal intubation into the airway along the guide strip, and completes the balloon inflation to complete the endotracheal intubation operation.~During or after the operation, when the sputum suction operation is needed, the parameters of the sputum suction machine are set on the operation screen to start the sputum suction operation, and the suction robot completes the sputum suction operation automatically."
46014630|NCT02892578|Other|electrocardiogram|
46014631|NCT00593996|Other|Ergocalciferol (vitamin D2)|50,000 IU 3 times weekly for 4 weeks
46014632|NCT00594074|Other|white wine|3.25 ounces of white wine twice a day with lunch and dinner
45465055|NCT01205971|Behavioral|Dental Preventive Services|Written oral health educational materials
45465056|NCT03928691|Drug|Magnesium Sulfate|4 gram MgSo4 diluted in 150 cc saline infused IV within 30 minutes as loading dose then the patient will receive the maintenance dose of 1gram MgSo4 per hour for 6 hours.
45465057|NCT01299883|Other|Integrated vs Non-integrated Risk Education|Integrated group receives education about risk factors for both cancer and CVD whereas the non-integrated group receives information about CVD only to assess differences in health behavior outcomes.
45465058|NCT01226147|Drug|Tamibarotene|4mg/day for 24 weeks.
45465059|NCT03823027|Device|SiPore15™|SiPore15™ is a taste- and odourless white powder, consisting of precisely engineered micrometre sized synthetic amorphous silicon dioxide. The device is made of pure silicon dioxide, SiO2, which has the CAS Number: 112926-00-8 and EC List number: 601-214-2.
46014633|NCT00594152|Drug|CIIIT|The intravenous infusion group received three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to subcutaneous insulin.
46014634|NCT00594542|Drug|lidocaine|Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
46014635|NCT00594698|Drug|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL 5% Dextrose for Injection in glass bottles, to be administered as a single continuous infusion during image acquisition. Infusion time not to exceed 60 minutes
46014636|NCT00594776|Device|Cone Beam CT Scan|The Cone Beam Computerized Tomographic (CBCT) device utilizes computerized tomographic technology, a special digital imaging plate and a computer to create a three-dimensional image. The special imaging plate and software allow for small details to be imaged without tissue overlap.
46014637|NCT00595010|Behavioral|SafeCare|Treatment will be based on an updated version of the SafeCare program, which specifically addresses parenting and discipline associated with child physical abuse. Participants will receive services from Comprehensive Home-Based Services.
46099855|NCT04159142|Drug|Nab-paclitaxel + Capecitabine|Nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and capecitabine given IV at 1000 mg/m^2 bid, d1-14 every 21 days x 6 cycles；
46099856|NCT00736060|Other|Observational|Summary of clinical and laboratory data
46099857|NCT04879121|Drug|Larotrectinib Sulfate|Given PO
46099858|NCT00654680|Drug|Vardenafil (Levitra, BAY38-9456)|5mg, 10mg or 20mg taken 1 hour prior to sexual intercourse
46014638|NCT00595166|Device|Vaginal Speculum Sheath|Patients received the sheathed speculum exam: The clinician will begin to place the sheath onto the speculum. The sheath is attached to a thin piece of cardboard. The proximal end of the cardboard is placed between the speculum blades and is pushed toward the speculum handle. The blades of the speculum are simultaneously guided to enter the 2 pockets of the sleeve, like fingers going into a glove. The speculum exam will then be completed according to usual procedures. In the event the sheathed speculum exam is unsatisfactory the clinician will do standard of care (the clinician's usual routine at the bedside).
46014639|NCT00595244|Drug|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
46014640|NCT00595322|Other|bevacizumab and radiation (IMRT)|bevacizumab 10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (cycle defined as 28 days). If the tumor volume remains < 40 cc, the patient will undergo stereotactic radiotherapy with IMRT (30Gy) beginning anywhere from day 7-10 of cycle 2 (5 doses of 6 Gy over 2 and a half weeks)
46014641|NCT00595712|Procedure|Iliac crest allograft|Opening wedge osteotomy of proximal tibia with allograft from iliac crest
46014642|NCT00595712|Procedure|Iliac crest autograft|open wedge osteotomy of proximal tibia using autogenous iliac bone graft
46014643|NCT00596024|Dietary Supplement|lutein/zeaxanthin|daily supplementation of lutein and zeaxanthin at dose of 12 mg/day
46014644|NCT00596024|Dietary Supplement|placebo|placebo capsules with the same size and coating as those of lutein/zeaxanthin supplements without active ingredients
46014645|NCT00596180|Drug|HBOT|total body exposure to greater than atmospheric pressure oxygen
45465060|NCT01127243|Procedure|day-case laparoscopic supracervical hysterectomy|patients discharged home the same day of the operation
45465061|NCT01127243|Procedure|inpatient LSH|patients discharged home the day after the operation
45465062|NCT01297855|Drug|Colistin|Colistimethate Sodium dose 2.5-5mg/kg/day
46014646|NCT00596258|Drug|A-007|applied topically for two 28-day cycles of 14 consecutive days of treatment each to the uterine cervix
46014647|NCT02892266|Other|Assessment of adherence, mental health, behavioral, quality of life and biological constructs|
46014648|NCT00596336|Drug|Imiquimod cream|Imiquimod (aldara) 0.5 % cream to site of vaccination on day 2 to 6
45465063|NCT01297855|Drug|Colistin plus Rifampicin|Colistin 2.5 to 5 mg/ Kg/ day Rifampin 10 mg/ Kg/ day
45465064|NCT01221779|Behavioral|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
46099859|NCT00654680|Drug|Placebo|Matching placebo
46099860|NCT00520741|Drug|Lacosamide|50 mg and 100 mg tablets provided for 200 mg twice daily dosing for up to 20 weeks.
46099861|NCT00520741|Drug|Lacosamide|50 mg and 100 mg tablets provided for 150 mg twice daily dosing for up to 20 weeks.
45465065|NCT01221779|Behavioral|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
45465066|NCT03817099|Other|Nutrition Intervention based on My Dia-RNP|Subjects in this group will be advised to follow My Dia-RNP and to incorporate diabetes-specific formula (Nutren®Untuk Diabetik)
45465067|NCT03817099|Other|Usual Care|Subjects in the group continue with the usual care
45465068|NCT03740477|Diagnostic Test|ECG|Eligible participants will receive a 30-second ECG recording during their visit at the Absentee Shawnee Tribal clinic
46014649|NCT00596336|Drug|influenza vaccine|trispecific influenza vaccine 0.5 ml subcutaneously
46014650|NCT00596414|Procedure|transjugular liver biopsy|liver biopsy through the transjugular route with hepatic-venous pressure gradient measurement
46014651|NCT00596414|Drug|placebo|
46014652|NCT00596414|Drug|midazolam|
46014653|NCT00596414|Drug|midazolam + pethidine|
46014654|NCT00596492|Drug|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
46014655|NCT00596492|Drug|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
46014656|NCT00596570|Procedure|PCI|Percutaneous coronary interventiom
46099862|NCT03682289|Drug|Ceralasertib|Given orally
46014657|NCT00596648|Drug|XL184|Capsules administered orally daily
46014658|NCT00596648|Drug|erlotinib|Tablets administered orally daily.
46014659|NCT00596726|Device|IMPELLA LP/LD 5.0|IMPELLA LP/LD 5.0 Support System is intended to be used for up to seven (7) days as a left ventricular cardiac assist device for postcardiotomy patients who, despite having been weaned from cardiopulmonary bypass (CPB), require hemodynamic support
46014660|NCT00596804|Drug|veltuzumab|once weekly intravenous dosing for 4 weeks
46099863|NCT03682289|Drug|Olaparib|Given orally
46099864|NCT03682289|Drug|Durvalumab|Given intravenously (IV)
46099865|NCT00729118|Drug|lenalidomide|combined with Vorinostat (SAHA) days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
46014661|NCT00622934|Drug|erythropoietin|300mg/kg erythropoietin 3 times on the first week of admission
46099866|NCT00729118|Drug|vorinostat|Vorinostat (SAHA) will be administered orally beginning at dose level 1 starting day +90 ±6 days after HSCT for days 1 and 15-21 of a 28-day cycle combined with lenalidomide days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
46099867|NCT04064632|Drug|Rilpivirine + darunavir/cobicistat|Switch to a dual ART
46099868|NCT03868007|Device|RIC|The RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
46099869|NCT03868007|Device|sham-RIC|The sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
45465069|NCT03930173|Drug|18F-fluciclovine|A single dose of 18F-fluciclovine will be administered intravenously for PET/CT imaging. The standard 10 mCi dose will be used for this study.
45465070|NCT03930173|Device|PET/CT of the brain|Each subject will undergo 18F-fluciclovine PET/CT of the brain which will be performed ≤ 30 days from equivocal MRI brain
45465071|NCT02631070|Drug|Luspatercept|
45465072|NCT02631070|Other|Placebo|
45465073|NCT03817177|Procedure|high flow nasal cannula oxygenation|high flow nasal cannula application in PACU
45837658|NCT05766696|Procedure|Atraumatic Restorative Treatment (ART)|"Conventional glass-ionomer restorations are placed using the Atraumatic Restorative Treatment (ART) technique. Essentially, cavities are prepared using hand instrument excavators. Afterwards, the cavity is conditioned (using a 10% polyacrylic acid conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer. During the curing phase, Vaseline will be applied to all restoration surfaces for moisture protection.~The treatment will be conducted in a class room.~As concomitant treatment, all participants will receive supervised toothbrushing during the study using 1,450 ppm fluoride toothpaste once a day."
45465074|NCT03817177|Procedure|nasal prong|conventional nasal prong application in PACU
45465075|NCT01225133|Other|Complex Ayurvedic Treatment|In the Āyurveda group treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.
45837659|NCT05766696|Procedure|Conventional Cavity Preparation|"Conventional glass-ionomer restorations are placed after conventional cavity preparation. Essentially, cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using a 10% polyacrylic acid conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer. During the curing phase, Vaseline will be applied to all restoration surfaces for moisture protection.~The treatment will be conducted in a mobile clinic.~As concomitant treatment, all participants will receive supervised toothbrushing during the study using 1,450 ppm fluoride toothpaste once a day."
45837660|NCT05766644|Other|Education|An 8-week program providing educational materials via a mobile app for chronic kidney disease management. Materials consist of videos, card news, and live online seminars with a Q&A session. Topics are on general disease information, nutrition, and exercise.
46014662|NCT00622934|Drug|placebo|placebo
46014663|NCT00596882|Other|Message Prime|Participants will be randomized to genetic prime messages or threat only message at the time of the intial telephone screen. Following phone screen, all eligibleparticipants will receive 13 weeks of Chantix with smoking cessation counseling.
46014664|NCT00596882|Other|Message Prime|Particpants will be randomized into 1 of 2 groups. 1 group will recieve a message detailing the negative helaht consequenes of smoking and the other group will receive this information along with information about the genetic incluences on smoking behavior.
45465076|NCT01225133|Other|Conventional Care|Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.
45465077|NCT05623501|Drug|Dihydromyricetin|Dose-escalation and lysine preparation
46014665|NCT00597194|Procedure|Hernia repair|Hernia repair laparoscopically (LH) or by open operation (OH)
46014666|NCT00597350|Dietary Supplement|Trigonella foenum-graecum (fenugreek)|2 slices of bread containing 5 grams of the natural herb fenugreek 2 times, 1 week apart
46014667|NCT02892032|Behavioral|Attention Modification Training|Subjects are taught to disengage attention from a certain stimuli
46014668|NCT02892032|Behavioral|No Attention Modification Training|Subjects are exposed to two stimuli, but attention is not manipulated in any way
46099870|NCT04064710|Procedure|Vertebral Body Augmentation|Use allograft tissue in patients with one or two level, thoracic or lumbar T6-L5, vertebral compression fractures.
46099871|NCT04064710|Device|Manual Surgical Instruments|Lenoss Medical manual surgical access and cavity creation instruments will be used when implanting the allograft tissue.
46099872|NCT04032509|Other|2 x 5 mL blood sample|2 x 5 mL blood sample to determine the performance of the automated VIDAS BTI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.
46099873|NCT00882518|Drug|Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)|200 mg or 300 mg, oral, single dose
46099874|NCT00882518|Drug|Chlorpromazine|50 mg, oral, double dose
46099875|NCT00736138|Procedure|training and pellots|training and pellots
45465078|NCT03932357|Radiation|CBCT|measuring soft tissue thickness using a CBCT
45465079|NCT01297933|Drug|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
45465080|NCT03930095|Behavioral|Acceptance-based Behavior Therapy|The protocol is widely based on Roemer and Orsillo (2007) acceptance model of GAD, using functional assessment, psychoeducation, mindfulness, commitment to valued behavior, and exposure techniques used in a willingness improvement verbal context.
45465081|NCT03930095|Behavioral|Non-directive Supportive Therapy|NDST consists in a form of therapeutic intervention from which all intervention principles pertaining to specific psychotherapeutic protocols are removed while maintaining the so-called common factors from different psychotherapy approaches. In other words, it is an unstructured therapy without specific psychological techniques other than those belonging to the basic interpersonal skills of the therapist, such as reflection, empathic listening, encouragement, and helping people to explore and express their experiences and emotions.
45837661|NCT05766631|Behavioral|DynamiCare Health|"Participants earn incentives for:~CM for opioid and cocaine abstinence. Accomplished via oral fluid (saliva) test kits given to participants.~Patients who test negative on opioids and cocaine are also eligible for a bonus if they additionally test negative for non-targeted drugs (except methadone).~Patients will receive notices of their medication pickup appointments through the app itself, and monetary rewards will be delivered to the Next Step debit card when the participant's presence at the clinic is verified by clinic records.~The app provides 72 self-administered modules based on the principles of cognitive behavioral therapy that are designed to aid in relapse prevention; small incentive rewards ($1) are provided for completion of up to 3 modules per week for the first weeks of treatment."
46014669|NCT00597662|Device|polylactide-caprolactone-trimethylenecarbonate copolymer|Polylactide-caprolactone-trimethylenecarbonate copolymer membrane is applied directly over the surgical scar on the visceral peritoneum
46014670|NCT00597662|Device|Icodextrin 4%|1 liter icodextrin 4% is instilled into the peritoneal cavity at the end of the operation
46014671|NCT00597974|Procedure|Angioplasty|(non-experimental) Carotid artery angioplasty and/or stent-supported angioplasty
46014672|NCT00597974|Device|Stent|(non-experimental) Precise™ Nitinol Self-Expanding Stent (Cordis Endovascular, Johnson & Johnson), S.M.A.R.T.® Control™ Stent (Cordis Endovascular, Johnson & Johnson), Wallstent® (Boston Scientific Medi-Tech)
46014673|NCT00597974|Other|Neurological and neuropsychological evaluations|Clinical examinations consisting of a neurological and neuropsychological evaluation
46014674|NCT00597974|Procedure|Angiography|(non-experimental) Coronary angiography
46014675|NCT00598052|Drug|Escitalopram|10mg/day
46014676|NCT04207814|Biological|biological sample|biological samples will be taken from the subjects included
46014677|NCT00598130|Biological|Fleece|Fibrin Patch
46014678|NCT00598286|Drug|[18F]FMPEP-d2|
46014679|NCT04326296|Drug|PD-L1 Monoclonal Antibody Combined With Lenalidomide|PD-L1 monoclonal antibody was administered by intravenous drip every 3 weeks.Lenalidomide was administered orally, 25mg once a day on days 1-21 of each repeat cycle of 28 days.
46014680|NCT04328324|Procedure|Endoscopy|Diagnostic upper Git endoscopy
45465082|NCT01298011|Drug|Gemcitabine and Abraxane|3 treatments for gemcitabine and abraxane every 28-days for 3 months, prior to surgery.
45465083|NCT03816943|Behavioral|Whatsapp|a WhatsApp message with encouraging words will be sent after bond up
46014681|NCT00598676|Device|biodegradable polymer Rapamycin-eluting stent|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
46014682|NCT00598676|Device|permanent polymer rapamycin-eluting stent (Cypher)|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
46014683|NCT00598676|Device|permanent polymer everolimus-eluting stent (Xience, Promus)|due to randomization, everolimus-eluting stent with permanent polymer will be implanted
46014684|NCT04326218|Other|Blood sample|"Serum samples will be sent for centralised analyses in Nice.~On these samples, different analysis will be performed :~anti-PLA2R1 and anti-THSD7A antibodies~anti-PLA2R1 and anti-THSD7A epitopes~HLA typing"
46014685|NCT00598910|Drug|Omacor|n-3 PUFA
46014686|NCT00598910|Drug|Placebo|Placebo
46014687|NCT04326374|Drug|TransCon hGH|Once weekly subcutaneous injection
46014688|NCT04326374|Drug|daily hGH|Once daily subcutaneous injection
46014689|NCT04326140|Device|mirror therapy|The affected side wears the machine, assists by the machine, and performs the same action with the good hand. According to the posture condition, selects two suitable actions in the three actions (all fingers open, all fingers close, all fingers open and close). The action is 10 minutes each.
46014690|NCT04326140|Device|robotic-assisted training|The hand brace is worn on the dorsal side of the impaired hand with 2 surface sensors attached to the extensor and flexor muscles of the arm to detect the surface electromyographic signals (sEMG) for active participation during exercise. The sEMG signals are processed so the patient can visualise the active movement of the muscle where sEMG electrodes are positioned. Different training modes allow the therapist to customise the level of assistance that the Hand of Hope provides. The difficulty level of each mode can be adjusted according to the patient's need.
46014691|NCT04326140|Device|sham mirror therapy|The mirror was masked. The intervention was the same as the mirror therapy.
46099876|NCT03866759|Behavioral|Determine the Incidence and Point Prevalence|Determine the Incidence and Point Prevalence of human immunodeficiency virus (HIV) Infection and the Most Common Sexually Transmitted Infections in Individuals With Sexual Risk Behavior.
46099877|NCT00740350|Procedure|Logan Basic|Logan Basic chiropractic adjustments during pregnancy.
45837662|NCT05766631|Drug|Methadone Treatment-As-Usual|Participants will receive treatment-as-usual at the methadone clinic, including daily methadone dosing, individual and group addiction counseling, and OP or IOP behavioral health services, depending on the clinic and the needs of the patient.
46014692|NCT00599066|Device|study cases|Application of a second M-Entropy probe on the forehead of the patient, which will happen in the OR along with the application of other monitors immediately before induction of general anesthesia.
46014693|NCT00599144|Procedure|videolaparocholecystectomy|Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder
46014694|NCT00599144|Procedure|videolaparocholecystectomy|Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.
46014695|NCT00599144|Procedure|videolaparocholecystectomy|Group3: control group without any local anesthetic use.
46099878|NCT03847337|Other|Telehealth-Screening Tool for Autism in Toddlers (STAT)|Structured autism screening tool
46099879|NCT03847337|Other|Telehealth-Autism Spectrum Disorder-Pediatrics (ASD-PEDS)|Semi-structured autism screening tool
46099880|NCT00740428|Procedure|Pregnants for receive the physical therapy guide|pregnants for the first time who will receive the physical therapy guide, perform the exercises under the supervision of a physical therapist, and complete an exercise compliance form and a log with information on urinary losses.
46099881|NCT04327037|Biological|Expanded Haploidentical Natural Killer cells|One dose (from 20x to >100x 10^6 /kg) of expanded haploidentical NK cells
46099882|NCT04327037|Drug|IL-2|6 doses of IL-2 (1 × 10^6 units/m2) from -1 day every other day.
46014696|NCT00599222|Biological|ranibizumab|0.5 mg intravitreal injection
46014697|NCT00599222|Procedure|TTT|Transpupillary thermotherapy (TTT)
46014698|NCT00599222|Procedure|Sham TTT|Sham Transpupillary thermotherapy (TTT)
46014699|NCT01326962|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg (max. 800 mg) iv every 4 weeks, 6 infusions
46014700|NCT01326728|Biological|Allogeneic stem cell transplant|Donors will undergo cell collection and recipients will receive cells (allotransplant).
46014701|NCT00599378|Behavioral|Implementation Intentions-based telephone counseling|Implementation Intentions-based telephone counseling
46099883|NCT00882362|Drug|OPC-14597 (Aripiprazole)|administered orally once daily, 3 to 15 mg daily, 52 weeks
46099884|NCT00851643|Biological|Octavalent HPV with 15 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
46014702|NCT01097707|Drug|LY500307|Administered orally, daily for 24 weeks
46014703|NCT01097707|Drug|Placebo|Administered orally, daily for 24 weeks
46014704|NCT00599456|Dietary Supplement|Omega 3 fatty acid vitamins|Omega 3 fatty acid vitamins, 2 capsules, by mouth, daily, for 3 months
46099885|NCT00851643|Biological|Octavalent HPV with 30 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
46099886|NCT00851643|Biological|Octavalent HPV with 60 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
46099887|NCT00851643|Biological|Octavalent HPV with 120 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
46099888|NCT00851643|Biological|Comparator: Quadrivalent HPV Vaccine (qHPV), (GARDASIL™)|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
46099889|NCT00529243|Drug|raltegravir|This is a single-arm, open-label, non-randomized pilot study in human immunodeficiency virus type 1 (HIV-1) positive patients who have an undetectable viral load on their current enfuvirtide containing medication regimen. The treatment regimen will consist of replacing enfuvirtide with MK-0518 400 mg twice a day given as part of the patient's HIV medication regimen. The study regimen will be administered for 24 weeks, with patients given the option of continuing on the study medication past that time if they wish to. Patients serve as their own control as they have viral control (HIV ribonucleic acid (RNA) below limits of quantification) for at least 6 months with enfuvirtide prior to switch to raltegravir.
46099890|NCT00636935|Drug|Antibiotics only|Antibiotic only for treatment for mild (pO2 > 70mmHg) PCP. Antibiotic Treatment with Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone.
46099891|NCT00636935|Drug|Antibiotics + Corticosteroids|Prednisone 40mg orally twice daily for 11 days, followed by 40mg once daily for 5 days, followed by 20mg once daily for 5 days and antibiotics (Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone).
46099892|NCT00636935|Drug|Corticosteroids + antibiotics|Drugs will be prescribed per standard of care for patients with PCP and pO2 < 70mmHg.
46014705|NCT00599456|Dietary Supplement|Placebo capsules|Placebo capsules,2 capsules, by mouth, daily for 3 months
46014706|NCT00599534|Drug|Montelukast|4 mg oral tablets
45465084|NCT03816943|Behavioral|Call|a telephone call will be made after bond up to provide encoring words
46014707|NCT00599534|Drug|Placebo|5mg tablets
46014708|NCT00599612|Drug|GW856553|A dose of 10mg GW856553 containing 50µCi of [14C]GW856553 will be delivered as 100mL of a 0.1mg/mL GW856553/0.5 µCi/mL oral solution.
46014709|NCT00599690|Procedure|Epi-LASK|10 eyes of 10 patients underwent epi-LASK, epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
46014710|NCT00599768|Other|ID-Pain DN4 Questionnaire|This is a non-interventional questionnaire validation study
46014711|NCT02878759|Device|Wristbot|The proposed technology comprises a hardware device with four motors that can apply torques to the human wrist about its three degrees of freedom (i.e. axes of rotation: wrist flexion/extension,abduction/adduction and forearm pronation/supination). This allows for guided and controlled movements of the wrist by delivering assistive, resistive, perturbation or no forces (patient actively moves the wrist). It contains a set of specialized software modules that a) allow for the objective, psychophysical assessment of sensory dysfunction in patients, and b) provide specialized training modules designed to improve sensory and motor functions of the wrist.
46014712|NCT00600002|Biological|GM-CSF|Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
46099893|NCT00654758|Drug|M200 (Volociximab), Carboplatin, Paclitaxel|Volociximab will be administered via IV infusion at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels during the first cycle. Volociximab will be given for at least 6 cycles (3 weeks/cycle) and subjects who have stable disease at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All three drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
46099894|NCT00700869|Procedure|mechanical ventilation|mechanical ventilation
46099895|NCT00656864|Drug|Pioglitazone|Starting dose at 15 mg for two weeks, then titrated up to 45 mg in the subsequent 2 weeks.
46099896|NCT00656864|Drug|Placebo|placebo
46099897|NCT04116801|Procedure|microsurgical resection|resection of cerebral metastases by microsurgery
46099898|NCT00658268|Drug|Clodronate|60 mg/ml, 10 ml, single dose mixed in bone graft at operation
46099899|NCT00658268|Drug|Placebo|10 ml, single dose mixed in bone graft at operation
46099900|NCT03728309|Device|JUVÉDERM VOLITE™ XC|Intradermal, needle in multiple microdepot injections across both cheeks.
46099901|NCT03683719|Drug|Delgocitinib cream|Cream for topical application.
46099902|NCT03683719|Drug|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
46099903|NCT00851253|Radiation|stereotactic radiosurgery|Given in 2 fractionated doses or 5 fractionated doses
46099904|NCT00613613|Drug|fenofibrate|Fenofibrate 145mg tablets once daily for 4 weeks
46099905|NCT00613613|Drug|fenofibrate|Fenofibrate 145mg tablets once daily for 4 weeks
46099906|NCT04298099|Drug|Ropivacaine|Given the reproducible efficacy of the erector spinae plane block for thoracic procedures, this pilot study will recruit patients scheduled to undergo thoracic surgery with the adjunct of an erector spinae plane block for perioperative pain. Participants will be assigned sequentially to either ropivacaine 0.2% at 0.3ml/kg or ropivacaine 0.5% at 0.3ml/kg.
45465085|NCT01221935|Other|Pristiq first-line treatment charts|300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment
46014713|NCT02891720|Device|Proteus Sensor System|The Proteus Sensor System (PSS) intervention includes 12 weeks of daily FTC/TDF with a weekly text messages transmitted to participants with estimated HIV risk reduction based upon the DBS algorithm.
46099907|NCT04030845|Procedure|breast reconstruction|The breast reconstruction mainly included autologous tissue flaps (latissimus dorsi myocutaneous flaps, pedicled tansverse rectus abdominis myocutaneous flaps, free transverse rectus abdominis musculocutaneous flaps, deep inferior epigastric artery perforator flaps, etc.), implant based breast reconstruction, autologous flaps combined with implant reconstruction, fat graft, etc.
46014714|NCT00600158|Drug|bupivacaine with hydromorphone|bupivacaine 0.125% with hydromorphone 6 mcg/ml epidurally at 10 ml/h
46014715|NCT00600158|Drug|lidocaine|lidocaine 2 mg/min intravenously (or 3 mg/kg in patients > 70 kg)
46099908|NCT04030845|Procedure|oncoplastic breast-conserving surgery|The oncoplastic breast-conserving surgery were mainly those surgeries using volume displacement or volume replacement techniques.
46099909|NCT04041817|Other|Trigger setting of pressure support ventilation|Trigger variations will be performed following increasing steps of 3 L/min every 15 minutes, from 0.2 to 15 L/min (0.2 - 3 - 6 - 9 - 12 - 15).
46099910|NCT02613195|Drug|Hydrogen-Rich Celsior Solution|Before the procedure, add hydrogen gas into Celsior solution. After harvesting the liver/kidney grafts, lavage and cold store the grafts with Hydrogen-Rich Celsior Solution.
46014716|NCT00600236|Procedure|blood sample|
45837663|NCT05766618|Procedure|Injectable platelet rich fibrin (i-PRF): in acceleration of orthodontic tooth movement|"Preparatory phase~Space closure will be done on a 17x25 stainless steel wire~Both molars will be indirectly anchored to the miniscrew~Extend closing coil spring of suitable length from the canine hock to the first molar hock for retraction.~Apply a force of 150gm for each side. The force is measured by a force gauge and activated each visit to keep it constant all over the retraction phase. PRF Injection protocol~The First injection will be 3 weeks before extraction~By the end of the fourth week the patients will be referred for pre-intervention records. Upper arch CBCT will be obtained to take preintervention measurements of the alveolar bone.~At the time of canine retraction patient will receive another injection immediately and an alginate impression will be taken~follow up every month and injection will be repeated month after month with an observational period of 5 months."
45837664|NCT05766605|Drug|Oxaliplatin|130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
45837665|NCT05766605|Drug|Doxorubicin|20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
46014717|NCT04325984|Drug|Dexamethasone|To the Dexamethasone group, at the moment of the induction of anaesthesia, dexamethasone 8 mg is administered.
46014718|NCT02891642|Device|Immunomagnetic Detection|Immunomagnetic separation will be assessed through analysis of the percentage of positive samples identified compared to cytological techniques.
46014719|NCT00600470|Behavioral|Doctor-office collaborative care (DOCC) management|DOCC is an evidence-based psychosocial treatment approach that incorporates (1) adaptation of an evidence-based collaborative care approach using the chronic care model and participatory management theory to enhance training, implementation, and sustainability; (2) revised protocol content that includes medication management for ADHD, brief anxiety management, and attention to parental/partner dysfunction; (3) technological developments to facilitate screening/assessment, monitoring, and communication; and (4) an improved methodology that includes new samples, measures, and settings.
46014720|NCT00600470|Behavioral|Treatment as usual (TAU)|TAU involves routine care: psychoeducation and referral to outside providers.
45465086|NCT01221935|Other|Pristiq second-line treatment charts|800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)).
45465087|NCT01221935|Other|SNRI or SSRI first-line treatment charts|800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs) (excluding Pristiq) within the past 6 months as a first-line treatment.
45465088|NCT01221935|Other|SNRI or SSRI second-line treatment charts|800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)(excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).
46014721|NCT04326062|Other|Main Study|The pharmacist will participate in the management of repeat prescribing and undertake medication reviews (which will address high risk prescribing and potentially inappropriate prescribing, deprescribing and cost-effective and generic prescribing) with adult patients. Pharmacists will also provide prescribing advice regarding the use of preferred drugs, undertake clinical audits, join practice team meetings and facilitate practice-based education. Throughout the six-month intervention period, anonymised practice-level medication (e.g. medication changes) and cost data will be collected.
46099911|NCT00520351|Drug|ClearCare|contact lens care system
46099912|NCT00520351|Drug|Optifree Replenish|contact lens care system
45465089|NCT05143918|Other|assessment of quality of life using questionnaire|assessment of quality of life in hypothyroid patients using SF 36 questionnaire
45465090|NCT01226225|Behavioral|Aerobic interval training|Patients will enter a training program during which aerobic interval training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
45465091|NCT01226225|Behavioral|Moderate endurance training|Patients will enter a training program during which moderate endurance training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
45465092|NCT05137678|Drug|glibenclamide|Glibenclamide was given orally or by nasal feeding
45465093|NCT01298089|Device|Carriazo Pendular microkeratome|
45465094|NCT01226303|Drug|ATRA|see the protocol
46014722|NCT04326062|Other|PROM Study|For this, a sub-set of patients (n=200) aged ≥65 years on ≥10 repeat medicines will be recruited and invited to a medication review with the pharmacist. PROMs and healthcare utilisation data will be collected using patient questionnaires and a six-week follow-up review with these patients will also be conducted.
46099913|NCT03722459|Device|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
46099914|NCT00850395|Drug|maraviroc|No intervention; any procedure at the discretion of the treating physician, in line with the SmPC
45680128|NCT03944785|Drug|XADAGO (safinamide)|XADAGO (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing off episodes.
46014723|NCT00600548|Drug|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
46014724|NCT00600548|Drug|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
46014725|NCT00600548|Drug|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
46014726|NCT00600548|Drug|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
46014727|NCT00600626|Drug|biphasic insulin aspart|
46014728|NCT00600626|Drug|insulin NPH|
46014729|NCT00600626|Drug|insulin aspart|
46014730|NCT00623090|Behavioral|educational internet site on prostate cancer screening|Healthy men between 45-70 receive the login information to access our educational internet site on prostate cancer screening.
46014731|NCT00623090|Behavioral|Educational print booklet|Healthy men between 45-70 receive a copy of our educational print booklet in the mail.
46014732|NCT00623090|Behavioral|Usual care|Healthy men aged 45-70 receive no intervention and are followed for one year, along with the men in the two intervention arms.
46014733|NCT00623168|Drug|Ribavirin|7 Day multiple dosing regime based on weight and dosage day
46014734|NCT00623246|Behavioral|MET|MET will involve motivational counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.
46014735|NCT00623246|Behavioral|ED|ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
46014736|NCT00600860|Other|No interventions|Only registration of clinical practice
46014737|NCT00601016|Drug|Imiquimod 5% cream|Imiquimod 5% cream applied topical on hemangioma once a day , 3 to 7 times a week for a maximum of 4 months.
46014738|NCT00601094|Biological|autologous dendritic cell-adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
46099915|NCT03951935|Other|Oswestry Disability Index (ODI) questionnaire|Participant's level of low back pain and the extent to which the pain impacts his/ her daily life activities and social life are estimated with the standardized Oswestry Disability Index questionnaire
46099916|NCT03951935|Diagnostic Test|self-paced walking test (SPWT)|walking back and forth at a self-selected pace along a hallway at the University Hospital until the onset of claudication, pain or until reaching the time limit of 30 minutes. Kinematic and electromyographic (EMG) data will be recorded every 3 minutes.
46099917|NCT04714411|Drug|Omadacycline|Omadacycline monotgherapy
46099918|NCT04188431|Drug|Dexamethasone|Is usually commercialized as dexamethasone phosphate as solution for injection
46099919|NCT04188431|Drug|Sodium chloride|prepared in the same intravenous volume to mimic experimental arm
46099920|NCT04692961|Device|Elastography|Use elastography to evaluate the stiffness of lower leg muscle after peroneal artery-based free flap harvested
46099921|NCT04819945|Device|GATT-Patch|Use of GATT-Patch for minimal, mild or moderate bleeding sites in open liver surgery
45465095|NCT01226303|Drug|ATRA + IDA|see the protocol
45465096|NCT03814759|Drug|TS-1 + cisplatin|S-1 20mg/m2, bid (D1~14, D22~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5)
45680129|NCT03927157|Biological|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
45680130|NCT03927157|Other|Placebo|Placebo subcutaneous injection
45680131|NCT03921424|Biological|V114|15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL dose.
46014739|NCT00601328|Drug|Calcitriol|
46014740|NCT00601406|Genetic|gene expression analysis|
45465097|NCT03814759|Radiation|radiation|radiation 45Gy per 5 weeks
45465098|NCT05101018|Drug|Romosozumab|Romosozumab (Amgen Inc., Thousand Oaks, CA) 210mg SQ administered each month
45465099|NCT05101018|Drug|Denosumab|Denosumab (Amgen Inc., Thousand Oaks, CA) 60 mg SQ administered every six months
45680132|NCT03921424|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each 0.5 mL dose.
45680133|NCT03921424|Biological|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine containing 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) in each 0.5 mL dose
45837666|NCT05766605|Drug|Lobaplatin|50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
46014741|NCT00601406|Genetic|gene rearrangement analysis|
46014742|NCT00601406|Genetic|polymorphism analysis|
46014743|NCT00601406|Other|laboratory biomarker analysis|
46014744|NCT00601406|Radiation|radiation therapy|
46014745|NCT02891486|Procedure|Spinal surgery|Elective spinal surgery performed
46014746|NCT00601562|Drug|Zidovudine|
46014747|NCT00601874|Drug|Pilocarpine|
46014748|NCT01326104|Biological|TTRNA-xALT|TTRNA-xALT 3 x 10^7/kg by intravenous injection once.
46014749|NCT01326104|Biological|TTRNA-DCs|TTRNA-DCs 1 x 10^7 by intradermal injection every 2 weeks for 3 total doses.
46099922|NCT03940313|Procedure|Prolotherapy|Musculoskeletal injection of lidocaine + 15% dextrose into damaged tissue
46099923|NCT03998215|Biological|Diphtheria booster vaccination|Participants received intramuscularly in the deltoid muscle one dose of the trivalent vaccine against diphtheria, tetanus and acellular pertussis
46099924|NCT03436823|Other|nurse semi-structured interview|The first session of rTMS is D1. From the first meeting to D14 semi -structured interviews are set up
46099925|NCT03436823|Other|Music & Relaxation with eyes closed|The first session of rTMS is D1. From the first meeting to D14 music & relaxation with eyes closed sessions are set up
46099926|NCT04008121|Combination Product|Fluorescein sodium and Zeiss FF450 fundus camera|Fluorescein sodium administered as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants
46099927|NCT04008121|Combination Product|MB-102 and Zeiss FF450 fundus camera|MB-102 administered 3 days after fluorescein sodium as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants
46099928|NCT04008121|Combination Product|Fluorescein sodium and commercially available optical angiography imaging system|Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants
45680134|NCT03915912|Behavioral|Mindfulness meditation|The study intervention consists of seven mindfulness sessions (six 1-hour telephone sessions and one 1-hour in-person session). The six weekly telephone-based mindfulness sessions will occur in a one-on-one format and will be followed by one in-person, one-on-one session, which will occur at the post-chemoradiation standard of care clinic visit.
45465100|NCT03929861|Drug|Fluconazole (BAYT006267) 150 mg capsules|Fluconazole 150 mg
46014750|NCT01326026|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
46099929|NCT04008121|Combination Product|MB-102 and commercially available optical angiography imaging system|Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants
45465101|NCT03929861|Drug|Fluconazole 150 mg capsules (DiflucanTM)|Fluconazole 150 mg
45465102|NCT03821623|Drug|Nicotinamide riboside|Nicotinamide riboside, a dietary supplement available over the counter under the name NIAGEN®, (ChromaDex Inc) is an exogenous NAD+ precursor that reverses age-related arterial dysfunction in aged mice, suggesting that declining NAD+ may play a key role in cardiovascular aging.
45465103|NCT03821623|Other|Placebo|Subjects will take placebo pills twice a day for 3 months
45465104|NCT05010694|Drug|GH35 Tablet|GH35 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.
45465105|NCT01225367|Device|ultrasound doppler monitoring|Regular noninvasive chest echo monitoring
45465106|NCT04878640|Procedure|patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy|patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy
45465107|NCT04878640|Procedure|patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy|patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy
45465108|NCT03820999|Other|Oral and written information on tick-bites and Lyme disease|See under study arm descriptions
45680135|NCT03914625|Drug|Asparaginase Erwinia chrysanthemi|Given IV or IM
45465109|NCT03928145|Drug|Chlorthalidone 25 mg|Chlorthalidone 25 mg taken orally in the morning for 12 weeks.
45465110|NCT03928145|Drug|Hydrochlorothiazide 50 mg|Hydrochlorothiazide 50 mg taken orally in the morning for 12 weeks.
45680136|NCT03914625|Biological|Blinatumomab|Given IV
45680137|NCT03914625|Drug|Cyclophosphamide|Given IV
45680138|NCT03914625|Drug|Cytarabine|Given IT or IV
45680139|NCT03914625|Drug|Dexamethasone|Given PO or IV
45680140|NCT03914625|Drug|Doxorubicin Hydrochloride|Given IV
46014751|NCT01326026|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted in a stepwise manner.
46099930|NCT03630809|Biological|HER2 DC1 Vaccine|Ultrasound (US) guided intranodal delivered vaccines will be administered at each participating site by a radiologist experienced in ultrasound guided procedures along with the principal investigator or his/her designee. Each dose will consist of between 1.0-2.0 x 10^7 cells and will be injected into 1 right and 1 left normal groin lymph nodes.
46099931|NCT00520039|Procedure|osteopathic manipulative medicine (OMM)|At each of the first three study visits, all subjects in the osteopathic manipulative medicine (OMM) group will receive OMM using the prescribed protocol.
46099932|NCT00577720|Drug|risedronate|35mg immediate release risedronate tablet before breakfast, once a week for 13 weeks
46099933|NCT00577720|Drug|risedronate|35mg delayed release risedronate tablet following breakfast, once a week for 13 weeks
46099934|NCT00577720|Drug|risedronate|50mg delayed release risedronate tablet following breakfast, once a week for 13 weeks
46099935|NCT00577720|Drug|risedronate|50mg delayed release risedronate tablet before breakfast, once a week for 13 weeks
46099936|NCT03630653|Procedure|Sentinel LN in breast cancer recurrence|Sentinel Lymph-Node (LN) procedure and Axillary LN dissection ; Mastectomy or breast conservative surgery
46099937|NCT00519649|Biological|Engerix™-B Kinder|Intramuscular injection, 1 dose
46099938|NCT03384173|Device|Near Infrared Spectroscopy|Application of regional NIRS sensors to brain and kidney sites in the first 48 hours after birth to monitor regional tissue oxygenation for the first 7 days of age.
46099939|NCT00740506|Behavioral|Frequency of Intercourse|
46099940|NCT04588129|Drug|LB-102|(N-Methyl amisulpride)
46099941|NCT00736216|Other|survey administration|Participants complete the Young Adult Survey online documenting demographic data; sexual history (i.e., whether they ever had sex, age of first sexual encounter, number of life time partners, condom use, sexually transmitted diseases [STDs], and pregnancy history); cigarette use; current and past drug use; knowledge of human papillomavirus (HPV) and cervical cancer; past history of Pap tests and STD screenings; attitudes towards HPV testing; vaccine knowledge and acceptability; sources of information about HPV; source of information about cervical cancer; identification of common STDs; perceived risk of acquiring STDs; perceived risk of acquiring HPV; social support; and religion.
45465111|NCT03928145|Drug|Amiloride 20 mg|Amiloride 20 mg taken orally in the morning for 12 weeks.
45465112|NCT03928145|Drug|Amiloride 10 mg|Amiloride 10 mg taken orally in the morning for 12 weeks.
45465113|NCT01226381|Drug|Von Frey electronic|This protocol is based on a study of the interaction setron / paracetamol at 4 different levels of plasma concentrations, by repeating the tests at set intervals, while concentrations of setrons down gradually (half-life of 8 to 10 am ) after a single administration. In addition, the interindividual variability of the effects of paracetamol will be studied, and linking with certain genetic polymorphisms reported by the subjects tested
45465114|NCT03928535|Device|High-FlowNasal Cannula|High-flowoxygenwas applied immediately after extubation through specific nasal cannula. Flow was initially set at 10 L/min and titrated upwards in 5-L/min steps until patients experienced discomfort.Temperature was initially set to 37°C, unless reported too hot by patients, and FIO2 was regularly adjusted to the target peripheral capillary oxygen saturation (SPO2) of greater than 92%. After 24 hours, high-flow was stopped and, if necessary, patients received conventional oxygen therapy.
45465115|NCT03928535|Device|Noninvasive Ventilation|Full face mask NIV was continuously delivered immediately after extubation for a scheduled period of 24 hours after extubation. Afterward, NIV was withdrawn and oxygen was administered by Venturi mask.Both PEEP and inspiratory pressure supportwere adjusted to target a respiratory rate of 25/min and adequate gas exchange (arterial oxygen saturation [SaO2] 92%, with pH of 7.35). The FIO2 was adjusted to maintain SPO2 at less than 92%. Sedatives to increase tolerance to NIV were not allowed.
45465116|NCT03819907|Combination Product|Audiovisual Guided Relaxation|Five-minute guided relaxation delivered via a computer screen and speakers
45465117|NCT03819907|Combination Product|Virtual Reality Guided Relaxation|Five-minute guided relaxation delivered via a Samsung Galaxy 7s and the Samsung adaptable VR headset.
45465118|NCT01129193|Other|Pharmacodynamic Studies|"Assess at baseline (pre-dose day 1 of cycle 1), approximately 24 hours after the first dose, pre-dose days 2 and 3, and pre-dose day 19 for histone acetylation of tumor cells (CLL patients) or mononuclear cells (PBMCs for lymphoma, myeloma, and solid tumor patients).~Cytokine studies will be collected pre-dose on days 1, 2, 8, 15, 19 of cycle 1, day 1 of cycle 2, and pre-dose days 1, 8, 15 of cycle 3."
45465119|NCT01129193|Other|Fatigue Inventory|Brief Fatigue Inventory should take each patient approximately 5 minutes to fill out this survey per instance on day 1 of every cycle.
45465120|NCT01129193|Other|Pharmacogenomic studies|Baseline germ line DNA from buccal swabs will be collected for analysis of drug (AR-42) metabolism SNPs and other biologic SNPs that might predict immune or disease response to therapy. Pharmacogenetic status of key metabolizing enzymes (eg, CYP3A5, UGT1A8) and transporter proteins (SLCO1B1, ABCG2) will also be considered for their role in drug clearance in individual patients.
45680141|NCT03914625|Drug|Leucovorin Calcium|Given PO or IV
45680142|NCT03914625|Drug|Mercaptopurine|Given PO
45680143|NCT03914625|Drug|Mercaptopurine Oral Suspension|Given PO
45837667|NCT05766605|Drug|Cisplatin|50 mg per square body surface area was used for monthly transhepatic arterial infusions.
45837668|NCT05766605|Drug|Oxaliplatin, Leucovorin, fluorouracil|"Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial.~infusions"
46099942|NCT03625973|Behavioral|3D-RT|Objects printed using 3D printing media will be used as stimuli in Reminiscence Therapy
46099943|NCT03625973|Behavioral|RT-Verbal|Verbal cues will be used as stimuli in Reminiscence Therapy
46099944|NCT00729196|Behavioral|Lifestyle Modification|Weekly group therapy for 20 weeks, followed by bi-weekly group therapy for 20 weeks
46099945|NCT00736294|Drug|Ramipril|5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
46099946|NCT00736294|Drug|Placebo|5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
46099947|NCT03478397|Other|Multicomponent mHealth Intervention|Women with HPV self-collected tests will receive a multicomponent intervention which includes SMS text messages to remind them to attend triage. In addition, CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage
46014752|NCT01097629|Drug|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants <65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month Treatment (TRT) Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
45465121|NCT01129193|Drug|AR-42|Administered orally three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
46014753|NCT01097629|Drug|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants <65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
46099948|NCT00736372|Drug|PX-12|Intravenous infusion, dose escalation, infused over a 72 hour period on days 1, 2 and 3 of a 21-day cycle until progression or development of unacceptable toxicity
46099949|NCT00740662|Procedure|Distal gastric bypass|Distal gastric bypass
45465122|NCT03817255|Other|Substance use questionnaire|Questions about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.
45465123|NCT03817255|Other|Physical activity|Questions about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
45465124|NCT01129271|Drug|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
45465125|NCT01129271|Drug|Matching placebo|"Pharmaceutical form: tablet~Route of administration: oral"
45465126|NCT03816631|Drug|Pimodivir|Participants will receive single oral dose of Pimodivir 600 mg (2*300 mg tablets) under fasted condition on Day 1.
45465127|NCT01129349|Drug|Oprozomib|Oral administration of Oprozomib on Days 1-5 of a 14 day cycle
45465128|NCT01222013|Drug|Imatinib Mesylate|patient will receive Imatinib (Glivec®), 300 mg/m²/day, per oral, in conjunction with chemotherapy, maximum dose allowed 400 mg/dia.
45465129|NCT01131143|Behavioral|Provider Voice|A phone call with the pre-recorded doctor's voice will be made to their patients who have been pre-screened for obesity before the patient's appointments prompting the patients to ask about physical activity, nutrition, and weight loss.
45465130|NCT01131143|Behavioral|Generic Voice|A phone call with a pre-recorded neutral voice will be made to the doctor's patients who have been prescreened for obesity before their patient's appointments. The call will prompt them to ask ask their doctor about physical activity, nutrition, and weight loss.
45465131|NCT03816475|Radiation|Hypofractionated radiotherapy|Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance.
45837669|NCT05766605|Drug|Lobaplatin, Raltitrexed|Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
45837670|NCT05766579|Device|Elastic-compressive stockings|Use of Elastic-compressive stockings at 21 mmHg and 32 mmHg.
45837671|NCT05766527|Biological|KM602|Multiple dose levels of KM602 will be administered, including 0.01 mg/kg QW, 0.1 mg/kg QW, 0.6 mg/kg QW, 3 mg/kg QW, and 10 mg/kg QW. KM602 is administered intravenously once a week, and each cycle is 21 days.
45837672|NCT05766514|Drug|Cladribine|Subjects will be given 5 mg/m2 cladribine intravenously on days 1-5 of cycle 1 and on days 1-3 of cycles 2, 5, 6, 9, 10, 13, 14, 17 and 18.
46099950|NCT00512707|Drug|Sildenafil citrate (open label)|On demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
46099951|NCT00512707|Drug|Testosterone gel|Testosterone Gel 1%: Starting active dose 10 g/day. Increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
45465132|NCT01131221|Other|laboratory biomarker analysis|
45465133|NCT05362045|Drug|Mavacamten|Specified dose on specified days
45465134|NCT00741988|Drug|Ixabepilone|ixabepilone 30 mg/m2
45465135|NCT00741988|Drug|Carboplatin|carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
45465136|NCT00741988|Drug|Bevacizumab|bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.
45465137|NCT01228253|Device|rTMS: repetitive transcranial magnetic stimulation|patients will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day)
45465138|NCT01228253|Device|SHAM rTMS: repetitive transcranial magnetic stimulation is off|patients will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day with the stimulator on off
45465139|NCT01567267|Behavioral|Experimental educational intervention|Educational intervention consisting of a 4-day-course in Evidence-based Medicine and Good Scientific Practice combined with the method of Problem-based Learning.
45465140|NCT01567267|Behavioral|Standard educational intervention|Educational intervention on the didactics of biology (4-day-course) not containing elements of Evidence-based Medicine, Good Scientific Practice or Problem-based learning.
45465141|NCT03924713|Behavioral|Supportive services|Assessment of behavioral, medical, and social needs, development of individual goals and action plan, follow-up to assist and work to ensure identified needs/goals are met. CHWs use their professional judgement to assess how long follow-up is required.
45465142|NCT02135302|Drug|eravacycline|Eravacycline (TP-434) is a parenteral and oral antibiotic of the tetracycline class that is highly active in vitro and in established animal infection models against both nosocomial and community-acquired methicillin-susceptible or -resistant Staphylococcus aureus strains, vancomycin-susceptible or -resistant Enterococcus faecium and Enterococcus faecalis, and penicillin-susceptible or -resistant strains of Streptococcus pneumoniae. In addition, eravacycline is highly active against clinically important species of Enterobacteriaceae (including those isolates that produce extended-spectrum β-lactamases and/or are carbapenem-resistant), Acinetobacter baumannii, and anaerobes.
45465143|NCT01131377|Drug|acetazolamide|"If ABGA is pH ≥ 7.43 & HCO3- ≥ 26mEq/L at 7am, they will receive acetazolamide 500mg via IV q 24h.~If ABGA is pH ≤ 7.35 at 7am, acetazolamide will skip."
45837673|NCT05766514|Drug|Cytarabine|Subjects will be given 20 mg cytarabine subcutaneously twice daily on days 1-10 of cycles 1, 2, 5, 6, 9, 10, 13, 14, 17 and 18.
45837674|NCT05766514|Drug|Decitabine|Subjects will be given 20 mg/m2 decitabine intravenously on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15 and 16
46014754|NCT01097629|Drug|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants <65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
46014755|NCT00602108|Procedure|adjuvant therapy|
46014756|NCT00602108|Procedure|conventional surgery|
46014757|NCT00602108|Radiation|hypofractionated radiation therapy|
46099952|NCT00512707|Other|Placebo gel|3 tubes of placebo gel equivalent to the amount of the testosterone gel will be applied during the placebo-controlled testosterone gel intervention for 16 weeks..
46099953|NCT00729274|Drug|normal saline solution|Two 4ml nebulizations with 30 minute interval
45837675|NCT05766514|Drug|azacitadine or decitabine|Subjects will be given either 20 mg/m2 decitabine intravenously on days 1-5 of each cycle or 75 mg/m2 azacitadine intravenously or subcutaneously on days 1-7 of each cycle. The treating physician will determine which drug each subject will receive.
46014758|NCT00602108|Radiation|intraoperative radiation therapy|
46014759|NCT04325516|Behavioral|Daily activities|"Participants will perform four tasks in a randomized order:~sit to stand~dorsi flexion of the foot~knee extension~hip extension"
46014760|NCT04971733|Drug|E2814|E2814 intravenous infusion.
46014761|NCT04308031|Drug|Ivabradine 5 mg [Corlanor]|Starting dose: Ivabradine 2.5mg twice daily (BID) Max Dose: Ivabradine 7.5 mg twice daily (BID)
46014762|NCT04308031|Drug|Digoxin 0.25 mg|Starting dose: 0.125mg once daily (QD) in estimated Glomerular filtration rate(eGFR)>60， 0.125mg once every other day (QOD) in estimated Glomerular filtration rate(eGFR)<60 Max dose: 0.25 once daily (QD)
46014763|NCT01324622|Device|Laminoplasty|Utilizing the ARCH Fixation System (Study device)
46014764|NCT01324622|Procedure|laminectomy|standard procedure
46014765|NCT01096849|Drug|levofloxacin|
46014766|NCT01096849|Drug|plazomicin|
46014767|NCT01096849|Drug|placebo|
46014768|NCT02878447|Radiation|External beam radiotherapy|External beam radiotherapy will be prescribed to a central plane using mega-voltage radiation encompassing all the assessed affected lung tissue at 3.5Gy weekly for 5 fractions to a maximum of 17G
46014769|NCT04307173|Drug|KBL693|"Part 1: 680 mg/day of KBL693 or Placebo;~Route of Administration: Oral"
46014770|NCT04307173|Drug|KBL693|"Part 2: 6800 mg/day of KBL693 or Placebo;~Route of Administration: Oral"
46014771|NCT04915261|Behavioral|Lenient Arm Restriction|The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
46014772|NCT04915261|Behavioral|Strict Arm Restriction|The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
46014773|NCT01324388|Biological|LY2189265|Administered subcutaneously
46099954|NCT03852953|Other|Under- or overdiagnosed cancer|Diagnosed with a cancer that was visible on prior mammograms
46099955|NCT03852953|Other|Screening|Invited or attended BreastScreen Norway
46099956|NCT00740818|Other|No Intervention|The patient will lay prone on the adjustment table 5 minutes, the approximate equivalency of a Logan Basic adjustment. Table will be in proper position according to Logan Basic protocol.
46099957|NCT00740818|Procedure|Sham Logan Basic Adjustment|A thumb contact will be used against the sacrotuberous ligament as opposed to underneath the ligament. Auxiliary contacts will also be sham adjustments; the spine will be contacted but no force applied.
46014774|NCT01324388|Drug|Metoprolol|Administered orally
46014775|NCT01324388|Drug|Lisinopril|Administered orally
46014776|NCT01324388|Drug|Placebo|Administered subcutaneously
46014777|NCT01102777|Behavioral|automated internet-mediated walking program|intervention participants are encouraged to walk daily to their step-count goal while wearing a pedometer provided by the study that will measure their daily step-counts. They are also encouraged to log into their personally tailored website to upload their step counts and obtain other information about the study and progress
45837676|NCT05766514|Drug|Venetoclax|Subject will take 400 mg venetoclax orally once daily on days 1-21 of each cycle.
46014778|NCT01102777|Other|Usual Care|Control group, instructed to wear the pedometer but not provided with walking goals or instruction.
46014779|NCT02878681|Drug|Ranibizumab|0.5 mg intravitreal injections
46014780|NCT02878681|Drug|Aflibercept|2 mg intravitreal injections
46014781|NCT02879461|Procedure|LUMBAR DESCOMPRESSION|ATRODESIS AND DESCOMPRESSIO OFF VERTEBRAL CANAL
46014782|NCT01324310|Drug|Romidepsin|Romidepsin 8 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.
46099958|NCT00740818|Procedure|Logan Basic adjustment|Logan Basic adjustment, as well as auxiliary and abdominal contacts, based on the Logan Basic protocol.
46014783|NCT01324310|Drug|Ketoconazole|Ketoconazole 400 mg oral once daily on Days 4-8
46014784|NCT05645666|Behavioral|Well-being therapy|Well-being therapy is a short-term, organized and problem-oriented treatment program that is based on Riff's psychological well-being model. Its purpose is to help patient in order to improve His/her functions in six dimensions; personal growth, environmental mastery, purposefulness of life, and autonomy, self-acceptance and positive relationships with others Therapists help patients find well-being experiences in their present and past lives and pay attention to these experiences, no matter how small or short they are.
46099959|NCT03960463|Device|Transcu O2®|Participants randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
46014785|NCT04325672|Biological|Convalescent Plasma|Anti-SARS-CoV-2 convalescent plasma obtained from patients identified as having recovered from COVID-19 with neutralizing antibody titers >1:64.
46014786|NCT01102231|Drug|Chemotherapy|Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)
46014787|NCT01102231|Drug|ERBITUX|The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes
46099960|NCT00740896|Behavioral|Smoking|Active Comparator: Participants smoke 8 cigarettes in 4 hours.
46099961|NCT00740896|Behavioral|Smoking|Sham Comparator: Participants are not allowed to smoke for 4 hours.
46099962|NCT00736528|Drug|PF-04447943|05 mg BID for 14 days
46099963|NCT00736528|Drug|PF-04447943|15 mg BID for 14 days
46014788|NCT01102231|Radiation|Radiotherapy|66 Gy (2 Gy by fraction, 5 fractions by week)
46014789|NCT04308733|Device|Anodal tDCS|patients will be stimulated over the contralateral pharyngeal motor cortex with anodal tDCS (2mA, 20 minutes) for 4 consecutive days
46014790|NCT02879539|Device|MP3000 sound coding strategy or ACE strategy with lower stimulation|
46014791|NCT01094743|Device|galyfilcon A prototype lens|Silicone hydrogel contact lens
46014792|NCT01094743|Device|lotrafilcon B lens|Silicon Hydrogel contact lens
46099964|NCT00736528|Drug|PF-04447943|45mg BID for 14 days
46099965|NCT00736528|Drug|Placebo|Placebo for 14 days
46099966|NCT03471767|Drug|AXS-05|Dextromethorphan Immediate Release + Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
46099967|NCT03471767|Drug|Bupropion SR|Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
46014793|NCT01095835|Drug|Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg|PEG-IFN alfa-2a 180 micrograms (mcg) was administered subcutaneously, once weekly from Week 0 to 48.
46014794|NCT01095835|Drug|Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg|PEG-IFN alfa-2a 135 mcg was administered subcutaneously, once weekly from Week 49 to 96.
46099968|NCT00849693|Drug|Placebo|Capsules identical in appearance, color, taste, and smell to study drug, orally, once daily for 10 weeks (acute treatment phase)
46099969|NCT00849693|Drug|fluoxetine|20 milligram (mg) orally, once daily for 10 weeks (acute treatment phase) and 20-40 mg orally, once daily for additional 6 months (extension phase)
46099970|NCT00849693|Drug|duloxetine|60 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
46099971|NCT00849693|Drug|duloxetine|30 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
45465144|NCT01131377|Drug|Saline|They will receive saline 50ml via IV q 24h.
45465145|NCT01300273|Dietary Supplement|Compound α-Ketoacid Tablet|30 patients will be treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day and supplemented with keto-amino acids (Ketosteril®, Fresenius Kabi) at a dosage of 100 mg/kg BW per day.
46014795|NCT01095835|Drug|Lamivudine (LAM)|Lamivudine 100 milligrams (mg) was administered orally, daily from Week 0 to 48.
45465146|NCT04457050|Drug|Sofosbuvir 400 milligram|single daily dose of 400 milligrams
46014796|NCT02878525|Procedure|Laparoscopic internal gastric banding|Laparoscopic internal gastric banding
46014797|NCT02878525|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
46099972|NCT02569294|Behavioral|Yoga intervention|Hatha-yoga intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by Hatha-yoga trained teachers. This program was developed previously in Montreal and the following were included at each session: 1) preparatory warm-up synchronized with breathing; 2) selected postures (e.g. forward , backward-, and side-bending asanas in sitting and lying positions); 3) deep relaxation; 4) alternate-nostril breathing or pranayama; and 5) meditation. Each participant received a DVD to encourage at-home practice.
46014798|NCT04308577|Other|Ketogenic diet with added MCT|The intervention is a ketogenic diet consisting of KetoCal 2,5:1 LQ MCT Multi Fibre (Nutricia), Liquigen (MCT)(Nutricia) and ketogenic meals provided by the hospital kitchen. The macronutrient composition of the ketogenic diet given approx.: Protein 11 E%, Carbohydrate 3 E%, Fat 86 E%.
46099973|NCT02569294|Behavioral|Hypnosis intervention|Hypnosis intervention included 6 sessions of 2 hours every 2 weeks. This was led by an anesthesist with experience in oncology and trained in hypnosis. Based on years of consultation with cancer patients, her team created a negotiating approach that fosters shared decision-making through using tasks that are centered on general well-being rather than on the health problem itself. Patients were asked to be actively involved. Several topics are addressed through tasks: eg. adjusting self-expectations. Patients were also required to keep a work-diary that was reviewed at the beginning of each session. At the end of the session, a 15-min hypnosis exercise is conducted. They receive CDs containing the hypnosis exercises and homework assignments.
45465147|NCT04457050|Drug|Daclatasvir 60 milligram|single daily dose of 60 milligrams for 12 weeks
46014799|NCT04308811|Biological|platelet rich plasma|Platelet rich plasma and intrauterine balloon applied intrauterine after hysteroscopic adhesiolysis of intrauterine adhesions
46014800|NCT04308811|Combination Product|amniotic membrane graft group|amniotic membrane applied on the intrauterine balloon after hysteroscopic lysis of intrauterine adhesions
46014801|NCT04308811|Device|Intrauterine balloon|intrauterine balloon applied intrauterine after hysteroscopic lysis of intrauterine adhesions
46099974|NCT02569294|Behavioral|CBT intervention|CBT intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by CBT-trained psychologists with experience in psycho-oncology. This program was developed by team leaders and is modelled on the work of Andersen et al. (2008) and Savard (2010). The intervention targets were: 1) breast cancer, meaning of illness, understanding stress and responses to it; 2) impact of treatment on body image; 3) impact of treatment on self-esteem; 4) fear of recurrence; 5) relationships with relatives and health professionals; and 6) life projects, return to daily activities and work. Relaxation training took place at the end of each session and participants performed tasks between sessions.
46099975|NCT03465761|Device|ExAblate|Bilateral side treatment of Essential Tremor
46099976|NCT00736606|Drug|simvastatin|One single dose of 40mg
46099977|NCT00736606|Drug|AZD9056 + simvastatin|AZD9056: 400 mg od, 8 days simvastatin: one single dose of 40 mg on day 7
46099978|NCT02569060|Other|Testing and Monitoring of Blood Glucose Levels|Point-of-care testing of HbA1c levels at the food pantry at approximately 3 month intervals
45465148|NCT04457050|Drug|Ribavirin 400 milligram|weight based dose, 1200 mg for weight > 75 kilogram, and 1000 milligram if weight < 75 kilograms for 12 weeks
45465149|NCT04457050|Drug|Ledipasvir 90milligram/Sofosbuvir 400 milligram Tab|single daily dose for 12 weeks
45465150|NCT01228409|Drug|Acitretin 17.5 mg/day|lower dose of Acitretin to 17.5 mg/day from 25 mg/day in those experiencing retinoid-related side effects
45465151|NCT01301911|Drug|Cipatinib|Cipatinib either at 200, 400, 800, 1200, 1400, 1600 or 1800 mg, p.o. once daily
45465152|NCT03470350|Drug|Galunisertib|treatment with capecitabine and galunisertib
45465153|NCT01301443|Drug|Subretinally injected RetinoStat|Single subretinal injections, with increasing doses. 9 patients with 3 patients at each dose followed, by 12 patients at maximum tolerated dose.
46099979|NCT02569060|Other|Primary care coordination|Referral to a local primary care provider, if none currently exists. Coordination of care with primary care provider.
45465154|NCT03468712|Procedure|Laparoscopic D2 distal gastrectomy|Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy
45465155|NCT03928613|Behavioral|tablet based Cognitive Training based on location information|Participants perform Tablet based Cognitive training using interactive voice services and tags three times (minimum 30 minutes per time) a week for 6 weeks
45465156|NCT01301521|Drug|water-soluble cinnamon extract (Cinnulin PF)|Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy
45465157|NCT05164588|Other|Statistics|Study and analyze the medicolegal aspects of different eye trauma cases ( patterns of injuries, mechanisms, causes, site of trauma and outcome)
45465158|NCT03928301|Behavioral|Wholetones Music|Participants listened to the Wholetones music for 10 nights consecutively. Participants began playing the music 30 minutes before going to bed and were asked to allow it to play continuously throughout the night.
45465159|NCT03928301|Behavioral|Classical Music|Participants listened to the classical music for 10 nights consecutively. Participants began playing the music 30 minutes before going to bed and were asked to allow it to play continuously throughout the night.
46014802|NCT02879773|Radiation|CTPVe|Non contrast computed tomography (CTPVe) scan during end inspiration and end expiration in supine position
46014803|NCT04908865|Drug|Belimumab|Belimumab will be administered.
45465160|NCT03814525|Radiation|Photobiomodulation|PBM will be applied with extra and intraoral LED devices. The LED plates speed up the treatment as they deliver all the energy at once, having the advantage of radiating several points at the same time. The applications of both will occur in the following experimental periods after the end of the surgeries: immediate postoperative, 1, 2, 7, 14, 30, 60 and 90 days.
45465161|NCT03814525|Radiation|Placebo Photobiomodulation|The person responsible for applying the PBM will simulate the irradiation by positioning the devices in the same locations described for the PBM group, but the equipment will be kept off
45465162|NCT04565392|Drug|Famotidine 20 milligram tablet|1 tablet every 12 hours and increase to 1 tablet every 8 hours if not improved by the second day of treatment
45465163|NCT03816787|Procedure|Negative pressure therapy|Participants assigned to the treatment group will receive wet-cupping therapy 1 times per week for 4 weeks
45465164|NCT03928379|Drug|LY3305677|Administered SC
45465165|NCT03928379|Drug|Placebo|Administered SC
46014804|NCT04908865|Drug|Standard therapy|Standard therapy will be continued.
46014805|NCT04308421|Device|Red light|Low irradiation 650 nm +/- 5 nm red light
45465166|NCT01226537|Drug|Taurine|500 mg taurine capsules twice per day for 6 months
45465167|NCT01226615|Drug|Chondroitin sulphate (Condrosan®)|800mg (two capsules of 400mg each) taken once a day for four months
45465168|NCT01226615|Drug|Placebo|Two placebo capsules taken once a day for four months.
45465169|NCT03470272|Device|FB Professional LED Red light therapy|FB Professional LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs. Measure before and after effects of device unit. Three measurements before of circumference of abdomen area and three measurements after comparing the results.
46014806|NCT01324232|Drug|AVP-923-45|AVP-923-45 (dextromethorphan 45 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
46014807|NCT01324232|Drug|AVP-923-30|AVP-923-30 (dextromethorphan 30 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
46014808|NCT01324232|Drug|AVP-923-20|AVP-923-20 (dextromethorphan 20 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
45465170|NCT03470272|Device|Effects of Red Light LED Therapy on Body Contouring|Intervention is to take a sample and measure before and after using a sham unit (placebo) and take three measurements of abdominal before treatment and three measurements after sham treatment and compare to controlled treatment.
45680144|NCT03914625|Drug|Methotrexate|Given IT or IV
45680145|NCT03914625|Drug|Pegaspargase|Given IV or IM
45680146|NCT03914625|Drug|Prednisolone|Given PO or IV
45680147|NCT03914625|Drug|Prednisone|Given PO or IV
45680148|NCT03914625|Radiation|Radiation Therapy|Undergo cranial radiation therapy
46014809|NCT01324232|Drug|Placebo|Matching placebo capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
45680149|NCT03914625|Radiation|Radiation Therapy|Undergo testicular radiation therapy
45680150|NCT03914625|Drug|Thioguanine|Given PO
45680151|NCT03914625|Drug|Vincristine Sulfate|Given IV
46099980|NCT02569060|Other|Diabetes-appropriate food packages|Food (perishable and non-perishable) appropriate for diabetes self-management available for pick-up at the food pantry twice monthly.
46099981|NCT02569060|Behavioral|Diabetes self-management education|Education materials drawn from evidence-based practice and adapted from existing diabetes education curricula to be flexible to individual, community, and site variations. The Immediate Intervention Arm receives more robust diabetes self-management education (with group education visits) than the Waitlist Control Arm.
45465171|NCT01301989|Behavioral|Sleep Counselor Intervention|Families in the sleep counselor arm of the study will receive 3 scheduled home visits by a trained sleep counselor during the first 3 months following enrollment. Two optional home visits may be scheduled to help families encountering ongoing barriers to improving their child's sleep. The intervention will be provided by trained, bilingual, culturally competent sleep counselors, who will assess home sleep conditions, work with the family to teach them how to improve sleep hygiene and the sleep environment, provide equipment as needed to improve the sleep environment (e.g. nightlight, inflatable bed, window shade, etc.) and guide the family to begin setting goals and making decisions to initiate and sustain behavioral and environmental changes to improve sleep.
46014810|NCT02878291|Biological|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
45465172|NCT01301989|Other|Sleep Education Control|"The control group will receive a low intensity intervention that provides information about sleep and the benefits of adequate sleep. We will give parents the National Sleep Foundation's handout, Information about Children's Sleep for Parents and Teachers"
45465173|NCT01226693|Drug|PH-797804 material sparing tablet|oral, 6mg, single dose
46014811|NCT02878291|Biological|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
46014812|NCT04841083|Device|Allay Lamp|The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10 lux) narrow band (20 nm) green light (peak wavelength 520 nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k).
46014813|NCT04306783|Other|In-home sensor monitoring|-Installed and maintained by Foresite Healthcare
46014814|NCT05350891|Procedure|endoscopic surgery|endoscopic surgery combined with adjuvant immunotherapy with/without chemotherapy
46014815|NCT01094119|Device|heated blanket|heated blanket
46014816|NCT01094119|Device|heated pad|patients will be warmed with a heated pad during surgery.
45465174|NCT01226693|Drug|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
45465175|NCT01226693|Drug|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
46014817|NCT01323920|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 IV
46014818|NCT01323920|Drug|Tacrolimus|Tacrolimus 0.05 mg/kg PO bid
46014819|NCT01323920|Drug|Methotrexate|Methotrexate 15 mg/m^2 IV
46014820|NCT01093885|Drug|Ambrisentan|"Drug is dispensed in tablet form. Ambrisentan with anti-fibrotic to assess benefit on skin~Dosing of ambrisentan will begin at 5mg daily for the first month. Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week."
45837677|NCT05766488|Device|Continuous glucose monitor|A continuous glucose monitor will be provided in the experimental arm of this study for 6 months. This monitor will be a Freestyle Libre 2 device.
46099982|NCT00527605|Drug|Dutasteride 0.5mg capsule|Dutasteride 0.5mg once daily orally
46099983|NCT00527605|Drug|Dutasteride matched placebo|Dutasteride matched placebo once daily orally
46099984|NCT00736684|Device|Proximal Femoral Nail AntirotationTM (PFNA)|intramedullary nailing
45465176|NCT01226693|Drug|PH-797804 material sparing tablet|oral, 6mg, single dose
45465177|NCT01226693|Drug|PH-797804 material sparing tablet|oral, 6mg, single dose
45465178|NCT01226693|Drug|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
45465179|NCT01226693|Drug|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
45837678|NCT05766488|Device|Traditional glucometer|A traditional glucometer device will be assigned in the standard of care arm of this study for 6 months.
45837679|NCT05766436|Drug|Dexmedetomidine|receive placebo ODF and 3 µ/kg nebulized dexmedetomidine (Precedex™ rxlist) prepared in 0.9% normal saline to a final volume of 3ml. Nebulization was performed using a wall nebulizer and wall oxygen source on 4 l/min.
45837680|NCT05766436|Drug|Melatonin|will receive placebo nebulizer and 0.4mg/kg of ODF melatonin (metacyst ™ nerhadou) orally allowing the film to dissolve in the patients Oro mucosal lining
45837681|NCT05766436|Drug|Placebo|placebo ODF and 0.9% normal saline nebulizer
46099985|NCT00736684|Device|Gamma Nail 3TM (Gamma3)|intramedullary nailing
45837682|NCT05766397|Drug|Methoxyflurane|Methoxyflurane belongs to the fluorinated hydrocarbon group of volatile anesthetic gases
45837683|NCT05766384|Drug|Hyperpolarized Xe129|Inhaled hyperpolarized 129Xe used as a signal agent for MRI of the lungs.
45837684|NCT05766319|Device|Withings ScanWatch|"Withings ScanWatch, from which the following features will be used:~Measurement of peripheral oxygen saturation (%)~Automatic recording of heart rate (beats/min)~Automatic recording of activity (step count) (numbers/day)"
45837685|NCT05766319|Device|Withings BPM Connect|"Withings BPM connect, from which the following feature will be used:~o Measurement of non invasive bloodpressure (mmHg)"
46099986|NCT00849381|Biological|GSK580299, GSK Biological's HPV vaccine|All subjects will receive 3 doses administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
46099987|NCT04865939|Procedure|sterile water irrigation|Continuous irrigation of bladder with sterile water during surgery (prior to entry into bladder).
46099988|NCT04865939|Drug|Gemcitabine|Intravesical gemcitabine instilled into bladder during surgery (drained prior to entry into bladder).
46099989|NCT02568982|Other|Exams and questionnaires|Blood sample 24hrs urinary cortisol and salivary cortisol, urinary labstick test, EKG, cardiac ultrasound, cardiac CT-scan, arterial and venous US ophthalmology examination spine X-Ray bone densitometry QoL questionnaires (SF-36, QoLCushing, Beck BDI-II)
46099990|NCT04480697|Drug|HPG1860|6 subjects randomized to active compound and 2 subjects randomized to placebo
45465180|NCT01226693|Drug|PH-797804 material sparing tablet|oral, 6mg, single dose
45465181|NCT01226693|Drug|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
45465182|NCT01226693|Drug|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
45465183|NCT01226693|Drug|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
45465184|NCT01226693|Drug|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
45465185|NCT04240210|Drug|Symtuza|The study is a prospective cohort analysis of change in adherence, tolerability and safety of subjects who reports poor adherence to ART due to intolerance/side effects from integrase inhibitor containing regimens when they are switched to DRV/COB/FTC/TAF and monitored for 4 months.
45465186|NCT05654233|Drug|Sulodexide|The recovery of pigmentation, fibrosis, pain and other indicators in the group taking sulodexide after surgery, one month after surgery and three months after surgery was observed
46099991|NCT02609269|Other|Decipher Cancer Classifier|The Decipher are gene expression-based tests that are used to better risk stratify or characterize tumor biology that are commercially available through Veracyte, Inc CLIA & CAP certified laboratory in San Diego, CA
46099992|NCT00741052|Drug|Ciprofloxacin|12 hourly oral dose of ciprofloxacin for 3 days
46099993|NCT00741052|Drug|Azithromycin|1 gm Azithromycin single dose
46099994|NCT04116411|Drug|Valganciclovir Tablets|Valganciclovir treatment of glioblastoma
46014821|NCT05645354|Behavioral|SmokefreeSGM|Participants will be enrolled in a text-based smoking cessation program specifically designed to respond to the needs of LGBTQ+ smokers.
46014822|NCT05645354|Behavioral|SmokefreeTXT|Participants will be enrolled in a text-based smoking cessation program specifically designed to respond to the needs of the general population
46099995|NCT04116411|Drug|Temozolomide 120 mg|Chemotherapy
46014823|NCT02878369|Procedure|Doppler measurement of blood flow in the outflow tract of the left ventricle and the femoral artery,Reading blood pressures displayed on the monitor.|
46014824|NCT01101997|Device|The Zeltiq System|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
46014825|NCT00597597|Drug|Erlotinib|During the treatment period, subjects will receive single agent erlotinib, 150mg/day.
46014826|NCT02891967|Other|bulk fill composite|cavities will be incrementally layered with resin composite and each increment will be cured as directed by the manufacturer with the light curing unit (XL 3000; 3M/eSPe), with an energy higher than 450 mW/cm² (±50 mw/cm²)
46014827|NCT02891967|Other|Nano resin composite (K Z350 xt)|cavities will be restored by bulk fill composite (3M ESPE) as one increment then will be cured as directed by the manufacturer with the light curing unit.
46014828|NCT00598065|Other|PET/CT|Synchronized PET/CT Imaging
46014829|NCT02892045|Device|MMG|neuromuscular monitoring device
46014830|NCT04326621|Other|Pressure Release Technique (PRT)|A pressure applied on muscles trigger points with the finger of a physiotherapist and exercises
46014831|NCT04326621|Other|Control|exercises
46014832|NCT04207827|Behavioral|xSmoker app|xSmoker - mHealth intervention consisted of using the app xSmoker
46014833|NCT04207827|Behavioral|SMS|Text messages with content based on the Motivation and Problem Solving approach and informed by our prior work.
46014834|NCT04207827|Other|Usual Care|Usual postnatal care
46014835|NCT00598299|Procedure|venous puncture|venous puncture
45465187|NCT01226771|Drug|"Ribavirin loading dose given"|PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
45837686|NCT05766319|Device|Withings Body|"Withings Body (Scale), from which the following feature will be used:~o Measurement of body weight (kg)"
46014836|NCT00598299|Other|obtain serum from perripheral blood or cord blood|obtain serum from perripheral blood or cord blood
46014837|NCT00598377|Drug|Tetracosactin|1 microgram tetracosactin, intravenous injection, once for the test
46014838|NCT04326543|Diagnostic Test|Swanson, Noolan and Phelham - IV edition (SNAP-IV); Conners' Parent Rating Scales (CPRS)|"Ratings on the Swanson, Nolan and Pelham Evaluation Scale - IV (Bussing et al., 2008), were assessed during baseline visit for participants at the time of research assessment, to exclude the presence of ADHD symptoms in the healthy subjects. This scale is composed of 26 items for ADHD symptoms and ODD and was administered at baseline and at follow-up visit.~Temperament assessment: we used the Mary Rothbart's Temperament Questionnaire, a caregivers' report measure designed to provide a detailed assessment of temperament.~ADHD Rating scales: the Long Version of Conners' Parent Rating Scale (Conners et al., 1998) was used to quantify ADHD comorbidity symptoms, as ODD and Anxiety traits, in the children and adolescents with ADHD.~Salivary cortisol: Sampling was performed during one ordinary weekday between 7 and 8 o'clock, within 60' after nocturnal awakening."
46014839|NCT04326387|Diagnostic Test|SAMBA II (Diagnostic for the Real World)|Point of care Isothermal-PCR Viral RNA Amplication for virus detection
46014840|NCT04326387|Diagnostic Test|Public Health England Gold Standard|Reverse Transcription PCR
46014841|NCT04326387|Diagnostic Test|Cambridge Validated Viral Detection Method|Reverse Transcription PCR
46014842|NCT04326387|Diagnostic Test|Radiological Detection|Chest X-ray & CT Scan detection of viral infection in the lungs
46099996|NCT04116411|Radiation|Radiotherapy 60 Gy|Radiation therapy
46099997|NCT04116411|Drug|Placebo oral tablet|Placebo treatment of glioblastoma
46099998|NCT04469621|Drug|SAR443122|Pharmaceutical form:capsule Route of administration: oral
46099999|NCT04469621|Drug|Placebo|Pharmaceutical form:capsule Route of administration: oral
46100000|NCT00706875|Behavioral|questionnaire|"A patient questionnaire, which includes validated instruments. Data collection methods are as follows:~In person at the medical appointment~Over the telephone~Mailed with self-addressed return envelope and prepaid postage~E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage"
46014843|NCT00598533|Device|Rapamycin + Probucol-eluting stent (ISAR stent)|due to randomization, Rapamycin- + Probucol-eluting stent will be implanted
46100001|NCT00706875|Behavioral|questionnaire|"A patient questionnaire, which includes validated instruments. Data collection methods are as follows:~In person at the medical appointment~Over the telephone~Mailed with self-addressed return envelope and prepaid postage~E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage"
46100002|NCT00706953|Drug|bortezomib; pegylated liposomal doxorubicin|1.3 mg/m2 IV bolus on Days 1,4,8,11 of each 21-day cycle; 30 mg/m2 IV infusion on Day 4 of each 21 day cycle
46100003|NCT03462017|Drug|SAR247799|Pharmaceutical form:Capsule Route of administration: Oral
46100004|NCT03462017|Drug|Placebo|Pharmaceutical form:Capsule Route of administration: Oral
45465188|NCT01226771|Drug|"Priming dose of ribavirin given"|Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks
46100005|NCT03462017|Drug|Sildenafil|Pharmaceutical form:Encapsulated tablet Route of administration: Oral
45465189|NCT01226771|Drug|"Group C (Standard-of-Care)"|PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
45465190|NCT03814447|Drug|anti- MESO CAR-T cells|Autologous genetically modified anti- MESO CAR transduced T cells
45465191|NCT03814447|Drug|Fludarabine|Dose: 30mg/m2/d
45465192|NCT03814447|Drug|Cyclophosphamide|Dose: 300mg/m2/d
45837687|NCT05766293|Device|extracorporeal shockwave device|Fibroblast cell lines (n=10) were subjected to Shockwaves from extracorporeal shockwave device
46014844|NCT00598533|Device|polymer based Zotarolimus-eluting stent (Endeavor Resolute)|due to randomization, Zotarolimus-eluting stent with polymer will be implanted
46100006|NCT03462017|Drug|Acetylcholine|Pharmaceutical form:Solution Route of administration: Transdermal
46100007|NCT00913419|Drug|Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories|
46100008|NCT00913419|Drug|Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme|
45837688|NCT05766293|Other|Fibroblast cell lines not subjected to shockwaves from extracorporeal shockwave device|Fibroblast cell lines (n=10) without shockwave exposure
45837689|NCT05766267|Drug|Rifabutin|Rifabutin (Rb) is added to the bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) regimen for first 8 weeks and continued for next 9 weeks with bedaquiline (B or BDQ) and moxifloxacin (M)
45837690|NCT05766267|Drug|Delamanid|Delamanid (D or DLM) is added to the bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) regimen for first 8 weeks and continued for next 9 weeks with bedaquiline (B or BDQ) and moxifloxacin (M)
46014845|NCT00598845|Procedure|Tumor biopsy study|Tumor specimens from endometrial cancer patients, collected preoperatively and during primary hysterectomy, are investigated.
46014846|NCT04207671|Procedure|Complete omission of chest tube|No chest tube implacement
46014847|NCT04207671|Procedure|Improved drainage strategy|A two-lumen central venous catheterization along the midclavicular line, second intercostal space for remedial gas-remove
46014848|NCT00599703|Other|fMRI Scan, pre- and post language evaluation|All subjects will undergo functional MR imaging, pre- and post-surgical language evaluation, and electrocortical stimulation mapping. The brain tumor patients will undergo these procedures twice.
46014849|NCT00599781|Genetic|gene transduced PBL and/or gene transduced HSC|infusions of autologous PBL and/or HSC transduced with retroviral vectors encoding ADA
46014850|NCT00599859|Dietary Supplement|lactose|consumption of 50g lactose/day in 2 divided doses mixed in water.
46014851|NCT00599859|Dietary Supplement|lactose|consumption of lactose 50g/day in 2 divided doses mixed in water
45837691|NCT05766267|Drug|Bedaquiline|Bedaquiline is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).
46100009|NCT00711412|Drug|Induction Therapy - Capecitabine|Two 21-day cycles will be given as induction. Capecitabine will be given at 1000 mg/m2 twice daily approximately 12 hours apart for 14 days, followed by seven days off.
46100010|NCT00711412|Drug|Induction Therapy - Oxaliplatin|Two 21-day cycles will be given as induction. Oxaliplatin will be given at 70 mg/m2 intravenously in 5% dextrose over two hours on days 1 and 8 of each cycle.
45599182|NCT02302417|Procedure|Spirometry|Classification of respiratory diseases by Spirometry will be performed to differentiate subjects between Asthma only, ACOS, and COPD only. Spirometry obtained from measurements in the past 6 months is acceptable for purposes of this study. For subjects without spirometry in the past 6 months, spirometry will be performed to obtain pre- and post-bronchodilator Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity (FVC) and reversibility
45837692|NCT05766267|Drug|Moxifloxacin|Moxifloxacin is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).
46100011|NCT00711412|Drug|Combination Therapy - Capecitabine|Two 21-day cycles will be given for combination therapy. Capecitabine will be given at 825 mg/m2 twice daily approximately 12 hours apart for five days (Monday through Friday) followed by two days off for 51/2 weeks.
46100012|NCT00711412|Drug|Combination Therapy - Oxaliplatin|Two 21-day cycles will be given. Oxaliplatin will be given at 50 mg/m2 intravenously in 5% dextrose over two hours on days 1, 8 and 15 of each cycle.
46014852|NCT00599937|Drug|ATRA|early introduction of ATRA
46014853|NCT00599937|Drug|ATRA and or Chemo as maintenance|patients were randomized both to receive or not receive intermittent ATRA (45 mg/m2/d, 15 days every 3 months) and to receive or not receive continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally), according to a 2-by-2 factorial design stratified on the initial induction treatment group
46014854|NCT02891421|Behavioral|Therapeutic Horseback Riding|Veterans were matched to a horse for best fit and the same horse was ridden each week. The warm-up exercises involved various repeated physical movements while the horse was walking or standing steady, such as head rotations, lifting arms, rotating ankles, flexing toes. The exercises began with riding at a walk during the early weeks, learning reining skills and riding positions, and progressed to light trotting. Veteran participants were able to build on skill sets related to grooming, tacking, mounting, and riding that were introduced in prior weeks. Skill progression was based on individual abilities and safety as determined by certified riding instructor and occupational therapist.
46014855|NCT02891421|Other|Standard Care|Standard Care: Participants received standard care
45837693|NCT05766267|Drug|Pyrazinamide|Pyrazinamide is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ). Pyrazinamide is part of control regimen (HRZE).
45837694|NCT05766267|Drug|Isoniazid|Isoniazid is part of control regimen (HRZE).
45837695|NCT05766267|Drug|Rifampin|Rifampin is part of control regimen (HRZE).
45837696|NCT05766267|Drug|Ethambutol|Ethambutol is part of control regimen (HRZE).
46014856|NCT00600093|Drug|Amantadine|IV Amantadine 200mg *1/d at the beginning of surgery and 24 hours following surgery
46014857|NCT00600249|Drug|Cetuximab|dosage : 5mg/ml one administration per week: 400 mg/m2 then 250 mg/m2 during 18 weeks
46014858|NCT00600249|Drug|Docetaxel|100mg/m2 every 21 days 6 cycles of 21 days
46100013|NCT00711412|Radiation|Combination Therapy - Radiation|1.8 Gy daily Monday through Friday to a total of 50.4 Gy for 6 weeks during combination therapy.
46100014|NCT00711412|Procedure|Evaluation for response and surgery|Four to eight weeks following the completion of therapy subjects will undergo evaluation for response and surgical resection.
46014859|NCT00600327|Device|EndoTex™ NexStent™|EndoTex™ NexStent™ is a flexible, fine mesh Nitinol stent used to treat patients that are at high risk of adverse events from carotid endarterectomy and require carotid revascularization of a target vessel that has a reference diameter between 4mm and 9mm and stenosis that is less than 30mm in length.
46014860|NCT00600327|Device|Filter Wire EZ™|EPI Fliter Wire EZ™ Embolic Protection System is indicated for use as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
46014861|NCT00600405|Drug|tamsulosin|Tamsulosin 0.4 mg orally daily for ten days.
46014862|NCT00600405|Drug|Standard therapy with ibuprofen and oxycodone.|Oxycodone: 5mg, one to two tablets every four to six hours as needed for pain. Ibuprofen: 800 mg, one three times a day with food as needed for pain.
46014863|NCT00600561|Behavioral|MBSR|Mindfulness-Based Stress Reduction Intervention
46100015|NCT01840007|Drug|Metformin Group|"The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.~Patients should take 3 tablets/day at the rate of 1tablet in morning, noon and evening to favor the absorbtion and reduce the risk of gastrointestinal intolerance. In case of missed dose, patients will be allowed to take 2 tablets on the next grip. The drug will be presented in its officinale form of Glucophage ® 1000 with specifications indicated in the Vidal dictionary. It will be provided each month, to patient, 3 boxes of 30 tablets of Glucophage ® 1000. The patient will be asked to rate each day, on a calendar, the number of tablets of Glucophage ® 1000 effectively taken. It will also ask to the patient to bring back used boxes of Glucophage ® 1000 to count any tablets not taken."
46100016|NCT05491161|Other|Longitudinal study|Longitudinal study following infant development from birth to 1 year of age
45465193|NCT04456192|Behavioral|Indoor Cycling Interval Exercise Training|"The 3-month intervention consisted of a physical exercise program involving three indoor cycling sessions per week, with a total of 36 training sessions. Subjects exercised on cycle ergometers Schwinn® Evolution® (Schwinn Bicycle Company, Boulder, Colorado, USA). Each session lasted approximately 55 minutes. Training sessions consisted of a 5-min low-intensity warm-up (cycling at 50-65% of maximum heart rate (HRmax)), 40 min of main training at an intensity of 65-95% of HRmax, 5 min of non-weight-bearing cycling, finishing with 5 min of low-intensity cool-down stretching and breathing exercises.~Main part of the training was interval. Each exercise session consisted of 3 to 4 high intensity intervals with intensity exceeding 80% of HRmax, often reaching anaerobic threshold. High intensity intervals lasted approximately 4-minutes and were interspersed by recovery periods at 65-80% of HRmax."
45465194|NCT01129427|Drug|Clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
45465195|NCT01129427|Drug|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
45465196|NCT01129427|Drug|Pantoprazole|"Pharmaceutical form: delayed-release tablet~Route of administration: oral"
45465197|NCT03816241|Other|Frame|Vignette is framed in a way that nudges participant to leave a legacy
45465198|NCT03816241|Other|Norms|Vignette informs the participant that most people choose an option to try to nudge participant into choosing that option as well
46014864|NCT01324830|Drug|day 1 to day 5|low to high dose
46014865|NCT01324830|Drug|day 1 to day 14|low to high dose
46014866|NCT02891577|Procedure|Ultrasonography|At the time of ICU admission, among critically ill patients with shock, the investigators will measure the diameter of the common femoral vein and that of the inferior vena cava by ultrasonography.
46014867|NCT00600639|Device|Non-invasive mechanical ventilation using a BiPAP Vision or any other ICU ventilators with NIV option|A mode of ventilation that does not require the insertion of the endotracheal tube, since the support is delivered throgh a full face or nasal mask
46014868|NCT00600639|Drug|standard medical therapy plus oxygen that includes salbutamol, prednisolone and antibiotics as needed|Standard medical therapy includes drugs like beta2-agonists, steroids, anthicolinergic agents- antibuiotics as needed
46014869|NCT00600639|Drug|standard medical therapy that includes salbutamol, prednisolone and antibiotics as needed|oxygen plus medical therapy for ARF
46100017|NCT03896659|Drug|Hydrocortisone Oral|Hydrocortisone 160 mg tablet
46100018|NCT03896659|Drug|Placebo Oral Tablet|Hydrocortisone-matched Placebo tablet
46100019|NCT03801941|Device|wearing ATLAS device during evaluation at 4th day|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities with or without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
46100020|NCT03801941|Other|wearing ATLAS device during evaluation at 5th day|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
45837697|NCT05766241|Behavioral|Sensory Strategies Training|In SST, participants will be introduced to the concept of sensory processing in the context of PTSD and will learn about the ways in which difficulties in this area can impact their affective, cognitive, and functional outcomes. Participants will learn about the effects of PTSD symptoms on their ability to regulate stressful situations and engage in social interactions, as well as the benefits of physical activity and proper sleep hygiene. Participants will also identify functional goals (e.g., reduce sensation-avoiding, better regulate physical and emotional reactions to trauma reminders, increase sensory sensitivity, etc.) which they will aim to achieve with the knowledge and resources gained from SST. Throughout the program, participants will learn various strategies to help with movement, sleep, and interacting with others, and will have opportunities to practice the strategies identified as being relevant to their specific needs during their baseline sensory assessment.
45465199|NCT05164510|Genetic|ct-DNA guided therapy|treatment according to ct-DNA results:For Patients with abnormal gene changes of corresponding targeted drugs are recommended to use corresponding targeted therapy or immunotherapy drugs;For Patients without abnormal gene changes of corresponding targeted drugs, Treatment of Physician's Choice (TPC) is recommended.
45465200|NCT03928067|Behavioral|PNF + SAF|Personalized normative feedback (PNF) to correct misperceived peer drinking norms abroad + sojourner adjustment feedback (SAF) to promote cultural engagement abroad.
45837698|NCT05766228|Other|Web-Based Intercultural Midwifery Training|The training program is a program where students can log in via the internet using the password given to them by a smartphone or computer. The web base is compatible with mobile phones and is suitable for use at any time of the day. The trainings were prepared and explained by the researchers on the web page in the form of a video presentation with the theory-based didactic classroom technique using a Power Point presentation. The training program covered six weeks and consisted of two sessions of 30 minutes each week. In the first five weeks, general information on the development of intercultural midwifery and the main components of cultural competence models are explained. In the last week, training was completed with case presentations in the form of two sessions.
46014870|NCT00623025|Drug|Creon 25000|6 to 9 capsules Creon 25000 per day
46014871|NCT00623025|Drug|Placebo|6 to 9 capsules placebo per day
46014872|NCT00600795|Other|CSF collection|CSF collection at time of VPS insertion
46014873|NCT00602160|Drug|FAHF-2 (TM)|"We propose to test 10 tablets administered orally three times daily (t.i.d.) for 6 months in the Phase II study. The subjects will be randomized to 1 of 2 groups; FAHF-2 or Placebo group.~Both groups will undergo physician supervised Double-blinded placebo controlled food challenges, once during screening before starting treatment and again after 6 months of therapy."
46014874|NCT00600873|Drug|R(+) pramipexole dihydrochloride monohydrate|100 mg tid orally daily
46014875|NCT04325997|Device|laryngoscope with mouth opener|Double-lumen tube combined with mouth gag for laryngoscope intubation
46100021|NCT00741208|Dietary Supplement|Soy Isoflavone|50mg soy isoflavone supplement consumed twice daily for a total of 100mg of soy isoflavones per day.
46100022|NCT03746951|Drug|Ropivacaine Hcl 0.5% Inj Vil 20Ml|Anesthetic agent used in peripheral nerve block
46100023|NCT02571673|Behavioral|Assessments|Usability outcomes will come from patient surveys and interviews and a nurse practitioner interview in Aim 1: Part 1. In Aim 1: Part 2, patients and their primary care providers will complete online surveys regarding feasibility. Health outcomes and data regarding health care actions will be collected from HN-STAR and the clinic note will be collected to assess feasibility of collecting these metrics in a future trial. Directly after each clinic visit, the NP will complete one brief online survey for each participant.
45465201|NCT03814291|Drug|IBI302|0.05mg/eye;Intraocular injection
45465202|NCT03814291|Drug|IBI302|0.15mg/eye;Intraocular injection
45465203|NCT03814291|Drug|IBI302|0.5mg/eye;Intraocular injection
46014876|NCT04325997|Device|video laryngoscope with mouth opener|Double-lumen tube combined with mouth gag for video laryngoscope intubation
46014877|NCT01324440|Biological|V710 (30 µg) with MAA|Single 0.5-mL injection (30-µg) of V710 with MAA, intramuscularly
46014878|NCT01324440|Biological|V710 (30 µg) without MAA|Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly
45465204|NCT03814291|Drug|IBI302|1mg/eye;Intraocular injection
45465205|NCT03814291|Drug|IBI302|2mg/eye;Intraocular injection
45837699|NCT05766215|Behavioral|Therapeutic Education|It consists of four structured phases: 1. Welcome nurse visit, 2. Diabetologic education course adapted to the detected needs, 3. Individualized follow-up through alternating quarterly appointments between nurses and endocrine physician, 4. Evaluation and discharge of the program
46100024|NCT00577408|Drug|depot naltrexone|On the afternoon of Day 7, patients assigned to Depot-BNT receive an intramuscular injection of Vivitrol (380 mg) in one buttock. The patient spends the night of Day 7 in the hospital and is discharged on the morning of Day 8. Each injection contains 192 mg of naltrexone. The double dose (384 mg) is what was found to produce optimal blockade and outcome in preliminary work. During the subsequent 6-month course of outpatient treatment, patients are dosed with two injections (384 mg total) of depot naltrexone at monthly intervals (weeks 4, 8, 12, 16, 20).
46014879|NCT04326231|Device|Usability assessment of Cognoa ASD Therapeutic Device|Usability assessment of Cognoa ASD Therapeutic Device
46100025|NCT00577408|Drug|Oral Naltrexone|For patients assigned to BNT-Oral, administration is clinic-based for at least the first two weeks, and doses are 50mg, 100mg, or 150mg, depending on whether one, two or three days will elapse before the next visit (typically 100 mg on Monday and Wednesday and 150 mg on Friday). The ultimate goal with BNT-Oral is for patients to take naltrexone (50 mg per day) on their own at home under supervision of their significant other/monitor.
45465206|NCT03814291|Drug|IBI302|4mg/eye;Intraocular injection
45465207|NCT05160454|Device|near infrared spectroscopy|evaluate cerebral blood flow with and without breatholding
46014880|NCT00598611|Drug|desloratadine|singel dose, oral, 20 mg
46014881|NCT00598611|Drug|desloratadine|single dose, oral, 5 mg
45465208|NCT03354429|Drug|Ticagrelor|Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.
45465209|NCT03354429|Drug|Placebo|Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.
45465210|NCT01129505|Behavioral|Nutrition & Exercise Lifestyle Intervention Program (NELIP)|"Nutrition- individualize total energy intake with a minimum of 2000 kcal/day with a restriction of not more than 33% total energy intake, total carbohydrate of 40-50% total energy intake, total fat intake of 30% of total energy intake (substituting monounsaturated fatty acids for saturated and trans-fatty acids), and approximately 30% dedicated to protein intake.~Exercise-25 minutes of walking per session, 3-4 times per week, each subsequent week increasing by 2 mins to a maximum of 40 mins/session.~Family-based Behavioural Treatment (FBBT) Coupled with the individualized NELIP for each woman, FBBT will be presented in 3 group sessions (including family members), focussing on strategies to make healthy lifestyle choices with behavioural strategies."
45465211|NCT05160298|Drug|Ropivacaine 0,2% Injectable Solution|Echo-guided bilateral erector spinae block
46014882|NCT04325724|Other|General evaluation|Demographic characteristic, psoriasis duration, disease duration, treatments
46014883|NCT04325724|Other|Dermatological evaluation|treatment and evaluation
46014884|NCT04325724|Other|Rheumatological evaluation|joints, enthesis, tendons, and other ultrasound abnormalities
46014885|NCT04325724|Other|para clinical data|biological data, medical imaging data
46014886|NCT04325724|Other|Patient reported outcomes (PROs)|Psoriatic arthritis impact of disease 12 (PsAID12), hospital anxiety and depression scale (HAD), SF 36
46014887|NCT00601185|Procedure|confocal microscopy in vivo|A dermatologist will perform a shave biopsy according to standard clinical procedures. This study will be carried out after the shave biopsy. The deep surface and the peripheral margins will be imaged on each patient.
46014888|NCT00598143|Behavioral|Vignette, questionnaires and Saliva Samples|The short vignette discusses the health implications of potential molecular markers of cancer risk assessment. The questionnaire asks several multiple-choice questions to assess the participant's interest in and understanding of molecular risk assessment. Patients are instructed to swish with 10cc of Scope mouthwash and to expectorate into a sterile 50cc conical tube.
46014889|NCT00598143|Behavioral|Urine Collection, Smoking cessation treatment|Single void urine specimens (approximately 50 ml) will be collected in pre-labeled specimen containers on a 3-monthly (±1 month) basis for 12 months. Standard evidence-based therapy for smoking cessation, including behavioral therapy and pharmacological therapy, is provided.
45465212|NCT05160298|Other|Control group|Sham block
45465213|NCT03816085|Other|Shoes|Shoes with different heel heights
45465214|NCT03927755|Other|Education|Physicians will undergo training on how to rapidly obtain appropriate images.
45465215|NCT05164198|Biological|Adalimumab and its biosimilars|"Active substance: Adalimumab~Pharmaceutical form: Prefilled syringe~Concentration: 100mg/mL~Route of administration: Subcutaneous injection"
46014890|NCT00601263|Drug|Anti-Asthma Herbal Medical Intervention (ASHMI)|We propose to test 3 daily doses in which 2,4, or 6 ASHMI or placebo capsules will be administered orally twice daily (BID) for 7 days.
46100026|NCT03391193|Biological|Multi-dose Quadrivalent Influenza Vaccine|0.5 mL, intramuscular
46100027|NCT03391193|Biological|Single-dose Quadrivalent Influenza Vaccine|0.5 mL, intramuscular
46100028|NCT02437981|Drug|PrEP|Oral pre-exposure prophylaxis (PrEP) for HIV infection using a daily combination tablet of tenofovir disoproxil fumarate and emtricitabine
46100029|NCT00741364|Dietary Supplement|vitamin D3 (cholecalciferol)|liquid vitamin D solution (vitamin D3 in ethanol) taken daily at one of three possible doses (400, 10000, or 40000 IU/d) for 4-6 weeks prior to radical prostatectomy
46100030|NCT03998137|Device|AUGMENT® Injectable Bone Graft|AUGMENT® Injectable Bone Graft
46014891|NCT05645640|Combination Product|Village doctor-led tailored health management|"Investigators will sketch features of cardiovascular risk factor combinations for the high-risk subjects and accordingly set tailored promotion targets for them. Subjects will receive individualized consultation about their cardiovascular risk profile and tailored health management led by village doctors. They will receive tailored health text messages pushed by village doctors 3 times a week, including contents in physical activity, healthy diet, smoking abstinence, responsible alcohol drinking, sleep, and medication adherence. They will be provided with a smart band, and supposed to daily wear the smart band to collect health data. The progress of tailored promotion targets will be evaluated every 3 months, and feedback will be given in the form of virtual rewards and punishments: completed (a virtual golden egg) and failed (a virtual bomb). According to the number of virtual golden eggs, participants could redeem project gift in real life."
46014892|NCT04325490|Drug|Liquid powder|apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
46014893|NCT04325490|Drug|Hydrocortisone cream 1%|apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
45465216|NCT05164198|Biological|Biological: Etanercept and its biosimilars|"Active substance: Etanercept~Pharmaceutical form: Prefilled syringe~Concentration: 50mg/mL~Route of administration: Subcutaneous injection"
45465217|NCT05164198|Biological|Golimumab|"Active substance: Adalimumab~Pharmaceutical form: Prefilled syringe~Concentration: 100mg/mL~Route of administration: Subcutaneous injection"
45465218|NCT05164198|Biological|Infliximab biosimilar|"Active substance: Infliximab~Pharmaceutical form: Prefilled syringe~Concentration: 120mg/mL~Route of administration: Subcutaneous injection"
46100031|NCT03998137|Procedure|Standard of Care|Autologous Bone Graft
46100032|NCT03332303|Drug|Estrace® Cream|Estrace® Cream
46100033|NCT03332303|Drug|Estradiol Vaginal Cream|Estradiol Vaginal Cream
46100034|NCT03332303|Drug|Vehicle Cream|Vehicle Cream
46100035|NCT04745611|Diagnostic Test|MRI|3T cranial MRI with T1-, and T2 weighted imaging, a FLAIR sequence, diffusion-weighted imaging and susceptibility-weighted sequence
46100036|NCT04745611|Diagnostic Test|Neuropsychological assessment|Montreal Cognitive Assessment (MoCA), Rey-Auditory Verbal Learning Test (RAVLT), Trail making A/B, Stroop, Digit Span Coding, Judgement of line orientation (JOLO), Boston Naming Task (BNT), Controlled Oral Word Associations Task (COWAT), Category Fuency, Test of Memory Malingering (TOMM)
45465219|NCT03819751|Procedure|MRI-targeted prostate biopsy|All participants receive traditional cognitive/visual registration biopsy and the above mentioned MRI/TRUS fusion biopsy (also known as software registration biopsy)
45465220|NCT03814369|Device|AmplifEYE|AmplifEYE colonoscopy
46100037|NCT04745611|Diagnostic Test|Questionnaires Patient|EuroQol-5D-5L (EQ-5D-5L), Utrecht Scale for Evaluation of Rehabilitation-Participation - Restrictions (USER-P-R), NeNeSCo-Q (questionnaire created for this study, including common neurological symptoms), Checklist for post-IC cognitive complaints (CLC-IC self-report), Hospital Anxiety and Depression Scale (HADS), Primary Care Post-Traumatic Stress Disorder (PC-PTSD-5), Utrecht Coping List (UCL) (subscale passive coping), PROMIS physical functioning short form, Items of Insomnia Severity Index (ISI) & Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), Social Support List (SSL-12-I)
45465221|NCT03740399|Procedure|spinal anesthesia|Investigators will perform spinal anesthesia for section
45465222|NCT05160220|Drug|Psilocybin|0.5 g dried Psilocybe cubensis mushroom material, 0.8 mg psilocybin.
45465223|NCT05160220|Drug|Placebo|0.5 g dried edible non-psychoactive mushroom material.
45465224|NCT03924245|Drug|Entinostat|Given by mouth
46100038|NCT04745611|Diagnostic Test|Questionnaires Family|EuroQol-5D-5L (EQ-5D-5L), Utrecht Scale for Evaluation of Rehabilitation-Participation - Restrictions (USER-P-R), Checklist for post-IC cognitive complaints (CLC-IC proxy-report), Hospital Anxiety and Depression Scale (HADS), Primary Care Post-Traumatic Stress Disorder (PC-PTSD-5), Utrecht Coping List (UCL) (subscale passive coping), Social Support List (SSL-12-I), Caregiver Strain Index (CSI)
46100039|NCT00729508|Biological|Cat-PAD|Cat-PAD dose 2X 4 administrations 2 weeks apart
46100040|NCT00729508|Biological|Cat-PAD|Cat-PAD dose 1X 4 administrations 2 weeks apart
46100041|NCT00729508|Biological|Cat-PAD|Cat-PAD dose 1X 4 administrations 4 weeks apart
46100042|NCT00729508|Biological|Cat-PAD|Cat-PAD dose 1X 8 administrations 2 weeks apart
45465225|NCT03924245|Drug|Olaparib|Given by mouth
45465226|NCT05164042|Biological|Allogeneic CD19 CAR-T cells|infusion of allogeneic CD19 CAR-T cells
45465227|NCT05647447|Drug|Osanetant|Osanetant 200 mg orally, twice per day
46014894|NCT00601341|Other|lumbosacral joint manipulation|lumbosacral joint manipulation
46014895|NCT00601341|Other|lumbar passive range of motion|lumbar passive range of motion
46014896|NCT00601341|Other|No active intervention|Lie on exam table for 3 minutes
45465228|NCT05219344|Procedure|Tissue flossing|After the standardized warm-up, participants will be instructed to stand still with their legs shoulder-width apart. The floss band (1.3 mm thick, 50 mm wide, 2 meters long, and strength level 3), consisting of a thick elastic latex band (COMPRE Floss, Sanctband), will be applied bilaterally around the distal third of the thigh. The applied pressure will be individualized by thigh circumferences, whereas low target pressure was chosen for this study, showing potential to elicit the most beneficial outcomes following flossing. The pressure will be monitored by the PicoPress device, which was placed at the middle distance of the application of the floss band to ensure that the entire surface of the pressure sensors was always completely covered. The flossing will be applied for 2 minutes with 2 minutes rest between sets. During flossing application subjects will be instructed to conduct 10 deep squats followed by 15 repetitions of knee extensions without added weight.
46014897|NCT00601497|Device|InterX 5000|20-30 minute device sessions on the following schedule: 3 times per week for 3 weeks, then 2 times per week for 3 weeks, then 1 time per week for 2 weeks.
46014898|NCT00601575|Drug|Lithium|
46014899|NCT00601653|Behavioral|Cognitive behavioral therapy plus general nutrition counseling (CBT+GN)|CBT+GN includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling.
45465229|NCT01225445|Drug|Ramipril|2.5 mg daily
45465230|NCT03814213|Other|CGA|Multi-level Health assessment
45465231|NCT03814213|Other|tailored care|Tailored care based on problems identified by CGA
45465232|NCT03924011|Device|Photobiomodulation therapy (PBMT)|PBMT sessions will be planned 2x/week after RT.
45465233|NCT03924011|Device|Sham laser|Sham laser sessions will be applied 2x/week after RT.
45465234|NCT05204212|Other|Left Atrial Appendage closure|Percutaneous closure of the LAA
45465235|NCT05623111|Drug|Incobotulinumtoxin-A 100 UNIT Injection|Perineural injection
45465236|NCT05623111|Drug|Saline|Placebo containing trace amounts of human albumin and sucrose, diluted with 5ml of sterile saline.
46014900|NCT00601653|Behavioral|Cognitive behavioral therapy plus low energy density diet counseling (CBT+LED)|CBT+LED includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling that centers upon eating higher volumes of low-calorie foods.
45465237|NCT03924089|Dietary Supplement|Oral nutritional supplement with probiotics|Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), with probiotics.
46014901|NCT00601809|Other|traditional conservative treatment (TT)|In the control group (TT: Traditional Treatment), the patients have been treated as in our daily surgical practice of traditional conservative treatment for ASIO, consisting in nil per os diet, nasogastric tube (NGT) decompression and intravenous fluid resuscitation therapy with electrolytes imbalances correction.
46014902|NCT00601809|Drug|Gastrografin®: G|The study group (GG: Gastrografin Group) received, beyond the traditional conservative treatment for ASIO above mentioned, a G meal with a follow-through study immediately.
45465238|NCT03924089|Dietary Supplement|Oral nutritional supplement without probiotics|Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), without probiotics.
46014903|NCT00601887|Drug|Meloxicam|
46100043|NCT00729508|Biological|Cat-PAD|Placebo
46100044|NCT00614471|Drug|Entecavir|0.5mg po daily for 24 weeks
46100045|NCT00614471|Drug|Entecavir|0.5mg po daily from week 13 to week 36
45465239|NCT03924089|Other|Dietary recommendations|Dietary recommendations
45465240|NCT05555329|Drug|Pomalidomide 4 mg every day in cycle 1|Pomalidomide 4 mg every day, on days 1-21 in a cycle of 28 days
45465241|NCT05555329|Drug|Pomalidomide 4 mg every other day in cycle 2|Pomalidomide 4 mg every other day, on days 1-21 in a cycle of 28 days
46100046|NCT00614471|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
46100047|NCT00614471|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week from week 21 to week 68
45465242|NCT05555329|Drug|Pomalidomide 2 mg every day in cycle 2|Pomalidomide 2 mg every day, on days 1-28 in a cycle of 28 days
46100048|NCT05742256|Drug|Oxycodone 1mg/kg|Test group 1 (OCA group):oxycodone 1mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml
46100049|NCT05742256|Drug|Oxycodone 1.5mg/kg|Test group 2 (OCB group): oxycodone 1.5mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml.
46100050|NCT05742256|Drug|Sufentanil|Control group (SF group): sufentanil 2ug/kg + flurbiprofen + ondansetron 16mg + 0.9% normal saline diluted to 100ml.
46100051|NCT03841513|Procedure|Laparoscopic Burch Colposuspension|The Burch Colposuspension is an anti-incontinence procedure where non-absorbable monofilament suture is used in the retropubic space to form a suture bridge between the anterior vagina and Cooper's ligament, thereby gently elevating the anterior vaginal wall and providing urethral support.
46100052|NCT02568748|Biological|CIK|Cytokine -induced killer cells in Egyptian patients with advanced hepatocellular carcinoma as treatment or adjuvant treatment in comparison with traditional treatment.
46100053|NCT02568748|Procedure|TACE|Trans-arterial chemoembolization
46100054|NCT02692781|Drug|MOD-6031|
45465243|NCT05555329|Drug|Pomalidomide 2 mg every day in cycle 3|Pomalidomide 2 mg every day, on days 1-28 in a cycle of 28 days
45465244|NCT05555329|Drug|Pomalidomide 4 mg every other day in cycle 3|Pomalidomide 4 mg every other day, on days 1-21 in a cycle of 28 days
45465245|NCT05390710|Combination Product|LAE005 + Afuresertib + Nab-Paclitaxel|LAE005: 1200 mg IV Q3W, Afuresertib: 125 mg QD, Nab paclitaxel:125 mg/m D1, D8 Q3W
46014904|NCT02891499|Procedure|Low-level laser therapy|"Immediate post-operative period (implantation day) Red emission (660 nm) Energy density: 4 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 One application, 10 seconds of non-contact irradiation (01 point at the area surrounding the miniscrew) at a distance of 15,5 mm.~Mediate post-operative period (after implantation day) Infrared emission (808 nm) Energy density: 8 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 6 applications every 48 hours after the day of implantation, 20 seconds of non-contact irradiation (01 point on the area surrounding the miniscrew) at a distance of 15,5 mm."
46014905|NCT02891499|Procedure|Mediate force application|Mediate force application protocol: orthodontic force application (150 gF) 4 weeks after the day of the implantation.
46100055|NCT02692781|Other|Placebo control|
46100056|NCT00736762|Other|GPR|The subjects randomised to the GPR program will participate in posture retraining techniques of approximately forty minutes, one time a week for ten weeks.
46100057|NCT00828009|Biological|bevacizumab|IV
46100058|NCT00828009|Biological|Tecemotide|
46100059|NCT00828009|Drug|carboplatin|IV
46100060|NCT00828009|Drug|cyclophosphamide|IV
46100061|NCT00828009|Drug|paclitaxel|IV
46100062|NCT00828009|Radiation|radiotherapy|radiotherapy is given 5 days a week for 6½ weeks during concomitant chemoradiotherapy
46100063|NCT00713596|Drug|Fibrinogen|One time application of 0.5 cc to 2.0 cc of fibrinogen following surgery.
46014906|NCT01325493|Drug|Ketamine|ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
46014907|NCT01325493|Drug|Normal Saline|Normal saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
46014908|NCT01323972|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)|4 different lots of the candidate malaria vaccine (257049) representative of either commercial (manufacturing) process or pilot plant process
46014909|NCT01325337|Drug|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
46100064|NCT00713596|Procedure|Septorhinoplasty|Septorhinoplasty to correct nasal deviation.
46100065|NCT00713596|Procedure|Taping after septorhinoplasty.|Simple taping over the nose following nasal surgery.
45465246|NCT05390710|Combination Product|LAE005 + Nab-Paclitaxel|LAE005: 1200 mg IV Q3W, Nab paclitaxel:125 mg/m D1, D8 Q3W
45465247|NCT05390710|Combination Product|Afuresertib + Nab-Paclitaxel|Afuresertib: 125 mg QD, Nab paclitaxel:125 mg/m D1, D8 Q3W
45465248|NCT05390710|Drug|Nab-paclitaxel|Nab paclitaxel:125 mg/m D1, D8 Q3W
45465249|NCT01228565|Other|Radiotherapy + Erbitux® + placebo|3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; Placebo local application, once a day, every day during the radiotherapy
46014910|NCT01325337|Drug|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
46014911|NCT01325337|Drug|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
46014912|NCT01325337|Drug|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
46014913|NCT01325337|Drug|minoxidil 5% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
46014914|NCT01324947|Drug|pomalidomide|Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity
46014915|NCT01101841|Drug|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
46014916|NCT01101841|Drug|Placebo capsules|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
46014917|NCT04325607|Procedure|Excision of HS followed by NPWTi|The NPWTi that will be used in this study will be the V.A.C. VERAFLO™ Therapy (KCI)
46014918|NCT04325607|Procedure|Excision of HS followed by NPWT|The NPWT that will be used in this study will be the V.A.C.® Therapy(KCI)
46014919|NCT04952545|Drug|ALXN2050|Oral tablet.
46100066|NCT00713596|Procedure|Cast applied to the nose after nasal surgery|A molded cast will be placed on top of the nose following nasal surgery.
46100067|NCT00713596|Other|Saline|Approximately 0.5 cc to 2 cc normal saline will be applied after the operation before the nasal taping and casting.
46014920|NCT04952545|Drug|Placebo|Oral tablet.
46100068|NCT04306445|Device|GF-IGB: Obalon Balloon|The balloon, which is attached to a thin catheter, is swallowed by the patient in a standing position. Once the two-step verification of balloon passage into the stomach by both fluoroscopy and pressure reading, the balloon is inflated to a volume of 250 ml with a nitrogen-mix gas, additional imaging of the inflated balloon is obtained, the catheter is ejected from the balloon, and the catheter is pulled out through the patient's mouth. The process is repeated at week 2 for the second balloon and between weeks 4-8 for the third balloon. All patients are given an individualized calorie prescription by a registered dietitian for a goal of up to 2 pounds of weight loss per week. The balloons are removed endoscopically 6 months after placement of the first balloon. Patients also attend monthly virtual individual diet coaching and monthly virtual group behavior coaching sessions both delivered by a registered dietitian for twelve months focused on long-term behavior change.
46014921|NCT01324401|Drug|Peanut flour OIT|Patients will receive daily escalating dosages (Peanut flour OIT) as determined in the modified rush phase as stated in the protocol. The dosage will be escalated until a daily dose of 4000 mg is reached. A Double-blind, placebo-controlled food challenge will then consist of two challenges performed on the same day. One challenge will consist of 7 doses of peanut given every 10-20 minutes in increasing amounts up to a total of 10 grams of whole peanut (5 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
46014922|NCT02877511|Drug|BAY987517|Applied liberally to the skin (Formulation: Y73-161
46014923|NCT02877511|Drug|Sunscreen Lotion (Y65-110)|Applied liberally to the skin
46014924|NCT05645679|Device|Hybrid Argon Plasma Coagulation System|Hybrid Argon Plasma Coagulation System
46100069|NCT04306445|Dietary Supplement|Medically Supervised Meal Replacement Program: My New Weigh|Patients are given an individualized calorie prescription by a registered dietitian for a goal of 2 pounds weight loss per week. Patients are seen in a group-based program once a week focused on long-term behavior change and use meal replacements for a nutritionally balanced very low-calorie diet for 20 weeks. 4-5 meal replacements are consumed per day. If only 4 meal replacements are consumed, individuals eat 3 servings of vegetables and 2 servings of fruit per day as well.
46014925|NCT01323660|Drug|GSK573719/GW642444 125/25|125mcg/ 25mcg QID (Once daily , inhaled)
46014926|NCT01323660|Drug|GSK573719/GW642444 62.5/25|62.5mcg/25mcg QID
46014927|NCT01323660|Drug|GSK573719 125|125mcg QID
46014928|NCT01323660|Drug|GSK573719 62.5|62.5mcg QID
46014929|NCT01323660|Drug|GW642444 25|25mcg QID
46014930|NCT01323660|Device|placebo|Comparator QID
46014931|NCT01324323|Drug|Romidepsin|14 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.
46014932|NCT01324323|Drug|Rifampin|600 mg oral once daily on Days 4-8
46014933|NCT05344963|Drug|Sodium-GLucose coTransporter-2 inhibitors|Evaluation of the modification of conventional and advanced echocardiographic parameters, focusing on speckle tracking and three-dimensional echocardiography (optional), in patients with HFrEF after treatment with the SGLT2i drugs Dapagliflozin and Empagliflozin
45465250|NCT01228565|Other|Radiotherapy+Erbitux+OTD70DERM|3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; OTD70DERM local application, once a day, every day during the radiotherapy
46100070|NCT04306445|Procedure|Endoscopic sleeve gastroplasty: (ESG)|Endoscopic sleeve gastroplasty is a weight loss procedure that uses an FDA 510K cleared endoscopic suturing device known as Overstitch to reduce the size of the gastric body. The procedure is completed with an endoscope. It is inserted through the mouth, down the esophagus, and into the stomach. Sutures with 8-10 bites 1.5-2 cm apart in a U-shape pattern are placed starting distally 6 cm proximal to the pylorus. Additional sutures are placed moving proximally up to 2 cm distal to the gastroesophageal junction. An additional row of sutures is then placed again in the distal to proximal stomach to complete the gastroplasty. All patients are given an individualized calorie prescription by a registered dietitian for a goal of up to 2 pounds of weight loss per week. Patients also attend monthly virtual individual diet coaching and monthly virtual group behavior coaching sessions both delivered by a registered dietitian for twelve months focused on long-term behavior change.
46014934|NCT05645601|Biological|CD19-CAR-NK|The relapsed/refractory B-cell hematologic malignancies patients will receive FC (F, Fludarabine, C, Cyclophosphamide) chemotherapy followed by 3 infusions of JD010 cells up to 2 dose levels (5x10^6/kg, 2x10^7/kg) after FC chemotherapy.
46100071|NCT00880568|Drug|MK-1496|MK-1496 (20 to 120 mg), orally, administered on Day 1 of each 21-day cycle
45465251|NCT03927677|Drug|Xanthine Oxidase Inhibitor|LC350189 200mg qd
45465252|NCT05159986|Procedure|Group that received aplication of Diadynamic currents associated to Exercise during eight weeks with three sessions a week|Diadynamic currents was performed followed by exercises (divided into Phase-1, Phase-2 and Phase-3 during eight weeks with three sessions a week).
45465253|NCT05159986|Other|Group that received exercise during eight weeks with three sessions a week|The intervention was divided into Phase-1, Phase-2 and Phase-3 during eight weeks with three sessions a week. Each session lasted 45 minutes.
45465254|NCT01226849|Drug|bortezomib, rituximab, ifosphamide, etoposide, carboplatin|Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended
45465255|NCT03813901|Other|Samalochana Counselling|Counselling program was individual, based on advaita vedanta and traditional philosophical grounds to answer individual fears, concerns,conflicts and difficulties in order to cope and recover.
45465256|NCT03813901|Other|Wait list control|Wait list had no intervention offered during the study period. Afterwards, they were offered the counselling for the same duration.
46014935|NCT02879227|Drug|Cisplatin|Arm cisplatin : 75mg/m2, day n*1 and day n*22, And radiotherapy 50 Gy, 2Gy/f
46100072|NCT00880568|Drug|MK-1496|MK-1496 (20 to 120 mg), orally, administered on Days 1 and 3 each week for 3 weeks (Days 1, 3, 8, 10, 15 and 17) of each 28-day cycle
46100073|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 0.1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
46100074|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 0.3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
46100075|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
46100076|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
46014936|NCT02879227|Drug|Oxaliplatin|85 mg/m2 every 2 weeks, 6 times And radiotherapy 50 Gy, 2Gy/f
46014937|NCT05645445|Device|virtual reality|patients who include intervention gruop during the ESWL process, patients will be shown videos with virtual reality glasses, which include nature and landscapes, giving people a feeling of comfort and peace, and making them feel like they are inside.
46100077|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 10 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
46100078|NCT04229615|Drug|Fluzoparib; Apatinib|Drug: Fluzoparib Orally twice daily; Apatinib Orally once daily
46100079|NCT04229615|Drug|Fluzoparib|Fluzoparib Orally twice daily
46100080|NCT04229615|Drug|Placebo|Placebo
46014938|NCT01323582|Drug|Erythromycin|200mg/5ml elixir administered orally three times a day half an hour prior to meals.
46100081|NCT03677063|Other|No dressing|Then, care is the same and exit-site remains covered with an occlusive dressing to promote tunnel epithelialization and healing. The shower is forbidden during this period.
46100082|NCT00881894|Drug|Rotigotine transdermal patch|Rotigotine 4.5mg/10cm^2 patch applied for 24 hours
45465257|NCT04110262|Other|High dietary sodium intake|Twenty five day feeding period of high dietary sodium (3400 mg/day)
45465258|NCT04110262|Other|Low dietary sodium intake|Twenty five day feeding period of low dietary sodium (2300 mg/day)
45465259|NCT01300429|Genetic|obtain tissue specimens|One core biopsy specimen will be placed in formalin and processed for cytogenetic and FISH analyses as well as DNA for ALK sequencing. The second core biopsy specimen will be immediately frozen in liquid nitrogen and stored in a -80 degree freezer for research specimen. Collection will be performed on-site at the time of the procedure.
46014939|NCT01323582|Drug|Azithromycin|The dose of Azithromycin given was determined based on the following study on 10 healthy subjects. In random order, each of ten healthy subjects underwent OBT studies following administration of AZI, at doses of 50mg, 100mg, and 133mg. The T½ and Tlag was then compared for the three doses by a randomized block analysis using Analysis of Variance followed by Tukey's multiple comparison. Results: The T½ for each of the respective doses of AZI (50mg, 100mg, and 133mg) was 129 ± 27, 128 ± 31, and 128 ± 16 minutes (p = 0.98). This data suggested that AZI at doses of 50mg, 100mg and 133 mg have fairly similar activity in its effects on gastric emptying in healthy subjects. Based on this analysis , we decided to use a dose of 50 mg/5 ml for administered TID prior to meals.
46014940|NCT00626041|Other|participant referral to primary care network physician|blood pressure, cholesterol and hemoglobin A1c screening and management
46014941|NCT05367765|Drug|Flumatinib|Flumatinib 600mg orally daily
46014942|NCT05367765|Drug|Imatinib|Imatinib 400mg orally daily (Reference drug instructions)
46014943|NCT05645367|Other|No intervention|This is a post-hoc analysis of a cross-sectional study.
46014944|NCT02891382|Behavioral|Diabetes education|Participants interact with a diabetes educator (DE), every two weeks.
46014945|NCT02891382|Behavioral|Goal setting|Goals for weight loss and change in levels of HbA1c
45465260|NCT03927365|Device|Inhalation from a salt particle inhaler with or without content|Inhalation from inhaler with (active) or without (placebo) content
45465261|NCT03352713|Behavioral|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
46014946|NCT02891382|Behavioral|Companion Support|Patient has a companion/team support partner to support achieving goals.
46014947|NCT02891382|Behavioral|Individual Reward|The cash reward is given to the patient with diabetes.
46014948|NCT02891382|Behavioral|Shared Reward|Patients with diabetes and their companion support will each receive 50% of the cash reward.
46100083|NCT04215107|Other|Standard breakfast meal|"The first ultrasound will be preformed during fasting. IUGR group will be served a standard breakfast meal, and perform the second ultrasound after 2 hours from the meal.~The control group will be crossover randomized to meal or prolonged fasting. It will be performed 4 ultrasounds: during fasting and 2 hours after standard breakfast meal. During fasting and during prolonged fasting."
46100084|NCT00711100|Other|Camel Snus|All subjects will sample Camel Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Camel Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Camel Snus is chosen for use) during abstinence phase.
46014949|NCT01323621|Drug|Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg|inhalation powder
46014950|NCT01323621|Drug|Fluticasone Propionate 250mcg / salmeterol 50mcg|inhalation powder
46014951|NCT01323621|Drug|Double-dummy placebo|inhalation powder
46014952|NCT01323621|Drug|Salbutamol as needed|inhalation powder
46014953|NCT00623298|Behavioral|Narrative Exposure Therapy|
46014954|NCT00623298|Behavioral|group IPT|
46014955|NCT00623298|Other|6 months-baseline|
46014956|NCT01323192|Drug|JNS001|Participants will receive JNS001 (18 mg, 36 mg, 54 mg or 72 mg per day) orally once daily for 8 weeks.
46014957|NCT01323192|Drug|Placebo|Participants will receive matching placebo orally once daily for 8 weeks.
46014958|NCT01323387|Device|Interbody Fusion|allograft spacer + anterior plate
45837700|NCT05766176|Diagnostic Test|COVID-19 Antibody|This descriptive study examines the levels of neutralizing antibodies against COVID-19 in health workers before and after the Quantitative Anti-SARS-CoV-2 Test is an examination to measure in vitro quantitative antibodies (including IgG) against the receptor binding domain (RBD) of the SARS-CoV Spike (S) protein. -2, which aims to assess the adaptive humoral immune response to the SARS-CoV-2 Spike protein. Measurement with the ECLIA method. Ratio Scale after the 2nd booster COVID-19 vaccine in Surakarta, Indonesia.
46014959|NCT05645289|Drug|Minodronate|The minodronate group: The group will include thirty-six patients. Patients will take 1 mg of minodronate tablets orally with 200 mL of water in the morning. They can not lie flat for at least 30 minutes after taking the tablets, and they can not eat anything except water for at least 30 minutes after taking the tablets once a day for 12 weeks, for a total of 84 times.
46014960|NCT05645289|Drug|Alendronate|The alendronate group: A total of 36 patients will be treated with alendronate. Patients will be orally given 10-mg alendronate tablets daily and 200 mL of water in the morning. They could not lie down and eat anything except water for at least 30 minutes after taking the tablets. The treatment lasted for 12 weeks, corresponding to a total of 84 doses.
46014961|NCT00623259|Biological|MVA-mBN120B|
46014962|NCT02891343|Other|2-hour period of hypoxia|During this period, the FiO2 will be set on 21% (normoxia condition). A filter will be put between the mask and the tubes connecting it to the machine generating hypoxia (equipment reference = Altitrainer NP190). On that filter a gas analyser will monitor the FiO2 and a capnography monitor (Capnostream 20, ORIDION) will also be installed.
46014963|NCT01321749|Procedure|Remote ischemic preconditioning (RIPC)|The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.
46014964|NCT01320033|Drug|CD2475/101 40 mg|Participants receive 40 mg of CD2475/101 tablets once a day for 16 weeks.
46014965|NCT01320033|Drug|Doxycycline 100 mg|Participants receive 100 mg of Doxycycline capsule once a day for 16 weeks
46100085|NCT00711100|Other|Marlboro Snus|All subjects will sample Marlboro Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Marlboro Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Marlboro Snus is chosen for use) during abstinence phase.
45465262|NCT05159674|Device|Dexmedetomidine+electroacupuncture compound anesthesia|Dexmedetomidine and acupuncture were given together to induce anesthesia
45465263|NCT03813979|Drug|Dolutegravir|Intake of a single-dose dolutegravir 50 mg tablet on an empty stomach
45465264|NCT01226927|Other|Automated intermittent bolus|Automated intermittent bolus delivery method of 0.2% ropivacaine at 5 mL every 30 minutes with a basal infusion of 0.1 mL/hr.
45465265|NCT05555121|Drug|Progesterone Effervescent Vaginal Tablet|On the day of Frozen Embryo Transfer (FET), women will have a blood test to determine progesterone levels. Depending on the result of progesterone level, the participant will be assigned to either the Endometrin 100 mg TID dose or the Endometrin 200 mg TID dose
46100086|NCT00711100|Other|Stonewall|All subjects will sample Stonewall and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Stonewall. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Stonewall is chosen for use) during abstinence phase.
45465266|NCT03924466|Drug|68GaNOTA-Anti-HER2 VHH1|"All subjects will receive at least one single intravenous injection of the IMP followed by a total body PET/CT prior to receiving standard-of-care therapy.~A second injection of the IMP can be administered before or during standard-of-care treatment, depending on cohort."
45465267|NCT01128647|Dietary Supplement|Fructose:glucose drink|
45465268|NCT01128647|Dietary Supplement|glucose drink|
45837701|NCT05766137|Procedure|Alveolar ridge preservation|Socket preservation
45837702|NCT05766124|Drug|Tissue Plasminogen Activator|Intrapleural administration of tissue plasminogen activator
45837703|NCT05766098|Genetic|Genotyping|Characterization of genetic profile of tumor tissues
46014966|NCT01320033|Drug|Placebo|Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.
46014967|NCT01101061|Drug|Romosozumab|Administered by subcutaneous injection
46014968|NCT01101061|Drug|Placebo|Administered by subcutaneous injection
46100087|NCT00711100|Other|Ariva|All subjects will sample Ariva and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Ariva. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Ariva is chosen for use) during abstinence phase.
46014969|NCT04325295|Procedure|Laparoscopic ovarian drilling|LOD will be done in the follicular phase.Follow up will be done on the next cycle by performing a TVUS examination at CD 13 and measuring the dominant follicles. Ovulation is considered if a follicle reached > 17 mm and is confirmed by measuring serum progesterone at CD 21.If ovulation is not achieved in the cycle following LOD, women will be prescribed Letrozole by the dose of 2.5 mg daily for 5 days starting from CD 3, and ovulation monitoring will be done similarly. If ovulation is not achieved, the dose is increased by 2.5 mg daily in the subsequent cycle until reaching the maximum dose of 7.5 mg daily for a total of 3 cycles.With persistent resistance to Letrozole in inducing ovulation, Gn will be prescribed for 3 cycles as in Gonadotrophin strategy
46100088|NCT00711100|Other|General Snus|All subjects will sample General Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of General Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if General Snus is chosen for use) during abstinence phase.
46100089|NCT03653741|Drug|Perampanel 6 MG|Perampanel is a drug approved and marketed in the USA for the treatment of epilepsy to prevent recurrent seizures. In a previous study, healthy volunteers have tolerated a single dose of perampanel at 6 mg quite well.
46100090|NCT02638376|Radiation|0.1% Riboflavin ophthalmic solution (KXL System With vibeX Rapid)|"KC Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.~PLEc Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off."
46100091|NCT02638376|Procedure|simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)|"The (Partial, Spherically Corrected) Topography-guided Transepithelial PRK Technique. Is performed with WaveLight® EX 500 excimer laser (Alcon Laboratories Inc, Ft Worth, Texas) customized platform.~This software utilizes topographic data from the linked topography device (Topolyzer; Wave- Light GmbH, Erlangen, Germany). The image of the planned surgery is generated by the laser software.~The topography-guided PRK is used to normalize the cornea by reducing irregular astigmatism while treating part of the refractive error. The maximum ablation depth of stromal ablation is set at 50um.~A 6.5-mm, 50-μm phototherapeutic keratectomy (PTK) was performed to remove the corneal epithelium. Partial topography- guided PRK laser treatment was applied. A cellulose sponge soaked in mitomycin C (MMC) 0.02% solution was applied over the ablated tissue for 20 seconds followed by irrigation with 10 mL of chilled balanced salt solution."
45837704|NCT05766085|Diagnostic Test|Dexamethasone suppression test|Determination of cortisol levels at 9.00 am after taking 1 mg of dexamethasone the previous evening at 11.00 pm (1mg DST)
46014970|NCT04325295|Drug|Recombinant FSH (rFSH)|A low-dose step-up protocol will be implemented. This starts on CD 3,The rFSH will be given through (IM) or(SC) injections with 75 IU and will be given once daily.Monitoring of the treatment will be done on CD 7 by TVUS and serum E2. Monitoring is individualized according to the response. Depending on the response and follicular growth, the dose may be adjusted by increasing 37.5 IU. If follicular growth failed, the dose is furtherly increased by the same amount until at least one follicle reaches 10 mm. The dose is maintained until at least one follicle reaches a diameter of 18 mm and no more than 2 follicles are bigger than 15 mm. Once reaching the desired diameter, the rFSH will be stopped and a trigger of ovulation by an IM injection of 5000 IU of hCG and sexual intercourse is encouraged on the day of trigger and the next day. Then serum P will be done 7 days after hCG injection to detect the occurrence of ovulation.
46014971|NCT02891187|Behavioral|Telephone follow-up|Patients will be called for postoperative care at 1-2 weeks, 6 weeks, and 3 months
45465269|NCT05554887|Other|Thrust manipulation|Participants will be positioned prone and the clinician will perform a high-speed, low-amplitude thrust into the most symptomatic segment of the thoracic spine. TM type, thrust direction, and number of thrusts will be at the clinician's discretion and will be based on the individualized assessment of the patient.
45465270|NCT05554887|Other|Sham thrust manipulation|The same protocol will be applied as the push thoracic manipulation application, but no push will be applied.
45465271|NCT03814135|Drug|Hipnos 3|1 tablet, oral, once a day.
45465272|NCT03814135|Drug|Hipnos 5|1 tablet, oral, once a day.
45465273|NCT03814135|Other|Hipnos 5 Placebo|1 tablet, oral, once a day.
46014972|NCT02891187|Behavioral|Outpatient Clinic Visits|Patients will return to the clinic at 1-2 weeks, 6 weeks, and 3 months
46014973|NCT05644743|Device|gemcitabine + cisplatin|Gemcitabine intravenous drip, day 1, 8； Cisplatin intravenous drip, day 1； 3 weeks is a cycle, and 6 cycles are used continuously.
46014974|NCT01317615|Drug|RAD001|Participants started RAD001 treatment with a dose of 5 mg/day once daily. A dose decrease to 5 mg every other day was allowed if tolerability issues arose.
45465274|NCT03814135|Other|Hipnos 3 Placebo|1 tablet, oral, once a day.
45465275|NCT03927599|Other|Data Collection|Colleciton of data from medical records only
46014975|NCT01317615|Drug|Paclitaxel|Paclitaxel was started at doses of 175 mg/m². Dose reductions of Paclitaxel to 135 mg/m2 was permitted if tolerability issues arose.
46014976|NCT01317615|Drug|Carboplatin|Carboplatin was started at doses of Area under the Curve 5 (AUC 5). Dose reductions of carboplatin to AUC 4 was permitted if tolerability issues arose.
46100092|NCT02568514|Device|Secure text messaging|A smartphone and web application that allows physicians and other health care professionals to communicate to each other by secure text message
45837705|NCT05766072|Other|EMOTION Kids coping with anxiety and depression (Kendall et. al, 2013) (Mestrende barn in Norwegian) Martinsen et al, 2014|The intervention is transdiagnostic and based on cognitive behavioral therapy where the children and their parents meet i groups led of school health nurses. They are learning coping skills to meet challenging and avoided situations, learning about emotion regulation, physical symptoms conitive restructuring and exposure/behavioral activation. Te manual is publshed in a US/English version and in a Norwegian version.
46014977|NCT02891109|Biological|Biological tests|From the blood: B and T cells extraction then co-culture B and T cells and characterization of lymphocytes by flow cytometry
46100093|NCT04180475|Device|MedRem application|Medication adherence smartwatch application
46100094|NCT02568592|Dietary Supplement|High Fat|High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)
46100095|NCT02568592|Dietary Supplement|Normal|Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)
46100096|NCT02568592|Dietary Supplement|Normal + Extra Fat|Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORMAL, with an additional 30% extra energy coming from fat.
46100097|NCT00656942|Device|Quantitative Sensory Testing (QST)|QST consists of a series of heat and cold stimulation tests.
46100098|NCT00827931|Drug|Tranexamic acid + Standard of Care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
46100099|NCT00827931|Procedure|Standard of Care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
46100100|NCT04158674|Drug|Levosimendan|Levosimendan 2.5mg/ml, solution to be diluted for infusion Dilution in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min
46100101|NCT04158674|Drug|Cernevit|mixture of 12 vitamins The dilution of the treatment is done in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min
46100102|NCT00526669|Drug|Lapatinib and Capecitabine|oral lapatinib (1250mg) administered as a monotherapy run-in followed by its combination with capecitabine
46100103|NCT02474927|Drug|Carfilzomib|Carfilzomib will be used in combination with the conventional therapy (plasma exchange and intravenous immunoglobulins)
45465276|NCT03711201|Behavioral|Group IORE|This group will undergo the IORE procedure before surgery (operation). On the day of surgery, the patient will be brought to the operating room by the anesthesiologist. Hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured at the service, preop unit and operating room. The anxiety level in the operating room will be measured by the ST-STAI scale.
45465277|NCT03819673|Behavioral|Intervention Group Care|children's assessment, setting weight management goals, provision of personalised meal plans, personalised diet and lifestyle optimization advice recommendations to children and their families, periodic re-evaluation every 3 or 6 months
46014978|NCT05644509|Biological|Oncolytic Virus Injection（Revottack）+PD-1|Intravenous injection of Revottack injection combined with PD-1(Toripalimab） inhibitor
46014979|NCT01078675|Drug|rosuvastatin calcium|5 mg, oral, once daily, 24 months
45465278|NCT01129661|Biological|CSL112 (reconstituted HDL)|Single escalating intravenous doses of CSL112
45465279|NCT01129661|Biological|normal saline (0.9%)|Single intravenous dose of normal saline (0.9%)
46014980|NCT01078675|Drug|rosuvastatin calcium|10 mg, oral, once daily, 24 months
46014981|NCT01078675|Drug|rosuvastatin calcium|20 mg, oral, once daily, 24 months
46014982|NCT04301791|Other|nutritional status|impact of nutritional status on clinical outcome of children admitted in PICU
46014983|NCT02878135|Procedure|fast application|
46014984|NCT02878135|Procedure|slow application|
46014985|NCT04875793|Diagnostic Test|Stool for Occult Blood Test and Colonoscopy with comprehensive medical checkups|participants will be drawn from all public government institutions inside Tabuk city(outreach). The institution head will be requested to give wellness cards to the eligible employee to receive comprehensive testing for free in addition to CRC test in selected public health centres.
45837706|NCT05766059|Device|Transcranial Magnetic Stimulation|The standard PAS protocol will be compared with the mirrorPAS protocol.
46014986|NCT02877199|Other|Triple therapy|Cohort of patients who received triple therapy combining pegylated-interferon/ribavirin + first generation protease inhibitor boceprevir or telaprevir as part of routine clinical practice
46100104|NCT00658346|Drug|Treatment initiation for HIV-1 group O infected patients|"The first line regimen is adapted according to the hemoglobin level and the AgHBs status :~If Hb > 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)~If Hb <= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)~If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)"
46100105|NCT00658346|Drug|Treatment initiation for HIV-1 group M infected patients|"The first line regimen is adapted according to the hemoglobin level and the AgHBs status :~If Hb > 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)~If Hb <= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)~If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)"
46100106|NCT00710866|Biological|Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)|Arm 1 (experimental group) received two spaced injections of the 0.5 mL (full) dose while arm 2 (comparison group) received the currently recommended two spaced injections of 0.25mL (half) dose of trivalent inactivated split virion influenza vaccine (VAXIGRIP®) manufactured by Sanofi Pasteur, Lyon, France.
46100107|NCT04158596|Device|Vibration Therapy|SDX-3101 is used for drug-free treatment of CRSsNP in adults.
46100108|NCT03640949|Drug|Vasopressin, Arginine|20 IE of vasopressin per dose for a maximum of four doses (80 IU)
46100109|NCT03640949|Drug|Methylprednisolone|40 mg methylprednisolone once
46100110|NCT03640949|Drug|NaCl|Placebo
46100111|NCT00827775|Drug|Carvedilol|Carvedilol 6.25 mg BID titrated weekly to maximum of 50 mg bid
46100112|NCT02544308|Drug|Lenalidomide|Experimental Arm
46100113|NCT02544308|Drug|Dexamethasone|Experimental Arm
46100114|NCT02544308|Other|No further treatment|Comparator Arm
45465280|NCT05446467|Drug|pembrolizumab+cisplatin + 5-FU|ivgtt, pembrolizumab 200mg d1+cisplatin20 mg/m2 qd d1-d3 + 5-fluorouracil 3000mg/m last for 120hours , six circles
46014987|NCT02879149|Device|AUGMENT® Bone Graft|AUGMENT® Bone Graft
46014988|NCT02879149|Procedure|Standard of Care|Autologous Bone Graft
46014989|NCT02877277|Dietary Supplement|Vitamin C|Oral intake of vitamin C tablet (500 mg) daily for 56 days
46014990|NCT02877277|Dietary Supplement|Placebo|Oral intake of placebo tablet daily for 56 days
46014991|NCT01100437|Drug|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush|Placebo capsules plus EMBEDA capsules crushed and mixed in solution administered orally at each patient's stable dose, given either once daily or twice daily
46014992|NCT01100437|Drug|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole|EMBEDA capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily with 150mL placebo solution
46100115|NCT04617808|Other|Questionnaire|"The regulatory scheme applied to all investigative centers is as follows:~Call from Center 15 by a major patient for secondary headache no traumatic. (i.e. not having been the victim of a head trauma during the 48 hours preceding the call)~Detection of the pattern of non-traumatic headache, by the regulatory assistant medical with registration of the word cephareg in the medical regulation software in order to alert the regulator about the possible inclusion of the patient~If possible, patient information on the collection of their data for research and possibility of opposing~Filling of a medical questionnaire by the regulating doctor~Weekly collection of medical questionnaires by investigating doctors"
46100116|NCT00707187|Drug|Cialis|35 pills of study medication (20 mg)
45465281|NCT05553613|Drug|Ticagrelor 90 MG Oral Tablet|efficacy and safety of 180 mg loading dose of ticagrelor administered within 12 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke and possible adverse effects.
46014993|NCT04306705|Drug|Tocilizumab|Administered as an intravenous infusion.
46014994|NCT04306705|Other|Standard of care|Standard of care therapy per local written policies or guidelines and includes balancing of electrolytes and acid-base, the provision of enteral or parenteral nutrients support, antibiotics therapy, oxygen therapy and noninvasive ventilation.
46014995|NCT04306705|Procedure|Continuous renal replacement therapy|Catheter insertion site is femoral vein.
46014996|NCT01322490|Biological|PROSTVAC-V|
46100117|NCT03998761|Drug|Micronized Progesterone|Progesterone will be started when endometrial thickness reached 8 mm or more. Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening). A maximum of 2 embryos will be thawed on the day of embryo transfer, which is four days or six days after the start of progesterone depending on day-3 or day-5 embryo transfer. After thawing, surviving embryos will be transferred into the uterus under ultrasound guidance. Estradiol and progesterone will be continued until the day of pregnancy test. If the pregnancy test is positive, the patients will continue to use 800 mg micronized progesterone until 7 weeks of gestation.
46100118|NCT03998761|Drug|Micronized progesterone plus dydrogesterone|Progesterone will be started when endometrial thickness reached 8 mm or more. Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening) plus dydrogesterone (Duphaston® 10mg, Abbott) at the dose of 10mg twice daily (morning and evening). A maximum of 2 embryos will be thawed on the day of embryo transfer, which is four days or six days after the start of progesterone depending on day-3 or day-5 embryo transfer. After thawing, surviving embryos will be transferred into the uterus under ultrasound guidance. Estradiol and progesterone will be continued until the day of pregnancy test. If the pregnancy test is positive, the patients will continue to use 800 mg micronized progesterone plus 20 mg dydrogestetrone until 7 weeks of gestation.
45465282|NCT05553613|Drug|Clopidogrel tablet|efficacy and safety of 300 mg clopidogrel followed by 75 mg once daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke and possible adverse effects.
45465283|NCT03901144|Drug|2% urea/20% glycerol cream|Moisturizing cream for topical application
45465284|NCT03901144|Drug|Miniderm® 20% cream|Moisturizing cream for topical application
45465285|NCT03901144|Drug|Diprobase® cream|Emollient cream for topical application
45465286|NCT01129739|Other|Human umbilical cord-derived MSCs|1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle
46014997|NCT01322490|Biological|PROSTVAC-F|
46014998|NCT01322490|Drug|GM-CSF|
45465287|NCT01129739|Other|cyclosporine A (CsA)|CsA 5mg/kg po for 6 months
45465288|NCT01129817|Other|Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation with matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
46014999|NCT01322490|Other|GM-CSF Placebo|
46015000|NCT01322490|Biological|Placebo|PROSTVAC V/F Placebo
46015001|NCT02877355|Drug|semaglutide|All subjects will receive 3 mg oral semaglutide for five days followed by 7 mg oral semaglutide for five days
46015002|NCT01314261|Drug|ABT-267|5 mg or 25 mg tablets
46015003|NCT01314261|Drug|Pegylated interferon (pegIFN)|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
46015004|NCT01314261|Drug|Ribavirin (RBV)|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
46015005|NCT01314261|Other|Placebo for ABT-267|Participants received matching placebo tablet at each dose level for ABT-267.
46015006|NCT02891616|Drug|fludeoxyglucose F 18|
46015007|NCT02891616|Device|Positron emission tomography-computed tomography|
46015008|NCT02891616|Drug|18F-fluorothymidine|
46015009|NCT02891616|Device|Positron emission tomography-magnetic resonance imaging|
46015010|NCT05661357|Drug|Disitamab Vedotin Combined With Fruquintinib|"Furquinotinib: 5mg, Qd, taken continuously for 3 weeks, then stopped for 1 week, 28 days as a cycle.~Vidicizumab: according to the instructions of Vidicizumab, d1, 2.0 mg/kg, intravenous drip (ivgtt)"
45837707|NCT05766033|Other|Enamel conditioning with a novel etchant paste|The maxillary and mandibular incisors, canines, and premolars for each patient will be conditioned using the Novel etchent paste on one side (experimental), while the other side (control) conditioned with a phosphoric acid gel 37% . Both systems use identical brackets and adhesive system (differ only with regard to the etching system).
46100119|NCT00736918|Behavioral|Case management|Case management, Usual clinical practice and Providing paper based information for suicide prevention
45465289|NCT01129817|Other|Manual therapy and exercise|Patients in this group was treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and was designed to be consistent with best current manual therapy practice in Norway. The particular dose and techniques were at the discretion of the treating therapist, based on each participant's objective and physical examination findings. In addition most of the patients in this group was given exercises or a home exercise program.
45837708|NCT05765994|Diagnostic Test|Modified hydrogen breath test|A modified technique to obtain expired hydrogen from the ventilator tubes is performed. A connection with a valve attached to a collecting bag is inserted at the end of the expiratory limb of the breathing circuit for exhaled air collection.
45837709|NCT05765981|Drug|VGN-R09b|VGN-R09b will be injected into bilateral putamen by stereotactic surgery.（Through the SmartFlow Ventricular Cannula or the parenchymal injection tube actually used in the research center）
45837710|NCT05765929|Other|Non-operative treatment|Patients will be treated with a walker-orthosis for 6 weeks. Weightbearing as tolerated
45837711|NCT05765916|Behavioral|Online mindfulness and acceptance intervention|"Session 1 aims to encourage participants to share their experiences; and introduce the purpose, content, delivery mode, duration, and frequency of the intervention.~Session 2 aims to explain how negative illness perceptions lead to fear of cancer recurrence; and introduce the signs, screening, treatment and prognosis of breast cancer, ways to reduce the risk of recurrence, and symptom management.~Session 3 aims to guide the participants to practice body scan and seated meditation.~Session 4 aims to guide the participants to practice detached mindfulness, promoting reflection on the negative effect of indulging in unhelpful thoughts.~In session 5, participants will receive several forms covering work, health, parenting style, intimate relationships, self-development and so on. Participant will be asked to choose one or two forms and set action plans.~In session 6, the facilitator will invite participants to recall positive experiences and practice the Self-care exercise."
45837712|NCT05765877|Drug|WX-0593 Tablets|60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.
46015011|NCT01321710|Behavioral|Sleep hygiene|"This intervention consists of behavioral strategies for minimizing maternal arousal and sleep disturbance as a result of night-time infant care. Key components include: infant proximity, low lighting, and noise attenuation.~It is administered to women during their last month of pregnancy."
46015012|NCT01321710|Behavioral|Dietary information|This intervention consists of dietary information aimed at improving postpartum sleep. The recommendations include avoiding alcohol, caffeine, and heavy meals before bed, as well as eating healthy foods.
46015013|NCT01321710|Drug|Acetaminophen|51-90mg depending on infant weight (12.5mg per kg infant weight). Administered 30 minutes prior to immunization and q4-6h for a total of 5 doses.
46015014|NCT01321008|Radiation|Radiation|50.4 to 54 Gy delivered 5 days a week for 28 to 30 treatments.
46015015|NCT01321008|Drug|Cyclophosphamide|750 mg/m2 by vein over 1 hour on Day 1 of a 21 day cycle.
46100120|NCT00736918|Other|Enhanced usual care|Usual clinical practice and Providing paper based information for suicide prevention
46100121|NCT05483127|Device|Verofilcon A toric soft contact lenses|Soft contact lenses for optical correction of ametropia and astigmatism
46015016|NCT01321008|Drug|Doxorubicin|50 mg/m2 by vein over 15 minutes on Day 1 of a 21 day cycle.
46015017|NCT01321008|Drug|Vincristine|1.4 mg/m2 (max dose 2 mg) by vein over 15 minutes on Day 1 of a 21 day cycle.
46015018|NCT01321008|Drug|Prednisone|100 mg by mouth daily on Days 1-5 of a 21 day cycle.
46015019|NCT05661396|Behavioral|Serious game rehabilitation|Three patients received therapeutic serious game rehabilitation in addition to conventional rehabilitation. The serious game was proposed to be played three times per week for four weeks, for a total of 12 sessions, with 15 min per session (= 45 minutes per week).
46015020|NCT01323530|Drug|Eribulin mesylate|Intravenous (IV) bolus or infusion.
46015021|NCT01323530|Drug|Capecitabine|Oral film-coated tablets.
46015022|NCT05645198|Drug|Oozfix|Directly apply carboxymetyl starch (Oozfix) 5 gram evenly at the suprapancreatic surgical bed after gastrectomy
46015023|NCT05645198|Drug|Greenplast|Directly apply Greenplast (Aprotinin 1000kIU/mL, Thrombin 500IU/mL, Fibrinogen 95mg/mL) 4 gram evenly at the suprapancreatic surgical bed after gastrectomy
46015024|NCT04325438|Other|Pharmaceutical Care|"Pharmaceutical care interventions are categorised into 2 aspects:~Pharmacists' expertise aspect: medications review, identification and solution for the drug-related problem, adverse events, and other medication-related clinical problems. Therapeutic drug monitoring (TDM) is performed for any dose adjustment to the Rifampicin.~Motivational behavioral intervention to improve medication adherence (i.e. medications information and counseling to study participants)."
46015025|NCT02891252|Procedure|outpatient procedure|
46015026|NCT01313637|Drug|GSK573719/GW642444 125/25mcg|125/25mcg
46015027|NCT01313637|Drug|GSK573719 125mcg|125mcg
46015028|NCT01313637|Drug|GW642444 25mcg|25mcg
46100122|NCT05483127|Device|Stenfilcon A toric soft contact lenses|Soft contact lenses for optical correction of ametropia and astigmatism
45465290|NCT02952261|Device|template-guided localization|Based on CT data, digital model of the navigational template was created using CAD software and imported to 3D printer. The navigational template serves as a guider to the localizer in lung nodule localization.
45837713|NCT05765825|Drug|serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.
45837714|NCT05765825|Drug|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m^2) after completion of serplulimab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
45837715|NCT05765825|Drug|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
46015029|NCT01313637|Drug|Placebo only|Placebo
46100123|NCT00658580|Drug|Cisplatin + etoposide|"Cisplatin 90 mg/m² day 1, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks"
46100124|NCT00658580|Drug|Epirubicin + ifosfamide + etoposide|"Epirubicin 60 mg/m² day 1, every 3 weeks~Ifosfamide (+ uromitexan) 1.5 g/m² days 1-3, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks"
46015030|NCT01320722|Drug|Vitamin D ergocalciferol|50,000 unit soft gel capsule once per week for 8 weeks
46015031|NCT01320722|Drug|Probenecid|500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total)
46015032|NCT01320722|Drug|Allopurinol|300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total)
46100125|NCT03624491|Other|Esophageal pressure measurement guided ventilation|Use of esophageal pressure measurements to guide mechanical ventilation
46100126|NCT00729742|Drug|Comparator: erlotinib + dalotuzumab|"Part II: All patients will receive 1 week of erlotinib 150 mg tablets per day.~Arm 1: Patients who experience a PET response will continue on erlotinib monotherapy until disease progression.~Arm 2: Patients who fail to receive a PET response will continue to take erlotinib in combination with dalotuzumab 10 mg/kg IV infusion once weekly. At the time of disease progression, patients on erlotinib monotherapy will be offered to crossover to dalotuzumab 10 mg/kg IV infusion once weekly in combination with erlotinib."
45837716|NCT05765825|Drug|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
46015033|NCT01320722|Drug|Placebo|Placebo soft gel once per week for 8 weeks
46015034|NCT01320722|Drug|Placebo|Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total)
46015035|NCT01313559|Drug|Pasireotide|Given IM
46015036|NCT01313559|Drug|Everolimus|Given PO
46015037|NCT01313559|Other|Laboratory biomarker analysis|Correlative studies
46015038|NCT02891330|Behavioral|Dietary and nutritional recommendations conducted by a nurse|Supplementary dietary and nutritional education
46015039|NCT00623337|Behavioral|Home visits|Home visits by community based surveillance volunteers (2 during pregnancy & 3 during 1st week of life) to promote facility delivery, careseeking during pregnancy and childbirth and essential newborn care practices and to identify & refer sick babies
46015040|NCT02891031|Drug|Rhus (Somagh)|500 mg twice daily after meal for 6 weeks
46015041|NCT02891031|Drug|Placebo|500 mg twice daily after meal for 6 weeks
46015042|NCT04325750|Procedure|TECAR Therapy|The intervention will be performed with the T-Care TECAR® therapy machine at the latent trigger points of both gastrocnemius. The professional will apply the therapy with the generator that emits radio frequency signals of 0.5 MHz at a variable power with a maximum of 300W. The frequency to be used will be 500MHz with an intensity of 40% and with direct current.
46015043|NCT04325750|Other|Placebo|simulated TECAR Therapy (machine off)
45465291|NCT02952261|Other|CT-guided localization|Percutaneous lung nodule localization was conducted under the real-time guidance of CT scan. This is the conventional method of transthoracic lung nodule localization.
45465292|NCT01129895|Behavioral|Health promotion|In each intervention clinic 5 workshops on the initiation of health prevention projects in each clinic will be organized by the intervention team and than the clinic will be followed by the intervention team for 6 months.
45837717|NCT05765825|Radiation|Thoracic radiation therapy (TRT)|Participants will receive concurrent thoracic radiation therapy (TRT) treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle.Following the induction phase, participants will continue maintenance therapy with serplulimab thoracic radiation therapy (TRT) treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 30 Gy in 10 fractions in the fifth and sixth cycle
45837718|NCT05765799|Other|Questionary|Questionary will be administrated to evaluated the information for patients on interventional radiology (dedicated consultation, information posters, explanatory video, information form, etc.).
46100127|NCT00729742|Drug|Comparator: erlotinib monotherapy|Part I: All patients will receive erlotinib 150 mg tablets per day until disease progression.
46100128|NCT04074863|Procedure|Darrach|Surgical treatment of painful DRU osteoarthritis with resection of distal ulna
46015044|NCT05661279|Drug|primitive intravenous paracetamol 1 gm.|intravenous paracetamol 1 gm will be given before induction of anesthesia
45837719|NCT05765773|Biological|"CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS"|200 volunteers who will be vaccinated with the CoviVac vaccine three times with an interval of 21 days intramuscularly at a dose of 0.5 ml.
46100129|NCT04074863|Procedure|Prosthesis|Surgical treatment of painful DRU osteoarthritis with distal ulna replacement with Herbert implant
46100130|NCT04801693|Drug|BI 1819479|BI 1819479
46100131|NCT04801693|Drug|Placebo|Placebo
46015045|NCT05661279|Procedure|Rhomboid intercostal block|the patients will be positioned in lateral decubitus with moving the scapula laterally by abducting the ipsilateral arm across the chest. under complete aseptic situations A high-frequency (6-12 MHz) linear US probe will be put medial to the medial border of the scapula in an oblique sagittal plane with the orientation marker directed cranially.at the T6-7 level, the tissue plain between the rhomboid major and intercostal muscles is identified, and a single injection of 20 mL of bupivacaine (0.25%) will be administered via 18-gauge Tuohy advanced in plane from a superomedial to an inferolateral direction,
46015046|NCT05661279|Procedure|Serratus anterior plane block|The patient will be positioned supine with his arm abducts at 90°. the US high frequency (6-12 MHz) linear probe of sonosite M turbo ultrasonography (FUJIFIM sonosite, Inc., Bothell, WA, USA) will be put in sagittal plane at the midaxillary line. identification of the fascial plane between the serratus anterior muscle and external intercostal muscles will be performed between the fourth and fifth ribs in the midaxillary area . At this point the18-gauge Tuohy needle will be advanced in plane with injection of 20mL of 0.25 % bupivacaine.
46015047|NCT04325360|Procedure|Cathodal Transcranial Direct Current Stimulation|20 minutes of cathodal stimulation at 2mA, with cathode electrode placed over the focal epileptic area (determined by EEG exam and located according to the 10-20 system), the anode electrode will be placed over the supraorbital region, contralateral to the cathode electrode.
46100132|NCT05742100|Drug|Darvadstrocel|expanded allogeneic adipose-derived mesenchymal stem cell therapy for the treatment of complex perianal fistulas
45465293|NCT03859336|Device|Transdermal Neuromodulation Stimulation|The TEN device administers a tuned high frequency electrical stimulation delivered to the cervical plexus (C2-C4) on the back of the neck for 20 minutes. This stimulation will activate common trigeminovagal pathways modulating noradrenergic signaling to attenuate sympathetic activity. This stimulation can subsequently regulate the activity of several deep-brain nuclei within the ascending reticular activating system (RAS). Nuclei in the RAS regulate powerful neuromodulators like norepinephrine (NE), acetylcholine (ACh), and serotonin (5-HT). The investigators will examine whether this modulation from TENS will decrease anxiety and improve sleep quality in the study participants.
45465294|NCT01301599|Drug|combination therapy|alpha blocker and 5-alpha-reductase inhibitor medication
45465295|NCT01301599|Drug|alpha blocker monotherapy|alpha blocker monotherapy group
45465296|NCT01301599|Drug|5 alpha reductase inhibitor monotherapy|5 alpha reductase inhibitor monotherapy
46015048|NCT04325360|Procedure|Sham Transcranial direct current stimulation|Participants will received 20 mins of Sham stimulation, where stimulation will happen for the first 30 seconds and in the last 30 seconds of the intervention (at 2mA), with no stimulation in the between time. The cathode electrode will be placed over the focal epileptic area (determined by EEG exam and located according to the 10-20 system),the anode electrode will be placed over the supraorbital region, contralateral to the cathode electrode.
46015049|NCT02890953|Drug|Pneumostem|direct intracerebroventricular injection of mesenchymal stem cells via ventricular tap
46015050|NCT02890953|Drug|Normal saline|direct intracerebroventricular injection of normal saline via ventricular tap
46015051|NCT05644652|Other|designed physical therapy program|"it will be applied for for 60 min weekly for 3 successive months in the form of three sets of exercises (20 minutes each) as follows:~Flexibility exercises to restore joint mobility of soft tissues.~Static and dynamic balance exercises~Functional strengthening exercises.~Functional gait training."
46015052|NCT05644652|Other|Nordic walking|it will be conducted according to the guidelines of the International Nordic Walking Federation
46015053|NCT02890875|Other|Ethanol lock|
45599183|NCT02302417|Other|ACOS clinical questionnaire|The 41-question questionnaire includes questions concerning the following: a) response to bronchodilator, b) disease progression, c) variations in symptom, d) atopic history, e) symptom triggers, f) vagal bias, g) burden of disease, h) symptom presentation, i) emotional aspects, and j) age of onset. In addition, two questions will capture patient perception of his/her respiratory disease and the physician's diagnosis
45599184|NCT03796637|Drug|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
46015054|NCT02890875|Other|Heparin lock|
46015055|NCT04324970|Device|Tookie Vest|Tookie Vest
46015056|NCT01312779|Device|Implantation of CEP Magna Mitral Model 7000TFX|Heart valve surgery: CEP Magna Mitral Model 7000 TFX
46015057|NCT01312467|Drug|metformin hydrochloride|
45837720|NCT05765747|Drug|Yunnan Baiyao|Yunnan Baiyao group will be given 4 times a day, 2 capsules each time after morning, afternoon and evening meals and before going to bed. One capsule of Baoxianzi will be provided for the first time to be taken at the same time with Yunnan Baiyao Capsule, which will be given continuously for 2 weeks.
45465297|NCT05390554|Behavioral|Buteyko Breathing Technique|"The child was instructed to sit and take a relaxed posture in a vertical chair, relax his shoulders and lean his lower back against the back of the chair.~Until conducting CP, the child was told to avoid alternate breathing, the child was asked to take a small breath in (two seconds), a small breath out (three seconds) and clutch the nose with empty lungs but not too clear on the 'out-breath. To prevent air from escaping through the airways, clutching the nose is necessary.~The researcher estimates how many seconds the child can continue safely before the need to breathe in again,~The child was told to hold their breath until the first need to breathe in was felt. Release the nose then and naturally breathe through it smoothly.~The first intake of breath after the CP should be no higher than the breath before taking the measurement; the child should not hold the breath for too long as this could lead the child to take a major breath after measuring the CP."
45465298|NCT03384693|Drug|Defibrotide|Defibrotide is an anticoagulant and fibrinolytic agent that has been shown to be an effective treatment in other endothelial disorders such as hepatic veno-occlusive disease.
45465299|NCT03815617|Dietary Supplement|Zircombi|Twenty-five IBS patients (Rome IV criteria) (M:F= 8:17; age 48 yrs ± 11 SD) were enrolled and randomized to treatment or placebo in a a crossover randomized double-blind two-block placebo-controlled trial. Abdominal pain and bloating, intestinal habits, severity of disease, intestinal permeability, and intestinal microbiota were performed at the different time points.
45837721|NCT05765747|Drug|Celecoxib 200mg|The celecoxib group will be given 1 capsule twice a day after breakfast and dinner for 2 weeks.
46100133|NCT03435107|Drug|Durvalumab|"Study treatment consists of durvalumab 1500 mg Q4W for patients > 30 kg, and will be repeated every 4 weeks. For patients ≤ 30 kg, weight based dosing of 20 mg/kg durvalumab Q4W will be used.~Response evaluation will be performed every 8 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study."
45465300|NCT03815617|Dietary Supplement|Placebo|Given as comparable packets. Same duration.
45465301|NCT03621592|Device|Cutimed® Sorbact®|Dialkylcarbomoyl chloride based wound dressing
45465302|NCT03621592|Device|Acticoat®|Silver impregnated contact layer dressing
45465303|NCT03923855|Device|BTL-899|BTL-899 therapy
45465304|NCT05622955|Other|Peer Empowered Endometriosis Pain Support (PEEPS)|The sessions will provide education on endometriosis, mindfulness, yoga, nutrition, and strategies to cope with chronic pain. Patients will additionally receive peer and clinician support to decrease the social isolation experienced by people with endometriosis
46100134|NCT03803683|Device|mLab App|The mLab App is a web application that uses an image processing algorithm to interpret the results of the OraQuick® In-Home HIV Test.
45465305|NCT05348967|Dietary Supplement|TECADRIOL|Food supplement with D-chiro-inositol and alpha-lactalbumin
45465306|NCT03923621|Procedure|EPSiT|Specialised fistuloscope to indentify sinus tracts, cautery tracts, remove causative hair, irrigation.
45837722|NCT05765721|Behavioral|FRAIL-SM Program|Patients in experimental group will receive a 8 week family-based frailty self-management program; patients in control group maintain their usual life activities.
45837723|NCT05765708|Other|Motor Imagery|Motor imagery is the mental execution of a movement without any overt movement or without any peripheral (muscle) activation. It has been shown that motor imagery leads to the activation of the same brain areas as an actual movement. Therefore, it is used to acquire new motor skills. Action Observation (AO) involves the dynamic process of observing purposeful actions with the intention of imitating and then practicing those actions.
46015058|NCT01310127|Drug|Bromfenac|bromfenac 0.9% QD starting 3 days prior to cataract surgery, on the day of surgery and for up to 45 days after surgery
46015059|NCT01310127|Drug|Nepafenac|nepafenac ophthalmic suspension 0.1% TID dosed 3 days prior to cataract surgery, on the day of surgery, and for up to 45 days after surgery
46015060|NCT01309893|Device|Investigational Lens|Lenses worn on a daily wear basis for one week
46015061|NCT01309893|Device|Air Optix Aqua lens|Lenses worn on a daily wear basis for one week
46015062|NCT01318902|Drug|Ixazomib|Ixazomib capsules.
46015063|NCT01318902|Drug|Dexamethasone|Dexamethasone tablets.
46015064|NCT05644938|Procedure|Standard workflow|The SW group was either transferred to angiosuite or received rTPA, if indicated, after the results of Magnetic resonance imaging (MRI) and Magnetic resonance angiography (MRA) at admission.
46100135|NCT03803683|Behavioral|HIV Prevention Information|Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the Centers for Disease Control and Prevention (CDC) website.
46100136|NCT03803683|Device|HIV Home Tests|Youth randomized into this arm will receive OraQuick® In-Home HIV Test.
46100137|NCT02568436|Radiation|low level laser therapy|low level laser therapy is intended to accelerate tooth movement
46100138|NCT03612791|Drug|Atezolizumab|atezolizumab administered IV 1200 mg Q3W, starting one week before EBRT (Week -1) and continued as an adjuvant for a total maximum of 20 cycles.
46100139|NCT03612791|Radiation|Radiotherapy|"Pelvic +/- para-aortic EBRT (IMRT): 45 Gy in 25 fractions over 5 weeks (Weeks 1-5, with simultaneously integrated boosts to macroscopically involved lymph nodes, if any, in order to deliver a total dose of 60 Gy to macroscopic lymph nodes (including the dose delivered by brachytherapy).~Uterovaginal brachytherapy (Week 7; maximum interval between EBRT and brachytherapy: 14 days). If appropriate and feasible, dose escalation will be assumed, particularly for advanced disease, with the objective to deliver a total dose of 85 Gy (equivalent dose in 2-Gy fractions with α/β=10 Gy) to 80% of the High Risk-Clinical Target Volume (HR-CTV), including 45 Gy through EBRT. The total dose might be lower in case of close proximity to organs at risk (OARs).~Total duration of RT (including brachytherapy) should be ≤ 55 days."
46100140|NCT03612791|Drug|Cisplatin|"Cisplatin infused 40 mg/m2 (maximum 70 mg) weekly IV during EBRT (Weeks 1-5).~Not administered: during the interval between EBRT and brachytherapy, or during brachytherapy, or if radiotherapy is interrupted."
46100141|NCT03998449|Biological|Vaccination against cholera|Participants will receive two doses of an oral cholera vaccine with an interval of 2-4 weeks.
46100142|NCT00614861|Other|Non-cancer pain management survey|Non-cancer pain management survey
45465307|NCT03923621|Procedure|Excision|Surgery to remove all affected tissue, followed by wound closure.
45465308|NCT05390398|Behavioral|Behaviour change guided lifestyle intervention|Participants in the intervention group receive personalized coaching from a lifestyle coach on adhering to the World Cancer Research Fund cancer prevention guidelines. The lifestyle coach is specialized in behaviour change techniques and uses these as the core of the lifestyle coaching. For each participant behavioural determinants will be assessed and targeted with specific applicable behaviour change techniques.
45465309|NCT03923777|Other|Active Surveillance|Agreeing to postpone treatment while continuing with a CT scan surveillance regimen to follow tumor growth. SABR should be offered if either the tumor is >3 cm in size or the VDT decreases to <400 days.
45465310|NCT03712059|Diagnostic Test|FIT test and colonoscopy|All included patients received FIT test and then colonoscopy, with the risk factors of CRC recorded. The diagnostic performance of predicting model (based on FIT and risk factors) and colonoscopy were compared.
45465311|NCT03712059|Diagnostic Test|Polypectomy and biopsy|All included patients received polypectomy, and then biopsy is performed on the edge of resection for patients with < 10 mm adenoma (confirmed by pathology or predicted by NBI images), with the complete resection rate of polyps being calculated.
45465312|NCT03712059|Diagnostic Test|Classification|Pathology of polyps is classified by endoscopists through NICE principle and the performance of classification between endoscopists and computer is compared.
45465313|NCT05390320|Procedure|PAOO|Periodontally accelerated osteogenic orthodontics will be applied to treat patients with moderate crowding.
46015065|NCT05644938|Procedure|One-stop|The OS group transferred directly to ﬂat-detector computed tomography to consider recanalization by either intervention or recombinant Tissue Plasminogen Activator (rTPA) in the angiosuite.
46015066|NCT05644860|Combination Product|Nanohybrid Compisite Group (Filtek Z250)|Orthodontic brackets shall be bonded with Nano hybrid composite
46015067|NCT05644860|Combination Product|Conventional Composite Group (Transbond XT)|Patients in which brackets will be bonded with conventional composite resin (Transbond XT)
46015068|NCT01313858|Drug|Simponi®|
46015069|NCT01313858|Drug|Methotrexate|Given concomitantly with Simponi®
46015070|NCT05644704|Other|Lower extremity and core muscle training|Lower extremity training: single leg balance training Core muscle training: pelvic control training
46015071|NCT05644548|Other|No intervention|No intervention
46015072|NCT01090765|Drug|TRC105|
46100143|NCT05742022|Drug|"Phospholipovit"|500 mg orally 2 times a day, for 12 weeks
46100144|NCT05742022|Drug|Placebo|500 mg orally 2 times a day, for 12 weeks
45837724|NCT05765695|Procedure|Radiofrequency ablation performed with a 19 gauge STARmed needle.|The ablation with radiofrequency is a safe and effective minimally invasive procedure that results in thermal tissue necrosis. A needle electrode is inserted into the thyroid nodule using ultrasound guidance and generates heat by alternating electric current causing thermal injury. Afterwards, the ablated tissue is gradually absorbed with progressive shrinkage of the nodule.
46015073|NCT01313780|Drug|Oxycodone/Naloxone|Dose and administration : Upto 40mg B.I.D per daily.
46015074|NCT01313780|Drug|Oxycodone(single compound)|Dose and administration : Upto 40mg B.I.D per daily.
46015075|NCT01090453|Biological|GSK2202083A vaccine|3 doses given at 2, 4 and 12 months of age
46100145|NCT05741944|Other|Care with the use of PERSARC|PERSARC is a personalized risk assessment tool which provides patients and STS professionals insight into the personalized risks and benefits of each treatment option based on patient's age, tumor size, tumor depth and histology. PERSARC will be used in multidisciplinary tumour boards to guide treatment advice and in consultation in which the oncological/orthopaedic surgeon informs the patient about his/her diagnoses and discusses the benefits and harms of all relevant treatment options
46100146|NCT05741944|Other|standard care|All patients in control condition receive usual care.
45465314|NCT05390320|Other|Fixed appliance|Fixed appliances will be applied to treat patients with moderate crowding without any acceleration methods.
45465315|NCT03923465|Procedure|Procedure: Periodontal surgery with entire papilla preservation (EPP) technique|After local anesthesia injection an modified flap is designed according to minimally invasive microsurgical techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.
46100147|NCT02692937|Procedure|Neurolysis|
46100148|NCT02692937|Other|Traditional neck-specific exercise program|
46100149|NCT00827541|Drug|Tigecycline|Tigecycline 50 or 100 mg intravenously. Therapy conducted according to the package leaflet of Tygacil and to international treatment guidelines. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
46100150|NCT05741866|Device|Chlorhexidine gluconate impregnated bordered polyurethane dressing|"PIVCs will be dressed and secured at the participating sites~RBWH and PUH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with non-sterile tape over extension tubing.~QCH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference."
45465316|NCT03923465|Device|EMD application|Application of Pref-Gel for 2 minutes and then the application of Enamel Matrix Derivatives (EMD) on the surgically exposed root surface.
45465317|NCT03923465|Device|Bone substitutes application|Following the application of EMD, filling the bone defect with bone substitutes.
45465318|NCT03814057|Diagnostic Test|24 hour urine creatinine excretion|two age corrected calculations of creatinine height index were obtained
45465319|NCT05533281|Drug|tropisetron|One tropisetron was given 30 minutes in advance, and then tramadol 1.5mg/kg was intravenously injected with a micropump at a constant speed within 1min.
45465320|NCT05533281|Drug|metoclopramide|One dose of metoclopramide was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed within 1min.
45465321|NCT05533281|Drug|dexamethasone|One dose of dexamethasone was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed within 1min.
46015076|NCT01090453|Biological|Prevenar 13®|3 co-administered doses
46100151|NCT05741866|Device|Standard bordered polyurethane dressing|"PIVCs will be dressed and secured as per standard practice at the participating sites~RBWH and PUH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1683) and non-sterile tape strip over extension tubing.~QCH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1682 or 1683) and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference."
46100152|NCT03916601|Drug|SAR341402|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
46015077|NCT01090453|Biological|Infanrix hexa™|3 doses given at 2, 4 and 12 months of age
46015078|NCT01090453|Biological|Menjugate®|3 co-administered doses
46015079|NCT01090453|Biological|Rotarix™|Oral, two doses
46015080|NCT01171534|Device|DermaClose fasciotomy closure|The DermaClose device provides continuous expanding of the skin around the wound until it has stretched enough to allow the skin edges to be sutured closed.
46015081|NCT01171534|Device|Vessel loop|Vessel loops and staples for fasciotomy closure
46100153|NCT03916601|Drug|Insulin Aspart|"Pharmaceutical form: suspension for injection~Route of administration: subcutaneous"
46100154|NCT03916601|Drug|Insulin Aspart|"Pharmaceutical form: suspension for injection~Route of administration: subcutaneous"
46015082|NCT01170598|Other|Exercise|After obtaining daily medical clearance, patients will be approached 4-5 days per week to perform 30-45 minutes of supervised exercise with a Canadian Society for Exercise Physiology (CSEP) - Certified Exercise Physiologist. All exercise sessions will be as tolerated, based on patient symptoms.
46015083|NCT01170364|Drug|Sibutramine|1 week of active sibutramine (15mg)
46015084|NCT01170364|Drug|Placebo|2 weeks of placebo
46015085|NCT01170208|Device|insulin dose software|The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.
46015086|NCT01313624|Drug|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
46015087|NCT01313624|Drug|Placebo|Placebo to match AZLI administered via nebulizer three times daily
46015088|NCT05324410|Drug|VX-840|Solution for oral administration.
46100155|NCT03916601|Drug|SAR341402|"Pharmaceutical form: suspension for injection~Route of administration: subcutaneous"
46100156|NCT04065022|Device|tACS at tremor frequency|tACS applied between the stimulation electrodes at tremor frequency
46015089|NCT05324410|Drug|Placebo|Placebo matched to VX-840 for oral administration.
46015090|NCT02877043|Procedure|resection pulmonaire|
46015091|NCT02891018|Device|paclitaxel controlled release balloon catheter Vasoguard TM|
45465322|NCT05533281|Other|normal saline|Equal dose of normal saline was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed within 1min.
45465323|NCT01228721|Device|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
45599185|NCT02342769|Drug|Dolutegravir/Abacavir/Lamivudin|Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
45599186|NCT03514927|Procedure|Contrast-Enhanced Ultrasound|Undergo CEUS
45599187|NCT03514927|Device|High-Intensity Focused Ultrasound|Under go HIFU
46100157|NCT00613691|Drug|SPI-1620|SPI-1620 in escalating doses from 0.5 μg/m2 intravenous over sixty seconds
46015092|NCT02891018|Device|paclitaxel release coronary balloon catheter SeQuent Please|
46100158|NCT00518323|Drug|Paliperidone ER|3 mg or 6 mg tablet once daily for 6 weeks
46100159|NCT00518323|Drug|Placebo|Once daily for 6 weeks
46100160|NCT00518323|Drug|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
46100161|NCT00518323|Drug|Paliperidone ER|6 mg or 12 mg tablet once daily for 6 weeks
46015093|NCT01169350|Radiation|fludeoxyglucose F 18|Undergo 18F FDG and 18F FMISO PET/CT scans
45599188|NCT03514927|Other|Laboratory Biomarker Analysis|Correlative studies
45599189|NCT03514927|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
45599190|NCT03514927|Procedure|Radical Prostatectomy|Undergo prostatectomy
46015094|NCT01169350|Other|18F-fluoromisonidazole|Undergo 18F FDG and 18F FMISO PET/CT scans
46015095|NCT01169350|Procedure|positron emission tomography|Undergo 18F FDG and 18F FMISO PET/CT scans
46015096|NCT01169350|Procedure|computed tomography|Undergo 18F FDG and 18F FMISO PET/CT scans
46015097|NCT01169350|Other|laboratory biomarker analysis|Correlative studies
46015098|NCT00623324|Drug|Aplindore|Tablets .05 - 5 mg BID dosing for 14 days
46015099|NCT00623324|Drug|Placebo|Placebo tablets to match the number of active tablets
46015100|NCT05661266|Device|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
46015101|NCT01169038|Drug|levaquin; ethambutol; rifampin and azithromycin.|"Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD~**Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. **We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway."
46100162|NCT03915431|Biological|NCS-01|single infusion
46100163|NCT03915431|Biological|Placebo|single infusion
46100164|NCT00707421|Drug|ketorolac acetate|
46100165|NCT00707421|Drug|fluorometholone|
46100166|NCT00707421|Drug|artificial lacrimal tears|
46100167|NCT00707499|Drug|BMS747158|Single dose administration.
46100168|NCT03255707|Device|eye patch|Occluding the better seeing eye for a given number of hours daily
45837725|NCT05765656|Behavioral|GP - pharmacist collaboration and pharmacist motivational interviewing|"Patients in the GP-CP clusters randomized to the intervention arm will be offered a joint GP-CP deprescribing intervention by their GP.~After the encounter, the patients will go to the pharmacy to get their medication dispensed. They will be given education materials. The pharmacist will plan with the patients 3 Motivational Interviews which will address the risks of using BZDR, and the benefits and modalities of stopping them. The pharmacists will receive a 2-day training course in MI. They will be given guidelines on BZDR deprescribing. If required, the pharmacists will be supported in their first MI.~Following each interview, the pharmacist will inform the GP by means of a formalized report of the points discussed. The pharmacist will inform the GP of the patient's choice or not to get involved in a deprescribing process and of the protocol followed. The objective of this exchange is to formalize the joint GP-CP intervention and to secure the deprescribing of BZDR."
45837726|NCT05765643|Other|Nurse parental support in symptom management using a mobile health App|Parents in this group will receive a mobile App that includes health assessment, monitoring, health education and nurse support using phone calls over a 3-month period
45837727|NCT05765630|Biological|BLOOD SAMPLES|BLOOD SAMPLES
45837728|NCT05765617|Drug|Calcitriol|The treatment group received calcitriol 2x400 iu per day for five days. Calcitriol uses Oscal, obtained from Kalbe Pharma
46015102|NCT04315012|Other|receive mobile app-based education|to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
46015103|NCT01167634|Behavioral|Deposit contract with a 1:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
46015104|NCT01167634|Behavioral|Deposit contract with a 2:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount twice the amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
46015105|NCT01167634|Behavioral|Deposit Contract with no match|Daily weigh-in for 24 weeks and if each daily goal met the daily deposit amount is paid back. Final weigh-in at 36 weeks with no financial incentive or deposit made.
46015106|NCT00624754|Drug|Formoterol/Budesonide|Budesonide/Formoterol 400/12: 800 µg b.i.d for 1 month
45837729|NCT05765617|Other|Placebo|Placebo give 2x1 per day for five day
45837730|NCT05765591|Other|Balneotherapy and aquatic exercises|Information has already been included in arm/group descriptions
46015107|NCT00624754|Drug|lactose|Lactose 2 puffs b.i.d for 1 month
46015108|NCT02886052|Behavioral|Therapist guided Internet-CBT for insomnia|
46015109|NCT02886052|Other|Active control|
46100169|NCT03255707|Device|dichoptic treatment|dichoptic treatment in the form of playing a video game (Lazy Eye Blocks ®) while wearing a red/green goggle.
46100170|NCT03570437|Drug|Paclitaxel|80 mg/m2 on three days in a 28 day cycle (with 6 cycles)
46100171|NCT03570437|Drug|Cediranib|20 mg per day
46015110|NCT01166386|Behavioral|FANCI|comprehensive neurobehavioral sessions with therapist administrating treatment components
46015111|NCT01166386|Behavioral|FANCI|Watching DVDs chosen by participants on various topics.
46100172|NCT03570437|Drug|Olaparib|Olaparib tablets, 300 mg twice-daily
46100173|NCT03846167|Drug|Imaging Drug FluorThanatrace (FTT)|[18F]FTT is an investigational radioactive PET drug used to see PARP-1 activity in tumors. This radioactive imaging drug is injected into the body to see how it goes into places where there is active breast cancer. Using an imaging scan called Positron Emission Tomography (PET/CT), the radioactive drug can be seen in the body.
45599191|NCT03766685|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
45599192|NCT02298127|Other|Auricular acupressure|For each auricular acupressure weekly session, magnetic ears tacks will be will be applied by certified traditional Chinese medicine practitioners according to the allocated group assignment, for a duration of one month.
45599193|NCT02342847|Other|N/A (non-interventional study)|
46015112|NCT01114828|Drug|OPC-41061|Once-daily oral administration of OPC-41061 at 3.75 mg after breakfast for 7 days
46015113|NCT01114828|Drug|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
46015114|NCT01313312|Biological|Botulinum toxin type A|"Dysport® was supplied to the study centres in vials containing 500 U of botulinum toxin type A (BTX-A). Depending on the dose administered up to 3 vials were required for the injection.~Each vial was reconstituted with sodium chloride for injection (0.9%). A total volume of 5.0 mL of the reconstituted product was injected for Dysport® 500 U and 1000 U, and 7.5 mL was injected for Dysport® 1500 U."
46015115|NCT01114672|Drug|50,000 Units Ergocalciferol|50,000 Units oral ergocalciferol to be given once weekly
46015116|NCT01114672|Drug|Placebo|oral placebo once weekly
46015117|NCT01114516|Drug|Indomethacin and antibiotics (cefazolin or clindamycin)|q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin
46100174|NCT00826449|Drug|Dasatinib|Starting dose of 70 mg by mouth daily for 21 day cycle.
46100175|NCT00826449|Drug|Erlotinib|150 mg by mouth daily every 21 day cycle.
46100176|NCT03632213|Drug|Losartan|Losartan group: 15 patients, both sexes, will receive Losartan 0.4 to 1.4 mg/kg/day orally for 12 months.
46100177|NCT03632213|Drug|Placebo|Placebo group: 15 patients, both sexes, will receive oral placebo for 12 months.
46015118|NCT02890940|Behavioral|Pet Therapy|"Patients will be asked to complete the standardized QLQ-C30/BN20 questionnaires. Following completion of the questionnaires, a trained pet therapy dog will be brought to the patients for approximately 10 minutes. After approximately 10 minutes, the dog will be removed and the patients will be asked to re-complete the standardized QLQ-C30/BN20 questionnaires. Patients will be photographed and videographed during this time.~Finally, patients will be asked to talk about how their perspectives on life have changed with their diagnosis. These responses will be captured for use in the art exhibit created from images collected during the study."
46015119|NCT01114438|Device|EndoBarrier Gastrointestinal Liner|EndoBarrier Gastrointestinal Liner is intended to remain in vitro for 12 months.
46015120|NCT01313078|Drug|Pegylated L-Asparaginase|Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks
46015121|NCT00625690|Other|questionnaire administration|Subjects will be asked to complete an additional detailed questionnaire regarding personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members.
46100178|NCT04041297|Other|Preoperative Pulmonary Rehabilitation|"Each prehabilitation session will last approximately 90 minutes and will include:~Endurance training at the ventilatory threshold, determined according to the initial CPET. The first session will last for 15 to 20 minutes then increase by 5 minutes each session to reach 45 minutes in total (including a 5-minute warm-up and 5 minutes of active recovery). The intensity will then increase by 5 or 10 W, as could be tolerated;~Peripheral muscle strengthening at 60% to 70% of the 1-repetition maximum of 3 main components (quadriceps press, whole-leg extension, and upper limb pull down). Three sets of 12 movements will carry out for each exercise and the load will increase weekly as tolerated;~Inspiratory muscle training using a threshold calibrated to at least 30% of the MIP. Patients will be encouraged to carry out 15 minutes of independent training daily and to increase the resistance regularly.~Education to bronchial drainage techniques as well as directed coughing."
46015122|NCT00625690|Procedure|computed tomography|The baseline and repeat screening CT scans will be performed with a multi-slice helical CT scanner (8 or more rows), at a low-dose setting (120kVp, 40-80mA, slice thickness of 1.25 mm or less). In a single breath-hold, contiguous slices from the thoracic inlet to the adrenal glands will be obtained. Contrast material will not be used. Multi-slice scanners will be used because they provide higher-resolution images. Diagnostic studies, including HRCT will be performed with a multi-slice helical CT at diagnostic settings (120kVp, 140-300mA, slice thickness of 1.25 or less) with the nodule retrospectively reconstructed at a 15cm field of view.
46015123|NCT00625690|Procedure|evaluation of cancer risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
46015124|NCT00625690|Procedure|study of high risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
46100179|NCT04150523|Other|Survey|The study will involve a 22 question online survey, administered through the online survey platform conjoint.ly. Conjoint.ly is a web-based survey tool used to conduct survey research, evaluations and other data collection activities. Participants will complete a conjoint.ly survey and choose between treatment (antibiotic vs no antibiotic) scenarios.
45599194|NCT03514849|Procedure|prophylactic cranial irradiation (PCI)|Patients in the control group are enrolled in the follow-up, and the patients in research group will receive prophylactic cranial irradiation （PCI） by 25 gy/10 fx.
46015125|NCT01114360|Drug|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 8 mg time-release melatonin pills, orally, once per night for 4 weeks.
46015126|NCT01114360|Drug|Placebo|Subjects received placebo pills (3 pills of 8 mg each) to be taken orally once per night for 4 weeks.
46015127|NCT01310036|Drug|Erlotinib|Erlotinib 150 mg was administered orally daily until disease progression or unacceptable toxicity.
46015128|NCT04324892|Drug|Treat to target|All patient will received protocolized treatment with an aim to achieve SDAI remission
46015129|NCT01309100|Device|Investigational Lens|Bausch & Lomb investigational silicone hydrogel lens on a daily wear basis for 1 week.
46015130|NCT01309100|Device|Acuvue Oasys Lens|Johnson & Johnson Acuvue Oasys contact lens on a daily wear basis for 1 week.
46015131|NCT01309100|Device|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens on a daily wear basis for 1 week.
46015132|NCT01075321|Drug|everolimus|Given orally
46015133|NCT01075321|Drug|lenalidomide|Given orally
46015134|NCT01075321|Other|laboratory biomarker analysis|Correlative studies
46015135|NCT01075321|Genetic|polymorphism analysis|Correlative studies
46015136|NCT01075321|Other|immunohistochemistry staining method|Optional correlative studies
46015137|NCT01075321|Genetic|microarray analysis|Optional correlative studies
46015138|NCT01075321|Genetic|fluorescence in situ hybridization|Optional correlative studies
46015139|NCT01114204|Drug|Ferumoxytol|IV Ferumoxytol
45599195|NCT03514849|Procedure|lobectomy + mediastinal lymph node dissection or systematic lymph node sampling|lobectomy + mediastinal lymph node dissection or systematic lymph node sampling
45599196|NCT03514849|Drug|postoperative adjuvant chemotherapy|If the postoperatively pathological examination of the patient is confirmed to be in pT1-2N0 stage, a single postoperative adjuvant chemotherapy (combining etoposide with cisplatin) is recommended. If patients are difficult to tolerate the side effects of cisplatin, we can replace cisplatin by carboplatin in the adjuvant chemotherapy scheme.
45837731|NCT05765578|Biological|Moderna COVID-19 Vaccine|Sterile liquid for injection
45837732|NCT05765578|Biological|Moderna mRNA1273.222 Booster|Sterile liquid for injection
45837733|NCT05765578|Biological|Pfizer COVID-19 Vaccine|Sterile liquid for injection
45837734|NCT05765578|Biological|Pfizer-BNT 162b2 Bivalent Booster|Sterile liquid for injection
45837735|NCT05765565|Device|Octaray multi-electrode catheter|Newly designed multi-electrode catheter for creating 3D electroanatomical CARTO maps.
46015140|NCT01114204|Drug|Iron Sucrose|IV Iron Sucrose
46015141|NCT01075243|Drug|Paracetamol 1000 mg|Paracetamol 1000mg
46015142|NCT01075243|Drug|Paracetamol 650 mg|Paracetamol 650 mg
46015143|NCT01075243|Drug|Placebo|Placebo
46015144|NCT01308476|Procedure|SMS reminder|daily SMS in the SMS group to remind of treatment with tiotropium
46015145|NCT01308476|Procedure|control group|no daily SMS to remind of treatment with tiotropium
46015146|NCT01078441|Drug|liposomal doxorubicin|Given IV
45599197|NCT02342691|Drug|BLXA4|BLXA4-ME is a member of a new class of chemically and metabolically stable lipoxin analogs featuring a replacement of the tetraene unit of native lipoxin-A4 (LXA4) with a substituted benzo-fused ring system. The full chemical name of the BLXA4-ME drug substance is (5S, 6R, E)-methyl 5,6-dihydroxy-8-(2-((R,E)-3-hydroxyoct-1-enyl) phenyl) oct-7-enoate.
45599198|NCT02342691|Drug|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
46015147|NCT01078441|Drug|bortezomib|Given subcutaneously.
46015148|NCT01078441|Drug|dexamethasone|Given orally
45837736|NCT05765565|Device|Pentaray multi-electrode catheter|Current standard multi-electrode catheter for creating 3D electroanatomical CARTO maps.
45837737|NCT05765552|Other|Dual-Task Training|Motor-cognitive dual-task exercises will be applied for 2 days a week for 8 weeks.Sessions will last for 30 minutes.
45837738|NCT05765552|Other|Control Group|Upper and lower extremity range of motion exercises will be applied for 8-10 repetitions for 1 set 2 times a week for 8 weeks.
45599199|NCT03766295|Drug|Masitinib|
45599200|NCT03766295|Drug|Gemcitabine|
45599201|NCT03766295|Drug|Placebo|
45837739|NCT05765539|Device|echOpen O1 Handheld Ultrasound device|"The performance of the Handheld ultrasound device (echOpen O1 device) will be assessed during these visits for all evaluation criteria.~One examination with the US machine by the midwife focused on 4 targets ;~One examination with a classic US machine by the same midwife (comparator) including the search for the four targets ;~One examination with the US machine by a second operator ; Review of the images obtained by the US machine by the referring radiologist at a separate point of time.~The mode of delivery and the vital status of the mother and newborn will also be collected.~Operator A will start by using either the echOpen O1 device or the US machine (random order, via sealed envelopes) and will then perform the other type of examination.~Another operator (Operator B) will come to perform an examination with the Handheld ultrasound device (blind to the result of the first operator).~The switch between operators A and B will also be random."
45837740|NCT05765500|Drug|Relugolix|Gonadotropin-releasing hormone (GnRH) antagonist, oral tablet taken 1x daily.
45837741|NCT05765500|Drug|Leuprolide|Gonadotropin-releasing hormone (GnRH) antagonist, intramuscular injection 1x every 3 months.
46015149|NCT01078441|Drug|cyclophosphamide|Given IV
46015150|NCT01308008|Behavioral|home exercise/physical activity (PA) enhancement program with behavioral support|Initial on-site personal trainer-based functional aerobic program followed by home intervention consisting of functional exercise training and enhanced physical activity with nurse telephonic behavioral support
46015151|NCT01308008|Behavioral|flex and toning health education program|Initial flex and toning program continued on follow-up along with health education
46015152|NCT04325048|Device|Cordio App|Adult patients positive to COVID-19 virus will record several predefined sentences via a smartphone / tablet and will answer questions via the app
46015153|NCT02890706|Device|Iodine Mapping using Subtraction in Pulmonary Embolism Computed Tomography versus Dual Energy Computed Tomography|Compare two techniques of the CT scanner
46015154|NCT00626665|Drug|Tadalafil|Tablets Tadalafil, 20 mg, alternate days, 6 weeks
46015155|NCT05644106|Device|personal sound amplification product, hearing aid|the device for hearing gain in sensorineural hearing loss
46015156|NCT01113892|Device|vascular grafts|All devices will be used to treat patients with peripheral arterial occlusive disease
46015157|NCT02877979|Drug|DS003 vaginal tablet|The trial will be conducted in three cohorts of 12 women each. In each cohort, participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17. In each cohort, therefore, 9 participants will receive DS003 vaginal tablets and 3 participants will receive placebo vaginal tablets.
45837742|NCT05765487|Drug|Sildenafil|Sildenafil Cream, 3.6%
46015158|NCT02877979|Drug|Placebo|
45837743|NCT05765487|Drug|Vehicle|No Active or experimental ingredients
46015159|NCT00626353|Other|Home-based rehabilitation|Rehabilitation at home during hospital stay and after discharge
46015160|NCT00626353|Other|Standard care|Standard care during hospital stay and in the municipality after discharge
45837744|NCT05765487|Drug|Placebo|Cream with only L-arginine
46015161|NCT04305847|Other|perioperative satisfaction assessment|Satisfaction assessment at 24 and 48 hours post operatively by self-administered survey questionnaire based on different scales: Evan-LR, Net Promotor Score, Satisfaction score.
45837745|NCT05765474|Behavioral|Practice Variable|This group receives the practice variable. The practice variable being studied will not be disclosed until completion of testing procedures.
46015162|NCT02881684|Device|Aspiration Therapy (AspireAssist®)|Use of the AspireAssist device in aspiration therapy
46015163|NCT02881684|Behavioral|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
46015164|NCT02876731|Device|PET-CT|NaF PET-CT
46015165|NCT02876731|Device|MRI|DWMRI
46015166|NCT04310332|Drug|1L-PEG|"The drug is 1L-PEG plus ascorbic acid (Plenvu®). It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational."
46015167|NCT04310332|Drug|4L-PEG|"The drug is 4L-PEG. It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational."
46015168|NCT01090063|Drug|Ustekinumab|Dosing will consist of a 45mg subcutaneous injection for patients weighing less than 100 kg and a 90 mg subcutaneous injection for patients whose weight is greater than 100 kg. Dosing will begin on week 0 followed by subsequent dosing on week 4 and week 16.
46015169|NCT00625768|Drug|AS1409|Study drug
45599202|NCT02344563|Drug|Meropem|
45837746|NCT05765474|Behavioral|No Practice Variable|This group does not receive the practice variable. The practice variable being studied will not be disclosed until completion of testing procedures.
45837747|NCT05765448|Other|Soy control|Soy isolate control meal
45837748|NCT05765448|Other|Intervention (Laver/nori (Porphyra umbillicus) macroalgae whole biomass)|Laver/nori (Porphyra umbillicus) macroalgae whole biomass treatment meal
45837749|NCT05765448|Other|Intervention (Laver/nori macroalgae (Porphyra umbillicus) protein isolates)|Laver/nori macroalgae (Porphyra umbillicus) protein isolates treatment meal
45837750|NCT05765448|Other|Intervention (Chlorella microalgae (Chlorella vulgaris) whole biomass)|Chlorella microalgae (Chlorella vulgaris) whole biomass treatment meal
45837751|NCT05765448|Other|Intervention (Chlorella microalgae (Chlorella vulgaris) protein isolates)|Chlorella microalgae (Chlorella vulgaris) protein isolates treatment meal
46015170|NCT01113580|Biological|CSL's 2010/2011 Formulation of Enzira® Vaccine|45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0
46015171|NCT01306214|Drug|Placebo|Placebo matching BI 10773 low dose
45465324|NCT01128725|Other|Alzhamyd|"The patients coming in consultation for a mnésique complaint will see each other offering the study. During a consultation, the following balance sheet will be accomplished :clinical Maintenance, collection of records and used treatments~psycho-behaviour Valuation through Neuropsychiatric Inventory (NPI) and through Inventory Apathy~Valuation of self-government in the activities of daily life (IADL). Further to this balance sheet, it is habitually offered on the subjects of advice (principally centered on the proposals of use of external helps for instance book memo, agenda and internal assistants medium notes-techniques and associations to keep information) and a new consultation 1 year afterwards including the same balance sheet.~In a supplementary way in this clinical valuation, a blood sample will be accomplished at the time of inclusion and 12 months afterwards."
45465325|NCT04802109|Device|wearing level D personal protective equipment|rubber gloves + surgical face mask + general isolation clothing
45465326|NCT04802109|Device|wearing Level C personal protective equipment with N-95|"C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing"
45465327|NCT04802109|Device|wearing Level C personal protective equipment with Powered Air-Purifying Respiratory|"C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing+Powered Air-Purifying Respiratory"
45465328|NCT05281159|Behavioral|Risk Information|This group will receive an SMS text message highlighting their risk for CRC on top of the content in the Control arm.
45465329|NCT05281159|Behavioral|Risk Information + Action|This group will receive an SMS text message highlighting their risk for CRC and the importance of taking quick action, on top of the content in the Control arm.
45837752|NCT05765422|Other|salivar and gum sampling|Saliva will then be collected by salivary spit and a mucosal smear will be taken using a swab passed at the junction of the tooth and the gum
45465330|NCT03525808|Device|AXIOS|Patient will receive either transgastric or transduodenal endoscopic drainage for walled-off necrosis that are adherent to the gastric or bowel wall.
46015172|NCT01306214|Drug|Placebo|Placebo matching BI 10773 low dose
46015173|NCT01306214|Drug|Placebo|Placebo matching BI 10773 high dose
46015174|NCT01306214|Drug|Placebo|Placebo matching BI 10773 high dose
46015175|NCT01306214|Drug|BI 10773|BI 10773 low dose once daily
45837753|NCT05765409|Other|TIMCA|"TIMCA is an individual therapy that will include the parents at certain points in the therapy .~It will consist of two sessions of MI, two sessions of CBT, five sessions of ABI and one final session of summary to conclude the therapy.~Out of 10 sessions, there will be three with the parents and the adolescent together."
45465331|NCT01228799|Procedure|trabeculectomy|trabeculectomy with mitomycin C 0.2mg/ml
45465332|NCT01228799|Procedure|Canaloplasty|Canaloplasty with implant of suture
45465333|NCT03813823|Behavioral|Fear tasks|All participants will be exposed to 5 fear tasks involving spiders, with increasing fear intensity.
45837754|NCT05765409|Other|Treatment as Usual|"TAU will consist of several approaches including analytical, cognitive-behavioral , intepersonal psychotherapy.~Each therapist will be asked to specify the approach used as well as the therapeutic axes."
45837755|NCT05765357|Drug|Trastuzumab for injection|Trastuzumab for injection manufactured by Chia Tai Tianqing. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.
46015176|NCT01306214|Drug|BI 10773|BI 10773 high dose once daily
45599203|NCT02344563|Drug|Mepem|
46015177|NCT00623402|Drug|Sorafenib|2x 400 mg orally per day (4 tablets)
46015178|NCT00623402|Drug|pegylated interferon α-2b|3 µg/kg body weight s.c. once a week
46015179|NCT01077739|Drug|fluorouracil (5FU)|standard FOLFOX regimen
45465334|NCT03709875|Device|TR Treatment|A virtual reality based system, consisting of two PC-based workstations, located at the patient's home and at the rehabilitation center, will be used. For the motor treatments the patient has to move the real end effector, following the trajectory of the corresponding virtual task displayed on his computer screen. The speech (mainly lexical based) and cognitive (attention focused) exercises will be delivered from the two Research Institutes to the patient's home. During the treatment at home, the patients will use wearable monitoring devices to monitor their status (speed, heart rate, respiratory rate, training load and single-lead ECG in real-time) and to provide real-time feedback during exercises.
45465335|NCT01128803|Procedure|injection of the cell therapy product|Between D-15 and D-30: Cytapheresis D0: 1st injection of the cell therapy product D21: 2nd injection of the cell therapy product D42: 3rd injection of the cell therapy product and 1 injection of dendritic cells not loaded D45: cutaneous biopsies if induration > 2mm
45837756|NCT05765357|Drug|Herceptin|Herceptin is the brand name of Trastuzumab for injection manufactured by Roche. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.
45465336|NCT03821311|Radiation|Computed tomography|End-inspiratory/end-expiratory CT is repeated 3 times corresponding to the 3 studied conditions: At baseline, through expiratory resistive loading using an adjustable PEP mask, and after 5 min of nasal high flow therapy at 25 L/min.
45465337|NCT03923153|Device|Inspiratory muscle training with PowerBreathe (IMT Technologies Ltd., Birmingham,England)|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 30% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
45465338|NCT03923153|Device|Sham group with PowerBreathe (IMT Technologies Ltd., Birmingham, England)|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 10% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
46015180|NCT01077739|Drug|leucovorin|standard FOLFOX regimen
45465339|NCT03813667|Behavioral|Intervention FamPALcare|"The FamPALcare intervention includes all standard care information on R-ALD home care plus 2 weeks of EOLPC coaching by community nurses experienced in EOLPC. The nurse uses the Conversation Ready pamphlet to guide discussion of EOL preferences. The nurse will: (1) support the patient and family in making decisions about EOL care options based on their preferences; (2) discuss options for EOL care when the patient's R-ALD symptoms become severe; (3) encourage completion of the advance directive forms at next physician appointment. The nurse will use teach-back processes to ensure that FamPALcare discussions are clear."
45465340|NCT05390242|Diagnostic Test|Radiographic study|Candidates undergo a radiographic study (Orthopantomography and Implant periapical radiography)
46015181|NCT01077739|Drug|bevacizumab [Avastin]|7.5 mg/kg iv infusion every 3 weeks OR 5 mg/kg iv infusion every 2 weeks
46015182|NCT01077739|Drug|capecitabine [Xeloda]|standard XELOX regimen
46015183|NCT01077739|Drug|oxaliplatin|standard XELOX or FOLFOX regimen
45465341|NCT03923075|Drug|Dexmedetomidine|INFUSION BEFORE INDUCTION OF ANAESTHESIA
45465342|NCT03923075|Other|0.9% saline|INFUSION BEFORE INDUCTION OF ANAESTHESIA
46015184|NCT02876497|Other|Define macrophages migration mode|Archival tumor samples analysis and blood sample testing
45465343|NCT03923231|Drug|Atazanavir 300mg/ Ritonavir 100 mg once daily|There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care
45465344|NCT03923231|Drug|Atazanavir 250 mg / ritonavir 80 mg|There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care. This dose of 250/ 80 is for participants weighing between 15 and 25 Kg
46015185|NCT01306058|Drug|TRC 105|15 mg/kg intravenous (IV) every 2 weeks
46015186|NCT01306058|Drug|Sorafenib|400 mg twice a day (bid) continuously in a 28 days cycle
46015187|NCT00626509|Drug|sunitinib malate|
45465345|NCT02861794|Procedure|Medacta International, GMK Sphere medially stabilized knee|Total Knee Replacement
45465346|NCT01227239|Drug|S-1|40mg/m2 orally twice a day (BID) for 5 days a week at 1st week, 2nd week, 4th week and 5th week.
45465347|NCT01227239|Drug|Oxaliplatin|40-60mg/m2/week intravenously on day 1, 8, 22 and 29.
45465348|NCT01227239|Radiation|Radiation|Total dose is 50.4Gy (1.8Gy X 28 fractions)
45599204|NCT03513913|Procedure|ICSI|Oocytes are fertilized by conventional in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
46015188|NCT00626509|Procedure|adjuvant therapy|
46015189|NCT00626509|Procedure|neoadjuvant therapy|
45599205|NCT03761225|Drug|Masitinib|
45599206|NCT03761225|Drug|Docetaxel|
46015190|NCT00626509|Procedure|therapeutic conventional surgery|
46015191|NCT02876653|Other|Polysomnography , blood collection, bone densitometry and Functional respiratory explorations|"Blood collection, Bone densitometry and Functional respiratory explorations are a specific interventions of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  healthy volunteers "
46015192|NCT02876965|Procedure|Muscle Stretching|Subjects completed one stretching session on the main muscle groups of the body weekly.
46015193|NCT02876965|Procedure|Physical Exercise|Subjects completed 3 moderate intensity aerobic physical exercise sessions weekly.
46015194|NCT02877901|Drug|long acting tolterodine 4 mg|receive one tablet at bed time for 4 weeks
46015195|NCT02877901|Drug|placebo|one tablet at bed time
46015196|NCT04306159|Procedure|Subcostal TAP|Subcostal transversus abdominis plane block
46015197|NCT04306159|Procedure|Modified RSB|Rectus Sheath Block under the guidance of surgical incision
46015198|NCT04306159|Other|General anesthesia|Traditional general anesthesia management
46015199|NCT01305200|Drug|supersaturated calcium phosphate rinse|Mouth rinse
46015200|NCT01305200|Other|placebo|Mouth rinse
46015201|NCT01305200|Other|questionnaire administration|Ancillary studies
46015202|NCT01305200|Procedure|quality-of-life assessment|Ancillary studies
46015203|NCT01305044|Behavioral|Tai Chi Chih|Tai Chi Chih (TCC), a westernized and manualized form of the ancient TC Chuan, consists of a series of 20 simple, repetitive, non-strenuous movements that involve no physical contact and emphasize a soft, flowing continuity of motion. This form of meditation through movement consists of a standardized protocol that emphasizes slow, fluid, continuous forms that integrate mental concentration, awareness, balance, shifting of body weight, gentle movement, imagery, muscle relaxation and breathing control. TCC was developed for use with elderly persons.
45465349|NCT01300585|Other|MRI|Patients who qualify for the study and consent to be included will undergo placement of areola and nipple markers that will be held in place with tape for the duration of the ordered MRI study. The markers consist of latex-free plastic tubing filled with vegetable based hydrogenated oil that is solid at room temperature. This creates a fat density marker that will define the areola but does not interfere with or create artifact onto the underlying tissue. The marker can be placed by the investigator or available MRI technician instructed in marker placement. The patient will then undergo the MRI. The patients participation in the study will end with the MRI.
45465350|NCT05390164|Diagnostic Test|skin biopsy|skin biopsy to be analyzed by ELISA
45465351|NCT01301677|Drug|Hydrocortisone|Hydrocortisone liquid formulation
45465352|NCT01301677|Drug|2PX+|strontium chloride hexahydrate in a penetration enhancing vehicle
45465353|NCT01301677|Drug|2PX-|strontium chloride hexahydrate without a penetration enhancing vehicle
45599207|NCT03761225|Drug|Prednisone|
45599208|NCT03761225|Drug|Placebo|
45837757|NCT05765331|Device|Chatbot|The AI chatbot is a kind of artificial intelligence technology that can help increase knowledge and understanding of men's health issues. That interacts with subjects through literal text and provides educational resources, advice, and assistance related to lifestyle changes. The chatbot is a valuable aid to increase men's health by providing information about enlarged prostate with urination problems and erectile dysfunction.
45465354|NCT01227317|Other|Prognostic value of Biomarkers|Mr pro ADM, Mr pro ANP, PCT, Copeptin and pro endothelin value to stratify the risk in SOB patients
45465355|NCT02648152|Device|Osteoarthritis|Total Hip Arthroplasty
45465356|NCT01301755|Procedure|Lung aspiration|direct lung tissue Aspergillus galactomannan antigen detection from aspirate by ultrasound-guided fine needle aspiration
45465357|NCT01128881|Biological|Factor IX Concentrate (purified, virus-inactivated)|Intravenous injection/infusion; dose for prophylaxis: 20-40 IU/kg bodyweight, twice weekly (which may be adjusted to the subject´s bleeding pattern and lifestyle); dose for bleeding episodes and surgery: according to the Summary of Product Characteristics and the Product Information Leaflet of the respective country.
46015204|NCT01305044|Behavioral|Health Education Classes|The Health Education classes serve as an attention control group, are led by gerontology specialists, physicians, and other health professionals, and focus on topics that are relevant to elderly cancer survivors.
45465358|NCT02618980|Other|endoscopic hemostasis|At endoscopy, stigmata of hemorrhage (SRH) will be treated by dual endoscopic local therapy (combining at least two of the following treatments: epinephrine injection, coaptive thermocoagulation, hemoclip therapy, argon plasma coagulation, bipolar coagulation).
45465359|NCT03927287|Diagnostic Test|Free PSA ratio test in patients after definitive treatment for localized prostate cancer|Free PSA ratio blood test done on biobank samples of patients after radical prostatectomy who developed biochemical recurrence.
45465360|NCT02613598|Drug|Bortezomib|
45465361|NCT02613598|Drug|Ruxolitinib|
45465362|NCT03718429|Drug|Rivaroxaban 2.5 mg Tablet|PD assessments will be conducted at 3 time points: i) baseline (while on standard of care antiplatelet therapy), ii) 7-10 days after adjunctive treatment with low dose rivaroxaban, and iii) 7-10 days after dropping aspirin.
45465363|NCT01225523|Drug|Paclitaxel; Cisplatin; 5-Fluorouracil|Two preoperative cycles with Paclitaxel 200 mg/m² d1, Cisplatin 60 mg/m² d1, 5-Fluorouracil 700 mg/m² d1-5 repeated every 3 weeks followed by resection
45465364|NCT01225523|Drug|Paclitaxel; Cisplatin; 5-Fluorouracil; Capecitabine|Two postoperative cycles with Paclitaxel 200 mg/m²/day d1, Cisplatin 60 mg/m²/day d1, 5-Fluorouracil 700 mg/m²/day d1-5 repeated every 3 weeks Among patients with no responses to preoperative chemotherapy, Capecitabine 625 mg/m² twice-daily dose as alternatives to infused 5-Fluorouracil in the postoperative chemotherapy regimen
45465365|NCT05390008|Other|Pelvic Floor Muscle Training|"In order to increase participants' PFM strength and endurance , PFMT was taught two days a week for 12 weeks. This training included two type of exercises that consisted of fast and slow PFM contractions.~Fast Contractions: This exercise was done in sitting position, While participants' arms were on thighs with their feet resting on the floor and sitting unsupported on the back of their seat. They were taught how to quickly contract and relax their PFM.~Slow Contractions: The practice position of this exercise was in sitting position as it happened in fast contraction. This training lasted for 12 weeks and it was divided into periods as 1-3 week, 4-6 week, 7-9 week, 10-12 week. In the forth coming weeks of this period, the number of exercise repetitions and the number of sets were increased."
45465366|NCT05390008|Other|Modified Pilates Exercise|"Before starting the 12-week practice protocol, the concept of stabilization was explained to the participants. Participants were taught how to control the core region by using the stabilizer device and the basic principles of pilates. The exercise program was planned that would last 50 minutes. This program was carried out as three-stage and these stages were warm-up phase, main exercise program and cool down phase. The allocated times for the warm-up phase was 10 minutes. The allocated time for the main exercise program was 30 minutes and active resting was done by performing breathing exercises in the 15th minute of the main exercise program. The allocated time for the cool down phase was 10 minutes. Each exercise was done as 10 repetitions then the next exercise was started.~The exercises of the second 6 weeks were performed by adding a red elastic exercise band at the beginner-intermediate level, which released 1.7 kg force with 100% stretching."
45465367|NCT01130129|Other|Ex-vivo treatments with flavonoids|Ex-vivo treatment of platelets with a range of flavonoids
45465368|NCT03813745|Other|early denudation|COCs will be denudated in 30 min after oocyte retrieval
45465369|NCT03813745|Other|late denudation|COCs will be denudated 2 hr after oocyte retrieval
45837758|NCT05765292|Dietary Supplement|Probiotic|The multiprobiotic which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the pa
46015205|NCT01304498|Biological|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine
45465370|NCT03922685|Combination Product|Dietary manipulation (25% carbohydrate diet) and behavioral (exercise)|The 25% carbohydrate diet consisted of Pulmocare-vanilla liquid, white roll, butter, and string cheese in proportions to achieve 33% of weigh-maintenance diet containing 25% carbohydrate, 20% protein, and 55% fat. Exercise was walking 1 hour on level treadmill at 50% of maximal effort starting 40 minutes after the beginning of the meal
45465371|NCT03922685|Combination Product|Dietary manipulation (25% carbohydrate diet) and behavioral (sedentary)|The 25% carbohydrate diet consisted of Pulmocare-vanilla liquid, white roll, butter, and string cheese in proportions to achieve 33% of weigh-maintenance diet containing 25% carbohydrate, 20% protein, and 55% fat. There was no exercise during this trial.
45465372|NCT04455646|Behavioral|CBT-based, mobile-delivered, intervention platform|App of this platform have been shown to be associated with reduced psychopathology symptoms,including depressive symptoms, following treatment (i.e., relapse prevention). GGDE, which was specifically designed to address MDD related maladaptive beliefs and symptoms,includes different CBT-based intervention modules (nine active and one sham), as well as means for data collection and response monitoring. The active treatment modules will differ in the proportion of adaptive vs. maladaptive statements and the emphasis on particular content (e.g loneliness vs. hopelessness).
46015206|NCT01304498|Biological|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine
45465373|NCT03815539|Device|0.1% sodium hyaluronate|In dry eye group, part of the subjects will be instilled with one drop of 0.1% sodium hyaluronate in one of their eyes, then they will be tested with the devices of Oculus Keratograph 5M and Optical Quality Analysis SystemⅡ at different time points (10min, 30min, 60min, 90min and 120min).
46015207|NCT01077193|Procedure|Gastric Plication|"A laparoscope will be inserted to visualize the surgical area and confirm absence of injury to any surrounding organ or structure. A flexible endoscope will be passed transorally into the gastric lumen to provide insufflation.~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure."
46015208|NCT05644028|Behavioral|Emotion Regulation Intervention for ADHD|The intervention will be based on principles from dialectic behavioral therapy. The overall aim of the intervention is to improve emotion regulation skills. The intervention will consist of eight face-to-face group sessions and a digital companion app that the participants can use to practice skills between the sessions. The groups will include mindfulness-based exercises, homework review, introduction to new skills, and peer discussions.
45465374|NCT01225601|Behavioral|Tabacco discontinuation|Tabacco discontinuation
45465375|NCT03922919|Drug|Cefotaxime Injection|Systematic use of cefotaxime.
45465376|NCT03922919|Procedure|Rectal swab|Rectal swab every 3 days during hospitalization and then 30 days after the first antibiotic infusion
45465377|NCT03922919|Drug|Cefotaxime/ceftriaxone|ceftriaxone or cefotaxime infusion at the discretion of the prescribing physician
45465378|NCT04455880|Other|SWE is a novel noninvasive dynamic ultrasound technique which refers to measurement for quantitative analysis of tissue elasticity|SWE is a novel noninvasive dynamic ultrasound technique which refers to measurement for quantitative analysis of tissue elasticity. The stiffer the tissue, the higher shear wave velocity is measured. Elastographic examinations were performed by physicians using Samsung HS70A ultrasound system with a Samsung CA1-7A convex transducer and S-Shear wave technique. During the examination, patients were lying in supine position, breathing levels kept steady to prevent noise and artifacts and minimum pressure were applied on the transducer to eliminate misleading tissue compression. A region of interest (ROI) box of 10 × 10 mm was positioned on placenta and six measurements were obtained from central and peripheral zones of placenta while avoiding vascular structures
45837759|NCT05765292|Dietary Supplement|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
45837760|NCT05765279|Drug|HH-120 nasal spray 1|HH-120 nasal spray 5 times daily for 3 consecutive days
45837761|NCT05765279|Drug|HH-120 nasal spray 2|HH-120 nasal spray 8 times daily for 3 consecutive days
45837762|NCT05765279|Drug|Placebo Comparator 1|Placebo nasal spray 5 times daily for 3 consecutive days
45837763|NCT05765279|Drug|Placebo Comparator 2|Placebo nasal spray 8 times daily for 3 consecutive days
46015209|NCT04299139|Other|chiropractic treatment|There is no intervention. Data that has been collected during the time a patient was attending a chiropractor. This data will be evaluated
46015210|NCT02876029|Other|Reference|the reference product used
46015211|NCT02876029|Other|Test product|The test Product used
46015212|NCT05661110|Other|Observational|All patients will be treated with standard of conversion treatment with HIPEC combined PD1/PDL1 inhibitor. After obtaining written informed consent, participants will have serial blood, tumor tissue collection. The blood collection (10 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. Participants will remain on the study for as long as they are being followed or treated at Affiliated Cancer Hospital & Institute of Guangzhou Medical University. Participants can withdraw from the study at any time.
46015213|NCT01074931|Drug|Lopinavir/ritonavir (Kaletra)|"Lopinavir/ritonavir(LPV/r) is an HIV protease inhibitor (PI) that is co-formulated with lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. As co-formulated in LPV/r, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.~The assignment of the patient to a lopinavir/ritonavir - containing regimen is not decided in advance by this protocol but falls within current practice and the prescription of lopinavir/ritonavir is clearly separated from the decision to include the patient in this study."
45465379|NCT03819205|Other|kinesiotaping|The participants will receive kinesiotaping treatment on the affected side for the hemiplegic CP's and for diplegic, tetraplegic CP's the side of upper extremity which children have been used to but have obstacles in daily life for 1 week at least 2-3 hours a day, renewing if it's necessary. The participants will be also recomended dealing with the grasping and releasing activities in daily living at about 2-3 hours a day. In a way that every patient has to be the control of themselves, 1 week before kinesiotaping, immediately after kinesiotaping and 1 week after the period of kinesiotaping, patients will be evaluated with box and block test, nine hole peg test, modified house clasification and the active/passive wrist dorsiflexion range of motion
45465380|NCT03922607|Drug|ABBV-157|ABBV-157 will be administered orally as capsule
45465381|NCT03922607|Drug|Placebo for ABBV-157|Placebo for ABBV-157 will be administered orally as capsule
45465382|NCT03813277|Drug|Dexmedetomidine|infusion
45465383|NCT03922763|Procedure|Anatomical cut|Surgeon-derived cut based on patient's anatomy
45465384|NCT03922763|Procedure|Cutting guide|Angle cut at 132.5 degrees based on cutting guide
45465385|NCT02522962|Behavioral|GroupCoreSIT|"Each group session lasts for 60 minutes. The physiotherapist will chose from an exercises bank of 32 exercises, each having up 5 levels of difficulty that are described and illustrated by photos. All exercises demand core activation, emphasise normal movement and emphasise somatosensory integration, feed forward and feed back strategies essential for balance.10-12 repetitions for each exercise with good quality of movement will be performed. Every session will start with exploring standing balance and end with active stretching/active relaxation, re-exploring balance and instructions for home exercises. The participants will perform 30-minute of exercises, optional to divide into smaller intervals, at home two days per week when there are no organized group training."
46015214|NCT04306003|Other|ERAS pathway|See ERAS pathway arm description.
46015215|NCT04306003|Other|Standard Perioperative Care|See control arm description.
46100180|NCT02611401|Behavioral|Mindfulness|"The MBI is based on MBSR protocol but in order to maximize the clinical utility in people with MS suffering from depressive symptoms, we will tailor mindfulness intervention on the needs of this specific population. We will apply a modified MBSR protocol integrated with techniques from Sensorimotor Psychotherapy.~The MBI comprises an 8-week group program. Participants will took part in a 3 hour single weekly sessions, and there will be also an additional all-day session of 7 hours. Each session will cover specific exercises and topics within the context of mindfulness practice and training. Participants will be required to carry out daily 45-min homework assignments, which consist on mindfulness exercises and mindfulness applications in everyday life."
46015216|NCT00626587|Device|Olympus NA-2C-1 Transbronchial needle aspiration (TBNA)|The TBNA apparatus (Olympus NA-2C-1) is inserted through the working channel, and is advanced until it reaches the target lesion which is localized by EBUS. Negative manual suction is applied with the 20 ml syringe. The specimens are then smeared on glass slides and immersed in 95% alcohol. At least 3 aspirates per lesion are obtained.
46015217|NCT04774159|Drug|Colchicine 0.5 MG Oral Tablet|"Colchicine 0.5 mg tablet daily~Active drug and placebo are of the same appearance and are indistinguishable. All investigators, study personnel and patients will be blinded to drug treatment assignment. Trial treatment supplies must be stored in a secure, limited-access location under the storage conditions specified on the IP supply label."
46100181|NCT02611401|Behavioral|Psychoeducation|"The control group is designed to control for the nonspecific elements of the MBI treatment. It will be based on a psycho-educational framework and will include some relaxation techniques. In each session is discussed a MS-related topic. Relaxation and gentle stretching exercises will be proposed at the end of each session. Homework and the material (photocopies, slides, etc.) discussed in group sessions is left to each participant to encourage participants to practice exercises between sessions.~This intervention will follow the same structure and weekly format of the MBI intervention. The only difference will be the absence of an all-day session."
46100182|NCT00825825|Drug|Escitalopram|One week of escitalopram taken orally at 10 mg followed by one week at 20 mg daily.
46015218|NCT04774159|Drug|Colchicine-Placebo|Colchicine-Placebo tablet
46100183|NCT00825825|Drug|Citalopram|One week of citalopram taken orally at 20 mg followed by one week at 40 mg daily.
46100184|NCT00825825|Drug|Placebo|Two weeks of placebo taken orally.
46015219|NCT02877745|Other|Stratification, no intervention|
46015220|NCT04871737|Biological|Recombinant NDV Vectored Vaccine for SARS-CoV-2|Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
46100185|NCT03802487|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet~Route of administration: Oral"
46100186|NCT03802487|Drug|14C-microtracer|"Pharmaceutical form: Solution for injection~Route of administration: Intravenous"
46100187|NCT03802487|Drug|Charcoal|"Pharmaceutical form: Granules for suspension~Route of administration: Oral"
46100188|NCT03483233|Other|fMRI and EEG study|fMRI and EEG study
46100189|NCT03783767|Behavioral|Leadership Intervention|Grade 6/7 teachers will take part in a workshop on developing transformational leadership among their Grade 6/7 students, and provide teachers with a 4-week training program. Teachers will implement a 4-week leadership development component to their Grade 6/7 students. Grade 6/7 students will then deliver a 10-week peer-led FMS program to Grade 3/4 students. The Grade 6/7 peer leaders will lead 2 x 30 min sessions per week during physical education classes, recess, or lunch times. In weeks two and three, peer leaders will be observed by members of the research team and provided with feedback using a structured checklist regarding their delivery in the session. Mid-way through the 10-week program teachers will deliver a booster leadership training component to the Grade 6/7 peer-leaders.
46100190|NCT00710710|Drug|BI 2536|Intravenous Infusion
46015221|NCT01303172|Biological|IMM-101|"IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.~A single 0.1 mL intradermal injection of IMM-101 (10 mg/mL) will be administered every 2 weeks for the first 3 doses followed by a rest of 4 weeks then every 2 weeks for the next 3 doses followed by every 4 weeks thereafter.~Chemotherapy plus IMM-101 will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles of gemcitabine."
46015222|NCT01303172|Drug|Gemcitabine|"Gemcitabine will be administered intravenously at 1000 mg/m2 over 30 minutes once weekly for 3 consecutive weeks out of every 4 weeks.~Chemotherapy will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles (i.e. approximately 48 weeks).~Dosage reduction with each cycle or within each cycle may be applied based upon the grade of Gemcitabine-related toxicity experienced by the patient using centre's standard protocol."
46015223|NCT01302938|Drug|Tolterodine ER|One 4 mg capsule will be taken with water every day with or without food. It should be swallowed whole without chewing.
46100191|NCT02692547|Device|Hybrid-logic closed loop system|All patients get to wear the pump
46100192|NCT00880334|Drug|Docetaxel|Given intravenously on Day 1 of each 21-day cycle
46100193|NCT00880334|Drug|vandetanib|taken orally once a day, every day
46100194|NCT00880334|Drug|Placebo|Taken orally once a day every day
46100195|NCT01033565|Drug|Natrol|5mg of sustained released melatonin. One tablet given 30 minutes prior to bedtime.
46100196|NCT05741554|Other|Rate of myometrial involvement in the population of 28 low grade serous ovarian carcinoma.|Presence of uterine myometrial metastasis at pathology examination after cytoreductive surgery
46100197|NCT04063930|Drug|LOKELMA 5 GM Powder for Oral Suspension|Sodium zirconium cyclosilicate (a hyperkalemia treatment)
46100198|NCT04063930|Drug|Placebos|Matching placebo
46100199|NCT04161872|Drug|Uricemin|Uricemin is a nutraceutical containing quercetin, rutin, bromelain and L-carnosine
46100200|NCT04161872|Drug|Placebo|Placebo
46015224|NCT01302938|Drug|Placebo|A placebo of Tolterodine ER 4 mg will be taken with water every day with or without food. It should be swallowed whole without chewing.
46015225|NCT05643872|Drug|PTX-022|QTORIN rapamycin 3.9% anhydrous gel
46015226|NCT01302548|Device|IRRISEPT|Device containing sterile water and chlorhexidine gluconate (CHG)
46100201|NCT03364439|Drug|Treatment plan|R-CHOP14 or R-CHOP21 for 6 cycles Restaging after 2, 4, 6 cycles Consolidation therapy with RT (36 Gy) if PET positive (PET after 6 R-CHOP cycles)
46100202|NCT04063774|Diagnostic Test|Dengue calculator|Clinical diagnostic algorithms of dengue generated by discrete and continuos Bayes formulas installed in a mobile device
46100203|NCT02634242|Other|Si-Wu-Tang (SWT)|The purpose of the current study was to check the physiological improvement of SWT on liver and skin and also the antioxidation in healthy adults.
46100204|NCT02634242|Other|placebo|The purpose of the current study was to check the physiological improvement of placebo on liver and skin and also the antioxidation in healthy adults.
46100205|NCT00658892|Biological|B7-DC cross-linking antibody rHIgM12B7|
46100206|NCT00658892|Other|flow cytometry|
45680152|NCT03914547|Behavioral|REDCHiP|REDCHiP includes 10 telehealth sessions. REDCHiP uses a three-pronged approach to reduce parents' FH. It uses T1D education and problem-solving to enhance parents' knowledge and skills. It uses child age-appropriate behavioral parent training to promote parents' skills and confidence in managing disruptive child behaviors and reducing their reliance on hypoglycemia avoidance behaviors. It uses cognitive-behavioral therapy strategies to help parents reduce maladaptive thinking/coping related to hypoglycemia fear.
45680153|NCT03914547|Behavioral|ATTN|Provides a similar attention control. ATTN includes 10 telehealth sessions.
45680154|NCT03896230|Drug|Ketamine Injectable Product|Three different doses of ketamine will be administered.
45680155|NCT03878316|Drug|Instranasal Oxytocin|Intranasal Oxytocin - concentrated formulation - 35 IU per dose
46015227|NCT01302548|Procedure|Usual Care|The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
46100207|NCT00658892|Other|immunologic technique|
46100208|NCT00658892|Other|laboratory biomarker analysis|
46100209|NCT00654914|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg per dose of vardenafil for the first four weeks. A further 8 weeks ( in two treatment periods of four weeks, respectively) where patients will either maintain the previous dosage regimen or will step up to 20 mg per dose of vardenafil or will step down to 5 mg per dose of vardenafil, at interval visits of four weeks .
46100210|NCT02638454|Procedure|Acute Resistance Exercise|1 bout of high-intensity resistance exercise at 80% of the individuals 1 repetition maximum
46100211|NCT00865566|Biological|DNA plasmid vaccine|4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
46100212|NCT00865566|Biological|Recombinant adenoviral serotype 5 (rAD5) vector vaccine|1 x 10^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid
45680156|NCT03876054|Device|Spinal cord stimulation (SCS)|Subjects will be implanted with market-released Abbott SCS systems
45680157|NCT03876054|Device|Dorsal root ganglion stimulation (DRG)|Subjects will be implanted with market-released Abbott DRG system
45680158|NCT03870334|Drug|BT-11 880 mg|Oral once daily tablet
45680159|NCT03870334|Drug|Placebo|Oral once daily tablet
45680160|NCT03861234|Drug|BI 836880|Solution for Intravitreal (IVT) injection
46015228|NCT01302392|Drug|Carfilzomib|20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days [Days 1, 2, 8, 9, 15, 16] for individual subjects).
46015229|NCT01302392|Drug|Best Supportive Care|"Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).~Optional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle)."
46015230|NCT01076647|Drug|insulin degludec|Will be injected subcutaneously (under the skin) once daily three times weekly.
46015231|NCT01076647|Drug|insulin glargine|Will be injected subcutaneously (under the skin) once daily administered at the same time each day.
46100213|NCT00865566|Biological|DNA vaccine placebo|1 mL IM via Biojector® in either deltoid
46100214|NCT00865566|Biological|HIV-1 recombinant adenovirus vaccine placebo|1 mL administered IM by needle and syringe in either deltoid
46100215|NCT02632370|Drug|Gliolan®|single dose of oral 5-ALA (20mg/kg bodyweight) at 3 hours (range 2-5 hours) given preoperatively
46100216|NCT02632370|Procedure|Fluorescence-Guided Surgery|performed utilizing blue light. At least 3-5 fluorescent tissue samples will be taken.
46100217|NCT03866473|Device|Retilux|670nm wavelength light
46100218|NCT03866473|Device|Sham Light Device|Broad spectrum light device
46015232|NCT04306081|Drug|Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are provided by Amgen
46015233|NCT04306081|Other|Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of Placebo in the abdomen, thigh or upper arm. The Placebo prefilled injector pens are provided by Amgen
46015234|NCT01074307|Drug|Low Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 1.25 milligram (mg) once daily for 2 weeks. The dose will be further escalated from 1.25 mg to 2.5 mg once daily after 2 weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
46015235|NCT01074307|Drug|High Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 3.75 mg once daily for 2 weeks. The dose will be subsequently increased to 5 mg, 7.5 mg, or 10 mg once daily every two weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
46015236|NCT01076335|Drug|Neoadjuvant Hormonal Therapy|Monthly or quarterly LHRH Agonist Depot injection (leuprolide or goserelin acetate) for one year.
46015237|NCT01076335|Drug|Docetaxel|35 mg/m2 by vein (IV) on Day 1, 8, 15 and 22 every 6 weeks.
46015238|NCT01309737|Drug|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
46015239|NCT01309737|Drug|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
46015240|NCT01309737|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
46015241|NCT01309737|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
46015242|NCT01074229|Drug|Placebo|placebo injection
46015243|NCT01074229|Drug|Drug .5% Ropivacaine|.5% ropivacaine 20 mls on each side of abdomen
46015244|NCT01074229|Drug|20 cc of 0.25% ropivacaine|Will receive a bilateral TAP block using 20 cc of 0.25% ropivacaine
46015245|NCT01106014|Drug|Selexipag|Selexipag 200 µg tablets
46015246|NCT01106014|Drug|Placebo|Placebo tablets matching selexipag
46015247|NCT01073605|Drug|Genotonorm|0.7 IU/kg/week or 0.03 mg/kg/day, daily subcutaneous injection
46015248|NCT01073605|Drug|Genotonorm|1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection
46015249|NCT01073605|Drug|Genotonorm|1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection Intermittent treatment (6 months with treatment and 6 months without)
46015250|NCT01073293|Biological|V503 Vaccine|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
46015251|NCT01073293|Biological|REPEVAX™ (Concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Day 1
46015252|NCT01073293|Biological|REPEVAX™ (Non-concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Month 1
46015253|NCT01105936|Drug|Paracetamol|665 mg sustained release paracetamol caplets
46015254|NCT01105936|Drug|Placebo|Placebo caplets
46015255|NCT01309659|Drug|iron sucrose|Patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
46015256|NCT01309659|Drug|iron sucrose|Following 12 weeks of observation patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
46015257|NCT04989166|Dietary Supplement|Nano-curcumin|Nano-curcumin soft gels
46015258|NCT04989166|Drug|Placebo|Placebo
46100219|NCT00658970|Drug|KX2-391|2 mg (starting dose)rising dose, oral dosing, twice daily, 21 day cycle(s); until progression or unacceptable toxicity develops
46100220|NCT00659048|Drug|Ciclesonide|Ciclesonide 200µg versus Placebo
46100221|NCT00659048|Drug|Placebo|placebo
46015259|NCT04870411|Biological|Blood sample|Humoral and cellular immune response. Sample before vaccination, 1 month, 3 months, 6 months and 12 months post-vaccination
46100222|NCT02623920|Drug|Brentuximab|Brentuximab vedotin IV over 30 minutes on day 1.Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
46100223|NCT02623920|Drug|Bendamustine|Bendamustine IV over 30-60 minutes on days 1-2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
46100224|NCT02623920|Drug|Rituximab|Rituximab IV on day 2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
46100225|NCT00525499|Drug|ASC-J9 cream|Topical application to the face twice daily for 12 weeks.
46015260|NCT05320705|Drug|Intra Operative Dexmedetomidine|Dexmedetomidine will be administered as a bolus dose, before the surgical incision with 1mcg/kg iv in 100 ml saline solution over 10 minutes followed by infusion rate of 0.5 μg/kg per h infusion via syringe pump during surgery and stopped at the end of operation. Similar bolus and infusion volumes of normal saline will be administered in the Control group (placebo) However, anaesthesiologists will be permitted to reduce dose of the study drug as necessary to preserve haemodynamic stability.
46015261|NCT04305535|Dietary Supplement|Peptidic+Probiotic|"Oligomeric oral nutritional supplement (Bi1 peptidic) and a mix of probiotics~Bifidobacterium animalis subsp. lactis BPL1,~Lactobacillus rhamnosus BPL15,~Lactobacillus rhamnosus CNCM i-4036~Bifidobacterium longum ES1"
46015262|NCT04305535|Dietary Supplement|Peptidic+Placebo|Oligomeric oral nutritional supplement (Bi1 peptidic) and a placebo
46015263|NCT04305535|Dietary Supplement|Polymeric+Placebo|Polymeric oral nutritional supplement and a placebo
45465386|NCT02522962|Behavioral|Standard care|The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities. The content of standard care may vary, and will be recorded for all the participants.
45465387|NCT03815461|Drug|Nab-paclitaxel and S-1|Nab-paclitaxel was administered at 125mg/m2 intravenously on day 1 and 8, S-1 （80, 100, or 120 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle for 4-6 cycles.
45465388|NCT01285102|Combination Product|irinotecan-eluting beads|Patients will be treated with drug-eluting irinotecan beads per protocol at up to 100 mg per dose every 3 weeks. Patients will receive chemoembolization using LC Bead, loaded with irinotecan. The beads size range used in the study will be 100-300µm (nominal) with a dose of up to 100mg irinotecan per treatment. The beads will be mixed with a non-ionic contrast media in the vial immediately prior to use according to the instructions for use. Irinotecan will be loaded onto the beads not more than 2 hours prior to the procedure. The study goal will be to deliver the full dose of 100mg of irinotecan per treatment
45599209|NCT02349945|Drug|follitropin alpha|"All subjects included in the study will receive recombinant FSH therapy (follitropin alpha: Gonal-f 150 I.U. s.c. every other day for 12 weeks). Follow up: 12 further weeks after end of treatment.~Previous studies included in the Cochrane meta-analysis used: hMG/hCG, 150 IU three times a week for 13 weeks; purified FSH, 150 IU/day for 12 weeks; rec hFSH, 150 IU/day for 12 weeks; rec hFSH, 100 IU on alternate days for 3 months. Therefore any dosage > 100 IU on alternate days is eligible. The duration of treatment is based on the duration of one spermatogenetic cycle."
45599210|NCT03513835|Diagnostic Test|Diagnostic screenings tests|Handgrip test, 12-minute walk test and 6-minute walk test. Biomarkers: acyl-carnitine profile and GDF-15.
45680161|NCT03861117|Procedure|Assisted strategy|Daily spontaneous breathing trial (SBT) with 7 cmH2O pressure support and 5 cmH2O positive end-expiratory pressure are performed to assess weanability. In case of success, a SBT with T-piece is performed to determine if the patients is at high risk of extubation failure. In this case and/or in the presence of risk factors, systematic non-invasive ventilation is applied after extubation.
45680162|NCT03861117|Procedure|Non assisted strategy|Daily spontaneous breathing trials (SBT) with T-piece are performed to assess weanability. In the presence of risk factors, systematic non-invasive ventilation is applied after extubation.
46015264|NCT04305223|Procedure|Dry Needling|Dry Needling is a treatment technique whereby a sterile, single-use, fine filament needle is inserted into the muscle to assist with decreasing pain and improving function through the release of myofascial trigger points (knots in the muscle).
46015265|NCT04305223|Other|Upper extremity stretching program|A standard home exercise program consisting of strengthening and stretching exercises for the upper quarter
46015266|NCT01104766|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
46015267|NCT01104766|Drug|Aripiprazole|Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
46100226|NCT00525499|Drug|placebo|vehicle control applied topically twice daily for 12 weeks
46100227|NCT00698256|Dietary Supplement|vegetable oil-based spread and oat-based drink (no brand name available)|spread and drink (9 g stanols/d)
46015268|NCT01104766|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
46100228|NCT00698256|Dietary Supplement|vegetable oil-based spread and oat-based drink (no brand name available)|Spread and drink (not containing added stanols)
46100229|NCT00824655|Biological|13vPnC|13vPnC will be administered by intramuscular injection at approximately 5 and 12 months of age.
46100230|NCT00824655|Biological|13vPnC|13vPnC will be administered by intramuscular injection at approximately 12 months of age.
46100231|NCT02614638|Other|One month of department-wide observation|A pharmacy technician will be present full time in the care unit from Monday to Friday between 8:30 and 17h for 1 month for observational purposes only. During this phase, the pharmacy technician observes the current practices of preparation and administration of medication by nurses. He / she will collect medication errors and other observational data.
46100232|NCT02614638|Other|Pharm Tech participates in department|Following a 1 month wash-out period, a pharmacy technician will again be present full time (in practice, two technicians will relay each other) in the care unit from Monday to Friday between 8:30 and 17h for 1 month. He/she will actively take part in drug care activities in the department: management of product pathways, verification of injectable preparation, advice, etc. Medication errors and other observational data will be collected.
45680163|NCT03860571|Drug|Placebo|Oral tablet
45680164|NCT03860571|Drug|BT-11|Oral tablet
45680165|NCT03854929|Drug|Ciprofloxacin|"Fluoroquinolone, ATC code: J01MA02~DNA-gyrase and topoisomerase IV inhibitor"
45680166|NCT03854929|Drug|Azithromycin|"Macrolide, ATC code: J01FA10~Binds to ribosomal 50S sub-unit inhibiting translocation of peptides thereby suppressing bacterial protein synthesis."
45680167|NCT03852628|Drug|2mg Buprenex and 380mg Vivitrol|Daily 2mg SL BUP (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8 ) IM NLTRX
45680168|NCT03852628|Drug|Placebo (SL pill qd, IM injection q4weeks)|Daily SL placebo (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8) IM Placebo
46015269|NCT04305379|Procedure|Augmented Bladder Neck Reconstruction|Augmented Bladder Neck Reconstruction including a Medial Umbilical Ligament Sling plus Intussusception
46015270|NCT04305379|Procedure|Standard Bladder Neck Reconstruction|Standard Bladder Neck Reconstruction with Intussusception Only
46015271|NCT02880280|Drug|Human Menopausal Gonadotropin|Human Menopausal Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
46015272|NCT02880280|Drug|Human Chorionic Gonadotropin|Human Chorionic Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
46015273|NCT04304287|Procedure|Preoperative autologous blood donation, 14 days before surgery|
46015274|NCT04304287|Procedure|Preoperative autologous blood donation, 72 hours before surgery|
46015275|NCT04304287|Procedure|Without preoperative blood donation|
46015276|NCT02879968|Other|Non-interventional study|
46100233|NCT04576546|Dietary Supplement|D-chiro-inositol|Supplementation of D-chiro-inositol (1000 mg/die), starting at least 4 weeks before rFSH administration
46100234|NCT04576546|Dietary Supplement|Myo-inositol|Supplementation of myo-inositol (4 g/die), starting at least 4 weeks before rFSH administration
46100235|NCT04133844|Biological|Blood sample|Blood sample collection from a peripheral catheter at ECMO initiation (H0), then 2h, 6h, 12h, 24h and daily from day 2 to day 7 or at ECMO discontinuation
46100236|NCT02617680|Drug|desflurane - oxygen in air|The manufacturer recommended age-corrected end-tidal concentrations of desflurane in air should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
46100237|NCT02617680|Drug|desflurane - oxygen in nitric oxide|The manufacturer recommended age-corrected end-tidal concentrations of desflurane with nitric oxide - oxygen should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
46100238|NCT02568280|Drug|Faster-acting insulin aspart|Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
46100239|NCT02568280|Drug|insulin aspart|Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
46100240|NCT04161794|Other|multimodal|2 g EPA/DHA as fish oil, repeated dietary counselling and twice weekly 2 x exercises
46100241|NCT02617524|Device|Valve Medical Dedicated Sheath version 00|The Valve Medical Dedicated Sheath is intended to be used as an introducer sheath during BAV procedures
46100242|NCT00525265|Drug|OPC-41061(Tolvaptan)|Subjects will be orally administered OPC-41061 7.5 mg or 15 mg once daily after breakfast for seven days.
46100243|NCT00525265|Drug|Placebo|Subjects will be orally administered placebo once daily after breakfast for seven days.
46100244|NCT00659204|Drug|nano-silver gel exposed|SilvaSorb® gel applied topically to the hands with a limited exposure time of 10 minutes
46100245|NCT00659204|Drug|alcohol-based hand gel|Purell gel applied topically to the hands with a limited exposure time of 10 minutes
45680169|NCT03847142|Other|ASTHMAXcel mobile application|ASTHMAXcel is a mobile application (patient-facing) that delivers guideline-based asthma education.
46015277|NCT04743271|Other|High-Fat Diet|The diet will consist of a breakfast, lunch, dinner, and snack
46015278|NCT04743271|Other|Low-Fat Diet|The diet will consist of a breakfast, lunch, dinner, and snack
46100246|NCT02568358|Other|Experimental Intervention: DNA-based testing of BAL fluid|DNA based testing needs 4.5 hours lab time in addition to standard testing
46015279|NCT04862455|Other|Hafnium Oxide-containing Nanoparticles NBTXR3|Given intratumorally/intranodally
46100247|NCT02623842|Device|Tonederm® (Radiofrequency non ablative)|The application of RF was performed by physical therapist trained in the technique of radio frequency through the Tonederm® brand device with capacitive transfer method using non-ablative handle with electrode in the region of the external urethral meatro and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration of 20 minutes. The temperature was measured by an infrared thermometer when it reached 41graus radiofrequency was maintained for 2 minutes.
46015280|NCT04862455|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
46100248|NCT02568202|Other|No treatment given|"This is an online web-based cross-sectional survey in which participants will complete one of two questionnaires.~There will be no treatment."
46100249|NCT04158830|Drug|Aspirin 81 mg Enteric Coated Tab - 1 tablet|take one (1) 81 mg tablet each evening
46100250|NCT04158830|Drug|Aspirin 81 mg Enteric Coated Tab - 2 tablets|take two (2) 81 mg tablets each evening
46100251|NCT03998917|Diagnostic Test|Discrimination of neuromuscular alterations protocol|Patients will perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
45599211|NCT02350101|Device|Rotational thromboelastometry|In bleeding patients point of care measurements are performed, in this case Rotational Thromboelastometry (ROTEM) to guide the use of blood products and coagulation factors.
45680170|NCT03847142|Other|Outpatient primary care|Usual care delivered through the outpatient primary care setting
46100252|NCT04158518|Radiation|Toxicities reduced treatment|"Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor."
46100253|NCT04158518|Radiation|Conventional treatment|"Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Concurrent cisplatin chemoradiotherapy delivered when responses to induction chemotherapy are less than 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor."
45680171|NCT03836261|Drug|Acalabrutinib|Acalabrutinib,
46100254|NCT02617602|Procedure|Goal directed therapy|"Based on transpulmonary thermodilution data, the following interventions will be implemented:~Global end diastolic volume (GEDV) ≤ 430 ml/m2 and extravascular water index (EVWI) ≤ 10 ml/kg: fluid load; GEDV ≥ 550 ml/m2 and EVWI ≥ 10 ml/kg: furosemide;~cardiac index (CI) ≤ 2 l/min/m2 - inotropic support:~decreased heart rate (HR): dobutamine, dopamine;~normal or increased HR: epinephrine, norepinephrine; CI ≥ 2 l/min/m2 and normovolemia: phenylephrine."
46100255|NCT02617602|Other|Control|
46100256|NCT03793465|Dietary Supplement|tart cherry concentrate|Consume 2 servings (1 ounce or 2 tablespoon/serving) per day for three days before cardiac surgery
46100257|NCT00737152|Other|RAS 130 with diet and exercise|Entire population, which will also include existing patients, will be treated with RAS 130 along with diet and exercise. By the end of 6 months: 3 months of study and 3 months of follow-up, the entire population will be divided into two groups which will be determined through endpoints. The first group will be subjects with diet and exercise and the second group will be subjects without diet and exercise. The endpoints for the division of the groups are given in the design of the study.
45599212|NCT02299219|Behavioral|Taking Charge: Managing Cancer Online|"n addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing Cancer Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol that consists of Cancer-specific education, self-management strategies, and social support that is available in English and French."
45680172|NCT03836261|Drug|Venetoclax|Venetoclax
45680173|NCT03836261|Drug|Chemoimmunotherapy|fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR)
45680174|NCT03836261|Drug|Obinutuzumab|Obinutuzumab
45680175|NCT03833531|Behavioral|ImRS|ImRs is a PTSD treatment that specifically addresses the troubling memories of the traumatic event and the personal meaning of the event and consist of 12 to 18 sessions in maximum 6 months.
46015281|NCT04862455|Biological|Pembrolizumab|Given IV
46015282|NCT04862455|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
46015283|NCT01104376|Drug|Efavirenz|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
45680176|NCT03833531|Behavioral|SFT|SFT is a treatment for personality disorders that takes at least one group-session per week, for the duration of one year.
45680177|NCT03826524|Drug|Epinephrine|Epinephrine 1mg 1:10000 (10cc) per dose
45680178|NCT03816839|Drug|Amcenestrant (SAR439859)|"Pharmaceutical form: Capsules~Route of administration: Oral"
45680179|NCT03811769|Other|Best Medical Therapy|The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies.
46100258|NCT00659282|Drug|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
46100259|NCT02617758|Drug|Fentanyl|Participants will receive single application of DURAGESIC fentanyl transdermal system 100 µg/h dose in one of the treatment periods.
46100260|NCT02617758|Drug|Fentanyl|Participants will receive single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose in one of the treatment periods.
46100261|NCT00737230|Other|educational intervention|
46100262|NCT00737230|Other|questionnaire administration|
45680180|NCT03811769|Procedure|Mechanical Thrombectomy|MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus BMT arm start of treatment is defined as the date and time of groin puncture (arterial access).
46015284|NCT01104376|Drug|voriconazole|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
46015285|NCT02875873|Drug|Plasma-Lyte|Plasma-Lyte will be used for fluid expansion and maintenance
46015286|NCT02875873|Drug|Saline 0.9%|Saline 0.9% will be used for fluid expansion and maintenance
46015287|NCT02875873|Other|Slow infusion speed|Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h. NOTE: This intervention will not be blinded.
46015288|NCT02875873|Other|Fast Infusion Speed|Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h. NOTE: This intervention will not be blinded.
46015289|NCT02880202|Other|Massage Therapy|The massage therapy is provided by certified massage therapists and delivered in the home setting. Techniques and duration of massage therapy is customized based on input from the patient and/or caregiver at the start of the session regarding nature and location of discomfort and other symptoms, and based on other factors such as contra-indications/complicating factors, medical issues, and additional diagnoses. The number of massage therapy interventions range from 2-3, 1 week apart, with each session lasting between 20-45 minutes in duration.
46015290|NCT02880124|Dietary Supplement|Solution ingestion|Subjects will be required to ingest 2 litres of the experimental solution, spread over the 2 hours of exercise. A first ingestion of 572 mL of solution will be made at rest, 30 minutes before starting exercise, and 286 mL will be ingested immediately before the start of exercise and every 30 minutes during the exercise period.
46100263|NCT00737230|Procedure|assessment of therapy complications|
45680181|NCT03798678|Drug|Carfilzomib|Given IV
46100264|NCT00737230|Procedure|gastrointestinal complications management/prevention|
46100265|NCT00737230|Procedure|management of therapy complications|
45680182|NCT03798678|Drug|Dexamethasone|Given PO
45680183|NCT03798678|Drug|Telaglenastat Hydrochloride|Given PO
46100266|NCT00737230|Procedure|quality-of-life assessment|
46100267|NCT02614716|Drug|LY3090106|Administered SC
46100268|NCT02614716|Drug|Placebo|Administered SC
46100269|NCT00737308|Other|ceramic crown|Zirconia
46100270|NCT00880256|Behavioral|mindfulness-based stress reduction|An 8-week course in mindfulness training
46100271|NCT04064788|Other|Consecutive Modified Constraint-Induced Movement Therapy|Consecutive mCIMT group received 6 hours per day mCIMT sessions for consecutive 10 days. Accompanied by a physiotherapist in 1 hour of the 6-hour restriction period, the family was guided within the remaining period and the activities were adapted to daily life.
46100272|NCT04064788|Other|Traditional physiotherapy|Traditional physiotherapy within a specific program
46100273|NCT04064788|Other|Intermittent Modified Constraint-Induced Movement Therapy|Intermittent mCIMT group received mCIMT session 6 hours per day for 10 days, spread over 5 weeks (two days per week). Accompanied by a physiotherapist in 1 hour of the 6-hour restriction period, the family was guided within the remaining period and the activities were adapted to daily life.
45680184|NCT03770260|Drug|Ixazomib Citrate|Given PO
45680185|NCT03770260|Drug|Pevonedistat|Given IV
46015291|NCT02880124|Behavioral|Constant load cycling|Subjects will be required to perform 2 hours of cycling exercise at a power output eliciting 60% of VO2max.
46015292|NCT02880124|Procedure|Expired gas sampling|Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution, every 30 minutes.
46015293|NCT02880124|Procedure|Indirect respiratory calorimetry|A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution, every 30 minutes.
46100274|NCT02623686|Other|Aroma Therapy Massage and Inhalation Patch|
46015294|NCT02880124|Other|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
46100275|NCT00655070|Device|Timi3 Transthoracic ultrasound|Low frequency ultrasound over the chest using Timi3 ultrasound device
46100276|NCT03767881|Device|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.
46100277|NCT04032392|Biological|autologous γδT cells|Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
46100278|NCT00737542|Drug|lidocaine|
46100279|NCT00737542|Drug|NACL 0.9%|
46100280|NCT00737620|Procedure|Prosthetic AV graft implantation|Surgical arteriovenous fistula creation with standard or propaten graft
46100281|NCT04032002|Other|Explorations|On Day 1 vascular fonctions explorations performed
45465389|NCT01285102|Procedure|hepatic artery embolization|Using a unilateral femoral approach, selective catheterization of the hepatic artery will be performed. Vascular access is obtained via the common femoral artery and a guide-wire advanced under fluoroscopic guidance. A microcatheter is then inserted over the guide-wire. The superior mesenteric artery is selected and an angiogram performed to identify any aberrant arterial anatomy and verify antegrade portal vein flow. The celiac axis is then selected and an angiogram completed. The catheter and guide-wire are used to select the proper hepatic artery and a limited angiogram performed to identify the branches of the hepatic artery. The right or left hepatic artery is selected distal to the cystic artery (if visualized), depending on the location of the lesions to be treated. The LC Bead, loaded with irinotecan will be delivered into the artery.
45465390|NCT03740243|Drug|Buprenorphine/naloxone|Buprenorphine/naloxone tablet or film
45465391|NCT03740243|Drug|Buprenorphine|Buprenorphine tablet
45465392|NCT03813043|Drug|Midazolam injection|Midazolam 2mg iv to be used as starting dose using Biased coins up and down method (BCM)
45465393|NCT01225679|Device|positive airway pressure, Non-invasive mechanic ventilation|"Vpap: 16 cm H2O inspiratory and 8 cm H2O expiratory pressures, 20 irpm.~Mechanic ventilation: tidal volume of 850 ml; 16 irpm; inspiratory pressure of 40 mmHg; PEEP: 5 cm H2O."
45465394|NCT03740087|Other|Omnivorous diet|Determine if the transfer of bovine miRNAs is carried out after a meal containing beef.
45465395|NCT03740087|Other|Vegan diet|Used as a baseline for miRNA levels in blood
46015295|NCT02880124|Other|Gastrointestinal|At the end of the time trial, subjects will be asked to fill out a short form on gastrointestinal issues they might have had during experimentation.
46100282|NCT04032002|Other|Blood samples|On Day 1 35ml taken
46100283|NCT03865381|Device|Onduo App|The Onduo App is a software application which tracks data relevant to diabetes care, such as, but not limited to, medication, meal logs and glucose readings, and activity data. The Onduo App connects wirelessly to a Care Team Console through the Internet. The Onduo App may also connect wirelessly to commercially available FDA-regulated (i.e., cleared and approved) medical devices and non-medical devices through the subject's Smartphone.
46100284|NCT02632058|Other|Cognitive Behavioral Therapy|
46100285|NCT00713206|Device|Dental Implant (Osseotite)|Root form titanium dental implant
46100286|NCT00865098|Drug|Cetuximab|Patients receive Cetuximab at an initial dose of 400 mg/m^2 of Cetuximab to be infused 6 or 7 days before starting radiotherapy, followed by subsequent weekly infusions at a dose of 250 mg/m^2 of Cetuximab and RT (72.0 Gy total in 42 fractions) for the next 6 weeks of the treatment course. Subjects will receive Cetuximab until radiographically documented progressive disease or unacceptable toxicity occurs or consent is withdrawn. If RT is delayed, administration of Cetuximab every 7 days is continued. If RT is discontinued for any reason, treatment with Cetuximab monotherapy every 7 days is continued.
46100287|NCT00880100|Drug|Ultrase® MT12|Ultrase® MT12 capsules will be given orally daily based on investigator's discretion to a maximum dose of 2,500 lipase units per kilogram (kg) body weight per meal or snack for 19 to 24 days during the treatment phase. Total maximum dose not to exceed 10,000 lipase units/kg/day.
46100288|NCT00729898|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46100289|NCT04130880|Diagnostic Test|Turkish Montreal Children's Hospital Feeding Scale|The Turkish version of the Montreal Children's Hospital Feeding Scale, and the Behavioral Pediatrics Feeding Assessment Scale will be completed.
46100290|NCT05741242|Biological|Personalized Synthetic Long Peptide Vaccine|Personalized Synthetic Long Peptide Vaccine
46100291|NCT00697398|Other|Transcranial stimulation|Stimulation to white
45465396|NCT01560325|Drug|CKD-516 inj.|CKD-516: 3.3~13mg/m2/day
45680186|NCT03761446|Behavioral|Bed rest|The participant will remain in bed rest for 10 complete days.
46015296|NCT02880124|Procedure|Blood sampling|A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain the vessel open. 15 mL of blood will be collected every 30 minutes, immediately before ingesting the solution.
46100292|NCT00697398|Other|Transcranial stimulation|Repetitive transcranial magnetic stimulation (rTMS)
46100293|NCT00659594|Drug|Ciclesonide|200µg Ciclesonide versus Placebo
46015297|NCT02880124|Behavioral|Time trial|Subjects will be required to complete a simulated 20-km time trial on the cycle ergometer set in linear mode (where resistance is proportional to pedalling cadence), starting at 70% of the peak power output for the cadence spontaneously adopted by the subject during 2 hours of exercise.
45680187|NCT03756792|Behavioral|Normal Education Material|Patients will receive standard educational material about Mohs micrographic surgery.
45680188|NCT03756792|Behavioral|Vignette|Patients will receive standard educational material about Mohs micrographic surgery and read a vignette detailing the typical experience of a Mohs patient.
45680189|NCT03741426|Drug|Olaparib|Olaparib 300mg twice daily, oral medication administered for at least 2 weeks and up until the morning of nephrectomy. Arms 2, 3 and 5
45680190|NCT03741426|Drug|Cediranib|Cediranib 20mg once daily, oral medication administered for at least 2 weeks until 36 hours prior to nephrectomy. Arms 1 and 3
45465397|NCT01227473|Behavioral|Mindfulness-based diabetes prevention education group|The mindfulness-based diabetes prevention group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, this group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the mindfulness-based diabetes prevention group, the instruction will be enhanced with a modified mindfulness meditation training designed to support the behavioral-change programming.
46015298|NCT01072357|Drug|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
45680191|NCT03741426|Drug|Durvalumab|Durvalumab 1500mg intravenous infusion administered once, no greater than 4 weeks prior to nephrectomy
45465398|NCT01227473|Behavioral|Conventional diabetes prevention education group|The conventional diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the conventional diabetes prevention group, the instruction will be enhanced with group exercises and discussions.
45465399|NCT05185531|Combination Product|PD-1 plus stereotactic body radiotherapy|neoadjuvant PD-1(Tislelizumab) plus stereotactic body radiotherapy (8 Gy × 3 fractions) in resectable HCC
45465400|NCT03928925|Other|Bougie|disposable tracheal tube introducer of approximately 70 cm in length
45465401|NCT03928925|Other|Endotracheal Tube with Stylet|endotracheal tube preloaded with a removable, malleable stylet
45465402|NCT03382899|Biological|Pegilodecakin|Pegilodecakin plus Pembrolizumab
45465403|NCT03382899|Drug|Pembrolizumab|Pembrolizumab Alone
45680192|NCT03727776|Drug|Adrenocorticotropic Hormone|Adrenocorticotropic hormone (ACTH) is a melanocortin peptide hormone that is normally produced in the pituitary gland and acts as a major regulator of adrenal cortex function. It stimulates the adrenal cortex to produce and secrete glucocorticoids. ACTH is available for clinical usage as an injectable gel (H.P. Acthar®).
46015299|NCT01072357|Drug|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks
46015300|NCT01072201|Drug|Triclosan and Fluoride|Brush twice daily
46015301|NCT01072201|Drug|Fluoride|Brush twice daily
46015302|NCT01103362|Drug|flibanserin|all patients will receive open-label flibanserin 100mg
46015303|NCT00591929|Other|Continuous Passive Motion|at least 48 hours of continuous passive motion following ORIF of fractures around the knee
46015304|NCT04412993|Other|withdraw blood samples|withdraw blood sample from gorup O donors
46015305|NCT04412135|Other|spirituality|Patients will take three questionnaires (FACIT-Sp, Euroqol 5 dimensions and ESAS)
46015306|NCT04208009|Behavioral|Advance care planning animated videos|Four advance care planning videos: 1) Description of ACP; 2) Explanation of the importance of engaging in ACP now; 3) Communicating wishes to one's loved ones and family members; and 4) Communicating wishes to one's doctor.
46015307|NCT01103284|Drug|DiaPep277|1.0 mg dose in 0.5 mL of solution
46100294|NCT00659594|Drug|Placebo|placebo
46015308|NCT01103284|Drug|Placebo|"40 mg mannitol in 0.5 mL of solution.~Dosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months"
45680193|NCT03707158|Behavioral|Therapist-led Face-to-Face Cognitive-Behavioral Therapy|Participants receiving face-to-face cognitive-behavioral therapy will participate in therapist-led, office-based or telehealth CBT treatment for up to 16 weeks. Sessions focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
45837764|NCT05765240|Drug|Hyaluronic Acid Topical Gels|Hyaluronic acid is a linear polysaccharide found naturally in different organs and tissues such as the extracellular matrix of connective tissue, synovial fluid, embryonic mesenchyme, and skin. The periodontal ligament is a key element found in periodontal tissues such as the gingiva, alveolar bone, and cementum. It plays a regulatory role in the inflammatory response, impedes the penetration of viruses and bacteria into the tissue, and is involved in inflammation, granulation tissue formation, epithelial formation, and tissue remodeling. There are no reported drug interactions or contraindications for the use of hyaluronic acid.
46015309|NCT04409249|Diagnostic Test|imaging, blood tests|PCR and CT results, hemogram, urea, creatinine, AST, ALT, LDH, D-Dimer, ferritin, lipase, amylase, CRP, procalcitonin, albumin, total protein, coagulation tests-PT, APTT, Fibrinogen-, Troponin T, CK , electrolytes, blood gas, bilirubins
46015310|NCT04134221|Diagnostic Test|Ultrasound assessment|Ultrasound assessment of internal carotid artery blood flow
46015311|NCT02893709|Drug|Omeprazole|Oral administration of omeprazole at therapeutic dose (20 mg daily) for a duration of 7 days
46015312|NCT04972396|Drug|ALT-801|Injected subcutaneously (SC)
46015313|NCT04972396|Drug|Metformin|Taken by mouth (PO)
46015314|NCT04972396|Drug|Atorvastatin|Taken by mouth (PO)
46015315|NCT04972396|Drug|Warfarin|Taken by mouth (PO)
46015316|NCT04972396|Drug|Digoxin|Taken by mouth (PO)
45465404|NCT03808753|Diagnostic Test|End-expiratory occlusion test (EEOT)|The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
45465405|NCT03808753|Other|mini fluid challenge (mFC)|The mFC is performed by injecting a first aliquot of 100 ml of crystalloid over 1 minute before completing the 4 ml/kg-FC over the residual 9 minutes.
46015317|NCT04972396|Drug|Ethinylestradiol and Levonorgestrel|Taken by mouth (PO)
46015318|NCT00625924|Behavioral|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States - Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
46100295|NCT05541016|Procedure|Biospecimen Collection|Undergo blood specimen collection for NavDx testing
46100296|NCT05541016|Drug|Cisplatin|Given IV
46100297|NCT05541016|Procedure|Computed Tomography|Undergo CT scan
46100298|NCT05541016|Radiation|Diffusing Alpha-emitter Radiation Therapy|Undergo DART
46100299|NCT05541016|Drug|Docetaxel|Given IV
46100300|NCT05541016|Procedure|Intensity-Modulated Proton Therapy|Undergo IMPT
46100301|NCT05541016|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
46100302|NCT05541016|Procedure|Magnetic Resonance Imaging|Undergo MRI
46100303|NCT05541016|Procedure|Modified Barium Swallow|Undergo MBSS
46100304|NCT05541016|Other|Observation|Undergo observation
46100305|NCT05541016|Procedure|Positron Emission Tomography|Undergo PET scan
46100306|NCT05541016|Other|Quality-of-Life Assessment|Ancillary studies
46100307|NCT04133610|Diagnostic Test|Self-sampling using digene HC2 DNA Collection Device|All women will undergo a clinician-collected cervical swab and self-collected cervicovaginal swab.
46100308|NCT04133610|Diagnostic Test|Self-sampling using Evalyn Brush|All women will undergo a clinician-collected cervical swab and self-collected cervicovaginal swab.
46100309|NCT04158050|Drug|IL5 Antagonist or anti-IL5R-antibody or Omalizumab|mepolizumab, reslizumab, benralizumab and omalizumab in severe asthma
46100310|NCT04133766|Behavioral|Community Based Nutrition Package (CNBP)|The Community-Based Nutrition Package (CBNP) is a multi-level intervention that comprises: advocacy and training for government stakeholders and employees; selection and training of master trainers who then cascade the training at provincial level; and selection and training of community-level Nutrition Mobilizing Teams. The Nutrition Mobilizing Teams then organize a 2-day community mobilization session in the catchment areas of each health post to develop a community nutrition plan, which is then implemented by community health workers and two additional volunteers under the mentorship of the Nutrition Mobilizing Teams and with the support of the community members that participated in the community mobilization session.
45465406|NCT03740321|Device|Embolization with tri-acryl gelatin (Embosphere) particles|Left, right and posterior branches of superior rectal artery will be embolized with tri-acryl gelatin particles in 500-700 and 700-900 micrometers in size until homeostasis will be achieved.
46100311|NCT00659672|Dietary Supplement|Whey Protein|40 grams per day Whey Protein
46100312|NCT00659672|Dietary Supplement|Soy Protein|40 grams per day soy protein
46100313|NCT00659672|Dietary Supplement|Control (carbohydrate)|40 grams per day maltodextrin
46100314|NCT02623608|Other|Reference breakfast|A high fat, high calorie breakfast
46100315|NCT02623608|Other|Active Ingredient 1|A high fat, high calorie breakfast including the Active Ingredient 1
46100316|NCT02623608|Other|Active Ingredient 2|A high fat, high calorie breakfast including the Active Ingredient 2
46100317|NCT02623608|Other|Active Ingredient 3|A high fat, high calorie breakfast including the Active Ingredient 3
46100318|NCT02623608|Other|Active Ingredient 4|A high fat, high calorie breakfast including the Active Ingredient 4
46100319|NCT00659750|Drug|Ciclesonide|200µg Ciclesonide versus Placebo
46100320|NCT00659750|Drug|Placebo|placebo
46100321|NCT03900208|Diagnostic Test|Hystological analysis of ventricular tissue|Sections (4μm thick) will be stained with hematoxylin and eosin stain (H&E) for diagnosis. After diagnosis, sections of the representative heart tissue will be stained with a PicroSirius Red/Fast Green for fibrosis evaluation. All stained samples will be examined under digital and light microscope. Beside the location of adipose/fibrous tissue in the right or left ventricles and in the septum, seven high magnification fields (40x) will be evaluated in five regions of the myocardium.
46100322|NCT00697476|Drug|topotecan, vorinostat|"Phase I study: vorinostat will be administered daily for a number of days per cycle variable from 7 to 14 according to the level of dose escalation; topotecan will be administered I.V. for 5 consecutive days every 3 weeks.~Phase II study: Patients will receive treatment at the recommended dose established by phase I part of the trial, for a maximum of 6 cycles or until disease progression, unacceptable toxicity or patient's refusal."
45680194|NCT03707158|Behavioral|Digital Cognitive-Behavioral Therapy|Participants receiving digital cognitive-behavioral therapy will complete an online, largely self-administered CBT program for up to 16 weeks with 8 modules and adjunctive therapist phone support. Treatment modules focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
46100323|NCT00659906|Behavioral|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
46100324|NCT00659906|Behavioral|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
45680195|NCT03698162|Device|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo STAR DCE-MRI
45680196|NCT03698162|Drug|Bevacizumab Injection|Bevacizumab will be give to participants who have recurrent high-grade glioma as part of standard of care.
46100325|NCT00696150|Procedure|determination of method with highest efficacy (ultrasound or nerve stimulator)|Use of ultrasound to guide the insertion of anterior psoas compartment block
46100326|NCT00696150|Procedure|nerve stimulator|The use of the nerve stimulator to guide insertion of the anterior psoas compartment block
46100327|NCT00696150|Procedure|loss of resistance|Use of ultrasound to guide the insertion of anterior psoas compartment block
46100328|NCT00660062|Drug|escitalopram|10 mg daily
46100329|NCT00660062|Drug|escitalopram|20 mg daily dosage
46100330|NCT00660062|Drug|escitalopram|30 mg daily dosage
46100331|NCT00660062|Drug|nortriptyline|100 mg daily dosage
46100332|NCT02617134|Biological|anti-MUC1 CAR-T cells|
46100333|NCT02634164|Dietary Supplement|Leucine Supplement|For this visit participants will ingest a powdered form of Leucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution
45465407|NCT03815305|Drug|Centella Asiatica Extract|centlla asiatica oral drug at 1100 mg dose
45465408|NCT03815305|Drug|Topical CA|1% centella asiatica ointment
45465409|NCT03815305|Drug|Petroleum jelly|vaseline album
45680197|NCT03691480|Procedure|simple exsufflation|simple exsufflation
45680198|NCT03691480|Procedure|Fuhrman catheter and ambulatory care|Fuhrman catheter and ambulatory care
45680199|NCT03663452|Behavioral|Targeted Assessment and Context-Tailored Implementation of Change Strategies (TACTICS)|TACTICS begins with a mixed methods assessment (using data from medical records, staff surveys, and staff interviews) to identify barriers and facilitators of PE use in each clinic. From a menu of implementation strategies that can be matched to local conditions, an implementation plan is developed in collaboration with clinic personnel and deployed to address specific barriers and leverage strengths at each clinic site over a 5-month period.
46100334|NCT02634164|Dietary Supplement|Isoleucine Supplement|For this visit participants will ingest a powdered form of Isoleucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
45465410|NCT03929003|Behavioral|Inspired|The investigators will be studying the ability of using videogame-based rewards to increase smoking abstinence when they are made contingent on meeting abstinence goals.
46100335|NCT02634164|Dietary Supplement|Leucine Supplement combined with Isoleucine Supplement|For this visit participants will ingest a powdered form of Leucine and Isoleucine in the amount of 0.3g/kg of lean body mass weight (equal in total dosage to other treatments) with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
45465411|NCT01560013|Drug|Naltrexone|Naltrexone, oral 50 mg per day.
45465412|NCT01225757|Device|Echocardiogram|Echocardiography will be utilized during the procedure to guide fluid management.
46100336|NCT04063540|Drug|Amiloride|Treatment by Amiloride vs placebo in crossover
46100337|NCT04063540|Drug|Placebos|Treatment by Amiloride vs placebo in crossover
45465413|NCT03709797|Procedure|Dry needling in infraspinatus muscle|Dry needling technique with multiple rapid needle insertion.
46100338|NCT02623374|Behavioral|self-help CBT intervention (SHCBT)|See 'Arms' section
45465414|NCT01302145|Drug|ASP1941|Tablet
45465415|NCT01302145|Drug|Metformin|Tablet
45465416|NCT01302145|Drug|Placebo|Tablet
45680200|NCT03663452|Behavioral|Prolonged exposure training|Providers will receive a 2-day workshop training in the delivery of prolonged exposure, followed by weekly phone clinical consultation.
46015319|NCT00625924|Behavioral|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
45465417|NCT00709852|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous)
45465418|NCT00709852|Drug|Gadoteridol (ProHance)|Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v.
45473994|NCT05666479|Device|Dexcom G6 Pro Continuous Glucose Monitor (CGM)|"A DexCom G6 CGM will be implanted on the subject's abdomen contralateral to the surgical site (i.e. left abdomen for right knee or right hip replacements) no less than 30 cm from the surgical site. This CGM shall be termed primary for study purposes. Subjects will wear the primary DexCom G6 CGM for the entirety of the following 10-day timeline: 3/4-days pre-operative, day of hip or knee replacement surgery, and 5/6-day postoperative recovery.~A second CGM will be implanted in subjects postoperatively while in the Post Anesthesia Care Unit (PACU). This CGM, termed secondary for study purposes, will be implanted immediately adjacent to the primary CGM. Subjects will wear the secondary DexCom CGM for the 7 days: day of hip or knee replacement surgery (postoperatively) and 5/6-day postoperative recovery."
46015320|NCT00625924|Behavioral|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
46015321|NCT04407533|Other|Diet tracking and survey|Mobile AI-based food diary application and online questionnaires
46015322|NCT02877589|Other|hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies and a screening questionnaire to detect risk factors of hepatitis B virus (HBV) and hepatitis C virus (HCV)|
46015323|NCT04309162|Other|Soft tissue therapy|Soft tissue therapy consists of various soft tissue manipulating techniques which includes the stroking, percussive and tapping manipulations. The treatment techniques are divided according to the body parts. under this techniques are tapping, flat finger kneading, Stroking, skin rolling etc.
46015324|NCT04328597|Procedure|Inguinal hernia repair|Inguinal hernia repair (open, laparo-endoscopic, robotic)
46015325|NCT01089361|Drug|Ketamine|The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
45473995|NCT01286675|Drug|Eltrombopag|oral eltrombopag, 50 mg, 100 mg, 150 mg, days 2-15
45473996|NCT04525690|Behavioral|Nudge|Clinicians will receive a default order upon entering the the admission order set. They will have the opportunity to opt-out and not order screening. Clinicians will receive the nudge each time they enter the admission order set for a new, eligible patient.
46100339|NCT04161560|Drug|Cetuximab-IRDye800|does of Cetuximab-IRDye800
45837765|NCT05765240|Procedure|Diode Laser Biostimulation|Laser therapy can amplify wound healing by increasing cell regeneration and modulating the immune response. In animal experiments with diode laser, it was observed that postoperative low-level laser application increased wound healing. Diode laser applied at frequencies of 20 mW and 670 nm and 200 mW and 820 nm accelerated clot organization and new vessel formation after tooth extraction.
46015326|NCT01089361|Drug|Normal Saline placebo|The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
46015327|NCT04399811|Diagnostic Test|Near-infrared Vision Photograph|The near-infrared image will be recorded (by a infrared camera connected to a laptop) for each enrolled patient
46100340|NCT02617212|Procedure|Implant surgery|The volunteers will receive one or two dental implant(s) placed by a surgical procedure, under local anesthesia and careful soft and hard tissue handling. After implant insertion, the volunteers will be randomly assigned to one arm.
46100341|NCT02617212|Device|Three abutment dis-/reconnections.|At the active comparator arm, each implant will receive a titanium healing abutment during the surgery, according to manufacturer's recommendations. Three dis-/reconnections of abutments will be performed after the soft tissue healing period: the first, after 8 weeks, for adjustment of the emergence profile by healing abutment changing; the second, 10 weeks after surgery, for intra-oral prosthetic abutment selection; and the third, 12 weeks after surgery, for the prosthetic abutment definitive connection with the manufacturer recommended torque.
46100342|NCT02617212|Device|No abutment dis-/reconnections.|Each experimental arm implant will receive its definitive prosthetic abutment at the surgical procedure. The manufacturer recommended torque will be applied so that no disconnection of the abutment will occur during and after completion of the treatment. The abutment will receive healing caps, which shall remain in position until the end of 12 weeks after surgery.
46100343|NCT00518011|Drug|Erlotinib|150 mg po daily
46100344|NCT00518011|Drug|Gemcitabine|As prescribed
45473997|NCT04176952|Drug|FOLFOX-A|"nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1.~Folinic acid: 350mg flat dose, IV over 2 hours, day 1.~Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)"
46015328|NCT01102972|Drug|Reyataz + Norvir + Truvada|atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg
46100345|NCT00737776|Drug|biphasic insulin aspart 30|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46015329|NCT01102972|Drug|Reyataz + Epzicom|atazanavir 400mg + abacavir 600mg/lamivudine 300mg
46015330|NCT02893319|Behavioral|Feeding and growth differences, 5oz vs 8oz bottle|Group A: 5oz bottle Group B: 8oz bottle
46015331|NCT04328753|Drug|Super Oxide water|Microsafe®, a recently available super-oxidized solution for gingival care, offers a completely improved approach for treatment of gingivitis. The neutral pH, super oxidized water was certified as an antiseptic .
46015332|NCT04328753|Drug|Chlorhexidine mouthwash|CHX is a regular bisbiguanide artificial antiseptic containing of two biguanide groups and four chlorophenyl rings linked by a hexamethylene bridge. The dicationic nature of CHX makes it interacting strongly with anions, which is related to its safety, efficacy, and side effects. It is available in three forms, digluconate, acetate and hydrochloride salts. CHX has broad spectrum antimicrobial activity
46015333|NCT04328753|Other|Distilled water|act as a negative control in this study
46015334|NCT04328363|Behavioral|Intervention|Social prescription of health assets related to the practice of physical activity and a healthy eating pattern to modify lifestyles.
46015335|NCT04963894|Other|Home functional balance physiotherapy|Experimental physiotherapy program is carried out at home to improve the balance of people with Parkinson's disease through exercises that simulate everyday functional contexts.
46100346|NCT02633930|Drug|Berberine|: given for 14 days at a dose of berberine 100 mg 3 tablets TID, lansoprazole 30 mg BID, amoxicillin 500 mg 2 capsules BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID
46100347|NCT02633930|Drug|clarithromycin|Clarithromycin-containing quadruple therapy group 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, lansoprazole 30mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID.
46015336|NCT04963894|Other|Conventional physiotherapy|Conventional control physiotherapy program is carried out face-to-face in a rehabilitation gym and in groups of 6 people. The conventional program of physiotherapy includes conventional therapeutic goals of rehabilitation in people with Parkinson's disease.
46100348|NCT02633930|Drug|Bismuth|Bismuth:given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID or given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and berberine 100 mg 3 tablet TID
46100349|NCT02633930|Drug|Lansoprazole|Lansoprazole 30mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID given to berberine-containing quadruple therapy group or clarithromycin-containing quadruple therapy group
46100350|NCT02633930|Drug|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus lansoprazole 30mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID as a dose given for clarithromycin-containing quadruple therapy or berberine-containing quadruple therapy.
46100351|NCT00698334|Drug|INH, Rifampicin, Ethambutol and Pyrazinamide|Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg [600 mg if more than 59 kg], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
46100352|NCT00698334|Drug|INH, Rifampicin, Ethambutol and Pyrazinamide|Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg [600 mg if more than 59 kg], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
46100353|NCT02568826|Drug|3-glycosyl-3-Odemethylthiocolchicine derivative|IDN 5243 is a new muscle relaxant molecule. This molecule has showed significant anti-inflammatory activity by intraperitoneal route at 10 mg/kg in both carrageenan induced oedema and granuloma tests. IDN 5243 is a new 3-glycosyl-3-Odemethylthiocolchicine derivative endowed with muscle-relaxant, anti-inflammatory and analgesic activities. The primary packaging of test formulation will be a glass vial containing a solution of IDN 5243, 4 mg/ 1 mL. The secondary package will correspond to the patient's kit and will be a box containing ten (10) vials. The box label will be provided with a tear-off label.
46100354|NCT04161482|Drug|Furosemide 80 mg (8 mg/mL)|Furoscix will be administered as a subcutaneous infusion.
46100355|NCT02623530|Other|Educational intervention|"Control Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through the Methodology of PBL without the support MEAPC.~Experimental Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through Methodology PBL, supported by the MEAPC."
46100356|NCT02568904|Other|Alcohol|every participant will drink vodka at a dose of 2ml/kg bodyweight
46100357|NCT02568904|Other|Glucose|oral Glucose tolerance test
46100358|NCT02568904|Other|Fructose|oral fructose tolerance test
46100359|NCT02568904|Other|vehicle|control (water)
46100360|NCT02623452|Drug|Insulin Lispro|Administered subcutaneously (SC)
46100361|NCT02633696|Drug|silybin phosphatidylcholine|
46100362|NCT02633696|Drug|Legalón SIL|
46100363|NCT00737854|Procedure|Surgical resection|20 patients with OLP will be selected for this study. Before this routine treatment modalities had been attempted. Removal of possible triggering drug was also considered. Local ethical committee approval will be obtained before the trial starts. Surgical procedure includes: removal of the tissue up to submucosa (containing antigenic properties that caused OLP). A specimen will be sent for histopathologic analysis. The graft sliced from healthy mucosa also up to submucosa. Then the graft trimmed on a gauze soaked in saline and adapted to recipient site. The graft was sutured in position. Checking will be done after 1 week and every two months up to 1 year. Punch biopsy will be done in 1 year after surgery for histopathologic investigations.
46100364|NCT04130724|Diagnostic Test|Blood ketone testing|Ketone testing will be done using a blood beta-hydroxybutyrate (BHB) test at least five (5) times per day.
46100365|NCT04130724|Diagnostic Test|Breath ketone testing|Ketone testing will be done using a breath acetone (BrAce) test at least five (5) times per day.
46100366|NCT04161170|Device|Digital integrated healthcare platform|Digital Integrated Healthcare Platform Utilizing AI-based Dietary Management Solution and Real-time Continuous Glucose Monitoring system
45837766|NCT05765201|Other|High IOP|Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 28mmHg (low IOP) in one eye and with IOP ≥ 60mmHg (high IOP) in the other eye
46015337|NCT02879500|Other|Diet beverages|
45473998|NCT04176952|Drug|AG|"nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first).~Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel)."
45473999|NCT05571774|Other|collection data|collection data
46015338|NCT04388579|Other|Pulmonary Rehabilitation|Respiratory Physiotherapy, Exercise Therapy, Patient Education
46015339|NCT01088503|Drug|ADP receptor inhibitors|Dosage regimen as determined by the treating physician.
46100367|NCT04062994|Behavioral|Nudge to reduce intraoperative hypotension|Providers will be alerted if their patients are at high risk of hypotension or at increased risk of sequelae from hypotension. Intraoperatively, if patients have more than 10 minutes of hypotension an alert will be displayed on the screen.
46015340|NCT01087489|Drug|4% lidocaine|The eye will be topically anesthetized with 0.5% proparacaine drops and 4% lidocaine drops and a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface followed in three rounds by additional 5% povidone iodine and a sterile cotton swab soaked in sterile 4% lidocaine applied with gentle pressure to the area designated for injection in the infero-temporal quadrant.
46100368|NCT04130646|Device|Transcranial Magnetic Stimulation|transcranial magnetic stimulation delivers magnetic pulses to the brain through the scalp/skull
46015341|NCT01087489|Drug|3.5% ophthalmic lidocaine gel|The eye will be topically anesthetized with 0.5% proparacaine drops and 5% povidone iodine will be placed over the eye. Two drops of preservative-free 3.5% lidocaine hydrochloride ophthalmic gel will be placed into inferior conjunctival sac. The patient will be asked to close the eye for 7 minutes. Next, a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface and allowed to remain in contact with the eye for at least 2 minutes. The eye will then be rinsed with antibiotic drops.
46015342|NCT04306627|Drug|Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment|comparative antihypertensive antilipidemic treatment assessment on carotid intima media thickness in both study groups
46015343|NCT04306471|Drug|Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are to be provided by Amgen.
46100369|NCT04130646|Device|transcutaneous auricular vagus nerve stimulation (taVNS)|non-invasive vagus nerve stimulation delivers electricity to the ear
46100370|NCT02633852|Drug|Aflibercept|
46100371|NCT00737932|Drug|Laquinimod|Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day, oral, for 8 weeks of treatment
46100372|NCT00737932|Other|placebo|Matching placebo for 8 weeks of treatment
45683895|NCT01574079|Other|Physical Therapy plus Mirror Therapy|The treatment group will receive traditional physical therapy intervention as described in the control group with the addition of mirror therapy. The participant will attempt to perform the flexion exercises with both lower extremities. The patient will be blinded to the affected lower extremity with a mirror, and will be looking at the image of the unaffected lower extremity superimposed on the affected lower extremity as he or she performs the activities.
45683896|NCT03135730|Genetic|ROHHAD|Suspected and Confirmed ROHHAD cases
46100373|NCT02633774|Drug|Propafenone|AAD(antiarrhythmic drug)
46100374|NCT02633774|Drug|Apixaban|anti-coagulation
45474000|NCT03629041|Device|Microneedle Patch|At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
46100375|NCT05741008|Radiation|Target range|Compared with conventional radiotherapy, the target dose is unchanged and the CTV2 volume is reduced.
46100376|NCT02633618|Biological|Analgecine|Extraction from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
46100377|NCT02633618|Biological|Neurotropin|a natural bio-product obtained from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
46100378|NCT00865020|Drug|Aliskiren|Aliskiren 150 mg tablets taken orally daily. 1 tablet for the first two weeks followed by 2 tablets for 10 weeks.
46100379|NCT00865020|Drug|Telmisartan|Telmisartan 40 mg capsules taken orally daily. 1 capsule the first 2 weeks followed by 2 capsules for 10 weeks.
46015344|NCT04306471|Other|Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months|The study subjects randomized to the control study arm will receive monthly subcutaneous injections of placebo 1 mL x 3 in the abdomen, thigh or upper arm. The study placebo prefilled injector pens are to be provided by Amgen.
46100380|NCT00865020|Drug|Placebo to Aliskiren|Placebo to Aliskiren tablets taken orally daily. 1 Tablet for the first 2 weeks and 2 tablets during the no treatment (withdrawal) week.
46100381|NCT00865020|Drug|Placebo to Telmisartan|Placebo to Telmisartan capsule taken orally daily. 1 capsule for the first 2 weeks and 2 capsules during the no treatment (withdrawal) week.
46100382|NCT00517933|Drug|Sildenafil Citrate|Sildenafil citrate (20mg 3 times a day [TID] orally for 12 weeks followed by 20mg TID open-label sildenafil for an additional 12 weeks)
46100383|NCT00517933|Other|Placebo|Placebo (20mg TID orally for 12 weeks followed by 20mg open-label sildenafil for 12 weeks)
46100384|NCT02633384|Other|SMOFlipid|Exclusive total parenteral nutrition using a new generation intravenous lipid emulsion composed of 30% LCT n-6 (soybean oil), 30% MCT (coconut oil), 25% monounsaturated fatty acids (olive oil), 15% LCT n-3 (fish oil) and α-tocopherol
46100385|NCT02633384|Other|Lipofundin|Exclusive total parenteral nutrition using a current intravenous lipid emulsion composed of 50% LCT (soybean oil) and 50% MCT (coconut oil)
46100386|NCT05740930|Other|Partition defocus myopia management spectacle lens|Participants in the intervention group will receive the partition defocus myopia management spectacles lens and receive follow-up checks.
46100387|NCT05740930|Other|Spectacle lenses with aspherical lenslets|Participants in the control group will receive the spectacle lenses with aspherical lenslets and receive follow-up checks.
46100388|NCT04031196|Procedure|QLB|QLB type 2 approach
46100389|NCT04031196|Procedure|TAP block|classic TAP block approach
46100390|NCT02633462|Procedure|scaling and root planing , Myo-inositol|scaling and root planing along with Myo-inositol supplementation (1 gm twice a day)
46100391|NCT02633462|Drug|Myo-inositol|only provided treatment with Myo-inositol supplementation (1 gm twice a day)
46100392|NCT00701038|Device|auto adjusting bi-level positive airway pressure device|auto adjusting bi-level positive airway pressure device is provided for treatment of obstructive sleep apnea.
46100393|NCT02638064|Procedure|Surgiflo injection|Curettage of sinus cavity then injection of surgiflo material
46100394|NCT04119336|Drug|Nivolumab|Given intravenously once per cycle
46100395|NCT04119336|Drug|Ixazomib|Given orally on days 1, 8, 15.
46100396|NCT04119336|Drug|Dexamethasone|Given orally on days 1, 8, 15, 22
46100397|NCT04119336|Drug|Cyclophosphamide|Given intravenously on days 1, 8, 15.
46100398|NCT02633228|Device|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of Oculentis® MplusX® multifocal intraocular lenses with an addition of +2.0 D in the distance-dominant eye and +3.0 D in the fellow eye.
46100399|NCT00655148|Biological|DTaP-IPV vero vaccine|DTaP-IPV vero 0.5 mL solution for intramuscular injection at 2, 3½, 5 and 16 months of age
46100400|NCT00655148|Biological|DTaP-IPV mkc vaccine|DTaP-IPV mkc 0.5 ml solution for intramuscular injection at 2, 3½, 5 and 16 months of age
45683897|NCT05249686|Other|Manual Therapy + Dry Needling|"Dry Needling: This is a minimally invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle in order to stimulate myofascial trigger points (MTrP) provoking one to six local twitch responses (LTR).~Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ)."
46015345|NCT04758481|Radiation|primary tumour radiotherapy|The study subjects will undergo primary tumour radiotherapy.
46015346|NCT04758481|Radiation|stereotactic body radiotherapy|The study subjects will undergo stereotactic body radiotherapy.
45474001|NCT03629041|Device|Patch with no microneedles|At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
46015347|NCT04758481|Radiation|maintenance radiotherapy|The study subjects will undergo maintenance radiotherapy.
46015348|NCT04296253|Genetic|SNP polymorphisms of the promoter regions pro - and anti-inflammatory cytokines and angiogenic growth factor|blood sampling
46015349|NCT04304989|Other|mHealth program|mobile health applications
46015350|NCT04304989|Other|usual care|usual care
46100401|NCT02631902|Behavioral|Exercise|Community-based exercise program with 3 weekly exercise sessions
46100402|NCT02631902|Behavioral|Dietary intervention|Community-based dietary intervention program
46100403|NCT05740774|Diagnostic Test|3D ultrasound|3D ultrasound scanning of the resected tongue tumor will be performed. The margin analysis will be made using the 3D ultrasound image.
46015351|NCT02877667|Device|planar acoustic wave device|accessory to laser treatment
46015352|NCT01082965|Drug|Donepezil|5 mg tablets once daily for 7 days and then 10mg on 8th day
46100404|NCT00857766|Drug|ADVAIR DISKUS™ 250/50mcg|ADVAIR DISKUS™ 250/50mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ADVAIR DISKUS™ 250/50mcg is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
46100405|NCT00857766|Other|Placebo|COPD subjects-Placebo DISKUS
46100406|NCT04161404|Drug|Brand name: Andrographis paniculata (Shine Hempedu Bumi) 1000mg capsules|Andrographis paniculata or hempedu bumi capsule is a traditional medicinal product registered under Ministry of Health Malaysia for general wealth being. It is traditionally used for anti-diabetic, anti-bacterial, anti-pyretic, anti-malarial, anti-inflammatory, antidiarrhoeal and other effects.
45680201|NCT03652740|Drug|Effects of commonly used medications on mood and medication preference|"Capsules will contain a commonly prescribed or over-the-counter medication, or placebo. A placebo is an inactive substance that looks like the study drug, but contains no active drug. The capsules given in this study may include sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, and antihistamines. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. Participants will not be informed of the specific drugs they will receive during or after the study. Participants will not receive any drug that is not named as a possible study drug in the written informed consent form. All the study drugs to be administered are legally marketed in the United States."
45680202|NCT03636282|Behavioral|Hockey FIT Program (Immediate Delivery)|"Hockey FIT is comprised of a 3-Month Active Phase and a 9-Month Minimally-Supported Phase.~Active Phase: 12 weekly, 90-minute group-based sessions consisting of classroom-based education and exercise. Outside of sessions, participants follow their individualized lifestyle prescriptions for healthy eating, physical activity (steps), and exercise. Participants are encouraged to regularly use health technology support tools customized to Hockey FIT. Minimally-supported phase: Participants are encouraged to continue with their healthy lifestyle behaviour changes and to regularly use the health technology support tools."
46100407|NCT04161404|Drug|Brand name: Andrographis paniculata (Shine Hempedu Bumi) 2000mg|Andrographis paniculata or hempedu bumi capsule is a traditional medicinal product registered under Ministry of Health Malaysia for general wealth being. It is traditionally used for anti-diabetic, anti-bacterial, anti-pyretic, anti-malarial, anti-inflammatory, antidiarrhoeal and other effects.
46100408|NCT04161404|Drug|Metformin (Glucophage) 1000mg|Metformin is an oral glucose-lowering drug of the biguanides class. Drug: Period 1 Subjects
46100409|NCT00517699|Drug|rituximab [MabThera/Rituxan]|750mg/m2 iv
46100410|NCT00517699|Drug|Methotrexate|8g/m2 iv
46100411|NCT00517699|Drug|Cytarabine|2g/m2 iv
46100412|NCT04161092|Procedure|Liver transplantation Ltx|Patients will be treated with Ltx at Sahlgrenska University Hospital, Göteborg, or Karolinska University Hospital, Huddinge.
46100413|NCT04161092|Other|Best alternative care|All available treatments as well as other experimental treatments are tolerated, however no cross-over to other arm will be allowed.
46100414|NCT03096275|Drug|MMF|Patients were treated with Glucocorticoids combined with methotrexate and mycophenolate mofetil
46015353|NCT01082965|Drug|Placebo|matching placebo
46015354|NCT01102426|Drug|Plitidepsin|plitidepsin: powder and solvent for concentrate for solution for infusion. 2 mg vial + 4 ml ampoule. 5 mg/m2 intravenously (i.v.) over three hours on Day 1 and 15 every 4 weeks. dexamethasone: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks at least one hour before plitidepsin infusion.
46015355|NCT01102426|Drug|Dexamethasone|4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.
46015356|NCT04304365|Other|Follow-up clinic visit|Participants will be scheduled for a visit with a provider in 1-2 weeks that will include an ultrasound examination.
46100415|NCT03096275|Drug|CYC|Patients were treated with Glucocorticoids and cyclophosphamide sequentially with azathioprine
46100416|NCT03096275|Drug|Glucocorticoids|Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered
46100417|NCT03096275|Drug|MTX|Patients in the experimental group are treated with Glucocorticoids combined with MTX and MMF
46100418|NCT03096275|Drug|AZA|Patients in the active comparator group were treated with Glucocorticoids combined with CYC followed by AZA
46100419|NCT02613468|Other|collection of periodontal records|"Clinic attachment level~Probing depth~Gingival index~Plaque index~Bleeding on probing were performed in all groups. These measurements were performed at the end of each trimester."
46100420|NCT02613468|Other|pregnancy parameters|Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.
46015357|NCT04304365|Other|Text message|Participants will be instructed that they will be contacted by research staff through text message 14 days after the initial visit. They will receive a survey link through text message at this time.
46015358|NCT04304365|Other|Low Sensitivity Pregnancy Test (LSPT)|Participants will be instructed on how to test their urine 14 days after the medication abortion for continued pregnancy. LSPT can detect hCG levels as low as 2000 mIU/ml.
46015359|NCT04308772|Behavioral|Web-based Physiotherapy|Participants will receive an exercise programme, based on those patients usually get in the form of an exercise leaflet, delivered via a web-based physio website (www.giraffehealth.com). Participants will be asked to complete their exercise programme as prescribed (at least once each day) and to fill out an online exercise diary which the physiotherapist can see remotely from the clinical site.
46015360|NCT02879422|Genetic|genetic analysis|
46015361|NCT02879656|Procedure|non-operative treatment|conservative treatment with 5 weeks cast immobilization
46100421|NCT02613468|Other|Initial Periodontal Therapy|Initial Periodontal Therapy is completed ( Supragingival and subgingival calculus elimination, root planning, polishing etc.) This treatment is considered to be the safest time for pregnant mothers was performed in 2 trimester.
46100422|NCT04161014|Drug|Nintedanib 150 MG [Ofev]|Nintedanib 150mg twice daily for 3 years
46100423|NCT04491643|Drug|Megestrol Acetate|At a dosage of 160 mg/day
46100424|NCT04491643|Drug|Rosuvastatin|At a dosage of 10 mg/day
46100425|NCT00699504|Drug|cangrelor|IV bolus 60 mcg/kg; 8 mcg/kg x 3 hrs
46100426|NCT00699504|Drug|cangrelor|30 mcg/kg bolus; 4 mcg/kg/min x 3 hrs. Oral placebo capsule
46100427|NCT00699504|Drug|cangrelor|60 mcg/kg bolus; 8 mcg/kg/min x 3 hrs. Oral placebo capsule
45465419|NCT05348811|Drug|HAIC combined with donafenib and sintilimab|"HAIC- GEMOX regimen, gemcitabine 1000 mg/m2, oxaliplatin 85mg/m2 (if the maximum tumor diameter > 10cm, the dose is 130mg/m2), the first day of each cycle (D1), Q3W. The maximum of 6 times.~Sintilimab will be given on the first day of each cycle (D1). 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.The longest treatment time is 24 months.~Donafenib was taken orally at 0.2 bid on an empty stomach (1 hour before or > 2 hours after meal) in the morning and evening of each administration day, with an interval of about 12 hours. Donafenib treatment is initiated within 1 to 3 days of each HAIC treatment until toxicity is intolerable, the investigator determines disease progression, death, informed consent is withdrawn, new antitumor therapy is initiated, or treatment is discontinued for any other reason specified in the protocol."
45465420|NCT01560091|Drug|silodosin|8mg PO Qday
45465421|NCT01560091|Procedure|Extra-corporeal shock wave lithotripsy|ESWL
46100428|NCT00699504|Drug|moxifloxacin|400 mg orally. Placebo IV bolus and infusion.
46100429|NCT00699504|Drug|placebo|placebo IV and oral
46100430|NCT02997605|Drug|GlucoCorticoid|"After inclusion in the study, the first part is an open follow-up period where all patients will receive 5 mg of prednisone daily for one month. After one month, if patients still have a DAS28 ≤3.2, they will be randomized into two arms: Group 1: GC tapering group / Group 2: Hydrocortisone replacement group.~After randomisation, there are four scheduled visits: M4, M7, M9 and M12. Patients withdrawing from GC therapy will be instructed, that if they start feeling unwell during or after the GC tapering protocol they should not taper the steroid dose any further, but contact the centre responsible for the protocol. If GC induced adrenal insufficiency is confirmed or strongly suspected, GC replacement will be secured using hydrocortisone."
46100431|NCT04156724|Device|Helmet vetilation|We will apply non-invasive positive pressure ventilation via a helmet as interface
46100432|NCT04491487|Other|pre-operative counselling|pre-operative Speech-Language Pathology (SLP) counselling before Total Laryngectomy
46100433|NCT03767543|Drug|INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
46100434|NCT00857454|Drug|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 60 days
46100435|NCT00660140|Drug|Gemcitabine|
45465422|NCT01560091|Drug|Tamsulosin|Tamsulosin 0.4mg PO Qday
46015362|NCT02879656|Procedure|operative treatment|surgery with volar locking plate with modified Henry's volar approach
46015363|NCT02881138|Drug|RC48-ADC|
46015364|NCT04308460|Procedure|arthrocentesis|lavage of the temporomandibular joint was done
46015365|NCT04308460|Procedure|operative arthroscopy|operative intervention inside the temporomandibular joint was done using arthroscope
46015366|NCT02879734|Other|Prophylactic laparoscopic omentopexy|Fixation of omentum with sutures to anterior abdominal wall during laparoscopic surgery
46015367|NCT02879344|Other|Blood draw|
46015368|NCT02879266|Biological|TetraVax-DV TV005|Contains 10^3 plaque-forming units (PFUs) of rDEN1Δ30, 10^4 PFUs of rDEN2/4Δ30(ME), 10^3 PFUs of rDEN3Δ30/31-7164, and 10^3 PFUs of rDEN4Δ30; administered by subcutaneous injection in the deltoid region of the upper arm
46015369|NCT02879266|Biological|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
46100436|NCT00660140|Drug|Carboplatin|
46100437|NCT03765437|Biological|Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
46100438|NCT04156958|Drug|Fruquintinib|Fruquintinib will be administered orally at a dose of 5 mg/d, 3 weeks on, 1 week off (4 weeks as a cycle) until progression, unacceptable toxicity, or withdrawal unless toxicity not relieved after dose adjustment.
46100439|NCT00696228|Dietary Supplement|Placebo|Placebo
45465423|NCT01311609|Other|Systane|Systane Lubricant Eye Drops [1-2 Drops in each eye four times daily (QID)]
46015370|NCT04308850|Drug|Vitamin D drops|Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
46100440|NCT00696228|Dietary Supplement|MUFA|MUFA
45465424|NCT03812887|Diagnostic Test|Photopatchtesting|Photopatchtesting to the sunscreen series and extended series, irradiated at both 24 and 48 hours
46100441|NCT00696228|Dietary Supplement|PUFA|PUFA
46100442|NCT00696228|Dietary Supplement|SFA|SFA
45465425|NCT03926975|Device|Scleral Lens|The contact lens will be worn on one eye.
45465426|NCT03926975|Other|No lens|No lens worn on the contralateral control eye
45465427|NCT03807427|Behavioral|READY-Nepal|Regulating Emotions through Adapted Dialectical behavior skills for Youth in Nepal (READY-Nepal) is a brief (10-session), emotion-focused intervention targeting prevention and reduction of trans diagnostic problems related to emotion regulation. The culturally adapted program is divided into 5 modules, and includes both didactic and experiential instruction in skills related to mindfulness, stress tolerance, emotional awareness and regulation, validation of self and others, and mastery of interpersonal relationships.
46015371|NCT04308538|Procedure|Standard Recession|Bilateral lateral rectus muscle recession will be performed through fornix approach using standard tables
46015372|NCT04308538|Procedure|Reduced Recession|Bilateral lateral rectus muscle recession will be performed through fornix approach using reduced numbers
46100443|NCT03760991|Drug|INSULIN GLARGINE (U300)|"Pharmaceutical form: Solution for injection in a prefilled pen~Route of administration: Subcutaneous"
46100444|NCT04160858|Other|Exercise|Spinal Cord Injury Exercise Guidelines: Participants will begin at the Starting Level which is 20 mins of moderate to vigorous aerobic activity 2x/week & 3 sets of 10 repeats of strength training 2x/week. They will progress to Advanced Level which is 30 mins of moderate to vigorous aerobic activity 3x/week and 3 sets of 10 repetitions of strength training 2x/week. The intervention duration is 6 months.
46100445|NCT04160858|Other|Control|Wait-list control
46100446|NCT02623296|Drug|GLPG1205|Once daily administration of 2 GLPG1205 capsules from Day 1 to Day 13
46100447|NCT02623296|Drug|Placebo|Once daily administration of 2 matching placebo capsules from Day 1 to Day 13
46100448|NCT02623296|Drug|Cocktail of CYP450 substrates|Single administration on Day 13 of cocktail of CYP450 substrates: warfarin tablet, omeprazole capsule and caffeine oral solution
46100449|NCT00525031|Drug|Temozolomide (TMZ)|150 mg/m^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.
46100450|NCT00525031|Drug|Pegylated Interferon Alpha-2b (PGI)|0.5 mcg/kg subcutaneous injection once weekly for a total of 8 weeks.
45680203|NCT03623633|Drug|denosumab|denosumab 60 milligrams subcutaneously every 6 months
45680204|NCT03623633|Drug|alendronate|alendronate 70 milligrams weekly
46015373|NCT02880904|Other|Photography|Photos will be taken of the vulvar lichen sclerosus lesions.
46015374|NCT02880670|Drug|BMS-986142|
46015375|NCT01101334|Drug|CS-7017|CS-7017, Two 0.25mg Tablets administered twice daily
46100451|NCT02692469|Procedure|Duodenal Switch|Bariatric procedure
45680205|NCT03623633|Drug|raloxifene|raloxifene 60 milligrams daily
46015376|NCT01101334|Drug|erlotinib|Erlotinib; One 150mg tablet administered once daily
46015377|NCT02880748|Other|Water exchange (WE) method|Water exchange (WE) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
46100452|NCT02692469|Procedure|Duodenal-ileal Bypass with Sleeve Gastrectomy|Bariatric procedure
46015378|NCT02880748|Other|Air insufflation (AI) method.|Air insufflation (AI) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
46100453|NCT02631824|Procedure|open reduction and internal fixation|Open reduction and internal fixation using an intramedullary nail
45465428|NCT03382041|Device|Carbon Fiber Implant|A cannulated rod, made of long carbon fiber reinforced polymer, with interlocking holes at its proximal and distal ends. The Nail provides for a slight bend. A Tantalum radiopaque marker along the Nail longitudinal axis provides for its visualization under fluoroscopy. The Nail proximal end is marked by a tantalum marker.
45465429|NCT03382041|Device|Titanium Implant|An intramedullary rod, also known as an intramedullary nail (IM nail) or inter-locking nail or Küntscher nail (without proximal or distal fixation), is a metal rod forced into the medullary cavity of a bone. IM nails have long been used to treat fractures of long bones of the body
45680206|NCT03623347|Other|TMZ and BEV induction before chemoradiotherapy|New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-based chemoradiotherapy.
45680207|NCT03603808|Device|Electroporation|Undergo electroporation
45680208|NCT03603808|Biological|HPV DNA Plasmids Therapeutic Vaccine VGX-3100|Given IM
46015379|NCT01327547|Drug|Maraviroc|150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
46015380|NCT01327547|Drug|Placebo|150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
46100454|NCT02631824|Device|TFNA|Trochanteric Femoral Nail Advance
46015381|NCT04387643|Dietary Supplement|Ayurvedic Kadha|Kadha (also called Kwath and Kashaya) is a type of ayurvedic formulation prepared by boiling herbs in water. Water and herbs are main ingredients of these preparations. The preparation of Kadha uses dry herbs, which are dried under the sun or in the shade, as directed for the individual herb. Then, the herbs are pounded to form a coarse powder
46015382|NCT04386785|Device|Radiofrequency (RF) Thermal Ablation of Incompetent Perforator Veins|The physician operator will access the IPV and advance the device to the target treatment position using ultrasound guidance. After providing local anesthesia to the vein and surrounding tissues, thermal ablation energy is delivered to the vein wall. After treatment is complete, the device is removed and vessel closure confirmed with duplex ultrasound.
46015383|NCT01308567|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
45465430|NCT03807271|Device|Calculated and graphically produced depth of anesthesia (Smart Pilot® View)|Smart Pilot® View is a device integrated in the ventilator used under general anesthesia. The depth of anesthesia is calculated based on age, weight, height and the medication given - both volatiles and intravenous. The device does not control the supply of medication directly, but provides an estimate of anesthesia depth that can help the anesthesia team to control the supply of anesthetic agents under general anesthesia, ie indirectly.
45465431|NCT01131533|Procedure|Vitrectomy|vitrectomy following intravitreal erythropoietin
45465432|NCT03812731|Drug|Ropivacaine|Intraoperatively after induction of anaesthesia caudal epidural block will be administered with 0.2% ropivacaine 1-ml/kg
45465433|NCT03812731|Drug|Fentanyl Citrate|Intraoperatively after induction of anaesthesia fentanyl 1-mcg/kg/hour will be administered
45680209|NCT03603808|Other|Laboratory Biomarker Analysis|Correlative studies
45680210|NCT03602976|Drug|Ursodeoxycholic Acid|weight-based dosing
45680211|NCT03601247|Device|silicone gel|"Patients who have consented to the study will receive two tubes labeled only left and right, corresponding to the side of the face to which the tube contents will be applied. One tube will contain silicone gel and the other tube will contain aquaphor. Neither the patient nor the surgeon will know what side will receive which treatment. These tubes will be given to patients at post-operative week 1 visit. Patients will be instructed to rub the solution into their eyelid incisions gently with their fingers for 2-3 minutes twice a day"
45680212|NCT03595072|Other|observation of VNS stimulation effects|ECOGs will be recorded during VNS stimulation and inter stimulation periods
46015384|NCT01308567|Drug|Docetaxel (XRP6976)|Pharmaceutical form: Solution for injection'; Route of administration: Intravenous
46015385|NCT01308567|Drug|Prednisone|Pharmaceutical form: Tablet; Route of administration: Oral
46100455|NCT02631824|Device|Augmentation (Cement)|Cement placement (3-6ml) through the cephalic blade under fluoroscopic vision. Cement contains 40% zirconuim dioxide, 15% hydroxiapatite, 45% polymethyl methacrylate (PMMA).
46100456|NCT02692157|Drug|Placebo|Placebo for Neurokinin 1,3 antagonist
46100457|NCT02692157|Drug|NT-814 50 mg|Neurokinin 1,3 antagonist 50 mg
46100458|NCT02692157|Drug|NT-814 100 mg|Neurokinin 1,3 antagonist 100 mg
46100459|NCT02692157|Drug|NT-814 200 mg|Neurokinin 1,3 antagonist 200 mg
46100460|NCT01973725|Drug|Icotinib Hydrochloride|Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.
46100461|NCT00660296|Other|Air insufflation use in colonoscopy|Air insufflation for colonic distension
46100462|NCT00660296|Other|CO2 use in colonoscopy|Co2 insufflation for colonic distension
46100463|NCT02704871|Other|SeptiCyte Lab molecular diagnostic test (non-interventional)|This is not an interventional study. Rather it involves evaluation of a molecular diagnostic test to distinguish between sepsis and infection-negative SIRS based on host response.
46100464|NCT00660374|Drug|insulin NPH|"Soft-treat-to-target dose titration scheme, injection s.c."
45465434|NCT03922841|Other|Pleural disease management|History, physical examination, pleural drainage, lab/radiographic investigations
45465435|NCT03806959|Other|Pan Capsule and colonoscopy in patients with IBS|Every patient will have both Pan Capsule and colonoscopy examinations Descriptive study only Usual biological tests (CBC, CRP, TSH, anti-transglutaminase antibodies) and measurement of fecal calprotectin.
45465436|NCT03351231|Drug|BMS-986242|Specified dose on specified days
46015386|NCT00592163|Drug|ZIO-101-C (Darinaparsin)|Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (>8 hours between doses) for 3 weeks followed by 1 week of rest
46100465|NCT00660374|Drug|EX1000|"Soft-treat-to-target dose titration scheme, injection s.c."
46100466|NCT00524485|Drug|aminolevulinic acid|
45465437|NCT03351231|Biological|Nivolumab|Specified dose on specified days
46015387|NCT00592241|Device|"Adi Insulin Pump Usability"|no intervention
46015388|NCT04324905|Drug|HIP1802|Test drug
45465438|NCT01228877|Other|exercise|Adduction, Abduction and Squat exercise three times a week for 16 weeks
46100467|NCT00524485|Procedure|laser therapy|
46100468|NCT02704949|Radiation|1/4 fluoroscopy dose|Use of 1/4 fluoroscopy dose while ureteroscopy is being performed
46100469|NCT02704949|Radiation|Full-dose|Use of full fluoroscopy dose while ureteroscopy is being performed
46100470|NCT00660452|Drug|Staloral|Sublingual immunotherapy with Staloral dust mites solution
45465439|NCT03807115|Other|Implementation of stroke mobility guidelines|Delivery of weekly online educational capsules on 4 evidence-based stroke recommendations (motor imagery/mental practice, rhythmic auditory stimulation gait therapy, task-oriented training including fitness and mobility exercises, and aerobic training) plus feedback on participant's awareness, agreement, satisfaction with, and perceived value of the content, perceived implementation success and facilitators and barriers encountered.
45465440|NCT03920033|Radiation|Salvage radiation therapy|Salvage radiation therapy for biochemical recurrence
45465441|NCT03381339|Device|Oscillating rotating power toothbrush|a battery powered oscillating rotating toothbrush will be used for twice daily regular home dental hygiene
45465442|NCT04493671|Drug|TBAJ-876 10mg|TBAJ-876 10mg tablets, oral suspension, orally administered
45465443|NCT04493671|Drug|TBAJ-876 25mg|TBAJ-876 25mg tablets,oral suspension, orally administered
46100471|NCT00857220|Drug|eszopiclone|One 2 mg tablet per day for 12 months
45465444|NCT04493671|Drug|TBAJ-876 50mg|TBAJ-876 50mg tablets,oral suspension, orally administered
45465445|NCT04493671|Drug|TBAJ-876 100mg|TBAJ-876 100mg tablets, oral suspension, orally administered
46100472|NCT00857220|Drug|eszopiclone|one 3mg tablet per day for 12 months
46100473|NCT02704793|Other|Bilateral 1 Hz Cerebellar rTMS|900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere every day for 5 consecutive days.
46100474|NCT02704793|Other|Sham (electrical stimulation)|900 pulses of 1 Hz electrical stimulation (less than 3 mili amperes) delivered over each cerebellar hemisphere every day for 5 consecutive days.
46100475|NCT00524173|Drug|Tenofovir & Emtricitabine|
46100476|NCT00524173|Drug|Tenofovir|
45465446|NCT04493671|Drug|TBAJ-876 200mg|TBAJ-876 200mg tablets, oral suspension, orally administered
45465447|NCT04493671|Drug|TBAJ-876 400mg|TBAJ-876 400mg tablets, oral suspension, orally administered
46015389|NCT04324905|Drug|HGP1705|Reference drug
46015390|NCT04375007|Other|Routine care|Physiotherapy intervention in routine care
46100477|NCT04157816|Other|Face-to-Face Training|This intervention is a traditional classroom-based (face-to-face) training program for non-specialist health workers offering instruction for the delivery of the Healthy Activity Program (HAP) in primary care settings. HAP is an evidence-based brief psychological treatment for depression. The classroom instruction follows the HAP manuals and is facilitated by an experienced counselor with certification as a Master Trainer, meaning that they have significant experience delivering HAP to patients with depression in clinical settings and also training other health workers in the delivery HAP. The total duration of classroom instruction is 6 days.
46100478|NCT04157816|Other|Digital Training|This 4-week digital training program for non-specialist health workers is accessed through a smart phone app and offers instruction in the delivery of the Healthy Activity Program (HAP) in primary care settings. HAP is an evidence-based brief psychological treatment for depression. The digital training covers the same content as the Face-to-Face training. The course includes 16 modules with video lectures, role-play videos, graphics, slide presentations, quizzes, and assessment questions. Participants also receive low-intensity support to enhance their learning experience and sustain engagement, including: 1) access to an automated 'Help Line' that participants can call any time with questions about the program; 2) weekly automated messages sent through the mobile app to encourage participants; and 3) automated messages and phone calls to participants who show prolonged periods of inactivity in the mobile app to offer technical support and help them complete the training program.
46015391|NCT02890719|Drug|Grazoprevir 100 mg/day|Grazoprevir 100 mg/ day 12 weeks
46015392|NCT02890719|Drug|Elbasvir 50 mg/d|Elbasvir 50 mg/day 12 weeks
46015393|NCT02890719|Drug|Grazoprevir 100 mg/day|Grazoprevir 100 mg/day 16 weeks
46015394|NCT02890719|Drug|Elbasvir 50 mg/day|Elbasvir 50 mg/d 16 weeks
46015395|NCT02890719|Drug|Ribavirin 1200 mg/day|Ribavirin 1200 mg/day 16 weeks
46015396|NCT05644275|Other|Data collection (demographic, clinical, functional and biomechanical outcomes in patients after ACL injury (conservative therapy and/or surgery) in patients of different ages and healthy controls)|Analysis of existing data from previous research projects MechSens (EKNZ 2019-01315) and RetroBRACE I and II (EKNZ 2019-00491 and EKNZ 2020-00551) as descriptive statistics (mean, standard deviation, range) for all parameters (for female or male patients with ACL injury and healthy subjects).
45465448|NCT04493671|Drug|TBAJ-876 Dose XXXmg for Food cohort|Based on exposure levels from initial cohorts, a dose will be chosen for the food-effect cohort.
45465449|NCT04493671|Drug|TBAJ-876 XXXmg for Part 2|Part 2, Multiple ascending dose (MAD) cohorts doses to be determined.
45465450|NCT04493671|Drug|Matching Placebo for TBAJ-876 tablet|Matching Placebo for TBAJ-876 tablets, oral suspension, orally administered
45465451|NCT03919721|Behavioral|Applied Behavioral Analysis|Children are receiving Applied Behavioral Analysis therapy to treat their autism. Therapy is comprised of 15-20 discrete programs that are intended to shape specific behaviors. Tutors collect data on child's performance towards goals. For each child, some of the programs will be tracked with paper data collection methods, others will use electronic data collection. This study is to test the usefulness of the electronic data collection system to replace paper in existing interventions.
46015397|NCT04373681|Other|patient-administered questionnaires|patient-administered questionnaires
46015398|NCT04324983|Other|Blood sample|"Additional blood sample of about 30 ml that will be drawn for biomarker analyses (2 EDTA = ethylenediaminetetraacetic acid and 1 Cell-search-tubes).The drawn blood for CTC-Analysis and biomarker identification will be promptly processed ac-cording to the established standards at the Institute for Tumor Biology (see below).~The histological analysis of the resected tissue during salvage surgery is carried out according to clinical routine (conventional haematoxylin and eosin stained and PSMA-Immunohistochemistry). Additionally, tissue samples will undergo molecularpathological analysis if this does not affect routine pathological examination."
46100479|NCT04157816|Other|Coaching Support|Individualized remote coaching is a form of high-intensity support that will be used to help sustain participant engagement in the digital training program and promote success in progressing through the course. Each week, a Coach will phone participants and offer encouragement and support related to the course. The phone call will last no more than 60 minutes. The Coach will be someone who has successfully completed the course, and therefore can offer first hand knowledge of the content. During the coaching session, the coach will review the participants' progress through the course, offer praise and encouragement, discuss any challenges or questions related to the course content, and review the participants' goals and plans for the upcoming week. Each participant will receive a maximum of 4 remote coaching sessions (1 per week over the 4-week training program).
46015399|NCT05644197|Other|Multidisciplinary program|"Multidisciplinary program:~APA interventions: 12 weeks Each week at home, cardio-respiratory endurance sessions for muscle strengthening and balance work from the Autohome interface (Neuradom) and one week supervised by an APA teacher.~Nutrition interventions: A group nutrition workshop at the Hôpital Privé de Provence.~Psychological intervention:~5 sessions of 1h30 in group, the first session will take place at the Private Hospital of Provence and the others by videoconference.~An individual session the week following the last group session.~-Visit with the urologist, 5 weeks after the prostatectomy."
46015400|NCT02893007|Other|Brief family-centered care (BFCC) program|The therapist provided the 4-session BFCC program twice a week for each dyad. The core principles treated family as a single unit and provided individually tailored interventions to improve family function through psychoeducation, social and emotional support, and actively raising questions to facilitate constructive awareness and changes. It was initially held to assess family function, then to provide information about BPD, to support and empower the dyads to change communication styles and resolve conflicts, and to sustain or improve family function in the cognitive, affective, and behavioral domains.
46015401|NCT04325061|Drug|Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily from Day 6 to 10 of randomization
46015402|NCT02893085|Biological|bile sample analysis|tumor mutation profile tumor genotype
45465452|NCT01131611|Behavioral|CBPT|Cognitive-Behavioral Based Physical Therapy
46015403|NCT02893085|Biological|biochemical markers, VEGF and MMPs, in bile samples|
45465453|NCT01131611|Other|Control-Attention|Standard of Care + weekly phone calls
45465454|NCT03815383|Biological|C-CAR088|Autologous BCMA-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.
45465455|NCT03711123|Behavioral|Group metacognitive therapy|10 weekly Group session of 90 minutes duration
45680213|NCT03587116|Drug|Standard of Care FIX Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FIX replacement therapy.
45680214|NCT03587116|Drug|Standard of Care FVIII Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
45465456|NCT03711123|Behavioral|Clinical management|10 weekly individual sessions With clinical management including guided self-help
45680215|NCT03582579|Behavioral|Training in Virtual Reality|Action Video Game Based Training in Virtual Reality
46100480|NCT02704559|Drug|DWC20155|
46015404|NCT01307319|Drug|BDP HFA|BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) nasal aerosol administered as a single actuation in each nostril daily for the 15 day treatment period. Each actuation contains either 40 or 80 mcg for a total daily dose of either 80 or 160 mcg depending upon the assigned treatment arm.
46100481|NCT02704559|Drug|DWC20156|
46100482|NCT02704481|Drug|Mifepristone|200mg oral mifepristone
46100483|NCT02704481|Drug|Misoprostol|800mcg buccal misoprostol
46015405|NCT01307319|Drug|Placebo nasal aerosol|Placebo formulated as a nasal aerosol spray and administered as a single actuation in each nostril daily for the 15 day treatment period.
46015406|NCT04367519|Diagnostic Test|Ultrasound measurement of Optic nerve sheath diameter|Ocular ultrasonography was performed with the patients placed in supine position with closed eyes. A layer of ultrasound gel was applied over the closed upper eyelid and the liner high frequency probe 7 - 12 MHz of SonoSite M-Turbo ultrasound machine was placed on the temporal area of the eyelid with the hand holding it resting on the forehead of the patient. The probe is then adjusted to a suitable angle in order to display the entry of the optic nerve into the globe. ONSD is then measured 3mm behind the globe in the transverse plane perpendicular to the optic nerve. For each eye one measurement will be made and the reported ONSD corresponds to the mean of the two values obtained for each patient. it was performed for all enrolled parturients within 24 hour before delivery and at 24 hour post-delivery.
46015407|NCT05644119|Device|V- loop Bonded Orthodontic Retainer|The V- loop bonded retainer is a unique design that not just provides tooth stability but also allows flossing with ease.
46015408|NCT05644119|Device|Straight Wire Retainer|The straight wire retainer is a fixed bonded orthodontic retainer. This involves attaching a metal wire to the back of the teeth to keep it in position.
46015409|NCT04365725|Drug|Remdesivir|Compassionate provision
46100484|NCT02704481|Drug|Placebo mifepristone|Matching placebo pill of 200mg mifepristone
46100485|NCT02704481|Drug|Placebo misoprostol|Matching placebo pills of 800mcg misoprostol
46100486|NCT04158206|Other|Maternal voice|Recording in the intensive care unit quiet and separate consultation room. For infants in the 'maternal voice group,' mothers were asked to tape what the mother wants to say to their babies and read of a child book from the independent publish, 'Xiao Qi's yellow persimmon' which talk about the mother who has a premature infants how to take caring of their baby. After reviewing the quality of the recording, the mother's voice recordings are compiled for 13 minutes with Sound Organizer. 2 , and the volume of the sound standard according to the American Academy of Pediatrics guidelines is 60 decibels in the incubator.
46100487|NCT03335267|Drug|CPX-351|Cytarabine:Daunorubicin Liposome Injection
45465457|NCT03922373|Drug|Group A: Benzonatate 100mg|Subjects in group A will be given benzonatate 100mg once after a 10-hour fast in the first day of the trail
45465458|NCT03922373|Drug|Group B: Benzonatate 200mg|Subjects in group B will be given benzonatate 200mg once after a 10-hour fast in the first day of the trail, and they will be given benzonatate 200mg thrice in the second and third day of the trail, in the fourth day, they will be given benzonatate 200mg once after a 10-hour fast.
45680216|NCT03582579|Behavioral|Training on a computer screen|Action Video Game Based Training on a computer screen
46100488|NCT04157972|Device|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
45680217|NCT03581227|Other|CAPTURE Tool|CAPTURE Tool: a self administered 5-item questionnaire with peak expiratory flow measurements
45465459|NCT03922373|Drug|Group C: Benzonatate 400mg|Subjects in group C will be given benzonatate 400mg once after a 10-hour fast in the first day of the trail
45680218|NCT03554174|Drug|Low Dose Psilocybin|0.1 mg/kg psilocybin capsule
46100489|NCT04157972|Device|PEP|A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.
46100490|NCT04130412|Procedure|open release|Open release of lateral retinaculae
45680219|NCT03554174|Drug|Placebo|microcrystalline cellulose capsule
46015410|NCT04365335|Behavioral|Assessment of work-related stress|Assessment of burnout, mindfulness, interoceptive awareness, anxiety, post-traumatic stress disorder, coping flexibility and sleep through questionnaires.
46015411|NCT04365335|Biological|Saliva sample collection|Saliva sample is collected before and after emotional stimulation in order to measure resting-state allostatic load biomarkers: DHEA, cortisol and chromogranine A levels
46015412|NCT04365335|Other|Cardiac and electrodermal recordings|Electrocardiogram and electrodermal activity (tonic and phasic) is collected at rest and after emotional stimulation.
46015413|NCT04365335|Behavioral|Assessment of behavioral response to emotional stimulation|"Emotional stimulation involves asking the participants to remember a recent event related to the COVID-19 crisis that has been emotionally difficult for them.~Perceived stress, situational awareness and emotions is assessed after emotional stimulation through questionnaires."
46015414|NCT02892929|Behavioral|Motivational interviewing|"The approach combines the principles of patient-centered care with strategies to motivate the change.~Since the first appointment, Motivational Interviewing techniques will be used aiming to work the ambivalence that is to seek treatment and modify the unhealthy behavior. From the second encounter until the appointment of 120 days, the participants will be subjected to individual encounters in which the MI approach will be applied focusing on behavior change."
46015415|NCT02892929|Behavioral|Prescriptive Consultation|Prescriptive consultation is the Methodology usual consultation, in which the patient has little room to express themselves and the health professional who determines what and how the patient will hold the care of your health.
46015416|NCT04328051|Other|Dental Implant Placement|Antibiotic prophylaxis will be done. After rinsing with 0.12 % chlorhexidine, patients will receive local anaesthesia. A crestal incision will be done and a mucoperiostic flap will be raised. As the commercial specifies, progressive diameter drills will be used under constant sterile saline irrigation to prepare the implant site. Once finished the drilling sequence, one investigator will open the opaque envelope to know which type of implant, depending on the connection, has to be placed by the surgeon. Dental implant will be placed crestally and depending if it has primary stability or not, it will be leaded submerged or non-submerged. The flap will be repositioned and sutured without tension with 4/0 polyamide. Postoperative instructions and medication will be prescribed and explained.
46015417|NCT01080391|Drug|Dexamethasone|40 mg orally or IV on days 1, 8, 15, 22
46015418|NCT01080391|Drug|Lenalidomide|25 mg orally on days 1-21
46015419|NCT01080391|Drug|Carfilzomib|20 mg/m², 27 mg/m² intravenously
46015420|NCT04359407|Other|Prone positioning|Change the positioning of the COVID patients who are intubated and mechanically ventilated from supine to prone
46015421|NCT00592397|Other|Balanced macronutrient diet intervention|Isocaloric dietary changes from typically Western diet to balanced macronutrient composition.
46015422|NCT04356365|Other|Cross-sectional study investigating the association of NPIs with mental health|Cross-sectional study investigating the association of NPIs with mental health
46100491|NCT02704325|Biological|rAAVrh74.MCK.GALGT2|Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the other side receiving saline alone.
46100492|NCT02704325|Other|PLACEBO (Saline)|Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the OTHER side receiving saline alone.
46100493|NCT04160702|Behavioral|Motivate-The-Bystander (MTB)|MTB is a motivational interviewing intervention designed to increase bystander intervention behaviors. During MTB, participants will discuss their knowledge and experiences with bystander intervention. Participants will then create a plan to increase their bystander intervention behaviors in the future. The interviewer will utilize a variety of motivational interviewing techniques to help guide the conversation towards change (e.g., asking questions in an open-ended manner, reflecting participants' personal values).
46015423|NCT04327817|Device|Multifidus stimulator|"Patient eligible for the study and have provided consent will have a baseline PET scan. Multifidus ReActiv8 Stimulator will be inserted using standard treatment for lumbar pain at Barts Health NHS Hospitals.~All patients who receive the Reactiv8 system will continue to receive multifidus stimulation 20Hz for the next 6 months as per standard of care of multifidus stimulation; at the end of this period, the patients will undergo PET scanning and questionnaires. Thereafter, stimulation will continue and 3rd PET scan will be performed at 1year post implant."
46100494|NCT04130256|Device|Electronic Pill Bottle|Electronic bottles that can beep and blink to send medication use reminders, record medication use data, and upload medication use data to a secure server.
46100495|NCT02704247|Device|CARDIOSPACE System|"autonomic nervous system test~tilt test~ultrasound exploration at rest (heart / vessels)~laser doppler + iontophoresis test~sub-maximal exercise test"
45680220|NCT03554174|Drug|Medium Dose Psilocybin|0.3 mg/kg psilocybin capsule
45465460|NCT03812497|Behavioral|Individualized Education Program|The every participants will have individualized education program about a way of dietary control and exercise in their usual life.
46015424|NCT04747483|Other|Extension Oriented Treatment Approach|"The EOTA intervention involves three components.~The first component is a series of active extension- oriented exercises:~Prone lying: Able to tolerate for 5 minutes, no pillow Prone lying on elbows: Able to tolerate for 5 minutes Prone press up exercise: 3 sets of 10 repetitions, move to end-range extension Repeated extension in standing: 3 sets of 10 repetitions, move to end-range extension The second component of the EOTA is subject education. Subjects are educated to maintain the natural lordosis of the lumbar spine while sitting, and are instructed to avoid prolonged sitting for greater than 20-30 minutes whenever possible.~The third component of the EOTA is mobilization of the lumbar spine to promote lumbar extension. The mobilization component consist of a series of up to 20 graded oscillatory mobilizations performed with the subject prone by using a grade I - IV mobilization force as described by Maitland."
46100496|NCT04156568|Drug|INH、RFT|6INH 10mg/kg 3INH+RFT 15mg/kg
46100497|NCT04478071|Drug|vadadustat|Participants will receive vadadustat once daily for 14 days.
46100498|NCT04478071|Drug|placebo|Participants will receive matching placebo once daily for 14 days.
45680221|NCT03540680|Other|Blood punction|"For the arms Term newborns (≥37GA) and Premature newborns the only intervention is a blood punction on the cordon.~For the arms Child between 7 and 15 years old with or without BPD the only intervention is a blood punction on peripheral blood."
45680222|NCT03530969|Behavioral|Self-Efficacy Assessment|"Health Care Professional's self-efficacy will be assessed by 12 ratings of self-reported confidence from (1) strongly disagree to (5) strongly agree in module-specific topics both before and after the training."
45680223|NCT03530969|Behavioral|UCLA Geriatrics Attitudes Scale|The UCLA Geriatrics Attitudes Scale is a 14-item scale developed to assess health care providers' attitudes toward older persons and caring for older patients.
46015425|NCT04747483|Other|EOTA+ Traction|"Subjects in the EOTA + traction group receive the EOTA components described above with Mechanical lumbar traction.~Intermittent traction being applied (30-sec hold, 10-sec rest) for 15 minutes. Traction started with 25% of the patients' body weight and increased until the patient indicated that the tolerance for pulling was reached, with a maximum of 50% of the total body weight.~2 sessions being given per week for 3 weeks."
46015426|NCT04351451|Procedure|thyroidectomy|total thyroidectomy
46015427|NCT04350983|Behavioral|Increased physical activity|PAP and enhanced individual support by physiotherapist to increase physical activity
46015428|NCT04348721|Other|online survey|"An online survey including 8 case-vignettes was sent to international liver transplant surgeons who had published on liver transplantation. The first part is related to surgeon's own experience. In the second part, the surgeons were asked to rate the difficulty of various situations in liver transplantation on a scale of 1 to 10 (level 1 was labeled as easier, and level 10 was labeled as difficult). In the third part, 8 case-vignettes corresponding to 8 clinical real-life situations are submitted to experts"
46015429|NCT04327739|Other|Intervention 1 Exercise|• Exercise programme Endurance and Resistant training exercise program (Duration: 45 minutes) • Muscle retraining of longus colli and endurance training of the deep cervical flexors. • Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM). • Active ROM exercises for the neck muscles • Upper limbs exercises with resistant bands • Stretching exercises for the neck and upper limbs muscles
46100499|NCT04215575|Device|glaucoma implant procedure (Baerveldt)|A 350 mm2 Baerveldt glaucoma implant was placed in the superotemporal quadrant in 25 patients randomized to BGI group. A limbus-based conjunctival flap was dissected, and the implant was sutured to sclera 10 mm posterior to the limbus. A scleral graft was used to cover the limbal portion of the tube, and the conjunctiva was closed.
46100500|NCT04215575|Device|glaucoma implant procedure (Ahmed)|A 184 mm2 Ahmed glaucoma implant was placed in the superotemporal quadrant in 56 patients randomized to AGV group. A fornix-based conjunctival flap was dissected, and the implant was sutured to sclera 10 mm posterior to the limbus. The Ahmed tube left patent and viscoelastic substance injected into anterior chamber. A scleral graft was used to cover the limbal portion of the tube, and the conjunctiva was closed.
46100501|NCT02614482|Drug|Fesoterodine|Administer medication to patients with overactive bladder
46100502|NCT04148027|Other|Treatment recommendation by emergency department physicians|Standard treatment after admission in the emergency department from a team of residents in internal medicine, neurology and general surgery.
46100503|NCT04148027|Other|Treatment recommendation by telemedical geriatric co-evaluation|Treatment recommendation from a board-certified geriatrician linked for co-evaluation by means of video transmission
46100504|NCT04130334|Procedure|After mechanical trephination, horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea|After mechanical trephination, horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea
45465461|NCT03922295|Procedure|Endoscopic tympanoplasty|"In the double flap group, graft is placed via elevation of both posterior and anterior flaps.~In the single flap group, graft is placed via elevation of posterior flap only"
46015430|NCT04327739|Other|Intervention 2 Exercise and INIT|"Exercise programme same as Intervention Group 1 and~Integrated Neuromuscular Inhibition Technique application. Integrated Neuromuscular Inhibition Technique application. (Duration: 15min) The protocol was applied to the following muscles: • Upper border of the trapezius muscle • sternocleidomastoid • levator scapulae muscle • splenius capitis muscle Integrated Neuromuscular Inhibition Technique includes the combination of the following technique: • Ischemic compression • Muscle energy technique • Straincounterstrain technique"
45342518|NCT00855556|Genetic|blood draw|"The blood collection is designed to obtain blood samples as a source of DNA for genotyping and to establish a plasma and serum storage repository for future assays. GCRC nurses will perform all blood draws associated with this study. The following procedures are designed to standardize sample collection:~Blood will be collected with the participant in the seated position with the reclining position reserved for those with a history of fainting during blood collection.~Participants will be instructed to drink plenty of water (e.g., at least 8 large glasses of water) prior to the clinic visit as this facilitates easier collection.~No fasting, activity or medication restrictions are required prior to or following blood collection.~Blood collection will follow completion of the questionnaires. They will be performed by a nurse or technician with documented class time and experience in phlebotomy. Technician certification will occur prior to blood collection."
45342519|NCT00711126|Drug|GW642444|2.5mcg IV
45465462|NCT03711045|Behavioral|eye-tracking|"After completing a demographics form, theBeck Depression Inventory,Beck Anxiety Inventory,Barratt Impulsiveness Scale and Ruminative Response Scale-21, each participant has to go to the eye-tracking room and seats in a height adjustable chair and places their chin in a chin rest which was positioned to make sure all participants' eye are in the same location relative to the camera and the monitor.~There are 18 trials and 2 filler trials in the free-view task, each of which contains 4 pictures on the same screen for 25 seconds. There is also a gap screen between each trial lasting for 2 seconds when participants were asked to fixate in the center of the screen. During the experiment, participants are instructed to watch the screen as naturally as possible, and the initial location of the fixation of each trial and the total dwell time of each emotional images(negative, happy, neutral and suicide-related)and the changes of the pupil size were recorded."
45465463|NCT03709719|Drug|Blinatumomab Injection|Blinatumomab 28 μg/day : D1 to D28
45465464|NCT03921983|Other|Oxygen supplementation|short term O2 supplementation during 1 hour
45465465|NCT03709641|Device|Restylane Defyne|Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL
46015431|NCT04327739|Other|Intervention 3 Exercise and SMT|"Exercise programme same as Intervention Group 1 and~Manipulation Care. Participants allocated to this group received Spinal Manipulation Therapy after the therapeutic exercise programme. Treatment was delivered by 1 chiropractor with a minimum 5-year experience of clinical practice. Pain provocation and static/motion palpation findings were used to determine areas of treatment in the cervical spine. The Manipulation Therapy technique included joint motion using a diversified thrust technique, and mobilization, a low-velocity type of joint oscillation. The type and the force of the applied spinal manipulation were individualized according to the age and physical condition of each participant. Soft passive stretching, light massage and hot packs were applied to the cervical and upper thoracic area before manipulation in order to prepare each participant."
45342520|NCT00711126|Drug|GW642444|5mcg IV
45342521|NCT00711126|Drug|GW642444|10mcg IV
45342522|NCT00711126|Drug|GW642444|100mcg inhaled
45342523|NCT00711126|Drug|GW642444|20mcg IV
45342524|NCT00711126|Drug|GW642444|500mcg oral
45342525|NCT02545036|Other|Traditional Chinese Medicine (TCM) daycare model|Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
45342526|NCT02544958|Device|Er:YAG laser|Er:YAG laser treats enlarged pores on both sides of the face for 4 treatments of 1 month interval.
45342527|NCT00715572|Drug|thyroxine|monotherapy with thyroxine
46015432|NCT04327739|Other|Control|Participants allocated to this group received general consulting istructions and a home based general exercise sheet
46015433|NCT01070329|Drug|Duloxetine|Participants received 30 milligrams (mg) duloxetine once daily (QD) by mouth (po) for 1 week, followed by 60 mg QD po for 7 weeks. Participants were given the option to take duloxetine 30 mg QD, po for a 2-week taper phase.
46015434|NCT01070329|Drug|Placebo|Participants received placebo QD, po for 8 weeks, followed by placebo QD, po during the 2-week taper phase.
46015435|NCT04327661|Drug|Tradipitant High Dose|Oral Capsule
46015436|NCT04327661|Drug|Tradipitant Low Dose|Oral Capsule
45342528|NCT00715572|Drug|thyroxine and triiodothyronine|combination with thyroxine and triiodothyronine
45342529|NCT02573298|Device|ice|local ice application for 30 minutes
45342530|NCT02573298|Device|cold gas|local cold gas application for 2 minutes
45342531|NCT00845260|Behavioral|Internet-based cognitive behavior therapy (CBT).|Self-help program and guidance by psychologist via e-mail during 10 weeks.
45474002|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive 30gr/day rapeseed oil. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
45342532|NCT00845260|Behavioral|Group CBT|Group cognitive behavior therapy (CBT) during 10 weeks.
45342533|NCT00715806|Device|Open MRI scanner.|Imaging in an Open MRI scanner.
45342534|NCT00715806|Device|Closed MRI scanner.|Imaging in a short-bore closed MRI scanner.
45342535|NCT00851500|Drug|K-604|K-604 is given for 26 weeks
45465466|NCT05166070|Drug|RD133|The enhanced MSLN-CAR-T cell design of this study is obtained by co-infecting T cells with two lentiviral vectors. One lentiviral vector expresses CD19-CAR and tEGFR molecular safety switch, and the other lentiviral vector expresses MSLN- CAR and dnTGFβRII receptors. dnTGFβRII receptor without intracellular signal is used to resist the inhibition of T cell function by the immune microenvironment of tumor tissue. In addition, for the safety of CAR-T cell application in vivo, tEGFR is used in the CAR design as a molecular safety switch for CAR-T cells.
45465467|NCT03926663|Drug|Dexmedetomidine|"Dexmedetomidine, a potent α-2 adrenoceptor agonist, is approximately 8 times more selective toward the α-2 adrenoceptors than clonidine.~Patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) + 0.2 μg/kg dexmedetomidine preincisional local infiltration of the nasal mucosa."
45465468|NCT03926663|Drug|Bupivacaine|patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) preincisional local infiltration of the nasal mucosa.
46015437|NCT04327661|Drug|Placebo|Oral Capsule
46015438|NCT01069861|Drug|sildanefil|Intravenous sildenafil citrate will be administered as a loading dose of 0.1 mg/kg given over 30 minutes. This will be followed by a maintenance treatment consisting of an intravenous infusion of 0.03 mg/kg/hr. The duration of the infusion will be determined by the need of the individual patient, but will be reviewed at Day 7 if still ongoing, and will not continue past Day 14.
46015439|NCT04344197|Other|global survey|surgery questionnaire
46015440|NCT02892851|Device|Deep brain stimulation of the subthalamic nuclei (STN-DBS)|"3 phases :~Parameter setting~Cross-over double-bind (ON/OFF)~Open Phase (ON)"
46015441|NCT04304521|Procedure|Lung recruitment maneuver|Lung recruitment maneuver is used to reopen or prevent collapsed lung under mechanical ventilation so as to decrease respiratory complications. LRM induces a transient increase in intra-thoracic pressure and decreases in venous return, leading to a decrease in left ventricular end-diastolic area and stroke volume.
46015442|NCT04327427|Other|Aspirin|Outcome Analysis of Aspirin in liver transplantation
46015443|NCT02875405|Procedure|Posterior left pericardiotomy|Patient will receive a posterior left sided pericardiotomy. The incision will be made posterior to the phrenic nerve and run from the inferior left pulmonary vein to the diaphragm.
46015444|NCT04342481|Other|Educational Screening tool|Educational Screening tool
46015445|NCT04306549|Other|Bulk-Fill and Microhybrid Composite Resins|Clinical Comparison of Composite Restorations (Two Bulk-Fill and one Microhybrid Composite Resin) to the USPHS Criterias
46015446|NCT04338347|Biological|CAP-1002 Allogeneic Cardiosphere-Derived Cells|Extracellular Vesicles (EVs) from Cardiosphere-Derived Cells (CDCs)
46015447|NCT02875717|Drug|Acetylsalicylic acid|
46015448|NCT02875717|Drug|low molecular weight heparin|
46015449|NCT04337957|Other|geriatric nephrology|Collection of the geriatrician's opinion
45342536|NCT00851500|Other|Placebo|placebo tablets are given for 26 weeks
45465469|NCT05481775|Drug|Anlotinib|Anlotinib 8mg qd po. Taking anlotinib daily for 2 weeks and stop for 1 week.
45465470|NCT05481775|Drug|Chemotherapy|Docetaxel 25mg/m2 + Cisplatin 25mg/m2 QW
45465471|NCT05481775|Radiation|Radiotherapy|Thoracic radiotherapy was delivered using the daily image-guided intensity modulated radiation therapy (IMRT) technique. The total radiation dose was 66-68 Gy to the gross tumor in 17-22 daily fractions.
46015450|NCT02875639|Drug|Yiqi prescription|
46015451|NCT02875639|Drug|Huoxue prescription|
46015452|NCT02875639|Drug|Buyang huanwu decoction|
46015453|NCT02875639|Drug|QISHEN YIQI DRIPPING PILLS|
46015454|NCT02875639|Drug|Placebo 1|Placebo 1：a drug which imitated QISHEN YIQI DRIPPING PILLS,but do not have active ingredient,just have the excipient.
46015455|NCT02875639|Drug|Placebo 2|Placebo 2：a drug which imitated Buyang huanwu decoction,but do not have active ingredient,just have the excipient.
45465472|NCT05481775|Drug|Immunotherapy|consolidation Immunotherapy (Tislelizhu 200mg iv. drip, Q3W, up to 12 months.)
45465473|NCT03711981|Procedure|TAP Block|
46015456|NCT04334837|Diagnostic Test|Copper Cu 64 Dotatate|The drug product contains Copper Cu 64 Dotatate filled in a glass vial, closed with butyl rubber stopper secured with an aluminum crimp seal. The drug product will be delivered by Curium to the clinical site. The EAP drug will be administered as an intravenous bolus injection. The dose will be administered according to the schedule detailed in the protocol.
46100505|NCT04130334|Procedure|: After mechanical trephination, horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea|: After mechanical trephination, horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea
46100506|NCT04713709|Combination Product|Nasus Pharma FMXIN001|A nasal spray of 4mg Naloxone Hydrochloride powder in a unit dose device
46100507|NCT04713709|Combination Product|Nasal Naloxone liquid spray|A nasal spray of 4mg/0.1mL Naloxone Hydrochloride solution in a unit dose device
46100508|NCT00879710|Drug|simvastatin or ezetimibe|Subjects will be started on either simvastatin or ezetimibe (we will alternate the subjects so that half the sample will initially be treated with simvastatin and half will be started on ezetimibe). The dose of Simvastatin (Merck) is 40 mg orally at nighttime for 6 weeks and the dose of ezetimibe (Schering-Plough) is 10 mg taken orally once a day. Subjects will be instructed on low-fat diet (therapeutic life style changes diet) recommended by American Heart Association by the bionutritionist.
46015457|NCT04741711|Procedure|An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava.|An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava. The choice of congestion treatment modalities to be implemented is left to the investigators' discretion, in accordance with European practice guidelines.
46015458|NCT04741711|Procedure|Usual care without ultrasound guidance|Usual care (i.e. without ultrasound guidance)
46015459|NCT04327349|Biological|Convalescent Plasma|Intervention to evaluate convalescent plasma transfer to COVID-19 patients admitted to ICU
46015460|NCT04333121|Other|weight|we can monitoring the growth of the infants by weight gain degree
46100509|NCT02703857|Drug|cefoxitin|Parenteral administration of 2g of cefoxitin at least 30 minutes before incision and then every 2 hours until closing
46100510|NCT04130178|Drug|Nerve block|block of the digital nerves in rheumatoid arthritis patient
46100511|NCT04130178|Drug|Saline injection|subcutaneous saline injection
46100512|NCT02703935|Behavioral|health talk and adventure-based training|To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included an associate professor, an assistant professor and a research student at a local university, a pediatric oncologist and oncology nurse and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer survivors.
46100513|NCT02703935|Behavioral|Placebo Control|They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museums and theme parks and galleries
45465474|NCT05389384|Device|Passive shoulder exoskeleton|Participants complete overhead working task with support of exo
45465475|NCT05389384|Behavioral|Fatigue protocol|Participants complete a fatiguing protocol
45465476|NCT05389384|Device|No exoskeleton support|Exoskeleton is worn, but no support provided
45465477|NCT05389384|Behavioral|No peripheral fatiguing protocol|Participants complete no fatiguing protocol
45465478|NCT01130285|Genetic|Lung Cancer Risk Test|Measurement of gene expression in normal bronchial epithelial cells obtained at time of bronchoscopy.
46015461|NCT04331015|Diagnostic Test|Pure tone audiometry|pure tone audiometry
46100514|NCT01565161|Behavioral|Home-Based Health Coaching|"The 6-month intervention arm consists of 3 components:~In-home coaching visits with a health educator trained in motivational interviewing to encourage behavior change. In addition to 4 monthly in-home coaching visits, participants receive 4 monthly coaching phone calls to supplement the in-person visits.~Use of mobile technology to deliver health information by text message - participants receive messages twice weekly for 16 weeks and then weekly for 8 weeks of the program. Those without a phone capable of receiving text messages receive postcards by mail.~Printed materials, including educational handouts, newsletters, and activities highlighting target behaviors, sent monthly for 4 months."
46100515|NCT01565161|Behavioral|Mailed materials|"We designed materials for our control group focusing on Developmental milestones during early childhood to provide information that participants would find relevant and helpful for parenting, but that would also not influence intervention behaviors, such as TV viewing or household routines related to sleeping, eating, or television viewing.~Participants received 4 monthly mailing packages, each focusing thematically on one of four milestone domains: motor, language, cognitive and social/emotional. Educational materials were adapted from the Center for Disease Control's Positive Parenting Tips for Healthy Child Development, and the mailing included child-appropriate incentives to reinforce the concepts presented in the educational materials."
46100516|NCT02623062|Drug|Compound Sodium Alginate Oral Suspension sachet|Contents of 2 sachets taken four times daily for 7 days
46100517|NCT02623062|Drug|Matched placebo|Contents of 2 sachets taken four times daily for 7 days
46100518|NCT04135638|Procedure|Cover Group|"Cover when the ILM flap is everted over the MH gap in a single layer"
46100519|NCT04135638|Procedure|Fill Group|"Fill when the ILM is folded into multiple layers within the MH"
46015462|NCT00593099|Drug|Bupropion|BUP [as the intermediate-release (IR) formulation] was inducted on Day 1 of the trial at 75 mg po qd x 3 days, then increased to 150 mg [as BUP SR formulation] qd x 4 days, and then increased to a final dose of up to 150 mg po bid (300 mg/day) by Day 15 (target quit date; TQD) as tolerated. This dose was continued for an additional eight (8) weeks at up to 150 mg po bid. Flexible dosing was permitted to allow for adjustments needed if a bipolar subject did not tolerate the full dose of BUP at 300 mg/day. BUP was discontinued at the end of Week 10.
46015463|NCT00593099|Drug|Placebo|matching placebo capsules (PLA) containing only a dextrose matrix.
46015464|NCT00593177|Drug|PTH (1-34) Gel / Placebo Gel|Topical dosing of gel twice daily for eight weeks.
46100520|NCT00597506|Drug|Bevacizumab|10 mg/kg intravenous bevacizumab given days 1 and 15 of each cycle
45342537|NCT00711204|Drug|Donepezil Hydrochloride (Aricept)|5mg (or 10mg) tablet, once daily, with a full glass of water.
46015465|NCT00593255|Drug|soluble human insulin|
46015466|NCT00593255|Drug|insulin aspart|
46015467|NCT00593255|Drug|insulin NPH|
45465479|NCT03710967|Device|Transcranial magnetic stimulation|Transcranial magnetic stimulation of the primary motor cortex
45465480|NCT01132079|Drug|cream treatment|
45465481|NCT05165914|Drug|Intravenous midazolam before emergence from general anesthesia|Intravenous administration of 0.03 mg/kg midazolam just before emergence from anesthesia.
45465482|NCT05165914|Drug|Intravenous normal saline before emergence from general anesthesia|Intravenous administration of normal saline just before emergence from anesthesia.
45465483|NCT04420975|Procedure|Definitive Surgical Resection|Undergo definitive surgical resection
45465484|NCT04420975|Biological|Nanoplexed Poly I:C BO-112|Given intratumorally
45465485|NCT04420975|Biological|Nivolumab|Given IV
45680224|NCT03530969|Behavioral|Course Evaluations|The evaluation surveys for each of the three modules will contain fifteen statements assessing post-training attitudes regarding the skills learned and application of skills in oncology clinical practice, measured on a 5-point Likert scale.
45465486|NCT04420975|Radiation|Radiation Therapy|Undergo radiation therapy
45465487|NCT01132157|Drug|Desflurane|In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
45465488|NCT01132157|Drug|Propofol|In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
45680225|NCT03530969|Behavioral|The Consultation and Relational Empathy (CARE) questionnaire|The Consultation and Relational Empathy (CARE) questionnaire is a 10-item self-report scale that measures a patient's satisfaction with how empathic their health care providers (HCP) was within a specific consultation.
46100521|NCT00597506|Drug|Everolimus|10 mg Everolimus(RAD001) daily by mouth, days 1-28
46100522|NCT03393611|Drug|CPX-351|Salvage Chemotherapy: CPX-351 at 120 u/m2 on Days -21, -19, and -17
45465489|NCT05389150|Drug|Fixed dose combination Pregabalin 150 mg / Tramadol 50 mg|Pregabalin/Tramadol (Laboratorios Silanes S.A. de C.V.), Pharmaceutical Form: Tablet Dosage: 150 mg / 50 mg Administration way: oral
46015468|NCT02892773|Device|Incentive Spirometry|"A respiratory therapist will provide instruction on Incentive Spirometry (I.S.) procedure performance before supervised therapy and monitoring begins.~Study participants will be asked to take 10 deep breaths through the I.S.'s mouthpiece, followed by a 60 second pause.~The 10-breath cycle will be repeated 3 times per therapy session.~Each I.S. therapy session will last about 15 minutes, 3 times per day.~Lung monitoring and deep breathing measurements will occur during a scheduled I.S. sessions on day 1, 3, and 5 after surgery."
46100523|NCT03393611|Drug|Fludarabine|Fludarabine 150 mg/m2 (30 mg/m2/day x 5 days, Day -7 to Day -3)
46100524|NCT03393611|Drug|Melphalan|Melphalan 140 mg/m2 (Day -2)
46100525|NCT03393611|Drug|Rabbit Anti-Human T-Lymphocyte Globulin|Rabbit ATG (rATG)-thymoglobulin 4.5 mg/kg (1.5 mg/kg/day x 3 days)
46100526|NCT03393611|Biological|Haplo-Cord Stem Cell Transplantation|Allogeneic stem cell transplantation using a haploidentical donor and umbilical cord blood unit.
46100527|NCT00698412|Device|Cane|This group use the cane every day since the baseline
45837767|NCT05765201|Other|Low IOP|Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 28mmHg (low IOP) in one eye and with IOP ≥ 60mmHg (high IOP) in the other eye
45465490|NCT05389150|Drug|Pregabalin 150mg|From Pfizer S.a. de C.V. Pharmaceutical Form: Capsule Dosage: 150 mg Administration way: oral
45465491|NCT05389150|Drug|Tramadol 50 mg|From Grünenthal de México, S.A. de C.V. Pharmaceutical Form: Capsule Dosage: 50 mg Administration way: oral
45837768|NCT05765188|Other|loop electrosurgical excision procedure|A retrospective study of 115 women who underwent both loop electrosurgical excision procedure (LEEP) and subse- quent pregnancy follow-up in a referral center was conducted.
45837769|NCT05765162|Behavioral|Patient reported ourcomes|Full screening for the perioperative periode
45837770|NCT05765149|Other|No intervention|This is an observational study, no intervention will be implemented.
46015469|NCT02892773|Device|EzPAP® Positive Airway Pressure|"A respiratory therapist will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins.~Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.~The 10-breath cycle will be repeated 3 times.~Each EzPAP® therapy sessions will last about 15 minutes, 3 times per day.~Lung monitoring will occur during a scheduled EzPAP® sessions on day 1, 3, and 5 after surgery."
46015470|NCT00593723|Radiation|IMRT|
46100528|NCT04157582|Other|Pilates training|"Pilates warm-up training (5 minutes) consisted of Breathing, the Chest stretch, the Toy soldier, Upper extremity PNF patterns, and Roll down.~Pilates mat training performed in 5 different positions (30 minutes).~One leg stretch, Hundreds, the Double leg stretch, Scissors, the Shoulder bridge, Oblique preparation, and the Hip twist were performed in the supine position(Fig.7).~Clare, the Side kick, Arm openings, the Lower lift, Leg lifts, and the Side bend were performed in the side-lying position.~Swan dive, the One leg kick, Swimming, the Breast stroke preparations, the Breast stroke performed in the prone position(Fig.8).~Half roll back, Oblique roll up were performed in the sitting position.~Swimming was performed in the kneeling position.~The Pilates cool down training (5 minutes) were the Spine stretch, Saw, Chest stretch, Toy soldier. (Cruz et al .,2011)"
46100529|NCT04157582|Other|Conventional physical therapy|"Gentle manual stretching exercises for (elbow flexors, wrist flexors , hamstring and calf muscle).~Strengthening Exercises for ( elbow extensors, wrist extensors and dorsiflexors)~Balance training (Wobble board training) :~Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror with hand support(with repetition 10times)~Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror without hand support(with repetition 10times)."
45465492|NCT03926351|Dietary Supplement|Omega-3 capsules|BASF AS is the developer of the gelatine capsules containing Omega-3 ethyl ester from fish oil concentrate, as the dietary (nutritional) ingredient. The additional capsule fill ingredients are food additives permitted in food supplements according to Regulation (EC) No 1333/2008 on Food additives.
45465493|NCT03926351|Dietary Supplement|Olive oil|Soft gelatine capsule containing 1000 mg olive oil, refined.
45680226|NCT03530969|Behavioral|Consumer Assessment of Health Care Providers and Systems Program (CAHPS)|"Patients perceptions of the quality of their interactions with their clinicians will be rated with 6 items from the Consumer Assessment of Health Care Providers and Systems Program (CAHPS)"
45680227|NCT03530969|Behavioral|Patient activation measure (PAM) scale|The PAM scale contains 22 items that assess patient engagement in their care process.
45465494|NCT03806101|Drug|PF-04965842|200 mg dose of PF-04965842 once daily (QD) for 3 days
45465495|NCT03806101|Drug|Rosuvastatin|Single 10 mg dose of rosuvastatin
45465496|NCT03812419|Drug|Esomeprazole 40 mg|Esomeprazole 40 mg In addition, the immunosuppressant combination of CsA (Sandimmune; Novartis, East Hanover, NJ, USA), MMF (Cellcept; Roche, Basel, Switzerland) and the corticosteroid prednisolone (Solupred; Sanofi Aventis, Tours, France).
45680228|NCT03516708|Drug|Epacadostat|Patients will receive epacadostat at the designated dose level starting the day of radiation therapy, throughout the chemotherapy, and until the day of surgery. If the patient dose not proceed with the surgery, epacadostat will be discontinued after the last biopsy is performed, and after the investigator confirms non-operative management plans.
46015471|NCT00593801|Drug|epoetin beta|250 IU/kg/week rhEPO treatment subcutaneously 3 times a week from the first week for 9 weeks, all infants received enteral iron 3-9 mg/kg/day
46015472|NCT00593801|Drug|epoetin beta|250 IU/kg/week subcutaneously 3 times a week, from the fourth week for 6 weeks, all infants received enteral iron 3-9 mg/kg/day
46015473|NCT00593879|Drug|Mecamylamine|2.5mg mecamylamine Hcl, tablet form taken twice a day (total of 5.0mg). For 7.5 mg dose group, 2 tablets taken morning, one tablet evening. At 10.0mg, 2 tablets taken twice daily.
46015474|NCT00594113|Other|Touch 2 Screen|"Multi-media presentation and survey to increase screening for colorectal cancer. Content of this presentation is based on the concept of implementation intentions, an advanced planning model taken from the Theory of Planned Behavior"
45465497|NCT03812419|Drug|Pantoprazole 40mg|Pantoprazole 40 mg In addition, the immunosuppressant combination of CsA (Sandimmune; Novartis, East Hanover, NJ, USA), MMF (Cellcept; Roche, Basel, Switzerland) and the corticosteroid prednisolone (Solupred; Sanofi Aventis, Tours, France).
46100530|NCT03689023|Other|A controlled multimodal intervention|The intervention is interdisciplinary, multimodal and patient activating and uses the existing setting and work flows at the Clinic as well as new interventions, ensuring that the patients receive education about cardiovascular risk factors, physical activity and healthy diet through a systematic approach including targeted patient education
45465498|NCT05373550|Behavioral|Effectiveness of a nursing educational intervention on quality of life, sexual function, and self-esteem in hysterectomized women: a mixed method approach.|Effectiveness of a nursing educational intervention supported by a technological tool (Libre mujer), on quality of life, sexual function and self-esteem in hysterectomized women: a mixed method approach.
45837771|NCT05765123|Other|Oral glucose tolerance test|A drink containing 75g of glucose together with 150mg carbon-13 sodium acetate in 300ml water
46015475|NCT00594113|Other|Touch screen intervention|Touch screen intervention
46100531|NCT02622984|Behavioral|RBIRT|Intervention group will receive the telehealth or remote behavior intervention and referral for substance use (RBIRT). Other group will receive treatment as usual which is SBIRT.
46100532|NCT02622984|Behavioral|SBIRT|"Face to face standard intervention considered treatment as usual."
46100533|NCT04032548|Drug|Placebo mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
45465499|NCT01132235|Biological|etanercept|50mgs subcutaneous injections twice a week for 12 weeks
45465500|NCT01302301|Procedure|Per oral endolumenal myotomy|flexible endoscopic submucosal esophageal partial myotomy
45837772|NCT05765110|Other|Dopaminergic OFF drug state|Experiment will be performed without dopaminergic medication
45837773|NCT05765110|Other|DBS OFF state|Turning off the stimulation during experiment
46015476|NCT00594191|Drug|Simvastatin|20 mg/day p.o., increased to 40 mg/day at day 15 if no safety end-point was met
46015477|NCT00594191|Drug|Placebo|Placebo with the same characteristics of the drug and at the same dose
45342538|NCT04042870|Behavioral|Joint Loosening Yoga|Sukshma Vyayama Joint Loosening Yoga was practiced Monday - Friday for four weeks. Each session included twelve joint loosening exercises performed in a chair, each performed 10 times with mindful awareness of physical movements and breath synchronization. Sessions lasted 15 minutes.
45837774|NCT05765110|Other|Dopaminergic ON drug state|Experiment will be performed with dopaminergic medication
45837775|NCT05765110|Other|DBS ON state|Experiment will be performed with stimulation (ON condition)
46015478|NCT00594269|Drug|Risperidone|Discontinuation
46015479|NCT00594269|Drug|Escitalopram|Discontinuation
46015480|NCT00594269|Drug|Citalopram|Discontinuation
46015481|NCT00594269|Drug|Sertraline|Discontinuation
46015482|NCT00594269|Drug|Paroxetine|Discontinuation
46100534|NCT04032548|Drug|Propolis mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
46100535|NCT04032548|Drug|Chlorhexidine mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
46015483|NCT00594347|Biological|Pneumo 23|Vaccine (Pneumo 23)
46100536|NCT02373683|Device|Vapotherm-Heliox|Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.
46015484|NCT00594347|Biological|Prevnar|Vaccine (Prevnar)
46015485|NCT04326959|Biological|Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium|Injection of Allogeneic Umbilical Cord Mesenchymal Stem Cells 2 million cell/cm3 in Nacl 1 cc/million cell and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
46015486|NCT04326959|Biological|Conditioned Medium|Injection of Conditioned Medium 1 cc/cm3 and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
46015487|NCT04326959|Biological|Triamcinolone Acetonide|Injection of Triamcinolone Acetonide 40 mg/cc/cm3 and booster in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
46015488|NCT01306929|Drug|pridopidine|45mg bid
46100537|NCT02633072|Device|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AMO® Tecnis® multifocal intraocular lenses with an addition of +2.75 D in the distance-dominant eye and +3.25 D in the fellow eye.
46015489|NCT02892617|Other|Bacteriological analysis of disc|
46015490|NCT02892695|Biological|anti-CD19 CAR-NK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD19 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD19.
46100538|NCT04032236|Other|caffeine|At room temperature (18-25 ° C) the same place and standard environment will be done. All involved cases will undergo a dental examination and within 30 minutes three samples of saliva will be taken, including first sample, after coffee drink and after drinking water. The pH of samples will be measured and the smoking cessation rate of the smoking cigarette smoker with simultaneous VAS (VISUAL ANALOG SCALA) will be measured. This data will be compared in-house and non-smoking control group
46100539|NCT02313389|Drug|Rituximab, Methotrexate, Temozolomide|Seven monthly R-MT cycles including high dose MTX (3.5g/m2, D1), TMZ, rituximab.
46100540|NCT00708682|Biological|13-valent pneumococcal conjugate vaccine|
45465501|NCT03922061|Biological|dmLT|double mutant [LT(R192G/L211A)] Enterotoxigenic Escherichia coli heat labile toxin (dmLT)
45465502|NCT03922061|Biological|fIPV|fractional-dose inactived polio vaccine
45680229|NCT03516708|Radiation|Short-course radiation|Short-course pelvic radiation therapy, 5 Gy x 5 fractions over 1 week
45680230|NCT03516708|Drug|CAPOX chemotherapy|CAPOX is typically capecitabine at 1000 mg/m2 PO BID (Days 1-14 of each 3-week cycle) and oxaliplatin 130 mg/m2 IV Q3W. The second cycle of epacadostat will begin when CAPOX starts. Patient will receive a total of 6 cycles of CAPOX chemotherapy.
45837776|NCT05765097|Device|Artificial pancreas treatment|five to seven days treatment by artificial pancreas system
46015491|NCT02892539|Radiation|Coronary Angiography|
46015492|NCT00594503|Drug|Hyperbaric oxygen therapy|Total body exposure to increased atmospheric pressure oxygen
46015493|NCT00594581|Drug|Juvista (avotermin) plus placebo, standard-care (within-subject controls)|Intradermal Juvista (avotermin) at 50ng or 200ng per 100μl per linear cm of wound margin
46015494|NCT00594737|Drug|memantine hydrochloride|memantine hydrochloride oral tablets, 10mg po bid
46015495|NCT00594893|Procedure|Mini Incision Approach|Mini Incision Approach
46015496|NCT00594893|Procedure|2 Incision Approach|2 Incision Approach
46015497|NCT00594971|Other|Organisational intervention|A shared care approach in which extra effort is put into improving the communication between the hospital and the primary sector.
46015498|NCT00594971|Other|Referral to a specialist palliative care team.|Discharge with referral to a specialist palliative care team. This is a patient-centred shared care model in which the palliative team helps to organise the patient's treatment and care.
46015499|NCT00595049|Drug|bosentan|Bosentan 62.5 mg bid for 4 weeks, then 125 mg bid
46015500|NCT00595205|Other|Hospital log review.|Reviewing of the hospital log to monitor for the occurrence of intussusception.
46015501|NCT00595283|Behavioral|Parent Child Interaction Therapy-Emotion Development (PCIT-ED)|PCIT-ED includes fourteen 1-hour therapy sessions over 14 weeks. Sessions will focus on positive parent-child interactions skills, ways to manage emotions, and relaxation techniques.
45837777|NCT05765045|Diagnostic Test|Nursing triage protocol|Medically approved and supervised standing order that allows trained ER nurses to start medical imaging (RX) for adult patients with minor traumata to the limbs.
46015502|NCT00595283|Behavioral|Developmental Education Parenting Intervention (DEPI)|DEPI includes 14 weekly, 1-hour education sessions covering a range of child development and parenting topics. Classes are in a small group format and will emphasize emotional and social development.
46015503|NCT04326881|Drug|SHR-1314|single dosing
46100541|NCT00661310|Other|Drug review 80+ -To reduce usage of hospital care|drug review performed by multiprofessional team, including clinical pharmacist, in order to optimize drug therapy and reduce usage of hospital care. Also patient education and follow-up
46100542|NCT02632292|Device|Absorb GT1|Bioresorbable vascular scaffold
46100543|NCT02632292|Device|Promus|Everolimus-eluting stent
46100544|NCT04063306|Other|none of intervention was given|this is an observational survey and no intervention is given
46100545|NCT02632916|Drug|Zoledronic Acid|Intravenous zoledronic acid 0.025mg/kg at baseline, 6 months, 12 months and 18 months
45342539|NCT05810857|Diagnostic Test|Motor Relearning Program|patients will receive Motor Relearning Program including static and dynamic sitting and standing balance while static sitting balance
45837778|NCT05764980|Behavioral|visual function evaluation|visual function evaluation
45837779|NCT05764928|Drug|BLEX 404|BLEX 404 Oral Liquid, PO, BID
45837780|NCT05764902|Behavioral|Patient-tailored intervention|The intervention group will receive various tailored interventions designed to address multiple patient preferences, including sleeping, eating, and resting habits, hobbies, visitation preferences, religious and spiritual needs, preferences for independence and privacy, and any other specific requests or requirements.
46015504|NCT00595673|Drug|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
46015505|NCT02892461|Procedure|Umbilical cord milking|As same as that in arm descriptions.
46015506|NCT00595829|Drug|XL019|XL019 capsules administered orally
45683898|NCT05249686|Other|Manual Therapy|Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ).
46015507|NCT00595985|Drug|sorafenib|sorafenib 400mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
46015508|NCT00596063|Biological|Wosulin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
46015509|NCT00596063|Biological|Novolin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
46100546|NCT02632916|Drug|Denosumab|Subcutaneous denosumab 1.0mg/kg at baseline, 6 months, 12 months and 18 months
45683899|NCT01922596|Drug|Ropivacaine|
45683900|NCT01922596|Drug|Placebo|
45683901|NCT01573767|Drug|Fluticasone propionate 100mcg|all subjects recieve open-label Flovent twice daily duirng the run in and treatment period
45683902|NCT01573767|Drug|Placebo|Placebo inhalation powder during treatment period
45683903|NCT01573767|Drug|Vilanterol|subjects will recieve 4 weeks via NDPI during treament period
45683904|NCT04396990|Drug|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
45683905|NCT04396990|Drug|Topical Prednisolone|Standard of care topical drop treatment
45683906|NCT04397068|Procedure|phaco-vitrectomy|phaco-vitrectomy. No other involvement drug or device. Standard of care procedure
45680231|NCT03508440|Procedure|Intratympanic injection|Injection will be up to 1cc of dexamethasone 24mg/mL. The procedure will be performed at supine position under a microscope. Local anesthesia will be achieved with topical phenol. A myringotomy will be made in the tympanic membrane. A 1 mL syringe connected to a needle will be used to slowly inject between 0.2 cc and 1.0 cc of solution through the myringotomy, with the subject's head turned 45 degrees to the opposite side. The subject will be asked to maintain positioning for at least 30 minutes and refrain from swallowing. The dose administered will vary due to subject-specific factors.
45680232|NCT03508440|Drug|Prednisone|Oral Steroid
46100547|NCT04156412|Device|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
46015510|NCT00596141|Device|OroScience Topical Oral Wound Emulsion|TOWE will be applied 3 times daily for a period of 7 days by the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site.
46015511|NCT00596219|Drug|celecoxib|celecoxib
46100548|NCT00712348|Drug|Taliglucerase alfa|Intravenous infusion every 2 weeks
46100549|NCT00881504|Drug|"Bevacizumab in combination with modified FOLFOX6."|Oxaliplatin 85 mg/m2 IV on Day 1 5-FU: 400 mg/m2 IV bolus on Day 1, followed by 2400 mg/M2 over 46 hours Leucovorin: 400 mg IV Day 1 Bevacizumab: 10 mg/kg IV on Day 1 Repeat cycles every 2 weeks until death, disease progression, unacceptable toxicity, patient refusal, or treatment delay > 4 weeks
46100550|NCT04160624|Procedure|transcatheter aortic valve replacement|Use Venus-A valve or J-Valve to perform TAVR procedure. Use cardiopulmonary bypass or cardiopulmonary bypass to provide ECLS
46100551|NCT00657176|Drug|OPB-31121|"100mg tablet~oral administration, Qd"
46100552|NCT00660686|Behavioral|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
46100553|NCT00660686|Behavioral|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
46100554|NCT00660764|Drug|Rosuvastatin|Oral
45680233|NCT03474107|Drug|Enfortumab Vedotin|Intravenous infusion
46015512|NCT00596297|Drug|bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 day after baseline; pars plana vitrectomy 4 weeks after baseline
46015513|NCT00596297|Procedure|pars plana vitrectomy|4 weeks after baseline
46100555|NCT02131493|Drug|S-1, Gemcitabine|
46100556|NCT02096159|Drug|trimethoprim-sulfamethoxazole|
46100557|NCT02096159|Other|placebo|
46100558|NCT02632136|Drug|TAP Block Group|Transversus Abdominus Plane (TAP) block: Bupivacaine (30 ml of 0.25%)is injected between internal oblique and transveralis facia. The location of needle and the bleb that is formed after the injection is inspected under diect laparoscopic vision.
46100559|NCT02632136|Drug|Peri-Portal Block Group|15 ml of 0.5% Bupivacaine is injected in the skin and subcutaneous tissue before inserting the ports. 7 ml out of it is injected at sub-umblical port and 4 ml each a the site of other two ports.
45680234|NCT03474107|Drug|Docetaxel|Intravenous infusion
45680235|NCT03474107|Drug|Vinflunine|Intravenous infusion
45680236|NCT03474107|Drug|Paclitaxel|Intravenous infusion
45680237|NCT03465696|Behavioral|Group #2 (Intervention)|"Group #2 (Intervention)~Survey 2 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
46015514|NCT00596375|Procedure|Lubricant Instillation|Lubricant jelly instilled in urethra prior to catheterization
46015515|NCT00596375|Drug|Lidocaine Lubricant|2% Lidocaine lubricant instillation prior to urethral catheterization
46015516|NCT00596531|Drug|Acamprosate|Oral administration, 666 mg, tid, for 4 months
46015517|NCT00596531|Drug|Placebo|Oral administration of 2 pills, tid, for 4 months
46100560|NCT00615095|Other|self-administered questionnaire and blood draw|Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.
46100561|NCT00615095|Other|self-administered questionnaire and blood draw|Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.
46100562|NCT00615095|Other|health questionnaire, blood draw and skin exam|Numbers will be randomly selected from a pool of prefixes. Numbers will be screened by computer for being working, non-business, non-fax, and non-modem numbers. After establishing eligibility for the study, we will send the potential control a letter further explaining the purpose of the study and its requirements. An interviewer will then call to arrange an appointment. During the interview, the subject will sign informed consent, be given the public health questionnaire, have 30 ml of blood drawn, and undergo the skin examination of arms and back.
45680238|NCT03465696|Behavioral|Group #3 (Intervention)|"Group #3 (Intervention)~Survey 3 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~What do you think would be the best way to describe this to a patient?~Stelara® acts in an almost all-natural way to help control psoriasis.~Stelara® blocks one of the genetic causes of psoriasis.~Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance~Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
46015518|NCT00596609|Drug|Intrathecal Morphine|"In the IT morphine group, prior to IT morphine injection (within 15 minutes of the injection), the neurophysiologist will be asked to obtain a set of TceMEP recordings. The recordings collected at this time will be labeled Baseline. These will serve as controls for subsequent recording comparisons.~In the IT morphine group, the time of IT morphine injection will be recorded, as well as the dose. A timer will be started. The neurophysiologist will then be asked to collect four additional sets of TceMEP recordings, at 5, 10, 20, and 30 minutes after morphine injection."
46015519|NCT00596765|Behavioral|Neuropsychological Cognitive Behavioral Therapy|Neuropsychological Cognitive Behavioral Therapy encompasses 2 foci: First emphasis is on neuropsychological compensatory strategies for the treatment of deficits in attention, memory, and executive functions. Secondly, cognitive behavioral intervention techniques are employed to support the patient in the process of coping with chronic illness: i.e. improve regulation of negative affect, diversify the impaired self-concept after acquired brain injury, and adjust important life-goals to changed circumstances.
46015520|NCT00596843|Behavioral|Motivational interviewing|6 one-on-one individual sessions lasting from 30 minutes to 1-hour each
46015521|NCT00596843|Behavioral|Educational intervention|6 1-hour sessions. 2 sessions are delivered by an interventionist and 4 sessions are delivered as videos
46015522|NCT00622973|Other|Imaging: diffusion-weighted MRI|Diffusion-weighted MRI of the entire pelvis to detect lymph node metastases
46015523|NCT00622973|Other|Sinerem (USPIO) enhanced MRI|USPIO (Sinerem) will be administered intravenously immediately after the first MR examination at a dose of 2.6 mg Fe/kg body weight diluted in 100 ml of saline (optimal dose according to: (9, 10)) during a period of about 30 minutes under medical supervision. Postcontrast MR imaging will be performed 24-36 hours after contrast medium injection.
46100563|NCT02631980|Drug|IV iron|Intravenous iron 15 mg/kg (max 1000 mg) in 250 ml 0.9% saline
46100564|NCT02631980|Drug|IV placebo|Intravenous 0.9% saline (250 ml)
46100565|NCT04216199|Device|Point of care Ultrasound|Point of care Ultrasound
45680239|NCT03445845|Drug|Secukinumab|Secukinumab : 150 mg per week for 5 weeks, and then every month by subcutaneous injection
46015524|NCT04326647|Other|Kinesiotaping|We used kinesiotaping in gastrocnemius and lumbar back
46015525|NCT04326647|Other|Exercise|Exercises about balance and gait
46015526|NCT00596999|Procedure|UCB and HPDSC|single dose of UCB followed by one unit of HPDSC
46015527|NCT00597077|Other|Rate vs rhythm control strategies for atrial fibrillation|Rate vs rhythm control strategies for atrial fibrillation
46100566|NCT00660920|Drug|Ponatinib|Comparison of different dosages of drug given orally once per day.
46100567|NCT04157660|Procedure|Oxygen application|Oxygen application Supplemental oxygen via mask
46015528|NCT00597077|Other|Rate vs rhythm control strategies in atrial fibrillation|rate vs rhythm control strategies in atrial fibrillation
46015529|NCT04326803|Biological|Hepatitis B recombinant vaccine|Administration of 20 mcg of hepatitis B recombinant vaccine im at month 0, 1 and 2
45465503|NCT05165680|Combination Product|combination of aerobic exercise and healthy diet|"The 30 patients in this group will receive iron supplements, a personalized low caloric diet therapy based on Harris-Benedict equation. A restricted balanced diet will be prescribed which will be included. Perform aerobic exercise in the form of walking on electrical treadmill three times/ week day after day for 12 weeks according to following parameters.~Type: moderate treadmill aerobic exercise~Time: 40 minutes (5 minutes warm up phase, 30 minutes target heart rate (THR) phase, 5 minutes cooling down phase)~Intensity: THR will be at 75% of maximum heart rate (which will be determined by submaximal graded exercise test and predicated MHR=220-age)~Frequency: three times per week for 12 weeks"
46100568|NCT04157660|Procedure|Sham room air|Room air will be applied via mask
46015530|NCT02892227|Procedure|Transmitral flow estimation|Estimation of the transmitral flow of the inferior vena cava and its variations
46015531|NCT00597233|Drug|insulin aspart|
46015532|NCT00597233|Drug|soluble human insulin|
45342540|NCT05810857|Diagnostic Test|Mirror Therapy|"Mirror Therapy protocol. The baseline treatment will be weight bearing in standing which is extension of knee and weight bearing in standing on inclined"
45342541|NCT05810844|Diagnostic Test|Motor Relearning Program (MRP)|MRP technique with a conventional physiotherapy treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke
46015533|NCT00597233|Drug|insulin NPH|
46015534|NCT00597311|Radiation|radiotherapy|"Short term radiotherapy 5x5 Gy during 5 days~Chemoradiotherapy 50 Gy + 5Fu/Lv"
46015535|NCT01064401|Biological|BIIB019 (Daclizumab High Yield Process)|Daclizumab High Yield Process for subcutaneous injection
46015536|NCT01064401|Drug|Interferon beta-1a Placebo|Placebo to interferon beta-1a intramuscular injection
46015537|NCT01064401|Biological|Interferon beta-1a|Interferon beta-1a for intramuscular injection
46015538|NCT01064401|Drug|Daclizumab High Yield Process Placebo|Placebo to Daclizumab High Yield Process subcutaneous injection
46100569|NCT01936831|Drug|Isoniazid|INH was available in 100 mg tablets. INH was administered orally daily in the morning on an empty stomach. Doses of INH were given according to the weight bands and by cohort.
46100570|NCT01936831|Dietary Supplement|Vitamin B6|Vitamin B6 was administered at >= 25 mg daily and was obtained locally for use by study participants.
46100571|NCT04157504|Other|Physical function assessment|Physical function assessment is a tool to evaluate mobility levels of patients
46100572|NCT00615173|Drug|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
46100573|NCT00615173|Drug|cyclophosphamide or azathioprine|Induction phase: CTX 0.75g/m2 monthly Maintenance phase: AZA 2mg/kg/d.
46100574|NCT00660998|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
46100575|NCT00660998|Drug|Placebo|Matching placebo
45342542|NCT05810844|Diagnostic Test|Neuro Development Treatment (NDT)|Neuro-Development Treatment NDT as well as conventional treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke patients
45342543|NCT05810831|Diagnostic Test|Massage with post isometric relaxation exercises|Post isometric relaxation will be performed in supine position with neutrally positioned head.
46015539|NCT00597389|Drug|Inderol (propranolol)|Children ingested a propranolol HCL 20 mg/5 ml solution twice daily for 10 days (and taper for 5 days). Medication was initiated within 12 hours post-trauma. Dose was calculated to be 2.5 mg/kg/d with a maximum dose of 40 mg.
46015540|NCT02892071|Drug|22% TCA peel|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with one treatment with a 22% TCA Blue Peel, to achieve a level 2 frost (medium depth peel). Each treatment will take about 20 minutes. A 22% TCA concentration will be created by combining 5.5 mL of 30% TCA (from a purchased commercial bottle) with 2mL of blue dye (commercial), immediately before application.
46015541|NCT02892071|Device|CO2 laser|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will receive one treatment with one pass of the fractionated ablative 10,600 nm CO2 (CO2RE Laser, Syneron) at Core 70 mJ, Ring 50mJ, 40% coverage, 1 pass, 8 mm square pattern. Each treatment will take about 20 minutes.
46015542|NCT02892071|Device|Qs-NdYag laser|Long pulsed Q-switched Nd:Yag laser. One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with Q-switched (Qs) 1064 Nd:YAG (Medlite C3; 6 mm spot size, collimated homogenous flat- top beam profile, energy fluence 2.0 J/cm2, 5Hz), with 5% coverage and 2 passes (or until mild erythema detected). Treatments will be performed at 2-week intervals for six sessions. Each treatment will take about 20 minutes.
46100576|NCT01467245|Procedure|Hypercapnia during thoracoscopy|keyhole surgery through the chest for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
46100577|NCT01467245|Procedure|Open surgery|open surgery for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
46100578|NCT00657254|Drug|Nexavar (Sorafenib, BAY43-9006)|Bay 43-9006 400mg (2 x 200mg tablets) orally twice daily until withdrawal.
46100579|NCT01455389|Drug|DOTAP:Chol-TUSC2|Starting Dose 0.045 mg/kg by vein on day 1 of each 21 day cycle; Phase II is Maximum Tolerated Dose from Phase I.
46100580|NCT01455389|Drug|Erlotinib|Starting Dose 100 mg by mouth each day of a 21 day cycle (except for first week of Cycle 1, if enrolled in Phase II delayed-schedule group). Phase II is Maximum Tolerated Dose from Phase I.
45465504|NCT04415515|Behavioral|RN case management|A Registered Nurse (RN) case manager makes phone contact with the member to review medications, health risks, care gaps/barriers, & to develop a case management plan that focuses on improving medication adherence & reconciliation, condition-based measures & outcomes, addressing psycho-social needs, & intensive post-admission care transition. RNs may refer the member to social workers,specialist providers, & support programs (including to more intense case management where the primary care physician is notified that RNs may contact them to support treatment & coordinate services).
45465505|NCT04415515|Behavioral|Community Health Worker Case Management|In selected UHC markets for defined time periods, members randomized to the treatment arm also received an enhanced version of the SCC that included in-home case management support from non-clinical Community Health Workers (CHW).
45465506|NCT04415515|Behavioral|RN Standard care coordination and disease management|RN Standard care coordination and disease management
45465507|NCT02528981|Drug|Probiotic|Lactobacillus GR-1 and RC-14
45465508|NCT02528981|Drug|Placebo|
46015543|NCT00597467|Device|VISA (comfilcon A) Silicone Hydrogel Soft contact lens|Test device
46015544|NCT00597467|Device|Acuvue 2 Soft Contact Lens|Control device
45465509|NCT01229033|Procedure|Ablation|Ablation of atrial tachycardia
46015545|NCT01306617|Drug|ABT-450|tablets
46015546|NCT01306617|Drug|ABT-333|tablets
46015547|NCT01306617|Drug|ribavirin|tablets
46015548|NCT01306617|Drug|ritonavir|capsules
46015549|NCT00597623|Other|Adalimumab (Humira®)|syringes for injections under cutaneous dose = 40mg vol = 0.8 ml
46015550|NCT00597623|Other|Placebo|syringes under cutaneous vol = 8 ml
45465510|NCT01229033|Procedure|Cardioversion|Cardioversion of atrial tachycardia
45465511|NCT04455568|Device|use EKG Wisdom bracelet|Non-invasive Wearable Device (use EKG Wisdom bracelet)
46015551|NCT00597779|Device|Dynamic Hip Screw (DHS); Trochanteric Fixation Nail (TFN)|Surgical stabilization of unstable intertrochanteric hip fractures using two commonly used implant categories
46015552|NCT04326569|Other|Blood sample|Blood sample to quantify copeptin
46015553|NCT02874625|Procedure|Dental restoration|
46015554|NCT02875795|Procedure|automatic speech processing tool|
46015555|NCT00597857|Drug|Hydrocortisone|Participants will receive a tapering low-dose of hydrocortisone in pill form for 10 days, twice a day, after the trauma.
46015556|NCT00597857|Drug|placebo|receipt of a placebo pill for 16 days
46015557|NCT00627133|Drug|levetiracetam|2 gram iv load, 500mg bid
46015558|NCT01306305|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2010-2011 season, containing per 0.5 mL dose:~15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus~15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus~15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
46015559|NCT00598013|Drug|Pioglitazone|The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
45465512|NCT01131689|Drug|sorafenib, TS-1|D1-14 S-1 dose of level 1/2/3/4 D1-21 Sorafenib 400mg twice daily Every 3 weeks-cycle
45465513|NCT04455490|Other|Self-control|We compared relevant scores of patients before and after surgery
45342544|NCT05810831|Diagnostic Test|Massage|conservative physiotherapy protocol including massage
45342545|NCT05810818|Diagnostic Test|Dry Needling|Dry needling treatment will be consisting of two treatments per week
45465514|NCT03812185|Device|Suctioning orogastric tube which is attached to TEE probe cover|Suctioning orogastric tube which is atttached to TEE probe cover.
45465515|NCT03401229|Biological|Benralizumab 30 mg SC + Mometasone Furoate|"Benralizumab injection is 30mg/ml SC clear to opalescent, colourless to yellow solution in accessorized pre-filled syringe.~Benralizumab 30 mg SC will be injected every 4 weeks for the first 3 doses - Weeks 0 , 4 and 8 and every 8 weeks thereafter - Weeks 16, 24, 32, 40 and 48. Total of 8 doses.~Mometasone Furoate Nasal Spray (MFNS) - intranasal corticosteroid - 2 doses (1 dose = 50 micrograms/actuation) in each nostril twice daily. Total daily dose of 400mcg. MFNS will be used for a minimum of 4 weeks prior to randomization and will be continued throughout the study."
46015560|NCT04303429|Drug|FOLFOX/XELOX/Capecitabine|Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
46015561|NCT00598091|Drug|gemcitabine|1000mg/m2, Days 1, 8, 15
46015562|NCT00598091|Drug|dasatinib|50mg, PO, QD
46015563|NCT00598091|Drug|gemcitabine|1000mg/m2, days 1, 8, 15
46015564|NCT00598091|Drug|dasatinib|50mg, PO, BID
45342546|NCT05810818|Diagnostic Test|Self Stretching|Self stretching groups both will receive a TrP manual interventions and stretching protocol
45465516|NCT03401229|Biological|Matching placebo SC + Mometasone Furoate|"Matching placebo injection is SC clear to opalescent, colourless to yellow solution in accessorized pre-filled syringe.~Matching placebo SC will be injected every 4 weeks for the first 3 doses - Weeks 0 , 4 and 8 and every 8 weeks thereafter - Weeks 16, 24, 32, 40 and 48. Total of 8 doses.~Mometasone Furoate Nasal Spray (MFNS) - intranasal corticosteroid - 2 doses (1 dose = 50 micrograms/actuation) in each nostril twice daily. Total daily dose of 400mcg. MFNS will be used for a minimum of 4 weeks prior to randomization and will be continued throughout the study."
45474003|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive diet associating 30gr/day of rapeseed oil and n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
46015565|NCT00623415|Drug|Flupirtine|300 mg daily (divided in two doses)
46015566|NCT00623415|Drug|Placebo|twice daily
46015567|NCT02874703|Other|Cardiac MRI/MRS|
46015568|NCT04326725|Drug|Plaquenil 200Mg Tablet|health workers under risk who took this medications
46015569|NCT01038427|Drug|Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals)|Mometasone nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
46015570|NCT01038427|Drug|Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray|Mometasone nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
46015571|NCT01038427|Drug|Placebo|Placebo nasal spray administered once daily (4 actuations) for 14 days.
46015572|NCT00598169|Biological|rituximab|375mg/m2 on Day 1
46015573|NCT00598169|Drug|bortezomib|Part A: Velcade Day 1 and Day 8 of a 28-day cycle, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2 Part B: Velcade on Days 1 and 8 of a 21-day cycle.
46015574|NCT00598169|Drug|carboplatin|"Carboplatin will be dosed to an AUC=5, calculated using the Calvert formula (5 x [creatinine clearance + 25]; the maximum dose of carboplatin is 750 mg.~Part A: AUC=5 (maximum 750 mg) IV administered on Day 9. Part B: AUC=5 (maximum 750 mg) IV administered on Day 2."
46015575|NCT00598169|Drug|dexamethasone|Part A: 20 mg IV on Days 8-10. Part B: 20 mg IV on Days 1-3 and on Day 8.
46100581|NCT01455389|Drug|Dexamethasone|8 mg orally 24 and 12 hours and 20 mg by vein 30 minutes before DOTAP:Chol-TUSC2 treatment followed by 8 mg orally at 12, 24 and 36 hours after treatment (total number doses = 5).
45465517|NCT03926429|Other|Standardised data collection|The following variables will be retrospectively assessed by medical record review using a standardised data collection form:demographics; gender, age; family or personal history of spondyloarthritis, psoriasis, uveitis, inflammatory bowel disease; clinical presentation; mono, oligo or polyarthritis, dactylitis, inflammatory joint pain, enthesopathy, axial symptoms, fever, extra-articular manifestations (conjunctivitis, anterior uveitis, circinate balanitis, skin rash); time interval between infection and musculoskeletal manifestations; causal microorganism if known, or triggering event; HLA-B27; radiographic sacroiliitis; treatments and outcomes (complete recovery at one year follow-up, relapse within 6 months after onset, or spondyloarthritis according to the ASAS criteria).
45465518|NCT05339230|Dietary Supplement|Salovum and SPC-flakes active or placebo|Foods for specific medical purposes or corresponding placebo
46015576|NCT00598169|Drug|etoposide|Part A: 100 mg/m2 IV Days 8-10. Part B: 100 mg/m2 IV daily on Days 1 to 3.
45465519|NCT05332132|Device|Heracure Device|Intrauterine Morcellation of Uteri Post-Surgery (Ex Vivo Study)
45465520|NCT05435053|Drug|Nivolumab|"Every 2 weeks (3 mg/kg, maximum of 240 mg) for up to 24 weeks~Nivolumab is an immune checkpoint inhibitor (PD-1-inhibitor)."
45465521|NCT05435053|Device|Irreversible electroporation (IRE)|"Percutaneous ablation of a primary in-situ (or locally-recurrent) or metastatic lesion.~Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is FDA-approved for medical use."
45680240|NCT03445845|Drug|TNF blocker|"TNF blocker (originator or biosimilar) :~infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,~etanercept: 50mg per week in subcutaneous injection,~adalimumab: 40mg every other week in subcutaneous injection,~certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,~golimumab: 50mg every month in subcutaneous injection, in case of overweight (>100kg) an inadequate response, 100mg every month is allow."
45465522|NCT01132391|Drug|Rectogesic® (glyceryl trinitrate 0.4% ointment)|375 mg of ointment(1,5 mg of glyceryl trinitrate ) / 12h DURING 6 MONTHS
45465523|NCT05165134|Other|Kinesiotape|Elastic tape used for mechanical correction of the deformity in study group and placebo in control group
45680241|NCT03445845|Biological|blood specimen|Blood specimen at each visits for measurement of bDMARS blockers concentration and anti-drug antibody concentration
45465524|NCT01130441|Behavioral|psychotherapy|short problem-solving skills therapy intervention
46100582|NCT01455389|Drug|Diphenhydramine|50 mg by mouth or by vein 30 minutes prior to treatment with DOTAP:Chol TUSC2
45465525|NCT05296642|Other|Moderate Cycling|Using the recumbent bicycle (95Ri, Life Fitness, Illinois) participants will be asked to sustain a moderate pace of 13 - 16 for 20 minutes of perceived exertion range using the Borg rate of perceived exertion scale (RPE).
45465526|NCT05296642|Other|Personalized Tourniquet System|An automated personalize tourniquet system (Delfi Medical, Inc., Vancouver, BC, Canada) will be used to perform blood flow restriction during BFR+AE. This system has a dual-purpose tourniquet cuff (11.5 x 86 cm) connected by airtight hose tubing to a personalized tourniquet device. The device automatically measures LOP and regulated pressure during exercise within clinically acceptable limits. Participants will be asked to lie in supine and a non-shedding stockinette protection sleeve will be placed at bilateral proximal thighs. Following, a tourniquet cuff will be placed bilaterally around the protection material and connected to the airtight hose tube.
45465527|NCT05281081|Drug|intraperitoneal levobupivacaine and morphine|istillation of the peritoneum with levobupivacaine mixture with morphine
45465528|NCT03921827|Device|Enhance External Counterpulsation Therapy|EECP therapy would be administered to this group for 1-hour a day for a total of 35 sessions
45465529|NCT05164900|Procedure|pterygium excision with sutures fixed conjunctival auto-graft|Pterygium excision with vicryl 8/0 fixed conjunctival auto-graft under local anesthesia. During the follow up period, indicators of ocular irritation were assessed.
45465530|NCT03812965|Drug|Botulinum toxin type A|2 units/point of botulinum toxin type A
45465531|NCT01303237|Drug|Cetuximab + RT|Cetuximab initial dose 400 mg/m² on week 1; Cetuximab maintenance dose 250 mg/m² continued for 7 weeks plus concomitant RT
46100583|NCT00911378|Procedure|Pressure support ventilation|These patients are weaned by gradual reduction of pressure support and extubated when they tolerate a pressure support of 7 cm of water for one hour.
45680242|NCT03437668|Drug|WSE|WSE tablets
45680243|NCT03437668|Drug|Placebo Oral Tablet|Placebo tablet
45680244|NCT03422861|Drug|Nabilone|Treatment regimen will involve nabilone capsule administration starting with 1mg BID orally first administered on POD #0. The patient will be continued on this medication for 72 hours
46015577|NCT00598169|Drug|ifosfamide|"Part A: 5000 mg/m2 mixed with an equal amount of Mesna as a 24 hour continuous IV infusion on Day 9.~Part B: 5000 mg/m2 mixed with an equal dose of Mesna administered via continuous infusion for 24 hours beginning on Day 2."
46015578|NCT00598169|Genetic|polymerase chain reaction|Correlate EBV/HHV-8 viral load changes with lymphoma response. HIV and EBV/HHV-8 viral loads will be assessed on baseline, day 2, 4, and 8 of week 1 of Part A.
45465532|NCT01132469|Procedure|Endoscopic Submucosal Dissection|5-years follow-up after Endoscopic Submucosal Dissection
45465533|NCT05085184|Drug|administration of UI018|Test
45465534|NCT05085184|Drug|co-administration of UIC201806 and UIC201602|Reference
45465535|NCT03921749|Device|Shockwave|"Both shockwave interventions will be administered without local anaesthesia. Three sessions will be administered at one-week intervals. During each session, 2000 pulses (1000 shots at the patellofemoral and tibiofemoral borders of the target knee and 1000 shots on the subchondral bone of the medial tibia condyle of the affected knee) will be delivered at 5 Hz. Energy flux density was 0.20 mJ/mm2 for patients in the focused group while radial shock waves were transmitted with 0.17 mJ/mm2 corresponding to a 3-bar energy level setting."
46015579|NCT00598169|Genetic|western blotting|Peripheral blood mononuclear cells will be collected at Day 1 prior to chemotherapy, Day 2, 4 and 8 (prior to chemotherapy) then weekly during Part A, just prior to each additional cycle of Part B and at treatment completion. Western blot using antibody specific for APOBEC3G and antibody against actin for internal control will be used to quantify APOBEC3G levels. Changes at will be compared with baseline using a paired t-test.
46015580|NCT00598247|Drug|Paclitaxel Poliglumex|Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks.
46015581|NCT00598325|Biological|3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)|1.0 ml injection IM given every 4 weeks (weeks 0, 4, 8, 12, 16)
45465536|NCT05260762|Dietary Supplement|Arabinoxylan|Dietary fiber product
45465537|NCT05260762|Dietary Supplement|Control|Potato starch
45465538|NCT01302535|Other|Yoga group with supervision (trainer)|The Yoga-with-trainer group will meet once a week (60 minutes) to practice yoga with a yoga instructor. The participants will be encouraged to practice yoga between the yoga classes at home for 30 minutes a day.
45465539|NCT01302535|Other|Yoga at home|The participants in the Yoga-at-home group will get a private doctor appointment (20 minutes) where they get instructions for two yoga exercises which they are encouraged to perform at home 15 minutes a day.
45465540|NCT01227863|Drug|MAXINOM®|Dexamethasone...............................................0,1% Neomicyn......................................0,35% polimixyn B...................................0,1%
45465541|NCT01227863|Drug|Maxitrol®|Dexamethasone...............................................0,1% Neomicyn......................................0,35% Polimixyn B...................................0,1%
45474004|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive with 30gr/day n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
46015582|NCT00598403|Drug|cefditoren pivoxil|400 mg, oral, single dose during 3 days
46015583|NCT00598403|Drug|Ciprofloxacin|250 mg, oral, twice a day for 3 days
46015584|NCT00598637|Device|Everolimus-eluting stent (Xience)|stent is implanted due to randomization
46015585|NCT00598637|Device|Zotarolimus-eluting stent (Endeavor Resolute)|stent is implanted due to randomization
46015586|NCT00598715|Device|Sirolimus eluting stent|Sirolimus-eluting stent will be implanted
46015587|NCT00598715|Device|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be implanted
46015588|NCT00598793|Drug|biphasic insulin aspart|
45680245|NCT03422861|Drug|Placebos|Treatment regimen will involve placebo capsule administration, identical in colour, shape, size, taste and smell to the nabilone capsules, starting orally first administered on POD #0. The patient will be continued on this medication for 72 hours
45680246|NCT03421496|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
46015589|NCT00598793|Drug|insulin glargine|
46015590|NCT00598793|Drug|metformin|
46015591|NCT00598793|Drug|pioglitazone|
46015592|NCT04325945|Device|Low level laser therapy|808nm low level laser therapy on acupuncture points
46015593|NCT00599105|Procedure|magnetic resonance imaging|MRI contrast agent, 0.1 mmol/kg
46015594|NCT01037413|Drug|EXC 001|Multiple intradermal injections of EXC 001 and placebo
46015595|NCT01037413|Drug|Placebo|Multiple intradermal injections of EXC 001 and placebo
46015596|NCT00599183|Other|MRI-Diffusion Tensor Imaging and Tractrography|MRI scan: Baseline: Conventional MRI (as part of clinical care) with additional diffusion tensor imaging (DTI)sequence (research). 6-week follow up: MRI with DTI and tractography as part of the research
46015597|NCT01326845|Drug|Deferasirox|
46015598|NCT02873845|Other|Preliminary validation of the COBQoL questionnaire|
45465542|NCT03349515|Drug|Provodine-Iodine Solution|Group A will receive three drops of povidone-iodine ophthalmic solution in each eye, with the right eye to receive the drops first. The eye drops will be administered by the study anesthesiologist. After application of either solution to the eyes of the patient, any change in ventilation can be detected and timed by observation of the capnography (end-tidal carbon dioxide) and direct observation of the chest wall with use of the iPhone stopwatch feature again. The capnograph is a standard monitor of respiration used during the administration of general anesthesia. Data collected at this time will include whether or not there was a change in respiration, what this change in respiration was, if assisted ventilation was required, how long assisted ventilation was required (if applicable), HR, BP, RR, SaO2 , ETCO2, InspSevo, and ExpSevo. This study intervention and data collection will take less than 5 minutes.
45680247|NCT03421496|Drug|Placebo|Matching oral solution
45680248|NCT03421496|Drug|Vigabatrin|Powder suspension
45680249|NCT03421353|Drug|AZD9150|"AZD9150 will be administered as a 1-hour intravenous infusion either weekly (QW) or every two weeks (Q2W), depending on which arm the patient is enrolled in.~AZD9150 will be provided as a liquid drug product in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement."
45680250|NCT03421353|Drug|Durvalumab|"Durvalumab will be administered as a 1-hour intravenous infusion either every three weeks (Q3W) or every four weeks (Q4W), depending on which arm the patient is enrolled in.~Durvalumab will be provided as a solution in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement."
45680251|NCT03421353|Drug|Cisplatin|Cisplatin will be infused over 30-60 minutes on Day 1.
45680252|NCT03421353|Drug|5-Flourouracil|5-flourouracil will be continuously infused over Days 1 to 4 every three weeks for up to 18 weeks.
45680253|NCT03421353|Drug|Carboplatin|Carboplatin will be infused over 30 to 60 minutes on Days 1, 8, and 15, depending on which arm the patient is enrolled in, for up to 18 weeks.
46015599|NCT01062763|Drug|spironolactone|25 to 50 mg once daily
46015600|NCT01062763|Drug|placebo|addition of placebo 1 to 2 tablets daily
46100584|NCT00911378|Procedure|Spontaneous breathing trials|These patients are weaned by giving a T piece trial with 8 cm of water pressure support and extubated when they tolerate it for one hour.
46100585|NCT03863353|Behavioral|Educational Intervention|This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.
46015601|NCT00599261|Procedure|ICD/pacemaker pocket revision|Pocket revision consists of complete removal of the fibrous capsule surrounding the device and leads
46015602|NCT00599417|Drug|Bacterial Lysates|Bacterial Lysates ampoules 3 mL, oral route, daily for 10 days, followed by 30 days free of medication and then 10 days of administration of the drug
46015603|NCT00599417|Drug|placebo|placebo controlled
46100586|NCT00661076|Drug|adefovir dipivoxil|10mg po daily for 96 weeks (arm 1) or 48 weeks (arm 2)
46015604|NCT00599573|Drug|ondansetron|Ondansetron 4mg BID for six weeks
46015605|NCT00599651|Device|Surfactant administered via Laryngeal Mask Airway (LMA)|Standard volume of Infasurf surfactant (3 mL/kg) will be injected in 2-4 aliquots into the proximal end of the LMA.
46015606|NCT00599651|Other|standard of care (nasal CPAP and supplemental oxygen)|Standard of care will be utilized which may mean surfactant is administered
46100587|NCT00661076|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 48 weeks
46100588|NCT04215965|Drug|Biphozyl (dialysate and replacement)|Replacement solution with phosphate and without calcium in CRRT with citratre-based antigoagulation
46015607|NCT01048099|Procedure|PRO Onc Assay and Treatment|Patients with HER2-negative metastatic breast cancer will be identified, and blood specimens will be obtained from each participant. The PRO Onc Assay will be performed on CTCs isolated from these specimens. When clinically indicated, fine needle aspiration biopsy will also be obtained and submitted for the PRO Onc Assay.
46015608|NCT01048099|Drug|Trastuzumab|8 mg/kg IV loading dose, followed by 6 mg /kg IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
46015609|NCT01048099|Drug|Pertuzumab|840 mg IV loading dose, followed by 420 IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
46015610|NCT00599807|Dietary Supplement|Vitamin D3 (cholecalciferol)|the intervention is a dietary supplement comparing the current standard (800 IU) to the current safe upper limit (2000 IU)
46015611|NCT00599885|Drug|telmisartan|telmisartan 40-80mg once per day for 8 months
46015612|NCT00599885|Drug|valsartan|valsartan 80-160mg once per day for 8 months
46015613|NCT00599963|Drug|paricalcitol|paricalcitol 1 mg/day
46015614|NCT01303965|Drug|Sirolimus|Start on Day -3 and continue for 1 year
46015615|NCT01303965|Drug|Tacrolimus|Start on Day -3 and begin tapering on Day +100 until Day +180.
45680254|NCT03421353|Drug|Gemcitabine|Gemcitabine will be infused over 30 minutes on Days 1 and 8 for up to 18 weeks.
45680255|NCT03421353|Drug|Nab-paclitaxel|Nab-paclitaxel will be infused over 30 to 40 minutes on Days 1, 8, and 15 for up to 18 weeks.
46015616|NCT01303965|Drug|Lenalidomide|Start between Day +30 and +120 and continue for 1 year.
46015617|NCT00600041|Drug|Pantoprazole|80 mg IV over 2 minutes, followed by 8 mg/h IV for 60 minutes
46015618|NCT00600041|Drug|Placebo|Identical infusion manner like experimental arm
46015619|NCT01045993|Device|Heat Device|8-Hour Heatwrap
46015620|NCT01045993|Device|Sham Device|Inactive wrap worn for 8 hours
46015621|NCT01045993|Drug|marketed analgesic|2 x 200 mg ibuprofen tablets
46015622|NCT01045993|Drug|Placebo|2 x placebo tablets
46015623|NCT05661123|Other|Complete decongestive therapy|"Education.~Skin care .~Pneumatic compression device .~Manual lymph draining .~Multilayer short stretch compression bandages.~Exercises."
46015624|NCT00600197|Behavioral|back school|A kind of educational program for low back pain
46015625|NCT02890563|Device|Class II Compression Stockings|
46015626|NCT04325867|Other|Tele-medicine platform|Electronic counselling of known pathology cardiovascular patients through a complex remote platform and dedicated experts. This project intend remote monitoring through wearable devices (e.g. ECG watches, pulse detectors, oximetry).
46015627|NCT05643963|Other|Dietary regimens|Food intake will follow a recommendation according to a specific list. Protective and non-protective food intake will be performed for specific time periods with biomarker assessment after each period.
46015628|NCT00600509|Drug|Levetiracetam|
46015629|NCT01303419|Device|CE-BMRI|Contrast-enhanced breast imaging using Magnetic Resonance
46015630|NCT01303419|Device|DE-CEDM|Breast imaging using Dual-energy, contrast-enhanced digital mammography
46015631|NCT01326533|Drug|hydroxychloroquine|Thirteen weeks of oral hydroxychloroquine (400 mg/day) provided as capsules
46015632|NCT01326533|Other|Placebo|Thirteen weeks of oral placebo provided as capsules
46015633|NCT00600587|Drug|neoadjuvant erlotinib therapy|150mg erlotinib taken once daily and continued uninterrupted for 42 days before evaluation/thoracotomy/radiotherapy.
45342547|NCT05810805|Other|gas component of digestive tract|Analyze the differences in gas components in different segments of the digestive tract in patients with different diseases, and analyze the correlation between specific gases and digestive tract diseases and non-specific symptoms.
45465543|NCT03349515|Drug|Group B will receive three drops in each eye of ophthalmic balanced salt solution.|Group B will receive three drops in each eye of ophthalmic balanced salt solution. The eye drops will be administered by the study anesthesiologist. After application of either solution to the eyes of the patient, any change in ventilation can be detected and timed by observation of the capnography (end-tidal carbon dioxide) and direct observation of the chest wall with use of the iPhone stopwatch feature again. The capnograph is a standard monitor of respiration used during the administration of general anesthesia. Data collected at this time will include whether or not there was a change in respiration, what this change in respiration was, if assisted ventilation was required, how long assisted ventilation was required (if applicable), HR, BP, RR, SaO2 , ETCO2, InspSevo, and ExpSevo. This study intervention and data collection will take less than 5 minutes
45465544|NCT05496010|Other|Dry Needling and Ischemic Compression Technique|"For Group A, Dry needling will be applied into trigger points which are active and present in the muscles, efficiently and within the safe limits taking all the safety precautions.~For group B, Ischemic Compression Technique will be applied on trigger points.~The complete treatment session will be comprised of 3 sessions per week for two weeks followed by follow up after 1 month until the symptoms have been improved for both the groups."
45465545|NCT01303315|Device|TANTALUS System|An Active Implantable Pulse Generator Medical Device for the treatment of Obesity and Diabetes Type 2 and Obesity
45465546|NCT01132625|Drug|AUY922|
45465547|NCT03349437|Device|Vitabreath Device|The VitaBreath device is designed for non-continuous use only and typical device use is expected to be for 2-3 minutes. The device should only be operated for less than 10 minutes at a time. After such time, the device should be turned off for at least 30 minutes
45465548|NCT03349437|Other|Pursed Lip Breathing|Pursed lip breathing (PLB) is the standard of care and will be used as the control condition comparator.
45680256|NCT03421340|Device|DSC|Stone removal without fluoroscopy using the SpyGlass device.
45680257|NCT03421340|Device|ERC|Standard of care stone removal with fluoroscopy.
45680258|NCT03401320|Drug|Letrozole ISM|2.5 mg Femara + single IM injection of 50-400 mg Letrozole ISM
46015634|NCT00600587|Drug|neoadjuvant gemcitabine/carboplatin therapy|3 cycles of neoadjuvant gemcitabine(1250mg/m2,d1,d8)/carboplatin(AUC=5,day1) chemotherapy before evaluation/thoracotomy/radiotherapy.
45680259|NCT03374085|Drug|CC-92480|CC-92480
45680260|NCT03374085|Drug|Dexamethasone|Dexamethasone
45680261|NCT03328026|Biological|SV-BR-1-GM|SV-BR-1-GM inoculation intradermally at 4 sites.
45680262|NCT03328026|Drug|Low dose cyclophosphamide|Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation.
45680263|NCT03328026|Drug|Interferon Inoculation|Post-inoculation low dose Interferon into the vaccination sites ~2 days after SV-BR-1-GM inoculation.
46015635|NCT01045447|Drug|insulin degludec/insulin aspart|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily with main meal. Dose was individually adjusted.
46015636|NCT01045447|Drug|insulin glargine|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
46015637|NCT00600665|Behavioral|PAINReportIt|A pain assessment data collection tool
46015638|NCT00600665|Behavioral|PAINUCope|A multimedia patient education program tailored to the participant's SCD pain management misconceptions
46015639|NCT00600665|Behavioral|PAINConsultN|A decision support tool for doctors that will provide algorithm-based pain medication therapies tailored to each participant's pain level
46015640|NCT04324827|Device|Graston Technique|FR is a dense foam cylinder that the person rolls before using the body weight to warm up and increase their ROM. There are different types that vary in size, shape and density.
46100589|NCT04215965|Drug|Prismocal B22 (dialysate) + phoxilium (replacement)|solution with phosphate and calcium in CRRT with citratre-based antigoagulation
46100590|NCT04692649|Other|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
46100591|NCT04692649|Other|cross body stretch|crossbody stretch performed by an individual
46100592|NCT02632214|Other|fMRI measure|
46015641|NCT04324827|Other|Dynamic stretch exercise|Dynamic stretch includes controlled movements in the active ROM for a joint. This type of exercise is actually the basis of sports movements used in training or competition.
45680264|NCT03328026|Drug|retifanlimab|retifanlimab 375mg administered as an intravenous infusion over 30-60 minutes every 3 weeks per randomization
46015642|NCT00623051|Procedure|Male Circumcision|
46100593|NCT03998371|Diagnostic Test|Low-coverage whole-genome sequencing of urine exfoliated cells|The level of CIN The extracted DNA from morning urine will be analyzed by UCAD to determine the level of CIN.
46100594|NCT00661700|Drug|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg Vardenafil or down to 5mg Vardenafil followed by 14 weeks treatment at preferred dose.
46100595|NCT00661700|Drug|Placebo|10mg placebo for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg placebo or down to 5mg placebo followed by 14 weeks placebo at preferred dose
46100596|NCT04215887|Device|Contactless Portable Respiratory rate Monitor|Novel hand-held respiratory rate monitor
45680265|NCT03321786|Other|The University of Pennsylvania Smell Identification Test (UPSIT)|"This standardized test, the most widely used olfactory test in the world, is derived from basic psychological test measurement theory and focuses on the comparative ability of subjects to identify odorants at the suprathreshold level. The UPSIT consists of four envelope-sized booklets, each containing ten scratch and sniff odorants embedded in 10- 50-µm polymer microcapsules positioned on brown strips at the bottom of the pages of the booklets."
45680266|NCT03309332|Device|AMPLATZER™ PFO Occluder|Implantation of the AMPLATZER™ PFO Occluder in the PFO
46015643|NCT00623129|Other|questionnaire administration|
46015644|NCT00623129|Procedure|electroacupuncture therapy|
46015645|NCT00623129|Procedure|management of therapy complications|
46015646|NCT00623129|Procedure|quality-of-life assessment|
46015647|NCT02875249|Other|patients stool collection|patients stool collection
46015648|NCT00623207|Drug|Atropine|I.V Atropine 0.5mg up to 2 mg
46015649|NCT00600899|Procedure|elastomeric pump with reservoir of 500 ml, infusion rate of 8 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 500 ml reservoir and infusion rate of 8 ml/h)
46015650|NCT00600899|Procedure|elastomeric pump with reservoir of 275 ml, infusion rate of 5 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 275 ml reservoir and infusion rate of 5ml/h)
46015651|NCT04205617|Other|produce prescription and nutrition education|Participants will receive diabetic appropriate groceries, diabetes education classes led by volunteer doctors and nurses, cooking demonstrations, shared meals, 1:1 and group coaching by dietitians.
46015652|NCT00600977|Drug|Doxorubicine|9mg/m² J1 J4 2 COURSES
46015653|NCT00600977|Drug|Doxorubicine pegylated|40 MG/M² J1 2 courses
46015654|NCT04695847|Drug|M1231|M1231 will be administered at escalated doses every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
46015655|NCT04695847|Drug|M1231|M1231 will be administered at the dose determined as RDE in part 1, every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
46015656|NCT01301625|Device|MitraClip Implant|Percutaneous mitral valve repair using MitraClip implant.
46015657|NCT00601055|Behavioral|Problem Solving-Rx Adherence (PSA)|In PSA, a therapist teaches the participant to identify problems related to depression, functioning, and treatment adherence; to generate multiple solutions; and to choose and implement one or more of those solutions.
46015658|NCT00601055|Behavioral|PID-C|In PID-C, a therapist identifies obstacles to treatment adherence and helps the participant overcome those obstacles.
46015659|NCT00601133|Other|Walking Test|"Timed Test 1: From sitting position walk 10 feet quickly, return to sitting position Timed Test 2: Walk 25 feet, turn around, and walk back~Tests conducted twice, once on departure from rehabilitation center, and again at a return visit 1 month later"
46015660|NCT00601133|Other|Balance Test|Machine balance test: Stand on a platform with a rail, shift weight and try to maintain balance and center of gravity; Results displayed.
46015661|NCT00601133|Behavioral|Questionnaire|To be completed when leaving the rehabilitation program and again at the study visit 1 month later, lasting about 5 minutes.
46015662|NCT00601133|Behavioral|Diary|Record any physical exercise done from departure of rehabilitation center to return visit 1 month later; includes exercises; approximately 5 minutes per entry
46100597|NCT04675567|Behavioral|Safety-Net Care Team Model|"Safety-Net Care Planning Team: Clinical expertise will be combined with peer-to-peer parent/guardian support for trauma-informed care delivery to both parent and child. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning."
45465549|NCT01227941|Drug|MK-4827 + pegylated liposomal doxorubicin|Initial evaluation of a 16-day dosing schedule: A loading dose of MK-4827 will be administered orally on Days 1-2 of the cycle and a maintenance dose daily on Days 3-16. Pegylated liposomal doxorubicin 40 mg/m^2 will be administered intravenously on Day 3 of each cycle. The maintenance dose of MK-4827 will be escalated, until the maximum tolerated dose (MTD) is determined. If the maintenance dose is escalated above the loading dose, the loading dose will be escalated to a level equal to the maintenance dose, for the subsequent cycle. Other dosing schedules of MK-4827 may be explored, including 7-, 10-, 21- and 28-day schedules.
45465550|NCT01227941|Drug|MK-4827 + pegylated liposomal doxorubicin|MK-4827 will be administered according to one or two dose schedules as determined in Part A. Pegylated liposomal doxorubicin 40 mg/m^2 will be administered intravenously on Day 3 of the cycle.
45465551|NCT05385991|Biological|ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)|ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001): Artificial Cell Membranes (ACM) containing recombinant SARS-CoV-2, beta- variant strain, spike protein and ACMs containing CpG adjuvant
45465552|NCT03919565|Drug|Tenofovir Disoproxil Fumarate|Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.
45465553|NCT03919565|Drug|Peginterferon Alfa-2a|Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
45465554|NCT03919565|Drug|Peginterferon Alfa-2b|Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
46015663|NCT00601211|Drug|Pilocarpine|
46015664|NCT00601289|Drug|temozolomide|
46015665|NCT00601289|Genetic|DNA methylation analysis|
46015666|NCT00601289|Genetic|microarray analysis|
45465555|NCT05648773|Behavioral|Messaging|Booster reminder message
45465556|NCT05648773|Behavioral|Financial Incentive|Financial Incentive for getting boosted within 2-weeks of the message
45465557|NCT05648773|Other|Placebo|Treatment as usual; no additional message and no incentive.
45465558|NCT03380091|Drug|Metformin|Oral medication daily
45465559|NCT03380091|Drug|Vitamin D|Oral medication daily
45465560|NCT02529293|Drug|BioChaperone Lispro U-100|Injection of BioChaperone Lispro U-100
46015667|NCT00601289|Genetic|protein expression analysis|
46015668|NCT00601289|Genetic|proteomic profiling|
46015669|NCT00601289|Other|laboratory biomarker analysis|
46015670|NCT04301947|Other|Standard warm-up protocol|Stationary cycling and lower limb stretching exercises
46100598|NCT00613769|Drug|trimethoprim-sulfamethoxazole + metronidazole|trimethoprim-sulfamethoxazole (160mg/800mg)p.o.+ metronidazole (1200mg)p.o.
46100599|NCT00613769|Drug|cefuroxime and metronidazole|cefuromime 1500mg i.v. + metronidazole 1500mg i.v.
46015671|NCT04301947|Other|Gluteal activation warm-up protocol|Standard warm-up protocol + Clam exercise (3 sets of 12 repetitions each)
46015672|NCT02891525|Dietary Supplement|50g glucose|
46015673|NCT02891525|Dietary Supplement|25g fructose|
46015674|NCT02891525|Dietary Supplement|220mg acesulfame-K|
46100600|NCT00661154|Drug|Bevacizumab|2-12microCi IV injection
46100601|NCT04157270|Device|Penumbra System|Penumbra System
46015675|NCT02891525|Dietary Supplement|250mL tap water|
46015676|NCT04304053|Drug|Treatment and prophylaxis|"Cases will be offered a therapeutic regimen hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7~Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7."
46015677|NCT04304053|Other|Standard Public Health measures|Isolation of patient and contact tracing as per national guidelines.
46015678|NCT00601445|Behavioral|Amount of sleep and wake|4 groups with different patterns of sleep and wake
46015679|NCT00601679|Other|NT-proBNP guided care|knowledge of NT-proBNP results
46100602|NCT00523705|Drug|escitalopram|10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
45465561|NCT02529293|Drug|BioChaperone Lispro U-200|Injection of BioChaperone Lispro U-200
45465562|NCT05191030|Behavioral|High-Stress Intervention|Those undergoing the High-Stress will be exposed to a gold-standard laboratory stressor, the Trier Social Stress Test (Kirschbaum et al., 1993), which reliably induces cortisol reactivity in most individuals.
45465563|NCT03919253|Combination Product|pyrotinib maleate tablets+nab-paclitaxel|pyrotinib maleate tablets: 400mg orally once daily continunously nab-paclitaxel: 125mg/m2 iv d1、8 of each 21 day cycle, 6cycles.
45465564|NCT05458648|Procedure|Cardiac Ablation for the treatment of persistent Atrial Fibrillation|Patients participating in the study will undergo a cardiac ablation for the treatment of persistent atrial fibrillation.
45465565|NCT01130675|Other|caffeinated coffee|8 oz. of caffeinated cofee/breakfast&noon meal. No intervention for 2nd arm.
46100603|NCT00523705|Other|placebo|Placebo tablets matched to drug
45465566|NCT05165290|Drug|Latanoprost ophthalmic solution, 0.005%|Commercially available, FDA-approved generic latanoprost ophthalmic solution, 0.005% (LAT) without modification will be used as the active control
45465567|NCT05165290|Drug|TC-002 latanoprost ophthalmic solution, 0.005%|TC-002 is formulated using the commercially available latanoprost drug substance; delivered drop to the eye is preservative-free.
45465568|NCT03379233|Combination Product|Concept2 inhaler|Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler
45465569|NCT03379233|Combination Product|Concept2 inhaler with patient application|Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler with application used for monitoring
45465570|NCT03815071|Drug|Ips-nsc cells|Total dose of ips-nsc cells will be administered at day0.
45465571|NCT01132703|Drug|Glyburide for Injection|Administered as specified in the Treatment Arm.
45465572|NCT01132703|Drug|Placebo|Administered as specified in the Treatment Arm.
46015680|NCT00601757|Behavioral|The Postpartum Prevention Program (PPP)|PPP includes interpersonal therapy sessions as well as distribution of educational material on postpartum depression. The group sessions will take place during the participant's last trimester of pregnancy. There will be four weekly sessions prior to delivery and one booster session within the first 2 weeks of the postpartum period.
46100604|NCT04157114|Drug|MAP4343|Subjects will receive daily oral doses of MAP4343 for 6 weeks in conjunction with 6 weeks of manual-guided counseling
46100605|NCT04157114|Drug|Placebo|Subjects receive matched placebo for 6 weeks in conjunction with 6 weeks of manual-guided counseling
46100606|NCT04157114|Behavioral|Standardized behavioral counseling|Subjects receive manually-guided counseling 1 time per week for a 6 week duration
46100607|NCT00193427|Drug|Docetaxel|30mg/m2 administered on days 1 and 8, 21-cycle days, 3 cycles
46100608|NCT00193427|Drug|Gemcitabine|1000 mg/m2 administered by 30-minute IV infusion on day 1 and 8, 21-cycle days, 3 cycles
46100609|NCT00193427|Drug|Carboplatin|AUC = 1.5 weekly x 7
46100610|NCT00193427|Radiation|Radiation|To 63 Gy
46100611|NCT00665678|Drug|paroxetine|treatment for three months with paroxetine
46100612|NCT00665678|Drug|placebo|treatment for three months with placebo
46100613|NCT05345327|Drug|Dapagliflozin|SGLT2 inhibitor
46100614|NCT05345327|Drug|Metformin|Metformin
46100615|NCT00657332|Procedure|blood sample draw|
46100616|NCT00657332|Procedure|urine sample|
46100617|NCT00523549|Drug|valsartan|160 mg or 320 mg tablets once a day
46100618|NCT00523549|Drug|amlodipine|5 mg or 10 mg tablets once a day
46100619|NCT04160312|Dietary Supplement|Mitopure™ (Proprietary Urolithin A)|Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
46015681|NCT00601757|Behavioral|Enhanced care as usual (ECU)|ECU includes the usual medical care provided for pregnant women at the Women's Primary Care Center at Women and Infants Hospital as well as the provision of educational material and a list of treatment resources for postpartum depression. Participants will also receive more intensive follow-up in terms of their mental health status than is typically provided in usual practice.
46015682|NCT00601913|Drug|erlotinib hydrochloride|
46015683|NCT00601913|Genetic|protein analysis|
46015684|NCT00601913|Genetic|western blotting|
46015685|NCT00601913|Other|immunohistochemistry staining method|
46015686|NCT00601913|Other|laboratory biomarker analysis|
46015687|NCT00601913|Other|liquid chromatography|
46015688|NCT00601913|Other|mass spectrometry|
46015689|NCT00601913|Procedure|neoadjuvant therapy|
46100620|NCT04160312|Dietary Supplement|Pomegranate Juice|100% Pomegranate juice (approximately 1 glass equivalent)
46100621|NCT04215653|Drug|Anaprazole Sodium|administered orally once every 30-60 minutes before breakfast for 4 weeks
46100622|NCT04215653|Drug|Rabeprazole|administered orally once every 30-60 minutes before breakfast for 4 weeks
46100623|NCT04215653|Drug|Rabeprazole Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
46100624|NCT04215653|Drug|Anaprazole Sodium Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
46100625|NCT04160780|Procedure|L-PRF|sinus augmentation using L-PRf as sole graft material
46100626|NCT04160780|Procedure|L-PRF mixed with xenograft|sinus augmentation using L-PRF mixed with xenograft as sole graft material
46100627|NCT04160780|Procedure|xenograft|sinus augmentation using xenograft as sole graft material
46100628|NCT02706119|Drug|Subcutaneous glargine insulin|Glargine insuline is an insulin analogue which has a prolonged duration of action. Insulin glargine is obtained by recombinant DNA technology in Escherichia coli.
46100629|NCT02706119|Drug|Regular insulin added to TPN bag|Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.
46100630|NCT02631668|Drug|ferrous succinate and vitamin C|As experimental group, when patients take the tablets of ferrous succinate, they also take vitamin C at the same time
46100631|NCT02631668|Drug|ferrous succinate|As active comparator, patients take the tablets of ferrous succinate with normal dosage in clinical practice
46015690|NCT00601913|Procedure|therapeutic conventional surgery|
46015691|NCT00601991|Biological|VEGF Trap|Drug under investigation
46015692|NCT00601991|Procedure|Bone marrow biopsy|To determine response to treatment
46015693|NCT00601991|Procedure|bone marrow aspiration|To determine response to treatment
46015694|NCT00601991|Procedure|Venipuncture|For test of free VEGF Trap compared to bound VEGF Trap and for routine clinical testing during treatment
46015695|NCT01301391|Drug|Milciclib Maleate|"150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity."
46015696|NCT00602069|Behavioral|Helping to Overcome PTSD through Empowerment (HOPE)|HOPE includes a maximum of 16 sessions of cognitive behavioral therapy. The sessions will emphasize stabilization and empowerment, both of which are identified as important goals by the theoretical and empirical literature on abused women and PTSD.
46015697|NCT00602069|Behavioral|Treatment as usual|Treatment as usual includes standard shelter services for abused women.
46015698|NCT01036321|Drug|Purified isoflavones|Soy-based isoflavone concentrate with methyl cellulose blend filler - Take 2 capsules daily
46015699|NCT01036321|Drug|Methyl cellulose blend|Placebo - Take 2 capsules daily
46015700|NCT04325633|Drug|1: Naproxen|Description : Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)
46015701|NCT04325633|Drug|2: Standard of care|Standard of care
46100632|NCT02631668|Drug|ferrous succinate|As another active comparator, patients take the tablets of ferrous succinate with double dosage
46100633|NCT00665756|Procedure|second Trabeculectomy|second trabeculectomy with mitomycin-c
46100634|NCT00665756|Procedure|Ahmed Implant|Ahmed silicone drainage device
45465573|NCT03815149|Device|Pipeline™ Flex Embolization Device with Shield Technology™|Neurointerventional procedures to treat intracranial (cerebral) aneurysms are minimally-invasive procedures performed by Interventional Neuroradiologists. The physician accesses the arterial system through a blood vessel in the groin followed by the insertion of a catheter. Pipeline™ Flex Embolization Device(s) with Shield Technology™,a flow diversion device, is implanted under high-magnification subtraction fluoroscopy, requiring the use of ancillary devices, such as micro-catheters and guidewires to complete the procedure under general anaesthetic. Procedural heparinisation and preloading with dual antiplatelet therapy (DAPT) using acetyl-salicylic acid and P2Y12 inhibitors such as clopidogrel or prasugrel are required.
45465574|NCT03919487|Procedure|Back to back colonoscopy|After first colonoscopy performing with polypectomy, the 2nd colonoscopy will be performed right after the 1st colonoscopy, and if the missed lesion during the 1st colonoscopy will be found, it should be removed.
45465575|NCT03711825|Drug|LYN-057|Administration of single dose of LYN-057 presented as extended release capsule containing 50 mg of memantine hydrochloride (HCl)
46100635|NCT02705885|Dietary Supplement|lozenges containing IgY|Patients consumed food supplement lozenges containing IgY after nonsurgical periodontal therapy
46100636|NCT02705885|Dietary Supplement|Placebo IgY|Placebo IgY
45465576|NCT03711825|Procedure|Imaging Assessment (MRI)|Imaging assessments [MRI] will be performed on specified days according to protocol
46100637|NCT04428541|Other|Questionnaire for visual function assessment of preverbal children|18 items questionnaire
46015702|NCT05643651|Drug|Rivaroxaban Oral Tablet or Suspension [Xarelto]|Administered in a body weight-adjusted 20 mg-equivalent total daily dose regimen
46015703|NCT05643651|Drug|Aspirin or Clopidogrel|Aspirin [3 ~5mg/(kg·d) once daily] or Clopidogrel [0.2~1.0 mg/kg(<2 years old),1 mg/kg(≥2 years old); once daily]
46015704|NCT05643651|Drug|Warfarin|Warfarin 0.05~0.12 mg/(kg·d) once daily. INR should maintain within 1.5 to 2.5
46015705|NCT04126889|Other|questionnaire survey|questionnaire survey
46015706|NCT04324749|Other|Roasted peanuts (group A)|After 2 weeks following a peanut-free diet, the participants of this group consume 25 g/ day of whole skin roasted peanuts (RP) within the habitual diet during 6 months.
46100638|NCT00661856|Dietary Supplement|Soy protein|25g of Soy protein with or with out 90mg of isoflavones ones a day given for a period of 24 months
46100639|NCT04215731|Drug|Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab|Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 4 cycles and mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 2 cycles
46015707|NCT04324749|Other|Peanut butter (group B)|After 2 weeks following a peanut-free diet, the participants of this group consume 2 tbsp/ day (32 g/ day) of peanut butter (PB) within the habitual diet during 6 months.
46015708|NCT04324749|Other|Control (group C)|After 2 weeks following a peanut-free diet, the participants of this group consume 2 tbsp/ day (32 g/ day) of control supplement (containing the same proportion of macronutrients as peanuts and peanut butter) within the habitual diet during 6 months.
46015709|NCT01061359|Drug|Epirubicin: Observational Study|Observational: Chemotherapy
46015710|NCT05643417|Drug|HAIC、Bevacizumab、Camrelizumab|HAIC: refer to genetic test results，D1 Bevacizumab：7.5mg/Kg, D2, Q3W Camrelizumab：200mg, D2, Q3W
46015711|NCT02891369|Other|No intervention. Descriptive study|
45465577|NCT03711825|Procedure|Imaging Assessment (U/S)|Imaging assessments (abdominal U/S) will be performed on specified days according to protocol
46015712|NCT04303975|Other|clinical measurements|Only clinical parameters were recorded, no intervention was made.
46015713|NCT05643339|Diagnostic Test|microvascular flow imaging|microvascular flow imaging
46015714|NCT00602147|Other|laboratory biomarker analysis|Blood or cheek cells wil be collected.
46015715|NCT04303741|Drug|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
46100640|NCT04215731|Procedure|Restaging|Restaging by pelvic magnetic resonance imaging (MRI)
46100641|NCT04215731|Radiation|Concomitant Chemoradiotherapy|Concomitant chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks)
46100642|NCT04215731|Procedure|Surgery|Radical surgery (TME or more extended surgery)
46100643|NCT04215731|Radiation|Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging)|Chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks)
46100644|NCT04215731|Drug|Induction chemotherpay with FOLFOX|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 4 cycles
46100645|NCT04383769|Other|questionnaires survey|data will be collected from the medical records already existed in the hospital and community-based organization (CBO) systems and entered into case report form (CRF). The expected number of participants is 5000. For each participant, the data will be collected prospectively for 24 months and retrospectively up to 5 years from the screening date. This study has no intervention and will not alter ART services whether be standard or DSD-ART at hospitals.
46100646|NCT00665834|Drug|rosuvastatin|rosuvastatin 20 mg from day 0 to (maximum) day 6
46100647|NCT00665834|Drug|placebo|placebo 20 mg from day 0 to (maximum) day 6
46100648|NCT00665834|Drug|rosuvastatin|rosuvastatin 20 mg from discharge until the end of the study
46100649|NCT00665834|Drug|atorvastatin|atorvastatin 80 mg from discharge until the end of the study
46100650|NCT04354675|Genetic|Automated program (ChatBot)|Pre-test counseling and information through a pre-test automated genetic counseling program (ChatBot)
46100651|NCT04354675|Genetic|Genetics counselor|Traditional in-person genetic counseling
46100652|NCT04354675|Other|BCGCKQ Survey|Survey assessing Breast Cancer Genetic Counseling Knowledge Questionnaire (BCGCKQ)
46100653|NCT04354675|Other|Satisfaction Survey|Survey assessing satisfaction with Decision-Genetic Testing
46100654|NCT04354675|Device|Genetic testing|Genetic testing for all participants will assess for a mutation in 47 genes commonly associated with hereditary cancer syndromes (Invitae's Common Hereditary Cancer Panel) for those who choose to complete testing.
46100655|NCT02704013|Drug|Oxybutynin|Anticholinergic
46100656|NCT00665912|Procedure|Standard post-lobectomy wound care plus use of PRP and PPPc prepared by GPS and Plasmax respectively|GPS is used to create the platelet rich plasma (PRP). Plasmax is used to create the concentrated platelet-poor plasma (PPPc). Both PRP and PPPc will be used for wound care in the thoracic cavity post-lobectomy.
46100657|NCT00665912|Procedure|Standard post-lobectomy wound care|Standard post-lobectomy wound care
46100658|NCT04327687|Device|Remote ischaemic conditioning|5 cycles of 5 minutes of upper limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual sphygmomanometer applied to the upper arm and activated to go through 5 such cycles automatically. The blood pressure cuff in the active treatment arm will inflate to 200 mmHg. RIC will be completed 1-2 times per day for six months.
45465578|NCT03607162|Diagnostic Test|DIAFEVER algorithm|PCT rapid test-based predictive algorithm
46015716|NCT04303741|Drug|Apatinib|Apatinib 250mg will be administered daily until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
46015717|NCT04303741|Drug|Eribulin|Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
46015718|NCT05643261|Other|Muscle and technique training|The strength training consists of three exercises (clam shell, side plank, calf raises) with an progressive overload after two to three weeks to ensure a continuous muscle stimulation. The technique training consists of different cutting variations with a focus on forefoot landings and conscious control of the knee to avoid high knee valgus movement and KAM respectively.
46100659|NCT04327687|Other|conventional therapy|conventional therapy
46100660|NCT00665990|Drug|Bevacizumab|Bevacizumab starting dose of 5 mg/kg every 3 weeks increasing in combination with Sorafenib and Cyclophosphamide until maximum tolerated dose
45474005|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women receive 30gr/day olive oil (standard group. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
46015719|NCT00626977|Drug|ropivacaine|15 ml of ropivacaine 0.125% peridural once
46015720|NCT00626977|Drug|ropivacaine and clonidine|15 ml of ropivacaine 0.0625% plus 75 mcg clonidine
46015721|NCT04302883|Diagnostic Test|Transesophageal Echocardiography (TEE)|Ultrasound of heart chambers via esophagus
46015722|NCT04302883|Diagnostic Test|Flexible Endoscopic Evaluation of Swallowing|Endoscopical swallowing study
46100661|NCT00665990|Drug|Sorafenib|Sorafenib 90 mg/m2 PO every 12 hours increasing in combination with Bevacizumab and Cyclophosphamide until maximum tolerated dose
46015723|NCT00623571|Other|Treatment of elderly patients in a GMW|
46015724|NCT00623571|Other|Treatment of elderly patients in GHHS|
46015725|NCT00627211|Procedure|CO2 insufflation|From the CO2 rack through the endoscopy rack CO2 will be insufflated to visualize the mucosa during oesophagogastroduodenoscopy.
46015726|NCT04303819|Drug|Exenatide treatment|12 weeks of exenatide injection, 5 μg twice a day by subcutaneous injection for 4 weeks, followed by 10 μg twice a day for 8 weeks, as recommended by the drug manufacturer.
46015727|NCT01301079|Drug|Ketamine|Patients in group ketamine was administrated ketamine (5mcg/kg/min) during the surgery.
46015728|NCT01301079|Drug|Saline|Patients in group N (placebo) was administrated saline during surgery.
46015729|NCT04303039|Drug|ABP-671|ABP-671 Tablet 1.0 mg
46015730|NCT05271721|Drug|epidural transforaminal injection of magnesuim sulfate|transforaminal fluroscopic guided
46100662|NCT00665990|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/m2 PO once daily increasing in combination with Bevacizumab and Sorafenib until maximum tolerated dose
46100663|NCT02703701|Behavioral|Physician at triage|A physician embedded at triage
46100664|NCT02703701|Other|Usual Care|No physician at triage
45474006|NCT04171570|Procedure|Coronary angiography and or Percutaneous coronary Intervention|Radial access punture site
46015731|NCT05271721|Drug|epidural transforaminal injection of dexmedtemodine|transforaminal fluroscopic guided
46015732|NCT05271721|Drug|transforaminal epidural injection of dexamethasone|transforaminal fluroscopic guided
46015733|NCT01036165|Device|RebiSmart™|The RebiSmart™ autoinjector contains Rebif® 132 mcg multidose cartridges for sc injection.
46015734|NCT05642871|Radiation|DKI and APT|DKI and APT in patients with ovarian malignancy before and after treatment
46015735|NCT01301001|Drug|Placebo oral capsule|Placebo 2 capsules am and 3 capsules pm
46015736|NCT01301001|Drug|Gabapentin|Gabapentin 1200 mg am and 1800 mg pm
46100665|NCT00666068|Other|corticotropin releasing hormone (CRH)|50 µg injected at 2200, 2300, 0000, and 0100
46100666|NCT00666068|Other|Placebo|injected at 2200, 2300, 0000, and 0100
46100667|NCT00666068|Other|Placebo|injected at 2200, 2300, 0000, and 0100
45680267|NCT03306992|Behavioral|Personalized Exercise Program|"The PEP intervention involves a combination of home-based exercise as well as in-patient exercise. The exercise modes will include basic transfer and calisthenics mobility, aerobic and resistance exercises and will be performed in various postures (supine, sitting, standing and walking) with variable challenges (level walking, bending, inclines, steps and squatting).~For patients randomized to the Intervention Group (Group 1), the PEP intervention will be personalized, implemented, and modified (based on the patients AM-PAC mobility stage) by a licensed physical therapist in face-to-face, virtual, or phone meetings (~30-40 minutes). An exercise education manual, specifically developed for this study, will be used by the physical therapist to educate the patients on all aspects of starting and maintaining the exercise intervention."
46015737|NCT01035463|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplant
46015738|NCT01035463|Drug|Carmustine|Given IV
46015739|NCT01035463|Drug|Cytarabine|Given IV
46100668|NCT04215497|Other|PSSE|"Physiotherapeutic Scoliosis-Specific Exercises (PSSE) group will receive exercise for 30-40 mins in a day, twice in a week, totally 8 weeks and 16 hours.~Control group will be taught the basic elements of corrective exercises and want them to do the practising during 8 weeks at home."
45680268|NCT03278106|Other|Laboratory Biomarker Analysis|Correlative studies
45680269|NCT03278106|Drug|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
45680270|NCT03255252|Drug|Cisplatin injection|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
46015740|NCT01035463|Drug|Etoposide|Given IV
46015741|NCT01035463|Drug|Lenalidomide|Given PO
46015742|NCT01035463|Drug|Melphalan|Given IV
46015743|NCT01035463|Biological|Rituximab|Given IV
46100669|NCT04153526|Procedure|Blood sampling|Blood samples will be obtained during routine clinical visits. Ideally, two 9mL blood samples (or equivalent volume) will be collected into EDTA or other appropriate blood collection tube at each time point except at baseline, where three EDTA 9mL tubes and one of 2.6mL (for study of whole blood) will be collected.
46100670|NCT04153526|Procedure|Surplus Tumour Tissue sample collection from surgery|In surgical patients, lung tumour samples and normal lung tissue will be obtained from surplus tissue removed at the time of surgery. No extra procedures (biopsies or surgeries) are requested for the study.
46100671|NCT04153526|Other|Collection or archival tumour tissue (If available)|Where available surplus tumour and normal tissue from archival tissue will be collected for analysis.
46015744|NCT01300923|Drug|Acamprosate|
46015745|NCT05642559|Other|questionnaire|Assessment of refractory chronic cough (RCC) or unexplained chronic cough (UCC) impact on HRQoL of the explored population and relationship with clinical variables. Development of a web application of the questionnaire.
46015746|NCT01300767|Device|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
46015747|NCT01300767|Device|Balafilcon A contact lens (PureVision® 2)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
46100672|NCT03121391|Procedure|Ventilator withdrawal algorithm|"Steps and decision trees in the algorithm include in descending order:~Ascertain patient consciousness, perform cuff-leak test, evaluate for indications for pre-medication, select a withdrawal method, assess for respiratory distress with Respiratory Distress Observation Scale, medicate for respiratory distress with morphine, make an extubation decision, ascertain need for continuous morphine, ascertain need for supplemental oxygen, assess for post-extubation stridor, treat post-extubation stridor"
45465579|NCT03919331|Diagnostic Test|Assessment of tidal volume using Electrical Impedance Tomography (EIT) during high flow nasal canula(HFNC)|After information and consent, patients under HFNC for de novo acute hypoxemic respiratory failure will undergo a ten minutes 4cmH2O continuous positive airway pressure(CPAP) test while monitored with 1)chest Electrical Impedance Tomography (EIT) 2) a pneumotachograph inserted on the ventilator circuit between the mask and the Y-piece and connected to a differential pressure sensor, and 3) respiratory inductance plethysmography (RIP). Airway flow signal will be acquired using an analog/digital converter and stored for further analysis with acknowledge software. This will allow converting EIT data into tidal volume (TV), and estimating TV under HFNC. RIP signals will allow evaluating asynchronism between chest and abdomen by calculating the phase angle, thus quantifying respiratory distress. Patients monitored with an arterial catheter, arterial blood gas measurements will be done during CPAP and HFNC. These measures will be collected the first day of HFNC, and everyday up to three days
45465580|NCT01585649|Drug|Lipegfilgrastim|Lipegfilgrastim 100ug/kg
45465581|NCT01377922|Drug|Amifampridine Phosphate|Amifampridine, 30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets), for 2 weeks.
45465582|NCT01377922|Drug|Placebo|Matching placebo tablets administered 3-4 times a day (to the individual patient's tablet count of active at baseline) over 2 weeks.
45465583|NCT02528903|Drug|MHAB5553A|Single intravenous administration, at various doses, depending on the cohort
45465584|NCT02528903|Drug|Matching placebo|Single intravenous dose
45680271|NCT03255252|Combination Product|radiotherapy|A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion).
45680272|NCT03254420|Device|Calypso beacon implant|Calypso beacon implant before radiotherapy
46015748|NCT01300767|Device|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
46015749|NCT05642481|Diagnostic Test|Therapeutic drug monitoring in plasma of mother and child and in breastmilk|Measurement of drug concentration in plasma of mother and if possible of child and in breastmilk
46015750|NCT02890173|Drug|CS-3150|
46015751|NCT02890173|Drug|Eplerenone|
46015752|NCT01300455|Drug|Suvorexant|40 mg tablets, orally once daily for 4 consecutive days in the evening
46015753|NCT01300455|Drug|Matching Placebo|Placebo tablets, orally once daily for 4 consecutive days in the evening
46100673|NCT00671138|Biological|Necator americanus|10 necator americanus larvae will be inoculated at week 0 with a further 5 larvae inoculated at week 12
46100674|NCT00671138|Other|Sham inoculation|A diluted amount of McIlhenny & Co Tabasco Pepper Sauce will be applied via a gauze dressing at weeks 0 and 12.
45680273|NCT03254420|Radiation|moderate hypofractionation Radiotherapy|moderate hypofractionation Radiotherapy
45680274|NCT03240523|Drug|Vilaprisan (BAY1002670)|Orally, 2 mg, once daily
46100675|NCT03504085|Other|Yoga: Active Hatha|Classical Hatha yoga with influences from Viniyoga and Iyengar yoga. Both Viniyoga and Iyengar yoga styles emphasize modifications and adaptations including the use of props such as straps and blocks in order to minimize the risk of injury and make the poses accessible to people with health problems and limitations
46100676|NCT03504085|Other|Yoga: Restorative|Restorative Yoga is a slow-paced yoga style that emphasizes relaxation and includes very little movement.
45680275|NCT03230747|Device|Edwards SAPIEN M3 System|SAPIEN M3 System includes the SAPIEN M3 valve and the SAPIEN M3 dock
45680276|NCT03220347|Drug|CC-90010|CC-90010 is an oral, potent and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.
45680277|NCT03214198|Drug|Vonoprazan|Vonoprazan tablets
45680278|NCT03203525|Biological|Bevacizumab|Given IV
45680279|NCT03203525|Drug|Fluorouracil|Given via pump
45680280|NCT03203525|Drug|Leucovorin|Given via pump
45680281|NCT03203525|Drug|Oxaliplatin|Given via pump
45680282|NCT03203525|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
45680283|NCT03203525|Drug|Temsirolimus|Given IV
45680284|NCT03203525|Procedure|Tumor Treating Fields Therapy|Use NovoTTF-100L(P) system
45465585|NCT03811795|Other|ECG monitoring with a Kardia Mobile monitor|The participants in the study will undergo a total of two follow-up visits after ablation (approximately 3 and 6 months) with a 12-lead electrocardiogram at each visit. An assessment of rhythm will be performed with daily transmissions as well as subject-activated event recordings for symptoms with the Kardia Mobile smartphone based monitor. The Kardia Mobile System is an FDA-cleared, clinical grade mobile ECG monitor coupled with a smartphone app that is able to record a single-lead ECG and securely transmit the tracings to the study investigators via the Kardia Pro commercial (HIPPA compliant) remote monitoring service for clinicians.
46015754|NCT05642169|Behavioral|HIIT|"The training sessions will have a frequency of 3 times per week (Monday, Wednesday and Friday) and the duration will be between 39 to 54 minutes, depending on the training week.~The training program will be developed with the own body weight of each participant. Therefore, a progression according to the needs of this population will be fulfilled. The session model could be multi-joint exercises with self-loads, where the difficulty of the exercises will be worked progressively. Throughout the main part of each workout, 30 seconds of work will be performed at the corresponding intensity and 30 seconds of rest. Halfway through the total repetitions, there will be 2 minutes of recovery."
46015755|NCT05642169|Behavioral|HIIT+PA|In relation to the 2 groups that will perform HIIT, the HIIT+AF will have to complete 10.000 steps per day. In this way, they will be focusing on increasing their daily physical activity. In addition, this group will perform the same HIIT training programme as the other experimental group.
45465586|NCT03919175|Drug|Umbralisib|Umbralisib is an investigational drug which blocks a protein called PI3K. PI3K is a protein that plays a role in the way cells grow. In this type of cancer, PI3K is increased and more active than usual. This helps the cancer cells to grow and survive.
45465587|NCT03919175|Drug|Rituximab|Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
45680285|NCT03192215|Drug|Apixaban|5 mg by mouth twice daily (2.5 mg for subjects meeting standard criteria for an adjusted dose).
45680286|NCT03192215|Drug|Aspirin|Aspirin 81 mg by mouth once daily.
45680287|NCT03182907|Biological|Bezlotoxumab|A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.
45680288|NCT03182907|Drug|Placebo|A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose.
46015756|NCT05642169|Behavioral|CON|This group will not suffer any changes in their lifestyle
46015757|NCT01107418|Drug|RO5185426|dosage b) orally twice daily, days 1-15 (morning dose)
46015758|NCT01107418|Drug|RO5185426|dosage c) orally twice daily, days 1-15 (morning dose)
46015759|NCT01107418|Drug|RO5185426|dosage d) orally twice daily, days 1-15 (morning dose)
46015760|NCT01107418|Drug|RO5185426|960 mg orally twice daily, from day 22 onward
46015761|NCT01107418|Drug|RO5185426|dosage a) orally twice daily, days 1-15 (morning dose)
46015762|NCT05642091|Device|ultrasound Elastography|application of shear wave force by ultrasound elastography
46015763|NCT05641935|Drug|Sulfur Hexafluoride Lipid Microspheres|Given IV
46015764|NCT05641935|Procedure|Contrast-Enhanced Ultrasound|Undergo CEUS
46015765|NCT05641935|Procedure|Computed Tomography|Undergo CT
46015766|NCT05641935|Procedure|Magnetic Resonance Imaging|Undergo MRI
46100677|NCT03299855|Other|Passation of neuropsychological test|Passation of MoCA and MMS tests associated with neuropsychological test
46100678|NCT00700102|Drug|Chemotherapy|As prescribed
46015767|NCT05641935|Other|Electronic Health Record Review|Review electronic medical record
46015768|NCT05641779|Device|pigtail|pigtail catheter insertion in chest in the pleural cavity
46015769|NCT05641701|Device|System On|The DBS system will be turned on, and the individual's stutter will be assessed.
46015770|NCT05641701|Device|System off|The DBS system will be turned off, and the individual's stutter will be assessed.
46015771|NCT01101178|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken with food.
46015772|NCT01101178|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken with food.
46015773|NCT05639205|Diagnostic Test|Lateral Flow Device|Regular asymptomatic staff testing with a Lateral Flow Device including support payments if unwell.
46015774|NCT05637645|Procedure|Midline Approach|In the midline approach, the spinal approach to the intrathecal space is midline with a straight line shot. After infiltration with lidocaine, the spinal needle is introduced into the skin, angled slightly cephalic. The needle traverses the skin, followed by subcutaneous fat. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
46015775|NCT05637645|Procedure|Paramedian Approach|The paramedian approach involves inserting the spinal needle 1 cm away from the midline in medial direction. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
46100679|NCT00700102|Drug|Bevacizumab|Bevacizumab, 5 mg/kg intravenously (IV) on days 1 and 14 of each 4 week cycle, or 7.5 mg/kg IV on days 1 and 22 of each 6 week cycle.
46100680|NCT04156256|Biological|CD123-CD33 cCAR T cells|CD123-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD123 and CD33 CARs.
46100681|NCT00671216|Drug|GSK233705|Subjects will receive 200 (mcg) microgram once daily as a single dose
46100682|NCT00671216|Drug|GW642444|Subjects will receive 50 mcg once daily as a single dose
46100683|NCT00671216|Drug|GSK233705 and GW642444|Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose
46100684|NCT00671216|Drug|Placebo|Placebo matching study medication will be inhaled by subjects
46100685|NCT02705729|Device|Ketac Universal|High-viscous glass ionomer restorative material used as posterior dental filling. This material does not require a dentin conditioning step.
46100686|NCT02705729|Device|Ketac Molar Quick|High-viscous glass ionomer restorative material used as posterior dental filling. This material requires a dentin conditioning step.
46100687|NCT02631512|Device|Woulgan Gel|Primary dressing gel to be applied to the wound bed, and to be covered with a secondary bandage.
46100688|NCT02631512|Device|Intrasite Hydrogel|Primary dressing hydrogel to be applied to the wound bed, and to be covered with a secondary bandage
46100689|NCT02705573|Drug|Mannitol|In the study, mannitol 20% with a dose of 1g / kg / BW (5 ml / kg / BW) will be compared to placebo with NaCl 0.9% in the dose of 5 ml / kg / BW. The study medication will be administered immediately before organ reperfusion. The follow-up of the study is 24 hours.
46015776|NCT05637645|Procedure|Taylors approach|his arm will have the procedure of spinal anesthetic performed via 'Taylor's approach' which is a paramedian approach to interspace L5 - S1. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
46015777|NCT05637021|Other|Carbon dioxide insufflated during colonoscopy|Carbon dioxide is insufflated to dilate the bowel lumen during colonoscopy.Record the amount of gas insufflated during colonoscopy.
46015778|NCT00623649|Drug|VCH 916|Dose escalation study with a full review of all safety data following each cohort.
46015779|NCT00623649|Drug|Placebo|Dose escalation study with a full review of all safety data following each cohort.
46100690|NCT00613847|Radiation|PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab|Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
45465588|NCT01303471|Drug|opioid (remifentanyl)|Infusion of remifentanyl (opioid) will be started at different levels for each group of the randomized study : 0 ng/ml (group 0), 1 ng/ml (group 1), 3 ng/ml (group 3) or 4 ng/ml (group 4)
45465589|NCT03372603|Drug|GSK2798745|GSK2798745 tablets will be available as white to almost white, round, film-coated tablets (micronized active pharmaceutical ingredient [API]) to be taken with a glass of water (approximately 240 mL).
46015780|NCT01101022|Drug|SPD489|1 capsule per day (30, 50 or 70 mg), daily throughout the double-blind treatment period (10 weeks)
46015781|NCT01101022|Other|Placebo|1 capsule per day, daily throughout the double-blind treatment period (10 weeks)
46015782|NCT05627193|Other|Teleclinic|Instead of visiting surgeon after travelling from far flung areas for a post surgery follow up appointment, the follow up visit will be done using telephone.
45465590|NCT03372603|Drug|Placebo|Placebo tablets will be available as white to almost white, round, film-coated tablets to be taken with a glass of water (approximately 240 mL).
45465591|NCT01560247|Procedure|Mechanical thrombectomy|Mechanical thrombectomy using a MindFrame device
45465592|NCT03919019|Other|Macuprev Group|oral supplementation (Macuprev) 2 capsules per day for 6 months
45465593|NCT03919019|Other|Placebo Group|oral placebo 2 capsules per day for 6 months
46015783|NCT05627193|Other|Physical Clinic|Patients will have to travel to come physically to hospital to meet the operating surgeon.
46015784|NCT05622435|Device|T10070, Plastic tube with a roll-on applicator filled with an ointment|6 times per day on both (upper and lower) eyelids of right eye during 7 to 9 days.
46015785|NCT01299909|Behavioral|Integrated Training for Smokers|8 classes in smoking cessation strategies, 2 weeks of nicotine patches, and access to the Freedom From Smoking online program
46015786|NCT01299909|Behavioral|Mindfulness Training for Smokers|8 classes of training in mindfulness meditation, 2 weeks of nicotine patches, and access to the MTS website.
46015787|NCT01299909|Behavioral|Quitline|Telephone-based smoking cessation treatment via the Wisconsin Tobacco Quit Line (WTQL) consisting of 2 weeks of nicotine patches, self-help materials, an interactive website, and unlimited follow-up calls to the WTQL at no cost.
46015788|NCT02879110|Dietary Supplement|Sulforaphane|Sulforaphane (SFN) is a compound within the isothiocyanate group of organosulfur compounds. It is obtained from cruciferous vegetables such as broccoli, Brussels sprouts or cabbages.
46015789|NCT02879110|Other|Placebo|Placebo tablet is composed of starch.
46015790|NCT04207515|Procedure|Procedures of wisdom tooth removal surgery under conscious sedation|The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
45465594|NCT03811717|Other|FAST+EX|Participants will perform 2-hours of low-intensity arm exercise (8 x 15 min bouts of arm ergometer exercise separated by 10 min of rest) during an 8-hour fast.
46015791|NCT04207515|Procedure|Procedures of wisdom tooth removal surgery under local anesthesia|The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
45465595|NCT03811717|Other|FAST|Participants will complete an 8-hour fast.
45465596|NCT03919409|Drug|TS-161|TS-161 capsules
45465597|NCT03919409|Drug|TS-161 Placebo|TS-161 matching placebo capsules
45465598|NCT03804541|Drug|Ensartinib|A novel, potent ALK inhibitor.The ALK inhibitor ensartinib has been validated in potency and selectivity assays indicating that it is more selective and up to 10 times more potent than competitive ALK inhibitors. Ensartinib has been active in animal models of non-small cell lung cancer (NSCLC) and neuroblastoma, a childhood cancer. Importantly, ensartinib has shown activity in models with ALK mutations that confer resistance to other small molecule ALK inhibitors.
46015792|NCT04324515|Procedure|Robotic gastric bypass with or without cholecystectomy|Study Arm: robotic gastric bypass without cholecystectomy Control Arm: robotic gastric bypass with cholecystectomy
45465599|NCT01377844|Drug|EGT0001442|
45465600|NCT01377844|Drug|Placebo|
45465601|NCT03709485|Other|rectal swab for microbial culture.|Rectal swab and culture.
45465602|NCT01329497|Other|systemic dietary instruction|systemic dietary instruction based on continuous quality improvement (CQI) team-oriented approach
46015793|NCT02880826|Behavioral|Measure the culture of safety in the reanimation units|
46015794|NCT02879188|Other|Physical Therapy|Patients will initiate inpatient physical therapy on the day of their surgery including attempted ambulation with an assistive device that is supervised by a physical therapist.
46015795|NCT02879188|Other|Standing|Patients will initiate inpatient physical therapy on postoperative day 1. On the day of their surgery they will dangle their feet over the edge of the bed with supervision of nursing.
46015796|NCT01298661|Other|Six-minute Step Test|The patients underwent a test where they need to step up and down a 20cm test during six minutes.
46015797|NCT01100944|Drug|PXD101with cisplatin+doxorubicin+cyclophosphamide|PXD101 will be given as a 48h continuous intravenous infusion (CIVI) starting on day 1, doxorubicin as a slow intravenous (IV) injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression.
46015798|NCT01100320|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken with food
46015799|NCT01100320|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken with food
46015800|NCT04309708|Device|Nimodipine pump infusion|Patients with nimodipine pump infusion with pump infusion line and other infusion equipments
45465603|NCT05065489|Other|No intervention|No intervention
45465604|NCT03710811|Drug|Insulin|Continuous Subcutaneous Insulin Infusion
45465605|NCT01229969|Other|Wii Fit Balance Games|Ski Slaloms and Table Tilt
45465606|NCT01229969|Other|NeuroCom EquiTest® System|Sensory Organization Test (SOT) and Limit of Stability (LOS).
45465607|NCT01303549|Drug|Anidulafungin|Anidulafungin once a day for 14 days: initial dose 200 mg/day IV administered in 180 minutes. Following doses 100 mg/day IV administered in 90 minutes.
45465608|NCT01303549|Drug|Liposomal amphotericin B|Liposomal amphotericin B once a day for 14 days: 3 mg/kg/day. IV administration during 60 minutes.
45680289|NCT03182907|Drug|Antibacterial drug treatment (ABD)|ABD will be administered for 10-21 days including the duration of ABD prior to the screening visit, during the screening period, and after the infusion of study treatment, per institutional guidelines, at the investigator's discretion. ABD is defined as the receipt of oral metronidazole, oral vancomycin, intravenous (IV) metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
45680290|NCT03118986|Drug|Olanzapine|olanzapine 0.1 mg/kg/dose (maximum 10 mg/dose) by mouth as a single daily dose based on actual body weight
46015801|NCT01100086|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken without food
46015802|NCT01100086|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken without food
46015803|NCT01297959|Drug|E-101 Solution 300 GU/ml|8 mL of E-101 Solution
46015804|NCT01297959|Drug|Saline solution|Saline solution matched to E-101
46015805|NCT04187716|Drug|Ferinject|"For patients undergoing chemotherapy, ferinject 1000mg will be injected within 24 hours or 24 hours after day 1 of the next chemotherapy cycle.~Patients using targeted therapies can be dosed at any time after recognizing Hb 8.0-10.5g / dL and injecting 1000 mg of ferinject."
46015806|NCT00626080|Drug|Insulin detemir|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
46015807|NCT00626080|Drug|Insulin NPH|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
46015808|NCT04309240|Drug|Rivaroxaban|Rivaroxaban 10mg orally per day for 90days
46015809|NCT02878876|Dietary Supplement|Oral consumption of milk with sequence A1-A2|Oral consumption of 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
45465609|NCT03710733|Radiation|Sequential boost|Boost (10 Gy/4 fx/1 week) is given after whole breast irradiation
45465610|NCT03710733|Radiation|Concomitant boost|Boost (8 Gy/15 fx/3 weeks) is given with whole breast irradiation
45465611|NCT03925571|Other|musicotherapy|If the patient is randomized in the experimental group, he listens the Music-care® playlists and chose two closed to his musical tastes. The playlists are unique compositions create by Music-care® (french company), not known from the general public, categorized by theme (jazz, rock, world music…).
45465612|NCT03709407|Other|cervical stimuli|Manouvres Godoy
45465613|NCT03709407|Other|terminus|Manouvres Vodder
46015810|NCT02878876|Dietary Supplement|Oral consumption of milk with sequence A2-A1|Oral consumption of 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
45465614|NCT03709407|Other|Placebo|placebo manouvre
46015811|NCT02878954|Other|No intervention (Observational study)|"160 patients will be recruited to:~Fill in questionnaires related to demographic characteristics, severity of disease and physical activity.~Perform a six-minute walk test Comparison between men and women will be performed."
45465615|NCT03709407|Other|Control group|lie down
45465616|NCT03811639|Procedure|Radio-frequency ablation|Ablation for atrial fibrillation
45465617|NCT03811639|Procedure|Cryoballoon ablation|Ablation for atrial fibrillation
45465618|NCT03925337|Device|Computer Aided Diagnostic Software|The research software is deep learning algorithm used to aid in the detection of polyps (abnormal tissue growths in the wall of the colon and adenomas (pre-cancerous growths) during colonoscopy. In its current form, the automatic polyp detection system is installed on a computer system unit that utilizes an an operating system.
45465619|NCT05400460|Procedure|Anatomical single-bundle reconstruction（ASBR method）|406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to the ASBR group to receive anatomic single-bundle reconstruction.We used hamstring as an autograft in the operation, and we chose the anatomical footprint of the anterior cruciate ligament for the positioning of the bone tunnel.Arthroscopic ASB ACL reconstruction was conducted with AMP technique.
45465620|NCT05400460|Procedure|Double-bundle reconstruction （DBR method）|406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to the DBR group to receive double bundle reconstruction.The hamstring autograft is still used for double-bundle reconstruction. The surgical approach is to treat the native ligaments as anteromedial bundles and posterolateral bundles and restore the structure of the two bundles of ligaments in the process of a
45474007|NCT03735043|Device|cardiac output by ccNexfin ©|Measurement of cardiac output by ccNexfin © comparatively to transthoracic echocardiography Subjects participating to the study will be simultaneously measured for cardiac output by ccNexfin © and transthoracic echocardiography. Echocardiographic measurements of cardiac output will be blinded to values measured by ccNexfin ©. For each participant, a first measurement of cardiac output will be performed in the supine position and then after 1 minute of strict left lateral position.
45680291|NCT03118986|Drug|Placebo Oral Tablet|Placebo tablets that look like olanzapine and will be dosed as if they are olanzapine
45680292|NCT03070236|Other|Survey|Select questions will be ask in the survey
46015812|NCT02878954|Other|Control session|"Out of the 160 participants of the observational study, at least 40 (20 men and 20 women) will be recruited.~In the control session participants will be seated in resting position for 15 minutes."
45680293|NCT03053141|Device|Rhythmia Mapping System|The Rhythmia Mapping System is a 3D electro-anatomical mapping system.
45680294|NCT03052608|Drug|Lorlatinib|ALK-positive NSCL treatment
45680295|NCT03052608|Drug|Crizotinib|ALK-positive NSCL treatment
46015813|NCT02878954|Other|Exercise session|40 patients will perform a single maximal exercise test on a treadmill. Speed will be maintained at 3.2 km/h and the grade will be increased with 2% every 2 min following Gardner's protocol.
46015814|NCT04309318|Procedure|Low pneumoperitoneum (10-12 mmHg) pressure range group|Patients who have elective laparoscopic surgery with 10-12 mmHg intra-abdominal pneumoperitoneum pressure
46015815|NCT04309318|Procedure|High pneumoperitoneum (13-15 mmHg) pressure range group|Patients who have elective laparoscopic surgery with 13-15 mmHg intra-abdominal pneumoperitoneum pressure
46015816|NCT01035229|Drug|Everolimus|Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.
46100691|NCT00613847|Radiation|PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab|Once safety and feasibility has been established in this group, then enrollment to the HER2 1+ cohort will commence. Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
46100692|NCT00595478|Behavioral|Motivational Enhancement Therapy (MET)/CBT+CM|Behavioral Treatment
46100693|NCT00595478|Behavioral|Motivational Enhancement Therapy (MET)/CBT|Behavioral Treatment
46100694|NCT02703389|Behavioral|Video|Animated video explaining acute otitis media and antimicrobial stewardship.
46100695|NCT02703389|Behavioral|Pamphlet|Contains same information as video.
46100696|NCT00516295|Drug|topotecan hydrochloride|Given IV
46100697|NCT00516295|Drug|vincristine sulfate|Given IV
46100698|NCT00516295|Drug|cyclophosphamide|Given IV
45465621|NCT05400460|Procedure|Central axial single-bundle reconstruction（CASBR group）|"406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to CASBR group.Arthroscopic ASB ACL reconstruction was conducted with transtibial technique and using Hamstring as autograft.Single-bundle reconstruction is used in CASBR reconstruction surgery.~The footprint of the implant on the lateral femoral condyle was chosen to be the location of the AMB bone canal in DB reconstruction surgery while the footprint of the implant on the tibial plateau was chosen to be the location of the bone canal of the PLB in DB reconstruction surgery."
45474008|NCT03860363|Device|Blood drainage post cardiac surgery|Blood drainage post cardiac surgery with Thoraguard Surgical Drainage System.
45474009|NCT03219723|Drug|Vonoprazan|Vonoprazan tablets
45680296|NCT03031730|Drug|Carfilzomib|Given IV
45680297|NCT03031730|Drug|Dexamethasone|Given PO
45680298|NCT03031730|Drug|Dexamethasone Sodium Phosphate|Given IV
46100699|NCT00516295|Biological|bevacizumab|Given IV
45680299|NCT03031730|Drug|Lenalidomide|Given PO
45680300|NCT03031730|Drug|Navtemadlin|Given PO
45680301|NCT03027804|Procedure|Ross Operation|Replacement of the aortic valve by means of pulmonary artery autograft
45680302|NCT03004443|Drug|Infliximab|Infliximab will be administered intravenously (IV) as 5 mg/kg body weight over a 2 to 2.5 hour period.
45680303|NCT03004443|Drug|Placebo|Saline solution will be administered intravenously over a 2 to 2.5 hour period.
46015817|NCT01035229|Drug|Everolimus Placebo|Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.
46015818|NCT01035229|Other|Best Supportive Care (BSC)|BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions
46015819|NCT02880436|Other|air pollution|impact of various pollution agents above threshold and their correlation with acute myocardial infarctions are analyzed
46015820|NCT01106404|Device|RestoreSensor Neurostimulation System|"Adjustments to stimulation settings are automatic when the AdaptiveStim feature of the device is turned ON and manual when the AdaptiveStim feature of the device is turned OFF."
46015821|NCT02880592|Other|Affinity Allograft|fresh hypothermically stored human amniotic membrane
46015822|NCT02880592|Other|Standard of care|offloading, debridement, infection management using appropriate dressings
46015823|NCT01059799|Drug|insulin degludec|Insulin degludec injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
45465622|NCT05400460|Other|rehabilitation training protocol|The rehabilitation program for all patients followed a standardized Process. The first day after surgery, quadriceps sets, straight-leg raises, and prone hangs were initiated. All of the patients were allowed to walk with crutches and braces but with no weightbearing. The range of motion (ROM) progressed from 0 to 90 degrees 3 to 7 days postoperatively and reached 115 degrees within fourth week. Closed kinetic chain exercises and full weightbearing were started in the sixth week. Patients progressed to running without braces at 4 to 6 months.
46015824|NCT01059799|Drug|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
45465623|NCT05400460|Other|Educate patients on return to sports and the importance of quadriceps strength|"Patients were interviewed by telephone preoperatively, 6 months postoperatively, and 1 year postoperatively to ask about Tegner scores and to encourage reasonable return to sports from 6 months postoperatively.~Inform patients of the possibility of osteoarthritis in patients undergoing ACL reconstruction preoperatively, 6 months postoperatively, and 1 year postoperatively in telephone interviews.Tell the patient that return to sports and quadriceps strength is a must if the knee cartilage damage is to improve."
45465624|NCT05061979|Drug|BAY1747846|Solution for intravenous (IV) injection, single dose
45465625|NCT03918707|Diagnostic Test|Rapid Whole Genome Sequencing (rWGS)|rWGS will be performed on blood samples from subjects in the prospective group in addition to standard of care laboratory testing and imaging studies. Blood samples will also be obtained from biological parents (if available), to determine if variants are inherited or de novo and for variant segregation.
46015825|NCT02874547|Behavioral|Intervention|During an in-person visit, patients receive a pamphlet in english and spanish and a storytelling Digital Versatile Disc (DVD) (developed for this project from interviews with hypertensive patients), supplemented by motivational interviewing delivered by the CHW. The CHW explores the patient's motivation to change associated with hypertension and counsels on risk factor control (tobacco, diet, physical activity). Patients receive a followup telephone call from the CHW in 2 weeks, 4 weeks, 2 months to support any changes or goals discussed at first visit. Six months after first intervention visit, patients are invited to schedule an in-person visit with the CHW at the health center to discuss goals and provide support for change.
45465626|NCT03372369|Other|View CDC Poster|The poster designed by the CDC to explain contraceptive effectiveness.
45465627|NCT03372369|Other|View Patient-Centered Poster|The poster designed by the research team to explain contraceptive effectiveness. This poster was developed through cognitive interviews with 26 North Carolina women, and the final version of this poster was found to be more useful, acceptable, and attractive than the CDC poster by the majority of women participating.
45465628|NCT05400382|Behavioral|Mindfulness|Meditation training to help reduce stress and reactivity to pain and other stressors.
45465629|NCT03796975|Drug|Combination of Pioglitazone and Metformin Tablets|15mg/500mg, oral, 2/day
45465630|NCT03796975|Drug|Metformin Hydrochloride Tablets|Oral metformin 850mg, 2/day in the control group
45465631|NCT01130753|Drug|Erlotinib|Erlotinib 150mg per day for 8 weeks
45465632|NCT05400070|Drug|neoadjuvant PD-1 inhibitor, anlotinib combined with chemotherapy|Sintilimab (200mg fixed dose) iv, d1, q3w + anlotinib 10mg, po, qd1-14, q3w+Chemotherapy
45474010|NCT03219723|Drug|Amoxicillin hydrate|Amoxicillin hydrate (potency)
46015826|NCT01106248|Drug|Eribulin Mesylate|1.4 mg/m^2 intravenous (IV) bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
45474011|NCT03219723|Drug|Clarithromycin|Clarithromycin (potency)
46015827|NCT01059175|Device|Additional Endocardial or Epicardial LV Lead|Addition of a second left ventricular endocardial or epicardial lead
45465633|NCT03925493|Behavioral|Graded Exercise Stress test (GXT) with Target Heart Rate Range|Patients assigned to one of two intervention groups will complete a GXT prior to the 4th CR session. The GXT will be completed in Baystate Medical Center's stress lab using standard protocols. This test will be used to set the target heart rate range, which will guide exercise intensity for the remainder of exercise training in cardiac rehabilitation.
45465634|NCT03925493|Behavioral|Heart rate monitors|Heart rate monitors (HRM) will be given to half of the patients randomly assigned to exercise stress testing group. Patients will receive a polar heart rate chest strap and polar watch. Patients will be asked to wear both, the chest strap and the watch during cardiac rehabilitation. Ultimately, we hope that the use of HRM is not necessary, but it may be needed to assure that patients in the THHR are able to consistently know their HR and adjust their exercise prescription. This will also increase the likelihood that there is a difference in heart rates between the THRR group from the RPE group.
45465635|NCT01302613|Drug|Capecitabine|Capecitabine will be delivered concurrently with the radiation therapy, at a dose of 1650 mg/m2 divided in even BID doses. It will only be taken on the days of radiation treatment (Monday-Friday, except for holidays). The A.M. dose of the capecitabine must be taken at least one hour prior to the radiation treatment.
45465636|NCT01302613|Drug|5-FU|5-FU 400 mg/m2, iv bolus on day 1 followed by 2400 mg/m2 iv over 46 hours of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
45465637|NCT01302613|Drug|Leucovorin|Leucovorin 400 mg/m2, IV, over 2 hours before 5-FU on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
45465638|NCT01302613|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 IV on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
45465639|NCT01302613|Radiation|radiation|"28-30 fractions of radiation, given once a day, five days per week (Monday-Friday, except for holidays). The prescribed fraction dose is 180 cGy; the total radiation dose is thus 5040-5400 cGy. The primary treatment fields will be treated with 25 fractions of 180 cGy/fraction with a boost of 3-5 fractions of 180 cGy subsequently delivered."
45465640|NCT01302613|Procedure|total mesorectal excision|Optimal surgical technique involving use of total mesorectal excision (TME) is mandated. The type of surgery, either low anterior resection with sparing of the sphincter mechanism or sphincter-eliminating abdominoperineal resection (APR), will be at the discretion of the attending surgeon.
45465641|NCT05399914|Other|S-NIPPV|Synchronized noninvasive positive pressure ventilation during the first 10 minutes after birth.
45465642|NCT03796897|Dietary Supplement|Leucine-enriched protein|Supplement contains 16g of protein given twice per exercise session (4 total exercise sessions)
45680304|NCT02923726|Device|Arm 1 (ATP+Shock)|Subjects will be randomized and device programmed to the respective arm.
45465643|NCT03796897|Behavioral|Habitual diet only|Habitual diet only (no supplementation) for 4 exercise sessions
45465644|NCT03918785|Dietary Supplement|Rice germ|25 g twice a day.
45465645|NCT03918785|Dietary Supplement|Wheat-based supplement|25g twice a day.
46015828|NCT01059175|Device|CRT-P or CRT-D|Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device
46015829|NCT04301869|Drug|Antibiotics|Oral versus intravenous therapy
46015830|NCT04301479|Drug|hydrocortisone sodium succinate|Steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal
46015831|NCT04301479|Drug|Saline|Control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal
45465646|NCT03709329|Device|Robot Assisted Gait Therapy|The robot-assisted gait treatment will receive 18 treatments per patient for 1 week, 3 times a week, and 6 weeks for 30 minutes a day.
45680305|NCT02923726|Device|Arm 2 (shock only)|Subjects will be randomized and device programmed to the respective arm.
45680306|NCT02914639|Drug|SF0166 Topical Ophthalmic Solution|
45680307|NCT02883049|Drug|Clofarabine|Given IV
45680308|NCT02883049|Drug|Cyclophosphamide|Given IV
45680309|NCT02883049|Drug|Cytarabine|Given IT, IV, or SC
45465647|NCT03709329|Device|Conventional Gait Therapy|The conventional gait therapy group receives a total of 18 classical gait training sessions once a day for 30 minutes and three times a week for 6 weeks. Classical gait training consisted of exercise training based on neurophysiological theories such as Bobath, restraint of rigid and cooperative movements by therapists, exercise training in sitting or standing posture, Gait training and balance training, weight training of the paralyzed lower limb.
45465648|NCT05399524|Other|Standard of Care|Neuronavigation and intraoperative 5-ALA
45680310|NCT02883049|Drug|Dasatinib|Given PO
45680311|NCT02883049|Drug|Daunorubicin Hydrochloride|Given IV
46015832|NCT01297491|Drug|BKM120|Buparlisib was supplied as 10mg or 50mg capsules. It was administered on a continuous once daily dosing schedule at a dose of 100 mg. The patient was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area.
46015833|NCT04303585|Procedure|SAP block|The anesthesiologist performs SAP block immediately before surgery under ultrasound guide
45680312|NCT02883049|Drug|Dexamethasone|PO or IV
45680313|NCT02883049|Drug|Doxorubicin Hydrochloride|Given IV
45465649|NCT05399524|Other|Additional pre- and intra-operative imaging|Additional DTI scan during routine pre-operative tumour MRI scan, additional use of intraoperative ultrasound in addition to normal to standard of care (Neuronavigation and intraoperative 5-ALA)
45680314|NCT02883049|Drug|Etoposide|Given IV
45680315|NCT02883049|Drug|Hydrocortisone Sodium Succinate|Given IT
45680316|NCT02883049|Other|Laboratory Biomarker Analysis|Correlative studies
45680317|NCT02883049|Drug|Leucovorin Calcium|Given PO or IV
45680318|NCT02883049|Drug|Mercaptopurine|Given PO
45680319|NCT02883049|Drug|Methotrexate|Given IT and IV
45680320|NCT02883049|Drug|Pegaspargase|Given IV
45680321|NCT02883049|Drug|Prednisone|Given PO or IV
45680322|NCT02883049|Radiation|Radiation Therapy|Undergo radiation therapy
45680323|NCT02883049|Drug|Thioguanine|Given PO
45680324|NCT02883049|Drug|Vincristine Sulfate|Given IV
45680325|NCT02881320|Drug|B/F/TAF (Adult Strength)|50/200/25 mg FDC tablets administered orally once daily without regard to food
45680326|NCT02881320|Drug|B/F/TAF (Low Dose)|30/120/15 mg FDC tablets administered orally once daily without regard to food
46015834|NCT04303585|Procedure|ESP block|The anesthesiologist performs ESP block immediately before surgery under ultrasound guide
46015835|NCT04324593|Device|Peripheral intravenous analysis (PIVA) algorithm|An IV line with an attached Deltran BP transducer will be used together with LabChart software to record venous waveforms during various interventions. These waveforms will be processed using the PIVA algorithm and the calculated values will be compared to those from Nellcor respiratory monitor, Capnograph and cardiac telemetry monitoring.
46015836|NCT01106092|Biological|GSK2036874A vaccine|Intramuscular, single dose
45837781|NCT05764863|Radiation|fMRI|The participant will then complete a series of working memory tasks under three distinct conditions as described above (visual spatial, visual non-spatial, auditory). The instructions and tasks will be administered via an MRI compatible monitor and headset system (NordicNeuroLab). During the tasks, the participant's brain activity will be recorded. Finally, at the end of the experiment, a high-resolution anatomical image of the brain will be acquired in order to facilitate the subsequent data processing steps and to define the position of the interparietal sulcus for each subject. The visit will be completed by a visual imaging questionnaire.
45465650|NCT03918863|Other|Neuromuscular electrical stimulation|Exercise protocol associated with neuromuscular electrical stimulation on vastus medialis and gluteus medius. Parameters: rectangular pulse shape, biphasic, symmetrical, pulse duration of 200μs, interbust interval of 10ms and frequency of 2.500Hz modulated in 50 bursts.
45465651|NCT03918863|Other|Exercise|Same protocol of exercises of the other group, without association of electrical stimulation.
46015837|NCT01106092|Biological|Zilbrix™/Hib vaccine|Intramuscular, single dose
46015838|NCT01106092|Biological|Poliorix™|Intramuscular, single dose
46015839|NCT01097668|Biological|ATX-MS-1467|Disease specific immune modulating treatment for multiple sclerosis
46015840|NCT04307290|Drug|Dexmedetomidine Hydrochloride, or Saline|drug infusion from 10 min before the start of surgery to the end of surgery
46015841|NCT04902430|Procedure|Power chain and Crimpable hook for En-Masse Retraction|"Retraction will start on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 212 g per side) extending between the crimpable hooks and the miniscrew"
46015842|NCT04902430|Procedure|T- Loop|Closing retraction T-loops will be fabricated using 0.017 x 0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine
46015843|NCT01325207|Radiation|Trastuzumab|Trastuzumab will be administered twice per week for 4 weeks, then once per week for 4 weeks, and then every 2 weeks
46015844|NCT01324349|Device|Veriset Hemostatic Patch|Topical hemostat
45465652|NCT03796585|Behavioral|Immunization Registry Training|Education highlighting practical strategies to improve pharmacies' willingness to adopt the immunization registry and improve their ability to integrate the immunization registry into their pharmacy workflow.
45465653|NCT03796585|Behavioral|Informational flyer|Informational flyer with ImmPRINT contact information
45465654|NCT01230047|Behavioral|Psychoeducational course|Psychoeducational course on mindfulness and lifestyle interventions for depression and anxiety
45465655|NCT05399212|Drug|FPT-20|FPT-20 should be used regularly, the daily maintenance dose is 1 tablet once a day(>6 to 12 months) until the therapeutic purpose is achieved.
46015845|NCT01324349|Device|Fibrin Sealant (TachoSil®)|Topical hemostat
46015846|NCT01095250|Drug|AIN457|
46015847|NCT01095250|Drug|AIN457|
46015848|NCT01095250|Drug|AIN457|
46015849|NCT01095250|Drug|Placebo|
46015850|NCT01324271|Device|Acclarent Tympanostomy Tube Delivery system (TTDS)|placement of tympanostomy tube under local anesthesia
46015851|NCT04325711|Drug|CSPCHA131|CSPCHA131 will be administered twice weekly in the first three weeks of a 4-week cycle.
46015852|NCT01095094|Drug|ritonavir|Given orally
46015853|NCT01095094|Drug|lopinavir|Given orally
46015854|NCT01323647|Biological|PoliorixTM|Single dose, intramuscular administration
46015855|NCT01323647|Biological|Infanrix+Hib|Single dose, intramuscular injection. Part of the local standard of care. No outcome measures associated.
46015856|NCT01094782|Other|Acupuncture|Subjects receive 6 acupuncture treatments for neck or back pain.
46015857|NCT01094782|Other|Sham Acupuncture|Subjects receive 6 sham acupuncture treatments for neck or back pain.
46100700|NCT03362099|Drug|Varenicline Tartrate or bupropion|the drug treatment will be chosen related to the polymorphism. If the polymorphism is favorable to varenicline the patient will receive varenicline, If it is favorable to bupropion the patient will receive bupropion, if not favorable to varenicline and bupropion the patient will receive bupropion + varenicline. If the patient has both favorable polymorphisms he will receive bupropion. Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
46100701|NCT04153370|Device|Airtraq|airtraq video laryngoscope was used for intubation of the infant
46100702|NCT04153370|Device|glidescope|glidescope video laryngoscope was used for intubation of the infant
46100703|NCT04153370|Device|c-mac|c-mac video laryngoscope was used for intubation of the infant
46100704|NCT04153877|Other|Kinesiotape|Kinesio-tape® is an elastic, hypoallergenic, cotton-fiber tape with acrylic heat-activated backing and is widely used within sports.
45465656|NCT03803371|Drug|Ultracet Tablets|Ultracet tablet (Janssen Cilag Farmacêutica Ltda) equivalent to Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg
45680327|NCT02881320|Drug|B/F/TAF (TOS)|2 x FDC of bictegravir 15 mg/emtricitabine 60 mg/ tenofovir alafenamide 7.5 mg (B/F/TAF 15/60/7.5 mg) (total dose 30/120/15 mg) administered orally as TOS, once daily without regard to food
46015858|NCT05645315|Drug|TQB2618 injection and TQB2450 injection|TQB2618 is a TIM-3 receptor monoclonal antibody; TQB2450 is a new sequence of innovative anti-PD-L1 fully humanized monoclonal antibody;
46015859|NCT04325555|Drug|PrEP|The investigators measure self-reported PrEP status as exposure, i.e., PrEP status is not confirmed via matched medical records or any other type of information directly collected form subjects.
46015860|NCT05645237|Radiation|radiotherapy|Radiotherapy is delivered with linear accelerators or cyberknife (external beam radiotherapy), or local irradiation with high dose rate brachytherapy (brachytherapy)
46015861|NCT00623285|Drug|Pregabalin|Pregabalin 150mg orally 60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive 150mg twice a day through the first 2 post-operative days for a total of six doses.
46015862|NCT00623285|Drug|Placebo/Lactose|Matching Placebo orally,60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive placebo twice a day through the first 2 post-operative days for a total of six doses. If the patient is unable to swallow and NG tube is in place, the medication can be dissolved in water and administered through the NG tube.
46100705|NCT03861559|Drug|mometasone furoate nasal spray|intranasal administration
45465657|NCT03803371|Drug|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets - tablet (Pfizer)|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets (Pfizer)
46100706|NCT03861559|Drug|placebo nasal spray|intranasal administration
45465658|NCT03918941|Device|Carey|mobile application
45465659|NCT03918941|Other|conventional information|leaflet, internet link and oral information
45474012|NCT03219723|Drug|Metronidazole|Metronidazole
45474013|NCT03375814|Drug|Crocin|This group (osteoarthritic patients) can receive crocin with conventional therapy
45474014|NCT03375814|Drug|Placebo Oral Tablet|The group that takes Placebo Oral Tablet. They received the conventional treatment and Placebo Pills..
46100707|NCT00738010|Device|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
46100708|NCT00738010|Device|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
46100709|NCT00738010|Behavioral|Control|Voluntary quadriceps muscle contractions.
46015863|NCT02878720|Device|Transcutaneous vagal nerve stimulation|"The stimulation of the auricular branch of the vagus nerve will be performed through an electric stimulator and two Ag-AgCl electrodes placed in the left external acoustic meatus at the inner side of the tragus. For sham stimulation, electrodes will be attached to the left ear lobe. tVNS will be delivered as trains lasting 30 s and composed by 600 pulses (intra-train pulse frequency = 20 Hz; pulse duration = 0.3 ms) repeated every 5 min for 60 min. The intensity of stimulation will individually adjusted to a level ranging above the detection threshold and below the pain threshold. In this range, when possible, the investigators will chose an intensity of 8 mA.~Each day, for 10 consecutive working days, each patient will receive a session of robotic therapy during the real or sham tVNS stimulation"
46015864|NCT01097044|Drug|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months. (3 implants in total)
46015865|NCT01097044|Drug|Placebo|One placebo subcutaneous implant every 2 months for 6 months. (3 implants in total)
46015866|NCT01322009|Drug|Probenecid and N-acetyl cysteine|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days or to receive placebos.
46015867|NCT01322009|Drug|Placebo|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.
46100710|NCT02705417|Procedure|preoperative color Doppler ultrasonographic vascular mapping|Preoperative color Doppler ultrasonographic vascular mapping was performed with linear probe. The patient extremity under scrutiny was placed under support, with tourniquet augmentation. Vessels were examined in both short (transverse) and long (longitudinal) axis. Anatomical variations, wall morphology and internal diameters at the antecubital fossa, the proximal (cranial), mid and distal (caudal) third of the arm and forearm were assessed in both extremities. Veins were evaluated for compressibility and adequate drainage to deep venous system. The presence of sclerotic, thrombosed and fibrosed segments were noted. Doppler waveforms were obtained in the long axis and volume flow (VF) calculated for arteries selected for potential access construction.
46015868|NCT01321697|Procedure|Routine Leg edema and groin dissection|The investigators will be documenting and reporting the variations in leg lymphatic drainage sentinel lymph node biopsy with inguinal-femoral lymph node dissection.
46015869|NCT01320683|Drug|oxaliplatin|Given IV
46100711|NCT02705417|Procedure|physical examination|Arterial pulse examination, differential blood pressure measurements and the Allen test in both extremities. Inspection of the superficial venous system with tourniquet enhancement in the arm was performed during venous assessment.
46100712|NCT02705417|Procedure|medical history|medical history with respects to diabetes mellitus, coronary heart disease, peripheral vascular disease
46100713|NCT02705417|Procedure|native arteriovenous fistula construction|surgigal creation of native arterial and venous anastomoses
46100714|NCT02705417|Procedure|arteriovenous graft placement|surgical placement of arteriovenous graft
46100715|NCT02705651|Drug|Somatostatin-Analog|A long-acting somatostatin-analog will be applied.
46100716|NCT02568670|Other|clinical signs|to remove the peripheral venous catheter according clinical signs
45474015|NCT03866213|Diagnostic Test|BiliSpec|BiliSpec will quantitatively measure the bilirubin content of a neonatal blood sample.
45680328|NCT02881320|Drug|B/F/TAF (TOS)|FDC of bictegravir 15 mg/emtricitabine 60 mg/ tenofovir alafenamide 7.5 mg (B/F/TAF 15/60/7.5 mg) administered orally as TOS, once daily without regard to food
45342548|NCT05810792|Drug|Histamine Dihydrochloride (HDC)|HDC is administrated in combination with IL-2 as peri- and post-operative treatment in patients undergoing surgery. 0.5 mg HDC is administered twice daily by subcutaneous injections 1 to 3 minutes after each IL-2 injection during three 3 week cycles, with 3-week resting periods inbetween. The first treatment cycle is initated 2 weeks prior to surgery, with an additional 2-3 days rest period during the surgical procedure, before the third treatment week is initiated.
45680329|NCT02881320|Drug|B/F/TAF (TOS)|2 x FDC of bictegravir 3.75 mg/emtricitabine 15 mg/ tenofovir alafenamide 1.88 mg (B/F/TAF 3.75/15/1.88 mg) (total dose 7.5/30/3.75 mg) administered orally as TOS, once daily without regard to food
46015870|NCT01320683|Drug|leucovorin calcium|Given IV
46015871|NCT01320683|Drug|fluorouracil|Given IV
46015872|NCT01320683|Biological|bevacizumab|Given IV
46015873|NCT01320683|Radiation|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Given IV
46015874|NCT01320683|Other|laboratory biomarker analysis|Correlative studies
46015875|NCT01320683|Other|pharmacological study|Correlative studies
46015876|NCT01320683|Drug|irinotecan hydrochloride|Given IV
46100717|NCT02705339|Drug|Rociletinib|
46100718|NCT02705339|Procedure|Biopsy|Standard of care biopsies will be taken at diagnosis and at the time of disease progression
46015877|NCT01320293|Drug|Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]|40mg subcutaneously, every other week for 6 months
46015878|NCT05661383|Device|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) combined with pleasant odors delivered during the iTBS procol.|"Device: MagPro X100 (MagVenture, Mag2Health, France) iTBS protocol targeting the left dorsolateral prefrontal cortex: 50 consecutive sessions allocated on 10 days (i.e., 5 sessions per working day, 1 hour apart, for 2 weeks).~One iTBS session: burst of 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., at 5 Hz) at an intensity of 90% of rMT. A 2 s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session.~Pleasant odorants will be delivered using passive diffusers placed in the room dedicated to the iTBS protocol, during the all-treatment duration. During the inclusion phase, 10 odors known to be pleasant will be presented to the subject. The 3 best rated by the subject will be chosen for olfactory stimulations. During the iTBS session, a randomly selected odor from the 3 will be presented at the same time as the iTBS treatment."
46015879|NCT05661383|Device|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) delivered alone.|"Device: MagPro X100 (MagVenture, Mag2Health, France) iTBS protocol targeting the left dorsolateral prefrontal cortex: 50 consecutive sessions allocated on 10 days (i.e., 5 sessions per working day, 1 hour apart, for 2 weeks).~One iTBS session: burst of 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., at 5 Hz) at an intensity of 90% of rMT. A 2 s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session."
46015880|NCT05645003|Device|High-frequency real-time rTMS protocol|It was planned to apply a total of 1200 beats to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.
46015881|NCT05645003|Device|Sham rTMS Protocol|It was planned to apply a to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.
46015882|NCT01318811|Drug|Dilute unfractionated heparin|Patients in the dilute heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started. Heparin will be delivered as a solution of 2 units/mL and the infusion will be prepared with 2,000 units of heparin in 1,000 mL of 0.9% NaCl and delivered intravenously proximal to the dialysis filter.
46015883|NCT01318811|Drug|Standard concentration unfractionated heparin|Patients in the standard heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started and delivered in a standard concentration intravenously proximal to the dialysis filter via a syringe. The concentration of heparin used will be 1,000 units of heparin per 1 mL of 0.9% NaCl.
46015884|NCT05644847|Other|Whole Body Vibration Training|WBV training will be performed on a commercial vibrating platform (Healthmate HM01-08VF Gym Fitness Equipment Step Vibration Machine, China), which produces vertical sinusoidal vibrations. Participants in the dynamic WBV group will be provided with dynamic exercises along with WBV training. The vibration speed level will be progressed from level 5 to level 10 during the course of the treatment sessions
46100719|NCT02705339|Procedure|Blood draw|-Approximately 4 teaspoons of blood will be drawn before treatment begins and at the time of disease progression to look at cell-free DNA
46100720|NCT00738088|Drug|gliclazide|Gliclazide 80mg bd for 6 weeks
46015885|NCT05644847|Procedure|Core Stability Training|Core stability exercises will include pelvic bridge, straight leg bridge, modified kneeling with elbow support and leg lifts and squats, with 60 seconds rest interval between each activity. All these core exercises will be performed on a stable surface and will be progressed in difficulty by increasing the no. of repetitions and no. of sets on a weekly basis. Every session will be preceded by 5 minutes of warm-up and end with 5 minutes of cool-down exercises.
46015886|NCT05644769|Other|Determine the presence of Human sequence Ang-(1-12) on no medication|Determine the presence of the human sequence of Ang-(1-12) in the plasma of ten normal male and female hypertensive patients on no medication.
46015887|NCT05644769|Drug|Human sequence Ang-(1-12) on Lisinopril 40mg every day|Determine the presence of the human sequence of Ang-(1-12) in the plasma of 10 normal male and female hypertensive patients after four weeks on Lisinopril 40 mg every day.
46015888|NCT05644691|Other|Lipikar Baume AP+M|application of Lipikar Baume AP+M twice daily for 3 months in parallel with the corticosteroid treatment
45680330|NCT02881320|Drug|B/F/TAF (TOS)|FDC of bictegravir 3.75 mg/emtricitabine 15 mg/ tenofovir alafenamide 1.88 mg (B/F/TAF 3.75/15/1.88 mg) administered orally as TOS, once daily without regard to food
46015889|NCT05644691|Other|Usual emollient|application of the usual emollient twice daily for 3 months in parallel with the corticosteroid treatment
46015890|NCT01093846|Drug|AIN457|300mg every 4 weeks
46015891|NCT01093846|Drug|AIN457|300mg every 2 weeks
45680331|NCT02865018|Drug|cetirizine|
45680332|NCT02852538|Behavioral|NEW FED TR|NEW FED TR is a five day treatment for adults with anorexia nervosa. It is a neurobiologically informed, interactive, family-based treatment that draws upon the specific etiological traits characterizing anorexia nervosa. It stands for Neurobiological research findings Enhanced With Family/Friends of those with Eating Disorders, addressing Trait Responses that both create a vulnerability to the illness and serve as markers for recovery through treatment (formerly reported as Temperament-Based Treatment).
45680333|NCT02795143|Drug|Isotretinoin|
46015892|NCT01093846|Drug|Placebo AIN457|Placebo to AIN457
46015893|NCT01315847|Drug|telcagepant|Single oral doses of telcagepant 1120 mg (Part I - Period 1) and 140 mg (Part I - Period 2; Part III - Period 1 and 2)
46015894|NCT01315847|Drug|[11C]MK-4232|Single intravenous doses of ~300 MBq [11C]MK-4232 administered as a 5 minute infusion (Part I - Baseline, Period 1 and 2; Part III - Period 1 Baseline and Period 1, and Period 2 Baseline and Period 2)
46015895|NCT05644535|Diagnostic Test|Cerebrospinal fluid densitometry|After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.
46015896|NCT05644535|Diagnostic Test|blood routine examination|After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.
46015897|NCT05644535|Diagnostic Test|Blood electrolyte examination|After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.
45680334|NCT02795143|Other|Placebo|
46015898|NCT04325399|Other|Volitional help sheet|
46015899|NCT01093534|Drug|Placebo|Matching solifenacin placebo tablet
46015900|NCT01093534|Drug|solifenacin|Tablet for oral administration
46100721|NCT04651855|Drug|Mesenchymal stem cells isolated from Wharton's jelly|Intrathecal administration of mesenchymal stem cells
46015901|NCT01314911|Drug|Oseltamivir|Subjects were prescribed Oseltamivir twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
45465660|NCT05399134|Dietary Supplement|Modified Functional Foods|"Subjects will be provided with ABREP-fortified bread, microfluidic co-flow noodles, and 5ibrePlus™-fortified white rice served in a mixed meal.~ABREP-fortified bread: Anthocyanins are known to exert anti-diabetic effects through modulating digestion, glucose uptake, insulin secretion and sensitivity. Moreover, inhibitory effects of anthocyanins on various carbohydrases, including a-glucosidase and a-amylase have been widely reported.~Microfluidic co-flow noodles: Microfluidic technology is employed to design noodle-food structures consisting of a mix of soy protein isolate and alginate as gelling agents to offer a type of novel noodles with proteins and negligible carbohydrate content.~5ibrePlus™-fortified white rice: 5ibrePlus™ is a patented novel fibre grain product by Alchemy Foodtech Pte. Ltd (WO 2017/142477) with reduced GI. Its main constituents are insoluble resistant starch and soluble fibre."
45465661|NCT05399134|Dietary Supplement|Control Functional Foods|Subjects will be provided with control function foods including white bread, beehoon noodles, and jasmine white rice served in a mixed meal.
45680335|NCT02790736|Drug|propranolol|active treatment
45465662|NCT01130909|Drug|AZD6765|75 mg
46015902|NCT01314911|Drug|Placebo|Subjects were prescribed the matching placebo twice daily for 5 days, and each dose consisted of one capsule of placebo.
46015903|NCT02891057|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z44-036)
46015904|NCT01093222|Drug|Erlotinib Hydrochloride|Given PO
46015905|NCT01093222|Drug|Sorafenib Tosylate|Given PO
45465663|NCT01130909|Drug|AZD6765|150 mg
45465664|NCT01130909|Drug|Ketamine|0.5 mg/kg
46015906|NCT02878018|Drug|Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula|Qi-Ji Shen-Kang formula:15g of field thistle,10g of common edelweiss herb,10g of spreading hedyotis herb,10g ofYunnan manyleaf Paris rhizome,10g of hairyvein agrimonia herb,10g of the root bark of the tree peony,15g of root of red rooted salvia, and 15g ofmembranous mikvetch root.Zhu-Bai formula:10g of glabrous greenbrier rhizome,5g of Chinese atractylodes rhizome,10g of amur corktree bark,10g of common edelweiss her),10g of field thistle,10g of lalang grass rhizome,10g of garden burnet root,5g of longbract cattail pollen,5g of rehmanniae radix, and 5g of Chinese angelica root.Yu-Shen formula:15g of membranous mikvetch root,10g of heterophylla falsestarwort root,10g of field thistle,10g of cogongrass rhizome,10g of spreading hedyotis herb,10g of root of red rooted salvia,10g of fresh root of rehmannia,10g of Asian puccoon,10g of wormwoodlike motherwort herb,10g of common cockscomb inflorescence,10g of gordon euyale,10g of root bark of the tree peony, and 5g of licorice root.
46015907|NCT02878018|Drug|angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressant|prednisone at a dose of 1-1.5 mg/(kg·d) and Tripterygium wilfordii polyglycosidium at a dose of 1 mg/(kg·d). For each patient, the specific Western medicines used and their doses may be adjusted at the discretion of his or her physician, but the classes cannot be changed.
45465665|NCT01130909|Drug|Placebo|125 mL sterile NaCl 0.9%
45465666|NCT04963231|Drug|Setmelanotide|Subcutaneous injection
45465667|NCT04963231|Drug|Placebo|Subcutaneous injection
45465668|NCT05398978|Other|e-Registration and mHealth|Registration to the electronic database Counseling through voice calls for facility delivery Text messages to promote facility delivery
45680336|NCT02790736|Drug|Placebo|inactive pill
46015908|NCT01313663|Drug|pazopanib|oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
45465669|NCT03918551|Drug|Febuxostat|Febuxostat is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 120 mg of febuxostat.
45465670|NCT03918551|Drug|Adenuric|Adenuric is manufactured by Menarini - Von Heyden GmbH, Germany (MAH: Menarini International Operations Luxembourg S.A., Luxembourg). Each film-coated tablet contains 120 mg of febuxostat.
45680337|NCT02784119|Procedure|temporary porto-caval shunt|temporary porto-caval shunt
45680338|NCT02773238|Procedure|Computed Tomography|Undergo FDG PET/CT
45680339|NCT02773238|Procedure|Computed Tomography|Undergo Tc-99m MAA or Tc-99m DTPA
45680340|NCT02773238|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
45680341|NCT02773238|Other|Laboratory Biomarker Analysis|Correlative studies
45680342|NCT02773238|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
46015909|NCT01313663|Drug|pemetrexed|pemetrexed IV 500 mg/m2 once every 3 weeks
46015910|NCT05644457|Genetic|Circulating tumour DNA dynamics|Circulating tumour DNA (ctDNA) can be identified in patients with a wide variety of cancers and has been shown to allow early prediction of disease relapse after treatment with curative intent in HNSCC.
46015911|NCT01092832|Drug|voriconazole|"Subjects 12 - <18 yrs (excluding subjects 12 - 14 yrs weighing <50kg): For IC, the loading dose is 6 mg/kg IV q12h on Day 1, followed by 4 mg/kg IV q12h thereafter. Oral therapy, if given, will be administered at a dose of 200 mg q12h. For EC, no loading dose is required, and subjects will be initiated on 3 mg/kg IV q12h. Oral therapy, if given, will be administered at a dose of 200 mg q12h.~Subjects 2 - <12 yrs, and subjects 12 - 14 weighing <50kg: For IC, the loading dose is 9 mg/kg IV q12h on Day 1, followed by 8 mg/kg IV q12h thereafter. For EC, no loading dose is required, and subjects will be initiated on 4 mg/kg IV q12. Oral therapy, if given, will be administered at a dose of 9 mg/kg q12h (maximum initial dose of 300 mg).~Subjects will be treated for a minimum of 14 days for invasive candidiasis/candidemia or a minimum of 7 days for esophageal candidiasis. Subjects will be treated for up to a maximum of 42 days."
46015912|NCT05661305|Other|Whole Genome Sequencing to compare healthy volunteers genome with that of cardiomyopathies patients.|Egyptian patients and their family members diagnosed with different types hereditary cardiomyopathies.Healthy Egyptian individuals to provide the first of its kind resource on human genetic variation in Egyptians, which is essential for understanding the significance of detected variations in patients with inherited cardiovascular disease and their families.
46015913|NCT02878564|Drug|Praziquantel|40 mg/kg, PO (orally administered tablets)
45465671|NCT03918473|Other|Mobilization with Movement|The MWM group will receive manual therapy with the following protocol: the participant will be relaxed and standing in a staggered stance with the involved foot on an eight-inch step and both feet facing forward. The clinician will be positioned in front of the participant's leg and a non-elastic belt will be placed around the distal leg of the participant and the clinician's pelvis. The clinician will then apply a sustained posteroanterior glide to the tibia through the belt by leaning backwards, while stabilizing the fixed talus and forefoot with both hands. The participant will perform a slow lunge until the end range of motion without their heel lifting off the ground. The belt will be kept perpendicular to the tibia throughout the movement and 2 sets of 10 repetitions will be applied.
45465672|NCT03918473|Other|Thrust Mobilization|The talocrural joint TM will be a high velocity low amplitude manual therapy technique. This technique will be applied with the participant in the supine position on a plinth. The clinician grasps the foot with one hand with the fifth finger contacting the anterior surface of the ankle at the talus. The other hand reinforces the contact points and both thumbs are placed on the sole of the participant's foot. The clinician gives slight caudal traction focused on the talocrural joint with the ankle dorsiflexed and everted. The therapist then applies a high-velocity thrust distraction technique to the talocrural joint. Only one thrust will be applied and no audible cavitation is required. This manual therapy technique will be performed once.
45680343|NCT02773238|Radiation|Radiation Therapy|Undergo functional avoidance radiation therapy
46100722|NCT02703233|Drug|Nitrous Oxide|
45465673|NCT04453930|Drug|Camrelizumab，an engineered anti-PD-1 antibody|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/5/6) and maintenance phase (Cycle onward).
45465674|NCT04453930|Drug|Platinum|"Carboplatin： Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/5/6).~Cisplatin： Cisplatin intravenous infusion was administered at a dose of 30 milligrams per square meter (mg/m^2) on Day 1，8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6)."
45465675|NCT04453930|Drug|Irinotecan|Irinotecan intravenous infusion was administered at a dose of 65 milligrams per square meter (mg/m^2) on Day 1，8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6).
45465676|NCT04453930|Drug|Apatinib|Apatinib was administered at a dose of 250 mg during the maintenance phase.
46015914|NCT04325477|Device|Nolix Device|The Nolix device is a single use, dynamic, and soft flexible intra-vaginal device for temporary management of SUI
45465677|NCT03796507|Drug|Temozolomide|oral temozolomide at 75 mg per square meter of body surface area daily for 21 days
45465678|NCT01130987|Other|Computerized handoff tool|Computer program that facilitates accurate transmission of patient information between residents
46015915|NCT02891135|Other|SLATE|Algorithm for collecting information required to determine if patient is eligible for immediate (same-day/same-visit) initiation of antiretroviral medications.
46015916|NCT04308070|Device|AQUABEAM System followed by catheter without hemostatic agent|The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter to achieve hemostasis post-Aquablation procedure.
46015917|NCT04308070|Device|AQUABEAM System followed by catheter with hemostatic agent|The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter with hemostatic agent to achieve hemostasis post-Aquablation procedure.
45465679|NCT01130987|Behavioral|Team training|Training in teamwork and reorganization of handoff processes to optimize transmission of information and team care
45465680|NCT04454008|Behavioral|executive function family training|Intervention programs include executive function training for children with ADHD and parenting guidance for parents
45465681|NCT04454008|Behavioral|treat as usual|Outpatient routine health education, behavioral guidance and family support
45465682|NCT01302769|Device|Standard treatment plus ear acupuncture|Standard treatment plus ear acupuncture
45465683|NCT05398822|Diagnostic Test|MRI|Texture analysis (TA) is a novel imaging biomarker that can assess heterogeneity in MRIs by measuring grey-level intensities distribution. This study hypothesizes that TA of MRI is an imaging biomarker that can predict local recurrence and distant metastasis.
45465684|NCT03796351|Drug|MT10107|"Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner."
46015918|NCT04307914|Radiation|External beam radiotherapy|The current standard of care for patients with uncomplicated painful bone metastases is palliative locoregional external beam radiotherapy, often in combination with systemic therapy and analgesics.
46100723|NCT02703233|Other|Oxygen|
45465685|NCT03796351|Drug|Botox|"Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner."
45465686|NCT03925259|Behavioral|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) is a 'third wave' behaviour therapy delivered on a one to one basis.
45465687|NCT04586062|Drug|Plasminogen|Human Plasminogen
45680344|NCT02773238|Procedure|Single Photon Emission Computed Tomography|Undergo Tc-99m MAA or Tc-99m Undergo Tc-99m sulfur colloid SPECT/CT
45680345|NCT02773238|Radiation|Technetium Tc-99m Albumin Aggregated|Undergo Tc-99m MAA SPECT/CT
46100724|NCT05740696|Procedure|ALF|Acute onset, no history of underlying liver disease, liver failure characterized by degree Ⅱ or above hepatic encephalopathy developed within 2 weeks
45342549|NCT05810792|Drug|Interleukin-2 (IL-2)|IL-2 is administrated in combination with HDC during three 3 week cycles as peri- and post-operative treatment in patients undergoing surgery. IL-2 is administered twice daily as a subcutaneous injection 1 to 3 minutes prior to the administration of histamine dihydrochloride; each dose of IL-2 is 16,400 IU/kg (1µg/kg).
46015919|NCT04307914|Procedure|MR-HIFU|MR-HIFU is a non-invasive treatment modality that delivers acoustic energy to heat tissue to ablative temperatures of more than 60°C. The combination of focused ultrasound with magnetic resonance imaging (MRI) enables physicians to perform localized tumor tissue ablation, with real-time temperature monitoring using magnetic resonance (MR) thermometry.
46015920|NCT02890979|Other|Cytology Specimen Collection Procedure|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
46015921|NCT02890979|Other|Laboratory Biomarker Analysis|Correlative studies
46015922|NCT02890979|Other|Quality-of-Life Assessment|Ancillary studies
46100725|NCT05740696|Procedure|SALF|The onset was acute, with no history of underlying liver disease, and clinical manifestations of liver failure appeared between 2 and 26 weeks
46100726|NCT05740696|Procedure|ACLF|On the basis of chronic liver disease, the clinical manifestations of acute liver decompensation and liver failure appear in a short period
45465688|NCT03796429|Drug|GS+Toripalimab|"Patients will be given treatment as below once recruited: PD-1 antibody Toripalimab（240mg, iv, q3w），combined with GS regimen(gemcitabine 1000mg／m2 ，d1,d8 + S1 40-60mg bid*14d，Q21d).~The treatment will be continued until emerging of disease progression or intolerable adverse effects (The upper time limit for treatment is 2 years)."
45680346|NCT02773238|Radiation|Technetium Tc-99m Sulfur Colloid|Undergo Tc-99m sulfur colloid
45680347|NCT02736981|Behavioral|Behavioral Weight Loss (BWL)|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching.
46015923|NCT02890979|Device|Swallowable Sponge Cell Sampling Device|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
46015924|NCT01313273|Drug|Lanreotide, non steroidal anti androgens and LHRH-a|"Lanreotide 120 mg. Injection every 28 days, to be administered till progression or for a maximum of 24 months.~Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression."
46015925|NCT01313273|Drug|Non steroidal anti androgens and LHRH-a|Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression
46015926|NCT01091974|Drug|armodafinil|Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)
46015927|NCT01091974|Drug|Placebo Comparator|Placebo for 47 days
46015928|NCT01091974|Behavioral|CBT-I|Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)
46015929|NCT01313117|Drug|Alpha lipoic acid|The baseline dose is 100 mg three times daily for four months. Dose escalation will occur until a maximum tolerated dose is found.
46100727|NCT02703155|Device|Home Oral Glucose Tolerance Test kit|Providing Home Oral glucose tolerance test kit to children with Cystic fibrosis for screening Cystic Fibrosis Related Diabetes
46100728|NCT04152941|Drug|Olaparib|Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy
46100729|NCT02705183|Radiation|Radiotherapy|Multifractionated post-operative radiotherapy, several weeks after surgery
46100730|NCT04062760|Drug|Standard diuretic therapy|The patients in this arm will be randomized to receiving oral furosemide in 2 daily divided doses at twice the intravenous dose administered during the past 24 hours. Unless serum potassium value is higher than 5 mmol/L, oral spironolactone or potassium canrenoate will be added; dose will be established based on serum creatinine value.
45465689|NCT03918395|Dietary Supplement|Placebo beverage|A placebo beverage will be consumed both post-exercise and pre-bed
46100731|NCT04062760|Drug|Early sequential nephron blockade|"After 24-72 hours of an algorithm-based treatment with high-dose intravenous furosemide started at the time of hospital admission, the patients in this arm will be randomized to receiving:~oral furosemide in 2 daily divided doses at a dose equivalent to that administered intravenously during the past 24 hours~metolazone at a dose based on serum creatinine value~acetazolamide at a dose based on serum creatinine value~spironolactone or potassium canrenoate (unless serum potassium value is higher than 5 mmol/L); dose will be established based on serum creatinine value"
45465690|NCT03918395|Dietary Supplement|Protein-polyphenol beverage|A protein-polyphenol beverage will be consumed both post-exercise and pre-bed
46015930|NCT01313039|Drug|AZ6244|AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15
46015931|NCT05644379|Drug|Cadonilimab Injection|Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
46015932|NCT05644379|Drug|Regorafenib|Regorafenib 80mg, po, orally once daily
46015933|NCT01091662|Drug|Eslicarbazepine acetate 1600 mg|1600 mg once per day
46015934|NCT01091662|Drug|Eslicarbazepine acetate 1200 mg|1200 once per day
46015935|NCT01312961|Drug|Dupilumab|Solution for injection, one subcutaneous injection.
46015936|NCT01312961|Drug|Placebo (for Dupilumab)|Solution for injection, one subcutaneous injection.
46015937|NCT01312961|Drug|Fluticasone/Salmeterol combination therapy|Oral inhalation twice daily.
46100732|NCT05344781|Other|Questionnaire|Questionnaire regarding relationship and sexual satisfaction
45465691|NCT05398666|Device|White LED light|Participants will be exposed to white LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
45465692|NCT05398666|Device|Green LED light|Participants will be exposed to green LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
45465693|NCT03796117|Device|Pulsed current|"For stage 1 of the study, which corresponds to analysis of the evoked torque, evaluation of the discomfort level, current intensity, analysis of neuromuscular efficiency and clinical efficiency, 2 configurations (PC1 and PC2) will be used.~PC1, will be set at a frequency of 100 Hz, phase duration of 1000 microseconds, ON-OFF time of 5s:10s.~PC2, will be set at a frequency of 100 Hz, phase duration of 200 microseconds ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the PC1 configuration will be used."
45465694|NCT03796117|Device|Russian Current|"For stage 1 of the study, which corresponds to analysis of the evoked torque, discomfort level, current intensity, neuromuscular efficiency and clinical efficiency, 2 configurations (RC1 and RC2) will be used.~RC1, will be set to a frequency of 100 Hz, burst duty cycle of 20%, ON-OFF time of 5s:10s.~RC2, will be set at a frequency of 100 Hz, burst duty cycle of 50%, ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the RC2 configuration will be used."
45474016|NCT03628417|Procedure|Calcium Electroporation|"If the patient agrees biopsies will be performed from the tumor area before and after electroporation during local anaesthesia. Maximum of 8 biopsies will be done, depending on the patient's number of metastases.~All patient's regardless of the number of metastases will have one biopsy from area treated with calcium and one from area treated with bleomycin, after the randomization code is revealed at day 180.~Patients with more than 6 metastases: One to two biopsies before treatment, one to two biopsies one week after treatment from metastases treated with calcium and bleomycin respectively.~All biopsies will be handled according to current guidelines and analyzed by a pathologist for amount of tumor tissue, inflammation, fibrosis and necrosis."
45680348|NCT02736981|Behavioral|BWL + Autonomous Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will receive coaching that places an increased emphasis on their values and personal choices, and also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training class).
46015938|NCT01312961|Drug|Fluticasone monotherapy|Oral inhalation twice daily.
46015939|NCT01312961|Drug|Albuterol|Oral inhalation as needed.
46015940|NCT01312961|Drug|Levalbuterol|Oral inhalation as needed.
46100733|NCT02705261|Behavioral|cognitive-behavior therapy|Internet based program to support parents in developing strategies to help their children
46100734|NCT05439148|Drug|OPC-61815 injection|Intravenous administration of OPC-61815 at 8 mg or 16 mg. 8mg group will be intravenously administered only on D1, once a day. 16mg group will be intravenously administered on D1，D3-D9, once a day.
46015941|NCT04914208|Device|DIY face mask|Participants are wearing a DIY face mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
46015942|NCT04914208|Device|Surgical face mask|Participants are wearing a surgical face mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
46015943|NCT04914208|Device|FFP2 respirator mask|Participants are wearing a FFP2 respirator mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
46015944|NCT04914208|Other|Waiting for 4 hours without wearing a mask|Participants do not wear any face mask for 4 hours (beginning between 8 and 9 a.m.).
46015945|NCT04914208|Other|Use of fluoridated toothpaste|Participants use fluoridated toothpaste.
46015946|NCT00626158|Drug|gemcitabine|1000 mg/m2 IV day 1 of every cycle for 100 minutes (each cycle 14 days)
46015947|NCT00626158|Drug|capecitabine|starting dose 1000 mg/m2 PO twice a day for days 1-7 of each cycle (each cycle 14 days)
46015948|NCT01311557|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
46100735|NCT02703077|Procedure|Spyglass|Endoscopic direct view of the bile ducts
46100736|NCT02703077|Procedure|Balloon dilation of the papilla|Using a hidrostatic balloon the major papilla will be dilated to facilitate the stone removal
46100737|NCT02703077|Procedure|EHL (electrohydraulic lithotripsy)|With a probe a direct view lithotripsy will be performed
46100738|NCT02703077|Procedure|ERCP (Endoscopic retrograde cholangiopancreatography)|Endoscopic procedure to identify and treat biliary diseases
46100739|NCT05344703|Device|Y Balance Plus Visual Perturbations|Stroboscopic glasses will be added to the protocol for the participants to perform the Y-balance lower quarter to examine the differences in Y-balance scores as well as examining the Y-balance's ability to predict injury and concussion with visual perturbations.
45465695|NCT05398432|Other|motivational interview|"After the pre-test data were applied to all patients, before starting the motivational interview seans, the patients were informed about the interview intervals, duration, and how many times they would be held. In the second week, motivational interview seans were started with the patients. seans with patients took place during the hemodialysis seans. A total of 6 seans were held, one seans per week. After the first seans of the self-care supported motivational interview, the Self-Care and Adaptation to Disease Training Guide prepared by the researcher in line with the literature was given to the experimental group. Self-care training was given in the first, second and third seans. Motivational interviews were conducted in the fourth, fifth and sixth seans. Motivational interviewing techniques were used for patients to realize their self-care activities. seans were held individually with the patients and each seans lasted approximately 15-20 minutes."
45465696|NCT01132781|Drug|Theophylline (Intervention Group)|200 mg twice daily of slow release theophylline
46100740|NCT05344703|Diagnostic Test|Y balance|Subjects will perform Y-balance without any interventional strategies.
45465697|NCT01132781|Drug|Placebo (Placebo Group)|200 mg twice daily of placebo drug
46100741|NCT02702843|Procedure|Laparoscopic cholecystectomy with Xenon light|Standard laparoscopic cholecystectomy with white light
46100742|NCT02702843|Procedure|Laparoscopic cholecystectomy (fluorescent cholangiography)|Laparoscopic cholecystectomy in infrared light after injection of indocyanine green pre-operatively.
46100743|NCT02705027|Device|Freka®-Trilumina versus Freka®-EasyIn|Direct placement of probe via endoscope
46100744|NCT05344547|Diagnostic Test|Cardiac risk ratio (CRR)|Cardiac risk ratio (CRR) was calculated according to Genest et al. (23) as serum total cholesterol (TC) level divided by serum high-density lipoprotein-cholesterol (HDL-c) level and woman with CRR at ≥3.5 was considered at risk of cardiac disease (24).
46100745|NCT02704637|Device|HS-1000|HeadSense (HS)-1000 device, a proprietary non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or abnormal brain-related conditions and providing decision-making support for physicians
46100746|NCT00516139|Drug|Lamotrigine|Open-label
46100747|NCT02704715|Procedure|general anesthesia,orbital operation|to evaluate the pain under general anesthesia
45465698|NCT03795961|Device|transcranial direct current electrical stimulation|anodal tDCS of M1 for 20 minutes, at 2 mA for 5 sessions (day after day)
45680349|NCT02736981|Behavioral|BWL + Extrinsic Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will have the opportunity to receive small monetary incentives in weeks 2-24 for tracking weight and calorie intake, and will be eligible for a raffle based on weight loss.
45680350|NCT02704208|Behavioral|Thrive With Me Control|Those assigned to the TWM control group will receive a weekly email with static HIV informational content. Information will be focused more on quality of life and general wellbeing issues and will not be specific to medication adherence.
46015949|NCT01311557|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
46015950|NCT01310777|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
46015951|NCT01310777|Drug|Brinzolamide 1% ophthalmic suspension|
46015952|NCT01310777|Drug|Brimonidine tartrate 0.2% ophthalmic solution|
46100748|NCT05344391|Other|BFR cycling|Cycling with BFR followed by shoulder exercises
46015953|NCT01310699|Device|Olympus Colonoscope CFHQ190AL|Technically improved colonoscope with close focus high definition narrow band imaging.
46015954|NCT01310075|Device|Alloderm|6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.
46015955|NCT01310075|Device|Surgimend|10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.
46100749|NCT05344391|Other|Cycling without BFR|Cycling without BFR followed by shoulder exercises
46100750|NCT02702531|Device|FloShield Defogging and Cleaning System|
45680351|NCT02704208|Behavioral|Thrive With Me Intervention|Those assigned to the TWM intervention will have 150 days to access tailored content on a mobile-enhanced website. They will also have social support through a network of other HIV-positive men. Finally they will track their daily ART medication adherence and mood through SMS and website use.
46015956|NCT01309997|Drug|imatinib mesylate|Given PO
46015957|NCT01309997|Biological|rituximab|Given IV
46015958|NCT01309919|Device|IUD|Placement of the IUD after delivery (vaginal or cesarean birth), either immediately (within 10 minutes of placental delivery) or delayed (within 48 hours of delivery). Subjects will also keep a bleeding diary for three months postpartum.
46015959|NCT01309919|Other|Diary|Subjects will keep a bleeding diary for three months
46015960|NCT04325165|Device|DBS Implantation|Bilateral implantation of PPN DBS electrodes
45465699|NCT05398276|Behavioral|Behavioral Exposure For Introceptive Tolerance|BE-FIT will consist of a 6-session one-on one program with a clinician that are approximately 45 minutes delivered, over the course of 3 weeks (twice/week). Sessions will coincide with scheduled cardiac rehabilitation sessions at RWJ Cardiac Rehabilitation Program. The elements of BE-FIT are (1) psychoeducation about avoidance/anxiety and values clarification and committed action for exercise and lifestyle PA; (2) graded, repeated exposure to bodily sensations and exercise to build tolerance of discomfort; (3) fading safety behaviors and elimination of exercise avoidance behaviors to promote tolerance of uncertainty and reduce catastrophizing; and (4) use of Fitbit activity tracker to facilitate physical activity monitoring and provide physical activity feedback and goal-setting.
45599213|NCT02299219|Behavioral|Standard Medical Care and Cancer Resource Center|"The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about Cancer (Cancer Resource Centre) and online assessments."
45599214|NCT03759197|Drug|188-0551 Spray|Topical Spray containing active drug
45680352|NCT02677064|Other|assessments|All laboratory assessments performed on this study represent standard of care at our institution. HLA allele typing is performed by the center's HLA laboratory according to standard typing procedures.
46015961|NCT01309841|Drug|NKTR-118|12.5 mg oral tablet once daily
45599215|NCT03759197|Drug|Vehicle Spray|Topical Spray containing no active drug
45680353|NCT02664337|Other|Decision tool|A survey will be created for each condition that reflects the most important aspects of the corresponding treatment process.
45680354|NCT02664337|Other|Standard treatment information|Participants will receive information pertaining to one of the 12 specified musculoskeletal conditions. This information will reflect information commonly distributed to patients seeking to make a decision concerning treatment for their condition.
46015962|NCT01309841|Drug|NKTR-118|25 mg oral tablet once daily
46015963|NCT01309841|Drug|Placebo|Oral tablet once daily
46015964|NCT01308749|Drug|Oxytocin|"Subjects will use the Syntocinon® Nasal Spray (oxytocin) twice daily for 8 weeks if they are randomized to that arm in the Randomized Phase. All subjects will use the Syntocinon® Nasal Spray twice daily for 8 weeks in the Open Label Phase.~Subjects ages 3-10 years old will be titrated up to a maximum dose of 24 International units (IU). Subjects ages 11-17 years old will be titrated up to a maximum dose of 32IU."
46015965|NCT01308749|Drug|Placebo|Placebo Nasal Spray
46015966|NCT01307891|Drug|Abraxane alone|100 mg/m2 weekly X 3 doses (Days 1, 8, 15) at 28-day intervals until disease progression or unacceptable toxicity. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).
46015967|NCT01307891|Drug|Abraxane + Tigatuzumab|Tigatuzumab will be administered as a loading dose of 10 mg/kg on Day 1, then 5 mg/kg on Day 15 and then every other week on Days 1 and 15 of subsequent cycles. It will be given as an IV infusion over 60 minutes or less. No dose reductions will be allowed. Tigatuzumab will be administered in combination with the Abraxane according to the intervention described for it.
46015968|NCT05644301|Drug|Celecoxib|Oral capsule, 200 mg, twice daily, for 12 weeks
46015969|NCT05644301|Drug|Minocyclin|Oral capsule, 100 mg, twice daily, for 12 weeks
46015970|NCT05644301|Drug|Placebo|Oral capsule, no active substance, twice daily, for 12 weeks
46015971|NCT04324931|Other|Biomechanical corrections|Biomechanical corrections is to be done to correct the varus deformity of knee joint and for pain management.
46100751|NCT00515827|Drug|Raltegravir (MK-0518)|400 mg tablet taken orally twice daily
46100752|NCT00515827|Drug|Placebo|400 mg placebo tablet taken orally twice daily
46015972|NCT04324931|Other|Conventional Physiotherapy|Conventional therapy includes Hydrocollatoral pack for 20 minutes, Interferential therapy for 15 minutes beat frequency 100 Hz, Sweep frequency 150 Hz and exercise program of 3 sessions for 20 minutes on alternative days for 3 weeks for management of knee osteoarthritis.
45465700|NCT05398276|Behavioral|Health Education Control|HEC is a time-matched control intervention that will be administered on the same delivery schedule as BE-FIT. The intervention content includes: (1) educational information about health topics relevant to healthy aging, and (2) Use of the Fitbit activity watch for PA monitoring. The 6 topics introduced in the HEC include: nutrition, sleep, brain health, emotional health, living with chronic conditions, how to be a smart patient. The health information will be conveyed through lectures and handouts. The goal of sessions will be to provide education, particularly as it relates to healthy aging. Patients will be given the same Fitbit as in the BE-FIT but will not be given PA goals.
46015973|NCT02890745|Drug|Empagliflozin|
45465701|NCT03925103|Procedure|3D VATS lobectomy|pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 3 dimensional display system
45465702|NCT03925103|Procedure|2D VATS lobectomy|pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 2 dimensional display system
45680355|NCT02663739|Device|Zenith® TXD|Zenith® TXD Dissection Stent Graft System for treatment of patients with aortic dissection of the descending thoracic aorta
46015974|NCT02890745|Drug|Placebo|
46015975|NCT01307579|Drug|Caspofungin Acetate|Given IV
46015976|NCT01307579|Drug|Fluconazole|Given IV or PO
46015977|NCT01307579|Other|Laboratory Biomarker Analysis|Correlative studies
46015978|NCT01057693|Drug|pregabalin (Lyrica)|Lyrica 150-300 mg/day. Medication is supplied as capsules and given 3 times daily.
46015979|NCT01057693|Drug|Placebo|Placebo is supplied as capsules and given 3 times daily.
46015980|NCT02875171|Drug|Anthracycline administration|Patients suffering from lymphoma or acute leukemia and requiring anthracycline administration were included
46015981|NCT01307501|Device|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
46100753|NCT02702453|Behavioral|website|The intervention arm will consist of 12 modules, 8 of which are consistent with the trajectory of prostate cancer and its treatment. Four modules address aspects of the prostate cancer experience that are important for patients and partners as well as providers and are designed to optimize the goal of supporting patients and partners in their sexual recovery.
46015982|NCT04325009|Drug|Lipitor 80mg Tab → Dong-A Atorvastatin 80mg Tab|"st period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~nd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~rd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~th period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab"
46015983|NCT04325009|Drug|Dong-A Atorvastatin 80mg Tab → Lipitor 80mg Tab|"st period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~nd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~rd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~th period: single oral administration of 1 tablet of Lipitor 80mg Tab"
46015984|NCT01034137|Drug|methotrexate|orally weekly in ascending dosages, starting at 10mg/week
46015985|NCT01034137|Drug|placebo MTX|orally weekly
46015986|NCT01034137|Drug|placebo TCZ|iv every 4 weeks
46015987|NCT01034137|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
46015988|NCT04302805|Drug|Privigen|Patients randomized to PE/rATG/IVIG group will receive IVIG 0.5g/kg infusions, on 1st, 3rd and 5th postoperative day.
46015989|NCT04302805|Drug|Thymoglobulin|All patients will receive 1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg.
46015990|NCT04302805|Other|Plasma Exchange|All patient will undergo Plasma Exchange before transplantation.
46015991|NCT02874469|Other|Diary|"The diary was specifically created for the purpose of the present study by personal working at ICU at CHRU of Lille (France).~All relatives, doctors and paramedics close to the patient during his hospital stay are allowed to write some comments inside the diary when he is comatose.~The diary will be implemented during the second period of the study within the first 8 hours after admission.~It will be given to the patients themselves at discharge or to their relatives in case of in-hospital death. An anonymous copy will be kept by investigators."
46015992|NCT02874079|Other|Blood sample and cotton skin swabs|
45465703|NCT03497767|Drug|Osimertinib|All participants will receive a dose of Osimertinib 80mg once daily
45465704|NCT03497767|Radiation|Stereotactic Radiosurgery (SRS)|Dose and fractionation depend on lesion size. All SRS must be completed within 21 days of randomisation and all lesions are to be treated within 7 days.
45465705|NCT01230203|Procedure|Computed tomography scan versus color duplex ultrasound|Computed tomography scan versus color duplex ultrasound
45465706|NCT05398042|Dietary Supplement|Ketone ester|A daily dose of 3x20g of ketone ester supplementation during a six week intervention period
45465707|NCT05398042|Dietary Supplement|Medium Chain Triglyceride (MCT) oil|A daily dose of 3x12.8g of MCT oil supplementation during a six week intervention period
46015993|NCT01056289|Drug|Desvenlafaxine Succinate Sustained-Release Formulation 50 mg|DVS SR 50 mg Reference Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
45465708|NCT04359238|Behavioral|Individualized excercise|The participants in the intervention group carry out regularly endurance and strength exercises.
45465709|NCT01231763|Other|No intervention (not applicable)|No intervention (not applicable)
45680356|NCT02663362|Other|To evaluate the reproducibility of acquiring multi-nuclear data on a new 3T Philips Magnet|Outside standard MR instrumentation there will be no interventions.
45465710|NCT03802045|Procedure|Electroacupuncture|"The interventions will be performed by acupuncture specialists with at least 3 years of clinical experience, who will receive prior training to ensure that they rigorously follow the study protocol and are familiar with the types of treatments, including details such as acupuncture points and manipulation of electroacupuncture parameters.~After the randomization, the acupuncturist will sequentially open the envelopes, and the individuals will be randomly assigned to one of five treatment groups: Low frequency EA (LF), high frequency EA (HF), alternating frequency EA (AF), control group (C) and placebo group (P), each containing 25 participants. The acupuncture points will be located and described according to the WHO Standard Acupuncture Locations. Based on the beneficial effects of previous clinical trials, the acupoints selected for this study will be: BL23, BL25, BL40, SP6 and KI3."
46015994|NCT01056289|Drug|Desvenlafaxine Succinate Sustained-Release Formulation 25 mg|DVS SR 25 mg Taper Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
46015995|NCT01056289|Drug|Placebo|DVS SR Placebo Abrupt Discontinuation Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
46015996|NCT01039675|Drug|500mcg/25mcg once daily|GSK573719/GW642444
46015997|NCT01039675|Drug|Placebo once daily|Inactive, excipients only
46015998|NCT02875093|Drug|ADI-PEG 20|Investigational Medicine
46015999|NCT02875093|Drug|Cytarabine|low-dose cytarabine 20 mg BID twice daily for 10 days, every 28 days
46016000|NCT01033825|Drug|Ciclesonide HFA Nasal Aerosol 320 mcg|Ciclesonide HFA Nasal Aerosol 320 μg once daily
46016001|NCT01033825|Drug|Ciclesonide HFA Nasal Aerosol 160 mcg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
46016002|NCT01033825|Drug|HFA Nasal Aerosol placebo|HFA Nasal Aerosol placebo once daily
46016003|NCT01033825|Drug|Ciclesonide Aqueous Nasal Spray 200 mcg|Ciclesonide Aqueous Nasal Spray 200 mcg once daily
45465711|NCT03802045|Device|Needle|Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used.
45465712|NCT03802045|Device|Adhesive Moxa|In the placebo group an adhesive moxa will be placed on each acupoint and the needle will be inserted over it.
45465713|NCT05397652|Drug|Tranexamic Acid Injectable Product|Patients from the experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously unlike the patients in the control group who will receive just sterile saline.
46016004|NCT01033825|Drug|AQ Nasal Spray Placebo|AQ Nasal Spray Placebo once daily
46016005|NCT01033825|Drug|Placebo plus Dexamethasone HFA|Dexamethasone capsules 6 mg once daily
46016006|NCT01033825|Drug|Placebo AQ plus Dexamethasone 6 mg|Placebo AQ plus Dexamethasone 6 mcg capsules once daily
46016007|NCT01033747|Drug|Deferasirox|10 mg/kg or 30 mg/kg orally daily
45465714|NCT05397652|Drug|Placebo|Patients from experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously unlike the patients in the control group who will receive just sterile saline.
45465715|NCT03918317|Device|AirXpanders AeroFormtissue expander|The AeroFormdevice will be placed in an immediate fashion at the time of mastectomy in a submuscular, prepectoral or dual-plane approach. The tissue expander will be minimally inflated intraoperatively to minimize dead space and while facilitating tension free closure. Participants will undergo standard postoperative management, and will be given instructions on utilization of the device, including daily expansion until desired volume is reached as determined b surgeon and participant agreement.
45465716|NCT01230281|Other|Black bean seed coat extract|1000 mg oral daily dose for 2 weeks
45465717|NCT01303705|Drug|Anti-OX40|Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8 of the study. The total anti-OX40 dose will be reconstituted in 100 ml 0.9% saline and infused over no more than 60 minutes intravenously. A single-use non-pyrogenic durapore membrane low protein binding filter (e.g.: Braun 1.2 micron air eliminating filter or equivalent) shall be used to filter the study product in the line between infusion bag and patient.
45680357|NCT02618408|Drug|SPN-810 (18 mg)|Subjects were randomized to receive SPN-810 low dose (18 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
46016008|NCT01033747|Drug|Deferasirox|5 mg/kg or 30 mg/kg orally daily
46016009|NCT00627055|Drug|LPV/r|LPV/r dosing = 400mg/100mg orally q12h for 48 weeks
46016010|NCT00627055|Drug|LPV/r + TDF/FTC or TDF/3TC|TDF/FTC (Truvada) 1 pill orally q 24 hr or TDF 300mg orally q 24 hr/3TC 300mg orally q 24 hr (or 3TC 150mg orally q 12 hr) for 48 weeks
46016011|NCT02875015|Drug|Liposomal Bupivacaine|20 mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars
46016012|NCT02875015|Drug|Bupivacaine Hydrochloride and Lidocaine|Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
46016013|NCT02875015|Procedure|Suburethral Sling|A retropubic, transobturator or mini-sling will be placed in the usual fashion followed by diagnostic cystoscopy.
46016014|NCT01091428|Drug|Alisertib|Alisertib tablets
46016015|NCT01091428|Drug|Paclitaxel|Paclitaxel intravenous infusion
45465718|NCT01303705|Radiation|Radiation|8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment. Imaging such as bone scan, MRI, CT scan, or radiograph must identify the target lesion as consistent with metastatic disease. Any bone lesion that is inducing pain or where there may be a clinical concern for potential pathological fracture will be selected over asymptomatic lesions.
46016016|NCT05049850|Drug|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly specific for IgG.
46100754|NCT04154696|Procedure|Liver transplantation of a graft after assessment by normothermic perfusion|Liver transplantation of a graft after assessment by normothermic perfusion
46100755|NCT02702375|Other|Fructose-containing Sugars|
46100756|NCT04031924|Other|Assessment of: 1. Functional Capacity 2. Physical Fitness 3. Physical Activity Level 4. Balance 5. Kinesiophobia 6. Psychological Status 7. Fatigue Severity|All liver transplantation patients who underwent transplant at least one year ago and healthy subjects were evaluated the first day they came.
45465719|NCT01303705|Drug|Cyclophosphamide|CTX will be administered on day 1 (Friday only) at a dose determined by cohort assignment. The drug should be diluted per institutional standards. An added dose of IV fluids may help prevent bladder toxicity. In this protocol, CTX will be administered intravenously over 30 - 60 minutes.
45465720|NCT01134341|Drug|Pralatrexate Injection|"Intravenous (IV) push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride).~10 or 15 mg/m2, depending on cohort assignment.~Dose reductions allowed for protocol-specified criteria.~Administered weekly for 3 weeks of 4-week cycle (weekly for 3 weeks with one week of rest) until criteria for discontinuation per the protocol are met."
46100757|NCT02702297|Other|single arm|Daily monitoring of vaginal fluid IL6 and fetal ECG. Daily maternal monitoring and delivery according to standard operating procedure. Post partum diagnosis of FIRS or EOS by analysing of fetal cord blood IL6 and clinical signs of sepsis. Diagnosis of histologic amniotic infection by histological analysis.
46100758|NCT00615875|Drug|naproxen|opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice.
46100759|NCT00615875|Drug|placebo|opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice
46016017|NCT04307758|Other|Muscle Strength Assesment-Make Test|For the make test, the examiner applies resistance in a fixed position and the person being tested exerts a maximum effort against the dynamometer and examiner. The examiner is only required to sustain an isometric contraction and read the highest value on an Hand Held Dynamometer.
46016018|NCT04307758|Other|Muscle Strength Assesment-Break Test|For the break test, the examiner applies resistance sufficient to overcome the maximum effort of the person being tested and cause the subject's joint to move in the opposite direction, which results in an eccentric contraction. During this test the limb must move at a constant velocity while the person being tested is asked to achieve a maximum contraction. In addition, the examiner must read the force output reading at the exact time the subject's limb begins to move from the Hand Held Dynamometer.
46016019|NCT04307680|Device|Peritron perineometer|Perineometry will be used to assess quality of each observed treatment modality.
46100760|NCT02630810|Other|Early oral hydration|starting oral hydration 1 hour following Cesarean Section using 100 ml clear water
46100761|NCT02630810|Other|Delayed oral hydration|starting oral hydration 6 hours following Cesarean Section using 100 ml clear water
46016020|NCT04307524|Procedure|laparoscopic repair|laparoscopic suture repair of cesarean scar niche
46100762|NCT05343845|Other|Observational study|After approval of the institution's ethics committee, 100 patients will be divided in two groups as pregnant women who did not smoke during pregnancy and pregnant women who smoked 5 or more cigarettes in a day. The local anesthetic, which dose will adjusted according to height and weight, and 20 µg fentanyl will be administered intrathecally to both groups. Results on the effectiveness of spinal anesthesia will be monitored.
45465721|NCT01134341|Drug|Bexarotene Capsules|"150 or 300 mg orally, depending on cohort assignment. Provided as 75 mg capsules and taken with a meal.~Dose reductions allowed for protocol-specified criteria and implemented per the Targretin® package insert.~Administered daily until criteria for study treatment discontinuation per the protocol are met."
45465722|NCT01134341|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks prior to start of study treatment, every 8-10 weeks throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene)."
45465723|NCT01134341|Dietary Supplement|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to start of study treatment, throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene)."
45465724|NCT04308304|Drug|MK-1942|MK-1942, oral, 1-mg, 5-mg and/or 10-mg capsules, BID dosing up to 28 days
46100763|NCT02630888|Drug|Memantine|Memantine association in the treatment of young patients with Bipolar I Disorder, partial responders or non-responders to the combination of (quetiapine + lithium) or (quetiapine + aripiprazole) from the ARIQUELI study.
45465725|NCT04308304|Drug|Donepezil|Donepezil, oral, 5-mg and/or 10-mg tablet (maximum dose 15 mg QD), QD dosing for up to 28 days
46016021|NCT04307524|Drug|medical treatment in the form of combined hormonal contraception|"patient will receive for three months daily without interruption, no pill-free interval drug names is Genera BAYERhealthcare"
46016022|NCT04307602|Other|Exercise - High Intensity Interval Training (HIIT)|Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled children
46016023|NCT04307602|Other|Exercise - Submaximal Steady State Training (SST)|Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled
46016024|NCT01096342|Drug|dinaciclib|Given IV
46016025|NCT01096342|Other|laboratory biomarker analysis|Correlative studies
46016026|NCT01039519|Drug|Ganetespib|Ganetespib 200 mg/m^2 during an approximately 1-hour infusion once weekly for three consecutive weeks followed by a treatment-free week. Participants who demonstrate acceptable tolerability and objective clinical benefit (defined by at least stable disease or objective response per RECIST) can continue to receive ganetespib until disease progression or appearance of unacceptable toxicity.
46016027|NCT04874740|Other|No intervention|No intervention
45465726|NCT04308304|Drug|Placebo|Placebo to MK-1942, oral, capsule, all dosage levels, BID dosing for up to 28 days.
45465727|NCT05402501|Behavioral|"Lifestyle intervention program Leef! met MS"|The lifestyle program consists of a three-months intensive program, followed by a 21-months 'inspiration' program with occasional meetings.
45465728|NCT05397262|Other|Hyperthermia|Deep Regional Hyperthermia (RHT) 1-2/week up to 10 sessions a type of cancer treatment in which body tissue is exposed to high temperatures (up to 113°F).
45680358|NCT02618408|Drug|SPN-810 (36 mg)|Subjects were randomized to receive SPN-810 high dose (36 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
45680359|NCT02618408|Drug|Placebo|Subjects were randomized to receive Placebo twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
45680360|NCT02553460|Drug|ITMHA|Given intrathecally (IT).
45680361|NCT02553460|Drug|Dexamethasone|Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
45680362|NCT02553460|Drug|Mitoxantrone|Given IV.
45465729|NCT05397262|Radiation|Radiotherapy|50,4 Gy (28 x 1,8 Gy) plus Boost: If R0: 5,4 Gy; If R1/2: 9 Gy
45465730|NCT05397262|Drug|Chemotherapy 5-Fluorouracil|600 mg/m^2 civ 120h; d 1-5, 29-33
45465731|NCT05397262|Drug|Chemotherapy Cisplatin|20 mg/m^2; d1-5, 29-33
45465732|NCT03800719|Behavioral|AWARD advice|"At baseline, brief smoking cessation advice following AWARD model will be delivered to subjects within about 2 to 5 minutes:~Ask about smoking history and habit~Warn about the risks of smoking using a leaflet~Advise to quit smoking as soon as possible and use nicotine replacement therapy (NRT) or SC services~Refer subjects to free smoking cessation services in Hong Kong if they agree~Do it again: smokers who have tried to quit but relapsed will be encouraged to quit again and those who have reduced smoking will be advised to further reduce or quit smoking"
45465733|NCT03800719|Behavioral|Health warning leaflet|At baseline, an A5-sized leaflet will be given to subjects, which includes information about risks of smoking, pictures of smoking-related diseases, and smoking cessation services provided in Hong Kong.
45465734|NCT03800719|Behavioral|Active referral to smoking cessation (SC) services|At baseline, subjects will be encouraged to seek smoking cessation services in Hong Kong. If subjects agree, their contact information will be sent to the preferred service providers for a quick appointment and follow-up.
46100764|NCT02630888|Drug|Placebo|Patients randomized to this group will receive a unit dosage identical to that contains 15 mg of memantine during the first week (V0); all have the dose of the placebo (similar to memantine) increased on the second week (V1) in two divided doses of a unit dosage identical to that contains 15 mg of memantine
46100765|NCT02699411|Device|Dry needling|dry needling Travell and Simons
46100766|NCT02699411|Other|Stability and propioception|Start excursion balance test, WOMAC; ROM, EVA.
46100767|NCT00671294|Drug|Ramelteon and Placebo (9 possible combinations total)|"Randomized sequence over two consecutive nights for a total of three treatment periods to include the following:~Ramelteon 4 mg, tablets, orally over two nights~Ramelteon 8 mg, tablets, orally over two nights~Ramelteon placebo-matching tablets, orally over two nights"
46100768|NCT02630576|Device|Neuromuscular stimulation|Single twitch and train-of-four stimulation protocols will be performed at the randomised side with growing current intensity
45465735|NCT03800719|Behavioral|Regular messages through Instant Messaging (IM)|A total of pre-set 26 messages will be sent to subjects through WhatsApp 12 weeks after baseline to remind the quit date and to encourage abstinence. Messages are tailored based on subjects' sociodemographic characteristics and smoking habit following Social Cognitive Theory and Transtheoretical Model. Messages will be sent with the schedule of once daily for 1 week (the week across the quit date), 3 times a week for 4 weeks (2 weeks each before and after the week with quit date) and once a week for remaining 7 weeks. The schedule will be adjusted according to the quit date and also smokers' requests. The format of regular messages will mainly be text-based but also include pictures, animations and videos.
45680363|NCT02553460|Drug|Pegaspargase|Given IV. If participant is allergic to pegaspargase, Asparaginase Erwinia Chrysanthemi will be used.
45465736|NCT03800719|Behavioral|Psychosocial support and referral to SC services through IM|Personalized interactive text or voice conversation will be provided by trained smoking cessation advisors through WhatsApp for 3 months after baseline. Advisors will periodically proactively send messages to subjects to initiate the conversation (e.g. asking recent progress of smoking cessation) and deliver evidence-based advice. Advisors will also actively refer subjects, if they have expressed the need, to smoking cessation services providers. A standard operation algorithm for advisors used in the pilot feasibility trial will be modified for the use.
45680364|NCT02553460|Drug|Asparaginase Erwinia Chrysanthemi|Asparaginase Erwinia Chrysanthemi will be used in case of allergy or intolerance of participant to PEG-asparaginase. Given IV (preferred) or intramuscularly (IM).
45465737|NCT03800719|Behavioral|Message on general health delivered by short message service (SMS)|After baseline, regular messages using SMS will be sent to subjects with similar frequency to Intervention group. The messages include information on general health and reminders on follow-up surveys and biochemical validation for quitting.
45465738|NCT01230359|Dietary Supplement|Pyridoxine hydrochloride|2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
45465739|NCT01230359|Other|Tang orange powder|2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
45465740|NCT05397184|Biological|Cryopreserved BE CAR7 T cells (BE752TBCCLCAR7PBL)|Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR7+ T cells/kg BECAR7 Total duration of treatment: 28 days Follow-up: 12 months
45465741|NCT01133015|Device|Fractional flow reserve|Fractional flow reserve measured by pressure wire
45465742|NCT01133015|Device|IVUS|intravascular ultrasound
45465743|NCT05396716|Device|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given during surgery.
45465744|NCT04286542|Diagnostic Test|Cold, dry air|Participants will be exposed to cold (<-10°C, <10% relative humidity), dry air for 15 minutes.
45465745|NCT01304485|Drug|Sodium Acetate C11|PET Imaging with Sodium Acetate C11
45465746|NCT03371355|Drug|Placebo|Placebo (Matched with ISIS 703802)
45465747|NCT03371355|Drug|ISIS 703802 40 mg|ISIS 703802 40 mg, administered via SC injection, once every 4 weeks for 6 doses.
45465748|NCT03371355|Drug|ISIS 703802 80 mg|ISIS 703802 80 mg, administered via SC injection, once every 4 weeks for 6 doses.
45465749|NCT03371355|Drug|ISIS 703802 20 mg|ISIS 703802 20 mg, administered via SC injection, once every week for 26 doses.
45465750|NCT03918005|Other|Low glycemic load diet|Foods with low glycemic index or glycemic load (brown rice, brown bread, whole wheat pasta, oat bran, yogurt, milk, apple, pear, peach)
45465751|NCT05591677|Drug|D-Cycloserine|D-cycloserine (DCS) is a partial NMDA receptor agonist that has demonstrable impact on rTMS and TBS's neuromodulatory effects. Participants will be asked to orally ingest one capsule 2-hours prior to their scheduled iTBS treatment time.
45680365|NCT02553460|Drug|Bortezomib|Given IV.
46016028|NCT01096186|Drug|IPX066 95 mg|23.75 - 95 mg CD-LD capsules
46016029|NCT01096186|Drug|IPX066 145 mg|36.25 - 145 mg CD-LD capsules
46016030|NCT01096186|Drug|IPX066 195 mg|48.75 - 195 mg CD-LD capsules
46016031|NCT01096186|Drug|IPX066 245 mg|61.25 - 245 mg CD-LD capsules
46016032|NCT01032889|Drug|Deoxycholic acid injection|
46016033|NCT01032889|Drug|Placebo|Phosphate buffered saline placebo for injection
46016034|NCT04301713|Other|Evaluation of rik of falls|An evaluation of the risk of falls will be carried out in the elderly in the province of Salamanca. This will attempt to identify the risk of falling as well as to be able to establish protocols for action of a preventive and rehabilitative nature.
45342550|NCT05810779|Other|dynamic surface exercise|Optimal arousal Physio ball Make the child bounce, active/passive on the Swiss ball, slow/fast 5 times 5 sets Combined frontal and transverse plane movements Physio ball/ bolster High sitting: one hand weight bearing followed by trunk rotation to reach the toy on opposite side 5-7 each side 1 set Combined frontal and transverse plane movements Platform swing Reaching the toy with both the hands kept overhead and 45°-60° diagonal to the mid line 5-7 times each side 1 set
45465752|NCT05591677|Device|Intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation (iTBS) will be administered with a magnetic stimulator using a figure-of-8 coil or equivalent FDA-approved device. Initial treatment coil localisation and individual calibration of stimulation intensity will be conducted by TMS-trained investigators/staff using standard approaches.67,68 Stimulation intensity will be at 90% of the individual's calibrated resting motor threshold. iTBS treatment session delivers 600 pulses and is approximately 3½ minutes in duration. The total pulse number applied over a course of 20 treatments will be 12,000. This regimen is analogous with the iTBS protocol approved by the US FDA to treat TRD.
45680366|NCT02553460|Drug|Vorinostat|Taken PO or NG.
45680367|NCT02553460|Drug|Cyclophosphamide|Given IV.
45680368|NCT02553460|Drug|Mercaptopurine|Given PO or NG.
46016035|NCT04307368|Other|FODMAP diet|8 weeks of diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP)
45680369|NCT02553460|Drug|Methotrexate|Given IV, IM or PO.
45680370|NCT02553460|Drug|Leucovorin Calcium|Leucovorin rescue PO or IV.
45680371|NCT02553460|Drug|Cytarabine|Given IV.
45465753|NCT05402423|Device|Computerized cognitive training plus aerobic exercise with the JDome System|"Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks).~Each session will involve the following activities:~30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia~30 minutes of aerobic training with the JDOME system,"
45465754|NCT05402423|Device|Computerized cognitive training plus aerobic exercise with standard exercise bike|"Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks).~Each session will involve the following activities:~30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia~30 minutes of aerobic training with standard exercise bike"
45465755|NCT05396482|Diagnostic Test|Pure tone audiometer|Pure tone audiometer
45465756|NCT03811327|Behavioral|Zero-time Exercise|A 2-hour group ZTEx training once per week for 2 consecutive weeks (totally 4 hours)
46016036|NCT04307368|Other|Elimination-rotational diet|During the patient's first visit an IgG antibody titration test against specific nutrients will be performed to determine food hypersensitivity. Based on the results of the obtained food panels, patients will be offered an elimination-rotational diet for a period of 8 weeks.
46016037|NCT04307368|Other|Classic diet|8 weeks of classic diet treatment (recommended by the gastroenterologist who supervises them).
46016038|NCT01049503|Other|Low fluoride and conventional dentifrices with different pH|Comparison of different dentifrice fluoride concentrations and pH on caries control
46100769|NCT02692625|Dietary Supplement|(L. reuteri Prodentis®).|The Test group is instructed to consume Probiotic lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every participating child.
46100770|NCT02692625|Dietary Supplement|Placebo lozenges|The control group is instructed to consume placebo lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every
46100771|NCT02841761|Drug|Midalozam|Syrup for oral use
46100772|NCT02841761|Drug|Aprocitentan|Capsules for oral use
46016039|NCT04292353|Other|Cognitive tests and Patient Reported Outcome|
46016040|NCT01029925|Drug|Dichloroacetate (DCA)|Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart
45465757|NCT05396326|Drug|Oxaliplatin|"The first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1.~The second and fourth cycles: intra-venous oxaliplatin 135mg/m2, day 1."
45465758|NCT05396326|Drug|Teysuno|Oral S-1, 40mg-60mg bid, day 1-14 for four 21-day cycles.
45465759|NCT05396326|Procedure|Transarterial arterial chemoinfusion and embolism (TACiE)|In the first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1; transcatheter arterial embolism of tumor feeding arteries, day 1, if applicable.
45465760|NCT03795571|Drug|Rituximab|Rituximab 375mg/m2，d0
45465761|NCT03795571|Drug|Gemcitabine|Gemcitabine 1000mg/m2，d1，d5
45465762|NCT03795571|Drug|Oxaliplatin|Oxaliplatin 75mg/m2，d1
45465763|NCT03795571|Drug|Dexamethasone|Dexamethasone 40mg/d，d1~d4
46016041|NCT04302415|Drug|There is no other intervention, only clinical treatment.|There is no other intervention, only clinical treatment.
46016042|NCT02873533|Other|geriatric care and longitudinal follow up|geriatric care and longitudinal follow up
46016043|NCT04302649|Drug|peritoneal dialysate at 37°C temperature|during a PET test, patients received peritoneal dialysate warmed at 37°C before infusion
46016044|NCT04301557|Drug|PD-1 Antibody|PD-1 antibody 240mg,I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment, and four cycles in the adjuvant treatment,
46100773|NCT05169398|Device|EUS-guided hepaticogastrostomy|EUS-guided hepaticogastrostomy would be performed with the MG-biliary stent (Niti-S, Taewoong Medical, Gyeonggi-do, Korea)
46100774|NCT02699489|Procedure|Laparoscopic donor nephrectomy|Laparoscopic donor nephrectomy performed via a standard 4-port distribution. Control of the hilar vessels is performed using extra-large Hem-o-Lok clips (Weck- Covidien, Research Triangle Park, NC) and graft extraction is performed via a pre-prepared Pfannenstiel incision
46016045|NCT04301557|Drug|Oxaliplatin|Oxiliplatin 130mg/m^2 (100mg/m^2 during radiotherapy),I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen
46016046|NCT04301557|Drug|Capecitabine|Capecitabine 1000mg/m^2,Bid,P.O,D1-D14,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen, and two cycles in adjuvant treatment in Capecitabine regimen
46016047|NCT04301557|Radiation|External beam radiotherapy|Neoadjuvant radiotherapy, 50Gy/25Fractions to the GTV, 45Gy/25Fractions to the CTV
46016048|NCT04301557|Procedure|Total mesorectal excision|Total mesorectal excision
46016049|NCT02874313|Device|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
46016050|NCT02874313|Drug|Pharmacological treatment|Conventional pharmacological treatment with oral antidiabetic drugs or insulin
46016051|NCT02874313|Other|Conventional anti-diabetic diet recommendations|
46016052|NCT01029691|Device|Positive Airway Pressure|Women will use positive airway pressure until delivery
46016053|NCT02874157|Biological|blood draw|
46016054|NCT01029535|Device|Cross-linked hyaluronic acid gel|Cross-linked hyaluronic acid gel (Juvederm® VOLUMA™) up to 4 mLs injected in each side of the face.
46016055|NCT04290481|Other|oxygen saturation and perfusion index screening|Oxygen saturation and perfusion index values that are measured by pulse oximeter is used for screening critical congenital heart disease.
46016056|NCT04301167|Behavioral|befriending|Participants are new users of the ALONE befriending intervention, which matches participants to volunteer befrienders who visit once weekly for a minimum of 12 months. It is a criterion of study involvement that participants commit to completing at least two data collection timepoints before being matched to a befriender.
46016057|NCT04302571|Behavioral|combined aerobic and resistance physical activity|Five training sessions weekly for 12 weeks are scheduled. Each session lasts 60 minutes divided into 45 minutes of aerobic workout and 15 minutes of circuit training. The aerobic workout consists of walking on a flat floor or on a slight uphill (maximum slope 3%): patients should walk until submaximal walking capacity (80% of their MWT) and rest as they would experience pain at the lower limbs; afterwards, they should start to walk again, once the pain was improved. Resistance training consists of calisthenics exercises focused on trunk and lower limbs muscles (bicycle, flutter kicks, squats, lunges, calf raises, wall sits and power press) with at least 3 repetitions for each exercise, interspersed by 30 seconds recovery. Duration of repetitions increases every 3 weeks.
46016058|NCT04302571|Behavioral|sham exercise|general recommendation to perform regular aerobic physical activity
46016059|NCT04301323|Drug|BHVI1 eye drops|Including 35 children enrolled to receive BHVI1 eye-drops once nightly
46016060|NCT04301323|Drug|BHVI2 eye drops|Including 35 children enrolled to receive BHVI2 eye-drops once nightly
46016061|NCT04301323|Drug|BHVI3 eye drops|Including 35 children enrolled to receive BHVI3, combination of BHVI1 and BHVI2, eye-drops once nightly
46016062|NCT02874235|Behavioral|Receptive music therapy|16 sessions of a length of one hour comprising of receptive music psychotherapy with 5 - 15 minutes of music listening included
46016063|NCT02874235|Behavioral|Psychological treatment|16 sessions of a length of one hour comprising of verbal based psychotherapy based on principles from Narrative Exposure Therapy or Cognitive Behavioral Therapies
45465764|NCT03795571|Drug|Lenalidomide Oral Capsule|Lenalidomide 10mg/d、15mg/d、20mg/d、25mg/d d1~d10； 21days a cycle
46016064|NCT04301635|Procedure|Maxillo-mandibular Advancement + Counterclockwise rotation|Maxilla: Lefort I osteotomy Mandible: Obwegeser-Dal-Pont osteotomy Movements: Advance and counterclockwise rotation
45465765|NCT01231919|Drug|Akt inhibitor MK2206|Given PO
45465766|NCT01231919|Other|diagnostic laboratory biomarker analysis|Correlative studies
45465767|NCT01231919|Other|pharmacological study|Correlative studies
46016065|NCT04615819|Other|Kidney Transplant Fast Track (KTFT)|Streamlined KT evaluation involving completion of most or all testing on the same day a patient arrives for their first pre-transplant clinic appointment. Or, a transplant clinic scheduler secures testing within a 4 week period.
46016066|NCT04615819|Other|Peer Navigation (PN)|Uses trained, previous KT recipients who meet weekly to monthly with patient participants to provide tailored information and assistance in completing the necessary steps to proceed to transplant.
46016067|NCT01028053|Drug|Flutemetamol (18F) Injection|All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq.
46016068|NCT04301245|Other|Educational program|"The educational program (EP) was offered during the initial session of the pulmonary rehabilitation. According to the french law, patients were free to participate or not.~The EP consisted of an educational diagnosis, educational workshops and an individual final assessment."
46016069|NCT04607317|Behavioral|Exercise program|a telehealth-delivered exercise program with the goal of progressing to 150 min/week (5 days per week, 30 minutes of steady state walking per day)
46016070|NCT04607317|Behavioral|Health Coach|The coach will work directly with each participant during their once-weekly virtual 1:1 meeting to progress intensity and duration. Participants will meet with the coach to review a brief social cognitive theory-based module, which will provide education on core behavior change concepts and the benefits of physical activity for those with epilepsy. The coach will review the previous week's exercise during meetings, and will then work with the participant to revise and reset goals for the coming week.
46016071|NCT04607317|Behavioral|Health Information|Participants will be contacted by a study coordinator via telephone every 2 weeks for health education. During this time, they will review resources and healthy lifestyle guidelines for people with epilepsy, including healthy diet, medication compliance, seizure precautions, stress management, and sleep hygiene.
46016072|NCT04300621|Drug|OTF 1|Participants will receive (S)-ketamine administered sublingually through OTF 1.
45680372|NCT02553460|Drug|Etoposide|Given IV. In case of participant allergy, etoposide phosphate (Etopophos®) will be given.
45680373|NCT02553460|Drug|Vincristine|Given IV.
45680374|NCT02530034|Drug|Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4|Given IV
45680375|NCT02530034|Other|Laboratory Biomarker Analysis|Correlative studies
45680376|NCT02530034|Other|Pharmacological Study|Correlative studies
45680377|NCT02516670|Dietary Supplement|Ascorbic Acid|Given IV
45680378|NCT02516670|Drug|Docetaxel|Given IV
45680379|NCT02516670|Other|Laboratory Biomarker Analysis|Correlative studies
46016073|NCT04300621|Drug|OTF 2|Participants will receive (S)-ketamine administered sublingually through OTF 2.
46016074|NCT04300621|Drug|OTF 3|Participants will receive (S)-ketamine administered sublingually through OTF 3.
46016075|NCT04300621|Drug|OTF 4|Participants will receive (S)-ketamine administered sublingually through OTF 4.
46016076|NCT01023217|Drug|Adefovir|Adefovir dipivoxil (Hepsera) 10 mg/day orally for 104 weeks
46016077|NCT01023217|Drug|Entecavir|Entecavir 1 mg/day orally
46016078|NCT01023217|Drug|Lamivudine|Lamivudine (Zeffix) 100 mg/day orally
46016079|NCT01095796|Drug|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
46016080|NCT01095796|Drug|Atripla|Atripla (EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily prior to bedtime
46100775|NCT02699489|Procedure|Open donor nephrectomy|Open donor nephrectomy performed via a supracostal incision above the 11th rib and an extra-pleural extra-peritoneal approach was adopted
46016081|NCT01095796|Drug|Stribild Placebo|Placebo to match Stribild STR administered orally once daily
46016082|NCT01095796|Drug|Atripla Placebo|Placebo to match Atripla tablet administered orally once daily prior to bedtime
46016083|NCT01023061|Drug|abiraterone acetate|Given PO
46100776|NCT00522457|Drug|ertumaxomab|Ertumaxomab will be intravenously administered to see if it can increase the patient's objective response rate.
46016084|NCT01023061|Drug|prednisone|Given PO
46100777|NCT00666302|Drug|tacrolimus ointment|topical
46016085|NCT01023061|Drug|leuprolide acetate|Given via injection
46016086|NCT01023061|Other|laboratory biomarker analysis|Correlative study
46016087|NCT01023061|Radiation|external beam radiation therapy|Undergo radiotherapy
45680380|NCT02516670|Other|Pharmacological Study|Correlative studies
45680381|NCT02516670|Other|Placebo|Given IV
46016088|NCT01023061|Drug|goserelin acetate|Given via injection
45680382|NCT02516670|Other|Quality-of-Life Assessment|Ancillary studies
46016089|NCT01027897|Drug|Doripenem|Doripenem 1 gm administered over 4 hours X 3 doses
46016090|NCT01027351|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine.|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB+OMV NZ) or two catch-up doses.
46016091|NCT01027351|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB).
46100778|NCT00666302|Drug|pimecrolimus cream|topical
46100779|NCT00671372|Drug|FOLFIRI regimen|Intravenous repeating dose
46100780|NCT00671372|Drug|bevacizumab|Intravenous repeating dose (for Cohort 6 subjects not previously treated with bevacizumab)
46100781|NCT00671372|Drug|cetuximab|Intravenous repeating dose
46100782|NCT00671372|Drug|dulanermin|Intravenous repeating dose
46100783|NCT00671372|Drug|irinotecan|Intravenous repeating dose
45465768|NCT04280848|Drug|UCPVax|"The UCPVax vaccination protocol will start at least one month after glioblastoma patients have completed the concomitant radiochemotherapy (Radiotherapy + Temozolomide RT/TMZ).~UCPVax vaccine will injected subcutaneously at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccination one month after the last injection and then every 8 weeks for 12 months maximum."
46016092|NCT04300465|Behavioral|10 week MySlainte Program|"The intervention consists of a 10 week community based lifestyle intervention program. It consists of a weekly 1 hour exercise class, a weekly 1 hour health promotion workshop as well as individualised goal setting, exercise prescription and optimisation of cardioprotective medications.~This program is delivered by a multi-disciplinary team; including a physiotherapist, occupational therapist, dietitian, clinical nurse specialist and physician. It will be delivered through a registered Irish charity, Croí."
46016093|NCT02873611|Device|MRI|patients will undergo an additional MRI testing of apprx. 0.5-1 hour.
45465769|NCT04280848|Drug|Temozolomide|6 additional monthly cures of Temozolomide (after concomitant radiotherapy and temozolomide) according to standard of care
45465770|NCT03795649|Drug|Tranexamic Acid|Imunomodulatory effect
45680383|NCT02437851|Procedure|Therapeutic Conventional Surgery|Undergo surgery to remove anal or perianal cancer (SISCCA)
46016094|NCT02873611|Procedure|genicular ablation procedure|
46016095|NCT02873299|Other|10 Hz rTMS of the right dorsolateral prefrontal cortex|Ten sessions of 10 Hz rTMS of the right dorsolateral prefrontal cortex
46016096|NCT02873299|Other|20 Hz rTMS of the right dorsolateral prefrontal cortex|Ten sessions of 20 Hz rTMS of the right dorsolateral prefrontal cortex
46100784|NCT00666380|Biological|Plasmodium falciparum Malaria Protein 010 (FMP010)|Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
45465771|NCT05396092|Behavioral|Integrated mindfulness-based Tai Chi Chuan|MBTCC will integrate components from both the MBI and TCC groups. The entire intervention consists of eight weekly sessions of two-and-a-half to three hours each.
45465772|NCT05396092|Behavioral|Mindfulness-based intervention|The MBI group is mainly based on the basic theory and research of the foundational mindfulness-based stress reduction program. The intervention consists of eight weekly sessions of two to two-and-a-half hours each.
45465773|NCT05396092|Behavioral|Tai Chi Chuan|TCC is mainly based on a nine-form Yang-style form of TCC, which is a brief and modified version of 64-form Yang-style TCC. The entire intervention consists of eight weekly sessions of two to two-and-a-half hours each.
45465774|NCT05396092|Behavioral|Sleep Hygiene Education|SHE is based on principles used in stimulus control and sleep hygiene education, which has previously been used as the control group in sleep-related research. The entire intervention consists of eight weekly sessions of two to two-and-a-half hours each.
46016097|NCT01027273|Behavioral|Prevent Return of Stroke|Prevent Return of Stroke is a community-based, peer-led stroke recurrence prevention program. This is a bilingual (English/Spanish) education program written at a 4th grade reading level, and contains simple, actionable, messages, easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes, to help reduce stroke recurrence risk factors. It consists of 6 sessions (1½ hours each) held over 6-weeks. Topics include learning the risk factors for stroke, controlling hypertension, LDL cholesterol, preventing blood clots, medication adherence, and stress management.The intervention arm will participate in the intervention shortly after enrolling in the trial.
46016098|NCT01027273|Behavioral|Prevent Return of Stroke|The intervention arm will participate in the intervention shortly after enrolling in the trial. The usual care arm will be offered the intervention after 12 months from enrolling in the trial.
46016099|NCT04300933|Behavioral|Electroencephalogram-based neurofeedback|In this project, SCD participants will receive electroencephalogram-based neurofeedback therapy, once a day, for 5 days. Then, the investigators will compare their memory changes between baseline and post-therapy visits.
46100785|NCT00856986|Drug|liraglutide|Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.
46100786|NCT00856986|Drug|insulin detemir|Insulin detemir subcutaneous (under the skin) injection once daily. Dose will be titrated (individually adjusted) based on fasting self-measured plasma glucose levels according to a pre-specified algorithm
46100787|NCT00856986|Drug|metformin|Metformin tablets, at least 1500 mg/day
45342551|NCT05810779|Other|trunk targeted training|"trunk training group (TTG) consist of exercises and activities focusing on the activation of the trunk muscles, pelvic control and proximal stabilization and these were combined with the trunk and gluteal muscle strengthening exercises.~The trunk elongation activities, the facilitation of spinal extension, weight shifting and weight-bearing activities The children in the TTG received 45-75-minute of physiotherapy twice a week for 8 weeks"
45465775|NCT01230515|Other|Individual patient interview, focus group and structured survey|
45465776|NCT01230515|Other|interview, focus group and structured survey|
46016100|NCT01022203|Behavioral|Structured Approach Therapy|The Structured Approach Therapy intervention includes education about the impact of PTSD on relationships; skills training to teach couples recognize and stop avoidance behavior; behavior activation training; emotion regulation training; and a couple-based intervention to teach Veterans with PTSD to identify and disclose trauma memories and related emotions to their partners. The couple is then trained to support disclosure while practicing empathic communication.
46016101|NCT01022203|Other|PTSD Family Education|The PTSD Family Education intervention provides education for Veterans with PTSD and their partners explaining the signs and symptoms of PTSD; psychological problems that are comorbid with PTSD; and treatments for PTSD. Skills training and psychotherapy are not included.
45465777|NCT01230515|Other|interview, focus group and structured survey|
46016102|NCT01296711|Biological|CDP6038 (olokizumab)|100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks
46016103|NCT04324281|Other|Investigation|cadaveric dissection
46016104|NCT05661045|Procedure|low-flow anesthesia|Changes in blood carboxyhemoglobin levels as a result of exposure to rebreathing during low-flow anaesthesia.
46016105|NCT01294917|Device|Multi-purpose disinfecting solution|For the cleaning, rinsing, and storage of soft contact lenses.
45465778|NCT01230515|Other|interview, focus group and structured survey|
46016106|NCT01294917|Device|Clear Care|Peroxide-based regimen for cleaning and disinfecting soft contact lenses.
46016107|NCT01294917|Device|Opti-Free RepleniSH|Multi-purpose disinfecting solution for the cleaning, rinsing and storing of soft contact lenses.
46016108|NCT01294683|Drug|Simvastatin|
45465779|NCT05402267|Procedure|Adenoidectomy|Adenoidectomy will be conducted in OA and CA groups
45465780|NCT04211272|Drug|Macitentan|Macitentan will be administrated as film-coated tablet in Part A and Part B.
45465781|NCT04211272|Drug|Sildenafil|Sildenafil will be administrated as film-coated tablet in Part A.
46016109|NCT01294683|Drug|Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)|
46016110|NCT01294683|Drug|Extended Release (ER) niacin/laropiprant (N/LRPT)|
46016111|NCT01294683|Drug|Placebo|
46016112|NCT01294449|Device|MADIT-CRT ICD|Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study.
45465782|NCT04211272|Drug|Riociguat|Riociguat will be administrated as film-coated tablet in Part A.
46016113|NCT01294449|Device|MADIT-CRT CRT-D|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study.
46016114|NCT01293123|Drug|Raltegravir|raltegravir 400 mg PO twice daily
45465783|NCT04211272|Drug|Rosuvastatin|Rosuvastatin will be administrated as film-coated tablet in Part B.
46016115|NCT01293123|Drug|Efavirenz|efavirenz 600 mg PO once daily
46016116|NCT01292187|Drug|Oral calcitonin at dinnertime|Oral calcitonin at dinnertime.
45465784|NCT01302925|Drug|PEP005 Gel|PEP005 Gel 0.05% for 2 consecutive days
45465785|NCT01302925|Drug|PEP005 Gel|PEP005 Gel 0.015% for 3 consecutive days
45465786|NCT03810937|Other|head position|head positioning in sniffing or flat position
45465787|NCT05402189|Drug|Ketodex, Fentanyl|"The patients will be randomized into 2 groups : group (KD) and group (OP) . Two 20 ml syringes, labelled loading and another two 20 ml syringes labelled maintenance will be given to each patient according to his group.~Group (KD): patients will receive 1mg/kg ketamine and 1ug/kg dexmiditomidine in their respective loading syringes diluted in 20ml normal saline. Then , they will receive ketamine 0.1 mg/kg /hr and dexmedetomidine0.2ug/kg/hr in their maintenance syringes prepared in 20 ml normal saline in a concentration of 1mg/ml ketamine and 1ug/ml dexmiditomidine respectively .~Group (OP): one of the loading syringes will contain fentanyl in a dose of 2ug/kg diluted in 20 ml normal saline and the other loading syringe will contain normal saline. Then, the patients will receive 0.5ug/kg/hr fentanyl through one of the maintenance syringes while the other syringe contains normal saline."
45465788|NCT01134419|Other|Computerized handoff tool|Informatics tool to aid in transfer of patient care information
45465789|NCT01134419|Other|Team training|Teamwork training and revisions of handoff structure to optimize teamwork skills and verbal communications
45465790|NCT01304563|Biological|TIV 2010/2011 influenza vaccine|TIV 2010/2011 influenza vaccine Intramuscular: 15 mcg TIV 2010/2011 vaccine x 1: Control
45465791|NCT01304563|Biological|TIV 2010/2011 influenza vaccine|Low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental
45465792|NCT01304563|Biological|TIV 2010/2011 influenza vaccine|Higher lower dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental
45465793|NCT01304563|Biological|INT|Low dose TIV 2010/2011 influenza vaccine delivered via a short needle intradermal device x 1: Experimental
45465794|NCT01231997|Drug|Udenafil|100mg Single Oral Dose of
45465795|NCT03795805|Procedure|total knee arthroplasty|Total knee arhroplasty
45465796|NCT03795805|Procedure|Tourniquet limb cuff|Tourniquet limb cuff and regular anesthesia
45465797|NCT03795805|Drug|Intaarticular lidocain|20 ml of 2% lidocain application intraarticular before surgery (intraarticular lidocain)
45474017|NCT03628417|Procedure|Bleomycin based electrochemotherapy|"If the patient agrees biopsies will be performed from the tumor area before and after electroporation during local anaesthesia. Maximum of 8 biopsies will be done, depending on the patient's number of metastases.~All patient's regardless of the number of metastases will have one biopsy from area treated with calcium and one from area treated with bleomycin, after the randomization code is revealed at day 180.~Patients with more than 6 metastases: One to two biopsies before treatment, one to two biopsies one week after treatment from metastases treated with calcium and bleomycin respectively.~All biopsies will be handled according to current guidelines and analyzed by a pathologist for amount of tumor tissue, inflammation, fibrosis and necrosis."
46016117|NCT01292187|Drug|Oral placebo at dinnertime|Oral placebo at dinnertime.
46016118|NCT01292187|Drug|Oral calcitonin at bedtime|Oral calcitonin at bedtime
46016119|NCT01292187|Drug|Oral placebo at bedtime|Oral placebo at bedtime
46016120|NCT01026493|Drug|temozolomide 60 mg x 21 days|Temozolomide 60 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
46016121|NCT01026493|Drug|temozolomide 75 mg x 21 days|Temozolomide 75 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
46016122|NCT01026493|Drug|ABT-888 20 mg x 21 days|20 mg bid x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
46016123|NCT01026493|Drug|ABT-888 40 mg x 21 days|40 mg bid x 21 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude further therapy
46016124|NCT01026493|Drug|Temozolomide 150 mg x 5 days|150 mg/m2 x 5 days (up to 200 mg/m2 after 2nd cycle)*, with a 28-day cycle; dose reduction to 125 mg/m2 if necessary. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
45465798|NCT03799237|Other|GOS trap and dengue NS1 antigen kit|The GOS trap lure and sticky surfaces to trap gravid Aedes mosquitoes. Three GOS traps will be placed on every 3 floors of the residential blocks. The traps will be changed weekly. Trapped Aedes mosquitoes will be identified to species. The mosquitoes will then be dissected, to remove the abdomen from the thorax. Five to seven abdomens of the same mosquito species will be pooled and tested for dengue NS1 antigen using the SD Biosensor Standard Q dengue NS1 antigen test kit. If the pool is tested positive for dengue NS1, the head and thorax of the respective abdomens will be subjected to the same procedure for dengue NS1 antigen test, individually. This may allow us to identify a focus where there could be dengue-infected individuals. Flyers/Posters will be disseminated besides, house-to-house approach to inform the residents of the findings and apartment blocks where these mosquitoes were found. The apartment management will also make use of social media disseminate this information.
45465799|NCT04072042|Drug|Apatinib monotherapy|patients will receive Apatinib 250mg tablet by mouth, bid.
45465800|NCT01133327|Device|Carotid Artery Stenting|"The Adapt Carotid Stent System is intended to deliver a self-expanding Stent to the extra-cranial carotid arteries via a sheathed percutaneous Monorail delivery system. The Adapt Carotid Stent is a closed cell, self-expanding, rolled nitinol (nickel-titanium alloy) sheet. The stent is thin, flexible and expands to appose the vessel wall.~The FilterWire EZ System is a temporary intravascular guide wire filtration system that is placed in the vessel distal to the lesion to be treated. It consists of either a polyurethane filter bag 1.5 cm in length or a Bionate (polycarbonate urethane) filter bag, 1.0 cm in length attached near the distal end of a 0.014 silicone coated stainless steel guide wire by means of a collapsible, self-conforming, Nitinol filter loop wire."
45465801|NCT03799315|Drug|Nicotine Replacement Therapy|All participants randomized to the JUST group will receive training on proper use of nicotine lozenges to aid in smoking cessation. Upon release from jail, participants will receive 2mg nicotine lozenges.
45680384|NCT02345629|Procedure|Cordotomy|Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours.
45680385|NCT02345629|Behavioral|Pain/Symptom Questionnaire|Pain and symptom questionnaire completed at baseline, by phone during first week of study, and once each month by phone during 6 month follow up.
45837782|NCT05764850|Genetic|Genome sequencing|"100 extensively phenotyped pediatric and young adult patients for genotyping, metabolomic and lipidomic analyses. Polygenic risk scores for type 1 diabetes and cardiovascular disease will be performed.~For patients older than 6 years who agree to do a second visit (optional), a Mixed Meal Tolerance Test (MMTT: the gold standard for assessing beta cell function) will be done as well as transcriptomic analysis."
45837783|NCT05764837|Other|Foam Rolling|Foam rolling was performed for 4 minutes with the goal of affecting the entire myofascial posterior chain.
45837784|NCT05764824|Dietary Supplement|Blueberry powder|25 g per day of blueberry powder
46016125|NCT01026493|Drug|ABT-888 40 mg x 5 days|40 mg bid x 5 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
46016126|NCT04580251|Procedure|Targeted axillary dissection|The surgical treatment procedure of targeted axillary dissection performed in patients in whom the pathological lymph nodes have been marked using the examined and compared markers (magnetic marker Magseed, iodine seed 125I, carbon suspension)
46016127|NCT01026103|Device|Tri Staple Technology stapler|This is a single arm study.
46016128|NCT02873767|Drug|PR1|"Active substance: UCB4019~Route of Administration: subcutaneously"
46016129|NCT02873767|Other|PL1|"Active substance: Placebo~Concentration: 0.9 % saline~Route of Administration: subcutaneously"
45465802|NCT03799315|Behavioral|Counseling|All participants randomized to the JUST group will receive one hour of in-person, individual, guideline-based smoking cessation counseling during their jail stay. Upon release from jail, they will receive four 30-minute counseling phone calls over 3 weeks. These phone calls will take place at 24 hours, day 7, day 14, and day 20.
45465803|NCT05387200|Drug|Masibone S|The investigators will evaluate the change of bone mineral density at lumbar spine measured by DEXA after 48 weeks of alendronate sodium trihydrate 70mg (oral solution) 1 bottle weekly and cholecalciferol 1000U/calcium 100mg 1T daily use.
45465804|NCT05387200|Drug|Fosamax|The investigators will evaluate the change of bone mineral density at lumbar spine measured by DEXA after 48 weeks of alendronate sodium 70mg (oral tablet) 1T weekly and cholecalciferol 1000U/calcium 100mg 1T daily use.
45465805|NCT05401955|Other|Physical exercise|An adapted physical exercise protocol
45465806|NCT05386810|Biological|Experimental vaccine|Sabin Inactivated Poliovirus Vaccine (Vero cell) (2.5ml)-investigational vaccine produced by Sinovac Biotech Co., Ltd. Inactivated Sabin poliovirus antigen (per 0.5ml): type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 2.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate,2 - phenoxyethanol for per injection.
45465807|NCT05386810|Biological|IPV control vaccine|Inactivated Poliovirus Vaccine - control vaccine produced by Sanofi. Inactivated poliovirus antigens: Mahoney strain for type 1 (40DU), MEF-1 strain for type 2 (8DU), Saukett strains for type 3 (32DU) in 0.5 ml mixture of 2- phenoxyethanol,ethanol,formaldehyde,hanks199 medium (containing amino acids, mineral salts, vitamins, glucose, polysorbate 80 and water for injection),hydrochloric acid or sodium hydroxide (for pH value adjustment),trace amounts of antibiotics (neomycin, streptomycin and polymyxin B)for per injection.
45680386|NCT02345629|Procedure|Sharpness Sensory Testing|Sharpness detection determined using 8, 10, 16, 20, 32, 64, and 128g weighted needle devices. Each stimulus applied for about 1 second in ascending order. Participants asked to rate each stimulus as producing the sensation of touch, pressure, sharp, or pain. The sharpness detection threshold defined as the mean force of the stimuli deemed ''sharp'' or ''painful'' from 3 trials separated by an average interval of 30 to 90 seconds.
46016130|NCT01291173|Drug|lisdexamfetamine dimesylate (SPD489)|SPD489-30mg capsules taken once daily for up to 11 weeks
45837785|NCT05764824|Other|Controlled and matched powder|25 g per day
45837786|NCT05764811|Drug|Canagliflozin 100mg|100 mg daily for a month
46016131|NCT01291173|Drug|lisdexamfetamine dimesylate (SPD489)|SPD489 50mg capsules taken once-daily for up to 11 weeks
46016132|NCT01291173|Drug|lisdexamfetamine dimesylate (SPD489)|SPD489 70mg capsule taken once-daily for up to 11 weeks
46016133|NCT01291173|Drug|Placebo|Placebo capsule taken once daily for up to 11 weeks
46016134|NCT02873455|Other|Short video clip including the circumstance of operation theater, and surgeon's interview|
46016135|NCT02872519|Drug|(S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG)|Given by IV
46016136|NCT02872519|Procedure|Positron Emission Tomography|Undergo scan
45342552|NCT05810766|Other|mobilization with movement|MWM at glenohumeral joint and then we will add progression by adding glides at sternoclavicular and acromioclavicular joint.5 sets of painless glides of 10 repetitions will be given, with 3-minute rest between sets.
46016137|NCT02872519|Other|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
46016138|NCT01291017|Drug|PD0332991|PD0332991 125 mg PO days 1 - 21
46016139|NCT01290315|Drug|Ferric Carboxymaltose (FCM)|One 500 mg dose at 100 mg/minute (Cohort I) or 750 mg dose at 100 mg/minute (Cohort II)
46016140|NCT01290315|Drug|Iron Sucrose / Iron Dextran|One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I), or a 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)
46016141|NCT01289847|Biological|Gammaplex|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.
45837787|NCT05764798|Drug|Experimental group: Shugan Jieyu Capsule combined with zolpidem|Shugan Jieyu capsule and zolpidem orally for 8 consecutive weeks
45465808|NCT05386810|Biological|single-person sIPV control vaccine|"Sabin Inactivated Poliovirus Vaccine (Vero cell) (0.5ml) -control vaccine produced by Sinovac Biotech Co., Ltd.~Inactivated Sabin poliovirus antigen: type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 0.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate for per injection."
46016142|NCT04830748|Other|Mechanical knee traction|Continuous knee joint mechanical traction will be applied to the patients positioned in supine lying position with the affected knee flexed at 25-30 degrees by a wedge placed under the affected knee. The thigh will be secured with a strap for stabilization and the leg will be held by the specially designed greave with the weight of traction hanging throughout a pulley system. The amount of traction will be set to about 10% of body weight. The treatment will be applied for 20 minutes continuously, once a day, 3 times per week for 4 weeks. The traction force will be progressed gradually during the program ( e.g.: weekly increase force by 1% of body weight if the patient can tolerate the duration of 20 min with the preset force).
45465809|NCT05401877|Procedure|therapies for breast cancer|the type of tumor removal surgery, combined therapy
45465810|NCT04910269|Biological|Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|The hIVIG product is administered as a single dose of 3.5 grams, or 35 milliliter at a concentration of 0.1 grams/milliliter.
45465811|NCT04910269|Other|Placebo|Infusion of 35 milliliters standard isotonic saline
45465812|NCT03711669|Behavioral|Immunosuppression withdrawal|IS will be tapered gradually over a period of 6 months. Azathioprine will be stopped during the first 3 months, reducing the dose 50% every month. Prednisone will be tapered 2.5mg monthly until total withdrawal. During withdrawal and the first year after stopping treatment patients will undergo laboratory tests on a monthly basis, afterwards follow-up will be done every 3 months until the end of the project.
46016143|NCT04830748|Other|Therapeutic exercises|"Therapeutic exercises will be divided into stretching and strengthening exercises:~Stretching will be done passively for the hamstring, rectus femoris and calf muscles. Each exercise will be done for 3 reps each with a hold period of 30-60 secs with a 30-60 rest period between reps.~Strengthening exercises will be done for the quadriceps and hamstring muscles ( inner range knee extension- knee extension in sitting- straight leg raise in flexion- prone hamstring curl- standing hamstring curl- straight leg raise in extension). Exercise will be done for 3 sets each will consist of 10 reps with a rest period of 2-3 minutes between sets. The starting weight should be 50% of the patient's 1 RM. The end position will be held for 5 seconds. Progression will be achieved by increasing the exercise rep and intensity gradually throughout the program. E.g.: weekly increase force by 5% if patient can tolerate an increased repetition of 20 rep with the preset force."
46016144|NCT02877784|Procedure|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
46100788|NCT00662246|Radiation|respiratory gated proton beam radiotherapy|- Prescription dose to PTV as according to the following dose escalation schema: Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.
46100789|NCT02702141|Drug|SGN-CD19B|Given intravenously Day 1 of 28-day or 42-day cycles
45465813|NCT01585727|Procedure|TME|Total mesorectal excision
45465814|NCT01585727|Procedure|TME|Total mesorectal excision
45465815|NCT01585727|Procedure|Neuromonitoring|Intraoperative neuromonitoring of pelvic autonomic nerves.
46100790|NCT02630732|Behavioral|Brain school|2 sessions of education provided by a therapist. The first session one day before surgery, the other two days after surgery. Education contains physiology of the central nerve system and the pain system. Information about acute pain, chronic pain and central sensitisation.
46100791|NCT02630732|Behavioral|Back school|Two education sessions ( one day before surgery and two days after surgery) with information about the biomechanics of the lumbar spine, physiology of the spine and ergonomics.
46100792|NCT05343533|Dietary Supplement|Probiotic|After baseline or initial testing, participants will be randomly assigned in a double-blind fashion to ingest on a daily basis for 6 weeks either a placebo or a probiotic supplement. Identical follow-up measurements will then occur each visit after taking their assigned supplement. After 6 weeks of administration, the supplementation protocol will stop and a final evaluation will be completed 3 weeks later (9 weeks after initial administration) to assess any residual impact of the assigned supplement after a 3-week washout.
46016145|NCT02877784|Other|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
46100793|NCT00666614|Other|Sleep Environment Intervention|Patients randomized to the sleep environment intervention months will experience a relaxation period before nighttime sleep, white noise as selected by the patient, stimulus control strategies, a window covering to diminish hallway light from entering the room, and a nurse-protected 90-minute uninterrupted sleep period at night.
46016146|NCT02877784|Other|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
46016147|NCT01021813|Drug|Suvorexant|Oral tablet (30 mg and 10 mg), administered daily before bedtime
45837788|NCT05764798|Drug|Control group: Placebo combined with zolpidem|Placebo and zolpidem orally for 8 consecutive weeks
46016148|NCT01021813|Drug|Dose-matched Placebo to Suvorexant|Oral tablet, administered daily before bedtime
45465816|NCT03442972|Drug|Teduglutide|Teduglutide
45465817|NCT03442972|Drug|Placebo|Placebo
45465818|NCT01134497|Drug|Placebo|The control arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus placebo by mouth on days 1-21 of a 21 day cycle
45837789|NCT05764746|Drug|Artemether-lumefantrine and Amodiaquine Drug Combination|AL and AQ will be given together for three days then followed by placebo for three days
45837790|NCT05764746|Drug|Artemether-lumefantrine then Artesunate amodiaquine|AL will be given twice a day for three days then followed by artesunate amodiaquine once a day for three days
45837791|NCT05764746|Drug|Artemether-lumefantrine|This will be the comparator arm as standard treatment, where only AL will be given twice a day for three days then placebo for three days
45837792|NCT05764720|Radiation|Daily Adaptive External Beam Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
46016149|NCT01025635|Drug|Azelaic acid foam 15%|Applied topically twice daily for 12 weeks
46016150|NCT01025635|Drug|Vehicle foam|Applied topically twice daily for 12 weeks
46016151|NCT04300387|Behavioral|multidisciplinary care|multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
45342553|NCT05810766|Other|conventional physical therapy|Hot pack for 15 minutes
45342554|NCT05810740|Drug|Binimetinib Oral Tablet|Two-period Crossover study
45342555|NCT05810714|Other|Best Practice|Receive usual care
45342556|NCT05810714|Other|Fecal Immunochemical Test|Receive FIT kit
45342557|NCT05810714|Behavioral|Health Education|Receive audio brochure
45342558|NCT05810714|Behavioral|Health Education|Receive video brochure
46016152|NCT01021423|Drug|Lenalidomide|15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
46016153|NCT01021423|Other|Placebo|Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
46016154|NCT02872207|Drug|BAY 987516 (Y65-122)|5 µL in one eye
46016155|NCT02872207|Drug|BAY 987516 (Y65-118)|5 µL in one eye
46016156|NCT02872207|Drug|Control|5 uL in other eye
46100794|NCT00666614|Other|Normal Hospital Environment|Normal Hospital Environment
46100795|NCT02699177|Device|CBF measurements|CBF measurements
46016157|NCT02873143|Other|No intervention|No intervention
45465819|NCT01134497|Drug|ZD4054|The experimental arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus ZD4054 (10mg daily) od by mouth on days 1-21 of a 21 day cycle.
45465820|NCT03370419|Behavioral|Treatment|Lifestyle intervention fostering the development of behavioral automaticity (habit strength) or dietary and physical activity behaviors.
45465821|NCT03370419|Behavioral|Usual care|Usual care
45465822|NCT03918161|Device|MRE exam|Magnetic Resonance Elastography
45465823|NCT05375656|Other|Cross-over study|Traditional Inuit Diet and Western Diet.
45465824|NCT03799081|Procedure|Fetoscopy|Fetoscopy is a procedure that enables viewing of the fetus through use of a hysteroscope
45465825|NCT03711591|Device|Conventus Cage PH device|The Conventus CAGE™ PH (PH Cage) is a permanent implant comprised of an expandable scaffold, made from nitinol and titanium, which is deployed into the medullary canal and provides a structure to which fractured bone fragments are attached using fragment screws.
45465826|NCT03798925|Other|None Intervention|It is observational study
45465827|NCT03921671|Combination Product|Ramucirumab|Combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with carcinoma thymic (or thymoma B3 with areas of carcinoma), relapsed and / or metastatic, in the first line.
45465828|NCT03709251|Behavioral|High Intensity Walking|Intense walking activity at an intensity of 70-80% of the maximum heart rate
45465829|NCT03709251|Behavioral|Casual Speed Walking|Moderate intensity (50-60% of Heart Rate maximum)
45465830|NCT03795727|Device|MD ring and precontoured sectional matrix by TOR VM|MD ring (separation ring) and precontoured sectional matrix (thickness 0.035mm hard) and a wedge was used to secure matrix in place
45465831|NCT03795727|Device|Circumferential matrix and tofflemire retainer by Kerr|Circumferential matrix (thickness 0.038mm) applied by tofflemire retainer and secured in place with wedge
45837793|NCT05764707|Drug|Acetaminophen|Patients will received 1000mg of intravenous acetaminophen within 30 minutes of skin closure.
45465832|NCT03921593|Procedure|Solid Organ Pancreas Transplantation with or without Kidney Transplantation|Deceased donor pancreas transplantation
45837794|NCT05764707|Drug|Placebo|Patients will received 1000mg of normal saline within 30 minutes of skin closure.
45837795|NCT05764668|Drug|Zihua Wenfei Zhisou Granule|14 daily- doses of Zihua Wenfei Zhisou Granule，one bag at a time (15 g/bag), three times/day
45837796|NCT05764668|Drug|Placebo|14 daily- doses of placebo，one bag at a time (15 g/bag), three times/day
45837797|NCT05763602|Drug|povidone-iodine topical ointment|Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing HELEF orthopedic repair.
46016158|NCT01020877|Drug|Metronidazole|Vaginal Gel, 0.75%
46016159|NCT01020877|Drug|Metronidazole|Vaginal Gel, 0.75%
45342559|NCT05810714|Other|Scheduled Notification|Receive scheduled reminder
45342560|NCT05810714|Other|Survey Administration|Ancillary studies
45342561|NCT05810701|Other|Comprehensive geriatric assessment and individualised physical training|Comprehensive geriatric assessment and relevant intervention (including medical and pharmacological optimisation, nutritional, social and psychological intervention, among others), and individualised physical training
45465833|NCT04891237|Biological|10,000 MG01 + 10,000 T517|Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
45465834|NCT04891237|Biological|30,000 MG01 + 10,000 T517|Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
46016160|NCT01020799|Drug|AZD7268|15 mg, oral, twice daily (BID)
46016161|NCT01020799|Drug|Escitalopram|20 mg, oral, once daily (QD)
46016162|NCT01020799|Drug|Placebo capsules|Placebo capsules to match AZD7268
45465835|NCT04891237|Other|Placebo|The same solution and presentation as the active treatment, but without active ingredients
45680387|NCT02345629|Procedure|Heat Pain Sensory Testing|Thermal ramps will applied using a 3.6 x 3.6 cm Peltier thermode (Medoc Inc.) from a baseline temperature set at 32C. Skin heated at a rate of 0.30C/s, and participants asked to signal when the stimulus is perceived as first becoming warmer and then painfully hot.
45342562|NCT05810688|Other|eating rehabilitation training|The experimental group will receive eating rehabilitation training, including oral care, saliva gland massage, oral exercise, feeding strategy, and swallowing skill education.
45465836|NCT03918083|Behavioral|Wellness|Assess the feasibility of an integrated, prescriptive, and trackable wellness intervention amongst residents at Orange Park Medical Center (OPMC) by combining five wellness elements including: exercise, mindfulness, sleep, social connectedness, and nutrition.
45465837|NCT03373006|Drug|Axumin PET/CT|Synthetic amino acid uptake agent injection followed by imaging
45465838|NCT03917849|Behavioral|Exercises program for patellar tendinopathy|To compare the effectiveness of the inertial flywheel resistance program versus slow heavy resistance in patients with chronic patellar tendinopathy
45465839|NCT03369951|Drug|Minocycline|Minocycline is a semisynthetic derivative of tetracycline and is indicated for the treatment of infections due to susceptible isolates of designated microorganisms.
45465840|NCT04842955|Device|Gamma tACS (40 Hz) over the superior parietal cortex|Single session of gamma tACS (40 Hz) over the superior parietal cortex
45837798|NCT05762367|Diagnostic Test|3T MRI with Gadobutrol injection|MRI will be performed in all participants before and after Gadobutrol injection
45680388|NCT02315898|Drug|Treatment-inhaled tPA|Enrolled patients with acute plastic bronchitis (fibrin airway casts) will receive inhaled tPA treatment. The tPA regimen will consist of 5mg every six hours for a total of 72 hours.
45680389|NCT02315326|Drug|Ibrutinib|"Arm A: Ibrutinib will be given once daily. The starting dose cohort (level 1) will receive 560 mg/day (4 x 140 mg capsules). During the dose escalation period of the study, the 3+3 design will be applied (see Table 3). Participants will be assigned to cohorts of increasing oral daily doses of ibrutinib (560mg, 840mg) until disease progression, intolerable toxicity or death. Three patients with recurrent/refractory PCNSL or recurrent/refractory SCNSL will be treated with daily oral ibrutinib for a 28-day cycle starting at dose level 1 and observed for toxicities during cycle 1. Arm B: Ibrutinib will be given at the MTD defined in Arm A."
45837799|NCT05762315|Behavioral|Audio Storytelling|The audio session is designed to deliver audio narrative developed following the Transformative Storytelling Technique and provide re-structurization of internal caregiver self-stories.
46016163|NCT01020799|Drug|Placebo tablets|Placebo tablets to match encapsulated escitalopram
46016164|NCT02872597|Drug|Ipratropium|
46016165|NCT02872597|Drug|0.9% Sodium Chloride|
46016166|NCT02872597|Drug|Albuterol|"albuterol prescribed by the clinical team per our PICU's Asthma Carepath"
46016167|NCT02872597|Drug|corticosteroids|systemic (IV or enteral) corticosteroid prescribed by the clinical team, typically methylprednisolone IV
46016168|NCT04299919|Procedure|Minimally invasive treatment|All hepatocellular carcinoma (HCC) patients received minimally invasive treatment, including transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or combined.
46016169|NCT04299919|Procedure|Hepatectomy|All hepatocellular carcinoma (HCC) patients received hepatectomy.
46016170|NCT01288989|Biological|IMC-3C5|Escalating doses of IMC-3C5 administered intravenously (i.v.), weekly or every other week
46016171|NCT01020487|Drug|Paricalcitol|Paricalcitol capsules taken with water.
46016172|NCT01020487|Drug|Placebo|Placebo capsules taken with water
46016173|NCT02872675|Dietary Supplement|HOST-DM059|"Experimental Supplement: HOST-DM059.~Participants will be asked to orally consume one powdered sachet each day, at the same time in the morning, reconstituted in tea/coffee/fruit juice, or sprinkled over cereal etc. Whichever method of consumption is chosen, this must be kept consistent across both supplementation phases."
45465841|NCT04842955|Device|Sham tACS over the superior parietal cortex|Single session of sham tACS over the superior parietal cortex
46016174|NCT02872675|Dietary Supplement|Maltodextrin|Placebo Comparator: Maltodextrin.
46016175|NCT04299217|Dietary Supplement|Zynamite®|Zynamite® is a novel mango (Mangifera indica) leaf extract standardized to contain 60% of the polyphenol mangiferin. Zynamite® is classified as a food or food supplement and is available for purchase within the EU. Zynamite® is not associated with any significant deleterious side effects.
46016176|NCT04299217|Other|Placebo|Placebo comparator (carrier)
46016177|NCT02873065|Drug|Ilaprazole|
45680390|NCT02315326|Drug|HD- Methotrexate (MTX)|Arm C1: HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a total of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments.The starting dose of ibrutinib is 560 mg/day (4x140mg capsules)
45465842|NCT04040192|Drug|Crisaborole 2%|Crisaborole ointment 2%
46016178|NCT02873065|Drug|Esoprazole|
46016179|NCT02872831|Device|22G SharkCore™ needle|The 2 dedicated passes from the SharkCore™ needle will be placed in a jar with formaldehyde-based fixative and sent for routine histopathology evaluation. The cassette will be processed, embedded in paraffin, and then prepared in hematoxylin and eosin to be evaluated by one pathologist, who was blinded to the randomization sequence, for the presence of a histologic tissue. If adequate histologic tissue is present, the specimen will be graded as optimal or suboptimal.
46016180|NCT02872831|Device|22G BNX EUS-FNA Needle|Aspirates will be placed onto glass slides and preserved with Diff-Quik stain (American Scientific Products, McGraw Park, Illinois, USA). In addition, a smear will also be placed in alcohol for Papanicolaou staining. Any additional material was sprayed into Hanks's solution and sent for cell block processing. The cytology technician or cytopathologist on site will verify adequacy of specimens. At least two passes will be obtained from the lesion unless the technician established the presence of malignant appearing cells.
46016181|NCT00628225|Behavioral|Counseling and Nicotine replacement (CN)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. General practitioners were encouraged to advise nicotine replacement.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement."
45465843|NCT04040192|Drug|Vehicle|Vehicle ointment
45465844|NCT01131767|Drug|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
45465845|NCT03795259|Drug|Rocuronium|After induction, rocuronium 0.6 mg/kg will be given by intravenously and patients will be orotracheal intubated when TOF value reaches 0%.
45465846|NCT03795259|Drug|Sugammadex|Continuous TOF measurement will continue until the value reaches %25. At this time, sugammadex 2 mg/kg will be given intravenously.
45465847|NCT03354052|Device|Real-rTMS + Gloreha device|The real rTMS will be delivered using a 8-shaped coil placed over the primary motor cortex (M1). The resting motor threshold (RMT) will be assessed at the place of the first dorsal interosseous (FDI) contralateral to the stimulated cortex. RMT of the FDI will be determined as the lowest strength of TMS needed to elicit 5 or more electromyographic responses ≥50 μV within 10 trials. Stimulation will be applied with frequency 10 Hz and intensity of 90% of RMT. Every session will last 15 minutes and includes 3000 pulses (30 trains of 10 seconds, following intertrain interval of 20 seconds). Rehabilitation programme will last 30 minutes and will be delivered using Gloreha® device, a proprioceptive stimulator under visual feedback. All the subjects enrolled will receive treatments for 2 weeks, 5 days per week.
46016182|NCT00628225|Behavioral|Counseling, Nicotine replacement and Bupropion (CNB)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. The general practitioner was encouraged to advice the patients to use both nicotine replacements and Bupropion-SR.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement and Bupropion-SR."
45465848|NCT03354052|Device|Sham-rTMS + Gloreha device|The sham rTMS will be delivered using a sham stimulator. All procedures will be performed as for the real treatment. Rehabilitation programme will last 30 minutes and will be delivered using Gloreha® device, a proprioceptive stimulator under visual feedback. All the subjects enrolled will receive treatments for 2 weeks, 5 days per week.
46016183|NCT01024855|Device|RevitaLens OcuTec MPS (Investigational MPS) and Opti-Free RepleniSH MPS (control)|multi-purpose lens care solution
45465849|NCT01229189|Dietary Supplement|Vitamin D|Maternal dose of 4000 IU daily for 20 weeks Neonatal dose of 400 IU daily for 24 weeks
46016184|NCT01014013|Drug|ertapenem sodium (MK0826)|a single daily dose of ertapenem sodium 1.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy if needed)
46016185|NCT01014013|Drug|Comparator: ceftriaxone sodium|a single daily dose of ceftriaxone 2.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy)
45465850|NCT01229189|Dietary Supplement|Placebo|Placebo will be supplemented to pregnant women and their neonates in the same pattern as in intervention group.
46016186|NCT02872051|Behavioral|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists, and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment"
46016187|NCT02872051|Other|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
45465851|NCT05481489|Drug|Atropine Sulfate|Atropine Sulfate 0.05% Ophthalmic Solution
45465852|NCT03795415|Behavioral|Gundo So|"Gundo-So was adapted from a program established in quebec. It has been implemented in Mali following 3 phases: 1) cultural adaptation; 2) validation using a pre-post intervention evaluation; 3) scale-up~The programm consists on 9 group meetings group spread over 9 weeks (for 8 WLHIV + 2 trained community-based leaders). Each meeting has some particular thematics with adapted tools."
45465853|NCT05341180|Drug|Polyethylene Glycol|Patients will be advised Anobliss (lidocaine with nifedipine) ointment for local application in the anal canal for one month for relief of pain and anal sphincter spasm. Polyethylene glycol syrup at a dose of 15-30 ml will be used for 2 weeks for relief of acute constipation. Patients will be assessed at 1 week and 1 month and evaluated for primary and secondary outcomes.
45465854|NCT05341180|Drug|Isabgol + Lactulose|Patients will be advised Anobliss (lidocaine with nifedipine) ointment for local application in the anal canal for one month for relief of pain and anal sphincter spasm. Isabgol husk at a dose of 2 teaspoons in 200 ml of warm water before bedtime and 30 ml of syrup lactulose at bedtime will be used for 2 weeks for relief of acute constipation. Patients will be assessed at 1 week and 1 month and evaluated for primary and secondary outcomes.
46016188|NCT01013701|Drug|fluticasone furoate|nasal steroid spray
46016189|NCT01013701|Other|placebo|nasal steroid vehicle without drug
46016190|NCT00628303|Biological|Motavizumab|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
46016191|NCT00628303|Other|Placebo|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
46016192|NCT01020019|Drug|Dronabinol|Dronabinol: 20 mg/TID
46016193|NCT01020019|Drug|Placebo|Placebo control
46016194|NCT01020019|Drug|Lofexidine|Lofex: .6 mg/ TID
46016195|NCT00627835|Drug|sorafenib|Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
46016196|NCT00627835|Drug|sorafenib|o Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
46016197|NCT00627835|Drug|sorafenib and cisplatin|Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
46016198|NCT00627835|Drug|sorafenib and cisplatin|o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
46016199|NCT00627835|Drug|sorafenib and cisplatin|Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
46016200|NCT02872441|Biological|blood sample|One blood sample of 50 milliliter 24 hours after the inclusion
46016201|NCT01024465|Device|ReShape Duo Balloon|ReShape Duo Balloon
46016202|NCT02872363|Other|Intervention A - Behavioural Regulation|"SMS reminder with 'Behavioural Regulation' message:~'Don't forget to make a diary note of your screening mammogram apt at (time)(date) at (site). Call 02033136644 to rearrange'"
45465855|NCT01134653|Other|Jump Stretch|distraction with early mobilization
46016203|NCT02872363|Other|Intervention B - Priority|"SMS reminder with 'Priority' message:~'Is your breast screening appointment on your priority list? Apt at (time), (date) at (site). Call 02033136644 to rearrange.'"
46016204|NCT04299607|Diagnostic Test|DPP Fever Panel II assay and DPP Micro Readers|Detection of common causes of acute febrile illnesses in Asia
46016205|NCT04205461|Procedure|Programmed ventricular stimulation|Programmed ventricular stimulation before pulmonary valve replacement. Voltage and activation mapping of right ventricle in a subset of patients.
46016206|NCT04300699|Other|Functional Geriatric Assessment|A series of 8 self-completed questionnaires for the identification of functional deficits which will be addressed via algorithm-guided interventions and assessments.
46016207|NCT01024387|Drug|AMG 479|
46016208|NCT01019317|Drug|Cytarabine|0.5 grams/m^2 over 2 hours(+/- 15 minutes) IV every 12 (+/-2) hours for 5 days (4 days in patients > 65 years and 3 days in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) > 3).
45465856|NCT05339464|Other|Family Wellness program|Weekly one-hour online workshops over an 8 week period. Families will also receive text message reminders as part of the intervention.
45465857|NCT03798613|Device|Apple Watch 4 Series Device|tracings from the apple watch 4 series watch
45465858|NCT03798613|Device|Continuous Telemetry Monitor|tracings from the continuous telemetry monitor
46016209|NCT01019317|Drug|Fludarabine|15 mg/m^2 to be given IV over 15-30 minutes every 12 (+/- 2) hours for 5 days. (4 days in patients > 65 years and 3 days in patients with PS > 3).
46016210|NCT01024309|Procedure|Mini-Posterior surgical approach for total hip arthroplasty|Mini-Posterior surgical approach for total hip arthroplasty
46016211|NCT01024309|Procedure|Direct Anterior surgical approach for total hip arthroplasty|Direct Anterior surgical approach for total hip arthroplasty
45465859|NCT01133483|Drug|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories Limited
46016212|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
46016213|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
46016214|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
46016215|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
46016216|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
46016217|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
46016218|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
46016219|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
45465860|NCT03369249|Behavioral|Link2CARE|The Link2CARE intervention consists of 4 sessions. Session 1 consists of a one-on-one meeting with a Health Coach, during which participants will be offered an oral rapid HIV test and STI test. Sessions 2, 3, and 4 are group-based. During these sessions, participants will engage in discussions and activities regarding sexual and substance use risk behaviors.
45465861|NCT05401721|Diagnostic Test|Serum copeptin|Blood test
46100796|NCT00666692|Drug|M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab|Volociximab will be administered via IV infusion once every three week at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels on Day 8 of the first cycle. Volociximab will be given for up to 6 cycles (3 weeks/cycle). Subjects who have stable disease or better and subjects who have disease that is not progressing at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All four drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
46100797|NCT00707746|Drug|mipomersen|
46100798|NCT00707746|Drug|placebo|
45465862|NCT01560481|Drug|Step A: metformin glycinate 620 mg single dose|metformin glycinate 620 mg single dose
45465863|NCT01560481|Drug|Step A: metformin glycinate 1240 mg single dose|metformin glycinate 1240 mg single dose
45465864|NCT01560481|Drug|Step A: metformin glycinate 2480 mg single dose|metformin glycinate 2480 mg single dose
46016220|NCT02877472|Device|porous tantalum rod|Patients with avascular necrosis of the femoral head after femoral head fracture surgery receive treatment of core decompression and porous tantalum rod implantation
46016221|NCT02877472|Procedure|core decompression|Patients with avascular necrosis of the femoral head after femoral head fracture surgery will undergo core decompression.
46016222|NCT02877238|Drug|Sevoflurane plus remote ischemic preconditioning|Inhalational anesthesia (Sevoflurane) in addition to remote ischemic preconditioning
46016223|NCT02877238|Drug|Total intravenous anesthesia plus remote ischemic preconditioning|Total intravenous anesthesia (propofol plus fentanyl) in addition to remote ischemic preconditioning
45465865|NCT01560481|Drug|Step A: metformin hydrochloride 1000 mg single dose|metformin Chlorhydrate 1000 mg single dose
45465866|NCT01560481|Drug|Step A: metformin glycinate 1240 mg,food intake|metformin glycinate 1240 mg, intake of food
45465867|NCT01560481|Drug|Step B: metformin glycinate 620 mg BID|metformin glycinate 620 mg BID, 8 days
45680391|NCT02315326|Drug|Rituximab + HD- Methotrexate (MTX)|Arm C2: Intravenous rituximab (500mg/m2) will be given on day 0, 14, and 28 of cycle 1 and day 14 and 28 of all following cycles. HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a maximum of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments. The starting dose of ibrutinib is 560 mg/day (4x140mg capsules; dose level 1) (see Table 4). Filgrastim will be given at days 7-11 and 22-26.
46016224|NCT01288911|Drug|enzalutamide|capsules
46016225|NCT01288911|Drug|bicalutamide|tablets
45465868|NCT01560481|Drug|Step B: metformin hydrochloride 500 mg BID|metformin Chlorhydrate 500 mg BID, 8 days
45465869|NCT03921437|Radiation|decision support intervention|CKD Guardian is the decision-maker and uses the e-book software to develop medical decision-assist tools, and applies this tool and decision-directed mode to introduce and select. The implementation steps include team discussion, option discussion and decision-making. The group is introduced with traditional care instructions for routine care.
45465870|NCT04795531|Drug|Insulin icodec|"You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
46016226|NCT01288443|Drug|Alirocumab|Two SC injections in the abdomen only.
46100799|NCT02702063|Other|passive leg raising test|Patients undergoing routine echocardiography are exposed to a passive leg raising test. Change in SV will be measured by TTE and compared to changes in SV measured by EC.
46100800|NCT02702063|Procedure|right heart catheterisation|CO in patients undergoing routine right heart catheterisation will be measured and compared between 3 methodologies: right heart catheterisation, TTE and EC
46100801|NCT02702063|Other|TTE vs. EC + calibration group|Patients will undergo routine echocardiography. CO and SV will be measured by TTE and compared to measurements obtained from simultaneous EC-measurements.
46016227|NCT01288443|Drug|Placebo (for alirocumab)|Two subcutaneous (SC) injections in the abdomen only.
45680392|NCT02315326|Drug|procarbazine|Arm D: THIS IS THE ONLY ARM RECRUITING: : Oral procarbazine (100mg/m2/day) will be given on Day 1 through 7 during each cycle. Patients will be maintained on a tyramine-free diet during procarbazine administration.
46016228|NCT01288443|Drug|Atorvastatin|Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.
45680393|NCT02288247|Drug|Enzalutamide|Oral
45680394|NCT02288247|Drug|Docetaxel|intravenous infusion
45680395|NCT02288247|Drug|Prednisolone|Oral
45680396|NCT02288247|Drug|Placebo|Oral
45680397|NCT02285842|Device|Primary hip resurfacing device|CONSERVE® Press-Fit Femoral Components
45680398|NCT02280525|Drug|Lenalidomide|2.5 mg by mouth daily on Day -2 to Day +14.
45680399|NCT02280525|Drug|Rituximab|375 mg/m2 by vein on Day -5 for participants with B-cell cancer.
46016229|NCT04324203|Other|Three-dimensional Virtual Reality and Horticultural Therapy|VR is a realistic, three-dimensional, and virtual environment formed by a combination of computer software and hardware
46016230|NCT01288209|Drug|TMC435|100-mg capsule taken by mouth once daily for 12 or 24 weeks.
46100802|NCT00662324|Behavioral|focus groups|"Focus group with MSKCC patients with lung, breast and prostate cancer who have taken part in clinical trials and other caregivers. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would have been useful to the patient you care for in his/her experience in a clinical trial.~The focus group to last from 60 to 90 minutes."
46100803|NCT00662324|Behavioral|focus groups|"Focus group with MSKCC patients with lung, breast and prostate cancer who have not taken part in clinical trials and other caregivers. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful if the patient you care for were ever to take part in a clinical trial sometime in the future.~We expect the focus group to last from 60 to 90 minutes."
45680400|NCT02280525|Drug|Fludarabine|"Lymphodepleting Chemotherapy Option #1: Fludarabine 25 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2.~Lymphodepleting Chemotherapy Option #3: Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2"
46100804|NCT00662324|Behavioral|focus groups|"MSKCC clinicians who work with lung, breast and prostate cancer patients. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful to your patients who take part in clinical trials.~Expect the focus group to last from 60 to 90 minutes."
46100805|NCT05343377|Diagnostic Test|circulate free methylated EBV DNA|Accuracy of circulating free methylated EBV DNA in predicting 2-year PFS
46100806|NCT00666770|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
46100807|NCT00666770|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
46100808|NCT00666770|Drug|Placebo|Matched placebo 30 minutes prior to bedtime
45680401|NCT02280525|Drug|Cyclophosphamide|"Lymphodepleting Chemotherapy Option #1: Cyclophosphamide 200 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4."
45680402|NCT02280525|Procedure|NK Cells|"Participant assigned to a dose level of NK cells based on when joined study. Starting dose level of NK cells 1 x 10^7 NK cells/kg given by vein on Day 0.~NK Cell Infusion Expansion Phase: Maximum tolerated dose of NK cells from Induction Phase."
45680403|NCT02280525|Drug|Cytarabine|Cytarabine 2 mg/m2 by vein on Days -6 to -2.
45680404|NCT02274805|Procedure|Adults presenting for surgery in the neck area|
45680405|NCT02239783|Device|total hip arthroplasty implant|
45680406|NCT02157883|Procedure|Pharmacokinetic sampling|Blood samples taken pre and post dosing with AZD9291+/- itraconazole
45680407|NCT02157883|Drug|AZD9291|AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
46016231|NCT01288209|Drug|Peginterferon alfa-2a (PegIFNα-2a )|PegIFNα-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
46100809|NCT04188353|Device|Optic nerve sheath diameter measurement|ONSD measurements done at screening (T1), 30 minutes after mannitol infusion (T2), 60 minutes (T3) and 120 minutes (T4)
46100810|NCT04188353|Drug|Mannitol|Mannitol at dose of 0.25 to 1 gm/kg over 20 minutes via a dedicated IV line
46100811|NCT00615563|Behavioral|NO BI Drug administered|
45465871|NCT04795531|Drug|Placebo insulin icodec|"You will get a pen for weekly injection and one for daily injection. One will be insulin degludec 100 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
46100812|NCT04053998|Procedure|Pancreaticoduodenectomy with portal vein resection|Pancreatic surgery with vein resection to achieve disease clearance.
46016232|NCT01288209|Drug|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is > 60 kg to <=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is <=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
45680408|NCT02157883|Drug|Itraconazole|Itraconazole tablets: 2x100mg bd, Part A days 6 to 19 only
46016233|NCT01288053|Biological|Allogeneic Stem Cell Therapy|Donor stem cells will be given to subject diagnosed with Crohn's disease
45680409|NCT02149667|Device|total hip arthroplasty implant|
46016234|NCT02889783|Other|record of urethral pain sensation during urodynamics study|Record of pain using a VAS scale during the first catheterizing of urodynamics study, at every centimeter
45680410|NCT02133898|Other|L-methylfolate|L-methylfolate, an FDA approved medical food will be administered in 15 mg capsule form once daily for 90 days
46016235|NCT01287195|Drug|Oral OKT3|1 mg or 2 mg Oral OKT3 will be given orally to participants once daily for 30 days
45680411|NCT02101944|Drug|Carfilzomib|Given IV
46016236|NCT01287195|Drug|Omeprazole|20 mg Omeprazole will be given orally to participants once daily for 30 days
46016237|NCT01287117|Drug|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
46016238|NCT01287117|Drug|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
46016239|NCT01287039|Drug|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
45680412|NCT02101944|Drug|Dexamethasone|Given IV
46016240|NCT01287039|Drug|Placebo|Matching placebo (20 mM sodium acetate, 7% sucrose), administered intravenously (iv) once every 4 weeks over 52 weeks, for a total of 13 doses administered. Each patient received a specific volume of placebo to match the volume of reslizumab on the basis of the patient's body weight.
46016241|NCT02889939|Other|UC + ETT|"UC: A 3-week UC period, where the participants were not offered any new rehabilitation activities but were allowed to continue their regular treatment for a maximum of 3 hours per week.~ETT: The rehabilitation facilities were located in a climate that allowed and encouraged both indoor and outdoor activities. The ETT was individually tailored. Participants exercised in the same room/place as the other participants in groups of 4-9. Physical exercise was scheduled 3.5-6 hours per day, 5½ days per week for 3 weeks. The training was characterized by repetitive mass practice of gradually increasing difficulty and noncompensatory strategies, such as enforcing use of the affected side.~Beyond scheduled activities, participants were encouraged to physically engage themselves in a challenging outdoor environment."
46016242|NCT05584527|Other|Heat exposure (32°C)|"The participants will be exposed to heat (32°C) for 24 hours in a climatic apartment.~During the exposure,~food intake and energy expenditure will be measured~several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~sleep brain activity will be monitored using a headband~urine and saliva samples will be collected."
46016243|NCT05584527|Other|Cold exposure (16°C)|"The participants will be exposed to cold (16°C) for 24 hours in a climatic apartment.~During the exposure,~food intake and energy expenditure will be measured~several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~sleep brain activity will be monitored using a headband~urine and saliva samples will be collected."
46100813|NCT00662402|Other|Extensive Consultations|receives 15 free hours of multidisciplinary consultations towards the preparation of their career development grant.
45680413|NCT02101944|Other|Laboratory Biomarker Analysis|Correlative studies
45465872|NCT04795531|Drug|Insulin degludec|"You will get a pen for weekly injection and one for daily injection. One will be degludec 100 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
45465873|NCT04795531|Drug|Placebo insulin degludec|"You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
45680414|NCT02101944|Biological|Pelareorep|Given IV
45680415|NCT02091141|Drug|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
45680416|NCT02091141|Drug|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
45465874|NCT03921359|Behavioral|SMARTfit training|For SMARTfit training, participants receive three 1-hour training sessions per week for 8 weeks. During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with. The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach & grasp, and (3) floor-to-stand; stand-to-floor and single limb standing. Participants will focus on practicing one pair of tasks during each session. There is an additional cognition component that can be manipulated using features provided by SMARTfit.
45465875|NCT03921359|Behavioral|Conventional physical training|For conventional physical training, participants receive three 1-hour training sessions per week for 8 weeks. During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with. The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach & grasp, and (3) floor-to-stand; stand-to-floor and single limb standing. Participants will focus on practicing one pair of tasks during each session.
46100814|NCT04135716|Diagnostic Test|Colonoscopy with assistance of Endo.Angel|Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
45680417|NCT02091141|Drug|Erlotinib|Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
45680418|NCT02091141|Drug|Vemurafenib|Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
46100815|NCT04135716|Diagnostic Test|Colonoscopy without assistance of Endo.Angel|Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
45465876|NCT05292898|Biological|LCAR-AIO Cells|LCAR-AIO Cells before treatment with LCAR-AIO cells, subjects will receive a conditioning regimen (IV infusion of cyclophosphamide 300 mg/m^2 and fludarabine 30mg/m^2 once daily (QD) for 3 days.
45680419|NCT02091141|Drug|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
45680420|NCT02091141|Drug|Vismodegib|Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
46100816|NCT05735158|Biological|KB105|Replication-defective, non-integrating HSV-1 vector expressing TGM1 formulated as a topical gel
46100817|NCT05735158|Other|Placebo|Visually matched excipient gel
46100818|NCT02698943|Procedure|Phacoemulsification|Phacoemulsification for cataract extraction with Envista MX-60 implantation
46100819|NCT02623140|Device|Biofreedom|PCI with Biofreedom stent
46100820|NCT02623140|Device|Orsiro|PCI with Orsiro stent
46016244|NCT05584527|Other|Thermoneutral exposure (24°C)|"The participants will be exposed to a thermoneutral environment (24°C) for 24 hours in a climatic apartment.~During the exposure,~food intake and energy expenditure will be measured~several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~sleep brain activity will be monitored using a headband~urine and saliva samples will be collected."
46100821|NCT00662480|Procedure|Screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm|Invited to vascular screening
45465877|NCT03917771|Other|Early lymphedema detection|Face-to-face consultation in Rehabilitation for early detection of lymphedema after surgery (1,6,12 months). Lower Limb measurement and care education
45465878|NCT03917771|Other|Usual follow-up|Usual follow-up carried out in GO consultation
46016245|NCT05578443|Drug|Astragalus|Astragalus tablets 20g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
45465879|NCT05274022|Other|Standard of Care Physical Therapy Program|Standard of care will follow best practice. The subjects and their physical therapists will be provided with a standardized set of exercises and guidance on what to cover during skilled physical therapy visits. As part of the study, all patients will receive the same exercise program. Exercises will include lower extremity strengthening, balance, and mobility exercises with the use of modalities as needed
45465880|NCT05274022|Other|Speed Walking Intervention|The 4-6 week program will consist of a warm up of active stretching. Following the warm up, subjects will perform a 2 minute warm up followed by 1 minute of walking at their fastest comfortable speed followed by 2 minutes of active recovery where they will walk at a speed of their choosing for 4cycles and then a 2 minute cool down. The program will be performed 12 visits over 4-6 weeks.
45465881|NCT03811249|Device|VisAbility™ Micro Insert|No (new) intervention will be administered during the course of this long term follow-up study. Subjects that previously participated in the VIS-2014 clinical trial that had VisAbility™ Micro Inserts surgically implanted in the eye(s) will be followed prospectively.
45465882|NCT01134809|Procedure|Major abdominal surgery|All adult patients having major abdominal surgery
45465883|NCT05261776|Other|pilates exercise|"Pilates exercise for 40 minutes (5 minutes for warm-up and 30 minutes of pilates and 5 minutes for cool down). These participants will continue their standard care.~Patients in Group-A will get 40 minutes of session, Alternative three days/ week for 12 weeks."
45680421|NCT02091141|Drug|Alectinib|Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
45680422|NCT02091141|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
45680423|NCT02071290|Device|Pneumatic tourniquet|"Four cycles of brief occlusion of bloodflow to the thigh (5 minutes) followed by reperfusion (5 minutes) using a pneumatic tourniquet~Remote Ischemic Conditioning"
45680424|NCT02066181|Other|Laboratory Biomarker Analysis|Optional correlative studies
45680425|NCT02066181|Other|Placebo Administration|Given PO
46100822|NCT03583697|Drug|BMN 111|Subcutaneous injection of 15 μg/kg of BMN 111 daily, Subject to adjustment per protocol
46100823|NCT03583697|Drug|Placebo|Subcutaneous injection of 15 μg/kg of placebo daily, Subject to adjustment per protocol
46100824|NCT05326698|Procedure|Medtronic NIM Eclipse for evoked potentials recording|Recording of somesthetic and motor evoked potentials during endoscopic posterior cervical foraminotomy.
46100825|NCT02630420|Drug|cetuximab and savolitinib|Dosage of combined cetuximab and savolitinib will be determine in Part 1 of the study, Part 2 will use the findings of Part 1 to further assess safety and to assess efficacy of this drug combination.
46100826|NCT00738166|Other|Organic or conventional diet|12 days on fully controlled organic 1 diet, organic 2 diet and conventional diet
46100827|NCT00738166|Other|Diet (organic or conventional)|organic or conventional diet
45680426|NCT02066181|Other|Quality-of-Life Assessment|Optional ancillary studies
45680427|NCT02066181|Drug|Sorafenib Tosylate|Given PO
46016246|NCT05578443|Behavioral|Routine treatment|Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.
46016247|NCT05575245|Device|Drug-eluting Stent|Drug-eluting Stent angioplasty
46016248|NCT05575245|Device|Excimer Laser Ablation Combined Drug-coated Balloon|Excimer Laser Ablation Combined Drug-coated Balloon angioplasty
46016249|NCT05572203|Dietary Supplement|Intrinsically labelled protein|It is a protein drink that includes Intrinsically labelled Casein ( from Arla Foods), 13C/2H-labelled Spirulina (from CK Isotopes), and 13C/2H-labelled amino acids (from CK Isotopes)
45465884|NCT05261776|Other|brisk walk|"Brisk walk on treadmill for 40 minutes (5 minutes for warm-up and 30 minutes of brisk walk on treadmill and 5 minutes for cool down). These participants will continue their standard care.~Patients in Group-B of 40 minutes of session, Alternative three days/ week for 12 weeks."
46016250|NCT01285401|Drug|VigantOL oil plus interferon beta-1a (Rebif)|VigantOL oil 6,670 International Units per day (IU/d) (167 microgram per day [mcg/day]), was administered orally for 4 weeks followed by 14,007 IU/d (350 mcg/d) administered orally for 44 weeks on top of Rebif 44mcg three times per week (tiw) administered subcutaneously.
46016251|NCT01285401|Drug|Placebo plus interferon beta-1a (Rebif)|Matching placebo daily, orally administered matched placebo for 48 weeks on top of Rebif 44 mcg tiw.
46016252|NCT01285401|Biological|Interferon beta-1a (Rebif®) alone|Rebif® 44 mcg tiw, sub-cutaneously alone.
45465885|NCT03795337|Radiation|Hypofractionated Radiosurgery|"Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife"
45680428|NCT01972217|Drug|Olaparib|Olaparib bid
46016253|NCT01285323|Drug|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
46016254|NCT01285323|Drug|Placebo|Matching placebo (acetate sucrose buffer), administered intravenously (iv) once every 4 weeks for a total of 13 doses.
46016255|NCT02889705|Other|Ultrasonographic examination|
45465886|NCT05238844|Drug|ATI-2173 25mg|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth.
45680429|NCT01972217|Drug|Placebo|Placebo bid
45680430|NCT01972217|Drug|Abiraterone|Abiraterone 1000 mg
45680431|NCT01972217|Drug|Prednisone or prednisolone|Prednisone or prednisolone 5 mg bid will be co-administered with the abiraterone in this study.
45680432|NCT01970865|Drug|PF-06463922|Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days
45680433|NCT01970865|Drug|Crizotinib|Oral, starting dose of 250 mg BID continuous daily dosing every 21 days
45680434|NCT01928576|Drug|Azacitidine|
45680435|NCT01928576|Drug|Entinostat|
45680436|NCT01928576|Drug|Nivolumab|
45465887|NCT05238844|Drug|Vebicorvir 300mg|Vebicorvir (formerly ABI-H0731) is an orally administered, potent and selective small molecule inhibitor of the HBV core protein
46016256|NCT01284621|Drug|BI 10773|medium dose, oral administration
46016257|NCT01284621|Drug|Ramipril|Medium dose oral administration on day 2-5
45465888|NCT05238844|Drug|Viread 300Mg Tablet|Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
45465889|NCT05585827|Behavioral|Online cognitive behavioral therapy|"The e-CBT treatment manual is an adjusted version of a previously published treatment manuals for neuropsychiatric symptoms in PD, which is tailored to the preferences and needs for each participant. This manual encompass both modules from manuals for depression in PD and anxiety in PD. Individualization is ensures by including several interventions modules in the manual, wherein 5 sessions are considered core modules, and four modules that can be offered depending on the patients individual needs. The participant may include partners or caregivers. The treatment is schedules to be completed within 13 weeks, with maximum ten sessions during this period. Following each e-CBT session, the participant will be asked to complete a short survey evaluating the acceptability and relevance of the session, and evaluate the therapeutic alliance."
45837800|NCT05762172|Other|early 18F-FDOPA uptake|"During the usual patient care protocol for the 18F-FDOPA TEP examination, a 10 min acquisition starts after a 15 minutes waiting period following the injection of the radiotracer. This allows the reconstruction of a single late image volume. In the framework of this project, the patient is placed in the machine at the time of injection so as to acquire early 18F-FDOPA uptake and then reconstruct intermediate image volumes in addition to the usual final volume.~The total duration of the patient's examination is therefore not changed."
45465890|NCT03921125|Device|Massimo for Pleth variability index|To assess fluid response
46016258|NCT01284621|Drug|BI 10773|medium dose oral administration
46016259|NCT01284621|Drug|Ramipril|Low dose oral administration on day 1
46016260|NCT01284621|Drug|Ramipril|Low dose oral administration on day 1
46016261|NCT01284621|Drug|Ramipril|Medium dose oral administration on day 2-5
46016262|NCT04323813|Diagnostic Test|Liquid biopsy|Detection and quantification of EMT-transcription factor mRNA levels in blood
46016263|NCT02890017|Other|postoperative hotel|"Outpatient surgery First night stay in a defined patient-hotel Patient come for consultation the next morning of surgery to remove the catheter and/or the compressive bandage. The absence of adverse events is checked, the discharge is confirmed and the evaluation questionnaire is given to the patient.~Postoperative consultation at 1 and 3 months."
46016264|NCT02890017|Other|conventional hospitalization|Hospitalization for surgery and first postoperative night stay. Postoperative consultation at 1 and 3 months
45465891|NCT05228080|Diagnostic Test|enzyme-linked immunosorbent assay(ELISA)|Peripheral blood samples will be drawn from each patient at study entry (before reperfusion therapy) and at 12,24 hours after reperfusion therapy.Serum will be immediately separated by centrifugation at 3000 rpm for 15 minutes and stored at -80°C. Endocan,ICAM-1,VCAM-1,MMP-9 levels will be determined in duplicate by commercially available enzyme-linked immunosorbent assay (ELISA).
45465892|NCT04785625|Combination Product|Bupivacaine Hydrochloride|INL-001 (bupivacaine hydrochloride) implant
45465893|NCT04785625|Combination Product|Placebo collagen-matrix implant|Placebo collagen-matrix implant
46016265|NCT01283139|Biological|Sifalimumab 200 mg|Sifalimumab 200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
45465894|NCT01229345|Drug|Breakfast & exercise|1859 kJ breakfast vs fast, exercise at 60% maximum aerobic capacity to expend 1859 kJ.
45837801|NCT05761184|Diagnostic Test|Serum collection for proteomic analysis|Serum collection for proteomic analysis
45465895|NCT05227768|Drug|VV116 25mg Group|4 subjects will receive VV116 25mg,orally; 2 subjects will receive placebo,orally.
45465896|NCT05227768|Drug|VV116 200mg Group|6 subjects will receive VV116 200mg,orally; 2 subjects will receive placebo,orally.
45465897|NCT05227768|Drug|VV116 400mg Group|6 subjects will receive VV116 400mg,orally; 2 subjects will receive placebo,orally.
45465898|NCT05227768|Drug|VV116 800mg Group|6 subjects will receive VV116 800mg,orally; 2 subjects will receive placebo,orally.
45465899|NCT05227768|Drug|VV116 1200mg Group|6 subjects will receive VV116 1200mg,orally; 2 subjects will receive placebo,orally.
45837802|NCT05761145|Diagnostic Test|Blood sample collection|Blood sample collection
46016266|NCT01283139|Biological|Sifalimumab 600 mg|Sifalimumab 600 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
46016267|NCT01283139|Biological|Sifalimumab 1,200 mg|Sifalimumab 1,200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
46016268|NCT01283139|Other|Placebo|IV Placebo every 2 weeks for 4 weeks and then monthly for 44 weeks
46016269|NCT01281969|Drug|Gamunex Intravenous Immunoglobulin|2.0 gm/kg total, IV (in the vein), over 2 days
45465900|NCT01230671|Other|Yoga|A 12 week yoga session will be offered to women with breast cancer.
45465901|NCT03795025|Other|Strength training 3x10RM + no training|Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg does not exercise.
46016270|NCT01281969|Drug|Placebo|Normal saline, IV (in the vein), over 2 days
46016271|NCT01281813|Drug|Darunavir|Participants will receive darunavir (per parent study) as oral suspension.
46016272|NCT01281813|Drug|Ritonavir|Participants will receive ritonavir (per parent study) as oral solution/suspension.
46016273|NCT04325139|Other|Questionnaire|Before colonoscopy, the following information was obtained by the colonoscopists through asking patients: the characteristics of last stool, the time of drinking first dose of laxative, the time of first defecation, the time of drinking last dose of laxative. The beginning time of colonoscopy was also recorded. During withdrawal phase, the quality of bowel preparation was evaluated based on BBPS scale.
45465902|NCT03795025|Other|Strength training 6x10RM + no training|Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 6 sets of 10 maximal repetitions, the other leg does not exercise.
45680437|NCT01911091|Behavioral|Exercise|A 5-minute warm-up and a 5-minute cool-down prior to and following each exercise session, respectively. There will be alternating days of interval training and aerobic training. The interval training will be performed on an upright stationary bike, while the aerobic training will be performed on a treadmill. The interval training will consist of five-minute bouts of higher intensity alternated with 4 minutes of lower intensity for a total duration of 45 minutes. Intensity will increase each week. The aerobic training component will be fixed at a moderate intensity, but will increase in duration each week from 45 minutes to 75 minutes to 90 minutes during the third and final week.
45465903|NCT03795025|Other|3x10RM + 6x10RM|Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg exercises with 6 sets of 10 maximal repetitions.
45465904|NCT03917615|Other|pelvic floor contraction|Ultrasound examination will be performed to asses urinary bladder displacement being a marker for pelvic floor muscle function
45680438|NCT01905813|Drug|INCB040093|Escalating doses starting at 100 mg every day (QD)
45680439|NCT01905813|Drug|INCB040093|INCB040093 monotherapy - dose to be determined at completion of Phase I of the study
45680440|NCT01905813|Drug|INCB040093 + itacitinib|INCB040093 dose to be determined at completion of Part 1 of the study + itacitinib at a starting dose of 400 mg, QD with escalations planned up to 600 mg QD.
46016274|NCT01090414|Drug|Idelalisib|Idelalisib tablets or capsules administered orally
45474018|NCT03375736|Device|whole body vibration|The children and young adults will receive the WBVT when standing still on a vibration platform of 20 Hertz and a peak-to-peak amplitude of 2 mm: sessions will be 18 minutes in length, 4 days per week for 4 weeks. Assessments will be performed at baseline and at completion of the intervention to examine the functional abilities of these children and young adults. The vibration frequency, duration and amplitude will be progressively increased over 2 weeks to the maximum of 3 minutes of 20 Hz with a peak-to-peak amplitude of 2mm.
45680441|NCT01880060|Behavioral|INCENT weight loss program|Tangible incentives seem to be effective in enhancing short term, but not long-term weight loss. The monetary rewards are based on participant quarterly weigh-ins and the monetary amount of incentive will be identical to the percentage of body weight lost. Participants who lose 1, 2, 3, 4, or 5% of their body weight will then be compensated with 1, 2, 3, 4, or 5 dollars per month. Dollar amounts for participants that lose more than 5% of initial body weight then increase by increments of 5 (e.g., 5-9% weight loss = $5; 10-14%=$10; 15-19%=$15; >20%=$20). These incentives will be based on quarterly weight and all percentage weight loss is calculated based on a participant's initial weight. commencement). Participants receive monthly checks that reflect the percent weight loss.
46016275|NCT01090102|Drug|Mesalamine (5-aminosalicylic acid, Apriso)|"Four mesalamine capsules once daily (1.5 gram/day) for the first 12 weeks, PO(by mouth).~Four placebo capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
46016276|NCT01090102|Drug|Placebo|"Four placebo capsules once daily (1.5g/d) for the first 12 weeks, PO (by mouth).~Four mesalamine capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
46016277|NCT02877160|Drug|AL-794 suspension|
46016278|NCT02877160|Drug|AL-794 tablet|
46016279|NCT02878096|Drug|[14C]-SK-1404|In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of [14C]-SK-1404.
46016280|NCT01287897|Drug|PF-04236921 SC injection|Placebo delivered SC, 2 doses separated by 4 weeks
46016281|NCT01287897|Drug|PF-04236921 SC injection|Drug dose level 1 delivered SC, 2 doses separated by 4 weeks
46016282|NCT01287897|Drug|PF-04236921 SC injection|Drug dose level 2 delivered SC, 2 doses separated by 4 weeks
46016283|NCT02877940|Device|ProSeal Laryngeal mask airway|ProSeal was inserted in mechanically ventilated patients undergoing elective surgeries.
46016284|NCT02877940|Device|Laryngeal Tube Suction- Disposable|LTS-D was inserted in mechanically ventilated patients undergoing elective surgeries.
46016285|NCT02877940|Device|i-gel|i-gel was inserted in mechanically ventilated patients undergoing elective surgeries.
46016286|NCT04306978|Other|CareLink Express RM system|CareLink Express remote monitoring system consists of implantable pacemaker CareLink Express station for implanted Medtronic cardiac devices and provides remote data transmissions
46016287|NCT04306978|Other|Standard follow-up|Follow-up will be provided according to the standard guidelines (HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations; 2008)
45465905|NCT04453696|Behavioral|Assessment scales-the Spielberger's State-Trait Anxiety Inventory, Modified Dental Anxiety Scale and a visual analog scale.|"STAI-S, like kinetic energy, refers to a palpable reaction or process taking place at a given time and level of intensity. STAI-T, like potential energy, refers to individual differences in reactions. Both of STAI-S and STAI-T scales includes 20 questions. For each question, the scores range from 1 (almost never) to 4 (almost always) points. For both scales, the sum of the scores ranges from 20 to 80. A score between 36 and 41 refers to a mean anxiety level, with values greater than 41 classified as a high level of anxiety.~The MDAS consists of 5 questions that measure anxiety at different stages of dental treatment. The options range from 1 (not anxious) to 5 (very anxious) for each question. The sum of the scores varies from 5 to 25; values between 19 and 25 indicate a high level of dental anxiety.~The VAS scale was included in the present study to determine how anxious the patients felt according to their own thoughts. Scores range from 0 (no anxiety) to 10 (extreme anxiety)."
45465906|NCT03794947|Procedure|Remote Ischaemic Conditioning|Induced ischaemia to a limb by inflating pressure cuffs around arms or legs to above systolic pressures (mmHg).
45465907|NCT03794947|Procedure|Sham Intervention|The sham intervention will inflate pressure cuffs to much lower levels for the same number of cycles.
45465908|NCT04453618|Drug|FE-SYHA1402 100mg|in either a fasted state or with a meal
45465909|NCT04453618|Drug|SYHA1402-25mg|SYHA1402 25mg, oral tablets
45465910|NCT04453618|Drug|Placebo-25mg|Matching placebo tablets
45465911|NCT04453618|Drug|SYHA1402-50mg|SYHA1402 50mg, oral tablets
46016288|NCT01090024|Drug|BI 671800|BI 671800
46016289|NCT01090024|Drug|Placebo|Placebo matching BI 671800
46016290|NCT04868890|Biological|Ampion|Inhaled Ampion
46016291|NCT04868890|Other|Placebo|Inhaled Placebo
46016292|NCT01281189|Drug|Dexpramipexole|Oral tablet 150mg twice daily for up to 18 months.
46016293|NCT01281189|Drug|Placebo|Oral tablet twice daily for up to 18 months.
46016294|NCT02877862|Behavioral|mAGIC app|7-day app to encourage uptake of genetic counseling
45465912|NCT04453618|Drug|Placebo-50mg|Matching placebo tablets
45465913|NCT04453618|Drug|SYHA1402-150mg|SYHA1402 150mg, oral tablets
45465914|NCT04453618|Drug|Placebo-150mg|Matching placebo tablets
45465915|NCT03920579|Drug|CKD-386 formulation 1|A single oral dose of 1 tablet under fasting conditions for each period
45465916|NCT03920579|Drug|CKD-386 formulation 2|A single oral dose of 1 tablet under fasting conditions for each period
45465917|NCT03920579|Drug|D326, D337 and D013|A single oral dose of 3 tablets(D326, D337 and D013) under fasting conditions for each period
45465918|NCT03798457|Other|No intervention|In this study there is no intervention
45465919|NCT03368859|Drug|Leucovorin|Intravenous
45465920|NCT03368859|Drug|Fluorouracil - bolus|Intravenous
45465921|NCT03368859|Drug|Bevacizumab|Intravenous
45465922|NCT03368859|Drug|Fluorouracil - infusion|Intravenous
46016295|NCT04306666|Other|Regional anesthesia|Injection of local anesthetics by a regional anesthesia named Walant block (Wide Awak Local anesthesia No Tourniquet)or by axillary brachial plexus block.
45465923|NCT03368859|Drug|ABT-165|Intravenous
45465924|NCT03368859|Drug|Irinotecan|Intravenous
45465925|NCT03798379|Other|Exercise|Strengthening, balance and aerobic exercises were explained to the patients examined before chemotherapy sessions and demonstrated by applying on the patient.
45465926|NCT04100590|Drug|Cannabis|Smoked active cannabis (7% THC) vs. placebo inactive cannabis (0% THC)
45465927|NCT01134965|Drug|Flibanserin plus Digoxin|Flibanserin 100 mg once daily for 7 days plus Digoxin 0.5 mg as single dose
45465928|NCT01134965|Drug|Digoxin|Digoxin 0.5 mg as single dose
45465929|NCT03810625|Drug|D-0502|D-0502 oral tablets
45465930|NCT01135043|Behavioral|education by brochure|educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum.
45465931|NCT01135043|Behavioral|control|patients with control group are educated about methods of collecting sputum by a physician, only in verbal explanation without brochure
45465932|NCT03794791|Behavioral|education|Education Methods including video playing of HCV Introduction (disease profile, risk factors for infection, outcomes, HBV/HCV coinfection, reinfection, etc) for 5 min, booklets of relative information distribution, physicians and nurses consulting in clinic.
45465933|NCT03794791|Behavioral|no education|Education Methods including video playing of HCV Introduction (disease profile, risk factors for infection, outcomes, HBV/HCV coinfection, reinfection, etc) for 5 min, booklets of relative information distribution, physicians and nurses consulting in clinic.
45465934|NCT03917693|Dietary Supplement|Phytin, rice extract|Consumption of a rice extract, called phytin for a period of 2 weeks
45465935|NCT03917693|Other|MCC, placebo|Consumption of MCC, a placebo, for a period of 2 week
45465936|NCT03462160|Other|Placebo control group|Placebo will be administered orally, after dissolving the sachet in lukewarm water, every evening during the meal. The placebo appearance will be similar to the probiotic.
45465937|NCT03462160|Dietary Supplement|Probiotic experimental group|Probiotic UroLact containing Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 will be administered orally, after dissolving the sachet in lukewarm water, every evening during the meal.
45465938|NCT05428917|Behavioral|Simple task|"The subject is seated on a chair facing a table, both hands resting on the table.~The subject is asked, for each block of 20 seconds, to perform flexion / extension movements of the fingers of the left hand at 0.5 Hz."
46016296|NCT04818892|Diagnostic Test|Serological Assay for SARS-CoV-2|LabCorp's Cov2Quant IgG™ assay which uses immunoassay that uses electrochemiluminescent technology (ECL) for quantitative determination of anti-receptor binding domain (RBD) IgG antibodies specific to SARS-CoV-2.
46016297|NCT02877628|Other|Pharmacokinetic-pharmacodynamic model in liver transplantation|Biological: tacrolimus and calcineurin dosage, donor and recipient CYP3A5 and ABCB1 genotypes determination
46016298|NCT01280955|Drug|Plerixafor|Matched sibling or Dual Cord donor subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.
45465939|NCT05428917|Behavioral|complex task|"The subject is seated on a chair facing a table, both hands resting on the table.~The subject is asked, for each block of 20 seconds, to perform an exercise based on the nine hole peg test"
45465940|NCT03810547|Drug|Propofol 10 Mg/mL Intravenous Emulsion|when spinal anesthesia is not satisfactory intervention drugs are used
45465941|NCT03096314|Drug|Vitamin D3|540,000 IU vitamin D3 delivered as a single, liquid enteral dose administered either orally or via naso/orogastric tube
45465942|NCT03096314|Drug|Placebo|A single, liquid enteral dose identical in appearance and consistency to cholecalciferol administered either orally or via naso/orogastric tube.
45465943|NCT03461926|Behavioral|(SB-related planning + daily text messages)|Participants will receive a one-on-one behavioral counseling session, and planning sheet as reference for developing strategies as part of their Action/Coping Plan. Participants will be asked to form 3-4 actions/coping plans specifying when, where, how, and for how long they would reduce workplace sitting time; and anticipate potential barriers and identify ways they could be overcome. Strategies will focus on increasing break frequency to every 30-45 minutes, achieving a break duration of 2-3 minutes, and increasing standing and light-intensity PA time, during work hours. Participants will receive sedentary behaviour-related text messages twice daily, depending on their preferences and schedule, which will act as mini-booster interventions.
45465944|NCT05424861|Behavioral|Acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points open. The most preferred points LI4 and SP6 were selected among the points that were reported to be effective in relieving luterus pain by scanning the literature on the points to be compressed. Acupressure will be applied to the points (bidirectional, right and left) for 2 minutes, for a total of 8 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is made without interruption. While practicing, the researcher will check the time using a digital wristwatch with a stopwatch.
45465945|NCT05424861|Other|Control group|No application will be made. The mothers in this group will fill in the visual analog scale, which evaluates postpartum uterine pain 3 times between 6-24 hours after birth.
46016299|NCT00623883|Procedure|Surgical removal of ACF|All ACF removed by either cold or hot colonoscopic biopsy forceps
46016300|NCT00623883|Procedure|Colonoscopic evaluation only|Stain-enhanced magnification endoscopy performed, ACF quantified at entry and after one year
46016301|NCT01280721|Drug|tolvaptan|Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
46016302|NCT04323969|Behavioral|Specific Modification Target|Participants will be instructed to increase their baseline foot progression angle by 15 degrees. Visual feedback during practice will be delivered using a mirror and guideline (tape placed on mirror). Verbal feedback will be incorporated to encourage participants to perform the modified foot progression angle as accurately as possible.
46016303|NCT04323969|Behavioral|Self-directed Modification|Participants will be instructed to modify their foot progression angle as much as is comfortable. A mirror will be used during practice for visual feedback, but no specific target or guide will be provided.
46016304|NCT02889471|Procedure|ERCP with NB|ERCP with NB catheter for introperative tans-nasobiliary cholangiography
46016305|NCT02889471|Procedure|ERCP alone|ERCP alone followed with standard laparoscopic cholecystectomy
46016306|NCT05560581|Behavioral|Digital self-efficacy training|Prior to the app participation, participants will receive psychoeducation on self-efficacy and will be instructed to define two autobiographical self-efficacy memories (own achievements, e.g., completion of an exam, success in a sporting event). During the week of app participation, they will be prompted three times per day and asked to perform an imagination task. Step by step, they will recall one of their autobiographic self-efficacy memories and focus on their character traits and abilities that were relevant for their achievement.
46016307|NCT05560581|Behavioral|Ecological Momentary Assessment|Participants will receive questions on mood and social/virtual contacts 3 times per day.
46016308|NCT01087762|Biological|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
46016309|NCT01087762|Biological|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
46016310|NCT01087762|Other|Placebo|Matching Placebo to CZP injection.
46016311|NCT04306354|Drug|Oxytocin nasal spray|Oxytocin nasal spray 24 UI twice daily as adjunctive treatment to conventional treatment during 10 days of detoxification of crack cocaine
46016312|NCT04306354|Drug|placebo nasal spray|Nasal spray with placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment.
46016313|NCT04306276|Drug|Dienogest 2 MG|Three-month treatment with DNG (2 mg daily; Visanne, Bayer Pharma, Germany) before IVF
46016314|NCT01078168|Drug|Acitretin|30mg per day from Day 1 to Day 28
46016315|NCT01078168|Drug|Placebo|Placebo
46016316|NCT04855786|Procedure|Thoracic duct drainage|drain placement into the thoracic duct
46016317|NCT01086358|Drug|Triptan|Usual prescribed triptans may include:sumatriptan, rizatriptan, naratriptan, almotriptan, eletriptan, zolmitriptan
46016318|NCT01086358|Drug|Treximet 85Mg-500Mg Tablet|Treximet is 85 mg sumatriptan plus 500 mg naproxen sodium
46100828|NCT00667082|Drug|NPI-0052 (marizomib) + vorinostat|"NPI-0052 IV injection over 1 to 10 minutes at doses ranging from 0.15 to 0.7 mg/m2 on Days 1, 8, and 15 of each 28-day Cycle~Oral vorinostat 300 mg was administered with food on Days 1 to 16 of each 28-day Cycle"
46016319|NCT01277601|Drug|TDF|TDF 300 mg tablets administered orally once daily
46016320|NCT01277601|Drug|Peg-IFN|Peg-IFN 180 µg administered via subcutaneous injection once weekly
46016321|NCT01277523|Drug|tiotropium high dose|2 actuations once daily
46016322|NCT01277523|Drug|placebo|2 actuations once daily
46016323|NCT01277523|Drug|tiotropium low dose|2 actuations once daily
46016324|NCT01081834|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)
46016325|NCT01081834|Drug|Placebo|One matching placebo capsule orally once daily for 26 weeks (Main Study)
46016326|NCT01081834|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 (Main Study)
46016327|NCT01276509|Drug|PF-00547659 SC injection|Placebo delivered SC, 3 doses separated by 4 weeks
46016328|NCT01276509|Drug|PF-00547659 SC injection|Drug dose level 1 delivered SC, 3 doses separated by 4 weeks
46100829|NCT05343299|Combination Product|Ambulatory surgery under Lidocaine alone|In this conventional procedure group, the anesthetic solution is administered subcutaneously and by infiltration into the surgical area. A maximum volume of 20 ml (dose dictated by the operation) of the solution is thus injected by the operator: Lidocaine 10mg/mL combined with adrenaline 0.005mg/mL administered at a dose of 10 to 20 mL, i.e. a total of 50 to 200 mg of lidocaine.
46016329|NCT01276509|Drug|PF-00547659 SC injection|Drug dose level 2 delivered SC, 3 doses separated by 4 weeks
46016330|NCT01276509|Drug|PF-00547659 SC injection|Drug dose level 3 delivered SC, 3 doses separated by 4 weeks
46016331|NCT01079962|Drug|Bisoprolol|Bisoprolol tablet will be administered orally at a dose of 5 milligram (mg) once daily in the morning for 12 weeks.
46016332|NCT01079962|Drug|Atenolol|Atenolol tablet will be administered orally at a dose of 50 mg once daily in the morning for 12 weeks.
46016333|NCT01274637|Drug|Dalteparin Sodium|5,000 IU/0.2ml (anti-Xa) administered once daily in prefilled glass syringes.
46016334|NCT01079806|Drug|Entecavir|Tablets/oral solution, 0.015 mg/kg up to 0.5 mg, administered orally, once daily, for 96 to144 weeks, depending on response
46016335|NCT01079806|Drug|Placebo|Tablets/oral solution, 0 mg, administered orally, once daily, for 48 to 96 weeks, depending on response
46016336|NCT00626314|Biological|myoblast|autologous myoblast
46016337|NCT00626314|Biological|sham|sham injection procedure
46016338|NCT04299178|Device|X-PLO2R POC|Portable Oxygen Concentrator (POC)
45465946|NCT03794713|Device|Patient support tool|The patient support tool, a software app installed on the smart phones plus a wrist connected to the smart phones by Bluetooth. The wrist could monitor the pulse, which was recorded to the app in the smart phone. Meanwhile, the app could inform to patients about the importance of medication, remind on the medicine intake, share the patients' data with themselves, and warn the patients if the wrist don't wear.
45465947|NCT03917459|Drug|LCZ696|LCZ696 50 mg = 24 mg/26 mg bid sacubitril/valsartan; 100 mg= 49 mg/51 mg bid sacubitril/valsartan or 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
45465948|NCT03917459|Drug|Enalapril matching placebo|Placebo to Enalapril 2.5 mg, 5 mg and 10 mg film-coated tablets
46016339|NCT00626470|Procedure|Addition of TSP to DHS|All patients operated with DHS. Of these two groups. One operated with TSP and one without.
45465949|NCT03917459|Drug|Enalapril|Enalapril 2.5 mg, 5 mg and 10 mg film-coated tablets
45465950|NCT03917459|Drug|LCZ696 matching placebo|Placebo to LCZ696 50 mg = 24 mg/26 mg bid sacubitril/valsartan; 100 mg= 49 mg/51 mg bid sacubitril/valsartan or 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tabletsLCZ696 50 mg, 100 mg and 200 mg
46016340|NCT02876770|Dietary Supplement|Experimental: Melatonin|Our protocol was composed of three experimental sessions. During each testing session, participants were requested to attend the laboratory at 20:00h where they ingested a standardized light meal. Melatonin (5 mg or 8 mg) or placebo were ingested in capsule in the evening at 21:00h in a double-blind randomized design
46016341|NCT02876770|Dietary Supplement|Placebo|In a double-blind randomized design, participants have taken placebo supplementation in one of the three experimental sessions
46016342|NCT01077622|Drug|ofatumumab 100 mg, 1000 mg / vial|ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
46016343|NCT01313676|Drug|fluticasone furoate/vilanterol|100/25mcg given once daily via novel dry powder inhaler
46016344|NCT01313676|Drug|fluticasone furoate|100mcg given once daily via novel dry powder inhaler
46016345|NCT01313676|Drug|vilanterol|25mcg given once daily via novel dry powder inhaler
46016346|NCT01313676|Other|Placebo|placebo comparator once daily via novel dry powder inhaler
46016347|NCT02891304|Other|Quarterly Feedback|Learning curves received quarterly vs. annually
46016348|NCT05661318|Other|Risk assessment|Collect clinical, laboratoary and genetics data from the participants after informed consent
46016349|NCT02890914|Other|Transvaginal Ultrasound Educational DVD|"American Institute of Ultrasound in Medicine, Gynecology: Beginners Only®"
45465951|NCT03461770|Other|CPAP|Patients will receive general anesthesia induction with CPAP at 5 cmH20 via face mask with a circular system. CPAP will use before extubation.The air-test will perform during anesthesia with transitory decreases inspired fraction of oxygen to 0.21 over a 5 min period. Recruitment maneuver will be perform if the air test is positive, ( SpO2 is ≤ 96%)
45465952|NCT01303081|Behavioral|Individual Rewards|If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
46016350|NCT00623376|Drug|nabilone then placebo|The subjects were first on Nabilone, then crossed over to placebo
46016351|NCT00623376|Drug|placebo then nabilone|the subjects were first on placebo then crossed over to nabilone
46016352|NCT01313286|Drug|LY2608204 Reference|Administered orally
46016353|NCT01313286|Drug|LY2608204 Test|Administered orally.
46016354|NCT05644392|Drug|Cadonilimab Injection|Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
46016355|NCT05644392|Drug|Regorafenib|Regorafenib 80mg, po, orally once daily
46016356|NCT01313208|Drug|etanercept|Administered by subcutaneous injection once weekly.
46016357|NCT01313208|Drug|Placebo|Placebo subcutaneous injection
46016358|NCT01313208|Drug|DMARD Therapy|Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine
46016359|NCT01312428|Device|Pelvic Alignment Level (PAL) Instrument|Pelvic Alignment Level Instrument Used
46016360|NCT01312428|Device|No Pelvic Alignment Level (PAL) Instrument|No Pelvic Alignment Level Instrument Used
46016361|NCT01075984|Drug|Posaconazole|
46016362|NCT01075984|Drug|Dextrose 5% in water|
46016363|NCT04306198|Device|Osteosynthesis with Trochanteric Fixation Nail (TFN), using a lag screw as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Trochanteric Fixation Nail (TFN), with lag screw as proximal fixation
46016364|NCT04306198|Device|Osteosynthesis with Trochanteric Fixation Nail (TFN), using a helical blade as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Trochanteric Fixation Nail (TFN), with helical blade as proximal fixation
46016365|NCT02876536|Device|TENS|The effect of TENS device will be compared in case and control groups.
46016366|NCT01024231|Drug|BMS-936558 (MDX1106-04)|
46016367|NCT01024231|Drug|Ipilimumab|
46016368|NCT01077544|Drug|Nilotinib|"Nilotinib capsules were delivered in bottles with dose strengths of 50mg, 150mg and 200mg.~Patients were administered nilotinib 230 mg/m2 (per BSA) bid, orally, rounded to the nearest 50 mg (max single dose 400 mg) for 28 days (1 cycle) for up to 12 cycles prior to protocol amendment 3 and up to 24 cycles post amendment 3. Capsules were to be swallowed whole with water. Apple sauce (puréed apple) may have been used as a vehicle for dosing where capsules were not able to be swallowed whole with water."
46016369|NCT04297969|Diagnostic Test|"objective pediatric vision screen GCK glow fixation"|2-axis, smart phone flash concentrated photoscreen using novel, low-detail, color glow fixation device
46016370|NCT04543201|Behavioral|Early START visit using checklist over telephone or zoom|"Prior to visit subject receives pre-visit educational guide and copy of advance directive form~Follow up surveys:~Immediate: provider feedback survey~2-4 weeks after visit: subject feedback survey and caregiver/family feedback survey~After subject death: caregiver/family survey"
46016371|NCT02871583|Procedure|lichtenstein|tension free mesh hernioplasty (lichtenstein) procedure will be applied for inguinal hernia repair
46016372|NCT02871583|Procedure|Kugel|preperitoneal mesh hernioplasty (Kugel) procedure will be applied for inguinal hernia repair
46016373|NCT02871817|Other|Paxos Checkup Study Mobile Medical Application|The Digisight Paxos Checkup TM is mobile vision assessment system which consists of an application installed on a mobile device with an Internet connection, an Internet Cloud-based vision care network and a web site. The Paxos Checkup app contains a set of quantitative near vision tests, which a patient can take at home or elsewhere using an Internet capable mobile device.
46016374|NCT04299763|Dietary Supplement|Oat Beta-glucan as a Supplement in Type 2 Diabetics|44 subjects were randomized into two groups, placebo (PL) and β-glucan (BG). Each person received a package with a supplement sufficient for 12 weeks, adding 5 g of supplement to breakfast, which could contain beta-glucan or not. Blood and stool samples were requested at the beginning and at the end of the intervention.
46016375|NCT02871427|Drug|Nelotanserin|Once Daily, Oral, at 20, 40, 60, or 80 mg dose
46016376|NCT01012999|Drug|sufentanil|Intra-nasal delivery, dosing range 0.5 mcg/kg, administered once at the beginning of the 30 minute study period
46016377|NCT00628381|Dietary Supplement|L-citrulline supplementation|L-citrulline, 1.8micromol/kg/min, during 8 hours continuously supplemented
46016378|NCT00628381|Dietary Supplement|L-alanine|L-alanine enteral infusion, isocaloric dosage (3.6 micromol/kg/min), during 8 hours, continuously supplemented
46016379|NCT04297813|Combination Product|Advanced medicinal Therapy (MSC combined with biomaterial)|Augmentation of alveolar ridge with MSC and biomaterial
46016380|NCT04297813|Procedure|Autologous bone graft|Augmentation of the alveolar ridge with bone graft
46016381|NCT00637663|Drug|Entecavir|entecavir 0.5 mg QD
46016382|NCT00637663|Drug|Lamivudine|lamivudine 100 mg QD
45465953|NCT01303081|Behavioral|Fixed Deposits|Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking.
46016383|NCT04299529|Diagnostic Test|In-vitro urinary diagnostic test|Urinary proteomic profiling (UPP) using established multidimensional urinary markers for progression to CKD (CKD273), left ventricular dysfunction (HF1 and HF2) and coronary heart disease (CAD238 and ACSP75) - in-vitro test certified in Germany and by extension in the EU (DE/CA09/0829/IVD/001, DE/CA09/0829/IVD/005).
46016384|NCT01017601|Biological|Seneca Valley virus-001|Given IV
46016385|NCT01017601|Other|placebo|Given IV
45680442|NCT01880060|Behavioral|Livin My Weigh|Livin My Weigh is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
45680443|NCT01869114|Drug|Sirolimus|Given PO
45680444|NCT01869114|Drug|Azacitidine|Given IV
46016386|NCT04488757|Diagnostic Test|functional Magnetic Resonance Imaging (fMRI)|Participants will undergo a one hour fMRI scan with pain-induction using heat-based QST protocol.
46016387|NCT04488757|Other|Allostatic Load Composite|All participants will be asked to provide saliva samples to measure cortisol response over time and dehydroepiandrosterone (DHEA) in addition to physiological measurements such as blood pressure/pulse, height/weight, and waist-hip ratio. Measurements will be taken at baseline and 4-month follow-up.
45465954|NCT01303081|Behavioral|Chosen Deposits|Participants will choose their deposit amount (XX = chosen deposit); this same amount will be returned upon success (that is, quit smoking by the target quit date, and having this confirmed by cotinine/anabasine tests). If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. The default deposit will be set to a certain monetary amount for consistency with other arms, and participants can increase or decrease this amount until they reach the amount they want to deposit.
45680445|NCT01843751|Drug|buprenorphine/naloxone|Buprenorphine/naloxone (Suboxone) is considered a well-investigated, highly effective medication-assisted treatment for opiate dependence, but it may only be supervised through the few specialist treatment facilities in the state, or by physicians who have historically been less likely to offer this service. The effectiveness of community physician treatment supervision has not been tested for those in the criminal justice system.
45680446|NCT01815983|Other|Videolaryngoscopy review.|Review of video recordings.
46016388|NCT04297735|Other|Standard of care group|Visits every 6 months is standard of care.
45465955|NCT01303081|Behavioral|Competitive Deposits (Pari-Mutuel)|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, and the payout for quitting on this arm will be Y x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
46016389|NCT04297735|Behavioral|Telemedicine group|Conduct monthly telemedicine 'skype' visit
46016390|NCT04297735|Behavioral|Telemedicine|Review details of medication indication and use, activity recommendations and changes, and knowledge of arrhythmia changes and activities which are helpful with arrhythmia changes.
45465956|NCT01303081|Behavioral|Usual Care|Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days and 3 months (among those eligible).
45465957|NCT03129646|Drug|Miltefosine|Miltefosine 10mg and 50mg capsules
45680447|NCT01756248|Drug|Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
45680448|NCT01744652|Drug|Crizotinib|"Arm A Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle.~Arm B Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group."
45680449|NCT01744652|Drug|Dasatinib|"Arm A Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle. Arm A Dasatinib Expansion Dose: MTD from dose escalation group.~Arm B Dasatinib dose: 140 mg by mouth daily in a 28 day cycle. Arm B Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle."
46016391|NCT01016977|Drug|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
46016392|NCT01016977|Drug|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
45680450|NCT01711541|Drug|Carboplatin|Given IV
45680451|NCT01711541|Drug|Cisplatin|Given IV
46016393|NCT02871661|Drug|Amitriptyline|Volunteers will take 25 milligrams of this medication every day from their enrollment until completing eight weeks long.
46016394|NCT02871661|Other|Kinesiotherapy|Volunteers will be taught to contract their pelvic floor muscles right before stretching it, following a home protocol, every day for eight weeks long.
46100830|NCT05343299|Combination Product|Ambulatory surgery under a combination of Lidocaine and Ropivacaine|In this experimental procedure group, the anesthetic solution is administered subcutaneously and by infiltration into the surgical area. A maximum volume of 20 ml (dose dictated by the operation) of the solution is thus injected by the operator: Lidocaine 10mg/mL combined with adrenaline 0.005mg/mL administered at a dose of 18 mL + ropivacaine 7.5 mg/mL 2 mL or 15 mg. For a total of 20 mL: lidocaine 9mg/mL, ropivacaine 0.75 mg/mL, adrenaline 0.005 mg/mL
46100831|NCT00667160|Drug|tacrolimus ointment|topical
45680452|NCT01711541|Drug|Fluorouracil|Given IV
46016395|NCT02871661|Device|IC (Quark)|Volunteers will visit physical therapy clinic once a week to receive twenty minutes of electrical stimulation with Interferential Current (Duapex 961 of Quark Medical manufacturer) in their perineal area, for eight weeks long.
45680453|NCT01711541|Drug|Hydroxyurea|Given PO
46100832|NCT00667160|Drug|pimecrolimus cream|topical
46016396|NCT01012765|Drug|Indacaterol|Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)
46016397|NCT01012765|Drug|Tiotropium|Tiotropium 18µg o.d. delivered via a proprietary inhalation device.
46016398|NCT01012765|Drug|Placebo|Placebo to indacaterol o.d. delivered via SDDPI
45680454|NCT01711541|Other|Laboratory Biomarker Analysis|Correlative studies
45680455|NCT01711541|Drug|Paclitaxel|Given IV
45680456|NCT01711541|Other|Placebo Administration|Given PO
45680457|NCT01711541|Radiation|Radiation Therapy|Undergo radiation therapy
45680458|NCT01711541|Drug|Veliparib|Given PO
45680459|NCT01584102|Behavioral|group fitness + education|15 weeks biweekly group fitness + 15 weekly nutrition and physical activity education
45680460|NCT01584102|Behavioral|group fitness classes only|15 weeks biweekly group fitness
46016399|NCT00628459|Dietary Supplement|micronutrient supplementation|Supplements are given daily, 5days/week, for 6 months, involving 15 mg iron (arm 1), 15 mg iron and 10 mg zinc (arm 2), or multiple micronutrient (arm 3): 15 mg iron, 10 mg zinc, 375 µg vitamin A, 5 µg vitamin D, 6 mg vitamin E, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 150 µg folic acid, 0.5 mg vitamin B6, 0.9 mg vitamin B12, 35 mg vitamin C, 10 µg vitamin K, 50 µg iodine, 0.6 mg copper.
46016400|NCT00627913|Procedure|Healon 5 injection|Healon 5 (2.3% Sodium hyaluronate) ophthalmic viscoelastic device will be injected into the anterior chamber as needed for pupillary dilation and adequate cataract extraction with intraocular lens placement.
46016401|NCT00627913|Procedure|Retrobulbar anesthetic injection|3-4cc of anesthetic (1% lidocaine/0.75% bupivicaine) will be injected with a 25 gauge needle into the extraocular muscle cone prior to patient and microscope positioning. Cataract extraction with intraocular lens placement will then proceed in standard fashion.
46016402|NCT01010503|Drug|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg/kg intravenous infusion once in 4 weeks
46016403|NCT00628537|Device|BION stimulation|"BION™ Experimental Group~The goal for the BION™ patients is to achieve 30 minutes of stimulation twice daily, using a cycled stimulation at frequencies adequate to produce tetanic contraction, (typically 25-35 pps) that raises the joint through full range of motion against gravity (a range graded as 3/5) based on the available range of motion.~Surface Stimulation Group~Patients will be instructed to stimulate twice daily for 30 minutes through surface electrodes placed according to instructions that the subject has been given. Every effort will be made to ensure that the parameters needed in this group are chosen to produce a similar type of contraction to that obtained with BION™ stimulation.~Control Group with conservative therapy (Range of motion exercises)~The research participant is instructed in self-administered, standard range of motion stretching exercises."
46016404|NCT00627991|Drug|Valsartan|
46016405|NCT05006053|Other|Interviews/Focus groups|Qualitative study (no intervention delivered)
46016406|NCT01009645|Behavioral|Fact Only Education Message|Participants randomized to this intervention will receive an educational brochure listing the facts of the influenza vaccine.
46016407|NCT01009645|Behavioral|Fact and Myth Educational Message|Participants randomized to this intervention will receive an educational brochure listing the facts and myths of the influenza vaccine.
46016408|NCT01009645|Behavioral|Fact, Myth, Why Educational Message|Participants randomized to this intervention will receive an educational brochure listing the facts, myths, and refutation of the myths of the influenza vaccine.
46016409|NCT01009645|Behavioral|Control Educational Message|Participants randomized to this intervention will receive an educational brochure created and used by the CDC in a previous influenza season.
45465958|NCT03129646|Drug|Paromomycin|Paromomycin sulfate equiv to 750mg paromomycin / 2ml amp
45465959|NCT03129646|Drug|Sodium stibogluconate|Sodium stibogluconate 33% 30 ml inj.
45465960|NCT03920891|Procedure|Cryoballoon Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a cryoballoon catheter.~Esophageal temperature will be monitored to prevent esophageal injury.~A 28mm second or third cryoballoon catheter will be used.~Esophageal temperature will be monitored to prevent esophageal injury.~Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~The procedure and cryoablation times will be evaluated.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
45465961|NCT03920891|Procedure|Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation|"Pulmonary vein isolation will be performed using a radiofrequency catheter.~Additional left atrium posterior wall isolation, left atrium anterior wall linear ablation, cavo-tricuspid isthmus ablation, superior vena cava-right atrial septal ablation.~If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~Evaluated the procedure and radiofrequency ablation time.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
46100833|NCT02701673|Drug|Busulfan|"Busulfan test dose administered by vein on Day -10. Test dose of 32 mg/m2 based on actual body weight. Busulfan pharmacokinetics performed with the test dose and the first dose on Day -8. Doses on Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1."
45465962|NCT03798145|Procedure|Surgical Retinotomy|Surgical removal of small areas of retinal to increase outflow through the posterior drainage pathway.
45465963|NCT03461692|Drug|patients under 14 years of age using Reduning injeciton|To assess in patients using Reduning injection's clinical features and drug adverse reaction during patients' hospital stay. The registry procedure will only for patients under 14 years of age using Reduning injection,observed from February 2018 to December 2018.
45465964|NCT03710655|Drug|Apitox - pure honeybee toxin|Intradermal injection of 0.01 microliters
45465965|NCT03710655|Drug|Placebo|Intradermal injection of 0.01 microliters
45465966|NCT04775797|Drug|AB-836|Capsules or Tablets
45465967|NCT04775797|Drug|Placebo|Capsules of Tablets
45465968|NCT04775797|Drug|AB-836|Tablets
45465969|NCT04775797|Drug|Placebo|Tablets
45465970|NCT04775797|Drug|Nucleos(t)ide Analogue|Tablets
45465971|NCT03461614|Other|Exercise group|Exercise group mainly conducted the 5 core stabilization exercises as described by McGill. These include the curl-up, side bridge, trunk extension, double leg lifts and bird-dog exercises that support respiratory functions. In other words, every single training session consisted of frontal, dorsal, and lateral core exercise. In general, participants always exercised in group so that for integration and motivation. During training weeks 1-2, participants exercises with 3 sets per exercise and 10 s contraction time and 10 repetitions. During training weeks 3-4, contraction times and repetitions were increased to 15 s and 15 repetitions. Additionally, increasing the complexity of exercises, adding opposite limb movements and increasing the lever arm of the exercises were done.
45465972|NCT03461614|Other|Control group|In addition to the service routine rehabilitation program mentioned above, participants in the Control group participated in leisure activities such as table tennis/basketball under service staff supervision for 45-60 minutes, 2 times a week, 6 weeks similar time period of Exercise group.
45465973|NCT03707613|Procedure|DWT learning curve|trainees learn to perform DWT after unsuccessful initial cannulation
45465974|NCT01135199|Drug|pomalidomide (CC-4047|
45465975|NCT03794869|Other|Percutaneous electrostimulation treatment (EPS)|Apply dry needles in a tight band of some of the muscles that most affect the appearance of low back pain, such as: paravertebral, lumbar quadrate, gluteus medius and pyramidal, and administer analgesic microcurrents.
46016410|NCT04297657|Other|Counselling|o An appointment was made with the women in the experimental group at a time when they were available and a suitable environment was arranged in the hospital. The counselling programme of the experimental group was conducted in four sessions one week apart. In addition, each woman in the experimental group was given a counselling booklet and compact disc. The interviews lasted between 15- 45 minutes. The topics of interest among women were noted in the interviews and after the information on the subject was received, feedback was given to the relevant woman through a phone call.
46016411|NCT04504903|Behavioral|Cognitive Behavioral Therapy For Work Success (CBTw)|Veterans will go to 12 weekly group sessions and will learn healthy thinking about work, positive behavioral coping related to work, and will form a work success plan based on their work goals.
45465976|NCT03794869|Other|Exercise program|It will be consist in a program of lumbo-pelvic stabilization exercises and strengthening of CORE.
45465977|NCT03461380|Dietary Supplement|Menopause Relief EP-40|Fixed combination of black cohosh and Rhodiola rosea
45465978|NCT03461380|Dietary Supplement|Low Dose Black Cohosh|6.5 mg black cohosh
45465979|NCT03461380|Dietary Supplement|High Dose Black Cohosh|500 mg black cohosh
45465980|NCT03461380|Dietary Supplement|Placebo|600 mg excipient
46016412|NCT04504903|Behavioral|Psychoeducation|Veterans will go to 12 weekly group sessions and will learn more information about their mental health conditions. Psychoeducation modules are from the Illness Management and Recovery program.
45465981|NCT03917537|Genetic|HNSCC patients have used Nivolumab|Using Whole-Genome Analysis on Cancer Tissue of Patients with Platinum-refractory Head and Neck Squamous cell carcinoma Who Underwent Nivolumab to Precisely Predict Responders: An Observational Biomarker Study
45465982|NCT03335163|Drug|Topiramate|"Topiramate - Participants will undergo a 6 week titrated regimen of oral topiramate to reach a maximum dose of 400mg per day:~Week 1 - topiramate PO 25mg daily Week 2 - topiramate PO 25mg twice daily Week 3 - topiramate PO 50mg twice daily Week 4 - topiramate PO 100mg twice daily Week 5 - topiramate PO 150mg twice daily Week 6 - topiramate PO 200mg twice daily"
45465983|NCT01133561|Drug|actozone A|pioglitazone 30 mg tablet , once daily dose for 10 weeks
46016413|NCT04472845|Radiation|1 week RT|RT will be delivered over 1 week
46016414|NCT04472845|Radiation|2 week RT|RT will be delivered over 2 week
45465984|NCT01133561|Drug|actozone B|one tablet of vehicle without active ingredient pioglitazone
45465985|NCT04749602|Drug|Nivolumab|40 mg of the nivolumab will be used intrapleurally (once).
45465986|NCT01230905|Radiation|PET scan and ultrasound|Nuclear rest/stress testing of the heart using N-13-ammonia paired with brachial artery ultrasound
45465987|NCT03461302|Drug|Topical coal tar|Solution carbonis detergens 10% in cremor vaselini lanette FNA and pix lihantracis 3% in zinc oxide paste
45465988|NCT03461302|Drug|Topical corticosteroids|Clobetasone butyrate 0.05% ointment
45465989|NCT03978650|Other|Observational|Participants from the Canadian Longitudinal Study on Aging will be evaluated for cognitive status, occurrence of falls, and fall-related injuries.
46016415|NCT01006291|Drug|insulin degludec|Injected s.c. (under the skin) once daily (alternative regimen). Dose was individually adjusted.
46016416|NCT01006291|Drug|insulin degludec|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
46016417|NCT01006291|Drug|insulin glargine|Insulin glargine injected s.c. (under the skin) once daily. Dose was individually adjusted.
46016418|NCT04296175|Drug|Epirubicin|90mg/m2, d1 every 2 or 3 weeks
46016419|NCT04296175|Drug|CTX|600mg, d1 every 2 or 3 weeks
46016420|NCT04296175|Drug|Paclitaxel|80mg/m2,d1,d8,d15, every 3 weeks
46016421|NCT04296175|Drug|ddEpirubicin|90mg/m2, d1 every 2 weeks
46016422|NCT04296175|Drug|ddCTX|600mg, d1 every 2 weeks
45465990|NCT01232075|Drug|Extended letrozole regimen|"Letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 2.5mg /day is administered from cycle day 1 to 9 .~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy ."
45465991|NCT01232075|Drug|Clomiphene citrate regimen|"Clomiphene citrate(Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg/day is administered from cycle day 3 to 7.~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy ."
45465992|NCT03461224|Radiation|accelerated hypofractionated RT|
45465993|NCT03461224|Radiation|conventional fractionated RT|
45465994|NCT03773822|Combination Product|Hydrocortisone + Flucortac|Low dose steroids
45465995|NCT03773822|Other|Placebo|Placebo
45465996|NCT03940300|Dietary Supplement|Fresh organic vegetables|"Individual participation in this program will take 12 weeks, from screening and enrollment through evaluation. Once enrolled, visits will occur on a weekly basis to ensure that participants receive each week's dose of fresh organic vegetables. At an optional Visit 13, offered 6 months after Visit 1, an additional health screening will be conducted."
45465997|NCT01131845|Drug|UT-15C SR (treprostinil diethanolamine)|Single dose, 1 mg UT-15C SR
45465998|NCT03926260|Other|ctDNA analysis|blood sample at Baseline, 3weeks, 9 weeks after treatment, at progression if applicable
45465999|NCT03711500|Drug|D-serine|Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
45837803|NCT05761015|Drug|therapeutic program including intermittent drug intake and multimodal rehabilitation program|"The prescribed NSAID molecule shall be chosen according to the patient's risk profile:~gastric/duodenal risk: age >65, history of ulcer with remission, history of inflammatory event, current low-dose acetylsalicylic acid treatment ;~cardiovascular risk (according to Agostino scale & SCORE);~The molecule with therefore be:~no risk: niflumic acid, 250 mg per intake;~gastric/duodenal risk only: diclofenac, 50-100 mg per intake, plus lansoprazole;~cardiovascular risk only: ketoprofen, 50-100 mg per intake;~double risk: ibuprofen, 200-400 mg per intake, plus lansoprazole. For the walk test, the highest dose of diclofenac or ketoprofen will be used. Then, the patient will be free to half the dose if pain relief is achieved so.~One gram of acetaminophen will be added to any NSAID intake. The number of intakes will be limited to twice a day (morning and evening) and to 10 times a week."
46016423|NCT04296175|Drug|Paclitaxel(with carbo)|80mg/m2,d1,d8,d15, every 4 weeks
46016424|NCT04296175|Drug|Carboplatin|AUC=2,d1,d8,d15, every 4 weeks
46016425|NCT02871349|Drug|Propranolol|Propanolol will be given on a titration schedule in which participants will begin with small doses (single capsules) of the drug and increase to a larger dosage (divided over 3 capsules) over the course of three weeks. Participants aged 15-24 years will undergo an MRI.
46016426|NCT02871349|Drug|Placebo|Placebo will be given in the form preferred by the participant and on the same schedule as the propanolol regime. Participants aged 15-24 years will undergo an MRI.
45466000|NCT03711500|Drug|Placebo|Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
45837804|NCT05759832|Device|Modified HFNC oxygen therapy|In the modified HFNC group, high-flow devices (AIRVOTM 2; Fisher & Paykel Healthcare, Auckland, New Zealand) were utilized for respiratory support. The nasal cannula used was a modified single nasal cannula.
46016427|NCT02871349|Device|Magnetic Resonance Imaging (MRI)|An MRI will be performed on participants aged 15-24 years.
45466001|NCT03810157|Device|Laser-assisted hatching system|The ZP was thinned or drilled with the Laser-assisted hatching system. The laser pulse was 0.296 ms. Laser aperture was 8μm.
45466002|NCT03461068|Dietary Supplement|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour oral glucose tolerance test.
46100834|NCT02701673|Drug|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
45466003|NCT03461068|Dietary Supplement|Placebo|Acute ingestion of a taste-matched placebo prior a 2-hour oral glucose tolerance test.
45466004|NCT01304719|Behavioral|Computer Assisted Healthy Families America Home Visitation|Computer modules added to home visitation protocol for Healthy Families America
45837805|NCT05759832|Device|Face mask|In the face mask group, oxygen was delivered via a face mask during bronchoscopy. The oxygen flow was set to achieve a saturation of pulse oxygen > 90%.
45837806|NCT05759676|Device|Cre8™/Cre8™ EVO drug-eluting stent|Patient with CAD who undergoing PCI with Cre8™/Cre8™ EVO drug-eluting stent
46100835|NCT02701673|Drug|Glutamine|Oral Glutamine, 15 g swished, gargled and swallowed four times a day starting on Day -8.
46100836|NCT02701673|Drug|Pyridoxine|Pyridoxine 100 mg by vein or mouth three times a day staring on Day -1
46100837|NCT02701673|Drug|Belinostat|Starting dose of Belinostat 100 mg/ m2/day by vein on Day -9 through Day -2.
46100838|NCT02701673|Drug|Azacitidine|Azacitidine 15 mg/m2/day by vein on Day -9 through Day -2.
46100839|NCT02701673|Drug|Gemcitabine|Gemcitabine 75 mg/m2 by vein administered as a loading dose followed by prolonged infusion on Days -8 and -3.
46100840|NCT02701673|Drug|Melphalan|Melphalan 60 mg/m2 by vein on Days -3 and -2.
45466005|NCT01304719|Behavioral|Healthy Families America Home Visitation|Healthy Families America Home Visitation Treatment as Usual
45466006|NCT03460912|Device|Bipolar and monopolar probes (SPESS MEDICA S.r.l. Via Buccari 16153 Genova (GE), Italy) administered to all participants.|Bipolar and monopolar probes (SPESS MEDICA S.r.l. Via Buccari 16153 Genova (GE), Italy) administered to all participants.They compared each others(bipolar vs monopolar) via amplitudes and latency values.
45466007|NCT03920501|Behavioral|Tele-Critical Care|Daily multidisciplinary rounds with a board certified physician through tele-critical care focusing on: 1) diagnosis; 2) active problems; and 3) therapeutic goals. In addition, the management of health care quality indicators will be conducted by a specially trained (Science of Improvement) board-certified intensive care physician.
45466008|NCT03711422|Drug|Afatinib|40mg daily
45466009|NCT03711422|Drug|Afatinib|160mg for 3 days every 3 weeks
45466010|NCT04132843|Drug|Gadobenate Dimeglumine|Given IV
45466011|NCT04132843|Drug|Gadobutrol|Given IV
45466012|NCT04132843|Procedure|Magnetic Resonance Imaging|Undergo MRI
45466013|NCT03364335|Drug|Leu Sil 1.0mg|Leu 1100 mg + 1mg Sil BID
45466014|NCT03364335|Drug|Leu Sil 4.0mg|Leu 1100 mg + 4mg Sil BID
45466015|NCT03364335|Drug|Leu Met Sil 1.0mg|Leu 1100 mg + Met 500mg + 1mg Sil BID
45466016|NCT03364335|Drug|Leu Met Sil 4.0mg|Leu 1100 mg + Met 500mg + 4mg Sil BID
45466017|NCT03364335|Drug|Placebo|Placebo
45466018|NCT03460678|Drug|Pemetrexed|Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium) administered as 500mg/m2 IV over 10 minutes on the first day of each 21-day cycle, until disease progression or unacceptable toxic effects
45466019|NCT03460678|Drug|Erlotinib|Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride) administered once daily until disease progression or unacceptable toxic effects
45837807|NCT05759637|Diagnostic Test|1mg DST|measurement of cortisol levels after 1 mg of dexamethasone (DST) at 11 pm
45837808|NCT05759117|Procedure|thoracentesis|A type of pleural procedure that will yield pleural fluid for subsequent analysis
45837809|NCT05758376|Behavioral|Recovery Bridge|Recovery Bridge is a Peer Specialist facilitated intervention designed to help Veterans being discharged from an inpatient psychiatric hospitalization bridge the gap to outpatient care and community living
45466020|NCT03810391|Drug|Butorphanol|intravenous loading dose of 15ug/kg butorphanol,and followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
45466021|NCT03810391|Other|physiological saline|intravenous infusion of the same volume of physiological saline
45466022|NCT02528591|Device|oscillometric device (Arteriograph®, Medexpert)|Central blood pressure recorded in the non-fistula arm using a validated oscillometric device (Arteriograph®, Medexpert).
45466023|NCT03460600|Other|Optical Coherence Tomography (OCT)|Optical Coherence Tomography is a fairly new imaging technique in ophthalmology
45466024|NCT04113733|Other|Sample Collection|Tissue biopsies will be performed at the time of colonoscopy along with blood and stool sample collection.
46016428|NCT01012609|Other|cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan|External beam radiation therapy (5940 cGy in 180 cGy fractions) with weekly cetuximab (250 mg/m2/dose).4-8 weeks rest, 10 cycles of irinotecan (16 mg/m2/day x 5 consecutive days x 2 weeks) with weekly cetuximab (250 mg/m2/dose) at about 21 day intervals. Research biological evaluations will be performed in consenting patients as an optional portion of the study. Cetuximab is to be given every 7 days (+/- 2 days). Cetuximab does not need to be given on Day 1 of each week.
45466025|NCT03898024|Drug|SHR-1222|Pharmaceutical form: water injection; Route of administration: subcutaneous
45466026|NCT03898024|Drug|Placebo|Pharmaceutical form: water injection; Route of administration: subcutaneous
45466027|NCT03630770|Drug|Medium-Chain Triglyceride (MCT) Oil|Infants receive 0.5 ml/oz of MCT oil to their prescribed feedings for 21 days or until hospital discharge.
45466028|NCT03917069|Drug|Chemotherapeutic Combinations|nab-paclitaxel 260mg/m2 d1+Carboplatin AUC=5 d1+ endostatin 15mg d1-14，q28d
45466029|NCT03917069|Drug|chemotherapy|paclitaxel 175 mg/m2 d1+Carboplatin AUC=5 d1, q21d
45466030|NCT01567345|Device|Implantable pump with continuous flow|Insertion of an implantable pump filled up with the analgesic solution. Connection of the catheter to the intrathecal space. Continuous morphine's flow is scheduled.
45466031|NCT01567345|Device|Implantable pump with programmable flow.|Insertion of an implantable pump filled up with the analgesic solution. Connection of the catheter to the intrathecal space. Programmable morphine's flow is scheduled.
45466032|NCT01229579|Drug|Zinc Sulfate|2.5 ml Zinc supplement syrup daily containing 10 mg of elemental zinc from day 14 to 18 weeks of age.
45466033|NCT01229579|Other|Placebo|2.5 ml placebo syrup daily with containing no elemental zinc from day 14 to 18 weeks of age.
45680461|NCT01500551|Drug|Tofacitinib|"Tofacitinib will be administered orally BID (twice daily) approximately 12 hours (±2 hours) apart, once in the morning and once in the evening, based on body weight for all subjects for all three index studies (A3921103, A3921104, and A3921165)~5 mg BID Dose Level:~Body Weight (Dose in tablet [mg BID] or solution [ml BID]) 5 - < 7 kg (2 mg or 2 ml) 7 - < 10 kg (2.5 mg or 2.5 ml) 10 - <15 kg (3 mg or 3 ml) 15 - <25 kg (3.5 mg or 3.5 ml) 25 - <40 kg (4 mg or 4 ml) >=40 kg (5 mg or 5 ml)~Oral solution (1 mg/mL concentration) will be used for subjects weighing <40 kg. Oral tablets (5 mg) will be used for subjects weighing >=40 kg; subjects who are unable to swallow tablets will have the option of taking oral solution.~Subjects will swallow study tablets whole and will not manipulate or chew tablets prior to swallowing."
45837810|NCT05757622|Drug|Propofol|Procedural sedation provided with propofol and remifentanil using target controlled infusions
45466034|NCT03460444|Dietary Supplement|MCT Oil Supplementation|Participants consume MCT oil (97-99% octanoic acid) twice per day for 14 days. Dosing will begin at 5ml/dose for Days 1-2, 10ml for Days 3-4, and 15ml for the remainder of the intervention.
45466035|NCT03916991|Other|Exercise|Hip focused Neuromuscular Activation Exercise
45466036|NCT03460288|Behavioral|Retraining (AAT)|The training program is based upon the approach-avoidance task (AAT) and can be easily performed on a computer, laptop or tablet. There is a total of 20 pictures, 10 slot-machine gambling related pictures and 10 neutral pictures that were already used in a prior study (Wittekind et al., submitted). The pictures appear on the computer screen and have to be either pushed or pulled. Pushing and pulling depends on a masked instruction (not related to the content of the pictures, but to the color of the frame). All gambling-related pictures are framed with the color that is instructed to be pushed, all neutral pictures are framed with the color that is instructed to be pulled.
45466037|NCT01131923|Drug|Amlodipine|Amlodipine Tablets, 10 mg
45466038|NCT03794557|Drug|Sterile Water Injection|Inhaled Sterile Water Injection
45466039|NCT03794557|Drug|PUL-042 Inhalation Solution|PUL-042 Inhalation Solution
45466040|NCT03460132|Device|Tomas® Anchorage System - DENTAURUM|self drilling, bone inserted, screw like device used for anchorage preparation during orthodontic treatment.
45466041|NCT03459976|Diagnostic Test|evaluate serum level HE4 in endometrial cancer|"HE4 in beignin endometrial diseases~HE4 in endometrial cancer"
45466042|NCT03801785|Other|Pacifier|The pacifiers used in this clinical trial have the same shape and material. They are produced by Artsana S.P.A. for soothing children. As such, the FDA has no jurisdictions over pacifiers (US FDA regulations May 15, 2012 https://www.fdaimports.com/blog/pacifiers-fda-change-abi-system/) because they are not medical devices intended for teething.
45466043|NCT03799939|Device|Intervention group|Polyvinylidene fluoride mesh (Dynamesh IPST) is used on intraperitoneal onlay position to prevent parastomal hernia.
45837811|NCT05757622|Drug|Remifentanil|Procedural sedation provided with propofol and remifentanil using target controlled infusions
45837812|NCT05757570|Drug|povetacicept|Administered by subcutaneous injection every 4 weeks
46016429|NCT04297501|Drug|Antiretroviral Therapy|All participants receive antiretroviral therapy to control virus replication and restore CD4+ T-cell count.
46016430|NCT04298749|Drug|GX-P1 or Placebo (dose level 1)|GX-P1 dose level 1 or placebo
46100841|NCT02701673|Procedure|Stem Cell Transplant|Stem cell transplant performed on Day 0.
46100842|NCT00738322|Drug|AZD1305|Solution for iv infusion, single dose
46100843|NCT00738322|Drug|Placebo|NaCl solution for iv infusion, single dose
46100844|NCT00856908|Drug|AZD1656|Tolerable dose given twice daily
46016431|NCT04298749|Drug|GX-P1 or Placebo (dose level 2)|GX-P1 dose level 2 or placebo
46016432|NCT04298749|Drug|GX-P1 or Placebo (dose level 3)|GX-P1 dose level 3 or placebo
46016433|NCT04298515|Diagnostic Test|Nesfatin-1|Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level
46016434|NCT01012219|Drug|niacin (+) laropiprant|open-label, single dose Tredaptive (1000mg ER niacin/ 20mg laropiprant) 2 oral tablets
46016435|NCT01012219|Drug|Comparator: aspirin|81 mg oral tablet once daily for 7 days
46016436|NCT01012219|Drug|Comparator: clopidogrel|75 mg oral tablet once daily for 7 days
46016437|NCT01012219|Drug|Comparator: laropiprant|40 mg oral tablet once daily for 7 days
46016438|NCT01012219|Drug|Comparator: placebo|placebo oral tablet once daily for 7 days
46100845|NCT00856908|Drug|Placebo|Tolerable dose given twice daily
46100846|NCT00522379|Drug|Rotigotine|2 mg/24 hr (one 10 cm^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
46100847|NCT00522379|Drug|Rotigotine|4 mg/24 hr (one 20 cm^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
46100848|NCT00522379|Other|Placebo|Placebo transdermal patch applied daily
46100849|NCT00522379|Drug|Rotigotine|6 mg/24 hr (one 10 cm^2 & one 20 cm^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
46016439|NCT04298125|Behavioral|Exercise in Pregnancy|Women in this group will participate in psychical activity 3 times per week in their community setting.
46100850|NCT00522379|Drug|Rotigotine|8 mg/24 hr (two 10 cm^2 & one 20 cm^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
46016440|NCT01011907|Drug|varenicline|12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
46016441|NCT01011907|Drug|placebo|12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).
46016442|NCT01011673|Drug|Metoclopramide|metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS
46100851|NCT00671684|Procedure|Endoscopic Mucosal Resection (EMR)|EMR is a common procedure in gastroenterology. The technique involves placing a band around a piece of mucosa in the GI tract. The band and the tissue are then removed using a cautery snare. The technique can be used to obtain tissue for diagnostic purposes or to remove lesions for therapeutic purposes.
45837813|NCT05756413|Behavioral|Self-determination theory|"SDT is relatively unique among theories of motivation due to its focus on the quality, rather than the quantity, of motivation. Central to SDT is the distinction between selfdetermined or autonomous and non-self-determined or controlled forms of motivation. These types of motivation differ from one another based on the degree to which actions are (or are not) fully self-endorsed by the individual. Autonomous motivation reflects freely chosen and fully or whole-heartedly self-endorsed reasons for engaging in a behavior, such as because it is important and because it is enjoyable. In contrast, controlled motivation reflects reasons for acting that are not self-endorsed because one is pressured into doing them because of internal pressure, such as this is something I should do, even though I don't really want to, or because of environmental contingencies because I have to; it is required that I do this."
46016443|NCT01011673|Drug|Ketorolac|ketorolac 30mg IVSS
46016444|NCT01311648|Biological|Recombinant Factor VIII (Kovaltry, BAY81-8973)|Main study: 25-50 IU/kg at least 2x/week for 6 months and at least 50 EDs, IV infusion; Extension study: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part A and extension study), IV infusion. Exposure day (ED): An ED is a unit of time (1 day) in which replacement treatment of Hemophilia is given to a patient.
46016445|NCT01311648|Biological|Recombinant Factor VIII (Kovaltry, BAY81-8973)|Main study: 15-50 IU/kg at least 1x/week for at least 50 EDs or until inhibitor development, IV infusion; Extension study: For participants having reached at least 50 EDs in main study - Part B: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part B and extension study), IV infusion. For participants who developed an inhibitor in main study - Part B: up to 200 IU/kg per day or 100 IU/kg twice a day at the discretion of the investigator and coordinating investigator until successful eradication of the inhibitor, or until failure, for up to18 months (treatment beyond 18 months required an agreement with the sponsor and coordinating investigator), IV infusion
46016446|NCT01011439|Drug|Milciclib Maleate|"150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity."
46016447|NCT04406857|Drug|Capecitabine|Given PO
46016448|NCT04406857|Radiation|Radiation Therapy|Undergo radiation therapy
46016449|NCT04406857|Drug|Ropidoxuridine|Given PO
46016450|NCT01311024|Biological|PCV GSK1024850A|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
46016451|NCT01311024|Biological|hepatitis B vaccine or hepatitis A vaccine|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
46016452|NCT02871193|Drug|Ropivacaine|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml
46016453|NCT02871193|Drug|Dexamethasone|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml and dexamethasone 5 mg
46016454|NCT02871193|Other|saline|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.9% saline 20ml
46016455|NCT01310868|Drug|5-ALA|5-ALA is used to generate tumour specific fluorescence as an aid to surgical resection of GBM, prior to the insertion of Gliadel wafers
46016456|NCT01310868|Drug|Gliadel wafers|The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.
46100852|NCT05343221|Device|High Fidelity Simulator|First of all, students will be given 1 hour of CPR training. Then they will be asked to apply with the High Fidelity CPR Simulator. This simulator is adult human sized and specialized for CPR practice. It will not be interfered during the application. The student's practice will be evaluated by an observer. The student will evaluate his/her satisfaction after the application is over.
46100853|NCT05343221|Device|Haptic|First of all, students will be given 1 hour of CPR training. Then they will be asked to apply with the 3D technology Haptic Device Simulator. This tool has a computer screen and a swing haptic pen. It will not be interfered during the application. The student's practice will be evaluated by an observer. The student will evaluate his/her satisfaction after the application is over.
45466044|NCT03459742|Behavioral|Gamification strategy|"The intervention is a gamification strategy, including game elements such as points, levels and rewards. Points are scored by completion of healthy challenges, i.e. a healthy snacks challenge, a steps challenge and activity challenge. Intervention takes place for 8 months from Mar to Nov. There will be three levels. Level 1 at baseline, level 2 expected at month 4 by 100% of participants and level 3 expected in month 8 by 70% of participants. A new cycle will start in 2019.~Rewards include an initial reward (Starting Kit), a structural reward and an activity reward. The Starting Kit is a box with souvenirs, information for students and teachers. A structural reward, at level 2, will be achieved collectively by all participating classes in one school. It consists of school infrastructure improvements to promote a healthy nutrition and PA (eg. climbing wall, shared bicycles, sports equipment). An activity reward (AR), when reaching level 3, consists of a fun and healthy activity."
46016457|NCT01310868|Radiation|Radiotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|60Gy in 30 fractions (2Gy per fraction given once daily, five days per week (Monday-Friday) over 6 weeks. Radiotherapy delivered to gross tumour volume with 2-3cm margin. Standard treatment following neurosurgery for glioblastoma
46016458|NCT01310868|Drug|Concomitant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|temozolomide given alongside the radiotherapy at 75mg/m2 daily from the first day of radiotherapy, until the last day of radiotherapy, but for no longer than 49 days. Standard treatment following neurosurgery for glioblastoma
46100854|NCT04156178|Biological|CD20-CD19 cCAR T cells|CD20-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
46016459|NCT01310868|Drug|Adjuvant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|Following a 4 week break after contomitant chemo/RT, temozolomide given 150-200mg/m2 TMZ 5/28 days for 6 cycles (dosage increase to 200mg/m2 on second and subsequent cycles dependent on haematological toxicity. Sites should follow local guidelines if different.). TMZ to be given on 5 consecutive days followed by 23 days with no TMZ, per cycle. Standard treatment following neurosurgery and concomitant chemo/RT for glioblastoma
46016460|NCT01273155|Drug|Belinostat|Belinostat was administered intravenously (IV) over 30 minutes on days 1 through 5 of a 21-day cycle. All patients were administered a single dose of 400 mg/m(2) of belinostat on Cycle 1 Day -7 for pharmacokinetic analysis (the total length of Cycle 1 was 28 days).
46016461|NCT05557851|Combination Product|Minnelide|Stressing the patient's pancreatic cancer by giving the anti super-enhancer Minnelide to increase endoplasmic reticulum (ER) stress and improve the progression-free survival (PFS) when patients are treated with standard of care (SOC) nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) plus gemcitabine.
46100855|NCT02567890|Behavioral|Internet-based DBI|Participants will go through a four week interactive program that will improve body acceptance. Includes some homework assignments and monitoring.
46100856|NCT02567890|Behavioral|Expressive writing|Participants will be asked to reflect upon issues related to body image.
45466045|NCT01230983|Drug|asparaginase|Given IV
45466046|NCT01230983|Drug|cytarabine|Given IV
45466047|NCT01230983|Drug|dexrazoxane hydrochloride|Given IV
45466048|NCT01230983|Drug|doxorubicin hydrochloride|Given IV
45466049|NCT01230983|Drug|leucovorin calcium|Given IV
45466050|NCT01230983|Drug|mercaptopurine|Given orally
46016462|NCT01005901|Drug|Glycopyrronium bromide|Glycopyrronium bromide 50µg was supplied as inhalation capsules for use via a Single Dose Dry Powder Inhaler (SDDPI)
46100857|NCT00856830|Drug|Novel Drug Combination|"This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin. Subjects will be treated with irinotecan (150 mg/m2) infusion on Day 1 followed by infusion of bendamustine on Days 1 and 2 at increasing dose levels using a 3+3 design (starting dose of 80-mg/m2/d with 20 mg/mg/d incremental increase to max 120 mg/m2/d) (Regimen A). This will be repeated every 3 weeks for a total of 3 cycles. Restaging for response will be performed prior to the next regimen.~All subjects will then be given carboplatin (AUC 6) on day 1 and etoposide (100 mg/m2) on days 1, 2 and 3 (Regimen B). They will receive 3 cycles of this regimen every 3 weeks prior to restaging.~At the end (3 weeks after) of the sixth total round of chemotherapy, subjects will be re-evaluated for response, and will be followed-up for recurrent disease every 8 weeks."
46100858|NCT04154228|Diagnostic Test|PET/MR scan|"Patients will undergo 18F-FDG PET/CT scans before therapy initiation, interim after 2/3 treatment cycles and end of treatment after therapy completion, as part of their routine evaluation, as well as additional follow-up scans, as clinically indicated and requested by referring physicians. Given signed written informed-consent forms, patients will undergo at each time point, immediately after completion of PET/CT, a PET/MR scan, following the same single injection of 18F-FDG. Standard preparation and acquisition protocols for FDG PET imaging will be employed.~PET/MR imaging will include conventional sequences as T1, T2, diffusion weighted imaging, and advanced vascular imaging (DCE-MRI)."
46016463|NCT01005901|Drug|Placebo|Placebo inhalation capsules were provided for use via a SDDPI
46016464|NCT02889549|Drug|ticagrelor|Different doses of ticagrelor (22.5/45/90 mg, twice daily, oral) treatment for 1 month
46016465|NCT02889549|Drug|clopidogrel|Standard dose of clopidogrel (75 mg, once daily, oral) treatment for 1 month
46100859|NCT04062916|Other|BSGE pelvic pain questionnaire and VAS scores|Patients were evaluated using the BSGE pelvic pain questionnaire in terms of pre-operative and post-operative pain assessment in order to determine the effects of endometriosis surgery on the quality of life. The patients were asked to indicate their levels of dyspareunia, dysmenorrhea, and chronic pelvic pain on a VAS on the pelvic pain questionnaire.
46100860|NCT02631356|Drug|Ringer's lactate solution|
46016466|NCT05549037|Procedure|Time of immunotherapy infusion|Time of immunotherapy infusion
46016467|NCT04968925|Device|ACUVUE Oasys 1-Day|TEST
46016468|NCT04968925|Device|Precision 1|CONTROL
46100861|NCT02631356|Drug|Succinylated gelatin|
46016469|NCT01266993|Biological|Nimenrix (GSK134612 vaccine)|Intramuscular, 1 dose
46016470|NCT01266993|Biological|Menjugate|Intramuscular, 1 dose
46016471|NCT04282525|Other|ECMO for hemodynamic or respiratory indication|ECMO for hemodynamic or respiratory indication
45466051|NCT01230983|Drug|methotrexate|Given IV
46016472|NCT01309386|Drug|Tapentadol ER|Tapentadol ER 100 to 400 milligram (mg) orally daily for 8 weeks (maximum up to 500 mg daily), as per Investigator's discretion.
46016473|NCT01309386|Drug|Morphine SR|Morphine SR 30 to 120 mg orally daily for 8 weeks (maximum up to 140 mg daily), as per Investigator's discretion.
46016474|NCT04295317|Drug|PD-1 blocking antibody SHR-1210|PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
46100862|NCT02614326|Behavioral|Autobiographical Memory Flexibility (MemFlex) training|As in experimental arm description
45466052|NCT01230983|Drug|prednisone|Given orally
45466053|NCT01230983|Drug|therapeutic hydrocortisone|Given IT
45466054|NCT01230983|Drug|vincristine sulfate|Given IV
45466055|NCT01230983|Radiation|radiation therapy|Radiation to cranium
45466056|NCT03810001|Behavioral|Mechanical Stimulation|micromanipulation technique before insertion of the microinjection needle into the oocyte and expulsion of the spermatozoon
45466057|NCT03334695|Biological|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1*10^11 vp in single-use vials.
45466058|NCT03334695|Drug|Placebo|Placebo will be administered as sterile 0.9% saline for injection.
46016475|NCT04295317|Drug|Capecitabine|Capecitabine 2500mg / m2/ d, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
46016476|NCT01266603|Drug|HDIL-2|720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle.
46016477|NCT01266603|Biological|recMAGE-A3 + AS15|300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
46016478|NCT04295551|Drug|Lopinavir / ritonavir tablets combined with Xiyanping injection|Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,
46016479|NCT04295551|Drug|Lopinavir/ritonavir treatment|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization
46016480|NCT01309308|Procedure|sweeping the membranes|The cervical length will be measured and the patient will be examined to determine the Bishop score. Later the the membranes will be swept.
46016481|NCT01309308|Other|No sweeping group|Cervical length will be measured by transvaginal USG and the patient will be examined to determine the Bishop score.
46100863|NCT02614326|Behavioral|Psychoeducation|As in experimental arm description
45680462|NCT01500551|Drug|Tofacitinib|For subjects rolling over from study A3921103 and actively participating in this study at the time of Protocol Amendment 6 and receiving a dosage of tofacitinib in accordance with the dosing scheme specified in Protocol Amendment 5, investigators will have the option of maintaining the subject's current dosage regimen from index study A3921103 (if the desired clinical response has been attained with no safety concern) or adjusting the dosage regimen in accordance with the dosing scheme specified in this section.
45837814|NCT05754294|Diagnostic Test|Polarization of red blood cells|Pre and perioperative data blood sample were collected for each patient 5 minutes (min) before the CPB start and 5 minutes before the end of the CPB for Complete Blood Count (CBC), Erythrocyte Sedimentation Rate (ESR) and Plasma Free Hemoglobin (pFHb). At the end of CPB the residual blood from the extracorporeal circulation was treated with cell-saver and the treated and concentrated red blood cells were collected in a transfusion bag. Two milliliters (ml) was taken from the bag, one ml was subjected to a blood gas test for the evaluation of the Hemoglobin (Hb) content and one ml was subjected inside a cuvette to the release of positive ions (polarization) with a charge of 50 Millivolt (mV) for a time of 5 seconds through charge circuit, after the trend of the conserved charge was measured through a multimeter, instrument that can measure multiple electrical properties.
45837815|NCT05746819|Other|Aggressive antipyretics therapy of fever vs usual care in the Malaria RCT study|After clinical trial of the Malaria RCT study, this study will compare children allocated to aggressive antipyretic therapy vs. usual care on the prevalence of structural brain abnormalities after recovery from CNS malaria.
46016482|NCT01266291|Drug|vigabatrin|Subjects will begin taking vigabatrin (Sabril) during the third month of the study. Upward titration will happen at a rate of 500mg per week until subjects reach their maximum tolerated dose, or 3g per day (whichever is lower). This dose may be decreased if needed under the supervision of the study doctor. Subjects who need to lower their dose or who stop taking Sabril will have their dosage decreased at a rate of 1 gm/week for one month under the supervision of the study doctor.
46016483|NCT00628771|Behavioral|CenteringPregnancy Plus (CP+)|The CenteringPregnancy model of group prenatal care involves skill-building in the areas of efficacy, risk assessment, negotiation, and prevention. CP+ integrates HIV prevention into prenatal care, builds on motivations for healthy pregnancy, and creates a sustainable model via reimbursement mechanisms for prenatal care. There will be ten 2-hour prenatal group sessions.
46016484|NCT00628771|Behavioral|Usual care|Usual care includes standard individual prenatal care and no prenatal group sessions.
46016485|NCT01004263|Drug|rizatriptan benzoate|Single dose of 5 mg or 10 mg orally disintegrating tablet at onset of migraine attack
46016486|NCT01308762|Biological|Heat killed whole cell M. obuense (IMM-101) 0.1 mg|"Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.~Dose levels to be administered are 0.1 mg, 0.5 mg and 1.0 mg."
46016487|NCT01308762|Biological|Heat-killed whole cell M.obuense (IMM-101) 0.5 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
45466059|NCT01304797|Drug|MM-302 Monotherapy|Escalating doses of MM-302 as a single agent
45680463|NCT01436656|Drug|LGX818|
46100864|NCT04063462|Drug|Pyrotinib|pyrotinib, single agent, 400mg p.o once daily until disease progressed
45680464|NCT01399385|Device|MR Imaging Techniques - 1|Group 1 will consist of subjects with a 10-year total CHD risk <10% (low)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
45680465|NCT01399385|Device|MR Imaging Techniques - 2|Group 2 will consist of subjects with a 10-year total CHD risk 10-20% (intermediate)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
46016488|NCT01308762|Biological|Heat killed whole cell M.obuense (IMM-101) 1.0 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
46016489|NCT01265823|Biological|Adalimumab|Adalimumab was administered as follows: 80 mg at baseline, followed by 40 mg every other week (eow; starting at Week 1 until Week 15). The study drug was self-administered via subcutaneous (sc) injection.
46016490|NCT02890836|Drug|Antihypertensiva, mainly Metyldopa|
45466060|NCT01304797|Drug|MM-302 in combination with trastuzumab|Escalating MM-302 at an every 4 week dosing schedule, while the dose of trastuzumab is fixed at an every 2 week dosing schedule
45466061|NCT01304797|Drug|MM-302 in combination with trastuzumab q3w|Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab is fixed at an every 3 week dosing schedule
45466062|NCT01304797|Drug|MM-302 in combination with trastuzumab and cyclophosphamide|Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab and cyclophosphamide is fixed at an every 3 week dosing schedule
46016491|NCT01004185|Drug|Asacol 400 mg|17-33kg = 3 Asacol 400mg AM & 2 Asacol 400mg PM; 33-<54kg = 5 Asacol 400 mg AM & 4 Asacol 400mg PM; 54-<90kg = 6 Asacol 400mg AM & PM
46016492|NCT01004185|Drug|Asacol 400 mg|17-<33kg = 2 Asacol 400mg & 1 placebo AM, 1 Asacol 400mg & 1 placebo PM; 33-<54kg = 3 Asacol 400mg & 2 placebo AM, 2 Asacol 400mg & 2 placebo PM; 54-<90kg = 3 Asacol 400mg & 3 placebo AM & PM
46100865|NCT04153448|Other|Measurement of functional capacity|Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
46100866|NCT02614404|Drug|Imatinib combination therapy|Imatinib plus dihydroartemisinin plus piperaquine
46100867|NCT02614404|Drug|Dihydroartemisinin-piperaquine|Standard of care
46016493|NCT01265511|Drug|Placebo|Oral tablets given bid for 28 days
46016494|NCT01265511|Drug|SCY-635|SCY-635 tablets, 300 mg bid for 28 days
46100868|NCT00522301|Drug|sorafenib tosylate|
45466063|NCT03459664|Behavioral|RECOVER|"For each patient baseline assessment and individual support by a diagnostic and crisis resolution home treatment team is available. In addition, patients will be treated with specific interventions based on their severity grade:~Grade 1 (mild): social support, information about mental disorder, e-therapy, consultation, self help, peer-support, supported employment.~Grade 2 (medium): psychotherapy (stepped short-term and group therapy), if applicable medical treatment, e-therapy, peer-support, supported employment.~Grade 3 (medium to severe): case management, psychotherapy (stepped short-term and group therapy), if applicable medical treatment, e-therapy, peer-support, supported employment.~Grade 4 (severe): assertive community treatment, psychotherapy, medical treatment, e-therapy, peer-support, supported employment."
46016495|NCT01265511|Drug|Pegasys|180 ug prefilled syringe given once per week for up to 48 weeks
46016496|NCT01265511|Drug|Copegus|tablets given bid for up to 48 weeks
46100869|NCT00522301|Other|immunoenzyme technique|
46100870|NCT00522301|Other|immunohistochemistry staining method|
46100871|NCT00522301|Other|laboratory biomarker analysis|
46100872|NCT00522301|Other|pharmacological study|
46100873|NCT00662636|Drug|dasatinib|Given orally
46100874|NCT00662636|Drug|lapatinib ditosylate|Given orally
46100875|NCT00662636|Other|pharmacological study|Correlative study (cohort II only)
46100876|NCT00662636|Other|laboratory biomarker analysis|Correlative study (cohort II only)
46100877|NCT00696462|Device|forced-air warming|forced-air warming device
46100878|NCT02629484|Other|Focused cardiac ultrasound|focused cardiac ultrasound is a goal-focused transthoracic echocardiography examination of the heart, aimed to improve the diagnostic accuracy of clinical assessment
46100879|NCT05726344|Drug|Lactulose|4 tablets of Bisacodyl (5 mg) + 250 mL (162.5g lactulose) of lactulose + 600 mL of water + 2 L of water
46100880|NCT05726344|Drug|Polyethylene Glycol 3350|4 tablets of Bisacodyl (5 mg) + 3 bottles Polyethylene Glycol 3350 (Polyethylene glycol 3350 60 g; sodium chloride 1.46 g; potassium chloride 745 mg; Sodium bicarbonate 1.68 g; anhydrous sodium sulfate 5.68 g; pineapple flavoring 483 mg) + 3 L of water
46016497|NCT04325178|Other|Protein, calorie and macronutrient controlled diet, derived from either omnivorous or non-animal sources, alongside unilateral resistance exercise, over a three-day period.|Participants received a control diet either derived from omnivorous or non-animal food sources, providing 1.8g.kg.day of protein, for a three-day period. Calories were calculated and set to place participants in a state of energy balance. Participants completed three bouts of unilateral resistance exercise, 5 sets of 30 maximal concentric knee extension contractions, on each morning that they received the control diet. During this three-day period participants also consumed a deuterium oxide tracer allowing for the measurement of muscle protein synthesis, in rested and exercised tissue, with incremental biopsies.
46016498|NCT04325100|Behavioral|Switch - Individual sessions|"Participants follow the Switch intervention through individual sessions (1 hour, twice a week, for around 2 months).~Participants are provided with a folder which presents the rational for each strategy. Take-home assignments are given and stored in the same folder. Participants are also given small cards (that can fit in their wallet) containing the key elements of each strategy.~The intervention manual can be obtained from the main investigator (in French)."
45466064|NCT03459664|Behavioral|Treatment as usual|"For each patient all common care options within the German health care system are available, depending on the severity grade 1 to 4.~This includes the following options: hospital based in-patient, out-patient treatment and day care, community based health care services, general practitioners, private psychiatrists and psychotherapists, self help."
45466065|NCT03458806|Diagnostic Test|AS Algorithm 1|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater aortic stenosis from controls having structurally normal hearts with no greater than mild valvular heart disease at any location.
46016499|NCT04325100|Behavioral|Switch - Group programme|"Participants follow the Switch group programme (2 hours, twice a week, for around 2 months).~During the group sessions, a powerpoint presentation and different media are used to present the different parts of the motivation model. Participants learn the different strategies (e.g., cognitive defusion, pleasure anticipation, problem solving) through individual and group exercises.~Participants are provided with a folder which presents the rational for each strategy. Take-home assignments are given and stored in the same folder. Participants are also given small cards (that can fit in their wallet) containing the key elements of each strategy.~The intervention manual and the presentation material can be obtained from the main investigator (in French)."
46016500|NCT04324788|Other|Group 1|The patients will be asked to go up and down 9-step stair with the highest speed they can make.
46016501|NCT04324788|Other|Group 2|The patients will be asked to go up and down 9-step stair with the highest speed they can make.
46016502|NCT01264965|Drug|long acting oxycodone|10mg twice daily
46016503|NCT01264965|Drug|extra strength acetaminophen|1,000 mg twice daily
45466066|NCT03458806|Diagnostic Test|AS Algorithm 2|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater aortic stenosis from controls having any findings other than moderate-to-severe or greater aortic stenosis.
45680466|NCT01399385|Device|MR Imaging Techniques - 3|Group 3 will consist of subjects with a 10-year total CHD risk >20% (high)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
46016504|NCT05644236|Other|mouthwash|After obtaining baseline information and randomizing the participants into two groups, dental scaling was performed, followed by clinical treatment. The participants were instructed to gargle twice daily for 7 days. All the participants were instructed not to eat or drink anything for at least 4 hours before the experiment. Oral hygiene, such as gargling and tooth brushing, was prohibited for 8 hrs before the visit.
46016505|NCT02890680|Procedure|Platelet-rich fibrin|
46016506|NCT02890680|Procedure|Control group|
46016507|NCT01264887|Drug|Tapentadol Prolonged Release|Titration to achieve sufficient pain relief to continue with effective analgesia for as long as the participant tolerates and wishes to continue treatment.
46016508|NCT01306968|Drug|hyperbaric oxygen|"The chamber will be compressed with air to 1.5 atm abs. Once the chamber is compressed to 1.5 atm abs, the subjects will don a hood and breathe 100% oxygen. Hoods will be supplied with oxygen with flows of at least 30 liters per minute and overboard dumping of excess gas. Each subject will complete 40 sessions.~The duration of the hyperbaric oxygen exposures will be 60 minutes (±2 minutes), timed from when the chamber hatch or door closes, and ending when the chamber hatch or door opens (door-to-door time equals 60 minutes). The total intervention exposure time is 50 minutes (±2 minutes). The interval to compress to the intervention pressure (1.5 atm abs) and will be 5 minutes (±1 minute). The interval to decompress from the study pressure will be 5 minutes (±1 minute)."
46016509|NCT01306968|Other|sham hyperbaric air|A pressure of 1.2 atm abs will provide an equivalent inhaled oxygen concentration of 25%. The duration of the sham exposures will be 60 minutes (±2 minutes). Each subject will complete 40 sessions.
45466067|NCT03458806|Diagnostic Test|MR Algorithm 1|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater mitral regurgitation from controls having structurally normal hearts with no greater than mild valvular heart disease at any location.
46016510|NCT04323423|Behavioral|interrupting sedentary behaviour with light physical activity|replacing sitting with light walking bouts at different frequencies/durations
46016511|NCT05644158|Procedure|Revascularization|Depending on the exact morphology of the lesion, patients with short superficial femoral artery lesions (<25 cm) will be subdivided into group 2A with endovascular treatment (percutaneous transluminal angioplasty with or without stenting) and patients with long superficial femoral artery lesions (>25 cm) will be subdivided into group 2B with open surgical treatment (femoropopliteal bypass) .
45466068|NCT03458806|Diagnostic Test|MR Algorithm 2|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater mitral regurgitation from controls having any findings other than moderate-to-severe or greater mitral regurgitation.
46016512|NCT05644158|Other|Exercise therapy|Home-based monitored exercise training (walking), 3 times a week, monitored with log book and activity sensors.
46100881|NCT00863928|Drug|belladonna 16.2 mg and opium 60 mg suppository|belladonna 16.2 mg and opium 60 mg suppository
45466069|NCT05575843|Other|Neurostatus-SMARTCARE|The Neurostatus-EDSS is assessed by HCPs while the examination is video-recorded. HCPs underwent extended training. For details of the examination refer to the second section of the detailed description.
45466070|NCT05575843|Other|Standard Neurostatus-EDSS|The Neurostatus-EDSS is assessed by neurologists while the examination is video-recorded. Neurologists underwent standard training.
45466071|NCT03920345|Device|MultiZYTE|Subjects can be treated either unilateral or bilateral, depending on their condition and the recommended treatment by the surgeon. The decision is a clinical one and is not influenced by the decision of whether to be included in the study or the subsequent outcomes and QoL analysis.
46016513|NCT01264419|Device|Silk Road Embolic Protection System|System that delivers a carotid artery stent, via transcervical access using reverse flow cerebral protection, as treatment for high-grade extracranial carotid artery disease
46100882|NCT04153214|Behavioral|cycling|Participants will have a portable pedal machine under their desk and will use it 60minutes per day
45466072|NCT03707535|Biological|CT-P13|3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid
45466073|NCT03707535|Biological|Remicade|3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid
45466074|NCT03793153|Procedure|Uterine Cooling Technique|Standard LSCS will be done except immediatelyfollowing delivery of the fetus the uterus will beexternalized in the usual fashion and the body of theuterus cephalad to the hysterotomy incision will bewrapped in sterile surgical towels saturated in sterile,iced normal saline. These towels will come from asterile cooling pot set to 30 degrees Fahrenheit. Theskin of the abdomen will be draped to prevent contactwith the cold towels. Iced saline-soaked towels will bekept in place for a minimum of 5 minutes and replacedat the discretion of the attending obstetrician until thehysterotomy is closed and the uterus is replaced intothe patient's abdomen.
45466075|NCT03458338|Diagnostic Test|estimated glomerular filtration rate and albuminuria|chronic kidney disease according to KDIGO
45466076|NCT03920423|Procedure|improvement of arterial depth|deepen radial arterial depth by injection of saline to more than deep cutoff point relative to result.
45466077|NCT03458182|Other|Added exercise|After completion of the standard exercise test, an intervention period of 2 minutes of low intensity exercise is added.
46016514|NCT04323345|Dietary Supplement|Natural Honey|Natural Honey supplement 1gm/kg/day divided into 2 to 3 doses for 14 days either orally or through nasogastric tube.
46016515|NCT04323345|Other|Standard Care|Supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.
46016516|NCT01263873|Device|Mallinckrodt (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
46100883|NCT05723692|Biological|ALTB-268|monoclonal antibody
46100884|NCT05723692|Other|Placebo|formulation buffer
46100885|NCT00667316|Behavioral|Set of questionnaires (respondent)|A set of questionnaires to determine risk factors for sick leave due to low back pain.
46100886|NCT00856518|Device|EMST|Pressure threshold device (Expiratory Muscle Strength Trainer) targeted at increase muscle force generation of expiratory and submental muscles.
45466078|NCT01133795|Drug|Midodrine plus Albumin|MIdodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks
46016517|NCT01263873|Device|Parker Flex-Tip (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
46016518|NCT01263639|Other|Orthopaedic Attending Biosketch Card|"The intervention group will receive an attending photo/biosketch card within 24 hours of admission while the control group will not. The biosketch card will include a picture of the attending orthopaedic surgeon with a brief synopsis of his or her: education background, specialty, surgical interests, research interests, and other interests including hobbies."
45466079|NCT03364023|Device|Neurothrombectomy|Medtronic Market-Released Neurothrombectomy Device
45466080|NCT01133873|Drug|Propoxyphene napsylate (XP20C)|100 mg capsules 6 times a day in ascending doses until a maximum tolerated dose is identified
45466081|NCT01133873|Drug|Placebo|6 times a day in ascending doses until a maximum tolerated dose is identified
45466082|NCT03458026|Other|Connected object use combined with SMS (text messages) of physical activity reminders|Watch connected used and receipt of SMS (text messages)
45466083|NCT03458026|Other|Without connected object|Any intervention except follow-up visit
45466084|NCT01304017|Other|Virtual Reality|The VR-therapy will include the playing of various virtual reality or video-games which encourages the use of the extremities while sitting and standing
45466085|NCT01304017|Other|Traditional Therapy|The traditional therapy will include exercise for balance and walking and for the upper extremity using traditional therapeutic tools such as balls, weights, chairs, bands, steps, etc.
46100887|NCT00856518|Device|Sham|The same device just like the EMST but does not provide a load on the target muscle group
45466086|NCT04767555|Procedure|ILM (inner limiting membrane) peeling|The standard technique for the removal of the inner limiting membrane is a dye-assisted ILM peeling established since 20 years as the standard of care to treat vision loss due to epiretinal membranes or macular holes in eyes with an otherwise stable retina, but not during retinal detachment surgery. Other dyes may show a stronger staining effect but since there is evidence of a potential toxicity of ICG the investigators use the well-tolerated and for this purpose approved trypan blue dye Membrane Blue ® (Dorc). This intervention will be performed in addition to standard vitreoretinal re-attachment surgery.
45466087|NCT01229813|Drug|bevacizumab, erlotinib|bevacizumab 7.5 mg/kg body weight every third week, erlotinib 150 mg daily
46016519|NCT01263639|Other|Standard of care - No biosketch card|Standard of care
46100888|NCT00506389|Drug|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing 3.0 mg, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia [USP] name corn starch), magnesium stearate, and lactose monohydrate.
46100889|NCT00506389|Drug|Placebo|The placebo tablets contained the following excipients: hydroxypropyl cellulose, maize starch (USP name corn starch), magnesium stearate, and lactose monohydrate.
46100890|NCT00667472|Drug|Ranibizumab|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
46100891|NCT00667472|Device|Pulsed Dye Laser|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
46016520|NCT01011283|Drug|decitabine|decitabine 20 mg/m^2 /day intravenous (IV) infusion for 5 days every 28 days
46100892|NCT01012375|Drug|AZD1446|10 mg capsule, oral dose
46100893|NCT01012375|Drug|AZD1446|80 mg capsule, oral dose
46100894|NCT01012375|Drug|AZD1446|80 mg capsule, oral dose
45837816|NCT05746650|Procedure|Electrical stimulation|Experimentally induced muscly injury via. neuromuscular electrical stimulation of the hamstring muscles
45837817|NCT05746650|Drug|Growth hormone (somatropin)|Daily injection of growth hormone
45466088|NCT01229813|Drug|bevacizumab|bevacizumab 7.5 mg/kg body weight every third week
45466089|NCT01229813|Drug|bevacizumab|bevacizumab 7.5 mg/kg body weight every third week.
45466090|NCT01229813|Drug|low dose capecitabine|capecitabine 500 mg twice daily
45466091|NCT03792997|Combination Product|combination therapy for high peripheral NK cells|lipid emulsion & prednisolone & LMWH
45837818|NCT05746650|Other|Control (No electrical stimulation, nor growth hormone)|No electrical stimulation, nor growth hormone
45837819|NCT05745649|Other|Resistance exercises|Resistance exercises
45837820|NCT05745649|Other|Ankle weights|Ankle weights
46016521|NCT01011283|Drug|azacitidine|azacitidine 75 mg/m^2 /day subcutaneous (SC) injection for 7 days every 28 days
46016522|NCT01263561|Procedure|ExPRESS shunt|ExPRESS miniature glaucoma drainage device
45837821|NCT05745064|Drug|TL-925|TL-925 is an oil-in-water emulsion containing the active pharmaceutical ingredient at a concentration of 0.1%.
46016523|NCT01263561|Procedure|trabeculectomy|trabeculectomy filtering surgery
46016524|NCT01009099|Other|breathing retraining|breathing retraining using a metronome
46016525|NCT01009099|Other|exercise training|treadmill exercise training
46016526|NCT01263483|Drug|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
46016527|NCT01263483|Drug|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
46016528|NCT01263483|Drug|Voglibose|Alogliptin placebo-matching tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
46100895|NCT01012375|Drug|Placebo|Matching capsule, oral dose
46100896|NCT05713552|Device|Acuvue Oasys 1 Day for Astigmatism with Legacy lidstock|CONTROL
46016529|NCT01306890|Biological|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
46016530|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
45837822|NCT05745064|Drug|Placebo|The composition of the placebo is identical to the active formulation, except for the inclusion of the active ingredient.
46100897|NCT05713552|Device|Acuvue Oasys 1 Day for Astigmatism with Amcor laminated lidstock|TEST
46016531|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
46100898|NCT00667706|Procedure|laparoscopic operation Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy will be performed employing a 5-6 trocar technique, and includes gastric resection starting 4-5 cm proximal to the pylorus, using a 38 fr. Bougie and endoscopic stapler with blue and green load.
46100899|NCT00667706|Procedure|laparoscopic operation Roux-en-Y Gastric bypass|Divided LRYGB will employ 5-7 trocars technique, and includes stapled jejunojejunostomy 30-50 cm distal to the Treitz ligament, gastric pouch of 20 cc., and antecolic, antegastric gastrojejunal anastomosis, either two layered hand-sawn, GIA, or EEA-25 -stapled, at surgeons preference. The length of the Roux limb will be 100 centimeters or 150 centimeters in patients with BMI of <50, and >50, respectively.
46100900|NCT01012453|Behavioral|A randomised clinical trial of the effect of classification and individual counselling|The trial to be conducted is a randomised single-blinded parallel study. It is divided in two stages, T = 0 and follow-up at T = 6 months. All included participants will have a clinical examination at the beginning and at follow-up in the trial. Half of the participants will be randomised to intervention, the other half to control. The participants in the intervention group will, after the first clinical examination, pass on directly to the intervention which includes an allergological examination (patch and prick testing). Three days later they will be examined by a physician who will interpret the patch test and give a thorough, individual guidance in skin protection and occupational safety. The clinical examination of all participants at follow-up will reveal the difference in outcomes in the intervention and the control group.
46100901|NCT00667784|Behavioral|Questionnaire|Questionnaires completed before the bone marrow or stem cells are collected, after the transplant, and 6 months after the transplant.
45466092|NCT03457012|Drug|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
45466093|NCT05337423|Device|Photobiomodulation|Group 1 will receive 630 nm LED and group 2 will receive sham treatment twice a week in the palmo-plantar areas of the hands and feet (4 J/cm2) for 4 weeks.
46100902|NCT05705128|Drug|Dexmedetomidine|Dexmedetomidine will be given with bupivaciane for postoperative pain control
46100903|NCT01565395|Drug|Incobotulinum Toxin A|Xeomin 70-100 units injected in the parotid and submandibular glands of subjects
45837823|NCT05743400|Drug|Thymoglobulin 25 milligrams (mg) Injection|Patients will receive thymoglobulin between 5 and 20 milligrams/kilograms (mg/kg) as an intravenous infusion over a period of 2 to 5 days depending on the dose and the transplant package chosen by the physician.
45837824|NCT05743400|Biological|blood test|"Thymoglobulin® serum levels~Time frame : samples will be drawn at the following points :~1 after each end of perfusion ;~1 though concentration before each perfusion ;~3 blood samples in 3 different days during the first week;~1 weekly for 2 weeks post HSCT."
46016532|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
46100904|NCT01565395|Drug|placebo|Sterile preservative free 0.9% saline
46100905|NCT00667940|Behavioral|Rater training workshop|Rater training workshop: rater error training, performance dimension training, behavioral observation training, and frame of reference training using lecture, video, and facilitated discussion
45466094|NCT05337423|Other|Moisturizer|Both groups will receive moisturizer.
45837825|NCT05731726|Drug|Serplilumab|"Serplilumab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w"
46016533|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
46016534|NCT02871973|Behavioral|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
46016535|NCT02871973|Behavioral|Handout|Handouts developed by Center for Disease Control and Prevention (CDC) to provide information regarding age-specific early childhood milestones
46100906|NCT04063228|Other|Simple Skill Group|will practice the following skills as needed: bed mobility, transfer, walking, and stairs.
46100907|NCT04063228|Other|Complex Skill Group|The program will consist of interventions at the impairments level with an emphasis on core strengthening, functional lower extremity strengthening, balance and endurance training, and at the skill acquisition level. Participants will learn pre-running skills (walking, stairs with handrail, walking backward, walking over obstacles, walking on toes, stairs without handrail, bounding), running skills (force generation in vertical plane: hopping, alternate hopping, running in place in gravity minimized position and against gravity; force generation in horizontal plane: bounding, alternate bounding, open chain movement for swing phase, running) and post running skills (running forward, backward, sideways, skipping, hopping).
46100908|NCT00662714|Drug|Repaglinide|oral; initial dose: 3x 0.5mg/d; 2 years
45466095|NCT04744532|Drug|Bosutinib (Phase 1 part)|Subjects will receive 100 mg, 200mg, 300mg or 400 mg of bosutinib once daily, orally.
46016536|NCT01263093|Drug|Clopidogrel|
46100909|NCT00662714|Drug|short-acting Insulin (Actrapid)|initial dose: 3x 0.05E/kg/d, injected; 2 years
45466096|NCT04744532|Drug|Bosutinib (Phase 2 part)|Subjects will receive 200mg/day or 300mg/day of bosutinib once daily, orally.
45466097|NCT03455920|Other|Clinical nurse (supernurse) evaluation|The first evaluation of the patient refered to the sleep clinic will be performed by the clinical nurse then discussed with the pulmonologist in charge.
46100910|NCT00668018|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg orally on demand prior to intercourse
46100911|NCT00871338|Biological|GSK2197870A|3 doses given at 2, 3 and 4 months of age
46100912|NCT00871338|Biological|Prevenar™|3 co-administered doses, intramuscular into right thigh
46100913|NCT00871338|Biological|Menitorix™|1 booster dose at 12 months of age
46016537|NCT01263093|Drug|LY2216684|
46016538|NCT01010971|Drug|Ciclesonide HFA 160 μg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
46016539|NCT01010971|Drug|Ciclesonide HFA 80 μg|Ciclesonide HFA Nasal Aerosol 80 μg once daily
46016540|NCT01010971|Drug|Placebo|Placebo HFA Nasal Aerosol once daily
46016541|NCT01306656|Drug|10,000 IU Vitamin D3|"Month 1: 20,000 IU vitamin D3 once a week~Months 2-6: 10,000 IU vitamin D3 once a week"
46100914|NCT00871338|Biological|Pediacel™|3 doses given at 2, 3 and 4 months of age
46016542|NCT01306656|Other|Placebo|"Month 1: Placebo once a week~Months 2-6: Placebo once a week"
46016543|NCT01306656|Dietary Supplement|Vitamin D|Daily multivitamin with 400 IU vitamin D.
46016544|NCT04327908|Other|Questionaire TESS and MSTS|answering TESS and MSTS questionnaire
46016545|NCT01008943|Biological|Autologous Muscle Derived Cells|Urethral injection of autologous muscle-derived cells
46016546|NCT02871271|Dietary Supplement|IQP-AS-121|
46016547|NCT04205071|Drug|Lorcaserin|Given PO
46100915|NCT00871338|Biological|Menjugate™|2 doses given at 3 and 4 months of age
46100916|NCT00824421|Drug|UK-453, 061|UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
46100917|NCT00824421|Drug|UK-453, 061|UK-453,061 750 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
46100918|NCT00824421|Drug|EFV +TVA|Efavirenz 600 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 tablets mg PO QD.
46100919|NCT04130100|Biological|Low Dose of Mesenchymal stem cell|Mesenchymal stem cell injection
46100920|NCT04130100|Biological|High Dose of Mesenchymal stem cell|Mesenchymal stem cell injection
46100921|NCT04130100|Drug|Sodium Hyaluronate|Sodium Hyaluronate injection
46016548|NCT04205071|Drug|Lorcaserin Hydrochloride|Given PO
45466098|NCT03455920|Other|Pulmonologist evaluation|The first evaluation of the patient refered to the sleep clinic will be performed only by the pulmonologist.
45466099|NCT01231061|Radiation|SBRT|•24 Gy in 3 fractions to cover at least 90% of the defined target volume
45466100|NCT01231061|Radiation|Radiosurgery|16 Gy in 1 fraction to cover at least 90% of the defined target volume
45466101|NCT03920813|Drug|Mercaptopurine|Dose of mercaptopurine was adjusted to maintain a target white blood cells (WBC) between 2.0-3.0 × 109/L.
45466102|NCT01649947|Drug|Paclitaxel|"Paclitaxel will be given at a dose of 200 mg/m2(by IV over 3 hours on Day 1). Cycles every 3 weeks for 4-6 Cycles.~Prior to receiving paclitaxel, all patients will receive the following premedication:~Dexamethasone 20 mg po 12 and 6 hours prior to paclitaxel infusion (patients may be treated with dexamethasone 20 mg iv < 1 hour prior to infusion with paclitaxel if the patient did not take the oral dexamethasone)~Diphenydramine 50 mg iv (or equivalent) < 1 hour prior to paclitaxel infusion~Ranitidine 50 mg iv < 1 hour prior to paclitaxel infusion (alternatively other H2-blockers may be used)"
45466103|NCT01649947|Drug|Carboplatin|Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel. Cycles every 3 weeks for 4-6 Cycles.
45466104|NCT01649947|Drug|Hydroxychloroquine|Hydroxychloroquine will be given as a flat dose of 200 mg orally BID (total daily dose of 400 mg). Cycles every 3 weeks for 4-6 Cycles.
45466105|NCT01649947|Drug|Bevacizumab|"Cohort 1 only:~Bevacizumab will be given by IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg. Cycles every 3 weeks for 4-6 Cycles."
45466106|NCT05409573|Other|double monitoring of EtO2|"A double monitoring of EtO2 will be performed during the procedure of intubation (from the beginning of the preoxygenation to the success of intubation):~In the pharynx (via a nasopharyngeal catheter) for the needs of the study~On the facemask (as the practice in the OR)"
46016549|NCT04205071|Other|Questionnaire Administration|Ancillary studies
46100922|NCT00514813|Drug|Dynepo|Subcutaneous injection either BIW, QW, Q2W or Q4W based on what is appropriate for the subject
46100923|NCT04129632|Behavioral|IEPF Wellness Tool|A daily 5 minute mindfulness exercise over 28 days
45466107|NCT03455530|Other|Industrial Hygiene-Enhance Community Health Worker Intervention|The intervention will be derived from audits and exposure assessments and focus groups with workers and owners in the same business types (excluded from the trial) conducted in an earlier part of the study, as well as a community advisory group (e.g., Hispanic Chamber of Commerce) . From this, we will generate educational materials specific for each small business sector. We will provide the CHWs with a list of industry-specific control options along with potential cost savings and benefits. For example, EPA estimates a cost saving of $13,000 per year for auto body shops that switch to the high-velocity low-pressure spray guns. Each list will be a comprehensive menu of options that contain multiple control measures including simple controls, such as keeping the lids on the solvent containers.
45466108|NCT01137461|Procedure|ultrasound-guided embryo transfer|Embryo transfer in oocyte recipients
45466109|NCT04720274|Device|Electromyopathy (EMG) Shorts|Participants will be asked to complete physical activities while wearing EMG shorts
45466110|NCT03709173|Behavioral|FuRST 2.0|Round 2 of cognitive pre-testing for a new functional rating scale
45466111|NCT03454750|Drug|177Lu-PSMA|177Lu-PSMA 3.7-5-5 GBq Intravenous Slowly in 15-30 ' Day 1/ every 8-12 weeks Four cycles every 8-12 weeks
45466112|NCT03793075|Drug|Ketamine|ketamine 5 mcg/kg/min will be used as intravenous anesthetic infusion
46016550|NCT01003639|Drug|Acetazolamide|Subjects will begin with four 250 mg tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
46016551|NCT01003639|Drug|Placebo|Subjects will begin with four tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
46100924|NCT00708279|Procedure|Osteopathic manipulation|Participant will be evaluated and treated for somatic dysfunction utilizing osteopathic manipulation once a week for 3 weeks, then once every 3 weeks for three more visits; a total of 6 interventions in 3 months.
46100925|NCT00597116|Drug|Vinorelbine|
46100926|NCT00597116|Drug|Vandetanib|once daily oral dose
45466113|NCT03793075|Drug|Propofol|propofol 17 mcg /kg/min
45466114|NCT01233167|Drug|clopidogrel|clopidogrel 75 mg po per day for 12 months
45466115|NCT01233167|Drug|placebo|placebo 75mg po per day for 12 months
45837826|NCT05731726|Drug|Capecitabine|Given PO
46100927|NCT04135404|Other|health-related telephone surveys|The Behavioral Risk Factor Surveillance System (BRFSS) is a health-related telephone surveys that collect state data about United States residents regarding their health-related risk behaviors, chronic health conditions, and use of preventive services (Secondary-data analysis).
46016552|NCT01003639|Behavioral|Formal weight loss counselling program|Teleconference, web-based from central location, using site visits and subject self-assessment tools
46016553|NCT01003249|Drug|Baclofen|"Subjects will be randomly assigned to placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
45466116|NCT01233167|Drug|clopidogrel and placebo|clopidogrel 50mg per day for 3 months,clopidogrel 25mg per day for 3 months,then placebo 75mg per day for 6 months
45466117|NCT05044208|Diagnostic Test|ECG monitoring|After clinical routine diagnostics an additional ambulatory ECG monitoring for 7 days is established
46016554|NCT01003249|Drug|Placebo|"Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
45837827|NCT05731726|Drug|Oxaliplatin|Given IV
46016555|NCT04297033|Drug|Lovastatin|lovastatin 40mg/d 12m
46016556|NCT04297033|Drug|Placebo|placebo
46016557|NCT04391803|Device|Pipeline™ Flex Embolization Device with Shield Technology™|The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular treatment of adults with intracranial acutely ruptured aneurysms not amenable to clipping and coiling.
46016558|NCT01001767|Drug|Lovaza|Lovaza one gram twice a day for 24 weeks
46016559|NCT01001767|Drug|Placebo|Placebo
45466118|NCT03710499|Procedure|Physical activity|Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit.
45466119|NCT01133951|Drug|OAC triple therapy|Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.
45466120|NCT01133951|Drug|Placebo|Omeprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 2 weeks.
45837828|NCT05731726|Drug|Celecoxib|celebrex
46016560|NCT04338295|Device|Tattoo machine (SOL Nova Device)|A SOL Nova Device (brand) tattoo machine will be used to stimulate hair regrowth.
46016561|NCT04294537|Procedure|TAP Block|At the end of surgery patients will receive bilateral ultrasound-guided single-shot TAP block: 0,15% levobupivacaine 0,75 mg/kg per side will be injected between internal oblique and transveralis fascia
46016562|NCT04294537|Procedure|LIA local infiltration|At the end of surgery 0,5% levobupivacaine 1.5 mg/kg, equally distributed between ports, injected in the skin and subcutaneous tissue during wound closure.
46016563|NCT04294537|Procedure|General anesthesia|"General anesthesia will be induced with fentanyl 1,5 mcg/kg, propofol 2 mg/kg, rocuronium 0,6 mg/kg; after intubation anesthesia will be mantained with sevoflurane (MAC 1).~30 minutes after induction will be administered paracetamol 15 mg/kg iv."
45680467|NCT01399385|Device|MR Imaging Techniques - 4|Group 4 no known risk factors (control subjects)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
46016564|NCT04294537|Drug|Postperative analgesia|"During first 48 hours after surgery all patients wil receive paracetamol 15 mg/kg iv every 8 hours and ibuprofen 10 mg/kg orally (or through gastric tube) every 12 hours after surgery.~In case of severe pain tramadol 0,5 mg/kg will be administered iv every 8 hours."
45466121|NCT01304095|Drug|Ranolazine|Patients in the ranolazine arm would start with 500 mg po BID of ranolazine and be force titrated to 1gm po BID after 2 weeks. Down-titration would only be allowed for side effects. This would be on top of all standard medical therapy.
45466122|NCT03454282|Other|FMD|The Fasting Mimicking Diet (or FMD) consists in a 5-day plant-based, low-calorie (about 600 Kcal on day 1, followed by about 300 KCal/day on days 2 to 5), low-carbohydrate low-protein diet
45466123|NCT03962972|Other|Frailty evaluation|It will be used a questionnaire that is called:The Centre of Excellence Self-Administered questionnaire (CESAM). The score of this questionnaire and its stratification of frailty in four levels with incident adverse health events in older community dwellers will be compare with the three validated frailty indexes which are the Cardiovascular Health Study frailty index, Study of Osteoporotic Fracture index and Rockwood frailty index.
45466124|NCT03707457|Drug|Nivolumab|Patients receive nivolumab intravenously (IV) over 30 minutes on Day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
45466125|NCT03707457|Drug|Anti-GITR Monoclonal Antibody MK-4166|Patients receive anti-GITR intravenously (IV) over 30 minutes on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
45466126|NCT03707457|Drug|IDO1 inhibitor INCB024360|Patients receive IDO1 inhibitor by mouth daily beginning on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
45680468|NCT01370512|Drug|Droxidopa|100 mg tablets by mouth three times a day
45680469|NCT01370512|Drug|Pyridostigmine|60 mg tablets by mouth three times a day
45680470|NCT01370512|Other|Placebo|Looks exactly like the study drug but contains no active ingredients
45680471|NCT01294020|Drug|Tacrolimus|Oral capsule
45680472|NCT01294020|Drug|Tacrolimus prolonged release|Oral capsule
45680473|NCT00944632|Drug|ZK 245186|Once daily topical non-occlusive application for up to 4 weeks
45680474|NCT00944632|Drug|Placebo (vehicle ointment)|Once daily topical non-occlusive application for up to 4 weeks
45680475|NCT00775853|Drug|6-[18F]Fluorodopamine|
45680476|NCT00775853|Drug|6-[18F]Fluorodopa|
45680477|NCT00775853|Drug|13N-Ammonia|
45680478|NCT00717795|Behavioral|interview and physical activity|For Arm 1 participants in the Physical Activity intervention condition will be assessed at baseline, and postintervention Follow-up (at 12 weeks post baseline).
46100928|NCT00668096|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5 mg or 10 mg or 20 mg, orally1 hour prior to sexual activity
46100929|NCT00668096|Drug|Placebo|Matching Placebo
45466127|NCT03707457|Drug|Ipilimumab|Patients receive ipilimumab intravenously (IV) over 90 minutes on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 21 days for up to 4 doses in the absence of disease progression or unacceptable toxicity.
45466128|NCT03797755|Radiation|palliative radiotherapy|Radiotherapy for palliating symptoms in stage IV cancer patients
46016565|NCT04296721|Behavioral|Intensive weigh-loss program|Intervention group: Intensive weight-loss program: 0-3 months very low calorie diet, 15 days substituting three meals for low calorie shakes, from 15 to 120 days substituting 1 meal and from 120 days to 12 months on a low calorie diet while starting a progressive exercise programme. Recommendations for good sleep habits will be given. The program will be carried out through group and individual sessions with the hospital dietician. After 3 months: group sessions with a nurse in the basic area. Group sessions led by hospital dietician. From 3 to 12 months: group sessions led by primary care nurse.
46016566|NCT04296721|Behavioral|Standard Dietary recommendations|Patients will be managed according to the usual recommendations: The common written diet (designed by a hospital nutritionist) and an exercise advice will be given according to patient age and level of activity, without any other assessment or additional visits.
45466129|NCT01134029|Behavioral|Stepped Care|This group receives 2 years of a stepped care intervention including provider visits, health educator sessions, phone calls and mailings and availability of self management and group sessions, text messaging and a smoker's quit line.
45466130|NCT04685798|Device|Diffusion-weighted imaging magnetic resonance imaging|The research MRI study of the head and neck will be performed on a Siemens 3T MRI Scanner system
46016567|NCT04336969|Behavioral|4T Education and Care|CGM data will be used to create customized weekly feedback to the participant/family by secure MyChart message.
46016568|NCT04294615|Other|FMT through a naso-jejunal tube|Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a naso-jejunal tube.
46016569|NCT04294615|Other|FMT through TET|Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a transendoscopic enteral tubing (TET) which is fixed to the cecum with clips under endoscopic guidance.
46016570|NCT02871037|Drug|PF-05221304|Single or repeated, escalating dose of PF-05221304
45466131|NCT03453814|Other|Music Therapy|Subjects will receive one hour of music twice a day for three days.
45466132|NCT03739697|Other|spontaneous breathing|spontaneous breathing during induction of anesthesia in infants
45466133|NCT01568294|Drug|pomalidomide|2 mg or 4mg oral pomalidomide once per day on Days 1-21 of a 28-day cycle
45466134|NCT03916913|Radiation|Local radiation therapy|Local radiotherapy on all sites of disease including primary and metastatic lesions
45837829|NCT05720741|Behavioral|Project THINK|Project THINK is a 30-minute self-guided digital intervention designed to teach children and adolescents how to change the way that they think. Specifically, Project THINK is based on the principles of cognitive restructuring, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project THINK uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for assessing the presence of unhelpful thoughts and replacing them with more helpful ones. Although never formally tested in a randomized trial, Project Think has been used by hundreds of students, and feedback has been very positive.
46016571|NCT02871037|Other|Placebo|single or repeated dose of placebo
46016572|NCT04295629|Procedure|Research on the effects of Ilioinguinal Nerve Block on Chronic Pain in Patients who undergo Inguinal Hernia with Spinal Anesthesia|The patients underwent inguinal hernia operation randomly classified into two groups in the operating room as; Group I (n:30); spinal block (SA): All patients were given SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space. Times when the block reached T10 level were recorded.
46016573|NCT04295629|Procedure|Ilioinguinal nerve block|Group 2 (n:30); SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space and as a ilioinguinal block (IHNB) 10 ml 5% bupivacaine was injected to patients with peripheric nerve block injection in the reanimation unit after the surgery.
46016574|NCT04282681|Other|Accelerometer Live-Streaming Tool|The only 'intervention' that will take place is the placement of the XLS tool(s) on the upper left chest and/or left wrist of the patient.
46016575|NCT01306032|Drug|ABT-888|PARP enzymes are critical for maintaining genomic stability by regulating a variety of DNA repair mechanisms. Individuals with deleterious mutations in the BRCA1 or BRCA2 tumor suppressor genes have an increased risk of developing breast and ovarian cancers due to impaired or defective DNA damage repair; these individuals have an increased susceptibility to DNA-damaging agents and PARP inhibitors. Inhibition of PARP inhibits the repair of DNA damage caused by alkylating agents such as cyclophosphamide. Metronomic cyclophosphamide has demonstrated efficacy in several tumor types. The PARP inhibitor ABT-888 has been shown to potentiate the action of cyclophosphamide in xenograft models. This combination is well tolerated in a Phase I study and showing promising activity.
46016576|NCT01306032|Drug|Cyclophosphamide|
46016577|NCT01263015|Drug|Dolutegravir|Dolutegravir (also known as GSK1349572) 50 mg taken once daily
46100930|NCT02614170|Other|Prospective Blood Draw|This is prospective collection blood and urine study. This is not a treatment trial or device trial.
46100931|NCT00668174|Behavioral|Exercise|Moderate intensity exercise, 5 days per week, 45 min per session, 50-70% max HR, divided into a 3-month individualized and 9-month maintenance period.
46100932|NCT00514735|Procedure|Medtronic Cardiac Ablation System|Arm 1 (Ablation Management): Ablation procedures using investigational catheters in left atrium. Cardioversion could be used to restore sinus rhythm if needed.
46100933|NCT00514735|Drug|Class I or III Antiarrhythmic Medications|Arm 2 (Medical Management): Class I or III antiarrhythmic drugs. Changes in dosing, antiarrhythmic drugs or combinations of antiarrhythmic drugs were allowed. Direct current cardioversions were also allowed at the discretion of the investigator.
46100934|NCT00671996|Drug|Mangafodipir|"Treatment will be undertaken with a ready-to-use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI.~Formulation content: MnDPDP 10 mmol/ml~Administered dose per cycle: 2 μmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an i.v. infusion over 5 min about 30 min prior to start of chemotherapy."
46100935|NCT00671996|Drug|Placebo treatment (0.9% NaCl)|Intravenous infusion, 2 micromol/kg, pretreatment 30 minutes before the start of FOLFOX treatment (during the first three FOLFOX treatments)
45837830|NCT05720741|Behavioral|Project SHARE|Intervention delivered in a web browser that focuses on encouraging feelings disclosure to trusted others using facts about the brain, testimonials from peers, and writing exercises (also referred to as Sharing Feelings Intervention; Schleider et al., 2021).
45466135|NCT01304953|Drug|Group P+P|"In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia."
45837831|NCT05715931|Drug|Toripalimab|Toripalimab, 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.
46016578|NCT01263015|Drug|Atripla|Atripla once daily on an empty stomach
46016579|NCT01263015|Drug|Abacavir/Lamivudine|taken once daily; also known as EPZICOM
46016580|NCT01263015|Drug|Abacavir/Lamivudine Placebo|matching placebo taken once daily
46016581|NCT01263015|Drug|Dolutegravir placebo|matching placebo taken once daily
46016582|NCT01263015|Drug|Atripla placebo|matching placebo taken once daily on an empty stomach
46100936|NCT00672152|Biological|WT1 derived peptides|"WT1 derived peptides consisting of 0.3mg (cohort 1) or 1mg (cohort 2) of each of the following peptides mixed with 1ml Montanide ISA 51 and 100mcg GM-CSF in a total volume of 2ml:~WT peptide #1: HLA-A2 restricted: RMFPNAPYL~WT peptide #2: HLA-A24 restricted: CMTWNQMNL~WT peptide #3: HLA-DR15 restricted: QARMFPNAPYLPSCL~WT peptide #4: HLA-DRw53 restricted: LKGVAAGSSSSVKWT~Immunization with the peptide pools will be given as 200 microliter intradermal and 1.8ml subcutaneously in opposite thighs."
46100937|NCT00662870|Biological|DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine)|0.5 mL, Intramuscular
46100938|NCT00662870|Biological|Pentacel: DTaP-IPV/Hib|0.5 mL, Intramuscular
46100939|NCT00672230|Dietary Supplement|Lutein supplement|Subjects will be randomized to take a lutein supplement(12mg/day) lactation weeks 5-8 or to not take a lutein supplement
46100940|NCT00672308|Other|Benefiber|
45466136|NCT01304953|Drug|Group P+T|"In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia."
45466137|NCT01304953|Drug|Group S+P|"In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia."
46016583|NCT04322955|Drug|Cabozantinib|2 x 20 mg capsules taken orally daily
46016584|NCT04322955|Drug|Nivolumab|480mg IV on first day of each 28-day cycle
46016585|NCT04322955|Procedure|Cytoreductive nephrectomy|Surgery removing as much tumor tissue as possible, possibly including surrounding tissues.
46016586|NCT04323267|Device|Limber Digital Application|A mobile application was recently developed to address these needs. The application provides evidence-based, symptom specific home-exercise video programs for MSK conditions, as well as clinically-validated outcome measures for tracking progress.
46016587|NCT04323267|Behavioral|Physical therapy Therapy|Therapy prescription 2 x a week for 8 weeks (specified by physician)
46100941|NCT00672308|Other|Benefiber with ORS|Benefiber (50 g/L)-supplemented, reduced-osmolarity WHO-ORS
46100942|NCT00672308|Other|Benefiber with ORS|
46100943|NCT00672308|Other|Benefiber with ORS|
46100944|NCT00672308|Other|the reduced-osmolarity WHO-ORS without added Benefiber|
46100945|NCT00672308|Other|the reduced-osmolarity WHO-ORS without added Benefiber|
46100946|NCT03325855|Other|None - Observational|None - Observational
46100947|NCT03252587|Drug|BMS-986165|Specified dose on specified days
46100948|NCT03252587|Other|Placebo|Specified dose on specified days
46100949|NCT02630264|Drug|Endostatins|"Specification: 1mL/division, 1×1012 VP/1.0mL~E10A preparation:~Thaw frozen E10A stored at -20°C vials at room temperature until E10A is liquid.~Swirl gently. Do NOT shake.~Method of administration~E10A was diluted with 0.9% sodium chloride to appropriate dose according to the longest diameter of the target lesion.~After local anesthesia, we penetrated the syringe under normal skin subcutaneously 5 mm into the tumor or vertically into the lymph node under direct visualization and withdrew it to confirm the absence of blood.~Applied local compression for 10 minutes and pasted a sterile sticker on the injection site to avoid bleeding."
46016588|NCT04322877|Procedure|Temporary pacing Study|Temporary delivery of CRT
46016589|NCT04322877|Radiation|Thoracic CT|As part of non-invasive mapping protocol
45837832|NCT05715931|Drug|Trastuzumab|Trastuzumab, 8 mg/kg IV loading dose at 1st administration and then 6 mg/kg IV on Day 1 of each 21 day cycle for 3 cycles before surgery and 3 cycles after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.
46016590|NCT04322877|Diagnostic Test|Acute hemodynamic study|Measurement of invasive dP/dTmax
46016591|NCT04322877|Diagnostic Test|Non-invasive body surface mapping|Cardioinsight body surface mapping
46016592|NCT04322877|Diagnostic Test|Invasive catheter-based mapping|Invasive electroanatomical mapping
46016593|NCT04322799|Procedure|Device: Randomization between prosthetic components|Patients are randomized between two types of cup components in total hip arthroplasty. Identical cups made of either highly-crosslinked polyethylene or conventional polyethylene.
46016594|NCT04322175|Drug|Meloxicam|Meloxicam Eye Drops
46016595|NCT01305564|Device|Denali inferior vena cava filter|The Denali inferior vena cava filter is a mechanical filtration device consisting of two levels of filtration (upper arms, lower legs), a retrieval hook to allow for retrieval using a standard snare, cranial and caudal anchors, and penetration limiters. The Denali filter is made from a laser cut nitinol tube.
46016596|NCT04322331|Other|no intervention|no intervention
46016597|NCT04322253|Drug|Neladenoson bialanate (BAY 1067197)|10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
46016598|NCT04324671|Device|nasofibroscopy|"Flexible videorhinolaryngoscope, PAL 11101VP*, 4.2 mm diameter. Using a computerized system including:~Light source: Explor ENT (HAL250). The software allowed audio, video recording and retrieval of recorded material."
46016599|NCT04322409|Device|Neuromuscular Electrical Stimulation|"5 sessions that consist of NMES over the peroneus longus muscle. This consists of a biphasic current with a phase duration of 240us delivered in a frequency of 75 pules per second, with a ramp-up time of 2-seconds, followed by a 50-s rest period (no stimulation). Each cycle will consist of 10 seconds of on time, and 50 seconds off, with 10 cycles being performed each session."
46100950|NCT02630264|Drug|Paclitaxel injection|"Specification:~30mg/5mL,~Usage:~160mg/m2 on day 3, according to instruction."
46100951|NCT02630264|Drug|Cisplatin injection|"Specification:~20mg~Usage:~Cisplatin 25mg/ m2 on day 3, 4, and 5,according to instruction."
46100952|NCT00668330|Drug|Ibandronate+alfacalcidol+calcium|Ibandronate 150 mg monthly plus daily alfacalcidol (1ug)500mg plus calcium
46100953|NCT00668330|Drug|placebo ibandronate+alfacalcidol+calcium|placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium
46016600|NCT04322409|Device|Transcutaneous Electrical Nerve Stimulation|5 sessions that consist of 11-minutes of TENS over the skin of the peroneus longus. This consists of a biphasic current will be continuously applied at 100 pulses per second, with a phase duration of 100us for 10 minutes. The intensity will be turned up until the point the subjects feel the current (sensory threshold)
46016601|NCT04321785|Other|Placebo|placebo capsule (mannitol)
46016602|NCT04321785|Other|Caffeine|caffeine capsule (80 mg of caffeine plus mannitol)
46016603|NCT05648175|Behavioral|e-CBT|The participant will submit their weekly homework and receive personalized feedback from their assigned therapist on OPTT. The feedback adds customization by acknowledging the participant's experiences in the past week and ensures the participant has understood the CBT concepts.
46016604|NCT05648175|Behavioral|e-CBT + Phone Call|In addition to the e-CBT program (see 1 above), the participant will receive a weekly phone/video call from their assigned therapist. The goal is to build on the therapeutic relationship and to add personalization with direct verbal encouragement. This phone/video call is limited to a one-time, 15-20 minutes call each intervention week.44 The purpose is to check with the patient on their treatment progress. The secure call will either be a phone or video (via Microsoft Teams) call, depending on the preference of the patient.
45837833|NCT05715931|Drug|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)|"Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:~Docetaxel 50 mg/m², IV on day 1 of each 14 day cycle; Oxaliplatin 85 mg/m² , IV on day 1 of each 14 day cycle; Leucovorin 200 mg/m² or Levoleucovorin 100 mg/m², IV on day 1 of each 14 day cycle; 5-FU 2600 mg/m², IV over 24 h on day 1 of each 14 day cycle."
45837834|NCT05714774|Device|HIFU treatment of prostate cancer|HIFU treatment using Focal One (EDAP TMS) combined with the acquisition of additional ultrasound images before, between, and after HIFU shots will be performed.
46100954|NCT03998059|Procedure|splenectomy|These patients should fail to have sustained response to multiple first- and second-line treatments of ITP and agree to have splenectomy.Before splenectomy, these patients will be reassessed and still diagnosed with ITP.Their platelet level will be raised to a safe state before surgery, and the laparoscopic splenectomy will be performed in Tianjin People's Hospital.
46016605|NCT05648175|Behavioral|e-CBT + Phone Call + Pharmacotherapy|In addition to the e-CBT program (see 1 above), the participant will receive standard pharmacotherapy following DSM-5 guidelines. A pharmacotherapy allocation system has been developed (Figure 1; Figure 2) that follows clinical guidelines. All medications will be prescribed by a psychiatrist on the research team. All medications are a part of the clinical standard of care. The medications will be provided to the participant through the normal process of receiving medication (i.e., pharmacy). Participants allocated to the e-CBT + Phone Call + Pharmacotherapy arm will begin the pharmacotherapy optimization process at the same time as they begin the e-CBT program. Oversight of medication in the e-CBT + Pharmacotherapy arm will be conducted by a psychiatrist on the team who will make a judgement regarding whether to alter the medications. This will not require any additional study visits/time commitment for the participants in this arm.
45837835|NCT05714384|Device|CeraSeal (Calcium Silicate-based Root Canal Sealer)|A calcium silicate-based root canal sealer will be used in cases requiring root canal retreatment.
46016606|NCT01305408|Drug|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
46016607|NCT01305408|Drug|Placebo|Matching placebo tablets, taken orally, once daily in the morning
46016608|NCT05648097|Device|Baldachin|"Environmental intervention: Equipment of a patient space of a patient with confirmed COVID-19 in open-space multiple bed Intermediate Care Unit areas with a mobile, optimally placed high efficiency particulate air (HEPA)-equivalent air filtration unit (Baldachin) in addition to existing room ventilation and hospital policy infection prevention and control measures."
46016609|NCT01261611|Biological|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 of up to 5 treatment cycles.
45837836|NCT05714007|Drug|Ferric derisomaltose|Single intravenous dose ferric derisomaltose
46100955|NCT00668408|Other|LTOT (oxygen therapy)|Patients on LTOT will receive oxygen for at least 15 hours/day from the liquid oxygen systems at a flow rate adjusted to raise resting SaO2 between 93 and 96% and / or PaO2 between 65 and 80 mmHg every day for 3 years.
46100956|NCT00668408|Other|Pharmacological therapy of COPD and CHF|"Optimal pharmacologic treatment will include :~Long (LABD, salmeterol, formoterol, tiotropium) - as well as short-acting (SABD, Salbutamol, terbutaline, ipratropium)bronchodilators (beta-2 agonists, anticholinergics)~Inhaled steroids (ICS, beclomethasone, fluticasone, budesonide always associated with LABD)~Beta-blockers~Diuretics~Angiotensin-converting enzyme (ACE) inhibitors alone or in associations with diuretics~Statins and any other treatment required for associated co-morbidities (eg insulin and/or anti-diabetic drugs, other antihypertensive, etc).~The treatment of the deseases will follow the international guidelines."
45466138|NCT01304953|Drug|Group S+T|"In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia."
45466139|NCT03453580|Radiation|multislice computed tomography portography|imaging modality
45466140|NCT03422666|Drug|Teduglutide|Teduglutide
45837837|NCT05714007|Drug|Ferrous succinate|Daily oral dose of 100 mg iron (ferrous succinate) tid postoperatively
46016610|NCT01261611|Biological|Botulinum toxin type A|I.M. injection on day 1 of treatment cycle 1.
46016611|NCT01261611|Drug|Placebo|I.M. injection on day 1 of treatment cycle 1.
46016612|NCT04321629|Combination Product|autologous adipose tissue transfer|experimental group: liposuction, adipose tissue preparation and intra-articular injection
46100957|NCT04630483|Other|INHA|NLR and PLR ratio will be assessed at postoperative 6th and 24th hours compared to preoperative values
46100958|NCT04630483|Other|TIVA|NLR and PLR ratio will be assessed at postoperative 6th and 24th hours compared to preoperative values
45466141|NCT03422666|Drug|Placebo|Placebo
45466142|NCT03794245|Behavioral|Men-Centered HIV Testing|The intervention involves bringing mobile HIV testing to venues where men congregate, talking to them as a group about HIV testing, and then providing testing at that venue.
46016613|NCT04321629|Combination Product|PRP injections|control group: blood collection, blood preparation and intra-articular PRP injection
46100959|NCT01012531|Biological|Subcutaneous injections with highly polymerized allergen extract|cluster schedule
46100960|NCT01012531|Biological|Subcutaneous injection with placebo|cluster schedule
46100961|NCT00668486|Drug|Lactic acid (Dermacid)|
45466143|NCT03794245|Behavioral|Linkage to Care for HIV+ Men|Men diagnosed with HIV are accompanied to the clinic and registered there with the help of a community health worker.
45466144|NCT03794245|Behavioral|Clinic-based HIV Testing|Individuals present to a clinic and request HIV counseling and testing
45680479|NCT00717795|Behavioral|interview and wait list|Participants in the control condition (Arm 2)will be assessed at baseline and 12 weeks post baseline (Follow-up). At this time, the PA intervention will be offered at no cost to the participants in the control condition. If the waitlist participant chooses to complete the PA intervention after the 12 week waitlist period, program satisfaction will be assessed after study completion.
46016614|NCT04321863|Other|Faecal calprotectin (FC)|FC is a surrogate marker of neutrophil influx into the gut lumen. It accurately predicts mucosal healing (MH) at colonoscopy, and thus is already widely used in clinical practice in disease monitoring in CD patients (standard of care).
46100962|NCT01012687|Drug|perindopril erbumine|8 mg tablet
46100963|NCT00662948|Drug|Rituximab|375 mg/m2 every 8 weeks during 24 months
45466145|NCT03794245|Behavioral|Clinic Referral for HIV+ Men|Individuals diagnosed with HIV are referred to the nearest clinic for treatment of HIV
45466146|NCT03410810|Diagnostic Test|MRI|MRI analysis
45466147|NCT03410810|Diagnostic Test|Neurodevelopmental/Neuropsychological Assessment|Standardized Cognitive and Developmental Tests
45466148|NCT03453190|Combination Product|Apremilast and Clobetasol|Patients will receive apremilast and clobetasol with tapering dosages over 16 weeks.
45466149|NCT02528669|Device|RX Navigait|The RX Navigait is an accelerometer that tracks the number to steps taken, duration of walking, and time of walking. In addition, this device sends messages to patients regarding daily walking goals and walking reminders.
45680480|NCT00647387|Device|Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)|Device
45680481|NCT00584883|Drug|ABT 510|ABT 510 (TSP-1 mimetic peptide) is a parenterally available nonapeptide analog of the heptapeptide and is a potent inhibitor of angiogenesis. ABT 510 competes with TSP-1 for binding to endothelial cells, but the exact mechanism of anti-angiogenesis is unknown. ABT 510 is administered by SQ injection. The starting dose of ABT 510 will be 20mg once daily (QD) SQ. Doses will be escalated by approximately 50% increments in consecutive cohorts of 3-6 patients until maximum tolerated dose is achieved.
45680482|NCT00215813|Drug|Poly I: Poly C12U (Rintatolimod)|200-400 mg IV infusions given twice weekly over a period of 30-60 minutes
45680483|NCT00179465|Drug|Tiagabine|Up to 36 mg daily
45680484|NCT00179465|Drug|Placebo|Placebo
45680485|NCT00134030|Drug|Cisplatin|Given IV
45680486|NCT00134030|Drug|Doxorubicin Hydrochloride|Given IV
46016615|NCT04321863|Other|quantitative Faecal Immunochemical Testing (qFIT)|Stool test for haemoglobin. It has been shown to predict mucosal healing in Crohn's disease and ulcerative colitis. This study will compare the ability of qFIT and FC to predict flare in CD (qFIT is a cheaper, more stable test with a quicker turn-around time than FC, and is also less labour intensive for the lab).
45466150|NCT03452254|Device|Active Bihemispheric Transcranial direct current Stimulation|"The session will start with the application of the with a couple of surface sponge electrodes (25-35 cm2) on the scalp. The treatment modality will be as follows:~Active tDCS: The anodic electrode will be put on affected M1. The cathodic electrode will be put on contralateral M1. We will apply a constant current of 2mA of intensity during 20 minutes while the patient performs the occupational therapy session."
45466151|NCT03452254|Device|Sham Bihemispheric Transcranial direct current Stimulation|"The session will start with the application of the with a couple of surface sponge electrodes (25-35 cm2) on the scalp. The treatment modality will be as follows:~Sham tDCS: We will use the same place and parameters of stimulation applied for the active group, but the stimulator will deactivate after 30 seconds of stimulation. This will ensure that the patient will feel the initial tingling sensation at the beginning of the tDCS which is a requisite for blinding. The occupational therapy session will last one hour."
45466152|NCT03452254|Other|Modified Constraint Induced Movement Therapy|"Both groups will perform the mCIMT during a period of seven consecutive days. This protocol consists of two elements:~Restriction of the movements of the non-affected hand by wearing a mitt during six hours a day: we will use a mitt that limits the movement of the fingers but allows the free movements of the wrist, elbow, and shoulder.~Intensive and individualized training of the affected arm during 2 hours a day guided by an occupational therapist: the two hours training will be divided into two sessions of one hour each. Sessions will be organized in three blocks: preparation, activation, and function. In the third block, devoted to function, the patient has to choose one activity of daily living that he wants to improve."
45466153|NCT01231139|Drug|Paracetamol|Intravenous paracetamol, 1 gram (100mls), administered over 30 minutes (every 4 hours for 3 days).
46100964|NCT00662948|Drug|Ibritumomab tiuxetan|One dose of 90Y Ibritumomab tiuxetan, 0,4 mCi/Kg
45466154|NCT01231139|Drug|0.9% Sodium Chloride Schedule:|Identical placebo: 100mls saline given intravenous over 30 minutes (every 4 hours for 3 days)
45466155|NCT03382574|Biological|Denosumab|Given SC
45466156|NCT03382574|Procedure|Salpingo-Oophorectomy|Undergo risk-reducing salpingo-oophorectomy
45466157|NCT01137695|Drug|Pramlintide|120 mcg SQ three times daily for 6 months.
45466158|NCT01137695|Drug|Pramlintide|360 mcg SQ three times daily for 6 months
45680487|NCT00134030|Drug|Etoposide|Given IV
45680488|NCT00134030|Drug|Ifosfamide|Given IV
45680489|NCT00134030|Drug|Methotrexate|Given IV
45837838|NCT05711862|Drug|SUVO|Participants will receive 20mg of SUVO for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
45466159|NCT01137695|Drug|Pramlintide|120 mcg SQ three times daily for 6 months
45466160|NCT01137695|Drug|Pramlintide|360 mcg SQ three times daily for 6 months
45466161|NCT02932501|Procedure|Conservative treatment|Disinfectant mouth rinses, Antibiotic therapy, Antifungal therapy
46100965|NCT00511147|Biological|IGIV3I Grifols 10%|IGIV3I Grifols 10% 1 g/kg/day given on two consecutive days, Day 1 and Day 2, for a total dose of 2 g/kg over two days.
46100966|NCT04153058|Procedure|Robotic Assisted AEG Radical Gastrectomy|Robotic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
45680490|NCT00134030|Biological|Peginterferon Alfa-2b|Given subcutaneously
45680491|NCT00134030|Other|Quality-of-Life Assessment|Ancillary studies
45680492|NCT00134030|Other|Questionnaire Administration|Ancillary studies
45680493|NCT00134030|Procedure|Therapeutic Conventional Surgery|Undergo amputation or limb salvage surgery
45680494|NCT00114101|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
45680495|NCT00114101|Other|Laboratory Biomarker Analysis|Correlative studies
45680496|NCT00114101|Drug|Lenalidomide|Given PO
45680497|NCT00114101|Drug|Melphalan|Given IV
45466162|NCT02932501|Procedure|Surgical treatment|Superficial debridement, Complete removal of necrotic bone, Complete bone resection, When applicable revision and soft tissue coverage
45466163|NCT02932501|Procedure|Adjuvant non-surgical treatment|Hyperbaric oxygen therapy Pentoxifylline and tocopherol Ozone therapy Low level laser therapy Pain relief Anti-inflammatory treatment Platelet rich plasma Parathyroid hormone and teriparatide Bone morphogenetic protein
45466164|NCT03451396|Drug|Lifitegrast|All subjects meet dry eye inclusion and will be treated with Lifitegrast gtts BID
45466165|NCT01231217|Other|Green tea (Camellia sinensis)|Patients are recommended to drink at least 5 cups of green tea per day
45466166|NCT01231217|Other|Coffee|Patients are recommended to drink as much coffee as they tolerate.
45466167|NCT03450694|Device|ultrasound|ultrasound is a non-invasive and not expensive method, availiable at almost all institutions.
45466168|NCT03632096|Radiation|Photobiomodulation|The parameters are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.
45466169|NCT03632096|Radiation|Sham|The sham group will have a simulation of laser application, following the same procedures as the active group, but with the device switched off.
45466170|NCT05322460|Other|CUMACA-M Program|The CUMACA-M Program will focus on a web-based tailored intervention, using artificial intelligence, for Long-Term Survivors of Breast Cancer. It will be structured into modules related to the specific needs of LS-BS, including physical, psychological, and social needs
45680498|NCT00114101|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
46016616|NCT04321863|Other|Serum and faecal zinc|Blood sample for serum zinc will be taken at same time as routine (standard of care) monitoring bloods which include CRP - no additional venipuncture will be required. A single stool sample will be sufficient to measure FC (as outlines above) and faecal zinc. This study will compare the ability of serum/faecal zinc and CRP at predicting relapse in patients with quiescent (inactive) luminal (affecting the small and/or large bowel) CD.
45466171|NCT05625295|Other|data collection protocol in clinical history|collection of data from the clinical history according to the established protocol
45680499|NCT00114101|Other|Placebo Administration|Given PO
45680500|NCT01382446|Drug|Chlorhexidine gluconate|0.12% Chlorhexidine Gluconate 15ml Twice Daily, administered via toothbrushing and swabbing teeth, tongue, gingiva, and oral mucosa.
45680501|NCT01382446|Other|Toothpaste|Brushing the teeth, tongue, gingiva, and oral mucosa twice daily with toothbrush and toothpaste.
46016617|NCT04321707|Radiation|15O-H2O PET/MR|All included patients will have a 15O-H2O PET/MR scan performed at baseline and a scan performed after NAC, prior to cystectomy.
46016618|NCT04321083|Diagnostic Test|INVOS|INVOS monitoring brain o2 saturation
45837839|NCT05711862|Drug|Placebo|Participants will receive 0mg of placebo for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
45680502|NCT01382212|Drug|paricalcitol|Paricalcitol soft capsule. Starting dose of paricalcitol was determined by the intact parathyroid hormone (iPTH) value (iPTH/120) from prior to Day 1, rounded down to the nearest whole number, not to exceed 16 µg 3 times weekly, no more frequently than every other day. Decisions to hold, maintain, increase, or decrease a dose were based on the iPTH, phosphorus, and calcium results generated from the most recent visit and within target Kidney Dialysis Outcomes Quality Initiatives (KDOQI) levels.
46016619|NCT04321161|Drug|Bicanorm|"Treatment of patients with relapsed AML after allo-HCT receiving DLIs with Bicanorm (1-1-1) for 7 days.~sodium hydrogen carbonate (1 g per 1 tablet) = sodium ion (11,9 mmol per 1 tablet) = sodium ion (273 mg per 1 tablet) = hydrogen carbonate ion (11,9 mmol per 1 tablet)"
46016620|NCT04207125|Behavioral|Multilevel psychotherapeutic intervention programme|"Part 1: Educational Training and Mentoring After transferring the patient from the intensive care unit to the transplant surgery unit, nurses are planning a nursing diagnosis called therapy recommendations and coping strategies, effective implementation. 3 days after the transfer, nurses start to give information twice a day (morning and evening) about the medication, which the patients are currently taking. The nurse is also handing out a folder, which contains information about the multilevel intervention programme.~Individual Treatment Approach Patients, who seem to be non-adherent during their outpatient follow-ups, are contacted through the co-investigators for a one-to-one session. The content of this session is to promote patients engagement in self-management of their chronic illness. The goal of the treatment is to improve the individual's ability to manage symptoms, treatments, physical and psychosocial consequences and lifestyle changes."
46016621|NCT04320771|Drug|Neladenoson bialanate (BAY 1067197)|10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
46016622|NCT04320693|Drug|IMMU-132|IMMU-132 will be administered as an intravenous infusion on Days 1 and 8 of 21-day treatment cycles
46016623|NCT05527977|Behavioral|Compensation Incentives to improve Clinical Documentation|"The investigators have identified six Diagnoses of Interest for the initiative. For each Diagnosis of Interest, the investigators have specified a series of clinically significant diagnostic details. Each physician will receive a compensation bonus from a pool of $20,000 based on the absolute number of times that he or she appropriately documented a Diagnosis of Interest.~The investigators will use SQL Server Management Studio 18.0 to create an initial dataset using ICD-10 codes from office visits during which a Diagnosis of Interest was addressed. The investigators will compare documentation during the 12-week against a 6-week period prior to the intervention. The 6-week period will not be used to determine compensation bonuses. Two blinded research assistants will review H&P's and progress notes from extracted visits to tabulate the number of times that clinical documentation met expectations."
45680503|NCT01381900|Drug|Placebo|Form=capsule, route=oral administration. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
46016624|NCT05555433|Other|NO INTERVENTION|no intervention
46016625|NCT05554107|Other|Training program|A 16-week training program consisting of 2-3 visits per week, and 60 minutes per visit. The program will be done as group exercise under supervision from physiotherapists and/or physicians with special interest in POTS.
46016626|NCT00624039|Other|UBM with pilocarpine in presbyopia|ultrasound biomicroscopic examination in both eyes 30 minutes after one drop of 2% pilocarpine hydrochloride (Ocucarpine®, Samil Pharm., Seoul, Korea) instillation before and two months after cataract surgery
46016627|NCT05523141|Drug|ASC10|"Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo for 5.5 days, in an double-blind manner~Part 2:~Two single oral doses of ASC10 will be administered to participants, in an open-label manner"
46016628|NCT05523141|Drug|Placebo|"Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo, in an double-blind manner"
46016629|NCT01304706|Drug|Fluocinolone Acetonide|0.2 μg/day
46016630|NCT05509023|Drug|ADX-914|Subcutaneous administration of ADX-914
45466172|NCT05024864|Diagnostic Test|Urea breath test|"After fasting for six hours prior to testing, the patient swallows a C13 Urea tablet or solution and waits. After 10 minutes, the patient exhales and breath is collected (breath bag). The production of 13CO2 is measured by a desktop analyzer (infrared mass spectrometry) and active H. pylori infection diagnosis is made based on previously established cut-off levels for H. pylori infection. In patients tested positive, eradication therapy according to the national society of gastroenterology guidelines will be prescribed at the caring physician's discretion.~Control of successful H. pylori eradication 6 weeks after completed eradication therapy is recommended to the treating physician."
45466173|NCT05321836|Other|Glucosamine Chondroitin|control group
46016631|NCT05509023|Drug|Placebo|Subcutaneous administration of Placebo
45680504|NCT01381900|Drug|Canagliflozin 100mg|Type=1, unit=mg, number=100, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
46016632|NCT05661240|Device|Tumor treating fields（EFE-P100）|Device: Tumor treating fields（EFE-P100） Subjects will use EFE-P100 until disease progression or for a maximum of 24 months.
45466174|NCT05321836|Combination Product|glucosamine chondritin & Physiotherapy|experimental group
45466175|NCT05617573|Procedure|Total knee arthroplasty due to advanced osteoarthritis.|Postoperative usage of intravenous methylprednisolone
46016633|NCT05661240|Drug|Docetaxel injection|Drug: Docetaxel injection Subjects will receive Docetaxel injection until disease progression or for a maximum of 24 months.
45466176|NCT02528825|Drug|Remifentanil titration|Initial concentration being 1.5ng/ml for the first patient The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
45466177|NCT03363321|Biological|PF-06741086|PF-06741086 subcutaneous injection
45466178|NCT05321680|Other|Treatment withdrawal|Tapering or suspension of antidementia drugs
46016634|NCT05506683|Other|MotoMeds pediatric telemedicine and medication delivery service (TMDS)|The intervention is use of a pediatric TMDS. Eligible children experiencing acute illness are examined over the phone by EMTs who follow a set of clinical guidelines to triage, assess, and develop treatment plans for participants. To evaluate the TMDS and as a safety measure EMTs will also examine most participants in-person a their homes following the phone exam.
46016635|NCT05661162|Device|CR 500™ SINGLE-DOSE GEL|CR 500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to attenuate the physiological degeneration of cartilage typical of osteoarthritic processes. The presence of sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility
46016636|NCT05464719|Drug|Loncastuximab Tesirine|Given by IV
46016637|NCT04324866|Diagnostic Test|Nasopharyngeal swab|Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection
46016638|NCT00624117|Behavioral|Progressive exercise|home-based exercise program, 2 to 3 exercise sessions per week
46016639|NCT05376345|Biological|LCAR-BCDR cells product|Before treatment with LCAR-BCDR cells, subjects will receive a conditioning regimen
46016640|NCT05371041|Device|Medtronic Percept Neurostimulator|This is a deep brain stimulator that can also record brain signals and deliver stimulation through a control algorithm based on brain activity.
46016641|NCT05370651|Device|BTL Emsella Chair|Subjects will sit on the device. The RNC will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased until the subject reaches 100%.
45466179|NCT04908709|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo sMRI
46100967|NCT04153058|Procedure|Laparoscopic Assisted AEG Radical Gastrectomy|Laparoscopic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
45466180|NCT04908709|Device|Proton Therapy|Target volume treatment
45466181|NCT01233245|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
46016642|NCT02889003|Drug|Pioglitazone + TKI|
46016643|NCT01303380|Drug|Canakinumab|
46016644|NCT01008553|Drug|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
46016645|NCT01008553|Drug|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
46016646|NCT05647005|Other|Classical music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. Sessions will be in the form of listening to classical music for 30 minutes after the babies are fed.
46100968|NCT00663104|Behavioral|exercise|exercise: 3 joint sessions/week for 12 months
46100969|NCT00663104|Behavioral|exercise + cimicifuga racemosa|exercise: 3 sessions/week for 12 months,cimicifuga racemosa (40 mg/d)
45466182|NCT02864563|Procedure|Blood sampling|"Blood sample at diagnosis to evaluate MYCN amplification in plasma.~In case of NB with a MYCN amplification, blood samples are also collected during treatment and follow-up."
45466183|NCT03776812|Drug|Relacorilant, 100mg QD|Relacorilant is supplied as capsules for oral dosing
45466184|NCT03776812|Drug|Nab-paclitaxel, 80mg/m^2|Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle
45466185|NCT03776812|Drug|Nab-paclitaxel, 100mg/m^2|Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle
45466186|NCT03776812|Drug|Relacorilant, 150mg QD|Relacorilant is supplied as capsules for oral dosing
45466187|NCT03361605|Drug|Propofol|Propofol administration
45466188|NCT03916757|Biological|V-Boost|Open label setting
45466189|NCT03792685|Other|Normo-carbohydrate meal intake|Subjects are going to receive the normo-carbohydrate meal.
45466190|NCT03792685|Other|High-carbohydrate meal intake|Subjects are going to receive the high-carbohydrate meal.
45466191|NCT03792685|Other|High-fat meal intake|Subjects are going to receive the high-fat meal.
45466192|NCT03792685|Other|High-protein meal intake|Subjects are going to receive the high-protein meal.
46016647|NCT05647005|Other|Harp music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. Sessions will be in the form of listening to harp music for 30 minutes after the babies are fed.
46100970|NCT00663104|Behavioral|wellness control, placebo|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months, placebo
46100971|NCT00672464|Drug|Olanzapine|Olanzapine zydis 15 mg QHS for 28 days
46016648|NCT05226663|Procedure|Computed Tomography|Undergo [18F]FFT PET/CT
45466193|NCT03758326|Other|Body App|Participants will indicate areas of concern on a virtual manikin using an electronic online interface. Body measurements will also be collected.
45466194|NCT05193903|Behavioral|Simulation|The participants in the intervention group receive two interactive simulations in addition to a general text module that provides sequential, animated information on the spread of the virus without prevention, the effectiveness of vaccination and potential side effects of vaccination on a herd protection level and the individual level.
45466195|NCT05193903|Behavioral|Text|"The participants in the control group receive two text-based information in addition to a general text module that provides information on the spread of the virus without prevention, the effectiveness of vaccination and potential side effects of vaccination on a herd protection level and the individual level.~Both conditions ensure the provision of a level of knowledge that at least corresponds to standard care."
46100972|NCT00672464|Drug|Metformin|Metformin capsules will be started at 500 mg twice a day (before breakfast and before dinner) for days 1-3, then 500 mg before breakfast and 1000 mg before dinner for days 4-7, and then 1000 mg twice a day thereafter.
46100973|NCT00672464|Drug|Simvastatin|Simvastatin will be started at 10 mg at bed time for the first week and 20 mg at bedtime thereafter.
46100974|NCT02701595|Drug|Amoxicillin|amoxicillin 1500 mg x3/day (for patients ≤70kg) or 2000 mg x3/day (for patients >70kg)
45466196|NCT05416970|Behavioral|SUPERIMPOSED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) LIFESTYLE CHANGES|To assess the impact of the SARS-CoV-2 spread related lifestyle changes on body composition analysis and metabolic syndrome components worsening as well as hepatocellular carcinoma occurrence.
45466197|NCT05321446|Device|GoHand(TM)|The GoHand(TM) is a therapeutic wearable that provides positive auditory feedback when the wrist and hand moves optimally during execution of dexterity tests and everyday movements.
45466198|NCT03794167|Drug|Busulfan|busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6
45466199|NCT03794167|Drug|Cyclophosphamide|cyclophosphamide 50mg/kg/day i.v. on days -3 and -2
46016649|NCT05226663|Radiation|Fluorine F 18 Fluorthanatrace|Given IV
46016650|NCT05226663|Procedure|Positron Emission Tomography|Undergo [18F]FFT PET/CT
46016651|NCT00623454|Behavioral|Cognitive behaviour therapy|Three hours with cognitive therapy focusing on the chest pain and palpitations.
45466200|NCT03794167|Drug|Etoposide|etoposide 400mg/m2 day i.v. on days -5 and -4
46016652|NCT05141877|Drug|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
46016653|NCT05141877|Drug|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
46016654|NCT05137041|Device|ITP FIRTECH|Infrared Therapy Patch
46100975|NCT02701595|Procedure|Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin|Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin
46100976|NCT00668642|Drug|Dutasteride|0.5 mg capsule given orally on daily basis
46100977|NCT00668642|Drug|Placebo|Identical placebo
45837840|NCT05708183|Dietary Supplement|Multiple micronutrient supplementation (MMS)|Ethiopia will distribute the UNIMMAP (United Nations International Multiple Micronutrient Antenatal Preparation) formulation that includes 30mg iron. The supplement contains 15 essential vitamins and minerals including: Retinol (Vitamin A-acetate) 800 μg; Vitamin E (as vitamin E-acetate) 10 mg; Vitamin D (as Cholecalciferol) 200 IU; Vitamin B1 (Thiamine mononitrate) 1.4 mg; Vitamin B2 (As Riboflavin) 1.4 mg; Vitamin B3 (As Nicotinamide) 18 mg; Vitamin B6 (as Pyridoxine 1.9 mg; Vitamin B12 (as Cyanocobalamin) 2.6 mg; Folic Acid 400 μg; Vitamin C (As Ascorbic Acid) 70 mg; Iron (As ferrous sulphate) 30 mg; Zinc (As zinc sulphate) 15 mg; Copper (as Copper Sulphate) 2 mg; Selenium (as Sodium selenite) 65 μg; Iodine (as Potassium Iodate) 150 μg.
45466201|NCT03794167|Drug|Melphalan|melphalan 50mg/m2/day i.v. on days -3 and -2
45466202|NCT05332821|Drug|PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|PD-1/PD-L1 inhibitors: atezolizumab, sintilimab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, toripalimab, durvalumab, penpulimab, and other ICIs; VEGF-TKI/bevacizumab: sorafenib, lenvatinib, donafenib, apatinib, anlotinib, bevacizumab/ bevacizumab biosimilar, and other anti-angiogenesis drugs; Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs only include marketed drugs but are not limited to HCC approval.
45466203|NCT05332821|Procedure|TACE|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);
46100978|NCT01565629|Behavioral|Computer assisted cognitive behavioral therapy.|Those who choose to participate will be required to attend 4 assessments - pre-treatment (week 0), mid-treatment (week 8), post-treatment, and a 4th assessment for a 3 month Follow-up. All children regardless of condition will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
46016655|NCT05014503|Other|Adaptive Therapeutic gaming|All children will be asked to use the adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
45680505|NCT01381900|Drug|Canagliflozin 300mg|Type=1, unit=mg, number=300, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
46100979|NCT00668720|Device|transcranial magnetic stimulation (Magstim rapid2)|Neuronavigated rTMS will be applied bilaterally to the auditory cortices, which will be identified through a structural MRI scan. Stimulation will be performed with 1 Hz frequency and an intensity of 110% motor threshold for 2000 stimuli (32 minutes) on each side, on five subsequent days.
46100980|NCT00668720|Device|sham stimulation|The official sham stimulator for the magstim rapid2 will be used. Sham stimulation will follow the same placement protocol and will also last 2x32 minutes on five subsequent days
45680506|NCT01381900|Drug|Metformin|The participant's stable dose of background therapy of metformin should be continued throughout the study.
46100981|NCT00668876|Dietary Supplement|Oral IMPACT|oral supplementation for 5 days(1 L/d )before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
46100982|NCT00668876|Dietary Supplement|Oral IMPACT|postoperative enteral infusion of the formula with arginine, omega-3 fatty acids, and RNA
45466204|NCT05462171|Diagnostic Test|Questionnaires|Participants will be asked to complete validated questionnaires (the five-item International Index of Erectile Function - IIEF-5, Premature Ejaculation Diagnostic Tool - PEDT, International Prostate Symptom Score - IPSS, Overactive Bladder - Validated 8-question Screener - OAB-V8, Hospital Anxiety and Depression Scale - HADS, Athens Insomnia Scale - AIS).
45466205|NCT01305031|Other|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-92%
45466206|NCT01305031|Other|100% oxygen|Use of 100% oxygen needed to achieve oxygen saturation in the preset limits 85-92%
45466207|NCT01231451|Drug|DMPA|All subjects will take DMPA
45466208|NCT05320900|Diagnostic Test|Chest auscultation|Chest auscultation data
45466209|NCT05401149|Drug|rt-PA|Recombinant Tissue Plasminogen Activator
45466210|NCT01233401|Other|Survey|Mothers and Other infant caregivers are surveyed at the end of the 2 week newborn well child visit about whether they chose to receive the Tdap vaccine at the pediatrician's office.
45466211|NCT05331651|Drug|Glycopyrronium in Combination With Tropisetron|Glycopyrronium (0.2mg) in Combination With Tropisetron (4mg) intravenously given at the ending of the surgery.
45680507|NCT01381900|Drug|Sulphonylurea|The participant's stable dose of background therapy of metformin plus sulphonylurea should be continued throughout the study.
45680508|NCT01744665|Drug|nilotinib|Nilotinib will be provided as 150 mg capsules. Patients will take nilotinib 300mg twice daily on study and dose modifications to 450mg once daily is permitted per protocol.
45680509|NCT03025126|Other|Multimedial Rehabilitation|
45680510|NCT03025126|Other|Usual care program|Usual care at home program according to healthcare professional's advice
46016656|NCT05014503|Other|Non-adaptive Therapeutic gaming|All children will be asked to use the non-adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
46100983|NCT00668876|Dietary Supplement|Parenteral nutrition|Parenteral nutrition
46100984|NCT02698553|Drug|Bupropion HCl XL tablet 150mg|The 150 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
46100985|NCT02698553|Drug|Bupropion HCl XL tablet 300mg|The 300 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
46100986|NCT00668954|Dietary Supplement|Pomegranate Juice|Group A drinks 8 oz. pomegranate juice/day for 12 weeks
46100987|NCT00668954|Dietary Supplement|Placebo Juice|Group B drinks 8 oz. placebo juice/day for 12 weeks
46016657|NCT04971915|Other|minimalist footwear|The intervention consists of wearing the minimalist footwear in recommended progression during the interventional period (6months). The intial load starts at 2,500 steps a day and will be gradually increased up according to the participant´s tolerance rate to the footwear wearing to fully use over the final period. Participants are instructed to report all issues and difficulties possibly connected to the intervention. There will be the opportunity to consult any issue connected with footwear or their wearing through the duration of the research.
46016658|NCT04901169|Drug|Angiotensin II|Infusion of Angiotensin II initiated if participants require norepinephrine at a rate of > 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
45680511|NCT05367232|Drug|ICP-033 tablet|Administered orally, once a day, 28 days per cycle
46016659|NCT04901169|Drug|Saline|Infusion of 0.9% saline initiated if participants require norepinephrine at a rate of > 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
46016660|NCT04896333|Other|Interaction and exposure with the Robot EBO|The participants will interact with the Robot EBO. The robot will be control by an operator that will conduct a dialogue. The dialogue will include questions related to the social, leisure, activities of daily living and informative areas.
46016661|NCT04885647|Drug|YPEG-rhEPO|YPEG-rhEPO，low dose，were subcutaneous injected once every two weeks for 13 weeks.
45680512|NCT04560933|Procedure|Blood sample collection|Blood sample collection
45680513|NCT01744197|Drug|Synera (lidocaine 70mg/tetracaine 70mg)|All subjects will receive 2 patch applications during this study: one Synera, one placebo. The 2 patch applications must be done on separate days. Only 1 patch will be used per application. Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second. Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.
45680514|NCT05369416|Other|Low sodium diet|Subjects will be started on a low sodium (food will be provided) for two weeks.
46016662|NCT04885647|Drug|YPEG-rhEPO|YPEG-rhEPO，low dose，were subcutaneous injected once every four weeks for 13 weeks.
46016663|NCT04885647|Drug|YPEG-rhEPO|YPEG-rhEPO, high dose，were subcutaneous injected once every two weeks for 13 weeks.
46016664|NCT04885647|Drug|YPEG-rhEPO|YPEG-rhEPO，high dose，were subcutaneous injected once every four weeks for 13 weeks.
46016665|NCT04724109|Drug|Equfina|Equfina oral tablets.
46016666|NCT04606407|Device|LungFit™|Patients will receive inhalations of 150 ppm for 40 min 4 times a day, up to 7 days (maximum 28 treatments)
46016667|NCT04565145|Drug|Kava Dietary Supplement|Participants will be given three 75mg kava capsules per day for one week
46016668|NCT04565145|Drug|Placebo|Participants will be given three placebo capsules per day for one week
45466212|NCT05331651|Drug|Normal Saline in Combination With Tropisetron|Normal Saline in Combination With Tropisetron (4mg) intravenously given at the ending of the surgery.
45466213|NCT05320744|Procedure|surgical extraction of impacted lower third molar|surgical removal of impacted third molar under local anesthesia.
45680515|NCT05369416|Other|high sodium diet|Subjects will be started on high sodium diet (regular diet supplemented with salt tablets to reach a daily intake of > 4200 mg/Day) for two weeks.
46016669|NCT04557501|Diagnostic Test|PSMA PET/CT guided intensification of therapy|PSMA PET/CT prior to treatment.
46016670|NCT04557501|Other|Control Arm|Control - Treatment without PSMA PET/CT
46016671|NCT02888847|Device|Philips Zoom! White Speed whitening lamp|bleaching protocol with descending built in light intensities
45466214|NCT01304251|Other|Short-term fasting|Short-term fasting, i.e. 24 hours before and 24 hours after administration of chemotherapy
45466215|NCT01304251|Other|Healthy nutrition|Eating according to the current guidelines for healthy nutrition as from 24 hours before until 24 hours after the beginning of administration of chemotherapy. Dietary instructions will be given by a dietician and actual food intake will be recorded in a journal.
45466216|NCT01134185|Drug|prucalopride|single oral dose of 2 mg prucalopride
45466217|NCT01134185|Drug|prucalopride|single oral dose of 2 mg prucalopride
45466218|NCT01134185|Drug|prucalopride|single dose of 2 mg prucalopride
45466219|NCT03797677|Device|MN 4000|Patients who required regular home airway clearance therapy were enrolled in the study and were prescribed therapy with the MN4000. Adherence to the prescribed therapy regimen and patient/caregiver satisfaction with the therapy was assessed. Pulmonary function, was assessed for each subject at baseline, after 1 month and after 3 months of home therapy. Results from the therapy period was compared to the baseline period, during which the subject received their regular airway clearance regimen. Airway Clearance Satisfaction surveys were conducted at baseline, after 1 month, and after 3 months of therapy. Results from the MN4000 therapy period were compared to the baseline period, during which the subject received their regular regimen
45466220|NCT05454293|Other|One Talk at a Time: Race|This intervention consists of short videos that include didactic modules and social modeling for having conversations with children about race, ethnicity, culture, and discrimination. The total intervention takes approximately 1.5-2 hours to complete online, and parents can move through the videos at their own pace.
45466221|NCT05454293|Other|One Talk at a Time: General|This intervention consists of short videos that include modules and handouts with tips for parent-child communication strategies for navigating difficult topics, such as dating and current events.
46016672|NCT02888847|Device|Philips Zoom! Advanced power whitening lamp|bleaching protocol with high light intensity
45466222|NCT03829046|Drug|Placebo|12 weeks of treatment
45466223|NCT03829046|Drug|Evolocumab|12 weeks of treatment
45466224|NCT05320588|Drug|BIO-106|BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)
45466225|NCT05320588|Drug|Pembrolizumab|Programmed death receptor-1 (PD 1)-blocking antibody
45466226|NCT03797599|Behavioral|20 minutes of mindfulness practice|A 20 minute audio guided mindfulness of breathing practice per session, for four sessions.
45466227|NCT03797599|Behavioral|5 minutes of mindfulness practice|A 5 minute audio guided mindfulness of breathing practice per session, for four sessions.
45466228|NCT03797599|Other|5 minute audio book|5 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything') per session, for four sessions.
45466229|NCT03797599|Other|20 minute audio book|20 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything'), per session, for four sessions.
45466230|NCT03797599|Other|25 minute audio book|25 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything'), per session, for four sessions.
45466231|NCT03361293|Device|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS) administered with a Neuroelectrics StarStim Enobio cap system (active mode)
45466232|NCT03361293|Behavioral|Cognitive training|BrainHQ Computerized cognitive training
45680516|NCT04565301|Drug|Dexamethasone|adductor canal block
46016673|NCT04533555|Genetic|Broad gene panel for young adult cancers|Genetic testing will occur using a broad gene panel for young adult cancers
46016674|NCT04533555|Genetic|Standard|Those in the standard group who are considered high risk will have genetic testing done using the standard of care panel as selected by their care provider.
46016675|NCT04320537|Other|abstinence from use of marijuana and other abused drugs|abstinence from use of marijuana use and other abused drugs
46016676|NCT04479267|Drug|Prednisone|Given PO
46016677|NCT04479267|Drug|Prednisolone|Given IV
46016678|NCT04479267|Drug|Methylprednisolone|Given IV
46016679|NCT04479267|Biological|Rituximab|Given IV
46016680|NCT04479267|Drug|Polatuzumab Vedotin|Given IV
46016681|NCT04479267|Drug|Cyclophosphamide|Given IV
46016682|NCT04479267|Drug|Doxorubicin Hydrochloride|Given IV
46016683|NCT04439799|Drug|Testosterone Cypionate 200 MG/ML|Participants in this group will receive intramuscular testosterone cypionate injections of 1 cc (200mg) once every 14 days for four months.
46016684|NCT04439799|Drug|Intranasal Testosterone|Participant in this group will receive Intranasal testosterone administered using a multi-dose dispenser, as two or three daily doses (5.5 mg per nostril, 11.0 mg single dose) for 4 consecutive months,
45466233|NCT03361293|Device|Sham tDCS|Sham Transcranial Direct Current Stimulation (tDCS) administered with a Neuroelectrics StarStim Enobio cap system (sham mode)
45466234|NCT01231529|Drug|GSK1349572|All subjects will receive a single dose of GSK1349572 50 mg. GSK1349572 is an experimental drug in the integrase inhibitor class being developed for the treatment of HIV infection. GSK1349572 is not approved by the FDA.
46016685|NCT04320459|Diagnostic Test|Bath Ankylosing Spondylitis Metrology Index (BASMI)|It characterises the spinal mobility of patients with ankylosing spondylitis. Cervical rotation, tragus-wall distance, lateral lumbar flexion, anterior lumbar flexion (modified schober), intermalleolar distance were measured. The total score of the 5 measurements was taken, the score range was 0-10, the low score meant that the spinal movement was better.
45466235|NCT05306704|Other|placebo Oil|participants will receive placebo(olive oil) orally in all visits from visit 1 to visit 4
45837841|NCT05708183|Dietary Supplement|Iron folate supplementation (IFA)|IFA delivered as part of routine antenatal care, according to current policy
46016686|NCT04320459|Diagnostic Test|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)|It assess the disease activity. It was evaluated with a 6-question questionnaire. After taking the answer of each question out of 10, the total of the points was calculated by dividing the number of questions.
46016687|NCT04320459|Diagnostic Test|Bath Ankylosing Spondylitis Functional Index (BASFI)|It assess functional status. It was evaluated with a 10-question questionnaire. After taking the answer of each question out of 10, the total of the points was calculated by dividing the number of questions.
46100988|NCT02698631|Procedure|Conventional AF ablation|"Conventional AF ablation will be carried out according to the standard procedure. Atrial anatomical MRI information will be integrated into the navigation system. Ablation procedure will be carried out with a Smart Touch® catheter (temperature 45 °C, 40W or 30W for anterior or posterior wall, respectively).~Both in first and re-do procedures, procedure endpoint will be electrical isolation of all pulmonary veins."
45466236|NCT05306704|Drug|25-Hydroxyvitamin D|Participants will receive vitamin D (100000IU) orally during all visits i.e. from visit-1 to visit-4
45680517|NCT04565301|Drug|neostigmine|adductor canal block
46100989|NCT02698631|Procedure|LGE-MRI guided AF ablation|"Post-processed LGE-MRI will be used to identify left atrial fibrotic patches and lesions surrounding pulmonary veins (re-do procedures). Both MRI atrial anatomical and fibrosis information will be integrated into the navigation system. Ablation procedures will be carried out with a SmartTouch® catheter (temperature 45°C, 40W or 30W for anterior or posterior wall, respectively).~Procedural end-point for first ablation procedures will be isolation of all pulmonary veins, and encirclement and isolation of all atrial fibrotic areas.~In re-do procedures, all left atrial fibrosis patches will be encircled and isolated and, for electrically non-isolated pulmonary veins, all anatomical gaps in lesions surrounding pulmonary veins (as identified in LGE-MRI) will be closed."
45680518|NCT04565301|Other|NaCl solutions|adductor canal block
45680519|NCT01732107|Drug|Dovitinib|Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule. Day 12 assessments are intended to be performed on the last dosing day of the 2nd week in cycle 1 and cycle 2 and day 26 assessments are intended to be performed on the last dosing day of the 4th week in cycle 1 and cycle 2.
45680520|NCT01743027|Drug|AL-4943A ophthalmic solution|
45680521|NCT01743027|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2%|
45466237|NCT01233479|Drug|systemic chemotherapy|
45466238|NCT01233479|Other|laboratory biomarker analysis|
45466239|NCT01233479|Procedure|therapeutic surgical procedure|
45466240|NCT01233479|Radiation|radiation therapy|
45466241|NCT03792529|Other|detect gene mutations of ctDNA and ctRNA|Samples were collected from patients at baseline, during therapy and after disease progression, and gene mutations of ctDNA and ctRNA were detected in the samples.
45466242|NCT03709095|Other|Sprint interval training|Participants utilized the arm ergometer for improving aerobic exercise capacity
45466243|NCT03709095|Other|moderate intensity continuous training|Participants utilized the arm ergometer for improving aerobic exercise capacity
45680522|NCT01743027|Drug|Olopatadine hydrochloride ophthalmic solution, 0.1%|
45680523|NCT01743027|Drug|AL-4943A ophthalmic solution vehicle|
45680524|NCT01380730|Biological|Evolocumab|Administered by subcutaneous injection
45680525|NCT01380730|Other|Placebo to Evolocumab|Administered by subcutaneous injection
45680526|NCT05364034|Other|Urban Afforestation Intervention Program|An afforestation intervention program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
45466244|NCT00238550|Drug|Cannabis based medicine extract (CBME)|
46016688|NCT04320459|Diagnostic Test|Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)|"It evaluates quality of life. Each statement on the ASQoL (18-item) is given a score of 1 or 0. A score of 1 is given where the item is affirmed, indicating adverse QoL. All item scores are summed to give a total score or index. Scores can range from 0 (good QoL) to 18 (poor QoL)."
46016689|NCT04320459|Diagnostic Test|Toronto Alexithymia Scale-20 (TAS-20)|It assess alexithymia. It is a 20 item questionnaire and each item is evaluated in a Likert type scale with five intervals (1= strongly disagree, 5=strongly agree). The total alexithymia score is the sum of responses to all 20 items, while the score for each subscale factor is the sum of the responses to that subscale. The TAS-20 uses cutoff scoring: equal to or less than 51 = non-alexithymia, equal to or greater than 61 = alexithymia. Scores of 52 to 60 = possible alexithymia.
46016690|NCT04320459|Diagnostic Test|Beck's Depression Inventory (BDI)|It assess depression status. It is a 21-question multiple-choice self-report inventory, each set is ranked in terms of severity and scored from 0 to 3 with a total summed score range of 0-63. Higher scores indicate greater depressive severity. Conventional cutoffs are 0-9 for normal range, 10-18 for mild to moderate depression, 19-29 for moderate to severe depression, and 30-63 for severe depression.
45466245|NCT01231685|Drug|Raltegravir|Subjects will maintain their nucleoside backbone and switch ritonavir-boosted protease inhibitor to Raltegravir 400 mg po BID for 48 weeks.
45466246|NCT01231685|Drug|Ritonavir-boosted protease inhibitor|Subjects will maintain their nucleoside backbone and remain on a ritonavir-boosted protease inhibitor at standard doses for for 48 weeks
45466247|NCT03632486|Other|Bedside Ultrasound|"Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck.~Lung ultrasound to assess for pleural effusions and sonographic b lines."
46016691|NCT02888769|Behavioral|Text Messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). Non-smokers will receive two general messages, two hypertension messages, one medication adherence message and one physical activity message per week. Smokers will receive one general message, two hypertension messages, one medication adherence message, one physical activity message and one smoking cessation message per week. Prior to study commencement, a bank of 280 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
46016692|NCT05523531|Other|Self-administered questionnaires|"Neuropathic Eye Pain Questionnaire~5-item Dry Eye Evaluation Questionnaire (DEQ-5)~Visual Impact Assessment Questionnaire~Concise Ophthalmic Pain Questionnaire~Questionnaire to evaluate the effectiveness and tolerance of treatments~Chronic pain questionnaire"
46100990|NCT02629562|Biological|B12019 and Neulasta|GCSF, Growth Colony Stimulating Factor
46100991|NCT04215263|Other|Questionaire|Patient was assessed using mini international neuropsychiatric interview
45466248|NCT03797287|Device|Tensor Tunnler|Create the bone tunnels during the arthroscopic rotator cuff repair procedure
45680527|NCT04010968|Drug|venetoclax and ibrutinib (I+VEN)|"The treatment will start with ibrutinib alone for 3 months (lead-in phase) from Month 1 to Month 3 and then venetoclax will be added from Month 4 with an initial ramp-up period.~The total duration of treatment with (I+VEN) will depend on the response achieved at Month 9:~if BM MRD at M9 < 0.01%, the treatment with (I+VEN) will be continued for 6 additional months until Month 15 and stopped then. MRD will be assessed at Month 15 (PB), Month 21 (PB) and Month 27 (PB and BM)~if BM MRD at M9 ≥ 0.01%, the treatment with (I+VEN) will be continued for 18 additional months until Month 27 and stopped then, whatever the results of MRD assessments that will be performed at the same time points as above."
46016693|NCT05523531|Procedure|Bilateral ophthalmologic examination|"Examination of the ocular surface and eyelids Slit lamp with fluorescein instillation: Oxford scheme and Break-up time, Schirmer's test, Oxybuprocaine test~Lipiview® test~Examination of corneal sensitivity with the Cochet-Bonnet esthesiometer~In vivo morphological examination of the subepithelial nerve plexus of the cornea by confocal microscopy"
46016694|NCT04320303|Biological|expanded NK cells|Donor derived expanded NK cells were infused to patients at around days 20±3d, and 27±3d post transplantation.
46100992|NCT00510835|Procedure|Early Goal Directed Therapy (EGDT)|Subjects will have a CVC inserted for continuous monitoring of their CVP and Scv02. Early structured treatment will be provided based on subjects' CVP, mean arterial pressure (MAP) and Scv02 measurements.
46016695|NCT04141761|Dietary Supplement|Visbiome|This group will receive Visbiome probiotic in powder form.
46016696|NCT04141761|Other|Placebo|This group will receive a placebo in powder form.
46016697|NCT04121169|Drug|IM-01|Antibodies react with C. difficile toxin, C. difficile bacteria and spores; neutralizes the toxin and inhibit the growth of spores and vegetative forms of C. difficile
46016698|NCT04119687|Biological|FX201|FX201, humantakinogene hadenovec, is a novel interleukin-1 receptor antagonist (IL-1Ra) gene therapy for IA administration that is being developed for the treatment of patients with OAK.
46016699|NCT04066959|Behavioral|Motivational Enhancement System (MES)|MES is a brief eHealth intervention delivered via an internet-based software application. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. The goal of MES is to increase motivation to complete daily diabetes care tasks. MES consists of two 20-minute sessions that integrate psychoeducation with motivation-enhancing therapeutic exercises and behavioral goal setting.
46016700|NCT04066959|Behavioral|Question Prompt List (QPL)|A QPL is a list of questions related to the physical and psychosocial aspects of diabetes and treatment that youth may want to ask their physicians during a clinic visit. The theoretical foundation for the QPL resides in social-cognitive theory which posits that behavioral performance is a function of self-efficacy and behavioral expectations. Thus, the goal of a QPL is to increase self-efficacy and active participation in clinical care. QPL is completed within 14-days of a diabetes clinic visit and results in a personalized set of questions for youth to bring to their clinic visit.
46016701|NCT04066959|Behavioral|Text Message Reminders (TXT)|TXT is a behavioral support strategy composed of one-way text message reminders to promote daily diabetes care task completion. TXT is supported by social cognitive theory which suggests that consistent task completion leads to perceptions of control and supports goal attainment. TXT may also foster a stronger relationship with diabetes care providers through greater communication and satisfaction. Youth will receive daily reminders to complete key diabetes care tasks.
46016702|NCT04021017|Drug|Estradiol Hemihydrate Transdermal System|Participants who have had their first period or have a bone age greater than or equal to 14 years will receive PrClimara® 25 (estradiol hemihydrate transdermal system - 25 mcg/day) as a weekly patch, for 24 months. Participants who have not yet had their first period and have a bone age below 14 years will receive an increasing dose of estrogen. These participants will be initiated on graduated dose of transdermal 17-β estradiol patches: 3.1 mcg/day (1/8 patch) for first six-months, 6.2 mcg/day (1/4 patch) for second six-months, 12.5 mcg/day (1/2 patch) for third six-months and 25 mcg/day (full patch) for final six-months.
46016703|NCT04323111|Procedure|metzenbaum's technique|surgical procedure for correction of caudal end nasal septal deviation
46016704|NCT03916185|Biological|RSV ΔNS2/Δ1313/I1314L Vaccine|10^6 plaque-forming units (PFU); administered as nose drops
46016705|NCT03916185|Biological|RSV 6120/ΔNS2/1030s Vaccine|10^5 plaque-forming units (PFU); administered as nose drops
45466249|NCT03797287|Procedure|Anchor Rotator Cuff Repair|The suture anchors (Smith and Nephew PEEK Helicoil Anchor) are inserted in bone and the sutures are then used to sew the tendons to bone arthroscopically.
45680528|NCT04010968|Drug|FCR|"All patients will receive 6 cycles of FCR administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6.~6 cycles of FCR will be administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6."
46016706|NCT03916185|Biological|RSV 276 Vaccine|10^5 plaque-forming units (PFU); administered as nose drops
46016707|NCT03916185|Biological|Placebo|Administered as nose drops
46016708|NCT04320069|Device|Omnipod Horizon™ Automated Glucose Control System|Omnipod Horizon™ Automated Glucose Control System use in Manual Mode
46100993|NCT00510835|Procedure|Protocolized Standard Care (PSC)|Routine equipment will be used to monitor subjects' blood pressure and oxygen levels. Early structured treatment is based on the subjects' systolic blood pressure and the study doctors' judgment of fluid status and perfusion status.
46100994|NCT00510835|Procedure|Usual Care (UC)|Attending physicians will provide routine care to subjects. Study measurements and treatments will be based on the physicians'/sites' standard practices.
46100995|NCT00663182|Drug|Entecavir|Entecavir 0.5 mg/d
45466250|NCT05402735|Diagnostic Test|Serum uric acid level|Serum uric acid level
45466251|NCT01305109|Biological|ORV 116E|Oral Rotavirus Vaccine 116E (ORV 116E), 10^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5mL at 4 week intervals
45466252|NCT01305109|Biological|Placebo|3 doses of 0.5 mL at 4 week intervals
45466253|NCT05280808|Device|Experimental phone app used for self-fitting of hearing aids|This software allows participants to set up hearing aids as appropriate for their hearing loss
45466254|NCT01138085|Drug|GSK1120212|MEK inhibitor
45466255|NCT01138085|Drug|GSK2141795|AKT Inhibitor
46016709|NCT03832257|Other|ECHO CT Intervention|weekly video conference between hospitalist and skilled nursing facilities
46016710|NCT03832257|Other|Matched Non-Participating Facilities|Matched Non-Participating Facilities
46016711|NCT03764553|Drug|Liposomal Irinotecan|Iv liposomal irinotecan
46016712|NCT03764553|Drug|Carboplatin|IV Carboplatin
46016713|NCT03764553|Drug|Capecitabine|PO Capecitabine
45466256|NCT05278858|Combination Product|MedJet Device with intralesional triamcinolone|A standard sterile disposable 5 ml syringe will be used to draw TAC using standard sterile protocol. This syringe will be attached to the Med-Jet along with a sterile barrel and disposable sterile tip. The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.1 ml of injected fluid). The optimal injection pressure used on the subject will start at 110 pounds per square inch (psi) and increased by 10 psi until a blanching wheal is observed. The optimal pressure will be recorded. The injections will be repeated multiple times at the optimal pressure until the targeted patch is completely treated.
45466257|NCT03361137|Drug|Emicizumab|Emicizumab via SC injection at a loading dose 3 mg/kg once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as the participant continues to derive sufficient benefit. Dosing was to be adjusted if the participant had a significant change in body weight.
45466258|NCT04817891|Device|HD-tDCS|Participants will receive HD-tDCS at up to 4 mA per channel for 20 minutes for 10 sessions. Dose determined through individualized computational models.
45466259|NCT03792217|Other|1.3% NaOCl|Endodontic irrigant
45466260|NCT03792217|Other|5.25% NaOCl|Endodontic irrigant
46016714|NCT03764553|Drug|Oxaliplatin|IV Oxaliplatin
46100996|NCT00616031|Drug|carboplatin|
45466261|NCT04800731|Other|observation no intervention|no intervention
46016715|NCT03764553|Drug|5-fluorouracil|IV 5-fluorouracil
46016716|NCT03764553|Drug|Leucovorin|IV Leucovorin
46100997|NCT00616031|Drug|nitroglycerin|
46100998|NCT00616031|Drug|paclitaxel|
46100999|NCT02629406|Other|Hypoxia|Intermittent hypoxia which consist of five hypoxic periods (13% O2 inspired fraction of oxygen) each lasting 6 min, with five normoxic intervals of same duration
46016717|NCT04319991|Dietary Supplement|Probiotics product|This Probiotics product is a supplement containing several types of probiotics and prebiotics which has been marketed for years in Taiwan. Each sachet contains 3 grams granule. Take 1 sticks 3 times per day with or without water before meals.
46016718|NCT04320225|Drug|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d )
46016719|NCT04320147|Device|Artemia|Before prostate biopsy, all patients be preceded by mpMRI.MR-targeted biopsy using Artemis device fusion of MRI and ultrasound images would be performed. MR targeted biopsy would be performed by radiologist.
46016720|NCT02888925|Other|Mooney test|
46016721|NCT02888925|Other|Benton Face Recognition test|
46016722|NCT02888925|Other|Face inversion effect test|
46016723|NCT02888925|Other|Face composite effect test|
46016724|NCT02888925|Other|Cambridge Face Memory Test|
46016725|NCT02888925|Other|Matching different view test|
46016726|NCT02888925|Other|Memorizing and recognition of new faces test|
46016727|NCT02888925|Other|Memorizing and recognition of new objects test|
46016728|NCT02888925|Other|Recognition of celebrities and access to semantic information test|
45680529|NCT01395784|Drug|pioglitazone|A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
45680530|NCT01380184|Drug|ridaforolimus|4 enteric-coated tablets, each containing 10 mg ridaforolimus, orally (total daily dose: 40 mg)
45680531|NCT01395394|Drug|Kuvan|Participants in the BH4 Non-Responder group will be given a 20 mg/kg body weight/day dose of Kuvan to take on a daily basis for two weeks. The last dose will be administered at the participant's study visit 2.
45680532|NCT01395394|Other|Meal Challenge|At each study visit, patients will receive a meal high in polyunsaturated fats that will promote a transitory increase in oxidative stress measures and endothelial dysfunction
45680533|NCT05362552|Other|Urban Afforestation Program|An afforestation program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
45680534|NCT00002826|Drug|paclitaxel|
45680535|NCT00002826|Drug|valspodar|
45680536|NCT01395316|Drug|Alemtuzumab|10 mg/ml alemtuzumab intravenous infusion, sterile clear, colorless solution. dosage: 2 cycles. Month 0 dosed over 5 consecutive days: month 12 dosed over 3 consecutive days.
45680537|NCT04331938|Drug|Regional anesthetic SPG block-bilateral|Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion on each side (5 mL on each side)
46016729|NCT02888925|Procedure|Lobectomy|In patients with anterior temporal epilepsy, at 6 to 12 months after inclusion, depending on surgery decision taken after pre-surgery conventional intercritical assessment
46016730|NCT03221751|Drug|prazosin hydrochloride|Prazosin is an oral capsule identical in appearance to prazosin capsules titrated in the same manner as prazosin.
46016731|NCT03221751|Drug|placebo|Prazosin is an oral capsule identical in appearance to prazosin capsules titrated in the same manner as prazosin.
46016732|NCT03219177|Behavioral|Patient education regarding indications for opioid use and side effects of opioid use after hand surgery|Patients in the active education group will be given information pre-operatively on the current opioid epidemic, alternative pain management strategies that should be tried before proceeding to prescription opioid use, appropriate indications for opioid use, and side effects of opioids.This information will be reinforced by the research coordinator and nursing staff in the post-anesthesia care unit.
46016733|NCT03219177|Other|Standard of care post-operative counseling|Patients will receive standard of care post-operative counseling. They will not be given pre or post-operative opioid education.
46016734|NCT05608941|Other|Respiratory muscle training|The training program will be carried-out with the Orygen Dual Valve. Individuals will perform a home-based intervention, split into two daily 20-min sessions (morning and afternoon), totaling 40 min per day, seven times a week, during eight weeks. Each daily session will be composed into four blocks of three minutes, with a two-minute rest between blocks. The initial training load for each participant will be set at 60% of his/her maximal baseline MIP and MEP for both inspiratory and expiratory strength training, respectively. Borg score of dyspnea and effort was also considered for adjusting training intensity, and scores from 4 to 6 were targeted. Once a week, a trained researcher will visit their homes, the MIP and MEP will be evaluated and the training load will be progressed to ensure that 60% of the new pressure values are maintained.
46016735|NCT05608941|Other|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring.
46016736|NCT01302834|Biological|cetuximab|400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks
45466262|NCT03782558|Procedure|Surgical transection of transverse ligament|Standard therapy for CTS. An incision is made at the base of the palm of the hand. Then the transverse ligament is cut, which releases the compression of the median nerve and improves the symptoms.
46016737|NCT01302834|Drug|cisplatin|100 mg/m2 IV on days 1 and 22 of IMRT
46016738|NCT01302834|Radiation|IMRT|35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.
46016739|NCT02866071|Drug|Ketamine Hydrochloride|50mg IN Ketamine Hydrochloride
46016740|NCT02866071|Drug|Placebo-Comparator|50mg IN Placebo
46016741|NCT05507775|Drug|Digoxin tablet|"Participants will be treated with digoxin tablets for 3 weeks. On the first they, participants will start with a starting dosage of 3x0.25mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.25mg. Participants aged >70 years or with body weight <55kg will initiate a starting dosage of 3x0.125mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.125mg.~After one week the blood concentration of digoxin will be measured. According to this blood concentration, the dose of digoxin will be adjusted."
46016742|NCT02888613|Procedure|mini laparotomy|The patient will be positioned supine. After induction of general anesthesia, a median umbilical incision will be performed. The average length of the incision of the laparotomy will be 10 cm (8-12 cm). The small intestine will be then mobilized medially and held by an orthostatic retractor. Arterial dissection and control as well as bypasses will be performed according to the conventional technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft.
45466263|NCT05624983|Diagnostic Test|acoustic otoemisions|TOAE and DPOAE
45466264|NCT05624983|Diagnostic Test|Otoscopy|presence of earwax checked by video otoscop
45466265|NCT05624983|Diagnostic Test|Audiometry|Hearing Threshold will be measured with the AD528 interacoustics
45466266|NCT05624983|Diagnostic Test|Tympanometry|Tympanic mobility will be measyred with the Titan interacoustics
45466267|NCT04798859|Other|Family centered in-home rehabilitation|Goal-oriented individualized intervention targeting brain injury related areas noted as challenging by the child and family
45466268|NCT04798859|Other|Control|Usual follow-up in the municipality
45466269|NCT03360747|Drug|AKCEA-ANGPTL3-LRx|AKCEA-ANGPTL3-LRx at dose 20 mg, administered via SC injection QW.
45466270|NCT04668794|Procedure|Osteosynthesis|Reduction and fixation of the carpometacarpal fracture dislocation of the hand with osteosynthesis (Kirschners wires, plate and screws)
45680538|NCT05362084|Procedure|lumbar medial branch block|lumbar medial branch block
45680539|NCT05365594|Device|Controlled Ankle Movement Boot|Walking boot used for orthopaedic foot injuries
45680540|NCT05365594|Device|EVENUp Lift|Orthotic shoe lift worn on contralateral foot to increase leg length
45680541|NCT01742091|Drug|LY2541546 - SC|Administered SC
45680542|NCT01742091|Drug|LY2541546 - IV|Administered IV
45680543|NCT01742091|Drug|Placebo - SC|Administered SC
46016743|NCT02888613|Procedure|mini lumbotomy|"After induction of general anesthesia, the patient will be positioned in right lateral decubitus at 45° of the table plane. The incision will be performed from the tip of the eleventh rib with a slightly sloping path to the outer edge of the rectus muscle. The average length of the incision of the laparotomy will be 10 cm (8-12 cm).~Abdominal aorta will be approached retroperitoneally. Arterial dissection and control as well as bypasses will be performed according to the conventional retroperitoneal technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft."
45599216|NCT02302495|Drug|Carfilzomib|"DOSING REGIMEN.~The regimen will have 2 parts:~Part 1. Induction. Nine 5 weeks cycles (35-days each) of weekly Carfilzomib Melphalan Prednisone are planned Carfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route followed by a 13-day rest period per 35-days cycle. Patients will start the first cycle day 1 with 20mg/m².~In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.~Part 2. Maintenance. Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year. Melphalan and Prednisone is not pursued at this phase of the study."
45680544|NCT01742091|Drug|Placebo - IV|Administered IV
46016744|NCT02890524|Device|night guard|60 days before and after intervention with the night guard
45680545|NCT01731951|Drug|Imetelstat|Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.
46016745|NCT02890524|Device|placebo night guard|60 days before and after intervention with the placebo night guard
46016746|NCT02890602|Drug|Darbepoetin alfa|Darbepoietin alfa will be administered subcutaneously at a fixed dose of 360㎍. If it is impossible, administration by intravenous infusion is okay.
46016747|NCT02890602|Drug|R-CHOP|R-CHOP regimen is a practical procedure in patients with Diffuse Large B-cell Lymphoma. Darbepoietin alfa will be administered to these patients.
46016748|NCT01259115|Drug|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
46016749|NCT01259115|Drug|Ketoconazole tablet|Ketoconazole 200 mg tablets taken orally twice daily.
46016750|NCT01259115|Drug|Placebo to match ketoconazole tablet|Placebo to match ketoconazole 200 mg tablets taken orally twice daily.
46016751|NCT01302366|Drug|TBL12|
46016752|NCT02888379|Drug|TOP1288|
46016753|NCT02888379|Drug|Placebo (for TOP1288)|
46016754|NCT01302054|Drug|Fesoterodine 8 mg|Fesoterodine sustained release tablets once every morning at 4 mg dose for first week, followed by 11 weeks at 8 mg strength.
46016755|NCT01302054|Drug|Placebo|Matching placebo for fesoterodine 4 and 8 mg for a total of 12 weeks.
46016756|NCT01301508|Drug|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 6 weeks
46016757|NCT01301508|Drug|AN2898 ointment, 1%|AN2898 ointment, 1%, applied twice daily for 6 weeks
46016758|NCT01301508|Drug|AN2898 ointment vehicle|AN2898 ointment vehicle applied twice daily for 6 weeks
46016759|NCT01301508|Drug|AN2728 ointment vehicle|AN2728 ointment vehicle applied twice daily for 6 weeks
46016760|NCT01301274|Drug|hypotonic|0.45% NaCl/5% dextrose IV maintenance fluids
46101000|NCT00672542|Biological|Proteasome siRNA and tumor antigen RNA-transfected dendritic cells|The safety and toxicity of vaccination with tumor antigen RNA-transfected dendritic cells (DC), derived from either untransfected or siRNA-transfected monocytes, will be evaluated in subjects with metastatic melanoma. Subjects will undergo leukapheresis and monocytes will be isolated. These monocytes will then be left untreated (Study Arm A) or transfected with either control siRNA (Study Arm B) or siRNA targeting immunoproteasome subunits LMP2, LMP7, and MECL1 (Study Arm C), then differentiated into DC in vitro . After the induction of maturation, these DC will be transfected with RNA encoding defined melanoma antigens MART, MAGE-3, tyrosinase, and gp100. These RNA-transfected autologous DC will be cryopreserved, then used to vaccinate subjects with metastatic melanoma, each of whom will receive a total of six intradermal (ID) injections using 1x10e7 DC at each cycle, administered weekly.
46016761|NCT01301274|Drug|isotonic|0.9% NaCl/5% dextrose IV maintenance fluids
46016762|NCT02890446|Behavioral|upper arm training on the InMotion 2 shoulder robot|"Both groups practiced shoulder and elbow exercises on a robotic arm device under an external focus or internal focus practice condition.~Practiced arm reaching in a clock-like design to facilitate horizontal shoulder flexion, extension, abduction, adduction.~12 sessions--3 times a week for 4 weeks"
46016763|NCT05643690|Diagnostic Test|UriFind Bladder Cancer Assay|The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the Assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.
46016764|NCT05643612|Diagnostic Test|Deep learning algorithm|A sequential two-stage 3D spleen injury detection framework to identify splenic injury in the CT scans
46016765|NCT05643456|Procedure|surgery|"69 Patients with exotropia of (40-55) PD who are ≥ 5 years old. The 1st group 30 patients had two muscles surgery; bilateral lateral rectus recession.~The 2nd group 39 patients had three muscles surgery; bilateral lateral rectus recession and unilateral medial rectus tucking."
45598250|NCT04436991|Diagnostic Test|Blood sampling|"At predefined time points through a venous catheter already in place. Max. volume to be withdrawn: Maximum 4ml/sample. Maximum 10 samples/patient.~A last blood sample will be taken, if necessary, after the end of antibiotic therapy, between day 7 and day 14. Though blood results preferably will be used from available data from tests already done during standard treatment.~Samples are collected in lithium-heparin tubes (without gel) and centrifuged immediately (within a maximum of 30 minutes after sampling) at room temperature: 8 minutes at 1885g.~Plasma is then collected and divided in two separated labelled Eppendorf tubes 1.5 ml and immediately frozen at - 80 °C. If this is not immediately possible, tubes are frozen at - 20 °C and at regular time points transferred to a freezer at - 80 °C (minimum twice a day)."
45837842|NCT05699317|Other|Thermal stimuli|"Thermal stimuli will be delivered delivered using a contact thermal stimulator (TCS model II.1, QST.Lab, Strasbourg, France).~Target temperatures will be set to reach 10°C (CEP) and 60°C (CHEP) at a rate of 300°C/s.~Stimulus duration will be set 200 ms. The stimulator will be manually held against the skin by the experimenter and slightly displaced within the first 10 cm of the distal extremity of the volar forearm being investigated, marked on the skin of the participant, after each stimulus. A total of 30 stimuli per temperature and testing site will be applied."
45837843|NCT05698992|Other|evidence-based individualized rehabilitation|The experimental group will receive structured individualized assessment based on physical, psychological or social needs and will be offered evidence-based interventions to promote rehabilitation and recovery.
46016766|NCT05367726|Other|patients having had skin coverage of the knee|the cutaneous cover is not always optimal to protect the prosthesis, an act of reconstructive plastic surgery is then necessary
46016767|NCT05643222|Device|red tint contact lenses|to compare the performance of these lenses.
46016768|NCT00623532|Behavioral|Mind-body exercises|
45598251|NCT04436991|Diagnostic Test|Sputum sample|Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
46016769|NCT00623532|Behavioral|Adapted Tai-chi|
46016770|NCT05367648|Dietary Supplement|Elio|Elio™ supplementation, a protein hydrolysate derived from fava bean protein extract
46016771|NCT05367648|Other|Placebo|Placebo comparator
46016772|NCT05642910|Drug|Azvudine|Patients received Azvudine orally, for 7 consecutive days (7 doses in total)
45598252|NCT04436991|Diagnostic Test|Hemoculture|Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
45598253|NCT04436991|Diagnostic Test|Urine sample|Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
45598254|NCT03296371|Procedure|Biospecimen Collection|Undergo saliva or buccal mucosa collection
45598255|NCT03296371|Other|Laboratory Biomarker Analysis|Correlative studies
45598256|NCT03296371|Other|Questionnaire Administration|Ancillary studies
46101001|NCT04213937|Drug|nab-paclitaxel|Drug: nab-paclitaxel 125mg/m2, i.v. d1, d8, Repeated every 3 weeks for 4-6 cycles.
45680546|NCT04560777|Other|CO-OP intervention|"The general structure of the intervention will follow the original key principles of CO-OP, with some adjustments to adapt it to the specificities of the ABI population (14 CO-OP sessions vs 10 in the original protocol).~The global strategy will be taught to the participant at the first session. The following sessions will be consisted of an process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the participant will be experiencing when performing the self-selected tasks. In addition, homework will be assigned to encourage the application and practice of the cognitive strategies discovered during the intervention sessions. Parents will be invited to attend the sessions if it will be possible for them. In any case, the global strategy, as well as the progress of the child, will be explained to the parents."
46101002|NCT04213937|Drug|Topotecan|Drug: Topotecan 1.25mg/m2/d, i.v, 1hour, d1-d5, Repeated every 3 weeks for 4-6 cycles.
46101003|NCT02630342|Behavioral|Mock MRI scanner|Using a mock scanner for preparation for MRI
46101004|NCT02630342|Behavioral|Preparation materials|links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan.
45837844|NCT05698914|Behavioral|Telehealth mindfulness-based intervention (MBI)|The telehealth MBI is adapted from Mindfulness-based cognitive therapy for chronic pain and consists of eight, weekly 75-minute individual sessions (90 minutes allotted for the first session) with a mindfulness interventionist delivering the intervention over telehealth (online with audio and video camera) in addition to the patient receiving their usual postsurgical care. Participants will begin the intervention after completing the 2-week postoperative assessment and within 4 weeks after surgery. Participants will be asked to practice skills between sessions approximately 20-40 minutes per day.
45466271|NCT03797365|Other|Classical rehabilitation|"Participants will benefit from two-phases perineal rehabilitation:~First phase will include the PFM's awareness and voluntary contraction learning with manual, biofeedback technics and functional electro stimulation. These exercises will call out the manual rehabilitation technics, biofeedback and electro stimulation. Each classical rehabilitation session will take 30 minutes with 20 minutes of active working, twice per week. About the self-training, there will be no consensus for optimal homemade exercises.~For the second phase, a behavior analyze will be summarized in order to update the favoring and inappropriate situations. The strategy put in place will be organized in unlearning of deleterious perineal habits and learning new behavior program. The main goal will be the perineal locking set up, which must be systematic before and during efforts. During this phase, the physiotherapist will twice weekly perform evaluations (similar to those in the first phase)"
45598257|NCT02213861|Drug|SHAPE|topical gel
45680547|NCT01731171|Dietary Supplement|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
45680548|NCT01731171|Dietary Supplement|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
46101005|NCT02630342|Behavioral|Child Life Specialist preparation|Child Life Therapist will coordinate the prepartion of the child
46101006|NCT02630342|Behavioral|Review Preparation Materials|Review of preparation materials at the hospital with member of research team
46016773|NCT05642910|Drug|Paxlovid group|Patients received Paxlovid orally for 5 consecutive days (10 doses in total).
45680549|NCT01741701|Drug|Oxaloacetate (OAA)|
45680550|NCT01741701|Drug|Placebo|
45680551|NCT01741545|Biological|Pegylated-Interferon-lambda|
45680552|NCT01741545|Drug|Ribavirin|
45680553|NCT01741545|Drug|Daclatasvir|
45680554|NCT01884350|Drug|Apixaban|
45680555|NCT01614795|Biological|Cixutumumab|Given IV
46016774|NCT05642832|Device|Throughflow titration phase|"Ventilation with Throughflow will be started at a duty cycle of 20% (TF titration 20%). After 10 minutes measurements will be collected. If Edi is above 5 µV, TF duty cycle will be increased by 20% (TF 40%). Measurements will be collected again after 10 minutes. TF duty cycle will be increased by 10% (TF duty cycle 50% and so on) and measurements collected every 10 minutes until Edi is below 5 µV or TF duty cycle reaches 100%.~Once the Edi target has been met, sedation will be progressively reduced to evaluate the effect of Throughflow on sedation requirements for controlling respiratory effort."
46016775|NCT05642754|Other|Overall uncertainty language|We are testing different forms of information about overall study uncertainty and margin of error around main result
46016776|NCT05642364|Behavioral|Joviality(TM)|5-week positive psychological intervention delivered using 3D virtual reality software that is immersive and uses a head-mounted display
45598258|NCT04478799|Device|Transcutanous Posterior Tibial Nerve Stimulation|children were managed by bilateral TPTNS following the procedure described in 2006 by Queralto et al(11). A positive auto-adhesive electrode was applied 1.5 inch above the medial malleolus over the S3 dermatome. A second negative electrode was applied just below the same malleolus. Electrical stimulation device (EMS physio Ltd, OX129 F, England) was connected to both electrodes. This device delivers a low frequency current (10 Hz), and the intensity was gradually increased till flexion of the big toe or spread out of the other toes in a fan shape occurred. Then the intensity was lowered to (10 Hz) again to avoid the motor response of the toes. Intensity was determined by the child's sensitivity. The procedure was done for 20-30 minutes and repeated2 times per week for 3 months
45680556|NCT01614795|Other|Laboratory Biomarker Analysis|Correlative studies
45680557|NCT01614795|Drug|Temsirolimus|Given IV
45466272|NCT03797365|Behavioral|Cognitive associated rehabilitation|The cognitive associated rehabilitation group randomized participants will have to execute twice a day the rehabilitation protocol. Each cognitive rehabilitation session will take three minutes. Participants will have to synergistically execute attentional tests (N-Back Test) and execute a perineal contraction during the contraction instructions. (10 randomized auditory stimuli in three minutes). The attentional tests' difficulty will be gradually increased each 15 days. N-Back Test modalities are the followings: the participant will visualize a series of random numbers. First difficulty step will be to click the dedicated button when the volunteer will see the indicated letter. The second difficulty step will be to click the dedicated button when she will see two consecutives times the same letter. The third difficulty step will be to click the dedicated button when she will see two times the same letter separated by one different letter, and so on…
45837845|NCT05698914|Behavioral|Telehealth Education|Participants will receive a written educational booklet at the time of randomization (within 2-4 weeks after surgery) and 8, weekly telehealth sessions lasting 30 minutes in addition to usual postsurgical care. The educational materials are reviewed individually with the participant during weekly telehealth sessions (online with audio and video camera) by a physical therapist.
45837846|NCT05695378|Drug|KM-819|Subjects will receive KM-819 400 mg orally daily.
45466273|NCT05256784|Combination Product|Natural probiotics|Two of the group members use daily Allium Sativum - garlic, one use Natural honey, and 1 Yogurt. It is verifying the immunity of the organism after 40 days of using natural probitotics.
45837847|NCT05695378|Drug|Placebo|Subjects will receive Placebo orally daily.
46101007|NCT02701439|Device|Small membrane filtration|"Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:~Abbreviated demographic and clinical evaluation~TB history and evaluation~Obtain three sputum samples - one early morning sample and two spot samples~HIV testing (and CD4 if positive)~Chest radiograph~Small membrane filtration intervention will be administered to both arms"
45466274|NCT01138241|Other|Tc99mDTPA renal clearance|"Tc99mDTPA renal clearance only for 200 patients~Plasma and urine 24 hr for creatinin, glucose, Creatinin clearance, Phosphatemia, uric acid, HCO3, protein, Microalbuminuria, ß2- microglobulinuria~serum creatinine prior and during TDF~TDF plasma levels ( only TDF use) using a validated high-performance liquid chromatography (HPLC)-mass method and stored PBMC for intracellular TDF levels~stored samples (PBMC) for pharmacogenomic study of transporter gene ie Organic Acid Transporter (OAT)~serum for cystanin C ( stored sample prior taking ARV and present time)~intensive 24 hours pharmacokinetic study of TDF in 20 patients"
45466275|NCT03751670|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation programmes will include breathing retraining and airway clearance techniques, exercises for thoracic mobility, muscle strength, cardiorespiratory exercise training, education and psychosocial support.
45466276|NCT03751670|Drug|Daily medical treatment|Patients will be treated with daily medication prescribed by the physician.
45466277|NCT04772417|Diagnostic Test|Standardized 1-minute sit-to-stand test|The individuals perform two tests from a standardized chair (seat height 46cm).
45466278|NCT04772417|Diagnostic Test|Individualized 1-minute sit-to-stand test|The individuals perform two tests from an individualized chair (seat height adjusted so that the starting position elicits a knee flexion angle of 90°).
45466279|NCT03797053|Procedure|Biological sample|"Biological sample performed :~before treatment~1 months after the beginning of treatment~every tumoral assessment"
45466280|NCT01138319|Genetic|DNA analysis|
46101008|NCT00506077|Drug|MK0249|MK0249 10mg (2 x 5 mg) tablet daily (qd) for 28 days.
46101009|NCT00506077|Drug|Comparator: Placebo (unspecified)|MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period.
46101010|NCT02701517|Drug|Cyclosporine + METHOTREXATE|MTX days +1, +3, +6 and +11 followed by rescue with folinic Ac. All patients receive CSA from day -7.
46101011|NCT02701517|Drug|Cyclosporine + CAMPATH-1H|CAMPATH-1H at a dose of 20 mg / day at 8-hour intravenous infusion on days -8 to -4. All patients will receive CSA from day -7.
46101012|NCT02630108|Procedure|Thermal Ablation|Thermal ablation in this trial includes radiofrequency ablation and microwave ablation, one of them can be chosen to be performed.
46101013|NCT02630108|Drug|EADM|EADM is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: EADM 30-60 mg per patient,depending on the situation of the patient.
45466281|NCT01138319|Genetic|mutation analysis|
45466282|NCT01138319|Genetic|polymerase chain reaction|
45466283|NCT01138319|Other|laboratory biomarker analysis|
46101014|NCT02630108|Drug|Ultra-fluid lipiodol|Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .
46101015|NCT02630108|Other|Gelatin sponge articles|Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.
46101016|NCT02700971|Procedure|Molecular Microscope Diagnostic system|Consented patients with locally advanced or metastatic melanoma with This trial will utilize a Molecular MicroscopeTM diagnostic system (MMDxTM) that combines the molecular and histopathological features of biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic System. This MMDxTM will be utilized to phenotype cutaneous melanoma biopsy samples to detect an immune responsive mRNA signature.
46101017|NCT00505921|Drug|Campath-1H|3 mg through the catheter Day 1 then 10 mg on Day 2, and 30 mg on Days 3 and 10 of chemotherapy treatment.
45466284|NCT03359811|Drug|Local Anesthetic Solution|A bolus or infusion of local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.
46101018|NCT00505921|Drug|G-CSF|10 mg/kg subcutaneously (sc) on day +5 (in a.m.) for Stem Cell Mobilization.
45466285|NCT03359811|Drug|Bupivacaine HCl|30 mg of Bupivacaine HCl in 10 cc of preservative free normal saline (PFNS) injected before surgical incision in each of the four quadrants.
45466286|NCT03359811|Drug|Liposomal Bupivacaine|65 mg of Liposomal Bupivacaine in 10 cc of PFNS injected before surgical incision in each of the four quadrants.
45466287|NCT05624905|Procedure|Percutaneous coronary intervention|Percutaneous Coronary Intervention Procedure
45466288|NCT05127772|Drug|HEC93077|Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
45680558|NCT01834586|Drug|Anesthetic Topical Adhesive Synera|"For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week"
46101019|NCT00505921|Drug|GM-CSF|250 m/m2 subcutaneously (sc) on Day +5 (in p.m.) for Stem Cell Mobilization.
46101020|NCT00505921|Drug|BCNU|300 mg/m2 IV over 1 hour on day -6
46101021|NCT00505921|Drug|Stem Cell Transplant|Stem cell infusion on Day 0.
45466289|NCT05127772|Drug|Placebo|Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
45466290|NCT03728426|Drug|Letermovir|"Patients will receive intravenous or oral letermovir at a dose of 480mg/day.~Patients weighing 40 or more kilograms will receive a second, loading, dose 12 hours after the first dose of letermovir treatment.~For patients receiving concomitant cyclosporine treatment, the letermovir dose will be 240mg/day."
45466291|NCT01140581|Drug|DRONEDARONE|Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg
46101022|NCT00505921|Drug|Preparative Regimen for Allogenic Stem Cell Transplantation|Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy on day 0.
45466292|NCT03707223|Behavioral|The Interfaces Program|career development program
45466293|NCT03707223|Behavioral|IPS|supported employment using the individual placement and support (IPS) model
45466294|NCT03792139|Drug|LY3200882|Administered orally.
45466295|NCT03792139|Drug|Itraconazole|Administered orally.
45466296|NCT04664738|Biological|10% PEP|PEP is comprised of platelet derived extracellular vesicles enriched in anti-inflammatory and angiogenic growth factors.
45466297|NCT04664738|Drug|TISSEEL|Fibrin sealant made from pooled human plasma
46101023|NCT00505921|Drug|Cytarabine|200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses),
46101024|NCT00505921|Drug|Etoposide|200 mg/m2 IV twice on day -5 to -2 (total 8 doses)
45466298|NCT04664738|Biological|20% PEP|PEP is comprised of platelet derived extracellular vesicles enriched in anti-inflammatory and angiogenic growth factors.
45466299|NCT03449290|Other|Kinesio taping|Kinesio taping was applied on both sides of rectus abdominus, obliquus internus, obliquus externus and sacrospinalis muscles with muscle technique
45466300|NCT03449290|Other|Sham Kinesio taping|Kinesio taping was applied on both sides of rectus abdominus, obliquus internus, obliquus externus and sacrospinalis muscles without any technique
45466301|NCT03792295|Drug|acetominophen, ibuprofen, oxycodone|Multimodal pain treatment group
45466302|NCT03792295|Drug|Oxycodone|Classic opiod pain treatment group
45466303|NCT03797131|Other|KB195 (a novel mixture of oligosaccharides)|KB195 (a novel mixture of oligosaccharides) for oral intake for 21 days.
45466304|NCT05390879|Other|Meditation|After the circuit, a 6 minutes long meditation auto-guided video.
45466305|NCT05390879|Other|Control|After the circuit, a 6 minutes long emotionally neutral video.
45466306|NCT05624827|Diagnostic Test|Testing DNA methylation test for predicting prognosis of untreated CIN 2|After being diagnosed with CIN 2, patients will first be contacted by telephone and invited to participate in the study. If patients agree to participate in the research, they will sign a consent to participate in the research. After that, we will perform a colposcopy and take a cervical swab for analysis with the QIAsure Methylation Test Kit (Qiagen, Gaithersburg, USA), which will determine the methylation of tumor suppressor genes FAM19A4 and has-mir-124. Patients will complete a questionnaire. The total duration of tracking in both groups will be two years. The QIAsure Methylation Test will be performed to analyze methylation. It is a methylation-specific PCR test that detects hypermethylation of the tumor promoter suppressor genes FAM19A4 and has-mir-124. The samples on which we will use this test are bisulfite-converted DNA obtained by triage test for high-risk HPV - Hybrid Capture 2 HPV DNA Test (hc2, Qiagen, Gaithersburg, USA).
45466307|NCT03449056|Drug|salbutamol|T2 - T1+1h30: High-nasal flow and salbutamol nebulization
45466308|NCT03448900|Behavioral|Multicomponent intervention|Motivational interview (50 minutes), on-line self-help material, support e-mail, group therapy, and second motivational interview (20 minutes)
45466309|NCT03448900|Behavioral|Brief advice|Brief advice (5-10minutes) and a self-help pamphlet
45466310|NCT01135433|Drug|ipragliflozin|oral
45466311|NCT01135433|Drug|Placebo|oral
45466312|NCT01135433|Drug|metformin|oral
45466313|NCT05594875|Drug|SHR-1921|Subject will receive a single dose of SHR-1921 at dose level 1/2/3 on Day of each cycles
45466314|NCT02095678|Procedure|liver biopsy|patients with HCC or metastatic lesions will have a liver biopsy performed after the experimental MRI. This biopsy will be examined to confirm the imaging results
45466315|NCT02095678|Device|free-breathing MRI|All patients will be asked to come in for an MRI scan using techniques developed which minimize the time a patient has to hold their breath to image the liver to <8 seconds and validate quantifiable techniques which improve liver image quality
45466316|NCT03793621|Drug|BI 730357|single rising oral dose
45466317|NCT03793621|Drug|Placebo|single rising oral dose
45466318|NCT04745273|Drug|Ondansetron 4 MG (Kemoset 4mg)|Ondansetron 4mg (iv) will administer to participants
45680559|NCT01614249|Dietary Supplement|Soybean oil soft gels|Each participant will receive OmegaVia soybean oil soft gels to take orally, one soft gel taken three times per day in the morning, mid-day and in the evening after meals for a period of 8 weeks
45680560|NCT01614249|Dietary Supplement|Fish oil omega-3 EPA-rich soft gels|A total of 3.0g of OmegaVia fish oil omega-3 EPA-rich soft gels will be taken orally per day as one soft gel in the morning, mid-day and evening after meals for 8 weeks with bi-weekly follow-up visits.
46101025|NCT00505921|Drug|Melphalan|140 mg/m2 IV on day -1.
46101026|NCT00505921|Drug|Campath|15 mg/day (days -6 to -4) for preparative regimen Allogenic Stem Cell Transplantation
45466319|NCT04745273|Other|Salin solution|Salin solution 2ml (iv) will administer to participants
46101027|NCT00505921|Drug|Fludarabine|30 mg/m2 IV/day (days -6 to -4)
46101028|NCT00505921|Drug|Cyclophosphamide|750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4).
46101029|NCT00505921|Radiation|Low dose total body irradiation|Low dose total body irradiation of 2 Gy day 0.
46101030|NCT02698709|Other|Analysis of anterior and posterior corneal surfaces|Corneal data obtained from a Scheimpflug-based topographer were converted to astigmatic vectors in accordance to the method proposed by Thibos
46101031|NCT00596960|Behavioral|Motivational Enhancement Therapy (MET)|MET is a 4 session intervention based on motivational approaches that was successful in project MATCH.
45466320|NCT01305187|Device|Hyaluronic Acid Filler|The dosage is individualized depending on the depth of the NLF. The goal is to achieve optimal correction of both NLF with single implantations of Belotero® Basic and Juvéderm® Ultra 3 respectively. Each subject will be injected with Belotero® Basic and Lidocaine containing Juvéderm® Ultra 3 according to a split-face design. The allocation of fillers to the side of the face will be randomized. The randomization method is block-wise with a ratio 1:1 to the groups Belotero® Basic left and Juvéderm® Ultra 3 right, Belotero® Basic right and Juvéderm® Ultra 3 left.
45466321|NCT01138397|Biological|Influenza virus vaccine (split virion, inactivated)|0.1 mL, Intradermal
45466322|NCT01138397|Biological|Influenza virus vaccine (split virion, inactivated)|0.1 mL, Intradermal
45466323|NCT03448822|Procedure|sentinel node procedure|a robot-assisted laparoscopic sentinel node procedure to detect occult lymph node metastasis
45466324|NCT03793777|Dietary Supplement|Aronia|daily supplementation
45466325|NCT03793777|Dietary Supplement|Placebo|daily supplementation
45466326|NCT05355389|Behavioral|Cognitive training|For the cognitive treatment intervention the widely used cognitive training program RehaCom will be used. This is a computer-aided program with more than 30 modules focusing on different domains of cognition. RehaCom has shown improvements in verbal learning, visuospatial memory, information processing speed, attention, executive functions, depression, fatigue and quality of life in PwMS (PMID 31927200, 28116167, 19825502, 23192417). Patients will train on their home computer without direct therapist supervision, using three RehaCom modules that are focused on improving working memory. Both patients in the combined intervention and the cognitive intervention group will be doing a 45-minute computer session respectively one and two days per week for a total of 12 weeks.
45466327|NCT05355389|Behavioral|Motor training|For the motor treatment intervention a patient-tailored aerobic training program will be used. Based on their baseline physical activity level patients can choose out of a number of aerobic activities of either mild, moderate or strenuous intensity, with a total training time of 90 minutes for the motor intervention group and 45 minutes for the combined intervention group, divided over at least two training sessions per week of at least 15 minutes per session. The training will be carried out individually at home, without therapist supervision. All physical activities will be logged using the sport watch equipped with a heart rate sensor and an accelerometer. Training intensity will be assessed using the patient's heart rate and the Rating of Perceived Exertion scale.
46101032|NCT00596960|Behavioral|Health education|Health education intervention will serve as the active control. The intervention will consist of 4 sessions of health education with a focus on sleep hygiene, nutrition, exercise and relaxation training.
46101033|NCT04729205|Drug|Promitil|The first 6 patients recruited to the study will receive 1.6 mg/kg Promitil. Dose escalation to cohort 2 (PROMITIL dose of 2mg/kg) will be authorized after 5 or 6 patients of cohort 1 have completed the second cycle with DLT detected in fewer than two patients. If ≥2 patients of Cohort 1 develop DLT, dose escalation will be halted and Cohort -1 (PROMITIL dose of 1.2 mg/kg) will be opened. Should ≥2 patients in Cohort -1 or Cohort 2 experience DLT events, the study will be discontinued. In parallel, on days 1 and 15 of each cycle, patients will be treated with the mFOLFOX6 regime, which involves concurrent treatment with oxaliplatin 85 mg/m2 IV and leucovorin 200 mg/m2 IV, immediately followed by 5-FU 400 mg/m2 IV bolus, and then continuous infusion of 5-FU 1200 mg/m2/day, for 2 days (46-48 h).
45466328|NCT01140659|Procedure|Video-assisted sympathectomy|All participants were randomized into two groups of 20 patients (G3 and G4) and underwent video-assisted sympathectomy, being followed for 12 months. During this period, the subjects completed a questionnaire about quality of life and carried out the measurements of sweat by VapoMeter.
45466329|NCT03448744|Drug|Thymosin Alpha1|Thymosin Alpha1 (1.6 mg subcutaneously injection twice a week) plus ETV (0.5 mg orally, daily) for 24 weeks, and followed by continuous ETV for at least 48 weeks
45466330|NCT03448744|Drug|Entecavir|ETV (0.5 mg orally, daily) for 72 weeks
45466331|NCT03792451|Drug|Pegvaliase|Treated with pegvaliase for one or more years or followed an unrestricted diet for 6 or more months while being treated with pegvaliase.
45466332|NCT03448588|Diagnostic Test|detection of serum selenium|For this case-control study, no intervention will be administered to participants, only serum sample will be collected for selenium assessment
46101034|NCT02631434|Procedure|sit-to-stand test|
46101035|NCT02631434|Procedure|six-minutes walking test|
45466333|NCT03797443|Drug|Ascorbic Acid|"Four escalating dose levels are planned in order to determine the MTD for Phase II~The dose level for Phase II patients will be determined following completion of the Phase 1b study based on response from 3-6 patients receiving the designated dose level of ascorbic acid."
45466334|NCT03797443|Drug|nab paclitaxel|30 minute IV infusions on days 1 and 8 repeated every 21 days, followed by Cisplatin
45466335|NCT03797443|Drug|Cisplatin|60minute IV infusion on days 1 and 8 repeated every 21 days followed by Gemcitabine
45466336|NCT03797443|Drug|Gemcitabine|30 minute IV infusion on days 1 and 8 repeated every 21 days
46016777|NCT05642364|Other|Inert Virtual Reality|Participants randomized to the control arm will receive a rigorous placebo following clinical trial guidelines of VR-CORE, which consists of 2-dimensional (2D) non-immersive visual content displayed on the HMD. Footage of wildlife and nature-based settings are visually displayed as part of the Sham VR with inert music that does not promote high levels of relaxation or distraction.
46016778|NCT01300650|Drug|Anakinra|Anakinra 100 mg subcutaneous injection daily
46016779|NCT01300572|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
46016780|NCT01300572|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
45466337|NCT01135589|Drug|Micafungin|i.v.
45466338|NCT01915810|Behavioral|Exercise Intervention|Complete SCwPA intervention
45466339|NCT01915810|Other|Laboratory Biomarker Analysis|Correlative studies
45466340|NCT01915810|Drug|Nicotine Patch|Receive nicotine patch
45466341|NCT01915810|Other|Questionnaire Administration|Ancillary studies
46016781|NCT01300572|Drug|Cyclosporine|Given PO or IV
46016782|NCT01300572|Drug|Fludarabine Phosphate|Given IV
46016783|NCT01300572|Biological|Indium In 111 Anti-CD45 Monoclonal Antibody BC8|Given IV (dosimetric dose)
46016784|NCT01300572|Other|Laboratory Biomarker Analysis|Correlative studies
46016785|NCT01300572|Drug|Mycophenolate Mofetil|Given PO or IV
46016786|NCT01300572|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
46016787|NCT01300572|Other|Pharmacological Study|Correlative studies
46016788|NCT01300572|Radiation|Total-Body Irradiation|Undergo TBI
46016789|NCT01300572|Radiation|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given via central line (therapeutic dose)
46016790|NCT05642286|Device|ALLVAS® robotic-assisted PCI|ALLVAS® robotic-assisted PCI
46016791|NCT01077154|Drug|Placebo|Administered subcutaneously for up to 5 years
46016792|NCT01077154|Drug|Denosumab|Administered subcutaneously for up to 5 years
45466342|NCT01915810|Other|Tobacco Cessation Counseling|Receive smoking cessation counseling
45466343|NCT01140737|Drug|Axitinib|Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily. A four week dosing period will be considered as 1 cycle of treatment. Axitinib treatment will be continued until disease progression, or the development of limiting toxicity.
45680561|NCT01597778|Biological|Haploidentical Bone Marrow Transplant|"The conditioning regimen consists of:~Fludarabine (Flu)30 mg/m2 IV Days -6, -5, -4, -3, -2 Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6, -5 Total body irradiation (TBI) 200cGy Day -1~The GVHD prophylaxis regimen consists of:~Cy 50 mg/kg IV Days 3, 4 Tacrolimus (IV or PO) beginning Day 5 Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day 5 until Day 35"
45466344|NCT03448510|Device|Irreversible electroporation|The subject will receive Irreversible electroporation procedure which is a novel ablation modality using electric pulses to create nanoscale defects in the cell membrane.
45837848|NCT05686200|Behavioral|Forearm isometric exercise intervention program|Experimental group using the intelligent gripper for forearm isometric exercise in the 3rd to 8th participants after operation, and using the smart mobile phone to install the forearm isometric exercise training game program software to provides an interactive and real- time exercise grip strength feedback mechanism, which are uses the interest of the participant to complete the forearm isometric exercise every day, and can implement the isometric exercise training for fistulization. Study nurses will track exercise adherence with telephone interviews 2, 4 and 8 participants after participant exercise intervention.
45837849|NCT05683600|Biological|Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001|Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
45466345|NCT03448510|Drug|Standard Medication|The subject will be prescribed with α-blocker or/and 5α-reductase inhibitors.
45466346|NCT05594095|Drug|PIK3CA inhibitor|PIK3CA inhibitor
45466347|NCT05594095|Drug|AKT inhibitor|AKT inhibitor
45466348|NCT05594095|Drug|Carrelizumab|Pd-1 mab
45466349|NCT05594095|Drug|Famitinib|VEGFR inhibitor
45466350|NCT05594095|Drug|Fluzoparib|PARP inhibitor
45466351|NCT05594095|Drug|Dalpiciclib|CDK4/6 inhibitor
45466352|NCT05594095|Drug|SHR-A1811|HER2 ADC
45466353|NCT05594095|Drug|TROP2 ADC|TROP2 ADC
45466354|NCT05594095|Drug|Everolimus|mTOR inhibior
45466355|NCT05594095|Drug|Aromatase Inhibitors or Fulvestrant|Letrozole/Anastrozole/Exemestane or Fulvestrant
45837850|NCT05683600|Biological|Placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
45466356|NCT05594095|Drug|Goserelin|For premenopause
45466357|NCT05594095|Drug|TPC|Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)
45466358|NCT05594095|Drug|RTK Inhibitor|Sorafenib, Apatinib, Famitinib
45466359|NCT01233713|Procedure|Hartmann's operation|Hartmann's operation is the surgical resection of the rectosigmoid colon with closure of the rectal stump and end colostomy, followed by a stoma reversal operation.
45466360|NCT01233713|Procedure|Primary anastomosis|Primary anastomosis refers to a colonic resection with primary anastomosis and covering proximal ileostomy, followed by a stoma reversal operation.
46101036|NCT02918435|Behavioral|WE CARE|The WE CARE (Well-child care visit, Evaluation, Community Resources, Advocacy, Referral, Education) survey consists of 12 questions used to identify six unmet material needs (education, employment, food security, housing, childcare, household utilities). It will be administered at health supervision visits during the WE CARE phase at each study site. The Family Resource Book will contain resource information sheets for each of these needs listing available community resources. A physician champion will conduct regular booster sessions every 4 months and train new providers should there be staff turnover.
45680562|NCT01597778|Biological|Double Umbilical Cord Blood Transplant|"The preparative regimen consists of:~Fludarabine 40 mg/m2 IV Days -6, -5, -4,-3, -2 Cyclophosphamide 50 mg/kg IV Day -6 Total Body Irradiation (TBI) 200 cGy Day -1 for patients who have received cytotoxic chemotherapy within the 3 months of enrollment or an autologous transplant within 24 months of enrollment or 300 cGy Day -1 for patients who have not received cytotoxic chemotherapy within the 3 months of enrollment and who have not received an autologous transplant within 24 months of enrollment.~The GVHD prophylaxis regimen consists of:~Cyclosporine beginning Day -3 with dose adjusted to maintain a trough level of 200-400 ng/mL.~Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day -3 until Day 35"
46101037|NCT02631278|Device|Intraoperative radiofrequency ablation|Intra-operative Radiofrequency ablation will be carried out and followed by surgical removal of the treated leiomyoma.
46101038|NCT00505765|Drug|AL-108|AL-108, 5 mg/day- one spray in each nostril once per day
46101039|NCT00505765|Drug|AL-108|AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
46101040|NCT00505765|Drug|Placebo|Placebo- 3 sprays in each nostril, twice per day
45680563|NCT01614093|Drug|Oxytocin|Single dose intranasal oxytocin (24 IU)
46016793|NCT05642130|Other|exersice program (Muscle energy technique)|Post isometric relaxation for upper trapezius and sternocleidomastoid muscles. the therapist moved the subject's head into the position that put each muscle in stretch, once resistance/ barrier was felt, that position was held and subjects were asked to isometrically contract the target muscle with 20% of maximal contraction for 5 sec against mild resistance from the therapist, relax for 5 sec followed by passive stretch until reaching a new barrier for 30 sec, 3 repetitions for each muscle, 3sessions /week over a period of 4 weeks, In addition to the program designed for control group
46016794|NCT05642130|Other|exersice program (stretching and strengthening exercises ) In addition to postural advices|static stretching exercise for upper trapezius and sternocleidomastoid . Repetitions: 3times/day, 3days/week over a period of 4 weeks, in addition to strengthening exercises of deep cervical flexors and scapular retractor muscles, 3sets of 12 repetitions with 6 sec hold. In addition to postural advices
46016795|NCT05642052|Dietary Supplement|low carb diet|low carb meals will be 50% less carbs than the regular meals
46016796|NCT05642052|Dietary Supplement|Regular diet|Regular diet
46016797|NCT01258101|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
46016798|NCT01258101|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 16 weeks
46016799|NCT01258101|Drug|ribavirin|800 mg orally daily
46016800|NCT01258101|Drug|ribavirin|400 mg orally daily
46016801|NCT05641974|Behavioral|Helpers Stay Quit Training|"The Helpers Stay Quit training emphasizes a tobacco-user centered, non-confrontational approach to encouraging others to quit smoking. Helpers Stay Quit trainees learn how to offer a 4-step helping conversation. The four steps of a helping conversation parallel the 4 core training modules of Helpers Stay Quit (Awareness, Understanding, Helping, Relating). A key learning objective of Helpers Stay Quit, is for Helpers to learn how to manage their own expectations for the process and outcome of a helping conversation (e.g. Helpers are taught that they cannot make anyone quit, but they can offer non-judgmental support, and information about effective cessation aids). Consequently, Helpers are taught to manage their own behavior when helping others (e.g. avoiding nagging or pushing a tobacco-user to quit). The helping conversation focuses on encouraging behavior change that is aligned with the tobacco user's current willingness/readiness to take any action toward quitting."
46016802|NCT05641662|Other|Heart Farming|Heart Farming is a mobile game. which can be played indoors and outdoors and stimulates players to be physically active. The game is built around a theme (farming) and users are challenged to collect products by being active. The phone will register movements and convert them into points and fruits and vegetables. For the basic playing only 10 minutes walking a day with the game is possible and is rewarded. For players who want more challenge and level of trading products and collecting products in groups is added. The game is adaptable to different levels of mobility and players can invite others to play with them. Players can see their own game results, progression, and active time.
46016803|NCT04319835|Device|OnZurf Probe|
45680564|NCT01614093|Drug|Placebo|Placebo- Sugar pill
46016804|NCT05640804|Drug|CTTQ Dasatinib tablet|Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Chia Tai Tianqing Pharmaceutical Group.
46101041|NCT00505765|Drug|Placebo|Placebo- one spray in each nostril, once per day
46101042|NCT00669344|Drug|Exelon (rivastigmine)|Capsules, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
46101043|NCT00669344|Drug|Placebo|Capsule, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
45599217|NCT02342457|Device|Child suspected of Hirschsprung disease|Children admitted for rectal biopsy, due to chronic constipation and suspected of Hirschsprungs disease, will undergo electrophysiological reading from the rectal inner wall, at thechosen site for biopsy before biopsy is performed. Histopathology and readings will be analyzed for corelation
45599218|NCT02342301|Behavioral|Standing Desk|Participants will be provided with a standing desk for 3 months
45599219|NCT02342301|Behavioral|Traditional Desk|Participants will use a traditional seated desk for 3 months
45680565|NCT04559607|Drug|Camrelizumab|Camrelizumab: 200mg, iv, Q3W
45680566|NCT04559607|Device|TACE|TACE if necessary
46016805|NCT05640804|Drug|Sprycel Dasatinib tablet|Sprycel Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Bristol Myers Squibb.
46016806|NCT05639478|Other|Foot-related exercises|Face to face foot-related exercises, supervised by physiotherapist and based in the specific software (Sistema de Orientação do Pé diabético, SOPED) and or booklet. The maximum duration of a session is 40 min and should be be performed 1-2 times/week. The subject should warm-up the foot-ankle and then start exercising in the order suggested by the physiotherapist. The foot exercises progresses from one set with 30 repetitions in a sitting position, to exercising standing, then performing the exercise on one foot only. Other progression criterion is to increase the number of sets performed. The effort scale regulates the individual effort for his/her progression.
46016807|NCT05638776|Drug|REGEND001 Autologous Therapy Product|Transplantation of Autologous Therapy Product by
45599220|NCT02306395|Procedure|Endometrial local injury|The way of intervention is to scratch the uterine cavity two cycles by a small spatula in the first 3-5 days after menstrual period.
45680567|NCT04559607|Drug|Apatinib|Apatinib: 250m, po, QD
45837851|NCT05655546|Other|Access to Cue Health COVID-19 Remote testing and treatment for COVID-19|Participants will receive at home COVID-19 test for themselves and others in their household.
45837852|NCT05648838|Device|Pivot Balloon Catheter|mornitoring acute RV failure and reduction of Functional Tricuspid Regurgitation
46016808|NCT05638776|Drug|Placebo|Transplantation of Placebo
46016809|NCT05633316|Device|Investigational device named ICSIA|Oocytes will undergo intracytoplasmic sperm injection using the ICSIA (the investigational) device.
46016810|NCT05633316|Device|Manual ICSI|Oocytes will undergo intracytoplasmic sperm injection using the ICSI manual protocol
46016811|NCT05631834|Procedure|Thoracic epidurale|Epidurale Perioperative infusion of Ropivacaine
46016812|NCT05631834|Procedure|Erector spinae block|erector spinae interfascia Perioperative infusion of Ropivacaine
46016813|NCT00623610|Procedure|islet cell grafts|Intraportal injection of an islet cell graft into the liver.
45599221|NCT02813447|Drug|Sertraline|
45599222|NCT02813447|Drug|Placebo|
45466361|NCT04951063|Radiation|Hypofractionated radiotherapy|"Split-course adaptive HRT-CHT is administered at the following three dose levels:~Level 1: DT 4500cGy/15 daily fractions/300cGy in the first course，DT 1500cGy/5 daily fractions/300cGy in the second course;~Level 2: DT 4000cGy/10 daily fractions/400cGy in the first course， DT 2000cGy/5 daily fractions/400cGy in the second course;~Level 3: DT 3000cGy/6 daily fractions/500cGy in the first course， DT 3000cGy/6 daily fractions/500cGy in the second course."
46016814|NCT00623688|Device|Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC)|Albuterol is delivered by metered dose inhaler with valved holding chamber. For children less than 6 years of age, a mask is also used.
46016815|NCT00623688|Device|Airlife Sidestream High Efficiency Nebulizer|Albuterol is delivered as a mist mixed with normal saline using a nebulizer machine and face mask or mouth piece.
46016816|NCT01300338|Device|Blood pressure monitor with telemetry|Blood pressure monitor for home use with readings uploaded to a web server viewable by the diabetes care manager
45466362|NCT04951063|Drug|Concurrent chemoradiotherapy|weekly infusion of docetaxel (25mg/m2) and cisplatin (25mg/m2) during RT
45466363|NCT04951063|Drug|Consolidation immunotherapy|Consolidative immunotherapy (PD-1 or PD-L1 inhibitor) up to 1 year is administered for those without disease progression after HRT-CHT.
45466364|NCT01560559|Procedure|Peroral endoscopic myotomy|"An endoscopy is performed under anesthesia with orotracheal intubation. After submucosal saline injection, an entry point in the submucosal space is created at 10 cm above the cardia. The endoscope will create a 12cm long tunnel in the caudal direction by submucosal dissection, stopping at 2cm below cardia. Then the muscular circular internal layer is sectioned on a 9cm length, starting 3 cm below the submucosal entry point. At the end the submucosal entry point is closed with metallic clips. A scanner is performed after the procedure so as to check the esophageal wall integrity. Alimentation is progressively introduced at day 1.~This is a study of a procedure - peroral endoscopic myotomy (POEM). No new, unapproved device is used. All endoscopic tools are already approved for endoscopic submucosal dissection and associated complications (hemorrhage or perforation): dissection knifes, hot biopsy forceps, endoscopic metallic clips."
45466365|NCT01305343|Procedure|Routinely performed surgical correction of spinal deformity|Routinely performed surgical correction of spinal deformity
45466366|NCT03448354|Procedure|HIPEC|HIPEC(paclitaxel 175mg/m2, 90min; open or closed technique) after IDS . IDS is recommended within 4 weeks after the 3rd NAC cycle. HIPEC procedure is allowed only in case of residual disease less than 5mm.
45599223|NCT02342145|Drug|Basiliximab,|Basiliximab was used 10mg each time on 0d(after transplantation) and +4 d .
46016817|NCT01300338|Device|Home blood pressure monitor without telemetry|Self monitor of blood pressure without telemetry
46016818|NCT05615376|Device|ECG application|The app together with the wearable device will record a V1 (Left wrist) or V2 (left ankle) ECG reading. These measurements will be conducted on Day 1 and Day 4.
46016819|NCT05615376|Device|12 lead ECG|The 12 lead ECG will measure corrected QT interval by recording RR and QT intervals on Day 1 and Day 4. This will be performed within the same episode of care as the wearable device ECG recording. There is no need to perform both at exactly the same time point, but within a 15 minute window.
46101044|NCT02698319|Behavioral|Copenhagen Triage Algorithm|The Copenhagen Triage Algorithm is a new triage method for faster triage in the ED
45466367|NCT03448276|Other|Training in the vibrating platform|20-minute workout will be held, which will include: heating (5 minutes and stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
45466368|NCT03448276|Other|Walk|Will be held 30 minutes of training, which will include the heating (5 minutes of stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
45466369|NCT03448198|Procedure|Total knee replacement|Primary knee gonarthrosis treated with navigated total knee replacement and computer-assisted patellar replacement.
45466370|NCT05624671|Other|bupivacaine,fentanyl|According to our institution protocol, intravenous (iv) hydration will not be given as preload and afterload and vasopressor infusion will not be initiated before spinal anesthesia. After the skin is prepared sterile and local infiltration with 2% lidocaine is done, from L3-L4 OR L4-L5 range on midline with the 16 gauge Tuohy needle and the loss of resistance technique epidural space is identified and then 26 gauge pencil point needle is passed trough the Touhy and the dura will be drilled. After the cerebrospinal fluid (CSF) is seen the fluid containing 5mg isobaric bupivacaine and 15µg fentanyl will be given in 30 seconds to patients. After the spinal needle is removed, the epidural catheter is placed 3-5 cm in the epidural space through Tuohy, and after the catheter is fixated, the patients will be placed in the supine position by placing a height under their right hip with a 15 ° angle.
45466371|NCT03447964|Other|dosing of sphingolipids|- Measuring the concentration of many species of sphingomyelins, ceramides, dihydroceramides and sphingosine
45466372|NCT03447886|Other|Phone interview|Collecting clinical and socio-demographic information.
45466373|NCT03763877|Drug|PXL770|Oral capsule
45466374|NCT03763877|Drug|Placebo Oral Capsule|Oral capsule
45466375|NCT00850954|Other|Informational Intervention|Receive information on secondhand smoke and supporting smoker in quitting
45466376|NCT00850954|Behavioral|Smoking Cessation Intervention|Receive smoking cessation materials based on TTM
45466377|NCT00850954|Other|Survey Administration|Ancillary studies
45466378|NCT00576082|Other|Cutaneous biopsy|Cutaneous biopsy in order to search Borrelia by means of culture and PCR in this tissue sample
45466379|NCT03578965|Drug|Cefazolin|-If patient has a penicillin allergy then clindamycin will be used. Prophylactic antibiotics should be administered prior to skin incision
45466380|NCT05178004|Other|Faecal and Urine sample collection|This is an observational study.
45466381|NCT03791905|Drug|Paclitaxel|chemotherapy drug
45466382|NCT03791905|Drug|Cisplatin|chemotherapy drug
45837853|NCT05645744|Biological|Prior MB-102 CAR-T cell investigational product.|No investigational product will be administered.
45837854|NCT05645744|Biological|Prior MB-106 CAR-T cell investigational product.|No investigational product will be administered.
45466383|NCT03791905|Drug|Oxaliplatin|chemotherapy drug
46016820|NCT02890290|Dietary Supplement|Marine Protein hydrolysate|The participants will take the supplement in form of tablets and will be instructed to take five tablets twice a day, preferably in relation to meals, however, not the dinner meal. Each tablet contains 300 mg of marine protein hydrolysates (Nx6.25). The tablets are produced by Flexipharma AS.
46016821|NCT02890290|Dietary Supplement|Placebo|Placebo tablets will be made based on gum arabicum. The tablets are produced by Flexipharma AS.
45466384|NCT03791905|Drug|5-FU|chemotherapy drug
45466385|NCT03791905|Drug|Leucovorin|chemotherapy drug
45466386|NCT03791905|Radiation|Intensity-modulated radiotherapy|radiotherapy technique
45680568|NCT04559373|Other|Virtual Reality and Field Training (VRFT)|The VRFT intervention involves the intensive practice of community ambulation skills. Some of the training sessions will be performed in a virtual environment, while others will consist of field training exercises in the community. During the intervention, stroke participants will be invited to practice different dimensions of community ambulation, such as postural transitions, avoiding other pedestrians, dual-task walking, etc.
46016822|NCT01300260|Biological|LY2189265|Administered subcutaneously
45466387|NCT03791905|Device|PET|Using PET to evaluate response to induction chemotherapy
45466388|NCT03447652|Other|Resistance Band Ankle Rehabilitation|Resistance Band - uses a tension band to provide resistance during ankle motion
45466389|NCT03447652|Other|Biomechanical Ankle Platform System Rehabilitation|Biomechanical Ankle Platform System Board Group - uses different levels of half spheres to increase the amount of motion allowed at the ankle.
45466390|NCT03447652|Other|Combination Rehabilitation|Combination Group - includes both the resistance band and Biomechanical Ankle Platform System programs.
45466391|NCT03789409|Dietary Supplement|Intermittent Fasting|The aforementioned intermittent fasting in arm/group descriptions.
45466392|NCT01305421|Procedure|grip test|Muscle strength measurement by hand-held dynamometer
45466393|NCT01232153|Device|Non invasive ventilation|Non invasive ventilation
45466394|NCT03447496|Procedure|Closed reduction|The children were treated with closed reduction.
46016823|NCT01300260|Drug|Placebo|Administered subcutaneously
46016824|NCT01300260|Drug|Insulin|Administered intravenously
45466395|NCT03447496|Procedure|Open reduction|The children were treated with Open reduction.
45466396|NCT03793933|Procedure|Liver resection|Surgery for the liver
45466397|NCT01138553|Drug|Mifepristone|200mg capsules daily for 5-28 days
45466398|NCT05624593|Device|P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
45466399|NCT05624593|Device|Predicate|The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
45466400|NCT05171374|Drug|Dabrafenib|Observational stusy. No intervention is planned
45680569|NCT01834274|Drug|Fasiglifam (TAK-875)|Fasiglifam (TAK-875) tablets
45680570|NCT01834274|Drug|Fasiglifam (TAK-875) Placebo|Fasiglifam (TAK-875) placebo-matching tablets
45466401|NCT05171374|Drug|Trametinib|Observational stusy. No intervention is planned
46016825|NCT01300260|Drug|Glucose|Administered intravenously
46016826|NCT01300260|Drug|Glucagon|Administered intravenously
46016827|NCT01256385|Biological|Cetuximab|Given IV
46016828|NCT01256385|Other|Laboratory Biomarker Analysis|Correlative studies
45466402|NCT03447418|Procedure|Multiple breath nitrogen washout|Lung Clearance Index (LCI) will be performed in healthy volunteers with a multiple breath nitrogen washout device.
45466403|NCT01138631|Device|Embryoscope|The embryoscope is an incubator with in-built photographic equipment
45466404|NCT03358407|Drug|GSK2983559|GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.
45466405|NCT03358407|Drug|Placebo|Placebo oral capsules matching GSK2983559 will be available for subjects.
45466406|NCT03447184|Drug|Androgen priming|"Androgen priming: with a low dose of recombinant hCG, aromatase inhibitor, and a depot GnRHa for 8 weeks Stimulation: a standard rFSH stimulation with either 300 IU rFSH or 300 IU (rFSH + rLH) Blood sampling: 6 blood samples to measure FSH, LH, E2, testosterone, and AMH Ultrasound examination: to count all antral follicles, 2-10 mm in each ovary Follicular fluid: to analyze E2, androstenedione, testosterone, progesterone, inhibin B.~Granulosa cells: to analyze gene expression in cumulus and mural granulosa cells of Luteinising hormone receptor (LHR), 3β-hydroxy-steroid-dehydrogenase (3ßHSD), inhibin-Ba (INHB-A) receptor, androgen and FSH receptor"
45466407|NCT03739541|Drug|[14C]-Benznidazole|A single dose level of 100 mg; 200 μCi (7.4 MBq)
46016829|NCT01256385|Drug|Temsirolimus|Given IV
45680571|NCT01834274|Drug|Sitagliptin|Sitagliptin tablets
45680572|NCT01834274|Drug|Sitagliptin Placebo|Sitagliptin placebo-matching tablets
45680573|NCT01834274|Drug|Metformin|Metformin tablets
45680574|NCT01739595|Drug|enclomiphene citrate|oral, capsules, taken one time daily, for 3 months
46016830|NCT05609760|Other|SIMAP|Pictographic depiction of medical indications alongside standard communication of these recommendations.
46016831|NCT05609760|Other|Usual Care|Standard communication by medical staff of treatment indications for asthma. An informative leaflet will be delivered as well.
46016832|NCT00637182|Drug|Anastrozole|
46016833|NCT04324398|Other|Cryotherapy|cold application
45599224|NCT02342145|Drug|cyclosporine A|Specifically cyclosporine A was used by intravenous drip infusion on 2mg/kg dosage from -1d and change to 5mg/kg twice oral when gastrointestinal function recovers. The blood concentrations of cyclosporine A was maintained 150-250ng/ml.
45599225|NCT02342145|Drug|Methotrexate|Methotrexate was used 15mg/m2 on +1d and 10mg/m2 on +3,+6,+11d by intravenous for prevention of graft-versus-host-disease.
45599226|NCT02342145|Drug|Mycophenolate mofetil|Mycophenolate mofetil was used 0.25g qd from 0d to 3 months for prevention of graft-versus-host-disease.
45599227|NCT02302573|Drug|contast-enhanced ultrasound with sonovue|contast-enhanced ultrasound with sonovue
46016834|NCT01298778|Drug|Duramorph 150|Duramorph 150 mcg x 1 dose spinally + placebo capsules 2 PO q 6 hrs first 24 hrs postop x 4 doses
46016835|NCT01298778|Drug|Acetaminophen|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
46016836|NCT01298778|Drug|Duramorph 300|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
46016837|NCT01298700|Drug|bimatoprost 0.01% ophthalmic solution|One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
45466408|NCT02014051|Drug|SyB C-1101|"SyB C-1101（rigosertib sodium） will be administered to two cohorts at either 280 mg/day or 560 mg/day.~The dose will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied. However, treatment will be limited to a maximum of 6 cycles including the first cycle."
45466409|NCT03447106|Procedure|laparotomy|This is a kind of traditional surgical method.
46016838|NCT01298700|Drug|bimatoprost 0.03% ophthalmic solution|One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
45466410|NCT03447106|Procedure|Laparoscopic|laparoscopic surgery
45466411|NCT03447106|Procedure|Robotic|the Da Vinci robot assisted gastric resection
45466412|NCT01138787|Dietary Supplement|Reference spread|Single dose (30 gr) of spread, containing 2250 mg PS
46016839|NCT01297920|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
45466413|NCT01138787|Dietary Supplement|Placebo spread|Single dose (30 gr) of regular light margarine
46016840|NCT01297920|Drug|Brinzolamide ophthalmic suspension, 1%|
45466414|NCT01138787|Dietary Supplement|Test spread|Single dose (30 gr) of innovatively processed spread containing 2250 mg PS.
45466415|NCT01135667|Drug|clopidogrel|clopidogrel 150 mg once daily for 30 days
45466416|NCT01135667|Drug|Prasugrel 10 mg|Prasugrel 10 mg once daily for 30 days
46016841|NCT01297920|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
46016842|NCT01255761|Biological|Certolizumab Pegol (CZP)|"400 mg subcutaneous injection at Weeks 0, 2 and 4~200 mg subcutaneous injection every two weeks, Week 6 through Week 52"
46016843|NCT04326972|Device|ultrasound|• All patients with inclusion criteria do for them chest ultrasound .
45466417|NCT05624437|Other|data record|data record
45466418|NCT03446950|Procedure|Vaginal Surgery|Patients will undergo elective surgery on vagina or bladder
45466419|NCT01135745|Device|Reclaim® Deep Brain Stimulation|Implant of leads in pre-defined brain area; implant of neurostimulators
45466420|NCT03793387|Procedure|AF-guided endobronchial marking|Bronchoscopic dye marking under CBCT-augmented fluoroscopic guidance
45466421|NCT03793387|Device|ENB-guided endobronchial marking|Bronchoscopic dye marking with ENB system
45466422|NCT03446872|Drug|ONIVYDE|irinotecan liposome injection
45466423|NCT03446872|Drug|5-fluorouracil|a nucleoside metabolic inhibitor
45466424|NCT03446872|Drug|Leucovorin|an active metabolite of folic acid
45466425|NCT01232231|Drug|pharmacological decolonization treatment|Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS trimethoprim-sulfamethoxazole 160/800mg po bid or doxycycline 100mg po bid all for 7 days
45680575|NCT01739595|Drug|Placebo|Oral capsule taken one time daily for 3 months
46016844|NCT01297062|Drug|Exenatide|IV Exenatide (therapeutic and supratherapeutic concentrations)
45466426|NCT01232231|Behavioral|Education|No pharmacological decolonization treatment but given education regarding personal hygiene and environmental cleaning
45599228|NCT03746015|Biological|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|Tetravalent Dengue Vaccine (TDV) subcutaneous injection
45599229|NCT02349321|Behavioral|Skhokho Supporting Success for Schools|All information describing each facet of the intervention are included in the arm/group descriptions.
45599230|NCT02349321|Behavioral|Skhokho Supporting Success for Families|All information describing each facet of the intervention are included in the arm/group descriptions.
46016845|NCT01297062|Drug|Moxifloxacin|Oral Moxifloxacin (400 mg)
46016846|NCT01297062|Drug|Placebo comparator|IV Placebo (matching volume of placebo)
46016847|NCT01254747|Device|Delefilcon A contact lens|Investigational silicone hydrogel, single vision contact lens for daily wear, daily disposable use
46016848|NCT01254747|Device|Lotrafilcon B contact lens (O2 OPTIX, AIR OPTIX)|Commercially marketed silicone hydrogel, single vision contact lens for daily wear, daily disposable use
46016849|NCT01254747|Device|Nelfilcon A contact lens (DAILIES AquaComfort Plus)|Commercially marketed hydrogel, single vision contact lens for daily wear, daily disposable use
46016850|NCT01254747|Device|Narafilcon A contact lens (1-DAY ACUVUE TRUEYE)|Commercially marketed (Europe) silicone hydrogel, single vision contact lens for daily wear, daily disposable use
46016851|NCT01296672|Drug|Finasteride|Finasteride 5mg every day by mouth for 3 months
46016852|NCT01296672|Drug|Placebo|Placebo every day by mouth for 3 months
46016853|NCT01254669|Behavioral|BNI-brief Negotiated Interview|use of a cognitive behavioral intervention to improve uptake of HPV vaccine
45466427|NCT05624203|Device|Extracorporeal cardiac shock wave therapy(ECSW)|Extracorporeal cardiac shock wave therapy (CSWT) is a cutting-edge technology developed in the world for more than 20 years. It is mainly used in the treatment of refractory angina pectoris of coronary heart disease. The mechanism of extracorporeal cardiac shock wave therapy is mainly due to the small attenuation, small shear stress and strong penetration force of shock wave when propagating in human tissues. Shear stress and hole effect are generated in the focal area of shock wave, which leads to the repeated formation/rupture of microbubbles in tissue/cell microenvironment, resulting in various physical and biological effects. These physical mechanisms trigger a series of biological effects, such as promoting the expression of various intracellular cytokines and angiogenic factors, activating related signal transduction pathways, inhibiting apoptosis and oxidative stress, and finally increasing the number of new blood vessels in the treatment area and improving the ischemic state.
45466428|NCT03446716|Behavioral|Sleep Extension|Child attempted to go to bed 90 mins in advance of their normal bedtime.
45680576|NCT01833494|Drug|PA21|
46016854|NCT04324476|Drug|Bevacizumab、Oxaliplatin、Irinotecan、Capecitabine|Drug: Bevacizumab 5mg/kg, iv, 30min, d1, 2w; Drug: Oxaliplatin 85mg/㎡, iv, 120min, d1, 4W; Drug: Irinotecan 150mg/㎡, iv, 90min, d15, 4w; Drug: Capecitabine 1000mg/㎡, bid, d2-8, 2w.
46016855|NCT04321473|Procedure|PCI on left main|PCI on left main coronary stenosis
46016856|NCT04206969|Behavioral|Transcultural psychotherapy|In addition to usual care, the participants receive transcultural psychotherapy
45466429|NCT03739385|Other|Exercise Intervention|The training interventions of all three groups (intergenerational group, peer group seniors, peer group children) will occur under professional supervision twice a week lasting over a 25-week period with training sessions lasting 45 minutes each. Control groups (control group seniors, control group children) receive no intervention.
45466430|NCT03707145|Behavioral|Consultation|The consultation will provide advice (including a short written report) about promoting healthy lifestyles, tailored to the individual
45680577|NCT01738971|Other|rapid access|Provision of box which the participant can take to local family planning clinic (contraceptive service) allowing rapid access (i.e. will be seen by a health professional for a consultation regarding contraception there and then).
45680578|NCT01738971|Other|one month progestogen only pill|Provision of 1 month supply of a progestogen only pill (levonorgestrel 35mcg - Norgeston, Bayer, UK)
45680579|NCT01738581|Device|Repetitive Transcranial Magnetic Stimulation|Applied to the premotor cortex at 1 Hz at 90% resting motor threshold for 1200 pulses.
45680580|NCT01738581|Behavioral|Sensorimotor Retraining|For sensorimotor retraining, a subset of the Learning-based Sensorimotor Training program was followed
45680581|NCT01738581|Behavioral|Non-specific Therapy|A non-specific massage and stretching program directed to the hand, wrist and forearm
46016857|NCT04206657|Drug|1mg KHK7580|Single oral dose administration of 1mg KHK7580
46016858|NCT04206657|Drug|3mg KHK7580|Single oral dose administration of 3mg KHK7580
46016859|NCT04206657|Drug|6mg KHK7580|Single oral dose administration of 6mg KHK7580
46016860|NCT04206657|Drug|12mg KHK7580|Single oral dose administration of 12mg KHK7580
46016861|NCT04206657|Drug|6mg KHK7580 for 8days|multiple oral dose administration of 6mg KHK7580 for 8days
46016862|NCT01295814|Drug|Adalimumab|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
46016863|NCT01295814|Other|inactive drug|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
46016864|NCT01254045|Drug|placebo|intranasal placebo (48 international units)
45466431|NCT03707145|Behavioral|Online Support|The participant will have access to an online platform 'FACET', to monitor themselves periodically, obtain feedback about their functional ability, receive recommended diet, exercise and physical activity interventions and record the adherence to any intervention.
46016865|NCT01254045|Drug|oxytocin 24IU|intranasal oxytocin (24 international units) and intranasal placebo (24 international units)
46016866|NCT01254045|Drug|oxytocin 48IU|intranasal oxytocin (48 international units)
46016867|NCT04324320|Diagnostic Test|medical assessment|"medical assessment includes the collection of~sociodemographic data~anthropometric data (weight, height, body mass index)~medical data~psycho-oncologic basis assessment (PO-BADO questionnaire)~pain assessment (VAS: visual analogue scale)~3 functional tests:~handgrip strength~6 Minute Walking Test~Timed Get up and Go Test"
45680582|NCT01738503|Drug|RBP-6000|18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL® Delivery System. Each injection of RBP-6000 is separated by a minimum of 28 days and given on alternate sides of the participant's abdomen.
46016868|NCT04324320|Diagnostic Test|psychological assessment|"psychological assessment includes several standardized screening and assessment questionnaires and tools:~quality of life: SF-36~anxiety, depression, stress: Hospital Anxiety and Depression Scale (HADS-D)~subjective stress perception: Perceived Stress Scale (PSS-10)~resilience: resilience scale (RS-13)~fatigue: Brief Fatigue Inventory (BFI)~disability related to pain: Pain Disability Index (PDI)~workability: Work Ability Index - short version (WAI-K)~psychological assessment based on the checklist of the International Diagnoses (IDCL) for ICD-10 and the ICD-10 checklist of symptoms for psychological disorders (SCL))"
45680583|NCT01738503|Drug|Subutex|Participants were inducted and stabilized over a 14-day period (study days -14 to -1) on SUBUTEX sublingual tablets. Tablets are placed under the tongue until dissolved.
45680584|NCT01738191|Drug|Atomoxetine|The study drug target dose is ATM 80mg per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.
45466432|NCT03707145|Behavioral|Empowered|The participant will be actively encouraged to contribute to their own consultation and take co-ownership and responsibility for the action plan.
45680585|NCT01738191|Drug|Placebo|
45680586|NCT01737879|Drug|Peginesatide|All participants will receive peginesatide for the first 24 weeks.
45680587|NCT01737879|Drug|Epoetin alfa|All participants converted to epoetin alfa at week 25 for a total of 32 weeks
45837855|NCT05640089|Other|fMRI-based neurofeedback|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
46016869|NCT01075282|Drug|Insulin Glargine|
46016870|NCT01075282|Drug|LY2189265|
46016871|NCT01075282|Drug|Metformin|
46016872|NCT01075282|Drug|Glimepiride|
46101045|NCT03243149|Device|fMRI - GE Medical System|"Recovery from PTSD symptoms has been modeled experimentally as fear extinction that depends on three interconnected brain regions that involve the amygdala where extinction memories are stored, the subcallosal/subgenual cortex within the medial PFC involved in consolidation of the extinction memory, and the hippocampus which mediates the context specificity of context specificity of extinction.~The two MRI systems are used for human research by many faculty and research groups at Duke and UNC, Chapel Hill. The center has two research dedicated General Electric MR 750 scanners with a field strength of 3 Tesla. These systems use a combination of General Electric production pulse sequences and custom research pulse sequences that have been developed by Brain Imaging and Analysis Center faculty and other MR physicists. The scanners are used for imaging and spectroscopy."
46101046|NCT02701127|Drug|Oral niacinamide, 1 gram daily|
45466433|NCT03793231|Combination Product|fungalAi platform technology|Electronic surveillance and radiologic diagnosis of invasive fungal infections using fungalAi and associated methodologies.
45466434|NCT03446638|Drug|FDA-approved drug or combination of drugs|Patients assigned to this arm will receive an FDA-approved drug or combination of drugs. Dosing and treatment schedule will follow the package insert for the selected drug(s).
45466435|NCT03446638|Drug|FLAG induction|Patients will receive 30 mg/m2 per day intravenously of fludarabine for 5 days and 2000 mg/m2 per day intravenously of cytarabine for 5 days. 5 mg/kg per day of granulocyte colony stimulating factor (G-CSF) may be given subcutaneously beginning on Day 1 of each treatment until absolute granulocyte count > 500/ microliter for 3 days.
45466436|NCT03446638|Drug|7 + 3 induction|Patients will receive 100-200 mg/m2 per day intravenously of cytarabine for 7 days, plus either 45-60 mg/m2 per day intravenously of daunorubicin or 9-12 mg/m2 per day intravenously of idarubicin for 3 days.
45466437|NCT03446638|Drug|Low-dose cytarabine|Patients will receive 20 mg/m2 per day subcutaneously of cytarabine for 10 days every 28 days.
45466438|NCT03446638|Other|Supportive care alone|Patients will receive one or more of the following: blood product transfusions, antibiotics, granulocyte colony-stimulating factor (G-CSF), erythropoietic stimulating factors, and iron chelation.
45466439|NCT03446638|Device|Computational biology simulations software|Genetic testing results for each patient randomized to this arm will be used by a computational biology simulations software program to generate a personalized map of dysregulated metabolic pathways contributing to the patient's disease. This map will then be used to digitally screen for potentially therapeutic FDA-approved drugs or drug combinations to target the dysregulated metabolic pathways.
45466440|NCT05401019|Drug|Pramipexole|Oral medication, once a day during 16 weeks
45466441|NCT05401019|Drug|Risperidone|Oral medication, once a day during 16 weeks
45466442|NCT03446560|Device|CPAP, conventional follow up|Positive airway pressure to splint the airway and to prevent apneas during sleep. Follow up of patients after initiation of treatment according to clinical routine at the study site. Patients are informed to call or visit the sleep center in case of problems with the CPAP device. At 3 months a follow up visit is scheduled at the sleep center. CPAP compliance data will be downloaded and all patients fill in a number of questionaires related to the CPAP treatment effects on sleep apnea symptoms and health related quality of Life. Mask fitting will be tested.
46101047|NCT02701127|Drug|Oral niacinamide, 3 gram daily|
45466443|NCT03446560|Device|CPAP, telemedicine based follow up|Follow up of patients by means of a telemedicine solution for surveillance of CPAP treatment, Compliance with and efficacy of CPAP can be followed up by the sleep center personnel on a regular basis. Patients with low compliance and mask fitting problems will be contacted by phone. At the end of the 3 months period a visit at the sleep center will be scheduled only for patients with low compliance, low treatment efficacy, or high mask leakage. All patients will be asked to fill in a number of questionaires related to CPAP treatment effects on sleep apnea symptoms and health related quality of Life.
46016873|NCT04324242|Other|abdominal hallowing maneuver|abdominal hallowing maneuver includes tucking navel in and up. To be able to control the effect of breathing it was instructed to start the maneuver at the end of the expiration. During the maneuver it was instructed to focus on increasing the thickness of TrA without increasing the thickness of IO and EO
45466444|NCT03707067|Device|Compression garments|Made-to-measure compression garments providing high pressures (> 30 mmHg at the ankle and >20 mmHg at the thigh - equivalent to European class-2 stockings)
45466445|NCT03707067|Other|Sham recovery drink|"Non-caloric beverage, labelled as a recovery drink proposed to enhance athletic recovery. Aspartame/acesulfame-k based sweetener, providing 0.5 g carbohydrate and 2 Kcal per serving"
45466446|NCT01135823|Procedure|Patient survey|
45466447|NCT03788863|Drug|Diflucortolone valerate (BAY866146)|Follow clinical administration
45466448|NCT05135572|Diagnostic Test|Fibromiyalgia and foot pain|Sensory and motor conduction studies will be performed in the lower extremities. Nerve conduction studies will be performed by another physician unaware of the patient's diagnosisFunctional status will be evaluated by using the Turkish version of the Fibromyalgia Impact Questionnaire (FIQ).Neuropathic Pain will be evalutaed by using the Turkish version of the Neuropathic Pain Questionnaire.
45466449|NCT03708939|Dietary Supplement|Glucose|Daily consumption of 5g of glucose, for 14 days.
45466450|NCT03708939|Dietary Supplement|Aspartame|Daily consumption of six commercially available sachets containing aspartame and glucose as bulking agent (1g each sachet), for 14 days.
45466451|NCT03708939|Dietary Supplement|Sucralose|Daily consumption of six commercially available sachets containing sucralose and glucose as bulking agent (1g each sachet), for 14 days.
45466452|NCT03708939|Dietary Supplement|Saccharin|Daily consumption of six commercially available sachets containing saccharine and glucose as bulking agent (1g each sachet), for 14 days.
45466453|NCT03708939|Dietary Supplement|Stevia|Daily consumption of six commercially available sachets containing Stevia and glucose as bulking agent (1g each sachet), for 14 days.
45466454|NCT03708939|Other|No Supplement|Follow up without any dietary supplementation.
46016874|NCT04324086|Device|Calcium hydroxide with XP-endo Finisher file|XP-endo Finisher files (FKG Dentaire, La Chaux-de-Fonds, Switzerland). file will be used with an endodontic motor X-Smart (Dentsply Sirona, Ballaigues, Switzerland) in removal of calcium hydroxide
46016875|NCT04324086|Device|Calcium hydroxide with Irrisafe Ultrasonic tip|passive ultrasonic irrigation (PUI) with an IrriSafe Ultrasonic tips (Acteon,France), which will be driven by an ultrasonic device (Newtron P5, Satelec, Acteongroup, Merignac, France) in reemoval of calcium hydroxide
46016876|NCT04324086|Device|Calcium hydroxide with side vented needle|conventional syringe irrigation with side vented needle (prime Dent, India) in removal of calcium hydroxide
46016877|NCT04326582|Other|Observation|Determine of percentage of each type of arthritis in children, it's prognosis and outcome of treatment in comparison with international guidelines
46016878|NCT01253811|Drug|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg body weight every 4th week
46101048|NCT02701127|Drug|Placebo|
46101049|NCT00672698|Procedure|SURGERY|ELECTIVE SURGICAL PROCEDURES
45342563|NCT05810675|Behavioral|Telehealth Early Intervention Program (TEIP)|The Telehealth Early Intervention Program (TEIP) that will be carried out by parents at home when interact with their children; and to train parents in delivering developmental and behavioral techniques to their children. The participating families will be randomized in parallel to treatment and comparison groups for teaching the knowledge and techniques: (1) Treatment group: providing the training of TEIP for parents via telehealth modalities as they learn critical skills with their child with the goal of increasing multidimensional child developments. Intervention provider will provide the training for parent-child dyad interaction to work with parents to implement these strategies at home environment.
45466455|NCT05669053|Behavioral|Super U Story intervention|Participants in this condition will be asked to play a Roblox adventure video game called 'Super U Story'. They will play the game once and have between 6 - 30 minutes to complete the game.
45466456|NCT05669053|Behavioral|Alternative Roblox game|Participants in this condition will be asked to play an alternative Roblox adventure video game called Rainbow Friends Story (colour story). They will play the game once and have between 6 - 30 minutes to complete the game.
45466457|NCT05669053|Behavioral|Online word search|Participants in this condition will have 20 minutes to complete a series of word searches online.
46016879|NCT01295580|Device|ARTZ|Hyaluronic acid (five 2.5 mL injections)
46016880|NCT01295580|Device|DUROLANE|Hyaluronic acid stabilized (one 3.0 mL injection + four weekly 0 mL sham injections)
45466458|NCT04659161|Drug|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.
45466459|NCT04659161|Drug|Placebo|Placebo Capsules
46016881|NCT01253577|Device|Sinus Stent with drug coating|Sinus stent coated with 370 ug of the corticosteroid mometasone furoate
46101050|NCT02700893|Drug|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants < 1000g - Renewable once 2.5 mg/kg for infants > 1000G - Possible additional dose of 1 mg/kg
45466460|NCT03446482|Other|observation of differents tasks|Evaluation by an external observer (nurse student in research stage or clinical research technician) of the distribution of medical time for the performance of the different tasks of anesthesiologist (in minutes)
45466461|NCT03129256|Drug|Apatinib Mesylate tablet combined with S-1 capsules|Oral use with low-dose Apatinib combined with S-1 until disease progression
45466462|NCT02950545|Device|Placebo Lenses|AcuVue Oasys Bandage Lenses with no prescription
45466463|NCT02950545|Device|Spherical Lenses|1-DAY ACUVUE® MOIST contact lenses
45466464|NCT02950545|Device|Toric Lenses|1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses
46101051|NCT02700893|Drug|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants < 1000g 0.2 µg/kg for infants > 1000g
46101052|NCT04154306|Dietary Supplement|Red clover|2 weeks of Red clover
46101053|NCT04154306|Dietary Supplement|Placebo|2 weeks of Placebo
46101054|NCT04213781|Device|HappyMed Video Glasses|HappyMed allows the immersion of patients in films, cartoons or concerts.
45466465|NCT05619679|Other|Kidney Transplantation|Kidney transplantation
46016882|NCT01253577|Device|Non Coated Sinus Stent|Sinus stent (visually identical) without drug coating
46016883|NCT02876692|Device|Machine perfusion|Deceased donor kidneys were preserved by hypothermic machine perfusion
46016884|NCT01295034|Dietary Supplement|conventional vitamin D treatment|Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.
46101055|NCT04213781|Drug|Propofol|The dosage is modified according to the Dixon's up-and-down method (using 0.5 µg/ml as a step size). The first patient in each group will start at a dose 3 µg/ml propofol. If patient manifests discomfort then the next patient will receive an increment of 0.5 µg/ml propofol, if patient is comfortable, then the next patient received a decrement of 0.5 µg/ml propofol.
46101056|NCT04213781|Drug|Sufentanil|0.1 µg/kg
46016885|NCT01295034|Drug|tiered/titrated vitamin D dosing|Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.
46016886|NCT01253421|Drug|amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride
46016887|NCT01253421|Drug|placebo|single-dose placebo capsule
46016888|NCT01077076|Drug|Zegerid|Zegerid taken once daily for 11 days.
46101057|NCT00669500|Behavioral|Lifestyle intervention|Alive!TM web-based, 12 week lifestyle intervention sent via NutritionQuest.
46101058|NCT02700737|Other|Image-based simulation modelling|"The first dataset will include the imaging parameters currently recommended by clinical practice guidelines (referred to as limited dataset)."
46016889|NCT01077076|Drug|Prilosec OTC™ Tablets|Prilosec OTC™ Tablets taken once daily for 11 days.
46101059|NCT02700737|Other|Imaging parameters currently recommended by clinical practice guidelines|"The second dataset will include an expanded list of parameters, inclusive of information that is available from traditional imaging parameters (as recommended by the guidelines) and simulation modeling (referred to as image-based modelling dataset)."
45466466|NCT01138865|Device|AutoSet Spirit--Wash--Modified-AutoSet Spirit|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
45466467|NCT01138865|Device|Modified-AutoSet Spirit--Wash-AutoSet Spirit|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
45466468|NCT03129334|Behavioral|LST Middle School Online|The adapted intervention will (1) utilize both online e-learning module (self-guided) and classroom-based sessions (facilitator led) to address PDA and concurrent ATOD abuse; (2) positively change social norms and challenge positive expectancies regarding PDA and ATOD abuse; (3) discourage diversion of prescription medications; (4) enhance protective factors by building social and self-regulation skills through interactive learning and behavioral rehearsal scenarios; and (5) incorporate booster sessions.
45466469|NCT05682807|Drug|Caffeine|5-10 mg/kg/day IV maintenance dose given after 24 h for 2 months.
45466470|NCT05682807|Drug|Probiotic Formula|probiotics sachets supplementation orally, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement after two months.
45466471|NCT01138943|Drug|Synthodont|"15 ml, tree times/day for 07 days~Arm: Chlorhexidine alcohol-base mouthrinse"
45837856|NCT05635669|Device|Sacral acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. In this group, paired electrodes from the electroacupuncture apparatus were attached transversely to the needle handles at bilateral Huiyang(BL35) and Zhongliao(BL33) .
46016890|NCT01077076|Other|Placebo|Placebo taken once daily for 11 days.
45466472|NCT01138943|Drug|Soludent|"15ml of 01% Chlorhexidine non alcohol-based, 3 times a day for 7 days~Arm: Experimental: non alcohol chlorhexidine mouthrinse"
45466473|NCT03446404|Diagnostic Test|Standing Computed Tomography|Provides weight bearing 3D view of knees.
46016891|NCT02876848|Other|OPTIMUM e-health tool|"If you are treated in a hospital that is using the OPTIMUM e-health tool (intervention group), once your care team receives any alerts, they may choose to:~Contact you over the phone or in person to provide medical advice on how to better take your pills,~Contact your pharmacist(s) and other doctors about your anti-cancer treatment."
46016892|NCT02876458|Other|Immediate coronary angiogram|An immediate coronary angiogram will be performed
46016893|NCT02876458|Other|Delayed coronary angiogram|A delayed coronary angiogram (between 48 to 96 hours) will be performed
46016894|NCT04781374|Drug|Neratinib|Oral, once daily with 28 consecutive days defined as a treatment cycle, dosage per protocol ,
46016895|NCT02876224|Drug|Atezolizumab|Atezolizumab 840 mg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
46016896|NCT02876224|Drug|Bevacizumab|Bevacizumab 5 mg/kg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
46016897|NCT02876224|Drug|Cobimetinib|Cobimetinib 60 mg or at dose determined during safety run-in phase will be administered orally once daily for 21 days of each 28-day cycle as specified in the arm descriptions.
46016898|NCT01294800|Drug|Preladenant|2, 5, or 10 mg tablets taken orally twice daily (BID)
46101060|NCT00505687|Drug|Rotigotine|"Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~The maximum rotigotine dose allowed is 16 mg/24 hours."
45466474|NCT05315583|Other|Collection of biological samples|All participants will have at each of the visits: a venipuncture sample of 2 dry tubes of 7 mL to make up 3 aliquots and a nasopharyngeal swab (optional). The aliquots of serum / plasma and the nasopharyngeal swab will be stored at -80°C until sent to the Pasteur Institute.
46016899|NCT01294800|Drug|Placebo tablet to match Preladenant|tablets taken orally BID
45466475|NCT01135901|Behavioral|Behavioural change programme|The programme consists of a introductory course, organised physical activity 2-3 times a week, meetings every 3rd month with lectures and theme nights, and organising self-help groups.
45466476|NCT03446248|Device|Corometrics-146 device|Fetal vibroacoustic stimulation with the Corometrics-146 fetal acoustic stimulator will be performed by placing the device on the maternal skin halfway between the pubic symphysis and the umbilicus and activating the device for 3 seconds.
46016900|NCT01294644|Drug|Deoxycholic acid injection|
46016901|NCT01294644|Drug|Placebo|Phosphate buffered saline placebo for injection
45466477|NCT03446248|Device|Mobile phone application|Fetal vibroacoustic stimulation with the mobile phone will be performed by placing and iPhone on the maternal skin halfway between the pubic symphysis and umbilicus and using the application to activate for 3 seconds the phone's built in vibration along with a 2,000 Hz tone at a sound level of 74 decibels when measured at 1 meter.
45466478|NCT03446014|Device|Fitbit Sub-Study|
45466479|NCT03358329|Combination Product|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
45466480|NCT01234805|Procedure|yoga therapy|Participates in yoga classes and yoga at home
45466481|NCT01234805|Other|questionnaire administration|Ancillary studies
45466482|NCT01234805|Procedure|quality-of-life assessment|Ancillary studies
45466483|NCT03445936|Device|Parietene Macro|Parietene Macro is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
45466484|NCT03445936|Device|Permacol|Permacol biologic implant is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
45466485|NCT05313009|Drug|Sotorasib and Tarloxotinib|Sotorasib 960 mg PO daily + tarloxotinib 150 mg/m2 IV weekly
45466486|NCT05313009|Drug|Sotorasib and Tarloxotinib|Sotorasib 960 mg PO daily + tarloxotinib IV weekly at the combination RP2D (RP2Dc).
46016902|NCT01293240|Device|lotrafilcon B contact lens|Commercially marketed, silicone hydrogel contact lens worn bilaterally on a daily wear basis for up to 30 days with a two week and four week evaluation visit.
46016903|NCT01253265|Drug|LY2439821|Administered subcutaneously
46016904|NCT01253265|Drug|Placebo|Administered subcutaneously
46016905|NCT01293084|Drug|0.12% saline|5mL of 0.12% saline inhaled once over 20 minutes
46016906|NCT01293084|Drug|7% saline|5mL 7% saline inhaled once over 20 minutes
46016907|NCT01293006|Drug|suvorexant|one tablet (30 or 40 mg suvorexant depending on participant age: 40 mg for participants <65 years of age and 30 mg for participants ≥65 years of age), orally, once daily, for 4 consecutive days
46016908|NCT01293006|Drug|Placebo|one tablet matching suvorexant, orally, once daily, for 4 consecutive days
46016909|NCT01292928|Device|Stent implantation|Stent implantation during the index procedure.
46016910|NCT01253187|Drug|EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|Treatment group A: Single 1 film-coated tablet (Ethinylestradiol [EE] 0.02mg / Drospirenone [DRSP] 3mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
46101061|NCT02631122|Procedure|Supraclavicular vs Retroclavicular Nerve Block|An ultrasound-guided supraclavicular or retroclavicular nerve block with 30 ml of 0.5% ropivicaine will be performed on patients scheduled for lower arm surgery; 25 ml to be delivered to the brachial plexus and 5 ml to the intercostal nerve
46016911|NCT01253187|Drug|EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca)|Treatment group B: Single 1 film-coated tablet (Ethinylestradiol [EE] 0.02mg / Drospirenone [DRSP] 3mg / L-5-methyltetrahydrofolate [L-5-MTHF] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
45466487|NCT03445780|Drug|Ethyl chloride spray|Skin cooling with ethyl chloride spray 5 seconds prior to injection
46016912|NCT01253187|Drug|L-5-MTHF 0.451mg (Metafolin)|Treatment group C: Single 1 coated tablet (L-5-methyltetrahydrofolate [L-5-MTHF] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
45466488|NCT03445780|Procedure|Pinching|Skin between the distal palmar crease and the palmo digital crease will be pinched for 5 seconds prior to injection
45466489|NCT03445780|Procedure|No Site of Procedure|Subjects will sit behind a screen with a small opening large enough to introduce the injected hand. They will not see any of the procedure
45466490|NCT04636775|Diagnostic Test|Microbiome|Nasal and buccal swabs, and stool sample, as well as the extracted DNAs
46101062|NCT02700659|Other|Cxbladder|Cxbladder is a non invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma.
46101063|NCT00669656|Drug|Prostate Health Cocktail|3 capsules daily PO up 12 months
45466491|NCT05364099|Drug|Lidocaine 1% Injectable Solution|2.5 ml of 1% Lidocaine will be administered via injection in suprascapular nerve in the suprascapular notch
45466492|NCT05364099|Drug|Triamcinolone Injection|0.5 ml 40mg/ml Triamcinolone will be administered via injection in suprascapular nerve in the suprascapular notch
45466493|NCT05364099|Procedure|Suprascapular Nerve Block|This procedure involves injection of a lidocaine and triamcinolone mixture into the suprascapular nerve in the suprascapular notch using ultrasound guidance for proper placement of drugs.
45466494|NCT03445702|Drug|Metformin|Metformin 1000mg once
45466495|NCT03445702|Drug|Placebo|Sugar pill manufactured to mimic metformin 1000mg
46016913|NCT01252563|Drug|Amlodipine|Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose. Dosage should be adjusted depending on the patient's symptoms. The dose can be raised up to 10 mg once daily for patients who show inadequate response.
45680588|NCT01879683|Drug|LiRIS® 400 mg|LiRIS® 400 mg is a drug-device combination product which is placed in the bladder during cystoscopy, remains in the bladder for up to 14 days gradually releasing lidocaine, and removed from the bladder via cystoscopy.
46016914|NCT01292226|Drug|mycophenolate mofetil|1 g PO BID for 24 weeks
46016915|NCT01292226|Drug|antibody induction|According to manufacturer recommendation
46016916|NCT01292226|Drug|Cyclosporine|According to manufacturer recommendation
46016917|NCT01292226|Drug|corticosteroid|According to manufacturer recommendation
46016918|NCT04207047|Device|Genius|"The Infini Radiofrequency System (K121481) is the predicate device. It is a minimally invasive radiofrequency device that employs a bipolar microneedle electrode system indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of facial wrinkles.~The Genius system is substantially equivalent to the Infini device with a digitally controlled direct drive mechanism for needle insertion and an improved needle design for easier needle insertion. The active tip of the Genius system is the substantially equivalent to the Infini device. The handpiece of the Genius system has also been redesigned to be lighter and more ergonomic."
46016919|NCT04207047|Device|eC02|The eCO2 Laser System (K091115) is indicated for use in dermatological procedures requiring ablation (removal), resurfacing and coagulation of soft tissue. Additionally, the 120 micron and 300 micron spot sizes are used in the treatment of wrinkles; rhytides, furrows, fine lines, textural irregularities, pigmented lesions and vascular dyschromia. The fractional 90 degree BellaV handpiece is intended to provide fractional CO2 treatment of skin and is not yet cleared.
46016920|NCT04207047|Device|PicoPlus|The PICOPLUS Laser System (K173700) is indicated for use in surgical and aesthetic applications in the medical specialties of dermatology and general and plastic surgery as follows:
45680589|NCT04415307|Other|Acupuncture|Acupuncture over acupoints.
45466496|NCT01136057|Biological|Collection of Anti-Influenza A Immune Plasma|
45680590|NCT04415307|Other|Far-Infrared heat-patch attachment|Far-Infrared heat-patch attachment over acupoints.
45680591|NCT04415307|Other|Acupuncture and Fir-Infrared heat-patch attachment|Acupuncture and Far-Infrared heat-patch attachment over acupoints.
45680592|NCT04415307|Other|Far-Infrared heat-patch attachment over acupoints without electric current passing.|Far-Infrared heat-patch attachment over acupoints without electric current passing.
45680593|NCT01605825|Drug|placebo/dalfampridine-ER|Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
45680594|NCT01605825|Drug|dalfampridine-ER/placebo|Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
46101064|NCT02700581|Procedure|low PEEP conventional ventilation|
46016921|NCT04207047|Device|LaseMD|The LaseMD Laser System (K171009) is a 1927 factional thulium laser indicated for use in dermatological procedures requiring the coagulation of soft tissue, treatment of actinic keratosis, and treatment of benign pigmented lesions such as, but not limited to lentigos (age spots), solar lentigos (sun spots) and ephiledes (freckles). The cleared LaseMD system is a 5W system.
46101065|NCT02700581|Procedure|moderate PEEP conventional ventilation|
45466497|NCT05302635|Other|Simulated group|"Students will be given training on nasogastic tube insertion and practice will be demonstrated in the laboratory based on the demonstration method and checklists, and will continue until students learn. Forms will be applied to students as a pre-test. A pilot scenario will be applied to two volunteer fourth year students.~Prebriefing: Students will be informed. Students will implement the scenario in the simulation laboratory and will wear uniforms. The student will be given 5 minutes for preparation, the application will be taken one by one and 15 minutes will be given for practice. Researchers will only observe during this time. During the application, the student will be scored according to the checklist. Students will be recorded with video.~Debriefing: Immediately after the end of the scenario, a debriefing session will be held with groups of 5 people. Feedback will be given on students' performance. Each session will last 20-30 minutes. Students will be given a post-test."
46101066|NCT02700581|Procedure|low PEEP protective ventilation|
46101067|NCT02700581|Procedure|moderate PEEP protective ventilation|
46101068|NCT00672776|Drug|paroxetine|
46101069|NCT00672776|Drug|placebo|
46101070|NCT02698085|Other|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
45342564|NCT05810662|Other|Lactated ringer and dextrose 5%|Fluid use perioperative
45466498|NCT01700335|Drug|SyB L-1101|"SyB L-1101（rigosertib sodium） will be administered to two cohorts at either 1200 mg/day or 1800 mg/day.~The dose will be administered intravenously for 72 continuous hours (3 days), followed by 11-day observation period. The treatment period of 14 days (3 days of administration + 11 days of observation) constitutes 1 cycle.~The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied."
45466499|NCT03445624|Drug|Infliximab|follow up the patients who received this drugs for 1 year by abdominal ultrasound,peripheral hemogram and colonoscopy
45466500|NCT05400941|Behavioral|Practice Led Intervention|This is a quality improvement intervention that includes learning collaboratives, practice facilitation, expert consultation and audit and feedback.
45680595|NCT04558905|Other|Face-to-face medical visits|Face-to-face medical visits
46101071|NCT02698085|Other|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula but without effect in the muscle because no penetrate in deep tissue
45342565|NCT05810636|Device|Garmin Vivosmart wearable device|Wearing smartwatches to collect data
46101072|NCT02629250|Procedure|SV maximization|When SpO2 ≥92%, mean arterial pressure (MAP) 65-100 mmHg, HR <100 bpm, Hb >8mg/dL and temperature ≥36℃, the patients will receive a 250 ml Ringer's lactate solution in 5 min as a fluid challenge for stroke volume (SV) maximization. The fluid challenge will repeat until the SV failed to increase by a factor of 10%. A reassessment on the SV maximization will be taken every 30 minutes and to restart algorithm when increased SV >10% or blood loss >250ml. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
46101073|NCT02629250|Procedure|supernormal DO2|Goal directed fluid therapy is administrated as group SV maximization. Then DO2I will be assessed. If at this stage the DO2I can not be greater than 600 mL/m2 (supernormal oxygen delivery goal), then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia.
46101074|NCT00616187|Drug|interferon beta treatment to add-on atorvastatin treatment|IFN-β-1a 22 µg s.c. 3 times weekly or IFN-β-1b s.c. every other day (3 months baseline) and add on oral daily 80 mg atorvastatin (9 months add on treatment)
46016922|NCT04207047|Device|LaseMD Flex|There are two new versions of the LaseMD system to be used in this study that are uncleared and investigational use only. The only change from the cleared system to the one of the LaseMD systems to be used in this study is that the watts have been increased to 20W and a new tip configuration with a larger 250+ um spot size. The other LaseMD system to be used in this study is the LaseMD FLEX. It also has 20W with larger spot size, a modified flat-top beam profile (as opposed to a Gaussian beam profile) and a faster scan rate. All other technical specifications remain the same as the cleared device.
46016923|NCT01290822|Device|BiVP|Biventricular pacing
46016924|NCT01290822|Device|AAI Pacing|Atrial pacing
46016925|NCT01075048|Drug|Tivantinib|ARQ 197 is supplied as a 120-mg capsule, administered twice daily at the dose determined in the Phase 1 portion of the study. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
46016926|NCT01075048|Drug|Placebo|Placebo to match ARQ 197, administered twice daily. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
46101075|NCT00616187|Drug|untreated to atorvastatin treatment|no treatment(3 months baseline)and oral daily 80 mg atorvastatin (9 months add on treatment)
46016927|NCT01075048|Drug|Cetuximab|Cetuximab 500 mg/ m^2 intravenous infusion over 120 minutes at the first cycle, then over 60-minutes at subsequent cycles. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
46016928|NCT01075048|Drug|Irinotecan|60 minutes after cetuximab, Irinotecan 180 mg/m^2 intravenous infusion over 30 - 90 minutes. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
46016929|NCT01290666|Device|Fistula Plug|Bioabsorbable fistula plug
46016930|NCT01252251|Drug|RAD001 (Everolimus) and Pasireotide (SOM230) LAR|Patients will be treated with SOM-230 (pasireotide) LAR 60mg IM once every 28 days and with RAD001 (Everolimus) 10mg PO daily. Each cycle is 28 days. An optional biopsy may be requested required after weeks of therapy. The biopsy may be performed between days 28 and 42.
46016931|NCT01289574|Drug|ASC-J9|Cream for twice daily topical application to the face
46101076|NCT05310227|Device|Nerivio|The device is a wireless wearable battery-operated stimulation unit controlled by a dedicated smartphone application. Treatments with Nerivio™ are self-administered by the user at the onset of a headache
46101077|NCT00663338|Drug|Rotigotine|Rotigotine 9.0mg patch (equivalent to 4mg/24hr transdermal absorption) once daily during the treatment phase.
45342566|NCT05810623|Drug|Intravesical Solution|Intravesical single dose instillation of chemotherapy within 24h from uretero-renoscopy
46016932|NCT02888301|Procedure|Computed Tomography|Undergo 18F-clofarabine PET/CT
46016933|NCT02888301|Radiation|Fluorine F 18 Clofarabine|Given IV
46016934|NCT02888301|Procedure|Positron Emission Tomography|Undergo 18F-clofarabine PET/CT
46016935|NCT04791748|Diagnostic Test|Vestibular tests|Screening vestibular test for patients without chronic vestibular deficits Complete vestibular test if not done yet in care of patients with chronic vestibular deficits
46101078|NCT02992015|Drug|Gemcitabine|Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
46016936|NCT04791748|Other|Virtual reality|Virtual reality protocol : doing tasks involving hand-eye coordination, in virtual reality, and in different sensory situations
46016937|NCT00624273|Drug|Sildenafil therapy|oral use
46016938|NCT02874976|Device|Active and Active Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
46101079|NCT04152902|Other|Objective outcome|The final outcome of surgical therapy was assessed according to a semi-quantitative scale graded as excellent, good, fair and poor, according to quantitative grades for dysphagia, reflux symptoms and oesophagitis
46101080|NCT04152902|Other|Quality of life|SF-36 Questionnaire
45680596|NCT04558905|Other|Alternating face-to-face medical visits and video medical consultations|Alternating face-to-face medical visits and video medical consultations
46101081|NCT02698007|Device|Laryngeal Mask Airway (LMA)|Fiberoptic bronchoscopy with the use of LMA
46101082|NCT01009567|Drug|Cabergoline|Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval
46016939|NCT02874976|Device|Active and Placebo Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
46016940|NCT02874976|Device|Placebo and active Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
46016941|NCT02874976|Device|Placebo and Placebo Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
46101083|NCT01009567|Drug|Control|Receive human albumin 20% infusion
46101084|NCT00669812|Drug|carmustine|
45342567|NCT05810584|Device|Revision LR femoral stem|Revision LR is a modular femoral stem used for hip replacement
45342568|NCT05810571|Procedure|preoperative remifentanil consumption|continuous remifentanil infusion will applied for peroperative analgesia
45680597|NCT04558749|Other|State-trait anxiety inventory scale|This scale is composed of two parts, part one measures anxiety traits and part two measures anxiety state. Each part comprises 20 statements. This scale is a (4) point scale, with a score ranging a minimum of 20 grades to a maximum of 80 grades.
45680598|NCT04558749|Other|Edinburgh Postnatal Depression Scale (EDPS)|The EPDS is a self-report measure that focuses on the cognitive symptoms of depression. It excludes somatic items that might generate false positives both during pregnancy and after childbirth.7 The EPDS consists of 10 items, each scored 0-3 points, with a potential scale score of 0-30.
45680599|NCT01727505|Device|Sequence A: Conventional-Volume Guarantee|"This is a crossover study. Infants will be randomly assigned to one of two sequences.~In sequence A, the infant will undergo a 24-hour period of conventional mechanical ventilation followed by a 24 hour period of volume guarantee ventilation.~Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).~During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.~During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study."
46016942|NCT04305964|Device|Nastent® (a distally perforated soft silicon nasal tube)|Insertion of the Nastent® to nostril during sleep hours
46101085|NCT00669812|Drug|cyclophosphamide|
46101086|NCT00669812|Drug|cytarabine|
46101087|NCT00669812|Drug|doxorubicin hydrochloride|
46101088|NCT00669812|Drug|epirubicin hydrochloride|
46101089|NCT00669812|Drug|etoposide|
46101090|NCT00669812|Drug|ifosfamide|
46016943|NCT04305964|Diagnostic Test|Polygraphy with WatchPAT™ 300|WatchPAT™ 300 is an innovative diagnostic Home Sleep Apnea Test (HSAT) that utilizes the proprietary Peripheral Arterial Tone signal (PAT™) to enable simple, accurate and reliable sleep apnea testing.
46101091|NCT00669812|Drug|melphalan|
46016944|NCT01252095|Drug|PG545|PG545 Lyophilized Powder for Subcutaneous Injection. Patients will be dosed once weekly until they exhibit disease progression, are discontinued for reasons of tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 500 mg planned.
46016945|NCT04306042|Drug|Nivolumab or Pembrolizumab|Nivolumab or Pembrolizumab
46016946|NCT04305886|Other|Discussion Guide|Written list of prompts to facilitate discussion
46101092|NCT00669812|Drug|methotrexate|
46101093|NCT00669812|Drug|prednisolone|
46101094|NCT00669812|Drug|vincristine sulfate|
46101095|NCT00669812|Procedure|autologous hematopoietic stem cell transplantation|
46016947|NCT04305730|Behavioral|Use of a pedometer following surgery|Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.
46016948|NCT04305730|Behavioral|Standard of care|Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
46016949|NCT01074658|Device|Medtronic CoreValve System|Transcatheter Aortic Valve Implantation of the Medtronic CoreValve System
46016950|NCT01074502|Drug|apremilast|apremilast 20 mgs orally twice a day for 12 weeks
46101096|NCT00669812|Procedure|biopsy|
46101097|NCT00669812|Procedure|peripheral blood stem cell transplantation|
46101098|NCT02697851|Drug|Microgynon 30®|
46101099|NCT02697851|Drug|Evotaz®|
46101100|NCT01012843|Drug|Amoxicillin-Clavulanate|oral 875/125 mg tablets of Amoxicillin/Clavulanate 2 times a day for 10 days
46101101|NCT01012843|Drug|Placebo|oral Placebo tablets two times a day for 10 days
46101102|NCT00669890|Drug|Gemtuzumab Ozogamicin|Dose Escalation
46101103|NCT00669890|Drug|Busulfan|Conditioning Regimen
46101104|NCT00669890|Drug|Cyclophosphamide|Conditioning Regimen
46101105|NCT00669890|Drug|Thymoglobulin|(Unrelated Donors only)
46101106|NCT00669890|Drug|Tacrolimus|GVHD Prophylaxis
46101107|NCT00669890|Drug|Mycophenolate Mofetil|GVHD Prophylaxis
46101108|NCT00669890|Drug|Methotrexate|GVHD Prophylaxis
46101109|NCT02697929|Drug|sugammadex|
46101110|NCT02697929|Drug|Neostigmine|
46016951|NCT01289028|Drug|Nilotinib|
45680600|NCT01727505|Device|Sequence B: Volume Guarantee-Conventional|"This is a crossover study. Infants will be randomly assigned to one of two sequences.~In sequence B, the infant will undergo a 24-hour period of volume guarantee ventilation followed by a 24 hour period of conventional mechanical ventilation.~Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).~During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.~During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study."
46016952|NCT04305652|Other|The Progressively Lowered Stress Threshold Model|PLST is a conceptual model for reducing behavioral symptoms in individuals with dementia. The PLST model provides the foundation for a psychoeducational intervention that assists formal and informal caregivers in understanding behaviors and planning care for individuals with dementia. If the model is to be applied at home, at least three home visits are made in line with the listed principles. While making a diagnosis during the first home visit, a maintenance plan for the problems is created in other home visits and the caregiver is trained to implement the care plan. After the home visits, the process is carried out by providing counseling through telephone calls or face-to-face interviews when necessary.
46016953|NCT02875990|Biological|Blood sample|
46016954|NCT04777474|Diagnostic Test|Enhanced contact endoscopy|The study subjects will undergo enhanced contact endoscopy - studied imaging technique
46016955|NCT04777474|Diagnostic Test|Narrow band imaging|The study subjects will undergo narrow band imaging - comparator procedure
46016956|NCT04777474|Diagnostic Test|IMAGE1S imaging|The study subjects will undergo IMAGE1S imaging - comparator procedure
46016957|NCT02890056|Behavioral|H2GO!|
46016958|NCT04303312|Other|Benzydamine Hydrochloride|Patients will rinse by mouth three times daily for 20 days
46016959|NCT04303312|Combination Product|Solcoseryl and pumpkin seed oil|Patients will receive by mouth three times daily for 20 days
46016960|NCT05590026|Drug|Pectointercostal and ESP block|Both Pectointercostal at between 4th and 5th costa and ESP block will apply at thoracal 6 level to the patient.
46101111|NCT00616265|Device|CPAP|Pressure device on airway to maintain it open
46016961|NCT04303546|Device|arterial stiffness measurements|We will measure arterial stiffness by VOPITB and with others devices to validate VOPITB
46016962|NCT05579184|Drug|[177Lu]Ludotadipep|"Patients will receive 100 mCi of [177Lu]Ludotadipep every 8 [±1] weeks (up to 6 times)~Test article code/name: [177Lu]Ludotadipep~Administration route: intravenous injection~Total dose strength: 4 to 6 x 3.7 GBq~Dosage form: solution for injection"
46016963|NCT04303624|Other|Health sciences survey|Large scale demographic survey evaluating attitudes of population towards organ donation for the self vs. family
46016964|NCT04305574|Behavioral|Use of social media during COVID-19|Participants' self-reported use of an official WhatsApp channel to receive and share news about COVID-19
46016965|NCT01250925|Drug|ReNu MultiPlus® MultiPurpose Solution|Contact lens care regimen
46101112|NCT00663416|Drug|NTx™-265: rhCG, then rEPO|"rhCG 10,000 IU, SC, on Day 1, 3, and 5 of study participation, then~rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation"
46016966|NCT01250925|Drug|OPTI-FREE® RepleniSH®|Contact Lens care regimen
46016967|NCT01250925|Drug|Clear Care®|Contact lens care regimen
46016968|NCT01285908|Drug|Intravenous Norepinephrine Infusion|
46101113|NCT00663416|Drug|Saline placebo|"Saline SC, on Day 1, 3, and 5 of study participation, then~Saline IV, on Day 7, 8, and 9 of study participation"
46101114|NCT04215341|Behavioral|Physiotherapy|A course of breathing retraining delivered by a physiotherapist and practiced by the participant at home.
46101115|NCT02700503|Behavioral|Encourage 2.0|Participants will be enrolled in the ENCOURAGE 2.0 family-based diabetes prevention intervention that was designed through our work in Aims 1 and 2 of the study. It is this modified population-level ENCOURAGE 2.0 family-based diabetes prevention intervention that will be studied.
45680601|NCT04564677|Device|Ifabond (Péters surgical)|Ifabond (Péters surgical) is a CE-marked synthetic surgical glue for internal and external use. The glue is non-toxic, biocompatible and biodegradable. It is commercially available and can be used for mesh fixation, as tissue adhesive, for sealing of sutured tissue and for hemostasis.
45342569|NCT05810571|Procedure|postopeartive controlled anlagesia with morphine|postoperative morphine patient controlled analgesia will be applied for postoperative analgesia
45680602|NCT04564053|Drug|LNA043|Single intra-articular injection on Day 1
45680603|NCT04564053|Drug|Placebo|Single intra-articular injection on Day 1
45680604|NCT01726803|Other|Early Physical Therapy with Usual Care|The early physical therapy arm includes 4 total sessions. The first 2 sessions include use of thrust spinal manipulation with exercises for range of motion and strengthening of the spine. The final 2 sessions include the exercise component only.
46101116|NCT00505375|Drug|CTLA-4 Ig|Intravenous infusion of 10 mg/kg of CTLA-4 Ig every other week for the first two doses and then every 28 days for a total of 27 doses
46101117|NCT00505375|Other|Placebo|Intravenous infusions of placebo every other week for the first two doses and then every 28 days for a total of 27 doses
46016969|NCT05577234|Other|Animal-assisted intervention|The dog accompanied by the zootherapist will participate in the care of sessions 1 and 2. During these two sessions, the dog will be present with the child in the waiting room until the end of the dental consultation. Session 3 will take place without the dog being present.The usual management with conventional behavioural strategies and possible administration of MEOPA will be implemented during the 3 treatment sessions.
45466501|NCT01312077|Drug|Levobupivacaine|peri- and intraarticular surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline. A catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. An elastomeric pump will deliver a continuous infusion of levobupivacaine 0.25% at 4ml/hr commencing 6 hours postoperatively and continuing for 24 hours.
46016970|NCT05577234|Behavioral|Venham scale modified by Veerkamp|The Venham scale modified by Veerkamp, based on observation of one's behaviour and used in current practice, ranges from 0 (relaxed) to 5 (totally disconnected from the reality of danger).
45466502|NCT01312077|Drug|Intrathecal morphine|intrathecal morphine bolus 200 micrograms
45466503|NCT05090098|Other|None intervention|None intervention
45466504|NCT01139099|Behavioral|Group Psychotherapy|integrated group psychotherapy, including the interpersonal and cognitive group therapy
45680605|NCT01726803|Other|Usual Care|The usual care intervention includes advice and education to remain active and provision of the Back Book highlighting these recommendations. Pharmaceuticals may be prescribed at the discretion of the primary care provider. Follow-up visits to primary care provided are recommended for all patients dissatisfied with their progress.
45466505|NCT03791983|Other|Scalp Acupuncture|Scalp acupuncture is a form of alternative medicine in which thin needles are inserted into the scalp. It is a key component of traditional Chinese medicine (TCM).
45466506|NCT03791983|Other|Body Acupenture|Acupuncture is a form of alternative medicine in which thin needles are inserted into the body. It is a key component of traditional Chinese medicine (TCM).
46016971|NCT01250769|Device|Manual Toothbrush|A standard size manual toothbrush to clean visible tooth surfaces
46016972|NCT01250769|Device|Interproximal Cleaning Device|An electronic device that combines water and air to clean between the teeth
46016973|NCT05574270|Device|IC-8 Intraocular Lens (IOL)|A small aperture extended depth of focus hydrophobic acrylic intraocular lens.
46016974|NCT01074268|Drug|insulin degludec|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
45466507|NCT03710031|Other|PNS Tracking|Through blood and stool samples the study team will track the interplay among PNS as they relate to diminished QOL. Symptoms tracked include neurocognitive dysfunction, fatigue, anxiety, depression and pain, inflammation (cytokines and C-reactive protein), gut microbiota [(GM) richness and diversity] and diet (macronutrients: carbohydrates, fats and proteins).
46016975|NCT01074268|Drug|insulin detemir|Injected s.c. (under the skin) once daily or twice daily (BID). Dose was individually adjusted.
46016976|NCT01074268|Drug|insulin aspart|Injected s.c. (under the skin) as mealtime insulin. Dose was individually adjusted.
46101118|NCT04153994|Procedure|Erector Spinae Plane Blockade|The ESPB is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
45466508|NCT03445546|Diagnostic Test|diagnostic test of platelet function|Light transmittance aggregometry and VerifyNow
45466509|NCT03793309|Drug|Vitamin D|Oral vitamin D
46016977|NCT04303234|Other|Artinibsa|local anaesthetic solution with a short latency time. Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains 4%Articaine 1:100000.
46016978|NCT04303234|Other|Artpharma|Its a special amide local anesthetic contain 4% articaine with epinephrine 1/200000 as a vasoconstrictor ,Contains only sulfite as a stabilizer (max 0.31 mg)
46016979|NCT01074190|Drug|Group 1|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
45466510|NCT01140893|Drug|Exenatide|"Research drug (exenatide or placebo), will begin at V0, after randomization. The initial dosage for the first month will be 5 µg SC BID. Injections can be administered at any time within the 60 minute period before the morning and evening meal.~From V1, research drug will be titrated from 5 to 10 µg SC BID. If gastro-intestinal adverse effects occur with 10 µg SC BID, the dosage will be back-titrated to 5 µg SC BID. Thus, the higher research drug dosage tolerated will be used during the study time."
45466511|NCT01140893|Drug|Placebo|Placebo
45466512|NCT01312155|Other|Intubation|Intubation, endotracheal
45466513|NCT03788785|Behavioral|Experimental arm|The specific tobacco cessation intervention will be based on meeting with trained nurses : three 1/2 hour session of assessment of current addictive behaviors and motivation to change smoking habits occurring within five days tops.
45466514|NCT03788785|Other|Control arm|In the control arm, patients will receive the current standard of care for these patients, namely referral to external care after general advice on tobacco cessation (self-help tools).
46016980|NCT01074190|Drug|Group 2|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
46016981|NCT01074190|Drug|Group 3|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
45466515|NCT03445468|Biological|IL-YANG Quadrivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
45466516|NCT03445468|Biological|IL-YANG Flu Vaccine Pre-filled Syringe|A single 0.5mL dose administrated as an intramuscular injection.
45466517|NCT04620551|Device|Sub-clinical stimulation|The third night of recording will involve sub-clinical thresholds of stimulation in all subjects.
46016982|NCT01073566|Device|Finesse|Finesse Insulin Delivery Patch
46016983|NCT01073566|Device|Pen/Syringe (Usual injection device)|Pen/Syringe
46016984|NCT01072396|Drug|Tiotropium|double blind randomized crossover
46016985|NCT01072396|Drug|Placebo|inhalation powder capsule identical to those containing tiotropium bromide inhalation powder
46016986|NCT01045096|Drug|Dexlansoprazole|Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.
45342570|NCT05810558|Procedure|glycine powder air-powered debridement|The intervention treatment consist sof glycine powder air-abrasive debridement (GPAD) using a handheld air polishing device, disposable subgingival nozzle, and glycine powder The nozzle is inserted to the depth of the pocket and all surfaces of the implant (mesial, buccal, distal, lingual) debrided for 5 seconds.
45466518|NCT05682729|Behavioral|Book Reading Intervention|Children read books containing relevant stimuli.
45466519|NCT03791827|Drug|Corticosteroid|corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.
45466520|NCT03791827|Drug|Hydroxychloroquine|Hydroxychloroquine is recommended as the basic therapy for lupus nephritis
45466521|NCT03791827|Drug|Cyclophosphamide|The typical therapy for cyclophosphamide is either 500 to 750mg/m2 once every month for 6 doses or 8 to 12 mg/kg/d for two consecutive days every two weeks for 6 to 8 doses through i.v.
45466522|NCT03791827|Drug|Mycophenolate Mofetil|The recommended dose of mycophenolate mofetil is 20 to 30mg/kg/d
45466523|NCT03791827|Drug|Azathioprine|The recommended dose of azathioprine is 1.5 to 2mg/kg/d
45466524|NCT03791827|Drug|Tacrolimus|The recommended dose of tacrolimus is 0.05 to 0.15mg/kg/d, Q12h
45466525|NCT03791827|Drug|Cyclosporine A|The recommended initial dose of cyclosporine A is 4 to 6mg/kg/d, Q12h
45466526|NCT03791827|Drug|Rituximab|The recommended dose of rituximab is 375mg/m2 once a week for 2 to 4 doses
45466527|NCT01139177|Device|Stenting of atherosclerotic lesion(s)|Stenting of atherosclerotic lesions post pre-dilatation of lesion(s)
45466528|NCT05682651|Procedure|tracheal stenosis follow-up file|Patients' age, gender, American Society of Anesthesiologists (ASA) classification, comorbidities, etiologic cause, intubation time, type of surgery, length of hospital stay, and morbidity/mortality information will be recorded.
45466529|NCT01232309|Dietary Supplement|Chitin-Glucan|3 x 500 mg capsules (tid) = 4.5 mg daily dose
45466530|NCT01232309|Dietary Supplement|Low Dose Chitin-Glucan|3 x 167 mg capsules (tid) = 1.5 g daily dose
45466531|NCT01232309|Dietary Supplement|Low Dose Chitin-Glucan + Olive Extract|3 x 167 mg capsules (tid) = 1.5 g daily dose (C-G) + 135 mg olive extract
45466532|NCT01232309|Dietary Supplement|Placebo|3 x 500 mg capsules (tid)
45466533|NCT03708861|Drug|maraviroc (300 mg QD) + atazanavir/ritonavir (300 and 200 mg /100 mg QD)|"Phase 1: switch from tenofovir disoproxil fumarate/emtricitabine (200/245 mg QD)+ atazanavir/ritonavir (300 /100 mg QD) to maraviroc (300 mg QD) + atazanavir/ritonavir (300 /100 mg QD).~Phase 2: switch from maraviroc (300 mg QD) + atazanavir/ritonavir (300 /100 mg QD) to maraviroc (300 mg QD) + atazanavir/ritonavir (200 /100 mg QD)"
45466534|NCT03789019|Drug|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
45466535|NCT03445312|Behavioral|not processing urine cultures|microbiology lab will not process culture unless called
45598286|NCT04439097|Other|Multicomponent physical exercise program associated with a Mediterranean diet|"In this basic structure of each sessions, traditional exercises of mobility, strength, balance and coordination are included with the main objective of improving functional capacities. But, besides, games and some activities are also included with the aim, not only of improving the functional capacity, but also working the cognitive functions to reinforce the global effects.~The Mediterranean diet will based in these main foods: 1) vegetables; 2) fruits; 3) fish or seafood; 4) legumes; 5) nuts; 6) bread or cereals; 7) white meat; 8) eggs; and 9)olive oil."
46016987|NCT01045096|Drug|Dexlansoprazole|Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days
45598287|NCT04439097|Other|Usual care|Usual care and participants continue with their life normally, without participating in a standardized exercise program, and they will be instructed to maintain their current physical activity level.
45680606|NCT04563741|Behavioral|MOVE!+UP|behavioral weight management intervention developed for Veterans with PTSD
45680607|NCT04563741|Behavioral|MOVE!|standard VA weight management intervention
45680608|NCT01726335|Drug|Risperidone prolonged release|Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
46016988|NCT01045096|Drug|Dexlansoprazole|Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days
46016989|NCT02876146|Drug|Benzimidazole|Withdrawal of benzimidazole after 4 years (non operable AE) or one year after surgery (curative hepatectomy)
46016990|NCT02874586|Other|Plasma exchange combination of immunosuppressive regimens|
46016991|NCT02875756|Procedure|10 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 10 times
46016992|NCT02875756|Procedure|20 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 20 times
46101119|NCT02700269|Other|mBEADS|Evaluate approaches using magnetic bead capture, isolation, and surface tension valve transfer of biomarkers to improve the sensitivity of already approved malaria RDTs.
46101120|NCT02700347|Drug|Pyrazinamide|
45598288|NCT02214797|Device|Etafilcon A, Lotrafilcon B , Senofilcon A|
45598289|NCT02357589|Procedure|2D laparoscopic cholecystectomy|
45598290|NCT02357589|Procedure|3D laparoscopic cholecystectomy|
45598291|NCT02357511|Device|Study Monitor used|
45598292|NCT02225639|Drug|PRC-063 25 mg|Oral 25 mg capsule - active
45598293|NCT02225639|Drug|Placebo|Oral placebo capsule
45680609|NCT01877421|Drug|2 mg KSL-W|
45680610|NCT01877421|Drug|4 mg KSL-W|
45680611|NCT01877421|Drug|6 mg KSL-W|
46101121|NCT02700347|Drug|Allopurinol|
46101122|NCT00594932|Drug|mycophenolate mofetil|First treatment month: mycophenolate mofetil ascending doses orally Second treatment month to end of study: mycophenolate mofetil 3 gms/day (or less if tolerance issues arise)
45466536|NCT01234961|Behavioral|Redesigning Daily Occupations|The ReDO is a 16-week group-based programme, comprising three phases. Phase I covers five weeks and has a special focus on occupational self-analysis, while Phase II, also comprising five weeks, is concentrated around goal setting and strategies for accomplishing desired changes in the patterns of everyday activities. During these ten weeks the group meets twice a week and each session lasts for 2½ hrs. Phase III consists of work placement for six weeks, if possible in relation to the woman's ordinary work but otherwise at another relevant work place. During Phase III the group meets three times (weeks two, four and six) in order to monitor the group placement. The groups are led by two licensed occupational therapists specifically trained for the ReDO programme.
45466537|NCT01234961|Other|Care as usual|The CAU group gets follow-ups by an officer at the Social Insurance Office, including contacts with the employer, but the additional support varies largely, from receiving relevant medical care, if any, to physical therapy and to more comprehensive rehabilitation programmes.
45466538|NCT04798755|Drug|Methotrexate|Inicial dose 15mg/week increasing up to 25 mg/week
45466539|NCT04798755|Drug|Adalimumab|At the Baselin visit adalimumab 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.
45466540|NCT04798755|Drug|Adalimumab+Methotrexate|"Adalimumab: at the Baseline visit 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.~Methotrexate:Inicial dose 15mg/week increasing up to 25 mg/week"
45466541|NCT03445234|Dietary Supplement|Blueberry|26 g/day freeze-dried powder, 2 weeks duration
45466542|NCT03445234|Dietary Supplement|Placebo|Placebo powder
45466543|NCT03445234|Dietary Supplement|banana|Acute ingestion of bananas 0.2 g carb/kg every 15 min exercise with water
45466544|NCT03445234|Dietary Supplement|No banana|water only
45466545|NCT01308229|Device|Nile PAX® paclitaxel-eluting coronary stent|Implantation of a Nile PAX bifurcation dedicated drug-eluting stent in coronary arteries to treat stenosis lesions
45466546|NCT03445078|Dietary Supplement|selenium supplementation|administration of selenium-rich corn powder 20g/d offering selenium 100μg/d
45466547|NCT03445078|Dietary Supplement|ordinary corn powder|ordinary corn powder,20g/d(selenium contain <0.5ug/20g).
45466548|NCT03357471|Drug|e-Device|"Active Substance: Certolizumab Pegol~Pharmaceutical form: Solution for injection~Route of administration: subcutaneous injection by e-Device"
45466549|NCT03444922|Other|Placebo|Ingestion of Placebo
45466550|NCT03444922|Other|BPA 4 ug/kg BW|Oral BPA ingestion of 4 ug/kg BW
45466551|NCT03444922|Other|BPA 50 ug/kg BW|Oral BPA ingestion of 50 ug/kg BW
45598294|NCT02225639|Drug|PRC-063 35 mg|Oral 35 mg capsule - active
45598295|NCT02225639|Drug|PRC-063 45 mg|Oral 45 mg capsule - active
45598296|NCT02225639|Drug|PRC-063 55 mg|Oral 55 mg capsule - active
45598297|NCT02225639|Drug|PRC-063 70 mg|Oral 70 mg capsule - active
45598298|NCT02225639|Drug|PRC-063 85 mg|Oral 85 mg capsule - active
45680612|NCT01877421|Drug|10 mg KSL-W|
45680613|NCT01877421|Drug|20 mg KSL-W|
45680614|NCT01877421|Drug|30 mg KSL-W|
45598299|NCT02225639|Drug|PRC-063 100 mg|Oral 100 mg capsule - active
45466552|NCT03791671|Other|individual balance training|One physiotherapist trains one Patient nearby a bar. The tasks changes in gage, visual feedback, vestibular feedback and underground. The Positions will be hodl for 10-30 seconds.
46101123|NCT00594932|Other|placebo|"oral placebo will be given in ascending doses during the first month and at full dose during the second and third month (or at lower dose if tolerance issues warrant). During the fourth month mycophenolate mofetil will be given in ascending doses to 3 gms/day (or less if tolerance issues arise) and continues until the end of the study at 6 months."
45466553|NCT03791671|Other|group balance training|Like the individual balance training
45466554|NCT01233791|Drug|Vaginal Diazepam Suppository|10mg compounded vaginal suppository
45466555|NCT01233791|Drug|Placebo Suppository|Patients will be asked to use one vaginal suppository every night for 28 days
45466556|NCT03444688|Other|Conventional Gait Training|Subjects allocated to the CT group will first perform active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. They will then perform conventional gait and balance therapy based on the proprioceptive neuromuscular facilitation (PNF) concept for 15 minutes. They will be given a 5 minutes rest. Finally, the CT subjects will undergo the over-ground gait training with or without aid or orthoses and with manual assistance from senior physiotherapist for 15 minutes, depending on the individual subject's abilities.
46016993|NCT04305418|Other|Mindfulness- Based Intervention|"Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment."
45466557|NCT03444688|Device|Gait rehabilitation with walker|For WT group, subjects will first go through active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. The main therapy consists of 2 parts with 5 minutes rest in between. During part 1, subjects will be trained on the robotic walker with the help of active body weight support (BWS) and functional electrical stimulation (FES) for 15 minutes with pelvic motion support function and lateral balance function being continuously provided. During part 2, subjects will also receive resistance/assistance forces on top of the BWS and FES training for 15 minutes.
46016994|NCT02875678|Drug|ABX-1431|Single-dose ABX-1431
45466558|NCT01308307|Device|photorefraction|photorefraction is a name of device.
45466559|NCT01139255|Behavioral|Podcasting + mobile media|Use of a weight loss podcast designed with health behavior theory
46016995|NCT02875678|Drug|Placebo|Single-dose matching placebo
45466560|NCT03788707|Other|Passive leg raising|After 30 seconds of lying flat, volunteers will have passive leg raising to 45 degrees. Expired CO2 will be measured via a face mask before and after leg raising.
46016996|NCT02874820|Radiation|[11C]BU99008|Baseline and blocked scans
46016997|NCT02874820|Drug|Idazoxan|Idazoxan dose up to 80mg
46016998|NCT04758676|Other|Nutritional and physiotherapy protocol, BIA|Study subjects will be treated using the nutritional and physiotherapy protocol, based upon the results of measurements, using bioimpedance analysis.
46016999|NCT04758676|Other|Standard of care|Study subjects will receive the current standard of care.
46017000|NCT04305028|Drug|Rivaroxaban|Rivaroxaban 2.5 MG (Xarelto) twice daily, tablet
45680615|NCT01877421|Drug|50 mg KSL-W|
46101124|NCT02700191|Device|uCor|
46101125|NCT02692079|Procedure|T-PRF|Flap Surgery
45680616|NCT01877421|Drug|75 mg KSL-W|
45680617|NCT01877421|Drug|100 mg KSL-W|
46017001|NCT04305028|Drug|Aspirin|Aspirin 75-100 mg once daily, tablet
46017002|NCT04304794|Procedure|Administration of iodinated contrast media|Each patient was exposed on iodinated contrast medium administered during computed tomography, coronary angiography or transcatheter aortic valve implantation.
46017003|NCT04304794|Drug|Prophylactic administration of antithyroid drugs before iodinated contrast media exposure|13 patients received thiamazole with (6 patients) or without (7 patients) sodium perchlorate, one day prior to iodinated contrast medium (ICM) and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily).
46017004|NCT01285518|Drug|PF-05231023|0.5 mg QD IV x 1 day
46101126|NCT02692079|Procedure|Allograft|Flap Surgery
46101127|NCT00616889|Drug|Seroquel|The dosage is flexible from 50-600 mg based on the investigator's clinical judgement and patient tolerance. It may be raised or lowered at will.
46017005|NCT01285518|Drug|PF-05231023|1.5 mg QD IV x 1 day
46101128|NCT04152746|Other|Periostin level|The serum periostin levels were planned to compare between the serum samples that were obtained from the two groups. The evaluation of the periostin levels of adenoid tissue and normal healthy mucosa were also planned.
46101129|NCT02697539|Other|AmF/SnF2|AmF/SnF2 dentifrice used twice daily for 2 minutes for 12 weeks
45342571|NCT05810558|Procedure|Ultrasonic instrumentation|The control treatment consists of supragingival and root debridement using an ultrasonic scaler on low-medium power and coronal polishing with fine grit paste
45680618|NCT01877421|Other|Placebo|Cetylpyridinium chloride (CPC) as an additive, isomalt as a bulk sweetener, peppermint powder for flavoring, sucralose as an intense sweetener, colloidal silicon dioxide is a flow enhancer, magnesium stearate as a process aid, and the proprietary gum base formulation.
46017006|NCT01285518|Drug|PF-05231023|5 mg QD IV x 1 day
46017007|NCT01285518|Drug|PF-05231023|15 mg QD IV x 1 day
46017008|NCT01285518|Drug|PF-05231023|50 mg QD IV x 1 day
46017009|NCT01285518|Drug|PF-05231023|100 mg QD IV x 1 day
46017010|NCT01285518|Drug|PF-05231023|200 mg QD IV x 1 day
46017011|NCT01285518|Other|Placebo|0.9% w/v sodium chloride injection, USP QD IVx 1 day
46017012|NCT01073020|Device|Allergan Adjustable Gastric Band Surgery|
46017013|NCT01073020|Other|Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group|Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group
46017014|NCT01073020|Procedure|Roux-en-Y Gastric Bypass (RYGB) Surgery|
46017015|NCT01073020|Other|Intensive Medical Diabetes & Weight Management (Why WAIT) - Bypass Group|Intensive Medical Diabetes & Weight Management (Why WAIT) - Bypass Group
46101130|NCT02697539|Other|mHA|microcrystalline zinc-hydroxyapatite (mHA) dentifrice dentifrice used twice daily for 2 minutes for 12 weeks.
46101131|NCT00673088|Drug|Ropinirole Hydrochloride|Restless Leg Syndrome
46017016|NCT02875600|Other|Nutri Drink|To determine the difference in baseline MR flow measurements and post prandial MR flow measurements between patients diagnosed with CGI and patients not diagnosed with CGI
46017017|NCT02874664|Drug|Rovalpituzumab Tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC)
46017018|NCT02889744|Device|Arctic Sun|Targeted temperature management for 24 hours with core temperature 36℃ or 33℃
46017019|NCT04754308|Diagnostic Test|Spirometry|The method of examination, Spirometry, is non-invasive (i.e. not an intervention that involves penetration into the body by means of incisions or injections.). It is a routine examination and there are no risks, adverse reactions, or discomforts associated with the examination.
46017020|NCT00623844|Behavioral|physical activity|activity program at kindergarten 5 * 30 min per week plus education of parents (letters, flyers, presentations, counselling) plus activity homework for children involving also the families
46017021|NCT04207554|Device|Test Device-Strip Format|Sponsor's investigational device
46017022|NCT04207554|Device|Test Device-Cassette Format|Sponsor's investigational device
46017023|NCT04207554|Device|Predicate Device|Commercially available device
46017024|NCT02875522|Other|Individualized, non-linear aerobic exercise training|Aerobic exercise performed on lower body stationary ergometer and an upper extremity arm crank. Intensity (50-95% workload maximum) and durations (20-45 min) are fluctuated daily to optimize training stress and adaptation
46017025|NCT02874196|Procedure|Standard arthrography|
46017026|NCT02874196|Procedure|Dual energy arthrography|
46017027|NCT02874196|Procedure|Arthro-tomosynthesis|
46017028|NCT02874196|Procedure|Arthro-tomography|
46017029|NCT02874196|Procedure|Surgery on painful prosthesis|Possibly performed during 6 months from arthrography
45342572|NCT05810532|Other|4 hours of fasting time|Oral intake is not allowed for 4 hours before sedation including water
45598326|NCT02372331|Other|ERAS perioperative management|"Preop Counseling~Preop biliary drainage (X) when Serum Total bilirubin < 14.62mg/dl and cholangitis (-)~Preop enteral nutrition~Oral bowel preparation (mechanical bowel preparation ) (X)~Preop fasting < 6 hours~Prevention of postoperative nausea and vomiting (PONV) (O)~Nasogastric intubation (X)~Near-zero fluid balance~Somatostatin analogues (X)~Postop routine artificial nutrition (X), soft diet at POD #2~Audit~Other items are same as conventional"
45680619|NCT01726023|Drug|Ceftazidime-avibactam|Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg
45680620|NCT01726023|Drug|metronidazole|Metronidazole 500mg/100ml solution for infusion
46017030|NCT01284114|Drug|Aliskiren|150mg/day for all as initial dose, 300mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
46017031|NCT02875444|Other|Angio-CT|
45680621|NCT01726023|Drug|Meropenem|Meropenem powder for solution for infusion 1000mg
46017032|NCT01283334|Drug|Carboplatin|Will be given as a 30 minutes intravenous (IV) infusion on days 1, 8, and 15 of each 28 day cycle. The starting dose of carboplatin will be area under the plasma-concentration time curve (AUC) = 2 mg/ml.min. Appropriate dose reductions will be done for toxicity for subsequent cycles.
46017033|NCT01283334|Drug|Cetuximab|Will be given on days 1, 8, 15 and 22 of each 29 day cycle. On week 1, a loading dose of 400 mg/m² will be given. From week 2 onwards, the dose of cetuximab will be 250 mg/m².
46017034|NCT01283334|Drug|RAD001|For phase I, dose escalation will be 2.5 mg, 5 mg, 7.5 mg or 10 mg given orally on a daily basis.
46017035|NCT01282866|Device|LightSheer Duet|LightSheer Duet HS handpiece
46017036|NCT01071070|Drug|paricalcitol|Initiation dosing based on 2 approved package inserts , followed by a dose adjusted by limited chemistry test value. See Arm Description for additional details.
46017037|NCT04304716|Drug|Regional Anesthesia|Block performed is an indwelling wound bed or popliteal catheter placed intraoperatively
46017038|NCT01282476|Drug|Panobinostat with Rituximab|Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
45680622|NCT01877265|Drug|LY2605541|
46017039|NCT02889822|Drug|Alprostadil Liposomes for Injection|"Single-dose tolerance test:10ug/20ug/50ug/100ug/200ug/300ug/400ug of Alprostadil Liposome for Injection,ivgtt,qd~Multiple-dose tolerance test:100ug,ivgtt,qd,continuous administration for 7 days."
46017040|NCT04323618|Device|Breathe Well|
45466561|NCT03444610|Biological|Blood transfusion escalation rate|3+3 dose escalation (3 patients/cohort) each started on a fixed rate (standard is 5 ml/kg/ hr).1st cohort start at 6ml/kg/hr till complete prescribed volume. Rate escalation by 1ml/kg/each cohort until dose limiting toxicities (DLTs) or max of 10ml/kg/hr. If no DLTs new cohort enrolled at the next planned rate. If DLTs seen in 1 patient in the cohort, another 3 patients treated with the same dose level.1ry phase I end point is maximum-tolerated rate (MTR) of blood transfusion that can be infused safely ( max rate at which 1 or fewer of 3 patients experienced DLT) or dose of 10ml/kg/hr. DLT is transfusion related adverse event lead to stop of transfusion. MTR is highest dose at which no more than 1of 6 patients experienced a DLT.15 additional patients enrolled at MTR to confirm safety.
45466562|NCT03356145|Drug|12 mL paracervical block|Injection of 12 mL of lidocaine
46017041|NCT04323696|Procedure|Staple line suturing reinforcement methods - Plication and Over-sewing|Sleeve gastrectomy procedure will be performed laparoscopically. The greater curvature of the stomach will be mobilised, and stomach will be sleeved using 39F calibration tube as the stent using 5-6 60 mm-stapler reloads depending on the length and thickness of the stomach. The staple-line is then reinforced using 3/0 absorbable sutures continuously throughout the staple-line. The two staple-line suturing methods in this study include over-sewing (through and through) and plication (Lembert).
46017042|NCT01282164|Procedure|Glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh >90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), cerebrovascular disease (CVD), seizure
45466563|NCT03356145|Drug|20 mL paracervical block|Injection of 20 mL of lidocaine
45466564|NCT01140971|Drug|Misoprostol|Vaginal application of 25 micrograms every 6 hours until cervical ripening reach Bishop 6 or more
45466565|NCT01140971|Device|Foley|After Foley introduction, every 6 hours vaginal exam was performed. The cases on Bishop score increase or occurred spontaneous exit of catheter or spontaneous labour had been initiated are considered success.The failure was adopted if after48 hours occurred no cervical modifications.
46017043|NCT01282164|Procedure|glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh >90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), CVD (cerebrovascular disease), seizure
46017044|NCT01250379|Drug|bevacizumab [Avastin]|10 mg/ kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
46017045|NCT01250379|Drug|Chemotherapy|Standard chemotherapy (doublets not allowed)
46101132|NCT02851979|Other|Olfactory stimulations|"Odors are disseminated using a portable fragrance device, a prototype developed by a research unit, CNRS UMR5292. The device is outside the incubator, the only part inside is a disposable Teflon tube. The odor flux stimulates distally the NBs' nostrils. Odoriferous compounds are placed in glass tubes. This allows the olfactometer to deliver three distinct odors (to avoid habituation) in a random scheme: spearmint odor, vanilla odor, and grapefruit odor (chemicals registered by Chemical Abstracts Service), while controlling for intensity (amount of compound), duration, and odor sequence. For the vehicle period, the glass tubes remain empty.~Stimulations occur every 5 minutes, for 5 seconds, they are mixed in medical gas to avoid infection. There are three 24-hour periods, and two 24-hour wash out periods, followed by a maximum of 3 days of surveillance."
46017046|NCT01072630|Drug|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
46101133|NCT00673166|Procedure|Staff incentive & supervision|Control & management of funds for incentive of staff; supervision
46101134|NCT00673166|Behavioral|Staff motivation|Supervision, control of funds
46101135|NCT02697695|Other|Laboratory Examination|Laboratory Examination before, 1 month, 3 month, 6 month and up to 12 month after LSK, LRNYGB, LOLGB
46101136|NCT00670124|Device|Hypothermia by the use of Blanketrol II, Cincinnati Sub-Zero|The patients are placed on a cooling mattress and body-core temperature is regulated to 33° C.
45466566|NCT03444532|Behavioral|12-week aerobic exercise and cognitive-behavioral therapy|12-week intervention of aerobic exercise training and four session of cognitive-behavioral therapy
45466567|NCT01306357|Drug|Somatropin|4 mg or 10 mg delivered by needle-free device
45598327|NCT02290717|Device|Fractional CO2 laser|
46017047|NCT01072630|Drug|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
45466568|NCT01136135|Other|CARDIAC MRI|To find a non-invasive alternative (with using cardiac MRI) to invasive endomyocardial biopsies for serial detection and follow-up of cellular rejection in heart transplant in childhood.
45466569|NCT03129022|Procedure|epidural anaesthesia|Women requesting epidural analgesia received a bolus of intravenous infusion of lactated Ringer's solution before initiation of the procedure. An 18-gauge Tuohy needle and closed-tip clear catheter with three lateral orifices were used in the sitting or lateral position, with a loss-of-resistance to air technique. Epidural catheters were routinely inserted 5-6 cm inside the epidural space. A test dose of 2 ml of lidocaine 2% was initiated followed by a loading dose of 10 ml of bupivacaine 0.25%. Analgesia is maintained throughout labor using 0.125% bupivacaine with fentanyl 2 μg/ml with patient-controlled epidural analgesia by means of a continuous epidural infusion (8 ml/h basal rate) and patient-controlled boluses (3 ml each) with 20-minlock-out intervals
45466570|NCT05623033|Other|The study is an observational study without intervention|The study is an observational study without intervention
45466571|NCT05608889|Behavioral|Total Worker Health Mindfulness Enhanced Program|"The intervention will be delivered during 12, 45-minute weekly meetings of Correctional Professionals while on shift. Those sessions will be a combination of a video, mindfulness activity, and a group learning activity. It will conclude with members stating personal goals that will be followed up at the next meeting.~Sessions will be scripted to make them easy to implement with high fidelity, and include tasks, learning activities, and wrap-up with practice instructions for each week. Coworkers will be responsible for running the sessions, which promotes shared norms and social support."
45466572|NCT03788629|Other|Talocrural joint MWM mobilization|There were two groups for this study. In addition to Bobath Concept, talocrural joint mobilization was performed.
45466573|NCT03788629|Other|Subtalar joint MWM mobilization|There were two groups for this study. In addition to treatment of control group, subtalar joint mobilization was performed.
45466574|NCT03444454|Behavioral|VRRS Khymeia|"Participants will receive an individualized exercise program set up by the therapist. The intervention applied to the experimental group will consist of 30 sessions of Khymeia VRRS training distributed in five sessions for week, each lasting 45 minutes.~Each session is constructed by alternating physical with cognitive activities. The sessions will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
45466575|NCT03444454|Behavioral|Usual care program|The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.
45598328|NCT02290717|Other|NB-UVB therapy|NB-UVB therapy (according to the standard treatment protocol of the SNIP, which the patient is already been treated with) will be continued for both treated and control sites during 6 months.
45598329|NCT02290717|Drug|Fluticasone Propionate Cream 0.05%|4 times a week (standard IPD protocol)
46017048|NCT04304638|Radiation|radiation or chemo-radiation|standard treatment for stage III lung cancer
46017049|NCT04304638|Drug|EGFR-TKI Inhibitor|the standard treatment for stage IV lung cancer with EGFR mutation
46017050|NCT04302532|Drug|Coenzyme Q10|antioxidant used to decrease oxidative stress and improve fertility prospects
46017051|NCT04302532|Drug|clomiphene citrate|ovulation induction drug
46017052|NCT01281306|Drug|LCZ696|LCZ696 was supplied as tablets in blister cards in 100 mg strengths.
46017053|NCT01281306|Drug|Valsartan|Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.
45342573|NCT05810532|Other|1 hour of fasting time|Oral intake is not allowed for 4 hours before sedation, while water is allowed to intake before 1 hour of sedation
45466576|NCT03444454|Behavioral|VRRS Khymeia plus active tDCS|"Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training.~The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
45466577|NCT03444454|Behavioral|VRRS Khymeia plus placebo tDCS|"Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training.~The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
45466578|NCT03342963|Drug|ASC-01|Aripiprazole 3 mg/sertraline 100 mg combination drug
45466579|NCT03342963|Drug|Aripiprazole and sertraline|Aripiprazole 3 mg and sertraline 100 mg
46101137|NCT02692001|Other|Intervention MealTrain menu|"Nutrition education was incorporated using an interpretive traffic light system menu labeling. Dietitians categorized current menu items as green, yellow and red based on fiber, added sugar, saturated fats, and sodium content. A section entitled Eat like a superhero was created to prime children to consider what their potential role models choose, and incorporates descriptive names, suggest sample breakfast, lunch and dinner meals with photographs of portion sizes. Original cartoon female grapes and male broccoli superhero characters were created to employ promotional techniques specifically to promote fruits and vegetable selection for boys and girls."
45466580|NCT03786055|Behavioral|Somatic Yoga and Meditation (SYM)|A Hanna somatics and somatic yoga and meditation (SYM) protocol was designed to address sensory-motor amnesia and reduce trauma which creates reflex patterns that lead to chronic muscular contractions. The movements use voluntary muscular contraction and slow controlled eccentric contraction, with the constant focus on sensation to increase the resting length of muscles. Movements are performed slowly and gently with the least possible effort and are never forced. The protocol is endorsed by the US Army Surgeon General as treatment for chronic pain. The meditations are trauma informed and evidence based supporting pain modulation, healing and well-being.
45466581|NCT05608733|Drug|Epidural catheter|Bony landmarks and the space between the lower lumbar vertebrae are identified. Subsequently, infiltration of the skin and subcutaneous cellular tissue with local anesthetic (Lidocaine 2% without epinephrine) is performed at the site to be punctured. A 17G Tuohy needle is inserted 2-4 cm through the skin, then the mandrel is removed, the low-resistance syringe is connected, and the loss of resistance is checked using the air or liquid technique, depending on the preference of the anesthesiologist. . Appreciating the loss of resistance in the embolus, the mandrel is then withdrawn and the epidural catheter is advanced to leave it an additional 5 cm inside the epidural space.
45598330|NCT02225795|Other|Hematopoietic stem cell transplantation|"Immuno-ablative regimen for HSCT:~Day Treatment~6 r-ATG 2 mg/kg~5 r-ATG3 2 mg/kg~4 r-ATG3 2 mg/kg~3 Cyclophosphamide with Mesna~2 Cyclophosphamide with Mesna~1 REST 0 PBSC infusion~3 Cyclophosphamide with Mesna~4 Cyclophosphamide with Mesna~6 Start GCSF"
46101138|NCT02629952|Other|Blueberry Tea|Blueberry Tea
46101139|NCT04213703|Other|No intervention|There is no intervention for this study
46101140|NCT00504829|Drug|LCP-AtorFen|40mg atorvastatin combined with 100mg fenofibrate in a tablet for once daily treatment of dyslipidemia and mixed dyslipidemia
46101141|NCT00504829|Drug|atorvastatin|dyslipidemia and mixed dyslipidemia
46101142|NCT00504829|Drug|fenofibrate|dyslipidemia and mixed dyslipidemia
46017054|NCT01281306|Drug|AHU377|AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.
46017055|NCT01281306|Drug|Placebo|Placebo was supplied as tablets in blister cards.
45598331|NCT02360553|Behavioral|ObeseGO!|The intervention group were received the obeseGO! intervention which is an internet-based intervention. The participants and the parents who are randomly chosen to enroll in this intervention group were provided with the ObeseGO! website. The website was accessed at www.obesego.com. The website consists of various informations on healthy lifestyle, diet and ways to overcome obesity.
45342574|NCT05810506|Other|In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.|In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.
46017056|NCT04304560|Drug|Dapagliflozin 10 MG|inhibitor of sodium-glucose cotransporter 2
46017057|NCT04304560|Drug|Placebo oral tablet|Similar Placebo oral tablet
46017058|NCT00626860|Biological|DC/tumor fusion vaccine|SC vaccinations administered to each patient at 3-week intervals for 2-3 doses
46017059|NCT04645810|Radiation|High-Dose-Rate Brachytherapy|High-Dose-Rate Brachytherapy Targeting only to AXUMIN PET Visible Lesion
46017060|NCT04643470|Drug|Zanubrutinib|Administered as specified in the treatment arm
46017061|NCT04643470|Drug|Placebo|Placebo to match zanubrutinib
46017062|NCT01250145|Drug|LY333334|Transdermal patch
46017063|NCT01250145|Drug|Placebo|Transdermal patch
46017064|NCT04323384|Device|Biotene® Oralbalance Moisturizing Gel|Biotene® Oralbalance Moisturizing Gel will be applied to the oral cavity according to the package directions.
46017065|NCT01067326|Drug|Aliskiren|150 mg Aliskiren once daily for a period of 4 months
46017066|NCT01067326|Drug|Placebo|1 pill per day by mouth for 4 months
46017067|NCT04319601|Drug|Rituximab|a new chemotherapy regimen
45466582|NCT05608733|Drug|Continuous sciatic nerve block|The patient is placed in the prone or supine position with the limb to be blocked flexed at 90°. Using a high-frequency linear transducer and using sterile technique, the popliteal sciatic nerve is identified in an axial axis. A 17G Tuohy needle is inserted plane and medial. Saline solution (5 ml) is applied to open the perineural space. Adequate hydrodissection and donut sign in the nerve are observed..A perineural catheter is then advanced 5 cm beyond the tip of the needle. The catheter is fixed with stitches and a transparent sterile dressing is placed.
46017068|NCT01279200|Other|Midcycle ultrasound + hCG injection|Mid-cycle ultrasound with administration of hCG (single dose of standardized pre-filled injection, 250 mcg, at time of ultrasound) when appropriate.
46101143|NCT04153916|Device|Neurotrigger eye blinking stimulator|"Phase 1 - The first stage is composed of a one-time participation for about three hours and involves:~Verifying compliance of the patients with the research inclusion and exclusion criteria~Completion of the study clinical report form (CRF) for this stage~Placement of the single use mini-electrodes that will be adhered to the facial skin near the non-blinking eye and coupled to the Neurotrigger stimulator to elicit eyelid closure.~Participants may be enrolled to the second phase up to one year from the first phase visit In the second stage the duration of the participation is about three weeks (six days a week) and includes daily use of the device for up to 10 hours a day. During nights the patient will continue is standard pattern of either eye closure or leaving the eye open, as the patient used to do prior to the study.~This stage will involve a patient with a partner that is designated to support the patient closely during the placement and adjustment of the system"
46017069|NCT01279200|Other|Urinary LH kits|Subjects randomized to monitoring with LH kits at home will keep a monthly calendar documenting when LH testing begins, day LH surge occurs and day(s) of intercourse/insemination.
46101144|NCT02701205|Biological|etanercept|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
46101145|NCT02701205|Biological|etanercept (half dose)|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
46101146|NCT02701205|Drug|placebo|two vials of placebo twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
45466583|NCT03706755|Drug|Norepinephrine: 1mcg/kg|intervention:Parturients will receive Norepinephrine: a bolus of 1 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.5 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
46101147|NCT00670280|Behavioral|Motivational Interviewing intervention|Those randomized to receive the Motivational Interviewing intervention will meet twice over a two-week period with a trained counselor while visiting the neonatal intensive care unit. Each visit will consist of a 45 minute session in which household smoking practices will be assessed and discussed. Two weeks after the child has been discharged from the hospital, the counselor will contact participants via telephone for a third 20-30 minute telephone meeting. After the third contact with the counselor, a letter will be mailed to participants summarizing information covered in the three meetings.
46101148|NCT00670280|Behavioral|Usual Care|Those randomized to receive the Usual Care intervention will receive written information on secondary smoke and infant health and will be assessed at 1 month, 3 months, and 6 months post-intervention.
46101149|NCT00670280|Behavioral|Usual Care - Reduced Measurement|Those randomized to the Usual Care - Reduced Measurement intervention will receive the same written information on secondary smoke and infant health as the Usual Care intervention but will be assessed only at the 6-month timepoint.
46101150|NCT00670436|Device|paclitaxel eluting PTCA balloon catheter (SeQuent Please)|paclitaxel eluting PTCA balloon catheter after bare-metal stenting of chronic total occlusion in a native coronary artery
45466584|NCT03706755|Drug|Norepinephrine 0,5mcg/kg|intervention: Parturients will receive Norepinephrine: a bolus of 0.5 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.25 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
46017070|NCT04640896|Drug|Trigger point injection with bupivacaine|Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
45680623|NCT01877187|Drug|Lipiodol|Lipiodol is used as a carrier for chemotherapy agents and also as an occlusion agent. In TACE procedures, Lipiodol is mixed with the chemotherapy agent(s) and delivered to the tumor via the hepatic artery, causing necrosis of the targeted tumor(s).
45680624|NCT04609761|Drug|Privigen Injectable Product (Intravenous Immunoglobulin)|Privigen, 2 g/kg BW every 4th week for 6 months (= 6 infusions).
46101151|NCT00670436|Device|paclitaxel eluting Taxus stent (Boston Scientific)|paclitaxel-eluting Taxus stents (Boston Scientific) in chronic total occlusion in native coronary arteries
46101152|NCT02699879|Drug|Pirfenidone|Pirfenidone will be administered according to the physician discretion as part of standard care.
46101153|NCT00911456|Procedure|Image-Guided Radiation Therapy using 3D Ultrasound Guided-Therapy|Subjects will have 3 x 3DUS during radiation therapy
45598332|NCT02360553|Behavioral|Pamphlets material|The control group will be given pamphlets material on diet and physical activity.
45598333|NCT02290795|Other|OCT imaging/HRT imaging|Standard follow up protocol with Optical coherence Tomography (OCT) imaging and Heidelberg Retinal Tomograph (HRT) imaging for glaucoma patients and patients scheduled for Ocriplasmin treatment In case of healthy controls the same investigations will be performed.
45598334|NCT02360241|Device|Robot|Use of the robot to locate the fictional needle
45598335|NCT02225873|Other|motor control exercises|Will carry out intermuscular coordination exercises through cranio-cervical training, following Jull et al. and exercises to increase strength-endurance on the neck flexor muscles
46017071|NCT04640896|Drug|Trigger point injection with normal saline|Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
46017072|NCT04640896|Drug|Lidocaine skin wheal|"Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection.~However, this skin wheal is not considered a trigger point injection."
45598336|NCT02225873|Other|muscle strength-endurance and proprioception|Will carry out proprioception exercises through articular repositioning training and exercises to increase strength-endurance on the neck flexor muscles. They will be performed in the same way as the experimental group protocol.
45598337|NCT02294149|Drug|mammalian Omega 3 Fatty acids|A mammalian oil derived Omega 3 FA that is a further concentrated and purified supplement as compared to the regular fish oil derived Omega 3 FA supplement.
46101154|NCT00911456|Procedure|Ultrasound Guided Imaging|"Subjects will undergo a CT scan and an US of your breast for the planning of radiation therapy after a breast conserving operation.~About 1 week after the start of radiation treatment subjects will have a second CT and US. During this visit subjects will have one CT and three US's. These US's will be performed by 3 different radiation therapists. Part of the current study is to compare the similarity of the 3 US pictures taken by different individuals."
46101155|NCT00911456|Procedure|3 DUS|3 DUS
46101156|NCT00670514|Behavioral|Nix Individual|Eight 40-minutes sessions at the local dental clinic during 4 months. Written material and counseling by a dental hygienist with special training in smoking cessation, according to a fixed program. A traditional smoking cessation program with a mixture of behavior therapy, coaching and pharmacological advises. Two questionnaires.
45598338|NCT02294149|Drug|placebo|
45598339|NCT02360163|Procedure|Traditional Landmark Technique (TLT)|
45680625|NCT01858532|Drug|Atrasentan|Film-coated tablet
45680626|NCT01858532|Drug|Placebo|Film-coated tablet
45680627|NCT01883492|Device|Femoral Stem|JMDN classification/Class III device
45680628|NCT01883492|Device|Acetabular Cup|JMDN classification: Class III device
46101157|NCT00670514|Behavioral|Fimpa dig fri|"One 30-minute counseling session at the local dental clinic, focusing on explaining the content of a traditional self-help program (Fimpa dig fri). The leaflet contains an 8-week program with instructions and tasks to perform. Two questionnaires."
46101158|NCT02699723|Drug|Arsenic Trioxide|Given PO
46101159|NCT02699723|Drug|Itraconazole|Given PO
46101160|NCT02699723|Other|Laboratory Biomarker Analysis|Correlative studies
46101161|NCT02629874|Drug|EA-230|at t=0 30, 90 or 180 mg/kg EA-230 will be administered intravenously over 2 hours.
46101162|NCT02629874|Drug|Endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
46101163|NCT02629874|Drug|Placebo|
46101164|NCT00504595|Drug|ACZ885 (investigational)|The ACZ885 was supplied in 6 mL colorless glass vials each containing nominally 150 mg ACZ885 (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
45598340|NCT02360163|Device|ultrasound guided peripheral intravenous access (USGPIVA)|
45598341|NCT02217449|Other|Prediction of histology|
45680629|NCT01883492|Device|Acetabular Liner|JMDN classification: Class III device
45680630|NCT01832480|Drug|MTZ 500 mg twice daily x 7 days|MTZ 500 mg twice daily x 7 days
46101165|NCT00504595|Drug|Placebo|Matching placebo of ACZ885 was supplied in the form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
46101166|NCT02699645|Drug|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg|1 capsule taken orally once daily for average of 72 months
46101167|NCT02699645|Drug|Placebo|1 capsule taken orally once daily for average of 72 months
46017073|NCT01273818|Drug|Gentamicin and cefazolin|80 mg topically, intra-operative,single dose and intravenous 1000 mg cefazolin 1 hour before operation
46017074|NCT01273818|Drug|Cefazolin|1000 mg cefazolin application intravenously 1 hour before operation
46017075|NCT01273818|Drug|Gentamicin|80 mg gentamicin application intraoperatively
45680631|NCT01832480|Drug|MTZ 2 g|MTZ 2 g
45680632|NCT04613960|Drug|Magnesium sulfate|MgSO4 (at a fixed daily dose of 64 mmol reconstituted in 0.9% saline) via continuous intravenous infusion for 14 days after onset
45680633|NCT04613960|Drug|normal saline|Placebo treatment
45680634|NCT04599140|Drug|CXCR1/2 Inhibitor SX-682|Given PO
45680635|NCT04599140|Biological|Nivolumab|Given IV
45680636|NCT04598984|Diagnostic Test|serum adipokines|Level of serum adipokines will be measured with flow cytometry
46017076|NCT01245387|Drug|Pegaptanib|Dosage recommendations for MACUGEN took place on the basis of the approved Summary of Product Characteristics (SmPC) and were adjusted solely according to medical practice. MACUGEN® is available as pre-filled syringe containing 0.3 mg MACUGEN® in 90 µL injection solution for intravitreal injection. Macugen injections were documented to reflect the routine clinical practice. Follow-up visits were only carried out and documented if they took place as part of the standard medical treatment for the respective case and were necessary for medical and/or therapeutic reasons.
46017077|NCT01037218|Drug|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
46017078|NCT01037218|Drug|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
46017079|NCT01038856|Drug|Erlotinib|Erlotinib supplied as tablets; oral dose of erlotinib of 150 mg daily to be continued for 16 weeks. Responders will continue for up to 12 months, non-responders will cease taking erlotinib
46017080|NCT04302688|Other||
46017081|NCT01066546|Drug|Dimebon tablet for oral administration|10 mg TID for Week 1, followed by 20 mg TID for remainder of study
46101168|NCT00673322|Biological|Gene Modified T Cells|One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
46101169|NCT04152434|Drug|Erenumab Auto-Injector|Assess synergy of add on medication to Erenumab
46101170|NCT02822521|Other|Mobile Application|A mobile health application that asks daily questions about participants' pain, function, and disease activity.
46017082|NCT02874118|Behavioral|Fried scale for frailty assessement|
45680637|NCT04598282|Device|Prokera Slim|Placement of an Adjunctive Cryopreserved Amniotic Membrane Treatment.
45680638|NCT04598282|Other|Standard of Care|Standard of care includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion).
45680639|NCT01858376|Dietary Supplement|Capros dietary supplement|Study participants will have 2 to 3 baseline blood draws, 3 blood draws while taking Capros supplements and 2 wash out blood draws after finishing 12 weeks of Capros supplementation. Participants will attend 7 to 8 study visits (depending on number of baseline visits needed) and at each visit participants will have their blood drawn as well as height, weight, blood pressure, and pulse measured.
45680640|NCT01831856|Drug|1g of F373280|Oral administration, one capsule each evening with dinner.
45680641|NCT01831856|Drug|Placebo|Oral administration, one capsule each evening with dinner.
46101171|NCT02822521|Other|Population Management System|Study staff will act as care managers behind a web-based dashboard to monitor participants' responses to the daily questions on the mobile application and connect them with their HCPs.
46101172|NCT00911846|Other|interview|interview using questionnaires
46101173|NCT00615797|Biological|Intravenous immunoglobulin|intravenous immunoglobulin 2g/kg total given over 2 days
45680642|NCT01831544|Device|HeartWare MVAD® System|The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system
46017083|NCT02873572|Behavioral|step 1: online assessment|Anonymous psychiatric and behavioral assessments to evaluate in particular addiction or pathological gambling/gaming and behavioral profile of gamblers/gamers. Once questionnaire completed, if the subjects want to continue to participate, they sent their email to investigators.
46017084|NCT02873572|Behavioral|step2: biomarkers of gamblers/gamers|"For each arm, subjects were divided into 2 groups: dependant or not dependant gamblers/gamers. Investigators focused on decision-making biomarkers following the following flow-chart:~psychiatric assesment and~registration of brain activity during a decision-making task in conditions of uncertainty (IGT) with its version for HR-EEG validated by investigators (Giustiniani, 2015)."
46017085|NCT01272804|Drug|PF-04937319|Subjects will be dosed with PF-04937319 for 14 days. The doses planned are 10, 30, 100 and 300 mg QD. All doses will be administered as tablets (10 and 100 mg strengths). In each Cohort, 9 patients will receive PF 04937319 and 3 will receive placebo. An additional cohort of 12 patients (9 active, 3 placebo) may be performed to explore a QD or BID dose. The dose for this additional cohort could be a dose already studied or a new dose that is within the exposure stopping criteria.
46101174|NCT00615797|Drug|standard interventions penicillin VK and haloperidol|Penicillin V K 500mg 12hrly po or 250mg 6 hrly for 10 days IM penicillin to be given at discharge, 1.2 million units if over 30 KG and 600,000 units if weight less than 30 KG haloperidol 0,025mg/kg/day orally in divided doses gradually increasing to a maximum of 0,05mg/kg/day
45466585|NCT03791515|Drug|Calcitonin Gene-Related Peptide|"A randomized clinical trial with a double-blinded, randomized, placebo-controlled crossover design. 30 PPTH patients will be included. All participants will receive continuous intravenous infusion of 1.5 µg/min CGRP over 20 min.~The following variables will be recorded before, during and after infusion (every 10 min over 60 min): headache intensity on a verbal rating scale from 0 to 10 and headache characteristics. At 90 min, participants will be discharged and instructed to fill out a headache diary for 24 hours from start of infusion."
45466586|NCT03791515|Drug|Placebo|"A randomized clinical trial with a double-blinded, randomized, placebo-controlled crossover design. 30 PPTH patients will be included. All participants will receive continuous intravenous infusion of 40 mL placebo (isotonic saline) over 20 min.~The following variables will be recorded before, during and after infusion (every 10 min over 60 min): headache intensity on a verbal rating scale from 0 to 10 and headache characteristics. At 90 min, participants will be discharged and instructed to fill out a headache diary for 24 hours from start of infusion."
45466587|NCT05235035|Behavioral|Night shift work|Subjects are exposed to irregular sleep and sleep misalignment due to hospital night shifts.
46017086|NCT01272804|Drug|Placebo|Placebo to match PF-04937319 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04937319 and 3 will receive placebo.
45680643|NCT01857206|Biological|Mammalian cell based flu vaccine|
45680644|NCT01857206|Biological|Egg based flu vaccine|
45680645|NCT01882088|Drug|Mucofalk|Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
45680646|NCT01881776|Procedure|ISB|"In SISB group; a 5 cm block needle (Stimuplex®A, B Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). 20 mL 0.5% ropivacaine was injected through the needle.~For CISB, a 5cm stimulating needle (Contiplex® Tuohy, B. Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). A nonstimulating catheter was inserted approximately 3 cm beyond the tip of the needle. 20 mL 0.5% ropivacaine was injected through the catheter."
45680647|NCT01708161|Drug|BYL719|BYL719 is a small molecule inhibiting PI3-Kinase.
46017087|NCT01269918|Drug|Remifentanil|Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
46017088|NCT01269918|Drug|Dexmedetomidine|a loading dose of dexmedetomidine was given at 0.5 to 1 micrograms/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 micrograms/kg/hour.
46101175|NCT04153838|Other|Cognitive test administration|Specifically chosen cognitive tests will be administered to all participants twice; with an approximate 12 month gap between initial testing and follow-up testing.
46101176|NCT02700113|Other|No intervention|Intervention is not a part of this study. This is a behavioral phenotyping study of minimally verbal individuals with Autism Spectrum Disorder.
46101177|NCT02631200|Behavioral|Advance care plan|Participants will be offered the opportunity to complete an ACP by a nurse trained as an ACP facilitator, who will discuss the process with them using standard materials. At least 48 hours later, they will complete an ACP document with the help of the ACP facilitator, working together with trained expert patients who will provide peer support at the time of ACP completion and subsequently by telephone, assisted where necessary by the ACP facilitator.
46101178|NCT05324813|Behavioral|Domain-Specific Episodic Future Thinking|Individualized intervention that provides systematic prompts to enable creation and envisioning of positive future events across multiple life domains.
46101179|NCT00513409|Biological|Synflorix|Intramuscular injection, 1 or 2 doses
46101180|NCT00513409|Biological|Infanrix Hexa|1 Intramuscular injection
46101181|NCT00513409|Biological|Havrix|1 Intramuscular injection
46101182|NCT02629640|Other|Medical history questionnaire|Epidemiological review of past medical/dental history; residential history; occupational history; family history of neurodegenerative disease.
45466588|NCT05693623|Other|cold application|cold application
45466589|NCT05682573|Diagnostic Test|hospitalized patient|Collect the patient's whole blood for testing
45466590|NCT03361956|Drug|JNJ-56136379|Participants will receive JNJ-56136379 tablet orally.
45466591|NCT03361956|Drug|Placebo|Participants will receive matching placebo tablet orally.
45466592|NCT03361956|Drug|NA (ETV or TDF)|Participants will receive NA (ETV or TDF) tablet orally as per approved label.
45466593|NCT05068648|Other|Manual Wheelchair (MWC) backrest configuration|Wheelchair backrest fitting, postural and functional assessment
45466594|NCT05371639|Drug|Tian Ma Bian Chun Zhi Gan Tablets|Tian Ma Bian Chun Zhi Gan Tablets, 0.1g per pill which contains 14mg Tian Ma Bian Chun Zhi Gan, 3 pills per time, 2 times per day for 36 weeks.
45680648|NCT01708161|Drug|AMG 479|AMG 479 is a monoclonal antibody directed against IGF1-R.
46101183|NCT02629640|Other|Clinical assessment and review|History of current illness; neurological examination including general appearance, full cognitive assessment and physical examination; MRI research brain scan.
45466595|NCT05371639|Drug|Placebo|Placebo identified to Tian Ma Bian Chun Zhi Gan, 0.1g per pill which contains 0mg Tian Ma Bian Chun Zhi Gan, 3 pills per time, 2 times per day for 36 weeks.
45680649|NCT04557423|Behavioral|Community-Based Education|A previously evaluated educational intervention delivered in community settings. Includes culturally- and linguistically-appropriate materials.
46017089|NCT05658666|Behavioral|Video feedback intervention (in Dutch: Video Interventie Ouderenzorg)|The video feedback trainer assesses the interaction between the person with dementia and the caregiver and acquires agreement from the caregiver on the goals of the intervention. Caregivers are trained during several feedback sessions using personal video footage of interaction between the person with dementia and the caregiver. The feedback focuses on basic interaction and attunement principles, and the team feeling competent. Recording starts with a nondemanding situation, enabling the caregiver to become aware of the principles they already apply and to learn how these principles can be used in more demanding situations. Subsequently, video footage is recorded in 1 to 3 situations, depending on the progress, of increasing difficulty, with about 4 weeks between 2 recordings. After each recording, a 1-hour feedback session is held. The intervention concludes with separate, 30-minute sessions for the formal and informal caregivers evaluating the intervention.
46017090|NCT01036594|Drug|Ketoconazole|200mg during first week of study (run-in phase), then 400mg po tid
46017091|NCT01036594|Drug|Hydrocortisone|"Hydrocortisone 20mg po qam and 10mg po qpm~If participant has ≥30% PSA decline at 12 week evaluation, treatment continues until progressive disease (by RECIST criteria OR by PSAWG criteria) is documented. After that, drug will be discontinued. If participant has <30% PSA decline, patient goes off study."
45680650|NCT04557423|Behavioral|Navigation to Screening|Community health educators provide navigation assistance to access clinic-based cervical cancer screening.
46017092|NCT01036594|Drug|Dexamethasone|"Dexamethasone 0.5mg po bid~If ≥ 30% PSA decline (Prostate-specific antigen) at 12 week evaluation, administration starts when disease progression (by RECIST criteria OR by PSAWG criteria) is documented."
46017093|NCT05657886|Other|Half swaddle|Half swaddle: HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.
45680651|NCT04557423|Behavioral|HPV Self-Sampling|An HPV self-sampling kit will be provided for home-based collection of cervical samples. Samples will be sent for analysis of HPV subtypes.
45466596|NCT04595591|Drug|2mg/kg/min|titration dosing speeds of propofol at 2mg/kg/min
45466597|NCT04595591|Drug|1mg/kg/min|titration dosing speeds of propofol at 1mg/kg/min
45466598|NCT04595591|Drug|0.5mg/kg/min|titration dosing speeds of propofol at 0.5mg/kg/min
45466599|NCT03709953|Drug|Apatinib|500 mg，po，QD； 28 days every cycle
45680652|NCT04557033|Other|Mindfulness intervention|My Moments® application (app) is a tool used to facilitate expressive art creation in a digital photography media
45680653|NCT01707693|Behavioral|Lifestyle Physical Activity Intervention|Physical Activity Information given plus Behavioral counseling using motivational interviewing & follow-up
45680654|NCT01707693|Behavioral|Information / Attention Comparison|Physical Activity information given & follow-up, no behavioral counseling
45837857|NCT05635669|Device|Abdominal acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. In this group, paired electrodes from the electroacupuncture apparatus were attached to the needle handles respectively at Zhongji(RN3) and one side of Dahe(KI12), as well as Guanyuan(RN4) and another side of Dahe(KI12).
46017094|NCT05657886|Other|Kangaroo care|The application was applied twice a day and for 60 minutes every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm, and the suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together. The researcher observed the application steps of the mother's KC, and the deficiencies, if any, were corrected by discussing with the mother during/after the application.
45466600|NCT03444220|Biological|Anaerobically Cultivated Human Intestinal Microbiota|30ml ACHIM will be administrated at week 0 and 2 with 14 days apart
45680655|NCT01722669|Drug|isoquercetin or quercetin|Single dose PK/PD study
45680656|NCT01707147|Drug|Trajenta tablet|Linagliptin
45680657|NCT01876251|Drug|PF-03084014|Tablet, 10 mg, twice a day
45680658|NCT01876251|Drug|PF-03084014|Tablet, 50 mg, twice a day
45680659|NCT01876251|Drug|PF-03084014|Tablet, 100 mg, twice a day
45680660|NCT01876251|Drug|Docetaxel|Solution for IV infusion 75 mg/m^2, every 3 weeks
45680661|NCT01876251|Drug|Docetaxel|Solution for IV infusion 100 mg/m^2, every 3 weeks
45837858|NCT05635669|Device|Alternating acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. The application of electroacupuncture is the same as Sacral group and Abdominal group.
46017095|NCT02874352|Device|high resolution impedance manometry with Automated Impedance Manometry analysis|
46017096|NCT02874040|Procedure|Endoresection|Endoresection of the tumor scar
46017097|NCT02874040|Procedure|Laser diode|Transpupillary thermotherapy by laser diode on the tumor scar
45466601|NCT03444220|Biological|Anaerobically Cultivated medium|30ml medium will be administrated at week 0 and 2 with 14 days apart
46017098|NCT04302610|Device|Heat and Moisture Exchange mask (ColdAvenger® expedition balaclava, USA,|A heat and moisture exchange mask will warm and humidify inspired air and therefore reduce airway heat and water loss during exercise. This will potentially reduce the incidence of and severity of EIB and may also have the potential to decrease the incidence of cough amongst athletes engaging in sports in cold dry environments
45466602|NCT05176275|Diagnostic Test|68Ga-NOTA-RP25|The proliferation and distribution of CD19 CAR-T cells in lymphoma patients were investigated by PET / CT after injection of 68Ga-NOTA-RP25
45837859|NCT05633680|Diagnostic Test|Peripheral blood sampling for circulating tumor cells|Patients had 3-4 ml of venous blood drawn on day 1 after admission, ethylene diamine tetra acetic acid (EDTA) was used for anticoagulation, samples were stored at 4 ℃, and CTCs analysis was performed within 24 hours after collection. .FU/3 ml was used as the unit for CTC quantification.
46017099|NCT04302610|Device|Sham treatment|Same as the HME mask but active HME parts withdrawn from devices and multiple holes made in mouth piece to improve ventilation of mask and reduce HME ability of mask
46101184|NCT02629640|Other|Participant follow-up|Hospital patient management system; regular telephone contact with patient/representative.
46101185|NCT02629640|Other|Blood or buccal sample|Codon-129 genotyping; storage for future research.
46101186|NCT02629640|Other|Post mortem examination|Brain tissue donation to the Edinburgh Brain and Tissue Bank for research,including investigations for evidence of prion disease.
46101187|NCT03150095|Behavioral|Health coaching|Patients will work with a health coach by telephone
46101188|NCT00705016|Drug|Cilengitide 2000 mg once weekly|Cilengitide 500 milligram (mg) will be administered as an intravenous infusion over 60 minutes, daily from Day 1 to 4 of the first week of each 3-week cycle, subsequently followed by 2000 mg dose of cilengitide on Day 8 and 15 of every cycle for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received cilengitide 2000 mg once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
45466603|NCT05608187|Biological|ILP100-Topical (emilimogene sigulactibac) 5x10^7 CFU/cm^2|Topical application of ILP100-Topical (emilimogene sigulactibac) at a dose of 5x10^7 CFU/cm^2 wound area.
45466604|NCT05608187|Biological|ILP100-Topical (emilimogene sigulactibac) 1x10^9 CFU/cm^2|Topical application of ILP100-Topical (emilimogene sigulactibac) at a dose of 1x10^9 CFU/cm^2 wound area.
46017100|NCT04301908|Drug|interferon|Antiviral therapy for patients with chronic hepatitis B and cirrhosis. Antiviral therapies included interferon and / or nucleoside (acid) analogs, and patients who were continuously treated for more than 6 months were included in the study.
45466605|NCT05608187|Biological|Placebo|Topical application of placebo (ILP100 dilution buffer mixed with the activation peptide SppIP).
45466606|NCT03444142|Drug|Exenatide LAR|2 mg, once weekly subcutaneously before breakfast during 4 weeks.
45466607|NCT03444142|Drug|Dulaglutide|.75 mg once weekly subcutaneously before breakfast during 4 weeks.
45466608|NCT03706599|Behavioral|Therapeutic education on fever|Session for therapeutique education on fever
45466609|NCT03706599|Behavioral|Therapeutic education on household accidents|Session for therapeutic education on household accidents
45680662|NCT01875471|Device|delefilcon A|Daily disposable soft contact lens to be worn at least 8 hours daily
45680663|NCT01875471|Device|narafilcon A|Daily disposable contact lens to be worn at least 8 hours daily
45680664|NCT01875237|Drug|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
45680665|NCT01875237|Drug|Melphalan|140 mg/m2 by vein on Day -2.
45680666|NCT01875237|Drug|Alemtuzumab|50 mg by vein on Day -1.
45680667|NCT01875237|Procedure|Stem Cell infusion|Stem cell infusion on Day 0. Goal is to administer more than 3 x 10^6 CD34+ cells/kg of peripheral blood progenitor cells (PBPC).
46017101|NCT01036438|Device|Mepilex Ag|Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
45466610|NCT04586075|Diagnostic Test|Trio Whole Genome Sequencing and Participant-Specific Research|"The initial evaluation begins with short-read genome sequencing of DNA extracted from blood of affected individual(s) and participating family members (The most common approach will be trio whole genome sequencing, which involves the affected child + their parents).~Additional evaluation may include: functional assessments, animal modeling, reverse phenotyping (may require an interim visit), epigenetic profiling, or clinical database matching through selective sharing of coded patient data with external collaborators (e.g., via Matchmaker Exchange and Phenome Central), long read genome sequencing, de novo genome assembly, RNA sequencing, and novel bioinformatics analyses"
45680668|NCT01875237|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml) between Day +1 and Day +45. Tacrolimus is changed to oral dosing when tolerated. Tacrolimus tapering should start on approximately Day +35 with the intention for the patient to be completely off the drug by approximately Day +45.
46017102|NCT01036438|Device|Mepilex without Ag|Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
46017103|NCT04304248|Drug|Albumin-bound paclitaxel, Carboplatin, Toripalimab|Eligible patients will receive Toripalimab 240mg + Albumin-bound paclitaxel 260mg/m2 + Carboplatin AUC5 for 3 cycles every 21 days (+/-3 days) as neoadjuvant treatment
46101189|NCT00705016|Drug|Cilengitide 2000 mg twice weekly|Cilengitide 2000 mg will be administered as an intravenous infusion over 60 minutes, twice weekly on Day 1, 4, 8, 11, 15, and 18 of each 3-week cycle for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants will receive cilengitide 2000 mg once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
46101190|NCT00705016|Drug|Cetuximab|Cetuximab will be administered as 250 milligram per square meter (mg/m^2) as infusion (initial starting dose of 400 mg/m^2) on Day 1, 8 and 15 of each 3-week treatment cycle. Cetuximab will be administered for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received Cetuximab 250 mg/m^2 once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
45680669|NCT01875237|Drug|Mini Methotrexate|5 mg/m2 by vein on Days +1, +3, +6.
45680670|NCT01875237|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
45680671|NCT01875237|Procedure|Donor Lymphocyte Infusion (DLI)|iCasp9 (BPZ-1001)-Modified T-cells) of 3 X 10^6/kg in 100 ml infused over approximately a one hour period between Day + 56 to Day +64.
45837860|NCT05604690|Biological|Avacc 10|Intranasal application of either low dose or high dose of Covid 19 vaccine.
46017104|NCT01268046|Drug|Estradiol oral capsule|1 oral capsule (1 mg estradiol) administered daily for one month
46017105|NCT01268046|Drug|transderman estrogen patch|transdermal estrogen patch (50 mcg/day) for one month
46017106|NCT01268046|Drug|trasdermal placebo patch|transdermal placebo patch with patch change every 84 hr for one month
45466611|NCT01306435|Other|Laser|3-week treatment with three Laser sessions per week
46017107|NCT01268046|Drug|placebo oral capsule|placebo oral capsule administered daily for one month.
45680672|NCT01875237|Drug|AP1903|0.4 mg/kg as a 2 hour infusion for patients that present with a clinical diagnosis of grade I GvHD. For patients with a clinical diagnosis of grade > 2 GvHD, a single dose of AP1903 0.4 mg/kg as a 2 hour infusion will be administered. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Patients who experience a partial response within 72 hours may receive a second dose of AP1903. Patients whose GvHD is progressing after 7 days, have no response by 14 days, or are not in a complete response at day 28 can receive secondary therapy.
45837861|NCT05604690|Combination Product|Outer Membrane Vesicles (OMV) : OMV alone in vehicle|OMV will be administered via intranasal route.
46017108|NCT04302298|Device|Virtual Reality|A machine which immerses the participant in a simulated environment where they can perform a procedure.
45837862|NCT05604690|Other|Placebo|Placebo will be administered via intranasal route.
46017109|NCT04732000|Drug|N-acetyl cysteine|Intravenous infusion started during the clinically indicated surgery at a rate of 50mg/kg over 1 hour followed by 50mg/kg over 3 hours. This will be an accumulated total of 100 mg/kg over 4 hours.
46017110|NCT04732000|Other|Normal Saline|Intravenous infusion at a time and rate to mimic the active treatment. The infusion will be given over 4 hours beginning during the clinically indicated surgery
46017111|NCT04729582|Biological|Primary human muscle stem cells (Satori-01)|Primary human muscle stem cells are isolated from patient's muscle tissue and expanded ex-vivo. They are injected into the urethral sphincter region as a one-time autologous treatment.
46017112|NCT04729582|Other|Placebo|Placebo is the injection solution without muscle stem cells.
46017113|NCT00627484|Procedure|Gastric bypass|NOTE: the surgery is not paid for by the study
46017114|NCT00627484|Procedure|Gastric banding|NOTE: the surgery is not paid for by the study
46017115|NCT00627484|Procedure|Sleeve gastrectomy|NOTE: the surgery is not paid for by the study
46101191|NCT00705016|Drug|5-fluorouracil (5-FU)|5-FU will be administered as an intravenous continuous infusion at a dose of 1000 mg/m^2 daily from Day 1 to 4 of each 3-week treatment cycle. 5-FU will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
46101192|NCT00705016|Drug|Cisplatin|Cisplatin will be administered as an intravenous infusion over 60 minutes, at a dose 100 mg/m^2 on Day 1 of each 3-week treatment cycle. Cisplatin will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
46101193|NCT02794805|Device|¹³C-Octanoate Breath Test|Octanoate Breath Test to be performed on subjects with suspected HCC
46101194|NCT00595868|Drug|Varenicline|0.5 milligrams two times per day for 3 days, then 1.0 milligrams two times per day for an addition 11 days - 2 months
46101195|NCT00595868|Drug|Placebo|same as Varenicline arm
45466612|NCT01306435|Other|Placebo Laser|3-week treatment with three Placebo Laser sessions per week
45466613|NCT03443986|Other|Resistance training associated with vibration|The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration and 5 minutes of slowdown.
45466614|NCT03443986|Other|Resistance training associated with vibration sham|"he workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration sham and 5 minutes of slowdown."
45466615|NCT05682417|Device|Body Map Assessment Tool: MOVE Tool|"In VR, a spherical object approaches with linear trajectory the body of patients, it can be sent to 4 parts of the body (mid-arm/waist/hip/mid-thigh) both left and right side. Several conditions are presented, either the trajectory leads the object to touch the body, or it passes at ≠ distances from it. Patient is instructed to move only if he thinks the object will touch his body.~Procedure begins with a measurement taken on 3 body locations via the Move tool (shoulders/hips/thighs) to create an avatar allowing the tool to determine whether or not movement was necessary. Then, the movement of the patient is recorded. For each object/body distance, the software determines if dodging was necessary. The overestimation of the body schema corresponds to the average distance from which the patient considers that the object would have touched her body and performs a dodging movement, compared to her real morphological dimensions. This generates a body limit distortion % for each body area."
45466616|NCT05682417|Other|PAQ questionnaire|This questionnaire has been translated and validated (French version, Luminet et al., 2021). This is a self-reported measure of alexithymia in 24 items. It is designed to measure all the components of alexithymia for both negative and positive emotions. Five subscale scores and six composite scores can be obtained from the questionnaire, with high scores indicating higher levels of alexithymia.
45466617|NCT05682417|Other|F-DFlex questionnaire|This questionnaire (Detail and Flexibility Questionnaire, French version of Maria et al, 2020) assesses cognitive rigidity. This questionnaire assesses two frequently impaired cognitive dimensions in people with anorexia nervosa, central coherence and cognitive flexibility in daily functioning using 20 self-completed items.
45466618|NCT05682417|Other|BSQ questionnaire|"The Body Shape Questionnaire (BSQ, translated and validated in French by Rousseau et al., 2005) is a one-dimensional Anglo-Saxon self-questionnaire of 34 items that assesses concerns about body shape over the past four weeks. Responses are scored on a 6-point Likert scale. A score of 1 (never) means the problem is not present, up to a score of 6 (always) which means the problem is always present. The higher the score, the more the concern/dissatisfaction with one's body tends to be pathological."
45466619|NCT05682417|Other|Silhouette testing|Body overestimation is assessed by the computerized silhouette test (adapted from Gardner & Brown, 2010, Van der Linder et al., 2017). Twenty-seven Body Mass Index silhouettes ranging from 11 to 40 are presented to participants in random order. For each silhouette presented, the participant answers whether or not the silhouette presented corresponds to her current silhouette. A body underestimation index is calculated as follows: Estimated figure average BMI - actual BMI.
45837863|NCT05602376|Behavioral|U=U testing messaging scripts|On site testing days randomized to the intervention, trained health promoters employed by the mobile testing venues will use U=U messaging scripts to invite men in the vicinity to seek HIV testing services on that day. On intervention days, the U=U messaging will also be used by counselors at the testing venue when referring those who test HIV positive to clinic-based ART initiation services provided by the local Department of Health
46017116|NCT00627484|Behavioral|Very low calorie diet|Weight loss with calorie restricted liquid diet. Subject will be asked to stay in our in-patient research unit for 2-3 weeks and consume only those foods supplied by our bionutrition unit. Expected weight loss should be between 7-10% of body weight. Subjects will receive the diet at no cost and will be compensated for their time.
46017117|NCT01267266|Drug|saracatinib|Given orally
46017118|NCT01267266|Other|hydrocortisone/placebo|Given orally
46017119|NCT01034176|Drug|levofloxacin|500 mg tablet, daily, 30 days
46017120|NCT01034176|Drug|placebo|no dose, tablet, daily, 30 days
46017121|NCT02889432|Drug|Oral Melatonin 10mg|
46101196|NCT02699801|Drug|propofol|propofol for post-sternal closure sedation
46017122|NCT02889432|Drug|Placebo|
46101197|NCT02699801|Drug|Dexmedetomidine|dexmedetomidine for post-sternal closure sedation
45466620|NCT05682417|Other|Eating Disorder Inventory - 2|"Allows self-assessment of symptoms of eating disorders. It is composed of 91 questions grouped into 11 subscales that assess specific cognitive and behavioral dimensions: desire for thinness, bulimia, body dissatisfaction, feeling of inefficiency, perfectionism, interpersonal distrust, interoceptive sensitivity, fears relating to maturity, asceticism. , impulsiveness and social insecurity. For each item, participants can answer always, usually, often, sometimes, rarely or never. The score for each item is between 0 and 3. The subscale scores are calculated by simply adding all the item scores for each specific subscale. This questionnaire has demonstrated good internal consistency, test-retest reliability, and validity (Garner, 1991)"
45466621|NCT05682417|Other|EDEQ questionnaire|"Or Eating Disorders Examination - Questionnaire (Fairburn & Beglin, 2008). This questionnaire assesses eating behaviors and concerns about weight and body shape, using 28 items focusing on these aspects over the past 28 days."
46017123|NCT04323540|Procedure|Peri-implantitis reconstructive surgery|"For both arms (excluding the already included information): defect debridement, removal of debris using titanium curettes, titanium brushes on the implant surface, irrigation with saline, application of sterile cotton pellets with saline solution. Grafting with (experimental) xenograft and soft tissue, or xenograft alone (control). Suture.~Specific to control group (active comparator): the peri-implant defect will be filled with xenograft, and a collagen membrane will be fitted and trimmed to the defect area.~Specific to test/experimental group: same as above (for control). In addition a soft tissue graft will be harvested from the palate and sutured to the buccal flap. The entire flap will then be sutured to the lingual flap."
46017124|NCT01033942|Drug|coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP|Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
46017125|NCT01033942|Drug|Placebo|Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
45466622|NCT05682417|Other|STAI questionnaire|The Spielberger Anxiety Scale (STAI) State and Trait. This questionnaire includes two distinct scales: one evaluating the current state of anxiety (STAI form Y-A: feelings of apprehension, tension, nervousness and worry that the subject feels at a precise precise moment) and the second evaluating the anxious personality trait (STAI form Y-B: feelings of apprehension, tension, nervousness, and worry that the subject usually feels). The Y version was developed in order to eliminate the items having appeal to depression compared to the initial form. Each scale has 20 items. This questionnaire has good psychometric qualities regarding validity, reproducibility and inter-individual sensitivity. It correlates well with other anxiety questionnaires in a literature review of anxiety questionnaires (Elwood, 2012).
46017126|NCT01033942|Behavioral|Many Men, Many Voices (3MV)|Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.
45680673|NCT01875237|Drug|Methylprednisolone|1.6 mg/kg per day by vein divided in 2 to 3 daily doses. Patients whose GvHD resolves as defined by a complete response within 72 hours, would have steroids stopped immediately. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Steroids can then be tapered as tolerated to no less than 0.6 mg/kg per day at day 28.
46017127|NCT01062256|Drug|Placebo|One placebo tablet administered orally as a single dose
46017128|NCT01062256|Drug|Guaifenesin|One 400 mg immediate release tablet administered orally as a single dose
46017129|NCT01062256|Other|Buckwheat Honey|10 mL administered orally as a single dose
46017130|NCT01029886|Drug|exenatide once weekly|subcutaneous injection, 2mg, once weekly
46017131|NCT01029886|Drug|liraglutide|subcutaneous injection, forced titration to 1.8mg, once daily
46017132|NCT02874274|Behavioral|Standard of Care|
46017133|NCT02874274|Behavioral|Home Visit Program (HVP)|The study team will also contact the subject by phone within one week of each vaccination visit to assess for any adverse effects related to vaccination, included but not limited to: injection site pain, tenderness, swelling, pruritus, induration, or erythema; systemic symptoms such as fatigue, chills, headache, anorexia, malaise, myalgias, or anaphylaxis. Subjects will be contacted 90 days (+ 14 days) following Visit 3 to inquire about any additional symptoms and healthcare utilization.
46017134|NCT01244763|Drug|Roxadustat|Oral capsule
46017135|NCT01244061|Drug|Varenicline|Varenicline 1mg twice daily
46017136|NCT01244061|Drug|Placebo|Matched placebo twice daily
46017137|NCT01243671|Biological|Adalimumab|
46017138|NCT04319679|Device|Extracorporeal shockwave therapy|6 times during 2 weeks
46017139|NCT04319679|Device|Sham therapy|6 times during 2 weeks
46017140|NCT01240785|Drug|metformin|metformin 1 g twice daily or maximum tolerated dose less than 2 g daily
46017141|NCT01240785|Drug|insulin|subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery
46101198|NCT02727907|Drug|BCD-033 (interferon beta 1a)|Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks
46101199|NCT02727907|Drug|Rebif (interferon beta 1a)|Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks
46101200|NCT02727907|Drug|Placebo|Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for12 weeks
46017142|NCT01240551|Drug|F-18 NaF|All participants will undergo a static F-18 NaF PET/CT imaging session at baseline, at 4-8 months, and at 10-14 months following enrollment (3 sessions over 1-year). Half of the participants (15 in each group) will undergo two baseline F-18 NaF PET/CT imaging sessions (within 14-days of each other) in order to evaluate the reproducibility of F-18 NaF PET imaging for a total of 4 sessions over a 1-year period.
46017143|NCT01239381|Radiation|Stereotactic body radiotherapy-proton|Dose will be determined by the size and location of the tumor(s); 2-3 treatments per week for two weeks
46017144|NCT01266876|Drug|Alirocumab|Alirocumab two SC injections in the abdomen only.
46017145|NCT01266876|Drug|Placebo|Placebo two SC injections in the abdomen only.
46017146|NCT01266642|Radiation|External Beam Radiation Therapy|Undergo HF-WBI
46101201|NCT00663650|Procedure|Permanent Section Control|After surgical excision of the tumor, margins will be sent for permanent section pathologic control to determine if the tumor was completely excised
46101202|NCT00663650|Procedure|Frozen Section Control|After surgical excision of the tumor, tumor edges will be analyzed by frozen section at the time of surgery. If tumor margins are positive with the frozen section, additional tissue will be excised and analyzed again. This process will be repeated until all tissue edges are clear of tumor. Finally, the area of tumor excision will be surgically reconstructed.
46101203|NCT02699567|Other|No intervention|
46101204|NCT00663728|Drug|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1 hour prior to sexual intercourse
46101205|NCT00663728|Drug|Placebo|Matching placebo
46101206|NCT01009801|Drug|doxorubicin-eluting beads|Patients receive oral placebo or everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
45466623|NCT05682417|Other|BECK questionnaire|Beck Depression Inventory (Beck, 1987). The inventory is composed of items related to depressive symptoms as well as physical symptoms. This is a questionnaire that gives a quantitative estimate of the intensity of depression. Investigators will use the abbreviated version consisting of 13 items, each item comprising 4 sentences corresponding to 4 degrees of increasing intensity of a symptom on a scale of 0 to 3. The total score corresponds to the sum of the different items and makes it possible to judge the presence of depression and its intensity.
45466624|NCT01305733|Drug|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
46017147|NCT01266642|Radiation|External Beam Radiation Therapy|Undergo CF-WBI
46017148|NCT01266642|Radiation|Hypofractionated Radiation Therapy|Undergo HF-WBI
46101207|NCT01009801|Drug|everolimus|Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
46017149|NCT01266642|Other|Laboratory Biomarker Analysis|Optional correlative studies
46017150|NCT01266642|Other|Quality-of-Life Assessment|Ancillary studies
46017151|NCT01266642|Other|Questionnaire Administration|Ancillary studies
46017152|NCT01266642|Radiation|Whole Breast Irradiation|Undergo HF-WBI
46017153|NCT01266642|Radiation|Whole Breast Irradiation|Undergo CF-WBI
46017154|NCT01033240|Drug|CS-1008 2 mg/kg|On a once a week basis CS-1008 will be administered intravenously starting at 2 mg/kg.
46101208|NCT01009801|Other|placebo|Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
46017155|NCT01033240|Drug|Sorafenib|On a daily basis, one sorafenib tablet, 400 mg, is taken orally twice a day. The total daily dose of sorafenib is 800 mg. The sorafenib tablets are taken at least 1 hour before or 2 hours after a meal.
46017156|NCT01033240|Drug|CS-1008 6/2 mg/kg|A 6 mg/kg loading dose of CS-1008 will be administered intravenously, followed by a 2 mg/kg/week maintenance dose on a once-a-week basis.
46017157|NCT01033240|Drug|CS-1008 6/6 mg/kg|A 6 mg/kg loading dose of CS-1008 will be administered intravenously, followed by a 6 mg/kg/week maintenance dose on a once-a-week basis.
46017158|NCT01033240|Drug|CS-1008 4 mg/kg|On a once a week basis CS-1008 will be administered intravenously at 4 mg/kg if tolerated.
46101209|NCT00670826|Device|vitalHEAT vH2 Temperature Management System|The vH2 system utilizes a combination of localized heat and vacuum application to one hand & forearm; this application opens AVAs in the palm of the hand and warms the extremity thus effectively warming the blood flowing to the body's core.
46101210|NCT00670826|Device|Arizant Healthcare Bair Hugger Temperature Management System|The Bair Hugger system is a forced air system providing convective warming via the circulation of warmed air through specially designed blanket which is placed over a portion of the body
46101211|NCT00617045|Drug|duloxetine|"Total treatment period is 12 weeks~30mg po qd times 1 week~60mg po qd times 11 weeks"
46101212|NCT02629718|Drug|NACT (Paclitaxel + Cisplatin or carboplatin)|Paclitaxel 150mg/m2 over 3 hours + Cisplatin 70mg/m2 or carboplatin AUC = 6, repeat per 21 days, 3 cycles.
46101213|NCT02629718|Procedure|radical surgery|Radical hysterectomy (Piver Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
46101214|NCT01009879|Drug|Etanercept|Etanercept 50 mg SQ qweek
46101215|NCT01009957|Drug|Everolimus|0.75 mg x 2 / day
46101216|NCT00670904|Other|Pharmacist-delivered group program for smoking cessation|Participants assigned to the treatment group participated in a pharmacist-delivered program at the clinic. The six-hour program consisted of three in-person sessions delivered at 2-week intervals over 5 weeks to a small group of smokers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
46101217|NCT00670904|Other|Brief standard care session for smoking cessation delivered over the telephone|Those assigned to the control group received one 5 to 10 minute session delivered by the clinical pharmacist over the telephone that included all the components of standard care recommended by the Clinical Practice Guidelines for brief interventions delivered by health care providers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
45466625|NCT01305733|Other|saline injection|saline
46017159|NCT01033240|Drug|CS-1008 6 mg/kg|On a once a week basis CS-1008 will be administered intravenously at 6 mg/kg if tolerated.
46101218|NCT04214795|Other|Observational study. Postnatal variables are recorded|Postnatal evolution is analyzed in both groups
46101219|NCT05492266|Device|Expiratory Muscle Strength Training|At visit 1, participants will be block randomized based on PWSS score (3-6 or 7+) to Expiratory Muscle Strength Training (EMST) for 6 to 8 weeks or no exercises. Participants in the EMST-150 group will perform 5 sets of 5 resistive expirations once a day with a 10-15 second rest between each repetition and a 1-2 minute rest between each set of 5 repetitions.
45598342|NCT02291107|Device|Lokomat (Hocoma, Zurich, Switzerland)|Patients allocated to the Experimental group performed a Robotic Assisted Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.
45598343|NCT02291107|Other|Conventional Physiotherapy|Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
46017160|NCT01266018|Drug|ADI-PEG 20 (Arginine deiminase pegylated)|ADI-PEG 20 was administered intramuscularly (IM) at a fixed dose of 320 IU/m^2 (36.8 mg/m^2) once weekly for 4 weeks followed by a 1-week follow-up (1 cycle)
46017161|NCT01032382|Drug|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
45598344|NCT02357355|Device|UIHC Driving Simulator|This is a driving simulator located in the basement of the hospital. A car will be facing a large video screen of a driving simulation.
45598345|NCT02218229|Device|Shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis
46017162|NCT01032382|Drug|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
46017163|NCT01029652|Drug|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
46017164|NCT01029652|Drug|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
46017165|NCT01029652|Drug|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
46017166|NCT01029652|Drug|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
46017167|NCT01029340|Biological|Recombinant Factor VIII (BAY81-8973)|Single dose of BAY81-8973 crossed over to single dose of Kogenate FS
46017168|NCT01029340|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Single dose of Kogenate FS crossed over to Single dose of BAY81-8973
46017169|NCT01029340|Biological|Recombinant Factor VIII (BAY81-8973)|Participants received IV injections of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia (CS/EP) for 6 months and by Chromogenic Substrate Assay/Adjusted to Label Potency (CS/ADJ) for 6 months, sequence according to randomization.
46017170|NCT01029340|Biological|Recombinant Factor VIII (BAY81-8973)|Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
46017171|NCT04301752|Diagnostic Test|MoCA|Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were <26. Maximum score is 30.
46017172|NCT04699786|Other|Arm A , Arm B, Arm C, & Arm D|All arms will receive the same intervention, but at different time points. All arms will be offered the option to learn their research results in personalized five-year risk estimate of getting Alzheimer disease dementia. Arms A & C participants will receive their risk estimate about two weeks after consent is signed and Arms B& D will receive their risk estimate about one year after consent is signed. The risk estimate returned to participants is based on research results from individual genotyping results, imaging or plasma amyloid testing & demographic characteristics. All arms will complete psychosocial and cognitive testing. Also, surveys used in this study will ask about participants' experiences and feelings after learning their risk estimate. All arms will receive follow up calls at one week post disclosure of the risk estimate and surveys two, six, and twelve months post disclosure. Arms A & C will have extra surveys at twenty-four months post disclosure.
45466626|NCT05210153|Drug|Sertraline|"Drug: Sertraline, a selective serotonin reuptake inhibitor (SSRI), is commercially known as Sidata® or Zoloft® in Serbia. The recommended dose for Major depressive disorder is 100 mg/day. It is recommended to start therapy with 50 mg/day, and in the case of lack of therapeutic effect dose should be increased in 50 mg increments every 2 weeks until intended pharmacological effect is reached. Dose can be increased up to the maximum dose is 200 mg/day. Sertraline is also indicated for treatment of Obsessive-compulsive disorder, Generalized anxiety disorder, Social anxiety disorder (Social phobia), Panic disorder (with or without agoraphobia) and Post-traumatic Stress Disorder by Medicines and Medical Devices Agency of Serbia.~Drug levels are expected to be 50% higher in CYP2C19 poor metabolizers as compared to normal metabolizers, but no specific dosing recommendations are given by the Medicines and Medical Devices Agency of Serbia."
45466627|NCT04451746|Drug|Combined Oral Contraceptive|The investigators consistently include patients who have been prescribed hormonal tablets for contraception, namely 1) COCs with bioidentical estrogen; 2) COCs with ethinyl estradiol 30mkg according to the scheme 21 + 7; 3) COCs with ethinyl estradiol 20mkg according to the scheme 21 + 7.
45466628|NCT03443830|Drug|Tyzivumab|Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb) Infused over 30 minutes
45466629|NCT03785899|Device|SPOCnew|"SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2). The revised new algorithm is turned on."
45466630|NCT03785899|Device|8s SpO2 averaging|The arterial saturation (SPO2) will be averaged over 8s.
45466631|NCT03785899|Device|SPOCold|"SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2). The former old algorithm is turned on."
45466632|NCT03785899|Device|2s SpO2 averaging|The arterial saturation (SPO2) will be averaged over 2s.
45466633|NCT04749459|Drug|ChapStick Moisturizer, Strawberry Flavor|A single topical application of ChapStick Moisturizer, Strawberry Flavor will be applied to the appropriate 40 square centimeter (cm^2) test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 milligram per centimeter square (mg/cm^2), using 80 +/-2 milligrams (mg) of material.
45466634|NCT04749459|Drug|ChapStick Moisturizer, Classic Flavor|A single topical application of ChapStick Moisturizer, Classic Flavor will be applied to the appropriate 40 cm^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm^2, using 80 +/-2 mg of material.
45466635|NCT04749459|Drug|ISO 24444:2010 P2 Standard Reference Sunscreen|A single topical application of ISO 24444:2010 P2 Standard Sunscreen will be applied to the appropriate 40 cm^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm^2, using 80 +/-2 mg of material.
46017173|NCT04304170|Dietary Supplement|VES002|The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
46017174|NCT04304170|Other|Placebo|The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
46017175|NCT04301206|Behavioral|Intervention Group|Empowerment of parents. When calling the medical helpline 1813 the parents will be offered to access the new material about sick children, compared to not getting this possibility.
46017176|NCT01265550|Device|Nissen fundoplication|laparoscopic antireflux surgery
45466636|NCT01139333|Genetic|gene expression analysis|
45466637|NCT01139333|Genetic|western blotting|
45466638|NCT01139333|Other|flow cytometry|
45466639|NCT01139333|Other|laboratory biomarker analysis|
45466640|NCT03438370|Other|Three monthly ART supply at CAGs|Sites where three monthly ART supply will be provided at outreaches
45466641|NCT03438370|Other|Six monthly ART supply at outreaches|Sites where six monthly ART will supply will be provided at outreaches
45466642|NCT04585295|Dietary Supplement|Betaine|50 mg/kg Betaine consumed twice daily for 7 days.
46017177|NCT01265550|Drug|baclofen|"Baclofen will be prescribed in a dose of 5 mg three times a day (TID) with meals.~The dose of baclofen will be increased by 5 mg TID every week until a total dose of 20 mg TID has been achieved."
45680674|NCT01875237|Behavioral|Questionnaire|Completion of a quality of life questionnaire that will take 10-15 minutes between Days + 28 and + 56, about twice a week until about 2 months after the T-cell infusion, and then 6 and 12 months after the stem cell transplant.
46017178|NCT01265550|Drug|Desipramine|Dose of 25 mg at bedtime (HS) for 1 week, then 50 mg HS for 1 week, then 100 mg HS until the next quarterly visit.
46017179|NCT01265394|Drug|[18F] Flutemetamol|Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.
46017180|NCT02889354|Behavioral|Cognitive-behavioral therapy|
45680675|NCT01874535|Drug|Esomeprazole 40 mg|Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
46101220|NCT05492266|Device|Maintenance Training|"At visit 2, participants with improved (decreased) PWSS of 2 or more points, for whom the family and/or surgeon is not currently considering surgical intervention for VPI, will be further randomized to continue maintenance EMST exercises or no exercises for 6 months. Participants in the maintenance group will complete 3-5 sessions exercise sessions each week (rather than daily training), with 2 sets of 5 resistive expirations (rather than 5 sets)"
45466643|NCT04585295|Dietary Supplement|BCAA Big 6|1 level scoop (~18 g) of NOW Foods BCAA Big 6, consumed once per day for 7 days.
45466644|NCT04585295|Dietary Supplement|Placebo|50 mg/kg Placebo consumed twice daily for 7 days.
45680676|NCT01722045|Drug|Intravitreal Aflibercept Injection (IAI)|
45680677|NCT01721109|Drug|EVG/COBI/FTC/TDF|150/150/200/300 mg STR administered orally once daily with food
45680678|NCT01874145|Drug|GA 20 mg/mL|Glatiramer acetate (GA) 20 mg/mL subcutaneous (SC) injection, the commercial product, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
46101221|NCT01010035|Other|Plasma kinetic study|this study is done with the injection of LDL-like nanoemulsion doubly labeled with 14C- cholesteryl oleate and 3H- cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood sample collected in a pre established period of time in 24 hours.
45466645|NCT03708783|Procedure|laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection|For patients with locally advanced upper or middle third gastric cancer, laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-preserving No. 10 lymph node dissection is performed.
45466646|NCT03785821|Dietary Supplement|BMSO|BMSO was extracted from Hualien No. 4 cultivate of bitter melon seed. BMSO were incorporated into capsules containing 0.5 g of oil. All persons took 3 capsules after each meal, i.e. 9 capsules (4.5 g of oil) daily, resulting in daily consumption of 2.3 g alpha-ESA in the BMSO group.
45466647|NCT03785821|Dietary Supplement|OO|Olive oil (extra virgin grade) was purchased from La Espanola (Acesur, Spain). OO were incorporated into capsules containing 0.5 g of oil, identical appearance to BMSO. All persons took 3 capsules after each meal, i.e. 9 capsules (4.5 g of oil) daily.
45466648|NCT03710382|Other|Walking epidural|Parturients in spontaneous or induced labor will receive combined spinal-epidural analgesia (CSE) using an infusion of bupivacaine 0.0625% and fentanyl 2 mcg/mL and will be encouraged to walk a minimum of 15 minutes every hour during the first stage of labor.
45466649|NCT03708705|Other|Risk model of tumor relapse|High risk factor model of tumor relapse after liver transplantation
45466650|NCT03438292|Dietary Supplement|Berberine|Two capsules of berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
45466651|NCT03438292|Dietary Supplement|TPGS emulsified berberine|Two capsules of TPGS/Quillaja extract emulsified berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
45466652|NCT03438292|Dietary Supplement|Quillaja extract emulsified berberine|Four capsules of Quillaja extract emulsified berberine. Each capsule contains 200 mg berberine. The total amount of berberine throughout is 800 mg.
45466653|NCT04782999|Diagnostic Test|Oral Glucose Tolerance Test|Standard test of glucose tolerance with ingestion of 75 g glucose followed by blood sampling.
45466654|NCT04782999|Diagnostic Test|Hyperglycemic clamp with infusion of saline, GLP-1 or GIP|"Blood glucose kept at 15 mmol/L via iv 20% glucose infusions.~Primed co-infusion of either:~Saline~GLP-1 (Prime dose 6 pmol/kg, infusion 1 pmol/kg/min)~GIP (Prime dose 3 pmol/kg, infusion 1.5 pmol/kg/min)."
45466655|NCT03791437|Device|Digital chest drainage system|patients who received Digital chest drainage system
45466656|NCT03791437|Device|Not use Digital chest drainage system|patients who not received Digital chest drainage system( traditional drainage system)
45466657|NCT01136213|Radiation|PET (Positron Emission Tomography) Study|5-HT1a auto-receptors will be visualized in vivo using 18F-MPPF PET study. Two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
45466658|NCT01136213|Other|Brain MRI (magnetic resonance imaging)|A brain MRI (magnetic resonance imaging)will be performed the day of the first PET study.
45466659|NCT01136213|Drug|Fluoxétine / Placebo|The two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
45466660|NCT03361176|Drug|Injectable sodium deoxycholate|Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline to the non-TMC group to maintain equal concentrations in each injection so that the final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point will be delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total maximal dose of up to 100 mg of SDOC.
45466661|NCT03361176|Combination Product|Injectable sodium deoxycholate with Triamcinolone acetate|Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate, 0.2 mL of 1% lidocaine with no epinephrine and then delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total dose of up to 100 mg of SDOC using a 30 gauge (or smaller) 0.5-inch needle. The final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point
45680679|NCT01874145|Drug|GA 40 mg/mL|Glatiramer acetate (GA) 40 mg/mL subcutaneous (SC) injection, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
45680680|NCT04415385|Drug|Camrelizumab|200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks.
45680681|NCT04415385|Drug|Apatinib|250 mg, orally once a day. Take about half an hour after a meal with warm water.
45680682|NCT01720797|Device|Micro-osteoperforation|Minimally invasive micro-osteoperforation procedure used to achieve rapid orthodontic tooth movement.
45466662|NCT05260125|Drug|Ultrasound-guided Suprascapular Nerve Block|"For suprascapular nerve block, a solution consisting of 5 ml 2% lidocaine, 1 ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml), 4 ml saline will be used.~Injections will be applied to patients in a sitting position and arm by the side. A linear probe with a frequency of 7-8 MHz on the SonoScape A8 ultrasound device will be used for suprascapular block under ultrasound guidance. the ultrasound probe was placed in the coronal plane over the suprascapular fossa. Suprascapular fossa was scanned from medial to lateral side to identify suprascapular nerve. After identification, solution of suprascapular nerve block will be injected into the area around the nerve under the scanning with in-plane technique with a 22 gauge 90 mm spinal needle."
45466663|NCT05260125|Drug|Anatomical Landmark-guided Suprascapular Nerve Block|"For suprascapular nerve block, a solution consisting of 5 ml 2% lidocaine, 1 ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml), 4 ml saline will be used.~Injections will be applied to patients in a sitting position and arm by the side. The suprascapular notch projection will be determined using the anatomical landmark technique defined by Dangoisse et al., and then suprascapular nerve block will be applied with a 22 gauge 90 mm spinal needle to the patients"
45466664|NCT03438214|Drug|Vancomycin Continuous infusion|Will be administered a loading dose of 25mg/kg followed of 2g infused in 24h. Serum levels will be measured after the end of the loading dose (peak) and after 24 hours (steady state). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and area under curve (AUC) /MIC≥400mg.h/L
45466665|NCT03438214|Drug|Vancomycin Intermittent infusion|Will be administered a loading dose of 25mg/kg followed of 1g every 12h. Serum levels will be measured after the end of the loading dose (peak) and one hour before the next dose (trough). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and AUC/MIC≥400mg.h/L.
45466666|NCT05620693|Biological|NY-ESO-1 TCR-T|NY-ESO-1 TCR-T treatment
46017181|NCT01029262|Drug|Lenalidomide|One 10 mg Lenalidomide capsule + 2 placebo capsules or (3 placebo capsules) once daily for subjects with a creatinine clearance ≥ 60 mL/min. Alternatively-one 5 mg Lenalidomide capsule + 2 placebo capsules (or 3 placebo capsules) once daily for subjects with a creatinine clearance between 40 and 60 mL/min. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
45466667|NCT01141127|Drug|Tranexamic Acid|Comparison of two dosage regimen of Tranexamic Acid
45466668|NCT05679999|Diagnostic Test|CIMT (Carotid artery intima media thickness measurement)|Carotid artery intima media thickness measurement with ultrasound
45466669|NCT04613206|Biological|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
45466670|NCT04613206|Biological|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
45466671|NCT03708822|Drug|Docetaxel and Cisplatin and Nimotuzumab|All patients enrolled in the study will accept docetaxel combined with cisplatin and Nimotuzumab as their firstline chemotherapy
45466672|NCT01232621|Other|Physician Introduction of research personnel|Physicians will introduce Research Coordinators (RCs) by name and acknowledge patient eligibility to participate in a research study using a standardized script.
45466673|NCT05682261|Dietary Supplement|UNIMMAP-MMS|The study participants in this arm will receive the United Nations International Multiple Micronutrient Antenatal Preparation-Multiple Micronutrient Supplements (UNIMMAP-MMS) containing 15 micronutrients including 30 mg of iron and 400 µg of folic acid.
45837864|NCT05602376|Behavioral|U=U adherence messaging scripts|After receiving standard ART initiation and adherence counselling from a DoH clinic nurse per South African National Guidelines, RCs will deliver a U=U message and hand participants a small business card with a brief U=U message on it. Participants will then receive monthly SMS booster messages (but can opt out) and monthly in-clinic booster messages during routine medical refill visits, again with a business card for messaging reinforcement.
46017182|NCT01029262|Other|Placebo|3 placebo capsules once daily. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
46017183|NCT04301284|Drug|CAD-1883|150 mg filled capsules
46017184|NCT04301284|Drug|Placebos|capsules
46017185|NCT02875210|Procedure|Laximeter measurement|
46017186|NCT02873416|Drug|Chemotherapy|Cisplatin：60mg/m2，Gemcitabine：1g/ m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
46017187|NCT02873416|Biological|Precision Cells|Precision Cells DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
46017188|NCT01028560|Biological|Allergen extracts (subcutaneous injections)|Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-2 injections until a predetermined maintenance dose is reached. This maintenance dose varies by extract and accords to the general practice guidelines of immunotherapy. To increase safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase (year 2-3)
46017189|NCT01028560|Other|Standard of care|standard of care asthma and allergy treatment
45466674|NCT05682261|Dietary Supplement|IFA|The study participants in this arm will receive iron-folic acid supplements with 30 mg of iron and 400 µg of folic acid.
45466675|NCT05682261|Other|Placebo|The study participants in this arm will receive placebo made of sugar (lactose anhydrous).
45466676|NCT01308385|Other|Conditioned pain modulation|When evaluating conditioned pain modulation, pressure pain threshold in the musculus quadriceps femoris act as test stimulus and 2 minutes cold pressor test (stirred ice and water) acts as the conditioning stimulus. The difference between pain thresholds before and after the cold pressor test is defined as the effect of CPM.
45466677|NCT04579666|Drug|Pegcetacoplan (APL-2)|Complement (C3) Inhibitor
45466678|NCT04579666|Other|Placebo|Sterile solution of equal volume to active arm
45466679|NCT05280444|Drug|Idarubicin Hydrochloride for Injection|The initial dose of idarubicin is 10 mg and the maximum tolerated dose is 20 mg. Idarubicin is first dissolved in water for injection to make a solvent of 2mg/ml, which is then mixed with lipiodol to make an emulsion with a ratio of 1:2. Lipiodol-idarubicin emulsion is slowly injected, followed by embolization with embolic agents.
46101222|NCT05324345|Behavioral|Prehabilitation group|All patients will be guided to use the WeChat mini-program which including details in text, pictures and videos of their individualized prehabilitation strategy after a complete assessment. Multimodal prehabilitation strategy includes conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence), physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training), nutritional suggestion and optimization (whey protein supplement), and psychological therapy. All movements can be practiced with the reference to the standard videos in the WeChat mini-program. Patients will check the prehabilitation content daily and form their own training tasks in the WeChat mini-program. Standardized short message interviews will be sent to patients twice a week to optimize adherence and promote timely feedback.
46101223|NCT04062136|Combination Product|stem cell transplantation|Transplantation of umbilical cord mesenchymal stem cells
46101224|NCT03996733|Other|Lecture|Principal investigator of the study will lecture about the ultrasound guided jugular central venous catheterization according to latest guidelines.
46101225|NCT03996733|Other|Demo Video|Investigators of the study prepared a detailed demo-video showing insertion of a jugular central venous catheter with USG guidance. Principal investigator will vocalize the video in real-time.
46101226|NCT03996733|Other|UltrasoundImaging|Participants will exercise the proper visualisation of the right jugular vein at T6 level with USG guidance on a human subject.
46101227|NCT03996733|Other|ModelTraining|"Participants will exercise the proper punction of juguler vein with USG guidance on the homemade jugular venous catheterization training model.~Training model will include carotid artery, trachea and plaure in accordance with the real anatomy."
45466680|NCT01308541|Drug|arm 1|"Bolus Dose: two bolus doses of 15.0 mg/kg (first dose) and 8.0 mg/kg (second dose), 40 minutes apart.~Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour."
45466681|NCT01308541|Drug|LUSEDRA|Mode of administration: intravenous (IV).Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour.
46101228|NCT04213625|Other|Surgeon Personal Background|"Experimental group will receive an information sheet with their surgeon's educational and personal background.~Personal Background~Favorite outdoor activity/form of exercise~Favorite hobby~Family information (children, pets)~Single sentence about how the clinician conceptualizes excellent patient care"
45466682|NCT01308541|Drug|Propofol (arm 3)|Mode of administration: intravenous (IV). A loading dose administered at a constant infusion rate of 0.20 mg/kg/min (0.50 mL/kg/min) for 10 minutes, followed by a constant-rate 2-hour infusion at 0.10 mg/kg/min; total dose infused over 130 minutes is 14.0 mg/kg.
45466683|NCT05679765|Drug|Greater Occipital Nerve Block with dexamethasone and lidocaine|Ultrasound guided Greater occipital nerve block on the side of headache
45466684|NCT05679765|Drug|Greater Occipital Nerve Block with 0.9% saline|Ultrasound guided Greater occipital nerve block on the side of headache
45466685|NCT05271708|Drug|Fespixon cream|Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
45466686|NCT05271708|Drug|Placebo Cream|Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
45466687|NCT03785431|Device|PCI with Phantom Bioresorbable Scaffold|Once baseline angiography is performed and all eligibility criteria are met, the patient is included in the study. The target lesion should be crossed with a standard coronary guidewire. Next, the NIRS/IVUS and OCT probe is inserted and a pullback is being performed to evaluate the lesion and vessel morphology. The predilatation with 1:1 non-compliant or semi-compliant balloon is mandatory. Thereafter the scaffold should be inserted and position across the target lesion. Lesions up to 14 mm should be covered with the 18 mm device, for lesions of 15-20 mm a 24 mm device should be used. The scaffold will be deployed with intent to achieve the inner diameter to the reference vessel ration of 1:1 using a single inflation. Post-dilatation using a non-compliant balloon should be performed to achieve complete scaffold apposition and reduce the residual angiographic stenosis below 20%. The final NIRS/IVUS and OCT of the target vessel should be performed.
45466688|NCT03706443|Other|Systane Complete|Lubricant eye drop which is based on propylene glycol 0.6%. Used for temporary relief of burning and irritation due to dryness of the eye.
45837865|NCT05600270|Device|Angled guidewire|Cannulation of the common bile duct using an angled-tip guidewire during ERCP
46017190|NCT01061710|Drug|varenicline|Dosage form: tablet 0.5mg, tablet 1mg. The usual adult dosage for oral use is 0.5 mg once daily after eating on Days 1 to 3; 0.5 mg twice daily after eating in the morning and evening on Days 4 to 7, and 1 mg twice daily after eating in the morning and evening on Day 8 and thereafter. The drug should be administered to subjects for 12 weeks.
46101229|NCT04062370|Drug|Ranibizumab|Patients will receive intravitreal injection of Ranibizumab 0.5 mg (1+PRN or 3+PRN) according to the study until month 6. Then, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN after month 6.
46101230|NCT04062370|Device|laser photocoagulation|After month 6, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN according the re-randomization at month 6.
46101231|NCT01015183|Drug|Zinc Sulfate|Zinc Sulfate: 100 mg of zinc element, per day, bid for two weeks start with chemotherapy
46101232|NCT01015183|Drug|Placebo|Placebo: as the same of intervention group
46101233|NCT01013077|Drug|Optive|Use a minimum of 2 drops per day for 1 month.
46101234|NCT01013077|Drug|Soothe|Use a minimum of 2 drops per day for 1 month.
46101235|NCT01013077|Drug|New Emulsion|Use a minimum of 2 drops per day for 1 month.
46101236|NCT02566954|Other|3D measurement of the lower limb by EOS|"The intervention is to performed an additional radiologic exam by the EOS® system of imaging. This imaging is not usually realized for the patient.~3 dimensional study of lower limbs and feet of children in standing position will be performed using the EOS® system (EOS® Imaging, France)"
46101237|NCT05297981|Procedure|Erector spinae plane block|The patient will be placed in lateral decubitus position. A high frequency linear probe of a transportable Fuji M-Turbo ultrasound system will be placed on the spinous process at T8 level on the parasagittal plane and then slide 2.5-3 cm laterally to visualize the transverse process and erector spinae muscle. Using the inplane technique,then 0.5 ml/kg of 0.25% bupivacaine will be injected between the muscle and transverse process. The same procedure will be performed bilaterally.
46101238|NCT05297981|Procedure|Quadratus lumborum block|The patient will be placed in the lateral decubitus position. A low frequency curved probe of a transportable Fuji M-Turbo ultrasound system will be placed horizontally in the anterior axillary line midway between the subcostal margin and the iliac crest to identify the triple abdominal muscle layers.A 22-G, 80-mm needle echogenic needle will be inserted in plane relative to the US probe, into the posterior aspect of the QL muscle (between QL and erector spinae muscle); this is known as QLB type 2. Then, 0.5 ml/kg of 0.25% bupivacaine will be injected behind the muscle as a bolus dose. The block will be performed bilaterally.
46101239|NCT00856284|Drug|Alogliptin|Alogliptin tablets
46101240|NCT00856284|Drug|Metformin|Metformin tablets
46101241|NCT00856284|Drug|Glipizide|Glipizide tablets
46101242|NCT04212377|Biological|Dendritic Cells for endometrial cancer|Our study population consists of 8 mEC patients who receive carboplatin / paclitaxel chemotherapy in a weekly schedule on weeks 1, 2, 3 and weeks 5,6 and 7. In week 8, myeloid and plasmacytoid DC (nDC) are loaded with tumor lysate and MUC1 and survivin PepTivators, injected intranodally. An extensive immuno-motoring will be performed on all patients. Patients who show stable disease, partial response, or full response continue with extended three-week chemotherapy regimens with intranodal injections of nDC at weeks 17, 20, and 23.
46101243|NCT00510289|Drug|Sorafenib|400 mg twice a day until progression or unacceptable toxicity develops.
46101244|NCT04062682|Behavioral|Healthy Diet|Receive counseling to meet guidelines for healthy dietary patterns
46017191|NCT04617886|Other|Sadness induction|"Sadness state will be induced with a Virtual Reality program. Mood induction will be done with an emotional induction procedure in virtual reality (Mood induction parks (Baños et al., 2006)). This technique has proven to be effective in previous studies (e.g., van Strien et al. 2013). Virtual reality software simulates an urban park and includes several methods of sadness induction: Velten's tasks (1968) (sentence formulations with negative content about the self; for example, I am not valuable, I see no future); visualization of a image bank with emotional content from the international system of emotional images (IAPS, Lang et al.,1999); listening to a piece of music and viewing a film scene that demonstrated his effectiveness in inducing positive affect (Donen et al. 1952; Eich and Metcalfe 1989; Gross and Levenson 1995), and an autobiographical memory test."
46017192|NCT04617886|Other|Happiness induction|"Happiness state will be induced with a Virtual Reality program. Mood induction will be done with an emotional induction procedure in virtual reality (Mood induction parks (Baños et al., 2006)). This technique has proven to be effective in previous studies (e.g., van Strien et al. 2013). Virtual reality software simulates an urban park and includes several methods of sadness induction: Velten's tasks (1968) (sentence formulations with negative content about the self; for example, I am not valuable, I see no future); visualization of a image bank with emotional content from the international system of emotional images (IAPS, Lang et al.,1999); listening to a piece of music and viewing a film scene that demonstrated his effectiveness in inducing positive affect (Donen et al. 1952; Eich and Metcalfe 1989; Gross and Levenson 1995), and an autobiographical memory test."
46017193|NCT01028014|Drug|Pseudoephedrine|Pseudoephedrine ER 120 mg by mouth once daily for 2 weeks
46017194|NCT01028014|Drug|Tamsulosin|Tamsulosin 0.4mg by mouth daily for 2 weeks
46017195|NCT01028014|Drug|Imipramine|Imipramine 25mg daily by mouth for 2 weeks
46017196|NCT01028014|Drug|Cyclobenzaprine|Cyclobenzaprine 10mg daily by mouth for 2 weeks
46017197|NCT01028014|Drug|Lactose capsule|Lactose capsule 1 by mouth daily for 2 weeks
46017198|NCT01028014|Drug|Solifenacin|Solifenacin 5mg by mouth daily for 2 weeks
46017199|NCT04300972|Diagnostic Test|Body/weight adaption|contrast media dose is adapted to weight and body type
46017200|NCT04300972|Diagnostic Test|Standard dose|a fixed amount of contrast media is used, independently of weight and body type
45466689|NCT03706443|Other|Systane Ultra|Lubricant eye drop which is based on polyethylene glycol 400 0.4% and propylene glycol 0.3%. Used for temporary relief of burning and irritation due to dryness of the eye.
45466690|NCT01136369|Device|OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (> 2 mm).~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required."
45466691|NCT03438136|Behavioral|Adult Broad Learning Experiment (ABLE)|"This intervention implements six factors from early childhood experiences: individualized scaffolding (having a responsive teacher), forgiving environment (allowing the learner to make and learn from mistakes), growth mindset (believing that abilities can develop with effort), open-minded learning (exploring new experiences), serious commitment to learning (adopting a learning lifestyle), and learning multiple skills simultaneously."
45466692|NCT03785353|Behavioral|PNE lecture|A translated (from English to Spanish) lecture on Pain Neuroscience Education
46017201|NCT01264770|Drug|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily and placebo injection once every two weeks
46017202|NCT01264770|Drug|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 150mg once daily and placebo injection once every two weeks
45466693|NCT05255055|Other|Physical Therapy|A manual therapy protocol and a therapeutic exercise protocol
45466694|NCT03438058|Other|Graft survival and/or Rejection appearance|
45466695|NCT01136447|Procedure|Ultrasound|Block catheter will be introduced using ultraosound
46017203|NCT01264770|Drug|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 100mg once daily and placebo injection once every two weeks.
46017204|NCT01264770|Drug|Adalimumab and placebo of fostamatinib|Adalimumab 40mg injection once every two weeks and placebo to fostamatinib twice daily.
46017205|NCT01264770|Drug|Placebo of fostamatinib, fostamatinib, and placebo injections|Placebo injection once every two weeks. Placebo to fostamatinib for six weeks, followed by fostamatinib 100mg twice daily (Group F) / fostamatinib 100mg twice daily then 150mg once daily (Group G).
46017206|NCT02873650|Drug|dabrafenib|Single dose of 100 mg dabrafenib on Day 1
46017207|NCT04301128|Other|Experimental|Patients in the experimental group were educated and followed with an android based mobile application which contains the informations related to the disease, treatment and its complications, monitoring and cure and provides side effect tracking.
46101245|NCT01013155|Drug|perindopril erbumine|8 mg tablet
46101246|NCT00618761|Other|hyperglycemic clamp test|hyperglycemic clamp test
45466696|NCT01306513|Biological|autologous bone marrow derived mesenchymal stromal cells|Intravenous administration of autologous bone marrow-derived mesenchymal stromal cells.
45466697|NCT03437980|Drug|propofol|A bolus of 0.7 mg/kg will be given initially, additional incremental doses of 20 mg propofol will be given if the patient complained of pain or moved arms towards the back. Patients will be sitting on the middle of the operating table facing towards the table's foot. The table's foot will be dropped 45 degrees for a comfortable chair position, Monitoring through pulse oximeter (SaO2), non-invasive blood pressure (NIBP) adjusted every 2 minutes automatic measuring and capnography tube in contact with nostrils.
46017208|NCT04301128|Other|control|Patients in the control group were informed same informations verbally and given an education book.
45466698|NCT05176119|Drug|Nalbuphine Injection|At the end of the surgery and just before discontinuation of sevoflurane and extubation the study medications will be prepared by the local pharmacy as 10 ml syringes that were handed to the anesthesiologist in charge in OR room who was blinded to the nature of the medications.
45466699|NCT05176119|Drug|Ketamine|At the end of the surgery and just before discontinuation of sevoflurane and extubation the study medications will be prepared by the local pharmacy as 10 ml syringes that were handed to the anesthesiologist in charge in OR room who was blinded to the nature of the medications.
45466700|NCT05176119|Drug|Saline|At the end of the surgery and just before discontinuation of sevoflurane and extubation the study medications will be prepared by the local pharmacy as 10 ml syringes that were handed to the anesthesiologist in charge in OR room who was blinded to the nature of the medications.
45466701|NCT01139489|Other|procalcitonin-guidance|If procalcitonin levels decrease to predefined levels, antibiotic therapy will be discontinued.
45466702|NCT05679531|Other|intervention|After filling out the patient information form, the patients who met the research criteria were chewed gum for an average of 15 minutes.
45466703|NCT03437902|Dietary Supplement|Rutin in combination with Vitamin C|Rutin and Vitamin C will be supplied as tablets containing 60 mg Rutin and 160 mg Vitamin C. The use of Rutin and Vitamin C will be under the trade name of RUTA C 60 ® manufactured by KAHIRA PHARM.& CHEM. IND. Company
45466704|NCT03437902|Dietary Supplement|Vitamin C|Vitamin C will be supplied as capsules containing500 mg of Vitamin C. The use of Vitamin C will be under the trade name of C-Retard ® manufactured by HIKMA Quality Company.
45466705|NCT05194085|Diagnostic Test|POC viral load testing|POC viral load testing- women randomized to have POC VL at enrollment, delivery and 6 months post-partum, will have a finger prick to obtain whole blood for the Cepheid Xpert HIV-1 RNA cartridge on the Xpert IV machine with results in 90 minutes. Women who are randomized to POC VL who have VL >200 c/ml will receive additional adherence counseling, following the STREAM protocol, [26] to address the challenges that they are having with ART use. At the delivery visit, infants of women in the POC VL arm will also have viral load testing done.
46017209|NCT04301050|Other|Yoga Intervention|Weekly 75-minute yoga classes.
46017210|NCT01027702|Biological|Infusion of donor lymphocytes|A donor lymphocyte infusion will be given to provide T cells. There will be a dose escalation: 3 x 10^4, 4 x 10^4, 5 x 10^4, 6 X 10^4, 8 x 10^4, and 10 X10^4 cells/kg body weight. At least three patients will be assessed at each dose to determine safety before dose is increased.
45466706|NCT05194085|Other|Wellness visit services for male partners|Wellness visits for men- additional prevention services for men randomized to the intervention arm, including dual syphilis and HIV testing, blood pressure, visual acuity screening, and COVID-19 screening as part of wellness
46017211|NCT01302080|Drug|sertraline|Non interventional study - drug, dose, duration etc as per USPI and clinician discretion
46017212|NCT01302080|Behavioral|psychotherapy|Non-interventional study- as above
46017213|NCT01238991|Biological|ACC-001|IM injection, dose of 3 micrograms, at Day 1, month 6, 12 and 18
45466707|NCT05283499|Drug|OPIOID|Analgesic assignment
45466708|NCT05283499|Drug|NON-OPIOID|Analgesic assignment
45466709|NCT03437824|Drug|Cyanocobalamin|1,000 mg, Once
45466710|NCT03437824|Drug|Placebo|0.9% Sodium Chloride, Once
46017214|NCT01238991|Biological|ACC-001|IM injection, dose of 10 micrograms, at Day 1, month 6, 12 and 18
46017215|NCT01238991|Biological|ACC-001|IM injection, dose of 30 micrograms, at Day 1, month 6, 12 and 18
46017216|NCT05643716|Behavioral|Aerobic Exercise|The aerobic exercise intervention is described in the Aerobic Exercise Arm description.
45466711|NCT05187767|Diagnostic Test|cf DNA and ct DNA|Quantification of the circulating free DNA and the presence of targeted circulating tumor DNA
46017217|NCT01238835|Device|SAPIEN XT™ Transapical aortic valve replacement|Transcatheter aortic valve implantation via the transapical approach
46017218|NCT02888457|Other|Nasopharyngeal sampling with a swab|
46017219|NCT01032070|Drug|erlotinib|oral
46017220|NCT01032070|Drug|etoposide|oral
46017221|NCT01237899|Drug|LY2623091|Administered orally.
45466712|NCT05176041|Other|Naser Al-Husban|observation
45466713|NCT05272891|Other|experimental group|audio book app
45680683|NCT01720797|Drug|Anesthestic|Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice.
45680684|NCT01720797|Other|Chlorhexidine|Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
46017222|NCT01237899|Drug|Placebo|Administered orally.
46017223|NCT01237899|Drug|Eplerenone|Administered orally.
46017224|NCT01264380|Drug|RO5185426|Single oral dose, fasted
46017225|NCT01264380|Drug|RO5185426|Single oral dose, with high fat meal
46017226|NCT01264380|Drug|RO5185426|Continuous administration, orally twice daily
46017227|NCT01263444|Drug|Brinzolamide 1% / timolol 0.5% Fixed Combination|
46017228|NCT01263444|Drug|Habitual prostaglandin monotherapy|Topical ocular therapy used daily as prescribed
46017229|NCT01263054|Device|TransDiscal System|Surgical Procedure using the TransDiscal System to perform disc biacuplasty.
46017230|NCT01263054|Other|Medical Management|Standard medical management, physical therapy, and lifestyle changes.
46017231|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 1.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 1.0 mg/kg IV once every 2 weeks for a total of 79 doses."
46017232|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 3.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 3.0 mg/kg IV once every 2 weeks for a total of 79 doses"
46017233|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 10.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 10.0 mg/kg IV once every 2 weeks for a total of 79 doses."
46017234|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 100 mg SC, on Day 1 and weekly or once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 100 mg SC once every 2 weeks for a total of 79 doses."
45680685|NCT01831466|Drug|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks
46017235|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 1,200 mg IV once every 4 weeks from Day 1 for a total of 8 doses.~Stage II: MEDI-545 1,200 mg IV once every 4 weeks for a total of 40 doses"
46017236|NCT01031836|Drug|MEDI-545 600|"Stage I: MEDI-545 600 mg IV once every 4 weeks from Day 1 for a total of 8 doses.~Stage II: MEDI-545 600 mg IV once every 4 weeks for a total of 40 doses."
46017237|NCT04301440|Device|The emission of electromagnetic with the probes|The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.
46017238|NCT04301440|Device|The emission of electromagnetic without the probes|The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.
46101247|NCT01013233|Behavioral|cognitive training|cognitive training over 6 weeks, consist of 6 meetings (a 45minutes), three sessions focus on concentration tasks and three sessions on memory problems.
45466714|NCT04547543|Other|Videoconsultation|Patient randomized on video-consultation group will have a video-consultation with the investigator within 3 months after the randomization. During this consultation, the investigator performs a clinical interrogation in order to collect anthropometric parameters: (sex, age, weight, height, body mass index (BMI)), blood pressure (by blood pressure monitor at home), the level of physical activity (by Actimetry over 7 days), smoking status and alcohol status
45466715|NCT05682027|Diagnostic Test|ultrasound of the diaphragm|"Parameters measured during ultrasound:~Thickening fraction; End-expiratory thickness, and; Diaphragm excursion."
45466716|NCT03437590|Drug|JNJ-55308942|JNJ-55308942 will be administered as oral solution.
45466717|NCT03437590|Drug|[18F]-JNJ-64413739|[18F]-JNJ-64413739 fluid for injection administered intravenously.
46101248|NCT01013233|Other|control group|no intervention
46101249|NCT00921076|Behavioral|Gait Analysis|A computerized motion analysis system to observe the effect of ankle arthroplasty versus ankle arthrodesis on the kinematic behaviour of the foot and ankle during gait.
46101250|NCT04152512|Behavioral|Questionnaire administration|Questionnaire administration (4 different forms: pre-treatment, 3-4 months after treatment, 1 year after treatment, 2-5 years (yearly) after treatment
46017239|NCT01237587|Drug|Duloxetine|Administered orally
46017240|NCT01237587|Drug|Placebo|Administered orally
46017241|NCT01031680|Drug|Dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
46017242|NCT01031680|Drug|Placebo|Matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
46017243|NCT01031446|Drug|cisplatin|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
46017244|NCT01031446|Drug|everolimus|Taken daily by mouth.
46017245|NCT01031446|Drug|paclitaxel|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
46017246|NCT01031446|Other|laboratory biomarker analysis|Blood collection
46101251|NCT05490472|Drug|JAB-2485 (Aurora A inhibitor)|Administered orally
46017247|NCT02873728|Procedure|Remote Ischemic Conditioning|Creation of Brief 5 min Ischemia to upper limb using a Blood pressure cuff
46101252|NCT05490472|Drug|JAB-2485 (Aurora A inhibitor)|Administered orally
46101253|NCT00663806|Behavioral|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days and brochure about UTI
46017248|NCT02873728|Other|Control|Puting blood pressure cuff on upper limb and inflating to 10mmhg for 5 min
46017249|NCT01030900|Biological|Campath|campath plus etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and rituximab every 3 weeks for up to 6 cycles
46017250|NCT01030900|Biological|Rituximab|rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and campath every 3 weeks for up to 6 cycles
46017251|NCT01030900|Drug|EPOCH|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) plus rituximab and campath every 3 weeks for up to 6 cycles
46017252|NCT01030822|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as a single dose
46017253|NCT01030822|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 3 doses
46017254|NCT04288882|Device|Enteroscopy|Role of Balloon-Assisted Enteroscopy (BAE) in management of Small Intestinal Disorders
46101254|NCT00663806|Behavioral|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days; not given brochure about UTI
46101255|NCT05113121|Diagnostic Test|, Humphrey visual field (24-2) analysis and optical coherence tomography on retinal nerve fiber layer (RNFL) and ganglion cell complex.(GCC)|, Humphrey visual field (24-2) analysis and optical coherence tomography on retinal nerve fiber layer (RNFL) and ganglion cell complex.(GCC)
46101256|NCT01015261|Procedure|Bone Marrow Transplantation|Allogenic Bone Marrow Transplantation
46101257|NCT01015261|Procedure|Chemotherapy|"Cyclophosphamide 1200 mg/m2 D15~Daunorubicin 45 mg/m2 D15-D18~Vincristine 1 mg/m2 D15, D22~Dexamethasone 24 mg/d D12-D28"
46017255|NCT02873494|Device|PHYSIOFLOW - PF05 Lab1TM|
46017256|NCT04694872|Other|Telerehabilitation Based LSVT BIG Exercise Protocol|Lee Silverman Voice Treatment-LOUD therapy is a protocol involving intensive speech therapy, which was initiated at the Lee Silverman Parkinson Center between 1987-1989 to heal hypophonia in individuals with PD. LSVT-BIG, on the other hand, is a protocol derived from LSVT-LOUD, used in neurorehabilitation, consisting of focused large-amplitude functional movements performed with great effort. Maximal Daily exercises consist of seven standard exercises. Functional component tasks, on the other hand, will be created for movements in which the patient has difficulty in daily life activities selected individually based on his complaints. In hierarchical tasks, daily life activities with difficulties will be studied with large amplitudes. Exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week, 60 minutes a day, 4 weeks protocol respectively.
46101258|NCT04155242|Diagnostic Test|Cytosponge test|The Cytosponge will be administered by the study nurse prior to the participant having the endoscopy, usually as part of the same visit to hospital. The capsule along with the string is swallowed by drinking a small glass of water. The participant is asked to hold the Cytosponge in situ for 5 minutes. The sponge contained within expands and is then drawn back by the research nurse up the oesophagus by the attached string, collecting cells as it moves upwards. This device received a letter of no objection by the MHRA for use in the BEST pilot trial (LRQ 0939857) but it is not CE marked. Cytosponge and research endoscopic biopsies will be couriered to the Fitzgerald laboratory, at the MRC Cancer Cell Unit on a regular basis. The specimens will be processed in conjunction with the Cambridge University Hospitals' NHS Foundation Trust tissue bank which is accredited to GLP standards.
46017257|NCT04694872|Other|Telerehabilitation Based Functional Balance and Mobility Exercise|"These exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week and 60 minutes a day for 4 weeks.~Exercises will get harder with each passing week and its progression will be adjusted to the patient."
46017258|NCT01026454|Drug|acyclovir|acyclovir 400 mg orally, twice daily for 12 weeks
46017259|NCT01026454|Drug|valacyclovir|valacyclovir 1.5 g orally, twice daily, for 12 weeks
46017260|NCT01026220|Biological|bleomycin sulfate|Given IV or SC
46017261|NCT01026220|Drug|doxorubicin hydrochloride|Given IV
45466718|NCT05253963|Device|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure will be used during the second night of polysomnography .
45466719|NCT01136525|Drug|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
46017262|NCT01026220|Drug|liposomal vincristine sulfate|Given IV
46017263|NCT01026220|Drug|vinorelbine tartrate|Given IV
46017264|NCT01026220|Drug|cyclophosphamide|Given IV
46017265|NCT01026220|Drug|etoposide phosphate|Given IV
46017266|NCT01026220|Drug|prednisone|Given IV
46017267|NCT01026220|Biological|filgrastim|Given IV or SC
46017268|NCT01026220|Drug|ifosfamide|Given IV
46017269|NCT00627562|Device|robot assisted endoscopic head and neck surgery using the DaVinci Robotic Surgical System|Planned endoscopic surgery of the head and neck performed with the DaVinci Robotic Surgical System
46017270|NCT04301362|Diagnostic Test|Thrombosis biomarkers|Blood samples shall be prepared according to the manufacturer's instructions and stored at -80°C until analysis. Thrombin generation will be measured using the commercial kit STG®-Tromboscreen kit (Stago). The D-dimers will be quantified using STA LIATEST® D-DI PLUS (Stago).
46017271|NCT01026142|Drug|Capecitabine|1000 mg/m2 po twice daily for 14 days every 3 weeks
46017272|NCT01026142|Drug|Capecitabine|1250 mg/m2 po twice daily for 14 days every 3 weeks
46017273|NCT01026142|Drug|Pertuzumab|840 mg iv loading, then 420 mg iv every 3 weeks
46017274|NCT01026142|Drug|Trastuzumab|8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks
46017275|NCT04300582|Procedure|Cardiac catheterization standard strategy|Cardiac catheterization by forearm approach 3 to 24 hours after thrombolytic completion in STEMI patients
46017276|NCT04300582|Procedure|Cardiac catheterization fast strategy|Cardiac catheterization by forearm approach within 3 hours after thrombolytic completion in STEMI patients
46017277|NCT05296876|Procedure|Carotid endarterectomy (CEA)|Surgeons follow the contemporary guideline combined with their experience and preference in order to perform CEA for patients. All patients will be assessed by SSPC evaluation system before CEA. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA and the type of CEA can be selected as conventional, eversion or a shunt or patch based on the discretion of the surgeon.
45466720|NCT03437434|Other|Visual Acuity|Ocular Examination
45466721|NCT05678829|Other|Education|The trainings for the Virtual Reality group will continue in accordance with the training titles according to the weeks, using virtual reality glasses.
45466722|NCT05632445|Drug|Apixaban vs. DAPT|Apixaban vs DAPT after LAAO
45466723|NCT03437122|Procedure|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
45466724|NCT03436966|Device|MULTI SLICE CT|Positive enteric contrast, can, however, obscure IV contrast enhancement of the bowel wall. In addition, positive oral contrast agents opacify but do not always well distend the bowel. IV contrast is administered and images are acquired in the portal venous phase, which is optimized for visceral organ evaluation.
45466725|NCT05271175|Device|Active intermittent theta burst stimulation|An accelerated iTBS (aiTBS) treatment (4 sessions with 30 minutes break between them) was administered daily for a 5-day period over the left DLPFC using the MagVenture Cool-B65 Active/Placebo (A/P) coil.
46017278|NCT02873260|Biological|TetraVax-DV-TV005|TetraVax-DV-TV005 contains 10^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10^4.3 PFU/mL of rDEN2/4Δ30(ME), 10^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10^3.3 PFU/mL of rDEN4Δ30. The vaccine is administered in 0.5 mL containing 10^3.0 PFU of each component with the exception of rDEN2/4Δ30 that is given at a dose of 10^4 PFU. TetraVax-DV-TV005 is administered by subcutaneous injection in the deltoid region of the upper arm.
46101259|NCT04155242|Diagnostic Test|Assessment of the panel of molecular biomarkers: IM-SCORE, TFF3 protein expression, methylation panel, p53 mutation|Molecular analysis of the specimen obtained by Cytosponge or endoscopic biopsies - TFF3 protein expression, methylation panel, p53 mutation. Endoscopic biopsies will be assessed for the presence of IM (according to the IM-score).
45466726|NCT05271175|Device|Sham intermittent theta burst stimulation|"An accelerated iTBS (aiTBS) treatment (4 sessions with 30 minutes break between them) was administered daily for a 5-day period over the left DLPFC using the MagVenture Cool-B65 Active/Placebo (A/P) coil. The MagVenture Cool-B65 Active/Placebo (A/P) coil is designed to support true double blinded clinical trials as it can produce active and placebo stimulation by flipping the coil and can mimic tapping sensation during placebo condition During the sham condition, the coil produced the same sound as the real active condition but did not deliver any stimulation on the side of the participant's skull."
45680686|NCT01831466|Drug|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks
46101260|NCT04155242|Diagnostic Test|Oesophagogastroduodenoscopy|"Endoscopy will be carried out with white light and NBI with optical magnification or near focus to inspect oesophagus and GOJ.~NBI magnification will be used to assess systematically the mucosal pit pattern at the GOJ and to look for light blue crest (LBC) sign.~Targeted biopsies will be taken from either areas with LBC or irregular pit pattern on NBI, followed by random biopsies as per clinical standard. A maximum of 6 biopsies will be taken at the GOJ (maximum 4 targeted and 4 random.. During the first 2 post RFA follow up, at discretion of the endoscopists, neo-suqamous biopsies can be taken in line with local policies.~Argon plasma coagulation ablation is allowed in a single island up to 5mm or up to 3 islands <3mm within the study endoscopy as long as this does not represent an obstacle to GOJ biopsies."
46101261|NCT00920920|Radiation|3D MRI-guided Brachytherapy|MRI-based 3D-4D brachytherapy in locally advanced cervical cancer
46101262|NCT01015339|Drug|Paclitaxel|80mg/m2 infusion,d1,d8 every 3 weeks
46101263|NCT01015339|Drug|capecitabine|Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
46101264|NCT01015339|Drug|capecitabine|Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
46101265|NCT01015339|Drug|cisplatin|80mg/m2, day 1 of every 3 weeks
46101266|NCT05110313|Biological|TILDRAKIZUMAB|"ILUMYA (tildrakizumab-asmn) is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses.~ILUMYA injection for subcutaneous use is a sterile, clear to slightly opalescent, colorless to slightly yellow solution supplied in 1mL single-dose prefilled syringe which contains 100 mg of tildrakizumab-asmn formulated in: L-histidine (0.495 mg), L-histidine hydrochloride monohydrate (1.42 mg), polysorbate 80 (0.5 mg), sucrose (70.0 mg), and Water for Injection, USP with a pH of 5.7-6.3. ILUMYA is supplied in a single-dose prefilled syringe with a glass barrel and 29-gauge fixed, 1/2-inch needle."
46101267|NCT05351242|Other|Thermotherapy/sauna bath|Thermotherapy/sauna bath
46101268|NCT02622906|Drug|Pasireotide|60 mg per month of the Pasireotide during 6 months
46101269|NCT02622906|Drug|Placebo|Vehicule injection per month during 6 months
46101270|NCT00673556|Drug|alefacept|Intramuscular (IM)
45466727|NCT05131217|Other|Acute bout of Continuous Moderate Intensity Exercise|In this experimental intervention subjects will cycle continuously at moderate intensity (VO2 corresponding to lactate threshold) until a 200 kcal equivalent energy expenditure is reached.
45466728|NCT05131217|Other|Acute bout of High Intensity Interval Training|In this experimental invention subjects will alternate between 1 minute of high intensity cycling (watts corresponding to 85% VO2peak) and 1 minute of low intensity cycling (watts corresponding to 35-40% VO2peak) until a 200 kcal equivalent energy expenditure is reached.
45466729|NCT05131217|Other|Control|In this intervention placebo, subjects will lay down on a flat, soft surface for 30 minutes in a dimly light room. They will not be allowed to use any electronic devices or read during this time to avoid potentially influencing continuous data recording.
45837866|NCT05600270|Device|Straight guidewire|Cannulation of the common bile duct using an straight-tip guidewire during ERCP
46101271|NCT00673556|Drug|placebo|Intramuscular (IM)
45466730|NCT04422652|Drug|Bupropion|Bupropion is an anti-depressant medication.
45837867|NCT05599594|Other|Aromatherapy|6 drops of aromatic oils used by the researcher will be dripped by the aromatic oils to take the fragrance by inhalation for 30 minutes.
45837868|NCT05594823|Other|Ambulatory heart failure management with Flexible Diuretic Regimen with furosemide|Subjects will be given a regimen that determines a variable daily dose of diuretic (furosemide) based on daily self-measured weights as part of the standard of care ambulatory management of chronic heart failure. Follow-up will occur at 90 days with routine bloodwork to monitor renal function.
45837869|NCT05594823|Other|Ambulatory heart failure management with fixed dose furosemide|Subjects will be prescribed a fixed daily dose of diuretic (furosemide) as part of the standard of care ambulatory management of chronic heart failure. Follow-up will occur at 90 days with routine bloodwork to monitor renal function.
46101272|NCT01010113|Other|Standard infant formula with prebiotics|From 0-6 months of age. As per standard requirement
46101273|NCT01010113|Other|Infant formula with synbiotics|From 0-6 months of age as per standard requirement
46101274|NCT05101733|Diagnostic Test|Nasal provocation|Nasal provocation with Alternaria alternata extract. Changes in nasal mucosa are measured with a rhinomanometry device
46101275|NCT05101733|Diagnostic Test|Skin-Prick Test|Skin-Prick-Test is administered to determine an allergy against Alternaria
46101276|NCT05101733|Diagnostic Test|Blood draw|For further analysis
46101277|NCT05101733|Diagnostic Test|Collection of nasal secretion|Allergy sufferers: After nasal provocation Non-allergics: After administration of isotonic nasal spray
46101278|NCT00699738|Behavioral|Breastfeeding|Breastfeeding
46101279|NCT00699738|Behavioral|Bottlefeeding|Bottlefeeding
46101280|NCT01010191|Other|Sugar pill|
46101281|NCT00675896|Drug|Quetiapine Fumarate Sustained Release|50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator
46017279|NCT02873260|Biological|rDEN3Δ30|Administered at a dose of 10^4 PFU by subcutaneous injection in the deltoid region of the upper arm.
46017280|NCT02873260|Biological|Placebo|Administered at a volume of 0.5 mL by subcutaneous injection in the deltoid region of the upper arm.
46017281|NCT01030666|Drug|Doxycycline|The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects.
46101282|NCT00675896|Drug|Placebo|1 tablet at HS for 2 days then 3 tablets at HS for 2 weeks
46101283|NCT05667688|Drug|Tinlarebant (LBS-008)|A single dose of Tinlarebant (LBS-008) will be administered to each study participant on study Day 1.
46017282|NCT01030666|Drug|Placebo|The patients of the doxycycline group will take 200 mg placebo once a day for 7 days after regenerative therapy of an infrabony defects.
46017283|NCT01030666|Procedure|modified/simplified papilla preservation flap; scaling|Following an intra-crevicular incision a mucoperiosteal flap was reflected to a height of 5 mm exposing the bony margin of the defect and allowing complete visualization of the infrabony lesion. The flap was designed according to the modified or simplified papilla preservation technique to obtain primary closure of the wound and the membrane respectively. The flap was extended at least one tooth mesially and distally of the defect side. After complete removal of inflammatory granulation tissue, the root surfaces were thoroughly scaled and root planed.
46017284|NCT01030666|Biological|Prefgel/Emdogain|When using EMD the root surfaces facing the infrabony defect were conditioned with EDTA (prefgel; Institut Straumann AG, Basel, Switzerland) for 2 min. first. Then the EDTA was washed out with plenty of saline. After drying the surfaces EMD was applied starting at the bottom of the defect and proceeding coronally.
46101284|NCT04212611|Drug|INFRA ORBITAL BLOCK|Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% levobupivacaine (group L) or ropivacaine (group R).
46101285|NCT01015417|Drug|Amoxicillin clavulanic acid|Postoperative administration of 2g, 3 times daily, since 5 days, of amoxicillin clavulanic acid (Augmentin or generic) oral form or parenteral form according to clinical patient and by the choice of medical teams
46101286|NCT01015417|Other|No medication|no postoperative antibiotics
46101287|NCT00675974|Device|Jobst Pressure Garment|Pressure garment therapy for 18 months post burn injury. May be Jobst pressure garment or Medical Z pressure garment.
46101288|NCT00675974|Device|Medical Z pressure garment|Pressure garment to be worn for 18 months post burn. May be Jobst pressure garment or Medical Z pressure garment.
45466731|NCT04422652|Behavioral|Behavioral activation therapy|Brief behavioral activation treatments administered via video tele-conferencing.
46101289|NCT04061824|Drug|Olostar Tab (olmesartan/rosuvastatin FDC(fixed dose combination))|In intervention group, patients had a pill of fixed-dose combination of Olmesartan medoxomil and Rosuvastatin, rather taking separated two pills.
46101290|NCT04061824|Drug|Two separated drugs(ARB(Angiotensin Ⅱ receptor blocker) and statin)|In control group, patients had two separated pills for hypertension and dyslipidemia. One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin, Pravastatin, Fluvastatin and Atorvastatin/Ezetimibe).
45466732|NCT04422652|Drug|Placebo|Double-blind placebo.
45466733|NCT04422652|Other|Clinical Management|Clinical management will serve as the attention control for the Behavioral Activation Therapy intervention.
46101291|NCT04212533|Dietary Supplement|Vitamin D|comparison between pre- and postoperative calcium and vitamin d level after vit d and calcium supplementation
46101292|NCT04212533|Dietary Supplement|rice starch tablets|rice starch tablets as placebo
45466734|NCT05677503|Diagnostic Test|CBC|measurement of CBC will be performed at the time of admission and by the time of discharge
45466735|NCT05677503|Diagnostic Test|(NT-proBNP)|measurement of serum NT-proBNP levels will be performed at the time of admission and by the time of discharge
45466736|NCT05677503|Diagnostic Test|(cTnT)|measurement of cTnT levels will be performed at the time of admission and by the time of discharge
45680687|NCT01831466|Drug|placebo ointment (vehicle)|placebo ointment (vehicle) BID (twice daily) for 12 weeks
45466737|NCT05127785|Procedure|LVAD or Heart Transplant|Patients undergoing advanced heart failure intervention including LVAD implantation or heart transplantation
46101293|NCT05035342|Biological|Fecal Microbiota Transplantation (FMT) capsules|Donated fecal matter will be sequentially diluted in 80% glycerol used as bacterial cryoprotectant, blenderized, sieved and centrifuged (4°C, 4000 tr/min, 20 min). The pellet is resuspended and manually pipetted into size 0 capsules (650 μL), which are closed and then secondarily sealed in size 00 capsules (hypromellose capsules, DR caps from Capsugel®, MA). Each capsule contains 1g ± 0,1g of fecal suspension corresponding to 0.5 to 0.8g of native stool. Capsules will be stored frozen at -80°C for up to 24 months pending use. The stability of biodiversity and viability of the frozen microbiota was regularly verified to ensure the efficacy of the transplantation (personal data).
45466738|NCT04398550|Other|Specific Carbohydrate Diet|Diet restricts all but simple carbohydrates and allows for inclusion of fresh fruits, vegetables, unprocessed meats, and homemade lactose-free cheese and yogurt.
45466739|NCT04398550|Other|Mediterranean Diet|Diet rich in whole vegetables, fruit, plant-based protein, and olive oil, with moderate amounts of seafood and dairy, and limited in sugar-sweetened goods, red meat, and nutrients like heme and sodium.
45466740|NCT05175807|Other|Mindfulness|Mindfulness (e.g., body scan, gentle yoga, sitting, grounding, and walking meditation), relaxation techniques, and cognitive rehabilitation exercises.
45466741|NCT01235117|Drug|azacitidine|
45466742|NCT01235117|Other|laboratory biomarker analysis|
45466743|NCT01306591|Drug|Bevacizumab 1|Bevacizumab, 1.25mg/0.05ml, every 6 weeks, 42weeks
45466744|NCT01306591|Drug|Bevacizumab|Bevacizumab, 1.25mg/0.05ml, 0week(baseline), 6week, 12week, 24week, 36week
45466745|NCT03708471|Procedure|Hybrid ablation|This intervention including thoracoscopic surgical ablation, percutaneous catheter ablation and cardiovascular risk control.
45466746|NCT03708471|Procedure|Thoracoscopic surgical ablation|This intervention including thoracoscopic surgical ablation and cardiovascular risk control.
45466747|NCT03098030|Biological|Dinutuximab|Dinutuximab injection, for intravenous (IV) use
45466748|NCT03098030|Drug|Irinotecan|Irinotecan injection, IV infusion
46017285|NCT01030666|Drug|0.12% chlorhexidine gluconate solution|Furthermore, all patients were advised to rinse with a 0.12% chlorhexidine gluconate solution (ParoEx; Butler, Kriftel, Germany) for 2 min. twice daily for 5-7 weeksafter surgery.
46017286|NCT01030666|Drug|Ibuprofen 400 mg (if necessary)|400 mg ibuprofen qd was prescribed for patient's comfort if necessary.
45466749|NCT03098030|Drug|Topotecan|Topotecan for injection
45466750|NCT04376632|Dietary Supplement|Pecan ADD|Raw pecan halves without dietary substitution instructions
45466751|NCT04376632|Dietary Supplement|Pecan SUB|Raw pecan halves with instructions to substitute pecans with isocaloric foods in the habitual diet
45466752|NCT01233947|Drug|AFP464|AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycle
45466753|NCT01233947|Drug|AFP464 + Faslodex|AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycles and faslodex administered per the package label
45466754|NCT01306669|Biological|Trivalent influenza vaccine|single dose of 0.5ml of Trivalent influenza vaccine for season will be administered into deltoid muscle of non-dominant arm
45466755|NCT01306669|Biological|Normal saline|Single dose of 0.5ml of normal saline will be administered into deltoid muscle of non-dominant arm
45466756|NCT01139645|Drug|Rabeprazole or Esomeprazole or Lanzoprazole|1/3 of the patients are taking Pariet (Rabeprazole) 20 mg once daily 1/3 of the patients are taking Nexium (Esomeprazole) 40 mg once daily 1/3 of the patients are taking Lanzor (Lanzoprazole) 30 mg once daily
45466757|NCT03791359|Other|CardioPulmonary Resuscitation|Whether the victim received CPR as per standard protocol.
45466758|NCT03436576|Drug|Autologous Serum 20%|Instillation of 1 drop of Autologous Serum 20% four times a day
45466759|NCT03436576|Drug|Autologous Serum 50%|Instillation of 1 drop of Autologous Serum 50% four times a day
46017287|NCT01030666|Drug|1% chlorhexidine gluconate gel (if necessary)|If soft tissue dehiscence was noted the patient was advised to use a 1% chlorhexidine gluconate gel (Chlorhexamed 1% Gel; GlaxoSmithKline, Bühl, Germany) twice daily
46017288|NCT01025752|Behavioral|Face to face cognitive behavior therapy|Ten session face to face cognitive behavior therapy for chronic low back pain
46101294|NCT05035342|Biological|Placebo capsules|"The placebo FMT capsules will be performed with the final dilution solution, ie the 80% glycerol solution used as a cryoprotectant. This solution will be double encapsulated like the FMT capsules."
46017289|NCT01025752|Behavioral|IVR based cognitive behavioral therapy|Ten session cognitive behavior therapy for chronic low back pain using interactive voice response therapy
46101295|NCT04155554|Drug|Bictegravir/emtricitabine/tenofovir alafenamide|Switch patients from dolutegravir/lamivudine/abacavir to bictegravir/emtricitabine/tenefovir alafenamide to study neuropsychiatric side effects and neurocognitive function
46101296|NCT04155554|Drug|Dolutegravir/lamivudine/abacavir|Continuing dolutegravir/lamivudine/abacavir to study neuropsychiatric side effects and neurocognitive function
46017290|NCT01030198|Device|RevLite (Laser Treatment)|
45466760|NCT03706287|Drug|anlotinib 8mg + AP/PC|anlotinib 8mg/d, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
45466761|NCT03706287|Drug|anlotinib 10mg + AP/PC|anlotinib 10mg/d, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
45466762|NCT03706287|Drug|anlotinib 12mg + AP/PC|anlotinib 12mg/d, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
45466763|NCT03706287|Drug|anlotinib + AP/PC|anlotinib doses to be determined following the completion of Phase I of the study, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
45466764|NCT05693389|Behavioral|acceptance and commitment therapy|ACT attempts to encourage psychological flexibility, acceptance of one's own experiences, and dedication to behaviours that are consistent with one's own values. ACT therapies focus on six key processes to improve psychological flexibility: engagement with the present moment, acceptance, defusion, self as context, values clarification, and committed action.
45466765|NCT05693389|Other|routine hospital care|the patients with bipolar disorders who receive routine pharmacological treatment
45466766|NCT03436342|Drug|68Ga-Pentixafor|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga-Pentixafor will be used to image lesions of MM and lymphoma by PET/CT.
45466767|NCT05115201|Procedure|Scaling and root planing with antibiotics|Patients will be given amoxicillin and metronidazole, 500mg and 400mg respectively (AMX+MTZ) to be taken thrice daily for 7 days, as an adjuvant to scaling and root planing.
45466768|NCT05115201|Procedure|Scaling and root planing only|Patients will be treated with scaling and root planing
45466769|NCT03791047|Other|Balance Analysis|Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
45466770|NCT05107193|Drug|afatinib|afatinib
45466771|NCT02522806|Procedure|endometrial biopsy|Endometrial biopsy (EB) between J17 and J22 of previous ovarian hyperstimulation cycle
45466772|NCT03791203|Behavioral|Calorie restriction (MACR)|This was a randomized, single-blind controlled trial with modified alternate-day calorie restriction (MACR) as the active intervention and normal habitual diet as control at Hospital University of Sains Malaysia.
45466773|NCT05569187|Drug|Ribociclib|Included patients who received doses (600 mg, 400 mg, and 200 mg) at 6 months and 1 year
45680688|NCT01831466|Drug|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks
45680689|NCT01831466|Drug|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks
46017291|NCT02873884|Behavioral|Case-management|
46101297|NCT04212299|Device|Northwestern University Flexible Sub-Ischial Suction Socket (NU-FlexSIS)|"The sub-ischial socket includes a firm, compressive, preferably cylindrical, fabric-covered silicone liner, a flexible inner socket, and a shorter rigid outer socket. The socket has proximal trim lines that do not impinge on the pelvis; they terminate distal to the ischial tuberosity and greater trochanter. For the NU-FlexSIS Socket, passive suction suspension is achieved using a one way valve and a liner with an internal seal.~Since the prosthetic socket is a custom-made device, it is considered Class I exempt by the Food and Drug Administration (FDA)."
46017292|NCT01301456|Biological|Placebo|Single subcutaneous injection of placebo
46017293|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
46017294|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
46017295|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
46017296|NCT01301456|Biological|Placebo|Single subcutaneous injection of placebo
46017297|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
46017298|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
46017299|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
46101298|NCT00663884|Drug|Mitiglinide|mitiglinide 10mg three times a day before a meal
46101299|NCT00663884|Drug|Voglibose|voglibose 0.2mg three times a day before a meal
46017300|NCT01301456|Biological|Placebo|Multiple weekly subcutaneous injections of placebo for 3 weeks
46017301|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
45598346|NCT02360007|Drug|Interim Buprenorphine Treatment (IBT)|"The Interim Buprenorphine Treatment (IBT) includes:~Buprenorphine (BUP)~Computerized adherence monitoring (CAM): BUP will be dispensed via a portable device that makes each day's dose available only at a predetermined time.~Mobile health clinical support: An Interactive Voice Response (IVR) system to deliver clinical support~Urinalysis and adherence monitoring with participants contacted via IVR for random call-backs~HIV+Hepatitis Education delivered via iPad"
46017302|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
45598347|NCT02294305|Drug|Vortioxetine|
46101300|NCT05324189|Diagnostic Test|Referable versus Non Referable Diabetic Retinopathy diagnostic test|Artificial intelligence read reports Referable versus Non Referable Diabetic Retinopathy
46101301|NCT00492115|Device|Continuous positive airway pressure (CPAP)|therapeutic Continuous positive airway pressure (tCPAP) nightly for 6 weeks
46101302|NCT00492115|Device|Placebo CPAP|Ineffective Continuous positive airway pressure (pCPAP) for 3 weeks followed by therapeutic CPAP for 3 weeks
46101303|NCT05347030|Other|Acupuncture|During the 12-week treatment, acupuncture will be administrated 3 times a week (once every other day) in the first 6 weeks, and twice a week in the last 6 weeks (with an interval of 2-3 days). Each treatment session will last 30 minutes.
46017303|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
46017304|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
46101304|NCT05347030|Other|Sham Acupuncture|During the 12-week treatment, Sham Acupuncture will be administrated 3 times a week (once every other day) in the first 6 weeks, and twice a week in the last 6 weeks (with an interval of 2-3 days). Each treatment session will last 30 minutes.
46017305|NCT01023256|Drug|MOR103|MOR103 0.3 mg/kg or placebo iv x 4 doses
46017306|NCT01023256|Drug|MOR103|MOR103 1.0 mg/kg or placebo iv x 4 doses
46017307|NCT01023256|Drug|MOR103|MOR103 1.5 mg/kg or placebo iv x 4 doses
46017308|NCT04303936|Device|SenseWear® armband device|"Metabolic Holter, Physical Activity and Lifestyle, Portable outpatient multi-sensor energy consumption in calories (EE), movement, physical activity, quality of life, sleep"
46017309|NCT04286620|Device|LASIK|Correcting errors of refraction
46017310|NCT01023022|Other|Medtronic CareLink® Network|The Medtronic CareLink® Network consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website
46017311|NCT04324424|Drug|HMS5552|single dose of HMS5552 25mg
46017312|NCT00627718|Device|HRT screening for macula edema|HRT screening for macula edema at time of initial diagnosis of macular degeneration
46101305|NCT00673634|Procedure|Standard preoxygenation|Spontaneous breathing of 100% oxygen in a facemask for 3 minutes.
46101306|NCT00673634|Procedure|BiPAP assisted preoxygenation|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4cm H2O and a positive end-expiratory pressure of 4cm H2O, for 3 minutes.
46101307|NCT05324111|Device|Kardia 6L|The Kardia 6L has CE marking. The purpose of this study is to extend the use of this device by a simple modification using existing equipment in the department. The device will be connected to the left leg electrodes using standard clinical crocodile clips and the other electrode applied to the chest in V1 and V6 positions to acquire the modified V1 and V6 leads
46017313|NCT05643404|Diagnostic Test|Cardiopulmonary exercise testing|Maximal functional capacity will be evaluated using incremental and symptom-limited cardiopulmonary exercise testing (CPET) on a bicycle ergometer, beginning with a workload of 10 W and increasing gradually in a ramp protocol at 10-W increments every 1 minute. We will define maximal functional capacity as when the patient stops pedalling because of symptoms, and the respiratory exchange ratio (RER) is ≥1.1. During exercise, patients were monitored with 12-lead electrocardiogram and blood pressure measurements every 2 minutes. Gas exchange data and cardiopulmonary variables were averages of values taken every 10 seconds. Peak oxygen consumption (PeakVO2) will be defined as the highest value of oxygen consumption during the last 20 seconds of exercise.
46017314|NCT05643404|Diagnostic Test|Echocardioghaphy|Doppler echocardiogram examinations were performed under resting conditions using 2-dimensional echocardiography. Left ventricular end-diastolic volume and left ventricular ejection fraction will be measured according to the European Society of Echocardiography
46017315|NCT02873182|Device|Autonomic nervous system monitoring|Two intracorporal electrode needles will be inserted beneath the skin of the genitalia. After insertion, the electrodes will be secured and connected by leads to two standard neurophysiological devices for differential amplification, display, and storage. Smooth muscle free-running (continuous) and stimulated EMG will be recorded.
46017316|NCT04324736|Other|no interventional study|no interventional study
46017317|NCT05643326|Device|40 Hz transcranial alternating current stimulation|42 sessions of 40 Hz transcranial alternating current stimulation (5 days/week for 9 weeks)
46017318|NCT05643326|Device|Sham stimulation|42 sessions of sham stimulation (5 days/week for 9 weeks)
46017319|NCT05367674|Behavioral|Summer Harvest Adventure|Biobehavioral intervention focusing on nutrition and lifestyle behaviors.
46017320|NCT05367674|Behavioral|My Summer Plate (MSP)|My Summer Plate (MSP)
46101308|NCT00856206|Biological|Rilonacept|Rilonacept 160 mg subcutaneous injection once a week
46101309|NCT00856206|Other|Placebo|Placebo subcutaneous injection once a week
46101310|NCT03997279|Drug|Saccharomyces boulardii|Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Saccharomyces boulardi 500 mg 1x1, for 3 week
46101311|NCT03997279|Drug|Placebo|Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Placebo 1x1, for 3 week
46101312|NCT04214171|Diagnostic Test|Gait and muscle strength will be assessed|The extensor moment of the hip during gait and evaluation of the muscular strength of the hip will be evaluated
46101313|NCT00664118|Procedure|Doula combined analgesia|Doula combined epidural analgesia in the latent phase of first stage of labor in primiparas
46101314|NCT00664118|Procedure|Analgesia without doula|Epidural analgesia in the latent phase of first stage of labor without doula accompany in primiparas
46101315|NCT01013389|Procedure|Actifuse ABX|bone substitute used for posterolateral instrumented lumbar fusion with interbody fusion
46101316|NCT01013389|Procedure|INFUSE, plus master granules (MGG)|bone substitute in posterolateral instrumented lumbar fusion with interbody fusion
46101317|NCT05323877|Device|Test Device (PerQseal+)|Percutaneous arterial closure device
46101318|NCT02629328|Device|CardioCel|Treatment with CardioCel implant
46101319|NCT05641714|Other|L test|The test includes standing up from a chair, walking in a straight line for 3 m, turning to the right, walking in a straight line for 7 m, turning around, walking back 7 m along the same line, turning to the left, walk 3 m in a straight line to the chair, and then sit down.
46101320|NCT05641714|Other|Timed Up and Go test|The test requires the individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.
46101321|NCT05641714|Other|10 meter walk test|In the test, the clinician measures the time taken to walk a distance of 10 m from a standing position. Participants are asked to walk along a 14 m long walkway.
45598348|NCT02294305|Drug|Placebo|
45598349|NCT02225951|Dietary Supplement|Nutritional product|
45598350|NCT02225951|Other|Standard breakfast according to ADA recommendations|
45680690|NCT01831466|Drug|placebo ointment (vehicle)|placebo ointment (vehicle) QD (once daily) for 12 weeks
46017321|NCT01058668|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for three weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
46017322|NCT01058668|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for three weeks.
46017323|NCT00623558|Drug|Cetuximab|400 mg/m2 first dose, then 250 mg/m2 weekly for 9 weeks
45680691|NCT01881620|Device|COMBI TEP : PET / enhanced CT scan|diagnostic imaging exam
46017324|NCT00623558|Drug|Docetaxel|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
46017325|NCT00623558|Drug|Cisplatin|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
46017326|NCT01301066|Drug|Pitavastatin|Pitavastatin 4 mg QD
45466774|NCT05404672|Other|Aerobic Training|Progressive breathing retraining exercises for a period of 4 weeks, for 15 minutes twice daily. As patients progressed to the seated posture, the controlled pause technique (exercise) will be introduced. 4 times a day followed by a sustained period of breathing control. In addition to this Aerobic Training (cycling, treadmill) will also be practiced for 30 minutes constituting 5 days/ week. Initial training would avoid upright position. Mild-to-moderate-intensity endurance training, progressing from semi-recumbent to upright position plus strength training will be practiced.
45466775|NCT05404672|Other|Conventional Treatment|Progressive breathing retraining exercises for a period of 4 weeks, for 15 minutes twice daily. As patients progressed to the seated posture, the controlled pause technique (exercise) will be introduced. 4 times a day followed by a sustained period of breathing control.
46017327|NCT01301066|Drug|Pravastatin|Pravastatin 40 mg QD
45466776|NCT03788395|Device|Symbicort Turbohaler plus Turbo+|Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) plus Turbo+ for three months.
45466777|NCT03788395|Drug|Symbicort Turbohaler without Turbo+|Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) without Turbo+ for three months.
45466778|NCT05174013|Drug|GSK3858279|GSK3858279 will be administered
45466779|NCT05174013|Drug|Placebo|Placebo will be administered
45466780|NCT02522650|Drug|Amiloride|5mg twice a day for 8 weeks
46017328|NCT01022398|Drug|cholecalciferol/placebo|10,000 IU by mouth weekly for 6 months
46017329|NCT05642936|Behavioral|didactic health education control|didactic classroom-based comparison group that follows standard guidelines for diet, exercise and substance use with no stress reduction component
46017330|NCT05642936|Behavioral|Transcendental Meditation technique|a mental technique derived from the Vedic tradition of ancient India and practiced by anyone for 20 minutes twice a day sitting
46017331|NCT05044234|Drug|Cedirogant|Capsule, Oral
46017332|NCT05044234|Drug|Placebo|Capsule, Oral
46017333|NCT05642624|Drug|Deoxycholic acid amphotericin B|Starting with 1mg and increasing by 5-25mg daily until the maintenance dose is 50mg/d.
45466781|NCT02522650|Drug|Triamterene|50mg twice a day for 8 weeks
45598351|NCT02357199|Other|Intensive oral care & didactic training|Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
45680692|NCT01830920|Drug|THR-184|THR-184 is a synthetic oligopeptide administered intravenously.
46017334|NCT05642546|Drug|NM8074|Novel, recombinant, humanized monoclonal antibody that selectively binds to human Factor Bb with high affinity and blocks the formation of Alternative Pathway (AP) driven C3 and C5 convertases
46017335|NCT05642546|Drug|Placebo|Saline Placebo
46017336|NCT05040178|Drug|Carglumic Acid|Current or previous treatment with Carbaglu, the dose of Carbaglu® prescribed will be determined by the investigator for each individual patient.
46017337|NCT05642390|Device|Breast implant|Patients operated for breast augmentation or reconstruction.
45466782|NCT05418842|Other|Prehabilitation|In addition to usual care, the prehabilitation group will exercise 3 times a week, starting immediately after diagnosis and throughout the pre-treatment period. Each exercise session will encompass 5-min warm-up and 45-min conditioning exercises. Aerobic training will be performed using low-volume high intensity interval training (HIIT). The HIIT duration is 16-20 minutes and it will be performed with 8-10 intervals of high intensity (1 minute) and 8-10 intervals of low intensity (1 minute). High intensity intervals will be set to an external load that represents 85-90% of estimated VO2Peak. In addition, patients will do resistance training at moderate intensity. Patients will complete 2 sets of 12 repetitions of 5 upper and lower body exercises.
46017338|NCT04324346|Drug|FEC75 (or EC90) x 6|Type of Chemotherapy
46017339|NCT04324346|Drug|FEC100 + Taxotere (EC90 + Taxotere) 3+3|Type of Chemotherapy
46017340|NCT04324346|Drug|Paclitaxel|Type of Chemotherapy
46017341|NCT05642234|Procedure|Epidural Ultrasonography|In this study, we measured the intervertebral distance and skin-epidural distance with the help of ultrasonography in the thoracic and lumbar regions in sitting and rider positions.
46017342|NCT05642156|Procedure|isolated Ultrafiltration (iso-UF)|isolated Ultrafiltration
46017343|NCT04300114|Drug|Fluzoparib|Fluzoparib capsules po. 150 mg twice daily
46017344|NCT04300114|Drug|Placebo|Placebo capsules po. twice daily
46017345|NCT02890238|Drug|Clomiphene citrate|50mg (clomid,) orally 2 times/day from 2nd- 7th day of the cycle
46101322|NCT05641714|Other|Six Minute Walk Test|This test measures the distance (in m) that an individual is able to walk at a comfortable speed for 6 minutes. Starting from a standing position, participants walk continuously around two pylons placed 30 m apart for 6 minutes. The distance is recorded end of the test.
46101323|NCT05641714|Other|The timed 360° turn test|Each participant turns around in place in a standing position for both sides.
46101324|NCT01013467|Behavioral|"CoCo colour coded blood pressure control"|The patients in the intervention group will receive a colour-coded blood pressure record booklet. The corresponding colour coded areas are divided into three areas of green, yellow and red following a traffic light system. The green area covers blood pressure readings up to a maximum of 140/90 mmHg, the yellow area includes systolic readings over 140 to 180 mm Hg and diastolic readings over 90 to 110 mmHg. The red area covers systolic readings over 180 mmHg and diastolic readings over 110 mmHg.
46101325|NCT00673868|Biological|CMV Specific Cytotoxic T Lymphocytes|CMV Specific Cytotoxic T Lymphocytes will be infused between days 30 and 40 post-transplant at a dose ranging from 2- 5 x e5 cells/kg.
46101326|NCT00920998|Drug|Z-338|oral
45680693|NCT01830920|Drug|Placebo|A normal saline solution identical in appearance to the active drug solution
46101327|NCT05323643|Device|Ultrasound|"musculoskeletal US will be performed using commercially -available equipment, with high frequency linear -array transducers and a standard gel interface. The higher frequency transducers provide better spatial resolution, while the lower frequency transducers provide a greater depth of tissue penetrance. Colour Doppler US is also performed in most cases as it plays an important role in supporting and confirming diagnoses, by providing valuable information about the pathophysiology of the abnormality.~The patients will be seated with hands placed on a table, to permit examination of both volar and dorsal aspects, in longitudinal and transversal axis. Examination of the hands and fingers usually requires a large amount of transmission gel, in order to avoid compression and to permit dynamic evaluation. When acute trauma with skin lesions is investigated, sterile transmission gel, or sterile acoustic standoff pads can be used"
46017346|NCT02890238|Drug|sildenafil citrate|20mg tab from 7th-11th day of the same cycle orally 3times/day
46017347|NCT02890238|Drug|Placebo|tab from 7th-11th day of the same cycle orally 3times/day
46017348|NCT00627796|Drug|Lanreotide-Autogel 120 mg|ATG120 mg is given as deep subcutaneous injection into the buttock. Each patient receives one deep subcutaneous injection of ATG120 mg at Visit 1 (V1) and subsequent injection every 4 weeks for 3 injections. Based on GH levels, the dosing interval has been determined as follows: if GH levels were > 2.5 mcg/l, ATG 120 mg is given every 4 weeks while if they were < 2.5 mcg/l ATG 120 mg is administered every 6 weeks for another 3 injections. Afterwards, the dose is maintained as above except in patients with GH levels <1 mcg/l receiving ATG 120 mg every 8 weeks. The estimated duration of treatment is 48-52 weeks according with dose titration.
46017349|NCT05641844|Device|RD2 Ver.02|Withdrawal of up to 15ml blood into tube containing 1.5 ml ACDA, preparation of RD2 Ver.02, and application of coagulating blood into the fistula with a semi flexible cannula, in the amount calculated during the water leak test (up to 16.5 ml total). Seal the fistula opening, by hand or other means, so blood will remain inside for 5 minutes for complete coagulation. Place absorbent dressing
46017350|NCT05641844|Other|debridement and suturing the internal opening of anal fistula|debridement and suturing the internal opening of anal fistula.
46017351|NCT05640206|Procedure|i-PRF|Arthrocentesis performed with two-needle technique, and then injection of i-PRF intra-articularly
46017352|NCT05640206|Procedure|Arthrocentesis|Arthrocentesis performed with two-needle technique
46017353|NCT05639582|Other|fractal analysis|fractal analysis is a method that numerically expresses bone changes.
46017354|NCT05639192|Biological|Asunercept|Asunercept (APG101) will be administered once per week as an i.v. infusion
46017355|NCT05639192|Other|Placebo|Placebo will be administered once per week as an i.v. infusion
46017356|NCT01262976|Biological|GSK's investigational vaccine 692342|Intramuscular, 2 doses
46017357|NCT01262976|Biological|Physiological saline|Intramuscular, 2 doses
46017358|NCT05633966|Drug|Kisspeptin 112-121|SC administration of kisspeptin for two weeks (pulsatile, every 90 minutes)
46017359|NCT01300286|Drug|RiaSTAP|One time dose of 70 mg/kg will be administered intravenously.
46017360|NCT05616728|Drug|EDP-235|capsule
46017361|NCT05616728|Drug|Placebo|capsule
46017362|NCT02890316|Other|Homeopathy remedy|Homeopathy remedy, prescribed by a physician and prepared by licensed pharmacy.
46017363|NCT02890316|Radiation|Radiation as adjuvant therapy for breast cancer|Daily radiation therapy.
46017364|NCT01300052|Drug|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 12 weeks
46017365|NCT01300052|Drug|Ointment Vehicle|Ointment Vehicle, applied twice daily for 12 weeks
45680694|NCT01881230|Drug|nab-Paclitaxel|nab-Paclitaxel 125 mg/m^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
45680695|NCT01881230|Drug|Carboplatin|Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
45680696|NCT01881230|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 on Days 1 and 8 of each 21-day treatment cycle.
45680697|NCT01856582|Biological|CD34+|CD34+ cells are selected using the CliniMACS System; without preparative regimen
46017366|NCT01299896|Other|Coordinated Care|CTQ coordinators will contact the participants for various information sessions about the participant's smoking. These participants will also receive our Connecting to Quit newsletter quarterly.
46017367|NCT01299896|Other|Usual Care|Standard therapy to help participants with smoking cessation.
46017368|NCT01299584|Drug|Remifentanil|Basically there is no treatment allocation. Subjects who would be administered of remifentanil at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
46017369|NCT00637208|Procedure|venographic occlusion of spermatic veins|Through the femoral vein a catheter is inserted into the spermatic veins in succession and the veins are occluded.
46017370|NCT01236573|Drug|Fludarabine|Fludarabine 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
45466783|NCT01306747|Behavioral|The Stanford Chronic Pain Self-Management Programme|The Stanford CPSMP is a patient education program consisting of six 2½ hour weekly sessions. Two trained instructors teach a group of 8-16 persons about managing pain.
45466784|NCT05681871|Dietary Supplement|Ferrous gluconate syrup or ferrous fumarate/folic acid tablets|Oral iron supplementation dosed based on body weight
45466785|NCT03791281|Behavioral|BASIS|
46017371|NCT01236573|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) over 1 hr.
46017372|NCT01236573|Biological|IL-12 transduced TIL|On day 0 (one to four days after the last dose of fludarabine), cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
46017373|NCT01236339|Device|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis
46017374|NCT01236339|Procedure|LVP|Large Volume Paracentesis
46017375|NCT01236339|Device|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis for subjects who failed LVP and crossed over to TIPS per protocol|
46017376|NCT01262898|Drug|GSK962040 (5 mg tablet)|5 mg tablet
45466786|NCT03791281|Behavioral|Attention Control|
45466787|NCT05416892|Other|Pharmaclass® software|Clinical decision support tool via artificial intelligence in order to improve the patient's medication management.
45466788|NCT04455256|Other|x box binding protein|Serum value (pg / mL) of x box binding protein (XBP-1), which is one of the unfolded proteins indicating endoplasmic reticulum stress, is measured.
46017377|NCT01262898|Drug|GSK962040 (25 mg tablet)|25 mg tablet
46017378|NCT01262898|Drug|GSK962040 (125 mg tablet)|125 mg tablet
46017379|NCT01262898|Drug|Placebo|matching placebo tablet
46017380|NCT01262820|Drug|Pazopanib|Pazopanib, 800 mg by mouth daily each 21 day cycle
46017381|NCT04323072|Procedure|Wide antrectomy|The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 2 cm.
46017382|NCT04323072|Procedure|Smal antrectomy|The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 6 cm.
46101328|NCT01010269|Device|Vanguard Complete Knee|Vanguard Knee is a metal and polyethylene system indicated for cemented tibial and femoral use.
45466789|NCT05618197|Other|Passive heating|~3x per week of 1 h hot water immersion (to the clavicle, @40°C, rectal temperature ~38.5°C and <39°C) sessions over a period of 6 weeks.
45466790|NCT04455958|Drug|Lopinavir/Ritonavir|Given PO
46017383|NCT04323228|Dietary Supplement|Oral supplement enriched in antioxidants|the intervention group will receive a commercially available antioxidant supplement, which will be given to patients with COVID-19 in the morning after breakfast.
46017384|NCT04323228|Dietary Supplement|cellulose-containing placebo capsules|The placebo group will receive an oral supplement at the same time in the same shape/size/color.
45466791|NCT04455958|Drug|Placebo Administration|Given PO
46017385|NCT04322916|Device|RM Pressfit vitamys|Implantation of a RM Pressfit vitamys hip cup
46017386|NCT04322760|Drug|Lidocaine 5% patch with Dexmedetomidine Bupivacaine|10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique and a patch of lidocaine 5% was applied to the skin between the arthroscopic ports
46101329|NCT01010269|Device|Vanguard High Flex RP|Vanguard High Flex RP is an extension to the existing Vanguard Knee and has been specifically designed to facilitate greater than 135 degrees of knee flexion.
46101330|NCT04152044|Other|Observation of different types of obesity and liver pathology in patients undergoing and oesophagectomy|Patinets undergoing surgery
46101331|NCT00593112|Drug|OROS methylphenidate|Concerta is given in capsule form with a minimum dose of 18 mg/day and a max of 126 mg/day. Subjects take Concerta once per day for 6 weeks.
46101332|NCT00593112|Other|No intervention|No intervention
46101333|NCT05323565|Drug|Dexmedetomidine|adjuvants to 0.25 bupivacaine in TAB block.
46101334|NCT01015495|Drug|ranibizumab|0.5 mg dose of ranibizumab. Treatment will be given at baseline, month 1, and month 2, and then monthly until OCT shows absence of subretinal fluid and FA shows absence of leakage
45466792|NCT04455958|Other|Questionnaire Administration|Ancillary studies
45466793|NCT01308697|Procedure|Operative fixation of flail chest|Plate fixation
45466794|NCT01308697|Other|Non Operative management|Non Operative treatment of Flail Chest
46017387|NCT04322760|Drug|Dexmedetomidine Bupivacaine|10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique without a patch of lidocaine 5%
46017388|NCT04322838|Diagnostic Test|MeDALL questionnaire for allergic diseases|Questionnaire about allergic symptoms and disease
46101335|NCT00676286|Procedure|3T MR Imaging|3TR Imaging
46101336|NCT00676286|Procedure|C-Choline PET Scanning|C-Choline PET Scanning
46101337|NCT00676286|Procedure|Gene Rearrangement|Gene Rearrangement
46101338|NCT05320354|Diagnostic Test|Microbial ID test|In addition to the standard of care procedure for patients suspected for a periprosthetic joint infection, the MID-test will be performed using the residual synovial fluid. Individual test results of the MID-test are not reported back to the participating sites in order to not interfere with the sites' standard of care approach.
46101339|NCT04188275|Diagnostic Test|Periodic ARV7 and miRNA evaluation|Determination of AR-V7 splice variants on circulating tumor cells and evaluation of circulating levels of miRNA by blood sample collection during PSA assessment at different time points along the treatment course (initiation, 8-weeks assessment, progression).
46101340|NCT00699894|Drug|aprepitant 40 mg|aprepitant 40 mg PO 1-3 hours prior to surgery
46101341|NCT00699894|Drug|ondansetron 4 mg|ondansetron 4 mg IV 2-5 minutes prior to induction of anesthesia
46101342|NCT01010347|Procedure|Volar Splint|A velcro volar splint is compared to a circumferential cast for the treatment of distal radial buckle fractures in children. These are to be worn until Pediatric Orthopaedics follows up with the patients at 3 weeks.
45466795|NCT03791125|Drug|Salvianolic Acid A|4 anticipated doses are 30 mg, 90 mg, 180 mg and 270 mg, respectively. All of these are single-dose study.
45466796|NCT03791125|Drug|Placebo Oral Tablet|Placebo tablets containing no salvianolic acid A will be given to healthy subjects.
45466797|NCT03341637|Biological|Tetravalent Dengue Vaccine (TDV)|TDV subcutaneous injection
46101343|NCT01010347|Procedure|Cast|A velcro volar splint is compared to a circumferential cast for the treatment of distal radial buckle fractures in children. These are to be worn until Pediatric Orthopaedics follows up with the patients at 3 weeks.
46101344|NCT00676442|Drug|PN400|naproxen/esomeprazole
45466798|NCT03341637|Biological|Placebo|Normal Saline (0.9% NaCl) subcutaneous injection
45466799|NCT03785509|Drug|DAPT, Statin|Compliance of DATP, Compliance of Statin, Drug Eluting Stent, Bare Metal Stent
45598352|NCT03133039|Procedure|surgery, bioabsorbable screw|In this study we compare bioabsorbable and titanium screw in the hallux valgus and hallux rigidus surgery
45598353|NCT05013983|Biological|Recombinant COVID-19 vaccine (Sf9 cells)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
45466800|NCT03788239|Other|Staples versus sutures|"Prolene suture: non-absorbable, sterile surgical suture composed of an isotactic crystalline steroisomer of polypropylene, a synthetic linear polyolefin. After completion of the procedure, deep tissues will closed with subcuticular prolene suture. Compared to the absorbable sutures, prolene is known to cause less infection since it is a monofilament material.~Staples: specialized staples used in surgery in place of sutures to close skin wounds. After completion of the procedure, deep tissues were closed with absorbable braided suture, then the skin will be closed by staples."
46017389|NCT04322838|Diagnostic Test|Registration of allergic symptoms|Daily registration of allergic symptoms from eyes, nose and lungs on scale from 0-10 and daily registration of use of anti allergic medication from 1st of August to 15th of October.
46017390|NCT04322838|Diagnostic Test|Skin Prick Test|Diagnostic skin test for sensitization to allergens
46017391|NCT04322838|Diagnostic Test|Specific IgE in serum|Diagnostic test for sensitization to allergens in serum
46017392|NCT04322838|Diagnostic Test|Nasal provocation test|Diagnostic test for allergic rhinitis. Patients and controls are exposed to an allergen with a nasal spray. Allergic reactions are measured with Linder score and Pean Nasal Inspiratory Flow (PNIF)
46017393|NCT04322838|Diagnostic Test|Basophil Activation Test|Basophil leukocytes are extracted from full blood and exposed to 6 different doses of allergen and activation of basophils are measured.
46017394|NCT04322214|Drug|Cobicistat 150 MG|once daily cobicistat (150 mg QD) for 5 days
46017395|NCT04322214|Drug|Placebo|once daily lactose capsules (as aspect cobicistat capsules)
46017396|NCT04322214|Drug|GHB|single oral dose of GHB (25 mg/kg) on days 5 and 17
46101345|NCT02595281|Other|Experimental arm|"Serum samples are collected:~at each neoadjuvant chemotherapy cycle~before surgery~at each adjuvant chemotherapy cycle~at each injection of bevacizumab as maintenance therapy~stop at the progression or after 24 months post chemotherapy"
46101346|NCT00698490|Biological|Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141|Intramuscular injection, 3 doses, 2 different formulations
46101347|NCT00698490|Biological|Herpes simplex virus containing gD-Alum|Intramuscular injection, 3 doses
46101348|NCT04321369|Diagnostic Test|Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals|This is an operational project. Patients will collect a sample from the tongue, nasal cavity and MT and then clinicians will collect a NP sample from the nostril corresponding to each participant's dominant hand.
46101349|NCT00664196|Biological|Gene Modified T Cells|One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
46101350|NCT05535010|Procedure|Transforaminal epidural steroid injection(TFESI)|TFESI procedure will be applied again in the 3rd week and 3rd month for the patients whose NRS score decreased by less than 50 percent after the first procedure.
46101351|NCT00616499|Drug|gefitinib|
46101352|NCT00616499|Procedure|neoadjuvant therapy|
45466801|NCT05093049|Device|Renuvion APR System|The Renuvion APR Handpiece (K191542) is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. The Renuvion APR Handpiece is compatible with the Electrosurgical Generators BVX-200H/P (K170188), and APYX-JS3/RS3 (K192867) owned by Apyx Medical that are indicated for delivery of radiofrequency energy and/or helium gas plasma to cut, coagulate, and ablate soft tissue during open and laparoscopic surgical procedures.
46017397|NCT02889276|Other|Functional Resistance Training|Supervised group-based Functional Resistance Training
46017398|NCT02889276|Behavioral|Unsupervised activity|General activity to meet 150 minutes of moderate intensity activity per week
46017399|NCT05656092|Drug|HIP0612|Test drug
46017400|NCT05656092|Drug|HPP2202|Placebo drug
46017401|NCT05656092|Drug|RLD2204|Reference drug
46017402|NCT05656092|Drug|HPP2201|Placebo drug
46017403|NCT01057810|Drug|Ipilimumab|5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
46017404|NCT01057810|Drug|Placebo|Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
46101353|NCT00616499|Procedure|therapeutic conventional surgery|
46101354|NCT04544761|Other|Structured Interview|Structured interview with research staff about your experience living with spinal cord injury
46101355|NCT04128384|Diagnostic Test|Limited electrophysiologic study including measurements of HV- and AH-intervals pre- and post-TAVR|For the purpose of obtaining intracardiac measurements, the quadripolar diagnostic catheter used as temporary pacemaker wire (5F, Woven, Boston Scientific) during TAVR was retracted from the apex and positioned at the His bundle to measure HV- and AH-intervals.
46101356|NCT05317936|Drug|Pirtobrutinib|Given by PO
46017405|NCT01262352|Drug|Ivacaftor|150 mg tablet, oral use, twice daily every 12 hours (q12h)
45837870|NCT05590741|Behavioral|Emotion Regulation Therapy via Telehealth|The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
46017406|NCT01262352|Drug|Placebo|Tablet, oral use, twice daily every 12 hours (q12h)
46017407|NCT01299272|Drug|LY2216684|
46017408|NCT01299272|Drug|Placebo|
46017409|NCT01299272|Drug|SSRI|Participants should have been on their SSRI for at least 8 weeks prior and were to continue on their stable dose throughout the study.
46017410|NCT02889198|Behavioral|Go NAP SACC|Go NAP SACC is a suite of online tools designed to help child care programs improve their nutrition environment. Tools include: self-assessment, goal setting, action planning, and tips and materials. In addition to these online tools, local technical assistance providers offer center directors an orientation on how to use Go NAP SACC and minimal ongoing technical assistance.
45837871|NCT05589272|Other|Active tDCS|cognitive training + active-tDCS tDCS twice a day (two 13 minute sessions per day, each 2mA / 25cm² = 0.08 current density; anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for five consecutive days.
45837872|NCT05589272|Other|Sham tDCS|cognitive training + sham-tDCS tDCS twice a day (two 13 minute sessions per day, each 2mA / 25cm² = 0.08 current density; anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for five consecutive days.
46101357|NCT05317936|Drug|Venetoclax|GIven by PO
46101358|NCT00676754|Procedure|Statens Serum Institut RT23 2TU tuberculin|
46101359|NCT03053453|Procedure|Spinal Surgery|TKA under standard of care spinal surgery.
45466802|NCT03788317|Drug|Botulinum toxin type A|Injections to hypertonic muscles
45466803|NCT01378858|Drug|Varenicline|Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.
45466804|NCT03790969|Device|26 gauge needle|smaller gauge needle
45466805|NCT03790969|Device|23 gauge needle|control group
45466806|NCT03706209|Drug|MP1032|hard gelatin capsules containing 50mg MP1032 as active ingredient
45466807|NCT03706209|Drug|Placebo|hard gelatin capsules containing no active ingredient
45466808|NCT03790735|Diagnostic Test|FISH|Targeted chromosomal aberrations detection
46017411|NCT04322292|Drug|C-CAR088|"Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10^6 anti-BCMA CAR+T cells/kg.~Divided into three dose ranges of low(1.0-3.0×10^6 CAR+T cells/kg),medium(3.0-6.0×10^6 CAR+T cells/kg) and high(6.0-9.0×10^6 CAR+T cells/kg).~Other Name: CBM.BCMA Chimeric Antigen Receptor T cell."
46017412|NCT01299116|Drug|DMPA|Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
45466809|NCT05272774|Behavioral|FOREST+|The intervention will be delivered as an online stress recovery intervention consisting of six weekly modules. Modules include an introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. These modules have been chosen after considering the themes that could be most useful for healthcare workers under high stress. Each module consists of a psychoeducational and an exercise component.
45466810|NCT03706131|Other|cervical mobilisation|manual therapy
45466811|NCT02522416|Device|Central corneal thickness measurement|
45466812|NCT03790891|Biological|CD19-TriCAR-T/SILK|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
45837873|NCT05587491|Device|Hybrid Argonplasma coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation
45837874|NCT05586022|Procedure|endovascular revascularization|percutaneous balloon dilatation, stent implantation, plaque resection, laser plasty, cutting balloon, drug balloon, cryoballoplasty, thrombolytic therapy with drugs or thrombectomy
46017413|NCT01299116|Drug|oral contraceptives|Oral contraceptives (any variety of formulations are permitted)
46017414|NCT01299116|Drug|Implanon®|Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
45837875|NCT05582915|Diagnostic Test|Blood sampling|4 ml of blood will be collected into EDTA tube for proteomic analysis at visit 0 and visit 1
46101360|NCT03053453|Device|Verasense Knee System device|Sensor measures and localizes peak load at the medial and lateral tibiofemoral joint interfaces. Loading data is thereby captured intra-operatively through the full range of movement (ROM) using the sensor system.
45837876|NCT05581797|Other|Psilocybin-assisted psychotherapy|8 sessions of interpersonal therapy and 2 doses of psilocybin
46017415|NCT01299116|Drug|ParaGard®|Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
46017416|NCT01299116|Drug|Mirena®|Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)
46017417|NCT04321590|Dietary Supplement|Combination of oat beta-glucan of different richness (35 and 70%) at low (3g) and high (5g) doses with green coffee bean extract (600 mg)|Dose-response study on the effect of two different types of oat beta-glucan with different b-glucan content (35% vs. 70%) in combination with a green coffee bean extract rich in polyphenols. Consumption of 2 sachets/day (providing 3 or 5 g/d beta-glucan plus 600 mg polyphenols) during 6 weeks
46017418|NCT04321512|Other|There is no intervention given to the subjects|Not appicable
46101361|NCT02614248|Other|Organic, Unrefined Coconut Oil|
46101362|NCT02614248|Other|Medline Remedy Phytoplex Z-Guard Skin Protectant|
45466813|NCT02891850|Drug|Riociguat (Adempas, BAY63-2521)|Film-coated tablets will be used in this study at a dosage of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg. Tablets will be administered orally.The starting dose is 1 mg TID; the intervals between drug intakes should be 6 to 8 hours. The dosage should be increased by 0.5 mg increments in 2 week intervals to 1.5 mg, 2.0 mg, and 2.5 mg TID (maximal total daily dose).
46017419|NCT04321902|Procedure|Laparoscopic cholecystectomy|"Method of operation~Surgery was started under general anesthesia~A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
46017420|NCT04207398|Procedure|Transjugular intrahepatic portosystemic shunts|Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver. A small metal device called a stent is placed to keep the connection open and allow it to bring blood draining from the bowel back to the heart. TIPS may successfully reduce internal bleeding in the stomach and esophagus in patients with cirrhosis and may also reduce the accumulation of fluid in the abdomen (ascites).
45466814|NCT02891850|Drug|Sildenafil|Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
45466815|NCT02891850|Drug|Tadalafil|Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
46101363|NCT00673946|Other|True saturation values displayed|Physicians will be presented with real saturations.
45466816|NCT05154448|Device|Non-Invasive Thermal Ablation of the Medial Branch Nerves (Neurolyser XR)|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
46101364|NCT00673946|Other|Altered saturation values displayed.|Physicians will be presented with saturation measurements three percentage points above the true values.
45466817|NCT05154448|Other|Sham procedure|Sham procedure done in an identical manner to the treatment arm, but without deploying acoustical energy
45466818|NCT03790813|Diagnostic Test|Intervention 1|Ki-67 and Oncotype DX® will be performed on the baseline core biopsy specimen prior to initiation of neoadjuvant systemic therapy.
45466819|NCT03790813|Diagnostic Test|Intervention 2|MRI will be performed prior to initiation of neoadjuvant systemic therapy and at the end of treatment.
45466820|NCT05608707|Behavioral|Physical activity intervention|The 12 week intervention will involve 2 weekly group exercise sessions incorporating strength and balance exercises, along with home-based exercise focused on increasing time spent walking.
45466821|NCT05608707|Dietary Supplement|Personalised nutrition intervention|Two Plant-based Protein and Fibre (PPF) product products have been selected from six initially developed, with best amino acid blend, taste, and bioavailability. Participants will be provided with the PPFs to consume daily as part of a personalised diet over 12 weeks.
45466822|NCT05145556|Device|Videolarygoscopy|In a randomised order we evaluate the first pass success rate of the tracheal tube into the trachea.
45466823|NCT05145556|Device|conventional laryngoscopy|In a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
45598354|NCT05013983|Other|Placebo control|Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium
45598355|NCT02357433|Device|High Doses CPFA|
45598356|NCT01672255|Drug|Fluoxetine|20 mg week 1, 40 mg week 2, 60 mg week 3, 80 mg week 4-6
45598357|NCT01672255|Drug|Placebo control|20 mg Week 1, 40 mg Week 2, 60 mg Week 3, 80 mg Week 4-6
45598358|NCT02222519|Drug|Rocuronium|Rocuronium 0.6mg/kg iv single dose
45837877|NCT05581030|Drug|Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)|"Hyper-CVAD consists of two combinations of drugs (courses A and B) given in an alternating fashion. The term hyper refers to the hyperfractionated nature of the chemotherapy, which is given in small doses, more frequently, to minimize side effects. CVAD is the acronym of the drugs in course a: cyclophosphamide, vincristine, doxorubicin and dexamethasone.~Course A: Cyclophosphamide days 1, 2 and 3. Vincristine days 4 and 11, Doxorubicin day 4, dexamethasone days 1-4 and 11-14, Cytarabine day 7. Mesna is also given orally with cyclophosphamide, to reduce the incidence of haemorrhagic cystitis, a common side effect of cyclophosphamide. Methotrexate, an antimetabolite, may be given when necessary to get chemotherapy past the blood brain barrier.~Course B: Methotrexate Day 1 and Cytarabine Days 2 and 3. Dosage is individualized to the patient."
46017421|NCT04207398|Other|Nonselective β-blocker (NSBB)+ endoscopic band ligation (EBL)|Combination therapy of nonselective β-blocker (NSBB) and endoscopic variceal ligation (EBL) will be used for participants in this group. NSBB, which will be titrated to the maximum tolerated dose aiming to decrease the heart rate by 25%, with a lower limit of 50 beats per minute, was started at day 5 after the index bleeding, unless a contraindication was present (severe arrhythmia, severe obstructive chronic obstructive pulmonary disease, or known intolerance). Endoscopic variceal ligation sessions started 2 weeks after the index bleeding and were performed every 2-4 weeks thereafter until eradication of varices, followed by endoscopic surveillance and retreatment, if indicated, every 6-12 months.
46017422|NCT01299038|Drug|rosuvastatin|Taken orally once a day for 4 weeks
46017423|NCT00623922|Behavioral|Patient education with individual nurse consultations|3 group meetings followed by 1-2 individual nurse consultations.
45837878|NCT05581030|Drug|Calaspargase Pegol|Calaspargase pegol 2000 IU/m^2 (capped at 3750 IU) will be administered beginning in cycle 1B of Hyper-CVAD, and will continue at this dose for the duration of the trial.
45837879|NCT05581030|Drug|Rituximab|Rituximab 375mg/m^2 will be administered once per cycle for patients with CD20+ ALL.
46017424|NCT04321356|Device|Triathlon PCR TKA|Total Knee Arthroplasty System
46017425|NCT04321356|Device|Triathlon PS TKA|Total Knee Arthroplasty System
46017426|NCT04321356|Device|Persona PCR TKA|Total Knee Arthroplasty System
46017427|NCT04321356|Device|Persona PS TKA|Total Knee Arthroplasty System
46017428|NCT04321434|Other|Hyperoxia|
46017429|NCT04321434|Other|Normoxia|
46017430|NCT04321434|Device|laser Doppler|laser Doppler
46101365|NCT05322863|Device|High-definition Transcranial Direct Current Stimulation|The HD-tDCS will be administered by the program device called Starstim (Neuroelectrics). All participants will receive the treatment by using the same model of device. The HD-tDCS device can be portable and controlled wirelessly via computer software developed by the manufacturer. The montages will be a '4 × 1 ring set-up', which is the most commonly used HD-tDCS setting. The centre anode electrode is surrounded by four return cathode electrodes. The anode will be placed over the left dorsal lateral prefrontal cortex. Conductive electrode gel will be applied on the scalp at all designated electrode stimulation areas. A cap appropriate for each participants' head size will be used to ensure that the electrodes are secured in place. Impedance checks will be performed using the Starstim software before each treatment session.
45837880|NCT05577741|Behavioral|Multisensory virtual reality pod (SENSIKS©)|Six sessions of 20 minutes of mindfulness.
45837881|NCT05577741|Behavioral|Cognitive bike (Vélo-cognitif®)|Six sessions of 20 minutes of cognitive bike (pedal + cognitive games).
45837882|NCT05577741|Other|Standard treatment|Standard of care treatment
46017431|NCT04321122|Procedure|ultrasound cyclo plasty|"The ultrasonic glaucoma treatment instrument produced by French EYE TECH CARE company is referred to as EyeOP1.It uses high-intensity focused ultrasound technique to make target part of the ciliary coagulative necrosis, reduce the production of aqueous humor and thereby lower the intraocular pressure. EyeOP1 is ergonomic and suitable for the human eye, making the treatment process more accurate, simple and fast."
46017432|NCT04321278|Drug|Hydroxychloroquine + azithromycin|Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
46017433|NCT04321278|Drug|Hydroxychloroquine|Active Control Group: Hydroxychloroquine. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
46017434|NCT01261338|Drug|olestra|non-absorbable dietary fat
46017435|NCT01260948|Drug|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
46017436|NCT01260948|Drug|Aricept®|10 mg Orally Disintegrating Tablet
46017437|NCT01025284|Drug|LY2523355|Administered intravenously as a 1-hour infusion
46017438|NCT01025284|Drug|Granulocyte colony-stimulating factor (G-CSF)|Administered subcutaneously
45466824|NCT01308775|Behavioral|SIS.NET, Routine Follow-up|"SIS.NET - One or two oncology related clinic visits per year (as recommended by the American Society of Clinical Oncology breast cancer follow up guidelines (18)), with additional access to oncology care driven by ongoing review of patient's self reported symptoms through web-based questionnaires.~Routine follow up care with appointment frequency determined by the treating medical oncologist or oncology/breast surgeon. Patients complete the same web-based symptom questionnaires within 30 days of a scheduled clinic visit but the results are not reviewed until their clinic visit."
45466825|NCT05175027|Drug|hypochlorous acid|Randomize
46017439|NCT01021852|Drug|MK-6096|MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.
46017440|NCT01021852|Drug|Dose-matched Placebo to MK-6096|Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.
46017441|NCT04300660|Other|neuropathic pain after thoracic surgery|analysis of perioperative factors implicated in the onset of postoperative pain after chest surgery and the incidence of neuropathic pain
46017442|NCT02872636|Device|Spinal catheter insertion with extracorporeal filtration of CSF|Extracorporeal filtration of CSF
46017443|NCT02872870|Behavioral|auditory lexical decision task|
46017444|NCT02872870|Device|electroencephalogram|
46017445|NCT02875054|Behavioral|Constraint induced movement therapy (CIMT)|Involves forcing use of ones affected upper extremity (UE) by physically restraining the less affected upper extremity
46017446|NCT02875054|Behavioral|Hand-arm bimanual intensive training (HABIT)|Facilitates the translation of gains to improve goal-directed bimanual performance.
45466826|NCT05102110|Diagnostic Test|Oricol Test|Assessment of rectal mucus for material from aero-digestive cancers.
45466827|NCT03705975|Other|Manual treatment|Scapula mobilization, glenohumeral joint mobilization
45466828|NCT03790501|Other|No intervention|As an observational study, no intervention will be associated with the study group.
45466829|NCT05089630|Biological|Pentamer (low)/gB(low)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of low dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
45466830|NCT05089630|Biological|Pentamer (med)/gB(low)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
46017447|NCT02873026|Drug|Triamcinolone Acetonide|Following the repair of the open globe eye trauma, the use of Triamcinolone Acetonide will be investigated
46017448|NCT00627640|Drug|Safinimide 50-100 mg/day|Safinamide, (S)-(+)-2-[4-(3-fluorobenzyloxy) benzylamino] propanamide methanesulfonate, is an a-aminoamide derivative
46017449|NCT00627640|Drug|Matching Placebo|Matching Placebo
46017450|NCT01056718|Drug|Nebivolol|Initial dose of 5 mg titrated (doubling of previous dose) to optimal blood pressure. The dose was titrated by doubling the previous dosage to achieve BP less than or equal to 130/80 mm Hg at 2 weeks and 4 weeks. The mean dose of nebivolol used week 4 through week 10 was 7.8 mg. It should be noted that nebivolol was added to the subject's existing stable antihypertensive regimen which included a mean of 2 other medications.
46017451|NCT01298570|Drug|Regorafenib (BAY 73-4506)|Regorafenib, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
46017452|NCT01298570|Drug|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
46017453|NCT01298570|Drug|Placebo|Placebo, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
46101366|NCT00491179|Drug|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks
46101367|NCT00491179|Drug|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks
46101368|NCT00676910|Drug|JNJ-26854165|
45466831|NCT05089630|Biological|Pentamer (med)/gB(med)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
45466832|NCT05089630|Biological|Pentamer (high)/gB(med)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of high dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
46017454|NCT01298570|Drug|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
46017455|NCT01259856|Drug|PEGASYS|The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
46017456|NCT01259856|Drug|Hydroxyurea|Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
46017457|NCT01259856|Drug|Aspirin|Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
46017458|NCT01020838|Drug|Florbetaben (BAY94-9172)|Single intravenous injection 1-5ml, 300 MBq (+/- 20%)
46017459|NCT00624000|Drug|IV tpa (Alteplase) vs IA tpa (Alteplase)|Alteplase was administered Either IA or IV x 1
46017460|NCT01259466|Drug|Nicotine patch|Transdermal Nicotine Replacement Therapy - 21 mg daily for 10 weeks
46017461|NCT01259388|Drug|Lithium Carbonate|Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time.
46017462|NCT01298492|Drug|PF-00547659|75 mg SC once monthly for 72 weeks. Subjects may escalate to 225 mg or de-escalate to 22.5 mg one time.
46017463|NCT05525910|Drug|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
45466833|NCT05089630|Combination Product|Placebo (saline)|Three doses of placebo (saline) are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
45466834|NCT03707418|Drug|Heparin Sodium|Intravenous Heparin titrated to Partial ThromboplastinTime (PTT) levels
45466835|NCT03707418|Drug|Bivalirudin Injection [Angiomax]|Intravenous Bivalirudin titrated to Activated Clotting Time (ACT) levels
45466836|NCT03785041|Drug|Levobupivacaine Hydrochloride 2.5 MG/ML|Intrarticular injection of tramadol in addition to levobupivacaine in different doses preemptive and postoperative
45466837|NCT03708666|Other|Telemonitoring of blood pressure|Blood pressure monitoring at least once a week.
45466838|NCT05087056|Combination Product|MenABCWY vaccine|Two doses of the MenABCWY vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, on a 0-, 24-month schedule in the ABCWY-24 Group, and a 0-, 48-month schedule in the ABCWY-48 Group.
45466839|NCT05087056|Combination Product|Placebo|Single dose of Placebo (saline solution in pre-filled syringe), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1441 in the ABCWY-24 Group, and at Day 721 in the ABCWY-48 Group.
46017464|NCT05525910|Drug|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
46017465|NCT05525910|Drug|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
46017466|NCT05525910|Drug|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
46017467|NCT05525910|Drug|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
46017468|NCT04320654|Other|exercise|The aim of this intervention is to increase patients average daily step count. The walking program is a behavior change intervention in which the pedometer will be used as a tool to help the patients monitor their activity levels.
46017469|NCT01297322|Other|Manual compression|Standard of Care
46017470|NCT01297322|Device|Cardiva VASCADE™ Vascular Closure System|Investigational Hemostatic Vascular Closure System
46017471|NCT02888886|Other|Questionnaires about food habits and tobacco|
46017472|NCT02888886|Other|Spirometry|
46017473|NCT02888886|Other|Carotid echography|
46017474|NCT02888886|Other|Blood sample|for genetic polymorphism analysis, CRP, homocysteine and cytokine tests, glycemia and dyslipidemia analyses
46017475|NCT00624078|Drug|Antivenin Centruroides (scorpion) F(ab)2 Anascorp™|three vials diluted in 20 to 50 mL normal saline administered intravenously. Subsequent single vial doses of Anascorp, up to a total of five vials administered at thirty minutes intervals until resolution of symptoms.
46017476|NCT00624156|Behavioral|Writing Intervention|Participants in the emotional disclosure condition will be instructed to write continuously for 20 minutes about their deepest thoughts and feelings regarding their cancer experience.
46017477|NCT00624156|Behavioral|Writing Intervention|Participants assigned to the control condition will be instructed to describe in a detailed, nonemotional manner their daily activities. The 20-minute writing task will be introduced as a time management intervention
46017478|NCT05396586|Behavioral|N-back|The training program is a personal device-based adaptive version of a visual N-back task, either devoid of game elements or embedded in a gamified platform game
45466840|NCT03708510|Device|Restorative materials- Filtek Silorane|Filtek Silorane
45466841|NCT03708510|Device|Restorative materials-Kalore|Kalore
45466842|NCT03708510|Device|Preparation-Er,Cr:YSGG Laser|Er,Cr:YSGG Laser
45466843|NCT03708510|Device|Preparation- Diamond Bur|Bur
45466844|NCT05537623|Behavioral|Safe Alternatives for Teens and Youths (SAFETY)|Please see description of experimental arm (arm one)
46017479|NCT05396586|Behavioral|Span|The training program is a personal device-based adaptive version of a visual working memory span task, either devoid of game elements or embedded in a gamified platform game
45466845|NCT05537623|Behavioral|Supportive Therapy|Please see description of active comparator arm (arm two)
46017480|NCT05396586|Behavioral|Multisensory|The training program is a personal device-based adaptive version of an N-back task that features visual stimuli (Unisensory) or visual stimuli paired with unique sounds (Multisensory) and is devoid of game elements
46017481|NCT05358210|Behavioral|Blueberry Consumption|Participants will consume 1 cup of frozen blueberries daily for the 12 weeks of the intervention. The study dietitian will provide educational materials and monitor compliance through weekly check-ins. Participants will be instructed to avoid all other high-anthocyanin foods including other berries, cherries, currants, cabbage, red wine, and eggplant.
45466846|NCT03710304|Drug|Oxytocin|20 IU oxytocin or placebo ampoules in 500 mL of intravenous solution infusion over 15 min after delivery of the baby.plus 2tab placebo buccal plus 110 ml saline by slow infusion
46017482|NCT05358210|Behavioral|Dried Date Consumption|Participants will consume 2-3 dried dates daily for the 12 weeks of the intervention, an isocaloric portion of fruit compared to the blueberry group. The study dietitian will provide educational materials and monitor compliance through weekly check-ins. Participants will be instructed to avoid all other high-anthocyanin foods including blueberries, other berries, cherries, currants, cabbage, red wine, and eggplant.
46017483|NCT05289570|Drug|Voxelotor|500 mg of voxelotor will be administered two times a day (for a total daily dose of 1000 mg per day) for 5 days. This dose may increase to a total maximum daily dose of 1500 mg (500 mg three times a day) if subject tolerates initial dose as determined by Principal Investigator (PI).
46017484|NCT05286528|Drug|Bosutinib|Bosutinib as prescribed in real world
45466847|NCT03710304|Drug|Tranexamic acid plus misoprostol|1 gm TA or separate placebo will be diluted in 100 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist before skin incision,
45466848|NCT03710304|Drug|misoprostol|400 μg misoprostol (2 tablets of 200 μg) will be give buccally after spinal anesthesia and few minutes before skin incision;
45466849|NCT05085730|Device|InMode Morpheus8 System|The InMode Morpheus8 System is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis and neoelastogenesis.
45466850|NCT05593965|Device|Delta-beta TMS|TMS will be delivered in a delta-beta pattern in which triplets of pulses delivered at 20 Hz (50 milliseconds between each pulse) are sent every 3 Hz (333 milliseconds between the start of each triplet).
46017485|NCT05286528|Drug|Imatinib|Imatinib as prescribed in real world
46017486|NCT05286528|Drug|Nilotinib|Nilotinib as prescribed in real world
46017487|NCT05286528|Drug|Dasatinib|Dasatinib as prescribed in real world
46017488|NCT05286528|Drug|Ponatinib|Ponatinib as prescribed in real world
46017489|NCT01297244|Drug|Tivozanib|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
45466851|NCT05593965|Device|Theta-gamma TMS|TMS will be delivered in a theta-gamma pattern in which triplets of pulses delivered at 50 Hz (20 milliseconds between each pulse) are sent every 5 Hz (200 milliseconds between the start of each triplet).
45466852|NCT05593965|Device|Arrhythmic TMS|TMS will be delivered in an arrhythmic pattern in which pulses are delivered with a random inter-pulse interval. The number of pulses and duration is matched to that of the Delta-beta TMS and Theta-gamma TMS.
45466853|NCT05611177|Other|machine learning analysis|We will use robust machine learning approaches, such as Random Forest, XGBoost or Neural Networks.
45466854|NCT04454944|Behavioral|LPG subsidy|Different subsidy rates, ranging between 0% and 100% (listed below) will be written on cards. Individuals will randomly select a card to display the subsidy rate for each household. The card will be concealed with a scratch-off sticker, with a higher likelihood of drawing a high price (low subsidy) than a low price (high subsidy) given that take up will be higher in the latter group.
45466855|NCT04454944|Behavioral|Distance allocation|We will set up fuel supply depots to increase the convenience and lower costs and hassle associated with traveling to an established filling station. The supply depots will mirror a recirculation model of LPG distribution currently being piloted by the National Petroleum Authority of Ghana. Households will be randomly assigned to one of the supply depots in advance or to continue refilling their cylinder at the filling station.
46017490|NCT04320420|Other|Adapted Physical Activity|"The APA program is defined in 3 stages:~STEP 1: during the initial chemotherapy over 3 months~3 supervised APA sessions/week on site:~two muscle strengthening sessions, stretching, flexibility in the gym~a cardio session (Nordic Walking: outdoors)~at home: exercise book if the patient wishes~STEP 2: during hospitalization for the autograft, over 1 month:~2 sessions/week supervised by an APA engineer + exercise book and encouragement of individual work~If the patient wishes, he can continue the exercises carried out with the APA engineer independently~STEP 3: after the transplant~the first 3 months:~2 supervised indoor sessions/week (muscle strengthening, stretching, flexibility),~1-hour cardio session/week independently~the following 3 months: 1 indoor session per week + independent exercises at home and walking or cycling sessions"
46017491|NCT02890160|Device|Firesorb|Sirolimus Target Eluting Bioresorbable Vascular Scaffold
46017492|NCT02890160|Device|XIENCE|Everolimus Eluting Coronary Stent System
46017493|NCT05183022|Device|Total30 Sphere Contact Lenses|Participants will be refit into Total30 Sphere contact lenses and followed for 1 month.
46101369|NCT02016599|Other|Monitoring and biospecimen collection|The study team will use monitoring methods normally used in the NICU (physical exams, echocardiograms, and ECG) and some new monitoring methods (Near-infrared spectroscopy or NIRS) to find out all the changes that a baby's heart and lungs go through during the first week after delivery. In addition, blood samples will be taken to assess lactate, troponin, and creatinine levels.
45466856|NCT05592249|Other|Dual Task MC|Dual Task MC group will receive 60 minutes motor - cognitive dual task intervention 5 day per week for 4 weeks in clinic.
45466857|NCT05592249|Other|Dual Task MM|Dual Task MM group will receive 60 minutes motor - motor dual task intervention 5 day per week for 4 weeks in clinic.
45466858|NCT04454710|Device|Pulsed Radiofrequency|Pulsed radiofrequency is a novel therapeutic modality with many potential applications in pain management.
45466859|NCT05605639|Drug|Bupivacaine|The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.
45466860|NCT05605639|Other|Placebo (physiological saline serum infiltration)|The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.
45466861|NCT05416268|Diagnostic Test|Electroretinography|Two different electroretinogram devices (Diopsys NOVA and LKC RETeval Devices) will be evaluated with two different electrode arrays (Diopsys Lid Electrodes and LKC RETeval Self-Adhering Electrode Arrays).
45466862|NCT05594173|Other|Food texture modification|Food prepared in three different consistencies: minced and moist, soft and bite-sized and regular, as defined by the International Dysphagia Diet Standardisation Initiative
45466863|NCT04454866|Drug|Single injection of penehyclidine|A dose of penehyclidine hydrochloride (0.5 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
45466864|NCT04454866|Drug|Continuous infusion of penehyclidine|A dose of penehyclidine hydrochloride (0.25 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of penehyclidine hydrochloride (0.25 mg/5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
45466865|NCT04454866|Drug|Placebo|A dose of placebo (normal saline 5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
45466866|NCT03790345|Drug|Pyridoxine|Adjuvant daily treatment with 200mg of pyridoxine
45466867|NCT03790345|Drug|Cobalamin|Adjuvant daily treatment with 2mg of cobalamin
45466868|NCT03790345|Drug|Placebo Oral Tablet|Adjuvant daily treatment with placebo
45466869|NCT04901728|Behavioral|Cultural Domain Analysis|80 and up to a maximum of 120 participants
45466870|NCT04901728|Behavioral|Focus Group Discussion|At least 18 and up to a maximum of 60 participants
46017494|NCT04125524|Diagnostic Test|Terahertz metamaterials|A diagnostic test used to identify specific tumour markers will be carried out on serum samples using terahertz metamaterials.
46017495|NCT02890394|Other|Suboccipital inhibition technique|Suboccipital inhibition technique involves the placement of the hands of the physiotherapist under the patient's head so that fingers can feel the spinous processes of the cervical vertebrae. Then fingers slowly leads upward to contact the occipital condyles. At this point the investigator should gently move your fingers down, finding the space between the condyles and the spinous process of the axis. Remember that the atlas has no spinous process. Then, flexing the metacarpophalangeal joints at 90 degrees, slowly raises the skull
45466871|NCT04901728|Behavioral|In-depth interview|At least 18 and up to a maximum of 36 participants
45466872|NCT05416190|Diagnostic Test|Lupus anticoagulant testing|The patient will have a visit during which a blood sample will be taken, a clinical examination will be performed, and data will be collected.
45466873|NCT04723186|Drug|MT1002 for Injection|MT1002 will be initiated as close to the start of PCI as possible. MT1002 should be initiated during diagnostics angiography when indication for PCI is confirmed, provided the PCI is indicated right after the coronary angiography. PCI can start after MT1002 initiation as soon as ACT is confirmed to be ≥ 200 sec or within 30 min after MT1002 starts, whichever occurs first. MT1002 will be administered by an intravenous injection of 0.90 mg/kg, 1.2 mg/kg, or 0.6 mg/kg (depending on the dose selected for the cohort) prior to the PCI procedure, immediately followed by an IV infusion of 1.8 mg/kg/hour, 2.3 mg/kg/hour, or 1.2 mg/kg/hour (depending on the dose selected for the cohort) until completion of the procedure. At completion of PCI, subjects will be continued on IV MT1002 for 4 hours from infusion start.
45466874|NCT05415566|Combination Product|toy nebulizer and toy mask|The treatment was administered using therapeutic play.
45466875|NCT03788005|Procedure|Early mobilization|Early mobilization as soon as possible and within a maximum of 12 hours following burr hole craniostomy for chronic subdural hematomas.
45466876|NCT04454788|Drug|Tenecteplase|Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as intravenous bolus over 5-10 seconds
45837883|NCT05576012|Biological|SOL-116|Participants will receive SC injection in a double-blind manner
45837884|NCT05576012|Biological|Placebo|Participants will receive SC injection in a double-blind manner
46017496|NCT04752696|Drug|Onvansertib|Oral capsule
45466877|NCT04454788|Drug|Standard Care (which may include intravenous Alteplase)|Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
46017497|NCT04752696|Drug|Nanoliposomal irinotecan|Intravenous infusion
46017498|NCT04752696|Drug|Leucovorin|Intravenous infusion
46017499|NCT04752696|Drug|Fluorouracil|Intravenous infusion
46017500|NCT04746378|Diagnostic Test|Computed Tomography, CSD|Measurement of the stone burden by cumulative stone diameter, the sum of linear longest diameters of all the stones to be treated within one patient as measured on the CT or by additional rendering software
46017501|NCT04746378|Diagnostic Test|Computed Tomography, SA|Measurement of the stone burden by surface area, the sum of surface areas of all the stones to be treated within one patient as measured on the CT or by additional rendering software
45466879|NCT03339999|Drug|AGN-242428|AGN-242428 administered as an oral capsule(s) once daily.
46017502|NCT04746378|Diagnostic Test|Computed Tomography, 3D|Measurement of the stone burden by volume of all the stones to be treated within one patient, as measured on the CT or by additional rendering software
46017503|NCT04735692|Other|Full mouth or quadrant SRP|Full mouth or quadrant SRP
46017504|NCT04320576|Device|Bulk-fill|Bulk-fill resin composite (bulk technique)
46017505|NCT04320576|Device|Nano-fill|Nano-fill resin composite (layering technique)
46017506|NCT04642638|Drug|INO-4800|INO-4800 will be administered ID on Day 0 and Day 28.
46017507|NCT04642638|Device|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0 and Day 28.
46017508|NCT04642638|Drug|Placebo|Sterile saline sodium citrate (SSC) buffer (SSC-0001) will be administered ID on Day 0 and Day 28.
46017509|NCT04642638|Device|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device will be administered following ID delivery of sterile saline sodium citrate (SSC) buffer (SSC-0001) on Day 0 and Day 28.
46017510|NCT04554732|Drug|Keratinocyte growth factor|At the end of 4 cycles of chemotherapy, primary efficacy end point data will be collected. After 20 evaluable subjects if ≥ 4 responses were noted, part 2 of the study will be activated. The decision rule is based on the lower bound of a one-sided 95% confidence interval; at least 4 out of 20 patients with response results in a lower bound greater than 5% success. The proportion with success and the lower bound of a one-sided exact confidence interval will be computed.
46017511|NCT05632536|Procedure|SACRAL ESP AND CAUDAL BLOCK|Application of ultrasound-guided sacral erector spinae plane (ESP) block or ultrasound-guided caudal block with 1mL/kg 0.25% bupivacaine (local anesthetic) to patients
46017512|NCT04499820|Dietary Supplement|Nutrof|DHA docosahexaenoic acid Omega 3s may be of interest in cases of retinopathies.
46017513|NCT04499820|Dietary Supplement|Meralut|vitamin A, natural flavonoids, lutein and zeaxanthin
46017514|NCT04485858|Device|CorNeat KPro|CorNeat KPro will be implanted into the subject's eye where the optic component snaps into the patient's trephined cornea and is sutured to the eye wall using 3 non-degradable sutures and the skirt component is placed under the conjunctiva
46017515|NCT04481256|Radiation|External beam radiotherapy|External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy
46017516|NCT04481256|Drug|Bintrafusp alfa|Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.
46017517|NCT04481256|Drug|Paclitaxel|Paclitaxel 50 mg/m2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
45466880|NCT03339999|Drug|Placebo|Placebo administered as an oral capsule(s) once daily.
45598359|NCT02357121|Device|Focal Laser Ablation|Focal laser ablation of prostate tissue using laser interstitial thermal therapy (LITT) under MR/ultrasound fusion guidance
45598360|NCT02220023|Drug|INOmax Inhalation|
45598361|NCT02352909|Other|Education|Education on running training modifications depending on symptoms (decrease running speed, spread running volume throughout the week, run/walk intervals, avoid downhill and stairs running). Education about symptoms will also be provided.
46017518|NCT04481256|Drug|Carboplatin|Carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
46017519|NCT02888964|Drug|Add-on therapy|Pioglitazone therapy
45466881|NCT03784729|Other|Acupuncture|"The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted. For the bilateral BL25, sterile disposable steel needles (Huatuo, Suzhou, China; 0.3 mm×75 mm) will be inserted to a depth of 50-70mm until until participates feel a sensation similar to electric shock radiating downward to the knees. For the other four acupoints (BL23, BL40, BL57 and KI3), the needles (Huatuo, Suzhou, China; 0.3 mm×40 mm) will be inserted to a depth of 15-25 mm, gently rotated three times and lifted to achieve de qi. It should be noted that the needle at KI3 will be inserted at an angle of 45°obliquely downward. There will be 18 treatment sessions with 3 times a week for continuous 6 weeks and a 30 min treatment per session."
45466882|NCT03784729|Other|Sham acupuncture|The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted into a depth of 2-3mm .No manipulation of needles without deqi will be conducted. The treatment duration and frequency of sessions for participants in the SA group will be the same as in the acupuncture group.
46101370|NCT05622292|Device|HARKIT I-Care Application|HARKIT I-Care Application is an application available in the google play store. The application is specifically developed for the secondary prevention of cardiovascular disease. The features included in the application are (1) Health information logging, (2) Health information education, and (3) Teleconsultation with a cardiologist. Information that can be logged includes smoking behavior, medications, weight, blood sugar level, blood pressure, cholesterol level, physical activity, and Quality of life. Educational content can be accessed by patients in the form of articles and short videos.
45466883|NCT04862650|Drug|Carboplatin|Given IV
45466884|NCT04862650|Biological|Cemiplimab|Given IV
45466885|NCT04862650|Drug|Paclitaxel|Given IV
45466886|NCT03790189|Biological|Subchondral and intra-articular injection of BMC|Bone Marrow concentrate will be injected intra-articularly and at the bone-cartilage interface both in the tibia and femur of patients affected by unicompartmental knee osteoarthritis
46017520|NCT04416516|Biological|ASN-002|ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
46101371|NCT04155476|Drug|Nitroglycerin Topical Product|application of NG topical to dorsals pedis and posterior tibial arteries.
45466887|NCT05163561|Biological|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A|SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
45466888|NCT05163561|Biological|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot B|SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
45466889|NCT05163561|Biological|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot C|SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
45466890|NCT05163561|Biological|Sii Licensed IPV|Poliomyelitis Vaccine (Inactivated), produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). Poliomyelitis Vaccine (Inactivated) is a highly purified, inactivated poliovirus vaccine.
45466891|NCT03788161|Other|Real Virtual Reality|Participants will receive a distraction by playing a game of virtual reality with a 3D application
46017521|NCT04387110|Drug|Ocrelizumab|Receiving either 1infusion (600mg) or 2 infusions (300mg).
46017522|NCT04364646|Behavioral|Personalized Integrated Chronotherapy|Based on their baseline sleep-wake schedule and real-life constraints (work and other responsibilities), an initial sleep schedule is set that allows 7.5 hours of sleep and provides time for participants to sit in front of the morning bright light.
46101372|NCT00674024|Drug|Pazopanib|
46101373|NCT00674024|Drug|Pazopanib (GW786034)(GW786034)|
46101374|NCT04502095|Drug|Clindamycin|Given PO
46101375|NCT04502095|Other|Diary|Complete drug diary
46101376|NCT04502095|Drug|Ertapenem|Given PO
46101377|NCT04502095|Drug|Levofloxacin|Given PO
46101378|NCT04502095|Drug|Nitrofurantoin|Given PO
46101379|NCT04502095|Drug|Trimethoprim-Sulfamethoxazole|Given PO
46101380|NCT00921232|Behavioral|Questionnaires|"During a consultation:~3 questionnaires (HADS, FRI, CRA)~and a form for the sociodemographic data"
45466892|NCT03788161|Other|Placebo Virtual Reality|Participants will receive a placebo distraction with a game of virtual reality with a 3D application without functioning
46017523|NCT04209738|Other|This is an observational study being conducted as a substudy of another trial.|This is an observational study being conducted as a substudy of another trial. No intervention is planned for Substudy.
46017524|NCT04207008|Other|iBDecide Decision Support Application|The iBDecide app provides an electronic tools to learn more about UC, track symptoms, create a nutrition diary, enter reminders for medication and clinic visits, as well as learn more about treatment options and compare UC medications.
46017525|NCT04122768|Behavioral|Multi-component physical activity tele coaching intervention|"A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed."
46017526|NCT04122768|Behavioral|Light coaching intervention|"A. Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity.~B.A step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period)."
46101381|NCT00664274|Behavioral|Cognitive remediation therapy|36 sessions of Computerized Cognitive Skills Training, 3 per week for 12 weeks.
46101382|NCT00664274|Genetic|COMT Genotyping|One time saliva sample is taken to genotype catechol-O-methyltransferase Val158/108Met alleles.
46017527|NCT04206930|Other|Art Therapy|1 session of 2 hours per week in a closed group for 10 weeks
46017528|NCT02889042|Other|MRI and biological assessment|performing a MRI and a biological assessment
46017529|NCT02888808|Other|Gastroscopy|Upper gastrointestinal endoscopy procedure
46017530|NCT05514600|Procedure|closure of parastomal hernia fascial defect|For subjects randomized to the fascial closure arm, the parastomal defect will be closed using barbed, running suture prior to placement of the mesh.
46101383|NCT00674102|Drug|ASA404|
45466893|NCT05174793|Other|dehydration and rehydration|dehydration and rehydration
45466894|NCT04510948|Behavioral|Patient Priorities Care|"Patient Priorities Care (PPC) is an innovative approach to shared decision-making that draws from existing professional training.~PPC requires the elicitation and documentation of patient health outcome goals and care preferences and the alignment of clinical care with health goals and healthcare preferences. This information will be collected and documented in the EHR by facilitators and shared with the clinicians who will then use the PPC approach with patients to inform and guide treatment decisions.~The PCPs will be trained in decisional strategies that have been shown to help align care with patients' health priorities. While encouraged to use these decisional strategies, PCPs will be free to make the recommendations they feel most appropriate for each patient.~This intervention has been developed to be integrated seamlessly into usual care."
46017531|NCT04320108|Device|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy 6 times during 2 weeks
46101384|NCT00503581|Procedure|Biopsy|Undergo biopsy
46101385|NCT00503581|Other|Laboratory Biomarker Analysis|Correlative studies
46101386|NCT00503581|Drug|Megestrol Acetate|given orally
46101387|NCT00503581|Other|Pharmacological Study|Correlative studies
46101388|NCT00503581|Other|Quality-of-Life Assessment|Ancillary studies
46101389|NCT00503581|Procedure|Therapeutic Conventional Surgery|undergo hysterectomy
46101390|NCT04968964|Device|DiviTum® TKa assay|-Determines serum enzymatic activity of TK1
46101391|NCT04968964|Other|Study Care Plans|-Study Care Plans will be completed prior to and post release of serum DiviTum® TKa value
46101392|NCT00677066|Procedure|Home oxygen therapy|Administer oxygen at home or in hospital
46101393|NCT05614258|Drug|ADG206|All participants in this study will receive the study drug ADG206 in one of the designed dosage level. ADG206 will be administered by intravenous infusion over 60-90 minutes on Day 1 of each treatment cycle until disease progression, intolerable toxicities or withdrawal of consent, or up to 2 years.
46017532|NCT03648918|Other|Blood Collection|Blood will be collected via venipuncture and analyzed. Blood samples will be analyzed for HLA haplotype (a genetic sequence related to type 1 diabetes susceptibility), plasma-induced signature, diabetes autoantibodies, complete blood count with differential, and serum and plasma for storage. For family members with diabetes, blood will also be tested for A1c.
46017533|NCT03582150|Device|Remote Monitoring with Ambulatory Detox|"Each Subject willing to participate will sign an Informed Consent and will receive a Subject Number.~Study staff will assist Subject in setting up the Soberlink Device as well as the Bluetooth enabled blood pressure cuff and Smartphone APP.~Study staff documents Subject's resting and standing blood pressure and pulse to establish a safety range for the study.~Subjects will use the blood pressure cuff and the Soberlink Device four times a day per a set schedule to determine blood pressure and pulse and blood alcohol concentration (BAC). Results will be sent to the Soberlink System for study staff to review.~If the Subject misses a Soberlink test, tests positive for alcohol, or the identity cannot be approved, the staff will be immediately notified by the Soberlink System.~The Subject will be enrolled on a Monday and evaluated by the study physician and return to the site for an evaluation by the study physician and staff on Tuesday, and a final assessment on Thursday."
46017534|NCT03456726|Drug|Tazemetostat|Tazemetostat will be provided as a 200 mg oral tablet.
45466895|NCT03705741|Behavioral|Resistance exercise|Resistance exercise twice a week during pregnancy week 23-34.
45466896|NCT03790267|Other|Questionnaire administration|One questionnaire (Euro Quality 5 Dimensions, EQ-5D) for the general assessment of patient's health status will be administered to all the patients in the study. One joint-specific questionnaires will be administered to patients depending on the surgery procedure they will be undergoing. Hip disability and Osteoarthritis Outcome Score - Short Form (HOOS-PS) for patients undergoing hip replacement (6); Knee injury and Osteoarthritis Outcome Score - Short Form (KOOS-PS) for patients undergoing knee replacement (7); the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES), for patients undergoing shoulder implants.
46017535|NCT03434418|Drug|osimertinib|80 mg oral administration daily
46017536|NCT03377478|Drug|Epclusa|Patients testing positive for HCV viremia will receive 12 weeks of Epclusa.
46017537|NCT03181932|Drug|Vancomycin inhalation powder|100 participants are to be treated with double-blind vancomycin inhalation powder (75 subjects ≤21 years old, 25 subjects >21 years old) for 24 weeks during Period 1.
46017538|NCT03181932|Drug|Placebo inhalation powder|100 participants are to be treated with double-blind placebo (75 subjects ≤21 years old, 25 subjects >21 years old) for 24 weeks during Period 1.
46017539|NCT03181932|Drug|Vancomycin inhalation powder|In the 24-week Period 2, all participants are to be treated with open-label vancomycin inhalation powder.
45466897|NCT04474678|Other|"My Logbook! - I know my way around!"|"Special issues/booklets of My Logbook - I know my way around! - Every booklet is based on evidence-based interventions. It illustrates psychosocial and interdisciplinary processes in a standardized way, resulting in a practical guide (My Logbook) to accompany the child throughout all stages of oncological treatment."
45466898|NCT05681403|Drug|Improved BEAM regimen|Mitoxantrone hydrochloride liposome, carmostine, etoposide and cytarabine will be used as conditioning regimen for ASCT in the lymphoma patients.
45466899|NCT03784885|Biological|AD07010|A protein based adjuvant
45466900|NCT03784885|Biological|Inactivated trivalent influenza vaccine|Inactivated trivalent seasonal influenza vaccine
45466901|NCT04454632|Other|Mirror therapy|affected arm stay behind the mirror while exercising
45466902|NCT04454632|Other|Visual feedback|visual feedback from mirror
45466903|NCT05155683|Device|Photobiomodulation (PBM) with infrared LED|All participants will receive 30 minutes of PBM (or PBM sham), with an abdominal strap containing 4 LED clusters with 72 devices that emit 830 nm wavelength with 20 nm spectral width, in continuous operating mode, 5 mW average radiant power per LED, 71 mW/cm² power density at aperture, 20.4 cm² of total area irradiated, 71 mW/cm² of irradiance at target, exposure duration of 1800 seconds, 127.8 J/cm² of radiant exposure, 2.6 kJ of radiant energy, per contact application technique, twice a week for a month, totaling 8 sessions.
45598362|NCT02352909|Other|Exercise program|A home-based program including strengthening and motor control exercises will be prescribed. The program will include 4 different phases of 2 weeks.
46017540|NCT02864862|Device|Immediate implant|
46017541|NCT02864862|Biological|SCTG|
46017542|NCT02864862|Biological|ADM|
46017543|NCT02583672|Drug|N-acetylcysteine|1800mg NAC twice daily (3600mg/day) orally for approximately 90 days.
46017544|NCT02888730|Drug|Tobramycin nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of tobramycin twice a dayAmpoules of tobramycin are filled by 5 ml containing 300 mg of tobramycin and 11.25 mg of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete.Antibiotic retained for the study, tobramycin is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. The study's product will be prepared with Base Tobramycin and excipients in accordance with TOBI's composition."
45598363|NCT02352909|Other|Gait retraining|Running gait will be modified to reduce knee loading while running (step frequency, impact, foot strike pattern).
46101394|NCT00677144|Drug|OS (oxalipaltin+S-1)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days
46101395|NCT00677144|Drug|XELOX (oxalipaltin+capecitabine)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
46101396|NCT04151654|Other|Footwear Assessment Score|It was assessed using the Sharpened Romberg test and Single Leg Stance test for static balance. It was assessed Berg Balance Scale for dynamic balance, and Timed Up and Go test for functional performance. Balance and performance tests were done with and without footwear in all individuals.
46101397|NCT00664352|Drug|Mannose-6-Phosphate (Juvidex)|"100µL of 300mM (8.46 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest."
45466904|NCT05155683|Device|Low-frequency ultrasound (LOFU)|Subsequently the demarcation of the target area for LOFU treatment (Thoor DGM Electronica, Santo André, São Paulo, Brazil), the application of the neutral conductive gel will occur for the use of low-frequency ultrasound for 30 minutes, which will occur with 22 cm² effective radiating area (ERA) size, <8 BNR emission intensity, 40 kHz frequency, continuous mode, 60W, 100 cm² of total treated area, twice a week for a month, totaling 8 sessions.
46017545|NCT02888730|Drug|Physiologic serum nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of placebo (Nacl 0.9%) twice a day.Ampoules of placebo are filled by 5 ml containing of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete. Placebo for the study is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. Patients in placebo arm will receive 5ml of sodium chloride with the same color (light yellow transparent) as tobramycin"
45466905|NCT05155683|Device|Muscle electrostimulation|The session will end with 20 minutes of Russian Current (Tensor DGM Electronica, Santo André, São Paulo, Brazil), whose carrier frequency occurs in 2500 Hz, which will be adjusted according to the parameters described by Evangelista et al. (2003), which are: pulse frequency of 30 Hz; up/down ramp of 2 seconds each; support/rest time of 13 seconds each. The current intensity used will be the maximum supported by each participant and that is comfortable and sufficient to provide visible contraction. The treatment will consist of eight sessions that will occur twice a week, totaling a month of treatment.
46017546|NCT02058264|Drug|BBI-4000|
45466906|NCT01309009|Drug|Nepadutant oral solution|Oral administration once daily for 7 days
45466907|NCT01309009|Drug|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
45466908|NCT01309009|Drug|Nepadutant oral solution|Oral administration once daily for 7 days
46017547|NCT01696734|Drug|Domperidone|Given PO
46017548|NCT01696734|Other|Questionnaire Administration|Ancillary studies
46017549|NCT01598298|Drug|duloxetine hydrochloride|Given PO
46017550|NCT01598298|Other|placebo|Given PO
46017551|NCT02888652|Drug|antiplatelet agents(Clopidogrel or Ticagrelor)|Clinical physicians according to patients condition to give different antiplatelet agents(Clopidogrel or Ticagrelor).We only observe clinical curative effect.
46017552|NCT01235949|Biological|GSK1024850A (SynflorixTM)|Intramuscular injection, 4 doses
46017553|NCT01235949|Biological|Infanrix hexa|Intramuscular injection, 3 doses
46017554|NCT01235949|Biological|Infanrix-IPV/Hib|Intramuscular injection, 1 dose
46101398|NCT00664352|Drug|Mannose-6-Phosphate (Juvidex)|"100µL of 600mM(16.93 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest."
46017555|NCT01235949|Drug|Ibuprofen|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
45837885|NCT05573503|Other|Bring it up - Assessment and support of patients' sexuality in cancer nursing|"Participants will attend a five week online university course, Bring it up - Assessment and support of patients' sexuality in cancer nursing. The course addresses theories and models about sexuality in relation to cancer illness, conversation techniques, models for addressing sensitive topics, methods for assessing the impact of cancer on sexuality, methods for preventing and treating sexual problems in relation to cancer, relevant nursing interventions for person-centred counselling about sexuality, and ethical aspects.~The teaching consists of literature, online lectures, seminars, clinical practice, and written exams. A university certificate will be issued to participants who pass all exams."
45837886|NCT05572580|Other|questionnaire|the patients are asked to fill in a questionnaire
45837887|NCT05565196|Behavioral|Birth companions|The intervention will have the following components: 1) Orient facilities and providers to benefits of BC; 2) Develop/update formal standard operating procedures (SOP) for implementing BC and develop plans to implement SOP; 3) Assess data required for implementation and an audit and feedback cycle for tracking coverage; 4) Assess and carry out modest structural changes in facilities to facilitate BC; 5) Use human centered design to develop materials/resources and a means to distinguish/recognize the BC, taking into account common barriers and misconceptions; 6) Prepare providers to integrate BC into care team; 7) Orient ANC clients to BC rationale and selection; 8) Prepare BCs to support women; 9) Iterate model and track intervention/policies.
45837888|NCT05556226|Drug|ABBV-154 Dose Formulation A|Subcutaneous Injection
46101399|NCT00664352|Drug|Mannose-6-Phosphate (Juvidex)|"300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest."
46101400|NCT00664352|Drug|Mannose-6-Phophate (Juvidex)|"300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest."
46017556|NCT01235949|Drug|Paracetamol|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
46017557|NCT00691158|Drug|Pramlintide (Amylin)|4.7 mls of Amylin 15mcg/ml IV bolus.
46017558|NCT00691158|Drug|Placebo (Normal Saline)|4.7 mls normal saline IV bolus x1
46017559|NCT00691158|Drug|2 Metreleptin|Receive .06mg/kg of metreleptin IV bolus x1
46017560|NCT00691158|Drug|Leptin plus Pramlintide|receive leptin IV bolus x1 and pramlintide bolus at Timepoint +0 and +30 minutes.
46101401|NCT00664352|Drug|Placebo|"100µL of placebo will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~Standard Care (moist wound healing dressings alone) will be applied to the other 3cm2 donor site."
46017561|NCT01235793|Drug|Temozolomide|The DRBEAT regimen will be similar to RBEAM. Rituximab and Carmustine will be given Day -6. Etoposide and Cytarabine will be given on Days -5 to -2. Temozolomide will be given via divided doses over five days starting on Day -5 to Day -1. A dose escalation design, known as EWOC (Escalation with overdose control) will be used to determine the target dose of temozolomide for this study. The starting dose given over five days will begin at 250mg/m2 (cumulative total dose of 1250 mg/m2), as previous data indicates this to be a safe dose. Based on the reported Dose Limiting toxicities from the previous patients, the EWOC statistical modeling will be performed to determine the next dose level.
46101402|NCT04151810|Drug|CDP1|"Single-dose Phase: Cohort 1:400mg/m2;Cohort 2: 500mg/m2;Cohort 3: 750mg/m2;~Multi-dose Phase:Cohort 1 Dosing regimen is the first administration of 400mg/m2, followed by 250mg/m2/W;Cohort 2,3 Dosing regimen is the first administration of 500mg/m2, followed by 500mg/m2/2W."
46101403|NCT00703534|Drug|AZD3355|Immediate Release capsule administered as a single dose, 65mg, twice daily for 4 weeks
46101404|NCT00703534|Drug|Placebo|capsule. administered as a single dose twice daily for 4 weeks
45466909|NCT04325308|Procedure|Protein-enriched human milk diet|1.2 g of human-based protein will be added to each 100 ml of human milk administered
45466910|NCT04325308|Procedure|Usual human milk diet|Human-based protein will not be added to the human milk administered.
45466911|NCT04454398|Biological|COVI-GUARD|COVI-GUARD (STI-1499) is a monoclonal antibody which targets the COVID-19 spike protein
45466912|NCT04454398|Other|Standard of Care|Standard of Care as determined by the Investigator
45466913|NCT04454398|Drug|Placebo|Diluent
45837889|NCT05556226|Drug|ABBV-154 Dose Formulation B|Subcutaneous Injection
46017562|NCT01258998|Drug|Akt inhibitor MK2206|Given PO
46017563|NCT01258998|Other|laboratory biomarker analysis|Correlative studies
46101405|NCT00703534|Drug|Gelusil®|Chewable tablets taken as needed
46101406|NCT00503425|Drug|Rituximab [MabThera/Rituxan]|1000 mg IV on days 1 and 15
46101407|NCT00674180|Behavioral|Workbook|The workbook developed as a do-it-yourself program in which participants completed self-help sheets that guided them to sections of the workbook most salient to their needs.
46101408|NCT00674180|Behavioral|Computer Intervention|The computer intervention was provided using a network system that included a file server plus 5 multimedia computers with touch screens. The expert software program was written to guide participants in using the workbook and tail behavioral goals based on their prior computer use and the answers they provided on baseline questionnaires. The three primary paths in the computer addressed nutrition, fitness, and psychobehavioral content.
46017564|NCT05601648|Drug|Psilocybin|Psilocybin (25mg tablet) plus supportive psychotherapy
46101409|NCT00674180|Behavioral|Staff Consultation|The staff consultation component included 6 closed-group workshop sessions and up to 18 telephone or face-to-face consultations with a registered dietician and/or a cognitive behavioral therapist. The workshop curriculum focused on specific activities and assignments in the workbook, and it encouraged use of the computer to identify problems and issues.
46101410|NCT00664508|Procedure|Motion analysis|Motion analysis will be administered to each of the three groups: Lateral approach, anterior approach and posterior approach
46101411|NCT01013545|Behavioral|JAE Intervention|The overall goal in each session will be for the caregiver-child dyad to be in a state of supported or coordinated joint engagement. In this state the child is aware of the other's activity, and may actively coordinate their attention between an object/toy and the caregiver. The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist.
46101412|NCT00674258|Biological|URLC10, TTK and KOC1|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), TTK- peptide(1mg) and KOC1- peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
46017565|NCT01235715|Drug|Evicel fibrin sealant|Used for hemostasis to control bleeding. It has been shown to stop bleeding in 2 minutes or less. It is a combination of a biologic activated component containing human fibrinogen and topical thrombin functioning on wet, actively bleeding tissue.
46017566|NCT01235403|Drug|Lacosamide|"Lacosamide : 50 mg tablets bid. Titration phase: (12 weeks) 100 mg/day: duration 1 to 3 weeks. Then uptitration to optimal therapeutic dose of 200 mg/day to 400 mg/day, in steps of 100 mg/day and a time period per step of 1 to 3 weeks.~Maintenance phase (12 weeks): Optimal therapeutic dose 200 mg/day to 400 mg/day.~Taper phase if needed: 3 to 4 weeks"
46017567|NCT01024036|Drug|Siltuximab|Siltuximab 11 mg/kg will be administered by 1-hour intravenous infusion every 3 weeks
46017568|NCT01024036|Drug|Placebo|Placebo will be administered by 1-hour intravenous infusion every 3 weeks
46017569|NCT01024036|Drug|Best Supportive Care (BSC)|BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.
45466914|NCT04584086|Device|MRI 3 tesla|"1.5 Tesla MRIs, usually used as pre-treatment and, between 3 and 6 months after irradiation, are replaced in the study by 3 Tesla MRIs (pre-treatment and at 6 months)~In addition, two additional MRIs, also performed with a 3 Tesla magnetic field, will be performed:~During treatment when half of the prescribed dose has been delivered.~1 month after the end of the irradiation."
45680698|NCT01829360|Behavioral|Treatment (interactive book reading, dialogic reading, shared book reading)|Children receive 2 rounds of treatment with interactive book reading. Each treatment teaches 30 words that the children do not know. Treatments vary in dose (the number of times the words is heard/taught in an individual book reading session: 4 vs. 6 vs. 9) and dose frequency (the number of times book reading sessions are repeated: 4 vs. 6. vs. 9). Across all dose x dose frequency combinations, children hear/are taught the 30 words 36 times, which has been shown to be the adequate overall intensity of the intervention.
45680699|NCT01856114|Drug|Fentanyl Buccal Tablet|Fentanyl buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
46017570|NCT01234467|Drug|Bendamustine|Dosage Form: Intravenous (60 minute infusion) Dosage: 120mg/m2 (ECOG = 0-2) or 90mg/m2 (ECOG = 3) Frequency: Day 1 and Day 2; Every 3 weeks of a 21 day cycle. Duration: 3-6 Cycles
46017571|NCT01234467|Drug|Rituximab|Dosage form: Intravenous Dosage: 375 mg/m2 Frequency: Day 1 of every 3 weeks of a 21 day Cycle Duration: 3-6 Cycles
45466915|NCT03339453|Drug|Nasal Glucagon|Administered nasally
45466916|NCT03339453|Drug|Intramuscular Glucagon|Administered IM
45466917|NCT01306903|Device|MECC|Minimized extracorporeal circulation
45466918|NCT01306903|Device|MOPS|Modified and optimized perfusion system Frankfurt
45466919|NCT01306903|Device|Super MOPS|Super modified and optimized perfusion system Frankfurt
45466920|NCT04454164|Biological|PRP|platelet rich plasma
45466921|NCT04454164|Drug|Saline|serum physiologic
45680700|NCT01856114|Other|Placebo Buccal Tablet|Placebo buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
45680701|NCT01856114|Behavioral|Questionnaires|Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
45680702|NCT01855958|Procedure|DIMST|The investigators used electro acupuncture of 2 Hz during 30 minutes.
46017572|NCT04300036|Dietary Supplement|longan syrup|Subjects will take 15 ml of longan syrup once a day for 3 months
46017573|NCT04300036|Dietary Supplement|Placebo syrup|Subjects will take 15 ml of placebo syrup once a day for 3 months
45680703|NCT01855958|Procedure|Placebo-sham|Electro acupuncture with rubber electrodes, without current passing.
45680704|NCT01855412|Other|PAD endovascular treatments|All FDA-cleared endovascular PAD treatments
45680705|NCT01614470|Drug|Ivacaftor|150 mg tablet, oral use, administered twice a day (q12h)
46101413|NCT05598736|Device|FlowOx 2.0|-40mmHg intermittent negative pressure for 60 minutes per day
46101414|NCT00677222|Biological|AMI MultiStem®|AMI MultiStem® administered via catheter into peri-vascular space of the target vessel, 2-5 days post PCI. There will be 3 dose escalation cohorts, 6 patients per cohort.
46101415|NCT00863772|Biological|tanezumab|5 mg dose Intravenously every 8 weeks for duration of study
46101416|NCT00863772|Biological|tanezumab|10 mg dose Intravenously every 8 weeks for duration of study
46017574|NCT02875912|Behavioral|Family Care Rituals|"Family members being enrolled are given a pamphlet outlining the Family Care Rituals. They are informed of the opportunity to perform these rituals, but that they are in no way obligated to do so.~Family members are then surveyed at enrollment, and 90 days post ICU discharge for symptoms of PTSD, as well as depression, and anxiety.~Family members, day-time nursing, and attending physicians are surveyed for concordance of care at enrollment and ICU day 5.~Demographic information is also collected on the patient and the family members at enrollment Nursing completes surveys while the patient is in the ICU noting what care rituals, if any, are being performed. Additionally, they are asked to complete a survey indicating their opinion of the impact on the care they deliver"
45598364|NCT03132961|Other|Infrasound exposure|All cohorts will receive an identical infrasound exposure of equal time duration, varying only the order in which the testing is performed. To simulate the frequencies generated by a common source of environmental infrasound (wind turbines), recordings measured at a full-scale research wind turbine at the University of Minnesota will be utilized to create an infrasound stimulus. The resultant sound file consists of the fundamental frequency at approximately 0.7 Hz, equal to the blade passage rate, plus the harmonic overtones of the fundamental frequency. The presentation level is 85 dB SPL. The stimulus will be presented in a sound field.
46017575|NCT01233999|Drug|botulinum toxin A|Botulinum toxin A will be injected into participants hand total 40units
46017576|NCT01233687|Drug|AMG 102 and erlotinib|"Dose Level -2 Dose level -1 Dose Level 0 AMG 102 5 mg/kg 7.5 mg/kg 15 mg/kg Erlotinib 150 mg 150 mg 150 mg~The first cohort of patients in the phase I portion will start at dose level 0 of AMG102."
46017577|NCT01023958|Drug|BI 6727, IV infusion|phase II
46017578|NCT01233609|Drug|Valproic Acid|One to four 250mg softgels by mouth daily (dose determined by body weight)
46017579|NCT01233609|Drug|Placebo|Dosage per subject weight- same schedule as the active comparator
46017580|NCT01232283|Drug|Apremilast|Apremilast 30mg by mouth (PO) twice a day (BID) for 32 weeks
46017581|NCT01232283|Drug|Placebo|Identically matching placebo by mouth BID for first 16 weeks. Placebo participants will be switched to receive apremilast 30 mg BID at Week 16-32.
46017582|NCT01232283|Other|Topical or Phototherapy Therapy|Topical therapies such as low-potency or weak corticosteroids or phototherapies such as light therapy are added for non-responders at Week 32, (< PASI-50) and added to their treatment regimen. The decision to add these treatments during this phase can only be made at the Week 32 visit.
46017583|NCT01232127|Drug|Atazanavir|Capsule, oral, 300 mg, once daily, 10 days
46017584|NCT01232127|Drug|Atazanavir|Capsule, oral, 400 mg, once daily, 7 days
46101417|NCT00863772|Other|Placebo|Placebo, Intravenously, every 8 weeks for duration of study
46101418|NCT01015573|Device|magnetic sensor system to measure the movements of finger tapping|
46101419|NCT01010425|Drug|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 1, s.c., single-dose
46101420|NCT01010425|Drug|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 2, s.c., single-dose
46101421|NCT01010425|Drug|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 3, s.c., single-dose
45466922|NCT05418686|Biological|Capillary colchicine dosage in colchicine-resistant Familial Mediterranean Fever patients.|"Adherence to colchicine therapy will be assessed by the Girerd questionnaire (6 questions ) completed by the patient at the inclusion visit.~A blood sample (8ml) is taken, including a haemogram, CRP and creatinine and proteinuria.~Standard on-site stool analysis for C. difficile toxin.~For research purposes, samples of:~Stool. If the patient is unable to produce stools on the day of the visit, a collection kit with 2 tubes containing a preservative will be given to him/her as well as a stamped envelope to take the sample at home and send it by post within 10 days according to a validated procedure.~A strand of hair with the diameter of a pencil and a minimum length of 2 cm, in the region of the posterior vertex.~In patients with baldness or bleached hair only: pubic and/or axillary hair, a pencil-sized strand.~Additional blood (5ml) and urine (2ml) samples for colchicine determination."
45466923|NCT05418608|Drug|Radiotracer|A novel SV2A imaging tracer which is used in conjunction with positron emission tomography scans.
45466924|NCT01306981|Drug|Ranibizumab|Intravitreal injection of ranibizumab, 0.5mg in 0.05ml
46017585|NCT01232127|Drug|Ritonavir|Capsule, oral, 100 mg, once daily, 10 days
46017586|NCT01232127|Drug|Ritonavir|Capsule, oral, 100 mg, once daily, 7 days
46017587|NCT01232127|Drug|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 10 days
46017588|NCT01232127|Drug|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 7 days
46017589|NCT01232127|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 10 days
46017590|NCT01232127|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 7 days
45466925|NCT01306981|Drug|Saline|Subconjunctival injection of 0.05ml saline 0.9% w/v
45466926|NCT05236725|Device|Remote Blood Pressure Cuff|specialized, Bluetooth enabled BP monitoring cuff
46017591|NCT01232127|Drug|Famotidine (FAM)|Tablet, oral, 20 mg, twice daily, 7 days
46017592|NCT01232127|Drug|Famotidine (FAM)|Tablet, oral, 40 mg, twice daily, 7 days
46017593|NCT01258608|Drug|Mapatumumab|Mapatumumab will be supplied as a lyophilized formulation in 10 mL vials containing 100 mg mapatumumab for intravenous infusion at the dose of 30 mg/kg.
46017594|NCT01258608|Drug|Placebo|Normal saline solution for intravenous infusion will be administered as placebo for mapatumumab
46017595|NCT01258608|Drug|Sorafenib|Sorafenib will be supplied as tablets, each containing 274 mg sorafenib tosylate, equivalent to 200 mg of sorafenib, to be administered 400 mg (2 x 200 mg tablets) orally twice daily.
46101422|NCT01010425|Drug|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 4, s.c., single-dose
46101423|NCT01010425|Drug|Placebo|Placebo, s.c., single-dose
46101424|NCT01010425|Drug|Human Growth Hormone|Human Growth Hormone, s.c., daily for 7 days
46017596|NCT01015612|Device|Medtronic CoreValve® System|The Medtronic CoreValve® System device is designed to replace the native aortic valve without the requirement for open heart surgery and without concomitant surgical removal of the failed native valve in patients with symptomatic severe aortic stenosis who have an elevated surgical risk
46017597|NCT04319874|Drug|Ganoderma lucidum|Participants take ganoderma lucidum spore powder once a day, 1000mg
46017598|NCT04319874|Drug|Chemotherapy|Subjects are treated with conventional chemotherapy
46017599|NCT04319874|Drug|Placebos|Subjects are treated with conventional chemotherapy and Placebos once a day, 1000mg
45680706|NCT01614470|Drug|Placebo|oral use, administered twice a day (q12h)
45680707|NCT01880528|Drug|lisinopril|Given PO
45680708|NCT01880528|Drug|placebo|Given PO
45680709|NCT01854944|Drug|Brexpiprazole 1mg to 4mg|
45680710|NCT01829048|Drug|PF-02545920|15 mg (2 mg X 2d, 5 mg X 2d, 8 mg X 3 d, then 15 mg) Q12h
46017600|NCT01231659|Drug|Everolimus|Everolimus 10 mg (2 tablets of 5 mg) once daily
46017601|NCT01231659|Drug|Letrozole|Letrozole 2.5 mg once daily
46017602|NCT02875288|Drug|liposomal bupivicaine|"The intervention that is being tested and who will perform the procedures; Two general surgeons will perform the procedure with either liposomal or plain bupivacaine.~The treatment procedures or regimens; The treatment procedure is direct, surgical site infiltration with either liposomal or plain bupivacaine.~Dosage level and justification; Liposomal Bupivacaine: 266 mg/20 mL liposomal bupivacaine diluted to 30 mL Plain Bupivacaine: 30 mL of 0.5% plain bupivacaine~Route of drug administration; Surgical site infiltration"
46017603|NCT01054222|Drug|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 4 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
46017604|NCT01054222|Drug|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 8 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
46017605|NCT01052428|Drug|metoprolol succinate (Toprol XL)|Toprol XL 100 mg once a day for 2 years
46017606|NCT01052428|Drug|Placebo|Placebo 100 mg once a day for 2 years
45466927|NCT05236725|Device|Blood Pressure (BP) monitoring smart phone app, BabyScripts™|app that works with the monitoring cuff
45466928|NCT05236725|Behavioral|Instructions|Verbal and written instructions to conduct BP checks at home
45680711|NCT01829048|Drug|PF-02545920|15 mg (5 mg X 2d, 10 mg X 2d, then 15 mg) Q12h
45680712|NCT01829048|Drug|PF-02545920|15 mg (5 mg BID for 7 days 10 mg BID for 7 days, then 15 mg BID for 4 days) Q12h
45680713|NCT01829048|Drug|Placebo|Placebo Q12h
45680714|NCT01854710|Drug|ADASUVE 10 mg 2 doses 2 hours apart|Inhaled loxapine 10 mg 2 doses 2 hours apart
45680715|NCT01854710|Drug|Inhaled Placebo|Staccato placebo via inhalation x 2 at 2 hours apart
45680716|NCT01854710|Drug|Oral moxifloxacin 400 mg|Oral moxifloxacin 400 mg single dose
45680717|NCT01854710|Drug|Oral placebo|Oral capsule identical in appearance to moxifloxacin
45680718|NCT01828034|Drug|Gemcitabine|
45680719|NCT01828034|Drug|Cisplatin|
45680720|NCT01828034|Drug|MEK162|
45680721|NCT01853696|Drug|loteprednol etabonate|
45680722|NCT01853696|Drug|prednisolone acetate 1%|
45680723|NCT01871805|Drug|Alectinib|Participants will receive alectinib as described in the arm descriptions.
45680724|NCT04551807|Procedure|Modified natural cycle|This treatment protocol is defined as a modified natural cycle as the participant will be instructed to (1) administer human chorionic gonadotropin (hCG) to assist with timing of the embryo transfer and (2) supplement the luteal phase with a low dose of progesterone.
45598365|NCT02222597|Device|infrascanner|
45680725|NCT04551807|Procedure|Programmed cycle|This protocol is designated as programmed because the endometrial development occurs only in association with administration of estradiol and progesterone. No ovulation occurs due to suppression of follicle development by the estradiol and the timing of the transfer is based on the number of days elapsed following initiation of exogenous progesterone.
46017607|NCT01052272|Drug|Ramipril|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
46017608|NCT01052272|Drug|Candesartan cilexetil|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
46017609|NCT01052272|Drug|Allopurinol|The starting dose of Allopurinol is 300 mg daily.
45598366|NCT02356965|Drug|Ketamine|Single dose of sublingual investigational medication administered when subjects develop moderate to severe pain after third molar extraction.
46017610|NCT01257204|Drug|Placebo|Tablets, oral, 0 mg, once daily, for 24 weeks
46017611|NCT01257204|Drug|Daclatasvir|Tablets, oral, 60 mg, once daily, for 12, 16, or 24 weeks
46017612|NCT01257204|Drug|Pegylated interferon alfa-2a|Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks
46017613|NCT01257204|Drug|Ribavirin|Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks
46017614|NCT01231581|Drug|GSK1120212|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
46101425|NCT04914676|Drug|Cytarabine|Subjects on this arm will prospectively receive consolidation therapy with cytarabine. Subjects will be treated with 1000 mg/m2 cytarabine intravenously every 12 hours on Days 1-3 of each consolidation cycle. Subjects will receive up to four consolidation cycles.
46101426|NCT04914676|Drug|Cytarabine|Subjects on this arm will have received consolidation therapy with cytarabine between 2/1/2017 and 2/1/2019. Subjects will have received 1000 mg/m2 cytarabine intravenously every 12 hours on days 1, 3, and 5 of each consolidation cycle and will have received up to 4 consolidation cycles.
46017615|NCT01231581|Drug|Gemcitabine|Intravenous gemcitabine infused over 30 minutes weekly for 7 weeks followed by one week of rest from treatment. Subsequent cycles will consist of 1000 mg/m2 intravenous infusion over 30 minutes on days 1, 8, and 15 followed by 1 week of rest from treatment for each 28-day treatment period.
46101427|NCT00677300|Drug|Raltegravir|400mg P.O. (orally) twice daily for 48 weeks
46017616|NCT01231581|Drug|Placebo|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
46017617|NCT01050634|Drug|Aromasin (exemestane)|25mg oral tablet, daily, for >1yr
46017618|NCT01020526|Drug|pregabalin|Oral capsule 75-450 mg/day
46017619|NCT01020448|Drug|Triptorelin (Decapeptyl®)|One intramuscular injection of triptorelin (Decapeptyl®) 22.5mg performed once all baseline procedures and assessments have been completed.
46017620|NCT02872324|Other|Procurement questionnaires|
46017621|NCT02872168|Other|Not intervention|None. there is no modification in the treatment of patients. A urine collection is carry out in patients during the day of their enrolment.
46017622|NCT04286230|Behavioral|Adherence to oral antibiotics assessed by Questionnaire|The purpose of the BIOTICA-questionnaire is to detect individual barriers preventing the optimal intake of oral antibiotics and thus, leading to inadequate adherence or persistence to the regimen.
46101428|NCT00677300|Drug|Darunavir|800 mg P.O. (orally) once daily
46101429|NCT00677300|Drug|Ritonavir|100mg once daily
46101430|NCT00677300|Drug|Tenofovir/Emtricitabine|300 mg/200 mg P.O. (orally) once daily
46101431|NCT01013623|Procedure|Surgery|surgical resection to remove all known disease
46101432|NCT01013623|Procedure|Surgery plus 2 adjuvant doses of BCG|Patients in the surgical resection + BCG arm will have an additional two visits to receive BCG. The first dose of BCG will be given no earlier than 4 weeks after surgery, and the second BCG dose will follow 2 weeks later. The actual doses are determined by the patient's pre-study tuberculin-reactivity status. Patients with a pre-study PPD induration of ≥10 mm will be given half the normal dose of BCG. Those with PPD induration of ≥20 mm will be given 25% of the normal dose.
45466929|NCT01307059|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
45466930|NCT05418530|Other|with pause- without pause|start with pause expiration
45466931|NCT05418530|Other|without pause-with pause|start without pause expiration
46017623|NCT04286230|Behavioral|Persistence to oral antibiotics assessed by Questionnaire|The purpose of the BIOTICA-questionnaire is to detect individual barriers preventing the optimal intake of oral antibiotics and thus, leading to inadequate adherence or persistence to the regimen.
45466932|NCT05552157|Drug|Gantenerumab|Subcutaneously every 4 weeks at escalating doses
45466933|NCT05552157|Drug|Matching Placebo (Gantenerumab)|Subcutaneous injection of placebo every 4 weeks
46017624|NCT01256658|Drug|COA566|COA566 tablets or dispersible tablets twice daily during 3 days; dosage according to body weight.
46017625|NCT01256502|Device|SERI® Surgical Scaffold|Breast reconstruction surgery
46101433|NCT01013623|Other|best medical therapy|Patients randomized to the Best Medical Therapy arm will decide on a course of medical therapy based on what the patient's medical oncologists feels is best for the patient. Best systemic medical therapy may include clinical trials of new agents or standard non-protocol treatments. Patients who progress on the best medical treatment arm may switch to a different medical therapy or, if still appropriate, may receive surgery.
46101434|NCT05293678|Drug|REGN15160 (IV)|Administered in single intravenous (IV) dose
46101435|NCT05293678|Drug|Matching Placebo (IV)|Administered in single IV dose
45466934|NCT04211350|Device|NightBalance Sleep Position Trainer (SPT)|NightBalance Sleep Position Trainer (SPT) avoids POSA patients from sleeping on their back by delivering a vibrational stimulus, via a small device which is worn in a chest strap during sleep, each time the patient rolls to their back. This prompts the patient to roll over onto their side.
45466935|NCT04211350|Device|Automatic Positive Airway Pressure (APAP)|Automatic Positive Airway Pressure (APAP) is a pump that provides a positive flow of air to keep the airway open.
45680726|NCT01719861|Drug|Desipramine HCL|Desipramine is a tricyclic antidepressant (TCA). All patients will start off with a 25 mg dose by mouth nightly (QHS), increasing weekly for 6 weeks. The target dose level at 6 weeks is 450 mg (maximum dosage) or the maximum tolerated dose (MTD) for each subject.
45680727|NCT01853618|Drug|Tremelimumab|3.5 mg/kg or 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
45680728|NCT01853618|Procedure|RFA|Performed on Day 36
46101436|NCT05293678|Drug|REGN15160 (SC)|Administered in single subcutaneous (SC) dose
46101437|NCT05293678|Drug|Matching Placebo (SC)|Administered in single SC dose
45466936|NCT05076799|Drug|100 ml lactulose combined with 1 L PEG|the participants were instructed to consume 100 ml lactulose combined with 1000 mL of PEG solution
45466937|NCT05076799|Drug|100 ml lactulose combined with 2 L PEG|the participants were instructed to consume 100 ml lactulose combined with 2000 mL of PEG solution
45466938|NCT05076799|Drug|200 ml lactulose|the participants were instructed to consume 200 ml lactulose alone
45466939|NCT05076799|Drug|3 L Polyethylene glycol solution|the participants were instructed to consume 3000 mL of PEG solution
45466940|NCT03784495|Drug|Melatonin 1mg|1 mg/day 30 minutes before sleep
45466941|NCT03784495|Dietary Supplement|Essential Aminoacids (eAA)|4g/day of Essential Aminoacids during breakfast. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.
45466942|NCT03784495|Combination Product|Essential Aminoacids + melatonin|4g/day of Essential Aminoacids during breakfast + 1 mg/day of Melatonin 30 minutes before sleep. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.
46017626|NCT04319952|Device|Primary Total Hip Replacement with Metafix™ femoral stem and Trinity™ acetabular cup or TriFit-CF™/TriFit-TS™ femoral stem and Trinity™ acetabular cup implanted by a single surgeon.|The participant will undergo surgery using the hip prostheses and direct anterior surgical approach used by their surgeon-investigator. A patient-specific femoral guide, generated by the OPS™ Plan preoperatively, will be used during the surgical step of the femoral neck resection. These are not study specific procedures as the OPS™ Plan is already in use by the surgeon-investigator in their standard of care practice.
46017627|NCT01256190|Biological|Fibrocaps (fibrin sealant)|human thrombin and fibrinogen topical powder
46017628|NCT01256190|Device|Gelatin sponge|absorbable gelatin sponge for topical use
46017629|NCT01255722|Drug|iobitridol|single IV injection
46017630|NCT01255722|Drug|iopromide|Single IV injection
46017631|NCT01255722|Drug|iomeprol|Single IV injection
46017632|NCT02888574|Drug|Intranasal Oxytocin|Intranasal oxytocin (Syntocinon; Novartis, Switzerland)
46017633|NCT02888574|Drug|Placebo|Placebo nasal spray
45466943|NCT03784495|Other|Placebo|an isocaloric amount of maltodextrin with the same flavor and appearance as the intervention product
45598367|NCT02356965|Drug|Placebo (for Ketamine)|Sublingual sugar pill developed to mimic ketamine sublingual dose.
45598368|NCT02222675|Procedure|Sonography assisted breast surgery|
46101438|NCT01565317|Other|Weight Achievement and Intensive Treatment (Why WAIT)|Weight Achievement and Intensive Treatment (Why WAIT) is a 12 -week multidisciplinary program for weight control and intensive diabetes management designed by the Joslin Diabetes Center for application in a multidisciplinary diabetes practice environment. Participants will be enrolled in a 12-week multidisciplinary intensive weight management including diet, exercise, behavioral and educational support. Participants will be enrolled in cohorts of 10-15 participants to encourage group interaction and support. Subjects will choose to come to the Joslin clinic every Tuesday or Wednesday evening for 2 hours. Participants will exercise for an hour and will attend a didactic session in the areas of nutrition, exercise and behavioral modifications.
46017634|NCT01231503|Biological|GSK Biological's Investigational Malaria Vaccine 257049|3 doses, intramuscular (IM) route, in left antero-lateral thigh, as follows: 1) RTS,S Neo-10-14 Group at less than (=<) 7 days, at 10 and 14 weeks (wks) of age; 2) RTS,S Neo-10-26 Group =< 7 days, at 10 and 26 wks of age; 3) RTS,S 6-10-14 Group at 6, 10 and 14 wks of age; 4) RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 5) Engerix-B Neo/RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 6) RTS,S 10-14-26 Group at 10, 14 and 26 wks of age; 7) RTS,S 14-26-9M Group at 14 and 26 wks of age and at 9 months of age
46101439|NCT00674336|Procedure|High Hydrostatic Pressure Processing|High Hydrostatic Pressure Processing is a technology, used in the food service industry, where foods are subjected to high pressure. These high pressures kill many pathogens without affecting the quality of the food.
46017635|NCT01231503|Biological|Engerix-B|1 dose, intramuscular route: left antero-lateral thigh at birth (=< 7 days of age)
46017636|NCT01231503|Biological|Tritanrix HepB Hib|3 doses, intramuscular route: right antero-lateral thigh at 6, 10 and 14 weeks of age
46101440|NCT02628392|Drug|DS-8500a|DS-8500a tablets 25mg, 50mg, 75mg
46101441|NCT02628392|Drug|Sitagliptin|capsules
46101442|NCT02628392|Drug|placebo|matching DS-8500a tablets and sitagliptin capsules
46017637|NCT01231503|Biological|BCG|1 dose, intradermal route, in shoulder at birth (=< 7 days of age)
46017638|NCT01231503|Biological|OPV|4 doses, orally, at birth (=< 7 days of age) and at 6, 10 and 14 weeks of age
46017639|NCT01231503|Biological|Rouvax|1 dose, intramuscular (IM) route, in left antero-lateral thigh, at 9 months of age
46017640|NCT01230489|Biological|MediHoney|In this group a Medihoney 2 x 2 will be used in place of the standard dry 2 x 2 currently used as the wound dressing. Also all indentations of the wound will be filled with Medi-Honey ointment prior to the application of the dressing.
46017641|NCT01229397|Biological|Inflexal V|vaccination with Inflexal V 0.25 mL administered twice, 4 weeks apart
46017642|NCT01229397|Biological|Inflexal V|Inflexal V 0.5 mL administrated once only
46101443|NCT02622750|Procedure|triple-branched stent graft|place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
46101444|NCT02622750|Procedure|four-branched Dacron graft|"The stent elephant trunk was inserted into the true lumen of the distal aorta in a bound, compressed state after the distal aorta was transected between the origin of the left subclavian artery and the left carotid artery. The distal aorta incorporating the stent graft was firmly attached to the distal end of the four-branched Dacron graft using the open aortic procedure. After the anastomosis was completed, blood perfusion of the lower body was started via the perfusion limb of the four-branched Dacron graft."
46101445|NCT00664586|Drug|Terameprocol (EM-1421)|Weekly (3 of 4 consecutive weeks) 24 hour continuous intravenous infusion
46101446|NCT02628782|Device|InSeal's Vascular Closure Device|Intravascular closure device
45466944|NCT03045068|Biological|Platelet Transfusion|"Post CPB- Platelet transfusion 20ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion.~Initial transfusion to occur proximal to the hemofilter on the MUF circuit for as long as MUF lasts~Subsequent platelet transfusion continued till completion via central venous access to the patient"
45466945|NCT03045068|Biological|FFP and Cryoprecipitate|"1 unit of cryoprecipitate administered during MUF and or after MUF as needed~FFP transfusion 10ml/kg during MUF and or after MUF as needed"
45466946|NCT03045068|Biological|PRBC and cell saver Transfusion|1. Transfuse for target Hematocrit > 40 in neonates with SV physiology; Transfuse for Hematocrit> 33 for 2-Ventricle physiology
45680729|NCT01853618|Procedure|TACE|Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
45680730|NCT01853618|Procedure|Cryoablation|Performed on Day 36
46017643|NCT05492097|Behavioral|Exercise Therapy|Traditional exercise therapy and NMES
46017644|NCT05492097|Behavioral|Exercise Therapy and Robotic Walking Training|Traditional exercise therapy and Robotic Walking Training
46017645|NCT01228071|Drug|testosterone gel 2%|40 mg testosterone gel 2%
46017646|NCT04319289|Other|aerobic interval training and Vitamin D supplementation,|"The participants in both groups A will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age .~Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting HR~Frequency: 3 days/week., for 12 weeks~Also all participants in this group are taking gne capsule containing (cholecalciferol 400 IU) every day ."
46017647|NCT04319289|Drug|Vitamin D supplementation only|One capsule containing (cholecalciferol 400 IU) was taken every day .
45466947|NCT03045068|Biological|Factor Concentrate (Bebulin)|1. Based on clinical bleeding and achievement of hemostasis
45466948|NCT04120246|Drug|Alpha-tocopheryloxyacetic Acid|Given PO
45466949|NCT04120246|Biological|Trastuzumab|Given IV
45466952|NCT05288114|Device|Signal Relief Patch|Eligible subjects will be provided a Signal Relief patch, the instructions for use, and patch placement materials (adhesive, athletic tape, or wrap as applicable for the location of the pain). Subjects will be instructed to use the patch daily for seven days. The patch must be worn constantly except when showing or swimming.
45598369|NCT02222675|Procedure|Conventional breast surgery|
45598370|NCT04478955|Diagnostic Test|Schirmer test|Tear tests Meibomian gland grading test
45598371|NCT02359695|Drug|Growth Hormone|A dose of 0.5 IU of growth hormone will be administered daily from the first day of the agonist until the day of hCG administration
45598372|NCT02294539|Drug|Losartan 50mg/amlodipine 5mg|once daily, 1T, PO medication
46017648|NCT04319289|Other|aerobic interval training only|"The participants in group C will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age (Gellish ,2007).~Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting heart rate (Broderick et al.,2014).~Frequency: 3 days/week. The whole training lasting for 12 weeks"
46017649|NCT04319133|Behavioral|Fasting|Doing fasting 2 days a week within 8 weeks
46101447|NCT02614092|Behavioral|Water-based Activity + Cognitive Training|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
46101448|NCT00502801|Drug|doripenem|1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
46101449|NCT04154852|Drug|Adalimumab|
46101450|NCT04154852|Drug|Methotrexate|
46101451|NCT04154852|Drug|Placebo|Placebo to replace adalimumab
46101452|NCT04154852|Drug|Folic Acid|
46101453|NCT00677456|Procedure|R-Y reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.
46101454|NCT00677456|Procedure|P-Y reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the P-Y.
46101455|NCT00677456|Procedure|Pouch reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border, the distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.
46101456|NCT00677456|Procedure|P-I reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels.To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border,The pouch was 20 cm long, with a 10-cm jejunal loop with the P-I.
45598373|NCT02294539|Drug|Losartan 100mg/amlodipine 5mg|once daily, 1T, PO medication
46017650|NCT01008475|Drug|EMD 525797 250 mg|EMD 525797 will be administered at a target dose of 250 mg as a 1-hour intravenous infusion for every 2 week until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
46017651|NCT01008475|Drug|EMD 525797 500 mg|"Safety part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
46017652|NCT01008475|Drug|EMD 525797 750 mg|EMD 525797 will be administered at a target dose of 750 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
46017653|NCT01008475|Drug|EMD 525797 1000 mg|"Safety part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
46101457|NCT04127448|Other|Exergaming Training Group|"Training was given using X-box 360 Kinect. Dr. Kawashima's brain and body exercise game comprising of multiple cognitive games out of which 4 selected games were played by the participants. These games were Traffic control (participants have to guide the colored cars into their matching colored tunnels by using their arms), balloon buster (players pop numbered balloons in order from the lowest to the highest), pop till u drop, (match the color that appears on screen with the balloon of same color) and strike a pose (participant have to remember the poses shown and then copy them after few seconds). Games were played for 10 minutes initially then the duration was gradually increased to 30 minutes each session for 3 days/week and duration of 6 weeks. The session included 5-minute warm up, 20-minute interactive gaming, and 5-minute cool down."
45466953|NCT05581537|Other|Systematic Desensitization|"Systematic desensitization: 2 techniques~Jacobson's technique (progressive muscle relaxation):~It involves tensing and releasing muscles that progress through the body throughout focusing on mental relaxation throughout releasing muscle tension~Guided imagery (vividly imagining):~It includes 2 types of imagery training/mental practice (MP) which includes visual imagery is based on the sensory (visual) perception of the imagined movement and Kinesthetic imagery is based on sensory-motor information (proprioceptive). MP will be conducted in a quiet room, where each patient will be given detailed instructions to perform both visual and kinesthetic practice"
45466954|NCT02525510|Other|Pump Eligible - Normothermia - Pump Both Kidneys|Normothermia and Machine Perfusion Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery. Recovered kidneys will receive machine perfusion prior to implantation.OPO's protocol
45466955|NCT02525510|Other|Pump Eligible - Hypothermia and Pump Right Kidney|"Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Right Kidney will receive machine perfusion prior to implantation and the Left Kidney will receive cold storage.~Recovered kidneys will be placed in University of Wisconsin for cold storage until reimplantation."
45466956|NCT02525510|Other|Pump Eligible - Hypothermia and Pump Left Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Left Kidney will receive machine perfusion prior to implantation and the Right Kidney will receive cold storage.
46017654|NCT01008475|Drug|Cetuximab|"Safety part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m^2 on Day 8 (Week 2) once weekly until DLT.~Randomized part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m^2 on Day 8 (Week 2) once weekly until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
45598374|NCT02294539|Drug|Losartan 50mg/Hydrochlorothiazide 12.5mg|once daily, 1T, PO medication
45680731|NCT01853462|Other|PNF training|Ten individual PNF sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
46017655|NCT01008475|Drug|Irinotecan|"Safety part: Irinotecan will be administered at a dose of 180 mg/m^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: Irinotecan will be administered at a dose of 180 mg/m^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
45466957|NCT02525510|Other|Not Pump Eligible - Normothermia|"Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery.~Pulsatile Perfusion of kidney grafts based on the respective OPO's protocol"
45680732|NCT01853462|Other|Balance training|Ten individual balance sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
45680733|NCT01719783|Biological|LAIV H5N2|2 doses provided intranasally
45680734|NCT01719783|Other|Placebo|2 doses of placebo provided intranasally
45680735|NCT04415619|Procedure|Xenograft bone substitute (Osteo-biol)|Xenograft bone substitute will be placed over the implant to cover the bone defect after extraction.
45680736|NCT01853384|Biological|HP802-247|Study Dosage / Usage: 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days.
46101458|NCT04127448|Other|Aerobic Exercise Group|Session of 30-35 minutes, 3 days a week for 6 weeks was given using treadmill (model no TMX58 220). Time and intensity was gradually increased over the duration of 6 weeks. Starting from 10 minutes in 1st week, every 5 minutes was added to aerobics phase to each week until patient reached to 35 minutes in week 6 maintaining the intensity of 40-60% of heart rate reserve (%HRR).
46101459|NCT00664820|Dietary Supplement|Probiotic capsules containing Lactobacillus rhamnosus GR-1 and L. reuteri RC-14|2 capsules daily for 3 months.
46101460|NCT00921154|Drug|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods with a 14 day wash-out period. Doses will be administered after an overnight fast.
46101461|NCT04126902|Other|interleukin-6, presepsin and pentraxin-3|measurements and compare
46101462|NCT01015651|Drug|remifentanil|anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 2 ng/ml.
46101463|NCT01015651|Drug|remifentanil|anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 4 ng/ml.
46101464|NCT00677612|Biological|VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
46101465|NCT04127136|Behavioral|Multi-disciplinary obesity management therapy|In twenty weeks, trainings by the physician, dietitian, psychologist and physiotherapist are conducted about medical information about obesity, using the technology to aid weight loss, what, when, how and why to eat, nutrition groups, ration management, water consumption, self-awareness, stress management, obesity and the association between the psychological processes, warming up and mobilization, correct stance and posture, and adequate physical activity. In addition to group meetings, in monthly individual meetings, the progress of the patients are evaluated.
46101466|NCT00677768|Other|No intervention|Sample collection
45680737|NCT01853384|Other|HP802-247 Vehicle|HP802-247 Vehicle consists of two separate components, a fibrinogen solution (Component 1) and a cell free thrombin solution which is identical to Component 2 except that no keratinocytes and no fibroblasts are present. A single dose is created when combined on the wound surface.
46017656|NCT04294303|Other|web based telemonitoring system|Subjects in the telemonitoring group were given an iPad with installed iHealth application, a scale, and an electronic blood pressure monitor (a mobile web-based telemonitoring system). These devices were interconnected via Bluetooth. The iPad had permanent internet connection. Patients were taught to use the equipment to check and record their weight, blood pressure, and heart rate every morning, for 45 days after the hospital discharge. Data was automatically uploaded via iHealth application in a secure database.
46017657|NCT04294303|Other|Conventional|Subjects in the control group received the standard patient teaching, including an instruction to self-monitor their weight.
46017658|NCT02870725|Behavioral|CBT Individual Psychotherapy|The 4-session CBT treatment will include receipt of a manualized cognitive behavioral intervention, delivered individually, to treat the depression symptoms (e.g. cognitive restructuring, behavioral activation) and teach adaptive coping strategies to manage their depression. Ideally, the intervention will also positively affect their chronic headaches (i.e. reduction of headache frequency, severity and level of disability). Each session is approximately 60 minutes with specific, reflective and guided activities related to a specific module within the intervention.
46017659|NCT01226745|Drug|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.15 milligram (mg) in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
46017660|NCT01226745|Drug|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.10 mg in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
46017661|NCT01226745|Drug|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.05 mg in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
46017662|NCT01226745|Drug|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
45680738|NCT01878890|Drug|Efavirenz 600mg|Efavirenz 600 mg (oral daily intake)
45680739|NCT01878890|Drug|Efavirenz 1200 mg|Efavirenz 1200mg (oral daily intake)
45680740|NCT01878890|Drug|Efavirenz 1800 mg|Efavirenz 1800mg (oral daily intake)
45680741|NCT01878890|Drug|Efavirenz 2200 mg|Efavirenz 2200mg (oral daily intake)
45680742|NCT04415606|Device|QuikClot Control+|Non-absorbable, sterile, X-ray detectable non-woven dressing impregnated with kaolin.
45680743|NCT04596644|Drug|Cannabis|Investigates two strengths of cannabis.
45680744|NCT01827332|Drug|Oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
45837890|NCT05549765|Procedure|Pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.
45837891|NCT05549765|Procedure|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
46017663|NCT01226745|Drug|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
46017664|NCT01226745|Drug|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
46017665|NCT02870647|Other|Echocardiographic, polygraphy, electrocardiography measurements and sleep questionnaire|each patient is asked to undergo an echocardiographic, polygraphy, electrocardiography measurements, and respond to 2 sleep questionnaires, both at inclusion and after 6 months
46017666|NCT01226511|Drug|Duloxetine|Administered orally
46017667|NCT01226511|Drug|Placebo|Administered orally
46017668|NCT02691351|Other|Prospective Registry|"Survival and disease status follow-up at 1st primary treatment, 1st salvage treatment and 2nd salvage treatment~Regimen~Response Evaluation~SUSAR(Suspected, Unexpected, Serious, Adverse Reaction) collection"
46017669|NCT01226121|Biological|Clostridial collagenase injectable|Finger manipulation performed 1, 2, or 4 days following collagenase injection
46017670|NCT01226043|Drug|Insulin Glargine|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
46017671|NCT04206579|Drug|10% Dextrose|A mixture of 150 cc dextrose 10% in oral formulation
46017672|NCT04206579|Drug|Natrium Dextrose|A mixture of 150 cc dextrose 10% + 20 cc sodium in oral formulation
46017673|NCT01001377|Drug|Cetuximab|Administered by intravenous infusion
46017674|NCT01001377|Drug|Panitumumab|Administered by intravenous infusion
46017675|NCT01225887|Drug|Nintedanib|Given PO
46017676|NCT04326829|Drug|QL1604|QL1604, IV infusion
46017677|NCT01001299|Drug|Drug cocktail|Drug cocktail (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) orally once daily, day 1 and day 20
46017678|NCT01001299|Drug|RO5185426|960 mg orally twice daily
46101467|NCT04118478|Behavioral|multi-component phased training program|The experimental group will develop a program that consists of three progressive phases with the predominance of one physical quality over the others. The first phase will have as its main objective to develop strength, through exercises with overload and in turn, it will be subdivided into 3 blocks of 3 weeks each: Neuromuscular adaptation, muscular power, muscular resistance. The second phase will have as its main objective to develop cardiorespiratory capacity through intermittent gait training and, in turn, will be subdivided into 3 blocks of 3 weeks each: Static gait, dynamic gait and dynamic gait with changes of direction. The last phase will have as its main objective to develop balance and flexibility, by strengthening the stabilizing muscles and range of motion. In turn, this phase will be subdivided into 3 blocks of 3 weeks each: Balance / static flexibility, balance / dynamic flexibility and balance / flexibility with a double task.
46017679|NCT01296932|Drug|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.
46017680|NCT01296698|Drug|Placebo|Dosage Form: Oral NRT; Dose: 0 mg; Frequency: up to 4 times per hour; Duration: 12 weeks
46017681|NCT01296698|Drug|Nicotine|Dosage Form: Oral NRT; Dose: 1 mg;Frequency: up to four times per hour; Duration:12 weeks
46017682|NCT01001221|Drug|cabazitaxel|"Pharmaceutical form: 60 mg/1.5 ml concentrate solution for infusion~Route of administration: Intravenous infusion over 60 minutes~Dosage:~Study part 1: 15, 20 or 25 mg/m^2 according to pre-defined dose escalation schedule~Study part 2: MTD as determined in Study part 1"
46017683|NCT01001221|Drug|gemcitabine|"Pharmaceutical form: According to United States Package Insert (USPI)~Route of administration: Intravenous infusion over 30 minutes~Dosage:~Study part 1: 700, 900 or 1000 mg/m^2 according to pre-defined dose escalation schedule~Study part 2: MTD as determined in Study part 1."
46017684|NCT01296152|Drug|depo-medroxyprogesterone acetate|At study entry/ Day 0, participants will receive Depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
46017685|NCT04326608|Other|physiotherapy|manual therapy and sef-care exercises
46017686|NCT02870257|Other|Strengthening protocol with progressive load|Strengthening protocol for scapular and shoulder muscles
45466958|NCT02525510|Other|Not Pump Eligible - Hypothermia|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery.
46017687|NCT02870257|Other|Strengthening protocol without progressive load|Strengthening protocol for scapular and shoulder muscles
46017688|NCT04373317|Drug|Pimavanserin|Fixed-dose Pimavanserin - Pimavanserin is a new antipsychotic agent, and pure 5HT-2A inverse agonist, that was approved by the FDA recently (2016) for the treatment of PDP. It is the only FDA-approved medication for PDP, but is still not the first-line AP used in PD. All participants assigned to pimavanserin will receive the FDA-approved dose of 34 mg (equivalent to 40 mg pimavanserin tartrate) daily without titration up or down; however, because pimavanserin is blinded to quetiapine, participants will undergo sham titration based on tolerability (i.e., overall adverse event profile) and efficacy (i.e., improvement in severity of psychosis).
45837892|NCT05542758|Other|Total Body HIIT Program|One repetition maximums (1RM) and body weight (BW) will be recorded at prior to and at 6 weeks to tailor the program. The circuit will be completed twice during each session and the exercises will include: squats, medicine ball forward chest throws, medicine ball overhead throw, farmers walk, seated shoulder press, seated row sitting on a fitness ball, aerobic riser step-ups, foot ladder drills, and twisting medicine ball passes. The anaerobic component will be completed once during a session and on a stationary bike. The progression of exercise:rest seconds will be 20:40 for Weeks 1-4, 30:30 for Weeks 5-8, and 40:20 for Weeks 9-12. Each session will start with a 5 minute warm up and end with a 5-minute cool down. Participants will be given real time feedback about heart rate (goal range: 85-95% HRmax) and exercise movement velocity. Participants will be encouraged to surpass the velocity of the previous repetition.
45837893|NCT05534815|Behavioral|Employment-based abstinence reinforcement|Participants will earn stipends for working with the employment specialist and wage supplements for working in a community job, but the stipends and wage supplements will depend on providing drug-free urine samples.
45837894|NCT05532696|Drug|ABT-101|Patients will receive ABT-101 by oral administration on a 28 days cycle
46017689|NCT04373317|Drug|Quetiapine|"Flexible-dose Quetiapine - Quetiapine, which is a mixed serotonin and dopamine receptor antagonist, is by far the most commonly used AP for PDP. However, scientific evidence for the efficacy of quetiapine in PDP is almost non-existent as most of the studies were underpowered, had high drop-out rates, and possibly underdosed quetiapine. Quetiapine immediate and extended release will be titrated as shown:~Baseline visit Quetiapine: 25 mg IR QHS, All participants must be up-titrated to 50 mg/day Pimavanserin: 34 mg QHS~Week 1 call Quetiapine: 50 mg XR QHS, Up-titration to 50 mg Pimavanserin: 34 mg QHS~Week 3 visit Quetiapine: 100 mg XR QHS, Up-titration as appropriate Pimavanserin: 34 mg QHS~Week 5 visit Quetiapine: 150 mg XR QHS, Up- or down-titration as appropriate Pimavanserin: 34 mg QHS~Week 6 call Quetiapine: 200 mg XR QHS, Up- or down-titration as appropriate Pimavanserin: 34 mg QHS"
46101468|NCT00674414|Biological|trastuzumab|Trastuzumab (Herceptin®) IV once weekly
46101469|NCT00674414|Drug|everolimus|Oral everolimus once daily
46101470|NCT00674414|Procedure|therapeutic conventional surgery|Patients undergo surgery
46101471|NCT02613390|Procedure|Magnetic Resonance Imaging (MRI)|MRI images of the spine taken of anesthetized participant in the operative prone position.
45466959|NCT03905746|Other|blood sample at Day 0|"40mL blood (plasma and PBMCs) will be performed at D0 (inclusion), at the time of routine exams.~(20 ml will be used for study analyzes ; 20mL will constitute the biological collection)"
45837895|NCT05528302|Other|Tech-CBT intervention|The Tech-CBT intervention is a manualised package that incorporates Cognitive Behavioural Therapy methods.
45837896|NCT05527184|Drug|IMGN151|IMGN151 is an antibody-drug conjugate (ADC).
46101472|NCT02613390|Behavioral|Questionnaires|Pain and symptom questionnaires completed at baseline and at follow up.
46101473|NCT02566876|Drug|Mixture of three Bifidobacteria|This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 70 children with FD or IBS and will be articulated in 16 weeks as follows. Fifty-nine children (median age 11.2 years, range 5.2-17.9) with IBS and FD were randomized to receive either a mixture of three Bifidobacteria or a placebo for 6 weeks. At the end, after a 2-week-''washout'' period, each patient was switched to the other group and followed for 6 further weeks. At baseline and at follow-up, patients and/or their parents completed a dairy for bowel habit and gastrointestinal symptoms, and a quality of life (QoL) questionnaire.
45837897|NCT05520073|Dietary Supplement|Lactobacillus plantarum|Lactobacillus product 1 pack daily
45837898|NCT05520073|Dietary Supplement|Vitamin C|Vitamin C tablet 1 pack daily
46017690|NCT01002547|Drug|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
46017691|NCT01002547|Drug|pioglitazone|Pioglitazone will be started on 30 mg/day, titrated to the maximal dose (45 mg/day) at two months and continued at this dose for the rest of the clinical trial.
46017692|NCT01002547|Dietary Supplement|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
46101474|NCT00674648|Biological|CMV-Peptide-Specific T cells|"In this phase I trial, five escalating dose levels will be tested. Each dose will be administered to groups of at least 3 and up to 6 patients. Dose escalation will be based on the dose limiting toxicity (DLT) observed in each treatment group (Confer Biostatistics).~The patient groups and donors are outlined as follows: Group I will receive a single dose of 5 x 105 T cells/kg body weight/dose; Group II will receive a single dose of 1 x 106 T cells/kg/dose; and group III will receive a single dose of 2 x 106 T cells/kg/dose; group IV will receive 3 weekly doses of 1 x 106 T cells/kg/dose; group V will receive 3 weekly doses of 2 x 106 T cells/kg/dose."
45598375|NCT02294539|Drug|Losartan 100mg/Hydrochlorothiazide 25mg|once daily, 1T, PO medication
45837899|NCT05515692|Procedure|Biospecimen Collection|Correlative studies
45466960|NCT03905746|Other|blood sample at Day 2 and Day 7|20mL blood (plasma and PBMCs) will be performed at Day 2 and Day 7 from recruitment, at the time of routine exams. These two samples will constitute the biological collection.
45466961|NCT03905746|Other|stool sample at Day 0|stool sample (2mL) will be performed at D0 (inclusion), at the time of routine exams.
45466962|NCT01305967|Drug|SB injection|Infusion SBinjection of 21.87ml/m^2, Intravenous route, 16times for 2.5 months
45466963|NCT02318264|Device|Kinesio Tape|Elastic tape placed over the skin
46101475|NCT04063072|Procedure|ERAS protocol|In gynecological surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting, the omission of intestinal preparation, the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.
46017693|NCT01002547|Drug|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
46017694|NCT01002547|Dietary Supplement|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
45466964|NCT05659147|Diagnostic Test|Research MRI without administration of intravenous secretin|Participants will undergo a research MRI examination. MRI images will be quantitatively analyzed and will be compared to / used to predict diabetes.
46017695|NCT01002547|Drug|Vitamin E-placebo|Placebo of vitamin E will be given to arm 3.
46101476|NCT00824265|Drug|OFC Infusion|Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
45466965|NCT05659147|Diagnostic Test|Research MRI with administration of intravenous secretin|Participants will undergo a research MRI examination with intravenous administration of secretin. MRI images will be quantitatively analyzed and will be compared to / used to predict exocrine and endocrine pancreatic insufficiency based on the reference standards of ePFTs or fecal elastase and blood hemoglobin A1c (HbA1c) and fasting glucose, respectively.
46101477|NCT00824265|Drug|FC infusion|Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250mg/m2 Days 1-3 every 28 days for 6 cycles
46101478|NCT05570422|Drug|KRC-01|KRC-01 is a solution that contains hydrogen peroxide 3% with sodium hyaluronate 1%. Hydrogen peroxide is the active ingredient for this radiosensitizer.
46101479|NCT05570422|Radiation|External Beam Radiation Therapy|"Target definition for EBRT will be based on 3D imaging by computed tomography, positron emission tomography with computed tomography, or MRI.~Intensity-modulated radiotherapy (IMRT) must be used.~IMRT should be given once daily Monday-Friday, 5 fractions per week."
46101480|NCT05570422|Drug|cisplatin|"Weekly concomitant cisplatin (40 mg/m2) during EBRT~Neo-adjuvant chemotherapy or other forms of antineoplastic treatment apart from weekly concomitant cisplatin (40 mg/m2) are not allowed.~Adjuvant chemotherapy (after completion of EBRT+BT) is not allowed."
46101481|NCT05570422|Radiation|brachytherapy|"BT treatment planning will be based on 3D-image-guided BT by MRI.~Low-dose-rate, pulsed-dose-rate, or high-dose-rate BT"
46101482|NCT04155086|Biological|the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis|The detection of the risk of fetal trisomy 21 by blood tests by 2 tests : free fetal DNA circulant analysis and first trimester serum screening
46101483|NCT05272930|Drug|Dienogest|Assessment of fibromyalgia effects after the use of dienogest
46101484|NCT02628470|Procedure|cervical manipulation|cervical high-velocity low-amplitude thrust manipulation
45680745|NCT01827332|Drug|Saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
45680746|NCT01719003|Drug|Metformin 500 mg bid|Metformin 500 mg twice daily
45680747|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
45680748|NCT01719003|Drug|Empagliflozin low dose qd|Empagliflozin low dose once daily
45680749|NCT01719003|Drug|Empagliflozin high dose qd|Empagliflozin high dose once daily
45680750|NCT01719003|Drug|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
45680751|NCT01719003|Drug|Metformin 500 mg bid|Metformin 500 mg twice daily
45680752|NCT01719003|Drug|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
45680753|NCT01719003|Drug|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
45680754|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
46017696|NCT04295161|Drug|Abiraterone Acetate|Abiraterone acetate immediate release formulations
46017697|NCT04367623|Other|Brain computer interface based therapy|Participants who decide to take part will be assigned to a treatment or a control group. Both groups will have the same assessments and the same number of therapy sessions. Therapy group will have a training that consists of Brain Computer Interface controlled Functional Electrical Stimulation followed by a physical practice of the dominant upper limb, while the control group will have a physical practice only. One experimental session will last about 60 min for both groups (including setup and therapy) and participants in each group will receive 20 sessions, about 3 times per week. The expected time needed for completion of 20 sessions is 7 weeks
46017698|NCT05240911|Drug|Levothyroxine Sodium Tablets|For patients in experimental group, initial levothyroxine dose is calculated through the Poisson regression model; and for patients in comparator group, initial levothyroxine dose is calculated through 1.6 ug/kg/d.
46101485|NCT02628470|Procedure|cervical control exercises|Exercises of flexion, extension and rotation of the cervical spine
46101486|NCT02628470|Procedure|Oscillatory mobilization technique|Joint mobilization technique type III according Maitland
46101487|NCT00855894|Drug|Pertuzumab|After a single administration of a loading dose of 840 mg IV, patients received a maintenance dose of 420 mg IV every 3 weeks (q3w).
46101488|NCT00855894|Drug|Erlotinib|Patients received 150 mg orally once a day which was reduced to 100 mg orally once a day in a protocol amendment dated 19 May 2010.
46101489|NCT02566096|Drug|transversus abdominis-plane block with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine|compare the analgesic efficacy of transversus abdominis-plane block with bupivicaine with morphine in patients undergoing major abdominal cancer surgery.
46101490|NCT04482244|Drug|Cannabidiol|Liquid taken orally
46101491|NCT04482244|Other|Placebo|Liquid taken orally
46101492|NCT02622594|Drug|Aminolevulinic Acid (ALA)|
46101493|NCT02622594|Device|Environ Cosmetic Roller|
46101494|NCT02622594|Device|BLU-U IIlluminator|
46101495|NCT02628860|Drug|Ferinject (Ferric Carboxymaltose)|"Ferinject® to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50 Kg .~Study drug may be administered as IV drip infusion or IV undiluted bolus injection."
46101496|NCT04874272|Other|Chaplain led post-code debrief|an emotional debrief (a discussion to process the emotional, existential impact of a medical code/cardiopulmonary arrest), which will be led by a chaplain
46017699|NCT02870491|Behavioral|Free Distribution|Caretakers of children under 5-years-old will have access to free ORS and zinc
46017700|NCT02870491|Behavioral|Preemptive Delivery|Caretakers of children under 5-years-old will have ORS and zinc delivered to their home
46101497|NCT00674726|Other|Observation and measurement of axilo-rectal temperature|Measurement of axilo-rectal temperature
45466966|NCT05659147|Genetic|Genetic Sequencing|Blood will be drawn to enable gene sequencing for gene mutations associated with heritable pancreatitis. We will assess the association between identified gene variants and the presence of diabetes and will construct models based on identified variants to predict progression to diabetes.
46017701|NCT04452253|Dietary Supplement|PS128|PS128 belongs to Lactobacillus plantarum subsp. plantarumand. Probiotic capsules contain 10 billion CFU (colony forming units) of PS128
46017702|NCT04452253|Dietary Supplement|PS23 live|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23
45466967|NCT05659147|Diagnostic Test|Blood Tests|Research blood draw (for markers of pancreatic endocrine insufficiency)
45466968|NCT05659147|Diagnostic Test|Stool Tests|Research stool collection (for fecal elastase as a marker of exocrine insufficiency)
46017703|NCT04452253|Dietary Supplement|PS23 heat-treated|The PS23 heat-treated probiotic capsule contain 10 billion of PS23 cells.
46017704|NCT04452253|Other|Placebo|The placebo capsule contains microcrystalline cellulose.
46101498|NCT00855816|Behavioral|Breathing training|relaxation training
46101499|NCT04061668|Other|single needle path PECS I and II block group|The probe is placed inferior to the clavicle . The US probe is placed below outer third of the clavicle showing pectoralis major and minor muscles and the thoraco- acromial artery then moved infero-laterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised . The probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles ise identified at 4th rib at the level of thoraco-acromial artery , the needle is inserted in plane with the probe from caudal to cranial using an inclined manner, 15mL of bupivacaine is put into the potential space between pectoralis minor muscle and serratus muscle (PECS II) then it is withdrawn to inject another 15 ml of bupivacaine in the plane between pectoralis muscles . The block will be performed with needle introduced in-plane with the ultrasound probe, and the local anesthetic injection is visualised.
45466969|NCT05659147|Other|Survey Completion|Participants will be contacted to complete a survey and their charts will be reviewed annually after research MRI to identify any evidence of subsequent development of pancreatic endocrine insufficiency or progression of pancreatitis. Survey and chart review will occur within +/- 14 days of the anniversary date.
45466970|NCT05659147|Diagnostic Test|Endoscopic pancreatic function tests (ePFTs)|At least two duodenal fluid aspirates will be collected over 15 minutes following secretin administration. Aspirates will be immediately pH tested and will be submitted for analysis of bicarbonate, enzyme (trypsin, amylase, lipase, chymotrypsin) activity, and total protein.
45466971|NCT05659147|Drug|Secretin|"Participants enrolled in Aim 1, Aim 3, and Aim 4 will receive intravenous secretin at a dose of 0.2 mcg/kg (maximum 16 mcg).~Participants in Aim 1 will receive two doses (1 during endoscopy and 1 during MRI). Participants in Aim 3 will receive one dose during MRI.~Participants in Aim 4 will receive two doses (1 during each MRI).~Secretin for intravenous use is FDA-approved for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of exocrine pancreas dysfunction. Safety and effectiveness of secretin in pediatrics have not been established. However, secretin is routinely used in children at CCHMC at the same dose at which it will be administered for this study."
45466972|NCT01568372|Other|Telephone follow-up|The intervention group received a telephone follow-up by a nurse on the 1st, 3rd, 5th and 10th postoperative day.
45466973|NCT03784573|Behavioral|Dog + handler|Dog + handler
45466974|NCT03784573|Behavioral|No dog|No dog
45680755|NCT01719003|Drug|Metformin 500 mg bid|Metformin 500 mg twice daily
45680756|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
46017705|NCT04325659|Device|Bridge Device|An FDA-cleared neuromodulator medical device, marketed for the treatment of opioid withdrawal
46017706|NCT04325659|Drug|Lofexidine|FDA-approved medication for the treatment of opioid withdrawal. Participants will receive capsules 4 times daily for 7 days. The active dose is 0.72 mg four times daily for Days 1-5, for a total daily dose of 2.88 mg. Doses on Days 6 and 7 will be 1.44 (2 active, 2 placebo capsules) and 0.72 mg (1 active, 3 placebo capsules), respectively.
46017707|NCT04325659|Drug|Placebo|Inactive study drug, encapsulated to look like the active study drug. Participants will receive capsules 4 times daily for 7 days.
46101500|NCT04061668|Other|double needle path PECS I and II block group|The US probe will be initially placed below outer third of the clavicle after skin sterilization showing pectoralis major and minor muscles and the thoraco- acromial artery then moved inferolaterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised, then the needle will be inserted in plane with the probe and 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis muscles. In the second puncture , the US probe will be moved toward anterior axillary line till pectoralis minor and serratus anterior muscles will be identified at 4th rib at the level of thoraco-acromial artery then the needle will be inserted in plane with the probe from caudal to cranial in an inclined way, 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis minor muscle and serratus muscle (PECS II).
46101501|NCT00708357|Drug|NG-monomethyl-L-arginine|intravenous administration, bolus over 5 minutes, dosage 6mg/kg
45837900|NCT05515692|Procedure|Computed Tomography|Undergo radiotherapy simulation using CT
46017708|NCT04325659|Device|Sham Bridge Device|Inactive Bridge Device which is applied and looks identical to the active Bridge Device
46101502|NCT00664976|Procedure|Electroconvulsive therapy|Electroconvulsive therapy
46101503|NCT00664976|Other|Treatment as usual|Pharmacological antidepressant as usual in the departments: Mood stabilizers as Lithium, lamotrigine, valproate, quetiapine, carbamazepine and olanzapine. Antidepressants + Psychosocial treatment as usual.
46101504|NCT00855738|Drug|Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide|"Gabapentin: up to 3.600 mg/d~Lamotrigine: up to 400 mg/d~Levetiracetam: up to 3.000 mg/d~Pregabalin: up to 600 mg/d~Oxcarbazepine: up to 2.400 mg/d~Tiagabine: up to 30 mg/d~Topiramate: up to 400 mg/d~Zonisamide: up to 500 mg/d"
46017709|NCT04441099|Drug|NBE-002|NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.
46017710|NCT01225731|Biological|tildrakizumab|SC administration of tildrakizumab at assigned dose
46017711|NCT01225731|Drug|Placebo|SC administration of Placebo
46017712|NCT04296409|Other|Turkish Deglutition Handicap Index|Swallowing function will be evaluated by the Turkish Deglutition Handicap Index.
46101505|NCT02628158|Procedure|Vitrectomy with internal limiting membrane removal|Vitrectomy with removal of epiretinal membrane and internal limiting membrane
46101506|NCT02628002|Device|Antigravity treadmill (Alter-G)|Test arm subjects will exercise according to the Bruce protocol unweighted to 75% of their body weight with additional unweighting to 50% during the test if unable to reach target at 75% weight. Once these subjects have reached their target heart rate on the Bruce protocol, patients will receive the Tc-99m injection as per standard clinical protocol and maintain target heart rate for 1 minute following the injection.
45837901|NCT05515692|Combination Product|Electron Beam Therapy|Undergo electron beam radiotherapy
45837902|NCT05515692|Procedure|High Frequency Ultrasound Imaging|Undergo HFUS
45837903|NCT05515692|Other|Questionnaire Administration|Ancillary studies
45837904|NCT05515692|Radiation|Radiation Therapy Treatment Planning and Simulation|Undergo radiotherapy simulation using clinical setup
45837905|NCT05515692|Procedure|Skin Biopsy|Undergo biopsy
46017713|NCT04319211|Other|Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.|The study will include those who isolate themselves at home for fear of contracting Coronavirus disease or suspected of having it. The last three sections of the International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants. Parameters such as housework, home care and family care, rest, sports and leisure physical activities, sitting time will be evaluated. Short Form 12 (Short Form12- SF12) quality of life scale will be used to evaluate health-related quality of life. Beck Depression Scale will be applied to investigate the stress levels of the individuals participating in our study.
46017714|NCT04294927|Procedure|Risk-reducing salpingectomy with delayed oophorectomy|"BRCA1: RRS at age 25-40 and RRO at a maximum age of 45 (advised between 35 and 45).~BRCA2: RRS at age 25-45 and RRO at a maximum age of 50 (advised between age 40 and 50).~BRIP1, RAD51C, RAD51D: RRS at age 25-50 and RRO at a maximum age of 55 (advised between 45 and 55)"
46017715|NCT04294927|Procedure|Risk-reducing salpingo-oophorectomy|"BRCA1 at a maximum age of 40 (advised between age 35 and 40)~BRCA2 at a maximum age of 45 (advised between age 40 and 45)~BRIP1, RAD51C, RAD51D: at a maximum age of 50 (advised between 45 and 50)"
46017716|NCT01007149|Drug|omalizumab|Omalizumab was supplied in 5mL vials with solution for subcutaneous injection.
46017717|NCT01007149|Drug|Placebo|Placebo was supplied in vials with solution for subcutaneous injection.
45680757|NCT01719003|Drug|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
46017718|NCT04295083|Behavioral|clay based group study|"Clay based group work sessions were applied to the experimental group for 60-90 minutes once a week for 6 weeks. The sessions are composed of structured or semi-structured activities prepared for the purpose of the literature by the researcher for the purposes such as acquiring new solutions and life skills to reduce loneliness and hopelessness of individuals aged 65 and over, and sharing their feelings, thoughts, and memories with other individuals. Clay Study Activity Booklet . Four expert opinions were obtained for the booklet created. Methods such as narration, sharing experiences, group practice, question-answer, learning by doing, imagining were used in the activity program. The physical, psychological, social and mental characteristics of the elderly were taken into consideration in the selection of these methods."
46017719|NCT04433767|Drug|Transdermal Nicotine patch|"Participants will begin a 12- week open label trial of transdermal nicotine patch during the day and remove it at night (16 hours). Dose titration starting at 3.5 mg patch/daily to maximum of 21mg patch/daily.~After week 12 , dose will be slowly tapered over 3 weeks."
46101507|NCT02628002|Device|Conventional treadmill/regadenoson|Subjects randomized to the control arm will proceed with the clinical standard regadenoson pharmacological stress SPECT study with adjunctive low-intensity walk on conventional treadmill during regadenoson and Tc-99m injections if tolerated. If they are unable to tolerate any treadmill exercise, they will receive regadenoson and Tc-99m injections at rest. Study patients will have stable systemic blood pressure with readings equal to or greater than 90 mmHg systolic. Other inclusion and exclusion criteria are described in detail below.
46017720|NCT00998335|Drug|Long-acting bedtime insulin detemir (Levemir)|This group will receive Insulin detemir. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl.
46017721|NCT00998335|Drug|Insulin detemir and pre-meal insulin aspart.|This group will receive Insulin detemir plus aspart. The group will start with Insulin detemir at bedtime. Then in three months they will Insulin aspart before breakfast, lunch and dinner.
46017722|NCT04204681|Diagnostic Test|Ultrasonography imaging|This study aimed to measure the tongue areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue areas.
46017723|NCT02871505|Drug|Benzathine Penicillin G|
46017724|NCT01294670|Drug|Vorinostat and Etoposide|Patients will be assessed in 3-week cycles. Escalating doses of vorinostat will be administered orally on a daily x 4 schedule in combination with a fixed dose of etoposide. Etoposide will be administered intravenously daily x 3 days. Cohorts of 3-6 patients will be treated with vorinostat and etoposide. In the phase II component, patients will be treated at the RP2D established in the Phase I component of the study, which was found to be 270 mg/m2/dose of Vorinostat and 100 mg/m2/dose of Etoposide.
46017725|NCT01006603|Drug|Saxagliptin|5 mg, oral tablet, once daily
46017726|NCT01006603|Drug|Glimepiride|1, 2, 3, 4 or 6 mg, oral encapsulated tablet, once daily
45837906|NCT05512260|Device|Individual decision aid (iDA)|A web-based iDA (accessible online with various content), will be developed towards individuals approached to cancer screening, although public and accessible to all who are interested in cancer and screening. DAs in screening usually include information on the disease, screening, screening tests, benefits and harms and some value clarification exercise (e.g., interactive questions) aiming at shedding light on the individual´s values and preferences, knowledge and lifestyle.
45837907|NCT05510544|Drug|Plerixafor,G-CSF|"G-CSF: 10 μg/kg/day, subcutaneously injected, every morning from day 1 to day 8.~Plerixafor injection: 0.24 mg/kg/day, subcutaneous injection, starting on the 4th day, once a day, up to 4 times in a row. Plerixafor injection and G-CSF administration site should be separated. The interval between plerixafor injection and stem cell collection was 10-11 hours."
46017727|NCT02870335|Other|Manual Therapy|The patient remained lying on the gurney and the treatment was performed in the order set forth below and included: overall bilateral manipulation of L5-S1-Sacroiliac, subsequently decompression hip joint, the tibiofemoral decompression, stretching rotators hip flexion or hip and knee mobilization technique downing head and base of the fibula, tibiofibular-talus tali posteriorización decompression and with the help of a wedge to facilitate technical.
45680758|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
46101508|NCT00665054|Drug|Levitra (Vardenafil, BAY38-9456)|5, 10, or 20 mg Vardenafil tablets orally prior to sexual activity
46101509|NCT00665054|Drug|Placebo|Matching placebo tablets orally prior to sexual activity
45680759|NCT01719003|Drug|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
45837908|NCT05510492|Other|EDUCATION|THE EXPERIMENT GROUP WAS GIVEN THEORETICAL AND APPLIED EDUCATION,
45837909|NCT05510492|Other|APPLIED EDUCATION|"the injection was applied on the model by the researcher with the demonstration method according to the Procedure Steps of Intramuscular Injection with the Z Technique from the Ventrogluteal Region. This process was first ensured by the nurses, and then"
45837910|NCT05509699|Drug|Surufatinib|The recommended dosage is 250 mg orally once daily (QD) within 1 hour after breakfast for continuous administration.
45837911|NCT05509699|Drug|Anti-PD-1/L1|Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.
45837912|NCT05506618|Diagnostic Test|Nasal Swab|Collection of one more nasal swabs
45837913|NCT05506618|Diagnostic Test|Nasopharyngeal swab|Collection of one more nasopharyngeal swabs
45837914|NCT05505903|Diagnostic Test|Temerature measurement|Temerature measurement on admission to WBN or NICU
46017728|NCT02870335|Other|Proprioceptive neuromuscular facilitation|Stretching were conducted in the hamstrings, psoas, adductors, pyramidal, quadriceps and right above.
46101510|NCT02566798|Drug|Extract of grape and olive|"Patients are taking capsules of OleograpeSEED 3 times a day (1mg/day) in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7"
46017729|NCT02870569|Drug|Donafenib 200mg|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the lower dose one.
46101511|NCT02566798|Drug|Lactose|"Patients are taking capsules of placebo 3 times a day in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7"
46101512|NCT00674960|Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
46101513|NCT02622516|Other|Intervention Group (IG)|"Therapeutic approaches to this proposal are intended to promote muscle relaxation to increase range of motion and analgesia of neck and shoulder girdle region, as well as the fascial release these regions with the intervention of cervical global pompage, exercises for body mobility for upper limb and trunk in the positions supine, lateral and dorsal, sitting and standing and gradually followed by proprioceptive exercises to the lower limbs and trunk in sitting and standing positions with aid devices such as foams, pool baguettes, balance boards, Swiss balls, steps, trampolines and BOSU ( BOSU® Home Balance Trainer ).~The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members."
46101514|NCT02622516|Other|Control Group (CG)|"The exercises consist of eye movements in different directions, slow and fast; head movements in different planes, with open and closed eyes, slow and fast; and body exercises such as lifting and sit, walk open and closed eyes, up and down ramps and stairs, as well as some activities and ball games.~The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members."
45680760|NCT01853228|Drug|Phase1 and Phase 2: decitabine|20 mg/m2 administered by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of 28-day cycle)
45680761|NCT01853228|Drug|Phase 1: cytarabine|1 g/m2, 2 g/m2, and 1.5 g/m2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle) for the determination of the maximum tolerated dose
45680762|NCT01853228|Drug|Phase 2: cytarabine|Phase 1 maximum tolerated dose administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle)
46017730|NCT02870569|Drug|Donafenib 300mg|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the higher dose one.
46017731|NCT00997321|Drug|propofol|propofol 1 millgram per kilogram intravenous bolus followed by 0.5 milligrams per kilogram as needed for moderate procedural sedation
46101515|NCT04476862|Drug|Cerliponase Alfa|Commercially available product provided to patient by participating clinic site.
46101516|NCT04476862|Device|Administration Kit|Commercially available administration kit provided to the patient by participating clinic site.
46101517|NCT00675038|Procedure|Liver Biopsy and MRI T2* MRI|Evaluation of iron overload with liver biopsy vs. MRI T2* MRI
46017732|NCT00997321|Drug|Ketamine|ketamine milligram per kilogram followed by 0.5 milligrams per kilogram as need for moderate procedural sedation
46017733|NCT01294592|Drug|Dutasteride plus tamsulosin|Take 1 capsule daily
46101518|NCT02622672|Dietary Supplement|water-soluble ubiquinol|100 mg/d
46101519|NCT02622672|Dietary Supplement|Placebo|glycerin.soy-lecithin, and water
45680763|NCT01705587|Drug|teriparatide|20 microgram once-daily subcutaneous injection
45680764|NCT01718535|Device|Spartan FRX CYP2C19 Test System|
46017734|NCT01294592|Drug|tamsulosin|Take 1 capsule daily when escalation criteria met
45466975|NCT03632018|Behavioral|HEART-PLAY|Participants assigned to the HEART-PLAY intervention will receive standard CR. Additionally, they will receive pedometers, group education, and educational materials introduced by peer Health Coaches for 12 months. Before or after their regularly scheduled CR appointments, they will meet at the clinic as a group twice per week to receive Health Tips and participate in discussions. At 8 weeks in to the 12-week CR, they will begin to discuss with their peer Health Coaches the transition from the formal CR setting into community-based exercise. As part of this transition, peer Health Coaches will slowly introduce group community walks and train participants in the proper use of resistance bands. Health Coaches will have talk with their assigned participants about relapse prevention and sustaining exercise following the termination of formal CR.
45466976|NCT03632018|Behavioral|Standard Cardiac Rehabilitation|During the 12-week intervention period, the STANDARD intervention participants will receive standard of care by attending the 36 sessions of standard CR as prescribed by his/her physician and administered by the Step Clinic.
45680765|NCT01705509|Drug|Ranolazine|The intervention will be ranolazine therapy after the initial CPET. The initial CPET will identify patients with underlying ischemia and serve as a baseline study. Patients whose CPET results meet the criteria for ischemia will be started on Ranexa 500mg BID and advanced within one week +/-4 days to 1000mg BID. A second CPET will be performed after 4 weeks +/- 4 days of maximum therapy. CPET results before and after therapy will undergo a statistical comparison. The initial off treatment CPET measurement will serve as the control to assess changes found during therapy.
46101520|NCT04152122|Diagnostic Test|The dynamic stereopsis test|The characteristics of preoperative dynamic stereopsis in 83 intermittent exotropia patients and its associations with clinical features were analysed, and the prognosis was followed up on the 1st day and 2nd, 6th and 12nd months postoperatively.
46101521|NCT04118400|Procedure|NIV-NAVA|NAVA mode during Non-invasive ventilation
46101522|NCT04118400|Procedure|Nasal CPAP or NIMV mode|Nasal CPAP or NIMV mode during Non-invasive ventilation
45466977|NCT05152173|Biological|EN3835|Participant will receive a maximum dose of up to1.8mg of EN3835 injection
46101523|NCT02567734|Procedure|CT-guided percutaneous irreversible electroporation|Patients undergo the irreversible electroporation ablation that induce protracted cell death by apoptosis through cell membrane perforation.All these procedures will be performed under the guide of Big bore multislice spiral CT scanning system.
45466978|NCT05152173|Other|Placebo|Participant will receive a maximum dose of up to1.8mg of Placebo injection
45466979|NCT01307137|Behavioral|Peer-led intervention|"An expert patient in the peer-led intervention will provide effective support for patients and families to accelerate adoption of CER for diabetes prevention and management in the elderly. This will lead to better self-efficacy and clinical outcomes.~Those veterans enrolled in the MOVE! and HARC programs that have showed success in management of weight and Diabetes will be offered to become peer-leaders.~Weight management success is defined as a loss of at least 5% of the weight since enrollment~Diabetes management will be defined as adequate control of HbA1c and/ or blood pressure and lipids.~The potentials peer-leaders will have a pre-assessment test to evaluate diabetes prevention and management knowledge and motivation and support skills."
45466980|NCT01307137|Behavioral|Telehealth Intervention|Participants in the TAP group will receive mobile phones that will be programmed to monitor specific clinical parameters and promote adoption of CER on prevention and management of diabetes, with protocols developed in part based on the input from the focus groups. These devices display messages, tips, reminders and questions regarding healthy lifestyle and clinical parameters of diabetes, which will be developed using best practice guidelines. Participants will be asked to respond to the questions daily if they can. Also they are asked to provide their daily weight, blood pressure, and glucose levels (the later only for patients with diabetes).
46017735|NCT00997243|Biological|lintuzumab|Cycle 1 600mg as an IV infusion (flat dose for all), given on days 2, 7, 15, and 22. Subsequent Cycles (cycles to be repeated every 28 days) 600mg as an IV infusion, given every other week, twice during each cycle, including one dose given during AZA therapy. Doses should be given at least 12 days apart. By convention, dosing on days 7 and 22 of each cycle will be encouraged, but due to expected issues of patient convenience (time, travel, etc.), the study requirements are every other week, twice during each cycle, with one dose during AZA treatment.
46017736|NCT00997243|Drug|5-azacytidine|75mg/m2 IV/SC daily on days 1-7.
46017737|NCT02869321|Drug|Fentanyl|
46017738|NCT02869321|Drug|Morphine Sulfate|
46017739|NCT02869321|Drug|Fentanyl placebo|
46017740|NCT02869321|Drug|Morphine Sulfate placebo|
46017741|NCT02869321|Procedure|Gastrostomy|
46017742|NCT01294436|Drug|Dapagliflozin|Oral Dose 5 or 10 mg
46017743|NCT04293913|Behavioral|illustrated communication material|Illustrated communication material was introduced to the patients in the intervention group. In the process (intensive care) that patients received mechanical ventilation support after the operation, agitation and sedation levels were monitored by the intensive care nurse who was to communicate with the patient using the Richmond Agitation Sedation Scale (RASS). According to this scale, having minimum -2 and maximum +2 points was accepted as the starting criteria for communication (Sessler et al., 2002). Communication was established with the illustrated communication material.
46017744|NCT04293211|Other|Simulation|To measure the efficacy of adding a high-fidelity simulation versus low fidelity simulation to the current B-Con Course. This will be assessed by evaluation of applying tourniquets properly and packing traumatic wounds as well as retention of these skills over a period of time amongst school teachers and security personnel.
46017745|NCT02870413|Behavioral|Telelactation services|Mothers will get unlimited access (for a three month period) to video calls with lactation consultants who are available 24/7. Mothers can use the service as demanded.
46017746|NCT04296487|Other|autologous chondrocytes|autologous chondrocytes implantation (ACI)
46101524|NCT04152356|Drug|PD-1|PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti-autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
46017747|NCT02869243|Drug|hrBMP4|"Patients will undergo a resection or biopsy of the tumour, confirmation of viable malignant glioma tumour cells and intratumour/interstitial placement under neuronavigational guidance of 2 or 3 catheters.~Catheters will be placed during a second procedure a few days later based upon the patient's condition.~Patients will receive intra-tumour and interstitial CED of increasing amounts of hrBMP4 solutions (starting dose of 0.5 mg) and 1:70 gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) in a total of 44-66ml over up to 4-6 days. Gd-DTPA will be co-infused with BMP4 to determine the extent of intra-tumour and interstitial drug delivery. HrBMP4 will be delivered as a continuous infusion via the intracranial catheters."
46017748|NCT02870179|Device|Pulse Oximeter|Measurement of physiological parameters
46017749|NCT02869477|Other|Data collection|
46101525|NCT04152356|Drug|Sorafenib|Sorafenib tosylate is a novel multi-target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet-derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
46017750|NCT00995371|Device|MILD® (Minimally Invasive Lumbar Decompression)|Image guided minimally-invasive lumbar decompression performed with arthroscopic devices.
46017751|NCT00995371|Drug|Epidural Steroid Injection|An Epidural Steroid Injection is injected into the space around the spinal cord and nerve roots called epidural space.
46017752|NCT02869555|Other|Data collection|
46017753|NCT02870023|Other|Balance training|
46017754|NCT02870023|Other|Strength training|
46017755|NCT01294358|Drug|Gemcitabine|Gemcitabine starting dose was 18mg/m(2)/24h via infusion pump on days 1-14. One cycle = 4 weeks for up to six cycles. Three to six patients enrolled per dose cohort. Patients were dosed at successive higher doses until maximum tolerated dose or up to 165 mg/m(2)/24h.
46101526|NCT04271956|Biological|Tislelizumab|Cycle (q21d): Day 1: Tislelizumab i.v. 200 mg
46101527|NCT04271956|Drug|Zanubrutinib|Cycle (q21d): Zanubrutinib p.o. 160 mg twice a day
46101528|NCT00911924|Device|iStent|Glaukos iStent, medication
46101529|NCT05255146|Device|Atricure Inc. Nitrous oxide Cryoprobe|Cryoanalgesia will be given by applying a nitrous oxide-cooled probe (AtriCure, Inc. 2000) locally to intercostal nerves in the 4th, 5th, and 6th rib spaces after completion of the surgical repair and before surgical closure. The probe will be cooled to -60°C and held on each location for 60 sec.
46017756|NCT00994279|Behavioral|Yoga|Yoga sessions
46017757|NCT00994279|Behavioral|Education|Educational Wellness Group
46017758|NCT01294046|Device|Deep Brain Stimulation of SPG for Migraine|Deep Brain Stimulation of SPG for Migraine
46017759|NCT02869711|Other|Health care quality management|
46017760|NCT01224639|Biological|TDV - Low Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8 x 10^3 PFU, TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, and TDV-4: 2 x 10^5 PFU, total virus per dose 2.2 x 10^5 PFU
45466981|NCT03575156|Biological|blood sample|36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
45466982|NCT03575156|Biological|urine sample|6 ml
46017761|NCT01224639|Biological|TDV - High Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, and TDV-4: 3 x 10^5 PFU, total virus per dose : 4.7 x 10^5 PFU. TDV administered intradermally.
45466983|NCT03790423|Drug|Injection of 18F-ASIS|Each patient will receive one injection of 18F-ASIS (approximately 200 Mbq)
45466984|NCT03790423|Other|PET/CT scan|Following one injection of 18F-ASIS the patients will be PET/CT scanned at 1 hour, 2 hours and 4 hours post-injection
46101530|NCT02628080|Drug|Atovaquone|Atovaquone has an EU marketing authorisation (held by Glaxo Wellcome UK Ltd) and is indicated for acute treatment of mild to moderate Pneumocystis pneumonia (PCP). It is also used in combination with proguanil for malaria prophylaxis.
45466985|NCT02226536|Behavioral|fractioned diet without glucose|Patients were divided into two groups: Diet Group was treated with placebo pills and glucose restrictive and fractionated diet. Control Group received only placebo pills. All individuals had their vestibular function evaluated by Computerized Dynamic Posturography and done visual analogue scale (VAS) in the first day and 30 days after diet intervention
45466986|NCT05234697|Drug|Remifentanil|Remifentanil was used for maintenance of anesthesia.
45466987|NCT03784807|Diagnostic Test|synovial calprotectin, confocal laser microscopy|Calprotectin will be determined in synovial fluid of patients with septic and aseptic failure of their prosthesis. CLSM will be used to detect presence of microorganisms in synovial fluid. Susceptibility to antimicrobials of bacterial strains isolated from patients with prosthetic joint infections will be assessed using planktonic cells and biofilm associated bacteria
45466988|NCT03490760|Drug|Durvalumab|Durvalumab 1500 mg (or 20 mg/m2 if <30 kg) IV every 4 weeks
45466989|NCT03490760|Radiation|Radiation Therapy|24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.
45466990|NCT03790033|Drug|Ucha-Shinki-Hwan|"Product name : Bosinji Granule Manufacturer : Tsumura & Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)~Bosinji extract is composed of following proportion of ingredient~Rehmannia Root 1.7g Achyranthes Root 1.0g Cornus Fruit 1.0g Dioscorea Rhizome 1.0g Psyllium Husk 1.0g Alisma Rhizome 1.0g Hoelen 1.0g Moutan Root Bark 1.0g Cinnamon Bark 0.3g Pulvis Aconiti Tuberis Purificatum 0.3g"
46017762|NCT01224639|Biological|Placebo|Phosphate Buffered Saline (PBS)
45466991|NCT03790033|Drug|Placebo|placebo granule
45466992|NCT02133404|Drug|ASP7991|oral
45466993|NCT02133404|Drug|Cinacalcet|oral
46017763|NCT01293968|Drug|Ibuprofen, Diphenhydramine and Aluminium MgS|3 times daily for 3 days
46017764|NCT01293968|Drug|Diphenhydramine and Aluminium MgS|3 times daily for 3 days
46017765|NCT04324190|Behavioral|Guided online support program|"Guided online support program consisting of several modules; Module General information ... is an unspecific control module (providing general information on hygiene etc. with no expected effect on outcomes)"
46017766|NCT04324190|Behavioral|WHO recommendations (waiting condition)|"During the waiting period, a german translation of the WHO recommendations Coping with stress during the 2019-nCoV outbreak is provided"
46101531|NCT00490945|Drug|VEC-162|
45466994|NCT02133404|Drug|Placebo|oral
45466995|NCT05167305|Other|This is an observational study|This is an observational study
45466996|NCT01307215|Drug|Ropivacaine|20mLs of 0.5%
45466997|NCT01307215|Drug|Ropivacaine|30mLs of 0.33%
45466998|NCT01307215|Drug|Ropivacaine|40mLs of 0.25%
45466999|NCT02015936|Behavioral|Six Week Physical Activity Intervention|Tailored Wii Fit prescription based on physical fitness assessments and a schedule of six home visits by an oncology RN.
45467000|NCT02015936|Other|Progress Reporting|Participants will keep a log to record the physical activities they have done with the Wii Fit during the 6-week period. Audio-recording may be included for quality control. Self-report data will be collected by Internet surveys through the University of South Florida (USF) Health Qualtrics application at baseline (T1) and at 6 weeks post-intervention (T2). The nurse will take small amount of the participant's hair (20 strands) for a hormone test during the first visit and last visit.
46017767|NCT02869867|Other|refrigerated cushion|refrigerated cushion
46017768|NCT04292665|Behavioral|Classical Massage|During the first interview, a booklet explaining the introduction, purpose, benefits and application steps of hand-foot massage will be given to the patients in the classical massage group. Hand and foot massage will be applied to the patients for 30 minutes in the form of right hand five minutes, left hand five minutes, right foot ten minutes, left foot ten minutes, using liquid vaseline in each session twice a day in the patient's own bed with individual applied sessions by the researcher. Patients will receive a total of 14 sessions of classical massage, twice a day, for seven days.
45467001|NCT05574751|Other|Titanium tacker|Mesh fixation with Titanium tacker
45467002|NCT05574751|Other|Polypropylene 0|Mesh was sutured and fixed with polypropylene 0
45837915|NCT05501899|Drug|Levocarnitine|Adults, or patients ≥ 50 kg: 990 mg PO (by mouth) bis in die (BID, twice a day) Children, or patients < 50 kg: 50 mg/kg/day PO divided BID (maximum daily dose of 2,000 mg)
46101532|NCT00678158|Radiation|intensity modulated radiation therapy|Patients will be accrued at each dose level beginning at 22 Gy with increments of 2 Gy up to 28 Gy. Patients with a soft tissue mass, lymph nodes or focal bone metastases with lesions large enough to be imaged on CT scan will be accrued. Starting at 24 Gy, patients will be stratified in to 3 treatment categories: lesions involving bone, bowel, or spinal cord. Patients will be enrolled in each treatment category until 10 patients in that cohort reach an evaluable timepoint of 3 months post-RT. The maximum accrual is 20 for 22 Gy, and 90 (30 per treatment category) for each subsequent dose level (24-28 Gy). Some of these patients have participated in the optional FLT-PET scan portion of the study. Some of these patients have under gone an optional MRI scan which take place within one hour of the radiation treatment .
46101533|NCT00678236|Other|Refobacin Bone Cement R|Insertion of a knee prosthesis fixed by Refobacin Bone Cement R
46101534|NCT00678236|Other|Refobacin Plus Bone Cement|Insertion of a knee prosthesis fixed by Refobacin Plus Bone Cement
46101535|NCT04279093|Other|No intervention, but participants will use a smartphone app daily to complete the EPDS|No intervention, but participants will use a smartphone app daily (ClinTouch DAWN-P) to complete the Edinburgh Postnatal Depression Scale
45837916|NCT05500365|Procedure|Catheter ablation therapy|Pace mapping procedure performed during catheter ablation therapy
45837917|NCT05498493|Behavioral|Cognitive Rehabilitation|The virtual small group format will include two to five participants and one facilitator per group. The three individual sessions are distributed at the beginning, middle, and towards the end of the training program. Individual Session 1 occurs after Group Session 1. It covers orientation to the training program, including orientation to and clarification of the Participant Handbook. Individual Session 2 occurs after Group Session 5 and involves review and implementation of training strategies. Individual Session 3 occurs after Group Session 9 and covers review of learned strategies, implementation of training strategies in daily life, and review of execution, obstacles, and adjustments required for individual projects.
46017769|NCT04292665|Behavioral|Benson Relaxation Exercise|During the first interview, patients will be given a booklet explaining the description, purpose, benefits and application steps of the Benson relaxation exercise. With individual counseling sessions, a total of 14 sessions of Benson relaxation exercises will be performed in a quiet room, twice a day for seven days, each session lasting 20 minutes. At the beginning of the application, patients will focus on their breaths by taking slow and natural breaths with the researchers' commands and will quietly say to yourself the words of the focus, sound, sentence or prayer they choose, which are meaningful to them.
46017770|NCT04292665|Other|Control|Patients will continue to receive standard nursing care and no further intervention will be made during the research.
46017771|NCT01293032|Procedure|Neoadjuvant Therapy|Undergo neoadjuvant therapy
46017772|NCT01293032|Procedure|Therapeutic Conventional Surgery|Undergo therapeutic conventional surgery
46101536|NCT00678314|Drug|Ropivacaine 0.2%|10 ml
46101537|NCT00678314|Drug|Ropivacaine 0.75%|3 ml
46101538|NCT00678314|Drug|Normal saline|10 ml
45680766|NCT04551183|Other|Surgeons CT scan analysis|Surgeons extract diameter by hand (Gold Standard method) then realised a semi-manual segmentation of the images to extract volumes and diameters of the aorta (espacially AAA)
46017773|NCT01293032|Other|Laboratory Biomarker Analysis|Correlative studies
46017774|NCT01293032|Genetic|Gene Expression Analysis|"Undergo Oncotype Dx gene expression profiling. The Oncotype DX gene expression profiling system will be used to calculate a Recurrence Score (RS)."
46017775|NCT01293032|Drug|Systemic Chemotherapy|Undergo chemotherapy
45680767|NCT04551183|Device|PRAEVAorta CT scan analysis|CT scans are analysed by the software under investigation : PRAEVAorta. It will extract volumes and diameters of the aorta (AAA espacially)
46017776|NCT01293032|Drug|Tamoxifen Citrate|Undergo hormonal therapy
46017777|NCT01293032|Drug|Aromatase Inhibition Therapy|Undergo hormonal therapy
45680768|NCT01853072|Drug|Nepafenac Ophthalmic Suspension, 0.3%|Test intervention
45680769|NCT01853072|Other|Nepafenac vehicle|Inactive ingredients used as placebo comparator
45680770|NCT01853072|Drug|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
46017778|NCT01292876|Device|Extracellular Matrix|Extracellular Matrix
46017779|NCT01224171|Drug|vedolizumab|Vedolizumab for intravenous infusion
46017780|NCT01224171|Other|Placebo|Placebo intravenous infusion
46101539|NCT02566720|Drug|Amantadine|Participants will initially receive amantadine at the starting dose of 50mg twice daily either by mouth or feeding tube. The dosage will increase every week by 50mg twice daily (100mg total dose increase) up to the target dose of 200mg twice daily. These are the usual doses and rate of increase that are offered to patients with brain injury.
46101540|NCT02566720|Procedure|MRI Tractography Study|Participants will initially receive a baseline MRI Tractography scan. The size of RAS fiber tracts will be measured prior to initiating treatment and near the time of discharge from the rehabilitation hospital or at approximately ninety-days.
45680771|NCT04555785|Drug|Wilate|Wilate ® will be given with platelets in cases of severe bleeding. Wilate ® is a 1:1 balanced mixture of von Willebrand Factor (2'000 IU) and Coagulation factor VIII (2'000 IU) and as such has anti-haemorrhagic potential. It is extracted from plasma, freeze-dried and virus-inactivated.
45680772|NCT04555785|Other|Placebo|Empty placebo will be given with platelets in cases of severe bleeding.
45680773|NCT01877720|Device|noninvasive respiratory support with NAVA mode and PSV|
45680774|NCT01870869|Device|Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection|Surgical implant
45680775|NCT01877408|Procedure|Open surgical circumcision|Open surgical circumcision using a technique approved by the WHO (dorsal slit)
46101541|NCT04151576|Other|aromatherapy massage|aromatherapy massage
46101542|NCT00675194|Drug|Cisplatin, Irinotecan, Capecitabine|
46101543|NCT00665522|Drug|fentanyl iontophoretic transdermal system (40mcg) No Placebo|40 mcg per dose, maximum of 6 doses/hour
46101544|NCT00665522|Drug|IV PCA with standard of care opioid analgesia|total maximum 80 doses/24 hours
46101545|NCT00675272|Drug|hydrocortisone|hydrocortisone 50mg iv. every 6 hours
46101546|NCT00675272|Drug|sodium chloride|sodium chloride every 6 hours iv
45680776|NCT01877408|Device|Unicirc device with tissue adhesive|Removal of foreskin with Unicirc disposal device and wound sealing with tissue adhesive.
45680777|NCT01717287|Drug|Raltegravir Film-coated Tablet|
45680778|NCT01717287|Drug|Raltegravir Chewable Tablet|
45680779|NCT01717287|Drug|Other Anti-Retroviral Therapy|At baseline, the investigator selected the other anti-retroviral therapies to be used in combination with raltegravir based on current treatment guidelines, the participant's treatment history, and prior anti-retroviral resistance testing
45680780|NCT04605393|Drug|Cannabidiol|CBD
45680781|NCT04605393|Drug|Placebo|Placebo
45680782|NCT04605393|Drug|Delta-9-THC|THC
46017781|NCT01292486|Device|Spectra Optia Apheresis System|In this study, the safety and effectiveness of the new device will be assessed in two ways. First, MNC collections in growth-factor mobilized cancer patients will be evaluated to confirm that the Spectra Optia is able to collect stem cells. Second, following stem-cell collection and transplant, the number of days required for the collected hematopoetic stem cells to engraft/recover will be compared with historical COBE Spectra engraftment/recovery data.
46101547|NCT02566642|Other|educational material|pts coming to preadmission testing will view self administered tutorial on the role of anesthesiologist
46101548|NCT00912080|Genetic|genomic signature|genomic signature analysis
46101549|NCT00678548|Behavioral|Pleasant guided imagery|CD with pleasant guided imagery
46101550|NCT00678548|Behavioral|Pain diary|Filling out a pain diary
45680783|NCT01827254|Other|sunitinib: observational study|Observational study evaluating patients who were treated with sunitinib in 1st line and in 3rd line
45680784|NCT01824602|Drug|Eslicarbazepine acetate 1800 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
45680785|NCT01824602|Drug|Eslicarbazepine acetate 1200 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
46017782|NCT01223937|Drug|Desmopressin|
46017783|NCT01223937|Drug|Placebo|
46017784|NCT01290224|Other|scrambler therapy|Undergo MC5-A therapy
46017785|NCT01290224|Procedure|sham intervention|Undergo sham procedure
46017786|NCT01290224|Other|questionnaire administration|Ancillary studies
46101551|NCT02627612|Behavioral|Pro Vetus|Volunteer mentors (a mix of Veterans and non-Veterans) in the civilian community work with transitioning Veterans for approximately four months within five transition domains (1. Employment/Education, 2. Housing, 3. Family and Legal, 4. Social/Community/ Physical Fitness and 5. Medical Care).
45680786|NCT01824602|Drug|Eslicarbazepine acetate 600 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
45680787|NCT01824602|Drug|Placebo|Placebo sugar pills
45680788|NCT01704651|Drug|Alvimopan|Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative.
46017787|NCT01223235|Biological|bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821|A maximum of 6 doses of the polyvalent-KLH vaccine and OPT-821 will be administered to each patient as per the schedule. Bevacizumab will be administered once every two weeks until week 11 and then once every three weeks according to the schedule. When the 6 vaccinations of the polyvalent-KLH vaccine +OPT821 are completed, patients may still continue to receive bevacizumab on the once every three week schedule.
46017788|NCT01290068|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
46017789|NCT01290068|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
46017790|NCT01290068|Device|Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
46017791|NCT00998881|Drug|Teneligliptin 20 mg|
46017792|NCT00998881|Drug|Placebo|
46017793|NCT01222767|Drug|Zalypsis|Zalypsis is provided as a lyophilized powder for concentrate for solution for infusion in a strength of 2.5 mg/vial.
46017794|NCT00993967|Drug|idebenone|Idebenone 1350 mg/d, patients < or equal 45 kg Idebenone 2250 mg/d, patients > 45 kg
46017795|NCT04278079|Procedure|Pars Plana Vitrectomy with Internal Limiting Membrane peel|Pars plana vitrectomy with staining and peeling of internal limiting membrane
45467003|NCT05227365|Device|Lenire|The sound stimulus of PS6 is comprised of sequences of tones and is spectrally modified according to the participant's hearing thresholds so that different components of the sound stimulus can be sufficiently heard by the participant irrespective of their hearing characteristics (audiological profile). The tongue stimulus of PS6 is delivered by an array of electrical signals via 32 transmucosal electrodes contacting the anterodorsal surface of the tongue. The sound and tongue stimulus parameters are presented with certain stimulus rates and timing relationships between modalities.
45467004|NCT03485378|Radiation|Stereotactic Ablative Radiotherapy|Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease
45680789|NCT01704651|Drug|Placebo|Perioperative administration of placebo, at same dosing interval as study drug.
46017796|NCT04259359|Drug|Insect Venom|Patients will be treated with bee venom immunotherapy (protocol can be selected by patient). Blood samples are taken before starting VIT to determine specific immunoglobulin E (sIgE) Levels for bee venom components. Patients are sting challenged and the outcome will be recorded.
45467005|NCT03761056|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
45467006|NCT03761056|Drug|Fludarabine|Administered according to package insert
45680790|NCT04610294|Device|Functioning Aerus air filtration/sterilization|"Two units of Aerus air sterilization system will be used in each operating room, and each will be set to high. Units used for the trial will be modified internally to be active and will be sealed to prevent operating room personnel from opening the system and determining a unit's status."
46017797|NCT04204603|Drug|CKD-506|Tablets for oral administration
46017798|NCT04204603|Drug|Placebo|Tablets for oral administration
45837918|NCT05498493|Behavioral|Brain Health Education Program|The active control group will control for non-specific effects inherent to supervised CR. Participants will receive a manualized brain health education (BHE) training program, matched with the adapted CR intervention for therapist time and homework. Once these participants complete the 12 weeks of the control intervention and undergo the post-intervention assessments, participants will be offered the 12 weeks active intervention to ensure that all study participants have the potential of benefitting from CR.
45467007|NCT03761056|Drug|Cyclophosphamide|Administered according to package insert
45680791|NCT04610294|Device|Deactivated Aerus air filtration/sterilization|"Two units of Aerus air sterilization system will be used in each operating room, and each will be set to high. Units used for the trial will be modified internally to be inactivated and will be sealed to prevent operating room personnel from opening the system and determining a unit's status. Units will be inactivated by removing the activated carbon, high-efficiency particulate filter, and ionization chamber. However, the fan will remain active as will the run lights."
45837919|NCT05495126|Diagnostic Test|Standard Limbic Access pathway|Relevant information for clinical referral (e.g. demographics) and basic clinical information (e.g. PHQ-9 & Gad-7 scores) are collected during the self-referral process which is then attached to the referral notes in order to facilitate the clinical assessment conducted by the clinician.
46017799|NCT01222533|Drug|Tiotropium medium|Tiotropium inhalation solution medium dose
46017800|NCT01222533|Drug|Tiotropium low|Tiotropium inhalation solution low dose
46017801|NCT01222533|Drug|Tiotropium high|Tiotropium inhalation solution high dose
46017802|NCT01222533|Drug|Tiotropium 18mcg|Tiotropium inhalation powder 18mcg
46017803|NCT01222533|Drug|Tiotropium placebo|Placebo inhalation solution
46017804|NCT01221753|Drug|docetaxel|
45467008|NCT01307293|Behavioral|Cognitive behavior therapy|6 or 12 sessions of cognitive behavior therapy.
45467009|NCT05177601|Device|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of mood disorders.
46017805|NCT01221753|Drug|cisplatin|Given intravenously on day 1 of each cycle
46017806|NCT01221753|Drug|5-FU|
46017807|NCT01221753|Radiation|IMRT|
46017808|NCT01221753|Drug|cetuximab|
46017809|NCT01221753|Drug|carboplatin|
45467010|NCT05177601|Device|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
45467011|NCT05177601|Drug|D-cycloserine|Daily oral D-cycloserine 100mg during TMS treatments (20 days).
45467012|NCT05177601|Drug|Placebo oral capsule|Daily oral placebo during the TMS treatments (20 days).
45467013|NCT03420794|Other|Timing of pre-operative oral non-narcotic analgesics in relation to minimally invasive hysterectomy|Patients will be screened, enrolled, consented, and randomized during the preoperative office encounter, typically occurring within the 30 days prior to surgery. Patients randomized to pre-admission administration (study group) will be provided with a prescription for a one-time dosing of routine oral non-narcotic analgesic medications to be filled at the Cleveland Clinic outpatient pharmacy. Both the study and the control groups will receive written pre-operative instructions. Those patients randomized to the standard practice of administration in the pre-anesthesia unit (control group) will be administered the same medications in the same doses by the nursing staff. Patients in both groups will undergo general anesthesia, orogastric tube placement, and minimally invasive hysterectomy (MIH). Postoperatively, these patients will be observed for differences in PACU narcotic uptake, pain scores, patient satisfaction, and surgical recovery.
46017810|NCT01221597|Biological|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
46017811|NCT01221597|Biological|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
46017812|NCT01221363|Behavioral|Life style intervention|Reduction of sedentary behavior through theory-based individually tailored lifestyle intervention.
46017813|NCT01221285|Biological|German cockroach (Blattella germanica) allergenic extract|Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
46017814|NCT02888223|Biological|SCT800|
46017815|NCT02888223|Biological|Xyntha|
46017816|NCT01014988|Drug|zanamivir aqueous solution|Zanamivir aqueous solution 10mg/mL is a clear, colorless, single use, sterile non-preserved preparation containing 10mg of zanamivir in each milliliter, and made isotonic with sodium chloride. It is presented in 20mL clear glass vials closed with rubber stoppers. Each vial contains 200mg of zanamivir.
46017817|NCT04299724|Biological|Pathogen-specific aAPC|The subjects will receive three injections of 5x10^6 each Covid-19/aAPC vaccine via subcutaneous injections.
45467014|NCT01568450|Drug|Oxycodone|Oxycodone XL 20mg(20mg once a day, fasted)
45467015|NCT01568450|Drug|Oxycodone|Oxycodone XL 20mg/day(20mg once a day, after high fat meal)
45467016|NCT01568450|Drug|Oxycodone|Oxycodone 20mg/day (10mg twice a day, fasted)
45467017|NCT05144139|Biological|COVID-19 mRNA vaccine|Intramuscular injection, COVID-19 mRNA vaccine/placebo, 21 days interval
45467018|NCT05640895|Procedure|Intravitreal injection site|Intravitreal injections will be made at varying sites; patients will report on pain perception
46017818|NCT01014910|Other|Continuous pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive continuous pulse oximetry monitoring throughout their hospital stay regardless of their need for supplemental oxygen.
46101552|NCT02627612|Behavioral|Team Red, White, and Blue (TM RWB)|TM RWB is a 501(c)(3) non-profit, Veteran support organization found in 2010. Its mission is to enrich the lives of America's Veterans by connecting them to their community through physical and social activity. Central to TM RWB's mission is that inspiring Veterans to become physically active will create opportunities to establish authentic connections to other Veterans, active duty military, and civilians as well as improve the chances for continued successful integration. Enrollment in TM RWB takes place by simply signing up online and providing a name, email address, and zip code (teamrwb.org). TM RWB is not designed as a mental health intervention.
46017819|NCT01014910|Device|Intermittent pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive pulse oximetry monitoring during vital signs checks (every 4 hours) and as indicated clinically when not on supplemental oxygen. When patients require supplemental oxygen they will be continuously monitored by pulse oximetry until their oxygen requirement has resolved.
46101553|NCT05324956|Other|No intervention|Individuals will not receive any interventions
46101554|NCT00678626|Drug|CP-751,871|Docetaxel administered every 3 weeks. CP-751,871 administered every 3 weeks. CP-751,871 administration (20 mg/kg IV) will continue after the docetaxel is stopped.
46101555|NCT00678626|Drug|Docetaxel|Docetaxel only is administered every 3 weeks. After progression, administration with CP-751, 871 (20 mg/kg IV) is permitted.
46101556|NCT00678704|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 10 mg tablet prior to intercourse on demand
46101557|NCT00678704|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 20 mg tablet prior to intercourse on demand
46101558|NCT00678704|Drug|Placebo|Placebo tablet prior to intercourse on demand
46101559|NCT04739254|Diagnostic Test|CardioFlux|Magnetocardiography
45467019|NCT05279222|Other|Gait adaptability training|All patients will receive two gait training interventions, each consisting of twelve one hour training sessions. The training sessions will be focussed on improving gait capacity.
45467020|NCT03740542|Procedure|Esophagectomy|Surgical removal of part of esophagus
45467021|NCT03740542|Procedure|Pyloroplasty|pyloric drainage procedure
46101560|NCT00678782|Drug|etanercept|etanercept 12.5mg, intraarticular injection administered once every two weeks for an eight week period
46101561|NCT00678782|Drug|placebo|Placebo (NaCl) 0.5 ml intraarticular injection
46101562|NCT04707352|Drug|Dapagliflozin|All eligible subjects will receive Dapagliflozin 10 mg each day. The study treatment will be provided for the duration of the trial from baseline (Day 1) through last visit (Day 180).
46101563|NCT04152590|Device|Uincare|Interactive digital healthcare system
46101564|NCT00678938|Behavioral|Smoking abstinence oriented expert system intervention|Participants received up to three counselling letters targeting smoking cessation
46101565|NCT00678938|Behavioral|Smoking reduction oriented expert system intervention|Participants received up to three counselling letters targeting smoking reduction
46101566|NCT04061278|Drug|4 cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy|4 Cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy, instead of Concurrent Chemoradiotherapy
46101567|NCT04061278|Drug|3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy|3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy, instead of definitive radiotherapy
45467022|NCT05546073|Other|Advanced point-of-care technology|"The intervention consists of:~focused lung ultrasound scan(FLUS)~venous blood samples for leucocytes with 5-part differential count, creatinin, sodium, potassium, urea"
45467023|NCT03784339|Other|Physiotherapy + education|Participants will take part in a 30 minute education session surrounding fear of movement and catastrophizing thoughts. They will then receive standard care, which will involve strength exercises and taping if needed.
45467024|NCT03784339|Other|Physiotherapy|Standard physiotherapy care
45467025|NCT05410496|Drug|Tenofovir Alafenamide 25 MG|To assess the safety, efficacy, and drug adherence improvement of TAF switching therapy in kidney or liver transplant patients with HBV infection.
45467026|NCT05141409|Device|Artificial Intelligence|Artificial Intelligence
46101568|NCT00679094|Drug|Bowman-Birk inhibitor concentrate|Given orally
46101569|NCT00679094|Other|placebo|Given orally
46101570|NCT00679094|Other|pharmacological study|Correlative studies
46101571|NCT00679094|Other|laboratory biomarker analysis|Correlative studies
46101572|NCT04061200|Drug|Semaglutide, 1.34 mg/mL|After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks. Participants will be randomized and up titrated to semaglutide 1.34 mg/ml or matching placebo once weekly during the following 26 weeks in a 1:1 ratio.
46101573|NCT04061200|Other|Placebo, 1,34 mg/mL|Participants will be randomised to either semaglutide or placebo as an add on treatment after 26 weeks of intervention with empagliflozin 25 mg.
46101574|NCT04061200|Drug|Empagliflozin 25 MG|After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks.
46101575|NCT00675350|Drug|Omacetaxine|1.25 mg/m2 subcutaneous twice daily for 14 days
46101576|NCT02565862|Drug|Daclatasvir|
46101577|NCT02565862|Drug|Metformin|
45837920|NCT05495126|Diagnostic Test|Limbic Access with AI pathway|"The same information as in the Limbic Access pathway is collected. However, additional information (i.e. disorder specific questionnaires) are collected for the most likely problem descriptors based on the ML-model predictions.~All information is attached to the referral in order to facilitate the clinical assessment conducted by the clinician."
46017820|NCT04298866|Other|Experimental Arm|"3T MRI, maximum 1H30 long duration, including diffusion tensor imaging, susceptibility weighted imaging, multiparametric acquisitions, without contrast perfusion acquisitions.~7T MRI, maximum 1H30 long duration, including contrast enhanced acquisitions~Neuropsychological battery including chronometric measures obtained through a computer interface"
46017821|NCT02872480|Other|ACTIVE Training|Participants will be asked to complete aerobic exercise on a stationary bike during 30-minute sessions. Intensity will progress under a standard procedure for healthy participants (60-80% of VO2max) and as tolerated by concussed participants (starting at 60% of symptom exacerbation).
45467027|NCT03700606|Procedure|High flow nasal cannula|8 liters per minute of blended oxygen through Fisher Paykel Optiflow Jr 2 nasal prongs.
45467028|NCT03700606|Procedure|Nasal CPAP|Nasal continuous positive airway pressure of 5-7 cm/H20 delivered using Ventilator or bubble cpap device through short nasal prongs or a nasal face mask.
46017822|NCT04297930|Device|Paul Glaucoma Implant Surgery|This group of patients had glaucoma surgery with the Paul Glaucoma Implant
46017823|NCT01019980|Drug|Diclofenac potassium|Diclofenac potassium
46017824|NCT01019980|Drug|Acetaminophen|Acetaminophen
46017825|NCT00993499|Drug|BIBW 2992|Dose escalation (19-40 patients): low or high dose oral + 12 addit. pat. at MTD, until progression or undue AEs
46017826|NCT00993499|Drug|Sirolimus (rapamycin)|Dose escalation (19-40 patients): several dose levels + 12 addit. pat. at MTD until progression or undue AEs.
46101578|NCT04152278|Diagnostic Test|cervicovaginal culture and qPCR for chlamydial trachomatis and wadallia chondrophila|three cervicovaginal swabs were obtained: one was used for a smear test of vaginal fluid pH evaluation and direct microscopy, the second swabs, cultured for aerobic and anaerobic bacteria and yeasts, the third was eluted in 2-sucrose-phosphate (2SP) based transport medium. Placental samples from the study group were cultured for aerobic and anaerobic bacteria. Placenta sample and 2SP medium were stored at -80°C until their analysis by real time PCR (qPCR)
46017827|NCT04293367|Other|High Intensity Interval Training (HIIT)|"HIIT involves exercising in blocks of time (typically 4-5 minutes) where a small percentage of the time (typically 1 minute) is spent above the anaerobic (lactate) threshold (the work interval) followed by the remainder of the time at a sub-anaerobic threshold (active recovery)."
46101579|NCT00912314|Procedure|PTNS|Monthly PTNS after 12 weeks of weekly PTNS
46101580|NCT04060888|Drug|Ustekinumab (approximately 6 mg/kg)|Participants will receive ustekinumab approximately 6 milligram per kilogram via IV route based on body weight-range.
45467029|NCT03784105|Drug|Codeine Phosphate|30 mL of codeine phosphate 10mg/5mL
45467030|NCT03784105|Drug|Siripus simplex|Sugar syrup
45467031|NCT05044689|Behavioral|Questionnaire|Questionnaire containing questions regarding diet, physical activity, past medical history and life style practices.
45467032|NCT05044689|Device|Bioimpedance/Body Composition Unit|Patients will provide information on body composition through the use of a bioimpedance machine which measures the body mass index, fat and total body water.
45837921|NCT05489588|Device|GORE® VIAFORT Vascular Stent|Treatment of unilateral symptomatic iliofemoral venous obstruction with the GORE® VIAFORT Vascular Stent.
46017828|NCT01014442|Drug|mycophenolate mofetil|1.5 g PO BID from Days 2 to 30 post-transplantation, 1 g PO BID Days 31 to 90 post-transplantation
46017829|NCT00628264|Drug|AP214|Three AP214 bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
46017830|NCT00628264|Drug|Placebo|Three placebo bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
46017831|NCT04298398|Behavioral|Mindfulness Based-Cognitive Therapy (MBCT)|MBCT is a program developed by Zindel Segal, Mark Williams and John Teasdale. During MBCT patients learn to decenter their negative thoughts and feelings, allowing the mind to move from an automatic thought pattern to conscious emotional processing. Mindfulness practices included in this program are breath awareness, body scan, sitting and walking meditation, and mindful yoga. The intervention will have the following structure: 8 weekly face-to-face meetings of 2 hours in a group format, daily home-based practice of learned skills, 4 hours of retreat/intensive group work after the fifth week, 6 months of home practice, 4 monthly consolidation face-to-face sessions.
46017832|NCT04298398|Behavioral|Emotion Focused Therapy Group for Cancer Recovery (EFT-CR)|EFT-CR is an evidence-based approach to psychotherapy, which combines aspects of person-centered, gestalt and existential therapies with contemporary emotion theory and dialectical constructivism (Elliott et al, 2004, Rice & Greenberg, 1984). On EFT-CR, therapist follows the client experience and guides the process, proposing therapeutic tasks when specific client behaviors occur. EFT-CR uses a set of emotion change principles which guide a process of emotional deepening process, from undifferentiated distress to secondary reactive emotions to primary maladaptive emotions to core pain and thence to primary adaptive emotions and emotional transformation (Elliott & Greenberg 2016). The intervention will have the following structure: 8 weekly face-to-face meetings of 2 hours in a group format, daily home-based practice of learned skills, 4 hours of retreat/intensive group work after the fifth week, 6 months of home practice, 4 monthly consolidation face-to-face sessions.
46017833|NCT04298398|Other|Treatment as usual (no intervention)|Treatment as Usual is the condition in which participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral and intervention for people identified with significant distress difficulties.
46101581|NCT04060888|Drug|Ustekinumab 90 milligram (mg)|Participants will receive 90 mg ustekinumab via SC route.
46017834|NCT04297774|Behavioral|virtual reality treatment|18 virtual reality training through Pablo system (30 minutes a time, 2-3 times a week). Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. The controller was attached to lower extremity or trunk to control the game, such as elevator, hot air balloon, shooting cans, etc.
45467033|NCT05253560|Diagnostic Test|The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.|Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease
45467034|NCT05177523|Diagnostic Test|MRI|Each enrolled subject will undergo a MRI at baseline and a second MRI at 2 years (+/- 3 months) follow-up.
46101582|NCT04060888|Drug|Placebo|Participants will receive placebo matching to ustekinumab IV or SC.
46101583|NCT00879398|Drug|Toviaz treatment|4 mg starting then can be followed by 8 mg
46101584|NCT04061122|Diagnostic Test|airway epithelial smear test|all patients will be subjected to all scheduled procedures: airways epithelial smear test, measurement of VOCs in exhaled air and airways slide sample culture
45467035|NCT05177523|Other|Neurocognitive examination for healthy subjects|Neurocognitive examination for healthy subjects will be performed at both baseline and follow-up
46101585|NCT05197036|Procedure|Total Knee Arthroplasty|A surgical procedure to replace both the tibial and femoral articular surfaces with titanium prostheses.
46101586|NCT04031534|Drug|F-Miso PET scan coupled with MRI|Patient will undergo F-Miso PET and MRI before surgery for their head and neck cancer. Hypoxia detect with imaging will be correlated with hypoxia detected by immunohistochemistry on tumour biopsy
46017835|NCT04297774|Behavioral|standard treatment|18 standard rehabilitation sessions (60 minutes a time, 2-3 times a week). The rehabilitative protocol focus on strengthening, endurance training, ambulation, and ADL training that included: (1) Hip flexor and knee extensor strengthening with resistance progressing used by weight bag or Thera-band. (2) Cycle ergometer riding with increase speed and resistance. (3) Gait pattern and speed correcting through treadmill and parallel bar. (4) Hand functional training and strategy teaching for feeding, dressing, and toileting.
45467036|NCT05177523|Other|blood sampling|Each enrolled subject will undergo a blood sampling (10 ml) at baseline
46017836|NCT04297774|Behavioral|balance training|18 balance training sessions (30 minutes a time, 2-3 times a week) (1) Facilitated the balance reaction through weight shifting exercise with standing on even surface to uneven surface, such as tilting board.(2) Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. (3) Changed the standing requirement, such as single legged stance or lunge stance. (4) Increased perception complications through cognition or upper extremity task to improve dual task attention.
45467037|NCT03784183|Other|Cognitive Stimulation (CS)|CS consists of a wide range of structured activities aimed at the general improvement of social functioning and the maintenance of different cognitive functions. It is a non-specific in-group approach that places particular emphasis on social interactions.
45598376|NCT02356809|Drug|Neovasculgen|Neovasculgen is an original gene construction that contains supercoiled plasmid DNA (1.2 mg) that encodes pCMV-vegf165 as the active substance. The drug will be supplied to the study centre as a sterile lyophilisate that will be then dissolved in 2 ml of water for injections immediately prior to administration. The drug will be administered intramuscularly (interosseous muscles of hand) at 4-5 injection sites in the dorsal surface of the hand.
46017837|NCT00996307|Biological|MF59-eH1N1_f|3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
46017838|NCT00996307|Biological|MF59-eH1N1_f|7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
46017839|NCT00996307|Biological|MF59-eH1N1_f|15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
46017840|NCT00996307|Biological|MF59-eH1N1_f|7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
46017841|NCT04293835|Diagnostic Test|Whether to have intestinal-related disease|All patients pathologically diagnosed with sigmoid or rectal cancer in Peking University Third Hospital from January 2010 to December 2018 were included in our study as the cancer group.To evaluate the relationship between the height of the sigmoid take-off and all baseline covariates in normal patients, the results of 200 patients without any intestinal-related abnormalities who underwent pelvic MRI in our center from January 2019 to June 2019 were reviewed as a normal group.
46017842|NCT04293991|Device|High Flow Nasal Cannula|Evaluate the use of HFNC in prevention of intubation in immunocompromised patients adimitted to icu.
46017843|NCT04293991|Device|Non Invasive Ventilation|Evaluate the use of HFNC in prevention of intubation in immunocompromised patient admitted to icu.
46101587|NCT00679250|Drug|levocetirizine|5 mg once nightly before visit
46101588|NCT00679250|Drug|placebo to levocetirizine|1 tablet once nightly before visit
46101589|NCT00679328|Device|Surgical implantation of OP-1 device or autograft bone graft material|Surgical implantation of OP-1 device or autograft bone graft material
46101590|NCT00679406|Behavioral|Brief Behavioral Treatment for Insomnia|Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
46101591|NCT04150952|Other|HRV-based training|Intervention based on HRV-guided training for the performance improvement of athletes. Pre-competitive HRV, subjective effort perception, anxiety and mood will also be analysed.
46101592|NCT04150952|Other|TRAD training|Traditional endurance training
46017844|NCT04263337|Drug|[11C] PiB|Per study protocol static PET images will be acquired after IV infusion of CPiB to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
46017845|NCT04263337|Drug|[18F] PBR111|Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
46017846|NCT04263337|Drug|[18F] Flortaucipir|Per study protocol static PET images will be acquired after IV infusion of F-T807 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
45680792|NCT01876706|Device|UroLift® System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, and Canada. The UroLift® System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 50 years of age or older. During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
45680793|NCT04609592|Drug|Lutathera|4 administrations of 7.4 gigabecquerel (GBq) (200 mCi) 177Lu Dotatate +/ 10% at the date and time of infusion, accumulative dose of 29.6 GBq (800 mCi). T
46101593|NCT02627768|Drug|No Intervention|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab or a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy will be observed.
46101594|NCT00675662|Behavioral|Lifestyle intervention|Lifestyle intervention with Trim Tots pre-school programme.
46101595|NCT00675662|Behavioral|waiting list control|waiting list control
46101596|NCT00696436|Drug|Azilsartan medoxomil|"Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.~Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."
46101597|NCT00696436|Drug|Azilsartan medoxomil|"Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.~Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."
45680794|NCT04609592|Drug|Gallium 68 Dotatate|Standard of care, 2 Megabecquerel (MBq)/kg (0.054 mCi/kg) up to 200 MBq (5.4 mCi)
46101598|NCT00696436|Drug|Valsartan|"Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.~Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."
45680795|NCT04609592|Procedure|Computed Tomography (CT)|Medical Imaging
46017847|NCT02869165|Drug|Conjugated equine estrogen topical cream|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
46017848|NCT02869165|Drug|Apricot kernel oil|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
46017849|NCT04292041|Other|Fasting mimicking diet|"3 cycles of programmed nutrition using a fasting mimicking diet (Chemolieve (R)), each cycle consisting of 4 days. Pre and post nutritional cycles, clinical and metabolic assessments are taken, as per protocol. Allowing for a 3 month washout time, the 'post' assessment is planned approximately 6 months from the initial (pre) assessment."
46101599|NCT00696436|Drug|Olmesartan|"Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.~Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."
46101600|NCT00696436|Drug|Placebo|Matching placebo, orally, once daily for up to six weeks.
46017850|NCT00629161|Drug|Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)|12 months period of Traditional Chinese Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
46017851|NCT00629161|Drug|placebo|12 months period of placebo plus 1 month period without placebo
45598377|NCT02359617|Drug|insulin delivery|Subcutaneous insulin (100 U/ml, NovoRapid®; Novo Nordisk, Bagsvaerd, Denmark) delivery with an insulin pump (Vibe-TM; Animas Corp., West Chester, PA, USA) and an insulin infusion cannula (SOF-SET MICRO QR 6mm; Medtronic MiniMed, USA) placed at the same site as the continuous glucose sensor.
45598378|NCT02359617|Device|glucose sensing|Glucose sensing with a continuous glucose sensor (Dexcom G4 Platinum Sensor; Dexcom Inc., San Diego, USA) placed at the site of subcutaneous insulin delivery.
45680796|NCT04609592|Procedure|Magnetic Resonance Imaging (MRI)|Medical Imaging
45680797|NCT04609592|Procedure|PET/CT|Medical Imaging
46017852|NCT01219959|Drug|Dianeal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose
46017853|NCT01219959|Drug|Dianeal, Extraneal, Nutrineal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin
46017854|NCT00993421|Drug|LY377604|Given daily, orally for 24 weeks
46101601|NCT00878072|Drug|Famciclovir|Famciclovir 1500 mg (3 x 500 mg tablets) oral as a single dose.
46017855|NCT00993421|Drug|Sibutramine|given daily, orally for 24 weeks
46017856|NCT00993421|Drug|Metoprolol|given daily, orally for 24 weeks (100 mg for 1 week followed by 200 mg for 23 weeks. Patients unable to tolerate 200 mg will be dose reduced to 100 mg), followed by a 2 week taper (1 week at 100 mg/day followed by 1 week at 50 mg/day).
46101602|NCT00617435|Dietary Supplement|vaccenic acid enriched diet|"The experimental milk fat, entitled vaccenic acid enriched milk fat (VAMF), has been obtained by feeding cows with a diet containing sunflower oil."
45680798|NCT01876082|Drug|PAZOPANIB treatment|"Pazopanib~800 mg per day~oral administration~at least 1 hour before or 2 hours after a meal,~until disease progression or for 12 months maximum"
46101603|NCT00617435|Dietary Supplement|Elaidic acid enriched diet|Mixture of vegetable oils (including partially hydrogenated oils)
46101604|NCT00617435|Dietary Supplement|control diet|Mixed of different oil
45680799|NCT01876082|Drug|Active Comparator: Vinblastine and Methotrexate|Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
45680800|NCT01704495|Drug|AZD5069|AZD5069 oral capsules self-administered twice daily.
45680801|NCT01704495|Drug|Placebo|Placebo oral capsules self-administered twice daily.
46101605|NCT02627378|Other|Extracorporeal Membrane Oxygenation|Patients received veno-venous Extracorporeal Membrane Oxygenation (ECMO) support
46101606|NCT02627378|Other|Non Extracorporeal Membrane Oxygenation|Patients received no Extracorporeal Membrane Oxygenation (ECMO) support
46017857|NCT00993421|Drug|Placebo sibutramine|given daily, orally for 24 weeks
46017858|NCT00993421|Drug|Placebo Metoprolol|given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)
46017859|NCT00993421|Drug|Placebo LY377604|given daily, orally for 24 weeks
46017860|NCT04292509|Device|SAP with stop before low|cross-over comparison from stop on low to stop before low
46017861|NCT04292509|Device|SAP with stop on low|cross-over comparison from stop before low to stop on low
46017862|NCT02868853|Behavioral|Photo App|Use of a mobile photo app that takes pictures of foods consumed and allows users to share these pictures with other members of the study in order to receive feedback.
46101607|NCT00680420|Procedure|fine needle aspiration biopsy|One extra biopsy will be taken from the pancreas only in patients who are already undergoing biopsy of a mass or cyst.
46017863|NCT02868853|Behavioral|Diet App|Use of a mobile diet app that allows users to track all foods and beverages consumed in order to calculate the calories consumed each day.
46017864|NCT02868853|Behavioral|Podcasts|Listen to 2 podcasts per week about healthy eating and exercise.
46017865|NCT01014208|Drug|OFATUMUMAB + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
45680802|NCT01716663|Device|Catheter Ablation|NAVISTAR® THERMOCOOL® SF Catheter with the CARTO® 3 System and the SOUNDSTAR® Ultrasound Catheter (with the CARTOSOUND® Software Module)
46017866|NCT01014208|Drug|RITUXIMAB + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. rituximab dose: cycle 1, day 1 - 375 mg/m2; cycle 1, day 8 - 375 mg/m2; cycle 2, day 1 and cycle 3, day 1 - 375 mg/m2. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
46017867|NCT04205578|Drug|dl-3-n-butylphthalide (NBP)|25 mg of NBP in 100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
46017868|NCT04205578|Drug|Normal Saline 0.9% Infusion Solution|100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
46017869|NCT04297540|Device|Active-tDCS group|Active anodal-tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 1.5mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
46101608|NCT04150484|Other|Mediterranean diet, physical exercise and mindfulness workshops|a group of dietary intervention, physical exercise and mindfulness and another control group, and a longitudinal follow-up was carried out for 6 months from the beginning of the intervention.
46101609|NCT00675740|Drug|rosiglitazone|tablets 4 mg daily
46101610|NCT00675740|Behavioral|physical exercise|stationary bike 5-6 times a week
46101611|NCT00675740|Other|control|control without intervention
46101612|NCT03045341|Drug|NB medication (Naltrexone Bupropion combination)|NB medication
46101613|NCT03045341|Behavioral|Behavioral Weight Loss (BWL) counseling|BWL counseling
46101614|NCT03045341|Other|Placebo|Placebo
45598379|NCT02222909|Other|Co-developed IT intervention|The IT-based intervention is being co-developed with the community based organizations in the intervention group, and comprises tools to improve referral and tracking of clients, use of volunteers, and direct communication with hospital staff members
46017870|NCT04297540|Device|Sham-tDCS group|Sham -tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA but the current will be applied for 30 sec. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 0mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
46017871|NCT00628420|Drug|ACP-104|25mg, 75mg, 125mg, 175mg, 225mg, or 275mg once a day for 2 weeks
46017872|NCT00628420|Drug|ACP-104|Patient will be given either 50mg, 100mg, 150mg, 200mg, 250mg, or 300mg daily for 2 weeks
46017873|NCT00628420|Drug|Placebo|patients will be given a placebo: 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, 200mg, 225mg, 250mg, 275mg, or 300mg (to match the doses given) daily for 2 weeks.
46017874|NCT00991939|Drug|Dexamethasone USP Micronized|The dose for dexamethasone is 30 mg/day for patients < 60 kg and 40 mg/day for patients > 60 kg. The patient will be dosed on days 1-4, 15-18 and 29-32. On the remaining days during the treatment phase of the study, the patient will receive placebo capsules.
46101615|NCT00675818|Device|Continuous venvenous hemofiltration (CVVH)|Continuous venovenous hemofiltration with a replacement fluid rate of 35 mL/kg/hr.
46101616|NCT00675818|Device|Continuous venovenous hemodialysis (CVVHD)|Continuous venovenous hemodialysis at a dialysate flow rate of 35 mL/kg/hr.
45598380|NCT02359539|Procedure|Regenerative therapy|Periosteal pedicle, Platelets rich fibrin
45680803|NCT04604301|Device|Celtra Quatro|Full ceramic crowns will be made from the high strength ceramic, Celtra Quatro
45680804|NCT01716585|Drug|ABT-450/r/ABT-267, ABT-333|ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
45680805|NCT01716585|Drug|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
45680806|NCT01716585|Drug|Placebo for ABT-450/r/ABT-267|Tablet
45598381|NCT02291263|Biological|bOPV/IPV (6 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 6 weeks of age
45598382|NCT02291263|Biological|bOPV/IPV (14 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 14 weeks of age
45598383|NCT02291263|Biological|bOPV/IPV (6 & 14 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 6 and14 weeks of age
45680807|NCT01716585|Drug|Placebo for ABT-333|Tablet
46017875|NCT00991939|Drug|Prednisone|Prednisone will be administered to study patients at a dose of 60 mg/day for patients less than 60 kg and 80 mg/day for patients > 60 kg for 21 days. The following schedule for tapering of prednisone will be used: after three weeks of treatment at either 60 mg/day (for patients < 60 kg) or 80 mg/day (for patients ≥ 60 kg), the dose will be reduced to 40 mg/day for 1 week, then 20 mg/day for 1 week, then 10 mg/day for 1 week, then 5 mg/day for 1 week and then stopped. Placebo capsules will be added as necessary during the treatment phase of the study, to maintain blinding.
45467038|NCT05177445|Combination Product|Phototherapy|"Prior to the beginning of the procedure the patient will be administered a nasal decongestant. Second to this, the patient will be advised to blow his/her nose. This step allows the physician a better view and allows the light exposure to reach the majority of the nasal mucosa(9).~To start the intervention the physician will introduce the phototherapy device inside the patient's nasal cavity as the patient sits in an upright condition. As the procedure is ongoing the physician will slightly rotate the device in order to minimize dryness and to irradiate all the nasal cavity. After the intervention the patient will be administered an emollient/moisturizing drug to further hydrate the nasal mucosa(9).~The intervention will have a crescent duration, the first one will be only two minutes and the following ones will increase 15 seconds each until a plateau is reached at 3 minutes in the 5th intervention."
45467039|NCT05177445|Combination Product|OT+Corticosteroids|Patients that present loss of smell 4 weeks after their coronavirus-19 infection and that have had a real-time polymerase chain reaction (reverse transcriptase polymerase chain reaction )and both oral corticosteroids (prednisone 40mg) and olfactory training will be applied, in the intervals of daily for 10 days and daily for the duration of the study respectively.
46101617|NCT00679484|Drug|olmesartan medoxomil + candesartan cilexetil placebo|Dosage form: tablet; frequency: daily; duration: 24 weeks
46101618|NCT00679484|Drug|olmesartan medoxomil placebo + candesartan cilexetil|Dosage form: tablets; frequency: daily; duration: 24 weeks
46017876|NCT04293445|Diagnostic Test|spirometry, FOT, Induced sputum, bloods, nasal brushes, nasal lavage, skin prick, throat swab|At the point of baseline visit, exacerbation and annual visit, the above tests will be performed to allow comparison of a participants profile before and during an exacerbation
46101619|NCT04214483|Other|No intervention|There is no intervention for this study.
45467040|NCT04563884|Other|Questionnaires|"Children 12 months to 5 years old will receive PEACH alone, children 5 years old to 11 years old will receive PEACH and SSQ-P, and children and adolescents over 11 years old will receive SSQ-P and SSQ-C (even between 11 and 13 years old, the PEACH also).~Questionnaires will be completed twice, 15 days apart."
45467041|NCT03784261|Drug|"Drug: Salirumab"|To examine the effects of salirumab in RA patients
45680808|NCT01716585|Drug|Placebo for ribavirin|Capsule
46101620|NCT00679562|Drug|Lactic Acid|Application of occlusive patches containing test product. For 24 hours and repeat 2 weeks later for participants with no reaction to Lactacyd Radiance
46101621|NCT00679562|Other|Distilled water|Application of patches containing distilled water for 24 hours
46101622|NCT00679640|Drug|Candesartan|Oral tablets
46101623|NCT02523287|Biological|Fluad|Randomized assignment
46101624|NCT02523287|Biological|Saline|Randomized assignment
46017877|NCT00629005|Behavioral|Constraint-Induced Movement Therapy + strength training|Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of resistance elastic band exercises
45467042|NCT03784261|Drug|"Drug: Tocilizmab"|To examine the effects of tocilizmab in RA patients
45467043|NCT03784261|Drug|"Drug: Abatacept"|To examine the effects of abatacept in RA patients
45467044|NCT02989402|Drug|Rivastigmine|15 cm2 patch sizes loaded with 27 mg of rivastigmine
45467045|NCT05140239|Other|No Intervention|Non Interventional
46017878|NCT00629005|Behavioral|Constraint-Induced Movement Therapy + range of motion|Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of unresisted arm movements for
46017879|NCT02869087|Device|Akesys Prava Scaffold|Implantation of the Akesys Prava Sirolimus Eluting Bioresorbable Peripheral Scaffold System
45467046|NCT01309321|Behavioral|Perinatal Handwashing Promotion|Pregnancy may serve as a unique opportunity to improve maternal handwashing behavior more deeply and sustainably than a handwashing promotion intervention at a different time. Primiparous women will receive an intensive handwashing promotion program delivered at 3 in-home visits between one month prenatal and 1 week post natal. The program will promote handwashing benefits, provide hardware to reduce barriers to handwashing, and educate mothers about the critical times for handwashing. Mothers will also receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
45467047|NCT01309321|Behavioral|Neonatal Health Promotion|Mothers will receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
45467048|NCT02984566|Device|Kilovoltage Intrafraction Monitoring|KIM is a novel intrafraction real-time tumour localization method. It involves a single gantry-mounted kV x-ray imager acquiring 2D projections of implanted fiducial markers. 3D positions are then reconstructed by maximum likelihood estimation of a 3D probability density function.
45680809|NCT01852292|Drug|Buparlisib|Buparlisib comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
46017880|NCT04291807|Behavioral|Video education|Procedure was presented to the cases via a video showing the steps in ERCP and questions had been answered by an experienced nurse
46017881|NCT02868697|Drug|TauroLock U 25000|taurolidine citrate, 4% citrate /25000 IU unit urokinase (TauroLock U25000
46017882|NCT02868697|Drug|(TauroLock Hep500)|1.35% taurolidine citrate (2H-1,2,4-thiadiazine-4,4'-methylenebis[tetrahydro-1,1,1',1'-tetraoxide], 4% citrate and 500 IU/ml heparin (TauroLock Hep500) (TauroPharmGmbH
46101625|NCT00921388|Other|Varenicline and smoking cessation counseling|All subjects receive smoking cessation counseling and varenicline 0.5mg daily for three days then twice a day for the next four days; then 1 mg twice a day for 11 weeks. Counseling is integrated within the exercise or relaxation treatment program.
46017883|NCT02868385|Drug|4x Praziquantel|Four consecutive praziquantel treatments (40 mg/kg): at baseline (week 0) and at week 2, 4, and 6.
46017884|NCT02868385|Drug|1x Praziquantel|One praziquantel treatment (40 mg/kg) at baseline
46017885|NCT02868307|Behavioral|Answering questionnaire|
46017886|NCT00993265|Drug|N-Acetylcysteine|2400 mg by mouth PO (1200 mg AM, 1200 mg PM), 12 weeks
46017887|NCT00993265|Drug|Placebo|placebo, 2 capsules by mouth in AM, 2 capsules by mouth PM, 12 weeks
46017888|NCT04211389|Drug|ARQ-151 0.3% cream|ARQ-151 0.3% cream
46017889|NCT04211389|Drug|ARQ-151 vehicle cream|ARQ-151 vehicle cream
46017890|NCT00993031|Drug|Lopinavir/ritonavir|LPV 200mg/r 50mg
46017891|NCT00993031|Drug|Efavirenz|600mg
45467049|NCT03783949|Drug|Ganetespib|Ganetespib dose during chemotherapy will be 150mg/m² (q3w) Ganetespib dose during maintenance treatment will be 100mg/m² (q1w)
45467050|NCT03783949|Drug|Niraparib|Niraparib starting dose during maintenance treatment will be 200mg or 300mg depending on subject's body weight and subject neutrophil count (QD)
45467051|NCT03783949|Drug|Carboplatin|In combination with Gemcitabine: Carboplatin dose will be AUC4 (q3w) In combination with Paclitaxel: Carboplatin dose will be AUC5 (q3w)
45467052|NCT03783949|Drug|Paclitaxel|Paclitaxel dose will be 175mg/m² (q3w)
46101626|NCT00921388|Behavioral|Exercise or relaxation treatment|One hour exercise sessions twice a week for 8 weeks, then once a week for 8 weeks, then once every other week for 4 weeks. Subjects in the control group receive a relaxation program that controls for contact time.
45467053|NCT03783949|Drug|Gemcitabine|Gemcitabine dose will be 1000mg/m² (q3w, d1 & d8)
45467054|NCT05681325|Dietary Supplement|green tea|It will be given 2 cups / day for 30 days. To prepare each cup, a tea pack will be immersed into a cup of hot water.
46017892|NCT00993031|Drug|Zidovudine|Zidovudine 300 mg
46101627|NCT04672564|Drug|Carrimycin|Carrimycin (400 mg) will be given once-daily for 14 days (2 x 200 mg tablets) after a meal, if a patient experiences an eating problem, carrimycin will be taken without food.
45467055|NCT05681325|Dietary Supplement|matcha tea|It will be given 2 cups / day for 30 days. To prepare each cup, a tea pack will be immersed into a cup of hot water.
45467056|NCT02861950|Drug|Caudal block with ropivacaine|Patients in this arm will receive a caudal block with ropivacaine
45467057|NCT02861950|Drug|penile nerve block with bupivacaine|Patients in this arm will receive a penile block with bupivacaine
45467058|NCT05681247|Drug|ezetimibe tablet|The subjects randomly received single oral administration of ezetimibe tablet 10 mg
45467059|NCT05681247|Drug|ezetimibe tablet(Ezetrol ®)|The subjects randomly received single oral administration of ezetimibe tablet (Ezetrol ®) 10 mg.
45467060|NCT03787927|Drug|Autologous Platelet Transfusion (room-temperature-stored)|The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.
46101628|NCT04672564|Drug|Placebo|Placebo will be given once-daily for 14 days (2 tablets) after a meal, if a patient experiences an eating problem, placebo will be taken without food.
45467061|NCT03787927|Drug|Autologous Platelet Transfusion (cold-stored 5 days)|The participant will receive an autologous platelet transfusion of their cold-stored platelets after 5 days of storage.
45467062|NCT03787927|Drug|Autologous Platelet Transfusion (cold-stored 10 days)|The participant will receive an autologous platelet transfusion of their cold-stored platelets after 10 days of storage.
45467063|NCT03787927|Drug|Autologous Platelet Transfusion (cold-stored 15 days)|The participant will receive an autologous platelet transfusion of their cold-stored platelets after 15 days of storage.
45467064|NCT03787927|Drug|Aspirin|Aspirin (325mg) will be administered the day before every transfusion.
45467065|NCT03787927|Drug|Clopidogrel|Clopidogrel (600mg) will be administered the day before every transfusion.
45467066|NCT05681169|Other|School-based HPV-counselling and HPV-vaccination.|"Scholl-based parental HPV-counselling~Scholl-based pupil HPV-counselling~Scholl-based HPVV"
45467067|NCT02374450|Procedure|Blood collection|For all hospitalised children suspected of having an AESI or meningitis, a sample of 5 ml of whole blood is collected and serum is stored.
45680810|NCT01852292|Drug|Buparlisib matching Placebo|Buparlisib matching placebo comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
45680811|NCT01852292|Drug|Paclitaxel|Paclitaxel is an intravenous infusion that is given once every week in 80 mg/m^2.
46017893|NCT00993031|Drug|Lamivudine|Lamivudine 150 mg
46017894|NCT01010776|Drug|Paliperidone Extended Release (ER)|Paliperidone ER tablets in the flexible dose ranging from 3 to 12 mg will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
46017895|NCT04291729|Drug|Ganovo+ritonavir+/-Interferon nebulization|Ganovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50μg / time for adults, twice a day up to 14 days.
45680812|NCT01715805|Drug|Cariprazine|Cariprazine capsules 1.5 to 4.5 mg/day
45680813|NCT01715805|Drug|Placebo|Dose-matched placebo capsule once per day
45680814|NCT01715805|Drug|Antidepressant Therapy (ADT)|ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.
46017896|NCT02868775|Procedure|cystoscopy, bladder hydrodistention and bladder biopsy|
46017897|NCT00637702|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|single dose and multiple dose, escalating
46017898|NCT04291963|Procedure|DGG + TUN|In the DGG group, CTG was obtained at palatal mucosa by means of intra-oral de-epithelialization of the FGG using a 2.3 mm diameter diamond burr (801G/023, EMS, Aldrich Co., USA) with NaCL 0.9% saline irrigation
46017899|NCT04291963|Procedure|SCTG + TUN|In SCTG group, graft was harvested through the single-incision approach at palatal mucosa
45837922|NCT05488119|Behavioral|Intervention to increase diabetes technology uptake|The design for this phase is a prospective pilot study. The intervention modules will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. The investigators will also evaluate youth diabetes management and technology use. Families will be compensated in a stepwise fashion. Virtual delivery of the pilot intervention will facilitate national recruitment and allow for recruitment during the pandemic or any ensuing limitations to in-person recruitment. I will recruit 20 families or providers to participate in the delivery of the pilot intervention designed in Phase 1 of the study via a stakeholder advisory board.
45837923|NCT05465005|Behavioral|Torque Generation|Relaxed, or flexing about the elbow to 25% or 50% of the maximum elbow torque that one can generate.
46017900|NCT04170985|Other|clinical Whole Genome Sequencing|Participants will receive cWGS as well as standard of care testing. The clinician/site PI will be blinded to the cWGS results until Day 180.
46017901|NCT02868619|Other|Functional MRI|functional MRI assessed on all the volunteers in condition of hunger and in Condition of satiety
46101629|NCT04212065|Drug|buprenorphine|To improve compliance with medication assisted therapy, decrease relapse and neonatal abstinence syndrome, we propose a randomized control trial of long acting subcutaneous buprenorphine compared to short acting sublingual buprenorphine/naloxone administration in pregnant and lactating women.
46101630|NCT02627534|Procedure|Ultrasonic debridement|All periodontal pockets received ultrasonic debridement (Cavitron, Dentsply) with specific inserts (UI25KSF10S, Hu-Friedy). All diseased sites were instrumented in one session by an experienced periodontist.
46017902|NCT02868619|Other|ADO-BEDS scale|Evaluate the severity of BED according to Marcus and Kalarchian temporary diagnosis criteria
46017903|NCT02868619|Other|R-CMAS scale|Evaluate the anxiety
46101631|NCT02627534|Procedure|Antimicrobial photodynamic therapy|After ultrasonic debridement, one randomly selected periodontal pocket received an additional aPDT performed by a trained operator (NMRBA). One pocket with probing depth ≥ 5mm in each patient was randomly selected to aPDT. After washing the pocket with saline solution, the photosensitizer (methylene blue 10mg/ml) was applied to the bottom of the pocket in a coronal direction. Following this, the pocket was exposed to a diode laser light with a fibre optic application for 1 min (Thera Lase DMC - Brazil), with wavelength of 660nm, power of 60mW and fluency of 129J/cm2.
46101632|NCT02566330|Device|EndoBarrier|The device is a 60-cm long, impermeable plastic sleeve that is open at both sides so food can pass through. The sleeve is anchored in the duodenal bulb and extends partially into the jejunum. This way the pancreatic and bile juices will only mix with the food after the sleeve, hereby creating a functional bypass of the duodenum and the proximal jejunum, which causes malabsorption of nutrients.
46101633|NCT04213235|Behavioral|Physical activity|The participants will receive the written exercise guidebook and a counselling by kinesiologist. Moreover, they will be instructed how to increase their physical activity level.
46101634|NCT02627456|Biological|PfSPZ Vaccine|PfSPZ Vaccine contains aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 P. falciparum sporozoites. PfSPZ Vaccine will be delivered by DVI in the pilot and main phases of the study. Participants will receive either 1 or 3 injections.
46101635|NCT02627456|Biological|PfSPZ Challenge Material|PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites used for CHMI trials. PfSPZ Challenge is not radiated, thus it is fully infections. It will be administered via DVI to participants in Arm 1c and 1d.
46101636|NCT02627456|Drug|PBS and HSA Diluent|The diluent for PfSPZ Vaccine and Challenge is composed of phosphate-buffered saline (PBS) and human serum albumin (HSA). Vials of sterile PBS (1.6ml) and HSA (0.5ml) will be shipped to the clinical site, where diluent composed of PBS and HSA is prepared. HSA is a licensed product which is approved for parenteral, IV administration to humans. The HSA lots are extensively tested to ensure that it is free of infectious agents as listed in the CoA and is approved for use by the Food and Drug Administration(FDA).
46101637|NCT02627456|Other|Normal Saline|Sterile isotonic (0.9%) normal saline will be procured in the US and shipped to Mali at ambient temperature. Like the product, normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe.
46017904|NCT00637741|Device|Everflex 200|
46017905|NCT02868931|Behavioral|INPUT|"Treatment and education program based on the self-management theory of behavioral medicine.~The program is delivered by certified and specially trained diabetes educators."
45467068|NCT00602576|Drug|sorafenib tosylate|Given orally
45467069|NCT00602576|Drug|temozolomide|Given orally
45680815|NCT01852214|Drug|Prasugrel|Patients receiving prasugrel will be treated with 60mg loading dose and 10mg maintenance dose
45680816|NCT01852214|Drug|Ticagrelor|Patients receiving ticagrelor will be treated with a 180mg loading dose and 90mg bid maintenance dose
46017906|NCT01018810|Drug|LY2525623 Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
46017907|NCT01018810|Drug|LY2525623 Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
46017908|NCT01018810|Drug|Placebo Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
46017909|NCT01018810|Drug|Placebo Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
46017910|NCT02867917|Drug|Volcolon sugar free|1 sachet contains 4 g powder 980mg/g psyllium fibers x 4 g per sachet = 3.92 g psyllium fibers/sachet
46017911|NCT02867917|Drug|Metamucil Orange|1 sachet contains 3.4 g psyllium fibers So 25 ml contains 0.425 g psyllium fibers
46017912|NCT02867917|Drug|Psyllium Orange|1 sachet contains 3.25 g psyllium fibers So 25 ml contains 0.406 g psyllium fibers
45467070|NCT04807972|Drug|ABBV-927|Intravenous (IV) Infusion
45837924|NCT05460715|Device|Quadra P anteverted|"Assess clinical performance by Harris Hip score collected during preoperative and postoperative visits at 3 months, 1, 2, 5, 7 and 10 years.~Assess radiological performance by standard radiographic examination performed before surgery, after surgery before discharge and during postoperative visits at 3 months, 1, 2, 5, 7 and 10 years.~Assessing the patient's perception of the prosthetic joint by means of FJS questionnaire collected during the preoperative visit and postoperative visits at 3 months and at 1, 2, 5, 7 and 10 years after surgery.~Assessment of functional recovery by gait analysis study~Collect the rate of complications throughout the course of the study"
45467071|NCT04807972|Drug|Budiglimab|Intravenous (IV) Infusion
45467072|NCT04807972|Drug|modified FOLFIRINOX|Intravenous (IV) Infusion
45467073|NCT05694871|Drug|Palbociclib|Given PO
45837925|NCT05444803|Other|femoral nerve block|Patients will be performed a femoral nerve block using bupivacaine thirty minutes before the performing of spinal block.
45837926|NCT05444803|Other|peri-capsular nerve group block|Patients will be performed a peri-capsular nerve group block using bupivacaine thirty minutes before the performing of spinal block.
46017913|NCT01018732|Biological|Novartis Meningococcal (MenACWY-CRM) vaccine|All subjects will have blood draws at Day 1, Day 8, and Day 29.
46017914|NCT01218867|Biological|Anti-VEGFR2 CAR CD8 plus PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose (Arms 1-7) or low dose (Arms 8-11) aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
45467074|NCT05694871|Biological|Cemiplimab|Given IV
45837927|NCT05764915|Drug|RGT-264 phosphate tablets|RGT-264 phosphate tablets will be administered orally once daily (QD).
45837928|NCT05443399|Behavioral|Modality - 3D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and generalization as 2D
45837929|NCT05443399|Behavioral|Modality - 2D-3D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 3D
45837930|NCT05443399|Behavioral|Modality - 2D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 2D
45837931|NCT05441215|Drug|nirmatrelvir|nirmatrelvir/ritonavir
45467075|NCT05694871|Procedure|Magnetic Resonance Imaging|undergo MRI
45467076|NCT05694871|Procedure|Computed Tomography|Undergo a CT Scan
45467077|NCT05694871|Procedure|Biospecimen collection|Undergo blood sample collection
45467078|NCT05694871|Other|Questionnaire Administration|Ancillary Studies
45467079|NCT05299359|Biological|TAK-019|TAK-019 intramuscular injection
45467080|NCT04500171|Behavioral|Colocare Instruction Sheet: SAM + CAM SMOG|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
45837932|NCT05441215|Drug|ritonavir|nirmatrelvir/ritonavir
45837933|NCT05434754|Other|eHealth Tool|text messaging algorithm
46017915|NCT01218867|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr
45837934|NCT05433415|Behavioral|Black Girls Move|Goal setting and monitoring. All BGM daughters will self-monitor their progress towards PA goals using a PA device, Fitbit®. Additionally, BGM daughters will self-monitor their progress towards diet goals using a mobile application, Start Simple with My Plate®. Further, all BGM mothers will use Fitbit® and Start Simple with My Plate® for self monitoring, however, mothers' data will not be analyzed for this study. Since the daughter/ mother relationship is critical to achieving behavioral change, BGM mothers will utilize Fitbit® and Start Simple with My Plate® as a mechanism to communicate, problem solve and support daughters' behavioral goals.BGM is situated within the contexts of environmental, cultural, interpersonal, and developmental factors impacted by structural racism. Intentionally engaging mothers and daughters in an asset based program provides a framework for mothers to model responses to structural racism i.e. racial socialization.
45837935|NCT05431777|Drug|Avelumab|As provided in real world setting
45837936|NCT05426200|Behavioral|Health Coaching|Patients will work with a health coach by telephone for up to 12 sessions over a 12-16 week period.
46017916|NCT01218867|Biological|Aldesleukin|Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
45467081|NCT04500171|Behavioral|CDC Colorectal cancer screening for life brochure: SAM + CAM SMOG|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
46017917|NCT01218867|Drug|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days
46101638|NCT02627456|Drug|Coartem|Artemether/lumefantrine (coartem) is a licensed antimalarial in the US and Mali for use for uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Artemether /lumefantrine is a Category C pregnancy drug. Thus all female participants will undergo pregnancy testing prior to receiving this drug.
46017918|NCT01018264|Drug|solifenacin succinate (VESIcare)|up to 10mg every day orally
46017919|NCT01018264|Drug|placebo|placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day
46017920|NCT04318899|Behavioral|Dialectical Behaviour Therapy adapted for adolescents (DBT-A)|DBT developed by Marsha Linehan (Linehan 1993a; 1993b) and adapted for adolescents (DBT-A) by Miller, Rathus & Linehan, 2007 consisting of 20 weeks of weekly individual therapy (60 minutes), multifamily skills training (120 minutes), family therapy sessions as needed and telephone coaching outside therapy sessions.
45467082|NCT04500171|Behavioral|Colocare Instruction Sheet: SAM + CAM - Superior rating SMOG - 5th Grade Level|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
45467083|NCT04500171|Behavioral|CDC Colorectal Cancer Screening for Life Brochure: SAM + CAM - Superior rating SMOG - 5th Grade Level|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
45680817|NCT04595630|Other|data collection from the hospital records|The clinical data from the patients enrolled in the study, such as the medical history, functional state, and EuroSCORE, and the hematological, basic renal, hepatic, and metabolic chemistry findings (including cTn as defined per the protocol), the operative data (operating time, blood loss, cardiopulmonary and cross-clamp time, number of arterial and venous grafts, the number of distal anastomoses, flow measured at all bypass grafts at the end of the intervention and the need for an assist device) and CCT scan data (at discharge from hospital facility) will be obtained from the hospital records. The data will be entered into a database.
46017921|NCT04318899|Behavioral|Dialectical Behaviour Therapy - Standard version (DBT)|DBT developed by Marsha Linehan (Linehan 1993a, 1993 b) consisting of 1 weekly session of individual therapy (60 minutes), 1 weekly session of skills training (120 minutes), and telephone coaching with individual therapists outside therapy sessions as needed.
46017922|NCT01018186|Drug|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
46101639|NCT02627456|Drug|ASAQ|"ASAQ is a fixed dose artemisinin based combination therapy that is indicated and approved for the management of uncomplicated P. falciparum malaria. It has been shown to be as effective as artemether~/lumefantrine when taken at a once/day dosage."
46101640|NCT02566408|Other|One-on-one interview|Undergo one-on-one interview about KAPs towards PA
46101641|NCT02566408|Other|Survey Questions|Complete survey
46101642|NCT00617513|Drug|Prucalopride|0.5 mg once daily
46101643|NCT00617513|Other|Placebo|o.d.
46017923|NCT01018186|Drug|Fluticasone propionate|Inhaled corticosteroid
45837937|NCT05410366|Other|Safe harbor clinical practice guideline|A safe harbor is a special type of clinical practice guideline which, under existing federal law, may serve as the legal standard of care, not just evidence of the standard of care. If a patient with a safe harbor condition satisfies all safe harbor inclusion criteria and does not meet any exclusion criteria, no imaging is required, and the patient may be discharged with specific instructions. If a patient is excluded from the safe harbor, then imaging decisions are per customary practice. The safe harbor clinical practice guidelines are provided to treating ED physicians, but they are not obligated to use them. The safe harbor pathways do not limit the diagnostic and therapeutic approach patients and physicians undertake during a clinical encounter. They have the liberty in this decision to proceed jointly down a clinical pathway most appropriate to the individual clinical circumstance.
45467084|NCT04500171|Behavioral|Colocare Instruction Video: Modified SAM + CAM -Superior rating|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
45467085|NCT04500171|Behavioral|Colocare Instruction Sheet: SAM + CAM Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
46101644|NCT00617513|Drug|Prucalopride|1 mg o.d.
46101645|NCT00617513|Drug|Prucalopride|2 mg o.d.
46101646|NCT02627222|Other|Pro-vitamin A biofortified cassava|Pro-vitamin A biofortified cassava is the product of international conventional breeding programs (non-GMO) in order to increase the pro-vitamin A content of cassava for improved nutritional intake
46017924|NCT00987337|Drug|Filibuvir|300 mg BID
46017925|NCT00987337|Drug|Filibuvir|600 mg BID
46017926|NCT00987337|Drug|Placebo|BID
46017927|NCT00992407|Drug|Risperidone long acting injectables|Risperidone long acting injectables will be administered intramuscularly (given into the skin) at a flexible dose of 25, 37.5 or 50 milligram (mg) every 2 weeks up to Week 52. A supplementary oral antipsychotic will also be administered for 3-4 weeks after the initial dose of injection.
46101647|NCT02627222|Other|White cassava|Conventional white cassava
45837938|NCT05407376|Other|Produce prescription (weekly produce delivery)|Participants will receive weekly produce deliveries and recipes sent directly to their homes for 6 months.
45837939|NCT05403853|Diagnostic Test|Venepuncture|Venous blood draw
46017928|NCT00992407|Drug|Risperidone tablets|Risperidone tablets will be administered orally as 0.5-10 mg daily up to Week 52.
46017929|NCT00986479|Drug|AZD6765|Single IV infusion of 150 mg AZD6765.
46101648|NCT00619463|Behavioral|Exercise|Eight weeks in an aerobic exercise program- 50 minutes of aerobic exercise on a treadmill - 3 days a week for 8 -16 weeks.
46101649|NCT00619463|Behavioral|Exercise|Aerobic exercise program - 55 min aerobic exercise on the treadmill 3 days a week for either 8 or 16 weeks
46101650|NCT02566486|Device|Reciprocating system|Different root canal instrumentation systems
46101651|NCT02566486|Device|Rotational system|Different root canal instrumentation systems
46101652|NCT00684476|Drug|venom immunotherapy|
46101653|NCT04214015|Other|No intervention|There is no intervention for this study
46101654|NCT02466737|Procedure|no axillary surgery versus SLNB|in cases with newly diagnosed breast cancer and clinically negative axillary status
46101655|NCT02466737|Procedure|SLNB versus completion ALND|in cases with 1-3 macrometastases in sentinel lymph nodes
46101656|NCT00594854|Drug|PN400 (VIMOVO)|PN400 tablet (500 mg delayed-release naproxen/20 mg immediate-release esomeprazole) given by mouth twice daily (bid).
46101657|NCT00594854|Drug|Diclofenac/Misoprostol|Over-encapsulated ARTHROTEC® 75 (75 mg diclofenac sodium/200 mcg misoprostol) capsules given by mouth bid.
46101658|NCT02566564|Drug|Lopain|intra-articular injection
46101659|NCT00679718|Drug|diquafosol tetrasodium (INS365) ophthalmic solution|
46101660|NCT00684632|Drug|Placebo|Placebo
46101661|NCT00684632|Drug|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
46017930|NCT00986479|Drug|Placebo to AZD6765|Single IV infusion of Placebo to AZD6765
46017931|NCT04299412|Device|DPP Fever Panel II assay|Multiplex lateral flow immunoassay (DPP® Fever Panel II Assay) that is able to detect (i) antigens produced by Dengue, Zika, Chikungunya, Malaria and Burkholderia and (ii) IgM directed against Dengue, Zika, Chikungunya, Leptospira, Rickettsia typhi and Orientia tsutsugamushi. The assay comes with a reader that provides results interpretation to the operator in a few seconds
46017932|NCT00986245|Drug|Ropinirole Prolonged release|Change Ropinirole immediate release or Pramipexole immediate release to Ropinirole prolonged release (PR) once-daily or twice-daily
46017933|NCT00989833|Drug|budesonide|400 yg x 1
46017934|NCT00989833|Drug|terbutaline|0.4 mg as-needed
46017935|NCT00989833|Drug|budesonide/formoterol|160/4.5 yg as-needed
46017936|NCT04292119|Drug|Lorlatinib|"Lorlatinib will be taken orally once daily for 28 days when combined with crizotinib or binimetinib. Lorlatinib will be taken orally once daily for 21 days when combined with TNO155.~Crizotinib taken orally twice daily for 28 days."
46017937|NCT04292119|Drug|Crizotinib|"Crizotinib will be taken orally twice daily for 28 days.~Binimetnib taken orally twice daily for 28 days."
46017938|NCT04292119|Drug|Binimetinib|Binimetinib will be taken orally twice daily for 28 days.
46017939|NCT04292119|Drug|TNO155|TNO155 will be taken orally once daily for 14 days.
46017940|NCT01218477|Drug|Dasatinib|Oral tablets, 100-140 mg once daily, depending on cohort (100 mg for those with chronic myeloid leukemia [CML]-chronic phase; 140 mg for those with CML-advanced phase)
46017941|NCT01218477|Drug|BMS-833923|Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
46101662|NCT00855582|Drug|Tadalafil|tablet once daily by mouth for 12 weeks.
46101663|NCT00855582|Drug|Placebo|Matching 2.5 or 5 mg placebo tablet once daily by mouth for 12 weeks.
45680818|NCT04594772|Drug|Folfirinox|Chemotherapy will begin with FOLFIRINOX - a standard regimen used in pancreatic cancer treatment, consisting of 5-fluorouracil (2400 mg/m2), irinotecan (180 mg/m2) and oxaliplatin (85 mg/m2). Treatment will continue for 2 cycles (4 doses), and then re-evaluation will be performed. If a decision to continue with FOLFIRINOX is made, it will be administered for another 4 cycles (8 doses).
45680819|NCT04594772|Drug|Gemcitabine|At the first planned analysis, if a switch is indicated based on prespecified criteria , gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) - another standard regimen in this setting - will be used. It will be administered for 4 cycles (12 doses).
45837940|NCT05403853|Diagnostic Test|Fingerstick|Capillary Blood Draw
45837941|NCT05396170|Procedure|phlebotomy|500ml of blood phlebotomized per standard of care to reduce symptoms from polycythemia
45837942|NCT05386277|Device|TufTex Single Lumen Embolectomy Catheter|The SLC Embolectomy Catheter is indicated for the removal of arterial emboli and thrombi
45837943|NCT05384405|Device|Active iTBS|MagPro X100
46017942|NCT04318509|Dietary Supplement|GMPOWER|(casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years
46017943|NCT01218243|Device|needle|For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.
46017944|NCT00989287|Biological|GSK2340272A|Two intramuscular injections in the deltoid region of the non-dominant arm.
46017945|NCT00989287|Biological|GSK2340269A|Two intramuscular injections in the deltoid region of the non-dominant arm.
46017946|NCT01218087|Device|Cranial cup device and Moldable positioner|The cranial cup device was used 12/24 hours (alternating with the moldable positioner device) and was evaluated for feasibility, safety and efficacy for preventing head shape deformity in hospitalized infants
46017947|NCT01218087|Device|Moldable positioner device|This moldable positioning device was used 24/24 hours as a comparison to the cranial cup device.
46017948|NCT04291339|Procedure|High-flow nasal oxygen technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
46101664|NCT00619541|Drug|Infusional 5-Fluorouracil|5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days. 5-FU will be administered for a maximum of 12 cycles.
46101665|NCT00619541|Drug|Sorafenib (Bay 43-9006)|Sorafenib 400 mg bid orally continuously. Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease.
46101666|NCT00680498|Drug|Ranibizumab|Ranibizumab 0.5 mg
46101667|NCT00680498|Drug|Ranibizumab plus Photodynamic therapy|Ranibizumab 0.5mg, combined with photodynamic therapy with Verteporfin (dosage per label)
46101668|NCT04211597|Other|Control|No scar prevention or treatment.
45467086|NCT04500171|Behavioral|CDC Colorectal cancer screening for life brochure: SAM + CAM Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
45467087|NCT04500171|Behavioral|Colocare Instruction Sheet: SAM + CAM - Superior rating Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
45467088|NCT04500171|Behavioral|CDC Colorectal Cancer Screening for Life Brochure: SAM + CAM - Superior rating Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
45467089|NCT05694793|Device|Glean Urodynamics System|Wireless, catheter-free urodynamics system
45467090|NCT03359850|Drug|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
46101669|NCT04211597|Other|Silicone gel|Dermatix® (Dermatix® Ultra, Menarini Asia-Pacific, Taiwan FDA approved)
46101670|NCT04211597|Other|microencapsulated polysaccharide and oligopeptide-1(Me-EGF) 40 mcg & 5 mcg|4ml (40 mcg) of Me-EGF spray will be given by the operating physician prior to wound closure, followed by daily application of 5 mcg until day +5 after delivery. Starting from day +14, participants will receive FDA approved Silicone gel to be applied to the Cesarean wound twice a day for two months. Participants also receive routine post-partum care as usual.
45467091|NCT01306123|Drug|Nascobal nasal spray (cyanocobalamin, USP)|Single intranasal administration
46017949|NCT04291339|Procedure|Mask ventilation technique|Oxygen will be supplied through the mouth and nose to the patients using facial mask during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
45680820|NCT04594772|Radiation|radiation therapy|Radiation therapy may be used prior to surgery, based on findings on the final pre-operative scan per standard of care. Radiation therapy will be delivered in patients with artery and venous involvement meeting the Intergroup definition for borderline resectable disease. Radiotherapy will be delivered via a hypofractionated approach over 10 fractions and will include target volumes to the primary tumor and elective coverage of vascular structures at risk. Radiation will be delivered with concurrent chemotherapy.
45837944|NCT05384405|Device|Sham iTBS|MagPro X100
45837945|NCT05378386|Device|Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System|The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular right ventricular outflow tracts (RVOTs) and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 transcatheter heart valve (THV).
46101671|NCT04151030|Procedure|PEG placement|Push PEG placement
46101672|NCT00679796|Procedure|Varicella (chickenpox) lesion sampling|
46101673|NCT04211519|Diagnostic Test|sampling|sampling from endodontically infected primary and permanent teeth by using paper point method
45837946|NCT05355818|Drug|Delgocitinib|Cream for topical application
45837947|NCT05355818|Drug|Cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active medical ingredient.
45837948|NCT05338125|Procedure|Micro-electrode measurement|Electrophysiological measurement with single-unit micro-electrode
46017950|NCT01218009|Drug|Placebo Spiromax|Placebo as a dry-powder inhaled orally using the Spiromax inhaler. During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.
46101674|NCT00680576|Behavioral|CBT, Cognitive Behavioral Therapy|Eight weekly sessions of individual Cognitive Behavioral Therapy, to develop skills enabling adolescents stop or reduce their drug use.
46101675|NCT00680576|Behavioral|FFT, Family Functional Therapy|Eight weekly sessions of Functional Family Therapy designed to strengthen family relationships and build skills to help the adolescent stop or reduce his/her drug use.
46101676|NCT02369471|Drug|GWP42006|
46101677|NCT02369471|Drug|Placebo|
46101678|NCT00679874|Other|Cardio-vascular MRI|Contrast enhanced CMR studies at baseline, in the middle of chemotherapy and as follow-up
46101679|NCT01793129|Device|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 72 hours
46101680|NCT01793129|Procedure|Normothermic Control|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
46101681|NCT00684710|Drug|PAZ-417|
46101682|NCT00684710|Drug|Placebo|
46101683|NCT01788683|Procedure|Regenexx SD|stem cell treatment
46101684|NCT01788683|Other|Exercise Therapy|exercise therapy control
46017951|NCT01218009|Drug|Albuterol Spiromax|"Albuterol as a dry-powder inhaled orally using the Spiromax inhaler. Each inhalation delivers 90 micrograms (mcg). During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total dose of 720 micrograms per day for those paricipants randomized to the Albuterol treatment arm.~The double-blind period is followed by a 40-week open-label period in which all study participants will take Albuterol Spiromax 90 micrograms (mcg)/inhalation as needed (PRN)."
45467092|NCT01306123|Drug|Vitamin B12-ratiopharm N, injection solution|One single intramuscular administration
45837949|NCT05335772|Behavioral|Action Observation and following Action Execution|VR-AOT patients will observe, rehearse and execute specific upper limb motor task belonging to activities of daily living.
45837950|NCT05335772|Behavioral|Landscape Observation and following Action Execution|VR-LO participants will observe virtually explorable landscapes lasting for a matched duration. Then, they will be asked to actively perform the same set of hand actions requested to VR-AOT experimental groups.
46017952|NCT04291183|Behavioral|horticultural therapy|Flowers and vegetables will be planted with the elderly. Growth of plants planted with the elderly will be observed and maintained
46017953|NCT04291417|Diagnostic Test|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients.
46017954|NCT00992017|Biological|Influenza A (H1N1) monovalent vaccine|Two 15-microgram intramuscular vaccine injections given together form one dose; two doses (four total injections) are given 21 days apart
46017955|NCT01217463|Drug|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is >6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
46017956|NCT02868151|Drug|Ascorbic Acid|Ascorbic acid oral supplementation 1g four times daily for the entire treatment period and 30 days after treatment by tapering the dose of the drug to half. The drug has to be started 2 days prior to initiation of treatment of cancer.
46017957|NCT02868151|Drug|Zinc acetate|Zinc acetate 50mg tablets orally twice daily for entire period of cancer treatment
46017958|NCT01217307|Drug|Metformin|Metformin 500mg twice daily during 4 months
46017959|NCT01217307|Drug|Placebo|Placebo twice daily during 4 months
46017960|NCT02868073|Biological|VXA-G1.1-NN (high dose) Oral Vaccine Tablet|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high dose.
46017961|NCT02868073|Other|VXA Placebo Tablets|The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
46017962|NCT02868073|Biological|VXA-G1.1-NN (low dose) Oral Vaccine Tablet|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the low dose.
45467093|NCT03787459|Drug|Arbidol|Oseltamivir plus Arbidol will be administrated from Days 1-7.
45467094|NCT03787459|Drug|Placebos|Oseltamivir plus placebos will be administrated from Days 1-7.
45467095|NCT00260572|Behavioral|Questionnaires to evaluate QOL|Questionnaire to evaluate QOL administered preoperatively and postoperatively at set intervals.
45467096|NCT00260572|Behavioral|Questionnaires to evaluate heartburn and quality of life|Questionnaires to evaluate heartburn and quality of life administered preoperatively and at set intervals postoperatively.
45467097|NCT00260572|Behavioral|Questionnaire to evaluate satisfaction with treatment|Questionnaire administered postoperatively at set intervals.
45467098|NCT00260572|Behavioral|Questionnaire to evaluate presence or absence of pain|Questionnaire administered preoperatively and at set intervals postoperatively.
45467099|NCT04930432|Drug|MCLA-129|MCLA-129 will be administered by intravenous infusion.
45837951|NCT05327647|Drug|Bicalutamide|Induction intravesical BCG with bicalutamide 150 mg for 90 days
46017963|NCT01217229|Drug|PLX3397|Capsules administered once or twice daily, continuous dosing. Subjects will begin with 900 mg/day, but should safety data allow in our PLX108-01 study, subject may dose at 1200 mg/day.
46017964|NCT04318743|Drug|Glepaglutide|GLP-2
46017965|NCT01013740|Drug|Vinorelbine|Vinorelbine
46017966|NCT01013740|Drug|Lapatinib|Lapatinib
46017967|NCT01013740|Drug|Capecitabine|Capecitabine
46017968|NCT02872246|Drug|BAY 987516|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
45467100|NCT05405504|Device|Remote Dielectric Sensing (ReDS)|Non-invasive device designed for the measurement of lung fluid using extremely low power electromagnetic waves. The ReDS Pro System V2.7 system has CE approval (3900874CE01) and FDA clearance.
45467101|NCT05683080|Other|Routine Clinical Care|Participants completing the research study will receive routine clinical care
45467102|NCT05247138|Device|BioRootTM RCS|BioRoot™ RCS is a hydrophilic mineral root canal sealer prepared from the mixture of a powder part and a liquid part. BioRoot™ RCS is a class III implantable medical device. This device is intended to be used in dentistry for permanent obturation of root canals of permanent and mature teeth with adjunction of gutta-percha points. Exposure to the sealer BioRootTM RCS starts from the day when the root canal treatment is performed until the end of individual observational period or the removal of the sealer in case of extraction or retreatment, if this event occurs before the end of individual observational period.
45467103|NCT04754698|Biological|CoronaVac|CoronaVac (Sinovac Biotech Ltd., Beijing, China)
45467104|NCT04803994|Drug|Atezolizumab|1200 mg atezolizumab intravenously Q3W (max 32 cycles, up to 24 months)
45467105|NCT04803994|Drug|Bevacizumab|15 mg/kg intravenously Q3W (max 32 cycles, up to 24 months)
46017969|NCT02872246|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
46101685|NCT00684866|Drug|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|(a) Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)
46101686|NCT00684866|Drug|Racemic Albuterol followed by levalbuterol HFA MDI|(a) Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)
46101687|NCT00854724|Drug|Puerarin, Placebo|400 mg, three times a day for 7 days
46101688|NCT00619697|Drug|biphasic insulin aspart|
46101689|NCT00619697|Drug|insulin glargine|
45467106|NCT04803994|Procedure|TACE|Locoregional therapy will be performed as a standard-of-care procedure
45467107|NCT04644328|Behavioral|Facebook Ads on the importance of staying safe during the Thanksgiving / Christmas holiday|Facebook ads to show a 15 second video clip recorded by MGH, Harvard and Lynn Community health center and other health care professionals. The ads will be shown before the Thanksgiving/Christmas holiday and will focus on staying safe - limiting travel and mask-wearing. The investigators will randomize exposure to the ad campaign at the ZIP code or county level.
45837952|NCT05327647|Biological|Control Arm|Induction BCG
46017970|NCT00627874|Device|+3D Lenses|wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
46017971|NCT04299256|Behavioral|Benson relaxation combined with music therapy|In the first interview, the patient information delivered a training booklet explaining the definition, purpose, benefits and application techniques of BRT and music therapy to the patients in the intervention group. After patients reviewed the details in the training booklet, a weekly schedule was planned for each patient based on their hemodialysis days. For the initiation of the intervention, patients were invited to the hemodialysis unit at the hospital 45 min prior to their hemodialysis sessions. All the participants wore black eye patches to provide a dim environment and to focus better on their breath and the music piece. Then, the patients information opened the music piece and gave Benson Relaxation Technique comments in a slightly lower voice. Each session lasted for 20 min, and the music piece was switched off as Benson Relaxation Technique ended. The music piece used in the study was Daniel Kobelco's non-verbal classical song.
46017972|NCT01018030|Drug|FFNS 110 mcg QD|Active Nasal Spray (AM) and Placebo Nasal Spray (PM)
46017973|NCT01018030|Drug|FFNS 110 mcg BID|Active Nasal Spray (AM) and Active Nasal Spray (PM)
46101690|NCT00619697|Drug|metformin|
46101691|NCT00619697|Drug|glimepiride|
46101692|NCT00680654|Drug|Riociguat (Adempas, BAY63-2521)|The investigational drug will be given twice per subject, as single dose administration of BAY 63-2521 (0.5 mg and 1.0 mg) during the hemodynamic investigation.
46101693|NCT00698568|Biological|Herpes simplex candidate vaccine- adjuvanted GSK 208141|Intramuscular injection, 3 doses
46101694|NCT00698568|Biological|Placebo|Intramuscular injection, 3 doses
46101695|NCT00616733|Drug|CS-0777 tablets|0.1 mg, once-weekly, for 12 weeks
46101696|NCT00616733|Drug|CS-0777 tablets|0.3 mg, once-weekly or once every 2 weeks, for 12 weeks
46101697|NCT00616733|Drug|CS-0777 tablets|0.6 mg, once-weekly or once every 2 weeks, for 12 weeks
46101698|NCT00680108|Drug|diquafosol tetrasodium (INS365) ophthalmic solution|
46101699|NCT02945969|Behavioral|Low Sodium Diet|Once randomized to the Intervention program, study participants will be grouped into intervention cohorts of approximately 10 participants per group to facilitate group counseling sessions. Both the intensive intervention phase and the maintenance phase will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake. Success of the intervention will be assessed by comparing the urine sodium measurements from 24-hour urine collections performed at screening, 12 weeks and 24 weeks.
46101700|NCT00680732|Dietary Supplement|Multiple micronutrients supplements (MMS)|Vitamin A 800 mcg; vitamin E 10 mg; vitamin D 5 mcg; vitamin B1 1.4 mg; vitamin B2 1.4 mg;niacin 18 mg; vitamin B6 1.9 mg; vitamin B12 2.6 mcg; folic acid 400 mcg; vitamin C 70 mg; iron 30 mg; zinc 15 mg; copper 2 mg; selenium 65 mcg; iodine 150 mcg
46101701|NCT00680732|Dietary Supplement|Iron and folic acid (IFA)|Iron 60 mg and folic acid 400 mcg
45837953|NCT05321342|Behavioral|BCCU|BCCU professional development (PD) modules will be provided to all staff in intervention schools as part of their standard, school-approved professional development practices to provide knowledge and awareness for bullying identification, prevention, and intervention. In addition, consented 3rd-5th grade teachers will participate in the BCCU intervention. The coaching follows the original Classroom Check-Up model (Reinke, Herman, & Sprick, 2011), embedding 5 steps (i.e., assessment of the classroom, feedback to teacher, goal setting and plan, ongoing coaching and guided practice in the TeachLivE© mixed-reality simulator [developed at UCF; Dieker, Hynes, Hughes, & Smith, 2008], and self-monitoring) and utilizing motivational interviewing (Miller & Rollnick, 2012) to empower teacher practice change.
45467108|NCT04744402|Drug|Autologous Chondrocyte Implantation (CartiLife®)|CartiLife consists of small beads (1 mm in diameter) in suspension, developed from pellet culture of autologous costal chondrocytes after multiplication. The beads are implanted in an injective manner with fibrin glue through minimal arthrotomy. The dose depends on the size (volume) of the defect, recommended dose is 480 pellets/cm^3 defect
45467109|NCT03130660|Device|Ultrasonography|Ultrasound guidance for central line
45467110|NCT03130426|Drug|iGlarLixi|Dose is titrated to achieve fasting normoglycemia
45467111|NCT03130426|Drug|Insulin Glargine|In those who need additional insulin or who cannot tolerate iGlarLixi, insulin glargine will be used. Dose is titrated to achieve fasting normoglycemia.
46017974|NCT01018030|Drug|Placebo Nasal Spray|Placebo Nasal Spray (AM) and Placebo Nasal Spray (PM)
46101702|NCT00680732|Drug|Chloroquine (CQ)|Tablets 100 mg of chloroquine base
46101703|NCT00680732|Drug|Sulphadoxyne-pyrimethamine (SP)|Tablets
46101704|NCT04210193|Drug|ALK Alutard 5-grasses|0.1 mL of 10 000 SQ-U/mL (1000 SQ-U) as an intralymphatic injection
46017975|NCT01217073|Drug|Omarigliptin|Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.
45467112|NCT03130426|Drug|Metformin|Dose is titrated to 2000 mg daily or maximal tolerated dose
45467113|NCT03130426|Behavioral|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
45598384|NCT02226029|Other|Lipid emulsion|"2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~Lipid emulsion 1: acid stable, particle size 0.6 µm~Lipid emulsion 2: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm~13C-markers will be mixed with emulsions"
45837954|NCT05320380|Drug|Anti-CD123 ADC IMGN632|Given IV
45837955|NCT05320380|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/biopsy
46017976|NCT01217073|Drug|Placebo to omarigliptin|Matching placebo to omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For matching placebo to omarigliptin 3 mg, participants received two matching placebo to omarigliptin 1.5 mg capsules.
46017977|NCT01217073|Drug|Pioglitazone|Pioglitazone 15 mg oral tablet or capsule administered once daily
46101705|NCT04210193|Drug|ALK Diluent|0.1 mL of ALK Diluent as an intralymphatic injection
46101706|NCT04653766|Drug|Ir-CPI - Dose 1|6 participants received a single intravenous dose of 1.5 mg/kg of Ir-CPI during 6 hours
46101707|NCT04653766|Drug|Ir-CPI - Dose 2|6 participants received a single intravenous dose of 3.0 mg/kg of Ir-CPI during 6 hours
46101708|NCT04653766|Drug|Ir-CPI - Dose 3|6 participants received a single intravenous dose of 6.0 mg/kg of Ir-CPI during 6 hours
46101709|NCT04653766|Drug|Ir-CPI - Dose 4|6 participants received a single intravenous dose of 9.0 mg/kg of Ir-CPI during 6 hours
46101710|NCT04653766|Drug|Placebo|For each dose group, 2 additional participants received a single intravenous dose of placebo during 6 hours (8 in total).
46101711|NCT00620243|Procedure|1: FDG PET|The study will evaluate the potential of PET imaging to identify early responders to chemotherapy. Patients entered into this study will undergo FDG PET within 2 weeks prior to chemotherapy and prior to initiation of the second course of chemotherapy. All images will be carried out in the same manner with respect to equipment, acquisition parameters, and time post injection, to ensure that changes in standard uptake value(SUV) correlate with metabolic changes. This will be correlated with response determined by changes in serum CA 125 levels.
45467114|NCT00114140|Drug|Temozolomide|"Concurrent chemoradiotherapy temozolomide given 75 mg/m^2 daily during radiotherapy for 6 weeks.~Post-Radiation Temozolomide given 150 mg/m2 daily on days 1-5 every 28 days with cycle one beginning 28 days post-radiotherapy. In the absence of grade 3 or 4 adverse events, a single dose escalation to 200 mg/m2/day could be attempted for cycle 2 and, if tolerated, that dose should continue for all subsequent cycles. Cycles were repeated every 28 days (+/- 2 days) for a total of 12 cycles."
46101712|NCT04151186|Biological|TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy|"Specification: 30 mL-100 mL, cell density of about (1-10) x10^6 cells/ml in each bag, number of T-cells about (1-10) x10^8 cells.) 300 ml for each infusion.~Storage: The prepared CAR T-cells are cryopreserved in a preserving medium . This product is manufactured under the current good manufacture practices (cGMP) conditions, with restrictions on chemical components, free from animal- or human-derived components and confirming to the United States Pharmacopeia (USP)<71> and <85> regulations.~Preservation: The frozen CAR T-cells are preserved in the liquid nitrogen transfer tank.~Usage: The frozen CAR T-cells are preserved at low temperature and transferred to the bedside. The cells are thawed by 36 degrees centigrade to 38 degrees centigrade. water bath. The frozen cells are gently massaged until complete thawing. Then they are transfused back to the patients intravenously. The transfusion will be finished within 5-10 min."
45467115|NCT00114140|Radiation|Radiation therapy|One treatment of 1.8 Gy given daily, 5 days per week (over 6 weeks) for a total dose of 54.0 Gy.
46101713|NCT00698932|Drug|Saxagliptin|5mg, oral tablet, once daily for 24 weeks
46101714|NCT00698932|Drug|Placebo|oral tablet, once daily for 24 weeks
46101715|NCT02566252|Drug|PUL-042 Inhalation Solution|PUL-042
45467116|NCT03342690|Drug|Eplerenone|"In adults, usually, administer the initial dose of 25 mg once daily according to the patient's serum potassium level and conditions, increase dosage up to 50 mg once daily after 4 week; patients with moderate renal impairment should start with 25 mg every other day and the maximum dosage should be 25 mg once daily.~Also, dose should be reduced or interrupted according to serum potassium level and patient's conditions."
45467117|NCT03130582|Drug|high-dose etoposide|an epipodophyllotoxin, is one of the most common chemotherapy agents for lymphoma without reciprocal resistance with other kinds of agents.
45467118|NCT03605524|Other|Sensory training|12 weeks sensory training
45467119|NCT04752540|Drug|Olorofim|single oral dose
45467120|NCT03371030|Procedure|Pronatus quadratus reparation|Displaced and intra-articular distal radius fractures treated with volar approach and plate fixation. Pronator Quadratus muscle repair.
45467121|NCT04341454|Drug|DWP14012 X mg|DWP14012 X mg, tablet, orally, once daily for 2 weeks
45467122|NCT04341454|Drug|DWP14012 X mg placebo|DWP14012 X mg placebo-matching tablet, orally, once daily for 2 weeks
45467123|NCT04341454|Drug|DWP14012 Y mg|DWP14012 Y mg, tablet, orally, twice daily for 2 weeks
45467124|NCT04341454|Drug|DWP14012 Y mg placebo|DWP14012 Y mg placebo-matching tablet, orally, twice daily for 2 weeks
46101716|NCT02566252|Drug|Cromolyn Sodium|Pre-treatment
45467125|NCT01567982|Device|tDCS, prefrontal cortex and parietal cortex|tDCS is a non invasive brain stimulation methods. We will use two anodes to stimulate prefrontal and/or parietal cortex using 2mA current for 20 minutes.
46101717|NCT02566252|Drug|Albuterol sulfate|Pre-treatment
46101718|NCT03983434|Dietary Supplement|Inulin|Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
46101719|NCT00823719|Drug|ofatumumab + ICE|"3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 milligrams (mg); cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg~ICE regimen:~ifosfamide + mesna - 5 grams (g)/meters squared (m^2)/24 hours (hrs) continuous on day 2 of dosing cycle; carboplatin - AUC 5 (800 mg maximum) on day 2 of dosing cycle; etoposide - 100 mg/m^2 on days 1, 2 and 3 of dosing cycle."
45467126|NCT03712345|Drug|IFX-1 low dose|Single IV infusions of IFX-1
45467127|NCT03712345|Drug|IFX-1 high dose|Single IV infusions of IFX-1
45467128|NCT03712345|Drug|Placebo|Placebo
45467129|NCT03370016|Procedure|Amount of Pneumoperitoneum Pressure applied during RARP|Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 8 mmHg (experimental) or 12mm Hg (standard technique)
45467130|NCT04659538|Device|CAPTIS Embolic Protection device|The CAPTIS Embolic Protection device will be deployed during standard of care TAVR procedure. The device's safety will be assessed up to one month post procedure. The device's technical performance and feasibility to capture and remove debris during the procedure will be evaluated.
45598385|NCT03154125|Drug|Sayana® Press|The active ingredient in Sayana® Press is Medroxyprogesterone acetate (MPA). Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) for subcutaneous injection.
45837956|NCT05320380|Drug|Cytarabine|Given IT and IV
45837957|NCT05320380|Drug|Fludarabine Phosphate|Given IV
45837958|NCT05320380|Drug|Hydrocortisone Sodium Succinate|Given IT
45837959|NCT05320380|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
45837960|NCT05320380|Drug|Methotrexate|Given IT
46017978|NCT01217073|Drug|Metformin|Metformin 500 mg oral tablet administered once or twice daily
46017979|NCT01217073|Drug|Placebo to metformin|Matching placebo to metformin oral tablet administered once daily
45467131|NCT05420870|Behavioral|exercise|"Six weeks of exercise intervention~To meet weekly 150 min of moderate to vigorous physical activity and twice weekly strength exercise General description of the exercise program~Main goal of the supervised exercise (1 hour per session, twice a week) are three folds. 1) Instruct participants to correctly perform prescribed exercises. 2) Encourage participants to be compliant to exercise program. 3) Participants were encouraged to hand in their exercise diary~Main goal of the home-based exercise is to perform calisthenics exercise daily. Participants were encouraged to perform at least one set of exercise (8-12 different exercises) and stretching (At least 3 days per week, but preferably most of the days) daily~Basic 8 exercises which increase ROM and strength of shoulder, lower back, Hip, Knee and ankle Additional 4 exercise to increase core strength and stability"
45467132|NCT05222230|Other|FFP3 Mask|Participans will wear FFP3 respirators during the study.
45598386|NCT02226107|Behavioral|Peer-PN|Participants in the peer-PN group will also receive two navigation telephone calls: 1) to schedule the colonoscopy, and 2) a reminder call one week before the procedure. It is expected that these phone calls will be shortly longer than the Pro-PN calls by 5-7 minutes because of the additional focus on culture and peer modeling. Peers will remind the patient about the procedure and address concerns, but will provide culturally specific, identity-based navigation, in which they will speak specifically about Latino rates of CRC screening while also modeling self-efficacy by describing what their experience was like before, during and after the colonoscopy procedure.
46017980|NCT00985621|Biological|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
46017981|NCT00985621|Biological|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
46017982|NCT00985621|Drug|oxycodone|oxycodone CR, 10-40 mg q12h
46017983|NCT00985621|Other|placebo|placebo
46017984|NCT01215981|Biological|Influenza vaccine|One dose of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
46017985|NCT01215981|Biological|Influenza vaccine|Two doses of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
46017986|NCT02887833|Other|Clinical biomarker (thermal sensory testing)|Thermal sensitivity testing: The area of CIBP and a corresponding unaffected (control) area will be assessed using warm and cool thermal rollers (Rolltemp, Somedic, Sweden). The control area will either be the contralateral side, or an area proximal to the affected site.
46017987|NCT01215513|Drug|Degarelix|
45837961|NCT05320380|Drug|Prednisolone|Given IT
46017988|NCT01215435|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before breakfast. The trial has 3 treatment phases for both treatment arms
46017989|NCT01215435|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before dinner. The trial has 3 treatment phases for both treatment arms
46017990|NCT01215357|Drug|Ecopipam|50mg tablets
46017991|NCT05433441|Procedure|ESPark Intervention|The treatment will include 15 sessions (1 session per week). An initial assessment will be carried out during the first session in order to determine the objectives and the personalized follow-up.
46101720|NCT00823719|Drug|ofatumumab + DHAP|"3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg.~DHAP regimen:~dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m^2/24 hrs continuous on day 1 of dosing cycle; cytarabine - 2 g/m^2 q12 hrs (2 doses) on day 2 of dosing cycle."
46101721|NCT03953170|Drug|Teduglutide|"Teduglutide (Gattex, Shire) was approved by the FDA in 2012 for use in adult patients with short bowel syndrome requiring parenteral support only.~The results of this study will not be used to justify a change of indication, or dose currently approved for Teduglutide, and will not be used to advertise the drug. This study meets all of the requirements for exemption from the IND regulations and an IND exemption has been confirmed by the FDA."
46101722|NCT03953170|Drug|Placebo|Placebo
46101723|NCT02565550|Dietary Supplement|low FODMAPs|low FODMAPs means excluding food which contains oligosaccharides.disaccharides,monosaccharides, and polyols
46017992|NCT00984295|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|A single 0.5 mL subcutaneous injection at Day 0
46017993|NCT00984295|Biological|Comparator: Tripedia|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
46017994|NCT00984295|Biological|Comparator: Comvax|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
46017995|NCT00984295|Biological|Comparator: Varivax|A single 0.5 mL subcutaneous injection at Day 0
46017996|NCT00984295|Biological|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
46017997|NCT04291027|Other|Land Based Exercise|Group exercise intervention will be held 2 times per week for 12 weeks and will include balance training, strengthening, gait training, and cardiovascular training.
46017998|NCT04291027|Other|Aquatic Exercise|Group exercise intervention will be held 2 times per week for 12 weeks and will include balance training, strengthening, gait training, and cardiovascular training.
46017999|NCT00628186|Device|external drainage tube [polyethylene pancreatic drainage tube]|External drainage tube was intubated with a 5F polyethylene pancreatic drainage tube with a small knob (Sumitomo Bakelite Co., Japan)(MD41515) across pancreaticojejunostomy in pancreaticoduodenectomy, and exteriorized through the jejunal limb.
46018000|NCT00628186|Device|internal drainage tube [polyethylene pancreatic drainage tube]|Internal drainage tube was intubated 5cm length of stent tube cut a 5F polyethylene pancreatic drainage tube with a small knob across pancreaticojejunostomy in pancreaticoduodenectomy, and pancreatic juice was led to reconstructed jejunum.
46101724|NCT02567500|Behavioral|Patients with auditory hallucination|"Patients with auditory hallucination (20 for each arm):~Evaluation at time 0 and 6 month after of:~The social cognitive marker (NEPSY II) : theory of mind and affect recognition~The emotional marker:~Differential emotion scale IV (DES IV): emotional individual stability~Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~Evaluation of diagnosis with DSM-IV criteria:~MINI-Kids~Psychosis section of Kiddie-SADS"
46101725|NCT02567500|Behavioral|Patients without auditory hallucination|"Patients without auditory hallucination (20 for each arm):~Evaluation at time 0 and 6 month after of:~The social cognitive marker (NEPSY II) : theory of mind and affect recognition~The emotional marker:~Differential emotion scale IV (DES IV): emotional individual stability~Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~Evaluation of diagnosis with DSM-IV criteria:~MINI-Kids~Psychosis section of Kiddie-SADS"
46101726|NCT00708591|Drug|Rapamycin|Oral Rapamycin once weekly at assigned dose in 4 week cycles. Dosing can continue until disease progression or severe side effects are seen.
45598387|NCT02226107|Behavioral|Pro-PN|Participants in the standard navigation group receive two phone calls: 1) to schedule the colonoscopy and 2) a reminder call one week before the procedure. The phone calls will each last approximately 15 minutes. During the second phone call, the patient will be reminded about the procedure and any concerns they may have will be addressed. Professional navigators will also be advised to not disclose their race or ethnicity or to discuss specific issues related to Latinos and CRC screening.
45598388|NCT02294617|Other|Electronic Cigarette|Subject will use electronic cigarette for 3 days.
46018001|NCT01017952|Drug|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
46101727|NCT00708591|Drug|Ketoconazole|Twice daily (200mg each time) at the start of the second week of therapy for 4 consecutive days. Dosing continues every week after the second week of therapy.
46101728|NCT04595266|Drug|FOLFOX regimen|"Leucovorin: 400 mg / m2 IV over 15 minutes on day 1 of each cycle. Fluorouracil (5-FU): 400mg / m2 IV bolus (15 min) followed by continuous IV infusion for 46 h of 2,400 mg / m2 on day 1 of each cycle.~Oxaliplatin 85 mg / m2 IV over 120 minutes on cycle day 1"
46101729|NCT04595266|Biological|Anti-EGFR or Bevacizumab|"In case of RAS wt colorectal cancer administer anti-EGFR together with FOLFOX6m, and in case of mutated RAS colorectal cancer administer Bevacizumab together with FOLFOX6m.~Treatment administered following Summary of medicinal Product Characteristics (SmPC) approved indications."
46101730|NCT04595266|Drug|LIVERPEARLS-Irinotecan|Chemoembolization of Irinotecan in 100 +/- 50 micron hydrogel microspheres. Irinotecan will be loaded at a dose of 100 mg. LIFEPEARLS® is a CE marked medical device consisting of microspheres for use in chemoembolization. This device allows the continuous release of irinotecan in liver tumors causing a specific necrosis. The penetration of irinotecan into the tumor tissue is deeper thanks to the microspheres, avoiding proximal occlusion of the vessels supplying the tumor.
46101731|NCT00708669|Device|TAXUS stent|Compared two kinds of stents:TAXUS stent, approved for commercialization in Japan(March 30th, 2007)
46101732|NCT00708669|Device|Cypher stent|CYPHER stent, approved for commercialization in Japan(March 25, 2004)
46101733|NCT02565940|Other|biopsy|
46101734|NCT04062604|Other|surgery|surgical treatment of femur fracture, hip and knee alloplasty, knee arthroscopy
46101735|NCT00708747|Drug|Albumin (5% serum-protein solution containing immunoglobulins)|5% albumin was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
45598389|NCT02294617|Other|Nicotrol Inhaler|Subjects will use the Nicotrol Inhaler for 3 days.
45598390|NCT03112161|Other|Eucaloric Feeding Period|
46018002|NCT01017952|Drug|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA) Inhalation Powder
46018003|NCT01214655|Drug|LY2523355|Administered as a 1-hour IV infusion for at least 2 cycles. Cycle length is 21 days. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
46018004|NCT01017874|Drug|Pemetrexed|500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles.
46018005|NCT01017874|Drug|Cisplatin|75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
46018006|NCT01017874|Drug|Gefitinib|250 milligrams (mg) administered orally once a day, every day of 21-day cycle, for maintenance in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy
46018007|NCT01017874|Drug|Gefitinib|250 milligrams (mg) administered orally once a day, every day of 21-day cycles administered as a monotherapy
46018008|NCT04299568|Device|Anti gravity treadmill training|Lower Body Positive Pressure (LBPP) treadmill training for 15 minutes
46101736|NCT00708747|Drug|Biseko|Standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
46101737|NCT03818854|Biological|Human Mesenchymal Stromal Cells|Immediately prior to administration, the study product will be thawed and diluted 1:1 with reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40). Additional reconstitution media is added to a final product volume of 300 mL.
46101738|NCT03818854|Biological|Cell Reconstitution Media|300 mL of reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40)
46101739|NCT00875420|Drug|RAD1901|10 mg Oral once a day for 28 days.
46101740|NCT00875420|Drug|RAD1901|25 mg Oral once a day for 28 days
46101741|NCT00875420|Drug|RAD1901|50 mg Oral once a day for 28 days.
46018009|NCT04299568|Procedure|Physical Therapy|Heat Therapy in combination with Electro-therapy for 10 minutes, followed by tibio-femoral and patello-femoral joint mobilization
45467133|NCT05420792|Behavioral|Peplau Interpersonal Relations based IPSRT will be applied to the intervention group|IPSRT based on peplau Interpersonal Relations theory will be applied to the intervention group. First of all, information about the study will be given. An informed consent form will be filled and a history will be taken from the patient. With the Life Events Chart, past attacks and life events, interpersonal relations will be compared. Interpersonal Circle will be made to better understand the individual and relationships. A Joint Study Plan, which summarizes the disease history, life events, and interpersonal circle, will be created and presented to the patient in summary form. The patient will be given psychoeducation about his illness, drugs and social rhythms. A Social Rhythm Metric (SRM) will be created and monitored throughout therapy to assess their daily routine. Early warning signs of impending attacks will be discussed, managing symptoms, situations that may disrupt social rhythm will be determined (travel, vacation, moving, changing job)
45467134|NCT03130348|Drug|Bortezomib|Given SC
45837962|NCT05315570|Other|BD4QoL platform|The BD4QoL platform consists of a set of services to allow patient monitoring and empowerment, through two main tools: Point of Care application to manage all patients data and follow-up by clinical investigators, and a mobile application (App) installed on participating subject's smartphone. Also, a web-form tool is delivered to allow the QoL questionnaire completion.
46018010|NCT00627952|Drug|amlodipine 10 mg|amlodipine 10 mg once daily
46101742|NCT00875420|Drug|RAD1901|100 mg Oral once a day for 28 days
46101743|NCT00875420|Drug|Placebo|Placebo Oral once a day for 28 days
46101744|NCT03802396|Drug|CN-105|"Three doses of CN-105 will be used in three successive cohorts of 67 patients each (50 receiving drug and 17 receiving placebo) 0.1 mg/kg (cohort 1) 0.5 mg/kg (cohort 2)~1 mg/kg (cohort 3)~The study drug will be administered by IV every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses."
46101745|NCT03802396|Drug|Placebo|Patients will receive placebo intravenously every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses, identical to those receiving the study drug.
46101746|NCT02567344|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS will be delivered at 110% rMT to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
46018011|NCT00627952|Drug|manidipine 20 mg|manidipine 20 mg once daily
46018012|NCT00627952|Drug|amlodipine 5 mg + delapril 30 mg|amlodipine 5 mg + delapril 30 mg once daily
46101747|NCT02567344|Device|Sham Repetitive Transcranial Magnetic Stimulation|rTMS will be delivered via an electronic sham coil that mimics real rTMS in appearance, sound, and feeling. Pulses will be delivered to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
46101748|NCT00684437|Behavioral|Focus Group|Focus group discussion and evaluation of various smoking risk informational messages. The focus group session should last about 1 hour and 30 minutes.
46101749|NCT00684437|Behavioral|Questionnaire|Questionnaires taking 15-30 minutes to complete.
46018013|NCT00627952|Drug|manidipine 10 mg + delapril 30 mg|manidipine 10 mg + delapril 30 mg once daily
46018014|NCT04299334|Procedure|adjustable neochordae Technique|"Classic ring annuloplasty will be done using Carpentier or physio ring, then neochordal placement will be done using the looping technique. The length of the chordae is adjusted to achieve the optimal length.~In this study, Surgeons use relatively short loops because of the augmentation of the length with extra loops suspended with Gortex. Placement of at least 8-12 chordae of the corresponding heads of the papillary muscle tip to achieve proper management of the prolapse and longevity of the repair."
46018015|NCT01015768|Device|ReNu Multiplus multipurpose disinfecting solution|A new lens (PureVision) soaked 6 hours to overnight in ReNu Multiplus
46018016|NCT01015768|Device|Control|A new lens (PureVision) is soaked for two hours in non-preserved saline
46101750|NCT00685022|Drug|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~Arm #A~Xopenex HFA MDI, albuterol HFA MDI"
46018017|NCT04426630|Other|mHealth for heart failure patients in Uganda|Patients at Uganda Heart Institute will be enrolled in an mHealth program intended to promote self-care for heart failure and improve their healthcare quality of life.
45467135|NCT03130348|Drug|Dexamethasone|Given PO
45467136|NCT03130348|Drug|Ibrutinib|Given PO
46101751|NCT00685022|Drug|Racemic Albuterol followed by levalbuterol HFA MDI|"Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~Arm #B~albuterol HFA MDI, Xopenex HFA MDI"
45467137|NCT03130348|Other|Laboratory Biomarker Analysis|Correlative studies
46018018|NCT01010230|Device|LMHF mechanical stimulation active device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
46101752|NCT03787264|Drug|Bendamustine|Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.
45467138|NCT01307527|Drug|Riboflavin|0.1%, applied every 5 minutes for 60 minutes
46101753|NCT03787264|Biological|Obinutuzumab|"Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v."
45837963|NCT05315310|Device|Soft Exosuit|A soft exosuit is a textile-based wearable robot that is worn on the paretic ankle. Soft exosuits provide assistive torques through retraction of Bowden cables that connect distally to anchor points on front and back of the ankle, assisting with dorsiflexion during swing for foot clearance, and plantarflexion during late stance to assist with propulsion, respectively. Exosuit assistance is provided synchronously based on the wearer's gait, as detected by integrated inertial measurement units.
46018019|NCT01010230|Device|LMHF mechanical stimulation placebo device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
46101754|NCT03787264|Biological|Acalabrutinib|"Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 100mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 100mg p.o."
46101755|NCT03787264|Biological|Venetoclax|"Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o."
46101756|NCT04209881|Other|ovarian reserve for Ankylosing spondylitis and control groups|"Additional organ diseases due to the pathophysiology of the disease may be seen in women with ankylosing spondylitis. therefore, we established the first group of women with the diagnosis of ankylosing spondylitis.~Women Who Are Diagnosed With Ankylosing Spondylitis Will Form The Study Group. and health women will be control group.~Clinical And Laboratory Parameters Will Be Evaluated For Ovarian Capacity Of These Women.~Amh Will Be Looked For (Pmol / L). Antral Folukul Census In The Overin Folukular Stage Will Be Valued As Number. Fsh (Iu / L) And Estradiol (Pmol / L) Values Will Also Be Recorded."
46101757|NCT00822237|Biological|Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)|VARIVAX (2007 process) in two 0.5 mL doses by injection ~6 weeks apart
46101758|NCT00822237|Biological|Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck)|VARIVAX (1999 process) in two 0.5 mL doses by injection ~6 weeks apart
46101759|NCT00822237|Biological|Measles, Mumps, and Rubella Virus Vaccine Live (MMR)|M-M-R II in two 0.5 mL doses by injection ~6 weeks apart
46101760|NCT02626286|Other|HIV quarterly global care|
46101761|NCT00617747|Drug|Zolmitriptan|5mg Nasal Spray
46101762|NCT00617747|Drug|Placebo|
45467139|NCT01307527|Device|Kera-X|3 mW/cm2, to the central 7.5 mm of the cornea, for 30 minutes
45467140|NCT03789955|Procedure|Fluoroscopic-guided TEB|When performing a fluoroscopic-guided thoracic epidural block (TEB), an 18-gauge Tuohy needle will be used for interlaminar epidural access. If the epidural space was accessed under fluoroscopic guidance and using the loss of resistance technique with air. All procedures will be performed with a paramedian approach under the true AP and lateral view at first, If the interlaminar space is not visible, the CLO view will be used. If the needle is deemed to be in the epidural space when the loss occurred, six fluoroscopic views will be obtained: true AP, CLO at 40 degrees, 50 degrees, 60 degrees, CLO measured, and lateral. The CLO measured angle will be determined by measuring the angle between the superior lamina and spinous process on the midsagittal plane on thoracic MRI or CT.
45598391|NCT03112161|Other|Overfeeding Feeding Period|
45598392|NCT03112161|Other|Underfeeding Feeding Period|
45837964|NCT05303532|Drug|Durvalumab|Fixed dose of 1500 mg via IV infusion upon enrollment visit and every 4 weeks thereafter.
45837965|NCT05302375|Other|iPath*D|Online pathway from screening to treatment for depression in cancer patients.
46018020|NCT01009840|Drug|IV busulfan|PK-directed dosing of IV busulfan for 4 days
46018021|NCT01009840|Drug|bortezomib|Single IV bortezomib at a dose of 1.3 mg/m^2.
46018022|NCT01009840|Procedure|Autologous Hematopoietic Stem Cell Transplant (HSCT)|
46018023|NCT04297696|Other|Therapeutic exercises|A program including warm-up period and neuromuscular exercises is applied progressively in two phases.
46018024|NCT04205500|Other|Specific carbohydrate diet|Specific carbohydrate diet (see arm description)
45837966|NCT05294718|Procedure|Internal shunt|glenn with internal shunt (veno-atrial shunt) where the surgeon established a shunt between distal SVC and the right atrium, Establishing a veno-atrial shunt.
46018025|NCT04420936|Behavioral|MAINTAIN PRIME Lifestyle Coaching|Participants will receive two years patient support consisting of supportive coaching via EHR patient portal and tracking tools with EHR. Participants will also receive primary care physician (PCP) support with real time progress reports with counseling tips via EHR prior to visits, notification of weight changes greater or equal to 10 pounds, and annual PCP feedback.
46018026|NCT04420936|Behavioral|Control tracking|Participants will receive two years of patient support consisting of prevention updates via EHR patient portal and tracking tools within the EHR. Participants in this group will not receive primary care physician (PCP) support.
45467141|NCT05402930|Diagnostic Test|Angiomammography|"Patients will receive their care in a standard manner. Breast MRI is one modality used by physicians to monitor response to neoadjuvant chemotherapy and will therefore be used as standard. A CESM exam will be added at the same time as the MRI.~Patients will have a physical exam, breast MRI and CESM before the start of chemotherapy (less than 2 weeks). These examinations will be repeated after cycle 2 (±1 week) and at the end of chemotherapy. After each cycle of chemotherapy, the tumor will be measured in two axes by the attending physician.~Histological examination of the surgical specimen will be used to determine the pCR. Responses observed on MRI and CESM will be compared to pCR."
45467142|NCT03358290|Drug|JTE-051|Active drug tablets containing JTE-051
45467143|NCT03358290|Drug|Placebo|Placebo tablets identical in appearance to the active drug tablets
45467144|NCT05209594|Behavioral|Healthy Relationships Program (HRP) for 2SLGBTQIA+ Youth|The Healthy Relationships Program (HRP) for Two-Spirit, Lesbian, Gay, Bisexual, Trans, Queer, Intersex, and Asexual + (2SLGBTQIA+) Youth is a small group positive mental health promotion program for gender, sexual, and romantic minority youth. It helps build resiliency and promote well-being among 2SLGBTQIA+ youth. It affirms, validates, and celebrates sexual and gender diversity, cultivates a caring and supportive community, and helps 2SLGBTQIA+ youth develop skills and strategies that promote healthy relationships. This trauma-informed, strengths-focused program explores stressors unique to 2SLGBTQIA+ youth, including identity and expression invalidation, stigma, prejudice and discrimination, internalized oppression, coming out, safety, and microaggressions. This program includes 17 sessions, each lasting approximately 45 minutes. It may be delivered in school-based Genders and Sexualities Alliances/Gay-Straight Alliances (GSA) or 2SLGBTQIA+ youth group settings.
45467145|NCT05209594|Behavioral|Standard GSA Programming|Students at comparison sites will participate in standard GSA programming, a safe space for 2SLGBTQIA+ youth and their allies to meet, develop relationships, support each other, socialize, and learn about sexuality and gender-related topics, and lobby for social change.
45598393|NCT02226185|Drug|Berberine hydrochloride|supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years
45837967|NCT05294718|Procedure|External shunt|Glenn with external shunt where the anesthesiologist connected the internal Jagular venous cannula which represent the SVC with the main lumen of the femoral cannula which represent the IVC through long venous extension
46018027|NCT04295980|Procedure|Surgical removal of the BAVMs|Resection the BAVM nidus by microsurgery.
46018028|NCT02872090|Drug|Indacaterol|inhalation
46018029|NCT02872090|Drug|Glycopyrronium|inhalation
45598394|NCT02226185|Drug|placebo|supplement of placebo two times per day for 2-3 years
45598395|NCT02291341|Drug|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
45598396|NCT02291341|Drug|Cymbalta®|60 mg capsule of Eli Lilly and Company
45598397|NCT02258633|Other|Interactive interview and tailored family centered seatbelt safety intervention|
45598398|NCT03112317|Other|Prevention of hypothermia|Patients are routinely warmed with forced air warming blankets, regular blankets, pre warmed intravenous fluid. Routines are ensured with use of the WHO Surgical Safety Checklist. The intervention is the use of operating theatre care measures to prevent mild hypothermia in surgical patients.
45598399|NCT02258711|Device|SIMPLE 2.0|SIMPLE 2.0 psychoeducative and self-monitoring smart-phone application plus treatment as usual.
46018030|NCT02872090|Drug|Tiotropium|inhalation
46018031|NCT02872090|Drug|Placebo|
46018032|NCT02872090|Procedure|photoplethysmography|inhalation
46018033|NCT04514458|Other|Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial)|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
46018034|NCT04282486|Other|Telephone interview|"Primary objective: potentially inappropriate medication prevalence~Secondary objective:~Number and type of medication Polypharmacy prevalence Medication regimen complexity using Medication Regimen Complexity Index Anticholinergic and sedative exposure using Drug Burden Index~A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions."
46018035|NCT04296058|Other|microvessel density|the vessel numbers in high power field with Anti-CD31 staining in tumor specimen
46101763|NCT04560400|Diagnostic Test|Conventional King-Devick test|Conventional King-Devick test involves a series of number reading task from left to right and top to bottom, intending to test subjects' neuro-ophthalmologic function
46101764|NCT04560400|Diagnostic Test|Reverse King-Devick test|Reverse King-Devick test involves a series of number reading task from right to left and bottom to top, intending to test subjects' neuro-ophthalmologic function
45467146|NCT05091710|Other|HF follow up care|The intervention will consist of follow up phone calls and visits during which the CHWs will remind patients about upcoming visits, ensure patient has sufficient medications, review medication schedule and provide education as needed.
46101765|NCT04041531|Other|blood sampling|venous blood sampling for oxygen affinity in-vitro test
46101766|NCT00619775|Device|PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device|Carotid artery stenting with distal embolic protection.
46101767|NCT00685100|Other|PDT plus intravitreal triamcinolone|PDT plus intravitreal triamcinolone
46101768|NCT00708903|Drug|neratinib|HKI-272
46101769|NCT00708903|Other|Placebo|Placebo
46101770|NCT00708903|Drug|Moxifloxacin|
46101771|NCT00619853|Behavioral|treatment approach - CIMT|CIMT, 2 months, 2Hr per day
46101772|NCT00619853|Behavioral|treatment approach - HABIT|HABIT-2 months, 2Hr per day
46101773|NCT00708981|Other|Multifactorial Intervention|"Study group will receive multifactorial intervention for advanced diabetic nephropathy:~Elements of multifactorial intervention:~BP control of <130/80mmHg and renal protection with reduction of proteinuria to <0.5g/day using therapy with ACE inhibitors and/or ARBs.~Tight glucose control with target of HbA1C of 7% and below using SMBG and Lantus/Apidra regimen.~Use of hypolipidemic therapy to achieve targets of LDL < 70 mg/dl, HDL > 40/50 mg/dl (M/F)and TG < 200 mg/dl.~Patient enhanced self-management provided by combined diabetes-renal education curriculum.~Behavior and social intervention~Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors carried out by clinical research coordinators."
46101774|NCT00637091|Drug|Cetuximab, irinotecan|cetuximab, irinotecan
46101775|NCT04138784|Other|Individualized comprehensive rehabilitation program|The program general contents were pain education, joint protection techniques, general care lifestyle habits, which were complemented by a problem-based session. The program plan was designed to fit patients' goals, priorities, and lifestyles after an initial interview.
46101776|NCT04138784|Other|Aquatic training|Patients received a 45 min-water exercise program which included balance and proprioception activities, isometric exercise, flexibility exercises, core stabilization exercises and aerobic/endurance exercises. All sessions were developed in groups and addressed by a qualified professional.
46101777|NCT00922857|Procedure|Respiratory rehabilitation|The training begins 5 days after the initial assessment. It consists of 3 weekly sessions for 8 consecutive weeks, including the following activities interspersed with periods of rest, according to the needs of patients
46101778|NCT04213391|Dietary Supplement|sulforaphane|Sulforaphane take 2550mg once a day.
46101779|NCT04213391|Dietary Supplement|Placebo|Placebo take 2550mg once a day.
46101780|NCT00690326|Behavioral|Behavioral change communication to promote physical activity|"treatment type: behavioral (lifestyle counseling)~treatment name: behavioral change communication to promote physical activity"
45598400|NCT02220179|Behavioral|The Resilience Program|Se the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'
45598401|NCT02352987|Drug|Neem plus propylene glycol plus salicylic acid|Leaf extract of neem plus propylene glycol (40%) plus salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
46018036|NCT04295746|Other|Serious Game ShopAut|"The serious game ShopAut, is a three-dimensional game conceptually based on classic 3D life simulation games. ShopAut aims to teach players the procedure of a shopping activity; to reinforce object categorization and recognition in a supermarket; to improve attention, orientation, and problem-solving skills; and to help the player engage in simple economic transactions.~The intervention provides a virtual training with ShopAut to train, experiment, and practice behaviours and actions that can be then transferred in real-life contexts."
46018037|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at 6.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
46101781|NCT00690326|Behavioral|Behavioral change communication to promote physical activity|"Arm B given placebo comparator ie pamphlet~Audiovisual module Physical activity frequency questionnaire"
45837968|NCT05288595|Device|CliniMACS Plus Instrument|Miltenyi Biotec's CliniMACS Plus Instrument is to be used to TCRαβ CD19 deplete products utilized in this protocol. The CliniMACS Plus is an automated cell separation platform which is functionally closed, maintaining a sterile system for cell depletion and enrichment utilizing a magnetic separation column. Reagents and supplies are to be used for research only but are manufactured and tested under a quality system certified to ISO 13485. Should CD34 selection be required to augment stem cell dose, Miltenyi Biotec's CliniMACS® Plus CD34 Reagent System is FDA approved as a Humanitarian Use Device (HUD). The approved indication was the treatment of patients with acute myeloid leukemia (AML) undergoing myeloablative transplant from matched related allogeneic donors. The CliniMACS® Plus reagent system was approved to obtain an enriched CD34+ cell population for hematopoietic reconstitution without the need for GVHD prophylaxis.
46018038|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at 12.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
45598402|NCT02352987|Drug|Salicylic acid|salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
46018039|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at 15.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
46018040|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
46018041|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
46018042|NCT00982657|Drug|Sunitinib|50 mg sunitinib daily (4 out of 6 weeks)
46018043|NCT02867683|Other|Vibrotactile Feedback|Balance training Vibrotactile feedback applied to the trunk
46018044|NCT02867839|Drug|Oxaliplatin plus S-1|8 cycles of adjuvant chemotherapy with Oxaliplatin plus S-1
46018045|NCT02867839|Drug|S-1 only|16 cycles of adjuvant chemotherapy with S-1 only
46101782|NCT00709137|Drug|spironolactone|tablet form. doses used range from 12.5-50mg po QDAY. Total duration would be until completion or study or medication intolerance.
46101783|NCT00709137|Drug|amiloride|amiloride 2.5-10 mg po QDAY. Duration until completion of study or until tolerance
46101784|NCT00617825|Other|cyrotherapy as a cool gel wrap|A cool gel wrap made of a hydrogel with silicon will be applied to the lower leg of skin affected by venous disorders for 30 minutes each day for 30 days during the study
46101785|NCT04150406|Dietary Supplement|Flexofytol|Curcuma extract
46101786|NCT04150406|Other|Placebo|placebo
46018046|NCT04119973|Other|standard treatment|standard medical treatment
45467147|NCT05091710|Other|HF Standard of Care (SOC)|SOC after discharge for HF is to notify patients of a follow-up visit at the hospital/clinic - about 7 days after discharge and provide patients about 30 days of medications at discharge. If a patient does not return for a follow-up appointment, there are no systems to track this missed visit, or to trigger active attempts to contact patients. For patients who come back to their scheduled 7-day visit, there is generally a 14-day visit followed by a 28-day visit.
45467148|NCT05069701|Diagnostic Test|SVV test|SVV test will be done with virtual reality glasses.
45467149|NCT05439928|Device|DEXCOM G6 CGM|Continuous glucose monitoring
45467150|NCT03789799|Other|TIAB: microcrystalline titanium dioxide with covalently linked monovalent silver ions|TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract
45467151|NCT03789799|Other|Placebo|Placebo vaginal capsule, composition: Sodium Hyaluronate, Aloe Barbadensis Extract
45467152|NCT03710148|Other|Natural exposure of deficient or excessive iodine|Natural exposure of deficient iodine from diet & drinking water, and of excessive iodine intake from drinking water
45467153|NCT05439772|Drug|Ondansetron|Patient will take one dissolvable tablet of ondansetron prior to initiating PEG consumption.
45467154|NCT05694715|Drug|Niraparib|Given orally
46018047|NCT02867293|Procedure|ultrasound guided ascitic fluid drainage|
46018048|NCT02867293|Procedure|operative drainage of ascites through small skin incision after induction of anesthesia|
46018049|NCT02867293|Device|ultrasound|
46018050|NCT02867137|Other|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
46018051|NCT02867371|Device|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
46018052|NCT02867215|Other|Barley bread|120g barley bread per day for 3 weeks.
46018053|NCT02867215|Other|Wheat bread|120g wheat bread per day for 3 weeks.
46101787|NCT03659266|Other|Robotic walking rehabilitation by Lokomat®|Lokomat sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of effective work of the march and 15 minutes of setting up.
46101788|NCT03659266|Other|Conventional walking rehabilitation|5 physiotherapy sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of walking and 15 minutes of stretching
45467155|NCT05694715|Drug|Irinotecan|Given intravenously (IV)
45467156|NCT05439538|Diagnostic Test|SERUM NGAL|Study the sensitivity and the specificity of serum NGAL to detect AKI in myeloma
45467157|NCT05683002|Dietary Supplement|Aronia supplementation|As described in experimental arm
45467158|NCT05683002|Dietary Supplement|Cellulose supplementation|As described in placebo comparator arm
46018054|NCT01005316|Drug|Induction Therapy|Per standard of care guidelines for immunosuppression at each clinical site.
46018055|NCT01005316|Drug|Tacrolimus|Per standard of care guidelines for immunosuppression at each clinical site.
46018056|NCT01005316|Drug|Mycophenolate Mofetil|Per standard of care guidelines for immunosuppression at each clinical site.
46018057|NCT01005316|Procedure|Intraoperative plasma exchange/pheresis|Per standard of care guidelines for immunosuppression at each clinical site.
46018058|NCT01005316|Procedure|Short-term post-operative plasmapheresis|Per standard of care guidelines for immunosuppression at each clinical site.
46101789|NCT01558427|Procedure|Surveillance|Active clinical surveillance
46101790|NCT01558427|Procedure|Salvage treatment|Surgical removal of metastases, or stereotactic body radiotherapy of metastases.
46101791|NCT04150172|Drug|Rebamipide SR 150mg|Test drug
46101792|NCT04150172|Drug|Rebamipide IR 100mg|Reference Drug
46101793|NCT02611245|Drug|Indocyanine green|This group of patients accepted intravenous injection from 0.5mg / kg to 5mg / kg ICG within 4 to 24 hours before surgery. All patients under general anesthesia to accept conventional thoracoscopy or thoracotomy. After entering the chest using fluorescence thoracoscopy system to collect the fluorescence and white-light images and record the video. After following the routine preoperative planning surgery, the researchers will carefully assess the possibility of the benign and malignant nodules and to communicate with the families of patients. If the patient's family expressed their willingness to dissect the nodules, the researchers will remove this extra pulmonary nodules. Resected specimens will send to routine pathological confirmation compared with the fluorescence results.
46101794|NCT02325011|Drug|Sativex® (Treatment A)|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
45467159|NCT01309399|Drug|Teriparatide|six weeks of teriparatide
46018059|NCT01005316|Drug|Immunoglobulins, Intravenous|Post-transplant course of intravenous immunoglobulin therapy per standard of care guidelines for immunosuppression at each clinical site.
45467160|NCT01309399|Other|placebo|placebo
46018060|NCT01005316|Drug|Prednisone|Maintenance corticosteroids per standard of care guidelines for immunosuppression at each clinical site.
46018061|NCT01004848|Behavioral|Peer-Led Lifestyle Education on Weight Loss|Project HEED (Help Educate to Eliminate Diabetes) is a bilingual lifestyle education program written at a 4th grade reading level, and contains simple, actionable, messages, is easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes. It consists of 8 sessions (1½ hours each) held over 10-weeks. Topics include diabetes prevention, finding and affording healthy foods, label reading, fun physical activity, planning a healthy plate, making traditional foods healthy, and portion control.
46018062|NCT01009294|Drug|Ataluren|Oral powder
45467161|NCT03187444|Procedure|Examinations|Several examinations are realized on each patients, in addition to the usual visit and after verification of the criteria of inclusion and signature of consent.
45467162|NCT05682924|Diagnostic Test|taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry|In the study, blood will be taken from patients with chronic myelogenous leukemia in the chronic phase to determine biochemical parameters (endothelin-1, homocysteine, VEGF (vascular endothelial growth factor)), as well as a study of microcirculation in these groups of patients using the method of laser Doppler flowmetry, to study the function of the endothelium.
45467163|NCT03311828|Biological|Daratumumab|Given IV
46018063|NCT01009294|Drug|Chronic Corticosteroid Therapy|Enrollment was stratified to ensure evaluation of approximately half of the participants were receiving chronic corticosteroid therapy and approximately half of participants were not receiving chronic corticosteroid therapy. Therefore, 3 out of 6 participants were receiving chronic corticosteriod therapy. For the participants receiving chronic corticosteriod therapy, a stable corticosteriod regimen was to be maintained during the study.
45467164|NCT03311828|Drug|Imaging Agent|Given Copper 64Cu-DOTA-daratumumab IV
45467165|NCT03311828|Procedure|Positron Emission Tomography|Undergo PET
45467166|NCT03311828|Other|Pharmacological Study|Correlative studies
45467167|NCT03789643|Drug|JTT-251|Active drug tablets containing JTT-251
45467168|NCT03789643|Drug|Placebo|Placebo tablets matching in appearance to the active drug tablets
45467169|NCT05439382|Procedure|Gingival recession regenerative surgery|Bilaminar technique was performed by the same trained operator, opening a primary flap in correspondence of the recession site. Tissue was harvested from palatal donor site and grafted beneath the primary flap
46101795|NCT02325011|Drug|Sativex® and fluconazole concomitantly (Treatment B)|"Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.~Fluconazole 200 mg twice daily (BID) for two days, will be administered at the following time points relative to the Day 1 Sativex dose: 1 hour pre-dose, and approximately 11, 24, and 36 hours post-dose."
46101796|NCT00690404|Drug|AZD2066|single oral dose
46101797|NCT00620009|Behavioral|Empathy Feedback|Discussion of empathy ratings between patients and therapists during psychotherapy sessions.
46101798|NCT02625584|Behavioral|Reading Together - Pausing for Reading|
46101799|NCT02625584|Behavioral|Reading Together - Dialogic Reading|
46101800|NCT02625584|Behavioral|Reading Together - Shared Reading Control|
45467170|NCT03710070|Device|Amplatzer vascular plug 4|See above
45467171|NCT03710070|Other|Sham Control|Angiography of the IMA without occlusion
45467172|NCT01309477|Drug|Tacrolimus Sustained-release Capsules (ADVAGRAF)|Started: 0.05-0.1mg/kg/d, one time per day, then adjusting the dose to maintain the blood level 5-10ng/ml in the induction treatment .
45467173|NCT05598554|Other|Telerehabilitation|Chair-based yoga with telerehabilitation was applied to the study group for 45 minutes a day, 2 days a week, for 6 weeks.
45467174|NCT05598554|Other|information|A one-session training was provided on the effects of exercise on quality of life.
45467175|NCT05439304|Other|No intervention|No intervention
45467176|NCT03709992|Drug|Trospium Chloride|30 mg of Trospium chloride tablet twice daily
45467177|NCT03709992|Drug|Tamsulosin|0.4 mg of Tamsulosin tablet once daily
45467178|NCT05598476|Other|5kg bag|a 5 kg bag is applied on the chest for 2 hours
45467179|NCT05439226|Other|CMNT diet|Hypocaloric CMNT diet plan: A diet plan with intermittent use of enriched traditional-Chinese-medicinal-foods CMNT diet
45467180|NCT01568762|Drug|VAK694|Intravenous infusion
45467181|NCT01568762|Drug|VAK694 placebo|Intravenous infusion
45467182|NCT01568762|Drug|QAX576|Intravenous infusion
45467183|NCT01568762|Drug|QAX576 placebo|Intravenous infusion
45467184|NCT03789565|Other|Biomarker test|Diagnostic biomarker study
45680821|NCT04594772|Procedure|Pancreatectomy|Pancreatectomy should occur within 4 to 8 weeks after the last dose of preoperative chemotherapy. Staging laparoscopy may be performed at the time of planned laparotomy but is not required. Either standard or pylorus-preserving pancreaticoduodenectomy, distal subtotal pancreatectomy, or total pancreatectomy may be performed. Surgical drains and enteral tubes (e.g. gastrostomy and/or jejunostomy tubes) may be placed at the discretion of the operating surgeon.
46018064|NCT04205422|Procedure|BIPAP|Biphasic Intermittent Positive Airway Pressure
46101801|NCT00577096|Drug|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg og body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl.
46101802|NCT00577096|Behavioral|Exercise|A home-based individualized exercise program that incorporated aerobic and strength resistance training.
46018065|NCT04205422|Procedure|APRV|Airway Pressure Release Ventilation
46018066|NCT04205188|Other|therapeutic exercises|aerobic- balance -stretching and strengthening exercises
46101803|NCT00577096|Biological|Autologous Peripheral Blood Stem Cell Transplantation|Standard PBSCT for multiple myeloma
46101804|NCT00577096|Biological|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
46101805|NCT00577096|Drug|Thalidomide|Fifty percent of the participants received 400 mg daily
46101806|NCT00577096|Drug|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
46101807|NCT00577096|Biological|Platelet Transfusion|Platelet transfusions were administered as needed
45467185|NCT03789487|Device|Device programming of CRT pacemaker or defibrillator|Stimulation vector optimization then AV delay optimization in order to obtain the highest systolic blood pressure (SBP) by using the Finapress® NOVA noninvasive device
45467186|NCT05191212|Procedure|indocyanine green|Cervical indocyanine green injection for the detection of sentinel lymph node
45467187|NCT05066126|Behavioral|Mixed-Presentation of Content|Participants in the high-mixed presentation of content conditions will receive a social media feed that varies greatly between topics, so that each subsequent post is on a different topic. In the low-mixed presentation of content condition, participants will be shown posts on any given topic grouped together.
46018067|NCT01009060|Drug|GSK239512|Histamine H3 Antagonist
45467188|NCT05438992|Drug|Bupivacaine 0.25% Preservative-Free Injectable Solution|local anesthetic drug injection for postoperative pain
45680822|NCT01393990|Drug|LY2228820|Administered orally
45680823|NCT01393990|Drug|Midazolam|
46101808|NCT00577096|Drug|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
45467189|NCT03783637|Other|Whole grain oats|A meal containing whole grain oats
45680824|NCT01393990|Drug|Tamoxifen|
45467190|NCT03783637|Other|Whole grain wheat|A meal containing whole grain wheat
45467191|NCT05361486|Other|Training on revised algorithm|relevant HCP working in study facilities will be trained on the relevant aspects of performing the G6PD testing, interpreting its result, evaluating patient's eligibility for RC and choosing the appropriate treatment as per their role accordingly
45467192|NCT05361486|Other|Enhancing Pharmacovigilance|Refresher training on PV reporting in the selected facilities. National PV forms will be reviewed and if required, modified in consultation with the national PV system.
45467193|NCT05361486|Other|Supervision of malaria services in selected facilities.|Supervisors in target regions will be trained as for the HCPs.
45680825|NCT05366374|Other|Swallowing assessment with Swallis DSA™ Device|The WALLIS DSA™ investigative device is designed to capture and display pharyngolaryngeal activity in subjects with or at risk of swallowing disorders. The DM is non-invasive: a miniaturized microphone and accelerometer are integrated into the form of a necklace, which will be positioned around the patient's neck to capture the vibroacoustic signals of swallowing during mealtime.
45680826|NCT00210184|Drug|Irinotecan associated to fluorouracil and leucovorin|
46018068|NCT01009060|Drug|Placebo|Placebo to match GSK239512
46018069|NCT00988429|Drug|800 mg QD Eslicarbazepine acetate|Oral, 800 mg QD, 2-week titration period and 12-week maintenance period
46018070|NCT00988429|Drug|1200 mg QD Eslicarbazepine acetate|Oral, 1200 mg QD, 2-week titration followed by 12-week maintenance period
46018071|NCT00988429|Drug|Placebo|Placebo tablet given QD
46018072|NCT01008904|Drug|magnesium oxide|Given PO
46101809|NCT00577096|Drug|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg of body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl
46101810|NCT00577096|Drug|Total Therapy II|Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone, cyclophosphamide,etoposide, and cisplatin (DCEP) (40 mg, 400 mg/m2, 40 mg/m2, and 15 mg/m2,respectively); and cyclophosphamide,doxorubicin, and dexamethasone (CAD) (750 mg/m2, 15 mg/m2, and 40 mg, respectively) for mobilization.
46101811|NCT00577096|Biological|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
46101812|NCT00577096|Drug|Thalidomide|Fifty percent of participants received 400 mg daily
45680827|NCT00210106|Device|Ablathermy|
46018073|NCT01008904|Other|questionnaire administration|Ancillary studies
46101813|NCT00577096|Drug|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
45467194|NCT05361486|Diagnostic Test|G6PD testing|G6PD test after Malaria Vivax diagnosis
46101814|NCT00577096|Biological|Platelet Transfusion|Platelet transfusions were administered as needed
45467195|NCT05361486|Drug|Tafenoquine|300 mg (2x150mg tablets) tafenoquine
46101815|NCT00577096|Drug|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
45467196|NCT05361486|Drug|Primaquine|0.5mg/kg/7 days
45680828|NCT04000282|Drug|SAR442085|Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous
46101816|NCT04211285|Diagnostic Test|e-GAB|android application for comprehensive geriatric assessment
45680829|NCT05368168|Device|Posterior tibial nerve stimulation (PTNS)|"Posterior tibial nerve neurostimulation in postoperative patients treated for rectal neoplasms for 6 weeks at a rate of 2 sessions per week (12 sessions).~The sessions will be carried out by the nursing staff of the anorectal functional testing cabinet. The sessions will begin 3 weeks after hospital discharge for patients without lateral ileostomy and after ileostomy closure for patients with lateral ileostomy."
45680830|NCT05364190|Drug|Canagliflozin|Canagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
45680831|NCT05364190|Drug|Empagliflozin|Empagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
45680832|NCT05368480|Other|Senior Companion Program|Receives a companion to socialize with them, help with daily tasks, etc.
45680833|NCT05362786|Drug|Allogeneic adipose-derived mesenchymal stem cells (MSC)|Two intravenous infusions delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 100x10^6 cells at day 0 and day 84
45680834|NCT05362786|Drug|Allogeneic adipose-derived mesenchymal stem cells (MSC)|Single intravenous infusion delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 200x10^6 cells at day 0
46018074|NCT01008904|Procedure|quality-of-life assessment|Ancillary studies
46101817|NCT04211285|Diagnostic Test|standard physician performed CGA|CGA by an experienced geriatrician blinded to the result of e-GAB
46101818|NCT02625506|Drug|Levobupivacaine|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine
46101819|NCT02625506|Drug|Levobupivacaine and Tramadol|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine in conjunction with tramadol
46101820|NCT00620399|Other|lumbar corset|
45680835|NCT00210964|Drug|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
45467197|NCT05361486|Other|Follow Up Visit at Day 3 [+2 days] after treatment start|It will be checked if all patients have a Follow Up Visit at Day 3 [+2 days] after treatment start
46018075|NCT04295590|Behavioral|Frequency comparison|One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to high-frequency low-intensity (5 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery).
46018076|NCT04295590|Behavioral|Intensity comparison|One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to low-frequency high-intensity (3 days per week of 8 x 1 min @ 100% peak work rate interspersed with 1-minute periods of active recovery).
46018077|NCT04291261|Drug|Uvadex|Extracorporeal photopheresis (ECP) with Uvadex is scheduled 3x/week in weeks 1+2, 2x/week thereafter till day 28 and 1x/week till day 56
46018078|NCT04291495|Diagnostic Test|ANDROSITOL®TEST|Sperm incubation with ANDROSITOL®DGN and evaluation of sperm motility and mithocondrial membrane potential
46018079|NCT04290559|Procedure|Reveal LINQ ILR implant before AF ablation|Patients will undergo insertion of a LINQ ILR before the atrial fibrillation ablation performed according to standard clinical practice.
45467198|NCT03089216|Procedure|Combined Bleaching(2x20)|one clinical session with two applications of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
45467199|NCT03089216|Procedure|Combined Bleaching(2x20) with arginine|one clinical session with two applications of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
45467200|NCT03089216|Procedure|Combined Bleaching (1x20)|one clinical session with one application of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
45467201|NCT03089216|Procedure|Combined Bleaching(1x20) with arginine|one clinical session with one application of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
46018080|NCT04290793|Drug|Pyrotinib|400mg administered as continuous oral once daily from the first day of the study
45467202|NCT03089216|Drug|8% arginine and calcium carbonate|using during all the treatment.
45467203|NCT03783793|Behavioral|Mindfulness Training App|Mindfulness training in the study was performed using a new app called Wildflowers. With this app participants were able to choose and complete a variety of guided meditations over the 3 week training period. Wildflowers includes guided meditations such as breathing, body scans, and open monitoring practices and also provides didactic content in the form of lessons and information about the benefits of mindfulness training.
46018081|NCT04290793|Drug|Epirubicin|90mg/m^2 d1 iv Q2W for 4 cycles
46018082|NCT04290793|Drug|Cyclophosphamide|600 mg/m^2 d1 iv Q2W for 4 cycles
45680836|NCT00210964|Drug|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
45680837|NCT00210652|Drug|RWJ 333369:|Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
46018083|NCT04290793|Drug|Taxanes|Albumin paclitaxel（125mg/m2 d1、8 iv Q3W for 4 Cycles）/Docetaxel(100mg/m2 d1 iv Q3W for 4 Cycles )
46018084|NCT04290793|Biological|Trastuzumab|the first cycle is a loading dose of 8 mg / kg, followed by 6 mg / kg. Iv Q3W for 1 year
46018085|NCT01004614|Drug|Amlodipine|3rd OD 5 mg tablet single oral dose administered with water
46018086|NCT01004614|Drug|Amlodipine|2nd OD 5 mg tablet single oral dose administered with water
46018087|NCT01004614|Drug|Amlodipine|3rd OD 5 mg tablet single oral dose administered without water
46101821|NCT04209959|Drug|nifekalant|Nifekalant was randomly given intravenously as a loading dose of 0.3 mg/kg, 0.4 mg/kg, or 0.5 mg/kg for five minutes without the continuous infusion for all study population, while blood pressure, surface electrocardiograms (ECG), intracardiac electrograms were monitored for half an hour. While nifekalant was given intravenously, QT interval, QTc interval and RR interval were recorded at 0, 1, 3, 5, 10, 15, 20 and 30minutes, respectively, because drug action almost disappeared within 30minutes since a single dose of intravenous nifekalant injection. These doses of nifekalant were determined based on the results of the previous study and the medicine operation instruction. Once AF continued after administration or Torsade de points was observed, external electrical cardioversion was given immediately.
46101822|NCT04209647|Other|REHIT Exercise|"-Start with warm-up period --> %50 of maximum work rate, 3 minutes~One Exercise Cycle consists of:~15 seconds exercise period: %100 of maximum work rate~15 seconds recovery period: %50 of maximum work rate~Total Duration: 10 minutes"
46101823|NCT04209647|Other|Continuous Aerobic Exercise|At %50 of maximum heart rate, 30-60 minutes aerobic exercise
46101824|NCT02565472|Other|White grape juice|
46101825|NCT02565472|Other|Apple juice|
46101826|NCT04209803|Drug|Minoxidil 5% topically and oral NAC 600 mg|Topical 5% Minoxidil and N-Acetyl-Cysteine 600 mg orally
45467204|NCT03783793|Behavioral|Cognitive Training With 2048|The training app for the control condition was based on an open source code for a popular cognitive training app called 2048 that is marketed as a fun and relaxing puzzle game. Within 2048, participants slide numbered tiles around a grid, matching tiles of the same value. Instead of tiles disappearing, as in Candy Crush or other similar grid-sliding games, matching 2 numbered tiles in 2048 combines them into 1 new tile displaying the sum of the previous 2 numbers. For example, two 2-tiles linked side-by-side become a 4-tile, whereas 2 matched 4-tiles become an 8-tile, and so on. The goal is to match tiles until the sum of 2048 is reached on a single tile. There is no time limit.
45467205|NCT03707106|Behavioral|CBT smoking cessation|an established protocol for smoking cessation based on cognitive behavioral therapy
45467206|NCT03707106|Behavioral|virtual reality based cue exposure|smoking cue exposure in virtual reality
45680838|NCT03997786|Drug|Tildrakizumab|Week 0 (Day 1), Week 4 (Day 28) and week 16 (Day 112)
45680839|NCT03997786|Drug|Placebo|(Weeks 0 to 16)
45680840|NCT03997786|Drug|Tildrakizumab|(Weeks 16 to 52)
45680841|NCT03997786|Drug|Tildrakizumab|at every 12 weeks in open label fashion till 5 years (240 weeks).
46018088|NCT01004614|Drug|Amlodipine|2nd OD 5 mg tablet single oral dose administered without water
46018089|NCT02871700|Behavioral|Action observation therapy|The patients were asked to observe everyday life actions of which they had motor experience or the actions belong to the motor repertoire of observers', they had better performance. The common categories of motor actions and tasks for stroke patients are selected in this study: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-extremity (UE) functional tasks practice.
46018090|NCT02871700|Behavioral|Mirror therapy|The MT group will receive 60 minutes of upper-limb training in a mirror box. MT treatment activities will include AROM exercises (10 to 15 minutes), reaching movement or object manipulation (15 to 20 minutes), and functional tasks practice (30 minutes) in a mirror box.
46018091|NCT02871700|Behavioral|Customary bilateral UE training|The participants in this group will receive dose-matched customary bilateral UE training programs for 1 hour per session. The treatment protocol of control group will also include: (a) AROM exercises (10 to 15 minutes), (b) reaching movement or object manipulation (15 to 20 minutes), and (3) functional tasks practice (30 minutes).
45680842|NCT03997786|Drug|Tildrakizumab|(Weeks 0 to 16)
45680843|NCT03997786|Drug|Etanercept|(Weeks 0 to 16)
45680844|NCT03997786|Drug|Placebo|(Weeks 16 to 52)
45680845|NCT05369104|Biological|Anti-Staphylococcus aureus Bacteriophages|Single intra-articular injection
45680846|NCT05365126|Behavioral|Complete Vocal Technique Voice Therapy|A Complete Vocal Technique (CVT) Practitioner will assess the patient's voice and voice problems using the CVT framework and then apply CVT therapy, a form of voice therapy
45680847|NCT05630638|Drug|Doravirine|Fixed dose combination of doravirine, lamivudine and tenofovir disoproxil
45680848|NCT05630638|Drug|Dolutegravir|Fixed dose combination of dolutegravir, lamivudine and tenofovir disoproxil
45680849|NCT05362162|Procedure|cervical plexus block|local anesthetic agent injection into the either Superficial or intermediate area
46018092|NCT02871076|Device|Acupuncture|Patients will be randomized to either treatment arm, verum acupuncture or sham placebo acupuncture.
46018093|NCT04297462|Drug|Oseltamivir 3 days|Non-inferiority study of 3 versus 7-days duration of PEP
46018094|NCT04297462|Drug|Oseltamivir 7 days|Active comparator
46018095|NCT00981409|Drug|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (<50 kg, 5 mg; 50 to 100 kg, 7.5 mg; >100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
46018096|NCT00981409|Drug|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
45467207|NCT03707106|Behavioral|progressive muscle relaxation|Progressive muscle relaxation for unspecific stress reduction
46018097|NCT04297228|Behavioral|Step by Step: A Family-Centered Healthy Lifestyle Intervention|
46018098|NCT04298710|Behavioral|Arm Cycling|20 minutes of arm cycling exercise at light to moderate intensity.
46018099|NCT04298710|Behavioral|Leg Cycling|20 minutes of leg cycling exercise at light to moderate intensity.
46018100|NCT04298710|Behavioral|Sitting|Remain seated for 20 minutes.
46018101|NCT02865655|Procedure|Hysteroscopic|
46018102|NCT04297072|Drug|Rivaroxaban (Xarelto, BAY-597939)|Non-vitamin K antagonist oral anticoagulants (NOACs). The prescription of drug is at the discretion of physician following the routine clinical practice.
46018103|NCT04297072|Drug|VKAs|Oral anticoagulant. The prescription of drug is at the discretion of physician following the routine clinical practice.
46018104|NCT02871310|Dietary Supplement|IQP-AS-118|1 tablet in the morning
46018105|NCT02871310|Dietary Supplement|Placebo|1 tablet in the morning
45467208|NCT03783481|Device|Mobile community|Install an application (app) on subjects' smartphone. Subject's will join the mobile community using the application through which they can check their own and other members daily steps and communicate with each other.
45467209|NCT03783481|Other|No Mobile community|No Mobile community
46018106|NCT04116853|Behavioral|ADAPTIVE Extended-Care Program|Each extended-care intervention phone call will be initiated by the interventionist, and will begin with a brief check-in followed by a discussion of any barriers experienced by participants in meeting their weight maintenance goals. Each call will end with a formal goal setting session. Calls are expected to last for approximately 10-20 minutes.
46018107|NCT04116853|Behavioral|STATIC Extended-Care Program|Each extended-care intervention phone call will be initiated by the interventionist, and will begin with a brief check-in followed by a discussion of any barriers experienced by participants in meeting their weight maintenance goals. Each call will end with a formal goal setting session. Calls are expected to last for approximately 10-20 minutes.
46101827|NCT05152342|Behavioral|Stigma Awareness Training for Legal System Staff|Multilevel intervention package addressing stigma associated with substance use and criminal involvement for staff and justice-involved clients enrolled in a diversion treatment program.
46101828|NCT05152342|Behavioral|Acceptance and Commitment Therapy for self-stigma|Multilevel intervention package addressing stigma associated with substance use and criminal involvement for staff and justice-involved clients enrolled in a diversion treatment program.
45467210|NCT01309555|Device|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
45467211|NCT03339726|Drug|New Formulation Phenylephrine HCl|2 doses of one tablet 12 hours apart
45467212|NCT03339726|Drug|Marketed Phenylephrine HCl|4 doses of one capsule 4 hours apart
46101829|NCT02567032|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
46101830|NCT02567032|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
46101831|NCT00618059|Drug|Pilocarpine|
46101832|NCT04701047|Device|vaginal pessary|insertion and follow up of a vaginal pessary
46018108|NCT01008748|Drug|Nicotine Replacement Therapy (NRT)|NRT for participants who smoke >10 cigarettes/day will consist of 2 weeks of 21 mg nicotine patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Nicotine Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches. Patch dispensation will occur at weekly treatment visits.
45837969|NCT05275543|Device|Paro Robot|Device: PARO therapy seal PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
46101833|NCT04701047|Procedure|Vaginal prolapse surgery|surgery and follow up after vaginal prolapse surgery
46018109|NCT01008748|Behavioral|Questionnaire|Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.
46101834|NCT05118334|Drug|Sintilimab|(IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W)until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
46018110|NCT01008748|Behavioral|Counseling|Each counseling session, whether face-to-face or over the phone, will last approximately 15 minutes. In-person counseling sessions occur at weeks -1, 0, and 3, with telephone counseling sessions occurring at weeks 0.5, 1, and 2. Counselors will conduct all sessions in Spanish.
46018111|NCT01008748|Behavioral|Self-Help Materials|Spanish-language self-help materials currently used by the NCI's Cancer Information Service.
46101835|NCT05118334|Drug|IBI310|(IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W) until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
46101836|NCT00863304|Biological|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
46101837|NCT00863304|Biological|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
46101838|NCT00863304|Drug|naproxen|naproxen 1000 mg daily for 16 weeks
46101839|NCT00863304|Other|placebo|placebo to match tanezumab and naproxen dosing
46101840|NCT05277077|Other|Pain neuroscience education|The experimental group will follow a PNE protocol based on previous procedure for a whole period of 6 weeks in addition the conventional treatment.
46101841|NCT05277077|Other|Conventional treatment|Patients from both groups will receive a conventional 6-week treatment programme (30 treatment sessions, five a week, for 90min duration).
46101842|NCT04210973|Drug|Anyu Peibo|Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
46101843|NCT04210973|Drug|Placebo|Placebo Capsule, twice per day, oral after breakfast and supper
46101844|NCT00695110|Drug|Oral testosterone undecanoate (TU) (300 mg T equivalents/dose)|Three capsules each containing 100 mg testosterone (T) as TU, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
46101845|NCT00695110|Drug|Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose)|Two capsules each containing 100 mg T as TU and 100 mg T as TE, BID. 400 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
46101846|NCT00695110|Drug|Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food)|Two capsules each containing 100 mg T as TU, BID for 8 days. 200 mg T equivalents BID 30 minutes after initiation of meals (breakfast and dinner), except for Day 8 when the morning dose was administered fasting. A 7-14 day washout period occurred between successive Treatment Periods.
45467213|NCT03339726|Drug|Placebo|4 doses of placebo capsule and tablet taken 4 hours apart
45467214|NCT05438368|Biological|bi-4SCAR GD2/CD70 T cells|Infusion of bi-4SCAR GD2/CD70 T cells at 10^6 cells/kg body weight via IV
46018112|NCT02865265|Procedure|Pecs II and parasternal blocks|"Pecs II block was performed at the level of the fourth rib in the fascial plane between the minor pectoral and serratus anterior muscles, and 20 ml of 0.5% levobupivacaine solution were injected.~An ultrasound-guided ipsilateral parasternal block was performed via two separate injections of 4 ml of 0.375% levobupivacaine at the level of the 2nd and 4th intercostal space underneath the external intercostal membrane between the major pectoral and intercostal muscles close to the surface of the 2nd and 4th rib."
46018113|NCT04295512|Behavioral|Unstuck and on Target (UOT)|Unstuck and on Target (UOT) is a cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. UOT is the first contextually-based executive functioning treatment that targets flexibility, goal-setting and planning through a cognitive behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. UOT will be adapted for use in mental health service settings. Mental health therapists will be trained in UOT and deliver to youth and caregivers.
46018114|NCT04289545|Dietary Supplement|Functional bread|Postprandial effects of bread containing galactomannan
46101847|NCT00695110|Drug|Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)|Two capsules each containing 150 mg T as TU and 150 mg T as TE, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days.
46101848|NCT04211051|Device|LungBrella marker implantation and VATS partial lobe resection|The enrolled patients will receive a plain chest CT scan,then the data be loaded into JediVision software. The JediVision software can navigate the location of nodule and facilitate the implantation of LungBrella marker in the operating room after general anesthesia,then the patients will receive VATS partial lobe resection .
46101849|NCT04213313|Drug|Treatment of bacterial keratitis|0.3% Levofloxacin Eye Drops or 0.3% Tobramycin Eye Drops QID
46101850|NCT04213313|Drug|Treatment of fungal keratitis|1% Fluconazole Eye Drops or 0.25% Amphotericin B Eye Drops QID
46101851|NCT04213313|Drug|Treatment of viral keratitis|0.1% Acyclovir eye drops QID ，Ganciclovir gel QN，Famiclovir tablets 0.25g TID
46101852|NCT04213313|Diagnostic Test|corneal scraping|culture and sensitivity of corneal ulcerated infiltrating edge tissue
46101853|NCT04213313|Other|Sequencing|polymerase chain reaction with sequence specific primers(PCR-SSP) and Sanger sequencing
45467215|NCT05669131|Other|Motor imagery training|Participants imagine themselves through their own eyes performing submaximal elbow flexion contractions.
45467216|NCT02951494|Other|AlterG Anti-gravity treadmill|Participants in this group will complete a 12 week aerobic exercise training protocol with 40% lower body weight support on an AlterG Anti-gravity treadmill
45467217|NCT03787225|Drug|NNC0174-0833|Participants will receive dose levels of 0.3, 0.9 or 1.8 mg of NNC0174-0833 subcutaneously. Each participant will receive only one dose.
45467218|NCT03787225|Drug|Placebo (NNC0174-0833)|Participants will receive NNC0174-0833 matched placebo subcutaneously.
45467219|NCT02900326|Other|Endurance exercise training|In each group, there will be a comparison of aerobic capacity, quality of life (with questionnaires), functional cerebral measurements (fRMI), and telomerase activity between before and after the 8 weeks program
45467220|NCT02900326|Other|Mindfulness-based-stress-reduction|
45467221|NCT02900326|Other|Both interventions together|
45467222|NCT02900326|Other|Vo2max measurements|
45467223|NCT02900326|Genetic|Telomerase activity on a blood sample|
45467224|NCT02900326|Other|Quality of life (questionnaires)|
46101854|NCT04187963|Other|Physical therapy|"The rehabilitation protocol for the IPT consisted of cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises. In addition, the GPT protocol followed the exact same pattern, except for 5-10 minute breaks for informal socialization between participants, at the beginning of the session, mid-session and at the end of the session.~Also, both groups had access to external cues, which were applied during a variety of tasks and environmental situations, like gait initiation and termination, heel strike and push-off, sideways and backwards stepping, walking while dual tasking, and walking over various surfaces and long distances."
46018115|NCT00628732|Drug|Cyclophosphamide and Topotecan|Two courses of cyclophosphamide at 50 mg/m2/dose and topotecan 0.8 mg/m2/dose by mouth every morning for 14 days each.
45467225|NCT02900326|Other|Cerebral IRMf|
45837970|NCT05269953|Device|Active stimulation|Participants assigned to the active stimulation arm will receive rhythmic MNS 2 minutes on and 1 minute off for 15 minutes. The strength of the stimulation will be set to 120% the intensity needed to produce a visible contraction within the thenar muscle.
46018116|NCT04289701|Other|Health Services for Systematic Hypertension Management|"The systematic hypertension management health services from the Hypertension prevention and control initiative in China project. Main services are as follows:~Healthcare provider training and patient education.~Standardized guideline-based hypertension diagnosis, treatment and management recommendation.~Patient-centered, pan-cycle continuous hypertension management via the organizing framework of NMAH and sharing digital platform.~Periodical Patient follow-up via blood pressure monitor-sharing system and in collaboration with other basic local public health programs.~Outcome and performance evaluation quarterly.~Incentives for healthcare organizations and primary healthcare providers, and subsidies to patients.~Certification for Honorary Hypertension Centers at county levels and establishment for hypertension clinics at primary care centers."
45467226|NCT03339297|Drug|Defibrotide|6.25 mg/kg via 2-hour IV infusion every 6 hours
45467227|NCT03339297|Drug|Standard of Care|Administered according to local institutional guidelines, physician preference, and patient need.
45598403|NCT02226263|Dietary Supplement|probiotics Lactobacillus acidophilus boucardii|Using sterile technique, the probiotic with 1x109 [CFU] Lactobacillus acidophilus boucardii strain was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks to fresh supplement breast milk or formula for preterm infants.
46101855|NCT03374332|Drug|Gemtuzumab Ozogamicin (GO)|Patients will be given gemtuzumab ozogamicin on days 1,4, and 7. Capped at 4.5mg individual doses. Total doses capped at 13.5mg.
45467228|NCT03789331|Other|Anogenital distance measurement|"The women were kindly asked to lay down in the lithotomy position with their thighs at 45° to the examination table. A digital caliper (Mitutoyo 500-752-10 ABSOLUTE Digimatic Coolant Proof Caliper 0-150mm / 0-6, Mitutoyo Corporation, Japan) was used to measure anogenital distance.~Anogenital distance anus to clitoris: will be measured in centimeters from the anterior clitoral surface to the center of the anus.~Anogenital distance anus to fourchette: will be measured in centimeters from the posterior fourchette to the center of the anus.~Two investigators who were blind to the gynecological status of the women will measure each distance three times, and the mean value of the six measurements of each anogenital distance will be used."
46101856|NCT03374332|Other|Donor Leukocytes|The product will be administered unprocessed on day 8/24 hours post GO (same day as leukapheresis) with a minimum of CD3+ cells and maximum of CD3+ cells/kg irrespective of the number of CD34+ cells.
46101857|NCT00742534|Drug|Intravenous L-Citrulline|This is a classic dose escalation using initial doses of 10 mg/kg of intravenous citrulline and advancing the dose by 10 mg/kg every 3 patients for a target peak plasma citrulline concentration of 100 umol/L. This regimen will be adjusted with pharmacokinetic data as it becomes available so that it may be adjusted to maintain appropriate serum levels of the urea cycle precursors and NO metabolites of interest.
46101858|NCT04211207|Other|non invasive monitoring value|heart's respiratory quotient as non invasive monitoring value
46101859|NCT03353584|Other|Virtual Reality Therapy|The VR intervention consists of an interactive audio and visual underwater experience designed to serve as a calming distraction activity. The VR software (Kind VR® Aqua) was developed by KindVR specifically for the purpose of pain distraction in a hospital setting.
45467229|NCT05434624|Drug|Midazolam|Before the procedure, all patients were given i.v. 0:02 - 0:04 mg / kg midazolam (zolamide 15 mg / 3 mL, and medications, Turkey) will be administered.
45467230|NCT05434624|Drug|Propofol|Propofol 0.5 mg/kg bolus dose will be administered to Group II. Maintenance will be provided with 60 mcg/kg/min propofol infusion, and the propofol infusion dose will be increased by 10 mcg/kg/min by titration until the BIS value is 40-60 during the procedure.
45680850|NCT02985268|Device|MitraClip|The MitraClip Clip Delivery System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus [degenerative MR] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.
45680851|NCT02985268|Drug|Optimal Medical Therapy|Optimal medical therapy administered as per the Guideline Direct Medical Therapy (GDMT) as defined in the 2013 ACCF/AHA Heart Failure Guidelines with maximum tolerated doses of an ACE-inhibitor or Angiotensin Receptor Blocker (ARB) and beta-blocker
45837971|NCT05269953|Device|Sham stimulation|Participants assigned to the sham stimulation arm will receive rhythmic MNS 2 minutes on and 1 minute off for 15 minutes. The strength of the stimulation will be set to 50% the intensity needed to produce a visible contraction within the thenar muscle.
45837972|NCT05268939|Diagnostic Test|LumiraDx SARS-CoV-2 & Flu A/B test|Swab Samples for Diagnostic test
46018117|NCT04131829|Drug|Fluoxetine - immediate treatment|Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
46018118|NCT04131829|Drug|Fluoxetine - delayed treatment|Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
46018119|NCT02867449|Behavioral|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
45837973|NCT05268939|Diagnostic Test|LumiraDx SARS-CoV-2 & RSV test|Swab Samples for Diagnostic test
46101860|NCT04210817|Other|No Intervention|There is no intervention for this study
46101861|NCT03264352|Drug|Allisartan Isoproxil|Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.
46018120|NCT02867449|Behavioral|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak & Foa (1997)
45680852|NCT02985268|Device|CRT-D|Cardiac Resynchronization Therapy with defibrillation therapy devices will be implanted according to the Heart Rhythm Society Guidelines for implanted devices.
45680853|NCT05630560|Other|Psychotherapy treatment|The psychotherapist will conduct psychotherapy as normally done by them in their practice. The treatment will thus be un-manualized and consist of a broad range of therapeutic orientations and treatment lengths.
45837974|NCT05263908|Drug|nirmatrelvir / ritonavir|The usual dosage in adults and pediatric patients (≥12 years of age weighing ≥40 kg) is 300 mg of Nirmatrelvir and 100 mg of ritonavir all taken together orally twice daily for 5 days.
46018121|NCT02866825|Biological|IFX-1|
45837975|NCT05259527|Drug|Ergocalciferol Capsules|Vitamin D2 50,000IU by mouth once weekly for 8 weeks then once per month thereafter.
46018122|NCT02866825|Biological|Placebo|
46018123|NCT04290715|Other|no intervention|no intervention
46018124|NCT02870998|Other|Active learning|1-day continuing education activity consisting of a lecture on patient education.
46018125|NCT02870998|Other|Passive learning|1-day continuing education activity consisting of a brief lecture on patient education and workshops.
45467231|NCT01309633|Drug|12.5mg sunitinib with Cisplatin and Gemcitabine|"1) Arm A~Day -6 to Day 0 (total 7 days):~Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
46101862|NCT03264352|Drug|Amlodipine 5mg|Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
46101863|NCT03264352|Other|Standard treatment by current guideline|No BP-lowering medications are used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
46101864|NCT04897919|Drug|Dihydroartemisinin-piperaquine 160 mg/20 mg Oral Tablet|Dihydroartemisinin-piperaquine is given as recommended by manufacturer and compared to the Artemether-lumefantrine group.
45467232|NCT01309633|Drug|25mg Sunitinib alternating with Cisplatin and Gemcitabine|"Arm B~Day -6 to Day 0 (total 7 days):~Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
45837976|NCT05259527|Dietary Supplement|Cholecalciferol Capsules|Vitamin D3 5,000IU by mouth daily
45837977|NCT05256641|Drug|Acalabrutinib|Given PO
45837978|NCT05249543|Behavioral|Unified protocol|Transdiagnostic cognitive-behavioral therapy
45837979|NCT05249543|Behavioral|Diagnosis-specific cognitive-behavioral therapy|Diagnosis-specific cognitive-behavioral therapy
45837980|NCT05228652|Other|Questionnaire|Three different questionnaires have been developed. They consist of multiple-choice questions and some open-ended questions.
45837981|NCT05226130|Device|Cervical transcutaneous vagus nerve stimulation (active comparator)|Active nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that stimulates the vagus nerve.
45837982|NCT05226130|Device|Cervical transcutaneous vagus nerve stimulation (sham comparator)|Sham nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that does not stimulate the vagus nerve.
45837983|NCT05225103|Behavioral|SAFETY-Acute intervention|The trauma-informed brief suicide intervention based on the SAFETY-A (single crisis session in addition to follow-up caring contacts). Delivered in addition to usual care in facilities.
45837984|NCT05225103|Behavioral|Enhanced Usual Care|Usual Care in Juvenile Facilities (e.g., suicide watch/observation and evaluation by contracted mental health professional within 24 hours). Usual care is enhanced because of the additional assessment information that can be shared with clinical staff
46101865|NCT04897919|Drug|Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet|Artemether-Lumefantrine is given as recommended by manufacturer
46101866|NCT00921544|Other|Sucrose|0.2 ml sucrose 24% given by mouth using a syringe and pacifier
46101867|NCT00921544|Other|Sterile water|Sterile water administered 2 mins prior to eye exam
46101868|NCT04885127|Other|Palliative Care + Digital Symptom Monitoring|Previously described in Arm description
45837985|NCT05219916|Procedure|Blood collection.|"One additional 80 mL blood collection will be collected from HIV patients during a scheduled blood collection as part of their regular follow-up.~Samples will be transported within 3-5 hours by a carrier approved for the transportation of infectious biological samples from the Croix Rousse hospital to the P3 laboratory of the Ecole Normale Supérieure, Lyon for analysis."
45837986|NCT05219318|Drug|Combination PD-1/PD-L1 ICI + VEGFR-TKI|The study will enroll patients achieving an objective response after 12 months of treatment with the combination PD-1/PD-L1 ICI + VEGFR-TKI as recommended in the Summary of Product Characteristics (SmPC)
45837987|NCT05219318|Other|Treatment pause|Combination regimens discontinuation until progression with the possibility to resume initial combination regimens at progression
45837988|NCT05214534|Other|blood supar measurement|The supar values will be measured afterwards on the tube bottoms of the patients included in the study from their usual collection
45837989|NCT05204732|Other|Intonation training|The participants will receive intonation training (1h/week) for four weeks, aiming for more gender congruent intonation patterns.
46018126|NCT05212441|Device|Light emitting diode therapy (LED therapy)|The patient's forearm is positioned on table with palm facuing upward during the therapy. For LEDT, the center of the light spot located at approximately 50% of landmark line from the medial epicondyle to the styloid process of the ulna, which is the center belly of ﬂexor digitorum superﬁcialis. The subject's forearm maintained in the rest state without moving during the therapy. LED is performed before exercise.
46101869|NCT04060732|Device|Flash Glucose Monitoring-FGM|"The Flash Glucose Monitoring-FGM is a real-time glycemic monitoring system called hybrid will be assigned to the enrolled patients at baseline until the end of follow-up after 12 months."
46101870|NCT00594386|Drug|Rotigotine|"Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: Allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours."
46018127|NCT05212441|Behavioral|Patient/family education program (Home program)|Patients and their families will instructed to learn the anti contracture positioning/splinting, scar massage and exercises program, application of the custom garments and inserts, and functional training to perform them on their own at home. Written and illustrative instructions and reciprocal demonstration sessions will be provided to the children and their families to ensure successful acquisition and delivery of rehabilitation skills at home program. The therapist will be reported about compliance with the home program every couple of days
46018128|NCT05212441|Procedure|Positioning & Splinting|"The wrist joint is splinted at 30 hyperextension, the MCP joint in 90 of flexion, the IP joints in extension, and the thumb in abduction. The webs of fingers kept in abduction. The hands are elevated above the level of the heart to minimize post-burn edema.~Splinting: Splints are tailored to help to maintain the functional or anti-contracture position of the injured body parts.The intervals for monitoring vary from once every hour to once every 4-6 hours, depending on types of splints and skin conditions. It is described as 10 hours on and two hours off. When the splint is taken off, active and/or passive ROM should be carried out."
46101871|NCT03893812|Device|MRI|diffusion weighted MR
45680854|NCT04022122|Procedure|Usual Care follow-up in a heart failure program.|Standard follow-up involves hospital and primary care for HF patients. In this context, physicians and nurses experienced in the care and management of HF direct care. HF care is based on 1) active detection of newly admitted HF patients, 2) planned educational interventions to improve self-care, 3) completion of a comprehensive psychosocial assessment of patients and caregivers, 4) discharge planning and home transition coordination involving the hospital HF team and Primary Care teams, 5) structured and planned evidence-based follow-up shortly after discharge from hospital.
46101872|NCT03893812|Device|Ultrasound|Color Doppler ultrasound
46101873|NCT03517852|Device|Human Intravital Microscopy|Intravital microscopy (IVM) allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.
46101874|NCT04857671|Drug|Botulinum Toxin Type A in saline water|"150 Allergan units Botulinum toxin A in a total of 3 ml sodium chloride (NaCl) 0,9% Braun.~5 IU of Botox per injection point (0,1ml); in total 150 IU per 30 injections points."
46101875|NCT04857671|Drug|Isotone saline water|3ml Na Cl (sodium chloride) 0,9% Braun. 0,1ml per injection point in total 30 injections points
46101876|NCT03466450|Drug|PF-04449913|"Glasdegib (3 dose levels will be evaluated: 100mg QD, 150mg QD and 200mg QD, or 75-50mg) will be administered:~During concurrent phase concomitantly with radiation and Extended to the resting period (glasdegib will not be stopped in the 4 weeks of radiotherapy resting period).~During adjuvant therapy with Temozolomide Oral Capsule. Additional treatment with glasdegib beyond 6 sequential TMZ cycles will continue until progression, unacceptable toxicity, non-compliance, consent withdrawal and/or 2 years of glasdegib administration."
46101877|NCT03466450|Drug|Temozolomide Oral Capsule|"During RT, patients will receive Temozolamide (TMZ). All patients will be given TMZ at 75 mg/m2~/d concurrently with RT for a maximum of 42 days. At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles."
46101878|NCT00685256|Other|counseling intervention|subjects and parents will receive genetic counseling
46101879|NCT00685256|Other|educational intervention|subjects and parents will receive education re: genetic testing
46018129|NCT05212441|Other|Therapeutic Exercises|"Passive ROM (PROM).~Active ROM (AROM) & Active-assistive ROM (AAROM): The exercise will focus on extending the wrist to 45 degrees, flexing the MCP joints to 90 degrees and keeping the IP joints in full extension, while maintaining a thumb web space. The exercises will performed in the following sequences; (1) MCP joints flexion and extension with the wrist in neutral or slight extension and the IP joints in neutral position. (2) IP joints flexion to only 30-40 degrees with the wrist stabilized in the neutral or slight extension, while the MCP joints held in full extension, (3) thumb and fingers abduction and adduction, and (4) thumb opposition (tip of the thumb to tip of the small finger). Each exercise was performed for 8-10 repetition, daily, for 6 days/week.~Stretching exercises: A low-load (low-intensity), long-duration stretch~Strengthening exercises: done in static mode initially and progress to dynamic strengthening using elastic bands."
46018130|NCT04298788|Other|Blue dishware|blue dishware is used for plates and bowls
46101880|NCT00685256|Other|survey administration|surveys will be administered to subjects and parents
46101881|NCT00685256|Behavioral|psychosocial assessment and care|psychosocial assessment and counseling will be provided
46018131|NCT02865421|Drug|stem cells|adipose tissue derived stromal vascular fraction
46018132|NCT02865421|Drug|platelet rich plasma|platelet rich plasma transplanted in bald area at a distance
45837990|NCT05204732|Other|Sham therapy + intonation training|The participants will first receive four weeks of sham therapy (with no expected effect on speech), during which information on voice functioning, voice surgery, voice hygiene, and transgender health care will be provided. In addition, during sham therapy, active intervention will be given around nonverbal communication. After four weeks of sham therapy, for ethical reasons, subjects in this group will also receive four weeks of intonation training (aiming for more gender congruent intonation patterns).
46018133|NCT04205344|Drug|Bupivacaine 5 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg
46018134|NCT04205344|Drug|Bupivacaine 10 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 10 mg
45837991|NCT05187533|Other|Osteopathic protocol of Sphenopalatine Ganglion Stimulation|Sphenopalatine Ganglion Stimulation to improve lacrimal and salivary gland secretion to improve ocular and oral dryness
45837992|NCT05187377|Drug|Growth Hormone|Growth hormone will be administered subcutaneously once daily. A starting dose of 0.15 mg/kg/week divided daily for 2 weeks to ensure safety and tolerance. The dose will then be increased to 0.3 mg/kg/week for 10 weeks. Doses will be titrated based on IGF-1 levels and monitored every four weeks up to a maximum dose of 0.45 mg/kg/week based on the package insert.
45837993|NCT05187377|Drug|Saline|Placebo (saline) will be administered subcutaneously once daily.
45837994|NCT05177588|Drug|Metformin Hydrochloride|Metformin 2000 mg/day
45837995|NCT05174078|Other|Medically-tailored meals|Medically tailored meals delivered to patients' homes for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
46101882|NCT00685256|Behavioral|supportive care|parents and children will be provided with supportive care
46101883|NCT00742612|Drug|ARC1779 Injection|Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The ARC1779 treatment group will be dosed to achieve a target ARC1779 steady-state plasma concentration of 3 Ug/mL, using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
46101884|NCT00742612|Drug|Placebo (normal saline)|Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The placebo group will be dosed to a steady-state plasma concentration using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
46018135|NCT01004146|Procedure|Incentive Spirometry|helps patient monitor their inspiratory tidal volume and assists in the preventing lower airway collapse
46018136|NCT01012414|Drug|paricalcitol|2 mcg oral paricalcitol daily
46018137|NCT01012414|Drug|placebo|placebo
46018138|NCT00975715|Drug|TRI476|TRI476 oral suspension doses, based on body weight twice daily
46101885|NCT00680966|Behavioral|Adolescent Coping With Depression/Functional Family Therapy|ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents
46101886|NCT02565394|Other|Micro Break with Dynamic Exercise Activities|Surgeons may elect to activate a web application (video) and perform targeted intraoperative exercises.
46018139|NCT00975715|Drug|Placebo to TRI476|Placebo oral suspension, taken twice daily
46018140|NCT00975715|Drug|Benzodiazepines|Benzodiazepines could be used as needed as rescue medication during the duration of the study.
46018141|NCT04295668|Behavioral|Usual care|The preoperative standard measures consist of physical activity recommendation and advice on both smoking cessation and alcohol intake reduction. Moreover, in patients presenting with anemia, the anesthesiologists will assess its etiology and treat it accordingly, and nutritional intervention will be performed by a registered dietitian in to those patients at risk of malnutrition (Malnutrition Universal Screening Tool ≥2).
45837996|NCT05174078|Other|Produce box and recipes|Weekly produce box and access to recipes via internet for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
45467233|NCT01309633|Drug|7.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine|Day -7: IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered.
45680855|NCT05630404|Drug|Surgical ESPB|"In group IE, transverse processes will be palpated before sewing the surgical incision by the surgery team. The local anesthetic solution will be administered after the needle contacts the transverse process and its location is confirmed by negative aspiration. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 5 mL of solution will be injected the proper injection site. Local anesthetic solution will be injected at 4 levels along the surgical incision line. A dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia."
45837997|NCT05171660|Drug|Sintilimab Injection|Sintilimab Injection: 200 mg, i.v., D1, Q3W, 8 courses
45837998|NCT05171660|Drug|Control Test|XELOX + Bevacizumab
46101887|NCT04138862|Behavioral|Product Labelling and Sensory modifications|the beverages varied in the label that was attached (no label or a 'Healthier Choice' label) and the sensory matching of the calorie reduction (sensory matched, reduced or enhanced).
46101888|NCT04150016|Procedure|percutaneous coronary intervention|Percutaneous coronary intervention (PCI), also known as coronary angioplasty, is a nonsurgical procedure that improves blood flow to your heart.PCI requires cardiac catheterization, which is the insertion of a catheter tube and injection of contrast dye, usually iodine-based, into your coronary arteries. Doctors use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI may be used to relieve symptoms of coronary heart disease or to reduce heart damage during or after a heart attack.
45837999|NCT05156034|Drug|SRK-001|Participants will receive IV doses of SRK-001.
45838000|NCT05156034|Drug|Placebo|Participants will receive IV doses of placebo.
45838001|NCT05153239|Drug|Irinotecan|Irinotecan 75 mg/m² intravenously Days 1 & 8 q3wk
45467234|NCT01309633|Drug|2.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine|Day -7: IV bevacizumab 2.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered
45467235|NCT03001310|Biological|AAV - CNGB3|Comparison of different dosages of AAV-CNGB3
45838002|NCT05153239|Drug|Lurbinectedin|Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 q3wk
45838003|NCT05153239|Drug|Irinotecan|Irinotecan 350 mg/m² intravenously Day 1 q3wk
45838004|NCT05153239|Drug|Topotecan|Topotecan 2.3 mg/m² oral or 1.5 mg/m² intravenously Days 1-5 q3wk
45838005|NCT05153239|Drug|Lurbinectedin|Lurbinectedin 2.0 mg/m² will be administered intravenously on Day 1 q3wk
45838006|NCT05144724|Procedure|Volume targeted ventilation|Positive pressure ventilation will be provided using a set tidal volume
45838007|NCT05144724|Procedure|Pressure targeted ventilation|Positive pressure ventilation will be provided using a set peak inflation pressure
45838008|NCT05143307|Biological|EBT-101|Long term follow up of participants who received EBT-101
45467236|NCT04686487|Procedure|stereotactic ablative radiotherapy|stereotactic ablative radiotherapy by targeting high energy heavy ion beams at a specific area of the body
45838009|NCT05140941|Drug|Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet|One Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet taken once daily for 84 days.
46101889|NCT03893266|Other|Interviews|An interview will be realized with each patient in order to precise the issues they have to reconcile their diabetes and their work. Some questions will be posed to the patients and they respond as they wish.
45838010|NCT05139368|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
45838011|NCT05133258|Other|Aspiration of middle ear fluid following standard-of-care delivery of ciprofloxacin and dexamethasone suspension|Micro-aspirate of middle ear fluid will be taken from participants with a Juhn Tym-Tap specimen trap following standard-of-care delivery of ciprofloxacin 0.3% and dexamethasone 0.1% suspension. Samples will be analyzed to measure antibiotic concentration in the middle ear fluid.
45838012|NCT05131477|Drug|KY1005|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
45838013|NCT05131477|Drug|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
46018142|NCT04295668|Behavioral|Prehabilitation|"i) Exercise training: Ambulatory exercise training sessions with two main components, namely: high-intensity endurance exercise training and strength muscular training.~ii) Promotion of physical activity: Pedometer-based program using a physical activity tracker linked to a mobile app.~iv) Nutritional optimization: Recommendations of a healthy balanced diet or adapted to their digestive symptoms. Daily amount of protein intake will be close to 2 g•Kg-1•day-1.~iv) Smoking cessation: Use of both cognitive behavioral intervention and pharmacological therapy by varenicline or nicotine replacement therapies.~v) Cognitive behavioral therapy: Weekly group sessions conducted by a clinical health psychologist, including psychoeducation, motivational and behavioral change, self-efficacy and adherence enhancement, coping strategies acquisition and patient empowerment."
46018143|NCT02866981|Other|Observation|
46018144|NCT00629317|Other|Moisturizer|Cetaphil cream(For 3 hours) + Aktilite ( Photodynamic Therapy for 8 minutes)
46101890|NCT00690560|Biological|rituximab|
46101891|NCT00690560|Drug|cyclophosphamide|
45838014|NCT05091346|Drug|E7386|E7386 tablet.
45838015|NCT05091346|Drug|Pembrolizumab|Pembrolizumab IV infusion.
45838016|NCT05091346|Drug|Lenvatinib|Lenvatinib capsule.
45838017|NCT05059873|Drug|Prednisone|Oral prednisone 40mg/day for five consecutive days
46018145|NCT00629317|Drug|Methyl Aminolevulinate|Methyl Aminolevulinate cream for 3 hours before Photodynamic therapy ( Aktilite)
46018146|NCT04298476|Procedure|Placement of an adductor canal nerve block|An adductor canal nerve block will be placed in a patient undergoing a knee arthroscopy in 1 of 3 locations with local anesthetic or placebo (without location definition or local anesthetic) to assess optimal placement of local anesthetic, pain management and anxiety scores post operatively.
46101892|NCT00690560|Drug|doxorubicin hydrochloride|
45838018|NCT05059873|Drug|Placebo|Oral placebo of 40mg/day for five consecutive days
45838019|NCT05055024|Drug|Mazindol|Drug: NLS-2
46018147|NCT02866591|Other|mammography according to an auto-compression procedure|
45838020|NCT05053971|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
45838021|NCT05053971|Procedure|Core Biopsy|Undergo core needle biopsy
45838022|NCT05053971|Drug|Entinostat|Given PO
46018148|NCT02866591|Other|mammography according to a standard procedure|
46018149|NCT02866591|Other|questionary|
46101893|NCT00690560|Drug|prednisone|
46101894|NCT00690560|Drug|vincristine sulfate|
46101895|NCT00690560|Radiation|yttrium Y 90 ibritumomab tiuxetan|
46101896|NCT00742690|Drug|terlipressin given by intravenous boluses and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given by intravenous boluses at the initial dose of terlipressin was 0.5 mg/4 hr. In case of non response, the dose of terlipressin was progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given intravenously at the dose of 1 g/kg of body weight on the first day followed by 20-40 g/day.
46101897|NCT00742690|Drug|terlipressin given by continuous intravenous infusion and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given as intravenous boluses at the initial dose of 0.5 mg/4 hr. In case of non response, the dose of terlipressin will be progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given at the dose of 1 g/kg of body weight at the first day followed by 20-40 g/day.
46101898|NCT00690638|Drug|PHX1149T|200 mg
46101899|NCT00690638|Drug|PHX1149T|400 mg
46018150|NCT02871154|Other|Delaying oocyte pick up beyond 39 hours post hCG|Unlike the traditional less-than 39 hours interval from hCG injection to oocyte pick up, we will extend the interval up to 47 hours
45680856|NCT05630404|Drug|US guided ESPB|"US guided ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia."
46018151|NCT03962491|Behavioral|Daily Self-Monitoring Surveys + Contingency Management|Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app, with the opportunity for monetary rewards for completing daily surveys.
46018152|NCT03962491|Behavioral|Daily Self-Monitoring Surveys|Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app.
46018153|NCT02866669|Behavioral|Practice Facilitation|ractices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. Practice facilitation is a highly customized, staged approach to helping a practice to implement process and structural changes to enhance the quality of care and improve patient and staff satisfaction
46101900|NCT00690638|Drug|Placebo|Placebo
46101901|NCT00742768|Dietary Supplement|Vitamin K2 in softgel|4 softgel capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 softgel capsules containing 30 µg MK-4 per capsule
46101902|NCT00742768|Dietary Supplement|Vitamin K2 in Gelpell|4 Gelpell capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 Gelpell capsules containing 30 µg MK-4 per capsule
46101903|NCT03195400|Diagnostic Test|Oral Glucose Tolerance Test|The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.
46101904|NCT03195400|Diagnostic Test|Hyperglycemic Clamp|Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.
46101905|NCT03195400|Diagnostic Test|Isoglycemic Intravenous Glucose Test|Test which exposes pancreas to blood glucose levels matched to the ones obtained at the OGTT.
46101906|NCT03195400|Diagnostic Test|Hyperinsulinemic Euglycemic Clamp and 2H20|Test is used to assess insulin effects on hepatic glucose production.
46101907|NCT00685412|Biological|VGX-3100|DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
46101908|NCT04656431|Drug|Hyperpolarized pyruvate (13C)|Given intravenously (IV) injection prior to imaging
45467237|NCT04974788|Other|Low Intensity Respiratory Muscle Training|Respiratory muscle training will be performed at 30% (low intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
45680857|NCT05630326|Other|comparing, prevalence|Comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
45680858|NCT05630326|Other|assessment|comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
46101909|NCT04656431|Procedure|Magnetic resonance imaging (MRI)|MRI scan takes an image of brain and/or spinal cord and will take up to 45 minutes to complete
46018154|NCT02866669|Behavioral|Peer Coach|Participants enrolled from practices that are randomized to the peer coach arm will be matched with peer advisors who will work with the participants for 12 months.
46018155|NCT02866669|Behavioral|Enhanced usual care|Practices in the usual enhanced care arm will receive a blood pressure medication algorithm developed using national guidelines and content experts on our study team. Practices will be provided the Joint National Committee (JNC) recommended protocol to measuring blood pressures. Practices will receive a laptop workstation that has access to the Patient Activated Learning System - an online education video system.
45467238|NCT04974788|Other|Medium Intensity Respiratory Muscle Training|Respiratory muscle training will be performed at 60% (medium intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
46018156|NCT02866513|Other|evaluate the variations of transpulmonary pressure during the use of APRV by clinicians.|
45467239|NCT04974788|Other|High Intensity Respiratory Muscle Training|Respiratory muscle training will be performed at 80% (high intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
46018157|NCT04290637|Other|Cold-water sea swimming|Continue sea swimming for 4-6 weeks
46018158|NCT04290637|Other|No cold-water sea swimming|Discontinue sea swimming for 4-6 weeks
46101910|NCT04210895|Other|Ginger powder footbath|40 ± 2 ° C warm water footbath with an additive of dried ginger powder reaching up to mid-calf level
45467240|NCT03783559|Drug|TACE|TACE
46101911|NCT04210895|Other|Warm water only footbath|40 ± 2 ° C warm water footbath without any additive reaching up to mid-calf level
46101912|NCT00862992|Drug|Cariprazine 3 mg|
45467241|NCT03783559|Drug|chemotherapy±target therapy|chemotherapy±target therapy
46101913|NCT00862992|Drug|Cariprazine 6 mg|
46101914|NCT00862992|Drug|Cariprazine 12.5 mg|
45467242|NCT03783247|Procedure|Pericapsular nerve group block|The regional block was performed with the patient in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees (Figs. 2, 3). In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 80-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution (20ml of bupivacaine 0.25%) was injected in 5-mL increments while observing for adequate fluid spread in this plane for a total volume of 30 mL
45680859|NCT05630326|Other|association|comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
45680860|NCT05630326|Other|evaluation|comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
46018159|NCT00978757|Drug|Ketamine|Ketamine: 0.25 mg/kg, intravenously, one dose.
46018160|NCT00978757|Other|Placebo|saline solution
46018161|NCT01214421|Drug|Tolvaptan|Tablets of 15 or 30 mg
46018162|NCT04102111|Drug|JNJ-67864238|Participants will receive oral tablets of JNJ-67864238 twice daily.
46101915|NCT02565316|Drug|Nepeta menthoides Boiss & Bohse freeze dried extract|
46101916|NCT02565316|Drug|Sertraline|
46101917|NCT00742846|Drug|Lidocaine + Kenalog|"5ml 1% Lidocaine + 1ml 40mg Kenalog®-10 into the shoulder joint~Intra-articular injection with local anesthetic and steroid"
46101918|NCT00742846|Drug|Lidocaine + Kenalog|"5ml 1% Lidocaine + 1ml 40mg Kenalog-10 into the subacromial space~Local anesthetic and steroid in to the subacromial space"
46101919|NCT00742846|Drug|Lidocaine|"5ml 1% Lidocaine alone into the shoulder joint.~intra-articular local anesthetic injection"
46101920|NCT00742846|Drug|Lidocaine|"5ml 1% Lidocaine alone into the subacromial space.~subacromial local anesthetic injection"
46018163|NCT04102111|Drug|Placebo|Participants will receive oral tablets of matching placebo twice daily.
45467243|NCT03783247|Procedure|Fascia Iliaca BLock|In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest & iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
46018164|NCT01214187|Drug|inhaled carbon monoxide|The intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.
45467244|NCT05225571|Other|no intervention|there is no any intervention in this study. it is an observational and cross-sectional study.
45467245|NCT03708276|Other|My MS Toolkit|My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.
46101921|NCT00620087|Procedure|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
46101922|NCT00620087|Procedure|Screening Mammography|A screening mammogram is used to look for signs of breast cancer in women who don't have any breast symptoms or problems. X-ray pictures of each breast are taken from 2 different angles.
46101923|NCT04123860|Other|ultrasonic hydrodynamic maxillary sinus lift buccal pad fat|ultrasonic hydrodynamic maxillary sinus lift and buccal fat pad as grafting material followed by immediate implant
45467246|NCT05215431|Diagnostic Test|periodontal examination's and determination of salivary antioxidants|Periodontal parameters such probing depth (PD), clinical attachment level (CAL) and gingival margin level has been recorded on six sites of each tooth using a manual periodontal probe. The degree of gingival inflammation has been assessed using the Loe and Silness (LSGI) gingival index. Activity of antioxidants in unstimulated saliva (GPX, SOD, UA) has been determined using the colorimetric method and commercial kits.
45467247|NCT05234190|Drug|QEL-001|QEL-001 is an autologous therapy that is composed of engineered regulatory T cells transduced with a lentiviral vector containing a CAR directed against HLA-A2. Treatment will be given via an IV infusion.
46018165|NCT01214187|Other|Oxygen|Room air oxygen concentrations will be administered as placebo
46018166|NCT02866903|Drug|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|Intraperitoneal (IP) OXAliplatin (OXA) in association with systemic FOLFIRI bevacizumab chemotherapy Intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI (Irinotecan IV + 5-FU IV) bevacizumab chemotherapy in escalation dose (every 14 days) starting with the level 1
46018167|NCT02866903|Drug|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|systemic FOLFIRI chemotherapy
45467248|NCT05694559|Behavioral|Genetic Testing and Counseling|Participants will complete testing
45467249|NCT05694559|Behavioral|Screening Form|Participants will complete forms with demographics and history
45467250|NCT05228028|Procedure|fascia iliaca compartement block|Ultrasound-guided suprainguinal FICB (30 ml of 0.375% ropivacaine with 75 µg of epinephrine) is done on the ipsilateral surgical side at the end of surgery.
45467251|NCT05228028|Procedure|quadratus lumborum block|Ultrasound-guided anterior QLB (30 ml of 0.375% ropivacaine with 75 µg of epinephrine) is done on the ipsilateral surgical side at the end of surgery.
45467252|NCT03713281|Device|Toric Multifocal etafilcon A with PVP|Investigational
45467253|NCT05176782|Drug|HTK cardioplegia|will receive HTK cardioplegia in volume 30 ml/Kg given by antegrade route through an aortic route cannula.
45467254|NCT05176782|Drug|Cold Cadioplegia|as the will receive group cold Blood Cardioplegia in volume 20mL/kg given by antegrade route through an aortic route cannula and repeated 10mL/kg/dose every 25minutes at 8-12°C for maintenance. This technique considered the standard management in this age.
46018168|NCT02866903|Drug|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|bevacizumab
46018169|NCT04289077|Other|Questionnaires|- Baseline questionnaire, version 1.0, October 29 2019, (Dutch) - Health care utilization, version 1.0, October 29 2019, (Dutch) - Decision-making, version 1.0, October 29 2019, (Dutch) - EORTC QLQ-C30, version 3.0, (Dutch) - DTF-QoL, version 1.0, October
46018170|NCT02865031|Drug|Decorin|Intravitreal Injection following ocular trauma to prevent scar tissue formation.
46018171|NCT02864875|Drug|Fibrinogen concentrate|Receive fibrinogen concentrate 50mg/kg of body weight after randomization
46101924|NCT04123860|Other|ultrasonic hydrodynamic maxillary sinus lift platelet rich fibrin|ultrasonic hydrodynamic maxillary sinus lift and platelet rich fibrin as grafting material followed by immediate implant
46101925|NCT04209413|Procedure|Patients referred for a knee ligamentoplasty|knee ligamentoplasty
45467255|NCT03706950|Drug|Elpida® + 2 NRTIs|Elpida® 20mg qd orally + 2 NRTIs standard prescribed ART therapy
45467256|NCT03339219|Drug|Cabozantinib|Cabozantinib tablets
45467257|NCT03706872|Other|Intervention group|The provision of an App for monitoring physical activity and weight with a smart watch and the administration of virtual advice through messages with mobile phone and the midwife's feedback, as well as the provision of usual prenatal care
45467258|NCT01310647|Drug|Testosterone|Transdermal testosterone (20µg/kg/day)from day 24 of the previous cycle to day 2 of the ICSI cycle
46018172|NCT03945019|Biological|CT-P13 SC (Infliximab)|Subcutaneous injection of CT-P13 SC
46018173|NCT03945019|Other|Placebo SC|Subcutaneous injection of Placebo SC
46018174|NCT01003990|Drug|Atazanavir|Tablets, Oral, 400 mg, once daily, indefinitely
46018175|NCT01003990|Drug|Atazanavir/Ritonavir|Tablets, Oral, 300/100 mg, once daily, indefinitely
46018176|NCT01003990|Drug|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, once daily, indefinitely
46018177|NCT01003990|Drug|Lopinavir/ritonavir|Tablets, Oral, 400/100 mg, twice daily, indefinitely
45467259|NCT01310647|Drug|Estradiol|Transdermal estradiol (200µg/day)from day 20 of the previous cycle to day 3 of the ICSI cycle
46018178|NCT01003210|Drug|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
46018179|NCT01002820|Drug|ganaxolone|liquid suspension, 50 mg/mL, up to 500 mg/day TID or 1500 mg/day, up to 1 year
46018180|NCT01012258|Biological|Cetuximab + concomitant boost radiotherapy|"Cetuximab 400 milligram/square meter (mg/m^2) intravenous (IV) infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m^2 IV infusion over 60 minutes, from week 2 to 7 along with concomitant boost radiotherapy: 72.0 Gray (Gy) total for 42 fractions in 6 weeks, initially~Once-daily fractions: 32.4 Gy in 18 fractions of 1.8 Gy for 3.6 weeks (5 fractions/week), followed by~Twice-daily fractions 39.6 Gy in 24 fractions for 2.4 weeks: morning dose 1.8 Gy/fraction for a total of 12 fractions 5 fractions/week; evening dose 1.5 Gy/fraction for a total of 12 fractions 5 fractions/week. Doses are separated by at least a 6-hour interval"
46018181|NCT00628810|Biological|bevacizumab|
46018182|NCT00628810|Drug|fluorouracil|
46018183|NCT00628810|Drug|irinotecan hydrochloride|
46018184|NCT00628810|Drug|leucovorin calcium|
46018185|NCT04298320|Drug|SHR-1210|SHR-1210 was administered 200mg iv every 2 weeks
46018186|NCT04298320|Drug|AIN 457|AIN457 was administered 150mg or 300mg ih every 2 weeks
46018187|NCT04298164|Behavioral|START programme|Acceptance and Commitment Therapy based programme for parents of children with Autism
45467260|NCT01310647|Drug|CombEq|"(150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI.~Valerate estradiol 4mg/day during 10 days, starting the second day of the cycle prios to the ICSI cycle."
45680861|NCT03593434|Drug|hyperpolarized Xenon gas|This present study will utilize existing study visits for the NHLBI study, with patients opting-in to have all of the procedures performed twice, with an intervening ACT, during one their study visits.
46018188|NCT04298164|Behavioral|Treatment as Usual|Treatment as usual in outpatient within outpatient psychology services
46101926|NCT00685490|Procedure|Vitrectomy w/o ILM peeling for macular edema with BRVO|Concurrent phacoemulsification and intraocular lens insertion in the capsular bag was performed, followed by PPV with separation of the posterior hyaloid from the optic disk and posterior retina with a posterior vitreous detachment was not present. Indocyanine green (ICG)-assisted peeling was performed in all consecutive patients between April 2000 and June 2003. 0.1% ICG solution was injected over the macular region. Immediately after application, the dye was washed out using a vitreous cutter. Repeated injection of ICG was not required. Triamcinolone acetonide (TA)-assisted ILM peeling was performed in all consecutive patients from July 2003 to November 2006.
46018189|NCT01011946|Device|Positron Emission Mammography|Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. Various PEM views will be performed on both your breast and axilla (underarm).
45680862|NCT04019314|Procedure|Blood Collection|Samples for proEnkephalin PENK will be obtained daily and aliquots of these samples will be stored for later batch assays.
46018190|NCT04296682|Procedure|Alveolar Ridge Preservation With Gingival Graft|Closure of the alveolus with the placement of a free gingival tissue graft removed from the individual palate.
46101927|NCT04135560|Drug|PF-07038124 and Vehicle|PF-07038124 0.06% and vehicle Ointment BID applied to 1% Body Surface Area (BSA)
46101928|NCT04135560|Drug|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 10% BSA
46101929|NCT04135560|Drug|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment BID applied to 10% BSA
46101930|NCT04135560|Drug|PF-07038124 or vehicle|PF-07038124 0.03% or vehicle Ointment BID applied to 10% BSA
46101931|NCT04135560|Drug|PF-07038124 or vehicle|PF-07038124 0.06% or vehicle ointment BID applied to 10% BSA
45680863|NCT04019314|Procedure|Blood Volume Analysis|A small amount of a radioactive isotope or tracer is injected and blood samples are taken at 6 time points during the test and analyzed.
46101932|NCT04135560|Drug|PF-07038124 or vehicle|PF-07038124 safe concentration or vehicle ointment BID applied to 20% BSA
45467261|NCT05682768|Procedure|Duct to Mucosa Pancreatico-Gastrostomy with trans-pancreatic transverse mattress U- Shaped sutures|Adding suporting sutures between th posterior gastric wall and ancreatic stump in whipple procedure, the sutures are Duct to Mucosa Pancreatico-Gastrostomy with trans-pancreatic transverse mattress U- Shaped sutures.
45680864|NCT05366608|Diagnostic Test|Serum level of 14.0- 3.0- 3.0- η protein and IL_.6|Serum level of 14.0- 3.0- 3.0- η protein and IL_.6 were estimated for all participants by ELISA.
45680865|NCT03995992|Behavioral|sport|10 days of sport (diving or multisport), once training per day
46018191|NCT04296760|Diagnostic Test|Rectal water-contrast transvaginal ultrasonography|Transvaginal ultrasound scan combined with the introduction of saline solution into the rectum
46018192|NCT04296760|Diagnostic Test|Sonovaginography|Transvaginal ultrasound scan combined with the introduction of saline solution into the vagina
46018193|NCT00975481|Drug|dimebon|Oral tablet; 20 mg dimebon, single dose
46018194|NCT00975481|Drug|dimebon|Oral tablet; 40 mg dimebon, single dose
46018195|NCT00975481|Drug|dimebon|Oral tablet; 60 mg dimebon, single dose
46018196|NCT00975481|Drug|placebo|Oral tablet or capsule; placebo, single dose
46101933|NCT04135560|Drug|PF-07038124 or vehicle|PF-07038124 safe concentration or vehicle BID applied to 10% BSA
46101934|NCT00690872|Biological|autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|
46101935|NCT00690872|Drug|carboplatin|
46101936|NCT00690872|Drug|gemcitabine hydrochloride|
46101937|NCT00690872|Genetic|polymerase chain reaction|
46101938|NCT00690872|Other|fluorescence activated cell sorting|
46101939|NCT00690872|Other|immunoenzyme technique|
46101940|NCT04842227|Procedure|Nerve block|"Step 1: A small amount of local anesthetic (3-5cc of 0.5% ropivacaine) is administered under ultrasound guidance in the area of the supraclavicular nerve at the base of the neck under sterile conditions. This provides dense anesthesia of the skin and eliminates the need to introduce larger quantities of local anesthetic directly to the skin around the incision (usually 20mL).~The second step involves introducing 10-15cc of 0.5% ropivacaine under ultrasound guidance into the compartment between the pectoralis major and minor muscles to anesthetize the medial and lateral pectoral nerves. NOTE: Usual care involves blind administration of local anesthetic diffusely to the tissues in this region without targeting any particular nerves, and requires larger volumes of anesthetic (40mL for the blind approach vs 10-15mL for the nerve block)."
46101941|NCT00694096|Drug|Sunitinib|"Imaging studies with complete analyses will be provided on all patients prior to institution of sunitinib therapy as well as after therapy at various early time points (1 week in 5 patients, 2 weeks in 5 patients, 3 weeks in 5 patients or 4 weeks in 5 patients) after institution of sunitinib therapy at 37.5 mg orally/day.~Imaging studies include:~FDG-PET scans FLT-PET scans H215O-PET scans DCE-MRI scans"
46018197|NCT00975481|Drug|alprazolam|Oral capsule; 1 mg alprazolam, single dose
46018198|NCT00975481|Drug|alprazolam|Oral capsule; 3 mg alprazolam, single dose
46018199|NCT01011868|Drug|BI 10773 placebo|BI 10773 placebo
46101942|NCT04123080|Device|Endoscopic band ligation assisted polypectomy|A conventional upper endoscope loaded with a band ligator was inserted in the colon and was advanced to the site of the pedunculated polyp. After approaching the lateral side of the stalk and grasping the mid-portion of the stalk using a tripod grasper. Then, the rubber band was released from the cap to ligate the stalk. Thereafter, we performed polypectomy of the remaining stalk just above the ligation by extending the electrosurgical snare.
46018200|NCT01011868|Drug|BI 10773 low dose|BI 10773 low dose
46018201|NCT01011868|Drug|BI 10773 high dose|BI 10773 high dose
46018202|NCT01011868|Drug|BI 10773 placebo|BI 10773 placebo
46018203|NCT04290013|Drug|norethisterone acetate|norethisterone acetate 15 mg daily from day 5 of the cycle to day 26.
46018204|NCT04290013|Drug|tranexamic acid tablets|tranexemic acid 1 gm three times daily from the first day of the menstrual cycle up to 5 days .The dose can be increased but not exceeding 4 gm per day.
46018205|NCT04288999|Drug|Chemotherapy|"Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours"
46101943|NCT04150094|Other|Pelvic floor muscle training (PFMT)|Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT without stimulus, coming once a week to a session supervised by physiotherapist and will be encouraged to perform the exercises at home during the other week days.
46018206|NCT04288999|Radiation|Preoperative radiotherapy|"Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy~Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)"
46018207|NCT04288999|Other|Procedure|"Surgery for Locally Recurrent Rectal Cancer (LRRC) will be performed within 42 days from registration for the patients in arm A, and between days 56 and 98 from the completion of the preCRT for the patients in arm B.~Appropriate surgical procedure will be performed to achieve R0 resection, such as low anterior resection, super low anterior resection, intersphincteric resection, Hartmann procedure, rectal amputation, pelvic exenteration, tumor resection, or lateral lymph node dissection"
46018208|NCT01213251|Device|Single Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular lead.
46101944|NCT04150094|Other|Pelvic floor muscle training + intravaginal vibratory stimulus|Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT with intravaginal vibratory stimulus. They will need to come once a week to a session supervised by physiotherapist to use the vibration device and will be encouraged to perform the exercises at home during the other week days.
46101945|NCT04808531|Drug|NanaBis™|NanaBis™ is a nanoparticle water soluble equimolar solution of d9-THC & CBD. One dose is equivalent to 2 actuations of the pump delivering 280 µL volume containing 2.5 mg d9-THC and 2.5 mg CBD
46101946|NCT04808531|Drug|Oxycodone CR|Oxycodone CR tablet is an opioid agonist supplied in 10 mg, 15 mg, 20 mg, 30 mg,40 mg, 60 mg and 80 mg tablets for oral administration. The tablet strengths describe the amount of oxycodone per tablet as the hydrochloride salt.
46018209|NCT01213251|Device|Dual Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular and Right Ventricular lead.
46101947|NCT04808531|Drug|Placebo Spray|Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
46101948|NCT04808531|Drug|Placebo Tablet|Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
46101949|NCT04808531|Drug|Oxycodone IR|Oxycodone immediate release (IR) tablet or capsule or oral solution used as breakthrough analgesia.
46101950|NCT02613780|Procedure|Crosslinking|corneal collagen crosslinking with riboflavin
46101951|NCT02613780|Procedure|Photorefractive keratectomy|
46101952|NCT02613780|Device|iDesign® Advanced WaveScan Studio|Used to map wavefront aberration in planning photorefractive keratectomy
46018210|NCT02865109|Drug|Nusinersen|Administered by intrathecal injection
46018211|NCT03934177|Dietary Supplement|Blueberry powder|Dried, powdered blueberries will be consumed at 24 g/day in two divided doses at least 4 hours apart.
46018212|NCT03934177|Dietary Supplement|Placebo powder|A placebo consisting maltodextrin will be consumed at 24 g/day in two divided doses at least 4 hours apart.
46018213|NCT02864017|Procedure|Enteral nutrition|
46101953|NCT00690950|Drug|Dutasteride|0.5mg capsule, taken once daily for 12 months
46101954|NCT04118244|Diagnostic Test|lung recruitment maneuver|The ventilator was switched to pressure control ventilation, inspiratory time was increased to 50%, the peak inspiratory pressure gradient (above PEEP) was set at 15cm H2O, and PEEP was progressively increased to obtain a stepwise increase of peak inspiratory to 20, 25, and 30 cm H2O every three breaths. The final recruiting pressure of 30 cm H2O was applied for six breaths.
46101955|NCT02625194|Drug|Oxygen|Oxygen is supplied through suction port during bronchoscope-guided intubation.
46018214|NCT02864017|Dietary Supplement|L-Citrulline|
46018215|NCT02864017|Dietary Supplement|Placebo|
46018216|NCT01213173|Drug|Succinate Metoprolol (Betaloc ZOK®)|treatment with 47.5mg for two weeks, if tolerated and without Systolic blood pressure<100mmHg and heart rate <45 bpm according to 12-lead Electrocardiogram at Week 3, the dosage will be titrated to 95mg and last for another 6 weeks
45467262|NCT01560715|Biological|intravitreal injection of autologous bone marrow stem cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
45467263|NCT05176236|Other|Pictographic tracheostomy care handouts|The handouts were developed and validated by Clinical and inter-professional experts based on the hospital's text-based tracheostomy home care instructions.
46018217|NCT01213173|Drug|Succinate Metoprolol (Betaloc ZOK®)|Treatment with 95mg for two weeks, and if tolerated and without bradycardia symptoms presented, Systolic blood pressure<100mmHg and heart rate <45 bpm according to 12-lead Electrocardiogram at Week 3，the dosage will be force titrated to 190mg and last for another 6 weeks
45467264|NCT03638895|Device|ECAL Indirect Calorimeter|The ECAL is an open-circuit portable indirect calorimeter that measures both volume of CO2 expired and O2 consumed using a small mixing chamber. Participants will breathe through a mouthpiece with a nose clip applied whilst lying in a restful and comfortable position for 15 minutes. ECAL device will provide breath-by-breath measurements of the resting energy expenditure and respiratory quotient which will allow both practitioners and participants to monitor their metabolic health and compare the effect of dietary and physical activity intervention over the course of the structured intensive lifestyle intervention (24-weeks).
46018218|NCT02864173|Genetic|Whole genome small nucleotide polymorphism genotyping|
46018219|NCT04095715|Other|Haemostasis consultation|Haemostasis consultation
46018220|NCT04095715|Biological|Standard management of patients suspected of thrombopathy|Standard management of patients suspected of thrombopathy
46018221|NCT04318431|Diagnostic Test|Data collection and rhinopharyngeal swab|Testing for SARS -Cov2 and other respiratory pathogens by PCR via nasopharyngeal swabbing and IgM/IgG rapid serology
46018222|NCT02866435|Drug|Insulin|In each clamp, a small intravenous catheter is placed in participant's arm for infusion of insulin together with potassium phosphate and glucose. Insulin is a hormone that body makes naturally and it causes blood sugar to decrease. Insulin (and glucose) will be infused in calculated doses to maintain blood sugar level in the target range of 95 mg/dl or 50 mg/dl depending on the clamp.
46018223|NCT02866435|Drug|Glucose|Glucose is administered together with insulin and potassium phosphate during each clamp via the intravenous catheter. Glucose is a sugar and it is used to carefully regulate blood sugar level.
46018224|NCT02866435|Drug|Potassium phosphate|Potassium phosphate is administered together with glucose and insulin during each clamp via the intravenous catheter. Potassium is a salt-like substance that is present in the blood.
46018225|NCT04287751|Device|CheckMeO2 Oximeter|Simultaneous recording with a current standard oximeter (Minolta i300) and prolonged recording device. Comparison of data from first night and incidence of obstructive sleep apnoea identified from additional nights of recording identified.
46018226|NCT01212159|Device|Self Monitoring Lipid Analyzer|The device is similar to a glucometer- Utilizing a lancet a small amount of blood is collected in a capillary tube and placed on a hand held monitor that records lipid values.
46018227|NCT00973765|Drug|bactrim|bactrim DS (800/160) 2 pills PO BID x 7 days
46018228|NCT00973765|Drug|placebo|placebo 2 pills po BID x 7 days
46018229|NCT04287595|Other|Inhalation aromatherapy with orange essential oil|
46018230|NCT01211769|Drug|Naltrexone|A pill of naltrexone chlorhydrate 50mg, associated to yellow liquid paraffin pills simulating borage seed and fish oil.
46018231|NCT01211769|Drug|PUFAs|Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs; associated to a pill with 50mg of talcum powder, identical to the pill of naltrexone.
46018232|NCT01211769|Drug|Placebo|A pill with 50mg of talcum powder, identical to the pill of naltrexone; associated to PUFAs Placebo pills (yellow liquid paraffin identical to the pills of borage seed and fish oil).
46101956|NCT02622126|Drug|hydroxyethyl starch (6% 130/0.4)|preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6%130/0.4) (Voluven).
46101957|NCT02622126|Drug|Hyperbaric bupivacaine|Sub arachnoid 10-12 mg hyperbaric bupivacaine
45680866|NCT03995056|Behavioral|high-intensity aerobic interval training|"The intervention group will follow a high-intensity interval training protocol on a cycle ergometer for 2 times per week and 1 time an individualised home workout program to have a total exercise amount of 3 hours.~Leisure time physical activity at baseline as well as during the intervention period will be assessed by Polar Active devices."
46018233|NCT01211769|Drug|Naltrexone + Placebo|A pill of naltrexone chlorhydrate 50mg, associated to Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs.
46101958|NCT02622126|Drug|Morphine|Sub arachnoid 200 meg morphine
46101959|NCT02622126|Drug|Isotonic 0.9 sodium chloride (NaCl) solution|10 ml/kg of isotonic 0.9 sodium chloride (NaCl) solutions will be used as co loading during the duration of the operation
45680867|NCT03792958|Drug|CM082|CM082 tablets taken orally 200、400、600 and 800 mg (QD or BID)
46101960|NCT02622126|Drug|Ephedrine|If severe hypotension (fall of > 20% of mean arterial pressure from baseline) occurred, vasopressors, 6 mg ephedrine (per dose) will be used.
46018234|NCT04287673|Other|Rehabilitation involving strongly the trunk|The Rehabilitation involving strongly the trunk (RIST) leaded by a physiotherapist was based on exercises in different postures performed by the child each day that strongly involve the trunk to cope with balance.
46101961|NCT02622126|Drug|Atropine|Bradycardia (fall of >30% of heart rate from baseline or <50 beats /minute and when associated with hypotension) will treated with 0.5 mg of atropine intravenous.
46101962|NCT02625272|Procedure|Group A|The novel hand-assisted laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were brought out through the hand-port incision at the beginning of the operation and divided extracorporeally.
45838023|NCT05051644|Behavioral|Steps 2 Change (S2C)|Participants assigned to S2C and health education control will be scheduled for 60-minute weekly group sessions held over four consecutive weeks in the outpatient OAT clinic. Session 1 will provide pain education including a discussion the biopsychosocial treatment model for chronic pain. Session 2 and 3 will introduce a progressive walking program with individual goals and weekly step count benchmarks and introduce activity pacing to address pain flare ups caused by cycles of over activity and subsequent sedentary behavior.. Veterans will be expected to increase their average step counts by 10% over their prior week's average starting in Session 2. Session 4 will help develop a treatment plan to continue walking and identify possible barriers to meeting goals.
45838024|NCT05051644|Behavioral|Control|The control will be matched for treatment exposure and individual attention. Treatment discussion will explicitly avoid problems associated with MOUD, substance use, and general self-management strategies. Importantly, group will explicitly avoid talking about pain coping skills and setting goals for daily step targets.
45838025|NCT05050227|Behavioral|cCBT Enhanced Collaborative Care|"Computerized CBT (cCBT) will be delivered supported by a depression care manger who will facilitate access to cCBT, promote and monitor cCBT use, reinforce CBT concepts (during outside CBT session homework), and monitor mental health symptoms for each participant."
45680868|NCT03789604|Biological|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
45680869|NCT03789604|Biological|CS1001 placebo|Participant will receive CS1001 placebo 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
46018235|NCT04288609|Other|Intendu|Cognitive remediation using VR adaptive platform for response inhibition, self-initiation, cognitive flexibility, sustained attention, divided attention, working memory, planning, persistence.
46018236|NCT04288609|Other|Paper and Pencil cognitive remediation training|Cognitive remediation using paper and pencil tasks for response inhibition, self-initiation, cognitive flexibility, sustained attention, divided attention, working memory, planning, persistence.
45680870|NCT04407520|Other|No patient treatment is associated with the study|No patient treatment is associated with the study.
45680871|NCT05632588|Other|Observational study|Observational surveillance study
45680872|NCT04407208|Biological|Convalescent plasma|The minimum titer of specific antibody is 1/80
46018237|NCT04288765|Drug|Daratumumab Only Product in Parenteral Dose Form|"Induction = 8 cycles Carfilzomib on Day 1st, 8th and 15th Lenalidomide: Day 1 to 21~Daratumumab:~Cycles 1-2: weekly Cycles 3-4: every two weeks Cycles 5-8: every month Dexamethasone: 40 mg weekly"
46018238|NCT01211613|Procedure|Manual Manipulation|Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
46101963|NCT00620633|Biological|WT1-sensitized T cells|Eligible patients who consent to enter this trial and for whom WT1 sensitized T cells have been generated in vitro, will receive a single dose of allogeneic WT1-sensitized T cells by bolus intravenous infusion. In this phase I trial, 6 dose levels of T cells will be evaluated, in sequential groups of 3 patients. Dose Escalation will be based on the incidence and severity of toxicities.
46101964|NCT04140188|Diagnostic Test|Senti-Scint (99mTc- pertechnetate combined with human albumin)|Senti-Scint will be injected via intradermal route to the breast with history of previous NSM.
45467265|NCT03638895|Behavioral|Diet, exercise & behaviour modification therapy|Standard care (SC) - participants receive standard care (diet, exercise & behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.
46018239|NCT01211613|Device|Mechanically-assisted manipulation|Doctor of chiropractic will use the Activator Instrument to apply a mechanically-assisted thrust to the lumbar spine of research participants.
46018240|NCT01211613|Other|Standard Medical Care|Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
46101965|NCT00314015|Procedure|Evaluation of the success rate of implants|Evaluation of the success rate of implants will be followed.
46101966|NCT00314015|Procedure|Questionnaires|Questionnaires will be used
46101967|NCT02622282|Other|Text Messages|Text messages will be sent one time per day. Text messages will include messages to motivate and inform participants on the importance of walking.
46101968|NCT02622282|Other|Phone Calls|Participants may receive a telephone call every two weeks for one month followed by once per month for two months.
46101969|NCT02622282|Other|Handout|Handout includes information specific to participant's condition and ways to promote an active lifestyle.
46101970|NCT00685568|Drug|celecoxib|Orally, twice daily for 3 months; 50 mg tablets. Celecoxib escalating doses starting at 4 mg/kg/day.
45467266|NCT01310725|Procedure|Coronary artery bypass grafting|Bypass of stenoses in coronary arteries using different types os vessels as conduit.
45467267|NCT05128968|Procedure|endotracheal intubation|Endotracheal intubation is performed in simple head extension or sniffing position using a McGrath MAC videolaryngoscope.
45467268|NCT03338673|Device|tDCS|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function
45467269|NCT03338673|Other|BrainHQ|BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
45467270|NCT01310881|Drug|NSI-189 Phosphate|Once daily oral administration
45838026|NCT05050227|Behavioral|Usual Care|Primary Care Provider supported usual care typically includes medication prescription and referrals to specialty mental health, including Primary Care - Mental Health Integration services.
46101971|NCT00685568|Other|placebo|Orally, twice daily for 3 months
46101972|NCT00306059|Procedure|Early goal directed therapy during 6 hours after occurence of the early phase of acute kidney injury|Directed therapy during 6 hours after occurence of the early phase of acute kidney injury.
46101973|NCT04121988|Diagnostic Test|MRI|"1 mm slice thickness with deep learning based reconstruction algorithm applied to the following sequences:~Coronal T2 weighted imaging~Dynamic contrast enhanced T1 weighted imaging~Coronal contrast enhanced T1 weighted imaging"
46101974|NCT02626208|Device|Nestorone®/Estradiol Contraceptive Vaginal Ring|Three arms of contraceptive vaginal rings contain a fixed dose (200 mcg/day) of Nestorone® and escalating doses (75 µg/d, 100 µg/d, or 200 µg/d /day) of estradiol
46101975|NCT04210739|Drug|Betamethason Sodium Phosphate|Injection of betamethasone in chronic non bacterial prostatitis patients using Trans rectal Ultrasound
46101976|NCT00696540|Drug|Inhalation of salbutamol diluted in hypertonic saline|The first of 3 nebulizations of 0.5 mg of Salbutamol is diluted in 3.5 ml of hypertonic (3%) saline. The second and the third are diluted in normal (0.9%) saline.
45467271|NCT03782389|Other|Preseason Periodic Health Examination Completion|all available players completed a mandatory PHE on one of three days during the first week of the season. Typically, the musculoskeletal and performance components of the PHE included: 1) anthropometric measurements; 2) medical history (i.e. previous injury history); 3) musculoskeletal examination tests; 4) functional movement and balance tests; 5) strength and power tests.
45467272|NCT03708081|Procedure|ProTaper Next|Root canal instrument
46018241|NCT02864797|Other|Health related quality of life collected via CHES|Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software. Thus, QoL's results are directly presented to clinicians via the CHES, in order to be considered as part of the supportive care strategy at the end of the study
45467273|NCT03708081|Procedure|TF Adaptive|Root canal instrument
45467274|NCT05560399|Drug|Iberdomide|Route of administration: oral pill. Schedule: Taken Once daily on days 1-21. Dose: will be tested at 1 mg, 1.3 mg, and 1.6mg. 1mg dose may be reduced to 0.75mg if not tolerated.
45467275|NCT05560399|Drug|Elotuzumab|Route of administration: IV Dose: 10 mg/kg for cycles 1 and 2. 20 mg/kg for cycle 3 and beyond. Schedule: Days 1, 8, 15, and 22 for cycles 1 and 2. Then taken on Day 1 (every 28 days) of each cycle thereafter.
45467276|NCT05560399|Drug|Dexamethasone|"Route of administration: Oral pill or IV Dose: 36 mg within 24 hrs of day 1 of each cycle and day 8, 15, and 22 of cycle 1 and 2.~40 mg on days 8, 15, 22 of cycle 3 and all subsequent cycles. (20 mg for > 75 years old).~Schedule: On days that Elotuzumab is administered, Dexamethasone to be taken 28mg orally (for ≤75 years old) or 8mg orally (for > 75 years old) between 3 and 24 hours before Elotuzumab plus 8 mg IV between 45 and 90 minutes before Elotuzumab for all patients.~On days that Elotuzumab is not administered but a dose of Dexamethasone is scheduled (Days 8, 15, and 22 of cycle 3 and all subsequent cycles), 40 mg orally for ≤75 years older and 20 mg for"
45467277|NCT04477161|Dietary Supplement|Ketone Ester Elite endurance Nutrition Drink|Subjects will take one bottle four times daily for four weeks
45467278|NCT04477161|Other|Stool Sample|Subjects will provide a stool sample at 2 timepoints.
45467279|NCT03783169|Other|Cardiovascular Sonographic Assessment|Maternal sonographic vascular measurements assessing volume status, cardiac output, and systemic vascular resistance by means of inferior vena cava collapsibility/caval index (ICV CI), end-point septal separation (EPSS) for determining left ventricular ejection fraction (LVEF), cardiac output determination (stroke volume x heart rate), stroke volume variation, & radial artery resistance index) augments standard vital sign assessment (pulse pressure and systolic / diastolic predominance)
45467280|NCT02949024|Drug|IVT Aflibercept|IVT aflibercept [2 mg (50 µL)]
45467281|NCT02949024|Drug|SC CLS-TA|[4 mg (100 µL)]
45467282|NCT05092815|Drug|HLX208|HLX208 450mg bid po
46018242|NCT01211535|Device|OPTI-FREE RepleniSH multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, rinsing, conditioning, disinfecting, and storing study contact lenses on a daily wear basis for 14 days
46018243|NCT01211535|Device|ReNu Biotrue multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, disinfecting, daily protein removing, and storing study contact lenses on a daily wear basis for 14 days
46018244|NCT01211535|Device|Silicone hydrogel contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and prescription worn on a daily wear basis for 14 days, with either OPTI-FREE RepleniSH or ReNu Biotrue used for contact lens care
46018245|NCT03848143|Drug|onabotulinum toxin A|Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
46018246|NCT04287439|Behavioral|Progressive muscle relaxation|Patients will receive a training session for progressive muscle relaxation exercise They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
46018247|NCT04287439|Behavioral|Mindfulness meditation|Patients will receive a training session for mindfulness meditation. They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
46018248|NCT04287439|Other|Attention matched control|Patients will receive a training session focusing on focusing on the anatomy and physiological functions of the pancreas, general information about type 2 diabetes including signs, complication, and treatment methods
46018249|NCT02863861|Drug|Dexmedetomidine-ketamine|
46018250|NCT02863861|Drug|propofol-ketamine|
46018251|NCT05406765|Drug|Bupivacaine Injection|One group will receive bupivacaine 15 mg and morphine 100 ug intrathecally
46018252|NCT03846505|Drug|Oxytocin|A 40-IU dose of oxytocin will be self-administered 30 minutes prior to the start of each weekly ABCT session.
46018253|NCT03846505|Other|Placebo|A placebo will be self-administered 30 minutes prior to the start of each weekly ABCT session.
46018254|NCT01011556|Drug|Subcutaneous Teriparatide|Administered subcutaneously once daily for 12 months
46018255|NCT01011556|Drug|Transdermal Teriparatide|Administered transdermally, applied once daily for 6 hours over 12 months
46018256|NCT01211145|Drug|Placebo|Placebo nasal spray
46018257|NCT01211145|Drug|Zolmitriptan|0.5 mg nasal spray
46018258|NCT01211145|Drug|Zolmitriptan|2.5 mg nasal spray
46018259|NCT01211145|Drug|Zolmitriptan|5.0 mg nasal spray
46018260|NCT02871622|Device|BioMatrix AlphaTM|Cobalt Chromium BA9 TM drug-eluting stent
46018261|NCT00977665|Drug|rasagiline mesylate|rasagiline 1 mg tablet/day for 48 weeks
46018262|NCT00977665|Drug|placebo|placebo tablet for 48 weeks
46018263|NCT04298008|Drug|AZD6738|AZD6738 (240 ) mg bid on D15-D28 Every 4 weeks
46018264|NCT04298008|Drug|Durvalumab|Durvalumab 1500 mg iv on D1 Every 4 weeks
46018265|NCT02871544|Other|BNP and NGAL|
46018266|NCT04295278|Diagnostic Test|MicroKine Dx system|Biomarker concentrations will be determined using the MicroKine Dx system and results will be compared to measurements taken using standard immunoassays.
46018267|NCT00628342|Drug|Esomeprazole|20mg Oral tablet once daily
46018268|NCT00628342|Drug|Esomeprazole|40mg Oral tablet once daily
46018269|NCT00628342|Drug|Placebo|Oral once daily
46018270|NCT04290325|Drug|HMPL-453|HMPL-453 tablet
46018271|NCT01210443|Drug|Sitaxentan|sitaxentan sodium 100 mg
46018272|NCT02870764|Drug|Dan-shen extract|A kind of injection made from a kind of Chinese herb: salvia miltiorrhiza
46018273|NCT02870764|Drug|Placebo|200mg glugose added into 250ml 0.9% saline injection by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
45467283|NCT05236257|Drug|Larotrectinib (Vitrakvi, BAY2757556)|Pediatric patients with IFS harboring an NTRK gene fusion.
45467284|NCT05236257|Drug|Standard of Care|Standard of care for the patients from the eligible external cohorts.
45467285|NCT05679960|Diagnostic Test|Urine PolypDx machine Versus Colonoscopy|"Urine samples of the participants in each group will be analyzed to check for preidentified metabolites that signified colorectal cancer~Colonoscopy, which is the gold standard for colorectal cancer diagnosis/screening will be performed on all the participants positive for metabolites signifying CRC on Urine PolypDx machine in all the groups"
45467286|NCT05694403|Other|Survey|Questionnaire
46018274|NCT02870764|Other|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
45838027|NCT05049096|Device|focused power ultrasound mediate inferior perirenal adipose tussue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
45838028|NCT05049096|Device|sham-control group|participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
46018275|NCT04287361|Other|Efficacy of intravenous clonazepam|Efficacy of intravenous clonazepam
46018276|NCT00624429|Drug|Budesonide respules|Budesonide respules 0.5 mg nebulized once a day for 4 months of the study.
45467287|NCT04994457|Device|Virtual Reality Visual Field|A head-mounted perimeter with a wireless remote connected to a laptop that monitors responses
45467288|NCT04994457|Diagnostic Test|Standard Automated Perimetry|Standard of care perimeter
46018277|NCT02864719|Other|Energy Conservation+Problem Solving Therapy|The intervention was delivered by telephone. Each EC+PST intervention session was planned to last approximately 45 minutes and occur twice a week for up to 4 weeks. Sessions terminated when the participants identified and solved two fatigue-related problems of their choice or had participated in the intervention for eight sessions. A Participant Workbook was used throughout the intervention. During eight intervention sessions, participants identified two fatigue-related problems and solutions for them, implemented the solution plans, and reviewed the implementations.
46101977|NCT00696540|Drug|Inhalation of salbutamol diluted in normal saline|The 3 nebulizations of 0.5 mg of Salbutamol are diluted in 3.5 ml of normal (0.9%) saline.
45467289|NCT01312116|Behavioral|iCBT|Internet-delivered cognitive behavior therapy, 8 weeks
45467290|NCT01312116|Behavioral|iPDT|Internet-delivered psychodynamic therapy, 8 weeks
46018278|NCT01007812|Device|Lotrafilcon B contact lens|Silicone hydrogel, toric, soft contact lens
45467291|NCT03782311|Behavioral|motivation and and oral hygiene instructions|Motivation and oral hygiene instructions were received OHSE-high and OHSE-low groups. After showing the modified-Bass tooth brushing technique and interdental cleaning on the model, patients were followed up while brushing and flossing their teeth to correct misapplications. It was advised to brush teeth twice a day and use the interdental cleaning devices once a day.
45467292|NCT05176002|Drug|Camrelizumab|Neoadjuvant Camrelizumab combined with radiotherapy
45467293|NCT04394481|Drug|Dexmedetomidine|IV injection (1 µg/kg - 100 mL) before anesthetic induction
46018279|NCT01007812|Device|Comfilcon A contact lens|Silicone hydrogel, toric, soft contact lens
46101978|NCT04212845|Drug|Bupivacaine;Dexamethasone Solution for Injection|8 mg Dexamethasone and %0.25 bupivacaine
46101979|NCT04212845|Device|Fluoroscopy|Fluoroscopy-guided transforaminal injection
46101980|NCT04212845|Device|Ultrasound|Ultrasound-guided erector spinae plane block
45838029|NCT05047978|Other|Cow's milk protein infant formula|A routine cow's milk-based infant formula
45838030|NCT05047978|Other|Partially hydrolyzed protein infant formula|A partially hydrolyzed cow's milk protein (PHP) infant formula
45838031|NCT05045664|Radiation|Standard|12 x 2 Gy involved site radiotherapy plus Rituximab
45838032|NCT05045664|Radiation|Experimental|2 x2 Gy involved site radiotherapy plus Obinutuzumab
45838033|NCT05045664|Drug|Standard|Rituximab with 12 x 2 Gy involved site radiotherapy
45838034|NCT05045664|Drug|Experimental|Obinutuzumab with 2 x2 Gy involved site radiotherapy
45467294|NCT04394481|Drug|Ropivacaine|Perinervous injection between C5 and C6 nerve roots / interscalene block (0.75% - 20 mL)
45467295|NCT04394481|Drug|Dexamethasone|IV injection (0.15 mg/kg) during anesthetic induction
45467296|NCT03781999|Dietary Supplement|Actiful|supplement containing 500 mg orange extract and 200 mg pomegranate actives
45467297|NCT03781999|Other|Placebo|Maltodextrin
45467298|NCT05682612|Other|outcome|hospital survivors and nonsurvivors
45467299|NCT05682612|Other|Subtype of COVID-19|Different subtype of COVID-19
45467300|NCT03782935|Dietary Supplement|Prenatal multivitamin mineral supplement|prenatal vitamin/mineral supplement with or without choline supplement
45467301|NCT04370847|Procedure|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using a 25-gauge spinal needle
46018280|NCT04204525|Diagnostic Test|Quantitative sensory testing|"Electrical detection and pain thresholds will be determined (at the sural nerve of the dominant leg and at the median nerve of both arms) with a constant current electrical stimulator.~Endogenous pain facilitation will be assessed by a temporal summation paradigm by delivering 20 electrical stimuli at the intensity of the electrical pain threshold.~Endogenous pain inhibition will be assessed by a conditioned pain modulation paradigm with electrical stimulation as test stimulus and the cold pressor test as conditioning stimulus.~EEG measurements with be performed with scalp EEG with 32 surface Sn electrodes in a headcap in referential montage following the standard 10-20 recording system.~A 5 minute resting state measurement will be performed with eyes closed, followed by EEG measurements during the condition pain modulation paradigm to assess the evoked-related potentials."
46101981|NCT00620165|Drug|levetiracetam|Subjects will receive levetiracetam titrated up over 6 weeks to a maximum dose of 3000 milligrams (mg) per day, and then continue at 1500 mg twice daily for an additional 6 weeks.
45680873|NCT03025360|Drug|Larotrectinib (Vitrakvi, BAY2757556)|Larotrectinib will be administered orally as capsule or liquid solution as specified by the treating physician.
45467302|NCT04370847|Drug|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
45467303|NCT04370847|Drug|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
45467304|NCT04370847|Procedure|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
46018281|NCT01208961|Drug|Epanova (4 g) and Lovaza (4 g)|Single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters, 4x1g capsules, taken with high-fat meals
45467305|NCT04370847|Radiation|lung ultrasound scans|lung ultrasound scans will be performed while the patient is in the supine position with left lateral tilt by 30 degrees using a 2-5 MHz curved array transducer. The echo comet score (ECS) which corresponds to the amount of EVLW will be obtained by the 28-rib interspaces technique. An increased amount of (EVLW) is diagnosed by multiple B-lines or 'comet tails' which are defined as discrete laser-like vertical hyperechoic reverberation artifacts that arise from the pleural line and extend to the bottom of the screen without fading and move synchronously with lung sliding. The sum of the B-lines found on each of the 28 chest-wall areas yields the ECS.
45467306|NCT04370847|Other|Ultrasound Assessment of the Inferior Vena Cava|The IVC largest and smallest diameters will be measured proximal to the opening of the M-mode using s2-4 MHz transducer placed longitudinally in the subcostal region.
45467307|NCT04370847|Other|Optic nerve sheath diameter|Optic nerve sheath diameter measurement will be conducted in two axes of transverse and oblique sagittal using a 12-4MHz linear array transducer. Depth of the optic nerve will be localized and marked at 3 mm behind the retinal and optic nerve junction transverse diameter of optic nerve sheath will be calculated. The reported ONSD corresponds to the mean of the four values obtained for each patient transverse and sagittal plane for both eyes.
45467308|NCT04370847|Drug|ringer acetate|1000 ml ringer acetate will be administered over 2 hours.
45467309|NCT04370847|Drug|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
45467310|NCT04370847|Drug|Intravenous Syntocinon|Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution.
45467311|NCT03708120|Other|Citrepel (Insect Repellent) EPA Reg. No. 84878-2|Citrepel (Insect Repellent) EPA Reg. No. 84878-2 is a pump spray formulation containing the active ingredient Citriodiol®, a tradename for Oil of Lemon Eucalyptus (OLE, Chemical Abstracts Service (CAS) No.: 1245629-80-4). Citriodiol® is derived from Eucalyptus citriodora leaves and contains a minimum of 65% p-Menthane-3,8-diol (PMD, CAS: 42822-86-6) and other constituents occurring naturally in the essential oil source material. The repellent is manufactured by Citrefine International Ltd and will be supplied by them in the pump spray bottle the manufacturer intends to use when the product is marketed with instructions for use on the product label.
45680874|NCT04009330|Diagnostic Test|POC Assay|"Interventions:~Blood Baseline - up to 40ml Day 3 - up to 40ml~Urine Baseline - 10ml Day 3 - 10ml~Study population:~Adults (18 plus) in ICU units diagnosed with ARDS."
46018282|NCT01208961|Drug|Lovaza (4 g) and Epanova (4 g)|Single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters,4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose ofEpanova (omefas),4x1g capsules, taken with high-fat meals
46018283|NCT01001572|Drug|Valsartan/amlodipine 160/5 mg|Valsartan/amlodipine 160/5mg film coated tablets taken orally once daily.
46018284|NCT01001572|Drug|Valsartan 160 mg|Valsartan 160 mg capsule taken orally once daily.
46018285|NCT01001572|Drug|Placebo|1 capsule or tablet taken orally once daily
46018286|NCT02866357|Other|No intervention|Just collection of nasopharyngeal aspirate for assessment
46018287|NCT01208415|Device|Endovascular repair for aortoiliac or iliac aneurysms.|Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Zenith® Connection Endovascular Covered Stent/ConnectSX™ and the Zenith® Flex AAA Endovascular Graft.
46018288|NCT02871232|Other|Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System of post-marketing surveillance of prescription medication abuse, misuse, and diversion|
46018289|NCT04287205|Drug|Dydrogesterone|79 women, aged between 18 and 45 years, who were examined at our tertiary gynecology outpatient clinic between April 2019 and March 2020, with surgically diagnosed endometriosis, were included in this study. They received a treatment with 5 mg dydrogesterone administered orally twice daily for 21 days; from the 5th to 25th day of each menstrual cycle, for a total of 6 months. They were evaluated pre- and posttreatment in terms of their age, parity, and body mass index (BMI). Female Function Sexual Index (FSFI) and visual analogue scale (VAS) scores were recorded pre- and posttreatment
46101982|NCT00620165|Drug|placebo|Subjects will receive identical placebo titrated up over 6 weeks to a maximum daily dose, and then continue twice daily for an additional 6 weeks.
46101983|NCT00685646|Drug|antiandrogen therapy|Up to 24 courses of therapy
46018290|NCT00628576|Drug|unfractionated heparin|UFH: Continuous i.v. infusion 100 IU/kg/4hrs initially and then adjusted to maintain APTT value 1.5 - 2.5 the pre-treatment value
46018291|NCT00628576|Drug|Tinzaparin (Leo)|FH (Tinzaparin): 175 iu/kg s.c. in the abdomen once daily
46018292|NCT01208337|Drug|Alemtuzumab|Alemtuzumab is a monoclonal antibody directed against the CD52 antigen. A single dose of 0.3-0.4 mg/kg is given to enrolled subjects at the time of intestine transplantation, 30 minutes after premedication with acetaminophen, diphenhydramine and methylprednisolone
46101984|NCT00685646|Drug|zoledronic acid|Up to 24 courses of therapy
46101985|NCT04209257|Device|Functional Electrical Stimulation.|Functional electrical stimulation - electrical stimulation applied to a muscle during an activity (i.e. ankle dorsiflexors during swing phase of gait). It assists / elicits muscle activation in order to achieve a task.
46101986|NCT00685724|Behavioral|Motivational Enhancement Therapy (MET)|MET is a client-centered, directive form of therapy designed to enhance clients' intrinsic motivation to change.
46101987|NCT00685724|Behavioral|Cognitive-Behavioral Therapy (CBT)|In CBT, clients learn to modify their thoughts as well as their behaviors by increasing awareness of the relationship between thoughts, emotions, and actions.
46101988|NCT04139720|Behavioral|e-book|sexual harassment prevention via education e-book
46018293|NCT04295122|Device|Phacoemulsification+ Endoscopic cyclophotocoagulation (ECP) laser|"A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion.~Phacoemulsification energy used during the cataract surgery will be recorded. If the patient has been randomised to ECP laser, the viscoelastic will be washed-out of the capsular bag. Further cohesive viscoelastic material will be injected through the main wound between the anterior capsule and iris, until the iris is close to or touching the cornea. A curved ECP probe will be inserted through the corneal incision wound/wounds and 360° of the anterior section of the ciliary processes will be treated. The power setting will be varied according to tissue response (starting power of 250 mW with continuous setting). 'Pops' should be avoided (but recorded) but no indentation used during treatment. Final power used and duration of surgery will be recorded."
46018294|NCT04370548|Drug|DARE-BV1clindamycin phosphate vaginal gel, 2%|One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) or placebo gel will be applied intravaginally as a single dose within 1 day of randomization.
46018295|NCT01208181|Drug|Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
46018296|NCT01208181|Drug|Etoricoxib 90 mg|One tablet orally once daily for 6 weeks.
46018297|NCT01208181|Drug|Placebo to Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
46018298|NCT01208181|Drug|Placebo to Etoricoxib 90 mg|One tablet orally once daily for 6 weeks
46018299|NCT02870842|Device|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
46018300|NCT02870842|Other|Respiratory management|Appropriate respiratory managements depending on the lung ultrasound findings
46018301|NCT01208103|Biological|Bevacizumab|Given IV
46018302|NCT01208103|Drug|Capecitabine|Given PO
46018303|NCT01208103|Drug|Oxaliplatin|Given CVC
46018304|NCT05410509|Procedure|Trans-arterial embolization (TAE)|Trans-arterial embolization (TAE) is a minimally-invasive procedure in which the tumor-feeding arteries are catheterized under x-ray guidance and therapeutically occluded. TAE of the kidney is routinely performed in clinical practice for traumatic or iatrogenic injury or to de-vascularize tumors such as angiomyolipomas, oncocytomas, and RCC. The procedure has a long clinical history of success with a very low major complication rate. TAE of RCC with or without percutaneous cryoablation (PA) has been described in retrospective case series as a mechanism to destroy the tumor, reduce bleeding complications from PA, or improve symptoms of RCC such as pain or hematuria. However, these findings have yet to be confirmed in a rigorous, prospective fashion.
46018305|NCT01206777|Drug|Rituximab|Dose 2 of Rituximab IVPB will be started at a rate of 100 mg/hr for the first 15 minutes. If tolerated, the remainder of the bag will be infused over 45 minutes.
46018306|NCT01001494|Drug|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
46018307|NCT01001494|Drug|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
46018308|NCT01001494|Drug|Placebo|Placebo twice-daily by inhalation for 24 weeks
46018309|NCT01205685|Drug|OSI-906|"In a pill form by mouth, twice a day (12 hours apart)~During the safety run portion of the study~Dose level 2 = 150 mg twice a day~Dose level 1 = 100 mg twice a day~Dose level -1 = 100 mg twice a day~Dose level -2 = 100 mg twice a day"
46018310|NCT01205685|Drug|Erlotinib|"During the safety run phase of the study:~Dose Level 2 = 100 mg/d~Dose Level 1 = 100 mg/d~Dose Level -1= 75 mg/d~Dose Level -2 = 50 mg/d"
46018311|NCT01205685|Drug|Letrozole|In a pill form, by mouth, once per day at 2.5 mg/d.
46018312|NCT01205685|Drug|Goserelin|For pre-menopausal patients only. Given as an injection once a month at 3.6 mg/month.
46101989|NCT00284297|Procedure|History taken and clinical examination|History is taken and clinical examination is followed
46101990|NCT00685958|Drug|enoxaparin (XRP4563)|14 days of treatment
46101991|NCT04784507|Procedure|En Bloc Resection|En bloc transurethral resection of bladder tumor (EBR-BT) using any energy source (laser and bipolar or monopolar energy)
46018313|NCT04362514|Behavioral|MEPC - Multi-component exercise program related to cycling|Structured and progressive multicomponent exercise program with and without bikes. Training period will last over 3 months with 8 sessions à 60 minutes. Training sessions will address motor competence (balance, strength, cycling skills and techniques) and cognitive skills required during cycling. Furthermore, fall-related psychological concerns will be addressed.
46018314|NCT04362514|Other|HRP - health-related presentations|HRP include 3 presentations on healthy aging (one per month) with a duration of 60 minutes
46018315|NCT01205529|Drug|Procainamide|One time intravenous infusion of Procainamide administered over 30 minutes. Dosage is calculated as 10mg/kg based on subject's ideal body weight.
45467312|NCT05198739|Other|Video Interaction Project (VIP) program|Video Interaction Project (VIP) is a strengths-based, family-centered intervention designed to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines. In VIP's core component, a VIP coach video-records the parent / child for 3-5 minutes playing/reading with a provided toy and/or book, then reviews the video with the parent to facilitate self-reflection on the interaction and identifies and reinforces strengths. In the US, VIP is delivered in the context of pediatric primary care visits, with a COVID-19 remote adaptation (see Section 6 for details). Research staff will delivery VIP through video calls with subjects in Brazil.
45467313|NCT03093428|Drug|Radium-223|Radium-223 is a calcium mimetic that hones in on bone metastases. It binds to new bone stroma and emits alpha particles, which induce double-stranded DNA breaks that result in tumor cell death.
45680875|NCT04766554|Device|Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter) and protocol-based interventions|In the intervention group, an alarm threshold below 15% of the baseline rSO2 value will be established. Based on the predetermined algorithm the rSO2 will be maintained at or above 85% of the baseline measurements. If the rSO2 reaches levels below 15% of the baseline values or below 50% in absolute value for over 30 seconds, protocol-based interventions will be performed to restore rSO2 to baseline levels.
46101992|NCT04784507|Procedure|Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)|Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)
46018316|NCT02870374|Behavioral|Answering specific quality of life questionnaire in kidneys transplantation population|
46018317|NCT04294966|Drug|Dextrose|Administering dextrose to health volunteers for our placebo group
46018318|NCT04294966|Drug|Dronabinol|THC (Marinol® [dronabinol]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users (Ménétrey et al., 2005; Issa et al. 2016).
46018319|NCT04294966|Drug|Dronabinol|THC (Marinol® [dronabinol]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users (Ménétrey et al., 2005; Issa et al. 2016).
46101993|NCT04138472|Drug|dexmedetomidine|intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.
46101994|NCT04138472|Drug|fentanyl|intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.
46101995|NCT04138472|Drug|lidocaine|intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.
46101996|NCT00620789|Drug|Escitalopram + CBT-I|"Escitalopram, 10 mg daily for the duration of the study (6 months)~CBT-I, four biweekly sessions during eight week Treatment phase."
46018320|NCT04295200|Other|Dry needling with electrical stimulation|Paravertebral dry needling to L3, 4, 5 multifidi. Electrical stimulation will be applied through the needles for up to 10 minutes total or to the participant's tolerance.
46018321|NCT01205451|Drug|Botulinum toxin type A|Botulinum toxin type A
46101997|NCT00620789|Behavioral|CBT-I plus placebo antidepressant medication|"CBT-I, 4 biweekly sessions, eight week Treatment phase.~Placebo,daily for duration of study(6 months)."
45467314|NCT03093428|Drug|Pembrolizumab|Pembrolizumab is a PD-1 inhibitor. Pembrolizumab binds to human PD-1 and blocks the interaction between PD1 and its ligands.
45467315|NCT03706716|Other|decision aid developed for pelvic organ prolapse|Conversation based upon the inter face in the Electronic patient journal.
46101998|NCT00620789|Drug|Escitalopram|"Escitalopram, 10 mg daily for the duration of the study (6 months)~SH, four biweekly sessions during eight week Treatment phase"
46101999|NCT00691184|Drug|Placebo|0% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
45467316|NCT03782155|Drug|glutamine supplementation|powder 14g
45467317|NCT03782155|Drug|HMB|powder 3g
46018322|NCT04294732|Drug|Bupivacaine|"bupivacaine is a local anesthetic drug which is already using in surgical procedures.~saline is isotonic solution of which has include %0,9 NACL."
46018323|NCT04294732|Drug|Only spinal anesthesia without peripheral nerve block|Only spinal anesthesia without peripheral nerve block
46018324|NCT04294888|Device|repetitive transcranial magnetic stimulation (rTMS)|rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.
46018325|NCT02887677|Drug|Dapagliflozin|Administration of dapagliflozin (film-coated tablet of 10mg, per os, q24h, 12 weeks)
46102000|NCT00691184|Drug|Terbinafine Hydrochloride|10% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
46018326|NCT02887677|Drug|Placebo|Administration of placebo (film-coated tablet of same color and texture with dapagliflozin, 10mg, per os, q24h, 12 weeks).
45467318|NCT03782155|Drug|Placebo|powder 17g
45467319|NCT04361019|Other|On-Line Survey|A survey has been sent by email to the students of the participating universities
46018327|NCT02871466|Drug|stem cells infusion|
46018328|NCT04332016|Other|biological samples collection|collection of whole blood samples, urine and stool samples, upper respiratory samples, post-mortem biopsies
46102001|NCT00691184|Drug|Terbinafine Hydrochloride|1% Terbinafine Hydrochloride Cream, twice a day for 7 days.
46018329|NCT01001104|Drug|LY2189265|Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.
46018330|NCT01001104|Drug|Placebo|Administered by SC injection, QW for 12 weeks.
46018331|NCT04296526|Behavioral|Exercise Prescription|To prescribe exercise programs that can be easily applied at home/dormitory/living place for students.
46018332|NCT04296526|Behavioral|Exercise Education|To organize sessions for how to proper exercise.
46018333|NCT04296526|Behavioral|Social Support|Supports such as peer influence or reminder phone messages
45467320|NCT04780035|Biological|EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|"The EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide).~The vaccine induces the specific immunity against the SARS-CoV-2 coronavirus following two intramuscular injections spaced 21 to 28 days apart.~The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations given 21 to 28 days apart."
46018334|NCT00628888|Behavioral|Unified Protocol for Adolescents (UP-A)|All participants will be offered the UP-A intervention, inclusive of 8 and 21 weekly sessions of an emotion-focused treatment with cognitive-behavioral elements, either immediately following randomization or after an 8-week delayed treatment waitlist. The UP-A sessions are delivered in a flexible manner. Several of the UP-A's treatment elements are fixed and received by all participants (psychoeducation about emotions and emotional behavior, awareness and mindfulness skills, antecedent cognitive reappraisal/problem-solving skills, emotion exposure strategies, and relapse prevention skills), although applied for varying numbers of sessions depending on clinical need. Other strategies (motivational enhancement, parenting strategies and crisis management strategies) are applied on an as-needed basis based on client needs.
46102002|NCT00691184|Drug|Terbinafine|Terbinafine tablet, 250mg, single dose in groups 1,2 and 3 at end of study.
46018335|NCT02870686|Procedure|ERCP without the use of fluoroscopy|ERCP removal of stone technique without the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with catheter aspiration of bile, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket- number of stones removed should compare number detected on EUS, (5) confirmation of complete stone clearance with radiocontrast.
46018336|NCT02870686|Procedure|ERCP with the use of fluoroscopy|ERCP removal of stone technique with the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with fluoroscopy images, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket, (5) confirmation of complete stone clearance with radiocontrast.
45467321|NCT04780035|Other|Placebo (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections)|The use of placebo: intramuscularly twice, given 21 to 28 days apart at a dose of 0.5 ml
45467322|NCT05352542|Biological|LCAR-H93T Cells|before treatment with LCAR-H93T cells, subjects will receive a conditioning regimen
46102003|NCT00854100|Drug|Antidepressant + placebo|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
46102004|NCT00854100|Drug|Antidepressant + cariprazine (0.1-0.3 mg/day)|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
46102005|NCT00854100|Drug|Antidepressant + cariprazine (1-2 mg/d)|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (1-2 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
46102006|NCT00509899|Drug|Ruxolitinib|5 and 25 mg tablets with a daily dosing range from 10 to 200 mg qd or bid.
45467323|NCT03782857|Behavioral|Intervention|Prevention of recurrent stroke, myocardial infarction and death Stepwise escalation of preventive medication Life style counselling including adherence to preventive treatment
45467324|NCT02735980|Drug|Prexasertib|Administered IV
45467325|NCT01309789|Drug|brentuximab vedotin|1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-2 and if response, Cycles 9-16)
45467326|NCT01309789|Drug|cyclophosphamide|750 mg/m2 IV every 3 weeks (Cycles 3-8)
45467327|NCT01309789|Drug|brentuximab vedotin|1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-6 and if response, Cycles 7-16)
45467328|NCT01309789|Drug|prednisone|100 mg daily PO on Days 1-5 every 3 weeks (Cycles 3-8)
45467329|NCT01309789|Drug|cyclophosphamide|750 mg/m2 IV every 3 weeks (Cycles 1-6)
45467330|NCT01309789|Drug|doxorubicin|50 mg/m2 IV every 3 weeks (Cycles 3-8)
45467331|NCT01309789|Drug|doxorubicin|50 mg/m2 IV every 3 weeks (Cycles 1-6)
45467332|NCT01309789|Drug|prednisone|100 mg daily PO on Days 1-5 every 3 weeks (Cycles 1-6)
45467333|NCT01309789|Drug|vincristine|1.4 mg/m2 IV every 3 weeks (Cycles 3-8)
45467334|NCT03707847|Drug|Crizotinib|250mg, BID, PO
45467335|NCT03707847|Drug|Etoposide Capsule|50mg, QD, PO, d1-10，21days for one cycle
45467336|NCT03707847|Procedure|Auto-HSCT|Auto-HSCT will be performed with patients who have achieved CR or VGPR.
46018337|NCT04204954|Other|Tea Tree Oil Shampoo|Twice a day eyelid margin cleansing for three days.
46102007|NCT04212767|Procedure|Alveolar socket preservation with Platelet-rich fibrin|The sockets of the test group will be filled with two platelet-rich fibrin membranes followed by suture
46018338|NCT04204954|Drug|Ciprofloxacin Ophthalmic Ointment 0.3%|Applied topically in the eyelid margin every four hours for three days.
46018339|NCT04204954|Other|Baby shampoo|Twice a day eyelid margin cleansing for three days.
46102008|NCT00691262|Drug|tacrolimus ointment|transdermal
46102009|NCT00620867|Drug|Ibuprofen|800 mg oral tablet three time daily with meals for 6 weeks
45467337|NCT03338400|Drug|Dexamethasone|Patients will be randomized to Dexamethasone arm will receive 8mg (2ml) of Dexamethasone at the time of induction.
45467338|NCT03338400|Drug|Normal saline|Patients randomized to normal saline will receive 2ml of Normal saline at the time of induction.
46018340|NCT04204954|Other|Blephaclean|Twice a day eyelid margin cleansing for three days.
46018341|NCT02870608|Other|lung and liver elastography measurement of fetus|
45467340|NCT03787147|Device|Google Cardboard|Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI). VRA is a the oculus or the google cardboard that helps decrease anxiety. The participant in the oculus or the Google cardboard arms are asked to watch VR videos during the spinal injection.
45467341|NCT03787147|Device|Oculus|Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI). VRA is a the oculus or the google cardboard that helps decrease anxiety. The participant in the oculus or the Google cardboard arms are asked to watch VR videos during the spinal injection.
46018342|NCT04344886|Procedure|Conventional (dual-phase) SPECT/CT|Conventional (dual-phase) SPECT/CT (after 10 and 150 minutes)
46018343|NCT04344886|Procedure|Multi-phase SPECT/CT|Multi-phase SPECT/CT (after 10, 90, 150, 210 minutes)
46018344|NCT04344886|Procedure|Conventional minimally-invasive radio-guided parathyroidectomy|Conventional minimally invasive radio-guided parathyroidectomy in a time span of 2-3 hours from radionuclide administration
46018345|NCT04344886|Procedure|Individualised minimally-invasive radio-guided parathyroidectomy|Individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.
46018346|NCT00998764|Drug|Bapineuzumab 0.5 mg/kg|I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
46102010|NCT00620867|Drug|celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
45467342|NCT03787147|Drug|Lidocaine Hydrochloride|All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
45467343|NCT03787147|Drug|Bupivacaine|All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
46018347|NCT01204671|Biological|Influenza vaccine GSK2321138A|One intramuscular injection
46018348|NCT01204671|Biological|FluarixTM|One intramuscular injection
46018349|NCT01204671|Biological|Influenza vaccine GSK2604409A|One intramuscular injection
46018350|NCT02887755|Device|Near-Infrared Spectroscopy (NIRS) Sensor|These sensors utilize NIRS to evaluate oxygenated and deoxygenated hemoglobin, total oxygenation index and total blood flow. This is done by bouncing infrared light off of chromatophores (located within red blood cells), which is then refracted off of the cells in the capillary beds to the topical sensor.
46018351|NCT01202955|Drug|Tolcapone|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
46018352|NCT01202955|Drug|Placebo|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
46102011|NCT00620867|Other|placebo|matched placebo orally for 6 weeks
46102012|NCT00922688|Drug|Dipeptide Alanyl-Glutamine|Intravenous supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
46102013|NCT00922688|Drug|Placebo|Intravenous and enteral supplementation of placebo is started 24 hours prior to surgery and continued 24 hours postoperatively.
46018353|NCT01202877|Drug|5-azacytidine|Starting dose: 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle.
46018354|NCT01202877|Drug|PKC412|Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
46018355|NCT01202409|Drug|Panitumumab|Starting Dose Level: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
46018356|NCT01202175|Drug|Nebivolol|Oral nebivolol 2.5-5mg once daily
45467344|NCT02620306|Drug|Fimsartan 60mg~120mg|Standard BP control group (SBP < 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
46018357|NCT01201785|Drug|Aspirin|After having been on aspirin 81mg/daily for at least one-week, patients switched their aspirin regimen on a weekly basis according to the following scheme: aspirin 81mg twice daily (bid) for one week; aspirin 162 mg once daily (od) for one week; aspirin 162 mg bid for one week; aspirin 325 mg od for one week. Pharmacodynamic assessments were made after each sequence (5 time-points). Afterward, patients resumed the dose of aspirin that they were on prior to entering the study.
46018358|NCT01201317|Drug|AZD2423|20 mg tablet
46018359|NCT01201317|Drug|AZD2423|150 mg tablet
46018360|NCT01201317|Drug|Placebo|Placebo
46018361|NCT04318353|Other|early enteral feeding within 2 days postoperative|Enteral feeding within 2 days postoperative
46018362|NCT04317885|Biological|Prizloncabtagene Autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
46018363|NCT01200069|Drug|Placebo infusion|Identically appearing placebo dose administered IV prior to ECT and subsequently on ECT treatments 2 and 3
46018364|NCT01200069|Drug|ibuprofen intravenous|IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT and subsequently on ECT treatments 2 and 3
46102014|NCT00922688|Drug|Dipeptide Alanyl-Glutamine|Enteral supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
46018365|NCT01199601|Behavioral|Concentrated postpartum counseling|Intrapartum testing and concentrated postpartum counseling for the female patient from a retrained provider focusing on correct breastfeeding practices, postpartum contraception, and infant vaccination.
45467345|NCT02620306|Drug|Fimsartan 60mg~120mg|Strict BP control group (SBP < 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
45680876|NCT05632510|Diagnostic Test|The Edinburgh Postnatal Depression Scale (EPDS)|The Edinburgh Postnatal Depression Scale (EPDS) is a self-administered questionnaire of 10 items, is recommended by the NICE guideline and French National Authority for Health for screening peripartum women, validated in French and well accepted.
46018366|NCT01199289|Drug|AMG 827|SC injection.
46018367|NCT01199289|Drug|Placebo|SC injection.
46018368|NCT01199055|Drug|CS-7017|Drug: CS-7017 from 0.25 mg BID to 0.50 mg BID for up to 4~6 cycles (1 cycle: 3 weeks)
46018369|NCT01199055|Drug|Carboplatin|Drug: Carboplatin IV, AUC of 6 mg/mL*min, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)
45680877|NCT03025048|Behavioral|A holistic dietary intervention for persons with spinal cord injury|A lifestyle program over 9 weeks combining individual consultations with a dieatitian and interdiciplinary group sessions
45680878|NCT03599050|Behavioral|Audiotaped Counseling Session|Patients and nurses will complete audio taped counseling session at least 3 months following the baseline visit. Patients will rate quality of nurse communication skills
46018370|NCT01199055|Drug|Paclitaxel|Drug: Paclitaxel IV, 200mg/m^2, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)
46102015|NCT02622204|Procedure|Corrective osteotomy|corrective osteotomy for varus alignment
46018371|NCT01198977|Behavioral|Brief telephone-based counseling|Brief telephone-based counseling using Motivational Interviewing and physical activity goal setting and problem solving
46102016|NCT04271917|Drug|cannabidiol|Use of cannabidiol as an alternative to standard of care treatment of acute pain.
46102017|NCT04271917|Drug|placebo|Inactive placebo oil to imitate CBD oil
46102018|NCT04271917|Drug|acetaminophen 500mg and ibuprofen 200mg combo|standard of care
45680879|NCT03593512|Procedure|Deep brain stimulation|Bilateral deep brain stimulation of the pedunculopontine nucleus
45680880|NCT03595462|Other|Snack|"Hummus and Pretzels- The study participants will be provided with a hummus and pretzels snack to consume every day for a week. The energy content of the hummus and pretzels will be ~240 kcal. The hummus and pretzels contain 6 g protein, 27 g carbohydrates, 0 g sugar, 4 g fiber, and 12 g fat.~Granola Bars- The study participants will be provided with two granola bars to consume every day for a week. The energy content of the two granola bars will be ~240 kcal. The two granola bars contain 4 g protein, 38 g carbohydrates, 16 g sugar, 2 g fiber, and 9 g fat."
45680881|NCT03595462|Other|No Snack|The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
45467346|NCT02620306|Drug|Losartan 50mg~100mg|Standard BP control group (SBP < 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
45467347|NCT02620306|Drug|Losartan 50mg~100mg|Strict BP control group (SBP < 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
45680882|NCT03990532|Radiation|treatment group(phase I)|"Dose-escalation plan (phase I)~Radiotherapy:~LEVEL 1: dose given at PTV-G will be 58.8Gy/28 fractions； 2.1Gy/per fraction; LEVEL 2: dose given at PTV-G will be 64.4Gy/28 fractions； 2.3Gy/per fraction; LEVEL 3: dose given at PTV-G will be 70Gy/28 fractions； 2.5Gy/per fraction Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine"
46018372|NCT01198977|Other|Education counseling|Mailed informational video of exercise programs
46018373|NCT01198587|Drug|Zinc Sulfate|"For children ages 6month to 1 year, 12.5mg orally daily for 14 days mixed in 60 mL of fluid.~For children aged 1 year and above 25mg orally daily for 14 days mixed in 60 mL of fluid."
46018374|NCT01198587|Drug|Placebo oral capsule|Effervescent oral capsules with similar taste to treatment drug Zinc Sulfate is provided to each patient randomized to the placebo arms of the study
46018375|NCT01198509|Drug|doxycycline|doxycycline - 100 mg twice per day, for 2 months
46018376|NCT01198509|Drug|vancomycin|vancomycin, 250 mg four times a day, for 2 weeks
46018377|NCT01198275|Drug|n-3 PUFAs|1.0 g of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in the average ratio EPA/DHA of 0.19:1.5, one capsule twice a day
46018378|NCT01198275|Drug|Placebo|1.0 g of olive oil,one capsule twice a day
46018379|NCT01198275|Drug|RASS inhibitors and/or RAS blockers|Patients on ACE-Is or ARBs were continued on the same agent. In those who were not on therapy, an ACE-I or an ARB was started. In all patients, an effort was made to achieve the highest tolerated dose.
46102019|NCT04643639|Device|CytoSorb hemoperfusion|Subjects will be treated with CytoSorb hemoperfusion (in stand-alone setup) for 6 hours at a flow rate of 250 ml/min during endotoxemia.
46102020|NCT04122222|Biological|Influenza vaccine|A single standard dose of inactivated trivalent influenza vaccine: Influvac® vaccines (Abbott, the Netherlands), intramuscularly.
46018380|NCT01198275|Drug|Amiodarone|Patients on amiodarone were continued at a maintenance dose of 200 mg daily, whereas those who were not taking amiodarone were started at a dose of 400 mg daily for 1 week and then continued on a maintenance dose of 200 mg daily.
45467348|NCT03337113|Other|Working Memory Training|The Working Memory Training condition: This condition will include 30 sessions across 4 weeks (10 remote sessions prior to initiation of the rTMS stimulation, and 20 lab sessions on rTMS stimulation days). Participants will complete three distinct WM tasks in each session: a visuospatial WM task, a backward digit span task, and a letter span task. In the training condition, the difficulty level of all three WM tasks will be automatically adjusted on a trial-by-trial basis. An identical protocol and software have demonstrated efficacy in increasing WM capacity, and this improvement in WM predicts reduction in addictive behavior.
45467349|NCT03337113|Other|Sham Working Memory Training|In the Sham WMT condition, the difficulty level of the WM tasks will not be adjusted; instead it will remain at the initial easy level throughout each task (i.e., three items in each sequence). All other aspects of the condition are identical to the active WMT condition.
45680883|NCT03990532|Radiation|treatment group (phase II)|Radiotherapy dose was prescribed according to phase I trial results; Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine
45680884|NCT03990454|Drug|SLC-391|SLC-391 is an AXL inhibitor
45680885|NCT03990064|Other|musicotherapy|receptive music therapy. The musical style of the session was chosen by the patient. The validated 'U' technique was employed.
45680886|NCT05632042|Behavioral|lifestyle modification (exercise and control of diet)|erectile dysfunction (ED) psoriatic men with metabolic syndrome that will receive lifestyle changes (12 weeks of low calorie diet and moderate-intensity walking on treadmill, the walking duration will be 40 minutes, the walking will be three times per week)
45680887|NCT03595306|Dietary Supplement|Prebiotic A - inulin|Pre-weighed packages will be given twice daily for 5 days.
45838035|NCT05037552|Procedure|Bipolar coagulation|"Cystectomy will be done via laparoendoscopic surgery After identifying the correct plane of cleavage, the stripping technique will be used. The cyst wall will be gently pulled down from the remaining ovary with two pairs of atraumatic forceps.~Once the whole cyst wall will be separated from the ovary cortex, bleeding of the remaining ovarian stromal tissue will be controlled by bipolar coagulation. Then, the remnant tissue will be examined using irrigation and coagulated with minimal bipolar power (20-W current) on any sites that are bleeding."
46018381|NCT01197417|Drug|Intravenous Magnesium Sulfate|40 mg/kg (max 2.4 grams), infused at a concentration of 40 mg/ml (1 ml/kg, max 60 ml), every 8 hours for a total of 6 doses
46018382|NCT01197417|Drug|Normal Saline Placebo|(1 ml/kg, max 60 ml), administered every 8 hours for a total of 6 doses
46018383|NCT04206267|Device|Acceledent|Device for accelerating tooth movement
46018384|NCT00977431|Drug|Temozolomide|During RT: 75 mg/m2 daily , 4 weeks after RT: given days 1 to 5 of 28 day cycles (150 mg/m2 in cycle 1, 200 mg/m2 in cycle 2 up to cycle 6)
46018385|NCT00977431|Procedure|Radiotherapy|Day 1 to day 42
46018386|NCT00977431|Drug|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period, fixed dose after RT
46018387|NCT00977431|Procedure|Radiotherapy|Day 1 to day 42
45680888|NCT03595306|Dietary Supplement|Prebiotic B - galactooligosaccharides(GOS)|Pre-weighed packages will be given twice daily for 5 days.
46018388|NCT00977431|Drug|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period , fixed dose after RT
46018389|NCT04290169|Drug|IncobotulinumtoxinA|IncobotulinumtoxinA will be injected in upper extremities according to recommended guidelines. Two methods will be used in the study: auditive electromyography (EMG) and ultrasound guided injection technique. The decision process of which muscles to inject will be based on information obtained through examination of hand function, the presence of increased muscle tone during the clinical examination as well as a positive response from auditive EMG
46018390|NCT04290169|Device|Video game|"The study will include the Nintendo Switch or similar consoles that include games that require the players to move their bodies while holding motion controllers in order to progress. The games included in this project has been chosen by staff at our hospitals Virtual Gaming Lab. The participants are recommended to train 30 minutes each day, 4 days a week, during the training periods. It is expected that the amount of training will vary among the participants. Thus, each participant will be instructed to keep a training-diary and weekly report number of hours played/trained through an online reporting system created with online form, an electronic data collection system available through the University of Oslo"
46018391|NCT02864095|Drug|Tranexamic acid (TXA)|IV and topical administration
46018392|NCT02864095|Drug|Epinephrine|
46018393|NCT02864641|Behavioral|Planet K|Planet K is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' chronic kidney disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
46018394|NCT04286893|Diagnostic Test|Flow mediated vasodilatation|Measurement of brachial artery diameter change before and after limb ischaemia.
46018395|NCT04286893|Diagnostic Test|High resolution ECG|Measurement HRV using high resolution ECG
46018396|NCT04286893|Diagnostic Test|Blood withdrawal|Measurement of endothelial inflammation markers
45598451|NCT02220335|Procedure|Pulmonary arterial denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
45680889|NCT03595306|Dietary Supplement|Prebiotic C - wheat dextrin|Pre-weighed packages will be given twice daily for 5 days.
45680890|NCT05631652|Device|PillSense System|The device is composed of an orally ingested PillSense capsule and a wireless handheld PillSense receiver for real-time display of sensor data. The capsule contains an optical sensor for in-vivo detection of blood. The sensor capsule is used for diagnosis in patients with suspected acute bleeding in the upper gastrointestinal tract.
46018397|NCT04290247|Diagnostic Test|Ultrasound|Ultrasound imaging for fracture diagnosis before conventional X-ray
46102021|NCT00686114|Drug|Paclitaxel|135mg/m2, day 1 and day 29 of the radiotherapy.
46102022|NCT00686114|Drug|Cisplatin|20mg/m2, days 1-3,days 29-31 from the beginning of radiotherapy.
46102023|NCT00686114|Drug|Tarceva|150mg/day,oral administration, from day 1 to day 42 (at the beginning of therapy)
46102024|NCT00686114|Radiation|Radiotherapy|Enlarged field radiotherapy
46102025|NCT00686114|Radiation|Radiotherapy|Conventional field radiotherapy
46102026|NCT01015729|Drug|Esomeprazole/ASA Fixed Combination|Capsule, oral, single dose
46102027|NCT01015729|Drug|Esomeprazole|oral, single dose
46102028|NCT01015729|Drug|ASA|Tablet, oral, single dose
46102029|NCT00698724|Drug|Xibrom, and Optive|Xibrom: two drops a day, three days before surgery and 21 days after surgery. Optive: three times a day for 21 days after surgery.
46102030|NCT00698724|Drug|Xibrom and Pred Forte|Xibrom: two drops a day, three days before surgery and 21 days after surgery. Pred Forte: three times a day for 21 days after surgery.
46102031|NCT00686192|Dietary Supplement|Calcium Carbonate|1500 mg per day
46102032|NCT02622048|Behavioral|Triple P Positive Parenting Programme|10 week self-directed (guided) parenting intervention promoting self-belief, parenting confidence/self-efficacy and problem solving skills.
46018398|NCT02863939|Device|Single photon emission computed tomography myocardial perfusion imaging|a novel cadmium-zinc-telluride (CZT) SPECT camera
46018399|NCT02863939|Other|exercise|
46018400|NCT00977197|Drug|Pregabalin|Dose: 75 mg twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study.
46018401|NCT00977197|Drug|Placebo|A matching placebo will be administered twice a day
46102033|NCT05299190|Other|Yoga intervention plus TAU|The yoga intervention consists of 8 weekly group sessions. The intervention is based on hatha yoga system. TAU is usual care participants receive from their health care provider
46102034|NCT05299190|Other|Clinical Monitoring plus TAU|clinical monitoring includes bi-weekly 15-20 minute telephone contact with participants. TAU is usual care participants receive from their health care provider.
46102035|NCT04117776|Other|Skin microbiological sampling (wash with 2% Chlorhexidine Gluconate)|3 microbiological samples, per application of agar on skin, after 24h of a first wash with 2% Chlorhexidine Gluconate : 1h before the second wash with the same washing product and then 1 to 2 h after, and 20 to 23h after this second wash.
46102036|NCT04117776|Other|Skin microbiological sampling (wash with mild soap)|3 microbiological samples, per application of agar on skin, after 24h of a first wash with mild soap : 1h before the second wash with the same washing product and then 1 to 2 h after, and 20 to 23h after this second wash.
46102037|NCT00922610|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every 2 weeks at a starting dose of 0.6micrograms/kg;subsequently every 4 weeks
46018402|NCT04065139|Drug|Pressurized intraperitoneal aerosol chemotherapy (PIPAC)|After insufflation of a 12 mmHg of capnoperitoneum at 37°C, two balloons safety trocars (10 and 12mm) are inserted into the abdominal wall. Injection of Doxorubicin (2.1 mg/m2 in 50 ml NaCl 0.9%) and Cisplatin (10.5 mg/m2 body surface in 150 ml NaCl 0.9%) with a flow rate of 0.7ml/s, the therapeutic capnoperitoneum is maintained for 30 min at body temperature.
46102038|NCT04135170|Combination Product|ALBC vs plain bone cement|The patients undergoing full-cemented primary total knee arthroplasty are allocated to either ALBC or plain bone cement and compare the effectiveness of ALBC use vs pain bone cement bone cement without antibiotic) with respect to revision due to PJI one year after primary TKA surgery.
46102039|NCT00686270|Drug|apricitabine|Initially 1200mg apricitabine twice daily orally. Following the determination of the optimum dose (800mg or 1200mg twice daily) in the pre-ceeding study AVX-301,patients may be switched to the optimum dose,if required.
46018403|NCT04065139|Drug|Standard chemotherapy|Patient will receive standard poly chemotherapy proposed by the oncologist or any new standard validated during the study, until progression or toxicity.
46018404|NCT04288297|Procedure|distal minimally invasive chevron osteotomy|With an electric motor-driven machine the resection of the medial eminence as well as a V-shaped osteotomy was performed in hallux valgus patients. Intraoperative fluoroscopy was used to identify the ideal osteotomy site and to control the Intervention. Fixation of the metatarsal head was achieved with a screw or with a K wire. Residual bone ridges were reamed and bone debris washed out.
46018405|NCT04288219|Device|Non-Invasive Positive Pressure Ventilation|Continuous positive airway pressure delivered by face mask at 10cmH2O
46018406|NCT04288219|Drug|Nifedipine|Nifedipine 30mg, Pharmacotherapy
46018407|NCT04288219|Other|supplemental oxygen|supplemental oxygen
46018408|NCT00974311|Drug|Enzalutamide|MDV3100, 160 mg orally per day
46018409|NCT00974311|Drug|Placebo|Placebo comparator
45680891|NCT03599830|Other|Cognitive test passations|"Tests :~MoCA2 Hopkins verbal learning test WAIS-IV Trail Making test Stroop Verbal fluences"
45680892|NCT03594916|Device|Active tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
46018410|NCT00974233|Drug|Bendamustine|90 mg/m2/day IV days 1 and 2 every 28 days for 6 cycles
46018411|NCT00974233|Drug|Rituximab|375 mg/m2 Day 1 every 28 days for 6 cycles
46018412|NCT00974233|Drug|Lenalidomide|5 mg/day days 1-28 of each 28 day cycle, up to 12 cycles maximum. Dose escalation to 10 mg/day allowed after one cycle as defined in the protocol.
46018413|NCT02866123|Other|ultrasonography|
46018414|NCT02866123|Radiation|pulmonary radiography|
46018415|NCT00629395|Behavioral|Captain's Log Computer Program|12 Computer Program
46018416|NCT04287907|Device|Monitor Group|Use of colorimetric end tidal CO2 to guide provider during provision of mask ventilation, where colour change indicates effective breaths
46018417|NCT03886909|Behavioral|Exercise|The exercise intervention is at least 2 weeks lasting (till the day transplant is taking place) 5-times weekly resistance training intervention combined with aerobic exercise (mostly walking).
46018418|NCT03886909|Behavioral|Prehabilitation Education|Participant will receive a prehabilitation and stem cell education class which will be held at the Penn State Cancer Institute.
46018419|NCT04270357|Procedure|Cholecystectomy|Cholecystectomy is the surgical removal of the gallbladder. Cholecystectomy is a common treatment of symptomatic gallstones and other gallbladder conditions
46018420|NCT03747757|Behavioral|Cognitive Behavior Therapy|Undergo CBT
46018421|NCT03747757|Other|Quality-of-Life Assessment|Ancillary studies
46018422|NCT03747757|Other|Questionnaire Administration|Ancillary studies
46018423|NCT02863627|Other|Newborn Care Pathway|consultation with the pediatric emergency, two telephone interviews to complete Questionnaires with the parents after the emergency department visit
46018424|NCT00972595|Drug|ondansetron clinical trial formulation|Single dose of an over-encapsulated 8 mg tablet of United Kingdom (U.K.) ondansetron (ZOFRAN™) in one of two treatment periods.
46018425|NCT00972595|Drug|ondansetron marketed formulation|Single dose of an 8 mg tablet of U.K. ondansetron (ZOFRAN™) in one of two treatment periods.
46018426|NCT01196091|Drug|LY2127399|120 mg administered via subcutaneous (SC) injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
46018427|NCT01196091|Drug|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose of corticosteroids, NSAIDs, antimalarials, or immunosuppressants will also be administered at the first dose
46018428|NCT01196091|Drug|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
46018429|NCT01196091|Drug|Standard of Care|
45680893|NCT03594916|Device|Sham tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
46018430|NCT01195623|Procedure|preoperative duplex examination|
46018431|NCT01195623|Procedure|Preoperative duplex|
46018432|NCT01195545|Device|Veritas® Collagen Matrix|biological mesh in hernia repair
46018433|NCT01194999|Device|Pubovaginal sling procedure|The procedure involves placing a band of sling material directly under the bladder neck (ie, proximal urethra) or mid-urethra, which acts as a physical support to prevent bladder neck and urethral descent during physical activity. The sling also may augment the resting urethral closure pressure with increases in intra-abdominal pressure.
46018434|NCT01194531|Device|24 Chromosome Aneuploidy Screening with Parental Support|Preimplantation Genetic Screening (PGS)
46018435|NCT00972517|Biological|GSK investigational vaccine GSK2340272A|Three intramuscular injections
46018436|NCT04286737|Other|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
46018437|NCT02863549|Device|MitraClip in tricuspid valve|MitraClip in tricuspid valve
46018438|NCT00972283|Drug|insulin degludec|Injected subcutaneously (under the skin) with main evening meal. Dose was individually adjusted.
46018439|NCT00972283|Drug|insulin glargine|Injected subcutanoeusly (under the skin) according to approved label. Dose was individually adjusted.
46018440|NCT00972283|Drug|insulin aspart|Injected subcutaneously (under the skin) at each main meal. Dose was individually adjusted.
45680894|NCT03989440|Drug|AXER-204|human NoGo Trap fusion protein
45680895|NCT03989440|Drug|Placebo|Phosphate buffered saline formulation
46018441|NCT05375253|Biological|Donor Enriched Activated Natural Killer Cell Infusion|αβ TCR/CD19 depleted (DEA-NK) cells on day +7 post T-cell replete Haplo-Tx with PTCY
46018442|NCT05366049|Other|using a medicine pacifier to give acetaminophen|While giving acetaminophen, the effect on the amount of taking the drug, pain and vital parameters are observed by using the drug pacifier.
46018443|NCT02887599|Procedure|Blood collection|1ml of blood specimen collection
46018444|NCT00969709|Drug|Levomilnacipran ER|Levomilnacipran ER, 40 mg, oral administration, in capsule form, once daily for 8 weeks.
46018445|NCT00969709|Drug|Levomilnacipran ER|Levomilnacipran ER, 80 mg, oral administration, in capsule form, once daily for 8 weeks.
46102040|NCT04117698|Drug|Antitubercular treatment (RIFATER ©)|"Treatment of ocular inflammation by antitubercular treatment  add-on of local corticosteroid therapy comprising:~RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months~associated with a treatment similar to the control group."
46102041|NCT04117698|Drug|Ethambutol|Ethambutol
46102042|NCT04117698|Drug|RIFINAH ©|RIFINAH ©
46018446|NCT00969709|Drug|Levomilnacipran ER|Levomilnacipran ER, 120 mg, oral administration, in capsule form, once daily for 8 weeks.
46018447|NCT00969709|Drug|Placebo|Matching placebo capsules, oral administration, once daily for 8 weeks.
46018448|NCT01193517|Drug|Azacitidine|Starting dose level 75 mg/m2/day subcutaneously on Days 1-5 of a 21 day cycle.
46018449|NCT01193517|Drug|Capecitabine|1500 mg/m2/day by mouth twice daily in divided doses on Days 1-14 of a 21 day cycle.
45680896|NCT03989362|Drug|Vopratelimab|Specified dose on specified days
46102043|NCT04210271|Behavioral|Buddy self-testing condition|
46102044|NCT04210271|Behavioral|Control self-screening condition|
46102045|NCT04118322|Other|aromatherapy (peppermint oil)|"The patients in the intervention group received routine medical treatment program and were asked to put one drop of peppermint oil upon lips following chemotherapy administration. Before peppermint oil application; the researcher theoretically and practically provided a training of 8-10 minutes about the use of peppermint oil and the patients were requested to apply this oil three times a day according to Oil Practice Guide (See Fig. 2) in the morning (09:00), at noon (15:00) and in the evening (21:00).~Aromatherapy essential oil used was a mixture of English peppermint (Mentha piperita; 3%) and sweet almond oil (30 ml)"
46102046|NCT04031612|Drug|Neoadjuvant therapy|Neoadjuvant therapy
46102047|NCT00700050|Drug|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
46102048|NCT00700050|Drug|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
46102049|NCT00700050|Drug|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
46102050|NCT00700050|Drug|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
46102051|NCT05299112|Dietary Supplement|Arginine|The intervention parenteral nutrition contains additional arginine (18% arginine content) as compared to standard parenteral nutrition (6.3% arginine content).
46102052|NCT05662709|Procedure|Tooth extraction|Tooth extraction in the most atraumatic way
46102053|NCT05662709|Procedure|Alveolar ridge preservation with L-PRF|Blood will be drawn from the patient, centrifugued and leukocyte and platelet-rich fibrin (L-PRF) will be obtained. L-PRF plugs and membranes will be prepared and placed in the socket after extraction
46102054|NCT00698802|Drug|EX1000|Treat-to-target titration scheme, s.c. injection
46018450|NCT01193517|Drug|Oxaliplatin|Starting dose level 90 mg/m2 by vein on Day 2 of a 21 day cycle.
46102055|NCT00698802|Drug|biphasic human insulin|Treat-to-target titration scheme, s.c. injection
46102056|NCT00686426|Dietary Supplement|Dairy Foods|Adequate dairy (> 3 standard daily servings)
46018451|NCT01193517|Drug|Azacitidine MTD|Highest tolerable dose of combination azacitidine with CAPOX found in Phase I.
46018452|NCT02866045|Procedure|EUS-guided fine needle biopsy|EUS-FNB is performed using a 22 or 25 G core biopsy needle (SharkCore FNB, Medtronic, Fridley, MN) by standard linear EUS-guided technique. The needle tip has six cutting edge surfaces and an opposing bevel to catch tissue as it is sheared off, enabling cohesive units of tissue acquisition with minimal tissue fracturing. 3 separate passes will be done into the lesion. Additional passes may be made if clinically necessary. No suction will be applied on the first pass. If the FNB sample obtained is deemed to be inadequate, negative pressure (using the standard suction syringe) will be applied to the needle on additional passes. The histology and cytology specimens will be processed as per standard clinical care.
46102057|NCT00686426|Dietary Supplement|Dairy Foods|< 1 standard dairy serving/day
46102058|NCT00618215|Behavioral|peer group educational implementation strategy|"Delivery CPG~Education session IQual group~Online training website (individual feed back)~Reminder (flow chart), individual feed back record form~Feed back by email~Registration in practice"
46102059|NCT00698880|Procedure|Right hepatic vein embolization|Embolization of the right hepatic vein
46102060|NCT02626988|Behavioral|Promotion of a biodiverse diet|Nutrition education combined with Agriculture Capacity building focused on a key set of nutritious crops. Component (C) 1 - Participatory Identification of Intervention Approach (PIIA); C2 - Local stakeholder consultation; C3 - Sensitisation of community; C4 - Formation of Diversity club. Club will receive capacity building from a Village health worker. The following topics will be covered species selected for promotion: 1. Where to locally source inputs and expected price, 2. How/when to prepare plots using organic inputs, 3. Planting and best-practice management practices, 4. Seed saving and storage and 4. Active Cooking demonstrations and Nutrition Education and counselling including Diversified cooking practices
45598452|NCT02220335|Drug|Standard treatment|Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.Patients in the standard treatment group will take one or combination of the following target drugs: endothelin receptor antagonist, 5'-PDE and prostacyclin. On the other hand, patients in the PADN group do not take any of the target drugs mentioned above.
45467350|NCT03337113|Device|repetitive Transcranial Magnetic Stimulation|"The rTMS Condition: rTMS will be delivered with a Magstim Rapid2 system using Magstim Air Film Coils. rTMS pulses will be delivered at 10 Hz (100% resting motor threshold, RMT) in 40, 5 second trains, with 15 second inter-train interval, for a total of 2000 pulses per session. Active or sham rTMS will be applied over the left DLPFC; corresponding with the standard F3 location on scalp (F3=left frontal lobe, location #3 for electrode placement using international 10-20 system for scalp measurements). Five consecutive daily sessions will occur on two consecutive weeks, for a total of 10 sessions. RMT, defined as the amount of energy required to induce movement in the contralateral abducer pollicis brevis in at least 50% of stimulations, will be assessed on first day of application."
45467351|NCT03337113|Device|Sham repetitive Transcranial Magnetic Stimulation|Sham rTMS will be identical to active treatment, with the exception that mu-metal plates attached to the sham coil block the magnetic field while providing a sensation of stimulation.
45467352|NCT01307683|Behavioral|Mindful Moms|"8 weekly 2-hour sessions, 2 booster telephone sessions, and 1 postpartum booster session"
45467353|NCT03706638|Dietary Supplement|Ferrous Sulfate|Patients would be randomized to either taking ferrous sulfate daily or every other day (on non consecutive days).
45467354|NCT05408884|Other|Social Support|"Social support phone buddy program."
46018453|NCT02866045|Procedure|Single incision needle knife biopsy|For patients allocated to the SINK group, after EUS confirmation, the esophagogastroduodenoscopy (EGD) will be repeated to perform the SINK biopsy. Under direct endoscopic visualization, a 10 mm linear incision will be made to the surface of the SEL using a conventional needle-knife sphincterotome with standard blended electrocautery (Endocut mode - ERBE system USA, Marietta, GA). A conventional biopsy forceps will then be introduced through the incision deep into the mass to obtain at least 3 samples. The incision will then be closed using 1 to 3 endoclips for prophylaxis against subsequent bleeding. The biopsies will be placed in formalin as per standard surgical pathology protocol.
46102061|NCT04213001|Diagnostic Test|ultrasonographic measurement|ultrasonographic measurement- Subcutaneous ultrasound echogenicity (SEG) and Skin and subcutaneous thickness measurement
45467355|NCT03781843|Drug|Genicular nerve block with lidocaine|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
45680897|NCT03989362|Drug|Ipilimumab|Specified dose on specified days
45680898|NCT03989206|Drug|Nemolizumab|Nemolizumab
45680899|NCT04009096|Biological|ChAd63 PvDBP and MVA PvDBP|one dose of 5 x 10^10 vp ChAd63 PvDBP and one dose of 2 x 10^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen.
46102062|NCT00691418|Dietary Supplement|docosahexaenoic acid (DHA)|600 mg per day of docosahexaenoic acid (DHA) starting at 22-24 weeks gestation until delivery.
46102063|NCT00691418|Dietary Supplement|placebo|placebo once per day starting at 22-24 weeks gestation until delivery.
46102064|NCT00691496|Behavioral|Behavioral intervention to reduce sexual risk among African-American men who have sex with men|5 week intervention to increase skill level of participants with talking to their social networks and sexual partners about reducing high risk sexual behaviors while preparing a healthy meal
45680900|NCT03594838|Other|HCV viremia testing approaches|Blood draw and HCV viremia testing is done at point of service (Intervention A) Blood draw at point of service and HCV viremia testing at a centralized laboratory (Intervention B)
46018454|NCT02863705|Drug|brimonidine tartrate/timolol malate Ophthalmic Solution|One drop of brimonidine tartrate/timolol malate (COMBIGAN®) Ophthalmic Solution in the affected eye, administered twice daily for 12 months
45680901|NCT05631262|Drug|SKB264|Subjects will receive SKB264 monotherapy.
46102065|NCT02626442|Other|Exercise|6 month group exercise class
45680902|NCT05631106|Behavioral|High Intensity Interval Resistance Training|During each group exercise session, the participants will be guided through a 5-minute warm-up, supervised to perform two sets of machine-based leg press, chest press, seated row, and shoulder press exercises at 30% of 1-RM, and guided through a cool-down. Each exercise set will be 40 -seconds in length with instructions to perform as many repetitions as possible followed by a 20-second rest in between sets and a three-minute rest between exercises.
45680903|NCT05631106|Behavioral|Stretching, Balance, and Range of motion|The stretching, balance, and range of motion intervention will include a rotating and varied routine of stretching exercises for large and small muscle groups, and activities to improve balance and range of motion. Participants will attend this intervention twice a week with each session lasting 30 minutes.
46102066|NCT00618293|Drug|Haemate HS|intravenous infusion of Haemate (dosage dependent on body weight)
46018455|NCT02863705|Drug|bimatoprost ophthalmic solution 0.01%|Bimatoprost ophthalmic solution 0.01% (LUMIGAN®) administered once daily in the evening 5 minutes after COMBIGAN® instillation if additional lowering IOP is needed
46018456|NCT01193283|Drug|Cyclophosphamide|30 my/kg for 4 days
46018457|NCT01193283|Drug|Cyclosporine|daily to a trough of 100 t0 200 ng/ml
46018458|NCT00971425|Biological|Pandemrix (GSK investigational influenza GSK2340272A vaccine)|2 doses intramuscular injections
46018459|NCT00971425|Biological|Fluarix™|1 dose intramuscular injection
46018460|NCT00971425|Biological|Placebo|1 dose intramuscular injection
46102067|NCT00618293|Other|NaCl-solution|intravenous infusion of 0.9%NaCl-Solution
46102068|NCT02627066|Behavioral|Volume Control|Persistent reduction in post-dialysis weight and dietary sodium restriction
46102069|NCT02627066|Behavioral|Volume Control + Exercise|Volume reduction intervention and comprehensive exercise counseling
46102070|NCT00621569|Behavioral|Dietary Approaches to Stop Hypertension-The DASH diet|The purpose of this study is to create a culturally appropriate diet to test the effectiveness of the intervention to lower blood pressure in a grou pof African American individuals at risk for developing hypertension (pre-hypertension) and those with mild hypertension (stage I).
46102071|NCT00621569|Behavioral|Intervention with no dietary component - information regarding useful life skills|Participants receive information regarding useful life skills in a group setting
46102072|NCT00862836|Drug|Vandetanib|100mg doses orally, once daily
46102073|NCT00621647|Drug|Quetiapine Fumarate|
46102074|NCT00621647|Drug|Quetiapine Fumarate|
46102075|NCT00621647|Drug|Placebo|
46102076|NCT02625350|Other|Instant noodle without soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle without soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
46018461|NCT02863471|Drug|Gemcitabine|1000 milligram (mg)/square meters (m2) body surface 60 minutes (min) intraperitoneal hyperthermic lavage
46102077|NCT02625350|Other|Instant noodle with soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle with soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
46102078|NCT02625350|Other|Glucose reference|First, fasting blood glucose was measured. Then, subjects consumed the glucose reference and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
46102079|NCT04209179|Drug|PCO371|PCO371 capsule
46102080|NCT04209179|Drug|Placebo|Placebo capsule
46102081|NCT00681356|Drug|4975, 15 and 5 mg|Direct instillation into the surgical site
46102082|NCT00681356|Drug|Placebo Comparator|Direct instillation into the surgical site
46102083|NCT00681356|Drug|4975 - 5 mg|Direct instillation into the surgical site
46102084|NCT02621970|Drug|Cisplatin 1|Cisplatin 25 mg/m2, D1-3
46102085|NCT02621970|Drug|Cisplatin 2|Cisplatin 100 mg/m2, D1
46102086|NCT02621970|Drug|Docetaxel|Docetaxel 60mg/m2, D1
46102087|NCT02621970|Drug|Xeloda|Xeloda 2000mg/m2, D1-14 in concurrent chemotherapy and Xeloda 2500mg/m2, D1-14 in adjuvant chemotherapy
46102088|NCT02621970|Radiation|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
45467356|NCT03781843|Drug|Genicular nerve block with saline|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
46018462|NCT01193127|Drug|OMS302 Solution|
46102089|NCT00820755|Drug|Cetuximab plus Platinum-based Doublet Chemotherapy|Single first dose of cetuximab 400 mg/m^2 infusion will be administered intravenously over 120 minutes (min) followed by cetuximab 250 mg/m^2 intravenous infusion over 60 min q1w with background platinum-based doublet chemotherapy up to maximum of 6 cycles, until progressive disease, unacceptable toxicity, or withdrawal of consent. Platinum based doublet chemotherapy will be administered as intravenous infusion as per study center included: vinorelbine 25 mg/m^2 on Day 1 (D1) and Day 8 (D8)+cisplatin 80 mg/m^2 on D1; or gemcitabine 1250 mg/m^2 on D1 and D8+cisplatin 75 mg/m^2 on D1; or gemcitabine 1000 mg/m^2 on D1 and D8+carboplatin at dose to reach area under curve (AUC)5 milligram*hour/milliliter (mg*hr/mL) on D1; or Docetaxel 75 mg/m^2 on D1+cisplatin 75 mg/m^2 on D1; or paclitaxel 175 mg/m^2 on D1+cisplatin 80 mg/m^2 on D1; or paclitaxel 200 mg/m^2 on D1+carboplatin at dose to reach AUC6 mg*hr/mL on D1, of each 3-week treatment cycle for a maximum of 6 cycles.
46018463|NCT01193127|Drug|OMS302 Mydriatic Solution|
46018464|NCT01193127|Drug|OMS302 Anti-inflammatory Solution|
46018465|NCT01193127|Drug|Balanced Salt Solution (BSS) Solution|
46018466|NCT01192815|Drug|erlotinib hydrochloride|Given orally or via gastronomy tube
46018467|NCT01192815|Radiation|intensity-modulated radiation therapy|IMRT will be given in 35 fractions over 7 weeks. The primary tumor and involved nodes (PTV70) will receive 2 Gy per fractions, intermediate-risk areas (PTV63) will receive 1.8 Gy per fractions, and subclinical disease sites (PTV56) will receive 1.6 Gy perfraction. The total doses will thus be 70 Gy, 63 Gy and 56 Gy, respectively.
46018468|NCT01192815|Other|pharmacogenomic studies|Optional correlative studies
46018469|NCT01192815|Other|gene expression analysis|Correlative studies
45467357|NCT03781843|Drug|Genicular nerve block with dextrose|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
45467358|NCT05205447|Drug|LY3410738|Oral LY3410738
45467359|NCT05205447|Drug|Itraconazole|Oral Itraconazole
45467360|NCT05205447|Drug|Carbamazepine|Oral Carbamazepine
45838036|NCT05037552|Procedure|Coagulation by FLOSEAL haemostatic agent|"Cystectomy will be done via laparoendoscopic surgery After identifying the correct plane of cleavage, the stripping technique will be used. The cyst wall will be gently pulled down from the remaining ovary with two pairs of atraumatic forceps.~Once the whole cyst wall will be separated from the ovary cortex, bleeding of the remaining ovarian stromal tissue will be controlled by either hemostatic sealants (FloSeal). Using a laparoscopic applicator, FloSeal will be applied to the surface of bleeding sites under direct vision and the ovarian cortex was gently pressed for 2 min with small gauze."
46018470|NCT01192815|Radiation|3-dimensional conformal radiation therapy|"The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions a week to 54 Gy in 27 fractions in 5.4 weeks. The boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation for additional 16 Gy at 2.0 Gy. The primary tumor and clinically/radiologically-involved nodes will thus receive 70 Gy in 35 fractions over 7 weeks, and uninvolved upper neck nodes will receive an elective dose of 54 Gy in 5.4 weeks.~The uninvolved lower neck nodes will receive 2.0 Gy per fraction at 3-cm depth to a total dose of 50 Gy in 25 fractions in 5.0 weeks through a matching AP or AP/PA lower neck field."
46102090|NCT00820755|Drug|Cetuximab 500 mg/m^2|Subjects who will be free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 500 mg/m^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.
46102091|NCT00820755|Drug|Cetuximab 250 mg/m^2|Subjects who will free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 250 mg/m^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.
45467361|NCT05347576|Drug|CKD-393(2)|QD, PO
45467362|NCT05347576|Drug|CKD-501, D759, D150, D029|QD, PO
45467363|NCT03786913|Diagnostic Test|Quantitative muscle ultrasound measurements|Quantitative ultrasound measurements will be performed to biceps, forearm flexors, quadriceps and tibialis anterior according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.
45467364|NCT03782779|Other|Breathing program and regular exercise|This program will be supervised by a physical therapist and will include learning and performing a diaphragmatic-abdominal breathing, and incorporating the new breathing pattern to a upper and lower limbs regular exercises as well as to daily life activities.
45467365|NCT03782779|Other|Regular Exercise|Regular upper and lower limbs exercises supervised by a physical therapist
45467366|NCT05335564|Other|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants will be shown parts of the website regarding general information about depression."
45467367|NCT01560793|Biological|VAX161 [STF2.HA5 H5N1]|dose escalating, 2 intramuscular doses given 21 days apart
45467368|NCT03707769|Device|TIPS microspheres|TIPS microspheres manufactured from GMP grade poly(lactide-co-glycolide) (PLGA) prepared as a paste with GranuGel.
45838037|NCT05028634|Biological|Tetanus, diphtheria, and acellular pertussis vaccine|Tdap
46018471|NCT01192815|Other|biopsy|Optional correlative studies
45467369|NCT05333146|Procedure|Cardiac Surgery|Cardiac surgery (e.g. coronary bypass surgery, cardiac valve surgery, ascending aortic surgery)
45838038|NCT05028634|Biological|Pneumococcal polysaccharide vaccine|PPSV23
46102092|NCT04671173|Device|Measurement of the Intra-Compartmental Pressure with the MY01 device|"All Participants will be monitored for clinical signs of symptoms of ACS, including the 7 Ps at a minimum of every 4-6 hours.~The Intra-Compartmental Pressure of the anterior compartment of the leg will be monitored with the MY01 device. The device should be inserted five centimeters (5 cm) from the fracture, if possible, in the muscle belly. The affected limb will then be splinted in a standard U-slab with no pressure on the monitored device."
45838039|NCT05028634|Biological|Seasonal influenza vaccine|Seasonal influenza vaccine
46102093|NCT00700128|Drug|frovatriptan|Frovatriptan 2.5 mg or placebo given Bid starting on the last day of OC before taking the 4 day HFI. They will take a total of 10 pills max per HFI.
46102094|NCT00700128|Drug|frovatriptan|frovatriptan 2.5 mg bid or placebo starting on the last day of OC and continuing during the 4 day HFI.
46102095|NCT00700128|Drug|placebo|placebo
46102096|NCT04212689|Device|Game Based Virtual Reality Exercises|A game-based virtual reality device named USE-IT will be added to the rehabilitation program. USE-IT is a technological rehabilitation system designed by the Department of Physiotherapy and Rehabilitation at Hacettepe University. It is a smart gaming device which has been used in patients who suffer from movement loss in their upper extremities due to various neurological and orthopedic reasons.
46102097|NCT04212689|Other|Conventional Physiotherapy and Rehabilitation|The conventional physiotherapy and rehabilitation program includes stretching exercises, neurodevelopmental approaches, static positioning, strengthening exercises, Transcutaneous Electrical Nerve Stimulation (TENS), hydrotherapy, cryotherapy.
46102098|NCT04135326|Other|Quality-of-Life Assessment|Ancillary studies
46102099|NCT04135326|Other|Questionnaire Administration|Ancillary studies
46102100|NCT04135326|Procedure|Transcranial Direct Current Stimulation|Undergo tDCS
46102101|NCT04662515|Procedure|Type of surgery|surgical or non-surgical extraction one or more teeth
46102102|NCT04662515|Drug|Dabigatran|
46102103|NCT04662515|Drug|Rivaroxaban|
46102104|NCT04662515|Drug|Apixaban|
46102105|NCT04662515|Drug|Edoxaban|
46102106|NCT04662515|Drug|Warfarin|
46102107|NCT04117542|Other|Observational|Observational data will be obtained through participant self-response, parental response, cognitive performance, and neural imaging.
46102108|NCT04660097|Drug|Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer|This trial is single-armed IIb stage clinical trial to study the efficacy and safety of Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer . We use the outcome of CASPIAN trial as control group. The primary endpoint is ORR according to the RECIST 1.1, and secondary endpoints are PFS, OS, satety and life quality.
46102109|NCT04117464|Behavioral|Behavioral activation therapy|Behavioral activation therapy administered on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
46102110|NCT04117464|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy administered on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
46102111|NCT04117464|Behavioral|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
46102112|NCT04117464|Other|Wait List Group|No psychological intervention
46102113|NCT00820599|Device|Sapien XT™ transcatheter heart valve and delivery system|
45467370|NCT03781687|Procedure|Bilateral ESP Block|Bilateral ESP Block will be performed at T8
45467371|NCT03781687|Procedure|Unilateral ESP Block|Unilateral ESP Block will be performed at T8 (right side)
45467372|NCT03781687|Device|Intravenous Morphine patient controlled analgesia device|24 hour morphine consumption will be recorded
45467373|NCT03092726|Drug|ASP8062|ASP8062 30 mg was administered orally as a single daily dose, taken preferably in the morning with or without food.
46018472|NCT01192815|Other|pharmacological study|Optional correlative studies
46018473|NCT01192815|Other|laboratory biomarker analysis|Optional correlative studies
45467374|NCT03092726|Drug|Placebo|Placebo was administered orally as a single daily dose, taken preferably in the morning with or without food.
45467375|NCT05048199|Device|pressure regulated volume-controlled mode of ventilation|"Cardiac output non-invasive monitor for measuring SV. Hemodynamic variables including heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP), stroke volume (SV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), and systolic time ratio (STR), Arterial oxygen saturation (Sao2), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be recorded.~These variables will be obtained before induction of anaesthesia (T1) skin incision (T2), then every 30 min till the resection of the urinary bladder (T3a, T3b, T3c, …. etc). The mode of ventilation will swift to the other mode 5 minutes after cystectomy (T4), then every 30 min till end of the urinary diversion (T5a, T5b, T5c, …. etc), end of surgery (T6), and postoperative every 4h for 24 hours( P1-P6)."
46018474|NCT01192815|Other|questionnaire administration|Optional ancillary studies
46018475|NCT01192815|Other|enzyme-linked immunosorbent assay|Optional correlative studies
46018476|NCT01192815|Other|polymorphism analysis|Optional correlative studies
46018477|NCT01192191|Drug|Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
46018478|NCT01192191|Drug|Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
46018479|NCT04317729|Device|Fujirebio INNOTEST® HCV Ab IV assay|Enzyme Immunoassay
46018480|NCT01307267|Drug|PF-05082566|Intravenous, Dose escalation, once per month
46018481|NCT01307267|Drug|rituximab|Intravenous, 375 mg/m2, once per week for 4 weeks
45680904|NCT03599596|Drug|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly until delivery
46018482|NCT01307267|Drug|PF-05082566|IV, Dose escalation, once per month
46018483|NCT01307111|Drug|Misoprostol|400 micrograms inserted buccally or vaginally, per the participants desire prior to the IUD insertion.
46018484|NCT01307111|Drug|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
46018485|NCT01306877|Device|EEA Hemorrhoid and Prolapse Stapling Set|Surgical device
46018486|NCT01306877|Device|Endosurgery Proximate PPH03 Stapling Set|Surgical device
46018487|NCT01191801|Drug|vosaroxin + cytarabine|"Vosaroxin days 1 and 4: 90 mg/m2 for induction 1; 70 mg/m2 for all other cycles~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
46018488|NCT01191801|Drug|placebo + cytarabine|"Placebo days 1 and 4: volume matched to vosaroxin~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
46018489|NCT01306643|Drug|Idelalisib|Tablet(s) administered orally twice daily
46018490|NCT04317495|Other|Computerized Cognitive Training (CCT)|After having four rTMS sessions without CCT, the patients will perform CCT (starting day 5) during the rTMS session, which typically last from 20-40 minutes. A course of rTMS therapy includes from 25-36 treatments, given daily, until the last 5-6 treatments, given as a 'taper' over 2 weeks. CCT will be paired with rTMS up until the taper begins. In addition, they will have assessments prior to and after the therapy.
46018491|NCT04317339|Drug|Zhigancao Tang granule|"Zhigancao Tang: Dissolve Zhigancao Tang granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed."
46018492|NCT04317339|Drug|Zhigancao Tang placebo granule|"Zhigancao Tang placebo: Dissolve Zhigancao Tang placebo granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed."
46018493|NCT05656833|Device|Fractional 1927nm Low-Powered Diode Laser|Clear & Brilliant Permea® Laser used on the side of the face randomized to receive laser
46018494|NCT05656833|Other|Topical Cysteamine|Topical Cysteamine cream will be used on the entire face.
46018495|NCT05656755|Other|Strengthening|The strengthening exercises were executed with the body weight without any additional weight and were composed of exercises like the squats, the lunges, the plank, and the mountain climbers
46018496|NCT05656755|Other|Running|running for two supervised training sessions of one hour, and one free session of 30 minutes per week during 24 weeks
46018497|NCT05656677|Behavioral|Passive parental involvement|One parent watching a procedural painful intervention, two nurses executing facilitated tucking
46102114|NCT04656353|Behavioral|Intervention Arm|Participants randomized to the Intervention Arm will be provided with the website link to the online self-help program and a questionnaire and a distress survey. They will be asked to use the website within two weeks and then to complete these documents after using it and mail them back in a self-addressed stamped envelope. Same documents will be administered at the 3-month follow-up period, and the participant will be given two weeks to complete and return it in a self-addressed stamped envelope. Additionally, participants will also be asked in the 3-month follow-up questionnaire if they are interested in attending a focus group to elaborate on their experience with the psychosocial self-help program. Those who have expressed an interest will be contacted. The focus groups will last about 1-1.5 hours and consist of 3-4 participants. Focus groups will be audio-taped and conducted in either English or Chinese.
46018498|NCT05656677|Radiation|Active parental involvement|One parent watching a procedural painful intervention and at the same time executing facilitated tucking
46018499|NCT01306331|Drug|Conceptrol|• Conceptrol® Vaginal Gel, which contains 100 mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
46018500|NCT01306331|Drug|Amphora|• Amphora™ gel, which will be delivered in 5 mL doses, is a clear, water-based, petroleum-free gel.
45680905|NCT03599596|Drug|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets twice before delivery
45680906|NCT04407130|Drug|Ivermectin + Doxycycline + Placebo|"Arm I: 200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose and 200 mg stat doxycycline day-1 followed by 100mg doxycycline 12hrly for 4 day (i.e. day2-day5)~Placebo one tablet D2-5"
45680907|NCT04407130|Drug|Ivermectin + Placebo|Arm II: Ivermectin - 200 mcg/kg (12 mg tablet) once per day D1-D5 + Placebo two tablets D1 followed by Placebo one tablet D2-5
45680908|NCT04407130|Drug|Placebo|Arm III: 3 Placebo tablets D1 followed by 2 tablets D2-5
45680909|NCT03599440|Other|Pressure line extensions|"Two types of extension lines are connected:~Perfusor® line 150cm (polyethylene)~conventional arterial extension line"
45680910|NCT03599284|Drug|Vicagrel 5mg|Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days
45680911|NCT03599284|Drug|Vicagrel 6mg|Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days
46018501|NCT05656287|Other|SMS texts + incentives + Wisepill device for medication monitoring|For the first two months, 54 participants will receive i) daily SMS medication reminders, ii) monthly mobile money for transport to the clinic, and iii) monthly mobile money incentives if >90% medication adherence. For the remaining four months, the participants will receive: i) weekly medication SMS reminders, ii) monthly mobile money for transport to the clinic, iv) monthly mobile money incentives if >90% medication adherence.
46018502|NCT05656287|Other|SMS texts only + Wisepill device for medication monitoring|For the first 2 months, 54 participants will receive daily SMS medication reminders, ii). For the remaining 4 months, the participants will receive weekly medication SMS reminders. All participants will also receive a Wisepill device for medication monitoring.
46018503|NCT05656287|Other|Wisepill device for medication monitoring only|Participants (54) in the Control arm will not receive SMS reminders or mobile money. All participants will also receive a Wisepill device for medication monitoring.
46018504|NCT00624663|Drug|Rivastigmine|Administration 1 (A): 1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule Administration 2 (B): 2 x 1.5 mg Exelon® Capsules (Novartis) Administration 3 (C): 2 x Placebo Capsules
45680912|NCT03599284|Drug|Vicagrel 7.5mg|Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days
45680913|NCT03599284|Drug|Clopidogrel 75mg|Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days
45680914|NCT05630950|Device|Smoking cessation mobile application|Mobile application for smoking cessation.
45680915|NCT05630950|Behavioral|Written material for smoking cessation|Written material for smoking cessation
45680916|NCT04407052|Drug|Double trigger|Final follicular maturation is triggered by the coadministration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
45680917|NCT04407052|Drug|HCG trigger|Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
46018505|NCT05656209|Dietary Supplement|Lactobacillus acidophilus|Lactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3G (containing 2*10^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
45838040|NCT05028075|Behavioral|Cobalt +|Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity) at enrollment; 0 months and then again at 6 months. The primary endpoint is assessed at 6 months. A secondary endpoint of persistence of effect is measured 3 months later-9 months post initiation. The intervention group receives usual Cobalt plus: 1) monthly automated text messaging reminders and links to Cobalt resources 2) intermittent mental health assessments which triage individuals to an appointment based on their results.
46018506|NCT04317573|Device|Personalised card|An individualised card containing the patient's eye drops regime was printed for the patient after his/consult with the physician to be brought home.
46018507|NCT01306253|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoides) of a single dose of 0.5 mL on Day 1"
46018508|NCT05655975|Procedure|upper gi endoscopy|In all patients undergoing RYGB gastric bypass, an upper gastrointestinal endoscopy will be performed at the 1st postoperative year to measure the diameter of the gastrojejunostomy anastomosis.
46018509|NCT02890823|Drug|Cholecalciferol|
45838041|NCT05021354|Combination Product|Lateral epicondylalgia|dry needling, stretching and eccentric exercise
46018510|NCT05655897|Device|GeminiOne Transcatheter Valve Edge-to-Edge Repair System|The transcatheter valve clamp system consists of a valve clamp, an adjustable bend mid-tube, and a manipulated inner tube. The adjustable bend introducer catheter consists of an adjustable bend outer tube and dilator. The valve clip is composed of nickel-titanium alloy, cobalt-chromium-nickel-molybdenum-iron alloy, and polyethylene terephthalate material and contains a closure clip, gripping tab, central mechanism, braid, and suture. The adjustable bend guiding catheter is used to provide access to the transcatheter valve clamping system and to reach the designated position. The adjustable curved mid-tube and manipulated inner tube are used to enable the delivery, gripping, and release process of the valve clips within the body.
46018511|NCT05655663|Other|Vascular investigation|Measure of of carotid stiffness
46018512|NCT02887443|Drug|Raxone (idebenone 150 mg)|Raxone (idebenone 300 mg t.i.d.) on days 3 and days 5 to 10
46018513|NCT02887443|Drug|Midazolam 2,5 mg|Midazolam (2,5 mg single oral dose) on days 1, 3 and 10
46102115|NCT04656353|Behavioral|Control Group|Participants randomized to the Control group will receive standard care (no intervention). They will be used as a baseline to compare groups and assess the effect of the intervention (i.e., the online psychosocial program). At the two weeks following randomization (T1) and the 3-month follow-up periods (T2), they will be asked to complete the questionnaire and distress survey and return them in a self-addressed stamped envelope. Participants will be given two weeks to complete the questionnaire and distress survey. The same documents will be administered at the 3-month follow-up period (T2). Once the 3-month follow-up is completed, each participant will be provided with the website link to view the self-help program.
46018514|NCT04317261|Diagnostic Test|Xpert Bladder Cancer Monitor (Xpert Monitor) test and assay of urinary metabolomics (gene expression of CRAT and SLC)|Urine sample is evaluated for RNA and urinary metabolites
46102116|NCT00700206|Drug|Ezatiostat Hydrochloride|"Dose Schedule 1-3000 mg orally per day in two divided doses for two weeks followed by 1 week with no treatment per three week cycle.~Dose Schedule 2-2000 mg orally per day in two divided doses for three weeks followed by 1 week with no treatment per four week cycle."
46102117|NCT00621101|Drug|1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
46102118|NCT00621101|Drug|1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany|administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling
46102119|NCT00621101|Drug|1 tablet Ezetrol(R) + 1 tablet Rapamune(R)|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
45680918|NCT03024814|Drug|Acetaminophen|"The first group will receive acetaminophen as the following~Loading dose: 20 mg/kg in the first 12-24 hours To be diluted in D5W up to 3-5 ml and to be infused over 15 minutes.~Maintenance dose: 7.5 mg/kg after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
45680919|NCT03024814|Drug|Dextrose 5|"The second group will receive placebo (D5W) as the following~Loading dose: 3-5 ml in the first 12-24 hours To be infused over 15 minutes.~Maintenance dose: 3-5 ml after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
45680920|NCT01852058|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall. Treatments were administered as needed with a minimum of a 12-week interval between doses.
45680921|NCT03024502|Drug|EPP-AF Gel 1%|Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
46102120|NCT00709215|Drug|Cordycepin plus Pentostatin|Cordycepin Plus Pentostatin on days 1, 2 and 3 of a 21 day cycle. Number of cycles until progression or unacceptable toxicity
46102121|NCT04622657|Other|dubousset functional test|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
45467376|NCT05048199|Device|volume-controlled mode of ventilation|"Cardiac output non-invasive monitor will be used for measuring SV. Hemodynamic variables including heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP), stroke volume (SV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), and systolic time ratio (STR), Arterial oxygen saturation (Sao2), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be recorded.~These variables will be obtained before induction of anaesthesia (T1) skin incision (T2), then every 30 min till the resection of the urinary bladder (T3a, T3b, T3c, …. etc). The mode of ventilation will swift to the other mode 5 minutes after cystectomy (T4), then every 30 min till end of the urinary diversion (T5a, T5b, T5c, …. etc), end of surgery (T6), and postoperative every 4 hours for 24 hours (P1-P6)."
46018515|NCT05359263|Drug|Dapagliflozin 10 mg|The intervention arm consists of dapagliflozin 10 mg orally once daily
46018516|NCT05359263|Drug|Placebo|The comparator arm consists of placebo orally once daily
46018517|NCT01305941|Drug|Everolimus|everolimus 5 mg PO daily as two 2.5-mg tablets
46018518|NCT01305941|Drug|Vinorelbine|vinorelbine 25 mg/m2 will be administered via IV infusion over 6-10 minutes weekly.
46018519|NCT01305941|Drug|Trastuzumab|2 mg/kg IV administered over 30 minutes weekly
45467377|NCT05330416|Device|Group Reference Strategy|Patients undergoing surgery for anoperineal suppuration in the context of Crohn's disease with detailed examination of the suppuration and drainage with a seton.
46018520|NCT05658549|Drug|N-acetyl cysteine|N-acetyl cysteine dosage 600 mg and 1200 mg
46018521|NCT02887365|Drug|tegafur-uracil|
45467378|NCT05330416|Other|Group Test Strategy|Patients undergoing surgery for anoperineal suppuration in the context of Crohn's disease with detailed examination of the suppuration without drainage via a seton.
45467379|NCT05176587|Other|Follow-up of patients undergoing bariatric surgery : integrated pathway|Integrated pathway : multidisciplinary, pre- and post-operative, care course for patients undergoing bariatric surgery
45467380|NCT05329168|Drug|Tonabacase (LSVT-1701)|4.5 or 6.0 mg/kg IV once daily for 4 days
45680922|NCT03024502|Drug|EPP-AF Gel 2%|Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
46018522|NCT05658315|Other|ApplTree smartphone application|ApplTree is a smartphone reminder application which allows the user to enter details of future tasks and events and then prompts the user to remind them to complete these at a pre-specified time. ApplTree was designed with people who experience memory and attention difficulties in mind and has a customisable user interface design to support attention and short-term memory when entering PM tasks. ApplTree was developed by Professor Jonathan Evans and Dr Matthew Jamieson (see Jamieson et al., 2020) and is owned by the University of Glasgow.
46018523|NCT05658159|Diagnostic Test|Vitamin D|Finger stick capillary blood sampling using test from ZRT Laboratories, Beaverton, OR
46018524|NCT05658159|Diagnostic Test|DXA scan|10 minute scan using scanner by GE Lunar, Madison, WI
46018525|NCT05658159|Other|Nutrition analysis|Analysis of 24-h recalls will be conducted by a registered dietician using Nutritionist Pro software by Axxya Systems, Redmond, WA
45680923|NCT03024502|Drug|Clotrimazole|Administration intravaginal of clotrimazol, 1x/day, 7 days
45680924|NCT03024580|Drug|Megestrol Acetate 160Mg Tablet|Megestrol acetate 160 mg PO daily
45680925|NCT03024580|Drug|Anastrozole 1Mg Tablet|Anastrozole 1 mg PO daily OR
46018526|NCT01305239|Drug|Aromasin|Aromasin 25 mg daily.
46018527|NCT04317027|Device|New Fighting Clothing|VO2max test Clothing examination- 2-hour walk in 6 kph/4% elevation under 30 degrees Celsius and 60% relative humidity
46018528|NCT05380557|Diagnostic Test|Germline genetic testing|Germline genetic testing will be provided to each patient
46018529|NCT05658081|Procedure|Kono-S group|patients in this arm will receive stapled Kono-S anastomosis after bowel resection
46018530|NCT05658081|Procedure|Side-to-side group|patients in this arm will receive stapled antimesenteric isoperistaltic side-to-side anastomosis after bowel resection
46018531|NCT05657847|Device|Photon-counting detector-CT|CT scan
46018532|NCT04317183|Drug|chamomile topical oral gel|Chemical constituents of chamomile, such as bisabolol, chamazulene, and the flavonoids apigenin and luteolin, possess anti-inflammatory properties.
46018533|NCT04317183|Drug|Miconazole Topical Gel|topical anti fungal agent
46018534|NCT04317183|Drug|BBC oral spray|Topical anesthetics and anti-inflammatory agent
46018535|NCT04317183|Drug|Oracure gel|Topical analgesic gel
46018536|NCT05657301|Drug|KH631|KH631: AAV vector containing a coding sequence for an anti-VEGF protein
46018537|NCT01194219|Drug|Apremilast|
46102122|NCT00698958|Procedure|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
46018538|NCT01194219|Drug|Placebo|Identical matching placebo
46018539|NCT01194219|Drug|Topical treatments or phototherapy|At week 32, participants considered partial responders or non-responders had the option of adding topical therapies and/or phototherapy to their treatment regimen.
45467381|NCT05460429|Biological|Live attenuated varicella vaccine|The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm. And the immunization schedule is one dose of live attenuated varicella vaccine on day 0.
45467382|NCT03786757|Drug|Rivaroxaban|Rivaroxaban 2.5mg/BID will be applied for 24 weeks unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
45467383|NCT05126511|Device|Application of CES via ear clips|Use of 100µA CES for one hour per day over PR program
45467384|NCT05126511|Device|Sham: No application of CES via ear clips|Use of Sham CES for one hour per day over PR programm
45467385|NCT04501562|Other|Examinations|Participants will undergo focused examinations that include measurement of height, weight, waist circumference, body composition analysis, baseline data collection and blood pressure examinations. Resting electrocardiography will be performed to ascertain sinus rhythm.
46018540|NCT01304693|Biological|ESBA1008 solution|Administered as a single intravitreal injection (Dose A, Dose B, Dose C, Dose D)
46018541|NCT01304693|Biological|Ranibizumab 0.5 mg|Administered as a single intravitreal injection
46018542|NCT04316793|Other|Dry needling|Intramuscular insertion of an OPTIMED 40mm x 0.3mm acupuncture needle in a trigger point of the infraspinatus muscle
45467386|NCT04501562|Other|Cardiovascular Tests|Specific quantitative cardiac ageing-related outcome parameters will be examined by multimodal techniques including two-dimensional transthoracic echocardiogram, and/or non-contrast magnetic resonance imaging/magnetic resonance spectroscopy.
45467387|NCT04501562|Other|Bio-specimen collection|Bio-specimens collected will include fresh blood, urine and/or stool specimens.
45467388|NCT04501562|Other|Clinical/health outcome collection|Health status will be tracked by telephone follow-up and/or matching at national disease registries at periodic intervals within one to five years, up to three decades.
45467389|NCT03786835|Other|Protein supplementation and regular physical activity|To determine if high protein diet and/or regular physical activity improves muscle and bone health
45467390|NCT04514757|Device|active tVNS|20 Hz, 250ms at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. Stimulation will continue until 5 days post-operatively or discharge.
46102123|NCT00698958|Procedure|Hospital based adaptation to non- invasive mechanical ventilation for 7 days|Hospital based adaptation to non- invasive mechanical ventilation for 7 days
46102124|NCT02611167|Biological|Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
45467391|NCT04514757|Device|sham tVNS|Current set a 0 mA, starting on post-op day 0. Stimulation will continue until 5 days post-operatively or discharge.
45680926|NCT03024580|Drug|Letrozole 2.5Mg Tablet|Letrozole 2.5 mg PO daily OR
46018543|NCT04316793|Other|Sham needling (SN)|Intradermal insertion of an OPTIMED 40mm x 0.3mm acupuncture needle over the infraspinatus region
46018544|NCT05657067|Behavioral|Emotionally Focused Family Therapy (EFFT)|The rationale behind EFFT is that mental health problems in children and adolescents often originate and/or are exacerbated by negative interaction patterns rooted in insecure attachment bonds within families. Therefore, the main treatment goal of EFFT is the development of secure attachment between parents and their children.
46102125|NCT02611167|Biological|Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
45467392|NCT05598242|Biological|Amniotic membrane extract eye drops (AMEED)|Following a 2-week wash out period, patients were allocated randomly to receive AMEED, administered as 1 drop in each eye 6 times daily, respectively, for 30 days.
45680927|NCT03024580|Drug|Exemestane 25 MG|Exemestane 25 mg PO daily
46102126|NCT02611167|Biological|Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
46018545|NCT05656989|Other|Periodontal clinical measurements and GCF sampling|Periodontal clinical parameters measurements probing depth (PD), clinical attachment loss (CAL), the dichotomous recording (present/absent) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were recorded at six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) per tooth, except the third molars using a manual periodontal probe. A sterile paper strip was gently placed into the gingival sulcus/periodontal pocket until mild resistance was sensed and left in place for 30 seconds.
46102127|NCT02611167|Biological|Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
46102128|NCT00699036|Drug|avandia|4 mg twice daily
45467393|NCT01982890|Other|Control|No intervention as this group is simply followed prospectively.
46018546|NCT01304147|Drug|Ketamine|A single dose of intranasal ketamine up to 50 mg
46018547|NCT01304147|Drug|placebo|Single dose of saline intranasal
46018548|NCT05661227|Drug|Dexmedetomidine|Whether apply DEX or not
46018549|NCT05661227|Drug|0.9% Sodium chloride|Whether apply DEX or not
46018550|NCT05661227|Device|Tourniquet(Early)|Timing of tourniquet application
46018551|NCT05661227|Device|Tourniquet(Late)|Timing of tourniquet application
46102129|NCT00699036|Drug|metformin|500 mg twice daily for 48 weeks
46102130|NCT00699036|Drug|losartan|losartan 50 mg once daily
46018552|NCT04325087|Device|iTBS|Administration of an iTBS protocol over the dlPFC
46018553|NCT04325087|Device|Placebo iTBS|Administration of a placebo TMS protocol over the dlPFC
46102131|NCT00709293|Drug|Anti-Thymocyte Globulin|Thymoglobulin (1.5 mg/kg body weight) will be infused through a peripheral intravenous line over a minimum of 6 hours. The infusion will be started at the time of donor visualization (once it is confirmed the transplant is proceeding). The peri-operative nurse or anesthesiologist will be responsible for drug infusion.
46102132|NCT00709293|Drug|Normal Saline|Normal saline will be utilized as a placebo comparator. It will be infused in the same fashion as the Thymoglobulin in the intervention arm.
45680928|NCT03024580|Drug|Tamoxifen 20Mg Tablet|Tamoxifen 20 mg PO daily
45680929|NCT03024580|Drug|Fulvestrant 50Mg Solution for Injection|Fulvestrant 500 mg IM d1, d14, d28 and q28 days
46102133|NCT04116216|Combination Product|High frequency repetitive transcranial magnetic stimulation|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
45680930|NCT03599128|Other|43.3 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
46102134|NCT04116216|Combination Product|Low frequency repetitive transcranial magnetic stimulation|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
46018554|NCT05643989|Procedure|Stoma formation|Trocar placement: the optical trocar (10 mm) will be inserted just near umbilicus . An abdominal revision is performed to determine the location of the tumor. Colon in 10 sm proximally to tumor is prepared for the discharge stoma formation. In the corresponding location on the anterior abdominal wall is formed incision of skin and subcutaneous tissue to the aponeurosis, the cut length is 2.5 sm. After that, aponeurosis crucial incision is performed. The previously prepared colon is brought out to the anterior abdominal wall with the help of a grasper. Discharge stoma is attached to a holding device; colon is fixed by the interrupted sutures (Polysorb 3-0). In the operating room, the stoma is opened, the intestinal patency is checked in both directions, and hemostasis is revealed. With the help of optics, the presence of intestinal tension is checked; if necessary, the colon is additionally mobilized.
46018555|NCT05643989|Procedure|Endoscopic self-expandable metal stent placement|The colonoscope is passed to the distal edge of the tumor and a biopsy of the tumor is performed (if the tumor has not previously been verified). Through the tumor stenosis radioscopically guided metal conductor with atraumatic distal end installs in the proximal colon. A covered or partially covered metal self- expanding stent is placed in the area of tumor stenosis by the conductor, symmetrically in relation to the area of tumor stenosis. Radioscopically and endoscopically guided disclosure of a SEMS is performed immediately after which there is an abundant discharge of gases and intestinal contents. Upon completion of the procedure, the patient is transferred to the patient's room. The next day, a control X-ray of the abdomen is taken.
46102135|NCT04116216|Combination Product|Sham repetitive transcranial magnetic stimulation|For sham stimulation, the stimulator positioned behind the patient will be turned off immediately after the determination of RMT, however, the coil will remain positioned over the patient's scalp (Cz, C3 and C4). A computer equipped with speakers will play an audio recording with the characteristic rTMS sound and no stimulation will be induced in the brain.
46102136|NCT00913497|Drug|insulin glulisine|Insulin glulisine (Apidra®) Sanofi-Aventis; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days
46102137|NCT00913497|Drug|insulin aspart|Insulin aspart (NovoLog®) Novo Nordisk; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days.
46102138|NCT04208711|Other|biological sample|whole blood sample
46102139|NCT05758779|Behavioral|Visualization of coronary Imaging and oral description|The participants is allowed to see their coronary CT scan including oral description. The study will test the effect on smoking habit and changes in LDL-C in one year.
46102140|NCT04212455|Other|Non-interventional study|This is an observational, non-interventional study
46102141|NCT04000061|Other|medical chart review|data generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations
46102142|NCT04000061|Other|data generated by direct IT export|data generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data
46018556|NCT01303445|Drug|Aggrenox alone|Aggrenox 1 capsule twice daily for 7 days
46018557|NCT01303445|Drug|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
46102143|NCT00819741|Drug|repaglinide|The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
46018558|NCT01303445|Drug|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
45467394|NCT04461938|Other|Fasting|The study intervention consists of one fasting cycle of 72 hours prior to biopsy/resection. Depending on clinical condition, patients can be hospitalized during the course of the study (e.g. need for medical assistance due to immobilization). Patients in good clinical condition will be admitted on day 3.
45680931|NCT03599128|Other|86.6 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
46102144|NCT00819741|Drug|metformin|The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
46018559|NCT01303445|Drug|Omeprazole alone|omeprazole 80 once daily for 7 days
46018560|NCT01188681|Drug|TRU-016 and bendamustine|TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
46018561|NCT01188681|Drug|Bendamustine|Bendamustine at 70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
46018562|NCT01188681|Drug|15 mg/kg TRU-016 and bendamustine|TRU-016 at 15 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
46102145|NCT00819741|Drug|repaglinide|The dose was started from repaglinide 1 mg three times daily. During the dose titration period, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose.
46102146|NCT04208555|Drug|Boric Acid Vaginal Suppository|Boric acid vaginal suppository (600 mg/day) for 14 days
46102147|NCT04208555|Drug|Terconazole Vaginal Suppository|Terconazole 80 mg vaginal suppository daily for 6 days
46102148|NCT00621725|Drug|AZD2171|Oral dose
46102149|NCT00862134|Drug|PR104|770 mg/m^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
46102150|NCT00862134|Drug|docetaxel|75 mg/m^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
46102151|NCT00862134|Drug|docetaxel|60 mg/m^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
45680932|NCT03599128|Other|173 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
46018563|NCT01188681|Drug|20 mg/kg TRU-016 and bendamustine|TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
46018564|NCT02887131|Other|Dynamic CT of the ankle|during inversion and eversion mouvement, with Aquilion One Toshiba scanner
45680933|NCT03599128|Other|Placebo|Reconstituted in water and given to subjects
46018565|NCT01302899|Drug|Aliskiren|Aliskiren 150 mg (Tablet)
46018566|NCT01302899|Drug|Placebo to Aliskiren|Aliskiren 150 mg Matching Placebo (Tablet)
46018567|NCT01302899|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule)
46018568|NCT01302899|Drug|Placebo to Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule) Matching Placebo
46018569|NCT01302899|Drug|Ramipril|Ramipril 10mg (Tablet)
46102152|NCT00862134|Drug|Granulocyte colony-stimulating factor|Subjects randomized to PR104/docetaxel will receive prophylactic G-CSF per package insert administration recommendations. Number of Cycles: until progression or unacceptable toxicity develops.
46018570|NCT04324775|Other|Exercise + Manual Lymphatic Drainage|Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, manual lymphatic drainage applied to rectus femoris for 5 minutes
46102153|NCT04188197|Other|JUUL|Subjects will be instructed to use the JUUL as often as they like during the 12-week product use period. They will also be instructed to use JUUL immediately before each cigarette to relieve their craving as much as possible before smoking their usual brand. The JUUL will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute JUUL for cigarettes by the end of the first week of use.
46102154|NCT04120428|Other|Aquatic exercise training program|The intervention will be performed in a pool in which the water surface line will remain in the imaginary line of the xiphoid process. Each season will last 50 minutes and will be divided in 3 phases as (1) warm-up (15 minutes), (2) main part (30 minutes) and (3) cool-down (5 minutes).
46102155|NCT00621803|Drug|Probiotic Lactobacillus casei rhamnosus (Lcr35)|
46102156|NCT02614014|Behavioral|Cognitive-behavior interventional program|
46102157|NCT04527029|Other|No interventions|It is an observational study. No interventions.
46102158|NCT00700284|Drug|placebo vaginal ring|vaginal ring containing no TMC120 (dapivirine)
46102159|NCT00700284|Drug|TMC120 (dapivirine) vaginal ring|vaginal ring containing 120 mg TMC120 (dapivirine)
46102160|NCT04187885|Behavioral|Group/Cohort 2: PAP|"Each experimental session will be carried out over 5 days of a week. Adolescents will take part randomly in four sessions.~Physical activity program will be identical between sessions and groups. 60 min of moderate to vigorous leisure activities and exercises will be proposed each day. Heart rate monitor will be used to control intensity of exercise during the physical activity program."
46102161|NCT00618527|Drug|mycophenolate mofetil (Cellcept)|1 gram po, bid
46102162|NCT00618527|Drug|human interferon beta 1a (Rebif)|44mcg sq injection every other day
45467395|NCT01879774|Other|Neuropsychological and motoric tests|"Neuropsychological tests~Mini Mental Status Test~Dem-Tect~Rey-Osterrieth Complex Figure Test~Trailmaking Test~Beck Depression Inventory~d2-R (optional)~Motoric tests~modified UPDRS (Unified Parkinson Disease Rating Scale) Part III~Timed-up-and-go Test~Halstead Fingertapping Test~AIMS (Abnormal involuntary movement scale)~EEG (only in patients with hyponatremia)~MRI (only in patients with hyponatremia)"
46018571|NCT04324775|Other|Exercise + Swedish massage|Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, swedish massage applied to rectus femoris for 5 minutes
46018572|NCT05643833|Other|no intervention|no intervention
46018573|NCT01187901|Drug|Erlotinib|Tarceva oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. Erlotinib(75mg)will be taken once daily for six months in combination with sulindac.
46102163|NCT02691533|Drug|ω3 PUFA (Polyunsaturated fatty acids) (10% Omegavan 100 ml)|
46102164|NCT02691533|Drug|ω6 PUFA (Polyunsaturated fatty acids) (10% Intralipid 100 ml)|
46102165|NCT02691533|Drug|No Lipid Emulsion/Placebo|
46102166|NCT00848484|Drug|MK5757|This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 25 mg capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 MK5757 50 mg capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days
46102167|NCT00848484|Drug|Comparator: Placebo|This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 one placebo capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 two MK5757 placebo capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days.
46018574|NCT01187901|Drug|Sulindac|Sulindac is a non-steroidal, anti-inflammatory indene derivative designed for the treatment of arthritic conditions. For this study, sulindac (150mg) will be taken twice daily in combination with erlotinib
46102168|NCT00621881|Drug|naproxcinod|750 mg bid
46102169|NCT05214053|Device|Cone Beam CT|Each patient will undergo a Cone Beam CT and a MDCT
46102170|NCT04115982|Drug|Cholecalciferol|One vial every 15 days during 2 months
46102171|NCT04115982|Drug|Placebos|One vial every 15 days during 2 months
46018575|NCT01187901|Drug|Placebo A|Erlotinib (Tarceva) will provide a 25 mg identical placebo. This will be provided by the Division of Cancer Prevention at the NIH who will receive the drug and placebo from the manufacturer, OSI/Genentech. Dosage for Placebo A will be 75 mg a day for 6 months.
45467396|NCT04494789|Drug|Fludrocortisone Acetate|50mcg
45467397|NCT04494789|Drug|Fludrocortisone Acetate|100mcg
45467398|NCT04494789|Drug|Fludrocortisone Acetate|200mcg
45467399|NCT04494789|Other|Standard Therapy|NO Fludrocortisone
46018576|NCT01187901|Drug|Placebo B|Sulindac will be encapsulated in 150 mg doses along with an identical encapsulated Placebo B. One 150 mg capsules of Placebo B will be taken twice per day with meals (breakfast and supper).
46018577|NCT01302119|Drug|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
46018578|NCT01302119|Drug|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
46018579|NCT05364411|Radiation|HYpofractionated, Dose-redistributed RAdiotherapy (HYDRA)|20 daily fractions, 5 times per week
46018580|NCT05364411|Radiation|conventional fractionated radiotherapy|35 daily fractions, 5 times per week
46018581|NCT01302041|Drug|Enzalutamide|Oral
46018582|NCT04327895|Behavioral|evaluation of the need for training|analyse of results of survey
45467400|NCT03786601|Other|Observation|The participants were assigned to different groups according to the results of HPV detection.
45467401|NCT05598164|Other|Botulinum toxin type A|"Patients of main group are treated with injection in internal sphincter botulinum toxin type A.~In the control group, the fissure is excised in combination with a injection in internal sphincter botulinum toxin type A."
45467402|NCT03787069|Drug|iv Lignocaine vs placebo|Lignocaine is available in an ampule of 10 ml containing 20 mg/ml of lignocaine or 2%, Lignocaine will be given in dose of 1.5 mg/kg I/V
45467403|NCT05278390|Radiation|Thoracic CT scan|Automated quantitative analysis of altered pulmonary volume
45467404|NCT05455203|Behavioral|ADAPT-ITT|ADAPT-ITT is an implementation framework that guides adaptation of evidence-based interventions (EBI) for specific settings/populations. It will be used to adapt target interventions with a Family and Community Advisory Board. It has 8 phases: (1) Assess the risk profile of Black families in Paterson and East Orange, (2) Adopt or adapt an EBI, (3) Administer novel methods with families and children to facilitate the adaptation process, (4) Plan on what aspects of the EBI need to be adapted/how best to evaluate the adapted EBI, (5) Identify additional experts to assist in the adaptation process, (6) Integrate material from experts to adapt the EBI, (7) Train staff to implement the adapted intervention, and (8) Test the adapted intervention. Given time and financial constraints, five phases will be completed at the end of the pilot study. Qualitative data collected from individual dyad interviews will be used to inform the data.
45467405|NCT01561027|Drug|CNV1014802|Administered as specified in treatment arm.
45467406|NCT01561027|Drug|Placebo|Administered as specified in treatment arm
45467407|NCT05260060|Behavioral|Treatment as usual: Control|Treatment usually delivered in service that may include but is not limited to cognitive behaviour therapy, exposure, eye movement desensitisation and reprocessing , behaviour therapy, family therapy.
46018583|NCT01301729|Drug|Docetaxel|100 mg/m2 iv every 3 weeks, 6 cycles (18 weeks)
46018584|NCT01301729|Drug|Paclitaxel|90 mg/kg iv (+/-10%) every 3 weeks for 6 3-week cycles (18 weeks)
45467408|NCT05260060|Behavioral|Group Metacognitive Therapy (Group-MCT): Experimental|Group metacognitive therapy (Group-MCT) focuses on developing adaptive control of worry, repetitive negative thinking and attention and modifies beliefs that maintain unhelpful thinking patterns. Treatment is 6 to 8 weekly sessions delivered by two trained mental health professionals, guided by a treatment manual, lasting approximately 90 minutes each session.
45467409|NCT04913961|Other|Supine Daoyin|During hospitalization, the rehabilitation group will receive conventional western medicine treatment and supine guidance therapy which consists of training and patient education. They will be evaluated with some tests for the study
46018585|NCT01301729|Drug|Trastuzumab|4 mg/kg iv loading dose on Day 1, 2 mg/kg iv on Day 8 and weekly thereafter
46018586|NCT05643677|Drug|Fruquintinib|4 mg PO, QD (3 weeks on, 1 week off)
45467410|NCT04913961|Other|western medicine conventional therapy|The control group will get the western medicine conventional therapy with some additional tests for the study.
45467411|NCT03786523|Behavioral|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
45467412|NCT03786523|Behavioral|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on feeding time.
46018587|NCT05643677|Drug|Irinotecan|participants will receive irinotecan, 100 mg/m2, intravenous drip, day1 and day 14 of every 4 weeks
46018588|NCT01187043|Drug|Proellex|1 capsule 1x/day of 1 mg(ARM1), 3 mg(ARM2), 6 mg(ARM3), 9 mg(ARM4) or 12 mg(ARM5)
46018589|NCT02890589|Device|SYNERGY stent|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations."
45467413|NCT05694325|Other|peripheral blood and bone marrow withdrawal|samples evaluation
45467414|NCT04447118|Drug|Pyrotinib|400 mg, once daily (QD), will be administered with water within 30 minutes after completion of a meal, at approximately the same time each day on a continuous daily dosing schedule, with 21 days as a cycle.
46018590|NCT02890589|Device|ABSORB (Everolimus-eluting Bioresorbable Vascular Scaffold)|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations."
46018591|NCT05357001|Other|Connective tissue manipulation|to remove muscle spasticity
46018592|NCT05357001|Other|stretching exercises|to remove muscle spasticity
46018593|NCT05643521|Other|Dietary composition of macronutrients and calories|Carbohydrate restriction
46018594|NCT05643443|Other|Gradual increase of force|steady force
46018595|NCT01186809|Biological|in vitro expanded Cytokine Induced Killer (CIK) cells|Three infusions of donor Cytokine Induced Killer (CIK) cells will be administered according to a dose escalating program, starting 3 weeks after second Donor Lymphocyte Infusions (DLI). Cytokine Induced Killer administrations will be separated by 3 weeks intervals
46018596|NCT05367713|Other|patients having had an osteitis of the cranial flap after craniectomy|description of management and failure of cranial flap after craniectomy
46018597|NCT05643287|Procedure|Periodontal treatment|Non-surgical periodontal treatment
46018598|NCT05643053|Other|thomas fixation|Use of the thomas tube holder for endotracheal tube fixation in patients operated in the prone position
46018599|NCT05643053|Other|elastic band|Use of the elastic band for endotracheal tube fixation in patients operated in the prone position
45467415|NCT04447118|Drug|Docetaxel|75 mg/m2, once every 3 weeks (Q3W), will be administered by intravenous infusion over 1 hour, with 21 days as a cycle.
45467416|NCT05225350|Behavioral|Dietary Intervention|"See previous text~Dietary intervention consisiting och each family recieving foodpackages for 5 dinner meals during three months."
45467417|NCT05532319|Combination Product|HAIC sequential TAE combined with lenvatinib and tislelizumab|Patients with unresectable hepatocellular carcinoma will receive hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab.
45467418|NCT01553032|Drug|Erbitux®|400mg/m2 initial dose, followed by weekly doses of 250mg/m2 Treatment duration: 7-8 weeks
45467419|NCT01553032|Radiation|Fractionated Radiotherapy|30-35 fractions of radiotherapy (6-7 weeks)
45467420|NCT05472649|Biological|Gene-Modified Cell Therapy|No investigational cell product will be administered
46102172|NCT05662631|Device|BioIntellisense BioSticker|"This study uses the BioIntellisense BioSticker for RPM, in combination with the BioSync mobile app on participants' mobile phones for data transmission, augmented by use of the BioHub as a backup transmission device. RPM monitoring of device data is accomplished through use of the AlertWatch software system.~BioSticker System TheBioSticker ® System is an FDA-approved remote monitoring wearable device intended for continuous collection of physiological data in home and healthcare settings. This includes heart rate, respiratory rate, skin temperature, estimated body temperature, frequency of severe cough episodes, activity level, sleep duration, body position, degree of incline while sleeping, step count, step symmetry, step strength, and on/off body times and other symptomatic and biometric data. Data are securely transmitted using AES-CTR 128 bit encryption via wireless connection from the device for storage, review, and further analysis."
45838042|NCT05015855|Other|NP-PC PrEP|All participating providers will be provided standard education around PrEP and HIV prevention, but half of the providers will be randomized to also partner with a nurse practitioner who will provide additional consultation to patients.
45838043|NCT05015855|Other|OBGYN-PrEP|"OBGYN-PrEP is based on PC4PrEP (R01MH107297) that has four steps: announce the policy that PrEP counseling is the responsibility of OBGYN providers to address the purview paradox; train providers to manage patients on PrEP; use a screening tool to identify women appropriate for PrEP; and implementation coaching to monitor and encourage PrEP counseling"
45838044|NCT05012631|Drug|Losartan|Losartan dosing for participants <16 years will be 0.7 mg/kg (maximum of 50 mg) once daily. The dose can be increased to 1.4 mg/kg (maximum of 100 mg once daily) after 2 weeks if the dose was tolerated (no hypotension or hyperkalemia). For patients ≥16 years, the starting dose will be 50 mg once daily which can be increased to 100 mg daily if tolerated after 2 weeks.
46018600|NCT05643053|Other|normal fixation adhesive tape|Use of the adhesive tape for endotracheal tube fixation in patients operated in the prone position
46018601|NCT05643053|Other|reinforced adhesive tape fixation|Use of the reinforced adhesive tape fixation for endotracheal tube fixation in patients operated in the prone position
46018602|NCT05642975|Procedure|Regional Block Comparison|Comparing postoperative pain and opioid consumption in groups
46018603|NCT01186419|Drug|SPD602 (FBS0701, SSP-004184)|Oral FBS0701 taken one time daily for up to 96 weeks.
46018604|NCT01301027|Drug|Pioglitazone|15mg/day pioglitazone for 2 weeks, then 30mg/day pioglitazone for the remaining 24 weeks
46018605|NCT01301027|Drug|Placebo|1 pill a day for 26 weeks
46018606|NCT01185639|Radiation|stereotactic body radiation therapy|For lung, liver, axial skeleton, and adrenal tumors a dose of either 54 Gy in 3 fxs or 5000 cGy in 5 fx using SBRT techniques
46018607|NCT04207385|Diagnostic Test|pharmacogenomics|pharmacogenomics
46018608|NCT04207385|Diagnostic Test|pharmacogenomics & therapeutic drug monitoring|pharmacogenomics & therapeutic drug monitoring
45467421|NCT05309811|Device|RLRL therapy|Each RLRL treatment lasts three minutes. RLRL treatments will be performed twice a day, with at least four hours between each RLRL treatment.
45467422|NCT05309811|Drug|Routine IOP-lowering medications|Medications prescribed for IOP control by glaucoma specialists in the outpatient.
45467423|NCT01561105|Other|IMPACT|IMPACT is a collaborative care management program for late-life depression
45467424|NCT05181124|Drug|coadministration of JP-1366 and aceclofenac|An open-label, multiple-dosing, fixed sequence, 3-period design
45467425|NCT05181124|Drug|coadministration of JP-1366 and meloxicam|An open-label, multiple-dosing, fixed sequence, 3-period design
45467426|NCT05181124|Drug|coadministration of JP-1366 and naproxen|An open-label, multiple-dosing, fixed sequence, 3-period design
45467427|NCT05181124|Drug|single-dosing of JP-1366 in Korean and Caucasian|An open-label, single-dosing, parallel design
45680934|NCT03594682|Other|Intervention/treatment|"experimentalgroup initial dose：~250mg qod~250mg qd/500mg qd by turn~500mg qd control group： 750mg qd"
45838045|NCT05000645|Behavioral|Grocery delivery|Each food delivery will contain approximately $35 worth of fresh fruits, vegetables, dairy products, and whole grain foods. These foods are not meant to supplant regular meals, rather make healthy eating more convenient.
45838046|NCT05000645|Behavioral|Unsweetened beverage delivery|Participants will receive unsweetened beverages to replace normal sugar-sweetened beverage intake.
45838047|NCT04990479|Biological|GAd-PEV|Priming phase including 1 GAd-PEV administration with Standard of Care pembrolizumab (cycle 4).
45838048|NCT04990479|Biological|MVA-PEV|Boosting phase including 3 boosting administrations of MVA-PEV with Standard of Care pembrolizumab (cycles 5, 6 and 7).
46102173|NCT03904121|Procedure|Curative operation|Postoperative morbidity, mortality, functional outcome, survival
46102174|NCT00622037|Drug|PEG-400 based artificial tear|Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
46102175|NCT00622037|Drug|Systane|Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
45467428|NCT05088759|Behavioral|Alert|The alert-based CDS will consist of an on-screen electronic dialogue box that will notify the clinician that the patient is at increased risk for cardiovascular events and is not at LDL-C goal according to current evidence-based clinical practice guidelines. The clinician will have the opportunity to proceed to an order template through which ezetimibe or a PCSK9 inhibitor can be prescribed. The clinician could also elect to learn more about current evidence-based clinical practice guideline recommendations for LDL targets. Finally, the clinician could elect to proceed without ordering more intensive lipid-lowering therapy or reading the guidelines but would have to provide a rationale for not prescribing ezetimibe or a PCSK9 inhibitor.
45680935|NCT01851590|Device|Resin Lacquer|30% Resin Lacquer is applied once daily for 9 months (Abicin®) in toenail onychomycosis.
45680936|NCT01851590|Drug|Amorolfine|5% Amorolfine Lacquer is applied once weekly for 9 months (Loceryl®) in toenail onychomycosis.
45680937|NCT01851590|Drug|Terbinafine|250 mg of Terbinafine is taken orally once daily for 3 months (Generics) in toenail onychomycosis.
45680938|NCT03598972|Other|intervention|elementary analysis
45680939|NCT03598816|Drug|Durvalumab|-Durvalumab infusion will start approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion
46018609|NCT04207385|Drug|Venlafaxine|Venlafaxine hydrochloride sustained-release capsules 75mg x 14 tablets x 1 case 75-225mg/morning
46018610|NCT01185561|Behavioral|Psychoeducational intervention|The intervention is group therapy for depression treatment based on cognitive behavioral therapy principles developed for women with type 2 diabetes. Specifically, the intervention comprises activities including (1) Education about how dysphoric symptoms (i.e., depressive symptoms, anxiety, and anger) affect glycemic control; (2) Recognition of dysphoric symptoms; and (3) Management of dysphoric symptoms using cognitive-behavioral skills.
46018611|NCT05642585|Drug|MY008211A tablets|Single oral
46018612|NCT05642585|Drug|Placebo|Single oral
46102176|NCT04208789|Diagnostic Test|Rapid Molecular Drug-Resistant Tuberculosis Test|"GeneXpert MTB/RIF assay is a nucleic acid amplification (NAA) test which simultaneously detects DNA of Mycobacterium tuberculosis complex (MTBC) and resistance to rifampin (RIF) (i.e. mutation of the rpoB gene) in less than two hours. This system integrates and automates sample processing, nucleic acid amplification, and detection of the target sequences. The primers in the XpertMTB/RIF assay amplify a portion of the rpoB gene containing the 81 base pair core region. The probes are able to differentiate between the conserved wild-type sequence and mutations in the core region that is associated with rifampicin resistance. The output of this procedure is detected, undetected, or indeterminate."
45680940|NCT03598816|Drug|Tremelimumab|-Tremelimumab will be administered first
45680941|NCT03598816|Device|TDS-IM v1.0 System|-Integrated electroporation device
45680942|NCT03598816|Biological|Neoantigen DNA Vaccine|-At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.
46102177|NCT04208789|Other|Artificial Intelligent Model|The artificial intelligent model is a model that developed from several associated factors with machine learning and deep learning method in order to classify the possibility of drug-resistant tuberculosis. The Artificial neural network will be built using deep learning software.
46102178|NCT04208789|Diagnostic Test|Drug Susceptibility Test|This procedure uses Löwenstein-Jensen (LJ) medium to determine whether the isolates of M. tuberculosis are susceptible to anti-TB agents. Media containing the critical concentration of the anti-TB agent is inoculated with a dilution of a culture suspension (usually a 10-2 dilution of a MacFarland 1 suspension) and control media without the anti-TB agent is inoculated with usually a 10-4 dilution of a MacFarland 1 suspension. Growth (i.e. a number of colonies) on the agent-containing media is compared to the growth on the agent-free control media. The ratio of the number of colonies on the medium containing the anti-TB agent to the number of colonies (corrected for the dilution factor) on the medium without the anti-TB agent is calculated, and the proportion is expressed as a percentage. Provisional results for susceptible isolates may be read after 3-4 weeks of incubation; definitive results may be read after 6 weeks of incubation. Resistance may be reported within 3-4 weeks.
46102179|NCT04490603|Behavioral|Virtual reality experience|Patients are to experice virtual reality with virtual reality experience equipment (headsets, headphones, smartphones) and virtual reality experience programs. The equipments and programs are commercialized products on the market rather than medical products.
46102180|NCT02691377|Device|acupuncture group|Acupoints include 11 on the head, two on the upper extremities, and two on the lower extremities. Before performing acupuncture, a small pad will be pasted on each acupoint. All the needles will insert the acupoints through these pads. Then, they will be twirled, lifted and thrust three times to elicit the Deqi sensation. Each session will last 30 minutes.
45467429|NCT03781609|Behavioral|Roller system group (RG)|They will first receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented. In addition, they will execute 750-1250 wheelchair propulsion repetitions on the roller system per each 1 hour session (2-3 x per week for 4-6 weeks) until they reach approximately 10,000 repetitions (10 sessions). Each session will focus on minimizing the force and frequency of pushes while using longer push strokes during propulsion.
45467430|NCT03781609|Behavioral|Overground group (OG)|They will first receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented. In addition, they will execute 750-1250 wheelchair propulsion repetitions overground per each 1 hour session (2-3 x per week for 4-6 weeks) until they reach approximately 10,000 repetitions (10 sessions). Each session will focus on minimizing the force and frequency of pushes while using longer push strokes during propulsion.
46102181|NCT02691377|Device|Sham Acupuncture group|The same acupoints with acupuncture group are selected.A placebo needle with a blunt tip will be used to perform sham acupuncture. They will only insert the pad and no skin penetration. The same procedure with acupuncture group will be performed.
45467431|NCT03781609|Behavioral|Placebo - Wheelchair skills group (WSG)|They will receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented.
46018613|NCT02887209|Behavioral|CBT-I|"Cognitive behavioural therapy for insomnia (CBT-I; Edinger & Carney, 2008) is a standard 4-session cognitive behavioural therapy for insomnia administered biweekly in individual format. The first session involves presenting treatment rationale and introducing a behavioural treatment regimen consisting of a series of sleep habit parameters to follow, and determining a personalized time in bed prescription. The second session involves reviewing past-week sleep diary, discussing the role of cognitions in insomnia, and discussing constructive worrying techniques and the use of thought records. The third and fourth sessions are used to assist in adjusting time in bed prescriptions, to positively reinforce efforts, and to help problem-solve any problems they might have encountered."
46018614|NCT05367557|Procedure|laparoscopic cholecystectomy|removal of the gallbladder by laparoscopy at pneumoperitoneum pressure setting of 12 or 8 mmHg
46102182|NCT00618605|Biological|Ad26.ENVA.01 HIV-1 vaccine|Recombinant adenovirus serotype 26 HIV-1 vaccine
46102183|NCT00509821|Drug|Enzastaurin 500 milligram (mg) Once Daily (QD)|1125 mg loading dose D(-)7 then 500 mg QD, oral, daily until disease progression, given with and without radiotherapy treatment.
46102184|NCT00509821|Drug|Enzastaurin 250 mg Twice Daily (BID)|1125 mg loading dose D(-)7 then 250 mg BID, oral, daily until disease progression, given with and without radiotherapy treatment.
46102185|NCT04208165|Other|ultrasound-guided nerve block PVB|Thoracic paravertebral block guided by ultrasound device which allows visualizing the surrounding anatomy and placement of the needle at the target location in real time.
45680943|NCT03598816|Procedure|Research blood draw|-Baseline, C2D1, C3D1, C5D1, C7D1, and C9D1
45680944|NCT05633758|Drug|Placebo|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of administration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
46018615|NCT01185249|Procedure|Weigh subjects on a scale in the standing position|Subjects will stand on a scale in the mornings, and the evenings for 3 days while hospitalized.
46018616|NCT05641961|Behavioral|Survivorship mobile application|Mobile phone application
46102186|NCT04208165|Other|ultrasound-guided nerve block TAB|Transverse abdominis plane block guided by ultrasound device which allows visualizing the surrounding anatomy and placement of the needle at the target location in real time.
46102187|NCT01010581|Drug|SC12267 (4SC-101)|oral administration
46102188|NCT01010581|Drug|Placebo|oral administration
46102189|NCT01010581|Drug|Methotrexate|oral administration
46102190|NCT01010581|Drug|Folic Acid|oral administration
46018617|NCT05641961|Other|Questionnaires|Questionnaires assessing cancer knowledge and system usability will be delivered to participants via Survivorship App
46018618|NCT05641883|Combination Product|CardiaMend with antiarrhythmic|Pericardial patch with antiarrhythmic drug (amiodarone) topically applied
46102191|NCT04382885|Drug|Cariprazine|Oral Solution
45467432|NCT04834635|Procedure|FundoRingOAGB|laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and with suture cruroplasty if present hiatal hernia
45467433|NCT04834635|Procedure|OAGB|laparoscopic one anastomosis gastric bypass with suture cruroplasty if present hiatal hernia
45467434|NCT02897648|Drug|Assessment of dermal administration of Beta-Lactams|Evaluation of Pharmacokinetic / Pharmacodynamic of dermal administration of Beta-Lactams
45467435|NCT03338010|Drug|LY2963016|Administered SC
46018619|NCT02886897|Biological|D-CIK and anti-PD-1 antibody|Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5*10^10 cells)were incubated with anti-PD-1 antibody and infused into participants.
46018620|NCT05641649|Drug|Sodium valproate and valproic acid extended release tablet|Test or innovator tablet formulation of sodium valproate and valproic acid will be administered orally to the volunteers on each study days in fasting condition. Volunteers will be receiving a single tablet of either of the formulations on the study days by a randomization technique so that each of them receives both formulations during the study period.
46018621|NCT04324697|Procedure|Horizontal alveolar bone augmentation|Horizontal augmentation in anterior maxilla using allograft shell and autogenous chips with no need for a second surgical site
46102192|NCT01010659|Device|Lacrimal Tube|Lacrimal Tube
46102193|NCT04208867|Behavioral|QI Collaborative|Facilities that participated in a QI collaborative to improve PCC for MH services
46102194|NCT01015963|Other|laboratory biomarker analysis|Perform DNA sample analysis
45467436|NCT03338010|Drug|Lantus®|Administered SC
46018622|NCT05619497|Other|Clinic-wide Trainings|The clinic-wide trainings combine principles of shared decision-making and trauma informed care to inform providers and clinic staff of an equitable approach to offering HIV prevention information. These care delivery approaches have been used in health education and counseling in a range of contexts and are effective strategies for care provision. Participants in this arm will receive care from providers and staff who received training.
46102195|NCT04208945|Drug|Colistin|500000 units of inhaled colistin three times daily for 10 days
46102196|NCT01016041|Device|everolimus stent|stenting
46102197|NCT01016041|Device|paclitaxel stent|stenting
45467437|NCT04750148|Diagnostic Test|6-minute walking test|The subject walks as far as possible for 6 minutes along a 30m long corridor.
45467438|NCT04750148|Diagnostic Test|2-minute walking test|The subject walks as far as possible for 2 minutes along a 30m long corridor.
45467439|NCT04750148|Diagnostic Test|10-meter walk test|The natural and fast walking speeds of the subject are measured over 10m. This speed is measured by the examiner as well as by the subject (self-tested version).
45467440|NCT04750148|Diagnostic Test|One leg stance test|The time held in unipodal equilibrium is measured by the examiner.
46102198|NCT03820661|Device|Ultrasound|High resolution ultrasound pre-operatively and intra-operatively
46102199|NCT05662475|Diagnostic Test|GCF (gingival crevicular fluid) collection|Prior to GCF (gingival crevicular fluid) sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Gingival fluid collection strips were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed GCF volume was estimated by a calibrated instrument. Then, the strips were sealed into sterile tubes before freezing at -80 °C. The readings were converted to an actual volume (μl) by reference to the standard curve.
45467441|NCT05309499|Drug|ferric carboxymaltose|ferric carboxymaltose is i.v. iron, 121 patiants will be randomised to this group
45467442|NCT05309499|Drug|ferrous sulphate|ferrous sulphate is oral iron, 121patiants will be randomised to this group
45467443|NCT05090254|Other|Treatment algorithms targeting cardiac output|Treatment algorithms targeting maximization or personalization of cardiac output
45467444|NCT03777631|Procedure|Catheter ablation|CA should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required.
45467445|NCT04959591|Drug|intravenous acetaminophen|experimental(pre): administration of IV acetaminophen
45467446|NCT04959591|Drug|intravenous acetaminophen|experimental(post): administration of IV acetaminophen
45467447|NCT04959591|Drug|Placebo|placebo comparator: administration of normal saline
45467448|NCT05598086|Drug|Tranexamic acid|local infiltration of TXA or normal saline in the post-operation would
46102200|NCT05662475|Procedure|Non-surgical periodontal treatment completed in 24 hours|After clinical periodontal parameters were recorded and GCF samples were obtained, non-surgical periodontal treatment was started under local anesthesia. All periodontal treatments were performed by a single investigator. Local infiltrative anesthesia was applied to the buccal and palatal/lingual areas of the maxilla and mandible of the patients. After anesthesia was achieved, scaler and ultrasonic tips of various thicknesses were used together to remove supragingival and subgingival hard attachments. Root surface smoothing was performed with region-specific periodontal curettes. The roughness of the surfaces was controlled using a periodontal probe. Polishing was performed. Oral hygiene education was given to each patient after treatment. Modified Bass technique was explained as a brushing technique. Interdental cleaning is explained. The patient was told not to use any chemical agent for plaque removal.
46018623|NCT05619497|Other|Clinic-wide Trainings and HIV Prevention Decision Support Tool (DST)|"The clinic-wide trainings combine principles of shared decision-making and trauma informed care to inform providers and clinic staff of an equitable approach to offering HIV prevention information. These care delivery approaches have been used in health education and counseling in a range of contexts and are effective strategies for care provision. Participants in this arm will receive care from providers and staff who received training.~The DST is founded on principles of decision-science and will address barriers to PrEP delivery. The DST will present HIV prevention information through a tablet in the clinical setting. The tool provides information about vulnerabilities to HIV and core characteristics of different HIV prevention methods, and the opportunity to explore these characteristics in depth, including efficacy, safety and side effects. The tool emphasizes the highly variable and individual nature of baseline risk."
45467449|NCT00753532|Dietary Supplement|200mg of Palm vitamin E (tocotrienols) or placebo|Individuals randomized in the (MRI+ve) and (MRI -ve) cohort respectively. In the MRI(+ve) cohort, 62 subjects received 200 mg softgels of Palm Vitamin E (tocotrienols) and 59 were assigned to placebo, taken orally twice a day for a study period of two years. In the MRI(-ve) cohort, 63 subjects received 200 mg softgels of Palm Vitamin E (tocotrienols) and 57 consumed placebo, taken twice a day for a follow up period of 1 year.
46018624|NCT05619497|Other|Standard Care with the HIV Prevention Decision Support Tool (DST)|Participants in this arm will receive usual care at a clinic that has not received training in shared decision making and trauma informed care. These participants will view the decision support tool. These participants were recruited in Aim 1 of this study.
46102201|NCT05662475|Diagnostic Test|HbA1c level determination in blood serum|Blood samples were taken from the patients and HbA1c concentration was measured in serum.
46102202|NCT02697305|Dietary Supplement|IV BCAA|in total dose of 0,4 g/kg in a 2 h intravenous infusion
46102203|NCT02697305|Dietary Supplement|ORAL BCAA|single dose of 0.4g/kg administered over 30s washed down with 500mL of tap water
46102204|NCT02697305|Other|ORAL Placebo|single dose of 0.4 g/kg administered over 30 s washed down with 500mL of tap water
46102205|NCT00622115|Drug|Enoxaparin|
46102206|NCT04208633|Procedure|Horizontal placement of the intraocular lens in the capsular bag|The eyes will be randomized (1:1) using a dedicated computer programme prior to the start of the study to have a vertical or horizontal placement of the intraocular lens in the capsular bag. The 0 and 180 degrees will be marked on the slit lamp prior to the surgery. The axes of the IOL will be orientated in reference to the midpoint of the optic haptic junction of the IOL. the fellow eye will receive the opposite placement (horizontal or vertical) of the IOL.
46102207|NCT04208633|Procedure|Vertical placement of the intraocular lens in the capsular bag|The eyes will be randomized (1:1) using a dedicated computer programme prior to the start of the study to have a vertical or horizontal placement of the intraocular lens in the capsular bag. The 0 and 180 degrees will be marked on the slit lamp prior to the surgery. The axes of the IOL will be orientated in reference to the midpoint of the optic haptic junction of the IOL. the fellow eye will receive the opposite placement (horizontal or vertical) of the IOL.
46102208|NCT00508651|Biological|MEDI-560|MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson^TM luer slip tip syringes. Each 0.2 mL dose contained 10^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.
46102209|NCT00508651|Biological|Placebo|Placebo was a frozen preparation filled into Becton Dickinson^TM luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.
46102210|NCT02696837|Device|ETT|
46102211|NCT02696837|Device|Proseal LMA|
46018625|NCT01184859|Drug|Desmopressin|Desmopressin oral lyophilisate melt tablet, in either the 10, 25, 50, or 100 μg dosage, for sublingual administration
46018626|NCT01184859|Drug|Placebo|Placebo melt tablet for sublingual administration
45467450|NCT02864888|Radiation|Radiation|Children with a diffuse, intrinsic brain stem glioma will receive radiation.
45467451|NCT02864888|Drug|Atengenal|Children with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
45467452|NCT02864888|Drug|Astugenal|Children with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
45467453|NCT03777553|Behavioral|Narrative Exposure Therapy for Justice-Involved Veterans|Behavioral intervention that uses narrative therapy and exposure to address repeated or complex trauma.
45838049|NCT04989218|Drug|Novel combination of chemotherapy and immunotherapy|This is a study of the combination of platinum based chemotherapy (gemcitabine and cisplatin) and doublet immunotherapy (durvalumab and tremelimumab) in the preoperative setting for intrahepatic cholangiocarcinoma with high risk features. Gemcitabine and cisplatin are chemotherapy agents used in the management of locally advanced and metastatic cholangiocarcinoma. Durvalumab is a programmed cell death ligand 1 (PDL1) blocking antibody, that improves the immune response against cancer. Tremelimumab is an antibody that targets cytotoxic T cell lymphocyte-associated protein 4 (CTLA4) on regulatory T cells. It also improves the immune response against cancer cells
46018627|NCT00623675|Dietary Supplement|Mineralox C|Mineralox C 2 capsules three times a day.
46018628|NCT02890511|Drug|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed consent.
46018629|NCT05609981|Other|Clinical medication review focused on deprescribing|"A pharmacist-led intervention consisting of a clinical medication review with the focus on deprescribing in older patients using multidose drug dispensing (MDD) systems.~Pharmacist are trained in deprescribing and a developed toolbox to support the intervention is provided"
46018630|NCT02887287|Drug|EEN|
46018631|NCT01184079|Biological|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months
45838050|NCT04985227|Other|Home weight monitoring|Parents will be provided with weighing scales to weigh their infant at home and plug in the weight in the patient portal for review by their primary care provider.
46018632|NCT01184079|Biological|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months
45467454|NCT03632408|Drug|Zopiclone|Oral, single dose, 7.5 mg
45467455|NCT03632408|Behavioral|hangover|as per subjects choice to consume alcohol
46018633|NCT04316403|Procedure|Er:YAG laser|This application was made before the onset of canine retraction in one side of the mouth
46018634|NCT05340699|Device|Defocus Distributed Multi-point lens|Wear DDM lens
46018635|NCT05340699|Device|Single vision lens|Wear single vision lens
46018636|NCT05337267|Drug|sintilimab (after the change)|0.3mg/kg，I.V.，single dose
46018637|NCT05337267|Drug|sintilimab (before the change)|0.3mg/kg，I.V.，single dose
46102212|NCT02696837|Drug|Rocuronium|
46102213|NCT02696837|Other|No Muscle Relaxant|
45467456|NCT03632408|Drug|Placebo oral capsule|oral
45467457|NCT03777475|Procedure|transarterial infusion|transarterial infusion
45467458|NCT05076760|Biological|MEM-288 Intratumoral Injection|Intratumoral injection of MEM-288, conditionally replicative oncolytic adenovirus vector encoding transgenes for human interferon beta (IFNβ) and a recombinant chimeric form of CD40-ligand (MEM40).
46018638|NCT04316325|Drug|Medical abortion|Trained abortion providers will counsel participants about medical abortion via videoconference or telephone, the abortion medications will be sent to the participants via mail or will be accessed at a pharmacy, the provider will follow up one week later with the participants to assess outcomes, and four weeks later the participant will take a pregnancy test to confirm completion of the abortion
46018639|NCT05333289|Biological|mRNA-1030|Sterile liquid for injection
46018640|NCT05333289|Biological|mRNA-1020|Sterile liquid for injection
46018641|NCT05333289|Biological|mRNA-1010|Sterile liquid for injection
46018642|NCT05333289|Biological|Active Comparator|Sterile liquid for injection
46018643|NCT01190865|Biological|HP802-247|One dose of HP802-247 consisting off 260 mL containing keratinocytes and fibroblasts totaling 5.0 x 10.6 cells per mL, plus fibrin.
46018644|NCT01190475|Drug|Active treatment with a high dose of BGS649|
46018645|NCT01190475|Drug|Active treatment with a low dose of BGS649|
46018646|NCT01190475|Drug|Placebo treatment to blind study|
46018647|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
46018648|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
45467459|NCT03337542|Biological|AR101|AR101
46018649|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
46018650|NCT01289990|Drug|Placebo|Placebo matching Sitagliptin
46018651|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
46018652|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
46018653|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
46018654|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
46018655|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
46102214|NCT02696837|Drug|Rocuronium|
46102215|NCT03753893|Other|No intervention used|no intervention used
46102216|NCT03997045|Behavioral|Supervised physical exercise program|Supervised physical conditioning program of two 60-minutes sessions per week during pregnancy, developed from gestational week 20 to 38. Each session consists of 25-30 minutes of cardiovascular exercise,15 minutes of strengthening exercises, 5 minutes of coordination and balance exercises and 10 minutes of pelvic floor muscles training.
46018656|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
46018657|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
46018658|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
46102217|NCT03996889|Device|Endovascular treatment of aneurysms of the popliteal artery by GORE VIABAHN® stent in elective surgery|"The intervention can be performed under local anesthesia (LA), regional locus (ALR) or general anesthesia (AG) (data collected) by first approach: percutaneous or conventional.~The data collected are:~Number of GORE VIABAHN® stent used (length and diameter of each)~Embolization of collaterals and other related actions~Operative complications~Intraoperative fibrinolysis~Collar cover> 2 cm~Lack of overlap in the overlap zone (nb: between 4 and 8 cm above the joint spacing)~Arteriography in profile, kink"
46102218|NCT01016119|Drug|Folrex|Folrex cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
46018659|NCT01289990|Drug|Placebo|Placebo matching Sitagliptin
46102219|NCT01016119|Drug|Placebo|Placebo cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
46102220|NCT01016197|Procedure|extensor tendon repair|Surgical repair of extensor tendon with bone anchor and splinting
46102221|NCT01016197|Procedure|Mallet splint for 4 weeks|"The patient will wear a mallet splint for fours weeks and then mobilise their finger."
46102222|NCT01016275|Device|Misago (stent placement)|Misago iliac stent
46102223|NCT00490555|Drug|Testosterone gel|Testosterone gel 10 g
46102224|NCT00490555|Drug|Dutasteride|dutasteride 0.5 mg orally
46102225|NCT00490555|Drug|Depo-Medroxyprogesterone (DMPA)|300 mg DMPA injection on Day 0 IM (into the muscle)
46102226|NCT00490555|Other|Placebo Testosterone gel|Place gel applied daily for 12 weeks
46102227|NCT00490555|Other|Placebo dutasteride|placebo pill for 12 weeks
46102228|NCT00490555|Other|Placebo DMPA|placebo DMPA injection Once
46102229|NCT00501085|Device|LAP-BAND AP Adjustable Gastric Banding System|Reduction of food intake due to creation of smaller stomach pouch.
46102230|NCT01014247|Drug|Avelox (Moxifloxacin, BAY12-8039)|Single dose of 400 mg
46102231|NCT01014247|Drug|Placebo|Single dose of matching tablet
46102232|NCT00049595|Biological|bleomycin sulfate|
46018660|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
46102233|NCT00049595|Biological|filgrastim|
46102234|NCT00049595|Biological|pegfilgrastim|
46102235|NCT00049595|Drug|ABVD regimen|
46102236|NCT00049595|Drug|BEACOPP regimen|
46102237|NCT00049595|Drug|cyclophosphamide|
46018661|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
46018662|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
46018663|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
46018664|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
46018665|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
46018666|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
46018667|NCT01289990|Drug|Placebo|Placebo matching Sitagliptin
46018668|NCT01289990|Drug|Sitagliptin 100mg|Sitagliptin once daily
46018669|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
46018670|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
46102238|NCT00049595|Drug|dacarbazine|
46102239|NCT00049595|Drug|doxorubicin hydrochloride|
46102240|NCT00049595|Drug|etoposide|
46102241|NCT00049595|Drug|prednisone|
46102242|NCT00049595|Drug|procarbazine hydrochloride|
46102243|NCT00049595|Drug|vinblastine sulfate|
46102244|NCT00049595|Drug|vincristine sulfate|
46102245|NCT01014325|Biological|Allergen extract|sublingual application
46018671|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
46018672|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
46018673|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
46102246|NCT01014325|Biological|Placebo|sublingual application
46102247|NCT01010737|Biological|Multimeric-001 250 mcg|Multimeric-001 (M-001) was administered twice at a dose of 250mcg via the IM route to 10 participants as a primer, followed by TIV boost immunization. in 19-23 days interval between them.
46102248|NCT01010737|Biological|Adjuvanted Multimeric-001 250mcg|Injection of Multimeric-001 250 mcg with Adjuvant Montonide isa 51 VG, 2 doses with interval of 19-23 days between them
46102249|NCT01010737|Biological|Placebo|Placebo injected with PBS (Phosphate Buffered Saline), 2 injections with the interval of 19-23 days between them.
46102250|NCT01010737|Biological|Adjuvant: Montonide isa 51 VG|Injection of Placebo with Adjuvant Montonide isa 51 VG, 2 injections with the interval of 19-23 days between them.
46102251|NCT01010737|Biological|Multimeric-001 500 mcg|Injection of Multimeric-001 with PBS, 2 injections with the interval of 19-23 days between them.
46102252|NCT01010737|Biological|Adjuvanted Multimeric-001 500mcg|Injection of Multimeric-001 500 mcg with Adjuvant Montonide isa 51 VG, 2 doses with the interval of 19-23 days between them
46102253|NCT01010737|Biological|TIV|Injection of the conventional flu vaccine: Vaxigrip to all study participants.
46102254|NCT00873860|Other|Placebo|Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
46102255|NCT00873860|Biological|CAT-354 150 mg|CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
46102256|NCT00873860|Biological|CAT-354 300 mg|CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
46102257|NCT00873860|Biological|CAT-354 600 mg|CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
46102258|NCT03854227|Drug|PF-06939999 dose escalation|PF-06939999 orally at escalating doses on a continuous basis
46018674|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
46102259|NCT03854227|Drug|PF-06939999 monotherapy|PF-06939999 at the recommended Phase 2 dose orally on a continuous basis
46102260|NCT03854227|Drug|PF-06939999 in combination with docetaxel|PF-06939999 orally on a continuous basis in combination with docetaxel
45467460|NCT04959123|Other|pharmacokinetic analysis|Non-compartmental descriptive pharmacokinetic analysis (i.e. without the need for mathematical modelling), with determination of the pharmacokinetic parameters of interest either directly from the experimental points (Cmax, Tmax), or from simple mathematical equations (calculation of the area under the curve (AUC) by the trapezoidal method, calculation of the terminal slope of elimination)
46102261|NCT04350905|Other|Mosquito Feeding|Mosquito feedings will be conducted with Aedes aegypti colonies raised at the CNM (National Malaria Center) Malaria and Vector Research Laboratory (MVRL), an established state of the art insectaries for mosquitoes was built in 2014 to ACL2 (arthropodcontainment level 2)-level specifications.
46018675|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
46102262|NCT05368961|Behavioral|Distraction|Distraction (interactive tablet)
46102263|NCT05368961|Other|Usual care|Anxiolytic ordered by anesthesiologist is usual care
46102264|NCT03853291|Behavioral|PICT Workbook|PICT Workbook: The PICT workbook is a 31-page manual, which includes: a) training using an observational assessment tool to detect pain in PWD, b) coaching and feedback by a research nurse in effective strategies for communicating with providers about PWD's pain, c) future planning for what steps to take when a pain symptom is detected, and d) updating the caregiver's skill set. Participants in the intervention condition also attended four weekly 30-minute sessions with an interventionist through a combination of online (video observation) and telephone coaching to go over the Workbook.
46102265|NCT03853291|Behavioral|Information Pamphlet|Pamphlet with information about pain and dementia and links to Alzheimer's Association
46102266|NCT00622271|Behavioral|Group Therapy|Self-management Group Protocol: The parent sessions will be structured by general topic area, but teaching of clinical and behavioral information will be derived from questions and problems posed by the group in order to actively meet the needs and concerns of participants. The parent sessions will be an interactive process of eliciting concerns and questions, presenting information to address those questions, and following up with a discussion to review concerns and strategies to address the behavioral aspects of the issues. The child sessions will be activity focused, with hands-on opportunities to practice the skills being taught.
46102267|NCT04207853|Other|whole body vibration em DM|The vibrating platform is a new biophysical modality of exercise. The individual exercises on a plate that oscillates up and down movements at a specific frequency and amplitude, and the exercises are performed static and / or dynamic. Vibration is supposed to activate muscle spindles and evoke contractions, which are induced by the complex spinal and supraspinal neurophysiological mechanism known as the tonic vibration reflex.
46102268|NCT04207853|Other|"Vibration sham em DM"|Sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to the connected platform for a time equivalent to the treatment protocol, as it will not be possible to visibly distinguish the vibratory stimulus. Participants who will undergo false vibration will not have contact with those who will perform the protocol effectively.
46102269|NCT04207853|Other|whole body vibration em NDM|The vibrating platform is a new biophysical modality of exercise. The individual exercises on a plate that oscillates up and down movements at a specific frequency and amplitude, and the exercises are performed static and / or dynamic. Vibration is supposed to activate muscle spindles and evoke contractions, which are induced by the complex spinal and supraspinal neurophysiological mechanism known as the tonic vibration reflex.
46018676|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
45467461|NCT01307839|Drug|5% lidocaine patch|Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours.
46018677|NCT04206345|Other|exercise with blood flow restriction|Elbow bending exercises with blood flow restriction will be performed to the exercise group.
46018678|NCT04206345|Other|exercise|Elbow bending exercises
46018679|NCT02886975|Behavioral|low protein diet plus α-keto acid|0.4-0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
46018680|NCT01190007|Drug|Caduet|One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks
46018681|NCT01189461|Drug|pegaptanib sodium|Upon enrollment, all subjects will be treated in the study eye with pegaptanib sodium 0.3 mg at the investigators' discretion based on visual acuity assessment up to a maximum of 48 weeks. The minimum dosing interval between injections will be at least 6 weeks.
46018682|NCT01189227|Procedure|Postoperative chemotherapy|Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
46018683|NCT01189227|Procedure|Perioperative chemotherapy|Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
46018684|NCT01300247|Drug|Fludarabine|Participants will receive 6 cycles (each 28-day cycle) of fludarabine at dose of 25 mg/m^2 IV, on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
46018685|NCT01300247|Drug|Obinutuzumab|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab at dose of 1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6.
46018686|NCT01300247|Drug|Bendamustine|Participants will receive 6 cycles (each 28-day cycle) of bendamustine at dose of 90 mg/m^2 IV, on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.
46018687|NCT01300247|Drug|Cyclophosphamide|Participants will receive 6 cycles (each 28-day cycle) of cyclophosphamide at dose of 250 mg/m^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
46018688|NCT02890277|Device|the high intensity focused ultrasound (Mianyang Sonic electronic LLC)|
46102270|NCT04207853|Other|"Vibration sham em NDM"|Sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to the connected platform for a time equivalent to the treatment protocol, as it will not be possible to visibly distinguish the vibratory stimulus. Participants who will undergo false vibration will not have contact with those who will perform the protocol effectively.
46102271|NCT03853213|Behavioral|Cognitive Bias Modification Training|"In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The letter appears in the neutral location on 90.6% of trials, thereby reinforcing participants' attending away from threat. In task 2, participants view a word or phrase corresponding to a threatening (e.g., dying) or benign (e.g., sleep) interpretation of a sentence (e.g., You have been waking up tired recently). They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback (Correct) is given for rejected threat interpretations and for benign interpretations. Otherwise, negative feedback (Incorrect) is given."
46102272|NCT03853213|Behavioral|Attention Control Training|In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The target letter is equally likely to appear in the threat location as the neutral location. Thus, participants' patterns of attention are not trained toward or away from threat. In task 2, participants view a word or short phrase corresponding to either a threatening or benign interpretation of a sentence that follows it. They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback and negative feedback are equally likely to be given regardless of whether participants endorse the threatening or benign interpretations.
46018689|NCT02890277|Drug|Fu Tiankang disposable vaginal filling suppository, Albothyl (Policresulen Solution) , and the gynecologic medical antimicrobial dressing gel (chitosan gel).|
46018690|NCT01289678|Drug|Interleukin-2|Famotine 20mg IV push daily just prior to the aldesleukin (IL-2) IL-2 18 million IU/m2 in 50 mL 5% D5 or NS IVPB over 15 - 30 minutes daily for 5 days
46018691|NCT02886741|Other|Quality Improvement Campaign|"How To Guide addressed development of a QI plan; small-scale tests of change- (PDSA cycles) to refine implementation approaches through iterative learning; and reliance on multi-disciplinary implementation teams. IHI recruited relevant professional organizations to identify faculty."
46018692|NCT02890082|Drug|Tamoxifen stim in early follicular phase|"Day cycle of the patient when ovarian stimulation begin (early follicular phase) = D1 to D3~Stimulation with simultaneously: TAM (tamoxifen) 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve)~Monitoring (ultrasound + blood test E2, LH (luteinizing hormone) and P) every 2 to 3 days +/- dose adjustment of FSH~Ovulation by blocking the GnRH antagonist (gonadotropin-releasing hormone : CETROTIDE) introduced according to the usual criteria,~Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days~Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia."
46018693|NCT02890082|Drug|Tamoxifen stim in late follicular phase|"Day cycle of the patient when ovarian stimulation begin (late follicular phase) = D4 to D14~Monitoring (ultrasound + blood test E2, LH and P) until a follicle of 15 mm~Ovulation induction by OVITRELLE® 250μg.~Continued monitoring (ultrasound + blood test E2, LH and P) 4 days after OVITRELLE® to the proper stage for the beginning of stimulation.~Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE~Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH~Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia."
46102273|NCT03610451|Behavioral|Floatation-REST plus usual care|Individuals will receive Floatation-REST plus usual care. Floating creates an environment with minimal visual, auditory, tactile, proprioceptive, and thermal input to the brain. The float rooms are lightproof and soundproof. A high concentration Epsom salt water solution allows individuals to effortlessly float on their back while remaining completely still, reducing both proprioceptive and tactile input to the brain. The temperature of the water is calibrated to the temperature of the skin (~94° F) and the temperature of the air is calibrated to the temperature of the water, making it difficult to discern the boundary between air and water, thus reducing thermal input to the brain while minimizing the need for thermoregulation of the skin.
46018694|NCT02890082|Drug|Tamoxifen stim in luteal phase|"Day cycle of the patient when ovarian stimulation begin (luteal phase) = D15 to D28~1 or 2 Monitoring (ultrasound + blood test E2, LH and P) to check the validity of the post-ovulatory phase~Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE~Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH~Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia"
46018695|NCT02886819|Other|vibration|Whole body vibration
46018696|NCT01289210|Drug|VTX-2337 plus radiotherapy|Radiation on Day 1. On Day 2, VTX-2337 3.0mg/m2 is administered intratumorally, followed by radiation. VTX-2337 3.0mg/m2 is then given weekly for 3 weeks in a 4 week cycle over 3 cycles.
46102274|NCT03610451|Behavioral|Usual care|Individuals will receive usual care on the inpatient unit of the Laureate Eating Disorders Program.
46018697|NCT01183221|Drug|Syntocinon|One dose of 24 IU (3 sprays/nostril)
46018698|NCT01183221|Drug|Placebo|Intranasal Placebo
46102275|NCT00691730|Other|laboratory biomarker analysis|Only sample collection, no other intervention - Correlative studies
46018699|NCT01183143|Drug|GONAL-f®|GONAL-f® will be administered subcutaneously to subjects between Day 2 and Day 5 of their cycle with a starting dose of 75 International Units (IU) per day for subjects who undergo ovulation induction (OI)/artificial insemination (IUI) and between 150 and 225 IU per day for subjects who undergo in-vitro fertilization (IVF). For subjects who undergo OI/IUI, the dose will be increased by 37.5 IU after Day 14 up to Week 4 if no ovarian response is observed.
46018700|NCT01183065|Drug|Pralatrexate With Vitamin B12 and Folic Acid|Patients will be treated with 30 mg/m2 of pralatrexate intravenously once weekly for 3 weeks in a 4 week cycle with vitamin supplementation. Patients will take 1.0-1.25 mg oral folic acid on a daily basis. Folic acid should be initiated during the 10-day period preceding the first dose of pralatrexate and dosing will be continued during the full course of therapy and for 30 days after the last dose of pralatrexate. Patients will also receive a vitamin B12 (1 mg) intramuscular injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with pralatrexate.
46018701|NCT01182441|Device|WATCHMAN Device|WATCHMAN Left Atrial Appendage Closure Technology
46018702|NCT01182441|Drug|Warfarin|Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0
46018703|NCT02886507|Dietary Supplement|NSK-SD (nattokinase)|Nattokinase is a fibrinolytic enzyme from the fermented soy product natto. Encapsulated 100mg/capsule, excipient include microcrystalline cellulose.
46018704|NCT02886507|Dietary Supplement|Placebo|The placebo capsules contain microcrystalline cellulose.
46102276|NCT04138160|Other|5:2 Intermittent energy restriction|Substantial (70%) energy restriction for 2 non-consecutive days/week interspersed with normal energy intake (isoenergetic) on the remaining 5 days of the week.
46102277|NCT04138160|Other|Continuous energy restriction|20% energy restriction each day relative to the energy requirement.
46102278|NCT04274231|Genetic|different effection|Analysis of the reasons for treatment
46102279|NCT04031378|Radiation|Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation|SBRT to a single dose of 24 Gy to up to 3 sites
46102280|NCT04031378|Drug|Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months|SBRT 24 Gy to up to 3 nsites, followed by by systemic therapy based on phenotype.
46102281|NCT02626052|Behavioral|Dizziness Handicap Inventory|A standardized questionnaire used to quantify symptoms of dizziness.
46102282|NCT02626052|Behavioral|Global Rating of Change|A standardized questionnaire used to review the overall outcome of the participants condition with physical therapy.
46102283|NCT02626052|Behavioral|Patient Acceptable Symptom State|A standardized questionnaire used to determine whether meaningful progress has been made
46102284|NCT02626052|Procedure|Spontaneous Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
46018705|NCT01182285|Drug|Valproic Acid|"Week 1:~(Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening"
46102285|NCT02626052|Procedure|Gazehold Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
46102286|NCT02626052|Procedure|Primary Vibration Test|A test used to identify asymmetry that may be present in the vestibular system through 60-100 MHz vibration applied to the mastoid bone. A WAHL massager is used to stimulate the inner ear by vibrating the mastoid bone. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
45467462|NCT01307839|Drug|placebo patch|Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours
46102287|NCT00686504|Drug|AZD2066|single dose of oral dose, 3 times per subject
46102288|NCT00686504|Drug|radioligand [11C] AZ12713580|single dose of iv administered 4 times per subject (3 times together with AZD2066)
46102289|NCT02626754|Drug|Sunitinib malate|Sunitinib 50mg will be given for 2 consecutive weeks then followed by one week of rest.
46102290|NCT00691886|Drug|dexmedetomidine hydrochloride|Dose of 0.4ug/kg/hr to 1.5ug/kg/hr to achieve a RASS score of -1 to-3 during the bronchoscopy procedure. Dexmedetomidine will infused a half hour before the proceudure is started and will continue throughout the procedure. Traditional sedatives (midazolam and or fentanyl) will be given prn.
46102291|NCT04148456|Procedure|Covered Endovacular Reconstruction of Aortic Bifurcation|"The occlusive lesion is then passed, either subintimal or endoluminal, using crossing wires and catheters.~After gaining re-entry into the lumen of the aorta, angiography will be confirmed proper positioning for those with a subintimal passage.~A 10-12 mm V12 LD balloon expandable ePTFE covered stent (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be expanded in the distal aorta approximately 20 mm above the bifurcation through the 9 Fr sheath.~The proximal 2/3 part of the aortic stent will be flared with a larger balloon, usually 16 mm, thereby creating a funnel shaped covered stent. Subsequently, two 8 mm V12 balloon expandable ePTFE covered stents (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be placed proximally in the distal 1/3 of the aortic stent, and then simultaneously deployed distally into the common iliac arteries creating a tight connection with the first aortic stent, thereby creating the new aortic bifurcation."
46102292|NCT04138004|Drug|polyethylene glycol in combination with lubiprostone|2-litre polyethylene glycol split-dose in combination with one 24 mcg tablet of lubiprostone
45467463|NCT01316809|Drug|AZD8055|Patients will start at 120 mg once daily
45467464|NCT05337943|Behavioral|CBT-I|Weekly sessions with a therapist to improve sleep for 8 weeks.
45467465|NCT05337943|Device|Bright Light Therapy|Daily light therapy for 30 minutes for 8 weeks.
45467466|NCT05008107|Other|Virtual reality|Using VR goggles to watch peri-operative instructional video.
45467467|NCT03708042|Combination Product|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
46018706|NCT01182285|Drug|Liothyronine Sodium|Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Cytomel for 4 weeks (25 micrograms twice a day)
46018707|NCT04315935|Drug|Butorphanol and Propofol|The two groups were given propofol for sedation, BG for butorphanol for analgesia and FG for fentanyl for analgesia
46018708|NCT04315935|Drug|Fentanyl and Propofol|Fentanyl (0.7-10 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
45467468|NCT03708042|Combination Product|Neoadjuvant Radiochemotherapy|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
46018709|NCT04316091|Drug|neoadjuvant chemotherapy+SPIONs/SMF|Intratumoral injection of SPIONs, followed by SMF, combined with conventional neoadjuvant chemotherapy
46102293|NCT04138004|Drug|polyethylene glycol alone|4-litre polyethylene glycol split-dose
46018710|NCT04316091|Drug|neoadjuvant chemotherapy|Conventional neoadjuvant chemotherapy only
46018711|NCT04188015|Biological|2.5mg ANX007|A single dose of 2.5mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.
46018712|NCT04188015|Biological|5.0mg ANX007|A single dose of 5.0mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.
46018713|NCT04188015|Other|Sham Procedure|The sham injection is preformed by applying pressure to the eye at the location of a typical IVT injection using the blunt end of a syringe without a needle.
46018714|NCT01182207|Drug|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
46018715|NCT01182207|Drug|YAZ®|3 mg/0.02 mg Tablets
46018716|NCT01181895|Drug|Vilanterol|Vilanterol inhalation powder inhaled orally once daily for 12 weeks
46018717|NCT01181895|Drug|Salmeterol Inhalation Powder|Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
46018718|NCT01181895|Drug|Placebo Inhalation Powder NDPI|Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
46018719|NCT01181895|Drug|Placebo Inhalation Powder Diskus|Placebo inhalation powder inhaled orally twice daily for 12 weeks
46018720|NCT04187781|Device|external microphone|External microphone is developed for direct transmission of speech into the hearing aids for better speech intelligibility, especially in noise.
46018721|NCT01181271|Drug|Busulfan (conditioning for AUTO transplant)|0.8 mg/kg intravenous (IV) bolus every six hours (Q6H) on days -8,-7,-6,-5 (total of 14 doses). The total daily dose of busulfan will be 3.2 mg/kg on days -8,-7, and -6 and 1.6 mg/kg on day -5
46018722|NCT01181271|Drug|Etoposide (conditioning for AUTO transplant)|Etoposide 30 mg/kg IV bolus every day (QD) on day -4. The total daily dose of etoposide will be 30 mg/kg.
46018723|NCT01181271|Drug|Cyclophosphamide (conditioning for AUTO transplant)|Cyclophosphamide 60 mg/kg IV bolus QD on days -3 and -2. The total daily dose of cyclophosphamide will be 60 mg/kg.
46018724|NCT01181271|Drug|Mesna (prior to AUTO transplant)|Mesna 15 mg/kg IV bolus on days -3 and -2 infused over 15 minutes and given 15 minutes prior to cyclophosphamide administration. This is followed by Mesna given 15 mg/kg IV bolus three times daily (TID) on days -3 and -2 infused over 15 minutes at 3, 6, and 9 hours after completion of cyclophosphamide infusion. Total daily dose of Mesna should be equivalent to daily dose of cyclophosphamide. Lastly, Mesna will be given at 15 mg/kg IV bolus QD on day -1. This makes a total of 9 doses of Mesna
46018725|NCT01181271|Other|autologous (auto) peripheral blood stem cell transplantation|Infusion of autologous peripheral blood stem cells on Day 0.
46018726|NCT01181271|Drug|Neupogen|Neupogen 5 mcg/kg subcutaneous (SQ) daily starting on day +1 until absolute neutrophil count (ANC) is greater than or equal to 1000 per micro liter on two separate occasions or greater than 5000 per micro liter once
46018727|NCT01181271|Drug|Fludarabine (conditioning for ALLO Transplant)|Fludarabine 30 mg/m2/day will be administered as a bolus infusion over approximately 30 minutes for 4 days on days -5, -4, -3, -2.
46018728|NCT01181271|Drug|Busulfan (conditioning for ALLO Transplant)|Busulfan will be administered by IV infusion over approximately 3 hours on days -5, -4, -3, -2. The dose of busulfan will be 0.8 mg/kg/day
45467469|NCT03777085|Drug|TQB2303|375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
45467470|NCT03777085|Drug|Rituximab|375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
46018729|NCT01181271|Other|non-myeloablative allogeneic (allo) transplant|Donor peripheral blood stem cells (PBSC) will be infused intravenously beginning on Day 0. The minimum total CD34+ cell dose will be 2 x 10^6 CD34+cells/kg of recipient's actual body weight with a maximum dose of 8 x 10^6/kg of recipient's actual body weight
45467471|NCT01328548|Drug|Zostavax|
45467472|NCT05108922|Drug|Donanemab|Administered IV
45467473|NCT05108922|Drug|Aducanumab|Administered IV
46018730|NCT01181271|Drug|Tacrolimus|Tacrolimus (FK506) will be given orally at a dose of 0.05 mg/kg orally (PO) twice a day (BID) starting day -3.
46018731|NCT01181271|Drug|Sirolimus|Sirolimus (rapamycin) will be given orally at a dose of 12 mg times one on day -3 and then the dose shall be 4 mg by mouth daily starting on day -2. The dose may then be adjusted according to serum levels at the discretion of the treating physician
46018732|NCT01181271|Drug|Methotrexate|Methotrexate will be administered once daily on days 1, 3, and 6 as an IV bolus over 15 minutes at a dose of 5 mg/m2
46018733|NCT00624741|Drug|Pergolide|Pergolide tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
46018734|NCT01180647|Drug|Extended-Release Naltrexone|380mg IM XR-NTX injection one week prior to release from jail; a second XR-NTX 380mg IM injection is offered 4 weeks later (monthly).
46018735|NCT01180647|Behavioral|Motivational Enhancement Counseling|The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
46018736|NCT02886663|Other|stimulation of the blind visual field|
46018737|NCT00969553|Drug|BI 6727|Dose level 1
46018738|NCT04285957|Other|Questionnaire administration pre test|"Pre-test:~Two expert physicians/physical therapist shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI);"
46102294|NCT04236635|Drug|Collagenase Clostridium Histolyticum Single Injection Technique|CCH was injected subcutaneously using a single injection technique. Dose per each administration was 0.07 mg.
46102295|NCT04236635|Drug|Collagenase Clostridium Histolyticum Multiple Injection Technique|CCH was injected subcutaneously using a multiple injection technique. Dose per each administration was 0.0653 mg.
46102296|NCT04138082|Other|Exposition to high-dB soundtrack|Already stated
46018739|NCT04285957|Other|Questionnaire administration - validation|Validation Two expert physicians shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI); In case the patient is unable to be interviewed due to aphasia cognitive or sensorial problems, a proxy would be interviewed both at T0 and at T1 (the same proxy would be interviewed both times)
46018740|NCT01179477|Device|Implantation of a QuickFlex® μ Model 1258T LV Lead|Implantation of a QuickFlex® μ Model 1258T LV Pacing Lead
46018741|NCT02863159|Device|Tecnis Multifocal 1-Piece IOL|+2.75D (ZKB00), +3.25D (ZKB00), +4.00D (ZMB00)
46018742|NCT03696043|Other|Axium Steatlh Image Guidance|The Axiem Stealth imaging guidance system uses a probe (AxiEM Registration Probe) and a side mount emitter (AxiEM Side Mount Emitter) to register the patient's head in relation to the probe. A trajectory (entry point and target) is then planned. This registration process takes an estimated 5-15 minutes to perform. A separate stylet (StealthStation EM Stylet) is designed specifically for the catheter and slides down the center of the catheter. A burr-hole is created at the predefined precise location and the catheter is passed to the target under electromagnetic guidance.
46018743|NCT03696043|Other|EVD placement|A sterile field is prepared about 10-12 centimeters posterior to the eye and about 2-3 cm lateral to the midline of the skull. An incision is made at this point and a burr hole is created using a hand drill. The catheter is advanced in a trajectory perpendicular to the skull, which results in a direction that is towards the ipsilateral medial canthus and ipsilateral tragus which are other landmarks that can be used.
46018744|NCT03692065|Drug|Apixaban 5 MG|Subjects will be randomized (1:1 ratio) to apixaban 5 mg bid (full dose) or apixaban 2.5 mg bid (reduced-dose) using a centralized IWRS (double blind study).
46018745|NCT01179399|Drug|TAK-960|TAK-960 administered orally once a day for 21-days of a 28-day treatment cycle. A 3 + 3 dose escalation scheme will be employed.
46018746|NCT01178853|Drug|Warfarin|Warfarin 5 mg once daily
46018747|NCT01178853|Drug|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
46018748|NCT01178853|Drug|Warfarin 5 mg + Pitavastatin 4mg once daily (QD)|Warfarin 5 mg + Pitavastatin 4mg
46018749|NCT02863393|Other|Diaphragmatic breathing exercise|Through diaphragmatic breathing exercise to verify the impact of this item interventions on patients' metabolism indicators.
46018750|NCT01178385|Behavioral|Cognitive-behavioral therapy|Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders. The BIACA intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
46018751|NCT01178385|Behavioral|Treatment as Usual|Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
46018752|NCT02863315|Device|tsDCS|"Both groups use the same DC-Stimulator Plus (NeuroConn GmbH, Ilmenaus, Germany).~In the tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 20 min, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system)~In sham tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 30s, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system). The current was discontinued after 30 s while the power indicator remained on."
46018753|NCT04286035|Drug|Bupivacaine Injection|Femoral nerve block with 20 ml %0.375 bupivacaine
46102297|NCT00621491|Drug|Warfarin|Single daily dose of Warfarin (5 mg/orally), adjusted to achieve an International Normalized Ratio (INR) between 2 to 3.5 times the normal value during six months
46102298|NCT00686660|Behavioral|cycling, walking|"In training period, patients do cycling on cycle ergometry. two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community. four days per week,18 weeks per non-training period, two non-training period per year, two years."
46102299|NCT00686660|Behavioral|cycling, non-walking|"In training period, patients do cycling. two times a week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't receive walk training."
46102300|NCT00686660|Behavioral|walking, walking|"In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community, four days per week, 18 weeks per non-training period, two non-training period per year, two years."
46102301|NCT00686660|Behavioral|walking, non-walking|"In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't walking at community."
46102302|NCT00622349|Drug|Cisplatin, Ifosfamide, Gemcitabine|Cisplatin 50 mg/m² day 1 Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
46018754|NCT04286035|Drug|Bupivacaine Injection|Adductor canal block with 20 ml %0.375 bupivacaine
46018755|NCT02865889|Procedure|Laparoscopy in Gynecologic Oncologic Indications|
46102303|NCT00622349|Drug|Ifosfamide, Gemcitabine|Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
45467474|NCT04415463|Device|Multisegmented fully covered self-expandable metal stent|Esophageal FC-SEMS
46018756|NCT02865889|Procedure|Conventional surgery (abdominal radical surgery)|
46102304|NCT00622349|Drug|Cisplatin, docetaxel|Cisplatin 50 mg/m² day 1 Docetaxel 75 mg/m² day 1 Cycles every 3 weeks
46102305|NCT00681434|Behavioral|bilateral upper extremity training|Bilateral symmetrical upper extremity training for proximal control for three hours per week for eight weeks.
46018757|NCT04286815|Device|Lentiviral Vector Gene Therapy|Lentiviral vector to transfer IL2RG complementary DNA to patients'bone marrow stem cells
46018758|NCT02865967|Other|Usual care + a-GPS|Clinicians will be provided a-GPS data on a regular basis for intervention group, but not control group such as their risk factors for asthma, quality of care, and asthma outcomes.
45467475|NCT03777241|Behavioral|Behavioral Intervention Team|Multidisciplinary team to assist with actively identifying and managing mental illness and substance abuse disorders at their earliest possible time during hospitalization.
46018759|NCT02865967|Other|Usual care|The subjects will be treat for their asthma by their physicians according to usual care.
46102306|NCT00681434|Behavioral|Unilateral upper extremity training|Unilateral upper extremity training for proximal extremity for three hours a week for eight weeks.
46102307|NCT00686816|Dietary Supplement|Low calorie diet|low calorie diet
46102308|NCT00686816|Dietary Supplement|Olestra|low calorie Olestra diet
46102309|NCT02625896|Behavioral|Intervention|Standard skydive from 4 000 m above mean sea level (AMSL) following standard safety recommendations and procedures including, if necessary, standard reserve parachute activation procedures. If necessary for safety, participants are asked to immediately leave the study at will. At 1 500 m AMSL, the participant is asked to begin to slow down the fall rate by increasing the body surface area to the relative wind. At no lower than 1 200 m AMSL, the participant is asked to deploy the main parachute. At main parachute deployment, while maintaining a stable body position with shoulders level to the horizon and unaltered heading, the participant is asked to increase the pitch angle of the long body axis attitude, raising the head, shoulders, and upper body up from the flat belly-to-relative-wind plane to a head-high body position, using any free fall technique the participant is comfortable with - as long as there is NO RISK for an unintentional backflip.
46102310|NCT02625038|Device|EUDAMED CIV-14-03-011940|
46102311|NCT05368181|Drug|Methylprednisolone|Methylprednisolone starts with the dose of 2 mg/kg for 5 days. If no signs of aGvHD, the dose of methylprednisolone is gradually taper with the following 16 days.
46102312|NCT02626676|Other|Educational Programme|Educational Programme consists of lectures and group dynamics about nutrition during hemodialysis sessions.
46018760|NCT04289857|Other|Neurodynamic training|Starting from a sitting position on a stretcher, with dorsolumbar flexion, it is required to maintain that posture throughout the exercise. Sliding with the straight leg sitting consists of performing alternate movements. First, knee extension and dorsal ankle flexion will be performed, increasing neural tension, combined with cervical extension (to decrease neural tension) in the first instance. Subsequently, knee flexion and plantar ankle flexion (decreasing neural tension) combined with cervical flexion (increasing neural tension) will be performed. The dosage of the technique will be: two seconds for each movement, with 10 repetitions of each one. All sessions will be led by one of the group's researchers.
46018761|NCT01288976|Device|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
46018762|NCT01288976|Drug|Medical Management|The Non-Surgical Medically Managed Heart Failure (HF) Group consists of patients with mitral regurgitation (MR) in whom the MR is managed non-surgically based on standard hospital clinical practice. Patients with MR who receive a pacemaker, Implantable Cardiac Defibrillator (ICD) and/or Cardiac Resynchronization Therapy (CRT) treatments may be included
46018763|NCT01288976|Procedure|Mitral Valve Surgery|The Mitral Valve Surgery Group consists of patients with MR in whom the MR is managed surgically (repair or replacement) based on standard hospital clinical practice. Patients with concurrent coronary artery bypass grafting (CABG) or aortic/tricuspid valve or and other cardiac procedure except atrial fibrillation surgery are excluded.
46018764|NCT05187169|Drug|VS-6766|Dual RAF/MEK inhibitor
46018765|NCT02863081|Other|Survey|Administered to healthcare providers
46018766|NCT02863081|Other|interview|Administered to patients and LAR (i.e., interviews)
46102313|NCT05662163|Procedure|TIVA|Anesthesia will be maintained with propofol (6-10 mg/kg/hour) and remifentanil (0.1-0.3 μg/kg/min).
46102314|NCT05662163|Procedure|GENERAL ANESTHESIA|Anesthesia will be maintained with sevoflurane (2 ml/min) 50% oxygen and remifentanil (0.1-0.3 μg/kg/min).
46102315|NCT02624960|Device|Accucinch Implant|Percutaneous implantation of the Accucinch Implant in the mitral subannular space
46102316|NCT02687633|Behavioral|JASPER|JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
46102317|NCT00687050|Dietary Supplement|peroral high-caloric supplemental nutrition|HIV-positive hemodialysis patients will be given daily supplemental nutrition (125 ml, 2 kcal/ml) on top of recommended high-protein, high-caloric regular diet
46102318|NCT00687050|Dietary Supplement|peroral supplemental nutrition|Chronic hemodialysis patients will be given daily peroral supplemental nutrition (125 ml/d, 2 kcal/ml) on top of their recommended high-protein, high caloric diet
46102319|NCT05367947|Behavioral|In-phase Bilateral Exercises of the upper limbs|"The intervention protocol consists of in-phase bilateral exercises for the upper limbs, which are adapted to different sport activities and to fitness functional exercises, organized in a circuit training. Specifically, each session will consist of 1-3 sets, consisting of 10-15 repetitions of 9 different exercises targeting large muscle groups of the upper limbs.~The specific exercises will include sports activities of basic technical skills of basketball (e.g., different types of passing, catching and throwing the ball) and volleyball (e.g., different types of passing and receiving the ball), whereas the fitness exercises will include shoulder rows, shoulder lateral raises, elbow flexions, elbow extensions, using resistance elastic bands, as well as exercises with the patients' own body weight (e.g., pushups, TRX).~The intervention phase for each participant will consist of 12 consecutive weeks, for 3 times per week, 30-60 minutes each session."
46102320|NCT00681512|Dietary Supplement|berry powder|"All subjects (lung cancer survivors and volunteers) will consume 20 grams of berry powder (blueberries, black raspberries, or a mixture of both) per day by mouth for the first 3 days, then 40 grams of berry powder by mouth every day for 4 to 5 weeks.~The berry powder is to be mixed in subject's routine intake of milk, yogurt, juice, or water.~All subjects will have the option to continue the berry regimen for an extended period. Subjects who choose to do so will not consume any berry powder for one week. After one week, subjects will begin consuming 40 grams of the berry powder every day for an additional 4 to 5 weeks."
46102321|NCT00639041|Dietary Supplement|n-3 LC-PUFA|n-3 LC-PUFA supplemented dairy products (yoghurt, cheese, butter): 3.3 g n-3 FA/d
46102322|NCT00639041|Dietary Supplement|Placebo|dairy products without special oils
45467476|NCT03777241|Behavioral|Standard of care|Participants in this group will receive standard of care.
45838051|NCT04980612|Behavioral|Mindfulness Based Pain Reduction|40 participants will participate in a MBPR program. It will be an optimized mindfulness program specifically designed for treating cLBP that we will develop and test in this project. The format is the same as MBSR: 8 weeks of weekly 2½-hour group sessions and a daylong retreat.
46018767|NCT02862925|Procedure|Fetal Scalp Stimulation|"During a routine vaginal exam, if there is concern for fetal distress based on local definitions, the midwife will gently stroke the fetal head with her finger. She will then observe for a rise in the fetal heart rate as observed by the Doppler monitor. A rise to above 15 beats per minute above the baseline is termed an acceleration and NEGATIVE test. Absence of an acceleration is a POSITIVE test and reason for intervention."
46018768|NCT00629473|Drug|NPI-0052 on Days 1, 8, 15 every 28 days|NPI-0052 dose ranging from 0.1 to 0.9 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 8, and 15 of 4-week cycles
46018769|NCT00629473|Drug|NPI-0052 on Days 1, 4, 8, 11 every 21 days|NPI-0052 dose ranging from 0.075 to 0.6 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 4, 8, and 11 of 3-week cycles
46018770|NCT00629473|Drug|Dexamethasone|20 mg oral or IV day before and day after NPI-0052 dosing.
45467477|NCT05039229|Other|Nozzles (NZ)|Technical intervention targeting alteration of nozzles or nozzle function along the production line, e.g. by manipulation of nozzle dimensions, alteration of operating pressure or shielding of the nozzle's output stream. How the intervention is to be carried out in detail in the respective factory is to be developed in collaboration with the factory staff. This can include local specific characteristics, specific location of intervention or others.
46102323|NCT00687128|Behavioral|Low-intensity treadmill exercise|Treadmill walking at 30% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
46102324|NCT00687128|Behavioral|Moderate-intensity treadmill exercise|Treadmill walking at 60% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
45467478|NCT05039229|Other|Cleaning of surfaces (CS)|Behavioural or technical intervention. This can include increased use of swabbing instead of flushing with water hoses or alterations in use of water hoses for cleaning. Examples for the latter are a reduced flushing frequency, reduction of number of employees executing the work, alterations of hose dimension or nozzles on hoses. How the intervention is to be carried out in detail in the respective factory is to be developed in collaboration with the factory staff. This can include local specific characteristics, specific location of intervention or others.
45467479|NCT05675202|Drug|TQ-B3525|TQ-B3525 is a new PI3K α/δ Kinase inhibitor
45838052|NCT04980612|Behavioral|Mindfulness Based Stress Reduction|10 participants will participate in MBSR program. MBSR is a standardized and manualized 8-week program, delivered once a week in 2½-hour group sessions and a daylong retreat. It trains individuals in several mindfulness practices, e.g. focus on breath, varying degrees and directions of object orientation, open monitoring of awareness of intero- and exteroceptive stimuli and thoughts, de-reification (i.e. the notion that thoughts and perceptions are not always true to reality), and meta-awareness (i.e., awareness of thinking) in addition to focused attention.The program typically includes audio-recordings and a workbook for home practice and has shown benefits in patients with cLBP.
46018771|NCT04286503|Drug|Carrimycin|Carrimycin
45467480|NCT04453306|Drug|Topiramate|topiramate 25mg is coated in tablets in an independent laboratory
45467481|NCT04453306|Drug|Placebo|innocuous substance is coated in tablets in an independent laboratory
45467482|NCT03777163|Biological|Butantan Institute Trivalent Seasonal Influenza Vaccine|Butantan Institute and Pasteur-Mérieux (present, Sanofi Pasteur) established a technology transfer in 1999 for the production of a trivalent influenza vaccine of inactivated split-virion using embryonated eggs. The technology transfer followed a progressive approach from importing the finished product, to packaging and quality control test for release (1999), and, finally, to the first batch of influenza vaccine entirely produced by Butantan (2011). In 2013, the Butantan vaccine was registered by the Brazilian National Agency of Sanitary Surveillance (ANVISA).
45467483|NCT03777163|Biological|Sanofi Trivalent Seasonal Influenza Vaccine|VAXIGRIP® was launched in 1968 and since then has been licensed in more than 100 countries and prequalified by WHO in 2011. Several clinical studies by Sanofi Pasteur have examined the safety and immunogenicity of Vaxigrip® in older children (8-10 years), adults (18-59 years), elderly (> 60 years),11,12 children (six months to three years) 13 and pregnant women.
45467484|NCT05682456|Dietary Supplement|High-fat shake|The high-fat shake consisted of 53% (w/v) fresh cream, 3% (w/v) sugar and 44% (w/v) water
46018772|NCT04286503|Drug|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate
46018773|NCT04286503|Drug|basic treatment|basic treatment
46018774|NCT03792841|Drug|acapatamab|Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer
46018775|NCT03792841|Drug|Pembrolizumab|Combined with acapatamab for investigational treatment of mCRPC
46018776|NCT03792841|Drug|Etanercept|Prophylaxis for acapatamab-related cytokine release syndrome.
46018777|NCT03792841|Drug|Cytochrome P450 (CYP) Cocktail|Evaluate the effect of co-administration of multiple dosing of acapatamab on plasma
46018778|NCT00970489|Drug|Omega -3 fatty acids|10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.
46018779|NCT00970489|Drug|Placebo|Olive Oil capsules
46018780|NCT00968617|Drug|MK2578|MK2578 1.0 mcg/kg/month
46018781|NCT00968617|Drug|MK2578|MK2578 2.0 mcg/kg/month
46018782|NCT00968617|Drug|MK2578|MK2578 3.6 mcg/kg/month
46018783|NCT00968617|Drug|Comparator: darbepoetin alfa|darbepoetin alfa
46102325|NCT00687128|Behavioral|Non-aerobic stretching exercise|Floor stretching exercise, 3-5 times per week at 20-60 minutes duration per session, progressive.
46102326|NCT00692042|Drug|AZD1704|One dose, by mouth
46102327|NCT02666105|Drug|Exemestane|One 25 mg tablet once daily for a minimum of 6 weeks
46102328|NCT04138238|Device|Supraflex Cruz Sirolimus-eluting Stent|Patient implanted with at least one Supraflex Cruz sirolimus-eluting stent as a part of planned clinical care
46102329|NCT00622817|Drug|xylometazoline HCL 0.05%|Receive four inhalation of 0.9% saline four times a day and one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day.
46102330|NCT00622817|Drug|Epinephrine 1mg|Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
46018784|NCT00968539|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections
46018785|NCT00968539|Biological|GSK investigational vaccine GSK2340269A|Two intramuscular injections
46018786|NCT00976573|Biological|bevacizumab|Given IV
46018787|NCT00976573|Drug|carboplatin|Given IV
46018788|NCT00976573|Drug|everolimus|Given orally
46102331|NCT04146740|Other|Structured Exercise for Experimental (Structured Exercise) Group|"Structured aerobic exercise regime of moderate intensity by using stationary cycle (3-5 MET) 10 min, brisk walk 10 min.~The combination of Stabilization exercise (10 repeatitions) and PFM training ( 20 repeatitions set).~Relaxation therapy including Mitchells physiological relaxation technique (10 repetitions) along with deep breathing exercises."
46102332|NCT04146740|Behavioral|Control treatment for both groups|Medical and dietary interventions like insulin in addition of the postural education and back care from Physical Therapist.
46018789|NCT00976573|Drug|paclitaxel|Given IV
46018790|NCT04204993|Device|Lumee Oxygen Platform|Two sensors will be inserted (one in the skin fo the upper arm and one on the side of the chest). A wireless patch reader is placed on top of the skin over the area where the sensor has been placed to measure local oxygen content.
46018791|NCT03661723|Drug|Pembrolizumab|Pembrolizumab is a drug (an antibody) that may treat cancer by working with the immune system
46102333|NCT04033913|Other|Self questionnaire|Patients who have successfully perform self-catheterization complete a self questionnaire on the importance of each criterion in choosing the catheter they have made.
46102334|NCT04137926|Diagnostic Test|MicRNAs battery|for MCI due to AD diagnosis
46018792|NCT03661723|Drug|Bevacizumab|"Bevacizumab (also known as Avastin) is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels."
46102335|NCT02432417|Drug|Chloroquine|CQ will start with one week before the start of radiotherapy and end on the last day of radiotherapy.
46102336|NCT00692120|Dietary Supplement|Cholecalciferol (vitamin D3)|50,000 IU once monthly for 12 months
46102337|NCT00692120|Dietary Supplement|Ergocalciferol (vitamin D2)|oral capsule 50,000 IU once monthly for 12 months
46102338|NCT00692120|Dietary Supplement|Ergocalciferol (vitamin D2)|oral capsule 1600 IU once daily for 12 months
46102339|NCT00692120|Dietary Supplement|Cholecalciferol (vitamin D3)|oral capsule 1600 IU once daily for 12 months
46102340|NCT00692120|Dietary Supplement|Placebo|oral placebo capsule once daily for 12 months
46102341|NCT02429609|Device|Moorfields Acuity Chart|
46102342|NCT04137848|Procedure|Osteopathic Manipulative Treatment (OMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|OMT: 4-week manual therapeutic program with a weekly session of osteopathic examination and manipulation of somatic disfunctions in ambulatory setting. MIRT: 4-week physical therapy with 4 daily sessions (1 hour each), 5days/week, in a hospital setting. The first session comprises cardiovascular warm-up activities, relaxation, muscle stretching, exercises to improve the range of motion of different joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes exercises to improve balance and gait using stabilometric platform,treadmill plus, crossover and cycloergometer. The third and fourth pertain occupational and speech therapy.
46102343|NCT04137848|Procedure|Sham Osteopathic Manipulative Treatment (SOMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|"SOMT: 4-week of sham osteopathic therapeutic program with a weekly session of osteopathic examination and manipulation in ambulatory setting.~MIRT: 4-week physical therapy with 4 daily sessions (1 hour each), 5days/week, in a hospital setting. The first session comprises cardiovascular warm-up activities, relaxation, muscle stretching, exercises to improve the range of motion of different joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes exercises to improve balance and gait using stabilometric platform,treadmill plus, crossover and cycloergometer. The third and fourth pertain occupational and speech therapy."
46102344|NCT00819585|Drug|Canakinumab|Canakinumab was supplied in glass vials as a lyophilized powder.
46102345|NCT00819585|Drug|Colchicine|0.5 mg capsule orally once daily for 16 weeks.
45467485|NCT05682456|Dietary Supplement|Reference shake|The reference shake consisted of 43% (w/v) full cream milk, 48% (w/v) full cream yoghurt, 4% (w/v) lemonade, 4% (w/v) fantomalt (Nutricia B.V., the Netherlands) and 1% (w/v) wheat fiber
46018793|NCT03661723|Radiation|Re-irradiation|Radiotherapy destroys cancer cells using radiation aimed at a cancer from a machine
46018794|NCT00629863|Drug|cisplatin|
46018795|NCT00629863|Drug|fluorouracil|
46018796|NCT00629863|Other|questionnaire administration|
46018797|NCT00629863|Procedure|diagnostic endoscopic procedure|
46018798|NCT00629863|Procedure|neoadjuvant therapy|
46018799|NCT00629863|Procedure|quality-of-life assessment|
46018800|NCT00629863|Procedure|therapeutic conventional surgery|
46018801|NCT00629863|Procedure|therapeutic endoscopic surgery|
46018802|NCT00629863|Procedure|ultrasound imaging|
46018803|NCT00629863|Radiation|radiation therapy|
46018804|NCT00629863|Radiation|radioisotope therapy|
46018805|NCT02865733|Drug|Remodulin|After Fontan operation, the mean pulmonary arterial pressure (mPAP)evaluated by CVP or transpulmonary pressure gradient(TPG) evaluated by Echo will be measured firstly, if the data met the criteria, and the patients were enrolled in the experimental group, the patients would be administrated intravenously of Remodulin® with the beginning of 5ng/kg/min, with the rate of 10ng/kg/min every 30 minutes up to 80ng/kg/min.
46018806|NCT02865733|Drug|distilled water|After Fontan operation, the mPAP (evaluated by CVP) or TPG (evaluated by Echo) will be measured firstly, if the data met the criteria, and the patients were enrolled in placebo group, then the patients would be administrated intravenously of distilled water with the beginning of 0.15ml/hr, with the rate of 0.3ml/hr every 30 minutes up to 2.45ml/hr.
46018807|NCT00976495|Drug|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 12 weeks
46018808|NCT00976495|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
46018809|NCT00976495|Drug|Hydrochlorothiazide|Tablets, Oral, 25 mg, once daily, 12 weeks
46018810|NCT00630019|Drug|1.5% levofloxacin ophthalmic solution|Topical application
45467486|NCT04411082|Drug|IMR-687|Oral administration of once daily IMR-687
45467487|NCT04411082|Drug|Placebo|Oral administration of once daily Placebo
46018811|NCT00630019|Drug|0.5% moxifloxacin hydrochloride ophthalmic solution|Topical application
46018812|NCT01288430|Drug|DS-2248|Oral capsules, of various strengths (1, 5 , 20 ,or 50 milligrams), once daily during 21-day cycles, until unacceptable treatment-related toxicity or tumor progression are observed.
46102346|NCT00819585|Drug|Allopurinol|100-300 mg orally once daily for 24 weeks.
46102347|NCT00819585|Drug|Placebo Matching Canakinumab|Subcutaneous injection.
46102348|NCT00819585|Drug|Placebo Matching Colchicine|Capsule orally once daily for 16 weeks.
46102349|NCT00687206|Drug|Valsartan 160mg plus HCT 25mg|valsartan 160 mg once a day for 6 months plus hydrochlorothiazide 25 mg a tablet once a day for 6 months
46102350|NCT00687284|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46102351|NCT02358395|Drug|BBI608|Administered continuously twice daily with doses separated by 9-15 hours.
46102352|NCT02358395|Drug|Sorafenib|Sorafenib 400 mg twice daily (800 mg total daily dose).
46102353|NCT00508261|Biological|Meningococcal vaccine GSK134612|Single dose intramuscular injection
46102354|NCT00508261|Biological|Infanrix™ hexa|Single dose intramuscular injection
46102355|NCT00508261|Biological|Meningitec™|Single dose intramuscular injection
46102356|NCT04146350|Procedure|PPV+/-Cat|pars plana vitrectomy+/-cataract
46102357|NCT04146350|Procedure|PPV+/-Cat+Gas|pars plana vitrectomy+/-cataract+gas tamponade
46102358|NCT04146350|Procedure|PPV+ILM+/-Cat+/-Gas|pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-gas tamponade
46102359|NCT04146350|Procedure|PPV+ILM+/-Cat+/-Oil|pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade
46102360|NCT04146350|Procedure|PSR|posterior scleral reinforcement
46018813|NCT02889848|Other|Saline|Saline injection
46018814|NCT02889848|Drug|EN3835|Comparison of maximum marketed dose and multiple doses EN3835
46018815|NCT01287416|Behavioral|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training (ASIST) is a 2-day, 14 hour suicide intervention skills training workshop.
46018816|NCT01287416|Behavioral|Resilience Retreat|The Resilience Retreat is a 2-day, 14 hour session
46018817|NCT05660252|Other|Collaborative request|The relative is approached by the clinical team and an organ procurement coordinator together.
46102361|NCT04146350|Procedure|PSR+ PPV+ILM+/-Cat+/-Oil （or Gas）|posterior scleral reinforcement+pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade (or gas)
46102362|NCT04146350|Procedure|Gas|gas tamponade alone
46102363|NCT00692354|Drug|CHR-2797 (tosedostat)|Drug was given orally, once daily, ensuring a dosing interval of approximately 24 hours. Dose escalations took place starting at 10mg and escalating (per protocol) as follows: 20, 40, 90, 130, 180, 240 and 320 mg
46102364|NCT03928847|Drug|Epigallocatechin-3-gallate (EGCG)|Epigallocatechin-3-gallate (EGCG) capsules
46102365|NCT02624726|Drug|5 Fluorouracil|5 Fluorouracil: 400mg/m2, bolus infusion in <5min followed by 5 Fluorouracil: 2400mg/m2, i.v in 46 hours continuous infusion (cycle repeated every two weeks)
46102366|NCT02624726|Drug|Leucovorin|Leucovorin: 400mg/m2, i.v in 2 hours infusion (cycle repeated every two weeks)
45467488|NCT05667714|Drug|SA58 Nasal Spray|SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
46018818|NCT05659394|Other|Standard Wound Care Alone|gold standard compression therapy
46018819|NCT05659394|Device|Stand Wound Care plus IPC|gold standard compression therapy plus IPC (WoundExpress)
46018820|NCT00998296|Drug|BIBW 2992|EGFR inhibitor
46102367|NCT02624726|Drug|Irinotecan|Irinotecan: 180mg/m2, i.v in 90min infusion (cycle repeated every two weeks)
46102368|NCT02624726|Drug|Aflibercept|Aflibercept: 4mg/kg i.v in 1 hour infusion (cycle repeated every two weeks)
46102369|NCT02687555|Behavioral|Cognitive Bias Modification of Appraisals (CBM-App)|
46102370|NCT02687555|Behavioral|Peripheral Vision Task (control condition)|
45467489|NCT05667714|Drug|Placebo|Placebo was provided by Sinovac Life Sciences Co. , Ltd.
46018821|NCT00998296|Drug|BIBF 1120|VEGF inhibitor
46018822|NCT01178073|Drug|ambrisentan|ambrisentan (target dose: 10mg)
46018823|NCT01178073|Drug|tadalafil|tadalafil (target dose: 40mg)
46018824|NCT00997984|Drug|extended-release guanfacine hydrochloride (SPD503)|dosed in AM
46018825|NCT00997984|Drug|placebo|dosed in the AM or PM
46018826|NCT00997984|Drug|extended-release guanfacine hydrochloride|Dosed in the PM
46018827|NCT04206111|Procedure|Preoxygenation|preoxygenation with high flow nasal cannula at 40l/min for 5min
46018828|NCT01177293|Drug|Amlodipine - reference|Amlodipine capsule, 10 mg, single dose, with water
46102371|NCT00681746|Drug|AZD6280|Single dose of oral solution or capsule(s). 3 times for the 2 subjects in Panel 1. Once for the 6 remaining subjects.
46102372|NCT00681746|Drug|(11C) flumazenil|Single dose of intravenous solution. 4 times for 2 subjects in Panel 1. 2 times for the remaining 6 subjects. (once together with AZD6280)
46102373|NCT02687399|Other|placebo|After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the placebo group will receive placebo for inyection sprayed on the exposed tissues of the knee.
46102374|NCT02687399|Biological|TT-173|After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the treatment group will receive TT-173 for inyection sprayed on the exposed tissues of the knee.
46102375|NCT02624882|Procedure|Positive rapid GAS test|"If TDR positive, the child will be treated with antibiotics alone:~Amoxicillin 50mg / kg / day in 2 divided doses for 10 days (maximum dose 3 g / day in 2 divided doses) Or if allergic to penicillins and in the absence of cross-known allergy to cephalosporins~Cefpodoxime 8mg / kg / day in 2 divided doses for 10 days (maximum dose 400mg / day in 2 divided doses) J10 A control visit will review all the children included in the study. If the surgeon deems it necessary, the patient will be reviewed in consultation up to three months."
46102376|NCT02624882|Procedure|Negative rapid GAS test|Usual care
46102377|NCT04265911|Biological|ASP3772 (subcutaneous)|Subcutaneous injection
46102378|NCT04265911|Biological|ASP3772 (intramuscular)|Intramuscular injection
46102379|NCT04265911|Biological|PPSV23 (subcutaneous)|Subcutaneous injection
46018829|NCT01177293|Drug|Amlodipine ODT - test|Amlodipine orally disintegrating tablet (ODT), 10 mg, single dose, without water
46102380|NCT04265911|Biological|PPSV23 (intramuscular)|Intramuscular injection
46018830|NCT04435288|Drug|week 24|"At the week 24 timepoint, there are 3 possible scenario's:~In patients that do not reach a state of clinical remission at week 24, blinded study medication will be interrupted and all patients will start open-label SC golimumab for an additional 36 weeks (up to max. week 60).~In patients that achieve sustained clinical remission at week 24, defined as absence of clinical arthritis, enthesitis and dactylitis at both week 12 and week 24, all study medication will be discontinued and prospective follow-up will be planned in SPARTACUS Phase B.~In patients that reach a state of clinical remission at week 24, but that did not yet reach this status at week 12, blinded study medication will be continued without any change in the treatment schedule for another 12 weeks."
46018831|NCT04435288|Drug|week 36|"At week 36, patients that have continued the blinded study medication, will be re-assessed regarding sustained clinical remission (at week 24 and 36): if yes, all study medication will again be discontinued and prospective follow-up will be planned in SPARTACUS Phase B. If no, these patients will start open-label SC golimumab for an additional 24 weeks (up to max. week 60).~If patients were in the open-label golimumab treatment arm, effectiveness of the treatment will be assessed by using the PASSI-question. Inadequate responders will be discontinued from the study and will be treated with standard-of-care medication at the discretion of their treating rheumatologist, whereas patients with an acceptable improvement in signs and symptoms will continue with the same (open-label) medication schedule."
46018832|NCT04435288|Drug|Week 48|"At week 48, all patients still remaining in SPARTACUS Phase A will have been treated with open-label golimumab (for a minimum of 12 weeks, but potentially up to 48 weeks). In patients reaching at this timepoint sustained clinical remission (at week 36 and 48), golimumab will be discontinued and prospective follow-up will be planned in SPARTACUS Phase B. For the other patients there are 3 possible scenarios:~If clinical remission for the first time at week 48, continuation without any change in the treatment schedule for another 12 weeks.~If an inadequate response (based on the PASSI-question), discontinuation from the study and standard-of-care medication~If an acceptable improvement (but no clinical remission), continuation open-label golimumab for an additional 12 weeks, with open-label methotrexate (unless contra-indicated) to fulfil Belgian reimbursement criteria for TNFi."
46102381|NCT02687477|Procedure|Pulmonary Arterial Denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
46102382|NCT02687477|Procedure|Sham procedure|patient in the sham group will receive sham procedure
46102383|NCT00819039|Drug|Aprepitant|Aprepitant administered orally or intraveously.
46102384|NCT00819039|Drug|Ondansetron|Ondansetron administered intravenously.
46102385|NCT04187261|Procedure|hip fracture surgeries|fixation or replacement
46102386|NCT00692510|Drug|AZD3480|Capsule, oral, dose once daily, 7 days
46102387|NCT00692510|Drug|Placebo|Capsule, oral, dose once daily, 7 days
46018833|NCT04435288|Drug|Week 60|At week 60 (final study visit of SPARTACUS Phase A), patients reaching sustained clinical remission (at week 48 and 60), will roll-over into SPARTACUS Phase B. All other patients will be discontinued and will be treated with standard-of-care medication (including TNFi, if in accordance with Belgian reimbursement criteria).
46018834|NCT01177137|Device|Conventional sound generator (SG)|Conventional SGs: Tranquil model sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate low-level noise, which is set at or just below the patient's mixing point (i.e., the noise level that just blends with the study participant's tinnitus)
46018835|NCT01177137|Device|Placebo sound generator (placebo SG)|Tranquil model placebo sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate a sound different from the active devices.
46102388|NCT00692510|Drug|Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)|"Cocktail mix which contains the following:~CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin)~single dose of mix"
46102389|NCT02687321|Other|Determination of CA 125 and HE4, Computed tomography|Blood sample collection to determinate tumor marker found in blood elevated by the presence of cancer recurrence.In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
46102390|NCT05758623|Device|Device|The experimental group was treated with magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd. Control group application β- Tricalcium phosphate bioceramics for treatment.
46102391|NCT00500539|Drug|omalizumab|The liquid formulation of omalizumab was packaged in a pre-filled safety syringe containing either 75 mg (0.5ml) or 150 mg (1.0 ml) of drug. The syringes were clearly marked so that the health care provider could differentiate between the 75 mg or 150 mg syringe.
46102392|NCT00687518|Drug|Erythropoietin|Intravenous injection of 50 U/kg of erythropoietin
46102393|NCT00687518|Drug|Placebo|Intravenous injection of equivalent volume of saline serum
46102394|NCT02303795|Drug|Rivaroxaban|Patients assigned to rivaroxaban will receive oral rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
46102395|NCT02303795|Drug|Warfarin|"Patients will take the warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0.~Patients with 65 > years old, should take warfarin (2,5mg/day) and all others patients should take 5mg/day."
46102396|NCT04139408|Device|Disposable Pulmonary Surgical Marker|The subjects will undergo Marker placement procedure, within 24h before VATS.
46102397|NCT04187417|Drug|topical tetracaine hydrochloride 1%|topical ophthalmologic anesthestic
46102398|NCT04187417|Drug|Placebo|Placebo
46102399|NCT01010815|Procedure|Colonoscopy biopsy|Colonoscopy biopsy will be performed in rectum, ascending and descending colon at study entry
46018836|NCT01177137|Behavioral|Standard of Care (SC)|The standard of care treatment will be similar to that typically provided to patients with severe tinnitus at participating military medical centers and as described in the American Speech-Language-Hearing Association (ASHA) Preferred Practice Patterns in Audiology (ASHA, 2006). Tinnitus management will be based on the patient's complaints, history, audiologic evaluation, and self-assessment. The goal of the tinnitus management is to reduce negative cognitive, affective, physical, and behavioral reactions to tinnitus and to improve the patient's well-being and quality of life. Specific treatment recommendations will be individualized to reflect the participant's concerns and abilities, as well as his or her engagement in the decision-making process regarding treatment options.
46018837|NCT01177137|Behavioral|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
46018838|NCT01177137|Behavioral|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
46018839|NCT02886429|Drug|Bupivacaine|Ultrasound guided paravertebral block with bupivacaine
45467490|NCT01307917|Dietary Supplement|flavonoids|for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.
46018840|NCT02886429|Drug|Dexmedetomidine|Ultrasound guided paravertebral block with dexmedetomidine
46018841|NCT01177059|Genetic|OZ1 transduced cells|Long term follow up of previously infused OZ1 transduced cells
46018842|NCT04315779|Procedure|Salpingectomy|Patients will undergo removal of the affected tube
46018843|NCT01176513|Drug|GE-148 (18F)|All subjects will receive an i.v. dose of GE-148 (18F) Injection at 10 mCi (370 MBq) to provide adequate image quality throughout the specified imaging period.
46102400|NCT01010815|Other|stool collection|Stool will be collected from participants at study entry
46018844|NCT01299389|Drug|Paliperidone palmitate|Paliperidone palmitate will be given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
46102401|NCT01010815|Procedure|colonoscopy biopsy|colonoscopy biopsy will be conducted in rectum, ascending and descending colon from participants 2 times during study - at active phase and inactive phase
46102402|NCT01010815|Other|stool collection|stool will be collected from participants 2 times during study - at active phase and inactive phase
46102403|NCT01016431|Other|Rate-adaptive pacemaker programming|The ICD will be programmed in a AAI-R mode, with peak atrial stimulation rate set at 85% of maximal predicted heart rate, and ongoing protection VVI backup at 40 bpm
45467491|NCT05060679|Other|Supportive therapy at the ICU|Non-septic ICU patients received adequate supportive treatment (fluid resuscitation, respiratory, anticoagulation, antimicrobial and vasopressor therapy along with sedation, ulcer prophylaxis and nutrition. Blood sampling for non-septic patients were the first (T1) and third (T3) postoperative morning at the ICU. Besides, 23 healthy outpatients were documented without sepsis or sepsis-related organ dysfuntion as a control group.
45467492|NCT05060679|Other|Sepsis therapy|Patients receiving sepsis therapy followed the international guidelines of the 2016 Surviving Sepsis Campaign (SSC) regarding respiratory, antimicrobial, anticoagulation, vasopressor and hydrocortisone therapy, along with adequate fluid resuscitation, sedation, ulcer prophylaxis and nutrition. Blood samples were collected at the ICU from this patient group at three time points (T1-3): T1: within 12 hours after admission; T2: second day morning; T3: third day morning of follow-up.
46102404|NCT01016431|Other|VVI at 40 bpm|ICDs will be programmed in VVI mode at 40 bpm
46102405|NCT00818883|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of chlorthalidone will be increased for the remaining 4 weeks of treatment."
46102406|NCT00818883|Drug|Azilsartan medoxomil and hydrochlorothiazide|"Azilsartan medoxomil 40 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of hydrochlorothiazide will be increased for the remaining 4 weeks of treatment."
46102407|NCT04049708|Other|Reliability of physical function|Test-retest reliability of physical function in hemodialysis patients
46102408|NCT01014481|Drug|tenofovir, lamivudine, efavirenz|initiate tenofovir 300 mg/day, lamivudine 300 mg/day, efavirenz 600 mg/day between at 4 weeks and at 12 weeks after tuberculosis treatment
46102409|NCT02167763|Device|VeraCept Intrauterine Copper Contraceptive|
46102410|NCT02167763|Device|TCu380 IUD|
45467493|NCT05060679|Other|Sepsis-related organ dysfunction therapy|Patient management of sepsis and sepsis-related organ dysfunction followed the international guidelines of the 2016 Surviving Sepsis Campaign (SSC) regarding respiratory, antimicrobial, anticoagulation, vasopressor and hydrocortisone therapy, along with adequate fluid resuscitation, sedation, ulcer prophylaxis, nutrition and renal replacement therapy (if needed). In this patient group, blood sampling was performed at three time points (T1-3): T1: within 12 hours after admission; T2: second day morning; T3: third day morning of follow-up.
46102411|NCT02624648|Behavioral|The Female Sexual Function Index (FSFI)|The Female Sexual Function Index (FSFI) Questionnaire to evaluate the sexual function
46102412|NCT02624648|Behavioral|The Female Intervention Efficacy Index (FIEI)|The Female Intervention Efficacy Index Questionnaire (FIEI) to evaluate the sexual function
46102413|NCT02624648|Behavioral|The Beck Depression Inventory II|The Beck Depression Inventory II will be used to evaluate or ward off depression
46018845|NCT01299389|Drug|Placebo|Matching Placebo will be given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
46018846|NCT02886351|Drug|Nitrous Oxide|Nitrous Oxide at 60%-70% concentration administrated by mask, to achieve cooperation in Pediatric dentisry
46102414|NCT02624648|Drug|Lepidium Meyenii Walp|They will receive a capsule of Lepidium Meyenii Walp twice a day for 120 days
46102415|NCT02624648|Drug|Placebo|They will receive a capsule of Placebo twice a day for 120 days
46102416|NCT00508027|Drug|Simvastatin|Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.
46102417|NCT02626598|Device|Blended Belotero|Belotero blended with 0.1 cc of 1% lidocaine with epinephrine per 1.0 cc Belotero will be injected to etched in fine facial lines
46102418|NCT01986101|Drug|Placebo|Placebo comparator
46018847|NCT02890667|Other|Incident cancer|The number of incident cancer cases
46018848|NCT01298999|Drug|YF476|25 mg: one capsule to be taken by mouth once daily for 12 weeks.
46018849|NCT01298999|Drug|Placebo|Matching placebo: one capsule to be taken by mouth once daily for 12 weeks.
46018850|NCT04324541|Diagnostic Test|PET scan of the brain with Flortaucipir|PET scan of the brain with non FDA approved Radio tracer.
46018851|NCT01007032|Biological|Cixutumumab|Cixutumumab intravenously
46102419|NCT01986101|Drug|SM-13496|SM-13496 20mg for Days 1-7 and beginning Day 8 flexibly dosed 20-60 mg/day for Weeks 2-6
46102420|NCT01986101|Drug|SM-13496|SM-13496 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6, 80 mg/day on Day 7 and beginning Day 8 flexibly dosed 80-120 mg/day for Weeks 2-6
46102421|NCT00500149|Drug|Vyvanse (lisdexamfetamine dimesylate)|Following completion of the open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day).
46018852|NCT00976027|Biological|Trivalent inactivated influenza vaccine High Dose|0.5 mL, Intramuscular
45467494|NCT03786289|Biological|Recombinant human serum albumin/erythropoietin fusion protein|Recombinant human serum protein/erythropoietin fusion protein 150μg-1200μg single subcutaneous injection at Day1
46018853|NCT00976027|Biological|Trivalent inactivated influenza vaccine|0.5 mL, Intramuscular
46018854|NCT01298765|Drug|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
46018855|NCT04296214|Drug|5-azacitidine|Cycles of 28 days
46018856|NCT04296370|Drug|Fluzoparib; Apatinib|Fluzoparib Orally twice daily; Apatinib Orally once daily
46102422|NCT00500149|Drug|Placebo|Placebo
46102423|NCT04139330|Drug|NPC-06|Infuse NPC-06 intravenously
46102424|NCT04145180|Other|Manual therapy|40 minutes of physiotherapy, based on manual therapy sessions over 6 weeks. Three times a week.
46102425|NCT04185779|Diagnostic Test|Colonoscopy|Diagnostic colonoscopy
46102426|NCT03997591|Other|Ready2E.A.T. PROGRAM|"Training tasks based on:~reaching activities during attention tasks, memory tasks, sequential tasks This group was assessed at T0 and then after 6 weeks of conventional therapy."
46102427|NCT00681902|Drug|Lidocaine|Jet lidocaine compared to jet placebo before needle insertion
46102428|NCT00681902|Drug|Placebo|Jet saline
46102429|NCT04185857|Drug|canrenone 50-100 mg orally once a day|After two biochemical and clinical evaluations under baseline conditions and after pharmacological washout from diuretics, betablockers, ARBs or ACEI (about 4 weeks) and MRAs (abut 6 weeks), PA patients will be treated with canrenone 50-100 mg orally once a day. After 1 or 2 weeks the dose will be doubled if necessary to control BP and serum potassium.
46102430|NCT04185857|Drug|olmesartan 10-20 mg orally once a day|"After one month of treatment with canrenone the patients will undergo a clinical and biochemical evaluation (FW1) in a manner identical to the two basal evaluations. After, they will continue with a combination therapy with canrenone, at the dose reached, plus olmesartan starting with 10 mg a day for oral administration, a dose that could be doubled, if necessary, to achieve normotension.~At the end of the second month of the double therapy, patients will undergo a biochemical re-evaluation at the Center of Hypertension (FW2) with methods identical to those performed in the two baseline evaluations and after one month of canrenone."
45467495|NCT03786289|Biological|Recombinant erythropoietin injection (CHO cells)|Recombinant erythropoietin injection (CHO cells) 10000IU single subcutaneous injection at Day1
45467496|NCT05059509|Biological|FB825|FB825, 5mg/kg, by 1 hour IV infusion on Day 1
45467497|NCT04886596|Biological|RSVPreF3 OA Lot 1|Lot 1 of the RSVPreF3 OA vaccine administered intramuscularly into the deltoid of the non-dominant arm at day 1 to the RSVPreF3_L1 Group (Part 1)
45467498|NCT04886596|Biological|RSVPreF3 OA Lot 2|Lot 2 of the RSVPreF3 OA vaccine administered intramuscularly into the deltoid of the non-dominant arm at day 1 to the RSVPreF3_L2 Group (Part 1)
45467499|NCT04886596|Biological|RSVPreF3 OA Lot 3|Lot 3 of the RSVPreF3 OA vaccine administered intramuscularly into the deltoid of the non-dominant arm at day 1 to the RSVPreF3_L3 Group (Part 1)
45467500|NCT04886596|Biological|RSVPreF3 OA Lot 4|Lot 4 of the RSVPreF3 OA vaccine administered intramuscularly into the deltoid of the non-dominant arm at day 1 to the RSVPreF3_L4 Group (Part 2)
45467501|NCT04886596|Drug|Placebo|Placebo administered intramuscularly into the deltoid of the non-dominant arm at day 1 to Placebo Group and before each subsequent RSV season to the RSV_1dose and Placebo groups.
46018857|NCT04296370|Drug|Fluzoparib|Fluzoparib Orally twice daily
46018858|NCT04296370|Drug|Physician's choice chemotherapy|"Investigators will declare one of the following regimens:~Capecitabine Vinorelbine"
46018859|NCT02870296|Behavioral|Enhanced Assessment and Education|Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
46018860|NCT04204720|Device|needle (Chiba)|intravascular injection using chiba needle during caudal epidural block
46018861|NCT04204720|Device|needle (Whitacre)|intravascular injection using whitacre needle during caudal epidural block
46018862|NCT04285333|Procedure|fascia iliaca block|ultrasound guided block with 20 mL lidocaine 1.5%
46018863|NCT04285333|Procedure|percapsular nerve group block|ultrasound guided block with 20 mL lidocaine 1.5%
46018864|NCT00997438|Dietary Supplement|Lipoic Acid|300 mg Lipoic acid tablets from Vital Nutrients
46018865|NCT00997126|Drug|Propofol|Propofol 1 mg/kg IV followed by 0.5 mg/kg prn sedation
46018866|NCT00997126|Drug|Alfentanil|Alfentanil 10 ug/kg IV followed by 5 ug/kg prn sedation
46018867|NCT01000636|Procedure|Metvix PDT|"Methyl aminolevulinate cream will be applied for 3 hours on the whole target field.~The target field will then be exposed to red light using Aktilite 128 lamp."
46018868|NCT00965419|Drug|Edivoxetine|0.1 mg/kg/day or participant specific known stable dose, rollover participants (LNBJ [No NCT number]) and (LNBF [NCT00922636]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
45467502|NCT04886596|Biological|RSVPreF3 OA vaccine|Revaccination doses of the RSVPreF3 OA vaccine administered intramuscularly into the deltoid of the non-dominant arm before each subsequent RSV season to the RSV_annual groups.
45838053|NCT04966091|Other|Completion of questionnaires|The quality of life questionnaire will be completed before starting the treatment and then during the embryo transfer and will be followed up at each embryo transfer over a maximum period of 18 months. We will also evaluate by means of a specific questionnaire the importance of work/life interactions management and consequences of absenteeism at work, consequences on professional evolution, anxious repercussions in the professional and private domains).
46102431|NCT01016509|Drug|Insulin|Insulin infusion will be started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. During insulin infusion, oral feeding will be stopped and parenteral nutrition (13±5 Kcal/kg-1/day-1) will be started. After the start of insulin infusion protocol a glycemic control will be provided every hour in order to obtain three consecutive values that were within the goal range. The infusion will be lasted until stable glycemic goal (80-140 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI. The treatment goal will be a fasting blood glucose level of 90-140 mg/dl and a non-fasting level of <180 mg/dl.
46018869|NCT04433494|Drug|TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg|TY-302 is taken orally. Tamoxifen is taken orally.
46102432|NCT01016509|Drug|Insulin|Continuous insulin infusion of 50 IU Actrapid HM (Novo Nordisk) in 50 ml NaCl (0.9% using a Perfusor-FM pump) will be started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell <180 mg/dl, insulin infusion will be tapered and eventually stopped.The infusion will be lasted until stable glycemic goal (180-200 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI in both group. The treatment goal will be fasting blood glucose and postprandial levels of <200 mg/dl.
46102433|NCT02626832|Other|Procedural|All subjects receive intravenous hypertonic saline and serial blood samples are drawn for AVP concentrations
46102434|NCT00639119|Drug|Ropinirole|8 + 8 weeks cross-over placebo controlled
46018870|NCT01000480|Drug|Pemetrexed|500 milligrams per square meter (mg/m²) intravenous infusion on Day 1 of a 21 day cycle for 2 cycles: with possibility of 2 additional cycles.
46018871|NCT01000480|Drug|Cisplatin|75 mg/m² intravenous infusion on Day 1 of a 21 day cycle for 2 cycles; with the possibility of 2 additional cycles.
46018872|NCT01000480|Radiation|Thoracic Radiotherapy|Administered at 2 gray (Gy)/fraction after completion of the pemetrexed and cisplatin infusions on Day 1 of Cycle 3 and will continue daily (5 days per week) until the total delivered dose reaches a therapeutic goal of 66 Gy, over approximately 7 weeks.
46018873|NCT02862691|Drug|Acetaminophen/Oxycodone (Oral analgesic)|2 oral tablets of acetaminophen 325 mg plus oxycodone 5 mg given once
46018874|NCT02862691|Drug|Bupivicaine (Injectable local anesthetic)|local injection of bupivicaine 0.5% at root of maxillary tooth or nerve block for mandibular tooth
45467503|NCT05694247|Device|CorNeat KPro|The optical component of the CorNeat KPro will be implanted into a circular disc of the cornea (as performed in standard penetrating keratoplasty surgery) and the skirt component will be embedded under a 360º conjunctival flap.
45467504|NCT05309343|Drug|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill, etc.
46018875|NCT02871388|Behavioral|CONECT|1 monthly in person + 1 monthly telephone + 4 monthly email contact for behavior modification. Focus on motivation, self efficacy and information provision.
46018876|NCT00965341|Drug|Testosterone|Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.
46018877|NCT00965341|Drug|Placebo|Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
46018878|NCT01175811|Drug|Insulin Lispro Premix|Participant dependent dose, administered subcutaneously for 24 weeks
46018879|NCT01175811|Drug|Insulin Glargine|Participant dependent dose, administered subcutaneously for 24 weeks
46018880|NCT01175811|Drug|Insulin Lispro|Participant dependent dose, administered subcutaneously for 24 weeks
46018881|NCT04293952|Other|Balance, Resistance, Aerobic, Cognition Exercises (BRACE)|BRACE is a combination of different exercises including Balance, Resistance, Aerobic, Cognition for fall risk reduction and to mobility in the elderly.
46018882|NCT04293952|Other|Balance Resistance Exercise (BRE)|this is the simple conventional treatment for the elderly in balance problems including warm-up, resistance exercises and cool-down exercises.
45467505|NCT03638661|Dietary Supplement|vegetable (canola, flaxseed) derived n-3 fatty acid|vegetable (canola, flaxseed) derived n-3 fatty acid was used for fat source.
45467506|NCT03638661|Dietary Supplement|soybean oil|soybean oil used formula
45467507|NCT03780985|Procedure|Intrauterine device insertion|Post-placental insertion of intrauterine device during Cesarean section
45467508|NCT03780985|Procedure|Cesarean section|to delivery of the fetus
46018883|NCT04293874|Behavioral|Personalized Meal Plan|Personalized dietary plans will be developed incorporating the NPAGCS, while personalizing the plan based upon anthropometric characteristics, gender, age and self-reported activity level upon entry into the investigation, goals, typical dietary consumption patterns, and food preferences. A trained research assistant will use the USDA MyPlate88 site (www.choosemyplate.gov) to enter participant characteristics and determine the appropriate calorie level. A daily checklist will be then generated outlining the number of daily servings that should be consumed for each food group. Information will also be provided regarding serving sizes for different foods in the respective food groups and education will be provided regarding tailoring personal dietary preferences to meet the guidelines. Participants will be provided with a printed copy of their meal plan and instructed to initiate it for a 8-week period.
46018884|NCT04293874|Behavioral|Dietary Omega-3LC intervention|Following randomization, participants will be provided with fish to be consumed for 6 weeks. As a component of the dietary intervention, participants in high and low omega-3LC group will be provided with frozen, wild caught salmon (or if they dislike salmon, prepackaged, individual use foil packs of chunk light tuna). Salmon and chunk light tuna were chosen due to high omega-3LC content, low methylmercury content, low cost and ease of use. Vacuum packed, frozen salmon will be delivered to participants in large freezer bags and instructed to arrange visit times to ensure they can go directly home following the visit. Instructions for safe storage, fish handling and recipes to avoid fatigue of fish will be also be provided to participants when they receive the fish.
46018885|NCT00965263|Biological|Cocaine vaccine (TA-CD)|TA-CD (82,360 μg; IM) were administered at weeks 1, 3, 5 and 9.
45467509|NCT03780985|Procedure|Suture|to fix the intrauterine device
45467510|NCT04989231|Biological|Investigational sIPV|Three intramuscular injections of the investigational vaccine (0.5 ml) at 0 month ,1 month and 2 months respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months
45467511|NCT04989231|Biological|Control IPV|Three intramuscular injections of the control vaccine (0.5 ml) at 0 month ,1 month and 2 months respectively;Single intramuscular injection of the control vaccine (0.5ml) at 18 months
45467512|NCT05597852|Device|SpaceOAR|SpaceOAR hydrogel spacer between the prostate and rectum, in an effort to decrease toxicity and improve patient's bowel quality of life.
45467513|NCT01561183|Procedure|Indirect pulp capping (IPC)|"Procedure: IPC~The IPC will be performed as follow:~Anesthesia~isolation the tooth~access to the lesion~incomplete removal of carious tissue from the cavity walls~indirect pulp capping with ≈2 mm layer calcium enriched mixture cement~permanent filling with sandwich technique"
45467514|NCT01561183|Procedure|Direct pulp capping (DPC)|"Procedure: DPC~The DPC will be performed as follow:~Anesthesia~isolation the tooth~access to the lesion~complete removal of carious tissue from the cavity walls result in pulp exposure~preparation of clot-free pulpal mound~direct pulp capping with ≈2 mm layer calcium enriched mixture cement~permanent filling with sandwich technique"
45467515|NCT01561183|Procedure|Miniature pulpotomy (MP)|"Procedure: MP~The MP will be performed as follow:~Anesthesia~isolation the tooth~access to the lesion~complete removal of carious tissue from the cavity walls result in pulp exposure~intentionally removal of pulp horn (≈1 mm)~preparation of clot-free pulpal mound~direct pulp capping with ≈2 mm layer calcium enriched mixture cement~permanent filling with sandwich technique"
45467516|NCT01561183|Procedure|Full pulpotomy (FP)|"Procedure: FP~The FP will be performed as follow:~Anesthesia~isolation the tooth~access to the lesion~complete removal of carious tissue from the cavity walls result in pulp exposure~pulpotomy~preparation of clot-free pulpal mound~direct pulp capping with ≈2 mm layer calcium enriched mixture cement~permanent filling with sandwich technique"
45467517|NCT04979169|Behavioral|Text Messaging|A series of theory-informed text messages encouraging them to contact their primary care provider and the UR LCS Program's Patient Navigator to coordinate screening, along with contact information to do so.
45467518|NCT01312545|Device|3DP|intervention involving local made implant with different fabricating technique-3-dimensional printing (3DP) technique.
45467519|NCT01312545|Device|Medpor|commercial porous polyethylene
45467520|NCT05597540|Drug|Short antibiotic treatment|7 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
46018886|NCT02869594|Other|Data collection|
46018887|NCT03642691|Biological|Ryplazim|Plasminogen IV replacement therapy
46018888|NCT04206189|Dietary Supplement|carbohydrate group - carbohydrate (400ml)|Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery. In contrast, patients in the control group are fasted water 2 hours before surgery according to the standard protocol.
45467521|NCT05597540|Drug|Usual antibiotic treatment|14 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
45467522|NCT01308073|Device|Hemodialysis with EMIC 2 filters|Patients with indication for routine continuous hemodialysis due to acute renal insufficiency
45467523|NCT02822846|Other|lung ultrasound|
46018889|NCT04283695|Drug|GX-I7 or [14C] GX-I7|IM GX-I7 or IV/IM microdose of GX-I7
46018890|NCT02886195|Drug|pemetrexed|500mg/m2 ivgtt d1, per three weeks
46018891|NCT02886195|Drug|cisplatin|80mg/m2 ivgtt d1, per three weeks
46018892|NCT02886195|Drug|Erlotinib|150mg po. every day
45838054|NCT04964544|Combination Product|5 mg rosuvastatin calcium with a Web App (combination product)|The combination product will be a Drug (Rosuvastatin calcium 5 mg) and Software as a Medical Device (Web App that features a Technology-Assisted Self-Selection (TASS) tool). Rosuvastatin calcium 5 mg will be taken orally, 1 tablet daily to use for lowering cholesterol, a key risk factor that can lead to heart disease.
46018893|NCT04267783|Diagnostic Test|Shear wave elastography|Investigate the feasibility of use of shear-wave elastography of the uterus during the third stage of labour and following placental delivery in order to predict uterine atony .
46018894|NCT05331963|Other|Kinesio Taping|Kinesio tape is designed in a specific way that it mimics the human skin nature. It more or less has the same width as the epidermis layer and can be stretched upto 40% of its resting length.Clinically, kinesio tape (KT) is used both alone and with other physiotherapeutic interventions, mainly for the pain control, to reduce inflammation, and to improve functional activity in patients with shoulder pain
46018895|NCT02862769|Drug|Lidocaine|. Perioperatively, when lidocaine is administered as a continuous infusion at clinically relevant doses (1-2 mg/kg/hr) results in plasma concentration below 5µg.mL-1. At this plasma level, it is adequate to attenuate sympathetic responses , decrease pain and demonstrate a significant opioid sparing effect.
46018896|NCT02862769|Drug|Saline|The second group will include those who receive a intraoperative placebo infusion(saline infusion) (Induction bolus dose of 1.5 mg/kg body weight followed by a continous saline infusion 1.5 mg/kg/hr.
46018897|NCT00965185|Drug|atorvastatin|20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.
46018898|NCT00965185|Drug|Placebo|Placebo
46018899|NCT01174563|Drug|erlotinib [Tarceva]|150 mg orally daily, with dose-reductions to 100 mg or 50 mg orally daily according to protocol
46018900|NCT02861599|Other|proprioceptive therapy|
46018901|NCT02861599|Other|speech therapy|
46018902|NCT01298531|Drug|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
46018903|NCT01298531|Drug|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 8 weeks following the prior 8 weeks of placebo.
46018904|NCT01298531|Drug|placebo|placebo subcutaneous (SC) injections once weekly for 8 weeks.
46018905|NCT02862145|Drug|MRX34|Treatment of melanoma with pharmacodynamics biopsy of tissue and blood
46018906|NCT02862145|Drug|Dexamethasone|Premedication during the week of treatment
46102435|NCT01010893|Biological|Vaccination with Fluval P and Fluval AB influenza vaccines|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).
46018907|NCT04284709|Other|cognitive-physical training|combined physical and cognitive training
46102436|NCT01010893|Biological|Vaccination with Fluval P monovalent influenza vaccine|Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant
46102437|NCT01011127|Drug|pravastatin, rosuvastatin|
46018908|NCT01174173|Drug|Ranolazine|ranolazine 1000 mg PO BID for 3 months
46102438|NCT00639197|Procedure|To tunnel|Using the standard Seldinger technique and under the guidance of ultrasound, the catheter will pass through a 3-5cm subcutaneous tunnel before it is eventually secured to reside at the internal jugular vein.
46102439|NCT00639197|Procedure|Standard (not to tunnel)|Using the standard Seldinger technique and under the guidance of ultrasound, the catheter is secured to reside at the internal jugular vein, without a subcutaneous tunnel.
46102440|NCT00912548|Drug|goserelin|"Zoladex™ administration:~Zoladex™ depot is available as a sterile disposable syringe. The depot is administered subcutaneously under the abdominal skin under sterile conditions. If necessary the injection site may be pre-treated with a local anaesthetic.~Sequence of administration Zoladex depot:~The substance is administered for 24 months (2 years) at 28-day intervals (a period of 34 days between 2 administrations must not be exceeded).~Dosage:~Each depot contains 3.6mg Zoladex. The substance Zoladex is contained in a while cylindrical rodlet .~Storage instructions for Zoladex™ Zoladex™ is kept a room temperature."
45467524|NCT03620955|Other|Justified risk stratification based on MRD after three course chemo therapy|All patients are routinely divided into different risk groups according to the NCCN guild based on cytogenetic and molecular abnormality. Then all patients are treated with anthracycline combined with cytarabine regimens for two courses . The patients without obtaining CR will go on one cycle of salvage therapy and then be bridged to allo-HSCT. Those acquiring CR will be given one more course of HDAC as consolidation treatment and then be detested MRD with flow cytometry after that. The patients with MRD positive would be moved to a higher risk class.The stratified therapy should be considered according to the new risk stratification.
45467525|NCT03776851|Drug|erythropoietin|erythropoietin 50 International Units (IU) per kilogram three times weekly by subcutaneous route
45467526|NCT03468322|Drug|AC-203|The investigational product is formulated as 1% topical ointment
45467527|NCT03468322|Drug|Vehicle|Vehicle-only control study medication is the same formulation as investigational product without active ingredient
45467528|NCT03337308|Combination Product|Bempedoic Acid + Ezetimibe Fixed-Dose Combination|bempedoic acid + ezetimibe FDC 180 mg/10 mg tablet
46102441|NCT00912548|Drug|tamoxifen|"Dose and period of Tamoxifen therapy:~Tamoxifen is administered in tablet form. Each day 2 X 10 mg or 1 X 20 mg Tamoxifen are taken in the form of the respective tablet.~Storage instructions for Tamoxifen Tamoxifen is stored at room temperature away from light."
46102442|NCT01016665|Drug|Anastrozole|Tamoxifen 20mg and anastrozole 1 mg
45467529|NCT03337308|Drug|Bempedoic Acid|bempedoic acid 180 mg tablet
45467530|NCT03337308|Drug|Ezetimibe|ezetimibe 10 mg overencapsulated tablet
45467531|NCT03337308|Drug|Placebos|placebo tablet or capsule to match bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or bempedoic acid 180 mg tablet, or ezetimibe 10 mg capsule
46018909|NCT02862379|Behavioral|home-based program|The objective of the rehabilitation program is to reduce the risk of falls after management of the risk factors identified. This intervention is a home-based program combining exercises, home modifications and education on fall risk factors
46018910|NCT04315623|Procedure|Regional citrate anticoagulation CRRT|Regional citrate anticoagulation Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.
45467532|NCT03631862|Drug|Apatinib|Apatinib is an orally administrated small molecule receptor tyrosine kinase inhibitor selectively targeting VEGFR-2, showing anti-tumor activity across a broad range of advanced cancers.
45467533|NCT03631862|Drug|CHOP Regimen|CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)
45467534|NCT04352673|Diagnostic Test|Elbow flexion and extension strength measurements using a hand-held dynamometer|Elbow flexion and extension strength of the participants will be measured in both arms in the supine, prone, and sitting positions using a hand-held dynamometer.
46018911|NCT04315623|Procedure|No-anticoagulation CRRT|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution.
46018912|NCT05281653|Behavioral|Neuromuscular exercise Training|Progressive neuromuscular exercise training
46018913|NCT05281653|Behavioral|Routine training sessions|Routine training sessions
46018914|NCT05661071|Other|Modified Mini Mental Test:|To assess the cognitive function of children
46018915|NCT05661071|Other|The Controlled Oral Word Association Test|To assess the cognitive function of children
46018916|NCT05661071|Other|The Central Nervous System Vital Signs|To assess the cognitive function of children
46102443|NCT00681980|Drug|Valproic acid|15 mg/kg/day
46102444|NCT00681980|Drug|costicosteroids|metypredsolone 1 g/day
46102445|NCT00681980|Drug|valproid acid plus corticosteroids|valporid acid 15 mg/kg/day plus corticosteroids 1 g/patient
46018917|NCT05661071|Other|Conners' Parent Rating Scale-48 (Parent Report)|To assess attention-deficit/hyperactivity disorder
46018918|NCT05661071|Other|Child Behavior Checklist 6-18 ages (Parent Report)|To assesses both child adaptive behaviors and problem behaviors.
46018919|NCT05661071|Other|Strengths and Difficulties Questionnaire (Self-Reported)|It is a brief emotional and behavioural screening questionnaire for children and young people.
45467535|NCT03468244|Biological|Personalized mRNA Tumor Vaccine|subcutaneous injection with personalized mRNA tumor vaccine at least four times
45467536|NCT03468088|Behavioral|Hand grip strengthening|Handgrip strengthening exercises will be added to the experimental group. This exercise is chosen based on literature review of EMG and biomechanical studies. Adjustable heavy grip hand gripper will be used as handgrip resistance at 10 repetitions maximum (RM). The exercise will be performed in standing position the patient's back will be rested in a wall, arm at 30º abduction, 60º abduction 90º abduction & with 90º ER. In this positions, the patient will be performed 3 sets of 10 squeezes each at a 1-minute interval.
45598453|NCT02291731|Drug|Continuous use of topical autologous serum|Silicone-hydrogel SCLs combined with 20% (v/v) autologous serum eye drops were used until complete re-epithelialization. SCLs were removed after total re-epithelialization and patients were subsequently randomized divided into two groups: (1) with and (2) without continuous use of topical autologous serum for an additional 2 weeks after SCLs removal.
45838055|NCT04954196|Drug|Amlodipine 5mg|"HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~The frozen embryo transfer will be performed 6 days after progesterone initiation.~The HRT will be maintained until the pregnancy test is performed: If the test is positive,HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative,HRT will be stopped gradually~Amlodipine administration: On the day of the first monitoring Dm (corresponding to D13 D16 of the cycle), a single per os dose of amlodipine 5 mg is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.The treatment will be maintained until the pregnancy test is performed then if the test is positive, the treatment will be maintained for a total duration of 7 weeks."
46018920|NCT05661071|Other|Brooke Lower Extremity Functional Classification|To determine the functional status of the lower extremity
46018921|NCT05661071|Other|Motor Function Measurement-32 Items|To assessment of motor function and progression of weakness in neuromuscular disorders
46018922|NCT05661071|Other|Four Square Step Test|A test of dynamic balance and coordination that clinically assesses the participant's ability to step over objects forward, sideways, and backwards.
46018923|NCT05661071|Other|Six Minutes Walk Test|It evaluates the walking function and physical capacity of children at the submaximal level.
46102446|NCT01016743|Device|repetitive transcranial stimulation (r-TMS)|Patients will be randomized into two groups: The first group of patients will receive an active unilateral stimulation over the motor cortex contralateral to the more affected body side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for 15 minutes).
46018924|NCT05661071|Other|Timed Performance Test|10 meters Walk& Run Test, Gower's(from a supine to a standing position), Right& Left Leg Standing, Ascent/Descent of 4 Steps
46018925|NCT00964795|Drug|Intravitreal Aflibercept Injection 2mg|
46018926|NCT01173471|Drug|AZD4017|tablet, oral, one tablet once daily, 28 days
46018927|NCT01173471|Drug|Placebo|matching placebo tablet, oral, one tablet once daily, 28 days
46018928|NCT01173471|Drug|AZD4017|tablet, oral 2 tablets twice daily, 28 days
46018929|NCT01173471|Drug|Placebo|matching placebo tablets, oral, 2 tablets twice daily, 28 days
46018930|NCT05168995|Drug|BDP/FF NEXThaler® 100/6 micrograms|"BDP/FF NEXThaler® 100/6 maintenance treatment: one or two inhalations twice daily (one inhalation in the morning and one inhalation in the evening).~BDP/FF NEXThaler® 100/6 maintenance and reliever treatment (MART)"
46018931|NCT01172847|Drug|oseltamivir [Tamiflu]|multiple oral doses
46018932|NCT01172847|Drug|rimantadine|multiple oral doses
46018933|NCT04285645|Other|Warmup|The intervention through exercises will consist in the application of the protocol described by Waldén et al. The objective of the application of this exercise protocol is to produce an improvement in the stability of the knee and the strength of the quadriceps. Before carrying out the exercises, a continuous race will be carried out for 5 minutes, once this first step is finished we will proceed to the realization of the exercises that will be, squats with both legs placing the hands on the hips, feet placed at the width of the shoulders, lowering with a straight back and without raising the heels of the floor, 3 series of 15 repetitions, squats on one leg with the hands on the hips and leg not supported extended forward, 3 sets of 10 repetitions with each leg and jump forward with one leg with the hands on the hips and jump back to return to the starting position, 3 sets of 10 repetitions with each leg
46102447|NCT00692900|Drug|intravenous docetaxel with intraperitoneal oxaliplatin|IV docetaxel 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal oxaliplatin escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
46102448|NCT00692900|Drug|intravenous oxaliplatin with intraperitoneal docetaxel|IV oxaliplatin 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal docetaxel escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
46102449|NCT00682058|Other|Follow-up post-bariatric surgery|Follow-up of those subjects who had bariatric surgery (as part of the parent LABS trial) immediately following the collection of baseline measures (body composition) in this study. Follow-up body composition measures will be acquired at 60 months and 84 months post-baseline measures (post-surgery).
46102450|NCT03800381|Other|Observational PK study|The study team will examine the PK and tolerability of the new HRZ 50/75/150 mg dispersible tablet in children with TB with and without HIV coinfection. Intensive PK testing will be performed after at least 4 weeks of treatment in children on first-line anti-TB therapy using the new pediatric HRZ FDC tablet.
45838056|NCT04954196|Drug|Placebo|"HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~The frozen embryo transfer will be performed 6 days after progesterone initiation.~The HRT will be maintained until the pregnancy test is performed: If the test is positive, HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative, HRT will be stopped gradually~Placebo administration:On the day of the first monitoring Dm (corresponding to D13-D16 of the cycle), a single per os dose of placebo (Microcrystalline cellulose) is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.. The treatment will be maintained until the pregnancy test is performed, then if the test is positive, the treatment will be maintained for a total duration of 7 weeks."
45838057|NCT04944290|Drug|Brinzolamide/brimonidine ophthalmic suspension|Test product
45838058|NCT04944290|Drug|Simbrinza 0.2%/1% Ophthalmic Suspension|Reference product
46102451|NCT00489853|Drug|budesonide/formoterol Turbuhaler 320/9µg|Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms
46102452|NCT00489853|Drug|formoterol Turbuhaler 9µg|Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily
46102453|NCT00489853|Other|Placebo|Placebo, 1 inhalation twice daily
46102454|NCT04137146|Device|Sacral Nerve Stimulation|"Implantation of a sacral nerve neurostimulation system: A single electrode (Interstim® model 3889-28; Medtronic, Minneapolis, MN) was inserted bilaterally into the sacral foramen (S3), connected to an internal pulse generator (Medtronic Interstim~® II 3058)"
46018934|NCT02861755|Behavioral|Positive Affect Skills Training|Blend of enhancements may include: 5-minutes of facilitator contact, an online discussion board, or gamification via virtual flower badges.
46102455|NCT04185467|Other|Intervention (rehabilitation exercise)|Patients in intervention group (exercise rehabilitation) will receive a multimodal program which includes a 90 minute program at the hospital gymnasium in a supervised environment a minimum of once but up to twice per week. Rehabilitation will include aerobic (brisk walking), resistance training and 30 minutes of 8 style Tai Chi. Participants will be advised to walk on days of non-attendance - this will be individualised with the aim to have participants increase to 30 minutes walking per day.
46018935|NCT02861755|Behavioral|5-week Emotion Reporting|
46102456|NCT00682136|Procedure|US-Guided Ropivacaine TAP Block|Bilateral injection of local anaesthetic into the Transversus Abdominis plane, guided by ultrasound.
46102457|NCT00693056|Drug|Placebo|Placebo (w/o API)
46018936|NCT00966355|Drug|Terlipressin|loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days
46102458|NCT00693056|Drug|RX-10100 5mg|5 mg/dose of RX-10100
46102459|NCT00693056|Drug|RX-10100 10mg|10 mg/dose of RX-10100
46018937|NCT00966355|Drug|Somatostatin|loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days
45680945|NCT05633758|Drug|Metolazone|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of administration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
46018938|NCT00966355|Drug|Octreotide|loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days
46018939|NCT02861209|Other|Implementation of a care pathway|The care pathway will consist of procedures of care in the hospital (e.g. consultations with doctors, contact moments with nurses, ...) that describe the initiation of an oral anticancer therapy and the further follow up. The care pathway should describe how care can efficiently be organised.
46018940|NCT02862301|Biological|blood sample|
46102460|NCT00693056|Drug|RX-10100 15mg|15 mg/dose of RX-10100
46102461|NCT04137302|Drug|Hydrocortisone administration|Hydrocortisone administration with collection of blood, urine and saliva samples before (1 week), during (5 days) and after (1 week) the 2 treatments
46102462|NCT04145336|Device|5cm 5-Fr PDS|High-risk patients receive 5cm 5-Fr PDS
46102463|NCT04145336|Device|7cm 5-Fr PDS|High-risk patients receive 7cm 5-Fr PDS
46102464|NCT04145336|Drug|Indomethacin|All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
46102465|NCT03686423|Procedure|Exercise Program|The exercise program will combine moderate intensity aerobic exercise with lower-extremity specific resistance training. A moderate level of intensity will be calculated based on results from a maximal graded exercise test (VO2R) conducted prior to the intervention.
46102466|NCT00499681|Drug|lapatinib ditosylate|Given once daily, 1500mg, for 2 weeks; Given once daily, 1500mg, for 14 weeks in Arm II
45838059|NCT04937166|Biological|DSP107|DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
46102467|NCT00499681|Drug|letrozole|Given once daily, 2.5mg, for 2 weeks; Given once daily, 2.5mg, for 14 weeks
46102468|NCT00499681|Other|placebo|Given once daily for 2 weeks
45680946|NCT03978442|Behavioral|Smoking Cessation Cognitive Behavioral Therapy (CBT)|12 sessions of cognitive behavioral therapy for smoking cessation, designed to help participants prepare for quitting smoking, make a quit attempt, and stay quit from smoking.
45838060|NCT04937166|Drug|Azacitidine|Azacitidine is an analog of the pyrimidine nucleoside cytidine.
46018941|NCT04283305|Other|Virtual reality approach avoidance training|In the VR-based AAT, patients are situated in a bar environment where drinks appear on a bar table in front of them. Patients are instructed to react to 100% of the alcoholic beverages with a push response with a controller, and to non-alcoholic drinks in 100% of the trials with a pull response. The stimuli set consists of 50 different beverages, which are displayed three times in total.
46018942|NCT04283305|Other|Computer-based approach avoidance training|In the computer-based AAT, patients are situated in front of a computer where drinks appear on the screen in front of them. Patients are instructed to react to 100% of the alcoholic beverages with a push response with a joystick, and to non-alcoholic drinks in 100% of the trials with a pull response. The stimuli set consists of 50 different beverages, which are displayed three times in total.
46018943|NCT01172535|Drug|Lopinavir/ritonavir|Heat-stable tablets of 100 mg lopinavir, 25 mg ritonavir, or liquid formulation of 80 mg lopinavir, 20 mg ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines
46018944|NCT05160493|Drug|S-ketamine and pregabalin|"S-ketamine and pregabalin~Drug: Pregabalin • 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14)~Drug: S-ketamine infusion • 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
46018945|NCT05160493|Drug|Normal saline and placebo capsule|Normal saline and placebo capsule
46102469|NCT02687009|Drug|Niclosamide|Niclosamide will be taken orally in the morning of each day from day 1-7 prior to surgery for resection of primary tumor. Niclosamide tablets must be chewed well prior to swallowing.
46102470|NCT00693212|Drug|methylphenidate|Dosing was flexible and dependent on clinical judgement, AEs and treatment response.
46102471|NCT00693212|Drug|methylphenidate|Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day
45838061|NCT04937166|Drug|Venetoclax|Venetoclax is a B-cell lymphoma (BCL)-2 inhibitor
45838062|NCT04936464|Device|transcutaneous tibial nerve stimulation (TTNS)|TTNS is a non-invasive, surface electrode therapeutic stimulation technique available for home administration that has been proposed as a treatment for overactive bladder.
46102472|NCT00693212|Drug|placebo|Dosing is identical to the MPH arm except that the pills will contain no active medication.
46102473|NCT03673943|Drug|64Cu-DOTATATE|Detection of somatostatin positive lesions in NET
46018946|NCT03255967|Behavioral|DSM-H|Multi-modal quality improvement program for improving the quality of care provided to PWD-informal caregiver dyads through HHC
46018947|NCT03255967|Behavioral|Standard of Care|Subjects receive care through usual home healthcare assignment process.
46018948|NCT00966277|Drug|Dalteparin|5000 units subcutaneous, by injection under the skin, daily for 16 weeks
46102474|NCT00693290|Other|low residue diet|Fleet (usual preparation) plus diet sheet for low residue diet
46018949|NCT03625063|Other|Exercise training group|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session each day at patient's room. Inspiratory muscle training (threshold loading device (Threshold®- Inspiratory Muscle Trainer) at 20-30% of maximal inspiratory pressure (MIP)), upper extremity aerobic exercise training (arm ergometer, at 60-80% of maximum heart rate, dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale) and progressive resistance training (shoulder flexors, shoulder abduction and knee extensors at 4-6 level according to modified Borg scale) will be performed in the treatment group during acute hematopoietic stem cell transplantation process.
46102475|NCT04471285|Procedure|acupuncture|acupuncture
46018950|NCT03625063|Other|Control training group|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session each day in patient's room.Upper extremity aerobic exercise training (arm ergometer, at 60-80% of maximum heart rate, dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale) and progressive resistance training (shoulder flexors, shoulder abduction and knee extensors at 4-6 level according to modified Borg scale) except inspiratory muscle training will be performed in the control group during acute hematopoietic stem cell transplantation process.
46102476|NCT04471285|Procedure|Sham acupuncture|Sham acupuncture
46102477|NCT00688298|Device|Prefyx PPS™ System|A mesh implant intended for use as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
46102478|NCT00688298|Device|Advantage ™ System|The Advantage Mesh implant is intended as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
46102479|NCT02687087|Device|Visco-ease|19.6 mg/mL of LMS-611
46102480|NCT02687087|Device|Placebo|Physiological Saline
45680947|NCT03978442|Drug|Bupropion|All medically eligible participants will be prescribed bupropion to begin 7 days before the quit date and continued through 12 weeks post-quit. Participants will be scheduled to begin at 150mg/day of bupropion for at least 3 days before titrating up to 300mg/day dose of bupropion.
45680948|NCT03978442|Behavioral|Cognitive Processing Therapy|12 sessions of CPT, which is a well-established trauma-focused psychotherapy for PTSD that has demonstrated efficacy and effectiveness in Veterans.
46018951|NCT02862223|Dietary Supplement|Neoprinol|
46018952|NCT01298141|Biological|agalsidase alfa|"Cohort 1: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes every other week (EOW)~Cohort 2: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes weekly"
46018953|NCT01171989|Biological|GSK2202083A vaccine|Intramuscular, one dose.
46018954|NCT01171989|Biological|Infanrix hexa™|Intramuscular, one dose.
46102481|NCT02686775|Behavioral|Patient coach|
46102482|NCT02686775|Behavioral|Standard care|
46102483|NCT00499603|Drug|Paclitaxel|80 mg/m^2 by vein once weekly over 1 hour on day 1(+/- 2 days) each week for 3 weeks and for 12 cycles.
46102484|NCT00499603|Drug|5-Fluorouracil|500 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
46102485|NCT00499603|Drug|Epirubicin|100 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
45598454|NCT03147339|Other|AGEs restricted diet|Diet modification to reduce advanced glycation end products in diet. for example to change ways of cooking, time of cooking and also omit some foods.
45680949|NCT03978442|Behavioral|Smoking Abstinence Reinforcement Therapy|Monetary reinforcement for smoking abstinence that is bioverified by breath carbon monoxide and saliva samples.
45680950|NCT03978442|Behavioral|Yoked Contingency Management|Participants in the yoked control will receive the monetary reinforcement of their yoked participant regardless of smoking abstinence or session attendance.
46018955|NCT01171989|Biological|Menjugate™|Intramuscular, one dose.
46018956|NCT01171989|Biological|NeisVac-C™|Intramuscular, one dose.
46102486|NCT00499603|Drug|Cyclophosphamide|500 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
46102487|NCT00499603|Drug|RAD001|30 mg by mouth weekly on Days 1, 8, & 15 for 12 cycles.
46102488|NCT04144868|Other|Normobaric Oxygen|
46102489|NCT00639353|Device|senofilcon A toric soft contact lens|contact lens
46102490|NCT00639353|Device|senofilcon A sphere soft contact lens|contact lens
46102491|NCT04144556|Other|Nintendo Wii and conventional physical therapy|"This group of patients will receive, in addition to the exercise program described below, a virtual rehabilitation program through Nintendo Wii. This program will include upper limb training and lower limb balance training. Participants will choose the games they want to perform the session with. Wii Fit (balance games) will be used for the treatment of the lower limbs, and Wii Sports (bowling, golf and tennis games) will be used for the treatment of the upper limbs."
46102492|NCT04144556|Other|Conventional Physical therapy|A warm-up period using a stationary bicycle, mobility exercises in supine position, active-assisted/passive kinesiotherapy of the lower and upper limbs, strengthening exercises in sitting position, balance, stability and coordination exercises and walking re-education exercises.
46102493|NCT05153083|Procedure|Open thoracic (TAA) and thoracoabdominal aortic aneurysms repair (TAAA)|Each participating center will be able to use its preferred European Conformity marked device, for cryoablation according to their normal clinical practice and according to the instructions for use.
46102494|NCT01946711|Drug|Budesonide|Inhalation
46102495|NCT01946711|Drug|Budesonide|Nasal spray
46018957|NCT01171989|Biological|Synflorix™|Intramuscular, one dose.
46102496|NCT00693446|Drug|Sirolimus|"In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time.~The initial dose will be 8 mg/day po. till a trough level is obtained and then titrated to maintain trough whole-blood concentrations between 5-15ng/ml.~The dose of sirolimus will be administrated once a day."
46102497|NCT00693446|Drug|Tacrolimus|"Patients receive Tacrolimus from day 0 to the end of the study. The time of first administration will be within the first 48 hours post transplant.~The dose of tacrolimus will be administrated twice a day. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~Patients receive also rATG , mycophenolate mofetil and corticosteroids."
46102498|NCT00693524|Drug|tacrolimus|oral
46102499|NCT00693524|Drug|Anti-IL2R AB|i.v.
46102500|NCT00693524|Drug|Mycophenolate mofetil|oral
46018958|NCT04324307|Drug|PD-L1/CTLA4 BsAb|PD-L1/CTLA4 BsAb 5mg/kg, iv，Q2W
46102501|NCT00693524|Drug|prednisone|oral
46102502|NCT00693602|Drug|Erwinase|Chemotherapy
46102503|NCT00682214|Drug|Cholecalciferol|Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
46102504|NCT00682214|Drug|Lactose placebo|Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
46102505|NCT04137380|Drug|Mirikizumab - IV|Administered IV
46102506|NCT04137380|Drug|Mirikizumab - SC|Administered SC
46018959|NCT04324307|Combination Product|GP|Gemcitabine 1000mg/m2, iv, D1,8,15, 28days/cycle; nab-Paclitaxel 125mg/m2，iv，D1,8,15, 28days/cycle;
46018960|NCT04324307|Combination Product|FOLFIRINOX|Fluorouracil 2400mg/m2，iv，D1, 14days/cycle; Oxaliplatin 68-85mg/m2，iv, D1,14days/cycle;Irinotecan135-180mg/m2，iv, D1, 14days/cycle;Calcium Folate 400mg/m2，iv, D1, 14days/cycle;
46018961|NCT01297517|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
46018962|NCT01297517|Drug|Brinzolamide ophthalmic suspension, 1%|
46018963|NCT01297517|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
46102507|NCT04137380|Drug|Placebo - IV|Administered IV
46102508|NCT04137380|Drug|Placebo - SC|Administered SC
46102509|NCT00693680|Dietary Supplement|Zincas Forte|25 mgZn/day + imipramine (100-200mg/day)
46102510|NCT00693680|Dietary Supplement|Placebo|placebo + imipramine (100-200mg/day)
46102511|NCT00682292|Drug|Thymoglobulin (ATG)|Thymoglobulin: 1.25 mg/kg per day from day 0 to day 7 post transplantation
45598455|NCT02223221|Procedure|IVF/ICSI|In vitro fertilization or intracytoplasmic sperm injection.
45598456|NCT02223221|Genetic|PGS|Selection of embryos are based on SNP-array-based preimplantation genetic screening for the number of all chromosomes on the 5th day of IVF/ICSI.
45598457|NCT02223221|Other|Without PGS|Selection of embryos are based on morphology criteria on the 5th day of IVF/ICSI.
46018964|NCT01171677|Behavioral|IntenSati|"IntenSati (a blending of the words intention and sati, the Pali term for mindfulness) combines simple yet vigorous physical movements taken from yoga, martial arts, kickboxing and dance with spoken positive affirmation (e.g. I believe I will succeed, I am strong and I am confident) that are recited simultaneously with the execution of the movements. Indeed, one of the most common reports of IntenSati practitioners is the power of the spoken affirmations to stick in your head long after the workout is complete. The literature suggests that both the kind of high level aerobic exercise provided by IntenSati as well as the positive affirmations may have measurable beneficial effects on cognitive function, mood, self efficacy and self esteem."
46018965|NCT01171521|Device|DermaClose Group|The DermaClose external tissue expander provides continuous expanding of the skin around a wound until it has stretched enough to suture the wound edges closed.
46102512|NCT00682292|Drug|Daclizumab|Daclizumab: 1mg/kg at day 0, 14, 28, 42 and 56 post transplantation
46102513|NCT02624336|Other|DTC1|15ml DTC1 twice a day, rinse for 30sec refrain from eating or drinking for 30min
46102514|NCT02624336|Other|Oradex|15ml Chlorhexidine gluconate 0.12% (w/v) twice a day, rinse for 30sec refrain from eating or drinking for 30min
46102515|NCT02624336|Other|Distilled water|15ml distilled water twice a day, rinse for 30sec refrain from eating or drinking for 30min
46102516|NCT00810069|Drug|Duloxetine Hydrochloride|Flexible dose of 60 or 120 mg daily
46102517|NCT00810069|Drug|Escitalopram|10 mg in both Early and Delayed Intervention. Flexible dose of 10 to 20 mg daily in Delayed Intervention.
46018966|NCT01296347|Drug|Ketamine|Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion
46018967|NCT01296035|Biological|Panitumumab|Panitumumab 2.5 mg/kg on D1, D8, D15, and D22 and Gemcitabine 800 mg/m2 on D1, D8, and D15 of each 28 day cycle.
46102518|NCT00693758|Drug|adenosine|intravenous infusion of adenosine (140microgr./min/kg)
46102519|NCT00693758|Other|modified end-tidal forcing system|changes in partial pressures of O2 and CO2 in inspired air
46018968|NCT01294787|Drug|indacaterol and glycopyrronium bromide (QVA149)|
45680951|NCT03598738|Drug|Esomeprazole 40mg|Esomeprazole 40mg oral tablet, once a day
46018969|NCT01294787|Drug|placebo|
46018970|NCT01294787|Drug|tiotropium|
46018971|NCT04207463|Drug|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
46102520|NCT00693758|Other|arm cuff occlusion|3 min. lasting upper arm cuff occlusion
46102521|NCT00693758|Device|Breathing gas|Changes in pO2 and pCO2 in inspired air mix
46018972|NCT04207463|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
46018973|NCT01294553|Drug|Administration of rosiglitazone/metformin|Subjects who are administered rosiglitazone/metformin at least once
46102522|NCT00693758|Device|Blood pressure cuff|supra-systolic arm occlusion with pressure cuff
46102523|NCT00693836|Genetic|genetic linkage analysis|
46018974|NCT04326023|Drug|PARP Inhibitors|olaparib, rucaparib, niraparib, talazoparib, veliparib
46018975|NCT01294397|Drug|Etanercept|Administered by subcutaneous injection once a week
46018976|NCT01294397|Drug|Denosumab|Administered by subcutaneous injection
46102524|NCT00693836|Genetic|loss of heterozygosity analysis|
46102525|NCT00693836|Genetic|mutation analysis|
46102526|NCT00693836|Genetic|polymerase chain reaction|
46102527|NCT00693836|Genetic|polymorphism analysis|
46102528|NCT00693836|Other|biologic sample preservation procedure|
46102529|NCT00693836|Other|medical chart review|
46102530|NCT00693836|Other|questionnaire administration|
46102531|NCT00693836|Procedure|evaluation of cancer risk factors|
46102532|NCT00688610|Other|laboratory value procalcitonin|"A. attending physician includes patient with acute respiratory infection in study, indicates antibiotic prescription and collects procalcitonin-value. Waits for decision from laboratory either change of decision or retention of decision. In case of change decision: antibiotic is not recommended, patient shall not take antibiotic. In case of retention of decision: patient may take the antibiotic.~B. attending physician includes patient with acute respiratory infection in study, indicates NO antibiotic and collects procalcitonin-value. Waits for decision from laboratory either change of decision or retention of decision. In case of change decision: antibiotic is recommended, patient has to be informed about. In case of retention of decision: no change."
46102533|NCT00682370|Drug|saline solution|intravenous infusion, single dose
46102534|NCT00682370|Drug|heme arginate|"intravenous infusion, single dose~0.3 mg/kg heme arginate"
46102535|NCT00682370|Drug|heme arginate|"intravenous infusion, single dose~1 mg/kg heme arginate"
46102536|NCT00682370|Drug|heme arginate|"intravenous infusion, single dose~3 mg/kg heme arginate"
46102537|NCT02625740|Device|Local exposition of target lesion to high intensity, low-frequency ultrasound|Target lesion was exposed to 60 seconds of high intensity, low-frequency ultrasound generated by the Genesis™ system ( CardioProlific Inc., Hayward, CA). The ultrasound catheter is removed after the exposition.
46102538|NCT02625740|Device|drug eluting ballon angioplasty|Target lesion was treated with an angioplasty, performed using the INPACT Admiral drug eluting ballon (Medtronic)
46102539|NCT02625740|Device|Flow occlusion with an angioplasty balloon|Inflation of a 2 cm long balloon catheter Admiral (Medtronic) , located distally to the treatment area, in order to obtain a flow cessation
46102540|NCT02625740|Drug|Local Paclitaxel infusion|Paclitaxel in a mixture with contrast medium at 1.0 µg/mm³ concentration was delivered to the treatment area for 60 seconds. The column of the Paclitaxel mixture filling the vessel was observed under the fluoroscopy and sustained during 60 seconds. The Paclitaxel /contrast medium mixture was then aspired with a 50 cc syringe and the distal balloon was deflated.
46102541|NCT02625740|Procedure|Angiographic control|A final angiographic control was performed with injection of 10 cc of contrast medium and compared with the pre-procedural one.
46102542|NCT00688922|Drug|Pravastatin|Take an initial dose of pravastatin to start as 10mg/day, which is the recommended initial dose by Health, Labour and Welfare Ministry of Japan, and a diet counseling.
45680952|NCT03594292|Device|FASTFORWARDTM Bunion|The participants will be assign to implantation of FASTFORWARDTM Bunion correction system surgery as a experimental group.
46018977|NCT01293695|Behavioral|Hypnosis|Hypnosis relaxation in five weekly sessions
46018978|NCT01293695|Other|Structured attention|Meets with therapist for five weekly sessions and receives structured attention/supportive counseling, but receives no hypnotic relaxation therapy
46018979|NCT01293539|Drug|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).~Standard dose:~2.5mg (3-6 month old) 3.0 mg (6-12 month old) 4.0 mg (1-3 year old) 5.0 mg (>3 years old)~Dose modification: decrease standard dose by 25% if there are signs of toxicity. Increase the dose by 25% if there is inadequate tumor response.~Frequency: 2 treatment cycles at 3-4 week intervals, with a third treatment cycle administered if the tumor requires it.~Dose not to exceed 0.5mg/kg, per treatment cycle."
46018980|NCT01292837|Drug|Levetiracetam|The initial dose is 20 mg/kg/day or 1000 mg/day, divided into two equal dose for the first two weeks, followed by 40 mg/kg/day or 2000 mg/day for two weeks. After reaching 60 mg/kg/day or 3000 mg/day, treatment will continue for 20 weeks.
46018981|NCT00965731|Drug|Erlotinib|Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)
46102543|NCT00693914|Behavioral|Series of tests/questionnaires|Developmental and Demographic, KINDL Health-Related Quality of Life, Adaptive Behavior Assessment System (ABAS-II),Behavior Rating Inventory of Executive Function (BRIEF), Wechsler Digit Span Task, Wide Range Achievement Test 3rd Edition (WRAT3),Wechsler Abbreviated Scale of Intelligence (WASI), Pediatric Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT), Recognition Memory Task: Face Stimuli, Recognition Memory Task: Verbal Stimuli, Self Ordered Search: Object, Self Order Search: Verbal
46102544|NCT02609373|Behavioral|Sleep intervention|"Session 1: Intervener & participant review 2-week sleep diary and actigraph data. Provide individualized sleep hygiene prescription.~Session 2: Review sleep diary; calculate sleep efficiency; identify adjustments needed.~Session 3: Review sleep-related vs. stress-related symptoms. Develop plan for sleep-related symptoms and discuss Sleep Restriction with Relaxation Exercises. Session 4: Reinforce progress and make corrections as required. If Sleep Restriction is not working, Stimulus Control is introduced.~Session 5-10: Provide reinforcement, assess adherence, answer questions, and offer encouragement and monitoring, including alterations as required.~Booster sessions: At 8 & 10 months: reinforcement, question answering, encouragement and monitoring."
46102545|NCT00694148|Drug|NT 201|"A Botulinum neurotoxin type A, free of complexing proteins~Detailed described in study protocol"
45598458|NCT03521011|Device|MSCT|Non enhanced MSCT Abdomen
46018982|NCT00965731|Drug|Erlotinib|For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2
46018983|NCT00965731|Drug|PF-02341066|For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2
46018984|NCT03252847|Genetic|AAV2/5-RPGR|Single, subretinal administration of AAV2/5-RPGR
45680953|NCT03594292|Procedure|Conventional surgery|The participants will assign to conventional surgery as a control group, the procedure is a standard treatment for the 1st metatarsal hallux valgus.
46018985|NCT04283539|Drug|systemic corticosteroid or biologic|Treatment with systemic corticosteroids or biologic therapies (for corticosteroid refractory patients or these in which corticosteroids are not the treatment of choice)
46018986|NCT02862067|Other|Assessment of cardiorespiratory fitness|Assessment of cardiorespiratory fitness
46018987|NCT02861989|Other|qualitative study|
46102546|NCT02609217|Other|Questionnaires and interviews|
45680954|NCT03594214|Diagnostic Test|serum vitamin d level measured by ELISA kit|serum vitamin d level will be measured by a blood sample from newly diagnosed breast cancer patients just after diagnosis (either by surgery specimen or FNA or excisional biopsy specimen) and before receiving any type of treatment for breast cancer
45598459|NCT02223299|Dietary Supplement|L-tyrosine|6g/d daily for 30 days
46018988|NCT00630175|Drug|zolpidem-MR (modified release)|
46018989|NCT00630175|Drug|zolpidem (SL800750)|
46018990|NCT00630175|Drug|placebo|
46018991|NCT02861911|Other|Current flow between sensory and motor threshold|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
46018992|NCT02861911|Device|Current intensity upper of motor threshold by Kneehab XP technology|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
46018993|NCT00965575|Drug|Melatonin|Sustained release formula (Brand: Jigsaw); dosage will be 9mg for all subjects. Taken 30 minutes prior to bedtime for four weeks.
46018994|NCT00965575|Drug|Placebos|Placebo. Taken 30 minutes prior to bedtime for four weeks.
46018995|NCT04282837|Diagnostic Test|AI classification of patients with obesity|Computational modeling techniques will be used for the precise reclassification of obesity into four subgroups, several variables according to the clinical experience and the modeling results will be selected for the cluster analysis.
46018996|NCT04285177|Procedure|Strabismus surgery|Resection or recession of the medial or lateral rectus muscle, or inferior oblique myectomy
46018997|NCT02862847|Other|stool samples|
46018998|NCT04285099|Device|Application of dual system in frequency A|The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
46018999|NCT04285099|Device|Application of dual system in frequency B|The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
46019000|NCT02862613|Procedure|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
45598460|NCT02223299|Dietary Supplement|L-Tryptophan|2g/d daily for 30 days
45598461|NCT02223299|Drug|deplin|15mg daily for 30 days
45598462|NCT02223299|Other|Placebo A|a sugar-pill that looks like a real medication
45598463|NCT02223299|Other|Placebo B|a sugar-pill that looks like a real medication
45598464|NCT02356341|Device|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
45598465|NCT02295007|Behavioral|text message|
46102547|NCT00694226|Behavioral|brief motivational intervention|Brief intervention, consisting in an intervention with the adolescent and a session with parents or mentors. The session with the adolescent lasted 60 minutes. Materials related to the interview were developed according to previous reports on the subject. After building a good rapport the interviewer involved the patient in an initial discussion about the results of the evaluation. This led to a review of the drugs used by the subject and an elicitation of positives and negatives of drug use. The relationship between drug use and current and long-term goals was explored. Discrepancies and problems in the future related to substance use were examined, and information and counseling was offered. The basic components of the motivational interview approach were contemplated, and several skills were used by the interviewers. The individual session with parents or mentors consisted in the presentation of educational materials and a brief counseling intervention on parenting skills.
46019001|NCT02862613|Biological|Precision Cells|DC cell suspension (1×107 DC+ physiological saline + 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
46019002|NCT03523351|Radiation|Radiation Therapy|Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, 3D-CRT, or IMRT technique may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.
46102548|NCT00694226|Behavioral|treatment as usual|Treatment as usual (TTU): After completion of the intervention, individuals and their families went on to receive standard care at the Child and Adolescent Psychiatry and Psychology Department according to the primary diagnosis.Individuals assigned to this group and their parents or tutors received standard care and no further intervention other than completion of the assessment protocol.
46102549|NCT04029051|Other|Focus thoracic ultrasound for dyspnea diagnosis|Focus thoracic ultrasound is composed by an advanced cardiac ultrasound with Doppler measures and a lung ultrasound.
46102550|NCT02626364|Drug|crenolanib|single-agent crenolanib at 100 mg PO TID
46102551|NCT02609139|Drug|PF-06650833|Up to 400mg modified release tablets administered under fasted conditions
46102552|NCT02609139|Drug|PF-06650833|100mg modified release tablet administered under fasted conditions
46102553|NCT02609139|Drug|PF-06650833|20mg modified release tablet administered under fasted conditions
46102554|NCT02609139|Drug|PF-06650833|Up to 400mg modified release tablets administered with high fat meal food intake
46102555|NCT02609139|Drug|PF-06650833|100mg modified released tablet administered with high fat meal food intake
46102556|NCT02609139|Drug|PF-06650833|20 mg modified release tablet administered with high fat meal food intake
46102557|NCT00682526|Device|SmartLink Wireless Monitoring System (K033642)|All EMS transported patients age 18 or over who have their ECG attempted to be wirelessly transmitted and with the intention to treat with coronary reperfusion therapy (PCI or thrombolytics)based on their initial presentation.
46102558|NCT02609295|Dietary Supplement|Placebo|1.2 g (two capsules) of medium-chain triglyceride (MCT) oil
46102559|NCT02609295|Dietary Supplement|ALA group|1.2 g (two capsules) of perilla oil
46102560|NCT04136834|Biological|PT01 (Pegtomarginase)|PT01 (Pegtomarginase) breaks down arginine in the blood stream, reducing the supply of arginine and stopping the cancer cells from growing. Normal cells can continue to make their own arginine inside the cell, so PT01 targets the rapidly growing cancer cells.
46102561|NCT04778475|Other|Intensive therapy|PT services twice a day for 3-5 days and then daily for the remainder of hospital stay
46102562|NCT04778475|Other|Standard of care therapy|PT services 3-5 times a week for 15 to 30 minutes
46102563|NCT00694460|Biological|Three 1 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 1.0 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
45680955|NCT04004182|Dietary Supplement|Fruit bar with addition of polyphenols|Fruit bar with addition of 600mg bilberry anthocyanins and 1200mg apple polyphenols
45680956|NCT04003948|Drug|Ibogaine Hydrochloride|Fixed or ascending doses of ibogaine will be administered for the treatment of opioid withdrawal syndrome.
46019003|NCT03523351|Drug|Systemic Therapy|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
46019004|NCT00965497|Drug|escitalopram|After confirmation of diagnoses and safety screening escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability. No other psychotropic medications will be permitted during the study. Medications for coexisting medical problems (e.g. hypertension) will be permitted. Study visits will include weekly visits for first 2 weeks and biweekly visits for next 6 weeks. Medications will be dispensed weekly or biweekly and the participants will be followed for 8 weeks.
46019005|NCT02859805|Other|validation of a diagnostic tool severity of non-motor symptoms in Parkinson patients|
46019006|NCT00963937|Drug|Sumatriptan 25 mg|One Sumatriptan 25mg tablet and one Matching Placebo tablet should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
46019007|NCT00963937|Drug|Sumatriptan 50 mg|Two Sumatriptan 25mg tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
46019008|NCT00963937|Drug|Placebo|Two Matching Placebo tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
46019009|NCT03375697|Drug|JNJ-63733657|Subjects will receive single (Part 1) or multiple (Part 2) ascending dose levels of JNJ-63733657 intravenously.
46019010|NCT03375697|Drug|Placebo|Subjects will receive matching placebo intravenously.
46102564|NCT00694460|Biological|Three 0.5 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.5 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
46102565|NCT00694460|Biological|Three 0.1mL doses of Rabies Vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
46019011|NCT04284241|Behavioral|Parents'Health-Education Handbook|We created a Parents' Health-Education Handbook to teach the newborns' parents to enhance their knowledge of pediatric stone, with a view to changing parents' cognition, attitude and behavior for preventing pediatric stone formation by this cluster randomized control trail.
46102566|NCT00694460|Biological|Two 0.1mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0 and Day 28 (a total of 2 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
46102567|NCT00694460|Biological|Two doses of JE vaccine|Vaccination with Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL only subcutaneously on Day 0 and Day 7 (a total of 2 doses)
46102568|NCT04776525|Drug|Ifosfamide|3 g/m2 each day for three days
46019012|NCT01170663|Biological|Ramucirumab (IMC-1211B) DP|8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle
46019013|NCT01170663|Drug|Placebo|Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle
46019014|NCT01170663|Drug|Paclitaxel|Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle
46019015|NCT04315155|Drug|Belinostat|"Doublet Regimen Dose levels for Part 1:~Belinostat Dose Level 1 (starting dose) 500 mg/m2 Dose Level 2 750 mg/m2 Dose Level 3 1000 mg/m2"
46019016|NCT04315155|Drug|nivolumab|Doublet Regimen Dose levels for Part 1 Nivolumab Dose Level 1 (starting dose) 360 mg Dose Level 2 360 mg Dose Level 3 360 mg
46019017|NCT04315155|Drug|ipilimumab|Triplet and Doublet Regimen Dose Levels for Phase 2 Ipilimumab Doublet Dose n/a Triplet Dose 1 mg/kg
46019018|NCT04315155|Drug|nivolumab|Triplet and Doublet Regimen Dose Levels for Phase 2 Nivolumab Doublet Dose 360 mg IV Triplet Dose 3 mg/kg
46019019|NCT04315155|Drug|Belinostat|Triplet and Doublet Regimen Dose Levels for Phase 2 Belinostat Doublet Dose RP2D Triplet Dose RP2D
46019020|NCT01170273|Dietary Supplement|vitamin D|cholecalciferol
46019021|NCT01170273|Dietary Supplement|placebo|placebo tablet
46019022|NCT04315077|Dietary Supplement|Oceanix®|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
46019023|NCT04315077|Other|Resistance Training|5 days of supervised and programmed whole-body resistance training.
46019024|NCT01170039|Drug|Lubiprostone|Lubiprostone will be given as 24 mcg orally twice a day.
46019025|NCT01170039|Drug|Placebo|A matched placebo pill will be given twice a day for 8 weeks.
46102569|NCT04776525|Drug|Doxorubicin|80 mg/m2 over four hours day 1
46102570|NCT00689000|Drug|CHR-2797 (tosedostat): Aminopeptidase inhibitor|"Phase I: Once daily, oral ingestion of CHR-2797 capsules (60mg, 90mg, 130mg or 180mg) depending on cohort~Phase II: Once daily, oral ingestion of 130mg CHR-2797 (recommended dose from Phase I) until progressive disease or withdrawal from the study"
46102571|NCT00489541|Device|Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent implantation
46102572|NCT00689156|Drug|Epirubicin, cyclophosphamide and docetaxel|Epirubicin 90 mg/m2 iv day 1 every 3 weeks plus Cyclophosphamide 600 mg/m2 iv day 1 every 3 weeks times 3 followed by Docetaxel 100 mg/m2 iv day 1 every 3 weeks times 3
46102573|NCT00689156|Drug|docetaxel, cyclophosphamide|Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
46102574|NCT04773873|Device|PFM Crowns on gold coping cast-on|Classic impressions are taken by the operators and sent to one and same laboratory who will deliver all the screw-retained PFM restorations. The crowns will be made using a gold coping cast-on synOcta gold abutment (Ceramicor) for wide (WN) or regular (RN) neck
46102575|NCT04773873|Device|hybrid abutment lithium disilicate crown|Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (e.max CAD). crystallization/ characterization/ glaze firing for the e.max CAD crown using an oven with specific firing programmes for e.max CAD. Adhesive cementation steps of the ceramic crown onto the TiBase
46102576|NCT04773873|Device|hybrid abutment ceramic polymer infiltrated crown|Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (Enamic). Surface polishing with rubber polishers. Adhesive cementation steps of the ceramic crown onto the TiBase
46102577|NCT00689234|Procedure|diaphragm plication 6 months after inclusion|thoracotomy
46102578|NCT00689234|Procedure|diaphragm plication at time of inclusion|thoracotomy
46019026|NCT01169649|Drug|MK-2206|MK-2206 will be given orally 200 mg qw as given in the prior Ph1 clinical trial that demonstrated safety, tolerability and adequate PK/PD values at this dose. Follow-up imaging scans will be performed every 12 weeks to evaluate response. Patients must take MK-2206 orally at least 2 hours before or 2 hours after food or a meal.
46102579|NCT01016821|Drug|Oxycodone|Intravenous, 1 mg, 5 times, in every 5 minutes, duration of drug administration 25 minutes
46102580|NCT04139174|Procedure|first premolar extraction and complete canine retraction.|measurements on panoramic radiograph will be done after first premolar extraction and complete canine retraction.
46102581|NCT01011205|Drug|Advagraf|Capsule
46102582|NCT01011205|Drug|Mycophenolate Mofetil|Solution for infusion
46019027|NCT01169493|Device|VVI-40|Pacing mode set to VVI-40, RV only pacing
46019028|NCT01169493|Device|RV DDD-40|ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
46019029|NCT01169493|Device|BiV DDD-40|ICD programmed to BiV pacing at a lower rate of 40
46102583|NCT01011205|Drug|Basiliximab|IV infusion
46102584|NCT01011205|Drug|Corticosteroids|IV bolus
46102585|NCT04143698|Device|endoscopic retrograde cholangiopancreatography|The duodenoscope will be passed to the duodenum in the standard fashion. Once the papilla has been identified in the duodenum, cannulation of the desired duct will be performed in the standard fashion, with the type of accessories used left to the discretion of the individual endoscopist performing the procedure. If cannulation is considered difficult, advanced cannulation techniques can be used per standard of care at the discretion of the individual endoscopist. The types of accessories used will be left to the discretion of the individual endoscopist and will be dependent on procedure indication and personal preference. Cross-over to the alternate duodenoscope type can be performed at any time if the desired technical maneuver cannot be performed with the designated duodenoscope.
46102586|NCT00694538|Device|Interferential Laser therapy|Two GaAlAs laser (810 nm, 100mW)were used. In the interferential laser treatment, two probes were simultaneously applied. In the conventional laser group, only one probe was switched on. Laser was applied at five points over the pain area. The laser emission mode was continuous with an energy dose of 6 joules per point and session, a power density of 1.09 w/cm2 and an irradiation time per point of 60 s. The average output power was 100 mW and the total energy dose delivered in a patient session was 30 J. Every treatment was along 15 sessions. Hence, the accumulated energy delivered on the whole was 450 Joules for the conventional group of patients (using one beam) and 900 Joules for the interferential one (using two beams).
46102587|NCT00809835|Drug|Galantamine|Daily 8 mg galantamine capsule
46102588|NCT00809835|Behavioral|Computer Assisted Cognitive Behavioral Therapy (CBT)|CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.
46019030|NCT01287104|Biological|Natural Killer (NK) Cell Infusion|Post-transplant Day 21 (plus-minus 3 days): (1 x 10(5), 1 x 10(6) or 1 x 10(7) natural killer (NK) cells/kg by intravenous (IV) infusion. Followed by a second NK cell infusion of the same cell dose, on Day 49 plus-minus 7 days.
46019031|NCT01287104|Biological|Stem Cell Infusion|Transplant Day 0: >4 x 10(6)/kg cluster of differentiation 34 (CD34)+ stem cells by IV infusion Filgrastim, 5 microgram/kg per day subcutaneous (SQ) from day 0 until absolute neutrophil count (ANC) >5000/microliters x2
46019032|NCT05593562|Drug|SPH3127|Oral 100 mg [14 c] SPH3127 mixed suspension
46019033|NCT01286558|Drug|40 mg telmisartan|once daily
46019034|NCT01286558|Drug|5 mg amlodipine|once daily
46019035|NCT01286558|Drug|5 mg amlodipine|once daily
46019036|NCT01286558|Drug|80 mg telmisartan|once daily
46019037|NCT01169103|Drug|recombinant human growth hormone (rhGH)|Initial rhGH dose 0.4mg administered by subcutaneous injection daily. Dose will be increased to 0.6 mg after one week and then increased to 0.8mg after two weeks.
46102589|NCT00694616|Device|AutoSet Spirit|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
46102590|NCT00694616|Device|Modified-AutoSet Spirit|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
46019038|NCT01169103|Drug|Placebo|Placebo will be administered by daily subcutaneous injections. Sham increases will be used.
46019039|NCT01286480|Behavioral|Clinic-based Educational Intervention|This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.
46019040|NCT05592158|Procedure|Socket preservation|After tooth extraction, the socket will be filled with a collagen plug and covered with an amnion-chorion membrane.
46019041|NCT01286168|Device|Sodium hypochlorite (Dakin's Solution)|10 ml of 0.125% sodium hypochlorite (Dakin's solution) irrigation to the drainage bulb two times a day
46019042|NCT01286168|Device|Chlorhexidine gluconate disk|Apply one chlorhexidine disk to the intervention drain site(s) and change every three days
46102591|NCT01014559|Drug|Oxycodone Naloxone|Oxycodone Naloxone PR Tablet taken twice daily
46102592|NCT01014559|Drug|Oxycodone PR Tablets|Oxycodone PR Tablets taken twice daily
46102593|NCT04027023|Drug|Diabetes mellitus Type 2 De-escalation treatment (DET)|"All employed drugs are approved in the US for treatment of type 2 diabetes and are used within their label. There will be defined individual treatment drug combinations at an earlier stage of diabetes as in standard treatment. The DET combination will be composed out of one each or more of the drugs and interventions listed below.~A. Relieve for the insulin-producing ß-cells insulin glargine (6 to 20 U at bedtime) insulin degludec (5 to 15 U at bedtime) B. Reduction of hormonal visceral lipid tissue activity/chronic inflammation Weight loss liraglutide (0.6 mg/day) exenatide (15 µg/day) C. Treatment of metabolic and vascular insulin resistance Pioglitazone (30 mg) D. Treatment of glucose toxicity Empagliflozin (SGLT-II inhibitor; 10 mg) Dapagliflozin (SGLTII-Inhibitor, 10 mg) Canagliflozin (SGLT-II inhibitor, 100 mg) Metformin (inhibition of hepatic glucose production, 500 mg)~To avoid hypos, all drugs are initially given in the lowest possible dose."
46102594|NCT00853242|Drug|Placebo|
46019043|NCT01286168|Procedure|Control|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.
46019044|NCT01286168|Device|Occlusive Adhesive Dressing|A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days.
46019045|NCT01286012|Drug|Soluble Ferric Pyrophosphate in liquid bicarbonate|Subjects will receive hemodialysis containing SFP at 2 µM (11 µg iron/dL of dialysate) at every dialysis session, for a total duration of 36 weeks.
46102595|NCT00853242|Drug|Genz-644470|
46019046|NCT01286012|Drug|Placebo: Conventional liquid bicarbonate|Subjects will receive hemodialysis containing conventional liquid bicarbonate lacking SFP at every dialysis session, for a total duration of 36 weeks.
46019047|NCT01286012|Drug|Erythrocyte Stimulating Agent (ESA)|ESA was administered according to the recommendation of a blinded central anemia management center (CAMC) based on the weekly hemoglobin value and its rate of change.
46019048|NCT01286012|Drug|Intravenous (IV) Iron|Approved IV iron preparations were administered per a protocol driven algorithm when patients serum ferritin value decreased below 200 ug/L.
46019049|NCT02889692|Drug|YiQiFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable."
46019050|NCT02889692|Drug|YangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable."
46019051|NCT02889692|Drug|YiQiYangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable."
46019052|NCT02889692|Drug|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
46019053|NCT02889692|Drug|Erlotinib®|"Erlotinib®,tarceva, 150 mg oral once a day until progression or unacceptable toxicity develops."
46102596|NCT00853242|Drug|Sevelamer carbonate|
45680957|NCT03594136|Device|Raumedic Neurovent-P-tel|Insertion of a Neurovent-P-tel in adults to study normal intracranial pressure
46102597|NCT04143230|Other|Screening for PC by means of two different screening tools|Screening of chronically ill patients admitted to an Internal Medicine Unit from the Emergency Department, for palliative care need, using of both the SIAARTI/NCCN screening tool (EST), and the Simplified Screening Tool (SST), derived from the first instrument.
46102598|NCT00912470|Procedure|ocular blood flow measurement|"Retinal blood flow (with scanning laser Doppler flowmetry, laser Doppler velocimetry + retinal vessel analyzer) each measurement once on the study eye~Choroidal blood flow (with laser Doppler flowmetry, laser interferometry, pneumotonometry)~Frequency distribution of alleles of genetic markers for NOS3, more precisely eNOS -786CC polymorphism and of ET-1 (EDN1), and the receptors ETA (EDNRA), more precisely EDN1/+138/ex1 del/ins, EDN1/K198N, EDNRA/C+1222T, EDNRA/C+70G polymorphisms"
46102599|NCT04701801|Diagnostic Test|MoCA test|Preoperative MoCA test and State-Trait Anxiety Inventory Test (STAI FORM ) questionnaire form will be filled in female patients between the ages of 18-65 by making a one-on-one interview with the patient and the MoCA test will be applied in the early postoperative period (1st week) to ensure its relationship with POCD will be checked.
46102600|NCT00689312|Drug|Enfalyte|Each patient will receive one 250 ml dose.
46102601|NCT00689312|Drug|Pediatric Electrolyte|Each patient will receive one 250 ml dose.
46102602|NCT00689312|Drug|Pedialyte|Each patient will receive one 250 ml dose.
46102603|NCT04117386|Diagnostic Test|HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong)|HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong) for swab sample collected from pterygium and normal conjunctiva and also for urine collected in Colli-PeeTM device (Novosanis, Belgium)
46102604|NCT04117386|Diagnostic Test|Bio-Plex® 200 system (Bio- Rad, Hercules, CA)|Bioplex was use for measure cytokine IL-6, IL-18 and VEGF from tears collected from Schirmer strip
46102605|NCT02609061|Procedure|Open flap debridement (OFD)|Open flap debridement (OFD) alone
46102606|NCT02609061|Procedure|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
46102607|NCT02609061|Procedure|OFD with Platelet rich fibrin (PRF)+1% Alendronate (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate gel placement
46102608|NCT04136678|Other|walking training|15 minutes of conventional walking training 15 minutes of treadmill backward walking training 15 minutes of treadmil forward walking training
46102609|NCT02608983|Dietary Supplement|Agar H1CC2013|Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2013 as part of normal diet for 28 days
46102610|NCT02608983|Dietary Supplement|Agar H1CC2012|Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2012 as part of normal diet for 28 days
46102611|NCT02608983|Dietary Supplement|Maltodextrin|Following a 28-day washout one 250ml drink / day containing 8g of maltodextrin as part of normal diet for 28 days
46102612|NCT00848250|Drug|Angiotensin Converting Enzyme Inhibitor|Patients randomized to this group will continue their current dose of ACE inhibitors until surgery
46102613|NCT00848250|Other|No ACE Inhibitor|Patients randomized to this group will stop their ACE inhibitors 48 hours before surgery
46102614|NCT00912626|Behavioral|One week follow up assessment results|FU-1 feedback group will receive child behavior assessment results and interpretation,and a brief intervention to encourage support options.
46102615|NCT04116294|Other|Computer-assisted prescription|The intervention is based on a computer-assisted prescription: when a PAR will be ordered, an alert will arise and explain the recognized indications for this examination and ask a confirmation for the prescription. This is a non-blocking system: physicians will be able to prescribe PAR even if the PAR is not appropriate.
46102616|NCT00694694|Drug|azithromycin + artesunate|Azithromycin 20mg/kg per day for three days (total 60 mg/kg) Artesunate 4mg/kg per day for 3 days
46102617|NCT00694694|Drug|artemether-lumefantrine|"Tablets are fixed-dose combinations and contain 20mg artemether and 120mg lumefantrine.~For children 5-14.9kg 1 tab 2x a day for 3 days For children 15-24.9kg 2 tablets 2x a day for 3 days For children 25-35kg 3 tablets 2x a day for 3 days"
46102618|NCT00700362|Procedure|Insulin infusion (aspart)|The insulin infusion, a fast acting insulin analog (aspart) in 1 Unit/ml of NaCl, starts when the patients full fill the eligibility criteria and has signed the informed consent. The intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
46102619|NCT00700362|Procedure|Standard care|Glucose control according to standard care at the ward, i.e., sliding scale insulin at the discretion of responsible physician.
46102620|NCT00682682|Other|Virtual Reality video distraction|"Virtual Reality involves wearing a helmet and playing a game called Snow world. This game has sound and is presented in 3D format. This game has immersive qualities that help user feel as if they are in the game."
45680958|NCT05633368|Other|Questionnaires|"Participants will be contacted every three weeks to assess depressive symptomatology and possible relapse.~Patient Health Questionnaire (PHQ-9)~Clinical Global Impression (CGI)~Scaling question regarding depressive symptomatology"
45838063|NCT04936464|Device|transcutaneous electrical stimulation (TENS)|The sham intervention is designed to appear almost identical to the TTNS intervention.
45838064|NCT04931017|Procedure|Biopsy|Undergo biopsy
46102621|NCT00682682|Other|Virtual Reality video game|"Virtual Reality video games involve wearing a helmet with vision and sound. this game is presented in 3D which gives the user the feeling of being in the game. The game used for this study is Snow World"
46102622|NCT04136600|Drug|EGFR antibody and Chemotherapy|"Drug: Cetuximab Cetuximab: 500 mg/m2 iv on Day 1 of cycle every 3 weeks, until disease progression.~Other Names:~Erbitux Drug: Nimotuzumab Nimotuzumab: 400mg iv on Day 1 of cycle, every week, until disease progression~Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles~Other Names:~5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~Xeloda Drug: S-1 S-1: 60mg for BSA>1.5, 50 mg for 1.5>BSA>1.25 , 40mg for BSA<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;"
46019054|NCT02889692|Drug|Gefitinib®|"Gefitinib®,Iressa, 250 mg oral once a day until progression or unacceptable toxicity develops."
46019055|NCT02889692|Drug|Icotinib®|"Icotinib®,Conmana 125 mg oral three times a day until progression or unacceptable toxicity develops."
46019056|NCT05569382|Drug|Verapamil|"1. week: uptitration with 120 mg capsules per day, until maximum dosage of 360 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration"
46102623|NCT04136600|Drug|Chemotherapy|"Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles~Other Names:~5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~Xeloda Drug: S-1 S-1: 60mg for BSA>1.5, 50 mg for 1.5>BSA>1.25 , 40mg for BSA<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;"
46102624|NCT00809757|Drug|Levalbuterol|90 ug Levalbuterol (2 actuations)
46102625|NCT00809757|Drug|Levalbuterol UDV TID|0.31 ug Levalbuterol UDV TID
46102626|NCT00809757|Drug|Placebo|Placebo (2 actuations)
46102627|NCT00594464|Drug|Rotigotine|"2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h patch;~Single patches and a combination of 2 of these patches for a dosage of up to 16 mg/24 h;~One (1) regimen on day of surgery, but exceptionally extended for up to 2 (two) weeks if the patient requires unexpected ventilation after surgery."
46102628|NCT00694772|Procedure|Electrocautery-tonsillectomy|standard of care electrocautery tonsillectomy
45680959|NCT03598582|Drug|Epoetin Zeta|"Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.~Response has been evaluated at 12 weeks according to IWG 2006 criteria. Patients with response continued on epoetin zeta. In non-responders, the patients have been excluded from the protocol."
46102629|NCT00694772|Procedure|Coblation-tonsillotomy|use of Arthrocare Coblation Technology to perform tonsillotomy
45680960|NCT03593980|Dietary Supplement|Cranberry juice|400ml cranberry juice
45680961|NCT04007380|Other|Continuous positive airway pressure (CPAP) therapy|The participants will undergo CPAP therapy for 4 consecutive months in the management of moderate-to-severe SRBDs
45680962|NCT03976882|Drug|Hetrombopag|Hetrombopag
46019057|NCT05569382|Drug|Bisoprolol|"1. week: uptitration with 2.5 mg capsules per day, until maximum dosage of 7.5 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration"
46019058|NCT05569382|Drug|Placebo|"1. week: uptitration with one capsules per day, until maximum dosage of three capsules/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration"
46019059|NCT05567744|Other|Registry|Registry
46019060|NCT02889770|Other|PEEP titration|Exposure to different PEEP levels
46019061|NCT00623792|Behavioral|Preoperative lifestyle Intervention|"6 month individual intervention consisting of weekly face-to-face and telephone sessions addressing diet, activity and preparation for surgery, followed by 3 booster telephone calls after surgery"
46019062|NCT00963547|Drug|MK-2206|[Part 1]: MK-2206 tablets will be given starting at a dose of 45 mg QOD and escalated to 60 mg QOD if tolerated, OR starting at a dose of 135 mg QW and escalated to 200 mg QW if tolerated. Dose reduction to 30mg QOD or 90 mg QW may be permitted. The dose of MK2206 will be increased or decreased as required to find the maximum tolerated dose (MTD) of MK2206 for both the QOD and QW dosing schedules in combination with trastuzumab. [Part 2] The Part 2 dosing level and schedule of MK2206 will be chosen from the MTD of either the QOD or QW dosing schedules depending on the toxicity profile and preliminary efficacy.
46102630|NCT00682760|Drug|Korean Botulinum toxin type A (KbtxA) and Botox injection|Each vial of Botox and KbtxA contained 100 U of BTX-A in a sterile vacuum-derived form without preservatives. Each vial of KbtxA was identical to the placebo (Botox) vial, and all vials were reconstituted with 2.0 mL of 0.9% sterile nonpreserved saline solution to a final dilution of 5 U /0.1 mL. The dose of BTX-A per injection site was 2.5 U to 5 U, and the location, number of injection sites. Using a 30-gauge needle, injections were angled away from the center of lid to reduce the risk of spread into the levator muscle. Injection sites include the upper medial and lateral eyelid margins, lower lateral lid margins, and above the eyebrow.
45680963|NCT03976882|Drug|Placebo|Placebo
45838065|NCT04931017|Procedure|Biospecimen Collection|Undergo blood sample collection
45838066|NCT04931017|Procedure|Bronchoscopy|Undergo bronchoscopy
45838067|NCT04931017|Drug|Extended Release Metformin Hydrochloride|Given PO
45838068|NCT04931017|Other|Questionnaire Administration|Complete questionnaires
45680964|NCT03024736|Other|buprenorphin|"if buprenorphine has better neonatal outcomes compared to methadone in~the treatment of opioid-maintained pregnant women"
45838069|NCT04925544|Drug|VK-2019|VK-2019 binds to EBNA1 and inhibits EBNA1 DNA binding activity. VK-2019 API is synthesized by Anthem BioSciences Pvt. Ltd and formulated into capsules by Emerson Resources Inc,
46102631|NCT00689468|Procedure|Cranial osteopathic manipulative treatment.|A series of five cranial osteopathic manipulative treatment sessions scheduled over three months, and provided by osteopathic physicians whose practices are limited to osteopathic manipulative treatment. Treatment modalities were limited to cranial osteopathy, balanced membranous/ligamentous tension, and/or myofascial release (applied directly or indirectly).
46102632|NCT00689468|Dietary Supplement|Echinacea purpurea|1:1 weight-to-volume 50% ethanol liquid extract of the fresh roots and dried mature seeds of Echinacea purpurea. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
46102633|NCT00689468|Procedure|Sham osteopathic manipulative treatment|Sham osteopathic treatment consisted of a series of five osteopathic examinations only (palpation of the cranial bones and muscles and other structures) without treatment maneuvers.
46019063|NCT00963547|Biological|Trastuzumab|Trastuzumab will be administered as a 90-minute IV infusion at a loading dose of 8 mg/kg followed by 6 mg/kg q3wk.
46102634|NCT00689468|Dietary Supplement|"Echinacea purpurea placebo"|An identically labeled placebo contained 50% ethanol, 45% filtered water, food coloring and thickeners. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
46102635|NCT00682916|Dietary Supplement|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
46102636|NCT00682916|Dietary Supplement|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
46102637|NCT00809445|Behavioral|On-site HIV rapid test and brief, prevention counseling|Participants will be offered an on-site oral fluid HIV rapid test with brief prevention counseling that addresses both risk reduction and motivation to be HIV tested based on an evidence-based counseling approach.
46102638|NCT00809445|Behavioral|On- site HIV rapid test & information|Participants will be offered an on-site oral fluid HIV rapid test with basic info.
46102639|NCT00809445|Behavioral|Referral for off-site HIV testing|Participants will be offered a referral list of HIV testing agencies in the community.
46102640|NCT00682994|Behavioral|Interview|Interview lasting about 5-10 minutes.
46102641|NCT00682994|Behavioral|Questionnaire|Questionnaires taking 20-30 minutes to complete.
46102642|NCT00695006|Other|Sham Traction|Traction <5lbs
46102643|NCT00695006|Other|Traction|Standard supine intermittent traction
46102644|NCT05326269|Drug|Terbutaline|Subcutaneous injection
46102645|NCT02624570|Drug|Midostaurin|Midostaurin, also known as PKC412 is a multi-kinase inhibitor of FLT3 (fms-like tyrosine kinase-3)
46102646|NCT04667247|Drug|FoTv|8 capsules three times a day for 14 consecutive days.
46102647|NCT04665453|Diagnostic Test|Electroencephalography|Recording of the brain electrical activity during sleep; background activity and sleep phases will be evaluated
46102648|NCT04665453|Diagnostic Test|Monitoring of vital functions|Measuring of respiratory rate, heart rate, SpO2, every 10 minutes after the medicine is given to the patient for the duration of EEG, and after 120 minutes. Blood pressure is measured at the time of application of the medicine, at the end of EEG and after 120 minutes.
45680965|NCT04747990|Procedure|Early Definitive Treatment|defined as treatment in accordance with the current guidelines (cholecystectomy or ERCP with endoscopic sphincterotomy during the same hospital admission or within 2 weeks of discharge)
45680966|NCT03598504|Device|Wearable EMG/Vibration device|The device is a combination of an EMG recorder/detector and a vibrator
46019064|NCT00963547|Drug|Lapatinib|Lapatinib tablets will be administered orally QD in doses of 500 mg, 750 mg, or 1000 mg.
46102649|NCT04665453|Drug|Melatonin 0,1mg/kg oral syrup|Melatonine in the form of syrup will be given orally to child.
46102650|NCT04665453|Drug|Dexmedetomidine 3 mcg/kg sublingually|Dexmedetomidine in the form of a solution will be given to child sublingually.
46102651|NCT04665453|Drug|Dexmedetomidine 3 mcg/kg intranasally|Dexmedetomidine in the form of nasal spray will be given to child intranasally.
46102652|NCT00695084|Behavioral|Constraint-Induced Movement Therapy|Intensive practice with the hemiparetic arm for 30 contact hours
46019065|NCT01285310|Drug|Apremilast 30 mg|30 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 30mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
45680967|NCT02985346|Biological|Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis|
46019066|NCT01285310|Drug|Apremilast 20 mg|20 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
46019067|NCT01285310|Drug|Placebo|Oral Placebo tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in active treatment / active treatment extension phase. Participants who are nonresponders will advance early to 20 mg Apremilast BID at Week 16.
46102653|NCT00695162|Other|quiet|no noise
46102654|NCT00695162|Other|non-speech noise|noise without speech
46102655|NCT00695162|Other|speech noise|noise with speech present
46102656|NCT05299034|Diagnostic Test|Multiparametric imaging|MR perfusion or multiparametric CT including NCCT, CTA and CTP
46102657|NCT05299034|Diagnostic Test|Non contrast CT+/- CT angiography|Non contrast CT or NCCT+CTA
46102658|NCT00695240|Device|Continuous bupivacaine analgesia infusion (ON-Q PainBuster Post-Op Pain Relief System)|Patients assigned to the study group had an ON-Q PainBuster Post-Op Pain Relief System (270 ml x 4 ml/hr, dual catheter, 2 ml per site, 72 hours continuous) with dual five inch fenestrated catheters placed at the sacrospinous ligament. One half percent bupivacaine was utilized.
46102659|NCT00689702|Drug|cetuximab, capecitabine|"Cetuximab 400mg/m2 in iv infusion as an initial dose on day 15, then a weekly dose of 250mg/m2 for 5 weeks during radiotherapy (days 22, 29, 36, 43, 50).~Capecitabine: 1250 mg/m² bd for 14 days (1 cycle); 825mg/m2 bd over 5 weeks during radiotherapy.~Radiotherapy: planned total dose of 45 Gy in 25 fractions using a four-field plan in 5 weeks."
46102660|NCT00683150|Other|Endothelial Function Test|Endothelial function tests performed within 20 days before surgery, when surgery begins (at the time of incision), every hour during surgery and then 1, 2, 3, and 5 days after surgery.
46019068|NCT01254630|Biological|V212|V212 viral antigen for HZ, 0.5 mL subcutaneous (SC) injection per dose, in a four dose regimen, approximately 30 days apart.
46019069|NCT01254630|Biological|Placebo|Vaccine stabilizer for V212 with no virus antigen, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart.
46102661|NCT00689780|Drug|AZD1940|Oral solution Multiple ascending dose given orally once daily at day 1-12
46102662|NCT00689780|Drug|Midazolam|Oral solution given orally once daily on day -1 and day 14
46102663|NCT00689858|Drug|Cilostazol, Ginkgo biloba and placebo|dosing time
45467537|NCT03468088|Behavioral|Conventional treatment|Ultrasound therapy will be used to treat both groups. Ultrasound will be applied; while the patient will be seated in an adjustable chair with back support, feet on the floor. The chair will be positioned beside a table. The patient's shoulder will be rested on the table beside the body and elbow will be flexed at 90°. A round-headed probe will be used that is put in direct contact with the patient's skin over the shoulder joint. Ultrasound gel will be used on all surfaces of the head in order to reduce friction and assist in the transmission of the ultrasonic waves.
45680968|NCT02979730|Other|Core Lab Test|For patients randomized to the Core Lab Testing Arm, ED physicians will order an influenza test to be performed in the core lab.
46019070|NCT01284140|Behavioral|Sleep and circadian rhythm promotion|This multifaceted intervention attempts to enhance sleep and circadian rhythmicity through improved scheduling of nursing procedures, enforcement of a day/night routine, increased light exposure during the day, and decreased light and sound exposure during the night. The intervention began the morning after enrollment and enforced a specific period of enhanced light exposure from 9:00 a.m. to noon. The initial target of 5,000 lux administered by light box (Sunsation, SunBox Co.) was reduced to 400-700 lux after the first 10 subjects were enrolled in the study.
46019071|NCT01284140|Behavioral|Usual care|Usual care.
46019072|NCT04207580|Other|Inclusion and follow up of pediatric patients with an idiopathic nephrotic syndrome,|"The study consists in collecting clinical, biological, psychological and social data of INS pediatric patients.~A bio collection is also created: blood, urine, hair and nails will be collected at the beginning of the INS (before starting immunosuppressive treatment)."
46019073|NCT01254318|Other|Standard Care|Health-care interventions will be recorded; no additional procedures outside the standard of care will be required.
46019074|NCT04319796|Other|Data set as defined by the ERN Research Workgroup of the European Commission|"The ERN-RND registry will be restricted to the minimum data set as defined by the ERN Research Workgroup of the European Commission. This includes the following data:~Name of specialist center~Pseudonym:~Date of birth: For confidentiality reasons the ERN-RND registry will restrict this information to the Year of birth~Sex~Date of death: For confidentiality reasons the ERN-RND registry will restrict this information to the Year of death~Age of onset~Orphacode for specific rare disease: https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=DE~Online Mendelian Inheritance in Man (OMIM) code as defined for genetic diseases: https://www.omim.org/~Human Phenotype Ontology (HPO) terms for key features: https://hpo.jax.org/app/~Agreement to be contacted for research purposes: Yes/No~Biological samples (Yes / No)~Link to a biobank (Link / No)~Classification of disability (Disease group specific score)"
46102664|NCT00683228|Behavioral|Counseling|Consecutive newborns exposed to secondhand smoke will be recruited into the study and randomized to have parents receive or not receive specific counselling on harmful effects of SHS exposure. Urine cotinine will be measured at several points during the study for each group
46102665|NCT00695630|Drug|Flumazenil|2 mL, 0.2 mg SM
46102666|NCT00695630|Drug|Placebo|2 mL sterile saline SM
46102667|NCT01614899|Drug|SM-13496 40mg|once daily orally
46102668|NCT01614899|Drug|SM-13496 80mg|once daily orally
45680969|NCT02979730|Other|ED Point of Care Test|For patients randomized to the ED Point of Care Testing Arm, the Research Assistant will perform influenza testing in the Emergency Department, using the Cobas Liat Influenza A/B assay
45680970|NCT05633134|Procedure|Arteriography and precision preoperative embolization|Arteriography and transcatheter arterial embolization of pelvic tumors 0-24 hours prior to surgery.
45680971|NCT05633134|Procedure|Arteriography|Arteriography of pelvic tumors 0-24 hours prior to surgery.
46019075|NCT01284062|Biological|Anrukinzumab|200 mg sterile liquid vial, administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
46019076|NCT01284062|Biological|Anrukinzumab|200 mg sterile liquid vial, dose level 400 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
46019077|NCT01284062|Biological|Anrukinzumab|200 mg sterile liquid vial, dose level 600 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12 Note: dosing in the 600 mg arm will be delayed until the safety of the 200 mg and 400 mg arms has been reviewed.
46102669|NCT01614899|Drug|Placebo|once daily orally
46102670|NCT00695708|Behavioral|Brain Fitness Program|Computer-aided cognitive program designed for intensive training of auditory perception, memory and attention
46102671|NCT00695708|Behavioral|Cogpack|Computer-aided cognitive program for cognitive abilities
46102672|NCT00690014|Drug|probenecid|500 mg q 6 hrs
46102673|NCT00683306|Drug|ZD1839 (Iressa)|Gefitinib supplied for oral use at the dose and schedule that the patient received in the previous gefitinib clinical study. In the case of placebo patients, the gefitinib dose will be as described in the protocol of their previous gefitinib clinical study.
46102674|NCT00690092|Biological|Spherule-derived coccidioidin|1.27 ug of sterile, injectable product (spherule-derived coccidioidin). Product was administered once by intradermal injection along with positive and negative control agents and results read after 48 hours.
46102675|NCT01475123|Drug|Nicorandil|15mg per day
46019078|NCT01284062|Other|placebo|200 mg liquid sterile vial, administered at matching dose level 200 mg, 400 mg or 600 mg intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
46102676|NCT04135898|Drug|SIBP-04|3mg/kg, infusion in 90 minutes
46102677|NCT04135898|Drug|Bevacizumab|3mg/kg, infusion in 90 minutes
46102678|NCT04208399|Drug|JNJ-56136379|JNJ-56136379 will be administered orally in fed condition.
46102679|NCT02624258|Biological|CD19 RNA redirected autologous T-cells (RNA CART19 cells)|Subjects will be treated with IV administration of RNA anti-CD19 CAR T cells for a total of six doses over 3 weeks. The first dose will be administered 1-4 days after infusion of cyclophosphamide 30mg/kg.
46102680|NCT00912392|Drug|Endostar|Endostar® 7.5mg/m2 on day 1 to day 14
46019079|NCT01253304|Drug|LY2189265|Subcutaneous (SC) injection
46102681|NCT00912392|Drug|Etoposide-Carboplatin|Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
46019080|NCT04319484|Drug|lenvatinib|1-2 months after liver transplantation, participants are given lenvatinib with an initial dose of 8 mg (body weight < 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight < 60 kg) or 12 mg orally once a day.
46019081|NCT04319484|Drug|Placebo|1-2 months after liver transplantation, participants are given Placebo with an initial dose of 8 mg (body weight < 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight < 60 kg) or 12 mg orally once a day.
46019082|NCT01253226|Drug|LY2127399 (Tabalumab)|Administered subcutaneously
46102682|NCT04208477|Procedure|one site blockade of the stellate ganglion|Ultrasound guided one site blockade of the stellate ganglion.
46102683|NCT00683462|Drug|Placebo|
46102684|NCT00683462|Drug|AZD3480|Capsules 5 mg/day (once a day) for 2 weeks
46102685|NCT00683462|Drug|AZD3480|Capsules 50 mg/day (once a day) for 2 weeks
46102686|NCT05661773|Device|the combined use of vacuum assisted suction and heat exchanger warming|Heat causes capillary vasodilation, where warming hands and toes improves blood flow while cooling them causes vasoconstriction. Applying a vacuum across a capillary bed increases the transcapillary gradient increasing the driving force of blood flow into tissues. The combination of these two mechanisms can work synchronously to improve blood flow to ischemic extremities and digits.
46102687|NCT04135820|Drug|BPI-7711|BPI-7711 180 mg
46102688|NCT04135664|Procedure|esophagectomy|esophagectomy with at least two-field (thoracic-abdominal) lymphadenectomy
46102689|NCT04135664|Combination Product|chemoradiation|concurrent chemotherapy and radiotherapy
46102690|NCT04135664|Other|active surveillance|No further adjuvant therapy
46102691|NCT00690170|Drug|Ketamine|Ketamine: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes
46102692|NCT00690170|Drug|Nicotine|Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg),IV (in the arm) followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)
46102693|NCT00690170|Drug|Placebo|Normal saline (sodium chloride 0.9%)administered via IV (in the arm) over 95 minutes
46102694|NCT00690170|Drug|Ketamine and Nicotine|"0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.~13.5 µg/kg of nicotineIV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)"
46102695|NCT02623868|Drug|CKD-519 50mg 2Tabs.|after taking Standard meal, CKD-519 50mg 2Tabs. administration.
46102696|NCT02623868|Drug|CKD-519 100mg 1Tab.|after taking Standard meal, CKD-519 100mg 1Tab. administration.
46102697|NCT02623868|Drug|CKD-519 100mg 1Cap.|after taking Standard meal, CKD-519 100mg 1Cap. administration.
46102698|NCT00689624|Drug|Irinotecan|Irinotecan will be administered at a dose of 150mg/m2 as a 30 min IV infusion on day 1
46102699|NCT00689624|Drug|Leukovorin|Leukovorin will be administered at a dose of 200mg/m2 as a 2-hour IV infusion on days 2 and 3
46102700|NCT00689624|Drug|Oxaliplatin|Oxaliplatin will be administered on day 2 at the dose of 65mg/m2 as a 2-hours IV
46102701|NCT00689624|Drug|5-FLUOROURACIL|5-FLUOROURACIL at the dose of 400mg/m2 as IV bolus and then, 600mg/m2 as a 22-hour continuous IV infusion, on days 2 and 3
46019083|NCT01253226|Drug|Placebo|Administered subcutaneously
45467538|NCT05694091|Other|Collecting clinical data, blood gas data, Magnetic Resonance Spectroscopy (MRS) data and blood sample|Collecting clinical data(before induction of anesthesia and first day after surgery), blood gas data(before induction of anesthesia and first day after surgery) ，MRS data (not more than 24h after surgery）and blood sample （before induction of anesthesia and first day, third day and 7th day after surgery）
46019084|NCT01252290|Drug|Lovaza™|4 capsules daily for 6 months
46019085|NCT02888418|Biological|Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha)|Injection vaccine produced by Beijing institute of biological products co., LTD, containing HPV antigen protein, 120μg/0.5ml/bottle
46102702|NCT00689624|Drug|Cetuximab|Cetuximab will be administered at the dose of 500mg/m2 as a 2-hour infusion on day 1 at least one hour before chemotherapy
46102703|NCT05298800|Biological|Vaccine|Different arms were administrated different vaccines
46102704|NCT05298488|Behavioral|Home office|Working from home
46102705|NCT05298488|Behavioral|Office|Working at the office
46102706|NCT05298956|Other|Low-level laser therapy (LLLT)|"Sham Comparator: Participants will receive 8 counts of 60 seconds of the same laser to the right forehead, however the laser power will be turned off and will be 0 Watts.~Transcranial infrared laser stimulation: Participants will receive 8 counts of 60 seconds of transcranial infrared laser stimulation to the right forehead. The wavelength will be 1064 nm and the laser power will be 3.4 Watts."
46102707|NCT02621528|Device|CeraFlex|The Lifetech CeraFlex™ study is a triple-arm study.
45467539|NCT03468010|Radiation|chemoradiation|radiation with concurrent ciplatin
45467540|NCT03468010|Drug|Paclitaxel, Cisplatin|The regimen of additional adjuvant chemotherapy following radiation is Paclitaxel, Cisplatin once 3 weeks.
46019086|NCT02888418|Biological|placebo|
46019087|NCT02888340|Other|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: one.
46102708|NCT02621684|Other|Community Health Activities Model Program for Seniors (CHAMPS)|"Physical activity questionnaire for older adults~Asks about activities in the past 4 weeks~41 questions and asks to notate how long the activity took"
46102709|NCT02621684|Other|Lifetime Total Physical Activity Questionnaire|"Questions about leisure time (27) and household activities (5)~Mark if participated in the activity during the past year, ages 51-65, 35-50, 23-34, and onset of puberty through 21 years"
46102710|NCT02621684|Other|Expanded Prostate Cancer Index Composite (EPIC)|"Measures urinary and sexual function before and after prostate cancer treatment~7 questions about urinary function~9 questions about sexual function"
46102711|NCT02621684|Other|International Physical Activity Prevalence Study Environmental Module|-The 17-item Physical Activity Neighborhood Environment Scale can be used to assess the environmental factors for walking and bicycling in various neighborhoods.
46102712|NCT02621684|Other|Godin Leisure-Time Exercise Questionnaire (GLTEQ)|-4 item query of usual leisure time exercise habits
46019088|NCT05503992|Other|Intervention package|The intervention package will include a mobile device configured with OpenSRP configured to facilitate clinical/service provision and stock management. The intervention also incorporates a training component on OpenSRP with accompanying follow-up supervisory visits for a limited period. Per the theory of changes, these activities will improve CHWs' knowledge and ability to use the platform for clinical care, dispensing, and workflow management, leading to an improved stock of commodities to meet preferred FP needs among last mile women.
46019089|NCT01252134|Device|Biotrue multipurpose solution|Contact lens care solution
46019090|NCT01252134|Device|Sauflon Synergi multipurpose solution|Contact lens care solution
46019091|NCT01252134|Device|OTE Elements multipurpose solution|Contact lens care solution
46102713|NCT02621684|Other|Questionnaire regarding behavior/lifestyle changes since diagnosis|
46019092|NCT01252134|Device|Silicone hydrogel contact lenses (Acuvue Advance)|Commercially marketed contact lenses
46102714|NCT02621684|Other|12 week Walking Program|
46102715|NCT02621684|Other|12 week Resistance Training Program|
46102716|NCT02623790|Other|Test meal (butter)|Subjects will eat one meal test containing 33g of lipids from butter (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
46102717|NCT02623790|Other|Test meal (cheddar cheese)|Subjects will eat one meal test containing 33g of lipids from cheddar cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
46102718|NCT02623790|Other|Test meal (cream cheese)|Subjects will eat one meal test containing 33g of lipids from cream cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
46019093|NCT01251744|Procedure|Blood sample|Blood sample at study entry, every two months during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
46019094|NCT01251744|Procedure|Cord blood sample|Cord blood sample taken at the time of delivery.
46019095|NCT01251744|Procedure|Saliva swab|Saliva swab taken at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
46019096|NCT01251744|Procedure|Urine sampling|Approximately 10 mL of urine will be sampled at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
46019097|NCT01251744|Procedure|Vaginal swab|Vaginal swab taken at study entry, every month during pregnancy and one month after pregnancy conclusion.
46102719|NCT00696098|Other|sodium butyrate|1 enema (60 ml) once daily containing 100mM
46102720|NCT00696098|Other|NaCl|1 enema (60 ml) once daily containing 0.9%NaCl
46102721|NCT02623634|Behavioral|Position, waveform|different positions and waveform
46102722|NCT02623556|Biological|ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm|All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
46102723|NCT02623556|Biological|ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm|All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
46102724|NCT00684008|Drug|CYT107 - Recombinant glycosylated human interleukin 7.|Patients will be treated with CYT107 60 to 210 days post transplantation, in 3 successive cohorts of 3 patients. Escalating doses of CYT107 will be given to successive cohorts. Patients will receive 1 dose of CYT107 by the subcutaneous route, once a week for 3 weeks. Dose level 1: 10 mcg/kg/dose for 3 doses; Dose level II: 20 mcg/kg/dose for 3 doses; Dose level III: 30 mcg/kg/dose for 3 doses. Only 1 treatment course for this initial study.
46102725|NCT00684008|Drug|rhIL-7 (CYT107)|10, 20, or 30 mcg/kg once a week for 3 consecutive weeks via the subcutaneous route.
46102726|NCT00696176|Drug|STAT 3 DECOY|single administration to a head and neck tumor
46102727|NCT05326724|Device|Acupuncture|The stainless steel needles are used to insert into the three points of Sishencong and the Baihui, and the Dazhui, once a week, once for 20 minutes, for 12 consecutive weeks.
46102728|NCT02623478|Drug|Insulin Lispro|Administered subcutaneously (SC)
46102729|NCT02621450|Biological|standart dialysis|dialysate sodium consentration 140 mEq
45467541|NCT05652348|Other|Establishment of organoid cultures and in vitro sensitivity testing|Generating patient-derived tumor organoid models as well as orthotopic mouse models from peritoneal carcinomatosis lesions and to investigate their response to different therapies.
46019098|NCT00624312|Drug|Procrit|"10 days prior to surgery - injection of 60,000 IU of Procrit~Day of surgery - injection of 60,000 IU of Procrit"
46019099|NCT00624312|Drug|Placebo|"10 days prior to surgery - injection with 60,000 IU of placebo~Day of surgery - injection with 60,000 IU of placebo"
46019100|NCT01251354|Drug|BN83495|1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops
46019101|NCT01251276|Biological|Modified Process Hepatitis B Vaccine|Modified Process Hepatitis B Vaccine given IM (intramuscular) as a single 1.0 mL (10 mcg) challenge dose on Day 1 of the Challenge Dose Study
46019102|NCT01251120|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks plus background DMARDs (including methotrexate)
46019103|NCT01251120|Drug|DMARD|Non-biologic DMARDs (including methotrexate) according to current best practice
46019104|NCT01250418|Drug|Ketamine group|ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
46102730|NCT02621450|Biological|low sodium dialysis|dialysate sodium consentration will be reducer from 140 mEq to 137 mEq
46102731|NCT04139954|Other|There is no intervention in the study|There is no intervention in the study
46102732|NCT00593840|Radiation|Intensity modulated radiation therapy|
46102733|NCT00696254|Behavioral|Nerve excitability measurement|
46102734|NCT02623088|Other|PAP Therapies (CPAP)|Patients with sleep apnea syndrome treated by PAP Therapies (CPAP) after diagnosis and followed 5-7 years.
46102735|NCT04135040|Dietary Supplement|L-Amino Acid|8 different lysine intakes (L-Amino Acid and food) will be tested for 8 hours each.
46102736|NCT00684086|Behavioral|Diabetes Self Management Program|
46102737|NCT04135430|Other|Survey|practice of an updated questionnaire at D0, D2 and D7
46102738|NCT00684164|Drug|Conivaptan|20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days
46102739|NCT00684164|Other|D5|Volume loading dose of D5 followed by an infusion of D5 over 24 hours for up to 4 days - or until the study endpoint of sodium ≥135mEq/L is reached.
46019105|NCT04319562|Procedure|needle-embedding therapy|"First group is comprised of Xinshu (BL15), Ganshu (BL18), Juque (CV14) bilaterally, and Xin and Gan of auricular point on the left ear. Second group includes Shentang (BL44), Hunmen (BL47), Jiuwei (RN15) bilaterally, and Xin and Gan of auricular point on the right side.~After skin cleansing with a 75% alcohol swab, intradermal thumbtack needle will be quickly inserted into the skin and embedded at acupoints mentioned above bilaterally. The needles will remain in the acupoints for 3 days and they will be removed by the therapists at next visit. This also can ensure better implementation of the blind method.Participants are required to receive this treatment twice a week. The specification of the needle used in the back shu point is φ9mm 0.20×1.5mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan), that in the auricular point is φ9mm 0.20×0.6mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan)."
46019106|NCT04319562|Device|shame needle-embedding therapy|The acupoint selection in this group is the same as in the needle-embedding therapy group, except that the shame intradermal needles will be used. After skin cleansing with a 75% alcohol swab, the shame intradermal needles，instead of insert into the skin, it can only stick on the surface of the skin. It also will be removed by the therapists after 3 days. This takes place twice a week. The specification of the shame needle is the same as above.
46019107|NCT05491356|Drug|Tissue Plasminogen Activator|Dosage of 1mg/mL mixed in 0.9% saline solution, intra-catheter administration, sterile
46019108|NCT05491356|Drug|Placebo|0.9% saline solution, intra-catheter administration, sterile
46019109|NCT05490810|Other|Trunk stabilization|"Trunk stabilization exercises with~Static back: A roll of towel was pressed against the back and the position was held for 10 secs and then released~Static gluteus: The gluts were pressed inside and hold for 10 secs and then released.~Abdominal bracing: Brace your abdomen by contracting your entire abdomen. From here Perform different exercises such as raising your arms and then raising your legs.~Pelvic bridging: In crook lying, engage your gluts and trunk lift your hips towards the ceiling. Hold the position for 10 secs and then release.~SLR with-hold at 30 and 45 degrees: Ask the supine patient to raise the leg up-to 45 degrees and hold for 10 secs. Then raise the leg up-to 30 degrees then hold for 10 secs."
46019110|NCT05490810|Other|Activation exercises|"Activation exercises with~Upper rectus abdominis (URA) and lower rectus abdominis (LRA): body supine with hips and knees flexed 90°, with feet locked. Participants flexed the trunk (i.e. crunch execution) against resistance at the level of the shoulders..~External oblique (EO) and internal oblique (IO): side-lying with the hip at the edge of the bench and feet locked by a second operator. Participants performed side-bend exercise against resistance at the level of the shoulder.~Lower erector spinae (LES) and upper erector spinae (UES): prone position with ASIS at the edge of the bench and feet locked by a second operator. Participants performed a back extension against resistance at the level of the shoulders."
46102740|NCT04135508|Drug|BAT1406|40mg/0.8ml
46102741|NCT04135508|Drug|Humira|40mg/0.8ml
46102742|NCT02621372|Other|platelet count|Correlation of esophageal varices with platelet count
46102743|NCT04135196|Other|voluntary forearm loading task|voluntary task, consisting of leaning onto the palm of the hand until a target force is reached. Each loading bout consists of 100 loading cycles, which takes approximately 2 minutes to complete. The task is performed 4 times per week during the intervention period.
46102744|NCT02621294|Other|Measuring protein requirement|a repeated measures design will be used on each athlete receiving eight graded intakes of protein on separate days in the form of AA in random order ranging from 0.2 to 3.5 g/(kg/d). Three baseline samples of breath and urine will be collected at 60, 45 and 30 min before the stable isotope is given orally. During a period of 150 to 270 min. after stable isotope ingestion, 5 breath and urine samples (every 30 min) will be collected to determine an isotopic plateau in breath and urine. The rate of release of 13CO2 from the oxidation of L-[1-13C] phenylalanine (F 13CO2) in breath will be measured and a breakpoint analysis will determine total protein requirement
46102745|NCT04134962|Diagnostic Test|3D Imaging FAO measurement and Clinical evaluation of the hindfoot alignment|"The Cone Beam under load is used for the diagnosis and monitoring of the foot and ankle. It has a CE marking for this purpose.~The images obtained by the Cone Beam under load (Ped Cat) will be analysed using the TALAS mathematical algorithm tool to measure the FAO.~The internal software of the Cone Beam under load will also be used to obtain a radiographic image corresponding to a 2D projection on which the tibio-calcaneal angle can be measured."
46102746|NCT02622932|Drug|Anlotinib and 14C-labeled Anlotinib|oral
46102747|NCT02617238|Other|Cardiovascular risk management based on PWV|"Arterial stiffness will be measured through the determination of the carotid-femoral pulse wave velocity (PWV).~In the PWV group, PWV will be measured at baseline, and then every 6 months. PWV measurement will guide the intensification of treatment. Measurements will be immediately available to the physician in charge of the patient, in order to adapt treatment. The therapeutic strategy is based both on the normalisation of BP and then on the BP-independent reduction in PWV, using commercially available antihypertensive medications.~In the conventional group, PWV will be measured at baseline, after 2 years, and at the end of the study. PWV values will be masked to the physician"
46102748|NCT04135274|Diagnostic Test|Neutrophil to lymphocyte ratio|Neutrophil to lymphocyte ratio
46102749|NCT02622854|Procedure|plasma exchange|see arm description
46102750|NCT02622854|Drug|conservative treatment|see arm description
45467542|NCT03776617|Procedure|scalp block|Scalp block will be performed five minutes before head pinning for elective craniotomy by blocking supraorbital, auriculotemporal, occipital and postauricular branches of the greater auricular nerves.
46019111|NCT01292603|Drug|Cyclophosphamide|Days 1-3 or Days 1-5 of cycles 1-6
46019112|NCT01292603|Drug|Fludarabine|Days 1-3 or Days 1-5 of cycles 1-6
46019113|NCT01292603|Drug|rituximab [MabThera]|One cycle of intravenous MabThera, followed by 5 cycles of subcutaneous MabThera
46019114|NCT01292603|Drug|rituximab [MabThera]|After 4 cycles of intravenous MabThera without experiencing grade 3 or 4 infusion-related reactions. patients will receive 1 additional cycle of intravenous MabThera and 1 cycle of subcutaneous MabThera.
46019115|NCT01292603|Drug|rituximab [MabThera]|6 cycles of intravenous MabThera
46019116|NCT01292057|Drug|Aripiprazole|Aripiprazole(up to 15 mg/day) for 8 days
46019117|NCT01292057|Drug|Placebo|Placebo to match active drug Aripiprazole for 8 days
46019118|NCT01291277|Device|Endoscopic Variceal Ligation|Ligation of esophageal varices
46019119|NCT01290887|Drug|Reslizumab|Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (±7 days), for approximately 24 months
46019120|NCT01290731|Drug|TMC435|100-mg capsule once daily for 12 weeks
46019121|NCT01290731|Drug|Pegylated interferon (pegIFN alpha-2a)|180 mcg injected subcutaneously (by a syringe under the skin) once weekly for 12 to 36 weeks (or until Week 48).
46019122|NCT01290731|Drug|Ribavirin (RBV)|200-mg tablets (daily dose: 600-1000 mg) taken orally (by mouth) two times a day for 12 to 36 weeks (or until Week 48).
45680972|NCT03593668|Drug|Metformin|"2-week dose adjustment period（0-2weeks）[before meals] 0-2d： - ;250mg，po; -. 3-4d： - ;250mg，po; 250mg，po. 5-6d： 250mg，po; 250mg，po; 250mg，po. 7-9d: 250mg，po; 500mg，po; 250mg，po. 10-11d: 250mg，po; 500mg，po; 500mg，po. 12-14d: 500mg，po; 500mg，po; 500mg，po.~10-week dose stabilization period（3-12weeks） Metformin Hydrochloride Tablet 500mg tid po."
46102751|NCT02620982|Device|ARIES (Extracorporal Shock Wave Application)|The treatment protocol includes 1 treatment per week for 6 weeks and an application of 5000 shockwaves per session in 5 treatment areas with 1000 SW each at energy level 4-5 (energy flux density (0.051-0.062 mJ/mm²), while moving the applicator along the penile shaft within the treatment areas. The maximum energy applied during this treatment would be 23.35J.
46019123|NCT01290341|Drug|NAFT-600 (naftin 2 % gel)|Topical; applied once daily for two weeks
46019124|NCT01290341|Drug|Placebo|Topical; applied once daily for two weeks.
45680973|NCT03593668|Drug|Benaglutide|"2-week dose adjustment period（0-2weeks） [before meals] 0-2d: -; 0.1mg，iH; -; 3-4d: -; 0.1mg，iH; 0.1mg，iH; 5-6d: 0.1mg，iH; 0.1mg，iH; 0.1mg，iH; 7-9d: 0.1mg，iH; 0.2mg，iH; 0.1mg，iH; 10-11d: 0.1mg，iH; 0.2mg，iH; 0.2mg，iH; 12-14d: 0.2mg，iH; 0.2mg，iH; 0.2mg，iH.~10-week dose stabilization period（3-12weeks） Benaglutide Injection 0.2mg，100ul，tid，iH"
45680974|NCT05632900|Procedure|Endoscopic ultrasound guided drainage of walled off pancreatic necrosis|It is Therapeutic procedure to treat walled off pancreatic necrosis.
45680975|NCT03598348|Drug|Apatinib+Capecitabine|Capecitabine 1000mg/m2 po bid, d1-14, Apatinib 250mg po Qd, Q21d
46019125|NCT01290263|Drug|Amgen 386|"For Cohort A, AMG 386 will be administered intravenously at 30 mg/kg every week.~For Cohort B Phase I, AMG 386 will be administered intravenously at beginning at starting dose level of 15 mg/kg every week.~For Cohort B Phase II, AMG 386 will be administered intravenously at the maximum tolerated dose determined in the Phase I portion of the study every week."
46019126|NCT01290263|Drug|Bevacizumab|The dose of bevacizumab will be 10 mg/kg and will be administered intravenously every other week.
46019127|NCT01290029|Drug|Cinacalcet|Single, oral dose of 0.25 mg/kg cinacalcet
46019128|NCT02890199|Drug|Bupivacaine liposomal|
46019129|NCT02890199|Drug|Lidocaine|
45680976|NCT03598348|Drug|Apatinib|Apatinib 250mg po Qd
46019130|NCT04324073|Drug|Sarilumab|(an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1
46019131|NCT01289639|Drug|fenofibrate|micronized fenofibrate 200 mg 1 po qd
46019132|NCT01289639|Drug|pioglitazone|pioglitazone 30 mg po qd
46019133|NCT01289639|Drug|placebo|placebo 1 capsule po qd
46019134|NCT01289015|Drug|NAFT-600 ( naftin 2 % gel )|Topical; applied once daily for two weeks
46019135|NCT01289015|Drug|Placebo|Topical; applied once daily for two weeks
46102752|NCT02617394|Other|Diaphragm scanning - traditional method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows. The second (post-block) diaphragm scan will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration.
45467543|NCT04795726|Drug|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.
46019136|NCT01288937|Drug|Milnacipran|"Patients will be randomly assigned to receive milnacipran 100 mg/day (including a 1 week dose titration period):~Day 1: 12.5 mg once Day 2, 3: 25 mg/day (12.5 mg twice daily) Day 4, 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)"
46019137|NCT01288937|Drug|Placebo|Patients will be randomly assigned to placebo for 9 weeks (including a 1 week dose titration period), matching the schedule of the study drug.
46019138|NCT01288469|Drug|Alirocumab|One subcutaneous (SC) injection in the abdomen only.
46019139|NCT01288469|Drug|Placebo (for alirocumab)|One SC injection in the abdomen only.
46019140|NCT01288469|Drug|Atorvastatin|Over-encapsulated tablet orally once daily in the evening with dinner.
46019141|NCT01288469|Drug|Placebo (for atorvastatin)|One over-encapsulated tablet of placebo for atorvastatin orally once daily in the evening with dinner.
46019142|NCT02890043|Procedure|robot-assisted spine surgery|robot-assisted spine surgery using Tirobot system
46019143|NCT02890043|Procedure|free-hand surgery|traditional free-hand surgery
46019144|NCT02890043|Device|TiRobot system|a robot-assisted spine surgery system
46019145|NCT01288079|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
46019146|NCT01288079|Drug|Duloxetine|Capsule, oral, once daily
46019147|NCT01288079|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
46102753|NCT02617394|Other|Diaphragm scanning - novel method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration. The second (post-block) diaphragm scan will be done will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows.
45680977|NCT03976258|Drug|buprenorphine/naloxone|This is an observational study. Buprenorphine/naloxone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
45838070|NCT04922840|Behavioral|High-intensity exercise (HIIT)|12 week intervention: Two weekly sessions of 35-40 min exercise: 10 min warm-up, followed by 4x4 min at 90-95% peak heart rate (HRpeak) interspaced by 2-3 min active breaks at 60-70% HRpeak and a third weekly session with continuous exercise for a minimum of 40 min at moderate intensity.
46102754|NCT02622776|Other|Vaginal DNA Collection|Vaginal self-swab, 6hr tampon collection and response to an acceptability questionnaire
46102755|NCT02617316|Other|Barefoot|barefoot running test was 20 minutes.
46102756|NCT02617316|Other|In shoes|In shoes test was 20 minutes.
46102757|NCT02616770|Drug|S1226 (4%)|3 ml Peflubron nebulized, with Medical Gas containing 4% carbon Dioxide, for 2 minutes as a single dose.
46019148|NCT00623753|Biological|EnvDNA, PolyEnv1, EnvPro|Description: The vaccine regimen is a series of 6 injections given 28 days apart. EnvDNA is administered intramuscularly as 100 mcg of recombinant DNA in 1.5 mL of PBS as injections #1, 2 and 5. PolyEnv1 is recombinant vaccinia virus administered subcutaneously as 107 pfu in 0.8 mL of PBS as injection #3. EnvPro is administered intramuscularly as 100 mcg of recombinant protein and 500 mcg of aluminum hydroxide (alum) adjuvant in 1.0 mL of PBS as injections #4 and 6.
46019149|NCT01287221|Drug|Rifampicin|300 mg, 2 times daily
46019150|NCT01287221|Drug|placebo|placebo
46019151|NCT01168401|Biological|NoV GI.1/GII.4 Bivalent VLP Vaccine|"2 Doses 28 days apart Cohort A: 18-49 Years~Cohort A1: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (5/5 mcg)~Cohort A2: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (15/15 mcg)~Cohort A3: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort A4: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (150/150 mcg)~Cohort B: 50-64 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort C: 65-85 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort D: 18-49 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)"
45467544|NCT04795726|Drug|Placebo|Matching placebo to be taken orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.
46019152|NCT01168401|Biological|Saline|Two doses 28 days apart
46019153|NCT05660213|Drug|Huaier granule|Treatment period: Huaier Granule, oral administration, 20g each time, 3 times a day. Continuous medication until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment. After disease progression, whether to continue the medication or not should be determined by the researcher and patient together.
46019154|NCT05660213|Drug|Atezolizumab + Bevacizumab|Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
46019155|NCT05660213|Drug|Camrelizumab+Apatinib|Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
46102758|NCT02616770|Drug|Saline (for 4%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
46019156|NCT05660213|Drug|Sintilimab+Bevacizumab|Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
46019157|NCT01287065|Drug|FF(100mcg)/Vilanterol(25mcg) AM|Inhalation powder
46102759|NCT02616770|Drug|S1226(8%)|3 ml Peflubron nebulized, with Medical Gas containing 8% carbon Dioxide for, 2 minutes as a single dose.
45680978|NCT03976258|Drug|Methadone|This is an observational study. Methadone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
45680979|NCT03976258|Drug|Naltrexone Injection|This is an observational study. Naltrexone injection for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
46019158|NCT01287065|Drug|FF(100mcg)/Vilanterol(25mcg) PM|Inhalation powder
46019159|NCT01287065|Drug|Placebo AM|Inhalation powder
46102760|NCT02616770|Drug|Saline (for 8%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
46102761|NCT02616770|Drug|S1226(12%)|3 ml Peflubron nebulized, with Medical Gas containing 12% carbon Dioxide, for 2 minutes as a single dose.
46102762|NCT02616770|Drug|Saline (for 12%)|3ml saline nebulized with Medical Air for 2 minutes as a single dose
45467545|NCT05175378|Other|Lifestyle intervention|We investigated the potential cardiovascular health effects of the Mediterranean dietary pattern on adult women with relapsing-remitting multiple sclerosis, in regards to body weight, body composition, cardiovascular blood biomarkers (fasting glucose, lipids, C-reactive protein), as well as depression and anxiety levels.
45680980|NCT03976258|Drug|Heroin|This is an observational study. Participants using heroin will be enrolled into this group.
45680981|NCT03598192|Procedure|TAP|The TAP group will be performed at four points at abdominis plane with ropivacaine 0.375%
45680982|NCT03598192|Procedure|PVB|The PVB group will be performed at paravertebral space T7 with ropivacaine 0.5%
46019160|NCT01287065|Drug|Placebo PM|Inhalation powder
46019161|NCT04314999|Diagnostic Test|Examination of stool samples|Tests for diagnosis of parasitic diseases
46019162|NCT01167153|Drug|Valsartan/Amlodipine|Valsartan/Amlodipine 80/5mg single pill combination (SPC)
45680983|NCT03598192|Drug|Ropivacaine|Ropivacaine has been treated the both group
46102763|NCT00499369|Drug|irinotecan hydrochloride|Given IV
46019163|NCT01167153|Drug|Nifedipine|Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg
46019164|NCT02886273|Other|Group 1|Observation
46019165|NCT02886273|Other|Group 2|Observation
46102764|NCT00499369|Drug|leucovorin calcium|Given IV
46102765|NCT00499369|Drug|fluorouracil|Given IV
46102766|NCT00499369|Biological|cetuximab|Given IV
46102767|NCT00499369|Biological|bevacizumab|Given IV
46102768|NCT02622464|Other|micro injection of SVF in vocal cords|
46102769|NCT02622698|Dietary Supplement|Prostat AWC|Prostat AWC- patients received protein supplementation after surgery
46102770|NCT02622698|Other|Placebo|Placebo- Patients did not take any protein supplementation after surgery
46102771|NCT02616692|Drug|Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]|Oral anti-cancer therapy (Sorafenib, an multiple kinase inhibitor), repeated transarterial chemoembolization (TACE) procedures, and hepatic arterial infusion chemotherapy (HAIC)
46019166|NCT02886273|Other|Group 3|Observation
46019167|NCT02886273|Other|Group 4|Observation
46019168|NCT01166763|Drug|vitamin D3|oral capsules, 10,000 IU per week for 6 months
46019169|NCT02886039|Other|Electroencephalogram|Prognostic evaluation of electroencephalogram score created with a retrospective cohort Creation of composite score to predict neurologic outcome in cardiorespiratory arrest
46019170|NCT02885961|Drug|Dabigatran|Anti-coagulant
46019171|NCT02885961|Radiation|FDG PET scan|Scan using PET combined with a high resolution CT scan (HRCT)
46019172|NCT02885727|Drug|Durvalumab|Evaluate if the combination of RT and durvalumab can improve median PFS compared to chemotherapy historical control data in metastatic pancreas cancer patients who have progressed through first-line chemotherapy
46019173|NCT02885727|Radiation|Radiation Therapy|The primary intent of RT in this study is to augment a pancreatic cancer-specific immune response when given with durvalumab.
46019174|NCT01166373|Behavioral|Enrollment video|Standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process
46019175|NCT01166373|Procedure|SSLF|sacrospinous ligament fixation to suspend the vaginal apex
46019176|NCT01166373|Procedure|ULS|uterosacral ligament suspension to suspend the vaginal apex
46019177|NCT01166373|Behavioral|PMT|perioperative behavioral therapy / pelvic muscle training with formal individualized PMT program that begins two to four weeks prior to surgery and continues for three months after surgery
46019178|NCT01166373|Other|Usual Care|usual care both before and after prolapse surgery with respect to pelvic muscle training
46019179|NCT05308407|Other|Focus Groups|No intervention involved in this phase of the study
46019180|NCT05308407|Other|Pilot randomized controlled trial|The intervention is a virtually delivered, 12 weekly group-based active video game-centered lifestyle physical activity intervention (POWER UP) targeting affect to improve function and quality of life in insufficiently active AYAs with central nervous system tumors.
46019181|NCT05307237|Device|Dexcom G6 Continous Glucose Monitoring Management|CGM data will be transmitted from the bedside iPhone to web-based platforms for: (1) Real-Time Management (via iPad-based FOLLOW app used by bedside RN and Digital Dashboard used by the remote monitoring team) and (2) Clinical Optimization (via CLARITY, by which a Diabetes RN Coordinator will conduct remote clinical management of patients from a central, Scripps Diabetes Hub.
46102772|NCT02620592|Drug|ZYDPLA1 tablet|The oral dose of ZYDPLA1 tablet administered with 240 ± 10 mL of water at ambient temperature.
45680984|NCT03598192|Drug|Sufentanil|Sufentanil has been included in Arm/Group Descriptions
45680985|NCT03597958|Genetic|Next generation sequencing (NGS)|NGS panel, whole exome / genome sequencing (WES/WGS), transcriptome analysis
45680986|NCT04003246|Radiation|Thoracic RT and Durvalumab|1500mg every 4 weeks [Q4W] intravenous [IV], first dose within 3 days of RT initiation
45680987|NCT04003246|Drug|Consolidative Durvalumab|1500mg every 4 weeks [Q4W] intravenous [IV] up to one year
45680988|NCT00218296|Drug|Usual Care Group|Nicotine replacement therapy
46102773|NCT02620592|Drug|Placebo tablet|The oral dose of placebo tablet administered with 240 ± 10 mL of water at ambient temperature.
46102774|NCT02620514|Behavioral|Education and Reminders|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will be provided education materials, and will receive scheduled educational reminder phone calls and text messages at 2,6,12, and 24 weeks from the baseline assessment.
46102775|NCT02620514|Behavioral|Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence.Participants will undergo one scheduled visit with a nurse practitioner or physician for education about inflammatory bowel disease (IBD) after the baseline assessment.
46102776|NCT02620514|Behavioral|Medication Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will undergo one scheduled visit with a nurse practitioner or physician to discuss medication side effects and medication inadequacy after the baseline assessment.
46102777|NCT02620514|Behavioral|Financial Support|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will receive information about patient assistance programs, copay cards, and a scheduled meeting with a social worker or financial advisor.
46102778|NCT02620670|Behavioral|Physical activity of moderate intensity for 3 days|The intervencion consist in a moderate-intensity physical activity exercise is a heart rate between 60 and 70% of maximum heart beats per minute for at least 30 minutes for three days
46102779|NCT02622308|Device|FlowOx™|FlowOx™ uses intermittent negative and atmospheric pressure, and is intended for use as an adjunct non-invasive therapy for the treatment of reduced peripheral circulation. Negative pressure cycles are created by alternating between removing air and venting the vacuum-chamber to atmospheric pressure. The vacuum cycle is controlled by the Control Unit (Pump). FlowOx™ is designed to assists wound healing indirectly by improving blood flow to the affected limb and augmenting the wound healing effect of the contact dressings and any associated medication. Treatment is planned to be applied while the participants are seated and it does not interfere with other activities normally enjoyed while seated. Treatment is recommended for one to two hours per session aiming to improve blood flow in the affected area and thus the clinical outcomes.
46019182|NCT05307237|Device|Usual Care - Blinded Continuous Glucose Monitoring Management|CGM data will be blinded and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours if not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring.
46102780|NCT02622152|Procedure|Right lateral position (2 hours)|Repositioning the patients for two-hours period on the right lateral position
46102781|NCT02622152|Procedure|Left lateral position (30 minutes)|Repositioning the patients for 30 minutes period on the left lateral position
46102782|NCT02622152|Procedure|Supine position (30 minutes)|Repositioning the patients for 30 minutes period on the supine position
46102783|NCT02622152|Procedure|Left lateral position (2 hours)|Repositioning the patients for two-hours period on the left lateral position
46019183|NCT04314765|Procedure|lower third molar extraction|the extraction is performed with one of the two type of flap based non randomization.
46019184|NCT00963235|Biological|13-valent pneumococcal conjugate vaccine|Three doses of 13vPnC given 6 months apart.
46102784|NCT02622152|Procedure|Supine position (2 hours)|Repositioning the patients for two-hours period on supine position
46102785|NCT02622230|Drug|Mianhuahua Flavonoids Tablets|"Tolerability Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(seven dose groups:0.3g-5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(six dose groups: 0.9g, 1.8g, 2.7g, 3.6g, 4.5g, 5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)"
46019185|NCT00963235|Procedure|Blood draw|Six blood draws pre-vaccination and 1 month post-vaccination, doses 1-3.
46019186|NCT02861833|Other|nursing support|Determining the Variability of adaptation strategies and correlations with specific nursing management, individual and contextual characteristics of patients with cancerous wounds
46019187|NCT04284163|Behavioral|Gamification|Teaching through gamification
46102786|NCT02622230|Drug|Placebo|Placebo to match with experimental groups
46019188|NCT04284163|Behavioral|Traditional teaching|Teaching through master lesson methodology
46019189|NCT00630097|Drug|modafinil|Modafinil, 100mg, 400mg, or 600 mg tablets QD for 4 weeks.
46019190|NCT04284085|Other|Psychoeducational intervention|Psycho-educational groups of 10 to 12 people, led by two professionals, one of them will always be a psychologist and an educator. In some sessions, other collaborators will be invited to participate, such as psychiatrists, educators, social workers, etc. who may act as external observers or implement the session. The number of sessions will be 13, one or two sessions a week and duration of 90 minutes.
46019191|NCT01165281|Drug|Oxycodone CR|One 5 mg to 40 mg capsule twice daily for 4 weeks.
46019192|NCT01165281|Drug|R331333 (referred to as JNS024 ER or CG5503)|One 25 mg to 200 mg capsule twice daily for 4 weeks.
46019193|NCT04283929|Other|Experimental: Intervention 1 (Int1)|This intervention will consist of the following additions to the EMR package. A link on the clinician's homepage to enrol a new HIV+ patient in the EMR which will open a form for (1) entering patient demographics (2) adding the contact home address or description of area, phone number (if available), (3) the peer educator contacts (4) recording the HIV+ result and date. A report will be added that is run every week to identify HIV+ patients not linked to care. The patients identified will be checked with paper records to ensure they have definitely not visited, then contacted after one, 2 weeks and 4 weeks if he/she did not show up. After two attempted contacts, if the patient is not yet linked to care he/she will be visited at home by the health facility social worker using routine home visits by health care providers.
46019194|NCT04283929|Other|Experimental: Intervention 2 (Int2)|The data on availability of VL results in the EMR will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for 8 months or more and does not have a viral load result in the EMR. The alert will be displayed on the patient summary and on the consult sheets, with text requesting the clinician orders a VL.
46102787|NCT01014637|Drug|Amorolfine (Antifungal)|Treatment with Amorolfine for 36 weeks
46102788|NCT01014637|Drug|RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)|Initial treatment with RV4104A ointment for 3 weeks, followed by treatment with ciclopiroxolamine 1% cream for 8 weeks and by cyclopirox 8% film-forming solution for 25 weeks.
46102789|NCT02616926|Procedure|Hepatic resection|Anatomical surgical resection of the liver including the tumor. Make sure the resection margin is negative during the process.
46102790|NCT02616926|Procedure|TACE|TACE will be performed according to the standard procedure of TACE and will be repeated every four months if needed
46102791|NCT02616926|Procedure|RFA|RFA will be performed 1 week after TACE.
46102792|NCT01014715|Other|Phase II - Preoperative Radiation followed by Lumpectomy.|Sequential investigative question. All procedures are standard of care
46102793|NCT02621996|Device|hammock|PN who will be positioned in hammock inside the incubator will be with the high trunk to about the 30th, and will be used a roll of restraint in the neck by keeping a slight lordosis to avoid suffocation risks. In two days of placement, should remain about 8 hours in the hammock, being removed during cleaning procedures, diet and medical evaluation and then immediately replaced in the hammock. The alternation of decubitus (right side, supine and left lateral) should be performed whenever the child is manipulated for these procedures.
46102794|NCT02621996|Device|containment nest|"In the control group, the position will follow the routine procedure of the Hospital Barão de Lucena, consisting of the use of restraint nests U, made with rolled sheet placed on the mattress of the incubator and covered by another sheet. The control group incubators will also be inclined at 30 ° as routine service. During the 8 position, switching the supine will also be held, side left and side right after the baby handling to cleaning procedures, diet and medical evaluation."
46102795|NCT00696566|Drug|Clopidogrel and Rifampicin|"Clopidogrel: loading dose of 600 mg, then 75 mg o.d. for up to 28 days~Rifampicin: 300 mg b.d. for up to 28 days"
46019195|NCT04283929|Other|Experimental: Intervention 3 (Int3)|The data on VL results in the EMR showing detectable virus will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for at least 12 months and the VL result in the EMR shows > 1000 copies/mm3. The alert will be displayed on the patient summary and on the consult sheets requesting actions to address treatment failure (change first line medication, start second line medication, repeat VL, counselling on treatment adherence). A report will also be added to regularly check for patients with high viral load.
46019196|NCT02861053|Other|regular and moderate physical activity|regular and moderate physical activity will be done 3 times per week more than usual
46102796|NCT01017133|Radiation|fludeoxyglucose F 18|Given IV
46019197|NCT02861053|Other|No regular and moderate physical activity more than usual|regular and moderate physical activity will be done as usual
46019198|NCT05250765|Device|Twistflex retainer|twisted 0.0195 dead-soft coaxial wire (Respond; Ormco, Orange, Calif)
46019199|NCT05250765|Device|Orthoflex retainer|Ortho-flextech (Reliance orthodontic products, Itasca III, USA)
46019200|NCT02860897|Drug|Premarin|Vaginal estrogen cream
46019201|NCT02860897|Drug|Vagifem|Vaginal estrogen tablet
46019202|NCT04314609|Device|Ultrasonography, fluoroscopy|success rate of Ultrasound guided SIJ steroid injection confirmed by contrast spread in fluoroscopy
46019203|NCT02860819|Drug|Veliparib|Veliparib 250mg BID, continuously
46102797|NCT01017133|Radiation|Fluorine F 18 EF5|Given IV
46102798|NCT01017133|Procedure|Positron emission tomography|Undergo scan
46102799|NCT04031066|Drug|Velmanase Alfa|infusion i.v. treatment
46102800|NCT04031066|Drug|Placebo|infusion i.v. treatment
46102801|NCT01017211|Other|auricular acupuncture|"Experimental group to receive ear needles in the Battlefield Acupuncture points.~Sham group to receive ear needles at points thought to be ineffective but standardized."
46102802|NCT01017289|Device|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
46102803|NCT00869258|Drug|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 1500 mg/m2/day (+/- 2days) Day 4 and 11: Gemcitabine 750 mg/m2/day (+/- 2days) Day 4 and 11: Docetaxel 30 mg/m2/day (+/- 2 days) Two week treatment regimen is followed by one week off, repeated for a total of 3 cycles
46102804|NCT00869258|Radiation|Radiation therapy with gemzar|Starting on week 12 +/- 5 days radiation therapy will be given in the standard manner over 5 weeks with daily radiation fractions Monday through Friday. Once a week gemcitabine will be given IV over 30 minutes at 250-300 mg/m2
46019204|NCT02860819|Drug|Gemcitabine|Gemcitabine 800mg/m2, day 1 and 8
46019205|NCT02860819|Drug|Carboplatin|Carboplatin AUC = 4, day 1
46019206|NCT05367453|Dietary Supplement|Tropical juice with probiotics (B.coagulans)|Once a day during all the intervention phase, volunteers with lactose intolerance should allow the spore-forming ability of B. coagulans in order to digest lactase from dairy products through regular consumption of Tropical juice with probiotics (B.coagulans)
46019207|NCT05367453|Other|a Tropical juice with no probiotics|Once a day during all the intervention phase, volunteers with lactose intolerance should consume a Tropical juice with no probiotics
46019208|NCT05367453|Other|lactase tablet|lactase tablet
46019209|NCT05367453|Other|placebo tablet (cornstarch)|placebo tablet (cornstarch)
46019210|NCT04284007|Drug|Perineural levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
46019211|NCT04284007|Drug|Perineural dexamethasone in addition to levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 4mg dexamethasone diluted in 2 ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
46019212|NCT04284007|Drug|Intravenous dexamethasone with perineural levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 4 mg intravenous dexamethasone diluted in 10 ml saline.
46019213|NCT02861677|Other|pharmaceutical care|
46019214|NCT02861287|Other|Economic evaluation|
46019215|NCT02965963|Drug|Dopamine|
46019216|NCT02965963|Drug|Metoclopramide|
46019217|NCT02965963|Drug|Placebos|
46019218|NCT02965963|Other|Rest|
46019219|NCT02965963|Other|Exercise - 60%|60% of VO2max
46102805|NCT01011517|Dietary Supplement|Muscadine grape seed supplement|Nature's Pearl 650 mg, two capsules daily
46102806|NCT03996811|Other|Exercise education|weekly telephone consultations concerning exercise. we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
46102807|NCT00696644|Drug|Teriparatide|20 mcg daily subcutaneous for 18 months.
46102808|NCT01017367|Drug|MDX-1100|MDX-1100 10 mg/kg i.v. over 60 minutes on days 1, 15, 29, 43, 57 and 71
46102809|NCT01017367|Drug|Placebo|Placebo
46102810|NCT00696722|Drug|placebo + atazanavir|"Placebo treatment first, atazanavir treatment second~4 day treatment"
46102811|NCT00696722|Drug|atazanavir + placebo|"Atazanavir treatment first, placebo treatment second~4 day treatment"
46102812|NCT02620436|Other|Core Mother Shelter Model|"Infrastructure, Supplies, Equipment: All MHs will have: latrines, lockable cupboards, doors, windows, lighting, mattresses, mosquito nets, cooking space and utensils, and a bathing site.~Policies, Management, Finances:. The policies, management, and financial structures will follow the same general principles, but will be site-specific to account for cultural variation.~Linkages with Health Facilities: Each MH will be operationally linked to the health facility and 1) ensure daily check-ins by a health facility staff; 2) ensure every pregnant woman has someone able to contact a staff if she is incapacitated; and 3) will orient women to procedures upon arrival. Clinical services will be conducted at the health facility."
46102813|NCT00696956|Device|Balloon angioplasty (uncoated conventional balloon)|endovascular therapy
46102814|NCT00696956|Device|Balloon angioplasty (conventional but coated with 3 µg/mm2 paclitaxel)|endovascular therapy
46102815|NCT02616848|Drug|Everolimus|
46102816|NCT02616848|Drug|Eribulin|
46102817|NCT02621918|Other|Progressive resistance training|
46102818|NCT02621918|Other|Aerobic training|
46102819|NCT02621918|Other|Placebo training|
46102820|NCT02620124|Drug|Natural cycle: Triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in additon to standard micronized progesterone 400 mg vaginally
45467546|NCT04453228|Other|Classification statistics|We classified skiers in the two snow seasons by injury site, type of injury, cause of injury, etc
45467547|NCT03780907|Drug|E2007|1 mg of E2007 was administered by mouth once daily.
45467548|NCT03780907|Drug|E2007|2 mg of E2007 was administered by mouth once daily.
46019220|NCT02965963|Other|Exercise - 85%|85% of VO2max
46019221|NCT01165203|Biological|Herpes Zoster Vaccine GSK1437173A|intramuscular injection
46019222|NCT01165203|Biological|Placebo|intramuscular injection
46019223|NCT00960661|Drug|exenatide|subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (26 weeks), twice a day
46019224|NCT00960661|Drug|insulin lispro|titrated based on pre-meal glucose level; three times a day
46019225|NCT00960661|Drug|Metformin|
46019226|NCT00960661|Drug|Insulin/ Glargine|
46019227|NCT04119193|Device|Novel smartphone application for blood pressure measurement|Continuous blood pressure measurements will be compared between the new application and the reference method (invasive radial arterial line) during 5 minutes of recordings.
46102821|NCT02620124|Drug|Hormone replacement cycle and triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in addition to standard Estradiol and progesterone support
46102822|NCT02617160|Device|MD-Logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
46102823|NCT02617160|Other|Control Group|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice
46102824|NCT04134650|Combination Product|Linagliptin + metformin|Linagliptin-Metformin 2.5/1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
46102825|NCT04134650|Drug|Metformin|Metformin 1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
46102826|NCT02621762|Device|Magnesium|Magnesium in dialysate increased
46102827|NCT02621762|Device|Bicarbonate|Bicarbonate in dialysate increased
46102828|NCT02621840|Behavioral|Mandatory On-Site Pre-Admission Testing|
46102829|NCT02620358|Other|T Tube for 120 minuts|Spontaneous Breathing Trial using T Tube for 120 minutes.
46102830|NCT02620358|Other|Pressure Support Ventilation of 8 cmH2O for 30 minutes|Spontaneous Breathing Trial using Pressure Support Ventilation of 8 cmH2O for 30 minutes
46102831|NCT02999074|Other|Resistance exercise|The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The progressive resistance exercise comprises 8 machine-based exercises, each performed in 3 sets, 12 repetitions at 60-80% of one repetition maximum (1-RM).
46102832|NCT02999074|Other|Aerobic exercise|The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The aerobic exercise will be performed on a cycle ergometer (or alternatively at a treadmill, elliptical, rowing ergometer, or combination) progressing from 60% to 70% VO2max with increasing duration. During weeks 7-18 the goal is to perform an extensive interval training.
46102833|NCT02999074|Other|Usual care during neoadjuvant chemotherapy/Exercise after surgery|The control group receives no exercise intervention during neoadjuvant CTx, which reflects the usual care condition. To investigate effects of different exercise timing, and to provide those patients also a potential health benefit and reduce drop-out and contamination, the control group will receive 18 weeks resistance or aerobic exercise (according to their personal preferences) after breast cancer surgery.
46019228|NCT04282993|Device|Wearable devices for identifying and measuring risk factors for ischemic stroke|Identifying and monitoring cerebrovascular risk factors using wearable devices
46102834|NCT00693784|Biological|Biostat® Disc Augmentation System|Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device
46102835|NCT00693706|Biological|Trivalent influenza vaccine GSK 138842A|IM injection on Day 0
46102836|NCT00693706|Biological|Fluarix|IM injection on Day 0
46102837|NCT03891394|Diagnostic Test|Human epididymis protein 4|Human epididymis protein 4 serum level in predicting persistent proteniuria
46102838|NCT00488683|Biological|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2-, 4-, and 12-months as IM injections in the anterolateral area of the right thigh.
46102839|NCT00488683|Biological|DTaP-Hib-IPV|IM injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2-, 3-, and 4-months in the anterolateral area of the left thigh.
46102840|NCT00488683|Biological|PCV|IM injections of 3 doses of 0.5 mL each of PCV supplied in pre-filled syringe were administered at 2-, 4-, and 12-months (Groups 2 and 3) or 13-months (Group 1) in the anterolateral area of the left thigh.
46102841|NCT00488683|Biological|MMR|IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months in the anterolateral area of the left thigh.
46102842|NCT00488683|Biological|Hib|IM injection of one dose 0.5 mL of Hib supplied in pre-filled syringe was administered at 13 months in the anterolateral area of the right thigh.
46102843|NCT00746200|Procedure|(electro)acupuncture|Frequency of electrostimulation: 15Hz; Duration of electrostimulation: 20min;
46102844|NCT00746200|Procedure|sham acupuncture|Superficial acupuncture needle stimulation at non-acupoints with TENS applied for seconds
46019229|NCT04282993|Other|Standard of care monitoring|Periodical medical examinations
46019230|NCT00960193|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1 and a single dose of 0.6 mg colchicine administered with Seville orange juice in the morning on Day 18 after an overnight fast of at least 10 hours.
46019231|NCT00960193|Other|Seville Orange Juice|240 mL of Seville orange juice administered in the morning and evening on Days 15 to 18.
46102845|NCT00746278|Procedure|Laparoscopic ovarian cystectomy using bipolar|Laparoscopic ovarian cystectomy using bipolar
46102846|NCT00746278|Procedure|Laparoscopic ovarian cystectomy using ultrasonic scalpel|Laparoscopic ovarian cystectomy using ultrasonic scalpel
46102847|NCT00746278|Procedure|Laparoscopic ovarian cystectomy using suture|Laparoscopic ovarian cystectomy using suture
46102848|NCT00746434|Drug|Roflumilast cream|Roflumilast cream 0.5%
46102849|NCT00746434|Drug|Placebo cream|Placebo cream
46102850|NCT02563366|Other|BM-MSCs|BM-MSCs are from third-party healthy volunteer donors.
46102851|NCT02563366|Other|Saline|Saline is the placebo of MSCs in this study.
46102852|NCT02563132|Procedure|Carbon dioxide insufflation|Carbon dioxide insufflation during diagnostic colonoscopy
46102853|NCT02563288|Drug|Esmolol|effect of esmolol on intraoperative sympathetic control and on extubation conditions.
46102854|NCT02563288|Drug|Dexmedetomidine|effect of dexmedetomidine on intraoperative sympathetic control and on extubation conditions.
46102855|NCT00711269|Drug|SM-13496 (lurasidone HCl)|Lurasidone HCl: 40 mg/day
46102856|NCT00711269|Drug|SM-13496 (lurasidone HCl)|Lurasidone HCl: 80 mg/day
46102857|NCT00711269|Drug|Placebo|
46102858|NCT00711269|Drug|Risperidone|
46102859|NCT01017445|Other|Boonme stick exercise|individual exercise daily
46102860|NCT01014793|Drug|cabergoline|cabergoline doses were increased at 6-week intervals, starting at 1.0mg/week followed by 2.0 and 3.5mg/week. Hormonal evaluations (IGF-I, GH and PRL) started before the first dose and were repeated at 6-week intervals after each cabergoline dose and after cabergoline withdrawal
46102861|NCT00286169|Drug|Amrubicin Hydrochloride|
46102862|NCT02697461|Other|Intrinsic Foot Strengthening|"Intrinsic foot strengthening is a commonly used intervention in clinic used to increase foot stability both in prevention of and in treatment of foot and ankle injury. Subjects allocated to the strengthening program will be educated in commonly used short foot exercises and toe yoga maneuvers that target the intrinsic muscles of the foot. No equipment will be required to perform the exercises."
46102863|NCT02697461|Other|Joint Mobilization|Joint mobilization is a commonly used clinical intervention used to decrease pain and increase joint range of motion. In the treatment groups who present with joint hypomobility, a forefoot inversion maneuver with a dorsally applied pressure in the lateral midfoot and rearfoot stabilized will be applied at the barrier before the physiologic end range of motion. A second mobilization will be performed at the distal segment of the 1st Tarsometatarsal joint. These mobilizations will be performed by a board certified orthopaedic physical therapist with 14-yrs of practice experience. No equipment will be required to perform the joint mobilization.
46102864|NCT00693472|Drug|Preladenant|Preladenant, one 25 mg capsule, administered orally every 12 hours
46102865|NCT00693472|Drug|Placebo|Matching placebo capsule administered orally every 12 hours
46102866|NCT00693472|Drug|Anticholinergic agents or propanolol|"Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.~Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol."
46102867|NCT00693472|Drug|Haloperidol|Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day
46102868|NCT02697149|Radiation|nonradiation-to-endoscopist endoscopic retrograde cholangiopancreatography|All patients received magnetic resonance cholangiopancreatography before the procedure. Characteristics of lesions (e.g. common bile duct stones, stenosis) in detail was identified. During the procedure, the endoscopist was not exposed to radiation. If fluoroscopy was needed, after contrast injection (sometimes not necessary), the endoscopist went outside of the operation room and observed the X-ray image by remote control of the fluoroscopy machine.
46102869|NCT02697149|Radiation|standard endoscopic retrograde cholangiopancreatography|Patients received standard endoscopic retrograde cholangiopancreatography. Fluoroscopy was normally used when necessary.
46102870|NCT00622661|Other|Low Glycemic Load Diet|consume both high and low glycemic load diets for 28 days each
46102871|NCT00622661|Other|High Glycemic Load Diet|consume both high and low glycemic load diets for 28 days each
46102872|NCT02565238|Device|BioMonitor 2|Implantation of BioMonitor 2
46102873|NCT03882736|Procedure|gluteal augmentation with flap in circumferential body lift|classic circumferential bodylift surgery, using two different well-known flaps for gluteal augmentation
46102874|NCT00498433|Drug|Aliskiren|300 mg tablet once daily
46102875|NCT00498433|Drug|Amlodipine|5 mg capsule once daily
46102876|NCT00498433|Drug|Placebo of Aliskiren|Matching placebo of aliskiren 300 mg tablet
46102877|NCT00498433|Drug|Placebo of amlodipine|Matching placebo of amlodipine 5 mg capsule
46102878|NCT02565160|Procedure|Intra-articular aspiration of Joint|Procedural sampling of the joint for diagnostic purposes
46102879|NCT02565160|Procedure|Joint irrigation washout|Procedural washout for treatment purposes
46102880|NCT02565160|Procedure|Total Joint Arthroplasty|
46102881|NCT02565160|Procedure|Revision Joint Arthroplasty|
46102882|NCT02689583|Biological|Antibiotic selection based on the antibiotic susceptibility testing|The biological intervention focused on the results from the antibiotic susceptibility testing. All patients should used the their susceptibility antibiotics according to antibiotic susceptibility testing of H. pylori. Considering the safety of drug usage, priority antibiotic selection was as follow: Amoxicillin > Clarithromycin > Levofloxacin >Tetracycline > Furazolidone > Metronidazole.
46102883|NCT02689583|Genetic|PPI selection based on the CYP2C19 gene polymorphism|PPI selection should based on the CYP2C19 gene polymorphism of patients. Patients have different metabolizers, such as poor metabolizers (PM), extensive metabolizers (EM) and intermediate metabolizer (IM). Different metabolism of patients should select different PPI or different doses of PPI. For IM and PM, in this study, patients selected the standard dose of Omeprazole. For EM, in this study, patients selected the Esomeprazole with increasing doses 50%-100%.
46102884|NCT02689583|Dietary Supplement|Probiotics usage based on the 16SrRNA sequencing|Different micro-environment in stomach may influence the antibiotic absorption. In this study, some patients could select probiotic as adjuvant therapy according to their micro-environment in stomach by 16SrRNA sequencing.
46102885|NCT00746746|Biological|HyperAcute vaccine|1.8 mL weekly
46102886|NCT00746746|Drug|Pegylated Interferon-Alpha 2b|6.0 mcg/kg weekly
46102887|NCT00498355|Drug|Ranibizumab|0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
45467549|NCT03780907|Drug|Placebo|Placebo once daily of oral tablet formulation to be taken in the morning, one hour before breakfast, with a glass of water.
46019232|NCT00960115|Biological|Tecemotide (L-BLP25)|After receiving a single low-dose cyclophosphamide, participants will receive weekly subcutaneous vaccinations with tecemotide (L-BLP25) (930 microgram [mcg]) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with tecemotide (L-BLP25) (930 mcg) will be administered every 6 weeks until progressive disease (PD).
46019233|NCT00960115|Drug|Single low dose cyclophosphamide|A single intravenous (IV) infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg/m^2) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
45467550|NCT03786211|Procedure|IANB by the guide of Panoramic|IANB will be injected by the guide of panoramic radiograph
45467551|NCT03786211|Procedure|IANB without the guide of Panoramic|IANB will be injected without the guide of panoramic radiograph, in the routine way.
46019234|NCT00960115|Biological|Placebo|After receiving single dose of saline, participants will receive weekly subcutaneous vaccinations with placebo that matches with tecemotide (L-BLP25) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with placebo will be administered every 6 weeks until PD.
46019235|NCT00960115|Other|Saline|A single dose of saline (sodium chloride, 9 grams per liter [g/L]) will be administered intravenously, 3 days prior to the start of placebo.
46019236|NCT02859883|Device|gastroscope FUSE™|All patients undergoing a diagnostic gastroscopy are eligible. Using the FUSE endoscope with side screen, the duodenal and accessory papilla are monitored. Data are collected by each operator. Clinical examination of patients is performed before they leave the centre.
46102888|NCT03439475|Biological|AMG 714|
46102889|NCT02564302|Device|MUSE Headband|MUSE Headband will help patients with mindfulness.
46102890|NCT01011595|Procedure|Cervical Mediastinoscopy|Surgical Meciastinal Lymph Node Staging
46102891|NCT01011595|Procedure|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
46102892|NCT01011595|Procedure|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
45467552|NCT01312623|Other|Remote ischemic preconditioning|Remote ischemic preconditioning at the left leg.
45680989|NCT00218296|Other|Reduction Group|Subject selects preferred method for reduction.
46102893|NCT04327271|Behavioral|Text-based VMMC follow-up|2wT clients will receive automated daily texts from days 1-13. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier. If 2wT patients do not respond to texts or return for any visit by day 14, they will be traced by SMS, phone or home visit. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. At Day 21, we will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.
46102894|NCT02564224|Procedure|Pursestring Wound Closure|Procedure: Pursestring Wound Closure
46102895|NCT02564224|Procedure|Conventional Wound Closure|Procedure: Conventional Wound Closure
46102896|NCT02564224|Device|prolene|
46019237|NCT04281355|Procedure|Omission of axillary lymph node dissection|Axillary lymph node dissection will be replaced by axillary radiotherapy in Randomisation B
46019238|NCT04281355|Radiation|Omission of regional irradiation|Regional irradiation will be omitted in the interventional arm of Randomisation A.
46019239|NCT04281277|Device|increase of mean arterial pressure at 80-85 mmHg.|increase of mean arterial pressure at 80-85 mmHg (with catecholamines or volemic expansion).
46019240|NCT04281277|Device|increase of mean arterial pressure at 65-70 mmHg.|increase of mean arterial pressure at 65-70 mmHg (with catecholamines or volemic expansion).
46019241|NCT04281121|Dietary Supplement|omega 3 fatty acids|: Life style modification, diet regimen and Omega-3 fatty acids supplementation: The dose of omega-3 fatty acids depended on the weight of patients according to World Health Organization recommendations 400 milligrams per 10 kilograms of body weight and had been given into two doses per day, before morning and evening meals
46019242|NCT00959647|Drug|Vismodegib|Vismodegib was supplied in capsules.
46019243|NCT00959647|Drug|FOLFOX|FOLFOX (folinic acid [FOL, leucovorin], fluorouracil [F, 5-FU], and oxaliplatin [OX]) was supplied as solutions for intravenous administration.
46019244|NCT00959647|Drug|FOLFIRI|FOLFIRI (folinic acid [FOL, leucovorin], fluorouracil [F, 5-FU], and irinotecan [IRI]) was supplied as solutions for intravenous administration.
46019245|NCT00959647|Drug|Bevacizumab|Bevacizumab was supplied as a solution for intravenous administration.
46019246|NCT02859493|Device|Saccharomyces cerevisiae|
46019247|NCT02859493|Device|Placebo|
46102897|NCT04539223|Drug|Evolocumab|Autoinjector 1-mL deliverable volume of 140 mg/mL
45467553|NCT03776773|Other|Pollution exposure|Pollution exposure and sleep data will be recorded by pollution sensor and polysomnography respectively. In order to compare the variations according to the pollinisation season and the allergic rhinitis status of the patients.
46019248|NCT02859649|Behavioral|neuropsychological test|neuropsychological test
46019249|NCT02861443|Behavioral|practice of colonic irrigation|
46019250|NCT02808403|Other|No intervention|No intervention; observation of routine medical care
46019251|NCT00957931|Procedure|Bone marrow transplantation|Bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.
46019252|NCT00957931|Biological|Mesenchymal Stromal Cells|
46019253|NCT00957853|Drug|Cetuximab|First dose of 400 mg/m^2 by vein on Days 1 and 8 over 2 hours, second dose of 250 mg/m^2 on week 2 and 3 (if applicable) given over 1 hour.
46019254|NCT00957853|Drug|IMC-A12|6 mg/kg/week by vein on Days 1 and 8 over 1 hour on weeks 1 and 2 and 3 (if applicable).
46019255|NCT00957853|Procedure|Surgical tumor resection|Surgical tumor resection on Day 10.
46019256|NCT02725567|Drug|ivacaftor|
46019257|NCT02858167|Device|FDG-PET|FDG injection followed by cerebral examination with X ray spiral CT after 40 minutes and FDG-PET after 60 minutes
46019258|NCT02858245|Other|No intervention - registry|
46019259|NCT00957229|Drug|GDC-0449|capsule, 150 mg, one pill daily, 18 months
46019260|NCT02604511|Drug|Ibrutinib|
46019261|NCT02858011|Other|Cash distribution during first 36 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
46019262|NCT02858011|Behavioral|Accompanying information sessions on health, child nutrition, household economics and education during first 36 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
46019263|NCT02858011|Dietary Supplement|Preventive Nutrition Packages during last 12 months|Fortified flour supplements for children (Supercereal Plus)and pregnant/lactating mothers (super Cereal)
46102898|NCT00743080|Procedure|Laparoscopic myomectomy and supracervical hysterectomy with GYNECARE MORCELLEX|"Laparoscopic myomectomy with GYNECARE MORCELLEX: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (GYNECARE MORCELLEX).~Laparoscopic supracervical hysterectomy using GYNECARE MORCELLEX: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of GYNECARE MORCELLEX. Abdominal cavity irrigation."
46019264|NCT02858011|Other|Cash distribution during the last 12 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
46019265|NCT02858011|Behavioral|Accompanying information sessions on health, child nutrition, household economics and education during the last 12 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
46019266|NCT02859571|Drug|Oxytocin|
46019267|NCT04282369|Device|HHHFNC|noninvasive ventilation modality
46019268|NCT04282369|Device|NCPAP|noninvasive ventilation modality
46102899|NCT00743080|Procedure|Laparoscopic myomectomy and supracervical hysterectomy with ROTOCUT G1|"Laparoscopic myomectomy with ROTOCUT G1: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (ROTOCUT G1).~Laparoscopic supracervical hysterectomy using ROTOCUT G1: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of ROTOCUT G1. Abdominal cavity irrigation."
46102900|NCT03382769|Device|Cochlear implantation|Unilateral implantation with a commercially approved Nucleus cochlear implant
46102901|NCT00746824|Drug|TM30339 and/or placebo|The drug and/or placebo will be injected in the abdominal area (site to vary for each injection). Injections will be administered twice daily for 28 days.
46102902|NCT01011751|Drug|Cyproterone acetate|Cyproterone acetate tablet-in-capsule.
46102903|NCT01011751|Drug|Medroxyprogesterone acetate|Medroxyprogesterone acetate tablet-in-capsule.
46102904|NCT01011751|Drug|Venlafaxine|Venlafaxine capsule.
46102905|NCT01011751|Drug|Leuprorelin|Leuprorelin injection.
46102906|NCT01011751|Drug|Flutamide|Flutamide tablet
46102907|NCT01011751|Drug|Placebo|Cyproterone acetate, medroxyprogesterone acetate or venlafaxine placebo-matching capsule.
46102908|NCT03672695|Combination Product|S 64315 (also referred as MIK665) and venetoclax|"The treatment combination period can only begin after the planned dose of venetoclax is reached. Depending on the administration dosing schedule, the combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) during which the patient continues to receive venetoclax daily. Once the planned dose of both drugs is reached the schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen for venetoclax.~S64315 should be administered 2 to 4 hours after venetoclax intake, via IV infusion. The dose escalation will start at 50 mg once a week and doses up to 250 mg once a week might be explored.~Venetoclax will be administered orally once a day. The dose escalation will start at 100 mg daily and doses up to 600 mg daily might be explored. Venetoclax must be taken with a meal (ideally during breakfast) in order to avoid reduced efficacy."
46102909|NCT02686619|Drug|Cyclosporine|Cyclosporine tablets orally once daily at dose level adapted to maintain concentration at 2 hours after administration (C2): 1000-1500 nanogram per milliliter (ng/mL) during Day 0 to Week 4, and 800-1200 ng/mL during Week 4 to Week 52. For Mycophenoate Mofetil + Sirolimus treatment arm, at Week 12, dose of cyclosporine will be reduced by 50% for 3 days, followed by 1/4 of the dose for 3 days, and then cyclosporine will be stopped.
46102910|NCT02686619|Drug|Daclizumab|Daclizumab 2 milligram (mg) per kilogram (kg) will be administered as intravenous infusion over 15 minute on Day 0 (during the 24 hours preceding renal transplantation) and at a dose of 1 mg/kg on Day14.
46102911|NCT02686619|Drug|Mycophenoate Mofetil|Mycophenoate mofetil 1 gram (g) (2*500mg tablets or 4*250mg capsules) will be given twice daily (daily dose of 2 g) orally for 12 months.
46102912|NCT02686619|Drug|Prednisolone|Prednisolone 250 mg intravenously on Day 0, followed by 0.5 mg/kg orally daily (maximum 40 mg daily) from Day 1 to Day 7, then 0.25 mg/kg orally daily (maximum 20 mg daily), then dose will be stepwise reduced by 2.5 mg per week to reach to a dose level of 10 mg daily and continued up to 6 months and finally drug will be discontinued after 8 months.
46102913|NCT02686619|Drug|Sirolimus|Sirolimus tablets will be given orally from week 12 to week 52, starting with loading dose of 10 mg daily for 2 days followed by 6 mg daily to adapt to trough concentrations of 8-15 ng/mL from week 12 to week 39, and 5-10 ng/mL from week 39 to week 52.
46102914|NCT00688636|Drug|infliximab|5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
46102915|NCT00688636|Drug|placebo|placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
46102916|NCT00870740|Biological|BIIB019 (Daclizumab High Yield Process)|SC injection
46102917|NCT00870740|Drug|Placebo|Placebo SC injection
46102918|NCT02563210|Other|airway resistance measurement|assessment of airway resistance
46102919|NCT01017523|Behavioral|Telephone support and behavior change|Diabetes self-management education provided over the telephone either for individual or couples
46102920|NCT01017523|Other|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
46102921|NCT02686853|Drug|Liposomal amphotericin B|
46102922|NCT02565082|Other|Blood sampling - healthy volunteers|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
46102923|NCT02565082|Other|Blood sampling - sickle cell patients arm - stable condition|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
46102924|NCT02565082|Other|Blood sampling - sickle cell patients arm- exsanguinotransfusion needed|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once, before and after the exsanguinotransfusion.
46102925|NCT02565082|Other|Blood sampling - sickle cell patients arm - vaso-occlusive crisis.|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
46102926|NCT02689505|Drug|BI 836880|
45467554|NCT03337152|Drug|primaquine|Participants receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
45467555|NCT03337152|Drug|chloroquine + primaquine|Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
46019269|NCT04282369|Device|NIPPV|noninvasive ventilation modality
46019270|NCT04282369|Device|NHFO|noninvasive ventilation modality
46019271|NCT04280809|Device|GaAlAs laser|GaAlAs laser (AMD Picasso, Dentsply Sirona, York, Pennsylvania, USA) with a wavelength of 810 nm was placed intraorally, at a distance of 1 cm in the position of the extracted tooth socket and circling in a 2 cm - diameter area. The power applied was 0.5 ± 20% W, continuously for 30 s. The total real energy released was 12.8 J and the real energy density applied was 4 J/cm2. Each patient was irradiated 3 times consecutively right after surgery, day 1 and day 2 after surgery
46019272|NCT02914561|Drug|Filgotinib|Tablet(s) administered orally once daily
46019273|NCT02914561|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
46019274|NCT02857933|Other|Physical Therapy|One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
46019275|NCT00956839|Drug|Vitamin D3 (Cholecalciferol)|"Arm 1 - Intramuscular vitamin D3 3,00,000 Units single dose~Arm 2 - Intramuscular vitamin D3 6,00,000 Units single dose~Arm 3 - Oral vitamin D3 500 Units/day for 6 months"
46019276|NCT00956293|Drug|Basiliximab|On day 0, 2 hours prior to transplant and day 4 post-transplant, 20 mg x2 were given to all participants. Post randomization, 20mg at weeks 7 and 12 were given to the Everolimus group.
46019277|NCT00956293|Drug|Enteric Coated Mycophenolic Acid (MPA)|A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.
46019278|NCT00956293|Drug|RAD001|Upon randomization, 3 mg (od) on Day 1, and 3 mg (1.5 mg every 12 hours) on Day 2 was given. Afterwards, the dosage was based on blood trough level (5 - 10 ng/mL).
46102927|NCT01017679|Drug|Gefitinib 500mg/Gefitinib 250mg|Gefitinib 500mg or 250mg is Taken Orally everyday by Experimental and controlled Arms respectively
46102928|NCT00743236|Procedure|cold ischemia procedure|Cold ischemia followed by partial nephrectomy
46019279|NCT00956293|Drug|Cyclosporin A (CsA)|Dosage was based according to blood level
46019280|NCT00956293|Drug|Corticosteroids|Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).
46102929|NCT00743236|Procedure|warm ischemia procedure|Warm ischemia followed by partial nephrectomy
46019281|NCT04204369|Other|Ultrasound education curriculum|"Participants were enrolled in a musculoskeletal ultrasound course including 2 components:~An online course (1-2 hours) to be done before the practical session. The videos were made available one (1) month prior to the practical course. This component reviewed the basics of ultrasonography, as well as the normal and abnormal appearance of relevant musculoskeletal structures (bone, tendon, ligaments, muscles, bursas, and nerves), and the ultrasound anatomy of high yield regions of the musculoskeletal system (shoulder, elbow, knee, ankle)~A practical session (4-6 hours) done during one of the usual academic days of the orthopedic residency program. This session covered the use of the ultrasound; the examination of the shoulder, elbow, knee, and ankle; ultrasound-guided musculoskeletal injections and aspirations; and ultrasound-guided distal radius fracture reductions. Ample practice time was given to the residents using means such as phantom models, cadavers, and real patients."
46019282|NCT04282291|Procedure|fascial block as postoperative analgesia|The tissue damage induced by the surgery generates a nociceptive pain which is accompanied by inflammatory mechanism (somatic pain), visceral and neuropathic pain, and why the treatment must be adapted to each surgical procedure. As the innervation of the upper abdominal wall depends mainly on the last intercostal nerves, the block of these nerves should be considered a good analgesic strategy to avoid the somatic pain. The placement of the local anesthetic in the serratus intercostal plane at the eighth rib (serratus intercostal plane block, SIPB) in the middle axillary line, managed to block the lateral and anterior cutaneous branches of the last intercostal nerves (T7-11). The results were satisfactory in the postoperative pain control of the patients with open cholecystectomy.
46019283|NCT04282291|Drug|Morphine|The continuous (basal) dose
46102930|NCT04565327|Drug|Hyperpolarized Carbon C 13 Pyruvate|Given IV prior to imaging
46102931|NCT04565327|Procedure|Magnetic Resonance Imaging (MRI)|Undergo MRI
46102932|NCT01017757|Procedure|High-resolution CT scanning|High-resolution CT scanning
46019284|NCT04282291|Device|PCA CADD Smith Medical pumps|perfusion
46019285|NCT00955825|Drug|300 IR|300 IR grass pollen allergen extract tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
46102933|NCT04187339|Biological|NGM395|NGM395 Dose 1
46102934|NCT04187339|Biological|NGM395|NGM395 Dose 2
46102935|NCT04187339|Biological|NGM395|NGM395 Dose 3
46019286|NCT00955825|Drug|Placebo|Placebo sublingual tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
46019287|NCT02859181|Dietary Supplement|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
46019288|NCT02859103|Drug|Desvenlafaxine|Patients will be provided 50mg dose of desvenlafaxine for 1 week titrated up to 100mg dose of desvenlafaxine for 7 weeks.
46102936|NCT04187339|Biological|NGM395|NGM395 Dose 4
46102937|NCT04187339|Biological|NGM395|NGM395 Dose 5
46102938|NCT04187339|Biological|NGM395|NGM395 Dose 6
46102939|NCT04187339|Other|Placebo|Placebo
46102940|NCT00746902|Device|nCPAP|Active nCPAP
46102941|NCT04130672|Procedure|Hot nasal packing with hot saline irrigation for hemostasis after adenoidectomy|After hot packing nasopharyngeal irrigation with 50 C saline
46102942|NCT04130672|Procedure|Cold nasal packing with cold saline irrigation for hemostasis after adenoidectomy|After cold packing nasopharyngeal irrigation with 22 C saline
46102943|NCT00743314|Other|screening questionnaire administration|
46102944|NCT00743314|Procedure|computed tomography|
46102945|NCT00743314|Procedure|lymphoscintigraphy|
46102946|NCT00743314|Procedure|single photon emission computed tomography|
46102947|NCT00743314|Radiation|intensity-modulated radiation therapy|
46102948|NCT00743314|Radiation|technetium Tc 99m sulfur colloid|
46102949|NCT02686541|Device|Atherectomy followed by Drug Eluting Balloon (DEB)|"Patient will undergo an intervention under anaesthesia. After pre-arthrectomy Intravascular ultrasound (IVUS) of the affected arterial segment, patient will undergo treatment with Arthrectomy, followed by post-arthrectomy IVUS analysis.~Following arthrectomy, the affected vessel will be treated by supplementary Ranger Drug Eluting Balloon (DEB).~During post-procedure, patients will be started on dual antiplatelets for 3 month post intervention followed by Aspirin for life unless contraindicated. Clinical follow-up, duplex ultrasound (to assess for re-stenosis) and Ankle Brachial Pressure Index (ABPI) will be performed at 1-month, 6-month and 12-month. Assessment of the symptoms, pulse, and clinical patency will be performed at each visit."
46102950|NCT02686463|Procedure|Laparoscopy|Laparoscopy is an operation performed in the abdomen or pelvis through small incisions (usually 0.5-1.5 cm) with the aid of a camera. It can either be used to inspect and diagnose a condition or to perform surgery.
46102951|NCT02686463|Procedure|Laparotomy|A laparotomy is a surgical procedure involving a large incision through the abdominal wall to gain access into the abdominal cavity. It is also known as a celiotomy.
46102952|NCT00639899|Procedure|Sclerotherapy|Super-selective retrograde venography and sclerotherapy of internal spermatic veins and associated venous bypasses and retro-peritoneal collateral
46102953|NCT00869024|Biological|Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells|Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).
46102954|NCT02685449|Drug|Insulin glulisine|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
46102955|NCT02685449|Drug|Insulin aspart|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
46102956|NCT02685449|Drug|Insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
46102957|NCT00697034|Drug|Capsaicin|natural alkaloid derived from hot chili peppers and activates vanilloid receptors that are also activated by endogenous cannabinoid anandamide applied three times daily
45467556|NCT03467620|Drug|Cannabidiol|Administration of one oral 25-mg capsule of Cannabidiol daily for a duration of 12 weeks
46102958|NCT00506779|Drug|Imatinib Mesylate|Phase I = Maximum tolerated dose (MTD) derived from dose escalation of 400, 500, 600 mg by mouth daily
46102959|NCT00506779|Drug|Paclitaxel|175 mg/m^2 by vein over 3 Hours every 21 Days
46102960|NCT02689193|Other|Blood sampling|Blood sampling (Volume depending on age, minimum 2.0 ml, maximum 10.9 ml extra)
46102961|NCT02616458|Other|ear pain counseling|The Ear Pain counseling materials reviewed concepts such as how to recognize ear pain and safely provide pain relief, and how to recognize danger signs that require urgent medical attention. Families were also encouraged to schedule an appointment in the CHC for a possible ear infection rather than going to the emergency department or urgent care facility after hours.
46102962|NCT02616458|Other|language power counseling|The Language Power materials explained the importance of frequent conversations between parents and children and of using encouraging rather than discouraging comments and the PRA reviewed age-appropriate activities in the Learning Games book, and the importance of daily reading using the provided children's book as an example.
46102963|NCT02685371|Behavioral|Breathing|Subjects will have to breath 1- Spontaneously 2- to produce a negative pressure of -15 to -30 cm of water and 3- to produce a negative pressure more than -30 cm of water.
46102964|NCT01017913|Other|TENS|The TENS equipment was calibrated on 20 hertz frequency, and a pulse width of 330 ms (standing in control number seven) with two channels.
46102965|NCT01017913|Other|Interferential currents|The IFC was adjusted to a base frequency of 4000 Hz, with a modulation frequency range of 20 Hz, ∆F of 10 Hz and slope of 1/1, in quadripolar mode.
46102966|NCT02619968|Other|experimental group|Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application. The Application of the tourniquet will be held in conjunction with exercises for the experimental group.
46102967|NCT00639977|Other|Acupuncture|20-minute session of acupuncture with needles inserted in specific points: Tong Zi Liao, Yang Bai and Jing Ming
46102968|NCT00639977|Other|Sham|20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians
46102969|NCT04130360|Behavioral|Problem-solving|The steps of problem-solving are explained to the participants. Then, they are presented two conflictive situations and they are asked to apply the problem-solving steps to find a solution. Once they finish, they are asked to apply the steps in a conflictive situation they have experience in the last month. In the end, they are reminded of the steps and encouraged to practice them in their daily conflicts.
46102970|NCT01017991|Other|Milk based infant formula with probiotic|formula supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days duration
46102971|NCT01017991|Other|Milk based infant formula|supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days
46019289|NCT04282135|Diagnostic Test|MCC IMS|Diagnosis by MCC IMS
45467557|NCT03467620|Drug|Placebo oral capsule|Administration of one oral placebo capsule daily for a duration of 12 weeks
45467558|NCT03780205|Other|Prescription glasses for bilateral amblyopia|Correction of refractive error with prescription glasses both eyes
45467559|NCT03780205|Other|Prescription glasses for unilateral amblyopia|Correction of asymmetric refractive errors with lenses
46019290|NCT02859025|Biological|anterior iliac crest graft|Anterior iliac crest spongy bone filled the defects followed by coverage with collagen membrane.
46019291|NCT02859025|Biological|lateral ramus cortical bone+BFPSC+NBBM|ramus cortical bone cage created a protected healing space and BFPSCs cultured over NBBM were put over the graft.
45467560|NCT02725580|Genetic|AT-GTX-501|CLN6 Gene delivered by Self-Complementary AAV9
45467561|NCT04751500|Procedure|Outpatient hysteroscopy|Direct visualisation and careful extraction of retained pregnancy tissue using a specific hysteroscopic technology known as a hysteroscopic tissue retrieval system.
46019292|NCT02859025|Biological|anterior iliac crest graft+BFPSC+NBBM|Anterior iliac crest spongy bone filled the defects and BFPSCs cultured over NBBM were put over the spongy bone.
46019293|NCT02869009|Drug|clopidogrel|
46019294|NCT02869009|Drug|Aspirin|
46019295|NCT01164579|Drug|Tasocitinib plus Methotrexate|Tofacitinib (CP 690,550) 10 mg BID, tablets + methotrexate (MTX) 10 mg/wk to 20 mg/wk, titrated over 2 months
46019296|NCT01164579|Drug|Tofacitinib plus placebo methotrexate|Tofacitinib (CP-90,550) 10 mg BID, tablets. Placebo to match methotrexate (MTX) capsules titrated as in Treatment Arm 1.
46019297|NCT01164579|Drug|Placebo tofacitinib plus Methotrexate|Methotrexate (MTX) 10 mg/wk to 20 mg/wk, capsules, titrated over 2 months. Placebo in tablets to match tofacitinib
46019298|NCT02859259|Drug|BMS-663068 (1 tablet at 600 mg)|BMS-663068 (1 tablet at 600 mg). A single dose of BMS-663068 administered orally as specified.
46019299|NCT02859259|Drug|BMS-663068 (4 tablets at 150 mg each tablet)|BMS-663068 (4 tablets at 150 mg each tablet). A single dose (4 tablets) of BMS-663068 administered orally as specified.
46102972|NCT04185233|Other|Games on an iPad|Many games will be programmed on the iPad and organized by age. The child will choose one game and play it during all the procedure time.
46102973|NCT04185233|Drug|Nitrous Oxide|Nitrous oxide will be provided to the child by a mask 3 minutes before the intervention and during all this one.
46102974|NCT04130048|Diagnostic Test|Ultrasound Elastography|Ultrasound elastography aims to assess the stiffness of a tissue, submitting it to an ultrasound impulse.
46019300|NCT04280731|Dietary Supplement|fermented quinoa|Quinoa drink fermented with lactic acid bacteria isolated from food
46019301|NCT02858947|Procedure|Aelite Flo|Microhybrid flowable composite
46019302|NCT02858947|Procedure|x-tra base|Bulk-fill flowable composite
46019303|NCT00958789|Device|Triathlon TS Knee System|Total knee replacement for revision cases
46019304|NCT02857777|Drug|Esketamine|Subjects will self-administer intranasal esketamine as per the treatment regimen.
46019305|NCT02858635|Other|Clinical and neuropsychological assessment, Blood and saliva samples|Clinical and neuropsychological assessment: impulsivity, aggressiveness, psychological pain, angor with specific scales and smartphone.
46102975|NCT04227067|Device|TENS|An electrical impulse is delivered to the skin around the painful area using pads attached to an electric generator.
46102976|NCT04227067|Device|SHAM TENS|A TENS generator without batteries is used. The pads are attached to the generator and to the skin around the painful area.
46102977|NCT00639431|Behavioral|direct observation|direct observation of another person's foot moving
46102978|NCT00639431|Behavioral|mental visualization|mentally imagining moving one's phantom foot/feet
46102979|NCT04130282|Biological|Pfs25-IMX313/Matrix-M1|3 doses of 10µg Pfs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56
46102980|NCT04184843|Other|iWalk Toolkit|"Intervention period: 5 months~Intervention:~A toolkit consisting of 3 components: an educational guide, a smartphone app, and an educational video.~Access to a clinical expert by email or phone"
45467562|NCT04751500|Behavioral|Expectant management|Leaving the retained pregnancy tissue alone to pass by itself
46019306|NCT05367375|Procedure|removing osteophyte at patellofemoral joint|to compare anterior knee pain between removing patellofemoral joint osteophytes and non-removing patellofemoral joint osteophytes after medial unicompartmental knee arthroplasty
46019307|NCT00630643|Biological|NI-0401 (anti-CD3 mAB)|0.05 mg up to 10 mg
46102981|NCT00488293|Procedure|Store and forward teledermatology|Standard electronic consult, standardized history, and image set
45467563|NCT04751500|Drug|Medical management|Giving medications to contract the womb to pass the retained pregnancy tissue
46102982|NCT02614430|Other|Vocational training|The intervention consists of a physical training program, individual motivational talks and guidance on labor market-oriented topics. Each program is customised to the patient's physical resources and conditions where. The framework for the intervention of physical activity 1 hours 3 times weekly with concurrent motivational talks for an overall maximum duration of 9 weeks. Based on an assessment of the patient is instructed about pain management, ergonomics, conflict management, diet, lifestyle, behavior modification, stress symptoms and preventive home training.
46102983|NCT04185077|Drug|Bivalirudin|Bivalirudin (Salubris Pharmaceuticals Co) was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion, a reduced-dose infusion (0.2mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of0.3mg/kgwasgivenif the activatedclotting time 5minutes after the initial bolus (measuredwith the Hemotec assay) was less than 225 seconds.
46102984|NCT04185077|Drug|Heparin|a bolus dose of 100 U/kg was administered according to current guidelines.Additional heparinwasadministered if the post-bolus activated clotting time was less than 225 seconds.
46102985|NCT04527965|Other|Customized diet to reduce liver fat|"Ad libitum diet high in plant-derived PUFA and lower in carbohydrates~Carbohydrates: 30 E% Fat: 50 E% (PUFA 10-15 E%) Protein: 20 E%~Key foods are provided"
46102986|NCT04527965|Other|Healthy Nordic diet|"Ad libitum diet, based on Nordic foods, high in carbohydrates (high fiber/low GI) and lower in fat~Carbohydrates: 50-55 E% Fat: 25-30 E% (PUFA 5-7.5 E%) Protein: 20 E%~Key foods are provided"
45467564|NCT04751500|Drug|Antibiotic|Giving antibiotics to reduce any inflammation/infection caused by the retained pregnancy tissue allowing it to pass by itself
45467565|NCT04751500|Procedure|Surgical management|Passing a small cannula/catheter/currette into the womb and mechanically scraping the womb lining to remove the retained pregnancy tissue
45467566|NCT04305249|Drug|ATG-017|Dosing will begin at 5 mg QD ATG-017 as starting dose. A treatment cycle will be 21 days for continuous dosing and 28 days for 7 days on/7 days off intermittent dosing of ATG-017 treatment.
45680990|NCT00217672|Biological|bevacizumab|Patients receive bevacizumab 15 mg/kg intravenously (I.V.) every 3 weeks until disease progression, unacceptable toxicity, or consent withdrawal.
46019308|NCT00630643|Drug|Placebo|Placebo
46019309|NCT03202849|Dietary Supplement|Vitamin D and A|A single dose of Vitamin A and Vitamin D will be given.
46019310|NCT03202849|Dietary Supplement|Vitamin D and Placebo|A single dose of Vitamin D plus a placebo will be given.
46019311|NCT04277533|Diagnostic Test|Serum γ-Glutamyl transferase (GGT), Total serum bilirubin (TSB), Serum calcium concentration (Ca2+), Peripheral blood neutrophil to lymphocyte ratio (NLR)|GGT, Ca2+, NLR and TSB are serum markers which had been studied for early detection and prediction of severity of NEC.
46019312|NCT04277221|Biological|Autologous Dendritic Cell/Tumor Antigen, ADCTA|ADCTA is an individualized cell immunotherapy co-culturing autologous dendritic cells derived from peripheral blood mononuclear cells (PBMNCs) with autologous tumor cell as antigen in order to evoke specific immune response.
46019313|NCT02445391|Drug|Capecitabine|Given PO
46019314|NCT02445391|Drug|Carboplatin|Given IV
46019315|NCT02445391|Drug|Cisplatin|Given IV
46019316|NCT01246986|Drug|LY2157299|Administered orally
46019317|NCT01246986|Drug|Sorafenib|Administered orally
46019318|NCT01246986|Drug|Ramucirumab|Administered IV
46019319|NCT01164501|Drug|BI 10773|BI 10773 tablets once daily
46102987|NCT04527965|Other|Control|"Ad libitum diet in accordance with the Nordic Nutrition Recommendations~Key foods are provided"
46102988|NCT01018069|Drug|AEG35156|2 hr infusion of 650 mg of AEG35156 on days 1, 2, 3 and 8. Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6. The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.
46019320|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 low dose
46019321|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 high dose
46102989|NCT02686307|Procedure|ICD Implant|Implantation of an implantable cardioverter/defibrillator
46102990|NCT02686385|Drug|Prednisolone|
46019322|NCT01164501|Drug|BI 10773|BI 10773 tablets once daily
46019323|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 low dose
46019324|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 high dose
46019325|NCT05322291|Behavioral|Mobil Application|The mobile application developed will be installed on the phones of hemodialysis patients
46019326|NCT04276831|Device|Laryngoscope McCoy|Subjects who fulfill inclusion criteria will be intubated using laryngoscope McCoy
46102991|NCT02686385|Drug|N-Acetylcysteine|NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
46102992|NCT04417777|Genetic|Blood Test|Blood analysis
46102993|NCT02686151|Drug|Letrozole|used after oocyte retrieval
46102994|NCT02686151|Drug|Polygeline|used after oocyte retrieval
46102995|NCT02686151|Drug|Sodium Chloride|used after oocyte retrieval
46102996|NCT02686151|Drug|dexamethasone|used after oocyte retrieval
46102997|NCT00868790|Drug|MK-3577|MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.
46102998|NCT00868790|Drug|Placebo to MK-3577|Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period
46102999|NCT00868790|Drug|Metformin|Two 500 mg tablets of metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
46103000|NCT00868790|Drug|Placebo to Metformin|Two placebo tablets to metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
46103001|NCT00496483|Drug|LCP Tacro (tacrolimus)|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
46103002|NCT00496483|Drug|Prograf|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
46103003|NCT00697580|Behavioral|Nutrition|Nutrition classes for 1 hour & 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
46103004|NCT00697580|Behavioral|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour & 30 minutes for 16 weeks + motivational interviewing (4 individual & 4 group sessions)
46103005|NCT00697580|Behavioral|Circuit Training & Nutrition|Circuit Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour & 30 minutes for 16 weeks + motivational interviewing (4 individual & 4 group sessions)
46103006|NCT04403893|Other|HANARO biliary stent placement|HANARO biliary stent placement
46103007|NCT02614352|Drug|Atorvastatin + Candesartan|
46103008|NCT02614352|Drug|AG1502|
46103009|NCT02616536|Other|Teaching methods|the two teaching methods will be given to two groups of students and their knowledge gain will be analysed
45467567|NCT04305249|Drug|ATG-017+Nivolumab|With the combination with nivolumab, a cycle of study treatment will be defined as 28 days. ATG-017 is planned initially to be continuously given 28 days in each cycle. ATG-017 dosing schedule in combination therapy will follow a similar dose escalation principle as with monotherapy but starting at 5 mg BID. Nivolumab will be specified dose on specified days.
46019327|NCT04276831|Device|Laryngoscope Macintosh|Subjects who fulfill inclusion criteria will be intubated using laryngoscope Macintosh
46019328|NCT04282057|Device|Radiofrequency|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45 degrees. The application was in capacitive mode, with a 7cm electrode, always in movement. The duration of the application was established in 15 minutes, maintaining the local temperature between 40 to 42 celsius degrees at the epidermis.
46019329|NCT04282057|Device|Aerobic exercise|Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen's formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (5 minutes); body (30 minutes); and cooling (from 5 to 10 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
46019330|NCT04282057|Device|Shock wave therapy|The shock wave device corresponds to the BTL-6000 X-Wave TM with a 20mm transmitter multifocal. The parameters used correspond to the pressure set between 2.8 and 3.5 bar, frequency 15 hertz and 3000 pulses per 10x15 cm area. It was used as a means contact gel for ultrasound, reference 033-051. In this procedure the participants found themselves in the supine position, with a pillow under the head and with the bending knees.
46019331|NCT04319640|Behavioral|Cognitive behaviour therapy for insomnia|CBT-I for children with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 5 weekly modules.
46103010|NCT02619890|Other|Brain Glioma Registry|
46019332|NCT04319640|Behavioral|psychoeducation for ASD|psychoeducation contains information about ASD, The treatment consists of 5 weekly modules.
46103011|NCT01018147|Procedure|4-dimensional computed tomography|Undergo 4-D CT imaging
46103012|NCT04133246|Behavioral|Focus group|Groups of 6 to 10 patients and spouses led by the psychologist about their parenthood lasting 2 hours
46103013|NCT04133246|Behavioral|Individual interview|Interview led by the psychologist about the patient's parenthood
46103014|NCT01018225|Drug|darifenacin|7.5 or 15 mg darifenacin, once a day for 6 weeks
46019333|NCT04275271|Behavioral|Educational intervention|Skill centered Protocol Training based on IMB model
46103015|NCT01018225|Drug|Placebo|Placebo pill, once a day, for six weeks
45467568|NCT03710161|Drug|Vitamin D|Vitamin D taken in two different dosages daily for six months.
45680991|NCT00217672|Drug|Docetaxel|docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
46019334|NCT00958711|Device|Unite Biomatrix|Collagen based, decellularized equine pericardial dressing for skin surface wounds
46019335|NCT00958711|Other|Saline and Gauze|gauze moistened with sterile saline
46019336|NCT01163721|Drug|Ranolazine|Ranolazine ER 1000 mg (two 500 mg tablets) administered orally twice daily
46019337|NCT01163721|Drug|Placebo|Placebo to match ranolazine administered orally twice daily
46019338|NCT03178981|Other|Use electronic cigarette or smoke conventional cigarette|Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
46019339|NCT02885493|Behavioral|tests|
46019340|NCT03150511|Drug|Tesamorelin 2 Milligrams (MG)|Daily self-administered study drug
46019341|NCT03150511|Drug|Placebo|Daily self-administered placebo
46019342|NCT04314453|Other|percutaneous endoscopic lumbar discectomy|Resection of the hypertrophied faceted joints, osteophyte formation and ligamentum flavum (LF) hypertrophy, with or without disc protrusion for degenerative spinal stenosis.
46019343|NCT00958243|Biological|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.5 mL intramuscular injection on Day 0 and Day 21
46103016|NCT00698438|Device|Ex-PRESS implantation|"I. Mobility check of the device. II. Administration of a local or topical anesthetic. III. Preparation and coverage of the eye by conventional sterile procedures. IV. Injection of viscoelastic material into the AC through a paracenthesis. V. Creation of a scleral tunnel up to clear cornea. VI. Creation of a (5 mm) conjunctival tunnel fornix based. VII. Lifting of the conjunctiva and tenon. VIII. Formation of a 2mm scleral incision at 0.3mm depth, 1.5mm from the limbus. IX. Application of 0.5µg/ml MMC under the tunnel for one minute.~X. Penetration into the AC using a 0.65mm stiletto, inside the tunnel of the sclera-corneal junction.~XI. Implantation of the Ex-PRESSTM through that pre-incision at the sclerocorneal junction.~XII. Introducer withdrawal. XIII. Tucking the plate under the scleral tunnel, and verification of the position inside the tunnel.~XIV. Reposition the conjunctiva with 1 - 2 sutures at the limbus. XV. Closing the conjunctiva with a suture."
46103017|NCT00698438|Procedure|Trabeculectomy|standard trabeculectomy
46103018|NCT03528551|Drug|Turoctocog alfa pegol|Turoctocog alfa pegol 75 IU/kg body weight will be administered once weekly as intravenous injections for a duration of 2 years.
46103019|NCT03528551|Drug|Turoctocog alfa pegol|Turoctocog alfa pegol 60 IU/kg body weight (for patients younger than 12 years) and 50 IU/kg body weight (for patients, 12 years or older) will be administered twice weekly as intravenous injections for a duration of 2 years.
46103020|NCT03528551|Drug|Turoctocog alfa pegol|Turoctocog alfa pegol 50 IU/kg body weight will be administered three times weekly as intravenous injections for a duration of 2 years.
46103021|NCT01018303|Dietary Supplement|AquADEK|Two AquADEK softgel vitamins on a daily basis x 12 weeks
46103022|NCT03996343|Device|Endotracheal intubation|COMPLETE
46103023|NCT03996343|Device|Laryngeal mask airway|COMPLETE
46019344|NCT00958243|Biological|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.25 mL intramuscular injection on Day 0 and Day 21
46019345|NCT00958243|Biological|Placebo|Placebo
46019346|NCT04280341|Biological|RC48-ADC in combinaton with JS001|"The study has 2 parts which include dose escalation phase and dose extension phase.~Dose escalation will use a 3+3 design and will enroll cohorts of 3-6 patients with HER2-Positive Advanced Malignant Solid Tumors sequentially at escalating doses of 2.0mg/kg and 2.5mg/kg to RC48-ADC and JS001 is fixed dose of 3.0mg/mg"
46019347|NCT01241760|Drug|Ribavirin|Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4
46019348|NCT01241760|Drug|Telaprevir|1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks
46103024|NCT00487981|Device|Precision Spinal Cord Stimulation|Stimulation on throughout the study once device is implanted
46019349|NCT01241760|Drug|Pegylated interferon alfa-2a|180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4
46019350|NCT01241760|Drug|Telaprevir|750 mg (2 oral tablets) every 8 hours for 12 weeks
46019351|NCT04280263|Drug|Caffeine|caffeine tables containing 150mg caffeine will be provided to patients with instructions to take twice per day
46019352|NCT04280263|Drug|Placebo oral tablet|oral placebo tablets matching the caffeine tablets and will be provided to patients with instructions to take twice per day
46019353|NCT02858557|Behavioral|Mediterranean diet|The Mediterranean diet is rich in complex carbohydrates and fibers and low in animal proteins and fats.
46019354|NCT02858557|Behavioral|Specific Carbohydrate Diet|The specific carbohydrate diet is a dietary program popular among patients with IBD. The diet allows carbohydrate foods consisting of mono-saccharides only, and excludes di-saccharides and most polysaccharides.
46019355|NCT00958165|Device|CardioFocus EAS-AC|PVI for PAF
46103025|NCT01014949|Other|Coronary microcirculation assessment|"Patients will arrive to the cardiac catheterization laboratory in a fasting state without discontinuation of their cardiac medications. After conventional diagnostic coronary angiography, 3000-5000 I.U. i.v. heparin will be administered, and a 6F coronary guiding catheter will be placed in the ostium of the coronary artery of interest. A 0.014 coronary pressure wire (Radi Medical Systems, Wilmington, Mass) will be calibrated, equalized to the guiding catheter pressure with the sensor positioned in the coronary ostium, and then advanced to the distal coronary artery (down to at least two thirds of the epicardial vessel length). Coronary flow reserve (CFR), fractional flow reserve (FFR) and the index of microvascular resistance (IMR) will be measured after an intravenous infusion of adenosine [140 ug/kg/min] to induce steady state maximal hyperemia."
46103026|NCT02685137|Drug|stannsoporfin|Intramuscular injection of stannsoporfin to treat jaundice.
46103027|NCT02685137|Other|Sham Injection|nothing
46103028|NCT01015027|Biological|REGN668|4 IV Cohorts (Dose 1, 2, 3, & 4)
46103029|NCT01012063|Drug|iron sucrose, erythropoietin-β|The 200 mg of iron sucrose diluted with 100 ml of normal saline was given intravenously over one hour and the 3000 IU of Epo-β was injected subcutaneously.
46103030|NCT01012063|Drug|normal saline|100 ml of normal saline was given intravenously over one hour and 0.5ml was injected subcutaneously.
46103031|NCT02689115|Other|Genetic relative expression|The genetic expression of NF-KB1 and IKK epsilon were quantified in both groups.
46103032|NCT03242915|Drug|Pembrolizumab|200mg IV every 3 weeks
46103033|NCT03242915|Drug|Carboplatin|AUC 5 IV every 3 weeks
46103034|NCT03242915|Drug|Pemetrexed|500 mg/m^2 IV every 3 weeks
46103035|NCT00861744|Biological|GSK Biological's investigational vaccine 209762|Subcutaneous injection, one dose
46103036|NCT00861744|Biological|M-M-R® II (Merck and Co)|Subcutaneous injection, one dose
46103037|NCT00861744|Biological|Varivax®|Subcutaneous injection, one dose
46103038|NCT00861744|Biological|Havrix®|Intramuscular injection, one dose
46103039|NCT00861744|Biological|Prevnar®|Intramuscular injection, one dose
46103040|NCT00638417|Behavioral|Maximal strength training|maximal dynamic strength training from 1 week after the operation, 5 training bouts a week for 4 weeks. The regimen consisted of 2 exercises, leg press and hip abduction, that included 4 series of 5RM involving the operated leg only. 5RM corresponds to approximately 85% of 1RM. When the patients managed to perform 6RM, the load was increased by 5kg. The series were separated by resting periods of 2 minutes.
46103041|NCT00638417|Behavioral|conventional rehabilitation|conventional rehabilitation program: inpatient treatment in a rehabilitation center. Individual sling exercise therapy in hip abduction/adduction, hip flexion/extension, exercises with low resistance (>12-15 repetitions37), or no resistance and exercises performed in water when sutures had been removed. Each session lasted 1 hour and was performed 5 days a week for 4 weeks.
45838071|NCT04921488|Device|screening colonoscopy|The screening colonoscopy will be performed by an investigator. The automatic detection and characterization system will be activated at the time of descent of the colonoscopy (after caecal intubation), with video recording (image without CAD EYE and image with CAD EYE). The investigator performing the colonoscopy will be blinded by the results of the CAD EYE.
46103042|NCT02685059|Drug|MEDI4736 (Anti PD-L1)|"MEDI4736 1.5g total i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~MEDI4736 in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736 in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3)."
46103043|NCT02685059|Drug|Placebo|"Placebo i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~Placebo in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736/Placebo in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3)."
46103044|NCT02685059|Drug|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
45680992|NCT03593122|Device|WO2085 Moisturising Cream|"Week 1: 2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).~Week 2-4: The frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day)."
45680993|NCT03597880|Other|obese patients|underwent bariatric surgery
46103045|NCT02685059|Drug|Epirubicin|Epirubicin 90 mg/m² 2-weekly for 8 weeks
46103046|NCT02685059|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
46103047|NCT00640055|Other|Coordinator|Coordinator (non-physician) assigned cause of death
46103048|NCT00640055|Other|Physician-assigned cause of death|Physician (gold standard) cause of death
45680994|NCT03592966|Dietary Supplement|Wild Blueberry Powder|Freeze-dried whole fruit blueberry drink.
45680995|NCT03592966|Dietary Supplement|Placebo|Freeze-dried placebo powder
46103049|NCT00603239|Drug|exenatide|subcutaneous injection, 5 mcg or 10 mcg, twice a day (BID)
46103050|NCT00603239|Drug|placebo|subcutaneous injection, volume equivalent to 5 mcg or 10 mcg of active drug, twice a day
46103051|NCT00700986|Drug|AZD9056|Oral tablet, 800mg, one single administration
46103052|NCT00700986|Drug|Placebo|Single dose
46103053|NCT04119726|Behavioral|Usual Text Messages|Regular messages about prevention and cure of CHD will be sent to both groups four times a week. The short texts will be selected from the guidelines in China to avoid misinformation. There are also some pictures or videos that help patients change their behaviour.
45838072|NCT04920032|Drug|TAS-102|Given PO
45838073|NCT04920032|Drug|Irinotecan|Given IV
45838074|NCT04920032|Combination Product|Standard Treatment|6 cycles for a 2-week regimen (infusional 5FU based) and up to 4 cycles for a 3-week regimen (oral capecitabine based) after randomization
45838075|NCT04920032|Diagnostic Test|Signatera MRD ctDNA Assay|To be performed within 6-8 weeks of Cycle 1 Day 1. A Mid-treatment ctDNA is to be completed within 6 - 8 weeks of starting treatment. ctDNA is to also be completed within four weeks after completion of study treatment (+/- two weeks)
45838076|NCT04913064|Other|Questionnaire Administration|Ancillary studies
45838077|NCT04913064|Drug|White Button Mushroom Extract|Given PO
46103054|NCT04119726|Behavioral|Personalized reminders|Personal information, life behavior and risk factors will be registered when patients are enrolled. According to the baseline information, personalized knowledge will be sent to patients in the intervention group. Besides, patients will receive drug information and regular medication adherence reminders daily according to patients' baseline prescription drugs and modifications.
46103055|NCT04119726|Behavioral|Internet-based counselling|"The internet-based counselling is the key module of social media in the intervention group. The consultation content mainly includes the feedback of coronary heart disease secondary prevention drug compliance, the feedback of risk factor level control, the feedback of life and behaviour habits, the feedback of adverse events, the feedback of health education knowledge improvement, the reminders of data upload, behaviour change, and health education learning.~When the patient has questions or discomfort during the medication, they can consult the applet and the applet will perform internet-based answers on the large database built by cardiologists. Meanwhile, social media will upload the question of consultation and report to the doctor according to individual differences in disease. If the patient is not satisfied with the auto-response, the patient can further consult his doctor and the doctor's response will be collected to improve the auto-response database"
46103056|NCT04119882|Diagnostic Test|Blood collection|New biomarker test
46019356|NCT04280185|Procedure|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is a way of intraperitoneal chemotherapy
46103057|NCT04186715|Device|Near-infrared spectroscopy|The Near-infrared spectroscopy probes will be placed in the frontal region.
46103058|NCT00699114|Drug|Placebo|Lactose as powder in gelatine capsules, single dose
46103059|NCT00699114|Drug|Ibuprofen 400 mg|Ibuprofen 400 mg as powder in gelatine capsules, single dose
46103060|NCT00699114|Drug|Ibuprofen 600 mg|Ibuprofen 600 mg as powder in gelatine capsules, single dose
46103061|NCT00699114|Drug|Ibuprofen 800 mg|Ibuprofen 800 mg as powder in gelatine capsules, single dose
46103062|NCT00699114|Drug|Paracetamol (acetaminophen) 500 mg|Paracetamol (acetaminophen) 500 mg as powder in gelatine capsules, single dose
46103063|NCT00699114|Drug|Paracetamol (acetaminophen) 1000 mg|Paracetamol (acetaminophen) 1000 mg as powder in gelatine capsules, single dose
46103064|NCT00699114|Drug|Paracetamol (acetaminophen) 1000 mg + codeine 60 mg|Paracetamol (acetaminophen) 1000 mg + codeine 60 mg as powder in gelatine capsules, single dose
46103065|NCT00639587|Drug|Ketotifen|Ketotifen dry syrup 0.1%; 1 mg b.i.d.; for 2 weeks
46103066|NCT00639587|Drug|Cetirizine|Cetirizine tablet; 10 mg o.d.; for 2 weeks and 5 mg b.i.d.; for 2 weeks
46103067|NCT00700518|Drug|placebo cream|placebo cream applied to 2 adjacent fingers of non-dominant hand one time
46103068|NCT00700518|Drug|Glyceryl Trinitrate|0.6mg of Glyceryl Trinitrate applied to 2 adjacent fingers on non-dominant hand one time
46103069|NCT00700518|Drug|Glyceryl Trinitrate|1.2mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
46103070|NCT00700518|Drug|Glyceryl Trinitrate|1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
46103071|NCT00700518|Drug|Glyceryl Trinitrate|2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
46103072|NCT00852930|Procedure|laser and MLD combined|The intervention is therapist administered laser and mld treatment combined
45838078|NCT04908176|Drug|Avapritinib|avapritinib tablets
45838079|NCT04908176|Drug|midazolam|midazolam syrup
45838080|NCT04906525|Behavioral|Resistance training|Participants will undergo 6 weeks of supervised resistance training
45838081|NCT04906525|Other|Conventional physical activity guidelines|Participants are given recommendations on physical activity guidelines
45838082|NCT04901624|Behavioral|Family Risk Messaging|"Family risk framing may engender concern for loved ones. It may also make it easier to mentally simulate family burdens with COVID-19 such as knowing how several people in the family becoming sick could adversely affect the lives of everyone in the family. Households randomized to family risk messaging will receive the following message: Antibody testing will help you understand your family's risk of getting COVID-19."
46019357|NCT02858479|Other|stimulation on painful area (area allodynic)|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds"
46019358|NCT02858479|Other|same stimulation on non-painful area|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds"
46019359|NCT02858479|Radiation|MRI scan|"2 sessions for 10 minutes :~11 controls stimulations for 6 s each spaced 20 s without stimulation.~11 allodynic stimulations for 6 s each spaced 20 s without stimulation."
46103073|NCT00852930|Procedure|laser alone|The intervention is therapist administered laser
46103074|NCT00852930|Procedure|manual lymphatic drainage|The intervention is therapist administered manual lymphatic drainage
46103075|NCT00852540|Drug|Retpamulin Ointment, 1%|Topical retapamulin (SB-275833) ointment, 1% (w/w), and placebo ointment, will be provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse-taper puncture-tip caps. Retapamulin or placebo ointment will be applied twice daily for 5 days.
46103076|NCT00852540|Drug|Linezolid|Adult and adolescent (=>12 years of age) subjects will receive one 600mg linezolid tablet (overencapsulated), or one placebo capsule, twice daily for 10 days. Pediatric subjects aged 5-11 years will receive 10mg/kg body weight of a 100mg/5mL oral linezolid suspension, or placebo suspension, twice daily for 10 days. Pediatric subjects <5 years of age will receive 10mg/kg of a 100mg/5mL oral linezolid suspension, or placebo suspension, three times daily for 10 days.
46103077|NCT00701142|Biological|Haemocomplettan® P|Single intravenous infusion
46103078|NCT00701142|Biological|Saline solution|Single intravenous infusion
46103079|NCT00861198|Other|ERCP as per medical indication|ERCP as per medical indication
46103080|NCT00701220|Drug|Atorvastatin Calcium|Atorvastatin Calcium starting at a 10 mg dose and may be increased up to 40 mg dose until cholesterol is lowered to an acceptable range. Blood will drawn every 2 weeks for the first 12 weeks to check the cholesterol level and adjust medication dosage. Cardiac MRI will be performed at the beginning and at the end of the 6 month study to measure the physical changes of the heart.
46103081|NCT00847704|Device|Assisted movement and enhanced sensation|Each subject will be tested before, after the 10 week treatment period and then 3 months later. Treatment sessions will occur 3 times per week and last approximately 30 minutes per treatment. The device will measure 3 of the functional tests prior to each treatment session.
46103082|NCT02613702|Procedure|Free Gingival Graft|Surgical technique (autologous graft): Free gingival graft technique, harvested from palate.
46019360|NCT00958009|Device|Rebidose®|The device is a ready to use single use auto injector containing Rebif® 44 mcg in a 0.5 mL prefilled syringe for sc injection
46103083|NCT02613702|Procedure|Original Free Gingival Graft technique|Surgical technique (autologous graft): Original technique of free gingival graft, positioned at the inferior incisors area at the donor area
46103084|NCT02613702|Procedure|Modified Free Gingival Graft technique|Surgical technique (autologous graft): Free gingival graft. positioned at the inferior incisors area and covered by a flap at the donor area
46103085|NCT00701298|Biological|peginterferon alfa-2b|Given SC
46103086|NCT00701298|Drug|decitabine|Given IV
46103087|NCT00701298|Other|laboratory biomarker analysis|Correlative studies
46103088|NCT00860574|Drug|treosulfan|Given IV
46103089|NCT00860574|Drug|fludarabine phosphate|Given IV
46103090|NCT00860574|Radiation|total-body irradiation|Low dose starting at 2Gy
46103091|NCT00860574|Procedure|peripheral blood stem cell transplantation|Given IV per institutional standard practice
46103092|NCT00860574|Drug|tacrolimus|Given IV or PO
46103093|NCT00860574|Procedure|allogeneic bone marrow transplantation|Given IV per institutional standard practice
45598466|NCT05256121|Other|AD Risk factors balance|"At baseline, participants in the intervention group will be asked to fill a daily risk-factor diaries (Risk factors log using the REDCap (Research Electronic Data Capture) software's survey).~In the Risk factors log, participants will need to answer shortly questions about their specific unbalanced risk factor.~In addition, during the 18-months intervention period, the study team will communicate with the participants by phone every 3-4 weeks to inquire about risk factors data. Before each phone call, participants' Risk factors log data since previous phone call will be analyzed. The team will propose alternative activities, and provide positive reinforcement and feedback."
46019361|NCT02857075|Other|Blood donation|Red cell concentrates derived from healthy blood donating people. In France, all blood donation is realized by the Etablissement Français du Sang, so all the study samples are from this center.
46019362|NCT02140255|Drug|Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|Chosen by the site investigator and dosed according to World Health Organization (WHO) or individual country or local standard guidelines.
46019363|NCT02140255|Drug|Nevirapine (NVP)|Administered orally. Dosed according to study step/participant's age/participant's weight.
46019364|NCT02140255|Drug|Lopinavir/Ritonavir (LPV/r)|Administered orally. Dosed according to study step and participant's age.
46019365|NCT02140255|Drug|Raltegravir (RAL)|Administered orally. Dosed according to study step and participant's age.
46103094|NCT00860574|Procedure|allogeneic hematopoietic stem cell transplantation|Given IV per institutional standard practice
46103095|NCT00860574|Drug|methotrexate|Given IV
46103096|NCT00496015|Biological|Pneumococcal conjugate vaccine GSK1024850A.|1 intramuscular injection.
46103097|NCT00496015|Biological|Infanrix hexa.|1 intramuscular injection.
46103098|NCT00496015|Biological|Meningococcal vaccine GSK134612.|1 intramuscular injection.
46103099|NCT00496015|Drug|Paracetamol.|Body weight of < 7 kg: none; Body weight of ≥ 7 kg to < 9 kg : 3 suppositories of 125 mg to be administered at 8h intervals after vaccination. Body weight of ≥ 9 kg: 4 suppositories of 125 mg to be administered at 6h intervals after vaccination.
46103100|NCT01018381|Procedure|PEIT|"For patients with HCC: Ethanol (99.5%) 3-15 ml/treatment(mean 8ml/treatment) , 2 times/week (mean 6 treatment/patient). For patients with a tumor size under 5 cm in diameter, we applied the formula of M. Ebara: V = 4/3∏ (r+0.5)3 (V: total Ethanol volume, r: radius of tumor).~Precise treatment was dependent on tumor size, outcomes after first PEIT treatment and time to recurrence of disease."
46103101|NCT01018381|Procedure|TOCE|For patients with HCC: Adriamycine was mixed with lipiodol, Adriamycine 20-60mg/treatment (mean 40mg/treatment),lipiodol 5-20ml/treatment(mean 12ml/treatment), 1-2 months between treatments, 2-5 treatments/patient (mean 3 times/patient), which depended on tumor size, outcomes after first TOCE and time to recurrence of disease.
46103102|NCT01018381|Procedure|TOCE plus PEIT|A combination of transarterial oily chemoembolization and pericutaneous ethanol injection therapy are given for patients with HCC.
46103103|NCT01018381|Procedure|TOCE plus RFA|For patients with HCC: A combination of transarterial oily chemoembolization plus radiofrequency ablation is given. For RFA: On mission 60w/s , 5minutes/circle, 2-4 circles/treatment, 1-2 treatments/week (tumor size under 2cm: 1 treatment; 2-4 cm: 2-3 treatments,over 4 cm: 3-5 treatments)
46103104|NCT01018381|Dietary Supplement|MGN-3|For patients with HCC or hepatitis B, arabinoxylan rice bran food supplement is given. 1 gram per day, every day, for a duration of 12 months. For the MGN-3 group, the interventional therapy was given with MGN-3 simultaneously.
46103105|NCT01018381|Drug|Entecavir|For patients with hepatitis B viral infection, a dose of 0.5mg/day, every day, was given for a duration of 24 months.
46103106|NCT00487825|Drug|Canakinumab (investigational)|Canakinumab was supplied in 6 mL colorless glass vials each containing nominally 150 mg canakinumab (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
46103107|NCT00487825|Drug|Placebo|Matching placebo was supplied in form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
46103108|NCT00487825|Drug|Methotrexate (MTX)|Methotrexate (MTX) was supplied in tablet form, each of 2.5 mg strength.
46103109|NCT00487747|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
46019366|NCT02140255|Drug|VRC01|40 mg/kg administered subcutaneously
46103110|NCT01012141|Dietary Supplement|phytochemical|
46103111|NCT01012141|Drug|Docetaxel|
46103112|NCT00487435|Drug|Tapentadol (CG5503) Extended Release (ER)|100, 150, 200, 250 mg oral tablet twice daily for 52 weeks
46103113|NCT00487279|Device|Defibrillator|ICD(Implantable Cardioverter Defibrillator)
46103114|NCT00487279|Other|Control|No Intervention
46103115|NCT04385875|Biological|Vaccine + extension of the ATI period|During the AELIX-002 trial participants received the following: DNA.HTI at weeks 0, 4, and 8 and MVA.HTI at weeks 12 and 20 (DDDMM) followed by ChAdOx1.HTI at weeks 0 and 12 and MVA.HTI at week 24 (CCM), starting at least 24 weeks after MVA.HTI week 20. After that, on ATI_extension trial, ATI will be extended for 48 weeks.
46103116|NCT04385875|Other|Placebo + extension of the ATI period|During the AELIX-002 trial participants received the following: Normal saline solution at weeks 0, 4, 8, 12, and 20 (PPPPP) followed by normal saline solution at weeks 0, 12 and 24 (PPP), starting at least 24 weeks after week 20 administration. After that, on ATI_extension trial, ATI will be extended for 48 weeks.
46103117|NCT00495625|Drug|Sunitinib Malate|Once daily oral doses on days 1-28 of each 42-day cycle. The dose for the first 2 cycles will be 37.5 mg daily for 28 days, every 42 days. Dose may be escalated to 50 mg daily for 28 days at the treating investigator's discretion.
46103118|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
45598467|NCT02223377|Drug|Morphine|Participant to be asked for their pain score, and if it is more than 4 out of 10 (NAS): to receive the 1st dose within 5 minutes after coming to PACU: 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
45598468|NCT02223377|Drug|Hydromorphone|Participant to be asked for their pain score, and if it is more than 4 out of 10 (NAS): to receive the 1st dose within 5 minutes after coming to PACU: 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
45680996|NCT03597802|Other|Exercise at workplace - Three times per week|The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
46019367|NCT00953407|Device|Nelfilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
46103119|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
46103120|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
46019368|NCT00953407|Device|Narafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
46019369|NCT00953407|Device|Etafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
46019370|NCT00953407|Device|Omafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
46019371|NCT00953407|Device|Hilafilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
46019372|NCT00953329|Drug|alefacept|Alefacept 15 mg IM once a week were to be administered for 12 weeks, which is the FDA approved dosage, duration, and frequency. This study allowed an additional 8 doses if subject did not achieve a 'clear' response with the original 12 weeks of treatment. Each enrolled subject must have failed a response to anti-TNF therapy prior to entering this study.
46103121|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
46103122|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
46103123|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
46103124|NCT00847626|Drug|Chlorthalidone|Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
46103125|NCT00847626|Drug|Chlorthalidone|Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
46103126|NCT00847626|Drug|Azilsartan medoxomil|Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
46103127|NCT00847626|Drug|Azilsartan medoxomil|Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
46103128|NCT00847626|Drug|Azilsartan medoxomil|Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
46103129|NCT04115904|Procedure|Ibuprofen for post operative pain|All treatment sessions were approximately 45 minutes in length to allow for acceptable time for completionof treatment and retreatment in one or two visits. Allthe clinical procedures were performed by the author.Following local anesthesia with 2% lidocaine with1:100,000 epinephrine (Septodont Saint-Maur desFossés, France) and rubber dam isolation the toothwas disinfected with 5.25% NaOCl (Ultra bleach,Bentonville, AR, USA).
46103130|NCT05297994|Biological|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
46103131|NCT05297994|Biological|Inactivated influenza split vaccine|solution for intramuscular injection, 0.5 ml
46019373|NCT02857153|Drug|Urapidil|If necessary, intravenous urapidil 0.2-0.5 mg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
46103132|NCT00851682|Device|MRI scan|Each patient will undergo one, contrast-enhanced MRI scan prior to his planned, standard of care procedure, either radical prostatectomy or brachytherapy, depending on the study arm. Patients will be randomized to be imaged with either a phased array body coil or an endorectal coil.
46103133|NCT04116138|Dietary Supplement|Salovum|Egg yolk powder enriched for anti secretory factor
45680997|NCT03597802|Other|Exercise at workplace - Four times per week|The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
46103134|NCT04116762|Device|TissuePatchDS-P™|The therapy to be used in the intervention arm is TissuePatchDS-P™. This is a preformed, standard-sized artificial adhesive that will be used between the parotid tissue and subcutaneous tissue. It can be cut to an appropriate size for the defect. The intention of this installation is to seal and close the potential space that is created with removal of superficial parotid tissue
46103135|NCT04116762|Device|Surgical Drain|A surgical drain used in superficial parotid surgery is a thin polyvinylchloride (PVC) tube, with perforations at the end, which is placed at the end of the procedure before the surgical wound is closed in the cavity created following removal of parotid tissue. The tube is connected to a closed vacuum system attached to a plastic bottle outside of the patient's body which acts to remove the fluid that collects after an operation.
46103136|NCT00860262|Drug|amlodipine|amlodipine 5mg for the first 2w then force titration to Amlodipine 10mg for remaining 6 w
46103137|NCT00860262|Drug|telmisartan|telmisartan 80mg for the 8w, no titration required
46103138|NCT00860262|Drug|telmisartan and amlodipine|telmisartan 80 and amlodipine 5mg for the first 2 weeks, then force titrated to telmisartan 80mg and amlodipine 10mg for the remaining 6w
46103139|NCT00701454|Other|No intervention|No intervention
46103140|NCT04119492|Behavioral|CO-OP Treatment Group|"Cognitive Orientation to Occupational Performance (CO-OP) is a cognitive approach to solving functional motor problems (Polatajko et al., 2001). Therapists teach children a global problem-solving strategy (Goal-Plan-Do-Check) as means to develop specific strategies for overcoming motor problems; the strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists trained in CO-OP will see children for one hour, once weekly for 10 weeks. Parents or caregivers will be encouraged to attend treat¬ment sessions so therapists can instruct them how to facilitate strategy use between treatment sessions. Children will select 3 functional motor goals to be addressed during treatment."
45680998|NCT03597724|Other|Questionnaire composed of 13 choice questions.|In this Discrete Choice Experiment (DCE), patients will be asked to choose which one of two hypothetical patients (Patient A and Patient B) suffering from sarcopenia with different levels of outcomes deserves the most the treatment. After completion of the choice tasks, respondents will be asked how difficult they found the choice tasks on a seven-point scale and to questions on their socio-economic and disease characteristics.
46103141|NCT00700830|Drug|insulin detemir|Initial dosage and the following dosages will be prescribed by the physician as a result of a normal clinical evaluation
46103142|NCT02613000|Other|No intervention|
46103143|NCT00860028|Drug|Extended Varenicline Pretreatment|4 weeks varenicline (Chantix) titrated to 1 mg oral tablet twice per day before the smoking quit date followed by 4 weeks varenicline (Chantix) 1 mg oral tablet twice per day treatment.
46103144|NCT00860028|Drug|Short-term Varenicline Pretreatment|3 weeks placebo + 1 week varenicline (Chantix)pretreatment + 4 weeks varenicline 1 mg oral tablet twice per day treatment following the smoking quit date.
46103145|NCT00701532|Drug|Modafinil and PET (brain imaging)|duration 90 days
46103146|NCT00701532|Drug|placebo|duration 90 days
46103147|NCT00859638|Behavioral|Physiotherapy|group self-management classes
45680999|NCT00216736|Drug|Dexamethasone|Single dose oral dexamethasone 8mg at time of ED discharge
45681000|NCT00216736|Drug|placebo|Single dose oral placebo at ED discharge
45681001|NCT03592810|Other|Settings of the extracorporeal membrane oxygenation (ECMO)|Compare the settings of the ECMO in different European hospitals and relate them to cerebral saturation and neurological outcome, using Cerebral Performance Category (CPC) score
46103148|NCT00859638|Behavioral|Occupational Therapy|group self-management classes
46103149|NCT00859638|Behavioral|Capacity Building|workshops and case reviews with primary health care team members
45681002|NCT01850030|Drug|Dydrogesterone 30 mg|Oral Dydrogesterone 10 mg tablets tid
46103150|NCT00700908|Behavioral|automated telephone intervention vs. usual care|
46103151|NCT00846846|Device|Endeavor® Zotarolimus Eluting Coronary Stent System|Endeavor® Zotarolimus Eluting Coronary Stent System in a patient population requiring stent implantation
46103152|NCT00846768|Drug|BI 1744 CL|
46103153|NCT00863798|Drug|Desvenlafaxine Succinate Sustained-Release 10mg|10 mg tablet, once daily dosing for 8 weeks
46103154|NCT00863798|Drug|Desvenlafaxine Succinate Sustained-Release 50 mg|50 mg tablet, once daily dosing for 8 weeks
46103155|NCT00863798|Drug|placebo|Matching placebo tablets (10 or 50mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
46103156|NCT00697658|Drug|Paliperidone ER|6 mg tablet once daily, variable treatment length.
46103157|NCT00859014|Biological|Autologous Bone Marrow Mononuclear Cells|Harvest of bone marrow from ischemic stroke patients, isolation of bone marrow mono-nuclear cells, and peripheral IV infusion of autologous bone marrow mono-nuclear cells
46103158|NCT00701688|Drug|Palifermin|Dose level 1 40 mcg/kg/day intravenous Dose level 2 60 mcg/kg/day intravenous Dose level 3 90 mcg/kg/day intravenous
46019374|NCT02857153|Drug|Phenylephrine|If necessary, intravenous phenylephrine 4-6 μg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
46019375|NCT02857153|Procedure|Low-level MAP|MAP is regulated to the goal level (60-70 mmHg) during general anesthesia.
46103159|NCT00699426|Drug|nexium|40 mg once daily is tested together with Yoghurt
46103160|NCT00699426|Drug|nexium|nexium and placebo are tested
46019376|NCT02857153|Procedure|High-level MAP|MAP is regulated to the goal level (90-100 mmHg) during general anesthesia.
46103161|NCT00699426|Dietary Supplement|Yoghurt|Yoghurt
46103162|NCT00699426|Drug|placebo+placebo|placebo and placebo are tested.
46103163|NCT00593606|Drug|Rotigotine|Strength: 2,4,6,and 8mg/24h, form: transdermal application, once daily application
46103164|NCT04119102|Drug|Duobrii|duobrii applied daily for 4 weeks followed by every other day for 4 weeks.
46019377|NCT02856997|Drug|Chidamide with ICE regimen|Chidamide and ICE regimen, dosage described in arm description
46103165|NCT02614118|Drug|Ketorolac tromethamine|10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment
46103166|NCT02614118|Drug|Acetaminophen|1000 mg oral Acetaminophen along with10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment.
46103167|NCT02614118|Drug|Placebo|placebo 45 minutes before root canal treatment
46103168|NCT04127942|Procedure|platelet-rich plasma injection therapy of TMD|The administer injected 1cc PRP in the superior temporomandibular disk joint space by ultrasound guidance.
46103169|NCT04134416|Drug|Donepezil|Donepezil shall be administered at the times stipulated in the study design as follows: one 5 mg tablet at night for 4 weeks and then one 10 mg tablet at night until the end of the trial (week 10).
46103170|NCT04134416|Behavioral|Intensive-Language Action Therapy|All patients participating in the study will receive in weeks 9 and 10 daily three and a half hours of ILATplus therapy. This therapy consists of 30 minutes of specific repetition training (tailored and reinforced by the therapist) before starting with classic ILAT for 3 hours/day during 10 consecutive days.
46103171|NCT04134416|Device|Transcranial direct current stimulation|Transcortical direct current stimulation (tDCS) will be applied using a STARSTIM neurostimulation device (Neuroelectrics, Barcelona). Each participant will receive either anodal or sham 20-minute sessions while receiving ILATplus. In the sham stimulation, the same helmet and electrode that is used in the active stimulation will be placed but, in this case, we will apply only a slight current at the beginning and end of the session with the objective of simulating the effects that are experienced with the active stimulation without producing significant cortical stimulation. The active electrode will be placed in the region of the lower right frontal rotation and the reference electrode in the extraencephalic zone (left clavicle). Combined rehabilitation sessions (ILATplus/tDCS) will be conducted, as indicated above, in weeks 9 and 10 of the trial.
46103172|NCT04134182|Drug|Nivolumab|3 mg/kg intravenously every 2 weeks during 16 weeks
46103173|NCT04134182|Drug|Ipilimumab|1 mg/kg intravenously every 3 weeks for four doses
46103174|NCT00870584|Drug|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of omalizumab for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
46103175|NCT00870584|Drug|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of placebo for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
46103176|NCT02616224|Other|No intervention|No intervention was administered in this study.
46103177|NCT02614508|Drug|Buparlisib|Given PO
46019378|NCT00953017|Drug|Miralax (PEG 3350)|Miralax 255gm bottle
46019379|NCT00953017|Drug|Amitiza (Lubiprostone)|Amitiza 24mcg gelcap
46019380|NCT00953017|Drug|Dulcolax (Bisacodyl)|Bisacodyl 5mg tab x2
46019381|NCT00953017|Drug|Golytely (polyethylene glycol)|Golytely 1 gallon
46019382|NCT00952705|Biological|Q/LAIV-BFS (MEDI8662)|A single dose of Q/LAIV-BFS delivered using the BFS delivery system (0.2 mL) on Day 0.
46019383|NCT00952705|Biological|FluMist/B/Yamagata|FluMist/B/Yamagata - 0.2 mL dose at Day 0
46103178|NCT02614508|Drug|Ibrutinib|Given PO
46019384|NCT00952705|Biological|FluMist/B/Victoria|FluMist/B/Victoria - 0.2 mL dose at Day 0
46103179|NCT02614508|Biological|Ofatumumab|Given IV
46103180|NCT02613806|Drug|Dexmeditomidine|Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
46019385|NCT00955357|Drug|Lacosamide|"Oral Lacosamide:~Subjects Titration Phase (6 Weeks):~Week 1 - 50 mg tablet Twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid~Maintenance Phase (24 Weeks):~200 mg tablet bid OR 150 mg tablet bid~Taper Phase (1 - 3 Weeks):~50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week"
46019386|NCT02338609|Drug|Everolimus|Blood sample and Tanner Stage assessment
46103181|NCT02613806|Drug|normal saline|Isovolumetric normal saline will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
46103182|NCT04134338|Other|To evaluate the effect of wound infection on costs|the degree of costs that is required for trating wound infection
46103183|NCT02616068|Drug|Transdermal Patch|Transdermal patch 100 mg once a day for 7 days
46103184|NCT02616068|Drug|Loxoprofen sodium|Loxoprofen sodium 60 mg per tablet by mouth, every 8 hours for 7 days
46019387|NCT02338609|Drug|Envirolimus drug class as prescribed by Physician|At the discretion of the investigator, patients may be treated with commercially available everolimus, as per local product information/ standard of care.
46103185|NCT02616068|Drug|Placebo (for loxoprofen sodium)|Placebo (for loxoprofen sodium 60 mg per tablet) by mouth, every 8 hours for 7 days
46103186|NCT02616068|Drug|Placebo (for transdermal patch)|Placebo (for transdermal patch 100 mg) once a day for 7 days
46103187|NCT04127084|Drug|SGLT2 Inhibition|Dapagliflozine 5-10 mg once daily tablet treatment or Empagliflozin10 mg once daily tablet treatment or Canagliflozin 100 mg once daily tablet treatment
46103188|NCT04126928|Diagnostic Test|Screening using DMFT and PUFA, orthopantomogram is taken and assessed using PAI, comprehensive clinical examination to diagnose pulpal and periapical conditions.|
46103189|NCT00697736|Procedure|Echocardiography with myocardial tissular Doppler mode|Echocardiography with myocardial tissular Doppler mode during rest and exercise on a table equipped with a cyclo-ergometer
46103190|NCT04031300|Device|Prototype 0.5|Investigational Medical Device collecting spectral Raman data non-invasively from tissue
46103191|NCT02615834|Procedure|Gentle chest pressure|Gentle pressure on the patient's right chest will be applied to achieve 12 breaths per minute.
46103192|NCT00870194|Drug|exenatide and sitagliptin|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; sitagliptin-100mg tablet orally once a day
46103193|NCT00870194|Drug|exenatide and placebo|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; placebo-tablet orally once a day
46103194|NCT00690430|Drug|Pasireotide|Pasireotide LAR 60mg i.m. injection - patients may also receive pasireotide 600 µg s.c 3 times a day for symptom control as needed
46103195|NCT00690430|Drug|Octreotide|Octreotide LAR 40mg i.m. depot injection - Patients may also receive octreotide 100 µg s.c. 3 times a day for symptom control as needed
46103196|NCT02619656|Procedure|CO2 insufflation|Patients were randomized to insufflation with CO2.
46103197|NCT02619656|Procedure|Ambient air insufflation|Patients were randomized to insufflation with ambient air.
46103198|NCT02619734|Biological|Infusion of Autologous Bone Marrow Mononuclear Cells|Autologous bone marrow-derived mononuclear cells will be administered by intramuscular injection into and around the leg ulcer. The number of injected cells will be from 5x108 to 1x109 total number of cells on Study Day 1.
46103199|NCT04060186|Procedure|Balloninflation|Patient will inflate into a ballon made by a handglove 2-3times/h from 8:00-20:00 after evacuation of chronic subdural hematoma.
45838083|NCT04901624|Behavioral|Personal Risk Messaging|"Personal risk framing may engender concern for oneself. Households randomized to personal risk messaging will receive the following message: Antibody testing will help you understand your risk of getting COVID-19."
45838084|NCT04901624|Behavioral|Loss Protection|Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive insurance on winning the baseline incentive for repeat antibody testing.
46103200|NCT02619500|Other|Home Exercise Program|A standardized home exercise program will be given to subjects that will include active range of motion of the cervical and thoracic spine and deep cervical flexion endurance exercises.
46103201|NCT02619500|Other|Patient advice, encouragement, and education|Therapists will provide each subject with advice and education pertaining to their condition as well as encouragement towards reducing pain and disability.
46103202|NCT02619500|Other|Thrust Manipulation|High velocity low amplitude (HVLA) thrust performed at or near the end range of a targeted segment in both the cervical and thoracic spine
46103203|NCT02619500|Other|Non-thrust Mobilizations|Repetitive and rhythmic accessory passive movements applied with either small or large amplitude at a targeted segment to both the cervical and thoracic spine
46103204|NCT04126304|Drug|Azithromycin|If the diagnosis is common cold, acute bronchitis or post-infection cough ，treated with non-macrolides when the mycoplasma colloidal gold test is negative, treated with azithromycin when colloidal gold test is positive.
46103205|NCT04126304|Drug|non-macrolides antibiotics|If the diagnosis is community-acquired pneumonia with negative mycoplasma antibody-granule agglutination, non-macrolides are used for treatment
45681003|NCT01850030|Drug|Micronized Progesterone 600 mg|Intravaginal micronized progesterone 200 mg capsules tid
46103206|NCT04126304|Diagnostic Test|Mycoplasma detection|"common cold, acute bronchitis or post-infection cough :MPlgM colloidal gold detection;Pharyngeal swab MP-RNA PCR, mutated gene detection at 2063 and 2064 site of macrolide-resistant 23S rRNA II region detection~community-acquired pneumonia:mycoplasma antigen antibody particle agglutination detection ;Sputum MP-RNA PCR, mutated gene detection at 2063 and 2064 site of macrolide-resistant 23S rRNA II region detection"
46103207|NCT04126304|Other|Data collection|"Common cold:On enrollment, day 3 and day 7, scores were collected based on the Canadian acute respiratory diseases and influenza scale (CARIFS scale), success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate.~Acute bronchitis :on enrollment, day 3, and day 7, the Likert 7 subscale was used to score the cough severity questionnaire, collect the success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate.~Post-infection cough:on the day after outpatient visit, day 3, day 7, and day 14, the cough severity questionnaire (Likert 7 subscale) was used to score the success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate."
46103208|NCT04126304|Other|Data collection|Acquisition of children hospitalized time, heating time, mixed infection, drug (azithromycin, tetracycline, quinolone) dose and use time, pulmonary complication (pleural effusion, atelectasis, necrotizing pneumonia, interstitial pneumonia, occlusive bronchitis, occlusive bronchiolitis, lung, emphysema, lung abscess, bronchiectasis, transparent), pleural puncture/drainage, bronchoscope, oxygen time, into the ICU, mechanical ventilation time, surgery, and deaths and re-visit, hospitalization, surgery and death within 30 days after discharge
46019388|NCT00955279|Drug|Placebo|Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
45681004|NCT01850030|Drug|Placebo progesterone|Placebo intravaginal micronized progesterone 200 mg capsules tid
45681005|NCT01850030|Drug|Placebo dydrogesterone|placebo oral dydrogesterone 10 mg tablets tid
45681006|NCT00215644|Drug|Matuzumab|Participants will receive matuzumab 800 milligrams (mg) intravenously (IV) every week, until disease progression (PD), unacceptable toxicity, death, or consent is withdrawn.
45838085|NCT04901624|Behavioral|Lottery Incentive|Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive a bonus lottery incentive with a 4 small (1 in 25) chance of winning $150 for repeat antibody testing.
46019389|NCT00955279|Drug|Golimumab|Golimumab will be administered subcutaneously at a dose of 200 milligram (mg) at Week 0 and thereafter at a dose of 100 mg every 4 weeks up to Week 24.
45598469|NCT02355873|Device|AN69ST hemofilter|
45598470|NCT02355873|Device|AN69 hemofilter|
45598471|NCT02226731|Device|Early Belfort-Dildy Balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed in the 15 minutes after randomization at the same time as the second line uterotonic treatment.
46019390|NCT00955279|Drug|Ustekinumab|Ustekinumab will be administered subcutaneously at a dose of 180 mg at Week 0 and thereafter at a dose of 90 mg at Week 8, 16 and 24 and matching Placebo was administered subcutaneously at Week 4, 12 and 20.
46019391|NCT00954733|Other|Arterial blood draw|One arterial blood draw
46019392|NCT00630721|Other|IFNbeta-1b|no drug was given under study arm. only blood draw on patients already on IFNbeta-1b.
45598472|NCT02226731|Device|Late Belfort-Dildy balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed if failure of second line uterotonic treatment, ie persisting bleeding 30 minutes after the beginning of this infusion.
46019393|NCT00954421|Device|Deep Brain Stimulation|Use of two ipsilateral thalamic Deep Brain Stimulation electrodes (one at the ventralis intermedius nucleus/ventralis oralis posterior nucleus border or VIM and one at the ventralis oralis anterior nucleus/ventralis oralis posterior nucleus border or VO) for treatment of disabling and medication refractory tremor secondary to head trauma or multiple sclerosis.
45598473|NCT02291809|Biological|REMUNE|Inoculation of HIV-1 Virus via Vaccination of Whole Killed GP120 Depleted P24 Antigen Vaccine
46103209|NCT02677792|Behavioral|Behavioral Family Intervention (BFI)|Participating families will receive standard medical care through the Wellness and Weight Clinic, as well as the BFI. The BFI is based on family systems (Minuchin et al., 1975) and social-cognitive (Bandura, 1998) theories. Each dyad will participate in simultaneous, but separate, 75-minute parent and child groups over a 3 month period. The groups will start off meeting every week for 8 weeks and then bi-weekly for 1 month. Thus, dyads will attend a total of 10 group meetings over the 3 month period (12.5 hours of total treatment contact).
46103210|NCT00746980|Drug|efalizumab|1 mg/kg subcutaneously once weekly for 48 weeks, following an initial conditioning dose of 0.7 mg/kg at week 0.
46019394|NCT02857309|Device|OPTIMIZER|The OPTIMIZER System delivers non-excitatory cardiac contractility modulation (CCM) signals to the heart that are intended to influence myocardial properties in patients with chronic heart failure. The system has no pacemaker or implantable cardioverter-defibrillator (ICD) functions.
46103211|NCT00863330|Biological|Tumor Infiltrating Lymphocytes (TIL)|Tumor harvest process tumor infiltrating lymphocytes. Non myeloblative chemotherapy consisting of cyclophosphamide and fludarabine. Infusion of TIL cells followed by high dose IL-2.
46103212|NCT02563054|Drug|5-Fluorouracil|Participants will receive 5-FU, 800 milligrams per meter-squared (mg/m^2) per day via IV infusion during Days 1 to 5 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
46103213|NCT02563054|Drug|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m^2 twice daily on Days 1 to 14 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
46103214|NCT02563054|Drug|Cisplatin|Participants will receive cisplastin, 80 mg/m^2 via IV infusion on Day 1 of each 3-week cycle, for a total of 6 cycles or upto disease progression in combination with either capecitabine or 5-FU.
46103215|NCT02614040|Other|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
46103216|NCT02614040|Other|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
46103217|NCT00698594|Biological|sublingual allergen extract|Group of children with allergic rhinitis 6-18 years old. receiving seasonally grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - seasonal SLIT group
46103218|NCT00698594|Biological|sublingual allergen extract|Group of children with allergic rhinitis 6-18 years old receiving yearly grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - yearly SLIT group
46103219|NCT00698594|Biological|placebo|Group of children with allergic rhinitis 6-18 years old receiving placebo in sublingual applicator (Staloral 300 IR, Stallergenes, France) (n=20) - placebo group
46103220|NCT00743470|Drug|lopinavir/ritonavir|lopinavir/ritonavir tablet; see arm for intervention description
46103221|NCT00743470|Drug|rifabutin|rifabutin capsule; see arms for intervention description
46103222|NCT02613962|Procedure|biopsy or surgical resection of tumor and blood sampling|
46103223|NCT00688324|Drug|Acamprosate|Acamprosate 333mg, ii tablets PO tid x 2 weeks
46103224|NCT02619578|Other|TEAS|According to the theory of traditional Chinese medicine, bilateral Baihui (GV20), Yingtang (EX-HN3), Zusanli (ST36) and Neiguan (PC6) were chosen as the acupuncture points. These acupoints were identified according to the traditional anatomic localization . Gel electrodes were applied to the skin after it had been cleaned with ethyl alcohol. The acupoints were then stimulated electrically with an intensity of 12-15 mA and dense-disperse frequency of 2/100 Hz for 30 min, using the Hwato electronic acupuncture treatment instrument (model No. SDZ-V, Suzhou Medical Appliances Co., Ltd, Suzhou, China). The intensity was adjusted to maintain a slight twitching of local muscles according to individual maximum tolerance, indicating a satisfactory of De-Qi phenomenon and thus adequate stimulation.
46019395|NCT02857309|Drug|Optimal medical therapy|OMT using standard heart failure (HF) drugs
46019396|NCT04261231|Procedure|Surgery and anesthesia|Elective surgery in adults
46019397|NCT02857465|Drug|Dexamethasone|single epidural injection of dexamethasone (8 mg) in addition to local anesthetics used for epidural analgesia
46103225|NCT02619578|Other|Con|The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation.
46103226|NCT02619578|Drug|propofol, remifentanil, vecuronium|Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v.
46019398|NCT02857465|Drug|Placebo|single epidural injection of sodium chloride 0.9% (2 mL) in addition to local anesthetics used for epidural analgesia
46019399|NCT02857465|Drug|Ropivacaine|NAROPEINE 7.5 mg/mL is diluted at the concentration of 1 mg/mL prior to the epidural use. The perfused dose depends on the efficacy of analgesia in reducing the delivery labor pain.
46019400|NCT02857465|Drug|Sufentanil|Sufentanil 0.5 mg/L is used as solution for injection for epidural analgesia and used in combination with ropivacaine. The administered dose is bolus of 15 to 20 micrograms diluted into 10 mL.
46103227|NCT02619578|Other|mechanical ventilation|Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
46103228|NCT02562820|Procedure|Intravenous infusion|Intravenous infusion of Ketamine
46103229|NCT02562820|Procedure|Intravenous infusion|Intravenous infusion of Normal Saline
46103230|NCT02615912|Other|PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5%|
46103231|NCT02615912|Other|Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5%|
46103232|NCT02615912|Other|Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5%|
46103233|NCT02615912|Other|Silwet* DA-63 (Momentive) 1.5%|
46103234|NCT02615912|Other|Sodium lauryl sulfate (Sigma Aldrich) 1.0%|
46103235|NCT02615912|Other|Water (control)|
45838086|NCT04893109|Drug|trastuzumab-emtansine|intravenous infusion
46103236|NCT05326646|Dietary Supplement|Low FODMAP diet|After the realisation of a wireless motility capsule, patients will underwent 6 weeks of low FODMAP diet after dietician education. Symptomatic scores (IBS-SSS, GIQLI, HAD) and stools samples (metabolomic and lipidomic) will be performed before and after the low FODMAP diet.
46103237|NCT02615756|Behavioral|Exercise|
45598474|NCT02226809|Device|Accelerometry|Application of TOF stimulus (40 mA, three to four times) and recording TOFr in the PACU
46103238|NCT04133090|Procedure|Autogenous block bone graft|Vertical and horizontal osteotomies were performed by means of a 6-mm diameter separation disc under copious irrigation with saline.The harvested bone graft was immediately placed in sterile saline solution to prevent dehydration. Sharp edges around the block graft were rounded under saline irrigation using a 4-mm round bur. The screw holes were properly made on both the recipient site and the block graft using a 1.3 mm drill. The graft was firmly fixed with 1.3 mm screws and a compatible driver. The periphery of the graft and the underlying gap between the screws and the recipient site, were covered with a mixture of particulate allograft and sterile saline solution to minimize resorption and to improve the adaption of the graft. All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.
46103239|NCT04133090|Procedure|i-PRF enriched allograft material+ screw tent pole technique|The i-PRF preparation was performed as follows: the blood sample collected in an 8 ml, non-coated plastic tube without anticoagulant was immediately centrifuged at a protocol of 2700 rpm for 2 min. After centrifugation, the liquid autologous fibrin material which comprised the 1 mL upper layer of the tube was collected, using a disposable syringe. The screw holes were made on the recipient site using a 1.3 mm drill. 7 mm long screws were fixed 2mm or 4mm higher than on the recipient site to provide the desired augmentation distance and stabilized by a compatible driver. i-PRF was mixed with allograft material in a sterile metal box. Polymerization was done in 3 to 5 minutes, then this material was applied to the underlying gap between the screws and the recipient site.All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.
46019401|NCT02857387|Biological|blood sample withdrawn|
46019402|NCT04273009|Device|Renew VS PTNS|These will be prescribed and applied as described above.
46019403|NCT04260139|Procedure|Calculation of metric variables on the colectomy specimens.|"Calculation of metric variables on the colectomy specimens including Lengths as mm~Proximal colon,~Ileum in cases with right hemicolectomy only,~Proximal border,~Tumor,~Distal border,~Total specimen,~Vascular pedicle, the longitudinal distance between the nearest bowel wall and the end of ligated major vascular pedicle depending on the tumor's localization, 2. Colonic mesenteric area as mm2."
46019404|NCT01241448|Drug|LY2409021|Administered Orally
46103240|NCT02619422|Other|Intensive cardiac rehabilitation program in less time|2 weeks, 5 days a week, and reinforcement sessions at 3, 6 and 9 months
46103241|NCT04123652|Drug|Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992|"An intravenous will be started. • Lidocaine - initial dose of 5.0 mg/kg +/- 1.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, not to exceed 7 mg/kg or 600 mg.~• Ketamine - initial dose of 0.1 mg/kg (based on actual weight) over 45 minutes (rounded to nearest 5 mg, up to maximum 15 mg), increased by 0.1 mg/kg (rounded to nearest 5 mg) each infusion based on tolerability of side effects During the infusion patient will be monitored by another MD for BP, PR, PO2. Patients will not be allowed to drive for 24 hours."
46103242|NCT00862940|Drug|Memantine|10 mg tablets twice daily
46103243|NCT00862940|Drug|Placebo|Tablets twice daily
46019405|NCT01241448|Drug|Placebo|Administered Orally
46103244|NCT04122716|Drug|Liraglutide|"Daily injections (3mg) with weight consultations starting at dose of 0.6 mg injections with 0.6 mg increments weekly until 3.0 mg is achieved. For subjects who do not tolerate the fast weekly up-titration of 0.6 mg study drug until the 3mg, the titration procedure can be prolonged with up to three weeks for each up-titration.~Subjects who do not tolerate the 3mg dose may in special circumstances stay at 2.4 mg, however the overall aim is to reach 3 mg for all study subjects.~The dosage and up-titration follow the recommendations from the summary of product characteristics."
46019406|NCT04319406|Procedure|Prolotherapy|Test group will be administered 12.5% Dextrose mainly into superior joint space according to symptoms of patient at baseline (0 week) and at biweekly intervals at 2 and 4 weeks i.e. a total of 3 injections. A 4th injection will be given at 6 weeks if required.
46019407|NCT04319406|Procedure|Dry needling|Only dry needling will be performed at baseline (0 week) and at biweekly intervals at 2 and 4 weeks i.e. a total of 3 injections. A 4th injection will be given at 6 weeks if required.
46019408|NCT01240356|Device|2-MHz transcranial Doppler ultrasound|2-hours of hands-free ultrasound will be insonated continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
46019409|NCT01240356|Device|2-MHz transcranial Doppler ultrasound insonation|2-hours of hands-free ultrasound delivered to in the intracranial vessels.
46019410|NCT04206540|Other|ABVN stimulation|Stimulate the Auricular Branch of the Vagus Nerve in the ear
46019411|NCT04206540|Other|Vagal Maneuvers|Stimulate the Vagus Nerve by using different techniques like drinking water, drinking ensure, cold stimulus, carotid massage, valsalva maneuver and others
46019412|NCT04206618|Drug|Teriparatide|1 subcutaneous injection daily for 12 months
46019413|NCT04206618|Drug|Denosumab|1 subcutaneous injection every 6 months for 12 months
46019414|NCT01239732|Drug|Paclitaxel|175 mg/m^2 on Day 1 every 3 weeks or at a dose of 80 mg/m^2 every week for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
46019415|NCT01239732|Drug|Bevacizumab|15 mg/kg intravenously on Day 1 of every cycle for up to 36 cycles of 3 weeks each or until disease progression or unacceptable toxicity, whichever occurs first
46103245|NCT04122716|Behavioral|Exercise|"150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations.~Exercise prescription will be performed under strict control of the scientific personnel.~There will be aerobic exercise and will include 4 sessions per week after the ramp-in period.~2 sessions per week will be performed under supervision of the staff and 2 sessions will be performed individually but monitored by the staff.~Supervised sessions include structured exercise with a duration of 45 min. Of this 30 min will comprise of interval-based spinning session and 15 min circuit training program focusing on large muscle groups.~Individual exercise includes aerobic exercise and general physical activity (e.g brisk walking and cycling to work).~Participants will use heart rate monitors during sessions."
46019416|NCT01239732|Drug|Carboplatin|AUC 5-6 mg/ml/min on Day 1 every 3 weeks for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
46103246|NCT00868166|Drug|Olesoxime|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
46103247|NCT00868166|Drug|Placebo Comparator|2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
46103248|NCT00868166|Drug|Riluzole|Riluzole given as add-on therapy 50mg bid
46103249|NCT00698672|Device|charnley OGEE|charnley OGEE
46103250|NCT00698672|Device|Spectron Reflection CoCr|Spectron Reflection CoCr
46103251|NCT00698672|Device|Spectron XLPE CoCr|Spectron XLPE CoCr
46103252|NCT00698672|Device|Spectron Reflection Oxinium|Spectron Reflection Oxinium
46103253|NCT00698672|Device|Spectron XLPE CoCR|Spectron XLPE CoCR
46103254|NCT00858780|Drug|Etanercept|50 mg etanercept once weekly + methotrexate
46103255|NCT00858780|Drug|Etanercept|25mg etanercept once weekly + methotrexate
46103256|NCT00858780|Drug|Placebo|Placebo comparator once weekly + methotrexate
46103257|NCT04132856|Other|Psychosocial Navigator|Services of psychosocial navigator
46103258|NCT04132856|Other|Communication of Summary Profile|Both patient/caregiver dyad and HCPs will receive a summary of the PAT results and levels of depression and anxiety.
46103259|NCT02619188|Other|PUQE-form inclusion|PUQE-form encompassing last 24 hours completion
46103260|NCT02619188|Other|Nutritional form inclusion|Food-list form encompassing last 24 hours completion
46103261|NCT02619188|Other|Blood sampling inclusion|Measurement of biochemical nutrition marker(s); Prealbumin
46103262|NCT02619188|Other|Intervention at discharge|PUQE-form, nutritional form and Blood sampling
46103263|NCT02615678|Device|Acupuncture|Acupuncture twice a week for 6 weeks then one treatment a week for 4 weeks. Total 16 treatments in 10 weeks.
46103264|NCT02613234|Device|cathode tDCS|"At the first randomized controlled stage, the experimental group will undergo five daily sessions of active brain-wave intervention by cathode tDCS (20min, 1mA) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.~At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA)."
45681007|NCT00215644|Drug|Epirubicin|Participants will receive epirubicin 50 milligrams per square meter (mg/m^2) on Day 1 of 21-day cycle up to a maximum of 8 cycles.
46103265|NCT02613234|Device|Sham cathode tDCS|"At the first randomized controlled stage, the control group will undergo five daily sessions of sham brain-wave intervention by cathode tDCS (20min, 1mA, the stimulator will be turned off after 5s) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.~At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA)."
46103266|NCT02619266|Other|Acupuncture|Acupuncture is the practice of inserting thin needles into specific points to improve health and well-being.
46103267|NCT02619266|Other|Sham Acupuncture|Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders.
46103268|NCT02619266|Drug|Megestrol Acetate|Megestrol Acetate 160mg tablet
46103269|NCT02619266|Drug|Placebo(Megestrol Acetate)|Starch pill manufactured to mimic Megestrol Acetate 160mg tablet
46103270|NCT00850200|Radiation|Proton Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
46103271|NCT00850200|Radiation|Conventional Photon Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
46103272|NCT00850200|Radiation|Intensity Modulated Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
45838087|NCT04893109|Drug|Trastuzumab SC|Muscular injection
45681008|NCT00215644|Drug|Cisplatin|Participants will receive cisplatin 60 mg/m^2 on Day 1 of 21-day cycle up to a maximum of 8 cycles.
45681009|NCT00215644|Drug|Capecitabine|Participants will receive capecitabine 1250 mg/m^2 daily in a 21-day cycles up to a maximum of 8 cycles.
45838088|NCT04893109|Drug|Paclitaxel|intravenous infusion
46019417|NCT02227147|Drug|rhNGF 20µg/ml|
46019418|NCT02227147|Other|Placebo|Formulation containing antioxidant
46019419|NCT02856919|Drug|brimonidine tartrate|Mirvaso® gel (5 mg/g brimonidine tartrate)
46019420|NCT02854735|Other|Imaging by CT and densitometry|Imaging by CT and densitometry, no intervention involved
46019421|NCT00948025|Device|Hollow tube nerve conduit, synthetic or biosynthetic|Appropriately size matched hollow tube nerve conduit (Neurotube, NeuroLac, NeuraGen, NeuroMatrix, NeuroFlex)
46019422|NCT00948025|Other|Processed Human Nerve Tissue|Implantation of appropriate length of processed human nerve tissue at time of surgery.
46019423|NCT02854579|Biological|neural progenitor cell|Neural progenitor cells are derived from the same aborted human fetal forebrain.
46019424|NCT02854579|Biological|Paracrine factors|The factors obtained from cultured human mesenchymal stem cells were concentrated 50 times
46019425|NCT02854579|Biological|progenitor cell and paracrine factors|Neural progenitor cells will be received after paracrine factors therapy
46103273|NCT02618954|Other|Articular ultrasound|(Device : Ultrasound) : Articular ultrasound of the Disease Activity Score (DAS) 28 articular joint
46103274|NCT02619110|Other|backward walking treadmill training|subjects accepted 30 minutes backward walking treadmill training. a week for four weeks.
46103275|NCT02619110|Other|conventional physical therapy|subjects accepted 30 minutes traditional physical therapy three times a week for four weeks
46103276|NCT02612766|Dietary Supplement|Pure, uncontaminated oats|
46103277|NCT04122092|Diagnostic Test|The level of plasma cfDNA CINs|The extracted cfDNA from PB will be analyzed by UCAD to determine the level of CINs
46103278|NCT02613156|Procedure|laparoscopic resection|The surgical instruments used for the laparoscopic group included conventional laparoscopic instruments (three 5 mm trocars, two 10 mm trocars, and two damage-free laparoscopic clamps), the STORZ high-resolution laparoscopic operating system (Germany), the GEN300 ultrasonic scalpel system (Johnson & Johnson, USA), a laparoscopic linear cutter stapler (Johnson & Johnson, USA), a laparoscopic ultrasound device, LigaSure, bipolar coagulation, titanium laparoscopic clips, and absorbable hemostatic gauze.
46103279|NCT00698906|Biological|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
46103280|NCT00698906|Biological|Engerix™-B|3-dose intramuscular injection
46103281|NCT04118946|Biological|platelet enriched plasma|PRP is prepared via a two-step centrifugation preparation of a blood sample, which is cured with an anticoagulant. Then either with be applied through urethral catheter in one arm or via submucos injection in anther one.
46103282|NCT00698984|Dietary Supplement|BONISTEIN(R) bone blend|2 Capsules per day over a period of 6 months
46103283|NCT00698984|Dietary Supplement|Placebo|2 capsules per day over a period of 6 months
46103284|NCT04116060|Dietary Supplement|Dietary Nitrate|Oral dietary nitrate supplementation with (0,12 mmol/kgBW sodium-nitrate)
46103285|NCT04116060|Dietary Supplement|Control|Placebo Comparator: Dietary sodium-chloride dissolved in water (0,12 mmol sodium-chloride/kgBW/day)
46103286|NCT00699062|Drug|singular|The participants randomized into this arm will receive singular 10mg q.n. plus combine therapy with inhaled ICS+LABA
46103287|NCT00699062|Drug|placebo|The participants allocated into this arm will receive placebo 10mg,q.n plus combine therapy with inhaled ICS+LABA
46103288|NCT02619032|Drug|Remifentanil|Intraoperative continuous infusion of remifenatanil. Remifentanil infusion was interrupted upon completion of surgical intervention.
46019426|NCT02854423|Device|percutaneous coronary interventions|Consecutive diabetic patients undergoing percutaneous coronary interventions with Biodegradable polymer Biolimus Eluting Stent or durable polymer Everolimus Eluting Stent implantation
46019427|NCT00947011|Drug|Placebo|1 tablet 100 mg once a day
46019428|NCT00947011|Drug|Januvia|1 tablet 100 mg once a day
46019429|NCT02856685|Drug|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome will be administered via IV infusion over 60 minutes once at the beginning (Day 1) of each 28-day cycle
46103289|NCT02619032|Drug|Fentanyl|Fentanyl 50 μg iv bolus at the induction of anesthesia and before the start of surgery.
46103290|NCT04134104|Procedure|Surgery for Colorectal malignant diseases either LAR or APR|Patients following LAR or APR were observed for the Bowel, Bladder, and Sexual Dysfunction
46103291|NCT00858234|Drug|Vorinostat|Vorinostat (MK-0683) three or four 100 mg capsules taken by mouth with food.
46103292|NCT00858234|Drug|Bortezomib|Bortezomib (1.0 or 1.3 mg/m^2) intravenous infusion.
46103293|NCT00697814|Drug|Clomiphene citrate|Clomiphene 50 mg/day for 12 weeks
46103294|NCT04116450|Procedure|Glaucolight illuminated microcatheter.|To study circumferential trabeculotomy for congenital glaucoma using Glaucolight illuminated microcatheter.
46103295|NCT00701844|Behavioral|Writing A (Experimental informative writing)|Experimental informative writing
46019430|NCT01962415|Drug|Hydroxyurea|Oral administration at 30 mg/kg/day.
46103296|NCT00701844|Behavioral|Writing B (Experimental noninformative writing)|Experimental noninformative writing
46103297|NCT00701844|Behavioral|Writing C (Control informative writing)|Control informative writing
46103298|NCT00701844|Behavioral|Writing D (Control noninformative writing)|Control noninformative writing
46103299|NCT04115592|Other|Cocoa butter|Consumption of cocoa butter made with chocolate confectionery
46103300|NCT04115592|Other|Cocoa butter oleogel|Consumption of cocoa butter oleogel made with chocolate confectionery
46103301|NCT04115592|Other|Sal seed oil|Consumption of sal seed oil made with chocolate confectionery
46103302|NCT04115592|Other|Sal seed oleogel|Consumption of sal seed oleogel made with chocolate confectionery
46103303|NCT00862082|Drug|PR104 550 mg/m^2 + sorafenib|550 mg/m^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
46019431|NCT01962415|Drug|Alemtuzumab|"Intravenous (IV) administration. The first dose for each arm will be a test dose (0.2 mg/kg max 5 mg). The treatment doses of alemtuzumab will be based on the patients' assigned stratum as determined by their age, lymphocyte count and presence of infection.~Stratum 1: 1 mg/kg (max dose of 30 mg); Stratum 2: 0.5 mg/kg (max dose of 30 mg); Stratum 3: No treatment dose, test dose only."
46019432|NCT01962415|Drug|Fludarabine|IV administration at 30 mg/m2/day or 1 mg/kg/dose, whichever is lower.
46019433|NCT01962415|Drug|Melphalan|IV administration at 70 mg/m2/dose.
46019434|NCT01962415|Drug|Thiotepa|IV administration at 200 mg/m2/dose
46019435|NCT02860663|Dietary Supplement|Vitamin D3|10 ug/d of vitamin D3 for 6 weeks
46103304|NCT00862082|Drug|PR104 770 mg/m^2 + sorafenib|770 mg/m^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
46103305|NCT00849186|Drug|sunitinib malate|oral
46103306|NCT00849186|Procedure|neoadjuvant therapy|IV
46103307|NCT00849186|Procedure|therapeutic conventional surgery|Surgery
46103308|NCT00692770|Drug|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
46103309|NCT00692770|Drug|Placebo|Placebo 2 tablets twice daily (BID)
46103310|NCT00849108|Drug|BMS747158|"dosages at rest and at stress were not to exceed a total of 14 mCi.~Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period.~Cohort 2: Patients to recieve IV bolus injections of BMS747158:~For the Pharmacologic (Adenosine) Stress:~Doses at rest were to range between 2.9 and 3.4 mCi.~Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~Doses at rest were to range between 1.7 and 2.0 mCi.~Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi."
46103311|NCT00867308|Drug|Lenalidomide 50 mg|
46103312|NCT00867308|Drug|Lenalidomide 15 mg|
46103313|NCT04119908|Device|Sublingual videomicroscopy|Measurement of sublingual capillary density by video microscopy
46103314|NCT04119908|Biological|blood sample|Collection of citrate tubes of 5 mL at baseline and at 36 months
46103315|NCT02613078|Behavioral|Gut-Directed Hypnotherapy|Hypnotherapy protocol is based on the Manchester protocol for gut-directed hypnotherapy and was adapted for children and adolescents. It consists of elements aiming at relaxation and suggestions for control and relief from pain and discomfort. The hypnotherapy will be provided using a CD. Children of the hypnotherapy condition will be instructed to practice with their CD on a daily basis (20 min each day, at least 4 times/week) during 4 weeks
46103316|NCT02613078|Dietary Supplement|Nutritional Supplement|SymbioLact® B a preparation of Bifidobacterium lactis and vitamin B7, Biotin. Number of living organisms in one dose is at least 1 x 10^9 cfu. SymbioLact® B will be used in the dose recommended in the pediatric patient information sheet - one dose of SymbioLact® B diluted in water or tee once a day together with a main meal during 4 weeks
46103317|NCT02613078|Behavioral|Self-Monitoring|Use of symptom diary that questions about main bowel complains (including pain or discomfort) during the day. Applied on a daily basis (about 2 min in the evening)
46103318|NCT02618876|Drug|Nalbuphine plus Bupivacaine|Addition of caudal Nalbuphine to the standard Bupivacaine
45838089|NCT04889521|Other|No intervention|No intervention. Study is cross-sectional observational.
45838090|NCT04883450|Diagnostic Test|Magnetic resonance imaging (MRI)|All enrolled participants will undergo magnetic resonance imaging (MRI) at their Baseline and 18-Month follow-up visit
46019436|NCT02860663|Dietary Supplement|Vitamin D2|10 ug/d of vitamin D3 for 6 weeks
46019437|NCT02860663|Dietary Supplement|25OHD|10 ug/d of vitamin D3 for 6 weeks
46103319|NCT02618876|Drug|Bupivacaine|Caudal Bupivacaine is the standard of care will be considered as a control
45838091|NCT04882540|Drug|brivaracetam|"Pharmaceutical form: Film-coated tablets~Concentration: 100 mg tablets~Route of administration: Oral use"
46019438|NCT04270513|Other|Endovascular treatment by Flying Intervention Team|After telemedicine-assisted decision for endovascular treatment, the Flying Intervention Team is transferred via helicopter to the primary stroke center and performs endovascular treatment in the local angiography suite.
46019439|NCT02854189|Device|Oxford unicompartmental knee arthroplasty|The Oxford unicompartmental knee arthroplasty was applied in all patients with medial osteoarthritis knee.The Oxford unicompartmental knee arthroplasty is mobile bearing unicompartmental knee arthroplasty.
46019440|NCT02854345|Device|Tomoscintigraphic parathyroid imaging on a CZT camera|
46019441|NCT04281823|Diagnostic Test|Cardiovascular Magnetic Resonance|Patients will undergo various CMR techniques designed to assess cardiovascular structure and function, tissue characteristics, and flow.
46019442|NCT02853877|Behavioral|Weekly Incentive|The tailored incentives intervention aims to assess the impact of tailored messaging and financial incentives on weight loss among obese employees.
46103320|NCT04132700|Device|Q-NRG Metobolic Cart Device|ICU pateints will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
46019443|NCT02854111|Other|ice cream|The ice cream was made by nutritionists in Ramathibodi Hospital. It consisted of cornstarch, milk, sucrose, milk powder, egg yolk, and banana which contained carbohydrate 73.9 g, fat 27.7 g, protein 18.9 g for a total of 620.9 kcal with a cost of 35 bahts. The time for complete ingesting 75-g glucose and ice cream was 5 and 15 minutes, respectively.
46019444|NCT02854111|Other|75 g-glucose|The 75-g glucose is used for standard oral glucose tolerance test.
46019445|NCT04269577|Behavioral|SSP training|Participants will practice the Swipe Slide Pattern (SSP) task. On day 1, participants perform two runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, nine trials of 30s are performed, alternated with rest periods of 14s. In addition, instructions are provided before each trial (i.e. view of the pattern, 4s), as well as an answer option (i.e. participants have circle a random number from zero to nine, 6s). For the following four days (day 2-5), participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform nine trials of 12 patterns each, alternated with rest periods of 14s. Instruction are also included. During at home practice, the same pattern as during scans is included, in combination with two new patterns.
46019446|NCT01239342|Drug|Akt Inhibitor MK2206|Given PO
46019447|NCT01239342|Drug|Everolimus|Given PO
46103321|NCT04120142|Other|Pulmonary rehabilitation+IMT|The experimental group receives inspiratory muscle training and aerobic exercise.
46103322|NCT04120142|Other|Pulmonary rehabilitation|The Active Comparator group received only aerobic exercise.
46103323|NCT00743548|Device|IB = Interdental brush, the intervention|IB is a small multi-tufted brush on a wire attached to a long angled handle that is inserted in a horizontal plane between the teeth. The IB is inserted once and removed.
46103324|NCT00743548|Device|DF = Dental floss, the positive control|DF is waxed dental floss; nylon covered with a water soluble unflavoured wax to facilitate easier access the contact points of teeth. DF is rubbed against the interproximal surfaces of the teeth 2-4 times on each surface.
46103325|NCT04132622|Drug|Levothyroxine Sodium|Levothyroxine Sodium Tablets (50 ug, calculated by Levothyroxine Sodium ), produced by Merck KGaA, Darmstadt.
46103326|NCT04132622|Drug|Traditional therapy|including steroids, vitamin C, hemodialysis and blood perfusion.
46103327|NCT00743626|Other|Diagnostic cervical cancer screening tests (Pap smear, HPV and/or p16)|If positive (Pap smear, HPV and/or p16) patients will be scheduled for 3 colposcopy follow up visits (1,12,18 months)
46103328|NCT02562976|Other|gastric atrophy and intestinal metaplasia|use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia
45838092|NCT04881721|Procedure|Urethropexy|Suture based (Mesh-free) surgery to stabilize the urethra for the treatment of stress urinary incontinence
46019448|NCT01239342|Other|Laboratory Biomarker Analysis|Optional correlative studies
46019449|NCT04319250|Other|ischemic compression|ATNs detected in a total of 13 muscles around the shoulder were applied constant pressure at the level of pain tolerated with the thumb (discomfort severity level 7 to 8 out of 10) and for 90 seconds. This method was applied twice a week for 6 weeks.
46019450|NCT04319250|Other|IASTM|"In order to apply EDYDM in the treatment of ATN, titanium plated stainless steel was divided into two parts, front and back, with two tools. The sweep was applied to the anterior muscle fibers at an angle of 45 ° for 40 seconds.~For each TN, continuous pressure was applied with swivel movement at tolerable pain level (discomfort severity level 7 to 8 out of 10) for 1 minute. The back group muscles were applied in the same way."
46019451|NCT04319250|Other|Rehabilitation Program|A rehabilitation program consisting of exercises and manual therapy used in the conservative treatment of rotator cuff tear for both groups was applied twice a week for 6 weeks.
46019452|NCT00946309|Drug|High Sulforaphane Extract (Broccoli Sprout Extract)|100 umol sulforaphane, every other day for 5 weeks
46019453|NCT00946309|Drug|Microcrystalline Cellulose NF (placebo)|250 mg every other day for 6 weeks
46019454|NCT04269499|Device|QuiremSpheres®|Radioembolization with QuiremSpheres® under MR imaging
46103329|NCT04119752|Dietary Supplement|Curcumin powder|10g of curcumin powder
46103330|NCT04119752|Dietary Supplement|Placebo|1g of sucralose
46103331|NCT00747058|Drug|PF-3864086|The dosage form is POS (powdered oral suspension). Each subject will have 5 periods and the frequency (and duration) is once per period. The doses have been left flexible within the protocol but are listed as: 3, 10, 30, 60, 120, 240, 480 and 720 mg with an option to insert an additional dose cohort as well.
46103332|NCT00747058|Drug|Placebo|Placebo
46103333|NCT00866918|Drug|Arsenic Trioxide|Given IV
46103334|NCT00866918|Drug|Cytarabine|Given IT or IV
46103335|NCT00866918|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
46103336|NCT00866918|Drug|Idarubicin|Given IV
46103337|NCT00866918|Drug|Mercaptopurine|Given orally
46103338|NCT00866918|Drug|Methotrexate|Given orally
46103339|NCT00866918|Drug|Mitoxantrone Hydrochloride|Given IV
46103340|NCT00866918|Drug|Tretinoin|Given orally
46103341|NCT03158285|Drug|Guselkumab|Participants will receive 100 mg of guselkumab as a sterile liquid for SC injection.
46103342|NCT03158285|Drug|Placebo|Participants will receive matching placebo as SC injection.
46103343|NCT00861692|Drug|argatroban|
46103344|NCT03157973|Other|Education intervention|eHealth tool and standardized nurse-led follow-up.
46103345|NCT03131765|Biological|YS-0N-001|Cancer vaccine
46103346|NCT02684747|Other|Autologous Transfusion|Participants will receive autologous transfusion on Day 21
46103347|NCT02684747|Other|Control - Normal Saline (Placebo)|Participants will receive saline on Day 21
46103348|NCT04422821|Device|Flash Glucose Monitoring|Flash Glucose Monitoring FreeStyle Libre™ (Abbott Diabetes Care, Alameda, CA) sensor placed subcutaneously that will be applied for 14 days, then removed and changed for the second sensor for the next 14 days.
46019455|NCT02853799|Other|Comparison of the Effects of Intermittent and Continuous Enteral Feeding on Glucose-Insulin Dynamics in Critically Ill Medical Patients|"Placement of feeding tube stomach (oral- or naso-gastric tube)~Randomized to receive either continuous feeding or intermittent feeding first. Once at goal nutrition for 4 hours, enter first 4-hour data collection interval. Next proceed with cross-over and complete a 4-hour washout period with the feed type. Finally enter second 4-hour data collection period. To enter into the first data collection period, the patient would require an insulin infusion.~There will be five blood glucose checks in each data collection period.~If two blood glucose concentrations are above 180 mg/dl then a regular insulin infusion will be initiated."
46019456|NCT02853799|Dietary Supplement|Osmolite 1.2 cal/ml Enteral Feeds|Osmolite 1.2 cal/ml Enteral Feeds via feeding tube (oral- or naso-gastric tube)
46103349|NCT04422821|Device|Self-Monitoring of Blood Glucose|Self-Monitoring of Blood Glucose with a standard glucose meter (iXell®; Genexo sp; Warsaw, Poland) performed through a skin-puncturing 4 times a day for 28 days.
46103350|NCT02689271|Other|MRI|VERDICT diffusion-weighted microstructure imaging sequence
46019457|NCT02888496|Drug|tocilizumab|3 monthly IV infusions in PMR patients
46019458|NCT01236534|Drug|Lubiprostone|24 mcg twice daily for 21 days.
46019459|NCT01236534|Drug|Placebo|matching placebo twice daily for 21 days.
46019460|NCT01235598|Other|Placebo|Placebo provided for the first subcutaneous injection in single-use vials at Week 0 (2 vials required), then Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4 and 6, followed by Certolizumab Pegol (CZP) 200 mg every 2 weeks from Week 8 to Week 40
46019461|NCT01235598|Biological|Certolizumab Pegol (CZP) 200 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
46019462|NCT01235598|Biological|Certolizumab Pegol (CZP) 400 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
46019463|NCT01235442|Drug|1=Etanercept|50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.
46019464|NCT01235442|Drug|2=Clobetasol propionate foam|0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses
46019465|NCT01163253|Drug|CP-690,550|5 mg oral BID
46019466|NCT01163253|Drug|CP-690,550|10 mg oral BID
46019467|NCT01162863|Drug|Lubiprostone|lubiprostone taken either at a dose of 8 mcg orally twice daily (BID) for 28 days or 24 mcg orally once daily (QD) for 28 days
46019468|NCT01162863|Drug|Placebo|taken orally for 28 days
46019469|NCT01162863|Other|Smartpill wireless motility capsule|Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus
46103351|NCT02685917|Procedure|Microfracture without Collagen Augmentation|Cartifill applied for collagen augmentation
46103352|NCT02685917|Procedure|Microfracture with Collagen Augmentation|Cartifill applied for collagen augmentation
46103353|NCT02689037|Procedure|Percutaneous transluminal angioplasty and stenting|Surgeons will plant stents after vascular angioplasty in target ICAS vessels within 5 days after randomization.
46103354|NCT02689037|Drug|Aspirin plus clopidogrel|aspirin 100mg daily and clopidogrel 75mg daily for 90 days
45838093|NCT04871100|Behavioral|Unified Protocol- Alcohol|Transdiagnostic cognitive behavior therapy for emotional disorders modified to include CBT for alcohol use.
46019470|NCT02885805|Drug|BAY987516|2.00 mg/cm2 ± 0.04 mg/cm2
45838094|NCT04871100|Behavioral|Problem Solving therapy|Skills based approach for managing negative moods and stress.
46019471|NCT02885805|Drug|SPF 15 Control|2.00 mg/cm2 ± 0.04 mg/cm2
46019472|NCT05304039|Behavioral|Questionnaires|Questionnaires about asthma control and quality of life
46019473|NCT05304039|Device|Spirometry|Spirometry monitoring at home
46019474|NCT05304039|Device|Fractional Exhaled Nitric Oxide (FeNO)|Measuring fractional exhaled nitric oxide at home
46019475|NCT05304039|Device|Corsano watch|Monitoring vital parameters at home
46019476|NCT05304039|Device|e-Nose|Breathprint will be performed using e-Nose
46103355|NCT04184921|Drug|Aspirin 100mg|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
46103356|NCT04184921|Drug|Osimertinib 80 MG|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
46103357|NCT00639665|Other|Cocoa|Polyphenol rich or poor cocoa was administered to study subjects to measure hemodynamic responses and the role of nitric oxide in the renal vasodilator response.
46103358|NCT00602927|Drug|Varenicline|Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - Day 13 1.0mg twice daily
46103359|NCT00602927|Drug|Placebo|Participants will take placebo pills for 13 days using the same regimen as the varenicline study period.
46103360|NCT00639743|Drug|placebo ( group B)|placebo ( group B)
46103361|NCT00639743|Drug|tenecteplase (group A)|tenecteplase (group A)
46103362|NCT02684513|Dietary Supplement|Oral Carbohydrate Beverage|The oral carbohydrate beverage will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
45838095|NCT04868123|Device|Transcutaneous Nerve Stimulation (TENS)|Transcutaneous nerve stimulation (TENS) is a simple home base treatment to manage pain. It involves electrical current applied to the skin through self-adhering electrodes, using a TENS3000 device (TENSPros.com).
46019477|NCT05304039|Procedure|Nasopharyngeal swabs and nasal lining fluid|Nasopharyngeal swabs and nasal lining fluid will be taken
46019478|NCT05304039|Device|Sputum induction|If patients produce sputum, the sputum will be analysed
46103363|NCT02684513|Dietary Supplement|Rehydration beverage|The rehydration beverage group will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
46103364|NCT04186559|Drug|Topical Pentoxifylline Gel (Vehicle +PTX)|Patients will be given 1 tube containing 20 ml of topical PTX gel (containing 1,000mg of PTX) to be applied no fewer than four times per day with complete consumption of the entire tube each day.
46103365|NCT04186559|Drug|Topical Placebo Gel (Vehicle)|Patients will be given 1 tube containing 20 ml of topical placebo gel to be applied no fewer than four times per day with complete consumption of the entire tube each day.
46103366|NCT02685683|Drug|GED-0301|During Induction period patient will receive mongersen 160 mg daily for 12 weeks. This study also offers subjects the option to continue with maintenance treatment at the discretion of the Investigator, beginning after the Week 12 Visit with alternating no IP for 4 weeks, followed by mongersen (GED-0301) 160 mg QD for 4 weeks, up through the Week 52 Visit during the Maintenance Period. At Week 52, subjects who have achieved an endoscopic improvement of >50% from baseline based on the SES-CD, as assessed by the central reader, and clinical improvement (HBI <7), will have the option to continue receiving treatment for an additional year, up through Year 2 (ie, the Week 100 Visit).
46103367|NCT00602537|Drug|Venlafaxine|75 to 375 mg
46103368|NCT00602537|Drug|Lithium Carbonate|300 to 2400 mg
46103369|NCT02685839|Device|Intelligent POWER Rehabilitation Cluster Machine|
46103370|NCT02685839|Other|general physical therapy|
46103371|NCT02688803|Drug|Dose dense AC-P|(doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)
46103372|NCT02688803|Drug|Dose dense AC|Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)
46103373|NCT02688803|Drug|FEC-D|FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)
46103374|NCT00638495|Drug|Nalfurafine Hydrochloride (TRK-820)|TRK-820 2.5, 5 and 10 microg is to be administered orally once daily, after supper in principle, for 28 days.
46103375|NCT00638495|Drug|Placebo|Placebo is to be administered orally once daily, after supper in principle, for 28 days.
46103376|NCT02684669|Drug|Naloxone|active drug infusion
46103377|NCT02684669|Drug|Normal saline|placebo comparator
46103378|NCT03041363|Drug|Triheptanoin|Triheptanoin will be administered for 7 days 4 times daily.
46103379|NCT03004547|Other|Measuring sodium content|Sodium MRI measurement of sodium content in the tissues of all participants
46103380|NCT02688725|Device|post mastectomy ultrasound|post mastectomy ultrasound
46103381|NCT02976935|Other|hyperpolarised 129 Xenon|Hyperpolarised 129 Xe to assess lung function
46103382|NCT00861614|Drug|Ipilimumab|5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, Up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
46103383|NCT00861614|Drug|Placebo|Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
46103384|NCT00485173|Device|INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate|All patients enrolled in this study will receive the investigational device.
46103385|NCT00495469|Drug|GSK189075|GSK189075 is available as a white, capsule-shaped tablet dosage form containing 50mg, 125mg, 250mg or 500mg of GSK189075 per tablet
46103386|NCT00495469|Drug|Placebo|Available as Placebo matching tablet to GSK189075
46103387|NCT00861380|Biological|Pneumococcal conjugate vaccine GSK1024850A|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
45838096|NCT04868123|Behavioral|Mindfulness Meditation|Mindfulness mediation is a guided mediation process to improve awareness of being present in the moment.
45838097|NCT04864392|Drug|LNA043 Dosing Regimen A|Injection to the knee
45838098|NCT04864392|Drug|LNA043 Dosing Regimen B|Injection to the knee
46103388|NCT00861380|Biological|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|"3 or 4 Intramuscular injections, depending on the age at the time of first vaccination.~Control 3+1 and Control 2+1 groups, only for children < 12 months of age at the time of first study vaccination."
46103389|NCT00861380|Biological|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections. Control 3+1 and Control 2+1 groups, only for children >= 12 months of age at the time of first study vaccination.
46103390|NCT00495391|Drug|Nitazoxanide|One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
46103391|NCT00495391|Drug|Placebo|One oral placebo tablet twice daily for 52 weeks.
46103392|NCT00495391|Biological|Peginterferon alfa-2a|Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
46103393|NCT00495391|Drug|Ribavirin|1000 mg (if <75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
46103394|NCT04378621|Drug|TNF-α inhibitor OR JAK inhibitor|Pharmacological anti-rheumatic treatment
46103395|NCT04378621|Other|Hand training|Physical hand training 10 min twice daily while on stable treatment
46103396|NCT00869960|Drug|tenofovir|tenofovir 300 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle)
46103397|NCT00869960|Drug|emtricitabine|emtricitabine 200 mg on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
46103398|NCT00869960|Drug|atazanavir|atazanavir 300mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
46103399|NCT00869960|Drug|ritonavir|ritonavir 100 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
46103400|NCT02618486|Procedure|Non surgical periodontal therapy|NSPT includes oral hygiene education, scaling root planing and mouth wash
46103401|NCT02615444|Dietary Supplement|Beta-glucan enriched oatcake|5 oatcakes enriched with oat beta-glucan will be consumed daily for six weeks
46103402|NCT02615444|Dietary Supplement|Isocaloric control|6.5 wheat based control snacks without beta-glucan will be consumed daily for six weeks
45838099|NCT04864392|Drug|LNA043 Dosing Regimen C|Injection to the knee
45838100|NCT04864392|Drug|LNA043 Dosing Regimen D|Injection to the knee
45838101|NCT04864392|Drug|Placebo|Injection to the knee
46103403|NCT02618564|Drug|Sennosides|Each group will be assigned different doses of sennosides and varying times of administration
46103404|NCT02615366|Drug|Tranexamic Acid|
46103405|NCT02615366|Drug|Placebo|
46103406|NCT00699296|Drug|Panobinostat (LBH589)|20mg/day p.o. on three times-a- week
46103407|NCT02615210|Device|SOC-directed biopsies using the SpyGlass System|The cholangioscopy procedure with the SpyGlass System is performed by a single operator with the SpyScope Access and Delivery Catheter positioned just below the operating channel of the duodenoscope. SpyBite Biopsy Forceps guided by the SpyScope Catheter are introduced and endoscopic-guided biopsy is taken at the level of the stricture. Target lesions will be identified under direct visualization using the SOC system, and 6-8 bites will be performed with the SpyBite forceps. Once SOC-directed biopsies are obtained, the SOC system will be withdrawn into the working channel of the duodenoscope and removed Patient will be contacted monthly to determine if they have undergone any additional procedures and to record potential adverse events.
46103408|NCT04119674|Biological|Anlotinib|Anlotinib With STUPP Regimen
46103409|NCT04119674|Drug|Temozolomide Capsule|Anlotinib With STUPP Regimen
46103410|NCT00494299|Drug|Sorafenib (Nexavar, BAY43-9006)|Multikinase Inhibitor; Sorafenib: 400mg bid of sorafenib
46103411|NCT00494299|Drug|Placebo|Placebo: matching placebo
46019479|NCT05304039|Procedure|Blood sample|Blood sample for standard care and 10 ml extra will be taken
46103412|NCT02618330|Device|retainer|24 h wearing whether 0.75-mm-thick or 1.00-mm-thick film retainer
46019480|NCT01162473|Dietary Supplement|Milk Oral Immunotherapy|Subjects will participate in a desensitization protocol over the course of 13 weeks to reach a goal maintenance dose of 8 ounces of cow's milk. Once reaching maintenance, subjects will continue on this dose for 12 additional weeks.
46103413|NCT05298176|Drug|Afatinib, Osimertinib, Carboplatin and Pemetrexed|This study consists of 2 parts. Part 1 is defined as a first line treatment with afatinib orally (30 mg once a day) for the first 6 weeks, followed by concurrent use of afatinib (20mg once a day, part 1B) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by afatinib monotherapy (30mg once a day). Part 2 comprises a 2nd line treatment with osimertinib (80 mg once daily) after failure of part 1, only in T790M positive patients for the first 6 weeks, followed by concurrent use of osimertinib (80mg once a day) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by osimertinib monotherapy (80mg once a day).
46103414|NCT00593684|Device|Silver Alginate|This is a sterile patch of polyurethane foam coated with silver alginate and maltodextrin matrix that is impregnated with 141 mg of ionic silver per 100 cm2.
46103415|NCT02615288|Dietary Supplement|Vitamin D3|
46103416|NCT02618096|Drug|Oxytocin|
46103417|NCT02618096|Drug|Dinoprostone|
46103418|NCT02618096|Procedure|Membrane sweeping|
46103419|NCT04134026|Drug|HIF-PHI|Drug will be dosed orally three times a week.
46103420|NCT04134026|Drug|Epoetin Alfa|The drug will be dispensed per the package insert or the country-specific product labeling.
46103421|NCT02963831|Biological|ONCOS-102|ONCOS-102 was administered by intraperitoneal infusion at weekly intervals for 6 weeks.
46103422|NCT02963831|Drug|Durvalumab|Durvalumab was administered by IV infusion once every four weeks for a total of 10 (Cohort A) or 12 four-week cycles.
46103423|NCT02963831|Drug|Cyclophosphamide|A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.
46103424|NCT00859898|Drug|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 24 weeks
46103425|NCT00859898|Drug|Metformin XR|Tablets, Oral, up to 2000 mg, once daily, 24 weeks
46103426|NCT00859898|Drug|Metformin XR|Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks
46103427|NCT00859898|Drug|dapagliflozin matching Placebo|Tablets
46103428|NCT00859898|Drug|metformin HCl Modified Release matching Placebo|Tablets
46103429|NCT02685761|Procedure|Midline Vertical|Cesarean section performed using a midline vertical skin incision, located between the umbilicus and pubis
46103430|NCT02685761|Procedure|High Transverse|Cesarean section performed using a transverse skin incision located above the pannus
46103431|NCT02684123|Drug|Apremilast|Subjects will get drug or placebo
46103432|NCT02684123|Drug|Placebo|
46103433|NCT02683967|Procedure|acupuncture|patients received a Delphi acupuncture at least 3 times during their fertility treatment cycle.
46103434|NCT00859586|Device|Miltenyi Magnetic cell sorter for CD3|Receipts will receive 1 x 10 to eighth power CD3 cells/kg of familial haploidentical positively selected cluster of differentiation 34 (CD34)+ stem cells from the same DLI donor.
46019481|NCT01162473|Drug|Milk Protein Powder|Milk protein powder will be administered in incremental doses during the desensitization protocol.
46019482|NCT01162473|Other|Food Challenge|
46019483|NCT04314921|Other|Yoga trainings|10-week yoga sessions, 2 times per week, 90 min per session.
46019484|NCT02885649|Drug|Enzalutamide|Given PO
46103435|NCT00638729|Drug|midazolam|midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time
46103436|NCT00638729|Drug|clonidine|pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time
46103437|NCT00638729|Drug|placebo|inert tablet p.o., 60-90 min prior to estimated induction time
46103438|NCT00697892|Drug|lopinavir/ritonavir|Two tablets of lopinavir 200mg / ritonavir 50mg orally twice daily with food for 26 days
46103439|NCT00697892|Drug|efavirenz|One 600mg tablet orally once daily before bedtime on an empty stomach for 26 days
46019485|NCT02885649|Other|Laboratory Biomarker Analysis|Correlative studies
46019486|NCT02885649|Procedure|Nephrectomy|Undergo partial or radical nephrectomy
46103440|NCT00697892|Drug|artemether/lumefantrine|4 tablets of artemether 20mg/lumefantrine 120mg twice daily with food. 2 three-day courses will be administered (with washout in between) during the duration of the trial.
46103441|NCT02683811|Behavioral|Diario della Salute (DDS-2)|The updated version of Diario della Salute program (DDS-2) includes: 1) teachers' manual, 2) a booklet for teens telling the story of four same-age students (e.g. experimenting with risky behaviours, conflicting feelings and thoughts, need for independence and control, etc.), 3) a booklet for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflicts, parental control and supervision, family communication, etc.).
46103442|NCT00699452|Drug|candesartan|Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)
46103443|NCT00699452|Drug|placebo|placebo
46103444|NCT02683733|Dietary Supplement|Bio-enhanced Curcumin Soft Gelatin Capsule|Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)
46019487|NCT02885883|Device|MRI 3T|
46103445|NCT02683733|Drug|5-Aminosalicylic acid|Dosage is as instructed by patient's physician
46019488|NCT01162239|Drug|Varenicline|All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid. Participants in the Extended Relapse Prevention plus varenicline will receive varenicline for up to 40 additional weeks.
46103446|NCT04118972|Behavioral|Mirror exposure and text prompt responses|Participants in the active interventions have three weekly mirror exposure sessions that are either guided with specific instructions as to where to look and how (only in functionality condition)
46103447|NCT02683655|Drug|Apatinib|Apatinib 500mg qd p.o.
46103448|NCT02683655|Drug|Apatinib|Apatinib 750mg qd p.o.
46103449|NCT00494221|Drug|AZD2171|oral tablet
46103450|NCT00494221|Drug|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|intravenous infusion
46103451|NCT00494221|Drug|Placebo Cediranib|oral tablet
46103452|NCT00909935|Drug|Dexmedetomidine|Initial 2 mcg/kg bolus administered over 10 minutes to achieve the Ramsey sedation score of 4 followed by an infusion of 1.5 mcg/kg/hr, which will run until patient is transferred to recovery area. Up to a further two boluses of 2 mcg/kg may be given to maintain an RSS of 4.
46103453|NCT00857948|Drug|ivermectin treatment conditioner|Application followed by thorough rinsing of the hair and scalp with water.
46103454|NCT00857948|Drug|Placebo, vehicle control|Application followed by thorough rinsing of the hair and scalp with water.
46019489|NCT01162239|Behavioral|Initial Individual counseling|Five 90 minute individual counseling sessions to occur during the first 12 weeks of initial treatment.
46103455|NCT02618174|Behavioral|Neutral Control Condition|Message about age of University of Birmingham
45838102|NCT04859829|Other|Current Intravenous Immunoglobulin (IVIG) treatment|Questionnaires every two months for patients with a diagnosis of autoimmune dysmotility that are receiving Intravenous Immunoglobulin (IVIG) treatment.
46019490|NCT01162239|Behavioral|Check-ins with medical staff|Monthly brief (10-15 minutes) meetings with medical staff.
46019491|NCT01162239|Behavioral|Extended Individual Counseling - Health Model|Monthly counseling sessions across a nine month period with content based on a health education model. Each session is 30-45 minutes in duration.
46019492|NCT01162239|Behavioral|Extended Individual Counseling - Relapse Prevention Model|Eleven individual counseling sessions across a nine month period with content based on a relapse prevention model. Each session is 30-45 minutes in duration.
46019493|NCT01161537|Drug|VX-770|Tablet.
46019494|NCT01161537|Drug|Placebo|Tablet.
46103456|NCT02618174|Behavioral|Food-based Control Condition|Message about variety of vegetables in the world
46103457|NCT02618174|Behavioral|Health Condition|Message about the health benefits of eating vegetables
46103458|NCT02618174|Behavioral|Descriptive Social Norm|Message suggesting most people eat plenty of vegetables
46103459|NCT02618174|Behavioral|Liking Social Norm|Message suggesting most people like eating vegetables
46103460|NCT04183751|Other|scale study|Forms and questionnaires will be used. The data will be collected by the researchers by face to face interview technique.
46103461|NCT02618018|Procedure|AT TORBI 709M|Cataract surgery with AT TORBI 709M 4-haptic toric IOL
46103462|NCT02688491|Drug|sunitinib|The investigators randomly assign assay-defined high risk patients of stageIII ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation.
46103463|NCT00866606|Biological|Benefix|BeneFIX for on-demand treatment of bleeding episodes were according to investigator prescription. FIX recovery was assessed by determining the FIX activity (FIX:C) levels in individual subjects. BeneFIX dosage for recovery assessments: single 75 IU/kg (±5 IU/kg) IV bolus infusion.
46103464|NCT02615132|Behavioral|iPad|Using iPad speech therapy apps on patients with post-stroke communication deficits
46103465|NCT02614976|Device|Padding|"Padding webrill (Covidian) TM 6"
46103466|NCT02617940|Other|fissure sealant|"Surfaces allocated to this group will be treated with resin-based sealant (FluroShield®, Dentsply, United States of America) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 30 seconds, followed by spray of water/air for at least 15 seconds. The sealant will be dispensed on the occlusal surface and light cured for 20 seconds (Optilight Max, Gnatus, Brazil)."
46103467|NCT02617940|Other|oral hygiene orientation|Surfaces allocated to this group will be treated with sterile water application, as a placebo, without anesthesia and rubber dam. The active treatment in this group will be only oral hygiene orientations.
46103468|NCT00857792|Drug|regadenoson|Subjects will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus).
46103469|NCT02613494|Drug|Hyoscine|300 micrograms twice daily, increasing to 300 micrograms three times daily
46103470|NCT02613494|Drug|Glycopyrrolate|1 milligram twice daily, increasing to 1 milligram three times daily
46103471|NCT02613494|Other|Placebo|Placebo twice daily, increasing to placebo three times daily
46103472|NCT00699530|Other|Cabergoline|Cabergoline 0,25 - 1,0 mg once a week, controlled by our outpatient clinic. The drug regimen is not influenced by participating in this study.
46019495|NCT04314297|Drug|Anlotinib In Combination With Durvalumab|"At the end of chest radiotherapy (c2d1), the simultaneous administration of androtinib hydrochloride capsule and PD-1 / L1 inhibitor was started. L~Arotinib hydrochloride capsule, 12 mg, Po, QD, was taken orally for two weeks, one week, three weeks as a cycle, completed in the first 14 days until the disease progress;~Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.~Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.~The choice of durvalumab / trepril mAb was at the discretion of the researchers."
46103473|NCT04119128|Device|Active Transcranial Direct Current Stimulation|Subjects will undergo 5 sessions of tDCS of up to 2mA, at 20 minutes per session, 1x per day. During active stimulation, the current will be active for the full 20 minutes.
46103474|NCT04119128|Device|Sham Transcranial Direct Current Stimulation|Subjects will undergo 5 sessions of tDCS, at 20 minutes per session, 1x per day. For sham tDCS, electrodes will be placed the same way as in the intervention group, for 20 minutes. However, the stimulator will deliver 2mA of current for only 30s. The current will not be active for the rest of the 20 minutes.
46103475|NCT02617862|Procedure|Examination under anaesthetic (EUA)|The EUA is scheduled as part of the routine clinical management of children with various ophthalmic conditions.
46103476|NCT02617862|Device|RetCam|The RetCam is a pediatric wide-field retinal camera that has been the mainstay for pediatric ophthalmic imaging since 1997. Imaging using the RetCam (during the EUA) is conducted as part of routine clinical magagement.
46103477|NCT02617862|Device|COSMOS|The COSMOS images will be captured (during the EUA) after the RetCam images. The COSMOS is designed to be used in the same way as the RetCam, but to produce higher quality images.
45681010|NCT03597490|Combination Product|Multimodal physical therapy with exercise|Multimodal physical therapy will compose of thermotherapy (hot pack or cold pack) and electrotherapy (transcutaneous electrical nerve stimulation or interferential current) and therapeutic ultrasound (at least two of them). Therapeutic exercise will compose of combination of range of motion, stretching, strengthening,neuromuscular and task specific exercises according to the clinical condition of patient under the supervision of a physiotherapist. Additionally, all patients will be allowed to carry on home exercise program.
45681011|NCT04747756|Other|Virtual Village|The purpose of this study is to create a virtual village for people aging with HIV, and to pilot test the virtual village intervention as a final step.
46019496|NCT02885571|Device|SomnoDent Flex with DentiTrac|
46019497|NCT04314063|Other|nasal swap|nasal swap to detect prevalence of staph aureus in food handlers
46019498|NCT04124133|Device|dressing with hyaluronic acid|Application of ialuset cream or gauzepad (hyaluronic acid)
46019499|NCT01233258|Biological|rFVIII (BAY81-8973) on demand|Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months and by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months, sequence according to randomization
46019500|NCT01233258|Biological|rFVIII (BAY81-8973) prophylaxis low-dose|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
46019501|NCT01233258|Biological|rFVIII (BAY81-8973) prophylaxis high-dose|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
46019502|NCT01232868|Biological|trivalent Influenza vaccine (TIV)|0.5 ml IM as a single dose in a prefilled syringe.
46019503|NCT01232790|Dietary Supplement|N-Acetylcysteine|N-acetylcysteine 1200mg bid for 3 days
46019504|NCT01232790|Drug|Placebo|Placebo
46019505|NCT01232556|Drug|Inotuzumab ozogamicin|1.8 mg/m2 on day 2 every 28 days by IV infusion, 3 to 6 cycles
46019506|NCT01232556|Drug|Rituximab|375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles
46019507|NCT01232556|Drug|rituximab + gemcitabine|rituximab 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2 to 6, every 28 days by IV infusion, 3 to 6 cycles; gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days, 3 to 6 cycles
46103478|NCT00697970|Biological|HBsAg formulated with different concentrations of MPL and Aluminium Salts|Intramuscular injection, 3 doses
46103479|NCT00697970|Biological|Engerix™-B|Intramuscular injection, 3 doses
46103480|NCT02617706|Device|Epiflo|Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
46103481|NCT00601835|Biological|Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine|0.5 mL, Intramuscular, single dose
46103482|NCT00601835|Biological|Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine|0.5 mL, Intramuscular, Single dose
46103483|NCT02617472|Device|Pelvic floor exerciser|Daily exercise using the study device
46103484|NCT00640367|Other|Alteplase IA and/or mechanical thrombolysis|loca intra-arterial recombinant tissue plasminogen activator and/or mechanical thrombolysis
46103485|NCT00640367|Drug|Alteplase IV|intravenous recombinant tissue plasminogen activator
46103486|NCT04133714|Device|multi-channel tDCS|multi-channel transcranial direct current stimulation, tDCS
46103487|NCT04133714|Device|single-channel tDCS|single-channel transcranial direct current stimulation
46103488|NCT00697424|Device|SleepStyle 200 Auto Series CPAP Humidifier|The device will record on internal software perceived sleep disordered breathing events. Events will also be scored manually on the polysomnography (PSG. Results will then be compared.
46103489|NCT00640445|Behavioral|Expressive Writing|In EW, people are asked to write about their deepest thoughts and feelings surrounding a significant life event for 20 minutes a day for 4 days
46103490|NCT00640445|Behavioral|Control Writing|Those assigned to control writing conditions are asked to describe factual information for 20 minutes a day for 4 days.
46103491|NCT04133558|Other|tracheal aspirate during routine care|tracheal aspirate during routine care
46019508|NCT01232556|Drug|rituximab +bendamustine|rituximab 375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles; bendamustine 120 mg/m2 on days 1 and 2 by IV infusion every 28 days, 3 to 6 cycles
46103492|NCT02688413|Device|MindMotionPRO|The MindMotionPRO, a certified device for medical use, is a virtual reality based system to train upper limb activities in a game scenario. The participant will receive 5 exercises sessions with the MindMotionPRO per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
46103493|NCT02688413|Other|Self-Directed Prescribed Exercises|GRASP is an arm and hand exercise program for stroke patients, designed to supplement standard rehabilitation therapies. The participant will receive 5 GRASP exercises sessions per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
46019509|NCT00946153|Drug|Lenvatinib|In the Dose-Escalation Component of the study, lenvatinib will be administered as continuous once-daily oral dosing. Dose-escalation will occur based on safety information obtained during Cycle 1. The recommended dose for the Expansion Component of the study will use the MTD in Cycle 1.
46019510|NCT04258891|Other|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2004 in European, North American and South American centers, who have estimated glomerular filtration rate and proteinuria follow-up and data from protocol and for cause biopsies for allograft survival assessment; Randomized controlled trials conducted over the past 20 years with available data on protocol biopsy within the first year and follow-up, clinical, biological and histological data.
46103494|NCT00697502|Drug|Capecitabine|"Capecitabine (XELODA) is supplied as biconvex, oblong film-coated tablets for oral administration and will be obtained from NUH Cancer Centre pharmacy.~Each light peach-colored tablet contains 150 mg capecitabine and each peach-colored tablet contains 500 mg capecitabine. Capecitabine is to be administered orally within 30 minutes after the end of a meal (breakfast, dinner). Tablets should be swallowed with about 200 mL of water (not fruit juices). Capecitabine will be administered for 14 days followed by a 7 day rest period."
46103495|NCT02617082|Radiation|partial breast irradiation|The prescription dose is 40.5Gy in 15 fractions in 3 weeks.
46103496|NCT04183829|Procedure|induced termination of pregnancy|Medically, induced termination of pregnancy (I-TOP) is defined as an intervention to voluntarily terminate a pregnancy (ie, induced abortion) by either surgical or medical means so it does not result in a live birth.
46103497|NCT04118816|Diagnostic Test|Polysomnography|overnight polysomnography recording at least six hours
46103498|NCT04118816|Diagnostic Test|Multiple sleep latency test|daytime naps at least four to five naps to evaluate daytime sleepiness and narcolepsy
46103499|NCT04118816|Other|Continuous positive airway pressure|continuous positive airway pressure treatment for sleep-disordered breathing
46103500|NCT04183517|Drug|PXS-5382A|Orally once daily or twice daily
46103501|NCT02688257|Other|MRI|Functional magnetic resonance imaging
46103502|NCT02688257|Other|Ultrasound|Optoacoustic imaging
46103503|NCT02688335|Device|Cloud9|Low-pressure Continuous Positive Airway Pressure (CPAP = 2 - 4 cm H2O).
46103504|NCT00640913|Procedure|Reversal of defunctioning stoma|Reversal of defunctioning stoma
46103505|NCT00857246|Drug|Cetuximab|
46103506|NCT00857246|Drug|Irinotecan|
46103507|NCT00857246|Drug|Cisplatin|
46103508|NCT00857246|Procedure|Surgery|
46103509|NCT00857246|Drug|5-FU|
46103510|NCT00857246|Radiation|Radiation|
46103511|NCT02683499|Procedure|Ultrasonic tips|These tips are going to be used to give the final shape of the prepared surfaces before taking the impression for the construction of the veneers.
46103512|NCT04184531|Other|Medical Data Collect|It is a retrospective clinical study and we will collect only the medical data registered in our hospital software
46103513|NCT04118582|Other|Body composition and resting metabolic rate analisys|
46103514|NCT00699686|Drug|Glargine|Daily bedtime subcutaneous insulin Glargine in individualized doses.
46103515|NCT00699686|Drug|Detemir|Daily bedtime subcutaneous insulin Detemir in individualized doses.
46103516|NCT02688101|Drug|DpC|iron chelator
46103517|NCT04184063|Drug|NBMI|NBMI active treatment
46103518|NCT04184063|Other|Placebo|Placebo for comparison
46019511|NCT01914367|Biological|cervarix|3 doses will be given, one on Day 0, one on Day 30 and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
46103519|NCT04183985|Device|Total knee arthroplasty prosthesis|In patients undergoing same-day bilateral total knee arthroplasty, after deciding the implant of TKA(anatomically aligned TKA implant or conventaional TKA implant) using random number table, compare the result of clinical outcome about two instruments.
46103520|NCT00640679|Drug|Abrupt Clopidogrel Interruption|Patients assigned to this group will receive Clopidogrel 75mg per day for an additional period of 4 weeks. Afterwards they will stop the drug abruptly.
46103521|NCT00640679|Drug|Clopidogrel Tapering|Patients assigned to this group will have Clopidogrel gradually decreased according to a fixed tapering schema of Clopidogrel and Placebo over 4 weeks.
46103522|NCT02682953|Drug|Neupogen|Pharmacological agents often used for stem cell mobilization will be utilized in this study.
46103523|NCT02682953|Procedure|Hyperbaric oxygen therapy|Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days
46103524|NCT02682953|Drug|Plerixafor|Pharmacological agents often used for stem cell mobilization will be utilized in this study.
46103525|NCT02683031|Other|Ca2+ ionophore|Ca2+ ionophore is a chemical agent used to perform oocyte activation after ICSI. It showed effective treatment to get better fertilization, pregnancy, and healthy livebirth in cases with total or partial fertilization failure.
46103526|NCT04183907|Behavioral|Transform|"The Partner, Blue Mesa Health, has developed a lifestyle intervention program for pre-diabetics that aims to prevent or delay the onset of type 2 diabetes through incremental changes to health behaviours. Transform is based on the CDC's National Diabetes Prevention Program (DPP). Blue Mesa Health adapted the National DPP into a digital experience by combining the use of technology- an app, wearable activity trackers (Fitbit) and digital scales- with the professional guidance of remote health coaches.~It is a 6-month intervention that helps individuals establish healthier lifestyle habits. Each participant strives to achieve 2 primary goals:~Attaining 5 to 7 percent weight loss from their starting bodyweight Engaging in at least 150 minutes of weekly physical activity"
46103527|NCT04184141|Drug|Hydroxyzine Hydrochloride|Hyroxyzine hydrochloride is given to the patient one hour before surgery.
46103528|NCT04184141|Drug|Alprazolam tablet|Alprozolam is given to the patient one hour before surgery.
46103529|NCT04184141|Drug|Placebo|Placebo candy
46103530|NCT02682407|Biological|OMS721 (narsoplimab)|Biological: OMS721 (narsoplimab)
46103531|NCT02682251|Other|PHR Messaging|PHR messaging of data pertinent to chronic resynchronization therapy and heart failure management (i.e. percentage LV pacing).
46103532|NCT02682329|Other|Hydrogen Peroxide and Carbamide Peroxide|Carbamide Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP 10% at home and HP 40% at office
46103533|NCT02682329|Other|Hydrogen Peroxide and Hydrogen Peroxide|Hydrogen Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP at home and HP at office
46103534|NCT00640991|Drug|glulisine insulin, glargine insulin|IV infusion of glulisine, SC injection of glargine
46103535|NCT04102709|Device|Health Tag|Health Monitoring Device
46103536|NCT00640757|Dietary Supplement|Methionine deficient diet|Hominex with a low protein diet
46103537|NCT00640757|Dietary Supplement|Methionine sufficient diet|Hominex, low protein diet and methionine capsules
46103538|NCT00638807|Drug|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
46103539|NCT00638807|Other|Placebo|Matched oral placebo for 6 weeks
46103540|NCT00856856|Device|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation in the treatment of coronary artery disease
46103541|NCT04128215|Behavioral|Control Period|Subjects will complete an 8-week control period of normal lifestyle, followed by the 8-week exercise period.
46103542|NCT04128215|Behavioral|Exercise Period|Subjects will complete an 8-week non-weight-bearing all-extremity high intensity interval training (NWA-HIIT). NWA-HIIT will consist of 4x4-min bouts at 90% of maximal heart rate (HRmax) interspersed by 3x3-min bouts at 70% of HRmax. A 10-min warm-up and 5-minute cool-down at 70% of HRmax will be included.
45681012|NCT03597412|Drug|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe 10mg
46103543|NCT00782327|Drug|Losartan|Daily maximal doses of Losartan will be 50mg for subjects under 50kg of weight and 100mg if the weight is over 50kg
45681013|NCT03597412|Drug|Monorova|Rosuvastatin 20mg
45681014|NCT03592732|Other|Blood sample|Blood sample
46103544|NCT00782327|Drug|Placebo|Daily placebo capsule
46103545|NCT00559091|Drug|ribavirin|Ribavirin will be administered orally, twice daily, in the morning and evening with food. The dose selected is 400 mg AM and 600 mg PM. Intrapatient dose escalations can also be performed in defined circumstances. The maximal dose administered will be 1000 mg AM and 1000 mg PM.
46103546|NCT00641615|Biological|RNF43-721|Doses of 0.5mg, 1.0mg, 3.0mg/body/week
46103547|NCT04108949|Behavioral|Tuning in to Kids|A psychosocial intervention focusing on emotion socialization and emotion coaching.
46103548|NCT04108949|Behavioral|Treatment as usual|See description included in arm/Group description.
46103549|NCT00493285|Biological|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10^4 TCID50
46103550|NCT00493285|Biological|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10 ^5 TCID50.
46103551|NCT00493285|Biological|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10^6 TCID50.
46103552|NCT05664035|Biological|Diagnosis of SPAD using immunization with PPV23|Diagnosis of SPAD using immunization with PPV23
46103553|NCT04182581|Biological|BCMA/CD19 Dual-Target CAR-T|BCMA/CD19 Dual-Target CAR-T target both BCMA and CD19. The subjects will receive CAR-T as one dose. The dosage ranges from 5×10^4 to 3×10^5 CAR+T/Kg.
46103554|NCT00641069|Device|Automated load-distributing band device|Blood pressure recording before and after starting up the automated band device
46103555|NCT02682173|Other|MR Abdomen|
45681015|NCT01870401|Device|Lutonix DCB|
45681016|NCT01870401|Device|Uncoated PTA Catheter|
45681017|NCT03597334|Behavioral|aerosol therapy|Aerosol inhalation therapy refers to a local administration method in which a drug is made into aerosol particles having a very small diameter and is inhaled by a patient and the drug directly acts on the airway
45838103|NCT04859829|Other|No Intravenous Immunoglobulin (IVIG) treatment|Questionnaires every two months for patients with a diagnosis of autoimmune dismotility that are not receiving Intravenous Immunoglobulin (IVIG) treatment.
46103556|NCT02682017|Other|Pork meat from pigs feed with a standard feed.|4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week.
46103557|NCT02682017|Other|Pork meat from pigs fed a feed with a Laminarin/fucoidan mix|4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week from pigs fed animal feed supplemented (5.37 kg/tonne of feed) with spray-dried laminarin and fucoidan (seaweed).
46103558|NCT01015105|Other|observation|observation
46019512|NCT01914367|Biological|Gardasil|3 doses will be given, one on Day 0, one on Day 60 ± 2 days and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
46019513|NCT02856529|Other|Training|The Basic Infection Control Skills License program (BICSL) includes meningitis and influenza vaccination as well as fit test to verify the correctly fitting of the respirator. Also, the license program includes training on hand hygiene and the use of personal protective equipment (PPE). To get the license, each participants must get the vaccination and attend one to one training session with a program trainer 34.
46103559|NCT04033835|Other|Mentalization Based Treatment-Introductory|Mentalization Based Treatment-Introductory
46103560|NCT04033835|Other|Treatment as usual|Treatment as usual
46103561|NCT00856778|Device|Virtue® Male Incontinence Sling|The VIRTUE® male sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from intrinsic sphincter deficiency. The sling is manufactured from polypropylene and is sold for single use only.
46019514|NCT02856529|Other|General session|A general session about the basic of infection control was conducted for this group. The lecture performed in the same way of the regular training fulfill.
46019515|NCT02856373|Procedure|RNS and RDN|The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation
46103562|NCT04076579|Drug|Olaparib|Olaparib taken by mouth twice daily
46103563|NCT04076579|Drug|Trabectedin|Trabectedin administered intravenously (IV) every 21 days
46103564|NCT02680925|Procedure|lung protective ventilation|TV 4 ml/kg during one lung ventilation and 6 ml/kg during two-lung ventilation with PEEP of 6 cmH2O
46103565|NCT02680925|Procedure|Conventional ventilation|TV 8 ml/kg during one lung ventilation and 10 ml/kg during two-lung ventilation without PEEP
46103566|NCT05663879|Drug|ID120040002|Drug: ID120040002
46103567|NCT05663879|Drug|Compound-X|Drug: Compound-X
46103568|NCT05663879|Drug|Placebo comparator|Placebo comparator
46103569|NCT02680769|Dietary Supplement|300 mg of citrate Mg|This group will take an oral supplementation of 300 mg of citrate magnesium
46103570|NCT02680769|Other|Placebo|This group will take a placebo
46103571|NCT04049903|Drug|MP0310|MP0310 will be examined for safety, tolerability, PK, and PD activity in subjects with advanced solid tumors
46103572|NCT05664503|Other|Assigned Interventions STOMA-M|The training, which includes information on stoma care, maintenance of daily life activities, and complication management, was given to the patients in the experimental group via the STOMA-M.
46019516|NCT02856607|Other|determine the prognosis of threated patients according to the clinical care pathway.|
46019517|NCT01160289|Drug|LY2452473|Administered orally, once daily for 12 weeks
46019518|NCT01160289|Drug|tadalafil|Administered orally, once daily for 12 weeks
46103573|NCT02687945|Procedure|Outpatient physiotherapy|
46103574|NCT02687945|Procedure|Self-guided physiotherapy|
46103575|NCT02687789|Other|Medical Device: WO3191|application of vaginal suppository WO3191: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
46103576|NCT02687789|Other|Medical Device: Vagisan® Lactic Acid|application of Vagisan® Lactic Acid: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
46103577|NCT05664347|Behavioral|Verbal teach to goal education|Participants were showed how to use correctly their inhalers and then asked again to show the technique. For each incorrect step, the patients were corrected and asked to repeat the steps until they mastered the technique. This process was repeated a maximum of three times.
46103578|NCT05664347|Behavioral|Video based teach to goal education|Participants were educated by the a video-based teach to goal method. using a smartphone, an educational video illustrating the correct technique for each of the inhalers used by the patient was displayed. After watching the video, the patients were asked to show again how to use their inhaler and for each wrong step the video was displayed again until mastering the correct technique a maximum of three times. At the end of the interview participants in the intervention group received a copy of the video via WhatsApp and were all invited to watch the video whenever needed.
46103579|NCT05663723|Device|Intervention group with the IV and V LED board|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in two wavelengths: 42 red (660nm) and 42 infrared (850nm); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
46019519|NCT01160289|Drug|placebo (tadalafil)|Administered orally, once daily for 12 weeks
46019520|NCT01160289|Drug|placebo (LY2452473)|Administered orally, once daily for 12 weeks
46019521|NCT02885415|Procedure|Gastrointestinal surgery|Major resectional gastrointestinal surgery (define as resection of part of gastrointestinal tract during esophageal, Gastric or colorectal surgeries)
46103580|NCT05663723|Device|Intervention group with the IV, V and Violet LED board|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in three wavelengths: 18 red (660nm), 18 infrared (850nm) and 36 violet (420nm). ); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
46103581|NCT05663723|Device|Control group with LED board without emitting light|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra (Cosmedical) model without the light emitting combination. LED blanket in the size of 10x12 cm and application time: 1 session of 20 minutes. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
46019522|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
46019523|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
46103582|NCT02680535|Device|AuroShell particle infusion|Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.
46019524|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
46019525|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
46019526|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
46103583|NCT02680691|Other|Robot, then conventional training|Robot assisted gait training from the baseline, then conventional gait training at 4 weeks after baseline
46103584|NCT02680691|Other|Conventional, then robot training|Conventional gait training from the baseline, then robot assisted gait training at 4 weeks after baseline
46103585|NCT02680613|Behavioral|Motivational SMS|Behaviour change messages delivered via SMS developed with the theoretical guidance of the Health Belief Model.
46103586|NCT02680613|Behavioral|Travel Voucher|A code for return public transportation to closest cervical cancer screening clinic included in the research.
45681018|NCT04414839|Device|Digital Intubation (Two-finger)|In the NGT Digital Intubation group (group B), the second and third fingers were placed in the posterior pharynx and depressed the tongue downwards. The NGT was passed through the nose into the posterior pharynx with the fingers in the pharynx to reach the esophagus. The thumb was placed under the jaw and pushed it forward to pave the way for tube insertion.
46103587|NCT00603473|Drug|gabapentin|Orally administered gabapentin
46019527|NCT01159431|Device|Trigeminal Nerve Stimulation|External stimulation of the supraorbital branch of the Trigeminal Nerve using a digital TENs unit
46019528|NCT04314141|Procedure|Evaluation of surgical outcomes, quality of life and patient's satisfactions with phalloplasty|"Send a questionnaire to patients to collect informations about:~Sexual quality of life before and after the surgery~Satisfaction after surgery~Data collection in medical file :~Surgery outcomes~Functional outcomes"
46019529|NCT02885259|Drug|rHuPH20|human immunoglobulin and one vial of recombinant human hyaluronidase
46019530|NCT01158261|Biological|EVICEL ™ Fibrin Sealant (Human)|Commercial Evicel
46019531|NCT02885103|Device|Nasal high flow (NHF)|NHF will be combinated with a nebulizer. Inhalation will be done on nasal cavity.
46019532|NCT02885103|Device|Nebulizer|Inhalation will be done will Nebulizer and via mouth
46019533|NCT04313829|Behavioral|Pharmacist Counseling Intervention|We used the counseling module (in the form of a guide book) for pharmacist-based counseling that had been validated regarding constructive content by an endocrinologist and a pharmacist expert in diabetes drug counseling. The module explained the T2DM causes and symptoms, the reasons for the importance of therapy, the non-pharmacological and pharmacological therapies available (drug names, strengths, indications, rules of use, side effects, interactions, and storage), the purpose of controlling blood sugar levels, medications that need to be avoided, and guidelines for missed doses. The pharmacists should explain all the content within the module in 15 minutes to each patient of the intervention group each month for 6 months. As an ethical consideration, the control group patients were given the same explanation module through pharmacist counseling after the study finished.
46103588|NCT02688023|Drug|oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1|The regimen consisted of irinotecan 150mg/m2 administered as an intravenous infusion on day 1, oxaliplatin 85 mg/m2 administered intravenously on day 2, leucovorin 200 mg intravenously on day 2, 5-fluorouracil 500 mg administered by intravenous bolus,followed by 2400 mg/m2 by 44 h continuous intravenous infusion starting on day 2. S-1 (40-60mg orally twice per day for 10 days) or capecitabine (1000mg/m2 orally twice per day for 10 days) can be substituted for intravenous 5-fluorouracil.14 days as a cycle, up to 4 cycles.
46019534|NCT01157169|Drug|Buprenorphine|8 mg Sublingual Tablets
46019535|NCT01157169|Drug|Buprenorphine|8 mg Sublingual Tablets
46019536|NCT04313907|Combination Product|low level laser therapy plus topical clonazepam|combination of treatment, low level laser therapy (15 joules, 6 sesions, 14 days) plus topical clonazepam (1 mg,3 times per day, 14 days)
46019537|NCT04313907|Drug|Sham laser plus topical clonazepam|Sham laser therapy (0 joules, 6 sesions, 14 days) plus topical clonazepam(1 mg,3 times per day, 14 days)
46019538|NCT04313907|Radiation|Active laser plus placebo of topical clonazepam|low level laser therapy (15 joules, 6 sesions, 14 days) plus placebo topical clonazepam(lactose,3 times per day, 14 days)
46019539|NCT01231620|Drug|Zanamivir|Zanamivir aqueous solution, 10 mg/mL, will be provided as a single use, sterile clear, colorless preparation in 20 mL clear glass vials.
46019540|NCT01231620|Drug|Placebo to match zanamivir|Placebo to match IV zanamivir will be provided as a normal saline solution of a matched volume.
46019541|NCT01231620|Drug|Oseltamivir|Oseltamivir will be provided as over-encapsulated 75 mg capsules.
46019542|NCT01231620|Drug|Placebo to match oseltamivir|Placebo to match oral oseltamivir will be provided as capsules with a common excipient of appropriate quality.
46103589|NCT05663645|Behavioral|Health insurance educational guide|The educational guide includes 4 content areas: 1) Definition of key insurance terms; 2) premiums, deductibles across the five 2023 health plans; 3) Summary of how premiums and deductibles can affect out of pocket costs; 4) Guide to finding in-network IVF providers and facilities.
46103590|NCT02680223|Device|Precision tinted lenses|Tinted lens for patient with reading difficulty or visual stress
46103591|NCT02680223|Device|Non-beneficial tinted lenses|Tinted lenses that are unlikely to help reading difficulty or visual stress
46103592|NCT00910013|Drug|Ropivacaine|0.5% intra-articular ropivacaïne (20cc)
46103593|NCT04182503|Other|No intervention|This is a multi-city observational cohort study without intervention.
46103594|NCT00486889|Biological|alglucosidase alfa|Dose: 20 mg/kg every 2 weeks; Route of administration: Intravenous infusion
46103595|NCT04182191|Drug|Tenoxicam|After extraction of at least one third molar, 89 patients will be treated with tenoxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed.
46103596|NCT02680379|Drug|Minocycline, then Minocycline/Lovastatin|Participants of this group will take 1 tablet of minocycline 50mg daily for 4 weeks, minocycline 100mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40mg for the following 12 weeks.
46103597|NCT02680379|Drug|Lovastatin, then Minocycline/Lovastatin|Participants of this group will take 1 tablet of lovastatin 20 mg daily for 4 weeks, lovastatin 40 mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40 mg for the following 12 weeks.
46103598|NCT03996421|Dietary Supplement|nutritional iron (14 mg) supplement in form of ferrous fumarate|nutritional iron (14 mg) supplement in form of ferrous fumarate
46103599|NCT03996421|Dietary Supplement|ferrous fumarate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
46103600|NCT00641693|Drug|Budesonide|16mg Nasal Spray
46103601|NCT00641693|Drug|Budesonide|32mg Nasal Spray
46103602|NCT00641693|Drug|Budesonide|64mg Nasal Spray
45681019|NCT04414839|Device|Video Laryngoscopy|In the NGT Video Laryngoscopy group (group A), first, the GlideScope blade was inserted under direct visualization via color monitor through the patient's mouth by employing jaw-thrust maneuver to preserve the cervical spine and by raising the tongue to obtain better visualization of the larynx space. Then, NGT was inserted through the selected nostril, advanced through the esophagus under direct vision to meet the measured length, and fixed after confirmation.
46019543|NCT05511558|Drug|[14C]-Fosgonimeton|Carbon-14 Radiolabeled Fosgonimeton
46103603|NCT00641693|Drug|Placebo|
45681020|NCT00213148|Drug|Anastrozole 1 mg|Subjects will be administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
45681021|NCT00213148|Drug|Anastrozole 5 mg|Subjects will be administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
45838104|NCT04851158|Device|Effectiveness of ShotBlocker on the perceived pain and satisfaction during intramuscular antibiotic injection|"Intervention: Verbal information was given to the participants prior to the intramuscular injection, and their written consents were obtained. The Structured Information Form consisting of five questions was applied by face-to-face interview method. Height and weight were measured, and BMI (kg/m2) was calculated and recorded in the Structured Information Form.~Application: ShotBlocker will be used on 35 patients during intramuscular injection.~Final assessment: VAS will be applied immediately after the intramuscular injection to determine the pain and satisfaction levels of the participants."
46019544|NCT01231464|Drug|fluticasone furoate nasal spray|fluticasone furoate nasal spray 110ug, once daily
46019545|NCT01231464|Drug|placebo|placebo
46019546|NCT01156311|Drug|dimethyl fumarate|Days 1-7: 120 mg three times a day (TID) for a total daily dose of 360 mg. Day 8 to Week 24: 240 mg TID for a total daily dose of 720 mg. Drug supplied as a capsule taken orally.
46019547|NCT02888028|Procedure|ICD remote monitoring|ICD remote monitoring additionally to regular in-office visits
46103604|NCT04183361|Diagnostic Test|ABR and salivary cortisone testing|"Three saliva samples at the workplace will be collected immediately after the morning shift. The first saliva sample was given 3 days (Tuesday) before arrival at the research place, the second sample 2 days (Wednesday) before arrival, and the third sample 1 day (Thursday) before arrival at the research site. One hour before saliva sampling, a respondent should not brush his/her teeth nor eat nor drink. Fifteen minutes prior to sample administration, the subject should rinse his/her mouth with a cold water. Samples will be analyzed using High Performance Liquid Chromatography (HPLC) at the Translational Medicine Division of the Srebrnjak Children's Hospital.~2. Collaboration in the process of assessing hearing health at the research place. The assessment includes: otoscopy, tympanometry and audiometry. Subjects will be tested for auditory evoked brainstem response in only one ear, with a more regular hearing threshold."
46103605|NCT00641225|Drug|SBI-087|Single IV doses of SBI-087 from 0.015 mg/kg to 2 mg/kg and Single SC doses of SBI-087 from 50 mg to 300 mg.
46019548|NCT02888028|Other|Control group|Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
46103606|NCT02681861|Drug|ASP6294 Intravenous|Intravenous (IV)
46103607|NCT02681861|Drug|ASP6294 Subcutaneous|Subcutaneous (SC)
46103608|NCT02681861|Drug|Placebo Intravenous|Intravenous (IV)
46103609|NCT02681861|Drug|Placebo Subcutaneous|Subcutaneous (SC)
46103610|NCT02503774|Biological|MEDI9447|Subjects will receive MEDI9447 until disease progression
46103611|NCT02503774|Biological|MEDI9447 and MEDI4736|Subjects will receive MEDI9447 and MEDI4736 until disease progression
46103612|NCT02687867|Drug|Dabigatran (Pradaxa)|As prescribed by treating physicians
46103613|NCT02687867|Drug|Vitamin K antagonist|As prescribed by treating physicians
46103614|NCT00743704|Other|ozoneexposure|subjects will be exposed to either ozone (250 ppb) or filtered air in an ozone challenge chamber for three hours. Ventilation will be increased to 20 l/min/m2 by intermittent exercise on a bicycle ergometer.
46103615|NCT02681939|Drug|Tulsi(Ocimum sanctum Linn.) capsules|
46019549|NCT01230060|Device|enVista|One-piece hydrophobic acrylic intraocular lens (IOL) implanted following cataract extraction surgery. Patients to be followed for 120-180 days following surgery.
46019550|NCT02853955|Device|Percutaneous edge-to-edge repair of the mitral valve|MitraClip in patients with recurrent MI after surgical mitral valve repair.
46103616|NCT02681783|Drug|aflibercept|Therapeutic/Pharmacological Classification: VEGF - Anti-neovascularization agent Route(s) of Administration: Intravitreal Injection Dosage Form: Solution 40 mg/ml Proposed Indication: Treatment of Pigment Epithelial Detachments (PEDs) associated with neovascular Age-related Macular Degeneration (nAMD), Central serous chorioretinopathy (CSR), and idiopathic Poplypoidal Choroidal Vasculopathy (iPCV).
46019551|NCT04281745|Biological|CORETOX Inj|Clostridium botulinum type A (Hall group); a lyophilized white power for injection with a colorless transparent vial. colorless transparent solution when dissolved with saline.
46019552|NCT02853721|Other|iPTH|iPTH assay six hours after surgery
46019553|NCT02853721|Other|no dosage of iPTH|Ca and P on postoperative day 1 and 2
46103617|NCT00486811|Drug|Tapentadol ER (100 to 250 mg twice daily)|50, 100, 150, 200, 250 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
46103618|NCT00486811|Drug|Matching Placebo (twice daily)|Matching Placebo during 15 weeks (3 weeks titration and 12 weeks maintenance)
46103619|NCT00486811|Drug|Oxycodone CR (20 to 50 mg twice daily)|10, 20, 30, 40, 50 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
46103620|NCT04183127|Other|No intervention|ACPs, qualified or in training, will be invited to participate by email. Interested participants will be provided with study materials and asked to complete an online eligibility questionnaire; if eligible, contact details will also be recorded. Participants will be invited to take part in a focus group about their experience in developing clinical competence and their opinions on role identity. Data collection will consist of focus groups.
46103621|NCT04060810|Other|MR CSF flowmetry|MR flowmetry in grey zone hydro cephalic patients followed by ventriculoperitoneal shunt
46019554|NCT02860429|Drug|Cinobufacini injection|cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.
46019555|NCT02860429|Drug|chemotherapy|Chemotherapy is the oxaliplatin combination with fluorouracil regimen.
46019556|NCT01155531|Drug|Sertraline plus Telenzepine|oral sertraline tablets at 0, 50, 100, or 150/day plus oral telenzepine capsules at 0, 1, 2, or 3 mg/day for 7 days in each combination
46019557|NCT02856061|Behavioral|Pivotal Response Treatment|Pivotal response treatment (PRT) is an empirically validated behavioral treatment for individuals with ASD that has its foundation in principles of Applied Behavioral Analysis. It was designed to improve social communication skills by addressing core deficits in social motivation or pivotal responses. By working specifically with each child's natural motivations, PRT focuses on naturalistic, functional skills, as opposed to rote skills. In this study, participants randomized to the PRT group will receive 6 hours of direct PRT, across three sessions per week, provided by Dr. Ventola's clinical team. Parents will have an additional one-hour session per week focused on PRT parent training using a practice-with-feedback model. Specific intervention goals in our target population include: Speech to respond to inquiries, Speech to inquire, Speech to comment, Reciprocal conversation, Monitor nonverbal information, and Perspective taking.
46103622|NCT04182347|Other|Health Research ToolKit Development|"The Toolkit will be an accessible, structured process for people with IDD and people with IDD's paid and unpaid caregivers to be engaged partners. Learning activities are focused on leadership, information about research, health for individuals with IDD. Learning activities will include topics:~What is health research? What is the health research process? How can individuals with IDD be involved in health research? Where is research happening? How to think like a researcher. Creating health stories for research and care advocacy.~The learning activities will teach individuals with IDD information and allow participants to practice the learning."
46103623|NCT00921700|Drug|Ibuprofen + Paracetamol|Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg in gelatine capsules
46103624|NCT00921700|Drug|Ibuprofen + Paracetamol + Codeine|Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg and codeine 60 mg in gelatine capsules
46103625|NCT00921700|Drug|Paracetamol + Codeine|Single oral dose of paracetamol (acetaminophen) 1000 mg combined with codeine 60 mg in gelatine capsules
46103626|NCT00921700|Drug|Placebo|Single oral dose of lactose as placebo in gelatine capsules
46103627|NCT02678195|Drug|Amoxicillin|Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
46103628|NCT02678195|Drug|Placebo|Placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
46103629|NCT02681627|Other|Endometrial scratch|If patient randomised to intervention arm, will have speculum examination followed by endometrial scratch with a wallace catheter
46103630|NCT02681627|Other|Touching the cervix|If patient is randomised to the control arm, she will have speculum examination followed by cleaning of the cervix with a cotton tip dipped in saline
46103631|NCT03996577|Drug|Lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
46103632|NCT03996577|Drug|placebo|the control group will be given the same volume of saline.
46103633|NCT02681705|Drug|Temozolomide|Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
46019558|NCT01138579|Drug|FBTA05|
46019559|NCT04313595|Device|RespirHó|"The system is a wearable, unobtrusive inertial-sensor-based device for long-term breathing pattern monitoring, also during daily life activities. It consists of three IMU-sensor units (3-axis accelerometer, 3-axis gyroscope, 3-axis magnetometer), positioned respectively on the patient's abdomen and thorax, and on a body area integral with thorax but not affected by espiratory movements. The peripheral units, placed on thorax and abdomen are used to record orientation changes during respiratory movements. The third unit is a central reference unit (hereafter CRU) that receives data from the other two units, save them on an SD card and communicate via Bluetooth with a smartphone / tablet / PC. Moreover, this unit detects only non-respiratory movement, representing not only a pure source of noise that must be removed from the thoracic and bdominal signals, but also a pure source of additional information regarding the state of ctivity of the subject ."
46019560|NCT02860195|Other|oral dose of alcohol|
46019561|NCT02860195|Device|alcotest|
46019562|NCT02860195|Biological|blood samples|
46019563|NCT02860195|Device|Transdermal monitor|
46103634|NCT02681705|Radiation|Craniospinal Radiation|Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (Temozolomide).
46103635|NCT00921622|Dietary Supplement|Vitamin D|1000 IU twice daily for up to 10 days
46103636|NCT00921622|Dietary Supplement|Vitamin C|500 mg twice daily for up to 10 days
46103637|NCT02681471|Other|5% Mannitol|Traditional monopolar TURP was performed by using and irrigation fluid containing 5% mannitol ( Resectisol Eczacibasi-Baxter).
46103638|NCT02681471|Other|0,9% Sodium chloride|Bipolar TURP was carried out by using a 24 Fr TURis (OLYMPUS) resectoscope and irrigation fluid containing 0,9 % sodium chloride.
46103639|NCT02681471|Device|monopolar resectoscope|
46103640|NCT02681471|Device|bipolar resectoscope TURis|
46103641|NCT00747292|Procedure|epidural|Patients in this limb receive epidural analgesia
46103642|NCT00747292|Procedure|PCA|Patients in this limb receive a PCA for their pain control
46103643|NCT00747292|Procedure|Spinal|Patients in limb will receive spinal analgesia
46103644|NCT00642395|Drug|Bortezomib|bortezomib-Melphalan
46103645|NCT03880552|Other|Primigravid women with singleton pregnancy at 35th week over|Primigravid women with singleton pregnancy at 35th week over; only observational study will be done in this group and the data will be recorded.
46103646|NCT00486265|Drug|AZD4877|intravenous infusion administered on days 1, 2 and 3
46103647|NCT00747370|Procedure|movement of midurethra, bladder neck, cervix and rectum|
46103648|NCT02679989|Behavioral|Intermittent Energy Restriction|Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions
46103649|NCT02679989|Behavioral|Continuous Energy Restriction|Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions
46103650|NCT01018459|Biological|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Ad35.CS.01 appears clear to slightly opalescent with no visible particles. Each 0.75 mL dose of the assigned dosage will be administered via intramuscular injection into the deltoid muscle. Dosages: 10^9 viral particles (vp)/mL, 10^10 vp/mL, 5 x 10^10 vp/mL, and 10^11 vp/mL.
46103651|NCT01018459|Drug|Placebo|Normal saline placebo control delivered via intramuscular injection into the deltoid muscle.
46103652|NCT03888976|Procedure|Cholecystectomy|Cholecystectomy with repair of duodenal wall.
46103653|NCT01018615|Drug|silymarin|capsules, 700 mg, twice daily, 12 days
46103654|NCT01018615|Dietary Supplement|green tea extract (EGCG)|capsules, 196.5 mg, twice daily, 12 days
46019564|NCT01155219|Drug|Geltim LP 1 mg/g|one drop in the conjunctival sac of each eye in the morning (84 days).
46019565|NCT01155219|Drug|Xalatan|one drop in the conjunctival sac of each eye in the morning (84 days).
46019566|NCT01098955|Behavioral|Acceptance and Commitment Therapy|6 x 60-minute counseling sessions delivered over a 5-week period
46103655|NCT05663021|Diagnostic Test|Ultrasound-guided core needle biopsy in breast|For patients who were not evaluated as progressive disease by the latest imaging measurement, repeated core needle biopsy is conducted within the baseline tattooed area after 2 to 4 cycles of neoadjuvant chemotherapy, depending on the total cycles of chemotherapy. Tissue is acquired from different sections of the lesion from different angles to minimize the impact of tumor heterogeneity. For each patient, 3 to 4 tissue specimens are collected and sent for pathological review to examine whether there is residual malignancy (residual cancer, pleomorphic tissue) in the tumor site that is tattooed.
46103656|NCT00743782|Drug|Synthetic Human Parathyroid Hormone 1-34|
46103657|NCT02678117|Drug|Pregabalin & Placebo|
46103658|NCT02678117|Drug|Magnesium sulphate & Placebo|
46019567|NCT01098955|Behavioral|Motivational and Behavioral Counseling|6 x 60-minute counseling sessions delivered over a 5-week period
46019568|NCT01098955|Drug|Varenicline|2 mg daily for 12 weeks
45681022|NCT00213148|Drug|Anastrozole 10 mg|Subjects will be administered orally with 10 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
46019569|NCT01229436|Drug|Xiapex|Xiapex 0.58 mg in diluent, 0.25 ml for MP joints and 0.20 ml for PIP joints, injection to cord over joint using either 26 or 27 gauge needle, maximum 3 injections with 30 days interval between injections to any single site, maximum 5 injections in this protocol
46019570|NCT01155141|Drug|H.P. Acthar Gel|Patients were treated with 40 units subcutaneously (SC) weekly for 2 weeks, then dose increased to 80 units SC weekly for 2 weeks followed by 80 units SC twice weekly to complete 16 weeks of therapy.
46103659|NCT02678117|Drug|Pregabalin & Magnesium sulphate|
46103660|NCT02678117|Drug|Placebo|
46103661|NCT01018849|Dietary Supplement|Cholecalciferol|cholecalciferol 150,000 IU by mouth every 2 months for 1 year
46103662|NCT01018849|Dietary Supplement|Placebo|placebo by mouth every 2 months for 1 year
46103663|NCT04102319|Diagnostic Test|serum hepcidin|it is a serum marker
46103664|NCT00743860|Drug|darapladib|experimental drug
46103665|NCT01018693|Drug|VAK694; Alutard Avanz SQ|
46103666|NCT01018693|Drug|VAK694 placebo infusion; Alutard Avanz SQ|
46103667|NCT01018693|Drug|VAK694 placebo infusion; Saline|
46103668|NCT00747526|Drug|Rabeprazole sodium 5 mg|Type= exact number, unit= mg, number= 5, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to Day 5; possible extension using 5 mg once daily up to 28 consecutive days.
46103669|NCT00747526|Drug|Rabeprazole sodium 10 mg|Type= exact number, unit= mg, number= 10, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to up to Day 14; possible extension using 10 mg once daily up to 28 consecutive days.
46019571|NCT00631033|Drug|Placebo|
46103670|NCT01018771|Procedure|Actifuse ABX|bone graft to be used in posterolateral instrumented lumbar fusion
46103671|NCT01018771|Procedure|INFUSE, plus Mastergraft granules|bone graft to be used in posterolateral instrumented lumbar fusion
46103672|NCT01025011|Device|Fundus photography, cubital blood draw|blood draw from a cubital vein to measure hemoglobin concentration taking a fundus photography with a Nidek AFC-230, no pupil dilation needed
46103673|NCT00747604|Biological|mecasermin [rDNA origin] injection|As prescribed by the physician.
46103674|NCT02151604|Drug|Inhalation of hyperpolarized xenon gas|The xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.
46103675|NCT00466921|Drug|lenalidomide|10 mg daily orally administered on days 1 - 21 followed by 7 days rest of a 28-day cycle, increasing dose by 5 mg every cycle, up to a maximum of 25 mg.
46103676|NCT02563912|Other|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
45681023|NCT00213148|Drug|Clomiphene Citrate 50 mg|Subjects will be administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
46019572|NCT00631033|Drug|Diazoxide|
46019573|NCT00631033|Drug|Metformin + Diazoxide|
46019574|NCT04262323|Device|novel mobile phone application for blood pressure monitoring.|Comparative blood pressure measurement with the mobile phone application and the non-invasive reference method (upper arm cuff).
46103677|NCT02563912|Other|Medication chart|Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
46103678|NCT02073292|Procedure|c-RFA|
46103679|NCT02073292|Procedure|tRFA|
46103680|NCT00601523|Drug|Placebo|Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
46103681|NCT00601523|Drug|Pramipexole|ER 0.375-4,5 mg
46019575|NCT01155063|Other|Aromasin (exemestane)|Aromasin (exemestane), tablets 25 mg, once a day
46019576|NCT01072825|Other|questionnaires|a descriptive questionnaire, SF-36, , bone questionnaires, Baecke physical activity questionnaire, voice evaluation
46103682|NCT01685008|Drug|MOR00208 (formerly Xmab 5574)|
46103683|NCT00466687|Biological|bevacizumab|10mg/kg, slow IV infusion, Days 1 and 14
46103684|NCT00466687|Drug|erlotinib hydrochloride|150mg PO qd
46103685|NCT00466687|Genetic|fluorescence in situ hybridization|Targeting multiple genetic aberrations in isolated tumor cells.
46103686|NCT00466687|Genetic|gene expression analysis|gene expression analysis
46103687|NCT00466687|Other|immunologic technique|immunologic technique
46103688|NCT00466687|Other|laboratory biomarker analysis|laboratory biomarker analysis
46103689|NCT00466687|Procedure|biopsy|biopsy
46103690|NCT01522768|Drug|Afatinib and Paclitaxel|All patients receiving therapy on trial with afatinib and trastuzumab will continue on afatinib and trastuzumab until disease progression or intolerable toxicity. All additional patients will be enrolled on afatinib and paclitaxel. Patients will be treated with afatinib and paclitaxel combination. Patients will receive oral afatinib 40 mg daily plus paclitaxel 80 mg/m^2 intravenously on day 1, 8, and 15 of a 28-day cycle.
45681024|NCT00213148|Drug|Clomiphene Citrate 100 mg|Subjects will be administered orally with 100 mg of clomiphene citrate once daily for 5 days in Cycle 2 and 3 (each cycle = approximately 1 month).
46103691|NCT01759459|Drug|Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
46103692|NCT01759459|Drug|Buffered Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
46103693|NCT01759459|Drug|Bacteriostatic Normal Saline|The medication will be administered immediately prior to receiving peripheral IV catheter placement
46103694|NCT00747838|Procedure|Minimally Invasive Maze Procedure|Minimally Invasive Surgical Correction of Atrial Fibrillation.
46103695|NCT02537795|Device|deep brain stimulation|Electrical stimulation of the anterior limb of the internal capsule or bed nucleus of the stria terminalis
46103696|NCT02537795|Procedure|anterior capsulotomy|
45681025|NCT01704261|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week
45681026|NCT01704261|Drug|Matching placebo to Omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
45681027|NCT01704261|Drug|Glimepiride|Open-label glimepiride tablet(s) administered orally once daily for a total daily dose >=4 mg. In the event of hypoglycemia, the glimepiride dose may be down-titrated to a minimum dose of 1 mg daily.
45681028|NCT01704261|Drug|Metformin|Open-label metformin tablet(s) administered orally once or twice daily for a total daily dose >=1500 mg
45681029|NCT01715571|Device|Viberect|"Men will be asked to perform vibratory stimulation of the penis in the privacy of their home, while focused on sexual thoughts for approximately 7-10 minutes (depending on erectile response) for 3 times a week, one day apart, throughout the four week period. Men can perform the stimulation once daily, as long as each session is more than 24 hours apart.~Men will record device use and intercourse attempts after device use in a diary."
45681030|NCT00212758|Drug|Nutropin AQ|Nutropin AQ
46019577|NCT01072825|Biological|blood sampling|LFT (AST, ALT), CRP, creatinine, glucose, Total Cholesterol, Triglycerides, HDL-CH, LDL-CH, 25OH vitamin D, PSA if> 45 years, Hematocrit, testosterone, sex hormone-binding globulin, free testosterone , oestradiol, prolactin, luteinizing hormone, TSH, androgeengevoeligheids test (CAG RL), oral glucose tolerance test
46019578|NCT01072825|Other|clinical evaluation|height, weight, blood pressure, chestcircumference, waist circumference, grip strength, measuring 2 ° and 4 ° finger, and Ferriman Gallwey score
46019579|NCT01072825|Other|Dermatology evaluation|Evaluation of the hair pattern, using the Leeds acne classification scale, acne scars through ECCA scale (échelle d'évaluation clinique des cicatrices d'acné), androgenetic alopecia, and sebummetrie
46103697|NCT02562742|Drug|SOF|SOF 400 mg tablets administered orally once daily
46103698|NCT02562742|Drug|REB|REB capsules administered orally in a divided daily weight-based dose according to the package insert for the approved Rebetol® labeling in Japan (< 60 kg = 600 mg , > 60 kg to ≤ 80 kg = 800 mg, and > 80 kg = 1000 mg)
46103699|NCT04182971|Other|Fruit|Phase 1 is 227g of orange fruit, Phase 2 is 230g of apple fruit
46103700|NCT04182971|Other|Fruit juice|Phase 1 is 250g of orange juice, Phase 2 is 235g of apple juice
46103701|NCT04182971|Other|Fruit juice plus fiber|Phase 1 is 157g of orange juice + 100g of orange pomace fiber (39% pomace by weight), Phase 2 is 129g of apple juice + 106g of apple pomace fiber (45% pomace by weight)
46103702|NCT00305851|Procedure|Music Therapy|Undergo therapeutic music video therapy
46103703|NCT00305851|Procedure|Psychosocial Assessment and Care|Undergo books on tape therapy
46103704|NCT00305851|Other|Quality-of-Life Assessment|Ancillary studies
46103705|NCT04183283|Drug|LY3526318|Administered orally.
46103706|NCT04183283|Drug|Placebo|Administered orally.
46103707|NCT00744016|Drug|Granulated mesalamine|0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning
46103708|NCT00744016|Drug|Placebo|Matching placebo capsules (4 capsules) were administered orally QD, in the morning
46103709|NCT05664269|Dietary Supplement|drink ingestion|drink ingestion of a vanilla-flavoured beverage from a non-transparent shaker
46103710|NCT05664269|Behavioral|resistance-type exercise|Lower body resistance-type exercise on the supine leg press and seated knee extension machine. Both machines 4 sets at 80% 1RM for 8-10 reps.
46103711|NCT00744094|Dietary Supplement|protein drink|250 ml protein hydrolysate solution
46103712|NCT00744094|Behavioral|Resistance training|12 weeks resistance training, 3 days per week
46103713|NCT01018927|Device|Administering three additional MRI images|Three additional MRI images to determine the role of cardiac MR (CMR) in detecting features of early myocardial infiltration
46103714|NCT02677883|Other|Manometry-guided thoracentesis|Arm I will undergo a standard of care therapeutic thoracentesis procedure, and in addition include pleural pressure monitoring (via an FDA-approved digital manometer) which is also standard of care but left at the discretion of physicians as per expert recommendations. In this group, the procedure will be stopped when the patient develops symptoms or when all the fluid has been removed, and will also be stopped if the pressure begins to fall quickly in the fluid collection.
46103715|NCT02677883|Other|Symptom-guided thoracentesis|Arm II will undergo a standard of care therapeutic thoracentesis procedure. In this group, the procedure but will be stopped when the patient develops symptoms or when all the fluid has been removed.
46103716|NCT04182893|Diagnostic Test|ctDNA and Exosome Combined Detection|Through the detection and analysis of blood and alveolar lavage fluid of 300 patients with pulmonary nodules and 100 healthy population, the diagnostic efficacy of ctDNA and exosomes combined detceion will be studied.
46103717|NCT00641303|Procedure|acupuncture therapy|Given weekly for 8 sessions
45598475|NCT02352441|Other|Implementation Intentions(II)|"Implementation Intention training will include:~Demonstration and practice using examples and personal goals identified at first session. Worksheets will be provided to practice IF-THEN statements to set Implementation Intentions. Additionally, at the end of each session, the participant will be instructed to perform and event based or time based task. The objective is to see if those receiving II training are more likely to carry out the assigned task than those who do not receive II training. They will also be expected to practice II at least 5 days/week using personal goals."
46019580|NCT01072825|Other|Bone evaluation|PQCT scanner, BMD assessment
46019581|NCT04313517|Other|Yoga|Each yoga session included warm-up practices (for the large joints, spine, and extremities), Simple postures (Asana), breathing exercises (pranayama) and meditation/relaxation. All the yoga participants were given handouts to practice everyday at work as its feasible
46019582|NCT04313673|Diagnostic Test|second trimester ultrasonography|Patients undergoing routine antenatal screening between 18-24 weeks and measuring cervical length with transabdominal ultrasonography in the same session
46103718|NCT00641303|Procedure|sham intervention|Given weekly for 8 sessions
46103719|NCT04182737|Drug|IgM-enriched polyclonal immunoglobulins titer-based treatment|Immunoglobulins will be administered in a personalized dose based on serum IgM-titers
46019583|NCT01154673|Drug|raltegravir|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
46019584|NCT01154673|Drug|maraviroc|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
46019585|NCT01154673|Drug|emtricitabine 200mg /tenofovir 300mg|emtricitabine 200mg /tenofovir 300mg QD
46019586|NCT01154673|Drug|lopinavir 400 mg/ritonavir 100mg|lopinavir 400 mg/ritonavir 100mg BID
46019587|NCT02884869|Device|Intubating Laryngeal Mask|Direct laryngoscopy
46019588|NCT01154283|Device|Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)|Noninvasive positive airway pressure ventilation
46019589|NCT00944125|Device|Dual Site LV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
46019590|NCT00944125|Device|BiV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
46019591|NCT02884713|Drug|Levofloxacin|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
46103720|NCT04182737|Drug|IgM-enriched polyclonal immunoglobulins Flat treatment|Polyclonal endovenous immunoglobulins enriched in IgM administered in standard fixed dosages
46103721|NCT02681393|Behavioral|Brochure and Telephone Support|Participants will receive both the Aerobic Exercise After Stroke educational brochure and 4 weekly motivational telephone support calls.
46103722|NCT02681393|Behavioral|Brochure|Participants will receive both the Aerobic Exercise After Stroke educational brochure.
46103723|NCT02679599|Other|B-MOBILE-CARDIAC smartphone application|
46103724|NCT02679599|Behavioral|Cardiac rehabilitation as usual|
46103725|NCT02537639|Device|Transesophageal echocardiography simulator|
46103726|NCT00641849|Behavioral|Group A|Minimum Intervention Group A will fill out data forms at zero (0), two (2), four (4), and six (6) months.
46103727|NCT00641849|Behavioral|Group B|Maximum Intervention Group B will fill out data forms at zero (0), one (1), two (2), three (3), four (4), five (5), and six (6) months.
46103728|NCT05663489|Behavioral|Bergen 4-Day Treatment (B4DT)|A concentrated and exposure-based psychological treatment over four consecutive days
46103729|NCT04181645|Drug|Biological: SHR-1210 Drug: Gemcitabine Drug:Paclitaxel-albumin|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. Gemcitabine Other Name: Gemcitabine Hydrochloride for Injection Paclitaxel-albumin Other Name: Paclitaxel-albumin Injection
46103730|NCT02679833|Dietary Supplement|Placebo|Toothpaste not containing the vitamin.
46103731|NCT02679833|Dietary Supplement|Cyanocobalamin|Toothpaste containing100 µg cyanocobalamin/g.
46103732|NCT00641927|Drug|Venlafaxine|37.5 mg - 375 mg daily, 12 Weeks
46103733|NCT00641927|Drug|Lithium Carbonate|300 mg - 2100 mg daily, 12 weeks
46103734|NCT04033523|Behavioral|HIIT|The HF group performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 3 days/week for 12 weeks
45598476|NCT02291887|Drug|Ranibizumab|Intravitreal injection of Ranibizumab
46019592|NCT02884713|Drug|Doxycycline|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
46103735|NCT00641459|Other|Observational BPSD treatment study|Observational BPSD treatment study
46103736|NCT02677571|Procedure|Paravertebral Thoracic block|
46019593|NCT02884713|Drug|Esomeprazole|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
46103737|NCT02677571|Procedure|Pectorals nerve block|
46103738|NCT02677571|Drug|Levobupivacaine 0.25%|
46103739|NCT02677571|Drug|Morphine|
46103740|NCT04182269|Other|Measurement of functional exercise capacity|The Glittre Activities of Daily Living (ADL) Test was used to evaluate functional exercise capacity.
46103741|NCT02681315|Device|HHHFNC 6 liter minute|Infants allocated to HHHFNC at 6 L/min. will be extubated to a HHHFNC flow of 6 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
46103742|NCT02681315|Device|HHHFNC 3 liters/min|Infants allocated to HHHFNC at 3 L/min. will be extubated to a HHHFNC flow of 3 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
46103743|NCT04181567|Other|electroconvulsive therapy|electroconvulsive therapy 2 times weekly
46103744|NCT04181567|Drug|agomelatine|agomelatine
46103745|NCT04181567|Drug|Placebo|placebo
46103746|NCT05664191|Drug|Levosimendan|Infusion at 0.1 µg/kg/min at day 1 and day 8
46103747|NCT05664191|Other|Placebo|Glucose 5%, solution for injection ECOFLAC at day 1 and day 8
46103748|NCT02681081|Other|Glucose Administration|For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.
46103749|NCT02681081|Other|Intermittent Fasting|For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).
46103750|NCT02681081|Other|Control|Normal food intake
46103751|NCT00642005|Procedure|Fisher and Paykel Humidifier (MR860)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation.
45838105|NCT04851158|Device|Effectiveness of local vibrator device on the perceived pain and satisfaction during intramuscular antibiotic injection|"Intervention: Verbal information was given to the participants prior to the intramuscular injection, and their written consents were obtained. The Structured Information Form consisting of five questions was applied by face-to-face interview method. Height and weight were measured, and BMI (kg/m2) was calculated and recorded in the Structured Information Form.~Application: Local vibrator device will be used on 35 patients during intramuscular injection.~Final assessment: VAS will be applied immediately after the intramuscular injection to determine the pain and satisfaction levels of the participants."
45838106|NCT04821856|Drug|Cannabidiol Oil|Cannabidiol (CBD) isolate 100mg/ml in MCT oil oral solution, manufactured by THC Pharma
45838107|NCT04821856|Drug|Placebo|MCT oil and flavoring solution, also manufactured by THC Pharma
45838108|NCT04808076|Procedure|Shunt surgery|Shunt operation
46103752|NCT00642005|Procedure|Standard insufflation|No humidifier or warmer will be used (device switched off). This will deliver laparoscopic insufflate at 0% humidity and 20 degrees C.
46103753|NCT02679521|Device|ESWT|"Radial extracorporeal shock wave therapy (rESWT) was performed by the principal investigator with a Swiss DolorClast device (EMS Electro Medical Systems Corporation; Dallas, Texas, USA).~The Swiss DolorClast device obtained Pre-Market Approval (PMA) by FDA as Class III orthopedic lithotripsy device to treat heel pain associated with chronic proximal plantar fasciitis on May 8, 2007 (PMA # P050004), and was re-classified as Class III Generator, Shock Wave, For Pain Relief (Product Code NBN) in the Spring 2009. The present study started on October 3, 2007.~Each patient received two sessions of rESWT one week apart, with 2,000 impulses per session (air pressure of the device set at 3.5 bar; impulses applied with the 15 mm applicator at frequency of 8 Hz)."
46103754|NCT02679521|Device|Placebo|Placebo treatment was performed identically as rESWT but with a clasp on the heel that prevented transmission of the impulses from the applicator to the skin at the treatment site.
46103755|NCT02677727|Other|EORTC QLQ-CIPN20|EORTC QLQ-CIPN20 is a 20-item chemotherapy-induced peripheral neuropathy-specific questionnaire which includes three scales assessing sensory (9 items: #31-36, 39, 40, 48), motor (8 items: #37, 38, 41-45, 49), and autonomic (3 items: #46, 47, 50) symptoms and functioning with each item measured on a 1-4 scale (1 - not at all; 4 - very much).
46103756|NCT00642083|Device|Viabahn stent-graft|The viabahn stent-graft is a combined ePTFE-Nitinol self-expanding stent-graft preloaded on a catheter-based delivery system. It was originally designed for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery lesions with reference vessel diameters ranging from 4.8 to 7.5 mm. This device is also increasingly used for the exclusion of popliteal aneurysms. Its flexibility might make the device ideal for the treatment of recurrent outflow stenosis in AV loop-fistula.
46103757|NCT02676011|Drug|IM atropine|Atropine (0.01 mg/kg) (1 ml) IM 30 minutes before induction of anesthesia
46103758|NCT02676011|Drug|IV atropine|Atropine (0.01 mg/kg) intravenously (10 ml) 3 minutes before induction of anesthesia
46103759|NCT02676011|Drug|Atropine mixed with second dose succinylcholine|Atropine (0.01 mg/kg) added to the second dose succinylcholine (1mg/kg) prepared to 5 ml syringe with normal saline
46103760|NCT02676011|Drug|IM normal saline|1 ml normal saline IM 30 minutes before induction of anesthesia
45598477|NCT02291887|Drug|Aflibercept|Intravitreal injection of Aflibercept
45598478|NCT02352285|Drug|Tolvaptan|Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
45598479|NCT02352285|Drug|Placebo|Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
46103761|NCT02676011|Drug|IV normal saline|IV 10 ml normal saline 3 minutes before induction of anesthesia
46103762|NCT02676011|Drug|Normal saline mixed with second dose succinylcholine|Second dose succinylcholine (1 mg/kg) prepared to 5 ml syringe with normal saline
46103763|NCT05662943|Drug|Intravitreal aflibercept injection|Intravitreal injection of aflibercept (0.2 mg / 0,05 ml; Bayer Co. Ltd.,)
46103764|NCT00643253|Behavioral|LC and Electronic Prompt|Women will receive: a) International Board of Certified Lactation Consultant (IBCLC) education/counseling during the pre-natal, intra-partum and post-hospital discharge period to promote early and continued exclusive breastfeeding. The protocol specifies 2 prenatal meetings, a hospital visit, and a home visit if indicated and accepted, and; b) Electronic Medical Record Prompts- will appear on the prenatal record 5 times throughout the pregnancy. They are brief discussion points re breastfeeding that the provider is asked to raise with their patients.
45838109|NCT04801680|Device|Mpact 3D metal cup|Subjects, among those whose clinical condition makes them eligible for a primary total hip arthroplasty, will be invited to participate to the study during preoperative visit. They'll receive the Mpact 3D metal cup device
46019594|NCT00912223|Biological|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~The conditioning regimen will consist of the following:~Rituxan 375 mg/m^2 on Day -13~Rituxan 1000 mg/m^2 on Days -6, +1, and +8~Fludarabine 30 mg/m^2 on Days -5 to -3~Cyclophosphamide 750 mg/m^2 on Days -5, -4, -3~Day 0 will be the day of the transplant.~The GVHD prophylaxis will consist of the following:~Tacrolimus .09 mg/kg/po (Day -2 thru Day +180). Doses will be adjusted to maintain blood levels of 5-15 ng/mL.~Methotrexate 5 mg/m^2 (Days +1, +3, and +6). Unrelated donor recipients will receive a fourth dose on Day +11."
46103765|NCT02677649|Other|cranberry|the effect of cranberry on the gut microbiota
46103766|NCT02677649|Other|placebo|the effect of placebo on the gut microbiota
46103767|NCT00465985|Drug|ACZ885|
46103768|NCT00465985|Drug|Placebo|
46103769|NCT00643331|Behavioral|Exercise|Exercise performed at gym and at home comprising strength, balance and impact exercise
46103770|NCT02679365|Procedure|lower segment cesarean section and double lock closure of rectus sheath|
46103771|NCT02679365|Procedure|lower segment cesarean section and continuous non-locking closure of rectus sheath|
46103772|NCT01025167|Dietary Supplement|Supportan(R) (Disease-specific enteral tube feed, food for special medical purposes)|500 ml per day / treatment period 11-14 weeks
46103773|NCT01025167|Dietary Supplement|Fresubin(R)|500 ml/a nutritionally complete enteral standard feed (isoenergetic)
45598480|NCT02220491|Radiation|Single-fraction radiotherapy|Volumetric modulated arc therapy (VMAT) delivering 15 Gy in one fraction to brain metastases
45838110|NCT04801654|Diagnostic Test|blood sample|preoperative and at 6 months and 1 year follow-up after the surgery the patients will take a blood sample
45838111|NCT04788095|Behavioral|Behavioral Intervention|Participate in an app-based mindfulness program
46103774|NCT02679443|Dietary Supplement|Folate and B12|Vitamin (folate and B12) supplementation started simultaneously with initiation of chemotherapy (within 24 hours of initiation of chemotherapy). The only difference from the delayed (no-intervention) arm is the timing of initiation of vitamin supplementation. Dose and mode of administration of vitamin B12 and folate supplementation remain similar in both arms.
46103775|NCT01019005|Device|Catheter|Catheter inserted into either perineural tibial nerve or wound
46103776|NCT05663255|Drug|Discontinuation of respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)|Discontinuation or reduction of at least one respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)
46103777|NCT02678975|Drug|Disulfiram|Disulfiram 400 mg daily
46103778|NCT02678975|Dietary Supplement|Copper|nutritional supplement with copper, 2 mg daily
46103779|NCT02678975|Drug|Alkylating Agents|Alkylating antineoplastic agent
45838112|NCT04788095|Other|Quality-of-Life Assessment|Ancillary studies
45838113|NCT04788095|Other|Questionnaire Administration|Ancillary studies
45838114|NCT04788043|Drug|Magrolimab|200 mg max, starting 1 mg/kg IV Infusion
46103780|NCT02677415|Other|Intravenous anesthetics|
46103781|NCT02677415|Other|local anesthesia|
46103782|NCT02677415|Other|Controlled ventilation|
46103783|NCT02677415|Other|Spontaneous breathing|
46103784|NCT00454051|Drug|Omalizumab|Omalizumab was supplied as a sterile, freeze dried preparation, to be reconstituted to deliver 150mg of omalizumab. Each vial was reconstituted with 1.4ml of sterile water for injection. The appropriate dose and dosing frequency of omalizumab were determined by baseline total IgE and body weight. A dosing table was used following the European Summary of Product Characteristics (SmPC) of omalizumab.
46103785|NCT00454051|Drug|placebo|Placebo was a physiological salt solution, administered according to the same administration scheme to respect the same dosing frequency and injected volume.
46103786|NCT04179851|Diagnostic Test|Thermal imaging of neck veins|Thermal imaging of neck veins
46103787|NCT04181489|Drug|Sintilimab|Sintilimab 200mg d0
46103788|NCT04181489|Drug|Rituximab|Rituximab 375 mg/m2 d0
46103789|NCT04181489|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 d1
46103790|NCT04181489|Drug|Doxorubicin|Doxorubicin 50 mg/m2 d1
46103791|NCT04181489|Drug|Vincristine|Vincristine 1.4mg/m2 (maximum 2mg) d1
46103792|NCT04181489|Drug|Prednisolone|Prednisolone 60mg/m2 d1-5
45838115|NCT04788043|Drug|Pembrolizumab|200 mg IV infusion
45838116|NCT04788043|Procedure|PET/CT|Scan
46103793|NCT02537561|Drug|Cisplatin|
45681031|NCT04549545|Device|Vivaer ARC Stylus|The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal valves in a single study session.
46019595|NCT04313439|Other|Online cognitive therapy (I-CT)|"The treatment is an online cognitive therapy consisting of a structured self-help program over ten weeks, divided into eight modules, administered in an encrypted web platform. The program is based on the treatment manual The treatment of Obsessions by Stanley Rachman. In this treatment, the participant is recommended to perform daily exercises in order to identify and modify interpretations made about the importance of their obsessive thoughts. A designated therapist have email contact with the participant within the encrypted platform."
46019596|NCT01154127|Drug|NVA237|50 μg via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
46019597|NCT01154127|Drug|Placebo|Matching placebo via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
46019598|NCT01228734|Drug|Cetuximab|Cetuximab was administered every 7 days at an initial dose of 400 milligram per square meter (mg/m^2) at 5 milligram per minute (mg/min) and 250 mg/m^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to cetuximab.
46019599|NCT01228734|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
46019600|NCT01228734|Drug|Folinic Acid|FA 200 mg/m^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
46019601|NCT01228734|Drug|5Fluorouracil|5-FU as a bolus of 400 mg/m^2/day intravenously over 2-4 minutes followed by 600 mg/m^2/day infusion over 22 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
46019602|NCT01227954|Radiation|intensity-modulated radiation therapy|30 Gy in 10 fractions to the whole brain using intensity-modulated radiation therapy excluding the hippocampal avoidance area. Bilateral hippocampal contours manually generated on the fused planning MRI CT image set by the treating physician according to protocol-specified contouring instructions. Hippocampal avoidance regions generated by three-dimensionally expanding the hippocampal contours by 5 mm.
46019603|NCT01153971|Drug|rituximab|1
46019604|NCT01153893|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 1 or 2 doses
46019605|NCT01153893|Biological|InfanrixTM|Intramuscular injection, 1dose
46019606|NCT00951379|Drug|Pioglitazone hydrochloride|Three (3) pioglitazone 15 mg capsules by mouth once daily for 24 weeks (+/- 1 week)
46103794|NCT02537561|Drug|Gemcitabine|
45681032|NCT04549545|Device|Sham|The sham control procedure will be performed in the study clinic using the Vivaer ARC Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
46103795|NCT02537561|Drug|Talazoparib|
46103796|NCT04179773|Other|Current care study|"Observational study in two parts:~Cross-sectional study of patients with digestive or ENT cancer with indication for conventional chemotherapy treatment according to management guidelines, the objective of which is to determine the frequency of cirrhosis.~Exposed/non-exposed cohort study of patients receiving a first course of conventional chemotherapy initiated in outpatient oncology clinic. (safety population).~Exposed subjects will be patients with cirrhosis, included consecutively. Non-exposed subjects will be non-cirrhotic patients. They will be selected non-consecutively according to the following criteria, for matching to exposed subjects: age (±5 years), type of cancer (digestive vs. ENT), treatment stage (curative vs. palliative). Two unexposed subjects will be selected for 1 exposed subject."
46103797|NCT02676089|Drug|CHF 5993 200/6/12.5 µg|
46103798|NCT02676089|Drug|CHF 1535 200/6 µg|
46103799|NCT02676089|Drug|CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg|
46103800|NCT02679053|Behavioral|Aerobic exercise|
45681033|NCT03982342|Device|Cather closure of patent ductus arteriosus (PDA)|Infants assigned to this group will have a catheter run from a blood vessel in the upper leg / groin area to the heart, where an FDA-approved device will be placed within the patent ductus arteriosus to occlude or plug it, thereby closing the ductus.
46019607|NCT00951379|Other|placebo|Three (3) pioglitazone placebo capsules by mouth once daily for 24 weeks (+/- 1 week)
46019608|NCT00951379|Other|laboratory biomarker analysis|Correlative studies
46019609|NCT02855749|Procedure|ultrasound-guided percutaneous tracheostomy|to compare the reliability of the traditional landmark method, ultrasound-guided long axis in plane applications and ultrasound-guided short-axis out of plane application in the implementation process percutaneous tracheostomy
46019610|NCT01153815|Drug|GSK1358820(Botulinum toxin type A)|"GSK1358820 (Botulinum Toxin Type A, also known as OnabotulinumtoxinA or Botox)"
46019611|NCT01153815|Drug|placebo|placebo
46103801|NCT02679053|Behavioral|Placebo control|
46103802|NCT02679209|Biological|Demineralized bone matrix in putty form|it is a type of bone graft from human cadavers.
46103803|NCT02679209|Biological|Amnion chorion membrane|A bioresorbable allograft membrane for guided tissue regeneration from amnion and chorion parts of the placenta from pregnant females for guided tissue regeneration.
46103804|NCT02679131|Drug|Belinostat|Belinostat will be administered once daily on days 1 to 5 of a 21-day cycle (up to 6 cycles) via 30-min. IV infusion.
46103805|NCT02675777|Other|Quality Improvement Intervention|"Group Health clinical leaders and clinicians implement all aspects of behavioral health integration (screening, assessment, and shared decision-making followed by treatment). The implementation strategy, which was refined during the pilot phase, will include:~Identification of a clinical champion and Local Implementation Team.~Participatory Design.~Training primary care providers and Medical Assistants.~EHR clinical decision support tools~Weekly facilitated Local Implementation Team meetings.~Performance monitoring with feedback, including monthly PDCA meetings with the Local Implementation Team and clinic leaders.~Learning sessions for primary care providers during implementation.~Social worker use of an EHR registry with weekly supervision.~Video and handout explicitly designed to shift attitudes about unhealthy alcohol use (overcoming misconceptions and stigma)"
46103806|NCT00484939|Drug|Bevacizumab|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Bevacizumab was supplied in single-use vials.
46103807|NCT00484939|Drug|Capecitabine|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Capecitabine was supplied as tablets.
46103808|NCT02677337|Other|chart abstraction|chart abstraction will be conducted pre and post education intervention to assess efficacy of education at point of care
46103809|NCT02677337|Other|Educational Program|
46103810|NCT02677025|Behavioral|Young Women's Health CoOp (YWHC)|Participants in this group will participate in two workshops of the young woman-focused intervention about HIV/STIs (sexually transmitted infections), sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues. Participants will develop personalized risk reduction action plans at the end of each workshop session.
46103811|NCT02677025|Behavioral|HIV Counseling/Testing|Participants will be tested for HIV and if positive will receive counseling in accordance with national standards.
46103812|NCT02675855|Other|GrafixPRIME®|Human tissue, Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.
46103813|NCT02675855|Procedure|Dressing Application|Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.
46103814|NCT02675855|Device|Off-loading (walking boot)|Patients will be fitted for an off-loading device (walking boot) and agree to comply with use of the device during the course of the study
46019612|NCT02855983|Procedure|Fat Grafting|Grafting of autologous fat tissue is a minimally invasive surgical technique that starts with the harvest of fat tissue from the abdomen or thighs using liposuction through incisions less than 2mm in length. The lipoaspirate is then processed to concentrate the adipose fraction and reinjected into the graft site. This surgical procedure involves the immediate transplantation of a patient's own tissue in a single operative procedure.
45467569|NCT03467464|Other|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention consists of 10 weekly EMDR sessions of 60 minutes and targets stressful daily life (i.e. a situation that caused anger, fear or confusion) events rather than traumatic images from the past. For each session, a standardised EMDR protocol is used that consists of the following consecutive steps: 1) determining and visualising a confusing and/or stressful daily life event that occurred during the past week; 2) formulating a negative and a positive thought based on the chosen event; 3) determining the amount of stress that is evoked by the chosen event; 4) patient focuses on the chosen event while being presented with a distracting stimulus; 5) evaluating the amount of stress that is caused by the chosen event; 6) linking positive thoughts to the negative one when the stress caused by the chosen event does no longer exist; 7) evaluation and closure of session.
46103815|NCT02675621|Other|Phenolic Beverage|
46019613|NCT01153425|Other|Virtual Bone Biopsy|MRI technology allowing generation of 3D images with considerably smaller voxel size than previous technology through the use of novel pulse sequences and advanced interpolation techniques.
46019614|NCT01153425|Drug|Teriparatide|Participants are clinically indicated for treatment.
46019615|NCT01153425|Drug|Zoledronic Acid|Participants are clinically indicated for treatment.
46103816|NCT00642161|Drug|budesonide|
46103817|NCT05663177|Drug|Almonertinib and metronomic oral vinorelbine|Ametinib 110mg once a day; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.
46103818|NCT00642551|Dietary Supplement|menaquinone-7|180 µg menaquinone-7 daily for three years
46103819|NCT00642551|Dietary Supplement|placebo|1 placebo capsule daily for three years
46103820|NCT02678897|Drug|Oxynorm on-demand|"We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5."
46103821|NCT02678897|Drug|Oxynorm via PCA|"We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5."
46103822|NCT04181957|Drug|Placebo oral tablet|Participants take one dose of placebo (lactose) tablet.
45467570|NCT02719574|Drug|FT-2102 (olutasidenib)|FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level
46103823|NCT04181957|Drug|Lisdexamfetamine Dimesylate|Participants take one 50mg tablet of lisdexamfetamine dimesylate once.
46103824|NCT02678741|Drug|TLPLDC Vaccine|Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine
46103825|NCT02678819|Device|Digital cognitive aid|Digital cognitive aid during anesthesia and intensive care crises.
46103826|NCT02678663|Procedure|Injection-assisted Cold Snare Polypectomy|Resection of a polyp after blue-tinted saline injection using a cold snare (without application of electrocautery)
46103827|NCT02678663|Procedure|Endoscopic Mucosal Resection|Resection of a polyp after blue-tinted saline injection using snare electrocautery
46019616|NCT01153347|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
46103828|NCT00643409|Drug|azithromycin SR (Zithromax; compound: CP-62,993)|Azithromycin SR 2.0 g by mouth in the form of a slurry x 1 dose
46103829|NCT00643409|Other|placebo|placebo
46103830|NCT00643409|Drug|levofloxacin|levofloxacin 500 mg capsule by mouth qd x 10 days
46103831|NCT00643409|Other|placebo|placebo
46103832|NCT04180007|Drug|Apatinib|500 mg Apatinib given orally once a day for 12 wk prior to RAI (131I) treatment.
46103833|NCT02675309|Drug|MT-8554|
46019617|NCT01153347|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
46019618|NCT02884557|Other|collection of gut biopsies collection of blood samples|Four to eight colon biopsies will be sampled during endoscopy. Thirty milliliters of blood will be sampled.
46019619|NCT01153269|Drug|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
46019620|NCT02884635|Drug|ASP1707|Oral
46019621|NCT02884635|Drug|Placebo|Oral
46019622|NCT02884635|Drug|Methotrexate|Methotrexate will be orally administered at stable dose from at least 28 days prior to screening through the screening and treatment periods until the end of the follow-up period.
46103834|NCT02675309|Drug|rosuvastatin|
46103835|NCT02675309|Drug|simvastatin|
46103836|NCT00453973|Drug|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.044 milligram per kilogram (mg/kg) with an interquartile range of 0.028 to 0.076 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
46103837|NCT00453973|Drug|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.024 mg/kg with an interquartile range of 0.017 to 0.035 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
46103838|NCT05662085|Other|No intervention|According to clinical practice.
46103839|NCT05662007|Other||no intervention
46103840|NCT01025245|Drug|remifentanil, MgSO4|Patients undergoing thyroidectomy will be randomly assigned to one of three groups. Remifentanil will be infused intraoperatively at 0.05 ㎍/㎏/min (group Ⅰ) or 0.2 ㎍/㎏/min (group Ⅱ & Ⅲ). Patients in group Ⅲ will be received 30 ㎎/㎏ MgSO4 at the induction of general anesthesia followed by a maintenance infusion of 10 ㎎/㎏/hr intraoperatively until skin closure.
46103841|NCT05661929|Other|Questionnaire CMQ|The questionnaire is used to diagnose cognitive distortions. It includes 50 items to identify 10 the most common cognitive biases.
46103842|NCT01025323|Behavioral|Lifestyle modification|DASH diet and exercise advice
45467571|NCT02719574|Drug|Azacitidine|azacitidine will be administered per site's standard of care
46019623|NCT02884479|Drug|PT-112|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
46019624|NCT02884479|Drug|Docetaxel|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
46019625|NCT01152021|Drug|Dexmedetomidine|An initial bolus of 2 mcg/kg of dexmedetomidine will be administered over 10 minutes. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a 1.5 mcg/kg/hr infusion is initiated until the MRI is complete.
46103843|NCT01025323|Behavioral|Lifestyle modification|DASH diet, exercise with systematic instruction by a dietician and/or coordinator
46103844|NCT02677259|Drug|17-beta estradiol|
46103845|NCT02677259|Drug|Micronized progesterone|
46103846|NCT00465361|Procedure|performance feedback with an educational module|individual performance feedback with an educational module
46103847|NCT05484479|Behavioral|Baduanjin training/exercise|For 6 months, MeTS elderly (25 elderly) with chronic periodontal disease will be trained using sixty-minute Baduanjin training/exercise (5 times weekly)
46103848|NCT05481359|Device|Ablamap Software|Subjects will receive cardiac ablation guided by the Ablamap software. The software will identify atrial fibrillation sources to help guide ablation therapy in patients with persistent atrial fibrillation.
46103849|NCT02677103|Device|radial extracorporeal shock wave therapy|he RSWT was delivered at 2 Hz with 2000 shock waves and the energy level of 0.26mJ/mm2 in calcific tendinitis of shoulder.
46103850|NCT02677103|Procedure|ultrasound-guided needle puncture|After injecting 3cc 1% Xylocain in the subcutaneous tissue, muscle layer and subdeltoid bursa, multiple back-and-forth puncture about 10-20 times (depending on the size of the plaques) within the calcific plaques will be performed.
46103851|NCT02677103|Procedure|RSWT and USNP|each subject will receive radial shock wave therapy after ultrasound-guided needle puncture, as described in the previous paragraphs.
46103852|NCT00464815|Biological|Meningococcal vaccine GSK134612|One intramuscular dose
46103853|NCT00464815|Biological|Mencevax™ ACWY|One subcutaneous dose
46103854|NCT02675387|Device|Buzzy|Two minute application of a hand held vibrating device (Buzzy, MMJ labs, Atlanta GA, USA) before the administration of anesthesia
46103855|NCT02675387|Drug|2%Lidocaine|1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle (30 Guage)
45467572|NCT02719574|Drug|Cytarabine|low-dose cytarabine will be administered per site's standard of care
46019626|NCT01152021|Drug|Propofol|An initial bolus of 1mg/kg of propofol will be administered over 1 minute. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a propofol infusion of 125 mcg/kg/min is initiated until the MRI is complete.
46019627|NCT00637221|Drug|NPL-2009|Single doses of either 50mg, 100 mg or 150 mg NPL-2009
46019628|NCT00624975|Biological|Peru-15 Vaccine|up to 1 x 10^9 CFU of Peru-15 given in 5ml single dose vials with 20 ml buffer solution, given once
46103856|NCT00642239|Drug|placebo|placebo in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
46103857|NCT00642239|Drug|Sodium Glycididazole|Sodium Glycididazole 700mg/m2 in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
46019629|NCT00624975|Biological|Placebo|25 mL of buffer solution (2.5 g sodium bicarbonate and 1.65 g ascorbic acid per 100mL potable water)
46019630|NCT01151085|Drug|Voriconazole|"Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
46019631|NCT01149681|Drug|APLIDIN (plitidepsin)|"Aplidin® (plitidepsin) lyophilized powder and solvent for concentrate for solution for infusion. (2 mg plitidepsin vial and 4 ml ampoule).~Plitidepsin will be administered at 5 mg/m2 intravenously diluted to a total volume of 250 ml in 0.9% saline or 5% dextrose solution on Day 1 and 15 every four weeks for a maximum period of 6 cycles."
46019632|NCT04313127|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular other name:Ad5-nCoV
46019633|NCT02883933|Other|Data collection|
46103858|NCT01022437|Other|Geranium Oil with component PN-34|Geranium oil as a topical application to the body that is numb, time to determine how long it takes for the feeling to return, if it does so, and if the return of feeling is maintained by daily topical application of oil over 12 weeks. This including the process of absorption, distribution and localization.
46103859|NCT00642317|Behavioral|Questionnaire|Questionnaire about tobacco and alcohol use, acculturation, and other related topics.
46103860|NCT04181021|Behavioral|Values Clarification and Attitudes Transformation (VCAT) Workshop|VCAT is a participatory workshop aimed to provide accurate information about abortion and family planning and space to engage in critical self-reflection, provoke dialogue on beliefs, values and professional ethics and responsibilities around providing abortion and contraceptive care, and provide a deeper understanding of the range of circumstances in which women seek abortion and contraception.
46103861|NCT02678507|Other|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|
46103862|NCT02676947|Drug|Tocilizumab|
46103863|NCT00464737|Drug|Rotigotine|Titration by Week 4 to two 20 cm2 patches (one placebo patch and one 4 mg/24 hrs patch)
46103864|NCT00464737|Drug|Rotigotine|Titration by Week 4 to two 20 cm2 patches (both are 4 mg/24 hrs patches)
46103865|NCT00464737|Other|Placebo|Titration by Week 4 to two 20 cm2 placebo patches. At all weeks, placebo patches are matched in size and appearance to active patches.
46103866|NCT00642629|Drug|STA 5326 mesylate|STA 5326 mesylate 100mg taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
46103867|NCT00642629|Drug|Placebo|Placebo taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
46103868|NCT02678585|Drug|Nalbuphine|53 patients received intravenous regional lidocaine plus nalbuphine
45681034|NCT03982342|Other|Conservative management of patent ductus arteriosus (PDA)|"Infants with a hemodynamically-significant patent ductus arteriosus randomized to this group will be treated by fluid restriction and possible diuretic use to reduce PDA symptoms, and allow time to permit the PDA to close or become reduced in size to the point where it is no longer considered hemodynamically-significant."
46103869|NCT02678585|Drug|Lidocaine|53 patients received intravenous regional lidocaine
46103870|NCT00453349|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
46103871|NCT00453349|Drug|Levofloxacin & Metronidazole|Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days
46103872|NCT02675153|Drug|Rapamycin|Participants with gastrointestinal strictures were treated with rapamycin 2mg daily at least six months.
45681035|NCT03592420|Behavioral|Interdisciplinary multicomponent interventions|
45681036|NCT03592420|Behavioral|Usual care|standard care
46019634|NCT01149369|Drug|Aprepitant|Aprepitant, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
46019635|NCT01149369|Drug|Placebo|Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
46019636|NCT01740427|Drug|PD-0332991|PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
46103873|NCT04033601|Behavioral|Non-pharmacological intervention|The non-pharmacological intervention will comprise sleep hygiene education, exercise training and relevant modules of cognitive behavioral therapy.
46103874|NCT01025401|Device|3-D accelerometric and magnetic sensors|sensors are positioned on the right wrist, the left wrist and on the head.
46103875|NCT02673437|Other|This is a non-interventional study|This is a non-interventional study
46103876|NCT04178915|Diagnostic Test|Bood leukocyte subsets|Determination of blood leukocyte subpopulations, myeloid suppressor cells of various origins, type 2 congenital lymphoid cells, depleted T cells, CD45RA+ CD45RB+ CD62L-IRC, T-cell differentiation stages (naive - memory cells - effector - terminally differentiated effectors), B cells (CD5+ B1 cells, CD11c+ ABC, differentiation stages: immature - naive - isotype-unswitched memory cells - isotype-switched memory cells - plasmoblast)
46103877|NCT04178915|Diagnostic Test|The cholesterol content of the cell membrane of T-cells and monocytes|The cholesterol content of the cell membrane of T-cells and monocytes with flow cytometry analysis
46103878|NCT02676557|Device|Exposed to the high pressure during the surgery|
45598481|NCT02220491|Radiation|Whole-brain radiotherapy|Whole brain radiotherapy delivering 20 Gy in five fractions to brain metastases
46103879|NCT02676713|Drug|pre-ovulation Decoction|HuoXueXiaoYi Decoction(Bupleurum 10g, Cyperus 10g, Salvia miltiorrhiza 20g, Red peony 10g,etc)has activating blood and absorbing clots effect, can inhibit the growth of ectopic endometrium, promote follicular growth, maturity, improve ovulation and the receptivity of endometrium.
46103880|NCT02676713|Drug|post-ovulation Decoction|"BuShenZhuYun Decoction(Bupleurum 10g,Poria 15g, Atractylodes 15g,Ligustrum 15g,etc) has dredging liver and nourishing kidney effect, can improve the function of corpus luteum.~All are made into granules."
46103881|NCT02676713|Drug|pre-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
46019637|NCT01740427|Drug|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
46019638|NCT01740427|Drug|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
46019639|NCT01740427|Drug|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
46103882|NCT02676713|Drug|post-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
46103883|NCT02673593|Drug|DS102|
46103884|NCT02673593|Drug|Placebo|
46103885|NCT04178525|Device|ChitoCare gel|ChitoCare gel is based on chitosan and used as an addition to standard care, accordingly with dressing change for 10 weeks.
46103886|NCT04178525|Device|Placebo gel|Placebo gel is used as an addition to standard care, accordingly with dressing change for 10 weeks.
46103887|NCT04181099|Other|Implant neck surface|The biofilm formation is tested on discs manufactured of zirconia with different surfaces in vivo using orthodontic devices that the participants carry over 24h
46103888|NCT04178369|Other|Proximal And Distal Tibiofibular Joint Manipulations|"For PTFJ, the experimental intervention will be based on previously published methods. Physiotherapist will make contact with the fibular head, extending to the popliteal fossa. The associated soft tissue will be pulled in a lateral direction until the metacarpophalangeal joint will be firmly stabilized behind the fibular head.~For DTFJ, the experimental intervention will be conducted according to previously published methods. Physiotherapist will grasp and stabilize the distal tibia with one hand and grasp the distal fibula between the finger and thenar eminence of the other hand. The fibula will be translated posteriorly until the restrictive barrier (end range) will be engaged. Then a high-velocity, low-amplitude thrust will be applied through the fibula in a posterior-superior direction."
46103889|NCT04178369|Other|Bobath Treatment|All participants will be given a 6-week-long physiotherapy and rehabilitation program based on the Bobath concept for 5 days a week, 45 minutes each. The techniques will be applied by a physiotherapist who is specialized in Bobath concept. 35 different techniques will be used to improve the selective control and weight transfer of the pelvis in sitting, standing and supine/side lying positions. Moreover, soft tissue mobilization will be also used to relieve tension and loosen stiff tissues to provide biomechanical alignment and reduce pain.
46103890|NCT04179617|Other|5% nicotine content JUUL pod|JUUL pods that contain 5% nicotine
46103891|NCT04179617|Other|3% nicotine content JUUL pod|JUUL pods that contain 3% nicotine
46103892|NCT00464269|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Film-coated tablet~Concentration: 2.5 mg, 10 mg and 25 mg~Route of Administration: Oral use"
46019640|NCT02853487|Device|Actigraphy|An actigraph from Philips
46019641|NCT02853487|Other|Diary|Questions on sleep times and awakenings and attacks in the morning and evening for 2 weeks.
46019642|NCT00879931|Drug|Methylprednisolone|Methylprednisolone
46019643|NCT00879931|Drug|Placebo|Placebo (NaCl 0.9%)
46103893|NCT00464269|Drug|Brivaracetam 2.5 mg|"Active Substance: Brivaracetam~Pharmaceutical Form: Film-coated tablet~Concentration: 2.5 mg~Route of Administration: Oral use"
46103894|NCT00464269|Drug|Brivaracetam 10 mg|"Active Substance: Brivaracetam~Pharmaceutical Form: Film-coated tablet~Concentration: 10 mg~Route of Administration: Oral use"
46019644|NCT01149057|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously, every 4 weeks for 96 weeks
46019645|NCT01737619|Procedure|Computed Tomography|Undergo PET/CT
46019646|NCT01737619|Drug|Indocyanine Green Solution|Given via superficial and deep cervical injection
46019647|NCT01737619|Other|Laboratory Biomarker Analysis|Correlative studies
46019648|NCT01737619|Procedure|Lymph Node Mapping|Undergo lymph node mapping
46019649|NCT01737619|Procedure|Lymphadenectomy|Undergo full lymphadenectomy
46019650|NCT01737619|Procedure|Positron Emission Tomography|Undergo PET/CT
46019651|NCT04281589|Other|if the ventilation parameter caused desaturation or hypercapnia we will change the parameter|we will increased fi02
46019652|NCT01227564|Biological|ACC-001 3 μg/ QS-21 50 μg|ACC-001 3 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
46103895|NCT00464269|Drug|Brivaracetam 25 mg|"Active Substance: Brivaracetam~Pharmaceutical Form: Film-coated tablet~Concentration: 25 mg~Route of Administration: Oral use"
46103896|NCT00642863|Dietary Supplement|Ferrous Sulfate (liquid) + vitamins A and D|a single daily dose of 1-2 mg/kg of elemental iron (5 mg from 6 wk to 9 mo and 15 mg from 9 to 18 mo.) and 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
46103897|NCT00642863|Dietary Supplement|vitamins A and D|a single daily dose (liquid) of 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
46103898|NCT00642863|Dietary Supplement|Ferrous sulfate (liquid)|Infants who become iron deficient/anemic at 9 or 18 mo will take a single daily dose of 3 mg/kg of elemental iron for 3 months.
46103899|NCT02674763|Drug|IMGN779|
46019653|NCT01227564|Biological|ACC-001 10 μg/ QS-21 50 μg|ACC-001 10 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
46019654|NCT01227564|Other|Placebo- Phosphate buffered saline (PBS)|Phosphate buffered saline IM on day 1, month 1, month 3, month 6, month 12, and month 18
46019655|NCT00739141|Drug|fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft|Cyclophosphamide 50 mg/kg/dose x 1 IV day -6 (1 dose) Fludarabine 30 mg/m2/dose x 5 IV days -6 to -2 (5 doses) Thiotepa 5 mg/kg/dose x 2 IV days -5 to -4 (2 doses) TBI 200 cGy/dose x 2 days -2 to -1 (2 doses). On transplant day, the cord blood cells will be given through your catheter. The immune suppressing drugs you will receive are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through your catheter. Later they can be given as tablets.
45681037|NCT01824290|Drug|Tadalafil|Administered orally by tablet form for heavy and middle weight participants. Administered orally by suspension for light weight participants.
46019656|NCT01148979|Drug|Lisdexamfetamine Dimesylate (Vyvanse)|Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.
46019657|NCT01148979|Drug|Placebo|Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.
46103900|NCT02674997|Biological|Factor VIII|Licensed Factor VIII products. Study is brand agnostic
46103901|NCT02676635|Behavioral|Ergonomics training and/or Safety Voice training|"Ergonomics training will focus on ergonomic principles specific to masonry such as goals of ergonomics, common musculoskeletal disorders among masons, modifiable work factors and risk factors, hazard analysis, hierarchy of controls, and current ergonomic solutions for masonry. Safety Voice training will focus on development of skills such as self-direction, self-control, accountability, responsibility, communication strategies, and leadership that can help them to develop a safety voice about safety in general, and ergonomics specifically."
46019658|NCT04281433|Other|Activa Bioactive|Before cavity preparation and restoration, masticatory muscles activity will be evaluated by using electromyography. An electromyography detects the electrical potential generated by muscle cells. A total of 40 posterior teeth will be selected for this study and grouped into 2 main groups (20 for each group)) according to presence of caries in one or both side in patient (unilateral or bilateral). Split mouth technique will be used. The affected teeth will be treated by removing the caries and restored tooth with bulk fill composite material, after restoring the affected teeth. Masticatory muscles activity will be evaluated by using electromyography to detect any changes in masticatory muscles activity before and after restoration.
45681038|NCT01824290|Drug|Placebo|Administered orally by tablet for heavy and middle weight participants. Administered orally by suspension for light weight participants.
45681039|NCT01824290|Drug|ERA as specific PAH treatment|All participants were taking endothelin receptor antagonist (ERA) (such as bosentan, ambrisentan and macitentan).
45838117|NCT04784260|Other|Microbiome analysis|Evaluate the bacterial composition in sperm from the different groups
45838118|NCT04778267|Drug|Bupivacaine Hydrochloride|We hypothesize that combined ESPB and PIPB are as effective as TPVB in controlling perioperative pain in patients undergoing modified radical mastectomy (MRM) with lesser complications using bupivacaine hydrocloride
46019659|NCT01735825|Device|paclitaxel-coated balloon catheter with Iopromide coating|Patients with coronary in-stent restenosis treated by drug eluting paclitaxel-coated balloon catheter
46019660|NCT01735825|Device|drug eluting stent with everolimus|Patients with coronary in-stent restenosis treated by drug eluting stent with everolimus
46019661|NCT01735825|Device|seal-wing paclitaxel-eluting balloon catheter|Patients with coronary in-stent restenosis treated by seal-wing paclitaxel-eluting balloon catheter
46019662|NCT02855905|Other|Exercise/Rest and cold/neutral temperature|Subjects were either exercising or resting in either cold or neutral environmental temperature
46103902|NCT04178291|Device|Ultrasonic scaler and Gracey currettes|Full mouth subgingival debridement using ultrasonic scaler and Gracey currettes
46103903|NCT04178291|Device|Air polishing with erythritol powder|Air flow PLUS
46103904|NCT04178681|Other|100% vegetable blend|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of vegetable fat blend.
46103905|NCT04178681|Other|100% AMF|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat.
46103906|NCT04178681|Other|100% cream|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat plus milk fat globular membranes.
45838119|NCT04778267|Drug|Dexamethasone phosphate|used as additive to bupivacaine
45681040|NCT03597100|Device|Cala TWO|Wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves
45681041|NCT03596944|Drug|Statin|Prescribed with statins for primary prevention
45838120|NCT04763356|Other|Symptom Care at Home with NP follow up|In the SCH-NP group all participants will report their CIPN related symptoms daily via the app, website or phone tree. Any concerning symptoms will trigger a call back from a nurse practitioner who will use a consensus and evidence based algorithm to prescribe therapies for the CIPN symptoms.
45838121|NCT04761627|Drug|Ustekinumab|Participants will receive subcutaneous (SC) injection of ustekinumab.
45838122|NCT04761627|Drug|ABP 654|Participants will receive SC injection of ABP 654.
46019663|NCT01148511|Drug|Ranibizumab 0.5 mg|Ranibizumab was supplied as a sterile solution in sealed glass vials.
46103907|NCT05379101|Diagnostic Test|Cardiac magnetic resonance image (CMR)|A magnetic resonance imaging study for assessment of cardiac structure and intracardiac flow
46103908|NCT05379101|Diagnostic Test|Transthoracic Echocardiogram (TTE)|An imaging test that uses soundwaves that cannot be heard (ultrasound) to take pictures of the heart and vessels.
46103909|NCT05379101|Diagnostic Test|Six-minute Walk Test|A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes
46103910|NCT05372315|Drug|Dextenza 0.4Mg Ophthalmic Insert|(dexamethasone ophthalmic insert)-for the treatment of ocular inflammation and pain following following ophthalmic surgery, and ocular itching associated with allergic conjunctivitis.
46103911|NCT04016675|Other|Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by Surgery|After assigned into the study group, subjects will be conducted with incisional biopsy. Based on the tumor type and tumor stage, subjects will be conducted with neoadjuvant radiotherapy/chemoradiotherapy followed by radical surgery and simultaneous orbital reconstruction. After surgery, adjuvant chemotherapy will be determined based on the tumor histology, local tumor invasiveness, proximity of the surgical margins from the tumor, and pronouncement of tumor margins on permanent section tissue review.
46019664|NCT02860117|Device|Ketamine continuous infusion|Ketamine 0.1% 250mL continuous infusion (0,2ml/kg/h)
46019665|NCT02860117|Drug|Placebo|Placebo continuous infusion (0,2 ml/kg/h)
46019666|NCT02853253|Dietary Supplement|SMOFlipid®|"SMOFlipid® (FreseniusKabi France, Sèvres, France). It is a 3rd generation LE containing a physical mixture of soybean oil (30%), MCT (30%), olive oil (25%) and fish oil (15%). Its ratio omega6/omega 3 is 2,5/1. SMOF will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day; daily increase: 0.5 to 1 g/kg/day ; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively."
46103912|NCT04016675|Other|Surgery Followed by Adjuvant Radiotherapy/Chemoradiotherapy|After assignment into the control group, subjects will receive radical surgery without simultaneous orbital reconstruction. Adjuvant radiotherapy / chemoradiotherapy will initiate within two weeks after surgery. Both the radiotherapy and chemoradiotherapy should be comparable between the study group and the control group when tumor characteristics in these two groups are identical.
46103913|NCT04180631|Diagnostic Test|Quantitative ultrasound imaging parameter (QUS)|Quantitative ultrasound imaging parameters (QUS) are analyzed to evaluate hepatic steatosis
46103914|NCT02673125|Genetic|MitoGrade|MitoGrade refers to the mitochondrial DNA assessment in embryos.
46103915|NCT00644267|Behavioral|Telemedicine|Telemedicine reporting of blood pressure, weight, physical activity
46103916|NCT00643643|Drug|Maraviroc (UK-427,857)|25 mg oral tablet once daily for 10 days
46103917|NCT00643643|Drug|Maraviroc (UK-427,857)|50 mg oral tablet twice daily for 10 days
46103918|NCT00643643|Drug|Maraviroc (UK-427,857)|100 mg oral tablet twice daily for 10 days
46103919|NCT00643643|Drug|Maraviroc (UK-427,857)|300 mg oral tablet twice daily for 10 days
46103920|NCT00643643|Other|Placebo|Matching placebo oral tablet twice daily for 10 days
46103921|NCT04179227|Other|Questionnaire Administration|Ancillary studies
46103922|NCT04179227|Other|Survey Administration|Ancillary studies
46103923|NCT04180787|Dietary Supplement|Beverage Consumption|Participants will consume either VPX Bang® Keto Coffee beverage or flavor-matched placebo beverage in each condition.
46103924|NCT02676869|Drug|IMP321 (eftilagimod alpha)|"Part A: Single subcutaneous injections of 1 mg (cohort 1), 6 mg (cohort 2) or 30 mg (cohort 3) of IMP321 administered every 2 weeks~Part B: Single subcutaneous injections of 30 mg of IMP321 administered every 2 weeks"
46103925|NCT02676869|Drug|Pembrolizumab|Administered according to the approved label.
46103926|NCT02676245|Behavioral|Viewing Newborn Screening movie|NBS Movie and printed brochure were viewed by the participants
46103927|NCT02676245|Behavioral|Viewing Residual Dried Blood Spot movie|DBS Movie and and printed brochure were viewed by the participants
46103928|NCT02674841|Other|Feedback on TUT|Access to live visual and auditory feedback on TUT and pulling force from an application on an iPad.
46103929|NCT02674841|Other|No feedback on TUT|Access only to live visual feedback on pulling force from an application on an iPad.
46103930|NCT02674841|Other|Exercise|3 exercises (knee extension, hip abduction and hip extension) using an elastic band with 3 sets of 10 repetitions at 10-12 RM 3 times a week for 6 weeks.
46103931|NCT02673047|Biological|botulinum toxin Type A|Botulinum toxin Type A (Botox®) injection as prescribed as standard of care in clinical practice.
46103932|NCT02672813|Procedure|Pectoral nerve I and II block|Under Ultrasound guidance, Pectoral nerve I and II block is given for every breast surgery by using 10 and 20 ml of 0.25% Ropivacaine respectively
46103933|NCT00643019|Behavioral|SAFE Behavioral Intervention|Group cognitive behavioral intervention sessions
46103934|NCT00643019|Other|Control|Individual Sexually Transmitted Infection Risk Reduction Counseling
46103935|NCT00643721|Other|dehydration|dehydration to 3% and 5% loss of total body water
46103936|NCT02676167|Behavioral|PrEP Intervention|
45838123|NCT04760691|Drug|Truvada alone|TDF/FTC 300 mg (milligrams) / 200 mg by mouth once daily
45838124|NCT04760691|Drug|Truvada plus Leuprolide|TDF/FTC 300mg/ 200 mg by mouth once daily Leuprolide 11.25 mg im once
45838125|NCT04760691|Drug|Truvada plus Estradiol 1 mg|TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 1 mg by mouth once daily
45598482|NCT03521713|Drug|EPORON|"Strength : 3000 IU/0.3 mL, 5000 IU/0.5 mL, 6000IU/0.6 mL~Formulation : Solution in PFS"
45598483|NCT03521713|Drug|EPREX|"Strength : 2000 IU/0.3 mL, 3000 IU/0.5 mL, 4000IU/0.6 mL~Formulation : Solution in PFS"
45598484|NCT02355717|Other|Observational Study|
46019667|NCT02853253|Dietary Supplement|Medialipide®|"Medialipide® 20% (B Braun Medical, Boulogne, France). It is a second generation LE containing soybean oil (50%) and MCT (50%). Its ratio omega6/omega 3 is 7/4. Medialipide will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day ; daily increase: 0.5 to 1 g/kg/day; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively."
46103937|NCT02672735|Other|Corrective Exercise Programming|Participants will be given a four-week corrective exercise protocol, with four corrective exercise sessions prescribed each week. Participants in the CEP Group will be required to complete a minimum of three of these four training sessions per week throughout the four-week corrective exercise program intervention. All corrective exercise programming will be created through the Fusionetics Human Performance System. This system, along with weekly compliance questionnaires, will also assess the compliance-level among the participants.
46103938|NCT04178447|Drug|Glepaglutide|Single dose of Glepaglutide 10 mg
46103939|NCT04180553|Diagnostic Test|Point of Care Ultrasound (POCUS)|The intervention group will receive a 4-view transthoracic echocardiogram including Parasternal long axis, parasternal short axis, apical 4-chamber, and supplemental subcostal short-axis/4-chamber views as needed. A standard 4-view thoracic lung ultrasound study will assess the left and right anterior chest wall, anterior axillary regions, as well as the costophrenic angle and posterolateral regions. At 5 discrete time intervals post-operatively, POCUS assessments will be used to adjust fluid resuscitation to fluid liberal (2cc/kg/hr) or fluid restrictive (0.8cc/kg/hr). Routine vital signs, biochemistry, and urine output as well as bedside physical exam will be assessed as usual. IV boluses of crystalloid will be permitted to treat hypotension with SBP <90mmHg with clinical signs of hypovolemia, but oliguria will not be used as a marker to titrate fluid infusion rates. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated.
46103940|NCT04180553|Other|Usual Care|"The control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated."
46103941|NCT05277155|Dietary Supplement|BEJO Red Ginger Extract|"BEJO Red Ginger Extract ingredients:~Zingiber officinale var. rubrum (Rhizome extract) 80 mg~Foeniculi vulgare Fructus (Fennel) 25 mg~Menthae arvensis Folium (Mint) 5 mg~Piper retrofractum Fructus (Javanese long pepper) 12.5 mg~Honey 7500 mg"
46103942|NCT05277155|Other|Placebo|Placebo composition: Substance without active ingredient
46103943|NCT02674919|Other|Nordic Hamstring|
46103944|NCT02674919|Other|Control|
46103945|NCT05584319|Drug|Empagliflozin 10 Mg|subjects in Empagliflozin group takes Empagliflozin 10mg per day
46103946|NCT02674607|Dietary Supplement|Spirulina|
45838126|NCT04760691|Drug|Truvada plus Estradiol 6 mg|TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 3 mg by mouth twie daily
46019668|NCT00547339|Radiation|stereotactic body radiation therapy (SBRT)- 45 Gy|Dose of SBRT - 45 Gray (Gy) in five fractions
45838127|NCT04760691|Drug|Estradiol 6 mg alone|Estradiol 3 mg by mouth twice daily
46019669|NCT00547339|Radiation|stereotactic body radiation therapy (SBRT) - 47.5 Gy|Dose of SBRT - 47.5 Gray (Gy) in five fractions
46019670|NCT00547339|Radiation|stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1)|
46103947|NCT02676323|Drug|Panobinostat|Panobinostat will be given orally (PO) on days 1, 3, 5, 8, 10, and 12.
46103948|NCT02676323|Drug|Fludarabine|Fludarabine will be given intravenously (IV), 30 mg/m^2/dose over 30 minutes, daily for 5 days (days 8-12).
46103949|NCT02676323|Drug|Cytarabine|Cytarabine will be given IV, 2 gram/m^2/dose over 4 hours, daily for 5 days (days 8-12).
46103950|NCT02676323|Drug|Intrathecal Triples|Given intrathecally (IT).
46103951|NCT02676323|Drug|Leucovorin|Leucovorin (5 mg/m^2/dose, max 5 mg) may be given PO or IV at 24 and 30 hours after each ITMHA.
46103952|NCT00643799|Drug|Celecoxib|200 mg oral capsule once daily for 6 months
46103953|NCT00643799|Drug|Naproxen|500 mg oral capsule twice daily for 6 months
46103954|NCT00643799|Drug|Placebo|Matched oral placebo for 6 months
46103955|NCT02672891|Device|condom balloon catheter|"The condom balloon catheters were inserted into the uterine cavity digitally or with forceps .Tight vaginal pack was inserted or cervical stitch was done to prevent displacement of the balloon catheter.~(2)-Insertion at Cesarean Section: The catheter was inserted through the uterine incision (pushing the tip to the fundus and the drainage port through the cervix into the vagina) or transvaginally and inﬂated after the uterine incision was closed."
46103956|NCT02676401|Drug|MT-3995 Low|
45838128|NCT04744454|Drug|Isauvuconazole group|Patients who are treated with Isavuconazole according to its protocol label.
45838129|NCT04735471|Genetic|ADI-001|Anti-CD20 CAR-T
45838130|NCT04735471|Drug|Fludarabine|Chemotherapy for Lymphodepletion
45838131|NCT04735471|Drug|Cyclophosphamide|Chemotherapy for Lymphodepletion
45838132|NCT04718181|Drug|risdiplam|Risdiplam will be administered orally at a single dose of 5 mg in different formulations. Dispersible tablet formulations (F21/F22) will be administered as swallowed tablet or as tablet dispersed in water. The powder for constitution to an oral solution will be administered as an oral solution constituted with purified water.
45838133|NCT04718181|Drug|omeprazole|Omeprazole will be administered orally as a capsule at a dose of 40 mg per day
46019671|NCT00547339|Radiation|stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 2)|
46103957|NCT02676401|Drug|MT-3995 Middle|
46103958|NCT02676401|Drug|MT-3995 High|
46103959|NCT02672969|Device|RapidVac Smoke Evacuator|"The intervention group, using the smoke evacuation (RapidVac Smoke Evacuator) in each OR, the data collection for the amount of surgical smoke and bio-aerosols' particles will be collected during pre-surgery and during surgery (every 30 mins).~Before using the smoke evacuation, the amount of surgical smoke and bio-aerosols' particles in the surgical field and OR environment will be measured by AeroTraxTM Handheld Airborne Particle Counter. This record includes the amount and size of smoke and bio-aerosol particles in each area such as anesthetic area (anesthesiologist physicians and nurses area); instrument preparation area (circulating nurses area) and surgical area (surgeons and scrub nurses areas)."
46103960|NCT05348213|Drug|Zanubrutinib plus R-ICE|Zanubrutinib 160mg/bid PO D1-21 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×[GFR(ml/min) + 25] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
46103961|NCT05348213|Drug|Decitabine plus R-ICE|Decitabine 10mg/m2 IV D1-5 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×[GFR(ml/min) + 25] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
46103962|NCT05348213|Drug|Chidamide plus R-ICE|Chidamide 20mg/d PO D1、4、8、11 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×[GFR(ml/min) + 25] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
46019672|NCT04269187|Drug|Theophylline|Theophylline oral 200 mg daily for 12 days
46019673|NCT02853565|Drug|CAN008|The dose escalation in the phase I study including 200mg in the first cohort and 400mg in the second cohort to Recommended for Phase 2 Dose (RP2D)
46019674|NCT02856217|Procedure|tunneling|In this arm of the study which is Peritoneal tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (creating a tunnel between vaginal apex and sacrum under peritoneum without disturbing the integrity of the peritoneum)
46019675|NCT02856217|Procedure|non-tunneling|In this arm of the study which is Peritoneal non-tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (incised and sutured peritoneum between vaginal apex and sacrum).
46019676|NCT04269109|Other|Multi-modal Opioid Sparing Pain Management Protocol|Incorporating multimodal opioid sparing ERAS techniques for cardiac surgery patients should show a decrease in the amount of opioids received, reduction in incidence of chronic pain, ileus, delirium, and potential for opioid addiction post-operatively. Between the dates of November 2018 through February 2019, a multi-modal, opioid sparing pain management protocol was evolving and a protocol was put into place. This study will compare outcomes before and after implementation of the protocol between the dates of September 1, 2018 - October 31, 2018 and March 1, 2019 - April 30, 2019.
46019677|NCT04268953|Drug|Tricaprilin|Tricaprilin formulated as AC-SD-03 mixed in 300mL water
46019678|NCT01227252|Drug|LY2886721|5 milligrams (mg) up to 35 mg, administered orally as capsules, daily for 14 days
46019679|NCT01227252|Drug|Placebo|Administered orally as capsules, daily for 14 days
46103963|NCT05348213|Drug|Tofacitinib plus R-ICE|Tofacitinib 5mg/bid PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×[GFR(ml/min) + 25] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
45681042|NCT04002310|Drug|BI 754132|One single injection
46019680|NCT02855671|Device|Infrared thermal imaging|Patients in all groups will undergo infrared thermal imaging of the face and anterior leg (centered on the knee)
46103964|NCT05348213|Drug|Pomalidomide plus R-ICE|Pomalidomide 4mg/d PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×[GFR(ml/min) + 25] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
46103965|NCT02674451|Procedure|Remote ischemic preconditioning|Blood pressure cuff inflation to 200 mmHG for three 5-minute periods each separated by 5 minute intervals within 1 hour of planned coronary angiography.
46019681|NCT01227018|Drug|STA-9090|Given IV
46103966|NCT00643877|Procedure|Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR|PHRAC which included of two parts(common hepatic artery chemotherapy and main tumor supplying artery chemotherapy) was performed 7 days before surgery： common hepatic artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg main tumor supplying artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg
46019682|NCT01227018|Radiation|Radiologic imaging|radiologic modalities used to evaluate response to treatment
46019683|NCT01227018|Procedure|blood draw|Venous blood will be drawn from those patients who give consent. Serum will be used to look for biomarkers predictive of response
45838134|NCT04713735|Dietary Supplement|Control: Placebo|Placebo
46103967|NCT00643877|Procedure|surgery|radical surgery only
46103968|NCT02676479|Device|Uterine Lavage Group|"The PI places the Lavage Catheter per instructions for use~Use of a tenaculum or cervical stitch is required~Use of saline to wash the cervix is required~Use of abdominal ultrasound guidance with a full bladder is required The PI records if there was clinically significant fluid loss through the cervix."
46103969|NCT00643175|Behavioral|Automated follow up|Treatment of osteoporosis after hip fracture is also being targeted as a future hospital quality assessment measure. Hospitals which have no plan in place to address osteoporosis treatment after hip fracture may be cited, and may have medicare money withheld. The goal of the study is to create an automated in-patient endocrinology consultation for osteoporotic hip fractures. We plan to gather patient data in a prospective manner including the endocrinologist recommendations, adherence to medical therapy after discharge, and future fracture rates. Planned interventions include only appropriate medical therapy for osteoporosis, DEXA bone scanning, and regularly scheduled telephone follow-up.
46103970|NCT02674295|Drug|Esketamine 50 mg|50 mg of oral esketamine, fortified with a microtracer dose of 14C-esketamine, as an aqueous solution mixed with apple juice for administration (80 mL total volume)
46103971|NCT02674295|Drug|Esketamine 20 mg|20 mg of intravenous esketamine in 30 mL, fortified with a microtracer dose of 14C-esketamine, as a 30-minute intravenous infusion.
46019684|NCT01659541|Device|Expiratory muscle stimulator|The expiratory muscle stimulator consists of two small electrodes (wire leads) implanted on the surface of the spinal cord on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
46103972|NCT04179071|Drug|Savolitinib|Subject will receive savolitinib tablet 600mg orally after a high-fat, high-calorie meal.
46103973|NCT04179071|Drug|Famotidine|Subjects will receive famotidine tablet 40mg orally after an overnight (minimum 8hours) of fasting.
46103974|NCT02672501|Drug|anti-CD19-CAR-T cells|a 2nd CAR, CD19 as target protein, 4-1BB as co- stimulator, and optimized the spatial conformation by a suitable hinge & transmembrane domain sequences
46103975|NCT05557487|Diagnostic Test|Low dose computed tomography|"Participants belonging to modified Lung RADS category 1 and 2 at baseline screening will undergo the LDCT next year after the discussion with the physicians in charge.~Participants with nodules belonging to modified Lung RADS category 3 and 4, growing nodules, or new nodules found on follow-up LDCT scans will undergo repeat CT every 3 to 6 months or be referred for diagnostic workup depending on the size and characteristics of the nodules as the regular clinical practice.~Volume doubling time (VDT) will be performed in the special groups with Lung RADS category 3 or 4, but the nodules with solid components ≧ 6mm and < 9mm. A repeat LDCT scan will be performed around 3 months after the baseline screening."
46103976|NCT02673983|Procedure|Endoscopic full-thickness biopsy|
46103977|NCT00643955|Other|muscle strength|muscle strength
46103978|NCT04180241|Procedure|POEM|Peroral endoscopic myotomy
46103979|NCT04179539|Diagnostic Test|V/Q PET/CT|Ventilation images are acquired after inhalation of Galligas prepared using a Technegas generator (Cyclopharm, Sydney, Australia). The patients is placed in a supine position and inhaled Galligas using the standard ventilation technique. Ventilation images are then acquired. Without the patient moving, 68Ga-MAA are then injected. Perfusion PET images are then acquired
46103980|NCT04179539|Diagnostic Test|CTPA|CTPA will be done according to the usual protocol in the radiology department of the investigator center
46103981|NCT02675933|Behavioral|Questionnaire|There will be a single page document, a patient-centered questionnaire, distributed to parents of study participants who have been randomized to the intervention arm.
46019685|NCT01659541|Procedure|Implantation of device|The expiratory muscle stimulator consists of two wire leads(each with two metal contacts) inserted onto the surface of their spinal cord on the lower back using a needle. The procedure to implant these wire leads is commonly used today for other purposes. This is a minimally invasive surgical technique with minimal risks. The wire leads are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box to stimulate the expiratory muscles and restore cough.
46019686|NCT01226472|Biological|KW-0761|In the first treatment course KW-0761 will be administered i.v. once a week for four weeks, followed by a 2-week observation period. Subsequent treatment courses are permissible for subjects demonstrating a response or maintaining stable disease and will consist of an infusion of KW-0761 every other week.
46103982|NCT02674139|Device|Copper T 380A IUD|intrauterine contraceptive device T-shaped loaded with cupper
46103983|NCT00910169|Other|inpatient treatment|Hospitalisation modalities are described but are naturalistic
46103984|NCT00644033|Drug|Frovatriptan|2.5 mg tablet administered once daily for 6 days starting 2 days before the anticipated onset of a MAM headache
46103985|NCT00644033|Drug|Frovatriptan|2.5 mg tablet administered twice daily for 6 days, starting 2 days before the anticipated onset of a MAM headache.
46103986|NCT00644033|Drug|Placebo|placebo tablet administered for 6 days, starting 2 days before the anticipated onset of a MAM headache.
46103987|NCT00484315|Device|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent placement
46103988|NCT00484315|Device|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement|TAXUS Express Stent Implant
46019687|NCT04268563|Drug|placebo|Oral rehydration solution
46103989|NCT02672267|Biological|Stem cells|human Allogeneic Low Oxygen mesenchymal stem cells; Ischemia tolerant
46103990|NCT02672267|Other|Placebo|Lactated Ringer's Solution
46103991|NCT05313581|Behavioral|START NOW WebApp|"The WebApp is based on the existing manualized START NOW skills training. START NOW aims to improve emotion- and stress regulation, social competence, effective management of encountered problems/crises, subjective well-being and resilience through improving an individual's level of psychological flexibility. It primarily employs a cognitive behaviourally oriented group skills training with integrated components from Dialectical Behavioural Therapy (DBT), Acceptance and Commitment Therapy (ACT), trauma-informed care and Motivational Interview (MI) techniques.~During the training, participants will encounter different exercises to help them train their skills. There are several mindfulness exercises in the form of audio tracks, containing, e.g., instructions on a breathing exercise. The skills training phase takes place over a period of 9 weeks (sessions 1+2, 9+10 and 11+12 are double session)."
46019688|NCT04268563|Drug|metformin|metformin tablet
46019689|NCT04268563|Drug|Sitagliptin|Sitagliptin tablet
46103992|NCT04178759|Procedure|Liver resection|Laparoscopic or open approach liver resection where at least 1 segment is removed
46103993|NCT02671799|Device|VenTouch System Implant|The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is intended for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable mainly to annular dilatation with or without papillary muscle displacement. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is used to reshape the base of the heart to bring the mitral valve leaflets into better coaptation. By doing so, it brings the mitral valve leaflets closer, allowing proper closure of the valve, and reducing or eliminating MR. There is provision of support to the ventricular myocardium below the annulus as well as the annulus, so the VenTouch System may allow long-term ventricular remodeling with positive impact on the functionality of the mitral valve.
46103994|NCT01019083|Drug|Placebo|Placebo will be given according to randomization list
46103995|NCT01019083|Drug|Placebo|Placebo will be given according to randomization list
45467573|NCT04716153|Other|Multifactorial sensory rehabilitation workshops|A multifactorial sensory rehabilitation Workshops : a multifactorial program in order to optimize the recovery of flavors, focused on smell and taste which integrates several non-drug interventions, which are part of the current recommendations: hydration of the mucous membranes with daily (3 times a day) liposomal sprays (nose and mouth), presentation of visual dishes.
46019690|NCT04268563|Drug|Sitagliptin/metformin|Sitagliptin/metformin tablet
46019691|NCT04319016|Other|pregnant women with laboratory-confirmed 2019-n-CoV|Clinical records and compiled data of all consecutive hospitalized and outpatient pregnant women with laboratory-confirmed 2019-n-CoV were included in a merged database
46019692|NCT04206462|Other|Questionnaire of eating habits|frequency and type of aliments
46019693|NCT01225146|Drug|ranibizumab|Ranibizumab is formulated as a sterile solution aseptically filled in a sterile 3-mL stoppered glass vial. Each vial contains 0.5 mL of 40 mg/mL (2.0-mg dose level) ranibizumab aqueous solution.
46019694|NCT01223196|Drug|Pioglitazone|This study will examine the effect of Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
45467574|NCT04716153|Other|Usual care|"The control group only receives the usual care provided for as part of routine care. It consists of a nutritional assessment at home by a dietician, with monitoring of intake and weight, in order to readjust nutritional support. A systematic search for oral mycosis is carried out in order to treat.~The foods that the patient prefers, identified from a list of authorized foods, are preferred or even fortified."
45467575|NCT04716153|Other|Tests and Questionnaire|fulfillment of Taste Strips Test, Sniffin'sticks test and FACT-BMT, HADS, l'EVA des ingesta and GPAQ questionnaires to assess the quality of life of patients
45467576|NCT03707964|Other|Crisis Resource Management Skill Training|Focused crisis resource management training which targets at the cognitive skills needed to monitor and challenge a superior's decision.
46019695|NCT01223196|Drug|Placebo|Inactive placebo for comparison to Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
46019696|NCT01222416|Radiation|Radiopharmaceutical Administration [18F]-FDG|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi,route IV. Time interval between administration and scanning: 60 +/- 10minutes post-injection.
46019697|NCT01222416|Radiation|Radiopharmaceutical: [18F]-FLT|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi), route = IV, Time interval between administration and scanning: 60 +/- 10minutes post-injection.
46019698|NCT01221948|Device|Deep Brain Stimulation|Rechargeable Deep Brain Stimulation System
46103996|NCT01019083|Other|Control|Control will be selected from the Arsenic non contaminated Area
46103997|NCT01019083|Drug|Zinc Sulphate|Zinc Sulphate will be given according to randomization list
46103998|NCT01019083|Drug|Albendazole and Secnidazole|Albendazole and Secnidazole will be given according to randomization list
46103999|NCT01019083|Other|Arsenic|Participant will be selected from the Arsenic Contaminated Area
46019699|NCT01221090|Behavioral|PDA|Technological assistance
46019700|NCT01221090|Behavioral|CDSMP|6-week classes
46019701|NCT01221090|Behavioral|PDA/CDSMP|Combined technology and education
46019702|NCT00950911|Drug|amg 162|120 mg SC injection of denosumab Q4W until the subject has access to commercially available product or for up to 2 years, which ever comes first.
46019703|NCT02855515|Procedure|Short-time diagnostic anaesthesia|Patients will undergo a short-time general anaesthesia in order to diagnose Obstructive Sleep Apnoea when relaxed.
46019704|NCT01220856|Drug|Reparixin|Reparixin + immunosuppression
46104000|NCT04098185|Device|CT|Non-contrast Multidetector Computed Tomography will be done for all patients using 16 or 64 MDCT scanner. Standard scanning parameters of chest CT are used with slice thickness 5 mm, 120kv and automated mAs.The evaluation of pleural effusion attenuation will be done using the average measure of 3 slices with greatest amount of fluid. A region of interest (ROI) is placed for measurement of Hounsfield unit values, where pleural fluid is observed to be most intense and the density values of the pleural fluid and of the aorta are quantitatively measured in the same section with taking care not to involve adjacent ribs, lung parenchyma or areas of pleural thickening.
46019705|NCT04206228|Drug|Intravenous iron isomaltoside|"The active drug, iron isomaltoside, will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment), over 30 minutes only (1,67 ml/min)."
46104001|NCT00463801|Drug|Daptomycin|
46104002|NCT04016519|Other|Gastrostomie|"Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term."
46104003|NCT04168645|Behavioral|Cognitive Behavioral Therapy|Up to 4 sessions of CBT (depending on length of stay) will be provided. The first session lasts 1.5 hours and subsequent sessions are 1 hour.
46104004|NCT02672345|Drug|Sevoflurane|The Sevoflurane Group will receive between 0.7 and 1.5% of sevoflurane CAM only during CPB period. While Not Sevoflurane Group will receive only intravenous anesthetic agents.
46104005|NCT02537483|Drug|IDP-120 Gel|Investigational Product: IDP-120 Gel
46104006|NCT02537483|Drug|IDP-120 Component A|Comparator Product: IDP-120 Component A
46104007|NCT02537483|Drug|IDP-120 Component B|Comparator Product: IDP-120 Component B
46104008|NCT02537483|Drug|IDP-120 Vehicle Gel|Comparator Product: IDP-120 Vehicle Lotion
46104009|NCT02537249|Drug|Dexmedetomidine|Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. After one-lung ventilation, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 20 minutes.
46104010|NCT02537249|Drug|Normal saline|Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
46104011|NCT04100369|Diagnostic Test|laboratory|Arm
46104012|NCT00644111|Drug|Bupivicaine, Hydromorphone|0.1% Bupivicaine with 0.015mg hydromorphone per mL at 6 mL per hour in Arm 2
46104013|NCT00644111|Drug|Saline Placebo|Saline placebo continuous epidural infusion of 6 mL per hour in Arm 1
45467577|NCT03707964|Other|Standard ACLS Training|Standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles.
46019706|NCT04206228|Drug|Placebo|The placebo will be prepared according to the randomisation code, and administered as a single intravenous infusion over 30 minutes only (1,67 ml/min).
46019707|NCT01218594|Drug|Endostatin|7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks
46019708|NCT01610557|Drug|Ranibizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
46019709|NCT01610557|Drug|Bevacizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
46104014|NCT04016441|Other|Survey|Participants will complete a survey online
46104015|NCT02673827|Other|Progressive muscle relaxation|Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation. Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.
46104016|NCT00644891|Drug|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
46104017|NCT00644891|Drug|amoxicillin|2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 ml
46104018|NCT05203445|Drug|Olaparib|Olaparib 300 mg orally BID
46104019|NCT05203445|Drug|Pembrolizumab|Pembrolizumab 400 mg intravenously q6weeks
46104020|NCT02670863|Other|Experimental Infant Formula|Standard bovine milk-based term infant formula supplemented with a prebiotic, fed ad libitum
46104021|NCT02670863|Other|Standard Infant Formula|Standard bovine milk-based term infant formula, fed ad libitum
45681043|NCT03592342|Drug|Clobetasol Propionate|Rivelin® patch is a two-layer patch comprised of a muco-adhesive, drug-delivery layer and a protective layer.
45681044|NCT01715415|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
45838135|NCT04713735|Dietary Supplement|bovine lactoferrin supplement|600 mg
46104022|NCT04178057|Biological|GB222 3mg/kg|Injection, strength 100mg/bottle, intravenous infusion, 3mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; low dose group.
46104023|NCT04178057|Biological|GB222 5mg/kg|Injection, strength 100mg/bottle, intravenous infusion,5mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; intermediate dose group 1.
46104024|NCT04178057|Biological|GB222 7.5mg/kg|Injection, strength 100mg/bottle, intravenous infusion,7.5mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; intermediate dose group 2.
46104025|NCT04178057|Biological|GB222 10mg/kg|Injection, strength 100mg/bottle, intravenous infusion,10mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; high dose group.
46104026|NCT02672189|Behavioral|EVA-Online|Internet-based cognitive behavioral therapy
46104027|NCT04177043|Diagnostic Test|HCV antibody and hepatitis B surface antigen (HBsAg) rapid diagnostic tests|HCV antibody and hepatitis B surface antigen (HBsAg) rapid diagnostic tests
46104028|NCT04177043|Drug|DAAs|Treatment with different regiments with DAAs
46104029|NCT04177979|Behavioral|Near-assisted learning through trained peers|Students randomly allocated to this group were overseen during sessions by trained peer instructors.
46104030|NCT02671877|Procedure|Transnasal fiberoscopy|Minimally invasive exploration ot the upper airways, performed in an awake or minimally sedated patient.
46019710|NCT00943735|Drug|Fesoterodine|Fesoterodine 4 mg and 8 mg QD
45467578|NCT03467308|Genetic|Markers in tissue samples: (TIGAR , TRIM59, P53, AKT, GSH)|"The followings markers will be investigated in tissue samples:~TIGAR expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry.~TRIM59 expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry.~P53 expression using immunohistochemistry. P53 nuclear localization is essential for its normal function in growth inhibition or induction of apoptosis.~Akt expression using western blot.~GSH using chemical methods."
46104031|NCT04097327|Other|Ectoin Dermatitis Cream 7% (EHK02)|Application of Ectoin Dermatitis Cream in accordance with the instructions for use
46019711|NCT00943735|Behavioral|Your Way|early intervention after treatment initiation and before patients have an opportunity to discontinue medication; reinforcing the treatable nature of OAB
46019712|NCT02853097|Other|Cytology Specimen Collection Procedure|Undergo blood collection
45467579|NCT03707886|Behavioral|Pain SMART|Pain SMART is a brief, one-visit shared medical appointment where providers in primary care and a behavioral health specialist (e.g., a psychologist) meet with a group of patients with chronic pain to discuss pain management approaches.
45467580|NCT03707886|Other|minimally enhanced usual care|The minimally enhanced usual care group will receive educational information via mail about non-pharmacological approaches to pain management.
46104032|NCT04175951|Device|Intraocular lens|Tecnis Eyhance is a monofocal IOL which give added intermediate vision without employing EDOF or multifocal technology and hence induces no glare and halos. Whereas monofocal IOLs such as RayOne do not give intermediate vision.
45467581|NCT03467230|Device|NoL Index|Use of the PMD-200 in an observational study
45681045|NCT01715415|Drug|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
45838136|NCT04696497|Diagnostic Test|Ultrasound|"Ultrasound measurements of muscle thickness, using a linear probe (high frequency) on four muscle groups:~Shoulder Side muscular compartment~Anterior Arm muscular compartment~Anterior thigh muscular compartment~Antero-lateral leg muscular compartment"
45681046|NCT01715415|Drug|Placebo for ABT-450/r/ABT-267|Tablet
45838137|NCT04696497|Diagnostic Test|Dynamometric muscular assessment|"The principle of electronic dynamometry is to measure an isometric force. To carry out these measurements, the examiner will stand on the side who has to be tested by exerting a pressure diametrically opposite to the patient's movement, thus preventing him/her from carrying out the movement. The patient will perform 3 tests for each movement, the best value will be collected by the examiner.~The reference position is :~Patient elbowed to the body bent at 90°, with trunk inclination at 30° in the resuscitation bed, lower limbs flat."
46019713|NCT02853097|Other|Laboratory Biomarker Analysis|Correlative studies
46019714|NCT00492817|Procedure|Stereotactic Body Radiotherapy|On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
46019715|NCT00943579|Drug|Kuvan®|Brand-name Kuvan® (sapropterin) will be administered to all subjects at a dose of 20 mg/kg/day for 16 weeks.
45681047|NCT01715415|Drug|Placebo for ABT-333|Tablet
45681048|NCT01715415|Drug|Placebo for ribavirin|Capsule
46104033|NCT04175795|Behavioral|My Personal Brain Health Dashboard|"The intervention of this study is grounded in the knowledge-to-action framework (Graham et al., 2006) and consists of providing feedback by sending participants their personalized health outcome profiles. As mentioned above, the context of our study is the BHN cohort. For all participants enrolled in the parent study, data on wide spectrum of health outcomes have been gathered. As part of the knowledge translation plan, a personalized profile of specific modifiable health outcomes called as My Personalized Brain Health Profile has been created for each participant (Appendix B). The profile covers information on brain health outcomes, health and quality of life ratings, and lifestyle factors."
46104034|NCT05269043|Device|Medimonitor|A digital solution consisting of smartphone/tablet based application gathering data from medical and other devices provided to the patients. These devices are as follows: tablet, smart inhaler, spirometer, blood pressure monitor, pulse oximetry device, particulate matter sensor.
46019716|NCT00489307|Drug|Dexamethasone|4 mg PO (by mouth) twice daily x 14 days
46104035|NCT04175717|Other|physiotherapy-led follow-up programme|In this study arm, the participants will receive a nine weeks exercise programme and four education sessions. During the exercise programme, the patients will exercise twice per week under supervision and once by themselves. The supervised exercise sessions will consisted out of a combination of a cardiopulmonary and strength training and the unsupervised session will be an activity, which the participants like doing. Additionally, when the patient shows a reduced maximal inspiratory pressure (indication for a reduced diaphragm strength), the patient will also be ask to do an inspiratory muscle training at home. Furthermore, they will participate in education sessions, where they learn things about the intensive care unit, the post-intensive care syndrome, relaxation techniques and how to carry on with exercising.
46104036|NCT02671487|Behavioral|Mind-Body Skills Groups|Mind-Body Skills groups consist of small groups of about 8-10 participants who learn and practice meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement.
46104037|NCT04177667|Dietary Supplement|Proxeed|Treatment with dietary supplement for male infertility for Proxeed Arm
46104038|NCT04177667|Other|Placebo|Treatment with placebo for Placebo Arm
46019717|NCT00489307|Drug|Placebo|Placebo PO twice daily x 14 days
46104039|NCT04177745|Other|Hot application|Before PVC was inserted, the researcher applied a hot application to the catheter insertion site (inner surface of the forearm) using a hot pack for one minute.
46104040|NCT04177745|Other|Cold application|Before PVC was inserted, the researcher applied a cold application to the catheter insertion site (inner surface of the forearm) using a cold pack for one minute.
46104041|NCT02671955|Drug|JNJ-61610588|Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
46104042|NCT02670785|Drug|Estradiol Vaginal Capsule (EVC)|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
46104043|NCT02670785|Drug|Placebo|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
46104044|NCT04092413|Device|Dermoscope|It is a non invasive tool that permits the visualization of morphological features that are not visible to the naked eye thus representing a link between macroscopic dermatopathology .
46019718|NCT04204213|Behavioral|Tai Chi Exercise|8 Section Brocade (Baduanjin) sitting Tai Chi classes + Healthcare Education seminars
46019719|NCT02852707|Behavioral|Chronic exposure to unilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to specific unilateral overhead movement patterns of the dominant extremity (throwing arm), such as throwing or hitting a ball (asymmetrical overhead sports)."
46019720|NCT02852707|Behavioral|Chronic exposure to bilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to bilateral overhead movement patterns of the upper extremities, such as swimmers (symmetrical overhead sports)."
46019721|NCT02852707|Behavioral|Not exposed|People not engaged in regular sports competition/exercise training.
46019722|NCT02852551|Drug|PAT-1251|
45838138|NCT04696497|Diagnostic Test|Manual muscular Assessment (MRC-SS)|Following the same positions as for the dynamometer, the examiner will evaluate the 12 motor functions according to the following 60-point rating. With the maximum quote of 5 point representing normal strength and 0 point the total absence of any muscular contraction
45838139|NCT04682366|Drug|Tamsulosin|Oral drug: 10 days of 0.4 mg of oral Tamsulosin
45838140|NCT04682366|Drug|Placebo|Oral drug: 10 days of identical-appearing placebo
45838141|NCT04661384|Biological|IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Given ICV
45838142|NCT04661033|Drug|Isatuximab SAR650984|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
45838143|NCT04656301|Drug|Psilocybin|A single dose of psilocybin 25 mg will be administered orally in the Biological Studies Unit of New York State Psychiatric Institute
46019723|NCT02852551|Drug|Placebo|
46019724|NCT01147809|Drug|Eltrombopag olamine|thrombopoietin receptor agonist
46104045|NCT04176809|Other|Routine Assessment of HRQoL coupled with Therapeutic Information|Participants will complete the EORTC-QLQ-C30 and EORTC-QLQ-BR23 questionnaires before their consultation via the CHES software. The scores will then be generated and provided to clinicians in a graphic form, describing scores course. Access to CHES web portal will also be open to participants outside consultation time points, to enable them to monitor HRQoL if necessary. Workshop 1, will help patients to recognize and react to the occurrence of possible adverse effects, and anticipate their occurrence through appropriate preventive means. In workshop 2, participants will have the opportunity to express their representations and experiences related to their diet and the consequences of disease and treatments on diet. In workshop 3, participants can describe their experiences of fatigue and how their life is affected by it. Moreover, they can identify possible causes and finally discuss solutions to better this symptom. Every month, a reminder letter will also be sent to participants.
46104046|NCT02670395|Drug|JNJ-54416076|JNJ-54416076 suspension will be administered orally.
46104047|NCT02670395|Drug|Placebo|Placebo solution will be administered orally.
46019725|NCT01147809|Other|Placebo|Placebo tablets with no active pharmaceutical ingredient
46104048|NCT02670317|Drug|Obinutuzumab|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
46104049|NCT02670317|Drug|Ibrutinib|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
46104050|NCT02670317|Drug|CHOP|Patients will receive a maximum of 6 courses of CHOP-21 in combination with Obinutuzumab (G) followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
46104051|NCT04176731|Device|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
46104052|NCT04088825|Other|CONUT screening system|"CONUT has been working from june of 2010 and it has detected risk of malnutrition in 32% of the evaluated patients. The method collects information from databases of Admission Service (affiliation, age, date) and Laboratory (albumin, cholesterol, total lymphocytes) and generates, in the report of analytical results, alert information about each patient's nutritional risk and also nutritional recommendations based on the risk identified."
46104053|NCT04175561|Other|Green prescription|Green prescription intervention will include horticultural activities such as planting, harvesting, learning about ecology and sustainable food growing.
46104054|NCT04033133|Device|tDCS|Subjects will get tDCS at intensities of 0, 1, 2, 3, and 4 mA.
46104055|NCT00644501|Drug|DiaPep277|1.0mg dose, injected subcutaneously at baseline and every 3 months thereafter (at 0, 3, 6, 9, 12, 15, 18, 21 months)for a total of 8 administrations.
46104056|NCT00644579|Drug|bLAC|bLAC high and low dose and placebo
46104057|NCT00644579|Drug|Placebo|Placebo
46104058|NCT02670239|Procedure|normothermic ex vivo lung perfusion|
46104059|NCT04077593|Device|RRate Mobile app|Test respiratory rate with RRate application
45599231|NCT03507985|Other|Two tests evaluating memory and attention|"The patient will perform two tests assessing memory and attention:~Regarding attention, the test used will be the Stroop Color Word Test, developed to measure visual selective attention, cognitive flexibility and inhibition.~For memory, the test used will be Rey's 15 words test. It provides an indicative standard for the evaluation of episodic verbal memory and learning abilities. This test was compared to the 16-item (18) free recall / booster test in normal aging and Alzheimer's dementia, and although it was more difficult, it . Since it allowed for the classification of participants from both groups without overlap"
45681049|NCT00211510|Device|Paradigm 722 sensor augmented pump|Subjects use the Paradigm 722 sensor augmented pump
45681050|NCT00211510|Device|Paradigm 715 insulin pump|Subjects use the Paradigm 715 insulin pump
45681051|NCT01869777|Procedure|bioelectric impedance analysis|Undergo bioelectric impedance analysis
45838144|NCT04651153|Drug|UCB7853|Subjects will receive UCB7853 at pre-specified time-points.
45681052|NCT04199260|Device|papilocare vaginal gel|Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
45838145|NCT04651153|Other|Placebo|Subjects will receive Placebo at pre-specified time-points.
45838146|NCT04649905|Procedure|Surgical Treatment|Surgical standard-of-care treatment for knee OCD
45838147|NCT04649905|Procedure|Nonoperative Treatment|Nonoperative standard-of-care treatment for knee OCD
45838148|NCT04644692|Other|Lung ultrasound|A lung ultrasound before and at the end of the stress test.
45681053|NCT03596710|Procedure|Image Guided Biopsy|Undergo image guided biopsy
45681054|NCT01714947|Drug|[^14C]-alisertib|[^14C]-alisertib oral solution
45681055|NCT01714947|Drug|alisertib|Alisertib enteric coated tablets
45681056|NCT03596632|Drug|Fenebrutinib|200-mg (100 µCi) oral solution 14C/12C]-fenebrutinib
45838149|NCT04642898|Behavioral|Standard UP Treatment|Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).
45838150|NCT04642898|Behavioral|Capitalization UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.
46104060|NCT05143697|Behavioral|Wellness Coaching for Families and Kids|The investigators propose to conduct a cluster-randomized pragmatic trial in 50 pediatric clinics in Kaiser Permanente Southern California (KPSC), to test the effectiveness of mBMI2Kids (a modified version of the BMI2 interven-tion) in pediatric clinics (randomization unit). Clinics serve over 45,000 children aged 2-8 yrs who are obese and have high racial/ethnic and socioeconomic diversity (53% Hispanic; 23% state-subsidized insurance). Clinics will be randomized into either 25 intervention or 25 usual care + attention control (enrolling 10,800 children). KP's long-standing electronic medical record (EMR) and stable membership, a research team embedded in care, existing team of lifestyle coaches, and ability to rapidly disseminate findings makes us uniquely positioned to conduct this study.
46104061|NCT02671565|Drug|Hyaluronic Acid injections|
46104062|NCT04087889|Biological|HB-adMSCs|Culture-expanded, adipose-derived mesenchymal stem cells donated by first blood relative
46104063|NCT00910325|Procedure|Laparoscopic-assisted transvaginal cholecystectomy|Trans-vaginal Cholecystectomy with Laparoscopic Assistance
46104064|NCT02669927|Other|Observational|
46104065|NCT02671721|Other|Maximal Compliance|PEEP will be set at the maximum static respiratory system compliance during a descending PEEP titration curve.
46104066|NCT02671721|Other|Transpulmonary Pressure|We will use transpulmonary pressure values obtained using an naso/orogastric tube during the operative procedure to titrate PEEP intraoperatively.
46104067|NCT02537093|Behavioral|Psychiatric Consultation|
46104068|NCT02671409|Other|Neural Mobilization (exercise)|Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
46104069|NCT05143463|Drug|NS101 IV infusion|Approximately 1 hour prior to start of study drug infusion, an IV port will be inserted into the antecubital region and a sterile normal saline solution infusion will be initiated at fixed rate in order to keep the vein open. The study drug will be infused over approximately 60 minutes at a constant rate. At the end of the infusion, 3 mL of saline solution will be injected to flush the remaining drug into the IV catheter. The end of infusion will be set to the end of the 3 mL flush. For safety reason (e.g., administration of rescue medication), the IV line will remain opened for approximately 1 hour following completion of infusion.
46104070|NCT02669771|Drug|enzalutamide|oral
45681057|NCT03596554|Other|Descriptive study|Description of the circulating values of Fibroblast Growth Factor 21 in X-linked hypophosphatemia children compared to controls in the VITADOS cohort (healthy children and adolescents aged 10-18 years), after age-matched, pubertal stage and sex).
46104071|NCT02537405|Drug|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule 10mg for one day
46104072|NCT02537405|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet 10mg for one day
46104073|NCT02668445|Other|Standard meal containing low or high carbohydrate content|
46104074|NCT02668367|Drug|BTA-C585 oral capsules|BTA-C585; Multiple ascending doses from 100 mg to 600 mg
46104075|NCT02668367|Drug|BTA-C585 matching placebo|Multiple ascending doses to match 100 mg to 600 mg BTA-C585 capsules
45599232|NCT02349399|Drug|Cyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics|Hormonal Contraceptive: Cyproterone Acetate 2 mg / Ethinylestradiol 35 μg
45599233|NCT02306473|Drug|Mannitol|Subjects will be challenged with inhaled mannitol according to already approved protocols.
45599234|NCT02232503|Genetic|Studied cohort|For the purpose of DNA isolation prior to genetic analysis of patients two samples of peripheral blood will be taken; first in the volume of 3.5 ml and second in the volume of 9 ml from each patient included into the study.
45681058|NCT04198636|Drug|LY01011|LY01011 injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
46104076|NCT02671253|Procedure|Myomectomy|The patient series consists of consecutive patients scheduled for elective laparotomic, traditional laparoscopic or robotic assisted laparoscopic myomectomy. The surgical method is selected based on clinician´s preference.
46104077|NCT04175171|Drug|Coprelotamab Injection|The single intravenous infusion of 8mg/kg Coprelotamab shall be administered within 90 minutes through infusion pump.
46104078|NCT04175171|Drug|Trastuzumab Injection|The single intravenous infusion of 8mg/kgTrastuzumab shall be administered within 90 minutes through infusion pump.
46104079|NCT04175093|Diagnostic Test|asymmetric dimethylarginine|measurement by ELISA of asymmetric dimethylarginine
46104080|NCT02669693|Dietary Supplement|bread without olives|
46104081|NCT02669693|Dietary Supplement|bread with olives|
46104082|NCT04176653|Drug|SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo|IMP will be provided as a solution to be injected by qualified clinical staff in patient's abdomen, upper arms or front of the thighs.
46104083|NCT00645125|Drug|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 mL
45681059|NCT04198636|Drug|Xgeva 120 MG in 1.7 ML Injection|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
46104084|NCT00645125|Drug|amoxicillin|2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 mL
46104085|NCT04175405|Procedure|Irradiation of implants with 635nm laser|Irradiation of implants with 635nm laser with a dose of 10J
46104086|NCT02669459|Drug|Imiquimod|12,5 mg imiquimod three times per week during 16 weeks
46104087|NCT02669459|Procedure|LLETZ|surgical treatment for CIN, current gold standard
46104088|NCT04176887|Drug|Levetiracetam Injection|The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.
46104089|NCT04176887|Drug|Phenytoin Injection|Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.
46104090|NCT04174937|Drug|Potentiator of antibiotics (PA)|Intervention is administered to patients in this Arm
45681060|NCT04414995|Drug|Paracetamol injection and Ibuprofen injection|Use of combination acetaminophen and ibuprofen to reduce morphine requirement inpatient after Total knee arthroplasty
45681061|NCT04414995|Drug|Paracetamol injection and normal saline|Use of paracetamol and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
46019726|NCT00943111|Drug|Eliglustat tartrate|"Primary analysis period (PAP): Eliglustat tartrate capsule 50 milligram (mg) twice daily (BID) orally from Day 1 to Week 4 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 8, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 52. Dose adjustments after Week 4 and Week 8 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was less than (<) 5 nanogram per milliliter [ng/mL] next higher dose was administered whereas if Genz-99067 trough plasma concentration was greater than or equal to (>=) 5 ng/mL same dose was continued. Pharmacokinetic (PK) assessment at Week 2 and 6 were used for dose adjustment after Week 4 and Week 8, respectively.~Long-term treatment period (LTTP): Participants originally randomized to eliglustat in PAP continued to receive eliglustat dose, based on their Genz 99067 plasma trough concentration at Week 6."
46104091|NCT04174937|Other|Placebo PA|Intervention is administered to patients in this Arm
46104092|NCT04085471|Diagnostic Test|CTHRC1 biomarker level in rheumatoid arthritis|measurment of levels of CTHRC1 in patients diagnosed as RA
46104093|NCT02668523|Device|Raindrop Near Vision Inlay|To improve the near and intermediate vision in subjects who have previously undergone cataract surgery (pseudophakic subjects)
46104094|NCT02667899|Device|deep brain stimulation|Deep brain stimulation means stimulate the brain with DBS.
46104095|NCT02667899|Device|transcranial magnetic stimulation|Transcranial magnetic stimulation means stimulate the brain with magnetic stimulation.
45681062|NCT04414995|Drug|Ibuprofen Injection and normal saline|Use of ibuprofen and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
45681063|NCT03975400|Behavioral|search engine advertisement campaign|This proposal aims to explore whether targeted and proactive online outreach through search engine advertisements, coupled with engaging, informative, and interactive online resources, can effectively reduce the duration of untreated psychosis and facilitate earlier treatment initiation in New York State.
46104096|NCT02667899|Other|Routine treatment|Means without above additional treatment.
46104097|NCT02667977|Other|0.9 Normal Saline|Use of 0.9 Normal Saline for maintenance IV fluids
46104098|NCT02667977|Other|0.45 Normal Saline|Use of 0.45 Normal Saline for maintenance IV fluids
46104099|NCT05276999|Other|Healthcare provider education|Mix of training and educational activities within the district continuing medical education system targeting community health workers and frontline providers focused on the importance of sore throat and it's link to RHD, clinical guidelines to differentiate patients at high or low risk for GAS pharyngitis and guideline based care for treating GAS pharyngitis
46104100|NCT05276999|Other|Community Awareness campaign|A district wide public health campaign to increase community awareness of sore throat, including school based education, VHT community sensitization, education of parents and patients, radio messaging, posters, signs and billboards.
46104101|NCT00645203|Drug|cefdinir|cefdinir oral suspension, 25 mg/kg once daily for 10 days
46104102|NCT00910403|Procedure|LASIK|Excimer Laser Ablation using LASIK
46104103|NCT02669381|Dietary Supplement|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
46104104|NCT02669303|Drug|platelet-rich plasma group|"Once randomized to platelet-rich plasma arm, the study subject will have 30cc of blood drawn and centrifuged using the Recover(TM) Platelet Separation Kit (Biomet Biologics, Warsaw, Indiana, USA). The extracted platelet-rich plasma part will be re-injected into the subacromial space of the subject's affected shoulder."
46104105|NCT02669303|Drug|Methylprednisolone group|Once randomized to Methylprednisolone arm, the study subject will have an injection with 2ml of Methylprednisolone (40mg/ml methylprednisolone acetate injectable suspension) (Pharmacia Upjohn, Kalamazoo, Michigan, USA) with 2ml of lidocaine hydrochloride 2% (Hameln Pharmaceuticals Ltd, Gloucester, UK) into the subacromial space of their affected shoulder.
46104106|NCT02671019|Behavioral|Guide to better alcohol habits|A treatment for harmful alcohol use based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.
46019727|NCT00943111|Drug|Imiglucerase|"PAP: Imiglucerase intravenous infusion every other week (q2w) up to Week 52 in doses equivalent to participant's past ERT dose prior to any unanticipated treatment interruption, dose reduction, or regimen change.~LTTP: Participants originally randomized to imiglucerase received eliglustat tartrate capsule 50 mg BID orally from Week 52+1 Day to Week 56 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 60, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to 5 years. The dose adjustments after Week 56 and Week 60 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was <5 ng/mL the next higher dose was administered whereas if the Genz-99067 trough plasma concentration was >=5 ng/mL the same dose was continued. The PK assessment at Week 54 and Week 58 were used for dose adjustment after Week 56 and Week 60, respectively."
46019728|NCT04268719|Diagnostic Test|wireless pH capsule recording|wireless pH capsule recording for up to 96 hours
46019729|NCT01147497|Drug|Misoprostol|400mcg of misoprostol taken buccally 2 hours prior to IUD insertion visit
46019730|NCT01147497|Drug|Placebo|Pill that is identical to the study drug in appearance, taste and smell, taken buccally 2 hours prior to IUD insertion visit
46019731|NCT01147341|Drug|Cimzia|prefilled 200mg Cimzia syringe SC q 2 weeks
46019732|NCT01147341|Drug|Placebo|prefilled saline syringe
46019733|NCT00950755|Biological|tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)|For the treatment of 1st or 2nd relapsed indolent B cell lymphomas or B cell lymphomas that have transformed to a more aggressive histology
46019734|NCT01147107|Drug|Raltegravir|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily
46019735|NCT01147107|Drug|Efavirenz|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
46019736|NCT01541761|Behavioral|Family groups|The group sessions are designed to facilitate on-going interaction among consistent groups of 6 - 8 parents and other care givers with infants the same age and will be coordinated with scheduled well child care visits. They will be conducted in English and Spanish. The groups will focus on nutrition and, parenting.
46104107|NCT00645281|Drug|tolterodine extended release|Tolterodine ER capsule 4 mg daily for 12 weeks
46104108|NCT02668835|Device|Non intervention-Monitoring device|Fox Insight self-monitoring android app and smartwatch Participants will be asked to wear a smartwatch with accelerometers, during day and night, for a period of 2 weeks. Additionally, a self-monitoring app on a smartphone is used, where the participant reports when they take any medication and performs a focused attention task to encourage resting tremor.
46104109|NCT02668835|Genetic|Non intervention-Genetic testing|
46104110|NCT02668757|Behavioral|HeartHab application intervention|The intervention patients will use the HeartHab application on a smartphone. During the study, the patients will use the HeartHab application for 4-6 weeks.
46019737|NCT02852473|Other|Continuous Positive Airway Pressure|CPAP requires subjects to wear a plastic pressurized mask/apparatus, which is connected via a filter and hose to a pump capable of supplying variable pressure (typically on the range of 4-20 cm H2O). The investigators plan to use a full-face mask to prevent subjects from reducing pressure by opening their mouths. If this cannot be tolerated or properly fitted, or is not compatible with the CPAP ventilator, subjects would use a nasal mask only and be asked to keep their mouths closed.
46104111|NCT02668679|Procedure|Sedation of children during gastroscopy with and without the presence of dream doctor|children and their parents with and without the presence of DD upon arrival to the Gastroenterology institute and throughout the induction of sedation, gastroscopy and recovery.
46104112|NCT02668679|Device|evaluation of stress with PPI and GSR|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of PPI and GSR
46104113|NCT02668679|Biological|blood specimens for stress hormones|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of stress hormones.
46104114|NCT02668679|Other|Physiological indices for evaluation of stress|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of blood pressure, pulse, saturation and body temperature.
46104115|NCT00645437|Drug|Levofloxacin|
46104116|NCT02668133|Dietary Supplement|the nutritional supplement to be used in this trial is a SQ-LNS|Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day
46104117|NCT02668133|Dietary Supplement|lipid-based nutrient supplement (SQ-LNS) with phytase|• Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration ~500 FTU/20 g SQ-LNS) added during manufacturing
46104118|NCT02668133|Dietary Supplement|0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc|delivered orally in sugar solution
46019738|NCT02852863|Other|Gum|Subjects will fast for a minimum of 8 hours. A baseline ultrasound assesment will be performed to evaluate gastric content. Next, subjects will chew sugarless gum for one hour with changes of gum every 20 minutes (a total of 3 gums will be chewed per subject). Once the last gum is chewed, the gum will be disposed in the trashcan. Three more ultrasound assessments will take place: immediately after one hour of chewing gum, and at the first and second hour after chewing gum has stopped. The content will be classified as empty, with fluids, or with solid. In case of fluids, volume will be measured.
46104119|NCT02668133|Dietary Supplement|1 mg isotopically enriched 68Zn|administered intravenously
46104120|NCT02668055|Biological|TB4|Computing area was in proportion to the slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitute cells stick in the wound surface
46104121|NCT02668211|Device|PROFEMUR Preserve Classic Femoral Components|
46104122|NCT02668913|Other|Diagnostic analysis|Molecular profiling
46019739|NCT00942409|Biological|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
46104123|NCT04176341|Other|a systematic proposal for non pharmacological interventions targeting the subject's empowerment among slackline, mindfulness, adapted physical activity, self-hypnosis, and Qi Gong|chronic pain patient consulting in Grenoble Alps University Hospital, and Hospital Mutualist Group who will one non pharmacological intervention between slackline, mindfulness, adapted physical activity, self-hypnosis, Qi Gong during 6 to 8 weeks.
46104124|NCT02671331|Procedure|Loop duodenal switch|The loop duodenal switch (L-DS) is a single anastomosis duodeno-intestinal bypass. In this simplified version of a BPD-DS, a sleeve gastrectomy is followed by a single anastomosis of the duodenum to the ileum in a loop fashion. The proposed benefits of this are to reproduce the excellent weight loss seen after a BPD-DS (an accepted and utilized bariatric procedure in the USA) but with the potential for reduced complications. With one anastomoses in the L-DS over two in the BPD-DS there is a theoretical lower probability of leaks, strictures, reduced anesthesia with shorter operative times, and decreased risk of internal hernia.
46019740|NCT01146951|Drug|Rufinamide (E2080)|"Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period.~Target maintenance dose:~15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) >= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)"
46019741|NCT01146951|Drug|Placebo|Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.
46104125|NCT02537171|Drug|apatinib|Patients will be randomly assigned on a 1:1 basis to treatment with Apatinib 750mg group or Apatinib 500mg group.
46104126|NCT00645515|Drug|Ziprasidone|Initial dose of 40 mg capsules twice daily on Days 1-3; dose could be flexibly changed within the range of 40 to 80 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
46104127|NCT00645515|Drug|Risperidone|Initial dose of 10 mg once daily on Days 1-3; dose could be flexibly changed within the range of 3 to 9 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
46019742|NCT01146873|Drug|Efavirenz (EFV)|Children are assigned to begin a EFV-based antiretroviral based regimen.
45681064|NCT03591718|Drug|BI 456906|Solution for injection
45681065|NCT03591718|Drug|Placebo|solution for injection
46019743|NCT01146873|Drug|Lopinavir/ritonavir (LPV/r)|Children are assigned to stay on their current LPV/r-based antiretroviral regimen.
46104128|NCT00644735|Drug|Esomeprazole|
45599235|NCT02349555|Dietary Supplement|Nutritional Supplement Blend|It is to be taken orally at a dose of 4 capsules per day, 2 capsules with breakfast and 2 capsules with dinner.
46104129|NCT00644735|Drug|Lansoprazole|
46104130|NCT04175015|Other|Smartie© sweet/candy|one chocolate sweet/ chocolate candy
46104131|NCT04176263|Behavioral|SBT|The SBT group will receive a 4-week split-belt treadmill training, 3 times a week using a standardized progression protocol. The sessions, including breaks, will approximately take 1 hour each. The training will be given by a trainer experienced with PD.
46104132|NCT04176263|Behavioral|TBT|The TBT group will receive a 4-week tied-belt treadmill training, 3 times a week. To make sure exposure of the two interventions is similar the sessions of the TBT group will be of similar length and progression level (approximately 1 hour each). The training will be given by a trainer experienced with PD.
46104133|NCT04175483|Other|assessment of subglottic diameter by ultrasonography|assessment of subglottic diameter by ultrasonography
46104134|NCT05069519|Behavioral|Personalized Smartwatch|"Participants will continue with standard care, but will receive a Fitbit and be encouraged to participate in at least 150 min. moderate-to-vigorous physical activity (5 sessions aerobic exercise, 30 min. per session; and 2 sessions of strength training) per week if their body condition allows throughout the intervention period. The previously established daily and weekly exercise prescription will be offered to participants based on their previous week Fitbit data.~PA improvements will be tailored over time based on each participant's previous week PA and they will be encouraged to increase PA by 5-10 min/week if possible depending on specific situations. Participants will save each workout and synchronize the Fitbit PA data to its app where they only share daily data and receive weekly personalized exercise prescriptions established in pilot studies."
46104135|NCT05069519|Behavioral|Facebook Health Education|Participants assigned to this condition will receive a Fitbit smartwatch, continue with standard care, but will receive health education tips developed in the investigators' previous studies from a private Facebook group in which only group members and researchers can access. Additionally, the investigators will track login counts, analyze their post activity and online sentiments via texting mining and natural language processing, and then offer weekly personalized feedback based on the data to facilitate social support
46104136|NCT04017299|Other|CHOISIR|Every patient will evaluate each device after 15 minutes of distraction once or twice a day according to the patient's wishes.
46104137|NCT02667743|Drug|Paclitaxel Micelles for Injection|
45681066|NCT01869699|Drug|Acetaminophen|acetaminophen 1 gram/100mLs intravenously administered over 15 minutes
45681067|NCT01869699|Drug|Placebo|Normal saline placebo Normal saline 100 mLs intravenous, administered over 15 minutes
45681068|NCT04198480|Drug|JMT103|2 mg/kg subcutaneously (SC) every 4 weeks with a loading dose of 2 mg/kg SC on study days 8 and 15.
45681069|NCT01714635|Device|Tecnis Multifocal Intraocular Lens|
45599236|NCT03737123|Drug|Carboplatin|Carboplatin AUC 4 IV Day 1 of each 21 day cycle
45599237|NCT03737123|Drug|Gemcitabine|Gemcitabine 1,000 mg/m2 IV Day 1 and Day 8 of each 21 day cycle
45599238|NCT03737123|Drug|Atezolizumab|Atezolizumab 1,200 mg IV Day 1 of each 21 day cycle
45599239|NCT03737123|Drug|Docetaxel|Docetaxel 75 mg/m2 IV Day 1 of each 21 day Cycle.
45599240|NCT03507907|Other|Mulligan Mobilization for Study Group|Mulligan Mobilization techniques were applied to the older adults who included in study group.
45681070|NCT01714635|Device|Monofocal Intraocular Lens|
46104138|NCT02667743|Drug|Paclitaxel Injection|
46019744|NCT01146873|Drug|Stavudine (D4T)|Children are assigned to stay on their current antiretroviral regimen which includes D4T.
46019745|NCT01146873|Drug|Abacavir (ABC)|Children stop taking D4T and switch to ABC.
46019746|NCT01146795|Drug|Carboplatin|Carboplatin will be administered at a concentration-time curve (AUC) of 5-6 (at the discretion of the physician) day 1 every 3 weeks in combination with Paclitaxel and Bevacizumab.
46019747|NCT01146795|Drug|Paclitaxel|Paclitaxel 175 mg/m2 over 3 hours day 1 every 3 weeks in combination with Carboplatin and Bevacizumab.
46104139|NCT02667743|Drug|Cisplatin|
46104140|NCT04176107|Behavioral|Informative video|Exposure to informative video before cesarean delivery
46019748|NCT01146795|Drug|Bevacizumab|Bevacizumab 15 mg/kg day 1 every 3 weeks in combination with Paclitaxel and Carboplatin.
46104141|NCT04070885|Procedure|Blood sample|A dry tube of 7 ml of blood, two 4 ml EDTA tubes, a 4 ml heparinized tube and an 8.5 ml ACD-A tube will be collected from the patient.
46104142|NCT04070885|Procedure|Urine sample|The urine will be taken from three 15 ml tubes.
46104143|NCT04173845|Drug|Tianqi Pingchan Granule|Tianqi Pingchan Granule are given twice a day
46104144|NCT04173845|Drug|Tianqi Pingchan Granule Placebo|Tianqi Pingchan Granule Placebo
46104145|NCT02666651|Drug|Tolvaptan|Tolvaptan is dispensed during hospitalization according to its product monograph and clinician discretion. It will be discontinued once serum sodium is normalized, or in the case of a drug related adverse event or hospital discharge.
46104146|NCT02666651|Other|No intervention|There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority will be used as a comparator.
46019749|NCT00625053|Procedure|Laparoscopic repair|Complete adhesiolysis between viscera and abdominal wall, complete dissection of round ligament and subumbilical fatty tissue to expose the posterior fascia at least 5 cm further than the cranial and caudal limits of the fascial defect or the original incision. Overlap of minimum 5 cm is calculated and mesh inserted in the abdominal cavity through 12mm optical trocar. Fixation of a antiadhesive composite mesh with helicoidal pins with maximum 15mm interval, double crown technique. No pressure decrease maneuver is done during mesh fixation or at another time during the operation. No transparietal suture fixation. No fascial closure.
46019750|NCT00625053|Procedure|Open midline incisional hernia repair|"Underlay retromuscular repair: Medial border of the anterior fascia opened, posterior aspect of rectus muscle dissected to reach lateral border of rectus sheet, bilaterally. Peritoneum and posterior rectus fascia closed with absorbable running suture. Polyester or light-weight polypropylene mesh is cut to fit the reconstructed area, to have 3cm overlap on caudal and cranial defect limits. Mesh is fixed by absorbable sutures. Anterior fascia is closed with absorbable running suture. Components separation upon need.~Intraperitoneal onlay repair: Mesh is inserted intraperitoneally and fixed by a complete running suture (optional fixation with helicoidal pins or stapler). Fascial defect is closed with interrupted or running absorbable suture. Components separation upon need."
46019751|NCT01146561|Biological|Tanezumab|single administration of tanezumab 20 mg sub-cutaneously
46104147|NCT02666807|Dietary Supplement|Ginger|Ginger 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks
46104148|NCT02666807|Dietary Supplement|placebo|Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks
46104149|NCT02671175|Drug|dihydroartemisinin-piperaquine|Children in both arms will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
46104150|NCT02671175|Drug|dihydroartemisinin-piperaquine placebo|Children will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
46104151|NCT02666573|Device|Fotosan 630, CMS Dental, Copenhagen, Denmark|The PDT system consists of a hand-held rechargeable light-emitting diode (LED) light source (Fotosan® 630 device, CMS Dental, Copenhagen, Denmark) and 0.1 mg/mL toluidine blue photosensitiser. The LED light source has a wavelength between 620 to 640 nm and peak of 630 nm and a power density between 2000 to 4000 mW/cm2.
46104152|NCT02666573|Other|Scaling and root planing|Scaling and root debridement of the residual pockets were performed using ultrasonic device and hand curettes until root surfaces felt hard and smooth. The sites were then polished using rubber cup and prophylaxis paste.
46104153|NCT00644813|Other|Scapular with glenoid neck fractures|
46104154|NCT02670941|Drug|Ginger|The ginger oil (GIN-106) was steam distilled from fresh ginger grown in Madagascar. The ginger oil contains 64.23% sesquiterpenes, 18.5% monoterpenes, and 3.28% aldehydes. The aroma of ginger is described as spicy, sweet, and warm.
46019752|NCT01146561|Other|Placebo|single administration of placebo to match tanezumab, sub-cutaneously
46019753|NCT00942175|Drug|Clopidogrel|Clopidogrel 75 mg, tablets, orally, once daily days 1-9.
46019754|NCT00942175|Drug|Clopidogrel and Lansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily days 1-9.
46104155|NCT02670941|Drug|Lavender|The lavender oil (LAV-110) was steam distilled from lavender grown in Kashmir Valley in India. The lavender oil contains 53.22% esters, 31.86% monoterpenols, and 4.88% oxides. The aroma of lavender is described as floral, fresh, herbaceous, and sweet.
46104156|NCT02670941|Drug|Orange|The orange oil (ORG-114) was cold-pressed and steam distilled from oranges in South Africa. The orange oil contains 97.21% monoterpenes, 0.73% aldehydes, and 0.7% monoterpenols. The aroma of orange is described as citrus, fresh, fruity, and sweet.
46019755|NCT00942175|Drug|Clopidogrel and Dexlansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily days 1-9.
46019756|NCT00942175|Drug|Clopidogrel and Omeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily days 1-9.
46104157|NCT02670941|Drug|Jojoba|"The jojoba oil is certified organic and pesticide-free pure oil. Jojoba has a mild scent and can be used as a fixative for other essential oils."
46104158|NCT02667041|Device|NeuroQore rTMS Device|
46104159|NCT02671097|Drug|Rosuvastatin|5 mg tablet single dose on Day 01 in Period 1 and on Day 08 in Period 2.
46104160|NCT02671097|Drug|BAY1841788 (ODM-201)|600 mg single dose, administered as 2 x 300 mg tablets on Day 01 in Period 2; 600 mg BID multiple dose, administered as 2 x 300 mg tablets on Day 04 to Day 08 in Period 2.
46104161|NCT02665169|Behavioral|Supervised physical exercise|Supervised physical exercises in Taiji and weight training. Free use and access into municipal recreation and training facilities for one year.
46104162|NCT02665169|Other|Health counselling|Health counselling, fall prevention strategies at home, information concerning municipal recreational services available.
46104163|NCT00645983|Dietary Supplement|Chamomile Extract|220 mg - 1100 mg daily
46104164|NCT00645983|Other|Placebo|1 to 5 capsules daily
46104165|NCT02666495|Other|Psychological Therapy - Schema Therapy|Psychological treatment using individual Schema-Mode Therapy for Anorexia Nervosa (iST-AN). A 60 session protocol will be used over an 18 month period, moving flexibly through five phases of treatment, guided by the psychological formulation: phase 1 - assessment, engagement & stabilisation; phase 2 - developing trust & understanding; phase 3 - developing awareness & acceptance; phase 4 - testing change & strengthening the healthy mode; phase 5 - consolidating change. A follow-up period of 6 months, with 5 further monthly sessions, will promote self-efficacy and further consolidate change. A total treatment package of 65 sessions will be offered, over 24 months.
46104166|NCT02667197|Other|Algorithm to determine overdose from opioid abuse|
46104167|NCT02665091|Behavioral|Peer Education Program|
46019757|NCT00942175|Drug|Clopidogrel and Esomeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily days 1-9.
46019758|NCT01145625|Drug|5% Minoxidil|half a cap (equivalent to 1g) 5% Minoxidil Topical Foam applied to the scalp once daily, every day, for 52 weeks
46019759|NCT01145625|Drug|2% Minoxidil|one ml of 2% Minoxidil Topical Solution applied to the scalp two times a day, every day, for 52 weeks
46019760|NCT02852941|Device|CardioScreen 1000|Haemodynamic Measurement System, Medis Impedance cardiography (ICG)
46019761|NCT02852941|Device|Tanita 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
46019762|NCT02855203|Radiation|Stereotactic Ablative Body Radiosurgery (SABR)|18-20Gy in 1 fraction
46104168|NCT05276921|Other|ultrasound|Quadriceps and abdominal muscle ultrasonography
46104169|NCT02665325|Drug|TSH-suppressive therapy|Thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer; followed by TSH-suppressive therapy 6 /12 months.
46104170|NCT05257421|Device|shockwave machine|shockwave therapy. 2000 impulses will be applied, 1000 on the TrPs and 1000 surrounding it, with Energy level up to 2,5 bars and frequency of 10Hz
46104171|NCT05257421|Other|leg and back exercises|"the exercise program will include 5 exercises that focuses on the back and lower limbs. These exercises are:~Bridge~Plank~Squat~Push-ups~Back extension Each exercise will be done for 3-5 sets."
46104172|NCT05257421|Combination Product|shockwave and exercises|both types of interventions will be applied for the patient
46104173|NCT02665403|Other|Play intervention|participants received around 30 minutes of hospital play interventions each day, conducted by hospital play specialists. Such interventions consisted of structured and non-structured activities. All these activities were given at the patients' bedside, with or without parental supervision, either once or spreading over an hour, depending on the ward routine.
46019763|NCT02855203|Drug|Pembrolizumab|Pembrolizumab at a dose of 200mg IV, 3-weekly will be delivered for a duration of 6 months, commencing 5 days (+/- 3 days) from the last dose of SABR.
46019764|NCT02852083|Drug|Pioglitazone|Pioglitazone 25 mg once daily, p.o.
46019765|NCT02852083|Drug|nivolumab|3 mg per kilogram of body weight every 2 weeks, p.o. (standard treatment)
46019766|NCT02852083|Drug|Treosulfan|Treosulfan 250 mg twice daily, p.o.
46019767|NCT02852083|Drug|Clarithromycin|Clarithromycin 250 mg twice daily p.o.
46019768|NCT02852395|Drug|JNJ-48816274|Oral dose; dose range of 5 mg up to 250 mg
46019769|NCT02852395|Drug|Placebo|Oral dose; appearance matched to JNJ-48816274
46019770|NCT02852629|Other|observational study|
46019771|NCT00602407|Drug|Cilostazol|
46019772|NCT01144377|Drug|LY2541546|Administered subcutaneously
46019773|NCT01144377|Drug|Placebo|Administered subcutaneously
46019774|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, once daily, 12 weeks
46019775|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 5 mg, once daily, 12 weeks
46019776|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 10 mg, once daily, 12 weeks
46019777|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 20 mg, once daily, 12 weeks
46019778|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 40 mg, once daily, 12 weeks
46019779|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 100 mg, once daily, 6 weeks
46019780|NCT00950599|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 6 and 12 weeks
46019781|NCT01144299|Biological|Fluarix™/Influsplit SSW®|Single intramuscular dose on Day 0
46019782|NCT04313205|Drug|JKB-122 in capsule or tablet form|JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form
46104174|NCT02665403|Other|control|Children received standard medical and nursing care, such as vital signs observation, pharmacological treatment and wound and pain management as a control treatment
46104175|NCT00463567|Drug|Indacaterol|In the morning, Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
46104176|NCT00463567|Drug|Formoterol (12 µg b.i.d.)|Formoterol 12 µg twice daily (b.i.d.) in the morning and in the evening via an aerolizer.
46104177|NCT00463567|Drug|Tiotropium (18 µg o.d.)|Tiotropium 18 µg once daily (o.d.) dry powder capsules delivered via a SDDPI.
46104178|NCT00463567|Drug|Placebo to Indacaterol|In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
46104179|NCT00463567|Drug|Placebo to Formoterol|In the morning and in the evening, placebo to formoterol delivered via Aerolizer.
46104180|NCT00646061|Drug|buscopan|
46104181|NCT00646841|Drug|Doxazosin gastrointestinal therapeutic system (GITS)|4 mg/day, and was titrated, if necessary, to 8 mg/day at Week 3 (Visit 5) or Week 5 (Visit 6).
46104182|NCT04173143|Device|Craniocervical flexion training with pressure biofeedback|Total 15 patients participated in this training group. Session was performed thrice in a week. Each session was givenfor approximately 20minutesPatients were asked to lie in supine hook lying position. After that Pressure biofeedback unit's air bag was clipped together and folded in three and positioned behind the neck just below the occiput. Patients were advised to perform Craniocervical flexion and practiced head nodding action to progressively target (reach the incremental targets) and hold the 5 pressure levels for 10 second between 22 mm Hg and 30 mmHg. A 2 minute second rest period was provided between each level. Minimum performance requirement was 26 mm Hg while ideal performance targets are 28 and 30 mm Hg... Patient will be re-assessed for all baseline variables after 4 weeks of training
46104183|NCT04173143|Other|Craniocervical flexion training without pressure biofeedback|Total 15 patients participated in this control group.Session was given 3 times in a week. Each session continue forapproximately 20 minutes. The patient lies in supine crook lying position. The patientwas maximally retracted the chin and asked to maintained it while the patient lifts the head and neck until the head is relatively 2 to 5 cm (1 inch) abovethe couch. The examiner places a hand under the head of patient on the table. Patients were instructed to perform10 repetitions for a hold of 20 seconds initially, increasing it by 10 seconds progressively.The entire session had a maximum of 4 sets. Patient will be re-assessed for all baseline variables after 4 weeks of training
46104184|NCT04786067|Drug|Belatacept|Patients will have tapering of their multi-drug immunosuppression, until Belatacept is the sole medication in their immunosuppression regimen. Belatacept will be administered as an infusion, as is routinely done clinically.
46104185|NCT00646139|Drug|Src kinase inhibitor KX2-391|
46104186|NCT00646139|Other|immunoenzyme technique|
45599241|NCT03507907|Other|Conventional therapy for Control Group|Conventional therapy was applied to the older adults who included in control group.
46104187|NCT00646139|Other|pharmacological study|
46104188|NCT00646919|Procedure|Nose swab|
46104189|NCT02665013|Behavioral|Tailored|Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the tailored intervention arm will receive vaccine information tailored specific to her concerns and values at each intervention point.
46104190|NCT02665013|Behavioral|Untailored|Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the untailored arm will receive vaccine information at each intervention time point, but it will not be tailored to her specific concerns.
46104191|NCT01323049|Procedure|Positive pressure extubation|Positive pressure extubation will be used for patients waking up from general anesthesia
46104192|NCT01323049|Procedure|Aspiration/suction extubation|Aspiration/suction extubation will be used for patients waking up from general anesthesia
46104193|NCT00645749|Biological|Helminth ova|2500 ova per dose (liquid form)
46104194|NCT03995797|Procedure|Laser therapy|Erbium YAG laser
46104195|NCT04167397|Other|Collaborative learning|Participants will be allocated to either single, dyad, triad or tetrad practice during initials skills training on an ultrasound simulator. Afterwards their competencies will be assessed with an individual transfer test on another simulator.
46104196|NCT01019161|Drug|AZD1152|100mg Lyophile, 5mL Diluent IV infusion
46104197|NCT01019161|Drug|C14 AZD1152|radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion
45599242|NCT02344329|Device|Topical wound dressing|Topical Wound Dressing
45599243|NCT02344329|Biological|Human Amnion Allograft|Change dressing every two to three weeks and TCC-EZ is changed weekly for 12 or until healed.
46019783|NCT02883621|Procedure|cap assisted upper endoscopy|A soft plastic cap is attached to the tip of the scope to allow pressing of the folds and thus enhance the visualization.
46019784|NCT02883621|Procedure|standard upper endoscopy|standard examination without using a cap
46019785|NCT02883699|Behavioral|Standard endurance training|Continuous vigorous training 2 x per week on a cycle ergometer
46019786|NCT02883699|Behavioral|Polarized endurance training|Continuous moderate training 1 x per week and aerobic high intensity interval training (HIIT) 1 x per week on the cycle ergometer
46019787|NCT02883699|Behavioral|Standard resistance training|Machine based hypertrophy training 2 x per week
46104198|NCT04173767|Device|high flow nasal cannula ventilation|High-flow nasal cannula (HFNC) ventilation therapy: supply heated & humidified air up to 60 L/min of flow; effects: positive end expiratory pressure effect, humidification.
46019788|NCT02883699|Behavioral|Daily undulating periodization resistance training|Machine based daily undulating periodization resistance training 1 x per week
46019789|NCT04313049|Device|JACO2|Performing tasks using joystick control
46019790|NCT04313049|Device|VOCAL CONTROL|Performing tasks using vocal control
46019791|NCT05201235|Device|MAEVAD|"MAEVAD is a training device which aims to improve VA span as a prerequisite for learning to read. By increasing the number of distinct visual elements that can be processed simultaneously during fixation, MAEVAD is intended to improve the reading (accuracy and fluency) and spelling (lexical) performance of dyslexics who have a VA span deficit. MAEVAD is designed to be used in total autonomy by dyslexic children with a VA span disorder. The therapy takes place over 6 weeks with 5 sessions of 15 minutes per week. In order to improve compliance, the therapy has been integrated into le Royaume d'Adelia, a serious game where the child will be able to collect materials at the end of each session that will allow him to create objects to customise a character."
46019792|NCT05201235|Device|DeCaLigne|"DéCaLigne is an intervention programme for the discovery of calculation with the number line. The objectives are to improve numerical representations in the form of a number line and to improve addition and subtraction skills. The overall principle is to move numbers or calculation results on a number line. This training does not stimulate VA span or the phonological dimensions involved in reading. This therapy is being adapted to be used in total autonomy at home and to correspond to the MAEVAD therapy in duration (5 sessions of 15 minutes per week for 6 weeks). It has also been integrated into the royaume d'Adelia in order to control the motivational effect of the serious game."
46104199|NCT00646217|Behavioral|Self Care Talk|6 weekly telephone sessions
46104200|NCT01025557|Other|Dietary intervention|Dietary treatments with beverages
46104201|NCT00647075|Dietary Supplement|Yunzhi extract|3.5 g/day
46104202|NCT00647075|Dietary Supplement|Placebo|Placebo (starch)
46104203|NCT04172753|Radiation|Radiotherapy on the MR-Linac|Radiotherapy is performed on the 1.5 T MR Linac
46019793|NCT01143207|Drug|Medroxyprogesterone acetate|Injectable hormonal contraceptive
46104204|NCT04172753|Diagnostic Test|Imaging on the MR Linac|Only imaging performed on the MR Linac
46104205|NCT01022515|Other|plasma EM66 & CgA levels assessment|After inclusion checking to eliminate the presence of pheochromocytoma / paraganglioma, a blood sample will be drawn to assess plasma EM66 and CgA levels.
46104206|NCT01022515|Other|usual follow up with regular EM66 & Cga levels assessment|"Patients with pheochromocytoma / paraganglioma will be followed-up as the international standards recommend.~Regularly, blood samples will be drawn for the usual assessment of CgA levels and also EM66 (research purpose) levels."
46104207|NCT04068389|Procedure|Pulmonary Tissue Collection|Pulmonary Tissue Collection
46104208|NCT04068545|Device|Device: Thoraguard Surgical Drainage System|Fluid drainage following thoracic surgery
46104209|NCT00484159|Procedure|Radiofrequency denervation of medial branches|Radiofrequency of medial branches that innervate the lumbar facet joints
46104210|NCT00484159|Drug|0.5% bupivacaine|Diagnostic medial branch block with 0.5% bupivacaine. Blocking the nerves that innervate the facet joints with a long-acting local anesthetic.
46104211|NCT00484159|Drug|2% lidocaine|Diagnostic medial branch block with 2% lidocaine. Blocking the nerves that innervate the facet joints with a short-acting local anesthetic.
46104212|NCT00484159|Procedure|Radiofrequency denervation|Radiofrequency lumbar facet denervation without a diagnostic block
46104213|NCT00484159|Procedure|Radiofrequency denervation|Radiofrequency lumbar facet denervation only if positive response to 2 diagnostic blocks.
46104214|NCT00484159|Procedure|Radiofrequency denervation|Lumbar facet radiofrequency denervation if positive response to a single diagnostic facet block
46019794|NCT04312893|Other|Acupuncture (Press Tack Needle)|Press Tack Needle (PYONEX made by Seirin Corporation). The needles appear identical to the press tack placebo with the only different is the needle itself which was removed in the placebo needles.
46019795|NCT04312893|Other|press tack placebo|press tack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element.
46019796|NCT01143051|Drug|epinephrine inhalation aerosol|Single dose 220 mcg/inhalation, 10 inhalations
46019797|NCT01143051|Drug|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 125 mcg/inhalation, 10 inhalations
46019798|NCT01143051|Drug|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation, 10 inhalations
46019799|NCT02883543|Drug|icotinib|Icotinib is orally administered three times per day.
46104215|NCT00484159|Procedure|Radiofrequency denervation|Radiofrequency lumbar facet denervation without a diagnostic facet block.
46104216|NCT02666417|Dietary Supplement|Fortified maize porridge (MNP+iron)|Maize porridge will be home-fortified with the MNP + iron. Maize porridge for the test meal will be fortified with labelled iron compounds
46104217|NCT02666417|Dietary Supplement|Fortified maize porridge (MNP+iron+GOS)|Maize porridge will be home-fortified with the MNP + iron + GOS. Maize porridge for the test meal will be fortified with labelled iron compounds
46104218|NCT00647153|Other|pharmacological study|Pre-infusion and 30 min., 1h,2h, and 3-4h post start of infusion. Day 1 and 2 post infusion.
46104219|NCT00647153|Procedure|single photon emission computed tomography|One day post infusion
46104220|NCT00647153|Radiation|iodine I 123 anti-CEA recombinant diabody T84.66|10mCi/mg
46104221|NCT00910637|Drug|Gestodene/EE Patch (BAY86-5016)|55 mg ethinyl estradiol & 2.1 mg gestodene, 21 days for 13 cycles
46104222|NCT00462865|Drug|Gemcitabine and Capecitabine and Avastin|avastin administered concurrently with chemotherapy (gemcitabine + capecitabine) for six cycles followed by single agent avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
46019800|NCT02883543|Drug|Chemotherapy|"Chemotherapy is given by intravenous administration. Three regimens are available in this study.~Regimen 1: etoposide 75mg/m2 d1-5 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 2: docetaxel 75mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 3: pemetrexed 500mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2"
46019801|NCT02883543|Radiation|Radiotherapy|5Gy/75.00Gy, 10f/2w for peripheral lung cancer, and 2.4Gy/59.52Gy, 20f/4w for central lung cancer.
46019802|NCT05199597|Drug|0.01% atropine|0.01%, room temp, Lab A
46019803|NCT05199597|Drug|0.05% atropine|0.05%, room temp, Lab A
46104223|NCT02666027|Device|Fluid Intravenous Alert (FIVA) 'on'|Fluid Intravenous Alert (FIVA) 'on' - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada (Figure 1). It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
46019804|NCT05199597|Drug|0.05% atropine|0.05%, refrigerated, Lab A
46019805|NCT05199597|Drug|0.05% atropine|0.05%, room temperature, Lab B
46019806|NCT01142661|Drug|Eribulin Mesylate|Eribulin Mesylate: A dose of 1.4 mg/m^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.
46104224|NCT02666027|Device|Fluid Intravenous Alert (FIVA) 'off'|The FIVA will be turned off. - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada. It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
46104225|NCT01025713|Drug|GS-9411|Inhaled GS-9411
46104226|NCT01025713|Drug|Placebo|Inhaled Placebo
46104227|NCT04173455|Drug|HZ-A-018|"In the dose-escalation part, subjects will be assigned to five cohorts with increaing dose level to determine DLT and MTD during the first 28-day cycle.~In the expansion part, subjects will be assigned to two fixed dose corhort."
46104228|NCT03839641|Other|High fat meal|60% fat meal
46104229|NCT03839641|Other|Low fat meal|20% fat meal
46019807|NCT01142193|Drug|USL255|
46019808|NCT01142193|Drug|Placebo|
46019809|NCT01142115|Device|Intermittent catheter CP063CC|intermittent catheterisation
46019810|NCT01142115|Device|SpeediCath|intermittent catheterisation
46104230|NCT02667353|Procedure|ECT|ECT was administered twice a week with a constant-current brief-pulse device (Thymatron, System IV). Motor and electroencephalographic seizures were monitored to ensure adequate duration and quality. Subjects were all treated with right unilateral (RUL) ECT with stimulus intensity 6 times the initial seizure threshold (ST), as determined by empirical dose titration at the first treatment, until remission (Montgomery-Åsberg Depression Rating Scale (MADRS) (27) < 10 in two consecutive ratings with a week interval). Subjects who failed to respond right unilateral ECT after the sixth treatment were switched to bitemporal ECT (1.5x seizure threshold).
46104231|NCT02667353|Drug|Etomidate|Anesthesia was achieved with intravenous administration of etomidate (0.2mg/kg).
46104232|NCT02667353|Drug|Succinylcholine|Anesthesia was achieved with intravenous administration of succinylcholine (1mg/kg).
46104233|NCT00462709|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
46104234|NCT02664857|Drug|Vitamin D|Group D will take 600 IU vitamin D per orally during 12 weeks. At first day and end of the 12 weeks serum vitamin D level will analyse with laboratory testing
46104235|NCT02664857|Drug|Placebo|Group P will not take orally during 12 weeks. This group will only observe by researchers.
46019811|NCT01140477|Device|Toric Accommodating Lens|Toric accommodating lens implanted after cataract extraction
46019812|NCT01140477|Device|Accommodating Lens|Accommodating lens implanted after cataract extraction
46104236|NCT04066673|Diagnostic Test|Stanford-Binet Intelligence Scale, 5th Edition|The SB5 is a descendent of the very first intelligence measure ever created. It tests general intellectual ability, and the Fifth Edition affords the ability to report Full Scale, Abbreviated, Nonverbal, and Verbal IQ scores
46019813|NCT01139775|Drug|Pemetrexed|Administered intravenously as a continuous 10-minute infusion
46019814|NCT01139775|Drug|Cisplatin|Administered intravenously as a continuous 1-hour infusion
46019815|NCT01139775|Drug|LY2603618|Administered intravenously as a continuous 1-hour infusion
46019816|NCT05224557|Other|No intervention|No intervention
46019817|NCT02883777|Behavioral|High Protein and Low Glycemic Index Diet|It will be evaluated a type of high protein diet with 1,3g/kg/day in kidney transplant recipients over 1 year after transplantation.
46019818|NCT02883777|Behavioral|Conventional Diet|Conventional diet over 1 year after transplantation.
46019819|NCT02883465|Procedure|Diaphragmatic ultrasound|"All patients will have a diaphragmatic ultrasound in the 4 hours before the extubation.~a record of the right and left diaphragmatic cupolas run, with a chest approach and using a 4-5 MHz (megahertz) cardiac or abdominal sensor. 3 acquisitions for each side~a record of the diaphragm thickening at the right and left apposition zones with a 10-12 MHz (megahertz) vascular sensor. 3 acquisitions for each side"
46019820|NCT04312425|Procedure|Modified rapid sequence induction|Modified RSI was put into use in day shift emergency surgery since March 1, 2018. In this scheme, dorsal elevated position and apneic oxygenation technic are applied. Positive pressure mask ventilation is avoided unless necessary. Sellick's technic is not used in this scheme.
46019821|NCT04312425|Procedure|Classic rapid sequence induction|In classic RSI scheme, patients are in supine position during induction and intubation. Sellick's technic is applied after sedatives and muscle relaxant are given.
46104237|NCT01019239|Procedure|Laparoscopic Washout|Pneumoperitoneum will be established via a blunt entry 12mm umbilical port. Two 5mm ports will be placed in the suprapubic and right lower quadrants. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. Peritoneal lavage will be performed in all four quadrants using at least 4 litres of warmed saline until the drainage is clear. Two non-suction Penrose drains will be placed.
46019822|NCT01283516|Drug|LDK378|LDK378 is a selective and a potent inhibitor of anaplastic lymphoma kinase (ALK) activity, is a capsule and is administered orally.
46019823|NCT04205721|Behavioral|School-based sexuality and HIV prevention scripted lesson plans|The revised life orientation content and implementation approach were designed to address gaps in prior implementation of the sexuality and HIV education content. By using scripted lesson plans and training teachers to use these, it was thought that students would get better information and lessons on the material important for HIV prevention.
45467582|NCT04947501|Drug|Cyclophosphamide|"Administration of CTV - cycles 1 and 4~Days 1 & 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients >10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients >10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg.~******* Administration of CDV - cycle 3 Days 1 & 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients >10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients >10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr."
45467583|NCT04947501|Drug|Topotecan|"Administration of CTV - cycles 1 and 4~Days 1 & 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients >10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients >10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg."
45599244|NCT02344329|Other|usual wound care|assessment, wound cleansing, debridement, moist wound environment, and off-loading
46019824|NCT01137435|Biological|ADACEL™:Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined|0.5 mL, intramuscular (IM)
45681071|NCT03596398|Genetic|GLA gene|Genetic test will be performed when enzyme activity is found abnormal in the whole blood test or confirmation is required. 5 ml of blood sample will be obtained and polymerase chain reaction (PCR) sequencing will be executed to determine mutations in the GLA gene.
45838151|NCT04642898|Behavioral|Compensation UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
46019825|NCT02883309|Other|intradialytic physical training program|Nine patients participated in the experimental group in a combined training program, which lasted 12 weeks with a frequency of 3 times a week, the training sessions were carried out within each dialysis session during the first 2 hours of the dialysis treatment, the working session involved a warm up period, aerobic exercise with pedals, or strength exercises based on free weight depending on the training stage. The Borg scale and the heart rate reserve were used to control the training intensity. The disability level was evaluated at the beginning and the end of the study through the World Health Organization Disability Assessment Schedule II, the aerobic capacity was evaluated through the six minute walk and the limbs strength was evaluated through a dynamometer.
46019826|NCT02883231|Other|taking peripheral blood|taking peripheral blood of no more than 3ml
46019827|NCT01283282|Drug|Clopidogrel|Clopidogrel 75 mg PO qday for 6 weeks
45599245|NCT03513679|Procedure|Surgical intervention|Surgery to decompress the spinal cord, either with or without concurrent fusion
45599246|NCT03709121|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed twice.
45681072|NCT01849874|Drug|MEK162, MEK inhibitor; oral|multiple dose, single schedule
45681073|NCT01849874|Drug|Physician's choice chemotherapy|"Patients will receive one of the following chemotherapies as determined by the physician:~Liposomal doxorubicin, anthracycline antibiotic; intravenous (multiple dose, single schedule)~Paclitaxel, mitotic inhibitor; intravenous (multiple dose, single schedule)~Topotecan, topoisomerase 1 inhibitor; intravenous (multiple dose, single schedule)"
45838152|NCT04598711|Behavioral|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 14 visits. Visits 1-3 occur on consecutive work days and visits 4-14 occur on alternating week days.
46019828|NCT01283282|Drug|Placebo|Placebo PO qday for 6 weeks
46019829|NCT01282814|Drug|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
46019830|NCT01282814|Drug|Effexor® XR|150 mg Extended-Release Capsule
45838153|NCT04598711|Behavioral|Sham Conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 14 visits. Visits 1-3 occur on consecutive work days and visits 4-14 occur on alternating week days.
46019831|NCT00941863|Drug|Sorafenib 100 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)
46019832|NCT00941863|Drug|Sorafenib 200 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)
46019833|NCT00941863|Drug|Sorafenib 400 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)
46019834|NCT00941863|Drug|Sorafenib 400 mg (200-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)
46019835|NCT00941863|Drug|Sorafenib 400 mg (Expansion)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion
46019836|NCT00602485|Other|Action Control Education|30 minute educational intervnetion
46019837|NCT00602173|Drug|Cilostazol|
46019838|NCT02854969|Behavioral|Device: Anapphylaxis|
46019839|NCT02852239|Drug|dabrafenib|Single dose dabrafenib 100 mg
46019840|NCT01282424|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
46019841|NCT02852785|Behavioral|PNF D2 for flexion; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for flexion during low-to-moderate loading condition
46019842|NCT02852785|Behavioral|PNF D2 for flexion; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for flexion during moderate-to-high loading condition
46019843|NCT02852785|Behavioral|PNF D2 for extension; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for extension during low-to-moderate loading condition
46104238|NCT01019239|Procedure|Hartmann's Procedure/ Primary Resection and Anastomosis|24 Pneumoperitoneum will be established via a blunt entry 12mm umbilical port. Two 5mm ports will be placed in the suprapubic and right lower quadrants to facilitate triangulation of instruments during manipulation and lavage. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. . In the absence of faeculant peritonitis, patients will be randomised to undergo Hartmann's procedure or primary resection and anastomosis (depending on standard practice in the individual unit).
46104239|NCT04172519|Other|Pre- and post prostatectomy supervised PMFT|intervention before and after surgery, supervised exercises
46104240|NCT04172519|Other|Unsupervised PMFT|intervention after surgery, unsupervised exercises
46104241|NCT04172519|Other|Supervised PMFT|intervention after surgery and supervised exercise
46104242|NCT03996031|Device|Plan to Thrive smartphone application|All participants in this single-arm pilot study will receive access to Plan to Thrive. This mobile care management program is comprised of modules including educational interventions, health behavior trackers containing built-in reminders, symptom monitoring, and navigator services (see attached content). Access to intervention modules and individualized navigator services according to patients' needs as captured by 1) their patient-reported outcome (PRO) assessments via Plan to Thrive's symptom monitoring feature, and 2) patient requests.
46104243|NCT00646295|Device|To measure the IOP (with Goldmann and Pascal DCT tonometers) and OPA (with Pascal DCT) in primary and upright gazes|Pascal Dynamic Contour Tonometer Goldmann Applanation Tonometer
46104244|NCT00647465|Drug|vaccine|IFNalpha 2b
46104245|NCT00647465|Drug|Placebo|Placebo
46104246|NCT04172207|Other|Sampling|After periodontal parameters measured, smear samples were obtained from the buccal mucosa and keratinized gingiva, and then a gingival biopsy was performed from the upper premolars.
46104247|NCT02665793|Other|DBPCFC to peanut cookie|
45467584|NCT04947501|Drug|Vincristine|"Administration of CTV - cycles 1 and 4~Days 1 & 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients >10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients >10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg."
46104248|NCT02665793|Other|Single-dose DBPCFC to peanut flour|Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
46104249|NCT02665793|Other|Single-dose DBPCFC to peanut butter|Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
46104250|NCT02665871|Biological|one dose of Influenza Vaccine|
46104251|NCT02665871|Biological|one dose of Influenza Vaccine|
46104252|NCT02665871|Biological|placebo|
46104253|NCT02665871|Biological|placebo|
46104254|NCT02664779|Other|Arrhythmia diagnosis with the 10 steps method|
45599247|NCT03709121|Drug|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) dosed twice.
46019844|NCT02852785|Behavioral|PNF D2 for extension; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for extension during moderate-to-high loading condition
46019845|NCT00602251|Drug|Terbinafine|
46019846|NCT01281956|Drug|PRX-00023|PRX-00023 (Selective 5HT1A agonist)
46104255|NCT02664779|Other|Arrhythmia diagnosis with the 6 steps method|
46104256|NCT02664779|Other|Arrhythmia diagnosis with the 4 steps method|
46104257|NCT00647543|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
46104258|NCT00647543|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
46104259|NCT00647543|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
46104260|NCT04172285|Behavioral|Physical activity|Home-based physical activity program
46104261|NCT04172285|Dietary Supplement|Physical activity and supplementation|Home-based physical activity program and amminoacid supplementation
46104262|NCT04172285|Other|Control|No intervention
45599248|NCT03709121|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed twice.
45599249|NCT02344095|Drug|weekly paclitaxel|Patients are treated with weekly paclitaxel 70mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks
46019847|NCT01281956|Drug|Placebo|Placebo
46019848|NCT02889536|Other|Focus group interviews|Focus group interviews. Two groups with patients referred to repair of parastomal bulging and three groups with patients attending the outpatient stoma clinics
46019849|NCT02889614|Other|Hypobetalipoproteinemia diagnosis (LDL-C ≤ 50 mg/dL without hypolipidemic treatment)|LDL-C dosage.
46019850|NCT00623870|Drug|RO5045337|Multiple ascending doses
46019851|NCT04323410|Procedure|Cast immobilization|Cast immobilisation is done using finger trap traction. The fractured forearm is splinted above elbow with dorsal cast without attempted reduction.
46019852|NCT04323410|Procedure|Percutaneus pinning|Reduction under fluoroscopic guidance and fixation using two crossing 1.6mm K-wires.
46104263|NCT00646373|Other|Low Prime|The CPB circuit will be primed with mannitol (50 g of 20% solution) and crystalloid solution (Ringer's lactate) for a total volume of approximately 1200 ml.
46104264|NCT00647621|Drug|Extended Phenytoin Sodium Capsules 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
46104265|NCT00647621|Drug|Dilantin® Kapseals® 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
46104266|NCT00461305|Drug|DRSP 3 mg/EE 20 µg (13 cycles)|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
46104267|NCT00461305|Drug|DRSP 3 mg/EE 30 µg (6 cycles)|1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
46104268|NCT04172129|Device|Total Hip Arthroplasty|
46104269|NCT04172051|Behavioral|Tony Robbins Date with Destiny|DWD is a 6-day immersive transformational experience led by Tony Robbins. It will be held at the PALM BEACH, FLORIDA Convention Center from December 5th through December 10th. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives.
46104270|NCT02666963|Drug|RTA 901 Capsules, 10 or 40 mg|
46104271|NCT02666963|Drug|Placebo|
46104272|NCT01022671|Drug|Belotecan|3.0 mg/m2, Day 1, 8, 15 every 4 weeks
46104273|NCT01022749|Drug|Vaccine|MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)
45467585|NCT04947501|Drug|Doxorubicin|"Administration of CDV - cycle 3 Days 1 & 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients >10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients >10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr."
46019853|NCT05561270|Device|White LED light|Exposure to white LED light for 1-2 hours/day x 10 weeks
46019854|NCT05561270|Device|Green LED light|Exposure to green LED light for 1-2 hours/day x 10 weeks
46019855|NCT01279850|Drug|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
46104274|NCT01022749|Biological|Vaccine anti-H1N1|patients who received the vaccine anti-H1N1
46104275|NCT02664623|Procedure|Individual dietary consultations|Individual dietary consultations with a dietician will be held at inclusion, month 1 and month 3. Consults consist of a personal interview where the dietician delivers comprehensive information to the patient on how to optimize calcium intake and reduce the risk of fractures; the dietician questions the subject on his/her diet and reassesses the quality and quantity of calcium intake during the 3 days preceding the consultation through a survey calculation software based on data from CIQUAL.
46104276|NCT02664623|Procedure|Dietary advice sheet|"At the beginning neurological consult, patients will be delivered a dietary advice sheet called Grio."
46104277|NCT01022827|Other|massage|For the massage group, a physical therapist with 8 years of clinical experience in manual therapy provided the massage on the posterior deltoid, infraspinatus, and teres minor of the involved shoulder for 18 minutes [about 6 minutes for each muscle and order was random] two times a week for 4 weeks. The techniques of massage included petrissage for 3 minutes and rolling for 3 minutes of soft tissues
46104278|NCT02664545|Device|BEAR Scaffold|A sponge, or scaffold, which is surgically placed between the torn ligament ends and sutures are used to repair the torn anterior cruciate ligament.
46104279|NCT02664545|Procedure|Tendon Graft|A graft of tendon (either two hamstring tendons from the back of the knee or bone-patellar tendon-bone graft from the front of the knee)
46104280|NCT01022905|Biological|Adjuvanted influenza A(H1N1) vaccines|Immunization (1-2 doses)
46104281|NCT00645905|Drug|adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded 40 mg eow through Week 48, withdrawal and observation for 360 days after last dose
46019856|NCT00949975|Drug|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
46104282|NCT00645905|Drug|placebo for adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded placebo eow through Week 48, withdrawal and observation for 360 days after last dose
46104283|NCT00647777|Drug|Olanzapine Tablets 5 mg|5mg, single dose fed
46104284|NCT00647777|Drug|Zyprexa® Tablets 5 mg|5mg, single dose fed
46104285|NCT04173611|Drug|EXPAREL|Injection into the Intrathecal space.
46104286|NCT04173611|Drug|Bupivacaine Hydrochloride|Injection into the Intrathecal space.
46104287|NCT04173611|Other|Placebo|Injection into the Intrathecal space.
45467586|NCT04947501|Drug|Ifosfamide|Administration of ICE - cycle 2 Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is <10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is <10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is <10 kg), IV over 2 hrs.
45681078|NCT01713933|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
46019857|NCT00949975|Drug|AZD9668|2 x 10 mg oral tablets twice daily (bid) for 12 weeks
46019858|NCT00949975|Drug|AZD9668|2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks
46019859|NCT00949975|Drug|AZD9668 Placebo|2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks
46019860|NCT00939055|Device|StomaphyX|Transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
46019861|NCT00939055|Procedure|Sham procedure|False procedure
46104288|NCT02664467|Device|Philips EnergyUp EnergyLight HF3419/01|Bright light therapy (10'000 lux) for 60 minutes after wake-up
46019862|NCT00602563|Behavioral|AMP|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word.
46019863|NCT00602563|Behavioral|Applied Relaxation (AR)|Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the physiological cues associated with anxiety and worry (Öst, 1987; Siev & Chambless, 2007)
46019864|NCT00602563|Behavioral|Clinical Monitoring (CM)|participants assigned to the clinical monitoring (CM) condition will receive the same information about the nature of GAD provided to participants in the active conditions
46019865|NCT00602563|Behavioral|Combining the AMP and AR|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word. Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways
46019866|NCT04268017|Device|FeetMe Monitor|"For gait parameters' evaluation, the investigator asks the participant to move in a straight line over a 10-meter mat. The participant had to start the feet in line and then start walking at a comfortable speed. During this time, the investigator records the gait parameters from the FeetMe Monitor® and Gaitrite® system.~An operator asked the patient to repeat 3 trials. The same sequence was repeated by three other operators. The same measurement is done 7 days later.~A questionnaire is given to assess the ergonomics of the device"
46019867|NCT00604357|Drug|anti-CD 25 mAb, Sirolimus, MMF|"Prior to reperfusion: 500 mg Prednisolone After OLT: anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure)~MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake)~Earliest, on day 10 after LT Sirolimus: 5 mg/d, thereafter a dosage of 2 mg/d (4 and 8 ng/mL)~Steroids: 1mg/kg BW (tapered every 2 days for 5 mg to a dosage of 20 mg, 2.5 mg every two days to 7.5 mg, reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter)."
46019868|NCT05381701|Procedure|Lung Ultrasound Score|Measuring the atelectasis area by ultrasound guidance from 12 different regions of the lung
46019869|NCT04269733|Device|Right ventricular pacing|Right ventricular pacing from a DDD pacemaker implanted due to high-degree AV block
46019870|NCT02854891|Other|autorefractometer, A-scan ultrasound|A measurement of refraction will be made by the Autorefractometer. A measurement of the eyes' biometer data will be made by A-scan ultrasound.
46104289|NCT02664467|Device|Philips EnergyUp EnergyLight HF3419/01|Placebo dim light (500 lux) for 60 minutes after wake-up
46019871|NCT00602719|Drug|Zolpidem|
46019872|NCT02854657|Behavioral|Skin Self- examination structured training|A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)
46019873|NCT00604435|Drug|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
46019874|NCT00604435|Drug|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
46104290|NCT02665715|Other|Low carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 30% Protein 30% Fat 40%
46104291|NCT02665715|Other|Standard carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 55% Protein 15% Fat 30%
46104292|NCT02665637|Drug|Trastuzumab|Each patient may receive single dose by intravenous infusion
46104293|NCT00647855|Drug|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
46104294|NCT00647855|Drug|Synthroid® Tablets 300 μg|2x300mcg, single dose fasting
46104295|NCT04062539|Device|Sentinel and Spider|Dual filter and single filter
46104296|NCT02666729|Procedure|AF Ablation with contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will be made aware of contact force data when performing procedure.
45467587|NCT04947501|Drug|Etoposide|"Administration of ICE - cycle 2~Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is <10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is <10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is <10 kg), IV over 2 hrs."
46104297|NCT02666729|Procedure|AF Ablation without contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will not be made aware of contact force data when performing procedure.
46104298|NCT04733183|Drug|Dacarbazine|Dacarbazine (DTIC), 1000 mg/m2 or 850 mg/m2 on Day 1 of every 21-day cycle (based on results and DSMB evaluation in the safety run-in part of the study)
46019875|NCT01136967|Drug|Lenvatinib|Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
46019876|NCT01218516|Biological|Farletuzumab|"Combination Therapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, farletuzumab (7.5 mg/kg) will be administered intravenously on Week 1 of all additional cycles.~Monotherapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
46104299|NCT04733183|Drug|onfekafusp alfa|L19TNF, 13 μg/kg, on Day 1, 3, and 5 of every 21-day cycle for a maximum of 6 induction cycles. Patients experiencing apparent or real benefit with minimal or acceptable toxicity from the first 6 cycles of treatment, can receive, at investigator's discretion, maintenance treatment of 13 μg/kg, on Day 1 every 21-day
46104300|NCT00648011|Drug|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fed
46019877|NCT01218516|Other|Placebo|"Combination Therapy: Placebo will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, placebo will be administered IV on Week 1 of all additional cycles.~Monotherapy: Placebo will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
46019878|NCT01218516|Drug|Carboplatin|Carboplatin will be administered intravenously to achieve area under the serum concentration-time curve of 5 to 6 mg/mL^min [AUC5-6].
46019879|NCT01218516|Drug|Paclitaxel|Paclitaxel 200 mg/m^2 will be administered intravenously.
46019880|NCT01218516|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 will be administered intravenously.
46019881|NCT01218516|Drug|Cisplatin|Cisplatin 75 mg/m^2 will be administered intravenously.
46104301|NCT00648011|Drug|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fed
46104302|NCT04173299|Procedure|early tips|patients with early tips
45467588|NCT04947501|Drug|Carboplatin|"Administration of ICE - cycle 2~Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is <10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is <10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is <10 kg), IV over 2 hrs."
46019882|NCT00938431|Drug|Lacosamide|Lacosamide oral solution (syrup) 10 mg/mL or 15 mg/mL
46104303|NCT04171973|Device|Driving an electric wheelchair in real condition|For the control group, 3 test circuits of pipes in real condition of increasing difficulty are tested. Patients perform 2 passes in this condition.
46104304|NCT04171973|Device|Driving an electric wheelchair in virtual condition|For the virtual reality group, the circuits have been digitized. Patients perform 2 passes in this condition.
46104305|NCT00646529|Drug|budesonide/formoterol (Symbicort)|
46104306|NCT00646529|Drug|budesonide (Pulmicort)|
46104307|NCT04171817|Drug|Chlorhexidine|The goal of this work is to assess the effect of chlorhexidine (CHX)-based interventions--specifically use of pre-session chlorhexidine shampoo for the dog and use of chlorhexidine wipes on the dog's fur--on patient exposure to hospital-associated pathogens during the sessions with the dogs
46104308|NCT00648089|Drug|EPO|Single Injection of 1000 U/kg Erythropoietin beta IV immediately after primary PCI
45467589|NCT04947501|Drug|Mesna|"Administration of CTV - cycles 1 and 4 Mesna 70 mg/kg (2100 mg/m2/day for patients >10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Administration of ICE - cycle 2 Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion.~Administration of CDV - cycle 3 Mesna 70 mg/kg ((2100 mg/m2/day for patients >10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion."
45467590|NCT03707808|Drug|intratumoral injection of autologous CD1c (BDCA-1)+ myDC|intratumoral injections plus intravenous administration
45467591|NCT03467074|Biological|influenza A/B vaccine|Regardless of the study enrollment, a two-time influenza vaccination at the start of the flu season is recommended every 4 weeks for all patients after stem cell transplantation. The vaccine is a trivalent inactivated non-adjuvanted influenza virus vaccine containing two influenza A viruses: pandemic H1N1, and H3N2, and an influenza B virus
45467592|NCT03091400|Drug|Atomoxetine|Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
46019883|NCT02851927|Procedure|Mini Thoracoscopy|Pleural biopsy using rigid mini thoracoscope
46019884|NCT02851927|Procedure|SemiRigid Thoracoscopy|Pleural biopsy using semirigid thoracoscope
46104309|NCT00646607|Drug|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|To assess whether a 3-month FOLFOX-4 treatment is at least equivalent to a 6-month FOLFOX-4 treatment
46104310|NCT00646607|Drug|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|standard treatment
46104311|NCT02666885|Radiation|Integration of PET/MRI in radiotherapy|Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
46104312|NCT02664389|Genetic|Genetic analysis|Sequencing of 200 selected genes in the different study populations
46104313|NCT00856544|Drug|CP-690,550|Film coated tablet, 5 mg PO BID, 1 year
46104314|NCT00856544|Drug|CP-690,550|Film coated tablet, 10 mg PO BID, 1 year
46104315|NCT00856544|Drug|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
46104316|NCT00856544|Drug|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
46104317|NCT02664233|Behavioral|Mobile and connected health|Patients will use a smart phone and a fitness tracker for self-monitoring of diet and physical activity for 3 months; 3) Smart phones will provide feedback with graphical presentation of self-monitored information to patients; 4) Patient self-monitored information will be integrated into Chronicle Diabetes, so that educators will be able to view this information and give feedback in a follow-up visit.
46104318|NCT00646685|Procedure|surgical technique: duct-to-duct biliary reconstruction|surgical reconstruction
46019885|NCT05381545|Behavioral|laser puncture, energy expenditure programming, and low-calories recommended diet programming|This research group will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week) combined with low calorie diet .This research group will receive an additional laser puncture (with 3-time per-week design). The following points will be directly contacted by laser, for two minutes: GB34&28, ST25&36&40, SP6, and CV4&9&12.
46019886|NCT05381545|Behavioral|energy expenditure programming and low-calories recommended diet programming|This research group will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week) combined with low calorie diet.
46019887|NCT04312815|Drug|SM03|SM03: 600 mg intravenous (IV)
46019888|NCT04312815|Drug|Placebo|Placebo: 600 mg intravenous (IV)
45467593|NCT03091400|Drug|Placebo|Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
46019889|NCT04312815|Drug|MTX|Methotrexate: 7.5-20 mg/wk oral
46019890|NCT05381389|Drug|Bupivacaine Hydrochloride in-plane approach for the interscalene block|20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an in-plane approach to the brachial plexues
46019891|NCT05381389|Drug|Bupivacaine Hydrochloride out of-plane approach for the interscalene block|20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an out of-plane approach to the brachial plexues
46019892|NCT01136811|Device|Computer assisted surgery|"use of computer assisted surgical device in vascular surgery~completion of the proximal (femoral) anastomosis portion of a lower extremity bypass procedure"
46019893|NCT00949117|Dietary Supplement|Ensure|Given orally
46019894|NCT00949117|Dietary Supplement|PediaSure|Given orally
46019895|NCT00949117|Drug|cyproheptadine hydrochloride|Given orally
46019896|NCT04312347|Drug|Tamoxifen dose adjustment|Patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype will receive tamoxifen dose escalation into 40 mg/day.
46019897|NCT04269811|Drug|Flu-Bu-Mel|5-day fludarabine + 2-day busulfan (3.2mg/kg) + 2-day melphalan (50-70mg/m2)
46019898|NCT00631267|Procedure|Manual Manipulation|The currently used method for reduction: using manual traction to reduce the distal radial fragment by hyperextension followed by hyperflection.
46019899|NCT00631267|Procedure|Finger Trap Traction|Using a finger trap traction device in vertical suspension. After 10min reduction by dorsal pressure.
46104319|NCT00646685|Procedure|surgical technique: roux-en-y biliary reconstruction|surgical reconstruction
46104320|NCT02663921|Other|Part A: Baseline-Week 2|"The study doctor will shine 2 different light bulbs (one a regular or incandescent bulb and the other an LED light bulb) on 12 different areas of patients skin approximately 6 square centimeters in size (less than 1 square inch or the size of your thumb nail). Each light bulb will be exposed to your skin for approximately 20 - 35 minutes. After exposure, the study doctor will perform skin assessments at 3 time points:~Immediately after the light exposure;~30 minutes after light exposure; and~1 hour after light exposure."
46104321|NCT02663921|Other|Part B: Week 4-Week 12|"The study doctor will perform the same 4 skin assessments used in Part A at each visit to assess potential changes in your skin: Digital Photography~Visual Clinical Assessment~Spectroscopy~Colorimetry"
46104322|NCT00648245|Drug|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered once per day for 21 days by nebulizer
46104323|NCT00648245|Drug|BIO-11006 Inhalation Solution|150 mg of BIO-11006 administered once per day for 21 days by nebulizer
46104324|NCT00648245|Drug|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered twice per day for 21 days by nebulizer
46104325|NCT00648245|Drug|Placebo|Placebo given once daily for 21 days by nebulizer
46104326|NCT00648245|Drug|BIO-11006|125 mg BIO-11006 given twice per day for 21 days by nebulizer
46104327|NCT00648323|Drug|Doxazosin mysylate GITS|Subjects initiated on 4 mg doxazosin GITS once daily at Visit 1 for four weeks. At Visit 2 (Week 4) increased to 8 mg Doxazosin GITS if efficacy response criteria not met.
46104328|NCT00648557|Drug|Levothyroxine Sodium Tablets 200 mg|3x200mcg, single dose fasting
46104329|NCT00648557|Drug|Synthroid Tablets 200 mg|3x200mcg, single dose fasting
46104330|NCT04170569|Behavioral|Yoga|Yoga Practice and Program: Yoga practice consisted of 10 weeks. Yoga practice involved following stages; 5-minute breathing exercises in standing or sitting position, 40-minute postpartum period specific asanas and last 15- minute deep relaxation in lying position were made by the researcher.
45467594|NCT04716634|Drug|Tislelizumab|Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD 1.
46019900|NCT00938041|Biological|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
46104331|NCT00856388|Drug|fludarabine phosphate|Given IV
46104332|NCT00856388|Drug|melphalan|Given IV
46104333|NCT00856388|Radiation|total-body irradiation|Undergo total-body irradiation
46104334|NCT00856388|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
46104335|NCT00856388|Biological|anti-thymocyte globulin|Given IV
46104336|NCT00648401|Drug|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fed
46104337|NCT00648401|Drug|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fed
46019901|NCT00604513|Other|Ready. Set. ACTION! Protocol|"The intervention included three components: theater sessions; booster sessions; and family outreach. After-school theater sessions were conducted in the fall in the intervention schools. Sessions included: a check-in about changes made over the past week; healthy snacks; a movement component that involved fun and easy activities; and creating/education. Children at intervention schools participated in weekly after-school booster sessions in the winter to further address the behavioral messages addressed during the intervention. Throughout the program, weekly Fun & Fitness packs were sent home to families that included a healthy food with a simple recipe using that food or fitness incentives for the family. There were also two family events: a theater performance, and a reception."
46019902|NCT00604513|Other|Control|The control condition also participated in a theater-based intervention that addressed a health topic unrelated to weight, hand-washing and overall personal hygiene.
46019903|NCT05381233|Other|Gross motor function classification System (GMFCS)|assessment
46019904|NCT05381233|Other|Arabic Version of Zarit burden Inventory measure|assessment
46019905|NCT05381233|Other|Arabic Version of Chalder Fatigue Scale (CFQ version 11)|assessment
46019906|NCT04266691|Other|nonIntervention|nonIntervention
46019907|NCT02851693|Device|Optical Coherence Tomography (OCT) with Vivosight|OCT used is Vivosight for diagnosis
46019908|NCT02851693|Device|Optical Coherence Tomography (OCT) with Skintell|OCT used is Skintell for diagnosis
46019909|NCT05379283|Drug|Lidocaine|effect of lidocaine on sweat production during exercise in the heat
46019910|NCT05379283|Other|control|one arm will be pretreated with topical lidocaine, the other arm will not
46019911|NCT02851849|Drug|LGD-6972-5 mg|5 mg LGD-6972 QD
46019912|NCT02851849|Drug|LGD-6972-10 mg|10 mg LGD-6972 QD
46019913|NCT02851849|Drug|LGD-6972-15 mg|15 mg LGD-6972 QD
46019914|NCT02851849|Other|Placebo|Placebo QD
45467595|NCT04716634|Drug|Fruquintinib|Fruquintinib is a potent, oral VEGFR tyrosine kinase inhibitor (TKI)
46019915|NCT01218438|Biological|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion with IGIV, 10%
46019916|NCT01218438|Drug|Immune Globulin Subcutaneous (Human), 20% Solution|Subcutaneous infusion with IGSC, 20%
46019917|NCT00605995|Drug|Simvastatin|20 mg taken orally once daily for the first 4 weeks. Dosage will be increased to 40 mg/day at the end of week 4.
45599250|NCT02344095|Drug|weekly cisplatin|Patients are treated with weekly cisplatin 40mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks.
45681079|NCT03759106|Other|home written exercise program|exercises such as picking up objects, placing objects, frequently prescribed at discharge
46019918|NCT05381077|Other|MRI|Whole body MRI (ZTE sequence)
46019919|NCT00604591|Drug|Tolcapone|200 mg by mouth three times a day
46019920|NCT00604591|Drug|Placebo|200 mg by mouth three times a day
46019921|NCT04204291|Procedure|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
46019922|NCT05380999|Diagnostic Test|Methylation tests of nucleic acids extracted from mature red blood cells (RBCs)|Up to 15 ml of peripheral blood will be collected from each subject, and the blood specimen will be processed to isolate mature red blood cells and extract the DNA and RNA from RBCs. DNA and RNA methylation will be tested by next-generation sequencing (NGS).
46019923|NCT00606073|Other|Universal IVF Medium + ISM1 Medium|Sibling oocytes will be equally divided and incubated separately in different 4-well culture dishes containing either IVF medium or ISM1 Medium and while ICSI will be returned to the same culture dish following injection. Fertilization assessment will be performed approximately after 15-20 hours for standard IVF and 12-18 hours post ICSI performance. After assessment, fertilized oocytes from different culture media will be transferred separately into fresh culture dishes containing ISM1 medium only. The zygotes will be incubated until embryo transfer on day 2 or 3. Embryo quality will be assessed according to the morphology of blastomeres as well as it's developmental stage.
46019924|NCT02691156|Diagnostic Test|Bilirubin Binding Capacity|Research laboratory assay of bilirubin binding capacity
46019925|NCT02691156|Diagnostic Test|End-tidal Carbon Monoxide|Noninvasive bedside test to measure exhaled end-tidal carbon monoxide levels for the detection of hemolysis
46019926|NCT02691156|Diagnostic Test|Carboxyhemoglobin|Laboratory assay of carboxyhemoglobin levels for the detection of hemolysis
46104338|NCT04132154|Procedure|Convective Forced-Air Active Warming|Underbody Blanket Model 585 of the 3M BairHugger Series
46019927|NCT05379205|Behavioral|Prehabilitation program (4 week before the surgery)|This intervention will include 3 complementary modules: (i) supervised physical exercise: aerobic and strength High Intensity Interval Training (HIIT), 3 times per week (ii) dietary behavior change: nutritional talk + an informative brochure + a video summary, a session per week and (iii) psychological support: psychoeducation, written and verbal emotional expression, promotion of coping strategies, progressive muscle relaxation training, problem-solving and social skills, and self-efficacy enhancing, among others. This psychological component will also include counseling regarding smoking and alcohol cessation and sleep hygiene.
46019928|NCT05379205|Behavioral|Postoperative program (12 week after the surgery)|"This intervention will include 3 complementary modules: (i) supervised physical exercise: aerobic and strength High Intensity Interval Training (HIIT), 3 times per week (ii) dietary behavior change: nutritional talk + an informative brochure + a video summary, a session per week and (iii) psychological support: psychoeducation, written and verbal emotional expression, promotion of coping strategies, progressive muscle relaxation training, problem-solving and social skills, and self-efficacy enhancing, among others. This psychological component will also include counseling regarding smoking and alcohol cessation and sleep hygiene.~NOTE: Both preoperative and postoperative programs will be administer to the participants assigned to the intervention group."
46104339|NCT02660099|Behavioral|Internet-delivered Cognitive Behavior Therapy|The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet platform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks. Both parents and adolescents are involved in treatment. Parents will also receive three lectures on 1, Autism spectrum disorder, 2, CBT and functional analysis and 3, Parental strategies
46104340|NCT02663999|Drug|diazepam nasal spray|diazepam nasal spray at two dose levels (DL). One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
46104341|NCT00648479|Device|The Guiding Star|
46104342|NCT00648479|Device|fluoroscopy (OEC 9800 - General Electric)|
46104343|NCT04169087|Other|QoR-15|The QoR-15 is the questionnaire to provide an evaluation of the postoperative quality of recovery. Patients undergoing surgery and general anesthesia are asked by the investigators to complete the QoR-15 questionnaire before and 24h after the surgery.
45467596|NCT05197452|Behavioral|COVID-19 Testing|"For in-person PCR testing, a nasal swab will be inserted shallowly into the participant's nose and rotated in each nostril. The swab will be broken off into a designated test tube and placed into a specimen bag along with a label. All specimens will be stored in a cooler until they are transported the Rush Laboratory for COVID-19 analysis.~For at home antigen testing, participants will download an app to their mobile phone and watch an informational video. The test will be self-administered by inserting a nasal swab into the nostril until a cap containing the swab touches the nose; rubbing the swab tip around the nose cavity 3 times; removing the swab and repeating in the other nostril. The nasal swab, a dropper, processing fluid, and a blue tooth connected analyzer are provided with the testing kit to analyze the sample for COVID-19. COVID-19 home test results are displayed on the participants smart phone after 15 minutes."
45467597|NCT05595668|Behavioral|Prism Adaptation - 15-degree prism goggles|Patients in the experimental condition will wear prism goggles while completing an iPad-administered aiming task. The prisms will shift the patients' vision 15 degrees rightward, causing a recalibration of visuo-motor information. Prism adaptation will be carried out for ten sessions for 15 minutes a day, over the span of two weeks.
46104344|NCT04171427|Other|Lithium liposome|Cosmetic product
46104345|NCT04171427|Other|Placebo|Cosmetic product vehicle
46104346|NCT04171739|Drug|Itraconazole oral solution|200 mg once daily on Days 6 to 15
46104347|NCT04171739|Drug|Rifampicin Oral Capsule|600 mg once daily on Days 6 to 15
46104348|NCT04171739|Drug|Olorofim|Single oral dose on Days 1 and 11
46104349|NCT02656043|Drug|XPF-005|Comparison of active treatment XPF-005 topical gel against Placebo (XPF-005 Vehicle Gel) applied to face for acne vulgaris.
46104350|NCT02656043|Drug|Placebo|
46104351|NCT02656277|Other|Decision Tool|
46104352|NCT02656277|Other|Information on Shoulder Dislocation|
46104353|NCT02656121|Drug|Vitamin D|6000 IU of vitamin D3
46104354|NCT02656121|Drug|Ovulatory Agent|only Clomophine Citrate
46104355|NCT04533815|Behavioral|LOCK sleep intervention|Nursing home staff are trained to use a collaborative problem-solving approach to sleep quality improvement using front-line huddling
46104356|NCT02659865|Drug|Placebo|Administered orally
46104357|NCT02659865|Drug|LY3039478 original formulation|Administered orally
46104358|NCT02659865|Drug|LY3039478 new formulation|Administered orally
46104359|NCT02656355|Other|Weight shift training and APA feedback|Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.
46104360|NCT02656355|Other|Weight shift training without APA feedback|Use COP trajectory to train weight shift on force plate.
46104361|NCT04169555|Procedure|Ultrasound|"The emergency physician will perform a point of care ultrasound. If signs of expansions of the pelvicalyceal cavities are found, an early CT scan will follow"
46019929|NCT05379205|Other|Usual Care|Usual care group will follow the usual institutional pre-surgery care: (i) medication management, (ii) assessment of the surgery-derived risks, (iii) smoking cessation and peri-operative blood management. A trained nutritionist will evaluate the nutritional status of all patients at the baseline providing oral protein/vitamin supplementation, when necessary. Patients allocated to the control group will receive basic expert' advice on lifestyle changes.
46019930|NCT00603031|Other|glucagon like peptide -1|continuous infusion 1,2 pmol pr. kg pr minute at 120 minutes
46019931|NCT00603031|Other|NaCl|infusion with NaCl for 120 minutes as placebo-arm
45467598|NCT05595668|Other|Prism Adaptation - 5-degree prism goggles|5-degree goggles are worn instead of the 15-degree prism goggles, while completing the same tasks as those assigned to the 15-degree condition.
46019932|NCT00603031|Other|glucose dependent insulinotropic polypeptide|continuous infusion with GIP-1 (3,6pmol/kg/min) at 120 minutes.
46019933|NCT04268329|Other|Educational website|A website is used to educate patients and family members about head and neck cancer.
46019934|NCT00935701|Device|Acupressure and Acupuncture|Acupressure involves the stimulation of specific acupoints by firm pressure, while acupuncture involves the insertion of very fine needles (the size of a strand of hair). The needles may be quickly inserted and removed or left in up to 5 minutes at a time.
46019935|NCT02851537|Other|an advanced technique as magnetic resonance spectroscopy (MRS)|subjects who had an advanced technique as magnetic resonance spectroscopy (MRS) It is based on the detection of cerebral metabolites, and the variations of their concentration to characterize different pathologies.
46019936|NCT05379049|Biological|Infliximab: Adalimumab; Etanercept;|Therapeutic drug monitoring, evaluation of clinical outcomes and laboratory analysis of biomarkers
45467599|NCT01318993|Drug|GSK1605786A|500 milligrams twice daily
46019937|NCT04266613|Diagnostic Test|TruGraf® Testing|5 mL collection PAXgene blood sample
46019938|NCT00604747|Other|Structure practice|there were 2 groups which received random practice and constant practice during acquisition phase
46019939|NCT04268095|Other|Dressing protocol|Patients are assigned with different postoperative dressing protocols.
46019940|NCT02851459|Behavioral|Baseline Survey|The baseline survey contains questions regarding level of existing vaccine hesitancy (Parent Attitudes about Childhood Vaccines (PACV) short scale and HealthStyles questions), demographic information, and intent to vaccinate their children. All study surveys will be completed on an electronic device.
46019941|NCT02851459|Behavioral|Pre-intervention Survey|Participants will be contacted two weeks after completing the baseline survey to answer questions about their moral beliefs. The survey will include questions form the Moral Foundations Questionnaire as well as additional questions. An algorithm will calculate the participant's moral matrix based on answers to these questions.
46019942|NCT02851459|Behavioral|Morally Congruent Message|"Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations. The fourth summarizes the contents of the prior paragraphs.~Participants randomized to the morally congruent arm will receive a vaccine-related message developed to appeal to their three most-emphasized moral foundations. The first paragraph focuses on the most emphasized foundation, the second on the third-most emphasized, and the third on the second-most emphasized."
46019943|NCT02851459|Behavioral|Morally Non-Congruent Message|"Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations.~Participants randomized to the morally non-congruent arm will receive a vaccine-related message developed to appeal to their three least-emphasized moral foundations. The first paragraph focuses on the least emphasized foundation, the second on the third-least emphasized, and the third on the second-least emphasized."
46019944|NCT02851459|Behavioral|Control Message|Participants randomized to the control arm will be provided with a short passage about the costs and benefits of bird feeding.
46019945|NCT02851459|Behavioral|Post-Intervention Survey|Immediately after reading the randomly assigned message participants will complete a follow-up survey assessing level of existing vaccine hesitancy (PACV short scale and HealthStyles questions) and intent to vaccinate their children.
45467600|NCT02761070|Drug|Temozolomide|
45467601|NCT02761070|Drug|Bevacizumab|
45467602|NCT03466840|Procedure|The coronally advanced lingual flap|": A full-thickness crestal incision is performed from the distal surface of the more distal tooth to retromolar pad and finishing with releasing incision. On the lingual side, a full-thickness muco-periosteal flap was elevated until reaching mylohyoid line. Then using a blunt instrument, it was localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. It is inserted into the inner part of the lingual flap about 5mm from the crest in an apical direction. The blunt instrument is inserted below the connective band, and with gentle traction in the coronal direction, this muscular insertion was detached from the lingual flap. Using a periodontal probe, the amount of advancement is measured."
45599251|NCT02344095|Device|oncothermia|"Thermotherapy is performed by applying oncothermia (EHY 2000) probe on the part of body where tumor is located and delivering energy. It is performed on day 1, 4, 8, 11, 15, 18, 21, and 24 (8 times in total every cycle). Oncothermia can be performed a day earlier than scheduled day or a day later than scheduled day. With tumors at multiple sites, oncothermia is performed several times changing sites that apply probe and type of probes.~- It takes 60 minutes to treat a site for oncothermia. Energy is gradually increased from 60W to 140W."
46104362|NCT04169555|Other|Standard care|Standard clinical care of patients. In regards of the clinical evolution and of biological results, a CT scan could be performed by the physician.
46104363|NCT02659553|Procedure|steatosis|Liver Transplantation with graft steatosis
46104364|NCT00648713|Drug|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fed
46104365|NCT00648713|Drug|Lamisil® Tablets 250 mg|250mg, single dose fed
46104366|NCT02659319|Behavioral|Family Lifestyle (FL)|12-week Family Food & Lifestyle intervention, aimed at improving family nutritional intake, activity levels, weight perception, and parental monitoring of child eating. Material is delivered in psychoeducational groups in the children's schools.
46104367|NCT02659319|Behavioral|Family Dynamics (FD)|The Family Dynamics intervention focuses on positive parenting (i.e., emotion coaching, praise, limit setting) and on child emotion regulation and positive problem solving. Material is delivered in psychoeducational groups in the children's schools.
46019946|NCT05378815|Procedure|PRP injection|3 weekly intra-articular injections of 5mL PRP under ultrasound guidance
46019947|NCT05378815|Procedure|Placebo injection|3 weekly intra-articular injections of 5mL NaCL under ultrasound guidance
46019948|NCT00603343|Drug|Mictonetten 5 mg, coated tablet|propiverine 10 mg b.i.d. (17-27.9 kg BW) or propiverine 15 mg b.i.d. (28-45.0 kg BW)
46019949|NCT00603343|Drug|placebo|placebo corresponding to body weight
46019950|NCT04266535|Device|Target controlled infusion|Target controlled infusion vs manually controlled infusion
46104368|NCT02659319|Behavioral|Peer Group (PG)|Peer Group intervention conducted throughout one semester of the school year that includes 12 sessions of a guidance-type curriculum during class time sensitizing children to the importance of social inclusion of all children
45467603|NCT03466840|Procedure|Modified periosteal releasing Incision|"A full-thickness muco-periosteal flap is reflected on the buccal side. Near the base of muco-periosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade, or a blunt instrument, with sweeping motion. This motion helps stretching the flap over the submucosa, thereby permitting the flap to be mobile.Using a periodontal probe the amount of advancement is measured."
45467604|NCT05308719|Device|High Flow Nasal Therapy|High Flow Nasal Oxygen (Airvo2 Device)
45467605|NCT03466762|Other|Non applicable|Non applicable
45467606|NCT05587868|Biological|COVID-19 Vaccine|Mandatory COVID-19 vaccination as part of the the Indonesian national government program.
45467607|NCT05175300|Device|Prosthesis with a second-generation ceramic-on-highly cross-linked polyethylene (CoPXE) couple.|Prosthesis with a second-generation ceramic-on-highly cross-linked polyethylene (CoPXE) couple.
46104369|NCT00649883|Biological|Influenza Trivalent Inactivated vaccines Novartis|Children 6 to <36 months of age will receive two 0.25 mL doses, and children 36 to <60 months of age will receive two 0.5 mL doses of investigational influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
45467608|NCT05175300|Device|Prosthesis with ceramic-on-ceramic (CoC) torque.|Prosthesis with ceramic-on-ceramic (CoC) torque.
45467609|NCT04714671|Other|The virtual version of the Social stress task : V-TSST|The task consists in a brief presentation about the abilities of participants followed by an arithmetic task in front of a virtual 3D audience projected and one researcher in a small room.First, participants have 5 minutes to prepare an exhibition about their qualities, their strengths and defects, and, why they identify with them. During this period virtual reality shows a closed curtain, and sounds from the audience can be heard. In the second phase, the curtain is raised and the participant must expose his speech during 5 minutes. Audience will remain attentive during 2 minutes, then audience will change to a restless attitude. The third phase consists of subtracting back a two-digit number from a four-digit number, as quickly as possible, starting again if participant makes a mistake. A debriefing of the test is scheduled at the end of the protocol, to remind patients of the purely fictional nature of this test. The visit will only end after a return to the baseline emotional state
45681080|NCT03759106|Other|telerehabilitation/exergame system|Video games using the Kinect camera that are carried out using the impaired arm and monitored by a therapist by videoconferencing
46019951|NCT00606385|Procedure|Liver resection|Laparoscopic or Open hepatectomy
46019952|NCT05378659|Behavioral|Montreal Cognitive Assessment|Cognitive evaluation of short term memory, visuospatial abilities, executive functioning, attention, concentration, working memory, language, and orientation to time and place
46019953|NCT05378659|Behavioral|Stroop Test|Evaluates Processing Speed and Executive Control
46019954|NCT05378659|Diagnostic Test|4AT Delirium|Screening tool to test for delirium post surgery
46019955|NCT05378659|Behavioral|Grooved Pegboard|Evaluation testing for dominant and non dominant sensory-motor speed
46019956|NCT05378659|Behavioral|NACC Cognitive Battery|A series of tests that evaluate attention, concentration, immediate verbal memory, immediate visual memory, discrimination, processing/motor speed, and validity and effort.
46019957|NCT05378659|Diagnostic Test|ERP Testing|An event-related potential ( ERP) is the measured brain response that is the direct result of a specific sensory, cognitive, or motor event. More formally, it is any stereotyped electrophysiological response to a stimulus. The study of the brain in this way provides a noninvasive means of evaluating brain functioning.
46104370|NCT00649883|Biological|Influenza Trivalent Inactivated vaccines|Children 6 to <36 months of age will receive two 0.25 mL doses, and children 36 to <60 months of age will receive two 0.5 mL doses of active control influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
46104371|NCT00648791|Drug|Finasteride Tablets 5 mg|5mg, single dose fasting
46104372|NCT00648791|Drug|Proscar Tablets 5 mg|5mg, single dose fasting
46104373|NCT02655809|Radiation|Fluoroscopic examination|
46104374|NCT00649181|Drug|Metolazone Tablets 5 mg|2x5mg, single dose fasting
46104375|NCT00649181|Drug|Zaroloxyn® Tablets 5 mg|2x5mg, single dose fasting
46104376|NCT02659475|Drug|PHEN/TPM ER (Qsymia®)|PHEN/TPM ER (Qsymia®)
45467610|NCT03466684|Other|BIA-guided fluid resuscitation protocol|"In both groups, a multi-frequency BIA with eight tactile electrodes (Inbody S10 Biospace, Biospace Co. Ltd., Seoul, Korea) was used to assess body fluid status every 6h within the first 72h after admission to the ICU and daily for a period of 4 days.~BIA recording was not adjusted by clinicians in fluid restrict, pharmacological and mechanical means of therapy.~In contrast, in group BIA, fluid resuscitation protocol with adjustment determined according to HL measured by BIA."
45467611|NCT03466684|Other|Traditional fluid resuscitation protocol|Traditional fluid resuscitation strategy determined by treating clinicians according to usual clinical parameters.
46019958|NCT05378659|Diagnostic Test|Blood Plasma and Serum sampling|Up to six 4 ml samples of both serum and plasma will be obtained to assess for inflammatory markers.
46104377|NCT04170257|Diagnostic Test|Endoscopic examination using white light, NBI and iodine staining|Participants' esophagus will be examined by three commonly used diagnostic techniques in the order of : 1. White light endoscopy (WLE); 2. Narrow Band Imaging (NBI) and 3. Iodine Staining Endoscopy (ISE) with 1.2% Lugol's iodine solution. The required observation time is no less than 1 minute for WLE and 2 minutes for NBI and ISE. Endoscopic images of each participant are routinely captured at every 5 centimeters in the esophagus, and information is recorded in detail for each focal lesion. Biopsies are taken from all visually abnormal areas found by any one of the three techniques, histopathologic diagnoses are rendered by two pathologists according to standard criteria and discrepancies are adjudicated by consultation. The recorded endoscopic images for each biopsied lesion are read by two trained researchers and the visualized feature of lesions are decomposed into several indicators (e.g. size, shape, color, and border of lesions) .
46019959|NCT05378659|Diagnostic Test|Cerebral Spinal Fluid Sample|At the time the spinal is placed for anesthetic purposes, 2ml of cerebral spinal fluid will be obtained to assess for inflammatory markers.
46019960|NCT01277510|Drug|cinacalcet capsule|Cinacalcet was prepared for oral administration as both capsules for sprinkling and film coated tablets for swallowing.
46019961|NCT01277510|Drug|placebo|Placebo tablets and capsules for sprinkling identical to active treatment.
45838154|NCT04598711|Behavioral|Muscle Power training|All participants undergo power training of the quadriceps muscles using unilateral and bilateral leg presses (Total Gym GTS, San Diego, CA), 3 times/week for 4 consecutive weeks (12 sessions). Power training will follow standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Power training is provided at visits 3-14.
45838155|NCT04598711|Behavioral|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-14.
46104378|NCT02655731|Device|PVI with HeartLight|Catheter ablation
46104379|NCT02663843|Device|i-gel airway|Fibreoptic intubation via i-gel airway device
46104380|NCT02663843|Device|air-Q airway|Fibreoptic intubation via air-Q airway device
46104381|NCT04444427|Drug|GLR2007|Administered orally, once daily for 21 days followed by a 7-day treatment holiday.
46104382|NCT02655965|Drug|Ropivacaine|Ropivacaine 3.5 mg/ml
46104383|NCT02655965|Drug|Clonidine|Clonidine 5µg/ml
46104384|NCT02655965|Drug|Sodium Chloride|Sodium Chloride 0.9 %
46104385|NCT04170179|Procedure|Systemic chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the peripherally inserted central catheter every 3 weeks
45467612|NCT05175222|Radiation|Laser therapy|Patients receive laser therapy in 7 points in oral cavity every day from the first day of conditioning chemotherapy till the second day post HSCT. Each point is irradiated for 1 minute.
46019962|NCT01277510|Drug|Standard of Care|All participants, regardless of treatment assignment, will receive standard of care with vitamin D sterols (calcitriol and its analogs), as prescribed by the treating physician.
46019963|NCT05380765|Behavioral|Native PATHS|A strengths-based, behavioral economic approach to increasing engagement and reinforcement for engaging in alternative activities.
45467613|NCT03466606|Behavioral|pre-habilitation|Personalized supervised resistance training and program to promote physical activity and healthy lifestyles
45838156|NCT04598711|Behavioral|Treadmill Training|All participants will undergo short burst interval treadmill training using self-selected and fast walking speeds.
46019964|NCT04323332|Drug|Traditional Chinese Medicine Prescription|Traditional Chinese Medicine Prescriptions have been recommended according to the Guidelines for the treatment of COVID-19 issued by National Health Commission of the PRC.
46019965|NCT00937495|Drug|vorinostat|400 mg given PO
46019966|NCT00937495|Drug|bortezomib|1.3 mg/m^2 given IV
46019967|NCT04323488|Behavioral|Lindamood-Bell Seeing Stars|Seeing Stars in a curriculum developed by Lindamood-Bell. It is published and openly available. It involves systematic training in the building blocks of skilled reading.
46019968|NCT00603421|Other|24 hour phone line|24 hour phone line is available as soon as the patient himself feels necessary. This phone line is supported by professionals of mental health, all specialised in borderline personality disorder
46019969|NCT00603421|Other|treatment as usual|Treatment as usual
46019970|NCT05378581|Device|Virtual reality mask|virtual reality mask Deepsen® with age-appropriate software Birdy®
46019971|NCT05378581|Other|control arm|usual process
46019972|NCT02851381|Drug|FG-3019|"The FG-3019 treatment will be administered over a 28-day cycle:~Dose: 35 mg/kg~Route: IV over one hour following completion of gemcitabine infusion~Schedule:~Days 1, 8, and 15~Please note that Day 8 infusion will on be completed during the first treatment cycle"
46104386|NCT04170179|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
46104387|NCT04170179|Drug|Toripalimab|240mg intravenously every 3 weeks
45467614|NCT04686903|Procedure|Epiduroscopy treatment|Device Epiduroscop, procedure mecahnical lysis, laser, radiofrequency + drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline) Follow-up: before procedure, 6 months and 12 months after procedure
45599252|NCT00157339|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 12 months
45599253|NCT00157339|Drug|injected insulin|patient specific dose, injected, before meals, 12 months.
46019973|NCT01268306|Device|B+L Biotrue MPS and B+L PureVision|Subjects use Bausch & Lomb (B+L) Biotrue MPS with B+L PureVision contact lenses
46104388|NCT02659163|Behavioral|mHealth wristband|A wristband containing several sensors worn by participants to collect daily objective patient-generated health behavior data on physical activity, sleep, and screen time
46104389|NCT02659163|Behavioral|mHealth scale|A wireless scale used by participants to measure and record daily weight.
46019974|NCT00606463|Device|Cardiac Ablation (Gen2 Cardiac Ablation System)|Ablation of isthmus-dependent atrial flutter
46019975|NCT04265833|Other|Biodentine|Biodentine has been shown to cause increased calcium ion release and this increase has been associated with the presence of pure tricalcium silicate and calcium chloride and the increased Ca(OH)2 formation
46104390|NCT02659163|Behavioral|EMA|Self-reported information on sugar sweetened beverage consumption collected via mobile messaging
46104391|NCT02659163|Behavioral|mHealth app|A mobile application that houses study data and provides two-way messaging between the study team and study participants.
45467615|NCT04686903|Procedure|Racz catheter epidural procedure|"Device Racz catheter, two procedures during clinical trial observation~First procedure after enrolment into the study mechanical lysis and drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)~Second procedure after 6 months mechanical lysis + drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)"
46104392|NCT02659163|Behavioral|Health Behavior Feedback|Provide feedback on patient-generated health behaviors data, along with standard of care recommendations, for self-guided
45467616|NCT04686903|Procedure|Caudal epidural block|"Technique Caudal epidural block~Three procedures during clinical trial observation :~First procedure after enrolment into the study drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)~Second procedure after 4 months drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg)~Third procedure after 8 months drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg)"
45467617|NCT04673422|Drug|Montelukast|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
45467618|NCT04673422|Drug|Placebo|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
45467619|NCT03090152|Procedure|Periarticular injection (Deep injection)|"Deep injection of cocktail containing Bupivacaine with Epi, 30mL; Morphine, 8mg/mL, 1mL; Methyprednislone, 40mg/mL, 1mL; Cefazolin, 500mg in 10 mL; saline, 22mL into the anterior capsule, the periosteum, the gluteus maximus, and the abductor muscles and fascia lata."
45467620|NCT03090152|Procedure|Periarticular injection (Superficial injection)|Superficial injection of 40mL 0.25% Bupivacaine into subcutaneous tissue prior to wound closure.
45467621|NCT03090152|Drug|Bupivacaine|EPCA: Bupivacaine 0.06%.
45467622|NCT03090152|Drug|Placebo|EPCA: Saline.
45467623|NCT03706404|Diagnostic Test|Point-of-Care ultrasound and testing|Point-of-Care ultrasound + Point-of-Care blood gas testing
46104393|NCT02659163|Behavioral|Integrated closed-loop feedback system|Daily feedback and weekly e-report cards on patient-generated longitudinal health behaviors along with clinical recommendations via mobile messaging
46019976|NCT04265833|Other|TheraCal LC|TheraCal LC (Bisco Inc, IL, USA) is a light-cured, resin-modified, calcium silicate-based material designed as a direct/indirect pulp-capping material. This agent has been shown to increase the pH on the pulpal surface thereby stimulating regenerative processes in the pulp, and ultimately contributing to the formation of dentin bridge
46019977|NCT04265833|Other|Calcium hydroxide|Calcium hydroxide (Ca[OH]2) is a successful pulp-capping agent activating the repair mechanism by stimulating the dentin-pulp complex. Ca(OH)2, with its bactericidal effects, protects the complex from bacterial effects and also has a stimulating effect on dentin remineralization
46104394|NCT02655341|Device|Body Composition Monitoring|using Fresenius device; two measurements before and after coronary intervention;
46104395|NCT02655341|Procedure|Coronarography|Preprocedural coronary arteriography is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the left coronary stem, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording.
45467624|NCT03466528|Drug|Magnesium Sulfate|Intravenous (Magnesium Sulphate) MgSO4 2 grams IV over 20 minutes
45467625|NCT03466528|Drug|Pabrinex|standard treatment
45467626|NCT04664985|Device|Mucogyne® ovule|hyaluronic acid, vaginal ovule
45467627|NCT04621604|Other|blood samples|Extra blood samples will be collected during chemotherapy administration to analyze pharmacokinetics of the iPD1
45467628|NCT03776929|Behavioral|Dialectical Behavioral Therapy|Dialectical Behavior Therapy (DBT) is a cognitive behavioral therapy that focuses on the balance between change and acceptance. DBT skills include four modules: two that enforce acceptance-oriented skills, mindfulness and distress tolerance, and two that promote change-oriented skills, interpersonal effectiveness and emotional regulation.
46019978|NCT05380297|Device|Speech analysis|Speech analysis to detect and monitor mild cognitive impairment
46019979|NCT00604903|Device|Implant of Pressure sensor.|Implant of an Remon ImPressure implantable pulmonary artery pressure sensor utilizing the corresponding delivering system.
46104396|NCT02655341|Procedure|Primary Percutaneous Coronary Intervention|An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
46104397|NCT02655341|Procedure|Renal Angiography|After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. This procedure is performed in the same time with primary PCI
46104398|NCT04170413|Drug|CeVUS|Contrast enhanced voiding urosonography
46019980|NCT00606541|Drug|Quetiapine XR|This is an investigator-initiated, single site study, consisting of two phases: 1) 8-week, open label treatment with quetiapine XR (50-400 mg/day) in subjects (n=55 in order to randomize 20 into each of the quetiapine XR and PBO arms in the 2nd phase of the study) with SAD; and 2) in those who demonstrate at least minimal improvement (i.e. CGI≤3), 12-weeks randomized, double-blind treatment with either quetiapine XR or placebo (PBO).
46104399|NCT02655497|Behavioral|Cognitive training|
46104400|NCT02655497|Behavioral|Psychosocial education|
46104401|NCT02655263|Drug|Somatropin|Somatropin infusion (Genotropin®)
46019981|NCT00606541|Drug|Placebo|Placebo
46019982|NCT04266067|Other|PNF exercise|Proprioceptive neuromuscular facilitation (PNF) is a form of neuromuscular retraining type containing the stimulation of sensory receptors to provide information about the body position and movement to facilitate the intended movement
46019983|NCT04266067|Other|Frenkel exercise|The Frenkel exercises consist of a series of slow, repetitive movements performed in different positions while lying, sitting and standing.
46104402|NCT02655263|Other|Ketone bodies|ketone bodies infusion
46104403|NCT02659085|Drug|Ketamine IV Infusion|Patients randomized to the experimental treatment receive intravenous infusions of racemic ketamine (0.5 mg/kg), delivered over a period of forty minutes thrice weekly (Monday, Wednesday, Friday) under supervision.
46104404|NCT02659085|Procedure|ECT|ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly.
46104405|NCT02659007|Other|yoga|8 weeks of yoga, twice a week. sitting, standing, and floor postures with meditation and breath work
46104406|NCT04171271|Behavioral|Activating kinesthetic motor imagery training|Participants in the activating kinesthetic motor imagery training group will imagine high effort exercises (e.g. planking, boxing, jumping, squats, push-ups) in the sessions in home using the study audio-video motor imagery script for 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
45838157|NCT04597047|Diagnostic Test|Capillary Collection & Testing|Two (2) fingersticks will be performed on each subject and capillary blood tested in the LumiraDx SARS-CoV-2 Ab test
46104407|NCT04171271|Behavioral|Relaxing kinesthetic motor imagery training|Participants in the relaxing kinesthetic motor imagery training group will imagine relaxing (low effort) exercises (e.g. breathing exercises, stretching, body awareness exercises) in home using the study audio-video motor imagery script 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
46104408|NCT04168697|Behavioral|Wim Hof method|8-week behavioral modification intervention instructing the participants in a combination of breathing exercises, cold exposure and meditation
46104409|NCT04170101|Procedure|deep NMB|0,6 mg/kg LBW Rocuronium is used to facilitate intubation, and followed by an infusion of 1 mg/kg LBW/h , further adapted to keep PTC < 3
46104410|NCT04170101|Procedure|moderate NMB|0,6 mg/kg LBW rocuronium is used to facilitate intubation, not followed by an infusion or extra bolus.
45467629|NCT03466372|Behavioral|biofeedback|treadmill walking with biofeedback regarding propulsion and other gait parameters
45467630|NCT04883775|Drug|MVT-2163|MVT-2163 is administered intravenously as a PET imaging agent.
46104411|NCT02663375|Device|ACURATE TA™ Transapical Aortic Bioprosthesis|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
46104412|NCT04171193|Drug|Isoflurane|Deep anesthesia with isoflurane to achieve burst suppression pattern for more than 80% of the time for 15 minutes measured in electroencephalogram and Bi-Spectral Index
46104413|NCT04171193|Drug|Sertraline Pill|Patients that did not respond to Isoflurane treatment, will star on sertraline to evaluate any enhancement in antidepressant efficacy after pre-treatment with isoflurane
45467631|NCT04883775|Drug|MVT-5873|MVT-5873 will be administered intravenously over at least 60 minutes.
45467632|NCT03466216|Drug|AlphaMedix|There is only a single treatment intervention.
46019984|NCT02851225|Other|telemedicine transmission of biological results|telemedicine transmission of biological informations
46104414|NCT02663141|Drug|Losartan|
46104415|NCT02663141|Drug|Intravitreal bevacizumab|
46104416|NCT02663141|Drug|Placebo|
46104417|NCT04171349|Drug|Articaine|Vial
46104418|NCT04171349|Drug|Dexmedetomidine|Vial
46104419|NCT02536547|Device|VAP|all patients with suspected VAP : biochemestry microbiology lung ultrasound
46104420|NCT00650039|Drug|placebo|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, placebo BID by mouth on Days 2 to 5.
46104421|NCT00650039|Drug|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg once daily (QD) by mouth on Days 2 to 5.
45599254|NCT02342067|Drug|Cenicriviroc|CVC 150 mg QD on Days 1-10, washout on Days 11-20, PGZ 45 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
45838158|NCT04597047|Diagnostic Test|Venous Draw & Testing|One (1) Venous Draw (to include one (1) 6.0 mL EDTA tube and one (1) 3.5 mL serum separator tube) will be collected from each subject. Blood will be tested in the LumiraDx SARS-CoV-2 Ab test
45467633|NCT03098654|Diagnostic Test|Blood glucose and blood pressure testing|Diabetes will be assessed using a 6-question risk assessment on a 10-point scale (based on a field-tested and culturally adapted International Diabetes Federation formula on DM risk factors and symptoms) and a random blood glucose test with a portable finger stick glucose monitor. Those with either: (1) a risk score of 5 or more, or (2) a random blood glucose with a value greater than 140 mg/dl, will be asked to return after fasting for at least 8 hours to have a fasting glucose test taken. Blood pressure will be assessed using a portable battery operated automatic BP cuff. The BP test will include three values taken at least 5-minutes apart and the 3 will be averaged to determine the final value.
45467634|NCT03098654|Behavioral|Diet and lifestyle counseling|All participants with elevated glucose or BP will receive personalized lifestyle counseling by trained counselors informed by lab results and that includes education on diabetes, hypertension, dietary assessment and recommendations, advice on physical activity, and the need to regularly monitor their glucose, BP, and adjust their diet, activity level, as needed. Personalized risk reduction plans will be negotiated with the client during their scheduled visits.
46104422|NCT00650039|Drug|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg twice daily (BID) by mouth on Days 2 to 5.
46019985|NCT00604981|Behavioral|Multisystemic Therapy (MST)|MST is an intensive, family centered, community based treatment originally designed for use with adolescents presenting with serious mental health problems. In this study, MST interventions are aimed at increasing adolescent and family adherence to dietary and exercise recommendations and targeting barriers within the family system, and the broader community systems within which the family is embedded (peers, schools, health care). Decreasing caloric consumption consistent with recommended intake targets, increasing daily exercise and decreasing sedentary activity, are treatment focuses depending on whether the adolescent has difficulty with this aspect of weight management or not.
46019986|NCT00604981|Behavioral|Shapedown|Shapedown, is a clinic-based, adolescent weight loss intervention. Shapedown utilizes psycho educational, behavior, and family therapy techniques in a 10-week group intervention. In order to match MST's length of intervention (6 months), three follow-up sessions are added at monthly intervals.
46019987|NCT00605059|Drug|[123I]AV94|Evaluation of [123I] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
46019988|NCT00936715|Drug|FTC/TDF|200/300 mg tablet administered orally once daily
46019989|NCT05378503|Drug|Qsymia 3.75Mg-23Mg Extended Release Capsule|From W0 to W2, once a daily.
46019990|NCT05378503|Drug|Qsymia 7.5Mg-46Mg Extended Release Capsule|"From W2 to W14, once a daily.~At W14, if the weight loss rate is 3% or more, from W14 to W56(the end of visit), once a daily."
46104423|NCT00649259|Drug|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
46104424|NCT00649259|Drug|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
45467635|NCT03098654|Drug|DM/HTN medications as needed|Subjects will receive DM or HTN medications prescribed by the CTC clinician as needed.
45467636|NCT05175066|Drug|Bisoprolol|For patients who were candidates to start therapy with anthracycline, bisoprolol was administrated as explained before to determine the effect of this drug on the reduction of anthracycline-induced cardiomyopathy.
46019991|NCT05378503|Drug|Qsymia 11.25Mg-69Mg Extended Release Capsule|At W14, if the weight loss rate is NOT 3% or more, from W14 to W16, once a daily.
45467637|NCT05175066|Drug|Placebo|Tablets with similar shape and size and color to bisoprolol were given to the patients whom undergone chemotherapy with anthracyclines to compare the effects between two groups.
45467638|NCT03786133|Diagnostic Test|Analysis of microbiological tests|Collection and comparison of microbiological data
45467639|NCT03466138|Device|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
45681081|NCT03596086|Drug|ADV/HSV-tk (gene therapy)|The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
46019992|NCT05378503|Drug|Qsymia 15Mg-92Mg Extended Release Capsule|At W14, if the weight loss rate is NOT 3% or more, from W16 to W56(the end of visit), once a daily.
46019993|NCT05378503|Drug|Placebo|From W0(Randomisation) to W56(the End of visit) once a daily.
46019994|NCT00606619|Other|Conventional feeding|Procedure of Conventional feeding group: Patients are supplied water on day 3 after operation, liquid diet on day 4 and 5 and soft diet on 6 day.
45681082|NCT03981796|Biological|Dostarlimab|Participants will be administered dostarlimab
46019995|NCT00606619|Other|Early oral feeding|Procedure of Early oral feeding group: Patients are supplied water on day 1 after operation, liquid diet on day 2 and soft diet on day 3 day.
46019996|NCT05378191|Drug|COMIRNATY|One dose of COMIRNATY
46019997|NCT00605137|Drug|insulin detemir|
46019998|NCT00605137|Drug|insulin NPH|
46019999|NCT00603499|Dietary Supplement|Magnesium chloride|Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.
46020000|NCT00603499|Other|Placebo|Subjects in the control group received inert placebo once per day during 4 months
46104425|NCT04401059|Drug|Elemene plus first or third generation EGFR-TKIs|"Elemene Injectable Emulsion: 20ml: 88mg, 6 injections each time, once a day, continuous intravenous drip for 5 days. Continue to use Elemene Oral Emulsion. For specific usage, refer to the drug label.~Elemene Oral Emulsion: 20ml: 176mg, 1 dose each time, 3 times a day. Use the Elemene Oral Emulsions until the disease progresses, the intolerable toxicity, the patient withdraws from the study, or dies for any reason.~First or third generation EGFR-TKIs: refer to the drug label."
46104426|NCT04401059|Drug|First or third generation EGFR-TKIs|refer to the drug label.
46104427|NCT02658773|Drug|lidocaine-Prilocaine cream|
46104428|NCT02658773|Drug|placebo cream|
46104429|NCT04170491|Diagnostic Test|Continuous EEG|Continuous EEGs will be performed with 21 electrodes and polygraphy (ECG and EMG) placed according to the international 10-20 system. In case of extensive neurosurgical defects, a reduced montage may be applied in patients from either group. This information will be added in CRF. The reduced montage in these cases is not expected to reduce the diagnostic accuracy and the outcome, as the neurophysiological changes are generally diffuse and will be detected by adjacent electrodes.
46020001|NCT04267627|Behavioral|Comprehensive Assistance: Rural Interventions, Nursing, and Guidance (CARING)|Cancer-related distress will be assessed using the NCCN Distress Thermometer amended to include HNC-specific areas of distress. For those participants experiencing high rates of distress, the nurse will provide targeted distress education. Education for participants exhibiting successful distress self-management, or with distress that has already resolved will focus on reinforcing surveillance and health promotion information contained in the Survivorship Care Plan. When indicated, the nurse will discuss potential referrals to support services with the patient, and they will decide jointly which referrals will be beneficial. Following the visits, the nurse will make agreed upon referrals using existing cancer center pathways, documenting these in the medical record. The nurse will follow-up with the patient via telephone 6 weeks following the telemedicine visit to determine uptake of the referral, documenting all referral information in the electronic medical record.
46020002|NCT00606775|Drug|Carvedilol|2.5-5mg/day
46104430|NCT00648869|Drug|metformin tablet, metformin gum|500 mg, 250 mg
46104431|NCT02654951|Other|Visual Feedback|"The visual feedback condition will use a monitor to display two cursors (empty circles) that will represent the participant's hands, and the circles will fill with red ink as the user starts to compensate outside a normal error band. The amount of red ink will increase proportionally to the magnitude of trunk compensation.~The goal of the participants will be to move their hands/cursors towards a target, while keeping the cursors as empty as possible."
46020003|NCT04265989|Device|Single BMS|Single bare metal stent covered the coronary artery aneurysm
46020004|NCT04265989|Device|Single or Double BMS|Single or double layer bare metal stents covered the coronary artery aneurysm
46020005|NCT04265989|Device|Single or Double BMS|Treated with single or double layer bare metal stents
46020006|NCT04265989|Device|BMS+DES|Treated with bare metal stent combined with drug eluting stent
46020007|NCT04267471|Behavioral|Tai Chi|Tai Chi is a traditional Chinese mind-body exercise, which combines deep-breath relaxation and gentle movements in sequence with meditation. Each session of Tai Chi will last 60 minutes, including a 10-minute warm-up, a 40-minute Tai Chi practice and a 10-minute cool-down.
46104432|NCT02654951|Other|Force Feedback|"A monitor will display the same cursors as in the visual feedback condition, however, the cursors will be completely empty and will not fill with color.~The force feedback cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. In addition, the magnitude of the cue will be proportional to the magnitude of trunk compensation.~The goal of the participants will be to move their hands/cursors towards a target, while moving the robots with the least resistance possible."
46020008|NCT04267471|Behavioral|Walking|Each session of walking will last 60 minutes, including a 10-minute warm-up, a 40-minute walking and a 10-minutes cool-down.
46020009|NCT00605371|Drug|Lamotrigine tablet|Lamotrigine extended release single dose tablet will be available with dosing strengths of 200 milligrams and 50 milligrams intended to be administered orally in fasted state. It will be a round standard convex shape tablet.
46020010|NCT00605371|Drug|Lamotrigine caplet|Lamotrigine extended release single dose caplet will be available with dosing strength of 200 milligrams and 50 milligrams intended to be administered orally in fasted and fed state.
46020011|NCT04267549|Drug|sintilimab|sintilimab is checkpoint inhibitor via blocking PD-1 (programmed cell death-1) site of signaling.
46104433|NCT04169945|Other|Ultrasonic instrumentation|Full mouth root surface debridement
46104434|NCT04169945|Other|Air polishing with erythritol powder|Air flow PLUS
46104435|NCT04169867|Biological|Collection of stool samples|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
46020012|NCT04267549|Drug|apatinib|a multi-target anti-angiogenic tyrosine kinase inhibitor (TKI)
46104436|NCT02536625|Other|prospective study|
46104437|NCT02655029|Drug|Perindopril/Indapamide/Amlodipine fixed dose combination|Dose selection is based on investigators management.
46104438|NCT02662673|Device|Focal High Intensity Focused Ultrasound (HIFU) treatment|Focal High Intensity Focused Ultrasound (HIFU) treatment for localized prostate cancer (maximum two foci). HIFU treatment is using high energy ultrasound focused at the focal point to achieve precise tissue destruction. This mini-invasive therapy is using an endo-rectal approach to deliver the treatment, using a probe composed of a combined imaging and treatment transducer. The treatment is monitored by real-time ultrasound. The treatment planning is performed by the urologist, contouring the area to be treated (MRI target + security margins around the tumor) and the treatment phase is automatically performed by the robotic device.
46104439|NCT02662595|Other|SMS reminder message|
46104440|NCT02662595|Other|Voice call + SMS message|
46104441|NCT02654795|Radiation|computed tomography|CT angiography will be performed with a dual-source CT scanner using prospective ECG gating, with detector collimation of 128x0.6 mm, a gantry rotation time of 280 ms, tube voltage of 100-120 kV, tube current of 280-380 mAs depending on the patient's body mass.
45681083|NCT03981796|Drug|Placebo matching dostarlimab|Participants will be administered placebo matching dostarlimab
46020013|NCT04267549|Drug|S1|S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which degrades 5-FU), and oteracil (which inhibits the phosphorylation of 5-FU in the gastrointestinal tract, thereby reducing the toxic effects of 5-FU in the intestinum).
46020014|NCT04267549|Drug|Nab paclitaxel|Nab paclitaxel is a albumin-bound well tolerated paclitaxel than traditional paclitaxel
45467640|NCT04571658|Other|Communication|The NEPTUNE Match study includes an interdisciplinary Communication Team that will translate findings from the Molecular Nephrology Board (MNB) to inform patients of the matching assessment with ongoing clinical trials. This team has considerable experience with conveying complex biomedical research information to patients and families and includes experts in precision nephrology, nephrology patient [adult and pediatric] communication, and health education.
46020015|NCT04265677|Other|Telemedicine FCR|Parents/guardians will be able to join family centered rounds using telemedicine (audio and visual)
46020016|NCT04265677|Other|Standard of care|Parents/guardians will not be able to join family centered rounds using telemedicine (audio and visual)
46020017|NCT01267994|Drug|Anakinra|100mg of anakinra administered by a subcutaneous injection for 84 consecutive days.
46020018|NCT00606853|Behavioral|Contingency Management|Rewards valued $1-$100 for abstinence or treatment attendance
46020019|NCT02850757|Device|U shaped Guedl's airway|To use U shaped Guedl's airway for assisting fiberoptic bronchoscope during endotracheal intubation
46020020|NCT02850757|Device|Modified William's airway|Use Modified William's airway for assisting fiberoptic bronchoscope dduring endo tracheal intubation
46020021|NCT05379751|Procedure|Fixation free Spigelian hernia repair with tentacle mesh|Spigelian hernias are repaired through the fixation free placement of a tentacle mesh in preperitoneal sublay thanks the friction exerted by the tentacle straps delivered by a proprietary needle passer crossing trouh the abdominal wall from the preperitoneal space until the subutaneous layer. This procedural approach should also grant a broad overlap of the implant over the hernial defect
46020022|NCT04203745|Device|Nonablative Fractional Diode Laser|The FRAX 1940 is a fractional 1940 nm solid-state diode laser that delivers linear arrays of microbeams to create nonablative microscopic treatment zones (MTZs) in the skin.
46104442|NCT04168853|Diagnostic Test|vascular reactivity of internal thoracic arteries|"Internal thoracic arteries analysis Myography Superoxide detection and confocal microscopy Immunochemistry Quantitative real time transcription-polymerase chain reaction (RT-PCR) analysis~Blood sampling and biochemical analysis"
46104443|NCT02662829|Behavioral|Community-based intervention|
46104444|NCT02662829|Other|Standard of care|
46104445|NCT02536859|Drug|insulin degludec|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
46104446|NCT02536859|Drug|insulin glargine|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
46104447|NCT02536937|Drug|eliglustat|"Pharmaceutical form: capsule~Route of administration: oral"
46104448|NCT04169633|Diagnostic Test|Cognitive Function Evaluation|Evaluation of cognitive function and evaluation of daily cognition
46104449|NCT00649337|Procedure|Comparison of Automated Whole Breast Ultrasound Screening with Blinded Screening Mammography|"AWBU is a computer-based system for performing and recording ultrasound scans of the whole breast. The transducer of any suitable high-resolution compound ultrasound equipment is attached to a mechanical arm guided by computer, and images are acquired in longitudinal rows, overlapping to assure complete coverage. The mechanical arm controls transducer speed and position, with a technician maintaining appropriate contact pressure and orientation vertical to the skin. Approximately 150-300 images per row are immediately displayed on the AWBU monitor, then permanently stored.~The AWBU software creates a continuous ciné loop of the images, creating the appearance of real-time scanning. With spatial registration, any point on an image can be identified as a distance from the nipple in a specific radius. Image review is optimized by playback on a high-resolution monitor to allow compressed image size, 3-D reconstruction, and adjustment of contrast, brightness and review speed."
46020023|NCT02850913|Drug|Doxycycline|"115 participants will be randomized to either oral Doxycycline 100 mg daily for six weeks.~Treatment will be initiated in hospital but will be continued at home.~Scheduled study clinic visits will be made by the participants at 6, 12 and 24 months.~Each participant will be visited at home at 2, 4 and 6 weeks for adherence monitoring and assessment of safety"
46020024|NCT02850913|Other|Placebo|- Placebo (matching capsules containing no active ingredients)
46020025|NCT00603655|Other|Low glycemic load diet|Low glycemic load diet
46020026|NCT00603655|Other|High glycemic load diet|High glycemic load diet
46020027|NCT05371561|Device|reusable respirators|Dentist wearing reusable respirator will examin the patient
46020028|NCT02850835|Other|Video Decision Aid|A video decision aid was developed inform patients about pelvic organ prolapse, to include female anatomy, and treatment options.
45681084|NCT03981796|Drug|Carboplatin|Participants will be administered carboplatin
46020029|NCT00934843|Drug|methylprednisolone (IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive ONE doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP (2 dose steroid)to intraoperative IVMP alone (single dose steroid) on the inflammatory response to CPB cardiopulmonary bypass.
46020030|NCT00934843|Drug|methylprednisolone (two doses IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
46020031|NCT05371327|Behavioral|Public deliberation|Public deliberation is a method for engaging the public in collective decision-making. Its goal is to facilitate debate and discussion that: 1) fosters the formation of reasonable and informed opinions, 2) permits participants to revise their perspectives and positions in light of new information and dialogue with others, and 3) encourages participants to consider not only their own preferences but also the greater goal of a policy or resolution that is justifiable for all persons affected by the issue under debate.
46020032|NCT04268251|Diagnostic Test|MRI with deep learning based denoising|1-mm coronal contrast-enhanced T1 weighted image with deep learning based denoising
46020033|NCT00607009|Behavioral|ALIVE|ALIVE email-based behavioral program based on the participants selected intervention - physical activity, fats/sugars or fruits/vegetabls
46020034|NCT04265521|Device|Biocool Footcare|BioCool Footcare is a footbath containing granulate of sodium percarbonate that will in this study be used for treatment of foot fungus, heel cracks, calluses and/or dry feet.
46020035|NCT00605605|Drug|Dextromethorphan|120 mg/day, single once daily dose taken after breakfast by oral route
45681085|NCT03981796|Drug|Paclitaxel|Participants will be administered paclitaxel
46020036|NCT04256395|Other|mobile internet survey on self-test|1. make a questionnaire, the content of which refers to the new coronavirus diagnosis and treatment guidelines released by the National Health Commission; 2. develop the mobile applet and carry out internet propagation; 3. background data could be identified according to computer technology, de duplication and de privacy; 4. once registered, the applet can automatically remind the self-test twice a day, and encourage to adhere to 14 days; 5. automatically compare with the standards and highly suspected population could be given medical guidance and encouraged to go to the fever clinic of the designated hospital for definite diagnosis.
46020037|NCT04267237|Drug|Atezolizumab|Atezolizumab 1680 mg will be administered by intravenous (IV) infusion on Day 1 of Cycles 1-12.
46020038|NCT04267237|Drug|RO7198457|RO7198457 will be administered by IV infusion at protocol-defined intervals for 12 cycles.
46020039|NCT05379517|Device|Pulsed ectromagnetid field therapy|Pulsed electromagnetic field therapy is an innovative therapy. The technology is based on a high intensity electromagnetic field, which positively influences human tissue. It is a form of non-invasive treatment, with good tolerance by patients. High-intensity electromagnetic fields excite neural and muscle cells, which stimulates the human body.
46020040|NCT05379517|Other|Pulmonary rehabilitation program (PRP)|This type of physiotherapy program includes: respiratory muscle training, coughing exercises, diaphragmatic training, aerobic training and strength training.
46020041|NCT05383105|Procedure|Virtual bronchoscopic navigation|Virtual bronchoscopy navigation (VBN) calculates the access to a solitary pulmonary nodule via a trans-parenchymal route. In contrast to the gold Standard transthoracic approach, with this technique also very small lesions (7 mm diameter), and lesions which cannot be reached via the transthoracic route - located in the inner two thirds of the lung - can be approached.
46104450|NCT02654561|Drug|Heparin Sodium|A bottle solution of Heparin Sodium(2ml:12500IU) is added to 50ml saline and administered i.v. continuously for 24 hours, which last 7 days or until the death or discharge. The same amount of 0.9% saline as the heparin group will be administered in the placebo group.
46104451|NCT02654561|Drug|Saline|For all the severe sepsis or septic shock patients, normal saline will be administered for fluid resuscitation according to the Guideline of Survival Sepsis Campaign.
46104452|NCT02654405|Dietary Supplement|Sodium Butyrate|6.57 gms of sodium butyrate per day for 12 weeks
46104453|NCT02654405|Other|Placebo|placebo capsules containing approximately 9 mg of sodium butyrate/day
46104454|NCT04169789|Dietary Supplement|Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)|L.reuteri high or low dose with cholecalciferol compared to cholecalciferol only.
45467641|NCT01308151|Other|Other|No interventions other than the culturally adapted manualised cognitive behavioral therapy
45681086|NCT03981796|Drug|Niraparib|Participants will be administered niraparib
45681087|NCT03981796|Drug|Placebo matching Niraparib|Participants will be administered placebo matching Niraparib
45599255|NCT02342067|Drug|Pioglitazone|PGZ 45 mg QD on Days 1-10, washout on Days 11-20, CVC 150 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
45599256|NCT02750501|Device|RELiZORB (immobilized lipase) cartridge|Hydrolyzing fats from enteral formula, ex vivo, with in-line enteral feed RELiZORB (immobilized lipase) cartridge
45599257|NCT02750501|Other|Impact Peptide 1.5|Impact Peptide 1.5 at a volume of administration from 500 mL to 1,000 mL per enteral feeding
45599258|NCT02344017|Drug|ODM-204|co-administered with prednisone, orally daily
45599259|NCT02344017|Drug|Prednisone|ODM-204 is co-administered with oral prednisone
46020042|NCT00605683|Drug|Safinamide (as add-on therapy)|Safinamide, (S)-(+)-2-[4-(3-fluorobenzyloxy) benzylamino] propanamide methanesulfonate, is an a-aminoamide derivative
46104455|NCT00649415|Drug|piroxicam|piroxicam 40 mg capsule QD for up to the first 3 days of the menstrual cycle
46104456|NCT00649415|Drug|valdecoxib|valdecoxib 40 mg capsule twice a day (BID), taken as required, on the first day of treatment in the menstrual cycle followed by oral valdecoxib 40 mg once a day (QD) for up to the first 3 days of the menstural cycle
46104457|NCT04171505|Drug|HPV vaccine|". Patients diagnosed with HSIL / CIN 2+ who met the inclusion criteria were submitted to cervical conization and subsequently enrolled in the study after signing the informed consent, approved by ethics commission.~We will take into account the date of administration of the first dose of vaccine. The types of vaccines administered can be: Bivalent vaccine (includes genotypes 16/18), Tetravalent (includeds genotypes 6, 11, 16 and 18) both funded in the region in different years, or not funded (Nonavalent vaccine; includes genotypes: 6, 11, 16, 18, 31, 33, 45, 52 and 58). To define the time of vaccination around the conization date, the administration of the first dose of vaccine will be taken into account."
46104458|NCT00650117|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)|single application
46104459|NCT00650117|Drug|Duragesic 25 mcg/h + Scotch Duct Tape (3M)|single application
45681088|NCT01868997|Drug|teprotumumab|
46104460|NCT00650117|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)|single application
46104461|NCT00650117|Drug|Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)|single application
46104462|NCT00650117|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)|single application
46020043|NCT00605683|Drug|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
46104463|NCT00650117|Drug|Duragesic 25 mcg/h + Microfoam Tape (3M)|single application
45681089|NCT01868997|Drug|normal saline|
45681090|NCT01875848|Drug|buprenorphine/naloxone|partial opioid agonist
46020044|NCT00605683|Drug|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
46020045|NCT05379361|Behavioral|Emotional Intelligence Development Program|It is a training program that was developed in line with the literature and preliminary research results and includes the bar-on emotional intelligence sub-dimensions.
46020046|NCT05379361|Behavioral|Plasebo Training Group|It is a training program that was developed in line with the literature and includes the environmental awareness skills education.
46020047|NCT01266902|Drug|Rilpivirine|25 mg once daily
46104464|NCT02654249|Device|Transanal hemorrhoidal dearterialization + mucopexy (THD).|Using an anoscope combined with a Doppler transducer the hemorrhoidal arteries are identified and ligated to decrease the blood flow to the hemorrhoidal plexus. In order to reduce hemorroidal prolapse a mucopexy is performed.
46104465|NCT02654249|Procedure|Ligasure™ hemorrhoidectomy|Excisional hemorroidectomy performed with Ligasure™
46104466|NCT02654249|Device|THD anoscope and doppler|An dedicated anoscope with an incorporated doppler probe sold by THD Lab S.p.A will be used for the THD procedure
46104467|NCT02654249|Device|Ligasure Vessel Sealing|A curved, small jaw, open sealer/divider sold by Covidien/medtronic will be used for the Ligasure™ hemorrhoidectomy
45681091|NCT01875848|Drug|opioid dose escalation|up to 25% increase in patient's current opioid dose
45681092|NCT04588142|Dietary Supplement|Probiotic|Non-elite athletes receive probiotic for 6 weeks
45681093|NCT04588142|Dietary Supplement|Placebo|Non-elite athletes receive placebo for 6 weeks
45681094|NCT04198402|Biological|Biological sampling|Blood sample (5mL) for metabolomic dosage and Fecal sample for ARN16s sequencing
45681095|NCT04198168|Drug|IV crystalloid fluid bolus|The participant receives IV fluid as a standardised bolus of 7 ml/kg (ideal body weight).
46020048|NCT04266847|Device|monofocal IOL,bifocal IOL,or trifocal IOL|phacoemulsification and implantation of IOL.IOL may be monofocal IOL,bifocal IOL,or trifocal IOL
46020049|NCT00605761|Drug|SB656933|50 mg treatment
46020050|NCT00605761|Drug|SB656933|150 mg treatment
46020051|NCT05365867|Behavioral|iCAN Group|See description in iCAN study arm.
46020052|NCT05363995|Behavioral|i-Sleep & BioClock Intervention|"The 'i-Sleep & BioClock' intervention aims at improving sleep and the biological clock among university students. It is incorporates evidence-based techniques such as cognitive behavioural therapy for insomnia (CBTi). The intervention has a duration of 5 weeks and consists of five modules:~psychoeducation on insomnia, sleep hygiene and the biological clock,~stimulus control and sleep restriction therapy,~worrying and relaxation exercises,~cognitive therapy to change dysfunctional thoughts about sleep, and~summary module, relapse prevention, and plan for the future.~The intervention is supported by e-coaches who give personalized written feedback. Students will fill in a sleep & light exposure diary daily."
46020053|NCT01266824|Drug|Proparacaine Hydrochloride Ophthalmic Solution|1 drop into each eye once prior to the first set of mydriatic (dilating) eye drops
46020054|NCT05383027|Behavioral|Music Listening Control (MLC)|MLC participants will engage in assigned music listening in the presence of their loved one with ADRD via a selected online platform (pandora or Spotify) for 10 minutes a day 5-7 days a week.
46020055|NCT05383027|Behavioral|Heart Focused Breathing|Heart-focused breathing participants will engage in heart-focused breathing using the inner balance device (shipped to their home), they will be asked to do this in the presence of their loved one with ADRD for 10 minutes a day 5-7 days per week.
46020056|NCT05355025|Behavioral|WiserAD|"See Arms"
45467642|NCT03465826|Behavioral|PainCOACH Pain Coping Skills Training|Migraineurs will participate in 4 weeks of daily headache monitoring, baseline questionnaires, followed by 8 weeks of the PainCOACH migraine mHealth Pain Coping Skills Training program (developed by Drs. Keefe and Rini based on social cognitive theory and in-person pain coping therapy sessions). Following the 8 week mHealth intervention, participants will immediately complete post-treatment assessments and later will complete follow-up assessments at 3 and 6 months.
45467643|NCT03465826|Behavioral|Treatment as Usual|Participants will keep headache diaries for 4 weeks, followed by baseline assessments + 8 weeks of daily headache monitoring (as a parallel to the PainCOACH intervention). Post-assessments will immediately follow, and participants later will complete follow-up assessments at 3 and 6 months.
45467644|NCT05513521|Other|High-velocity interval training|For the velocity training protocol, the 11 exercises will be completed at 40% of their 1RM. In the first three weeks of training, the loading volume will be increased gradually. During week one participants will complete one set of each exercise. Week two will consist of two sets, and weeks 3-12, three sets. Keiser pneumatic resistance machines are interfaced with a laboratory computer, which allows the transfer and analysis of data including force, velocity, and power.
45467645|NCT05513521|Other|Resistance training|For the load training protocol, the 11 exercises will be completed at 79% of their 1RM. In the first three weeks of training, the loading volume will be increased gradually. During week one participants will complete one set of each exercise. Week two will consist of two sets, and weeks 3-12, three sets. Keiser pneumatic resistance machines are interfaced with a laboratory computer, which allows the transfer and analysis of data including force, velocity, and power.
45467646|NCT04527588|Other|Questionaire Michigan|Patient-Reported Outcome Measures (PROMs) are important clinical items for evaluating injuries and recovery of the hand. The Michigan Hand Questionnaire is one of the most important.
45467647|NCT03130114|Drug|Azithromycin|Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 10 mg (0.35 ml) / kg of azithromycin syrup per day, for three days
45467648|NCT03130114|Other|Placebo|Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 0.25 ml / kg of placebo drug syrup per day, for three days
45467649|NCT03638739|Other|Twice-weekly exercise|An individualized exercise plan, incorporating aerobic and resistance exercises, following the Physical Activity Guideline recommendations will be provided for each participant.
46020057|NCT05355025|Behavioral|Attention control|"See Arms"
46020058|NCT04266769|Device|LightForce Orthodontic System|The LightForce Orthodontic System is a a digital treatment planning platform and patient-specific 3D printed polycrystalline alumina brackets for the treatment of malocclusion
46104468|NCT02662751|Other|Routine Imaging Assessment|"Patients will have the usual post-stroke/TIA imaging assessment according to routine procedures in each participating center. The latter most often begin with an angiography of the supra-aortic trunks but may also include a range of other imaging exams depending on the patient's condition.~Routine Imaging Assessment refers to an imaging strategy and not a specific device. The devices used depend on what is available in participating centres and the routine choices made by those centers."
46104469|NCT02662751|Device|LDWBA first (CT scan)|"Patients randomized to this arm will start their post-stroke/TIA imaging assessment by a low-dose, whole-body angiography (LDWBA). The latter can be followed by routine imaging assessments if required.~LDWBA: This is a low dose scanner protocol comprising a CT acquisition and an iodine contrast medium injection. The acquisition includes a propeller during the arterial phase of the contrast agent injection in the cervical and thoracic levels with cardiac gaiting (ECG gating to reduce cardiac motion artifacts), continuing with pelvic abdominal arterial acquisition. The second propeller is made on the abdomen and pelvis at the portal time of injection. The reconstruction will be carried out in pulmonary, mediastinal and bone windows. The dose will be calculated for each patient."
45467650|NCT05681988|Procedure|Early minimally invasive image guided endoscopic hematoma evacuation|The intervention group will first receive BMT (as defined below) upon admission and early minimally invasive image guided endoscopic hematoma evacuation as an add-on therapy to BMT. Surgery will be performed within 6-24 hours after SSICH symptom onset. Surgery will be performed in an emergency operating theatre or a hybrid operation theatre equipped with intraoperative CT (in hybrid OR), neuronavigation, and neuro-endoscopy.The position and progress of the trocar towards the hematoma cavity will be monitored with neuro-navigation. The endoscope (LOTTA® system, Karl Storz Endoscopes, Germany; Minop®, BBraun, Tuttlingen, Germany or equivalent) will be inserted into the trocar and tracked using neuro-navigation. Using the pre-planned trajectory, the hematoma will be entered. Using continuous suction and irrigation, the hematoma will be aspirated and/or washed out.
46020059|NCT04253119|Drug|Antiretroviral/Anti HIV|NNRTI plus two NRTIs or PI boosted by ritonavir with 2 NRTIs per the usual standard of care of the investigator in AIDS clinics of Russia
46020060|NCT01266590|Drug|LY2216684|Administered orally
46020061|NCT01266590|Drug|Digoxin|Administered orally
46020062|NCT01266122|Behavioral|Behavioral intervention|The behavioral intervention will consist of 4 group sessions and 4 individual sessions over 3 months. The overall focus is on psychosocial concerns and HIV risk.
45467651|NCT05681988|Procedure|Best medical treatment (BMT)|The control group will receive the current gold standard treatment for SSICH according to the guidelines (BMT). This involves strict blood pressure control (SBP<140mmHg), if needed with intravenous or intraarterial blood pressure lowering agents, reversal of anticoagulation if applicable, intensive care surveillance and nursing on a ICU or stroke unit, control of seizures as well as glucose levels as needed and neurointensive monitoring if deemed necessary
46020063|NCT00607555|Device|Insertion of specialized feeding tube for monitoring of EAdi|The specialized feeding tube will be inserted into the esophagus and positioned at the level of the crural diaphragm. EAdi will be measured with miniaturized coated stainless steel electrodes mounted on the feeding tube. The tube is connected to a monitor where EAdi will be recorded continuously throughout the entire study period
46020064|NCT04252027|Other|Sample collection|Plasma and urine sample collection
46020065|NCT04264975|Procedure|fecal microbiota transplantation|Fecal microbiota transplantation (FMT) is the administration of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient's microbial composition and confer a health benefit
46020066|NCT00603811|Biological|VAX102 [Flagellin.HuM2e]|dose ranging, 2 i.m. doses given 28 days apart
45467652|NCT03130270|Drug|Apatinib mesylate tablet|"Patients with locally recurrent or metastatic nasopharyngeal carcinoma (NPC) after second-line treatment are assigned to receive apatinib mesylate tablet. A treatment cycle was defined as 28 days (4 weeks). The starting dose was 500 mg, orally, qd; tolerance assessment for a cycle, patients with poorly tolerance were treated with low dose (500 mg, qd), and patients with well tolerance were treated with high dose (750 mg, qd). All patients continuous treatment until progression disease or non-tolerated toxicity.~Note: good tolerance was defined that no grade 3/4 hematology or/and non hematologic side effects occurred within 4 weeks after initiation treatment; poor tolerance was defined that grade 3/4 hematology or/and non hematologic side effects appeared within 4 weeks after initiation treatment."
45467653|NCT03780361|Drug|Aflibercept Injection|Total 5 times of monthly intravitreal aflibercept injections will be done.
45467654|NCT05183646|Drug|DMX-200|DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor.
45467655|NCT05183646|Drug|Placebo|Patients will receive 120 mg capsules of Placebo twice daily
45467656|NCT04943445|Drug|carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles|Patients without disease progression will proceed to the concurrent radioimmunotherapy phase of the trial.
46020067|NCT00603811|Biological|Placebo|Placebo
46020068|NCT05089435|Device|EZYPRO® ECG Recorder|EZYPRO is an ECG monitoring patch designed to enhance the arrhythmia detection rate by applying 14 days in a home setting environment.
46104470|NCT00648947|Drug|Clopidogrel Bisulfate Tablets 75 mg|75mg, single dose fasting
45467657|NCT04943445|Radiation|Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles.|Patients without disease progression will proceed to the consolidation immunotherapy phase of the trial.
45467658|NCT04943445|Drug|Consolidation immunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses.|Consolidation immunotherapy
45467659|NCT02522572|Drug|plerixafor|Plerixafor will be dosed subcutaneously and administered based on group assignment.
46020069|NCT01265498|Drug|obeticholic acid|25 mg daily for 72 weeks
46020070|NCT01265498|Drug|placebo|placebo capsule, 25 mg daily for 72 weeks
46020071|NCT00603967|Procedure|Dual x-ray absorptiometry (DXA)|Baseline, 6 months, and 12 months
46020072|NCT00603967|Procedure|Blood draw|Baseline - genotyping Baseline, 6 months, and 12 months - markers of bone turnover and hormonal assays
46020073|NCT00603967|Behavioral|Questionnaire|"Menopausal symptom questionnaire - baseline, 3 months, 6 months, 12 months~Cognitive tests - baseline, 6 months, 12 months~Depression assessment - baseline, 6 months, 12 months~Dietary calcium intake questionnaire - baseline"
46104471|NCT00648947|Drug|Plavix® Tablets 75 mg|75mg, single dose fasting
46104472|NCT00649493|Drug|Rabeprazole Sodium Tablets 20 mg|20mg, single dose fed
46104473|NCT00649493|Drug|Aciphex® Tablets 20 mg|20mg, single dose fed
45467660|NCT02522572|Drug|Bortezomib|Bortezomib will be given via IV push over 3-5 seconds and administered based on group assignment.
46020074|NCT00607711|Drug|oral palifosfamide tris|Capsule(s) given daily for 15 days followed by a 6 day rest. This is a dose escalation arm.
46020075|NCT01265420|Biological|Injectable clostridial collagenase|Injection of 0.58mg clostridial collagenase into Dupuytren's cord, up to three injections
46020076|NCT04324658|Device|Lactiplus|capsules containing L. gasseri LA806
46020077|NCT05545826|Device|Vibrotactile coordinated reset|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants with early stage Parkinson's disease
46020078|NCT04323644|Procedure|Surgery|Emergency or elective surgery
46020079|NCT01264718|Behavioral|Parent Mentors|After random assignment to the Parent Mentor group, minority low-income parents of Medicaid/CHIP eligible children met with Parent Mentors to receive instruction and help on completing, submitting applications for, and maintaining Medicaid/CHIP coverage for their child.
46020080|NCT01264016|Device|Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose (BG) tests with subject's capillary fingerstick using the investigational Tradewind meter and investigational sensor. Study staff tested subject venous blood. All BG Results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
46020081|NCT01263782|Drug|Carboplatin|AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.
46020082|NCT01263782|Drug|Pemetrexed|500 mg/m2 by vein on day 1 of each 21 day cycle.
46020083|NCT01263782|Drug|Bevacizumab|15 mg/kg by vein on day 1 of each 21 day cycle.
46020084|NCT01263782|Drug|Cixutumumab|20 mg/kg by vein on day 1 of each 21 day cycle.
46020085|NCT01263704|Drug|Cyclophosphamide|150 milligrams per square meter (mg/m^2) intravenously (IV) on Days 1-3 of each 28-day cycle for 6 cycles
46020086|NCT01263704|Drug|Fludarabine|12.5 mg/m^2 IV on Days 1-3 of every 28-day cycle for 6 cycles
46020087|NCT01263704|Drug|Rituximab|375 mg/m^2 IV Day 0 of Cycle 1, 500 mg/m^2 IV Day 1 of Cycles 2-6. Each cycle was 28 days.
46104474|NCT02654093|Drug|Cholecalciferol|
45467661|NCT02522572|Other|plasmapheresis|Plasmapheresis will be administered based on group assignment.
46020088|NCT01263470|Drug|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
46020089|NCT01263470|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
46020090|NCT01263470|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
46020091|NCT01263470|Drug|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
46020092|NCT01263470|Drug|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
46020093|NCT01263470|Drug|Placebo|Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.
46020094|NCT04322942|Diagnostic Test|Monocyte Distribution Width|Monocyte Distribution Width as part of the CBC result.
46020095|NCT04322630|Other|Change in Soluble MER Concentration|Measuring change in soluble MER Concentration post compared to pre bypass for each patient.
46020096|NCT04322786|Drug|ACE inhibitor|Any prescription of ACE inhibitor
46020097|NCT04322240|Drug|Alpha lipoic acid|Participants will be prescribed 600 mg/day ALA (thiotacid) orally, for 3 months, and will be advised not to discontinue this medication
46020098|NCT01262456|Drug|Desmopressin|
46020099|NCT01262456|Drug|Placebo|
46020100|NCT02889380|Drug|No Intervention|This study will retrospectively collect the data from the subjects who had been treated with 0.25 mg of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available ART outcome.
46020101|NCT02889302|Drug|KPS-0373|24 weeks
46020102|NCT02889302|Drug|Placebo|24 weeks
46020103|NCT04321694|Drug|KHK2455|
46104475|NCT02654093|Drug|Raloxifene|
46104476|NCT02654093|Drug|Cholecalciferol and Raloxifene co-administration|
45467662|NCT05074225|Other|Electrodesiccation and Curettage vs Excision|"Factorial Assignment.~At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS)."
45467663|NCT04602507|Drug|Ivermectin|Routinary care offered in the hospital plus ivermectin 400 µg/kg (2 drops per kg) orally in a single dose.
45467664|NCT04602507|Other|Placebo|Routinary care offered in the hospital plus placebo (2 drops per kg) orally in a single dose
45467665|NCT02522338|Drug|iohexol|10 ml de l'iohexol (300 mgI/ml)
45467666|NCT03780595|Drug|Passiflora incarnata|Passiflora pills administration up to 6 pills per day
45467667|NCT03780595|Drug|Control|Control pills administration up to 6 pills per day
45467668|NCT03706326|Biological|Anti-MUC1 CAR-T cells|Using the T cells from the patients' blood to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.
46020104|NCT04321850|Drug|Zinc Sulfate 50 Mg Tab|The tablets were manufactured specifically for this study.
46020105|NCT04321850|Drug|Placebo oral tablet|The tablets were manufactured specifically for this study.
46020106|NCT04321616|Drug|Hydroxychloroquine|Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 800 mg x 2 loading dose followed by 400 mg x 2 every day for a total of 10 days.
46020107|NCT04321616|Drug|Remdesivir|Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. A loading dose of 200 mg at inclusion will be given.
46020108|NCT04321616|Other|(Standard of Care) SoC|The standard of care will be supplied to all patients not receiving a drug intervention.
46020109|NCT04321772|Other|High Intensity Interval Resistance Training|Subjects trained one leg with HIIRT
46020110|NCT04321772|Other|Traditional Resistance Training|Subjects trained the other leg with HIIRT
46020111|NCT04207658|Behavioral|Valsalva's Style Pushing|The second stage of labour is defined as the time passed after the cervical dilatation reaches 10cm. The expulsion stage is the time between the sight of baby's head in the vulva and the end of labour. the participants are given information about the study after self introduction of each gravid is done for completing baseline obstetric data forms by midwives. Also, blood samples for pre and postpartum haemoglobin level changes are collected. The perineal area is examined for postpartum tears through pad checks. Vital findings (respiration, pulse and TA) are evaluated prior to their transfer to the delivery room. Just after the birth, mothers are tested for pH, pO2, pCO2 and lactate levels in blood while the newborns are tested for pH, pO2 (mmHg) and pCO2 levels through umbilical artery along with 1st min and 5 min APGAR analysis. The visual scale is utilized for determination of first 24-hour fatigue and they are recorded in follow-up forms.
46020112|NCT00623948|Device|A fully implanted gluteal stimulation (GSTIM) system|A fully implanted gluteal stimulation system
46020113|NCT04321304|Device|Sham transcranial direct current stimulation|Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
46020114|NCT04321304|Device|Transcranial direct current stimulation at 2 mA|Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
46020115|NCT04321304|Device|Transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
46104477|NCT02662439|Device|Body Composition Monitor (BCM)|In the experimental group, the diuretic therapy adjusted according to the result of the BCM analysis.
46104478|NCT04168619|Drug|Discontinue methotrexate|According to the international guideline, patients with Roenigk grade 3a which indicate methotrexate-induced liver injury may continue methotrexate with a repeat biopsy in 6 months. In patients with Roenigk grades 3b or 4, indicate significant liver fibrosis/cirrhosis, methotrexate should be discontinued.
46020116|NCT00932893|Drug|PF-02341066|PF-02341066, 250 mg BID will be administered orally on a continuous schedule
46020117|NCT00932893|Drug|Pemetrexed|Pemetrexed, 500 mg/m^2, will be administered by i.v. infusion over 10 minutes on Day 1 of each 21-day cycle
46104479|NCT04168619|Other|Medication depends on clinical judgement|Once discontinued methotrexate, based on subject's clinical condition and prescribe alternative treatment
46104480|NCT02654171|Drug|AK0529|AK0529 is a novel compound being developed for the treatment of RSV infection. The enteric coated drug pellets with sugar core can be administered orally with apple sauce/purée or yoghurt, or by flushing with 10% dextrose water via a nasogastric or other feeding tube, or upon a glucose wafer.
46104481|NCT02654171|Drug|Placebo|The placebo was made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed primarily of microcrystaline cellulose pellet.
46104482|NCT00650195|Drug|Metolazone Tablets 10 mg|10mg, single dose fasting
46104483|NCT00650195|Drug|Zaroloxyn® Tablets 10 mg|10mg, single dose fasting
46104484|NCT04170959|Drug|Metformin|Metformin 500 mg given 14 days before start until the end of radiation therapy. Once daily during the first 7 days, afterwards twice daily until the end of treatment.
46104485|NCT04170959|Other|No metformin|Standard of care without metformin.
46104486|NCT04169399|Drug|Toripalimab|240mg intravenously every 3 weeks
46104487|NCT04169399|Radiation|Stereotactic body radiotherapy|Radiotherapy dose was 36 ~ 54Gy, divided into 6 times of irradiation, and the radiation was performed within 2 weeks.
46020118|NCT00932893|Drug|Docetaxel|Docetaxel, 75 mg/m^2, will be administered by i.v. infusion over 1 hour on Day 1 of each 21-day cycle
46020119|NCT04321070|Drug|Clindamycin Phosphate|A thin film of investigation product will be applied to the affected areas of the face once daily
46020120|NCT04321070|Drug|Clindamycin Phosphate RLD|A thin film of investigation product will be applied to the affected areas of the face once daily
46020121|NCT04321070|Drug|Placebos|A thin film of investigation product will be applied to the affected areas of the face once daily
46020122|NCT04321226|Device|Femtosecond Laser guided Arcuate Keratotomy|Astigmatism will be reduced in cataract surgery using a low energy Femtosecond Laser device
46020123|NCT02889224|Other|Obese|
46020124|NCT02889224|Procedure|Hypercortisolism|
46020125|NCT02889224|Other|Hydrocortisone|
46020126|NCT02889224|Other|Control|
46104488|NCT00848354|Biological|Phase 1: Etanercept|Phase 1: prefilled syringe 50mg/ml, administered once weekly for study weeks 0 - 24
46020127|NCT02889146|Other|Conventional Physical Therapy|Control group will receive respiratory therapy according to the service routine and conventional physical therapy. Conventional physical therapy will be offered by the hospital physical therapists, according to their own criteria. Consists of passive, assisted and resisted mobilization, positioning in bed, transferring to bedside or chair, orthostatism and deambulation, however without a definition of a protocol. The physical therapist will be responsible for the choice of the techniques employed in each session. There will be no previous definition of the next sessions. No technology equipment will be used in this group, since they are not available in the routine care.
46020128|NCT02889146|Other|Early and progressive mobilization program|Protocol group will receive respiratory therapy according to the service routine and motor physical therapy according to the program of early and progressive mobilization. Patients will receive the program once daily during the intensive care unit stay, offered by a trained physical therapist, at the adequate level according to the level of consciousness and muscle strength. The program contains by techniques for muscle length and muscle strength maintenance or gain, aerobic exercises, exercises for gait rehabilitation and cognitive components. Patient will progress to the next level of the protocol completing the previous level. Technology equipment available: functional electrical stimulation device, dumbbells, cycle ergometer, fixed walker, ambulation assistive device and video game.
46020129|NCT02889146|Other|Respiratory therapy|Respiratory therapy according to the service routine.
46104489|NCT00848354|Drug|Phase 1: Methotrexate|Phase 1: oral tablet, 2.5mg, dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
46020130|NCT01260896|Drug|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
46020131|NCT01260896|Drug|Effexor® XR|150 mg Extended-Release Capsule
46104490|NCT00848354|Drug|Phase 2: Optional ETN, SSZ, HCQ, MTX|"Phase 2: All therapies are optional and may include any combination of the following: ETN, SSZ, HCQ, MTX Phase 2: Optional ETN: prefilled syringe 50mg/ml, dose variable after study week 24 to week 128.~Phase 2: Optional SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: MTX: oral tablet, 2.5mg dose variable after week 24 to week 128."
46104491|NCT00848354|Drug|Phase 1: Methotrexate|Phase 1: oral tablet, 2.5mg dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
46020132|NCT00932737|Drug|Placebo|1-5 tablets per episode
46104492|NCT00848354|Drug|Phase 1: Conventiaonal DMARD|Phase 1: SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations. OR Phase 1: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations.
46104493|NCT02614664|Device|NIRS|Cerebral oxygenation monitor which is standard of care for this surgery.
46104494|NCT00848120|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
46104495|NCT04116164|Drug|111In-DOTA-h11B6|4-6 mCi 111In labeled to 2 mg DOTA-h11B6; 0, 8 or 18 mg additional h11B6.
46020133|NCT00932737|Drug|HBB 20 mg|Active drug, one to five tablets per episode
46020134|NCT00607399|Drug|SGX523 Capsules|This is a dose escalation study
46020135|NCT00939523|Drug|Lapatinib|All participants will be asked to take Lapatinib daily for six months during the research study.
46104496|NCT00600821|Drug|Bevacizumab|Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.
46020136|NCT04264741|Device|repetitive transcranial magnetic stimulation (rTMS)|The iTBS group received 900 pulses per day: 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz), 2 s on and 8 s off for 5 min, at 100% resting motor threshold (rMT), over the left DLPFC (F3, EEG system) (4 weeks, 20 daily sessions). A figure-8-shaped Cool-B70 stimulation coil from MagPro X100 device (MagVenture, Farum, Denmark) was used for accurately targeted stimulation. Motor threshold was determined over the left motor cortex, by finding the lowest intensity that produced a motor response in the right abductor pollicis brevis muscles (APB), which produced five motor-evoked potentials responses of at least 50 mV in 10 trials.
46020137|NCT04264741|Device|sham repetitive transcranial magnetic stimulation (rTMS)|The iTBS group received 900 pulses per day: 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz), 2 s on and 8 s off for 5 min, at 100% resting motor threshold (rMT), over the left DLPFC (F3, EEG system) (4 weeks, 20 daily sessions). A figure-8-shaped sham Cool-B70 stimulation coil from MagPro X100 device (MagVenture, Farum, Denmark) was used for accurately targeted stimulation. Motor threshold was determined over the left motor cortex, by finding the lowest intensity that produced a motor response in the right abductor pollicis brevis muscles (APB), which produced five motor-evoked potentials responses of at least 50 mV in 10 trials.
46020138|NCT05382247|Device|ultrasonography|"Full history taking, thorough clinical examination, review of participants medical files.~Patients will be typically examined during spontaneous respiration to help assessement of diaphragmatic motion.~The supine position will be used whenever possible to avoid overall variability, side-to-side variability, and for greater reproducibility.~Patients can be examined in quiet respiration and during deep breathing or sniff maneuver.~For uncooperative patients appropriate sedative for age will be used. Assessement of diaphragmatic function: the analysis of the dome excursion with M mode approach Evaluation of diaphragmatic thickness and thickening during inspiration by analyzing the apposition zone."
46020139|NCT04264429|Device|Infrapatellar strap|Orthotic device which is positioned over the patellar tendon
46104497|NCT00600821|Drug|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg*min/ml, iv infusion, every 3 weeks.
46104498|NCT00600821|Drug|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
46104499|NCT00600821|Drug|AG-013736 (axitinib)|AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-
46104500|NCT00600821|Drug|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg*min/ml, iv infusion, every 3 weeks.
46104501|NCT00600821|Drug|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
46104502|NCT00699764|Biological|Herpes simplex candidate vaccine- adjuvanted GSK208141|Intramuscular injection, 3 doses
46104503|NCT00699764|Biological|Placebo injection|Intramuscular injection, 3 doses
46104504|NCT02658383|Other|Cleaner cookstove received after visit 2|The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 2).
46104505|NCT02658383|Other|Cleaner cookstove received after visit 4|The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 4).
45467669|NCT03706326|Biological|PD-1 knockout Engineered T cells|Using the T cells from the blood of the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients.
46104506|NCT02653703|Other|Topical L-menthol 40%|Naturally occurring local anaesthetic, counterirritant and TPRM8-agonist. CAS Number: 2216-51-5
46104507|NCT02653703|Other|Vehicle, topical ethanol 96%|Organic solvent CAS Number: 64-17-5
46104508|NCT04168463|Device|Two Joy for All robots (one cat and one dog)|Intervention will include the opportunity to interact with the Joy for All robot animals.
46104509|NCT04168541|Other|Oral Nutrition Supplement|Product intake of oral nutrition supplement provided
46104510|NCT02653781|Behavioral|Realistic simulation|The students enrolled and selected according to the inclusion criteria will be randomized into two groups. The experimental group will experience the combined teaching methodology: dialogue-exhibition and realistic simulation.
46020140|NCT04264429|Other|Elastic band|Orthotic device which is positioned over the patellar tendon
46020141|NCT01260584|Drug|Prasugrel|One 10 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
46020142|NCT01260584|Drug|Clopidogrel|One 75 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
46020143|NCT00607945|Drug|Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant|Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32
46104511|NCT02653781|Behavioral|control group|The control group will have contents exposed solely from the dialogue-exhibition.
46020144|NCT00607945|Dietary Supplement|conjugated linoleic acid (CLA)|3.2 g/day, capsule, week 0 to week 32
46020145|NCT00607945|Dietary Supplement|conjugated linoleic acid (CLA)|6.4 g/day, capsule, week 0 to week 32
46020146|NCT05176327|Device|Exoskeleton training with Ekso NR|Walking exercise with Ekso NR
46104512|NCT02653781|Behavioral|Simulation workshop|Check the performance of students in face of simulated situations on medication administration by intramuscular and intravenous routes experienced in the Skills and Care Simulation Laboratory.
46104513|NCT02653781|Behavioral|Test realistic simulation|Occurs after the end of the three-month intervention. At that time, students from the control and intervention groups will be asked to take a knowledge retention test in cognitive assessment format and OSCE format (objective structured clinical examination).
46104514|NCT00649571|Drug|Doxycycline Monohydrate Tablets (100 mg|100mg, single dose fasting
46104515|NCT00649571|Drug|Adoxa Tablets 100 mg|100mg, single dose fasting
46104516|NCT02662283|Drug|Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
46104517|NCT02662283|Drug|Reh-acteoside|Oral take and reh-acteoside (0.4g bid) for 8 weeks
46020147|NCT05331313|Genetic|DNA sequencing|The aim of this study is to perform DNA sequencing on abnormal plasmocytes obtained from patients with multiple myeloma, in order to identify alterations which are associated with the existence of this disease. DNA analyses will be performed in a single experiment once all samples have been collected.
46104518|NCT04170803|Device|Dry Needling|The participant will undergo true or sham dry needling treatment with simultaneous monitoring using the NIRS head cap.
46104519|NCT04170803|Other|Sham Dry Needling|"The participant randomized to the sham group will undergo placebo dry needling which is functionally mimicking trigger point dry needling"
46104520|NCT02653937|Drug|Tsumura's shigyakusan|"Shigyakusan appears in the early 3rd Century. Four herbal crude medicines included are the following:~Root of Bupleurum falcatum L Unripe fruit of Citrus aurantium Linne var. daidai Makino, Citrus aurantium Linne, or Citrus natsu-daidai Hayata (Rutaceae) Root of Paeonia lactiflora Pall Root and stolon of Glycyrrhiza uralensis Fisher or Glycyrrhiza glabra Linne"
46020148|NCT00609349|Device|ETED, CPET, RHC|"exercise tricuspid echo doppler (ETED): allows the estimation of systolic pulmonary arterial pressure at exercise cardiopulmonary exercise test (CPET) allows to measures exercise capacity (peakVO2)~right heart catheterisation (RHC): is the gold standard for the measurement of pulmonary arterial pressure values"
46020149|NCT04262635|Drug|Cetuximab, Capecitabine|Maintenance treatment ( ArmA )
46020150|NCT04262635|Drug|Cetuximab|Maintenance treatment ( ArmB )
46020151|NCT00608101|Drug|Fludrocortisone|Oral Fludrocortisone 0.2 mg x 2 prior to each experimental period on Day 1
46020152|NCT00608101|Drug|Dexamethasone|Oral Dexamethasone 0.75 mg x 2 administered prior to each experimental period on Day 1
46104521|NCT02657993|Behavioral|Hypnosis|"The hypnosis intervention involves three parts. First, participants will receive three, face-to-face hypnosis sessions delivered by doctoral-level psychology professionals. The sessions are based on materials developed by experienced psychologists in the Integrative Behavioral Medicine Program at the Icahn School of Medicine at Mount Sinai. Second, participants will be taught how to use hypnosis themselves (self-hypnosis) to help manage their pain. Third, participants will receive a hypnosis recording to listen to in-between sessions and throughout the course of the study. At home hypnosis practice will be recommended.~Participants will be asked to complete questionnaires over a period of 12 months."
45467670|NCT03706326|Combination Product|CAR-T combined with PD-1 Knockout T cells|Using the T cells from the blood of the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients
46020153|NCT04264039|Biological|anti-CD19 UCAR-T cells|Dose range:1 to 5 ×10^7 cells/Kg, Dose level one: 1×10^7 cells/Kg, Dose level two: 3×10^7 cells/Kg, Dose level three:5 ×10^7 cells/Kg
46020154|NCT04264039|Drug|Fludarabine|30mg/m^2 per day for 6 days
46020155|NCT04264039|Drug|Cytoxan|300mg/m^2 per day for 2 to 6 days determined by tumor burden at baseline
46020156|NCT04264039|Drug|Melphalan|50 to 70 mg/m^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
46020157|NCT00608179|Drug|Glimepiride|Glimepiride (Amaryl) 4 mg oral dose during protocol, given once during each protocol.
46020158|NCT00608179|Drug|glyburide|Glyburide (Dia-Beta) 10 mg oral dose during protocol, given once during each protocol.
46020159|NCT00608179|Other|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure-120 minutes
46020160|NCT00608179|Other|glucose clamp|hypoglycemic glucose clamp procedure -120 minutes
46020161|NCT00608335|Drug|Micafungin|IV
46020162|NCT00927589|Drug|carboplatin|Intravenous repeating dose
46020163|NCT00927589|Drug|docetaxel|Intravenous repeating dose
46104522|NCT02657993|Behavioral|Attention Control|"The attention control intervention involves three face-to-face meetings with a doctoral-level psychology professional. During these sessions, participants will be asked to discuss with the interventionist their experience of taking aromatase inhibitors and associated musculoskeletal pain. The interventionist will not lead the patient in imagery, relaxation, evaluation of thought processes, or even simple discussion. Rather interventionists will allow the patient to direct the flow of the conversation and will provide support and empathy. Interventionist contact time in AC sessions will be identical to that in the hypnosis group. Overall, the attention control intervention will control for professional attention.~Participants will be asked to complete questionnaires over a period of 12 months."
46104523|NCT02653547|Other|standard multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
46104524|NCT02653547|Other|high-frequency multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
45467671|NCT04657666|Drug|Nabiximols|oromucosal spray
46020164|NCT00927589|Drug|trastuzumab|Intravenous repeating dose
46020165|NCT04264117|Procedure|FlexAbility (Mesh-like irrigated tip catheter) group|"AF catheter ablation (PV isolation and linear ablations)~30 sec ablation in each point~35W in anterior LA, 30 W in posterior LA~Irrigation flow rate 13mL/min~Measuring procedure time, Ablation time~Rhythm follow-up based on guidelines"
46020166|NCT04264117|Procedure|TactiCath (Contract force monitoring catheter) group|"AF catheter ablation (PV isolation and linear ablations)~contact force >10g, target force-time integral 400 in each point~35W in anterior LA, 30 W in posterior LA~Irrigation flow rate 15mL/min at 30W ablation, 30mL/min at 35W ablation~Measuring procedure time, Ablation time~Rhythm follow-up based on guidelines"
46020167|NCT05145517|Device|Open repair|Open repair of the aorta and peripheral arteries
46020168|NCT04262557|Diagnostic Test|Sunrise® solution|Type II medical device with the CE label. It is a chin sensor associated to an integrated and connected platform.
46020169|NCT04262557|Diagnostic Test|Polysomnography|Gold standard method to diagnose SAS used as comparator
46020170|NCT04262245|Procedure|Traditional Irrigation|irrigation with syringe
46020171|NCT04262245|Device|Xp-endo Finisher (XPF)|irrigation activation file
46020172|NCT04262245|Device|Passive Ultrasonic Irrigation|irrigation activation method
46020173|NCT04262245|Device|EndoActivator|irrigation activation method
46020174|NCT00932425|Device|Cardionet Mobile Cardiac Outpatient Telemetry (MCOT)|Patients will be assigned to wear the telemetry device for 21 days
46020175|NCT04260061|Device|training systems|Participants will receive 18 intervention sessions for about 6-9 consecutive weeks in a clinical setting (75 minutes per session, 2-3 sessions per week). For each intervention session, participants will first receive 10 minutes of warm-up followed by 50 minutes robotic-assisted training (robotic-assisted training includes 10 minutes passive training mode, 20 minutes active training mode, and 20 minutes robot-participant interactive training mode) and then 15 minutes of functional activity without robotic-assisted (content will be related to robotic-assisted training and will be based on the action function and preferences of the participants).
46020176|NCT05254873|Other|Long term follow-up|Long term follow-up for patient who completed the EYE-TAR(MA) study.
46104525|NCT02653547|Other|standard multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
46104526|NCT02653547|Other|high-frequency multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
46104527|NCT02657759|Dietary Supplement|CARDICHOL|
45467672|NCT04657666|Drug|Placebo|oromucosal spray
45467673|NCT05278507|Device|Arrowga+rd Blue Advance Protection PICC Placement|The PICC will be placed by a qualified healthcare professional, in accordance with institutional policies and procedures and the device's IFU.
46104528|NCT02657759|Dietary Supplement|PLACEBO|
46104529|NCT02657603|Drug|Lidocaine|Lidocaine injected through the new Catheter (LAX)
45467674|NCT05278507|Device|Sham Comparator PICC placement|The sham comparator PICC will be placed by a qualified healthcare professional, in accordance with institutional policies and procedures and the device's IFU.
45467675|NCT04882917|Drug|M4076|M4076 will be administered orally, in Part 1A and Part 1B.
46104530|NCT02657603|Drug|Lidocaine|Lidocaine injected through the new Catheter (SAX)
46104531|NCT02657603|Procedure|LAX insertion of catheter|ultra sound guided cather insertion in the long axis (LAX) of the adductor canal
46104532|NCT02657603|Procedure|SAX insertion of catheter|ultra sound guided cather insertion in the short axis (SAX) of the adductor canal
46104533|NCT02657447|Drug|Betalutin with lilotomab dose 1|15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 1
45599260|NCT02343861|Behavioral|Tailored leaflet group|Parents in intervention group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients. In addition to general information, parents in intervention group will also receive the tailored leaflet including the estimated amount of emollients based on the body surface area.
46020177|NCT04264195|Other|Constraint-induced movement therapy: PEPS-MIT|"All participants of control and experimental groups received standard stroke rehabilitation. After regular office time, a 2 hours' peer group session was provided, 5 days/week, 4 consecutive weeks, to both groups. One patient 'leads' the group exercises under a therapist's supervision. The therapist is mainly helping and correcting patients during the various exercise tasks.~• Specific for the experimental group was that patients performed all manipulation tasks with forced use of the paretic hand/arm by wearing a soft-padded mitten at the non-paretic hand, preventing manipulation with that hand. Patients were encouraged to wear the mitten also for 3 hours/day at home, while performing ADL and learned exercises. Behavioural strategies included a treatment contract and daily use of the home activity checklist which was checked by patient's caregiver and signed by both patient and caregiver. Each treatment day the activity checklist was submitted to the therapist who gives feedback."
46020178|NCT04264195|Other|Bimanual manipulation exercises (PEPS-Bimanual)|"All participants of control and experimental groups received standard stroke. After regular office time, a 2 hours' peer group session was provided, 5 days/week, 4 consecutive weeks, to both groups. One patient 'leads' the group exercises under a therapist's supervision. The therapist is mainly helping and correcting patients during the various exercise tasks.~Specific for the control group was that patients performed all manipulation tasks bimanually, as they used to do in occupational therapy activities. Patients were also asked to document their 'at home' activities in an activity checklist that was regularly checked by the therapists."
46020179|NCT04263883|Device|Study or Experimental Group|3D PCO to make mirror image therapy (reverse posture training) during the patient walking on motorized treadmill, This way of functional training will deliver via the use of the adjustable cervicothoracic orthosis during the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image traction.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill based on Harrison et al., approach, this program will be repeated 2-3 times /week for 10weeks.
45467676|NCT05174676|Device|Dextreme|"A unique robotic device capable of applying motor error enhancement forces during upper limb practice in a virtual environment. The forces stimulate the body's instinctive adaptive response, which does not require the use of cognition to correct the movement.~The setting of stroke patients in a simulated environment enhances patient motivation and participation. The completion of games (tasks) is a great indicator for the patients that they are progressing in the treatment and are on their way to recovery."
46020180|NCT00932113|Drug|Methotrexate|"2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.~Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study."
46104534|NCT02657447|Drug|Betalutin with lilotomab dose 2|15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 2
45467677|NCT04858347|Device|Total knee replacement|Implantation of the GEMINI SL Fixed Bearing PS knee prosthesis. The operation technique of the GEMINI SL Fixed Bearing PS knee prosthesis will be followed.
46020181|NCT00932113|Drug|Adalimumab (Humira)|2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.
46020182|NCT00931801|Drug|atazanavir/raltegravir|Atazanavir/r 300/100mg once daily plus raltegravir 400mg twice daily
46020183|NCT00931801|Drug|atazanavir/raltegravir|Atazanavir 300mg twice daily plus raltegravir 400mg twice daily
46020184|NCT00931801|Drug|atazanavir/tenofovir/emtricitabine|Continue baseline regimen of atazanavir/r 300/100mg once daily plus tenofovir and emtricitabine
46020185|NCT04263805|Other|Vignette with emphasis on research climate|A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without a research environment factor (i.e. an environment where other researchers commit detrimental research practice)
46020186|NCT00931723|Drug|Quetiapine fumarate XR|Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.
46020187|NCT00931723|Drug|Lithium|Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.
46020188|NCT00931723|Drug|Placebo|Oral treatment twice daily.
46020189|NCT05026021|Biological|Blood sample|For each patient blood (17 ml of whole blood) will be collected during a peripheral venous blood sample carried out in the the standard care at inclusion visit, M3 visit (3 months after inclusion) and M6 visit ( (6 months after inclusion)
46020190|NCT04263415|Drug|Semaglutide|semaglutide inrun period of 4 weeks with 0.5mg/week s.c. followed by 1mg/week sc for 12 weeks
46020191|NCT04263415|Other|Placebo|once-weekly injection with placebo pen for 16 weeks
46020192|NCT05025397|Drug|Danavorexton|Danavorexton intravenous infusion.
46104535|NCT02657681|Device|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability. Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the motor cortex, over the representational field of hand area contralateral to the more affected side of the body.
45467678|NCT04645966|Biological|MenABCWY|Neisseria meningitis groups A, B, C W, and Y vaccine
46020193|NCT05025397|Drug|Danavorexton Placebo|Danavorexton placebo-matching intravenous infusion.
46020194|NCT05025397|Drug|Propofol|Propofol intravenous bolus.
46020195|NCT05025397|Drug|Sevoflurane|Sevoflurane inhalation.
46020196|NCT05025397|Drug|Propofol|Propofol intravenous infusion.
46020197|NCT00608803|Drug|ZIO-201-T and doxorubicin|ZIO-201-T given for 3 consecutive days every 3 weeks. Doxorubicin is given once every 3 weeks. This is a dose escalation arm.
46020198|NCT05234359|Diagnostic Test|Serology Testing|A simple home sampling kit containing volumetric absorption microsampling devices (Mitra(R) cartidge device, Neoteryx LLC) will be used by the participants to collect a finger stick blood sample (10 ul; a few drops). Kits will be delivered to participants' homes and returned by mail. An instructional video will be provided.
46020199|NCT05234359|Diagnostic Test|Stool sample|Stool samples collected for genetic, microbial and viral analysis.
46020200|NCT00931411|Other|Formulation 609580 20|Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
46020201|NCT00931411|Other|Formulation 609209 (Lipikar Baume)|Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
46020202|NCT04250935|Diagnostic Test|Patients with cognitive dysfunction|Mini Mental Test Those with a score below 21 points
46020203|NCT00931255|Drug|Tacrolimus|3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol
46020204|NCT00931255|Drug|Sirolimus|5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol
46020205|NCT05204485|Procedure|Fibular intramedullary nail|The standard manufacturers approved technique will be performed including the use of 2 distal interlocking screws and the use of a minimum of 1 fibula pro tibia fixation screw depending on the patients' anatomical characteristics.
46020206|NCT05204485|Procedure|Open reduction and internal fixation|An open approach (direct lateral or posterolateral incision) will be carried out. The reduction will be performed using standard techniques of clamping and traction. Fixation will be performed after reduction of the fracture with a plate and screw construct. The surgeon will then proceed to perform surgical fixation of other associated fractures or ligament injuries as indicated. This will most often include open reduction and internal fixation of the medial malleolus with screws through a separate medial incision.
46020207|NCT04263103|Other|SJ-RS-WL2015 visual training program software|It is a software with perceptual learning methods for binocular functions
46104536|NCT02657681|Device|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain).
46104537|NCT00649649|Drug|Quinapril Hydrochloride Tablets 40 mg|40mg, single dose fed
46104538|NCT00649649|Drug|Accupril® Tablets 40 mg|40mg, single dose fed
46104539|NCT00592904|Drug|E2007|Perampanel doses will be up-titrated in 2 mg steps at minimum weekly intervals starting at 2 mg daily and up-titrated to 12 mg daily (taken orally).
46104540|NCT02657291|Drug|Ropivacaine|Local anesthetic
46104541|NCT02657291|Device|Ultrasound|Ultrasound guided block
46104542|NCT02662205|Other|Psychotherapy Group|Traditional process group
46020208|NCT00609193|Drug|lithium|standard clinical care
46020209|NCT00609193|Drug|quetiapine|standard clinical care
46020210|NCT00930553|Biological|alemtuzumab|Alemtuzumab 12 mg/day IV infusion on 5 consecutive days if the participants had no prior alemtuzumab exposure (ie, first treatment course). All subsequent treatment courses were for 3 days only.
46020211|NCT00609427|Behavioral|MEMO programme (Inst Universitaire de Geriatrie, Montreal)|8 weekly group training sessions in mnemonic strategies, administered by clinical psychologist.
46020212|NCT00609427|Behavioral|External memory aids training|8 weekly group sessions of training in the use of external memory aids, administered by clinical psychologist
46020213|NCT00609505|Other|Telemedicine|Telemedicine genetic counseling
46020214|NCT00609505|Other|Face-to-Face|Face-to-face genetic counseling
46104543|NCT02662205|Other|Yoga class|Yin yoga class
46104544|NCT02662205|Other|Yoga Therapy Group|Yoga psychotherapy group integrating yoga and process dialogue
46104545|NCT04118426|Radiation|Cognitive testing|"Patients will have their cognitive function tested by the use of standardized cognitive test and fill in questionnaires.~Cognitive function will be assessed by standardized cognitive tests: Hopkins verbal learning test (HVLT), Trail Making Test part A and B (TMT A and TMT B), Pased Auditory Test (PASAT), Wechsler Adult Intelligence Scale coding and digit span (WAIS-IV), Controlled Oral Word Association Test (Cowat) and STROOP colour and word test (STROOP)~Questionnaire include; Quality of life; EORTC QlQ-C30 (QlQ-C30), FACIT-Fatigue Scale (Version 4) (FACIT), Pittsburg Sleep Quality Index (PSQI), Hospital Anxiety and Depression Scale (HADS), Patient's Assessment of Own Functioning Inventory (PAOFI)."
46020215|NCT04262089|Drug|Pembrolizumab (Keytruda)|Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 2 administrations per patient, integrated into standard-of-care protocol prior to surgery. Based on the well-established time lines, the interval between diagnosis and standard of care hysterectomy is sufficient to treat patients with two cycles of pembrolizumab without interfering with standard of care.
46104546|NCT02662127|Device|SIGVARIS® Class 2 - RAL: 23-32.|Below knee graduated elastic compression stocking
46104547|NCT00699920|Drug|Coarsucam|Oral route, once daily, dose according to bodyweight range Duration of treatment: 3 days
46020216|NCT04262011|Procedure|immediate treatment|Patients allocated to the immediate treatment group will receive full mouth treatment, and will use 0.12% chlorhexidine mouthwash, every 12 hours for a week, and will receive oral hygiene instructions throughout the follow-up period. Patients will be evaluated at the beginning, at 3 and 6 months.
46020217|NCT04262011|Procedure|postponed treatment|Patients allocated to the late treatment group will be assessed at baseline, 3 and 6 months. After the end of the follow-up period, they will receive non-surgical periodontal treatment performed in four sessions.
46020218|NCT04261933|Drug|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
46020219|NCT00609817|Drug|GCS-100|GCS-100 160mg/m2 IV (in the vein) on Study Days 1, 4, 8 and 11 for up to 12 consecutive 21-day treatment cycles. Three patients will be assigned to each cohort until maximum tolerated dose is reached. The dose levels: 1) 160 mg/m2; 2) 210 mg/m2; 3) 280 mg/m2; 4) 370 mg/m2
46104548|NCT00699920|Drug|Coartem|Oral route, twice daily, dose according to bodyweight range Duration of treatment: 3 days
46104549|NCT02661893|Drug|JNJ-42847922|A single oral dose of 40 milligram (mg) (=2*20 mg) dose of JNJ42847922 on Day 1, Day 5 and Day 12.
46104550|NCT02661893|Drug|Rifampin|Oral dose of rifampin 600 mg (2*300 mg) on Day 5 and once daily dosing of rifampin with an oral dose of rifampin 600 mg (2*300 mg) on Days 5 to 12.
46104551|NCT04131608|Diagnostic Test|CBC ,Serum ferritin ,HBA1C|Diabetic patients will be applied to CBC, HBA1C and serum ferritin
46020220|NCT00609817|Drug|Bortezomib/Dexamethasone|Bortezomid 1.3 mg/m2 and dexamethasone 20 mg/day plus an additional 20 mg of dexamethasone on the day following each of the GCS-100/bortezomib and dexamethasone dosing. GCS-100/bortezomib and dexamethasone dosed on Study Days 1, 4, 8 and 11 of each 21-day cycle after disease progression is noted.
46104552|NCT04170881|Other|Exposed/non exposed - Epidemiology|visit of daycares and environmental measurement will be performed
46104553|NCT02653235|Biological|Salmonella typhi vaccination|
46104554|NCT02653235|Biological|Placebo|
46104555|NCT02653469|Other|Augmented ventilation|When the patient's PPV is within grey zone, patient's tidal volume is maintained with augmented tidal volume of 12 ml/kg (from normal ventilation of 8ml/kg) for 2min duration.
46104556|NCT02653469|Other|Fluid loading|We record the stroke volume index (SVI) values before and after volume expansion with 6ml/kg of balanced crystalloid
46104557|NCT00855920|Drug|Rilonacept|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 (Baseline).
45467679|NCT04645966|Biological|Bivalent rLP2086 (60-µg Dose)|Trumenba (half dose) - Meningococcal Group B vaccine
45681096|NCT03973294|Device|EIT-measurement|"The use of electrical impedance tomography (EIT) (SentecTom BB2, Landquart, Switzerland) allows the investigators to obtain a visual and quantitative representation of the areas of ventilation and aeration of the lung. The fundamental principle of lung EIT relies on the application of small alternating electrical currents into the thorax and voltage measurements using electrodes on the skin surface generating cross-sectional images representing impedance change in a slice of the thorax. It is a radiation-free imaging method which has the advantage to reveal real-time information.~An array of electrodes (textile belt with 32 integrated electrocardiographic electrodes) has to be placed around the thorax to inject currents and to measure the resulting voltages on the thoracic surface."
46104558|NCT00855920|Drug|Indomethacin|Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
46104559|NCT00855920|Other|Placebo (for Indomethacin)|Placebo (for Indomethacin) orally TID for 12 days.
46104560|NCT00855920|Other|Placebo (for Rilonacept)|Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 (Baseline).
46020221|NCT00929695|Drug|prednisone|immunosuppressive drug
46020222|NCT00929695|Drug|methylprednisolone|immunosuppressive drug
45681097|NCT03591172|Drug|Propolis|Using propolis as a final irrigation in revascularization
46020223|NCT00929695|Other|questionnaire administration|Ancillary studies
46020224|NCT00609895|Drug|INSULIN GLARGINE|
46104561|NCT04168307|Device|Ankle trainer device|The ankle trainer provides passive stretch in dorsal flexion of the ankle as well as active plantar flexion.
46104562|NCT04168307|Other|Conventional physiotherapy|The patients were instructed in stretching exercises using a non-elastic band
46104563|NCT02657213|Device|Minimed 640G with smartguard activated|Patients will be equipped with a Minimed 640G insulin pump coupled with Enlite sensor with SmartGuard activation
45681098|NCT03591172|Drug|Nano-propolis|Using Nano-propolis as a final irrigation in revasculariztion
45681099|NCT03591172|Drug|saline|Using saline as a final irrigation in revasculariztion
45681100|NCT04197622|Drug|Hydrochlorothiazide|12,5 mg of hydrochlorothiazide (1/2 tablet of 25 mg) administered orally in a single dose.
46020225|NCT04261465|Drug|Olaparib|PARP INHIBITOR
46104564|NCT02657213|Device|Minimed 640G with smartguard off|Patients will be equipped with Minimed 640G insulin pump coupled with Enlite glucose sensor without SmartGuard activation
46104565|NCT00649727|Drug|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
45467680|NCT04645966|Biological|Bivalent rLP2086 (120-µg Dose)|Trumenba - Meningococcal Group B vaccine
46020226|NCT04261465|Drug|Paclitaxel|Chemotherapy
46020227|NCT04261465|Drug|Carboplatin|Chemotherapy
46020228|NCT05115643|Behavioral|Immobilization|Immobilization of left arm using a brace and sling.
46020229|NCT05095519|Drug|18F-DCFPyL|18F-DCFPyL will be administered with a single dose of 3.5 MBq per kg (2-4 MBq per kg), maximum 400 MBq), administered as a slow (over 30 seconds) intravenous injection
46020230|NCT04260919|Procedure|Chest physiotherapy|
46020231|NCT04260997|Dietary Supplement|Lactobacillus gasseri BNR17™ capsule|Once per day (QD), 12 weeks
46020232|NCT04260997|Other|Placebo capsule|Once per day (QD), 12 weeks
46020233|NCT04260763|Behavioral|Social Cognition Group|Each session lasts 90 minutes and includes three 20-minute work packages tapping different social cognition skills; specifically affect recognition and theory of mind/mental state attribution in this study. Examples of the work packages include guessing the emotions of others based on their facial expressions, activities such as indicating how confident participants feel about guessing emotions when looking at more ambiguous pictures, and watching/discussing video clips with content relevant to the group.
46104566|NCT00649727|Drug|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
46104567|NCT00650273|Drug|Azithromycin Tablets 600 mg|600mg, single dose fasting
46104568|NCT00650273|Drug|Zithromax® Tablets 600 mg|600mg, single dose fasting
45467681|NCT04645966|Biological|Bexsero|Bexsero - Meningococcal Group B vaccine
45467682|NCT04645966|Drug|Prophylactic Liquid Paracetamol (PLP)|PLP administration during primary vaccinations 1 and 2
45467683|NCT04645966|Biological|Nimenrix|Nimenrix - Meningococcal Group A, C, W and Y vaccine
46020234|NCT04260763|Device|Novel Mobile App|"The novel homework app was designed to deliver tasks to the participants between group therapy sessions. Three types of task were delivered by the app; 'Stories', 'Emotions', and 'Facts and Guesses'. The 'Stories' task was designed to encourage participants to think about how thoughts, emotions and actions interact. Participants were presented with a short vignette and asked to identify the emotion or behaviour of a character. 'Emotions' aimed to target affect perception by presenting faces of different emotion presentations and asking clients to select the correct emotion from a list of three, whilst 'Facts and Guesses' aimed to address difficulties with jumping to conclusions in social situations by showing clients a photograph of a social situation and asking them to determine whether a given statement about the photo was a fact or a guess. Confidence in answers was also assessed in order to encourage flexible thinking."
46020235|NCT05080465|Biological|Autologous BM MSC|A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.
46104569|NCT04319939|Other|Assist Control Mode and Pressure Support Mode Mechanical Ventilation|Diaphragm ultrasound measurements (end expiration and peak inspiration thickness) will be performed in assist control mode and pressure support mode mechanical ventilation in each participant. The participant will thus serve as his/her own control for these interventions.
46020236|NCT00610285|Other|Fabrication of thermoplastic face (The Orfit thermoplastic face mask system is routinely used for the treatment of brain and head)|Each patient in the protocol will receive their regularly scheduled SRS treatment plus an additional mock treatment using the non-invasive immobilization system.
46020237|NCT04260841|Device|bed in 45 degrees for passive leg raising test|fluid responsiveness is tested by the passive leg raising test
46020238|NCT00610519|Dietary Supplement|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the throat.
46020239|NCT00610519|Dietary Supplement|placebo|0:1% of Lemon VIP (Florasynth,Israel), spraying to the throat.
46104570|NCT00848042|Device|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions
46104571|NCT02657135|Behavioral|Cognitive/Neuropsychological Testing|These tests will be used to determine how the participant will continue with future procedures, and depending on results, may involve the participant returning to complete subsequent testing.
45467684|NCT04645966|Other|Placebo|Normal Saline
45467685|NCT04645966|Drug|Scheduled Liquid Paracetamol (SLP)|SLP administration after primary vaccinations 1 and 2.
46020240|NCT05063617|Device|SCI Step Together|The 8-week program features weekly blocks of content. Each week builds from the previous week and targets specific components related to the three basic psychological needs (autonomy, relatedness, competence). The overall cadence of each weekly block is maintained throughout. For example, each week contains: 1) education modules 2) a worksheet or guided practice to apply the strategies in their own goals for that week along with embedded questions to discuss with their community coach 3) behavioural support from the community coach and 4) peer support from the discussion group.
46020241|NCT05062213|Other|Moisturizer Body Lotion|Moisturizer Body Lotion
46104572|NCT02657135|Other|Vestibular/Ocular-Motor Testing|These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI and will include dizziness, balance, ocular-motor coordination, and reflexes.
46104573|NCT02657135|Other|Cervical (Neck) Evaluation|These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI including neck mobility and pain levels.
46104574|NCT02657135|Other|Sleep Evaluation|These evaluations will focus on assessing insomnia (duration, frequency, daytime consequences), combat exposure, and the presence and severity of trauma history.
46104575|NCT02657135|Other|HDFT MRI|This MRI aims at providing qualitative and quantitative assessments of the nature, location, and extent of white matter injury.
45467686|NCT04645966|Drug|Therapeutic Liquid Paracetamol (TLP)|TLP administration after primary vaccinations 1 and 2
45467687|NCT03773809|Other|Vitamin D capsule|The intervention was given by oral administration of vitamin D3 capsule each of which contains 40000 IU of vitamin D3. The capsule was manufactured and supplied by Beximco Pharmaceutical Limited, Bangladesh. The placebo was also be manufactured and supplied by the same pharmaceutical company and was similar in size shape & appearance to vitamin D3 capsule but contained all the ingredients of vitamin D capsule other than the vitamin D3
45467688|NCT03773809|Other|placebo|oral administration of placebo
45467689|NCT04840095|Drug|Ketones|Sports supplement that is administered mid-scan.
45467690|NCT04840095|Drug|Glucose|Supplement is administered mid-scan.
45467691|NCT05172492|Device|Endocare|Endocare will be administred through a virtual reality headseat used one to twice a day.
46104576|NCT02657135|Other|MR Spectroscopy (MRS)|This is a noninvasive diagnostic test for measuring biochemical changes in the brain.
46104577|NCT02657135|Other|MEG (Magnetoencephalography)|This is a non-invasive neurophysiological technique that measures the magnetic fields generated by neuronal activity of the brain.
45467692|NCT05172492|Device|Digital control|Digital control will be administred through a virtual reality headseat used one to twice a day.
45599261|NCT02343861|Behavioral|Control group|Participants (parents of children with atopic dermatitis) in control group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients.
46020242|NCT04260607|Drug|Ketamine Hydrochloride|"Experimental Procedure~Baseline evaluation of suicidal severity (BSSI) & degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~The experimental and placebo arms will receive a single dose of IV ketamine, 0.5 mg/kg in 100 cc NS or 100 cc of NS infused over 40 minutes.~Post ketamine re-evaluation of outcome measures at four and twenty-four hours will determine clinical effectiveness of ketamine intervention~Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~Post ketamine re-evaluation of outcome measure at one-week post infusion will elucidate ketamine's durability of effect."
46020243|NCT04260607|Drug|Normal saline|"Experimental Procedure~Baseline evaluation of suicidal severity (BSSI) & degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~The placebo arms will receive a single dose of 100 cc of NS infused over 40 minutes.~Post Placebo infusion re-evaluation of outcome measures at four and twenty-four hours~Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~Post Normal Saline re-evaluation of outcome measure at one-week post infusion."
46020244|NCT04875325|Other|Standardized surveillance|Standardized 3-monthly surveillance with routine imaging and serum tumor marker testing.
46020245|NCT00927355|Drug|Pioglitazone|6 month treatment with pioglitazone 15mg for four weeks with dose increased to 30mg if no adverse effects (swelling of lower extremities, liver enzyme elevation) noted at the four week mark.
46020246|NCT00927355|Drug|Placebo|"The placebo pills also start out with one (15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician."
46020247|NCT00923845|Drug|Pentostatin|Pentostatin: 2- 4mg/m^2(CrCL based dosing) intravenous (IV) on days 1, 8, and 15
46020248|NCT00923845|Drug|Sirolimus|Sirolimus: 4 mg by mouth (PO) on days -3 to +7 post-transplant (No Sirolimus administered after day 7 post-stem cell transplant (SCT))
46020249|NCT00923845|Drug|Cyclophosphamide|Cyclosporine: 2 mg/kg every 12 hours PO or IV starting on day -4 of hematopoietic stem cell transplant (HSCT)
46020250|NCT00923845|Procedure|Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|Allogeneic Hematopoietic Stem Cell Transplant
46020251|NCT00923845|Procedure|Th2 rapa cells|Th2 rapa cell Transplantation
46020252|NCT00923845|Procedure|Donor Lymphocyte Harvest|Apheresis
46020253|NCT00923845|Procedure|Induction Therapy|Pentostatin and cyclophosphamide (PC) conditioning regimen.
46020254|NCT00923845|Procedure|GVHD prophylaxis|Short course of sirolimus plus maintenance therapy with sirolimus A.
45681101|NCT03592654|Behavioral|infant telehelp|Adapted from Early Start Denver Model (ESDM), a naturalistic developmental behavioral intervention
46020255|NCT00923845|Procedure|Donor Hematopoietic Stem Cell Harvest|Following lymphocyte harvest, donors for recipients will undergo stem cell mobilization and harvest.
46020256|NCT05329597|Genetic|Genotyping|Genotyping is performed using the subjects' blood cells
46020257|NCT05329519|Behavioral|Listening music|Patients in both groups underwent VATS with wedge recession and the same surgical methods were employed. After the surgery, the patients in the music group performed deep breathing and coughing exercises while listening to music for thirty minutes a day with a MP3 player (Goldmaster Goldsmart Mp3-159 Player) and head phones on postoperative days 1, 2, and 3. We prepared a list of popular songs of different genres, including Turkish classical, folk, pop and rock music, classical music and foreign music, and allowed them to choose the song to be listened.
46020258|NCT04256239|Behavioral|Dignity Therapy|Intervention aimed at enhancing patients' sense of personhood, purpose, meaning, and self-worth and reducing psychosocial and existential distress
46104578|NCT00698126|Drug|soluble human insulin|Observational study; use of the products as in the normal clinical practice conditions
46104579|NCT00698126|Drug|biphasic insulin aspart|Observational study; use of the products as in the normal clinical practice conditions
45681102|NCT03596008|Dietary Supplement|Active drink|The freeze-dried strawberry powder (25 g) in active drink
45681103|NCT03596008|Dietary Supplement|Placebo drink|Placebo drink
46020259|NCT04260451|Other|ventilation|"Driving Pressure Limited Ventilation~Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 10 to 2 cmH2O during one-lung ventilation.~1. Lung recruitment: stepwise increase of positive end expiratory pressure 5,10,15 cmH2O with tidal volume 5mL/kg, inspiratory:expiratory 1:1, respiratory rate 10. and driving pressure up to 20 cmH2O. Then decremental PEEP titration is performed using a volume-controlled ventilation until the lowest driving pressure (plateau pressure minus PEEP) is found. This individualized PEEP is adjusted during one-lung ventilation."
46020260|NCT04260373|Drug|[14C]SHR4640|Patients will receive single dose of orally [14C]SHR4640 on Day 1.
46020261|NCT05052541|Drug|THC/CBD|Oral solution containing 5mg THC and 50 mg CBD per 1 ml
46020262|NCT05052541|Drug|THC|Oral solution containing 5mg THC per 1 ml
46020263|NCT05052541|Drug|Placebo|Oral solution containing no active drug
46104580|NCT02657057|Device|PTNS|The needle and electrode are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
45599262|NCT03676751|Drug|Azithromycin|Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
46104581|NCT02657057|Device|TENS SNS|Electrodes are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
46104582|NCT00701012|Procedure|preservation of nerve fibers around IMA|low ligation
45599263|NCT03676751|Drug|Placebo|Oral suspension of placebo for azithromycin
46020264|NCT04260685|Drug|Lidocaine|IV bolus of 1.5mg/kg lidocaine 1% followed by continuous infusion of 1.5mg/kg/h
46020265|NCT04260685|Drug|Esmolol|IV bolus of esmolol 0.5 mg/kg followed by continuous infusion of 100-300 ug/kg/min
46020266|NCT04259593|Other|exercise training|
46020267|NCT05052151|Other|Low dialysate temperature|35°C
46020268|NCT05052151|Other|High dialysate temperature|37°C
46020269|NCT05052151|Other|Low dialysate bicarbonate concentration|30 mmol/L
46020270|NCT05052151|Other|High dialysate bicarbonate concentration|38 mmol/L
46020271|NCT05013853|Procedure|Restoration teeth|Remove caries and restore with resin composite
46020272|NCT00610831|Device|DIRECTVIEW CR Mammography|4 views screening mammogram
46020273|NCT05013463|Drug|Hydroxychloroquine Pill|Oral Hydroxychloroquine, 200mg BID
46020274|NCT05013463|Drug|Indapamide Pill|Oral Indapamide, 2.5 mg OD
46020275|NCT05011591|Other|Swimming economy|Detailed in arm's section
46104583|NCT00701012|Procedure|resection of nerve fibers around IMA|high ligation
46020276|NCT00922987|Drug|Lyrica (pregabalin)|The daily dose may range from 150mg to 600mg, administered as two single doses. The treatment should be started with 150mg daily dose (2x75mg). Depending on response and tolerability after 7 days may the dose be increased to 300mg/day (2x150mg) and after further 7 days to maximum dose 600mg/day (2x300mg)
46020277|NCT00610909|Drug|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in increments of 12.5 mg daily for the first week and increased at 12.5 mg increments at visit weeks to a maximum of 50 mg daily, as determined by the investigator. The investigator will adjust dosage based on clinical response. Following the completion of the double-blind phase, patients on placebo and non-responders to the study drug will be tapered off the study drug back to 0 over 2 weeks, and they will be referred to their Primary Care Physician, Internist or Gastroenterologist to be prescribed treatment for Irritable Bowel Syndrome.
46020278|NCT00610909|Drug|Placebo|Placebo
46020279|NCT05331079|Other|Cryotherapy|20 minutes of cryotherapy on the dominant knee with ice bags
46020280|NCT05046691|Behavioral|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
46104584|NCT02661659|Biological|Multipeptide vaccine S-588210|
46104585|NCT04168151|Other|lung recruitment protocol|lung recruitment protocol applied to postcardiac surgery hypoxic adult patients with measurement of trans alveolar pressure as an index for lung recruitment
45599264|NCT02302651|Device|MR guided High Intensity focused ultrasound|High Intensity Focused Ultrasound is a totally non-invasive procedure that can destroy tumors transcutaneously; safety and efficacy profile are dramatically increased by the MRI guidance
46020281|NCT00928135|Drug|Xylitol|15% xylitol solution for aerosol; Dosage: 5 ml twice a day (BID)
46020282|NCT00928135|Drug|Hypertonic saline|7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)
46020283|NCT04259827|Other|Neuronation|Online cognitive training app, with exercises created for patients with mild cognitive impairment
46020284|NCT04259827|Other|Aspecific online games|Online gaming without cognitive training
46104586|NCT02661425|Other|EnteraGam|Serum-derived bovine immunoglobulin/protein isolate (SBI) is the nutritional ingredient in EnteraGam. SBI contains a minimum of 50% immunoglobulin. The protein isolate is a light-colored powder. Each packet contains SBI (5.0 g) and the following inactive ingredients: dextrose (5.0 g) and a trace amount of sunflower lecithin.
46104587|NCT02656901|Device|auto total endovenous anesthesia|a closed-loop controller guided by the BIS steering the infusion pumps (Alaris Medical UK Ldt, Hants, Uk) as already approved by ClinicalTrials.gov Identifier: NCT00392158
46104588|NCT02656901|Device|Manual Desflurane anesthesia|General anesthesia will be maintained with desflurane (Baxter D-Vapor Desflurane Vaporiser) to obtain a BIS value as close as possible to 50 and between 40
46104589|NCT02656901|Device|Manual Sevoflurane anesthesia|General anesthesia will be maintained with sevoflurane ( Baxter Vapour 2000 Sevoflurane Vapouriser) to obtain a BIS value as close as possible to 50 and between 40 and 60.
46020285|NCT00928057|Device|4mm x 32G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 4mm PN, with no pinch up.
46104590|NCT02656901|Device|Manual total endovenous anesthesia|In ManualTIVA group, the anesthesia will be maintained with propofol (Injectomat TIVA Agilia, Fresenius Kabi, Bad Hamburg, Germany) to obtain a BIS value as close as possible to 50 and between 40 and 60.
46104591|NCT00847886|Drug|LX3305|Daily oral intake of LX3305 for 14 days.
46104592|NCT00847886|Drug|LX3305 Placebo|Matching placebo dosing with daily oral intake for 14 days.
46104593|NCT00847886|Drug|Methotrexate|Once weekly stable-dose methotrexate.
46104594|NCT04315649|Other|3D movie viewing|3D movie viewing
46104595|NCT02653157|Other|MDR-GNB|
46104596|NCT00847808|Drug|Dexlansoprazole MR QD|Dexlansoprazole MR 30 mg, capsules and dexlansoprazole MR placebo-matching capsules, orally, each once daily for up to 6 weeks.
46104597|NCT02656979|Drug|Latanoprost|Between measurements on day 1 and day 2, the subjects will receive a drop of latanoprost which is an IOP lowering drug once daily in one eye.
46104598|NCT02656667|Device|neuromuscular electrical stimulation|quadriceps strenghthening with neuromuscular electrical stimulation (medical device)
46104599|NCT02656667|Device|cycle ergometer training|quadriceps strenghthening with cycle ergometer training
46104600|NCT02656667|Other|Conventional pulmonary rehabilitation|excercise training on treadmill
46020286|NCT00928057|Device|8mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
46104601|NCT00701168|Device|yttrium Y 90 microspheres (Therasphere®)|This is a local therapy for unresectable liver tumors with limited treatment options. It may be repeated under special circumstances.
46104602|NCT04168229|Device|Mermaid 9 ITE|A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and receiver housed in an in-the-ear hardware.
46104603|NCT04168229|Device|Mermaid 9 BTE|A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and Receiver housed in a behind-the-ear hardware.
46104604|NCT04017455|Drug|Atezolizumab|3 cycles of atezolizumab 840 mg
46104605|NCT04017455|Drug|Bevacizumab|3 cycles of bevacizumab 5mg/kg
46104606|NCT05298020|Drug|Envafolimab|400mg,sc,d1,Q4W
46104607|NCT05298020|Drug|Endostar|210mg，CIV72h，d1-3，Q4W
46104608|NCT05298020|Drug|Nab paclitaxel|125mg/m2,iv,d1,d8,Q4W
46104609|NCT05298020|Drug|Gemcitabine|1000mg/m2, iv,d1,d8，Q4W
46104610|NCT02536469|Drug|HuMax-IL8|HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle
46104611|NCT02661581|Behavioral|Peer Support|The intervention is lifestyle change. First, the peer leaders will be trained how to conduct diabetes self-management education and support sessions. During the first 3 months, all the participants will attend the diabetes self-management education sessions. The participants in the intervention arm will also receive diabetes self-management support sessions as well. In the end of the first 3 months, the intervention group participants will receive weekly support sessions for 9 months.
46020287|NCT00928057|Device|5mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 5mm PN, with no pinch up.
45467693|NCT05041231|Device|Photobiomodulation therapy (PBT)|"Any invasive procedures will be done. The treatment in question will be done by a device that looks like a bracelet, which is placed on the hand/fingers to emit light/laser and does not cause pain or temperature change. There will be 8 photobiomodulation sessions, 2 per week, 10 minutes each session.~The dosimetric parameters of the therapy will be carried out in a standardized and personalized way, with programming of the light and all the necessary information so that the device can carry out the application of the treatment application of electromagnetic waves in the red and infrared spectral range 660-1000 nm)."
45467694|NCT05041231|Device|Sham Photobiomodulation therapy (Sham PBT)|Similar to active PBT, however, the device will not provide the active electromagnetic waves)
45467695|NCT05170386|Other|Cognitive training Therapy|"Cognitive training Therapy include: Writing the reminiscences~• Solving a table• Writing a letter making a calendar and writing a note about the daily activities on it Facing patients' fears instead of avoiding them.Using role-playing to prepare for potentially problematic interactions with others.Learning to calm one's mind and relax one's body."
46104612|NCT02652845|Behavioral|Wellness Engagement Program|This intervention is an evidence based and community informed program designed to stimulate physical activity and increase healthy food choices among participants. The intervention includes weekly lessons, personal support in the form of biweekly check in calls with a peer support coach and weekly physical activity and nutrition classes.
46104613|NCT04170647|Drug|Plasminogen Activators|standard dosage of 0.9 mg/kg or reduced dosage of 0.6 mg/kg, divided into a 15% bolus and an 85% venous infusion
45467696|NCT05170386|Other|instructive conventional treatment|instructive conventional treatment breathing relaxation exercise inform of diaphragmatic breathing Practice sleep hygiene such as keeping a regular sleep schedule. Get regular exercise. Minimize noise. Minimize light. Manage the temperature so that you're comfortable.
45467697|NCT04645654|Behavioral|Hypnosis|Three sessions of 30 minute hypnosis, based on standardised script, focused on pain management.
45467698|NCT01313611|Drug|Rituximab + bendamustine|Induction phase: rituximab and bendamustine on Day 1, Bendamustine on Day 2, Rituximab on Day 8, Rituximab on Day 15, Rituximab on Day 22, bendamustine on Day 29, Bendamustine on Day 30
45681104|NCT03595930|Drug|Arnuity|ARNUITY consist of Fluticasone Furoate, is an Inhaled corticosteroids (ICS) medicine taken as one inhalation, once daily, for the control and prevention of asthma in adults and children aged 12 years and older.
46020288|NCT05331547|Device|BioFreedom BA9 (SS) Ultra DCS|BioFreedom Ultra stent for treatment of STEMI patients. Besides, in patients who are clinically indicated for a stage procedure, we aim to assess the angiographic and endovascular healing of BioFreedom Ultra stent at one month
46104614|NCT02661347|Drug|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
46104615|NCT02661347|Device|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which sub-threshold transcranial electric current (in the range of 0.4-2 mA) is applied via two conductive saline soaked electrodes placed on the scalp using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator.
46104616|NCT02661269|Device|Videomicroscopy of the sublingual microcirculation|Measuring total vessel density with the Cytocam-IDF camera.
46104617|NCT02661269|Device|Bio-impedance measurements.|measuring resistance and reactance with the BIVA method.
46104618|NCT00649805|Drug|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose applesauce
46104619|NCT00649805|Drug|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose applesauce
46104620|NCT02652689|Radiation|Diagnostic ultrasound radiation|Recording Doppler ultrasound signals from the right chest wall
46104621|NCT02656589|Drug|Capecitabine|Capecitabine will be administered orally at a dose of 2500mg/m2 daily for 3 months (Day 1 to 14 of a 21-day cycle)
46104622|NCT02656589|Drug|Trastuzumab|patients will receive herceptin intravenous infusion at a dose of 6mg on day 1 of each cycle
46104623|NCT00600353|Drug|Palonosetron|Palonosetron 0.25 mg IV over 30 seconds
46104624|NCT00600353|Drug|Aprepitant|Aprepitant 125 mg PO and Aprepitant 80 mg PO
46104625|NCT00600353|Drug|Dexamethasone|Dexamethasone 4 mg IV and Dexamethasone 4 mg IV push
45681105|NCT03595852|Drug|Cefazolin|Cefazolin will be given to patients in the experimental arm prophylactically prior to surgery
46020289|NCT00927901|Drug|Indacaterol maleate 400 μg|Indacaterol maleate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
46104626|NCT02661191|Drug|oral cholecalciferol|Inhaled corticosteroids and long-acting beta-agonists, salbutamol
46104627|NCT02660879|Other|Written Document Educational Resource|A 2 page document with pictures discussing how to use an inhaler properly.
46104628|NCT02660879|Other|Online Video Education|Education which included step-by-step instruction on how to use their inhalers correctly as well as a webcam element that allowed users to see themselves practice their inhalers along with actors on screen.
46104629|NCT02652533|Device|Ultrasound Shear Wave Elastography|The investigators have recently published a very small study in neonates/infants with suspected BA showing that US liver shear wave speed (i.e. - liver stiffness) can differentiate BA from other causes of cholestasis, potentially with a very high degree of accuracy. Additional research is needed to confirm these very preliminary results and determine if liver shear wave speed measurements either before or after (including longitudinally) Kasai can predict key outcomes.
46104630|NCT02660957|Behavioral|self-determination smoking cessation|a self-help quitting leaflet plus a series of brief interventions using the AWARD model
46020290|NCT00927901|Drug|Indacaterol acetate 400 μg|Indacaterol acetate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
46020291|NCT00927901|Drug|Indacaterol xinafoate 400 μg|Indacaterol xinafoate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
46020292|NCT00927901|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler.
46020293|NCT04255771|Drug|Gemcitabine|Standard GC (gemcitabine and cisplatin) regimen: gemcitabine 1000-1200mg/m2 intravenous infusion on days 1 and 8, cisplatin 70mg/m2 on the second day of intravenous infusion, every 3 weeks (21-day regimen) is a cycle, A total of 3 cycles.
46020294|NCT04255771|Drug|Placebos|Use a placebo as a comparison
46020295|NCT04859725|Device|Hyperspectral Imaging with Snapscan camera|Before, during and after the resection, HSI data ('datacubes') will be acquired by the SnapScan camera of all relevant areas of the exposed cortical surface and subcortical cavity walls. The exact points of which the datacubes will be acquired are defined by unequivocal single points on the routinely used neuronavigational system. From the points from which the datacubes have been obtained a corresponding tissue sample will be obtained (labeled biopsy) if tumor tissue is to be expected in that particular point, based on the current standard of care assessments intraoperatively using white light illumination on the microscope, intraoperative navigation and intraoperative ultrasound. As such, normally looking brain in the resection cavity wall, will only be biopsied if tumor free margins should be proven as part of the standard-of-care operative procedure (non-critically eloquent brain regions).
46020296|NCT05329363|Diagnostic Test|PEPITS Programme|"The programme has three main phases:~Phase I: Introduction phase (Session 1) Phase II: Pathology and care work phase (Sessions 2 - 3 - 4) Phase III: Recovery and stepping stone phase (Sessions 5 - 6 - 7) The programme provides information, keys and new skills to the patient through 3 phases focusing on pathology and recovery."
46020297|NCT05329363|Other|Usual care|Patients will receive the same psychiatric care as the experimental group except of the PEPITS programme.
46020298|NCT01218204|Drug|10mg atorvastatin|10mg
46020299|NCT01218204|Drug|80mg atorvastatin|80mg
46020300|NCT01218204|Drug|GSK1292263 Placebo|Placebo
46020301|NCT01218204|Drug|100mg GSK1292263|100mg
46020302|NCT01218204|Drug|300mg GSK1292263|300mg
46020303|NCT01218204|Drug|800mg GSK1292263|800mg
46104631|NCT02660957|Other|placebo comparator|suggest a healthy life style as a placebo comparator
46104632|NCT00691210|Drug|Vorinostat|"Dose escalation scheme (400 mg)~Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells."
46020304|NCT01218204|Drug|10mg ezetimibe|10mg
46104633|NCT00691210|Drug|Niacinamide|"Dose escalation scheme (20, 40, 60, 80, 100 mg/kg rounded to 100 mg)~Niacinamide is a water soluble B-vitamin that has been evaluated for use in the treatment of pellagra, bullous pemphigoid, and as a radiation sensitizer in head and neck cancer."
46104634|NCT00691210|Drug|Etoposide|"Dose escalation scheme (0, 25, 50, 100 mg/m2)~Etoposide is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase II inhibitor."
46020305|NCT01218204|Other|Washout|No interventions - washout period
46020306|NCT00926575|Drug|oral beclomethasone 17,21-dipropionate|Two tablets QID for 50 days
46020307|NCT00926575|Drug|Placebo|Two tablets QID for 50 days
46020308|NCT01218126|Drug|losmapimod|comparison of different dosages of drug 2.5 mg, 7.5 mg or 15 mg
46020309|NCT01218126|Drug|placebo|placebo comparison with active
46020310|NCT05456412|Other|JAK inhibitor treatment|Standard care
46020311|NCT01217892|Drug|dapagliflozin|2.5 mg tablet, taken orally, twice daily
46020312|NCT01217892|Drug|dapagliflozin|5 mg tablet taken orally, twice daily
46020313|NCT01217892|Drug|dapagliflozin|10 mg tablet taken orally, once daily
46020314|NCT01217892|Drug|metformin|>/= 1500 mg total daily dose, tablets taken orally, twice daily
46020315|NCT01217892|Drug|placebo|placebo
46020316|NCT01217814|Drug|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
46020317|NCT01217814|Drug|Placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
46020318|NCT01217814|Drug|Golimumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
46020319|NCT01217814|Drug|methotrexate (MTX)|"Pharmaceutical form: tablet or solution for injection~Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)"
45467699|NCT05230992|Device|Cryoprobes First|In this experimental group, the Cryoprobe is used in first and the classic biopsy forceps in a second time. This medical device under study is the flexible, single-use Cryoprobe, supplied in sterile condition, 1.1 mm in diameter, 1150 mm long, with extraction tube, 817 mm long (reference 20402-401), or 757 mm long (reference 20402-402) marketed. These cryoprobes are covered by a CE marking. Cryoprobes must be used in conjunction with the Erbecryo®2 device and its accessories.
45681106|NCT03595852|Drug|Placebos|IV normal saline will be given to patients 30-60 minutes prior to incision
46104635|NCT02660723|Other|Healthy Volunteers|A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
46104636|NCT02536703|Device|Lotus Valve System|Lotus Valve System
46104637|NCT02652143|Device|AneVivo (Medical device for in vivo culture of embryos)|
46020320|NCT01217814|Drug|Folic/folinic acid|"Pharmaceutical form: tablet~Route of administration: oral Folic/folinic acid continued according to local standard."
46020321|NCT01217190|Drug|Ondansetron (ODFS)|Test Article
46020322|NCT01217190|Drug|Zofran (ODT)|Comparator
46020323|NCT01136733|Drug|Lenvatinib|taken orally, once a day
45467700|NCT05230992|Device|Cryoprobes Second|In this second experimental group, the same medical devices are used but in the other order.
45467701|NCT03706248|Other|Blood Draw|20 ml of blood will be drawn from subjects via venipuncture
45681107|NCT03591016|Other|Recording number of IV attempts|Recording number of IV attempts in the operating room
46020324|NCT01136733|Drug|Everolimus|taken orally, once a day
46104638|NCT02652143|Other|comparator for embryo culture in vitro|
45681108|NCT03595696|Other|Core Muscle Strength Training|Targeted weekly workouts consisting of low-impact aerobic exercises and resistance exercises designed to address muscle imbalance common in women who exhibit DRA and to prompt automatic core engagement while performing compound, multi-joint movements.
45681109|NCT04197466|Other|Pelvic Floor Exercise Group|The exercise program will be tailored according to the pelvic floor muscle strength, including fast and slow contractions. The number and duration of exercises will be increased according to progress..
45681110|NCT04197466|Other|Kinesio tape|Kinesio tape application will be performed by ligament technique to the sacral region.
46104639|NCT02652065|Other|Acetylcholine iontophoresis|Acetylcholine will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
46104640|NCT02652065|Other|Sodium Nitroprussiate iontophoresis|Sodium Nitroprussiate will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
46104641|NCT02652065|Other|ppi water iontophoresis|ppi water will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
46104642|NCT02652065|Other|Laser Doppler recording|Skin blood flow will be recorded by laser Doppler during 2 minutes before iontophoresis, and during 30 minutes following iontophoretic delivery of vasodilators.
45467702|NCT04608838|Biological|JTR-161|JTR-161 (1 or 3 × 10^8 cells/subject) will be suspended and administered in an intravenously infusion.
45681111|NCT04197466|Other|Electrical stimulation|External electrical stimulation will be performed in the lying, sitting, stand up positions for 30 minutes
45467703|NCT04608838|Biological|Placebo|Placebo will be suspended and administered in an intravenously infusion.
46020325|NCT05178693|Drug|ASTX727|Cedazuridine 100mg + 35mg decitabine
46020326|NCT05178693|Radiation|Lutathera|Peptide receptor radionuclide therapy (PRRT)
46020327|NCT01136655|Drug|80/2.25 μg Symbicort pMDI|inhalation
46020328|NCT01136655|Drug|80/4.5 μg Symbicort pMDI|inhalation
46020329|NCT01136655|Drug|Foradil Aerolizer 12 μg|inhalation
46020330|NCT01136655|Drug|40 μg budesonide HFA pMDI|inhalation
46020331|NCT01136655|Drug|placebo HFA pMDI|inhalation
46020332|NCT04312581|Device|Extracorporeal shock wave therapy|3 sessions of radial- extracorporeal shock wave therapy rESWT one week apart, 2000-3000 impulses at 0.25-0.84 millijoule /mm2with a pressure 2.8 bar and 15 Hz frequency.
46020333|NCT04312581|Other|Conventional rehabilitation|physical & occupational therapy
46020334|NCT01135017|Drug|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
46020335|NCT01135017|Drug|Placebo (for Dronedarone)|"Film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
46020336|NCT02883153|Drug|Zirconium-89 girentuximab PET/CT|Thirty patients (suspected of ccRCC) will be included in whom conventional diagnostics are inconclusive. During a multidisciplinary team (MDT) the hypothetical next step in the clinical process will be noted. Subsequently, in these patients a Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq). The results of the PET/CT will be discussed during the MDT and will be used to decide what the next step in the clinical process will be. This step will be compared with the hypothetical next step from the MDT before the scan. Whether or not the PET/CT scan had impact on clinical decision making will be assessed for each individual patient.
46020337|NCT01134783|Behavioral|CHOICES Intervention|Academic course on healthy weight behaviors followed by participation in a social networking and social support website.
46020338|NCT01134705|Drug|Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
46020339|NCT01134705|Drug|Placebo Nasal Aerosol|HFA Vehicle Aerosol
45467704|NCT03465748|Device|OrthoK|orthok (orthokeratology) is the science of changing the curvature or shape of the cornea to change how light is focused on the retina at the back of one's eye. Specially designed molding retainer contact lenses are placed on the eye at night and are removed upon awakening.
45681112|NCT04197388|Device|Inspiratory muscle training device|Inspiratory muscle training, 6 cycles of 30 breaths for 12 weeks.
45681113|NCT03590860|Drug|LY3322207|Administered by SC injection
45681114|NCT03590860|Drug|Placebo|Administered by SC injection
46020340|NCT00927823|Drug|PF-04691502|Once daily continuous dosing. Dose escalation to Maximally tolerated dose (MTD) until progression or discontinuation.
46020341|NCT01134627|Drug|Minocycline|Participants who are self-administering Rebif® (IFN beta-1a) 44 microgram (mcg) as subcutaneous (sc) injection thrice weekly will also receive minocycline 100 milligram (mg) tablet twice daily as an add-on therapy in accordance with clinical practice for 96 weeks.
46020342|NCT01134627|Drug|Placebo|Participants who are self-administering Rebif® (IFN beta-1a) 44 mcg as sc injection thrice weekly will also receive placebo tablets twice daily for 96 weeks.
46020343|NCT04992715|Diagnostic Test|[99mTc]-NM01 SPECT/CT|Technetium-99m radiolabelled anti-PD-L1 single-domain antibody (NM01) single-photon emission computed tomography (SPECT)/computed tomography (CT)
46020344|NCT01134393|Drug|telmisartan/amlodipine|start low dose and uptitrate to high dose on the basis of BP goal
46020345|NCT05331469|Drug|NPH basal insulin titration|Comparing both arms NPH basal insulin titration in reducing hba1c after 3 months
46020346|NCT00610753|Behavioral|Family Behavior Therapy|This treatment is usually delivered in two phases: In the first phase there is an initial investigation of family behavior around feeding using a family meal followed by family therapy focused on enhancing feeding of the anorexic child in order to promote weight gain. In the second phase, once weight gain is well established the adolescent is given greater autonomy over feeding and in later sessions over other issues.
46020347|NCT00610753|Behavioral|Systems Family Therapy|This therapy is applied in three phases. 1. In the first 2 or 3-sessions the treatment is explained to the family and an initial examination of family issues begins. 2. In the second phase family interactions and psychological processes are explored with clarification for family members. 3. In the third phase knowledge of family patterns is refined aiming for behavior change.
46020348|NCT04246957|Behavioral|general quality of life questionary|Every patient will have to fill out a general quality of life questionary : DLQI (Dermatology Life Quality Index)
45467705|NCT03779815|Drug|[18F]Florbetaben|"Drug: [18F]Florbetaben~[18F]Florbetaben PET/CT Imaging for detecting amyloidosis in multiple myeloma~Other name: Neuraceq~Amount: 300 MBq ± 20% bolus, 10mL intravenously"
45467706|NCT03465670|Device|CHX|Patients received a 21-day supply of 0.2% chlorhexidine (CHX) according to the randomization list, and were instructed to use 10 ml of the assigned mouthrinse for 1 minute, t.i.d. for 21 days. After rinsing, patients were asked to avoid washing their mouth or drinking for 30 minutes. Patients were asked to return the mouthrinse bottles (either empty of filled) at the end of the experimental period (day 21), in order to assess the level of patient compliance with the assigned CHX regimen.
45467707|NCT03465670|Device|CHX+HA+ADS|Patients received a 21-day supply of 0.2% chlorhexidine (CHX) containing 0.2% hyaluronic acid (HA) and Anti-Discoloration System (ADS) according to the randomization list, and were instructed to use 10 ml of the assigned mouthrinse for 1 minute, t.i.d. for 21 days. After rinsing, patients were asked to avoid washing their mouth or drinking for 30 minutes. Patients were asked to return the mouthrinse bottles (either empty of filled) at the end of the experimental period (day 21), in order to assess the level of patient compliance with the assigned CHX regimen.
45467708|NCT03776383|Other|Antibiotic use feedback letter|Mailed letters indicating that the physician prescribes more antibiotics than 75% of their peers
45467709|NCT04449588|Drug|BDB-001 Injection|BDB-001 Injection+Conventional treatment
45467710|NCT04449588|Other|Conventional treatment|Conventional treatment only. Local guidelines should be integrated to choose the best supportive care.
45467711|NCT03465358|Other|Items completion|"Patients will complete his Motor Function Measure in the usual way, except items 18, 19 and 22 which will be completed twice: once using conventional material and once on a digital tablet.~The order of completion between conventional material or digital tablet will be allocate randomly."
46104643|NCT00650429|Drug|Ziprasidone|IM ziprasidone at an initial dose of 10 or 20 mg for the first 3 days; additional doses could be administered according to clinical need, with the maximum total daily IM dose of 40 mg. On Day 4, IM treatment was switched to oral (PO) treatment at an initial dose of 40 mg twice daily for the first 2 days; doses could be subsequently adjusted within the range of 40 to 80 mg twice daily. Total treatment duration was 6 weeks.
46020349|NCT04246957|Behavioral|specific quality of life questionary|Every patient will have to fill out a specific quality of life questionary : Hair Specific Skindex 29.
45467712|NCT03779893|Combination Product|BioCoat® by Premier®.|Bioactive pits and fissure sealant
45681115|NCT04197154|Behavioral|Threat manipulation (control, no threat)|Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin reacts to heat normally and it is safe for them to participate. A skin-sensitivity reading shows participants a scale that is in the green (no danger) zone.
46104644|NCT00691132|Drug|phenethyl isothiocyanate|Given orally
45467713|NCT03779893|Combination Product|3M™ Clinpro™ Sealant.|conventional pits and fissure sealant
45467714|NCT05166252|Behavioral|Time out from smartphone use during meal time|"One parent will be instructed to install a study app. Further, he/she press a button within the App to start a time out from the smartphone at the beginning of a meal (i.e. calls and message are blocked and the parent needs to press an extra button in order to leave the app). The app instructs all other family members to turn off their phones and to put them away. Then, the parent is instructed to take a picture with their smartphone from the smartphone-free family meal table . The time-out is over as soon as the parent presses the stop button."
45467715|NCT05166252|Behavioral|Control condition|The same as the experimental condition but without a timeout from smartphone use.
45467716|NCT04534582|Drug|HLX14|healthy volunteers receive HLX14 (60mg) once
46104645|NCT00691132|Other|placebo|Given orally
45467717|NCT04534582|Drug|EU-Prolia®|healthy volunteers receive EU-Prolia® (60mg) once
45467718|NCT04534582|Drug|US-Prolia®|healthy volunteers receive US-Prolia® (60mg) once
45467719|NCT04534582|Drug|CN-Prolia®|healthy volunteers receive CN-Prolia® (60mg) once
45467720|NCT03773731|Behavioral|High intensity interval training (HIIT)|Exercise training on bicycle ergometer with high intensity bouts of 1 min interspersed by low intensity recovery intervals
46020350|NCT00922441|Drug|Fimasartan 60 mg group|Fimasartan 60 mg
46020351|NCT00922441|Drug|Fimasartan 120 mg group|Fimasartan 120 mg
46020352|NCT00922441|Drug|Reference (Valsartan 80 mg) group|Reference (Valsartan 80 mg)
46020353|NCT01217112|Drug|GWP42003|100 mg capsules, PO, BD, 91 days
46020354|NCT01217112|Drug|GWP42003|5 mg capsules, PO, BD, 91 days
46020355|NCT01217112|Drug|GWP42004|5 mg capsules, PO, BD, 91 days
46020356|NCT01217112|Drug|Placebo|0 mg capsules, QDS, PO, 91 days
46020357|NCT01216332|Drug|High-dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
45467721|NCT03773731|Behavioral|Moderate intensity continuous training (MICT)|Exercise training on bicycle ergometer with moderate intensity (60 - 65 % of individual maximal power output)
45467722|NCT04482634|Other|Remote controlled exercise|Breathing, aerobic, posture, stretching, upper and lower extremity strengthening exercises.
45467723|NCT04482634|Other|Home exercise|Breathing, aerobic, posture, stretching, upper and lower extremity strengthening exercises.
46020358|NCT01216332|Drug|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine
46104646|NCT04262219|Behavioral|iShare|The iShare intervention consists of a two-episode educational podcast series containing information about breast cancer patients' sexual problems, approaches for addressing sexual concerns, and information about discussing sexual concerns with patients, such as initiating a conversation about sexual health and asking questions to assess sexual concern. Both episodes feature expert guests and relevant discussions or case studies.
46020359|NCT00922207|Drug|Adefovir|From week -4 to week 2
46104647|NCT02652299|Biological|Synovial biopsy|Synovial tissue for analysis and biobank.
46104648|NCT02651909|Other|blood sampling|blood sampling for TEG analysis, Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
45467724|NCT03780049|Procedure|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
45467725|NCT03780049|Drug|H101|Patients receive H101 0.5ml dissolved in 10ml normal saline in each session of HAIC
45467726|NCT03780049|Drug|Placebos|Patients receive normal saline 10ml in each session of HAIC
46104649|NCT04167839|Other|Sensory diet|Sensory diets are one of the interventions occupational therapists use in school-based settings to manage manifestations of sensory processing disorder. Sensory diets are composed of exercises and multisensory activities that are tailored for children and provide them sensorimotor experiences to facilitate their participation in daily activities.
45467727|NCT05154864|Procedure|SBUF-SMUF|Intra-operative continuous ultrafiltration
46020360|NCT00922207|Drug|Entecavir|From week -4 to week 2
45467728|NCT04452760|Other|Physical exercise|Physical exercise intervention
45467729|NCT04452760|Other|Testing sessions|Testing sessions
45467730|NCT04252287|Drug|Canagliflozin 100 mg|Participants will receive 100 mg immediate-release, over-encapsulated tablets (as a capsule) orally once daily.
45467731|NCT04252287|Drug|Placebo|Participants will receive matching placebo capsules orally once daily.
45467732|NCT05681754|Procedure|Experimental: RCT using hydraulic calcium silicate sealer and L-PRF + GTR|Endodontic treatment with hydraulic calcium silicate sealer, followed by periodontal surgery using GTR +/- LPRF
45467733|NCT05681754|Procedure|Experimental: RCT using conventional sealer and L-PRF + GTR|Endodontic treatment with conventional sealer followed by periodontal treatment with PRF + GTR
45467734|NCT05681754|Procedure|Experimental: RCT using hydraulic calcium silicate sealer and GTR|Endodontic treatment with hydraulic calcium silicate sealer, followed by periodontal surgery using GTR only
45467735|NCT05681754|Procedure|Active Comparator: RCT using conventional sealer and GTR (bone substitute + collagen membrane)|Endodontic treatment with conventional sealer followed by periodontal treatment with GTR only
45467736|NCT02577536|Other|No Interventions|No Interventions will be conducted under this study.
45467737|NCT03465202|Drug|Capecitabine|
46020361|NCT00922207|Drug|Placebo|From week -4 to week 2
46020362|NCT00922207|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly, from week 1-48
45467738|NCT03465124|Device|Femtosecond Laser|Femtosecond Laser assisted Cataract Surgery will be performed unilateral in randomized order. Contralateral eye will receive conventional cataract surgery
45467739|NCT03465124|Other|Manual Cataract Surgery|conventional cataract surgery as control
45467740|NCT04247139|Other|Kefir|commercial versus traditional kefir
45467741|NCT04195958|Drug|Omalizumab|Omalizumab will be administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency will be determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening.
45467742|NCT05540262|Drug|Edaravone|Edaravone injection 30mg three times a day
45467743|NCT04245423|Behavioral|Collaborative Care for Opioid Use Disorders and Mental Health Conditions|CC is delivered using the investigators' Foundations for Integrated Care model. The first line pharmacotherapy is buprenorphine-naloxone. The second line pharmacotherapy included is extended-release injectable naltrexone. Pharmacotherapy is accompanied by brief problem-solving therapy, cognitive-behavioral therapy, and/or motivational interviewing. The primary care physician, in consultation with the addictions psychiatrist and care manager, also will provide psychotropic medications for psychiatric disorders. In-person and telephone visits consist of the care manager carrying out intervention activities over 6 months. Visits are at baseline (90-minute intake appointment), home or office induction when in moderate opiate withdrawal if buprenorphine is prescribed, twice a week for two weeks with telephone calls in between visits, then weekly, and when stable once a month. There will be a final visit at 6 months. The intervention includes routine collection of urine drug screens.
45467744|NCT04245423|Behavioral|Augmented Usual Care|If not already waivered, PCPs will be trained and waivered to treat OUD with medications. All practices will have mental health clinicians to treat mild psychiatric disorders. Other than that, the research team will provide no support to the PCP or practice staff. However, an addiction psychiatrist is available for consultation for OUD.
45467745|NCT04245423|Behavioral|Collaborative Care for Opioid Use Disorders and Mental Health Conditions Plus Certified Recovery Specialists|This intervention includes the Collaborative Care Intervention plus Certified Recovery Specialist to assist with treatment engagement and retention.
45467746|NCT02735200|Drug|Application of topical vitamin d3 (Top-D)|Topical Vitamin D3 will be applied on the skin, externally, 1 gram daily for 120 days
45467747|NCT02735200|Other|Application of Aloe vera gel|"aloe vera gel will be applied~Dosage: 1 gram Duration: 120 days Frequency: Daily"
45467748|NCT05203926|Procedure|MRI scan|Subjects will undergo T1 and STIR sequence MRI of sacroiliac joints (SIJ ) (pelvis MRI) as well as SIJ plain X-ray for assessment of radiographic sacroiliitis. The study will utilize 3 Tesla with phased array coil to maximize signal to noise ratio for image quality. This is a single procedure, which takes about 60 minutes. 1 radiologists, blinded to all clinical information, will evaluate for presence of acute and structural lesions. Images will be scored for presence or absence of acute and/or structural lesions in a global manner.
45467749|NCT05308329|Device|Intra-coronary imaging device|Culprit/nonculprit lesions are accessed by intra-coronary imaging device including intravascular ultrasound and optical coherence tomography.
45467750|NCT05308329|Behavioral|PCI procedural characteristics|Procedural characteristics include the information about angiographical characteristics, type of stent, pre/post POBA, and thrombectomy.
45467751|NCT05681676|Other|Blood samples before and after standard of care of polymyalgia rheumatica|Blood samples were taken before glucocorticoid treatment and three months after.
45467752|NCT01312311|Drug|Docetaxel, Cisplatin|Docetaxel 35mg/m2 D1 & D8 Cisplatin 70mg/m2 D1
46020363|NCT05316103|Device|Probe-based confocal laser endomicroscopy targeted optical biopsy|After intravenous injection of fluorescein sodium, pCLE-based targeted optical biopsy will be performed.
45467753|NCT03465046|Combination Product|intensive therapies(CIMT/BIT): protocol 1 or protocol 2|"The therapies applied in both protocols are intensive therapies that allow the execution of unimanual activities or bimanual activities with the affected upper limb with different doses.~the protocols were carried out at home through the family"
45467754|NCT01568840|Other|Global Postural Reeducation Group|Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in manual therapy maneuvers and global postural reeducation treatment.
45467755|NCT01568840|Other|Segmental Exercises Group|Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in segmental exercises (stretching and strengthening) treatment.
46020364|NCT04255459|Other|Moist Snuff|Moist Snuff product
46020365|NCT04255459|Other|Camel Snus|Camel Snus product
46020366|NCT04255459|Other|Cigarettes|Cigarette product
46020367|NCT04255459|Other|No tobacco usage|No tobacco usage
46020368|NCT01134315|Drug|Paricalcitol|
46020369|NCT01134315|Drug|Calcitriol|
46020370|NCT04253431|Device|Droplet lancing device (HTL-Strefa S.A.)|
46020371|NCT04253431|Device|Microlet 2 lancing device (Bayer)|
46020372|NCT04253431|Device|OneTouch Delicia lancing device (LifeScan)|
46020373|NCT04253431|Device|ReliOn lancing device (ReliOn)|
46020374|NCT04253431|Device|Accu-Chek Softclix lancing device (Roche)|
45467756|NCT04592445|Device|Satera GSN Ablation|The Axon procedure consists of a small needle puncture made in the groin to pass standard sheaths, wires, and access devices into the femoral vein, using standard access methods. The right GSN will be ablated transvenously from the right intercostal veins where it crosses at the 10th and 11th thoracic vertebrae from the intercostal vein intersection with the azygos vein. Placement of the access devices and Axon catheter is confirmed using standard fluoroscopic imaging. Once positioning is confirmed, GSN ablation can commence accordingly .
46020375|NCT04253431|Device|BGStar lancing device (Sanofi Aventis)|
46020376|NCT04253431|Device|Ultra-Fine 33G lancets (BD)|
46020377|NCT04253431|Device|Droplet 33G lancets (HTL-Strefa S.A.)|
46020378|NCT04253431|Device|OneTouch Delicia Extra Fine 33G lancets (LifeScan)|
46020379|NCT04253431|Device|HaemoFine 33G lancets (HTL-Strefa S.A.)|
46020380|NCT04253431|Device|Softclix 28 G lancets (Roche)|
46020381|NCT04253431|Device|ReliOn Ultra-Thin Plus 33G lancets (ReliOn)|
46020382|NCT04253431|Device|GlucoJect Dual S lancing device (Menarini)|
46020383|NCT04253431|Device|Microlet 28G lancets (Bayer)|
46020384|NCT04253431|Device|BGStar Ultra-Thin 33G lancets (Sanofi Aventis)|
46020385|NCT01216176|Drug|Anastrozole|
46020386|NCT01216176|Drug|AZD0530 (saracatinib)|
46020387|NCT01216176|Drug|Placebo|
46020388|NCT05330845|Biological|IL6 assessment|Blood IL6 will be assessed during trial
46020389|NCT05330845|Biological|CRP and PCT assessment|Blood CRP and PCT will be assessed during trial
46020390|NCT01133847|Drug|Methylphenidate|Appropriate dosage to be individually determined; daily for 16 weeks
46020391|NCT01133847|Behavioral|Intensive reading instruction|Individualized phonologically-based instruction delivered 4 days per week for 45 min. per day by a highly trained tutor.
46020392|NCT01133847|Behavioral|Parent Training|Nine sessions on parenting a child with ADHD
46020393|NCT01133847|Drug|Mixed Salt Amphetamine|Appropriate dosage to be individually determined; daily for 16 weeks; prescribed only if child does not show a beneficial treatment response to Concerta
46020394|NCT01133847|Drug|Atomoxetine|Appropriate dosage to be individually determined; daily for 16 weeks
45467757|NCT04592445|Device|Sham Control|The sham procedure consists of a small needle puncture made in the groin to pass a standard femoral introducer sheath approximately 10 cm into the femoral vein, using standard access methods. The Axon Catheter and associated access accessories will not be inserted into the patient. The sham procedure duration will be similar to the treatment time for subject receiving the Axon therapy (~30 minutes).
45467758|NCT02946918|Drug|Levothyroxine|Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps. Initial dose 1.5-1.8 mcg per kg, orally and daily
45467759|NCT03464968|Drug|Oxaliplatin,5FU, leucovorin|mFOLFOX
45467760|NCT03464968|Drug|irinotecan,5FU, leucovorin|mFOLFIRI
45467761|NCT03464890|Other|P926 - LICHTENA DermAD CREMA VISO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
46020395|NCT01133847|Drug|Guanfacine|Appropriate dosage to be individually determined; daily for 16 weeks
45467762|NCT03464890|Other|P927 - LICHTENA DermAD CREMA CORPO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
45467763|NCT03464890|Other|P926 - LICHTENA DermAD CREMA VISO - PLACEBO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
45467764|NCT03464890|Other|Untreated control area|Untreated skin area of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
45467765|NCT05073744|Drug|Nalbuphine|Nalbuphine hydrochloride injection or morphine hydrochloride injection is used for perioperative tumor ablation
45681116|NCT04197154|Behavioral|Threat manipulation|Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin is very sensitive and their nerve fibers are very responsive and they may have adverse reactions to the heat-pain application. A skin-sensitivity reading shows participants a scale that is in the red (higher danger) zone.
46020396|NCT05000125|Diagnostic Test|Hologic's Genius Digital Diagnostics System|Genius Digital Diagnostics is a digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
46020397|NCT02887950|Other|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.
46020398|NCT02887950|Dietary Supplement|Equikilon-3 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 3 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
45681117|NCT04197154|Behavioral|Conditioning of moderate pain|"During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues ON signaling the activation of sham electrical stimulation) are paired to unconditioned moderate-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message OFF) is paired to 'baseline' pain of lower intensity."
46020399|NCT02887950|Dietary Supplement|Equikilon-6 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 6 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
46020400|NCT05310253|Drug|Fludrocortisone|pill of fludrocortisone
46020401|NCT05310253|Drug|Placebo|placebo pill
45467766|NCT05073744|Drug|Morphine|Morphine hydrochloride injection is used for perioperative tumor ablation
45467767|NCT04448002|Behavioral|AIM2ACT|AIM2ACT is a mobile health tool that is designed to facilitate collaborative asthma management between early adolescents and their caregivers. AIM2ACT contains the following components: 1) ecological momentary assessment to identify personalized strengths and weaknesses in asthma self-management behaviors; 2) collaborative identification and tracking of goals that help early adolescents to become increasingly independent in managing their asthma; and 3) a suite of engaging skills training videos to help dyads understand how to use AIM2ACT and work together to set asthma self-management goals, develop and achieve the goals articulated in a behavioral contract, and engage in problem-solving communication.
45467768|NCT04448002|Behavioral|mHealth Attention Control Condition|Dyads in the mHealth attention control condition will not receive personalized asthma management feedback, will not be guided through collaborative identification and tracking of asthma self-management goals, and will not have access to skills training videos. Instead, dyads will receive static educational information on their smartphones about behavioral management techniques they can use to target improving asthma self-management.
45467769|NCT05146596|Device|use low level light therapy,The Dr.Tai's energy cap|30 minutes each time, three times a week, a total of 12 times.
46020402|NCT05310253|Behavioral|Trier Social Stress Test (TSST)|psychosocial stress induction
46020403|NCT05310253|Behavioral|Placebo Trier Social Stress Test (P-TSST)|control condition
46020404|NCT02883075|Other|Supine position|Spinal anesthesia in sitting position then 2 minutes in Supine position after spinal anesthetic administration
46020405|NCT02883075|Other|Right lateral position|Spinal anesthesia in sitting position then 2 minutes in the right lateral position after spinal anesthetic administration
46020406|NCT02883075|Other|Left lateral position|Spinal anesthesia in sitting position then 2 minutes in the left lateral position after spinal anesthetic administration
46020407|NCT04984525|Drug|SYNB1934|SYNB1934 is formulated as a nonsterile solution intended for oral administration
46020408|NCT04984525|Drug|SYNB1618|SYNB1618 is formulated as a nonsterile solution intended for oral administration
46104650|NCT02564458|Behavioral|Interval Exercise Training/Motivational Accelerometry|During the 5-12 weeks before allogeneic stem cell transplant, the patient will participate in an at home, interval exercise training (IET) program, as well as wear a physical activity tracker, the FitBit Surge, combined with a weekly motivational call, termed Motivational Accelerometry (MA). The combined intervention is referred to as (IET/MA). The first week of the IET program consists of the participants being asked to engage in 30 minutes of aerobic exercise at any intensity for 3-4 days. For weeks two and beyond, patients be asked to undergo 3-4 sessions of IET, consisting of a 5 minute warm-up and five 2-minute intervals, with the goal of reaching 80% MHR, separated by 3 minutes of recovery/light activity in between each interval. Each exercise session is a total of 30 minutes. In addition, each week prior to transplant, the patient will receive a weekly check-in/motivational call from the study staff in order to track progress and motivate the patient to continue participation.
46020409|NCT01133379|Device|12027-019|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
46020410|NCT01133379|Device|12027-020|Rinse with 20 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
46020411|NCT01133379|Device|12027-021|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste
46020412|NCT04253353|Drug|tafamidis|61 mg capsule
46020413|NCT04253353|Drug|rosuvastatin|10 mg tablet
46104651|NCT02651753|Drug|Lipitor + Lipidil supra|Reference Drug: Lipitor + Lipidil supra
46104652|NCT02651753|Drug|CKD-337|Test Drug: CKD-337
46020414|NCT04259437|Other|High Protein, Energy Dense Nutritional Supplement|Ready to drink oral supplement
46020415|NCT04259515|Drug|Del Nido|Del Nido cardioplegic solution administered in a single dose at 15-20mg/Kg with a maximum dose of 1L of solution, administered antegrade or retrograde. In those patients in wich the crossclamping time exceed 90 to 120 minutes a manteinance dose of 500ml will be administered.
46020416|NCT04259515|Drug|Buckberg|Buckberg cardioplegical solution administered antegrade and/or retrograde at 1-2ml/Kg for cardiac arrest induction. Arrest manteinance with antegrade and/or retrograde administration at 1-2ml/Kg every 15 to 20 minutes. Reperfusion dose with antegrade or retrograde administration at 15-20 ml/Kg before removing the aortic crossclamp.
46020417|NCT04259671|Device|My Autism Passport (MAP) Application|Families will be given the application to upload to their mobile device and will be provided information on how to use the App by the research team. MAP is a mobile alternative to the paper version, and offers additional benefits such as the ability to set reminders, see regional developmental service agencies and other resources on a map, and directs the caregiver to information so that they may further their understanding about how to support their child.
46104653|NCT00855218|Drug|Sorafenib (Nexavar, BAY43-9006)|800 mg sorafenib (4 tablets) will be taken daily (400mg b.i.d. [twice daily], 2 tablets). Transarterial Chemoembolization (TACE) using DC Bead
46020418|NCT01132755|Procedure|Diagnostic peritoneal lavage|The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon. Caudal traction will be applied to the abdominal wall to provide a firm abdominal wall to insert the needle through, minimizing the peritoneum from tenting down closer to visceral structures. Intraperitoneal placement of the catheter will be confirmed by injection of saline into the needle with no resistance and with the saline in the hub of the needle falling into the peritoneal cavity spontaneously. A guide wire will be placed through the Veress and utilizing the Seldinger technique, a 9Fr peritoneal catheter will be placed.
46020419|NCT05154669|Other|Financial counseling|The goals of the financial counseling will be to: (1) screen and refer participants to financial benefits and empowerment programs; (2) help participants create and maintain a household budget to meet short- and long-term goals; and (3) help participants link smoking cessation to their budgeting goals.
46020420|NCT05154669|Drug|Nicotine Replacement Therapy Agent - Patches|24 hour dosing system that provides regular, measured nicotine to the bloodstream through the skin. Nicotine patches are available in 3 dosages: 21 mg, 14mg, and 7mg. Patches will be adjusted based on withdrawal symptoms, urges, and comfort. After 4-6 weeks of abstinence, taper ever 2-4 weeks in 7-14 mg steps as tolerated.
45467770|NCT05308251|Procedure|Lichtenstein Mesh Hernioplasty|The inguinal canal was opened and the hernia sac was dissected from the spermatic cord The deep inguinal ring was tightened with one or two polypropylene 2/0 sutures. The posterior wall of the inguinal canal was supported using the standard polypropylene mesh and fixed with 2/0 polyproline. The ilioinguinal nerve, iliohypogastric nerve, and genital branch of the genitofemoral nerve were preserved and care was taken to prevent entrapment.
46104654|NCT00855218|Drug|Placebo|4 tablets of placebo will be taken daily (2 tablets b.i.d). TACE using DC Bead
46104655|NCT00748150|Biological|Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009|1 dose, 0.5 mL of Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009
46104656|NCT02651675|Biological|AAV directed hLDLR gene therapy|A novel adeno-associated viral (AAV) vector with human low-density lipoprotein receptor (hLDLR) gene
45681118|NCT04197154|Behavioral|Conditioning of high pain|"During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues ON signaling the activation of sham electrical stimulation) are paired to unconditioned high-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message OFF) is paired to pain of lower intensity."
46020421|NCT05154669|Drug|Nicotine Replacement Therapy Agent - Lozenges|"General Info 24 hour dosing system that provides regular, measured nicotine to the bloodstream through the skin.~Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch, the idea is to taper the amount of lozenges used until you no longer need it. Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch and lozenge, the idea is to taper the amount of gum chewed until you no longer need it. Comes in 4mg or 2mg. Initial dosing is 1-2 lozenges every 1-2 hours (minimum of 9/day). Taper as tolerated"
46104657|NCT00744172|Procedure|laparoscopy|laparoscopic hysterectomy
46020422|NCT05154669|Drug|Nicotine Replacement Therapy Agent - Gum|Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch and lozenge, the idea is to taper the amount of gum chewed until you no longer need it. Initial dosing is 1-2 pieces every 1-2 hours (10-12 pieces/day). Taper as tolerated
46020423|NCT04312035|Procedure|end-range mobilization|accessory technique applied on the tibiofemoral joint with the aim of increasing extensibility of the periarticular tissues
46020424|NCT04312035|Procedure|Non end-range mobilization|accessory technique applied on the tibiofemoral joint with the aim of alleviating pain
46020425|NCT04312035|Procedure|Control|hands-on cutaneous technique
46020426|NCT04311957|Drug|Continuation of boosted PI|"Continuation of the same second-line regimen taken prior to entry:~LPVr 400 mg/100 mg BID or ATVr 300 mg/100 mg QD + 2 NRTIs"
46020427|NCT04311957|Drug|B/F/TAF|Single-tablet, fixed dose combination of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily.
46020428|NCT02882997|Behavioral|an interactive computer game|Duck Duck Punch is an interactive computer game designed to elicit repetitive practice of paretic arm movements in stroke patients.
46104658|NCT00744172|Procedure|vaginal|vaginal hysterectomy
46104659|NCT00744172|Procedure|abdominal|abdominal hysterectomy
46104660|NCT00650507|Procedure|Remote ischemic preconditioning (RIPC)|The RIPC stimulus will be delivered in the OR prep room after the induction of anesthesia (while the anesthesiologist and staff are inserting vascular cannulae and preparing the patient for surgery). Whenever possible, the left lower limb will be selected for delivery of the stimulus. An appropriate sized cuff will be selected and connected to a hand aneroid sphygmomanometer. A second cuff and hand aneroid sphygmomanometer will be placed beside the one connected to the study subject. The cuff on the limb will be inflated and deflated to provide a total of four cycles of limb ischemia and reperfusion.
46104661|NCT00650507|Procedure|SHAM|For this group, the procedure will be identical for that described for the RIPC stimulus, with the exception that the blood pressure cuff placed on the subject will not be inflated, but the second cuff, that has been placed beside, will be inflated.
46104662|NCT00748228|Dietary Supplement|dietary sodium|10 mEq/day
45467771|NCT04384198|Procedure|Sonolysis|Continuous transcranial Doppler sonography (TCD) using a 2-MHz diagnostic probe with maximal diagnostic energy
46020429|NCT02882997|Behavioral|standard activities|For community dwelling stroke survivors this is a hard copy, written/illustrated home exercise program for the paretic arm. For inpatient stroke patients this is standard recreational activities organized by the facility during non therapy hours (evenings and weekends).
46020430|NCT00637455|Drug|fexofenadine HCl|
46020431|NCT00919711|Drug|Actonel®|Oral Actonel® (Risedronate) in total a 150mg per month (one 75mg tablet to be taken on each of 2 consecutive days per month).
46104663|NCT00748228|Dietary Supplement|dietary sodium|300 mEq/day
46104664|NCT00748228|Dietary Supplement|dietary sodium|150 mEq/day dietary sodium
46104665|NCT02651519|Drug|0.25% ropivacaine hydrochloride|stellate-ganglion block with 0.25% ropivacaine hydrochloride
46104666|NCT02651519|Drug|saline|stellate-ganglion block with saline
46104667|NCT00748306|Drug|GSK2190915 - 100mcg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
46104668|NCT00748306|Drug|Placebo|Matching Intervention Drug
45681119|NCT04197154|Behavioral|Extinction|"During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the nocebo and control visual cues (i.e., on-screen messages ON and OFF) to pain stimuli of only lower intensity."
45681120|NCT04191382|Drug|Amcenestrant (SAR439859)|Pharmaceutical form: Capsules, Route of administration: Oral
45681121|NCT04191382|Drug|Letrozole|Pharmaceutical form: Tablets, Route of administration: Oral
46020432|NCT00919711|Drug|Denosumab|Denosumab 60 mg, once every 6 months, Subcutaneous
46104669|NCT02651441|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV on day1 and day8, repeat every 3 weeks.
46104670|NCT02651441|Drug|Cisplatin|Cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
46104671|NCT02651441|Biological|D-CIK|8×10^9 D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
46020433|NCT01131585|Procedure|Active laser photocoagulation|Active laser photocoagulation procedure at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.
46020434|NCT01131585|Drug|Sham injections|Sham intravitreal injections at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
46104672|NCT01063348|Drug|N-Acetyl Cysteine|Week 0 (Visit 1) - Week 3 (V2): 1200mg/day (600mg po qam and 600mg po qpm) Week 3 (V2) - Week 6 (V3): 2400mg/day (1200mg po qam and 1200mg po qpm) Week 6 (V4) - Week 12 (V5): 3000mg/day (1200mg po qam and 1800mg po qpm)
46104673|NCT01063348|Drug|Placebo|Matching placebo capsules taken in same amount of pills as the active medication.
46104674|NCT02651129|Other|Noise measurement|We will be measuring noise levels in the operating room
46104675|NCT00855062|Drug|minocycline|100 mg capsule every 12 hours by mouth
46104676|NCT00855062|Drug|minocycline placebo capsule|1 capsule every 12 hours by mouth
46104677|NCT00744250|Drug|Pancrelipase|PANCRECARB MS-16
46104678|NCT02651207|Other|Questionnaire based study looking at pain scores felt by patients either having a lidocaine injection or ethyl chloride spray prior to insertion of a contraceptive implant|
46104679|NCT02564536|Drug|Pacritinib|-Patients should take pacritinib at approximately the same times every day with a glass of water, with or without food.
45467772|NCT05681598|Drug|Hydroxyurea|The treatment started with a dose of 15mg/kg/day of HU. This initial dose was increased in steps of 5mg/kg/day every three months up to 35mg/kg/day or a maximal tolerated dose.
45681122|NCT01703091|Drug|Ramucirumab|Administered IV
45681123|NCT01703091|Drug|Placebo|Administered IV
45681124|NCT01703091|Drug|Docetaxel|Administered IV
46104680|NCT02564536|Drug|Decitabine|-From commercial stock
46104681|NCT02651285|Other|G-CSF medium|incubation of IVF embryos with a specific medium containing G-CSF
46104682|NCT02651285|Other|Control|incubation of IVF embryos with a medium without G-CSF
45467773|NCT04373902|Procedure|Physiological-based cord clamping|See 'Arm'
45681125|NCT03023644|Behavioral|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will an iPad with a web-based software program. The 25 sessions will be completed individually by the child with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the child can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
46020435|NCT01131585|Drug|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg/0.05 ml intravitreal injection at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
46020436|NCT01131507|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® [pancrelipase] 3,000 lipase units delayed release capsules) from open capsules mixed with a small amount of apple juice or apple sauce will be administered orally starting at the same dose as administered at the end of study PR-011 (NCT01100606), with dose increments of 3,000 lipase units. The dose will be adjusted based on participants' age and body weight. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day unless clinically indicated. Total duration of study treatment will be up to 12 months.
46020437|NCT01131351|Drug|Delamanid|OPC-67683 film-coated tablets
46020438|NCT01131351|Drug|Optimized Background Regimen (OBR)|OBR was selected at the discretion of the study investigator and included at least 2 anti-TB medications based on World Health Organization (WHO's) guidelines for the programmatic management of drug-resistant TB. Study investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
46104683|NCT03887104|Device|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
46104684|NCT00748462|Device|Fractional CO2 Laser|"the treatment settings:~Pulse duration : 5 to 7ms depending on skin reaction~Spot Density: 49 MTZ/cm2 (Low density)~Power: 15 W = (75 - 105) mJ/MTZ"
46104685|NCT00854828|Procedure|Surgical intervention|Surgical intervention as appropriate for adults with symptomatic lumbar scoliosis
46104686|NCT00854828|Other|Non-operative intervention|Non operative intervention as appropriate for treatment of adults with symptomatic lumbar scoliosis such as: injections, medications, physical therapy, etc.
46104687|NCT02614820|Procedure|Remote Ischemic Preconditioning Training Apparatus|
46104688|NCT00847730|Device|V.A.C. Negative Pressure Wound Therapy System|This is a non-invasive wound treatment system that uses controlled, localized negative pressure to create an environment that promotes wound healing in chronic and acute wounds
45467774|NCT05515302|Other|Audio Clip|Selected Audio clips will be introduced to the study subjects during the Burns Dressing Changes. The Audio Clips will be selected as per subjects preference.
45467775|NCT04348708|Genetic|HMI-102|HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene
45467776|NCT01312350|Drug|neoadjuvant docetaxel/cisplatin/fluorouracil|2 cycles of neoadjuvant Docetaxel/cisplatin/5-fluorouracil therapy followed by CCRT Neoadjuvant chemotherapy (docetaxel 75mg/m2 D1, cisplatin 75mg/m2 D1, 5-fluoruracil 759mg/m2/day, D1-4, every 3 weeks) CCRT protocol is same with that of control arm.
45467777|NCT01312350|Drug|No treatment before definitive CCRT|concurrent chemoradiation therapy radiation: 70Gy/35fractions chemotherapy: cisplatin single 100mg/m2/day D1, D22, D43
45467778|NCT02522182|Behavioral|Nurse-led Intensive Secondary Prevention Programme|Information related to intervention description have been already included in arm/group description
46020439|NCT04311879|Device|Soft tissue Diode laser application|post-operative soft tissue diode laser application
46020440|NCT04311879|Other|Placebo|mock diode laser application
46104689|NCT00600119|Drug|placebo|placebo, oral, once daily (QD)
46020441|NCT00919633|Drug|interferon alfa-2b|subcutaneous continuous infusion at one of three doses for 48 weeks
45467779|NCT02522182|Behavioral|Usual Treatment|Information related to intervention description have been already included in arm/group description
45467780|NCT03464812|Behavioral|DSMES|It is primarily an educational intervention that is focused on assisting patients improve their management and coping with type 2 diabetes.
46020442|NCT00919633|Drug|peginterferon alfa-2b|1.5 μg/kg subcutaneous weekly for 48 weeks
46104690|NCT00600119|Drug|NKTR-118|5 mg, 25 mg, 50 mg or 100 mg, oral,once daily (QD)
46104691|NCT02651051|Dietary Supplement|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to breakfast meal
46020443|NCT00919633|Drug|ribavirin, USP|All patients will receive oral ribavirin
46104692|NCT02651051|Other|High Fat Breakfast Meal|A standardised high fat breakfast served to all participants. The macronutrient distribution of the breakfast is 12% protein, 3% carbohydrate, 85% fat (1771 kJ; 423 kcal total)
45467781|NCT05160558|Drug|BIIB132|Administered as specified in the treatment arm
46104693|NCT04032821|Drug|Alkotinib（300mg)|1. First empty stomach, after the meal.2. After eating first, after fasting.
45467782|NCT05160558|Drug|BIIB132-Matching Placebo|Administered as specified in the treatment arm
45681126|NCT01712685|Drug|18F-VM4-037|Drug being tested for use in cancer imaging studies. It may help tumor tissue show up more clearly during scans.
45681127|NCT01712685|Procedure|PET/CT|
46104694|NCT02650973|Drug|CHS-1701|
46104695|NCT02650973|Drug|Pegfilgrastim|
46104696|NCT02660567|Procedure|Amr maneuver|sustained traction of the anterior and posterior lips of the cervix by ovum forceps downwards and anteriorly until maximum yield for about 90 seconds
45467783|NCT03464656|Drug|Fairhaven Pro for men|"Fairhaven Pro for men~The antioxidant formula (Fairhaven Health) contains:~B12 (1000 mcg)~Zinc (30 mg)~Selenium (140 mcg)~Arginine (350 mg)~L-carnitine tartrate (2000 mg) , providing 1,340 mg of L-carnitine~CoQ10 (200 mg)~Vitamin C (120 mg) and Vitamin E (200 IU)"
45467784|NCT03464656|Diagnostic Test|Semen analysis|"Full semen analysis according to WHO semen laboratory manual 5th edition will be done pre and 3 months post-treatment.~After complete liquefaction, each sample was evaluated for both macroscopic parameters such as color, pH, ejaculate volume, age of the sample and viscosity. An aliquot of the sample was examined for sperm concentration, total sperm count, total and progressive motility and sperm morphology using the WHO fifth edition guidelines (WHO, 2010). Semen analysis was done manually using a hemocytometer. Sperm motility was assessed and categorized as progressive or non-progressive. Morphology was assessed by a single experienced technician using the Diff-Quik staining protocol. Kruger's strict criteria were used for morphology assessment with 4% normal morphology as a cut-off (WHO, 2010)."
46020444|NCT00919633|Device|external drug infusion pump|pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
46020445|NCT04311801|Diagnostic Test|Optical Coherence Tomography|Every patient underwent OCT examination before and after surgery.
46020446|NCT05143905|Drug|AZD7503|Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).
46020447|NCT05143905|Drug|Placebo|Randomised participants will receive placebo by SC injection
46020448|NCT04859647|Other|Method of Levels Therapy|MOL is a flexible, client-led psychological therapy that allows people to talk freely about important problems and life goals.
46020449|NCT04255225|Behavioral|Walking for 10 minutes|Participants will walk on a treadmill for 10 minutes at a moderate intensity.
46020450|NCT04255225|Behavioral|Walking for 20 minutes|Participants will walk on a treadmill for 20 minutes at a moderate intensity.
46104697|NCT00866294|Drug|paroxetine IR 10mg tablet|1 or 2 tablets once a day
46104698|NCT00866294|Drug|paroxetine IR 20mg tablet|1 tablet once a day
45467785|NCT03464656|Diagnostic Test|Sperm DNA fragmentation|Sperm DNA fragmentation was evaluated using the Halosperm kit from Halotech DNA, S.L. (Madrid, Spain) as per manufacturer instructions. The method is based on the sperm chromatin dispersion test (Fernández et al., 2003). A minimum of 500 spermatozoa were scored and reported as percentage of sperm with spermatozoa with fragmented DNA. Normal value is measure at a cut-off value of more than 30%
45467786|NCT03464656|Diagnostic Test|Static Oxidation reduction potential in semen|Oxidative stress was assessed by measuring the static oxidation-reduction potential (sORP) of neat liquefied semen samples using the MiOXSYSTM System (Aytu Bioscience, Inc., Englewood, USA). This is a galvanostatic measure of the electron transfer from reductants (antioxidants) to oxidants under a steady low voltage reducing current. Thus, providing an aggregate measure of all current oxidant activity and antioxidant activity in a sample. Higher sORP values (millivolts, mV) indicate a higher oxidant activity relative to the antioxidant activity and therefore greater state of oxidative stress.
45467787|NCT05129982|Device|whole body vibration|whole body vibration is a modality of physical therapy
46020451|NCT04255225|Behavioral|Walking for 30 minutes|Participants will walk on a treadmill for 30 minutes at a moderate intensity.
46020452|NCT00926029|Drug|Fluoride|Brush twice daily
46104699|NCT00866294|Drug|matched placebo to paroxetine IR 10mg or 20mg|1 or 2 tablets once a day
46020453|NCT00926029|Drug|Triclosan, fluoride|Brush twice daily
46020454|NCT00926029|Other|Metal salt|Brush twice daily
46104700|NCT00866294|Drug|Paroxetine CR 12.5mg tablet|1 or 2 tablets once a day
46104701|NCT00866294|Drug|Paroxetine CR 25mg tablet|1 or 2 tablets once a day
46104702|NCT00866294|Drug|matched placebo to paroxetine CR 12.5mg or 25mg|1 or 2 tablets once a day
46104703|NCT02660333|Dietary Supplement|Placebo|Maltodextrin - 11g/day
46104704|NCT02660333|Dietary Supplement|Prebiotic|Fructooligosaccharide - 11g/day
46104705|NCT02660333|Dietary Supplement|Synbiotic|Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019 - 11g/day
46104706|NCT02660255|Drug|Cannabidiol|Formulation: 100mg/ml CBD (Epidiolex) Solution
46104707|NCT00649103|Drug|Quinapril Hydrochloride Tablets 40 mg|40mg, single dose fasting
45467788|NCT03464578|Procedure|Therapy of proximal humeral fractures (irrespective conservative or operative)|
46020455|NCT04254835|Drug|Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein|Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride
46104708|NCT00649103|Drug|Accupril® Tablets 40 mg|40mg, single dose fasting
46104709|NCT04131530|Diagnostic Test|The diagnosis of Artificial Intelligence and endoscopist|When the colon mucosa is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI.
46104710|NCT02660177|Drug|Metamizole|metamizole IV administration
46104711|NCT00701246|Drug|ferrous sulfate|
46104712|NCT00701246|Drug|folic acid|
46104713|NCT00701246|Drug|placebo (folic acid)|
46020456|NCT04254835|Drug|Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein|Conventional Fluoride varnish
46020457|NCT04254991|Diagnostic Test|ImmunoXpert™|The ImmunoXpert™ technology employs a biochemical assay that measures a proprietary combination of three biomarkers of the immune system coupled with pattern recognition algorithms that classify the source of an infection as bacterial or viral
46104714|NCT02648711|Drug|CRLX101|infusion CRLX101 weekly
46104715|NCT02648711|Drug|Bevacizumab|infusion weekly CRLX101 + bevacizumab biweekly
46104716|NCT02648711|Drug|mFOLFOX6|infusion weekly CRLX101 for 3 or every 4 weeks and in combination with bi-weekly mFOLFOX6
46104717|NCT00701324|Drug|BI 811283|dose escalation BI 811283, Arm B (3 weeks)
46104718|NCT00701324|Drug|BI 811283|dose escalation BI 811283, Arm A (day 1)
46104719|NCT00701324|Drug|BI 811283|dose escalation BI 811283, Arm A (day 15)
46104720|NCT02648399|Procedure|surgery：BCND（bilateral central lymph node dissection）|
46104721|NCT02648399|Procedure|surgery：UCND（unilateral central lymph node dissection）|
46104722|NCT02648555|Behavioral|Daily walking|Participants will be instructed to walk briskly for >40 minutes, 7 days a week.
46020458|NCT04980547|Device|ACUMED® Scapholunate Repair System Group|To address the technical difficulties associated with the RASL procedure, Dr. Mel Rosenwasser developed an external over-the-top jig that in theory enables accurate and easy scapholunate-axis screw placement. The Acumed Scapholunate Repair System was designed treat patients with acute or chronic, static or dynamic scapholunate instability in the absence of significant capitolunate osteoarthritis, scapholunate ligament repair, scapholunate reduction, lunotriquetral ligament repair, lunotriquetral reduction, and carpal instability. This new Scapholunate Repair System features a targeting guide designed to enable the surgeon to reproducibly place the implant in optimal position. The implant allows physiologic intercarpal scapholunate rotation by means of a free rotation design. The procedure can forestall progressive osteoarthritis and the need for secondary salvage procedures.
45467789|NCT05512494|Biological|Quadrivalent Influenza Vaccine (Split Virion), inactivated|The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. The four influenza strains（including 4 antigens H1N1, H3N2, BV and BY, 15μg for each) in 0.5 mL of sodium chloride,disodium hydrogen phosphate,sodium dihydrogen phosphate water for per injection.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.
46104723|NCT02648555|Behavioral|Dietary recommendations|"Participants will be instructed to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting at least one week before embryo transfer and continuing until delivery. They will be also recommended to avoid high-glycemic index meals (high-carbohydrate, low-fiber), such as snacks, candies, fiber-free juices, coconut water, and sugar-sweetened beverages, particularly carbonated soft drinks and sport drinks.~Patients suffering from nausea usually do not tolerate solid food. As a result, fiber-free juices and sugar-sweetened beverages account of most of their caloric intake, which may cause non-adherence to the protocol. Women with nausea or vomiting will be treated with ondansetron."
46104724|NCT00854360|Drug|Beclomethasone dipropionate HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
46104725|NCT00854360|Drug|Placebo|HFA Vehicle Aerosol
46104726|NCT02650661|Behavioral|Online health management program|"Web-based health management program designed according to SMASH strategy, which includes (i) Assessment, (ii) Acceptance, (iii) Preparation for change, (iv) Commitment, (v) Planning, (vi) Promoting environment, (vii) Execution, (viii) Feedback and Maintenance, and (ix) Core perspectives, for 6 months.~The program consists of four areas: self-assessment, self-planning, self-learning, and self-monitoring. The learning session includes SMASH strategies and 10 Rules for Highly Effective Health Behavior."
46104727|NCT02650661|Behavioral|Health coaching|Personalized tele-coaching for 6 months by health coaches who were trained by the Smart Management and Coaching for Health (SMACH) program
45467790|NCT04343248|Drug|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for six weeks
45467791|NCT04343248|Drug|Placebo|Placebo administered orally twice daily for six weeks
45467792|NCT04343248|Dietary Supplement|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
45681128|NCT04195516|Other|web based training,individual counseling, using reminders|"Health Promotion Model based Health Promotion Program will be applied to the experimental group. Health promotion program; The Web-based Health Promotion Program includes individual counseling and reminder practices.~Within the context of the Web Based Health Promotion Program, 8 weeks of training to improve healthy eating and physical activity behaviors, individual counseling will be given.~Colorful picture reminders will be sent to the experimental group through Whatsapp groups.~At the end of the intervention, cognitive and physical measurements of the students will be done at 1st, 3rd and 6th months."
45681129|NCT03590782|Other|Erector Spinae Block|An ultrasound guided erector spinae block will be performed.
45681130|NCT05103267|Device|Tauropace|TauroPace™ contains disinfecting substances to eradicate environmental microbial contamination on the surface of cardiac implantable electronic devices (CIEDs). The surface of the CIED is moistened with TauroPace™ during the implantation procedure to create a hostile environment on the surface of the CIED.
45681131|NCT03023800|Procedure|Macular buckling|Surgical procedures of macular buckling, drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis, and inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous body through pars plana, under systemic anesthesia.
45467793|NCT03464188|Behavioral|Project Cornerstone|"Project Cornerstone basic elements are:~The intervention is lay navigator-led with regular supervision by a specialist palliative care clinician;~6 base telephone/in-person sessions: Sessions cover specific topics (every 1-2 weeks, 20-60 minutes/session; by phone or in-person), followed by monthly follow-up and additional coaching sessions as needed;~Regular caregiver distress thermometer screening and problem support and self-care coaching.~Caregivers receive a Project Cornerstone Family Supporting Family (FSF) Binder that organizes intervention materials and contains educational information pertaining to the 6 base coaching sessions. Project Cornerstone begins within 60 days of a care recipient being diagnosed with advanced cancer and ends 1 year after care recipient death."
46020459|NCT04254913|Drug|MT-1186|Suspension
46020460|NCT04254757|Procedure|Two different treatment|One group treated by percutaneous endoscopic surgery. The another group treated by open decompression and fusion surgery
46104728|NCT02650661|Behavioral|Workshop|Total three sessions are to be held at 3-, 5-, and 7-month after the initiation of the enrollment. Each session includes 30-minute health education, 1-hour health management strategy workshop, and 30-minute team coaching.
46020461|NCT01130493|Drug|IPX066|experimental product
45467794|NCT05121636|Device|MetaFix Collared Stem|Patients received the MetaFix Collared stem during there Total Hip Arthroplasty
45681132|NCT03023800|Procedure|Vitrectomy|Surgical procedures of small gauge vitrectomy, internal limiting membrane peeling, and gas (C3F8, 14%) tamponage, under local or systemic anesthesia
45681133|NCT03590548|Diagnostic Test|gausher disease|lab investigation and radio logical
46020462|NCT01130493|Drug|CLE|active comparator
46020463|NCT04255069|Drug|Placebo|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
46020464|NCT04255069|Drug|Dose 1 JKB-122|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
46020465|NCT04255069|Drug|Dose 2 JKB-122|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
46104729|NCT02650661|Behavioral|Standard health educational booklet|"Standard health educational booklets about 10 Rules for Highly Effective Health Behavior that are organized according to the Trans-theoretical Model (TTM).~Booklets are provided at 0-, 2-, and 4-month after the enrollment."
46104730|NCT00650351|Drug|Ciprofloxacin Extended-Release Tablets 1000 mg|1000mg, single dose fed
46104731|NCT00650351|Drug|Cipro® XR Tablets 1000 mg|1000mg, single dose fed
46104732|NCT04117880|Drug|Ataluren|Oral
46104733|NCT02650739|Procedure|Macular hole surgery|Vitrectomy with internal limiting membrane removal and gas tamponade
45467795|NCT03464032|Drug|BCD-135|Monoclonal anti-PD-L1 antibody
45467796|NCT05102292|Drug|HLX208|HLX208 450mg bid po
45467797|NCT05310162|Behavioral|Food, fun and family|"The intervention consists of a series of change of habits in the way children eat, the reduction of the recreational time of screens and healthy habits of physical activity. This intervention, which is called Food, Fun & Family (FFF), is aimed at parents and has been shown to be effective in reducing the consumption of empty calories by children. It teaches parents skills to reduce their daily energy intake of added sugars and saturated fats, it also seeks to reduce screen time.~The intervention contains information and recommendations, through guides, in which precise instructions are given about how to maintain a healthy environment at home."
45681134|NCT04196998|Drug|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
45681135|NCT04196998|Drug|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
46020466|NCT04253275|Genetic|blood samples|"Blood samples will be taken at inclusion, 12h, 24h, 48h, 7d, 3m and 1y for patients ; at inclusion, 3m and 1y for controls.~Microvesicles samples will be taken at inclusion, 7d and 3M ; at inclusion and 3M for controls."
46020467|NCT04253275|Diagnostic Test|MRI without injection|MRI at inclusion for controls
46020468|NCT04252651|Other|Blood Draw|This study will involve blood draws to test for specific cytokines
46020469|NCT01130337|Drug|Capecitabine [Xeloda]|1.000 mg/m2 orally every 12 hours from day 1 to day 14 of every cycle for 6 cycles
46020470|NCT01130337|Drug|Oxaliplatin|130 mg/m2 intravenous infusion day 1 of every cycle
46020471|NCT01130337|Drug|Trastuzumab [Herceptin]|First dose 8 mg/kg, subsequent cycles 6 mg/kg, intravenously, day of every cycle for 15 cycles
46020472|NCT04901689|Drug|Leronlimab|Leronlimab 700 mg
46020473|NCT04901689|Drug|Placebo|Placebo
46020474|NCT04252963|Drug|MUCOLASE tablet (streptokinase • streptodornase)|streptokinase • streptodornase 5mg
46020475|NCT04252963|Drug|Placebo|Placebo of MUCOLASE tablet
46020476|NCT04258657|Drug|paclitaxel-albumin and S-1|neoadjuvant chomotherapy with paclitaxel-albumin and S-1 for advanced gastric cancer
46020477|NCT04252729|Procedure|Psychotherapy|Psychotherapy sessions based on Psychoanalytic Psychosomatics
46104734|NCT02648633|Radiation|Stereotactic Radiosurgery|Subjects will receive a single large dose of radiation to one or more lesions.
46104735|NCT02648633|Drug|Nivolumab|3 mg/kg of nivolumab will be administered through IV infusion every two weeks following stereotactic radiosurgery.
46104736|NCT02648633|Drug|Valproate|Subjects will begin regimen of valproate prior to radiosurgery and continue to receive therapy concurrently with nivolumab. Subjects will receive valproate daily with a target serum level of 75-100 μg/ml.
46104737|NCT00853970|Drug|Bromfenac Ophthalmic Solution|sterile ophthalmic solution
45467798|NCT05310162|Behavioral|Counseling|"Simple verbal instructions will be given in the consultation to reduce the time of use of screens and refined sugar.~For refined sugar reduction, parents will be told to avoid sugary drinks, add sugar to drinks (juices, milk, etc.), and avoid snacks and sweets. It will also be indicated that the screen time should be less than two hours a day and in no case use them two hours before sleeping."
45467799|NCT03463798|Device|Sonar|Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly
45467800|NCT03463798|Device|Structured light plethysmography (SLP)|Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly
45467801|NCT03705936|Device|rTMS|rTMS is a non-invasive brain stimulation technique. It can regulate brain activities with electrical pulses sent to the brain through electromagnetic induction.
45467802|NCT03705858|Drug|Ac-Lintuzumab|225Ac-lintuzumab will administered at 4 dose levels: 0.25, 0.5, 0.75 or 1 µCi/kg intravenously (IV) over 30 ± 10 minutes. The starting dose will be 0.5 µCi/kg. A dose of 0.25 µCi/kg will be studied only if 0.5 µCi/kg is determined to exceed the MTD. The lintuzumab dose will be adjusted to maintain a specific activity of 0.16 µCi/µg
45467803|NCT03463720|Other|Infected|Extremity wound, infected
46020478|NCT01130103|Drug|Paroxetine|Paroxetine (controlled release) 12.5-50 milligrams (mg) daily for 22 weeks
46104738|NCT00853970|Drug|Placebo Comparator|sterile ophthalmic solution
46104739|NCT03960827|Other|Endurance Training|Participants randomized to ET engage in four center-based ET sessions each week for 12 weeks; each session lasting roughly 1-hour with a 40-45 minute stimulus phase and the remaining time being used to warm up and cool down. Each week, two of the sessions occur on a cycle ergometer and two involve treadmill exercise (4 total sessions per week). During all sessions, the participant's heart rate is monitored to ensure they maintain exercise intensity at 70% of heart rate reserve (± 5%). Periodically during training sessions perceptual data from participants are recorded, which is used to track the subjective experience of participants and in interpreting adherence data.
46104740|NCT03960827|Other|Restistance Training|Participants randomized to RT engage in four center-based RT sessions each week for 12 weeks; each session lasting roughly 1-hour with a 40-45 minute stimulus phase and the remaining time being used to warm up and cool down. The prescription is a 2-day split, meaning approximately half of the major muscle groups are exercised each session and each muscle group is exercised twice per week. Two sessions per week include seven exercises that focus on the hips/thighs, back and biceps, and the other two sessions per week include seven exercises that focus on the chest, shoulders, triceps, calves and abdominal muscles. The first set per muscle group is a warm-up performed at 50-70% of prescribed loads that are based on 10-repetition maximum (RM). Three sets per exercise are then performed at 10RM intensity. Load increases when a participant is able to perform 12 repetitions for 2 of 3 sets of an exercise. During all sessions, heart rate is monitored and perceived exertion is recorded.
46104741|NCT04131296|Diagnostic Test|influenza screening|positive influenza screening
46104742|NCT04116008|Other|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from recovery room followed by 2.-4.-6.-12.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 4 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
46104743|NCT02652377|Drug|EDP-494|10, 100 and 200 mg capsules
46104744|NCT02652377|Drug|Placebo|placebo to match EDP-494
46104745|NCT02644733|Procedure|head of bed elevation 30 degree|the intraabdominal pressure will be measured by nasogastric tube when the head of bed elevated to 30 degree
46104746|NCT02644733|Procedure|urinary catheter|the intraabdominal pressure will be measured by urinary catheter when the patient in supine position
46104747|NCT02648321|Behavioral|Motivational Interviewing|Motivational Interviewing is a patient-centered, tailored counselling intervention for exercise, through which patients' motives to change are identified. Personal ideas and ambivalence are explored. The discrepancies between the present behavior and the patient's own future goals are amplified. The patient's intrinsic motivation for change is increased through the process.
46104748|NCT02648321|Behavioral|Health Education|General education about healthy lifestyle and diet.
45467804|NCT03463720|Other|Not infected|Extremity wounds, non-infected
45681136|NCT04196998|Drug|Tenofovir alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
45681137|NCT04197232|Other|clinical evaluation|- In children: general clinical evaluation, birth weight, APGAR, ECG, admission to ICU, hospital admissions in perinatal age, presence of malformations; complete blood count, inflammatory index, complement, antibiotic treatment, brain ultra-sound, presence of infection, presence of sepsis, presence of necrotizing enterocolitis, growth curve, presence of recurrent infections, developmental milestones, response to vaccines, admission to hospital in the first year of life.
45681138|NCT04196452|Drug|Ipilimumab|Specified dose on specified days
45681139|NCT03590392|Biological|ChAdOx1 Chik|ChAdOx1 Chik, a replication-deficient simian adenoviral vector expressing CHIKV antigens.
46020479|NCT01130103|Behavioral|Prolonged Exposure Therapy|Weekly for 10 weeks
46020480|NCT04254523|Device|Programmed intermittent epidural bolus (PIEB) of bupicavaine|Programmed intermittent epidural boluses of bupivacaine 0,1% are administered every hour. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia. Standardized patient-controlled epidural boluses are available as top-ups.
46104749|NCT00651287|Drug|quinapril 20 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks, and if a responder, continued on quinapril 20 mg for an additional 6 weeks
45467805|NCT05156658|Drug|Etonogestrel (ENG) Subdermal Implants|Etonogestrel is available as a single, white/off-white, soft, radiopaque, flexible, ethylene vinyl acetate copolymer implant, 4 cm in length and 2 mm in diameter containing 68 mg of etonogestrel. Store at 25°C (77°F); excursions permitted between 15 and 30°C (59-86°F) [see USP Controlled Room Temperature]. Avoid storing ENG at temperatures above 30°C (86°F).
46020481|NCT04254523|Device|Continuous epidural infusion (CEI) of bupivacaine|A continuous epidural infusion of bupivacaine 0,1% is administered at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia. Standardized patient-controlled epidural boluses are available as top-ups.
45467806|NCT03463642|Dietary Supplement|vitamin D3|100,000IU
45467807|NCT03463642|Dietary Supplement|Pill|Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate
45467808|NCT03463642|Dietary Supplement|orange syrup|100 drops orange syrup
45467809|NCT03463642|Other|mineral oil|Paraffinum Liquidum,Isopropyl Palmitate,Parfum
45467810|NCT03463642|Dietary Supplement|Penetrator|Tangerine essential oil (10ml)
45467811|NCT05140824|Drug|Placebo|0.9% sodium chloride solution
45467812|NCT05140824|Biological|TJ202 injection|TJ202 injection
45467813|NCT03463564|Device|Insulin pump|Continuous subcutaneous insulin infusion consisting of the delivery of insulin lispro as basal rate and boluses administered before meals.
45467814|NCT03463564|Drug|Insulin injections|Four injections of insulin daily consisting in three bolus of a rapid-acting analog lispro or aspart before breakfast, lunch and dinner and one injection of insulin glargine or degludec at bed-time of basal insulin
45467815|NCT05092386|Biological|Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine|The investigational vaccine was manufactured by Sinovac Research & Development Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and diphtheria CRM197 in 0·5 mL of aluminum phosphate ,sodium chloride,polysorbate 80 and succinic acid per injection.
45467816|NCT05092386|Biological|Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13)|The control vaccine was manufactured by WALVAX Biotechnology Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,disodium hydrogen phosphate and sodium dihydrogen phosphate per injection.
45467817|NCT05092386|Biological|Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( Pfizer PCV13)|The control vaccine was manufactured by Pfizer. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,sodium chloride ,succinic acid ,polysorbate 80 and water for injection per injection.
46020482|NCT04254523|Device|Continuous epidural infusion (CEI) of morphine|A morphine infusion (0,1mg/ml) is administered in both groups at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia.
45467818|NCT03463252|Drug|Progesterone|MPA oral 250mg-500mg qd for 3 months per cycle
45467819|NCT03463252|Device|Mirena®|levonorgestrel intrauterine sustained release system (LNG-IUS) placed in uterus for 3 months per cycle
45467820|NCT03463252|Drug|GnRH agonist|GnRH-a intramuscular injection 3.75mg once a month for 3 months per cycle
45467821|NCT05080452|Diagnostic Test|Dynamic infrared thermography (DIRT)|Visualizing hot spots
45467822|NCT05309538|Other|Modified eply & Semont maneuver|repositioning maneauvers
45467823|NCT05309538|Other|betahistine & Modified eply & Semont maneuver|antihistamine plus repositioning maneuvers
45467824|NCT04241614|Other|No interventions|No interventions
45467825|NCT05098912|Other|Manual acupuncture|Manual acupuncture using filiform needle
45467826|NCT05098912|Other|Thread embedding acupuncture|Thread Embedding acupuncture using Polydioxanone thread
45467827|NCT04210726|Drug|25% Hypertonic Saline Bath|25% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 25%).
46020483|NCT02882919|Behavioral|Check Yourself v2.0|In the intervention group, adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to increase motivation for healthy behaviors. Primary care providers will receive a summary report of health risk behaviors prior to their adolescent patient's primary care appointment.
46020484|NCT04258501|Other|Mulberry fruit|
46020485|NCT04258501|Other|Mulberry leaf|
46020486|NCT04258501|Other|White bean|
46020487|NCT04258501|Other|Apple|
46020488|NCT04258501|Other|Elderberry|
46020489|NCT04258501|Other|Turmeric|
46020490|NCT04258501|Other|Rice porridge|
46020491|NCT00625209|Drug|placebos|placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of fludrocortisone given through the nasogastric tube once a day for seven days plus placebo of activated protein C given as a continuous infusion for 96 hours
45467828|NCT04210726|Other|0.9% Isotonic Saline Bath|0.9% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 0.9%).
45467829|NCT03463174|Procedure|Mandibular overdenture|Placement of an implant in the mandibular midline.
45467830|NCT03463174|Other|Mandibular complete denture|No intervention.
46020492|NCT00625209|Drug|hydrocortisone and fludrocortisone and placebo|hydrocortisone will be given as 50mg iv bolus every 6 hours for seven days and a tablet of 50µg of fludrocortisone will be given once a day via the nasogastric tube for seven days and a placebo of activated protein C will be given as a continuous infusion for 96 hours
46104750|NCT00651287|Drug|quinapril 20 mg plus hydrochlorothiazide 12.5 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 20 mg plus hydrochlorothiazde 12.5 mg daily (Accuzide tablets) for 6 weeks
46104751|NCT00651287|Drug|quinapril 40 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 40 mg oral tablet daily for 6 weeks
46104752|NCT02648243|Behavioral|Structured intervention at discharge and tailored follow up post discharge|"At discharge, pharmacist-delivered personalized intervention would include the following (30-60 minutes session): The pharmacist will perform medication reconciliation and will check the appropriateness and accuracy of discharge medications. - Other potential interventions that could be done by the pharmacist include in addition to medication initiation: dose and/or frequency optimization, changing ACEI with ARB if necessary, changing to another statin if needed, identification of inappropriate or duplicated therapy, etc.~The pharmacist will ensure that a follow-up plan for medication monitoring after discharge is communicated to the patient. The pharmacist will also provide a tailored and thorough counseling to the patient. In addition to the pharmacist delivered intervention at discharge (as described above), the study pharmacist will schedule 2 follow-up sessions (30-60 minutes each session) with the patients at 4 weeks of discharge and at 8 weeks of discharge."
46104753|NCT00910793|Drug|Inuvair|6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
46104754|NCT02648087|Device|With and without SDB|Screening of sleep-disordered breathing (SDB)
46104755|NCT02647931|Behavioral|Voice therapy for Muscle Tension Dysphagia|Voice therapy for Muscle Tension Dysphagia
46104756|NCT02647853|Drug|TAT4 Gel concentration A|
45467831|NCT05095350|Biological|Probiotic powder|Probiotic powder containing 10 strains from Lactobacillus and Bifidobacterium genus.
45467832|NCT05095350|Biological|Placebo powder|Placebo powder containing maltodextrin and no probiotics.
45467833|NCT03463096|Other|High G acceleration on a long-arm human centrifuge|Gx (chest-to-back) and Gz (head-to-toe)
45467834|NCT05041530|Device|REBUILD Bioabsorbable|REBUILD is an investigational medical device designed to be used with third-party suture to distribute suture tension in abdominal wall closures.
45467835|NCT03462940|Dietary Supplement|Tauroursodeoxycholic acid|Tauroursodeoxycholic acid is an ambiphilic bile acid. It is the taurine conjugate form of ursodeoxycholic acid.
45467836|NCT03011450|Drug|K-877|
45467837|NCT03011450|Drug|Fenofibrate|
45467838|NCT03011450|Drug|Placebo (for K-877)|
45467839|NCT05078736|Other|Moderate intensity intermittent training|In group A participants will receive moderate intensity intermittent training including running of 5 km with 1-min at 70% of maximal aerobic speed with interval of 1-min passive recovery, exercises will be performed by gym trainer for 5 weeks including 3 days/week
45467840|NCT05078736|Other|Moderate intensity continuous training|In group B participants will receive moderate intensity continuous training ran continuously the same 5 km at 70% of maximal aerobic speed, exercises will be performed by gym trainer for 5 weeks including 3 days/week.
45681140|NCT01867671|Biological|Peanut Oral Immunotherapy - Liquid Extract|Used during initial dose escalation for doses 0.1 to 0.8 mg.
46020493|NCT00625209|Drug|recombinant human activated protein C and placebos|activated protein C will be given as a continuous infusion at a dose of 24 µg/kg/h four 96 hours and hydrocortisone placebo as an iv bolus every 6 hours and fludrocortisone placebo once a day through the gastric tube will be given for seven days
46020494|NCT00625209|Drug|recombinant human activated protein C and hydrocortisone and fludrocortisone|96 hours continuous infusion of 24µg/kg/h of activated protein C plus seven day treatment with 50mg iv bolus of hydrocortisone every 6 hours and 50µg of fludrocortisone via the nasogastric tube once a day
46020495|NCT04254445|Other|Personalized training video|Using a few demographic and medical details of the patients, provided by the medical staff, the video generator will create a 2-minute personalized custom video, suitable to the age, gender, language, and medical condition of the patients. No identifying information will be used, to protect patient's privacy.
46020496|NCT02882841|Other|Biopsies, stool and blood collection|
46020497|NCT04254601|Device|Narrow band ultraviolet B.|NBUB: DIXWELL EMLY 98 -ABRP 64 ,made in France. Red LLL, InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia)
46104757|NCT02647853|Drug|TAT4 Gel concentration B|
46104758|NCT02647853|Drug|Placebo|
46104759|NCT02650505|Drug|LEO 43204|
46104760|NCT02650505|Drug|LEO 43204 Vehicle|
45467841|NCT03462862|Other|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high bio compatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
45467842|NCT03462862|Other|Bre-Flex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, poly-amide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon removable denture is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
46020498|NCT04254601|Drug|topical erythromycin cream 2% (Akne-Mycin- Egypt)|"two times per day on the entire face from the beginning to the end of the treatment period .~The face is washed thoroughly with warm water and gentle soap, rinse well, and pat dry, patients were advised to wait 30 minutes before applying the aknemycin. To help keep new pimples from breaking out, the aknemycin was applied to the whole area usually affected by acne, not just to the pimples themselves"
46104761|NCT02650427|Drug|Sitagliptin|100mg or 200mg or 600mg, daily for 3 weeks ± 7 days
46104762|NCT02650583|Other|Educational Intervention|Receive Enhancing Connections Program
46104763|NCT02650583|Other|Questionnaire Administration|Ancillary studies
45467843|NCT05072028|Drug|[14C]DBPR108|[14C]DBPR108, single dose of 100 mg (radioactivity of 150 µCi), oral
45467844|NCT03462784|Other|Demographic, physical examination, data will becollected .|"Demographic data collected includ clinical diagnosis, sex, race, genotype, and phenotype.~Historical data included information regarding immunizations, infection exposures, surgical procedures, organ dysfunction(Organ dysfunction was defined as a history of requiring medical treatment for heart disease, diabetes (Type 1 or 2), hypoparathyroidism, hypothyroidism, growth hormone deficiency, or gonadal failure) age at transfusion initiation, chelation therapy, type of RBC product, transfusion reactions, and antigen matching. Data will be collected from chart review, patient interviews, blood banking records, and laboratory"
46104764|NCT02650349|Other|fMRI|
46104765|NCT00652613|Radiation|3 Dimensional Radiation Therapy|Radiation with 6 MV photons to dose of 70Gy/ 35#/ 7 weeks
46104766|NCT00652613|Radiation|Intensity Modulated Radiation Therapy|IMRT with 6 MV photons to a dose of 66Gy/30#/ 6 weeks
45467845|NCT03638856|Drug|Misoprostol 200Mcg Tab|patient takes 2 tab of 200 mcg of Misoprostal 3 hr before hysteroscopy
45467846|NCT04136626|Device|Perspectives OCD|The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work) and behavioral skills (e.g., exposure and response prevention).
45467847|NCT04136626|Device|The Health and Well-Being Program|The website includes 12 modules related to general health and well-being (e.g., sleep and nutrition). Each module contains educational information and questions about an indvidual's experience with the given topic.
45599265|NCT02343783|Other|Allergic Skin Reaction (ASR) Testing and Skin Blister Induction|Participants will not receive any intervention in this study. Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. The cell populations and inflammatory mediator responses in suction skin blister fluid after allergic skin reaction (ASR) in participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed.
45681141|NCT01867671|Biological|Placebo for Peanut Oral Immunotherapy - Liquid Extract form|Similar in appearance, texture, and taste to peanut liquid extract.
45681142|NCT01867671|Biological|Peanut Oral Immunotherapy - Peanut Flour|This will be used for the remainder of dose escalation, build-up, and maintenance.
46020499|NCT04840381|Behavioral|Questionnaire administrations|Administration of an ad hoc questionnaire to register food frequency consumption and meal time, main recipes; phisical activity questionnaire and list of questions concerning the previous and actual health status of participants
46020500|NCT01129557|Drug|Aliskiren|
46104767|NCT02650037|Procedure|Air Test|The Air Test simply consisted in breathing room air for 5 min on arrival into the postoperative anesthesia care unit while measuring peripheral oxygen saturation by Pulse oximetry
46104768|NCT00651365|Drug|JNJ-38877605|
46104769|NCT04166747|Other|Virtual Reality experience|Participants will receive virtual reality based experience and will be assessed for its influence on happiness, functional fitness components and quality of life of older age groups.
46020501|NCT01129557|Drug|Valsartan|
46020502|NCT04976413|Behavioral|Eye Movement Desensitization and Reprocessing (EMDR) psychotherapy|Experimental arm will receive eight phase EMDR treatment using manualized standard protocol. Selection of targets for reprocessing through EMDR will be made according to adaptive information processing model's postulations, that links traumatic events with the symptoms of depression and anxiety. Time period allocated to EMDR treatment is 12-14 weeks.
46104770|NCT02647775|Procedure|multi-port VATS|Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
46020503|NCT04976413|Behavioral|Counselling as usual|Control arm will receive counseling as usual for 12-14 weeks
46020504|NCT04831567|Radiation|MIBG-I131|Radiopharmaceutical
46020505|NCT04884295|Drug|XVR011|Single dose of XVR011 via intravenous (IV) infusion
46020506|NCT04254679|Drug|Opioid analgesics|"Current standard of care in the participating centers Prescription of around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs/COX-2) and a supply of opioids to be used as a rescue in case of breakthrough pain.~The specific round-the-clock analgesia and rescue opioid regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference."
46104771|NCT02647775|Procedure|single-port VATS|Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
46104772|NCT02644811|Drug|Topical anesthesia (buccal and palatal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
46104773|NCT02644811|Drug|Local anesthesia (buccal and palatal)|Injection of 1,5 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
46104774|NCT02644811|Procedure|Extraction of the maxillary first premolars|Careful extraction of the maxillary first premolars after mobilization.
46104775|NCT02644811|Drug|Topical anesthesia (buccal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
46104776|NCT02644811|Drug|Local anesthesia (buccal)|Injection of 0.3 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
46104777|NCT02644811|Device|Molarblock|Molarblock is a Stainless steel ligature connecting the maxillary second premolar with the maxillary first and second molar.
46104778|NCT02644811|Device|Spider Screw K1 short neck|The Spider Screw K1 (Health Development Company, Sarcedo, Italy) is a self-drilling and self-tapping screw. Short neck screws (SCR-1508 and SCR-1510) with a diameter of 1.5 mm and length 8 or 10 mm are used.
45681143|NCT01867671|Biological|Placebo for Peanut Oral Immunotherapy - Peanut Flour|Similar in appearance, texture, and taste to peanut flour.
46020507|NCT04254679|Drug|Non-opioid analgesics|"Prescription of around-the-clock non-opioid analgesics (acetaminophen alone or combined with NSAIDs/COX-2).~The specific non-opioid analgesia regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference."
46104779|NCT02647463|Behavioral|Attachment and Biobehavioral Catch-up (ABC)|
46104780|NCT00651443|Drug|Galiximab|Galiximab 500 mg/m2 IV once weekly times 4, followed by Galiximab 500 mg/m2 IV once monthly times 4 as an extended dosing regimen.
46104781|NCT02649881|Procedure|The heart subject will undergo OCT|
46104782|NCT00650897|Drug|Escitalopram|10-20 mg once daily
46104783|NCT02644655|Biological|CD19-specific chimeric antigen receptor|Cyclophosphamide 500 mg - 2000 mg/m2 (day 2) with or without Fludarabine 30 mg/m2 /day, 4 days (day 6, 5, 4, 3); nCAR19-T transfusion：day 0(5×105/kg，1×106/kg，3×106/kg).
46104784|NCT02644499|Drug|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic dise
46104785|NCT02644499|Drug|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
46104786|NCT02644499|Drug|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
46104787|NCT02644499|Drug|Prednisolone|Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop)
46104788|NCT02644499|Drug|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
46104789|NCT00652691|Biological|filgrastim|
46104790|NCT00652691|Drug|carboplatin|
46020508|NCT05330533|Radiation|scrotal duplex|Scrotal colour doppler ultrasonography
46020509|NCT01129011|Drug|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
46020510|NCT01129011|Drug|Naproxen|Naproxen 500 mg dosed twice daily (bid) orally
46020511|NCT04254211|Other|NLR|neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR)
46104791|NCT00652691|Drug|cyclophosphamide|
45467848|NCT01312194|Procedure|Root canal therapy in one visit|Patient was anesthetized with local anesthetic solutions, and the caries was removed. The tooth was isolated with rubber dam and access to pulp chamber was completed. Cleaning and shaping preparation was achieved with manual and rotatory endodontic instruments.The ideal working length was determined by an electronic apex locator and periapical radiography. Irrigation was performed with 5.25%NaOCl solution. The smear layer was removed by 10% citric acid. The cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
45467849|NCT01312194|Procedure|Root Canal Therapy in two-vist|The treatment protocol was the same as described for one visit group. In the first visit, after cleaning, shaping and smear layer removal, the root canals were medicated with a calcium hydroxide paste and sterile distilled water (1:1) and the pulp chamber was sealed with a minimum 3mm thickness temporary filling restoration. After 10-12 days, during the second visit, the medication was removed, and the cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
45467850|NCT03462472|Behavioral|Lower leg heating|Immersion of lower legs in a circulating water bath at a temperature of 42 degrees Celsius
45681144|NCT03992950|Other|Maneuvers for occluding esophagus|Cricoid pressure: pressure on the cricoid ring Paratracheal pressure: pressure on the left paratracheal region below the cricoid level
45681145|NCT04028206|Dietary Supplement|Hydroxymethylbutyrate|Hydroxymethylbutyrate supplementation at 3.0 g/day with dietary advice.
46020512|NCT04253041|Behavioral|Effects of Instagram Exposure on Lifestyle Satisfaction|Participants will complete initial measures of sociodemographic information, the Sociocultural Attitudes Towards Appearance Scale, The Physical Appearance Comparison Scale-Revised, and baseline measures of body appreciation, body satisfaction, and mood using online Visual Analogue Scales via Qualtrics. Female undergraduate students will be randomly assigned to one of three groups. The Fitspiration and Body Positive groups will view a series of 15 Fitspiration or Body Positive images sourced from Instagram while the control group will view 15 interior design images sourced from Instagram. After viewing images, participants will complete posttest measures of body satisfaction, body appreciation, and mood using Visual Analogue scales. Thereafter, participants will be provided with four, brief short answer questions regarding their perspective on the images observed.
46020513|NCT02882607|Behavioral|Mzanga Samala Moyo Wako ([Mzanga] Peer Groups|8 small group sessions led by community young women, focused on reproductive health, including HIV, STI and unintended pregnancy prevention; includes skill-building for self-efficacy
46020514|NCT04203589|Behavioral|The Explorer Baby Early Intervention Program|Centered based intervention, once or twice a month, 6 months follow up
46020515|NCT04203589|Other|Neurodevelopmental Therapy|Centered based intervention, once or twice a month, 6 months follow up
46020516|NCT02882763|Other|Parents As Teachers (PAT)|A trained PAT parent educator (pediatric nurses in this study) visits families at their homes, approximately two times a month (individual frequencies may vary depending on specific risk factors) until the children are three years old. PAT is an educational home visitation program that aims to a) help parents to understand child developmental aspects and improve their parenting skills, b) detect developmental shortcomings, c) prevent child abuse and neglect, and d) enhance school preparedness. Additionally, the project offers monthly group meetings.
46020517|NCT02882373|Dietary Supplement|Arginine|Given PO
46020518|NCT02882373|Drug|Placebo|Given PO
46020519|NCT04824781|Other|Qualitative interview|Participants will be interviewed about their experiences of recovery from paranoia.
46020520|NCT04258735|Diagnostic Test|Genomic analysis|WES, RNASeq, ctDNA, Exosome
46104792|NCT00652691|Drug|topotecan hydrochloride|
46104793|NCT00652691|Procedure|autologous hematopoietic stem cell transplantation|
46104794|NCT00652691|Procedure|peripheral blood stem cell transplantation|
46020521|NCT04873765|Biological|Pegfilgastrim Megalabs|Administration of 6 mg of Pegfilgrastim Megalabs subcutaneous single dose
46104795|NCT02649725|Behavioral|patient's satisfaction|Questionnaire based measurement.
46104796|NCT02649803|Behavioral|asthma APP|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the nearest community hospital or Shanghai Children's Medical Center, whichever is nearer to the subject's home, for their future onsite visits (V2-V5). The patient's caregiver will be instructed to install the asthma APP at their smart phone and learn how to use this APP.
46104797|NCT02647541|Dietary Supplement|Nutritional intervention|Consultation with a dietitian, nutritional recommendations to achieve the expected energy expenditure, with or without supplementation with enriched formulas.
46104798|NCT04166825|Diagnostic Test|fibrin clot properties|Assessment of thrombin generation and efficiency of fibrinolysis.
46104799|NCT00652769|Procedure|Endobronchial or Endoscopic Ultrasound|Patients with anterior mediastinal or subcarinal disease will undergo EBUS. Patients with posterior, subcarinal or AP window disease will undergo EUS. Patients with no mediastinal disease on CT scan will undergo EBUS.
46104800|NCT00652769|Procedure|Bronchoscopy, CT-guided biopsy, PET scan, Mediastinoscopy|Investigations will be determined by the multi-disciplinary team responsible for the patient
46104801|NCT02536157|Device|Thermoplastic splinting|
46104802|NCT02647697|Drug|Radiprodil oral|"Active Substance: Radiprodil~Pharmaceutical Form: dry granules for oral suspension~Concentration: 30 mg~Route of Administration: oral use"
46104803|NCT02647307|Drug|DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg)
46104804|NCT03785327|Device|tDCS|Participants either complete active and sham tDCS sessions one week apart or an autism training program.
46104805|NCT03785327|Behavioral|Autism Training|Autism Information Presentation developed by Dr. Grace Iarocci's Autism & Developmental Disorders Lab at Simon Fraser University
46104806|NCT02649569|Device|Monitoring Device|Wear activity monitor
46104807|NCT02649569|Other|Quality-of-Life Assessment|Complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30
46104808|NCT02649647|Procedure|Conventional resection|The conventional technique requests an excision of at least 10 cm of bowel proximal to the tumor, and the sigmoid colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
46020522|NCT04873765|Biological|Pegfilgastim Amgen|Administration of 6 mg of Pegfilgrastim Amgen subcutaneous single dose
46020523|NCT04254055|Other|exercises|Those subjects included in the experimental group will receive an intervention through a program with plyometric, proprioceptive and strength exercises. The subjects included in the control group will not receive any intervention.
46020524|NCT05247229|Behavioral|Middle school after-school education program|The intervention assesses the impact of a middle school after-school education program on shellfish and toxin knowledge and clam harvesting planned behaviors. The intervention takes place weekly during the school year. The curriculum centers around teaching children about local traditional ecological knowledge and traditional harvesting and gathering practices.
46020525|NCT04245241|Other|High-flow nasal cannula (HFNC)|24 patients who receiving HFNC within 24 hours after extubation were prospectively enrolled in this study. EIT was used to monitor regional lung ventilation distributions at baseline (conventional oxygen therapy) and three flow rate levels of HFNC therapy (20, 40 and 60 L/min).
46020526|NCT04252885|Drug|Lopinavir and Ritonavir Tablets|As indicated in arm/group descriptions
46020527|NCT04252885|Drug|Arbidol|As indicated in arm/group descriptions
46104809|NCT02649647|Procedure|Proximally extended resection|The modified technique requests an excision of the whole sigmoid colon and rectum proximal to the tumor, and the descending colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
46104810|NCT02649491|Other|Cohort Observation|Study participation will be offered to women, newly diagnosed with a gynecological malignancy who are due to be treated with pelvic radiotherapy.
46104811|NCT00650975|Device|Laser Thromboablation|Laser Thromboablation using the Spectranetics CVX-300® excimer laser system
46104812|NCT00650975|Device|PTCA (Direct Stenting)|Balloon predilatation or Direct Stenting using conventional techniques according to local standards and device specific instructions for use
46104813|NCT02649179|Drug|Ropivacaine|All wounds were infiltrated with 0.75% ropivacaine 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
46104814|NCT02649179|Drug|0.9% saline|All wounds were infiltrated with 0.9% saline 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
46020528|NCT04258345|Other|ASB Feeding Study|Participants will undergo a washout period and then scheduled for blood draw after which ASB feeding period will begin followed by a second blood draw.
46020529|NCT04252417|Drug|MD1003|Single oral dose administration of MD1003 at Day 1
46020530|NCT02887872|Other|Electrical stimulation-dynamic hand orthosis|Each participant participated in the electrical stimulation-dynamic hand orthosis regimen. Repetitive grasp/release motions were performed for 30 minutes while wearing the dynamic hand orthosis. This was followed by 15 minutes of electrical stimulation applied to forearm extensor muscles. This regimen was performed daily, 5X/week for 6 weeks.
46020531|NCT04939207|Diagnostic Test|CT-FFR|CT-images will be processed by an algorithm to calculate FFR-values of the full coronary tree
46020532|NCT04939207|Diagnostic Test|Angiography-derived FFR|FFR-values are calculated during coronary angiography based on the acquired images of the coronary arteries
46104815|NCT02644577|Drug|Metformin|
46104816|NCT02644577|Other|Starch|
46104817|NCT02644421|Drug|VVZ-149|
46104818|NCT02644421|Drug|Lidocaine|
46104819|NCT02644421|Drug|Placebo|
46104820|NCT02649257|Procedure|cataract surgery|
46104821|NCT02649257|Device|intraocular lens (MC 6125 AS)|
46104822|NCT02649257|Device|capsular tension ring (CTR 13/11)|
46104823|NCT04167449|Dietary Supplement|HRG80 Hydroponic Red Ginseng|Powdered root preparation of Panax ginseng standardized to 31.7 mg total ginsenosides
46104824|NCT04167449|Dietary Supplement|Conventional White Ginseng|Powdered root preparation of Panax ginseng standardized to 9.8 mg total ginsenosides
46104825|NCT04167449|Dietary Supplement|Placebo|Visually identical placebo capsule containing rice flour
45467851|NCT03462472|Behavioral|Lower leg transcutaneous electrical nerve stimulation (TENS)|Bilateral lower leg transcutaneous electrical nerve stimulation (TENS) using burst mode at a 3Hz burst rate, 100Hz frequency, and 250 µs pulse duration, sufficient to evoke skeletal muscle contraction
46020533|NCT04939207|Diagnostic Test|Angiography with invasive FFR-measurements|during coronary angiography, a specialized pressure wire is passed through the coronary stenosis to calculate FFR based on the difference between the actual pressure and the expected pressure in the hypothetical healthy coronary artery.
45467852|NCT05026944|Other|Percussive massage and static stretching exercises|All the study participants will perform 15 minutes treadmill, 15 minutes stationary bicycle at day one. After 24 hours participants with positive DOMS will be treated with 5 minutes of percussive massage and 5 minutes of static stretching exercises. The group will be assessed on Numeric Pain Rating Scale and Short-Form McGill Pain Questionnaire for pain and degree of passive ankle dorsi flexion for calf muscle length at baseline before intervention and immediate 24 hours, 48 hours and 72 hours after the completion of treatment session.
45467853|NCT05026944|Other|static stretching exercises|All the study participants will perform 15 minutes treadmill, 15 minutes stationary bicycle at day one. After 24 hours participants with positive DOMS will be managed with 5 minutes of static stretching exercises only. The group will be assessed on Numeric Pain Rating Scale and Short-Form McGill Pain Questionnaire for pain and degree of passive ankle dorsi flexion for calf muscle length at baseline before intervention and immediate 24 hours, 48 hours and 72 hours after the completion of treatment session.
46020534|NCT04253821|Other|muscle tonus, stiffness and elasticity,six-minute walk test, Pulmonary function tests, The neck disability index|The muscle tonus, stiffness and elasticity of upper trapezius (UT), semispinalis capistis (SSC), pectoral muscles (PM) and sternocleidomastoideus muscles (SCM) were measured by using MyotonPro® device. Functional capacity was measured with six-minute walk test. Pulmonary function tests was evaluated with spirometer. The neck disability index (NDT) was applied. The forward head posture was determined by measurements of craniovertebral angle (CVA). Physical activity levels of participants were evaluated by Physical Activity Index (FIT).
46020535|NCT04253743|Other|Nevada Healthy, Hunger-Free Kids Demonstration Benefits|SNAP households with children under age 5 incomes below 75% of the federal poverty level living in Clark County, Nevada received $40 in extra SNAP benefits per eligible child, and access to case management and nutrition education.
46104826|NCT02647229|Other|Isosmotic bowel cleansing preparation|Isosmotic Preps contain polyethylene glycol (PEG) and are osmotically balanced, high-volume, nonabsorbable, and nonfermentable electrolyte solutions.
46104827|NCT02647229|Other|Colonic Hyrdrotherapy|FDA approved method of colon cleansing using constant warm water lavage with a contained temperature and pressure controlled device administered by a trained technician
45467854|NCT03462394|Other|Current Script|This is the version of the phone call script currently used at NYU Langone Health.
46104828|NCT00651599|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
46104829|NCT00651599|Drug|Placebo|Placebo treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
45467855|NCT03462394|Other|Alternate Script Iterations|Intervention includes various iterations of the phone call script (different wording or script structure).
46104830|NCT02647151|Drug|METHYLAMINOLEVULINATE HYDROCHLORIDE|"This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed."
46104831|NCT02647151|Drug|AMINOLEVULINIC ACID HYDROCHLORIDE|"This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed."
46104832|NCT04167293|Radiation|stereotactic body radiotherapy|Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks.
46104833|NCT04167293|Drug|Sintilimab|Sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year. The first course of sintilimab will be given within 4-6 weeks after completion of SBRT.
45467856|NCT03705780|Other|the short OSAS scale|Parents fill in the short OSAS screening scale in preoperative interview，calculate score of the scale.
45467857|NCT03705780|Diagnostic Test|fentanyl test|In the operating room，giving 1 mcg/kg fentanyl when the End-tidal concentrations of sevoflurane were maintained at 3.0 and the spontaneous respiratory frequency was stable after eyelash reflex disappeared and pharyngeal airway insertion, observing the changes of respiratory rate
46020536|NCT04258189|Drug|JNJ-64417184|Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.
46020537|NCT04962841|Other|Nutraceuticals|To observe the effect on cognitive and physical impairment.
46020538|NCT04253197|Device|Ultrasound|Pregnant women in 3rd trimester with anterior placenta previa and lower cesarean section scar. Ultrasound was done and according to parameters of the morbidly adherent placenta, a staging system was conducted.
46020539|NCT00919867|Drug|SPD503|SPD503 extended-release 4mg orally administered tablets. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
46104834|NCT04166357|Diagnostic Test|neuromuscular ultrasound|Neuromuscular ultrasound refers to a field in medicine in which ultrasound is used to diagnosis and guide treatment for people with neuromuscular diseases. Neuromuscular ultrasound is often combined with electrodiagnosis, and particularly nerve conduction studies and EMG, to improve the accuracy of diagnosis and add anatomic information to the functional information obtained with electrodiagnosis. It has been demonstrated that neuromuscular ultrasound adds value to the diagnosis of nerve disease in over 80% of cases.
46020540|NCT00919867|Drug|VYVANSE|VYVANSE 50mg orally administered capsules. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
46020541|NCT00919867|Drug|SPD503 and VYVANSE|SPD503 4mg tablets + VYVANSE 50mg capsules orally administered together. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
46020542|NCT04252261|Drug|sulforaphane|To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
45467858|NCT02734810|Drug|Liprotamase Powder for Oral Solution|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement therapy
46020543|NCT04252261|Drug|placedo|To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
46020544|NCT01215942|Drug|LY2127399|Administered Subcutaneously
46020545|NCT04258033|Drug|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
46020546|NCT04251871|Drug|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|"Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.~Traditional Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days."
46104835|NCT02536391|Drug|Ipatasertib (capsule)|Orally administered single dose of Ipatasertib formulated as a capsule.
46104836|NCT02536391|Drug|Ipatasertib (tablet)|Orally administered single dose of Ipatasertib formulated as a tablet.
46104837|NCT00651053|Device|EUS|Sensitivity and specificity of EUS will be compared with PFT as reference standard.
46104838|NCT02644187|Device|BF-RhodoLED|Infrared light, with total dose of 37J/cm2.
45467859|NCT03705702|Other|Education Program|The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education, which will include information about the pathophysiology of asthma, medication and peak flow meter instructions, self-monitoring techniques, environmental control techniques and avoidance strategies. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active and maintain a healthy lifestyle.
46020547|NCT04251871|Drug|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)|Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
46020548|NCT04924543|Other|Online self-learning training module|Training module in optical diagnosis of IBD-associated dysplastic lesions during gastrointestinal endoscopy
46020549|NCT04924543|Other|Refresher training|Brief refresher training in optical diagnosis of IBD-associated dysplastic lesions during gastrointestinal endoscopy
46020550|NCT01128621|Drug|GSK1292263|Tablet
46020551|NCT01128621|Drug|GSK1292263 matching placebo|Tablet
46020552|NCT01128621|Drug|Sitagliptin|Tablet
46020553|NCT00918463|Drug|dasatinib|100 mg daily dosing
46020554|NCT04257877|Procedure|Blood sampling|Blood samples for proteomic analysis in plasma of both groups
46020555|NCT04251793|Other|Observation|Soft tissue implant measurements and radiographs
46104839|NCT02644187|Device|Aktilite CL128|Infrared light, with total dose of 37J/cm2.
45467860|NCT03705702|Behavioral|Behavioral intervention|The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting 40 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own PA data and the behavioural change stage, an individual action plan will be established with realistic goals to increase PA. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time. Techniques such as weekly goal-setting, motivational interviewing, activity tracker vibration instructions, self-management, positive reinforcement, relapse prevention and strategies to overcome barriers will be included.
46020556|NCT04811989|Behavioral|Instructive video on diabetic foot care|In the video, the diabetic foot care is presented verbally and appropriately captioned, as well as exemplified by real patients and health professionals from the hospital
46020557|NCT04811989|Behavioral|Informative leaflet with real-time guided reading|The leaflet has information about diabetic foot care. Researcher will guide its reading with patients.
46104840|NCT02644187|Drug|BF200-ALA/5-aminolevulinic acid|Prodrug applied to whole treatment area previous to illumination with either light source.
46104841|NCT02536235|Other|heat|activated heating pad to lower abdomen
46104842|NCT04166279|Other|Single rehabilitative treatment|The rehabilitation treatment, performed by a physiotherapist trained in oncological rehabilitation, was carried out with a 6-week exercise program for 12 sessions (60 minutes/session, 2/week).). The protocol included a first phase consist in low impact aerobics warming (15-20 minutes), then diaphragmatic breathing and postural exercises for the midline alignment. The awareness of abdominal breathing represents the preliminary phase for a complete psychophysical relaxation of the patient, an important prerequisite for the correct execution of subsequent mobility, stretching and strengthening exercises of spine, scapula and upper limb. Subsequently, isometric strengthening exercises for shoulder stabilizing muscles, first passively and, subsequently, with supervision, were performed. Specific exercises, for passive mobilization and stabilization of the scapula, cervical pumping and stretching of the pectoral muscles, have been performed.
46104843|NCT04166279|Other|Group rehabilitative treatment|Four-five patients for group. The rehabilitation treatment, performed by a physiotherapist trained in oncological rehabilitation, was carried out with a 6-week exercise program for 12 sessions (60 minutes/session, 2/week). The protocol included at first week mainly breathing techniques, then we introduced exercises gradually more active, according to the improvements of the execution. The exercises had the aim to improve the opening of the scapular chain and to increase the amplitude of the range of motion in order to stimulate better neuromuscular control during the movement of scapular retropulsion, to stretch the pectoral muscles following the rhythm of the breath and the tissues affected by post-surgical scars and fibrotic effects, finally to reinforcing, against gravity, the musculature of the shoulders and back.
46020558|NCT04811989|Behavioral|Informative leaflet to read at home|Patients receive a leaflet about diabetic foot care to read at home.
46020559|NCT04811989|Behavioral|Face-to-face teaching|Face-to-face teaching includes the teaching about diabetic foot care during the consultation by health professionals.
46020560|NCT04251637|Other|Cardiac output monitoring with Starling SV.|Intraoperative monitoring of cardiac output by esophageal Doppler, NICOM Starling SV and collection of values for each patient at at least 7 predefined intraoperative times.
46104844|NCT00651131|Drug|daptomycin|daptomycin i.v. 4 mg/kg q24h for 7-14 days
46104845|NCT04167137|Drug|SYNB1891|Up to four 21-day cycles of escalating doses of SYNB1891 intratumoral injection on Days 1, 8 and 15 of Cycle 1 and Day 1 of cycles 2-4.
46104846|NCT04167137|Drug|Atezolizumab|Administered in accordance with its recommended dose and schedule (1200 mg IV Q3W) on Day 1 of each of the 4 planned 21-day cycles.
46104847|NCT00651677|Procedure|HAL proctectomy|Hand-assisted laparoscopic proctectomy
46104848|NCT00651677|Procedure|"straight laparoscopic proctectomy"|"straight laparoscopic proctectomy"
46104849|NCT00651677|Procedure|Hand-assisted laparoscopic proctectomy|hand-assisted laparoscopic proctectomy
46104850|NCT00651677|Procedure|SL Proctectomy|Straight laparoscopic proctectomy
46104851|NCT02644031|Procedure|mtwo rotary system|post-treatment pain after using mtwo rotary system
46104852|NCT02644031|Procedure|safe-sider rotary system|post-treatment pain after using safe-sider rotary system
45467861|NCT04980846|Other|Driving under the influence of alcohol with a driving simulator|"Participants will drive in three different states (sober, drunk above and below the legal limit) on designated circuits using a driving simulator. After the initial sober driving session, participants are administered pre-mixed alcoholic beverages (e.g., vodka orange). Participants are expected to achieve a target BrAC of 0.35 mg/l (legal limit in Switzerland is 0.25 mg/l BrAC) before the second driving session starts. Finally, the third driving session starts when the participants' BrAC drops to 0.15 mg/l. Heart rate, skin conductance, accelerometer, eye movement, radar, facial expression, and speech will be recorded by a smart-watch, an eye-tracker, microphones and an onboard camera, respectively.~Participants will be blinded to their alcohol levels during the study. They will have to rate their symptoms and their performance via questionnaires before and after each driving session. Further, capillary blood and oral fluid samples will be collected."
46020561|NCT04251559|Other|oral glucose loading test|oral glucose loading test was performed to all participants. gestational diabetes and control group were compared in terms of menarche age.
46020562|NCT05048641|Other|Whatsapp reminder|Subjects who are allocated to the intervention group received reminder via WhatsApp Messenger at one month before the scheduled calendar month of biannual mammography follow-up.
46104853|NCT02644031|Procedure|hand files|post-treatment pain after using hand files
46104854|NCT02646995|Dietary Supplement|modified lipid formulation|Tested oils will be used in liquid form and encapsulated in soft gelatin capsules.
46104855|NCT02646995|Dietary Supplement|Fish oil|Fish oil will be used in liquid form and encapsulated in soft gelatin capsules.
46104856|NCT00651833|Drug|S-1|All patients will receive S-1 orally at a dose of 25 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the third stage only if 7/31 (23%) or more patients have achieved a confirmed response (CR or PR) in stages 1 and 2 combined.
45467862|NCT04976790|Behavioral|Chinese Tuina therapy|Firstly, the patient is in the prone position, and the doctor use the method of rolling or kneading the Bladder meridians on both sides of the spine. The waist will be focused on to manipulate preferentially and then using the same technique on the patient's back, buttocks and lower limbs. Secondly, the physician will perform the manipulation on the patient's waist and the posterolateral side of the lower limbs by pressing, kneading, plucking. The doctors press the acupoints, including Mingmen(DU04),Shenshu(BL23),Yaoyangguan(DU03),Huantiao(GB30), Weizhong(BL40),Chengshan(BL57),and Ashi points, with the elbow or the thumb to achieve Deqi sensation. Thirdly, the The doctor uses the method of pressing acupoints, including Tianshu(ST25),Qichong(ST30),Chongmen(SP12),Daimai(GB26),Jingmen(GB25) on both sides. Fourthly, the patient is required to face the doctor in a lateral position for pulling manipulation on the both sides of lumbar vertebrae.
46020563|NCT05330065|Drug|bevacizumab and camrelizumab|"Stage 1 was classical 3+3 dose escalation with pts assigned to one of the following 3 cohorts, Cohort A:Avastin 5mg/kg once every 2 weeks and camrelizumab 100mg once every 2 weeks;Cohort B:Avastin 7.5mg/kg once every 2 weeks and camrelizumab 100mg once every 2 weeks;Cohort C:Avastin 7.5mg/kg once every 2 weeks and camrelizumab 200mg once every 2 weeks.DLT was observed for 28 days."
45467863|NCT04976790|Drug|Flurbiprofen Cataplasms group (FCG).|One Flurbiprofen Cataplasm was applied to the left and right sides of the waist, twice daily, for 14 days
45467864|NCT05011084|Device|Game Ready Cryotherapy with Compression Group|Instead of using the traditional ice-pack cryotherapy (without compression), patients randomized into this group will use the Game Ready device, which uses cryotherapy with compression, during their post-operative treatment care.
45467865|NCT05011084|Other|Control Cryotherapy Group|Patients randomized to the control group will use the standard of care, which is using traditional cryotherapy (i.e., an ice pack without compression)
45467866|NCT04858594|Other|Planned Chemotherapy|standard oncologic supportive care including antibiotic prophylaxis
45467867|NCT04789564|Diagnostic Test|cardiovascular magnetic resonance (CMR)|Testing CMR on patients of 7 days and 6 months after myocardial infarction
45467868|NCT05535920|Drug|LOKELMA 5 GM Powder for Oral Suspension|Patients will use Lokelma supplementation on off-dialysis days (4 days/week) while receiving hemodialysis with 3.0 K+/2.5 Ca++ mEq dialysate bath. The individual starting dose will be 5.0 grams, and may be titrated weekly in 5.0 gram increments up to 15.0 grams to maintain K+ between 4.0 and 5.5 mEq/L.
45467869|NCT04452838|Drug|Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)|4 mg administered under fasted condition.
46020564|NCT05120193|Device|Mapping and Ablation|Minimally invasive catheter mapping and ablation procedure
46020565|NCT01128543|Drug|lapatinib and Vinorelbine|Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks.
45681146|NCT04028206|Device|Low-magnitude High Frequency Vibration (LMHFV)|Low-magnitude High Frequency Vibration is a non-invasive biophysical intervention which provides mechanical stimulation with no reported adverse effects. Our previous studies on bone showed that LMHFV can help boost the patients' bone mineral density (BMD) and muscle health.
46020566|NCT01128387|Drug|Panitumumab|dose escalating 1.5mg/kg or 2.5mg/kg weekly during radiation. Cisplatin on Days 1 and 29, Fluorouracil on Days1-4 and Days 29-32.
46020567|NCT01214850|Biological|Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)|
46104857|NCT04167215|Procedure|superior gluteal artery flap and lumbar artery falp|Doppler ultrasound will be used to confirm location of the superior gluteal artery perforators or lumbar perforators . Flaps will be designed to allow deepithelialization and dissection . After complete sketolization of the flap it will be analyzed for viability and trimmed to achieve the desired bulk.
46104858|NCT04167215|Procedure|The gluteal pocket|pocket will be created by undermining in a plane just superficial to the gluteal muscle from the lower body lift line inferiorly extending to within 5 cm of the inferior gluteal crease. should extend only over the medial half of the buttock.
46020568|NCT01214850|Biological|MenACWY-CRM conjugate vaccine|
46104859|NCT04167215|Procedure|infragluteal dermal lifiting flap|dermal flap will be performed for lifting the ptotic buttocks with ill-defined infragluteal fold. This deepithelialized dermal flap allows for the creation of a well-defined stable infragluteal fold through an incision of the infragluteal fold and exposure of ischial tuberosity and anchor it to the ischial tuberosity.
46020569|NCT01214850|Biological|Japanese Encephalitis vaccine|
46020570|NCT01128153|Drug|Saxagliptin|5 mg tablet once daily for 24 weeks to be taken orally
46020571|NCT01128153|Drug|Placebo|tablet once daily for 24 weeks to be taken orally
46020572|NCT04318782|Device|Pharmacodynamic thrombectomy|Pharmacodynamic thrombectomy using AngioJet ™ PE Thrombectomy Catheter
46020573|NCT00925015|Biological|Dalotuzumab 10 mg/kg|Dalotuzumab at 10 mg/kg was intravenously administered once weekly
46020574|NCT00925015|Biological|Cetuximab|Following pre-treatment with a histamine-receptor antagonist, Cetuximab was administered with an initial intravenous infusion of 400 mg/m^2, followed by subsequent once weekly intravenous infusions of 250 mg/m^2
46020575|NCT00925015|Drug|Irinotecan|Irinotecan was administered with an intravenous infusion of 150 mg/m^2, once every other week for 42 days
45467870|NCT04452838|Drug|Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B)|4 mg administered under fasted conditions.
46020576|NCT00925015|Biological|Dalotuzumab 15/7.5 mg/kg|Dalotuzumab was intravenously administered, with the first infusion of 15 mg/kg, followed by subsequent infusions of 7.5 mg/kg
46020577|NCT01127763|Drug|RAD001|
46020578|NCT01127763|Drug|Carboplatin|
46104860|NCT02649413|Drug|Prednisone|Children with Idiopathic Nephrotic syndrome will start 60 mg/m2 prednisone.children that response in 8 days will receive an adjusted dose while the rest of the group will receive the 4 weeks usually dose.
45838159|NCT04587518|Behavioral|Personality-Based Cognitive Behavioral Therapy|The study treatment will take place across 18-sessions. The first session will involve psychoeducation regarding BPD.The next two sessions with include exercises drawn from Behavioral Activation (i.e., identification of value-based goals) and Motivational Interviewing (i.e., pros and cons [long and short-term consequences] of tolerating emotions, engaging in prosocial behavior, and delaying gratification). Next, patients will receive 5 sessions of cognitive interventions (i.e., cognitive reappraisal related to situations/emotions, schema related to relationships, 5 sessions of behavior change skills (i.e., acting opposite to emotion-driven urges, exposure, assertiveness training), and 5 sessions of mindfulness skills (i.e., nonjudgmental emotion awareness, compassion training, urge surfing). Finally, treatment will conclude with 2 sessions of Relapse Prevention strategies. All sessions will last for 60 minutes in duration.
46020579|NCT04251403|Diagnostic Test|Mucosal Irrigation|Following routine endoscopic evaluation, investigators will utilize the ERBEJET 2 device (ERBE USA Inc), which is commercially available for the treatment of mucosal lesions, to sample cells from the mucosal surface of the stomach. The aspirate will be collected for cytologic/pathologic assessment.
46020580|NCT04251325|Other|Basic Life Support Courses|4 hours basic life support courses for laypersons
46020581|NCT04257409|Other|Physical intervention by exercise|12 week lasting exercise intervention
45467871|NCT04452838|Drug|Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)|4 mg administered under fed conditions.
45467872|NCT04452838|Drug|Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A)|4 mg sprinkled on apple sauce administered under fasting conditions
45467873|NCT04452838|Drug|Fesoterodine BIC SR4 fed (Treatment E in Part B)|4 mg administered under fed conditions
45467874|NCT05534594|Drug|18F-PSMA-1007|As explained under 'Arms'.
45467875|NCT04452682|Other|COVID 19 impact|The impact of COVID-19 pandemic on Critical limb threatening ischemia and emergency vascular practice
45467876|NCT02967848|Other|99mTc-mebrofenin hepatobiliary scintigraphy (HBS)|99mTc-mebrofenin HBS is a SPECT imaging procedure that allows evaluation of global and local liver function. Mebrofenin, bound to albumin, is taken up by hepatocytes in a similar manner to organic anions such as bilirubin. After hepatic uptake, the mebrofenin is excreted into the bile canaliculi. Dynamic imaging tools allow measurement of clearance rates for global function, and 3D SPECT imaging with corresponding CT allows visualisation of the local liver function with respect to anatomy. HBS allows direct visualisation of hepatocyte function.
45467877|NCT02967848|Other|Indocyanine Green|ICG is a fluorescent dye injected into the patient. The dye is exclusively excreted by the liver. The ICG clearance rate is measured in the finger of the subject.
45467878|NCT02967848|Other|Liver Elasticity|This is an Ultrasound measurement of the elasticity of the liver.
45467879|NCT01383746|Device|Yttrium microsphere injection|Radiation therapy
45467880|NCT04743388|Biological|BNT162b2|Vaccine against SARS-Cov-2 of the Pfizer/BioNTech companies
45467881|NCT04743388|Biological|Other vaccine against SARS-Cov-2|Any other vaccine authorized and administered by the Greek Ministry of Health against SARS-Cov-2
45467882|NCT04188860|Drug|A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel|"A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel would be given for all patients:~Camrelizumab: 200 mg every time, every 3 weeks, which would be sustained until the appearance of disease progression on intolerable adverse events, and no more than 24 months~Albumin-bound paclitaxel: 200-300 mg every time, every 3 weeks, no more than 6 courses"
45467883|NCT05458700|Other|Collect information|Collect information from the patients to support the design of innovate clinical trials
45467884|NCT05425862|Drug|Pidnarulex|Pidnarulex is a treatment that is designed to stop the action of a particular protein in the body called Polymerase I, that cancer cells rely on. Laboratory studies show that pidnarulex targets a process involving Polymerase I within cells, which can lead to a decrease in cancer growth. Pidnarulex has been shown to have some anticancer activity in ovarian cancer and haematological cancers.
46020582|NCT04250779|Device|CapMedic smart inhaler device|The CapMedic device provides active coaching to promote correct and regular use of MDI.
46020583|NCT04250779|Behavioral|Video-based guidance|Patients are shown a video of how to use inhalers correctly and any questions are answered by the clinician. They are also encouraged to use inhalers regularly and correctly at home.
46020584|NCT05252299|Other|Rolling Fresher Group|The use of telemedicine to provide remote CSS installation instruction via audio and visual input by a Certified child passenger safety technician (CPST)
46020585|NCT01127607|Drug|lisdexamfetamine|3 week with-in subject lead in phase to find optimal dose ranging from 30 mg to 70mg
45467885|NCT05425862|Drug|Talazoparib|Talazoparib belongs to a class of drugs called PARP inhibitors, which is currently being used to treat various types of cancer. Talazoparib blocks the function of PARP, a protein that is involved in repairing DNA in cells. By stopping damaged DNA in cells from being repaired, this will lead to accumulation of DNA damage in the cancer cell and ultimately cancer cell death. Talazoparib has established anticancer activity in breast, ovarian and prostate cancers with underlying DNA repair defects. This class of drug have also been used in combination with other treatments such as radiation or chemotherapy to further increase cell death within the cancer.
45467886|NCT04469036|Other|Virtual Pediatric Trauma Center|Telehealth
45467887|NCT02251106|Device|Lumbar corset (Quickdraw, Aspen Medical Products)|The corset (a.k.a. brace) is made of webbing and elastic. It is wrapped around the trunk and tightened with Velcro and a series of cords (like tying shoes).
45467888|NCT05422040|Other|Dry needling|Invasive treatment will be performed on the most symptomatic lumbar iliocostalis muscle.
45467889|NCT05422040|Other|Tecartherapy treatment|Treatment will be carried out with deep thermotherapy in the lumbar region.
45467890|NCT03631238|Diagnostic Test|Blood sampling for total cholesterol and homocysteine and cognitive assessment by psychometric tests.|"all participant are subjected to cognitive assessment by psychometric tests by using the arabic version of Mini Mental State Exam (MMSE) and Memory Assessment Scale (MAS).~Blood samples were collected in the morning using 10 mL yellow top (plain) Vacutainer tubes.~Lipid profile (triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL)) were measured by Assiut university labs using Cholesterol Kits and analyzed by COBAS Integra analyzer.~Total cholesterol levels were calculated using the sum of the LDL and HDL plus one-fifth of triglyceride levels.~Samples of serum homocysteine are collected, centrifuged to separate plasma within 30 minutes after venipuncture and stored in specialized container in the Department of Clinical Pathology at (-20◦C) temperature.~Total homocysteine was measured by ELISA technique, Sinogen kits (Research Use Only) and Statfax-2100 microplate analyzer."
45467891|NCT02207114|Other|Biomarker Algorithm Intervention|The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.
46020586|NCT00924781|Drug|MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline|MK2578 was to be administered intravenously (IV). Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to every week (QW) or once every 4 weeks (QM) dosing schedules within each cohort.
46020587|NCT00924781|Drug|MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 2 were to receive 1 mcg of MK2578 for every 350 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
46020588|NCT00924781|Drug|MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 3 were to receive 1 mcg of MK2578 for every 200 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
45467892|NCT01383668|Drug|sirolimus|Given PO
45467893|NCT01383668|Drug|gold sodium thiomalate|Given IM
46020589|NCT05252065|Other|Cardiac biomarkers, Echocardiography,Cardiac magnetic resonance imaging|Troponin I, troponin T, hypersensitive troponin, brain natriuretic peptide and NT-proBNP are detected for cardiac biomarkers;echocardiography and cardiac magnetic resonance imaging are used to measure the functions of heart and vessels.
46020590|NCT05251987|Biological|PD1+ T Cell Expression|The expression of PD1+ T cells was detected by flow cytometry in peripheral blood
46104861|NCT04167059|Behavioral|Telehealth-delivered participation strategies to increase physical activity|Therapists and primary caregivers will meet online on 6 occasions at fortnightly intervals over a 12 week period. Sessions will enable the development of strategies that will aim to increase the amount the participant stands and walks. Throughout, the therapists and primary caregivers will discuss physical activity needs, determine relevant activities, modify the program as necessary and plan additional goals.
45467894|NCT01383668|Other|pharmacological study|Correlative studies
45467895|NCT01383668|Genetic|RNA analysis|Correlative studies
45467896|NCT01383668|Genetic|polymerase chain reaction|Correlative studies
45467897|NCT03656068|Drug|Nitazoxanide 500mg BID|Patients will receive 500mg of Nitazoxanide BID daily for 24 weeks
45467898|NCT02187848|Drug|SAR408701|Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous
46020591|NCT01127451|Drug|Denileukin diftitox|Denileukin diftitox intravenous infusion over 30-60 minutes.
46020592|NCT04759651|Other|Functional Outcome of Sleep Questionnaire Turkish version (FOSQ-TR)|Sleep related quality of life questionnaire.
45467899|NCT01382030|Drug|EIA chemotherapy|ifosfamide 1500 mg/m² iv days 1 - 4, etoposide 125 mg/m² iv days 1 and 4, and adriamycin 50 mg/m² iv day 1
45467900|NCT01383590|Biological|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart.
46020593|NCT04759651|Other|Epworth Sleepiness Scale (ESS)|Subjective level of daytime sleepiness.
45467901|NCT04460222|Procedure|Rotational Thromboelastometry to guide blood product transfusion pre invasive procedure|"Rotational Thromboelastometry will be performed pre procedure and blood component will be transfused if~EXTEM CT more than 80 sec then FFP will be transfused at 15 ml/kg MCF less than 35 mm then Platelet will be transfused at 10 ml/kg~FIBTEM MCF less than 7 mm then Cryoprecipitate will be transfused at 5 ml/kg"
46020594|NCT04759651|Other|Berlin Questionnaire|Evaluation of high-risk for Obstructive Sleep Apnea.
46020595|NCT04759651|Other|Stop-Bang Questionnaire|Evaluation of high-risk Obstructive Sleep Apnea.
46104862|NCT02643953|Behavioral|Incentives|1) provision of incentives to encourage women to attend primary health care and use family planning, antenatal, delivery and postnatal services; 2) conditional cash transfers to promote uptake of services; 3) targeted community health education and advocacy activities; 4) community maternal audit/accountability activities, with community-led activities aimed at promoting utilization of services
46104863|NCT02643953|Behavioral|Community|1) outreach services by PHCs; 6) PHC strengthening including training of health providers; and 2) training and kitting of community health rangers who will be trained to follow up women at home to ensure that they do not default but that they continue to use PHC services until delivery.
46020596|NCT04759651|Other|Insomnia Questionnaire|Subjective evaluation of insomnia.
46020597|NCT04759651|Other|Restless Leg Syndrome Questionnaire|Subjective evaluation of Restless Leg Syndrome.
46020598|NCT04759651|Other|Zung Self-rating Depression Scale (SDS)|Subjective test for evaluation of depressive mood.
45467902|NCT04460222|Procedure|Conventional transfusion methods to guide blood product transfusion pre invasive procedure|Transfusion will be given If INR: 1.5 - 2.5 FFP will be transfused at 10 ml/kg If Platelet Count is 20,000/mm3-50,000/mm3 Platelet will be transfused at 10 ml/kg If Fibrinogen < 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg
46020599|NCT04759651|Other|Beck Anxiety Inventory|Subjective test for evaluation of anxiety.
46020600|NCT01127373|Radiation|Multi-Beam Intensity-Modulated Radiation Therapy|IMRT with multiple beams will be utilized to treat the breast or chest wall and axillary, supraclavicular and internal mammary lymph nodes. Treatment will be delivered once a day, 5 days a week for approximately 5 weeks. All missed radiation treatment visits will be made up. Daily set-up error will be checked prior to the delivery of every treatment.
45467903|NCT01381796|Drug|NP101|comparison of NP101 with minor patch modifications
45467904|NCT01381796|Drug|sumatriptan succinate|tablet, 100 mg
45467905|NCT04523194|Other|Optical Coherence Tomography (OCT) and Computed Tomography Angiography (CTA)|Subjects underwent CTA, then OCT during cardiac catheterization as part of their standard clinical care.
45467906|NCT04390282|Behavioral|Application-based support system|All participants (experimental and control group) will be invited to a separate appointment at the vascular open clinic at baseline and after three months and measured regarding weight, blood pressure, Ankle Brachial Pressure Index, six minutes walking test and pain. To calculate the estimate 10-year risk of manifesting clinical cardiovascular disease, the Framingham Risk Score will be used. Further, a questionnaire will be answered at baseline and after three months containing the instruments, VascuQoL-6, Health Education Impact Questionnaire and Medication Adherence Report Scale-5.
45467907|NCT04375228|Drug|Rituximab|375mg/m^2 IV weekly for 4 doses
45467908|NCT04375228|Drug|Tocilizumab|4mg/kg IV once a month for up to 2 doses
45467909|NCT02521714|Drug|Lenalidomide|
45467910|NCT02944383|Drug|Gemcabene|Gemcabene tablets administered orally once daily, for 12 weeks.
46020601|NCT01127373|Behavioral|BreastQ questionnaire-|MSKCC Department of Surgery. For patients who received a mastectomy with or without reconstruction, the questionnaire will be administered at baseline and 5-7 months after treatment.
46020602|NCT01214616|Drug|afatinib 20mg|patient to receive afatinib low dose po daily in combination with vinorelbine iv
46020603|NCT01214616|Drug|afatinib 40mg|patient to receive afatinib high dose po daily in combination with vinorelbine iv
46020604|NCT01214616|Drug|vinorelbine IV 25 or 20mg/m2|patient to receive standard dose vinorelbine once a week for four times per cycle
46020605|NCT01213836|Drug|Seroquel XR- quetiapine fumarate extended release|Seroquel XR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken once a day for 10-16 days.
46020606|NCT01213836|Drug|Seroquel IR - quetiapine fumarate|Seroquel IR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken twice a day for 10-16 days.
46104864|NCT02643641|Biological|BM32|BM32 is a mixture of 4 different recombinant proteins directed at the major grass pollen allergens, adsorbed on aluminum hydroxide
46104865|NCT02643641|Biological|Placebo|Placebo contains aluminum hydroxide only
46104866|NCT02643563|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% is used for low-volume ultrasound-guided interscalene brachial plexus block.
46104867|NCT02643563|Drug|Ropivacaine 1%|Ropivicaine 1% is used for low-volume ultrasound-guided interscalene brachial plexus block.
46104868|NCT02643563|Drug|Bupivacaine 0.5% + epinephrine 1:200,000|Bupivacaine 0.5% + epinephrine 1:200,000 is used for low-volume ultrasound-guided interscalene brachial plexus block.
46104869|NCT02643797|Behavioral|Medical Assistant Health Coaching|One-on-one behavioral health screening and tailored intervention by the MA health coach with patients who have type 2 diabetes.
45467911|NCT02944383|Drug|Placebo|Placebo tablets administered orally once daily, for 12 weeks.
45467912|NCT02096588|Drug|Simvastatin|Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily.
45467913|NCT02096588|Drug|Doxorubicin/cyclophosphamide|The standard chemotherapy regimen that must be planned for all participants in order to take part in this study. The regimen is given every 2 or 3 weeks per standard of care, at the direction of the treating physician.
45467914|NCT04328584|Procedure|surgical navigation system|Navigation system providing surgeons with an additional view of the chest wall lesion
45467915|NCT03768089|Drug|Placebo (matched to VX-121 suspension)|Placebo matched to VX-121 suspension for oral administration.
45467916|NCT03768089|Drug|VX-121 (Suspension)|Suspension for oral administration.
45467917|NCT03768089|Drug|TEZ/IVA|Fixed-dose combination tablet for oral administration.
46020607|NCT01213836|Drug|Placebo matching Seroquel XR|Placebo matching Seroquel XR dose 400-700 mg (in tablet form). Dose taken once a day for 10-16 days.
46104870|NCT02647073|Device|Canary 01 Mobile Vital Signs Monitoring Device|The prototype has several main components, including several commercially available sensors to measure heart rate, respiration, and motion data, an enclosed case containing circuitry for processing and transmitting data, and a mobile phone/system interface to store and transmit data.
45467918|NCT03768089|Drug|IVA|Tablet for oral administration.
45467919|NCT03768089|Drug|Placebo (matched to TEZ/IVA)|Placebo matched to TEZ/IVA for oral administration.
45467920|NCT03768089|Drug|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
45467921|NCT03768089|Drug|VX-121 (Tablet)|Tablet for oral administration.
45467922|NCT03768089|Drug|Placebo (matched to VX-121 tablet)|Placebo matched to VX-121 tablet for oral administration.
45467923|NCT02501018|Biological|CLBS12|Intramuscular transfusion of CLBS12.
45467924|NCT02501018|Drug|SOC|Standard of care (SOC) is defined as pharmacotherapy with approved drugs (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids).
45467925|NCT03548584|Drug|Brexpiprazole|Tablet
45467926|NCT03548584|Other|Placebo|Tablet
45467927|NCT04327804|Diagnostic Test|Odd/Even birth year intervention groups|The nostril used and order of testing will be different in each arm.
45467928|NCT01381640|Drug|Marketed paracetamol|marketed formulation
45467929|NCT01381640|Drug|Experimental paracetamol formulation|Experimental formulation
45467930|NCT04483973|Drug|Ebselen|Glutathione peroxidase mimetic
45467931|NCT04483973|Drug|Placebo|Matching placebo containing excipients
45467932|NCT04283890|Drug|Ipilimumab and nivolumab|The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
45467933|NCT04283890|Drug|Melphalan chemosaturation via percutaneous hepatic perfusion|The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
45467934|NCT01491620|Device|532 nm KTP laser|Laser treatment sessions on the neck and/or chest
45467935|NCT01136603|Device|TIGR Mesh|TIGR mesh as a reconstruction material for the repair of the abdominal wall post Lipectomy, TRAM / DIEP flap.
45838160|NCT04573504|Drug|Augmentin/Flagyl or Augmentin/Clindamycin|Women who suffer a severe vaginal laceration at Prentice Women's Hospital will be randomized to receive 5-days of oral antibiotics or placebo pills after getting a standard one-time dose of IV antibiotics at the time of repair.
45838161|NCT04573504|Drug|Placebo|Placebo
46020608|NCT01213836|Drug|Placebo matching Seroquel IR|Placebo matching Seroquel IR dose 400-700 mg (in tablet form). Dose taken twice a day for 10-16 days.
46020609|NCT01127061|Behavioral|Exercise training|4 months of exercise training that is custom-designed based on individual cardiopulmonary stress test data. Regimen starts at low intensity (60% of heart rate reserve) and frequency (20 minutes, 3 days per week) and increases with a goal of 70% of heart rate reserve and exercising 60 minutes 4-7 days per week.
46020610|NCT00924703|Drug|rAvPAL-PEG|The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.
46020611|NCT01213524|Behavioral|sensorimotor replacement|denicotinized cigarettes
46020612|NCT01213524|Drug|42 mg transdermal nicotine replacement|2 21-mg nicotine patches
46020613|NCT01213524|Drug|Placebo transdermal nicotine|2 placebo patches matched to 21-mg nicotine patches
46020614|NCT01213524|Other|usual brand smoking|participant smokes usual brand of cigarette
46020615|NCT01212744|Drug|rAvPAL-PEG|0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day, 0.4 mg/kg/day, 0.6 mg/kg/day, 0.8 mg/kg/day
45467936|NCT04253002|Behavioral|Robinson's Culturally Adapted Coping with Stress Course (A-CWS)|Participants randomized to the experimental condition will take part in the Adapted Coping with Stress Course (A-CWS). The A-CWS is a 15-session, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills to adaptively cope with stress, using standard cognitive-behavioral strategies such as relaxation training and cognitive restructuring. Emphasis is given to the identification of individual and contextual factors associated with suicide risk and the unique day-to-day experiences of the youth, providing options for adaptive coping (e.g., positive thinking) that are culturally consistent. The A-CWS is structured and manualized to allow its transportability to service providers working in similar environments with similar youth.
45467937|NCT04253002|Behavioral|Standard Care Control Condition|Students meeting criteria for study inclusion and randomized into the standard care condition will be referred to the school-based health center (SBHC) mental health provider for case management. Standard care may range from (1) brief intervention by the SBHC mental health provider to (2) outside referral to local community service providers; these determinations will be made by the SBHC mental health team.
45681147|NCT04028206|Behavioral|Elastic-band Exercise|"Subjects enrolled in the elastic-band exercise group will be instructed with 1 session of group training (at baseline) and 1 follow-up home visit (at 4 weeks) including instructions on 5-10 min warm-up and cool-down routines, 30 min chair-based resistance exercises using Thera-Bands as previously reported with training to both upper and lower body muscle groups including both hand and knee extensor muscles. The subjects will be instructed to perform the instructed exercises 3 times per week, one hour after HMB intake, for 12 weeks. The elastic band strengths will be progressively increased from 1.3 kg to 2.1 kg (yellow to green) of tensional force as instructed by a qualified coach in our project team based on each subject's multiple repetition maximum, where multiple repetition maximum is defined by reaching fatigue by 8 repetitions of stretching."
45681148|NCT04601649|Behavioral|PrEP Talk|The study is designed to provide education, support, and referrals for PrEP.
45838162|NCT04560972|Drug|Atezolizumab|Given IV
45681149|NCT03967054|Drug|Ivermectin|Ivermectin (6 mg tablet) given monthly from July-October each rainy season as a 3-day course of approximately 300 mcg/kg/day as estimated by height bands.
45838163|NCT04560972|Drug|Carboplatin|Given IV
45838164|NCT04560972|Drug|Etoposide|Given IV
45838165|NCT04560972|Drug|Protein Phosphatase 2A Inhibitor LB-100|Given IV
45838166|NCT04557046|Diagnostic Test|Nasal Swab|Collection of one more nasal swabs
45838167|NCT04557046|Diagnostic Test|Nasopharyngeal swab|Collection of one more nasopharyngeal swabs
45838168|NCT04557046|Diagnostic Test|Throat swab|Collection of one more throat swabs
45838169|NCT04557046|Diagnostic Test|Fingerstick|Collection of capillary blood from one or more fingersticks
45838170|NCT04557046|Diagnostic Test|Saliva specimen|Collection of free drool
45838171|NCT04545385|Drug|TEV-48574|subcutaneous infusion
45838172|NCT04545385|Drug|Placebo|Matching Placebo
45838173|NCT04542421|Diagnostic Test|Lung ultrasound use in patients hospitalized with COVID|Hospitalists will be taught to use lung ultrasound in the management of their patients with COVID
45838174|NCT04532814|Other|Exercise|Cycling 60% VO2 max
45838175|NCT04521335|Drug|Disulfiram|Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
46020616|NCT01212588|Drug|mifepristone|Mifepristone 600mg (3x200mg tablets) once daily for seven days
46020617|NCT01212588|Drug|Placebo|3 tablets once daily for seven days
46020618|NCT00918385|Drug|Nilutamide|Nilutamide 150mg orally each day for 28 days per cycle. After first progression, Nilutamide 150mg orally each day in combination with Dasatinib 100mg orally each day for 28 days per cycle.
45467938|NCT04314206|Drug|VNRX-5024|"Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours [q12h] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours [q8h] dosing for 9 days with a single morning dose on Day 10)"
45467939|NCT04314206|Drug|Placebo for VNRX-5024|"Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours [q12h] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours [q8h] dosing for 9 days with a single morning dose on Day 10)"
46020619|NCT00918385|Drug|Dasatinib|Dasatinib 100mg orally daily x 28 days per cycle. After first progression, Dasatinib 100mg orally each day in combination with Nilutamide 150mg orally each day for 28 days per cycle.
45467940|NCT01139723|Drug|MINT1526A|Intravenous escalating dose
45467941|NCT01139723|Drug|bevacizumab|Intravenous repeating dose
46104871|NCT00651209|Drug|Tenofovir|All patients receive 600 mg/day, oral telbivudine for 24 weeks. Patients with non-detectable HBV DNA continue 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 1) Patients with detectable HBV DNA receive 300 mg/day, oral tenofovir plus 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 2)
46104872|NCT04002479|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
46104873|NCT00652925|Drug|Celecoxib|Higher dose, 6 mg/kg/dose BID
46104874|NCT00652925|Drug|Celecoxib|Active drug at lower dose
46104875|NCT00652925|Drug|Naproxen|Control comparator, 15 mg/kg/dy target dose
45467942|NCT03508258|Other|Non-interventional|Non-interventional
45467943|NCT03508258|Other|Non-Interventional|Non-Interventional
45467944|NCT04105868|Other|Neurofeedback|Participants will receive feedback during a computerized task that is based on their own visuocortical activity evoked by attention to negative distractors and task-relevant stimuli on the computer screen.
45467945|NCT05068037|Other|ACUPUNCTURE|standard acupuncture TCM (analgesia, vomiting)
45467946|NCT05068037|Other|ANTIEMETICS|NO ACUPUNCTURE, WITH ANTIEMETICS
46104876|NCT00653003|Drug|Leflunomide|tablets, 20mg, single-dose
46104877|NCT00653003|Drug|ARAVA|Tablets, 20mg, single-dose
46104878|NCT02646605|Other|depression screening|Patient Health Questionnaire
46104879|NCT02643719|Behavioral|Relaxation Therapy|Between 30-60 minutes after the standard of care medication administration (metoclopramide, magnesium, prochlorperazine, ketorolac, or steroids at discretion of treating physician), patient receives training in relaxation therapy.
46104880|NCT02643719|Drug|Topiramate|"Preventive medication prescriptions given to the patient along with written instructions and information about side effects:~Topiramate 25mg tabs (with a plan to increase to 100mg)"
46104881|NCT02643719|Drug|Standard of Care|Standard discharge instruction sheet plus standard of care medication as prescribed by treating physician. The clinical team will be instructed to address post-discharge care as appropriate
45467947|NCT05068037|Other|NOTHING|NO ACUPUNCTURE, NO ANTIEMETICS
45467948|NCT01383512|Device|ARMEO Spring|Use of the device 1 hour per day, 5 days per week during 4 weeks
45838176|NCT04521335|Drug|Copper Gluconate|Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
45467949|NCT01383512|Other|Self rehabilitation|Subject have to realised alone rehabilitation exercises 1 hour per day, 5 days per week during 4 weeks.
45467950|NCT01141361|Procedure|GPS recording(s) of walking capacity in PAD patients|Home-based GPS recording(s) of walking capacity in PAD patients. Two evaluations will be performed. The second evaluation will be performed six months after the initial assessment (test 1) and only for patients with GPS maximal walking distance below 2000 meters at test 1. It is expected that some patients at test 2 will have undergo surgery or endovascular treatment.
46020620|NCT05253235|Behavioral|SAAF|A 7 session online intervention designed to augment protective processes associated with deterrence of substance use
46104882|NCT02643719|Drug|Abortive Medication (Naproxen and Sumatriptan)|All participants will receive abortive medication for acute treatment of their migraine. Preferred medications are Naproxen (500mg) and Sumatriptan (100mg)
46104883|NCT04166201|Procedure|double mesh hernioplasty with modified chevrel's technique|hernioplasty done by modification of the chevrel's technique , no dissection further than 1 cm of the midline laterally, the medial flaps of the anterior rectus sheath is dissected of the anterior surface of the rectus abdominis muscle and sutured together reforming the posterior rectus sheath , one polypropylene mesh was fixed over the posterior rectus sheath and the other was tailored to raw area of the rectis abdominis muscle and sutured to the lateral free edges of the anterior rectus sheath
46104884|NCT00865904|Drug|VX-809|Capsules
46104885|NCT00865904|Drug|Placebo|Placebo matched to VX-809 capsules.
46020621|NCT05253235|Other|Receipt of parenting book|Parents will receive a copy of the book, Parenting for Liberation: A Guide for Raising Black Children
46020622|NCT05253157|Other|Virtual Reality Augmented remote rehabilitation|XRHealth offers remote skilled therapy treatments such as education, exercise, and VR-augmented activities. The platform consists of the VRHealth portal with multiple immersive applications for measurement, motor-cognitive training, and mindfulness/cognitive behavioral applications for symptom relief, the external control application, and the XR Health data portal with real-time analytics for evaluating performance. Contraindications for VR use are assessed. Treatment sessions are 60 min long. Duration and frequency are based on clinical judgement. VR interventions used are; VR motor-cognitive: ReAct, Color Match, Memorize, Rotate, and Balloon Blast; VR Reliever: Relax 8, Luna, and Mindset. An external VR portal and mirroring software allows the clinician to view patient activities in real time. Additionally, the clinician can remotely monitor patient performance via the external portal and adjust parameters accordingly.
46020623|NCT04902391|Other|Health Services|The Acute Mental Health Care Bundle consists of 3 core elements, including: (1) ED triage, (2) ED assessment and care, and (3) follow-up care.
46104886|NCT02648867|Device|Continuous Maternal Feedback|The PushCoach device consists of a modification of the standard fetal scalp electrode and a separate apparatus designed to detect movement of the fetal head by detecting movement of an FSE. The PushCoach will be attached to the patient by an adhesive pad over the sacrum and extend between the patient's legs approximately 2-3 inches from the vaginal introitus. It assesses the movement of the FSE attached to the fetal scalp during pushing. The amount of fetal movement will be measured and recorded. The PushCoach device is connected to a laptop computer which will provide optical and auditory feedback to the patient about descent of the fetal head with maternal expulsive efforts.
46020624|NCT04727281|Other|Quality of life assessment using the Kidney Disease Quality of Life 36 (KDQOL-36) short form and Malnutrition-Inflammation Score|"Data about nutritional status using the Malnutrition-Inflammation Score, and Quality of life assessment using the Kidney Disease Quality of Life 36 (KDQOL-36) short form. Dialysis related data, The time needed for the patient to recover from a dialysis session (in minutes), Detailed history taking, Thorough physical examination, Laboratory Investigations:~• Hemoglobin , Serum sodium and potassium , Serum creatinine and blood urea , Serum phosphorus, serum calcium , Serum PTH level , Serum albumin ,CRP ,Total iron-binding capacity ."
45838177|NCT04515615|Drug|Camrelizumab|Camrelizumab, 200 mg IV for 30-60 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
46020625|NCT04766125|Behavioral|Adverse event information|All patients have access to the standard material about adverse events related to the surgery. One arm will additionally receive elaborated adverse event information from a nurse and a surgeon
45467951|NCT03440476|Behavioral|e-checkup to go|The e-checkup to go substance program is designed to motivate individuals to reduce their consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
46020626|NCT04765033|Drug|Nebulized 5% Hypertonic saline|nebulized
46020627|NCT04765033|Drug|Placebo|Nebulised
46020628|NCT05251831|Drug|Intradermal injection|Platelet-rich plasma (PRP) therapy uses injections of a concentration of a patient's own platelets.
46104887|NCT02649101|Drug|Thalidomide|Thalidomide tablet 100mg qn po.
46020629|NCT04761679|Behavioral|Applying the Mepilex foam|Mepilex foam will be directly applied on the nasal bridge directly between the skin and the N95 mask.
46020630|NCT04899037|Other|No intervention|This is an observational study of participants that either choose or not choose to utilize an OID. This is not an intervention prescribed study, however, participants may choose uptake of standard of care intervention and obtain and utilize an OID. An OID is an FDA-approved device commonly recommended to patients with conductive, mixed, or singled-sided hearing loss. There is no experimental intervention evaluated in this study.
45467952|NCT03440476|Behavioral|Feedback-only booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm. The content is clearly automatically generated.
45681150|NCT03967054|Drug|Placebo oral tablet|placebo in the same size, color and shape at the ivermectin tablet
46020631|NCT04257643|Other|aquatic based exercise.|exercise under water with the patient standing in a swimming pool, for 60 minswith water to the neck and then practice the arm exercise plus the diaphragmatic breathing exercise. The duration of the exercise programs was selected to be 60 minutes, 3 days per week for 8-week intervention
46104888|NCT02649101|Drug|Physician's choice chemotherapy|Investigators will declare no constraint of regimens.
46104889|NCT04117568|Other|Blood sampling|Blood sampling at 3-5 occasions per admission
45467953|NCT03440476|Behavioral|Feedback-plus-personal-contact booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm. The email is sent from an individual on the research staff.
45467954|NCT01136759|Drug|Tenofovir 1% gel|One applicator of tenofovir 1% gel administered vaginally for 7 consecutive days
45467955|NCT01136759|Other|Placebo gel|One applicator of placebo gel administered vaginally for 7 consecutive days
46020632|NCT04257643|Other|land-based exercise.|land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise.Land-based exercise program: Supervised program consisted of 60-min sessions, three times a week, over 8 weeks. The exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. Then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. Then the last 10 minutes for cooling down for stretching exercise for the arm muscles [14]. Women were asked to exercise continuously for 60 mins, by performing the arm exercises by repeating the session, and were instructed to exercise at moderate intensity .
46020633|NCT04703725|Behavioral|Psychosocial Care|"First Follow-Up: One of the implementation of the module~Second Follow-up: Implementation of the second module; Breathing Exercises and EFT~Third Follow-up: Emotional preparation about egg pick up process, individual application of coping methods~Fourth Follow-up: Implementation of the second module; Briefing about Breathing Exercises and EFT embryo transfer process~Fifth Follow-up: Implementation of the second module; Breathing Exercises and EFT~Sixth Follow-up: Individual application of coping methods until the learning process of pregnancy test result~Seventh Follow-up: Providing information about the first periods of pregnancy after treatment resulting in pregnancy and providing information about the psychosocial problems that may be encountered. Identifying psychosocial problems that may be encountered after unsuccessful treatment and individual application of coping methods to help cope."
46020634|NCT00637819|Drug|Leflunomide|A loading dose of LEF 100mg daily for 3 days, followed by LEF 20mg daily for the remainder of the study or matching placebo
46020635|NCT05253079|Other|subcostal transversus plane block|Patient in TAP block group will receive oblique subcostal TAP while in supine position using a linear 6-13 MHz ultrasound transducer. The operator will place the ultrasound probe obliquely on the upper abdominal wall along the subcostal margin near the xiphisternum of the sternum in the midline of the abdomen. The landmarks, which included the rectus abdominis muscle and underlying transversus abdominis muscle, will be identified near the costal margin and xyphoid. The probe will be then moved laterally until the aponeurosis of the external, internal oblique, and transversus abdominis are seen, and then the probe will be moved further laterally until the transversus abdominis muscle is identified. The operator will direct the needle toward the transversus abdominis, and the local anesthetic solution will be injected after negative aspiration between the rectus abdominis and transversus abdominis muscles along the subcostal line (in-plane superomedial to inferolateral)
45467963|NCT01136837|Other|primary pcı|
45467964|NCT01141439|Drug|Extra-fine hydrofluoroalkane-beclomethasone dipropionate|Initiation of HFA-BDP (any dose) in steroid naive patients via MDI
45467965|NCT01141439|Drug|Extra-fine hydrofluoroalkane-beclomethasone dipropionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via MDI
45467966|NCT01141439|Drug|Fluticasone propionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as FP via MDI
45681151|NCT03590236|Other|Graded exposure therapy|Patients included in this group received graded exposure therapy consisting on counselling, a graded activity through postural exercises and individual training focused on 5 activities selected by the patients. The treatment will include 5 sessions added to the 12 sessions of physiotherapy.
45838178|NCT04515615|Drug|Oxaliplatin|Oxaliplatin: 130 mg/m^2 IV for 2-6 hour in first day which will be administered at least 30 min after completion of camrelizumab administration, every 3 weeks. Repeated every 21 days, 21 days for a cycle.
45681152|NCT03590236|Other|Physiotherapy|Physiotherapy intervention will include soft tissue mobilizations and myofascial release combined with deep-pressure massage to decrease trigger point-related pain and tension. In addition joint mobilization and muscle energy techniques will be included.
45838179|NCT04515615|Drug|Tegafur gimeracil oteracil potassium capsule|Tegafur gimeracil oteracil potassium capsule: 80 mg/m^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Repeated every 21 days. 21 days for a cycle.
45838180|NCT04508582|Diagnostic Test|Cardiovascular magnetic resonance|Imaging of the heart with CMR, without use of contrast agents.
45467967|NCT01141439|Drug|Beclomethasone dipropionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as CFC-BDP via MDI
45467968|NCT01141439|Drug|fluticasone propionate|Initiation of FP (any dose) via MDI in steroid naive patient
45467969|NCT01141439|Drug|Chlorofluorocarbon beclomethasone dipropionate|Initiation of CFC-BDP (any dose) via MDI in steroid naive patient
45467970|NCT03303040|Other|Electrical stimulation of hemidiaphragm|Electrical impulses
45467971|NCT03192436|Device|Ultrasound|Low-intensity (Ispta < 720 mW/cm2, Isppa < 190 W/cm2) transcranial focused ultrasound
45467972|NCT05549531|Drug|ACT-1004-1239 (10 mg)|ACT-1004-1239 will be administered as 1 capsule of 10 mg strength to be taken under fed conditions.
45681153|NCT01702311|Drug|Bedtime insulin Aspart (Novolog)|Bedtime insulin aspart supplementation based on blood glucose value in the bedtime supplementation arm.
45838181|NCT04508582|Diagnostic Test|Echocardiography|Imaging of the heart with ultrasound.
46020636|NCT05253079|Other|erector spinae plane block|Patients in ESPB group will be turned to the lateral position and receive ESPB at the level of the 7th thoracic (T7) transverse process using a linear 6-13 MHz ultrasound transducer. The transducer will be positioned vertically 3 cm to the side of the midline to visualize the muscles of the back, the transverse process, and the pleura between the two transverse processes. Then, a 22G 10-mm needle will be introduced in the cranial-caudal direction toward the transverse process (T7) using the in-plane method till the needle tip crosses all the muscles. The tip of needle should be in the plane between the transverse process and the erector spinae muscle. After ensuring negative aspiration, the local anesthetic solution will be injected below the muscle. the procedure will be repeated on the other side
46020637|NCT04758715|Other|Food provided from a commercial meal service provider for a week|Meals from a commercial meal service provider provide for a week to participant
46020638|NCT04256863|Behavioral|Breakfast / Lunch|Participants in the BFL group will participate in 16 weekly, group based sessions weekly sessions in which they will be exposed to standard behavioral therapy (SBT) for weight control. Each 90-minute session will cover one weight control topic (self-monitoring, modifying the home food environment, physical activity, goal setting, stimulus control, stress-related eating, motivation, problem solving, healthy eating on a budget, social influences and weight loss maintenance) and an experiential learning activity. These hands-on activities will help teens build skills to adhere to 1) their calorie goal (1,400 - 1,600 calories/day) and 2) the prescribed timing for consumption (>50% of their energy needs consumed before 3PM every day of the week. Sample meal plans will be provided to help with adherence. .
46020639|NCT04256863|Behavioral|Dinner (DIN)|Participants randomized to the Dinner (DIN) group will participate in the same 16-week intervention as those in the BFL group; however, the topics covered in the experiential learning session will pertain to skills needed to adhere to prescribed calorie goals NOT to timing. They will be instructed to consume >50% of their energy needs after 3PM daily.; however, given that most teens consume the bulk of their calories after 5PM, the focus will be on general calorie goals vs. timing., Teens in this group will also be provided sample meal plans that outline how to spread out their calorie intake across breakfast (200), lunch (300), after school snack (200 calories), Dinner (700 calories), after dinner snack (200 calories for 1,600 calorie diet only).
46104890|NCT02648945|Other|Exercise|first, Verbal Memory task was completed by each participant. Participant then started walking on the treadmill at either a speed of 3.0 mph (4.8 km/h) for sedentary individuals or 3.5 mph (5.6 km/h) for active individuals with grade 0% (Hanson, 1984). This was followed by an increase in grade of 2% for every 2 mins with the speed remaining constant until targeted HR was reached. A heart rate (HR) monitor (POLAR®) was used to measure HR throughout the test and rating of perceived exertion (RPE) was done at the end of every 2 min stage. Exercise was stopped as soon as participant reaches targeted HR or requests to stop because of fatigue or any discomfort. Participant was then given time to cool down until HR reached or fell below 120 bpm and was allowed to take a break for approximately 1 min before proceeding with the second set of Verbal Memory Task. Upon completing the memory test, the participant was allowed to leave
46104891|NCT02613260|Behavioral|FIT Outreach|This arm will consist of priming patients with a postcard and a possibly a phone call two weeks prior to them being mailed a FIT kit. The FIT kits will be mailed to the patients with a letter from their clinic's care team informing them why they should complete the FIT and wordless instructions to help them complete the FIT. Two weeks after the FIT kit is mailed the patients that have not returned the kit will receive up to two reminder calls. During the phone calls the outreach workers will use health coaching techniques to encourage patients to complete the FIT. All written materials have been translated into English and Chinese and during phone calls patients will be spoken to in the language that they are most comfortable using.
46104892|NCT04166045|Device|Sham Treatment Location|The device applies transcutaneous electrical nerve stimulation to the bicep
46104893|NCT04166045|Device|Verum Treatment Location|The device applies transcutaneous electrical nerve stimulation to the hand
46020640|NCT00631501|Drug|Placebo|
46104894|NCT00700154|Procedure|Insulin infusion|The infusion, a fast acting insulin analog in 1 Unit/ml of NaCl, starts prior the surgery the operation day for all patients and stops during the postoperative care in the control group (conventional therapy), the intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
46020641|NCT00631501|Drug|Doxycycline|
46020642|NCT04746547|Drug|Dolutegravir 50 MG|Twice daily dolutegravir with rifampicin containing TB treatment
45681154|NCT04196608|Drug|Ceftolozane/tazobactam|Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria
45467973|NCT05549531|Drug|Itraconazole (200 mg, o.d.)|Itraconazole 200 mg will be administered as capsules (2 x 100 mg capsule) to be taken under fed conditions.
45838182|NCT04508582|Diagnostic Test|Blood test|Time- matched blood samples will be taken from patients to assess immune cell phenotype and function, paying particular attention to neutrophil and T-cell phenotype. Plasma samples will be collected for the analyses of cardiac specific factors (BNP, troponin) as well as measurement of steroid hormones (progesterone and oestradiol), and soluble inflammatory and anti-inflammatory mediators
46104895|NCT00651911|Drug|urate oxidase|First injection of Rasburicase will be done the day of initiation of chemotherapy, or the day before, according to hyperuricemia. Additional doses are permitted q12h during the first 72 hours of chemotherapy if hyperuricemia persists or subject is considered to be at significant risk of tumor lysis complications.
46104896|NCT02643485|Procedure|Forefoot surgery|Forefoot surgery (Chevron, Scarf, Lapidus, Arthrodesis)
46104897|NCT00651989|Other|optical coherence tomography foveal thickness measurement|In the same session in one randomly selected eye of each subject three consecutive measurements of foveal thickness were performed using both time-domain OCT and spectral-domain OCT.
46104898|NCT02643407|Drug|Docetaxel|60mg/m2
46104899|NCT02643407|Drug|Nedaplatin|80mg/m2
46104900|NCT02643407|Drug|Cisplatin|75mg/m2
46104901|NCT02643329|Drug|BF-Gliclazide Tablet 80mg|BF-Gliclazide Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
46104902|NCT02643329|Drug|Diamicron 80mg Tablet|Diamicron 80mg Tablet is manufactured by Les Laboratoires Servier Industrie, France
46104903|NCT03245489|Drug|Pembrolizumab|200mg intravenous (IV) over 30 minutes
46104904|NCT03245489|Drug|Clopidogrel|75mg/day oral
46104905|NCT03245489|Drug|acetylsalicylic acid|81mg/day oral
46104906|NCT04165655|Behavioral|Keep Achieving (KA)|The 10-week group based activity programme will consist of 10 sessions each lasting 50 minutes.
46104907|NCT02643017|Drug|Dexmedetomidine|Administration of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
45467974|NCT03739463|Dietary Supplement|MAG-DHA|375 MG of MAG-DHA per capsules, two capsules BID
45467975|NCT03739463|Dietary Supplement|Oleic acid|375 MG of sunflower oil (oleic acid) per capsules, two capsules BID
46104908|NCT02643017|Drug|normal saline|Administration of same amount of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
46104909|NCT02643173|Other|Volatile anesthetics|
45467976|NCT02953834|Drug|kisspeptin 112-121|Dose: 0.313-12.5 mcg/kg Duration: up to 16 hours
45467977|NCT02953834|Other|Insulin Resistance Test|Eat or drink a standard meal OR drink a standard drink containing 75 grams of sugar
46104910|NCT02643173|Other|Intravenous anesthetics|
46104911|NCT02646215|Device|Threshold inspiratory muscle training|Inspiratory muscle training
46104912|NCT02646137|Drug|Transarterial chemoembolization (TACE)|TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles
46104913|NCT02646137|Procedure|Radiofrequency ablation combined with TACE|Radiofrequency ablation (RFA) is an alternative therapy for HCC and liver metastases that can destroy a tumor by inducing thermal injury to the tissue through electromagnetic energy deposition
45467978|NCT02953834|Other|Placebo|Receive intravenous fluids for up to 16 hours that do not contain any study drug
45467979|NCT01141517|Behavioral|Not-On-Tobacco smoking cessation program|Adolescent quit-smoking program; Not-On-Tobacco
45467980|NCT01232699|Behavioral|Internet Obesity Treatment|Participants will engage in self monitoring, will receive skills training to help cope with environmental triggers, and will receive nutrition advice.
45467981|NCT01232699|Behavioral|Internet Obesity Treatment with MI|In addition to weekly group meetings, self-monitoring through recording calorie and fat intake daily as well as exercise, participants will meet one-on-one with an MI counselor on-line in order to augment an individual's motivation to change behavior.
45467982|NCT01232699|Behavioral|Contingent MI|Participants will attend weekly behavioral internet meetings. They may or may not receive Motivational Interviewing depending on their class attendance.
45467983|NCT04452370|Drug|oral etoposide + anlotinib|anlotinib 12mg qd, d1-14，21days/cycle oral etoposide 75mg qd，d1-10，21days/cycle
45467984|NCT03865030|Device|audiovestibular function|"Hearing test- includes a pure tone audiometry, speech audiometry and discrimination level.~tympanometry- Includes inserting headphones into the participants ears and computer calculation the compliance of the eardrum.~otoacoustic emission: Includes headphones insertion and calculation of the inner ear audiological function.~Video head impulse test.~- Dizziness handicap inventory questionnaire. questionnaire filled by the participants provides a subjective data regarding the severity of the dizziness."
45467985|NCT03819088|Dietary Supplement|Zinc|Given PO
45467986|NCT01232777|Drug|Bevacizumab|A single dosage of: 0.625mg(0.025cc)or 0.75mg(0.03cc) will be given intravitreally.
45467987|NCT03129412|Radiation|radical radiotherapy|radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will be assigned to those who got PR,SD after chemotherapy.
45467988|NCT03248271|Drug|Insulin Lispro|Insulin
46020643|NCT04782037|Drug|L-Methylfolate Calcium|Folic acid is one of the water-soluble B vitamins, which is synthetically-produced and found in fortified foods and supplements. It is essential for the synthesis and repair of DNA and RNA and metabolism of amino acids which are required for cell division. There is damage to the intestinal mucosa in most diarrhea cases; therefore, the role of folic acid has been studied as adjuvant therapy for diarrhea since folic acid plays an important role in the synthesis of DNA especially in rapidly regenerating cells.
46020644|NCT04257019|Other|Lavender oil|Inhalation of Lavender oil
45467989|NCT05538221|Diagnostic Test|SILEMA|SILEMA consists of a webcam connected to a laptop, a LED reflector, and a software. To carry out gait analysis with SILEMA, an Evaluator must place six yellow auto-adhesive markers over certain anatomical landmarks in the lower limbs, namely, greater trochanter, external femoral condyle, head of the fibula, lateral malleolus and base and head of the fifth metatarsal. The patient is asked to walk barefoot through an eight meter walkway at a self-selected speed, while a webcam connected to a laptop records a video. Then, an Operator, making use of the software, processes the video, obtaining spatio-temporal and joint kinematic parameters.
45467990|NCT01139957|Procedure|Evaluation of Cancer Risk Factors|Ancillary studies
45467991|NCT01139957|Other|Quality-of-Life Assessment|Ancillary studies
45467992|NCT01139957|Other|Questionnaire Administration|Ancillary studies
45467993|NCT01139957|Procedure|Study of High Risk Factors|Ancillary studies
45467994|NCT03443206|Other|anonymous social support|Participants randomized to the intervention condition will be able to communicate with one another and offer social media-based forms of support (e.g., post music, photos, etc).
45467995|NCT03443206|Other|psychoeducation|educational materials related to mental health
45467996|NCT03443206|Other|online resources|links to online mental health resources
45467997|NCT04213677|Drug|Dapagliflozin|Participants will receive dapagliflozin 10mg po qd. Additionally, participants will receive lifestyle modification and nutrition education.
46020645|NCT04257019|Other|Almond oil|Inhalation of Almond oil
46020646|NCT04257019|Other|Water|Inhalation of water
46020647|NCT01211262|Drug|IMCgp100|For each arm, the study will be divided into two parts: In part 1, dose escalation, the MTD or RP2D for each dosing regimen will be established. In part 2, dose expansion, a cohort of participants will be treated at the RP2D or MTD.
46020648|NCT01211184|Dietary Supplement|Water administration|patients undergo hip surgery after receiving 800 ml water by mouth in the morning before the surgery.
46020649|NCT01211184|Dietary Supplement|carbohydrate drink|800 ml carbohydrate drink by mouth the evening before surgery and 400 ml carbohydrate drink by mouth 2 hours before surgery
46104914|NCT02646137|Procedure|Microwave ablation combined with TACE|Microwave ablation (MWA) is an appealing alternative therapy for HCC in which a microwave antenna is placed directly into the tumor, emitting an electromagnetic wave which agitates water molecules in the surrounding tissue, producing friction and heat, thereby inducing cell death via coagulation necrosis
46104915|NCT04165421|Behavioral|Family intervention group|Education and Family conversations
46104916|NCT00653081|Procedure|Physical therapy method called Supervised Exercises|Performed at ullevaal Hospital, 45 min each time, 2-3 times pr week in max 12 weeks
45467998|NCT04213677|Drug|Placebo|Participants will receive placebo po qd. Additionally, participants will receive lifestyle modification and nutrition education.
45467999|NCT03247036|Drug|IV thrombolytic (t-PA) treatment vs not|Acute Stroke Protocol
45468000|NCT04921995|Drug|Tislelizumab|"Chemotherapy (including but not limited to following):~GP regimen: gemcitabine 1000mg/m2 d1, d8 + cisplatin 25 mg/m2 d1-3, every 3 weeks for 4-6 cycles; GX regimen: gemcitabine 800mg/m2 d1 + capecitabine 750 mg/m2 d1-14, every 3 weeks for 4-6 cycles.~Capecitabine: 750 mg/m2 d1-14, every 3 weeks until unacceptable toxicities or patient's withdraw.~anti-PD-1 antibody: Tislelizumab concurrently with chemotherapy: 200mg, every 3 weeks for 12 weeks. Tislelizumab in maintenance period: 200mg every 3 weeks or 400mg every 6 weeks, until one year or disease progression, or in the case of intolerable toxicities."
45468001|NCT05038943|Device|Paragonix SherpaPak Cardiac Transport System|Transportation of cardiac allografts in a device maintaining constant optimal temperature to minimize freezing tissue injury
46020650|NCT01211184|Behavioral|Fasting.|The patient is fasting from midnight before the surgery.
46020651|NCT00924469|Drug|Abiraterone|Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day at least 1 hour before a meal or 2 hours after a meal for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
46020652|NCT00924469|Drug|Leuprolide|Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks in Group 1 and Group 2.
46020653|NCT00924469|Drug|Prednisone|Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
45468002|NCT03129867|Drug|Ticagrelor|Ticagrelor 60mg or 90 mg as routine use of each Center
45468003|NCT04452448|Device|LASIK|All cases were operated upon using Wavelight Allegretto EX-500 excimer laser (Alcon Laboratories, Inc., Fort Worth, TX) with wave front optimized ablation profile WFO. The Moria II microkeratome (Moria, Anthony, France) was used in all cases.
45468004|NCT04917549|Other|detection of oral lesions|oral lesions in patient diagnosed with COVID-19
45468005|NCT05152108|Device|BCI feasibility test|Testing the feasibility of BCI device by determining the accuracy of BCI control
45468006|NCT01235273|Drug|Growth Hormone|growth hormone administration
45468007|NCT01235273|Other|Placebo|standard placebo
45468008|NCT05147896|Drug|Semaglutide Oral Tablet|Semaglutide Oral Tablets will be introduced to the active arm as per protocol for regular therapy introduction.
45681155|NCT04196608|Drug|imipenem- relebactam|Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria
45681156|NCT04022200|Device|Paclitaxel DCB|The length of the DCB catheter should be chosen to exceed the target lesion for at least 2mm (at both proximal and distalends). The catheter(s) will be inflated for 30 to 60s with a minimum of 7 atm. Predilation of the diseased coronary segment with a uncoated balloon/scoring balloon/cutting balloon before the use of DCB will be encouraged. DES should be implanted if the angiographic result after DCB alone therapy is not satisfactory due to significant recoil/residual stenosis or dissection (Type C-F).
45681157|NCT03971578|Other|No Intervention Provided|No Intervention Provided
46020654|NCT05423652|Device|Lung point of care ultrasound|Point of care ultrasound of the lungs will be performed to enhance physical assessments as needed to make clinical decisions for patients with CHF, COPD and/or pneumonia. The majority of images will be acquired and uploaded to a web-based portal by community paramedics in patients' homes and interpreted remotely by hospital-based physicians on call for the home hospital.
46020655|NCT05423652|Other|PRESUNA software|PRESUNA is a new medical software that enables clinicians to summarize POCUS findings and document them on a platform that provides a visual summary of findings over time. PRESUNA also provides POCUS educators and learners to see the learners' progress over time in terms of the accuracy of their assessments when compared to POCUS experts providing longitudinal mentorship.
46104917|NCT00653081|Procedure|Radial Extracorporeal Shockwave Therapy|Radial Shock Wave therapy performed at ulleval Hospital, once a week, 4-6 times, 3-5 points each time.
46104918|NCT00653549|Drug|Torsemide|Tablets, 20 mg, single-dose
46104919|NCT00653549|Drug|Demadex|tablets, 20 mg, single-dose
46104920|NCT02642861|Drug|Cyclobenzaprine|cyclobenzaprine administration for 2 weeks
46104921|NCT02642861|Drug|Calcium Carbonate|Calcium carbonate for 2 weeks
46020656|NCT00631579|Drug|Rasburicase (SR29142)|
45468009|NCT01140035|Other|Administration of continuous insulin infusion for glycemic control in brain dead donors|As per protocol
45468010|NCT04886583|Device|Gabi Baby Band|Every enrolled patient must wear the Gaby Baby Band on the left arm in the aim to perform data analytics after the test has been performed
45468011|NCT01137149|Behavioral|Behavioral Activation Therapy|Behavioral activation is a 12 week psychotherapeutic intervention utilizing a semi-structured format. Initial sessions focus on specific areas (Assessment and orientation, Activation, Problem Solving, Goal Setting, Overcoming Barriers, Avoidance) interspersed as needed by sessions that focus on individual issues and applications. In these sessions the therapists maintains the session structure, but can use techniques presented in earlier sessions based on their functional analysis of the particular case. Parents participate in at least two of the ATA sessions but more active parental participation can be included as needed.
45468012|NCT01137149|Behavioral|Treatment as Usual- Psychotherapy|The TAU condition will be implemented consistent with usual and customary clinical practices within the Child Psychiatry Clinic at Seattle Children's Hospital (SCH. Within the SCH system, TAU for a depressed adolescent will typically consist of an individual therapy approach with adjunct family sessions and pharmacotherapy as deemed necessary by the primary therapist. The therapeutic approach typically used is cognitive behavioral but is administered in an eclectic, non-manualized fashion. Therapists for the TAU arm of the study will be care providers currently working within the SCH system. For this phase of the study, we will draw on clinicians whose level of experience is comparable to that of the Behavioral Activation therapists.
45468013|NCT04763109|Other|Whole-body Magnetic Resonance Imaging|Whole-body Magnetic Resonance Imaging at baseline, 1 month, and 12 months
45838183|NCT04505410|Drug|Tofacitinib|10mg tofacitinib tablets taken twice daily for eight weeks
46020657|NCT04256551|Other|Heali mobile application + Registered Dietitian|The Heali mobile application is a dietary resource validated by RD's which uses AI and ML to scan menus and barcodes to provide individuals with information regarding nutritive content and applicability to one's diet using an overall food score and traffic light system. Users have the ability to choose a number of therapeutic diets including LFD, SCD, GERD, and Lectin Free to name a few, but for this study, the app will be isolated to only the LFD. RDs employed by Heali provide real-time messaging to users. For this study, participants will be given access via cell phone login and password (names will not be used). Participant usage information will be de-identified and automatically sent to excel for study authors to perform statistical analysis.
45468014|NCT04401917|Drug|[18F]NOS|Participants will undergo approximately 60 minutes of dynamic whole-body scanning, including the brain, starting at approximately the time of injection of [18F]NOS. PET/CT imaging sessions will include an injection of ≤ 6.5 mCi (approximate range for most studies is anticipated to be 3.5-6.5 mCi) of [18F]NOS.
45468015|NCT02525692|Drug|ONC201|
45468016|NCT01232855|Genetic|protein expression analysis|
45468017|NCT01232855|Genetic|western blotting|
45468018|NCT01232855|Other|flow cytometry|
45468019|NCT01232855|Other|laboratory biomarker analysis|
45468020|NCT02725840|Radiation|Proton beam radiation therapy.|Proton bean radiation therapy interact differently with tissue with the result that protons are absorbed completely within the tissue instead of primarily passing through the entire body. The maximal depth of penetration is dependent upon the incoming velocity (energy) of the protons. Proton therapy utilizes this property to deliver radiation with very little dose beyond the targeted lesion. The dose-rate will be managed as part of the standard of care.
45468021|NCT02725840|Radiation|X-ray based radiation therapy|The three-dimensional (3D) mapping of radiation dose distributions permits detailed assessment of local vascular damage as a function of treatment factors of dose, dose-rate. The dose-rate will be managed as part of the standard of care.
45468022|NCT02725840|Procedure|Computed Tomography (CT) Scan|Computed Tomography (CT) Scan of the chest will be performed at 1, 3, 6, 12, 18 and 24 months
46020658|NCT04256551|Other|Heali mobile application|The Heali mobile application is a dietary resource validated by RD's which uses AI and ML to scan menus and barcodes to provide individuals with information regarding nutritive content and applicability to one's diet using an overall food score and traffic light system. Users have the ability to choose a number of therapeutic diets including LFD, SCD, GERD, and Lectin Free to name a few, but for this study, the app will be isolated to only the LFD. For this study, participants will be given access via cell phone login and password (names will not be used). Participant usage information will be de-identified and automatically sent to excel for study authors to perform statistical analysis.
46104922|NCT02641535|Other|exercise under hot and humid conditions protocol|"acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously~experiment days (2 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (35 deg. centigrade & 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously."
46104923|NCT02641535|Device|BC membrane protective garment|
46104924|NCT02641535|Device|NBC mask|
46104925|NCT02641457|Drug|Aflibercept|12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
46104926|NCT02641457|Drug|Ranibizumab|12 eyes received an intraocular injection of 1.25mg ranibizumab and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
46104927|NCT02641223|Device|spinal cord stimulator|Pt asked to wear FitBit device prior to and after spinal cord stimulator placement.
46104928|NCT02641613|Procedure|retroclavicular block|retroclavicular block for forearm or hand surgery
46104929|NCT02641613|Procedure|supraclavicular block|supraclavicular block for forearm or hand surgery
46104930|NCT04131452|Other|Filling out the forms including IDAS-II, BAI, SF-36 and FSFI|Participants will fill out certain validated forms including the expanded version of the inventory of depression and anxiety symptoms (IDAS-II), Beck Anxiety inventory (BAI), Short Form Survey (SF-36) and Female Sexual Function Index (FSFI).
45468023|NCT02725840|Procedure|Pulmonary Function Test (PFT)|Pulmonary function test (PFT) will be performed at pre-treatment, and at 6 and 12 months.
45468024|NCT04728711|Drug|ADX-629|ADX-629, 600 mg administered orally twice daily (PO bid) for a minimum of 1 week
45468025|NCT04728711|Drug|Placebo|Placebo, 600 mg administered orally twice daily (PO bid) for minimum 1 week
45598485|NCT02226887|Procedure|MESH|"Pre-operative :~It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~Surgical technique:~Peristomal incision with electrocautery~Release the handle of ileum~Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~We add the mesh between the edges of the defect during fascia closure.~The skin is sutured purse string style.~Post-Op~Hospital discharge after verification of normal digestive transit."
45681158|NCT04196296|Behavioral|Psychoeducation|Online psychoeducation about social anxiety, evidence-based treatments that target social anxiety, and treatment referral/resource information.
46104931|NCT02646059|Other|Text message|Text messages would be sent via the messaging platform of Guangzhou Blood Center. The feedback of sending status (received, failed to receive, or unknown) would be marked on every number. Four to six months follow-up, blood donation rate would be checked.
46020659|NCT04256551|Other|Standard Dietary Education|An educational guide to the implementation of the elimination and reintroduction phases of the diet, a suitable/unsuitable food guide, 19 substitutes for unsuitable foods, a guide of example meals (i.e., breakfast-6 recipes, lunch-8 recipes, dinner-12 recipes, and snacks/beverages-13 recipes), and tips for reading labels and eating a balanced diet while following the LFD. The website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System.
46020660|NCT00924313|Drug|(C-11 Acetate)|11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
46020661|NCT04256473|Drug|mutant pro-urokinase|Intravenous administration
46020662|NCT04256473|Drug|Alteplase|Intravenous administration
45468026|NCT05530967|Other|TT|"This intervention uses questionnaire at three-time intervals (i.e., days 5, 10, and 30) and abstraction of PAP use data (days 1 - 35). Consecutive adults with moderate-severe OSA and recommended to PAP treatment will be invited to the study. Once the patient has been prescribed PAP therapy a research associate will call the patient before receiving their new PAP device. The research associate will utilize an IRB approved telephone script to discuss study details, conduct eligibility screening (inclusion/exclusion criteria), and to ask whether the patient is interested in participating.~The research associate will then send the patient an IRB approved digital information sheet. The information sheet will provide the patient an option to mark Yes if they are willing to participate in the study or No if they are not willing. Patients who indicate their willingness to participate will receive the Triage Tool in accordance with the study protocol."
45681159|NCT04196296|Behavioral|Motivation|Online exercises/activities regarding social anxiety (and treatment thereof) based in principles from Acceptance and Commitment Therapy (ACT) and Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET).
46020663|NCT01209780|Biological|TIV|Investigational egg-derived trivalent subunit influenza vaccine.
45681160|NCT04552743|Drug|MGTA-145|A chemokine receptor type 2 (CXCR2) agonist protein, administered via intravenous (IV) infusion over 3 to 10 minutes.
45681161|NCT04552743|Drug|Plerixafor|An azamacrocycle CXCR4 chemokine receptor antagonist, administered at 0.24 mg/kg subcutaneously, reduced to 0.16 mg/kg in patients with renal dysfunction (per package insert).
46020664|NCT01209780|Biological|TIVf|US licensed trivalent inactivated subunit influenza vaccine -Fluvirin (Novartis Vaccines and Diagnostics) is approved for use in subjects ≥4 years.
46020665|NCT01209780|Biological|Comparator TIV|US licensed trivalent subunit inactivated influenza vaccine- Fluzone (Sanofi Pasteur) is approved for use in children <4 years.
46020666|NCT00916357|Drug|Humalog|
46020667|NCT00916357|Drug|Humulin-R|
46020668|NCT00916357|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
46020669|NCT00916279|Device|Lutonix Paclitaxel-Coated Balloon|PTCA
46020670|NCT05329753|Device|Mobile health application|Health intervention through a smartphone application that favors the process of learning
46020671|NCT04849897|Device|Experimental: Virtual Reality Guided Imagery|Platform and VR Goggles
46020672|NCT04849897|Other|Active Comparator: Audio Only Guided Imagery|Audio Recordings of Guided Imagery via an iPAD
46020673|NCT00631345|Behavioral|Group-Based Lifestyle Intervention (Phases 1 and 2)|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for the first 6-months of treatment (Phase 1) for a total weight loss of 5-7%. During Phase 2 (months 7-24) participants will be encouraged to continue weight loss as long as their BMI does not fall below 20 kg/m2, but the primary focus will be on weight maintenance. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
46020674|NCT00631345|Other|Individual Education Program (All Phases)|Comparison participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the RD will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle and will receive the lifestyle intervention manual and video series at the conclusion of their participation. These participants will be approached about the continuation at 24 months. If they agree to participate, these participants will continue to receive a monthly newsletter and will also receive biannual RD contacts.
46020675|NCT00631345|Behavioral|Self-Directed Maintenance (Phase 3)|Individuals from the lifestyle intervention group in the original HELP PD project who are randomized to self-directed maintenance will receive biannual nutrition counseling from the study RDs. In these sessions, the RD will cover basic aspects of transition from the group maintenance to individual maintenance, answer questions about healthy eating and activity to support weight loss, and discuss existing community resources that may fit the participants' needs as they attempt to maintain their weight loss, physical activity and dietary goals.
46020676|NCT00631345|Behavioral|Extended Group Maintenance (Phase 3)|The extended group maintenance condition will consist of monthly CHW-led group meetings, monthly individual telephone contacts with the CHW, biannual RD contacts, and other contacts as needed. During Phase 3, the objectives for Phase 2 of the initial program will be continued. That is, participants who were successful at weight loss (≥ 7% of initial body weight) are encouraged to either maintain their weight loss or to advance towards their own personal goals. Participants who were not successful are encouraged to problem solve the reasons for lack of success. The groups will focus on maintaining the healthy behaviors that produced weight loss and/or problem solving to overcome barriers to weight loss.
45468027|NCT05530967|Other|VE|A randomly selected sub-group of participants (n=30) will also receive an animated education video that provides targeted information and encouragement for self-managing your PAP problem(s). Patients in this sub-group will be asked to view a maximum of 2 different videos that are less than 2 minutes in duration. These videos are aligned with practice guideline recommendations for addressing PAP problems early in treatment. The videos will be sent digitally from Somnoware™.
45468028|NCT04927923|Other|hope-focused motivational interview|The eight-week hope-focused motivational interview will be applied to each individual individually during dialysis treatment. Within the scope of the study, a hope tree will be created for each individual together with the patients to be used in the evaluation process of the interview sessions. Through the hope tree, it is aimed for the individual to set goals, to discover the obstacles and solutions in achieving these goals.
45468029|NCT01140113|Procedure|Modified Ultrafiltration|After weaning from bypass patients had undergone to modified ultrafiltration for 15 minutes with a filtration flow at 300 ml/min
45468030|NCT03086330|Drug|Semaglutide|Semaglutide, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
45468031|NCT03086330|Drug|Placebo|Semaglutide placebo, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
45468032|NCT05009225|Other|Comprehensive ED AF management tool|Managing atrial fibrillation (AF) patients in the emergency department (ED) is complex, often requiring many separate decisions: How to best reduce the heart rate? Should emergency physicians attempt cardioversion? If so, how? Does this patient need stroke prevention? The investigators' CDSS provides emergency physicians with a one-stop, evidence-based resource that addresses all aspects of ED AF management.
45468033|NCT05522699|Behavioral|Cough suppressive therapy|"The cough suppressive therapy based on the treatment regime Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough (PSALTI) developed by S. Chamberlain et al (Thorax. 2017 Feb;72(2):129-136)."
45468034|NCT05522699|Behavioral|General healthy lifestyle instructions|The general healthy lifestyle instructions are based on the recommendations from the The Public Health Agency of Sweden.
45681162|NCT03590158|Behavioral|TRF|Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
45681163|NCT03590080|Drug|Methylprednisolone|
46020677|NCT05252455|Behavioral|pelvic and abdominal mechanics exercise|"starting from 24 weeks of pregnancy, participate in the pelvic and abdominal mechanics exercises offered by the Good Pregnancy College of Shanghai Tongren Hospital once a week. Each class lasts one hour until the 38th week of pregnancy (attend at least 10 times)"
45681164|NCT03593278|Drug|ACT-246475|Single s.c. dose of 16 mg ACT-246475 including 3.7 MBq (100 μCi) 14C-radiolabeled ACT 246475
45681165|NCT04028362|Drug|Neuromuscular Blocking Agents|Patient who will receive neuromuscular blockade will be follow during their ICU lenght stay.
45681166|NCT03023410|Procedure|VERASENSE|Sensor-Assisted Revision TKA
45681167|NCT03594058|Drug|Solabegron modified release tablets, low dose|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
46020678|NCT04698421|Biological|Blood collection on admission and longitudinally|Biological samples will be collected in the normal diagnosis and follow-up process. Only blood will be taken in larger quantity (6 tubes of 7mL).
46104932|NCT02646059|Other|Telephone|Status (response, no answer, line issue, wrong number or refused to be interviewed) of every donor in this groups would be marked. Four to six months follow-up, blood donation rate would be checked.
46020679|NCT05217823|Device|Er:YAG laser|
46104933|NCT02642939|Drug|Mifepristone|Mifepristone is an antagonist of the GR-II (glucocorticoid) receptor, yet has little affinity for the GR-I (mineralocorticoid) receptor. Mifepristone is also a potent antagonist at the progesterone receptor, and may block the androgen receptor to a limited degree.
45681168|NCT03594058|Drug|Solabegron modified release tablets, high dose|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
45681169|NCT03594058|Drug|Matching Placebo|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
45468035|NCT02069782|Other|Home visiting|Home visits are used to assess family needs, provide support and education, and make referrals to relevant community services. The goals of the programs are to improve child health and development, promote positive parenting, prevent child maltreatment, improve maternal and child health, and increasing parental self-sufficiency.
45598486|NCT02226887|Procedure|NO MESH|"Pre-operative :~It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~Surgical technique:~Peristomal incision with electrocautery~Release the handle of ileum~Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~The skin is sutured purse string style.~Post-Op~- Hospital discharge after verification of normal digestive transit"
45598487|NCT02226887|Radiation|Post-operative Imaging|Abdominal Tomography 1 year after ileostomy closure
45681170|NCT01712061|Drug|PF-04634817|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
45681171|NCT01712061|Drug|Placebo|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
45681172|NCT03591094|Drug|PTI-428|Active
45681173|NCT03591094|Drug|Placebo|Placebo
45681174|NCT03970954|Drug|low-dose IL-2|Subcutaneous injection of low dose of IL-2 for induction course of 5 days, the 10th day after the beginning of periods. At most 5 courses of low dose of IL-2.
46020680|NCT05217823|Other|hand instruments|
46020681|NCT01209078|Drug|GSK1322322|GSK1322322 1500mg BID
46020682|NCT01209078|Drug|Linezolid|Linezolid 600mg
46020683|NCT01209078|Drug|GSK1322322 placebo|Placebo
46020684|NCT01209078|Drug|Linezolid placebo|placebo
46020685|NCT04708561|Behavioral|Speech and language therapy|"The intervention focuses on understanding the thoughts of the characters. Twenty written stories will be used, which end with statements that can be interpreted literally, ironically, as a lie, a request or a faux-pas (maladroitness). At the end of each story, the participant should explain what the characters want to mean by their statement.~To help the participant in his understanding of the character's intention, he will be asked:~1) To mention as many intentions as possible that can be associated with the target statement presented out of context (eg: it's hot here that can be interpreted literally, ironically, as a lie or a request) and to imagine contexts in connection with interpretation; 2. Analyze the relevant elements of the context (environment, the relationship between the characters, knowledge of the characters); 3. To judge the probability of the possible interpretations (pt 1) by justifying using the elements of the context analyzed previously (pt 2)."
46020686|NCT04849585|Other|semi-directed entretien|semi-directed entretien
46104934|NCT02642549|Behavioral|Girls for Health|"The G4H '1000 Hours' Bridge Program will offer English, science and math training, career workshops, opportunity to 'shadow' a health provider, a mentored safe space club to facilitate economic empowerment, training on gender equity and human rights, and communication/leadership skills. Cash transfers for vacations will be provided to support participation. Girls who receive 5 credits on their SSCE exams and pass the health training institute (HTI) entrance exam are eligible for admission. A Foundational Science Training (FST) program will be provided to the '1000 Hours' participants who gain admission to a HTI to strengthen their ability to the pass the HTI weeding exams. The FST will focus on English, math and science training, and safe spaces for social support development."
45468036|NCT04143009|Behavioral|Enhanced Friendship Bench|EFB will include the following: integrating problem solving therapy- based ART adherence support into existing counseling sessions and providing opportunities for participants to address HIV-specific concerns, such as stigma, disclosure, mother-to-child HIV transmission or other issues women identify during counseling sessions, and retention strategies to support engagement in care for HIV-infected women with PND. This intervention will include 4 individual prenatal and 2 group postnatal counseling sessions. To provide additional social support, one support session will be added, at which participants will be invited to bring a person of her choice who can be a support to her in managing both her HIV and/or depression. To assist women with receiving their medication during late pregnancy and postpartum, a trained psychosocial counselor will conduct up to 6 home visits. At each home visit, counselors will be able to deliver a participants' medications and conduct a counseling session.
45468037|NCT04143009|Other|Enhanced Standard Care (Control)|Standard care for mental health in public facilities in Malawi includes options for basic supportive counseling by the primary provider or nurse, medication management by the primary provider, referral to the clinic psychiatric nurse or mental health clinic, or in more severe cases referral to the psychiatric units at tertiary care hospitals. For this study, standard care will be enhanced by a trained study research assistant who will provide mental health evaluation; brief supportive counseling; information, education, and support on common mental disorders; and (if indicated) facilitation of referral to the clinic's psychiatric nurse or mental health clinic. The study research assistant will have up to 3 follow-up contacts with the participant to assess whether she has followed up on recommended referrals or treatment plans and to assess whether any further outreach is indicated.
45468038|NCT05006027|Procedure|Percutaneous coronary intervention via the snuffbox approach|Percutaneous coronary intervention using a 7-Fr thin wall sheath (Prelude IDeal, MERIT MEDICAL, South Jordan, UT, USA) via the snuffbox approach
45468039|NCT04830345|Biological|ATGC-100 100U|Clostridium botulinum toxin type A
45468040|NCT04830345|Biological|Botox 100U|Clostridium botulinum toxin type A
45468041|NCT01232933|Device|VPS System|Use of the navigational VPS system during catheter placement
45468042|NCT02686372|Biological|TCR-T|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
45468043|NCT02686372|Biological|No intervention and TCR-T (at crossover)|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
45468044|NCT03631394|Other|beetroot and anthocyanin|Beetroot and anthocyanin will be taken for 7 days during the study two hours prior to eating.
45468045|NCT03631394|Other|beetroot and placebo|Beetroot and placebo will be taken for 7 days during the study two hours prior to eating.
45681175|NCT03970720|Drug|Metoclopramide|10 mg metoclopramide four times a day
45681176|NCT03970720|Drug|Placebo|10 mg matching placebo capsules four times a day
45681177|NCT04195672|Device|NIPE (MDoloris®) and CBS values|"During different procedures of care with the bed-side nurse, NIPE ware recorded. Monitoring started 15 minutes before care and continuously recorded until 10 minutes after the procedure. Pain assessment was evaluated by the CBS under 3 periods for each patient: 1- before any procedure (T1) representing the baseline, 2- during the procedure of care (T2), and 3- after the procedure (T3). Investigator who performed the CBS was blind to NIPE during the procedure recording.~This study did not change the procedure of care before or after and had no impact on care"
46020687|NCT04691557|Other|Mobile Health Application|YoungAsthma is a web-based mobile health app has been developing user-focused for adolescents with asthma and evidence-based by the research team. It is the integrated version of the knowledge content to software that enables effective management of asthma by strengthening the interaction between adolescents and healthcare professionals.
45681178|NCT03592186|Behavioral|Parenting Wisely+|Parenting Wisely+ experimental intervention
45681179|NCT03592186|Behavioral|Treatment as Usual|Treatment as Usual
46020688|NCT04691557|Other|Usual Care|Adolescents in the control group, an asthma training covering also individualized specific conditions is provided by specialist training nurse for 15-30 minutes in the nursing room of the outpatient clinic for all children. In this nursing intervention that is only one-off and consist face-to-face training with adolescents video and visual materials included in the routine of the outpatient clinic for the use of devices and drugs are used.
46020689|NCT04672135|Drug|REM0046127|Oral solution: 100 mg/mL REM0046127
46020690|NCT04672135|Drug|Placebo|Oral solution with 0 mg/mL REM0046127
46020691|NCT04584385|Diagnostic Test|EEG|EEG monitoring
46020692|NCT05212909|Behavioral|General Anxiety Disorder-7 scale|The General Anxiety Disorder-7 scale was used to evaluate the level of anxiety in anesthesiology providers.
46020693|NCT04318470|Diagnostic Test|mNGS|Metagenomic next generation sequencing for microbial DNA
46020694|NCT04318158|Drug|Bupivacaine|single shot US guided TAP block using 20 ml bupivacaine 0.25%.
46020695|NCT04318158|Drug|Dexmedetomidine|Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg dexmedetomedine on each side.
46020696|NCT04318158|Drug|Fentanyl|Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg fentanyl on each side.
46020697|NCT05422014|Behavioral|Life Care Specialist (LCS)|"Life Care Specialist (LCS) will :~Provide patients with individualized risk assessment for opioid misuse.~Act as patient's Pain Coach. Providing targeted education and behavior-based pain treatment options.~Train and provide CWC evidence based non-pharmaceutical pain management techniques, using the Community Resiliency Model.~Use the Opioid Risk Tool (ORT) as the method to identity the risk of substance misuse.~Provide education, support and resources, as well as local, state, and national resources to enhance the whole health aspect of the position. These resources include but are not limited to: written documents that outline the key concepts of the pain management techniques taught by the LCS and a list of hotlines and websites.~LCS, when applicable, will provide education for caretakers on the risk of opioid use and the non -pharmaceutical pain management protocol.~Provide follow up for all patients in intervention group."
46020698|NCT05418426|Device|IVR Dose 1|Estradiol 80 ug/progesterone 4 mg
46020699|NCT05418426|Device|IVR Dose 2|Estradiol 160ug/progesterone 8 mg
46020700|NCT05418426|Drug|Oral Reference|estradiol 1mg/progesterone 100 mg
46020701|NCT05416710|Diagnostic Test|Invitae's 84 gene multi-cancer panel.|Invitae's Multi-Cancer panel analyzes 84 genes associated with hereditary cancers across major organ systems.
46020702|NCT01207596|Drug|Hydromorphone|Oral hydromorphone extended release, once daily
46020703|NCT00915343|Drug|hydrocortisone (modified release), oral tablet 20 and 5 mg|The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state. The dose was the same as patients have had before entering the trial
46020704|NCT00915343|Drug|Hydrocortisone, oral tablet, 10 mg|The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM). The morning dose was administered in the fasting state. The total daily dose was the same as in the experimental treatment arm.
46020705|NCT04667533|Drug|Desidustat|"A total of 24 participants will be enrolled.~The study is divided into three cohorts as given below:~Cohort I: Single-dose 100 mg~Cohort II: Single-dose 150 mg~Cohort III: Single-dose 200 mg"
45468046|NCT01329653|Behavioral|aerobic training|12 weeks of aerobic training, 4X/week
45468047|NCT01329653|Behavioral|Wait list|wait list control condition
45468048|NCT00872950|Drug|3,4-DIAMINOPYRIDINE|Treatment will begin with a low dose and will be increased as clinically needed as tolerated. The upper limit will be a total of 100mg/day.
45468049|NCT03233217|Biological|QIV-HD by IM|IM, injected into the upper arm (deltoid area)
45468050|NCT03233217|Biological|QIV-SD by SC|SC, injected into the upper arm (posterior region)
46020706|NCT04578301|Other|No Intervention|No Intervention
46020707|NCT05220865|Procedure|Hall Technique|"Only food scraps or debris will be removed from the caries cavity.~The smallest crown size will be selected that covers all cusps and approaches the contact points with a slight springback feel.~If the contact points are tight, orthodontic elastic separators will be placed through the contacts and the SSC will be placed at the second appointment 3-5 days later.~The SSC will be loaded with glass ionomer luting cement and placed evenly on the tooth.~The child will be asked to bite firmly until the crown is pushed down over the tooth.~If the child is unable or unwilling to bite down on the SSC, finger pressure will be used to seat the crown~The child will continue to bite on a cotton roll until the cement hardens~Excess glass ionomer cement will be removed from the crown margins with hand instruments and dental floss."
46104935|NCT02641301|Drug|Sustained release morphine sulfate, 30 mg|A single oral administration of a capsule of sustained release morphine sulfate, 30 mg, on one day.
46104936|NCT02642783|Behavioral|Descriptive analysis|subjects were asked to assess the sensory profile by tasting the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
46104937|NCT02642783|Behavioral|acceptability test|subjects were asked to assess the acceptability of the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
45468051|NCT03233217|Biological|QIV-HD by SC|SC, injection into the upper arm (posterior region)
45468052|NCT01568996|Drug|broccoli sprout extract - sulforaphane (BSE-SFN)|50 µmol capsules, taken orally, once a day for 28 days
45468053|NCT01568996|Drug|broccoli sprout extract - sulforaphane (BSE-SFN)|100 µmol capsules, taken orally, once a day for 28 days
45468054|NCT01568996|Drug|broccoli sprout extract - sulforaphane (BSE-SFN)|200 µmol capsules, taken orally, once a day for 28 days
46104938|NCT03370913|Biological|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
46104939|NCT04165187|Other|Body Awareness Therapy|Body scanning, stretch-release movements, centralization, contact with the ground, postural stability, movement flow and free breathing will be performed during sessions in lying, sitting and standing positions.
46104940|NCT04165187|Other|Home exercise program|Home exercise program will consist of joint range of motion, stretching, strengthening and proprioceptive exercises for lower extremity.
46104941|NCT03679949|Drug|Oxycodone|Oxycodone, 2.5 mg
46104942|NCT03679949|Drug|Cannabis (THC:CBD = ~ 1:0)|Cannabis with high THC concentration and negligible CBD concentrations
46104943|NCT03679949|Drug|Cannabis (THC:CBD = ~ 0:1)|Cannabis with high CBD concentration and negligible THC concentrations
46104944|NCT03679949|Drug|Cannabis (THC:CBD = ~ 1:1)|Cannabis with equivalent CBD and THC concentrations
46104945|NCT03679949|Drug|Placebo|Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone
45468055|NCT01141985|Device|LenSx Laser modified disposable contact lens|Modified Disposable Contact Lens Patient Interface: Like the current disposable contact lens, a single unit is used for each procedure only once, and is then discarded. It is similarly mounted onto the distal end of the system's focusing objective and serves as a sterile barrier between the patient and the laser. In place of a separate suction ring that is used in the current contact lens, the modified contact lens has an integrated suction ring and curved applanation surface. These features result in significantly lower elevation of intraocular pressure and significantly easier application by the surgeon in preliminary testing. Identical to the current contact lens, the suction ring is applied around the patient's limbus and mild suction is applied to stabilize the eye.
45468056|NCT05520905|Other|TelePrEP|HIV pre-exposure prophylaxis delivered via telemedicine.
45468057|NCT04090502|Other|Dry needling in hamstring muscle trigger points|Participants with nonspecific mechanical low back pain will be assessed for the hamstring muscle. Subsequently, the most sensitive areas associated with the shortening of the muscle will be located and the technique will be applied to this area.
46104946|NCT02642471|Procedure|no systematic pelvic lymphadenectomy|systematic pelvic lymphadenectomy is omitted in surgical treatment
46104947|NCT02640989|Biological|Seasonal trivalent influenza vaccine, Anflu®|Seasonal trivalent influenza vaccine manufactured by Sinovac Co., Ltd.
46104948|NCT02640989|Biological|Seasonal trivalent influenza vaccine, VAXIGRIP|Seasonal trivalent influenza vaccine manufactured by PasteurSanofi Pasteur
46104949|NCT02640989|Biological|Seasonal trivalent influenza vaccine, Fluarix|Seasonal trivalent influenza vaccine manufactured by GlaxoSmithKline Biologicals
46104950|NCT02642705|Other|High intensity interval training N|Exercise training and ambient air breathing
45468058|NCT04090502|Other|Dry needling in hamstring muscle not trigger points|Participants with nonspecific mechanical low back pain will be assessed for the hamstring muscle. Subsequently, the most sensitive areas associated with the shortening of the muscle will be located and the technique will be applied out of this area.
45468059|NCT02681614|Device|Uronav guided biopsy|"All biopsies will be completed in the outpatient setting in the ambulatory operating room prior to routine prostate brachytherapy under general anesthesia.~Patients will be prepped in a dorsal lithotomy position with insertion of a Foley catheter. The perineum will be shaved as needed, and cleansed with antiseptic solution, and the scrotum will be elevated with a towel roll to expose the perineum."
45468060|NCT02681614|Device|Magnetic resonance imaging|An MRI (magnetic resonance imaging) is a scan that uses radio waves and a strong magnetic field to provide images of internal organs and tissues. This is not part of the study but will have been done per standard treatment. An MRI will occur at the screening visit and last visit of the study.
45598488|NCT02226887|Radiation|Pre-operative Imaging|Contrast study is used to ensure the integrity of the distal anastomosis
45598489|NCT02226887|Other|Blood Test and C-reactive protein at 4th day|All patients undergo a Blood Test study of C-reactive protein on day 4 by protocol within the unit before discharge.
46104951|NCT02642705|Other|High intensity interval training H|Exercise training and hypoxic breathing
46104952|NCT02642705|Other|Constant load exercise training N|Exercise training and ambient air breathing
46104953|NCT02642705|Other|Constant load exercise training H|Exercise training and hypoxic breathing
46104954|NCT02642705|Other|Hypoxic conditioning at rest|Hypoxic breathing at rest
46104955|NCT02642705|Other|Normoxic conditioning at rest|Normoxic breathing at rest (placebo)
46104956|NCT00653627|Biological|BCG|Mycobacterium bovis Bacille Calmette-Guerin
46104957|NCT02645747|Drug|Aflibercept (Eylea, BAY86-5321)|"Eylea (intravitreal aflibercept) is an anti-Vascular Endothelial Growth Factor (VEGF) drug indicated for neovascular age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME) and visual impairment due to macular edema (ME) secondary to central or branched retinal vein occlusion (RVO).~RVO, both branch and central, is the second most common type of retinal vascular disorders after diabetic retinal disease. Central retinal vein occlusion (CRVO) is characterized by an obstruction of the central retinal vein combined with variable amounts of retinal arterial insufficiency."
46104958|NCT00653237|Device|I-gel and LMA Supreme: supraglottic airway devices|Insertion of a supraglottic airway device
46104959|NCT04165499|Combination Product|Combination of Plant Extracts (BSL_EP026)|Each participant will consume 2 capsules daily, in the morning and in the evening.
46104960|NCT04165499|Combination Product|Control|Each participant will consume 2 capsules daily, in the morning and in the evening.
46104961|NCT00653315|Drug|Tramadol APAP|Tablets, 37.5mg/325mg, single dose
46104962|NCT00653315|Drug|Ultracet|Tablets, 37.5mg/325mg
46104963|NCT00652223|Biological|CYT005-AllQbG10|Immunomodulator CYT003-QbG10 in combination with commercial house dust mite extract as used for routine SIT
46104964|NCT02640833|Drug|Duvelisib|Duvelisib will be taken continuously. This is a defining dose study, therefore the dose of Duvelisib may change.
46104965|NCT02640833|Drug|Venetoclax|Venetoclax will be taken continuously. This is a defining dose study, therefore the dose of Venetoclax will change.
46104966|NCT00653393|Drug|Tranylcypromine|Tablets, 10 mg, single-dose
46104967|NCT00653393|Drug|Parnate|Tablets, 10 mg, single-dose
46104968|NCT02640599|Other|Vestibular Rehabilitation + Aerobic Exercise|Subjects in the experimental group will undergo traditional Vestibular Rehabilitation as well as participate in an aerobic exercise training program.
46104969|NCT02640599|Other|Vestibular Rehabilitation|The control group will receive standard care which includes participation in vestibular physical therapy treatments 1-2 times per week.
46104970|NCT02645669|Procedure|Study site|The probiotic is in the form of a lyophilized powder containing approximately 5 billion colony forming units (CFU) of the Saccharomyces boulardii. At the time of administration, the probiotic mixture was mixed with fructooligosaccharide in the ratio of 4:1 to induce growth and activity in S boulardii. This was applied after scaling and root planing.
46104971|NCT02645669|Procedure|Control site|Only Scaling and Root planing was done.
46104972|NCT02645903|Drug|Transversus Abdominis Plane Block|Cases to whom used bupivacaine with ultrasound guided transversus abdominis plane block was applied after standard general anesthesia were determined as Group 1
46104973|NCT02645903|Drug|standard general anesthesia|Cases to whom applied alone standard general anesthesia were determined as Group 2
46104974|NCT02645981|Drug|Donafenib|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects
46104975|NCT02645981|Drug|Sorafenib|Control
46104976|NCT02535767|Drug|Primaquine|A single low dose of primaquine will be crushed and dissolved in water, and administered in weight-based doses.
46104977|NCT02535845|Behavioral|Project Voice|Project Voice tablet-based intervention plus informational video
46104978|NCT02535845|Behavioral|HPV Informational Video|Informational video only
45468061|NCT03064269|Biological|CD19 CAR-T cells|CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells
45681180|NCT03598114|Behavioral|Program Sustainability Action Planning Model and Training Curricula|The Program Sustainability Action Planning Model and Training Curricula's conceptual model is driven by the theory of change and incorporates aspects of Kolb's experiential learning theory to produce a six step process: defining the program, assessing the program, developing an action plan, executing the action plan, evaluating sustainability, and reassessing and modifying. The study team will deliver in-person, hand-on workshops incorporating each of these aspects of the conceptual model. Following the workshop, intervention states will partake in technical assistance activities with the study team to track progress and troubleshooting challenges.
45681181|NCT03599674|Behavioral|Family Bridge Program|Families receive Family Bridge Program services which include orientation to the hospital, concrete needs assessment, communication preferences assessment, communication coaching, follow-up during the hospital stay, and a follow-up phone call after discharge.
46104979|NCT02640521|Behavioral|Chart Reminders & New York State Quit line referral system|Investigators at New York University Medical School, Bellevue and Lincoln Hospital will work closely to (1) develop chart reminders appropriate for each of their clinics (2) to prompt providers to ask about in home smoking at every medical visit and (3) to establish a New York Quit line referral system in the pediatric practice, including clearly defined roles and responsibilities for each step. The New York State Quit line service includes proactive telephone calls with mailings of self-help material, free nicotine replacement therapy for those who qualify, and referrals to local treatment programs, ensuring that health literacy levels of materials is maximized, amending the training curriculum for providers as necessary, and modifying patient education materials that are part of the provider tool kit to focus on the negative impact of secondhand smoke.
46104980|NCT04165265|Device|Constant-Care|"Constant-Care (CC) (https://ibd.constant-care.com) is a web-application and contains an education and a disease monitoring package. An algorithm is established in the disease monitoring package, which consist of two variables; fecal calprotectin (FC) and a disease activity questionnaire (validated), Simple Clinical Colitis Activity index (SCCAI) for UC. The FC is obtained through CalproSmart app (it only takes 18 min) and the questionnaire is filled out in CC. Afterwards, the data are analyzed by CC and presented in a Total Inflammatory Burden Score (TIBS) as well as a visual traffic light of disease for the patients"
46104981|NCT02640443|Drug|Sulfamethoxazole|60 mg sulfamethoxazole per kg bodyweight (maximal of 3g) divided in 2 doses per day during 3 weeks
46104982|NCT02640365|Drug|MM-398|unresectable Advanced non-colorectal cancer
46104983|NCT02640365|Drug|Irinotecan|unresectable metastatic colorectal cancer
46104984|NCT02640365|Drug|Leucovorin (LV)|unresectable metastatic colorectal cancer
46104985|NCT02640365|Drug|5-fluorouracile (5-FU)|unresectable metastatic colorectal cancer
46104986|NCT02640365|Drug|bevacizumab|unresectable metastatic colorectal cancer
46104987|NCT02640365|Drug|MM-398|unresectable metastatic colorectal cancer
45681182|NCT04195360|Other|Standardized mobilization procedure|5 minutes bed rest (h1), followed by 3 minutes passive leg raise (PLR), followed by 5 minutes bed rest (h2), followed by 3 minutes sitting on the egde of the bed (sit), followed by 3 minutes standing/walking on the spot (sta), followed by 5 minutes bedrest (h3)
45681183|NCT04195282|Other|Plasma exchange|Patients will receive treatment of plasma exchange for three times in two weeks. The volume of fresh frozen plasma used in plasma exchange is about 2000 millilitre per time.
46104988|NCT02645591|Procedure|Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP).
46020708|NCT05220865|Procedure|Modified Hall Technique|"Food scraps or debris will be cleaned from the caries cavity and infected soft carious dentin tissue will be excavated with hand instruments.~The smallest crown size will be selected that covers all cusps and approaches the contact points with a slight springback feel.~If the contact points are tight, orthodontic elastic separators will be placed through the contacts and the SSC will be placed at the second appointment 3-5 days later.~The SSC will be loaded with glass ionomer luting cement and placed evenly on the tooth.~The child will be asked to bite firmly until the crown is pushed down over the tooth.~If the child is unable or unwilling to bite down on the SSC, finger pressure will be used to seat the crown~The child will continue to bite on a cotton roll until the cement hardens~Excess glass ionomer cement will be removed from the crown margins with hand instruments and dental floss."
46104989|NCT02645591|Biological|AmnioFix®|Dehydrated human amnion/chorion membrane (dHACM) wrapped around the nerve bundles at the end of Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) surgery.
46104990|NCT02645591|Behavioral|Questionnaire|Questionnaire completed about erectile function before surgery, and at 6 weeks, 3 months, 6 months, and 12 months after surgery.
46104991|NCT02645513|Behavioral|Malaria text message reminders to health workers|Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria
46104992|NCT02645513|Behavioral|Malaria, pneumonia, and diarrhea text message reminders to health workers|Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria, pneumonia, and diarrhea
46104993|NCT02645513|Behavioral|Control|No text message reminders
46104994|NCT02642003|Drug|Granulocyte Colony Stimulating Factor|
46104995|NCT00653705|Other|Yogurt drink with probiotic bacteria BB12|Probiotic yogurt dairy drink with Bifidobacterium Lactis and prebiotics. One bottle a day for 16 weeks.
45468062|NCT04220840|Procedure|Damage control strategy|"The damage control strategy constitutes a two stage procedure.~Emergency surgery:~limited resection oft he diseased colonic segment with oral and aboral blind closure, abdominal lavage, temporary vacuum assisted abdominal closure~Second look surgery (48-72 hours later):~reexploration with~definite reconstruction (Colorectal anastomosis -/+ diverting ileostomy vs. end colostomy)~lavage, vacuum assisted abdominal closure, third look 72 hours after emergency surgery"
45468063|NCT05515211|Diagnostic Test|Foot length|Foot length will be measured from the midpoint of the heel to the longest toe.
45468064|NCT01381484|Drug|10% Argireline|10% Argireline (La jolie gel®, Pacific health care, Thailand) were instructed to apply the gel over the face and periorbital area twice daily for a period of 3 months.
45468065|NCT02943993|Drug|Edoxaban|Prescribed according to approved label
45468066|NCT02620150|Drug|Escitalopram|10 week trial
45468067|NCT02620150|Other|Placebo|10 week trial
45468068|NCT05198219|Device|Ambu® aScope™ 4 Rhinolaryngo|Patient indication following a rhinolaryngoscopy
46020709|NCT04651621|Device|continuous theta burst stimulation over the SMA|Each cTBS session consists of bursts of three pulses delivered with a rate of 50 Hz, with bursts repeated at a rate of 5 Hz for a total duration of 40 seconds, summing up to 600 pulses, 100% of motor threshold (MT) and applied over bilateral SMA. The target is located in the anterior-posterior direction over the transition between pre-SMA and SMA proper, (cortical point where a vertical line will pass through the anterior commissure). The center of a figure-of-eight coil will be placed over the target, guided with neuronavigation equipment that utilizes the anatomical brain image from the pre-cTBS scanning session.
46020710|NCT04651621|Device|sham continuous theta burst stimulation over the SMA|The same stimulation parameters but a concealed sham coil will be used with only superficial magnetic stimulation to mimic the sensation of the active stimulation
46020711|NCT00632047|Other|active surveillance|
45468069|NCT05198219|Device|Conventional reusable rhinolaryngoscope|Patient indication following a rhinolaryngoscopy
46104996|NCT00653705|Other|Placebo|Vanilla flavored dairy drink. One bottle a day for 16 weeks.
46104997|NCT02641925|Procedure|Omentum preserving|The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed during gastrectomy with lymph node dissection.
46104998|NCT02641925|Procedure|Total omentectomy|Whole omentum will be removed during gastrectomy with lymph node dissection.
46104999|NCT02641847|Drug|docetaxel|
45468070|NCT04098302|Drug|Dutasteride Capsules|1 mg/day oral dutasteride (2 x 0.5 mg capsules)
45468071|NCT04098302|Drug|Placebo Capsules|Placebo capsules with matching appearance as Dutasteride Capsules
46020712|NCT00632047|Other|educational intervention|
45468072|NCT02596126|Drug|Cardiovascular Polypill|"Cardiovascular Polypill contains Aspirin, Atorvastatin and Ramipril.~Participants will receive one of the following cardiovascular polypill:~(A) Aspirin 100 mg, Atorvastatin 40mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).~or~(B) Aspirin 100 mg, Atorvastatin 20mg, and Ramipril (2.5 mg, or 5 mg, or 10mg)."
45468073|NCT02596126|Drug|Treatment Prevention for Secondary CV|ESC Guideline (2013 guideline on management of stable coronary disease) recommended pharmacological treatment for event prevention.
45468074|NCT01137305|Other|VR- training|"Prospective randomization if 50 subjects to either three months of structured VR- training or no training; basic VR- skills assessment and a serial assessment of defined soft skills: self- efficacy, stress- coping and motivation prior to randomization; basic VR- skills measured within seven modules of the VR- simulator LapSim®: camera and instrument navigation, coordination, grasping, lifting and grasping, clip applying and diathermy cutting in different levels of difficulty- medium and hard referring to time to complete task, economy of instrument motion and tissue damage; intervention group: sessions of 45 minutes each twice a week for three months; control group: no training"
45468075|NCT05497115|Behavioral|Trauma Resilience and Recovery Program|The Trauma Resilience and Recovery Program is a stepped model of care that is designed to deliver education at the bedside about mental health recovery after traumatic injury as well as risk assessment and brief intervention for high-risk patients (Step 1), foster symptom self-monitoring and continued education (Step 2), screen for PTSD and depression 30 days post-injury (Step 3), and provide a referral and warm handoff to mental health services if needed (Step 4).
45468076|NCT05288517|Behavioral|Lock to Live|Lock to Live is an anonymous web-based self-administered decision aid for safe firearm and medication storage (Public URL: http://lock2live.com/).
45468077|NCT01383434|Procedure|Bone Marrow Transplant|Matched sibling, haploidentical or matched unrelated donor bone marrow transplant following chemotherapy
45468078|NCT05420246|Drug|Ainuovirine|The regimen including Ainuovirine will be given to HIV-1 infected/AIDS patients.
45468079|NCT05494541|Other|Crizanlizumab|Patients who initiated crizanlizumab between November 1, 2019 and January 31, 2021 (index period) were selected into the treatment cohort.
46020713|NCT00632047|Procedure|examination|
46020714|NCT00632047|Procedure|long-term screening|
46020715|NCT04203043|Drug|Pycnogenol Oral Product|pycnogenol use to prevent hyper pigmentation after foam sclerotherapy
46020716|NCT04203043|Other|Placebo|Placebo
46105000|NCT02641847|Drug|doxorubicin or epirubicin|
46105001|NCT02641847|Drug|cyclophosphamide|
46105002|NCT02641847|Drug|gemcitabine|
46105003|NCT02641847|Drug|cisplatin|
46105004|NCT02640287|Biological|Blood or bone marrow samples|
46105005|NCT02536001|Device|One mesh Endofast reliant system|One mesh (anterior One mesh Endofast reliant system) will be used to correct both anterior and apical prolapse
46105006|NCT02536001|Device|two meshes Endofast reliant system|Two meshes (anterior and posterior Endofast reliant system) will be used to correct separately the anterior compartment and the apical compartment
46105007|NCT00653471|Device|Microcapmicro-stream device with Smart CapnoLine Plus|nasal oxygen mask tested to determine accuracy of endtidal CO2 monitoring
46105008|NCT00653471|Device|Microcap micro-stream device with CapnoLine|CO2 measured via nasal cannula
46020717|NCT04435015|Drug|Camostat Mesylate|Participants will be given Camostat mesylate three times daily.
46105009|NCT00653471|Device|TG-920 main-stream device (Nihon Kohden, Tokyo, Japan).|CO2 measured via nasal cannula
46020718|NCT04435015|Drug|Microcrystalline Cellulose, NF|Participants will be given Microcrystalline Cellulose (placebo) three times daily.
46020719|NCT04235725|Other|Harmonized Depression Outcome Measures|This is an observational study where retrospective data on previous disease status and patient characteristics will be collected and combined with longitudinal data from these data sources on outcomes during the study timeframe.
46105010|NCT02641769|Biological|Stem Cell Transplantation|intervention with transplantation of autologous purified stem cells
45468080|NCT04133883|Procedure|Ultrasound, Haemophilia Joint Health Score|Systematic joint examinations of ankles, knees and elbows
45598490|NCT04465513|Dietary Supplement|Best Standard of Care + CARDIO|Combination of dietary supplement with clinical care
45598491|NCT04465513|Dietary Supplement|Best Standard of Care|Combination of placebo with clinical care
46105011|NCT02640131|Behavioral|Biomedical Component|Bio-medical: The bio-medical component includes an appointment with urologist pre-operatively and 5 follow-up appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.
46105012|NCT02640131|Behavioral|Psychosocial Component|Psychosocial: aims to support maintenance of intimacy, pro-erectile therapy use, and regular satisfying sexual activity. At each time point, participants receive standardized sexual health counselor (SexHC) counseling and manualized support.
45681184|NCT04195282|Other|RL-1 Novel Human-derived Bio-artificial Liver Treatment|Patients will receive RL-1 Novel Human-derived Bio-artificial Liver treatment for three times in two weeks. The volume of plasma exchanged in the system is about 4000 millilitre per time.
45468081|NCT01381250|Behavioral|cognitive behavior therapy|The treatment was based on established cognitive behavior therapy methods, as described in self-help books (Hodgins, 2002; Ladouceur & Lachance, 2006). The text was divided into eight modules and was adapted for Internet use. The first four modules had a motivational interviewing focus and included building motivation for change by letting the participant answer open-ended questions that would evoke talk of change. The participants were encouraged to ask for input from their relatives on different aspects of their gambling. In addition, the first four modules included time line follow-back and mapping of the reasons for gambling. The remaining four modules were based on CBT. Each module included information and exercises and ended with three to eight essay-style questions. Feedback on homework assignments was usually given within 24 hr after participants had sent their answers via e-mail. Once weekly, a telephone call was made by the therapists to each participant.
45468082|NCT05488613|Drug|Midostaurin|Midostaurin was administered in two different dosing options. Either as 2x25mg daily or 2x50mg daily.
45468083|NCT04281316|Device|Nasal High Flow installation|"Participants randomized in NHF group will receive the nasal high flow (NHF) treatment delivered by myAirvo2.~Nasal High-Flow (NHF) is a treatment delivering heated, humidified, and optionally oxygen-enriched, air at high flow rates through a nasal cannula. The physiologic effects of NHF are an improvement in gas exchanges including a reduction in hypercarbia an optimization in breathing patterns with a reduction of work of breathing and high compliance as delivered via a comfortable nasal interface"
45468084|NCT04281316|Device|Non Invasive Ventilation|Participants randomized in the Non Invasive Ventilation group will receive treatment as in their usual care.
45681185|NCT04020874|Behavioral|HuTT-2x|tackling and blocking training twice/week
45681186|NCT04020874|Behavioral|HuTT-4x|tackling and blocking training four times/week
45681187|NCT04029766|Drug|HSK3486|
45681188|NCT04193644|Behavioral|Mindfulness and Self-Compassion focussed exercises during walking training|Mindfulness and Self-Compassion focussed exercises during walking training with moderate intensity
45681189|NCT04193644|Behavioral|Walking training|Walking training with moderate intensity
45681190|NCT04195048|Other|Risk factors|Risk factors: modifiable and unmodifiable risk factors
45681191|NCT04195126|Device|CytoSorb haemadsorption device|CytoSorb (Cytosorbents Inc.) aspecific blood purification device used in an extracorporeal circulation system without dialysis column. Anticoagulation is managed by siodium citrate-Calcium system, using the Gambro CVVHDF capable device.
45681192|NCT04190290|Other|Physiotherapy Adapted Program|3 days / week mobilisations and respiratory exercises and body image exercises
46020720|NCT04170361|Other|Conventional Chest Physiotherapy|All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.
45681193|NCT04190290|Diagnostic Test|Evaluation and Control|Manual muscle test MRC score, peak-expiratory-flow test, hand strength test, 6 minutes walking test, SF-36, EDI-3 and EDQOL
45468085|NCT04281316|Other|Training session|The patients in the Nasal High Flow (MyAirvo) arm will receive two hours training adaptation session in the hospital
45468086|NCT04281316|Other|Education session|Participants randomized in the Non Invasive Ventilation group will receive an additional educational session of one hour for improving compliance.
45468087|NCT04047290|Drug|AK112|AK112 is a PD1/VEGF bispecific antibody.
45468088|NCT01233089|Device|Lotrafilcon B contact lens, investigational|Investigational silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly
45468089|NCT01233089|Device|Lotrafilcon B contact lens, commercial (AIR OPTIX AQUA)|Commercially available silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly.
45468090|NCT01233089|Device|Lotrafilcon B multifocal contact lens, commercial (AIR OPTIX AQUA MULTIFOCAL)|Commercially available silicone hydrogel, multifocal, contact lens worn on a daily wear basis and replaced monthly.
45468091|NCT01233089|Device|Contact lens care system (ClearCare)|Commercially available, hydrogen peroxide-based system for cleaning, disinfecting, and storing contact lenses
45468092|NCT04240366|Procedure|Control intervention|patients treated with balloon-based ablation of AF by PVI
45468093|NCT04240366|Procedure|Experimental intervention|patients treated with balloon-based ablation of AF by PVI
46020721|NCT04170361|Other|Conventional Chest Physiotherapy+Incentive Spirometry|All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals.
46020722|NCT04817293|Other|Questionnaire|Questionnaire SSD-12 and EQ5D5L
46020723|NCT04817293|Other|medical consultation|Medical consultation during the visit with data collection
46105013|NCT02640131|Behavioral|Attention Control|Couples will attend 30-minute clinic consultations with an Urologist and a Survivorship Counsellor (SurvC) at 3-4, 7-8, and 12-13 months post radical prostatectomy (RP). Couples will receive a Kegel Exercise booklet and receive appointment-specific chapters of the Challenging Prostate Cancer: Nutrition, Exercise, and You (CPC) manual (a patient self-help manual written by the Princess Margaret Prostate Centre team). The core topics discussed during the counselling sessions include: preparation for immediate post-RP recovery, Kegel exercises, nutrition and prostate cancer (PC), exercise and PC, and maintaining healthy lifestyle change.
46105014|NCT00599027|Drug|Mometasone furoate nasal spray (MFNS)|Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.
46105015|NCT00599027|Drug|Placebo nasal spray|Placebo nasal spray once daily (two puffs per nostril) in the morning.
46105016|NCT02645357|Other|computer reminders on clinical practice|on-screen, point-of-care computer reminders on clinical practice.
45468094|NCT05278611|Drug|EP-9001A|The initial dose of the study was set as 1 mg, and the doses were escalated sequentially in the order of 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, and 25 mg
45468095|NCT05278611|Drug|placebo|placebo
45468096|NCT05487131|Behavioral|electrical stimulation|different types of weak electrical stimulation will be used
46020724|NCT04408651|Behavioral|LIIT.CI ACT|4-week online self-management intervention based on Acceptance and Commitment Therapy and adapted to people with chronic medical conditions
46020725|NCT04408651|Behavioral|LIIT.CI CFT|4-week online self-management intervention based on Compassion-Focused Therapy and adapted to people with chronic medical conditions
46105017|NCT02645357|Other|Control group|control group
46105018|NCT03272633|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Receive IHC
46105019|NCT03272633|Biological|Irradiated Allogeneic Cells|Correlative studies
46105020|NCT00652379|Drug|Pegvisomant|Pegvisomant s.c 15-30 mg 2 times a week
46105021|NCT00652379|Drug|Somatostatin analog (lanreotide or octreotide)|Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog
46105022|NCT00655187|Other|Collection of information|Information regarding demographic characteristics, medical history, previous participation in rotavirus clinical trials and vaccination history will be collected.
46105023|NCT00655187|Procedure|Collection of stool samples|Stools samples will be collected during hospitalisation for RV testing and genotyping of RV positive samples.
46105024|NCT02639975|Drug|PBF-677|once daily oral administration
46105025|NCT02639975|Drug|Placebo|once daily oral administration
46105026|NCT04164797|Drug|endostar+chemoradiotherapy|antiangiogenic drug+chemoradiotherapy
46105027|NCT04164797|Other|chemoradiotherapy|chemoradiotherapy
46105028|NCT00654017|Drug|placebo|Placebo comparator to be given per protocol.
45468097|NCT05420168|Other|Automatic tool to identify inappropriate antibiotic prescriptions|The system will identify inappropriate antibiotic prescriptions.
46105029|NCT00654017|Drug|sildenafil|oral sildenafil citrate at an initial dose of 25 mg, which could have been up-titrated to 50 mg at Visit 3 based on the patient's efficacy, safety and tolerability responses; at Visits 4 and 5, the dose could remain the same, be increased to 100 mg, or decreased to 25 mg depending on the safety, efficacy, and tolerability
46105030|NCT02639819|Drug|ɛ-Aminocaproic Acid|Intervention: intravenous ε-Aminocaproic Acid within 3 hours of symptom onset
46105031|NCT02645201|Dietary Supplement|Gastrus|to compare Gastrus 4x108 tbl twice a day to placebo tbl
46105032|NCT02645201|Other|Placebo|to compare Gastrus 4x108 tbl twice a day to placebo tbl
46105033|NCT02638025|Device|OCT|Anterior Segment Spectral-domain Optical Coherence Tomography
46105034|NCT02639741|Drug|Melatonin|Preoperative melatonin tablet will be given and postoperative pain scores will be evaluated
46105035|NCT02639741|Drug|Vitamin C|Preoperative vitamin C tablet will be given and postoperative pain scores will be evaluated
45468098|NCT03449992|Dietary Supplement|nitrate-rich beetroot juice|Nitrate-rich beetroot juice supplementation was administered for 15 consecutive days to participants in this arm
45468099|NCT03449992|Dietary Supplement|Placebo|Placebo drink
45468100|NCT04755699|Device|Transcutaneous Electrical Stimulation|The study involves the administration of various electrical pulses being delivered to muscles and/or the spinal column with an investigational neurostimulator to evoke various limb movements in order to improve functional movement.
45468101|NCT01137383|Drug|Pegaferon (pegylated interferon alpha 2a) + ribavirin|pegylated interferon 180 micrograms subcutaneously weekly - ribavirin (oral, in two divided daily doses) 800 mg for genotype 2 and 3, 1000 or 1200mg (weight less than or greater than 75kg) for genotypes 1 and 4 - Duration: 24 weeks for genotype 2 and 3, 48 weeks for genotypes 1 and 4
45468102|NCT03449836|Combination Product|Streptococcus salivarius 24SMBc + Strept. oralis 89a|nasal spray based on Streptococcus salivarius 24SMBc + Strept. oralis 89a
45468103|NCT03449836|Combination Product|fluticasone + mometasone|nasal spray based on fluticasone + mometasone
45468104|NCT03449836|Other|placebo|nasal spray based on isotonic solution
45468105|NCT01142765|Biological|AdCh63 MSP1, MVA MSP1, challenge|1 dose of AdCh63 MSP1 5 x 1010 vp intramuscularly and 1 dose MVA MSP1 2.5 x 108 pfu intramuscularly 8 weeks later (range 6-12 weeks) followed by sporozoite challenge 12-28 days later
45468106|NCT01142765|Biological|AdCh63 AMA1, MVA AMA1, challenge|1 dose of AdCh63 AMA1 5 x 1010 vp intramuscularly and 1 dose MVA AMA1 2.5 x 108 pfu intramuscularly 8 weeks later (range 6-12 weeks) followed by sporozoite challenge 12-28 days later
45468107|NCT01142765|Biological|AdCh63 AMA1, AdCh63 MSP1, MVA AMA1, MVA MSP1, challenge|1 dose of AdCh63 AMA1 5 x 1010 vp intramuscularly and 1 dose AdCh63 MSP1 5 x 1010 vp intramuscularly co-administered into separate arms followed 8 weeks later (range 6-12 weeks) by 1 dose of MVA AMA1 2.5 x 108 pfu intramuscularly and 1 dose MVA MSP1 2.5 x 108 pfu intramuscularly co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge 12-28 days later.
45468108|NCT01142765|Biological|AdCh63 MSP1, AdCh63 ME-TRAP, MVA MSP1, MVA ME-TRAP, challenge|1 dose of AdCh63 MSP1 5 x 1010 vp intramuscularly and 1 dose AdCh63 ME-TRAP 5 x 1010 vp intramuscularly co-administered into separate arms followed 8 weeks later (range 6-12 weeks) by 1 dose of MVA MSP1 2.5 x 108 pfu intramuscularly and 1 dose MVA ME-TRAP 2 x 108 pfu intramuscularly co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge 12-28 days later.
46020726|NCT04576429|Procedure|venous puncture|"Venous punctures will be performed:~for patients of cohort A and B1:~before the first immune checkpoint inhibitors monoclonal antibodies infusion (baseline);~between week 6 and week 8 (before the immune checkpoint inhibitors monoclonal antibodies infusion);~each 3 months up to 12 months.~for patients of cohort B2:~before the radiotherapy;~within the 6 weeks after the end of radiotherapy;~at the 2 following evaluations (every 3 months)."
46020727|NCT04576429|Procedure|tumoral biopsy|Cutaneous biopsy: superficial skin, or extended skin biopsy, if it is indicated for patient's care.
45468109|NCT01142765|Biological|Sporozoite challenge|Non-vaccinated controls for sporozoite challenge
46020728|NCT04573309|Drug|ALXN1840|Administered orally as tablets.
46020729|NCT04203277|Other|IVY|a combination of practice education and quality improvement interventions
46020730|NCT00631813|Drug|Prucalopride|0.5 mg bid
46105036|NCT02639741|Other|Placebo|Preoperative placebo tablet will be given and postoperative pain scores will be evaluated
46105037|NCT04164719|Drug|TNX-102 SL|Subjects will place TNX-102 SL sublingual tablets under the tongue until dissolved, and not to crush or chew them
46105038|NCT02639663|Device|dental device|"Leboride~Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~Control group: participants will not receive any device for breastfeeding pain control~Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device."
46105039|NCT01149083|Drug|Carboplatin|Given IV
46105040|NCT01149083|Other|Laboratory Biomarker Analysis|Correlative studies
46105041|NCT01149083|Drug|Veliparib|Given PO
46105042|NCT02639507|Procedure|Vitrectomy|
46105043|NCT00654173|Drug|Rosuvastatin|
46105044|NCT00654173|Drug|Simvastatin|
46105045|NCT00654173|Drug|Atorvastatin|
46105046|NCT02645435|Procedure|hip replacement|Total hip replacement
46105047|NCT02645279|Other|oral 30% glucose|30% glucose solution was administered orally through a teat. 1 mL 30% glucose solution was added following placement of the teat into the mouth of the newborn. After suckling of 0.5-1 mL glucose solution, the motionless and sleepiness of newborn was evaluated. If the target conditions was not achieved, 0.5-1 mL increments of glucose was added until the newborn kept motionless or asleep.
46105048|NCT02645279|Drug|IV midazolam|IV 0.1 mg/kg midazolam was administered.MRI was routinely performed and the newborns who did not keep motionless or asleep and had motion artefacts were sedated with intravenous 0.5 mg/kg propofol.
46105049|NCT02639585|Drug|Daclinza and Sunvepra|direct acting antiviral agent against to hepatitis C virus
46105050|NCT04164251|Other|Screening mammography|The purpose of the study was to evaluate the feasibility of securing inpatient breast cancer screening mammograms for non-adherent hospitalized women prior to hospital discharge.
46105051|NCT04164953|Procedure|Surgical treatment|Surgical treatment of Dupuytren's disease. Average from 2 to 4 joints per hand operated on simultaneously
46105052|NCT02639195|Other|Treatment|Retrospective chart review of patients treated with manual therapy.
46105053|NCT02881151|Device|Deep brain stimulation|Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.
46105054|NCT04164329|Drug|General anesthetic|General anesthesia (propofol, fentanyl, sevorane, remifentanyl, rocuronium)
45468110|NCT05419544|Behavioral|Holy Quran Recital effect|The intervention group, listened to holy Quran recitation for 10 minutes twice a day 4 hours a part (10 am and 2 pm) for 2 consecutive days (usually the 2nd and the 3rd day post-operative) after extubation and gaining alertness. We have chosen Surah Al-Rehman because it is considered as the most rhythmic surah of the Quran and the recitation of Qari Abdul Basit is very soothing and effective as he has recited from the deep of the heart. The listing was by a disposable head phones for an I pad for each hospital. The control group received usual care by their nurses.
45681194|NCT04194736|Other|Ultrasound scan|"First ultrasound scan from 1 day to 6 days after the placement of the percutaneous central venous catheter.~Second ultrasound scan from 7 days to 13 days after the placement of the percutaneous central venous catheter if no thrombosis was detected at the first ultrasound scan."
45681195|NCT04198558|Drug|MEDI0618|MEDI0618 A novel human immunoglobulin antibody
45681196|NCT04198558|Drug|Placebo|Placebo
46020731|NCT00631813|Drug|Prucalopride|1 mg bid
45681197|NCT04197544|Procedure|endoFAVI|EndoFAVI creation to patients that require vascular access for hemodialysis.
45681198|NCT04194892|Biological|Pegilodecakin|Administered SQ
46105055|NCT02800655|Device|Digital Health Feedback System|"This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their ARV medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their ARV medications.~Other Names:~DHFS"
45681199|NCT04028752|Biological|Blood collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in the arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
46105056|NCT04164095|Procedure|lappg|Preservation of pylorus and vagus nerve by laparoscopy
46105057|NCT02637869|Other|Alternative Payment Model|Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
45681200|NCT04197778|Drug|DDO-3055 tablet|DDO-3055 tablet, 2 single doses separated by 6 days.
46020732|NCT00631813|Drug|Prucalopride|2 mg bid
46020733|NCT00631813|Drug|Placebo|bid
46020734|NCT04404049|Biological|UB-421(25 mg/kg) Q2W|Monoclonal antibody by IV infusion plus standard ART
46020735|NCT04404049|Biological|UB-421(25 mg/kg) Q4W|Monoclonal antibody by IV infusion plus standard ART
46105058|NCT02639039|Drug|Cortisone Injection|Exact location and technique of injection within the region of the involved greater trochanter will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but CI is the only treatment.
46020736|NCT04642105|Device|Sensor-Dot and Plug 'n Patch system|We will use a small, unobtrusive wearable (Sensor-Dot) to measure different biosignals (EEG, ECG, EMG, motion, skin temperature, respiration and oxygen saturation) for up to one year using newly developed skin adhesives and patches (Plug 'n Patch system)
46105059|NCT02639039|Procedure|Trigger Point Dry Needling|Exact location of needle insertion, technique and number of penetrations within the region of the involved posterolateral hip will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but TDN is the only treatment.
46105060|NCT00689728|Biological|LY2127399|LY2127399 will be administered as a single IV infusion over 30 minutes.
46105061|NCT00689728|Drug|Placebo|Placebo will be administered as a single IV infusion over 30 minutes.
46105062|NCT02639117|Drug|Vismodegib|Vismodegib 150 mgs po qd for 3 months
46105063|NCT04163939|Other|Vista Therapy Collar|The patient will wear the cervical collar
46105064|NCT04163939|Other|Placebo|The patient will not wear the cervical collar
46105065|NCT00655265|Drug|Colesevelam hydrochloride film-coated tablets|tablets
46105066|NCT00655265|Drug|Placebo|Tablets
46105067|NCT04163861|Diagnostic Test|2d speckle tracking echocardiography|2d speckle tracking echocardiography
46105068|NCT04163861|Diagnostic Test|serum BNP level|serum BNP level of HFpEF study subjects
45468111|NCT03449524|Drug|75mg CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
45468112|NCT03449524|Drug|150mg CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
45468113|NCT03449524|Other|Placebo|Placebo
45681201|NCT04028830|Other|Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC|Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC
46020737|NCT04552873|Drug|Urea|"the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)~If hyponatremia persists beyond D8 after initiation of the study treatment (urea or placebo), that is to say after the date of the collection of the primary endpoint, it will be possible to introduce corticosteroids (fludrocortisone or others). These treatments will be collated.~If during patient monitoring the serum sodium exceeds 145 mmol / L, treatment should no longer be administered."
46020738|NCT04552873|Other|PLACEBO|the control group will be treated during 5 days by ergytonyl dose per administration : 5mL
46020739|NCT04639141|Combination Product|Synbiotic|Prebiotic + Probiotic
46020740|NCT04639141|Behavioral|Gut-directed Hypnotherapy|Psychotherapy sessions
45681202|NCT04028830|Other|Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support|Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support
45681203|NCT04194658|Drug|Letrozole 2.5mg|Pretreatment letrozole 12.5 mg for 2 days prior to misoprostol.
46020741|NCT00911989|Device|NOTES toolbox|Using SFT for endoscope access during Transvaginal Sleeve Gastrectomy procedure. Visualization will occur through endoscope
46020742|NCT04635163|Other|None intervention|None intervention
46020743|NCT04911517|Combination Product|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
46020744|NCT04617379|Behavioral|Stretching|One-year stretching program for 15 minutes every day
46020745|NCT04507243|Device|Active - HD tDCS|Non-invasive neuromodulation using HD electrodes placed on the scalp to deliver a constant, low current at 2 mA.
46020746|NCT04507243|Device|Sham - HD tDCS|Sham neuromodulation using HD electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
46020747|NCT04503655|Other|Training|"Training dedicated on implementation of organizational and therapeutic measures (for prevention and management of complications) to reduce lenght-of-stay after TF TAVI."
46105069|NCT02638961|Other|IMT|Patients allocated to IMT arm will receive standard medical treatment and will be instructed to train at home twice daily, for 20 minutes each session, and during 12 weeks using a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them will be instructed by a respiratory therapist and educated to maintain a diaphragmatic breathing during the training period. The subjects start breathing at a resistance equal to 25-30% of their maximal inspiratory pressure (MIP) for 1 week. The respiratory therapist examines the patients at weekly intervals by checking the diary card and measuring their MIP each time. The resistance is modified each session according to their 25-30% of their MIP measured.
46105070|NCT02638961|Other|FES|Patients allocated to FES arm will receive standard medical treatment and will be trained in a FES program of both legs by a physiotherapist for 45 minutes a day, 2 days per week for a total of 12 weeks. Eight adhesive electrodes are positioned on the skin over the quadriceps and gastrocnemius muscles of both legs. The stimulator is configured to deliver a direct electrical current at 25 Hz for 5 seconds followed by a 5-second rest. The intensity of the stimulation is adjusted to achieve a visible muscle contraction without discomfort.
46105071|NCT02638961|Other|Standard treatment|Patients allocated to this arm will not receive any physical therapy, only standard medical treatment. They will be checked weekly by a physiotherapist who measures their maximal inspiratory mouth pressure each time.
46105072|NCT02562586|Device|Closed Suction Drainage System|patients undergoing total hip replacement have received a closed suction drainage for 24 hours after the surgical procedure
46105073|NCT04162613|Other|Different measures of muscle function such as muscle strength, hop tests, postural orientation and muscle activation|"The participants will be assessed with a physical test battery at baseline including: Isokinetic knee strength, Isometric strength of trunk and lower extremity, Single-leg hop for distance, side hop, postural orientation (single leg-squat, stair descending, forward lunge, Single-leg hop for distance, side-hop), hip and ankle range of joint motion, muscular activation pattern, 3D movement analysis and proprioception test.~At follow-up (2 years), the participants will be asked to answer a survey about new ACL injuries and return to sport/previous activity level."
46105074|NCT02562664|Drug|CC|100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle
46105075|NCT02562664|Drug|Placebo tablets|Placebo tablets taken twice daily continuously for three cycles.
45468114|NCT04972565|Behavioral|Usual Care plus Inspiratory Muscle Training (IMT)|Participants will receive usual care and will also be provided with a personalized prescription for an IMT program for 8 weeks. Participants will perform two daily IMT sessions of 30 breaths (< 5 minutes/session), 5 days per week in their home environment. IMT intensity will be progressed weekly by 5-10% of the baseline maximal inspiratory pressure if the Borg Dyspnea score is < 7.
45598492|NCT02355795|Behavioral|low-fat diet|Energy from total fat, protein and carbohydrates are 20%, 14% and 66%, respectively
45598493|NCT02355795|Behavioral|moderate-fat diet|Energy from total fat, protein and carbohydrates are 30%, 14% and 56%, respectively
46020748|NCT04853563|Other|PEEP|High PEEP targeted to 10 cmH2O to be maintained during the period of mechanical ventilation compared with low PEEP maintaining 3-5 cmH2O
46020749|NCT03880279|Biological|TAC01-CD19|Dose-escalating cohorts plus expansion groups
46020750|NCT04237441|Other|observation|observation before and after multidisplinary team conference was implemented
46020751|NCT00637897|Drug|docetaxel|
46020752|NCT00637897|Drug|ixabepilone|
46020753|NCT00637897|Drug|paclitaxel|
46020754|NCT00637897|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
46020755|NCT00637897|Drug|paricalcitol|
46105076|NCT02562664|Drug|Metformin|wMetformin (Cidophage , Amon , Egypt) 500 mg twice daily continuously for three cycles.
46105077|NCT02635919|Device|mSMART|A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
46105078|NCT02564614|Drug|RO7070179|RO7070179 (13 mg/kg/week) will be administered as 2-hour IV infusion.
46020756|NCT03992443|Drug|CUSA-081|Participants received 1 or 2 doses of CUSA-081, 0.70 mg/2 mL, directly into the catheter lumen
46020757|NCT04349839|Device|Acrodat software|Acrodat is a newly developed software medical device to access disease activity in acromegaly based on five parameters: IGF-I, tumour size, comorbidities, symptoms and quality of life.
46020758|NCT04334707|Procedure|Kidney Biopsy|A kidney biopsy is a procedure that involves taking a small piece of kidney tissue for examination with a microscope. A licensed health care provider will perform a kidney biopsy.
45468115|NCT01234181|Procedure|Hypoxia-stressed BMSCs transplantation to cure MI|Experimental group: intracoronary injection of 10^7 BMSCs Sham Comparator: inject the same volume saline
45468116|NCT03443752|Other|Shotokan-Karate|The Shotokan-Karate training program will be ran over a period of 12 weeks. Classes will be conducted 3 times per week at the Movement Disorders Rehabilitation Centre in Waterloo, Ontario. The program will be conducted by a trained professional (principal investigator), and there will be volunteers who ensure the safety and well-being of participants.
46105079|NCT04164017|Device|EUS-guided FNB with Syringe Suction|For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
45681204|NCT04194502|Diagnostic Test|Transesophageal echocardiogram (TEE)|All patients enrolled in the study will undergo a pre-operative research TEE and an intra-operative clinical TEE.
46105080|NCT04164017|Device|EUS-guided FNB without Syringe Suction|For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
46020759|NCT04329949|Drug|Relacorilant, 100 mg and 25 mg|Relacorilant is supplied as capsules for oral dosing.
46020760|NCT04329949|Drug|Nab paclitaxel|Nab-paclitaxel is administered as IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle.
46020761|NCT03926689|Behavioral|SMS messages|A package of at least monthly SMS messages delivered to all adults in households with an individual in the 1000-day period between pregnancy and a child turning 2 years of age.
46105081|NCT04060576|Procedure|Dry needling treatment with a thinner needle|We will make an application with the dry needling technique with a fine needle on the myofascial trigger points of the gastrocnemius muscle.
46105082|NCT04060576|Procedure|Dry needling treatment with a medium-sized needle|We will make an application with the dry needling technique with a medium-sized needle on the myofascial trigger points of the gastrocnemius muscle.
46105083|NCT04060576|Procedure|Dry needling treatment with a thickest needle|We will make an application with the dry needling technique with the thickest needle on the myofascial trigger points of the gastrocnemius muscle.
46105084|NCT02635763|Procedure|Femoral nerve and the lateral cutaneous nerve block|Femoral nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide;the lateral cutaneous nerve block was performed using 0.5% ropivacaine (5ml) under ultrasound guide
46105085|NCT02635763|Procedure|Lumbar plexus and sacral plexus nerve block|Lumbar plexus block was performed using 0.5% ropivacaine (25ml) under ultrasound guide; sacral plexus nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide
46105086|NCT04060498|Behavioral|Mindfulness intervention|MBI-p focuses on simplicity, for both facilitators and patients; and use acceptance and embracing attitude for fear and sadness. The ultimate aims are to help patients achieve a greater sense of peace and calmness, and facilitate participants in handling everyday stress and conflicts.
45468117|NCT03443752|Other|Tai-Chi|The Tai-Chi training program will be ran over a period of 12 weeks. Classes will be conducted 3 times per week at the Movement Disorders Rehabilitation Centre in Waterloo, Ontario. The program will be conducted by a trained professional (principal investigator), and there will be volunteers who ensure the safety and well-being of participants.
45468118|NCT03961256|Drug|Exenatide SR|Exenatide SR 2 mg subcutaneous (SQ) weekly
45468119|NCT04929197|Device|PERSBRA|"After the patient is in the semi-prone position, the body shape and breast position images are obtained by the stereo scanning technology, and then using 3d printing technology to print PERSBRA.~PERSBRA maintain a favorable new breast position in the supine position during routine radiotherapy, the cardiopulmonary dose during radiotherapy can be reduced by wearing PERSBRA."
45598494|NCT02355795|Behavioral|high-fat diet|Energy from total fat, protein and carbohydrates are 40%, 14% and 46%, respectively
45598495|NCT02355951|Other|blood draw|
45598496|NCT03517501|Drug|ART-123|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
45598497|NCT03517501|Drug|Placebo Comparator - Placebo|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
45598498|NCT02295163|Procedure|Stellate ganglion block|7 ml of 0.5% bupivacaine will subsequently be injected next to the stellate ganglion to produce a sympathetic block.
45598499|NCT02295163|Procedure|Sham procedure|7 ml of 0.9 % sodium chloride will subsequently be injected next to the stellate ganglion
46020762|NCT03926689|Behavioral|Standard SII SBCC|Home visits/IPC; community events including food demo and key life events; and Bhanchhin Aama radio program episodes
46020763|NCT04597099|Drug|Micronized progesterone|oral micronized progesterone suspension, 100 mg oral dose at 0800 during each study admission
46105087|NCT04060498|Behavioral|Psychoeducation intervention|Psychoeducation focuses on disseminating information about common mental disorders, psychosis (its causes, risk factors and trajectory), and methods of treatment for psychosis.
46105088|NCT00654407|Drug|Rosuvastatin|
46105089|NCT00654407|Drug|Atorvastatin|
46105090|NCT00654407|Drug|Simvastatin|
46105091|NCT00691054|Drug|Abraxane|One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4. Treatment cycles will be repeated every 28 days for as long as disease is not progressing and patient tolerates treatment
46105092|NCT00748696|Dietary Supplement|Fortimel Extra®|260kcal and 20g protein per day
46105093|NCT00748696|Other|resistance training|3 sessions of resistance training per week
46105094|NCT00748696|Other|combined treatment|260kcal and 20g protein per day 3 sessions of resistance training per week
46105095|NCT02563756|Procedure|Unicompartmental knee replacement|Participants with a medial gonarthritis are operated with a medial unicompartmental prosthesis
46105096|NCT02563756|Procedure|Total knee replacement|Participants with a medial gonarthritis are operated with a total knee replacement
46105097|NCT00598871|Drug|Thymosin Beta 4 (Tβ4)|There are 2 groups: active drug and placebo. The patients in the active arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times daily (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
46105098|NCT00598871|Other|Placebo|There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of 0.00% Tβ4(w/w) eyedrops to the affected eye, 2 drops four times a day (QID) (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
46105099|NCT00744406|Behavioral|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
46105100|NCT00744406|Behavioral|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
45681205|NCT04194580|Behavioral|Phisical activity intervention|The prevalence of overweight in chilean children in the among the highest in the world and increasing quickly. The investigators recently evaluated an after-school program of recreational physical activity to control overweight, obesity and other cardiovascular risk factors in primary school children Temuco. This program reduced adiposity and increased the fitness.
45681206|NCT04028518|Drug|r-PA|"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time."
45681207|NCT04028518|Drug|r-PA|"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time."
46020764|NCT04597099|Drug|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
46020765|NCT04597099|Drug|Flutamide|Flutamide, 250 mg taken orally twice daily for four weeks before study admission.
46020766|NCT04597099|Drug|Estradiol patch|Two 0.1 mg/day transdermal estradiol patches will be applied 3 days prior to each inpatient admission; on the morning of study admission, these two patches will be removed and immediately replaced with two new 0.1 mg/day patches.
46020767|NCT03915535|Dietary Supplement|Eicosapentaenoic acid + Docosahexaenoic acid|Monoglyceride Omega-3 fish oils
45468120|NCT03443596|Biological|Early intensive BP control|Participants in the early intensive BP control arm are treated with BP lowering medications, with an aim to bring the systolic BP to 140-160mmHg and maintain this level for 72 hours post-ictus
45468121|NCT03443518|Procedure|Psoas Compartment Block (PCB)|30 ml of bupivacaine 0.25% will be infused over 3 minutes at the anatomical landmark for Psoas Compartment Block (PCB)
45468122|NCT03443518|Procedure|Local Anesthesia infiltration|Lidocaine 5 ml of 2% will be injected subcutaneous as local infiltration.
45468123|NCT03443518|Drug|Normal saline 0.9% IV infusion|Normal saline 0.9% IV infusion at the same rate of the Remifentanil infusion(0.05-0.1 μg/ kg/min).
45468124|NCT03443518|Drug|Remifentanil infusion|Remifentanil infusion with rate 0.03-0.1 μg/ kg/ min to achieve Visual Analog Scale (VAS) 3 or less
45468125|NCT03443440|Other|Neurocognitive Testing|neurocognitive testing, computerized
45468126|NCT04914689|Other|Internal focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving mirror feedback. Participants will be instructed to perform each functional task in a manner that keeps their knee in line with their toes.
45468127|NCT04914689|Other|Visual internal focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving visual feedback via laser. Participants will be instructed to perform each functional task in a manner that does causes the laser to move up and down but not side-to-side.
45468128|NCT04914689|Other|Auditory external focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving auditory feedback. Participants will be instructed to perform each functional task in a manner that does not cause the auditory tool to elicit a noise.
45468129|NCT03443362|Procedure|Punch Biopsy|A 3 mm punch biopsy will be taken from lesional and non-lesional skin as a routine procedure.
45468130|NCT03443362|Procedure|Blood sampling|Blood sampling
45468131|NCT01234259|Device|Venus Freeze (MP2 V2 System|Facial wrinkles and temporary cellulite and circumference reduction treatments
45681208|NCT04028518|Drug|Alteplase for Injection|"Drug: Alteplase for Injection Dose:50mg; 20mg~Mode of admin:~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h."
45681209|NCT03023956|Procedure|Locking plates were used for proximal humeral fractures.|
45681210|NCT04028440|Biological|Autologous γδT cells|Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
45681211|NCT04748068|Device|7-Fr Glidesheath Slender|The 7 Fr Glidesheath Slender is a recently developed thin-walled radial sheath. It combines an ID of 2.46 mm, with an OD of 2.79 mm, representing thereby the thinnest 7 Fr sheath currently available on the market
45681212|NCT04748068|Device|Cordis 7-Fr radial sheath|Avanti+ Catheter Sheath Introducer, Cordis, USA, outer diameter: 3.02 mm
45681213|NCT04194268|Radiation|Carbon Ion|12 x 4 Gy (RBE)
45838184|NCT04505410|Other|Fast Mimicking Diet|FMD is a five day meal plan that includes foods such as soups, snacks, bards, teas and supplements (omega-3 fatty acids) for a total of 66 items per box. The diet is plant-based, gluten free and dairy free without any artificial preservatives, chemicals or biologically active ingredients.
45468132|NCT01142063|Drug|Neratinib|Tablet, a 240 mg single oral dose
45468133|NCT01142063|Drug|Neratinib|Tablet, a 240 mg single oral dose
45468134|NCT01142063|Drug|Neratinib|Tablet, a 240 mg single oral dose
45468135|NCT01142063|Drug|Neratinib|Tablet, a 240 mg single oral dose
45468136|NCT03443284|Behavioral|Health Partner|Health Partner is a combination of an iPhone or iPod Touch Operating System mobile application and a health care provider portal.
45468137|NCT03443284|Behavioral|Standard Care|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Providence Health & Services.
45468138|NCT04987762|Drug|Adhansia XR|Methylphenidate extended-release capsules taken once daily (12.5 mg, 25 mg, 35 mg, 45 mg, 55 mg, and 70 mg)
45468139|NCT01142843|Drug|green propolis mouthwash|The subjects were instructed to brush their teeth as usual and to rinse with the 10mL of Mouthwash contain 5% Green Propolis, twice a day, for one minute, right after their meals in the morning and at night. The treatment was performed during three months
45468140|NCT04330625|Biological|REMD-477|REMD-477 will be administered as a subcutaneous injection for four weekly doses
46020768|NCT03915535|Dietary Supplement|Eicosapentaenoic acid|Monoglyceride Omega-3 fish oil
46020769|NCT04816513|Drug|Ustekinumab|Ustekinumab will be administered as SC injection.
45681214|NCT04190212|Behavioral|High-intensity interval training + standard care|HIIT sessions will include: (1) warm-up for 2 minutes at 50% of peak power output (PPO); (2) 2 x 8-minute interval training blocks (total: 16 minutes) of 30-seconds at 80-100% of PPO interspersed with 30-seconds active recovery, 4 minutes of recovery will be permitted between the blocks; and, (3) 2 minute cool-down at 25% of PPO after the last 30-second exercise bout.
45681215|NCT04190914|Other|pulp regeneration for necrotic primary teeth|a pulp regeneration procedure will be applied for necrotic primary teeth with different intracanal medication compared to conventional pulpectomy used in treatment for necrotic primary teeth
45681216|NCT01711983|Device|GORE® CARDIOFORM Septal Occluder|Percutaneous Atrial Septal Defect Closure
46020770|NCT03858283|Behavioral|Mindfulness Based Health Care (MBHC) Program|Mindfulness Based Health Care (MBHC) Program for Caregivers of Alzheimer's Disease Patients. The duration of this group was 8 weeks. The program included one session per week, with each session lasting 1 hour and 30 minutes
46020771|NCT04203511|Drug|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks on Day 1 of each 21-day cycle for 4 cycles, followed by a consolidation part of INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to12 cycles.
46020772|NCT04203511|Drug|Placebo|Placebo administered intravenously every 3 weeks on Day 1 of each 21-day cycle for 4 cycles, followed by a consolidation part of placebo administered intravenously on Day 1 of each 28-day cycle for up to 12 cycles.
46020773|NCT04203511|Drug|Pemetrexed|Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle with either carboplatin or cisplatin (nonsquamous NSCLC only) for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
46020774|NCT04203511|Drug|Cisplatin|Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle with either etoposide or pemetrexed (nonsquamous NSCLC only) for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
46020775|NCT04203511|Drug|Carboplatin|Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle with either pemetrexed (nonsquamous NSCLC only) or paclitaxel for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
46020776|NCT04203511|Drug|Paclitaxel|Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle with carboplatin for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
46105101|NCT00744406|Drug|Antidepressant medication (sertraline ,paroxetineor or venlafaxine)|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
46105102|NCT00748774|Behavioral|Questionnaire|Two questionnaires taking about 10 minutes to complete.
46105103|NCT00748930|Other|Retrospective Chart Review and Data collection|Retrospective Chart Review and Data collection
46105104|NCT00741520|Device|CPAP|Control - no treatment
46105105|NCT00741520|Device|CPAP|CPAP: The airway pressure will be determined by an overnight sleep study titration.
46105106|NCT00744562|Drug|OMP-21M18|0.5, 1, 2.5, 5, and 10 mg/kg weekly until day 56. If patient has not progressed may continue with original dose administered every other week until progression
45468141|NCT04959604|Procedure|ICG-marking endoscopically|Preoperatively the participants will receive an endoscopic marking at four points around the tumour with the fluorescent dye indocyanine green.
45468142|NCT03747497|Drug|contezolid acefosamil|IV and oral contezolid acefosamil given twice a day for 10 to 14 days
45468143|NCT03747497|Drug|linezolid 600 mg|IV and oral linezolid given twice a day for 10 to 14 days
45468144|NCT02521558|Behavioral|Intervention Group|The investigators are interested in how practicing memory tasks can improve memory in patients with MCI and with AD. Specifically, patients will perform a set of cognitive rehabilitation tasks designed to train memory in order to determine if these tasks are effective in improving memory or slowing the progression of Alzheimer's disease. Patients will practice memory tasks for about an hour daily, for a total duration of 6 months. A research assistant or clinician will conduct weekly check-ins with each participant assess whether or not participants in the Intervention Group exhibit weekly improvements and to determine if patients are regularly adhering to the tasks.
45598500|NCT02223533|Device|19Gx500-mm Pajunk InfiltraLong® catheter|Before completing the surgery, the surgical team inserted a 19Gx500-mm Pajunk InfiltraLong® catheter with multiple perforations in the last few centimeters before the tip to allow for local anesthetic administration.
45681217|NCT04747678|Drug|Ivermectin|retrograde study of common and rare adverse effects of multiple doses of ivermectin used during the coivd 19 pandemic in egypt
45681218|NCT04027972|Drug|Combination of Neostigmine and Glycopyrrolate|Intravenous or transdermal
46105107|NCT00690820|Drug|Pancrelipase Delayed Release|12,000 unit Capsules, dosed individually based on fat intake.
46105108|NCT00690820|Drug|Placebo Comparator|Placebo
46105109|NCT00741676|Procedure|laparoscopy-assisted distal gastrectomy|10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.Dissected stomach and lymph node are collected through additional 3~5 cm incision at the preexisting epigastric incision.Finally, Billroth II reconstruction is performed.
46105110|NCT00741676|Procedure|open distal gastrectomy|Approximately 15~20 cm length incision is made from falciform process to periumbilical area. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.
46105111|NCT02562508|Procedure|3 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
46105112|NCT02562508|Procedure|2 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
45598501|NCT02223533|Drug|morphine|After the intervention patients had access to intravenous morphine via a patient-controlled analgesia
45598502|NCT02231021|Drug|alogliptin|alogliptin 25 mg add-on background medication metformin
45681219|NCT04027972|Device|I-Box by Dynatronics|Electric field conducting drugs through the skin without compromising its integrity
45681220|NCT04028128|Dietary Supplement|Cocoa group|Athletes performed a training program and consumed 5 g of cocoa (425 mg of flavonoids) mixed with semi-skimmed fat milk, daily for 10 weeks.
46020777|NCT04203511|Drug|Etoposide|Etoposide administered intravenously every 3 weeks on Days 1-3 of each cycle with cisplatin for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
46020778|NCT04203511|Radiation|Radiotherapy|Total dose of 60 Gy ± 10% (54 to 66 Gy) in 2 Gy daily fractions.
46020779|NCT04308499|Behavioral|Digital cognitive-behavioral therapy for insomnia (dCBTI)|Internet-based cognitive-behavioral therapy for insomnia (CBT-I) structured into 6 weekly sessions accessed using either a computer or a smartphone
45468145|NCT02521558|Behavioral|Control Group|"The Control Group will not receive any cognitive rehabilitation tasks for a six month period. Instead, they will simply be given booklets of puzzles (e.g., word search, number puzzles, etc.) to work on for the duration of 6 months.~A research assistant or clinician will conduct weekly check-ins with each participant assess whether or not participants in the control group feel like they are benefiting from the puzzles.~Participants in the Control Group will be given a standard battery of neuropsychological tests prior to the the puzzles and after the puzzles to assess any changes in memory, language, attention, and executive functioning."
45468146|NCT03745703|Behavioral|MOCHA|(see above)
45468147|NCT04451824|Device|CL-100|Red Light LED device for circumferential reduction
45468148|NCT05179031|Dietary Supplement|First Reference product (dextrose, containing 25 g of carbohydrates)|Reference dextrose solution containing 25 g of available carbohydrates
46020780|NCT04308499|Behavioral|Sleep hygiene education (SHE)|Recognized and commonly prescribed set of sleep hygiene instructions comprised of comprise a website and a downloadable booklet
46020781|NCT04203121|Radiation|low dose whole brain radiation to treat Alzheimer disease|"subjects 1-5 : 9Gy in 5 daily fractions~subjects 6-10 : 5.4Gy in 3 daily fractions"
46105113|NCT02562352|Other|TAPER program|Patients will be randomized to receive the TAPER program at study start or delayed intervention at 6 months.
46105114|NCT00749086|Device|balloon kyphoplasty|Balloon Kyphoplasty, a variant of Vertebroplasty, in which a balloon is first placed into the fractured vertebra and inflated with fluid in order to create a cavity. Then, the balloon are deflated and removed. This may restore part of the vertebral height loss due to the fracture and facilitate the injection of the cement with low pressure.
46105115|NCT00749086|Procedure|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
45468149|NCT05179031|Dietary Supplement|Second Reference product (dextrose, containing 25 g of carbohydrates)|Reference dextrose solution containing 25 g of available carbohydrates
45468150|NCT05179031|Dietary Supplement|Third Reference product (dextrose, containing 25 g of carbohydrates)|Reference dextrose solution containing 25 g of available carbohydrates
45681221|NCT04028128|Dietary Supplement|Placebo group|The athletes performed the same training program of the cocoa group and they took for 10 weeks 5 g of maltodextrin mixed with semi-skimmed fat milk.
45838185|NCT04505410|Drug|Ustekinumab induction|Participant will be initiated with ustekinumab induction therapy as second line biologic therapy
46020782|NCT04687033|Device|Transcranial direct current stimulation|This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down-regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
46020783|NCT04299685|Other|Interview|Qualitative family interviews of 20 family units, or more until data saturation, of at least one parent and one adolescent (aged 10-19 year old) will be conducted based on deductive thematic approach. Each interview will last for about an hour, be conducted in Cantonese, and audio-taped for transcription in verbatim in Chinese.
46020784|NCT04297891|Other|Clinical rating scale to measure Ataxia disease severity and progression|SARA is a clinical scale developed by Schmitz-Hübsch et al which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.
45838186|NCT04505410|Drug|Infliximab induction|Participant will be initiated with infliximab induction therapy as second line biologic therapy
45838187|NCT04502563|Other|Remote monitoring and predictive analytics|Subjects will undergo remote monitoring, remote monitoring data will be analyzed on a predictive platform, alerts indicating HF worsening shared with treating team, and algorithmic response to alerts implements.
46020785|NCT04297891|Other|Clinical rating scale to measure spastic paraplegia disease severity and progression|A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.
46105116|NCT00749164|Procedure|MSC transplantation|1-2X10^6 MSC per kg
46105117|NCT00689338|Drug|Anidulafungin|Anidulafungin Intravenous Administration
46105118|NCT00689338|Drug|Fluconazole|Oral Administration of Fluconazole
45468151|NCT05179031|Dietary Supplement|High protein tube feed|Nutritional product containing 25 g of available carbohydrates
45468152|NCT05179031|Dietary Supplement|High-protein tube feed with additional amino acid|Nutritional product containing 25 g of available carbohydrates
45468153|NCT05179031|Dietary Supplement|Oral Nutritional Supplement for diabetes patients|Nutritional product containing 25 g of available carbohydrates
45468154|NCT05179031|Dietary Supplement|Oral Nutritional Supplement for diabetes patients (new formula)|Nutritional product containing 25 g of available carbohydrates
45468155|NCT05179031|Dietary Supplement|ONS for disease related malnutrition|Nutritional product containing 25 g of available carbohydrates
45468156|NCT05179031|Dietary Supplement|Plantbased ONS for disease related malnutrition|Nutritional product containing 25 g of available carbohydrates
46020786|NCT04297891|Other|Disease-specific severity index for adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)|"The DSI-ARSACS is a valid measure of disease severity for the adult ARSACS population that is able to distinguish between patients with different clinical profiles.~It considers the 3 components (pyramidal, cerebellar, neuropathic) of the disease, and documents its content validity, internal consistency, and construct validity."
45468157|NCT04452058|Other|Radiomic Algorithm|Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction
45468158|NCT01140269|Other|PCR test|PCR samples will test for Staphylococcus aureus (including MRSA) from wound swab and positive blood culture samples to augment treatment decisions. Serial PCR testing will follow after positive results to catalog pathogen loads over the course of treatment in a blinded fashion.
45468159|NCT03443050|Other|Unstable|This group will train over unstable surfaces to enhance balance abilities
46020787|NCT04297891|Diagnostic Test|Next-Gen Sequencing (NGS)|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
46105119|NCT00689338|Drug|Voriconazole|Oral Administration of Voriconazole
46105120|NCT00749242|Other|orthopedic brace|antalgic drugs and orthopedic brace
46105121|NCT00749242|Device|balloon kyphoplasty|introduction of balloon into the vertebral body, inflation of the balloon which creates a cavity, then balloon is deflated and removed , then introduction of the cement into the cavity.
46105122|NCT00686998|Drug|AZD2624|Oral Suspension
46105123|NCT00686998|Drug|Olanzapine|PO BID
46105124|NCT00686998|Drug|Placebo|
46105125|NCT00744640|Drug|gemcitabine, oxaliplatin, capecitabine|gemcitabine day 1 and 8, oxaliplatin day 1, capecitabine days 1-14, q3weeks
46105126|NCT00749320|Other|Arterial Spin Labeling Magnetic Resonance Imaging|ASL MRI performed at different time intervals on participants receiving sunitinib or pazopanib for treating RCC
46105127|NCT00848718|Drug|MK-2206|MK-2206 given by mouth (PO) on Days 1, 3, 5, and 7 of each 21-day cycle (30 mg, 45 mg, or 60 mg) OR MK-2206 PO on Day 1 of each 21-day cycle (60 mg, 90 mg, 135 mg, 200 mg , or 250 mg)
46105128|NCT00848718|Drug|docetaxel|Administered as an IV infusion on Day 1 of each 21-day cycle
46105129|NCT00848718|Drug|erlotinib|Administered daily (QD) PO in each 21-day cycle
46105130|NCT00848718|Drug|carboplatin|Administered as an intravenous (IV) infusion on Day 1 of every 21-day cycle
45468160|NCT03443050|Other|Stable|This group will train over stable surface to enhance balance abilities
45468161|NCT01142141|Other|manual therapy, kinesiotherapy|
45468162|NCT01235429|Behavioral|Partners in Care|Participants will be offered 12 group diabetes self-management educational lessons delivered by trained community health workers.
46105131|NCT00848718|Drug|paclitaxel|Administered as an intravenous (IV) infusion on Day 1 of every 21-day cycle
46105132|NCT00848718|Drug|corticosteroid|Administered PO twice a day (BID) on Days 1-3 of each 21-day cycle
46105133|NCT02612844|Drug|NNC0143-0406|Subject will receive one single dose only Subcutanesously (s.c., under the skin)
46105134|NCT02612844|Drug|insulin aspart|Subject will receive one single dose only. Subcutanesously (s.c., under the skin)
45468163|NCT01235429|Behavioral|Partners in Care|Diabetes self-management education
45468164|NCT03740867|Other|Pulmonary rehabilitation|Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components.
45468165|NCT03442660|Other|Data collection|Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional diagnostic or treatment procedures will be required. Subjects will be asked to complete electronic (or on paper when it's not possible to use electronic version) questionnaires.
45468166|NCT04226807|Other|Early Postpartum Phone Call|Participants receive a phone call 2-3 weeks after birth asking about overall wellbeing, screening for complications and postpartum depression and referring to lactation or WIC as needed.
45468167|NCT03109600|Biological|Vi-DT (Bio Farma)|Typhoid Conjugate Vaccine
45468168|NCT03109600|Biological|Vi polysaccharide vaccine|Vi polysaccharide vaccine
45468169|NCT03109600|Biological|Influenzae vaccine|1 dose of Influenzae vaccine
45468170|NCT03109600|Biological|Pneumococcal conjugate vaccine|1 dose of Pneumococcal conjugate Vaccine
45468171|NCT01142921|Device|Anti-reflux Tannenbaum biliary stent|Anti-reflux Tannenbaum biliary stent
45468172|NCT01142921|Device|Ordinary Tannenbaum biliary stent|Ordinary Tannenbaum biliary stent
45468173|NCT03442348|Dietary Supplement|Omega 3 fatty acid|Participants in the bottom median of dietary fibre intake (<15 g per day) will be randomised into one of two arms. Participants in the second arm (N>32) will be required to take one 500mg capsule of Omega 3 along with a meal daily for 6 weeks.
45598503|NCT02231021|Drug|Pioglitazone|pioglitazone 30 mg add-on background medication metformin
45598504|NCT02231021|Drug|alogliptin + pioglitazone|alogliptin 25 mg and pioglitazone 30 mg add-on background medication metformin
45598505|NCT02295241|Other|No intervention|This is an observational trial, no interventions are being used.
45468174|NCT03442348|Dietary Supplement|Inulin fibre|The participants in the control arm (N>32) will be asked to take 20 g of fibre (resistant starch + inulin) per day that are known favour production of SCFAs in the colon for a period of 6 weeks. The inulin powder will be provided in pre-weighed sachets containing 10g each which can be taken mixed in water or a suitable beverage of choice taken twice (morning and evening) per day.
45681222|NCT04027660|Device|Immediate Zirconia Dental Implant|"For the Exposed Group the Intervention will be the following~The Surgical procedure will envolve :~Administration of Articain 1:200.000~No flap procedure~Place a Zirconia Implant on the alveolar post extraction socket~Place xenograft biomaterial in the jumping gap~Place a provisional crown/individualized healing abutment~The Prosthodontic procedure will evolve:~Final Impression with a IOS~Placement of the Final Crown~3 month post crown post op~3 IOS will be made for volumetric evaluation :~before tooth extraction~3 month of Osseointegration for final impression~3 month after final crown is placed~Final STL evaluation will be performed on a specialized software for volumetric measurements"
46020788|NCT04280497|Drug|Administration procedures|"Hydrocortisone hemisuccinate / hydrocortisone placebo will be given as 50 mg intravenous bolus every 6 hours;~9 alpha fludrocortisone / 9 alpha fludrocortisone placebo will be given as a 50 μg tablet via a nasogastric tube once per day in the morning.~Study drugs will be started immediately after randomization (day 0 of the study), until discharge from ICU for a maximal duration of 7 days. Study drugs will be stopped without tapering off."
46020789|NCT03690037|Drug|Tranexamic Acid 100 MG/ML|Tranexamic Acid: 100 MG/ML Solution for injection
46105135|NCT00883337|Drug|Interferon β-1a|"Sterile preservative-free solution packaged in graduated pre-filled syringes~Subcutaneous injection~Ascending doses from 8.8 to 44 mcg according to local standard for Rebif®"
45838188|NCT04502563|Other|Sham comparator|Subjects will wear a sensor, but data from the sensor will not generate alerts and will not be shared with the treating team.
46105136|NCT00883337|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
45838189|NCT04477304|Behavioral|Opioid Naive, OR|Visits where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days and clinician is on the clinic list as a treating member of the clinic
46105137|NCT00838110|Drug|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 26
46105138|NCT00838110|Drug|Placebo|10 mg TID for week 1 followed by 20 mg TID through Week 26
46105139|NCT00838110|Drug|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 12
46105140|NCT00838110|Drug|Placebo|20 mg matched Placebo (Cohort 2) 10 mg TID for week 1 followed by 20 mg TID through Week 12
46105141|NCT04163783|Drug|[14C]-BGB-3111|20-mg capsule containing ~200 μCi of [14C]-BGB-3111,
45468175|NCT01142219|Drug|L-arginine|L-arginine was administered orally at a dose of 0.1g/kg/day during 6 months.
45838190|NCT04477304|Behavioral|At-risk for long-term use, OR|Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days and clinician is on the clinic list as a treating member of the clinic
45838191|NCT04477304|Behavioral|Long-term opioid recipient|Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days and clinician is on the clinic list as a treating member of the clinic
46020790|NCT03690037|Drug|Tranexamic Acid 500 MG|Tranexamic Acid: Tranexamic Acid 500mg Tablets
46020791|NCT00910273|Drug|etanercept|etanercept 50 mg/week
46105142|NCT04163783|Drug|BGB-3111|Three 20-mg capsules of BGB-3111 and three 80-mg capsules of BGB-3111
46105143|NCT00654485|Drug|Rosuvastatin|
46105144|NCT00654485|Drug|Atorvastatin|
46105145|NCT00655343|Drug|ATG-Fresenius S|"20 mg rabbit immunoglobulin (IgG) in 1 ml of sterile solution~20 mg/kg body weight per day diluted in 500 ml physiological saline, slow intravenous infusion at days -3, -2, -1 prior to transplantation"
46105146|NCT04162379|Drug|Oral tablet|Patients will be allocated as single group and will take oral prednisolone (sulopride10 mg) single dose every two days for 4 successive weeks then the next two weeks as washout period (stop dosing gradually by taking 5 mgs for 3 successive dosing every 2nd day over a week, then stop the oral steroid drug totally over the 2nd week of the washout period. The second period of the study will start by taking the oral prednisolone (sulopride10 mg) every fourth day for the next 4 weeks after which the patient will get another washout two weeks period (stop dosing gradually 5 mg for 3 successive dosing every 4th day then stop the drug totally).
46105147|NCT02637791|Device|Virtual glove|The intervention (the virtual glove) consists of a hand-mounted power unit, with four infra- red light emitting diodes (LEDs) mounted on the user's finger tips. The LEDs are tracked using one or two Nintendo Wii motes mounted by the computer screen on which the games are displayed to translate the location of the user's hand, fingers and thumb in 3D space. Three games have been produced especially for the project with the help of therapists and stroke patients. In order to play them, users have to perform the movements of reach to grasp, grasp and release, pronation and supination that are necessary to effect many activities of daily living.
46105148|NCT02637635|Procedure|Autologous fat transplantation|100 ml of autologous fat will be injected to the reconstruction area 3 month prior the breast reconstruction with expander prosthesis.
45468176|NCT01142219|Drug|Placebo|Mannitol was administered orally at a dose of 01 g/kg/day for six months.
45838192|NCT04462458|Device|Medacta Anatomic Ribbon Surgery (M-ARS ACL)|M-ARS ACL allows to reconstruct the anterior cruciate ligament using the Anatomic Ribbon Technique
45468177|NCT03442270|Other|No Intervention|This is an observational study, so standard of care will be followed.
45468178|NCT01142999|Drug|Sunflower oil|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
45468179|NCT01142999|Drug|Control group|This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.
45468180|NCT01142999|Drug|Aquaphor ointment|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
45468181|NCT01142999|Drug|Cetaphil cream|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
45468182|NCT03441802|Other|High quality extra virgin olive oil|Cases and controls were given 40 g/die high quality extra virgin olive oil
45468183|NCT02943447|Drug|Cilofexor|Tablet(s) administered orally once daily, with food
45468184|NCT02943447|Drug|Placebo to match cilofexor|Tablet(s) administered orally once daily, with food
45468185|NCT03679013|Drug|Oral Gabapentin and Intravenous Acetaminophen (IV APAP)|Scheduled multimodal pain regimen consisting of oral Gabapentin paired with intravenous Acetaminophen following cardiopulmonary bypass surgery.
45468186|NCT03679013|Drug|Opiate based pain regimen.|Standard of care opiate based pain regimen.
46020792|NCT04156087|Drug|Durvalumab 50 MG/ML|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
46105149|NCT02637635|Procedure|Expander prosthesis|breast reconstruction with expander prosthesis.
46105150|NCT00837876|Drug|Sorafenib|400 mg taken by mouth 1 time per day.
46105151|NCT00837876|Drug|Erlotinb|150 mg taken by mouth 1 time per day.
45468188|NCT01140425|Drug|PF-00232798|600 mg oral solution once daily x 7 days
45468189|NCT01140425|Drug|PF-00232798|300 mg oral solution once daily x 7 days
45468190|NCT01140425|Drug|Placebo|Oral solution once daily x 7 days
45468191|NCT01140425|Drug|Moxifloxacin|400 mg tablet single dose
45468192|NCT04111497|Drug|Glasdegib|Given PO
45468193|NCT04884412|Procedure|Surgery under general anesthesia with experimental targeting|Surgery will be performed under general anesthesia. The electrodes will be inserted directly on the targets without MER, with PARKEO_2 targets provided by the Bordeaux University Hospital, based on the machine-learning model developed in Bordeaux.
45681223|NCT04194112|Diagnostic Test|immediate urine cytology|Forty-eight hours after primary TURBT, IUC was retrieved and patients were scheduled for repeat TURBT 2 to 6 weeks later according to the predetermined protocol. The primary outcome was to determine the role of positive IUC to predict positive biopsy findings on repeat TURBT.
45838193|NCT04454645|Behavioral|mABC|Intervention targets parenting sensitivity and nurturance.
45838194|NCT04454645|Behavioral|mDEF|Intervention targets parenting enhancing infant cognitive development
46105152|NCT00655421|Other|Unaided Visual Inspection|Simple unaided visual inspection of the oral cavity with a bright white light source by trained Primary Health Care Worker
46105153|NCT00655421|Device|VelScope|Examination of the oral cavity through a VelScope by trained Primary Health Care Worker
46105154|NCT00655421|Other|Toluidine Blue Assisted Oral Examination|Examination of the oral cavity after the local application of Toluidine Blue dye by trained Primary Health Care Worker
45468194|NCT04884412|Procedure|Usual Surgery|In the control group, surgery will be performed as usual in each centre under local or general anaesthesia. This group represents the current state of the art of deep brain stimulation in these centres.
45468195|NCT04890275|Other|Blood flow restricted resistance exercise (BFR)|Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg inflated to 50% limb occlusion following standard BFR guidelines. Participants will then perform leg press including 1 set of 30 reps, then 3 sets of 15 reps at 20% 1RM. Rest for 5 minutes without cuff inflation. Cuffs will be re inflated and participants will perform knee extension including 3 x 15 repetitions at 20% 1RM.
45468196|NCT04890275|Other|Resistance exercise without blood flow restricted (NON-BFR)|Participants will follow the same exercise protocol as the blood flow restriction group but with out BFR.
45468197|NCT03441724|Diagnostic Test|Mechanocardiography|Mechanocardiographic recording
45468198|NCT01235663|Behavioral|advisory support|regular advisory support to the prolong breast-feeding period
45468199|NCT02844777|Drug|Placebo|200 mg applied once-daily for 28 days
45468200|NCT02844777|Drug|5% VDA-1102|200 mg applied once-daily for 28 days
46105155|NCT00911027|Drug|Contrast-enhanced ultrasound guided biopsy|"One to two bolus (each 2.4mL) of SonoVue per patient in the optimization part~One to four bolus (each 2.4mL) of SonoVue per patient in the main part"
45468201|NCT02844777|Drug|10% VDA-1102|200 mg applied once-daily for 28 days
45468202|NCT01236443|Drug|HPPH|3 mg/m2 IV
46020793|NCT04156087|Drug|Tremelimumab|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
45468203|NCT03441568|Device|Modified Diprobase formulation (BAY987534)|The modified Diprobase formulation will be applied topically twice daily over 14 days on the whole body and face.
45468204|NCT04003142|Drug|Fezolinetant|Oral tablet
45468205|NCT04003142|Drug|placebo|Oral Tablet
45468206|NCT03991013|Drug|Dolutegravir 50 mg|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a lead-in supplementary dose of 50 mg dolutegravir taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
45681224|NCT04191928|Drug|Apixaban|Apixaban is an orally administered highly selective factor Xa inhibitor, belonging to the class of direct-acting oral anticoagulants (DOAC) along with rivaroxoban and edoxaban. Factor Xa is an essential mediator of the clotting pathway in humans. Apixaban is currently approved by the FDA for treatment of VTE, prophylaxis of DVT in patients undergoing knee and hip replacement surgeries and for reducing the risk of embolic stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
45681225|NCT04193332|Device|NIR optical imaging camera|NIR optical imaging assisted identification of parathyroid glands during thyroid surgery using parathyroid gland autofluorescense
46020794|NCT04156087|Drug|Gemcitabine|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
46020795|NCT04156087|Procedure|Minimally Invasive Surgical Microwave Ablation (MIS-MWA)|Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab
46020796|NCT04202653|Drug|ETV|entecavir 0.5 mg qd
46020797|NCT04202653|Drug|TQ-A3334|TQ-A3334 po qw
46020798|NCT04202653|Drug|TQ-B2450|TQ-B2450 q3w iv
46020799|NCT04202731|Behavioral|PBS Study|Sleep extension intervention
46105156|NCT00911027|Procedure|ultrasound guided systematic biopsy|Current practice of ultrasound guided systematic biopsy
45468207|NCT03991013|Drug|Placebo|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a matching placebo taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
45468208|NCT03441490|Behavioral|Guided-ICBT for adolescents with anxiety|Internet-based cognitive behavioural therapy with therapeutic guidance through mail, 8 weeks.
45468209|NCT03441490|Behavioral|Guided-ICBT with chat|Internet-based cognitive behavioural therapy with therapeutic guidance through chat, 8 weeks.
45468210|NCT03441490|Behavioral|Guided-ICBT with learning support|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through mail, 8 weeks.
45468211|NCT03441490|Behavioral|Guided-ICBT with learning support and chat|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through chat, 8 weeks.
45468212|NCT03620877|Behavioral|Personalized intervention|Personalized intervention by a preventive nurse, relying on validated prevention models, in improving participation in the colonoscopic screening of siblings
45468213|NCT03966833|Behavioral|IPT-G|14 weeks of group-based interpersonal therapy (IPT-G)
45468214|NCT03966833|Behavioral|Unconditional Cash Transfer|Lump sum cash transfer
46105157|NCT00707070|Drug|efalizumab plus placebo|1 mg/kg/week subcutaneous for 24 weeks
46105158|NCT00707070|Drug|efalizumab plus acitretin|1 mg/Kg/week for 24 weeks plus oral acitretin 0.4 mg/kg/day
46105159|NCT02637713|Device|Stretta|Stretta is an FDA approved device that delivers Radiofrequency energy delivery to the lower esophageal sphincter. It is approved for the management of GRED.
45838195|NCT04448249|Behavioral|APN intervention|"APN intervention is divided into five main steps:~clinical and paraclinical examinations,~appraisal of patient's knowledge,~health education on hypertension and treatments,~setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary,~decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
45838196|NCT04438161|Behavioral|PERCCS: Personalized Education Regarding Clinical and Community Supports|A brief follow-up to the screening provided to 50% of the consented families (randomly assigned) that links their specific familial risks to community interventions.
46020800|NCT00910039|Drug|sunitinib malate|Treatment will be administered on an outpatient basis. Patients will receive sunitinib 37.5mg once daily in the morning without regard to meals in repeated 6-week cycles comprising daily therapy for 4 weeks followed by a 2-week rest period. Patients who tolerate this dose may increase the dose to 50 mg once daily.
46020801|NCT00910039|Other|cognitive assessment|The memory test has six alternate forms. The other tests measure motor and information processing speed and are relatively resistant to the effects of practice. The total time for test administration, including the QOL and symptom measures, is 40 minutes.The difference between the pre-treatment baseline and follow-up assessment scores will be determined by the reliable change (RC) index. This index is derived from the standard error of measurement (SEM) for each test in the battery: 1 (deterioration), 2 (no change), or and 3 (improved).
46105160|NCT02637713|Procedure|Radiofrequency (RF) Energy to the LES (Stretta Procedure)|The Stretta procedure is performed endoscopically under moderate sedation or general anesthesia which uses radiofrequency (RF) energy applied to the lower esophagus over 14 minutes per FDA approved procedures.
46105161|NCT04115670|Behavioral|Group of educational intervention on the neurophysiology of pain and physical exercises|"The physiotherapist of the institution will execute the intervention on the group:~3 first pedagogical sessions on the neurophysiology of pain, distributed: 1 group session, 1 individual session at home, 1 in a personal interview format. These 3 sessions will last 2 weeks to be completed.~Afterward, the protocol of physical exercise training will begin, supervised by the same physiotherapist who carried out the three initial sessions. There will be 15 sessions of specific and individualized physical exercise, in small groups of maximum 5 people. The duration of this part will be 10 weeks, so that from week 1 to 5 is 2 times per week, and from week 6 to 10 just 1 time per week."
45681226|NCT04193722|Drug|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy in a multiperson hyperbaric oxygen chamber. Standard hyperbaric oxygen therapy provided as reimbursed by insurers.
45681227|NCT04193800|Other|10-week rotation in primary care setting|Ten paramedics underwent a 10 week rotation into a GP practice in the Leeds area of South Yorkshire, England.
45681228|NCT02080312|Drug|Magnevist (gadopentetate dimeglumine)|
45468215|NCT02521402|Biological|Biovance|decellularized, dehydrated human amniotic membrane
45468216|NCT01236599|Other|Polyethylene for thermoregulation in the preterm infant|3 groups with 30 preterm infants (PI) each one: 1) PI under radiant warmer, drying, wrapped in sterile field preheated (traditional care), 2) PI under radiant warmer, wrapped in polyethylene bag after drying, with their naked face and access to umbilical catheters or venous access, and 3) PI under radiant warmer, without drying, wrapped in polyethylene bag, with their naked face and access to umbilical catheters or venous access. Body temperature (BT) and incubator temperature (IT) were measured every 15 minutes from birth until 120 minutes of extra uterine life.
46020802|NCT03667573|Device|tsDCS Dosage (A)|mild electrical stimulation delivered to lumbosacral spinal cord
46020803|NCT03667573|Device|tsDCS Dosage (B)|mild electrical stimulation delivered to lumbosacral spinal cord
46020804|NCT03667573|Other|textured shoe insoles|textured shoe insoles
46105162|NCT04115670|Behavioral|Control group|The control group will follow its normal course of activity
46105163|NCT02638727|Drug|L-Citrulline|This group treat with L-Citrulline (3 grams per day)
46105164|NCT02638727|Drug|placebo|This group treat with placebo dayley
46105165|NCT00686920|Drug|Rifaximin|Oral
46105166|NCT02562118|Drug|Lenvatinib + Letrozole|Single agent lenvatinib daily continuously x 2 weeks, followed by letrozole 2.5mg daily + lenvatinib x 12 weeks. Lumpectomy or mastectomy should be considered after completing 14 weeks of pre-operative lenvatinib + letrozole for curative intent in non-metastatic patients and for local control for patients with metastatic disease. If surgery is planned, it should preferably be performed within 2-12 weeks after completing neoadjuvant endocrine therapy, and after toxicities (if any) from the neoadjuvant endocrine therapy have resolved. If the patient is deemed inoperable after 14 weeks of lenvatinib + letrozole, a final biopsy will be obtained, and the patient discontinued from the study and treated as per standard clinical practice by the treating physician.
46105167|NCT00741754|Other|Mouthrinse with HcT20|Mouthrinse for 1 minute with 10ml, twice a day. During seven weeks
45468217|NCT03441412|Drug|Ticagrelor 90mg|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
45681229|NCT04027582|Other|didactic teaching and simulator practice|the trainee will undergo didactic teaching on fiber-optic intubation followed by hands on practice on their assigned simulator
46020805|NCT00632437|Procedure|Speckle-Contrast Imaging|Imaging camera scan that uses reflected red light to take pictures of the amount of blood flowing in brain and the amount of oxygen in blood.
46020806|NCT00909181|Drug|Oxybutynin|"Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"
46020807|NCT00909181|Drug|Placebo|"Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"
46020808|NCT02691169|Drug|18F-DCFPyL|18F-DCFPyL is a sterile diagnostic radiopharmaceutical used for PET imaging.
46020809|NCT04270123|Other|EORTC QLQ-BR45 questionnaire|The EORTC QLQ-BR23 questionnaire has been updated with a further twenty-two items to create the EORTC QLQ-BR45. This updated questionnaire contains items to encapsulate advancements in knowledge about the epidemiology of breast cancer and side effects experienced with new treatments. This study will test the psychometric properties of the EORTC QLQ-BR45 as a measure of quality of life in patients with breast cancer.
46020810|NCT05579665|Biological|Platelet-rich Plasma|Research participants own blood will be used to prepare the platelet rich plasma injectate.
46105168|NCT00741832|Device|Conical Positive Expiratory Pressure Device (C-PEP)|"Conical positive expiratory pressure device (C-PEP) in this study was designed on the principle of expiratory flow retardation. The principle occurs when exhaling through a small tube diameter, i.e. a small straw, pursed lip breathing, or positive expiratory pressure. Expiratory retardation, results from a decrease in tube diameter, creates flow resistance during exhalation. With flow resistance, the greater the flow the greater the back pressure, and the less the flow the lower the pressure. Expiratory retardation was applied in an attempt to facilitate exhalation and to relieve the air trapping.~The optimal design was found to be: cone shape, proximal diameter is 2.0 cm, distal diameter is 0.6 cm, and length is 2.5 cm.~Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing with the C-PEP device."
46105169|NCT00741832|Other|Control breathing|Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing normally.
46105170|NCT00744718|Drug|Bevacizumab|Bevacizumab 10 mg/kg every 3 weeks
46105171|NCT00744718|Drug|Carboplatin|Carboplatin AUC 5 every 5 weeks
46105172|NCT00741910|Drug|Semapimod|semapimod IV 60 mg x 3 days q 6 - 10 weeks
46105173|NCT00845832|Drug|Placebo|iv on days 1 and 15 (Parts 1 and 2)
46105174|NCT00845832|Drug|rituximab [MabThera/Rituxan]|0.5g iv on days 1 and 15 (Parts 1 and 2)
46105175|NCT00845832|Drug|tocilizumab [RoActemra/Actemra]|2mg/kg-8mg/kg iv in Part 1 and selected dose in Part 2, on weeks 4, 8 and 12---Arm 1\n8mg/kg iv on weeks 4,8 and 12 (Parts 1 and 2)--- Arm 2
46105176|NCT02562274|Dietary Supplement|Placebo|Subjects are received placebo treatments once daily for 8 weeks
46105177|NCT02562274|Dietary Supplement|MP 50 mg/day|Subjects are received MP 50 mg/day treatments once daily for 8 weeks
45681230|NCT04199884|Behavioral|Active IU-focused Psychoeducation Intervention|This paradigm was an IU-focused psychoeducation intervention wherein participants were provided psychoeducation about the nature of IU and anxiety, given strategies to cope with fear of uncertainty, and provided examples and information as to how they can expose themselves to uncertainty.
46020811|NCT05579665|Biological|Conditioned Medium From Umbilical Cord Mesenchymal Stem Cell Culture (MSCs) Secretome|Conditioned Medium UC-MSCs Secretome which will be injected into the affected knee using ultrasound guidance.
45468218|NCT03441412|Drug|Epinephrine|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
45468219|NCT03441412|Drug|Metoprolol|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
45468220|NCT05275959|Other|Multidimensional non-drug instrumental intervention|"The intervention group adopted an intervention strategy based on the RE-AIM framework with 22510S as the core.~22510S is a set of intervention strategies where 2 is 2 hours or more of outdoor physical activity per day for school-aged children, of which 1 hour should be moderate-to-vigorous physical activity; 2 is no more than 2 hours per day of television viewing or screen-based electronics use. 5, school-age children should eat 5 portions of vegetables and fruit the size of an adult's fist, about 300 to 500 grams of cooked or chopped raw vegetable leaves and about 200 to 400 grams of fruit per day; 1, 1 portion of meat per day, equivalent to 1 adult hand The 1 is to eat one portion of meat per day, the size and thickness of one adult hand, about 80 to 110 grams; the 0 is to not drink sugary drinks; and the S is for school-age children to get a reasonable amount of sleep each day."
45468221|NCT01235819|Drug|Insulin|Exenatide Sitagliptin
46020812|NCT05579665|Drug|Low Molecular Weight Hyaluronic Acid|low molecular weight hyaluronic acid which will be injected into the affected knee using ultrasound guidance.
46105178|NCT02562274|Dietary Supplement|MP 1500 mg/day|Subjects are received MP 1500 mg/day treatments once daily for 8 weeks
46105179|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 placebo
46105180|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 200 mg
46105181|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 placebo
45468222|NCT01235819|Drug|Sitagliptin|Sitagliptin 100 mg per day oral
46105182|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 80/CoQ10 100 mg
46105183|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 100 mg
46105184|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 80 /CoQ10 200 mg
46105185|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 200 mg
46105186|NCT02562196|Device|tdcs|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
45468223|NCT01235819|Drug|Exenatide|Exenatide 10 micrograms daily twice
45468224|NCT05275569|Procedure|True acupuncture + standard antiemetic treatment|"Participants will receive electroacupuncture once daily from day 1 to day 4. The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz. They will receive fosaprepitant 150 mg intravenous IV + palonosetron 0.25 mg IV + dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy."
45468225|NCT05275569|Procedure|Sham acupuncture + standard antiemetic treatment|"The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid de qi sensation. They will receive fosaprepitant 150 mg intravenous IV + palonosetron 0.25 mg IV + dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post-chemotherapy(the antiemetic drugs are the same as the true acupuncture group)."
46020813|NCT03944161|Dietary Supplement|Oral nutrition supplement|Hypercaloric and high protein supplement
46020814|NCT03944161|Other|Nutritional advice|Advice given by the clinician
46020815|NCT04268797|Device|HR rTMS|high frequency repetitive transcranial magnetic stimulation (HF rTMS) with H7-coil applied once daily during the twenty days
46020816|NCT04268797|Device|sham|SHAM HF rTMS coil once daily x 20 days
46020817|NCT01286987|Drug|Talazoparib|Oral capsule with multiple dosage forms given once daily
45468226|NCT03954431|Diagnostic Test|Contrast-media enhanced breast CT(CE-BCT)|The breast CT device will take multiple pictures of the subject's breast and create a 3-D image of the breast.
45468227|NCT03954431|Drug|Iodinated Contrast Agent|The CE-BCT diagnostic test will use an iodinated contrast agent. This drug is FDA approved for contrast-enhanced x-ray imaging examinations, though not specifically for dedicated breast computed tomography.
45468228|NCT05272527|Behavioral|Transition to Motherhood Program|Transition to Motherhood program includes 5 sessions. The first session covers the pregnancy process, the second session deals with the birth process, the third session deals with the postpartum period, the fourth session deals with infant care, and the fifth session deals with breast milk and breastfeeding and immunity. Trainings are online. In addition to the lecture technique, the training includes auxiliary techniques such as models, videos, case studies, training cards, and applied demonstrations. The program was completed by telephone follow-up in the first and fourth weeks postpartum.
45468229|NCT04867096|Other|Physical activity|Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
45468230|NCT01234415|Device|Rhinoplasty|Rhinoplasty is performed under general anaesthesia; the duration is 1 to 2 hours. The surgical approach for implantation of the biomaterial is external rhinoplasty. The incision is made at the columella (base of nose) and becomes internal for the scar to be as unobtrusive as possible. The septum skeleton is then destroyed in order to place the synthetic biomaterial. The biomaterial is remodelled in order to have a natural external aspect of the nose. The incision is closed and the wicks are put in place in the nose for 4 days. A cast and a sticker will be put in place after surgery to maintain properly the biomaterial.
45468231|NCT04743609|Diagnostic Test|nasopharyngeal samples|rapid antigen test for Sars Cov-2, influenza and RSV. multiplex RT-PCR for a subgroup of 500 patients
45468232|NCT03441256|Device|LION procedure|Laparoscopic implantation of an impulse generator and four leads for electrical stimulation of femoral and sciatic nerves.
46020818|NCT05598671|Procedure|PCNL without reverse insertion of a ureteral catheter|The ureteral catheter was not retrograde inserted during PCNL
46105187|NCT00591864|Device|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
46105188|NCT00885755|Drug|Standard taxane therapy|As prescribed
46105189|NCT00885755|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3-week cycle (only in patients who have progressed)
46105190|NCT00885755|Drug|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, and 6mg/kg iv on day 1 of each subsequent cycle
46105191|NCT00749554|Device|Disc biacuplasty|The lesion duration will be 15 minutes with a ramp rate of 2°C per minute and a peak set temperature of 45°C (Temperature in posterior annulus of disc reaches 65°C).
45468233|NCT03441256|Device|NMES|Conventional neuromuscular electrical stimulation via surface electrodes.
45468234|NCT01234493|Procedure|fixation|Syndesmosis fixation with one 3.5mm fully threaded three cortical screw
45468235|NCT01234493|Procedure|no fixation|No syndesmosis fixation.
45468236|NCT04599933|Drug|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
45468237|NCT04599933|Drug|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
46020819|NCT01286753|Drug|Vemurafenib|Vemurafenib 960 mg orally twice daily.
46020820|NCT01286129|Procedure|Nasal allergen challenge|Allergen sprayed into nostrils. Allergen used will be house dust mite or cat allergen. Allergens will be given in increasing ten-fold dilutions until a positive response occurs.
46020821|NCT05590013|Drug|Pectointercostal and ESP block|Pectointercostal plane block will apply at the 4-5. intercostal space and ESP block will apply athe T6 level bilaterally
46020822|NCT05589389|Other|High Healthy Eating Index Diet with Minimally Processed Meat|Participants will consume a diet with a high Healthy Eating Index along with meat that is minimally processed.
46020823|NCT05589389|Other|High Healthy Eating Index Diet with Further Processed Meat|Participants will consume a diet with a high Healthy Eating Index along with meat that is further processed.
45468238|NCT03441022|Device|Amiigo Watch Only|Subjects will be asked to wear a wrist band with capabilities to detect their heart rate or rhythm on the basis of PPG on either wrist around the time of their cardioversion procedure. Data will be acquired from the wrist band at the same time as the electrocardiogram (ECG) monitor to which subjects are hooked up for the purposes of the cardioversion.
45468239|NCT03441022|Device|Amiigo Watch + BodyGuardian|Subjects will be sent home after the cardioversion with a 30 day heart monitor called the BodyGuardian. This device continuously monitors their heart rate and rhythm and they will wear this on the chest. Subjects will also wear the wrist monitor over the same 30 day period.
45468240|NCT03564197|Other|18F-PD-L1|18F-PD-L1 PET/CT scan
45468241|NCT03638115|Device|VaSecure™|Drug Coated PTA Balloon Catheter
45468242|NCT03440788|Drug|Brentuximab Vedotin|Brentuximab vedotin (BV) will be prescribed to patients in accordance with indication for treatment as second or subsequent line therapy after failure of at least one type of first-line therapy for patients with relapsed or refractory HL who are not candidates for ASCT, or for patients with relapse after ASCT within routine hematological practice. Dose, preparation, administration etc - as in Instruction for use (Prescribing information).
45468243|NCT03620799|Procedure|Manual therapy|A manual intervention technique is employed to the intervention group based on a roller treatment.
45468244|NCT03440710|Procedure|BET|Balloon Eustachian Tuboplasty
46020824|NCT05589389|Other|Typical Healthy Eating Index Diet with Minimally Processed Meat|Participants will consume a diet with a typical Healthy Eating Index along with meat that is minimally processed.
45468245|NCT03942536|Other|Focus Group Discussion|At 12-month follow-up, a purposeful, convenience sample of study participants and their significant others, Community Health Workers trained as Health Navigators, and local program staff, will be invited by research staff to participate in focus group discussions to collect qualitative data on pregnancy care, experience of navigating obstetrical emergencies, financial hardships, and Health Navigation program feasibility/acceptability. Particular attention will be paid to recruiting study subjects involved in complex obstetrical emergencies, cases that involved significant delays in transfer of care, cases resulting in significant morbidity/mortality, as well as cases that involved efficient/successful care coordination, referral, and transportation.
45468246|NCT03128788|Procedure|thoracic epidural catheterization|thoracic epidural catheterization thoracic epidural catheterization for the management of postoperative pain
45468247|NCT01380860|Procedure|Colostomy with mesh implantation|Colostomy with mesh implantation
45468248|NCT01380860|Procedure|Simple colostomy|Colostomy with no mesh implantation.
45468249|NCT03440632|Device|FES|Functional electrical stimulation of the ankle dorsiflexors during walking, using a (superficial) neurostimulator with tilt sensor.
45468250|NCT02612337|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
45468251|NCT02612337|Drug|Placebo|Single intratympanic injection of placebo
45468252|NCT03440554|Diagnostic Test|Whole Body Non-Contrast MRI|Whole Body Non-Contrast MRI in Prostate Cancer Patients
45681231|NCT04199884|Behavioral|Health-focused Psychoeducation Intervention|This intervention is a health-focused psychoeducation intervention wherein participants learn ways to engage in healthy behaviors, such as getting adequate sleep, eating healthier, and exercising regularly.
45681232|NCT03969706|Drug|Abemaciclib 200 MG|Subjects will be treated with abemaciclib 200mg by mouth once every 12 hours. Dosing will be continuous and administered on a 28-day cycle
45681233|NCT04199806|Other|Questionnaire review|Review data from questionnaires received about MMS experience.
46020825|NCT05589389|Other|Typical Healthy Eating Index Diet with Further Processed Meat|Participants will consume a diet with a typical Healthy Eating Index along with meat that is further processed.
46020826|NCT05570123|Dietary Supplement|Flexofytol Forte|Bioactive extract of Curcuma longa and Boswellia serrata. 2 tablets a day, one in the morning, one in the evening
46020827|NCT05570123|Dietary Supplement|Placebo|2 tablets a day, one in the morning, one in the evening
45681234|NCT04027504|Dietary Supplement|Fitabisc|Biscuits containing antioxidants
45681235|NCT04027738|Other|PRP|The patients received a single 3-ml injection of PRP. Approximately 10-mL of venous blood was drawn from each patient and centrifuged using an Arthrex autologous conditioned plasma (ACP) kit (a low-leukocyte ACP system), spun at a speed of 1500 rpm for 5 minutes. The platelet concentration obtained was approximately 2-3 times greater than the baseline platelet concentration.
45681236|NCT03964792|Genetic|DREPAGLOBE drug product|Each patient will receive a single IV infusion of DREPAGLOBE drug product
46020828|NCT05566925|Other|Direct access to physiotherapist for assessment, diagnosis and treatment.|Patients with knee osteoarthritis will be interviewed about their experience of being assessed, diagnosed and treated by a physiotherapist first in primary care.
46020829|NCT01285349|Behavioral|Couple HIV/STI prevention intervention|
46020830|NCT01285349|Behavioral|Couple-based HIV/STI prevention|
46020831|NCT01285349|Behavioral|Individual HIV/STI prevention|
46020832|NCT01285349|Behavioral|Couple Wellness Promotion|
46020833|NCT01284959|Drug|risperidone|risperidone 3mg, PO, 3 times
46020834|NCT01284959|Drug|paliperidone ER|paliperidone ER 6mg, PO,3 times
46020835|NCT01284959|Drug|placebo|lactose PO, 3times
46020836|NCT01284491|Device|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
45468253|NCT05418998|Behavioral|Executive function (EF) training|EF training will involve at-home computer- or tablet based training to improve several EF processes, including divided attention, response inhibition, switching, and working memory updating. Training session duration = 30 min x 3 session/week.
45468254|NCT02824575|Drug|Rebastinib|50 mg or 100 mg po BID continuously. Cycle duration: 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
45468255|NCT02824575|Drug|Paclitaxel|Paclitaxel 80 mg/m2 weekly. Cycle duration = 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
45468256|NCT02824575|Drug|Eribulin Mesylate|Eribulin 1.4 mg/m2 day 1 & 8. Cycle duration : 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
45468257|NCT05101330|Device|Bilingual prescription medication labels|The bilingual PML contains English and Chinese medication-related instructions for participants.
45468258|NCT01380704|Drug|ABT-436|QD Days 1-7
46020837|NCT01284491|Device|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
46020838|NCT01283009|Drug|Inactive Substance|Inactive Substance will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
46020839|NCT01283009|Drug|Methylprednisolone|Methylprednisolone will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
46020840|NCT05659277|Other|Workplace Stress and Irregular shift hours|The physiological, psychological, and cognitive impacts that workplace stress and irregular shift hours have on first responders.
46105192|NCT00749554|Device|Sham biacuplasty|Probes not inserted into disc, no RF electricity applied.
46105193|NCT00749710|Procedure|clopidogrel|ORIF - surgical treatment
46105194|NCT00749710|Procedure|no antiaggregant therapy|ORIF - surgical treatment
46020841|NCT01282463|Drug|Docetaxel|Docetaxel: 75 milligram/square meter (mg/m2) on Day 1 of each 21-day cycle
46020842|NCT01282463|Biological|Ramucirumab DP|Ramucirumab (DP): 10 milligram/kilogram (mg/kg) intravenous (IV) on day 1 of each 21-day cycle
46020843|NCT01282463|Biological|Icrucumab|12 mg/kg I.V. on day 1 and Day 8 of each 21-day cycle
46020844|NCT01282229|Device|LANAP|Laser Assisted New Attachment Procedure (LANAP protocol) using the FR Pulsed Nd:YAG laser
46020845|NCT01281917|Drug|Velcade|Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22)
46020846|NCT01281917|Drug|Temsirolimus|Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)
46105195|NCT00913302|Behavioral|Cardiovascular Training|cardiovascular training, 3 times/week for 30-60 minutes, over 12 weeks
46105196|NCT04058548|Diagnostic Test|Sit to stand test|Participants will complete a sit to stand test in addition to a 6 minute walk test
46105197|NCT00749866|Drug|Gentamicin|Nebulised 80mg twice daily
46105198|NCT00749866|Drug|Saline|Nebulised 4mls 0.9% Saline twice daily
46105199|NCT00655577|Behavioral|Exercise|Supervised, mainly home-based balance, strength and jumping exercises
46105200|NCT04058236|Other|human albumin 5%|Human Albumin 5% will be given as fluid management for this group in accordance to goal directed therapy and guided by stroke volume variation of approximately 12-15%. This percentage of SVV has been validated as a threshold above which fluid administration increases stroke volume with an area under the receiver operating characteristics curve reported at 0.87. If the SVV remains more than 15% for more than 2 minutes, 250ml of fluid replacement according to patient group will be given. These boluses are given in aliquots over 30 min to avoid effects of rapid volume expansion. and the same fluid and technique will be carried out within 24 hours intra and post operatively in the Intensive Care Unit (ICU). All clinical parameters and fluids including blood that will be given will be recorded.
45468259|NCT01380704|Drug|Matching Placebo|QD Days 1-7
45468260|NCT04759300|Device|C-MAC VS|patients undergoing tracheal intubation using the C-MAC VS
45468261|NCT04759300|Device|C-MAC VL D -blade|patients undergoing intubation using the C-MAC VL D-blade.
45468262|NCT03641937|Device|INVSENSOR00011|INVSENSOR00011 - investigational sensor that will be placed on the subject's chest and/or back for the duration of the study.
45468263|NCT01380626|Procedure|exercise training|strength and endurance training, 5 time per week.
45468264|NCT04754464|Dietary Supplement|synbiotic|Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8-Lb1, L. fermentum K11-Lb3, acacia gum (gum arabic), maltodextrin, sucralose and flavour twice a day resolved in water
46020847|NCT01281839|Drug|TMC435|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
46020848|NCT01281839|Drug|Placebo|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
46020849|NCT01281839|Drug|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
46105201|NCT04058236|Other|gelofusine.|Gelofusine will be given as fluid management for this group in accordance to goal directed therapy and guided by stroke volume variation of approximately 12-15%. This percentage of SVV has been validated as a threshold above which fluid administration increases stroke volume with an area under the receiver operating characteristics curve reported at 0.87. If the SVV remains more than 15% for more than 2 minutes, 250ml of fluid replacement according to patient group will be given. These boluses are given in aliquots over 30 min to avoid effects of rapid volume expansion. and the same fluid and technique will be carried out within 24 hours intra and post operatively in the Intensive Care Unit (ICU). All clinical parameters and fluids including blood that will be given will be recorded.
46105202|NCT04164875|Diagnostic Test|Temperature measurement|The 'intervention' is repeated rectal temperature measurements
46105203|NCT02638649|Procedure|Lung ultrasound|At each call, the paramedic will initially evaluate the patient clinically conducting a standard history and physical exam. The paramedic will then use the portable U/S machine to look for the presence of either unilateral or bilateral B-lines indicating possible pneumonia (in the case of unilateral B-lines) or pulmonary edema (in the case of bilateral B-lines). The paramedic will then document the presence or absence of B-lines for each lung on the prehospital study sheet. The paramedic will then use the U/S to evaluate for the presence of pleural effusions, lung sliding and pericardial effusion.
46105204|NCT02638649|Device|ultrasound|
46105205|NCT00742066|Drug|Irbesartan|Single dose 600mg orally
46105206|NCT00742066|Drug|Felodipine|single dose 10mg Felodipine ER
46105207|NCT00742066|Drug|Placebo|Single dose tablet orally
46105208|NCT02635529|Procedure|OFD+ DFDBA|After Phase I therapy, patient's were assigned for OFD+DFDBA group. Mucoperiosteal flap were reflected.After Open Flap Debridement (OFD), DFDBA graft was placed for the treatment of intrabony defects.
46105209|NCT02635529|Procedure|OFD+ DFDBA+ AM|After Phase I therapy, patient's were assigned for OFD+DFDBA + AM group. Mucoperiosteal flap were reflected. After Open Flap Debridement (OFD). DFDBA and AM was placed for the treatment of intrabony defects.
46105210|NCT00837486|Device|Reclaim™ DBS System|
46105211|NCT00742144|Drug|ofatumumab|Ofatumumab (GSK1841157), a clear colorless liquid, is supplied in a glass vial. Each vial contains 100mg of ofatumumab in 5mL.
46020850|NCT01281839|Drug|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
46020851|NCT01281137|Genetic|polymorphism analysis|SNPs will be genotyped in whole blood samples taken at baseline.
46105212|NCT00742222|Radiation|Electronic Brachytherapy|34 Gy administered over 10 fractions, twice a day times five days. The radiation therapy treatment will be complete upon the 5th day.
46105213|NCT00742222|Radiation|Intracavitary accelerated partial breast irradiation|3.4 Gy BID x 5 days
46105214|NCT00845676|Drug|Pegylated interferon alfa-2a + Ribavirin|Pegylated interferon alfa-2a 180 mcg subcutaneous injection once weekly for 24 weeks Ribavirin 1000-1200mg daily, dosed according to body weight and divided twice daily, for 12-24 weeks
46105215|NCT00707148|Drug|Placebo|Saline (0.9% NaCl) administered as a single 0.5 mL intramuscular injection into the deltoid.
46105216|NCT00707148|Biological|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap). Administered as a single 0.5 mL intramuscular injection into the deltoid.
46020852|NCT01281137|Other|laboratory biomarker analysis|Biomarkers will be assessed in blood and serum samples at different time points.
46020853|NCT01281137|Procedure|quality-of-life assessment|Quality of life will be assessed using the Breast Cancer Prevention Trial (BCPT) Symptom Scales and the IBCSG Trial 35-07 QL Form.
46020854|NCT01280981|Drug|Tranexamic acid|Tranexamic acid at an oral dose of 1.3 g administered 3 times per day for up to 5 days (maximum of 15 doses) during menstruation for 9 menstrual periods.
46020855|NCT02889653|Drug|Any oral antithrombotics (antiplatelets or anticoagulants)|
46105217|NCT00742300|Procedure|Autologous hematopoietic stem cell transplantation|Transplantation of CD34-selected autologous hematopoietic stem cells after high-dose chemotherapy with cyclophosphamide (200mg/kg) and rabbit-antithymocyteglobulin (90mg/kg)
46105218|NCT02611908|Drug|ibrutinib|Cohort 1 420 mg PO daily Cohort 2 560 mg PO daily Cohort 3 700 mg PO daily Cohort 4 840 mg PO daily
46105219|NCT02611908|Drug|obinutuzumab|obinutuzumab 100 mg IV on day 1, 900mg IV on day 2, 1000mg IV day 8, 15, 28 then q 28 days for a total of 8 doses.
46105220|NCT02561884|Drug|Olostar Tab.|
46105221|NCT02561884|Drug|Co-administration of Olmetec and Crestor|
46105222|NCT00655655|Drug|everolimus|Given orally
46105223|NCT00655655|Drug|vatalanib|Given orally
46105224|NCT00655655|Other|pharmacological study|Correlative study (Cohort IIA only)
46105225|NCT00655655|Other|laboratory biomarker analysis|Correlative study (Cohorts IIA and IIB)
46105226|NCT00655655|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Correlative study (Cohort IIA only)
46105227|NCT00655655|Procedure|ultrasound imaging|Correlative study (Cohorts IIA and IIB)
46105228|NCT00845520|Device|Lens implantation +1.00 D postop target|Lens implantation +1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
46105229|NCT00845520|Device|Lens implantation -1.00 D postop target|Lens implantation -1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
46105230|NCT00845520|Device|Lens implantation 0.00 D postop target|Lens implantation 0.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
46105231|NCT02638571|Other|enhanced education on pulse use in complementary foods|Enhanced Nutrition education with sessions and counseling by health extension workers
46105232|NCT00844896|Behavioral|DEF-only|"The DEF protocol is from the National Child Traumatic Stress Network (NCTSN). DEF provides a sequential methodology for clinicians to assess medically traumatized children and their families and to plan specific interventions for them.~In the present study, the DEF intervention is both a generalized approach taught to all Shriners Hospitals for Children (SHC)- Boston clinical staff, and for those participants of the present study, consists of an optional meeting with a member of the SHC Psychiatry Department. During this meeting, parents will have the chance to review any areas of pain, anxiety, or support that came up during their interviews or any other areas of concern about their child or his/her hospitalization that they wish to raise."
46105233|NCT00844896|Behavioral|DEF + COPE|"All enrolled participants will be offered the chance to meet with a psychiatric clinician for the DEF component of the intervention.~For those assigned to receive COPE (Creating Opportunities for Parent Empowerment), parents will receive one of two versions of the materials: one for children less than one year old, and one for children ages 1-5 years. The COPE program was adapted for children with burns and developed to target major stressors that parents experience when their children are hospitalized, such as the loss of parental control. COPE also contains a behavioral component to help parents to carry out the recommendations provided to them. Each of these versions of the COPE program is essentially self-administered to parents via audio tapes and activity workbooks."
46105234|NCT00654719|Dietary Supplement|NutriDrink|Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
46105235|NCT00654719|Dietary Supplement|Placebo|Nutritional supplementation containing only 12 kcal/day
46105236|NCT05483400|Drug|Tiragolumab and atezolizumab|three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous.
46105237|NCT00654797|Procedure|glucose control with computer generated recommendations|Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
46020856|NCT01280903|Behavioral|STAR Intervention|The 24-week modified Staying Active with Arthritis (STAR) intervention, guided by self-efficacy theory and modified to address comorbid hypertension, consists of 6 weekly individual face-to-face exercise sessions by a licensed physical therapist, 9 biweekly telephone counseling sessions by a registered nurse to continue the use of self-efficacy strategies, and lower extremity exercise and fitness walking being carried out at home between sessions. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
46105238|NCT00837330|Drug|ranibizumab 0.5 or 0.3 mg/0.05 cc|ranibizumab 0.5 or 0.3 mg/0.05 cc administered intraocularly on a monthly basis for 3 months, followed by monthly examination with the option of further ranibizumab treatment or other therapies at the discretion of the treating physician
46105239|NCT00703638|Drug|cisplatin|Cisplatin administered intravenously, 75 mg/m^2 over 1-2 hours on day 1 of a 21 day cycle
46105240|NCT00703638|Drug|pemetrexed disodium|Pemetrexed 500 mg/m^2 intravenously (IV) will be given as a 10-minute intravenous infusion (after cisplatin) on day 1 of a 21 day cycle
46105241|NCT00703638|Drug|sorafenib|daily oral sorafenib (200 mg or 400 mg bid)
46105242|NCT00837096|Device|V.A.C. Therapy|Negative Pressure Wound Therapy (NPWT) distributes negative pressure across a wound base by means of a specially engineered dressing with the specific intent to help promote wound healing.
46105243|NCT00837096|Device|Moist wound therapy (MWT)|Gauze Pads, Transparent Films, Hydrogels, Foam, Hydrocolloids, alginate, collagen, and antimicrobial
46105244|NCT00703794|Device|The AXIUM Progressive Coil System|Embolization of aneurysm
46105245|NCT05478564|Other|Intraoperative fluids and vasoactive drugs management protocol|Limitation of hypotensive events during open surgery for abdominal aorta repair
46105246|NCT00885677|Device|Medtronic CareLink® Network|"Continuous monitoring via a disease remote management system.~Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur."
46105247|NCT02581943|Drug|Carboplatin|Given IV
46105248|NCT02581943|Other|Laboratory Biomarker Analysis|Correlative studies
46105249|NCT02581943|Drug|Paclitaxel|Given IV
46105250|NCT02581943|Biological|Pembrolizumab|Given IV
46105251|NCT02581943|Other|Quality-of-Life Assessment|Ancillary studies
46105252|NCT02637479|Device|GammaKnife®|
46105253|NCT02637479|Device|18F-2-fluoro-2-deoxy-D-glucose - positron emission tomography (FDG-PET)|
46105254|NCT02637479|Device|MRI|
46105255|NCT04162301|Drug|CS3002|CS3002 tablet will be orally administered daily for 3 weeks followed by 1 week off treatment, defining a treatment cycle of 28 days in duration.
46105256|NCT02637401|Behavioral|Dialectical Behaviour Therapy|
46105257|NCT00885365|Drug|tobramycin / Bramitob|300mg/4ml solution, via a nebuliser, over a 4-week treatment in a twice-daily regimen
46105258|NCT00885365|Drug|tobramycin / TOBI|300mg/5ml solution administered via nebuliser, over a 4-week treatment in a twice-daily regimen
46105259|NCT00827112|Drug|maraviroc|maraviroc (Selzentry, Celsentri) 150mg QD + atazanavir (Reyataz) /ritonavir (Norvir) (300/100mg) QD OR maraviroc (Selzentry, Celsentri) 150mg QD+ darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR maraviroc (Selzentry, Celsentri) 150mg QD+ lopinavir/ritonavir (Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
46105260|NCT00827112|Drug|maraviroc|emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + lopinavir/ritonavir(Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
46105261|NCT00689104|Drug|Mirabegron|Tablets
46105262|NCT00689104|Drug|Tolterodine|Capsules
46020857|NCT01280903|Behavioral|Attention-Control|Attention-Control is a 24-week general health education program for older adults that consists of 6 weekly telephone sessions by a registered nurse followed by 9 biweekly telephone sessions by a registered nurse. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. Topics include cancer screenings; immunizations; osteoporosis; low vision; hearing loss; talking with your primary care provider; eating healthy (two parts); sleep and aging; injury prevention (two parts: balance problems and falls); oral health; foot care; and mental health (depression). During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
46020858|NCT04323605|Other|"Outpatient assistance program for transplant patients (AMA-ALLO) based on a navigation nurse"|"Integration of a post-transplant navigation nurse starting at the first post-transplant consultation (starting from D100 +/- 10 days post-transplant). Different times for post-transplant telephone monitoring (every week for the first 2 months, then every 15 days for the next 3 months then once a month for 7 months)"
46020859|NCT01280591|Drug|Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|Participants received two Naproxen sodium 220 mg / DPH (Diphenhydramine hydrochloride) 25 mg tablets orally, single dose
46020860|NCT01280591|Drug|Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|Participants received one Naproxen sodium 220 mg / DPH 50 mg tablet and one matching placebo capsule orally, single dose
46020861|NCT01280591|Drug|Naproxen sodium 440 mg (BAYH6689)|Participants received two Naproxen sodium 220 mg tablets orally, single dose
46020862|NCT01280591|Drug|DPH 50 mg|Participants received two DPH (Diphenhydramine hydrochloride) 25mg tablets orally, single dose
46105263|NCT00689104|Drug|Placebo to Mirabegron|Matching mirabegron placebo tablets.
46105264|NCT00689104|Drug|Placebo to Tolterodine|Matching tolterodine placebo capsules.
46105265|NCT02635217|Device|Carbon dioxide insufflation|using an automated carbon dioxide insufflator the gas will be infused on demand during the endoscopies
46105266|NCT02635217|Device|room air insufflation|using standard care room air will be infused on demand
46105267|NCT02635217|Procedure|EGD (Esophagogastroduodenoscopy) before Colonoscopy|the order of endoscopies will be randomized as well
46105268|NCT02635217|Procedure|Colonoscopy before EGD (Esophagogastroduodenoscopy)|
46105269|NCT02118467|Drug|Norepinephrine|Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
46105270|NCT02118467|Drug|Epinephrine|Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
46105271|NCT02118467|Drug|Phenylephrine|Dose range 0.3 to 3.0 mcg/kg/minute, titrated to target blood pressure.
46105272|NCT02118467|Drug|Vasopressin|Dose range 0.1 to 0.6 milliunits/kg/minute, titrated to target blood pressure.
46105273|NCT00702078|Behavioral|closer collaboration between hospital and primary healthcare system|Follow-up from the hospital and the primary healthcare in cooperation
46105274|NCT00702078|Behavioral|usual care|follow-up according to todays best practice
46105275|NCT00702156|Drug|Bisoprolol|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
45468265|NCT04754464|Dietary Supplement|microcrystalline cellulose|Consumption of 6 g powder containing microcrystalline cellulose, maltodextrin , sucralose and flavour twice a day, resolved in water
46105276|NCT00702156|Drug|Placebo|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
45468266|NCT03780608|Drug|AZD6738|AZD6738 will be administered at 240 mg twice daily on days 1 to 7 in Cycle 0 (lead-in period) and therafter at 240 mg BD on days 22 to 28 in a 28-day cycle.
45468267|NCT03780608|Drug|Durvalumab|. Durvalumab will be administered at 1500 mg every 4 weeks from cycle 1 day 1.
46020863|NCT04323683|Genetic|Microarray|High throughput technique for determining global gene expression of the condition of interest
46020864|NCT01280357|Device|Monica AN24 (K101081)|If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
45468270|NCT03691298|Device|Suturefix Ultra and Suturefix Curved Suture Anchor|Fixation device intended to provide secure fixation of soft tissue to bone to stabilize hip
45468271|NCT03440242|Device|JJVC Contact Lens|etafilcon A with PVP DD
45468272|NCT03440242|Device|Marketed Contact Lens|nelfilcon A DD
45468273|NCT03631316|Drug|Generic Valganciclovir|900 mg daily during 4 days
45468274|NCT03631316|Drug|Innovative Valganciclovir|900 mg daily during 4 days
45468275|NCT03440164|Other|Sylimarin and Sylibin|We compared the plasma levels of Silibinin after a dosage of Silibinin-phosphatidylcholine complex, equivalent to 45 mg Silybin oily-medium soft-gel capsules after the conventional 70-mg Silymarin tablets, in 23 healthy volunteers
46020865|NCT01280357|Device|Philips 50XM|If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
46020866|NCT04323917|Diagnostic Test|Liquid biopsy|Detection and quantification of EMT-transcription factor mRNA levels in blood
46105277|NCT02106611|Other|Clinical Assessment|HL treatment will be determined by review of available medical records as archived at MSKCC. Recorded variables will include: (1) RT - field, fractional and cumulative dose, and duration; (2) chemotherapy - regimen, planned interval, dose per cycle, and cumulative dosages. Patients will also be asked to complete the FACT-LYM questionnaire and the FACIT Fatigue questionnaire.
45468276|NCT05414708|Behavioral|Art Therapy|During the art research intervention session, the art therapist will walk you through the creation of various types of art and may spend time asking you about the artwork, how you are felling, as well as your past experiences.
45468277|NCT03608865|Drug|Durvalumab with Tremelimumab|Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart. Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. All trial treatments will be administered on an outpatient basis. Durvalumab 1500mg + tremelimumab 750 mg will be administered as a 60 minute each one IV infusion every 4 weeks. Sites should make every effort to target infusion timing to be as close to 60 minutes as possible. However, given the variability of infusion pumps from site to site.
45468278|NCT04751578|Device|IMPEDE-FX Embolization Plug|Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft
45468279|NCT03532451|Drug|Nivolumab|Nivolumab 480 mg intravenously (IV) over approximately 30 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) followed by RC with bilateral (standard or extended) PLND as soon as possible but within 6 weeks after the last neoadjuvant infusion.
46020867|NCT04323761|Drug|Remdesivir|Intravenous infusion administered over a 30 to 120 minute period
46020868|NCT05566223|Drug|Fludarabine|Day -7 to Day -3 : Fludarabine 25 mg/m^2/dose as a 1 hour intravenous infusion per institutional guidelines once a day for 5 doses beginning on Day -7. Fludarabine will be started approximately 1 to 2 hours after the cyclophosphamide on Day -6 and Day -5.
46020869|NCT05566223|Drug|Cyclophosphamide|Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
46020870|NCT05566223|Biological|CISH Inactivated TIL|Day 0 : Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes at assigned dose level.
46020871|NCT05566223|Drug|Aldesleukin|Days 1-4 : Aldesleukin at 720,000 U/kg as an intravenous infusion, every 8 -12 hours but, no more than 24 hours apart as tolerated for up to 6 doses.
45468280|NCT03532451|Drug|Nivolumab/Lirilumab|Nivolumab 480 mg IV over approximately 60 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) with at least a 30 minute rest between infusions followed by lirilumab 240 mg IV over approximately 60 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) followed by RC with bilateral (standard or extended) PLND as soon as possible but within 6 weeks after the last neoadjuvant infusion.
45468281|NCT04704531|Drug|Sodium Hyaluronate Ophthalmic 0.4% BID|Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno BID.
45468282|NCT04704531|Drug|Sodium Hyaluronate Ophthalmic 0.4% QID|Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno QID.
45468283|NCT04704531|Drug|Sodium Hyaluronate Ophthalmic 0.4% Six times per day|Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno six times per day.
46020872|NCT05566223|Drug|Pembrolizumab|Administered as maintenance therapy in some patients starting at first follow-up (400 mg/dose starting Day 28 /Week 4 then every 6 weeks thereafter until disease progression, unacceptable toxicity, or up to 24 months)
45468284|NCT01569230|Procedure|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 9 Acupuncture points(SP9,GB34, ST36, ST35, Xiyan(EX-LE5), BL60, GB39, SP6 and KI3)were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
45468285|NCT01569230|Procedure|sham acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 9 same acupuncture points as in the standardized acupuncture group. Each session was 20 minutes long
45468286|NCT01569230|Procedure|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
45468287|NCT01569230|Other|Waiting|No interventions were applied to the patients in this group.
45468288|NCT03506633|Dietary Supplement|MitoQ|"A mitochondrial-targeting antioxidant MitoQ or a placebo will be given to each subject in a crossover, double-blinded design and measures of leg function and leg blood flow will be measured."
45468289|NCT02637531|Drug|IPI-549 (eganelisib)|IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)
45468290|NCT02637531|Drug|Nivolumab|Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).
45468291|NCT04738552|Device|Nelli|Nelli detects and registers activity that is indicative of seizure events. Nelli captures, stores, and processes video and audio recordings from each patient. Biomarker data is collected during periods of rest for the length of an examination period, which may span several days or months (when used inside and outside of a hospital setting, respectively), as prescribed by a treating physician.
45468292|NCT01237925|Drug|Dexchlorpheniramine 1% gel|Small amount applied over the lesion twice a day for 7 days
45468293|NCT01237925|Drug|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
45468294|NCT01380548|Dietary Supplement|Placebo|Placebo; once/day; for 12 weeks
45468295|NCT01380548|Dietary Supplement|Iron alone|Iron (3 mg); once/day; for 12 weeks
45468296|NCT01380548|Dietary Supplement|Low-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (12.5 mg) and iron (3 mg); once/day; for 12 weeks
45468297|NCT01380548|Dietary Supplement|Medium-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (25 mg) and iron (3 mg); once/day; for 12 weeks
45468298|NCT01380548|Dietary Supplement|High-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (50 mg) and iron (3 mg); once/day; for 12 weeks
45468299|NCT01313247|Drug|paracetamol|1000 mg 4 times daily
46020873|NCT01274351|Drug|Nilotinib|administered orally at a dose of 300 mg twice daily for 24 months
46020874|NCT01271933|Drug|pregabalin|controlled release tablet; 165-495 mg/day; given once daily
46105278|NCT02106611|Procedure|Stress cardiac MRI|Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
45468300|NCT01313247|Drug|placebo tablets|Placebo pills eqv paracetamol are given 2 tablets 4 times daily instead of paracetamol
46020875|NCT01271933|Drug|placebo|matching placebo tablet; given once daily
46020876|NCT01269125|Drug|Leuprolide|single injection of 3.75 leuprolide every 28 days, 3 dosages
46020877|NCT01269125|Procedure|IVF|Assisted Reproduction Technique.
46105279|NCT02106611|Procedure|Stress echocardiogram|Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
46020878|NCT01268891|Drug|Placebo|Once daily; tablet; orally; 18 weeks
46020879|NCT01268891|Drug|Azilect®|1 mg daily; tablet; orally; 18 weeks
46020880|NCT01268501|Device|Lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal, soft contact lenses FDA-approved for up to 4 weeks recommended replacement schedule and up to 6 nights of extended (overnight) wear.
46020881|NCT04323527|Drug|Chloroquine diphosphate|150mg chloroquine diphosphate tablets. Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
45468301|NCT03109678|Device|Crossover Ambu Aura-i™ / Rüsch Super Safety Silk™|After unsuccessful blind intubation in the Ambu Aura-i™ / Rüsch Super Safety Silk™ group: crossover design using the Ambu Aura-i™ mask in combination with the LMA ETT™ tracheal tube
45468302|NCT03109678|Device|Crossover Ambu Aura-i™ / LMA ETT™|After unsuccessful blind intubation in the Ambu Aura-i™ / LMA ETT group: crossover design using the Ambu Aura-i™ mask in combination with the Rüsch Super Safety Silk™ tracheal tube
45468303|NCT03109678|Device|Crossover FASTRACH™ / Rüsch Super Safety Silk™|After unsuccessful blind intubation in the FASTRACH™ / Rüsch Super Safety Silk™ group: crossover design using the FASTRACH™ mask in combination with the LMA ETT™ tube
45468304|NCT03109678|Device|Crossover FASTRACH™ / LMA ETT™|After unsuccessful blind intubation in the FASTRACH™ / LMA ETT™ group: crossover design using the FASTRACH™ mask in combination with the Rüsch Super Safety Silk™ tube
46105280|NCT00707382|Genetic|(1) Genotyping for CYP4502D6 and 2C19 polymorphisms|"In this study arm (1), the genotype information is given to the physician in charge of treatment and can be used to direct the pharmacological treatment according to local guidelines. In the guidelines the genotype is translated to the clinical designation normal, slow or fast metabolizer of CYP2D6 or normal or slow metabolizer of CYP2C19. Different treatment options for the different genotypes are described."
46105281|NCT00707382|Other|(2) Intense clinical monitoring|In this study arm (2) the genotype information is not revealed. The intervention consists of an intensified clinical monitoring of treatment effect, side effects and patient perspective. Staffpersonnel is trained in the use of a clinical manual that builds on a selection of validated questions from the Scale for the Assessment of Positive Symptoms (SAPS), Side effect score (Udvalg af Kliniske Undersøgelser (UKU) and Rating of Medical Influences (ROMI). The manual has to be used at least once in a quarter (every third month), which is monitored by the study personnel. Data registered by the patients primary contact person are not used as outcome measures in the study but only as intervention tool for the optimisation of the medical antipsychotic treatment.
45838197|NCT04431661|Procedure|Optical Coherence Tomography|OCT (DragonFly, Abbott Vascular) will be performed after angiography. OCT images will be acquired using the 6F guide catheter compatible DragonFly System (Abbott Vascular, Santa Clara, USA). The catheter will be introduced into the first coronary artery via a standard 0.014-inch angioplasty wire, after prior injection of an intracoronary bolus of nitro-glycerine (according to the hemodynamic conditions of the patient). To remove all blood adequately from the imaging site, nonocclusive flushing will be performed using continuously inject via an automated power injector, and the OCT catheter will be pulled back at a speed of 18 mm/second to guarantee sufficient time to acquire images of a 54 mm long segment (frame density: 10 frames/mm).
45468305|NCT01313325|Other|Hippotherapy|Children will receive treatment by a licensed physical therapist using hippotherapy as the treatment strategy. This includes sitting on a horse who's movement is controlled by a horse leader, with the PT directing the movements required of the horse, as well as supplying supplemental cues to the participant. Alternative positions (such as sitting backward and sideways) may also be used during the treatment session.
46020882|NCT01268267|Device|Ninja 2 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter and an investigational sensor. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
45468306|NCT03439696|Procedure|Thoracoscopic surgery|Video-assisted thoracoscopic surgery for pulmonary or mediastinal lesions.
45468307|NCT01142453|Drug|Interferon beta 1a|A dosage of 44 µg interferon beta 1a subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase (depending on the respective preliminary therapy)
46020883|NCT01267253|Drug|Brivanib Alaninate|Given PO
46020884|NCT01267253|Other|Laboratory Biomarker Analysis|Correlative studies
46105282|NCT00707382|Other|(3) Control|In this studyarm (3), (Control) treatment followed usual local practice. The genotype information was not revealed.
46105283|NCT02638415|Procedure|HVPG-guided therapy|"Patients with an HVPG over 20mmHg will be suggested to receive transjugular intrahepatic portocaval shunt (TIPS) or surgical shunt operation.~Patients with an HVPG between 16 and 20mmHg can choose either endoscopic treatment or TIPS according their willingness and indication.~Patients with an HVPG below 16mmHg will be treated by endoscopy plus Carvedilol, until endoscopic treatment fails."
45468308|NCT03439618|Other|time-restricted feeding|At the beginning, all enrolled patients were fed by continuous feeding. When the amount calorie of feeding enteral nutritional suspension increased to 80% target calorie (target calorie: 25kilocalorie/kg.d), the patients was randomly into continuous feeding and time-restricted feeding group. In continuous feeding group, the enteral nutritional suspension was fed at constant speed for 24h.In the time restricted feeding, feeding time should be at 7:00-9:00, 11:00-13:00 and 17:00-19:00 at constant feeding speed.
45468309|NCT03439618|Other|continuous feeding|At the beginning, all enrolled patients were fed by continuous feeding. When the amount calorie of feeding enteral nutritional suspension increased to 80% target calorie (target calorie: 25kilocalorie/kg.d), the patients was randomly into continuous feeding and time-restricted feeding group.In the continuous feeding, the total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h.
45468310|NCT01238003|Other|Interpretation of blood test results|Interpretation of blood test results
45468311|NCT03562767|Behavioral|Group-based Cognitive Behavioral Intervention|This intervention will include six 1-hour group sessions held biweekly for twelve weeks. Each sixty-minute session will consist of 15 minutes of diabetes education regarding exercise and food planning and approximately 45 minutes of CT-CB presentations/engagement activities. Participants will be encouraged to bring along their family members or friends for support.
45468312|NCT03562767|Behavioral|Web-based Cognitive Behavioral Intervention|This intervention will include six 1-hour web-based sessions held biweekly for twelve weeks. Subjects in the web-based CT-CB will be asked to reserve a 1 hour period for a web call from the Behavioral Interventionist team. Text reminders will be sent to the participants prior the sessions. During this period, approximately 15 minutes will be reserved for diabetes exercise and food planning education and approximately 45 minutes of CT-CB engagement activities.
45468313|NCT03562767|Behavioral|Usual Care|Usual care group participants will continue to receive care and follow up from their primary care providers as per the American Diabetes Association guidelines with log books, education regarding self-management strategies and appropriate referrals as needed.
45468314|NCT04701424|Device|CamAPS HX Closed-loop|"The CamAPS HX closed-loop system comprises:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data."
45468315|NCT04701424|Other|Multiple Daily Insulin Injections (Control)|Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
45468316|NCT05396807|Device|AI|The aim of using AI software to support physicians in choosing the most effective treatment.
45599266|NCT02302729|Dietary Supplement|Micronutrients|Nutrient Quantity Nutrient Quantity Zinc 9 mg Copper 0.3 mg Iron 12.5 mg Vitamin D3 5 mg Folic Acid 160 mcg Vitamin E 5 mg Iodine 90 mcg Calcium 200 mg Vitamin A 250 mg Phosphorus 150 mg Vitamin C 40 mg Magnesium 40 mg Vitamin B12 0.9 mcg Selenium 17 mcg Thiamine 0.5 mg Manganese 0.17 mg Niacin 0.5 mg Biotin 8 mg Riboflavin 6 mg Vitamin B5 1.8 mg Vitamin B6 0.5 mg
45599267|NCT02302729|Behavioral|Responsive feeding|"Strategy~Mother ensures that feeding area is set up with infant and mother able to see one another.~Mother mirrors the infant's facial expressions to attract the infant's attention.~Mother interprets infant's behavior with a positive voice, Oh, you like the spinach. Mother extends infant's behavior by saying, Oh the cereal is all gone and doing a consistent hand signal Mother models eating, makes positive comments in a nurturing tone. Mother offers finger food or use of utensil"
45599268|NCT02302729|Dietary Supplement|Placebo|Riboflavin Vitamin B2
45838198|NCT04431661|Procedure|Coronary Angiography|The coronary angiography will be performed according to the strategies described in the consensus statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent for Life (SFL) groups.Transradial or transfemoral 6F/7F approaches are recommended. The choice of diagnostic catheters, guiding catheters, guidewires, pre-dilatation, atherectomy devices, and post dilatation is let to the investigator's discretion.
46105284|NCT02638415|Other|routine therapy|Patients start treatment without HVPG measurement and receive endoscopic therapy plus Carvedilol.
46105285|NCT02638415|Drug|Carvedilol|Patients in HVPG group with HVPG below 16mmHg and all patients in non-HVPG group will take Carvedilol 12.5mg/d if they have no contraindications.
46105286|NCT00703872|Drug|Oral HDV-Interferon + ribavarin|Naive pateints
46105287|NCT00703872|Drug|Injectable HDV-Interferon + ribavarin|Nonresponders
46105288|NCT00703950|Procedure|cup feeding|Method to feed: cup. This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using cup
46105289|NCT00703950|Procedure|bottle feeding|bottle feeding This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using bottle
45468317|NCT04451356|Device|Bioimpedance Spectroscopy|This analysis will be performed at baseline using the portable whole-body multifrequency bioimpedance analysis device (BCM®Body Composition Monitor - Fresenius Medical Care D GmbH). The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM® measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid overload. All calculations are automatically performed by the software of the BCM® device. In addition, this analysis will provide the LTI and FTI for the included patients.
45468318|NCT04451356|Device|Arterial Stiffness|Arterial stiffness assessment will be performed by applanation tonometry (SphygmoCorTM; PWV Inc., Westmead, Sydney, Australia) with the patient being recumbent, 10 minutes before the measures were done. The carotid and femoral pulse will be acquired by applanation tonometry sequentially, allowing a single operator to acquire the measurement. The transit time from the R-wave of the simultaneously acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference between these 2 transit times is divided by distances measured from the body surface to estimate the arterial path length in order to calculate carotid-femoral PWV.
45468319|NCT04451356|Diagnostic Test|Echocardiography|Echocardiographic evaluations will be made in each patient at baseline. All echocardiographic measurements will be carried out according to the recommendations of the American Society of Echocardiography by an observer unaware of the lung ultrasound and bioimpedance results. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).
45599269|NCT02343705|Device|Latella Knee Implant System|
45599270|NCT03513601|Drug|(R)-CHOP regimen|(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
45838199|NCT04431661|Procedure|Per cutaneous coronary intervention|Based on coronary angiography and OCT analyses by the investigators, PCI will be performed, preferentially for the identified culprit lesion(s) only. The guiding catheters, guidewires, pre-dilatation, atherectomy devices, and post dilatation are left to physician discretion. The use of semi- or non-compliant balloons number and diameter of drug eluting stent(s) will also be left to the physician discretion, but post dilation will be strongly recommended in case of PCI. OCT can eventually be performed after stent implantation to guide, post dilation strategy.
45838200|NCT04419675|Other|Observational Cohort, usual care = physical therapy|usual care = physical therapy
45838201|NCT04418440|Dietary Supplement|Souvenaid oral nutritional supplement (Nutricia)|Daily dose of a commercially available oral nutritional supplement based around the active compound recipe Fortasyn Connect, produced by Nutricia, Danone.
45838202|NCT04408066|Diagnostic Test|Sample Collection/Performance Evaluation (A)|"This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.~Sample types include:~Nasal/Throat/Nasal Throat Combo/ Nasopharyngeal (as per sites SOC) Swab~Whole Venous Blood"
46020885|NCT04378777|Procedure|Biological sample collection|During patient hospitalization: Nasal secretion samples by nasal swabs (for non-intubated patients), whole blood (blood draw/phlebotomy) and sputum secretions by endotracheal aspiration (for intubated patients) will be obtained to proceed with immunologic analysis of samples. DNA will be collected from whole blood at enrollment for genetic analysis (e.g., genome-wide association study [GWAS]). After hospital discharge: Collection of biologic samples (involving nasal swabs and blood draw/phlebotomy) will occur up to 12 months.
46020886|NCT04378777|Procedure|Data Collection: Clinical Care Assessments|Baseline data and assessments obtained as part of ongoing clinical care will be collected throughout hospitalization for COVID-19. After hospital discharge, clinical status and activity assessments will occur up to 12 months.
46105290|NCT00702312|Behavioral|Low-salt educational programme|Subjects will attend a health promotion cooking programme and receive written tailored low-salt Bengali educational tool. This tool has been developed specifically for this population group from Phase 1 and 2 study.
46105291|NCT00702312|Behavioral|Low-salt Bangladeshi educational programme|A multi-component low-salt educational programme tailored to the Bangladeshi kidney disease patients delivered in the community.
46105292|NCT00702312|Behavioral|Low-salt Bangladeshi educational programme|A multi-component Low-salt educational programme tailored to the Bangladeshi kidney disease patients residents in Tower Hamlets delivered over 5 months.
46105293|NCT00742456|Dietary Supplement|Glucose solution|single oral intake of 250 ml glucose solution (75gr sugar in 250ml of water)
46105294|NCT00742456|Dietary Supplement|Placebo|single intake of placebo solution (250ml of sweet flavored water, no sugar added), orally
46020887|NCT02889419|Device|Evaluation of underwear Selfia®|Patients are evaluated for a week using their usual underwear for the realization of SC. At the end of the week, they receive Selfia ® adaptated underwear and they use it for one week for a new evaluation. Finally, underwear will be given to patients and during follow-up consultations in routine at 6 months and 1 year, he will be asked if they reused or bought underwear.
46020888|NCT02889497|Biological|the first batch vaccine|
46020889|NCT02889497|Biological|the second batch vaccine|
46020890|NCT02889497|Biological|the third batch vaccine|
45468320|NCT04451356|Diagnostic Test|Lung ultrasonography|Examinations will be performed in the supine position. Scanning of the anterior and lateral chest will be performed on both sides of the chest, from the second to the fourth (on the right side to the fifth) intercostal spaces, at parasternal to mid-axillary lines. B-lines will be recorded in each intercostal space and were defined as a hyperechoic, coherent US bundle at narrow basis going from the transducer to the limit of the screen. B-lines starting from the pleural line can be either localized or scattered to the whole lung and be present as isolated or multiple artifacts. The sum of B-lines produces a score reflecting the extent of lung water accumulation (0 being no detectable B-line).
45468321|NCT03560193|Drug|2%Chlorhexidine-70%Isopropanol|2% Chlorhexidine-70% isopropanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
45468322|NCT03560193|Drug|5%Povidone Iodine- 69%Ethanol|5%Povidone Iodine- 69%Ethanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
45468323|NCT04451434|Drug|Danicopan|Oral tablet
45468324|NCT04679181|Other|Telemedecine|telemedical consultation
45468325|NCT04451200|Drug|Busulfan Injection|injections doses will be personalized by PK at days -7 and -4
46105295|NCT00707460|Behavioral|Dietary Intervention (Macronutrient composition)|"The Traditional Diet and Healthy Store-Bought arms differ from the control group and one another by their macronutrient composition. Please, see design section for more detail on this item.~All groups are exposed to nutrition education on serving size and portion size."
46105296|NCT00689026|Drug|Lubiprostone|Two 24 mcg lubiprostone capsules, which will be taken orally the morning and evening of the day of the 4L PEG prep (before and after the 4L PEG prep).
45468326|NCT01143233|Other|control formula|infants are fed a commercial hydrolyzed formula
45468327|NCT01143233|Other|intervention formula 1|formula has hydrolysed protein and a different protein content
45468328|NCT01143233|Other|intervention formula 2|formula has hydrolysed protein, different protein content and pro- and prebiotics
45468329|NCT01143233|Other|intervention formula 3|formula has hydrolysed protein, different protein content and pro- and prebiotics
45468330|NCT02359929|Biological|Autologous mesenchymal stromal cells (MSCs)|Infusion of MSCs delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 1000000 cells/kg.
45468331|NCT04693858|Behavioral|Child Anxiety Learning Modules (CALM)|CALM is a cognitive-behavioral intervention for childhood anxiety. CALM consists of five modules. The primary components include psychoeducation, relaxation training (C), behavioral exposure (A), cognitive restructuring (L), and relapse prevention (M). There is also an optional parent psychoeducation module. Students randomized to the CALM condition will receive the 5 modules over 8 weeks.
45468332|NCT04693858|Behavioral|Child Anxiety Learning Modules--Relaxation (CALM-R)|CALM-R serves as an active comparison condition to CALM and consists of 5 modules of relaxation skills. The key components of CALM-R include psychoeducation, deep breathing, progressive muscle relaxation, guided imagery, and relapse prevention. Students randomized to the CALM-R condition will receive the 5 modules over 8 weeks.
45468333|NCT01585883|Behavioral|Self-management Intervention|Individual, face-to-face 7-session self-management intervention delivered by a specialist oncology nurse/clinical case manager as a home-based approach using a manual for each session. The intervention is delivered through scheduled home visits (7 sessions about one-hour in length), telephone coaching (2 sessions/week to reinforce use of strategies and for symptom monitoring: 15 minutes), and nurse moderated online peer chat or chat that is self-initiated at other times (7 weekly sessions about one hour in length).
46020891|NCT01266317|Drug|Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids|Standard Steroid Treatment, Plasma exchange will consist of 1.5x estimated plasma volume exchanges, Rituximab
46020892|NCT01266161|Drug|Ibuprofen 600 mg ER|One 600 mg caplet dosed at 0, 12, 24 and 36 hours
46020893|NCT01266161|Drug|Placebo|One placebo caplet dosed at times 0, 12, 24 and 36 hours
46020894|NCT01265849|Biological|LI|LI 400 IU (2.0mL total daily) 1.0 mL peritumoral, 1.0 mL perilymphatic 5x weekly x3 consecutive weeks administered as neoadjuvant therapy prior to SOC, (surgery followed by radiation or concurrent radiochemotherapy with cisplatin 100 mg/m^2 intravenously x3) to determine if LI plus CIZ affects the 3-5 year overall survival.
46105297|NCT00689026|Other|Polyethylene glycol with electrolytes|Standard oral dosing of 4L Polyethylene glycol colonoscopy preparation the day prior to their scheduled colonoscopy.
46105298|NCT04058002|Other|Multiprofessional treatment and Educational Program Associated (EPA+C+BCAA) with supplementation of creatine and BCAA.|17 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times). Patients will be supplemented with creatine 5 grams and maltodextrin 100g, 30 minutes before training. At breakfast they will also ingest 5 grams of BCAA (1,200 milligrams of leucine, 600 milligrams of isoleucine and 600 milligrams of valine per dose)
46105299|NCT04058002|Other|Multiprofessional treatment and Educational Program Associated (EPA+C) with supplementation of creatine only.|17 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times). Patients will be supplemented with creatine 5 grams and maltodextrin 100g, 30 minutes before training. At breakfast they will also ingest 5 grams of placebo.
46105300|NCT00598559|Drug|IV Acetaminophen|Arm 1: 1 g IV Acetaminophen every 6 hours administered for five days. Arm 2: 650 mg IV Acetaminophen every 4 hours administered for five days. Arm 3: The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
46105301|NCT00686686|Biological|Infliximab|Intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 and possibly at week 12.
46105302|NCT02637167|Drug|Rifaximin|Rifaximin has negligible intestinal absorption after oral administration, giving it a good safety profile. Unlike systemically available antibiotics, this antimicrobial allows localized enteric targeting of bacteria and is associated with a minimal risk of systemic toxicity or side effects.
46105303|NCT02637167|Drug|Saccharomyces boulardii|The same advantage described above to Rifaximin applies to S. Boulardii, which might be therapeutically sufficient with the advantage of being less disruptive to the instestinal microbiota than broad-spectrum antibiotics.
45838203|NCT04408066|Diagnostic Test|Sample Collection/Performance Evaluation (B)|"This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.~Sample types include:~Whole Venous Blood~Fingerstick Capillary Sample"
45838204|NCT04406584|Procedure|Injection into olfactory cleft|Already stated above.
45468334|NCT03085238|Device|M-Trap|Device(s) will be surgically implanted in the peritoneal cavity. Up to three (3) M-Trap devices will be surgically implanted via laparotomy in the right and left paracolic (pelvic) gutters and behind segment 6 of the liver within the peritoneal cavity of the patient at the time of surgical resection. Patients will receive standard platinum-based chemotherapy. If the cancer is diagnosed to have recurred, M-Trap devices with captured tumor cells will be removed via minimally invasive surgery (laparoscopy).
45468335|NCT04678479|Drug|Ganaxolone|ganaxolone
45468336|NCT03431831|Behavioral|Intervention Control|diet recommendations of 1200 calorie limit for women daily and 1400 limit for men daily. Decreased foods that are high sugar, highly processed, low nutrient simple carbohydrates. Increased foods that are whole foods, lean proteins, complex carbohydrates and healthy fats. Switch from high calorie drinks to water for beverages.
45468337|NCT03431831|Behavioral|Counselling|Usual care as listed in comparator intervention plus motivational interviewing to identify areas of barriers and how to overcome them, to help patient set achievable food, physical activity and beverage goals for themselves weekly and monthly. To identify whether knowledge or confidence counseling is more important for each participant and follow up with them. To help them learn self-management techniques for overeating.
45468338|NCT03431831|Drug|Contrave|In addition to usual care as described in the comparator intervention, these participants will be prescribed Contrave and raised to the therapeutic dosage within one month. They will be monitored closely for side effects and meds adjusted accordingly.
46105304|NCT04057534|Behavioral|Standard therapy for AUD plus Chess-based cognitive treatment|"Behavioral: standard AUD Cognitive Behavioral Therapy (CBT) in Clinical setting.~Patients who voluntarily submit to enter a qualified detoxification treatment program will be examined, either in-patient, out-patient, or in a day-clinic setting at the Department of Addictive Behaviour and Addiction Medicine. Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week. The tasks of the treatment were created by our cooperation partner, the psychologist Juan Antonio Montero. He is currently successfully applying this battery as an add-on therapy. The training battery is designed to strengthen cognitive functioning in specific domains such as short-term memory, focal attention, selective attention, pattern recognition, visuospatial abilities, metacognition and also inhibition."
45468339|NCT03431831|Drug|Contrave and Counseling|This group of participants will receive a combination of all the above interventions including diet/physical activity prescription, motivational interviewing and Contrave.
45468340|NCT01142531|Radiation|Chest CT scan|"Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~90 quality ref mAs with care-dose ON~120 kV~Pitch 1.4~Rotation time 0.33 s~Acquired images 64 x 0.6 mm"
46105305|NCT04057534|Behavioral|Standard therapy for AUD|Behavioral: standard AUD Cognitive Behavioral Therapy (CBT) in Clinical setting. Patients who voluntarily submit to enter a qualified detoxification treatment program will be examined, either in-patient, out-patient, or in a day-clinic setting at the Department of Addictive Behaviour and Addiction Medicine.
45468341|NCT04668118|Drug|Diquafosol|As a P2Y2 receptor agonist, diquafosol can be used to stabilize the tear film by stimulating P2Y2 receptors on the corneal epithelial cells and conjunctival goblet cell, which increase the secretion of tear fluid and mucin on the ocular surface, thereby repairing the ocular surface and stabilizing the tear film.
45468342|NCT03442556|Drug|Carboplatin|Given IV
45468343|NCT03442556|Drug|Docetaxel|Given IV
45468344|NCT03442556|Other|Laboratory Biomarker Analysis|Correlative studies
45468345|NCT03442556|Drug|Rucaparib Camsylate|Given PO
45468346|NCT03442556|Drug|Rucaparib|Given PO
45468347|NCT02251821|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplant
45468348|NCT02251821|Drug|Busulfan|Given IV
45468349|NCT02251821|Drug|Cyclophosphamide|Given IV
45468350|NCT02251821|Drug|Fludarabine Phosphate|Given IV
46020895|NCT01265849|Drug|Cyclophosphamide|Cyclophosphamide was administered IV bolus (one time only) at a dose of 300mg/m^2 three days prior to beginning treatment with LI. Standard of care (SOC) for previously untreated squamous cell carcinoma of the head and neck is currently surgery followed by radiotherapy (60-70Gy in 30 to 35 fractions over 6 to 7 weeks) for higher risk subjects (subjects determined at surgery to have adverse features per the National Comprehensive Cancer Network (NCCN) guidelines, such as, positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread, etc. that would pre-dispose them for higher risk of recurrence) radiotherapy is combined with concurrent chemotherapy (cisplatin 100mg/m^2 intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
45468351|NCT02251821|Other|Laboratory Biomarker Analysis|Correlative studies
46020896|NCT01265849|Drug|Indomethacin|One 25mg capsule of indomethacin was self administered orally (BID) beginning on day one of LI treatment daily until the day before surgery.
45468352|NCT02251821|Drug|Melphalan|Given IV
45468353|NCT02251821|Drug|Methotrexate|Given IV
45468354|NCT02251821|Drug|Mycophenolate Mofetil|Given IV or PO
45468355|NCT02251821|Drug|Ruxolitinib|Given PO
45468356|NCT02251821|Drug|Tacrolimus|Given IV or PO
45468357|NCT02251821|Radiation|Total-Body Irradiation|Undergo TBI
45468358|NCT02251821|Procedure|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplant
45468359|NCT05395325|Other|Kinesiotaping|Kinesio tape would be applied (1)over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. (2) from above the scapula spine to the medial deltoid. (3) from medial border of scapula to anterior deltoid.This intervention would be executed for five days per week for three weeks.
45468360|NCT05395325|Other|Hand rehabilitation program|In the thirty-minute hand rehabilitation program, a motor-relearning theory would be implemented into the intervention by teaching the participants how to use their upper limb properly without any compensatory motions. Therefore, for establishing a correct movement pattern, an occupational therapist would provide a hand-guided activity, in which the participants could practice reaching movement as well as hand grasp and release in a more natural way. Besides, the therapist would also help the patients release their muscle tone by stretching the spastic muscles for five minutes before and after this hand rehabilitation period
46020897|NCT01265849|Dietary Supplement|Zinc|One capsule daily self administered beginning on day one of treatment with LI until one day before surgery
46020898|NCT01265849|Procedure|Surgery|Excise tumor and nodes
45468361|NCT05395325|Other|Steroid injection|all the steroid injection would be executed by physicians. The 23G needles would be used for the injections. The examiners would be clear and familiar with the protocol, and the injections would be executed for only one time during the study period in experimental group.
45468362|NCT03439540|Dietary Supplement|Plantago major|Individuals receive Plantago major daily, for 12 weeks
45468363|NCT03439540|Dietary Supplement|Placebo|Individuals receive placebo daily, for 12 weeks
45468364|NCT03439384|Device|Home Telemonitoring|Patients will monitor their weight, blood pressure, oxygen saturation and symptoms with sensors and a tablet computer provided to them. Patients are asked to do this everyday for 60-days. A monitoring nurse will be receiving the data electronically and reviewing on a daily basis.
45468365|NCT05394701|Dietary Supplement|Omega-3 LipoMicel® soft gels|A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
45468366|NCT05394701|Dietary Supplement|RxOmega-3 soft gels (Enteric)|A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
45468367|NCT05394701|Dietary Supplement|Omega-3 Complete soft gels (Non-Enteric)|A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
45468368|NCT03439306|Device|Pulse Oximeter|The Pulse Oximeter are placed on the left and right Index fingers of each subject of the healthy adult volunteer group to evaluate the SpO2 accuracy performance.
45468369|NCT03784781|Biological|Biopsy|Mucosal biopsies under general anesthesia of the segmental bronchi of the right or left lower lobe
45468370|NCT03784781|Biological|Blood collection|Blood collection (+15mL/ current care)
45468371|NCT03784781|Biological|Bronchoalveolar lavage|Bronchoalveolar lavage fluid (3mL/Kg)
46020899|NCT01265849|Drug|Cisplatin|Cisplatin was administered 100mg/m^2 IV concurrent with radiotherapy. The chemotherapy agent (cisplatin 100mg/m^2) was administered intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
45468372|NCT03439150|Diagnostic Test|Absolute flow and resistance measurement|Absolute flow and resistance measurements immediately after PPCI of the culprit vessel (in a STEMI setting) and repeated absolute flow and resistance measurements after 3-7 days
45468373|NCT05383703|Drug|Treatment of MNC-168 enteric-coated capsules as a single oral drug|Treatment of live bacterium MNC-168 as a single oral agent as a single oral drug in subjects with advanced malignant solid tumors. First, live fungi can directly or indirectly inhibit tumor growth or induce tumor cell apoptosis through their metabolites or surface proteins, and can also regulate the immune system, especially the tumor microenvironment, to play an antitumor function. Second, tumor immunotherapies exhibit different response levels in different populations, and live bacterial analogs derived from gut microbes may enhance the response to immunotherapy in weakly responding patients.
45468374|NCT03538821|Dietary Supplement|Intact cod protein from fillet|Intact cod protein from fillet 8 g protein daily for 8 weeks
45468375|NCT03538821|Dietary Supplement|Intact cod protein from residual material|Intact cod protein from residual material, 8 g protein daily for 8 weeks
45468376|NCT03538821|Dietary Supplement|Control|Control group receive tablet containing fillers
45468377|NCT03438994|Diagnostic Test|Play.Care|iPad based game to assess movement as the player interacts with the screen
45468378|NCT03428477|Drug|Icosapent Ethyl|Composition: soft amber to light yellow, oblong gelatin capsules. One capsule contains 1g pure EPA-EE Dose: 4 capsules per day
45468379|NCT03428477|Other|Placebo|"Composition: soft, amber to light yellow, oblong gelatin capsules containing light mineral oil:~Dose: 4 capsules per day"
45468380|NCT05414162|Diagnostic Test|Cardiac MRI|Hematooncology patients under CAR T-cell therapy will receive 3 MRI examinations: at baseline, within 2 weeks of start of CAR T-cell therapy, and at 6 months follow-up.
45468381|NCT03438760|Behavioral|Science + Phonological Awareness|The goal is to facilitate phonological awareness during science lessons. Because phonological awareness does not relate to science learning, this is a placebo.
45468382|NCT03438760|Behavioral|Science + Grammar Intervention|The goal is to facilitate science learning by providing models, prompts, and experiences with grammatical structures related to science processes.
45468383|NCT03438760|Behavioral|Science + Vocabulary Intervention|The goal is to facilitate science learning by providing models, prompts, and experiences with vocabulary related to science processes.
45598506|NCT04465123|Drug|Spironolactone or hydrochlorothiazide|"Patients will be received spironolactone or hydrochlorothiazide in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone 100 mg every 12 hour for 72 hours.~If serum potassium levels >4 mEq/L, patients will be received hydrochlorothiazide 50 mg every 12 hour for 72 hours."
46020900|NCT01265849|Radiation|Radiotherapy|Total 60 to 70 Gy (2Gy per day) in 30 to 35 fractions over 6 to 7 weeks to subjects determined at surgery to be at lower risk for recurrence (per NCCN guidelines). For subjects determined at surgery to be at higher risk for recurrence due to having positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread etc. (per NCCN guidelines), radiotherapy (as above) is combined with concurrent chemotherapy (cisplatin 100 mg/m^2) intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
46020901|NCT01265615|Drug|Paricalcitol|paricalcitol group (6-8 μg daily per os - orally - without special diet)
46020902|NCT01265615|Drug|Calcitriol|calcitriol group (2-4 μg daily orally under with dietary restrictions of vitamin D)
46020903|NCT01265615|Drug|Cholecalciferol|cholecalciferol group (intake of cholecalciferol with recommended daily allowance equals 1200-2400 IU per day)
45468384|NCT02509689|Behavioral|Global Z-Score Neurofeedback Training|"The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.~Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions."
45468385|NCT03425201|Drug|Niraparib plus Cabozantinib|Non-randomized trial will comprise 2 stages. A dose escalation phase will characterize the safety, tolerability, DLTs and MTD, of oral niraparib plus cabozantinib in patients with urothelial or renal cell carcinoma. Subsequently, the phase II will further evaluate the safety and antitumor activity of this combination in patients with urothelial carcinoma.
45468386|NCT03438604|Drug|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
45468387|NCT05413538|Behavioral|Mindfulness training|The intervention recordings will teach the basic concepts of mindfulness through simple guided meditations with content supported by science. Each recording has the same format that included (1) a daily theme, (2) a meditation exercise echoing the theme, (3) a suggested exercise for practice, and (4) an invitation for participants to give a short response to their meditation experience at the end of the recording.
45468388|NCT03631160|Device|TAES treatmen|"In the acupoints group patients are treated with low-frequency pulse electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) at SP6 and BL 32 points during the operation in the operating room ,and at CV3 and CV4 acupoints for 45 minutes in postanesthesia Care Unit. After Deqi, electroacupuncture stimulation apparatus is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 ~ 30 milliamp (mA) (gradually increase to the patient's maximum tolerance) and maintained until the end of treatment."
45468389|NCT03631160|Device|Sham TAES treatmen|"Participants in the acupoints group receive shallow acupointing at SP6, BL 32 ,CV3 and CV4 (nonacupoints located 1 inch beside acupoints, about 20mm).Specifically, the acupoint is shamed without manual stimulation and Deqi and the stimulation apparatus is inefficiency without actual current output ."
45468390|NCT03433378|Drug|Tretinoin cream, 0.05%|Tretinoin cream, 0.05%
45468391|NCT03433378|Drug|RETIN-A® (tretinoin) cream, 0.05%|RETIN-A® (tretinoin) cream, 0.05%
45468392|NCT03433378|Drug|Vehicle of the test product|Vehicle of the test product
45468393|NCT03433300|Device|Ottobock Kenevo/C-Leg|Microprocessor-controlled prosthetic knee
46020904|NCT01265615|Dietary Supplement|Supplemental|intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day
46020905|NCT05548517|Behavioral|Time Restricted Eating (TRE)|9-hour eating window
46020906|NCT05548517|Behavioral|Calorie Restriction|daily calorie restriction
46020907|NCT05545865|Other|Low Flavanol Cocoa Powder|Measure the response 2 and 6 hours post low flavanol cocoa intake
45468394|NCT03433300|Device|Ottobock 3R60/3R62|Nonmicroprocessor-controlled knee
45468395|NCT01143311|Genetic|Arm A|"4 distinct biopsies will be taken~in a non UV-exposed area (inner arm)~in a UV-exposed area (external surface of the forearm)~in a pretumoral region (actinic keratosis)~inside the tumor"
45468396|NCT03433222|Device|HF-LED-RL Phototherapy|"The starting dose of 480 J/cm2 will be administered to Group 1's HF-LED-RL phototherapy randomized subjects and the HF-LED-RL dose will be escalated in the subsequent group to 640 J/cm2. Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity in 2 or more subjects and is considered the upper limit of subject tolerance.~All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks."
46020908|NCT05545865|Other|High Flavanol Cocoa Powder|Measure the response 2 and 6 hours post high flavanol cocoa intake
46020909|NCT05545865|Other|Vine to Bar Chocolate - 2 servings|Measure the response 2 and 6 hours post chocolate intake
46020910|NCT05545865|Other|Vine to Bar Chocolate - 1 serving|Measure the response 2 and 6 hours post chocolate intake
46020911|NCT05545865|Other|Vine to Bar Chocolate covered almonds|Measure the response 2 and 6 hours post chocolate covered almond intake
46020912|NCT01264835|Device|Slotted Anoscope|SA411
46105306|NCT04057534|Behavioral|Standard smoking cessation therapy for TUD plus Chess-based cognitive treatment|"Behavioral: standard smoking cessation therapy for TUD in group therapy setting.~Patients who voluntarily submit to enter a qualified smoking cessation program will be examined in an out-patient setting at the Department of Addictive Behaviour and Addiction Medicine. They receive a six-week standard therapy (one 1,5 hours group therapy per week). Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week. The tasks of the treatment were created by our cooperation partner, the psychologist Juan Antonio Montero. He is currently successfully applying this battery as an add-on therapy. The training battery is designed to strengthen cognitive functioning in specific domains such as short-term memory, focal attention, selective attention, pattern recognition, visuospatial abilities, metacognition and also inhibition."
45468397|NCT03433222|Device|Mock Therapy|"Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit. The mock therapy unit only generates warmth and does not emit LED-RL.~All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks."
46105307|NCT04057534|Behavioral|Standard therapy for TUD|"Behavioral: standard smoking cessation therapy for TUD in group therapy setting.~Patients who voluntarily submit to enter a qualified smokind cessation program will be examined in an out-patient setting at the Department of Addictive Behaviour and Addiction Medicine. They receive a six-week standard therapy (one 1,5 hours group therapy per week). Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week."
46020913|NCT00623909|Device|AvicennaTM class IV laser application|AvicennaTM class IV laser for application over the skin of human subjects in the treatment of post-thoracotomy pain syndrome. Six sessions, twenty minutes applications over a period of six weeks.
46105308|NCT04164485|Biological|Functional collagen scaffold transplantation|Injectable collagen scaffold combined with autologous adipose-derived cells will be injected into submucosa of vocal cord and paraglottic space under the surgical microscope
46020914|NCT01264679|Drug|Ferumoxytol|IV Ferumoxytol
46105309|NCT04164485|Biological|Autologous adipose cell transplantation|Autologous adipose-derived cells will be injected into the submucosa of vocal cord and paraglottic space under the surgical microscope
46105310|NCT00750022|Behavioral|Individualized IC treatment|Individuals will receive IC measurement at baseline and three months. Nutrition and physical activity plan will be developed and adjusted from measured RMR and lifestyle.
46105311|NCT00750022|Behavioral|Usual Care|Individuals will receive standard dietary plan. Women will receive 1200 Kcal/day and men will receive 1600 Kcal/day. Individuals will receive RMR measurement at three months. RMR information will be used to help improve eating behavior.
46105312|NCT01827605|Other|ZEVALIN|Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc).
46020915|NCT02889341|Dietary Supplement|DHA|
46020916|NCT02889341|Other|Placebo|
46020917|NCT05542667|Combination Product|Giomer varnish|After dryness and isolation are accomplished, Giomer varnish ( PRG coat barrier, by Shofu) will be applied once at the first treatment visit, one drop of PRG Coat Barrier ACTIVE will be added to the container provided in the package containing PRG Coat Barrier BASE the materials will be mixed together with a disposable tip provided by the kit a thin layer is to be applied and left untouched for 3 seconds according to manufacturer instructions and finally varnish is to be light-cured.
46020918|NCT05542667|Combination Product|Fluoride varnish|After dryness and isolation are accomplished, fluoride varnish (Biflourid 10, by Voco ) single-use type, the foil in the single-use Bifluorid 10 will be pierced using Micro-Tim brush, then a thin layer of the varnish is to be applied using a micro brush for four sessions at a frequency of one session each week, the varnish will be left undisturbed for 10-20 seconds then air-dried according to manufacturer instructions.
46020919|NCT05542043|Other|Data collection|"The data includes anamnestic and clinical data from women whose placental histology reveals a diagnosis of placental dysfunction.~Maternal data on the following characteristics: age, ethnicity, BMI, pregnancy, parity, number of abortions without curettage, multiple births, previous birth mode.~Risk factors for placentation disorders (increased maternal age, increased pregnancy and parity, increased BMI, placenta previa, nicotine abuse, multiple births, hypertension, diabetes, infections, bleeding, abortion curettage, hysteroscopy ± cavum curettage, caesarean section, fibroid removal, Asherman' s syndrome, status after IVF, endometritis) and birth mode.~Data on peripartal and postpartum surgical measures."
45468398|NCT03383666|Device|PulseRider® Aneurysm Neck Reconstruction Device|Neck Reconstruction Device
45468399|NCT01236131|Other|no intervention|Not Applicable- no intervention
45468400|NCT05016076|Drug|Dexamethasone 8 mg|In the designated patients, 8 mg of dexamethasone or placebo will be given intravenously within 10 minutes after the induction of anesthesia.
45468401|NCT05016076|Diagnostic Test|Applied inspiratory pressure (10, 15, 20, or 25 cmH2O)|A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea determined by end-tidal capnography occurs, a mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure (PEEP), at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator (Carestation 620, Datex-Ohmeda, Inc., Madison, WI, USA).
45468402|NCT05016076|Device|Tracheal intubation using video intubating stylet, video laryngoscopy, or direct laryngoscopy|In video intubating stylet group, a tracheal tube (ConvaTec, Berkshire, England, UK) in appropriate sizes is preloaded over the Trachway® video intubating stylet (TVI-4050, Markstein Sichtec Medical Corp, Taichung, Taiwan), which is introduced into oral cavity to visualize the epiglottis and guided to glottis via a monitor after full neuromuscular blockade is achieved. In video laryngoscopy group, a tracheal tube is preloaded over a GlideRite® stylet, which is specifically designed to work with GlideScope® video laryngoscope (Verathon Medical, Bothell, WA, USA). GlideScope® blade size 3 (GS-3) or 4 (GS-4) is used in all patients. In direct laryngoscopy group, tracheal tubes are prepared with a hockey stick-shaped stylet, and direct laryngoscopy is performed using a size-3 or -4 Macintosh blade (Rüsch Inc., Duluth, GA, USA).
45468403|NCT05016076|Device|Goal-directed hemodynamic therapy targeting cardiac index|Subjects of the GDHT group will be managed according to the ERAS algorithm utilizing ProAQT® parameters to maintain the cardiac index ≥ 2.5 l·min-1·m-2. In brief, if cardiac index < 2.5 l·min-1·m-2, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is < 10%. If cardiac index < 2.5 l·min-1·m-2 despite the stroke volume variation of ≥ 10% following fluid challenge, continuous intravenous infusion of dopamine 5-10 μg·kg-1·min-1 will be administered. If mean arterial pressure is < 70 mmHg despite cardiac index ≥ 2.5 l·min-1·m-2, intravenous infusion of norepinephrine 2-10 μg·min-1 will be used.
45468404|NCT05016076|Drug|Placebo (0.9% sodium chloride)|Placebo of 0.9% sodium chloride will be given intravenously within 10 minutes after the induction of anesthesia.
45468405|NCT01145027|Other|Breakfast tray|The sensorial stimulus will be a breakfast meal, with excellent presentation and aroma, composed by favorite food items previously related by the individual for this meal. The meal will not be offered for immediate intake, it will be placed in front of the volunteer for perception of the smell and taste.
45468406|NCT03707405|Behavioral|Ride-On Cars Training with Different Postures|All programs will include 120 minutes/per session, 2 sessions/per week. All participants will continue their regular therapy during the whole study. The treatment strategy of ROC training with different postures will be based on the exploratory learning which focuses on providing opportunities to the participants to explore environmental properties with various motor patterns during the intervention.
46020920|NCT01263665|Device|25 cm GORE® VIABAHN®|25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, possibly in conjunction with an additional overlapping VIABAHN® device (2.5, 5, 10, 15, or 25 cm lengths) based on the enrolled patient's lesion length (greater than or equal to 20 cm length).
46020921|NCT04323371|Diagnostic Test|ELISA|Blood and derived fluids will be collected from 26 ADHF CS patients admitted to intensive care at Niguarda Hospital and locally stored.Stocked samples will be shipped to the Central Laboratories at Milano Uni and MilaIFC-CNR for the metabolomic and biomarkers analysis,respectively.To evaluate interleukin-6 (marker of systemic inflammation),angiopoietin-2 (marker of endothelial permeability), syndecan-1 and heparan sulfate (markers of endothelial glycocalyx),2 aliquotes of serum samples will be used by IFC CNR.The biomarkers will be assessed through ELISA analytical techniques, based on the interactions inside a microplate between a primary pre-coated antibody and the specific protein contained in serum samples.A secondary antibody, link to a horseradish peroxidase (HRP) detection system, is able to recognize and bind the antigen, and to produce a colorimetric reaction after the addition of enzyme substrate which is proportional to the amount of the target protein bound
46020922|NCT01263509|Drug|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
46020923|NCT01263509|Drug|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
46020924|NCT01263197|Drug|LY2216684|administered orally
46020925|NCT01263197|Drug|albuterol|administered orally
46020926|NCT01263197|Drug|propranolol|administered orally
46020927|NCT01263197|Drug|placebo for LY2216684|administered orally
46020928|NCT01263197|Drug|placebo for albuterol|administered orally
46020929|NCT01263197|Drug|placebo for propranolol|administered orally
46020930|NCT01263119|Drug|Warfarin|10-mg warfarin oral dose
46020931|NCT01263119|Drug|LY2216684|18-mg LY2216684 oral dose
46105313|NCT01827605|Drug|BEAM|"BEAM REGIMEN day -6 Carmustine* 300 mg/ m2 i.v. in 250ml dextrose 5% solution~from day -5 to day -2 Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr Etoposide 100 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr~day 0~UReinfusion of autologous stem cells following this rules:~Patient collecting ≥6x106 CD34+ cells/kg use >4x106 CD34+ cells/kg for ASCT and keep >2x106 CD34+ cells/kg for back up;~Patient collecting 4-6x106 CD34+ cells/kg use >2x106 CD34+ cells/kg for ASCT and keep >2x106 CD34+ cells/kg for back up;~Patient collecting 2-4x106 CD34+ cells/kg use all CD34+ cells for ASCT and keep no back up.~day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC > 1500/mmc"
46105314|NCT04057300|Drug|Ticagrelor 90mg|Ticagrelor tablet
45468407|NCT03086018|Device|Successor hearing aid to Juna|The participants will all be experienced hearing instrument device users and will be switched from their current (control) devices to the new test device which succeeds the Juna device.
45468408|NCT03319953|Drug|TAK-041|TAK-041 suspension
45468409|NCT03319953|Drug|Placebo|TAK-041 placebo-matching suspension
45468410|NCT03319953|Drug|Second Generation Antipsychotics (SGA)|Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.
45468411|NCT03433144|Drug|Tranexamic Acid Injectable Solution|the drug will be given to patients intravenously at a dose of 10mg/kg pre-operatively after induction on general anesthesia
45468412|NCT03433144|Other|Placebo (normal saline 0.9%)|An equivalent amount of normal saline (0.9%) will be given to the patient pre-operatively after induction of general anesthesia. The amount of saline given will correspond to the same amount of fluid which would have been given had the patient been in the intervention group.
45468413|NCT05303129|Biological|Blood sampling|Blood sampling for Lymphocyte typing (Neutrophil/Lymphocyte ratio (NLR), CD4+ and CD8+ lymphocyte counts )
45468414|NCT03433066|Procedure|Advanced platelet-rich fibrin mixed with biphasic alloplast|mucoperiosteal flaps will be reflected to expose the defects , which will be debrided properly and finally filled with the freshly prepared Advanced platelet-rich fibrin mixed with the biphasic alloplast.
46020932|NCT05537597|Procedure|active M1-rTMS|"Magnetic stimulation will be carried out using a MagPro X100 machine with a MCF-B70 figure-of-eight coil (Magventure, Farum). All rTMS sessions will be assisted by a neuronavigation system (TMS Navigator，Localite GmbH), maintaining the M1 target and the orientation of coil stable during stimulation sessions. The M1 target was defined as the hand knob region, which corresponds to the motor cortical representation of the hand, regardless of the location of pain.~Stimulation paradigm consists of 20 trains of pulses with an intra-train frequency of 20 Hz, resulting in 2000 pulses for a total duration of 20 minutes.~The stimulation intensity will be 80% of RMT, defined as the lowest stimulation intensity necessary to induce a visible muscle twitch of the hand contralateral to the stimulated hemisphere.~Participants will receive 7 sessions of treatment once a day in the same time continuously for 7 days, and keep antiparkinsonism drugs unchanged throughout the whole study."
46020933|NCT05537597|Procedure|sham rTMS|"The sham protocol was similar to the rTMS protocol. Sham stimulations will be performed with a MCF-P-B65 figure-of-eight coil (Magventure) to M1, assisted by a neuronavigation system.~The following stimulation parameters will be used: stimulus frequency 20 Hz; stimulus intensity 80 % of RMT; total stimulation pulses 2,000; total stimulation time 20 min.~Participants will receive 7 sessions of treatment once a day in the same time continuously for 7 days, and keep antiparkinsonism drugs unchanged throughout the whole study."
46020934|NCT01262651|Drug|Nabiximols|
46105315|NCT04057300|Drug|Clopidogrel 75mg|Clopidogrel tablet
46105316|NCT04057300|Drug|acetylsalicylic acid (ASA) 81mg|acetylsalicylic acid tablet
45468415|NCT03433066|Procedure|Biphasic alloplast mixed with saline|mucoperiosteal flap will be reflected to expose and clean the intrabony defect ,then it will be filled with biphasic alloplast mixed with saline.
45468416|NCT01142609|Behavioral|eGet|eGet individual counseling sessions from home will be scheduled weekly for 12 weeks.
45468417|NCT01384214|Biological|botulinum toxin Type A|750 U at Visit 1
45468418|NCT03432988|Behavioral|Nursing Solution-Focused|Two two-hour training modules were designed. In each module, participants watched videos that illustrated solution-focused communication on fluid adherence, and practiced the skills in role-plays. Solution-focused communication on IDWG. In the case of IDWG improvement, nurses were trained to congratulate the patient and then to explore in detail, from a stance of curiosity, how s/he had accomplished the weight reduction. Nurses were trained to invite patients to share specific behavioral details, to describe their own behavior from the perspective of significant family members and also to compliment patients on their accomplishments and to invite them to keep track of anything else they might find useful to control fluid intake over the next days.
45468419|NCT02927834|Drug|6 day Prednisone|6 day prednisone burst
46105317|NCT02638181|Procedure|trabeculectomy|
45468420|NCT02927834|Drug|Augmentin|Antibiotic augmentin for 3 weeks
45468421|NCT02927834|Drug|21 day Prednisone|21 day prednisone burst
45468422|NCT01236209|Other|Webpage|one arm having access to a webpage with information about coping with pain and relaxation exercises
45468423|NCT01236209|Other|Webpage and situation feedback|having access to the same web-page with information about coping with pain and relaxation relaxation and completing 3 diaries and receiving situational feedback for 4 weeks at home through a web enabled mobile phone.
46105318|NCT02561728|Device|Hangar Helmet|Child will be fitted with the Hangar Helmet
45468424|NCT03432910|Other|CPAP Titration using a Bilevel S/T mode with minimal pressure support and background rate|The study performs within clinical routine with this exception that instead of the usually applied CPAP mode a modified BiLevel S/T mode is used. The modified BiLevel S/T mode meets the same requirements as the CPAP mode while providing the Forced Breath Technique to classify apneas as central or obstructive.
46105319|NCT02561728|Device|P-Pod Helmet|Child will be fitted with the P-Pod Helmet
46105320|NCT00655967|Drug|Acamprosate (Campral)|"During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance >50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.~Treatment compliance will be monitored by counts of returned medication. Records of all concomitant medications will be taken at each study visit as well as reports of adverse events (as shown above)."
46020935|NCT01262651|Drug|Placebo (GA-0034)|
46105321|NCT00655967|Drug|Acamprosate|During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance >50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.
45468425|NCT03757637|Other|NLSCP|Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. In addition to receive hospital routine case manager care, patients in this groups will further receive either NLSCP (Exp-1). Patients will be provided the same major education and counseling contents for the first two section of interventions through face-by-face by trained research nurses at time of (1) first intervention: one day before hospital discharge in post-operation, and (2) second intervention: first OPD visit (first week after hospital discharge). This group will receive a face-to-face education or counseling by trained research nurse.
46105322|NCT00750100|Drug|human chorionic gonadotropin|hCG 200IU in the late follicular phase
46020936|NCT01262573|Procedure|Closure of vaginal cuff|Closure of the vaginal cuff
46105323|NCT00750100|Drug|recombinant gonadotropins|200 IU per day during controlled ovarian stimulation
46105324|NCT00655031|Dietary Supplement|Pomegranate Concentrate (POMx)|3.3 oz bottle containing antioxidants equivalent to 8 oz of pomegranate juice taken once daily for 7 days prior to infection and for 4 days after.
46105325|NCT00655031|Dietary Supplement|Placebo|3.3 oz bottle containing fruit flavored juice low in antioxidants taken once daily for 7 days prior to infection and for 4 days after.
46105326|NCT00655109|Drug|Olopatadine|Ophthalmic solution
46105327|NCT00655109|Drug|Fluticasone|Nasal spray
46105328|NCT00655109|Drug|Saline|Nasal spray
46105329|NCT00655109|Drug|Artificial tears|Ophthalmic Solution
46105330|NCT00656045|Behavioral|Dietary|All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
46020937|NCT04323059|Dietary Supplement|Standardized milk-based formulation|Nutritional formulations prepared from locally available food stuffs for reversing childhood malnutrition
46020938|NCT04323215|Device|Support system|A support system named Provement will be used to provide behavioral treatment.
46105331|NCT00656045|Behavioral|Physical Activity|The Physical Activity arm will receive an activity goal (200 minutes/week of moderate-intense physical activity).
46105332|NCT00656045|Behavioral|TV Watching|The TV Watching arm will receive a TV watching goal of watching less than 10 hours of TV/week.
46105333|NCT02632877|Drug|Pirfenidone with MODD|Patients with diabetic foot ulcer will be treated three times a day with a smooth layer (standar finger tip unit 0.5g for an area of 100 to 120 square centimeters) of KitosCell Q (Pirfenidone with MODD) in form of gel and the wound will be covered with a bandage.
46020939|NCT04322903|Behavioral|Passport to Freedom (P2F)|During the P2F sessions, the women learn to understand and process the impact of multiple traumas on women's lives and health and learn specific strategies to overcome the symptoms of trauma and everyday stress. Each session will begin and end with a mindfulness exercise to provide different strategies the women can use when these women are in a stressful situation. At the end of each session, the participants will complete a session evaluation. The women will also have a home visit or telephone call with a community health navigator who will conduct a social determinant of health screenings assessment to determine what identified social barriers these women may have. The community health navigator will help with linking the participant to a community agency that addresses the identified problem. Four weeks after the completion of the program, the women will be contacted for a follow-up interview to learn the effectiveness of the program sessions.
46020940|NCT04322045|Diagnostic Test|multi-parametric MRI|Multi-parametric MRI will be suggested for those PSA ≥4 ng/mL, PI-RADS v2 score will be used to evaluate images.
46020941|NCT04322201|Device|continuous drainage of ascitic fluid using an intra-abdominal double lumen central venous catheter|Ultrasound-guided placement of an intra-abdominal double lumen central venous catheter, using aseptic Seldinger technique, for continuous drainage of ascitic fluid up to 7 days in Intensive Care
46020942|NCT04322201|Procedure|Ultrasound-guided intermittent large-volume paracentesis|Ultrasound-guided intermittent large-volume paracentesis through 14 Gauge catheter
46105334|NCT02632877|Drug|Ketanserin|Patients will be administered ketanserin twice a day usign the standar finger tip unit (0.5g for an area of 100 to 120 square centimeters) and the wound will be covered with a bandage. This arm is a control for evolution of diabetic foot ulcer.
46105335|NCT04163705|Diagnostic Test|blood sample collection|Routine Laboratory Analysis
46105336|NCT00656123|Biological|Colon GVAX|Dose escalation: 1.4x10^8 to 7x10^8 cells administered in up to 15 intradermal injections on Day 2 of Cycles 1-4
46105337|NCT00656123|Drug|cyclophosphamide|200 mg/m^2 administered IV on Day 1 of Cycles 1-4
46105338|NCT04032431|Behavioral|Telerehab VR intervention|Training with VR system using software specifically designed to reproduce activities of daily living
46105339|NCT04163471|Device|Radial artery mechanical compression for hemostasis|Transradial hemostasis following arterial catheterization procedures
46105340|NCT00657449|Drug|valdecoxib|valdecoxib 80 mg (two 40 mg tablets) by mouth on Day 1 and valdecoxib 40 mg tablet once daily on Days 2-8
45468426|NCT03757637|Other|ICT supported HAP|Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. In addition to receive hospital routine case manager care, patients in the groups will further receive ICT supported HAP (Exp-2) intervention. For this groups, patients will be provided the same major education and counseling contents for the first two section of interventions through face-by-face by trained research nurses at time of (1) first intervention: one day before hospital discharge in post-operation, and (2) second intervention: first OPD visit (first week after hospital discharge). The group will receive the interactive mobile phone App.
45468427|NCT03269396|Procedure|Larynx Allograft Transplantation|This study is a prospective clinical trial designed to assess the efficacy and safety of laryngeal transplantation. A total of 10 patients will be enrolled over a five-year timeframe. Study length is 5 years.
45468428|NCT04000594|Drug|RO7234292 (RG6042)|RO7234292 (RG6042) will be administered in two IT doses of the same dose level at an interval of 28 days during the treatment period (Day 1 and Day 29). Each dose of RO7234292 (RG6042) will be administered as a single IT bolus injection.
45681237|NCT04199494|Other|Antibiotic Stewardship Program|The patient do the routinely preoperative lab tests, including the rectal swab (RS). The Antibiotic Stewardship Program (ASP) has been shown to effectively reduce unnecessary antibiotic use and optimize the treatment of infectious diseases. To be successful, multiple aspects should be considered in the ASP. Initially, the infection control specialists will follow the routine activity of each department in order to define what could immediately be improved. Internal antibiotic prophylaxis and therapy guidelines will be defined and shared between groups. The RS, collected at the preoperative testing, is evaluated by the infection control specialist. In case of identification of MDR bacteria, each patient will receive a tailored AP based on the antibiograms of the RS. In any case, the infection control specialist will choose the best solution for the patient avoiding the key antibiotics
46020943|NCT02889185|Device|RTX1 IMAGIN EYE retinal camera|In addition to the routine examination including OCT, an imaging using RTX1 IMAGIN EYE retinal camera will be performed.
46020944|NCT01262027|Drug|Dovitinib|500 mg by mouth for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle.
46020945|NCT01261793|Drug|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
46020946|NCT01261793|Drug|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
46020947|NCT01261793|Drug|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
46105341|NCT00657449|Drug|rofecoxib|rofecoxib 50 mg (two 25 mg capsules) by mouth once daily for 8 days
46105342|NCT04160195|Biological|Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells|Dose-escalation trial starting dose: 0.66 x10^6 CAR+ T cells/kg (weight-based dosing one time) (up to a maximum dose of 10x10^6 CAR+ T cells/kg based on cohort) infuse on day 0
46105343|NCT04160195|Drug|Cyclophosphamide|500 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
46105344|NCT04160195|Drug|Fludarabine|30 mg/m^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
46105345|NCT04159883|Other|strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles)|Simple progressive strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles), the program has been evident to be significantly effective in improving self-reported knee pain and function. This program included: 1) Isometric quadriceps contraction, 2) Isotonic quadriceps contraction, 3) Isotonic hamstring contraction, 4) Isotonic quadriceps contraction with resistance band, 5), straight leg raising, 6) Side-lying hip abduction, 7) Partial Squats,
46105346|NCT04159883|Other|"My Dear Knee smart phone application"|"The innovative app has been designed for Android and iPhone Operating System (iOS). The app provides guides with the Arabic language. It designed to be attractive for the older adult and easy to use. the exercises are demonstrated with colorful animated images to make easy to follow by the patients.~The app supports features such as alerts, monitoring system by the physical therapist and remote follow-up. The app provides automatic recording of exercise adherence, including the time and the number of sessions completed for the week in the physical therapist's account."
46105347|NCT00911261|Drug|Oxymorphone Extended Release|"Study Medication: Oxymorphone ER 5 mg, 10 mg, 20 mg, and 40 mg tablets~Rescue Medication: Oxymorphone IR 5 mg and 10 mg tablets~Treatment will consist of up to 12 months of dosing with Oxymorphone ER."
45468429|NCT03170180|Drug|Sunitinib|sunitinib 37.5mg daily
45468430|NCT03170180|Drug|Gefitinib|Gefitinib 250mg daily
45468431|NCT03170180|Drug|Imatinib|Imatinib 400mg daily
45468432|NCT03319667|Drug|Isatuximab SAR650984|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous (IV)"
45468433|NCT03319667|Drug|Bortezomib|"Pharmaceutical form: Lyophilized powder for injection~Route of administration: Subcutaneous"
45468434|NCT03319667|Drug|Lenalidomide|"Pharmaceutical form: Capsules~Route of administration: Oral"
45468435|NCT03319667|Drug|Dexamethasone|"Pharmaceutical form: Tablets, ampoules or vials for injection~Route of administration: Oral/Intravenous"
46020948|NCT04321967|Drug|Nitroglycerin Paste|1g of 2% Nitroglycerin paste topical application
46020949|NCT04321967|Drug|Dermabond|Topical skin adhesive
46105348|NCT00686374|Biological|Adalimumab|Participants who enrolled into the study from blinded therapy in Study M06-806 received open-label (OL) therapy at a dose dependent on their body weight. Participants weighing ≥ 40 kg received 40 mg of adalimumab every other week (eow), and those who weighed < 40 kg received 20 mg of adalimumab eow. Starting at Week 8, participants who had a disease flare may have been switched to every week (ew) treatment at the same dose of adalimumab received while on eow treatment. Participants who enrolled from OL therapy in Study M06-806 continued to receive the same dose they were receiving (i.e., 40 mg ew or 20 mg ew) at the Week 52 visit of Study M06-806. Adalimumab dose could have been decreased to the next lower treatment level for those with body weight changes. Participants who responded to treatment may have also had their dosage frequency decreased from ew to eow dosing, as well as a decrease in dosage.
46105349|NCT00750178|Drug|vorinostat (MK0683 )|"Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28~Total treatment period is 28 days"
46020950|NCT04321655|Other|High Intensity LASER Therapy (HILT)|"The total energy will be delivered to the patient during one session will be 1,250 J through three phases of treatment.~Initial phase (710 and 810 mJ (millijoule)/cm2 for a total of 500 J)~Intermediate phase (handpiece will be applied on the joint line just proximal to the medial and lateral tibial condyles with 25 J, a fluency of 610 mJ/cm2, and a time of 14 s for each point and a total of 250 J)~Final phase (same as the initial phase (500 J) except that scanning will be slow manual scanning ) The application time for all three phases will be approximately 15 min with the total energy delivered to the patient during one session of 1,250 J"
46105350|NCT04159961|Drug|DWJ211|Inject the Drug into submental fat and abdominal fat via subcutaneous
45468436|NCT02521480|Device|Active Transcranial Magnetic Stimulation|TMS is a non-invasive treatment. During TMS treatment, a coil, which creates a magnetic field, will be placed on the left prefrontal area of the head. Active TMS will stimulate for 4 seconds, pause for 26 seconds, and repeat this for approximately 40 minutes. There will be a total of 3000 pulses during treatment. We expect TMS to decrease pain and depression. In order to find out if this is true, we will compare real TMS with sham (inactive) TMS.This will allow us to decide if active TMS is successful because of electrical stimulation, or because of the support, concern, and understanding of the research team.
46105351|NCT00750256|Drug|GSK1278863A|GSK1278863A planned doses from 2mg to 450mg which may change based on safety or PK from previous cohorts.
45468437|NCT02521480|Device|Sham Transcranial Magnetic Stimulation|Inactive treatment (simulation of active TMS)
45468438|NCT04698590|Device|Wavefront Guided Scleral Lenses|Custom wavefront guided, higher order aberration correcting scleral lenses
46105352|NCT00750334|Drug|clofarabine|Drug given Daily x 14 days and 7 days of rest for 21 day cycle
45468439|NCT04698590|Device|Traditional Scleral Lenses|Traditional scleral lenses
45681238|NCT04193488|Behavioral|MTP block|In the MTP Group, a high frequency HFL-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Using the parasagital scan, the block needle (50 mm 22 Gauge) will be advanced from the caudal to the cervical target of the paravertebral space. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml saline is performed. Once the needle tip has been confirmed, 20 ml of 0.25% bupivacaine will be given to the block. The same procedure will be applied 3 cm later than the incision line.
45681239|NCT04193488|Behavioral|ESP block|In the ESP group, a high-frequency 15-6 megahertz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Once the erector spinae muscle and transver projections have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml saline injection, this plane will open. Twenty milliliters of 0.25% bupivacaine will be given for the block. The same procedure will be applied from the other 3 cm lateral of the incision line.
45681240|NCT04193488|Behavioral|No Block group|No regional plan block will be applied to the control group. Conventional analgesic methods were applied.
46105353|NCT00750334|Drug|clofarabine|Drug given Daily X 14 days and 7 days of rest for 21 day cycle
46105354|NCT00750412|Behavioral|TeenScreen Program|Adolescents who are randomized into the TeenScreen program and their parent/guardian will receive post-screening information, a facilitated referral, and case management services from a research social worker.
46105355|NCT04056832|Procedure|Single Strip Pericardium|The anterior pericardium is taken in accordance with the measurements made using an aortic annulus sizer or Ismail sizer. The diameter of the annulus valve is converted to circumference of the aortic valve according as a measure of the length of the pericardium. Measurement of aortic commissure height is done by measuring the distance between the lowest point of the valve attachment to the highest point on the commissure as a measure of pericardium width. The pericardium is immersed in 0.6% glutaraldehyde solution for 10 minutes, then rinsed and soaked with saline solution 3 times for 6 minutes each. After the pericardium becomes firm it is cut to be a single strip according to the length and width in the previous measurement. It is then sutured to the aortic valve annulus.
45468440|NCT03432754|Behavioral|Mindfulness-Based Attention Training|The mindfulness-based attention training is closely modeled after the traditional mindfulness-based stress reduction (MBSR) protocol, it incorporates formal MBSR practices such as breath exercises, body scans and long sitting meditations. Specifically, MBAT is an abbreviated version of MBSR with a focus on the cognitive components.
46105356|NCT04056832|Procedure|Mechanical Prosthetic Valve|Median incision is performed at the surgical site. Sternal retractor is placed at the sternum after median sternotomy being performed. Aortic valve is measured using aortic annulus sizer. Pledgeted suture is performed for the mattress. Sutures are performed to attach the mechanical prosthetic to the aortic annulus.
46020951|NCT04321655|Other|Ibuprofen Gel Phonophoresis (IGP)|Continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis. (8 min/ one session each day for 3 days/week for 8 weeks).
46020952|NCT04321655|Other|Transcranial Direct Current Stimulation (tDCS)|Anode electrode -C3/C4 (contralateral side of the most affected knee), Cathode electrode- contralateral supraorbital area. (2 mA intensity for 20 minutes, one session/day for 3 days/week for 8 weeks)
46105357|NCT02561416|Behavioral|MBSR|Session 1: Recognising the present moment Session 2: Engaging with the breath Session 3: Practice, practice, practice Session 4: Stress and the flow of emotions Session 5: Stress and thoughts: finding another place to stand Session 6: Interpersonal mindfulness / mindful communication. Session 7: Applying mindfulness Session 8: Making mindfulness a part of your life
46105358|NCT02561416|Behavioral|FibroQol|"Session 1: General information. Expectations of the patients. History of the illness. Principal and secondary symptoms in FM. Physiological mechanisms involved in the genesis of pain.~Session 2: Relaxation training-I. Session 3: Diagnosis. Pharmacological and non-pharmacological treatments. Prognosis. Current model of health care in Catalonia. Units specialized in the treatment of FM.~Session 4: Relaxation training-II. Session 5: Strategies to increase self-esteem and regulate emotions. Pain experience and recurrent invalidation. Social support (family and friends).~Session 6: Relaxation training-III Session 7: Benefits of physical exercise in FM. Session 8: Relaxation training-IV."
46105359|NCT02561416|Drug|TAU|In Spain the treatment as usual provided in FMS is mainly pharmacological and adjusted to the symptomatic profile of the patient. Counselling about aerobic exercise adjusted to patients' physical limitations is usually also provided.
46105360|NCT00571948|Other|more meat and a vegetable oil rich in omega-3 fatty acids|"The vegetable-potato-meat-meal was given 5 to 7 times a week for at least during the seventh to tenth month.~The intervention meals had more meat (about 13 % of weight) and rapeseed oil (rich in omega-3 fatty acids)."
46105361|NCT00571948|Other|Babyfood with usual meat content and corn oil|The active comparator (which is the control group) got babyfood with usual meat content (8%) and with corn oil, which is rich in omega 6 linoleic acid
46105362|NCT04054726|Device|Active Transcranial pulsed current stimulation (tPCS)|Active tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anode will be placed on the scalp over the cerebellum area (2 cm under the inion). Cathode will be placed over the dorsal cord. Stimulation will be given for 20 mins.
46105363|NCT04054726|Device|Sham Transcranial pulsed current stimulation (tPCS)|Sham tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anode will be placed on the scalp over the cerebellum area (2 cm under the inion). Cathode will be placed over the dorsal cord. The electric current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
46105364|NCT00752284|Procedure|Coronectomy|Coronectomy Group. Removal of crown of lower wisdom tooth, trim down root below crestal bone and primary closure
46020953|NCT04321655|Other|Conventional Physiotherapy (CPT)|"Warm-up exercises: Walking at the usual speed on a flat surface for 10 min ( 3sets X10 Reps X 3 min rest in between)~Hamstring and calf gentle stretches. ( 3sets X10 Reps X 3 min rest in between)~Straight leg raise (SLR) ( 3sets X10 Reps X 3 min rest in between)~Quadriceps setting ( 3sets X10 Reps X 3 min rest in between)~Pillow squeeze ( 3sets X10 Reps X 3 min rest in between)~Heel raise ( 3sets X10 Reps X 3 min rest in between)~One leg balance ( 3sets X10 Reps X 3 min rest in between)~Step ups ( 3sets X10 Reps X 3 min rest in between)~Quadriceps strengthening exercises ( 3sets X10 Reps X 3 min rest in between)"
46105365|NCT00752284|Procedure|Total Excision|Total excision of lower third molar
46105366|NCT00752362|Device|Milennium Matrix® (Control)|Percutaneous coronary intervention with bare metal stent
46020954|NCT04207541|Behavioral|Brief motivational interview|Client (who has suboptimal diabetic control with oral anti-diabetic agent) will be advised for insulin initiation with brief motivational interviewing in one session of individual education.
46105367|NCT00752362|Device|Infinnium®|Percutaneous coronary intervention with paclitaxel-eluting stent
46105368|NCT00752362|Device|Supralimus®|Percutaneous coronary intervention with sirolimus-eluting stent
46105369|NCT04054258|Device|App support Programme (ASP) group|All subjects will continue their usual care with prescribed medical treatments, ED nursing advice, and follow-ups as indicated. In addition to the above usual care, bi-weekly 20 minutes telephone follow ups will be provided by a trained research nurse (B) up to 3 months. Patients can ask related health problems if any. The nurse will address their problem by providing advices or refer them to the ED follow up clinic if the problems cannot be solved by the nurse.
46105370|NCT00684424|Other|Non-Interventional Study|Observational Only
46020955|NCT05532605|Other|cardiac rehabilitation phase I protocols|cardiac rehab phase I protocols: ankel pumps, limbs ROMs, bed mobility. Do 5-10 minutes daily of breath awareness practice on your own.
46020956|NCT05532605|Other|Cardiac rehab phase I protocols + Mindfullness base therapy|cardiac rehab phase I protocols: ankel pumps, limbs ROMs, bed mobility. Do 5-10 minutes daily of breath awareness practice on your own. Plus Mindfullness base therapy
46105371|NCT00752440|Other|Inspiratory muscle training (IMT)|IMT (30 min 7 times per week, for 8 weeks)
46105372|NCT00745186|Drug|Glucagen|0.2 mg or 1 mg Glucagen single injection
46105373|NCT00745186|Drug|Mayne Glucagon|0.2 mg or 1 mg Mayne Glucagon
46020957|NCT04321499|Genetic|lung cancer|PCR for SHOX2 and PTGER4
46105374|NCT00750646|Device|MEMS cap|The Medication Event Monitoring System will be used to assess the level of subject adherence to recommended topical eye drop therapy.
46105375|NCT04056364|Biological|sputum cytology|Sputum cytology refers to the examination of sputum (mucus) under a microscope to look for abnormal or cancerous cells. Sputum, or phlegm, is the fluid that is secreted by cells in the lower respiratory tract such as the bronchi and the trachea. It differs from saliva, in that it contains cells that line the respiratory passages.
46105376|NCT00750724|Drug|"25 mg sodium hyaluronate GO ON"|25 mg sodium hyaluronate, 2 ml., intraarticular weekly for 5 weeks
46105377|NCT00750724|Drug|normal saline,2 ml., intraarticular weekly for 5 weeks|
46105378|NCT00685750|Procedure|Collection of tumor and blood samples|Samples will be collected before and after standard treatment
46105379|NCT02561104|Procedure|Laser-assisted cataract surgery.|
46105380|NCT02561104|Procedure|Traditional manual phacoemulsification|
46105381|NCT00752518|Drug|bortezomib|
46105382|NCT00752596|Drug|Azimilide 2HCl|One tablet of 125 mg/day azimilide 2HCl, taken until the study is terminated
46105383|NCT00923728|Drug|AVN944|
46105384|NCT00745264|Drug|Diractin|100 mg Ketoprofen to 2 joints
46105385|NCT00745264|Drug|Diractin|400 mg ketoprofen to 4 joints
46105386|NCT00745264|Drug|Diractin|100 and 400 mg Ketoprofen used concomittant with heat
46105387|NCT00745264|Drug|Diractin|100 and 400 mg Ketoprofen concomittant with moderate exercise
46105388|NCT00752674|Other|Neuromuscular balance|
46105389|NCT00750802|Drug|AZD6280|10mg Capsule, oral, single-dose
46105390|NCT00750802|Drug|AZD6280|40mg Capsule, oral, single-dose
46105391|NCT00750802|Drug|Lorazepam|2mg tablet, oral single-dose
46105392|NCT00750802|Drug|Placebo|
45681241|NCT03023098|Device|Conventional PTA|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a conventional balloon
46020958|NCT04321577|Procedure|Radical surgery|Radical surgery is proposed to participants with pT1b, pT2 or pT3 tumors in the cholecystectomy specimen without evidence of disseminated disease with staging imaging techniques. A resection of the gallbladder bed or an anatomic resection of the hepatic segments IVb/V is performed. A lymphadenectomy of the hepatic hilum is associated in all cases. Common bile duct resection is performed in patients with involvement of the cystic margin.
46105393|NCT00750958|Procedure|NetGuard Automated Clinician Alert System|Monitoring System for in-hospital patients who are typically unmonitored. Identifies and alarms for cardiac rhythm changes.
46105394|NCT00745342|Behavioral|Family Teamwork Intervention|Families in the teamwork group received quarterly psychoeducational interventions at regular clinic visits, focusing on promoting family teamwork and reducing diabetes-specific family conflict and diabetes burnout.
46105395|NCT02563444|Device|Ultrasound fusion guiding system - TUS A-500 (Aplio 500)|
46105396|NCT00751192|Device|HIV-testing motivational videos|
46105397|NCT00751192|Device|Standard public health text|
46105398|NCT00751270|Biological|AdV-tk|Three different dosing levels of AdV-tk (3x10e10, 1x10e11, 3X10e11) were evaluated. A single injection of AdV-tk at the assigned dose level was administered, followed by 14 days of the oral prodrug valacyclovir. Patients then received standard of care radiation therapy and chemotherapy.
46105399|NCT00751270|Drug|Valacyclovir|The oral prodrug valacyclovir was given beginning 1-3 days following the AdV-tk. Valacyclovir tablets were taken three times a day for a total of 14 days.
46105400|NCT00751504|Drug|Quetiapine|Dosage form: tablets Dosage: between 300 mg/die and 600 mg/die Frequency: once daily Duration: 6 weeks
46105401|NCT00751582|Dietary Supplement|Food supplementation and nutrition education|Food supplementation and nutrition education for three months
46105402|NCT00751582|Behavioral|Nutrition education|Nutrition education for children for three months
46105403|NCT00751582|Other|Control Group|No Nutrition Education
46105404|NCT00751660|Other|laboratory biomarker analysis|
46105405|NCT00751660|Other|screening questionnaire administration|
46105406|NCT00751660|Procedure|bronchoscopic and lung imaging studies|
46105407|NCT00751660|Procedure|computed tomography|
46105408|NCT00751660|Procedure|endoscopic biopsy|
46105409|NCT00751660|Procedure|quality-of-life assessment|
46105410|NCT00576628|Drug|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Recommended starting dose 1.2 micrograms/kg sc monthly
46105411|NCT02561650|Drug|COV155|COV155 tablets
46105412|NCT00752830|Drug|AZD0328|Oral capsule, single dose
46105413|NCT00683878|Drug|Dapagliflozin|Tablets, Oral, 5.0 mg, once daily, up to 48 weeks
46105414|NCT00683878|Drug|Dapagliflozin|Tablets, Oral, 10.0 mg, once daily, up to 48 weeks
46020959|NCT04321889|Device|defurocumarinized bergamot loaded in a nanotechnological essential oil release system|Patients will be treated either with placebo cream or with defurocumarinized bergamot loaded in a nanotechnological system of essential oil release in the pharmaceutical form of cream 2 times a day for 4 weeks. The subject will be monitored throughout the treatment and for at least 4 weeks after the end of the treatment.
46105415|NCT00683878|Drug|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, up to 48 weeks
46105416|NCT00683878|Drug|Thiazolidinedione (Pioglitazone)|Tablets, ≥ 30 mg, Once daily, up to 48 weeks
46105417|NCT00884741|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimentional conformal radiation therapy
46105418|NCT00884741|Biological|Bevacizumab|Given IV
46105419|NCT00884741|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
46105420|NCT00884741|Other|Laboratory Biomarker Analysis|Correlative studies
46105421|NCT00884741|Other|Placebo|Given IV
46105422|NCT00884741|Other|Quality-of-Life Assessment|Ancillary studies
46105423|NCT00884741|Drug|Temozolomide|Given orally
46105424|NCT00656279|Behavioral|Intensive dietary phosphorus education|Intensive dietary phosphorus education will be completed using the Phosphorus Point System Tool, a booklet listing phosphorus points for food items based on the phosphorus content. Patients will be allotted a maximum of 32-40 phosphorus points daily. Points consumed will be tracked by the patients via daily tracking sheets which require patients to list the phosphorus food items consumed, the number of points, and the time and amount of phosphate binders. Patients in this group will also receive intensive education about phosphorus additives. As a part of the program that supports the tool, patients will receive weekly telephone calls for the first 6 weeks to address any questions about the tool and find phosphorus point values of foods not listed within the tool.
46105425|NCT02632799|Device|NHF small cannula|NHF 8 l/min by Airvo 2 by small cannula
46105426|NCT02632799|Device|NHF big cannula|NHF 8 l/min by Airvo 2 by large cannula
46105427|NCT02632799|Device|CPAP|Nsal CPAP 5cm H2o by face mask
46105428|NCT00657527|Drug|Rosuvastatin|
46105429|NCT00657527|Behavioral|Cholesterol lowering diet|
46105430|NCT00598481|Genetic|Gene Therapy|Infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with busulfan
45598507|NCT04465123|Drug|Placebo|"Patients will be received spironolactone placebo or hydrochlorothiazide placebo in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone placebo every 12 hour for 72 hours.~If serum potassium levels >4 mEq/L, patients will be received hydrochlorothiazide placebo every 12 hour for 72 hours."
46020960|NCT04321889|Other|Placebo|nanotechnological system loaded with placebo cream
46020961|NCT04321421|Other|hyperimmune plasma|administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
46020962|NCT02889107|Other|personal frequency modulated systems|patients used personal frequency modulated systems for at least 4 hours daily for 10 weeks
46105431|NCT00598481|Drug|Busulfan|Busulfan is used for non-myeloablative conditioning
46105432|NCT00598481|Drug|PEG-ADA|polyethylene glycol (PEG)-ADA is discontinued prior to gene therapy
46105433|NCT04159649|Drug|Letrozole 2.5Mg Tablet|Gonadotropins with or letrozol in fixed Gn RH antagonist IVF protocol
46020963|NCT04320875|Other|Transcranial direct current stimulation|Anode electrode -C3/C4 (International 10-20 electroencephalogram system), contralateral side of the most affected knee) Cathode electrode- contralateral supraorbital area. 2 mA intensity for 20 minutes, one session/day for 3 days/week for 8 weeks)
46105434|NCT04159649|Drug|Gonadotropins|Gonadotropins without letrozol in fixed Gn RH antagonist IVF protocol
46105435|NCT04159649|Procedure|endometrial sample in the pretreatment cycle|All participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
46105436|NCT00880763|Drug|Vaniprevir|Vaniprevir oral capsule administered twice daily (200, 600 or 1200 mg/day) for 28 days
46105437|NCT00880763|Drug|Pegylated Interferon (peg-IFN)|Open-label peg-IFN alfa-2a subcutaneous injection (sourced locally) administered weekly, 180 micrograms, for 6 weeks
46105438|NCT00880763|Drug|Ribavirin|Open-label ribavirin (sourced locally) administered orally twice daily, 600 to 1000 mg/day, for 6 weeks
46105439|NCT00880763|Drug|Comparator: Placebo|Placebo to vaniprevir oral capsule twice daily for 28 days
46105440|NCT00657683|Biological|Monovalent GBS-CRM glycoconjugate vaccine|1 dose of GBS conjugate vaccine
46105441|NCT00657683|Biological|Placebo|1 dose of placebo
46105442|NCT04159727|Other|stool and blood analysis|High throughput sequencing and quantitative PCR
46105443|NCT00884273|Drug|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
46105444|NCT00884273|Drug|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.
46105445|NCT00884273|Drug|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin.
46105446|NCT04159337|Other|The method of gene mutation detection|All samples were detected by large-panel, whereas some of which were also detected by WES.
46105447|NCT00657761|Drug|Enfuvirtide|90 mg/12h sc for 7 days
46105448|NCT00657761|Drug|Placebo|0.9% saline solution/12h sc for 7 days
46105449|NCT04159493|Drug|Estriol|Vaginal Application
46105450|NCT04159493|Drug|Placebo|Vaginal Application
46105451|NCT00657839|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil bid
46105452|NCT00657839|Drug|Placebo|Matching placebo
46105453|NCT00884117|Drug|Oseltamivir|Participants may receive treatment at the discretion of the investigator according to local practice standards, and there is no protocol-specified intervention. However, analyses will be presented separately for participants treated with oseltamivir during the course of the study.
46105454|NCT04163315|Other|dMRI, fMRI and electrocorticography|Patients included in the study will perform the pre-operative MRI (fMRI and fMRI) with a specific High Resolution Angular Diffusion (HARDI) sequence and a functional rest sequence. The additional scan time for this specific sequence is approximately 25 minutes, with no foreseeable negative impact on the patient
46105455|NCT04159181|Other|Lactulose|Oral solution lactulose (20g lactulose/200mL water).
46105456|NCT04159181|Other|Picoprep|Cathartic to accomplish an evacuation of the colonic content.
46105457|NCT04159181|Other|Placebo (water)|oral administration of Water (200mL).
46105458|NCT00884039|Drug|anecortave acetate|anterior juxtascleral depot of 15 mg anecortave acetate
46105459|NCT00884039|Drug|30 mg anecortave acetate|anterior juxtascleral depot of 30mg anecortave acetate
46020964|NCT04320875|Other|Conventional Physiotherapy|"Warm-up exercises: Walking at the usual speed on a flat surface for 10 min ( 3sets X10 Reps X 3 min rest in between)~Hamstring and calf gentle stretches. ( 3sets X10 Reps X 3 min rest in between)~Straight leg raise (SLR) ( 3sets X10 Reps X 3 min rest in between)~Quadriceps setting ( 3sets X10 Reps X 3 min rest in between)~Pillow squeeze ( 3sets X10 Reps X 3 min rest in between)~Heel raise ( 3sets X10 Reps X 3 min rest in between)~One leg balance ( 3sets X10 Reps X 3 min rest in between)~Step ups ( 3sets X10 Reps X 3 min rest in between)~Quadriceps strengthening exercises ( 3sets X10 Reps X 3 min rest in between)"
46105460|NCT00657995|Device|Artificial Pancreas (STG-22)|safe tool
46105461|NCT02636621|Device|Brazilian Dental Appliance|Brazilian Dental Appliance is an oral appliance worn only during sleep that supports the jaw in a forward position to help maintain an open upper airway.
46105462|NCT02636621|Other|Placebo|The placebo consists in a protective dental plate worn only during sleep that do not interfere in the size of the upper airway.
46105463|NCT02632565|Drug|Lidocaine|
46105464|NCT02632565|Drug|Saline|
46105465|NCT04158947|Drug|Afatinib|"Dose-escalation Phase (Phase I) - Afatinib Dose-escalation will proceed on the basis of dose limiting toxicity (DLT) during Cycle 1 starting at 20 mg/day.~Dose level 1: 20 mg/day; Dose level 2: 30 mg/day; Dose level 3: 40 mg/day; Dose level 4: 50 mg/day.~Dose-evaluation Phase (Phase II) - Patients will receive the highest dose of Afatinib with T-DM1 found in Phase I as study therapy"
46105466|NCT04158947|Drug|T-DM1|"Dose-escalation Phase (Phase I) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Phase II) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days."
46105467|NCT02632643|Behavioral|Sensorimotor education with a view to obtaining an optimal FWS further to the relaxation of the masticatory, lingual and labial system. Learning of mandibular micro-movements in 5 directions.|
46105468|NCT00835770|Drug|dimethyl fumarate|BG00012 capsules
46105469|NCT00835770|Drug|Placebo|Capsules taken to maintain the blind in the 240 mg BID treatment group.
46105470|NCT00658073|Procedure|Kidney transplantation with MSCs infusion|Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.
46105471|NCT00658073|Procedure|kidney transplantation without MSC infusion|kidney transplantation with standard immunosuppressive treatment regime
46105472|NCT04163237|Drug|PD-1|PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti- autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
46105473|NCT04163237|Drug|Sorafenib|Sorafenib tosylate is a novel multi- target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet- derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
46105474|NCT04159259|Other|Low fiber diet|Participants will be provided with a low fiber diet in the form of packed out meals and snacks for 24 days in total (days 5-14 and days 36-49)
46020965|NCT05529251|Radiation|Radiotherapy boost|"Radiotherapy boost 20 to 30 Gy, in daily 2 Gy fractions and 5 fractions per week :~20 Gy if no more disease is visible (node < 1 cm in large diameter)~24 Gy for nodes <= 2 cm~30 Gy for nodes > 2 cm"
46105475|NCT04159259|Other|Pea Fiber Bar|Participants will be provided with a low fiber diet plus 1-3 daily pea fiber bars from days 15-35
46105476|NCT04159259|Other|Low fiber diet|Participants will return to the low fiber diet for days 36-49- this phase is the same as phase 1.
46105477|NCT02636777|Other|no intervention|Patients will be allowed to continue their usual treatment as recommended by their care team.
46105478|NCT00658229|Behavioral|Strength training group|After 5-10 months on androgen deprivation therapy the patients in the intervention group go through a four months strength training intervention. The patients will perform three strength-training sessions per week, two under supervision of a sport instructor. Each session will consists of one-three sets of nine strength-training exercises, performed at an intensity of 6 or 10 repetitions of maximum (6-10 RM).
46105479|NCT02636543|Other|Questionnaire after the reading of letter B.|Oral questionnaire after the reading of letter B.
46105480|NCT02636543|Other|Questionnaire after the reading of letters A and B|Oral questionnaire after the reading of letters A and B during individual interview.
45599271|NCT03513601|Drug|(R)-CVP regimen|The dose of the chemical was reduced by 20%，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt)， oral cyclophosphamide .
46105481|NCT00880685|Drug|Memantine|10-30mg, daily for 8 weeks
46105482|NCT02636465|Other|flight simulationin obese healthy adults or obese patients with or without COPD, OHS|
46105483|NCT00658307|Device|repetitive transcranial magnetic stimulation (rTMS)|"1 Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
46105484|NCT00658307|Device|repetitive transcranial magnetic stimulation (rTMS)|"20Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
46105485|NCT00658307|Device|sham repetitive transcranial magnetic stimulation (rTMS)|"The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
46105486|NCT00835380|Biological|Hepatitis A Vaccine, Purified Inactivated (VAQTA™)|Subjects will be given a 25-U/0.5 mL intramuscular injections of VAQTA™ at Day 1 and Month 6.
46105487|NCT02612298|Drug|Arotinolol Hydrochloride|Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks.
46105488|NCT02612298|Drug|Metoprolol succinate sustained-release tablet|Metoprolol succinate sustained-release tablet,oral, 23.75-71.25mg, qd for 12 weeks.
46105489|NCT00880607|Drug|Intrathecal morphine|Morphine injection is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain.
46105490|NCT00880607|Drug|Extended Release Epidural Morphine|DepoDur™ is a preparation of extended release lipid encapsulated morphine and is used specifically for epidural injection, outside the spinal fluid, for postoperative pain. This study is a prospective randomized double-blinded trial examining the effectiveness of single dose intrathecal morphine versus single dose extended release epidural morphine for postoperative pain control in pediatric posterior spinal fusion patients.
46105491|NCT04158791|Procedure|pars plana vitrectomy with epimacular membrane removal and internal limiting membrane peeling|25-gauge pars plana vitrectomy with a solution of 0.15% trypan blue, 0.025% brilliant blue G, 4% polyethylene glycol (MembraneBlue Dual) assisted ERM/ILM removal performed by a single surgeon (GV); no air-fluid exchange was performed during surgery. In phakic eyes, phacoemulsification with intraocular lens implantation was performed at the time of vitrectomy.
46105492|NCT00656435|Drug|Bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
46105493|NCT02636231|Drug|Endostatins|Endostar (Endostatins) is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.
46105494|NCT02636231|Radiation|IMRT|IMRT is to give GTV 60Gy in 27 fractions.
46105495|NCT02632487|Behavioral|Exercise|Center-based walking + balance, stretching, and light resistance
46105496|NCT02632487|Behavioral|Non-Exercise Physical Activity (NEPA)|Behavioral counseling paired with technology intervention to monitor physical activity
46020966|NCT05529251|Drug|Carboplatin AUC7|Carboplatin at dose (mg) = AUC7 (mg/ml x min) x (DFG ml/min + 25)
46020967|NCT05529251|Drug|3 cycles of EP|3 Cycles of EP chemotherapy, administred every 3 weeks following standard practice
46020968|NCT01261325|Drug|Placebo|Daily oral dose of two equal intakes of placebo in a double-blinded way for the 12-week treatment period
46105497|NCT02636309|Behavioral|physical therapy at work|gymnastcis, exercise orientation, ergonomics, acupuncture at work setting
46105498|NCT00835068|Other|No intervention|As it is a non interventional study, patient receives his usual treatment (BeneFIX) as determined by the physician
46020969|NCT01261325|Drug|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 100 mg/ day in a double-blinded way for the 12-week treatment period
46105499|NCT00658463|Drug|Rosuvastatin|rosuvastatin 20 mg/day during 6 weeks versus placebo during 6 weeks in a cross-over design
46105500|NCT00658463|Drug|Placebo|Placebo
46105501|NCT00656591|Drug|Methotrexate|Methotrexate
45599272|NCT03648827|Drug|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
46105502|NCT00658853|Behavioral|4 times 4 minutes high aerobic intensity one leg cycling|3 times per week for 10 weeks
46105503|NCT00658931|Drug|Drug treatment with Cymbalta|Drug treatment with Cymbalta
46105504|NCT00834912|Drug|Tramadol hydrochloride|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
46105505|NCT00834912|Drug|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fed condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
46105506|NCT00834912|Drug|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Trillium Healthcare) fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
46105507|NCT02535689|Drug|Tofacitinib|Oral administration of tofacitinib, 5 mg
46105508|NCT02535689|Drug|Placebo|
46105509|NCT02632331|Drug|ASP8825|Oral
46105510|NCT00707538|Drug|BMS747158|2 IV injection of ~11 mCi (total) F-18 labeled compound
46105511|NCT04162535|Drug|Lidocaine 1% Injectable Solution|"Lidocaine 1% Injectable Solution Intervention Protocol for the TIVA and Lidocaine Arm~Induction: 1.5 mg / kg i.v. bolus before induction (at the vein catch).~Maintaining anesthesia: continuous infusion with Lidocaine 2 mg / kg / h, up to a maximum of 200 mg / h during maintenance (after IOT until waking)~Infusion with 1% Lidocaine will be reduced to 1.0- 1.5 mg / kg / hour, max 100 mg / hour, for the first 48 hours postop"
46020970|NCT01261325|Drug|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 200 mg/ day in a double-blinded way for the 12-week treatment period.
46105512|NCT04162535|Biological|Blood extraction|The patients will donate after consent 10 ml of blood prior and after surgery for further study
46105513|NCT04162535|Drug|Sevoflurane|Patients will receive a general volatile anesthesia with Sevoflurane as anesthetic agent
46105514|NCT04162535|Drug|Propofol|Patients will receive a general anesthesia with Propofol as anesthetic agent
46105515|NCT05472324|Drug|TQC2731 injection|TQC2731 is a humanized monoclonal antibody based on human thymic stromal lymphopoietin (TSLP) sequence.
46105516|NCT05472324|Drug|Placebo|The drug is a placebo Comparator.
46020971|NCT01261325|Drug|Antiepileptic drugs with market authorization available per country|
46020972|NCT01260701|Drug|Akt Inhibitor MK2206|Given PO
46020973|NCT01260467|Drug|memantine|10 milligrams orally twice a day
46020974|NCT01260311|Drug|Fesoterodine|Any dose of Fesoterodine
46105517|NCT02632019|Drug|Gemcitabine|Gemcitabine 1000mg/m2, Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
46105518|NCT02632019|Biological|Dendritic cell-precision T cell for neo-antigen combined with gemcitabine treatment|"Gemcitabine: Gemcitabine 1000mg/m2, Physiological saline 100ml: IV (in the vein) once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.~PNAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63."
46020975|NCT00623987|Drug|warfarin accordingly INR value|warfarin accordingly to INR value between 2.0-3.0
46020976|NCT01259375|Drug|Amrubicin|Synthetic 9-aminoanthracycline Patients will receive 40mg/m2/day intravenously
46020977|NCT05536037|Drug|Metformin|Given PO
46020978|NCT05536037|Procedure|Biopsy|Undergo biopsy
46020979|NCT05487053|Procedure|Continuous adductor canal block|Postoperative analgesia in this group will be carried out by continuous infusion of local anesthetics through a catheter installed in the region of the middle third of the adductor canal. Ropivacaine 0.2% solution will be used for postoperative analgesia. Local anesthetic infusion rate is 4 ml/h to 10 ml/h.
46020980|NCT05487053|Procedure|Continuous femoral nerve block|Postoperative analgesia in this group will be carried out by continuous infusion of local anesthetics through a catheter installed to the femoral nerve in the area of the femoral triangle. Ropivacaine 0.2% solution will be used for postoperative analgesia. Local anesthetic infusion rate is 4 ml/h to 10 ml/h.
46105519|NCT00707616|Other|Oral glucose tolerance test|one time 75g oral glucose tolerance test for measurement of insulin secretion and action
46105520|NCT00659009|Other|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
46105521|NCT00659009|Other|Sea level equivalent barometric pressure|Sleep in barometric pressure equivalent to sea level.
46105522|NCT00659009|Other|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
46105523|NCT00659087|Procedure|Femoral Block|Those receiving femoral block postoperatively
46105524|NCT00659087|Other|Usual Care|Those receiving only usual pain management postoperatively
46105525|NCT00659243|Drug|rhBSSL|0.15 g/L rhBSSL added to pasteurized breast milk; one week treatment
46105526|NCT00659243|Drug|Placebo|One week treatment
46105527|NCT00883493|Drug|Quetiapine fumarate XR|Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
46105528|NCT00883493|Drug|Lithium carbonate|Twice daily from Day 1 to Day 56. From Day 1 to Day 7, the total daily dose of lithium could be increased gradually within the dose range 300 mg/day to 1800 mg/day. From Day 8 to Day 56, the total daily dose could be adjusted from 600 to 1800 mg/day
46105529|NCT04158713|Drug|Intermittent Preventive Therapy with Dihydroartemisinin-Piperaquine|Monthly DP fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery. All participants will (continue to) receive daily cotrimoxazole (CTX) (one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim) and anti-retroviral drugs.
46105530|NCT00659321|Drug|nicotine acid|16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication
46105531|NCT00659321|Drug|placebo|16 weeks treatment with placebo
46020981|NCT05468021|Other|Educational intervention|Randomized Clinical Trial (study design) to evaluate the effectiveness of an educational intervention to increase vaccine uptake among socioeconomically disadvantaged adults. The intervention will consist of a health promoter with an educational toolkit addressing misinformation, distrust, and hesitancy regarding the COVID-19 vaccine. An educational website with videos addressing COVID-19 vaccine will be available to study participants to boost information provided in the educational toolkit.
46105532|NCT02636153|Other|normal diet|Diet containing 1500mg of phosphorus
46105533|NCT02636153|Other|restricted phosphate diet|Diet containing 500mg of phosphorus
46105534|NCT04158479|Device|ECMO|ECMO for circulatory and/or respiratory support
46105535|NCT04032353|Other|Medical Consortium|subjects received intensive follow-up by coordinators according to the predifined protocol of MCSC
46105536|NCT00659399|Drug|Fondaparinux|Arixtra 2.5 mg by subcutaneous injection once daily for 8 weeks or until disease recurrence or grade 3, 4 adverse events.
46020982|NCT02888873|Other|Charisma|"The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma was used in combination Gluma2 Bond etch&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.~Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups."
46105537|NCT00659477|Drug|insulin glargine|once daily
46105538|NCT00911339|Drug|Atorvastatin|Atorvastatin 10 mg associated with stent genous
46105539|NCT00911339|Drug|Atorvastatin|Atorvastatin 80 mg associated with stent genous
46105540|NCT05863234|Drug|PPMX-T003|The therapeutic agent is administered continuously intravenously
46020983|NCT02888873|Other|Charisma Classic|"The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma classic was used in combination Gluma2 Bond etch&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.~Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups."
46105541|NCT05863208|Device|Artificial intelligence|ASUS EndoAim AI Endoscopy System (ASUS, Taiwan) is used to help the detection of colon adenoma
45599273|NCT03149133|Other|Heavy hypertrophy training|Training with 75-80 % of 1-RM
46105542|NCT05863208|Device|Endocuff vision|Endocuff vision (Olympus, UK) is used to help the detection of colon adenoma
46105543|NCT05863208|Device|High-definition endoscope|High-definition endoscope (EVIS-EXERA 290 video system, Olympus Optical, Aizu, Japan) is used under white light for the detection of colon adenoma
46105544|NCT05863195|Biological|Bevacizumab|Given IV
46105545|NCT05863195|Biological|Cetuximab|Given IV
46105546|NCT05863195|Procedure|Computed Tomography|Undergo SPECT/CT and/or CT
46105547|NCT05863195|Drug|Floxuridine|Given via HAI pump
45599274|NCT03149133|Other|Light hypertrophy training|Training with 35-50 % of 1-RM
45599275|NCT03513523|Dietary Supplement|Group 1 NRPT|Two capsules of NRPT and two placebo will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
46020984|NCT05456321|Device|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS)
46020985|NCT05456321|Behavioral|Cognitive Training|Computerized Cognitive Training
46105548|NCT05863195|Drug|Fluorouracil|Given IV
46105549|NCT05863195|Procedure|Implantation|Undergo surgery to place the HAI pump
46105550|NCT05863195|Procedure|Intrahepatic Infusion Procedure|Undergo HAI
46105551|NCT05863195|Drug|Irinotecan|Given IV
46105552|NCT05863195|Drug|Leucovorin|Given IV
46105553|NCT05863195|Drug|Oxaliplatin|Given IV
46105554|NCT05863195|Biological|Panitumumab|Given IV
46105555|NCT05863195|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
46105556|NCT05863182|Behavioral|Juntos Familia Family based intervention|Students and parents will participate in weekly 2.5 hour sessions around topics related to managing experiences with prejudice, discrimination and racism.
46105557|NCT05863169|Device|fNIRS-Neurofeedback|Neurofeedback of cortical oxygenation in 4 channels (2 left hemisphere, 2 right hemisphere); 8 training sessions, each session includes 2 feedback blocks (2*12 activation/deactivation trials) and one transfer block (8 activation/deactivation trials)
46105558|NCT05863156|Diagnostic Test|Right side lying position|In the study, 60 participants were placed in the right side lying position (intervention 1)
46105559|NCT05863156|Diagnostic Test|Semi Fowler|In the study, 60 participants in the semi-sitting position (intervention 2)
46105560|NCT05863156|Diagnostic Test|left side lying position|In the study, 120 participants in the left side lying position (control group).
46105561|NCT05863143|Behavioral|Nutritional and Exercise|Provide Nutritional Education Program and Falls Module Exercise (FME) to the intervention group
46105562|NCT05863117|Diagnostic Test|Reveal Rapid TP (from MedMira)|Point of care tests for HIV and Syphilis
46105563|NCT05863104|Drug|Glycopyrronium Bromide (GPB) Cream|Application of cream to each axilla
46105564|NCT05863091|Device|HiCardi+|A patch-type electrocardiogram device is attached to a patient undergoing pulmonary function tests.
46105565|NCT05863091|Device|HiCardi+|A patch-type electrocardiogram device is attached to a patient on a ventilator in an intensive care unit.
46105566|NCT05863065|Other|Exposure to a Virtual Reality scenarios|Exposure to a personalized, relaxing Virtual Reality scenario deployed by a Head-mounted tool (Oculus Quest 2). The administration was deployed in one session.
45468441|NCT03432754|Behavioral|Lifestyle Education|"The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning and mind wandering in older adults, will comprise of scientific health and lifestyle information. Lectures will be focused on concepts presented in the book The Culprit and the Cure: Why lifestyle is the culprit behind America's poor health and how transforming that lifestyle can be the cure. Meetings will cover how to begin and maintain a more nutritious diet, classifying healthy choices across food groups, completing stretching/toning exercises, and reviewing homework."
46105567|NCT05863052|Biological|Immunotherapy|immunotherapy
46105568|NCT05863039|Other|Blood flow restriction|Strength training of the lower leg muscles using blood flow restriction
46105569|NCT05863039|Other|Regular training type 1|Strength training of the lower leg muscles using high loads
46105570|NCT05863039|Other|Regular training type 2|Strength training of the lower leg muscles using low loads
46105571|NCT05863026|Behavioral|THEORY BASED INTEGRATED DENGUE EDUCATION MODULE (IDEM)|THEORY-BASED INTEGRATED DENGUE EDUCATION MODULE (IDEM)
45468442|NCT03432676|Drug|Epacadostat|Given PO
46105572|NCT05863013|Other|ADL-Glittre Test|They will receive standard care described plus perioperative pulmonary rehabilitation, with 20 preoperative sessions and 60 postoperative sessions. Preoperative sessions will be held 2X/week, in addition to home sessions 3X/week. Each outpatient session will last 2 hours and will consist of therapeutic education, aerobic exercises, resistance training of lower limbs, upper limbs and abdominal wall and respiratory muscle training (RMT), which will include breathing pattern, positive expiratory pressure and training of inspiratory and respiratory muscles. home will last 1h, unsupervised and personalized MRT plus 30 min of aerobic walking at 60-80% of maximum HR intensity. Participants will receive a portable pedometer and HR monitor. Postoperative rehabilitation will be offered only to the IG, from 1 month after surgery, with 60 sessions divided into 24 outpatient sessions performed 2X/week and 36 home sessions 3X/week. The postoperative program will last 12 weeks.
46105573|NCT05863000|Other|Online questionnaire/survey|Participants are expected to answer a short survey based on their overall experiences with their own health. No participants will therefore be followed for more than the duration of time it takes a subject to answer the questionnaire (approx 15 minutes). Randomly selected volunteers of around 30 respondents will afterwards be invited to participate in a qualitative interview with the intend to elaborate their questionnaire responds.
46105574|NCT05862974|Drug|LPM3480392|Intravenous infusion of 30min duration
46105575|NCT05862974|Drug|Placebo|Intravenous infusion of 30min duration
46105576|NCT05862948|Device|ENDO-Aid by Olympus|Colonoscopy assisted by ENDO-AID device
46105577|NCT05862922|Device|Analgesia Nosiception İndex Monitoring|"ANI is a monitor that can be measured continuously and non-invasively. It measures parasympathetic tone - based on electrocardiography - by analyzing minimal changes in heart rate that occur under anesthesia, in the early stages of awakening, and in each respiratory cycle of awake patients. At the end of the measurement, a value between 0-100 is obtained.~Parasympathetic modulation (stress level, e.g., pain) is obtained with a minimum value of 0 and a maximum of 100. ANI values measured in the early period of recovery correlate with pain scores. When compared with hemodynamic parameters, it has been reported that the ANI response is more sensitive to nociceptive stimuli occurring in the intraoperative period."
46105578|NCT05862883|Drug|Rutan 25 mg|"Active ingredient: (3,6-bis-O-galloyl-1,2,4-tri-O-galloyl-β-D-glucose). Active substance: Rutan 25 mg. Excipients: potato starch, calcium stearate, lactulose."
46105579|NCT05862883|Other|Control group|Taking basic therapy without Rutan
46105580|NCT05862857|Behavioral|HIV-focused mobilization|Patrons and employees of drinking venues that are randomized to HIV-focused recruitment will receive a recruitment card offering free HIV testing at the local clinic
46105581|NCT05862857|Behavioral|Multi-disease-focused mobilization|Patrons and employees of drinking venues that are randomized to HIV-focused recruitment will receive a recruitment card offering free health screenings that may include hypertension, diabetes, HIV, malaria (if febrile), and TB (if symptomatic), and pregnancy at the local clinic
46105582|NCT05862844|Behavioral|Promise women project (Promote Cervical Cancer Prevention Methods Among Muslim Women in Virginia )|The Intervention Arm involves a 90-minute educational session tailored to Muslim women. They will learn about HPV infection risks, cervical cancer risks, and benefits of early screening and HPV vaccination. Discussions cover transmission, consequences, risk factors (behaviors, infections, family history), and importance of early detection. The session provides information on screening methods, check-ups, and HPV vaccine safety. Participants actively engage in discussions, ask questions, and share thoughts. The session empowers women with knowledge to make informed decisions about their health, promoting cervical cancer prevention.
46105583|NCT05862831|Biological|PM1003 Injection|Subjects will receive PM1003 by intravenous administration.
46105584|NCT05862818|Behavioral|Day shift protocol - Diet order A-B|Research participants will be assigned to day shift condition and Diet A-B order condition.
46105585|NCT05862818|Behavioral|Day shift protocol - Diet order B-A|Research participants will be assigned to day shift condition and Diet B-A order condition.
45468443|NCT03432676|Biological|Pembrolizumab|Given IV
46020986|NCT05456321|Device|Sham tDCS|Sham Transcranial Direct Current Stimulation (tDCS)
46020987|NCT05452109|Other|Blood Flow Restriction|Blood flow restriction with low load (30-50% 1RM) for 2 sessions in a week for 6 weeks during classical training will be applied.
46020988|NCT05452109|Other|Classical Training Alone|Classical training same as Group 1with moderate to high load (70-90% 1RM) for 2 sessions in a week for 6 weeks will be applied without blood restriction.
46020989|NCT00624143|Drug|ORAL VORICONAZOLE and IV Amphotericin B|Oral Voriconazole will be given in dose of 6mg/kg 12 hourly on day1 then 4mg/kg 12 hourly daily or IV Amphotericin B 0.5 mg/kg/day weekly thrice till the completion of induction or recovery of ANC >1000/MM3 or development of fungal infection
46020990|NCT05284799|Biological|OVX836 480µg|One single administration intramuscularly at Day 1
45468444|NCT03432598|Drug|Tislelizumab|Administered 200 mg intravenously (IV) as specified in the treatment arm
46020991|NCT05284799|Biological|Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)|One single administration intramuscularly at Day 1
46105586|NCT05862818|Behavioral|Night shift protocol - Diet order A-B|Research participants will be assigned to simulated night shift condition and Diet A-B order condition.
46105587|NCT05862818|Behavioral|Night shift protocol - Diet order B-A|Research participants will be assigned to simulated night shift condition and Diet B-A order condition.
46105588|NCT05862805|Procedure|Sample Collection and Endometrial Biopsy|Participants will provide daily samples of menstrual blood for a single cycle and undergo a single endometrial biopsy for HEEC culture.
46105589|NCT05862792|Drug|Liposomal bupivacaine|We will inject liposomal bupivacaine into the surgical bed.
46105590|NCT05862779|Dietary Supplement|Placebo Group|The placebo group will receive 4 g per day of corn oil and 40 g per day of maltodextrin.
46105591|NCT05862779|Dietary Supplement|Whey Protein + Placebo|The whey protein + placebo group will receive 40g per day of whey and 4g per day of corn oil.
46105592|NCT05862779|Dietary Supplement|Omega 3 + Placebo|The omega 3 + placebo group will receive 4 g per day of fish oil and 40 g per day of maltodextrin.
46105593|NCT05862779|Dietary Supplement|Omega 3 + Whey Protein|The omega 3 + whey group will receive 4g per day of fish oil and 40g per day of protein.
46105594|NCT05862753|Drug|induction by Etomidate bolus|General anesthesia induction by Etomidate bolus with different concentration in either of the two arms. First arm, has the concentration (0,2 mg/kg) commonly used of Etomidate to induce anesthesia. Second arm, has the concentration (0,3 mg/kg) usually proposed in medical literature.
46105595|NCT05862740|Procedure|Laparoscopic Debulking Surgery in advanced ovarian cancer|Laparoscopic debulking will be conducted until the surgical target is achieved or the operation is converted to laparotomy.
46105596|NCT05862740|Procedure|Standard laparotomic Debulking Surgery in advanced ovarian cancer|Debulking by laparotomy in patients when debulking could not be accomplished by laparoscopy.
46020992|NCT05284799|Biological|Placebo|One single administration intramuscularly at Day 1
46020993|NCT05245253|Radiation|Positron Emission tomography|Patients will be tested with PET-examination at 3 weeks, 3 months and 1 year after the trauma
46020994|NCT05646095|Behavioral|Bolstering Sleep and Adjustment in Foster Environments (B-SAFE)|We will adapt CBT for insomnia for children in foster care using a trauma-informed approach that considers the child's individual history, unique family environment, and child welfare policies regarding safe sleep practices.
46020995|NCT05635019|Behavioral|BWL+VOUCHER|This group will receive the BWL program as well as food vouchers, in the form of grocery store gift cards. Participants will be allowed to select to receive gift cards to a grocery store or supermarket from a pre-determined list of stores. Gift cards worth $40 will be emailed or mailed to every 2 weeks after the BWL session.
46105597|NCT05862714|Drug|Fluconazole|400 mg stat. Follow up at 4 weeks
46105598|NCT05862714|Drug|Itraconazole|1000 mg stat. Follow up at 4 weeks
45468445|NCT03432598|Drug|Paclitaxel|Administered 175 mg/m² IV as specified in the treatment arm
46105599|NCT05862701|Drug|Permethrin|5% permethrin cream
45468446|NCT03432598|Drug|Gemcitabine|Administered 1250 mg/m² IV as specified in the treatment arm
45468447|NCT03432598|Drug|Etoposide|Administered 100 mg/m2 IV as specified in the treatment arm
45468448|NCT03432598|Drug|Pemetrexed|Administered 500 mg/m² IV as specified in the treatment arm
45468449|NCT03432598|Drug|Cisplatin|Administered 75 mg/m²/day IV as specified in the treatment arm
46105600|NCT05862701|Drug|Sulphur|10% Sulfur ointment
46105601|NCT05862688|Other|antimicrobial therapy|antimicrobial therapy
46105602|NCT05862675|Other|exosomes|In the experimental group and the control group1, the clinical efficacy and prognosis were observed after received exosomes, and the hematological indexes were measured.
46105603|NCT05862662|Other|MOVE Program|Mobility Opportunities Via Education functional therapy program.
46105604|NCT05862636|Behavioral|Mindfulness Training|"All participants will follow a mindfulness course consisting of group sessions of 2-3h duration that are organized (nearly) weekly and are spread over a period of eight weeks. The specific timeline and organisation of the course may differ between the participating sites but all courses will involve a comparable amount of contact hours with the mindfulness trainer. Each session consists of guided experiential mindfulness exercises (e.g., body scan, breathing space, breath focus, walk meditation), sharing of experiences of these exercises, reflections in small groups, psychoeducation, and review of home practices.~The mindfulness courses are based on one of the two most well-known MBIs, Mindfulness-Based Cognitive Therapy (Segal et al., 2002) and Mindfulness-Based Stress Reduction (Kabat-Zinn, 1990), or a combination thereof. Courses follow a standardised protocol with group sessions and daily homework tasks taught by experienced and certified mindfulness trainers."
46105605|NCT05862623|Drug|AER-01|AER-01 solution for inhalation delivered via nebulizer
46105606|NCT05862623|Drug|Placebo|Placebo for solution for inhalation delivered via nebulizer
46020996|NCT05635019|Behavioral|BWL+HOME|This group will receive the BWL program as well as home-delivered boxes of groceries of low-energy density foods conducive to weight management guidelines. Groceries will include shelf-stable and perishable products like lean meats, fresh vegetables, and fruits. Every 2 weeks, participants assigned to this group will be allowed to select a choice of one of 4 boxes with slightly varied contents. Each box will have approximately $40 worth of groceries.
46105607|NCT05862610|Drug|Trilaciclib plus chemotherapy|Trilaciclib: 240mg/m2 IV d1,within 4h before chemotherapy epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
46105608|NCT05862610|Drug|Chemotherapy|epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
46105609|NCT05862597|Diagnostic Test|HRV and Pulse diagnosis|Palpation of the 6 pulse positions (right cun, right guan, right chi, left cun, left guan, left chi) measured by the pulse diagnostic instrument.
46105610|NCT05862584|Other|Questionnaires|Distribution of questionnaires to patients to be completed on a weekly basis.
46105611|NCT05862558|Device|Shockwave Balloon|Intravascular lithotripsy (IVL) performed with the Shockwave balloon (Shockwave Medical Inc) enables treatment of calcified stenosis of the peripheral arteries by using sonic pressure waves to selectively disrupt superficial and deep calcium without impacting healthy tissue
46105612|NCT05862532|Dietary Supplement|TeTrimTeas welsh Herbal tea with rhubarb root|TeTrimTeas welsh Herbal tea with green tea and rhubarb root
46020997|NCT05635019|Behavioral|Behavioral weight loss counseling (BWL)|The behavioral weight loss program consists of 14 individual lifestyle counseling sessions provided over 24 weeks. Each session will be approximately 15-20 minutes. Visits will be scheduled weekly for the first 4 weeks (weeks 1, 2, 3, and 4) and every-other week from weeks 6-24 (weeks 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24). The sessions will provide behavioral, dietary, and physical counseling.
46105613|NCT05862532|Dietary Supplement|TeTrimTeas welsh Herbal tea with senna|TeTrimTeas welsh Herbal tea with green tea and senna
46105614|NCT05862532|Dietary Supplement|TeTrimTeas welsh Herbal tea with green tea|TeTrimTeas welsh Herbal tea with green tea
46105615|NCT05862519|Dietary Supplement|Reset|Pure for Men Reset is a Vegan, Proprietary Blend of Toxin Eliminating Cleanser: Cascara Sagrada Bark, Senna Leaf, Psyllium Husk, Licorice Root, and Aloe Vera Gel. Taken on Day 1 to Day 5.
46105616|NCT05862519|Dietary Supplement|Stay Ready Fiber|Stay Ready Fiber is a Vegan, 100% Natural, Proprietary Blend of Digestive Aids: Psyllium Husk, Aloe Vera Extract, Chia Seeds & Flaxseed. Taken from Day 7 through Day 21.
46105617|NCT05862519|Dietary Supplement|Libido|Supplement designed to support endurance and increased arousal. Contains L-Citrulline, L-Arginine and Black Pepper Fruit Extract (Piper Nigrum). Taken from Day 7 through to Day 28.
46105618|NCT05862519|Dietary Supplement|Testosterone supplement|Supplement designed to enhance testosterone production. Contains Ashwagandha, Zinc, Vitamin D, Maca, and Tongkat Ali. Taken from Day 28 through Day 84.
46105619|NCT05862506|Behavioral|Daily Mile|The intervention consisted of walking, jogging or running for ~ 15 min (~ one mile) of exercise at a pace self-selected by each individual child, outside the school buildings during recess time, three times a week during 10 weeks. Children were instructed to maintain active for the full 15 min and, if necessary, to stop for resting only occasionally.
46105620|NCT05862493|Diagnostic Test|FOCUS echocardiography|Preoperative FOCUS echocardiography. Based on FOCUS information: correction of low level of venous return and/or step-up monitoring and/or vasoactive drugs
46020998|NCT05241275|Drug|Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Progressive Pulmonary Fibrosis
46020999|NCT05154695|Device|LASER|The eligible participants first received LLLT with a 685-nm wavelength and an output of 30 mW at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.
46021000|NCT05154695|Device|A.therapeutic ultrasound group|Group A receives 1 MHz therapeutic ultrasound for 5 min at a frequency of 2-3 times per week at the painful upper trapezius muscle.
46021001|NCT05154695|Drug|B.prolotherapy group|Group B receives hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
46105621|NCT05862480|Other|Spray with Hypochlorous Acid Group|For Each Patient included . A prescription of a nasal spray in each nostril/3 hours and two oral sprays/3 hours by a solution of hypochlorous acid (NEED DEFENDER) for 5 days
46105622|NCT05862480|Other|Spray with Placebo Group|For Each Patient included , A prescription of an identical to the intervention nasal spray in each nostril/3 hours and two oral sprays/3 hours by Placebo for 5 days.
46105623|NCT05862467|Behavioral|Written Exposure Therapy (WET) via telehealth|Written Exposure Therapy (WET) via telehealth
46021002|NCT02889029|Device|new 3D device|dedicated tailored stents wrought by 3D computer-assisted conception
46105624|NCT05862441|Drug|AV2-SA2|AV2 is a combination of FDA GRAS-label approved organic compounds (natural essential oils: carvone, eugenol, geraniol, and nerolidol) that is postulated to be able to prevent viral entry and proliferation by deactivating the infectious virions before they enter the cell. Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis. Implementation of AV2-SA combination therapy would ensure permanent lesion clearance by on the one hand inactivation of HPV by AV2, and on the other hand elimination of the lesion by SA treatment.
46105625|NCT05862441|Drug|SA|Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis.
46021003|NCT05116787|Drug|BCX9930 monotherapy|Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily
46021004|NCT05116787|Drug|Placebo|Administered orally twice daily
46105626|NCT05862428|Drug|Rectal misoprostol|This intervention group receive Misoprostol transrectally before undergoing total abdominal hysterectomy
46105627|NCT05862415|Other|therapeutic Exercise|"The circular training method was used in the resistance training phase. During the aerobic training phase, a series of movements from moderate intensity to vigorous intensity was performed. The step loading periodization principle was taken into account in both resistance training and aerobic exercises.~The RT lasted approximately 20-25 min per session and included two sets of 8-20 repetitions, with a rest interval of 1-2 min. The RT exercises included: squat, barbell bent-over row, overhead press, plank, lateral pull down, triceps push down, barbell curl, leg extension, leg curl, lunge, barbell bench press, crunches etc.~For the aerobic training: Intensity was established between 50-65% and 80-85% of HRmax for both groups (SAG and ASG). Aerobic training includes walking and running periods and was carried out on a 400 m outdoor track. In periodization, especially 1st-4th."
46105628|NCT05862402|Drug|Dose-adjustment by PKPD|Dose-adjustment by pharmacokinetic and pharmacodynamic using Monte Carlo simulation
46105629|NCT05862350|Other|aromatherapy inhalation with lavender essential oil|patients in the experimental group will receive aromatherapy inhalation by 4 drops of 50% lavender essential oil，which is diluted with coconut essential oil， on the cotton chip in the diffuser clip for 8 hours each night during sleep
46105630|NCT05862350|Other|aromatherapy inhalation with coconut essential oil.|patients in the experimental group will receive aromatherapy inhalation by 4 drops of 100% coconut essential oil on the cotton chip in the diffuser clip for 8 hours each night during sleep
46105631|NCT05862337|Drug|Anlotinib hydrochloride capsules, Penpulimab injection|"Anlotinib hydrochloride capsules is a multitargeted receptor tyrosine kinase inhibitor.~Penpulimab injection is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1)."
46105632|NCT05862337|Drug|Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo|placebo control, no active substance.
46105633|NCT05862324|Biological|TAC01-CLDN18.2|TAC01-CLDN18.2 preceded by lymphodepletion with fludarabine or clofarabine, cyclophosphamide, and nab-paclitaxel.
46105634|NCT05862311|Diagnostic Test|ELISA|ELISA(enzyme-linked immunosorbent assay)
46105635|NCT05862298|Diagnostic Test|venous excess ultrasound score|Venous congestion is classified into 4 grades. If the Inferior vena cava is not plethoric, there is deemed to be no congestion (grade 0), and further Doppler examination is not performed. When the IVC is plethoric but there are no severely abnormal waveforms (defined as S-wave reversal on hepatic, >50% pulsatility on portal, and a monophasic pattern on intrarenal Doppler), congestion is considered to be mild (grade 1). Plethoric IVC with at least 1 severely abnormal pattern is considered to be moderate congestion (grade 2), while 2 or more abnormal Doppler patterns constitute severe congestion (grade 3)
46105636|NCT05862246|Other|Clinical examination|No intervention, only clinical examination
45468450|NCT03432598|Drug|Carboplatin|Administered AUC 5 as specified in the treatment arm
46021005|NCT05107661|Behavioral|Telephone Prompt|Scripted messaging to remind subjects to complete their colorectal screening (colonoscopy or fecal test)
46021006|NCT05079269|Other|Crystalloid Solutions|As above
45599276|NCT03513523|Dietary Supplement|Group 2 NRPT|Four capsules of NRPT will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
45599277|NCT03513523|Other|Group 3 Placebo|Four placebo capsules will be taken once daily in the morning for 26 weeks.
46021007|NCT04913129|Other|Exercise Training|8 week home-based exercise therapy 4-5 times/week
46021008|NCT04323995|Other|Sprint Interval Training|Sprint interval training of 2 weeks and more.
46021009|NCT04652063|Other|Osteopathic Manipulative Medicine|Osteopathic evaluation and treatment (gentle touch according to published protocols) will take about 15 - 20 minutes, and will be performed every 7 - 10 days during the infant's NICU stay once they reach at minimum of at least 28 weeks corrected gestational age and until they reach 36 weeks corrected gestational age.
46021010|NCT04540835|Drug|Calcium phosphate desensitizer|Calcium phosphate containing desensitizing agent that creates hydroxyappatite
46105637|NCT05862220|Diagnostic Test|D-Dimer vs CTPA|CTPA was performed after performing blood sampling using Siemens Somatom definition AS 24 slice scanners. Non-ionic water-soluble contrast Omnipaque 350 mg I/mg or Visipaque 320 mg I/mg was injected at 4 mm/s maximum dose 100 ml using a Medtron pressure injector.OR, A blood sample was taken before starting the patients on any thrombolytic treatment. The latex agglutination test was used to measure plasma D-dimer level; this was done using a Sysmex CA-7000 automatic coagulation unit. The positivity threshold was above 250 ng/ml.
46105638|NCT05862194|Drug|Lazertinib|Patients who previously received first or second-generation EGFR-TKI treatment, and who started administrating Lazertinib during the index period
46105639|NCT05862194|Drug|Platinum-based Chemotherapy|Patient who started administering platinum-based chemotherapy after prior first or second-generation EGFR-TKI treatment during the index period
46105640|NCT05862181|Procedure|DEB-TACE plus HAIC or HAIC alone|the patients received DEB-TACE plus HAIC or HAIC at least twice during this observational study
46021011|NCT04320641|Other|ACUPRESSURE|Acupressure points were determined in a certain order considering the direction of the meridian. The order of application was in the form of Spleen 6th point (SP 6) and 4 point of the Large Intestine (Li 4). In total, 4 points in the upper / lower extremities and 6 acupressure points along with parallel points were studied in each attempt.
46105641|NCT05862168|Drug|Tislelizumab|The participants will receive 3 cycles of Tislelizumab, with 21 days each. 200mg of Tislelizumab will be used intravenously on the first day of each cycle.
46105642|NCT05862168|Drug|Albumin paclitaxel|The participants will receive 3 cycles of Albumin paclitaxel, with 21 days each. 200mg/m^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.
46105643|NCT05862168|Drug|Cisplatin|The participants will receive 3 cycles of Cisplatin, with 21 days each. 20mg/m^2 of Cisplatin will be used intravenously on days 1 through 3 of each cycle.
46021012|NCT02888795|Drug|hypertonic dextrose prolotherapy|five intra-articular injection at 2-weeks intervals in weeks 0, 2, 4, 6, 8.
45681242|NCT03023098|Device|Drug-eluting balloon|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a drug-eluting balloon
46021013|NCT04320095|Device|Bizact tonsillectomy device|Bizact tonsillectomy device is an advanced bipolar instrument that uses radiofrequency energy and pressure to ligate vessels interposed between its jaws. The energy produced by the device is automatically adjusted based on tissue impedance in an attempt to minimize thermal tissue damage.
46105644|NCT05862168|Drug|5-Fluorouracil|The participants will receive 3 cycles of 5-Fluorouracil, with 21 days each. 600mg/m^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.
46105645|NCT05862142|Other|No intervention|No intervention
46105646|NCT05862129|Procedure|surgical operation|Radical operation for the perianal abscess
45599278|NCT03647111|Drug|Crizotinib|Crizotinib 250mg po bid
46021014|NCT04232735|Other|Tool and training|"The Source tool aims to assist health care providers with giving evidence based information about treatment outcomes by providing visualizations of personalized predictions of treatment outcomes for different treatments of oesophageal and gastric cancer. These predictions result from recently designed and updated prediction models on the survival, toxicity, complications and health related quality of life of oesophageal and gastric cancer patients.~The training aims to teach participants to inform patients about outcomes of treatment. The training is placed in the context of shared decision making (SDM), following the 4-step model by Stiggelbout et al., 2015.8 The training is provided in small groups (3-6 participants) by an experienced trainer and supported by professional actors. The training aims to address knowledge, attitude and skills."
46021015|NCT04207307|Behavioral|Multimodal exercise program|Multimodal exercise intervention (machine-based resistance, coordination and endurance training).
46021016|NCT04207307|Behavioral|Usual Care|General recommendations for healthy ageing, no machine-based strength training intervention.
46021017|NCT04005287|Drug|WST-057 (4% pirenzepine) Lose Dose 2mL|Topical Solution
46021018|NCT04005287|Drug|WST-057 (4% pirenzepine) High Dose 4mL|Topical Solution
46105647|NCT05862116|Other|Survey form|Patients will be asked to fill a survey form that consists of socio-demographic information, Turkish Health Literacy Scale -32, Short Form-36 Health Survey and Oswestry Disability Index.
46105648|NCT05862103|Other|Treatment Strategies|AMI emergency treatment process, pre-reperfusion medication, reperfusion strategy selection, and early cardiac rehabilitation after reperfusion
46105649|NCT05862090|Drug|RLD2301|Take it once a day per period.
46105650|NCT05862090|Drug|RLD2007|Take it once a day per period.
45681243|NCT03962686|Drug|statin Oral Tablet plus PCSK9i|Patients in the third study cohort will receive for statin oral therapy plus 140 mg twice a month PCSK9i therapy via subcutaneous injection before to practice surgical intervention for carotid artery obstruction.
45681244|NCT04193020|Other|Surveillance card|Surveillance card and additional examination to find novel markers and better assess the existing ones
46105651|NCT05862077|Device|Wearable Hip Assist Robot(EX1)|EX1 is a hip-type assist device developed by Samsung Electronics.
46105652|NCT05862077|Behavioral|Exercise Program 1|Exercise program 1 for fast walking by applying resistance and assist mode of EX1
46105653|NCT05862077|Behavioral|Exercise Program 2|Exercise program 2 for normal walking by applying resistance and assist mode of EX1
46105654|NCT05862077|Device|Without Wearable Hip Assist Robot(EX1)|Overground walking without EX1
46105655|NCT05862064|Drug|epirubicin,cyclophosphamide,paclitaxel,Carrelizumab|Conventional chemotherapy in combination with carrelizumab
46021019|NCT04005287|Drug|Placebo Low Dose|Topical Solution
46105656|NCT05862064|Drug|epirubicin,cyclophosphamide,paclitaxel|Conventional chemotherapy
46105657|NCT05862025|Diagnostic Test|Echocardiography evaluation|"Patients will undergo mandatory transthoracic echocardiography during assessment of Staphylococcus aureus bacteremia.~Later, they will also undergo mandatory transesophageal echocardiography.~Both test will be performed during the first 14 days from bacteremia onset."
46105658|NCT05861973|Behavioral|Adaptive SMARTer intervention (SMARTer)|Participants will receive calorie, fat, and physical activity goals, a Smartphone application for self-monitoring their diet, activity and weight, online educational readings, and brief bi-weekly remote health sessions with a Health Promotionist. They will also be loaned a Fitbit tracking device and a wireless bluetooth scale for 6 months.
46105659|NCT05861973|Behavioral|Diabetes Prevention Program Participants (DPP)|In accordance with the Center for Disease Control curriculum, participants will receive a participant log for tracking physical activity, food intake, and weight, a paper participant guide with worksheets, logs, and psycho-educational materials, and 16 hour long remote sessions with a Health Promotionist.
46021020|NCT04005287|Drug|Placebo High Dose|Topical Solution
46105660|NCT05861947|Drug|AUR106|Once or twice daily
46105661|NCT05861934|Behavioral|Distant reiki group|ccording to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced twice a week for 6 weeks by researchers who have completed the Phase 2 training. The time of remote reiki application will be planned by talking with the patient.
46105662|NCT05861921|Other|Single-retainer Lithium Di-silicate Resin Bonded Fixed Partial Denture|Lithium Di-silicate as final restorative material for resin bonded Fixed Partial Denture replacing missing upper anterior tooth.
46105663|NCT05861908|Other|Filtek™ Bulk Fill restoration|restoration of class II caries with different bulk-fill technique
45468451|NCT03318497|Drug|3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT|Given IV The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.
46021021|NCT03763799|Procedure|PCR-based microbiological diagnosis strategy|A multiplex PCR-based testing, will be used in addition to standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
46021022|NCT03763799|Procedure|Standard microbiological diagnosis strategy|Standard strategy will be based on with standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
46105664|NCT05861908|Other|Heated Filtek™ Bulk Fill restoration|restoration of class II caries with different bulk-fill technique
46105665|NCT05861908|Other|G-aenial™ BULK Injectable restoration|restoration of class II caries with different bulk-fill technique
46105666|NCT05861908|Other|Sonicfill3 restoration|restoration of class II caries with different bulk-fill technique
46105667|NCT05861882|Other|functional movement screen|FMS consists of seven test component which are used to evaluate various main movement models.Individuals completed one by one deep squat, high stepping, single line lunge, shoulder mobility, straight leg raises, trunk stability push-ups, rotation stability which are component tests. Subcomponent tests assess asymmetry by measuring the individual bilaterally. Each component test was scored on an ordinal scale (0 to 3 points), with a maximum score of 3, based on the quality of the movement. Less than 3 points indicated that the individual performed some form of compensation or was unable to complete the entire movement.While individuals were doing these tests, they were recorded in the video , the final scoring was done by evaluating the images. The scores of the component tests were summed, resulting in a composite score between 0 and 21 points, with a maximum score of 21
46105668|NCT05861882|Other|survey application|Participants are evaluated with kasari physical activity survey. According to the FIT score, physical activity level is commented as sedentary between 0-20, poor between 21-40, normal between 41-60, good between 61-80 and perfect between 81-100
46105669|NCT05861882|Other|Y balance test|YBT, which is performed in the standing position on one leg , is dynamic a test. Participants stood on the footplate in the centre of the Y Balance Test area and then, it was given instruction them that they should maintain a single leg stance while reaching as far as possible with the opposite leg and return to the starting position on the centre platform without losing balance.In the test, individuals were asked to reach the maximum distance in 3 directions (anterior, posteromedial and posterolateral), allowing 3 trials for each leg. The maximum reach distance was recorded for each consecutive trial
46105670|NCT05861882|Other|Core stabilization assessment|The flexor muscle endurance test is initiated with the subject in a sitting position, with the back leaning against an apparatus angled 60 degrees from the floor. Both knees and hips are flexed to 90 degrees and the support apparatus is withdrawn and the time the person maintains the position is recorded The extensor muscle endurance test is performed with the upper trunk extended towards the end of the bed on which the test is performed and the pelvis, knees and hips fixed. The time the upper trunk maintains its level is recorded The lateral bridge test was performed with the individual lying in the full side bridge position (left and right side separately). Individuals supported themselves on one elbow and their feet while lifting their hips off the floor to form a straight line from head to toe. The test was terminated when the individual lost the straight back posture and/or their hips touched the floor.
46105671|NCT05861817|Device|Laser theapy|participants were randomized into either the LLLT group or sham treatment group by a computer-generated random number. The participants were treated using LLLT (904nm and 2.5 J/ sinus). treatment was delivered for one month
46105672|NCT05861791|Drug|Fentanyl|opioid group receives only fentanyl citrate 1200mcg for continuous infusion drug
46105673|NCT05861791|Drug|ketorolac tromethamine with nefopam hydrochloride|non-opioid group receives ketorolac tromethamine 150mg with nefopam hydrochloride 100mg for continuous infusion drug
46105674|NCT05861778|Drug|89Zr-Girentuximab|A single administration of 37 MBq (±10%) 89Zr-TLX250, containing a mass dose of 10 mg of girentuximab, followed by whole body PET/CT scans were performed at 0.5h, 4h, 24h, 72 hours and 7±1 days post administration.
46021023|NCT04319861|Procedure|Anal fistula plug procedure|A fistula probe was used to identify fistula tracts, and internal and external openings. Gentle mechanical debridement was performed with a blunt curette to remove the necrotic tissue with care not to enlarge the track, then hydrogen peroxide and sterile saline were used to repeatedly to irrigate the fistula. The anal fistutla plug was filled into the fistula, and sutured with a figure-of-eight 2-to-0 Vicryl suture to ensure the plug was fixed in the internal opening of the fistula, avoiding the anal fistula plug being extruded. Trimming the plug at the external fistula and the external opening was left open to ensure adequate drainage.
46021024|NCT03757481|Other|no intervention|SF-36 questionnaire , PembQoL, Villalta score ,PembQoL
46105675|NCT05861752|Behavioral|Treatment as usual|both groups will undergo a psychiatric assessment including interviews, impulsivity tests and fill out questionnaires and leave blood samples. The clinical population will be followed regarding treatment as usual
46105676|NCT05861739|Behavioral|Endometriosis Self-care Support Program|ESSP will be applied to the women in the intervention group in four sessions, one week apart. In the first and second sessions, a self-care training program will be applied. In the third and fourth sessions, motivational interview will be made by contacting the women by phone.
46105677|NCT05861726|Behavioral|Aerobic exercise|a moderate kind of physical activity with a heart rate between 65 & 70% maximum heart rate
46105678|NCT05861726|Other|None (control group)|None (the control group)
46105679|NCT05861713|Drug|Hydrating Cream|The experimental group will apply the Hydrating Cream to the affected skin area at least twice daily with a cotton swab, while the other limb was the control group.
46105680|NCT05861687|Drug|Esomeprazole|Administered once a day per-oral (PO) with the dose of 0.4 mg/kg
46105681|NCT05861687|Drug|Lansoprazole|Administered once a day per-oral (PO) with the dose of 15 mg if individual's body mass was <30 kg, and 30 mg if it was >30 kg
45468452|NCT03318497|Procedure|Computed Tomography|Undergo PET/CT
45468453|NCT03318497|Procedure|Positron Emission Tomography|Undergo PET/CT
46105682|NCT05861687|Drug|Amoxicillin|Administered thrice a day per-oral (PO) with the dose of 25 mg/kg
46105683|NCT05861687|Drug|Clarithromycin|Administered twice a day per-oral with the dose of 7.5 mg/kg
46105684|NCT05861674|Biological|HH-003(20mg/kg)|20 mg/kg Q2W intravenously for 48 weeks
46105685|NCT05861674|Biological|HH-003(10mg/kg)|10 mg/kg Q2W intravenously for 48 weeks
46105686|NCT05861674|Drug|TAF|TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period
46105687|NCT05861661|Other|The study do not include an intervention|The study do not include an intervention
46105688|NCT05861648|Drug|Folic Acid Oral Tablet|Dietary Supplement: Folic acid 2.5mg/day
46105689|NCT05861648|Dietary Supplement|Placebo|Dietary Supplement: Placebo
46105690|NCT05861635|Drug|Disitamab Vedotin combined with Tislelizumab|"Subjects who meet the requirements of the protocol will receive neoadjuvant treatment, and the specific administration arrangement is as follows:~Disitamab Vedotin, 2 mg/Kg, q2W, 8cycle Tislelizumab, 200mg, iv, q3W, 6cycle"
46105691|NCT05861622|Other|Moisturizer|The test product is a novel moisturizer, that contains active ingredients, including rambutan extract, niacinamide, and glycoin.
46105692|NCT05861609|Procedure|Usual care|Usual care with respect to Spinal Cord Stimulation implantation
46105693|NCT05861609|Procedure|Standardized pain medication tapering|A standardized pain medication tapering program before Spinal Cord Stimulator implantation.
46105694|NCT05861609|Procedure|Personalized pain medication tapering|A personalized pain medication tapering program before Spinal Cord Stimulator implantation.
46105695|NCT05861596|Device|Repetitive Transcranial Magnetic Stimulation|Participants suffered from acute stroke with dysphagia in single hospital who were determined by CT/MRI and clinical evaluation. The aim of this study is to compare the effects of rTMS, Neuromuscular electrical stimulation (NMES) and conventional swallowing therapy to those of sham rTMS, Neuromuscular electrical stimulation(NMES) and conventional swallowing therapy. One group will receive Neuromuscular electrical stimulation(NMES), to sham One group will receive Neuromuscular electrical stimulation(NMES),traditional swallowing therapy and rTMS therapy five times per week for 2 weeks ; Another group will receive Neuromuscular electrical stimulation(NMES) and traditional swallowing therapy with shame rTMS five times per week for 2 weeks. MEP character, FEES, degrees of dysphagia, FOIS, and SSA were used for evaluated swallowing function before the therapy and after 2 weeks therapy.
46105696|NCT05861596|Device|Neuromuscular electrical stimulation combined with conventional swallowing training|Participants suffered from acute stroke with dysphagia in single hospital who were determined by CT/MRI and clinical evaluation. The aim of this study is to compare the effects of rTMS, Neuromuscular electrical stimulation (NMES) and conventional swallowing therapy to those of sham rTMS, Neuromuscular electrical stimulation(NMES) and conventional swallowing therapy. One group will receive Neuromuscular electrical stimulation(NMES), to sham One group will receive Neuromuscular electrical stimulation(NMES),traditional swallowing therapy and rTMS therapy five times per week for 2 weeks ; Another group will receive Neuromuscular electrical stimulation(NMES) and traditional swallowing therapy with shame rTMS five times per week for 2 weeks. MEP character, FEES, degrees of dysphagia, FOIS, and SSA were used for evaluated swallowing function before the therapy and after 2 weeks therapy.
46105697|NCT05861583|Other|fat tissue|fat tissue sample collected while cosmetical liposuction
46105698|NCT05861583|Other|lipoedema tissue (stage 1)|lipoedema tissue sample (stage 1) collected while medical liposuction
46021025|NCT02888717|Procedure|'OSNA stadification during surgery'|"The para-aortic dissection surgery is performed in the usual way. The lymph nodes are isolated from fat tissue during surgery, and cut into 4 slices sterile.~Slices A and C are sent OSNA analysis~Slices B and D are sent ultimately histological analysis (1 cup HES or 5 cup HES + IHC) The nodes of less than 5 mm will be sent in final histological analysis due to the inability to cut into 4.~After the analysis, the report indicates whether the node is:~Free (-): <250 copies~Micrometastatic (+): 250 ≤ - <5,000 copies,~Macrometastatic (++): ≥ 5000 copies."
46105699|NCT05861583|Other|lipoedema tissue (stage 2)|lipoedema tissue sample (stage 2) collected while medical liposuction
46105700|NCT05861583|Other|lipoedema tissue (stage 3)|lipoedema tissue sample (stage 3) collected while medical liposuction
46105701|NCT05861557|Drug|Toripalimab|240mg, Q3W，I.V., D1, 2 cycles (1cycle of toripalimab before and after the SBRT radiotherapy, respectively), followed by the maintenance of toripalimab for 6 months after the surgery.
46105702|NCT05861557|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Subjects were treated with SBRT radiotherapy (8Gy*5Fx), after 1 cycle of immunotherapy
46105703|NCT05861544|Dietary Supplement|Pomegranate juice|The pomegranate juice that will be used in the experiment is a 100% natural product without conservatives. It will kindly be donated from the company Rodi Hellas SA, Pella, Greece. The product is in line with the quality assurance certificates by the International Organization for Standardization (ISO 22000:2005), Global Gap, Grasp and Kosher.
46021026|NCT03741569|Device|Transabdominal Fetal Heart Rate|"Doppler, ECG and acoustic sensors will be placed on the mother's abdomen to capture the heart rate of the fetus and mother as well as uterine contractions.~For each of the participants, we will make two 15-minute recordings: one with conventional ECG electrodes and one with ECG textile electrodes"
46021027|NCT03616379|Behavioral|Psychoeducational Control|The Psychoeducational Control condition will consist of a brief script describing the body's response to stress and will not discuss cognition or the role of interpretation or affect labeling during stress.
46105704|NCT05861531|Behavioral|Oromotor stimulation|This will begin around 33 weeks corrected, the day following the first NTrainer measurements. The oral stimulation program will be modeled after the protocol designed and studied for preterm infants and will be implemented for a goal of 10 consecutive days within a 14 day period. This includes 10 minutes of stroking the cheeks, lips, gums, and tongue, and the final 5 minutes consisting of mid tongue stroking, eliciting a suck with gloved finger, and sucking on a pacifier provided in the NICU. This will occur 15-30 minutes before a scheduled tube feeding when the infant is tolerating bolus enteral feeds of 120 ml/kg/day for at least 48 hours. This will occur behind a curtain to ensure blinding of staff and parents. Modifications will be made for infants that remain intubated and only 10 minutes of the stroking of the cheeks, lips, gums, and tongue will occur. Stimulation will cease if episodes of oxygen desaturation and/or apnea/bradycardia occur during the stimulation.
45468454|NCT03318497|Other|Laboratory Biomarker Analysis|Correlative studies
46021028|NCT03616379|Behavioral|Affect Regulation|In the Affect Regulation Condition, participants will be provided instructions for how to reappraise negative thoughts in the context of stress by developing statements consistent with more benign interpretations of stress (e.g., This won't last forever.).
46021029|NCT03616379|Behavioral|Affect Labelling|In the Affect Labeling Condition, participants will be provided with instructions for how to verbalize their emotional response during the stressor.
46021030|NCT04320173|Drug|Lidocaine patch 1.8%|Three patches are applied to the subject's back for 12 hours.
46105705|NCT05861531|Behavioral|Reading curriculum|Written packets with biweekly lessons. The first two lessons include how to begin to read and talk to their baby. The second two lessons include reading or talking about the day using infant directed speech. The final two lessons include continuing to engage with the baby through interactive reading.
46105706|NCT05861531|Behavioral|LENA recording|The LENA device provides 24 hours of language recordings placed inside an infant vest. The recordings are uploaded to a computer which analyzes total adult word counts, infant vocalizations, conversational turns, background noise, and silence.
46105707|NCT05861531|Behavioral|LENA linguistic feedback|LENA recordings of adult word counts, infant vocalizations, and conversational turns will be provided in printed form after each recording with review of each recording and progress over time.
46021031|NCT04320173|Drug|Lidocaine patch 5%|Three patches are applied to the subject's back for 12 hours.
45599279|NCT03148977|Procedure|Graft|Autogenous skin grafting is the only definitive treatment for the full thickness burn injuries, and thus represents the centerpiece of modern burn care.
46105708|NCT05861531|Behavioral|No oromotor stimulation|This will begin around 33 weeks corrected, the day following the first NTrainer measurements. The standard care group will not receive any stimulation but will have a study personnel present behind a curtain to ensure blinding of family, staff, and investigators. The study personnel will remain behind a curtain for 10-15 minutes prior to a feed for 10 days over a 14-day period beginning when the infant is tolerated 120 mL/kg/day for at least 48 hours.
46105709|NCT05861518|Behavioral|Hypnosis|In the hypnosis group, patients were given hypnosis sessions of approximately 30 minutes each, in groups of three, once a week. In this way, session standardization was achieved. Arm catalepsy was suggested in all patients. The first session was used as hypnosis induction, progressive muscular relaxation and introduction to hypnosis. In the second session, in addition to the first session, self-hypnosis training was given. The second session was applied as the same 3rd session. In these patients, in addition to analgesia suggestions, the feeling of worthlessness was especially studied with the recommendation of a psychiatrist.
46021032|NCT04320173|Drug|Lidocaine medicated plaster 5%|Three plasters are applied to the subject's back for 12 hours.
46021033|NCT03420833|Device|Cardiac resynchronization therapy pacemaker (CRT-P)|A pacemaker is an implantable, battery-powered minicomputer that sends electrical pulses to the heart whenever it detects a slow heartbeat or no heartbeat at all. When it senses a slow heartbeat or lack of heartbeat, it sends electrical impulses to restore a normal rhythm. Cardiac resynchronization therapy pacemakers, or CRT-Ps, treat heart failure by resynchronizing electrical impulses in the heart's four chambers, improving the heart's ability to pump blood to the body effectively and efficiently.
46105710|NCT05861505|Drug|Neoadjuvant systemic therapy (CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B)|"Standard first line systemic treatment:~CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B~CAPOX 4x (12 weeks) FOLFOX/FOLFIRI 6x (12 weeks)~Maximum 4 cycles of CAPOX or 6 cycles of FOLFOX/FOLFIRI +/- bevacizumab regardless of the location of primary tumor or RAS/BRAF mutation"
46105711|NCT05861505|Other|Repeat local treatment|"Choice of repeat local treatment is to the discretion of the local investigator, and may be selected on a per patient basis.~The safety, feasibility and preferred type of surgical resection(s) is at the discretion of the liver surgeon (whether or not combined with thermal ablation).~The safety, feasibility and preferred type of thermal ablation(s) is at the discretion of the interventional radiologist (whether or not combined with surgical resection)."
46105712|NCT05861492|Other|Fatigue Differential Diagnosis Aid|The Fatigue Differential Diagnosis Aid is a systematic questionnaire covering the symptoms and signs of fatigue and the collateral clinical data trying to facilitate the diagnostic process in the care of patient with symptoms of fatigue.
46105713|NCT05861284|Device|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation method that can induce long-term changes in connections between neuronal networks.
46105714|NCT05859971|Drug|SLN mapping using technetium-99m +/- isosulfan blue dye|The isosulfan blue dye injection will be performed by the participating surgeon in the operating room; as per standard of care, injection will be subareolar. Incisions will be planned based on the technetium-99m activity or at the lateral aspect of the pectoralis muscle, per usual care.
46105715|NCT05859971|Device|SLN mapping with ICG fluorescence using the Asimov Platform|2 ml (5 mg) of ICG solution will be injected intradermally in 1-4 injection sites in the lateral areolar region. After injection, gentle manual massage will be performed for 5 minutes. ICG imaging will be obtained prior to incision. After incision is made (following standard of care procedures), the axilla will be visualized using the Asimov Platform to assess for ICG-fluorescence in sentinel lymph nodes.
46105716|NCT05859724|Biological|NM26-2198|IL-4R/IL-31 bispecific antibody for subcutaneous administration
46105717|NCT05859724|Other|Placebo|Placebo for NM26-2198
46105718|NCT05859685|Other|Experimental|"Manual therapy techniques:~Talar dorsal sliding technique. Dorsal mobilization of the talus, with the patient in the supine position and ankle dorsiflexion, without pain or discomfort. The physiotherapist will exercise an anteroposterior mobilization of the talus, with a dorsal glide~Mulligan movement mobilization technique: The patient will be in a standing position, with the ankle to be treated forward. You will be given an aid or support in the upper extremity to maintain stability."
46105719|NCT05859685|Other|Control|The patients included in the control group underwent the same techniques as those indicated for the experimental group, but without sliding or placing joint tension. The periodicity and times of administration will be the same
46105720|NCT05859659|Diagnostic Test|This study does not intervene in this process.|This study does not intervene in this process.
46105721|NCT05859503|Other|Closure Strategy with Perclose-Proglide system|Patients who have required Perclose-Proglide system in Percutaneous Interventional Procedure
46105722|NCT05859503|Other|Closure Strategy with figure-of-8|Patients who have required the manual compression with figure-of-8 in Percutaneous Interventional Procedure
46105723|NCT05859256|Other|Experimental|The intervention consists of the application of a treatment protocol based on an initial active warm-up consisting of 3 active exercises, walking for 1 minute performing slow and controlled movement of the ankle, raising the heels, 15 repetitions, dorsiflexion of the ankle in the standing position. gentleman, 15 reps. Subsequently, the floss band will be placed, performing again the 3 active warm-up exercises with the band on. After this, the passive manual techniques will be carried out for the remaining time, removing the flossing at the end of the latter, and actively mobilizing again.
46021034|NCT03207503|Procedure|fMRI|Patients will undergo fMRI imaging to assess areas of the brain that are active during emotion regulation. No clinical benefit of MRI imaging is anticipated.
46021035|NCT04321733|Drug|Amoxicillin Clavulanate|Intravenous drug intake of our drug.
46021036|NCT03002519|Biological|PLX-R18|Intramuscular (IM) administration of PLX-R18
46021037|NCT02915549|Other|Progressive Feeding without MEF|This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
45599280|NCT03507829|Drug|Human insulin isophane, Humulin N (Eli Lilly)|Human insulin isophane, Humulin N (Eli Lilly)
46021038|NCT02915549|Other|Progressive Feeding with MEF|This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
46105724|NCT05859256|Other|Control|The same procedures will be carried out, but placing the flossing without tension and performing the Kaltenborn manual techniques without sliding and without joint mobilization.
46105725|NCT05859152|Other|Zona Pellucida-Bound Sperm Selection for ICSI|one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that was bound to the ZP of an immature oocyte.
46021039|NCT02914301|Device|Babyscripts Prenatal App|The use of a mobile digital app to facilitate certain aspects of standard prenatal care.
46105726|NCT05859152|Other|Routine Embryologist Selected Sperm|one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that has been selected based on morphology and mobility characteristics by the embryologist per routine.
46105727|NCT05859022|Other|Roux-en-Y gastric By-pass (RYGB) surgery|RYGB procedure requires 1-2 hours of operating time and two to three days length of hospital stay. Use the Kit-RYGB by J& company.
46105728|NCT05859022|Other|Bariatric Arterial Embolization (BAE) procedure|use of Embosphere Microspheres (EM) that are designed to offer controlled, target embolization.
46105729|NCT05858931|Procedure|vaginal repair|vaginal repair
46105730|NCT05857930|Drug|OM-85|OM-85 capsule (3.5mg) contents will be mixed with adequate quantity of water, fruit juice or milk/formula and orally administered once a day for 6 consecutive months.
46105731|NCT05857930|Drug|Placebo|Placebo capsule contents will be mixed with adequate quantity of water, fruit juice or milk/formula and orally administered once a day for 6 consecutive months.
46105732|NCT05857384|Drug|IHL42X|IHL-42X consists of a film coated solid tablet containing acetazolamide within a soft gel capsule with a liquid formulation of dronabinol.
46021040|NCT02914301|Device|Placebo|No Mobile App, Usual care
45681245|NCT04199338|Other|The Effect of Web Based Education Based on Self-Care Deficiency Theory on Self-Care Power and Self-Efficacy and Perceived Social Support in Patients Receiving Peritoneal Dialysis|"In the study, which will last for 3 months, the patients in the intervention group will receive pre-test Web-based training based on the Self-Care Deficiency Theory. And an intervention group will be expected to use the website weekly. Also weekly reminder messages will be sent regularly.~Following the final test, individuals in the enterprise group will be asked to evaluate their views on the website in writing with the WAMMI test."
46021041|NCT02693093|Drug|NI-03|
46021042|NCT02693093|Drug|Placebo|
46105733|NCT05857384|Drug|Acetazolamide 250 MG|A solid tablet containing 250 mg acetazolamide
46105734|NCT05857384|Drug|Dronabinol 2.5 MG|A soft gelatin capsules containing 2.5mg dronabinol
46105735|NCT05855681|Other|therapeutic exercises|strengthening exercise and stretching exercise
46105736|NCT05855317|Other|Blood sample|Additional blood samples will be taken on a catheter, used for standard care.
46105737|NCT05855031|Diagnostic Test|Transient Elastography|One transient elastography 1-2 weeks after randomization
46105738|NCT05853991|Other|osteopathic manipulative treatment|The intervention will be based on the specific assessment and treatment of the preterm developed by the team and validated through different studies.
46105739|NCT05853991|Other|Active comparator|Application of affective touch
46105740|NCT05853991|Other|Placebo|Application of static touch
46105741|NCT05853640|Other|Usual care|Usual care at the orthopedic department consists of a clinical examination, radiological imaging, and a diagnostic injection. A recommendation to get physical therapy treatment in primary care will be provided, but this intervention will not be controlled by the investigators in any capacity.
46021043|NCT02029001|Drug|Nilotinib (400 mg BID)|Patient with advanced pigmented villonodular synovitis and tumors with mutations of ABL1, KIT, PDGFRA, PDGFRB, DDR1, DDR2, CSF1R, or amplification/translocation of the genes and/or of the ligands.
46021044|NCT02029001|Drug|Everolimus (10 mg QD)|Patients whose tumor harbors mutations or amplification of the PIK3CA, PIK3R1, AKT1, AKT2, mTOR, RICTOR, RAPTOR genes, or with TSC1, TSC2 or PTEN loss (defined as complete loss of both gene copies OR loss of one copy + mutation on the other copy or loss of one copy + loss of expression using immunohistochemistry).
46021045|NCT02029001|Drug|Sorafenib (400 mg BID)|Patients whose tumor harbors mutations of VEGFR1-3, PDGFRB, FLT3, BRAF (other than V600 mutations), CRAF, HRAS, KRAS or RET or amplification/translocation of the genes and/or of the ligands.
46021046|NCT02029001|Drug|Lapatinib (1500 mg QD)|Patients whose tumor harbors mutations or amplifications of HER2
46021047|NCT02029001|Drug|Pazopanib (800 mg QD)|Patients whose tumor harbors mutations of VEGFR1-3, PDGFRA, PDGFRB or KIT* or amplification /translocation of the genes and/or of the ligands.
46021048|NCT02029001|Drug|Olaparib (300 mg BID)|Mutation BRCA1/2 (somatic and germline) or BRCA like and mutations of HDR pathway genes (RAD51 family gene, PALB2, ATM, etc...); except in stomach; except for patients eligible to Olaparib's available labels in France.
46021049|NCT02029001|Combination Product|Durvalumab + Tremelimumab|Any molecular types of tumor (which are known to be immunogenic or with high mutation load), except lung, urothelial and head and neck or CNS tumors, or patients who fulfill conditions to receive any other MTT of the MOST Plus study.
46021050|NCT01940471|Drug|TAF|25 mg tablet administered orally once daily
46105742|NCT05853640|Other|HIPSTER|"Patients will be provided with usual care at the orthopedic department, which consists of a clinical examination, radiological imaging, and a diagnostic injection.~In addition, participants in this group will be referred to physical therapists trained in administering a semi-structured, individualized, progressive treatment. This 16-week intervention targets known physical and psychological impairments in people with long-standing hip and groin pain, using exercise therapy and patient education."
46021051|NCT01940471|Drug|TDF|300 mg tablet administered orally once daily
46021052|NCT01940471|Drug|TAF Placebo|Tablet administered orally once daily
46105743|NCT05853211|Combination Product|Aligner and inter-arch elastics|Correction of class II malocclusion by class II elastics on clear aligners
46105744|NCT05852561|Other|Group Superficial+Deep Serratus Anterior Plan Block|The block will be performed after induction of general anesthesia and surgical positioning. 15 ml of 0.375% Bupivacaine + epinephrine 5 µg/ml will be administered between the serratus anterior and latissimus dorsalis muscles. The same concentration of block fluid will be applied between the serratus anterior and the outer intercostal muscle.
46105745|NCT05852561|Other|Group Deep Serratus Anterior Plan Block|30 ml 0.375% Bupivacaine + epinephrine 5 µg/ml will be administered between the serratus anterior and outer intercostal muscle.
46021053|NCT01940471|Drug|TDF Placebo|Tablet administered orally once daily
46105746|NCT05852509|Behavioral|TPA4You|TPA4You integrates technology components in the form of video-conferencing (e.g., Zoom) with a health coach, wearable sensor (e.g., Fitbit), and personalized text messaging into a package to (a) tailor physical activity (PA) prescriptions based on the family care partners of persons with heart failure (HF-FCP)'s feedback and individual wearable sensor data, (b) provide tailored PA coaching sessions using video-conferencing, and (c) motivate daily exercise using text messages.
46105747|NCT05852509|Behavioral|Attention control group|Participants will be given booklets, provided by the NIA, AHA, and National Alliance for Caregiving, that include content about self-care for FCPs' health and well-being, but not specific to PA or exercise. Participants will receive text messages every other day to encourage them to wear the Fitbit device, and to provide friendly greetings and reminders of upcoming survey data collection.
46105748|NCT05852314|Behavioral|Culturally Adapted Manual Assisted Therapy (CMAP-SI)|C-MAP has been adapted from a self-help guide called Life After Self-Harm based on the principles of CBT. It is a brief problem-solving therapy comprising have 4 sessions weekly and then 4 fortnightly and last about 50 minutes each. The manual has been translated to Urdu giving special consideration to cultural adaptation of phrases and concepts to reflect Pakistani culture. Additionally, culturally appropriate case scenarios were incorporated and a consensual view to addressing cultural factors such as gender role, family conflicts and financial difficulties was taken. The culturally adapted intervention consists of the following components: evaluation of self-harm attempt, crisis skills, problem-solving and CBT techniques to manage emotions, negative thinking, interpersonal relationships, and relapse prevention strategies. Participants will receive sessions according to adapted CMAP-SI manual.
46105749|NCT05846425|Other|Nose-breathing training|13 days of controlled nose-breathing training at a specific frequency with a duration of approximately 15 min a day
46105750|NCT05846425|Other|Mouth-breathing training|13 days of controlled mouth-breathing training at a specific frequency with a duration of approximately 15 min a day
46105751|NCT05845619|Behavioral|Enhanced virologic monitoring|"The pilot intervention will include the following components:~More frequent viral load collection: Participants who enroll in the first 3 months of the pilot study period will be eligible for a 3-month follow-up visit and will have viral load assessed again at that time.~Rapid return of viral load results: Mentor mothers (peer counselors) will be trained to return viral load results to patients. Viral loads will will be processed with GeneXpert point of care technology.~Enhanced viral load counseling: Mentor mothers will reinforce adherence with all patients with undetectable levels via scripted messaging to reward and encourage healthy behavior. For those with any detectable levels, mentor mothers will be trained to provide targeted counseling with scripted messaging according to viral load level (undetectable, low-level viremia (50-1000), high viral load (>1000))."
46105752|NCT05844865|Other|Biospecimen Collection (Blood, Ascites/Peritoneal Wash Fluid and/or Tumor Samples)|Subjects with a known diagnosis of GI PC, with a planned standard of care surgery.
46105753|NCT05844293|Drug|FXI-GalNAc-siRNA|FXI-GalNAc-siRNA solution for injection
46105754|NCT05844293|Other|Placebo|Saline
46105755|NCT05842993|Device|Hydrogen generator|Patient inhales hydrogen gas for 2 hours per day in the flow rate of 2L/min via nasal cannula by applying hydrogen generator (HZS-2700A, Qingdao Haizhisheng Corp.,LTD, Qingdao, China) for 12 weeks.
46105756|NCT05842993|Device|Analogue machine|Patient inhales normal air for 2 hours per day in the flow rate of 2L/min via nasal cannula with analogue machine for 12 weeks. This machine has the same appearance as the hydrogen generator.
45599281|NCT03507829|Drug|Standard of care|Sliding scale short acting insulin for hyperglycemia; Sulphonylurea for NODAT
45599282|NCT03507829|Drug|Insulin lispro, Humalog (Eli Lilly) in insulin pump|Insulin lispro, Humalog (Eli Lilly) in insulin pump
45599283|NCT02232581|Drug|Alovudine - low|
46021054|NCT01613495|Drug|Placebo|After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
46105757|NCT05842941|Drug|DNL343|DNL343 is administered orally once daily per day for 24 weeks.
46105758|NCT05842941|Drug|Matching Placebo|Matching placebo is administered orally once daily per day for 24 weeks.
46105759|NCT05836896|Genetic|MDC-CAR-BCMA001 (BCMA directed CAR T-cells)|Single-dose intravenous infusion of MDC-CAR-BCMA001 at the respective dose level following a conditioning chemotherapy
46105760|NCT05831709|Other|Exercise program|The intervention consists of a supervised exercise program
46105761|NCT05831579|Radiation|Proton GRID Radiotherapy|The proton GRID radiotherapy prescription dose is 20 Gy x 3 fractions to the tumor, with an integrated dose of 6 Gy x 3 fractions to the PTV. Treatment to multiple lesions within the PTV is allowed (ex. a dominant lesion plus satellites). Multiple proton GRID radiotherapy plans may be delivered on the same day or different days, but they cannot overlap.
46105762|NCT05829421|Other|Impairment-specific occupational therapy (OT) intervention|"In parallel with standard practice, patients receive an OT intervention adapted to the specific underlying cognitive impairments that are likely to disturb their performance of ADLs.~The intervention is individualised through a 3-step process: a) a list of dysfunctional ADL process skills is forwarded by the OT to the neuropsychologist (NP), b) the NP identifies the cognitive impairments which are most likely to cause the dysfunctional ADL process skills through a cognitive assessment, c) based on the identified cognitive impairments, the NP and the OT select in collaboration the cognitive strategies that are most likely to benefit the individual patient from a pre-prepared intervention manual. Because of the large heterogeneity in how cognitive impairments impact on ADL performance, the exact way of implementing the selected cognitive strategies into the practice of the individual patient is left to the OT´s clinical judgement."
46105763|NCT05827978|Biological|mRNA-1010|Sterile liquid for injection
46105764|NCT05827978|Biological|Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine|Sterile suspension for injection
46105765|NCT05826639|Procedure|Temperature-sensitive radiofrequency ablation|Endobiliary radiofrequency ablation prior to ERCP-guided biliary stenting that utilizes a temperature-sensitive endobiliary RFA catheter
46105766|NCT05825768|Device|Breast MRI|Breast Magnetic Resonance Imaging prior to breast conserving surgery with and without intravenous contrast agent.
46105767|NCT05825768|Diagnostic Test|standard breast imaging|The control group that receives standard preoperative imaging only (breast ultrasound and mammography)
46105768|NCT05825001|Behavioral|Smoking Cessation Intervention|Receive active EFT stimulus
46105769|NCT05825001|Behavioral|Smoking Cessation Intervention (control)|Receive control EFT stimulus
46105770|NCT05825001|Other|Medical Device Usage and Evaluation|Use iCOquit Smokerlyzer carbon monoxide monitor
46105771|NCT05819684|Drug|SHR-4602 for injection|be administered via intravenous (IV) infusion
46105772|NCT05818137|Biological|Sotatercept|SC injection at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg every 21 days plus background PAH therapy.
46105773|NCT05817461|Drug|AZD0780 tablet|oral, fasted
46105774|NCT05817461|Drug|[14C]AZD0780 Solution for Infusion|intravenous
46105775|NCT05817461|Drug|[14C]AZD0780 Oral Solution|oral, fasted
46105776|NCT05817370|Behavioral|Enhanced Training on screening and treatment of HSIL (e-STH)|Tailored training developed to overcome key barriers and promote facilitators unique to implementing HSIL screening and treatment. The development will be driven by the implementation science committee over 3 iterations every 4 months for up to a year to refine the adoption of strategies with the greatest breadth to facilitate implementation.
46105777|NCT05817110|Other|Participant Cohort|Patients coming to the facility for chest x-rays for any reason, will undergo x-rays as ordered by their treating clinician. In case of any nodule detection by qXR, it will be classified either as low-risk (Lung nodule malignancy score ) LNMS or high-risk LNMS confirmed by radiologist. Then if patient is eligible will be included in the study and a CT Scan will be requested upon enrolment of the patient.
46105778|NCT05809310|Procedure|Percutaneous intervention (stent) for PA stenosis|Percutaneous intervention (stent placement) in one or both of the branch pulmonary arteries
46105779|NCT05808673|Biological|Post-change CMAB807X|for subcutaneous injection only
46105780|NCT05808673|Biological|Pre-change CMAB807X|for subcutaneous injection only
46105781|NCT05808673|Biological|Xgeva®|for subcutaneous injection only
46105782|NCT05807906|Other|virtual reality application|The patient will continue to monitor the virtual reality application during the fistula puncture procedure.
46105783|NCT05806411|Diagnostic Test|Analysis of calcific aortic valves|Microbiologic analysis of calcofic aortic valves
46105784|NCT05794022|Other|MRI|1 MRI at 1 month with gadolinium injection
46105785|NCT05794022|Biological|Biocollection|Biocollection from blood (H0, H4, H24, H48, 1 month, 1 year), urine (H48) and faecal (initial hospitalisation) samples.
46105786|NCT05794022|Behavioral|Quality of life questionaries|EQ-5D-5L and HAD questionaries at 1 month and 1 year.
46105787|NCT05793372|Other|Retrospective study of clinical features|Retrospective study of clinical features
46105788|NCT05785637|Procedure|Polygraphy diagnostic at home|Polygraphy diagnostic at home for patients under non-invasive mechanical ventilation.
46105789|NCT05785182|Procedure|Open Fracture|Patients 18 years of age or older with open fracture. Provision of informed consent.
46105790|NCT05785182|Procedure|Infected Fracture|Patients 18 years of age or older with infected fracture. Provision of informed consent.
46021055|NCT01613495|Drug|Octreotide|They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
46105791|NCT05776420|Behavioral|Food voucher|A voucher of $65 (or $85 for people in larger households) that can be redeemed for food at grocery stores.
46105792|NCT05775003|Dietary Supplement|Exercise|8 week exercise training program - consisting of weight training and cardiovascular exercise
46105793|NCT05773326|Drug|Temsirolimus|TORISEL® (temsirolimus) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma.
46105794|NCT05766475|Behavioral|ROSE Program: In Person|In-person preventative intervention for postpartum depression that includes content on building social support and communication skills in relationships, navigating the role transition to motherhood, and learning about signs and symptoms of depression after delivery.
46105795|NCT05766475|Behavioral|ROSE Program: Virtual|Virtual ROSE covers the same content (e.g. improving social support and communication) and is delivered by the same facilitators as the in-person intervention via telehealth.
46105796|NCT05765071|Biological|Botulinum toxin A|Botulinum injections will be prepared by diluting 100 units of botulinum toxin A with 5.0mL of saline (20.0U/mL). A total of 100 units (5.0mL) of botulinum toxin A will be injected into the tibialis anterior, peroneus longus and peroneus brevis muscles of the affected leg. Under ultrasound guidance, the injectant will be deposited at two sites in each muscle near the motor points.
46105797|NCT05765071|Biological|Normal saline|A total of 5.0mL of normal saline will be injected into the tibialis anterior, peroneus longus and peroneus brevis muscles of the affected leg. Under ultrasound guidance, the injectant will be deposited at two sites in each muscle near the motor points.
46105798|NCT05764460|Diagnostic Test|Neuropsychological tests|Neuropsychological tests for general cognition, social cognition and language.
46105799|NCT05760521|Other|Provider Educational Intervention|Following the informed consent (10 min) and sociodemographic survey (5 minutes), the providers in Arm A will be offered education of two days, six hours each day, with support and follow-up. They will also be asked to complete brief knowledge and confidence surveys pre-post-intervention (30 minutes total).
46105800|NCT05755360|Drug|Semaglutide|Participants will be treated with commercially available oral semaglutide according to routine clinical practice at the discretion of the treating physician. The decision to switch from DPP4i treatment to oral semaglutide is at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study.
46105801|NCT05750745|Drug|Sensodyne Sensitivity & Gum|Sensodyne Sensitivity & Gum toothpaste is containing 0.454% w/w SnF2.
46021056|NCT01429493|Radiation|Conventional Radiotherapy|Conventional radiotherapy will be used (8 Gy/ 1 fraction).
46105802|NCT05750745|Drug|Crest Cavity Protection Fresh Lime|Crest Cavity Protection Fresh Lime is containing 1150 parts per million (ppm) fluoride as Sodium fluoride (NaF).
46105803|NCT05750745|Drug|Sensodyne Repair and Protect|Sensodyne Repair and Protect toothpaste is containing 5.0% w/w calcium sodium phosphosilicate (CSPS).
46105804|NCT05746897|Drug|NM1F Injection|"This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of NM1F as monotherapy and in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors.~The study consists of two parts: NM1F monotherapy dose escalation (Phase 1a), NM1F dose escalation in combination with a fixed dose of pembrolizumab (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period."
46105805|NCT05746897|Drug|Pembrolizumab injection|"This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of NM1F as monotherapy and in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors.~The study consists of two parts: NM1F monotherapy dose escalation (Phase 1a), NM1F dose escalation in combination with a fixed dose of pembrolizumab (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period."
46105806|NCT05744232|Behavioral|Low calorie total diet replacement|"Summary~Weeks 1-12: TDR phase~Weeks 13-14: Food reintroduction phase I~Weeks 15-16: Food reintroduction phase II~Weeks 17 till 20: Food reintroduction phase III~Weeks 21 till 24: Maintenance phase"
46105807|NCT05744232|Other|Usual care|Participants allocated to the control group will be offered and continue benefiting from standard care. Participants will not be stopped from pursuing any behavioural weight management programme but if they do, this will be recorded.
46021057|NCT01429493|Radiation|Biological image-guided radiotherapy with conventional dose.|Biological image-guided radiotherapy on the positron emitting tomography (PET) positive lesion with conventional dose (8Gy/ 1 fraction) will be used.
45468455|NCT05403320|Device|Continuous cuff pressure regulation|Within 24 hours, AnapnoGuard tube will be connected to AnapnoGuard 100 control device. It includes an automatic high-sensitive subglottic capnograph which measures every few minutes the carbon dioxide level in the subglottic space. If the level of carbon dioxide is above the threshold (established by animal studies) the system will increase the cuff pressure by a formula, if the level is below the threshold, the system will decrease the cuff pressure by 1 mmHg. Variations of cuff pressure are allowed only between pressure limits set by the user (minimum and maximum)
46021058|NCT01429493|Radiation|Biological image-guided SBRT with dose-escalation.|Biological image-guided stereotactic body radiotherapy (SBRT) with dose-escalation on the PET positive lesion will be used.
46105808|NCT05736159|Diagnostic Test|Method of assessment of school maturity|Psychophysiological examination of the functional readiness of the child for admission to school.
46021059|NCT01321073|Device|Model 10642 Implantable Intravascular Catheter|This clinical study consists of the Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System (Model 8637) to deliver Remodulin Injection. This study will focus on the safety of delivery of Remodulin Injection in the treatment of patients with PAH who meet the approved Remodulin Injection indication, using the approved formulation, and approved intravenous route of administration.
46105809|NCT05736159|Diagnostic Test|Assessment of school adaptation|Psychophysiological examination of the success of school education of first graders.
46105810|NCT05725382|Device|The NOL monitor (Pain Monitoring Device monitor-PMD200™)|NOL-guided perioperative remifentanil administration
46105811|NCT05720000|Device|Photobiomodulation|Patient will receive the application of the low-power 660 nm Newskin MMO red LED in the immediate postoperative period. The application will be made punctually over the entire length of the wire, which measures 5 cm, totaling 10 application points with 1 cm of distance between them. The LED application will be repeated twice a week, with a minimum interval of 48 hours, totaling 9 laser applications over 30 days.
46105812|NCT05720000|Procedure|PDO thread|The participant's face will be cleaned with a 0.2% chlorhexidine solution. 0.1 ml of injectable anesthetic (2% lidocaine hydrochloride without vasoconstrictor, XYlestesin) will be administered in the skin layer at the point of incision in the glabellar region with a 30-gauge needle. A subincision will be made with a 21-gauge cannula in the glabellar ridge and then an injectable thread will be applied in the deep dermal layer below the glabellar ridge in the same direction as it.
46105813|NCT05718297|Drug|Brigatinib|"Brigatinib is administered for 3 years or until progression of disease, or unacceptable toxicities or withdrawal of consent, whatever occurs first. After the treatment period of 3 years, patient's ongoing treatment will be managed according to local standard and best clinical practice.~Brigatinib should be taken approximately at the same time each day. It may be taken with or without food. Patients shall be instructed to swallow the tablets whole and not crush or chew them."
46105814|NCT05718297|Drug|Durvalumab|Patients in the control arm will be observational, or, as per investigators choice, patients may receive durvalumab, administered within the label in the respective country.
46105815|NCT05718180|Other|Transperineal imaging|To measure the difference between ultrasound parameters based on maternal position: to measure the variation of AoP (Angle of progression), MLA (Midline Angle), PAA(pubic arch angle expressed in grades) HSD (head-symphysis distance) HPD(head perineum distance) expressed in millimeters, in the supine position and kneeling squat position in the same woman during the expulsion phase, in the resting step and during the push.
46105816|NCT05718141|Other|COMET-GB|"Online self-guided single session intervention - comprised of 4 modules based on the core principles of CBT, combined with principles from positive psychology. Each module includes short reading exercises, informational videos, and writing exercises.~Cognitive Restructuring (labelled Flexible Thinking)~Behavioural Activation (labelled Positive Activities)~Gratitude~Self-Compassion~The initial intervention modules and assessment will take participants approximately 60-75 minutes to complete (15-20 minutes for the assessment measures only)."
46105817|NCT05716542|Other|Physical Activity Intervention|Fitbit wearable device, home exercise sessions, and telehealth appointments with physical therapist.
46105818|NCT05713695|Behavioral|Full MISSION|MISSION is a time-limited, cross disciplinary, team-based wraparound approach that provides 6 months of psychosocial treatment combined with assertive outreach, empowering clients to access and engage in care and community services to promote recovery. The MISSION treatment curriculum integrates 3 evidence-based practices: 1) Critical Time Intervention (CTI), a time-limited form of assertive community treatment; 2) Dual Recovery Therapy (DRT), which is integrated mental health and substance use group therapy; and 3) Peer Support (PS), offering support for people in recovery by people in recovery.
46105819|NCT05713695|Behavioral|Linkage Only Delivered by a Peer Specialist|Linkage only is provided via Peer Specialists whom have lived experiences similar to that of our participants. Linkage only includes informal treatment planning and linkages and supports to needed community services.
46105820|NCT05710406|Drug|Encorafenib|Given PO
46105821|NCT05710406|Biological|Cetuximab|Given IV
46105822|NCT05710406|Procedure|Biospecimen Collection|Undergo collection of blood samples
46105823|NCT05710406|Procedure|Computed Tomography|Undergo CT
46105824|NCT05710406|Procedure|Magnetic Resonance Imaging|Undergo MRI
46105825|NCT05710406|Other|Patient Observation|Undergo observation per usual care
46021060|NCT00694733|Drug|Placebo injection|Normal saline injection IM monthly for 4 months
46021061|NCT00694733|Drug|Depo Lupron/Aromatase inhibitor|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and aromatase inhibitor months 4-8.
46021062|NCT00694733|Drug|Depo Lupron/placebo|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and placebo months 4-8.
46105826|NCT05705921|Radiation|Radiotherapy standard|Standard moderately hypofractionated radiotherapy in prostate cancer
46021063|NCT00694733|Drug|placebo|Placebo Cream 1ml applied twice daily for four months
46021064|NCT00694733|Drug|Estrogen cream|Estrogen cream 1 ml twice daily, dose titrated to maintain estradiol level between 60 and 280 pg/ml.
46021065|NCT04320953|Device|Non-contact MCE system|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the study subject positions himself (herself) on the examination bed in Room A, while the operating doctor sits in Room B at the remote control workstation instructing her to swallow the capsule via the audio-visual exchange system. After the capsule entering the stomach, the doctor manipulated the two joysticks on the remote control workstation, mobilizing the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric examination.
46021066|NCT00242021|Behavioral|Fatty acid composition of a margarine (spread)|
46021067|NCT01259297|Drug|Aliskiren|Aliskiren 150/300 mg once daily
46021068|NCT01259297|Drug|Amlodipine|Amlodipine 5 mg
46021069|NCT01259297|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 12.5/25 mg
46021070|NCT01259297|Drug|Placebo for Aliskiren|Placebo for Aliskiren 300 mg
46021071|NCT01259297|Drug|Placebo for Amlodipine|Placebo for Amlodipine
46021072|NCT01259297|Drug|Placebo for Hydrochlorothiazide (HCTZ)|Placebo for HCTZ 12.5/25 mg
46021073|NCT01126437|Drug|tiotropium 18 mcg|HandiHaler
46021074|NCT01126437|Drug|tiotropium 1.25 mcg (2 actuations/day)|soft mist inhaler 2 actuations=2 puffs/day
46021075|NCT01126437|Drug|tiotropium 2.5 mcg (2 actuations/day)|soft mist inhaler (2 actuations=2 puffs/day)
46021076|NCT01258595|Biological|High-Dose Trivalent Inactivated Influenza Vaccine|0.5 mL Intramuscular
46021077|NCT01258595|Biological|Trivalent Inactivated Influenza Vaccine|0.5 mL, Intramuscular
46021078|NCT05596799|Behavioral|Facing Eating Disorder Fears Condition|The first session consists of diagnosis and general psychoeducation on anorexia nervosa and treatment for anorexia nervosa. After psychoeducation and baseline questionnaires are complete, sessions 2-12 include exposure-based virtual treatment for common eating disorder fears (food, weight gain, body sensations, and social situations).
46021079|NCT01257737|Drug|HPN-100|Participants received individualized doses of HPN-100 orally, three times daily (TID) with meals. The initial dose was the same dose administered at the end of the HPN-100-005SE, HPN-100-007, or HPN-100-012SE studies. Dose adjustments (including frequency adjustments) were permitted as judged clinically appropriate by the investigator based on assessment of ammonia-scavenging needs (e.g., severity of the UCD defect, dietary protein intake, and urinary phenylacetylglutamine [PAGN] excretion). The maximum recommended dose of HPN-100 in participants weighing less than 20 kg was 0.53 mL/kg/day (equivalent to 600 mg/kg/day of NaPBA), and was 11.48 mL/m²/day in heavier subjects (equivalent to 13g/m²/day of NaPBA). The maximum HPN-100 dose recommended per protocol was 17.4 mL/day, which is equivalent to 20 g/day of NaPBA.
46021080|NCT01126359|Drug|Lidocaine|Interventional dressing change: iv or po pain medication with injection of 1% lidocaine retrograde up the suction tube into the sponge.
46105827|NCT05705921|Radiation|Radiotherapy Hypo-FLAME|Ultra-hypofractionated focal lesion ablative microboost in prostate cancer
46021081|NCT01126359|Drug|Placebo-Saline|Control dressing change: iv or po pain medication and injection of 0.9% normal saline retrograde up the suction tube.
45599284|NCT02232581|Drug|Alovudine - medium|
45599285|NCT02232581|Drug|Alovudine - high|
46021082|NCT00637533|Procedure|Lumbar sympathetic block with Botulinum Toxin type A|
46021083|NCT01125813|Biological|recombinant Factor VIII|intravenous infusion of factor FVIII every other day.
46021084|NCT00996892|Drug|Cobimetinib|Repeated oral dosing.
46021085|NCT00996892|Drug|Pictilisib|Repeated oral dosing.
46021086|NCT05113095|Biological|Darvadstrocel|Darvadstrocel injection
46105828|NCT05704855|Behavioral|Combined Exercise + Behavioural Counselling|The combine exercise intervention will consist of three 30-minute, supervised, remotely-delivered resistance training classes as well as three 30-minute, unsupervised aerobic training (i.e., walking) sessions each week. Participants will also participate in bi-weekly, 45-60 minute, remotely-delivered, group-based behavioural counselling sessions delivered via videoconferencing (i.e., Zoom). Participants will be asked to participate in the intervention for 8 weeks.
46105829|NCT05704855|Behavioral|Active Control|The active control group will participate in three 30-minute, supervised, remotely-delivered classes targeting balance and flexibility. The program will be delivered at a low-intensity by a Registered Kinesiologist via videoconferencing (i.e., Zoom). Participants will be asked to participate in the program for 8 weeks.
46105830|NCT05704543|Drug|Buprenorphine Extended-Release Injection|Administered as a subcutaneous injection.
46105831|NCT05703711|Behavioral|mHealer|MHealer is a software application installed on smartphones that provides psychosocial treatment support and patient condition tracking.
46105832|NCT05696730|Other|Communication intervention about sexuality in people with COPD|"COSY is a communication intervention which consists of one face to face counselling (75 min) and two 30-min telephone call counselling.~Patients assigned to the intervention group will get the COSY communication intervention with a special focus on the positive impact of sexuality on wellbeing plus specific motivation for physical activity. Together with the patient, a personalized re-enforcement instrument, the COSY-Compass, is elaborated to set individual goals and motivation for physical activity over the whole intervention period (3 months).~Participants will learn to understand the positive effect of regular physical activity on physical, mental, and cognitive wellbeing and a more fulfilling sex life as well as get inspiration about the spectrum and possible expressions and manifestations of caring and intimacy with oneself."
45468456|NCT05403320|Device|Intermittent cuff pressure regulation|ET cuff pressure will be manually measured three times per day using a portable manometer, and kept constant within 20-30 cmH2O
46021087|NCT04311645|Drug|Activated charcoal|Activated charcoal
45468457|NCT05403320|Device|Automatic subglottic secretion drainage|Within 24 hours, AnapnoGuard tube will be connected to AnapnoGuard 100 device control which provides continuous subglottic secretion drainage (two different suction lines) and venting/rinsing (a third dedicated line)
45468458|NCT05403320|Device|Manual subglottic secretion drainage|Subglottic secretions will be manually drained with a 10 mL syringe, using the only dedicated lumen
45838205|NCT04399772|Behavioral|Cognitive Functional Therapy+ pathway|"The CFT+ intervention comprises 4 main components: (1) making sense of pain: context-based patient education focusing on the multidimensional nature of pain and disability, while reducing the threat of structural damage and correcting unhelpful beliefs; (2) exposure with control: graded exposure to painful, feared, or avoided activities with body relaxation; (3) lifestyle changes: encouraged to perform physical activity based on preference and taught strategies to manage stress and poor sleep, (4) focus on coping strategies in life and how these strategies influence the current situation.~After CFT+, patients can be offered the comparator pathway should that be clinically indicated from these criteria: the patient does not feel ready to stop treatment AND Analgesic treatment is inappropriate OR Social situation is problematic OR Significantly psychological distress that requires further treatment by psychologist. This decision is based on a multidisciplinary team conference."
46021088|NCT04311645|Dietary Supplement|Dry seeds|Dry seeds
46021089|NCT01257581|Drug|creatine|creatine monohydrate powder
46021090|NCT01257581|Drug|tamoxifen|Tamoxifen citrate capsules
46021091|NCT01257503|Drug|Hyland's Cold 'n Cough 4 kids|5 ml PO q4h prn cold symptoms
46021092|NCT01257503|Drug|placebo|liquid made to look like the active homeopathic remedy
46021093|NCT04205032|Device|Test of the different devices integrated in cardiospace II|"The different devices included in CARDIOSPACE II will be tested~Electrocardiogram~Vascular Doppler~LaserDoppler and iontophoresis~Brachial blood pressure~Continuous blood pressure recorded at the finger level~Ultrasound~Ambulatory Electrocardiogram / SAO2 (arterial oxygen saturation)"
46021094|NCT02870452|Behavioral|Hypnosis|4 weekly individual sessions of Hypnosis, conducted by a certified psychologist, with the approximate duration of 90 minutes.
46021095|NCT02870452|Behavioral|Cognitive-Behavioral Therapy|4 weekly individual sessions of CBT, conducted by a certified psychologist, with the approximate duration of 90 minutes.
46021096|NCT00995566|Drug|Sitaxentan sodium|Please note that this is a non-interventional study and no drug is actually given as an intervention. Instead, patients prescribed THELIN are being followed under real world circumstances. However at the request of the QA group at CT.gov, we were instructed to add sitaxentan sodium as the intervention type, regardless of the fact that this is a non-interventional study.
45468459|NCT05403320|Diagnostic Test|Tracheobronchial colonization assessment|Tracheal aspirate will be performed after intubation and after 72 hours for microbiological colture
45468460|NCT05403320|Diagnostic Test|Microaspiration assessment|Tracheal aspirates will be performed 72 hours after intubation, and collected in a predefined study center to measure pepsin and salivary amylase
45599286|NCT02232581|Drug|Placebo|
46105833|NCT05686681|Behavioral|Brief Behavioral Activation for Improving Social Connectedness|"Brief Behavioral Activation for Improving Social Connectedness (BBAISC): BBAISC was developed to address social connectedness. Grounded in Behavioral Activation (Lejuez et al., 2011), BBAISC is a structured, 6-session skill-building intervention that has 4 key elements (Pepin et al., 2020):~Psychoeducation: Psychoeducation focused on homebound status, social connectedness, and associated changes in behavior.~Behavioral Activation intervention rationale: Framing how changing behavior can positively impact social connectedness (i.e., improve social connectedness and reduce loneliness).~Exploration of life areas, values, and activities: Focused on identifying life areas and values most relevant to the participant. Then, these values are used to generate activities that are aligned with those values.~Activity monitoring and planning: Participants are encouraged to schedule and organize their day based on what is important rather than their current mood or feeling state."
46021097|NCT01257425|Drug|Triptorelin Pamoate (Pamorelin® LA 11.25 mg)|"Pamorelin® LA 11.25 mg administered as standard IM injection (= reference group) at Day 1 and Day 85.~Triptorelin Pamoate (Pamorelin® LA 11.25 mg) applied subcutaneously (s.c.) at Day 1 and Day 85."
46105834|NCT05686564|Drug|ALXN1840|bis-choline tetrathiomolybdate
46105835|NCT05685108|Device|Ultrasound stimulation intensity|A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve.
46105836|NCT05685108|Device|Ultrasound stimulation site|A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve and the cervical vagus nerve.
46105837|NCT05672381|Procedure|Lower extremity and/or upper extremity surgery|Lower extremity and/or upper extremity surgery
46105838|NCT05672355|Procedure|Biospecimen Collection|Undergo blood sample collection
46105839|NCT05672355|Biological|mRNA COVID-19 Vaccine|Given IM
46105840|NCT05672355|Biological|Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1|Given IM
46105841|NCT05671900|Drug|Gemcitabine 1000 mg, Docetaxel 37.5g|6 weekly instillations of gemcitabine (1 gram of gemcitabine in 50 ml of sterile water) followed immediately by docetaxel (37.5 mg of docetaxel in 50 mL of saline) and subsequent monthly maintenance installations for those with no evidence of disease.
46105842|NCT05661409|Drug|Sugammadex|"Sugammadex is a FDA-approved drug that is in routine clinical use for NMB reversal.~Patients will be randomized to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated."
46105843|NCT05661409|Drug|Placebo|Normal saline will be used as placebo. The inclusion of a placebo group would allow us to examine if patients may recover spontaneously over that time without needing any sugammadex at all, and what parameters may predict that subset of patients. It will also improve the dose response modelling, in that randomization has been weighted so that patients who are least likely to need sugammadex (i.e. if they achieved a TOF count of 4 twitches without fade) are more likely to be in the placebo group or at the lowest dose of sugammadex that is being tested.
46105844|NCT05655507|Drug|SAGE-217|Administered as capsules
46105845|NCT05646368|Dietary Supplement|Formulation #1|Subject will receive a single dose of formulation #1 of a multivitamin/mineral supplement
46021098|NCT00995488|Drug|ABI-007 (Abraxane®)|ABI-007 is a novel albumin-bound paclitaxel combining a protein with a chemotherapeutic agent in the particle form.
46021099|NCT04293172|Drug|Brilinta|"Patients in the open-label Run-in period (patients aged 6 to <24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight >9 to ≤12 kg) or 15 mg twice a day (body weight >12 to ≤24 kg) for 14 days.~The double-blind IP will be based on 5 weight bands:~6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day~>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day~>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day~>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day~>48 kg: ticagrelor 45 mg or matching placebo, twice a day"
46105846|NCT05646368|Dietary Supplement|Formulation #2|Subject will receive a single dose of formulation #2 of a multivitamin/mineral supplement
46105847|NCT05645432|Drug|Brexanolone|Brexanolone IV infusion
46105848|NCT05623683|Other|Intermittent Walking|Wearing comfortable clothes and their usual walking shoes, participants will walk on a treadmill to accrue 30 minutes of walking. Participants will be instructed not to use the treadmill side rails for balance or support during walking. Participants will walk on the treadmill for 3 blocks of 10 minutes with 2 blocks of 5-minute rest (sitting on a chair) in-between. A safety button to stop the treadmill will be available to the participants, so they can stop walking anytime. If participants feel that they are about to lose balance, they are allowed to hold on to the side rails to regain balance and terminate the trial.
46105849|NCT05623683|Other|Continuous Walking|Wearing comfortable clothes and their usual walking shoes, participants will walk on a treadmill to accrue 30 minutes of walking. Participants will be instructed not to use the treadmill side rails for balance or support during walking. Participants will rest for 10 minutes (sitting in a chair) before walking on the treadmill for 1 continuous block of 30 minutes. A safety button to stop the treadmill will be available to the participants, so they can stop walking anytime. If participants feel that they are about to lose balance, they are allowed to hold on to the side rails to regain balance and terminate the trial.
46105850|NCT05619705|Behavioral|Healthy for Two-Home Visiting (H42-HV)|The H42-HV intervention includes health coaching calls, H42 web based app, mobile phone-based tracking.
46105851|NCT05619705|Behavioral|"Usual Home Visiting Plus (mHIP-HV)"|A brief video on maternal warning signs that is available in English or Spanish.
46105852|NCT05618301|Drug|Motixafortide|Motixafortide is to be administered as a subcutaneous injection at a dose of 1.25 mg/kg
46105853|NCT05618301|Drug|Natalizumab|Natalizumab will be administered as an IV infusion at a flat dose of 300 mg
46105854|NCT05618301|Procedure|Leukapheresis|Leukapheresis consisting of a 1 Blood Volume procedure
46105855|NCT05615649|Device|MED-EL BONEBRIDGE Bone Conduction Implant|Subjects will be implanted with the MED-EL BONEBRIDGE Bone Conduction Implant System. Subjects will be fit with the appropriate external audio sound processor.
46105856|NCT05615337|Behavioral|MBSR|"The MBSR is an eight-week group-based psychoeducational program. It is performed in weekly group sessions with the duration of 2.5 hours and a half-day retreat of 4 hours.~The program involves focused attention, consisting of body scan, yoga, and meditation. This program trains participants to be attentive to their thoughts, emotions, and sensations. There are also discussions on relevant topics related to the physiology of stress and strategies of coping. Materials for home practice are provided."
46105857|NCT05615337|Behavioral|HPP|The HPP has the same structure of MBSR, including different components such as music, nutrition, cognitive enhancement, risk factors for dementia, and physical activity. During the half-day retreat participants are involved in watercolor painting activities. Materials for home practice are also provided.
46105858|NCT05614661|Behavioral|Mom Power|Experimental participants will receive virtual Mom Power via phone/internet connection. Control participants will receive mail information and confirmation phone calls.
46105859|NCT05610163|Drug|Capecitabine|Given PO
46105860|NCT05610163|Drug|5-fluorouracil|Given IV
46105861|NCT05610163|Drug|Leucovorin calcium|Given IV
46105862|NCT05610163|Drug|Irinotecan|Given IV
46105863|NCT05610163|Drug|Oxaliplatin|Given IV
46105864|NCT05610163|Radiation|Long Course Chemoradiotherapy|Receive LCRT
46105865|NCT05610163|Procedure|Computed Tomography|undergo CT
46105866|NCT05610163|Procedure|Magnetic Resonance Imaging|undergo MRI
46105867|NCT05610163|Procedure|Sigmoidoscopy|undergo sigmoidoscopy
46105868|NCT05610163|Procedure|biopsy|undergo biopsy
46105869|NCT05604066|Diagnostic Test|Magnetic Resonance (MR) Elastography|Magnetic resonance imaging (MRI) imaging technique that creates a visual map (Elastogram) to show the stiffness of body tissues
46105870|NCT05604066|Diagnostic Test|MRI structural imaging|MRI structural imaging will be done at the same time as MR elastography.
45468461|NCT05403320|Diagnostic Test|VAP assessment|Patients will be follow to detect clinical, radiological or microbiological signs of VAP. If suspected, a tracheal aspirate or a bronchoalveolar lavage is performed to confirm the diagnosis
46105871|NCT05594147|Drug|Non-TKIs|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
46105872|NCT05594147|Drug|Other TKIs|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
46105873|NCT05594147|Drug|Regorafenib (Stivarga, BAY73- 4506)|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
46105874|NCT05594147|Drug|Sorafenib (Nexavar, BAY43-9006)|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
46105875|NCT05586958|Drug|Tigulixostat|Xanthine Oxidase Inhibitor
46105876|NCT05586958|Drug|Placebo|Matching placebo
46105877|NCT05582850|Drug|DT-9081 - dose escalation|Patients will be dosed orally once daily. The schedule might be adjusted in case of toxicities.
46105878|NCT05582850|Drug|DT-9081 - expansion|A homogeneous patient population will receive DT-9081 at the recommended clinical dose (RCD).
46105879|NCT05577390|Other|Intraneural Facilitation Treatment™|Intraneural facilitation™ uses three manual holds to bias blood flow to closed endoneurial capillaries. The first is the facilitation hold, which is thought to pressurize the nervous system and bias circulation from the artery into the epineurium. This hold stretches the nerve further than the artery, increasing the amount of elastin in the artery and enlarging the opening of the arterial junction increasing blood into the epineurium. The secondary hold then increases epineurial blood into the transperineurial vessels increasing pressure into the endoneurial capillaries of the site being treated. The third hold, known as the sub hold, encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of Bernoulli's principle. The series of stretches will be repeated on the affected side for the treatment duration.
46105880|NCT05577390|Other|Standard Physical Therapy Treatment|The standard physical therapy treatment includes muscle stretching, balance, and strengthening exercises known to improve neuropathy symptoms.
46105881|NCT05573464|Drug|BGF MDI HFO 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
46105882|NCT05573464|Drug|BGF MDI HFA 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
46105883|NCT05568264|Other|Physical Therapy intervention|The intervention is based on five principles: active learning, caregiver engagement, environmental enrichment, strengths-based approach, and dose. The intervention will start in the NICU and continue until 12-months corrected age. Infants in the intervention group will receive up to two therapist visits per week in addition to standard of care physical therapy. Caregivers will be asked to work with their infant on activities provided by the therapist. The therapist will provide resources to support the caregiver in working on these activities with their child, and caregivers will be asked to complete the activities for as much time as possible, throughout the day. Therapists will work with caregivers to identify ways to incorporate activities into their day. Caregiver engagement and caregiver ability to complete sessions and activity recommendations will be monitored.
46105884|NCT05565092|Drug|ALXN1820|ALXN1820 will be administered subcutaneously.
46105885|NCT05562557|Behavioral|Motivational Enhancement|To encourage intrinsic motivation to engage in fatherhood activities
45468462|NCT03432442|Drug|Ivermectin|Ivermectin once every 24 hours for three administrations
46105886|NCT05562557|Behavioral|HERO Dads Fatherhood Program|Fatherhood engagement curriculum to increase awareness, knowledge, and skills for parenting and co-parenting
46105887|NCT05562557|Behavioral|Contingency Management|To reinforce healthy behaviors, including attendance at services
46105888|NCT05562557|Behavioral|Case Management|Referrals to treatment, social services, and employment services
46021100|NCT04293172|Drug|Placebo|"Patients in the open-label Run-in period (patients aged 6 to <24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight >9 to ≤12 kg) or 15 mg twice a day (body weight >12 to ≤24 kg) for 14 days.~The double-blind IP will be based on 5 weight bands:~6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day~>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day~>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day~>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day~>48 kg: ticagrelor 45 mg or matching placebo, twice a day"
46021101|NCT01256879|Drug|Drug: cimetidine|cimetidine 200mg total dose (single dose) as either CimTest-A capsules, CimTest-B capsules, sorbitol-free solution, or commercial cimetidine solution
46105889|NCT05561790|Behavioral|eCBT-I|Automated digital administration of sleep hygiene, sleep optimization, stimulus control therapy, deactivation/relaxation training, and cognitive therapy modules via mobile or web application, lasting approximately six weeks.
46105890|NCT05556525|Other|Fluorescein|Given IV
46105891|NCT05556525|Device|Image-Guided Needle Confocal Laser Endomicroscopy|Undergo nCLE
46105892|NCT05556525|Procedure|Ultrasound-Guided Transbronchial Needle Aspiration|Undergo EBUS TBNA
46021102|NCT04293250|Procedure|Compare the severity of postoperative pain of the physical activity group Vs non-physical activity group|Compare postoperative pain scores for the physical activity Vs non-physical activity group
46021103|NCT04292938|Dietary Supplement|Low carbohydrate ketogenic diet|Dietary modification, including the use of supplements, with the aim of reaching a lipid/carbohydrate-protein 3:1 ratio with a minimum 1g/Kg/die in protein
46105893|NCT05551715|Device|Software development for individualized refractive surgery|Software development for individualized refractive surgery
46105894|NCT05546554|Drug|Suvorexant|5 mg (and up to 20 mg) Suvorexant given orally
46105895|NCT05546554|Drug|Placebo|Matching Placebo given orally
46105896|NCT05541055|Device|digital CBT-I|A fully-automated and personalized digital intervention based on principles from cognitive behavioral therapy for insomnia.
46105897|NCT05541055|Other|Sleep hygiene education|Participants will be provided with sleep hygiene advice which will be delivered digitally all at once upon allocation to the SHE arm. Participants will be able to revisit content during the trial as they wish.
46105898|NCT05540574|Drug|Zolpidem|5mg (and up to10mg) Diphenhydramine given orally
46105899|NCT05540574|Drug|Placebo|Matching Placebo given orally
46105900|NCT05535387|Behavioral|FamilyNet smart speaker/mobile application|In a 4- to 6-week period, families will use a prototype of the FamilyNet integrated and coordinated smart speaker/mobile application designed to provide families with in-situ experiential support for building positive behavior plans. The prototype FamilyNet program will guide families in creating and implementing positive behavior plans to foster positive child behavior, consistent parenting, and promote a positive parent-child relationship.
45468463|NCT01238159|Radiation|CCRT+MIDLE chemotherapy|Patients are planned to be treated with CCRT plus MIDLE chemotherapy
46021104|NCT04293718|Other|papillary gum biopsies|1 or 2 papillary gum biopsies were performed simultaneously, 1 for histological examination and 1 for immunohistochemistry
46021105|NCT02869672|Biological|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
46105901|NCT05533242|Drug|Lu-177 labeled 6A10-Fab-fragments|The antibody 6A10 is a specific CA12 Inhibitor, a highly specific glioma cell-associated enzyme; all tumor cells are CA12-positive, while its expression in normal brain is very low, and Lu-177 has a comparable β-emission, but a significantly low γ-Emission.
46021106|NCT02869672|Biological|Hualan Biology ACYW135 meningococcal polysaccharide vaccine|Hualan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
46021107|NCT01125189|Drug|Daclatasvir|Tablets, oral, 20 mg, once daily, 12-24 weeks, depending on response
46021108|NCT01125189|Drug|Daclatasvir|Tablets, oral, 60 mg, once daily, 12-24 weeks, depending on response
46021109|NCT01125189|Drug|Placebo|Tablets, oral, 0 mg, once daily, 24 weeks
46021110|NCT01125189|Drug|peg-interferon alfa-2a|Syringe, subcutaneous Injection, 180 µg, once weekly, 24 or 48 weeks depending on response
46105902|NCT05529303|Behavioral|Such as art therapy, play therapy, breathing techniques|The Cognitive Behavioral Therapy (CBT) model suggests that the individual's dysfunctional thoughts about self, the world, and/or others are based on irrational or illogical assumptions. An individual's self and his/her view of the world are central to the determination of his/her feelings and behaviors and thus can be changed through changing the individual's thoughts, feelings, and behaviors. CBT techniques are in line with the use of expressive art techniques. The common goal in both CBT and expressive arts is to achieve behavior change in the individual. An intervention program has been prepared by the researcher in line with this literature information.
46105903|NCT05527678|Other|Questionnaires|Written or by phone
46105904|NCT05514535|Drug|Semaglutide|Participants will receive once-weekly semaglutide s.c. for 40 weeks. Semaglutide 0.25 mg will be given at week 0 and then the dose will be escalated at weeks 4, 8 and 12 to 0.5 mg, 1 mg, 2 mg respectively.
46105905|NCT05514535|Drug|Insuline glargine U100 (reduced)|Participants will receive insulin glargine U100 s.c. once-daily. Insulin glargine dose will be reduced by 10 U at initiation of semaglutide and then again at each semaglutide dose escalation up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
46021111|NCT01125189|Drug|ribavirin|Tablets, oral, 1000 or 1200 mg based on weight, once daily, 24 or 48 weeks depending on response
46105906|NCT05514535|Drug|Insuline glargine U100 (titrated)|Participants will receive titrated insulin glargine U100 s.c. once-daily up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
46105907|NCT05512143|Device|Transcranial magnetic stimulation|Participants will undergo a standard course of TMS treatment (30 sessions/6 weeks).
46105908|NCT05506254|Drug|hLB-001|hLB-001 gene therapy
46105909|NCT05504070|Device|Venclose System (digiRF generator w EVSRF catheter)|The Venclose System is intended for use in endovascular coagulation of blood vessels in patients with superficial vein reflux.
46105910|NCT05504070|Device|Venclose MAVEN System (digiRF generator w MAVEN catheter)|The Venclose MAVEN System is intended for use in endovascular coagulation of blood vessels in patients with perforator or tributary vein reflux.
46105911|NCT05501678|Drug|Diphenhydramine|25mg (and up to 50mg) Diphenhydramine given orally
46105912|NCT05501678|Drug|Placebo|Matching Placebo given orally
45838206|NCT04399772|Behavioral|Interdisciplinary pain management pathway|"Treatment at the Interdisciplinary University Pain Center are based on elements from cognitive-behavioral therapy, Acceptance and Commitment Therapy, and Mindfulness-Based Stress Reduction programs.~Individualized combination of (1) medical treatment with a specialist pain consultant+specialist pain nurse (ie, individual adjustment of analgesics to improve effect and reduce side effects), (2) one or more of the following: individual consultations with a specialist pain psychologist, physiotherapist or social worker with cognitive-behavioral therapy training as well as participation in a group program with relaxation therapy, acceptance and commitment therapy or standardized mindfulness-based stress reduction programs."
46105913|NCT05499650|Behavioral|Supervised Exercise Regiment|Subjects will undergo supervised aerobic exercise. There will be a set goal mean energy expenditure of at least 1000 kcal/wk after a two-week ramp-up period. The protocol will include 30 minutes of moderate-intensity exercise with a treadmill and cycle ergometry, two times weekly. Strenuous resistance training and swimming will be withheld from this protocol due to the potential concerns for safety in exacerbating dissections. Heart rate and ratings of perceived exertion will be quantified during the therapy with a standard set heart rate ad pulse pressure threshold for discontinuing exercise protocols.
46105914|NCT05498662|Device|T3 Pro dental implant system|treatment of tooth loss with T3 Pro dental implants
46105915|NCT05498038|Behavioral|Aerobic Exercise|Participants are asked to complete at least 20 minutes of aerobic exercise every day, excluding clinic visits.
46105916|NCT05496166|Combination Product|chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy|Induction treatment stage: SHR-1316(Adebrelimab)，20mg/kg,+Cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, iv, 4 cycles. Patients who are able to receive surgery after assessed by two surgons would receive surgery or radiotherapy randomly. Adjuvant/ maintenance treatment stage: SHR-1316，20mg/kg, iv, q3w,up to 1 year
46105917|NCT05491642|Drug|BAY3283142|Oral administration
46105918|NCT05491642|Drug|Placebo to BAY3283142|Oral administration
46105919|NCT05489185|Drug|Tranexamic acid|Intravenous or topical administration
45838207|NCT04375982|Diagnostic Test|Venepuncture|Blood tube will be collected from standard venepuncture
46105920|NCT05489185|Other|Physiologic saline|Placebo
46105921|NCT05487586|Drug|ceftazidime avibactam group|Non-Interventional Study
46105922|NCT05481593|Behavioral|Scheduled Coaching + Gamified Rewards|Participants will receive scheduled coaching calls and receive gamified rewards (i.e., earning points over time and converted to monetary gifts)
46105923|NCT05481593|Behavioral|Scheduled Coaching Calls + Independent Rewards|Participants will receive scheduled coaching calls and receive fixed rewards (i.e., non-increasing)
46105924|NCT05481593|Behavioral|No Scheduled Coaching Calls + Gamified Rewards|Participants will not have scheduled coaching calls and receive gamified rewards (i.e., earning points over time and converted to monetary gifts)
46105925|NCT05481593|Behavioral|No Scheduled Coaching Calls + Independent rewards|Participants will not have scheduled coaching calls and receive fixed rewards (i.e., non-increasing)
46105926|NCT05475925|Drug|DR-01|DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.
46105927|NCT05469581|Other|A set of preventive interventions to improve adherence in vulnerable elderly people|"reviewing the list of medications, delivery of an ordered list of medications, and checking medication regimen understanding;~delivering a leaflet on the correct/safe taking of medications, discussion, explanation, and verification of understanding of the content;~a counseling about the importance of adherence;~handing over the medication dispenser (if the elderly person does not have one yet),~delivering of a personal medication card, which shows the timeline of taking prescribed medication."
46105928|NCT05465304|Drug|Azithromycin|The assessment of efficacy of azithromycin in preventing premature labour.The duration between administrating azithromycin as monotherapy and polytherapy and labour is calculated
46105929|NCT05463731|Drug|Remternetug (IV)|Administered IV
46105930|NCT05463731|Drug|Remternetug (SC)|Administered SC
46105931|NCT05463731|Drug|Placebo|Administered IV or SC
45468464|NCT01964547|Drug|Sativex|Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
46105932|NCT05461521|Other|Family members of patients admitted to the ICU|"At inclusion:~Collection of demographic data, Anxiety-Depression Scale (HADS), Insomnia Severity Index (ISI), Resilience Insomnia Severity Index (ISI), Resilience Scale (CD RISC 10), Peritraumatic Dissociation Peritraumatic Dissociation Experience Scale (PDEQ) and MEDEC questionnaire.~Venous blood sampling at 350 relatives~Upon discharge of the patient (alive or deceased): Resuscitation questionnaire, HADS, ISI and PDEQ.~3 months after discharge: Demographic questionnaire, Post Traumatic Stress Disorder questionnaire (PCL-5), THS Past Trauma Experience Questionnaire, HADS experiences, HADS, ISI, CD RISC 10, MEDEC and Who- assist questionnaire (Question 2) on the use of psychoactive substances.~6 months after patient discharge: PCL-5, HADS, ISI, CD RISC 10, MEDEC, Who-assist (Question 2) and Prolonged Grief disorder (PG-13) questionnaire on bereavement if patient died in the ICU."
46105933|NCT05461521|Other|Health care professionals|All professionals in all categories and in all participating departments will be asked to complete questionnaires to assess the level of conflict, work stress and burn out in the units : Masclach Burnout Inventory (MBI), Job Content Questionnaire (JCQ), Ethical Decision-Making Climate Questionnaire (EDMCQ), Professional Quality Of Life scale (ProQOL), Connor-Davidson Resilience scale (CD-RISC 10), Cultural Awareness Scale (CAS).
46105934|NCT05461521|Other|Patients|Inclusion (at D3 after admission to the ICU): collection of demographic data Discharge from the ICU: characteristics of the stay and outcome (alive/deceased)
46105935|NCT05458024|Drug|Vitamin D 2|300,000 international units (IUs) of Ergocalciferol in 6 50,000 IU capsules.
46105936|NCT05458024|Drug|Vitamin D2 Placebo|Inert substance will be administered in 6 capsules indistinguishable from the 50,000 IU
46105937|NCT05456685|Drug|Mirvetuximab soravtansine|Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called folate receptor alpha (FRα). It is being developed for the treatment of subjects with recurrent platinum-sensitive, high grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with FRα expression. FRα positivity will be defined by the Ventana FOLR1 Assay.
46105938|NCT05456685|Drug|Carboplatin|Carboplatin is considered to be the treatment agent of choice in relapsed PSOC.
46105939|NCT05455450|Other|Eye movement desensitisation and reprocessing therapy|Up to 16 EMDR sessions (minimum of 8 sessions), and 1-month follow-up session, as well as attending neuropsychiatric appointments (NPC). Participants will be given the choice of attending EMDR physically face-to-face or virtually via a video-consultation platform. Sessions will normally be attended weekly, with treatment completed within 6 months. Sessions will be 60-90 minutes long. EMDR will follow the standard 8-phase protocol, with additions so that it is tailored for FND presentations. The FND-specific EMDR therapy protocol has been developed for the trial by the chief investigator.
46105940|NCT05455450|Other|Neuropsychiatric care|Standard medical care consisting of 1-3 30 minute appointments with neuropsychiatrist over the course of the 9-month trial period.
46021112|NCT01256567|Biological|Ramucirumab|Ramucirumab administered as an intravenous (I.V.) infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.
46021113|NCT01256567|Drug|Docetaxel|Docetaxel administered by intravenous (I.V.) infusion at a dose of 75 milligrams per square meter (mg/m^2) every 3 weeks.
45468465|NCT01964547|Drug|Placebo|Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
45468466|NCT03432208|Procedure|GI consult|
45468467|NCT01380314|Drug|Miltefosine + Imiquimod|150 mg x d during 28 days and cream applied every other day during 3 weeks
45468468|NCT01380314|Drug|Miltefosine 150 mg x day + Placebo|150 mg x d during 28 days and cream applied every other day during 3 weeks
46021114|NCT00996736|Drug|Natamycin|5% natamycin plus 0.02% preservative, one drop to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until 3 weeks after enrollment.
45468469|NCT01145105|Procedure|neural dynamics techniques treatment|Treatment group- will receive neural mobilizations techniques, to improve movement of the sciatic nerve.
45468470|NCT01145105|Procedure|placebo treatment|Control group- will receive placebo treatment that will include mobilization to the upper limb. After the placebo treatment, these patients will receive neural mobilizations techniques.
45468471|NCT03432130|Other|Structural training program|15-week experimental structural training protocol
45468472|NCT03110510|Drug|Fluorouracil|5FU 400mg/m2 bolus and then 2400mg/m2, continuous infusion D1-2
45838208|NCT04375982|Diagnostic Test|Fingerstick|Capillary blood will be collected by fingerstick
46021115|NCT00996736|Drug|Voriconazole|1% voriconazole plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
46021116|NCT00996658|Drug|Placebo|Placebo matching linagliptin tablets once daily
46021117|NCT00996658|Drug|Linagliptin|Linagliptin tablets once daily
46021118|NCT01124643|Biological|Replagal|0.2 mg/kg administered intravenously [IV] every other week
46021119|NCT05109195|Other|Standard of Care (SOC)|Participants will not receive any intervention as a part of this study. Participants will receive SOC treatment.
46105941|NCT05453370|Device|CALMA m-health app|CALMA is an app for smartphones that provides evidence-based tools to prevent suicide. Out of Crisis modality consists of 4 sections: Moments, Agenda, Profile and Tips. The I need help modality uses DBT skills presented in a card format. The Problem-solving Card is the first one showed and helps the user to know if the problem that triggered the crisis can be addressed through a problem-solving strategy. If not, the next step is to use the CALMA thermometer (to identify the intensity of the emotion) and the DBT Skills Cards. They are based fundamentally in two groups of DBT skills, emotional regulation and distress tolerance. If distress worsens or does not diminish the Emergency Card is activated, offering the user the option to make one or several calls to emergency contacts and providing the option to use the geolocation function to show all emergency services near the user's location so that he/she can consult personally. All participants will also receive mental health treatment.
46105942|NCT05453370|Other|Treatment As Usual (TAU)|Participants who do not receive the application will continue the usual mental health treatment (psychotherapeutic and/or psychopharmacological) by their usual treating professionals throughout the duration of the study.
46105943|NCT05442333|Procedure|surgical resection with safety margin|"• The patients with preoperative radiotherapy:~will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).~6 weeks post radiation for wound dehiscence~3 months post radiation for local swelling or recurrence~6 months post radiation for local recurrence, joint stiffness or pathological fractures.~The patients with postoperative radiotherapy:~will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).~6 weeks post radiation for wound dehiscence~3 months post radiation for local swelling or recurrence~6 months post radiation for local recurrence, joint stiffness or pathological fractures."
46105944|NCT05440240|Procedure|Percutaneous needle fasciotomy|Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
46105945|NCT05440240|Drug|Corticosteroid injection|Depo-Medrol
46105946|NCT05440240|Other|Saline injection|Isotonic saline
46105947|NCT05436392|Behavioral|Peer Comparison Feedback|USAP anesthesia providers will receive monthly alerts via USAP's smartphone-based practice management application, text message, or email presenting individual-level data on their benzodiazepine administration patterns versus other USAP providers, using data from the USAP clinical and quality data warehouse.
46021120|NCT04310631|Drug|Ranibizumab Injection|Ranibizumab Injection (0.5 mg/0.05 ml): Three monthly intravitreal injections
46021121|NCT04309851|Diagnostic Test|deep learning|the deep learning method is a field of study involving artificial neural networks and similar machine learning algorithms with many hidden layers.
46105948|NCT05436392|Behavioral|Patient Informational Letter|Breif informational letters will be distributed to eligible patients within the 2 weeks prior to surgery. Letters will be produced on USAP letterhead and signed by the USAP Chief Quality Officer. Letter text will state USAP's commitment to brain health and avoiding potentially unnecessary medications for patients undergoing surgery. It will also include a statement encouraging patients to discuss anesthesia plans with their clinicians at the time of surgery to aid tailoring of care to individual needs. Letters will be distributed directly to patients via text link, email, or hard copy as a component of standard pre-operative instructional communications and other educational and patient outreach materials related to clinical care.
46105949|NCT05430854|Biological|Daxdilimab|Daxdilimab will be administered subcutaneously as two injections for each dose.
46105950|NCT05429593|Drug|Semaglutide|Tablet given orally
46105951|NCT05429593|Drug|Dapagliflozin|Tablet given orally
46105952|NCT05429593|Drug|Semaglutide/dapagliflozin|Tablet given orally
46105953|NCT05417958|Other|Extremely thick blenderized tube feed|Commercial blenderized tube feed, not diluted
46105954|NCT05417958|Other|Mildly thick blenderized tube feed|Commercial blenderized tube feed, diluted with ingredients contained in blend
46021122|NCT05108025|Drug|Topical Powder|Topical Powder mixed with diluent
46021123|NCT05108025|Drug|Placebo Topical Powder|Placebo Topical Powder mixed with diluent
46105955|NCT05412524|Behavioral|reading|Mothers and, if desired, mother's partner will read to preterm infant as frequently and as much as they are able to. Reading is the intervention. The variable of interest is parents' and infants' change in salivary oxytocin receptor gene methylation (OXTRm) over time.
46105956|NCT05412251|Radiation|health promotion program|Multi-domain intervention 120 minutes cognitive training, 120 ~180 minutes physical exercise per weeks, and 60 minutes diet nutrition education per month
46105957|NCT05405881|Other|Proprioception measurement tool|No intervention, as it is a psychometric properties study
45838209|NCT04350866|Other|Expert Recommendations for Implementing Change (ERIC) bundle of strategies|"Develop a formal implementation blueprint/checklist~Conduct educational meetings; Develop & distribute educational materials~Organize implementation meetings~Audit and provide feedback~Facilitation~Increase demand with marketing to patients~Promote adaptability~Involve patients and family; Use their feedback; Prepare them to be active participants"
46021124|NCT01256411|Drug|LCZ696|Participants received LCZ696 200 mg as the starting dose with optional down titration to 100 mg for tolerance and optional up titration to 400 mg for adequate blood pressure control.
46021125|NCT01256411|Drug|Amlodipine|Optional add-on of amlodipine (5-10 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
46021126|NCT01256411|Drug|Hydrochlorothiazide (HCTZ)|Optional add-on of hydrochlorothiazide (HCTZ) (12.5-25 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
46021127|NCT00996580|Drug|DR-103|"One tablet daily.~Four 91-day cycles of the DR-103 regimen:~42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by; 21 days combination therapy of 25 mcg EE/150 mcg LNG followed by; 21 days combination therapy of 30 mcg EE/150 mcg LNG followed by; 7 days of 10 mcg EE."
45468473|NCT03110510|Drug|Irinotecan Hydrochloride|Irinotecan 180 mg/m2
45468474|NCT03110510|Drug|leucovorin calcium|Leucovorin 200 mg/m2
46105958|NCT05391633|Behavioral|Recorded Maternal Voice|60-minute looped recording of maternal voice, played once daily for 14 total days.
46105959|NCT05391633|Behavioral|Placebo Recording|60-minute blank recording played once daily for 14 total days.
45681246|NCT04192864|Procedure|Lingually based triangular flap|"A lingually based triangular flap was used to remove the impacted third molar. An incision was made adjacent to the distal surface of the mandibular second molar and extended along the sulcus to the distobuccal corner of the mandibular second molar, an oblique vestibular incision was made and extended into the vestibular fornix of the mandible. Aligned with the mesiobuccal cusp of the second molar.~It was continued posterosuperior towards the anterior border of the mandibular ramus An incision will be made from the anterior border of the mandibular ramus to the distal surface of the mandibular second molar."
46105960|NCT05384431|Dietary Supplement|Muscle5 and TRIM7|Intake of MUSCLE 5 and TRIM 7 supplements on a daily basis for 12 weeks
46105961|NCT05384431|Other|Mixed exercise|Mixed exercise (aerobic and resistance) three days per week for 12 weeks
46105962|NCT05375266|Other|Sampling|This is an observational study. Consequently, study participation does not alter the therapy of the treated disease. Blood will be drawn from patients at several time points during and after radiotherapy (RT) and therapy with immune checkpoint inhibitor (ICI) for detailed immunomonitoring of the patients. In addition, faeces and sputum of the patients for microbiomic and metabolomic measures will be collected. Whenever possible, adequate tissue samples are taken from the center of the tumor and a biopsy is taken from the edge of the tumor including the adjacent mucosa in the nearby area without affecting the pathological assessment (study group). Blood, faeces and sputum will be taken from patients of the control group prior to surgery. After surgery, only blood will be taken.
46105963|NCT05370313|Behavioral|Market Price Condition (control)|Nicotine/tobacco products available in the Experimental Tobacco Marketplace at market price. Cigarette taxes increased across trials at the same magnitudes used in the tax conditions.
46105964|NCT05370313|Behavioral|Tobacco Parity Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all tobacco products are placed in the high-tax tier while products that do not contain tobacco (e.g., herbal cigarettes and nicotine-free ENDS) are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier.
46105965|NCT05370313|Behavioral|Nicotine-Content Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, products with greater than 3 mg nicotine per single unit are placed in the high-tax tier, products with 0.6-3.0 mg/unit in the medium-tax tier, and those with 0.5 mg/unit or less in the no-tax tier.
46105966|NCT05370313|Behavioral|Harm-Reduction Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all combustible products with high abuse liability are placed in the high-tax tier. All non-combustible products or combustible products with low abuse liability are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier.
46021128|NCT01124175|Drug|Losartan|100 mg Tablets
46021129|NCT01124175|Drug|Cozaar®|100 mg Tablets
46105967|NCT05370313|Behavioral|Modified Risk Tobacco Product (MRTP) Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all non-MRTP tobacco products are placed in the high-tax tier, MRTPs are placed in the medium-tax tier, and Nicotine Replacement Therapy products are placed in the no-tax tier.
45838210|NCT04329325|Biological|Blinatumomab|Please see detailed summary.
46021130|NCT04259554|Device|OFC rTMS|repetitive transcranial magnetic stimulation over right orbito-frontal cortex with 1Hz (360 pulses in 6 trains á 60 pulses with 30s intertrain-interval)
46105968|NCT05368623|Diagnostic Test|Color fundus photograph|Subjects will undergo color fundus photography before and after pharmacological dilation of pupils.
46105969|NCT05368623|Diagnostic Test|Optical Coherence Tomography (OCT) of the retina|Subjects will undergo OCT of the retina after pharmacological dilation of pupils.
46105970|NCT05368623|Drug|Mydriatic Agent|Pharmacological dilation of pupils will be done by instilling mydriatic agent in eyes of Subjects
46105971|NCT05366842|Drug|Stravix lyopreserved placental tissue (LPT)|Participants will undergo surgical implantation of Stravix lyopreserved placental tissue (LPT) during a standard of care radical prostatectomy.
46105972|NCT05366842|Procedure|Radical prostatectomy|Standard care (no placement of tissue)
46105973|NCT05366075|Other|Intervention 1 (simple exercise program)|Up to four sessions per day (total duration 20-30 minutes/day). Performed at the hospital on all weekdays from baseline until hospital discharge (around 1 week). At discharge, the participants will be encouraged to continue with the exercise program at home.
45681247|NCT04192864|Procedure|Buccally based triangular flap|The impacted teeth was removed using a buccal based triangular flap. It will be extended along the sulcus to the distobuccal corner of the second molar . The incision was continuous, with a relieving vertical incision, oblique into the mandibular vestibular fornix, aligned with the mesiobuccal cusp of the second molar.
45838211|NCT04329325|Drug|dasatinib|Please see detailed summary.
46105974|NCT05366075|Other|Intervention 2 (comprehensive exercise program)|Two daily sessions (morning and afternoon) of 20 minutes' duration each. Performed at the hospital on all weekdays from baseline until hospital discharge (around 1 week).
45838212|NCT04329325|Drug|dexamethasone|Please see detailed summary.
45838213|NCT04329325|Drug|methotrexate|Please see detailed summary.
45838214|NCT04293341|Behavioral|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and [positive] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
46021131|NCT00625521|Drug|ASF 1096 0.5 % cream applied twice daily|
46021132|NCT00625521|Drug|Cream vehicle for ASF 1096 cream applied twice daily|
46021133|NCT01256177|Drug|Quetiapine Fumarate (SEROQUEL) Extended Release|Quetiapine fumarate extended release(XR) will be administered orally, once daily in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
46105975|NCT05357768|Other|data collection and analysis on Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue|"Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue of cases negative for all Ewing's sarcoma molecular fusions, will be analyzed for the presence of CIC-DUX4 / BCOR-CCNB3 translocations fusion at each Institution.~Treatment, outcome, and prognostic factors will be related with the molecular re-classification."
46105976|NCT05357586|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders is a manualized, evidence-based form of cognitive behavioral therapy aimed at targeting emotion regulation processes that underlie common forms of emotional disorders such as anxiety, depression, and commonly co-occurring mental health challenges.
46021134|NCT01256177|Drug|Placebo|Placebo matching quetiapine extended release(XR) 50 mg, 200 mg, and 300 mg tablets will be orally administered once daily, in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
46021135|NCT02882451|Dietary Supplement|pinaverium bromide|
46105977|NCT05349721|Drug|PTC857|PTC8657 will be administered as an oral solution twice a day.
46105978|NCT05349721|Drug|Placebo|Matching placebo will be administered as an oral solution twice a day.
46105979|NCT05344885|Behavioral|DPT-Standard|The parent training intervention includes 7 modules, recommended to be completed within 7- to 10-weeks period. Module's content includes videos and texts guiding the parent through the training process; interactive features, such as multiple-choice questions with direct feedback. Additional features embedded within the platform include downloadable materials, and a Q&A section that contains frequently asked questions.
46105980|NCT05344885|Behavioral|DPT-Enhanced|DPT-Enhanced will include all the ingredients of DPT-Standard, but with additional features. The program itself is based on pre-defined decision rules that are either event or time based based on evidence based practice in promoting effective parental engagement. Each component includes a short learning phase, followed by a 1-2 week focusing phase. The focusing phase is designed to encourage and help parents to practice and acquire learned skills in their day-to-day lives, by making these skills more salient in their mind.
46105981|NCT05339126|Device|RNS System|The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
46021136|NCT02882451|Dietary Supplement|Vitamin C|
46021137|NCT00999544|Drug|Aprepitant 0mg|Aprepitant 0mg, p.o. pretreatment
45468475|NCT01238237|Drug|Superselective Intraarterial Cerebral Infusion of Cetuximab|Intraarterial Mannitol 25% 3-10 ml to open the blood brain barrier followed by Intraarterial Cetuximab single dose (starting at 100mg/m2 and escalating up to 500mg/m2)
45468476|NCT03432052|Procedure|centralization|Wrist centralization involves aligning the distal ulna with the middle finger metacarpal and passing a large Kirschner wire or a small Steinmann pin through the middle finger metacarpal, carpus, and ulna for temporary stability. This is followed by soft tissue balancing in order to counteract the volar and radial directed force vectors consisting of reefing the ulnocarpal wrist capsule and transferring the extensor carpi ulnaris muscle distally and flexor carpi ulnaris muscle dorsally on the wrist.
45599287|NCT02341833|Drug|Sevoflurane|In the sevoflurane group, the anesthetic agent has to be administered immediately after arrival in the operating room to reach an end-expiratory target concentration of 2%. This concentration of sevoflurane should be maintained until the procedural cardiac arrest and for at least 15 min.
45599288|NCT04464499|Diagnostic Test|ECG measurement|Simultaneous recording of a single-lead ECG signal with the Withings BPM Core and ECG signal for the reference 12-lead ECG
46021138|NCT00999544|Drug|Aprepitant 40mg|Aprepitant 40mg, p.o. pretreatment
46021139|NCT00999544|Drug|Aprepitant 200mg|Aprepitant 200mg, p.o. pretreatment
46021140|NCT00999544|Drug|Oxycodone 0mg, p.o.|Oxycodone 0mg, p.o.
46021141|NCT00999544|Drug|Oxycodone 20mg, p.o.|Oxycodone 20mg, p.o.
46021142|NCT00999544|Drug|Oxycodone 40mg, p.o.|Oxycodone 40mg, p.o.
46021143|NCT00999544|Drug|Oxycodone 0mg, IN|Oxycodone 0mg, IN
46021144|NCT00999544|Drug|Oxycodone 15mg, IN|Oxycodone 15mg, IN
46021145|NCT00999544|Drug|Oxycodone 30mg, IN|Oxycodone 30mg, IN
46021146|NCT02869984|Drug|Ramosetron|
46021147|NCT01124097|Drug|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
46021148|NCT01124097|Drug|Placebo|Tablets will be used.
46021149|NCT02882529|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
46021150|NCT01123941|Biological|Typherix|1 dose, 0.5 mL containing 25 mcg of Vi polysaccharide
46021151|NCT01123941|Biological|NVGH Vi-CRM197|1 dose of 0.5 mL containing 25 mcg of Vi-CRM
46021152|NCT01123395|Drug|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
46021153|NCT01123395|Drug|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet dissolved in apple juice
46021154|NCT01255787|Drug|Vortioxetine|Vortioxetine tablets
46021155|NCT01255787|Drug|Placebo|Vortioxetine placebo-matching tablets
46105982|NCT05336955|Other|Intake and quarterly assessment:|The START Plan is designed to evaluate the mental health needs of persons with IDD and measure the capacity of the formal and natural support systems. Family caregivers, or the person primarily responsible for day-to-day care of the person, participate in a formatted interview conducted by START coordinators. The START coordinator completes the initial START Plan during intake and quarterly thereafter. Based on informant responses, an intensity rating is assigned to determine the type, frequency, and duration of services to be provided. Quarterly assessment is conducted to inform development or modification of the Cross-Systems Crisis Prevention and Intervention Plan (D.2.b.2.). Hypothesized causal pathway: Family caregiver engagement in assessment enables the START team to efficiently and effectively identify needs and socially valid solutions that strategically reduce use of emergency services and increase mental health stability.
46105983|NCT05336955|Other|Consultation & coping skills coaching:|Mental health service consultation is provided by START clinical and medical directors in order to prevent and de-escalate crises. Coping skills coaching, provided by START coordinators, helps to determine with the person, their family, and the system of care how to promote well-being and stability. Successful coping skills for the person are incorporated into the Cross-Systems Crisis Prevention and Intervention Plan. All methods are manualized and reported to meet model fidelity. Hypothesized causal pathway: Providing consultation and coping skills coaching to youth and young adults with IDD, their families, and their system of care increases capacity for crisis prevention and stabilization, reduces emergency service use, and increases quality of care, leading to long-term stability.
46105984|NCT05336955|Other|24-hour urgent crisis response and intervention:|START teams have 24-hour, in-person mobile crisis intervention services. Emergency calls come from a variety of sources; clients, emergency rooms, service providers, families, and law enforcement. START provides immediate telephonic response and in-person evaluation within two hours of the initial contact. Hypothesized causal pathway: Real-time, immediate support enables the successful enactment of crisis evaluation and stabilization. This reduces severity of the crises and allows for diversion from emergency service use.
46105985|NCT05336955|Other|Service linkages, referrals, outreach, & training:|START teams work with stakeholders to develop and maintain linkage agreements. The purpose of these agreements is to enhance the capacity of the system as a whole and develop partnerships to reduce disparities and gaps in the service array. START coordinators conduct crisis prevention-focused outreach visits with the person and/or their system of care. Examples include training during home- and school-based visits, family caregiver coaching to implement new plans or strategies, and checking in with the person to monitor their level of stability. Hypothesized causal pathway: Increased person-centered collaboration and dialogue across systems of care promotes patient perceived quality of care, the identification of more effective strategies that support their mental health needs, and results in reduced use of emergency services.
46105986|NCT05332236|Diagnostic Test|Parent-Adolescent Communication Scale (questionnaire)|Observational psychometric validation study
46021156|NCT01123161|Device|hypothermia and anti-shivering treatment|Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine and surface warming
46105987|NCT05329766|Drug|Domvanalimab|Administered as specified in the treatment arm
46105988|NCT05329766|Drug|Quemliclustat|Administered as specified in the treatment arm
46105989|NCT05329766|Drug|Zimberelimab|Administered as specified in the treatment arm
46105990|NCT05329766|Drug|Fluorouracil|Administered as specified in the treatment arm
46105991|NCT05329766|Drug|Leucovorin|Administered as specified in the treatment arm
46105992|NCT05329766|Drug|Oxaliplatin|Administered as specified in the treatment arm
46105993|NCT05324449|Drug|Cannabidiol 100 MG/ML|pharmaceutical grade cannabidiol
46105994|NCT05318287|Behavioral|Walk with Me|Walk with Me is a perinatal grief mobile application to provide supportive care to bereaved parents. The application includes modules to guide bereaved parents through strategies to help support them through their grieving.
46021157|NCT01123161|Drug|Group1: IV t-PA and normothermia|Group 1 will t-PA as standard of care and normothermia
46105995|NCT05318235|Other|No intervention|No intervention
46105996|NCT05316233|Device|VOLITE XC|Intradermal Injection
46105997|NCT05316233|Device|VOLITE XC|Subdermal Injection
46105998|NCT05315440|Other|graston tecnique|Graston technique involves the use of steel tools that are used non-invasively on the skin to identify and treat areas that have stiffness or inflammation. These areas can be located with greater precision than the manual technique precisely because the instruments do not compress in contact with the patient's skin, as is the case with the physiotherapist's fingertips. Thanks to the instruments it is therefore possible to detect the areas of altered consistency and to treat them by pressing a minimum pressure.
46105999|NCT05315440|Other|Conventional rehabilitation|30 minutes of passive and active assisted mobilization guided by the therapist, 30 min of Continous passive movement in flexion and abduction and 30 minutes of electrostimulation.
46106000|NCT05309915|Drug|STP707|STP707 Powder for Injection, contains 2 (siRNA) and (HKP+H) delivery system.
46106001|NCT05304871|Drug|Cefazolin|infusion
46106002|NCT05304871|Other|saline|infusion
45681248|NCT04027270|Other|Physical Therapy|Physical therapy 1-2 times per week for 3 months postoperatively to include lifestyle education, manual therapy, and exercise.
46021158|NCT01255631|Device|PEMF Device|"The PEMF device we will use in this study is FDA approved for adjunctive use in the palliative treatment of post-operative pain and edema in superficial soft tissue (510(k) number: K903675). There are no side effects to use of a PEMF device. In the treatment arm, the PEMF would be automatically delivered for 15 minutes every two hours for one month. The manufacturer (Ivivi Technologies, Inc., Northvale, NJ) has already designed a lightweight, disposable device that can be placed around the patient's arm and taped in place. The patient would keep the device in place for two weeks, when they return for a followup visit and receive a fresh device to wear for an additional two weeks."
46021159|NCT01255631|Device|Sham PEMF Device|Inactive PEMF device, delivers no PMF
46021160|NCT00999466|Drug|AZD8848|Nasal spray, solution 0.6mg/ mL. Once weekly for 7 weeks, 8 doses in total.
46106003|NCT05297604|Radiation|Non-Invasive Intravascular Laser Irradiation Of Blood|Participants will receive the treatment for 20 minutes. The laser to be used is infrared-red, power 100 mW ±20%, wavelength 660nm ±10 nm, energy parameter 60J, continuous application. The technique is not invasive, the irradiation point is by continuous and direct transcutaneous application to the radial artery by means of a bracelet that inserts the laser beam. One session will be performed.
46106004|NCT05297604|Radiation|Placebo application of laser|Simulated radiation. One session will be performed.
46106005|NCT05296096|Other|Protein dosage and rehabilitation team delivered exercise prescription|"The dietitian and rehabilitation team will be consulted on enrollment and will assess the patient for nutritional and functional status using the institutional criteria and physical exam. The study dietitian will prescribe the protein goal based on the randomization assignment and age group. For the high protein arm, protein goals will be 3g/kg/day for ages 1-1yrs, and 2.4g/kg/day for ages greater than 12 years.~The rehabilitation team will determine the appropriate highest level of mobility (HLM) for the day in collaboration with the medical team on morning rounds. The rehabilitation team will prescribe passive or active participation in two 30-minute HLM sessions, individualized to their baseline function and clinical status and/or restrictions."
46106006|NCT05293314|Diagnostic Test|an exhaled breath test|All exhaled breath samples were collected by trained investigators following the same protocol. All participants fasted for at least 6 hours before breath collection. To reduce potential confounding factors, all participants were asked to not ingest spicy food, alcohol, or coffee the night before exhaled breath collection. Exhaled breath was collected in Tedlar air bags (DuPont de Nemours). The night before breath collection, the Tedlar bags were baked at 60 °C for 3 hours to fully release possible contaminants and continuously purged with high-purity nitrogen 4 times. Participants first gargled with pure water and then performed a single deep nasal inhalation followed by complete exhalation via their mouth into Tedlar bags. A total of 1000 mL of exhaled breath was collected from each participant.
46106007|NCT05281978|Behavioral|Decrease Sedentary Time + Increase MVPA group|12 week home-based exercise program to promote engagement of 150 min/week of moderate-vigorous intensity exercise; personalized step count goals to increase daily volume of physical activity and displacement of sedentary time
46106008|NCT05281978|Behavioral|Increase MVPA group|12 week home-based exercise program to promote engagement of 150 min/week of moderate-vigorous intensity exercise
46106009|NCT05281406|Drug|Osimertinib|80 mg daily or reduced dose 40 mg daily
46106010|NCT05281406|Drug|Pemetrexed|500 mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
46106011|NCT05281406|Drug|Cisplatin|75mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
46106012|NCT05281406|Drug|Carboplatin|AUC 5 mg/mL/min i.v. d1 of every 21-day cycle for a maximum of 4 cycles
46106013|NCT05277350|Drug|SNIPR001|SNIPR001 is a live biotherapeutic product consisting of genetically modified bacteriophages specifically targeting Escherichia coli
46106014|NCT05277350|Drug|Placebo|Matching placebo
46106015|NCT05275582|Behavioral|CARE|"Behavioral intervention including~-30 minute meeting alone with behavioral health educator (in person or virtual using VA's VVC system) 4 weeks of optional self monitoring using an app of substance use behavior, mood, other behavioral processes 2 optional 15-minute phone calls with behavioral health educator"
46106016|NCT05275478|Drug|TNG908|TNG908, a selective PRMT5 inhibitor, will be administered orally
46106017|NCT05265299|Drug|Aspirin 81mg|Aspirin 81mg once daily
46106018|NCT05265299|Drug|Aspirin 162 mg|Aspirin 162 mg once daily
46106019|NCT05265299|Drug|Aspirin 325mg|Aspirin 325mg once daily
46106020|NCT05262712|Device|Vibro-tactile stimulation|Vibro-tactile stimulation will be administered to the feet of participants via C2 tactors (diameter: 3.05 cm, height: 0.79 cm, operating frequency: 200-300 Hz see https://www.eaiinfo.com/tactor-info/). Vibro-tactile stimulation will be triggered by force-sensing resistors (TEA CAPTIV T-SENS FSR, see https://www.teaergo.com/products/tea-captiv-t-sens-fsr/).
46106021|NCT05262712|Other|Placebo Control|Devices mounted, no stimulation
46106022|NCT05256888|Behavioral|Time-restricted eating|12 weeks of time-restricted eating (10-hour window)
46106023|NCT05256888|Behavioral|Healthy lifestyle education|Weekly tips on healthy lifestyle behaviors (e.g., diet, exercise, sleep) for 12 weeks
46106024|NCT05255666|Drug|Pembrolizumab|400 mg intravenously
46106025|NCT05255666|Drug|Liposomal Irinotecan|Starting at 50 mg/m^2. The dose may be increased to 70 mg/m^2 if tolerated or dose reduced to 35 mg/m^ if treatment-emergent severe adverse event (TESAE) occurs.
46106026|NCT05255562|Procedure|Combined Serratus Anterior Plane Block|Combined deep and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
46106027|NCT05255562|Drug|Thoracic Paravertebral Block|Thoracic paravertebral block will be applied to the patients under real-time ultrasound guidance.
46106028|NCT05250414|Device|MED-EL Cochlear Implant System|Cochlear implant and audio processor
46106029|NCT05249036|Procedure|Ultrasound guided arterial cannulation|Arterial cannulation will be attempted at the site of the radial artery of the non-dominant hand, using real-time ultrasound guidance
45838215|NCT04293341|Behavioral|Cognitive Processing Therapy for PTSD|CPT is a well established evidence-based psychotherapy for PTSD. CPT focuses on teaching patients to evaluate and change the upsetting thoughts that they have had since their trauma.
46106030|NCT05249036|Procedure|Palpation guided arterial cannulation|Arterial cannulation will be attempted at the site of the radial artery of the non-dominant hand, using palpation technique (standard-of-care)
46106031|NCT05246514|Drug|Trastuzumab deruxtecan|administered as an IV infusion
46106032|NCT05245500|Drug|MRTX1719|MRTX1719 is a potent PRMT5-MTA inhibitor
46106033|NCT05236075|Device|shearing wave collar|Collar inducing shearing wave to treat obstructive sleep disorders
46106034|NCT05233722|Other|Exercise|1 hour of one-legged knee-extensor exercise followed by 4 hours of rest
46106035|NCT05233722|Procedure|Insulin infusion|2 hours of Euglycemic Hyperinsulinemic Clamp
46106036|NCT05233722|Drug|Placebo|Administration of 800 mg of calcium tablets
46106037|NCT05233722|Drug|Rapamycin|Administration of 16 mg of Rapamycin tablets
46106038|NCT05233592|Device|CGM|Patients wear a CGM to measure the effects of the COVID-19 booster vaccine on blood sugar levels.
46106039|NCT05221892|Drug|Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin|Tablets to be taken 30 minutes before each of 4 trips.
46106040|NCT05221892|Drug|Ginger|Tablets to be taken 30 minutes before each of 4 trips.
46021161|NCT00999466|Drug|Placebo|Nasal spray, solution. Once weekly for 7 weeks, 8 doses in total.
46021162|NCT01255163|Drug|Exendin-4 SC|Exenatide 5 mcg or 10 mcg SC twice daily
46106041|NCT05216172|Drug|AZD1656|active drug
46106042|NCT05216172|Drug|Placebo|placebo
46106043|NCT05215847|Drug|ARD-101|Twice daily, oral administration
46106044|NCT05206422|Device|Doraya catheter|Temporary deployment of the Doraya catheter in ADHF patients
46106045|NCT05204797|Procedure|Robot-assisted UKA|Cemented unicompartmental knee arthroplasty via mini-invasive medial approach and robotic assistance. Tourniquet will be used in all patients.
46106046|NCT05204797|Procedure|Standard technique UKA|Cemented unicompartmental knee arthroplasty via mini-invasive medial approach and standard technique. Tourniquet will be used in all patients.
46106047|NCT05201534|Other|Interventions in Mathematics and Cognitive Skills - Experimental|"After study participants have completed screenings to meet our inclusion criteria, participants will take part in the pre-training MRI brain scan (if eligible) and behavioral assessments and will then be assigned to the intervention for 8 weeks.~During this training, participants will spend three days each week completing a set of problems at their home on a tablet that we provide them. Participants will receive one-to-one training with a member of our research team once a week.~Following the completion of the 8-week training program, participants will be asked to complete a second MRI brain imaging session (for those who completed pre-training MRI) and post-measure appointments in order to assess immediate effects of the training program. Participants will also be invited to return for follow-up testing after six months in order to assess the long- lasting effects of the training program."
46106048|NCT05201534|Other|Interventions in Mathematics and Cognitive Skills - Active Comparator|"After study participants have completed screenings to meet our inclusion criteria, participants will take part in the pre-training MRI brain scan (if eligible) and behavioral assessments and will then be assigned to the intervention for 8 weeks.~During this training, participants will spend three days each week completing a set of problems at their home on a tablet that we provide them. Participants will receive one-to-one training with a member of our research team once a week.~Following the completion of the 8-week training program, participants will be asked to complete a second MRI brain imaging session (for those who completed pre-training MRI) and post-measure appointments in order to assess immediate effects of the training program. Participants will also be invited to return for follow-up testing after six months in order to assess the long- lasting effects of the training program."
46106049|NCT05197348|Behavioral|Meaning-Centered Group Psychotherapy (MCP).|"The MCP program is divided into eight sessions:~Session1: Psychoeducation about Meaning in life, Sources of Meaning, etc. Session 2: Cancer illness and meaning. Session 3: Historical Sources of Meaning (the past) Session 4: Historical Sources of Meaning (present and future). Session 5: Attitudinal Sources of Meaning. Session 6: Creative Sources of Meaning. Session 7: Experimental Sources of Meaning. Session 8: End of psychotherapy, farewell, and facing the future with hope."
46106050|NCT05197348|Behavioral|Cognitive Behavioral Psychotherapy (CBT).|"The CBT divided into eight sessions:~Session1: Presentation of psychotherapy, establishing the goals of psychotherapy. Presentation of the participants. Updated information about psychological consequences of cancer.~Session 2. Increase in enjoyable activities. Behavioral activation. Progressive muscle relaxation training. Slow breathing training.~Session 3. Cognitive model of coping with cancer. Psychoeducation on negative thoughts. Training in detecting negative thoughts. Presentation of cognitive distortions Session 4. Training in cognitive restructuring techniques. Session 5. Training in problem-solving skills. Session 6. Being aware of participants needs. Self-care. Assertiveness skills training.~Session 7. Setting goals for the future. Session 8. Summary, relapse prevention, and end of psychotherapy."
46106051|NCT05194306|Drug|Perla® Cold Preservation solution|Perla® must be cooled to 2° to 6 °C prior to use. The cold Preservation Solution is used to flush the isolated organ immediately before removal from the donor and/or immediately after removal from the donor. The solution is then left in the organ vasculature during hypothermic storage and transportation.
46106052|NCT05183035|Drug|Fludarabine|Intravenous (IV) infusion
46106053|NCT05183035|Drug|Cytarabine|Intravenous (IV) infusion
46106054|NCT05183035|Drug|Gemtuzumab Ozogamicin|Intravenous (IV) infusion
46106055|NCT05183035|Drug|Azacitidine|Intravenous (IV) infusion or subcutaneous injection
46106056|NCT05183035|Drug|Venetoclax|Orally via tablet or powder suspension
46106057|NCT05174806|Drug|Topical Pravibismane|Topical Pravibismane
45599289|NCT02232659|Device|70cc TAH-t for Destination Therapy|Use of the approved SynCardia 70cc TAH-t for patients who are in biventricular failure (approved use), but who are ineligible for cardiac transplant (experimental use).
46021163|NCT01255163|Drug|Placebo SC|Placebo SC twice daily
46021164|NCT01123083|Biological|Otelixizumab|infusion
46106058|NCT05174806|Other|Standard of Care|Standard of care treatment without investigational topical pravibismane (MBN-101) or other topical antibiotics.
46106059|NCT05161650|Dietary Supplement|Ketone monoester (3-OHB)|Commercially available ketone supplement
46106060|NCT05161650|Dietary Supplement|Placebo drink|Isocaloric placebo
46021165|NCT01123083|Biological|Placebo|Infusion
46021166|NCT05541887|Other|Muscadine Wine Polyphenol|dealcoholized muscadine wine with alcohol content <0.5%
46021167|NCT05541887|Other|Placebo|this placebo beverage is formulated with matching sugar and organic acid content to the muscadine wine polyphenol. Food coloring is added to match the color of the intervention
46021168|NCT02870062|Other|Daily baths with chlorhexidine wipes, oral spray and standard shampoo|Description already mentioned in arm/group descriptions.
46021169|NCT02870062|Other|Daily baths with placebo wipes, oral spray and shampoo|Description already mentioned in arm/group descriptions.
46021170|NCT02869516|Other|Clinical data collection|
46021171|NCT02870140|Device|SUPRAFLEX|Percutaneous Coronary Intervention
46021172|NCT02870140|Device|XIENCE|Percutaneous Coronary Intervention
46106061|NCT05161338|Diagnostic Test|MICROBIOME GENETIC ANALYSIS|Vaginal samples will be taken. A floxed nylon swab will be rotated against the posterior vaginal wall, Nucleic acid extraction and genetic analisys will be performed
46106062|NCT05161338|Diagnostic Test|VAGINAL PH VALUE|Intravaginal Ph value meassurement.
46021173|NCT01254305|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER (40 -120 mg/day) Study drug is to be given orally, in capsule form, once daily for 8 weeks
46106063|NCT05161338|Diagnostic Test|SERUM PROGESTERONE LEVELS|Determination of serum P4 levels On the day of embryo transfer scheduling (prior to the onset of exogenous progesterone administration) and on the embryo transfer day-.
46106064|NCT05161338|Diagnostic Test|SERUM OESTRADIOL LEVELS|Determination of serum E2 levels On the day of embryo transfer scheduling (prior to the onset of exogenous progesterone administration) and on the embryo transfer day.
46106065|NCT05147805|Drug|Treprostinil Palmitil|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.
46106066|NCT05147805|Drug|Placebo|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.
46106067|NCT05147454|Other|Quantitative Sensory Testing|Non-invasive assessment of Sensory Profile
45681249|NCT04027192|Drug|BAY2328065 LSF|20 mg/mL LSF (liquid service formulation), orally
46021174|NCT01254305|Drug|Paroxetine, Sertraline, Citalopram or Fluoxetine.|Paroxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Sertraline (50, 100, or 150 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Citalopram (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks or Fluoxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks
46021175|NCT01254305|Drug|Placebo|Matching placebo capsules, oral administration, once daily dosing
46106068|NCT05136885|Drug|SLS-005|Administration: Infusion Dose: 0.75 g/kg weekly
46106069|NCT05136885|Drug|Matching Placebo|Administration: Infusion Dose: equivalent weight-based volume as described for trehalose
46106070|NCT05136105|Behavioral|Preventive Narrative Exposure Therapy (PreNET) family intervention|"Sessions: (1) Participants are invited to narrate the event in detail, in line with the protocol of the trauma-focused intervention NET. Furthermore, participants and caregiver(s) will receive a brief psychoeducation about expected symptoms and supportive behaviour in the aftermath of sexual violence.~(2) Two weeks after session 1, the second session focuses on caregiver only and their emotions. The narration of the event is read to the caregiver(s). Caregiver(s) receive assistance regulating their emotions. They receive psychoeducation on how to support their child.~(3) Two weeks after the second session, the children assisted by their caregivers lay a chronological lifeline of their most important life experiences. The chronology and the context of the traumatic events is reinforced. The narration of the sexual abuse is read again to the child and the caregiver(s). The caregiver(s) are encouraged to support emotionally their child during the renarration."
46106071|NCT05128019|Behavioral|ICIT|Patients in the intervention group will receive a number of consultations with their GP based on the ICIT
45681250|NCT04027192|Drug|BAY2328065 tablet|50 mg tablet, orally
45681251|NCT04027192|Drug|Placebo LSF|Matching Placebo LSF, orally
46021176|NCT04280926|Diagnostic Test|Cardiac Troponin Testing|Fresh serum or lithium heparin plasma samples will be measured with the Atellica IM TnIH assay (Siemens Heatlhineers).
46021177|NCT01122927|Drug|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg) pill taken orally once per day
46021178|NCT02869906|Other|FFR and iFR|The investigators aimed to assess the reliability of the instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR) measurements in non-culprit coronary lesions during the acute and subacute phase of ST-segment elevation myocardial infarction (STEMI).
46021179|NCT02869828|Device|Monitoring by arterial catheter and Spot-on|
46106072|NCT05108428|Drug|Capecitabine|Capecitabine 825 mg/m^2 twice daily orally 5 days per week on days of planned radiation therapy.
46106073|NCT05108428|Radiation|Radiation Therapy|Participants will receive varying doses of radiotherapy based on MRI guidance, beginning at 28-33 fractions (1.8 Gray units) .
46021180|NCT02869828|Device|Monitoring by oesophagal probe and Spot-on|
45681252|NCT04027192|Drug|Placebo tablet|Matching Placebo tablet, orally
45681253|NCT04027192|Drug|Midazolam|1 mg per day, orally
45681254|NCT04406506|Device|nasogastric|• The insertion of NG tubes were performed by the ICU physician and the position was checked by auscultation of gas from 50 ml syringe by injecting 20 ml of air in the NG and by X-ray abdomen to be sure from the site of NG tube
45681255|NCT04406506|Device|nasojejunal|"The nasojejunal tube is silicone or polyurethane tube with an inner stylet that is positioned (under fluoroscopic guidance) beyond the ligament of Treitz.~Patients were placed in right lateral position"
45681256|NCT04406506|Drug|(erythromycin 250 mg IV bolus)|prokinetic (erythromycin 250 mg IV bolus) given to assist the passage of the tube through the pylorus
45681257|NCT03828292|Drug|Belantamab mafodotin|Belantamab mafodotin will be administered as an intravenous infusion.
45681258|NCT03828292|Drug|Bortezomib|Bortezomib solution for injection will be administered subcutaneously.
46021181|NCT01254227|Drug|Deferasirox and Deferoxamine|
46021182|NCT04311333|Diagnostic Test|Endostomal three-dimensional ultrasonography|Examination with rectal probe enclosed by water-filled balloon. Rectal mode. Dynamic examination in different positions with and without increased intra-abdominal pressure.
46021183|NCT04311333|Diagnostic Test|Computerized tomography of the abdomen|"Supine position, without increased intra-abdominal pressure. Experienced radiologist interprets the examination.~If adequate examination has already been performed within the last 10 months, these images will be used and the patient will thus not undergo computerized tomography within the study."
46021184|NCT04311333|Diagnostic Test|Clinical examination|Patients will be clinically examined with inspection and palpation in supine and erect position with and without increased intra-abdominal pressure.
46106074|NCT05108428|Drug|FOLFOX regimen|Standard of Care FOLFOX regimen consists of 8 cycles (each cycle is 14 days) of 5-fluorouracil, leucovorin, and oxaliplatin. Dosage is as follows: Oxaliplatin 85 mg/m^2 IV over 2 hours day 1 each cycle. Leucovorin (optional) 400 mg/m^2 IV over 2 hours day 1 each cycle. 5-fluorouracil bolus* (optional) 400 mg/m^2 IV push day 1 of each cycle, and 5-fluorouracil infusion 2400 mg/m^2 IV continuous infusion over 46 hours day 1 each cycle.
46106075|NCT05107869|Other|High Saturated Fat|High saturated fat meal
46106076|NCT05106387|Other|Noninterventional|No investigational treatment will be given in this noninterventional extension study
46106077|NCT05096234|Drug|[ 18F]F-AraG PET|Dose: 5 mCi (±10%) Mode of Administration: Intravenous (IV)
46106078|NCT05093855|Drug|BDB-001 Injection|Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
46106079|NCT05081804|Dietary Supplement|Carbohydrate Preoperative Drink|Patients randomized to the intervention will drink the preoperative drink two hours prior to surgery
46106080|NCT05061823|Drug|Bintrafusp alfa|Participants who are continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight which is (i.e.) milligrams per kilogram (mg/kg) per dose in a parent protocol, will receive an intravenous infusion of bintrafusp alfa at the dose specified based upon the participant's parent protocol once every 2 week or, 2400 mg once every 3 weeks. Participants who are entering the rollover study after discontinuation of treatment in a parent study will receive bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
46106081|NCT05055011|Other|Electronic Health Record Review|Review of medical records
46106082|NCT05055011|Other|Survey Administration|Complete survey
46106083|NCT05045794|Device|VitaSmart Liver Machine Perfusion System|Following donor liver retrieval, preservation using static cold storage, and back table preparation in the transplant center operating room, the organ will be flushed with Belzer UW Machine Perfusion Solution (MPS) and perfused through the cannulated portal vein using cold, actively oxygenated MPS that is circulated at low pressure for 90 minutes to 5 hours. After disconnection from the device, donor liver implantation and reperfusion will proceed in accordance with institutional care standards.
46106084|NCT05045794|Other|Static cold storage|Donor liver retrieval and preservation using standard of care cold storage methods
46021185|NCT04311333|Diagnostic Test|Evaluation at laparotomy/laparoscopy|During laparotomy or laparoscopy, inspection and/or palpation of the stoma at the abdominal wall orifice is performed.
45599290|NCT02337231|Dietary Supplement|soybean oil and borage oil|Compare the capacity of humans with GG, GT and TT genotypes at rs174537 taking soybean and borage oils to metabolize medium chain PUFAs.
45599291|NCT03507751|Drug|Meropenem|1.0 gram of meropenem given intravenously every 8 hours
45599292|NCT03507751|Procedure|CRRT|Continuous renal replacement therapy for three days
45599293|NCT02341677|Procedure|SmartTarget - Biopsy|MRI to ultrasound fusion guided prostate biopsy
46021186|NCT00995410|Drug|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole to be taken by mouth once daily
46021187|NCT04311255|Procedure|regional anesthesia for the upper limb|pecs-II block and intercostal nerve block
46021188|NCT02691299|Drug|Fruquintinib|Fruquintinib is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
46021189|NCT02691299|Drug|Placebo|Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
46106085|NCT05044936|Drug|Cannabidiol Oil|"The dose that will be used for each administration of CBD will be 0.5mg/kg of body mass. As there are no recommendations for CBD from the FDA or through previous research in humans, and especially for CBD cream, the dosage is based on the United Kingdom's governing body recommending maximal amounts of CBD ingestion being 1 mg/kg per day. Further, the practical amount that companies recommend is anywhere from a pea size to a handful, which can range from high and low amounts. Using 0.5mg/kg of body mass allows for a moderate use of the lotion, as well as leaving extra quantities throughout the day should people want to use CBD outside of their post-workout recovery strategies outside of a laboratory setting. To convert the amount of CBD to the amount of lotion, we will divide the amount of CBD (0.5 mg/kg) by 4.85 (the amount of mg of CBD per gram of lotion). This will calculate the amount (in grams) of lotion each participant will receive."
46021190|NCT00995020|Procedure|Straight Wire Excision of Transformation Zone|Straight wire excision of transformation zone is a electrosurgical conization method,which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
45838216|NCT04293341|Behavioral|Cognitive Behavioral Therapy for MDD|CBT for MDD is a well established evidence-based psychotherapy for depression. CBT for MDD focuses teaching patients how to change their behaviors and challenge their negative thoughts to improve their mood.
46021191|NCT00995020|Procedure|Large Loop Excision of Transformation Zone (cone biopsy)|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20-25 mm depth. The loop is applied to the cervix outside the lateral margin of TZ and brought slowly to the controlateral TZ margin.
46106086|NCT05044936|Other|Resistance Exercise|Participants will complete eccentric-based leg press (4-s lowering phase and 1-s upward phase) for 10 sets of 8 repetitions at 70% 1RM in order to induce muscle damage using a leg press machine. Three minutes of rest will be permitted between sets. Following the 10th leg press, participants will complete 4 sets of 20 consecutive plyometric lunges using only their body weight. Two minutes of rest will be permitted between sets. The muscle damaging protocol will be done upon completion of the 4th set of plyometric lunges.
46106087|NCT05036408|Other|Behavioral, Psychological or Informational Intervention|Participate in group psychological intervention
46106088|NCT05036408|Other|Educational Intervention|Attend educational session
46106089|NCT05036408|Procedure|Manipulative and Body-Based Intervention Procedure|Undergo osteopathic manual treatments
46106090|NCT05036408|Behavioral|Occupational Therapy|Participate in occupational therapy
46106091|NCT05036408|Other|Physical Activity|Participate in physical activity
46106092|NCT05036408|Procedure|Physical Therapy|Participate in physical therapy
46106093|NCT05036408|Other|Questionnaire Administration|Ancillary studies
46106094|NCT05033743|Drug|Secnidazole 2 GM Oral Granules|Once weekly 2g oral secnidazole for 18 weeks
46106095|NCT05021900|Drug|Tenalisib|Tenalisib will be administered 800mg BID, orally
46106096|NCT05021900|Drug|Tenalisib|Tenalisib will be administered 1200mg BID, orally
46106097|NCT05020015|Biological|TAK-007|TAK-007 intravenous injection.
46106098|NCT05020015|Drug|Chemotherapy Agents|Fludarabine and cyclophosphamide as per standard of care.
46106099|NCT05014646|Drug|Cholestyramine|Given PO
45598508|NCT04658303|Drug|Pimonidazole|Pimonidazole is not used with therapeutic intent, and has a non-hazardous designation. It has been widely used for in-vivo evaluation of intratumor hypoxia, and patients will take PO pimonidazole before the scheduled biopsy. Patients receive an oral dose of pimonidazole, a safe chemical tracer up to 24 hours prior to biopsy. Pimonidazole allows for true hypoxia staining; pimonidazole binds hypoxic proteins covalently, creating an antigen that facilitates the imaging, flow cytometry, and scRNA-seq experiments proposed. Pimonidazole has been previously used in patients and is safe and well tolerated, without anticipated adverse events.
46021192|NCT01122381|Drug|ethosuximide|ethosuximide (ESX)
46021193|NCT01122381|Other|placebo comparator|placebo
46021194|NCT00996034|Biological|NicVAX|1.0 mL of Nicotine Conjugate Vaccine(x4), I.M. at 3 week intervals between SPECT studies
46021195|NCT00996034|Radiation|[123I]5-IA-85380|up to 10 mCi of [123I]5-IA-85380, I.V. on each of two SPECT Scan days
46021196|NCT00996034|Drug|Nicotine bitartrate|0.5-1.5 mg of Nicotine bitartrate, I.V. on each of two SPECT Scan days
46021197|NCT04311021|Other|No intervention|No intervention
46021198|NCT04278196|Other|AI-Box|AI-box is a system fixed adjacent to magnet controlled capsule endoscopy. Patients who accept the check of magnet controlled capsule endoscopywill be enrolled .
46021199|NCT01253447|Drug|Akt inhibitor MK2206|200 mg orally (PO) once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
46021200|NCT01253447|Other|laboratory biomarker analysis|Correlative studies
46106100|NCT05014646|Drug|Leflunomide|Given PO
46106101|NCT05012982|Device|AirBand|The AirBands will be placed at each of the two training sessions and inflated while an ultrasound probe is placed over the femoral artery. The cuff will be inflated until the artery reaches 60% occlusion. The force will be applied using a wireless Bluetooth signal; participants will not be asked to adjust the device. Participants will be observed by a certified Personal Therapist throughout the training session in order to determine compliance and ensure safety as is standard protocol for a physical therapy session.
46106102|NCT05012982|Device|uninflated AirBand|Uninflated AirBand will be used as the control intervention during the session in which BFR is not performed
46106103|NCT05006833|Behavioral|Brief Provider Training - Bundled Approach|At each clinic randomized to bundled training, providers will be invited to participate in one, in-clinic, group-based training. Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on introducing the HPV vaccine in a bundle of the other two adolescent vaccines (Tdap and MenACWY).
46106104|NCT05006833|Behavioral|Brief Provider Training - Benefits Approach|At each clinic randomized to benefits training, providers will be invited to participate in one, in-clinic, group-based training . Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 11- to 12-years of age, and prevents cancer.
46106105|NCT05006833|Behavioral|Parent Interactive Text Message - Bundled Approach|Text messages sent to parents will focus on receiving all three adolescent vaccines.
46106106|NCT05006833|Behavioral|Parent Interactive Text Message - Benefits Approach|Text message will state that the HPV vaccine prevents cancer, is safe and effective, and is recommended for 11- to 12-year-olds.
46106107|NCT04995666|Device|Phonak Audeo hearing aid|Rechargeable hearing aid
46106108|NCT04995029|Drug|Transmucosal Buprenorphine|Transmucosal (TM) buprenorphine as selected by the Investigator per local prescribing guidelines, administered either under the tongue (sublingual) or between the gum and cheek (buccal)
46106109|NCT04995029|Drug|Extended-release Buprenorphine|Administered by subcutaneous injection
46106110|NCT04984226|Drug|Sodium bicarbonate|Sodium bicarbonate will be dosed at 0.8meq per kilogram of ideal body weight daily (1meq is approximately 84mg). We will use the Devine formula to determine ideal body weight. Investigational Drug Services at both UC Davis and Vanderbilt will compound the sodium bicarbonate. Sodium bicarbonate 650 mg tablets will be over-encapsulated and matching placebo capsules will be prepared. Participants will be limited to a maximum of 9 capsules daily (maximum dose = 5850mg of sodium bicarbonate). Capsules will be dispensed to patients in two separate 8-week allotments. The dose will be rounded to the nearest whole capsule and depending on participant preference may be divided into portions taken twice or thrice daily. Given the high probability of interruption in sodium bicarbonate supply and availability, we may need to change brands of sodium bicarbonate intermittently.
46106111|NCT04984226|Drug|placebo|The placebo and filler for for sodium bicarbonate capsules will be comprised of microcrystalline cellulose. Capsule appearance for control and sodium bicarbonate will be the same.
46106112|NCT04979806|Drug|Cefepime-zidebactam (FEP-ZID)|3 g (2 g FEP + 1 g ZID) IV q8h
46106113|NCT04979806|Drug|Meropenem|1 g IV q8h
46106114|NCT04971954|Other|Nicotine gum|Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication
46106115|NCT04971954|Other|Placebo gum|The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.
46106116|NCT04969471|Device|enVast stent|In addition to conventional treatment, the treating physician will deploy as the first measure to obtain reperfusion, a enVast stent at the occlusion site in order to withdraw the clot.
46106117|NCT04969471|Procedure|conventional treatment|Treatment strategies may include balloon angioplasty, manual aspiration thrombectomy and/or coronary stenting.
46106118|NCT04951206|Device|Fractionated CO2-laser|All women will be undergoing FxCO2-laser therapy as this treatment is a criterion for enrollment.
45598509|NCT04465279|Device|Trifocal diffractive intraocular lens|Trifocal IOL having foldable single-piece fully diffractive pupil dependent aspheric IOL. Which have been made of hydrophilic acrylic with an ultraviolet (UV) and blue light inhibitor. It has an optic diameter of 6.15 mm and an overall diameter of 10.75 mm; it has +3.5D additional power for near vision and +1.75 D additional power for intermediate vision, consisting of 26 diffractive steps.
46021201|NCT04230382|Diagnostic Test|Diagnosis of diabetes (OGTT)|Blood sample will be collected for glucose, HbA1c and magnesium. Standard OGTT will be conducted with 75g of glucose (repeated, if disgnostic).
46021202|NCT01121991|Drug|Recombinant Human-Luteinizing Hormone (Luveris)|Recombinant Human-Luteinizing Hormone (Luveris) was administered once daily subcutaneously at a starting dose of 150 IU per day beginning on stimulation Day 6.
45598510|NCT02231099|Procedure|Prolift + M|prolapse surgery with mesh
45681259|NCT03828292|Drug|Dexamethasone|Dexamethasone tablets will be administered orally.
46021203|NCT04277728|Diagnostic Test|hypoperfusion-hypodensity mismatch|hypoperfusion-hypodensity mismatch on computed tomography
46021204|NCT00994240|Procedure|Electrodessication & Curettage|Electrodessication & Curettage 1 or 3 cycles
46021205|NCT01253369|Drug|Pazopanib|
46021206|NCT04292548|Diagnostic Test|taking saliva samples to determine TAS, TOS and LL-37|
46106119|NCT04951206|Drug|Clobetasol Propionate 0.05% Ointment|Clobetasol propionate 0.05% ointment obtained from a commercial manufacturer
46106120|NCT04948853|Behavioral|Individual Placement Support - Supported Employment|Individual, person-centered intervention designed to help individuals living with mental illnesses obtain and sustain meaningful employment. This is an evidence-based practice for individuals with severe mental illnesses.
46106121|NCT04942340|Drug|Atipamezole & Caffeine|In this arm, subjects will be infused with Atipamezole (2 g/kg) and caffeine (15 mg/kg) across 5 minutes
46106122|NCT04942340|Drug|Dexmedetomidine Hydrochloride & Saline|In this arm, subjects will be infused with Precedex & Saline at 15 mg/kg across 5 minutes
46106123|NCT04932525|Procedure|Biopsy|Blood and tumor samples for Genetic Profiling research
46106124|NCT04927637|Procedure|imaging 24 hours following intravenous administration of ICG|Patients will be administered a single, FDA approved, ICG, 2.5-5mg/kg dose 24 hours prior to surgery. ICG fluorescence images will be acquired By a FDA approved surgical imaging device prior to surgical debridement. The wound will be irrigated as per standard procedure and another ICG fluorescence image will be acquired. The need for repeat debridement or tissue cultures will be left up to the treating surgeon.
46106125|NCT04925479|Drug|Asciminib Pediatric formulation group|"Asciminib Pediatric formulation group: Mini-tablets will be supplied as size 0 capsules containing 1 mg mini-tablets, taken orally:~10 mg (10x 1 mg tablets in capsule) 15 mg (15x 1 mg tablets in capsule) 20 mg (20x 1 mg tablets in capsule) 30 mg (30x 1 mg tablets in capsule)"
46106126|NCT04925479|Drug|Asciminib Adult formulation group|"Asciminib Adult formulation group:~40 mg tablets BID, taken orally. 20 mg tablets BID, taken orally."
46106127|NCT04909723|Combination Product|NOV-001|NOV-001 is an investigational combination product composed of NB1000S, a recombinant live biotherapeutic product, and NB2000P, a botanically derived polysaccharide.
46106128|NCT04909723|Biological|NB1000S|A recombinant live biotherapeutic product.
46106129|NCT04909723|Drug|NB2000P|A botanically derived polysaccharide.
46106130|NCT04909723|Drug|Placebo|Placebo
46106131|NCT04905654|Drug|Levcromakalim|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
46106132|NCT04905654|Drug|Saline|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
46106133|NCT04896229|Other|Talk STEM Familia Treatment Condition|This study has one intervention and two arms: experimental and treatment as usual. Participants randomized to the treatment condition will receive the TSF technology in addition to the vocabulary instruction, monitoring, or resources delivered by English Language Development programs (ELD) and schools. TSF will deliver frequent, brief, dual-language exercises to help families learn, practice and apply SAV words in conversation. Audio-visual lessons will support learning at all literacy levels, regardless of prior familiarity with STEM subjects. The complete TSF tool will contain approximately 72 minutes of video modeling and 12 hours of interactive exercises delivered over 24-weeks in brief, interactive, easy to assimilate lessons.
46021207|NCT04292236|Dietary Supplement|Lauric Acid, Perilla Oil and Diindolylmethane|Colonic release capsules containing lauric acid (2400mg), perilla oil (2100mg) and diinodlylmethane (500mg) given to volunteers 1 hour prior to standardised breakfast and lunch meal. Placebo group given cellulose capsules of same volume prior to standardised breakfast and lunch meal.
46021208|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
46021209|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
46021210|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was 2 oral doses of 150 mg each: one controlled-release (CR) tablet at 07:30 (after an overnight fast of at least 10 hours) and 19:30 (after a fast of at least 2 hours) on clinic days.
45681260|NCT03828292|Drug|Pomalidomide|Pomalidomide capsules will be administered orally.
46021211|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was three oral doses of 100 mg each: one immediate-release (IR) tablet at 07:30 (after an overnight fast of at least 10 hours), 15:30 and 23:30 (both dosages after a fast of at least 2 hours) on clinic days.
46021212|NCT00994162|Device|EZCare/V1STA Negative Pressure Wound Therapy System|Vacuum Source and dressing kit that generates negative pressure over the wound.
46021213|NCT04310943|Drug|Tislelizumab|Tislelizumab, 200mg, Q3W ,use until disease progression
46021214|NCT04292158|Device|SomnoTouch|"The patient will be equipped with the SomnoTouch device. This device is able to record and estimate the following data:~ECG data PPG data Heart rate Respiration rate Blood pressure (mmHg) Oxygen saturation (%).~All patient will be stored for further analysis."
46021215|NCT04292158|Device|MOX|"The patient will be equipped with the MOX device. This device is able to record and estimate the following data:~Accelerometers data Activity Body posture~All patient will be stored for further analysis."
46021216|NCT04293640|Diagnostic Test|Parasternal electromyogram measurement|Three electrodes are applied to the chest (two to parasternal muscles, one reference electrode to clavicle). Measurements of EMG signals are recorded on appropriate software.
46021217|NCT02868814|Drug|Pregabalin Release Tablets|
46021218|NCT02868814|Drug|Pregabalin Release Tablets|
46021219|NCT02868814|Drug|Placebo|
46021220|NCT04292314|Drug|Omega 3|Omega-3 supplementation (300-400mg EPA & 200-300mg DHA) per day for 8 consecutive months up to 10 months
46021221|NCT04292314|Drug|Nigella Sativa Oil|Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months
46021222|NCT04292314|Drug|Hydroxyurea|hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.
46021223|NCT04292314|Drug|Honey|Natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.
46021224|NCT04292314|Drug|Deferoxamine|deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.
46021225|NCT04292314|Procedure|blood transfusion session|Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
46021226|NCT00993928|Behavioral|Home-based sleep intervention|Participants will be asked to practice behaviors consistent with the stimulus control sheet and to read the sleep hygiene booklet.
46021227|NCT01253291|Drug|LY2127399|Administered subcutaneously every 4 weeks for 48 weeks
46021228|NCT04292002|Behavioral|Test@Work|Offer of a general health check including opt-in sexual health consultation and HIV testing, weight/height, Body Mass Index (BMI), blood pressure, mental health screen. Provision of tailored health advice and a resource pack with information and signposting.
46021229|NCT01121757|Drug|azacitidine|Azacitidine 75 mg/m2 SC or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.
46021230|NCT01121757|Drug|lenalidomide|Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.
46021231|NCT04319471|Drug|Capecitabine/S-1|Drug: Capecitabine/S-1
46106134|NCT04890483|Device|Transcranial direct current stimulation|tDCS: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head. The electrodes will be located of the primary motor cortex. The electrode with positive charge (anode) will be positioned at contralateral to the dominant limb and the negative charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb. The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes. During the session, patients will remain seated. Number of sessions: five times, once per day.
46106135|NCT04887922|Device|MIR Spirobank G|FDA-approved, Bluetooth digital spirometer
46106136|NCT04887922|Device|ZEPHYRx®|ZEPHYRx® has developed a 1) digital Bluetooth-enabled IS that allows for the continuous and objective remote monitoring of patient compliance with pre- and postoperative IS via a smartphone app and online provider dashboard.
46021232|NCT04319471|Drug|Chemotherapy|Gemcitabine (1000mg/m2) D1 D8+ nidaplatinum (80-100mg/m2) D2 q3w ×4-6cycle
46021233|NCT04319471|Radiation|Head and neck radiotherapy|IMRT is uesd for the synchronous oligometastatic Nasopharyngeal Carcinoma；
46021234|NCT04319471|Other|Local Consolidative Therapy|radiotherapy，surgery or interventional therapy for all metastatic sites.
46106137|NCT04887922|Device|Conventional spirometer|Will be provided to participants
46021235|NCT02882217|Drug|XC8 (histamine glutarimide)|
46106138|NCT04881656|Other|Help is in Your Hands|HIIYH is a set of 16 online educational modules for caregivers of children with social-communication delays or elevated likelihood of ASD.
46106139|NCT04878406|Drug|NNC0480-0389|A single dose of subcutaneous NNC0480-0389. The study will last for a maximum of 72 days.
46106140|NCT04878406|Drug|Placebo (NNC0480-0389)|A single dose of subcutaneous placebo (NNC0480-0389) The study will last for a maximum of 72 days.
46106141|NCT04878406|Drug|Semaglutide|A single dose of subcutaneous Semaglutide 0.5 mg The study will last for a maximum of 72 days.
46106142|NCT04878406|Drug|Placebo (Semaglutide)|A single dose of subcutaneous placebo (semaglutide) The study will last for a maximum of 72 days.
46106143|NCT04877730|Device|Fully Closed Loop (FCL)|Closed loop without a meal anticipation module without announced carbohydrate
45598511|NCT02231099|Procedure|conventional vaginal prolapse surgery|conventional vaginal prolapse surgery;anterior colporrhaphy, posterior colporrhaphy
45598512|NCT02292043|Drug|HTEA|HTEA
45598513|NCT02401347|Drug|Talazoparib Tosylate|Participants receive Talazoparib tosylate at 1 mg by mouth daily.
45681261|NCT04193098|Biological|CTL|CTL injection
46106144|NCT04877730|Device|Fully Closed Loop with meal anticipation module (FCL+)|Closed loop with a meal anticipation module and without announced carbohydrate
46106145|NCT04877730|Device|Hybrid Closed Loop (HCL)|Closed loop without a meal anticipation module with announced carbohydrate
46106146|NCT04870034|Drug|Binimetinib|Given PO
46106147|NCT04870034|Drug|Palbociclib|Given PO
46106148|NCT04870034|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45681262|NCT04193098|Biological|Toripalimab|Toripalimab injection
45838217|NCT04293341|Behavioral|Cognitive Behavioral Therapy for Panic Disorder|CBT for Panic Disorder is a well established evidence-based psychotherapy. CBT for Panic Disorder focuses teaching patients how to change their behaviors through exposure practices and challenge their anxious thoughts to reduce their experience of panic attacks and avoidance.
45838218|NCT04288921|Diagnostic Test|Swab|Swab samples for diagnostic test
46021236|NCT02882217|Drug|Placebo|
46021237|NCT01253135|Biological|Fibrin|Topical application of fibrinogen spray, followed by thrombin spray
46021238|NCT01253135|Other|White Petrolatum|Topical application
46021239|NCT02882061|Procedure|Thoracic spinal manipulation|The most hypomobile (stiff) and/or painful segment between T1-T4 will be determined , and this is the segment to which the examiner will apply the thrust. The manipulation will be performed with subjects lying supine. The examiner will use a 'pistol grip' to apply pressure on the articular pillars of the thoracic segment bilaterally in order to block the inferior vertebrae of the hypomobile segment. The subject will cross their arms over their chest to the point where the elbows are aligned. This will allow the examiner to apply pressure through both elbows in an anterior-to-posterior direction. The examiner will assure the direction of force is felt into his/her stabilizing hand. The subject will be asked to take a deep breath in and then exhale completely. A grade V (HVLA) thrust will be applied at the end of the subject's exhalation. If a cavitation is not heard or felt by either the subject or examiner, a second thrust will be performed.
46021240|NCT02881905|Device|ball attachment|it is attachment part that connects the overdenture to the implant
46021241|NCT02881905|Device|cm loc attachment|It is a new attachment made of peek material
46021242|NCT00993616|Drug|belinostat|Given IV
46021243|NCT00993616|Drug|carboplatin|Given IV
45598514|NCT02295319|Other|Individual discharge|"See previous description in Arms"
45598515|NCT02231255|Drug|Sifrol®|
45598516|NCT02352051|Drug|Atomoxetine|the drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
45681263|NCT04192942|Other|protocol of management of major burn in intensive care unit|primary assessment first aid management laboratory investigation radiological investigation surgical intervention
45681264|NCT04021186|Other|Prevention of hyperglycemia|Bigger focus on postoperative blood-glucose levels in order to reduce incidents of hyperglycemia and other surgical complications.
45681265|NCT04026724|Drug|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
45681266|NCT04026802|Other|In-Bed Resistance Training Device|Physical Therapy using the in bed training device
45681267|NCT04026802|Other|Standard of Care|Does not include early implementation of physical therapy
46021244|NCT01120899|Drug|Minocycline|Participants take 100 mg minocycline pills twice daily for 24 months.
46021245|NCT01120275|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
46021246|NCT01120275|Other|laboratory biomarker analysis|Correlative studies
46021247|NCT00991510|Drug|mycophenolate mofetil (Myfenax)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
46021248|NCT00991510|Drug|mycophenolate mofetil (Cellcept)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'R' (reference drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
46021249|NCT01119963|Drug|17-alpha-hydroxy-progesterone caproate, Makena®|Intramuscular (IM) injection of 17P,Makena® (250mg) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
46106149|NCT04868305|Procedure|Intramedullary nail|"Intertan nail (Smith & Nephew)* or Gamma 3 nail (Stryker)*~* All of the above-mentioned products are subjects to change into an equivalent product"
46021250|NCT01119963|Drug|Castor Oil (Placebo)|IM injections of Placebo (castor oil) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
46021251|NCT02868736|Device|Synovasure PJI Lateral Flow test and Synovasure PJI ELISA Test|
46021252|NCT01252667|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
46021253|NCT01252667|Drug|Clofarabine|Given IV
46021254|NCT01252667|Drug|Cyclosporine|Given PO
46021255|NCT01252667|Other|Laboratory Biomarker Analysis|Correlative studies
46021256|NCT01252667|Drug|Mycophenolate Mofetil|Given PO
46021257|NCT01252667|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
46106150|NCT04868305|Procedure|Hip arthroplasty|"Total hip arthroplasty:~Cemented: Lubinus (Link)*, Exeter (Stryker)*~Uncemented: Restoration Modular (Stryker)*~Cup: Cemented Avantage dual mobility cup (Zimmer Biomet)*~Hemiarthroplasty:~Cemented: Lubinus (Link)*, Exeter (Stryker)*~Uncemented: Restoration Modular (Stryker)*~All of the above-mentioned products are subjects to change into an equivalent product"
46106151|NCT04864834|Biological|SOK583A1 (40 mg/mL)|IVT administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
45598517|NCT02352051|Drug|methylphenidate|the drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg
46021258|NCT01252667|Other|Pharmacological Study|Optional correlative studies
46021259|NCT01252667|Radiation|Total-Body Irradiation|Undergo TBI
46021260|NCT04292626|Diagnostic Test|SPECT with 99mTc-1-thio-D-glucose|One single intravenous injection of 99mTc-1-thio-D-glucose, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
46021261|NCT02881827|Radiation|Low level laser therapy|Supported by the physical phenomenon of stimulated emission postulated by Albert Einstein in 1916 the laser (light amplification by Stimulated Emission of Radiation) is a device consisting of solid source materials, liquid or gas that produces beams of light when excited by a source of energy. This bright feature is a particular type of electromagnetic radiation, which differs from that emitted by conventional incandescent sources. These are the effects attributable to LLLT analgesic, anti-inflammatory and biostimulates and has been widely used due to low power densities and wavelengths with a penetration capacity in tissues without the generation of photothermal effects, which makes its feasible use multiple applications in Health area.
46021262|NCT02881827|Other|Placebo|Simulation of treatment with the device switched off
46106152|NCT04864834|Biological|Eylea EU (40 mg/mL)|IVT administration of 2 mg of Eylea in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
46106153|NCT04861571|Dietary Supplement|Dietary intervention with very low calorie diet (VLCD)|The VLCD program will last 8 weeks. The only sources of nutrition during this phase are the Optifast® products providing up to 800 kcal per day. Two liters (67.63 fl oz) of water should also be consumed each day. Participants will be instructed to use 5 replacement meals per day (800 kcal total) with 40% of calories as protein, 40% as carbohydrate, and 20% as fat.
46106154|NCT04861571|Other|Control Arm|The control group will consume a lower calorie diet and will be instructed to reduce their usual intake of normally consumed foods by up to 500 kcal per day but no less than 1200 kcal per day.
46106155|NCT04857398|Drug|insulin icodec|"Participants will get insulin icodec once a week for 6 weeks. The medicine will be injected under the skin.~The study will last for 15 to 22 weeks."
46106156|NCT04851873|Genetic|OAV101|Gene Therapy
46106157|NCT04851691|Behavioral|EHR CDS|"When a clinician initiates a new antipsychotic prescription for a patient with dementia, a three-pronged electronic health record clinical decision support tool pops up: (1) Alerting clinicians that antipsychotic prescriptions increase patient mortality; (2) Offering non-pharmacological behavioral resources for caregivers via a link to the IDEA! strategy resources on how caregivers can best manage a patient's behavioral disturbance non-pharmacologically, which will be available in the EHR to include in the patient's after visit summary; and (3) Defaulting prescriptions to a low supply of pills in to order to minimize harm. In addition, the PI will email all providers randomized to the intervention arm in order to make them aware of the components of this intervention and its motivation."
46106158|NCT04851691|Other|Usual Care|Patients will receive usual care from their physicians.
46106159|NCT04851288|Dietary Supplement|MitoQ|MitoQ is a biochemically modified form of ubiquinol
46106160|NCT04851288|Dietary Supplement|Placebo|Each placebo capsule contains inert excipient and is identical in appearance
46106161|NCT04849884|Device|CORI™ KNEE TENSIONER|Robotic TKA procedure with the REAL INTELLIGENCE™ CORI™ Surgical System including the use of the CORI™ KNEE TENSIONER accessory.
46106162|NCT04826432|Drug|Pasireotide 0.9 MG/ML|0.9 mg of pasireotide subcutaneously (s.c.) twice daily (14 doses) every 12 +/- 2 hours
46106163|NCT04826432|Other|Saline water|0.9 ml of saline water s.c. twice daily (14 doses) every 12 +/- 2 hours
46106164|NCT04825288|Biological|XB2001 or Placebo|XB2001 is a True Human monoclonal antibody that blocks the biological activity of IL-1α with a high degree of affinity and specificity. IL-1⍺ is a key mediator of inflammatory responses and is implicated in the pathophysiology of various diseases, including cancer, cardiovascular and rheumatologic diseases. Ample evidence supports targeting IL-1⍺ to block pathological inflammatory processes associated with many diseases.
46106165|NCT04818346|Drug|INCB054707|INCB054707 will be administered once daily
46106166|NCT04818346|Drug|Placebo|Placebo or INCB054707 will be administered once daily
46106167|NCT04814407|Diagnostic Test|Blood-derived DNA methylation detection|Up to 20 ml of blood will be collected from each subject, and the blood specimen will be processed to isolate plasma cell-free DNA and immune-derived cells (circulating T cells). Circulating methylated tumor/immune signature will then be identified.
46106168|NCT04812548|Drug|sabatolimab|Sabatolimab will be administered at a low dose (Safety run-in (Part 1) cohort 1) or a high dose (Safety run-in (Part 1) cohort 2 and Expansion (Part 2)) via i.v. infusion over 30 minutes on Day 8 of every treatment cycle.
46106169|NCT04812548|Drug|azacitidine|A standard dose of azacitidine will be given subcutaneously or intravenously every day for seven consecutive days on days 1-7 of a confirmed treatment cycle. In keeping with standard clinical practice, the alternative schedules for five consecutive days on days 1-5, followed by a two day break, then two consecutive days on days 8-9 will be permitted (alternative schedule).
46106170|NCT04812548|Drug|venetoclax|Venetoclax film-coated tablets will be administered at a dose of 400 mg orally or corresponding reduced dose for concomitant use with P-gp inhibitors or moderate or strong CYP3A4 inhibitors, once a day, from C1D1 to C1D14 during the treatment cycle. No ramp-up for venetoclax is necessary.
46106171|NCT04803773|Device|"UFOGUIDE patient transducer"|The transducer is maintained by a flexible/rigid structure, consisting of a support base, and three to four feet forming an arch around the area to be treated. These feet exist in several lengths (10, 20, 30, 40 cm) depending on the area to be treated and can be easily mounted on the base by fast attachment. The structure is based on the principle of granular jamming: it is flexible in its normal state, and can be stiffened by the application of depression within the feet.
46106172|NCT04794075|Other|Therapeutic Education and Nursing Support Program for Supportive Care|"In addition to the conventional oncology follow-up, patients will participate in an initial educational assessment day within 15 days before or after their first dose of hormone therapy.~A discussion between the patient and the pivot nurse will then make it possible to define personalized objectives, thus guiding the choice of workshops in the outpatient educational program."
46106173|NCT04791267|Behavioral|Community Health Navigator Program|Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
45598518|NCT04465981|Diagnostic Test|Sampling|Test is to validate the utility of INanoBio's automated protein arrays in detecting antibodies against SARS-CoV-2 proteins.
45599294|NCT02306629|Biological|Epratuzumab sc|Active substance: Epratuzumab, Pharmaceutical form: Solution for injection, Route of Administration: Subcutaneous,
45599295|NCT02306629|Biological|Epratuzumab iv|Active substance: Epratuzumab, Pharmaceutical form: Solution for Infusion, Route of Administration: Intravenous,
46106174|NCT04790604|Behavioral|Community Health Navigator Program|Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
46106175|NCT04789044|Drug|NTX-001|• PEG fusion is the application of a polyethylene glycol (PEG) using a combination of sequenced reagents to a freshly performed nerve coaptation, or neurorrhaphy, to allow the axonal membranes of the proximal and distal axonal stumps to fuse back together and re-establish full axonal continuity.
46106176|NCT04783181|Biological|AAV BBP-631|intravenous
46021263|NCT02881827|Other|Control|"A scientific control group allows the experimental study of a variable at a time, and is a vital part of the scientific method. In a controlled experiment, two identical experiments are conducted. In one, the treatment - tested factor - is applied. In another - control - the tested factor is not applied.~For example, when testing a drug, it is important to carefully check the suspected drug effects are produced by the drug. Doctors can it with a double-blind study in a clinical trial: two (statistically) identical groups of patients are compared, one gets the drug and the other receives a placebo. Neither subjects nor investigators know which group receives the actual drug, which serves to prevent bias and isolating effects of such drugs."
46021264|NCT02868580|Drug|Triumeq|Triumeq, a combination of dolutegravir, abacavir and lamivudine is an anti-retroviral therapy indicated for people with HIV-1 infection.
46021265|NCT05098509|Drug|RAD011|Cannabidiol Oral Solution (containing synthetic cannabidiol)
46106177|NCT04771403|Device|FMPD AP algorithm|The Fading Memory Proportional Derivative (FMPD) insulin infusion algorithm determines insulin delivery rates based on proportional error, defined as the difference between the current CGM level and the target CGM level, and the derivative error, defined as the rate of change of the CGM. The FMPD algorithm utilizes derivative and proportional glucose errors to determine delivery rates of insulin.
46106178|NCT04771403|Device|MPC AP system|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal inputs. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure. The metabolic expenditure then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM.
46106179|NCT04771403|Device|Dexcom G6 Continuous Glucose Monitoring (CGM) System|The Dexcom G6 CGM measures interstitial glucose through a sensor transmitter. This glucose value is reported to the MPC algorithm during this intervention.
46106180|NCT04767997|Dietary Supplement|Probiotic formulation|Participants will be asked to take one capsule daily, containing 3 billion CFU of the probiotics.
46106181|NCT04767997|Dietary Supplement|Placebo|Participants will be asked to take a placebo capsule daily.
46106182|NCT04749004|Behavioral|Promotion of physical activity|Provision of motivational stimuli (commitment contracts, nudges, financial incentives) to increase amount of steps taken
46106183|NCT04727944|Other|Reach and grasp tasks in healthy participants using MEG technique (Experiment 1)|"Human participants will perform reach and grasp movements to various objects (e.g. a cube, sphere, or rod) driven either by perceived action affordances, or instruction cues. A rotating carousel will be used to present subjects with various objects affording different types of grasps (e.g. a precision pinch, a whole hand 'power' grasp, or a tripod grasp).~Prior to the experiment, subjects will be tested outside the scanner by asking them to grasp each object as they would naturally to ensure that each object elicits the expected grasp type. Subject-specific, 3D-printed head-casts will be created based on high resolution MRI scans from each subject, and worn by subjects during the MEG experiment (Experiment 1) to reduce within-session head movement associated with reaching and grasping.~At the end of this session an experimental task is added: detection of tons in presence of multitonal masks, in order to verify how beta peaks might be generated by a stimulus auditory."
46106184|NCT04727944|Other|Reach and grasp tasks in healthy participants using EEG technique (Experiment 2)|Experiment 2 consists of a task of reaching for and grasping several objects (e.g. a cube, sphere, or rod) ; the task used for experiment 2 is the same as that used for experiment 1. EEG signals will be measured.
46106185|NCT04707469|Drug|Oral semaglutide|Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 68 weeks.
46106186|NCT04705467|Device|Gynecological brachytherapy|Management of gynecological malignancies is done through brachytherapy treatment, which involves the delivery of radiation via radioactive sources that are placed into or in close proximity to the tumour.
46106187|NCT04704284|Diagnostic Test|Zero Echo Time Magnetic Resonance Imaging (ZTE MRI)|Magnetic Resonance Imaging (MRI) with zero echo-time (ZTE) that uses proton density differences rather than T2 relaxation time differences to achieve contrast.
45838219|NCT04280692|Biological|PfSPZ Challenge|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites
45838220|NCT04280692|Drug|Sulfadoxine-Pyrimethamine|Sub-curative 500mg/25mg single dose regimen
45838221|NCT04280692|Drug|Piperaquine|Sub-curative 480mg single dose regimen
45838222|NCT04280692|Drug|Artemether lumefantrine|Three day curative regimen 20mg/120mg
45838223|NCT04280692|Drug|Primaquine|Single low dose regimen 0.25 mg base/kg
46021266|NCT05098509|Drug|Placebo|Matching Placebo for RAD011
46021267|NCT02868658|Biological|Blood sampling|
46021268|NCT02868658|Other|Nasal swab|
46021269|NCT02881749|Radiation|Total skin electron beam therapy (TSEBT)|"TSEBT will be given in 6 fractions at 2 Gy per fraction every Monday, Wednesday, and Friday over the course of 2 weeks (total TSEBT dosage is 12 Gy). Supplements up to 8 Gy will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions, scalp, etc. Discrete tumors may receive additional boost up to 8 Gy."
45681268|NCT04020796|Dietary Supplement|Beetroot juice|Thirty-seven hypertension, with age 40-70 years were randomized to receive a 500ml volume of beetroot juice contains 11.5 mmol of inorganic nitrate or mineral water in a single moment.
45681269|NCT03832348|Device|PET scan imaging|3 PET scans will be performed after each 3 first infusions of Pembrolizumab
46106188|NCT04702022|Diagnostic Test|18FDG PET / CT|The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events will be applied.
46021270|NCT02881749|Drug|mechlorethamine gel 0.016%|The maintenance period for this study includes one year of weekly mechlorethamine gel 0.016%. This period will not begin until the observation period (30 days) has been completed. During the first week of the maintenance period, patients will apply mechlorethamine gel to the entire body surface daily. After the first week, patients will apply mechlorethamine gel to entire body surface one time per week for the rest of the maintenance period.
46021271|NCT00629044|Biological|Assessing the blood level of cholesterol 24 S Hydroxylase|Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.
46106189|NCT04698525|Drug|Valproate Sodium|Comparison between two actives
46106190|NCT04698525|Drug|Memantine|Memantine
46106191|NCT04697459|Other|chronic phase|1h of intradialytic execise, starting 30 min after hemodialysis beginning : 30 min of low-intensity (Borg Scale 11-14) aerobic exercise + 30 min of resistance training, frequency : 3 times a week for 16 weeks.
46106192|NCT04697459|Other|acute phase|30 min of low-intensity (Borg Scale 11-14) aerobic exercise, starting 30 min after hemodialysis beginning
46106193|NCT04680845|Behavioral|Self-affirmation|According to self-affirmation theory (Steele, 1988), defensiveness arises because people are motivated to defend their global sense of self-worth, which in the present case is threatened by perceptions of hearing aids/loss. However, if a person's self-image can be bolstered (affirmed) in a domain that is important to them, thereby preserving self-integrity, the individual should be less likely to process the threatening (i.e., stigmatizing in the present context) information defensively (Steele, 1988).
46106194|NCT04678635|Other|Chronic transcranial direct current stimulation|Chronic transcranial direct current stimulation
46106195|NCT04672538|Procedure|Low Vt protocol|Low Vt protocol - tidal volumes (Vt) 6 ml/kg, respiratory rate required for end tidal carbon dioxide (EtCO2) of 36-38 mmHg, PEEP 5 centimeter of water (cm-H20) , I:E ratio 1:2
45598519|NCT02227277|Drug|Peg-IFN-α2b|"Arm 1: At week 4 of the treatment, ART will be interrupted. Viral load will be monitored every 2 weeks. ART will be resumed at the earlier of a) a single measurement of VL > 50 c/ml or b) 16 weeks of treatment, and subjects will be observed for the remaining 4 weeks (total of 20 weeks on treatment).~Arm 2: In week 4, participants in arm 2 will add peg-IFN-α-2b to their ART regimen for a period of 20 weeks."
45681270|NCT04026100|Biological|CTA101|Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses. Subjects will been distributed into low dose (0.2×10^6), medium dose (2×10^6), and high dose (3×10^6).
46021272|NCT00629044|Biological|Assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects
46021273|NCT00629044|Biological|assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects
46106196|NCT04672538|Procedure|High Vt protocol|High Vt protocol - tidal volumes (Vt) 10 ml/kg, respiratory rate required for EtCO2 of 36-38 mm Hg, PEEP 5 cmH2O, I:E ratio 1:3.
46106197|NCT04667104|Drug|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously once every 4 weeks.
46106198|NCT04667104|Drug|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally once daily.
46106199|NCT04667104|Drug|Tenofovir alafenamide (TAF)|TAF film-coated tablet will be administered orally once daily.
46106200|NCT04667104|Drug|Entecavir (ETV) monohydrate|ETV monohydrate film-coated tablet will be administered orally once daily.
46106201|NCT04667104|Drug|PegIFN-alpha2a|PegIFN-alpha2a injection will be administered subcutaneously once weekly.
46106202|NCT04666740|Drug|Pembrolizumab|Pembrolizumab 200 mg IV every 3 week. After the first 6 months (8 cycles), on C9D1 Pembrolizumab 400 mg IV every 6 week.
46106203|NCT04666740|Drug|Olaparib|Olaparib 300 mg twice day orally daily continuously (POLAR) as a maintenance therapy. After the first 6 months (8 cycles), on C9D1 olaparib 300 mg twice a day orally will be continued.
46106204|NCT04660812|Drug|AB680|AB680 is a cluster of differentiated CD73 Inhibitor
46106205|NCT04660812|Drug|Etrumadenant|Etrumadenant is a dual adenosine receptor (A2aR and A2bR) antagonist
46106206|NCT04660812|Drug|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclononal antibody
46106207|NCT04660812|Drug|Bevacizumab|Bevacizumab is administered as part of standard chemotherapy regimen
46106208|NCT04660812|Drug|m-FOLFOX-6 regimen|mFOLFOX-6 regimen is administered as part of standard chemotherapy regimen
46106209|NCT04660812|Drug|Regorafenib|Regorafenib is adminstered as part of standard chemotherapy regimen
46106210|NCT04659369|Drug|CMAB819|for injection only
46106211|NCT04659369|Drug|Nivolumab|for injection only
46106212|NCT04651439|Drug|Filgrastim|"Injection of ZARZIO 30 MU/0,5mL and/or ZARZIO 48 MU/0,5mL, over a period of 5 consecutive days (1 injection per day during 30 minutes - - day 1 : set up standard treatment). The filgrastim solution will be diluted in 20 mL of 5% Glucose. The dose of ZARZIO administrated depends of the patient's weight :~20 to < 30kg = 0,3 mL of ZARZIO 48 MU/0,5mL (subcutaneous route)~30 to < 60kg = 0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~60 to < 90kg = 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~90 to < 120kg = 2x0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~120 to 150kg = 0,5 mL of ZARZIO 30 MU/0,5mL + 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~> 150kg = 2x0,5 mL of ZARZIO 48 MU/0,5mL (by IV)"
46106213|NCT04651439|Drug|Placebo|"Injection of 20 mL of Glucose 5% solution over a period of 5 consecutive days (1 injection per day during 30 minutes - day 1 : set up standard treatment). The dose given is equivalent to that used for filgrastim :~20 to < 30kg = placebo not available because the injection must be done subcutaneously so the blind cannot be respected.~30 to < 60kg = 20mL of Glucose 5% solution (by IV)~60 to < 90kg = 20mL of Glucose 5% solution (by IV)~90 to < 120kg = 20mL of Glucose 5% solution (by IV)~120 to 150kg = 20mL of Glucose 5% solution (by IV)~> 150kg = 20mL of Glucose 5% solution (by IV)"
46106214|NCT04649801|Procedure|Atrial fibrillation ablation|Catheter ablation
46106215|NCT04647526|Drug|[Lu-177]-PNT2002|Participants randomized to Arm A will receive 6.8 GBq (±10%) of [Lu-177]-PNT2002 every 8 weeks for 4 cycles
46106216|NCT04647526|Drug|Abiraterone|Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone)
46106217|NCT04647526|Drug|Enzalutamide|Enzalutamide (160 mg orally qd)
46106218|NCT04641819|Drug|Yangzheng Compound Mixture|"At the end of the treatment period, the investigator can decide whether to continue the medication based on the improvement of the subjects' sleep disturbance.~Medication during the follow-up period: subjects will enter the follow-up period after completing one course of Yangzheng Compound Mixture treatment or the end of the treatment period. Visits will be conducted once every 3 weeks, at least 2 times and no more than 4 times. For subjects in the experimental group, doctors can decide whether the patients should continue to receive Yangzheng Compound Mixture therapy in the follow-up period according to the improvement of sleep disorders, while for subjects in the control group, the patients can choose to start receiving Yangzheng Compound Mixture therapy in the follow-up period according to their own wishes and doctors' suggestions."
46106219|NCT04641819|Other|Conventional Treatment|Including treatment of sleep disorders and tumor which shall follow the clinical guidelines.
46106220|NCT04641663|Dietary Supplement|Multi-target Dietary Supplement (MTDS)|"The Multi-Target Dietary Supplement (MTDS) is comprised of 51 ingredients designed to simultaneously target and support the cellular processes implicated in the progression of the aging phenotype (oxidative stress, inflammatory processes, insulin resistance, and membrane and mitochondrial deterioration). The MTDS is unique in that it was specifically designed as a multi-target intervention to support the complex cellular perturbations associated with aging. Components of the formulation were chosen based on scientific consensus of documented effectiveness for one or more of the targeted processes, long-term evidence of safety, and synergistic or additive interactions between components.~The MTDS is divided into morning and evening doses to maximize availability of the components to the peak activity level of the cellular processes that require those components."
46106221|NCT04635774|Drug|Insulin|40 IU via four activations of an intranasal spray
46106222|NCT04635774|Drug|Saline|Four activations of an intranasal spray containing placebo (normal saline).
46106223|NCT04634799|Drug|TM5614|TM5614 is provided in 30 mg tablets and 6 tablets (180 mg) will be taken in the evening for up to 7 days.
46106224|NCT04634799|Other|Placebo|Matching placebo will be provided and participants will take 6 tablets in the evening for up to 7 days.
46106225|NCT04632381|Drug|Zotatifin|Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor (eIF) 4A1-mediated translation that imparts its regulation through a reversible enhancement of eIF4A1 binding to RNAs (ribonucleic acids) with specific polypurine motifs within the 5'-untranslated region (UTR).
46106226|NCT04632381|Drug|Placebo|5% dextrose injection, USP
46106227|NCT04622930|Device|Smartphone-delivered CBT for SAD|12-week Smartphone-delivered CBT for SAD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for SAD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
46106228|NCT04615923|Drug|Pridopidine|"Administration: Oral~Dose: 45mg twice daily"
46106229|NCT04615923|Drug|Matching Placebo|"Administration: Oral~Dose: one capsule twice daily"
46106230|NCT04603651|Drug|Bamlanivimab|Administered intravenously (IV).
46106231|NCT04603365|Drug|Pamiparib|Given PO
46106232|NCT04603365|Drug|Temozolomide|Given PO
46106233|NCT04591912|Behavioral|mind. body. voice|The mbv program consists of 10 weekly sessions that include a variety of practices, including: cognitive dissonance exercises, contemplative practices, guided discussion and community building.
46106234|NCT04591873|Other|telemedicine|Using telemedicine system to communicate
46106235|NCT04591873|Other|traditional communication tools|Use telephone or direct verbal communication
46106236|NCT04588207|Drug|Urea|"Groups On Urea, Then Off Urea and Off Urea, Then On Urea will receive urea during period 1 and period 2 of the study, respectively. The investigators will use the new American formulation of oral urea (i.e., Ure-Na™), which is packaged as a powder and mixed with 4 ounces. of water for oral consumption. Urea will be started at a dose of 15 grams of urea per mouth once daily. Dose titration will be based on the absolute increase in PNa on days 7 and 14. The urea dosing scheme will involve increasing from the starting dose of 15 grams/day to 30 grams/day (in 2 divided doses) based on the change in and absolute value of PNa, and subsequently, from 30 grams/day to 60 grams/day (in 2 divided doses) when indicated. The maximal dose of urea administered will be 60 g/day."
46106237|NCT04587089|Procedure|Irrigation|Irrigation and aspiration in the root canals with 1% sodium hypochlorite (Milton's solution).
46106238|NCT04587089|Procedure|Filling with Guedes-Pinto Paste|The root canals will be filled with Guedes-Pinto Paste, which is a composite of 3 medications: Rifocort® (dermatologic ointment), camphorated paramonochlorophenol (PMCC) and iodoform. It will be prepared at the moment of use with the same proportion in volume of 3 visually identical parts, one for each of its components.
45468477|NCT05179967|Device|WeFlow-JAAA Stent Graft System|WeFlow-JAAA Stent Graft System consists of abdominal main body of inner embedded stent graft , abdominal main bifurcation stent graft, extension stent graft and branch stent graft. The abdominal main body of inner embedded stent graft is composed of abdominal main embedded covered stent and conveyor, the abdominal main bifurcated stent graft is composed of abdominal main bifurcated stent and conveyor, the extended stent is composed of extended stent graft and conveyor, and the branch vascular stent graft is composed of branch vascular stent and conveyor. The abdominal main body of inner embedded stent graft, abdominal main bifurcation stent graft, extension stent graft and branch vascular stent graft are pre-installed in the corresponding conveyor respectively.
46106239|NCT04587089|Procedure|Filling with CTZ Paste|The powder that composes the CTZ paste will be previously manipulated in a 1:1:2 ratio (500mg of Chloramphenicol, 500mg of Tetracycline and 1,000mg of Zinc Oxide) by Formula & Ação (F&A) and incorporated into the eugenol liquid at the time of use, with the aid of a flexible spatula nº 24 and on a sterile glass plate. The cleaning of the coronary chamber must be carried out with saline solution and drying with sterile cotton balls and the CTZ paste must be inserted into the cavity.
46106240|NCT04580160|Device|Duo Venous Stent System|Subjects with nonmalignant iliofemoral venous outflow obstruction presenting with nonthrombotic (NT), acute thrombotic (AT) or chronic postthrombotic (CPT) disease pathogenesis will be selected for study participation.
46106241|NCT04565015|Biological|GC5107|Intravenously infused at a dose of 300 - 900 mg per kg (of body weight) every 21 or 28 days for 12 months
46106242|NCT04560660|Drug|Ketamine|FDA approved anesthetic medication with rapid acting antidepressant effects.
45468478|NCT03319719|Device|Belotero® Balance with integral lidocaine|Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
45468479|NCT03319719|Device|Belotero® Balance|Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
45468480|NCT01142687|Dietary Supplement|dihydrocapsiate capsule|"Group 1: 1 dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner.~Group 2: 3 dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner~Group 3: Placebo 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner"
46021274|NCT01119105|Drug|BC-3781|BC-3781 dose 100mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
46021275|NCT01119105|Drug|BC-3781|BC-3781 dose 150mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
46106243|NCT04560660|Drug|Midazolam|FDA approved sedative medication with dissociative effects.
46106244|NCT04556526|Biological|Ad26.ZEBOV|Participants in Group A will receive 0.5 mL IM injection of Ad26.ZEBOV vaccine. Participants in Group B will receive Ad26.ZEBOV 6 weeks after delivery/termination of pregnancy.
45468481|NCT03128554|Other|Intervention with Training and Materials|Peer-Led Continuing Medical Education Session and Provider/Patient Handouts
45468482|NCT03128320|Drug|BAY1193397|Single dose of 1 mg BAY1193397 given in the fasted state
45468483|NCT03128320|Drug|BAY1193397|Single dose of 5 mg BAY1193397 given in the fasted state
45468484|NCT03128320|Drug|Placebo|Single dose of placebo given in the fasted state
46021276|NCT01119105|Drug|Vancomycin|Vancomycin is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
46106245|NCT04556526|Biological|MVA-BN-Filo|Participants in Group A will receive 0.5 mL IM injection of MVA-BN-Filo vaccine. Participants in Group B will receive MVA-BN-Filo 6 weeks after delivery/termination of pregnancy.
46106246|NCT04551638|Other|Psychological assessment with the Repertory Grid Technique|The RGT is a constructivist psychological tool to explore the structure and content of personal identity.
46106247|NCT04517916|Device|Zephyr Valve|Subjects prescribed Zephyr Valve treatment for their emphysema/COPD and treated with the Zephyr Valves.
46106248|NCT04517435|Drug|ME-401|ME-401 (60 mg) will be given by mouth every 21 days for 6 cycles on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle. Dose escalation will be performed in a standard 3+3 design
46106249|NCT04517435|Drug|Rituximab|"375 mg/m2 IV/subcutaneous rituximab day 1 of 21-day cycle.~First dose of rituximab will be given IV and subsequent doses can be either IV or SQ based on institutional guidelines."
46106250|NCT04517435|Drug|Cyclophosphamide|750 mg/m2 IV Cyclophosphamide day 1 of 21-day cycle
46106251|NCT04517435|Drug|Doxorubicin|50 mg/m2 IV Doxorubicin day 1 of 21-day cycle
46106252|NCT04517435|Drug|Vincristine|1.4 mg/m2 (max 2 mg) IV Vincristine
46106253|NCT04517435|Drug|Prednisone|100mg PO Prednisone Days 1-5 of 21-day cycle
46106254|NCT04510675|Device|Test Article|Omeza Collagen Matrix
46106255|NCT04510675|Other|Negative Control|Occlusive Patch of 0.9% sodium chloride, NaCl
46106256|NCT04493957|Behavioral|ACCOMPAGNE Education Program|"The following workshops will be organised :~Presentation workshop~Cognitive skills workshop~Perception and Environment workshop~Responsibilities workshop~Representation workshop -~Caregivers workshop,~Solutions workshop"
46021277|NCT01118949|Drug|Lacosamide|Lacosamide is supplied as 50 mg, 100 mg, 150 mg, and 200 mg tablets. Subjects will begin a Dose-Titration Phase of Lacosamide at 100 mg/day (50 mg bid, approx. 12 hours apart, once in the morning and once in the evening) for 1 week. Three (3) weekly increases will follow until the subject reaches a dosage of 200 mg/day, 300 mg/day, or 400 mg/day, as deemed clinically appropriate. The final titration will be followed by a 6-week Maintenance Phase. Subjects who complete the Maintenance Phase have the opportunity to enroll in an open-label extension study; those who do not enroll will begin a 3-week End-of-Study Phase when Lacosamide will be tapered off gradually at a recommended rate of 200 mg/day/week.
46021278|NCT04310865|Drug|Yinhu Qingwen Granula|"Yinhu Qingwen Granula is a kind of herbal granula made from Yinhu Qingwen Decoction, which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days."
46106257|NCT04493957|Behavioral|Usuals recommandations|Recommendations consist of a description of the cognitive and sensorimotor risk factors specific to the patient for driving and advice for the adaptation of driving or the recommendation of the stopping of driving. It is usually served by oral or written to the patient, with mention in the patient's file of the recommendation and issued in the presence of his close companion.
46106258|NCT04478617|Drug|Metronidazole Vaginal|Vaginal metronidazole 0.75% (MetroGel or Vandazole) will be inserted per vagina days 1 through 5 prior to date of surgery.
46106259|NCT04462289|Behavioral|Proactive Outreach|Motivational electronic offer of tobacco cessation support via motivational texting program with care connection to patient's choice of smoking cessation programs
46106260|NCT04452721|Other|dynamic compression system|It is a harness that the patient wears all day long for an average duration of 1 year, and that remodels the chest by exerting a moderate pressure on it
46106261|NCT04452292|Other|Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma|Treatment assigned to targetable mutation. Or, for tumors that are by and large without any targetable mutation follow Large-Cell Neuroendocrine Carcinoma (NCCN) guideline-directed best front-line treatment for specific non-small cell carcinoma/adenocarcinoma.
46106262|NCT04452292|Other|Treatment for Small Cell Lung Cancer|Treatment assigned to a targetable mutation or the current standard-of-care regimen for the treatment of small cell lung cancer.
46106263|NCT04439357|Drug|Trametinib Dimethyl Sulfoxide|Given PO
46106264|NCT04439318|Drug|Trametinib Dimethyl Sulfoxide|Given PO
46106265|NCT04432064|Device|Active TI-NDBS|In the active TI-NDBS condition, subjects will receive stimulation for 60 minutes applied to the brain through scalp electrodes. There will be a maximum of 2 mA per electrode pair and no single region will receive more than 2 mA because the currents will be administered to distinct regions. At the beginning of each stimulation period, the current will increase slowly at a constant rate for 30 seconds until it reaches the appropriate intensity. At the end of the stimulation, the current will decrease slowly for 30 seconds until it reaches zero.
46106266|NCT04432064|Other|Sham TI-NDBS|This is the control condition in which participants will receive sham stimulation for 60 minutes.
46106267|NCT04432064|Device|tDCS|This is a well established method of brain stimulation and will be used to compare against the efficacy of TI-NDBS in the reduction of nicotine craving and inhalation. Participants will receive stimulation for 60 minutes.
46106268|NCT04431999|Drug|Whole blood transfusion|Severe trauma patients with a life threatening bleeding will be managed with 3 whole blood bags for the 1st and 2nd pack. The later packs will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.
46106269|NCT04431999|Drug|Fractionated blood products transfusion|Severe trauma patients with a life threatening bleeding will be managed with 3 packed red blood cells (PRBCs), 3 lyophilised plasma units and 1 dose of platelets for the 1st. The 2nd pack will consist of 3 packed red blood cells (PRBCs) and 3 lyophilised plasma units. Then, the later pack will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.
45468485|NCT04567667|Drug|[14C] BMS-986278|Specified dose on specified days
45681271|NCT04192552|Other|PAUSE Perioperative DOAC Management|"Apixaban & Rivaroxaban: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~Dabigatran (see below):~CrCl ≥50: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~CrCl <50: Hold DOAC for 4 days before procedure. Re-start DOAC 2+ days post-procedure."
46021279|NCT04310865|Drug|Yin Hu Qing Wen Granula(low does)|This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).
45468486|NCT04567667|Drug|Kinevac®|Specified dose on specified days
46021280|NCT04310865|Other|standard medical treatment|Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.
46106270|NCT04431518|Drug|JULUCA 50Mg-25Mg Tablet|One dose of JULUCA will be taken daily for up to 14 days
46106271|NCT04424966|Drug|Infigratinib|The Phase 0 study will include treatment of recurrent high-grade glioma participants with 125 mg of infigratinib 7 days prior to surgical resection. Participants with tumors demonstrating PK-response will continue treatment with the same dose continuously for 21 days in 28-day cycles after surgery.
46106272|NCT04401605|Other|Fermented Food-supplemented Diet|Fermented foods include Kimchi, Sauerkraut, Yoghurt, Kefir and more.
46106273|NCT04401605|Other|Regular Diet|No change in diet.
46021281|NCT01252355|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
46021282|NCT01252355|Drug|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
46106274|NCT04397159|Behavioral|Combination Exercise|Flywheel Resistance Plus Aerobic Exercise
46021283|NCT01252355|Drug|Interferon-beta (IFN-beta)|"Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.~Administration according to the package insert."
46106275|NCT04361045|Behavioral|StriveWeekly|"The intervention (app.striveweekly.com) delivered eight modules: introduction module, six skills modules, and wrap-up module. The two program brand name versions had identical content, but different aesthetic schemes. Modules were released week-by-week, and participants self-guided through content. To facilitate skills practice, every module was accompanied by: a weekly intro email and reminder emails; an extras section for tips/suggestions; and a weekly prize drawing. The Dashboard section of the intervention displayed user progress. The Campus section of this dashboard provided: campus-specific announcements; referrals to relevant campus wellness resources; and an anonymous livestream of all campus users' activity.~Strategies/skills included: Psychoeducation; Self-monitoring; Behavioral activation; Cognitive restructuring; Sleep hygiene; Time management; Interpersonal avoidance exposures; Physical exercise; Mindfulness; Maintenance planning."
46021284|NCT01118325|Drug|ticagrelor|Drug oral treatment
46021285|NCT01118325|Drug|clopidogrel|Drug oral treatment
46021286|NCT01117857|Drug|Duloxetine|One-week placebo lead-in, followed by Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg per day for the remaining 7 weeks of the study.
46106276|NCT04358276|Other|Computer-Assisted Intervention|Complete online course
46021287|NCT02888405|Other|High-carbohydrate diet|
46106277|NCT04358276|Device|Dermatoscope|Receive dermatoscope
45468487|NCT03128476|Dietary Supplement|Essence of Chicken|Brand's Essence of Chicken (BEC) is produced via a water extraction process from chicken meat for several hours under high-temperature, followed by centrifugation to remove fat and cholesterol, vacuum concentration to 3- to 4-fold, sterilization by high temperature and pressure before bottling. This kind of chicken essence is rich in protein, and low in sugar and fat, conveniently available and consumable, and easy for household storage.
46021288|NCT02888405|Other|Low-carbohydrate diet|
46021289|NCT01251887|Dietary Supplement|Linoleic Acid|
46021290|NCT01251887|Dietary Supplement|Docosahexaenoic Acid|
46106278|NCT04358276|Other|Educational Intervention|Receive study packet
46106279|NCT04358276|Other|Educational Intervention (Physician)|Receive physician directed letter and educational package
46106280|NCT04358276|Other|Questionnaire Administration|Ancillary studies
46106281|NCT04358276|Other|Text Message|Receive text messages
46021291|NCT01251887|Dietary Supplement|Eicosapentaenoic Acid|
46106282|NCT04344873|Other|Placebo|Placebo injection at day one and day fourteen.
46106283|NCT04344873|Drug|Abatacept 10 mg/kg|Abatacept injection at day twenty eight and day forty two.
46106284|NCT04340258|Device|Cesium-131|Cs-131 brachytherapy seed is a low-energy-gamma isotope that is contained in a titanium capsule. Dosing will be determined by a radiation oncologist study team member based on CT scan and intraoperative findings. The number of seeds and spacing will be outlined preoperatively based on the proposed square area of exposure in the resection bed. The plan is to deliver a total of 60-70Gy of radiation to the site.
46021292|NCT00991276|Drug|pregabalin|capsules; 300 mg once-per-day; 4 weeks of treatment
45468488|NCT03128476|Dietary Supplement|Placebo (Energy matched)|
45468489|NCT03318783|Drug|GSK2256294|GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.
45468490|NCT03318783|Drug|Placebo|Placebo will be administered in a single dose once daily enteral for a duration of 10 days.
46021293|NCT00991276|Drug|placebo|capsules; 0 mg once-per-day; 4 weeks of treatment
46021294|NCT00991276|Drug|pramipexole|capsules; 0.5 mg once-per-day; 4 weeks of treatment
46021295|NCT02869282|Other|Blood samples|Additional blood samples at baseline, 6, 12, 18 and 24 months.
46021296|NCT02869282|Other|Urine samples|Additional urine samples at baseline, 6, 12, 18 and 24 months.
46021297|NCT02869204|Other|Leucocyte - Platelet rich Plasma|Autologous L-PRP are studied regarding it's accelerating effect on tissue repair.
46021298|NCT02869204|Dietary Supplement|Vitamin C|A daily dietary supplement of 500 mg Vitamin C. Provided from POD2-3 until POD30
46021299|NCT02869204|Dietary Supplement|Zinc|A daily dietary supplement of 44 mg Zinc. Provided from POD2-3 until POD30
46021300|NCT02869204|Dietary Supplement|L-Arginine|A daily dietary supplement of 5 g L-Arginine. Provided from POD2-3 until POD30
46021301|NCT04291846|Drug|SHR1459 fasted in P1, high-fat diet in P2|SHR1459 administration in fasted condition in period 1, SHR1459 administration after high-fat diet in period 2
46021302|NCT04291846|Drug|SHR1459 high-fat diet in P1, fasted in P2|SHR1459 administration after high-fat diet in period 1, SHR1459 administration in fasted condition in period 2
46021303|NCT04291924|Diagnostic Test|Dynamometry|A test for maximal muscle strength and explosive power in the lower limbs
46021304|NCT02869126|Procedure|Tomoscintigraphy with D.SPECT camera (SPECTRUM Dynamics®, Israel)|"During stress test, intravenous injection of 99mTc-Sestamibi (between 80 and 150 MBq according to weight) in patient~Stress conventional acquisition with D.SPECT camera 20 min after injection~60 min after 99mTc-Sestamibi injection, rest injection of thallium-201 (50% activity of stress 99mTc-Sestamibi)~double isotope acquisition 5 min after thallium-201 injection~injection of 99mTc-Sestamibi at rest (activity 3 times higher), after 2 hours from first 99mTc-Sestamibi injection~rest conventional acquisition 20 min later"
46021305|NCT02869126|Drug|99mTc-Sestamibi|"First intravenous injection between 80 and 150 MBq according to patient weight and second injection with 3-time-higher activity, 2 hours after the first~For tomoscintigraphy"
46106285|NCT04340258|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks. The drug will be infused through a peripheral line or an indwelling catheter. The first dose will be given 2 weeks prior to surgery. Post-surgery, pembrolizumab will be started between 2 and 6 weeks and will continue every 3 weeks for a duration of 6 months. Study Drug may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. The Investigator's Brochure contains specific instructions for the preparation of the standard of care pembrolizumab infusion fluid.
46106286|NCT04336683|Device|Interstitial and intracavitary brachytherapy|Standard of care in interstitial or intracavitary brachytherapy is to insert the brachytherapy needle and applicator with no standard real-time image guidance. Interstitial brachytherapy is done under general anesthesia. Trans-abdominal and trans-rectal standard 2D ultrasound is used in some cases, but is typically not consistent and therefore its value is limited. Pre-procedure imaging in the form of MRI is used to help guide needles insertion as well as the clinical exam. Post-procedure CT is done for radiation planning
46106287|NCT04301271|Drug|Simvastatin 40mg|12 weeks 40 mg Simvastatin add-on
46106288|NCT04301271|Drug|Placebo oral tablet|12 weeks Placebo add-on
46106289|NCT04291859|Drug|Lu AF28996|capsule, orally, doses and dose escalation scheme will be decided upon at dosing conferences
46106290|NCT04287218|Behavioral|TG-iConquerFear|The theoretical frame of iConquerFear is based on the Common-Sense Model of illness, the Self-Regulatory Executive Function model and Relational Frame Theory. The intervention includes elements of attention training, increasing metacognitive awareness, acceptance & mindfulness, promotion of appropriate screening behavior, and values-based goal setting. The electronic platform comprises 5 modules containing educational text, interactive exercises, short videos featuring doctors, therapists and patients' perspectives.
46106291|NCT04287218|Behavioral|aTAU|Active control group
46106292|NCT04285567|Drug|Obinutuzumab|Obinutuzumab 1000 mg will be administered IV on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
46106293|NCT04285567|Drug|Venetoclax|Venetoclax 20 mg will be administered orally, once daily starting on Day 22 of Cycle 1 for 7 days, then ramp up from 50 to 400 mg/day during Cycle 2 and continue at 400 mg/day from Day 1 of Cycle 3 till end of Cycle 12.
46106294|NCT04285567|Drug|Fludarabine|Fludarabine will be administered in a dosage of 25 mg/m^2 IV on days 1, 2, and 3 of Cycles 1-6.
46106295|NCT04285567|Drug|Cyclophosphamide|Cyclophosphamide will be administered in a dosage of 250 mg/m^2 IV on Days 1, 2, and 3 Cycles 1-6.
46106296|NCT04285567|Drug|Rituximab|Rituximab will be administered at a dose of 375 mg/m^2 IV on Cycle 1, Day 1 followed by 500 mg/m^2 on Day 1 of Cycles 2-6.
46106297|NCT04285567|Drug|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m^2 IV on 2 consecutive days of Cycles 1-6.
46106298|NCT04281472|Biological|efgartigimod PH20 SC in stage B|Stage A: efgartigimod PH20 SC, Stage B: efgartigimod PH20 SC
46106299|NCT04281472|Other|placebo in stage B|Stage A: N/A, stage B: placebo
46106300|NCT04280718|Biological|Efgartigimod PH20 SC|Subcutaneous administration of efgartigimod
46106301|NCT04269655|Device|Cloud-Based Continuous Glucose Monitoring|The CGM data will be transmitted via bluetooth to a smartphone. The smartphone will automatically transmit values to a secure cloud-based platform, which then populates to the: (1) web-based, CGM data management tool for evaluation purposes (both groups), and (2) Digital Dashboard for monitoring and intervention (intervention only).
46106302|NCT04229134|Behavioral|Project CONNECT|Home based pain self-management intervention using peer reinforcement to promote engagement and skill uptake
46021306|NCT02869126|Drug|Thallium-201|"Injection of thallium-201 (50% activity of first 99mTc-Sestamibi injection)~For tomoscintigraphy"
46021307|NCT00990652|Drug|Bortezomib|Before surgery, an injection of bortezomib is given on days 1, 4, and 8. After surgery, bortezomib is given on days 7 and 21 of each cycle (1 cycle = 28 days).
46106303|NCT04228783|Biological|Ad26.ZEBOV|Participants will receive IM injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5*10^10 vp, Lot A, B, and C) on Day 1 (Groups 1, 2, 3 and 5) and an Ad26.ZEBOV booster dose on Day 177 (Group 5).
46106304|NCT04228783|Biological|MVA-BN-Filo|Participants will receive IM injection (0.5 mL) of MVA-BN-Filo as Dose 2 (1*10^8 Inf U, Lot 1, 2, 3 and 5) on Day 57.
46106305|NCT04228783|Biological|Placebo|Participants will receive IM injection (0.5 mL) of placebo (0.9 % saline) as Dose 1 on Day 1, followed by placebo as Dose 2 on Day 57 (Groups 4 and 6) and a booster of matching placebo on Day 177 (Group 6).
46106306|NCT04188119|Drug|Avelumab|(Arm A) Avelumab + Proto Pump Inhibitor (PPI)
46021308|NCT00990652|Drug|Temozolomide|After surgery, temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle (1 cycle = 28 days).
46106307|NCT04188119|Drug|Aspirin|300mg tablets
46106308|NCT04188119|Drug|Lansoprazole|30mg
46106309|NCT04183218|Procedure|Biospecimen Collection|Undergo biospecimen collection
46106310|NCT04183218|Device|Cardiac Event Monitor|Receive cardiac monitor
46106311|NCT04183218|Other|Chemoradiotherapy|Undergo CRT
46106312|NCT04183218|Radiation|Radiation Therapy|Undergo RT
46106313|NCT04174170|Drug|Brexpiprazole|Up to 3 mg pill
46021309|NCT02867878|Drug|Adenosine|
46106314|NCT04174170|Drug|Sertraline|Up to 150 mg pill
46106315|NCT04174170|Other|Placebo|Pill
46021310|NCT02867878|Drug|Saline solution|
46021311|NCT00990340|Device|T-jet® containing TevTropin®|Needle-free delivery method for 14 days before cross-over to other arm
46106316|NCT04170023|Drug|ALXN2050|Oral FD inhibitor
46106317|NCT04162665|Radiation|MR guided radiation therapy|-Image-based treatment planning and intensity modulated radiotherapy (IMRT) is permitted.
46106318|NCT04162665|Procedure|Blood for ctDNA|-Prior to start of radiation, after the completion of radiation therapy and prior to starting chemotherapy (2-4 weeks after radiation completion), at the completion of chemotherapy and prior to surgery (2-4 weeks after chemotherapy completion), and 6 months after surgery
46021312|NCT00990340|Procedure|TevTropin® needle-syringe injection method|comparison of delivery methods for 14 days before cross-over to other arm
46106319|NCT04146428|Behavioral|clinician-mediated JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the clinician/therapist.
46106320|NCT04146428|Behavioral|parent-mediated JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the parent.
46106321|NCT04142658|Drug|Apixaban 5 MG|"For patients that do NOT meet the following criteria~age ≥ 80 years~weight ≤ 60 kilograms~creatinine ≥ 1.5 mg/dL (133 micromol/L)"
46021313|NCT01207440|Drug|Ponatinib|Ponatinib tablets.
46021314|NCT00990184|Drug|Colesevelam|colesevelam HCl 3.75 g once daily orally with the evening meal
46021315|NCT00990184|Other|placebo|tablet (s) orally given with evening meal
46106322|NCT04142658|Drug|Apixaban 2.5 MG|"For patients that meet at least 2 of the following criteria~age ≥ 80 years~weight ≤ 60 kilograms~creatinine ≥ 1.5 mg/dL (133 micromol/L)"
46106323|NCT04142658|Drug|Warfarin|Active Control Intervention
46106324|NCT04142658|Device|On-X Aortic Mechanical Valve|Inclusion Criterion: Implantation of an On-X mechanical valve in the aortic position at least 3 months (90 days) ago.
46106325|NCT04138394|Drug|Ascorbic Acid|Patients will receive intravenous vitamin C (50 mg/kg every 6 hours for 96 hours).
46106326|NCT04138394|Drug|placebo|Patients will receive a similar amount of placebo (either D5W or saline) delivered in the same manner as the vitamin C.
46106327|NCT04129931|Drug|MCT|Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily
46106328|NCT04129931|Drug|Clazakizumab|12.5 mg subcutaneous injection given once every 4 weeks for 16 weeks. Lab driven dose reductions will be made based on safety lab data. If criteria are met for dose reduction, the participant will be reduced to a 6.25 mg dose.
45838224|NCT04278560|Device|Transcranial direct current stimulation (tDCS)|tDCS will be delivered via six gel electrodes with placement and current parameters optimized based on a standard brain to maximize the average normal component of the generated electric field over the left dlPFC. Current delivered by anyone electrode will never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
45838225|NCT04278560|Device|Sham stimulation|An 'active' sham will be used in which very low-level currents are transferred between the same electrodes used in the active condition throughout the 20-minute session. However, currents will be designed to mimic the cutaneous sensations induced by tDCS yet not significantly influence cortical tissue.
46106329|NCT04129931|Drug|Broncho-Vaxom|7 mg taken orally once a day, on an empty stomach, for 16 weeks
46021316|NCT00986830|Device|FinESS Sinus Treatment|
46021317|NCT00990106|Drug|prazosin hydrochloride|"Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) then titrating the dose upward gradually."
46021318|NCT00990106|Drug|placebo|placebo
46021319|NCT02867566|Drug|IBI301 plus CHOP|Six cycles. IBI301: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
46021320|NCT02867566|Drug|Rituximab plus CHOP|Six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
46106330|NCT04129931|Drug|Imatinib Mesylate|Two 100 mg tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. If the drug is well tolerated, participants will titrate up to four 100 mg tablets once a day with a meal and an 8 oz glass of water for 14 weeks. Safety labs will be collected at each study visit to monitor the tolerability of each participant.
46106331|NCT04129931|Drug|Cavosonstat|50 mg capsule orally twice a day for 16 weeks.
45468491|NCT03128242|Drug|Oxytocin|intranasal administration of oxytocin (24IU)
46021321|NCT02868502|Device|Goldmann tonometer|IOP measurement in the sitting position and lateral decubitus
46106332|NCT04129931|Other|Placebo|"MCT Matching Placebo: MCT matching placebo packets. Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily~Clazakizumab Matching Placebo: 12.5 mg subcutaneous saline injection given once every 4 weeks for 16 weeks.~Broncho-Vaxom Matching Placebo: 7 mg matching placebo taken orally once a day on an empty stomach for 16 weeks~Imatinib Matching Placebo: Two 100 mg placebo tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. Then four 100 mg placebo tablets once a day with a meal and an 8 oz glass of water for 14 weeks.~Cavosonstat Matching Placebo: 50 mg matching placebo capsule orally twice a day for 16 weeks."
46106333|NCT04129580|Device|reSET-O app|The reSET-O app, owned by Pear Therapeutics, Inc., is designed to work as cognitive behavioral therapy, adjunctive to medication assisted treatment, for opioid use disorder. The app provides psychoeducation related to opioid use and dependence, coping skills, and skills to avoid relapse,
46106334|NCT04126070|Drug|Androgen Deprivation Therapy|Given per standard care for duration of study. Regimens include Leuprolide (Lupron Depot) intramuscularly every 3 months, Goserelin acetate (Zoladex) subcutaneously every 4 weeks, or degarelix (Firmagon) subcutaneously every month per standard of care.
46106335|NCT04126070|Drug|Nivolumab|Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage; up to 28 cycles total.
46106336|NCT04126070|Drug|Docetaxel|Given once every 3 weeks intravenously at pre determined dosage for cycle 1-6.
46106337|NCT04124614|Drug|Brexpiprazole|Up to 3 mg pill
46106338|NCT04124614|Drug|Sertraline|Up to 150 mg pill
46106339|NCT04124614|Other|Placebo|Pill
46106340|NCT04124406|Device|Cologuard|multi-target stool Deoxyribonucleic Acid (MT-sDNA) screening test
46106341|NCT04104256|Behavioral|Nudge #1: Alert highlighting the safety/potential harms to patients of undergoing pre-op tests|"Nudge 1:~UCLA Ophthalmologists and Anesthesiologists ADVISE AGAINST routine pre-op testing.~UCLA Pre-op Eval and Planning Center (PEPC) will order any needed labs on the day of surgery.~Routine pre-op tests are inappropriate.~Routine pre-op tests do NOT increase patient safety and go AGAINST local and national guidelines Hard stop before allowing the ordering of a pre-op test where physicians must provide accountable justification: EXPLAIN WHY GOING AGAINST GUIDELINES"
46106342|NCT04104256|Behavioral|Nudge #2: Alert highlighting the financial harms to the patient experiencing pre-op tests|"Nudge #2:~UCLA Ophthalmologists and Anesthesiologists ADVISE AGAINST routine pre-op testing.~UCLA Pre-op Eval and Planning Center (PEPC) will order any needed labs on the day of surgery.~Routine pre-op tests are inappropriate.~Routine pre-operative tests can increase the patient's out-of-pocket costs without improving the safety or medical outcomes of cataract surgery and go AGAINST local and national guidelines~Nudge includes hard stop before allowing the ordering of a pre-op test where physicians must provide accountable justification: EXPLAIN WHY GOING AGAINST GUIDELINES"
46106343|NCT04104256|Behavioral|Nudge #3: Alert highlighting potential psychological harms to the patient of experiencing pre-op tests|"Nudge 3:~UCLA Ophthalmologists and Anesthesiologists ADVISE AGAINST routine pre-op testing.~UCLA Pre-op Eval and Planning Center (PEPC) will order any needed labs on the day of surgery.~Routine pre-op tests are inappropriate.~Routine pre-operative tests can cause aggravation and psychological stress for the patient without improving the safety or medical outcomes of cataract surgery and go AGAINST local and national guidelines~Hard stop before allowing the ordering of a pre-op test where physicians must provide accountable justification: EXPLAIN WHY GOING AGAINST GUIDELINES"
46021322|NCT02868502|Device|Pneumatonometer|IOP measurement in the sitting position and lateral decubitus
46106344|NCT04104256|Other|Usual Care|Patients will receive usual care from their physicians.
46106345|NCT04103814|Drug|magnesium-cannabidiolic acid cream|Patients will receive Mg-CBDa (magnesium-cannabidiolic acid) cream for topical treatment of hallux rigidus or hallux valgus.
46106346|NCT04103814|Drug|Placebo cream|Patients will receive placebo cream (neutral emollient containing no active agent) for topical treatment of hallux rigidus or hallux valgus. The ingredients of the placebo cream are as follows: Butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.
46106347|NCT04097067|Radiation|Radiation Therapy|Low dose radiotherapy with 20 Gy (10x2Gy)
46106348|NCT04096430|Behavioral|ENGAGE approach (child-oriented goal-setting)|See description of experimental arm.
46021323|NCT02868502|Device|Tonopen XL|IOP measurement in the sitting position and lateral decubitus
45468492|NCT03128242|Drug|placebo|intranasal administration of placebo (24IU)
45468493|NCT01313689|Drug|Ofatumumab|Ofatumumab IV, initial dose 300 mg, followed 1 week later with 2000 mg once weekly for 7 weeks, followed 4 weeks later by one infusion of 2000 mg every 4 weeks for 4 infusions, for a total of 12 infusions over 24 weeks. After 24 weeks of ofatumumab treatment, patients who have achieved at least stable disease or better, and whom the investigator would deem appropriate for the therapy to continue, would undergo a second randomisation (2:1) to either 1) an additional ofatumumab dose regimen of 2000 mg once every 4 weeks for up to an additional 24 weeks, or 2) no further therapy (i.e. observation only).
46021324|NCT02868502|Device|ICare rebound tonometer|IOP measurement in the sitting position and lateral decubitus
45468494|NCT01313689|Drug|Physicians' Choice|Non-ofatumumab containing regimen as per physicians' choice for up to 6 months. Permitted therapies include treatments approved for CLL, and well established standards of care for CLL.
45468495|NCT01145339|Drug|Lactase|1 chewable tablet of the test drug or comparative drug 30 minutes before the standard lactose dose (25 g).
45468496|NCT03903094|Other|Non-Interventional|Overview of anticholinergic burden, rather than to evaluate specific drugs
46021325|NCT02868424|Drug|fRPE cells|fRPE cells transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure
46021326|NCT02867722|Drug|aminolevulinic acid HCl|Drug will be administered to consented patients
46106349|NCT04095442|Device|Cepacol|Twice-daily use of Cepacol per the manufacturer's guidelines
46106350|NCT04095442|Device|Tom's Natural Mouthwash|Twice-daily use of Tom's Natural Mouthwash per the manufacturer's guidelines
46106351|NCT04082780|Drug|Rifamycin SV MMX|Intervention arm
46106352|NCT04082780|Other|Placebo|Placebo arm
46106353|NCT04075799|Other|high-intensity interval training|The HIIT protocol consists of 8 weeks using stair climbing three times per week. The warm-up will consist of 2 minutes of ascending and descending the stairs at a comfortable pace. The high-intensity intermittent exercise will comprise 6-12 x 30-seconds bouts of ascending at an all-effort. A 30- seconds walking recovery will occur between the exercise bouts. Post-exercise the subject will walk during a 2-minute cool down. Every session will last between 10 to 15 minutes. The number of bouts (6-12) will be increased progressively over the weeks. The first (week 1) and final week (week 8) of the exercise program will be monitored by a trained exercise physiologist. During supervised visits, heart rate and rating of perceived exertion (OMNI scale) will be measured at the end of each bout and after active recovery. Subjects will have the option to request further monitoring if desired.
46106354|NCT04042610|Behavioral|Electronic Prompt for Interrupting Sitting Time|An electronic prompt via the IOS application Stand-Up will be given through the Amazfit BIP device to interrupt sitting time every hour during the office workers workday. The office worker will engage in 2 minutes of physical activity with each prompt.
46106355|NCT04040634|Drug|Intensive Control of Systolic Blood Pressure (SBP)|Participants in the Intensive arm have a goal of SBP <120 mm Hg. The use of angiotensin converting enzyme (ACE) inhibitors/angiotension receptor blockers (ARB), thiazide-type diuretics, and calcium channel blockers (CCB) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine + amlodipine
46106356|NCT04040634|Drug|Standard control of Systolic Blood Pressure (SBP)|The same medications used in the Intensive BP arm will be used for the Standard BP arm.
46106357|NCT04027946|Drug|LMB-100|Patients will receive LMB-100 on days 1, 3 and 5 of a 21 day cycle for up to 2 cycles.
46106358|NCT04027946|Drug|pembrolizumab|Patients will received pembrolizumab on day 1 of each subsequent 21 day cycle.
46106359|NCT04027946|Diagnostic Test|Mesothelin Expression|Testing for mesothelin expression performed at screening
46021327|NCT04291222|Device|Iron biocorrodable coronary scaffold system|Implantation of Iron biocorrodable coronary scaffold system
46106360|NCT04027946|Diagnostic Test|TrueSight Oncology 500|Testing for ROS1, ALK and EGFR variations performed at screening.
46106361|NCT04027075|Behavioral|Rewire app users|Use of the Rewire app involves completing 12 modules and 12 practice sessions over 30 days.
46106362|NCT04016285|Device|Aquamantys|The Aquamantys bipolar sealer is a device used during surgery to help reduce bleeding in the joint. The system uses radiofrequency energy and sterile saline (salt water) to close small blood vessels in the knee to help reduce bleeding.
46106363|NCT04016285|Device|Tourniquet|Standard of care for reducing bleeding during the total knee arthroplasty
46106364|NCT04007770|Other|Acupuncture|10 treatments of acupuncture over the course of 10 weeks with a +/- 7 day window
46106365|NCT04007770|Other|Sham Acupuncture|10 treatments of sham acupuncture over the course of 10 weeks with a +/- 7 day window. After the 16-week study concludes patients in this group will have the option of receiving up to 10 sessions of real acupuncture; however, these sessions must be completed within 6 months of study conclusion.
46106366|NCT04007770|Other|16 week waiting period + optional Acupuncture|Optional real acupuncture after 16 weeks waiting period. This arm is Closed to accrual.
46106367|NCT03994627|Drug|Olaratumab|Administered intravenously (IV)
45681272|NCT04192552|Other|ASRA Perioperative DOAC Management|"Apixaban & Rivaroxaban: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~Dabigatran (see below):~CrCl >80: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 50-80: Hold DOAC for 4 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 30-49: Hold DOAC for 5 days before procedure. Re-start DOAC 1+ days post-procedure.~*Low-dose heparin bridging can be used if at high A-TE risk"
45681273|NCT04020640|Other|no intervention|Measure human intake using stable isotope technique
45681274|NCT04192162|Other|Mud therapy application|Aplication the mud pack therapy from 20 minutes
46021328|NCT02867800|Drug|Diphenhydramine|"(Standard of Care) Premedication~Diphenhydramine: 1 mg/kg IV or PO q 8 hours (maximum=50 mg)"
46106368|NCT03977662|Combination Product|Co-transplantation of PTG with pancreatic islets|Co-transplantation of allogeneic parathyroid glands (PTG) with adult pancreatic islets (both PTG and pancreatic islets obtained from same deceased donor) in people with Type 1 diabetes in the intramuscular (IM) site with stable function of liver or kidney allografts on chronic immunosuppression
45681275|NCT04192162|Other|Sulfur water application|Aplication the sulfur water in bath from 20 minutes
45681276|NCT04192162|Other|Hygienic water|Exercise in hygienic water
46021329|NCT02867800|Drug|Acetaminophen|"(Standard of Care) Premedication~Acetaminophen: 10-15 mg/kg PO q 6 hours (maximum=1000 mg)"
46021330|NCT02867800|Drug|Methylprednisolone|"(Standard of Care) Premedication~Methylprednisolone: 0.25-0.5 mg/kg IV q 6 hours"
46021331|NCT02867800|Drug|Meperidine|"(Standard of Care) Premedication~Use as needed (PRN) Meperidine: 0.5 mg/kg IV q 4-6 hours (for rigors)"
46106369|NCT03977363|Drug|Anticoagulant drugs|Anticoagulant drugs
46106370|NCT03973502|Drug|18F-DOPA PET|One hour later all patient will be injected intravenously with 185 MBq (5mCi) 18F-FDOPA. PET emission data acquisition in 3-dimensional mode will be started at 60 minutes after tracer injection for 30 minutes.
46106371|NCT03960840|Biological|Rapcabtagene autoleucel single agent|Single infusion of rapcabtagene autoleucel
46106372|NCT03960840|Drug|Ibrutinib|Tablets or capsules for oral daily use
46106373|NCT03950674|Biological|Pembrolizumab 200 mg|IV infusion
46106374|NCT03950674|Drug|Cisplatin|IV infusion
46106375|NCT03950674|Drug|Carboplatin|IV infusion
46106376|NCT03950674|Drug|Pemetrexed|IV infusion
46106377|NCT03950674|Dietary Supplement|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
46106378|NCT03950674|Dietary Supplement|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
46021332|NCT02867800|Drug|Alemtuzumab|"(Standard of Care) Immunosuppression~Alemtuzumab:~A test dose of alemtuzumab, 3 mg, should be administered IV over 2 hours the first day. If the test dose is tolerated, administration of three treatment doses should begin within 24 hours. The three treatment doses should be administered on consecutive days. 10 mg/m2 should be given the first day, 15 mg/m2 the second and 20 mg/m2 the third."
46106379|NCT03950674|Drug|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
46106380|NCT03950674|Drug|Saline solution|IV infusion
46106381|NCT03949972|Other|Biosampling|Biosampling at initial visit and follow-up visits
46106382|NCT03911661|Other|Fearon warfarin dosing algorithm|Blood test drawn by patient using a point of care INR monitor
46021333|NCT02867800|Drug|Thymoglobulin|"(Standard of Care) Immunosuppression~Thymoglobulin: A 4 mg/kg dose of anti-thymocyte globulin should be administered in place of each alemtuzumab dose not completed."
46021334|NCT02867800|Drug|Fludarabine|"(Standard Conditioning Regimen)~Fludarabine should be administered 30 mg/m2 IV daily for five days. It should be infused over 30 to 60 minutes."
46106383|NCT03911661|Other|Usual care|Historical management of warfarin by patient's usual care providers
46106384|NCT03909477|Diagnostic Test|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
46106385|NCT03909477|Diagnostic Test|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
46106386|NCT03909477|Diagnostic Test|Pulmonary Function Tests (PFTs)|Participants will have their lung function evaluated using PFTs
46106387|NCT03909477|Diagnostic Test|Six Minute Walk Test (6MWT)|Participants >35 years of age will perform the six minute walk test as a measure of exercise capacity
46106388|NCT03909477|Diagnostic Test|Cardiopulmonary exercise testing (CPET)|Participants <35 will perform cardiopulmonary exercise testing as a measure of exercise capacity
46106389|NCT03909477|Diagnostic Test|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
46106390|NCT03909477|Diagnostic Test|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
46106391|NCT03906331|Drug|Selpercatinib|Open-label expanded access
46106392|NCT03898856|Drug|Crofelemer|125 mg tablets taken by mouth twice daily for 28 days
46106393|NCT03898856|Diagnostic Test|Diagnostic tests for cause of chronic diarrhea|Diagnostic tests include: Esophagogastroduodenoscopy, Colonoscopy, biopsies of the upper gastrointestinal tract (duodenum) and lower gastrointestinal tract (colon), genetic testing for Congenital sucrase-isomaltase deficiency (CSID),Prometheus IBcause Chronic Diarrhea panel, Thyroid Panel, Stool osmolality, Stool Ova and Parasites, Stool Culture, Stool Qualitative Stool Fat, Stool Reducing Substances, Laxative Screening, Lactulose Hydrogen Breath Test, Gastrin Level, Calcitonin Level, Vasoactive Intestinal Polypeptide(VIP) level.
46021335|NCT02867800|Drug|Melphalan|"(Standard Conditioning Regimen)~Melphalan should be administered 140 mg/m2 IV 3 days before marrow infusion. It should be infused within 60 minutes of preparation and over a maximum of 30 minutes. It should be infused immediately after the fludarabine infusion is complete."
46021336|NCT02867800|Drug|Thiotepa|"(Standard Conditioning Regimen)~Thiotepa should be administered 8 mg/kg IV 3 days before marrow infusion. It should be infused immediately after the fludarabine infusion is complete. The thiotepa should be infused over one hour."
46021337|NCT02867800|Drug|Cyclosporine|"(Standard GVHD Prophylaxis) Calcineurin inhibitor~Cyclosporine: Administration will commence no later than at least 36 hours before marrow infusion; Cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml."
46021338|NCT02867800|Drug|Tacrolimus|"(Standard GVHD Prophylaxis) Calcineurin inhibitor~Tacrolimus: Administration will commence no later than at least 36 hours before marrow infusion; Tacrolimus doses will be adjusted to maintain a level of 8-15 ng/ml."
46021339|NCT02867800|Drug|Methotrexate|"(Standard GVHD Prophylaxis)~Methotrexate will be given at a dose of 15 mg/m2 IV on day 1 and a dose of 10 mg/m2 IV on days 3, 6 and 11. Dosing shall be based on actual weight."
46106394|NCT03874923|Other|Fluid challenge|After randomisation, patient will receive 250 ml or 500 ml of fluid challenge. VO2 will be assessed before fluid challenge, immediately, 30 minutes and 60 minutes after fluid challenge.
46106395|NCT03874052|Drug|Ruxolitinib|Given PO
46106396|NCT03874052|Drug|Venetoclax|Given PO
46106397|NCT03872414|Behavioral|Anterior cingulate cortex activation|"Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior cingulate cortex.~The anterior cingulate cortex is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing."
46106398|NCT03872414|Behavioral|Primary auditory cortex activation|"Functional Magnetic Resonance Imaging Participants in each group will be trained using functional magnetic resonance imaging to regulation brain activity in primary auditory cortex. The primary auditory cortex is a brain region that is NOT specifically involved in emotion processing. Activation of this region is NOT expected to improve emotion processing; and thus activation of this brain region serves as control/placebo condition in the current design (placebo comparator)."
46106399|NCT03851159|Dietary Supplement|Nyaditum resae®|Heat-killed Mycobacterium manresensis
46106400|NCT03851159|Other|Mannitol|Placebo
46106401|NCT04491877|Biological|RSV vaccine formulation 1|Pharmaceutical form: Suspension of virus Route of administration: Intranasal
46106402|NCT04491877|Biological|RSV vaccine formulation 2|Pharmaceutical form: Suspension of virus Route of administration: Intranasal
46106403|NCT04491877|Biological|Placebo|Pharmaceutical form: Suspension Route of administration: Intranasal
46106404|NCT03837041|Other|Reconditioning Proprioception|Proprioceptive training using Delos Postural Proprioceptive System
46106405|NCT03836755|Diagnostic Test|Metacos|Evaluation of stability of implant by RSA technique
46106406|NCT03829410|Drug|Onvansertib|Onvansertib orally.
46106407|NCT03829410|Biological|Bevacizumab|Bevacizumab intravenously.
46106408|NCT03829410|Drug|FOLFIRI|FOLFIRI intravenously.
46021340|NCT02867800|Drug|Abatacept|"(Investigational)~Abatacept will be administered intravenously at a dose of 10 mg/kg based on actual weight with a maximum of 750 mg. In cases where the calculated dose is less than or equal to 110% of a simple multiple of a 250 mg vial: 250 mg (275mg), 500 mg (550 mg) or 750 mg (825 mg), the dose may be rounded down to the nearest multiple. No rounding up of the abatacept dose is permitted."
46021341|NCT02867800|Procedure|Marrow infusion|"(Standard)~A procedure that infuses healthy cells, called stem cells, into your body to replace damaged or diseased bone marrow. A bone marrow transplant may also be used to treat certain types of cancer"
46021342|NCT02867800|Drug|Sirolimus|"(Standard GVHD Prophylaxis)~Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used."
46106409|NCT03826147|Dietary Supplement|Nitrate-rich beetroot juice|Daily supplementation with ~100 kcal of nitrate-rich beetroot juice containing 400 mg of dietary nitrate (James White Drinks, UK).
46106410|NCT03826147|Dietary Supplement|Nitrate-depleted beetroot juice|Daily supplementation with ~100 kcal of nitrate-depleted beetroot juice (James White Drinks, UK).
46106411|NCT03819153|Drug|Semaglutide|Participants are to inject semaglutide with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject semaglutide under their skin. Participants will inject semaglutide 1 time a week on the same day of the week. Participants' dose of semaglutide will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
46021343|NCT02867800|Drug|Mycophenolate Mofetil|"(Standard GVHD Prophylaxis)~Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used."
46021344|NCT00983476|Behavioral|in-person MOVE! SMI|Individual and group in-person sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
46106412|NCT03819153|Drug|Placebo (semaglutide)|Participants are to inject placebo (semaglutide) with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject placebo (semaglutide) under their skin. Participants will inject placebo (semaglutide) 1 time a week on the same day of the week. Participants' dose of placebo (semaglutide) will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
46106413|NCT03814746|Drug|Crizanlizumab (SEG101)|Crizanlizumab will be supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for infusion IV.
46106414|NCT03814746|Drug|Placebo|Placebo will be supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of placebo. This is a concentrate for solution for infusion IV.
46106415|NCT03793478|Drug|Quizartinib|"Administered orally once daily starting on Day 6 and continuing through Day 28;~Optional low intensity consolidation with chemotherapy:~Administered orally once daily starting on Day 1 and continuing through Day 28"
46106416|NCT03793478|Drug|Fludarabine|30 mg/m^2/day IV infusion given over 30 minutes on Days 1 through 5 (administered based on body weight)
46106417|NCT03793478|Drug|Cytarabine|"2000 mg/m^2/day IV infusion given over 3 hours on Days 1 through 5 (begin 4 hours after the start of fludarabine) (administered in accordance with standard of care);~Optional high intensity consolidation with chemotherapy and quizartinib:~500 mg/m^2/day as a continuous 96-hour IV infusion on Days 1 through 4;~Optional low intensity consolidation with chemotherapy:~75 mg/m^2/day as once daily subcutaneous or IV on Days 1 through 4 and Days 15 through 18"
46106418|NCT03793478|Drug|Intrathecal (IT) triple chemotherapy prophylaxis|IT cytarabine, methotrexate, and either prednisolone or hydrocortisone; doses are based on the participant's age and standard practice at each site
46106419|NCT03793478|Drug|Etoposide|"Optional high intensity consolidation with chemotherapy and quizartinib:~100 mg/m^2/dose once daily as an IV infusion over 3 hours on Days 1 through 5"
46021345|NCT00983476|Behavioral|web-based MOVE! SMI|online sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
46021346|NCT00629200|Drug|Sodium Stibogluconate|400 mg/m^2 IV daily on days 1-5.
46021347|NCT00629200|Drug|Interferon Alpha-2b|3x10^6 units subcutaneously three times weekly
46106420|NCT03782623|Diagnostic Test|Analysis of eicosanoid profile prior to and after PRBC transfusion|Using liquid chromatography-mass spectrometry to analyze the eicosanoid profile in patient plasma and aliquoted of the PRBCs prior to and after PRBC transfusion.
46106421|NCT03763604|Drug|Abemaciclib|Administered orally.
46021348|NCT02867488|Other|Soybean oil in salad dressing|
46106422|NCT03749538|Other|Transcranial direct current stimulation session.|Patients with systemic autoimmune myopathies will receive or not acute transcranial direct current stimulation session.
46106423|NCT03711604|Drug|Tenalisib|BID Orally
46106424|NCT03708627|Drug|Bimatoprost Ophthalmic|Bimatoprost, aka Lumigan, one drop in one eye nightly
46106425|NCT03705416|Procedure|Endoscopy|endoscopic suturing of stomach
46106426|NCT03705416|Procedure|Surgery|Vertical sleeve gastrectomy (VSG) surgical reduction of stomach, or (RYGBP) , or gastric bypass procedure
46021349|NCT02867176|Drug|Gabapentin|The gabapentin (Neurontin, Pfizer, Mexico) group was instructed to take one 300-mg capsule the night before surgery and 1 capsule every 8 hours on the day of surgery and for the first 3 postoperative days.
46106427|NCT03702621|Drug|liposomal Bupivacaine|20 mL liposomal bupivacaine are injected into the liposomal bupivacaine group
46106428|NCT03702621|Drug|Bupivacaine Hydrochloride|"40 mL of 0.125% bupivacaine hydrochloride are injected into the liposomal bupivacaine group.~60mL of 0.25% bupivacaine hydrochloride are injected into the standard bupivacaine group"
46106429|NCT03691441|Procedure|Resection|Definitive surgery should generally be performed within 2 weeks, but not more than 4 weeks after randomization. The appropriately indicated neck dissection(s) may be performed either prior to, during the same session, or within 2 weeks after the resection of the primary tumor, but not later than 4 weeks following randomization. The primary tumor is to be resected with clear margins (R0) and en bloc in all cases. Frozen section assessment must be routinely and readily available.
46106430|NCT03691441|Radiation|Radiotherapy|6-7 weeks standard risk-adapted adjuvant radiotherapy 56-66 Gy, start within 6 weeks post-surgery Arm B: 6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization, 70-72 Gy, SIB possible
46021350|NCT02867176|Drug|Ketorolac|The ketorolac group (Dolac, Siegfried Rhein, Mexico) was instructed to take their 10-mg tablets every 8 hours on the day of surgery and for the first 3 postoperative days.
46106431|NCT03691441|Drug|Chemotherapy|The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU. According to local routine, chemotherapy protocols as listed in study protocol should be used.
46106432|NCT03691441|Procedure|Salvage neck dissection|+/- Salvage neck dissection 12±2 weeks after treatment
46021351|NCT02868034|Behavioral|SMT|"All patients receive 2 SMT sessions in the first week. The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort."
46106433|NCT03689387|Other|the Medical Program Information Systems (PMSI)|The selection of the files will be carried out using the Medical Program Information Systems (PMSI) and search convocations for post-stroke follow-up consultations conducted by the Secretariat of Neurological MPR Amiens University Hospital.
46106434|NCT03688295|Other|No antibiotics|Patients will not receive antiobitherapy post surgery for CAA
46106435|NCT03688295|Drug|Antibiotics|Patients will receive antiobitherapy post surgery for CAA
46106436|NCT03684876|Procedure|diuretic use|use of diuretic
46106437|NCT03677544|Other|laparoscopic approach with an extended pelvic lymph|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation
46106438|NCT03655665|Drug|Ofloxacin otic solution|Three drops of ofloxacin otic 0.3%. intra and post-operatively for 3 days post-surgery on one ear.
46106439|NCT03648606|Other|mesure of skin temperature|"The infants are placed in a closed incubator to study the variability of the heart and respiratory frequencies according to the regulation of the incubator and to quantify the time spent outside. Data will be collected during the first 10 days of life of the preterm infant. Skin temperatures at six body sites (the abdomen, pectoral region, eye, hand, thigh and foot) were measured (using infrared thermography) during nocturnal polysomnography in 29 9-day-old preterm neonates (postmenstrual age:~209 9 days). The investigators then determined whether the duration of the W episode depended upon the local skin temperatures measured at the start, during and end of the episode."
46106440|NCT03641690|Other|Empirical antimicrobial therapy|All patients with pulmonary symptoms received empirical antimicrobial therapy with ceftriaxone and rovamycin or levofloxacin on admission and this was subsequently adapted to any documented bacterial infection if positive.
46106441|NCT03633370|Other|Multifaceted intervention including 3 components|Multifaceted intervention including Dispatcher training to improve cardiac phone recognition, mobile application to send bystanders on cardiac arrest location before first professionals rescuers and motivational support for volunteer bystanders
46021352|NCT02868034|Behavioral|Mobilizing Exercises|Mobilizing exercises will include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
46106442|NCT03625752|Device|Active Comparator: Active tDCS + Active TUS|Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes. Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
46021353|NCT02868034|Behavioral|Activation Exercises|Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
46106443|NCT03625752|Device|Sham|Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes. Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
46106444|NCT03607838|Drug|SI-6603|SI-6603 will be injected into an intervertebral disc.
46106445|NCT03607838|Drug|Sham injection|The injection will be performed without needle placement into an intervertebral disc.
46021354|NCT02868034|Behavioral|SMT extended|This treatment involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
46106446|NCT03604627|Other|Coronal calcium score measurement|"A medical interview with clinical examination by a cardiologist for screening cardiovascular risk factors, including smoking, and looking for symptoms of heart disease as part of routine care.~In accordance with routine care, a fasting and fasting blood test will be performed performed on exam day at Bichat Hospital or at another time, close to the patient's home according to his availability. The biological blood test will include the measurement of plasma triglyceride concentrations, total cholesterol and its HDL and LDL fractions, blood glucose, glycated hemoglobin and serum creatinine with estimated glomerular filtration rate according to the CKD-EPI formula. Sample urinalysis will include measurement of creatinine, proteinuria, and microalbuminuria.~An electrocardiogram (ECG) rest, a cardiac ultrasound, a test and respiratory function tests (EFR) will be performed as part of routine care. Coronal calcium score measurement will be performed as part of the research."
46106447|NCT03600701|Drug|Atezolizumab|Given IV
46106448|NCT03600701|Procedure|Biopsy|Undergo biopsy
46021355|NCT00982228|Drug|insulin degludec|Injected subcutaneously once daily. Dose was individually adjusted.
46021356|NCT00982228|Drug|insulin glargine|Injected subcutaneously once daily. Dose individually adjusted.
46021357|NCT00982228|Drug|insulin aspart|Injected subcutaneously as mealtime insulin. Dose was individually adjusted.
46021358|NCT02867956|Drug|Apatinib|Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.
46106449|NCT03600701|Procedure|Biospecimen Collection|Undergo collection of blood
46106450|NCT03600701|Drug|Cobimetinib|Given PO
46106451|NCT03600701|Procedure|Computed Tomography|Undergo CT scan
46106452|NCT03600701|Procedure|Magnetic Resonance Imaging|Undergo MRI
46021359|NCT02867956|Drug|Etoposide|Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles
46021360|NCT04290832|Behavioral|CO Intervention|"South Africa: Values clarification and attitude transformation (VCAT) workshop with conscientious objection content, debrief session(s) with termination of pregnancy (TOP) providers to give them an opportunity to share concerns/challenges, meeting(s) with facility mangers to facilitate continued support and provision of TOP care~Mexico: Training on abortion and conscientious objection law, posters on law, offer of legal assistance for abortion providers, scholarship to attend conference awarded on basis of quality of abortion care"
46021361|NCT04291066|Drug|N-Acetyl cysteine|Carbonyl scavenger and multi-vitamins with minerals to neutralize reactive carbonyl groups on the lipid aldehydes in patients with TBI
46021362|NCT04290910|Behavioral|Weight Loss Program|There are three components of the intervention, this includes: psychology, nutrition, and physical activity. For the psychological portion, a therapist will assess the participant at baseline to determine if there are barriers associated with making lifestyle changes. For nutrition, the dietitian will assess the participant and create a meal plan based on their nutritional needs and guide the participant to reaching their nutritional goals. The psychological and nutrition portion may be interchangeable depending on the participants needs. For physical activity, the personal trainer will assess the participant and create an exercise plan that consists of resistance training and weight bearing exercises suitable for the participant while also guiding the participant to reach their exercise goals.
45468497|NCT04825821|Procedure|Clinical and ultrasonographic assessment|Routinely assessment by objective examination and transvaginal ultrasonographic scan 6, 12, and 24 months after the surgical procedures
46021363|NCT01260350|Drug|SOF|Sofosbuvir (SOF) tablets administered orally once daily
46106453|NCT03593317|Drug|Spironolactone|The doses used in the study are the doses used in standard clinical practice. Initial dose is 25 mg/day until study end . The duration of treatment for each patient is 12 months.
46106454|NCT03593317|Drug|Placebo|Placebo will be taken once a day at the same time of day. The duration of treatment for each patient is 12 months.
46106455|NCT03577990|Behavioral|Interactive Technology Enhanced Coaching (ITEC)|As participants wear the activity tracker, take their BP and weight, along with input of food intake and medication-taking, data is transmitted in real time via Bluetooth Smart technology to the Fitbit Plus dashboard. All data is tracked, analyzed, and transparently displayed for participants to view and better understand their condition, and actively engage in self-care. Staff monitor data and communicate with participants to encourage active engagement in action plans by sending tailored coaching messages (ITEC) via the Fitbit Plus dashboard to the treatment arm weekly for 3 months, and biweekly for 3 months to motivate and support (BP control, medication adherence, and lifestyle modifications). After 6 months, the treatment arm will be monitored an additional 3 months with no tailored coaching for sustainability.
46106456|NCT03577990|Behavioral|Interactive Technology-No Coaching (IT)|After receiving usual care for 3 months, the control arm will receive the same electronic monitoring as the treatment arm and data will be captured in the same manner with the Fitbit Plus dashboard. Participants will be expected to use the information from the dashboard and the CDSMP workshop as a guide to self-care without coaching (IT). Staff will only monitor data. Control participants will not be contacted between repeated measures data collection periods, except to send reminders if they are not participating daily.
46106457|NCT03565497|Behavioral|Wellness Education Control Condition|As per arm of the same name
46106458|NCT03565497|Behavioral|Mindfulness Training|As per arm of the same name
46106459|NCT03565497|Behavioral|Mindfulness Training Plus IE|As per arm of the same name
46106460|NCT03531814|Behavioral|Medication Event Monitoring System (MEMS)|A computerized method of tracking the dates and times of a pill bottle being opened.
46106461|NCT03522688|Drug|Dexmedetomidine|The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour.
46021364|NCT01260350|Drug|RBV|Ribavirin (RBV) capsules administered orally in a divided daily dose
46106462|NCT03522688|Drug|Normal saline|The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
46106463|NCT03519581|Device|Micropulse Laser Treatment|Participant's study eye will be dilated prior to being comfortably seated at the slit lamp for treatment. Application of micropulse laser on retinal surface will occur using TxCell Scanning Delivery System in a 7 x 7 grid to surround the fovea.
46106464|NCT03519581|Device|Sham Treatment|Participant's study eye will be dilated prior to being comfortably seated at the slit lamp for treatment. No actual laser treatment will occur.
46106465|NCT03516656|Drug|Standard heparin dose|Patients will be placed on heparin infusions per their surgeon's discretion.
46106466|NCT03516656|Drug|Real time heparin dose adjustment|Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
46106467|NCT03515603|Procedure|Endoscopic resection|Transsphenoidal endoscopic resection of pituitary adenoma
45468498|NCT03431662|Procedure|Ellipse IM HTO Nail|A CT scan will be performed at 3 and 6 months postoperatively to assess the healing of the osteotomy site. Endpoint is 6 months.
45468499|NCT03431662|Procedure|TomoFix|A CT scan will be performed at 3 and 6 months postoperatively to assess the healing of the osteotomy site. Endpoint is 6 months.
45468500|NCT03431506|Behavioral|Vestibular rehabilitation|Vestibular Rehabilitation Exercises
45468501|NCT03431428|Procedure|transanal surgery|Transanal surgery could Preserve anus to reduce trauma and improve the quality of life
46106468|NCT03515603|Procedure|Microsurgical resection|Transsphenoidal microsurgical resection of pituitary adenoma
46021365|NCT01260350|Drug|PEG|Peginterferon alfa-2a (PEG) administered via subcutaneous injection once weekly
46106469|NCT03506308|Device|LUTONIX 035 Drug Coated Balloon PTA Catheter|All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
46106470|NCT03494127|Device|Use of GEL BALL FITTED MODULAR CUSHION|DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks
46106471|NCT03494127|Device|Use of SQUISHINS FITTED MODULAR CUSHION|DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks
46106472|NCT03479905|Other|Salter nasal cannula|Oxygen will be delivered by using standard nasal cannula
46106473|NCT03479905|Other|Face mask|Oxygen will be delivered via face mask during colonoscopy
46106474|NCT03479905|Device|High Flow Nasal Cannula|A high flow nasal cannula will be placed on the patient at a setting of FiO2 100% and titrated up to 60L/min depending on patient tolerance. 60 L/min is the max flow rate and will be used as tolerated for maximum benefit.
46106475|NCT03479268|Drug|Ibrutinib|Given PO
46106476|NCT03479268|Other|Laboratory Biomarker Analysis|Correlative studies
46106477|NCT03479268|Drug|Pevonedistat|Given IV
46106478|NCT03479268|Other|Pharmacokinetic Study|Correlative studies
46106479|NCT03479268|Other|Pharmacological Study|Correlative studies
46106480|NCT03478462|Drug|CLR 131|IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose
46106481|NCT03476226|Other|Cognitive Dysfunction Coping Strategy Teaching Sheet|Demographic sheet, Fact-Cog3, and teaching tool at baseline then week 4 and 8 Fact Cog3 and reinforcement of tool, at week 16 evaluation and Fact-Cog3
46106482|NCT03459092|Drug|Botulinum toxin type A|Botulinum toxin injection in the horizontal extraocular muscles.
46106483|NCT03459092|Procedure|Strabismus surgery|Strabismus surgery on the horizontal extraocular muscles
46106484|NCT03458884|Other|Cardiorespiratory interval training|A structured cardiorespiratory interval training program on an ergometer cycle 3 days a week for 8 weeks.
46106485|NCT03441165|Procedure|ligament reconstruction and meniscus transplantation|ACL reconstruction ACL revision MAT
46106486|NCT03437421|Dietary Supplement|Vitamin D3 (cholecalciferol)|"Patients with 29≤ 25-OH-D3 ≥20 ng/mL will receive 200 000 UI orally the first month (100 000 UI at T0 + 100 000 UI at T0+15 days, UVEDOSE™ Laboratoires Crinex, Montrouge, France) followed for the last 2 months by one daily dose (5 drops orally = 1 000 UI/day, DÉDROGYL™ , DB Pharma, La Varenne-Saint-Hilaire, France).~Patients with : 19≤ 25-OH-D3 ≥10 ng/mL will receive orally 300 000 UI (100 000 UI at T0 + 100 000 UI at T0+23days + 100 000 UI at T0+45days; UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™ ).~Patients with : 25-OH-D3 <10 ng/mL will receive orally 400 000 UI (100 000 UI at T0 + 100 000 UI at T0+15days + 100 000 UI at T0+30 days + 100 000 UI at T0+45days, UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™)."
46106487|NCT03432481|Procedure|Unicompartmental Knee Arthroplasty Surgery|Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)
46106488|NCT03432481|Device|Bodycad Unicompartmental Knee System (BUKS)|Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)
45468502|NCT03431428|Procedure|Miles surgery|Miles surgery cut off the anus, enlarge the trauma and reduce the quality of life.
45468503|NCT03431428|Drug|Preoperative chemoradiotherapy|After preoperative radiochemotherapy, two cycles of XELOX were given at the interval of waiting operation.
45468504|NCT04501055|Behavioral|perineal nerve block|An anesthesia method to block perineal nerve
45468505|NCT04501055|Behavioral|periprostatic block|An anesthesia method to block periprostate
45468506|NCT03431272|Drug|Lifitegrast|Eye drop
46021366|NCT01260350|Drug|LDV|Ledipasvir (LDV) tablets administered orally once daily
46021367|NCT01260350|Drug|GS-9669|GS-9669 tablets administered orally once daily
46021368|NCT01260350|Drug|LDV/SOF|LDV/SOF fixed-dose combination (FDC) tablet administered once daily
46106489|NCT03416270|Drug|Ertugliflozin|Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) once daily for 12 weeks
46106490|NCT03416270|Drug|Placebo|Placebo once daily for 12 weeks
46106491|NCT03414034|Drug|Onvansertib|Onvansertib orally
46106492|NCT03414034|Drug|Abiraterone|Abiraterone orally
46106493|NCT03414034|Drug|Prednisone|Prednisone orally
46106494|NCT03379168|Device|Microfragmented Adipose Tissue (Lipogems)|Lipogems is a technique to harvest, process, and inject minimally manipulated adipose tissue. This procedure is enzyme free and requires no clonal expansion or manipulation. Lipoaspirate is harvested most commonly from the abdomen and washed in saline solution, then processed through a closed-system device that micro-fragments the adipose tissue. This mechanical process retains the vascular architecture, mature pericytes, and MSCs for autologous injection. Lipogems is currently FDA-approved for orthopedic and arthroscopic procedures; thus, this would be an on-label use for knee injections.
46106495|NCT03379168|Drug|Corticosteroid injection|Cortisone is a standard of care injection to reduce joint inflammation.
46106496|NCT03379168|Drug|Saline|Sterile saline injection will act as a placebo group.
46106497|NCT03362931|Device|XEN45|XEN45 unilaterally implanted in the study eye
46106498|NCT03361436|Drug|Eribulin Mesylate|Given IV
46106499|NCT03361436|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
46106500|NCT03361436|Other|Laboratory Biomarker Analysis|Correlative studies
46106501|NCT03361436|Other|Quality-of-Life Assessment|Ancillary studies
46106502|NCT03361436|Other|Questionnaire Administration|Ancillary studies
46106503|NCT03361436|Procedure|Therapeutic Conventional Surgery|Undergo surgery
46106504|NCT03360019|Device|Activlink insole|Dementia patients will wear the provided insole inserted into their own shoes. The insole will have a small electronic sensor that measures acceleration, foot force, and/or orientation.
46021369|NCT04150120|Device|e-health device with application|In this project we focus on eHealth solutions for patients and/or their families in situations where they could benefit from enhanced communication options with specialist staff. In this design space we use a model where a 4G-enabled tablet computer is lent to the families for the length of the study, thus avoiding economic requirements on the families and keeping the equipment uniform. The tablets run an application that enables multiple forms of direct and bi-directional communication in real-time with specialist staff at the hospital. For the staff, the technical situation is different; here we have in earlier demonstrators used web-based solutions accessed with existing computer equipment.
46021370|NCT04291378|Radiation|Proton versus photon radiation therapy|The intervention is proton radiation therapy versus photon radiation therapy
46106505|NCT03360019|Other|Activlink Phone Application|Smartphone tool used for monitoring location
46106506|NCT03284866|Other|Laboratory Biomarker Analysis|Correlative studies
46021371|NCT04273828|Procedure|Lumbar decompressive surgery|Patients with lumbar degenerative diseases and symptoms of nerve compression (radiculopathy or neurogenic claudication) who will undergo surgical treatment for neural decompression (discectomy, foraminotomy or laminectomy).
46106507|NCT03284866|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
46106508|NCT03284866|Other|Saline|Given IM
46106509|NCT03282097|Behavioral|DECAD decision aid|A mammography decision aid that will help caregivers of patients with Alzheimer's make decisions about stopping or continuing breast cancer screening.
46106510|NCT03282097|Other|Home safety guide|The home safety guide provides tips about important actions older adults can take to prevent falls, poisoning, and bathroom hazards and protection against abuse, fire and other related hazards.
46106511|NCT03281564|Other|Quality of life after Essure® removal|Questionnaire to assess the quality of life 1, 3, 6 and 12 months after laparoscopic removal of Essure® device
46106512|NCT03260894|Drug|Pembrolizumab|Pembrolizumab 200 mg administered intravenously every 3 weeks.
46106513|NCT03260894|Drug|Epacadostat|Epacadostat 100 mg administered orally twice daily.
46106514|NCT03260894|Drug|Sunitinib|Sunitinib 50 mg administered orally once daily; 4 weeks on, 2 weeks off for 6-wk cycle.
45468507|NCT03773497|Other|Common Snack Combination|Combination of Chips, Pretzels, and Popcorn.
45468508|NCT03773497|Other|Cheesy Broccoli Snack|Oven-roasted, freeze-dried, cheese flavored broccoli
46106515|NCT03260894|Drug|Pazopanib|Pazopanib 800 mg administered orally once daily.
46106516|NCT03245008|Drug|MT-5547|Solution for injection in pre-filled syringe
46106517|NCT03245008|Drug|MT-5547-matching placebo|Solution for injection in pre-filled syringe
46106518|NCT03220893|Procedure|Digital Tomosynthesis Mammography|Undergo DBT
45468509|NCT03773497|Other|Cheesy Broccoli with Daikon Radish Snack|Oven-roasted, freeze-dried, cheese flavored broccoli with Daikon radish powder
46106519|NCT03220893|Radiation|Scintimammography|Undergo MBI
46106520|NCT03203473|Drug|Ipilimumab|YERVOY is thought to work with the body's immune system to increase the activity of T cells and cause the body to attack cancer cells
46106521|NCT03203473|Drug|Nivolumab|Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs
46106522|NCT03201094|Device|Neuromuscular Electrical Stimulation (NMES)|Neuromuscular electrical stimulation twice daily during study period.
46106523|NCT03201094|Dietary Supplement|High Protein Supplementation|High protein supplementation with whey protein shakes taken three times a day during study period.
46106524|NCT03191786|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered via IV infusion once every three weeks (QW3).
46106525|NCT03191786|Drug|Vinorelbine|Vinorelbine will be administered per relevant local guidelines and Summary of Product Characteristics (SmPC) management.
46106526|NCT03191786|Drug|Gemcitabine|Gemcitabine will be administered per relevant local guidelines and SmPC management.
46106527|NCT03185208|Drug|Lithium Carbonate|See lithium carbonate arm
46106528|NCT03185208|Drug|Placebo oral capsule|See placebo arm
46106529|NCT03158051|Behavioral|Home Blood Pressure Monitoring|Intervention arm participants will receive a home blood pressure monitor, home blood pressure log, and training on accurate home monitoring. They will be asked to share their home blood pressure readings during health coach telephone calls.
46106530|NCT03158051|Behavioral|Telephone Health Coaching|Intervention arm participants will receive a health coach phone call every 2 weeks for 6 months, for a total of 12 calls. During each call, the health coach will review and discuss home blood pressures and address barriers and concerns to hypertension management. During each telephone call, the coach will guide the participant on selecting health behavior goals. Intervention arm participants will also receive handouts about hypertension management during the study visits and after health coach calls.
46021372|NCT01260194|Drug|trastuzumab [Herceptin]|Loading dose of 8 mg/kg on day 1, followed by 6 mg/kg intravenous infusion every 3 weeks until disease progression in combination with standard chemotherapy
46021373|NCT00629278|Biological|trastuzumab|
46021374|NCT00629278|Drug|aromatase inhibition therapy|
46106531|NCT03142568|Drug|Sildenafil|Infants will be randomized using a 3:1 scheme to receive sildenafil or placebo.
46106532|NCT03142568|Other|Placebo|Infants randomized to the placebo group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
46106533|NCT03140644|Other|Patients with thoracic sarcoidosis|Ultra-low dose CT scan and MRI with UTE
46106534|NCT03132831|Other|Determine the DMS of the Total Hip Prosthesis of the University Hospital of Amiens (PTH) and the Total Knee Prosthesis (PTG)|To determine the DMS of the orthopedic department of the Amiens University Hospital after Total Hip Prosthesis (PTH) and First-line Total Knee Prosthesis (PTG) with its confidence interval and to compare it according to the patient's day of operation
46106535|NCT03117179|Other|Discharge from patient after consultation in emergency department|Discharge from patient after consultation in emergency department
46106536|NCT03115567|Drug|Triamcinolone|6 weeks of twice daily application of 0.1% triamcinolone cream to the face, chest, and back.
46106537|NCT03114930|Other|"To study the absence of increased complications and events occurring in the mother-newborn"|"To study the absence of increased complications and events occurring in the mother-newborn couple who made a standard exit compared to the mother-newborn couples who had benefited from an extra day of  Hospitalization in maternity."
46106538|NCT03103698|Device|To demonstrate the monitoring of perioperative analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
46106539|NCT03103698|Other|Standard preoperative evaluation of analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
46106540|NCT03092180|Drug|Intravenous Infusion|Intravenous infusion of follow medicine at disease onset: methyprednisolone and/or human intravenous immunoglobulin
46106541|NCT03077386|Behavioral|ENCOMPASS Intervention|Patients will be matched to a CHN who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (i.e., social, financial, insurance), helping patients set health related goals, liaising with a patient's employer, facilitating health care referrals and appointments, monitoring appointments, and facilitating transportation to appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in person or over the telephone using motivational interviewing principles
46106542|NCT03051659|Drug|Eribulin Mesylate|Eribulin mesylate is developed from a natural substance found in a sea sponge. Eribulin mesylate works by preventing cancer cells from multiplying
46021375|NCT00629278|Drug|cyclophosphamide|
46021376|NCT00629278|Drug|docetaxel|
46021377|NCT00629278|Drug|doxorubicin hydrochloride|
46021378|NCT00629278|Drug|epirubicin hydrochloride|
46021379|NCT00629278|Drug|fluorouracil|
46021380|NCT00629278|Drug|paclitaxel|
46021381|NCT00629278|Drug|releasing hormone agonist therapy|
46021382|NCT00629278|Drug|tamoxifen citrate|
46021383|NCT00629278|Procedure|adjuvant therapy|
46021384|NCT00629278|Radiation|radiation therapy|
46021385|NCT04126798|Other|Behavioural|Assessment of the 2BALANCE protocol: dual-task protocol consisting of a motor task, cognitive task, and motor-cognitive dual-tasks
46021386|NCT04320758|Other|conventional preparation design|chamfer finish line
46021387|NCT04320758|Other|biologically oriented preparation technique|shoulder less preparation design
46021388|NCT04207112|Drug|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
46021389|NCT04207112|Drug|Pretomanid|Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
46021390|NCT04207112|Drug|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
46021391|NCT04207112|Drug|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
46021392|NCT04207112|Drug|Clofazimine|Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
46021393|NCT04207112|Drug|Standard Drugs|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
46021394|NCT01259726|Biological|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for seven days
46021395|NCT01259726|Biological|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for 7 days
46021396|NCT01259726|Other|Placebo|10 mL placebo once daily for 14 days
46021397|NCT01259726|Biological|VP20621|VP20621 as oral liquid once daily for 14 days
46021398|NCT05527730|Device|Comparison of PRO-FIT or SELF-FIT fitting|add
46106543|NCT03051659|Drug|Pembrolizumab|Pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells.
46021399|NCT01259492|Drug|Placebo|Placebo Comparator: Placebo
46021400|NCT01259492|Drug|Ritalin LA 20 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.
46021401|NCT01259492|Drug|Ritalin LA 30 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 60, or 80 mg.
46106544|NCT03011528|Drug|VDC-IE x2|"Week 1, 5, 9 and week 13:~Vincristine, IV, D1, 1.5mg/m²~Doxorubicine, IV, D1-D2, 37.5mg/m²~Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, 7, 11 and week 15:~Ifosfamide, IV, D15 to D19, 1.8g/m²/d~Etoposide, IV, D15 to D19, 100mg/m²/d"
46106545|NCT03011528|Drug|VDC-IE|"Week 1 and week 5:~Vincristine, IV, D1, 1.5mg/m²~Doxorubicine, IV, D1-D2, 37.5mg/m²~Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, and week 7:~Ifosfamide, IV, D15 to D19, 1.8g/m²/d~Etoposide, IV, D15 to D19, 100mg/m²/d"
46106546|NCT03011528|Drug|TEMIRI|"Week 9, 12, 15 and week 18:~Temozolomide, PO, D1 to D5, 150mg/m²/d~Irinotecan, IV, D1 to D5, 50mg/m²/d"
46021402|NCT04320446|Behavioral|Test in the morning|The exercise test was performed between 8 a.m and 11 a.m
46021403|NCT04320446|Behavioral|Test in the afternoon|The exercise test was performed between 5 p.m. and 8 p.m.a
46106547|NCT03011528|Drug|Consolidation BuMel|"After induction phase and local treatment (surgery and/or radiotherapy) and before PBSC:~Busulfan, IV, D-5 to D-2, dosa according to the weight~Melphalan, IV, D-1, 140 mg/m²~Peripheral Blood Stem Cell infusion:~- PBSC infusion, D0, at least 3.10^6 CD34/kg"
46106548|NCT03011528|Drug|Maintenance|"* 1st year : VC~Vinblastine, IV, 3mg/m², once a week (except during radiotherapy: 1mg/m², 3 times a week)~Cyclophosphamide, PO, 25mg/m² continuously"
46106549|NCT03011528|Procedure|Local treatment by surgery|Surgical excision of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy. Radiotherapy can be added
46106550|NCT03011528|Radiation|Local treatment by radiotherapy|Radiotherapy of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy
46021404|NCT05568524|Other|BFRT|Low-load (30% 1RM) resistance exercise with blood flow restriction
46106551|NCT02982902|Biological|CMV specific adoptive t-cells|It is expected that the cell dose will be in the range of 10^3 - 10^5 virus - specific, antigen selected T cells per kg of recipient weight.
46106552|NCT02976636|Behavioral|Family-based behavioral therapy|Traditional family-based, group-based behavioral therapy for weight loss. Parent and child groups will be held separately. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
46021405|NCT05568524|Other|Control|Moderate-to-high load (60%-80% 1RM) resistance exercise
46021406|NCT05560958|Device|BIOTRONIK EP catheters (AlCath, MultiCath, ViaCath), external devices (Qubic RF, Qubic Stim, Qiona) and transseptal sheaths (Senovo bi-flex)|Ablations and diagnostic catheters are indicated for temporary transvenous application in patients with cardiac arrhythmias during electrophysiology study (EPS) or catheter ablation interventions. They will be used in combination with external devices like RF generators, external pacemakers cardiac stimulators and / or irrigation pumps.
45468510|NCT03773497|Other|Uncooked Broccoli Snack|Uncooked, freeze-dried broccoli with ranch-type dip
45468511|NCT02528513|Drug|midazolam|Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to RASS score (-3 to 0).
46021407|NCT00624026|Drug|Memantine-HCl|20 mg per day (once daily)
46021408|NCT05513378|Device|Needle guide|Please see the arm/group description
46106553|NCT02976636|Behavioral|Parenting training|Parenting skills training for parents. Parent and child groups will be held separately and only parents will receive this training. Children will not receive any additional materials. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
46021409|NCT05512910|Drug|Minocycline|200 mg minocycline orally or via nasogastric tube prior to successful reperfusion, followed by 100 mg every 12 hours times for a total of 5 days. If vomiting occurs within half an hour of the first dose, the clinician should assess the necessary of re-administering 100mg based on the severity of vomiting.
46021410|NCT02888990|Drug|Dasatinib|
46021411|NCT05479994|Drug|BGB-11417|Administered orally
46106554|NCT02971761|Drug|Enobosarm|Given PO
46106555|NCT02971761|Other|Laboratory Biomarker Analysis|Correlative studies
46106556|NCT02971761|Biological|Pembrolizumab|Given IV
46106557|NCT02964559|Biological|Pembrolizumab|Given IV
46106558|NCT02944058|Procedure|Multiloc nail|Intervention is surgery with Multiloc nail
46106559|NCT02944058|Procedure|Philos plate|Intervention is surgery with Philos plate
46106560|NCT02898818|Other|vaginal and oral swab sample, questionnaire|vaginal and oral swab sample and questionnaire
46106561|NCT02898818|Other|papa smear|Papnicolaou Papa Smear test
46106562|NCT02893293|Drug|Ferumoxytol-enhanced magnetic resonance imaging|Eligible patients receive a single ferumoxytol-dose and follow-up magnetic resonance imaging to evaluate success of stem cell transplant
46021412|NCT05476016|Device|Near-infrared (NIR)|NIR spectral assessment of glycated nail keratin vs HbA1c
46021413|NCT05463302|Device|Active sleepgift blanket|Participants for group1 will be provided with real/active sleepgift blanket first for 10 consecutive nights and then cross over.
46021414|NCT05463302|Device|Sham Sleepgift Blanket|Participants for group 2 will be provided with sham sleepgift blanket for 10 consecutive nights and then cross over.
46021415|NCT00624104|Dietary Supplement|Food (fat free meal)|Fat free meal (40% of REE)
46021416|NCT05295758|Behavioral|PAL2|"Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education~Other Names:~Pragmatic personalized, adaptable approach to lifestyle and life circumstance"
46021417|NCT02889068|Other|Blood sample|
46021418|NCT05280158|Drug|mRNA-1273 (Moderna COVID-19 vaccine)|Study Drug will be administered via intramuscular injection (IM). Only one dose of study drug will be administered for the study.
45838226|NCT04278560|Behavioral|Behavioral intervention to increase physical activity|Study staff will complete face-to-face and telephone counseling sessions with each participant, tailored to their state of readiness to increase physical activity levels. The participant will be provided with a goal to increase their average daily step count by 20% from baseline. The staff member will review the participant's stated barriers to exercise and provide them with a list of strategies they may use to augment their step counts throughout each day. Bi-weekly face-to-face counseling sessions will then be completed to review and discuss activity performance and answer any questions the participant may have regarding their efforts to increase physical activity.
46021419|NCT05273450|Behavioral|Quitline Information with Reinforcement|The intervention arm involves direct referral to the Ohio Tobacco Quitline, with up to two brief follow-up telephone calls from the research team to elicit motivation to quit, emphasize benefits of calling the quitline, encourage use and address concerns. Participants are surveyed at baseline and at 3-month follow-up to assess awareness and use of the quitline.
46021420|NCT05252078|Drug|Anlotinib hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
46021421|NCT05252078|Drug|TQB2450|TQB2450 is an injection in the form of 600 mg; 1200 mg, iv, D1.
46021422|NCT05118386|Drug|RSM01|"Cohort 1: RSM01 300 mg IV~Cohort 2: RSM01 300 mg IM~Cohort 3: RSM01 1000 mg IV~Cohort 4: RSM01 3000 mg IV~Cohort 5: RSM01 ≥ 300 mg - ≤ 600 mg IM"
46106563|NCT02893293|Device|Magentic Resonance Imaging|Both arms will receive MRI
46106564|NCT02860000|Drug|Alisertib|Given PO
46106565|NCT02860000|Drug|Fulvestrant|Given IM
46021423|NCT05118386|Other|Placebo|"Cohort 1: Placebo IV~Cohort 2: Placebo IM~Cohort 3: Placebo IV~Cohort 4: Placebo IV~Cohort 5: Placebo IM"
46106566|NCT02860000|Other|Laboratory Biomarker Analysis|Correlative studies
46021424|NCT05101928|Drug|Ozurdex 0.7mg Ophthalmic Implant|A 0.7mg intravitreal dexamethasone implant will be used for the treatment of posterior, intermediate and panuveitis for minimum of 6 months.
46021425|NCT05101928|Drug|Prednisone|The comparator will be a prednisone taper which is currently the standard care for the uveitis types of focus.
46021426|NCT05069714|Drug|MTX-hold|Temporary discontinuation of methotrexate for 1 or 2 weeks
46021427|NCT05051540|Device|Sigvaris Compreflex Inelastic Compression Wrap|Compreflex compression system using wraps to apply compression of 30-40 mmHg.
46021428|NCT05049512|Other|Multi-nut OIT|Finely ground pure peanut, almond, cashew, hazelnut, and walnut.
46021429|NCT05048966|Behavioral|Group Wellness Class 1|Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours.
46106567|NCT02805023|Biological|BGC101 (autologous EnEPC preparation)|Intramuscular injections - single treatment session
46106568|NCT02805023|Biological|Control medium|Intramuscular injections - single treatment session
46106569|NCT02770859|Procedure|POEM (Per Oral Endoscopic Myotomy)|Per-Oral endoscopic myotomy (creating a muscle [esophagus] opening), an incision-less (no cutting of the surface of the body) endoscopic procedure, is an effective non-surgical alternative to release the muscle & sphincter of the LES for the treatment of achalasia
46106570|NCT02725905|Behavioral|Multi-Modal Education (MME)|"The MME curriculum focuses on developing weight management counseling (WMC) skills through several components: 1) a web course focused on WMC knowledge and clinical skill competencies; 2) WMC role-play exercises for an opportunity to use an algorithm to practice patient-centered WMC; 3) personal weight management exercises to increase awareness of Assist activities (e.g. daily food monitoring using mobile apps, etc); 4) obesity bias assessments, video, and discussions to modify attitudes of implicit weight bias; 5) a formative web-based encounter to interact with and receive feedback from a standardized patient; and 6) an enhanced clerkship rotation focusing on providing learning to preceptors and allowing students to observe preceptors counseling patients who are overweight or obese."
46021430|NCT05048966|Behavioral|Group Wellness Class 2|Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours.
46106571|NCT02725905|Behavioral|Traditional Education (TE)|Current curriculum may consist of topics related to biology, population health, or counseling skills. TE also may include sporadic stand-alone lectures or small group discussions conducted separately or as a part of a patient interviewing or behavioral course.
46106572|NCT02724878|Drug|Bevacizumab|
46106573|NCT02724878|Drug|Atezolizumab|
46106574|NCT02691923|Drug|Fluorescein|
46106575|NCT02691923|Drug|Fluorescein + ALA|
46106576|NCT02672475|Drug|Galunisertib|Given PO
46106577|NCT02672475|Other|Laboratory Biomarker Analysis|Correlative studies
46106578|NCT02672475|Drug|Paclitaxel|Given IV
46021431|NCT04207034|Procedure|flap surgery with diode laser|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1: 80,000 epinephrine) , Laser application will be carried out , with the help of 810 nm (A.R.C LASER FoxTM) diode laser with a flexible optic tip of 300µm . The sulci will be lased with a repeated beam ( 0.2 sec on 0.3 sec off) at an output power of 1.0 W.~Intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure."
46021432|NCT04207034|Procedure|flap surgery|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1:80,000 epinephrine) ,intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure"
46106579|NCT02601950|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
46106580|NCT02600507|Drug|Lumateperone (ITI-007)|
46106581|NCT02600507|Drug|Placebo|
46106582|NCT02578680|Biological|Pembrolizumab 200 mg|IV infusion
46106583|NCT02578680|Drug|Cisplatin|IV infusion
46106584|NCT02578680|Drug|Carboplatin|IV infusion
46106585|NCT02578680|Drug|Pemetrexed|IV infusion
46106586|NCT02578680|Dietary Supplement|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
46106587|NCT02578680|Dietary Supplement|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
46106588|NCT02578680|Drug|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
46106589|NCT02578680|Drug|Saline solution|IV infusion
46106590|NCT02464072|Procedure|Subtotal Parathyroidectomy|Subtotal parathyroid resection leaving the estimated mass of two normal parathyroid glands in situ. The type of operation is the intervention. No new device or drug is involved.
45681277|NCT03022942|Other|GROUP Costal mobilization & Diaphragm Release|Costal mobilization technique (Rib raising): The patient will be lying. The Therapist supports the last four pulps of both hands at the rib angles, gently traverses the rib angles in the posterior-anterior direction, using the stretcher as a lever to facilitate the elevation of the costal angles. Siting: The Therapist hugs the patient by supporting the ribs of the fingers at the rib angles, gently traverses the rib angles bilaterally in the anterior-lateral direction. Manual Diaphragm Release Technique: The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
46106591|NCT02464072|Procedure|Total Parathyroidectomy + 45 autografts|Immediate autograft of 45 fragments of parathyroid tissue, after a total parathyroidectomy.This type of operation is the standard intervention at the institution at the moment. No new device or drug is involved.
46106592|NCT02464072|Procedure|Total Parathyroidectomy + 90 autografts|Immediate autograft of 90 fragments of parathyroid tissue, after a total parathyroidectomy.The type of operation is the intervention. No new device or drug is involved.
46106593|NCT02459171|Other|Questionnaire|Once at enrollment, subjects will complete an enrollment question to capture poultry exposure and other demographic information. Information will be updated if needed at annual follow-up and at final visits.
46106594|NCT02459171|Other|Blood sample|"Participants will have a 3-mo blood sample drawn for serological testing at enrollment, and at annual follow-up and final visits.~For subjects who test positive for influenza A by rapid test or PCR (index case) on nasal swab at the biweekly or weekly visits, two 3-ml blood samples will be obtained from the index case on day 1 for serological testing for antibodies against avian influenza viruses and for isolating and studying PBMCs. Blood samples will also be obtained on day 1 from all household contacts of the index case. Additional 3-ml blood samples will be obtained on day 14 for serology and PBMCs."
46106595|NCT02459171|Other|Nasal wash|Nasal washes will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Nasal washes will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
46106596|NCT02459171|Other|Throat swab|Throat swabs will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Throat swabs will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
46106597|NCT02454907|Other|Communication with the clinic|Over the course of the study, subjects will receive brief periodic communications on their cellular phone from the doctor's office.
46106598|NCT02385266|Drug|D-Cycloserine|Pharmaceutical intervention aimed at altering central nervous system function takes place over 4.5 months with daily use of d-Cycloserine.
46021433|NCT02888912|Other|EQUIA|Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
45838227|NCT04263194|Device|rTMS|25 min of high frequency (20 Hz) repetitive TMS applied at 100% of resting motor threshold (rMT).
46021434|NCT02888912|Other|Gradia Direct Posterior|The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
46021435|NCT04320524|Device|Technology-Assisted Respimat Adherence Digital Behaviour Change Intervention|3 weeks
46021436|NCT04839380|Drug|ruxolitinib cream|ruxolitinib cream 1.5% will be applied twice daily as a thin film
46106599|NCT02385266|Drug|Placebo (for D-cycloserine)|Lactose filled capsules to mimic DCS 200mg capsules
46106600|NCT02379988|Radiation|Verify radiation dose to heart and lung|This is a pilot study to determine whether the addition of inspiratory hold (breath holding) can decrease the radiation dose that the heart and lung receives for patients being treated for left sided breast cancer.
46106601|NCT02351765|Drug|Acelarin|First-in-class nucleotide analogue
46106602|NCT02351765|Drug|Cisplatin|Platinum-compound chemotherapy drug
46106603|NCT02329652|Device|Networked Neuroprosthetic System for Grasp and Trunk|Receive implanted networked neuroprosthesis
46106604|NCT02251431|Drug|BYDUREON|Exenatide-extended release, Cohorts A and B
46106605|NCT02251431|Drug|Placebo|Cohort A only
46106606|NCT02191488|Drug|5-aminolevulinic acid|
46106607|NCT02105766|Drug|Alemtuzumab|Immunosuppressant
46106608|NCT02105766|Drug|Sirolimus|Immunosuppressant
46106609|NCT02105766|Drug|Cyclophosphamide|Immunosuppressant
45838228|NCT04263194|Device|Sham rTMS|Placebo intervention will consist in the same procedure but using a sham rTMS coil.
45838229|NCT04247126|Drug|SY-5609|An oral CDK7 Inhibitor
45838230|NCT04247126|Drug|Fulvestrant|Estrogen receptor antagonist
45838231|NCT04247126|Drug|Gemcitabine|Nucleoside metabolic inhibitor
45838232|NCT04247126|Drug|Nab-paclitaxel|Taxane-type chemotherapy
45838233|NCT04241250|Device|EAW+SCES (exoskelton and spinal cord epidural stimulation)|Three months of exoskeleton training followed by 6 months of epidural stimulation.
46106610|NCT02105766|Drug|Pentostatin|Immunosuppressant
46106611|NCT02105766|Procedure|Radiotherapy|Immunosuppressant and myelosuppressant
46106612|NCT02006069|Device|MPP|"All patients enrolled in the study will be implanted (according to current Guidelines) with an MPP compatible CRT device.~The MPP feature will be evaluated in two study phases. Patients randomized to MPP in Phase I will have MPP programmed per the physician's discretion (no mandated MPP programming) and patients randomized to MPP in Phase II will have MPP programmed per protocol requirements (mandated MPP programming)."
46106613|NCT02000089|Drug|Secretin|inject Secretin to stimulate pancreatic digestive fluid, which is collected in duodenum near ampulla via endoscope suction port. This fluid will be assessed for biomarkers.
46106614|NCT02000089|Diagnostic Test|MRI|MRI abdomen with contrast (MRCP) will be clinically indicated for abnormal novel CA-19-9 lab results.
46106615|NCT02000089|Other|Tumor marker gene test with CA19-9|A tumor marker gene test that will be used to stratify individuals into one of several circulating tumor marker reference ranges for CA19-9. The variants in the genes FUT3 and FUT2 affect the levels of CA19-9.
46021437|NCT04795700|Behavioral|MSC intervention|Patients in the intervention group had access to conventional care, in addition to receiving the 8 weeks MSC intervention sessions. The intervention was provided by trained nurses, including one researcher and one MSC therapist. The intervention is mainly out-of-hospital intervention, supplemented by short-term in-hospital intervention. Among them, the first and second weeks of the intervention project in the hospital phase focus on guiding the research subjects to understand the content of mindful self-compassion and emotions, and carry out basic mindful self-compassion training; the content of the 3-8th week of the intervention program outside the hospital, Focus on the maintenance of mindful self-compassion training and the promotion of mindful life. Each face-to-face group contact lasted about 1 hour, depending on the complexity of the patients' problems.
46021438|NCT04685720|Device|LungFit|LungFit for NTM is an experimental device that produces Nitric Oxide from the ambient air.
46021439|NCT04678544|Device|Scalp cooling system 2|The investigational device which will be used in this study is the Paxman Scalp Cooling System 2. This device is manufactured by: Paxman Coolers Limited. This is a free-standing, electrically-powered, mobile refrigeration unit which circulates a refrigerated liquid coolant, at a pre-set temperature and flow rate, through a cooling cap which is attached to, and covers, the top of the patient's head. The Paxman Scalp Cooling System is intended to be used for scalp cooling of patients who are receiving chemotherapy for the treatment of solid tumors, in order to reduce the risk of chemotherapy-induced alopecia.
46021440|NCT04654052|Drug|Clopidogrel|Clopidogrel during 11 months
46021441|NCT04654052|Drug|Previous treatment|non-intervention
46021442|NCT04530344|Drug|ruxolitinib|ruxolitinib cream is a topical formulation applied as a thin film to affected areas BID.
46106616|NCT01985867|Dietary Supplement|Lactobacillus casei rhamnosus Lcr35|Eligible children will receive Lactobacillus casei rhamnosus Lcr35 (8×10^8 CFU, twice daily, orally for 4 weeks)
46021443|NCT04530344|Drug|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
46106617|NCT01985867|Dietary Supplement|Placebo|Eligible children will receive placebo (maltodextrin), twice daily, orally for 4 weeks
46106618|NCT01946139|Procedure|comparison of screening methods|Undergo HPV screening using HC2, APTIMA and OncoHealth HPV E6/E7 assays
46021444|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg|Participants in the dose-escalation cohort received a single 20 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 20 mg oral co-precipitate (CP) tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
46021445|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg|Participants in the dose-escalation cohort received a single 40 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 40 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
46021446|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg|Participants in the dose-escalation cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
46106619|NCT01946139|Other|laboratory biomarker analysis|Correlative studies
46106620|NCT01946139|Other|questionnaire administration|Ancillary studies
46106621|NCT01946139|Procedure|quality-of-life assessment|Ancillary studies
46106622|NCT01837745|Drug|rhTSH stimulation|Intramuscular injections of rhTSH (0.9 mg) on two consecutive days on LT4 treatment
46106623|NCT01837745|Drug|I131|An activity of 1.1 GBq of I131 is given orally 24 hours after the second injection of rhTSH.
46106624|NCT01837745|Other|Follow up|"10 (+/- 2 months) after randomization: a neck ultrasound and a serum Tg measurement after rhTSH or LT4 stimulation~2 years (+/- 2 months) after randomization: a serum Tg measurement under LT4 treatment (Tg/LT4)~3 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~4 years (+/- 2 months) after randomization: a serum Tg/LT4~5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~8 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~10 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~12 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4"
46106625|NCT01495234|Device|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
46106626|NCT01495234|Device|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
46106627|NCT01494493|Device|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS used in conjunction with an allograft bone dowel.
46021447|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg|Participants in the dose-escalation cohort received a single 120 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 120 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
46106628|NCT01494493|Procedure|Autogenous bone/allograft bone dowel|An allograft bone dowel containing autogenous bone taken from the patient's iliac crest.
46106629|NCT01494454|Device|rhBMP-2/BCP/TSRH® or rhBMP-2/BCP/CD HORIZON® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, either the TSRH® Spinal System or CD HORIZON® Spinal System.
46106630|NCT01494454|Device|Autograft/TSRH® or autograft/CD HORIZON® Spinal System.|Either the TSRH® Spinal System or the CD HORIZON® Spinal System with autogenous bone taken from the patient's iliac crest.
46106631|NCT01494441|Procedure|rhBMP-2/BCP|The rhBMP-2/BCP device component consists of recombinant human Bone Morphogenetic Protein-2 ( rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
46106632|NCT01494441|Device|rhBMP-2/BCP/TSRH® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, the TSRH® Spinal System.
46106633|NCT01494441|Device|Autograft/TSRH® Spinal System|The control device will be autogenous bone from the iliac crest of the patient used in conjunction with the TSRH® spinal System.
46106634|NCT01494428|Device|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS will be used in conjunction with an allograft bone dowel.
46106635|NCT01494428|Device|Autogenous bone/allograft bone dowel|An allograft bone dowel contains autogenous bone taken from the patient's iliac crest.
46106636|NCT01491542|Device|INFUSE® Bone Graft/MASTERGRAFT® Granules/CD HORIZON®|The INFUSE® Bone Graft component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2(rhBMP-2) and an absorbable collagen sponge (ACS)carrier. The MASTERGRAFT® Granules will be used as a type of bulking agent to provide compression resistance.
46106637|NCT01491542|Device|Autogenous Bone / CD HORIZON® Spinal System|The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System.
46106638|NCT01491464|Device|rhBMP-2/ACS/INTER FIX™|The INTER FIX™ device containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS).
46106639|NCT01491464|Device|Autogenous bone/INTER FIX™|The INTER FIX™ device containing autogenous bone taken from the patient's iliac crest.
46106640|NCT01491451|Device|rhBMP-2/ACS/INTERFIX™|INTERFIX™ device containing recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the absorbable collagen sponge (ACS) carrier.
46106641|NCT01491451|Device|Autogenous bone/INTERFIX™|INTERFIX™ device containing autogenous bone taken from the patient's iliac crest.
46106642|NCT01491425|Device|rhBMP-2/ACS//LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
46106643|NCT01491425|Device|Autogenous Bone//LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
45468512|NCT02528513|Drug|Fentanyl|Fentanyl is used with bolus dosage of 1-2ug/kg and maintenance dosage of 1-2ug/kg/h, with the dosage adjusted to critical care pain observation tool（CPOT）score(0-1).
45838234|NCT04241250|Device|EAW+TS (exoskelton and transspinal stimulation)|Three months of exoskeleton training followed by 6 months of transspinal stimulation.
45838235|NCT04220619|Diagnostic Test|Tranesophageal Echocardiography|RescueTEE during ACLS versus Conventional ACLS
45838236|NCT04200352|Drug|TEV-50717|Oral tablets are 6, 9, and 12 mg.
46021448|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg|Participants in the dose-escalation cohort received a single 140 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 140 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
46106644|NCT01491399|Device|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
46106645|NCT01491399|Device|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
46106646|NCT01491386|Device|rhBMP-2/ACS/LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
46106647|NCT01491386|Device|Autogenous Bone/LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
46106648|NCT01367002|Drug|Carboplatin/Paclitaxel|Paclitaxel 175 mg/m2 will administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. 100% of patients will receive Carboplatin/Paclitaxel.
46106649|NCT01367002|Drug|Trastuzumab|Paclitaxel 175 mg/m2 will be administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. On day 1, an 8 mg/kg loading dose of trastuzumab will be administered over a 90 minute period. Beginning on day 21, patients will receive 6mg/kg of trastuzumab, administered intravenously every 21 days and continued indefinitely every 21 days after 6 cycles of cytotoxic therapy are completed and until progression of the disease or prohibitive toxicities occur. 50% of patients will receive Carboplatin/Paclitaxel with the addition of Trastuzumab.
45838237|NCT04198766|Drug|INBRX-106 - Hexavalent OX40 agonist antibody|The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).
46106650|NCT01124214|Procedure|endomicroscopy|endomicroscopy scope lens has capability to optically evaluate mucosa/submucosa as a microscope
46106651|NCT00858273|Dietary Supplement|Antioxidant supplement|1 capsule daily with dinner
46021449|NCT01117623|Drug|HCC Child-Pugh A expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh A in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
46021450|NCT01117623|Drug|HCC Child-Pugh B expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh B in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
46106652|NCT00858273|Other|Diabetes treatment|Intensification of diabetes treatment regimen, including education and counseling, home blood glucose monitoring, multiple daily insulin injections (MDI), diet plan, and frequent phone contact with a certified diabetes educator
46106653|NCT00858273|Drug|Regular Insulin|Regular Insulin, IV, to maintain blood glucose in normoglycemic range (70-140) during metabolic study
46106654|NCT00624234|Behavioral|Tutoring Program I|Tutoring Program I is a structured multi-sensory program that is designed to gradually present the range of sounds and letters with focus on accuracy of phonological concepts and application of those concepts in phrases and sentences. The instruction uses a sequenced defined lesson plan with accuracy and automaticity criteria for skill progression. A range of manipulative and kinesthetic activities is outlined to maintain learner engagement in the intensive intervention design.
46106655|NCT00624234|Behavioral|Tutoring Program II|Tutoring Program II is designed to teach visual and speech elements of reading separately at first, and then bring them together for maximum efficiency. The program uses the idea of teaching concepts about the structure of words. For example, students transfer the rules they have learned about one vowel or structure to another without specific instructions on the new one. Tutoring Program II incorporates pictures and activities to help remember strategies for increasing basic reading skills. Speed drills are also used for development of decoding automaticity.
46021451|NCT01117623|Drug|NSCLC expansion cohort: Regorafenib 100 mg|Non-small cell lung cancer (NSCLC) participants in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
46021452|NCT05625308|Dietary Supplement|Epigallocatechin gallate, Folic acid, Vitamin B12, and Hyaluronic Acid|One tablet per day containing 200 mg of EGCG, 400 mcg of Folic Acid, 1 mg of Vitamin B12 and 50 mg of Hyaluronic Acid.
46021453|NCT02888834|Other|Adverse drug reaction|
45838238|NCT04198766|Drug|Pembrolizumab 200 mg|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
45838239|NCT04198766|Drug|Pembrolizumab 400 mg|Pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
46106656|NCT04158167|Drug|oxytocin|24 International units of oxytocin or palcebo will be given intranasally. The order of administration will be counterbalanced
46106657|NCT00659555|Drug|pazopanib eye drops|Pazopanib will be administered as eye drop solution via topical ocular route. Pazopanib eye drops will be available as white, colorless solution.
46106658|NCT00659555|Drug|Ketoconozole tablets|Ketoconozole will be administered as tablets via oral route. Ketoconozole tablets will be present as white, rounded, scored tablets
46106659|NCT02635997|Drug|antiresorptive therapy|
46106660|NCT00659867|Device|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|chromoscopy-guided endomicroscopy with targeted biopsies
46106661|NCT00659867|Device|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|Standard endoscopy with random and targeted biopsies
46106662|NCT00660101|Biological|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
46106663|NCT02635607|Drug|Follitropin Beta|Patients will start stimulation with a daily s.c. injection of 150IU follitropin beta on menstrual cycle day 3. A modification of the rFSH dose will be allowed from stimulation day 6 onward in case that a high ovarian response occurs at the discretion of the investigator.
46021454|NCT04291664|Drug|Abiraterone Acetate|Abiraterone Acetate 1000mg will be administered orally once daily
46021455|NCT04291664|Drug|Prednisone 5Mg Tab|"Prednisone 5mg will be administered orally twice daily with Abiraterone Acetate 1000mg~Prednisone 5mg will be administered orally twice daily with DST-2970 for 28 days after dosing of Abiraterone Acetate is stopped"
46021456|NCT04291664|Drug|DST-2970 (Abiraterone)|DST-2970 will be administered orally twice daily for 28 days (for every cycle) after dosing of Abiraterone Acetate is stopped
46021457|NCT04310553|Procedure|Irreversible electroporation|Patients with locally advanced pancreatic cancer diagnosed by cell / histopathology will receive nano knife treatment if the target lesion is not suitable for surgical resection or the target lesion is suitable for surgical resection but patients give up surgery and choose nano knife combined with chemotherapy. Patients who have not previously received first-line chemotherapy will receive systemic chemotherapy for 4-6 cycles of treatment. Imaging evaluation will be performed every 6-8 weeks (± 7 days) during chemotherapy.
46106664|NCT02635607|Drug|Ganirelix|Ganirelix 0.25mg daily s.c. will start after 4 days of rFSH stimulation
46106665|NCT02635607|Drug|Ganirelix|Ganirelix 0.25mg daily s.c. will start when at least one of the following criteria are fulfilled: (i) the presence of at least one follicle measuring≥12 mm; (ii) serum E2 levels>600 pg/ml; and (iii) serum LH levels>10 IU/l.
46106666|NCT02635607|Drug|rhCG|An amount of 250ug rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed
46106667|NCT02635607|Drug|triptorelin|0.2mg triptorelin will replace rHCG to trigger in case of high risk of overstimulation
46106668|NCT04156841|Diagnostic Test|mapping agent|according to different tracer methods, patients are divided into the implementation of a single mapping agent and implementation of combination of blue dye and radiotracer agent.
46106669|NCT04156841|Procedure|neoadjuvant chemotherapy|Patients were divided into two groups based on whether they were receiving neoadjuvant chemotherapy.
46106670|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection
46021458|NCT04289402|Other|Personalized tDCS|The participant will receive 10, 20-minutes sessions of personalized tDCS Monday-Friday, at approximately the same time of day, over two consecutive weeks.
46106671|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 2.5 ug per dose, intramuscular injection
46106672|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 5.0 ug per dose, intramuscular injection
46106673|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection
46106674|NCT00844428|Drug|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
46106675|NCT00660335|Drug|RG1068 (synthetic human secretin)|Single-dose, IV infusion
46106676|NCT00660413|Device|TOF-Watch SX (Acceleromyography)|Randomization of AMG to dominant or non-dominant arm. MMG at contralateral arm.
46106677|NCT04156685|Drug|Part A, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fasting condition
46106678|NCT04156685|Drug|Part A, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fasting condition
46106679|NCT04156685|Drug|Part B, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fed condition
46106680|NCT04156685|Drug|Part B, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fed condition
46106681|NCT00707772|Drug|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: 800 milligram per day (PO)
46106682|NCT00707772|Drug|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: [=<75 kg: 1000 mg; >75 kg: 1200 mg per day (PO)]
45681278|NCT03022942|Other|GROUP Manual Diaphragm Release|The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
46106683|NCT00660491|Other|exercise training|moderate intensity exercise group, and high intensity exercise group
46021459|NCT04289402|Other|Active-Sham|The participant will receive 20, 20-minute sessions of active-sham stimulation Monday-Friday, at approximately the same time of day, over two consecutive weeks.
45681279|NCT03948490|Device|ReMind iPad app|Evidence-based program to improve attention and memory through (1) cognitive training and (2) teaching compensatory skills in patients with brain tumors.
46021460|NCT04187469|Drug|Moxifloxacin, Isoniazid, Rifampicin|"Moxifloxacin 400 mg/day, Rifampicin ≤50 kg 450 mg/day > 50 kg 600 mg/day, Isoniazid 300 mg/day.~All treatment is taken daily, for a duration of up to 6 months depending on treatment arm."
46021461|NCT04187469|Drug|Rifampicin,Isoniazid,Pyrazinamide,Ethambutol|"Rifampicin ≤50 kg 450 mg/day, >50 kg 600 mg/day, Isoniazid 300 mg/day, Pyrazinamide 1500mg/day, Ethambutol ≤50 kg or the elderly 750mg/day, >50 kg 1000mg/day.~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm."
46021462|NCT04187144|Drug|Gepotidacin|Gepotidacin will be available as tablets at a unit dose strength of 750mg. Participants will administer two 750 mg tablets, BID. Each dose will be taken with water after consumption of food.
46106684|NCT02611284|Procedure|LISA|All infants were supported with nCPAP while breathing spontaneously during instillation. A 5Frenchgamma sterilized multi-access catheter specifically designed to deliver surfactants for Neonates was placed 1-2 cm below the vocal cords by direct laryngoscopy without the use of a Magill forceps. Beractant was used as exogenous natural surfactant, (100mg/kg; 4ml/kg) and administered in two aliquots during 1-3 minutes. Positive pressure inflations were given by a mask and bag only if the infant was apneic or bradycardia develops despite the interruption of the procedure. The surfactant administration catheter was removed after surfactant instillation and nCPAP support was maintained. A second dose of surfactant was administered during the first 3 days of life if more than 40% of FiO2 was needed while on nCPAP with at least 6 cm H2O pressure.
46106685|NCT02611284|Procedure|INSURE|"The INSURE technique was performed using Beractant (4ml/kg) after endotracheal intubation. A multi-access catheter for Neonates/Pediatrics designed to deliver surfactants (KimVentTrach Care Technology ®, United Kingdom) was pre-connected to the endotracheal tube and used for surfactant administration without having to disconnect the ventilator. While surfactant was administered all infants were connected to pressure support ventilation modality (PSV) combined with volume guarantee (VG), Dräger ventilator). A tidal volume of 4ml/kg was initially adjusted.~After surfactant administration, all infants were to be extubated, in accordance with our institutional extubation guidelines, if FiO2< 0.35; for a target Oxygen Saturation (SpO2) of >90%, and if a consistent respiratory effort was present. Extubation was supported with nCPAP in all patients."
46106686|NCT02535377|Other|Sperm cryopreservation|Sperm from the different groups are cryopreserved to evaluate their resistance to preservation.
45681280|NCT03948490|Device|Healthy SMS texting|Participants receive a daily message sent at a random time (within their chosen timeframe(s); e.g. 9am-9pm). Messages will focus on patient-based education-focused health-related quality of life and cognitive education such as internal and external cognitive compensatory strategy training, fatigue management, and coping skills.
45681281|NCT03948490|Behavioral|In-person cognitive rehabilitation|The in-person cognitive rehabilitation will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning.
46021463|NCT04187144|Drug|Placebo matching nitrofurantoin|Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Participants will administer 1 capsule BID. Each dose should be taken with water after consumption of food.
46021464|NCT04187144|Drug|Nitrofurantoin|Nitrofurantoin will be available as over-encapsulated 100 mg capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Participants will administer one 100 mg capsule, BID. Each dose should be taken with water after consumption of food.
46021465|NCT04187144|Drug|Placebo matching gepotidacin|Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Participants will administer two tablets, BID. Each dose should be taken with water after consumption of food.
46106687|NCT00834834|Drug|Fluoxetine|Starting dose of 20 mg daily will increase over 4 weeks, depending on tolerability, up to 40 mg daily. Treatment will last 6 months.
46106688|NCT00834834|Behavioral|DBT|One 60-minute individual therapy session and one 90-minute group therapy session every week. Treatment will last 6 months.
46021466|NCT04320212|Procedure|lumber epidural analgesia|the lumber epidural analgesia will be given after induction of general anesthesia.
46021467|NCT04320212|Procedure|erector spinae analgesia|the erector spinae analgesia will be given after induction of general anesthesia.
46021468|NCT01116687|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
46021469|NCT01116687|Other|laboratory biomarker analysis|Correlative studies
46021470|NCT04139486|Procedure|combined EMBOTRAP II or III and Contact Aspiration|refer to title
46021471|NCT04139486|Procedure|Contact Aspiration alone|refer to title
46021472|NCT00625599|Other|Osteoporosis Prevention Information|Primary investigator designed osteoporosis prevention information.
46021473|NCT02867020|Drug|Apalutamide|APALUTAMIDE 240-mg orally once daily (4 x 60-mg tablets) will be administered on a continual basis. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days.
46106689|NCT00834834|Drug|Citalopram|Dose set by study psychiatrist, up to 60 mg daily. Treatment will last 6 months.
46021474|NCT02867020|Drug|Abiraterone|Abiraterone acetate 1,000 mg (four 250 mg tablets) should be taken orally once daily, in combination with oral dose prednisone 5mg twice daily continuously. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days
46021475|NCT02867020|Drug|ADT|Dosing of goserelin (dose and frequency of administration) will be consistent with the prescribing information and should only be adjusted if clinically indicated to achieve and maintain subcastrate concentrations of testosterone (50 ng/dL or 1.7 nM).
46021476|NCT02867020|Drug|Prednisone|Subjects will receive prednisone 10mg/day.
46021477|NCT05071677|Procedure|Discussion|Participate in treatment planning meeting
46106690|NCT02631863|Drug|Aminolaevulinic acid|Aminolaevulinic acid with illumination
46021478|NCT05071677|Other|Interview|Participate in interview
46021479|NCT05071677|Other|Survey Administration|Complete survey
46021480|NCT05067855|Other|Pilates exercise program group|Pilates exercise program group will do a warm-up for 10 minutes and then perform five exercises includes standing footwork, hundreds with knee straight, articulating bridge, rolling like a ball, plank for 25 minutes. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
46106691|NCT02631863|Drug|Placebo|Placebo with illumination
46106692|NCT00834366|Drug|Tramadol HCl|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.
46021481|NCT04320056|Other|Standard administration of oxygen flow|"The investigator recommended SpO2 target of 90-94%. The investigator will recommend that low/high SpO2 alarms be set at 88% and 96% if continuous oximetry is used.~In this group the SpO2 was recorded any time with FreeO2 device - recording mode"
46106693|NCT04157933|Drug|009-A1|Inhaled apomorphine via Staccato aerosol, Dose 1 (low dose) each day for first 5 days, then 3 doses Dose 1 (low dose) q 2 hr on Day 6
46106694|NCT04157933|Drug|009-A2|Inhaled apomorphine via Staccato aerosol, Dose 2 (middle dose) each day for first 5 days, then 3 doses Dose 2 (middle dose) q 2 hr on Day 6
46106695|NCT04157933|Drug|009-A3|Inhaled apomorphine via Staccato aerosol, Dose 3 (high dose) each day for first 5 days, then 3 doses Dose 3 (high dose) q 2 hr on Day 6
46106696|NCT04157933|Drug|009-A0|Inhaled placebo via Staccato aerosol, Dose 0 (placebo) each day for first 5 days, then 3 doses Dose 0 (placebo) q 2 hr on Day 6
46106697|NCT04157933|Drug|009-B1 (active --> placebo) crossover|Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 2
46021482|NCT04320056|Device|Automated oxygen administration - FreeO2|In this group, oxygen administration will be delivered with FreeO2 (automated oxygen titration) with SpO2 target set at 92% (to maintain oxygenation in the recommended SpO2 target: 90-94%)
46021483|NCT03834272|Combination Product|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015 and tissue will be imaged in vivo with the LUM imaging device.
46021484|NCT03817502|Drug|Cariprazine|Cariprazine capsules, oral administration, once daily.
46021485|NCT03817502|Drug|Placebo|Matching placebo capsules, oral administration, once daily.
46021486|NCT03814304|Other|Personalized tDCS|The participant will receive 20, 20-minute sessions of personalized tDCS on Monday-Friday, at approximately the same time of day, over four consecutive weeks.
46021487|NCT03814304|Other|Active-Sham|The participant will receive 20, 20-minute sessions of active-sham stimulation on Monday-Friday, at approximately the same time of day, over four consecutive weeks.
46021488|NCT04319978|Drug|Dexamethasone injection|Dexamethasone is a synthetic corticosteroid. Dexamethasone is an adequate measure for reducing pain and edema in the post-operative recuperation period following 3rd molar surgery. A single dose of IM 8mg dexamethasone will be used for each patient.
46021489|NCT01114737|Drug|Sapropterin dihydrochloride|A dose of 20 mg/kg/day will be administered. Route of administration is oral (intact).
46021490|NCT01114737|Drug|Placebo|Placebo (tablet without active ingredient) is dosed once/day for the first 13 weeks of the study.
46021491|NCT00624182|Biological|Peptide vaccine for URLC10|Increasing the doses of URLC10 peptides will be administered by subcutaneous injection on day 1, 8, 15, and 22 of each 28-day treatment cycles. Doses of 0.5, 1.0, 2.0mg/body are planned. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
46021492|NCT00624182|Drug|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, and 15. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
46106698|NCT04157933|Drug|009-B2 (placebo --> active) crossover|Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 2
45468513|NCT02528513|Drug|propofol|After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to RASS score (-2 to 0).
46106699|NCT02631785|Other|Cognitive Behavioral Therapy|"Psychologists will deliver the COPING CAT treatment for reducing anxiety symptoms. It is a manualized treatment that was extensively used before. The treatment will include 10- 14 sessions, mostly individual but also two parents meetings. All the treatments will occur in the Department of Psychology in Haifa University as a part of a clinical trial. The treatment will take place in a room that was designed for this purpose fully equipped with cameras, microphone and double sided mirror. All sessions will be audio and video recorded and will be closely monitored by the PI. To increase protocol adherence and verify the adequacy of the treatment delivered, all clinicians will complete routine forms with the content of each session."
46106700|NCT00704574|Drug|insulin detemir|No extra intervention, only normal clinical practise for treatment of type 1 diabetes
46106701|NCT04157777|Other|Perineum massage with olive oil|"Descriptive form used for data collection included questions about women's sociodemographic features, medical and obstetric history and previous and present birthsof women participated in the study.~The Reeda Scale The scale is consisted of five parameters of healing: Redness, Edema, Ecchymosis, Discharge Approximation.~Pregnant women who came to the delivery room and met the criteria were randomly selected and assigned to experimental and control group according to age and educational status.~There was not any change in the birth process of the delivery room during data collection and the pregnant women received routine care and treatments.~REEDA scale was administered by other midwives who worked at the puerperal room where pregnant women stayed after birth and did not know their groups because those who gave vaginal birth were early discharged from the hospital as they could answer only the first three parameters of REEDA scale."
46106702|NCT04156529|Behavioral|ESU position|Semi-elevated supine (ESU) position was given during tube feeding
46106703|NCT04156529|Behavioral|ESRL position|Semi-elevated right lateral (ESRL) position was given during tube feeding
46106704|NCT00660647|Drug|Adalimumab|Adalimumab injection 0.8 ml (40 mg) s.c. every second week in up to 2 years
46106705|NCT00660647|Drug|Placebo|Saline injection 0.9%, 0.8 ml s.c. every second week up to 2 years
46106706|NCT02632097|Procedure|Lichtenstein Hernioplasty with Histoacryl|"Procedure/Surgery: Lichtenstein Hernioplasty with Histoacryl:~0.5 ml of cyanoacrylate glue is used for mesh fixation"
46106707|NCT02632097|Procedure|Lichtenstein Hernioplasty with Sutures|Procedure/Surgery: Lichtenstein Hernioplasty with Sutures: non-absorbable suture (polypropylene 2/0) is used for mesh fixation Other Name: prolene 2-0
46106708|NCT04156451|Procedure|Fluid resuscitation and furosemide administration (bolus and continuous) with central venous pressure target 8 - 10 mmHg|Crystalloid loading or furosemide administration with the CVP target 8-10 mmHg is reached in septic shock patients
46106709|NCT04156451|Procedure|Fluid deresuscitation and furosemide administration (bolus and continuous) with central venous pressure target 0 - 4 mmHg|active fluid removal with furosemide bolus and continuous or crystalloid loading until the CVP target 0-4 mmHg is reached in septic shock patients
46106710|NCT00660725|Drug|Vandetanib|Vandetanib is a pill that will be self-administered orally on Days 1-14 of each 14-day cycle. The dose of vandetanib each subject will receive will be determined by a dose escalation schedule (either 200 mg or 300 mg per day), which will be followed to determine the MTD of the study drug combination (vandetanib + GemOx). In the absence of disease progression, unacceptable toxicities, or other complications, the vandetanib and GemOx combination may continue per protocol for a maximum of 6 cycles, or 12 weeks. In subjects who show response or stable disease, vandetanib may be continued as a single agent beyond the 6 cycle maximum, at the investigator's discretion.
46106711|NCT00660725|Drug|Gemcitabine|30-minute IV infusion of 1000 mg/m^2 gemcitabine on Day 1 of each 14-day cycle.
46106712|NCT00660725|Drug|Oxaliplatin|Immediately following gemcitabine IV: 2-hour IV infusion of 85 mg/m^2 oxaliplatin on Day 1 of each 14-day cycle.
46106713|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
46106714|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
45598520|NCT03147183|Drug|Thymoglobulin|This study will use non-probability, convenience sampling from patients kidney transplants who receive induction immunosuppressive therapy with thymoglobulin
45598521|NCT02292121|Procedure|Intestinal permeability|5h-intestinal permeability test 10-hour overnight fasting subject who first emptied his bladder drinks a solution of mannitol and lactitol. 2 hours after, the subject drinks 500mL of water in less than 30 minutes. All urine samples are collected during the 5h-test for measurement of lactitol and mannitol.
45838240|NCT04198701|Device|Medtronic PulseSelect Pulsed Field Ablation (PFA) System|Adult subjects with a history of drug refractory recurrent symptomatic atrial fibrillation (AF) will undergo ablation of pulmonary veins and confirmation of entrance block and, where assessable, exit block with the PulseSelect PFA System.
46106715|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
45598522|NCT02292121|Other|a solution of mannitol and lactitol|
45598523|NCT03147105|Behavioral|arm ergometry|home based arm ergometry, at least 4-5 sessions/week for 12 weeks
46106716|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
46106717|NCT00844194|Drug|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
46106718|NCT00844194|Drug|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
46106719|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
46106720|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
46106721|NCT00844194|Drug|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
46106722|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
46021493|NCT04322474|Device|Catheter-based left atrial appendage occlusion|Catheter-based implantation of left atrial appendage occluder
46106723|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
46106724|NCT00844194|Drug|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
46106725|NCT02632253|Procedure|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min. The HIIT group will perform two supervised HIIT trainings and one self monitored MICE training per week.
46106726|NCT02632253|Other|MICE|MICE is also performed on a cycle ergometer at an intensity of 70-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform two supervised and one self monitored MICE training per week.
46021494|NCT03347084|Device|Excitation|Administration of LIFUP, a method of deep brain stimulation, according to excitation paradigms using the following parameters: Tone Burst Duration = 50ms; Pulse Repetition Frequency = 10Hz; ISPTA = 720 mW/cm2. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
46021495|NCT03347084|Device|Inhibition|Administration of LIFUP, a method of deep brain stimulation, according to inhibition paradigms using the following parameters: Tone Burst Duration = 50ms and Pulse Repetition Frequency = 10Hz. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
46106727|NCT04157387|Other|Cyriax inferior capsular stretching + Manual Therapy|Electro-therapy 10mins Manual therapy : Kalternbon grade 1 and 2 Mobilization : Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets), Active ROM exercises : 10 reps x 3 sets Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction (10reps x 2 sets ,each) Cyriax inferior capsular stretching
46106728|NCT04157387|Other|Manual therapy|"Before starting capsule stretching technique, Analgesic short-wave diathermy may be given for 10 minutes.~Kalternbon grade 1 and 2 Mobilization : Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets), Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction (10reps x 2 sets ,each)"
46106729|NCT00660803|Drug|Fulvestrant|
46106730|NCT04157543|Other|electroacupuncture|acupuncture with electricity
46106731|NCT00661115|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
46106732|NCT00661115|Drug|Placebo|Placebo. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
46106733|NCT04157699|Drug|TDF tablet|TDF tablet 300mg QD
45681282|NCT03948490|Behavioral|Telehealth cognitive rehabilitation|The telehealth cognitive rehabilitation will take place over secure UCSF Zoom. It will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning
46106734|NCT04157699|Drug|QL-007|QL-007 tablet
45681283|NCT04191694|Other|Chewing Gum|Patients will be given a packet of chewing gum on arrival in the post-operative recovery room. They will be asked to start chewing gum in the recovery room and then asked to chew gum according to their preference over course of the following 24 hours.
45681284|NCT04191694|Drug|Ondansetron 4 MG|Ondansetron 4mg intravenously, intra-operatively as part of standard hospital caesarean section protocol
45681285|NCT04191850|Procedure|Single Port Video-Assisted Thoracoscopic Surgery|Single Port Video-Assisted Thoracoscopic wedge resection was performed for primary spontaneous pneumothorax.
46106735|NCT00665717|Drug|Pravastatin|40 mg tablet; QD; 4 days
46106736|NCT00665717|Drug|Raltegravir|400mg tablet; BD 4 days
46106737|NCT00665717|Drug|Pravastatin and raltegravir|pravastatin 40mg tablet QD for 4 days; raltegravir 400mg tablet BD for 4 days
46106738|NCT02611596|Drug|Ranolazine|24 weeks of the assigned medication
46106739|NCT02611596|Drug|Placebo|Placebo for 24 weeks
46106740|NCT00661349|Drug|Lopinavir/ritonavir|2 ITIAN (o 1 ITIAN+TDF)+ lopinavir/ritonavir, 2 tablet 200/50 mg to 12 hours
46106741|NCT00661349|Drug|Nevirapine|2 ITIAN (o 1 ITIAN+TDF)+ nevirapine, 2 tablet 200/50 mg to 12 hours
46106742|NCT00702858|Drug|Blue Citrus|Five 700 mg Capsules three times a day to equal 15 capsules per day for 3 months
46106743|NCT00702858|Drug|Placebo|Five Placebo capsules three times a day to equal 15 capsules per day for 3 months
46106744|NCT04156607|Other|Kinesio taping|For the fascia technique, one part of the band which were divided by 4 fans is adhered on Achilles tendon to the heel with a 0% stretch. Then the plantar fascia was stretched by the examiner and the toes were extended (ankle dorsiflexion, toe extension) and the divided part of the band was applied toward the metatarsal heads with paper-off technique (5-15%).
46106745|NCT04156607|Other|Sham taping|''I'' bant were cut from the middle point of the Achilles tendon to the metatarsal heads. The band was applied from the Achilles tendon to the metatarsal heads without any stretching of plantar fascia and band.
46021496|NCT02881983|Other|the presentation of pictures (static stimuli) or videos (dynamic stimuli)|
46021497|NCT03304418|Drug|Radium Ra 223 Dichloride|Radium Ra 223 dichloride will be delivered intravenously at 55 kBq/kg (1.49 mCi)/kg (+/- 10% total dose) for a total of six cycles. 1 cycle= 28 days. The first cycle will commence at study enrollment, then cycles 2-6 will commence after the completion of radiotherapies at 4 week intervals
46106746|NCT02631005|Other|"Walk With Ease"|Six-week walking program
46106747|NCT00826176|Drug|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was to be administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could have been administered if necessary. At 1-2 PTC after the last administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was to be administered.
46106748|NCT00665873|Device|PORT-A-CATH (Smiths Medical Inc., MN)|Port a Cath implanted by surgical cut-down
46106749|NCT00665873|Drug|Amoxicillin and clavulanic acid|1 gr i.v. before the procedure
46106750|NCT05297916|Other|enteral feeding|to intake oral feeding or delay it
46106751|NCT04156061|Other|Delivery of CT scan results|Method of results delivery - verbal or visual.
46106752|NCT00707850|Drug|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: [=<75 kg: 1000 mg; >75 kg: 1200 mg per day (PO)]
46106753|NCT00665951|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 200/50mg; 2 tablets; single dose
45838241|NCT04191889|Combination Product|Hepatic Arterial Infusion combined with Apatinib and Camrelizumab|"Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets Procedure: 1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times.~2. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 8th day 30minutes after meals, once a day, for continuous medication.~3. On the 22nd day of treatment, namely the second session of HAIC, intravenous infusion of Camrelizumab 200mg every 3 weeks.~4. The cumulative maximum drug use period is up to 2 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
46021498|NCT03304418|Radiation|Radiation|"All external beam radiations oligometastatic sites will commence after cycle 1 of Radium-223 but prior to cycle 2 of Radium-223. All subjects will receive Stereotactic body or hypofractionated radiation to sites of bone disease seen on imaging studies. Patients will have the primary tumor sites and 5 or fewer sites of bone-only metastasis treated with external beam radiation.~Any of the following regimens are considered ablative, acceptable and are biologically equivalent to 60Gy EQD2:~Single fraction: 16 Gy total at 16 Gy per fraction (SBRT)~Three fractions: 24 Gy total at 8 Gy per fraction (SBRT)~Five fractions: 30 Gy total at 6Gy per fraction (SBRT).When using five fractions, can reduce to 25 Gy total at 5 Gy per fraction (SBRT) or to a minimum of 20 Gy total at 4 Gy per fraction (SBRT), per treating investigator.~Six fractions: 32.4 Gy total at 5.4Gy per fraction (Hypofractionated)"
46021499|NCT05131269|Drug|Dextrose 15 % in Water|A 15% dextrose solution is given to shoulder segments four times with 2 weeks interval (week 0,2,4, and 6)
46021500|NCT05131269|Drug|Normal Saline 20 mL Injection|A Normal Saline 0.9% is given to shoulder segments four times with 2 weeks interval (week 0,2,4, and 6)
46106754|NCT00665951|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 sachets with granules; single dose
46106755|NCT00665951|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 tablets; single dose
46106756|NCT02631707|Other|High protein diet|The intervention diet is higher in protein than the control diet.
45468514|NCT02528513|Drug|Dexmedetomidine|After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to RASS score (-2 to 0).
45468515|NCT02528513|Procedure|Procedure:sedation assessment|The nursing staff continuously monitored the sedation depth and adjusted the dosages of sedative and analgesic drugs to maintain the sedation target level. The sedation depth were assessed and recorded every 4 h (or more frequently when indicated).
46106757|NCT02631161|Other|Equia Forte|Restoration of cavities with a Glasshybrid material (Equia Forte)
46106758|NCT02631161|Other|Filtek Supreme XT/Clearfil SE Bond|Restoration of cavities with a composite resin based material after placing an adhesive
45468516|NCT02528513|Procedure|Procedure:Weaning|the respiratory therapists managed patients with a daily interruption of continuous sedation and the spontaneous breathing trial (SBT) protocols daily.
45468517|NCT02528513|Drug|midazolam(used for passing the SBT safety screen)|After the spontaneous breathing trial safety screen is passed,in the midazolam group, midazolam will continue to be used for sedation, with the dosage adjusted to RASS score (-2 to 0).
45468518|NCT03431116|Radiation|ultrasound|to detect the placental site
46021501|NCT03292874|Diagnostic Test|high resolution MRI (hrMRI)|high resolution MRI (hrMRI) and standard MRI (sMRI) will be obtained at baseline and again in approximately 1 year in patients on prostate cancer active surveillance.
46021502|NCT00625677|Biological|NeisVacC (Meningococcal C conjugate vaccine)|Dosage
46106759|NCT02631083|Other|Breakfast, lunch, snack and dinner|These meals (cereal, rice and bread meals) will be tested in subjects for their glycaemic response (CGMS) and substrate utilization (calorimeter)
46106760|NCT00661739|Drug|Bendamustine|Dose-level Bendamustine(mg/m²): I:50; II:60; III:60; IV:70; V:70 Dose-level Paclitaxel (mg/m²): I:60; II:60; III:80; IV:80; V:90 Treatment will be given on day 1,8,15 and repeated on day 29. When the recommended dose has been determined a total of 48 pts will be treated at this dose level.
46021503|NCT00625677|Biological|Menjugate (Meningococcal C conjugate vaccine)|Dosage
46021504|NCT03258008|Drug|Utomilumab|Utomilumab given by vein on Cycle 1 Day 1. Cycle 1-2 100 mg, Cycle 3-12 50 mg until progressive disease, toxicity, or 1 yr.
46106761|NCT00878969|Drug|valsartan (ARB)|
46106762|NCT00878969|Drug|ramipril (ACE inhibitor)|
46106763|NCT00878969|Drug|Placebo|
46106764|NCT02630849|Procedure|intercostal muscle flap and pericostal no-compression suture|intercostal muscle flap and pericostal no-compression suture of the intercostal space
46106765|NCT02630849|Procedure|Standard suture technique of the intercostal space|Standard suture technique of the intercostal space associated with an intrapleural intercostal nerve block
46106766|NCT02630927|Drug|AG-519|AG519 will be tested.
46106767|NCT02630927|Drug|Placebo|Placebo will be tested.
46106768|NCT04057235|Device|FlareHawk Interbody Fusion System|Expandable lumbar intervertebral body fusion device
46106769|NCT00843726|Radiation|Arm 1 stereotactic body radiation therapy|Patients undergo 1 high-dose fraction
46106770|NCT00843726|Radiation|Arm II stereotactic body radiation therapy|Patients undergo 3 high-dose fractions
46021505|NCT03258008|Biological|ISA101b|ISA101b 100 mcg/peptide given subcutaneously every 4 weeks x 3 doses beginning cycle 1 day 1.
46021506|NCT05116605|Other|Photobiomodulation (PBM)|Photobiomodulation (PBM) is light therapy in both the visible and near-infrared range (non-UV). This light is absorbed through the skin and functions at the cellular level, providing a lowering of inflammation and oxidative stress. Participants will undergo 20 minute sessions three times a week for 4 weeks using the NovoTHOR as the only intervention.
46021507|NCT01113879|Behavioral|Aerobic exercise|An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate.
46021508|NCT01113879|Behavioral|Stretching|Stretching will occur for 50 minutes a day, three days/week for 12 weeks.
46021509|NCT00979576|Drug|BIBF 1120 M + Pemetrexed|BIBF 1120 medium dose bid+ Pemetrexed 500 mg/m^2
45838242|NCT04182425|Other|Infant formula|Healthy full-term infants fed on an infant formula marketed on the French market
46021510|NCT00979576|Drug|BIBF 1120 H + Pemetrexed|BIBF 1120 high dose bid+ Pemetrexed 500 mg/m^2
46021511|NCT00979576|Drug|BIBF 1120 RD + Pemetrexed|confirmed dose of BIBF 1120 bid + Pemetrexed 500 mg/m^2
46021512|NCT00979576|Drug|BIBF 1120 L + Pemetrexed|BIBF 1120 low dose bid+ Pemetrexed 500 mg/m^2
46021513|NCT00979576|Drug|BIBF 1120 Placebo + Pemetrexed|placebo BIBF 1120 bid + Pemetrexed 500 mg/m^2
46106771|NCT00661817|Behavioral|Lifestyle Modification Program|"Participants will receive a behavior change prescription and skills training, offered via the Internet or through a combination of tailored print materials and an interactive voice response system, together with support strategies to enhance the intensity of the interpersonal and social-environmental support."
46106772|NCT00661817|Behavioral|Usual Care and Reading Materials|"Participants in this group will receive usual medical care provided by their own primary care providers. They will also receive the NHLBI's Aim for a Healthy Weight brochure at the baseline study visit and again at the beginning of Year 2."
46106773|NCT02630771|Procedure|Pressure pain threshold|Pressure algometry over thenar eminence, bilateral masseter muscles measured at baseline and during conditioned pain modulation
46106774|NCT00843492|Drug|Fondaparinux sodium|After randomization (Day 1), subjects will receive subcutaneously once daily fondaparinux 2.5 mg [0.5mL] (1.5 mg [0.3mL] in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
46106775|NCT00843492|Drug|Nadroparin|After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
46106776|NCT00666107|Biological|Gardasil|Intramuscular injections of Gardasil at Day 0, Month 2 and at Month 6
46106777|NCT02631629|Other|Non-fortified foods|The non-fortified placebo foods are eggs, cheese, yoghurt and crisp bread (without vitamin D added).
46106778|NCT02631629|Other|Fortified foods|The fortified intervention foods are eggs, cheese, yoghurt and crisp bread (with about 20 mcg/day).
46106779|NCT04156139|Device|HFNC|The gas flow rate was set at 45~55 L/min. The inhaled oxygen concentration will be dynamically adjusted to maintain SpO2 ≥ 92%. The temperature will be set at 37 °C.
46106780|NCT04156139|Device|NPPV|The PEEP is initially set as 5 cm H2O, the inspiratory pressure is 10 cm H2O, and the target tidal volume is 6-8 ml/kg.
46106781|NCT00666185|Drug|Micafungin|IV
46106782|NCT00666185|Drug|Fluconazole|IV
46106783|NCT00833976|Drug|Lovaza|4 grams per day
46106784|NCT00913224|Drug|Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)|
46106785|NCT00913224|Drug|Voltaren 50 mg Tablets (Geigy Pharmaceuticals)|
46106786|NCT00666341|Drug|placebo|Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
46106787|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)
46106788|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)
46106789|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)
45838243|NCT04181996|Drug|Colchicine Oral Product|Patients will be randomized to receive either placebo or colchicine
45838244|NCT04181996|Drug|Placebo oral capsule|Patents will be randomized to receive either placebo or colchicine
46106790|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)
46106791|NCT00666419|Other|Measurement, weight, and muscle strength test|10-12 year old schoolchildren will be weighed, measured for height, and tested for strength of their abdominal and paravertebral muscles
46106792|NCT04154657|Procedure|conductance catheter measurement|biventricular parallel conductance catheter measurement at rest and stress conditions, + CMR at rest and stress
46106793|NCT00833898|Device|Paced respiration as part of PEPRR|The FDA approved RESPeRATE™ is the size of a portable compact disk (CD) player with a visual display, an elastic belt-type respiratory sensor, and a set of headphones. During a relaxation session, the device analyzes respiratory pattern of the subject and creates a melody of pleasant tones selected by the subject (one for inhalation and one for exhalation). The subjects can observe a cartoon figure on the screen of the device that indicates their inhalation and exhalation. The subject synchronizes their breathing to these tones as the exhalation tone is gradually increased in duration with a target of less than 10 breaths/minute. Subjects were encouraged to use RESPeRATE 3-5 times a week for 20 minutes.
46106794|NCT00833898|Behavioral|PEPRR|PEPRR consist of 8 sessions, each lasting approximately 60min. The first 4 sessions are weekly, followed by biweekly mtgs for the remaining 4 sessions. Sessions begin the week that the patient receives the transfusion of donor cells. Session 1-4 are conducted at the hospital where the patients receive their transplant. Once discharged from the hospital, sessions will be conducted at the outpatient BMT clinic to coincide with patients' post-transplant visits. Sessions are devoted to a separate topic with the goal of assisting the caregiver in development & application of various stress-mgmt techniques such as effective problem-solving, identifying & challenging cognitive distortions, relaxation techniques, coping skills training, effective use of social support & goal setting.
46106795|NCT00661973|Drug|budesonide|inhaled budesonide (turbohaler) 400 micrograms twice a day for 4 weeks
46106796|NCT00666575|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime for 28 days
45838245|NCT04179162|Drug|Bacillus Calmette-Guérin (BCG)|Patients will receive once-weekly intravesical BCG therapy (TICE strain, 50 mg) at weeks 2 (+/- 2 days), 3 (+/- 2 days), 5 (+/- 2 days), 6(+/- 2 days), 8 (+/- 2 days), and 9 (+/- 2 days).
46106797|NCT00666575|Drug|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime for 28 days
46106798|NCT00666653|Drug|pramipexole|
46106799|NCT00707928|Drug|nitroglycerine|nitroglycerine 100 microgram intravenous.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
46106800|NCT00707928|Other|NSS|NSS.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
46106801|NCT00666731|Other|medical chart review|Demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history.
45838246|NCT04179162|Drug|Gemcitabine|Patients will receive gemcitabine at their specified dose level, given in a twice weekly fashion, with 72 to 96 h (+/- 1 day) between doses, at weeks 1, 4, 7, and 10.
45838247|NCT04168489|Device|active rTMS|(rTMS) is received preliminary approval because of its noninvasive and safe analgesic effect.
46021514|NCT02867332|Biological|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
46106802|NCT00666731|Other|questionnaire administration|Collection of personal information, medical history, diet and lifestyle habits, any past or current environmental exposures and to re-create a family tree for any cancers that have occurred in any family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, year of birth, age of death) will be recorded.
46106803|NCT00666731|Other|study of socioeconomic and demographic variables|Repository
46106804|NCT00666731|Procedure|Excess human biological tissue|Tissue procurement.
46106805|NCT00666731|Procedure|quality-of-life assessment|Cancer care.
46106806|NCT00662285|Dietary Supplement|Iron supplement: Niferex 100 mg|A: 100 mg pr day in 8 days
46106807|NCT00666809|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg BID p.o. for 12 weeks + 4 weeks follow-up
46106808|NCT00666809|Drug|Placebo|Placebo BID p.o. for 12 weeks + 4 weeks follow-up
46106809|NCT00666887|Drug|Minocycline|100 mg twice daily to be taken for up to 2 years
46106810|NCT00666887|Drug|Placebo|placebo twice daily for 2 years
46106811|NCT00667043|Drug|remifentanil and propofol|Patients will receive: propofol, continuous intravenous infusion, concentration 10 mg/ml, 1-4 mg/kg/hour and remifentanil; continuous intravenous infusion 0,050 mg/ml, 0.1-0.3 microgram/kg/min. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
46106812|NCT00667043|Drug|fentanyl and midazolam|Patients will receive: midazolam; continuous intravenous infusion, concentration 5 mg/ml, 2-10 mg/hour and fentanyl; continuous intravenous infusion, concentration 0,050 mg/ml, 0.025-0.5 mg/hour. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
46106813|NCT02631473|Drug|50mg NANO-efavirenz|OD
46106814|NCT02631473|Drug|400mg NANO-Lopinavir|BID
46106815|NCT02631473|Drug|200mg NANO-Lopinavir|BID
46106816|NCT02631473|Drug|100mg Ritonavir|BID
46106817|NCT02631473|Drug|300mg NANO-Efavirenz|OD
46106818|NCT02631473|Drug|600mg Sustiva|OD
46106819|NCT02631473|Drug|200mg NANO-Efavirenz|OD
46106820|NCT02631473|Drug|Kaletra® (lopinavir 400mg/ritonavir 100mg)|BID
46106821|NCT02631473|Drug|+/- 200mg NANO-Lopinavir|BID
46106822|NCT02631473|Drug|+/- 200mg ritonavir NORVIR|BID
46106823|NCT02631473|Drug|400mg Sustiva|
46021515|NCT02867332|Drug|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
46021516|NCT02867332|Drug|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
46021517|NCT04122742|Procedure|skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 SRT patients included.|Performed with a 3 mm diameter punch under local anesthesia. The procedure can be done in a consultation office respecting a strict asepsis.
46106824|NCT00825162|Biological|CSL Limited Influenza Virus Vaccine|Single or two-vaccination regimen (0.25mL)
46106825|NCT00825162|Biological|CSL Limited Influenza Virus Vaccine|Single or two-vaccination regimen (0.5mL)
46106826|NCT00825162|Biological|CSL Limited Influenza Virus Vaccine|Single vaccination regimen (0.5mL)
46106827|NCT00662441|Drug|Levitra (Vardenafil, BAY38-9456)|10mg taken 1 hours before sexual intercourse
46106828|NCT04154501|Drug|CNTX-6016|Oral Dose CNTX-6016
46106829|NCT04154501|Other|Other: Placebo|Oral Dose Placebo
46106830|NCT00708006|Drug|HGS1029|Escalating doses by IV (in the vein), on days 1, 8 and 15 of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity
46106831|NCT00911573|Drug|Tigecycline|50 mg IV every 12 hours up to 14 days
46106832|NCT00911573|Drug|Clindamycin (or Vancomycin if needed)|For clindamycin 10mg/kg (not to exceed 900mg) IV every 8 hours up to 14 days. For vancomycin 15mg/kg (not to exceed 2g/day and adjusted as needed for renal impairment) IV every 8 hours
46106833|NCT04155827|Other|SIT|Sprint interval training of 4*4, with 30 seconds of all out workout followed by 4 minutes of active recovery for 4 cycles.
46106834|NCT02630381|Device|Unfocused extracoporeal shock wave therapy|"Shock waves are acoustical pulses that are characterized by high amplitude (~500 bar) and short rise time (~20 ns), which are followed by a longer low-magnitude negative wave (~-100 bar). Extracorporeal shock waves are widely used to disintegrate kidney stones, which is called lithotripsy. In orthopedics, shock wave therapy, called orthotripsy, is used safely in a variety of musculoskeletal disorders like non unions, osteonecrosis of the hip, Achilles and patellar tendinopathy, lateral epicondylitis of the elbow and fasciitis plantaris.~Until recently extracorporeal shock wave therapy for musculoskeletal disorders was applied with a focused character, in which the waves converge in a focal point similar to lithotripsy. For the prevention of fractures in osteoporosis a focused character is not preferable because large skeletal regions have to be treated, so unfocused shock waves have been developed."
46106835|NCT00667433|Drug|Raltegravir + Truvada|Raltegravir 400 mg tablet BID PO X 104 weeks; Truvada 200/300 mg tablet once a day PO x 104 weeks
46106836|NCT02630147|Other|Vanilla scent|"A 12-hour continuous recording for monitoring hemoglobin oxygen saturation, electrocardiogram and respiratory movements will be performed while the infant is exposed to vanilla scent (from vanilla solution on the infant's pyjamas).~In addition, a 3-hour polysomnography will be done in a sub-sample on the morning following the night recording with vanilla solution."
46021518|NCT04122742|Other|Generation of Induced Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsy|induced Pluripotent Stem Cells (iPSC) production of patients with CREBBP mutation and differentiation into cortical neurons and pyramidal neurons
46021519|NCT04122742|Other|Histone acetylation profiles of cells of SRT patients with CREBBP mutations|Study of acetylome by liquid chromatography coupled with tandem mass spectrometry (LC-MS / MS) Validation of specific acetylation targets by ChIP-Sequencing
46021520|NCT04122742|Other|Functional involvement of identified epigenetic alterations|Transcriptome analysis with RNA-Seq Generation of isogenic iPSC clones by correction of CREBBP mutations in SRT patients by CrispR-Cas9.
46106837|NCT00667667|Device|vertical vibration device (Vibrafit whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with vertical device
46106838|NCT00667667|Device|side alternating vibration device (Board 3000 whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with side alternating device
46106839|NCT00667667|Behavioral|stretching and wellness (control group)|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months
46021521|NCT04122742|Biological|Culture of lymphoblastoid line from blood sample|Achievement of a ficoll Culture of lymphoblasts and conservation Establishment of lymphoblastoid line and conservation
46021522|NCT02867410|Other|No intervention|
46106840|NCT00662519|Drug|Neulasta (Pegylated)|Subjects will receive 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
46106841|NCT00662519|Drug|Placebo|Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
46106842|NCT00662519|Dietary Supplement|Mixed Meal Tolerance Test (MMTT)|This is a 2 hour test to find out how much C-peptide is being produced. C-peptide is used to measure the insulin being made by the cells of the pancreas. Both groups will have this test performed.
46106843|NCT00662519|Other|Blood test|HbA1c is a blood test that measures the average blood sugar control and will be performed in both groups.
46106844|NCT00662519|Other|DNA Test|The HLA test looks at the different chromosomes (DNA) for diabetes and will be performed in both groups.
46106845|NCT00662753|Device|Home monitoring|Participants will receive a home blood pressure monitor and be taught how to use it. They will have an education session to review treatment goals, medications, diet and exercise. They will be asked to see their primary care provider at least every 3 months and the research nurse at 3, 6 and 12 months.
46106846|NCT00662753|Other|monitor & phone call|Participants will receive all of the same interventions of the home monitoring group plus they will receive scheduled telephone follow up by the research nurse
46106847|NCT00667901|Drug|riluzole|
46106848|NCT00667901|Genetic|protein expression analysis|
46021523|NCT02867098|Drug|XmAb5871|
46106849|NCT00667901|Genetic|reverse transcriptase-polymerase chain reaction|
46106850|NCT00667901|Genetic|western blotting|
46106851|NCT00667901|Other|immunohistochemistry staining method|
46106852|NCT00667901|Other|laboratory biomarker analysis|
46106853|NCT00667901|Other|pharmacological study|
46106854|NCT00667901|Procedure|neoadjuvant therapy|
46106855|NCT00667901|Procedure|therapeutic conventional surgery|
46106856|NCT00667979|Drug|Levitra (Vardenafil, BAY38-9456)|10mg and 20mg to be taken 12, 18, 24 hours prior to sexual intercourse
46106857|NCT00667979|Drug|Placebo|Matching placebo
46106858|NCT00668057|Drug|Levitra (Vardenafil, BAY38-9456)|5 mg Vardenafil orally 1 hour prior to sexual intercourse
46106859|NCT00668057|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil orally 1 hour prior to sexual intercourse
46021524|NCT02702180|Drug|Molgramostim|300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation
46021525|NCT02702180|Drug|Placebo|Placebo nebulizer solution for inhalation
46021526|NCT02702180|Device|PARI eFlow nebulizer system|PARI eFlow nebulizer system
46021527|NCT00980980|Drug|Chlorhexidine bath and nasal mupirocin|The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)
46021528|NCT02888600|Behavioral|Mindfulness Training|Guided mindfulness meditation and stress management training
46106860|NCT00668057|Drug|Levitra (Vardenafil, BAY38-9456)|20 mg Vardenafil orally 1 hour prior to sexual intercourse
46106861|NCT00668057|Drug|Placebo|5 mg matching placebo
46106862|NCT00668057|Drug|Placebo|10 mg matching placebo
46106863|NCT00668057|Drug|Placebo|20 mg matching placebo
46106864|NCT00668135|Drug|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg orally on demand prior to intercourse
46106865|NCT00668135|Drug|Placebo|Matching placebo
46106866|NCT04155905|Procedure|fistulotomy and marsupialization of wound edges|after defining the fistulous track it was laid open (marsupialization) was done together with marsupialization of the wound edge with vicryl 3\0 sutures
46106867|NCT04155905|Procedure|fistulotomy|after defining the fistulous track it was laid open (marsupialization)
46106868|NCT00911417|Device|Pathway Jetstream Atherectomy System|The Pathway Jetstream System is a commercially available rotating, aspirating, expandable catheter for active removal of plaque and blood clots in peripheral arteries of the lower limbs.
45468519|NCT01320007|Drug|Preset increase in frusemide dose|"All patients in Group 1 will have the Optivol function and alerts switched on. Optivol levels will be downloaded monthly via the Medtronic Carelink Network (for those patients who have it) or during pacemaker follow up appointments.~If the Optivol alarm goes off, all patients will be requested to contact a member of the research team by phone and those with rising Optivol (irrespective of the presence or absence of heart failure symptoms) will be requested to increase the dose of diuretic that they are on by 50% for 1 week then revert to their usual dose after 7 days. A routine renal function check will be performed at the end of the week."
46021529|NCT02888600|Behavioral|Health Education|Guided health education and stress management training
46021530|NCT02888522|Biological|immunomodulation|Immunomodulation depending on chimerism
45838248|NCT04168489|Device|sham rTMS|The sham rTMS is inactive and similar to placebo effect.
45838249|NCT04163432|Drug|Durvalumab|Durvalumab is administered at a dose of 1500mg for patients who weigh >30 kg. If weight falls to ≤ 30 kg, weight-based dosing at 20mg/kg will be a utilized
46021531|NCT02866864|Other|Animal allergy +|Allergic symptom occurs when subject contact animal
46021532|NCT02866864|Other|Animal allergy -|Allergic symptom does not occur when subject contact animal
46021533|NCT04128748|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
46021534|NCT04128748|Drug|Quizartinib|Given PO
46021535|NCT00980200|Drug|Dose 4 QD|QD once daily
46021536|NCT00980200|Drug|Dose 3 QD|QD once daily
46021537|NCT00980200|Drug|placebo|placebo
46021538|NCT00980200|Drug|Dose 2 QD|QD once daily
46021539|NCT00980200|Drug|Dose 1 BD|BD twice daily
46021540|NCT04116502|Drug|Ruxolitinib|10mg of ruxolitinib twice daily (bd)
46021541|NCT04116502|Drug|Hydroxycarbamide|Via standard hospital mechanisms
46021542|NCT04116502|Drug|Interferon-Alpha|Any formulation, via standard hospital mechanisms
46021543|NCT04290442|Procedure|adductor canal block|The block is performed in supine position under ultrasound guidance using 22 G Touhy needle advanced in plane and 15 cc of 0.5% Ropivacaine ( local anesthetic) with dexmedetomidine 20-30 mcg depending on the age of the patient is injected at midthigh level lateral to the femoral artery in adductor canal to provide sensory blockade to the anterior aspect of the knee.
46021544|NCT04290442|Procedure|SPANK|SPANK: The block is performed in supine position, using 22 G Touhy needle, under ultrasound guidance, needle is advanced in plane to posteromedial shaft of femur taking care to avoid popliteal artery, and 0.5% ropivacaine 15 cc, dexmedetomidine 20-30mcg and dexamethasone 4 mg is injected into inner thigh above the knee provide sensory block to posterior aspect of the knee.
46021545|NCT04290442|Drug|Ropivacaine|ropivacaine 0.5% will be use in the block
46021546|NCT02866708|Device|Intermittent negative pressure device|This intervention study will be designed as a randomized cross-over study.
46021547|NCT02866786|Drug|Metformin|
46021548|NCT02866786|Drug|ethinyl estradiol and cyproterone acetate|Oral Contraceptive Pill
46021549|NCT00979654|Drug|Sifalimumab|All participants will receive intravenous (IV) sifalimumab as fixed dose of 500 mg every 2 weeks (Q2W) on Day 1, Week 2, and Week 4, then every 4 weeks (Q4W) thereafter for a total of 156 weeks. The initial fixed dose of 500 mg is increased to 600 mg with subsequent protocol amendment.
46021550|NCT02866552|Drug|Stromal Vascular fraction|
46021551|NCT02866552|Drug|Ringer lactate|
46021552|NCT02866474|Dietary Supplement|population living at home with meals on wheels|
46021553|NCT02866474|Dietary Supplement|population living in an EHPAD|
46021554|NCT00978562|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
46021555|NCT00978562|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
46021556|NCT00978562|Drug|Ferumoxytol Non-Stoichiometric Magnetite|Given IV
46021557|NCT00978562|Drug|Gadolinium|Given IV
46021558|NCT04289974|Drug|Palbociclib|Palbociclib (125 mg PO qDay for Days 1-21 of each 28-day cycle) combined with Fulvestrant (500 mg IM on Days 1, 15, and 29, and then once monthly thereafter)
46021559|NCT04031716|Behavioral|Meditation|Participants assigned to the Meditation intervention will receive focused attention meditation training preoperatively, and encouraged to meditate for 20 minutes per day before surgery. In the postoperative inpatient period, the participants will be offered standard holistic health care, reinforcement of meditation training, and encouragement to practice at least 20 minutes of guided focused-attention meditation with breath as their focus, utilizing the MUSETM headband for bio-feedback, every day during their hospital stay. They will be asked to continue using the MUSETM neurofeedback-assisted meditation after hospital discharge, until their visit to repeat pain testing, at which time they will return the MUSETM headband.
46021560|NCT02866630|Biological|Blood samples|Six additional blood samples will be taken from in-situ catheters during heart surgery
46021561|NCT02866162|Genetic|High-throughput exome sequencing|
46021562|NCT02865616|Drug|MET-2|Microbial Ecosystem Therapeutics (MET) is a new treatment approach for debilitating recurrent Clostridium difficile infection that has been developed as an alternative to fecal transplantation.
46106869|NCT02630303|Device|LED-RL Phototherapy|"The maximum recommended starting dose (MSRD) (160 J/cm2) will be administered to Group 1's LED-RL phototherapy randomized subjects and the LED-RL dose will be escalated in subsequent groups using the classical method for dose escalation as described by Spilker: starting with dose (X) increased by an equal amount (in this instance: X=160 J/cm2, 2X=320 J/cm2, 3X=480 J/cm2, 4X=640 J/cm2). Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity and is considered the upper limit of subject tolerance.~All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks."
46106870|NCT02630303|Device|Mock Therapy|"Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit and only generates warmth and does not emit LED-RL.~All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks."
46021563|NCT02865616|Drug|Vancomycin|Patients will be on vancomycin to control symptoms up until the time of the treatment. Patient must hold their p.o. vancomycin for 24 hours prior to receiving the first dose.
46021564|NCT02865460|Drug|Ubiquinol|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
46106871|NCT04155983|Drug|Ropivacaine|The drug will be administered in the same dosage in both arms. The location of the injection will vary by arm.
46106872|NCT00668369|Procedure|Gradual immunosuppression drug withdrawal.|Ater obtention of biological samples (peripheral blood, liver tissue) enrolled patients undergo gradual decrease in the doses of immunosuppression drugs (tacrolimus, cyclosporine A and/or mofetil mycophenolate) until complete discontinuation or appearance of rejection.
46021565|NCT02865460|Drug|Placebo|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
46021566|NCT01206816|Drug|BI 6727 + BIBW 2992|BI 6727 administered i.v. every 21 days + BIBW 2992 given orally once a day
46021567|NCT01206582|Biological|Hemin|10 iv infusions for 8 weeks
46106873|NCT02631317|Behavioral|Advance hospital notification by EMS|Advance hospital notification by EMS
45681286|NCT04191772|Other|Periodized, home-based running program|All participants will perform a home-based supervised exercise training program. Participants will receive weekly training instructions using a smartphone-based heart rate monitor application (Polar® app). Training sessions will involve running and the design of the training program will be based on linear periodization, where aerobic capacity is built firstly through a period of high-volume/low-intensity training before the proportion of high-intensity training is increased. The total duration of the exercise program will be 12 months with three weekly training sessions. Training progression will be dependent on initial VO2max values and running experience. VO2max classification is based on reference values described in V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics.
45681287|NCT04026022|Drug|Fentanyl Transdermal System|Patients will be treated perioperatively with a new pain management, that has been modified to integrate the 2017 ESA guidelines on prevention/treatment of postoperative delirium. Moreover patients will be administered a 12µg/h Fentanyl TTS in the ER or PACU. The ER TTS will only be administered if the patients still has mild to intense pain after initial intravenous (i.v.) treatment as well as reposition of the fractured hip. Further aspects of the modified management are: avoiding benzodiazepines, allowing oral fluids up to 2 hours before surgery, intraoperative monitoring of anaesthesia depth and at least 1,8 ltr crystalloid infusion per day.
45681288|NCT04026022|Drug|Placebo|Placebo plaster in the ER or PACU
45681289|NCT04020406|Biological|Antibacterial Activity|Antibacterial Activity of Urea Solution against Ocular Bacterial Isolates
46021568|NCT01206582|Biological|Albumin|10 iv infusions for 8 weeks
46021569|NCT05409456|Other|mild aerobic exercise|mild aerobic exercise given to group A on treadmill
46021570|NCT05409456|Other|moderate aerobic exercise|moderate aerobic exercise given to group B on treadmill
46021571|NCT01259102|Drug|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
46106874|NCT02631317|Behavioral|stroke team notification|stroke team notification
46106875|NCT02631317|Behavioral|key performance indicators feedback form|"a key performance indicators real-time feedback form as continuing quality improvement"
46106876|NCT02631317|Behavioral|standard informed consent procedures|standard informed consent procedures with public poster of thrombolysis
46106877|NCT02631317|Behavioral|performance of thrombolysis at CT-room|performance of thrombolysis at CT-room or emergency room
46106878|NCT00668447|Dietary Supplement|Soy Isolate|20 grams of powder mixed in beverages or food daily for one year
46106879|NCT00668447|Dietary Supplement|Control protein|20 grams of powder mixed in beverages or food daily for one year
46021572|NCT00978250|Drug|5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)|FdCyd, a fluoropyrimidine nucleoside analog, has a short (10-minute) half-life and is rapidly degraded in vivo by cytidine deaminase. However, co-administration with THU, an inhibitor of cytidine/deoxycytidine deaminase, has been shown to increase the area under the curve (AUC) of the parent compound more than 4-fold. Increased FdCyd exposure allows it to be taken up intracellularly and converted to its triphosphate, which is incorporated into deoxyribonucleic acid (DNA) and inhibits the action of the enzyme DNA methyltransferase (DNMT). Inhibition of DNMT, and in turn DNA methylation, can result in the re-expression of tumor suppressor genes.
46021573|NCT01259024|Device|transarterial chemoembolization using a drug-eluting bead|Up to 2 vials of LC Beads will be administered. One 2 mL vial each of 300-500 and 500-700 um LC Beads with 37.5 mg/mL doxorubicin will be prepared and mixed with radiographic contrast. Under fluoroscopic control, the vial of 300-500 um vial will be infused, followed by the vial of 500-700 um LC Beads. If the artery does not reach stasis prior to administration of both vials, and there is residual antegrade flow in the feeding artery, it will be treated with bland embolization similar to chemoembolization.
46106880|NCT00668447|Dietary Supplement|Novasoy isoflavones|3 tablets daily for one year
46106881|NCT00668447|Dietary Supplement|Placebo tablets|3 tablets daily for one year
46106882|NCT00668603|Drug|17-b-estradiol|2mg oral daily for 6 months
46106883|NCT00668603|Drug|17-b-estradiol + medroxyprogeterone acetate|2mg E2 + 5mg MPA daily for 6 months
46106884|NCT00668603|Drug|17-b-estradiol hemihydrate|1 mg skin gel daily for 6 months
46106885|NCT00668603|Drug|placebo pill + gel|placebo daily for 6 months
46106886|NCT00662987|Drug|7 days of amoxicillin|Received 7 days of amoxicillin (dosed 40mg/kg divided bid up to maximum daily dose of 800 mg)
46106887|NCT00662987|Drug|3 days of amoxcillin followed by 4 days of placebo|3 days of amoxicillin (40 mg/kg divided bid up to maximum daily dose of 800 mg) followed by placebo
46106888|NCT00663065|Drug|PAZ-417|
46106889|NCT00663143|Procedure|Stromal Cells Sample|Human Bone Marrow Stromal Cells will be obtained from 5 patients. Stromal cells will be obtained from subjects undergoing bone graft procedure to repair traumatic mandible fractures. Bone graft specimens will be obtained from the ileac crest. This will allow easy access to bone marrow specimen without additional pain or complications. A total of 5 ml of bone marrow will be obtained from each patient.
46106890|NCT00668681|Device|EndoRefix|
46106891|NCT00668759|Drug|Vernakalant Injection|10-minute infusion of 3 mg/kg vernakalant injection followed by a 15-minute observation period, followed by an additional 10-minute infusion of 2 mg/kg of vernakalant if required (if the subject is still in AF).
46106892|NCT00668759|Drug|Amiodarone Injection:|60-minute infusion of 5 mg/kg amiodarone followed by a maintenance infusion of 50 mg amiodarone over an additional 60 minutes (equivalent to approximately 15 mg/kg over 24 hrs).
46106893|NCT00668837|Drug|Paliperidone|
46106894|NCT02630225|Behavioral|Critical Time Intervention|"The Critical Time Intervention approach strengthens an individual's long-term ties to services, family and friends as well as provides emotional and practical support to individuals during the critical time of transition back to the community. CTI contains three phases:~Phase 1 - The Support Specialist gets to know the individual, assesses the individual's need and implements a transition plan intended to link the individual to services and supports in the community.~Phase 2 -- The Support Specialist monitors and adjusts the systems of support that were developed in Phase 1.~Phase 3 -- The Support Specialist helps the individual develop and implement a plan to achieve long-term goals and finalizes the transfer of responsibilities to caregivers and community providers."
46106895|NCT02630225|Other|Treatment as Usual|"Services provided by HMC physicians and staff that are part of standard care for patients with firearm-related injuries. This care could include:~All necessary medical care and scheduled follow-ups with subspecialty services~Evaluation by social work with referral to appropriate community services~Screening for alcohol use~Discharge planning services~Financial counseling"
45838250|NCT04163432|Drug|Pemetrexed|Pemetrexed dosing is adjusted for kidney function. Pemetrexed is dosed at 500mg/m2 for patients with a creatinine clearance ≥ 45 mL/min (by Cockcroft-Gault formula). If creatinine clearance is < 45 mL/min, pemetrexed is dosed at 400 mg/m2.
46106896|NCT02630225|Behavioral|Motivational Interviewing|A brief intervention to elicit the goals and needs of participants. As needed, this will included referrals to community resources.
46106897|NCT02630225|Other|Multi-Agency Attention|Intervention cases will receive attention from a multidisciplinary team of professionals. This team will help the study Support Specialist identify service recommendations and provide case management guidance.
46106898|NCT02631395|Other|Exercise|Three teams participated in a seven--month, three--times--a--week shoulder--muscle strength--training program while three teams participated in a comparable handball training program but did not conduct any specific upper--body strength training.
46106899|NCT02631395|Other|Control group|The three teams in the Control Group trained as normal throughout the season and participated in a comparable handball training program, but did not conduct any specific upper--body strength training
46106900|NCT00663221|Dietary Supplement|Anthocyans, Calcium and Vitamin D|
46106901|NCT00663221|Dietary Supplement|placebo|
46106902|NCT00824850|Biological|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
46106903|NCT00824850|Biological|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
46106904|NCT00668993|Behavioral|EFT - the Emotional Freedom technique|"EFT combines cognitive strategies with somatic procedures adapted from acupuncture and related systems for altering the cognitive, behavioural, and neurochemical foundations of psychological problems. It is often referred to as psychological acupuncture. Few adequately controlled studies have been conducted on EFT however acupuncture has been quite extensively studied, with hundreds of research reports published"
46106905|NCT00596687|Drug|Insulin glargine|Insulin glargine once daily SQ
46106906|NCT00596687|Drug|Regular insulin|Sliding scale regular insulin SQ four-times daily before meals or every 6 hours if patient NPO
46106907|NCT00596687|Drug|Insulin glulisine|scheduled glulisine given SQ at mealtime TID; none given if patient NPO
46106908|NCT02631239|Drug|Methotrexate|1g/m2/d IV *1d
46106909|NCT02631239|Drug|Etoposide|200mg/d PO *3d
46106910|NCT02631239|Drug|Dexamethasone|40mg/d PO *3d
46106911|NCT02631239|Drug|Pegaspargase|2500IU/m2/d IM *1d
46106912|NCT02631239|Radiation|Radiotherapy|50-56Gy
46106913|NCT00663299|Device|Endovascular Embolization Device|The TRUFILL DCS and TRUFILL DCS ORBIT Detachable Coils are each an embolic coil system that consists of a platinum detachable coil, a delivery system (delivery tube and coil introducer) and a syringe. Each system has been designed to deliver, position and detach embolic coils in order to embolize intracranial aneurysms
46106914|NCT00663377|Drug|losartan|losartan 50-100mg for 16 weeks
45681290|NCT03949270|Behavioral|BETA-Text text messaging intervention|Patients in the text messaging arm will receive daily, weekly, and monthly text messages. The daily message asks whether or not the patient has taken their breast cancer medication. The weekly message asks about any side effects and their severity. The monthly text message asks about any barriers that the patient might be experiencing. Concerning responses to any of the text messages will prompt contact from the office of the treating physician.
45681291|NCT04020328|Drug|Leflunomide 20 mg+prednisone 0.5mg/kg/d|Leflunomide plus low dose glucocorticoids to have the immunosuppressive therapy to those progressive IgA nephropathy with eGFR<50ml/min
46106915|NCT00669149|Drug|clopidogrel + aspirin|
46106916|NCT00669149|Drug|heparin + clopidogrel + aspirin|
46106917|NCT00669149|Drug|enoxaparin + clopidogrel + aspirin|
46106918|NCT00669149|Drug|bivalirudin + clopidogrel + aspirin|
46106919|NCT00669227|Other|autologous stem cells|intracoronary administration at the same day of cell aspiration using the stop flow technique
46106920|NCT00669227|Other|placebo suspension|intracoronary administration at the same day as cell aspiration
46106921|NCT04032275|Other|Chronic hepatitis B infection|Chronic hepatitis B infection patients
46106922|NCT00663455|Drug|Reduction of cyclosporine A (CSA)-dosing|Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
46106923|NCT00663533|Device|Vas-X|mechanical vasectomy device
46106924|NCT00669695|Drug|Atorvastatin treatment|Atorvastatin treatment: tablets of 40 mg Atorvastatin will be administered orally, respecting the dosage of 40 mg/day, for 6 months.
46106925|NCT00669695|Other|CPAP device|This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.
46106926|NCT00669695|Other|sham CPAP treatment|This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.
46106927|NCT00663689|Drug|erlotinib|erlotinib 150mg qd until disease progression or unacceptable toxicity.
46106928|NCT00669773|Drug|Adriamycin|Arm A: 4 cycles of adriamycin at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of docetaxel at 75mg/m2 3 weekly
46106929|NCT00669773|Drug|Docetaxel|Arm B: 4 cycles of docetaxel at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of adriamycin at 75mg/m2 3 weekly.
46106930|NCT00669851|Drug|AI-700|
46106931|NCT00824616|Drug|MK-0941|MK-0941 tablets 5 mg or 10 mg, taken 3 times daily, with increasing doses to maximally effective dose.
46106932|NCT00824616|Drug|Placebo|Placebo tablets, taken 3 times daily.
46106933|NCT00824616|Drug|Insulin|Insulin glargine (rDNA origin) injection solution for subcutaneous (SC) injection, taken once daily.
46106934|NCT04155671|Drug|POF|Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
46106935|NCT04155671|Drug|FOLFOX plus PAC(ip)|FOLFOX plus intraperitoneally paclitaxel
46106936|NCT05443620|Device|Weight vest|A vest weighing up to a maximum of 15 kg.
46106937|NCT05443620|Device|Wheelchair|Wheelchair in which participants will be sitting to reduce loading on lower extremities.
46106938|NCT05439330|Device|MRI of teeth and surrounding structures|included above
46106939|NCT00663845|Drug|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1h prior to sexual intercourse
46106940|NCT00663845|Drug|Placebo|Matching placebo
46106941|NCT00708240|Drug|Escitalopram|Escitalopram will be provided in unit doses commercially available, with a starting dose, minimum effective dose, and maximum effective dose of 5 mg, 10 mg and 20 mg, respectively, given once daily.
46021574|NCT04319900|Drug|favipiravir tablets+chloroquine phosphatetablets tablets|"Favipiravir tablets+ chloroquine phosphate tablets group: 50 patients (anticipated).~Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.~Chloroquine phosphate tablets: a total of 1000mg split into two times on day one; from day two to day three, 500mg, once a day; from day four to day ten, 250mg, once a day. Maximum of 10 days for oral administration of the drug."
46021575|NCT04319900|Drug|Favipiravir tablets|Favipiravir tablets group: 50 patients (anticipated). Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.
46021576|NCT04319900|Drug|Placebo|Placebo for favipiravir tablets is produced by Zhejiang Haizheng pharmaceutical co, LTD, batch no. 21812252, Placebo for chloroquine phosphate tablets is produced by the Chinese people's liberation army academy of military science military medical research institute production, batch no. 20200215. All placebos were complied with the quality inspection standard.
46021577|NCT01257698|Drug|Dorzolamide 2%-timolol 0.5% topical eyedrops|Dorzolamide 2%-timolol 0.5%, 1 drop in operated eye twice daily until gas bubble completely resorbed. Patients randomized to this arm are instructed to use this drop in addition to standard post-operative eye drops.
46021578|NCT01257542|Drug|Dextromethorphan|A single 10 mL dose of Children's Triaminic Syrup (Dextromethorphan Hydrobromide 7.5 mg per 5 mL (total dose of 15 mg)
46106942|NCT04153721|Behavioral|Name Digital Solution|"The digital solution offers a pre-operative program of information (pathology, treatment modalities, protocols to be followed) and training (stress management, psychological support, optional: nutritional preparation, physical exercise, reduction of alcohol and tobacco consumption).~In the post-operative phase, patients must daily assess their state of health (temperature, weight, wound, nausea / vomiting, urine / stool) and well-being (physical, moral, sleep, pain), from day 1 to day 7 after discharge, to facilitate the detection of complications by the medical team"
46106943|NCT04155515|Drug|TG-2349|TG-2349 400mg
46106944|NCT04155515|Drug|DAG181|DAG181 200mg
46021579|NCT01257542|Drug|Placebo|A single 10 mL dose of matching placebo syrup
46021580|NCT01257230|Drug|tiotropium Respimat low dose|IMP
46021581|NCT01257230|Drug|placebo Respimat|placebo representing comparator
46106945|NCT04155515|Drug|Ribavirin|Ribavirin 1000mg/1200mg
46106946|NCT00664001|Dietary Supplement|Anti-oxidant supplementation|Daily dose of 1g L-ascorbic acid, 400 IU of alpha-tocopherol acetate, and 600mg of alpha-lipoic acid in sealed capsules as anti-oxidant supplementation.
46021582|NCT01257230|Drug|tiotropium Respimat high dose|IMP
46021583|NCT01113801|Drug|LY2382770|Subcutaneous injection given monthly for 12 months
46021584|NCT01113801|Drug|Placebo|Subcutaneous injection given monthly for 12 months
46021585|NCT01256684|Drug|Placebo|Placebo vaginal suppository
46021586|NCT01256684|Drug|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
46021587|NCT01256684|Drug|DHEA|Vaginal suppository containing 0.50% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
46021588|NCT01204710|Biological|Olaratumab|15 milligrams per kilogram (mg/kg) intravenous (IV) Days 1 and 8
46021589|NCT01204710|Drug|Mitoxantrone|"Mitoxantrone 12 milligrams per square meter (mg/m²) IV Day 1~Mitoxantrone is to be administered for up to 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤144 mg/m²)"
46021590|NCT01204710|Drug|Prednisone|5 mg orally (PO) twice daily (BID) on each day
46106947|NCT00664001|Dietary Supplement|Matched placebo for anti-oxidant supplementation|Matched placebo for anti-oxidant supplementation
46106948|NCT00670163|Behavioral|Enhanced Partner Therapy (EPT)|EPT, a biomedical intervention, is designed to reduce the rate of sexually transmitted infection (STI) reinfection and, therefore, incident STIs. Men who have sex with men (MSM) with incident STIs will be given partner treatment packets that contain informational brochures, reference cards, prophylactic medications, and condoms for their sexual partners.
46106949|NCT00670163|Behavioral|Communidades Positivas (CPOS)|The behavioral intervention, CPOS, is based on a combination of social-action theory and diffusion of innovation and is designed to reduce the frequency of unprotected sex with nonprimary partners. In CPOS, MSM who are recognized by their peers as leaders will be trained to implement a community center that provides information, support, and empowerment to MSM, their friends, and partners. CPOS will include a training program of at least 14 sessions. During these sessions, MSM leaders will be provided with information about HIV/STIs and their prevention and ways to strengthen leadership skills. The 2-hour group sessions will occur two times a week for 7 weeks. While the training sessions are underway, MSM leaders will be asked to work with community leaders to form a community center from which they will carry out HIV/STI prevention and promotion of sexual health activities for 18 months.
46106950|NCT00670163|Behavioral|Standard Care|Standard care will consist of usual care for STIs.
46021591|NCT02881359|Device|LifeSeal® Kit|used as an adjunct to suture or staple line during standard surgical repair of the GI tract (anastomosis or linear) to provide re-inforcement and help reduce leaks.
46021592|NCT00625755|Biological|Electrofusion DC vaccine|To assess the safety and efficacy of vaccinations
46106951|NCT00664079|Other|Blood draws|17 mls of blood will be drawn over a 5 day period from either a central venous catheter/arterial line or with scheduled phlebotomy. The following labs will be run tT3, fT3, rT#, tT4, fT4, TSH, and tyrosine.
46106952|NCT00824382|Drug|BI 1744 CL 2 Âµg|2 puffs of 1 Âµg/actuation delivered by the RespimatÂ® inhaler
46021593|NCT01256450|Drug|Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
46021594|NCT01256450|Drug|Placebo|buccal soluble film; applied to the buccal mucosa twice daily
46106953|NCT00824382|Drug|BI 1744 CL 5 Âµg|2 puffs of 2.5 Âµg/actuation delivered by the RespimatÂ® inhaler
45838251|NCT04163432|Drug|Carboplatin|Carboplatin dosing is adjusted for kidney function.The total dose (in mg) of carboplatin will be calculated using the Calvert Formula utilizing a target AUC of 5 and a patient's GFR in mL/min.
45838252|NCT04152954|Device|Radiofrequency ablation of cervical medial branches|Radiofrequency ablation of cervical medial branches
45838253|NCT04151706|Drug|CD8+ Memory T Cell Infusion|Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation
45838254|NCT04151706|Drug|Thiotepa|5 mg/kg/day: IV for 2 consecutive days (days -6 to -5)
46021595|NCT01204398|Drug|telmisartan+amlodipine fixed dose combination|after 2 weeks placebo wash-out, patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
46021596|NCT04306575|Other|Trans-venous lead extraction|Patients with a dysfunction or infection of a cardiac pacemaker or a defibrillator are indicated for extraction of these devices, so lead extraction is done transvenously to remove these leads
45838255|NCT04151706|Drug|Fludarabine|25 mg/m2/day: IV for 5 consecutive days (days -6 to -2)
46021597|NCT04318236|Behavioral|HERMES (Online Self-Help Intervention based on problem-solving therapy)|"The Online Self-Help Intervention is an online program based on the problem-solving therapy (an evidence based approach of psychotherapy). All participants will receive the exact same intervention.~However, what will be experimentally varied are the four listed interventions."
46021598|NCT01111851|Drug|Fosaprepitant 150 mg|a single intravenous infusion of 150 mg fosaprepitant dimeglumine over 20 minutes on Day 1 15 minutes after consumption of a standard light breakfast meal
46021599|NCT01111851|Drug|Aprepitant 165 mg|a single oral 165 mg aprepitant capsule 15 minutes after consumption of a standard light breakfast meal
46021600|NCT01111851|Drug|Aprepitant 250 mg|a single oral 250 mg dose achieved by administering two 125 mg aprepitant capsules 15 minutes after consumption of a standard light breakfast meal
46106954|NCT00824382|Drug|BI 1744 CL 10 Âµg|2 puffs of 5 Âµg/actuation delivered by RespimatÂ®
46106955|NCT00824382|Drug|Placebo|2 puffs delivered by the RespimatÂ® inhaler
46106956|NCT00670319|Drug|Raloxifene HCL|Raloxifene HCL 60 mg orally once daily
46106957|NCT00670319|Drug|Raloxifene HCL|Raloxifene HCL 120 mg orally once daily
46106958|NCT00670319|Drug|Placebo|Placebo one tab orally per day
46106959|NCT00664157|Behavioral|Facial expression recognition of emotion|Facial expression recognition test Lexical decisiontest
46106960|NCT00664157|Behavioral|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
46106961|NCT00670397|Drug|HPPH|IV
46106962|NCT00708318|Drug|i.v. fentanyl and AeroLEF|"Period I: subjects received an intravenous dose of fentanyl (200 µg) (Treatment A).~Period II: subjects were randomly assigned to receive either 2 mL (Treatment B) or 3mL (Treatment C) of AeroLEF delivered by nebulization with an AeroEclipse BAN."
46106963|NCT00670475|Drug|Piroxicam|In this interventional arm gel of piroxicam (manufactured by Iran najo co,Iran), repackaged in a 60 g anonymous tubes will be administered to the patients.
46106964|NCT00670475|Dietary Supplement|Olive Oil|"virgin olive oil prepared directly from olive fruit from olive gardens of north of iran, Gilan province will packaged in a 60 g anonymous tubes."
46106965|NCT00704886|Other|video|video of dementia
46106966|NCT04154033|Drug|Naltrexone|Topical naltrexone cream (1%)
46106967|NCT04154033|Other|Placebo Cream|Topical placebo cream
46021601|NCT01111851|Drug|Dexamethasone (12-8-16-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg twice daily), and Day 4 (8 mg twice daily) with or without a meal.
46021602|NCT01111851|Drug|Dexamethasone (12-8-8-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg), and Day 4 (8 mg twice daily) with or without a meal.
46021603|NCT01111851|Drug|Ondansetron|The intravenous (I.V.) infusion of ondansetron 32 mg will begin 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1 and will be administered as a 15-minute infusion
46021604|NCT01111851|Drug|MK0999|I.V. infusion of MK0999 containing ~100 MBq (~3 mCi) containing ≤ 5 ug of MK0999)
45468520|NCT01320007|Other|No intervention|The Optivol data for these patients will be downloaded periodically (at each scheduled device check) and recorded but will not be available at follow up in the heart failure clinic.. These patients will act as controls for group 1 patients. They will undergo baseline investigations and then will undergo routine heart failure treatment and follow-up in the heart failure clinic. These will include a routine clinical evaluation, body weight and blood analysis as per the heart failure clinic protocol. Medications will be reviewed and changed according to clinical needs.
45468521|NCT03430960|Other|Phone Call|Participants will be followed-up via phone call by Acute Pain Research Nurse
46106968|NCT05530356|Drug|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
46106969|NCT05530356|Drug|Iohexol Inj 300 MG/ML|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
46106970|NCT05530356|Drug|Dextran 40|Diagnostic aid/agent used to measure glomerular size selectivity
46106971|NCT05530356|Procedure|Renal Biopsy|Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
46106972|NCT05530356|Radiation|Positron Emission Tomography|Imaging study performed to study renal oxidative metabolism
46106973|NCT00664313|Drug|Linezolid|600 mg po daily for 112 doses (16 weeks)
46106974|NCT00664313|Drug|Placebo|Placebo given daily for 112 doses (16 weeks)
46106975|NCT00670553|Drug|panobinostat|
46021605|NCT01256294|Drug|Generic Tacrolimus|Generic Sandoz tacrolimus supplied as capsules of 0.5 mg, 1 mg and 5 mg dose strengths.
46021606|NCT01256294|Drug|Branded Tacrolimus|Capsules supplied at dose strengths of 0.5 mg, 1 mg, and 5 mg.
46021607|NCT04310241|Behavioral|Patching therapy, Glasses|Patching, glasses and strabismus surgery are commonly employed measures in treatment of amblyopia and strabismus.
46106976|NCT00664391|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in small quantity, with abundantly rinse after use, during 21 days
46106977|NCT00833040|Drug|Sublingual sufentanil NanoTabs™ and placebo NanoTabs™|During the Titration Phase, patients titrated to the dose of sufentanil that provided adequate pain relief without intolerable side effects. Dosages were 20, 30, 40, 60 and 80 mcg. During the Double Blind Phase, patients were randomized to one of six sequences and took 7 doses of sufentanil (dosage determined in the titration phase, and 3 doses of placebo.
46106978|NCT02629913|Device|mementor somnium|
46106979|NCT02629913|Other|wait list|delayed access to mementor somnium
46106980|NCT02629835|Other|intravenous 8 mg dexamethasone and perineural 0.8 ml of saline solution|
45838256|NCT04151706|Radiation|Hyperfractionated TBI|Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy)
46106981|NCT02629835|Other|intravenous 0,8 ml of saline solution and perineural 8 mg of dexamethasone|
46106982|NCT00664469|Drug|ezetimibe|ezetimibe 10 mg/day over a 6-week course of treatment.
46106983|NCT00664469|Drug|Comparator: Simvastatin 20, 40 and 80 mg|Simvastatin 20, 40 and 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
46106984|NCT00664469|Drug|Comparator: Atorvastatin|Atorvastatin 20, 40 & 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
46106985|NCT00664469|Drug|Comparator: Rosuvastatin|Rosuvastatin 10, 20 & 40 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
46106986|NCT00664547|Behavioral|Diet Weight Loss|
46021608|NCT01256060|Drug|Intranasal Oxytocin|We are selecting morning and afternoon dosing to try to influence most hours where youth are in settings with increased potential for social interaction (school, after school). Medication will be administered by the parents before school and early afternoon. All patients will receive their first dose by the study physician to educate parents and themselves on proper administration and determine safety of first dose.
46106987|NCT00664547|Behavioral|Exercise Weight Loss|
46021609|NCT02880501|Device|proximal femoral nail antirotation|Twenty patients with intertrochanteric femoral fracture scheduled to undergo proximal femoral nail antirotation (PFNA) implantation.
46021610|NCT01255904|Drug|Chloral Hydrate|Oral chloral hydrate 50 mg/kg
46106988|NCT00664547|Behavioral|Exercise Without Weight Loss|
46021611|NCT01255904|Drug|Dexmedetomidine|Intranasal dexmedetomidine 3 mcg/kg
46106989|NCT02629757|Drug|β-elemene|β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles
46106990|NCT00843024|Drug|Sumatriptan and Naproxen Sodium|Sumatriptan succinate and naproxen sodium
46106991|NCT00843024|Drug|Placebo|Placebo to match
46106992|NCT04154813|Drug|Topiramate|The initial dose of 25mg/d is rapidly increased to the target dose (100mg/d) or below the maximum tolerable dose if the patient can tolerate it.
46106993|NCT04154813|Drug|Fluoxetine|Fluoxetine was increased from 20mg/d to the target dose (60mg/d) or below the maximum tolerable dose within 2 weeks.
46106994|NCT04154813|Behavioral|cognitive behavioral therapy (CBT)|CBT psychotherapy, once a week for three months.
46106995|NCT04154813|Behavioral|dialectical behavior therapy (DBT)|DBT psychotherapy,once a week for three months.
46106996|NCT00664703|Drug|Lobeline sulfate|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
45838257|NCT04151706|Drug|Busulfan|6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg
45838258|NCT04151706|Drug|Cyclophosphamide|60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg
46021612|NCT01255904|Other|Oral placebo|Oral saline administered
46021613|NCT01255904|Other|Intranasal placebo|Intranasal saline administered
46021614|NCT01255670|Drug|penicillin and metronidazole in peritonsillar abscess|Peroral Penicillin: 1000 000 IU 3 times a day for 10 days Peroral metronidazole: 500 mg 3 times a day for 7 days
46021615|NCT01255592|Drug|AZD5069|Oral dose bid
46021616|NCT01255592|Drug|Placebo|Oral dose bid
46106997|NCT00664703|Drug|Methylphenidate HCl|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
46106998|NCT00664703|Drug|Placebo|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
46106999|NCT00670787|Drug|Combination pill of losartan and hydrochlorothiazide|Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
46107000|NCT00664781|Drug|rucaparib (CO-338; formally AG-014699 or PF-01367338)|
46107001|NCT00664781|Genetic|protein expression analysis|
46107002|NCT00664781|Genetic|western blotting|
46107003|NCT00664781|Other|immunohistochemistry staining method|
46107004|NCT00664781|Other|liquid chromatography|
46107005|NCT00664781|Other|mass spectrometry|
46107006|NCT00664781|Other|pharmacological study|
46107007|NCT04154969|Other|Physiotherapy including Vestibular rehabilitation|vestibular exercise (VOR TX1)
46107008|NCT04154969|Other|conventional Physiotherapy|conventional Physiotherapy
46107009|NCT00670865|Other|Electronic discharge summary system|The customized electronic discharge summary program will be used to generate patient discharge summaries.
46107010|NCT00670943|Other|Platelet function testing|
46107011|NCT00832650|Drug|fesoterodine fumarate|8 mg OD for 14 days
46107012|NCT00832650|Drug|placebo|OD for 14 days
46107013|NCT00832650|Drug|solifenacin|10 mg OD for 14 days
46107014|NCT04153487|Drug|Ascorbic Acid Injectable Product|Intermittent Intravenous Infusion of Ascorbic Acid (Vitamin C) 2.5 gm / 6 hours for 96 hours
46107015|NCT04153487|Drug|Placebo|Placebo saline / 6 hours for 96 hours
46107016|NCT00708396|Drug|Escitalopram|First week; 10mg/d of Escitalopram Weeks 2-5; 20mg/d of Escitalopram After 4 weeks of 20mg treatment (2-5 weeks of the study) - if partial/no response according to YBOCS score and clinical judgment, the dose will be increased up to 30mg for 4 weeks (weeks 6-9) and in case of partial/ non response the dose will be increased up to 40 mg until the completion of the study (weeks 10-13).
46107017|NCT00671021|Other|Platelet aggregation|Platelet aggregation TxA2 formation
46107018|NCT04153799|Biological|CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells|The first dose group: 0.5 × 10^6/kg CAR positive T cells; The second dose group: 1.58 × 10^6 / kg CAR positive T cells; The third dose group: 5 × 10^6/kg CAR positive T cells. The above dose allows a 20 % error; For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
46107019|NCT00671099|Dietary Supplement|Omega-3 Polyunsaturated Fatty Acid|A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
46107020|NCT00671099|Dietary Supplement|Placebo|Placebo
46107021|NCT00665093|Drug|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
46107022|NCT00665093|Drug|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
46107023|NCT00595517|Drug|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
46021617|NCT01255436|Other|SMS text reminders|Patients in the intervention arm will receive 2 text messages per week delivered via SMS on randomly chosen days and times during the 12-week study period. The aims of the messages are to remind patients to take their blood pressure medications daily, what the target blood pressure is, and the benefits of daily intake of anti-hypertensive medications.
46021618|NCT01255436|Other|Usual Care|Patients in the usual care arm will receive the care usually provided by their physicians. This consists of consultations, medical advice, and prescriptions for maintenance medications. They will not be sent any SMS text reminders from the study.
46021619|NCT01203930|Drug|Idelalisib|Idelalisib 150 mg tablets administered orally twice daily
46107024|NCT00671255|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
46021620|NCT01203930|Drug|Rituximab|Rituximab 375 mg/m^2 administered intravenously once weekly x 8 weeks
46021621|NCT01254890|Drug|Azacitidine|75 mg/m^2 subcutaneously (SQ) or by vein (IV) daily for 7 days per 28 day cycle.
46021622|NCT01254890|Drug|Sorafenib|Starting dose level 200 mg by mouth two times a day in a 28 day cycle. In Phase II, Sorafenib administered per MTD dose from Phase I. Drug doses separated by approximately 12 hours.
46021623|NCT01203852|Drug|Metoprolol|"Metoprolol 50 mg twice daily titrated to 100 mg twice daily~Note: due to discontinuation of the manufacture of chlorthalidone 15 mg, effective Jan 1, 2013; the starting dose of chlorthalidone will be 25 mg 4 times per week (Mon, Wed, Thur, Sat) with subsequent titration to 25 mg daily."
46021624|NCT01203852|Drug|Chlorthalidone|Chlorthalidone 25 mg 4 times per week titrated to 25 mg daily
46021625|NCT01105533|Drug|PF-00337210|0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous
46021626|NCT01105533|Drug|PF-00337210|1mg Capsule Once Daily (Dose Escalation) Continuous
46021627|NCT01105533|Drug|PF-00337210|2mg Capsule Once Daily (Dose Escalation) Continuous
46107025|NCT00671255|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 5 weeks.
46107026|NCT00671255|Drug|Placebo|Ramelteon placebo-matching, tablets, orally, each night for up to 35 consecutive days.
46021628|NCT01105533|Drug|PF-00337210|4mg Capsule Once Daily (Dose Escalation) Continuous
46107027|NCT00911651|Drug|Salbutamol|400 µg inhalation once
46107028|NCT00911651|Drug|ipratropium bromide|80 µg inhalation once
46107029|NCT00665249|Behavioral|Motivational Interviewing|See MotivationalInterviewing.org
46107030|NCT00665249|Behavioral|Spirit-Only Motivational Interviewing|Non-directive elements encompass the use of MI-consistent, and avoidance of MI-inconsistent, behaviors, as well as attention to MI-spirit.
46107031|NCT00665249|Other|Self-Change|Participants are followed for 8 weeks, without therapeutic intervention. At end of assessment period, they receive 4 sessions of full MI.
46107032|NCT00665327|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg IV QD for a minimum of two doses followed by moxifloxacin 400 mg PO QD for a total treatment duration of 7 to 14 days
46107033|NCT00665327|Drug|Levofloxacin|Levofloxacin 500 mg IV QD for a minimum of two doses followed by Levofloxacin 500 mg PO QD for a total treatment duration of 7 to 14 days. For patients who have a documented or calculated creatinine clearance of 20 - 49 ml/minute, the IV and PO dose of Levofloxacin will be a 500 mg loading dose followed by 250 mg QD for a total treatment duration of 7 to 14 days
46107034|NCT00671333|Procedure|LRTI|"Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, trapeziectomy using a cruciate osteotomy and rongeurs, creation of a metacarpal base bone tunnel using a high speed burr, harvesting of entire FCR tendon through two transverse volar incisions, ligament reconstruction and tendon interposition using Fibre Wire suture. Closure of capsule with Vicryl. Closure of skin with running Prolene suture."
46021629|NCT01105533|Drug|PF-00337210|6mg Capsule Once Daily (Dose Escalation) Continuous
46107035|NCT00671333|Procedure|Ascension PyroDisk|Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, distal 2 mm of trapezium and dorsal cortex of both trapezium and metacarpal removed using osteotomes/rongeurs. A hole is drilled through the trapezium from dorsal to resected distal surface, and a second hole is drilled through the first metacarpal from the resected base to the dorsal surface. A slip of FCR is harvested. The tendon is woven through the trapezium, the central hole in the device, and the metacarpal tunnel then sutured back onto itself. Closure of capsule with Vicryl. Closure of skin with running Prolene suture.
46107036|NCT00823836|Drug|ropinirole PR/XR|"Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period."
46107037|NCT00823836|Drug|ropinirole IR|"Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period."
46107038|NCT00671411|Drug|Ultrasound with intravenous microbubble contrast injection|"Intravenous line will be inserted. After the ultrasound microbubble contrast has been suspended into solution, contrast will be injected intrav via hand bolus with a total activated suspension of 0.2 mL (30 uL octaflouropropane),followed by 10 mL saline flush, with option to rebolus 4 addit time's for tot dose of 150 uL. Post contrast cine images of renal mass will be obtained on commercially available US units primarily using low mechanical index settings & Contrast Pulsed Sequence (CPS®) technique. Images will be acquired at predetermined intervals, for up to 8 min post contrast admin. Manufacturer's guidelines incl immediate post flush image capture, as well as post admin image capture at intervals as 1 min, 2 , 4 & 8 mins. Additional, temporary higher mechanical index imaging of kidney for the purpose of flash bubble destruction may be optionally triggered using manufacturer's preset settings & energy w/i FDA guidelines. This will only be performed while imaging the kidney."
46021630|NCT01105533|Drug|PF-00337210|9mg Capsule Once Daily (Dose Escalation) Continuous
46107039|NCT04154735|Drug|Fludarabine|A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
45468522|NCT03430960|Other|Mobile App Survey|Participants will be followed-up via mCare mobile app
45468523|NCT04980157|Behavioral|CARES-HCV|CARES-HCV is an educational intervention to promote both hepatitis c screening and colorectal cancer screening among diverse baby boomers in the area.
46021631|NCT01105533|Drug|PF-00337210|8mg Capsule Once Daily (Dose Escalation) Continuous
46021632|NCT01105533|Drug|PF-00337210|4mg Capsule Twice Daily (Dose Escalation) Continuous
46021633|NCT01105533|Drug|PF-00337210|6mg Capsule Twice Daily (Dose Escalation) Continuous
46021634|NCT01105533|Drug|PF-00337210|6mg Capsule Twice Daily (Dose Expansion) Continuous
46021635|NCT01203072|Drug|DU-176b|DU-176b 5mg tablets oral, once daily for 2 weeks
46021636|NCT01203072|Drug|DU-176b|DU-176b 15mg tablets, oral once daily for 2 weeks
46021637|NCT01203072|Drug|DU-176b|DU-176b 30 mg tablets, oral, once daily for 2 weeks
46021638|NCT01203072|Drug|DU-176b|DU-176b 60 mg tablets, oral, once daily for 2 weeks
46107040|NCT04154735|Drug|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
46107041|NCT04154735|Drug|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
46107042|NCT04154735|Drug|Alemtuzumab|A protein that kills the immune cells that are thought to be causing Crohn's; it is commonly used in the treatment of leukemia and lymphoma
46107043|NCT04154735|Drug|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
46107044|NCT04154735|Drug|Rifaximin|An antibiotic used to treat irritable bowel syndrome and relapsing C. difficile infection; it inhibits DNA-dependent RNA polymerase
46107045|NCT04154735|Drug|Tacrolimus|A medication which suppresses the immune system and inhibits T-lymphocytes; commonly used to lower the risk of organ rejection following transplant
46107046|NCT00665405|Radiation|CT scan|Thoracic CT scan
46107047|NCT00665483|Other|Skin Prick Test|Skin Prick Test
46107048|NCT00705042|Drug|Etanercept|
46107049|NCT04030806|Other|Mirror therapy intervention and control intervention|"The exercise protocol will be composed of bimanual activities, performed by both the hands of the patient (paretic and healthy). The same protocol will be applied for both groups (intervention group and control group).~Initially, the desensitization of the limbs will be accomplished by brushing the skin with objects of different textures (sponge, brush, cloths). Afterwards, isolated exercises of fingers (flexion-extension, opposition), wrists (flexo-extension), forearms (prono-supination) and elbows (flexo-extension) and functional exercises such as cleaning a table with a cloth, tightening sponges, roll balls. Each exercise will be performed slowly and repeated for 15 times, totaling three series of each exercise. The protocol used will be based on the proposal of Rothgangel and Braun (2013). The intervention will be carried out by the author of the project and by students of scientific initiation."
46107050|NCT00879437|Drug|Valproic acid|"Daily (pre-XRT, During XRT, Post-XRT and Maintenance Therapy) Started at 15 mg/kg/day divided into three doses a day as soon as patients have recovered from surgery but no later than the first day of XRT.~Dosage will be adjusted in increments of 5 mg/kg/day every 3-5 days to achieve and maintain trough concentrations between 85 and 115 mcg/ml"
46107051|NCT00879437|Drug|Bevacizumab|All patients will receive bevacizumab (10 mg/kg iv) during the maintenance phase every two weeks for a maximum duration of therapy of 24 months.
46107052|NCT00879437|Radiation|Radiation therapy|Radiation therapy will start within 30 days of the definitive surgical procedure. Primary brain malignant gliomas will receive a total dose of between 54.0 and 59.4 Gy in 30-33 fractions over 6-7 weeks. Total dose will be 54.0 Gy for completely resected tumors and brainstem gliomas. The total dose will be 59.4 if the tumor is located in the brain but not the brainstem, and the tumor was incompletely resected. Primary spinal cord malignant gliomas will receive a total dose of between 50.4-54 Gy in 28-30 fractions over 5-6 weeks.
46107053|NCT04043832|Diagnostic Test|quantitative ultrasonic technique|Collection of all quantitative ultrasonic data was performed by one ultrasound physician
46107054|NCT00665639|Drug|micafungin|IV
46107055|NCT00665639|Drug|caspofungin|IV
46107056|NCT00671489|Dietary Supplement|Omega-3 Polyunsaturated Fatty Acid|A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
46107057|NCT00671567|Drug|Ramelteon|Ramelteon, 8 mg, tablets, orally, once daily for up to 5 weeks.
46107058|NCT00671567|Drug|Ramelteon|Ramelteon, 16 mg, tablets, orally, once daily for up to 5 weeks.
46107059|NCT00671567|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
46107060|NCT04153253|Drug|Aflibercept Injection [Eylea]|"Three monthly based intravitreal injections were given followed by PRP if the hemorrhage was sufficiently cleared.Intravitreal injection was done in sterile operating room, after sterilization and toweling with application of sterile speculum, Betadine 5% drops was instilled into the conjunctiva and kept for two minutes followed by wash with balanced salt solution. Injection of 2mg /0.05m aflibercept was given 4 mm from the limbus in phakic eyes and 3.5 mm in pseudophakic with compression by sterile cotton tip on the site of injection, Paracentesis was done in cases of very high IOP following injection. At the end of procedure check of visual acuity was done (to be at least light perception).~PRP was done if the hemorrhage is sufficiently cleared after the third injection."
46021639|NCT01203072|Drug|Placebo|Matching placebo oral tablets, once daily for 2 weeks
46021640|NCT01105377|Drug|entinostat|Given orally
46021641|NCT01105377|Drug|azacitidine|Given SC
46021642|NCT01105377|Other|laboratory biomarker analysis|Correlative studies
46021643|NCT04309071|Other|Dietary intervention|Salivary insulin responses to a standardized mixed meal
46021644|NCT01105065|Drug|brimonidine 0.15%|One drop in each eye three times a day for 8 weeks.
46021645|NCT01111539|Drug|Escitalopram|Escitalopram capsule administered orally, once daily without regard to meals.
46021646|NCT01111539|Drug|Aripiprazole|Aripiprazole capsule administered orally, once daily without regard to meals.
46021647|NCT01111539|Drug|Blinded capsule|Blinded capsule administered orally, once daily.
46021648|NCT02880345|Drug|PEMBROLIZUMAB|
46021649|NCT02880345|Radiation|hypofractionated radiation|
46107061|NCT04153253|Procedure|Vitrectomy|Was done under local peribulbar anesthesia. After sterilization and toweling, wash with diluted betadine 5% was done. Insertion of three 23 valved cannulas beginning with the lower temporal one for infusion, clearance of anterior vitreous was done followed by core vitrectomy, peripheral vitrectomy , removal of posterior hyaloid aided by triamcinolone staining , trimming and removal of any vascular epicenters followed by vitreous base shaving with 360 scleral indentation, endolaser treatment was done for all eyes followed by fluid air exchange, 20% SF6 was used only if there is active significant bleeding during surgery or if there is intraoperative retinal tears, removal of cannulas was done at the end of surgery. All eyes received combination of topical steroid and antibiotic eye drops as postoperative treatment.
46107062|NCT00671645|Drug|capecitabine, bevacizumab|Capecitabine 825 mg/m2 bid (on each therapy day of first 4 Therapy weeks) Bevacizumab 5 mg/kg weight; day 1, 15, 29
46021650|NCT02880267|Device|CGM|Glucose challenge during a clinic session to assess CGM performance compared to a laboratory reference measurement.
46021651|NCT02879955|Other|Glucose + Fructose|Ingestion of the separate monosaccharides glucose (25 g) and fructose (25 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
46021652|NCT02879955|Other|Sucrose|Ingestion of the disaccharide sucrose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
46021653|NCT02879955|Other|Isomaltulose|Ingestion of the slowly digestable disaccharide isomaltulose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
46107063|NCT00675857|Drug|NC-503 (eprodisate disodium)|capsules of 400 mg Dosage: 4 capsules (1600 mg) BID for 26 weeks
46021654|NCT02879955|Other|Sucrose + Acarbose|Ingestion of the disaccharide sucrose (47.5 g) and the alpha glucosidase inhibitor acarbose dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
46107064|NCT00675857|Other|placebo|Dosage: 4 capsules BID for 26 weeks
45838259|NCT04151667|Drug|Daratumumab Injection|Patient will receive daratumumab (1800 mg in 15 ml) administered by manual subcutaneous injections weekly for the first 8 weeks, every other week for the next 16 weeks and every 4 weeks after.
46021655|NCT02880033|Drug|deferiprone|to test the action of deferiprone on lymphocytes from patients and controls ex vivo
46021656|NCT02880033|Drug|placebo|to control the action of placebo on lymphocytes from patients and controls ex vivo
46021657|NCT04308993|Procedure|percutaneous transhepatic choledochoscopy|percutaneous transhepatic choledochoscopy
46021658|NCT05052645|Procedure|Auricular acupuncture|Placement of acupuncture needles in specific points on the ear in two consecutive treatments spaced 7 days apart.
46021659|NCT00625911|Drug|morphine|intravenous patient controlled analgesia, standard protocol
46021660|NCT00625911|Drug|morphine ketamine|low dose ketamine added to 2/3 standard dose of morphine
46021661|NCT04110496|Drug|RTX-134|RTX-134 is a cellular therapy containing AvPAL
46021662|NCT05052255|Drug|RVU120|RVU120 will be administered as a single oral dose every other day for a total of 7 doses over a 3 week treatment cycle until disease progression or unacceptable toxicity.
46021663|NCT01111149|Other|Sugar Pill|Sugar pill created and masked by the pharmacy to be used as a control.
46021664|NCT01111149|Drug|Varenicline|Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study.
46021665|NCT01111149|Drug|Bupropion HCl|in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study
46107065|NCT02629601|Behavioral|Active Rewards|Vitality standard active rewards wellness program for physical activity promotion
46107066|NCT02629601|Behavioral|Lottery 1|Participants have 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward
46107067|NCT02629601|Behavioral|Lottery 2|Participants have 1 in 2 chance of winning 2 times the reward and 1 in 200 chance of winning 80 times the reward
46107068|NCT02629601|Behavioral|Broadcasting winners|Participants are told how many individuals won the lottery during that week.
46107069|NCT02629601|Behavioral|Active Rewards Doubled|Vitality standard active rewards wellness program for physical activity promotion with double the magnitude of incentives
46107070|NCT00675935|Other|Fall Prevention Tool Kit prototype using a randomized design|Based on the results from Phase 1, Phase 2 and consistent with the literature that suggests that multifaceted, tailored interventions are most effective against inpatient falls, the FPTK prototype will be comprised of two interrelated components 1) The Fall Risk Alert and Communication Plan (translates an individual patient's fall risk assessment into a decision support intervention that communicates fall risk status to team members.) and 2) The Patient Safety Plan of Care PSPOC (translates an individual patient's fall risk assessment into a decision support intervention that creates a tailored evidence-based plan of care). The goal of the FPTK Intervention is to communicate risk status and recommended tailored discipline specific-interventions to prevent falls.
46021666|NCT01254656|Drug|lersivirine|Lersivirine 500 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
46021667|NCT01254656|Drug|lersivirine|Lersivirine 750 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
46021668|NCT01254656|Drug|efavirenz|Efavirenz 600 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
46021669|NCT01254656|Drug|lersivirine|Lersivirine 750 mg tablets PO taken once daily + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
46021670|NCT01254656|Drug|lersivirine|Lersivirine 1000 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
46107071|NCT02629523|Drug|Afatinib|Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
46107072|NCT02629679|Behavioral|Regular scholastic system and organized sports|This group will consist of children involved in regular school system who at the same time participate in organized sport in sport-clubs
46021671|NCT01254656|Drug|etravirine|Etravirine 200 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules taken twice daily + 1 optimized NRTI
46021672|NCT05544188|Diagnostic Test|Differential diagnostic|Physiotherapy aimed at correcting functional pathologies of the musculoskeletal system assessed by differential diagnosis (removal of trigger points, stretching of shortened muscles and mobilization of joint blockages)
46021673|NCT01110915|Device|Medtronic Advisa MRI Implantable Pulse Generator (IPG)|Advisa MRI IPG is a dual chamber, multi-programmable IPG indicated to restore heart rates, improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders. The IPG is indicated for use in patients who may benefit from rate-responsive pacing to support cardiac output during varying levels of activity and has been modified for use during an MRI exam.
46021674|NCT01110915|Device|Medtronic CapSureFix MRI™ active fixation MRI lead|The Medtronic CapSureFix MRI™ active fixation MRI lead is a transvenous, bipolar, silicone, steroid eluting and active fixation pacing lead. It is based on the commercially available Medtronic Model 5076 lead and has been modified for use in the MRI environment. The MRI lead is used for both atrial and ventricular applications.
46107073|NCT02629679|Behavioral|Regular scholastic system|The group will consist of children who are regularly in school, but not being involved in organized sport activities
46107074|NCT04152005|Other|Observation|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
45468524|NCT03856528|Other|collection of patient data|Patient data will be obtained using digital patients records systems. The following data will be assessed: Demographics and baseline patient characteristics (e.g., gender, age, hospital admission and discharge dates), diagnoses, comorbidities (history of meningitis and/or encephalitis, epileptic disorders, remote stroke, remote intracranial bleeding, remote autoimmune disease, neurodegenerative disorders), laboratory features (blood cultures, lumbar puncture), features of neuroimaging (e.g., time admission-to-CT), therapeutic features (incl. time admission-to-treatment), Patients' outcome measures (Glasgow Outcome Score)
46021675|NCT01254344|Drug|ertapenem sodium|Ertapenem sodium 1 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
46107075|NCT00671801|Drug|Irinotecan|200 mg/m^2 by vein over 90 minutes once every 2 weeks on days 1 and 15.
46107076|NCT00671801|Drug|Lenalidomide|Given orally at escalating doses beginning 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
46107077|NCT04153331|Other|Nasal swab|Patient included in emergency with a nasal swab
46107078|NCT04152161|Biological|BCG vaccine SSI|Participants will receive a single 0.1 milliliter (mL) volume of BCG vaccine SSI, administered intradermally in deltoid region of the upper arm.
46107079|NCT04152161|Biological|Placebo|Participants will receive a single 0.1 mL volume of normal saline, administered intradermally in deltoid region of the upper arm.
46107080|NCT00676325|Procedure|Surgical treatment of Anterior Vaginal Prolapse|seventy patients with greater anterior vaginal prolapse, whit stress incontinence or not, were randomly assigned to either colporrhaphy or polypropylene mesh repair (NAZCA TC™ POP REPAIR SYSTEM ) . The primary outcome was recurrent anterior vaginal prolapse, and secondary outcomes were effects on quality of life and sexual symptom scores, operative time, blood loss, length of hospitalization, and adverse events.
46107081|NCT00676325|Device|NAZCA TC™ POP REPAIR SYSTEM ,promedon® , argentina.|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction .
46107082|NCT00676325|Procedure|surgical treatment for anterior vaginal wall prolapse|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not requiring surgical correction were eligible for participation.
46107083|NCT00676481|Behavioral|HIV risk education|Education for Phase III participants about potential risk of HIV infection before being asked to take a rapid HIV test in the ED
46107084|NCT00672035|Biological|Biological: heat-labile enterotoxin of E. coli (LT)|LT patch applied on either the deltoid or the lower back.
46021676|NCT01254344|Drug|ceftriaxone sodium|Ceftriaxone sodium 2 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
46107085|NCT00676559|Drug|Efalizumab|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.
46107086|NCT00676559|Drug|Ranibizumab|Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
46107087|NCT00672113|Drug|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS 30 mg followed by Coracten 30 mg then back to nifedipine GITS 30 mg
46107088|NCT00672113|Drug|Coracten|Coracten 30 mg followed by nifedipine GITS 30 mg then back to Coracten 30 mg
46107089|NCT00676637|Drug|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
46021677|NCT01254344|Drug|placebo to metronidazole|Placebo (0.9% sodium chloride) administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
46107090|NCT00676637|Device|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
46107091|NCT00877799|Drug|CR845|CR845 (0.024 mg/kg) administered the day after surgery (Day 1)
46107092|NCT00877799|Drug|CR845|CR845 (0.008 mg/kg) administered the day after surgery (Day 1)
46107093|NCT00877799|Drug|CR845|CR845 (0.040 mg/kg) administered immediately after surgery (Day 0)
46107094|NCT00877799|Drug|Placebo|Matched placebo administered the day after surgery (Day 1)
46107095|NCT00877799|Drug|Placebo|Matched placebo administered immediately after surgery (Day 0)
46107096|NCT00672347|Drug|Clonidine|1 mcg/kg
46107097|NCT00672347|Drug|Morphine|20 mcg/kg
46107098|NCT00672347|Drug|Bupivacaine plus clonidine and morphine|"bupivacaine 0,166% 1 ml/kg~clonidine 1 mcg/kg~morphine 20 mcg/kg"
46107099|NCT00672347|Drug|Bupivacaine|Caudal anesthesia with bupivacaine 0,166% 1 ml/kg
46107100|NCT00676871|Drug|MEDI-538|Dose one of MEDI 538 as a continuous IV infusion - dose level is 5 mg/m2/24h (Phase 1)
46107101|NCT00676871|Drug|MEDI-538|Dose two of MEDI 538 as a continuous IV infusion - dose level is 10 mg/m2/24h (Phase 1)
46107102|NCT00676871|Drug|MEDI-538|Dose three of MEDI 538 as a continuous IV infusion-dose level is 15mg/m2/24h (Phase 1)
46107103|NCT00676871|Drug|MEDI-538|Dose four of MEDI 538 as a continuous IV infusion - dose level is 30 mg/m2/24h(Phase 1)
46107104|NCT00676871|Drug|MEDI-538|Dose five of MEDI 538 as a continuous IV infusion - dose level is 45 mg/m2/24h (Phase 1)
46107105|NCT00676871|Drug|MEDI-538|Dose six of MEDI 538 as a continuous IV infusion - dose level is 60 mg/m2/24h (Phase 1)
46021678|NCT01254344|Drug|metronidazole|Metronidazole 500 mg administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
46021679|NCT02879877|Drug|UCB7858|
46021680|NCT02879877|Drug|Placebo|
46021681|NCT05051007|Drug|fentanyl|patients will receive 1 mcg/kg of fentanyl (the drug will be diluted to 10 mcg/mL)
46107106|NCT00676871|Drug|MEDI-538|Phase 2 part of the study, 20 to 60 patients will be treated with MEDI 538 as a continuous IV infusion through a central line catheter. The dose of MEDI-538 will be determined in the Phase 1 part of the study.
46107107|NCT00676949|Biological|5 peptide vaccines of KOC1, TTK, CO16, DEPDC1, MPHOSPH1|1mg each of 5 peptides with IFA. 4 weekly s.c. administration.
46107108|NCT02629445|Device|Cardiac Resynchronisation Defibrillator|Defibrillation testing of cardiac defibrilator
46107109|NCT00677027|Other|lentinan|Five dose levels of escalating concentrations of the test substance will be tested during the study periode. All patients will recieve each dose, which is to be taken daily for two weeks.
46107110|NCT00677027|Other|placebo|Placebo
46107111|NCT00672581|Drug|ZD4054|10mg, Oral tablet, single dose
46107112|NCT00595127|Drug|Cyclophosphamide|Cyclophosphamide (10mg/kg/day x 4days)
46107113|NCT00595127|Drug|Fludarabine|Fludarabine (30mg/m^2/day x 5 days)
46107114|NCT00595127|Radiation|Total body irradiation (TBI)|TBI (450 cGY in a single fraction)
46107115|NCT00672659|Drug|Citalopram + Pipamperone|Citalopram, 40 mg daily, 8 weeks Pipamperone, 5 mg twice daily, 8 weeks
46107116|NCT00672659|Drug|Citalopram|Citalopram, 40 mg daily, 8 weeks Placebo, dummy, twice a day, 8 weeks
46107117|NCT00877487|Drug|SPD489 (Lisdexamfetamine dimesylate)|1 capsule (either 30, 50, or 70mg strength) per day for 6 weeks.
46107118|NCT00877487|Drug|Placebo|1 capsule (identical to drug capsules) per day for 4 weeks during the double blind period.
46107119|NCT02629211|Device|NaviAid™ AB|NaviAid™ AB Procedure
46021682|NCT05051007|Drug|Lidocaine IV|patients will receive 1 mg/kg lidocaine (the drug will be diluted to10mg/mL)
46107120|NCT00677261|Procedure|Sciatic Nerve Block|Patients randomized to Group 1 will receive a single sciatic nerve block using the infragluteal parabiceps approach, using 20 ml of 0.5 % Ropivacaine. A sham injection of the posterior capsule and fat pad using 50 cc of normal saline will be conducted at the conclusion of the surgery.
46021683|NCT02881671|Genetic|genetic blood analysis|patients will undergo a blood sample (15 ml) to analyse their genetic profile
46021684|NCT02879565|Other|Semi structured interviews + EEG exams|
46021685|NCT04310319|Dietary Supplement|Sodiumchloride|Subjects will receive 4 capsules containting 750 NaCl each 2dd, making a total of 6 grams NaCl per day.
46021686|NCT04310319|Dietary Supplement|Protein|Subjects will receive 2dd 40 ml of a protein beverage containing 0.5 grams of protein per ml, making a total of 40 grams of protein per day.
46107121|NCT00677261|Procedure|Posterior capsule infiltration with local anesthetic|Patients randomized to Group 2 will receive a Sham sciatic nerve block using 20cc of normal saline as described above as well as extensive local anesthetic infiltration of the posterior capsule and fat pad with a solution of 50 ml of 0.2% ropivicaine.
46107122|NCT00677261|Procedure|Sham sciatic block and sham posterior infiltration|Patients randomized to group 3 will only receive a continuous femoral nerve catheter, A sham sciatic nerve block with 20cc of normal saline as well as a sham injection of the posterior capsule and fat pad will be performed with 50cc of normal saline.
46107123|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group C (high dose) will receive a loading dose of EACA of 100 mg/kg over ten minutes followed by a continuous EACA infusion at 40 mg/kg/hr, which will be continued until the end of surgery.
46107124|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group A (low dose) will receive a loading dose of EACA of 25 mg/kg over ten minutes followed by a continuous EACA infusion at 10 mg/kg/hr, which will be continued until the end of surgery
46021687|NCT04310319|Dietary Supplement|Placebo comparator (salt)|Subjects will receive 4 placebo capsules (identical to salt capsules) 2dd.
46107125|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group B (intermediate dose) will receive a loading dose of EACA of 50 mg/kg over ten minutes followed by a continuous EACA infusion at 20 mg/kg/hr, which will be continued until the end of surgery
46107126|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group D (extra low dose) will receive a loading dose of EACA of 12.5 mg/kg over ten minutes followed by a continuous EACA infusion at 5 mg/kg/hr, which will be continued until the end of surgery
46107127|NCT02629289|Drug|HSP-130|
46107128|NCT02629289|Drug|US-approved Neulasta|
46107129|NCT02629289|Drug|EU-approved Neulasta|
46107130|NCT00677339|Drug|L-arginine|L-arginine 6g orally daily
46021688|NCT04310319|Dietary Supplement|Placebo comparator (protein)|Subjects will receive 2dd 40 ml of placebo beverage (identical to protein beverage).
46021689|NCT05044845|Behavioral|Interview|Semi structured interview will be conducted virtually using an online video-conferencing platform, phone or in person.
46021690|NCT01102803|Behavioral|Individual Cognitive Behavioral Therapy (CBT)|The aim of CBT is to help participants become more comfortable with heights situations. Participants will receive 2 sessions over two weeks of individual CBT.
46021691|NCT01102803|Drug|D-Cycloserine|D-Cycloserine
46107131|NCT00677339|Drug|Vitamin D|Cholecalciferol 50000 IU once monthly orally
46107132|NCT00677339|Drug|Placebo L-arginine|placebo L-arginine once daily
46107133|NCT00677339|Drug|Placebo Vitamin D|placebo vitamin D orally once monthly
46107134|NCT00672893|Other|Vibration Response Imaging|12 seconds of recording lung sounds
46107135|NCT00672971|Other|4% dimethicone foam|The dimethicone foam is applied to dry hair and left on the hair for approximately 15 minutes. The product is then removed by washing the hair with baby shampoo. The foam is applied two time, separated by an interval of 7-9 days.
46107136|NCT00672971|Other|1% permethrin|Nix® Cream Rinse is applied as indicated on the product labeling. The cream rinse is applied to wet hair and left on the hair for 10 minutes. The hair is then rinsed with tepid water to remove the product, toweled dry, and combed with a detangling comb. The product is applied two times, separated by an interval of 7-9 days.
46107137|NCT00673205|Drug|Bicalutamide|150mg p.o. daily
46107138|NCT00673205|Drug|Placebo|
46107139|NCT00673283|Device|bi-plane chest radiography|Bi-plane radiography of the thorax
46021692|NCT01102803|Drug|Placebo|Sugar Pill
46021693|NCT01254188|Drug|Nilotinib|This was an open-label, single-arm, prospective, multi-center, Phase IIIb clinical study with nilotinib 300 mg bid treatment in newly diagnosed CML-CP patients not previously treated with imatinib therapy and diagnosed within 6 months of study entry. For patients insufficiently responding to nilotinib 300 mg bid, the dose may have been increased to 400 mg bid. Among patients with adverse events who had dose reduction, this study also allowed a possible re-escalation to 300 mg bid.
46021694|NCT01109979|Drug|Estradiol+MPA|1 single pill dose daily containing estradiol 1 mg + medroxyprogesterone acetate 2.5 mg
46021695|NCT01109979|Drug|Estradiol+Drospirenone|1 single pill dose daily containing estradiol 1mg + drospirenone 0.5 mg
46021696|NCT01102491|Drug|Ramosetron|ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days
46021697|NCT01102257|Drug|Omega-3 EFA Supplement|"The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 EFAs comprised of:~2000 mg EPA 1000 mg DHA"
46107140|NCT04153019|Other|Psychoeducational and rehabilitative intervention|Psycho-educational session: 3 weekly face-to-face consultations between a dyads and trained nurses, helping them to cope with cancer cachexia strengthening dyadic coping resources; 2) Rehabilitation program: 3 sessions with physiotherapists including educational component for patients self-management on physical activity and goal-setting, personalized program of exercises stretching and relaxation + 3 home sessions per week, self-managed by dyads.
46107141|NCT00677495|Dietary Supplement|Gluten-free diet|Gluten-free diet
46107142|NCT00677573|Drug|Fostimon|450 IU for 4 days then adjusted
46107143|NCT00677651|Procedure|Adipose Biopsy|Adipose tissue will be sampled from the abdomen and buttock
46107144|NCT00677651|Procedure|Blood sample|Blood will be sampled from an IV line
46107145|NCT00677651|Radiation|CT Scan|Single image at the level of the liver
46107146|NCT00677651|Radiation|DEXA|Whole body scan
46107147|NCT02628431|Device|Elfi tech monitor|
46107148|NCT00677105|Drug|JNJ-26481585|
46107149|NCT00677729|Drug|solution contains 1 mg salbutamol plus 3% hypertonic saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline every 20 minutes for a total of 3 doses
46107150|NCT00677729|Drug|solution contains 1 mg salbutamol plus 0.9% saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl) every 20 minutes for a total of 3 doses
46021698|NCT01102257|Drug|Olive Oil|Placebo group will take 5 capsules a day containing 3.0 grams of olive oil
46021699|NCT01253564|Drug|RO5185426|960 mg b.i.d. orally
46021700|NCT04309149|Dietary Supplement|MCT fats|Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period (21 days taking the new products with 2 days between each new product trialled).
46021701|NCT01108809|Drug|Telmisartan or Telmisartan and Hydrochlorthiazide|Telmisartan 80mg +/- Hydrochlorthiazide 12.5mg or 25mg
46021702|NCT01253408|Drug|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects will receive either 2.5 mg bid, or 5 mg bid, taken orally with water for 2 days.
46021703|NCT01253408|Drug|Placebo|Placebo will match study drug; taken orally with water twice per day for two days.
46021704|NCT02879799|Other|Implement Family Integrated Care|Specially trained FICare nurses will provide education and support for families to provide care for the baby while they are present in the NICU. Study mothers will meet with veteran parents for additional support. Families will keep a log of their activities and costs.
46021705|NCT05506982|Drug|Psilocybin|Given PO
46021706|NCT05506982|Behavioral|Psychotherapy|supportive care
46021707|NCT05506982|Other|Quality-of-Life Assessment|Ancillary studies
46021708|NCT05506982|Other|Questionnaire Administration|Ancillary studies
46021709|NCT02879643|Drug|Marqibo|The focus of the study design and statistical analysis is to determine whether Marqibo® can be substituted for standard vincristine and successfully administered to patients with relapsed ALL in three different treatment cohorts: (A) treatment with the UK ALL R3 regimen; (B) treatment with UK ALL R3 regimen without mitoxantrone, and (C) treatment with ALL maintenance therapy. Secondary objectives include estimating rates of serious toxicities and therapy delays in each of these cohorts.
46107151|NCT02629055|Other|Respiratory EMG|Titration of non-invasive ventilation on surface respiratory muscle activity
46107152|NCT02628509|Device|cardiac devices|patients receiving mechanical circulatory support or undergoing trans aortic valve replacement
46107153|NCT02635295|Behavioral|Mobile cooperation during the clinical practicum|"The intervention include (1) use of mobile application in nursing student - nurse teacher (NT) cooperation during the 5 weeks clinical practicum and (2) training at the beginning of the clinical practicum in the functions of the mobile application by the researcher.~Students in the intervention group use mobile application for documentation of the terms of hours, learning diaries, objectives as well as mid-point and end-evaluation during the clinical practicum. NT and students have direct access to documents in the mobile application and to wireless communication regardless of time and place. The actions in the mobile application are automatically saved and shared between student and the NT."
46107154|NCT02635139|Behavioral|Breakfast skipping|18h fasting period in the morning
46107155|NCT02635139|Behavioral|Dinner skipping|18h fasting period in the evening
46021710|NCT02879487|Device|Monopolar needle electrode|Colpotomy during total laparoscopic hysterectomy
46021711|NCT02879721|Drug|Candesartan|Angiotensin II, type 1 receptor inhibitor, (candesartan) 8 mg once daily for
46021712|NCT02879721|Drug|Enalapril|Angiotensin-converting enzyme (ACE) inhibitor (enalapril) 5 mg once daily
46021713|NCT05036343|Device|InPen®|A smartpen that has been FDA approved for children with diabetes age seven years and older that uses an app on a smartphone to help calculate insulin doses using the amount of carbohydrates that will be consumed at a meal along with what the current blood sugar reading is, to give a correction dose as well. The InPen app also serves as a log book to record insulin doses given, blood sugar at the time of a meal, and amount of carbohydrate eaten.
46021714|NCT01253174|Drug|EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|single oral administration of 1 coated tablet SH T470FA (Yasmin, film-coated tablets with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)
46021715|NCT01253174|Drug|EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|single oral administration of 1 coated tablet SH T04532A (film-coated tablet with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin
46021716|NCT01253174|Drug|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated tablet SH T04532C, containing 0.451 mg Metafolin
46021717|NCT01108731|Drug|Milnacipran|"Patients will take an increasing number of 12.5mg pills for the first 9 days during the ramp up period and then take one 50mg pill in the morning and one 50mg pill in the evening for the remaining 8 weeks of the study."
46107156|NCT02628275|Behavioral|Moderate to vigorous physical activity|55-90% maximum heart rate for 150min/week (current recommendations)
46107157|NCT02628275|Behavioral|Light physical activity|40-55% maximum heart rate for 150min/week
46107158|NCT02628353|Dietary Supplement|placebo|1 capsule of placebo product (100 mg carboxymetylcellulose) in one visit
46021718|NCT01108731|Drug|Placebo|"Patients will take an increasing number of placebo pills for the first 9 days during the ramp up period and then take one pill in the morning and one in the evening for the remaining 8 weeks of the study."
46107159|NCT02628353|Dietary Supplement|phenolic compound|1 capsule of phenolic compound product (100mg phenolic compound + 100 mg carboxymetylcellulose) in one visit
46107160|NCT02628197|Dietary Supplement|calcium (500mg) and vitamin D (250I.U.)|calcium (500mg) and vitamin D (250I.U.) was given twice a day for 6 months
46021719|NCT04308447|Device|AbleLite|The AbleLite device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
46107161|NCT02628197|Procedure|Scaling and root planing|scaling and root planing was done in the test group along with calcium (500mg) and vitamin D (250I.U.)
46107162|NCT00673751|Drug|GLP-2|450 nmol subcutaneous
46107163|NCT00673751|Drug|Placebo|
46021720|NCT01253018|Behavioral|Robot Therapy|Robot assisted arm exercise for 60 minutes progressing each month through three robot modules: wrist, planar, and alternating sessions on the wrist and planar robot 3x/week for 12 weeks.
46107164|NCT00911885|Behavioral|Dietary Intervention|The efficacy of the two dietary change interventions will be compared in a randomized controlled trial, with 120 patients per group. The two approaches are 1) the American Heart Association (AHA) Dietary Guidelines; and 2) a simple dietary change condition that focuses on increasing fiber. Patients in both conditions will receive intensive dietary instruction for 3 months, followed by a 9 month maintenance phase. Both conditions will receive dietary instructions via individual and group sessions led by registered dietitians.
46021721|NCT01253018|Behavioral|Transition to Task Training|Robot therapy as described for 45 minutes and 15 minutes of task specific arm exercise using the hemiparetic arm 3x/week for 12 weeks.
46021722|NCT04308915|Behavioral|Game-based cognitive training|A suite of 5 games is presented to the participants for training working memory
46021723|NCT04308525|Behavioral|Early ambulation|Early ambulation will help prevent postoperative infections, especially pneumonia and urinary tract infections. Additionally it will prevent constipation by promotion of bowel-movement and function and prevent thromboembolic complications. Patients undergoing surgery with a free fibula flap are currently unable to ambulate for 6 to 7 days while a split-thickness skin-graft is healing. We will apply a pressure dressing to the wound which makes ambulation possible immediately after surgery (or after return from the ICU). Likewise, all other patient groups will be encouraged to fully ambulate on POD (post-operative day) 1 or POD 2.
45838260|NCT04151667|Drug|Dexamethasone Oral|The dexamethasone starting dose will be 20 mg PO once a week. Commercial dexamethasone will be used. Dexamethasone is often supplied in 4 mg tablets. Accordingly, patients will take 5 (4 mg tablets) one day of the week prior to the administration of daratumumab if this corresponds to a daratumumab dosing days. In non daratumumab dosing days, dexamethasone will be taken by the patient at home, usually in the morning with breakfast.
46021724|NCT04308525|Behavioral|Early oral feeding|To monitor the patients' nutritional status, blood samples will be taken to identify risk of refeeding syndrome and patients will be evaluated according to the current guidelines from the ENT (ear-, nose-, throat-) department. We wil use the ESPEN guidelines for nutritional risk screening (NRS-2002), which have been validated for head and neck cancer patients to perform a risk assessment for malnutrition. A consultation with a clinical dietician will be arranged in order to calculate the required daily nutritional intake. Patients in risk of refeeding syndrome will be closely monitored in the outpatient clinic during the time from the MDT(Multi Disciplinary Team) conference to the day of surgery. Patients in need of additional nutritional support will be provided with supplementary energy/protein drinks. Some patients may need closer monitoring, guidance regarding extra meals and to have a nasogastric tube placed to get used to the tube and optimize pre-operative nutritional status.
46021725|NCT04308525|Other|Multimodal opioid-sparing analgesia|"On-label use of already approved drugs including perioperative dexamethasone, administered with the aim of reducing opioid intake.~Pre-operatively the patients are given 400 mg of Celebra. During surgery 24 mg of dexamethasone is administered. The post-operative regimen consists of 12 mg of Dexamethasone 48 and 96 hours post-operatively, 200 mg of Celebra morning and evening (maximum 14 days) and 1g of paracetamol times four times daily. Morphine will only be administered when assessed necessary with a dose of 10 mg p.n. maximum six times a day."
46021726|NCT04308525|Procedure|Goal-directed fluid therapy|Focus on avoidance of over-hydration. Aim for fluid-load after surgery: max: +1000-1500 ml
46107165|NCT00677963|Drug|sulphur hexafluoride, gadopentate dimeglumine|CE-US, using 2 x 2.4 ml sulphur hexafluoride and MRI, using 1 x 0.2 ml/kg gadopentate dimeglumine
46107166|NCT00673829|Biological|Gene Modified T Cells|Gene Modified T Cells Phase Ia: One time infusion Modified TCells given through a vein in the arm or a catheter over a 30-60 minute period
46107167|NCT00673829|Biological|Gene Modified T Cells and Interleukin 2|One time infusion Modified T Cells without or with (randomized) continuous infusion outpatient interleukin 2 (IL2) for two weeks
46107168|NCT02628119|Procedure|Intra-procedural access flow|"Intra-procedure access flow technique:~Room temperature saline is injected into the vascular access blood stream during angioplasty via ReoCath(tm) 6 French antegrade or retrograde flow catheters. When the saline is injected into the access, an injection thermistor located close to the proximal end of the catheter records the temperature of the injected saline. A second thermistor located close to the distal tip of the catheter then records the thermodilution within the access and the HVT100 endovascular flow meter calculates and displays intragraft blood flow in ml/min."
46021727|NCT04308525|Procedure|CAD/CAM system for reconstructive plates|Computer-assisted design and modelling (CAD/CAM) are a system for pre-operative planning and construction of reconstructive plates used for mandibular reconstruction. This will help reduce the operating-time, as the maxillofacial surgeon will bring a pre-bent reconstructive plate to the procedure instead of manually forming it during surgery. Already implemented for several procedures in the department.
46107169|NCT02628119|Procedure|Standard Angioplasty|Intervention based on 2 Dimensional fluoroscopy views
46107170|NCT04152629|Drug|Methylphenidate Hydrochloride|CR Methylphenidate Hydrochloride given once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg or 100 mg)
46021728|NCT04308525|Other|Functional discharge criteria|Introduction of a number of functional discharge criteria to avoid prolonged postoperative hospitalisation
46021729|NCT04308525|Other|Standard/historical postoperative regimen|Non-formalised historical peri- and postoperative regimen.
46021730|NCT02881437|Drug|IgHy10|Sub Cutaneous IgHy10 administration
46107171|NCT04152629|Drug|Lisdexamfetamine Dimesylate|Lisdexamfetamine Dimesylate given once daily (10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg)
46107172|NCT02628977|Behavioral|Peer Based Sleep Health Education and Social Support|Participants randomly assigned to the intervention arm will receive Obstructive Sleep Apnea education and social support from a trained Peer Educator.
46021731|NCT01108341|Drug|Bendamustine hydrochloride|Bendamustine will be administered at 90 mg/m^2 as a 30-minute intravenous (iv) infusion on days 1 and 2 of each cycle.
46021732|NCT01108341|Drug|Ofatumumab|Ofatumumab will be administered at 300 mg as an iv infusion on day 1 and 1000 mg on day 8 of cycle 1 and 1000 mg on day 1 of each subsequent cycle.
46107173|NCT02628977|Behavioral|Attention Control Group|Participants assigned to this arm of the study will receive standard sleep literature, providing information about OSA and access to available sleep services.
46021733|NCT01108263|Drug|INTEGRA™ Flowable Matrix (Collagen)|INTEGRA™ Flowable Wound Matrix is an advanced 3-D porous matrix comprised of granulated cross-linked bovine tendon collagen and glycosaminoglycan. It provides a scaffold for cellular invasion and capillary growth. The collagen and glycosaminoglycan mix is hydrated with saline and applied on the wound bed.
46107174|NCT04152707|Device|Splendor X|The Splendor X has two wavelengths in one system: Nd:YAG (1064nm) and Alexandrite (755nm).
46021734|NCT01252940|Drug|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily (QD)
46021735|NCT01252940|Drug|PI|Protease inhibitors (PIs) included amprenavir, atazanavir, darunavir, fosamprenavir, Kaletra (lopinavir/ritonavir, coformulated), ritonavir, and saquinavir. PIs were administered according to prescribing information.
46021736|NCT01252940|Drug|RTV|Ritonavir (RTV) was administered according to prescribing information.
46021737|NCT01252940|Drug|NRTIs|NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF, Truvada® (emtricitabine/tenofovir DF, coformulated), and zidovudine. NRTIs were administered according to prescribing information.
46021738|NCT02879331|Procedure|10 coils in upper lobes|
46021739|NCT02879331|Procedure|15 coils in upper and lower lobes|
46107175|NCT00673907|Other|Wood smoke particles|Subjects are exposed at rest to the exposures for 3 h in our climate chamber
46107176|NCT02535299|Drug|Liraglutide|GLP-1 analog (1.2mg-1.8mg/day) treatment for 6 months
46107177|NCT02535299|Drug|Metformin|Metformin(1500mg-2000mg/day) treatment for 6 months
46107178|NCT00673985|Other|Percutaneous Transluminal Angioplasty|Balloon Angioplasty
46107179|NCT00673985|Device|LifeStent NT™ Self-Expanding Peripheral Stent|Balloon angioplasty plus stent
46107180|NCT05209763|Procedure|More intensive rehabilitation|Patient exercises with physiotherapists, staff assists with normal activities during the day, activation, and mobilization in and out of bed according to the patient's ability.
46107181|NCT05209763|Dietary Supplement|More intensive nutrition|"in addition, the patient will be administered hydroxymethylbutyrate at a dose of 3 g/day - in case of ONS indication (oral nutrition support, formerly sipping) in this form (Ensure advance plus 2 times a day), in case of non-indication or impossibility or intolerance of this form then in the form of a food supplement (Myotec HMB). The minimum total dose delivered is 12 g/5 days.~in case of hypovitaminosis D and serum Ca concentration up to 3.0 mmol/l, vitamin D will be administered at a dose of 3000 IU/day - cumulative 15000 IU/5 days (missing dose can be given at the end of the cycle in one dose)~inclusion of probiotics in standard doses"
46021740|NCT02879331|Procedure|cycloergometry|
46107182|NCT02628041|Radiation|Permanent Iodine-125 seed implant|"Permanent Iodine seed implant is performed under general or epidural anesthesia with the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, the prostates is scanned and the dosimetry is generated. Catheters are inserted in the prostate and the seeds are injected using the Nucletron automatic after loader according to the dosimetry plan.~The catheters are removed at the end of the procedure."
46107183|NCT02628041|Radiation|High-Dose-rate Prostate Brachytherapy|"High-Dose-Rate Prostate brachytherapy is performed under general or epidural anesthesia, the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, catheters are inserted in the prostate to assure adequate coverage. The patient is returned in dorsal decubitus and a CT scan or Ultrasound scan is performed. A inverse-planning dosimetry plan is generated to deliver 19 Gy to the target volume. The patient is treated and then the implant is removed and anesthesia is reversed."
46107184|NCT00674063|Drug|alefacept|IV
46021741|NCT04319744|Other|other|Our hypothesis is that playing video games may have positive effects on videostile use, but there is no research on this subject Our goal is to compare the performances of anesthesia assistants who have played video games with those who did not.
46107185|NCT04151459|Drug|Metformin|Use Metformin for 3 months to treat PCOS
46107186|NCT00674141|Drug|Dexamethasone soduim phosphate|nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment
46107187|NCT00678197|Other|Access Intervention|
46107188|NCT00678197|Other|Bonus/Pay-for-Performance Intervention|
46107189|NCT00678275|Drug|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen with ATG: ATG FRESENIUS dosing: 10mg/kg/day, (day -3, -2,-1) when randomised Arm A
46107190|NCT00678275|Drug|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen WITHOUT ATG when randomised Arm B
46107191|NCT00878501|Drug|AZD1386|oral, during 4 weeks
46021742|NCT04206878|Diagnostic Test|Point-of-care birth test|Collect quantitative data through clinical chart and form abstractions; collect qualitative data through in-depth interviews with caregivers, health workers and policymakers
46021743|NCT01252238|Drug|Aliskiren|Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.
46107192|NCT00878501|Drug|AZD1386|oral, during 4 weeks
46107193|NCT00878501|Drug|Placebo|Oral, during 4 weeks
46107194|NCT00674375|Other|Electronic risk alerts|Electronic risk alerts within the electronic medical record system will automatically calculate a patient's Framingham Risk Score during office visits for chest pain. These alerts will recommend electrocardiogram performance and aspirin therapy for patients with Framingham Risk Score at least 10%, and will recommend against exercise stress testing for patients with a Framingham Risk Score less than 10%.
45468525|NCT04537351|Biological|CYP-001|The active agent in CYP-001 is Cymerus mesenchymal stem cells (MSCs), which are derived through a proprietary induced pluripotent stem cell (iPSC) and mesenchymoangioblast (MCA)-derived production process.
45468526|NCT03436264|Other|MRI|fMRI
45468527|NCT03318315|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
45468528|NCT03318315|Biological|Inactivated influenza H7N9 vaccine|Monovalent 2017 H7N9 inactivated influenza vaccine
46021744|NCT01252238|Drug|Valsartan and Aliskiren|Subject taking combination of valsartan and aliskiren.
46021745|NCT01252238|Drug|Amlodipine|Taking Amlodipine as prescribed by MD for management of high blood pressure.
45681292|NCT04020094|Combination Product|MVA-BN-Brachyury|"Cycle= 21 days. Neoadjuvant Therapy: Treatment will be given for 2 neoadjuvant cycles. MVA-BN-Brachyury will be administered as intratumoral injection on Day 1 of each of 2 neoadjuvant cycles. PROSTVAC-V will be administered as a subq injection on Day 1 of Cycle 1 (the first neoadjuvant cycle) and PROSTVAC-F will be administered as a subq injection on Day 1 of Cycle 2 (the second neoadjuvant cycle). Atezolizumab will be given as an infusion on Day 1 of each 2 neoadjuvant cycles.~MVA-BN-Brachyury will be injected intratumorally into the prostate. Injections will target PI-RADS 4 and 5 lesions.~Surgery: Patients will undergo SOC radical prostatectomy Adjuvant Therapy: Systemic treatment with atezolizumab and PROSTVAC-F will be reinitiated between 3 to 8 weeks after surgery and will continue for an additional 6 cycles. PROSTVAC-F will be given as a subq injection on Day 1 of each cycle. Atezolizumab will be given as an infusion on Day 1 of each cycle."
45681293|NCT04025476|Drug|Steroids|IV and oral steroids
46107195|NCT04162145|Device|Active BRIDGE device placement|The active BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
46107196|NCT04162145|Device|Inactive BRIDGE device placement|The inactive or sham BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
46107197|NCT02627885|Behavioral|Internet-based CBT|Through the use of CBT material at an Internet-platform, we aim for behavioral changes in the subjects to improve everyday level of functioning and quality of life.
46107198|NCT02627885|Other|SMT|Standard Medical Treatment includes pharmacological management and other typical medical interventions for the patient group but no behavioural interventions
46107199|NCT00674453|Drug|Lasofoxifene|Oral tablet, 0.25 mg, daily, 2 years
46107200|NCT00674453|Other|Placebo|Matching placebo tablet given once daily for 2 years
46107201|NCT02634671|Other|schizophrenia|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia with a control group using an experimental paradigm based on electroencephalography (EEG)
46107202|NCT02634671|Other|the 22q11 deletion syndrome|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
46107203|NCT02634671|Other|control group|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the schizophrenia and 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
46107204|NCT02627807|Radiation|IMRT using individualized CTV|Intensity modulated radiotherapy (IMRT) using individualized CTV based on disease extension risk atlas and computer-aided delineation is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
46021746|NCT01101477|Procedure|TCI titration by different Cet.|"Induction:~After topical xylocaine and alfentanil 5μg/kg iv 1 minute before, Cet 2.0μg/ml is started on the TCI pump ('Vial Injectomat TIVA Agilia syringe infusion pump, Fresenius Kabi, France). The sedative level will be accessed by sedation scale OAA/S every 30 seconds till OAA/S ≦3(Responds only to name called loudly). The current Ce will be set as the maintenance Cet.~If desired OAA/S is not achieved after reaching 2.0μg/ml,Cet will be increased every 90 seconds by the regimens be assigned until OAA/S ≦3. The current Ce will be set as the maintenance Cet.~Maintenance:~The Cet will be increased according to the assigned regimens if:~Patients become irritant and interfere procedures.~Patients open eyes or talk to express uncomfortable.~The Cet will be decreased if:~Systolic blood pressure is less than 90mmHg;~Mean arterial blood pressure is less than 65mmHg;~Oxyhemoglobin saturation is less than 90 %~with any duration."
46021747|NCT00624260|Other|semi-annual systematic PET-TDM|semi-annual systematic PET-TDM
45468529|NCT03318315|Biological|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N2) and 2 influenza B subtypes (B Yamata lineage and B Victoria lineage).
45468530|NCT03318315|Other|Phosphate Buffered Saline (PBS) diluent|Diluent for Adjuvanted 2017 Monovalent Inactivated Influenza A/H7N9 vaccine (2017 H7N9IIV)
45681294|NCT04025320|Other|Intraneural Facilitation|Intraneural Facilitation utilizes three manual holds. Firstly, the contralateral joint is placed in a maximal loose-pack position to pressurize the nervous system and bias circulation from the artery into the epineurium. Now that we have increased this pressure we begin the secondary hold to bias the increased epineurial blood into the transperineurial vessels that bridge the epiperineum and the endoneurial capillaries of the site being treated. Now that the pressure has increased into the open endoneurial capillaries, the goal is to open up ischemic endoneurial capillaries and this is hypothesized to open by providing the third hold. The third hold is known as the sub hold and encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of bernoulli's principle. This treatment will take 50-60 minutes.
46021748|NCT00624260|Other|PET-TDM for current indication|PET-TDM for current indication (high isolated markers or before a metastasis curative resection)
46021749|NCT04308213|Device|Marrow Cellution System|The treatment will be carried out in the operating room under ordinary hospitalization and provides the intra-articular application of 9 ml of autologous bone marrow aspirate in the glenohumeral joint affected by arthrosis. To obtain the necessary amount, a bone marrow aspirate of about 12 ml will be taken from the iliac crest by means of the Marrow Cellution System, Geistlich Italia. This autologous bone marrow aspirate will be injected using the same syringe into the glenohumeral joint affected by arthrosis under amplioscopic control.
46107205|NCT02627807|Radiation|IMRT using traditional CTV|Intensity modulated radiotherapy(IMRT) using traditional CTV is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
46107206|NCT02627807|Drug|Gemcitabine and cisplatin (induction chemotherapy)|Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who participate in another randomized trial (NCT01872962) at the same time receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy.
46107207|NCT02627807|Drug|Docetaxel and cisplatin (induction chemotherapy)|Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who haven't participated in other trials receive docetaxel (75 mg/m² d1) and cisplatin (75mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles before radiotherapy.
46021750|NCT05503394|Behavioral|Peer support WeChat platform intervention|Primary caregivers of children with biliary atresia are selected as the study population and divided into intervention and control groups in chronological order at a children's hospital in Shanghai. Primary caregivers who visit the hospital between August 2022 and October 2022 are assigned to the control group and primary caregivers who visit the hospital between January 2023 and March 2023 are assigned to the intervention group. The intervention group will receive a peer support WeChat platform intervention from the day of surgery to one month postoperatively. The level of negative emotions and caregiver burden will be compared between the two groups after the intervention. The intervention group receives the same routine care as the control group.
46107208|NCT02627807|Drug|Cisplatin 100mg/m² concurrent chemotherapy|Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC. Patients who participate another clinical trial (NCT01872962) at the same time receive cisplatin (100mg/m² d1) every 3 weeks for 3 cycles concurrently with radiotherapy.
46107209|NCT02627807|Drug|Cisplatin 80mg/m² concurrent chemotherapy|Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC.Patients who haven't participated in other trials receive cisplatin (80mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles concurrently with radiotherapy.
46107210|NCT00674531|Procedure|Artery resection|Artery resection
45468531|NCT03779971|Other|Control Diet|Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain no pulses, legumes, or beans.
46021751|NCT05503394|Behavioral|Routine nursing care group|Provide routine inpatient education and post-discharge follow-up to primary caregivers of biliary atresia.
46021752|NCT04932447|Behavioral|Inspiratory Muscle Strength Training|30 breaths/ day, 5 days/week for 24 weeks.
45838261|NCT04151667|Drug|Lenalidomide Pill|"Lenalidomide will be given orally on days 1-21 of a 28 days cycle. The starting dose of lenalidomide will be based on the patient creatinine clearance per the package insert.~Specifically patients with a creatinine clearance ≥ 50 ml/min will receive 25 mg of lenalidomide PO Days 1-21. Patients with a creatinine clearance ≥ 30 but less than 50 ml/min will receive 10 mg of lenalidomide.~Patients with a creatinine clearance < 30 ml/min are not eligible but patients who experience a deterioration in the renal function during screening or treatment may continue on lenalidomide therapy as long as the risk / benefit profile is deemed acceptable, that study therapy is in the best interest of the patient and after discussion with the study principal investigator / sponsor."
46021753|NCT01251770|Drug|0.45% NaCl/dextrose 5%|Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m^2 body surface.
46021754|NCT01251770|Drug|0.3% NaCl/dextrose 5%|Drug: 0.3% NaCl/dextrose 5% IV maintenance fluids. Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m^2 surface.
46021755|NCT01101321|Drug|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Totowa) x 1 dose taken without food.
46021756|NCT01101321|Drug|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Wilson) x 1 dose taken without food.
46107211|NCT00678431|Dietary Supplement|Resveratrol with Glucose, and Malate|Dietary supplement delivered in grape juice
46107212|NCT00678431|Dietary Supplement|Placebo|Liquid placebo
46107213|NCT00678509|Biological|TTK peptide mixed with Montanide ISA 51|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
46107214|NCT00674687|Drug|2-weeks placebo then gabapentin|Placebo for 2 weeks followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 1 week
45468532|NCT03779971|Other|Lentil Containing Diet|Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain lentils.
46107215|NCT00674687|Drug|1-week placebo then gabapentin|Placebo for 1 week followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 2 weeks
46107216|NCT02628821|Other|Preterm Infants treated with non-invasive ventilation.|
46107217|NCT02634749|Other|Systematic introduction of taste portions|A systematic introduction of plant foods from the Nordic diet
46107218|NCT02634749|Other|Protein reduced complementary foods|Specially prepared, protein-reduced, age-adjusted milk cereal drinks, baby cereals and baby milk, and commercially available baby foods in glass jars
46107219|NCT02634749|Other|Nordic diet|Taste portions, homemade and industry manufactured main meals with a predominance of Nordic ingredients
45468533|NCT03779971|Other|Chickpea Containing Diet|Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain chickpeas.
45468534|NCT03436186|Other||no intervention
45468535|NCT04460183|Drug|RESP301, a Nitric Oxide generating solution|Product application requires inhalation using a standard handheld nebulizer.
45468536|NCT04460183|Other|Standard of Care|Participants will receive institutional SOC for the treatment of COVID-19.
46107220|NCT00656747|Drug|Avelox (Moxifloxacin, BAY12-8039)|Subjects will be randomised to moxifloxacin 400 mg PO OD (5 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.
46107221|NCT00656747|Drug|Amoxicillin clavulanic acid|Subjects will be randomised to amoxicillin-clavulanic acid 875/125 mg PO BID (7 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.
46107222|NCT00678743|Drug|Omacor + simvastatin|Omacor 4 grams/day plus simvastatin 80 mg/day. Simvastatin dose adjusted at Investigator discretion after week 6.
45681295|NCT04025320|Other|Sham|A physical therapist will perform the SHAM light therapy at the same site as the INF therapy location, at the Neuropathic Treatment Center. The SHAM light therapy will last 50-60 minutes and consists of using an anodyne unit for application of near-infrared light therapy. The unit will not be switched on, but the pads will be placed on the subject and the subject will be blinded to the unit being on. The anodyne therapy pads will be placed in the following locations on the affected lower limb: two on the plantar aspect of the foot in a T formation and one pad on the medial and lateral side of the calf. A double folded towel will be wrapped around the subject's foot at the electrode sites to blind the subject's from the light not emitting from the electrodes, due to the anodyne unit being off.
46021757|NCT04309929|Drug|Analgesics|All patients will undergo the anesthesiological and surgical treatment provided for the patient's clinical conditions and in no case will the patients undergo a change in the normal diagnostic-therapeutic path due to participation in this study.
46107223|NCT04152317|Drug|Misoprostol 200mcg Tab|In the misoprostol 200mcg group there will be one tablet of 200mcg and three identical tablets in shape, size and color without pharmacological properties. These four tablets will be single dose administered via vaginal route for each participant.
46107224|NCT04152317|Drug|Misoprostol 800mcg Tab|In the misoprostol 800mcg group there will be four tablets of 200mcg. These four tablets will be single dose administered via vaginal route for each participant.
46107225|NCT02628665|Drug|photosensitizer(photofrin)|photosensitizer(photofrin): 2mg/kg
46107226|NCT02628665|Device|630 nm laser irradiation (DIOMED)|630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds.
45681296|NCT01874288|Drug|DI-Leu16-IL2|DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
46107227|NCT00674843|Radiation|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
46107228|NCT00678977|Drug|Pazopanib (GW786034)|initial dose 400mg daily in 21-day cycles; increase in dose up to 800mg daily following evaluation of safety and tolerability
46107229|NCT00678977|Drug|Gemcitabine|Gemcitabine on Days 1 and 8 of each cycle; initial dose 600 mg/m2 increase to 1,000mg/m2 after evaluation of safety and tolerability; increase to 1250mg/m2 after evaluation of safety and tolerability
46107230|NCT00678977|Drug|Cisplatin|Cisplatin on Day 1 of each 21-day cycle initial dose 60mg/m2; increase to 80mg/m2 after evaluation of safety and tolerability
46107231|NCT00674921|Drug|cotrimoxazole|cotrimoxazole 800/160 mg once daily as indicated by the start and end times of the specified arms for continued prevention of HIV-related infections
45681297|NCT02080468|Drug|lomitapide|20 mg
45681298|NCT02080468|Drug|EE/norgestimate|1x0.035-mg EE/0.25-mg norgestimate tablet
45681299|NCT04020016|Drug|Nalbuphine ER|Cohort 1: 6-8 subjects will receive 1 dose of 27mg and observed for 4 days. Cohort 2: 6-7 subjects will receive 1 dose of 54 mg and observed for 4 days. Cohort 3: 6-7 subjects will receive 1 dose of 108 mg and observed for 4 days. Cohort 4: 6-8 subjects will receive 1 dose of 162 mg and observed for 4 days. Cohort 5: 6-8 healthy subjects will receive dosing of NAL ER and observed for 4 days.
46021758|NCT01101165|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken without food
46021759|NCT01101165|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken without food
46107232|NCT00674921|Drug|Placebo|starch, magnesium stearate, sodium lauryl sulphate
46107233|NCT00674999|Biological|Amnion|Application of Amnion with processing procedures involving the use of trypsin-EDTA
46107234|NCT00674999|Biological|Amnion|Application of Amnion with processing procedures involving the use of Dispase II
46107235|NCT00674999|Drug|Polysporin/Bacitracin/Mycostatin|Application of Prepared antibiotic ointment: Polysporin, Bacitracin and Mycostatin combined
46107236|NCT00882713|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Subcutaneous injection every 4 weeks (starting dose of 120, 200 or 360 micrograms, based on previous ESA therapy)
46107237|NCT04053101|Device|PET CT|Every patient undergoing a PET CT at the time of diagnosis of muscle invasive bladder cancer from January 2005 to December 2017 in Bordeaux (Institut Bergonié and University Hospital).
46021760|NCT01100853|Drug|VIVITROL injection and VIVITROL Placebo Injection , 24 weeks|Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
46107238|NCT02627729|Device|Linear cutter-Circular stapler|a 5 to 6 cm-long colonic pouch will be created with a 80 mm linear cutting-closing stapler. The anastomosis of j-pouch will be routinely strengthened with 3:0 vicryl sutures. Then, a pouch to anal anastomosis will be performed
46107239|NCT02627729|Device|Circular stapler|a 5 to 6 cm-long colonic segment will be left at the distal part and a side-to-end anastomosis will be performed.
45681300|NCT04020016|Drug|Nalbuphine ER -|Cohort 6: • 6-8 subjects with mild hepatic impairment and 6-8 subjects with moderate hepatic impairment. Doses will be subsequently escalated for each subject starting at 27 mg on Day 1 to twice daily, 12 hours apart, 27 mg, 54 mg, 108 mg, and 162 mg over 13 days.
46107240|NCT04162223|Biological|Subcutaneous fat injection of Recombivax-HB|Subcutaneous fat injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
46021761|NCT02881281|Other|educational program for Development of problem-solving skills|
46021762|NCT02881281|Other|no education program|no education program
46107241|NCT04162223|Biological|Intramuscular injection of Recombivax-HB|Intramuscular injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
46107242|NCT04151381|Drug|Aminophylline|"the control group (n =15 ) the patients will receive 20 ml of normal saline IV ,20 minutes before induction of general anesthesia .~Amiopphylline 2mg:(n = 15) the patients will receive 2 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .~Aminophylline 4mg: (n = 15) the patients will receive 4 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .The study drugs will be given by an anesthetist unaware of the study protocol."
46107243|NCT04151537|Behavioral|Personal Activity Intelligence|The intervention group is provided with a PAI monitor (wristband) with a user interface (app) to track their own PAI level and are instructed to obtain at least 100 PAI on a weekly basis.
46107244|NCT04151537|Behavioral|Physical Activity Guidelines|The control group is recommended to follow national PA guidelines, meaning 150 minutes of moderate-intensity PA or 75 minutes of vigorous-intensity PA, or a combination there of. The control group is provided with a PAI monitor (wristband) without any user interface and are thus blinded to track their own PAI level.
46107245|NCT00675077|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
46107246|NCT00809133|Drug|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
46107247|NCT00809133|Drug|Carboplatin|AUC6 given on day 1 of 21 day cycle
46107248|NCT00809133|Drug|BIBW 2992|Escalating dose cohorts
46107249|NCT00809133|Drug|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
46107250|NCT00809133|Drug|BIBW2992|MTD dose of part A
45681301|NCT02985112|Device|FFR and IVUS-NIRS|
45681302|NCT04025164|Radiation|Hypofractionated Radiotherapy|daily fractions, 2.66 Gy/3.2 Gy per fraction to whole breast/tumor bed, five fractions per week
46021763|NCT00626067|Device|Fully functional monitoring device|Pt received fully functional monitoring dispenser for use with their Travatan eye drops
46107251|NCT00809133|Drug|Paclitaxel|175mg/m2 given on Day 1 of 21 Day cycle
46107252|NCT00809133|Drug|Carboplatin|AUC6 given on day 1 of 21 day cycle
46107253|NCT00809133|Drug|Bevacizumab|Escalating dose Cohorts - 5mg / kg, 7.5mg / kg and 10mg / kg given Day 1 and Day 15 of a 28 days cycle
45468537|NCT03710083|Device|Guardian™ Sensor (3)|Use two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days.
45681303|NCT04025164|Radiation|Conventional fractionated Radiotherapy|daily fractions, 2 Gy per fraction, five fractions per week
45681304|NCT04191226|Diagnostic Test|Multi-gene panel testing|A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis
45681305|NCT04021966|Procedure|Vaginal laser application|"One laser treatment cycle consists of 3 vaginal laser applications with a 4-weeks interval. Each application lasts around 5 minutes.~The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~A vaginal probe will be gently inserted and manually rotated to provide a 360° treatment of the vaginal mucosa."
45681306|NCT01874054|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
45681307|NCT01874054|Drug|bendamustine|90 mg/m2 on Days 1 and 2 of 3-week cycles
45681308|NCT04022746|Procedure|Magnetic Resonance Elastography|Undergo multiparametric MRI/MRE
45681309|NCT04022746|Procedure|Magnetic Resonance Imaging|Undergo multiparametric MRI/MRE
45681310|NCT01873742|Other|STIC feedback system|This condition includes the use of the STIC feedback system.
45681311|NCT04024540|Dietary Supplement|isocaloric dietary restriction|Very low caloric diet
46021764|NCT00626067|Device|Partially functional monitoring device|Patient received a particually functional Travatan Compliance Monitoring Dispenser
46021765|NCT00626067|Device|Non-functional monitoring device|Patient received a non functioning Travatan Compliance Monitoring Dispenser
46021766|NCT01100307|Drug|pegaptanib sodium|Intravitreal injection of 0.3 mg every 6 weeks
46021767|NCT01100307|Other|sham injection|sham injection every 6 weeks
46107254|NCT00809133|Drug|BIBW 2992|Escalating dose cohorts
46107255|NCT00809133|Drug|BIBW 2992|Escalating dose cohorts
46107256|NCT00679133|Drug|MGCD265|Oral daily administration; 7 days on / 7 days off
46107257|NCT04151771|Other|Low-load blood flow restriction training|The intervention group will perform the exercises of the lower limbs using LL-BFRT with an occlusion pressure of 70% of arterial occlusion pressure with low training loads (30% of the 1 repetition maximum).
46107258|NCT04151771|Other|Usual outpatient pulmonary rehabilitation|The control group will perform outpatient pulmonary rehabilitation as established.
45681312|NCT04024540|Procedure|Bariatric surgery|Laparoscopic vertical sleeve gastrectomy
45681313|NCT04766242|Other|Spiritual healing|"The spiritual healing will be based on an assessment of the total health situation of the individual patient. Spiritual healing will mainly consist of a treatment where the healers hold their hands for some time at different parts of the patient's body, known as power points, outside the patients clothing. The consultation might also include possible life-style advice. The treatments will last for 45-60 minutes each time."
46021768|NCT01099917|Drug|Maitake|"Patients will receive the oral mushroom extract 3mg/kg by mouth twice daily for 3 months. Patients will serve as their own controls, with blood counts after Maitake compared with baseline counts. Rather than a wait list control, at study entry we will obtain from MDS patient charts 2 CBC/differential/platelet values drawn within 12-24 weeks prior to starting the protocol.~Healthy control volunteers will be recruited to this study as participants for expanding the baseline normal values for neutrophil and monocyte function as measured by the respiratory burst test."
46021769|NCT02879097|Biological|CBT124|Induction Phase: CBT124 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
46021770|NCT02879097|Biological|EU-sourced Avastin®|Induction Phase: EU-sourced Avastin® 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
46021771|NCT02879097|Drug|Carboplatin|Induction Phase: Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles.
46021772|NCT02879097|Drug|Paclitaxel|Induction Phase: Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles.
46021773|NCT04307901|Device|Colon capsule endoscopy|Endoscopy performed using PillCam2 camera capsule for oral ingestion
46021774|NCT04307823|Other|Treadmill training|"3 days per week, starting at shorter duration 5-20min and progressed to 30- 40mins.~Training% or Intensity was kept 40-70%,~Training Heart Rate (HR) was calculated through formula:~HR max HR rest*Ex intensity + HR rest Rate of Perceived Exertion (RPE) 9-14 ON 6 -20 RPE scale The session was terminated if sustained ventricular arrhythmia, symptomatic drop in blood pressure, ST elevation, or development of severe symptoms"
46107259|NCT00675155|Radiation|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
46107260|NCT02634593|Behavioral|Low glycemic load snacks|Intervention to replace standard night-time food and drinks with lower glycemic load options
46107261|NCT00912275|Drug|lapatinib plus oral vinorelbine|Lapatinib -dose level -I, I, II, III 1000mg po daily;dose level IV:1250mg po daily; Oral vinorelbine at the dose level reached on days 1, and 8 of a 21 days cycle. Dose level -I:30mg/m2,I:40mg/m2,II:50mg/m2,III:60mg/m2,IV:60mg/m2,V:80mg/m2
46107262|NCT00675233|Drug|HPPH|Given IV
46107263|NCT00675233|Procedure|laser therapy|Escalating light doses with 665 nm light
45681314|NCT04766242|Other|Usual care|The care the general practitioner (GP) prescribe when the patients are diagnosed with moderate depression.
45681315|NCT01873586|Procedure|Posterolateral Fusion|
45681316|NCT04024774|Biological|Biological samples|blood samples, urine samples, tissue samples
45681317|NCT04024774|Genetic|Genetic test|anamnesis and NGS sequencing
45681318|NCT04025398|Behavioral|Cognitive remediation program|Comparison between a cognitive remediation program (REHABILITUS) (group 1) and a training group of manual activities (group 2)
45681319|NCT04025398|Behavioral|Control group|"Comparison between a cognitive remediation program (Réhabilitus) (group 1) and a training group of manual activities (group 2)"
45681320|NCT04029610|Procedure|Local anesthesia with lidocaine and adrenalin.|Local anesthesia with lidocaine and adrenalin.
45681321|NCT04029610|Drug|lidocaine and adrenalin|lidocaine and adrenalin
45681322|NCT04029610|Drug|lidocaine and arterial blockage|lidocaine and arterial blockage
46107264|NCT04151303|Procedure|Cervical cerclage|Cervical cerclage and cervical cerclage removal
46021775|NCT04307823|Other|Treadmill protocol and Respiratory training|"Treadmill protocol~Spirometry:~Volumetric exercises, using incentive Spirometer 10-15 repetitions~Slow breathing training:~5 minutes: spontaneous breathing, 4 minutes: controlled breathing (15 breaths/min) 4 minutes of controlled breathing (6 breaths/min) Treatment provided for 3 days in a week for a period of 4 weeks"
46021776|NCT02880969|Behavioral|answering questionnaires|
46107265|NCT04152395|Other|EVAR|Patients undergoing EVAR
45681323|NCT04024852|Other|Intervention group|When Air Quality Health Index is below level 5, the intervention group did daily mild exercise (walking) outdoors for 30 minutes. When Air Quality Health Index is equal to or above level 5, the group is advised to do mild exercise indoors for 30 minutes.
46021777|NCT01099215|Biological|PVS-10200|PVS-10200 is composed of allogeneic human aortic endothelial cells cultured in a gelatin matrix.
46021778|NCT02878941|Procedure|Synovial Fluid Analysis|Synovial fluid aspiration (act of using an 18 gauge needle to obtain synovial fluid from the elbow) in the emergency room for patients with the eligible elbow fracture (as defined in inclusion/exclusion criteria) is performed in conjunction with the anesthetic injection as part of standard of care. The elbow will be prepped as per usual for the anesthetic injection. An 18 gauge needle will be inserted through a lateral approach. The subject's elbow will be aspirated. The syringe with the aspirate would be removed from the needle while the needle would remain in the subject's elbow joint. The syringe with anesthetic would then be connected to the needle, and the anesthetic would be injected into the elbow joint. Therefore, no risks from a separate aspiration would be conferred to the patient.
46107266|NCT02608749|Behavioral|Integrated care (IC)|Integraded care (IC) Weekly professional led exercise program for 90 mins with reinforcemen on osteoporosis related educations and caremangements from study educational booklet and CD rom for 3-month. The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.
46107267|NCT02608749|Behavioral|Lower extremity exercise (LEE)|Lower extremity exercise (LEE) group subjects were invited to BB site to receive 2 sessions of 45-mintute training using isotonic strength training machines on major muslce groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist.
46107268|NCT02608749|Behavioral|Home care (HC)|Home care (HC) group subjects were invited to LK site. For examining whether the exercise video could help elderly people to maintain their exercise and improve their muscle strength or not, the investigators provided exercise video to subjects, and encouraged them to play this exercise at least 2 hours for one week.
46107269|NCT00675311|Behavioral|DM-Standard|Device/t+ Medical Diabetes Management System
46107270|NCT00675311|Behavioral|Disease Management Plus|Plus is one of the randomized arms of the study. Patients assigned to this arm receive support from Disease Management nurses and technology.
46107271|NCT00882557|Drug|daptomycin|intradialytic: 9 mg/kg during the last 30 minutes of dialysis
46107272|NCT00882557|Drug|daptomycin|6 mg/kg administered after a hemodialysis session
45681324|NCT04026880|Drug|Testosterone Enanthate|25 mg testosterone enanthate administered by intramuscular injection weekly for 12 weeks
45681325|NCT04026880|Drug|Placebo|Placebo administered by intramuscular injection weekly for 12 weeks
45681326|NCT04190992|Other|E-based & personalized breast reconstruction surgery decision aid|This decision aid contains information regarding surgical options, including breast reconstruction and mastectomy, such as the advantages and disadvantages, the complication probabilities of each option, a value clarification exercise for the patient's self-evaluation, and a summary of the participant's decision-making process.
45681327|NCT04190992|Other|Usual care|A pamphlet introduce the introduction of types of surgery
45681328|NCT04191070|Device|infrazygomatic miniscrew|class II correction by distalization using infrazygomatic crest miniscrew
45681329|NCT04191070|Device|zygomatic miniplate|class II correction by distalization using zygomatic miniplate
45681330|NCT04190602|Device|NeoChord Artificial Chordae Delivery System, Model DS1000|The intended use of the device is for the placement of artificial chordae when the natural chordae tendinae have become elongated or ruptured due to degenerative valve disease.
46021779|NCT02879019|Other|Stretching exercise group|In each stretching class, approximately 20 exercises will be performed. The total duration of the session will be approximately 30 minutes.
46021780|NCT02879019|Other|Walking training group|Patients will perform two walking session per week, each consisting of 15*2-min walking bouts, with 2-min of rest in between. The intensity will be set at heart rate corresponding to the pain threshold.
46021781|NCT05087745|Biological|Tumor Infiltrating Lymphocytes|Adoptive transfer of 1x10^9-5x10^10 autologous TILs to patients i.v. in 30-120 minutes.
46021782|NCT02878863|Drug|Paeoniflorin + phosphatidylcholine or silymarin|
46021783|NCT02878863|Drug|Phosphatidylcholine or silymarin|
46021784|NCT02881125|Drug|Nortriptyline Hydrochloride|Given PO
46021785|NCT02881125|Drug|Paclitaxel|Given IV
46107273|NCT02627573|Procedure|Unrelated allogeneic stem cell transplantation|
46107274|NCT02627573|Drug|Busulfan|
46107275|NCT02627573|Drug|Fludarabine monophosphate|
46107276|NCT02627573|Drug|Tacrolimus|
46107277|NCT02627573|Drug|Mycophenolate mofetil|
46107278|NCT02627573|Drug|Cyclophosphamide|
46107279|NCT02627573|Drug|Thymoglobulin|
46107280|NCT00656825|Drug|P144 cream|P144 cream will be given at a dose of 100 μg/mL
46107281|NCT00656825|Drug|P144 cream|P144 cream will be given at a dose of 200 μg/mL
46107282|NCT00656825|Drug|P144 cream|P144 cream will be given at a dose of 300 μg/mL
46107283|NCT00656825|Drug|Placebo|Placebo will be randomly given to 4 subjects in each panel
45468538|NCT05631353|Device|Carriere Motion Appliance|"Patient will be randomly allocated into two groups:~Group I: conventional mandibular anchorage using passive lingual arch. Group II: anchorage by direct mini-screws. In the group I, Class II elastics will be attached from the maxillary canine to the mandibular first molar bilaterally with passive lingual arch in the lower arch as anchorage means.~In the group I, Class II elastics will be attached from the maxillary canine to mandiular miniscrews bilaterally.~For each patient, two CBCT radiographs will be obtained: one preoperatively and another after completion of distalization."
45468539|NCT01243697|Drug|desogestrel|Tablets of 75 µg, once daily during 112 days
46107284|NCT00675389|Behavioral|Peer Health Workers Intervention|Peer health workers are themselves PLWHA on ART who have demonstrated good ART adherence for at least 6 months. The peers are responsible for ~15-20 patients and are expected to visit the patients in their homes once every two weeks. At these visits, peers record a review of symptoms, client self-report of adherence, and a pill count. At the clinic, peers assist with patient organization and share their experiences, particularly with patients about to start ART. Peer health workers undergo an initial, intensive two day residential training course and are provided with a bike and basic supplies, and a modest amount of remuneration to encourage compliance with their responsibilities and promote a high program retention rate.
46107285|NCT00675389|Behavioral|Peer Health Workers and Mobile Phone Intervention|In addition to the peer health worker intervention, this arm adds a mobile phone intervention consisting of the following: during home visits, peers with mobile phones, using data collected on their home visit forms, send real-time text messages containing this clinical and adherence data back to the central clinic to be reviewed by clinical staff within a 24 hour period. Peers may also call, toll-free, back to a central clinic Warmline with any questions or concerns.
46107286|NCT00675467|Behavioral|Focus Group - Parent/Caregiver|A 1 1/2 hour group session with other parents/caregivers.
45468540|NCT03638271|Diagnostic Test|Cardiac magnetic resonance imaging|Patients in different sex and age groups diagnosed with any type of nonischemic cardiomyopathy clinically or with echocardiography will undergo cardiac magnetic resonance imaging and compare their results.
45468541|NCT01244165|Device|Cytrix|
45468542|NCT01244165|Other|Other treatments for pelvic organ prolapse|Treatments for pelvic organ prolapse using other products (standard of care for treatment of pelvic organ prolapse)
45468543|NCT04703101|Drug|Capecitabine|Given IV
45468544|NCT04703101|Drug|Fluorouracil|Given IV
45468545|NCT04703101|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45468546|NCT04703101|Drug|Leucovorin|Given IV
45681331|NCT04024384|Drug|Daratumumab|Daratumumab, 16 mg/kg, once a week for 8 weeks (cycles 1 and 2); then every 2 weeks for 16 weeks (cycles 3-6), then every 4 weeks thereafter (cycles 7-12).
46021786|NCT02880657|Dietary Supplement|SODB®|Subjects are supplemented with SODB®, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
46021787|NCT02880657|Dietary Supplement|Placebo|Subjects are supplemented with Placebo, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
46021788|NCT02880735|Device|Non Invasive Ventilation.|Non Invasive Mechanical Ventilation through oronasal mask. Mode: Bilevel with rate backup (spontaneous/time). Inspiratory Pressure: 30-10, Expiratory Pressure : 4-15, Backup Rate;14-25 rpm. Use Time: During Sleep.
46107287|NCT00675467|Behavioral|Focus Group - Pediatric Patient|A 1 1/2 hour group session with other pediatric patients.
46107288|NCT00679445|Device|NeoVista Ophthalmic System|A single procedure using the NeoVioasta Ophthalmic System plus an injection of Lucentis.
46107289|NCT00675545|Drug|Docetaxel, Carboplatin|"Docetaxel Form: A white, lyophilized powder in vials of 50, 150, and 450 mg each, which should be stored at room temperature in a light-protected area.~Carboplatin Form: Taxotere is supplied as a sterile, non-aqueous, viscous solution with an accompanying sterile diluent (13% ethanol in water for injection). 20 and 80 mg strengths are available."
46107290|NCT00679523|Drug|AN2690 Solution, 5.0%|Once daily application for 180 days
46107291|NCT00679523|Drug|AN2690 Solution, 7.5%|Once daily application for 180 days
46107292|NCT00675701|Drug|placebo|capsules
46021789|NCT02880813|Other|Infusion|infusion of nutrients
46107293|NCT00675701|Drug|lixivaptan|capsules
46107294|NCT00675701|Drug|moxifloxacin|tablets
45468547|NCT04703101|Drug|Oxaliplatin|Given IV
45468548|NCT04703101|Other|Quality-of-Life Assessment|Ancillary studies
45468549|NCT04703101|Behavioral|Surveillance|Undergo NOM
45838262|NCT04151667|Drug|Bortezomib Injection|Bortezomib will be given weekly subcutaneously in an effort to decrease the toxicity of the therapy. Specifically patients will receive a starting dose of bortezomib of 1.3 mg/m^2 Days 1,8,15 of a 28 day cycle. Bortezomib will be administered in the cancer center per standard of care procedures.
46021790|NCT05354193|Other|vasoplegic syndrome|"In all included patients, 3 milliliters of venous blood will be collected before cardiopulmonary bypass, 3 milliliters of venous blood 15 minutes after the reversal of heparin with protamine and a small fragment of aortic tissue. Samples of biological material will be compared between the control and vasoplegic groups for the difference in amount and type of miRNA present.~For the diagnosis of vasospastic syndrome, the following criteria were adopted: mean arterial pressure < 65 mmHg, cardiac index < 2.2 L / min / m2, refractory to replacement of at least 1000 milliliters of crystalloid, excluding other causes such as tamponade, bleeding and cardiogenic shock"
46107295|NCT05326191|Diagnostic Test|Ultrasound|All study interventions/procedures will happen during the participants routine clinic visit in which they will receive their routine Ultrasound scan, followed by an additional research scan, which will take approximately 2-3 minutes. A blood sample will also be taken from participants as part of their routine pregnancy care. Residual blood from the same sample will be used to conduct an additional test to quantify Placental Growth Factor (PlGF). Participants will also be asked questions about their relevant medical history and demographic data which is also routinely collected as part of their pregnancy record.
46107296|NCT00808899|Drug|Temsirolimus|Temsirolimus
46107297|NCT00808899|Drug|Irinotecan|Irinotecan
46107298|NCT00808899|Procedure|Surgical Resection of Primary Tumor|Surgical Resection of Primary Tumor
46107299|NCT00808899|Drug|Cyclophosphamide|Cyclophosphamide
46107300|NCT00808899|Drug|Doxorubicin|Doxorubicin
45468550|NCT04703101|Procedure|Total Mesorectal Excision|Undergo TME
45838263|NCT04147468|Other|Virtual Reality|For the VR intervention, we focus on using our developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the participant. The research team will travel to the family to conduct the intervention to ensure the treatment adherence. The participants will be asked to move their arms to 'pop' as many virtual objects as possible.
46021791|NCT05004285|Drug|[F-18]Florastamin|A single dose of [F-18]Florastamin at 10 ± 1 mCi is IV administered at Visit 2, and [F-18]Florastamin PET/CT images are obtained from the head to thigh after 110 ± 10 minutes.
46021792|NCT01107405|Drug|Loteprednol etabonate base (QD)|Loteprednol Etabonate ophthalmic base once daily dosing for 2 weeks
45468551|NCT03318003|Device|Auto-PAP|Women will be using the Auto-PAP device nightly from randomization to end of pregnancy
45468552|NCT01145573|Dietary Supplement|Calcium or Placebo|Participants are randomized to take either 1000mg of calcium or placebo from week 16 of pregnancy until delivery.
46021793|NCT01107405|Drug|Loteprednol etabonate base (BID)|Loteprednol etabonate ophthalmic base BID dosing for 2 weeks
46021794|NCT01107405|Drug|Loteprednol etabonate base (QID)|Loteprednol Etabonate ophthalmic base four times/day dosing for 2 week
46107301|NCT00808899|Drug|Etoposide|Etoposide
46107302|NCT00808899|Drug|Cisplatin|Cisplatin
46107303|NCT00808899|Drug|Topotecan|Topotecan
46107304|NCT00808899|Procedure|PBSC|Peripheral Blood Stem Cell Harvest
46107305|NCT00808899|Radiation|Radiation Therapy|Radiation Therapy
46107306|NCT00808899|Drug|13-cis-retinoic acid|13-cis-retinoic acid
46107307|NCT00808665|Drug|Dexmedetomidine|Patients will be given 0.7 mcg/kg/hr of dexmedetomidine over the first hour of surgery, followed by continuous infusion of 0.5 mcg/kg/hr of dexmedetomidine for the next 2 hours of surgery. Dexmedetomidine dose will be reduced to 0.2 mcg/kg/hr for the duration of the procedure and continued at that rate for four hours postoperatively. Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
45468553|NCT04687813|Drug|Placebo|Placebo is a tablet with the same appearance as FTP-198
45468554|NCT05288231|Diagnostic Test|Diagnostic of ECG|All participants who enrolled in the study will be performed ECG, cardiac enzyme and echocardiography
45468555|NCT01320709|Drug|Piroxicam ( BAYl1902)|Single dose of 20 mg piroxicam (i.e., 1 piroxicam capsule + 3 placebo capsule)
45468556|NCT01320709|Drug|Piroxicam ( BAYl1902)|Single dose of 40 mg piroxicam (i.e., 2 piroxicam capsules + 2 placebo capsule)
45468557|NCT01320709|Drug|Placebo|Single dose of placebo (i.e., 4 placebo capsules)
45468558|NCT01320709|Drug|Piroxicam ( BAYl1902)|Single dose of 80 mg piroxicam (i.e., 4 piroxicam capsules)
46021795|NCT01107405|Drug|Loteprednol etabonate suspension|Loteprednol etabonate ophthalmic suspension dosed four times daily for 2 weeks.
46107308|NCT00808665|Drug|0.9% Saline|Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
46107309|NCT04586517|Other|Heavy-load resistance training|Supervised heavy-load resistance training during chemotherapy treatment
46107310|NCT04586517|Other|Control|Activity as usual during chemotherapy
46107311|NCT04576533|Behavioral|walk out from operating room|After the surgery of laparoscopic colectomy or laparoscopic rectectomy surgery (Dixon technique), patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb
46107312|NCT00808509|Biological|adalimumab|40 mg every other week via subcutaneous injection
46107313|NCT00808509|Drug|methotrexate|At least 10 mg/week administered orally or subcutaneously
45468559|NCT01238315|Biological|HuCNS-SC|Surgery to implant human CNS stem cells
45468560|NCT03317379|Behavioral|Peer mentorship|Weekly meetings with a recovered peer mentor once per week. Dyads discuss eating disorder symptoms and how to overcome them.
45468561|NCT03317379|Behavioral|Social support mentorship|Weekly meetings with a social support mentor who has not personally struggled with an eating disorder, once per week. Dyads engage in activities unrelated to the eating disorder (e.g., a movie, a community event, volunteer work).
45683907|NCT04396678|Behavioral|PrEP standard of care+behavioral intervention|The intervention includes three main components: 1) group PrEP engagement sessions, which include four educational sessions that situate PrEP in a broader framework of access and barriers to care, provider/patient communication, sexual health, HIV/STI education, harm reduction around drug use, stigma, risk compensation and safe sex, and health/science literacy; 2) peer navigation, which aims to help women navigate healthcare engagement with the SPARC nurse practitioner and other providers; and 3) an mHealth component, consisting of a two-way text messaging system through which women will receive automated daily messages and weekly messages requesting adherence reports.
46021796|NCT01107405|Drug|Vehicle of loteprednol etabonate|Vehicle of loteprednol etabonate ophthalmic dosed once, twice or four times daily for 2 weeks.
46021797|NCT01097577|Drug|pregabalin|1 capsule (75 mg) by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
46021798|NCT01097577|Drug|Placebo|1 capsule by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
46021799|NCT01097421|Drug|Pramipexole Extended Release|
46021800|NCT02878629|Device|Mandibular Advancement Devices|
46107314|NCT05754723|Behavioral|e-Psychotherapy/Psychoeducation|Participants will receive six weekly self-guided psychoeducation sessions. Then, after 6 weeks participants will complete monthly clinical questionnaires for 6 months. Also, participants will begin bi-weekly journaling exercises for 6 months. Based on the journaling entries, if the AI algorithm detects MDD, GAD, SAD or ADHD that requires treatment will make a referral to the diagnosis-specific e-CBT (MDD, GAD, SAD or ADHD). If after 6 months, no referral decision is made by the AI algorithm no extra follow-up will be provided. Once the AI makes a referral recommendation, participants will be placed in a diagnosis-specific e-CBT program specific to the diagnosis determined by the AI algorithm (MDD, GAD, SAD, or ADHD). The asynchronous e-CBT programs will consist of 12 weekly modules and homework. Weekly homework is reviewed by a therapist, who will provide personalized feedback based on the participant's preferred method (i.e., text, video, or audio).
46107315|NCT05754645|Other|Blood withdrawal|venous punction with blood withdrawal Vaginal and rectal swab, done by patient itself
46021801|NCT02878395|Procedure|Ileocolic resection|
46021802|NCT04205877|Device|Transcatheter PDA Closure|Device utilized for closure of PDA, study is to help assure continued safety and effectiveness of FDA approved Amplatzer Piccolo Occluder device as well as other devices used off label for PDA closure in premature infants less than 2 kg at the time of device implant.
46107316|NCT02608827|Device|Resperate®-InterCure Ltda|The device-guided breathing - Resperate®-InterCure Ltda, uses sound to guide and therefore reduce the respiration rate in individuals.
46107317|NCT02608827|Other|Music group (GC)|The patients in this arm will hear slow music - Music group (GC).
46107318|NCT04444869|Drug|Cisplatin injection|Standard dose cisplatin given concurrently with radiation therapy
46107319|NCT04440657|Behavioral|Self-Assured Parenting program|Parents will receive parenting education for 10 weeks
46107320|NCT04400331|Drug|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
46107321|NCT02608593|Procedure|Strattice|Implant based reconstruction with strattice cover of part or all of implant
46107322|NCT05754411|Drug|[14C]STI-1558|Fasting oral administration of 600 mg [ 14C ] STI-1558 ( about 100 μCi ) solution.
46107323|NCT02627651|Other|cognitive and motor assignments|walking on treadmill, performing cognitive assignment; and performing the cognitive assignment while walking .
46107324|NCT05326113|Other|Physiotherapy|After POEM, patient underwent physiotherapy consisting of diaphragmatic breathing and dynamic stabilization exercises and PPIs
46107325|NCT05326113|Drug|Control group|All patients will be treated with standard course of PPIs after POEM without physiotherapy.
45468562|NCT03317379|Behavioral|Recovery Record use with mentor|Recovery Record is a smart phone or web-based application designed to provide recovery support to eating disorder patients. Includes a number of features aimed to promote recovery, such as a meal tracking, prompts for completing meals/snacks, tracking for additional symptoms such as stress and mood, motivational messages, information about coping strategies, and capacity to share logged data with clinicians and mentors.
45468563|NCT03780283|Drug|Anlotinib Hydrochloride|Participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD or had unacceptable toxicity
45468564|NCT04299581|Drug|Camrelizumab|a PD-1 immune check inhibitor
46021803|NCT01251614|Biological|Adalimumab|Adalimumab by subcutaneous injection every other week (eow)
46021804|NCT01251614|Drug|Methotrexate|Methotrexate 0.1 mg/kg at Week 0 and up to 0.4 mg/kg per week (maximum dose of 25 mg/week) orally.
46021805|NCT01251614|Biological|Placebo to Adalimumab|A single subcutaneous loading dose at Week 0 followed by eow dosing beginning at Week 1.
46021806|NCT01251614|Drug|Placebo to Methotrexate|Orally once a week
46021807|NCT01106625|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
46021808|NCT01106625|Drug|Placebo|One matching placebo capsule orally once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
46021809|NCT01106625|Drug|Metformin|The patient's stable dose of background metformin therapy should be continued throughout the study.
46021810|NCT01106625|Drug|Sulphonylruea|The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
46021811|NCT01251380|Biological|Botulinum toxin type A|Intramuscular (IM) injection on day 1 of each treatment cycle.
46021812|NCT04307979|Dietary Supplement|High-fat coffee|A high fat coffee that consists of 29 grams of added fat from grass fed ghee, and MCT oil.
46021813|NCT04307979|Dietary Supplement|Black coffee|A regular black coffee with no added caloric content.
45468565|NCT04299581|Combination Product|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
46107326|NCT04305951|Procedure|Comprehensive acupuncture therapy (CAT) (Hwato®/ Dongbang®)|"CAT will be conducted for 2 sessions per week for 12 consecutive weeks.~The following 15 body acupoints with only manual stimulation will be used: Shen-Men (HT7), He-Gu (LI4), Wai-Guan (TE5), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6) in two sides, and Zhong-Wan (CV12), Guan-Yuan (CV4), and Shui-Gou (GV26) in midline. Electrical stimulation will be conducted on six pairs of frontal acupoints located on the frontal, parietal, and temporal scalp areas.~Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) will be inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation is additionally delivered on the 6 pairs of the frontal acupoints. Each session of treatment will last 30 min."
46107327|NCT04305951|Procedure|Comfy Acupressure for the Elderly (CAE)|"CAE intervention will be conducted for 3 times per week for 12 consecutive weeks.~CAE consists of 12 steps which need about 15 min to complete and mainly concentrates on the acupoints on face, head, neck, and shoulder. The detailed CAE Operation Guide will be provided for the provider and the video demonstration is accessible at https://www.youtube.com/watch?v=pAqNIZPKmnM."
46021814|NCT04309539|Procedure|Fascia iliaca block|"A linear probe will be placed in the sagittal plane to the inguinal ligament to obtain an image of bow-tie sign formed by the muscle fascias, a spinal needle will be inserted 1 cm cephalad Using an in-plane approach, the fascia iliaca is penetrated, 30 mL of bupivacaine 0.25% before spinal anesthesia."
46107328|NCT00807885|Drug|hylenex-facilitated subcutaneous Lactated Ringer's infusion|single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution
45468566|NCT03779737|Behavioral|Muscular Resistance training|
45468567|NCT03779737|Behavioral|Cardiorespiratory training|
46107329|NCT05754177|Dietary Supplement|Probiotic|Participants in this arm will receive a daily dose of 1x10^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria), administered orally by 1 capsule a day, for 84 days
46107330|NCT05754177|Other|Placebo|Participants in this arm will receive an equivalent placebo for 84 days.
46107331|NCT04276857|Device|Irreversible electroporation (NanoKnife® )|IRE is a unique treatment modality as it ablates tumor cells without using heat or radiation and hence does not cause injury to nearby blood vessels, ducts, and bowel. This makes it particularly appealing for the treatment of locally advanced unresectable pancreatic cancers. This local treatment for cancer involves delivering brief pulses of high voltage electrical current across the tumor (either percutaneously or open surgery), which results in the formation of tiny holes (nanopores) in the cell membranes.
46107332|NCT00807573|Drug|Paclitaxel|Day 1: Paclitaxel (90 mg/m^2 over 60 minutes) Day 15: Paclitaxel (90 mg/m^2 over 60 minutes)
46107333|NCT00807573|Drug|Pemetrexed|Day 1: Pemetrexed (500 mg/m^2 over 10 minutes) Day 15 Pemetrexed (500 mg/m2 over 10 minutes)
46107334|NCT00807573|Drug|Bevacizumab|Day 1:Bevacizumab (10 mg/kg over 20 minutes) Day 15: Bevacizumab (10 mg/kg over 20 minutes)
45838264|NCT04147468|Other|Functional Strength Training|For the functional strength training, participants will receive repetitive progressive resistance exercise during goal-directed functional activity with the participants focus on the activity being performed. The research team will also go to the family to conduct the FST intervention.
46021815|NCT04309539|Procedure|combined LFCN block with PENG block|With the patient supine, the linear probe is placed parallel to the inguinal ligament. LFCN appear as a hypoechoic oval structure between the tensor fascia lata and Sartorius muscles. The needle is inserted in plane. 5 mL of LA is injected. The PENG block will be performed in the supine position. A curvilinear probe will be placed transversely over the anterior inferior iliac spine and then rotated counterclockwise 45 degrees. the ilio pubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A spinal needle will be inserted in plane to the plane between the psoas tendon and the pubic ramus. 25 mL of bupivacaine 0.25% will be injected
45468568|NCT03779737|Behavioral|Habitual training|
45468569|NCT03316911|Behavioral|MKit|MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
45468570|NCT01238393|Drug|intravitreal ranibizumab|monthly injections x3 +/- 2nd series of 3
45468571|NCT01244399|Dietary Supplement|Inositol|
45468572|NCT03776305|Drug|Imipenem|1-h infusion of 0.5 g of imipenem diluted in 100 mL of normal saline solution, delivered via infusion pump at a constant flow rate, every 6 h. The imipenem PK studies were carried out during administration of the fourth dose of each regimen (18-24 h after the start of the regimen). Blood samples were obtained by direct venipuncture at the following times: before (time zero) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 5 and 6 h after the fourth dose of each regimen.
45468573|NCT04491331|Procedure|prone position|Unsupported prone position with arms along the body in neutral position will be used first without any supportive device except support of heels with a soft cylindrical device, head will be held in a neutral position using prone head rest. After recording of all measered values, the prone position using the prone position support system will be tested. The support system allows free movement of the lower thorax and abdomenal wall, upper arms are elevated and angled in 90 degrees (in shoulders and elbows). Heels will be positioned at the level of the heart using a supportive cylindrical device. Head will be held in a neutral position using prone head rest.
45468574|NCT04938193|Diagnostic Test|68Ga-citrate PET/CT|PET/CT Imaging with 68Ga-citrate PET/CT injection
46021816|NCT01251146|Drug|Bisoprolol|Bisoprolol will be administered at a dose of 5 milligram (mg) once daily for 2 weeks. If heart rate is less than or equal to 65 beats per minute (bpm), then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 7.5 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate is still greater than 65 bpm, then the dose will be further increased to 10 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
46021817|NCT01251146|Drug|Atenolol|Atenolol will be administered at a dose of 50 mg once daily for 2 weeks. If heart rate is less than or equal to 65 bpm, then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 75 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate still greater than 65 bpm, then the dose will be further increased to 100 mg once daily for 2 weeks. After 2 weeks, If the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
45468575|NCT01106391|Device|"Cordis AAA stent graft system INCRAFT TM"|
45468576|NCT01146509|Drug|Aricept (donepezil hydrochloride)|Donepezil hydrochloride tablet: initial 5 mg/day dose was taken orally, once a day. At Week 4 visit, the dose was increased to 10 mg/day at the discretion of the investigator.
46021818|NCT04309695|Device|Zenflow Spring System|The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
46021819|NCT04307745|Other|Primary prevention|The primary prevention that the 4 groups put in place for the upper limp athletes
46021820|NCT02888678|Behavioral|Economic Strengthening (Impumelelo)|Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
45468577|NCT03775993|Drug|Human growth hormone|Administration of growth hormone
45468578|NCT03775993|Other|Placebo|Administration of placebo
45468579|NCT01145729|Behavioral|Biomarker Feedback|Providing providers biomarker feedback on childhood secondhand smoke exposure
46021821|NCT02888678|Behavioral|HIV Prevention Education (Vhutshilo 2.2)|HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.
46021822|NCT04910217|Procedure|Conventional rehabilitation|Patients will undergo conventional rehabilitation
46021823|NCT04910217|Procedure|Leg/lower body exerciser device intervention.|Patients will undergo leg/lower body exerciser device therapy.
46021824|NCT04910217|Procedure|Lokomat intervention|Patients will undergo therapy with Lokomat Pro FreeD device intervention.
46021825|NCT00626145|Procedure|saline infusion|Patients receive intracoronary injections of saline 7 days after PCI.
46021826|NCT00626145|Procedure|autologous bone marrow mononuclear cells infusion|Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.
46021827|NCT02878707|Drug|Dexmedetomidine|Intraoperative dexmedetomidine infusion
46021828|NCT02878551|Other|Prehabilitation program|multimodal prehabilitation intervention composed of exercise, nutritional supplement and psychological well-being
46021829|NCT01096017|Drug|Terbutaline Turbuhaler®|0.4 mg, inhalation, single dose
46021830|NCT01096017|Drug|Salbutamol pMDI|200 μg, inhalation, single dose
46021831|NCT01096017|Other|pMDI placebo pMDI|Placebo pMDI 2 inhalations
46021832|NCT01096017|Other|Placebo Turbuhaler®|Placebo Turbuhaler 1 inhalation
46021833|NCT00626223|Drug|5-MTHF (5-methyltetrahydrofolate)|50 mg intravenous at the end of each hemodialysis session
45468580|NCT01320787|Drug|18F-fluoroacetate|18F-fluoroacetate injection as a single intravenous bolus with a maximum volume of 4 mL followed by a saline flush of 20 to 50 mL.
46021834|NCT00626223|Drug|folic acid|5 mg per day of oral folic acid
46021835|NCT04908111|Biological|ChAdOx1-MAGEA3-NYESO|"Patients will commence their standard of care chemotherapy in combination with an immune checkpoint inhibitor in three weekly cycles. Patients will be screened during the first two cycles of standard of care treatment to confirm whether they are eligible to take part in the trial.~Patients who are to receive the trial vaccines (in the safety run in stage and in Arm A of the NSCLC randomisation cohort) will continue to receive their standard of care treatment plus:~First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of standard of care treatment.~First boost MVA-MAGEA3 vaccine 21 days later.~Only for patients who have not progressed: Second prime ChAdOx1-MAGEA3-NYESO vaccine 15 week following the first prime vaccine.~Second boost MVA-MAGEA3 vaccine 21 days following the second prime vaccine.~Patients in Arm B will continue to receive their standard of care treatment only throughout the trial (i.e. no trial vaccines)."
46107335|NCT00842712|Drug|Cilengitide|Cilengitide (Cil) will be administered at a dose of 1000 milligram (mg) as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
46107336|NCT00842712|Drug|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
46107337|NCT00842712|Drug|Cetuximab|Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m^2) as intravenous infusion over 2 hours on Day 1.
46107338|NCT00842712|Drug|Cisplatin|Cisplatin (Cis) will be administered at a dose of 75 mg/m^2 as intravenous infusion on Day 1.
46107339|NCT00842712|Drug|Cisplatin|Cis will be administered at a dose of 80 mg/m^2 as intravenous infusion on Day 1.
45681332|NCT04023916|Drug|Sintilimab-R-CHOP|"Drug:Sintilimab:~Sintilimab:200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 200 mg IV on Day 1 of Cycles 9-14.~Drug: Rituximab Rituximab:Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m^2 IV on Day 1 of Cycle 1-8, during induction treatment.~Drug: Cyclophosphamide Cyclophosphamide will be administered at a dose of 750 mg/m^2 IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Doxorubicin Hydrochloride Liposome Injection Doxorubicin Hydrochloride Liposome Injection will be administered at a dose of 35 mg/m^2 IV on Day 2-3 of Cycle 1-6, during induction treatment.~Drug: Vincristine Vincristine will be administered at a dose of 1.4 mg/m^2 (maximum 2 mg) IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Prednisone Prednisone will be administered at a dose of 40 mg/m^2 orally on Days 1-5 of Cycle 1-6, during induction treatment. Prednisolone may be given if prednisone is unavailable."
45838265|NCT04125186|Diagnostic Test|Baseline EpiNP survey|The survey takes approximately 20 to 30 minutes to complete, and consists of the following: Short Form Health Survey version 2.0 (SF-12v2.0); Lower Urinary Tract Symptoms (LUTS) Tool; Patient Perception of Bladder Condition (PPBC); Self-report Medical History and Current Medication Form; Nocturia Impact Diary (NID); Disease-Specific Healthcare-Seeking Behavior and Treatment; Epworth Sleepiness Questionnaire (ESS); Patient Reported Outcome Measurement Information System Fatigue-Short Form version 1.0 (PROMIS F-SFv1.0); Patient Health Questionnaire (PHQ-8); Work Productivity and Activity Index (WPAI-SHP); Sexual health questions; lifestyle and sociodemographic questions; additionally, only men will complete the International Prostate Symptom Score (IPSS).
46021836|NCT04908111|Biological|MVA-MAGEA3|"Patients will commence their standard of care chemotherapy in combination with an immune checkpoint inhibitor in three weekly cycles. Patients will be screened during the first two cycles of standard of care treatment to confirm whether they are eligible to take part in the trial.~Patients who are to receive the trial vaccines (in the safety run in stage and in Arm A of the NSCLC randomisation cohort) will continue to receive their standard of care treatment plus:~First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of standard of care treatment.~First boost MVA-MAGEA3 vaccine 21 days later.~Only for patients who have not progressed: Second prime ChAdOx1-MAGEA3-NYESO vaccine 15 week following the first prime vaccine.~Second boost MVA-MAGEA3 vaccine 21 days following the second prime vaccine.~Patients in Arm B will continue to receive their standard of care treatment only throughout the trial (i.e. no trial vaccines)."
46021837|NCT04908111|Combination Product|Standard of care treatment|Patients will continue to receive standard of care treatment (chemotherapy and checkpoint inhibitor).
46107340|NCT00842712|Drug|Gemcitabine|Gemcitabine (Gem) will be administered at a dose of 1250 mg/m^2 as intravenous infusion on Days 1 and 8.
46107341|NCT00842712|Drug|Vinorelbine|Vinorelbine (Vin) will be administered at a dose of 25 mg/m^2 as intravenous infusion on Days 1 and 8.
46107342|NCT00842712|Drug|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion once weekly over 1 hour on Days 1, 8 and 15 of each 3-week cycle until progressive disease, death, unacceptable toxicity, or consent withdrawal.
46107343|NCT00842712|Drug|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1, 4, 8, 11, 15, and 18 of each 3-week cycle followed by once weekly administration after end of chemotherapy until progressive disease, death, unacceptable toxicity, or consent withdrawal.
46107344|NCT00842712|Drug|Cetuximab|Cetuximab will be administered at a dose of 400 mg/m^2 as intravenous infusion over 2 hours on Day 1 of Cycle 1 followed by 250 mg/m^2 intravenous infusion over 1 hour once weekly on Days 8 and 15 of Cycle 1 and Days 1, 8, and 15 of all subsequent cycles until progressive disease, death, unacceptable toxicity, or consent withdrawal.
46107345|NCT00842712|Drug|Chemotherapy|Cis 80 mg/m^2 intravenous infusion on Day 1 + Vin 25 mg/m^2 or Cis 75 mg/m^2 intravenous infusion on Day 1 + Gem 1250 mg/m^2 intravenous infusion on Days 1 and 8 of each 3-week cycle will be administered along with Cil and cetuximab as per Investigator's discretion up to a maximum of 6 cycles.
46107346|NCT00705120|Other|Bone Marrow Cell Transplantation|
46107347|NCT00705120|Radiation|Irradiation, Total Body|
46107348|NCT00705120|Drug|Cyclophosphamide|
46107349|NCT00705120|Drug|Cyclosporin|
46107350|NCT00705120|Procedure|Mesenchymal Stem Cell Transplantation|
46107351|NCT00705120|Drug|Busulfan|
46107352|NCT00708474|Device|OsseoFit™ Porous Tissue Matrix™|Bone void filler
46107353|NCT00842244|Drug|axitinib|Twice daily oral dose of axitinib continuously depending upon side effects observed. Starting dose is 5mg twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
46107354|NCT00842244|Drug|capecitabine|Given orally twice daily for 14 days followed by 7 days of drug free period. Starting dose is 1000mg/m^2 twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
46107355|NCT00842244|Drug|cisplatin|Given through a vein on Day 1 of every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. The starting dose is 80 mg/m^2 on day 1.
46107356|NCT00832416|Drug|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
46107357|NCT00832416|Drug|Placebo|One Placebo tablet daily.
46107358|NCT00705198|Drug|Temozolomide (for newly diagnosed malignant glioma)|"Temozolomide treatment for newly diagnosed malignant glioma. The usual dose for adults in combination with radiotherapy is 75 mg/m2 orally once daily for 42 consecutive days. After a 4 week rest period, monotherapy at 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle is administered. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules."
46021838|NCT02880423|Procedure|tubal ligation group II|"Every woman , who is eligible to enter the study in terms of the above criteria , will receive a detailed explanation of the study and will review the consent form , and then be asked whether she agrees to participate in . If so , the participant will stamped on the informed consent form .~The control group will be women who undergo tubal ligation method BTL during cesarean section . All women will be invited to follow up about three months after surgery. The women will answer questionnaire to quantify the symptoms of menopause by NAMS , blood test for AMH and sonar and Doppler examination of both the ovaries"
46021839|NCT02880423|Procedure|salpingectomy group I|women who agreed to participate in the study and assigned randomly to this group will have salpingectomy during cesarean section for sterilization.
46021840|NCT04123275|Other|No intervention wil be done. Patient characteristics and the standard care before and after withdrawal of life-sustaining treatment in all potential cDCD donors, will be studied. .|
46021841|NCT04307199|Procedure|Amniotic membrane sweep|Amniotic membrane sweeping is defined as the manual detachment of the inferior pole of the amniotic membranes from the lower uterine segment. This is performed with consent by a clinician digitally through a circular motion during a vaginal examination. If the cervical os is closed massage of the cervix will be accepted.
46107359|NCT00705198|Drug|Temozolomide (for relapsed malignant glioma)|"Temozolomide treatment for relapsed malignant glioma. The usual dose for adults is 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules."
46107360|NCT00705198|Radiation|Radiotherapy (for patients with newly diagnosed malignant glioma)|Although the study protocol does not clearly define how long this intervention is applied, radiotherapy is generally administered 5 days/week for 6 weeks to patients with newly diagnosed malignant glioma.
46107361|NCT00708630|Behavioral|Extended information on side effects|More detailed information on possible side effects of vaccine
46107362|NCT00702936|Drug|TELMISARTAN|80 mg daily
46107363|NCT00702936|Drug|RAMIPRIL|5 mg daily
46107364|NCT00705276|Drug|Lactic acid (Dermacyd Femina Delicata)|
46107365|NCT00841776|Drug|Duac|Clindamycon and benzoyl peroxide topical gel once a day for 12 weeks
46107366|NCT00841776|Drug|Ziana gel|Clindamycin and tretinoin gel once a day for 12 weeks.
46107367|NCT00708786|Device|ICD|Ventricular arrhythmia treatment
46107368|NCT00708786|Device|CRT-D|Ventricular arrhythmia treatment
46107369|NCT00683800|Drug|desvenlafaxine succinate (DVS) SR|Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days.
46107370|NCT00683800|Drug|Placebo|Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days.
46107371|NCT00683644|Drug|Zinc|Zinc taken once daily
46107372|NCT00683644|Drug|Placebo oral capsule|Placebo capsules taken once daily
46107373|NCT00745576|Drug|SAM-531|
46107374|NCT00753064|Drug|Antiscorpion venom serum(AScVS).|"AScVS therapy group~If the score is 5 and if the patient belongs to pediatric group(>12-14): 1 vial AScVS as i.v. slow bolus after test dose If the score is 5 and if the patient is adult: 2 vials of AScVS as i.v. slow bolus after test dose. For injection, 1 vial will be dissolved in 10 ml distilled water and given over a period of 4 to 5 minutes.~According to the scores 1 vial for pediatric and 2 vials for adult patient will be increased as shown below:~Vials of AScVS Composite score Child Adult 5-10 2 4 > 10-15 3 6 >15- 21 4 8"
46107375|NCT00753064|Drug|T.Prazosin|Prazosin therapy Prazosin (30 micrograms/Kg/dose): 500 micrograms for pediatric patient, and 1mg for adult patients) will be given every 3 hourly orally till complete recovery.
46107376|NCT00753064|Drug|AScVS + Prazosin|Combination AScVS and Prazosin therapy In this group, AScVS therapy will be given as mentioned in AScVS therapy group and in addition, prazosin(500 micrograms for pediatric patient and 1mg for adult patients,30 micrograms/Kg/dose) every 3 hourly will be given.
46107377|NCT00751738|Drug|azimilide dihydrochloride|oral, once daily until sponsor stopped the study
46107378|NCT00751816|Drug|systemic chemotherapy|
46107379|NCT00751816|Other|survey administration|will be administered before, during, and after medical intent-to-cure treatment to describe head and neck cancer survivors' physical and functional well-being.
46107380|NCT00751816|Procedure|adjuvant therapy|
45681333|NCT04023838|Procedure|artery puncture and coronary angiography|We will perform coronary angiography through a Judkins 5 French diagnostic catheter and will take a basic view. At the end of the examination, the radial sheath is removed and the right conventional radial approach is performed for about 4 hours and the left snuffbox approach for about 2 hours using the compressive bandage method. The hemostatic device will use ez ClotRadial® (SOYEON medical Co., Ltd., Wonju, Korea).
46021842|NCT01106157|Drug|Anti-Thymocyte Globin (ATG)|Anti-Thymocyte Globin (ATG) will be given as 0.5/mg/kg on day 1 and 2mg/kg on day 2.
45681334|NCT01849562|Drug|Sovaprevir|NS3/4A protease inhibitor
45681335|NCT01849562|Drug|ACH-3102|NS5A inhibitor
45681336|NCT01849562|Drug|RBV|
45681337|NCT01849562|Drug|Placebo|
46107381|NCT00751816|Procedure|management of therapy complications|
46107382|NCT00751816|Procedure|musculoskeletal complications management/prevention|
46107383|NCT00751816|Procedure|physical therapy|weekly visits coordinated with adjuvant treatment as part of standard care
46107384|NCT00751816|Radiation|radiation therapy|
46107385|NCT00685360|Drug|Delamanid|Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.
46107386|NCT00685360|Drug|Optimized Background Regimen (OBR)|"Selection and administration of the treatment medications (i.e., OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.~Study Investigator could change OBR for a participant based on participant's tolerability and drug susceptibility testing (DST) results."
46107387|NCT00685360|Drug|Placebo|Placebo tablets matching 50-mg tablets of delamanid
46021843|NCT01106157|Drug|Placebo|Saline infusions will be given on Day 1 and Day 2 followed by placebo injections given in identical volumes in identical syringes
46021844|NCT01106157|Drug|Pegylated GCSF|6 doses of pegylated GCSF (6mg/dose) will be given subcutaneously every 2 weeks beginning after the ATG infusion.
46021845|NCT01094301|Device|The SPR System|The SPR System is an investigational two-staged device which delivers stimulation to the shoulder. Subjects with chronic post-stroke shoulder pain who meet eligibility criteria for the first stage (SPR Trial Stage) will receive a temporary Lead and External Stimulator. Subjects who qualify and who agreed to proceed will advance to the second stage (SPR Implant Stage) which uses an Implantable Pulse Generator (IPG) and Implantable Lead. Subjects will be followed until 36-months after IPG stimulation has been started.
46021846|NCT04835571|Other|Optimization of cardiovascular risk management|"Treatment goals were set according to current guidelines (Perk et al. Eur Guidelines on CVD prevention in clinical practice (2012). Eur heart J. 2012;33(13):1635-701):~blood pressure <140/90 mmHg~Tot cholesterol <5 mmol/l~LDL <1,8 mmol/l~Waist circumference: men <94 cm, women <80 cm~BMI <25 kg/m2~HbA1c without diabetes mellitus <42 mmol/mol, HbA1c with diabetes mellitus <52 mmol/mol~Antithrombotic treatment (or anticoagulants, if indicated)~Physical activity 30 min/day, 5 days/week, alternatively high-intensity training at least15 min/day, 5 days/week or a combination of the two.~Healthy diet, including low levels of saturated fats, high intake of vegetables, fruits, whole-grain and fish~Smoking cessation~Low alcohol consumption~Patients were encouraged to follow the above recommendations through support of the study physicians, who made individual assessments of all patients and adjusted ongoing medical treatment to reach treatment targets."
46021847|NCT04828005|Drug|Nalmefene hydrochloride|3mg Nasal spray
46021848|NCT04828005|Drug|Naloxone hydrochloride|4mg Nasal Spray
45468581|NCT01244945|Dietary Supplement|L. reuteri DSM 17938|L. reuteri will be administered at 1x10^8 CFU dosage in form of tabs. In order to ensure colonization (run in), 4 tabs will be administered per os daily (4x10^8CFU/die) for 15 days. Then administration will continue with 2 tabs daily (2x10^8 CFU/die) for 90 days.
45468582|NCT01244945|Other|Placebo Group|Placebo tabs identical in form, taste and consistency to active tabs
46021849|NCT04306887|Drug|TQ-B3101 capsule|Escalating doses starting at 200 mg bid.
46021850|NCT02877459|Device|AeriSeal System|Subjects will undergo two bronchoscopy procedures two months apart and will be treated with AeriSeal foam unilaterally, in two sub-segments during each bronchoscopy (4 segments treated in total).
46021851|NCT04306497|Drug|TCM prescriptions|TCM prescriptions1:Take decocted or granule, one dose a day; TCM prescriptions2:Take decocted or granule, one dose a day.
46021852|NCT02878161|Drug|methotrexate(necessary)|Methotrexate will be received orally with dosage of 10mg/ week for every patient and MTX dose must be stable for at least 4 weeks.
46021853|NCT02878161|Biological|infliximab|infliximab :intravenous injection 200mg,every times,0,2,6,14week ,4 times)
45468583|NCT05273203|Behavioral|FIM-1|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
46021854|NCT02878161|Biological|etanercept|Etanercept :hypodermic injection,25mg/twice a week
46021855|NCT02878161|Biological|adalimumab|Adalimumab:hypodermic injection,40mg/twice a week
46021856|NCT02878161|Drug|leflunomide (permitted, not necessary)|LEF will be permitted if patient had received for 1 month before enrollment and will not be changed for 14 weeks.
46021857|NCT02878161|Drug|NSAIDs (permitted,not necessary)|NSAIDs will be allowed if patient had received for 1 month before enrollment and will not be changed for 14 weeks.
46021858|NCT02878161|Drug|Glucocorticoids (permitted,not necessary)|Glucocorticoids (prednisone less than 10mg/day, or equal dosage of other similar drugs) will be permitted if the patient had received for 1 month before enrollment and the dosage will not be changed during the period.
45468584|NCT05273203|Behavioral|FIM-2|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
45468585|NCT05273203|Behavioral|FIM-3|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
45681338|NCT04023760|Drug|Apixaban|Study subjects given a single-dose of apixaban 10 mg.
45681339|NCT04026490|Behavioral|Immediate Intervention|The Interventionist will use motivational interviewing skills, assess ethnic and racial microaggressions, and provide support, screen for posttraumatic stress, and, if appropriate, link student to advanced care. The student may meet with the Interventionist several times during the remainder of the school year. These meetings will be approximately 10-30 minutes in length and occur during the school day in a private location determined by the Interventionist. The student may be referred to additional resources as a result of the meetings. The meetings will be documented by the Interventionist using a case management system (in RedCap).
46021859|NCT02877069|Device|VYC-12 HA injectable gel|VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection.
46021860|NCT02877225|Drug|Ibrutinib|Ibrutinib (test treatment) 140 milligram (mg), tablet.
46021861|NCT02877225|Drug|IMBRUVICA|IMBRUVICA (reference treatment), 140-mg capsule
46021862|NCT01093755|Drug|dexlansoprazole|Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months
46021863|NCT01093755|Drug|Omeprazole|Escalating doses of omeprazole (20-60 mg/day) for 6 months
46021864|NCT01093599|Behavioral|Quit Line plus MTS|This provides the quit line intervention plus the Mindfulness for Smokers Intervention.
46021865|NCT01093599|Behavioral|Quit Line Only|The quit line only intervention includes phone counseling, Quit Smoking Materials and 4 weeks of nicotine patches.
46021866|NCT01092663|Drug|Colesevelam HCl|Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
46021867|NCT01092663|Drug|Sitagliptin|Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.
45838266|NCT04125186|Diagnostic Test|Bladder diary|It consists of four components: measurement of waist and neck circumference, daily voiding diary (to assess voiding patterns, including frequency, volume, associated urgency, and incontinence episodes over a 24-hour period), NID (to assess nocturia impact), and assessment of morning sleepiness for 3 consecutive days and nights (including the morning of the fourth day).
46021868|NCT02877147|Other|SEBTC|SEBTC benefits were issued on EBT cards using either the existing EBT delivery systems for the Supplemental Nutrition Assistance Program (SNAP) or Supplemental Nutrition Assistance Program for Women Infants and Children (WIC). Sites selected only one of the two EBT systems to be used to implement SEBTC prior to random assignment; households were not randomized to a specific delivery system.
46021869|NCT01078623|Drug|Aclidinium 200 μg / formoterol 12 μg|Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily
46021870|NCT01078623|Drug|Placebo|Placebo control twice daily
46021871|NCT01078623|Drug|Formoterol 12 μg|Formoterol fumarate 12 μg twice daily
46021872|NCT01078623|Drug|Aclidinium 200 μg|Aclidinium bromide 200 μg twice daily
46021873|NCT01078623|Drug|Aclidinium 200 μg / Formoterol 6 μg|Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily
45838267|NCT04125186|Diagnostic Test|Testing of EpiNP baseline survey, bladder diary and a qualitative interview|This part briefly reviews the usability of the EpiNP survey and bladder diary. The feedback obtained after qualitative interview will be used to refine and finalize the instructions sent to the participants in the main part.
46021874|NCT04879251|Other|No intervention|No intervention
46021875|NCT01092507|Biological|Japanese encephalitis chimeric virus vaccine (JE-CV)|0.5 mL, Subcutaneous
45468586|NCT05273203|Behavioral|Control|No football training will be performed during 6 months period. Participation only in measurements at baseline and at 6 months.
46021876|NCT01092507|Biological|Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)|0.5 mL, Subcutaneous
46021877|NCT05051397|Biological|HYPERCAPNIA|Controlled moderate hypercapnia PaCO2 50mmHg under general anesthesia with mechanical ventilation
46021878|NCT05051397|Biological|NORMOCAPNIA|Controlled normocapnia PaCO2 40mmHg under general anesthesia with mechanical ventilation
46021879|NCT02877381|Procedure|Revision Total Knee Arthroplasty (TKA)|Femoral component exchange, tibial component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision TKA, randomization will be done to ensure equivalent numbers of each type of revision TKA between the treatment groups.
46021880|NCT02877381|Procedure|Revision Total Hip Arthroplasty (THA)|Femoral component exchange, acetabulum component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision THA, randomization will be done to ensure equivalent numbers of each type of revision THA between the treatment groups.
46021881|NCT02878239|Other|Steps 1|Kinematic characteristics are obtained by the portal gait analysis system in the patients. Kellgren-Lawrence Scores are obtained according to their radiography.
46107388|NCT04060264|Biological|BCD-148|"Active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period).~QW - once weekly"
46107389|NCT04060264|Biological|Soliris|"Active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period)."
46021882|NCT02878239|Other|Steps 2|Kinematic characteristics are obtained by the portal gait analysis system in the subjects.Physical examinations are taken to avoid other diseases.
46107390|NCT00684814|Drug|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered after an overnight fast of at least 10 hours
46021883|NCT01078545|Drug|Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)|Leuprolide acetate 11.25 mg every 3 months sc or im, number of injections during the trial - 5 in Poland, Leuprolide acetate 3.75 mg every 1 month sc or im, number of injections during the trial - 12 in Ukraine.
46107391|NCT00684814|Drug|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered after an overnight fast of at least 10 hours
46021884|NCT01202760|Drug|LY2127399|
46021885|NCT01202760|Drug|Placebo|
46107392|NCT00576472|Drug|Methylphenidate|Please see detailed description for dosing information and study design.
46107393|NCT00823212|Device|PROMUS Coronary Stent System|PROMUS is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
46107394|NCT00823212|Device|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating that is the same as on the PROMUS [XIENCE V] stent).
46107395|NCT00823212|Drug|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
46107396|NCT00823212|Drug|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
46107397|NCT00807495|Drug|Alisertib|Alisertib capsules
46021886|NCT01091259|Drug|Irinotecan|
46107398|NCT05753943|Drug|QUALI|Medication 1 pill at night
46107399|NCT02561494|Drug|Nefopam|
46107400|NCT02561494|Drug|Saline|
46107401|NCT05748795|Procedure|bronchoscopy brochoalveolar lavage|"2%lidocaine gel will be used to anaesthesize nasal mucosa.6ml lidocaine 2%diluted in 5cc normal saline lidocaine spray solution will be used for anaesthesizing the vocal cords and mucosa of the bronchial tree(13).~Intravenous midazolam (0.01-0.1mg\kg) will be given to achieve conscious sedation in selected cases(13).~Flexible Bronchoscopy will be done under continuous monitoring for O2 saturation, heart rate, blood pressure and respiratory rate.~The bronchoscope will be introduced into the nasal cavity and advanced to the level of the vocal cords. Lidocaine will be instilled through the bronchoscope to the vocal cords and tracheobronchial tree.~Using sterile bronchoscope in the lobar bronchus of tumor location,100 mL of sterile normal saline in fractionated doses will be injected and then BAL will be removed by suction to be collected in sterile side-way bottles."
46107402|NCT00751894|Drug|Pegfilgrastim (Neulasta, Amgen)|sequential Bayesian study
45468587|NCT03316131|Drug|Verinurad|Randomized patients will receive orally once daily fixed dose of verinurad in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
45838268|NCT04125186|Other|No other intervention|No other intervention
45838269|NCT04119453|Drug|Rivoceranib|Film-coated tablets
46021887|NCT01091259|Drug|Bevacizumab|
46107403|NCT00745732|Drug|ZD6474 (ZACTIMA)|ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth
46107404|NCT00745732|Radiation|Radiation Therapy|"Phase I: 45 Gy at 3 Gy per fractions once a day.~Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day."
46107405|NCT02608125|Drug|PRN1371|
46107406|NCT00576316|Drug|Symbicort Turbuhaler 160/4.5|
46107407|NCT05421156|Procedure|Subtotal Laparoscopic Hysterectomy|Subtotal laparoscopic hysterectomy involves removing the main body of the uterus and leaving the cervix in place by laparoscopy.
46107408|NCT05421156|Procedure|Total Laparoscopic Hysterectomy|Total laparoscopic hysterectomy involves removing the whole uterus and cervix by laparoscopy
46107409|NCT00745810|Other|Cardiopulmonary bypass|sequential changes of oxidative injuries before and after cardiopulmonary bypass
46107410|NCT00823134|Device|ApneaLink Plus|Device used to evaluate for the presence of obstructive, central or mixed apneas
46107411|NCT00745888|Other|Chemiluminescence Analyzer|measure reactive oxygen species
46107412|NCT00755872|Drug|Risedronate|Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
46107413|NCT00755872|Drug|Risedronate|Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
46107414|NCT00755872|Drug|Risedronate|Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
46107415|NCT00755872|Drug|Risedronate|Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
46107416|NCT00755950|Dietary Supplement|Silymarin|280 mg three times daily for four weeks
46107417|NCT00755950|Dietary Supplement|Silymarin|420 mg three times daily for four weeks
46107418|NCT00755950|Other|Lactose monohydrate|Lactose monohydrate 326.95 mg three times daily for four weeks
45838270|NCT04114734|Behavioral|Park Rx|Participants will be advised to visit a specific park at a specific frequency and duration
46107419|NCT00756028|Drug|Patients receiving short protocol IVF/ICSI-treatment.|Injection s.c. Orgalutran® (Ganirelix)0.25 mg once daily from day 5 of FSH-stimulation until HCG-day
46021888|NCT05328375|Behavioral|Telehealth-enhanced Hybrid CR|Participants in this group attend a total of 24 CR sessions (5 clinic-based + 19 home-based) over a 12-week period. Clinic-based sessions occur during the first week of the program and at the end of each month. Home-based sessions take place remotely once or twice per week via telehealth, depending on the week of the program. Patients are provided with onboarding sessions, remote patient monitoring devices (tablet, pulse oximeter, blood pressure monitor and cuff) and home-based exercise equipment (e.g., stationary bike and weights). Each CR session (clinic and home) is 60 minutes in duration and includes aerobic and resistance exercise training. Patients will also be asked to complete educational videos, as well as document their physical activity, dietary intake, medication management and homework sessions via surveys. Patients will be encouraged (but not required) to achieve ≥30 minutes of moderate aerobic activity, such as brisk walking, on ≥5 days per week.
46107420|NCT00756028|Drug|Long protocol|Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)
46107421|NCT02560948|Biological|Placebo solution|4 x 2 injections over 21 days
46107422|NCT02560948|Biological|gpASIT+TM|4 x 2 injections over 21 days
46107423|NCT02560090|Behavioral|Surveys|The following information will be collected: demographics, literacy screener, depression screener, medication adherence, self-efficacy, tobacco use, patient activation, health questionnaire, eating patterns, diabetes self-management assessment, stages of change questionnaire, vitals, and self-care behaviors.
46107424|NCT02560090|Behavioral|Telephonic Nurse Intervention|A nurse will contact patients by phone at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
46107425|NCT02560090|Behavioral|In-person Community Health Worker|An in-person Community Health Worker will contact patients in-person at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
46107426|NCT00831792|Drug|TK1258|4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day).
46107427|NCT00705354|Drug|Bacitracin|Nasopore sponge soaked with Bacitracin, placed in middle meatus of the nose. No post-op oral antibiotics
46107428|NCT00705354|Procedure|Nasopore sponge soaked with saline|Nasopore sponge soaked with saline placed during surgery and will receive routine oral antibiotics post-operatively
46107429|NCT00575380|Drug|AzaSite Eye Drops|One drop two times a day for two days and once a day for the next five days.
46107430|NCT00575380|Drug|Vigamox Eye Drops|One drop three times a day for seven days
46107431|NCT00840996|Drug|Lidocaine|perioperative intravenous lidocaine (2 mg/kg/h) with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
46107432|NCT00840996|Drug|placebo|perioperative placebo IV saline infusion of 2 mg/kg/h with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
45681340|NCT04026490|Behavioral|Waitlist Intervention|In order to compare outcomes contemporaneously, students from waitlisted schools will be asked to complete baseline and follow-up surveys, which will be collected at approximately the same time as in the immediate intervention schools. The data will be captured for analysis at the end of the study. Students will complete intervention following the waitlist period.
46107433|NCT02559934|Drug|SR-T100 Gel|0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract)
46107434|NCT05526534|Device|heated humidified high flow nasal cannula oxygen therapy, HFNC|HFNC can accurately provide 21% ~ 100% oxygen concentration through air oxygen mixer. And through the heating and humidification device to provide 37℃, relative humidity of 100% gas, the maximum flow of 70L/min.
45681341|NCT03022786|Other|Order set|Inpatient order set and ambulatory care guide offer guidance on initial compression to decrease edema, obtaining gradient compression stockings, how to access evaluation by vascular medicine for pain or dermatology for evaluation of allergic contact dermatitis if itch persists, etc
46107435|NCT05526534|Device|Nasal cannula oxygen|Nasal cannula oxygen has become a routine part of postoperative treatment
46107436|NCT00756184|Device|TDA adherence monitor for travoprost therapy|monitoring adherence to travoprost therapy
46107437|NCT00756184|Device|TDA and travoprost monotherapy|Patients will be prescribed travoprost therapy and will be followed up in a standard clinical fashion with a attention placebo at both baseline and 6 months
46107438|NCT00756340|Drug|Bevacizumab|"Bevacizumab IV every 2 weeks~Dose Level 0- 8 mg/kg~Dose Level 1 (starting dose)- 10 mg/kg~Dose Level 2- 10 mg/kg"
46107439|NCT00756340|Drug|Everolimus|"Everolimus~Dose Level 0- 4 mg/m2~Dose level 1 (starting dose)- 4 mg/m2~Dose Level 2- 5 mg/m2"
46107440|NCT00705510|Drug|0.05% cyclosporin eye drop|use the medication twice daily for 3 months
46021889|NCT05328375|Behavioral|Traditional CR|Participants in this group attend a total of 24 clinic-based CR sessions according to standard of care protocols over a 12-week period. Each CR session is 60 minutes in duration and includes aerobic and resistance exercise training. In addition to scheduled sessions, patients will be asked to complete educational videos, as well as document their physical activity, dietary intake, medication management and homework sessions via surveys. Patients will be encouraged (but not required) to achieve ≥30 minutes of moderate aerobic activity, such as brisk walking, on ≥5 days per week.
46107441|NCT05434780|Other|Kinesiology taping|Kinesiology tape is an elastic tape applied to skin with specific amount of tension as per requirement. The underlying mechanism investigated by several studies is the space enhancement and skin uplifting that increases the blood flow in the targeted area and promotes healing.
46107442|NCT00680914|Biological|Pneumococcal vaccine GSK1024850A (Synflorix)|3 doses administered intramuscularly.
46107443|NCT00680914|Biological|Prevenar|3 doses administered intramuscularly.
46107444|NCT00680914|Biological|GSK Biologicals' Hiberix™|3 doses administered intramuscularly.
46107445|NCT00680836|Drug|Placebo|orally two times per day for 14 days
46021890|NCT05381844|Other|Blood sampling|30 ml blood sampling for virological research
46107446|NCT00680836|Drug|Rifaximin|550 mg orally two times per day for 14 days
45468588|NCT03316131|Drug|Febuxostat|Randomized patients will receive orally once daily fixed dose of febuxostat in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
45838271|NCT04109313|Drug|LOU064|selected dose of LOU064 taken orally twice a day (morning and evening) from day 1 to week 52 of the Treatment period.
46021891|NCT01091103|Drug|Enzalutamide|
46107447|NCT00753844|Biological|URLC10|Biological: URC10 Patients will be vaccinated once in one week to the eighth vaccine and will be vaccinated once in two weeks from the ninth vaccine. On each vaccination day, the URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by endodermic injection.
45468589|NCT03316131|Drug|Dapagliflozin|Randomized patients will receive orally once daily fixed dose of dapagliflozin in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
46021892|NCT01078389|Drug|Febuxostat|Febuxostat capsules
46021893|NCT01078389|Drug|Placebo for Febuxostat|Febuxostat placebo-matching capsules
45838272|NCT04099251|Biological|Nivolumab|Specified dose on specified days
45838273|NCT04099251|Other|Placebo|Specified dose on specified days
46021894|NCT01090323|Drug|ICL670|Daily doses of ICL670 were taken orally 30 minutes before breakfast. The doses range from 5-40 mg/kg and were determined based on the patient's trend in serum ferritin over time during the core study (0109) and on the frequency of blood transfusions the patient received. The treatment duration was up to 4 years.
46021895|NCT00626301|Drug|LPV/r|LPV/r 230/57.5 mg/m2 orally q12h or the adjusted dose based on therapeutic drug monitoring of LPV/r prior to enrollment as maintenance monotherapy
46021896|NCT02878005|Device|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction
46107448|NCT02560168|Device|MyoVista device|MyoVista device is a standard EKG device with additional capabilities in detecting cellular level myocardial electrophysiological signals. The device involves placing leads on the chest, similar to a traditional EKG device
46107449|NCT02560168|Device|Computed tomographic coronary angiography|Traditional method of detecting coronary artery disease. CTA will be performed using 64-detector row or higher scanners with electrocardiographic gating in accordance with the Society of Cardiovascular Computed Tomography (SCCT) guidelines. Approximately 80 to 100 ml of intravenous contrast, followed by 50 to 80 ml of saline, will be administered at a rate of 5 ml/s via a power injector through an antecubital vein (on forearm near the elbow).
46107450|NCT02560168|Device|Transthoracic Echocardiography|
46107451|NCT00754000|Other|Observation|AE monitoring and EPIC QOL survey
46107452|NCT00754078|Radiation|Tomotherapy|30 fractions of tomotherapy treatment
46107453|NCT05428306|Drug|A1: Ibuprofen/Acetaminophen Fixed dose combination (Laboratorios Silanes S.A. de C.V.)|Formula : 200 mg/ 500 mg Pharmaceutical Form: Tablet Dosage: 400 mg / 1000 mg (2 tablets) Administration way: oral
46107454|NCT05428306|Drug|A2: Ibuprofen (Motrin®, Pfizer S.A. de C.V.)|A2: Pharmaceutical Form: tablet Dosage: 400 mg (1 tablet) Administration way: oral
45838274|NCT04097353|Behavioral|Harvesting Hope for Kids (HH4K)|Weekly meetings at university-based farm
45838275|NCT04097353|Behavioral|Surviving Strong for Kids (SS4K)|Enhanced usual care
46107455|NCT05428306|Drug|A3: Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.)|A3:Pharmaceutical Form: tablet Formula: Acetaminophen 500 mg Dosage: 1000 mg (2 tablets) Administration way: oral
46107456|NCT05424796|Combination Product|Physiological saline|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, hemostasis was achieved by checking the saline soaked cotton pellet.
46107457|NCT05424796|Combination Product|Hemostasis and cavity disinfection with NaOCl|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, 2.5% NaOCl soaked cotton pellets were placed over canal orifices.
45468590|NCT03316131|Other|Dapagliflozin matched placebo|Randomized patients will receive orally once daily fixed dose of dapagliflozin matched placebo in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
45838276|NCT04093986|Other|Chart Review|Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women.
45838277|NCT04093986|Other|Survey|Women who choose to participate directly and provide information in survey format will receive a brief survey and the option to upload their medical records (if available) into Cincinnati Children's maintained REDCap database.
46021897|NCT02878005|Device|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
46021898|NCT00626457|Behavioral|Behavioral weight-loss/lifestyle interventions|6-month intervention (28 weekly classes)
46021899|NCT02876991|Procedure|Sodium fluoride PET|"Sodium fluoride Pet is realized maximum after 4 weeks from choline PET (inclusion).~Injection of 4MBq 18F-FNa/kg of body weight is followed after 60 min (± 5 min) by acquisition of images on Biograph 6 PET/CT scanner (SIEMENS).~Data from sodium fluoride PET are interpreted independently and blind from other data by 3 medical doctors (2 at hospital of Nancy and 1 at hospital of Strasbourg) (for inter-judge reproducibility); a second interpretation of data is consensually realized by 2 of 3 readers, limited to discordant analyses (metastatic status or not, and/or number of lesions); results from this second interpretation are final results."
46021900|NCT01201356|Drug|Fingolimod|0.5 mg/day
46021901|NCT04872153|Behavioral|Dividat Senso Exergames|"The intervention period in the rehabilitation setting will be equal to the length of the stay in the rehabilitation clinic (between 2-3 weeks, according to each cantonal/regional regulations and insurance coverage) and will include short daily training sessions using the Senso (5x/week à 10- 15min), resulting in 15 to 20 training sessions in total.~Each session contains various combinations of the Dividat exergames (each of the games lasts around 2-3min)."
46021902|NCT00637611|Drug|Fexofenadine HCl|
45468591|NCT03944447|Drug|Cannabis, Medical|Patients will be given medical cannabis recommendations and certifications commensurate with the state law in which the encounter occurs. The variations in mechanisms between the states for recommending, registering, certifying, and developing mandated treatment plans or doses will be adhered to; however, variations in state law and cannabis programs should not cause variation in the study design because the end-result is still the same with patients being treated with medical cannabis.
46107458|NCT05424796|Device|Hemostasis and cavity disinfection with KTP laser|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, complete hemostasis and cavity disinfection were achieved using a KTP laser (SMARLITE D, Deka, Calenzano FI, Italy).
46107459|NCT00757198|Drug|remifentanil|remifentanil infusion
46107460|NCT00757198|Drug|remifentanil|remifentanil infusion
46107461|NCT00757354|Procedure|Metal on Metal cementless hip|Metal on Metal hip arthroplasty
46107462|NCT05421052|Other|Unmet health needs|The students who have unmet health needs during the last 6 months will respond to the questionnaire to assess the causes and other factors
46107463|NCT05418322|Behavioral|Oral Hygiene Intervention|The oral hygiene instructions given in the two methods will be prepared in Bahasa Malaysia and English versions with the same content to avoid bias. The oral hygiene education will be validated by three dental specialists. A similar large dental teeth model and toothbrush will be used for the purpose of oral hygiene demonstration.
46107464|NCT00921778|Device|Lapcone|Use of Lapcone during LSH
46021903|NCT00626535|Drug|Esomeprazole|20mg Oral Once Daily
46021904|NCT00626535|Drug|Matching placebo|Oral Once Daily
46107465|NCT00921778|Procedure|laparoscopic supracervical hysterectomy|laparoscopic supracervical hysterectomy
45468592|NCT03944447|Device|RYAH-Medtech Inhaler|Our research study will involve incorporation of RYAH-Medtech company's devices into our protocols. They have an inhaler and a transdermal patch for both hemp-derived CBD and cannabis. RYAH has developed an integrated phone app for tracking product use and patient response. They are currently involved in clinical trials in Europe. OMNI Medical will integrate the partner with RYAH device for several reasons. Primary goals will involve using their integrated smart phone app to collect and secure large quantities of data. Secondary goals will include FDA approval as a medical device. The specific cannabis strain will be tracked using scannable QR codes programed into the smart phone app. This will allow us to track patient feedback and capture data on usage. OMNI Medical will have patients use RYAH's products as part of and FDA Investigational Device Exemption, which requires an IRB. Use of the devices would be completely voluntary by study participants.
46021905|NCT05400642|Device|THRIVE|Apneic ventilation
46021906|NCT05400642|Device|mechanical ventilation|mechanical ventilation in Positive Pressure
45468593|NCT03779659|Device|Synapse TENS device|At the time of local anesthetic application the TENS device will be activated and placed on the buccal and lingual alveolar mucosa adjacent to the tooth receiving the restorative treatment using the pad applicator. The tip of the device with the electrodes are placed in a vertical up and down motion for approximately ten seconds. Following this, the level of pain and anxiety are measured using the Wong Baker Scale and Visual Analog Scale. The TENS device is used for achieving localized pain relief at the site of local anesthetic injection prior to injecting the anesthetic agent (such as lidocaine or articaine). Following this, once the clinician ensures that the patient is pain free then local anesthetic injection is given and following that the dental procedures are conducted.
46021907|NCT01200810|Other|placebo|Given orally
46021908|NCT01200810|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
46021909|NCT01200810|Drug|bicalutamide|Given orally
46021910|NCT04317378|Device|Braun thermoscan /, IRT 6520|The temperature will be measured in both ears with an ear thermometer. Practically, we will measure the temperature twice when generel anaesthsia is established, and immidiately before and after the MRI scan.
46021911|NCT01200342|Drug|Genasense|900 mg by vein over 1 hour on Days 1, 3, and 5 of a 21 day cycle.
46021912|NCT01200342|Drug|Paclitaxel|175 mg/m^2 by vein over 3 hours on Day 3 of a 21 day cycle following Genasense.
46107466|NCT00757744|Behavioral|Behavioral Drug and HIV Risk Reduction Counseling (BDRC)|once weekly individual counseling
46107467|NCT00757744|Behavioral|Drug counseling|individual drug counseling
46021913|NCT01200342|Drug|Carboplatin|"Carboplatin starting dose in mg (AUC= 6) is administered over 30 minutes IV Piggyback (IVPB). Carboplatin will be dosed after Paclitaxel dose on Day 3 every 3 weeks.~The total dose of Carboplatin is calculated using a formula based upon a participant's glomerular filtration rate (GFR in mL/min) and Carboplatin target area under the concentration (AUC)."
46021914|NCT01199016|Procedure|Tympanocentesis|To be performed as needed on children presenting with acute otitis media
46021915|NCT01199016|Procedure|Nose/throat swab|To be performed at every study visit
46021916|NCT01199016|Biological|Observational|Observational Study Only
46021917|NCT01198548|Drug|leucovorin calcium|Given IV
46021918|NCT01198548|Biological|bevacizumab|Given IV
46021919|NCT01198548|Dietary Supplement|cholecalciferol|Given PO
46021920|NCT01198548|Drug|fluorouracil|Given IV
46021921|NCT01198548|Drug|oxaliplatin|Given IV
45468594|NCT03779659|Drug|Topical anesthetic gel|"The local anesthetic gel is typically used for achieving localized pain relief at the site of local anesthetic injection and this is part of standard care that is followed prior to dental procedures.~The amount of local anesthetic used will not exceed the maximum allowable dose, which will be calculated for each patient based on his/her age and weight prior to the dental procedure"
45681342|NCT03022786|Other|Motivational Interviewing training for home health aides|"Home Care aides trained about use of compression stockings and use of motivational interviewing as a tool to help patients make behavior changes to reduce leg swelling. This is part of our 'tool kit'.~There will be a focus group comprised of providers. This focus group will explore the perceptions of the providers and what unmet needs remain for the patients."
46021922|NCT01198548|Other|pharmacological study|Correlative studies
46021923|NCT01198470|Device|TRIUMPH® Lumbar Artificial Disc|The TRIUMPH® Lumbar Artificial Disc is an articulating artificial disc inserted using a posterolateral approach to the lumbar spine.
46021924|NCT00977938|Drug|Placebo & Aspirin|
46021925|NCT00977938|Drug|Clopidogrel & Aspirin, Prasugrel & Aspirin|
46021926|NCT02716675|Biological|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
46021927|NCT02716675|Biological|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
46021928|NCT04289662|Drug|K-924 LD|Pitavastatin 2 mg / Ezetimibe 10 mg tables
46021929|NCT04289662|Drug|K-924 HD|Pitavastatin 4 mg / Ezetimibe 10 mg tables
46021930|NCT04128709|Device|Urodynamics Testing|The non-invasive device connects to the end of urinary catheter that the patient uses for routine daily catheterization. Once urine flows into the device the patient presses a single button in order to obtain a pressure measurement which is recorded and stored in the device along with the time and date. The measurement(s) can later be transmitted wirelessly to a smart phone that contains an app for the device.
46021931|NCT04227925|Biological|Trichuris trichiura|Infective eggs from human whipworm, Trichuris trichiura
46021932|NCT00632515|Behavioral|Questionnaire|Questionnaire regarding awareness of screening tests and attitudes toward colorectal cancer screening, taking 30-45 minutes to complete.
46021933|NCT04259203|Behavioral|Erickson hypnosis|Erickson hypnosis sessions performed by an experienced hypnotherapist, according to a pre-established protocol : 5 sessions (1 per week). Between each session : exercise of auto-hypnosis by the patient himself, at home
46021934|NCT00977548|Drug|Erlotinib|Participants took erlotinib at least 1 hour before, or 2 hours after they ate a meal or snack. Participants were advised to take erlotinib at around the same time every day.
46021935|NCT04290208|Drug|Acetaminophen|IV Acetaminophen
46021936|NCT04290208|Drug|Acetaminophen|Acetaminophen liquid syrup
46021937|NCT04290208|Drug|Placebos|Flavored, non-medicated (placebo) liquid syrup
46021938|NCT04290208|Drug|Placebos|IV salt solution (non-medicated)
46021939|NCT03223597|Drug|Radium-223 dichloride|Registry of patients who receive Radium-223.
46021940|NCT02865382|Procedure|white light was used for colonoscopy withdrawal|
46021941|NCT02865382|Procedure|OE mode was used for colonoscopy withdrawal|
46021942|NCT01090011|Drug|Cetuximab|BIBW 2992 medium dose plus high dose level of cetuximab
46021943|NCT01090011|Drug|Cetuximab|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
46021944|NCT01090011|Drug|BIBW 2992|BIBW 2992 medium dose plus high dose level of cetuximab
46021945|NCT01090011|Drug|BIBW 2992|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
46021946|NCT03206905|Procedure|Endoscopic Sleeve Gastroplasty|endoscopic, rather than surgical approach, to perform sleeve gastroplasty
46021947|NCT03206905|Behavioral|Diet and Exercise|nutritional/exercise counseling
46021948|NCT04257331|Behavioral|Stars and Rain Education Institute for Autism (SREIA) Parent Training Programme|The SREIA program is grounded in applied behavior analysis and developmental theories. It aims to reduce child behavioral problems and promote child development by improving parental attitudes and parenting styles. The program targets parent-child dyads from families of children with ASD aged between three and six years. It is delivered five days a week for 11 weeks. Fourteen two-hour lectures on weekly themes (such as knowledge of ASD, parent-child interaction, and behavior management techniques) are offered throughout the 11 weeks and attended by all participating parents. For the remaining time, additional training in ABA principles and practice are tailored for the different functioning groups. The program offers a combination of individual counselling and group sessions, as well as a mixture of didactic and interactive delivery modes. All sessions are delivered in person. Some sessions are only for parents and others are participated in by both parent and child.
45681343|NCT03022786|Other|Tools & Education|Engaged physical therapists to evaluate patients for ability to don stockings, to assess need for strengthening exercises or leg exercises to improve venous return. This is part of our 'tool kit'
46107468|NCT04052074|Other|Music Therapy|We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be performed using mp3 players or mobile phones.
46107469|NCT04052074|Other|simulation with therapeutic education|Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through earphones
46107470|NCT04052308|Behavioral|ABPM|Ambulatory Blood Pressure Monitoring at Baseline and at the end of the study
46107471|NCT04052308|Behavioral|The arterial stiffness and endothelial reactivity|The arterial stiffness and endothelial reactivity will be assessed at baseline and at the end of the study
46107472|NCT04052308|Behavioral|Euroqol EQ-5D-5L|Answer Euroqol EQ-5D-5L at baseline and at the end of the study
46107473|NCT04052308|Behavioral|Lectures about knee OA|Patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).
46107474|NCT04052308|Behavioral|Continuous intensity exercise|40 min of treadmill physical exercise (40 min on treadmill at 60% of reserve heart rate.)
46107475|NCT04052308|Behavioral|Exercises with varying intensity and interval|40 min of treadmill physical exercise ( 40 min on treadmill with alternating intensity between 50% (2 min) and 80% (1 min) of HR, resulting in an average load of 60% ((50% 2) + 80% / 3)), 20 min of sub-maximal strength training and 10 min of cooling exercises.
46107476|NCT00679432|Procedure|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
46107477|NCT00679432|Drug|budesonide-MMX® 6 mg|6 mg/day, 6 mg tablets
46107478|NCT00679432|Drug|budesonide-MMX® 9 mg|9 mg/day, 9 mg tablets
46107479|NCT00679432|Drug|Placebo|Placebo
46107480|NCT00679432|Drug|Asacol® 400 mg|2400 mg/day, 400 mg tablets
46107481|NCT02560870|Drug|Active Comparator:Aloe Vera mouthwash|mouthwash( Aloe Vera),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
46021949|NCT04300803|Biological|Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression|Expanded Access Program, Non-Interventional Study
46021950|NCT04242355|Behavioral|Transcranial Magnetic Stimulation (TMS)|Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
46107482|NCT02560870|Drug|Active Comparator:Chlorhexidine mouthwash|mouthwash( Chlorhexidine ),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
46107483|NCT00679354|Drug|cilengitide|Given IV
46107484|NCT00679354|Other|laboratory biomarker analysis|Correlative studies
46107485|NCT00679354|Other|pharmacological study|Correlative studies
46107486|NCT02559700|Behavioral|Brain training programme|An online package of brain training programmes
46107487|NCT02560714|Device|SImmetry Sacroiliac Fusion System|"SImmetry~The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
46107488|NCT02560792|Behavioral|Positive Affect Condition|"Participants read: Most people exercising at this intensity say that it feels good, and that it makes them feel energized and more positive, and more relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to positive feelings, and what specifically about this exercise might make you, personally, feel good."
46107489|NCT02560792|Behavioral|Negative Affect Condition|"Participants read: Most people exercising at this intensity say that it doesn't feel very good, and that it makes them feel tired and not so positive, and not very relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to negative feelings, and what specifically about this exercise might make you, personally, feel bad."
46107490|NCT02560792|Behavioral|Control Condition|Participants receive no information about affective response
46107491|NCT04050826|Drug|Lidocaine 2.5% and Prilocaine 2.5% cream, USP (Actavis Pharma incorporated, USA)|Topical application
46021951|NCT02877615|Drug|S 44819 150 mg twice a day|One sachet of S 44819 150 mg and one sachet of placebo twice a day
46107492|NCT04050826|Drug|Lidocaine 2.5% and Prilocaine 2.5% cream (E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., USA)|Topical application
45681344|NCT04025710|Device|BIOMONITOR III and BIOMONITOR IIIm|"Insertion of BIOMONITOR III or BIOMONITOR IIIm~three scheduled in-office follow-ups~48-hour Holter ECG"
45681345|NCT04020952|Other|"st.st 0.019×0.025 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
46107493|NCT04050826|Drug|Oraqix Parodontal-Gel (Dentsply Detrey GmbH, Germany)|Topical application
46021952|NCT02877615|Drug|S 44819 300 mg twice a day|Two sachets of S 44819 150 mg twice a day
46021953|NCT02877615|Drug|Placebo|Two sachets of placebo twice a day
46021954|NCT02437279|Procedure|Surgery of the tumor|
46021955|NCT02437279|Drug|Infusion with ipilimumab 3 mg/kg q3wks|
46021956|NCT02437279|Drug|Infusion with nivolumab 1 mg/kg q3wks|
46021957|NCT01251653|Drug|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
46021958|NCT01251653|Drug|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
46021959|NCT01251653|Drug|docetaxel|Maximum Tolerated Dose of Afatinib in combination with docetaxel
46107494|NCT04050826|Device|Dermal open flow microperfusion|"Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~16 dOFM probes will be implanted per participant (8 test-sites; 2 dOFM probes per test-site).~From each dOFM probe 13 samples will be taken (1 pre-dose, 12 post-dose)."
46107495|NCT04050826|Procedure|Blood sampling|1 sample will be taken pre-dose and 12 samples post-dose.
46021960|NCT01251653|Drug|gemcitabine|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
46021961|NCT00910663|Drug|Mycophenolate Mofetil|250 mg Capsule
46107496|NCT00757900|Biological|MUTAGRIP|Purified polyvalent vaccine for active immunisation against influenza.The vaccine is an inactivated split virus mixture of different group A and B viral strains. One 0.5 ml dose, intramuscular route.
46107497|NCT00757978|Drug|memantine|memantine 10mg twice a day
46107498|NCT00757978|Drug|placebo|1 capsule of placebo twice a day
46107499|NCT00754702|Drug|Vinorelbine|Vinorelbine p.o (50 mg 3 times a week) until disease progression or appearance of unacceptable toxicity
46107500|NCT00754702|Drug|Lapatinib|Lapatinib p.o every day without interruption disease progression or appearance of unacceptable toxicity
46107501|NCT00754780|Drug|Pirfenidone|Capsule 800 mg TID, oral
46107502|NCT00822900|Drug|Progesterone|Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone or placebo) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 71 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone/placebo will be combined with a 20% Intralipid mixture for infusion.
46107503|NCT00822900|Drug|Placebo|"Placebo stock solution is the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid is based on the mg/kg/hr volume. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid is administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours."
46107504|NCT00682786|Drug|5FU|
45838278|NCT04083235|Drug|Irinotecan Liposomal Injection|Irinotecan liposome injection is irinotecan in the form of the sucrosofate salt, encapsulated in liposomes for i.v. infusion. It is supplied in sterile, single-use vials containing 10 mL of irinotecan liposome injection at a concentration of 4.3 mg/mL free base equivalent (FBE).
46021962|NCT00910663|Drug|CellCept®|250 mg Capsule
46107505|NCT00682786|Radiation|Radiation|
46107506|NCT00682786|Procedure|Surgery of resectable lesions|
46107507|NCT00682786|Drug|Irinotecan|
46107508|NCT00840450|Drug|Gleevec/Paclitaxel|"One treatment cycle:~Gleevec: 300 mg twice a day orally for 4 consecutive days, then off for 3 days, every 7 days for 28 days.~Paclitaxel: 80 mg/m^2/week intravenously, 3 weeks on, one week off, every 28 days.~After 3 treatment cycles, decision made to continue or not with the combination based on tolerance and lack of progression."
46021963|NCT04306185|Procedure|OVARIAN FRAGMENTATION|BILATERAL OVARIAN CORTEX FRAGMENTATION USING LAPAROSCOPIC SCISSORS
46021964|NCT01077375|Drug|Placebo|"Placebo tablets, oral administration, twice daily for 10 weeks during randomized, double-blind treatment period. Duloxetine capsules, oral administration, 30 mg/day for 1 week after randomization to effect a duloxetine down-taper.~Placebo tablets, twice daily for 1 week during double-blind down-taper treatment period."
46021965|NCT01077375|Drug|Milnacipran|"Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses for 10 weeks during randomized, double-blind treatment period. Placebo capsules, 1 capsule/day administered for 1 week after randomization to maintain double-blind duloxetine down-taper.~Milnacipran tablets, 100 to 0 mg/day, oral administration, twice daily in divided doses for 1 week during double-blind down-taper treatment period."
46021966|NCT00624299|Drug|Botox|Botox injection (100 ius) per muscle
46021967|NCT00624299|Other|Saline|Saline injection
46021968|NCT02877849|Device|MRI: Brain Imaging data collection|This study has no intervention, it is observational. We will collect brain imaging data and behavioral assessments.
46021969|NCT02877771|Device|t:slim insulin pump with predictive low glucose suspend|To assess the functionality of a predictive low glucose suspend (PLGS) system that uses Continuous Glucose Monitoring (CGM) values to suspend basal insulin delivery when hypoglycemia is predicted as well as resume basal insulin delivery once Continuous Glucose Monitoring (CGM) values begin to increase.
46021970|NCT04306653|Drug|ACTH|patients with acute gout will receive 100 IU ACTH IM
46107509|NCT00754858|Drug|belotecan hydrochloride|
46107510|NCT00754858|Drug|cisplatin|
46107511|NCT05402748|Other|placenta-MSCs derived exosomes|Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of Placenta-MSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial.
46107512|NCT00755014|Other|red wine|One group (n=20) that consumed red wine (100 ml) daily for 3 weeks Another group (n=20) that consumed beer (250 ml) daily for 3 weeks
46107513|NCT00705588|Drug|Tadalafil|Orally, titrated to maximum 20mg od
46107514|NCT00705588|Drug|Vardenafil|Orally, titrated to 10 mg bid
46107515|NCT00755092|Behavioral|Doula|Doula support for nulliparous women from the beginning of regular contraction of uterus to the end of delivery
46107516|NCT00755092|Behavioral|Doula|Doula support for multiparous women from the beginning of regular contraction of uterus to the end of delivery
46021971|NCT04306653|Drug|Betamethasone|patients with acute gout will receive 6 mg of betamethasone
46021972|NCT04306731|Dietary Supplement|Nanotechnology Structured water Magnalife|Nanotechnology Structured water Magnalife is drinking water that has been modified using nanotechnology to change the structuring of water molecules
46107517|NCT00705744|Drug|Lactic acid (Dermacyd Femina)|
46021973|NCT04306731|Drug|Trimethoprim|Antibiotic
46107518|NCT00755170|Drug|Vinorelbine|Metronomic vinorelbine (p.o) 30 mg total dose/day, every Monday, Wednesday and Friday of each week, continuously without intervals for the equivalence of 6 cycles maximum
46107519|NCT00755170|Drug|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
46107520|NCT00705822|Drug|Docetaxel + Estramustine + Hydrocortisone|"Docetaxel iv 80 mg + Oral estramustine-pills 140 mg + Oral hydrocortisone-pills 20 mg.~Combination of these 3 drugs every 3 weeks"
45468595|NCT01145807|Drug|TDT067|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
46021974|NCT04306731|Dietary Supplement|Ordinary bottled drinking water|Placebo
46107521|NCT00705822|Drug|Docetaxel + Prednisone|Docetaxel iv 80 mg + oral prednisone-pills 5 mg. Combination of these 2 drugs every 3 weeks.
46021975|NCT02877537|Drug|Salbutamol|bronchodilation obtained with 2 inhalations of salbutamol (100 µg per dose) with inhalation chamber
46107522|NCT00755248|Procedure|Coronary Artery Bypass Grafting|Coronary Artery Bypass Grafting on- or off-pump
46107523|NCT00840294|Drug|Ciprofloxacin|
46107524|NCT02561026|Biological|Frozen plasma|patients randomized to receive frozen plasma transfusions
46107525|NCT04030884|Dietary Supplement|Honey and water mixture|"60 gr of organic Turkish BlackSea Region Chestnut Honey and 100 ml Spring water mixture both mixed in room temperature and ingested up to two hours before the surgery by participants who were nill by mouth from midnight prior to the operation day."
46107526|NCT00755404|Drug|PD Solution|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 180 days.
46107527|NCT00755404|Drug|PD solution containing L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 180 days.
46107528|NCT00703170|Drug|Temsirolimus|
46107529|NCT00703170|Drug|Pegylated liposomal doxorubicin|
45681346|NCT04020952|Other|"st.st 0.016×0.022 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
45681347|NCT04020952|Other|"st.st 0.017×0.025 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
46107530|NCT05370040|Biological|AAHI-SC2 Vaccine|AAHI -SC2 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike protein delivered by nanostructured lipid carrier (NLC) Vaccine
46021976|NCT02877537|Procedure|Forced oscillation technique|before and after bronchodilation
45681348|NCT03961750|Other|OTAGO|12 Week exercise class programme
46021977|NCT02877537|Procedure|Plethysmography|
46021978|NCT02877693|Radiation|Thoracic MRI Scan|is to demonstrate the MRI scan will not adversely affect the functionality of the ICD system. To do so, the ICD system will be exposed to MRI scan of thoracic region, where the radiofrequency (RF) component of the scan is maximized.
46021979|NCT01250873|Drug|LY2216684|po administration
46107531|NCT05370040|Biological|AAHI-SC3 Vaccine|AAHI-SC3 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike and nucleocapsid protein delivered by nanostructured lipid carrier (NLC) Vaccine
46107532|NCT05370040|Biological|EUA or approved vaccine|Janssen or Pfizer vaccines (control arm)
46021980|NCT01250873|Drug|Sertraline|po administration
46021981|NCT01250171|Biological|Secukinumab 10 mg/kg|Secukinumab was prepared in a sterile water solution.
46107533|NCT02612142|Behavioral|physical exercise|endurance-training or stretching (sham exercise)
46107534|NCT05354674|Drug|Bevacizumab|"AEM A：The specialist's decision to add bevacizumab to chemotherapy will be based on their own judgment~ARM B：The patient's PET/CT imaging, pathology, and clinical information were input into the signature, and the FOLFOX+Bevacizumab regimen was selected when the output label was 1. FOLFOXIRI chemotherapy regimen was selected when the output label was 0"
46107535|NCT00758056|Genetic|polymorphism analysis|
46107536|NCT00758056|Other|laboratory biomarker analysis|
46107537|NCT00758056|Other|questionnaire administration|
46107538|NCT00758134|Drug|Trastuzumab (Herceptin)|Trastuzumab 6 mg/Kg every 3 weeks i.v. (loading dose 8 mg/Kg i.v.)
46107539|NCT02560636|Drug|Pembrolizumab|Pembrolizumab - Trial Treatment
46107540|NCT02560636|Radiation|Radiotherapy|Radiotherapy
45681349|NCT04020718|Behavioral|Brief telephone advice plus tailored text messages|All patients are offered brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training and a text message program tailored to readiness to quit and quit date. Content is personalized with user's name and Massachusetts General Hospital resources.
45838279|NCT04083235|Drug|Oxaliplatin|Oxaliplatin injection, USP is supplied in single-dose vials containing 50 mg, 100 mg or 200 mg of oxaliplatin as a sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL.
45838280|NCT04083235|Drug|5Fluorouracil|Fluorouracil injection, USP is a colorless to faint yellow, aqueous, sterile, nonpyrogenic injectable solution available in 50 mL and 100 mL pharmacy bulk package. Each mL contains 50 mg fluorouracil in water for injection, USP.
46021982|NCT01250171|Biological|Canakinumab 10 mg/kg|Canakinumab was prepared in a sterile water solution.
45838281|NCT04083235|Drug|Leucovorin|Leucovorin Calcium for Injection is supplied in vials ranging from 50-500 mg and available as an injectable solution or lyophilized powder for reconstitution.
46107541|NCT00758212|Biological|Mesotherapy|The regular seasonal trivalent Influenza vaccine( Vaxigrip) will be diluted 1:10 in saline.The diluted vaccine will be given intra-dermally using Mesotherapy,namely multiple injections given at one time in the torso, back and axillae.
46107542|NCT00679042|Biological|Islets of Langerhans transplantation|"Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:~Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant"
46107543|NCT05167864|Drug|Onabotulinumtoxina for Injection|cosmetic injection into the glabella area (eyebrow area)
46107544|NCT05167864|Drug|Abobotulinumtoxina for Injection|cosmetic injection into the glabella area (eyebrow area)
46107545|NCT05167864|Drug|IncobotulinumtoxinA for Injection|cosmetic injection into the glabella area (eyebrow area)
46107546|NCT05167864|Drug|PrabotulinumtoxinA for Injection|cosmetic injection into the glabella area (eyebrow area)
46107547|NCT02560480|Device|magnetic resonance imaging|to diagonose groin injury exactly in magnetic resonance imaging
46107548|NCT00680056|Drug|Formoterol plus Placebo (Tiotropium)|Formoterol 12mcg-capsules (2x/d) + Placebo (Tiotropium) (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
46021983|NCT01250171|Biological|Placebo|The placebo solution for infusion contained 5% glucose.
46021984|NCT02888327|Drug|AL-794|
46021985|NCT02888327|Drug|Oseltamivir|
46107549|NCT00680056|Drug|Formoterol plus Tiotropium|Formoterol 12mcg-capsule (2x/dia) + Tiotropium 18mcg-capsule (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
46107550|NCT00758368|Drug|Apomorphine|Participants in both arms will receive the study drug apomorphine for 6 months. One group will receive it continuously using a portable pump during waking hours, and the other group will receive it intermittently by bolus injections. The continuous delivery group will receive up to 100 mg apomorphine per 24 hours, delivered subcutaneously by ambulatory pump. The intermittent delivery group will receive up to 5 subcutaneous injections totaling up to 20 mg daily.
45681350|NCT04020718|Drug|Mailed nicotine replacement therapy|Patients who report continued smoking at Early or Late assessment (depending on random assignment) will be offered a 4 week supply of patches and/or lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette).
45838282|NCT04083235|Drug|Nab-paclitaxel|Nab-paclitaxel is a lyophilised powder containing 100 or 250 mg of paclitaxel formulated as albumin-bound particles in single-use vials for re-constitution. Each mL of the reconstituted formulation will contain 5 mg/mL paclitaxel.
46021986|NCT02888327|Drug|Digoxin|
46021987|NCT02888327|Drug|Midazolam|
46107551|NCT00755482|Drug|Aquamin F|
46107552|NCT00755482|Drug|Placebo (maltodextran)|
46107553|NCT00755638|Biological|ACE-031|single subcutaneous dose of ACE-031
46107554|NCT04968886|Diagnostic Test|Diagnostic Test: viability test on sputum and comparision with culture results (reference test)|Diagnostic Test: viability test on sputum and comparision with culture results (reference test)
46021988|NCT02888327|Drug|Pitavastatin|
46021989|NCT02888327|Drug|JNJ-63623872|
46021990|NCT01077063|Procedure|paracentesis|surgical drainage of malignant ascites
46021991|NCT01077063|Device|Pleurx catheter|take home catheter drainage system that the subject uses himself/herself as needed.
46021992|NCT01248065|Drug|Vitamin D3|vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
46021993|NCT01248065|Drug|Ciclesonide|Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)
46021994|NCT01250756|Biological|7-pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
46021995|NCT01250756|Biological|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
46107555|NCT05435794|Device|CPAP|Fixed-pressure CPAP device for the treatment of sleep apnea with optional humidification and heated circuit. This device is a Class II device. It has a remote monitoring function allowing service providers to track the use of the device.
46021996|NCT01250756|Biological|DTaP|0.5 mL per dose, 4 doses
45838283|NCT04083235|Drug|Gemcitabine|Gemcitabine for injection is a lyophilised powder for solution for infusion, with each single use vial containing 200 mg, 1 g or 2 g of gemcitabine.
46021997|NCT01250054|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
45838284|NCT04068610|Drug|Standard of Care|"Parts of FOLFOX are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 2400 mg/m2 administered by continuous IV infusion over 46 to 48 hours Q2W (Day 1-2 of every 14-day cycle). Note: 5-FU will be administered as infusion only.~Bevacizumab 5 mg/kg IV infusion Q2W (Day 1 of every 14-day cycle)"
46107556|NCT05435794|Device|MAD|mandibular device orthosis made to measure from the dental impressions of patients, made by the specialist in the masticatory apparatus for the treatment of sleep apnea.
46107557|NCT05435638|Diagnostic Test|Serum chemistry|Approximately 5 mL whole blood will be collected after an ≥8 h fast for serum biochemistry assessments at the Screening visit, and on and on Days 7 and 84 of treatment and at the follow-up visit on Day 91. Serum chemistries will include assessment of total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), lactate dehydrogenase (LDH), alkaline phosphatase, glucose, sodium, potassium, blood urea nitrogen (BUN), and creatinine.
46107558|NCT05435638|Diagnostic Test|Hematology|Approximately 5 mL whole blood will be collected after an ≥8 h fast for complete blood count (CBC) at the Screening visit, and on Days 7 and 84 of treatment and at the follow-up visit on Day 91. The CBC assessment will include a red blood cells (RBC), hemoglobin, hematocrit, platelet count, mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean platelet volume (MCV), white blood cells (WBC), neutrophils (% and abs.), lymphocytes (% and abs.), monocytes (% and abs.), eosinophils (% and abs.), basophils (% and abs.), large unstained cells (% and abs.).
46107559|NCT05435638|Diagnostic Test|Urinalysis|"General urinalysis will be performed, by dipstick, at the Screening visit, and on and on Days 7 and 84 of treatment and at the follow-up visit on Day 91.~Approximately 7-10 mL urine will be collected. Urinalysis will include pH, specific gravity, blood, nitrites, glucose, ketones, protein, bilirubin urobilinogen and leukocytes. A microscopic examination of the urine will be performed only if clinically indicated."
46107560|NCT05435638|Diagnostic Test|Physical Examination|"A complete physical examination will be performed at Screening, at all in-clinic study visits, and at the End of Study visit.~The physical examination will cover a careful assessment of all body systems, including the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, GI, urogenital, musculoskeletal, neurological, dermatological, hematologic/lymphatic, and endocrine systems. Particular attention will be placed on the areas affected by the disease.~• Symptom-directed physical examinations will be performed at all other study visits."
46107561|NCT05435638|Diagnostic Test|Vital Signs|Vital sign measurements (body temperature, pulse and resting systolic and diastolic blood pressure) will be measured at Screening, at all in-clinic study visits, and at the End of Study visit. Vital signs will be measured in supine position after at least five minutes of rest.
46021998|NCT01250054|Device|Comfilcon A contact lens|Commercially marketed (Europe), silicone hydrogel, multifocal contact lens for daily wear use
46107562|NCT05435638|Diagnostic Test|ECG Test|A 12-lead, resting, digital ECG will be taken for each participant at Screening and on Days 42 and 84, after the patient has been supine for at least 5 min. At minimum, the following ECG parameters will be recorded: heart rate (HR), PR, QT and QRS intervals and QTC. The report will be signed by the Investigator, who will record in the CRF whether it is normal, abnormal but not clinically significant, or abnormal AND clinically significant. In the latter case the eligibility of the participants will be reviewed.
46107563|NCT05435638|Diagnostic Test|PK|"Blood PK analyses will be performed on ≥5ml blood collected in 5-mL K-EDTA CRO coded pre-labeled tubes, refrigerated immediately after collection. Plasma will be separated by centrifugation within 2h, and then frozen at -20C.~Blood samples will be collected on Days 1, 7 and Day 84 predose, and on Day 91, at any point during the study visit."
46021999|NCT00977470|Drug|Erlotinib|150 mg taken orally once daily
46022000|NCT00977470|Drug|Hydroxychloroquine|1000 mg taken orally once daily after erlotinib
46022001|NCT04319666|Device|Left main stenting with intravascular lithotripsy|Intravascular lithotripsy (IVL) will be used to modify coronary artery calcification prior to stent implantation in left main coronary disease. Intravascular ultrasound (IVUS) will be used pre and post IVL and post stenting.
46022002|NCT04289896|Other|Plyometric exercise|"The plyometric program to be followed by the subjects assigned to the experimental group during the four weeks includes: Squat jumps, alternate lunge, cyclic horizontal jump, horizontal left leg jump, horizontal right leg jump, vertical left leg jump, right leg vertical jump, squat box jumps, box jumps left leg, box jumps right leg, box to box squat jumps, box to box left leg, box to box right leg.~In all the exercises the subjects will be able to help themselves with the arms and a rest period of 120 seconds will be left between each series.~The intervention will be carried out prior to training, keeping a minimum of 48 hours of rest between sessions."
46107564|NCT05435638|Diagnostic Test|IGA scoring|"Lesions severity will be assessed using the Investigator's Global Assessment (IGA) scale,which is a 5-point scale (from 0 =no disease to 4=severe disease) based on Simpson et al. 2020, IGA for atopic dermatitis (see Table 4; Simpson et al. 2020).~The IGA score is selected using the descriptors below that best describe the overall appearance of the lesions at a given timepoint. It is not necessary that all characteristics under morphological description are present. Excoriations should not be considered when assessing disease severity."
46022003|NCT01245374|Device|Norditropin NordiFlex®|Daily administration by a subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice
46022004|NCT02865304|Drug|endostar|
46022005|NCT04289272|Behavioral|Dove Confident Me|Dove Confident Me is a school-based intervention co-created by researchers at La Trobe University (Australia), the Centre for Appearance Research UWE, teachers, students, and education experts, and the Dove Self-Esteem Project (the social mission for personal care brand Dove). The five-session intervention is aimed at adolescents aged between 11-13 years, and targets recognised risk factors for body dissatisfaction, by addressing societal appearance ideals (Session 1), media literacy (Session 2), appearance comparisons (Session 3), appearance-related conversations and teasing (Session 4), and promoting 'body activism' (Session 5). The intervention consists of classroom-based discussion and small group activities, and uses audio-visual materials and worksheets to facilitate learning.
45681351|NCT04020718|Behavioral|Proactive telephone coaching|Patients who report continued smoking at Early (4-week) or Late (8-week) assessment of response will be randomized to receive proactive telephone coaching or not. Proactive coaching will consist of an attempt to reach the patient by telephone in order to review quit activities, provide information about locally available pharmacologic and behavioral treatment options and information sharing with patient's primary care provider. The coach is trained in core Tobacco Treatment Specialist activities.
45681352|NCT04027348|Drug|Dexamethasone|Given IV
46022006|NCT04075474|Device|silver diamine fluoride|38% SDF on primary upper anterior teeth
46022007|NCT04075474|Device|sodium fluoride|5% NaF on primary upper anterior teeth
46107565|NCT05435560|Drug|Dexmedetomidine|During the imaging scan subjects will receive an initial bolus of dexmedetomidine over 10 minutes. After the bolus has been administered, a constant infusion of dexmedetomidine will be maintained for the remainder of the scan (about 60 minutes).
46107566|NCT05435560|Drug|Saline|During the imaging scan subjects will receive an initial bolus of saline over 10 minutes. After the bolus has been administered, a constant infusion of saline will be maintained for the remainder of the scan (about 60 minutes).
46107567|NCT00680992|Drug|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
46107568|NCT02559154|Drug|Bortezomib|
46107569|NCT02559154|Drug|Dexamethasone|
46107570|NCT02559154|Drug|Doxorubicin|
46107571|NCT02559154|Drug|Cyclophosphamide|
45681353|NCT04027348|Drug|Metoclopramide|Given IV
46107572|NCT02559154|Drug|Mitoxsnteone|
46107573|NCT02559154|Drug|Thalidomide|
46107574|NCT03798964|Other|Placental analysis|Analysis of placenta to determine expression of heparanase
45598524|NCT02223611|Drug|S1 capsule|Within four weeks after the completely resection, S-1 was administered orally twice a day, after meals on days 1 to 14. The actual dose of S-1 was selected as follows: in a patient with body surface area (BSA)<1.25 m2 40mg twice a day, 1.25 m2≤BSA<1.5 m2 50mg twice a day, and 1.5 m2≤BSA 60mg twice a day. Cisplatin (75 mg/m2) was administered intravenously on day 1 The treatment regimen was repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
45598525|NCT02223611|Drug|Vinorelbine|Vinorelbine (25 mg/m2) is administered intravenously on day 1, and day 8. Cisplatin (75 mg/m2) is administered intravenously on day 1. The treatment regimen is repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
46107575|NCT05435248|Drug|HS-10375|HS-10375 will be administered orally once daily in a continuous regimen
46107576|NCT05435092|Radiation|3D-reconstruction CT|Three dimensional CT (3D CT):Method of surface rendition of anatomy by means of a special computer software to capture 3D bone models used to improve the outcomes of Total Knee Arthroplasty (TKA).
46107577|NCT02559076|Behavioral|Ten Steps leaflet advice for healthy lifestyle|Ten steps leaflet advice for healthy lifestyle
46107578|NCT00805389|Biological|Engerix-B™|2 doses intramuscular injections
46107579|NCT00805389|Biological|Fendrix™|2 doses intramuscular injections
46107580|NCT00805389|Biological|GSK Biologicals' Hepatitis B vaccines (GSK223192A)|2 doses intramuscular injections 3 different formulations of (GSK223192A), each administered to 1 group
46107581|NCT00805389|Biological|HBsAg (Booster injection)|Single dose intramuscular injection
46107582|NCT00678886|Biological|otelixizumab infusion plus physician determined standard of care|infusion
46107583|NCT00678886|Biological|placebo infusion plus physician determined standard of care|infusion
46107584|NCT04016103|Device|MY01 - Continuous Compartmental Pressure Monitor|Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure
46107585|NCT05747469|Drug|local anaesthetic injection|Subcutaneous local anesthesia with 1% lidocaine without epinephrine is administered to the skin overlying the joint.
46107586|NCT05747469|Procedure|Human Adipose Allograft|Light axial traction of the digit is used to open the joint space when introducing the 18-gauge needle. Fluoroscopy is used to assist with visualization 1 cc of Leneva is injected into the CMC joint and 0.5 cc in the IP, PIP and DIP joints. The puncture is dressed with a band-aid and coban wrap, which will be worn for 48 hours. Return to work and normal use of the hand is recommended at 48 hours. No narcotics are prescribed.
46107587|NCT05747235|Radiation|CT chest|All patients will undergo MSCT chest at both inspiratory and expiratory phases in supine position without any contrast media.
46107588|NCT03704103|Other|iSage|The provider will choose a treatment algorithm within the iSage app and set the parameters to make insulin dose adjustments no less frequently than every 7 days. The patient is instructed to perform daily fasting glucose measurements and follow the app's recommendations for insulin adjustment.
46022008|NCT00977314|Device|The Sonitus Bone Conduction Hearing System|Comparison of HINT scores (Speech front with noise at better ear) at 30 days tested with the device in place verses with the device removed.
46107589|NCT00914199|Procedure|Percutaneous coronary intervention (PCI)|Implantation of coronary stent in bifurcation lesion.
46107590|NCT03689049|Procedure|SPIDER|The SPIDER intervention will include a family physician-led inter-professional practice team participating in 3-4 Learning Collaboratives over a period of 12 months, reviewing validated and comparable practice EMR data and working with a QI Coach to develop strategies and implement changes to improve care for elderly patients living with complex care needs and taking ten or more unique medications.
46107591|NCT03689049|Procedure|Usual Care|Physicians and their teams enrolled in this arm will follow the best scientific evidence available to provide standard care that is in the best interest of their patients.
46107592|NCT02607969|Other|Home program|Parents will be educated about the home program which consisted of positioning the neck and head, sleep in alternating head positions and in side-laying to increase head shape symmetry and place infants, when awake and under supervision, regularly in the prone position a day to stimulate normal motor development (tummy time), decreasing the time spent in car seat at supine position. Environmental settings also were given to challenge the baby look through from the side no flattening to room, place colorful and sonorous toys or mirror on the opposite of the flattening side, and stimulate active rotation by communicating with baby from this side. Handling strategies, stretching and strengthening exercises will given for CMT
46107593|NCT03672279|Diagnostic Test|CogCheck|Novel self-administered cognitive assessment tool
46107594|NCT00804843|Drug|Atorvastatin/niacin extended-release|80 mg tablet atorvastatin once daily, 10 mg tablet placebo to atorvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
45468596|NCT01145807|Drug|Placebo|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
46107595|NCT00804843|Drug|Atorvastatin|10 mg tablet atorvastatin once daily, 80 mg tablet placebo to atorvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
46107596|NCT00804843|Drug|Simvastatin|(Russia and Brazil) 80 mg tablet simvastatin once daily, 10 mg tablet placebo to simvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
46107597|NCT00804843|Drug|Simvastatin|(Russia and Brazil) 10 mg tablet simvastatin once daily, 80 mg tablet placebo to simvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
45681354|NCT04027348|Drug|Octreotide|Given IV
45681355|NCT04195204|Drug|Tropisetron|Investigators administrated intravenously Tropisetron 5mg before anesthesia and once daily for 7 days after surgery.
45598526|NCT03520777|Other|Art Intervention|Type of artist intervention will be determined by the subject and the assigned artist.
45598527|NCT03147027|Procedure|VT ablation|Substrate mapping for VT will be performed with the CARTO electroanatomical system.
45598528|NCT03147027|Other|medication|medication to prevent sustained VT and ICD therapies
45681356|NCT04195204|Drug|Placebos|Investigators administrated intravenously saline solution as a placebo
45681357|NCT04406350|Procedure|Intraoperative tight control of respiratory end-tidal gases|Control of ET CO2 and ET O2 during conduct of anesthesia.
46022009|NCT00977314|Device|SoundBite|
46022010|NCT00977314|Device|SoundBite Hearing System|
46022011|NCT03969082|Behavioral|Bibliotherapy|Students will read to patients during 30 minutes. They will read aloud and pause regularly to encourage patients to reflect on what is being read, on the thoughts the poem or book has stirred or on how the reading matter relates to their own lives.
45468597|NCT01145807|Drug|Transfersome|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
45468598|NCT03898895|Combination Product|Radiotherapy+anti-PD-1 antibody|The total radiation dose is over 45Gy without damaging organic fucntion. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed. Camrelizumab 200mg intravenously every 3 weeks will be initiated within 7 days after radiotherapy. Patients will receive camrelizumab until clinical or radiographic disease progression, unacceptable toxicity, death or withdrawal. If disease progression is confirmed by radiologic examinations, another 200mg camrelizumab should be applied to the patient, then another radiologic examination will be performed 4 weeks later to confirm or exclude progression. If progression is confirmed, the camrelizumab should be stopped.
46022012|NCT02866396|Drug|Pregabalin|Pregabalin continued at the same preoperative dose 1h before surgery associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
45468599|NCT01245569|Drug|Foster® 100/6 µg/unit dose|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
45598529|NCT03517345|Dietary Supplement|Prebiotic|Prebiotic (Inulin+Oligofructose) consumed as 10 g/d in yogurt (200 g/d)
46022013|NCT02866396|Other|Naive patient|Pregabalin 150mg PO initiated 1h before surgery Associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
46022014|NCT01087203|Biological|Tanezumab|20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
46022015|NCT01087203|Biological|placebo|Placebo to match tanezumab 20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
46022016|NCT04289350|Diagnostic Test|fetal heart rate variability|An observational study. No intervention
46022017|NCT02865226|Other|paravertebral block by the anesthetist before incision (paravertebral block guided by ultrasound)|
46022018|NCT02865226|Other|paravertebral block by the thoracic surgeon at chest closure (paravertebral block visual).|
46022019|NCT01246583|Drug|CP-690,550 Ointment 1|2% CP-690,550 Ointment 1 twice daily for 4 weeks
46022020|NCT01246583|Drug|Vehicle 1|Vehicle 1 twice daily for 4 weeks
46022021|NCT01246583|Drug|CP-690,550 Ointment 2|2% CP-690,550 Ointment 2 twice daily for 4 weeks
46022022|NCT01246583|Drug|Vehicle 2|Vehicle 2 twice daily for 4 weeks
46022023|NCT01084239|Radiation|Cardiac Computed Tomography|A contrast enhanced cardiac CT was performed in addition to standard evaluation. Reconstructed data sets were evaluated for the presence of coronary artery calcium, coronary atherosclerotic plaque and stenosis, LV function and incidental findings.
46022024|NCT01244906|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
46022025|NCT00626613|Drug|Risperdal,reminyl|Risperdal:The dosage of treatment medication will begin with 0.5 ml/ per day (0.5mg), The maximum dose will be 2ml/ per day reminyl:8 mg/ per day
46022026|NCT01080807|Drug|Armodafinil|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
46022027|NCT01080807|Drug|Matching Placebo|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
46022028|NCT01079949|Drug|r-hLH + r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from stimulation Day 1(S1) at a starting dose of 300-450 International Unit (IU) and then dose adjusted depending on the ovarian response till recombinant human choriogonadotropin (r-hCG) administration day. Recombinant human luteinizing hormone (r-hLH, Luveris®, Lutropin alfa) injection will be administered subcutaneously once daily at a constant dose of 150 IU with flexible start, depending on the follicular growth (when the lead follicle is greater than 14 mm in size), along with r-hFSH treatment as a separate injection till r-hCG administration day.
46022029|NCT01079949|Drug|r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from S1 at a starting dose of 300-450 IU and then dose adjusted depending on the ovarian response till r-hCG administration day.
46107598|NCT00822120|Biological|bleomycin sulfate|
46107599|NCT00822120|Biological|filgrastim|
46107600|NCT00822120|Drug|ABVD regimen|
46107601|NCT00822120|Drug|BEACOPP regimen|
45468600|NCT01245569|Drug|Seretide Accuhaler® 500/50 µg/actuation|Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
45468601|NCT03787745|Procedure|Ischemic postconditioning|After 60 seconds of reperfusion, ischemic postconditioning with an adequately sized balloon (60 reperfusion/60 seconds re-occlusion, four cycles) will be performed
46107602|NCT00822120|Drug|cyclophosphamide|
46107603|NCT00822120|Drug|dacarbazine|
46107604|NCT00822120|Drug|doxorubicin hydrochloride|
46107605|NCT00822120|Drug|etoposide|
46107606|NCT00822120|Drug|prednisone|
46107607|NCT00822120|Drug|procarbazine hydrochloride|
46107608|NCT00822120|Drug|vinblastine sulfate|
46107609|NCT00822120|Drug|vincristine sulfate|
46107610|NCT00804687|Other|Placebo|Single-dose of 1 milliliter (ml) placebo solution will be administered orally and/or placebo tablet orally in one of the treatment periods.
46107611|NCT00804687|Drug|JNJ-39220675|Single-dose of JNJ-39220675 will be administered as 1 ml of 10 milligram/milliliter solution orally in one of the treatment periods.
45681358|NCT04023136|Procedure|partial hepatectomy by laparotomy on healthy or pathologic parenchyma.|Preoperative flow and MRI + intraoperative measures of flow and pressures
46022030|NCT01079949|Drug|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.
46022031|NCT01079949|Drug|GnRH antagonist|The GnRH antagonist will be administered at a starting at a dose of 0.25 milligram (mg) subcutaneously daily in the morning when the ultrasound discovers a follicle of greater than or equal to (>=) 14 mm, and maintained until at least one follicle of >=18 mm and two additional follicles of >=16 mm with appropriate plasma estradiol levels for the number and size of the existing follicles.
46022032|NCT04306263|Dietary Supplement|Enriched infant formula|Infant formula enriched with dairy ingredients: osteopontin, prebiotics and probiotics
46107612|NCT00804687|Drug|Pseudoephedrine|Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods.
46107613|NCT05742633|Other|Active release technique|"Active Release Technique will be applied with patient in prone lying, knee flexed at 90. The therapist will place his elbow tip on taut band of piriformis and direct pressure will be applied, patient will then be asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This will be repeated 5-7 times.~A total of 18 sessions will be given over a period of 6 weeks (3 sessions per week)"
46107614|NCT05742633|Other|Self-myofascial release|"Patient position in prone lying Therapist will be standing beside the patient at the waistline, working on the contralateral side.~Piriformis muscle will be located by an imaginary line drawn between the midpoint of the lateral aspect of the sacrum and the greater trochanter. A contact will be established in the gluteal area about 3 cm from the sacrum. Patent will be guided to use a foam roller followed by a massage ball.~A total of 18 sessions will be given over a period of 6 weeks (3 sessions per week)"
46107615|NCT00678652|Biological|10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|10 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
46107616|NCT00678652|Biological|25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|25 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
46107617|NCT00678652|Biological|50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|50 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
46107618|NCT00678652|Biological|75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|75 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
46107619|NCT05740605|Behavioral|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|"HABIT-ILE (Hand-Arm Bimanual Intensive Therapy including Lower Extremities) is an intensive therapy that continuously incorporates postural control and LE function. This motor learning-based approach include specificity of the practice, motivation, shaping of the task, intensive blocks of training and Hands-Off. Moreover, the therapy is goal-oriented to increase functional independence during daily living. This therapy has shown impressive improvements in children with PC."
46107620|NCT05740605|Behavioral|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities at home|The HABIT-ILE therapy at home will follow the same principles as the classic HABIT-ILE. The therapy will take place in the patient's home and a close person (caregiver) will accompany the patient during the therapy. A device will be used to facilitate the implementation of home therapy. Supervision of the therapeutic process will be done remotely by a team of trained supervisors. One hour of remote supervision per day will be scheduled within 6.5 hours of therapy.
46107621|NCT05740605|Behavioral|Follow-up Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|HABIT-ILE follow-up at home follow the same principles as classic HABIT-ILE but is delivered at the patient home with 4 hours per week in autonomy and 1 hour per week under supervision.
46107622|NCT05740605|Behavioral|Usual Care|Usual care is all the weekly physiotherapy and occupational therapy sessions that the patient usually receives.
46107623|NCT02607657|Drug|Eplerenone 25 mg|
46107624|NCT02607657|Drug|Eplerenone 50 mg|
46107625|NCT02607657|Drug|Eplerenone 100 mg|
46107626|NCT02607657|Drug|Eplerenone 50 mg twice a day|
45468602|NCT03787745|Procedure|Conventional|State of the art primary PCI, however thrombectomy is not allowed
45468603|NCT01314859|Drug|Nifedipine|"Oral Treatment with Nifedipine capsules (10mg)~Initial dose: 20 mg of nifedipine (2 capsules of 10 mg).~Maintenance Dose: 20 mg of nifedipine (2 capsules of 10 mg) every 6 hours.~Maximum Duration of the treatment: 48 hours."
45598530|NCT03517345|Dietary Supplement|Control|The only yogurt consumed as 200 g/d without prebiotic.
46107627|NCT02607657|Drug|Eplerenone 25 mg twice a day|
46107628|NCT03658642|Behavioral|Clinical Decision Support (CDS)|This clinical decision support tool will improve the clinician's ability to identify those with OUD, initiate BUP and refer the patient to ongoing Medication Assisted Treatment (MAT)
46022033|NCT04306263|Dietary Supplement|Standard formula|Infants receiving a standard infant formula.
46022034|NCT04306263|Dietary Supplement|Breastfeeding arm|Infants exclusively or predominantly breastfed (>75%).
46107629|NCT04015947|Device|CelluTome® Epidermal Harvesting System|split-thickness skin grafts from a matched bone marrow donor using the CelluTome® Epidermal Harvesting System
46107630|NCT04921228|Behavioral|Heart rate variability biofeedback|"5 days of 3-min HRV readings to establish baseline HRV~After meeting with study personnel to review HRV biofeedback (BF) practice with the app, participants will be asked to begin HRV BF training for 5 min a day~Participants will increase the length of HRV BF training by 5 min every few days until they reach 20 min a day of HRV BF training~Participants will aim for 20 min of daily HRV BF training for 6 consecutive wks out of the 8-wk total BF training protocol~Study personnel will follow the participants' progress with training via the online portal provided through the Optimal HRV app and have brief (15-min) check-in appts. with participants to discuss how they are experiencing HRV BF, what they find helpful, and barriers to their practice if they are having difficulties~After completing the 8-wks of BF training (including 2 wks of 5-min titrations to the full 20-min protocol), participants will be asked to take 3-min HRV readings for 5 days to assess post-intervention HRV"
46107631|NCT00840060|Behavioral|AMALS|Addressing multiple aspects of language simultaneously
46107632|NCT00840060|Behavioral|DTA|Discrete Trial Approach
46107633|NCT00574912|Drug|Placebo|single dose of Placebo injected s/c at 8am and monitor blood glucose over 24 hours
46107634|NCT00574912|Drug|Insulin Glargine 0.5 u/kg body wt SC|8 weeks later, a differing dose (0.5, 1.0, 1.5, 2.0 u/kg body wt.) of Insulin Glargine and monitoring over a 24 hour period each separated by 8 weeks (5 separate study visits)
46107635|NCT00574912|Drug|Insulin Glargine 1.0 u/kg body wt SC|
46107636|NCT00574912|Drug|Insulin Glargine 1.5 u/kg body wt SC|
46107637|NCT00574912|Drug|Insulin Glargine 2.0 u/kg body wt SC|
46107638|NCT00922896|Drug|Gemcitabine, Cisplatin, Erlotinib (Tarceva)|"Erlotinib 100 mg po q d daily AND~Gemcitabine 1000 mg/m² with 250 mL of normal saline intravenously infusion over 30 mins on Day 1, 8~Cisplatin 25 mg/m2 with 150 mL of normal saline intravenously infusion over 60 mins on D1,8~Every 3 weeks"
46107639|NCT00674128|Device|Cyanoacrylate tissue adhesive (Dermabond)|Skin closure will be performed with cyanoacrylate tissue adhesive.
46107640|NCT00674128|Device|Polyglactin 910 suture (Vicryl)|Skin closure will be performed with polyglactin 910 suture.
46107641|NCT04900636|Device|Telemedicine Arm|Patients with DM1 ≥ 18 years of age, users of closed loop hybrid systems, assigned to a follow-up program using a telemedicine platform combined with face-to-face visits according to protocol.
46107642|NCT00760942|Dietary Supplement|Similac special care 30|Liquid pre-term formula 30Kcals/oz. used as human milk fortifier.
46107643|NCT00760942|Dietary Supplement|Similac human milk fortifier|Powdered human milk fortifier.
45468604|NCT01314859|Drug|Atosiban|"Intravenously Treatment with Atosiban (7.5mg/ml)~Initial Dose: IV bolus injection during 1 minute + Intravenous infusion 7.5 mg/ml during 3 hours.~Maintenance: Maintenance intravenous infusion 7.5 mg/ml at least 18 hours to a maximum of 45 hours.~Maximum Duration of the treatment: 48 hours."
46107644|NCT00761020|Drug|Mefloquine|To determine the seroconversion rate (sensitivity) to Plasmodium falciparum Merozoite Surface Protein 1 (Pf MSP-1) antigen by ELISA assay in the infectivity control and mefloquine cohorts as part of a larger project to support the qualification of anti-MSP-1 antigen-specific antibody assays as valid surrogate endpoints for malaria infection.
46107645|NCT00761020|Other|Control|No Intervention
46107646|NCT00804141|Drug|N-methylnaltrexone bromide (MOA-728)|MOA-728 will be administered as per the dose and schedule specified in the arm.
46107647|NCT04049032|Behavioral|In-Person Perinatal OUD Treatment|Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care.
46107648|NCT04049032|Behavioral|Perinatal OUD Treatment via Telemedicine|Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care..
45468605|NCT03765125|Dietary Supplement|collagen peptide test|Collagen peptides from bovine skin with an average molecular weight of approx. 2,000 g/mol. Average particle size is about 150 μm.
45468606|NCT03765125|Dietary Supplement|collagen peptide placebo|collagen peptide placebo
45468607|NCT03779425|Other|Virtual Reality Physical Therapy|Participants will undergo a non-weight bearing knee range of motion virtual reality physical therapy session.
45598531|NCT02355561|Drug|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg formulation 1 of JNJ-54861911 tablet as Treatment A under fasted conditions in one of the treatment periods.
45681359|NCT04023214|Diagnostic Test|Peripheral (digital) arterial tonometry|This will be measured using the EndoPAT system (Itamar Medical)
46022035|NCT00910429|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study
46022036|NCT03432949|Drug|Dexamethasone plus Radium-223|Dexamethasone will be administered as 0.5 mg capsules by mouth per day during the duration of the Radium-223 treatment.
46022037|NCT00909727|Drug|Ivacaftor|150-mg tablet given orally q12h for up to 48 weeks
46022038|NCT00909727|Drug|Placebo|Tablet given orally q12h for up to 48 weeks
46107649|NCT00761098|Drug|Standard Care|Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
46107650|NCT00761098|Drug|Experimental|25% Salt Poor Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
46107651|NCT03556137|Drug|[18F]FTC-146|Adult participants will be injected with 5-10 mCi of [18F]FTC-146 and undergo a PET/MRI scan.
46107652|NCT00677092|Drug|Imatinib mesylate|400 mg p.o. daily for 4 months. Dosage was reduced to 200 mg if participants develop gastrointestinal intolerance or alopecia.
46107653|NCT02607579|Drug|Exparel|
46107654|NCT02607579|Drug|Ropivacaine|
46107655|NCT03539367|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
46107656|NCT03539367|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
46107657|NCT00677014|Device|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
46107658|NCT00677014|Device|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
46107659|NCT00677014|Device|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
46107660|NCT03591640|Diagnostic Test|Blood test|Standard blood test
46022039|NCT00977080|Drug|Paricalcitol|Paricalcitol dosed per label by region (participants were to receive cinacalcet if they developed hypercalcemia)
46107661|NCT05730309|Behavioral|Customized discharge and expedited referral instructions|The intervention for subjects with LVH on research POCUS will consist of three elements: 1) disclosure of presence of LVH to subject, ED team and primary care physician (PCP) (if applicable); 2) educational discharge instructions describing high BP, HTN, LVH, implications for development of cardiovascular disease (such as development of heart failure, stroke), options for treatment (lifestyle, medications) and importance of follow-up; A preliminary version will be refined prior to the start of the trial by feedback from ED physicians and patients. Refinement will target content, phrasing, and literacy level. 3) referral to outpatient care, consisting of one of two options, based on whether the subject has an established PCP. For subjects with existing PCP, the study team will call the office, inform about study participation, LVH findings, and secure a follow-up appointment. For those with no PCP, study team will arrange for follow-up to special clinic.
45468608|NCT02528279|Drug|Coartem|"Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight > 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food."
46107662|NCT02607267|Other|LSG and LRYGB|The role of the Edmonton Obesity Staging System in predicting post-operative outcome and 30-day mortality after metabolic surgery (LSG and LRYGB)
46022040|NCT00977080|Drug|Cinacalcet|On-label oral cinacalcet by region with low dose vitamin D receptor activator (VDRA) (either doxercalciferol at US sites or alfacalcidol at non-US sites)
46107663|NCT04048954|Device|Applitabac|Smartphone application in screening on tabagism complications
46107664|NCT04847986|Behavioral|acceptance and commitment therapy (ACT)|Caregivers assigned to this intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 8 weeks through Zoom videoconferencing with psychoeducation materials provided.
46107665|NCT04847986|Behavioral|Control group|The control group will receive care as usual with psychoeducation materials provided.
46107666|NCT03416361|Dietary Supplement|4000IU Vitamin D3|Chewable blackcurrant flavoured tablets (two per day)
45468609|NCT01315015|Other|Contrast enhanced breast MRI|Gadolinium contrast is administered as a bolus with a standard dose of 0.1 mL/kg followed by a saline flush of 30 mL.
46107667|NCT04049968|Device|Mobile health application (APP)|The mobile health application (APP) was applied to patients with oral cancer.
46107668|NCT04049968|Other|Routine health care and instruction|Traditional routine health care and instruction was applied to patients with oral cancer.
45468610|NCT01238627|Drug|Nicotine Sublingual Tablet Mint (NSTM)|A single dose of an experimental NSTM, with a 36-hour washout between visits
45468611|NCT01238627|Drug|Marketed Nicotine Tablet|A single dose of a marketed Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
45598532|NCT02355561|Drug|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment B under fasted conditions in one of the treatment periods.
45598533|NCT02355561|Drug|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment C under fed conditions in one of the treatment periods.
46022041|NCT04098055|Device|Custom-Made Foot Orthoses|The foot orthoses were custom made using phenolic foam molds of the feet. They consisted of a polypropylene layer of 2 mm from heel to just proximal to the metatarsal heads, an upper sheet of 30 Shore A polyethylene foam.
46022042|NCT04098055|Device|Placebo|The insole made using phenolic foam molds of the feet. They consisted of an upper sheet of 30 Shore A polyethylene foam.
46022043|NCT05581381|Behavioral|empathy training program|Empathy training, a total of 8 weeks of training (1 time a week, 1 hour each time)
46022044|NCT03873649|Other|Bronchoscopy with lavage|"Bronchoscopy will be performed according to standard clinical procedures. Bronchoscopy will be performed under conscious sedation with continuous cardiopulmonary monitoring and the subject's upper airway will be anesthetized with topical lidocaine. The bronchoscope will be passed through the naris or mouth to the upper airway and then into the lower airway. 360cc of sterile saline will be instilled into 2 sub-segments by instilling and aspirating 3 aliquots of 60cc sequentially into each sub-segment.~Venipuncture to obtain peripheral blood mononuclear cells (PBMCs) for the proposed assays.~Cells collected will be analyzed for various T-cell subsets and gene expression to help determine the type of immune response."
46022045|NCT00975676|Other|gas chromatography / tandem mass spectometry|Determination of estrogen levels through gas chromatography.
45681360|NCT04023292|Drug|Endocrine therapy|Use before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
46022046|NCT03770221|Behavioral|CATCH|Brief, intensive case management service.
46022047|NCT03770221|Other|Financial Incentive|Financial incentive for maintaining contact with CATCH service providers.
46107669|NCT05723211|Behavioral|Vinyasa yoga group|Participants will be instructed to perform a pre-recorded 60-minute vinyasa yoga session 3 times a week for 4 weeks.
46022048|NCT03766087|Procedure|decompressive craniectomy|decompressive craniectomy is decompression at the supratentorial level that is achieved by removing part of the skull and by making an opening, in the dura mater (with or without plastic surgery), without compromising the venous sinus.
46107670|NCT05723211|Other|Non-active control group|Participants will be instructed to sit quietly for 60 minutes and watch a nature documentary during this time. The participants will be asked to maintain their current lifestyle habits and refrain from starting a new exercise and/or yoga program.
46107671|NCT00761254|Drug|Domperidone|Initially, 10mg of oral Domperidone will be administered 2-4 times a day as needed. This dosage may be increased or decreased depending on how the subject responds to the drug.
46022049|NCT02866240|Device|Cathodal Transcranial Direct Current Stimulation (tDCS).|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
46107672|NCT00761332|Drug|teriparatide|treatment will be prescribed according to usual standard of care
46107673|NCT00761332|Drug|antiresorptives|treatment will be prescribed according to usual standard of care
46022050|NCT02866318|Device|Echocardiography|
46022051|NCT00629356|Genetic|dengue fever|
46022052|NCT02865148|Behavioral|Cognitive behavioral therapy|CBT-based protocol tailored to advanced breast cancer patients with a focus on managing a broad array of symptoms including psychological distress, pain, and fatigue. Important features of the protocol are: 1) a unique motivational interviewing component in the first session that will focus on patients' motivation for engaging in the protocol, confidence (i.e., self-efficacy) to learn new strategies, and potential barriers to adopting recommendations for lifestyle change; and 2) protocol that targets multiple symptoms, and 3) adapted to meet the unique needs of advanced breast cancer patients.
46107674|NCT03356925|Diagnostic Test|Xpert Ultra Point of Care testing|The intervention is the point of care Xpert Ultra TB diagnostic compared to the standard of care centralised TB testing at a centralised facility
46107675|NCT04741438|Drug|Nivolumab and IPILIMUMAB|"The combination of Nivolumab+Ipilimumab will be given to patients as follows:~Nivolumab: 3 mg/kg IV over 30 minutes every 2 weeks for 4 cycles.~Ipilimumab 1 mg/kg IV over 60 minutes every 6 weeks for 4 cycles. After completion of 4 courses with ipilimumab, patients continue receiving nivolumab IV at the dose of 480 mg Q4W in the absence of disease progression or unacceptable toxicity for a maximum of 18 months.~Nota Bene: A cycle is defined as a 6-weeks period.~The planned treatment period is 24 months~Nivolumab and Ipilimumab must be injected the same day every 6 weeks (Q6W). In case of toxicity, dose will be delayed, but will not be reduced."
46107676|NCT04741438|Drug|Pazopanib Oral Tablet [Votrient]|"Treatment by pazopanib 800 mg/day per os, continuously during a maximum 24 months.~In case of toxicity, dose will be delayed and reduced."
46107677|NCT03321201|Procedure|Cauterization|To ensure the stability of the graft during cuttings, four sealing wraps will be installed, which will be removed after cauterisation is completed. Autograft and conjunctiva will be approximated by surgical forceps and will be cauterized using a bipolar cutter (Erbe ICC 50) with a force 1-3 / 20. Forceps will be released slowly to prevent elevation of the graft. The same procedure will be performed 10 times until graft is well firmed. Graft stability will be checked up with a sponge and additional cauterization will be preformed if needed.
45681361|NCT04023292|Drug|Endocrine therapy|Use before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
46022053|NCT00629434|Other|diabetes education via telemedicine|This arm will receive diabetes group education via telemedicine
46022054|NCT00629434|Other|diabetes education in-person|In this arm the group of patients with diabetes will receive diabetes education in-person
45598534|NCT02231333|Drug|S-adenosylmethionine (SAMe)|
45598535|NCT02231333|Drug|pentoxiphylline (PTX)|
46022055|NCT04289194|Drug|HCR040 (Phase 1)|(Phase 1) Intravenous administration. Open label dose escalation, 3 patients in cohort 1 (1 million cells/kg) and 3 patients in cohort 2 (2 million cells/kg)
46022056|NCT04289194|Drug|Placebo (Phase 2)|(Phase 2) Intravenous administration of vehicle solution
46107678|NCT03321201|Procedure|Fibrin glue|Fiber adhesive (Tissel 1 mL kit4-iu) will be prepared according to manufacturer's instructions. Preparation time will be approximately 10-15 min per kit. Once mixed the fibrin glue is usable up to 4 h. For the purpose of the study preparation of the fibrin glue will be performed by a nurse.
46107679|NCT00839436|Drug|CYT107|
46107680|NCT00761410|Device|P.F.C. Sigma RP-F Total Knee Replacement|An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design
46107681|NCT04049188|Radiation|Single-Fraction Palliative Radiation Therapy|All subjects will be undergo single-fraction palliative radiation therapy who have cancer and associated bone metastases and symptomatic bone pain.
46022057|NCT04289194|Drug|HCR040 (Phase 2)|(Phase 2) Intravenous administration of the maximum tolerated dose (1 million cells/kg or 2 million cells/kg)
46022058|NCT03935854|Other|LCHF, Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 16 weeks
46022059|NCT04289584|Other|Strength and proprioception exercises|Strength and proprioception exercises will be performed with the athlete in different positions depending on the exercise. There will be 3 series with 30 repetitions and 10-second breaks between sets. Each exercise session will be held for 15 minutes. Theraband® exercises are: unipodal balancing on hard surface with open and closed eyes, unipodal balancing on soft surface, squats, lateral walk, isometric contractions with garter and dynamic leg opening, tiptoe, and eccentric hamstring curl with garter.
46107682|NCT02607345|Dietary Supplement|Zusto|25gr
46107683|NCT02607345|Dietary Supplement|Glucomedics®|25gr
46107684|NCT00709020|Drug|white button mushroom extract|Dose escalation with six evaluable subjects per dose level. Doses begin at 5 g/day, then 8 g/day, then 10 g/day then 13 g/day.
46022060|NCT03857191|Dietary Supplement|Nutritional psychocomportemental rehabilitation|Nutritional psychocomportemental rehabilitation
45681362|NCT03948958|Other|Evaluation of the catheter function|Catheter function will be measured by the CINAS (Catheter injection and aspiration classification)
45681363|NCT03948958|Other|Catheter tip location, thrombus, sleeve and device damage visualization|Catheter tip location, thrombus, sleeve and device damage will be visualized by linogram
46107685|NCT00709020|Other|flow cytometry|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
46107686|NCT00709020|Other|high performance liquid chromatography|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
46107687|NCT00709020|Other|laboratory biomarker analysis|Performed on blood samples taken pre-treatment on day 1 and on day 85 after treatment.
46107688|NCT00709020|Other|mass spectrometry|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
46107689|NCT00709020|Other|pharmacogenomic studies|Performed on blood samples taken on days 1, 8, 15, 29, 57 and 85 of treatment.
46107690|NCT00709020|Other|pharmacological study|Performed on blood samples taken pre-dose and at 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours after White Button Mushroon extract on day 1 of treatment and pre-dose on days 8, 15, 29, 57 and 85 after start of treatment.
46107691|NCT05520528|Behavioral|Language intervention with group sessions and independent tasks with emphasis on improving reading and writing skills among persons with aphasia|The participants will read through a designated book incrementally across multiple weeks at home and complete reading, writing, and discussion related to weekly readings in a group setting.
46107692|NCT03388762|Dietary Supplement|GlucoSupreme™ Herbal|This study will assess changes in glycemic parameters and other biomarkers over a twelve week period, with two blood draws (Baseline and 12 weeks). Additionally, an IRB-approved research associate will call each study participant at the 6-week mid-point of the study to assess compliance and collect data on any adverse events.
46107693|NCT03388762|Other|Placebo|The placebo utilized in this clinical trial will be formulated by the manufacturer to be as similar as possible to the active intervention in appearance, odor, and other key characteristics. Packaging for the control will be identical to packaging for the Active Comparator.
46107694|NCT02612220|Procedure|BioFoam® Surgical Matrix|Complete hemostasis is achieved by direct application of BioFoam® (Cryolife Inc., Kennesaw, GA) to the transection surface area of the liver. In addition, the surgeon may use conventional methods such as argon beam coagulation and warm sponges. If more than one syringe of BioFoam® is required to cover the entire transection surface area, a second syringe maybe used. BioFoam® Surgical Matrix will be used according to the supplier's instructions.
46107695|NCT02612220|Other|Conservative hemostasis|Complete hemostasis will be achieved without the use of topical agents
46107696|NCT04627246|Biological|Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides (PEP-DC vaccine)|"SOC: Subgroup1: intravenous mFOLFIRINOX for twelve 14-day cycles. Subgroup2: intravenous gemcitabine twice, on days 1 and 8, and oral capecitabine for 14 days of 21-day cycles, for eight cycles.~PEP-DC vaccine: At least 5 subcutaneous vaccinations starting on cycle 8 (subgroup1) or cycle 5 (subgroup2) of chemotherapy: Subgroup1: every 4 weeks, on day 3 of every second 14-day cycle, and then every 4 weeks starting from the first nivolumab administration. Subgroup2: Every 3 weeks, on day 9 of each 21-day cycle, and then every 4 weeks starting from the second nivolumab administration.~Nivolumab: intravenous, starting after the last chemotherapy cycle. Administered as a flat dose of 240mg every 2 weeks during the vaccination period until the last vaccine dose or at least for 8 weeks after the end of last chemotherapy cycle if vaccination stops earlier. Then, as a maintenance therapy at 480 mg every 4 weeks until appearance of new lesions or unacceptable toxicity for a maximum of 2 years."
46107697|NCT05311072|Procedure|pulmonary endarterectomy or balloon pulmonary angioplasty|A multidisciplinary team make the final treatments for patients with CTEPH depending on their disease and preferences.
46022061|NCT04289818|Other|Health Coaching|Health Coaching as face to face with a coach
46022062|NCT03812809|Drug|BPI-7711|BPI-7711: 180mg, QD, oral
46107698|NCT00761488|Device|AcrySof® Toric IOL|Implanted into the study eye
46107699|NCT00761566|Other|Real preconditioning followed by Sham preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure. The subjects will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg.
46022063|NCT04083157|Biological|Intradermal hepatitis B vaccine with imiquimod|Intradermal hepatitis B vaccine with topical imiquimod pretreatment
46107700|NCT00761566|Other|Sham preconditioning followed by Real preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg. They will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure.
46107701|NCT00761644|Drug|Doxil|Day 1 of each 21 day cycle, beginning dose level 10 mg/m^2 by vein over 3 hours.
46022064|NCT04083157|Biological|Intramuscular hepatitis B vaccine with aqueous cream|Intramuscular hepatitis B vaccine with topical aqueous cream pretreatment
46107702|NCT00761644|Drug|Bevacizumab|Day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.
45598536|NCT03517267|Diagnostic Test|ultrasound and FNA|The nodule to undergo FNA will be chosen according to TIRADS ACR criteria and the ATA risk criteria ( if there is a disagreement between the methods whether to perform FNA the FNA will be performed ) If both methods do not recommend FNA , but the referring doctor has requested the procedure or the patient is unable to stay on follow up , the FNA will be performed .
46022065|NCT05522101|Device|Mini-sized MCE|AKES-31SW capsule endoscopy（Mini-sized MCE), its diameter is 9.5mm, length is 24.5mm, weight is 3.0g, shooting frequency is 0.5-6fps, image resolution is 480*480, working time is not less than 8 hours. Mini-sized MCE is 0.6 times of traditional MCE in volume and weight, which is the smallest capsule in clinical application
46107703|NCT00761644|Drug|Temsirolimus|Days 1, 8 & 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes.
46107704|NCT04049812|Device|PEMF|
46107705|NCT04049812|Device|Hot pack|
46107706|NCT04049812|Device|TENS|
46107707|NCT04049812|Device|Sham PEMF|
46022066|NCT05522101|Device|Normal-sized MCE|Pillcam SB 3 capsule endoscopy（Normal-sized MCE), its diameter is 11.4mm, length is 26.2mm, weight is 3.0g, shooting frequency is 2-6fps, image resolution is 340*340, working time is not less than 8 hours.
46022067|NCT00975286|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
46022068|NCT00975286|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
46022069|NCT00975286|Drug|Insulin glargine|Dose to be adjusted to maintain a fasting SMPG between 100 and 80 mg/dL (5.6 and 4.4 mmol/L), inclusive.
46022070|NCT00975286|Device|Pen auto-injector|Lantus® SoloStar® OptiClik®
46022071|NCT00975286|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
46022072|NCT00975286|Drug|Thiazolidinedione (TZD)|TZD (either rosiglitazone or pioglitazone) if given, to be continued at stable dose up to Week 24.
46022073|NCT00907777|Biological|Pneumococcal conjugate vaccine GSK 1024850A|One dose of vaccine will be injected intramuscularly into the deltoid.
46022074|NCT00907777|Biological|Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)|One dose of vaccine will be injected intramuscularly into the deltoid.
46022075|NCT03741517|Radiation|18F-FDG-PET|Fludeoxyglucose F18
46107708|NCT04049734|Drug|oral losatan|50 mg of oral losartan one hour before the ERCP once
46107709|NCT04617418|Behavioral|Change in touchscreen interactions|The investigators will measure the changes in touchscreen interactions using the TapCounter app by QuantActions
46107710|NCT02559388|Drug|Montelukast|
46107711|NCT02559388|Drug|placebo|Placebo (For Montelukast) Placebo pills manufactured for mimic 10 milligram montelukast pills
46107712|NCT03181204|Procedure|Bronchial biopsy|The bronchial biopsy is part of this study's inclusion criteria and is required during routine care for the patient. Bronchial fibroscopy is performed under general or local anesthesia. Biopsies are performed using forceps and according to current recommendations. One biopsy will be fixed immediately in RCL2 medium while the others (between 3 and 6) will be kept in isotonic saline and rapidly prepared for air-liquid-interface (ALI) cell culture.
46107713|NCT03181204|Procedure|Skin biopsy|The skin biopsy will be performed after local anesthesia by hypodermic injection of a 1% Xylocaine solution. A single sample of a skin fragment about 3 mm in diameter will be necessary.
46107714|NCT03181204|Procedure|Blood sample|The blood sample will be taken at the end of the cutaneous biospy, approximately 20 ml of blood will be collected.
46107715|NCT03168256|Drug|CF101 2mg|CF101 tablets, 2mg BID for 16 weeks
46107716|NCT03168256|Drug|CF101 3mg|CF101 tablets, 3mg BID for 16 weeks
46022076|NCT03741517|Radiation|68Ga-DOTATOC-PET|DOTA-tyr3-Octreotide Ga68
46022077|NCT03741517|Radiation|Computed tomography|Computed tomography of thorax and abdomen with 3-phase contrast
46022078|NCT03741517|Other|Core needle biopsy|Core needle biopsy of metastatic lesions
46022079|NCT03741517|Other|Phlebotomy|Phlebotomy from peripheral vein
46022080|NCT04270396|Behavioral|Presence or absence of implant|We procedure to observed clinically the sample size, to be able to determine if the dental implant was present or no. If the implant was absent we recorded if it was early( prior to restoration) or late ( after prosthesis was delivered).
46107717|NCT03168256|Drug|Apremilast 30mg|Apremilast tablets, 30mg BID for 16 weeks
46107718|NCT03168256|Drug|Placebo Oral Tablet|Placebo tablets, BID for 16 weeks
46022081|NCT05553223|Behavioral|Microdoses of activity|Short bouts of low-intensity exercise (walking) will be used to break up prolonged sitting.
46107719|NCT00761722|Drug|azacitidine|"Arm 1:~Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.~Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle.~Arm 2:~All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle."
46022082|NCT02866084|Device|Device|"The following parameters will be set for active treatments using the CVS Device:~A standardized CVS time-varying waveform lasting approximately 19 minutes will be used. Treatments will be administered up to twice daily. The two daily treatments should ideally be separated by at least one hour.~The waveform schedule will consist of a warm sawtooth delivered to one ear and a cold sawtooth delivered to the other ear. The warm sawtooth will go from body temperature to 42 °C, and the cold sawtooth will go from body temperature to 17 °C. The two waveforms will be delivered simultaneously, but will have different oscillation frequencies."
45468612|NCT04904029|Other|Digital Assessment Routing Tool [DART]|"DART is a first contact web-based and mobile health system that uses clinical algorithms to triage patients and recommend management pathways. Participants complete an online web-based questionnaire that follows a clinical reasoning process commonly observed in face-to-face physiotherapy consultations. Based on the participant's answers, the clinical algorithm generates sets of questions, leading up to a triage disposition with recommended management pathway. The triage outcomes with management pathways are classified;~Medical care~A&E referral~Urgent GP~Routine GP~Consultant review~Physiotherapy care~Post-fracture or surgery physiotherapy~Physiotherapy referral~Physiotherapy referral plus psychosocial support~Self-management~Self-management with SOS~Continue self-management advice"
46107720|NCT00761800|Drug|Lactic acid|
45468613|NCT04904029|Other|Physiotherapy-led remote triage (usual care)|Participants will receive usual physiotherapy-led remote triage services by a registered health care professional. This service is either a telephone or video consult and includes any diagnostic procedure (e.g. patient history, remote assessments) and treatment, such as management advise or home-based exercise therapy. Participants may seek help elsewhere or opt-out the study at any point, which will not affect their usual physiotherapy-led remote care
46107721|NCT04582708|Device|NERv's Inline Device|NERv's Inline Device is comprised of multiple sensors. It attaches in line to existing catheters or peritoneal drains that are currently approved for medical use. This allows the device to measure the pH and electrical conductivity of effluent fluids that are drained through peritoneal drains.
46107722|NCT00761878|Procedure|Exposure to plasma energy|Non-invasive exposure to pulsed plasma to the unbroken skin over half of the facial area
45468614|NCT01321021|Drug|Losartan, Diphenhydramine, Placebo|placebo controlled crossover study with two arms: Losartan 40mg, Diphenhydramine 40mg
46107723|NCT02558998|Other|Survey|
46107724|NCT04529434|Other|Star Homes|110 identical novel-designed houses, known as Star Homes, include the critical structural components e.g. building orientated to provide optimal shading throughout the day, light-weight & durable roof, facade and openings screened from insects to reduce insect entry while assuring airflow, an outdoor fly-proof latrine, and solar power providing electric light at night etc.
46107725|NCT04529434|Other|Traditional African houses|A traditional mud house: with wattle and daub walls, a thatched roof, and no electricity or piped water supply.
46022083|NCT03707431|Behavioral|Web-based CBT|The eight child modules include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) deep breathing and relaxation, 4) implementing coping skills at school, 5) cognitive skills (e.g., reducing negative thoughts), 6) lifestyle interventions, 7) staying active (e.g., pleasant activity scheduling), 8) relapse prevention. The eight parent modules are: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I (using attention and praise to increase coping), 4) operant strategies II (using rewards to increase positive coping and reach school goals), 5) modeling, 6) lifestyle, 7) communication, 8) relapse prevention.
46107726|NCT04507906|Drug|Nivolumab Combined with Anlotinib|In combination dose finding phase, Phase 1b will begin with Dose Level 1; anlotinib 12 mg/day orally (from days 1 to 14 in a 21-day cycle) and nivolumab (360mg q3w, intravenously) will be administered to eligible subjects on a 21-day treatment cycle. Two dose de-escalation steps are included: Dose Level 2 (anlotinib 10 mg/day orally, from days 1 to 14 in a 21-day cycle) and nivolumab 360mg q3w, intravenously) and Dose Level 3 (anlotinib 8 mg/day orally, from days 1 to 14 in a 21-day cycle) and nivolumab 360mg q3w, intravenously).If RP2D was reached in Part A, eligible patients would be enrolled and receive nivolumab (360mg q3w, intravenously) plus anlotinib (RP2D, QD from day 1 to 14 of a 21-day cycle) .
46107727|NCT02558920|Other|Fructose-containing Sugars|An intervention in which calories from food sources of fructose-containing sugars are substituted, added, subtracted, or replaced ad libitum in the diet
45468615|NCT01238705|Drug|Felodipine add Irbesartan|"Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.~Irbesartan,150mg/day, Sanofi - Aventis Pharmaceutical company, Registration Number: H20080074."
45838285|NCT04068610|Drug|Experimental|Parts of FOLFOX are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 2400 mg/m2 administered by continuous IV infusion over 46 to 48 hours Q2W (Day 1-2 of every 14-day cycle). Note: 5-FU will be administered as infusion only. Bevacizumab 5 mg/kg IV infusion Q2W (Day 1 of every 14-day cycle) Durvalumab 1500 mg IV Q4W Oleclumab 3000mg IV Q2W x 4 then Q4W
46022084|NCT03707431|Behavioral|Pain Education|The pain education website provides publicly available educational information about pancreatitis and abdominal pain. There is general information about pancreatitis from available web sources (e.g., National Pancreas Foundation) as well as information about chronic pain in childhood. The content does not include any instruction in the behavioral and cognitive skills taught within the WebMAP program.
46107728|NCT04471636|Device|Withings ScanWatch|The smart watch is capable of recording SpO2, ECG, and heart rate.
45468616|NCT01238705|Drug|Felodipine add Metoprolol|"Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.~Metoprolol Succinate,47.5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: J20050061."
45468617|NCT03779347|Drug|Praziquantel|Praziquantel to treat schistosomiasis during pregnancy
45468618|NCT03779347|Diagnostic Test|UCP-LF CAA|UCP-LF CAA to diagnose Schistosomiasis during pregnancy
45468619|NCT03779347|Diagnostic Test|composite diagnostic|composite diagnostic reference test based on extensive egg microscopy, serology, qPCR on egg DNA, and POC-CCA to diagnose Schistosomiasis during pregnancy
45468620|NCT05253677|Device|CT-guided PCI|CT-guided PCI with standardized pre-procedural planning and online guidance.
45468621|NCT05253677|Device|IVUS-guided PCI|use of IVUS during PCI procedure (standard of care)
46022085|NCT02864758|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Tablets, 20mg once daily
46022086|NCT02864758|Drug|Vitamin K antagonists|Tablets, dose is based on International Normalized Ratio
46107729|NCT00762112|Drug|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 24 months.
46107730|NCT00762190|Drug|TAK-559 and insulin|TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
46107731|NCT00762190|Drug|Insulin|TAK-559 placebo-matching, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
46107732|NCT00762346|Drug|zometa|zometa 4mg i.v. every 4 weeks for up to 2 years
46107733|NCT04375930|Other|STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION|STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION: It is consist of skills, discharge, compilation and algorithm education.
46107734|NCT04375930|Other|Control|It consists of only skills and discharge education
46107735|NCT00762658|Drug|AN2728 Ointment, 5%|
46022087|NCT02864758|Drug|dabigatran (Pradaxa)|Tablets, 150 mg twice daily
46022088|NCT04204798|Drug|Dexmedetomidine|"Dexmedetomidine is infused from 4 pm to 8 am during ICU stay for no more than 3 days.~For non-intubated patients, the infusion rate is adjusted to reach a Richmond Agitation-Sedation Scale (RASS) of -1, or a maximal rate of 0.2 microgram/kg/h, or the occurrence of any adverse events.~For intubated patients, the infusion rate is adjusted to reach a RASS of -1, or a maximal rate of 0.7 microgram/kg/h, or the occurrence of any adverse events."
46022089|NCT04204798|Drug|Placebo|"Normal saline is infused in the same rate for the same duration as in the dexmedetomidine group.~Propofol sedation is administered when considered necessary."
46022090|NCT00908011|Drug|Ezetimibe|10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks
46107736|NCT00762658|Drug|AN2728 Ointment, 2%|
46107737|NCT00762658|Drug|AN2728 Ointment, 0.5%|
46107738|NCT00762658|Drug|AN2728 Ointment Vehicle|
46107739|NCT00762658|Drug|Betnesol®-V Creme, 0.1%|
46022091|NCT00908011|Drug|Rosuvastatin (standard care)|Increased dose of rosuvastatin to 20mg/day
46107740|NCT00762658|Drug|Protopic® Ointment, 0.1 %|
46022092|NCT02864836|Procedure|Samples collection|5 samples collected for each patient (tumor biopsy, healthy tissue around the tumor, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins 4 samples for each patient (healthy tissue, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins
46022093|NCT00976456|Drug|Bevacizumab + Pemetrexed|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks
46022094|NCT00976456|Drug|Bevacizumab + Pemetrexed + Carboplatin|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks
46022095|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
46022096|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
46022097|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
46022098|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
46022099|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
46022100|NCT05518435|Other|None, observational study|The MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3).
46022101|NCT00629512|Drug|Esomeprazole|20mg oral daily
46022102|NCT00629512|Drug|Esomeprazole|40mg oral daily
46022103|NCT00629512|Drug|Placebo|
46022104|NCT01711021|Drug|d-Amphetamine Transdermal System|Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.
46022105|NCT01711021|Drug|Placebo patch|Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.
46022106|NCT02864680|Other|Electroretinography|
46022107|NCT02864680|Other|Contrast sensitivity test during Electroencephalography|Stimuli are black and white grids, having different range of spatial frequencies, presented with different contrasts on a grey background thanks to a computer monitor, in a dark room. Participants are requested to maintain central fixation. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
46107741|NCT02558452|Drug|Tacrolimus once daily (Advagraf)|Antibody induction by antithymocyte Globulin (ATG) or Basiliximab possible but not mandatory
46107742|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
46107743|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
46107744|NCT00762736|Drug|Pioglitazone|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
46107745|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
46107746|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
46107747|NCT00762736|Drug|Pioglitazone|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
46107748|NCT00762814|Device|Gait tests with and without the use of a tactile sensory cue (electrical stimulation using a TENS unit)|Eligible subjects will be perform walking tests involving the use of the TENS device (Select Unit by Empi) on the lower leg bilaterally during gait: uncued (wearing the unit but, but with the device turned off) or with a tactile cue (wearing the device with it turned on until a tactile stimulus is felt). The TENS unit is a battery-operated, single-channel electrical stimulator worn around the proximal calf that can used to provide a constant tactile stimulus. All subjects will undergo a single visit in which the two walking conditions are tested. During these visits, the patient will perform the same gait assessments measured with the device turned off as well as turned on. Testing the two conditions on the same day/time will provide the investigators with a consistent comparison of the two tested conditions, as mobility and function in patients with PD can vary significantly within and between days.
45468622|NCT05505643|Device|Endocare SlimLine Cryoprobe|"The Endocare(TM) SlimLine (TM) Cryoprobe is a single use, disposable device designed for use with Endocare Cryocare Surgical Systems. Endocare cryoprobes are designed to deliver cold temperatures for cryoablation using high-pressure argon gas circulated through the cryoprobe, followed by active thawing using helium gas.~The Cryocare CS Surgical System is intended for use in open, minimally invasive, or endoscopic surgical procedures in the areas of general surgery, urology, gynecology, oncology, neurology, dermatology, ENT, proctology, pulmonary surgery, and thoracic surgery. The system is designed to freeze/ablate tissue by the application of extreme cold temperatures."
45468623|NCT05505643|Procedure|Lumpectomy|Patients randomized to cryoablation who experience disease recurrence may undergo crossover to lumpectomy.
46107749|NCT02915224|Drug|Chlorambucil|Participants will receive chlorambucil as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
46107750|NCT02915224|Drug|Obinutuzumab|Participants will receive obinutuzumab as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
46107751|NCT02870920|Drug|Tremelimumab|
46107752|NCT02870920|Drug|Durvalumab|
46107753|NCT02870920|Other|Best Supportive Care|
46107754|NCT02813824|Drug|Acetylsalicylic acid lysinate 300 mg|Daily dose during 4 years
46107755|NCT02813824|Drug|Placebo (for Aspirin 300)|Daily dose during 4 years
46107756|NCT02813824|Drug|Acetylsalicylic acid lysinate 100 mg|Daily dose during 4 years
46022108|NCT02864680|Other|Visual simultaneity test during Electroencephalography|Two vertical bars are showed on a monitor, on the link and right of point of central fixation. Bars appear simultaneously or with a 10 to 200 ms asynchrony. Participants must determine whether stimuli are simultaneous or asynchronous and answer pressing the link button for simultaneity or right button for asynchrony. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
45468624|NCT01146587|Device|GangTrainer GT1|30 minutes of treatment on the GangTrainer GT1 and 30 minutes of Conventional Physiotherapy every workday for 8 weeks
45468625|NCT01146587|Device|Lokomat|30 minutes of treatment on the Lokomat and 30 minutes of Conventional Physiotherapy every workday for 8 weeks
45468626|NCT01146587|Other|Conventional Physiotherapy|60 minutes of Conventional Physiotherapy every workday for 8 weeks
45468627|NCT01561261|Other|Continuous tissue perfusion monitoring by near-infrared spectroscopy (NIRS) and intramuscular pressure (IMP)|Continuous monitoring of tissue perfusion using NIRS in all 4 leg muscle compartments and IMP via indwelling catheters in anterior and deep posterior compartments. These measures will not provided in real time to treating physicians. All clinical care, including the diagnosis of ACS, will be according to the current standard-of-care practiced at each institution, Clinicians may use the indwelling IMP monitor to obtain up to 2 discrete measures of IMP if they encounter a clinical situation in which they would normally measure IMP as an adjunct in their normal standard-of-care for the monitoring and diagnosis of compartment syndrome. Patients who undergo fasciotomy will also have NIRS and IMP values recorded from all 4 leg compartments immediately before and after fasciotomy.
45468628|NCT01321099|Other|NaFeEDTA|Labeled iron as FeSO4 or NaFeEDTA added to a test meal
46107757|NCT02813824|Drug|Placebo 100 (for Aspirin 100)|Daily dose during 4 years
46107758|NCT05306782|Device|transcranial Electrical Stimulation|transcranial Random Noise Stimulation, transcranial Direct Current Stimulation, or Sham are administered (by means of surface electrodes) on associative motor regions during speech therapy sessions (20 minutes, in the initial part of the sessions; 1.5 mA).
46107759|NCT05306782|Behavioral|Speech Therapy|Speech Therapy is associated to transcranial electrical stimulation or sham, during stimulation sessions. Total duration of the single session: 45 minutes
46107760|NCT02669680|Drug|G-CSF|G-CSF subcutaneously, 5 μg/kg daily on day 0-4, then every 3rd day over 26 days (days 7, 10, 13, 16, 19, 22, 25) = 12 doses
46107761|NCT02669680|Other|Standard therapy|
46107762|NCT00673894|Drug|Sitagliptin|Glutamine 30g +sitagliptin 100mg
46107763|NCT00673894|Drug|Placebo|Glutamine 30g +placebo (matching sitagliptin 100 mg)
46107764|NCT04195984|Device|Mi-thos® valve and transapical delivery system|Transcatheter mitral valve replacement system
46107765|NCT00763126|Behavioral|stress level|Stress levels
46022109|NCT02864680|Other|Face perception test during Electroencephalography|Faces filtered in different spatial frequence ranges are showed randomly on a monitor, in a dark room. Participants must maintain a central fixation thank to a fixation cross. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
45468629|NCT01321099|Other|Phytase|Labeled iron as FeSO4 added to a test meal with or without phytase and with or without vitamin C
46022110|NCT02864680|Other|CAST (cannabis abuse screening test)|
46022111|NCT02864680|Other|PANSS (Positive And Negative Symptoms Scale) test|
46022112|NCT02864680|Other|Delayed Matching to Sample (DMS) test|
46022113|NCT02864680|Other|Spatial Working Memory (SWM) test|
46022114|NCT02864680|Other|Rapid Visual Information Processing (RVP) test|
46107766|NCT00763204|Drug|AN2728 Cream, 2%|
45468630|NCT01321099|Other|Vitamin C|Labeled iron as FeSO4 added to a test meal with or without vitamin C
45468631|NCT05213897|Device|SARS-CoV-2 Antigen Assay|To demonstrate that non-laboratory personnel can accurately perform the SARS-CoV-2 Antigen assay in the intended use environment using nasopharyngeal samples by demonstrating that the assay can achieve a ≥ 80% sensitivity and specificity when it is compared to the results of a high sensitivity EUA SARSCoV-2 RT-PCR assay using nasopharyngeal samples.
46022115|NCT02864680|Other|Test for attentional performance (TAP) / Divided Attention|
46022116|NCT02864680|Other|Collection of saliva sample|In case of specific consent of participant to ancillary study, for ancillary study
46022117|NCT05517265|Drug|Calquence|acalabrutinib (+/- obinutuzumab) according to Calquence® SmPC.
46022118|NCT05517265|Drug|Calquence|acalabrutinib according to Calquence® SmPC.
46022119|NCT02864602|Drug|IV dexamethasone|An infusion of IV dexamethasone
46022120|NCT03788083|Drug|Trimix|Intratumoral TriMix injection
46107767|NCT00763204|Drug|AN2728 Cream, 1%|
46107768|NCT00763204|Drug|AN2728 Cream, 0.3%|
46107769|NCT00763204|Drug|AN2728 Cream Vehicle|
46107770|NCT00763204|Drug|Betnesol®-V Creme, 0.1%|
46107771|NCT02558140|Biological|RO6874813|RO6874813 will be administered at a single low dose of 0.5 mg/kg via IV infusion in a 7- day PK run-in period (Cycle 0). Dose level for RO6874813 will be escalated to determine MTD and RP2D for RO6874813.
46107772|NCT02558140|Biological|RO6874813|RO6874813 at RP2D will be administered by IV infusion as per dosing schedule determined in Part 1.
46107773|NCT02558218|Drug|Systane Ultra|Further to standard medication (tobradex quid for 20 days), participants were administered Systane Ultra quid for 2 months
46107774|NCT02558218|Drug|tobradex quid (Standard)|Standard medication (tobradex quid for 20 days)
46022121|NCT03788083|Drug|Placebo|Intratumoral placebo injection
46107775|NCT00763438|Drug|Sertindole|Flexible dose
46107776|NCT00763516|Radiation|Proton radiation and chemotherapy|"Neoadjuvant Chemotherapy Capecitabine (Xeloda®) 1,000 mg by mouth twice a day 5 days/week (M-F) on radiation days only~Proton radiation 50.4 cobalt gray equivalent(CGE) in 28 fractions over 6 weeks~Surgery: Gross total resection of primary tumor and regional lymph nodes done 6 weeks after completion of radiation~Adjuvant Chemotherapy starting 2-8 weeks after surgery Suggested Regimen: Gemcitabine (Gemzar®) 1,000 mg/m2 IV total of 18 doses"
46107777|NCT02558842|Other|Education Strategy|"Interview with the patient and their contacts, even during hospitalization, Delivering educational material about TB distribution free; Advise the patient about the BHU nearest their home, where it will follow the treatment of tuberculosis. Provide the address and telephone contact BHU this writing.~During the time of TB treatment, contact the patient to see if it is adhering to treatment and answer questions about the disease and treatment, The contact will be performed weekly for the first month, biweekly for the other months.~During the treatment period, contact BHU to monitor the progress of the case. Monitoring will be terminated: when the patient is discharged after cure of BHU or when the patient is absent for more than 30 days from the last scheduled visit."
46107778|NCT02158000|Other|group A|one tab every 8 hs Diosmin ( 500mg) beginning from the day of ovum retrieval in addition to aspiration of the fluid by an IUI catheter
46107779|NCT01737502|Drug|Auranofin|Given PO
46107780|NCT01737502|Drug|Sirolimus|Given PO
45468632|NCT03773263|Drug|sequential IVM system|The immature oocytes will be cultured in sequential oocyte IVM medium 1 for 6 hours (37℃, 5% CO2). After flushed 3 times, COCs were removed into sequential oocyte IVM medium 2 for further cultivation.
46022122|NCT04289506|Diagnostic Test|mRNA expression|The primary objective is the external validation of our filed patent-claims panels of mRNA biomarkers, which in the inflammatory and SIRS/Sepsis panels have better discriminatory properties than any other published biomarker panel for detecting individuals with severe inflammation and differentiating infectious and non-infectious origin of organ failure (Sepsis/SIRS).
45468633|NCT03773263|Procedure|intracytoplasmic sperm injection (ICSI)|intracytoplasmic sperm injection (ICSI)
45468634|NCT03773263|Procedure|Thawed embryo transfer (TET)|Patients administrates oestrogen (Progynova) 3mg twice a day for 10 to 12 days. From the day when endometrium reach a thickness of 8 mm and above, luteal phase support will be given with 10 mg progesterone (Dydrogesterone Tablets,) triple per day and utrogestan (Laboratories Besins International, Paris, France) 0.2g triple per day, until 14 days after embryo transfer.
46022123|NCT00993148|Drug|maraviroc|150 mg tab by mouth once daily for 96 weeks
46022124|NCT00993148|Drug|darunavir|800 mg tab by mouth once daily for 96 weeks
46022125|NCT00993148|Drug|ritonavir|100 mg capsule by mouth once daily for 96 weeks
46022126|NCT03775369|Other|endurance training|physical activity and exercising (PAE)
46022127|NCT03775369|Other|social support and counseling|social support and counseling
46022128|NCT03775369|Other|resistance training|physical activity and exercising (PAE)
46022129|NCT03661177|Other|Sovereign nation diet|We will pilot a RCT with delayed intervention to provisionally assess health impacts of consuming a diet that is 50% indigenous foods for four weeks.
46022130|NCT05505955|Drug|HRS-5965|Subjects took HRS5965 tablets in Part 1, Part 2 and Part 3.
46022131|NCT05505955|Drug|Placebo|Subjects took Placebo in Part 1 and Part 2.
46022132|NCT04223947|Procedure|DIGESTIVE ENDOSCOPY|DIGESTIVE ENDOSCOPY
46022133|NCT00907621|Procedure|Acupuncture with Seirin 020x15 mm sterile acupuncture needle|Bilateral insertion of a Seirin 020x15mm sterile acupuncture needle to a depth of 12mm for 30 seconds during 3 consecutive working days at the WHO designated acupuncture point St36.
46022134|NCT04755439|Procedure|DHCA|DHCA THE USE OF SEREBRAL PROTECTİON TECHNİQUE
46107781|NCT01737502|Other|Laboratory Biomarker Analysis|Correlative studies
46107782|NCT01737502|Other|Pharmacological Study|Correlative studies
46107783|NCT00674986|Device|Accu-Chek 360° View Blood Glucose Analysis Tool|
46107784|NCT00674986|Device|Accu-Chek Aviva Glucose Meter|
45598537|NCT02348229|Procedure|ERAS protocols|Normal meal allowed until 6 h before surgery and Carbohydrate drink until 2 h before surgery
46022135|NCT04230811|Diagnostic Test|Corneal impression membrane (Millicell Cell Culture Insert, 12mm, hydrophilic PTFE 0.4µm (PICM01250))|Application of corneal membrane to the cornea for 3-5 seconds, after anaesthesia
46022136|NCT03403699|Biological|Generation of inducible pluripotent stem cells|Generation of inducible pluripotent stem cells from peripheral blood cells.
46022137|NCT03401047|Drug|Estradiol|Subjects will receive graded doses of transdermal estradiol patches for up to 7 days. Blood estradiol tests will be performed daily, and the number of estradiol patches used will be adjusted to maintain serum estradiol levels of 250-400 pg/ml. Estradiol is a natural hormone.
46022138|NCT03384589|Biological|PCV13|Vaccine against pneumococcal disease
46022139|NCT03617497|Diagnostic Test|scalp EEG and polysomnography|48 hour 22 channel EEG with polysomnography
46022140|NCT03617497|Diagnostic Test|scalp EEG with foramen ovale electrodes with polysomnography|long-term scalp EEG with additional foramen ovale electrodes with polysomnography
45681364|NCT03948958|Other|Catheter-related colonization|TIVAD colonization will be investigated by microbiological culture of the tip and chamber content
46022141|NCT05332951|Other|Interpersonal Reactivity Index|Questionnaire to be completed by the patient
46022142|NCT03601117|Device|Dorsolateral Prefrontal Cortex Accelerated Theta Burst Stimulation|"Participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC.~Stimulation intensity will be standardized at 80% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Brainsway TMS system."
45468635|NCT03773263|Drug|traditional IVM system|COCs were aspirated and the immature oocytes will be cultured in traditional standard oocyte IVM system (Sage). 30 and 44 hours after cultivation, the maturity of oocytes will be assessed.
45468636|NCT01245725|Drug|Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25mcg/kg i.v. bolus followed by a 0.15mcg/kg/min i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.~Patients will receive tirofiban (Aggrastat) on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion."
45468637|NCT01245725|Drug|Placebo|"Placebo will be dosed as an i.v. bolus followed by an i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.~Patients will receive placebo on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion."
45468638|NCT01143545|Biological|Allogeneic Tumor Cell Vaccine (K562)|Subcutaneous injection monthly for 6 months
45681365|NCT03948958|Other|patient-reported outcome measures (PROM) related to the presence of the TIVAD|PROM will evaluate patient's experiences regarding the TIVAD insertion, dwell time, and removal using the Leuven Patient Reported Experiences at Port removal (Leuven PREP) questionnaire.
46022143|NCT03601117|Device|Anterior Cingulate Cortex Accelerated Theta Burst Stimulation|"Participants will receive iTBS (intermittent theta burst stimulation) to the anterior cingulate cortex (ACC).~Stimulation intensity will be standardized at 80% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Brainsway TMS system."
46022144|NCT03587233|Behavioral|Physical assessment|Besides the demographic features of the participants, the interventions on physical assessment will be performed including weight in kilogram and height in meter; and weight and height will be combined to report body mass index in kg/m2. The waist circumference will be measured to understand the central fattening from costal margins or above umbilicus in cm. If it is measured above 95cm for men and 80cm for women is considered as higher than normal; if higher than 110cm for men and 88cm for women is considered as having risks for obesity, diabetes, cardiovascular diseases etc. Hand and pinch grip power will be assessed. It the elbow is in extension upper extremity power, and if it is flexed at 90 degree and forearm is supported on the table handgrip power is to assess.
46022145|NCT03587233|Device|Analyses of body composition|The analyzes of body composition will be measured with bioelectrical impedance analysis method by a body composition analyzer.
46022146|NCT03587233|Behavioral|physical activity level assessment|The physical activity level will be assessed through the intervention titled with the Turkish version of the 'International Physical Activity Questionnaire-Short Form'. It consists of seven questions searching for the amount of walking and low, moderate and high intensity physical activities as total time in minutes per day and frequency in days per week. Sitting, as a sedentary behavior, will be evaluated separately. The scores will be achieved by the multiplication of the minutes, days and metabolic equivalent time values in a week, and over the last 7 days. Walking score and total weekly walking duration will be calculated as medium and vigorous; the physical activity level will be classified as low, moderate and high level activity.
46022147|NCT03581695|Other|Blood test|Blood test
46022148|NCT03531073|Drug|Methotrexate|This study is observational and patients will receive treatment for their psoriatic arthritis as clinically indicated. As per standard practice in this observational cohort, patients are most likely to be treated with methotrexate as the most common first line therapy in PsA. This cohort is the basis of a TWiCs (Trials Within Cohorts) study design and interventional studies will be nested within this in future. Whilst the cohort will receive treatment for their PsA as part of their routine clinical care, this treatment will be decided according to routine care and not protocolised.
46022149|NCT03517111|Behavioral|Nutrition/substance use prevention|Parenting program focusing on diet improvement and substance use prevention
46022150|NCT03517111|Behavioral|Substance use prevention only|Parenting program focusing only on substance use prevention
46107785|NCT02559232|Drug|Direct Oral Anticoagulant (DOAC)|Treatment pattern following the summary of product characteristics
45681366|NCT03948958|Other|Macroscopic evaluation of the port chamber and catheter|Macroscopic evaluation of the port chamber and catheter will be performed after port removal.
45681367|NCT04198090|Behavioral|SGM Competency Training Program|A validated, two-hour long SGM curriculum created by the Fenway Institute and tailored for oncology
46022151|NCT03517111|Behavioral|Academic success program|Program focusing on academic success and college acceptance
46107786|NCT00758446|Drug|BLX-028914|50 mg capsules, p.o, daily, 14 days
46107787|NCT00758446|Drug|BLX-028914|15 mg capsules, p.o, daily, 14 days
46022152|NCT04225429|Drug|Tazemetostat|800mg/dose taken orally twice every day.
46107788|NCT00758446|Drug|placebo|capsules, p.o, daily, 14 days
46022153|NCT00907153|Dietary Supplement|Vitamin D|Vitamin D 300 mcg by mouth once daily for 12 weeks
46022154|NCT00907153|Drug|Placebo|Placebo by mouth once daily for 12 weeks
46107789|NCT00673816|Drug|Sunitinib Malate|Participants were expected to receive 9 months of sunitinib malate therapy administered in 6 cycles. Each cycle consisted of a daily oral dose of 50 mg sunitinib malate for 4 weeks followed by a 2-week rest period).
46107790|NCT00763594|Behavioral|Brief Relational Therapy|16 weeks of psychodynamically informed and therapy alliance focussed psychotherapy adapted for treating Major Depressive Disorder.
46107791|NCT00763594|Behavioral|Interpersonal Psychotherapy|16 weeks of Interpersonal Psychotherapy for Major Depressive Disorder
46107792|NCT00763672|Other|Transmission of sFlt-1 results to the investigator|Transmission of sFlt-1 results by the laboratory to the investigator
46107793|NCT00763672|Other|No transmission of the sFlt-1 results to the investigator|The laboratory do not transmit the sFlt-1 results to the investigator before the end of the study.
46107794|NCT00764842|Device|Encore CLP® Hip stem|Subjects with osteoarthritis, rheumatoid arthritis or avascular necrosis of the natural femoral head who have received the Encore CLP® Hip stem and are willing to participate in the study.
45468639|NCT01143545|Drug|Celecoxib|400 g po bid
45468640|NCT01143545|Drug|cyclophosphamide|50 mg po bid
46022155|NCT05579821|Diagnostic Test|Typhoid DPP assay|The index test used in this study diagnose typhoid fever by detecting IgA antibodies against LPS and HlyE antigen in patient's serum.
46107795|NCT02558062|Other|BAC ONE administration|BAC ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and Cellvizio viewer software will be used to detect BAC ONE signal in the distal lung.
46107796|NCT00673660|Behavioral|Patient Compliance|Compliance of patients to statin treatment and reasons of compliance or non compliance will be obtained by Patient Reported Outcomes (PROs) every 3 months.
46107797|NCT00763906|Device|norepinephrine infused at the clinician's discretion|
46107798|NCT00763906|Device|norepinephrine infused under computerized fuzzy logic control|
46107799|NCT00763984|Behavioral|Usual Care|This group will receive routine care, however, it is possible that that control condition participants will receive Pelvic Floor Muscle Training (PFMT) instruction from their health care providers. We will monitor control women's knowledge, adoption and maintaining of PFMT.
46022156|NCT03984799|Procedure|Bronchoscopy|Samples obtained during bronchoscopy and blood samples will be evaluated to define inflammatory markers of COPD
46022157|NCT00904033|Drug|Calcitriol|Calcitriol tablet taken once per week.
46022158|NCT00904033|Behavioral|Exercise|Exercise consisting of progressive walking and resistance band training
46022159|NCT00904033|Dietary Supplement|Multivitamin|
46022160|NCT05175625|Biological|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm
46107800|NCT00763984|Behavioral|Bladder Health class|Modeled on our intervention with older women, Bladder Health Class (BH Class) will include Pelvic floor muscle training (PFMT), defined by the International Continence Society as repetitive selective voluntary contraction and relaxation of specific pelvic floor muscles, and bladder training (BT), defined as a program of scheduled voiding with gradually progressive voiding intervals. The BT instructions will be modified for this pregnant group. We will monitor control women's knowledge, adoption and maintaining of PFMT and BT.
46107801|NCT00764062|Drug|Amoxicillin|Amoxicillin :drug
46107802|NCT00758914|Dietary Supplement|Vitamin E|200 IU alpha-tocopherol or placebo for 1 year.
46107803|NCT00759070|Drug|Tenofovir + emtricitabine + efavirenz|"Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)~+ Efavirenz 600 mg, (Sustiva, Bristol-Myers Squibb) once daily"
46107804|NCT00759070|Drug|Tenofovir + emtricitabine + lopinavir/ritonavir|Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)QD Lopinavir/ritonavir 400 mg/100 mg, (Kaletra, Abbott) BID
46107805|NCT00764140|Biological|tumor growth factor concentration|spot urine or blood collection will be used to measure specific tumor growth factor
46107806|NCT00672958|Drug|Vortioxetine|Encapsulated immediate-release tablets.
46107807|NCT00672958|Drug|Placebo|Vortioxetine placebo-matching capsules.
46107808|NCT00764218|Device|Positive airway pressure treatment|Positive airway pressure treatment as long as necessary
46107809|NCT00764218|Other|No positive airway pressure treatment|No treatment
46107810|NCT00764296|Other|no treatment|collection of samples of wound biofilm in Acute and Chronic Wounds
45468641|NCT03779035|Drug|Gemcitabine|1000mg/m2
45468642|NCT03779035|Drug|Capecitabine|1250mg/m2
45468643|NCT01586117|Drug|Amifostine|intrarectal Amifostine administration 1500mg QD x 5 weeks
45468644|NCT01238783|Drug|AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension|Topical ocular dosed 3 times per day for 3 days
45468645|NCT01238783|Drug|AL-15469A 0.5%|Topical ocular dosed 3 times per day for 3 days
45468646|NCT01238783|Drug|AL-6515 0.3%|Topical ocular dosed 3 times per day for 3 days
45468647|NCT01238783|Drug|Vehicle|Topical ocular dosed 3 times per day for 3 days
45468648|NCT03633149|Behavioral|Computer tablet-delivered C4H|Two session CHOICES intervention targeting ineffective contraception and risky alcohol use and/or cigarette smoking and/or marijuana use to reduce the risk of a substance-exposed pregnancy delivered on a computer-tablet.
46022161|NCT05175625|Biological|Saline placebo|0.9% sodium chloride (1 mL); a single intramuscular injection into the deltoid muscle of the non-dominant arm
46022162|NCT05171569|Device|Virtual care with remote automated monitoring (RAM)|Use of Cloud Diagnostics connected health kit for at home monitoring with virtual clinical from nursing and perioperative physician team.
46022163|NCT02647177|Other|Pancreatic Cyst Aspiration|10 CC of pancreatic cyst aspiration
46107811|NCT00764296|Other|no treatment|collection of samples for the evaluation of Wound Biofilm in Acute and Chronic Wounds
46107812|NCT00764374|Drug|YM443|oral
46107813|NCT00759226|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 (30 min)
46107814|NCT00759226|Drug|Cisplatin|Cisplatin 30 mg/m2 (90 min)
46107815|NCT00759226|Drug|5-FU|5-FU 750 mg/m2 (24h CI)
46022164|NCT00903877|Drug|T3|Patients receive T3 in a dose of 25mcg and 50mcg
46022165|NCT00632593|Procedure|Laparoscopic Gastric Bypass|
46022166|NCT00632593|Procedure|Laparoscopic Gastric Bypass|
46022167|NCT03353389|Other|No AKI|Subjects will be allocated into this group if they did not acquire Acute Kidney Injury during admission.
46022168|NCT03353389|Other|CA-AKI|"CA-AKI is defined by any patient who developed AKI (as per definition below) within 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown."
45681368|NCT02703688|Behavioral|Healthy Homes|The Healthy Homes Behavioral Intervention (HHBI) will be delivered during 8 sessions over 10 weeks using home visitations. The first 6 sessions occur weekly and provide education about healthy dietary intake including caloric recommendations for preschool aged children, healthy sleep goals, active play and screen time limits, and family routines and organization. Each session will include a parent-child interaction component to teach child behavior management skills related to intervention goals. Two final sessions occur every other week to provide problem solving and planning for maintenance of treatment effects.
46022169|NCT03353389|Other|HA-AKI|"HA-AKI is defined by any patient who developed AKI (as per definition below) after 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown."
46022170|NCT02555839|Drug|Pomalidomide|4mg capsule on d1 through 21 of a 28 day cycle
45598538|NCT02348229|Procedure|ERAS protocols|No bowel preparation
46022171|NCT02555839|Drug|Dexamethasone|40 mg (≤75 years) or 20mg (>75 years) oral on d1, 8, 15, 22 of a 28 day cycle
46022172|NCT02555839|Drug|Pomalidomide|4mg capsule on d1 through 14 of a 21 day cycle
46022173|NCT02555839|Drug|Dexamethasone|cycle 1-8: 20mg PO (≤75 years) or 10mg (>75years) on Days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle; from cycle 9 onwards: Dexamethasone 20mg PO (≤75 years) or 10mg (>75years) on Days 1, 2, 8, 9 of a 21 day cycle
46022174|NCT02555839|Drug|Bortezomib|cycle 1-8: Bortezomib (1,3mg/m2) s.c. on day 1, 4, 8, 11 of a 21 day cycle; from cycle 9 onwards: Bortezomib (1,3mg/m2) s.c. on day 1 and 8 of a 21 day cycle,
46022175|NCT05332249|Procedure|Surgery|Patients who undergo spinal surgery for degenerative spinal disease
46022176|NCT01241591|Drug|CP 690,550 5 mg|CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
46022177|NCT01241591|Drug|CP 690,550 10 mg|CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
46022178|NCT01241591|Biological|Etanercept 50 mg|Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks
46022179|NCT01241591|Other|Placebo|Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.
46022180|NCT05463679|Drug|Enzastaurin|500 mg QD orally in the form of four 125 mg tablets with background standard of care
46022181|NCT05463679|Drug|Placebo|Placebo to match enzastaurin 500 mg QD orally in the form of four 125 mg tablets with background standard of care
46022182|NCT02513251|Other|Chronic pain|Chronic pain patients would complete the Traditional Chinese-Cantonese version of Short Form McGill Pain Questionnaire
46022183|NCT05456503|Drug|FPI-2620|Radiotracer
46022184|NCT03464461|Drug|Ketorolac|IV drug
46022185|NCT05332171|Behavioral|Pyhsiohterapy and rehabilitation|Before starting the exercise program, 10 repetitive warm-up exercises will be given including the lower and upper extremities and distal joints. The exercises will be started with 5 repetitions in the first week. Depending on the patient's tolerance, the intensity of the exercise will be increased as 10 repetitions, 15 repetitions and 20 repetitions, and optional rest will be allowed between exercises. It is aimed that the patients reach 20 repetitions in the 6th week at the latest.
45598539|NCT02348229|Procedure|ERAS protocols|No nasogastric placement; if used, remove on the 1st postoperative day
45598540|NCT02348229|Procedure|ERAS protocols|Vasoactive drugs used if need be
45598541|NCT02348229|Procedure|ERAS protocols|Temperature management
45598542|NCT02348229|Procedure|ERAS protocols|Intra-abdominal drains not to be used
45598543|NCT02348229|Procedure|ERAS protocols|Intraperitoneal Ropivicaine infusion
45598544|NCT02348229|Procedure|ERAS protocols|"On the 1st postoperative day Nasogastric catheter removed /Urinary catheter removed.~Oral non-opioid analgesia/Drinking 0.5L liquid. Active mobilisation"
45598545|NCT02348229|Procedure|ERAS protocols|On the 2nd postoperative day：Drains removed Oral diet was initiated
45598546|NCT02348229|Procedure|ERAS protocols|3-4th postoperative day： Stop oral non opioid analgesia
45598547|NCT02348229|Procedure|ERAS protocols|On the5-6th postoperative day Check discharge criteria
46022186|NCT03315247|Behavioral|Telephone-Based CBT|The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks at regular time intervals and recording consumption using food records, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and reducing vulnerability to overeating by solving problems and challenging negative thoughts. Participants are expected to complete CBT homework between sessions, such as completing food records, engaging in pleasurable and self-care activities, and completing a variety of worksheets.
46022187|NCT04319705|Drug|Azithromycin|Azithromycin, 500mg, 3 times per week, 12-week treatment period, administered orally
46022188|NCT04319705|Drug|Placebo oral tablet|capsule containing placebo, 3 times per week, 12-week treatment period, administered orally
46022189|NCT04319393|Behavioral|Cognitive Behavioral Therapy|"The CBT intervention was carried out through six two-hour sessions over a month. The intervention group was divided into three subgroups of 18 to 19 nurses each. It was required for each subgroup to attend two CBT sessions to complete the intervention.~The CB therapist followed the same structure in the delivery of each CBT session. The CBT session was delivered in five modules: generating objectives and outcomes, enhancing self-esteem and interpersonal relationships, changing beliefs regarding symbolic mortality, and changing attitudes regarding death anxiety. The first session began with highlighting the objectives of the CBT. Then, a detailed presentation of the intervention modules was provided to the nurses with integration of CBT exercises, including cognitive restructuring, graded exposure, mindfulness meditation, interpersonal skills training, and activity scheduling"
46022190|NCT04319315|Other|survey|online survey
46022191|NCT00906373|Biological|IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)|intravenous infusions 10 mg/kg on Day 1 of each 3-week cycle
46022192|NCT00906373|Biological|IMC-A12 (cixutumumab) - 20 mg/kg|intravenous infusions 20 mg/kg on Day 1 of each 3-week cycle
46022193|NCT00906373|Drug|Sorafenib|400 milligrams (mg) twice per day orally
46022194|NCT02850445|Drug|Olanzapine|All patients with schizophrenia were under medication treatment at the baseline. Individualized plan of antipsychotic medication for the patients were determined by psychiatrist who were blind to the group allocation. Medications could be changed at any time during the course of the study if the change was clinically warranted, the drug can also be any other antipsychotic medication.
46022195|NCT02850445|Other|Cognitive behavior therapy|Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Cognitive behavioral therapy.
46022196|NCT02850445|Other|Rehabilitation treatment|Rehabilitation treatment include three modules: medication management, symptom management, and social kill training. Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Rehabilitation treatment therapy.
46022197|NCT02850445|Other|Case management|Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Case management.
46022198|NCT04220203|Drug|Tucatinib|300 mg orally two times per day
46022199|NCT04220203|Drug|Capecitabine|1000 mg/m^2 orally two times per day on Days 1-14 of each 21-day cycle
46022200|NCT04220203|Drug|Trastuzumab|Loading dose of 8 mg/kg into the vein (IV; intravenously), followed by 6 mg/kg IV once per 21-day cycle
46022201|NCT02850211|Drug|Celecoxib|1 capsule of 200mg Celebrex PO(per oral) twice a day for 14 days
46022202|NCT02850211|Drug|Ibuprofen|1 tablet of 385mg Ibuprofen PO(per oral) twice a day for 14 days
46022203|NCT02850211|Drug|Tramadol|1 tablet of 50mg Tramadol PO(per oral) twice a day for 14 days
46022204|NCT02850289|Drug|Pegylated interferon (PEG-INF) alfa-2a|Pegylated interferon (PEG-IFN) alfa-2a will be administered as per investigator's discretion and will be in line with the current product monograph.
46022205|NCT02850289|Drug|Ribavirin|Ribavirin will be administered as per investigator's discretion and will be in line with the current product monograph.
46022206|NCT02393521|Device|Shindo® vibration mattress|vibration therapy was self-administered while the subject was laying in supine in a polyurethane mattress
46022207|NCT05176171|Procedure|Photorefractive Keratectomy with Corneal Cross-Linking|To our knowledge, this study is one of the first to compare the visual results of non-topography-guided and topography-guided photorefractive keratectomy (PRK) applying sequential and simultaneous corneal cross-linking (CXL) treatment for keratoconus. Considering recent advances in cross-linking and imaging in keratoconus, the outcomes of this study can lead us to several non-invasive algorithm management options.
46022208|NCT04984057|Drug|PS is stopped when the pressure is equal between bPDA and aPDA.|PS is given and stopped when the pressure is equal between bPDA and aPDA. the pressure is measured using ultrasound
46022209|NCT04984057|Drug|PS is given according to the 2019 European RDS management guideline|PS is given according to the 2019 European RDS management guideline
46022210|NCT05331781|Procedure|Ultrasound-Guided Transversus Abdominis Plane Block|patient in the supine position, ultrasound will be used to identify the plane between the internal oblique and transversus abdominis muscle to inject 20 ml of local anesthetic for each side
46022211|NCT05331781|Drug|Morphine|intrathecal 150 microgram morphine in a 0.5 ml volume will be added to bupivacaine as an adjuvant to spinal anesthesia
46022212|NCT04202887|Drug|Low Dose Fentanyl|10ml bolus: bupivacaine 0.1% + 25mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 1mcg/ml
46022213|NCT04202887|Drug|High Dose Fentanyl|10ml bolus: bupivacaine 0.1% + 100mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 2mcg/ml
46107816|NCT00759226|Drug|Folinic Acid|Folinic Acid 200 mg/m2 (30 min)
46107817|NCT00672646|Drug|AZD1386|95mg, oral solution, single dose
46107818|NCT00672646|Drug|Naproxen|500mg, capsule, single dose
46107819|NCT00672646|Drug|Placebo|AZD1386 Placebo oral solution
46107820|NCT04048798|Other|Oxygen therapy via HFNC|Oxygen treatment will be applied to the patients via HFNC before and after surgery
46107821|NCT04048798|Other|Oxygen therapy via face mask|Oxygen treatment will be applied to the patients via face mask before and after surgery
46107822|NCT00764530|Device|Alumina/Alumina|CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell
45838286|NCT04065438|Device|LIPOSORBER® LA-15|"LIPOSORBER® LA-15 is a blood purification therapy; selectively removes apoprotein B-containing lipoproteins such as LDL from circulating blood and rapidly reduces the plasma cholesterol level. It was originally developed for prevention of coronary atherosclerosis progression in patients with serious hyperlipidemia such as familial hypercholesterolemia.~In the late 1980's, LDL-A was used to improve dyslipidemia in Nephrotic Syndrome, initially to prevent organ damage. LDL-A was found to improve both the dyslipidemic condition and clinical symptoms (proteinuria and hypoproteinemia)."
45838287|NCT04006119|Biological|Ad-RTS-hIL-12|"intratumoral injection of Ad-RTS-hIL-12~2.0 x 10^11 viral particles (vp) per injection"
46107823|NCT00764530|Device|Standard|Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head
45838288|NCT04006119|Drug|Veledimex|20mg/day 15 oral daily doses of veledimex
45468649|NCT03633149|Behavioral|Person-delivered C4H|Two session CHOICES intervention targeting ineffective contraception and risky alcohol use and/or cigarette smoking and/or marijuana use to reduce the risk of a substance-exposed pregnancy delivered by a counselor.
45468650|NCT03633149|Behavioral|Brief Advice|Brief advice delivered by a research associate about healthy behaviors for women including use of contraception and alcohol, tobacco, and marijuana use
45468651|NCT05206513|Drug|Placebo|Capsule, administered once daily orally or via gastrostomy tube
46107824|NCT00764998|Biological|Fluviral|
45468652|NCT05206513|Drug|Valbenazine|Capsule, administered once daily orally or via gastrostomy tube
45468653|NCT05451667|Drug|YJ001 for Spray Use|YJ001 (active ingredient)
45468654|NCT05451667|Drug|Placebo of YJ001 for Spray Use|Hydroxypropyl Methylcellulose
45468655|NCT03301415|Drug|Valganciclovir|Valganciclovir, 16 mg/kg/dose given orally twice daily for four months
45468656|NCT03778801|Diagnostic Test|fibromyalgia syndrome and chronic neck pain|We assessed pain intensity, kinesiophobia, fatigue, depression, physical activity level and disability in patients with fibromyalgia syndrome and chronic neck pain, and healthy individuals in this cross-sectional study.
45468657|NCT05196919|Biological|XT-150|XT-150 is a plasmid Deoxyribonucleic acid (DNA) formulated in buffered, D mannose saline solution.
45468658|NCT05196919|Biological|Placebo|Phosphate-buffered saline for injection
45468659|NCT01145963|Other|Control pasta|control pasta
45681369|NCT02703688|Other|Usual Care|A pediatrician with experience delivering weight management treatment to children will deliver a single session, 1-hour treatment to families. Content to be delivered during the session will include lifestyle recommendations currently recommended by the AAP.
45681370|NCT04190758|Other|Care as usual|No intervention will be given. The study will follow the effects of care as usual.
45681371|NCT04023448|Procedure|transverse coloplasty pouch|a transverse coloplasty pouch was performed before end to end colon-rectum (or anal canal) anastomosis
45681372|NCT04022902|Other|No intervention|This is an exploratory qualitative study to understand the needs of patients with pneumoconiosis, and the care-giving experience of their family caregivers.
45681373|NCT02704312|Radiation|Radiotherapy by Prone and decubitus|Dosimetric comparison of doses in target volumes and organs at risk
45838289|NCT04006119|Drug|Cemiplimab-Rwlc|Infusion every 3 weeks (350mg)
45838290|NCT04004793|Behavioral|Intensive lifestyle intervention|Participants were will be asked to follow a weight management programme, in accordance with the American Diabetes Association guidelines. Weight loss will be induced with a diet replacement phase using an energy restriction diet (energy deficit by 500~750 kcal/day) for 3 months, with <35% as fat, >15% as protein. The minimum energy intake is 1200kcal/day for men and 1000kcal/day for women.. Additionally, participants were encouraged to increase physical exercise (≥150 minutes of brisk walking every week or ≥10000 steps per day).
45681374|NCT02080546|Procedure|Cut-Coag|"Incision using electrothermal cautery, with an attempt made to use the cut (continuous low-voltage, high-current) for colpotomy incision following the initial scoring of the cervico-vaginal tissue on the coag (pulsed high-voltage, low-current) mode."
45838291|NCT04004793|Drug|Dapagliflozin 10 MG Oral Tablet|The treatment of Dapagliflozin (Forxiga®) will be initiated and maintained at 10mg every morning until the completion of the study.
45838292|NCT04004793|Drug|Placebo Oral Tablet|The treatment of placebo will be initiated and maintained at 10mg every morning until the completion of the study.
45838293|NCT04002180|Drug|Vedolizumab (Genetical Recombination)|Vedolizumab IV infusion
45838294|NCT04002011|Drug|Warfarin|It will be started on postoperative day 1 or later when oral anticoagulation is secondary indicated. Daily dose will be adapted to obtain an international normalized ratio of [2.0-3.0]. Other anticoagulants will be not administrated.
45838295|NCT04002011|Drug|Dabigatran|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
46107825|NCT00759460|Drug|Sertindole|12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
46107826|NCT00759460|Drug|Olanzapine|10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
46107827|NCT00765154|Drug|darunavir|two 400mg tablets (800mg) once daily
46107828|NCT00765154|Drug|ritonavir|one 100mg capsule once daily
46107829|NCT00759616|Device|Oxford Partial Knee|Oxford Partial Knee
46107830|NCT00764686|Other|Exercise and Education|One hydrotherapy class, one land-exercise class and one education session daily, for five days. Each exercise class and education session is one hour in duration.
46107831|NCT00764686|Other|Exercise and Education|Two hydrotherapy classes, one land-exercise class and one education session daily, for five days. Each exercise class and education are one hour in duration.
46107832|NCT00764764|Procedure|shoulder treatment|shoulder exercise, joint mobilization, home program, posture
46107833|NCT00764764|Procedure|Shoulder AND cervical treatment|Cervical and shoulder joint mobilization, exercise, posture, and home program
46022214|NCT04202887|Device|Gastric Ultrasonography|"The Gastric US will be performed using a portable device with an abdominal probe by the same operator (EF) for all women. The Cross Sectional Area (CSA) of the antrum will be measured in the supine position with the head elevated 45 degrees. CSA will be calculated using the formula (AP x CC x pi)/4, where AC is the anterio-posterior diameter and CC the cranio-caudal diameter. Three consecutive measurements will be performed and the average of the three will be used as the final data. The cutoff used to define a full stomach will be a CSA above 381 mm2, which has been validated in previous studies on laboring woman. Gastric US will be performed immediately after verification of effective epidural analgesia (T0) and intrapartum, two hours after the first measurement (T2h), corresponding to a cumulative dose of 37-97mcg fentanyl in Group LF and 124-240mcg fentanyl in Group HF."
46107834|NCT00672490|Drug|Quetiapine Fumarate|"Oral treatment, twice daily. 100 mg/day at Day 1, 200 mg/day at Day 2, 300 mg/day at Day 3, 400 mg/day at Day 4, from 400 mg/day to 600 mg/day before Day 8, from 600 mg/day to 800 thereafter, judged by the investigator.~Tablets"
46107835|NCT00672490|Drug|Lithium|Oral treatment, twice daily. 250 mg/day to 2000mg/day from Day1 to Day 7, 500mg/day to 2000mg/day thereafter, judged by the investigator.
46107836|NCT04048096|Dietary Supplement|Krill Oil|Aker Biomarine Superba Krill Oil
45838296|NCT04002011|Drug|Rivaroxaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
46107837|NCT04048096|Dietary Supplement|Placebo|Mixed vegetable oil
46022215|NCT05331703|Other|designed physical therapy program in addition to program of virtual reality.|physical therapy program in addition to program of virtual reality.
46022216|NCT05331703|Other|designed physical therapy program in addition to program of mirror therapy.|physical therapy program in addition to program of mirror therapy.
46022217|NCT02850367|Dietary Supplement|Nitrate|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
46022218|NCT02850367|Dietary Supplement|Nitrate and L-Arginine|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
46022219|NCT02850367|Dietary Supplement|Nitrate and L-Citrulline|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
46107838|NCT00770302|Drug|Saxagliptin|Oral tablet, once daily for 1 (single-dose) and 5 (multiple-dose) days
46107839|NCT00922012|Device|Electromagnetic Stimulation Therapy|Electromagnetic Stimulation Therapy for 24 weeks
46107840|NCT00759850|Device|Drug Eluting Stent (DES)|Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met. All patients received in the CCU 70U/Kg i.v. bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose). All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI. Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months). Stenting procedures were performed according to standard techniques. The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion. The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.
46107841|NCT02557984|Drug|Placebo|Placebo Pill
46107842|NCT02557984|Drug|Amisulpride|400 mg Amisulpride
45838297|NCT04002011|Drug|Apixaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
45838298|NCT04002011|Drug|Edoxaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
46022220|NCT02850367|Dietary Supplement|Placebo|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with a placebo.
46022221|NCT02850367|Biological|Evaluation of post-ischemic vascular reactivity|After the intake of the supplement. Concentration of hemoglobin (g/mL) in the quadriceps with the device : NIRS system Oxymon, ARTINIS.
46022222|NCT02850367|Biological|Neuromuscular evaluations|After the intake of the supplement. Measure the stretching force in the ankle (N)
46107843|NCT02557984|Drug|Naltrexone|50 mg Naltrexone
46107844|NCT00765466|Drug|AVR118|daily doses of 4.0 mL AVR118 subcutaneously
46107845|NCT00759928|Drug|Erlotinib|150 mg once daily by mouth
46107846|NCT00759928|Drug|Sorafenib|400 mg twice daily by mouth
46107847|NCT00670930|Drug|omalizumab at a dose of 0.016mg/kg/IU/mL|
46107848|NCT00670930|Drug|Placebo|
46107849|NCT00670540|Other|procedure of Deep Vein Thrombosis (DVT) and PE (Pulmonary Embolism) diagnosis|patients with a clinical suspicion of Venous ThromboEmbolism (VTE = Deep Vein Thrombosis or Pulmonary Embolism) were eligible
46107850|NCT00591786|Drug|Sugammadex|After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered.
46107851|NCT00770536|Drug|A1: AMG 386 10 mg/kg + Liposomal doxorubicin|Liposomal doxorubicin 50 mg/m2 IV Q4W in combination with AMG 386 10 mg/kg IV QW
46022223|NCT02850523|Other|Cognitive Behavioural Therapy for Perinatal Anxiety|The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population.
46107852|NCT00770536|Drug|A3: AMG 386 15mg/kg + Liposomal doxorubicin|A3: AMG 386 15 mg/kg IV QW + Liposomal doxorubicin 50 mg/m2 IV Q4W
46022224|NCT05117203|Device|WB-EMS (Whole body electrostimulation)|Application of physical exercise and electrical stimulation on the abdominal muscles through the WB-EMS during 20 minutes training session with specific exercise (CORE)
46022225|NCT05117203|Device|EMS|Application of physical exercise and electrical stimulation on the abdominal muscles through the EMS during 20 minutes training session with specific exercise (CORE)
46107853|NCT00770536|Drug|B1: AMG 386 10 mg/kg + Topotecan|B1: AMG 386 10 mg/kg IV QW + Topotecan 4 mg/m2 IV days 1, 8, 15, of a 28 day dosing schedule
46022226|NCT05117203|Device|WB-EMS off|Application of physical exercise without electrical stimulation on the abdominal muscles through the WB-EMS off during a 20 minutes training session with specific exercise (CORE).
46107854|NCT00770536|Drug|B3: AMG 386 15mg/kg + Topotecan|AMG 386 15mg/kg IV QW + Topotecan 4mg/m2 IV days 1, 8, 15 of a 28 day dosing schedule
46022227|NCT05324215|Procedure|Transversalis fascia plane block and rectus sheath block|Transversalis fascia plane block and rectus sheath block will be administered after the surgery.
46022228|NCT05324215|Device|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
45468660|NCT01145963|Other|Experimental pasta B|experimental pasta
45468661|NCT01145963|Other|Experimental pasta C|experimental pasta
45468662|NCT05449015|Drug|1% atropine|Daily application can be used for mydriasis and refraction examination Weekly long-term application can be used to control myopia
46107855|NCT00770614|Drug|sodium bicarbonate solution|154 mEq/L in dextrose and H2O
46107856|NCT00770614|Drug|Isotonic saline|0.9% sodium chloride
46107857|NCT00770614|Drug|Placebo|Placebo
46107858|NCT00765544|Device|Anklebot|The Ankle-Bot (Wheeler et al., 2004) is a stand-alone robot assisted device that is worn via a leather boot and knee brace (Fig.1). The Ankle-Bot can assist ankle movement throughout 3 planes. The percentage of force generated by the Ankle-Bot can be adjusted from no help, 0% assistance to 100% assistance. The device is low impedance and a subject can easily over come the forces generated by the Ankle-Bot. The Ankle-Bot will guide and assist the subject into ankle flexion, extension, inversion and eversion.
46107859|NCT00765544|Device|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill .
46107860|NCT04048174|Other|Topical probiotic treatment with Lactococcus lactis W136|Nasal and sinus irrigation with reconstituted live probiotic bacteria
45468663|NCT03510689|Diagnostic Test|echocardiography|Resting echocardiograms (Vivid E9 or E95, GE Healthcare) with conventional measures of systolic and diastolic function, in conjunction with posthoc quantitation of novel measures of strain and strain rate will be obtained at each study time point.
45468664|NCT03510689|Other|Cardiopulmonary Exercise Testing|A cardiopulmonary exercise test (CPET, also called V02 test) will be completed at each study time point utilizing a standard clinical protocol, on either a stationary bike or treadmill. The purpose of this test is to estimate maximal oxygen consumption (V02 max) as in index of cardiopulmonary fitness. Resting ECG, heart rate, and BP will be obtained prior to beginning the test, during each stage of the test and for 5 minutes after the test is stopped.
45468665|NCT03510689|Other|Blood Collection|We will obtain blood samples (approximately 16mL) at baseline and (approximately 12mL) at each follow-up visit. Typically these will be drawn via peripheral venipuncture, however if patients have a port-a-cath in place, blood may be drawn from the port instead.
45468666|NCT04883983|Drug|Open Label Placebo|Pain medication will be prescribed per standard treatment for initial prescription. Pain medication request at followup will be filled with open label placebo. Pain assessment surveys will be used at 2, 6, and 12 week followups.
45468667|NCT04883983|Drug|Patient medication as standardly prescribed|Pain medication will be prescribed per standard treatment for initial prescription. On request for additional pain medication, pain medication will be prescribed as per the standard protocol. Pain assessment surveys will be used at 2, 6, and 12 week followups.
45468668|NCT01238939|Drug|NK012 and 5-FU|NK012 infusion on Day 1 of each 28 day cycle 5-FU continuous infusion on Days 1 and 15 of each 28 day cycle
45468669|NCT01320163|Device|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
46107861|NCT04048174|Other|Saline irrigation|Nasal and sinus irrigation with saline solution
46107862|NCT00770926|Behavioral|Live Well, Be Well|Lifestyle change program using personal contact and telephone counseling
46107863|NCT00771004|Drug|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily for one week; increased to Pioglitazone 45 mg, tablets, orally, once daily for up to two weeks.
46107864|NCT00771004|Drug|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to three weeks.
46107865|NCT00674362|Biological|Certolizumab pegol|Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
45468670|NCT01320163|Device|Laryngeal Mask Airway|supra-glottic airway device
46107866|NCT00674362|Biological|Placebo|Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
45468671|NCT01146743|Procedure|EUS-guided gallbladder drainage|EUS-guided gallbladder drainage was performed with a linear-array echoendoscope. The initial puncture was performed at the antrum of the stomach or bulb of the duodenum and was chosen to access the gallbladder body or neck and avoid visible vessels. After removal of the needle, a 6F or 7F bougie were inserted and then removed to dilate the tract. Afterward, nasobiliary drainage tube or stent was placed.
45468672|NCT01146743|Procedure|percutaneous transhepatic gallbladder drainage|Under ultrasound guidance, needle punctured to gallbladder via percutaneous transhepatic route.
46107867|NCT00820950|Drug|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 0.5%
46107868|NCT00820950|Drug|Dovonex® calcipotriene 0.005%|Cream applied once or twice daily for up to 56 days.
46107869|NCT00820950|Drug|Diprolene® AF betamethasone dipropionate 0.05% cream.|Cream applied once or twice daily for up to 56 days
46107870|NCT00820950|Drug|Placebo cream|Cream applied once or twice daily for 56 days
45468673|NCT03778879|Drug|CCX872-B|CCX872-B concurrent with stereotactic body radiation therapy for pancreatic adenocarcinoma.
45468674|NCT01239017|Biological|REGN475|
45468675|NCT01239017|Other|Placebo|
45468676|NCT02732938|Drug|PF-04136309|PF-04136309 oral dosing
45468677|NCT02732938|Drug|Nab-paclitaxel|Nab-paclitaxel IV dosing
45468678|NCT02732938|Drug|Gemcitabine|Gemcitabine IV dosing
46022229|NCT05317819|Drug|ADI-PEG20|Treatment for hepatocellular carcinoma
46022230|NCT05317819|Other|Placebo|Treatment for hepatocellular carcinoma
46022231|NCT05118295|Device|SAVI Scout®|Savi Scout marker is placed within 1 cm of the breast tumor
45681375|NCT02080546|Procedure|V-mode|"Incision using electrothermal cautery in the V mode. The V mode combines real-time tissue sensing technology with the cut and coag waveforms to reduce the amount of thermal spread to the tissue without sacrificing hemostasis during monopolar electrothermal procedures."
46022232|NCT05070559|Other|Active Release Technique|"Patients in this group will receive Active Release Technique along with conventional therapy. ART will be given with patient seated, elbow flexed and resting on the treatment table, forearm in midprone & wrist in neutral position and then the therapist will work on the common extensor tendon by applying pressure to the tendon distal to their attachment at the elbow. The patient will start with the elbow bent and wrist straight. As the therapist hold the muscles, the patient will extend the elbow and pronate and flex the wrist while the therapist move the pressure proximally, attempting to release adhesions around and between muscle planes. Total of 15 repetitions for of 10 minutes.~CONVENTIONAL THERAPY:~Hot pack for 15 minutes~TENS for 15 minutes~Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)"
46022233|NCT05070559|Other|Graston Technique Group|"Patients in this group will receive IASTM along with conventional therapy. In graston technique proper application of GT3 which include application of a cream to the common extensor tendon. The GT3will be then used to common extensor tendon. In areas of increased tissue restriction, more required pressure with GT3 is applied using increased force and shorter strokes over the areas of restriction. Ice will be offered as needed for pain management after each session.~The study includes interventional protocol of 4 weeks. The sessions will be given 3 times a week for 4 weeks.~CONVENTIONAL THERAPY:~Hot pack for 15 minutes~TENS for 15 minutes~Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)"
46022234|NCT02850133|Other|aerobic exercise training|aerobic exercise training for 36 sessions within 12-16 weeks
46022235|NCT04202419|Device|FRAX 1940 nm laser|A fractional 1940 nm solid-state diode laser will deliver linear arrays of microbeams to create nonablative microscopic treatment zones (MTZs) in the skin, in order to treat pigmented skin lesions.
46022236|NCT02849821|Other|hypobaric pressure chamber|hypobaric chamber: ascent within 10 minutes, 3 hour exposure to hypoxic conditions simulating an altitude of 4,000 m.a.s.l., afterwards controlled descent under continuous pulsoximetric control
46107871|NCT00820950|Drug|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 1.0%
46107872|NCT00820950|Drug|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 1.5%
46107873|NCT00765934|Drug|Rapydan|lidocaine / tetracaine 70/70 mg patch
45468679|NCT03775447|Procedure|Lumbar Puncture|Lumbar Puncture for collection of Cerebrospinal Fluids
45468680|NCT03773029|Dietary Supplement|soy isoflavone|100 mg soy isoflavone (as 2 capsules)
45468681|NCT03773029|Other|placebo|2 capsules of placebo
45468682|NCT03160859|Other|Control|Unsedated colonoscopy with water exchange (WE) where the residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water is removed predominantly during insertion.
45468683|NCT03160859|Device|Study method|Unsedated colonoscopy with water exchange (WE + cap) and the addition of a cap fitted to the colonoscope.
45681376|NCT02080546|Device|Valleylab G3000 Electrosurgical Device|Use of surgical device Valleylab G3000 Electrosurgical Device
46107874|NCT04049344|Drug|Decitabine; Oxaliplatin|Patients receive Decitabine 10 mg/day for 5 consecutive days (d1-5) plus Oxaliplatin 75mg/m2 2-week-cycle (d6, d20) within 4 weeks. One cycle is defined as 4 weeks of treatment and total of 6 cycles are designed for patients.
46107875|NCT00709176|Behavioral|Brief FOCUS Program|Dyads randomized to this arm received the FOCUS Brief Program, two home visits and one phone call by a trained nurse.
46107876|NCT00709176|Behavioral|Extensive FOCUS Program|Dyads randomized to this arm received the FOCUS Extensive Program, 4 home visits and two phone calls by a trained nurse.
46107877|NCT00670306|Drug|Cetrorelix Pamoate|Cetrorelix Pamoate IM, 52 mg week 0, 26 mg week 2,
45681377|NCT04022824|Other|OSA|Patients with OSA (apnea hypopnea index ≥15) based on sleep study
45681378|NCT04022824|Other|Non-OSA|Patients without OSA (apnea hypopnea index <15) based on sleep study
45681379|NCT03023254|Other|Hydrotherapy|3-week Avène hydrotherapy
45681380|NCT03022240|Drug|Propofol|The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)
45468684|NCT03775135|Other|Questionnaires|Different questionnaires about identity development and psychosocial functioning will be administered
45468685|NCT01146821|Dietary Supplement|0.20 gm/kg fish oil|Group 2: 7 patients will receive 0.20gm/kg of ideal body weight [IBW] fish oil in addition to standard care
45468686|NCT01146821|Dietary Supplement|0.50 gm/kg fish oil|Group 3: 7 patients will receive 0.50 gm/kg of ideal body weight [IBW] fish oil in addition to standard care.
46107878|NCT00703248|Procedure|Osteopathic Manipulative Treatments|"opening the thoracic inlet~pectoral traction for 1 minute bilaterally~rib raising for a total of 4 minutes- 2 minutes on each side of the thoracic spine ]~thoracic pump at a rate of 60 times per minute for a total of 5 minutes bilaterally~abdominal pump at a rate of 30 times per minute for a total of 5 minutes bilaterally."
46107879|NCT00709254|Drug|i.v. fentanyl|single dose, 200 ug
46107880|NCT00709254|Drug|3 mL AeroLEF (500 µg/1 mL)|A single dose of 3mL (500 µg/1 mL) of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)
46022237|NCT02849821|Other|Sigmoidoscopy|To retrieve biopsies from the colon during the course of the study 3 sigmoidoscopies were performed. The first sigmoidoscopy was performed 1 day before the stay in the hypobaric chamber. The second sigmoidoscopy was performed directly after the hypobaric chamber and the third sigmoidoscopy was performed 1 week after the hypobaric chamber. During each sigmoidoscopy 6 biopsies were taken with standard size forceps (2.4 mm). One biopsy was analysed by real-time quantitative polymerase chain reaction (PCR), one biopsy was analysed by Western blotting and another biopsy was analysed for gene gene-expression by in situ hybridisation. Two biopsies were analysed by immunohistochemistry (IHC) and one biopsy was stained with hematoxylin and eosin (H&E).
45468687|NCT03778723|Drug|Total intravenous anesthesia (TIVA)|Propofol (1.5-2 mg/kg/h) infusion, Midazolam (0.12 mg/kg/h) infusion
45681381|NCT03022240|Drug|Sevoflurane|The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)
46022238|NCT04202575|Procedure|Tube clamping|Clamping of the tube between the additional and standard venous reservoir
45468688|NCT03778723|Drug|Inhalation Anesthesia|Sevoflurane at a concentration of 2-2.5%
46022239|NCT02155933|Other|Blood sampling|Blood sampling for later hormone measurements
46022240|NCT00905437|Drug|Placebo|Placebo as an adjunct to standard of care
46022241|NCT00905437|Drug|Pregabalin|75 mg BD for 14 days
46022242|NCT05081947|Behavioral|COMPASS|COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). An example of the patient login page can be viewed here: www.compass-southwark.co.uk. COMPASS aims to support people in managing the challenges of living with a long-term condition. COMPASS is based on research which shows the benefit of combining mental and physical healthcare. The proposed COMPASS program consists of 11 online sessions for patients to work through over approximately 12 weeks. The sessions can be worked through in any order the patient would like. The sessions are split into four quadrants - North, East, South and West - which explore different elements of managing the LTC challenges that were identified from the evidence-based systematic review. Sessions contain information, interactive tasks, goal setting and patient stories.
46107881|NCT00709254|Drug|3 mL AeroLEF (500 µg/1 mL)|A multiple doses of 3mL (500 µg/1 mL)of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)every 12 hours for a total of five doses over a 3 days
45468689|NCT03778723|Drug|Rescue fentanyl|Fentanyl in repeated doses (50 µg) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value) are used for maintenance of analgesia
45468690|NCT03436030|Other|Simple breathing manuevers during brief echocardiographic imaging|Valsalva, Muller, light mask CPAP, leg raising, hand grip.
45468691|NCT01245959|Drug|Docetaxel, cisplatin and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
45468692|NCT01245959|Radiation|Concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
46022243|NCT04219111|Genetic|Clariom|Clariom S Assay
46022244|NCT05007691|Device|Occlusal splint|Occlusal splints are hard, made of polymer biocompatible material using digital additive technology.
46022245|NCT01238861|Biological|Benralizumab 2 mg|EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.
45681382|NCT03022240|Drug|Ametop|Each patient will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to induction.
46022246|NCT01238861|Biological|Benralizumab 20 mg|EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.
46107882|NCT00766012|Drug|AZD2066|Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16. Specific dose depends on dose panel.
45681383|NCT03022240|Drug|Ondansetron|Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
45681384|NCT02701738|Dietary Supplement|Overeating Protocol|Subjects will ingest 30% more calories per day than their calculated daily energy requirements (~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
46022247|NCT01238861|Biological|Benralizumab 100 mg|EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.
46107883|NCT00766012|Drug|Placebo|Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16.
46107884|NCT04048018|Diagnostic Test|Blood draw and IGRA test|One to two blood samples will be obtained from participants in all arms in order to conduct testing.
46107885|NCT02558608|Procedure|DIPL|dissection of the inferior pulmonary ligament
46022248|NCT01238861|Other|Placebo|EOS+ and EOS- participants received two placebo injections subcutaneously.
46107886|NCT02558608|Procedure|WR|wedge resection of the lung bleb
46107887|NCT02558608|Procedure|thoracoscopic surgery|surgery performed by video assisted thoracoscopy
46022249|NCT02888561|Drug|Dobutamine|Dobutamine will be infused at the time of coronary angiography while coronary and LV haemodynamics are measured using a Combowire (dual pressure and flow sensor tip guide wire) and left ventricular conductance catheter.
46107888|NCT00672256|Behavioral|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
46107889|NCT02558686|Other|Eccentric Exercise|Individuals will perform 3 sets of 10 repetitions of eccentric exercise of the infraspinatus muscle after the application of trigger point dry needling
46107890|NCT02558686|Other|Detuned Ultrasound|Individuals will received 10 minutes of detuned ultrasound on the infraspinatus muscle after the application of trigger point dry needling
46107891|NCT02558686|Other|Placebo|Individuals will not perform any action after the application of trigger point dry needling
46022250|NCT02888561|Drug|Nitrite|Nitrite will be infused at the time of coronary angiography while coronary and LV haemodynamics are measured using a Combowire (dual pressure and flow sensor tip guide wire) and left ventricular conductance catheter.
46107892|NCT00760318|Drug|Keppra|There will be flexible dose titration increasing by 250 mg per week for 12 weeks to a maximum of 3000 mg divided BID.
46107893|NCT00591630|Drug|Zevalin|(111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.
46107894|NCT00591630|Drug|Carmustine|300 mg/m^2 by vein.
46107895|NCT00591630|Drug|Etoposide|200 mg/m^2 by vein every 12 hours.
46107896|NCT00591630|Drug|Cytarabine|200 mg/m^2 by vein every 12 hours.
46107897|NCT00591630|Drug|Melphalan|140 mg/m^2 by vein.
46107898|NCT00591630|Drug|Rituximab|"Arm 1, Arm 2 = 250 mg/m^2 by vein;~Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;~Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy."
46107899|NCT00591630|Procedure|Stem Cell Transplant|Injection of stem cells (Autologous SCT)
46107900|NCT00766168|Other|HDS HI 1.54; pahrifocon A|Contact Lens
46107901|NCT00766168|Device|FluoroPerm 30 RGP; paflufocon C|Contact lens daily wear
46107902|NCT02557828|Procedure|arterial line placement|radial arterial cannulation placed via palpation or ultrasound technique
46107903|NCT00760396|Drug|VGX-1027|Subjects will
46107904|NCT00760630|Device|FFR/CFR and IVUS|All patients with clinical indication for cardiac cath will have FFR and IVUS
46107905|NCT00771394|Drug|Tamsulosin hydrochloride|oral
46107906|NCT00771394|Drug|Solifenacin succinate|oral
46107907|NCT00670228|Drug|Insulin Glargine (LANTUS)|Subcutaneous insulin glargine was initiated 90 prior to the insulin glulisine infusion discontinuation (i.e. 48 hours after randomization) and titrated as per physician preference to maintain the plasma glucose between 90-130 mg/dL
46107908|NCT00670228|Drug|Insulin Glulisine (Apidra)|"Prior PCI, subjects received a single IV bolus of insulin glulisine. The dose was 0.025 U/kg based upon patient reported weight.~Then IV insulin glulisine infusion was started within one hour of the IV insulin glulisine bolus and administered at a minimum rate of 2 U/h for 48 hours. The infusion was titrated in order to achieve and maintain the plasma glucose between 90 and 130 mg/dL."
46107909|NCT00670228|Drug|Standard Therapy|Standard insulin therapy titrated to blood sugar control
46107910|NCT02557360|Dietary Supplement|S-adenosyl-L-methionine|Patients will be treated with S-adenosyl-L-methionine, tablets 800 mg twice a day (daily dosage 1600 mg) for six months
46022251|NCT04319549|Other|Ketorolac Tromethamine irrigant|Ketorolac tromethamine, a potent NSAID available in both oral and injectable forms, is over 400 times more potent as a selective inhibitor of COX-1 over COX-2 than many other drugs. When ketorolac tromethamine was used as an intracanal medicament in teeth with irreversible pulpitis undergoing root canal treatment, it contributed to significant post operative pain relief.
46022252|NCT04319549|Other|sodium hypochlorite irrigant|NaOCl is the gold standard and the most commonly used root canal irrigant. NaOCl is able to dissolve the organic tissues inside root canal due to its alkalinity (pH11), which causes amino acid degradation and hydrolysis through the production of chloramine molecules. In addition, it possesses highly antibacterial effect and its low cost makes it the most frequently used root canal irrigant. Dual rinse is considered an effective time saving root canal irrigant with a better antibacterial property in comparison to NaOCl alone. In addition to its effectiveness on smear layer removal and reduction in the debris accumulation during root canal instrumentation.
46022253|NCT00903409|Drug|Simvastatin + Lovaza® (omega-3-acid ethyl esters)|Open-label Simvastatin + Lovaza® (omega-3-acid ethyl esters) [formerly known as Omacor]
46107911|NCT00771628|Device|Flex-It Stylet|Patients will be intubated using the GlideScope with an ETT fitted with a Flex-It stylet.
46107912|NCT00771628|Device|Standard malleable stylet|Patients will be intubated using the GlideScope with an ETT fitted with a standard malleable stylet.
46107913|NCT00766246|Drug|bevacizumab|15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance
46107914|NCT00766246|Drug|docetaxel|75 mg/m2 administered in 21-day cycles on day 1 of each cycle for first line treatment
46107915|NCT00766246|Drug|carboplatin|AUC=6 administered in 21-day cycles on day 1 of each cycle for first-line treatment
46022254|NCT02850055|Other|Conventional Physiotherapy|"Leaflet care and health habits of the temporomandibular joint.~Program of cranio-cervical and temporomandibular exercises.~Massage of the cervical muscles and self care document for home."
46022255|NCT02850055|Other|Specific Manual Therapy|"Leaflet care and health habits of the temporomandibular joint.~Program of cranio-cervical and temporomandibular exercises.~Massage of the cervical muscles and self care document for home.~Specific manual therapy techniques focusing on the temporomandibular joint and temporomandibular muscles."
46022256|NCT02849665|Other|Kangaroo Position|
46022257|NCT01237223|Drug|Aliskiren/Amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg tablet
46022258|NCT01237223|Drug|Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg tablet
46022259|NCT01237223|Drug|Aliskiren 150 mg|Aliskiren 150 mg tablet
46107916|NCT00766402|Drug|Tramadol /acetaminophen|Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.
46107917|NCT00766402|Drug|Diclofenac|Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
46107918|NCT00771706|Drug|Proton Pump Inhibitor|The PPI arm will consist of a two week course of PPI at a dose 1mg/kg/dose twice daily (minimum dose: 7.5 mg BID; maximum dose: 30 mg BID)
46107919|NCT00771706|Drug|Placebo|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
46107920|NCT00771862|Procedure|perineural ropivicaine|Subjects will be randomized to one of two groups: ropivicaine 0.2% infusion for days 0-1 then infusion with normal saline (placebo) for days 1 through catheter removal (POD 4 or 5) or ropivicaine 0.4% infusion for day 0 through catheter removal (POD 4 or 5). The infusion rate will be set at 7-11 mL/h.
46107921|NCT00771940|Drug|Ghrelin|Solvent, cont. infusion
46107922|NCT00772096|Drug|n-3 fatty acids|
46107923|NCT00760786|Drug|Intensive lipid lowering plus Omega3-fatty acid|Atorvastatin 40mg qd plus Omega3-fatty acid 2.0mg qd
46107924|NCT00760786|Drug|Moderate lipid lowering plus Omega3-fatty acid|atorvastatin 10mg qd plus Omega3-fatty acid 2.0mg qd
46107925|NCT00760786|Drug|Intensive lipid lowering plus placebo|atorvastatin 40mg qd
46107926|NCT00760786|Drug|Moderate lipid lowering plus placebo|atorvastatin 10mg qd
46107927|NCT00760864|Drug|TAK-715 and methotrexate|TAK-715 25 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
46022260|NCT01237223|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule
46022261|NCT01237223|Drug|Placebo of Aliskiren|Aliskiren placebo tablet
46022262|NCT01237223|Drug|Placebo of Amlodipine|Amlodipine placebo capsule
46022263|NCT01237223|Drug|Placebo of Aliskiren/amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg placebo tablet
46022264|NCT01237223|Drug|Placebo of Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg placebo tablet
46022265|NCT01236755|Device|single-vision glasses|Daily wear of glasses to correct vision in the first seven months of the study
46022266|NCT01236755|Device|ortho-k lenses|Nightly wear of lenses to correct vision in day time in the second seven months of the study
46022267|NCT01236365|Drug|Atorvastatin|10 or 20 mg daily
46022268|NCT01236365|Drug|Atorvastatin Placebo|10 or 20 mg daily
46022269|NCT01235975|Biological|Meningococcal vaccine GSK 134612|Intramuscular injection
46022270|NCT01235975|Biological|MencevaxACWY TM|Subcutaneous injection
46022271|NCT00903331|Drug|ACT-064992 (macitentan)|ACT-064992 (macitentan) tablet, 10 mg, once daily
46022272|NCT00903331|Drug|Placebo|matching placebo, once daily
46022273|NCT02849431|Behavioral|Mindfulness-based intervention|A version of mindfulness-based cognitive therapy that has been adapted for people with a diagnosis of borderline personality disorder. This comprises eight weekly session, each lasting ninety minutes.
46022274|NCT01235741|Drug|Pramlintide+Metreleptin|Group A: Subcutaneous Injection once a day (QD): Pramlintide 360 mcg+Metreleptin 5.0 mg for 1 week followed by Pramlintide 360 mcg+Metreleptin 5.0 mg twice a day (BID) for 15 weeks.
46022275|NCT01235741|Drug|Placebo|Group B: Subcutaneous Injection-twice a day (BID): Placebo equivalent volumes to active doses.
46022276|NCT02849353|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
46107928|NCT00760864|Drug|TAK-715 and methotrexate|TAK-715 50 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
46107929|NCT00760864|Drug|TAK-715 and methotrexate|TAK-715 100 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
46107930|NCT00760864|Drug|Methotrexate|TAK-715 placebo-matching, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks
46022277|NCT02849353|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
46022278|NCT04206527|Behavioral|Training of AHSAs on PCC for FP|ASHAs provided with training on FP methods and counseling plus PCC for FP
46107931|NCT00766480|Drug|cisplatin|Given IV
46022279|NCT04206527|Behavioral|Enhanced FP training|Participation in an enhanced FP training including PCC
46022280|NCT04571827|Other|Dry Needling|"Deep dry needling procedure~All subjects received a deep dry neddling technique on a latent myofascial trigger point of the upper trapezius muscle by isolating it by a pincer grasp with the thumb and index finger. This myofascial trigger point was previously found following the diagnostic criteria described by Travell & Simons and Fernández-de-las-Peñas et al., and the deep dry needling intervention applied was based on the technique described by Hong.~The patients were placed in a prone position. Prior to the technique, the area was disinfected with an antiseptic solution. Fifteen incisions were made with a 0.26x40mm monofilament needle. The number of local twitch response made were noted. After removing the needle, at the end a soft compression was made with a cotton to reduce the possible appearance of bleeding."
46107932|NCT00766480|Drug|fluorouracil|Given IV
46022281|NCT01235507|Drug|methotrexate|stable dose as prescribed
46022282|NCT01235507|Drug|tocilizumab [RoActemra/Actemra]|8 m/kg (maximum 800 mg) intravenously every 4 weeks for a total of 6 infusions
46107933|NCT00766480|Radiation|radiation therapy|Patients undergo radiotherapy
46022283|NCT04708015|Other|No Intervention|A retrospective chart review of medical records
46107934|NCT00772174|Drug|Pioglitazone and Metformin|Pioglitazone 15 mg, tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone 15 mg, tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
46107935|NCT00772174|Drug|Metformin|Pioglitazone placebo-matching tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone placebo-matching tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
46107936|NCT00772252|Other|liver support treatment|plasma exchange for liver support treatment
46107937|NCT00766714|Device|Cook K-SOFT-5100 catheter|A Cook K-SOFT-5100 catheter was used for embryo transfer in human IVF/ICSI
46107938|NCT00766714|Device|Frydman classical catheter|A Frydman classical catheter was used for embryo transfer in human IVF/ICSI
45681385|NCT04022434|Dietary Supplement|Placedo|Subjects will mix the placebo in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
45681386|NCT04022434|Dietary Supplement|Alanine|Subjects will mix the alanine in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
45681387|NCT04196374|Genetic|Genomic Sequencing|Whole Genome Sequencing and reporting of actionable genomic results for genes included on the ACMG secondary findings list.
45681388|NCT04196686|Device|VR/AR|VR/AR headset with either passive or active content such as playing a game or watching a movie
45681389|NCT04196686|Other|Ice Bath|Participants immerse hand in ice bath and starting again with their original assigned group and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
45681390|NCT03957850|Behavioral|Cognitive Reappraisal Training|The training procedure is adapted from a study by Denny & Ochsner (2014). Before the task, participants are instructed that they will be presented pictures and that these pictures will be preceded by a condition specific cue signaling the appropriate strategy during picture viewing. Participants are instructed to indicate their affective response to the image on a rating scale. The task involves 4 conditions: 1) Negative-decrease: participants are asked to view negative pictures and to decrease their affective response by reappraising the negative event. 2) Negative-attend/ 3) Neutral-attend/ 4) Positive-attend: participants are asked to view pictures and to respond naturally to them without trying to alter their affective response. The training task will be repeated over 4 training sessions.
46022284|NCT01933477|Other|MCH-focused ART services|Post-partum women who are breast feeding will be retained in the antenatal clinic to receive continued MCH-focused ART services until after the end of breastfeeding and once infants' final HIV status is determined.
46022285|NCT01868269|Drug|Dexamethasone acetate|"First step:~immunosuppressive treatment with dexamethasone"
46022286|NCT01868269|Drug|dexamethasone and cyclophosphamide|second step (in case of insufficient response): immunosuppressive treatment with dexamethasone and cyclophosphamide
46107939|NCT00772486|Biological|ISF35|Subjects participating in this study will receive a course of three infusions of 3x10^8 ISF35-transduced cells at periods of not less than 14 days apart followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) at monthly intervals.
46107940|NCT00766792|Procedure|Nocturnal dialysis|Switch to nocturnal dialysis (3 times 480 min/week)
46107941|NCT00766792|Procedure|Standard dialysis|Standard dialysis (3 times 240-270 min/week)
46107942|NCT00772564|Drug|Atorvastatin|Oral Atorvastatin
46107943|NCT00766870|Drug|Lu AA34893|Per oral doses, divided in twice daily administrations as capsules during 8 weeks, followed by a two-week tapering period
46107944|NCT00766870|Drug|Venlafaxine extended release|Per oral, once daily, during 8 weeks, followed by a two-week tapering period
46107945|NCT00766870|Drug|Placebo|Per oral doses, twice daily as capsules during 10 weeks
46107946|NCT00772720|Drug|raltegravir|raltegravir 400 mg BID for 7 days
46107947|NCT00772720|Drug|Placebo|Placebo BID for 7 days
46022287|NCT01868269|Drug|dexamethasone and rituximab|third step (in case of insufficient response): immunosuppressive treatment with dexamethasone and rituximab
46107948|NCT00775216|Behavioral|"Behavioral counseling plus telephone helpline"|A trained behavioral counselor will place phone calls to Phase 2 intervention participants. These calls will be used to provide tailored physical activity advice and to extend our partnership with the Metro Nashville Parks and Recreation Department, directing participants to community centers close to their homes or workplaces where they can access a variety of physical activities (e.g., indoor pools, walking tracks, fitness centers, greenways, etc) using a newly developed electronic database. Following an orientation to the Metro Parks services which will be held at either Hadley Regional Park or Coleman Regional Park, participants will be directed to the Metro Parks facility most convenient to them.
46107949|NCT00766948|Other|There is no intervention, this is a biorepository.|There are no interventions in this study.
46022288|NCT01235351|Drug|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily, 225 mg daily, and 300 mg daily based on genotype
46107950|NCT00775294|Drug|Maraviroc|Healthy male volunteers will take maraviroc 300 mg orally twice daily for 15 doses (8 days)
46107951|NCT00772798|Drug|Paclitaxel, Carboplatin and Vorinostat|Intravenous paclitaxel (175 mg/m2) and carboplatin (AUC 5) and oral vorinostat 400 mg day 1-14 every three weeks.
46107952|NCT00772876|Drug|P1446A-05|P1446A-05 capsules will be given once daily for 28 days in each 28 day cycle for 4 such cycles. The starting dose, for first cohort will be 75 mg once daily. Subsequent cohorts of patients will receive higher doses till the recommended phase II dose is identified.
46022289|NCT01235351|Drug|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily
46022290|NCT01234883|Drug|multiple electrolyte solution|IV multiple electrolyte solution dosed as clinically indicated for rehydration
46022291|NCT01234883|Drug|saline|IV solutions dosed as clinically indicated for rehydration
45468697|NCT03778645|Procedure|Adrenal Venous Sampling|Adrenal Venous Sampling via an Antecubital Approach
46022292|NCT01234649|Drug|Metformin XR plus placebo|Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
46107953|NCT00767026|Behavioral|COPE (Creating Opportunities for Parent Empowerment)|Twenty-four hours after admission to the hospital, this group will receive Phase I of the study which includes information focusing on what parents can expect during their child's hospital stay, and how they can help their child cope with the experience. Prior to discharge parents will receive additional information pertaining to Phase II of the study. At 3 days post discharge, the participants will receive a follow up phone call to reiterate the information provided in Phase II and ask parents about questions or problems since discharge. One week following, participants will be asked to complete assessments. At 6 weeks after the hospitalization they will receive Phase III, which includes, additional information on behaviors parents can expect to see in their children following a hospitalization. Parents will be given a workbook that will teach them techniques to help their child cope. Then at 6 weeks after the last intervention phase, participants will again complete assessments.
46107954|NCT00767026|Behavioral|Standard education|This group will receive standard education regarding medication management and seizure first aid. This group will also receive information, oral and written, that will discuss tests to be administered during the hospitalization. The usual care group also receives a call at home within one week after discharge from a nurse to ask if they had any problems with their stay, and if they have any further needs or questions.
46022293|NCT01234649|Drug|Metformin XR plus liraglutide|Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)
46022294|NCT02876679|Drug|Cyclophosphamide|GVHD prophylaxis: All patients will receive post-transplant 50mg/Kg/day cyclophosphamide (day +3 and +4) AND cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil in case of an HLA-matched unrelated donor
46107955|NCT00570778|Drug|indacaterol/glycopyrrolate|Inhalation capsule indacaterol/glycopyrrolate 300/50 μg inhaled once daily via a single dose dry powder inhaler for 7 days.
46107956|NCT00570778|Drug|indacaterol|Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
45468698|NCT01561573|Device|Point of care ultrasound|A bedside ultrasound machine will be used to image the colles fracture during the fracture reduction process.
45468699|NCT01143623|Dietary Supplement|Probiotic|L. acidophilus, L. paracasei, B. lactis; 2.5 billion cfu capsule once per day
46022295|NCT02876679|Drug|Anti-Thymocyte Globulin|GVHD prophylaxis: 2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1) All patients will receive cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil (MMF) in case of an HLA-matched unrelated donor.
46022296|NCT02876679|Drug|Conditioning regimen|30 mg/m2/day fludarabine for 5 days (day-6 to day-2) 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
46107957|NCT00570778|Drug|placebo|Placebo inhalation capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
46107958|NCT00775372|Drug|Clarithromycin 250mg/5mL|
46022297|NCT01075815|Drug|Recombinant human luteinizing hormone (rhLH)|
46022298|NCT01075815|Drug|Recombinant follicle-stimulating hormone (rFSH)|
46022299|NCT04306107|Device|Prone position during non-invasive respiratory support|HFNC and NIV application with patient on prone position
46022300|NCT00626691|Behavioral|Walnut consumption|Subjects will be randomized to receive either 0.75 oz (22.5 g) or 1.5 oz (45 g) of walnuts daily for the first 6 wk period, followed by a 6 wk washout period, and an additional 6 wk period during which they will receive the reverse dose of walnuts daily. Each serving of walnuts will be pre-weighed and pre-packaged.
46107959|NCT00668746|Drug|Minocycline HCl microspheres|At Baseline and all interim visits, a single unit dose of 1mg minocycline HCl (with approximately 3mg PGLA) will be professionally administered subgingivally into periodontal pockets at each site exhibiting a PD ≥ 5mm.
46107960|NCT00767182|Other|blood sample|biological markers evaluated : D-Dimer, sEPCR
46107961|NCT04047940|Drug|LY900020|Administered orally
46022301|NCT00905359|Procedure|Aperius™ PercLID™ System|Aperius™ PercLID™ System: implantation with the Interspinous Process Device Aperius.
46022302|NCT00905359|Procedure|Standalone Decompressive Surgery|Lumbar decompressive surgery without instrumentation or fusion
46022303|NCT01072149|Drug|Fluticasone Furoate (FF)/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
46107962|NCT04047940|Drug|Metformin XR|Administered orally
46107963|NCT04047940|Drug|Atorvastatin|Administered orally
46107964|NCT04047940|Drug|Valsartan|Administered orally
45468700|NCT01143623|Dietary Supplement|Probiotic|L. acidophilus, L. paracasei, B. lactis; 10 billion cfu capsule once per day
46022304|NCT01072149|Device|placebo|placebo
46022305|NCT04413253|Drug|Lifitegrast 5% Ophthalmic Solution|To reduce signs and symptoms of dry eye disease
46022306|NCT04413253|Drug|Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution|To determine the outcomes of reduction of signs and symptoms of dry eye disease with DEXTENZA as an added therapy, in addition to Xiidra therapy.
45468701|NCT01143623|Other|Placebo|Placebo
45468702|NCT04326478|Drug|Azithromycin|Enrolled children in the intervention arm of this study will receive a single weight-based dose of azithromycin (20 mg/kg, to a maximum dose of 1 gram) administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera.
46107965|NCT00773110|Drug|20% Human albumin solution|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), 20% Human serum albumin(300 mL), 0.9% sodium chloride solution (200 mL) and heparin (10,000 IU)
46107966|NCT00773110|Drug|Gelofusin|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), Gelofusine (300 mL, 4% succinylated gelatin, a synthetic colloid) and heparin (10,000 IU)
46107967|NCT00773188|Drug|bevacizumab [Avastin]|7.5mg/kg iv or 15mg/kg iv every 3 weeks
46107968|NCT00773188|Drug|cisplatin|75mg/m2 iv according to a standard chemotherapy treatment protocol
46022307|NCT01071915|Drug|Degarelix 240/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
46022308|NCT02876445|Other|ZARIT Burden Interview|ZARIT Burden Interview completed Day 0 and 1 year
46107969|NCT00773188|Drug|vinorelbine|15mg/m2 iv according to a standard chemotherapy treatment protocol
46107970|NCT00767260|Drug|BM-MNC+HOT|Autologous Bone Marrow Mononuclear cell Infusion Combined With Hyperbaric Oxygen Therapy
46107971|NCT00767260|Drug|BM-MNC|Autologous Bone Marrow Mononuclear cell Infusion
46022309|NCT02849275|Other|Lactose Free 1% Milk|isocaloric study treatment containing lactose free 1% milk consumed once daily over 4-5 weeks as a control.
46022310|NCT02849275|Other|Probiotic Treatment|Probiotic treatment, consumed once daily, over 4-5 weeks.
46022311|NCT02876133|Device|narrow band imaging withdrawal|colonoscope withdrawal and mucosal inspection performed under narrow band imaging
46022312|NCT02876133|Device|white light withdrawal|colonoscope withdrawal and mucosal inspection performed under white light imaging
46107972|NCT00767260|Device|HOT|Hyperbaric Oxygen Therapy
46107973|NCT00767260|Drug|SMT|hypoglycemic drugs or exogenous insulin
45681391|NCT03957850|Behavioral|Control Training|The task in the control group is implemented to account for unspecific effects and is as similar as possible to the CR task except that it involves no negative-decrease (i.e., no reappraisal) condition. Instead, the control task only involves the three attend conditions (negative- attend, neutral-attend, positive-attend).
46022313|NCT01679119|Drug|Cyclophosphamide|Cyclophosphamide 750mg/m2 IV, given day 1
46107974|NCT02557126|Drug|URC102|
46107975|NCT02557126|Drug|Placebo|
46107976|NCT00767494|Drug|Travoprost/Brinzolamide fixed combination|Eye Drops, suspension once daily
46107977|NCT00767494|Drug|Azopt|Eye Drop Suspension, 1 drop BID
46107978|NCT00767494|Drug|Travatan|Eye Drop Solution, 1 drop BID
46107979|NCT00773500|Other|Electronic prescribing|Implementation of a commercially available electronic prescribing system with clinical decision support
46022314|NCT01679119|Drug|Vincristine|Vincristine 1.4mg/m2(max 2mg)IV given day 1
46022315|NCT01679119|Drug|Prednisolone|Prednisolone 100mg OD Oral given days 1-5
46107980|NCT00773578|Device|Measurement of exhaled nitric oxide (eNO)|Chemiluminescence NO analyzer Measurement of lung function (spirometry)
46107981|NCT00773578|Device|Measurement of biomarkers of nasal inflammation|Nasal lavage
46022316|NCT01679119|Drug|Rituximab|Rituximab 375mg/m2 IV given day 1
46022317|NCT01679119|Drug|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin 0.8mg/m2 IV given on day 2
46022318|NCT01679119|Drug|Gemcitabine|Gemcitabine up to 1g/m2 IV given day 1 and day 8 (Patients with ECOG PS 0-1: starting dose: 875mg/m2 (1st cycle). If tolerated can be escalated to 1g/m2 in cycle 2 and subsequent cycles. Patients with ECOG PS 2: starting dose 750mg/m2 (1st cycle). If tolerated can be escalated to 875mg/m2 in cycle 2 and then escalated to 1g/m2 in cycle 3 and subsequent cycles.)
46107982|NCT02557204|Procedure|conventional technique|the nasogastric tube will be inserted gently through a selected nostril with the head being maintained in the neutral position.
46107983|NCT02557204|Procedure|head in the lateral position technique|the patient's head will be turned to the right lateral position. Nasogastric tube will be inserted through the right nostril without any maneuvers of the neck.
46107984|NCT02557204|Procedure|endotracheal tube assisted technique|Nasogastric tube will be inserted the trimmed 7.5 mm internal diameter endotracheal tube what cut proximal end with sterile scissors and endotracheal tube will be advanced blindly into the oral cavity to a depth of approximately 18 cm without laryngoscope together the nasogastric tube.
46107985|NCT02557204|Procedure|videolaryngoscope technique|Nasogastric tube was inserted transnasally and advanced into esophagus under direct vision.
46107986|NCT03874468|Device|X-ray|standing anteroposterior radiographs of the full-length lower limb with patients in the standing position. ( HKA Long Film Radiographs ).
46107987|NCT00773656|Other|Whole blood sample|70 ml per patient for collection of biological sample
46107988|NCT00775762|Drug|aspirin|Aspirin (75-100 mg)die for three months
46107989|NCT00775762|Drug|clopidogrel|Clopidogrel (75mg) die for three months
46107990|NCT00775762|Drug|clopidogrel plus aspirin|clopidogrel 75 mg die plus aspirin 75-100 mg for three months
46107991|NCT00775840|Drug|Candesartan|Candesartan up to 32 mg, tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
46022319|NCT04778787|Drug|Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)|Patients will receive dapagliflozin at a dose of 10 mg daily during hospitalization in addition to ongoing therapy
46022320|NCT02876289|Drug|Perampanel|
46022321|NCT04304391|Procedure|Resective Gingival Surgery|Gingivectomy and gingivoplasty:Resective gingival surgical procedured
46107992|NCT00775840|Drug|Placebo|Candesartan matching-placebo tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
46107993|NCT00775918|Drug|Doxycycline monohydrate 100mg tablets|Bioequiavelnce Doxycycline monohydrate 100mg tablets fed conditions
46107994|NCT00878189|Drug|PF-03084014|10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily
46107995|NCT00775996|Drug|Clorazepate Dipotassium 15mg Tablets|
45468703|NCT04326478|Biological|Placebo|Enrolled children in the placebo arm of this study will receive a single dose of non-antibiotic placebo administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera.
46107996|NCT00773812|Drug|mecamylamine|The dosage is titrated at 6 weeks of .5mg, 2 weeks of 2.5 mg, and 6 weeks of 5.0 mg. One pill is taken once daily.
46107997|NCT00773812|Drug|placebo|One pill is taken once daily.
46107998|NCT00773890|Drug|TRF-1101|once daily treatment with 300 mg orally for 12 weeks
45598548|NCT02348229|Procedure|conventional pathway group|No solid foods at dinner before surgery and no liquids 12 h before surgery. Routine bowel preparation Nasogastric placement on the morning of surgery
46022322|NCT04304157|Drug|Dexmedetomidine|Dexmedetomidine (DEX) a potent α 2 agonist that have unique analgesic, anxiolytic and sedative profile has been called upon as attractive adjunct in general as well as regional anesthesia with enticing results. Several studies have pursued DEX median effective dose (ED50) in different settings e.g., co induction agent with Propofol, in laryngeal muscle insertion and with local anesthetic to enhance the quality of spinal anesthesia
46022323|NCT04305717|Device|ReDS-guided strategy|A discharge scheme based on specific target value given by the device
46022324|NCT04937413|Drug|Evolocumab|Evolocumab subcutaneous injection
46022325|NCT02875587|Drug|Cabergoline|Cabergoline (Dostinex; Pfizer, Italy) at a daily dose of 0.5 mg is administered orally at bed time for 8 days starting on the day of HCG administration
46022326|NCT02875587|Drug|Calcium gluconate|Intravenous 10% calcium gluconate, 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1, day 2, and day 3 after ovum pickup. Intravenous infusion will be performed within 30 minutes.
46107999|NCT00773890|Drug|Placebo|Daily treatment with TRF-1101 vehicle for 12 weeks
46108000|NCT00767728|Drug|Granulated mesalamine|0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning.
46108001|NCT00767728|Drug|Placebo|Matching placebo capsules (4 capsules) were administered orally QD, in the morning.
46108002|NCT00774124|Other|telemonitoring|Women will transmit their blood glucose levels, fetal movement counts, and insulin doses via the Internet and/or IVR system at least three times per week
46108003|NCT00774124|Other|Standard of care|Health data (blood glucose levels and insulin doses) will be recorded in a paper log book which will be reviewed at prenatal visits.
46108004|NCT00776074|Drug|Leuprorelin (GF)|Leuprorelin (GF) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
46108005|NCT00776074|Drug|Leuprorelin (GC)|Leuprorelin (GC) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
46108006|NCT02628587|Drug|Generic clopidogrel|"Comparison of different brands of clopidogrel:~*Clopidogrel (generic) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3."
46108007|NCT02628587|Drug|Patent clopidogrel|"Comparison of different brands of clopidogrel:~*Clopidogrel (Plavix) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3."
46108008|NCT04162457|Dietary Supplement|Stevia|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
46108009|NCT04162457|Dietary Supplement|Glucose|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
46108010|NCT04162457|Dietary Supplement|Maltodextrin|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
46108011|NCT04162457|Dietary Supplement|Water|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
46108012|NCT02634437|Drug|Ulipristal acetate|
46108013|NCT00668200|Drug|Reclast (ZOL446, zoledronic acid)|"5 mg i.v. annually (real-life, physician prescribed)"
46108014|NCT00668200|Dietary Supplement|Calcium|1500 mg elemental calcium daily in divided doses (the divided doses were 2-3 times per day depending on the formulation)
46108015|NCT00668200|Dietary Supplement|Vitamin D|800 IU vitamin D daily, particularly in the immediate 2 weeks following zoledronic acid administration
46108016|NCT00679601|Drug|AN2690|AN2690 7.5% Solution, once daily for 28 days
46108017|NCT00675779|Drug|oral contraceptive (Mercilon)|oral contraceptive (20ug EE, 150ug DSG) 1 tablet a day p.o. for 21 days with 7 day break for 6 months
46022327|NCT00904969|Device|The AMS Male Transobturator Sling System|The AMS Male Transobturator Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD) secondary to radical prostatectomy. The Male Transobturator Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
46108018|NCT00675779|Drug|atorvastatin + oral contraceptive|atorvastatin 20mg po a day for 6 months + oral contraceptive (20ug EE, 150ug DSG) 1 tablet po a day for 21 days with 7 day break for 6 months
46108019|NCT00774280|Drug|BuCy vs BuFlu|Arm 1:BuCy Arm 2:BuFlu
46108020|NCT04151147|Procedure|Concentrated Growth Factor (Test group)|The patients' blood was collected in 9 ml glass tubes and immediately centrifuged to prevent coagulation in special centrifuge device. The CGF program was set up as follows: accelerated for 30 seconds so as to reach 2700 rpm, rotated for 2 minutes, then reduced to 2400 rpm, then rotated again for 4 minutes and accelerated to 2700 rpm, rotated for 4 minutes, then accelerated to 3000 rpm for 3 minutes, and decelerated for 36 seconds to stop. The middle layer in the tube was separated by the ''Buffy coat'' containing the CGFs fibrin gel using forceps and scissor. Then, this fibrin gel was inserted in the extraction cavity.
46108021|NCT04151147|Procedure|Non-Concentrated Growth Factor (Control group)|Third molar extraction was performed under local anesthesia. Following the extraction, the socket was sutured and natural healing process was observed. This side was considered as a control group.
46108022|NCT00774358|Drug|Interleukin-2|We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.
46108023|NCT02627417|Drug|Dapsone (Disulone®)|Experimental group will receive dapsone at a fixed dose of 100 mg per day for a total of 12 months unless they fail to respond to the treatment.
46108024|NCT02627417|Drug|"Prednisone (Cortancyl®) alone followed by monitoring and standard of care"|Patients randomized in the control arm will be treated only prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks. After this 3 weeks period, patients from arm B will be left without treatment and monitored.
46108025|NCT02627417|Drug|Prednisone (Cortancyl®)|Experimental group will receive prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks.
46108026|NCT00774436|Procedure|focal cryotherapy|Those men meeting the re-staging biopsy criteria will subsequently be treated with focal cryotherapy. Clinical follow-up visits will be scheduled at 6 + 2 weeks, 3 + 1 months and 6 + 1 months after focal cryotherapy, at which time, a digital rectal examination and PSA test will be performed. Standard quality-of-life questionnaires, are completed by all patients treated by the Urology Service (whether on not they are treated on an IRB protocol).
45838299|NCT03998618|Behavioral|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions, patients in the Acceptance and Commitment Therapy condition will practice various mindfulness exercises, clarify their values, and set specific goals consistent with their values. Sessions will incorporate discussion of patients' cancer experiences. Through in-session and home practice of skills, participants will learn new and more adaptive ways to respond to fatigue. Participants will receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.
46108027|NCT02556892|Drug|Ibrutinib|Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.
46108028|NCT00774514|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of vasodilators Acetylcholine (5-20 mg/min), sodium nitroprusside (2-8 µg/min), bradykinin (100-1000 pmol/min) and verapamil (10-100 µg/min)
46108029|NCT00679679|Drug|Metformin|Metformin 750 mg BID for 4 months
46108030|NCT00679679|Drug|Placebo|Diet counseling and exercise
46108031|NCT00774592|Behavioral|FOYC|FOYC is a face-to-face, eight-session, group behavioral intervention based on protection motivation theory and emphasizing skills and decision-making.
46108032|NCT00774592|Behavioral|Goal for it (GFI)|GFI is a one-session parent intervention consisting of a 20-minute video followed by a discussion regarding the process of setting and reaching goals.
46108033|NCT00774592|Behavioral|Wonderous Wetlands|Wonderous Wetlands is an eight-session, group intervention for youth. It includes field projects and discussions based on ways to save our environment.
46108034|NCT00774592|Behavioral|Caribbean Informed Parents and Children Together (CImPACT)|CImPACT is a parent intervention addressing parental monitoring and communication with youth. It consists of a 20-minute video, a condom practice, and role play simulating a parent-child discussion.
46022328|NCT00904969|Device|AdVance Male Sling|A transobturator sling for the treatment of post-prostatectomy incontinence
46022329|NCT01070979|Drug|Estradiol acetate|Tablet containing 0.9 mg E3A, daily oral administration.
46022330|NCT01070979|Drug|Estradiol|Tablet containing 1 mg estradiol, daily oral administration.
46108035|NCT00774592|Behavioral|Bahamian Focus on Older Youth (BFOOY)|10 session HIV prevention program
45598549|NCT02348229|Procedure|conventional pathway group|Routine use of anesthesia medicine. Standard 5-trocar laparoscopy-assisted procedure. I.V. fluids not restricted (Ringer's lactate 20 ml/kg in the first hour, then at the rate of 10-12 ml/kg/h) Routine use of abdominal drainage tubes and placement of catheters.
46022331|NCT01070979|Drug|Conjugated equine estrogens|Tablet containing 0.625 mg CEE, daily oral administration.
46108036|NCT00774592|Behavioral|Health and Family Life Curriculum (HFLE)|Standard Grade 10 curriculum
46108037|NCT00838578|Biological|KRN330|KRN330 will be dosed at 0.5 mg/kg weekly until disease progression.
46108038|NCT00838578|Drug|Irinotecan|Irinotecan will be dosed at 180 mg/m2 biweekly until disease progression.
46022332|NCT04928209|Other|Speech-Language Teletherapy|Access to speech-language teletherapy will be provided as a supplement to Usual Care for subjects randomized to this group. Access is provided by way of 1) direct referral by the clinical team to a teletherapist; 2) availability of a teletherapy slot. All teletherapy providers will be licensed speech-language pathologists (SLPs) and/or credentialed teachers of the deaf (TODs) with specialized training to work with children who are D/HH using an LSL approach. Fluent English and Spanish speaking providers will be matched to the child's home, native language. Teletherapy itself is within routine clinical care and is not considered a research activity. Children who randomize to the Low TT study arm will receive access to an 18-month course of weekly teletherapy, in accordance with the centers' standard of care. The exact details of the therapy course and frequency will be determined based on individual family needs.
46022333|NCT01234337|Drug|Sorafenib (Nexavar, BAY43-9006)|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.
46108039|NCT00774826|Drug|R-CVP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1, Vincristina: 1,4 mg/mq day 1 Prednisone: 40 mg/mq day 1-5,
46108040|NCT00774826|Drug|R-CHOP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1 Doxorubicina: 50 mg/mq day 1 Vincristina: 1.4 mg/mq day 1 Prednisone: 100 mg/mq day 1-5
46022334|NCT01234337|Drug|Placebo|Capecitabine was administered orally at a dose of 1,000 mg/m^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
46022335|NCT01234337|Drug|Capecitabine|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle.days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily,
46022336|NCT02848963|Drug|Ketamine-propofol mixture|Ratio of Ketamine-propofol mixture will be compare for every groups.
46108041|NCT00774826|Drug|R-FM|Rituximab: 375 mg/mq day 1, Fludarabina: 25 mg/mq day 1-3, Mitoxantrone: 10 mg/mq day 1,
46108042|NCT00656981|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
46108043|NCT00656981|Drug|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
46108044|NCT02634515|Drug|Julphar Insulin R (soluble human insulin, biosimilar)|investigational insulin, Julphar Insulin R (soluble human insulin)
46108045|NCT02634515|Drug|Huminsulin® Normal (soluble human insulin, reference)|marketed product, Huminsulin® Normal (soluble human insulin
46108046|NCT00705900|Drug|LCD|2 applications / day for 12 weeks
46108047|NCT00705900|Drug|calcipotriol|2 applications / day for 12 weeks
46108048|NCT00679835|Drug|daptomycin|i.v. daptomycin given at 8 mg/kg or 10 mg/kg by a one or two hour infusion.
46108049|NCT00774904|Drug|Losartan|Angiotensin II Type 1 Receptor Blockers
46108050|NCT00829296|Drug|nebivolol|Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached
46108051|NCT00829296|Drug|Metoprolol|Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached
46108052|NCT00774982|Drug|Delayed Release 6 mercaptopurine|oral tablet, 1 x 40 mg Delayed Release 6MP tablet, single-dose
46108053|NCT00774982|Drug|6 Mercaptopurine|Oral Tablet, 2 x 50 mg 6MP Reference, single-dose
46108054|NCT00881621|Drug|Lapatinib and Capecitabine|Lapatinib 1250-mg PO daily one hour before or after meals Capecitabine 1000 mg/m2 PO twice daily on days 1-14 of 21-day cycle for a total of 8 cycles
46108055|NCT02634281|Drug|Varenicline|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
46108056|NCT02634281|Drug|placebo|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
45598550|NCT02348229|Procedure|conventional pathway group|1st postoperative day: Keep Nasogastric catheter Removal of urinary catheter Opioid analgesic by intramuscular injection Parenteral nutrition until flatus. I.V. fluids not restricted Mobilization in bed
45598551|NCT02348229|Procedure|conventional pathway group|2nd postoperative day Patient is advised to get out of bed until 24-48h after surgery
46022337|NCT01070043|Drug|Amlodipine 5mg/Valsartan 80 mg|Combination therapy of Amlodipine/Valsartan 5mg/80mg one dosage daily with one single tablet size for 8 weeks.
46022338|NCT01070043|Drug|Valsartan|"For run-in period, Valsartan 80 mg daily in one dosage with one single tablet size for 4 weeks.~Monotherapy for double blind treatment period in one dosage (Valsartan 160mg) daily with one single tablet size for 8 weeks"
45468704|NCT01316497|Procedure|Remote ischemic preconditioning (RIPC)|RIPC was performed by applying a blood pressure cuff around the child's leg. The cuff was inflated to 40 mmHg above the systolic pressure in 4 cycles of 5 minutes. Every cycle of ischemia was followed by 5 minutes of reperfusion. The first RIPC cycle started after anesthesia induction when invasive arterial blood pressure was monitored. Appropriate cuff size was used choosing between four sizes. For reproducibility RIPC was performed on the right leg with only a few exceptions, when the leg was used for invasive catheters.
45468705|NCT01316497|Procedure|Control|The cuff was applied on the leg without inflation in the control group.
45468706|NCT01320241|Device|self-expandable 125I radioactive seeds-loaded-stent|Patients undergo placement of a self-expandable 125I radioactive seeds-loaded-stent on day 1.
46022339|NCT02849119|Procedure|Laparoscopic or robotic partial nephrectomy|Laparoscopic or robotic partial nephrectomy of a small renal masses (T1a) through transperitoneal or retroperitoneal approach
46022340|NCT04772391|Other|Exercise Sessions|Participant will complete up to 8 exercise sessions
46108057|NCT00818766|Drug|cefazolin or vancomycin|Cefazolin IV every eight hours post-operatively for 48 hours or until all chest tubes were removed, whichever occurred first. Participants under 80 kg received 1 gram of cefazolin and participants who were 80 kg or more received 2 grams of cefazolin. Participants who were penicillin-allergic received 1 gram of vancomycin every 12 hours for 48 hours or until all chest tubes were removed, whichever occurred first.
46022341|NCT04718545|Procedure|Mucogingival surgery|The gingival recession at mandibular incisor site will be covered by a gingival graft harvested from the palate.
46108058|NCT00818766|Drug|Placebo|Participants received IV placebo for 48 hours post-operatively or until all chest tubes were removed, whichever occurred first.
46022342|NCT02849197|Procedure|surgery for pilonidal sinus disease|surgical treatment of pilonidal sinus disease via primary closure, Limberg flap0 technique and Modified Limberg flap technique.
46022343|NCT01074255|Drug|EMEND|EMEND (Aprepitant,125 mg oral capsules) is administered 1 hour prior to chemotherapy on treatment Day 1. EMEND (80 mg) is administered on the morning of Days 2 and 3. EMEND is concomitantly administered with a regimen of a corticosteroid and a 5-HT3 antagonist.
46022344|NCT02962063|Biological|durvalumab|Durvalumab can be given irrespective of CBC, at the discretion of the treating physician.
46022345|NCT02962063|Drug|carboplatin AUC 2/paclitaxel|
46022346|NCT02962063|Radiation|External beam radiation (EBRT)|Radiation will be delivered starting on a Monday or Tuesday between Days 29-30, based on the first induction durvalumab dose administered on Day 1. Patients will be treated 5 days/week at 1.80 Gy/day, to a total planned dose of 41Gy in 23 fractions. Induction Day 15 has a -1/+2 day window, and Day 29 has a -1/+1 day window.
46022347|NCT02962063|Procedure|esophagogastrectomy|Patients undergo surgical resection 6-10 weeks after the completion of chemoradiation.
46022348|NCT02962063|Drug|Tremelimumab|Tremelimumab will be administered once at 300 mg on Day 29 prior to chemoradiation only.
46022349|NCT02848807|Dietary Supplement|NUTRIDRINK Compact Protein|high-energy, high-protein, oral liquid nutritional supplement; dosage: 2x125 ml per day, 7 days per week for 12 weeks (3 months)
46022350|NCT01073943|Drug|PicoPrep|PicoPrep (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PicoPrep pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. Subjects randomized to the PicoPrep group will begin treatment (1st sachet) one day before colonoscopy between 4:00 and 6:00 PM, and will complete the treatment (2nd sachet) at least 6 hours later, between 10:00 PM and 12:00 AM. Subjects will consume approximately (5) 8 oz. glasses of clear liquids following the first sachet administration in the afternoon and (3) 8 oz. glasses of clear liquids following the second sachet administration in the evening, one day before colonoscopy.
46022351|NCT01073943|Drug|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
46108059|NCT00779350|Drug|sertraline 100 mg tablets|
46108060|NCT04150601|Device|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
46108061|NCT04150601|Device|PEP|A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.
46108062|NCT04150601|Other|Spontaneous Exhalation|A slow vital capacity maneuver will be performed according to the guidelines, from total lung capacity to residual volume
46108063|NCT00680537|Procedure|Exercises|Completion of a series of shoulder exercises for 6 weeks post device implant
46108064|NCT00705978|Drug|Pancreatin|Pancreatin with 40000 lipase units per capsule, 2 capsules per main meal (3 main meals) plus 1 capsule per snack (2-3 snacks)
46108065|NCT00705978|Drug|Placebo|placebo
46108066|NCT04150835|Drug|Xingnaojing injection|Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
46108067|NCT04150835|Drug|Xingnaojing placebo injection|Xingnaojing placebo injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
46022352|NCT01073943|Drug|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
46108068|NCT04150835|Other|Standard care|Guidelines-based standard care for acute ischemic stroke.
46108069|NCT00667888|Radiation|Conventional Fractionated Intensity Modulated Radiotherapy|A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).
46022353|NCT05273125|Behavioral|Gait disorders and falls risk assessment|Implementation of a standardized assessment of the fall risk and gait disorders in the memory clinic in addition to usual care.
46022354|NCT05254483|Behavioral|UNICEF kid power program immediately|"The intervention will be delivered via the UNICEF Kid Power website (https://www.unicefkidpower.org/) and any screened device such as a computer, smartphone, smart TV or an electronic tablet can be used to watch the videos and perform the assigned physical activity.~Participants will self-select activities 5 days a week. The participants will have the choice to undertake the physical activity in bouts and accumulate it over the course of the day.~To promote adherence to intervention, a weekly email with reminder to perform the physical activity will be sent to parents. In addition, research-based articles on the importance of physical activity and behavior change in children will also be emailed."
46108070|NCT00667888|Radiation|Hypofractionated Intensity Modulated Radiotherapy|A total dose of 72 Gy will be delivered in 30 fractions to the PTV.
46108071|NCT00680615|Behavioral|Tailored, enhanced condition|Intervention will provide a personalized, interactive tobacco cessation Web application, based on existing empirically validated smokeless tobacco cessation programs.
46108072|NCT00680615|Behavioral|Usual Care|The Usual Care condition will provide access to typical smokeless tobacco cessation information and links to commonly available Web-based smokeless tobacco cessation resources.
46108073|NCT02556970|Procedure|Single port VATS|Performing video-assisted thorascopic surgery through a single port
46108074|NCT02556970|Drug|Paracetamol|1g intraoperatively
46108075|NCT02556970|Drug|Diclofenac|75mg intraoperatively
46108076|NCT02556970|Device|Camera (5mm diameter 30 degree videothoracoscope)|
46108077|NCT02556970|Device|Forceps grasper|
46108078|NCT02556970|Drug|0.25% Levobupivicaine intercostal nerve block|Multi-level intercostal blocks will be placed subpleurally under thorascopic visualisation.
46108079|NCT00776464|Device|Noveon laser|Two wavelenghts of light
46108080|NCT00594815|Drug|Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine|Immunochemotherapy
46108081|NCT00776542|Drug|Minocycline 100mg Tablets|
46108082|NCT04150679|Procedure|duodenojejunostomy access loop|ROUX en Y hepaticojejunostomy with duodenojejunal anastomosis as permanent access
46108083|NCT04150679|Procedure|hepaticojejunostomy without access loop|ROUX en Y hepaticojejunostomy without access loop
46108084|NCT00776620|Drug|Glimepiride 1mg Tablets|
46108085|NCT00680693|Behavioral|Mindfulness training|8 weekly 2-hour classes
46108086|NCT00680693|Behavioral|Psycho-educational support group for women with IBS|8 weekly 2-hour meetings
46108087|NCT00776698|Drug|bevacizumab [Avastin]|7.5mg/kg every 3 weeks for 3 cycles (cohort 1) or 15mg/kg every 3 weeks for 3 cycles (cohort 2). Preferred dose every 3 weeks for 9 cycles (cohort 3).
46108088|NCT00776698|Drug|cisplatin|80mg/m2 iv every 3 weeks for 3 cycles
46108089|NCT00776698|Drug|etoposide|100mg/m2 iv for 3 consecutive days, every 3 weeks for 3 cycles
46108090|NCT04161833|Dietary Supplement|OPERA|All patients were required to take an OPERA® capsule (dietary supplement where α-lipoic acid, Boswellia Serrata, methylsulfonylmethane and bromelain are combined in a single capsule) once daily,from enrollment up to sixth months.
45681392|NCT04192318|Behavioral|Bridging the Gap|Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.
46022355|NCT05254483|Behavioral|UNICEF kid power program for waitlist control|The wait-list control group will perform physical activity as usual and will only receive a weekly email on the importance of healthy dietary habits in children. The intervention will last 12 weeks. At the end of the study, the wait-list control group will be offered the UNICEF Kid Power intervention for a duration of 12-weeks
45468707|NCT01320241|Device|self-expandable biliary nitinol alloys stent|Patients undergo placement of a conventional self-expandable biliary nitinol alloys stent on day 1.
45468708|NCT01246427|Drug|BRN01|2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
46108091|NCT00680147|Behavioral|brief informational intervention to promote HPV vaccine acceptance|Teen and parent participants will receive a brief informational intervention that provides basic facts about the HPV vaccine, including the health benefits and three-dose requirements, along with information regarding where to go to receive the vaccination. A coupon for a free HPV vaccination will provided to the parent for use by their teenage daughter.
46108092|NCT02634047|Device|conventional technique|transesophageal echocardiography probe was inserted using a traditional blind insertion technique.
46022356|NCT05254483|Device|ActiGraph Accelerometer|The participants will be mailed accelerometers and instructed to wear for 7 consecutive days during their waking hours, prior to the start of intervention. The mail containing the accelerometer will accompany pictorial instructions, explaining in detail the correct way of wearing it.
46108093|NCT02634047|Device|videolaryngoscope technique|transesophageal echocardiography probe was advanced into esophagus under direct vision using videolaryngoscope
45468709|NCT01246427|Drug|Placebo|2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
46108094|NCT00820248|Biological|panitumumab|Given IV
46108095|NCT00820248|Drug|cisplatin|Given IV
46108096|NCT00820248|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
46108097|NCT00820248|Radiation|accelerated radiation therapy|Patients undergo accelerated fractionation radiotherapy
46108098|NCT00820248|Radiation|intensity-modulated radiation therapy|Patients undergo radiotherapy
46108099|NCT00680303|Behavioral|The Lidcombe Program for early stuttering|
45468710|NCT04308616|Other|Blood samples|Blood samples
45468711|NCT04674163|Biological|Blood sample and Cerebrospinal fluid (CSF) collection.|An additional blood sample (25 ml) and a cerebrospinal fluid (CSF) sample (2 ml) will be taken.
45468712|NCT03435874|Biological|ChAd63 RH5|Vaccine
45468713|NCT03435874|Biological|MVA RH5|Vaccine
46108100|NCT00680303|Behavioral|The Lidcombe Program for early stuttering|
46108101|NCT00680303|Behavioral|The Lidcombe Program for early stuttering|
46108102|NCT04150757|Drug|Intranasal ketamine|Patients with vaso-occlusive episode and sickle cell disease in moderate to severe pain determined at triage will receive intranasal ketamine while awaiting IV placement.
46108103|NCT04150211|Dietary Supplement|Polyherbal Exten(d) vs Placebo|Supplementation during 4 weeks
45681393|NCT04192318|Other|Communities that Care (CTC)|In CTC programs stakeholders elect evidence-based prevention strategies that are most appropriate for their community. These evidence-based strategies target their community's specific needs, such as reducing risk factors while supporting and increasing protective factors.
45681394|NCT04192318|Other|Treatment as usual|Treat and release
45681395|NCT02704390|Drug|ORADUR®-Methylphenidate|ORADUR®-Methylphenidate is available in three dosage forms, 22 mg, 33 mg or 44 mg. Subjects will continue to receive ORADUR®-Methylphenidate at the previously determined optimal dose for 24 months.
46108104|NCT04150367|Drug|Isoniazid|Solution for injections, 100 mg/ml, 5 ml. Participants will get the dosage according to the instruction for use.
46108105|NCT04150367|Drug|Rifampicin|Participants will get the dosage according to the instruction for use.
46108106|NCT04150367|Drug|Ethambutol|Participants will get the dosage according to the instruction for use.
46108107|NCT04150367|Drug|Rifampicin|Participants will get the dosage according to the instruction for use.
45468714|NCT03435874|Biological|Rabies Vaccine|Vaccine
45468715|NCT05119751|Drug|tree 12 SQ-Bet|DAILY DOSE OF AIT TABLET
45468716|NCT05119751|Drug|GRASS 2800 BAU|DAILY DOSE OF AIT TABLET
45468717|NCT05119751|Drug|RAGWEED 12 AMB A 1-U|DAILY DOSE OF AIT TABLET
45468718|NCT05119751|Drug|HDM 12 SQ-HDM|DAILY DOSE OF AIT TABLET
45468719|NCT03430804|Other|Bishop score calculation of modified Bishop score in numbers by digital vaginal examination|Measurement of cervical length by transvaginal ultrasound and digital examination of Bishop score in 320 parturients undergoing labour induction at term
45468720|NCT03470116|Device|Laryngoscopy with Mac Grath|Patients of this group will benefit MacGrath MAC video laryngoscopy for intubation after curarization
45468721|NCT03470116|Device|direct laryngoscopy|Patients of this group will benefit direct laryngoscopy for intubation after curarization
45838300|NCT03998618|Behavioral|Education/Support|Across six weekly 50-minute sessions, patients in the education/support condition will discuss their concerns, including symptoms and other cancer-related stressors, with a therapist providing psychological support. The therapist will direct patients to resources for practical and health information and contact information for psychosocial services. Sessions will include an orientation to the patient's medical center, education regarding common cancer-related symptoms and quality-of-life concerns, and an overview of resources for addressing these concerns. The therapist will also describe resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants will receive handouts on session topics and will be asked to review them as homework.
45838301|NCT03988595|Other|Exercise Treatment|Exercise sessions will consist of individualized, walking delivered following a non-linear (i.e.,exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
45838302|NCT03985527|Device|Transvenous nerve stimulation|Acute transvenous nerve stimulation during a commercial implant of remedē® System or commercial transvenous cardiac device (de novo pacemaker or implantable cardiac defibrillator).
45838303|NCT03969563|Behavioral|Mindfulness-based Stress Reduction|8-week Mindfulness-based Stress Reduction class that trains participants in mindfulness, meditation, and yoga.
45838304|NCT03969563|Behavioral|Brain Health Education|8-week Brain Health education class that teaches participants about brain-behavior relationships, nutrition, aging facts, sleep, and memory.
46108108|NCT04150367|Drug|Isoniazid|. Participants will get the dosage according to the instruction for use.
46108109|NCT04150367|Drug|Ethambutol|Participants will get the dosage according to the instruction for use.
46108110|NCT00680927|Other|46 hrs Holter ECG recording|Maximum of 2 46 hrs external Holter ECG recordings are required.
46108111|NCT02634203|Procedure|Balloon Pulmonary Angioplasty (BPA)|Balloon pulmonary angioplasty (BPA) will be done via femoral vein. 2 sessions will be performed during the same hospitalization following by additional sessions at an interval of 2-3 weeks until a mean PAP< 30 mmHg is achieved A pulmonary angiography and a right heart catheterization will be performed at each BPA session
46108112|NCT02634203|Drug|Riociguat|The starting dose will be 1 mg three times daily as recommended. The dose will be titrated every 2 weeks according to the peripheral systolic pressure. Dose should be increased by 0.5 mg three times daily every two weeks to a maximum of 2.5 mg three times daily, if systolic blood pressure is ≥95 mmHg and the patient has no signs or symptoms of hypotension.
45681396|NCT04147390|Drug|prescribe topical 0.03 % tacrolimus|prescribe topical 0.03 % tacrolimus 3 times a day for 12 months
45681397|NCT04147390|Drug|prescribe mycophenolate mofetil(MMF)|MMF orally 1 g twice daily for the first 6 months and then 1 g daily for the next 6 months
45681398|NCT02706964|Device|Positron emission tomography/x-ray computed tomography|A whole-body PET/CT will be performed to identify the site and extent of spread.
46108113|NCT00680381|Behavioral|MTI, Minimal Transitional Intervention|Following 12 weeks of Functional Family Therapy (FFT), semi-weekly phone calls from a therapist for eight weeks.
46108114|NCT00680381|Behavioral|GTI, Group Transitional Intervention|Following 12 weeks of FFT, weekly one-hour sessions of group therapy for eight weeks.
45681399|NCT02706964|Device|Magnetic resonance imaging|A brain MRI will be performed.
45681400|NCT02706964|Device|x-ray computed tomography (CT)|A CT scan will be performed to identify the site and extent of spread.
46022357|NCT01073865|Drug|ZD9393 (Zoladex) 10.8 mg|10.8 mg (goserelin acetate): one subcutaneous depot injection once every 12 weeks (± 7 days).
46022358|NCT01073865|Drug|ZD9393 (Zoladex) 3.6 mg|3.6 mg (goserelin acetate): one subcutaneous depot injection once every 4 weeks (± 7 days).
46022359|NCT02900053|Device|tDCS|tDCS for transcranial Direct-Current Stimulation
46022360|NCT02900053|Device|Placebo tDCS|Placebo tDCS for transcranial Direct-Current Stimulation
46022361|NCT04862065|Device|Alinity s Anti-HCV II|For all donor specimens with investigational Alinity s Anti-HCV II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
46022362|NCT04714645|Device|VR neglect training|Patients will undergo 1 session a day for 30 minutes for 5 consecutive days. The training consists of 5 different VR tasks specifically designed for neglect training.
45468722|NCT04647721|Device|Radiesse injectable implant (dermal filler)|Subdermal injection.
45838305|NCT03968991|Diagnostic Test|VISIODOL® (Diagnostic tool)|Tool for assessing pain in the blind subject (with congenital or acquired deficiency)
45838306|NCT03968107|Other|Reference ultrasound examination|Use of antenatal ultrasound examination to visualize and position the intestinal structures involved in digestive malrotation at high risk of volvulus and comparison to fetal MRI results.
45838307|NCT03934437|Behavioral|mLTCR|mHealth-enhanced Linkage to Care and Retention
46022363|NCT04714645|Device|VR control training|Patients will undergo 1 session a day for 30 minutes for 5 consecutive days. This is a placebo training, where patients will also wear the HMD. Patients will be immersed in a virtual environment without a specific task.
46022364|NCT01064635|Drug|Letrozole|letrozole for 2-3 years after Tam
46022365|NCT01064635|Drug|Letrozole|Letrozole for 5 years after Tam
45468723|NCT04647721|Device|Restylane injectable implant (dermal filler)|Subdermal injection.
45598552|NCT02348229|Procedure|conventional pathway group|3-4th postoperative day： Remove nasogastric tube after flatus Oral liquids started. Encouraged to walk in the ward.
45681401|NCT02708758|Behavioral|Medical Nutrition Therapy|individualized medical nutrition therapy from a qualified nutritionist which took into consideration a woman's pre-pregnancy weight, activity level, dietary intake and weight gain, instructions on how to self- monitoring capillary glucose levels two to four times daily until the levels had been in the recommended range (fasting glucose levels no more than 95 mg/dL and 1 hour postprandial less than 140 mg/dL). Drug therapy will begin with metformin or insulin when capillary glucose levels are not met the recommended levels after at least two weeks of treatment.
46108115|NCT00680381|Behavioral|STI, Systems Transitions Intervention|Following 12 weeks of FFT, an individualized eight-week series of therapist meetings with the adolescent, family, police, teachers, coaches and others who can support the adolescent's reduced drug use.
46108116|NCT04161521|Procedure|Novel Technique of Placenta Accreta in Menoufia University Hospital|"Classical CS to decrease haemorrhage from placental bed.~Delievery of the fetus.~At the delivery 10 UI of oxytocin IV will be injected.~The placenta is not attempted to be delievered.~Opening of the broad ligament via round ligament division and ligation.~Gentle dissection of the urinary bladder from lateral to medial.~Bilateral uterine artery clamping at low level below the placental bed .~Gentle attempt to deliver The placenta.~If the placenta is delievered we will do bilateral uterine artery ligation at multiple levels and multiple square compression sutures(if needed) for proper hemeostasis at the placental bed. Then closure of uterine incision.~If the placenta is not delievered we will do segmental ressection of lower uterine segment including the placenta .~Intraperitoneal drain insertion."
46108117|NCT00681005|Drug|rabeprazole|20 mg bid for 14 days
46108118|NCT00681005|Drug|pantoprazole|pantoprazole 40 mg bid
46108119|NCT02626325|Other|High-carbohydrate or High-monounsaturated fat diets|
45838308|NCT03934437|Behavioral|LTCR|Linkage and Retention Services (Standard-of-Care)
46108120|NCT04150055|Behavioral|Mindfulness Coach|Mindfulness Coach is an mHealth delivered mindfulness therapy.
46108121|NCT00681161|Other|continuous positive airway pressure (CPAP)|Standard of care treatment for OSA, requires a mask attached by tubing to a device providing continuous pressure of air at a given cm of water pressure, acting as a splint to open airway at night to relieve obstruction.
46108122|NCT00912353|Drug|AZD7268|Single Oral
46108123|NCT00912353|Drug|Placebo|Single Oral
46108124|NCT04149665|Device|simple blind observation|Device that measures continuously the angle of bed by mechanical Ventilation to assess the time the bed is above 35°.
46108125|NCT02633969|Drug|Indomethacin Capsules low dose|
46108126|NCT02633969|Drug|Indomethacin Capsules high dose|
46108127|NCT00684827|Drug|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~Arm #A~Xopenex HFA MDI, Pirbuterol HFA MDI"
46108128|NCT00684827|Drug|Racemic Albuterol followed by levalbuterol HFA MDI|"Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~Arm #B~Pirbuterol HFA MDI, Xopenex HFA MDI"
46108129|NCT04149119|Device|Attractive Target Sugar Baits (ATSB)|Within the intervention area, a total of four ATSB station will be deployed (external wall). ATSB stations will be monitored by community health workers through weekly visit and all stations will be replaced 6months after deployment.
45838309|NCT03904264|Device|Receiver in the canal (RIC) hearing aids|The RIC hearing aids fitted to subjects in arm 1 of the study will be manufactured by Widex.
46022366|NCT05229679|Diagnostic Test|HPV testing|All women age 23-29 resident in the pilot counties will be invited to HPV screening as of the study start date. The same invitation as currently used for women aged 30 and upwards will be used. This information clearly states that it is possible to opt out of the program and that data from the screening program will be collected to regional and national quality registers who will systematically evaluate the quality of the care. At the screening station, the samples are collected identically regardless of primary screening test used - there is no change in the procedures used neither for the woman or for the midwives taking the sample. HPV testing will be performed using the same purchased, CE-marked and accredited HPV screening platforms as currently used for women aged 30 and upwards. The cytology is according to the liquid-based cytology method.
46022367|NCT00930007|Other|Blood sampling|Blood sampling for later hormone measurements
46108130|NCT00820170|Drug|Dasatinib and Paclitaxel|"A treatment cycle will consist of 28 days, according to the following schedule:~Dasatinib 120MG PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.~The trial will initially test the combination of weekly paclitaxel and dasatinib given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort will test dasatinib given with a different schedule, 5 days on and 2 days off, omitting dasatinib the day prior and the day of administration of paclitaxel."
46108131|NCT00681239|Dietary Supplement|Modified Atkins diet and KetoCal|10 gram per day Modified Atkins diet and 10 oz per day of KetoCal shake.
46108132|NCT02627027|Drug|Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg|oral administration
46108133|NCT02627027|Drug|CKD-395 0.25/750mg|oral administration
45838310|NCT03903692|Device|Marine polysaccharide dressing|The MPS-Ag dressing used in this study has a unique gelling action which helps to remove dead, damaged, and infected tissues from the wound by trapping and removing them later at dressing changes. It is designed to provide intimate contact with the wound for gentle healing. It also contains ionic silver.
45681402|NCT02708680|Drug|entinostat|An orally available histone deacetylases inhibitor (HDAC)
45838311|NCT03903692|Device|Carboxymethylcellulose dressing|The CMC-Ag dressing used in this study incorporates two technologies to help eliminate the key barriers to healing that are exudate, infection, and bioburden. It can be used on chronic and acute wounds that are infected or at risk of infection with varying exudate levels.
45468724|NCT01239251|Other|GlowCap device|Participants will be provided with a device called the GlowCap for a period of 30 days. The device has visual and auditory cues to help patients remember to take their medication at the same time each day. The GlowCap will be programmed to glow when it is time for each patient to take her medication. The GlowCap will initially glow bright orange for the first hour from the time the patient is scheduled to take the medication. During the second hour, the GlowCap system will play music in addition to continuing to glow. If after 2 hours the patient still has not opened the medication bottle, she will receive a phone call reminding her to take her medication.
46022368|NCT04697485|Drug|Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg|"Low-Dose, Triple Polydiuretic Therapy (LDTPT) Treatment consists of:~Loop diuretic (bumetanide 0.5 mg)~Mineralocorticoid receptor antagonist (eplerenone 25 mg)~Sodium-glucose co-transporter 2 inhibitor (SGLT2i): Farxiga® (dapagliflozin) 5 mg"
46108134|NCT00681317|Drug|AZD6280|oral
46108135|NCT00709332|Drug|Norgestimate; Ethinyl Estradiol; Folic acid|
45468725|NCT03430726|Other|Probiotic yogurt drink|Food product; yogurt drink containing a multi-strain probiotic.
46108136|NCT00913536|Other|Using Cone beam CT in patients with Bladder Cancer|Using cone beam CT scanner will help to increase the accuracy of your radiotherapy treatment. The cone beam CT scanner is a part of the radiotherapy treatment unit.
46108137|NCT00684905|Drug|bicalutamide|
46108138|NCT00684905|Drug|leuprolide acetate|
46108139|NCT00684905|Procedure|adjuvant therapy|
46108140|NCT00684905|Procedure|neoadjuvant therapy|
46108141|NCT00684905|Procedure|quality-of-life assessment|
45468726|NCT03772795|Other|Orthodontic Alignment|"Group 1:- Teeth alignment in this group started using round 0.014 NiTi arch wire. The 0.014 NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. During this stage, only tipping movement was applied."
45468727|NCT03772795|Other|Orthodontic Alignment|Group 2: Teeth alignment using clear aligners.
45468728|NCT01236833|Drug|Lactated Ringer's Solution|2.5 ml per kg every 3 hours, via nasogastric tube, orogastric tube or orally, until the infant reaches 80 ml/kg/day of milk feeding or for a maximum of 14 days
45468729|NCT03775057|Other|MyDoseCoach app|The intervention involves the use of the MyDose Coach application, which has been previously programmed with the following titration scheme according to fasting glucose.
45468730|NCT03470038|Drug|NGF|Intramuscular injection
45838312|NCT03886610|Other|Healthy controls|individuals without spinal cord injury
46108142|NCT00684905|Radiation|brachytherapy|
46108143|NCT00685061|Drug|Thymoglobulin|Induction
46108144|NCT00685061|Drug|Campath-1H|Induction
46108145|NCT00685061|Drug|Daclizumab|Induction
46108146|NCT02633813|Drug|Naftifine hydrochloride 2%|Topical application for two weeks
46108147|NCT02633813|Drug|Placebo|Topical application for two weeks
46108148|NCT02633813|Drug|Naftin® 2% (Naftifine hydrochloride 2%)|Topical application for two weeks
46108149|NCT00818454|Drug|Combivent CFC MDI|
46108150|NCT00818454|Drug|Albuterol HFA MDI|
46108151|NCT00818454|Drug|Respimat Combivent|
45468731|NCT03470038|Drug|Isotonic saline|Intramuscular injection
45468732|NCT03250325|Biological|TBI-1301|Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide pre-treatment.
45838313|NCT03886610|Other|Subacute SCI patients|individuals with spinal cord injury ≥ 2 weeks
45838314|NCT03886610|Other|Chronic SCI patients|individuals with spinal cord injury ≥ 24 months
45838315|NCT03884998|Drug|Copanlisib|Given IV
45838316|NCT03884998|Biological|Nivolumab|Given IV
45838317|NCT03878849|Drug|2X-121|Every patient will receive daily oral administrations of 3 x 200 mg 2X-121 hard gelatin capsules in a 28-day cycle.
45838318|NCT03878849|Device|2X-121 DRP®|A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
46022369|NCT02768935|Procedure|blood sample|blodd sample at 12 months
46022370|NCT01073631|Drug|voriconazole tablet|200 mg PO bid (orally, twice a day)
46022371|NCT00626769|Dietary Supplement|aglycone genistein|2 capsules per day containing 27 mg of aglycone genistein, calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
46108152|NCT02626247|Dietary Supplement|Vitamin A +Long chain PUFA|3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
46108153|NCT02626247|Other|Placebo|3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
46108154|NCT02627105|Behavioral|Beef group|Subjects in the beef group will be asked to consume 4 or more servings of beef per week (and to avoid all other red meats) during the 6 month study.
46108155|NCT02627105|Behavioral|Non-beef group|Subjects in the non-beef group will be asked to avoid all red meats during the 6 month study.
46108156|NCT05758818|Drug|Placebo|Participants will receive a single dose of placebo on Day 1, Day 8 or Day 15 of part 2
46108157|NCT05758818|Drug|Moxifloxacin (positive control)|Participants will receive a single dose of moxifloxacin on Day 1,Day 8, or Day 15 of Part 2
45468733|NCT03250325|Drug|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
45468734|NCT03778333|Biological|Autologous mesenchymal stem cells|IV therapy with autologous bone-marrow derived mesenchymal stem cells
45681403|NCT02708680|Drug|atezolizumab|A humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death ligand 1 (PD-L1).
45681404|NCT02708680|Drug|Placebo|A pill containing no active drug ingredient
45681405|NCT03932656|Behavioral|Combined schema-therapy and cognitive behavioral therapy|A six-week inpatient psychotherapeutic program consisting of one small group and one big group therapy per day, one individual session per week, daily sport activities, imagery and relaxation techniques. The therapeutic approach presents a combination of schema-therapy and cognitive behavioral therapy. Schema-therapy will follow guidelines for the treatment of individuals with borderline personality disorder (Farrell and Shaw 2012). A later step in the therapy - strengthening of the called Healthy Adult (that is the ability to perceive situations realistically, think rationally, plan time, set appropriate goals, or behave assertively) will be done by standard cognitive behavioral strategies (cognitive restructuring, core beliefs work, time planning, problem solving, assertiveness training). A detailed description of the program is going to be published in a paper.
46108158|NCT05758818|Drug|Milademetan|"Participants will receive a single dose of Milademetan on Day 1 for part 1~Participants will receive a single dose of milademetan on Day 1, Day 8, or Day 15 of Part 2"
45683908|NCT03133546|Drug|Osimertinib|"Osimertinib is administered orally at 80mg once daily. Doses should be taken approximately 24 hours apart at the same time point each day. The appropriate number of osimertinib tablets will be provided to patients to be self-administered at home. AstraZeneca will supply osimertinib as tablets for oral administration.~AstraZeneca will supply osimertinib as tablets for oral administration."
46022372|NCT00626769|Dietary Supplement|placebo|2 capsules per day containing calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
46108159|NCT02626403|Device|Anodal tDCS|Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3, F4, CP5, and CP6 in order to stimulation the fronto-parietal cortex bilaterally.
46022373|NCT04305171|Procedure|non-surgical periodontal treatment|scaling and root planing, home care instruction
46022374|NCT04294797|Diagnostic Test|Blood draw|One additional blood sample for study purpose from the day before surgery, postoperative 1, 3 and 8.
46022375|NCT02875743|Drug|Posaconazole|
46108160|NCT02626403|Device|Sham tDCS|Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
46108161|NCT02611440|Behavioral|Pharmaceutical care|"Initial interview with pharmacist (at the hospital discharge): Evaluation aimed to identify barriers to adherence to drug treatment followed by an information session on the disease, the benefit of drugs and the importance of diet and lifestyle habits. Pharmacist advices focused on how to take medication and how to manage adverse events will be provided.~Telephone interviews with hospital clinical pharmacist - patient (at M3 M6 and M9): The objective is to review with the patient its medication-taking routine and its potential difficulties, to motivate adherence to treatment and lifestyle/dietary rules, to give advices about therapeutics and how to take medication.~HCP contacts CP to determine the prescription refill. Final interview with HCP pharmacist (at M12): The objective is to take stock with the patient about its taking drug load."
46108162|NCT00828984|Drug|macrogol 3350-based oral osmotic laxative|Given PO
46108163|NCT00828984|Other|Placebo|Given PO
46108164|NCT00828984|Other|Laboratory Biomarker Analysis|Correlative studies
45468735|NCT03816748|Device|High flow nasal cannula, HFNC|The HFNC used in this study can supply more than 40-60 L/min of oxygen flow, which is many times higher than the traditional nasal cannula. In addition, HFNC provides heating and moisturizing functions, so the patients 'nasal and oropharyngeal cavities do not dry out. This way, the patients can wear HFNC continuously for many days. Furthermore, when the patients close their mouths, HFNC can create a PEEP of 6-8 cmH2O, which helps with lung expansion after chest surgeries and lowers the risk of pneumonia related to lung collapses.
46022376|NCT01073163|Drug|Bendamustine|Bendamustine at 90 mg/m^2 IV on Days 1 and 2 of a 28-day cycle.
46022377|NCT01073163|Drug|Rituximab|Rituximab at 375 mg/m^2 IV on Day 1 of a 28-day cycle.
46022378|NCT04305483|Procedure|Laser Bleaching|Content; There are 35% hydrogen peroxide, potassium nitrate, sodium fluoride, sodium hydroxide, thickener, glycol derivative. The way of application; Gingival protection is applied. The gel is applied to the labial surfaces of the teeth with a thickness of 1-2 mm. The use of laser increases the effectiveness of the gel. Operator and patient use protective glasses during laser application. The gel shows its effectiveness in about eight minutes. Then the gel is removed with the help of saliva absorber. The procedure is repeated until the desired degree of whitening is achieved. Then it is checked with a color scale.
46108165|NCT05758584|Other|Intervention|Vibrating tourniquet
46108166|NCT05758584|Other|Distraction card|Distraction card
46022379|NCT04305483|Procedure|Chemical Bleaching|"Total Blanc Office Teeth Whitening System (H35) will be used as chemical whitening agent. Content; There are 35% hydrogen peroxide, thickener, plant extracts, amide, release agent, glycol, paint and water. Method of Application; Gingival protection is applied. A 1 mm thick layer of gel is applied to all of the labial surfaces of the tooth. The whitening agent remains on the tooth surface for 20 minutes. At the end of this period, the gel is removed with saliva absorber and the surface is cleaned with a moist gauze."
46108167|NCT00828750|Drug|Eltrombopag oral tablets|Eltrombopag oral tablets once daily
46108168|NCT05758740|Behavioral|E-health enhanced behavioural change intervention|Participants will first receive a face-to-face brisk-walking training programme with lectures and demonstrations following a standardized brisk training content. The training will be provided face-to-face at the elderly community centres and parks. Each training session lasts for one hour and is two times per week for two weeks. After that, a conventional behavioural change intervention will begin following a standardized intervention implementation manual and the physical activity amount will be logged by the participants using a logbook. Physical activity counselling will be conducted by a trained research assistant face-to-face at the elderly community centre. Each counselling session lasts for one hour and is once per week for 12 weeks.
46108169|NCT05758740|Behavioral|Conventional behavioural change intervention|Participants will first receive a face-to-face brisk-walking training programme with lectures and demonstrations following a standardized brisk training content. The training will be provided face-to-face at the elderly community centres and parks. Each training session lasts for one hour and is two times per week for two weeks. After that, e-health enhanced behavioural change intervention will begin following a standardized intervention implementation manual and using participants' own smartphones installed with two Apps (i.e., Samsung Health and WhatsApp). The physical activity amount will be logged by the smartphone using Samsung Health. Physical activity counselling will be conducted by a trained research assistant remotely using a smartphone. The remote counselling sessions totally last for accumulatively 1 hour per week for 12 weeks.
46108170|NCT05306808|Other|physiotherapy class|The supervised 1-hour group exercise class will be conducted twice a week, with a maximum of 8 patients in each class. Subjects will be given a home log for exercise recording. If subjects are unable to attend exercise class for any reason (eg., low counts or feeling unwell, etc.), they will be advised to continue xercises at home. On the day of one of the exercise classes each week, there will be an additional 1-hour group education/ discussion session which may be conducted by PT, OT, APN, dietician or medical social worker. Topics covered will include physical activity, management of fatigue, lymphoedema, neuropathy, brain fog, return to work, stress, nutrition, sexuality, psychosocial and caregiver issues. There will be 10 sessions of educational class in total for each subject.
46108171|NCT04030494|Diagnostic Test|BP measurement|sequential BP measurement with Withings WPM04 and sphygmomanometer with dual observer auscultation
46108172|NCT04030494|Diagnostic Test|AF detection|single lead ECG with Withings WPM04 and 12 lead ECG
46022380|NCT04304859|Diagnostic Test|BASIC|Validation
46108173|NCT04030494|Diagnostic Test|VHD detection|phonocardiogram with digital stethoscope of Withings WPM04 and Doppler echocardiography
46108174|NCT00667810|Drug|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
46108175|NCT00667810|Drug|bapineuzumab|Bapineuzumab 1.0 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
46108176|NCT00667810|Drug|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
46108177|NCT00819390|Drug|Chloroquine|Taken orally, once daily, at a dose of 250 mg for 12 weeks.
46108178|NCT00819390|Drug|Placebo|Taken orally, once daily for 12 weeks.
45681406|NCT03932656|Drug|Psychopharmaceuticals|Pharmacotherapy will be implemented according to the National Institute for Health and Care Excellence guidelines and will target comorbidities if present to such extent that warrants a pharmacological intervention. If not needed, patients will not use medication. Most patients will be recommended to hospitalization by their outpatient psychiatrists who prescribe the medication. If needed, medication will be changed to meet the guideline standards (i.e., tapering off benzodiazepines or augmentation with a mood stabilizer). The medication will be controlled but not directed by the study.
45681407|NCT03931642|Drug|RCHOP|"D1 : Rituximab 375 mg/m² IV + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.~From D1 to D5 : Prednisone 60 mg/m² PO."
45681408|NCT03931642|Drug|Blinatumomab|Blinatumomab by continuous vein infusion
46108179|NCT00876395|Drug|Everolimus|Everolimus was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).
46108180|NCT00876395|Drug|Placebo|Everolimus placebo was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).
46108181|NCT00876395|Drug|Trastuzumab|Trastuzumab, 2 mg/kg weekly was used intravenously.
46108182|NCT00876395|Drug|Paclitaxel|Paclitaxel, 80 mg/m2 weekly was used intravenously.
46108183|NCT05758662|Diagnostic Test|18F-sodium fluoride Positron Emission Tomography (18F-NaF PET), Cardiac Computed Tomography (CT), Transthoracic Echocardiography (TTE)|Patients undergo a hybrid 18F-NaF-PET CT scan and TTE at five years after TAVI
46108184|NCT00776854|Device|Noveon laser|870 and 930nm wavelengths
45681409|NCT04147312|Drug|Fufang E'Jiao Jiang|Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
45468736|NCT03778567|Drug|Telbivudine|CHB patients who are receiving adefovir or tenofovir disoproxil fumarate are recruited. At the time of recruitment (0 month, baseline), lamivudine is switched to telbivudine while adefovir or tenofovir disoproxil fumarate was continued. The patients are followed-up for 24 months.
45468737|NCT05037461|Radiation|High-dose-high precision MR-guided radiotherapy|MR-guided radiotherapy as described in the group information
45468738|NCT03784066|Drug|Durvalumab|"All patients will be treated with postoperative radiotherapy (66 Gy in standard fractionation).~In case of positive section margins or extracapsular extension, 3 cycles of cisplatin 100 mg/msq on days 1, 22, and 43 will be added to standard fractionation radiotherapy (66 Gy).~Durvalumab monotherapy (1500 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 6 cycles postoperative."
45468739|NCT03784066|Combination Product|Durvalumab + Tremelimumab|"All patients will be treated with postoperative radiotherapy (66 Gy in standard fractionation).~In case of positive section margins or extracapsular extension, 3 cycles of cisplatin 100 mg/msq on days 1, 22, and 43 will be added to standard fractionation radiotherapy (66 Gy).~Durvalumab + Tremelimumab combination therapy: Tremelimumab (75 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 3 cycles postoperative, Durvalumab (1500 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 6 cycles postoperative."
45468740|NCT05168683|Drug|Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing with light meal|Dosing or radiolabelled ALLN-346 fast or slow release tablets or capsules. Scintigraphic images will be taken
45468741|NCT05168683|Drug|Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing in fasted/fed state|Selected dosing of Part One treatments in fasted and/or fed states
45468742|NCT03435328|Device|TENS|"Duration of stimulation: 5 minutes.~Frequency: will be fixed at 50 Hertz.~Pulse duration: 250 µs.~Intensity: optimal intensity of TENS (amplitude will be gradually increased to the maximum intensity that the subject will be comfortable and tolerate it).~Sessions: only one session"
45468743|NCT01320319|Other|Placebo|Capsule form, 960 mg to be taken three times a day.
45468744|NCT01320319|Dietary Supplement|Experimental: Nutritional Supplementation with EPA|Capsule form, EPA, 960mg to be taken three times a day.
45468745|NCT03113123|Drug|PrEP with Truvada®|"Associated with:~STD screening/treatment for syphilis, gonorrhoea and chlamydiae~HIV screening/therapy~Questionnaire~Addiction, social or psychological follow-up care if needed~Peer interactive counselling (peer counselors/nurses/physicians experienced with therapeutic education) at the baseline visit and at every follow-up visit up to 6 months. After 6 months, counselling will be provided at the request of participants if they need it. Counselors will remain in contact with the participants between visit to answer any questions relative to PrEP, treatment and prevention, and to facilitate participants interactions with study sites."
45468746|NCT04267276|Drug|Part 1: BI 1265162 - intravenous|Intravenous solution
45468747|NCT04267276|Drug|Part 2: BI 1265162 - oral|Oral solution
45468748|NCT03772639|Other|Shared decision making|Decision-making processes focused on the knowledge of the disease for set up adjusted care management about their necessities and engaging in recommended health behaviors
46022381|NCT04304235|Device|Pediatric Rapid Sepsis Trigger (PRST) tool|The digital platform consists of a mobile application integrating a pulse oximetry sensor attached to this device, with embedded smart algorithms that predict a critically ill state, or level of risk (below) in a child presenting at the hospital. The platform also includes an interactive dashboard located in strategic locations (e.g., laboratory, consultation rooms), which connects to the mobile application through a secure local network and displays the triage data to provide real-time monitoring for the physicians who manage the patients.
45468749|NCT01239407|Behavioral|Culturally focused psychiatric consultation|"The consultation is comprised of 3 visits:~1a. Psychiatric diagnostic interview, self-rated questionnaires (in-person consultation).~1b. Intervention focused on learning about depression and how to treat it using culturally relevant resources.~2. Follow-up visit two weeks later to go over patients' questions, homework if applicable, and patients' ability to meet the goals outlined in the first visit (in-person or phone visit).~3. 6-month follow up: 6 months after the initial consultation, patients are asked about mental health symptoms and mental health treatment they might be receiving (phone visit unless patient requests in-person)."
45468750|NCT04451122|Other|cleansing the eyelid margins|using eyelid cleaning wipes to cleansing the eyelid margins
45468751|NCT01247129|Procedure|Delay procedure of SIEA flap.|Ligating the deep inferior epigastric artery ipsilaterally to the planned raising of the SIEA flap 2 weeks prior to the reconstructive procedure.
45468752|NCT05030285|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT intervention includes 6 sessions via video-conferencing that has been tailored for people living with cognitive impairment. The sessions incorporate the use of psychoeducation and relaxation videos to improve home-based practise for long-term outcomes.
45468753|NCT01143857|Drug|Varenicline|Varenicline 2.0 mg/day or Placebo
46022382|NCT04304235|Other|Emergency Triage and Treatment (ETAT) guidelines|These are the triage guidelines currently applied in the study hospital sites. This will be the comparator group.
46108185|NCT04161443|Other|physiotherapy|"Treatment will be performed three sessions per week for 4 weeks with postural advice and home exercise program with daily record of home diary.~The selected outcome measures will be taken on initial visit (pre intervention), session 6 and final session 12 (post intervention)."
46108186|NCT02633657|Drug|HORIZANT 300 mg|HORIZANT 300 mg once daily
46108187|NCT02626169|Drug|Clopidogrel|Clopidogrel 75 mg once a day by mouth for 30 days
46108188|NCT02626169|Drug|Ticagrelor|Ticagrelor 90 mg twice daily by mouth for 30 days
45468754|NCT03750292|Device|HEPAirX air filter|It is a trademarked, patented (U.S. Patent # 7,802,443), U.S. FDA approved Class II medical re-circulating air cleaner, built by Air Innovations, Inc. (North Syracuse, NY) to provide improved indoor air quality in the bedrooms of asthmatic children. Units to be used in the proposed study have a 99.97% efficient filter for particles 0.3 µm in size. The device provides a clean air delivery rate (CADR) of 9 per hour with 1.8 of them being outdoor air.
46022383|NCT02875665|Device|geko(TM) device|The geko(TM) device will be used to electrically stimulate the posterior tibial nerve
46022384|NCT02875821|Drug|Ipragliflozin|Patients treated with ipragliflozin (50 mg/day) as add on therapy to metformin and pioglitazone dual therapy (triple therapy) for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Experimental Group)
46108189|NCT00685217|Procedure|TVT Secur (Gynecare)|Sling device for stress urinary incontinence
46108190|NCT00685217|Procedure|TVT (Gynecare)|Sling procedure for stress urinary incontinence
46108191|NCT04139915|Drug|Dactolisib|TORC1 inhibitor
46108192|NCT04139915|Drug|Placebo|Placebo capsule
46108193|NCT00685451|Behavioral|Cognitive Behavioral Therapy (CBT)|
46022385|NCT02875821|Drug|metformin with pioglitazone|Patients maintain metformin and pioglitazone dual therapy for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Control group)
46022386|NCT04723095|Other|Follow-Up|Receive follow up
46022387|NCT04723095|Other|Medical Chart Review|Review of medical records
46022388|NCT04721535|Drug|DWJ1248|Orally, 1 tablet of DWJ1248 TID, up to 14 days
46108194|NCT04148183|Drug|Metformin group|We add treatment with Metformin (850 mg/day), treatment was administered for 8 weeks
46108195|NCT04148183|Drug|Rosiglitazone group|we add Rosiglitazone (4 mg/day), treatment was administered for 8 weeks
46108196|NCT04148183|Drug|Placebo oral tablet|We add Placebo, treatment was administered for 8 weeks
46108197|NCT00681395|Drug|ABT-143|once daily for 6 days
45468755|NCT03750292|Device|control air filter|A placebo mode was added to the HEPAirX to provide only recirculation (without filtration or ventilation using outdoor air) and temperature control of the room air. The placebo filter is made of metal.
45468756|NCT02934659|Device|Atlas(TM) Knee System|The Atlas System is an extra-capsular knee implant designed to unload the medial knee.
45681410|NCT04147312|Drug|placebo containing low-dose fufang E'Jiao Jiang|placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
45681411|NCT03931564|Procedure|PRESERFLO Microshunt implantation|The intervention consists of the microshunt implantation augmented with mitomycin C application.
46022389|NCT04721535|Drug|Placebo|Orally, 1 tablet of placebo TID, up to 14 days
46108198|NCT00681395|Drug|ABT-335|once daily for six days
46108199|NCT00681395|Drug|Rosuvastatin|Once daily for 6 days
46108200|NCT02633579|Drug|erythromycin lactobionate|intravenous administration of erythromycin
46108201|NCT02633579|Drug|Atropine|intravenous administration of atropine
46108202|NCT02633579|Drug|Erythromycin with atropine|intravenous administration of erythromycin with saline
46108203|NCT02633579|Drug|Saline|intravenous administration of saline
46108204|NCT00685529|Drug|Racemic formoterol|12 µg of racemic formoterol fumarate BID
46108205|NCT00685529|Drug|Arformoterol tartrate inhalation solution|15 µg of nebulized arformoterol tartrate inhalation solution BID
46108206|NCT00685529|Drug|Racemic formoterol|24 µg of racemic formoterol fumarate BID
46108207|NCT02633345|Dietary Supplement|Probiotic tablets|Tablets with both Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2. Two tablets a day for four weeks
46108208|NCT02633345|Dietary Supplement|Placebo|Placebo tablets
46108209|NCT00594659|Behavioral|Psychotherapy|Nine session treatment
46108210|NCT00594659|Behavioral|Computerized Psychotherapy|Nine session computer delivered treatment
46108211|NCT00594659|Behavioral|Motivational enhancement therapy|Two session treatment
46108212|NCT00685607|Drug|loperamide-simethicone|Four caplets containing 2 mg loperamide HCl and 125 mg of simethicone each, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
46108213|NCT00685607|Drug|matching placebo|Four placebo caplets matching the caplets in Arm 1, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
46108214|NCT00681551|Drug|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg
46108215|NCT00681551|Drug|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg and another 0.1 mmol/kg 30minutes later.
46108216|NCT00912431|Drug|ABT-126|ABT-126 administered on Day 1 of Period 1
46022390|NCT02875119|Drug|Griffithsin Gel|"Griffithsin Gel is a large biologic molecule that is intended for vaginal rather than systemic administration. In addition, Griffithsin Gel is being developed for the prevention of HIV infection and not as a therapeutic agent. The concentration of Griffithsin Gel associated with prevention of HIV in vitro and in vivo has been established in non-clinical studies (see Section 5). Studies have demonstrated that Griffithsin Gel is highly potent for HIV prevention and is effective at very low concentrations.~One 4 mL dose of PC-6500, designed to provide an adequate vaginal concentration of GRFT for the prevention of HIV, based on preclinical data, will be evaluated. Rising dose tolerance is not the goal of this study because GRFT is likely to be minimally absorbed systemically, if at all."
46022391|NCT02875119|Drug|Placebo Gel|Placebo Gel
46022392|NCT04757415|Other|Traction straight leg raise technique for hamstring|traction straight leg raise technique is used along with gluteal exercises
46108217|NCT00912431|Drug|Placebo|Placebo for ABT-126 administered on Day 1 of Period 2
46108218|NCT04161365|Procedure|Direct visual urethrotomy|Urethral stricture is treated with urethrotomy under visual control
46108219|NCT04161365|Procedure|Autologous fat grafting|Autologous fat graft is gathered and injected to stricture
46108220|NCT00657059|Drug|irbesartan|In the ARB lead-in phase, each subject will be on a strict sodium-restricted diet ( < 5 g NaCl/day), and then given a stable dose (150mg ~ 300mg/day) of irbesartan (Aprovel) for 3 months until reaching the target blood pressure (BP) level of ≤ 125/75 mmHg. Patients will continue ARB treatment in the drug treatment phase and at lease 3 years in the follow-up phase.
46108221|NCT00657059|Drug|methylprednisolone (MP) or prednisone (pred)|Patients will take oral Pred ( 0.5 mg/kg/d) on alternate days, and on the first, third and fifth months of the drug treatment phase, patients will be given intravenous pulse therapy with methylprednisolone ( 0.5 g/day) for 3 successive days. And after 6 months, Pred should be tapered to be stopped until the end of the 12-month course of treatment.
46108222|NCT00657059|Drug|mycophenolate mofetil (MMF)|Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt < 50kg) for the first 6-month of drug treatment phase, then to 0.5 bid (wt ≥ 50kg) for the remaining 6-month.
45468757|NCT05159284|Drug|Hydrocortisone Ophthalmic|1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop, for a total of 14 days of treatment. Repeat on day 28: 1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop. Patients in the intervention arm will receive two 14-day cycles of hydrocortisone.
45468758|NCT05159284|Device|MGD Rx EyeBag® eyelid warming device|Eyelid warming device used once daily for 10 minutes followed by lid massage for 12 weeks by patients in both control and intervention arm.
45468759|NCT05159284|Device|Lephanet® lid wipes|Lid hygiene with Lephanet® lid wipes used twice daily for 3 weeks followed by once daily for 9 more weeks by patients in both control and intervention arm.
45468760|NCT05159284|Device|Thealoz Duo® artificial tear with trehalose 3% and sodium hyaluronate 0.15%|Artificial tear supplementation with Thealoz Duo® 4 times daily for 12 weeks by patients in both control and intervention arm.
46022393|NCT04757415|Other|Gluteal activation exercises,Hotpack|only gluteal activation exercises were performed without traction straight leg raise technique
46022394|NCT04304313|Drug|Sildenafil citrate tablets|0.1g/day for 14 days
46108223|NCT00667732|Drug|exenatide|5mcg twice a day, increasing to 10mcg twice a day for 24 weeks
46108224|NCT00667732|Drug|placebo|5mcg twice a day, increased to 10mcg twice a day for 24 weeks
46108225|NCT04161209|Drug|Citalopram|Single dose administration of citalopram (20mg)
46108226|NCT04161209|Other|Placebo|Lactose placebo tablet
46108227|NCT00767962|Other|talc pleurodesis under medical thoracoscopy|talc pleurodesis under medical thoracoscopy for recurrent primary spontaneous pneumothorax
46108228|NCT00767962|Other|pleurodesis under video-assisted thoracoscopy surgery|pleurodesis under video-assisted thoracoscopy surgery for recurrent primary spontaneous pneumothorax
46108229|NCT04161053|Drug|Rifaximin|Rifaximin 550 mg twice daily for 6 months
46108230|NCT04161053|Drug|Nitazoxanide|Nitazoxanide 500 mg twice daily for 6 months
46108231|NCT00777010|Other|Ketogenic diet|carbohydrate restricted diet
46108232|NCT00777010|Other|Healthy high carbohydrate diet|higher carbohydrate diet
46108233|NCT00685841|Drug|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
46108234|NCT00685841|Drug|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
46108235|NCT00685841|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
46108236|NCT00685841|Drug|Salmeterol MDI|Salmeterol MDI 42 mcg BID
46108237|NCT00685841|Drug|Placebo|Placebo BID MDI
46108238|NCT04145609|Behavioral|Multidisciplinary team (MDT) care and Acute kidney disease (AKD) clinic|Multidisciplinary team (MDT) care: NPDS care model Acute kidney disease (AKD) clinic: layered approach
46108239|NCT00681785|Drug|dalteparine (Fragmin)|transurethrals surgery with and without dalteparine
46108240|NCT04139759|Other|hand massage|In the hand massage group (n = 28), hand massage was applied to the hand without fistula for 8 minutes, 3 times a week, for 4 weeks.
46108241|NCT04139759|Other|foot massage|Foot massages were applied to both feet of the patients in the foot massage group (n = 28), 3 times a week, for 4 weeks and patting and kneading movements were repeated 3-4 times.
46108242|NCT00671788|Drug|Dasatinib|Given orally
46108243|NCT00671788|Other|Laboratory Biomarker Analysis|Correlative studies
46108244|NCT02626481|Drug|Daratumumab|patients treated with Daratumumab (16 mg/kg) and Dexamethasone (40 or 20 mg regarding age of patient)
46108245|NCT02626481|Drug|Dexamethasone|patients treated with Dexamethasone (40 or 20 mg regarding age of patient)
45468761|NCT03778255|Procedure|Sentinel Lymph Node Biopsy|"Injecting carbon nanoparticles (CNP)[Not Equipped with near-infrared fluorescent vascular imager] or CNP combining Indocyanine Green(ICG)[Equipped with near-infrared fluorescent vascular imager].~Identifying and removing sentinel lymph nodes.~Staining all nodes using hematoxylin-eosin staining."
45468762|NCT03718000|Device|Daily self-weighing (DSW)|DSW was conducted using digital WiFi scales during the holiday season. Participants received electronic graphic feedback of their weight fluctuations immediately after weight measurement.
45598553|NCT02348229|Procedure|conventional pathway group|"5-6th postoperative day：Oral diet was changed from liquids to semi-fluids and normal food.~Drains removed"
45598554|NCT02227433|Drug|Brentuximab Vedotin|
46108246|NCT00779818|Device|Electrical acupuncture|Treatment by electrical acupuncture
46022395|NCT01072929|Drug|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
46108247|NCT00779818|Device|Laser|Treatment by laser
46022396|NCT01072929|Drug|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
46022397|NCT02875197|Other|Running on a treadmill at 6 different speeds|All subjects will be required to run at 6 prescribed speeds (2.5, 3.0, 3.5, 4.0, 5.0, and 6.0 m/sec) on a treadmill completing at least 10 consecutive strides, or running for 30 seconds.
46108248|NCT00777166|Drug|oxytocin|oxytocin 5 units diluted with normal saline to a total volume of 10 mL
46022398|NCT04753749|Drug|Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin)|Subjects will receive DAPT during 1 month post procedure, followed by P2Y12 inhibitor monotherapy (cessation of aspirin) for the next 11 months
45468763|NCT01316653|Behavioral|GROW Healthier|Group sessions that meet once weekly for 3 months (intensive phase) with choice of phone call session as preferred by participant, phone call coaching monthly for 9 months (maintenance phase), and monthly cues to action to use one's built environment for healthy activities for 24 months (sustainability phase)
45468764|NCT01316653|Behavioral|GROW Smarter|Group sessions that meet six times over the course of three years with quarterly newsletters.
45468765|NCT03435172|Device|Device-ADRCs intravenously infusion|Medical Device: ADRCs Generated by Celution 800 IV Device and then Infused into Peripheral Vein.
45468766|NCT01239173|Drug|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
45468767|NCT01239173|Drug|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
45468768|NCT01239173|Drug|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
45681412|NCT03931564|Procedure|Trabeculectomy|The usual care / control group will undergo a standard fornix based trabeculectomy augmented with mitomycin C application.
46022399|NCT04753749|Drug|Standard DAPT|Subjects will receive standard treatment: P2Y12 inhibitor and aspirin (DAPT) during 12 months after procedure
45468769|NCT01239173|Drug|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
45468770|NCT03778099|Drug|Cinnamon Cap 500 MG|The Cinnamomum cassia (C. aromaticum) capsules will be purchase from Spring Valley company (distributed by Wal-Mart Stores, Inc. USA) by the investigator.
45468771|NCT03778099|Drug|Placebo|450 mg of starch and 50 mg of cinnamon powder
45468772|NCT05122078|Device|ANI|Investigators will attach the ANI monitor V2 (MDoloris Medical Systems, Lille, France) to the patient and monitor Analgesia Nociception Index (ANI) during anesthesia. Remifentanil infusion rate is adjusted according to ANI monitoring. The ANI is adjusted to be between 50 and 70.
45468773|NCT05122078|Other|Control|Remifentanil infusion rate is adjusted according to the conventional method of blood pressure and heart rate monitroing. Blood pressure and heart rate are controlled to be within 20% of baseline. Investigators will not monitor ANI in this group.
45598555|NCT03517189|Procedure|Aorta no-touch|Participants will be submitted to aorta no-touch off-pump coronary artery bypass surgery.
45598556|NCT02351973|Drug|Hydrochlorthiazide|"HCTZ 25mg to 50mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
45681413|NCT04146766|Combination Product|eHealth|The study was randomized (wait-list-control), and it was estimated that 60 subjects were randomly assigned to the immediate treatment group and the wait-list-control group. The two groups were tested for baseline before intervention in the eHealth. After the first questionnaire evaluation, the experimental group was involved in the eHealth for three months, and after three months, the experimental group and the waiting intervention control group were post-tested. To assess the effectiveness of the two groups before and after the eHealth . Control group that waits for intervention in the fourth month from the beginning of the fourth month to the end of the sixth month
46108249|NCT00777166|Drug|oxytocin|oxytocin 10 units diluted with normal saline to at total volume of 10 mL.
46108250|NCT00681941|Drug|Sevelamer carbonate (Renvela®)|Sevelamer Carbonate Tablets Dosed Three Times A Day
46108251|NCT02557906|Procedure|Breast reconstruction - implant and an ADM (SurgiMend)|Skin or nipple sparing mastectomy and immediate breast reconstruction with implants and SurgiMend
46108252|NCT02557906|Procedure|Breast reconstruction- autologous tissue|Skin or nipple sparing mastectomy and immediate breast reconstruction with autologous tissue
46108253|NCT02557906|Procedure|Breast reconstruction- implant + dermal sling/LD flap|Skin or nipple sparing mastectomy and immediate breast reconstruction using an implant and a dermal sling or a latissimus dorsi flap
46108254|NCT04160741|Other|Radiation and warm environment|"Exposure to hot environment (30°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
45468774|NCT03063203|Drug|Decitabine|"After 2 cycles, patients with progressive disease or relapse (a clear progression with at least >20% bone marrow blasts and an increase of at least 50% from prior biopsy) should be removed from protocol and proceed to salvage treatment according to center preference~Transplant eligible patients who achieve CR, CRc, or CRi, after 3 cycles with a suitable donor will proceed to conditioning regimen and transplant~Transplant eligible patients with PR after 3 cycles may be removed from protocol and proceed to salvage treatment according to center preference~Transplant eligible patients with a suitable donor who achieve mLFS, CR, CRc, or CRi, may proceed to transplant after at 3 cycles~Transplant ineligible patients with (CR, CRc or CRi, PR) will continue on maintenance doses~Transplant ineligible patient with SD after cycle 4 may be removed from protocol and proceed to alternative treatment or continue on protocol according to treating physician's preference."
46108255|NCT04160741|Other|Warm environment|"Exposure to hot environment (30°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
46108256|NCT04160741|Radiation|Neutral environment with radiation|"Exposure to neutral environment (20°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
46022400|NCT04696887|Behavioral|Tele Tai Chi Intervention for Persons Aging with Long-Term Mobility Disabilities|• 8-week Tele Tai Chi intervention, participants will use a tablet or computer to join a small-group, online class (1hr, twice weekly) from home; during each session, participants will exercise as a group along with the pre-recorded video lessons and have the opportunity for social interaction (via video chat) before and after class.
46022401|NCT04305015|Device|NOL Guided Analgesia|NOL values exceeding 25 will typically be treated with boluses of fentanyl 50 µg at roughly 5-minute intervals. The target will be maintained until surgery ends
45468775|NCT03063203|Procedure|Bone marrow biopsy/aspirate|"Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression or relapse~Biopsy/aspirate on Cycle 1 Day 10 is for participants enrolled at Washington University only~Biopsy/aspirate on Cycle 2 Day 28 is at the discretion of the treating physician"
45681414|NCT04021342|Dietary Supplement|Montmorency tart cherry concentrate|Based on previous analysis done by our laboratory each 60 ml of Montmorency tart cherry concentrate contains approximately 73.5 mg of anthocyanins (cyanidin-3-glucoside equivalents) and 178.8 mg of total phenolics (mean gallic acid equivalents)
45468776|NCT03063203|Procedure|Peripheral blood draw|-Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression/Relapse
46022402|NCT04305015|Other|Routine opioid management|Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 50 µg can be given per clinical judgement
46022403|NCT04304937|Other|patient reported outcome measure|2 questionnaires are tested against each other
46022404|NCT01231607|Drug|1mg Finasteride active|1mg finasteride active, by mouth once daily
45468777|NCT03063203|Procedure|Skin biopsy|"Optional but if refuse skin biopsy then participant can provided buccal swab~There is no required time frame for this sample - it may have been collected months or even years prior to the first dose of decitabine~If WBC at time of enrollment is >30,000/µl, skin biopsy should be collected at the time of C1D28 bone marrow biopsy or thereafter"
45468778|NCT03063203|Procedure|Buccal swab|-Baseline (if skin biopsy declined) and Cycle 2 Day 28
46108257|NCT04160741|Other|Neutral environment without radiation|"Exposure to neutral environment (20°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
45468779|NCT04484155|Device|Minimally Invasive Micro Sclerostomy (MIMS)|The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction . The drainage channel is created by a Stainless Steel surgical tool.
45468780|NCT03435094|Drug|Binosto 70Mg Effervescent Tablet|Assess the effect of alendronate 70mg effervescent tablet on bone turnover markers and patient reported outcomes.
45468781|NCT03435094|Drug|Fosamax 70Mg Tablet|Assess the effect of alendronate 70mg tablet on bone turnover markers and patient reported outcomes.
45468782|NCT03772483|Procedure|Local anesthesia with conventional syringe|"Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
46022405|NCT01231607|Drug|0.02mg dutasteride|0.02mg dutasteride active, by mouth once daily
46022406|NCT01231607|Drug|0.1mg dutasteride|0.1mg dutasteride active, by mouth once daily
46022407|NCT01231607|Drug|0.5mg dutasteride|0.5mg dutasteride active, by mouth once daily
46022408|NCT01231607|Drug|Finasteride placebo|finasteride placebo, by mouth once daily
45468783|NCT03772483|Device|Local anesthesia with conventional syringe + VR device|"Virtual reality device (Noon VR, Gear FX) is placed on the face of the patient, playing a video of soothing and peaceful natural landscapes.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
45681415|NCT04021342|Dietary Supplement|Placebo|Placebo beverage matched for calorie content and visual properties of the cherry concentrate
45681416|NCT04021888|Other|Exercise|Education of patients and their caregivers, deep breathing exercise, aerobic exercise and resistance training with elastic bands
46022409|NCT01231607|Drug|Dutasteride placebo|dutasteride placebo, by mouth once daily
46022410|NCT04304547|Drug|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2|"Subject of sequence A takes IP in the following order:~Each tablet of CKD-828 and D097 and D337 be taken at once~CKD-348 T1 1 tablet~CKD-348 T2 1 tabet"
46108258|NCT00657137|Drug|apricoxib + lapatinib + capecitabine|"apricoxib: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert"
46108259|NCT00657137|Drug|placebo + lapatinib + capecitabine|"placebo: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert"
46022411|NCT04304547|Drug|CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,|"Subject of sequence B takes IP in the following order:~CKD-348 T1 1 tablet~CKD-348 T2 1 tablet~Each tablet of CKD-828 and D097 and D337 be taken at once"
45468784|NCT03434938|Behavioral|Motivational interviewing|"MI sessions' goals will to obtain patients' collaboration, creating a shared tailored approach to complement the individual geriatric rehabilitation plan, and reinforcing engagement and adherence at 3 months.~All 20-minutes sessions will follow the logical sequence of MI by Rollnick and Millner (engaging, focusing, evoking and planning) in a semi-structured format to ensure homogeneity. Content will include: 1) Creating engagement with patients by exploring their preferences, values, goals, and their knowledge and expectations about rehabilitation and recovery, 2) enhancing motivation by evoking patients' strengths and abilities, 3) follow-up and reinforcement, and 4) adapting the plan to the improved abilities and to home setting after discharge."
45468785|NCT01236911|Other|Calcium Measurement|after moderate-severe TBI (less as 24 hrs)
46108260|NCT00777244|Drug|MITOTANE|mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance on day 2 to 3 g/day, on day 3 to 4.5 g/day, and on day 4 to 6 g/day. A dose of 6 g/day will be administered until first mitotane blood level is assessed. Further adjustment of dosage will be performed according to blood concentrations and tolerability.
46108261|NCT04160819|Other|Assigned Interventions|Participants in the NI group received an iNIP according to energy and protein intake requirements in addition to dietary advice based on face-to-face interviews with their family members during hospitalization. After discharge, phone calls are adopted for prescribing iNIPs.
46108262|NCT04160897|Drug|Entecavir|entecavir naive for chronic hepatitis B patients
46022412|NCT04304547|Drug|CKD-348 T2, CKD-348 T1, CKD-828, D097, D337|"Subject of sequence C takes IP in the following order:~CKD-348 T2 1 tablet~Each tablet of CKD-828 and D097 and D337 be taken at once~CKD-348 T1 1 tablet"
46108263|NCT04160897|Drug|Tenofovir Disoproxil|tenofovir disopropyl naive for chronic hepatitis B patients
45468786|NCT03772561|Drug|AZD5363+Olaparib+Durvalumab|Patients will receive AZD5363 orally twice a day 4 days-on/ 3 days-off starting 14 days prior to cycle 1 day 1 (C1D1). Olaparib continuously twice a day at 300mg and Durvalumab intravenously at 1500mg once every 4 weeks will commence at C1D1. Treatment will continue until disease progression or the development of unacceptable toxicities.
46022413|NCT01231373|Drug|polidocanol injectable foam, 0.125%|active placebo for blinding
46022414|NCT01231373|Drug|polidocanol injectable foam, 0.5%|0.5% polidocanol foam injection
45838319|NCT03877796|Device|Drug Response Predictor® (DRP)|A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
45683909|NCT03133546|Drug|Bevacizumab|Bevacizumab is administered at 15mg/kg intravenously on day 1 of every 3-week cycle. Bevacizumab for intravenous administration will be supplied by Roche.
45683910|NCT03132922|Genetic|Autologous genetically modified MAGE-A4ᶜ¹º³²T cells|Infusion of autologous genetically modified MAGE-A4ᶜ¹º³²T on Day 1
45838320|NCT03872427|Other|Pharmacodynamic Study|Correlative studies
45838321|NCT03872427|Drug|Telaglenastat Hydrochloride|Given PO
45838322|NCT03831711|Drug|Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Given IV
45838323|NCT03831711|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
46022415|NCT01231373|Drug|polidocanol injectable foam, 1.0%|1.0% polidocanol foam injection
46022416|NCT01231373|Drug|Vehicle|injection of vehicle comparator
46022417|NCT00975130|Biological|SC golimumab|Subcutaneous golimumab at a dose of 50 mg administered once monthly.
46022418|NCT00975130|Biological|IV golimumab|Intravenous golimumab administered up to 3 times (month 7, 8, 10) during a period of 6 months at a dose of 2 mg/kg of body weight.
46022419|NCT01230827|Drug|CNTO 148 (Golimumab)|Patients will receive subcutaneous (SC) (under the skin) injection of golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 248.
46022420|NCT01230827|Drug|Placebo|Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive SC injection of placebo every 4 weeks from Week 16 through Week 48.
45838324|NCT03831711|Procedure|Positron Emission Tomography|Undergo PET/MRI
45838325|NCT03831711|Device|Investigational software and coils in PET/MR scan|General Electric (GE) Healthcare non-approved PET scanner coils and software
46022421|NCT01230827|Drug|Methotrexate|All patients will receive their fixed dose of commercial methotrexate (10 to 30 mg per square meter) weekly throughout the study duration.
45838326|NCT03809624|Drug|INBRX-105 - PDL1x41BB antibody|The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
46022422|NCT01230749|Drug|JNJ-41443532|Participants will receive JNJ-41443532 tablet(s) orally in JNJ-41443532 250 mg arm (1 X 250 mg) and JNJ-41443532 1000 mg arm (4 X 250 mg) in morning and evening, for 28 days.
46108264|NCT00777322|Procedure|Excimer laser ablation, and collagen cross-linking|Surgery is performed with topical anaesthesia. The central corneal epithelium is removed. Excimer laser ablation is applied (typically 15-30 seconds). Residual bed thickness is checked with an ultrasonic pachymeter. Topical application of riboflavin 0.1% in dextran is commenced at 5 minute intervals. When an adequate saturation of the anterior chamber with riboflavin has been achieved, cross-linking treatment will proceed. Output from the UV light generating equipment is measured with a UV light meter and set at 3mW/cm². Thirty minutes of treatment is given, interrupted at five minute intervals by the application of more topical riboflavin drops. Finally the eye has a bandage soft contact lens placed, with preservative free topical antibiotic, steroid, and cycloplegic drop application.
46108265|NCT03874624|Diagnostic Test|two-dimensional speckle tracking|Analysis of myocardial left atrial strain using two-dimensional speckle tracking echocardiography.
46022423|NCT01230749|Drug|Pioglitazone 30 mg|Participants will receive tablet pioglitazone 30 mg orally in morning for 28 days.
46022424|NCT01230749|Drug|Placebo|Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.
46022425|NCT02865694|Other|Cascade|
46022426|NCT04292392|Other|preop ACB, followed by Intra-articular block during TKA surgery|"Preoperative ACB (adductor canal block), followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~Ropivacaine 5mg/ml (49.25ml)~Epinephrine 1mg/ml (0.5ml)~Ketorolac 30mg/ml (1ml)~Clonidine 0.1mg/ml (0.8ml)~Saline 48.45ml"
45468787|NCT03430570|Behavioral|Tablet TRAC Emotion Regulation Intervention|The intervention focuses on developmentally appropriate strategies for emotion regulation during difficult situations, particularly those related to risk, using 3 primary groups of strategies identified during qualitative work in Project TRAC (R34 MH078750): 1) getting away (physically or cognitively) from triggers for strong emotions, 2) releasing emotional energy in healthy ways (physically or verbally) or 3) changing cognitions and appraisals about emotional triggers. Using strategies effective in TRAC, teens will engage in games to practice and apply strategies to risk scenarios, as well as personalize content learned.
46108266|NCT00682019|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 8 hours before sexual intercourse
45468788|NCT03772405|Drug|Nascum Plus|nasal application of nascum plus
46022427|NCT04292392|Other|preop ACB+IPACK block|Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block
46108267|NCT00682019|Drug|Placebo|matching placebo
46108268|NCT00779896|Drug|Tazarotene|Topical 0.1 cream - apply to lesions on alternate days and at 2 week interval increase to once-daily application, if tolerated.
46108269|NCT00682097|Drug|RO4998452|Escalating oral doses
45468789|NCT03772405|Other|ACC|4 hours challenge to grass pollen in the allergen challenge chamber (ACC)
45468790|NCT03430414|Diagnostic Test|Transcriptome Analysis|Transcriptome Analysis of Formalin Fixed Paraffin Embedded biopsies
45468791|NCT05497297|Drug|HSK7653 tablets|HSK7653, tablet, oral
45468792|NCT01239485|Drug|Irinotecan|"Chemotherapy: irinotecan, etoposide, and cytarabine daily for 5 days (on days 0, 1, 2, 3, & 4) -30 min: Atropin ivs 0 hour: irinotecan X mg/m2 in D5W 100 mL IV over 60 min 0 hour: etoposide 100 mg/m2 in x3 N/S mL IV over 60 min 12 hour: cytarabine 2,000 mg/m2 over 3 hr~*if age ≤ 3 yrs: calculate all drugs in kg base (30kg=1m2) Irinotecan dose is escalated by 25-30% in successive cohorts. The starting irinotecan dose (level 1) is 20 mg/m2/dose on days 0 to 4."
46108270|NCT00682097|Drug|placebo|Oral doses
46108271|NCT00779974|Other|Evaluation|For this research study each enrolled subject will have a clinical exam, including range of motion (ROM), and strength testing. The lift off and belly compression tests will be performed. An ultrasound of the shoulder will be done to determine the integrity of the subscapularis tendon. An EMG will be done to determine functionality of the subscapularis.
46108272|NCT02556268|Drug|Riociguat (Adempas, BAY 63-2521)|0.5 mg, Oral (fasted conditions), 1 single dose
46108273|NCT02556268|Drug|ATRIPLA|600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
45683911|NCT03132922|Radiation|Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation|Up to 10 subjects will be considered for Radiation sub-study. Radiation with an intensity of 1.4Gy for 5 days before infusion of MAGE-A4c1032T cells
45683912|NCT01551303|Drug|Oxytocin|Liquid metered-dose nasal spray, 30 IUs, administered once.
45683913|NCT01551303|Drug|Placebo|Matched nasal spray placebo
45683914|NCT01550757|Behavioral|Embedded Peer Mentor|This intervention/condition consists of a formerly homeless individual embedded in the PACT or H-PACT clinic team. This person is responsible for community-based follow-up for homeless patients randomly assigned to him or her. In addition to structured, scheduled meetings with assigned study subjects, the peer mentor will also participate in PACT/H-PACT team meetings and serve as a liaison between the study subject and his or her primary care team. Peer mentors will be hired as VA term employees in Research.
45683915|NCT03561220|Radiation|Standard of Care IMRT (Photon)|As this trial is pragmatic, all treatment will be standard of care.
46108274|NCT02556268|Drug|COMPLERA|200 mg emtricitabine, 25 mg rilpivirine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
45468793|NCT03430336|Other|CDSS provides drug-therapy relevant information|External computerized decision support system (CDSS: RpDoc® eMMa Software, RpDoc® Solutions GmbH, Saarbruecken) provides drug-therapy relevant information about participating patients with polypharmacy on demand to the general practitioners (GPs) such as data about diagnoses and treatments. The information is based on claims data gathered from all health care professionals involved in the care of the patient (e.g. specialized physicians, other GPs, psychotherapists as well as data about hospital stays and prescription data from pharmacies).
45468794|NCT03430336|Other|Modification of medication|GPs can add and modify patient's data within the CDSS (e.g. remove drugs which are not taken by the patient anymore, add most recent laboratory findings about kidney function etc.) to enrich and update claims data based information.
45468795|NCT03430336|Other|Assessment of medication appropriateness|GPs systematically assess the appropriateness of the medication supported by the CDSS, which will alert in case of drug-drug, drug-disease, and drug-age interactions as well as other inappropriateness, such as prescriptions with regard to incorrect dosage or Dear Doctor letters.
46108275|NCT02556268|Drug|STRIBILD|150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
45468796|NCT03430336|Other|Medication plan|GPs print out the updated medication plan including also recommendations for medication use and reasons for prescription in lay language (also available in foreign languages for patients with migration background) as well as recommendations on drugs to use / to avoid including over-the-counter drugs (OTC) (optional) and hand it out to the patient.
45468797|NCT03430336|Other|Guidance in medication process|GPs receive guidance via the CDSS (e.g. recommendations addressing certain types of medication errors and high risk prescribing, developed by the German Society for Internal Medicine in collaboration with other scientific medical societies).
46108276|NCT02556268|Drug|TRIUMEQ|600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine, i.e. 1 tablet, once daily
46108277|NCT02556268|Drug|Antiretroviral protease inhibitor|Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents
46108278|NCT00682175|Other|Observational|Pulmonary Artery pressure (PA), pulmonary capillary wedge pressure (PCWP), cardiac output (CO), and cardiac index (CI). This data will be collected after 24 ± 2 and 48 ± 2 hours of standard heart failure therapy
46108279|NCT00780052|Drug|c-myb AS ODN|Subjects will be admitted to the hospital to receive c-myb AS ODN as a 24-hour continuous intravenous infusion over 7 days. Dose level is increased with each new subject to determine if there is a MTD.
45468798|NCT03434860|Dietary Supplement|probiotic|"The multiprobiotic Symbiter which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of probiotic per day."
45468799|NCT03434860|Dietary Supplement|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
45468800|NCT01146041|Drug|Rivastigmine|Rivastigmine 1.5 mg Capsules
46108280|NCT00780130|Other|No Intervention|male & female college students ages 20 to 50, asymptomatic normals
46108281|NCT02626637|Other|Physical activity coaching|Children and adolescents will receive the study intervention, which includes exercise coaching and prescription, that is be incorporated into the standard care they receive from the nurse practitioners during their outpatient visits.
45468801|NCT03411148|Behavioral|Weekly exercise sessions with physical therapist and psychologist|Eight weekly sessions integrating techniques from physical therapy and cognitive behavioral therapy. At the start of each session participants play virtual reality games that target balance and functional gait and then discuss their balance confidence and activity avoidance behaviors with a behavioural counselor. Weekly homework assignments ask participants to report on thoughts causing them to avoid activities and to slowly engage in activities that present increasing levels of fear.
45468802|NCT03411148|Behavioral|Home-based exercises|Stretching and other exercises are safely taught by physical therapist and then practiced at home following a provided schedule. Participants receive periodic calls to discuss progress.
45468803|NCT01146899|Other|Provider Alert|Provider influenza vaccine alert
45468804|NCT04450810|Other|Observation of serum and salivary NLRP3 levels|Evaluation of serum and salivary NLRP3 levels
45683916|NCT03561220|Radiation|Standard of Care Proton Therapy|As this trial is pragmatic, all treatment will be standard of care.
45683917|NCT03561220|Radiation|Proton Arm 1: Standard Proton Therapy|78.0 Gy (RBE) in 39 fractions
45683918|NCT03561220|Radiation|Proton Arm 2: Hypofractionated Proton Therapy|60.0 Gy (RBE) in 20 fractions
46108282|NCT00780286|Device|Polymer based lubricating liquid|5 mls of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
46108283|NCT00780286|Device|Moi-Stir|2 sprays (0.35 mL) of the radiolabeled commercial device. A blend of Water, sorbitol, carboxymethylcellulose, sodium, methylparaben, propylparaben, potassium chloride, dibasic sodium phosphate, calcium chloride, magnesium chloride, sodium chloride, flavor.
46108284|NCT00875615|Drug|Carboplatin|Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
46108285|NCT00875615|Drug|Cisplatin|Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
46108286|NCT00875615|Drug|Sorafenib|Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.
46108287|NCT00768352|Other|Educational intervention|An educational intervention which will consist of a standardized PowerPoint presentation that will cover general mental health topics such as depression and substance abuse. The presentation will also include discussion of common and validated mental health screening and assessment tools, as well as how to use these tools in a clinical setting. An educational packet will be provided to the residents and will include the screening tools, information on motivational interviewing and the behavioral stages of change, information on common medications prescribed for mental health disorders, and a bibliography of reputable resources for mental health topics.
46108288|NCT02626559|Drug|liposomal bupivacaine/plain bupivacaine peri-articular injection|Injection of a mixture of liposomal and plain bupivacaine around the knee during total knee arthroplasty.
45468805|NCT04450576|Diagnostic Test|Glycosylated hemoglobin|Glycosylated hemoglobin levels associated with correlative measures of diastolic cardiac function
46108289|NCT00780520|Dietary Supplement|alanine-glutamine infusion|
46108290|NCT00682409|Other|MR Imaging|MR imaging in the post operative follow-up of cholesteatoma in children
45468806|NCT03430258|Device|high-flow nasal cannula|high flow of air with supplemental oxygen was delivered by an Optiflow cannula interface using an AIRVO 2 blower humidifier
45468807|NCT03430258|Device|Conventional oxygen therapy|Conventional oxygen therapy
46108291|NCT00777400|Drug|Efalizumab|1 mg/kg of efalizumab administered sub q once weekly
46108292|NCT04143737|Behavioral|Healthy lifestyle intervention|38 women participated in the intervention group which was located in a community center in Zur-Baher neighborhood. The intervention consisted of 20 weekly sessions on nutrition, physical activity, stress management skills, and self-monitoring. All taught by professional facilitators (nutritionists, exercise trainers, health coaches, and psychotherapists). Baseline data was collected
45468808|NCT05155735|Procedure|Replantation|Surgical reattachment of a severed body part
46022428|NCT04292392|Other|preop ACB+IPACK block, followed by Intra-articular block during TKA surgery|"Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block, followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~Ropivacaine 5mg/ml (49.25ml)~Epinephrine 1mg/ml (0.5ml)~Ketorolac 30mg/ml (1ml)~Clonidine 0.1mg/ml (0.8ml)~Saline 48.45ml"
46022429|NCT00903175|Drug|everolimus|Everolimus was administered orally at 10 mg/day. Everolimus is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
46022430|NCT00903175|Drug|sunitinib|Sunitinib was administered orally 50 mg daily, on a schedule of 4 weeks on/2 weeks off. Sunitinib was supplied as hard gelatin capsules of 12.5 mg, 25 mg, or 50 mg strength according to local practice.
46022431|NCT01229735|Drug|Levetiracetam|250 mg and 500 mg levetiracetam tablet 1000 mg/day (500 mg bid) levetiracetam (maximum to 3000 mg/day) Duration: maximum 52 weeks
46022432|NCT01229735|Drug|Topiramate|25 mg and 100 mg topiramate tablet 100 mg/day(50 mg bid) topiramate (maximum to 400 mg/day) Duration: maximum 52 weeks
46022433|NCT03866200|Drug|resveratrol|125 mg/day or 5 ml once per day for 90 days
46022434|NCT03866200|Drug|Placebo|5 ml once per day for 90 days
45468809|NCT05155735|Procedure|Primary wound closure|Primary wound closure with removal of exposed bone
45468810|NCT03430180|Drug|Naloxone hydrochloride|Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
45468811|NCT03430180|Drug|Placebo|One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
45468812|NCT03777787|Dietary Supplement|Denatonium Benzoate|A single intragastric administration of denatonium benzoate (1 µmol/kg)
46022435|NCT05510843|Drug|THB001|100 mg capsules for oral administration
46022436|NCT02742493|Other|0.028 bonded to canines|lower fixed canine and canine retainer (0.028 stainless steel bonded to canines) and upper removable Hawley (Intervention A)
46022437|NCT02742493|Other|0.027 7-strand bonded to all 6|lower fixed canine to canine retainer (7-strand Twistflex 0.027 bonded to all six anterior teeth) and upper removable Hawley (Intervention B)
46022438|NCT02742493|Other|removable Hawley-type|lower Hawley-type and upper Hawley removable retainer (Control)
46022439|NCT02848495|Genetic|Non-Interventional|
46022440|NCT02848183|Drug|Cytarabine|
46022441|NCT02848183|Drug|Idarubicin|
46022442|NCT02848183|Drug|Mitoxantrone|
46108293|NCT00768508|Drug|Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy|Ondansetron 4 ug/kg b.i.d.for 12 weeks
46108294|NCT00768508|Drug|Naltrexone 50 mg/day + Cognitive Behavioral Therapy|Naltrexone 50 mg/day for 12 weeks
45468813|NCT03777787|Dietary Supplement|Water|A single intragastric administration of water
45468814|NCT03428854|Drug|LNG-IUS|Levnorgestrel containing IUD
45468815|NCT03774589|Procedure|Magnetic Compressive Anastomosis|The magnetic compressive anastomosis will be used to complete the anastomosis during bilioenteric anastomosis.
45468816|NCT03774589|Procedure|Manual Anastomosis|A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
45468817|NCT03428776|Behavioral|Standard Compliance-linked incentives|Standard mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification
45468818|NCT03428776|Behavioral|Intelligent Compliance-linked incentives|Intelligent mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification
45468819|NCT03428776|Other|Record keeping|Electronic immunization records on cloud-based software platform and use of biometric identification
46022443|NCT02848183|Drug|Etoposide|
46022444|NCT02848183|Procedure|Hematopoietic stem cell transplantation|
45468820|NCT04854031|Device|Cochlear Implants|Individuals with cochlear implants will be tested on their hearing ability. Auditory recordings of speech will be played to participants from a loudspeaker. Recordings will be edited to add competing noise sources and to adjust talker voice pitch. Synthetic sounds will be manipulated to control auditory cue salience in detection tasks.
45468821|NCT04807387|Device|Vaginal Stent A|Ring stent
46108295|NCT00768508|Drug|Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy|Combination of ondansetron 4 ug/kg b.i.d. and naltrexone 50 mg/day for 12 weeks
46022445|NCT00974974|Drug|IPX066|extended-release carbidopa-levodopa capsules
46108296|NCT00768508|Other|Placebo + Cognitive Behavioral Therapy|Placebo comparator
46108297|NCT00682487|Other|Hair sampling for cortisol|Hair sampling for cortisol
46108298|NCT00682487|Other|Hair sampling for cortisol|Hair sampling for cortisol
46108299|NCT00777478|Drug|capiri-sutent|A dose escalating study in a 3 + 3 design will be performed. At MTD dose 14 additional patients will be treated. First, the optimal dose of sunitinib in a continuous schedule will be determined, thereafter, further dose escalation of capecitabine and irinotecan will be investigated.
46108300|NCT04143425|Diagnostic Test|3-Tesla conventional magnetic resonance imaging|T1-weighted, T2-weighted, fluid-attenuated inversion recovery, and contrast-enhanced T1-weighted imaging
45468822|NCT04807387|Device|Vaginal Stent B|Flower stent
46108301|NCT04143425|Diagnostic Test|Advanced imaging without contrast use|Diffusion-weighted imaging, amide proton transfer-weighted imaging, electrical properties tomography, and 2hG-magnetic resonance spectroscopy
46022446|NCT00974974|Drug|IR CD-LD|immediate-release carbidopa-levodopa tablets
46022447|NCT02715583|Drug|11C-Acetate|
45468823|NCT04807387|Device|Vaginal Stent|Vaginal stent chosen from A or B that is the most comfortable
45468824|NCT03430102|Diagnostic Test|Indicor|Calculation of LVEDP via analysis of PPG waveform with Valsalva
45468825|NCT03774511|Other|High-Intensity Interval Exercise & Moderate Intensity Interval Exercise|Different Interval intensities Exercise
45468826|NCT03430024|Other|Association of Myosin VI with oestrogen receptor|"Gene expression analysis - RNA will be extracted from 100mg of tissue and then subjected to RT-qPCR to determine the relative expression levels of several genes, including MVI and ER Targets. We will use the same approach to determine which isoforms of MVI are expressed in the tissue.~Protein content analysis - Total protein will be extracted from 100 mg of tissue and western-blot analysis will be used to determine the relative amounts of MVI. Moreover, we will use cell fractionation to determine relative amounts of nuclear versus cytoplasmic protein.~Genomic analysis - Chromatin-immunoprecipitation (ChIP) experiments we be performed upon 100 mg of tissue sample. Here we will determine the localisation of MVI on the genome within the different tissues."
46108302|NCT04143425|Diagnostic Test|Dynamic susceptibility contrast-weighted imaging|Cerebral blood volume and vessel architectural imaging parameters
46108303|NCT00780598|Drug|Tosedostat|"In Part A, approximately 70 subjects will be randomized to one of 2 dose regimens of tosedostat which will be administered orally, once daily. The dose regimens of tosedostat will be:~120 mg for 6 months once daily, OR~240 mg (induction dose) once daily for 2 months, followed by 120 mg(maintenance dose) for 4 months~In Part B a further 130 subjects will receive the dose regimen of tosedostat identified in Part A as being appropriate, based on the interim analysis during Part A."
46108304|NCT00780754|Drug|dutasteride|0.5mg
46108305|NCT00780754|Procedure|prostate biopsy|prostate biopsy
46108306|NCT02633423|Procedure|Use of PEEP before and after CPB|PEEP will be set in order to reach an airway pressure of 5 cmH2O
46108307|NCT02633423|Procedure|No use of PEEP before and after CPB(ZEEP)|No PEEP will be used
46108308|NCT02633423|Procedure|Ventilation with CPAP during CPB|A continuous Positive Airway Pressure (CPAP) will be applied during CPB
46108309|NCT02633423|Procedure|No ventilation during CPB|No ventilation will be provided during CPB. Patients will be deconnected from ventilator. Lungs will completely collapse.
46108310|NCT05031910|Other|Medical Device Usage and Evaluation|Undergo virtual reality imaging via VR/3D-CEPs
45468827|NCT05482555|Procedure|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).
45468828|NCT05482555|Procedure|Surgical cut-down and arterial puncture under direct vision|Surgical cut-down and arterial puncture under direct vision.
46108311|NCT05031910|Other|Best Practice|Receive standard of care
46108312|NCT05031910|Procedure|Resection|Undergo surgical resection
46108313|NCT00780832|Behavioral|Dietary Caffeine reduction|Participants are counseled about reduction of dietary caffeine, given written information and a bladder control log.
45683919|NCT01685073|Drug|Zolpidem extended-release|nightly administration of zolpidem extended-release
46022448|NCT02848417|Drug|Curcumin|Perform a randomized phase I/II study comparing curcumin (increased bioavailable form, body cell mass-85, 400 mg twice a day) to glutathione (liposomal bioavailable form 630 mg bid), with a 3 month intervention and assessment of safety, efficacy and biomarker response to therapy.
46022449|NCT02848417|Drug|Glutathione|Perform dynamic modeling studies before and after 3 months of therapy, repeating the method used previously in order to compare the response to exercise across groups and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.
46108314|NCT00780832|Drug|Anticholinergic medication|Detrol LA 4mg. orally, once daily for 30 days
46108315|NCT00597701|Drug|Baclofen|Baclofen 10 mg by mouth every 8 hours for 72 hours or until discharge if before 72 hours.
46108316|NCT00597701|Drug|Placebo|Placebo
46108317|NCT00597701|Drug|Lorazepam|"Lorazepam was provided to all subjects (both arms of the study), as indicated by clinical condition. Standard symptom-triggered dosing of lorazepam for alcohol withdrawal was used. That is, the size and the frequency of the dose of lorazepam was determined by the severity of the alcohol withdrawal symptoms."
46108318|NCT02556658|Device|General anesthesia managed by the Smartpilot® View|General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
46022450|NCT02848417|Other|Placebo|"Placebo liquid 120 ml per/ bottle~Placebo capsules 60 capsules per bottle 400 mg /cap~With the addition of a Partner PI, redox/methylation expert Dr. Richard Deth, perform studies of antioxidant and methylation-related metabolic status prior to, during and after acute exercise in GWI subjects before and after interventions."
46108319|NCT02556658|Device|General anesthesia managed without the Smartpilot® View|General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium. The maintenance of anesthesia will be directed by desflurane and sufentanil. The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
46108320|NCT02632955|Drug|Drug Eluting Balloon|After pre dilation of the lesion with regular angioplasty balloon, drug coated balloon Lutonix(R) by Bard Inc. will be introduced over the lesion as quickly as possible. Lutonix is a paclitaxel coated balloon which delivers the drug locally. The diameter of the drug coated balloon will be same as the diameter of the largest balloon used for pre dilation. Drug coated balloon will be inflated not exceeding the rated burst pressure. The minimum inflation time will be 1 minute.
46108321|NCT02632955|Procedure|Regular angioplasty|After predilation of the lesion with regular balloon, the same balloon will be reintroduced without the drug to be inflated for a minimum of 1 minute. This angioplasty will not deliver any local drug.
46108322|NCT04048486|Other|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages & Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
46022451|NCT04221841|Other|descriptive|correlation
46108323|NCT04048486|Other|Physical development and General Health|Physical development and General health examination
46108324|NCT04048486|Other|Developmental Red flags|Developmental Red flags Questionnaires
46108325|NCT04160273|Diagnostic Test|patient questionnaire and telephone follow-up|PDI scale is filled in before returning home and follow-up at one month and one year thanks to a telephone call during which the patient answers the PCL-S questionnaire
46108326|NCT04048720|Behavioral|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as the pair customarily does. If the child becomes restless and dysregulated, the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comforting touch, soothing words and eye contact. Each dyad will be offered eight group FNI sessions.
46108327|NCT00657293|Behavioral|Arm training program|Patients will undergo a specific arm training program (ATP) three times a week for the duration of the 6 week program. The ATP will consist predominantly of resistance exercises. Muscle groups targeted during the ATP will include deltoid, biceps and triceps, pectoralis and latissimus. Subjects will train using multi station gym equipment and free weights.
46108328|NCT00657293|Behavioral|Purdue pegboard test (sham)|In an attempt to make the groups comparable in terms of attention, the control group will perform the purdue pegboard test of finger dexterity. The tasks will be performed in a sitting position with the arms supported on a table. This test will consist of 4 timed tasks where as many pins as possible will be placed on a pegboard in a given time. Performance of the pegboard test is likely to improve with practice which may serve to motivate the patients to continue practicing over the 6-week period. Subjects will perform this activity 3 times per week with supervision provided by a physiotherapist.
46108329|NCT00780988|Biological|Autologous tumor cell + CpG vaccine|
46108330|NCT00780988|Procedure|Autologous hematopoietic and immune cell rescue (transplantation)|
46108331|NCT02535455|Behavioral|ACES Pilot|This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).
46108332|NCT02556034|Other|Disease evaluation.|Patients will complete a self-evaluation of 28 joint counts for swelling and tenderness and assess their disease activity on a Visual Analog Scale. A 28 joint count and VAS will then be assessed by a nurse and by a rheumatologist. The same rheumatologist will examine all patients and two nurses will each randomly assess half the total enrolled patients. The nurse will be blinded to the patient's joint count and VAS, and similarly, the rheumatologist will be blinded to both the patient and nurse's assessments.
46108333|NCT04031573|Drug|Ivabradine|Ivabradine will be administered via the enteral route, every 12 hours, at doses ranging from 2.5 to 5 mg to achieve a target heart rate between 80 and 94 bpm
46108334|NCT04031573|Drug|Ivabradine|Ivabradine will be administered via the enteral route, every 12 hours, at doses ranging from 5 to 7.5 mg to achieve a target heart rate between 80 and 94
46022452|NCT04204642|Other|CAA patients data collection|Demographic and clinical data of each patient, including index event that led to the diagnosis (cerebrovascular disease, dementia, gait disturbance, TFNE, seizures, headache), vascular risk factors, history of brain injury or neurosurgery, familial history, and pharmacological treatment will be collected by neurologists in charge.
46022453|NCT02847403|Drug|Exenatide|Patients will be injected subcutaneously 2 mg long-acting exenatide once-weekly. No dose titration is foreseen.
45468829|NCT03769597|Drug|Iohexol Inj 300 MG/ML|After injecting a loading dose of 5ml of iohexol bolus, blood samples will be taken at given times for 24 hours. The urinary samples will be taken at each urination, with measurement of the exact volume and times
45468830|NCT03434782|Drug|In-office dental bleaching|The group will receive in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 3 sessions, with a 7-day interval.
45468831|NCT03434782|Drug|Low Level Laser Therapy|It will be used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and apical region of the incisors, canines and premolars.
46022454|NCT02847403|Other|placebo|patients will be seen at the Center for Cognitive Disorders and Dementia according to their usual schedule.
46022455|NCT04801537|Other|normal body temperature and warm extremities|environmental temperature is set according to the standard method to keep normal body temperature and warm extremities
46022456|NCT04801537|Other|normal body temperature and cold extremities|environmental temperature is set according to the standard method to keep normal body temperature, but cold extremities
46022457|NCT02863900|Other|cohort of BC of each subtypes|
46022458|NCT02848339|Drug|aspirin|aspirin desensitization
46022459|NCT04288492|Behavioral|Respiratory biofeedback|Repeat the inspiration and exhalation breaths for a fixed period of time using a biofeedback device (ResCalm)
46022460|NCT04288180|Other|No intervention|There will be no intervention in this study. Adults with social anxiety disorder will complete research assessments related to fear and safety learning.
46108335|NCT04031573|Drug|Placebo|Placebo will be administered via the enteral route, every 12 hours.
46022461|NCT02847481|Procedure|fecal microbiota transplantation|fecal microbiota transplantation
46022462|NCT02847481|Drug|placebo fecal microbiota transplantation|placebo fecal microbiota transplantation
46022463|NCT02847481|Procedure|FMT with antibiotic pre-treatment (v1)|FMT with antibiotic pre-treatment (v1)
46022464|NCT02847481|Procedure|FMT with antibiotic pre-treatment (v2)|FMT with antibiotic pre-treatment (v2)
46108336|NCT00682721|Drug|Placebo|Matching placebo two pills once daily
46022465|NCT04287634|Other|Segmental Mobilization|Hot fermentation =10 minutes Soft tissue mobilization =5 minutes Targeted segmental mobilization= 3 sets of 10 repetitions Home plan exercise= cervical muscles stretching, postural care.
46108337|NCT00682721|Drug|Valacyclovir|1 gram daily x number of days active in the study
45468832|NCT03434782|Drug|5% potassium nitrate / 2% sodium fluoride gel|5% potassium nitrate / 2% sodium fluoride gel will be applied for 10 minutes on the vestibular surface of all pre-bleached dental elements, following the manufacturer's protocol.
45468833|NCT01320397|Drug|Rostafuroxin|6 microgram capsules
45468834|NCT01320397|Drug|Rostafuroxin|50 micrograms capsules
45468835|NCT01320397|Drug|Rostafuroxin|500 micrograms capsules
46022466|NCT04287634|Other|Entire Spine Mobilization|Hot fermentation=10 minutes Soft tissue mobilization=5 minutes Entire spine mobilization =3 sets of 10 repetitions Home plan exercises=cervical muscles stretches, postural care.
46022467|NCT04795453|Other|score system to predict the need for surgery|two and more grades of NEC is assessed using the score system to predict the need for surgery
46022468|NCT04795453|Other|usual method to predict the need for surgery|two and more grades of NEC is assessed using the usual method to predict the need for surgery
46022469|NCT04287712|Diagnostic Test|Plasma lipids|Plasma lipids were detected by an Ultimate 3000 ultra-high-performance liquid chromatography (UHPLC) system coupled with Q-Exactive MS (Thermo Scientific) . Then a detection model was built based on plasma lipids using machine learning algorithm.
46022470|NCT04288102|Biological|UC-MSCs|3 does of UC-MSCs(4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6.
46108338|NCT00671554|Biological|Melaxin (autologous dendritoma vaccine) and BCG|Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million CFU of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration.
46108339|NCT00686465|Other|PET/CT scan|Patients will undergo whole body FDG-PET/CT imaging
46108340|NCT00768742|Device|VizAblate Intrauterine Ultrasound-Guided RF Ablation|VizAblate enables a minimally invasive procedure to visualize, target and treat uterine fibroids using ultrasound visualization and RF energy.
45468836|NCT01320397|Drug|Losartan|Losartan 50 mg once a day
45683920|NCT01685073|Behavioral|MET/CBT|a standardized 12-week therapy consisting of motivational enhancement therapy (MET) and cognitive behavior therapy (CBT) for treating cannabis use disorders will be administered to all study participants
46022471|NCT04288102|Biological|Saline containing 1% Human serum albumin（solution without UC-MSCs）|3 does of placebo（intravenously at Day 0, Day 3, Day 6）
46022472|NCT02848261|Behavioral|Developmental Demands|Education and training related to use of CGM in this age group
46022473|NCT02848261|Behavioral|Distress Reduction|Education and training on reducing distress
45468837|NCT03428698|Device|Aminogam|A lower third molar was extracted. All the surgical tools and materials as well as the surgical field were sterile. A full-thickness flap was raised and, if necessary, osteotomy and tooth sectioning were performed using a straight handpiece with dedicated burs under copious irrigation with sterile saline solution. The extraction was completed with curved and straight extractors, the socket was closely inspected and the dental follicle was removed. Depending on the group to which the patient was assigned, one of the following procedures was carried out.
46108341|NCT00781066|Procedure|Controlled cord traction|"Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn), hold it in one hand.~Place the other hand just above the woman's pubic bone and stabilize the uterus by applying counter-pressure during controlled cord traction.~Keep slight tension on the cord and await a strong uterine contraction (2-3 minutes).~With the strong uterine contraction, encourage the mother to push and very gently pull downward on the cord to deliver the placenta. Continue to apply counter-pressure to the uterus.~If the placenta does not descend during 30-40 seconds of CCT, do not continue to pull on the cord:~Gently hold the cord and wait until the uterus is well contracted again;~With the next contraction, repeat CCT with counter-pressure."
46108342|NCT00781066|Procedure|No controlled cord traction|"Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn).~No CCT will be used and no fundal pressure. The placenta will be delivered physiologically, and signs for placental separation will be awaited (gush of blood from the vagina, descent of the umbilical cord, and increase in the height of the uterus in the abdomen as the lower segment was distended).~After separation, delivery of the placenta will be aided only by maternal expulsive efforts and/or gravity."
45838327|NCT03809624|Drug|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
46108343|NCT02626091|Procedure|Left-sided colonic resection|"During interventions, anastomosis perfusion will be estimated (outcomes: visual appreciation of the surgeon, ICG fluorescence-based enhanced reality and series of peri-operative samplings) in order to validate the accuracy of ICG fluorescence-based enhanced reality technique.~In any case, the resection will be performed according to the surgeon's appreciation."
46022474|NCT02848261|Behavioral|Remote Monitoring|Education and training on the use of remote monitoring
46108344|NCT02556814|Drug|Caffeic acid tablets|Oral administration of caffeic acid tablets 0.3g three times per day for 3 months
46022475|NCT02848261|Behavioral|Fear of Hypoglycemia|Education and training on reducing fear of hypoglycemia
46022476|NCT02848261|Behavioral|No intervention|No intervention - serves as the control group
45468838|NCT03434704|Drug|"Conditioning treatment Thiotepa-Treosulfan-Fludarabine"|Thiotepa iv 5 mg/kg/bid (total dose TD 10 mg/kg) day -3,-2; Treosulfan iv 14g/mq/day (TD 42 g/mq) as a single daily dose day -6, -5, -4; Fludarabine iv 30 mg/m2 (TD 150 mg/m2) day -6, -5, -4, -3, -2. Thiotepa TD 5 mg/kg and treosulfan TD 36 g/mq dose reduction according to age > 65 years.
45468839|NCT03434704|Procedure|PBSC graft|(target 4-8 × 106 CD34+ cells/kg patient body weight)
45468840|NCT03434704|Drug|GvHD prophylaxis|"Sirolimus orally, monitored two times a week to maintain a target therapeutic plasma level of 8-15 ng/ml from day +5.~Mycophenolate 15 mg/kg bid i.v. or per os day +5 through +28. Cyclophosphamide 50 mg/kg i.v. day +3+4. Mesna: >80% of the cyclophosphamide dose in 3 divided doses from day +3 daily through day +5."
45468841|NCT03434704|Drug|Primary antifungal prophylaxis|Posaconazole delayed-release tablet [available in 100 mg tablets]: 300 mg twice daily on the first day followed by a maintenance dose of 300 mg once a day, starting on the day 0 to day 85.
45468842|NCT03768973|Procedure|Elective cardiac surgery|Both groups will undergo elective cardiac surgery as an intervention.
45468843|NCT02521636|Other|Antibiotic therapy randomization|
45468844|NCT02521636|Other|Serum PCT dosage|
46022477|NCT04287244|Device|Transcutaneous Spinal Direct Current Stimulation|tSDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
46022478|NCT02848105|Drug|VPA|Valproic acid with 1000mg loading dose with 500mg q12 4 hours later to maintain a trough level above 75ug/ml
46022479|NCT02864524|Other|Manipulative and Massage Therapy|
45468845|NCT03774277|Behavioral|Packed Promise for a Healthy Heart|"Voucher for fresh vegetables and fruits (referred to as a fresh check); Home delivered food boxes that contain Dietary Approaches to Stop Hypertension (DASH)-approved ingredients for preparing low-salt, and traditional healthy Chickasaw meals; Heart-healthy recipes (available at getfreshcooking.com) that are tailored to traditional Chickasaw diet and culture; Educational materials; Personalized invitation to attend local cooking demonstrations; Assistance to link the Fitbit and AYA app"
45468846|NCT03325504|Biological|Cultured Mesenchymal Stem Cells|Cultured Mesenchymal Stem Cells obtained from expanded bone marrow
45468847|NCT03325504|Procedure|Autologous iliac crest graft|Autologous iliac crest grafting
45838328|NCT03808662|Radiation|Sterotactic Body Radiotherapy/SBRT|In general, it is recommended using 9-10 Gy x 3 or 10 Gy x 5 fractions given every other day. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10≥70), assuming α/β ratio of 10 and using the linear-quadratic model: BED = nd x [1 + d/(α/β)] where n is number of fractions and d is dose per fraction. Sometimes BED ≥80 Gy is preferred, with lower doses ≥50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.
45838329|NCT03808662|Drug|Standard of care|Standard of care per physician discretion
46022480|NCT02864524|Other|Exercise Program|
46022481|NCT02847871|Behavioral|PRISME-3P program|"PRISM-3P program will consist on a visit in the geriatric centre:~Consultation with the geriatrician to rule a condition associated with loss of mobility and not known until now.~Perform a nutritional assessment by a dietician followed by appropriate care management.~Educational activity based on exercises and physical activity and balance: MAPA teaches exercises to develop strength and balance; gives tips to increase time spent on non-sedentary activities and enhance endurance followed by a monthly phone coaching.~At 3 months, in case of no improvement of the SPPB score of 1 point, a training of 10 weeks with two sessions per week will be perform by the MAPA individually or in small patients groups;~Implementation of a information exchange processing (mail, phone and book binding) between the various stakeholders."
46108345|NCT02556814|Drug|Dexamethasone|Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
46022482|NCT04288024|Behavioral|Weight-shifting training|"Postural task: Participants are standing with their weak side on the force plate. During the task, they wight-shift from side to side ranging from 10 to 90 percent of their body weight.~Suprapostural task: Participants hold a tray with their arms beside the body, 90 degrees of elbow flexion. They rotate the tray left and right for 45 degrees respectively.~During their task, participants should weight-shift and rotate the tray at the same time."
46022483|NCT02847793|Behavioral|Gaze training|Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial. (A total of 576 trials will be distributed in a 2-day intervention).
46108346|NCT02556814|Drug|placebo|Oral administration of placebo tablets 0.3g three times per day for 3 months
46108347|NCT00682955|Drug|Zinc Sulphate|20 mg per day, Zinc Sulphate tablet has been given to subjects.
45468848|NCT04779151|Drug|Dostarlimab|Substance: immunoglobulin G4 (IgG4) humanized monoclonal antibody (mAb) that binds with high affinity to PD-1 Manufacturer: Tesaro Inc. Dose: 500 mg every 21 days for the first 4 cycles, followed by 1,000 mg every 42 days cycle (ie, Q6W)
45468849|NCT04779151|Drug|Niraparib|Substance: Inhibitor of poly-adenosine diphosphate [ADP] ribose polymerase (PARP) Manufacturer: Tesaro Inc. Dose: Flat-fixed dose (if <77kg or platelets <150,000 μL: 200mg; if >/=77kg and platelets >/= 150,000μL: 300mg)
46108348|NCT00682955|Drug|Zinc Sulphate|20 mg per day of Zinc Sulphate in suspension form has been given to subjects.
46108349|NCT00686621|Drug|Posaconazole|Posaconazole oral suspension 400 mg twice daily with meal or nutritional supplement. Alternatively, if meal or nutritional supplement is not tolerated, posaconazole should be administered at a dose of 200 mg four times a day.
46108350|NCT00683033|Behavioral|Contingency Management|For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking is delivered. Expired carbon monoxide (CO) tests are conducted twice daily and urinary cotinine tests are conducted once each week. Participants earn the opportunity to win prizes for submitting samples that meet smoking abstinence criteria (e.g., CO ≤ 6ppm; cotinine ≤ 30ng/mL).
45468850|NCT04449640|Procedure|Hysteroscopic septum resection.|Resection of a uterine septum by hysteroscopic surgery.
45838330|NCT03789591|Drug|Hydroxyurea|The alternative arm will use PK data to choose a starting hydroxyurea dose to achieve an AUC of 115 mg*h/L to approximate maximum tolerated dose. On the standard arm, participants will start at the traditional, weight-based dose of 20 mg/kg/day. Following selection of the starting dose, all participants will follow the same dose escalation and laboratory monitoring procedures.
46108351|NCT00683033|Behavioral|Brief smoking cessation counseling|For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking. Expired carbon monoxide tests are conducted twice daily and urinary cotinine tests are conducted once each week.
46108352|NCT04142879|Device|Viz Device Software|Viz uses artificial intelligence to automatically detect, triage and notify stroke specialists of suspected large vessel occlusion (LVOs) and computed tomography angiogram (CTA) imaging. Viz includes functionality to automatically process computed tomography perfusion (CTP) images. Additionally, Viz includes a mobile non-diagnostic image viewer and HIPAA-compliant secure messaging.
46108353|NCT00683111|Drug|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
46108354|NCT00683111|Drug|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
46108355|NCT04138901|Procedure|Ultrasound guided subcostal transversus abdominis plane block (TAPB)|At the end of surgery, an anesthesiologist will perform bilateral subcostal TAP block with 0.375% ropivacaine 15ml at each site under ultrasound guidance.
46108356|NCT04138901|Drug|Ropivacaine 0.75% Injectable Solution|0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
46108357|NCT04138901|Device|21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)|0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
46108358|NCT00690209|Procedure|Autologous bone marrow derived stem cells myocardial transplantation|
46108359|NCT04138745|Other|Transverse Thoracic Plane Block|A bilateral plane block in the transverse thoracic space
46108360|NCT00690287|Drug|AZD6370|Oral single doses a+b+c, o.d., suspension
46108361|NCT00690287|Drug|AZD6370|Oral single dose, o.d., b.i.d. and q.i.d., suspension
46108362|NCT00690287|Drug|Placebo|Placebo
46108363|NCT00922649|Device|Insulin Pump therapy|Initiation of Insulin pump therapy in patients on >2 OAs (Cohort A), basal insulin ± OAs (Cohort B), or basal-bolus insulin ± OAs (Cohort C.
46108364|NCT05298995|Biological|GD2-CART01 (iC9-GD2-CAR T-cells)|Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells, infused i.v. as a single dose
46108365|NCT04142411|Drug|Insulin|Ultrasound guided perineural injection therapy (PIT)
46108366|NCT04142411|Drug|Sodium Hyaluronate|Ultrasound guided perineural injection therapy (PIT)
45468851|NCT04760587|Behavioral|smart devices in adolescent weight control|The study will apply mobile phone applications and smart watches to understand the relationship between weight control behaviors and weight control health outcome in adolescent.
45468852|NCT02891226|Drug|Mirikizumab|
46108367|NCT04142411|Device|Ultrasound|Philips Neuromuscular Ultrasound
46108368|NCT00683189|Drug|Warfarin|Oral administration (QD), variable dosage: patients will undergo blood test for PT/INR at baseline and afterwards, at weekly bases for 4 weeks. The INR will be kept in a safe range of 2-2.5
45468853|NCT02891226|Drug|Placebo|
45468854|NCT01561417|Drug|activated recombinant human factor VII|One single dose administration, injected i.v. (into the vein)
45468855|NCT01561417|Drug|activated recombinant human factor VII|One single dose administration, injected i.v. (into the vein)
45468856|NCT03654274|Drug|Relugolix|Relugolix 40-mg tablet administered orally once daily
45683921|NCT01922674|Procedure|Standard open tension-free inguinal hernia repair with mesh|
45838331|NCT03783026|Drug|Apremilast|Tablets for oral administration
45468857|NCT03654274|Drug|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg) and NETA (0.5 mg) administered orally once daily
46022484|NCT02847793|Behavioral|Placebo intervention|Participants are exposed to the same amount of time to the experimental stimuli used in the experimental group but there is no contingency between participants' gaze patterns and the end of each of the 576 trials.
45468858|NCT03772015|Diagnostic Test|Magnetic resonance imaging|MRI will be performed using a standard body spiral in the supine position with 5 mm section thickness, on the axial, coronal and sagittal planes and the diffusion weighted images acquired will be evaluated by a specialised radiologist who will be blind to the participants.
45468859|NCT03771781|Drug|Empagliflozin Tablets|Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets.
46022485|NCT02847325|Drug|AC0058TA|50 mg AC0058TA 100 mg AC0058TA 200 mg AC0058TA 400 mg AC0058TA
46108369|NCT00667576|Drug|Maxacalcitol|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
46108370|NCT00667576|Drug|Paricalcitol|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
46022486|NCT02847325|Drug|Placebo capsules|Placebo capsules
46022487|NCT04216303|Diagnostic Test|hemoglobin A1c|The hemoglobin A1c test (A1c) screens for, helps diagnose, and monitors diabetes and prediabetes.
46108371|NCT04141787|Drug|Ceftriaxone|"Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice."
46108372|NCT04141787|Drug|Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)|"Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice."
46022488|NCT02847013|Drug|TAP block w Liposomal bupivacaine|TAP block w Liposomal bupivacaine diluted to 0.66% (20 mLs)
46022489|NCT02847013|Procedure|TAP block w normal saline|TAP block w normal saline -preservative free 0.9% sodium chloride (20mLs)
45468860|NCT03771781|Drug|Empagliflozin Tab 25 MG|Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets( Jardiance®）.
46022490|NCT02844595|Behavioral|Standard cognitive-behavioural smoking cessation treatment|"Standard cognitive-behavioural smoking cessation treatment is an effective treatment for tobacco dependence. The treatment elements are: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem solving training, change tobacco related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks."
46022491|NCT02844595|Behavioral|Standard cognitive-behavioural smoking cessation treatment and behavioural activation|"Behavioural activation will be applied along with standard cognitive-behavioural smoking cessation treatment. The treatment elements are: those present in the standard cognitive-behavioural smoking cessation treatment, plus analysis of the relationship between behaviour and mood, identification of situations and behaviours that decrease mood, identifying avoidance behaviours, and identifying thoughts of rumination and worry, self-report of pleasant daily activities, pleasant activity scheduling to increase engagement in rewarding activities, and to reduce patterns of behavioural avoidance.~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks."
45468861|NCT03772093|Device|Trabert current|Trabert current is an interrupted direct current of low frequency (143 Hz) applied via medium sized electrodes supported on a thick moist viscose sponge. These electrodes are placed near the spinal column along the thoracolumbar region. The electrodes are separated from each other by a distance of 3-4 cms.The current is passed through electrodes placed on the body. The intensity of the current is gradually increased short of pain. The feeling should be a pronounced but a comfortable 'tingling' sensation ('comfortably strong'). By doing this, the optimum current strength specific to the patient is found. The intensity of the current is slowly increased in the first few minutes as patients get used to the sensation. It is thought that this current provides pain relief, reduces muscle spasm and increases blood flow.
46022492|NCT01233869|Drug|Bosutinib|Once daily oral dose of 200 mg of bosutinib
46108373|NCT02557594|Drug|Viread 300mg|single dose administration after 10hr fasting
46108374|NCT02557594|Drug|DA-2802 319mg|single dose administration after 10hr fasting
45468862|NCT03772093|Other|Manual massage|Therapeutic massage is the manipulation of the soft tissue of whole body areas to bring about generalised improvements in health.Massage is thought to work through a mechanical action and a reflex action. A mechanical action is created by moving the muscles and soft tissues of the body using pressure and stretching movement. This mechanical action is based on breaking up fibrous tissue and loosen stiff joints.It may help heal damaged muscle, stimulate circulation, clear waste products via the lymphatic system, boost the activity of the immune system, reduce pain and tension and induce a calming effect.
45468863|NCT03774199|Device|NightOwl|The NightOwl is a finger and/or forehead mounted device with, among other functions, the capability to acquire double-wavelength PPG, from which SpO2 can be derived
46108375|NCT00687011|Drug|Palonosetron and Dexamethasone|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent, plus single IV dose of dexamethasone 8 mg administered 15 minutes before chemotherapy (in the event of a shortage of IV dexamethasone, a single oral dose of dexamethasone 20 mg or a single IV dose of methylprednisolone 125 mg could be administered).
46108376|NCT00777868|Drug|Low Strength IDP-108|Topical application once a day for 9 months
46022493|NCT01233869|Drug|Bosutinib|Once daily oral dose of 400 mg of bosutinib transitioned to 200 mg/day
46022494|NCT01233869|Drug|Placebo|Once daily oral dose of placebo
46022495|NCT02847091|Drug|Ipragliflozin|Oral administration, 50mg once daily
45468864|NCT04140721|Drug|Placebo oral tablet|Placebo pill identical to moxonidine administered for 4 weeks
46022496|NCT02847091|Drug|Insulin|Patients are receiving insulin therapy from at least 12 weeks before Visit 1 (is allowed ±10% dose modification if clinically needed, and is reduced within a 20% to 40% range at Visit 1 and then is controlled up to Visit 8 based on criteria of this study).
45468865|NCT04140721|Drug|Moxonidine Pill|Moxonidine pill administered for 4 weeks
46022497|NCT02846935|Drug|Decitabine|2-4 capsules depending on the weight of participant. Dec capsules are ingested ~60 minutes after THU capsules.
46022498|NCT02846935|Drug|Tetrahydrouridine|2-4 capsules depending on the weight of participant. Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days.
46108377|NCT00777868|Drug|High Strength IDP-108|Topical application once a day for 9 months
46108378|NCT00777868|Drug|High Strength IDP-108 under occlusion|Topical application once a day for 9 months
46108379|NCT00777868|Drug|Vehicle|Topical application once a day for 9 months
46108380|NCT00687089|Other|Sexual, cognitive functional tests and measurement weight|
46108381|NCT00683267|Drug|4975, highly purified capsaicin|One dose administered by direct instillation into the surgical site
45468866|NCT03434626|Behavioral|ACP Education|Decision aid and Goals of Care Designation form information administered by Navigator
46022499|NCT02844751|Biological|[StroMed + platelet rich plasma (PRP)]|[Day 0] - Because no enzymes or drugs are added with this mechanical process, the resulting cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Also Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
46022500|NCT02844751|Biological|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 7,14 and 30
46108382|NCT00683267|Drug|Placebo|One dose administered by direct instillation into the surgical site
45468867|NCT03434626|Other|Usual care|Usual care includes reviewing Goals of Care Designation form and Greensleeve with physician
45468868|NCT03768895|Radiation|MRI|"The technique used was coronal and axial T1 and T2*WI sequences of the pelvis and femurs.~The MRI machine used is a HITACHI AIRIS-II1 model, with permanent vertical magnetic field of 0.3 Tesla, and the used sequences areT1, T2*WI."
45468869|NCT03705624|Other|Enhanced Community Case Management (CCM)|Enhanced Community Case Management for malaria (CCM) involving weekly active screening for fever using a research-grade thermometer by a trained health worker. A measured temperature ≥37.5°C or reported fever in the last 24 hours will prompt screening with a conventional rapid diagnostic test (RDT). RDT positive individuals will be treated with AL according to national guidelines
45468870|NCT03705624|Other|Monthly Screening and Treatment (MSAT)|Monthly Screening and Treatment (MSAT) regardless of symptoms with a conventional RDT. Screening will be performed by research staff with 25-35 days between screening rounds; RDT positive individuals will be treated with AL according to national guidelines.
45683922|NCT01922908|Biological|MSC Infusion|Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset
45683923|NCT01922908|Biological|Placebo Comparator|Normal saline
45683924|NCT04768270|Other|no intervention|It is an observation trial.
45683925|NCT05240950|Drug|Anti-CEA CAR-T Cells|"The study will evaluate the safety of intravenous infusion of anti-CEA CAR-T (+) cells in humans at doses of 1×10^6/kg, 3×10^6/kg, and 6×10^6/kg using a standard 3+3 design and preliminarily observe the efficacy."
45683926|NCT05241574|Radiation|Radiotherapy boost|Additional endorectal high rate irydium brachytherapy boost, 2 fractions of 10 Gy each.
46108383|NCT00683345|Drug|Anakinra|Anakinra 0.67 ml (100 mg) daily subcutaneously for 4 weeks.
46108384|NCT00683345|Drug|Placebo|Saline 0.67 ml daily subcutaneously as placebo drug.
46108385|NCT04138667|Other|complex decongestive therapy|Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
46108386|NCT00687245|Drug|esomeprazole magnesium|capsules, oral, qd, one day
46108387|NCT00690521|Drug|metolazone or hydrochlorothiazide|The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance. A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day. A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5 If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
46108388|NCT00683501|Drug|DNB-001|four dosages of DNB-001, one placebo dosage
46108389|NCT02625701|Procedure|Goal-directed therapy|Optimize CO with additional fluid according to dynamic indices (PPV, SVV, Stroke volume)
46108390|NCT02625701|Procedure|Restrictive fluid therapy|Keep normovolemia with basal crystalloids infusion (3-6 ml/kg/h) and compensate additional fluid losses with colloids or crystalloids.
46108391|NCT00683579|Drug|Early Treatment with HAART|HAART with possibility of de-intensification
46108392|NCT00683579|Other|No treatment|No treatment. For group 2, participants do not yet meet DHHS guidelines. For group 4, treatment is not initiated due to unwillingness or providers' expectation of poor adherence.
46108393|NCT00683579|Drug|HAART Treatment - standard care|Initiation of HAART per DHHS guidelines, i.e. starting treatment and CD4+ T cells less than 350 cells/mm3 or HIV RNA >100,000 copies/ml
46108394|NCT00666718|Drug|Insulin Glargine|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
46108395|NCT00666718|Drug|Insulin Lispro Protamine Suspension (ILPS)|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
46108396|NCT00666718|Drug|Insulin Lispro|subcutaneous injections prior to meals, 24 weeks
45468871|NCT03774043|Other|Acute Intermittent Hypoxia|Patients will breath 9%-11% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
45468872|NCT03774043|Other|Sham Acute Intermittent Hypoxia|Patients will breath 21% oxigen for 1.5 minutes interspersed with 1.5 minutes of room air, 15 times for a total of 45 minutes.
46022501|NCT02844751|Biological|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 30 and 60
45468873|NCT03434314|Procedure|Minimally-Invasive Segmental Artery Coil-Embolization|During one single MISACE session 3-7 segmental arteries will be occluded. The procedure is conducted through a peripheral artery access in local anaesthesia. Microcoils or vascular plugs will be used for the occlusion itself.
46022502|NCT02844829|Other|Prostate MRI|MRI of the prostate prior to prostate biobsy
46108397|NCT00683735|Drug|Sitagliptin|100 mg once daily in the morning
46108398|NCT00683735|Drug|Metformin|up to 2000 mg/day
46108399|NCT00683735|Drug|Placebo|500mg 1-0-0-0
46108400|NCT00683735|Drug|Placebo|100mg 1-0-0-0
46108401|NCT02625467|Procedure|Penetrating keratoplasty|Conventional Penetrating keratoplasty technique
46108402|NCT02625467|Procedure|Pachymetry and Excimer laser assisted lamellar keratoplasty|Ablation profile focusing on topography and pachymetry with Schwind Amaris excimer laser
46108403|NCT02625467|Drug|Treatment posterior to surgery|Fluoroquinolone topical antibiotic (Moxifloxacin, Vigamox) and topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)
46108404|NCT04139681|Drug|A. Vogels Sore Throat lozenges|5 times 1 A. Vogels sore throat lozenges daily for 4 days
46108405|NCT04047394|Drug|PEGylated recombinant candida urate oxidase|PEGylated recombinant candida urate oxidase is a combination of 20kDa linear polyethylene glycol (PEG) linked to Candida utilis recombinant uricase by succinimide succinate
46108406|NCT00683813|Behavioral|vCRP|The vCRP includes online intake forms, one-on-one chat sessions with vCRP nurse, dietitian and exercise specialist, data collection (exercise heart rate, blood pressure, glucose- if diabetic), peer-support group chat sessions, ask-an-expert chat sessions, education, progress reports and online resources. VCRP patients will receive access to the website, a heart rate monitor and a blood pressure monitor and trained in their use. The heart rate monitors allow for exercise heart rate data to be stored and downloaded to their home computer and then uploaded to the vCRP webserver. The exercise data will be reviewed weekly. A letter to the patient's primary care physician will be sent to outline the vCRP intervention, the treatment algorithms to be used and indicate under what circumstances the vCRP nurse and/or patient may contact them with regards to their management. After the 4 month intervention, patients will be discharged into the care of their primary care physician.
45468874|NCT04937088|Drug|ASA|Liquid aspirin formulation
45468875|NCT03774355|Drug|CG1801|Administration CG1801 2mg single dose in phase 1 and Administration CGL1802 2mg single dose phase 2.
46022503|NCT02844673|Drug|Hydroxyurea|Patients will receive fixed dose Hydroxyurea therapy (15 mg/Kg/day) with standard monitoring
46022504|NCT02844673|Device|Mobile Directly Observed Therapy|Mobile DOT will consist of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Patients will receive alerts on their cell phone at pre-arranged times to remind them to take their medications.
46022505|NCT02847247|Drug|CCRE|Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).
46108407|NCT02625779|Drug|Valproate and Placebo|
46108408|NCT02625779|Drug|Valproate and Cytidine-containing Drug|
46108409|NCT02625779|Drug|Valproate and Creatine-containing Drug|
46108410|NCT00667420|Drug|panitumumab, epirubicin, oxaliplatin, xeloda|pilot study
46108411|NCT04141319|Drug|Ketorolac|30ml of local infiltration solution containing 60mg ropivacaine
46108412|NCT04141319|Drug|Ropivacaine|30ml of local infiltration solution containing 6mg ketorolac
46108413|NCT04141319|Drug|Epinephrine|30ml of local infiltration solution containing 0.1mg epinephrine
46108414|NCT00683891|Drug|FazaClo (clozapine, USP) ODT|
46108415|NCT00683969|Drug|mycophenolate mofetil (CellCept)|1g bid for 36 weeks
46108416|NCT00683969|Drug|placebo|po bid for 36 weeks
46022506|NCT00992992|Biological|Tositumomab and Iodine I 131 Tositumomab followed by CHOP|Patients will receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of Tositumomab (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of 35 mg Tositumomab containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,000-149,000 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose. Approximately 13 weeks following the therapeutic dose, CHOP will be administered every 21 days for a total of 6 cycles.
46022507|NCT04201951|Drug|Tranexamic acid injection|Participant in group A will receive 2 ampules of 5 milliliters (mL) Tranexamic acid applied to 20 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus
45468876|NCT03774355|Drug|CGL1802|Administration CGL1802 2mg single dose in phase 1 and Administration CG1801 2mg single dose phase 2
46022508|NCT04201951|Other|Glucose water 5%|Group B will receive 30 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus
46022509|NCT04202029|Device|thoracic impedance monitoring|Thoracic impedance measurement identifies the respiratory frequence using the changes of impedance during inspiration and expiration via an ECG.
46022510|NCT04202029|Device|pulseoxymetry|Pulseoxymetry is meassuring the heart rate and the oxygen saturation in the arterial blood
46022511|NCT04202029|Device|non-invasive blood preassure monitoring|Non-invasive blood preassure is a method using a blood preassure cuff to identify the blood preassure.
45468877|NCT04924842|Other|Review of medical file|Review of medical patient file, including patient tracing, brief summary of the disease course, barrier gestures, social distancing.
45468878|NCT04924842|Other|Phone call interview|less than 15 minutes phone call
46108417|NCT00778024|Drug|fluoxetine HCL 40 mg capsules|
46108418|NCT00853658|Drug|Enalapril|Enalapril 10 mg film-coated tablet and administered orally.
45468879|NCT03434236|Dietary Supplement|low dose Lipinova (30 mL daily)|Lipinova is a nutritional supplement containing concentrated n-3 PUFA (EPA and DHA) and metabolites
45468880|NCT03434236|Dietary Supplement|Placebo|Placebo will have a similar appearance, smell and taste as the nutritional supplement
45468881|NCT03434236|Dietary Supplement|high dose Lipinova (60mL)|Lipinova is a nutritional supplement containing concentrated n-3 PUFA (EPA and DHA) and metabolites
45683927|NCT05241574|Drug|Additional consolidation chemotherapy|Three additional cycles of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX4) consolidation chemotherapy
46022512|NCT02847715|Device|ePRIME|ePRIME is an remote monitoring pathway that includes an online system for patients to self-report symptoms and AE following cancer treatments. ePRIME allows AE reporting from home and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for serious symptoms to the relevant clinical team and providing patient advice on managing mild and moderate symptoms.
46022513|NCT00992836|Biological|Influenza A (H1N1) 2009 monovalent vaccine|Two doses of vaccine, delivered 21 days apart, with each dose consisting of two 15-microgram intramuscular injections
46022514|NCT04754425|Procedure|Biopsy|Undergo biopsy
46108419|NCT00853658|Drug|Aliskiren|Aliskiren 150 mg titrated to 300 mg film-coated tablet and administered orally.
46108420|NCT00690677|Drug|LBH589|"LBH589 will be administered orally at a dose of 30mg (1 - 20mg capsule and 2 - 5g capsules) on Monday, Wednesday and Friday of each week (three times a week). Patients may continue treatment with oral LBH589 until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.~The LBH589 capsules should be swallowed by mouth with a glass of water in the morning. The recommended way to take LBH589 is after not eating for at least 2 hours. You should also not eat for another 2 hours after taking your LBH589 capsules. The daily dose of LBH589 should be taken at approximately the same time each day. You should avoid eating grapefruit, seville oranges, or drinking grapefruit or seville orange juice during the study."
45468882|NCT03771547|Diagnostic Test|ERCP|
45468883|NCT03429790|Combination Product|intra-operative cell salvage|intra-operative cell salvage collects the patient's blood lost during an operation, processes it and returns it to their own circulation.
45468884|NCT03429790|Combination Product|allogeneic blood transfusion|transfuse allogeneic blood to patients if blood transfusion is needed.
45468885|NCT03768817|Other|No Intervention|This is a non-interventional retrospective medical record review study. No study investigational product will be administered in this protocol.
45468886|NCT05681364|Other|metabonomics|profiles of metabolites in serum and exhale breath condensate (EBC) at baseline and after pulmonary rehabilitation
45468887|NCT03224104|Drug|TG02|"The initial cohorts of Groups A and B will receive TG02 at 200 mg on intermittent schedules in combination with either RT or TMZ. TG02 will be escalated to 250 mg if the dose decision criteria are met in the first cohort.~The initial cohort in Group C will receive TG02 alone at 250 mg on intermittent schedules. It will be continued at this dose if feasible or decreased to 200 or 150 mg if not tolerated."
45838332|NCT03775460|Drug|Methotrexate|Participants in the intervention group will receive methotrexate along side prednisolone
45838333|NCT03775460|Drug|Placebo|Participants in the control arm will receive placebo along side prednisolone
45468888|NCT03224104|Radiation|Radiation Therapy|For group A standard involved-field hypofractionated RT will be administered at 39.9 Gy in 15 fractions of 2.66 Gy for 3 weeks
45468889|NCT03224104|Drug|Temozolomide|For group B TMZ will be given in the standard 28-day cycle regimen (150-200 mg/m2) for 5 days.
46022515|NCT04754425|Procedure|Biospecimen Collection|Undergo collection of blood and bone marrow
46108421|NCT02625857|Biological|JNJ-64041809 (Cohort 1A and 1B)|JNJ-64041809 will be administered IV at a lower dose in Cohort 1A (1x10^8 colony forming units [CFU]) and at a higher dose in Cohort 1B (1x10^9 CFU).
46022516|NCT04754425|Drug|Erdafitinib|Given PO
45468890|NCT05177562|Other|No intervention|There is no intervention in this study
45468891|NCT01320475|Drug|Sufentanil|Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)
45468892|NCT01320475|Drug|Ketamine|Epidural infusion of levobupivacaine (1,25 mg/ml) and saline (1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of ketamine (2 µg/kg/minute) Up to the third postoperative day (6 PM)
45468893|NCT03428620|Other|High Velocity Low Amplitude mobilization|Mobilizations will be performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
45468894|NCT03428620|Other|Exercise protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
46022517|NCT04753723|Combination Product|Gentamycin with Platform Wound Device|Treatment of wounds with gentamycin and covered with platform wound device.
46022518|NCT04751851|Behavioral|Medium duration withdrawal programme with ACT|"10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.~8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT."
46022519|NCT04751851|Behavioral|Long duration withdrawal programme with ACT|"10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.~8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT."
46022520|NCT04751851|Behavioral|Medium duration withdrawal programme without ACT|10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.
46022521|NCT04751851|Behavioral|Long duration withdrawal programme without ACT|10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.
46022522|NCT02844517|Device|Artificial Pancreas|Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump and continuous glucose monitor. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
45468895|NCT05309148|Behavioral|Training on eye tracker based device|The intervention is based on the principle of visual biofeedback. The patient sees where his gaze is and can objectively assess and correct his visual error.
46022523|NCT03841084|Drug|Oxygen|"Conservative oxygen management strategy- reduces oxygen on the inoblender in the ECMO circuit.~Liberal oxygen management strategy - does not reduce the oxygen on the inoblender via the ECMO circuit"
46108422|NCT02625857|Biological|JNJ-64041809 (Cohort 2A and 2B)|JNJ-64041809 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
46108423|NCT00781300|Drug|Loteprednol Etabonate 0.5%|Patients in the Loteprednol Group received Loteprednol Etabonate 0.5% associated with Tobramycin 0.3% in separate eyedrops for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week
45838334|NCT03775460|Drug|Prednisolone|Participants in both arm will receive prednisolone, which will be the same dosage: 40 mg (initial dose) decreasing dosage for 20 weeks
46108424|NCT00781300|Drug|Dexamethasone 0.1%|The patients in Dexamethasone Group received Dexamethasone 0.1% associated with Tobramycin 0.3% in a single eyedrop for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week.
46108425|NCT04140851|Dietary Supplement|Dietary fiber intervention|Dietary intervention
45468896|NCT05309148|Behavioral|Training with a neuropsychologist|The intervention is based on classical neuropsychological techniques aimed at correcting oculomotor disorders and improving visual attention (blank, psychometric, etc.)
45468897|NCT05309148|Behavioral|Training on eye tracker based device and with a neuropsychologist|This is combination of the first and second interventions
45468898|NCT03768739|Procedure|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves a flexible laryngoscope that contains a light source and video camera on the end through the open passages of your nose and to the back of the throat in order to visualize the swallowing mechanism.
45838335|NCT03735797|Diagnostic Test|Bone marrow aspirate or peripheral blood sample collection|Collection of specimen samples only
46022524|NCT03901729|Drug|BAY 1753011|Tablet; 30mg or 5mg unit; 30mg once daily in the morning; Oral
46022525|NCT03901729|Other|Placebo BAY 1753011|Tablet; Once daily in the morning; Oral
46022526|NCT03901729|Drug|Furosemide|Tablet; 40mg unit; 80mg once daily in the morning; Oral
46022527|NCT03901729|Other|Placebo Furosemide|Tablet; Once daily in the morning; Oral
46022528|NCT04292782|Procedure|anterior Quadratus lumborum block|ultrasound anterior quadratum lumborum block with 1 ml/kg 0.2% ropivacaine
46022529|NCT04292782|Procedure|caudal block|ultrasound guided caudal block with 1 ml/kg 0.2% ropivacaine
45838336|NCT03717753|Other|Pathway|The study team emphasizes that all components of the pathway are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the pathway will receive these standard of care components. Both groups will receive identical postoperative follow-up.
46022530|NCT03834844|Behavioral|Meditation|Guided Meditation for 10-15 minutes daily for 6 days/week for 6 weeks
46022531|NCT03834844|Other|AF Education|6 weekly education modules on topics related to AF
46022532|NCT03834844|Other|Phone Calls|Weekly phone call to discuss patient concerns or questions
46022533|NCT02846857|Other|15-week intervention with sensor-augmented pump|A sensor will be inserted on the day before the start of the intervention by the participant. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have been previously shown how to use the study insulin pump.
46022534|NCT02846857|Other|15-week intervention with single-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks.
46022535|NCT02846857|Other|15-week intervention with dual-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have to reconstitute glucagon everyday.
46022536|NCT02846857|Device|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
46022537|NCT02846857|Device|Continuous glucose monitoring system|Enlite sensor®, Medtronic
46022538|NCT02846857|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
46022539|NCT02846857|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
46022540|NCT04287322|Behavioral|Tactile-kinesthetic stimulation|"Tactile-kinesthetic stimulation involved three sessions per day; morning, afternoon, and evening for 10 days starting day 3 of life (initial contact). The stimulation included three phases; Phase 1: With neonates in prone position, moderate pressure was used to provide 12 strokes with palms of the hands, each stroke lasting 5 seconds. The strokes were provided in each area as follows: head, neck, shoulders and back.~Phase 2: In supine position, twelve moderate pressure strokes with palms of the hands, 5 seconds each, were provided in each area as follows:forehead,cheeks,chest, abdomen, upper limbs (each separately), lower limbs, palms and soles.~Phase 3: Kinesthetic stimulation was done for 5 minutes. The intervention comprised five passive flexion and extension movements of each large joint."
46022541|NCT04287322|Behavioral|Recorded maternal voice|Following informed written consent from mothers,maternal voice was recorded (5 minutes talking to her baby and 10 minutes singing) using Philips Electronics, SA2RGA04KS, Netherlands. Recorded voice was played back inside the incubator or cot via micro audio system, which has been validated for safety and feasibility in previous studies (Doheny et al., 2012. Preterm neonate lay in supine/lateral position and recorded maternal voice was played for 15 minutes three times a day (morning, afternoon, evening) starting on day 3 of life up to day 12 of life (10 days).
46022542|NCT03833128|Drug|Low Dose REN001|Oral
46022543|NCT03833128|Drug|High Dose REN001|Oral
46022544|NCT02844205|Other|quotation of the newborn behavioral observation scale|quotation of the newborn behavioral observation scale by 12 experimented nurses. Patient will be filmed during an usual care and nurses will quote the scale thanks to the video.
46022545|NCT04672525|Drug|Rifabutin|2 tablets of 150 mg per day rifabutin tablet daily for 12 weeks in 1 administration with a companion treatment
46022546|NCT04672525|Drug|Rifampicin|10 mg/kg per day (range 600 mg to 1,200 mg) rifampicin tablet in 1 daily dose for 12 weeks with a companion treatment
46022547|NCT00992446|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
46022548|NCT00992446|Drug|Bortezomib|Given IV
46022549|NCT00992446|Drug|Carmustine|Given IV
46022550|NCT00992446|Drug|Cytarabine|Given IV
46022551|NCT00992446|Drug|Etoposide|Given IV
45468899|NCT03429634|Procedure|Balloon-Stent Kissing technique|All patients underwent coronary angiogram that confirmed true bifurcation lesions, and received PCI treatment,Balloon-Stent Kissing Technique (BSKT)for the interventional treatment of coronary bifurcation lesion
46108426|NCT04140851|Dietary Supplement|Normal diet|Normal diet
46022552|NCT00992446|Drug|Melphalan|Given IV
46108427|NCT00781378|Drug|rt-PA|rt-PA 100 mg continuous intravenous infusion for 2 hours
46108428|NCT00781378|Drug|rt-PA|rt-PA 50 mg continuous intravenous infusion for 2 hours
45468900|NCT03429634|Procedure|Jailed Wire technique|All patients underwent coronary angiogram that confirmed true bifurcation lesions, and received PCI treatment, Jailed Wire technique(JWT) for the interventional treatment of coronary bifurcation lesion
45468901|NCT03773887|Other|collection of liver biopsies collection of blood samples|blood and ascites samples; extraction of explants, hepatic resection parts; hepatic parenchyma on liver biopsies
45468902|NCT04858542|Behavioral|Educational Vocal Health Modules|We have developed four educational health modules (total duration of approximately 30 minutes). First, these modules explain how masks impact communication and voice, then they describe health strategies to improve communication and voice, and finally, they give real-life examples of how the strategies can be implemented into the work setting.
45468903|NCT03434002|Other|Training by Virtual Reality Simulation|Those Randomized 15 residents will be receive Local Anesthetic Systemic Toxicity simulation training by Virtual Reality simulation and after two weeks, they will be evaluated by investigators by using the same performance evaluation tool.
46108429|NCT00687791|Device|ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery|Study of the safety and effectiveness of the ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery
45468904|NCT03434002|Other|Training by Mannequin Based Simulation|Randomized other 15 residents will be receive Local Anesthetic Systemic Toxicity simulation training by mannequin based simulation and after two weeks, they will be evaluated by investigators by using the same performance evaluation tool.
46108430|NCT00687869|Behavioral|Case management|Case management with patient-information-notes, telephone hotline, individual counselling using home visits, e-mail and telephone contact, web portal
46108431|NCT00687869|Behavioral|Case management|Usual stroke aftercare plus patient-information-notes
46108432|NCT00684125|Device|Blake Drains (Blake drain, Ethicon USA)|19F Blake drain located in the posterior pericardial cavity
46108433|NCT00684125|Device|Standard mediastinal drainage|Mediastinal drainage will be accomplished using 28F or 32F chest tube located in the anterior mediastinum
46108434|NCT02625389|Drug|Lipiodol® Ultra Fluid with surgical glues|Lipiodol® Ultra Fluid and surgical glue mixture may vary from 20 to 80% and should be administered via selective arterial catheterization only.
46108435|NCT00687947|Drug|CGRP|CGRP (0.5 ug/min) infused intravenously over 20 min
46108436|NCT00666562|Dietary Supplement|Defined Green Tea Catechin Extract|Given orally
46108437|NCT00666562|Other|Laboratory Biomarker Analysis|Correlative studies
46108438|NCT00666562|Other|Pharmacological Study|Correlative studies
46108439|NCT00666562|Drug|Placebo|Given orally
46108440|NCT00666562|Procedure|Therapeutic Conventional Surgery|Undergo surgery
46108441|NCT04048499|Device|the Colour Assessment and Diagnosis (CAD) test|The CAD test (City Occupational Ltd, London, UK) measures the severity of red-green and yellow-blue colour vision loss according to red-green and yellow-blue thresholds which are expressed in CAD units and diagnoses accurately the subject's class of colour vision
45468905|NCT05177406|Other|Aimovig|patients newly initiating Aimovig therapy
45468906|NCT03768661|Procedure|Single-incision Laparoscopic cholecystectomy|laparoscopic cholecystectomy performed through a single device located at a unique umbilical incision
46022553|NCT00992446|Drug|Rituximab|Given IV
46022554|NCT00992446|Drug|Vorinostat|Given PO
46022555|NCT04452565|Drug|Drug: NA-831|NA-831 is a neuroprotective drug, available at 30 mg capsule
46022556|NCT04452565|Combination Product|NA-831 and Atazanavir|"Drug: NA-831 Neuroprotective drug Other Name: Traneurocin 30 mg capsule~Drug: Atazanavir Sulfate Antiviral drug Other Name: Atazanavir Sulfate 200 mg tablet"
46022557|NCT04452565|Combination Product|NA-831and Dexamethasone|"Drug: NA-831 Neuroprotective drug Other Name: Traneurocin 30 mg capsule~Drug: Dexamethasone anti-inflammatory drug Other Name: Dexamethasone 4 mg"
46108442|NCT00684281|Other|Neurological and neuropsychological consultation, MRI|Neurological and neuropsychological consultation, MRI for the month 0, 18 and 36
46108443|NCT00684281|Other|Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA|Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA, months 0/18/36
46108444|NCT00769054|Drug|Ropivacaine|Local Infiltration Analgesia with 1 % Ropivacaine
46108445|NCT00769054|Drug|Isotonic NaCl|Local Infiltration with NaCl
46108446|NCT04138979|Drug|cyclophosphamide|First use of chemotherapy after breast cancer
46108447|NCT00694265|Procedure|Decompression|Surgical decompression of the median nerve
46108448|NCT00694265|Procedure|Conservative treatment|Conservative treatment typically consisted of splinting and corticosteroid injections
46108449|NCT04016129|Biological|4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR|4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR Patients who have relapsed after CD19 CART immunotherapy or have CD19 negative B cell malignancies
46022558|NCT04452565|Combination Product|Atazanavir and Dexamethasone|Drug: Atazanavir Sulfate Antiviral drug Other Name: Atazanavir Sulfate 200 mg tablet Drug: Dexamethasone anti-inflammatory drug Other Name: Dexamethasone 4 mg
46022559|NCT04615195|Other|cries 13 questionnaire|"Participant will be contacted by telephone by a clinical research assistant to answer the CRIES 13 questionnaire.~In large families, the CRIES-13 of the holder of parental authority and of the child will be applied for each of them whose age corresponds to the inclusion criteria."
46022560|NCT04285840|Other|Venous ACT|Matched/paired venous ACT samples will be drawn at the same time as arterial ACT samples to compare the results agreement between venous and arterial ACTs. Subjects undergoing atrial fibrillation ablations will continue to have Heparin dosed on the arterial ACT sample results only per the standard of care. Heparin will not be administered based on venous ACT levels obtained during this study.
46022561|NCT04440319|Behavioral|Intervention group|Intervention group is individual with T2DM who will receive DM Nutrition education for 3 months. There are 75 subjects in Intervention group at 2 districts and 4 Public Health Care (PHC).
46022562|NCT00629668|Genetic|TNF-alpha and HBV genotype|
46022563|NCT00629668|Other|TNF-alpha and HBV genotypes|
46022564|NCT04408885|Other|Rehabilitation|Non-surgical interventions to patients with an Anterior cruciate ligament injury. Rehabilitation regime is the regime provided by the physician at the rehabilitation clinic.
46022565|NCT02863120|Drug|liposomal bupivacaine|
46022566|NCT02863120|Drug|bupivacaine HCl|
46022567|NCT02863120|Drug|Ropivacaine|
46022568|NCT02863120|Drug|Saline|
46022569|NCT04201795|Other|Laser|laser with no emision will applied
46022570|NCT04201795|Other|pressure and traction tecnique|pressure and traction in plantar fascia with hands will be applied
46022571|NCT03823534|Drug|Ketorolac|IV Ketorolac to be given over the course of the first 24 hours after surgery. See arm/group description for further details.
46022572|NCT03823534|Drug|Normal saline|An IV normal saline placebo prepared by the hospital pharmacy.
46022573|NCT03823534|Drug|Acetaminophen|acetaminophen 500 mg PO Q4 hours PRN for mild pain
46022574|NCT03823534|Drug|Oxycodone Acetaminophen|oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate to severe pain
46022575|NCT03823534|Drug|Morphine|morphine IV PRN (or other opioid) for severe breakthrough pain
46022576|NCT03823534|Drug|Hydrocodone/Acetaminophen|At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours. Those with preexisting liver disease will be prescribed the equivalent in oxycodone.
46022577|NCT03823534|Drug|Oxycodone|Upon discharge, patients will be prescribed the equivalent of 1-2 hydrocodone 5mg Q4 hours upon should they have preexisting liver disease and are unable to consume acetaminophen.
46022578|NCT02846701|Drug|duloxetine|The concentration of duloxetine is measured by liquid chromatography coupled to tandem mass spectrometry on blood sample
46022579|NCT04344301|Other|Audio recording|The investigators will audio record the visits of patients in the intervention group. An RA will enter the exam room and begin the recording with the patient's permission. The patient and clinician can choose to stop or start the recording at any time. Once the visit is complete, the RA will enter the room, turn off the recording, and bring the patient to a private room where the RA will follow standardized instructions demonstrating how to access recordings. Patient access to recordings will be possible via a secure web-based platform. Patients will also receive reminders to listen to their recordings.
46022580|NCT00970294|Behavioral|Health Promotion Program|10 week health promotion program 3-4 times per week
46022581|NCT04327063|Drug|Saline|Injection of the solution of Saline not exceeding 30 mL of maximal volume.
46022582|NCT04327063|Drug|Ropivacaine|Dilution of Ropivacaine 7.5 mg/ml to 5 mg/ml not to exceed 3 mg/kg of maximal dose and 30 ml of maximal volume
45468907|NCT03768661|Procedure|Laparoscopic Cholecystectomy|laparoscopic cholecystectomy performed using three-trocars standard technique
46022583|NCT04285918|Procedure|Percutaneous device closure|If there is no relevant AF detected for 6 months during intermittent follow-up or ICM, device closure of PFO is recommended for high-risk PFOs but is decided ultimately at the discretion of the attending physician. If there is any relevant AF identified from ICM or other modalities during follow-up, adequate secondary prevention with anticoagulants should be carried out. All this process and decision making should be a part of routine clinical practice.
46022584|NCT02844283|Drug|Ad-HGF|
46022585|NCT02844283|Other|0.9% NaCl|
46022586|NCT04565431|Drug|Tysabri|Participants with RRMS who are planning to begin treatment with Tysabri will be compared to a group of healthy individuals who are matched for age, gender, and education.
46022587|NCT02844361|Other|autologous stem cell transplantation|Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback
46022588|NCT02844361|Other|conventional chemotherapy|Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy
46022589|NCT04286698|Other|Complex decongestive physiotherapy|MLD was administered 5 days a week for 4 weeks, with each session lasting 30 minutes [25]. Compression therapy was applied to the patients by wearing a compression mask (FM Velcro Fastener, LIPOELASTIC), made of polyamide, cotton, viscose, and elastane, that covered the submandibular region, the masseter region, and the neck. The compression mask is specifically designed for the healing and recovery of tissues after plastic and aesthetic surgeries. The patients were advised to wear the compression masks for at least 4-6 hours per day for 4 weeks and gradually increase wearing time according to their tolerance. The patients were asked to perform skin care by themselves. Skin care was applied using a low pH skin lotion to moisturize the skin. Neck, face/mimic, tongue, and posture exercises were performed by patients while the compression mask was worn and under the supervision of a physiotherapist, with 10 repetitions 5 times a week for 4 weeks.
45468908|NCT02521246|Drug|Candesartan + Chlorthalidone|
45468909|NCT02521246|Drug|Candesartan + Chlorthalidone|
46108450|NCT00666328|Drug|clevidipine|"Clevidipine injectable emulsion (0.5 mg/mL) in 20% lipid emulsion in 100 mL bottles was administered intravenously to all patients via a single dedicated line.~Clevidipine was infused at an initial rate of 2.0 mg/h for the first 1.5 minutes. Thereafter, titration to higher infusion rates were to be attempted as needed to obtain the target systolic blood pressure (SBP) range (SBP ≤160 mmHg to ≥140 mmHg). Titration to effect was to proceed by doubling the dose every 1.5 minutes, up to a maximum of 32.0 mg/h, until the desired effect (SBP within the target range) was attained. The clevidipine infusion rate could be increased or decreased to maintain systolic blood pressure for up to a maximum of 96 hours."
46022590|NCT04286698|Other|Home program|Self-MLD and exercises (neck, face/mimic, tongue, and posture exercises) were shown to the patients in this group. Self-MLD included self-administered lymph drainage of the axillary, posterior, lateral, and anterior neck areas; the pre- and retro-auricular regions; the lateral and anterior regions of the face; and the lower jaw region. Then the order is reversed back to the starting point [3]. A video of self-MLD and a text including exercise descriptions were shared with patients and their relatives to ensure that the self-MLD and exercises were performed accurately and regularly at home. Self-MLD was recommended to be applied once a day, and the exercises were advised to be performed for 10 repetitions each, 10 times a day for 4 weeks. The patients were called by phone during the second week after their first evaluation as a control and to motivate the patient for performing self-MLD and home exercises properly.
46108451|NCT00694343|Drug|HES 130/0.4 (6%) in sodium chloride (solution for infusion)|500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
46108452|NCT00694343|Drug|Ringer's Lactate solution|1000 mL Ringer's Lactate solution
46022591|NCT05337865|Other|Aerobic exercise test.|Aerobic exercise test at a treadmill.
46022592|NCT02864056|Other|Tai Chi|Ancient Chinese form of mind/body gentle exercise; this will be done while standing to improve postural balance.
46022593|NCT05242861|Radiation|Brachytherapy|Applicator, dose, schedule, technology, image, 3D print, efficacy, toxicity of brachytherapy
46022594|NCT02863822|Behavioral|Low FODMAP Diet|Subjects in the experimental arm, will be educated in the low fermentable oligo-di-monosaccharides and polyols (FODMAP) diet.
46022595|NCT02863822|Behavioral|Choose My Plate Diet|Subjects in the active comparator arm will be educated in the ChooseMyPlate.gov Diet.
46108453|NCT00781534|Drug|Ginseng|Each of the 3 arms will be compared to determine if there is any clinical difference in blood sugars between the 3 groups
46108454|NCT00781534|Drug|Ginseng|
46022596|NCT05337787|Other|flipped classroom approach|All students in the experimental group were trained only according to the flipped classroom approach.
46022597|NCT04292704|Radiation|the fractional CO2 laser|The fractional CO2 laser therapy mechine: the wavelength is 10.6 μ m, the output power is 40 w, the action time is 2000 μ s and the lattice spacing is 700 ~ 1000 μ m
46022598|NCT04292704|Drug|Clotrimazole|Clotrimazole vaginal tablets
46108455|NCT00781534|Drug|ginsenoside RE|active metabolite of ginseng
46108456|NCT00781534|Dietary Supplement|Placebo (sugar pill)|placebo group
46108457|NCT00778180|Drug|furosemide 80 mg tablets|
46108458|NCT00688415|Drug|VTX-2337|Escalating doses of the investigational drug will be administered to cohorts of patients until the highest tolerated dose is identified.
46108459|NCT00781690|Device|Evodial hemodialysers and Evodia blood lines|Maximum 8 weeks treatment with Evodial dialysers with reduction of heparin dose
46108460|NCT00769210|Drug|Simvastatin|Simvastatin 40 mg tablet
45681417|NCT04021420|Device|SONOCLOUD|"The SonoCloud System is an active implantable medical. The SonoCloud is indicated to locally and transiently increase the permeability of the blood brain barrier to facilitate the passage of substances into the cerebral parenchyma.~The SonoCloud System consists of :~an implantable ultrasound transducer,~a needle connection device,~an external radiofrequency generator, and~an ultrasound resonator. The SonoCloud® is designed to be fixed to the skull. The device is placed in a burr hole or in place of a bone flap and ultrasound energy is delivered directly to the brain tissue, without traversing the skull bone. The device is activated by connecting the implant to the external generator system using the transdermal needle. Once connected to the external generator, the implant delivers low-intensity pulsed UltraSound (US) for duration of 120-270 seconds. A total of 3 US dose levels will be evaluated (0.78, 0.9 and 1.03 MPa)."
46108461|NCT00690911|Drug|adalimumab|40mg dose subcutaneously using sterile technique. The site research staff will instruct and supervise subjects or a designee or nurse on proper injection technique during site visit evaluations. Subjects or a reliable designee will administer injectable study drug at home in between site visit evaluations.
46108462|NCT00781846|Drug|ridaforolimus|oral tablets, daily for 5 days/week
46108463|NCT00781846|Drug|bevacizumab|IV infusion
46108464|NCT00853580|Drug|Lovastatin ™|Lovastatin starting at 20mg for 2 weeks, increasing to 40mg for 14 weeks. Total duration of trial is 16 weeks.
45468910|NCT02521246|Drug|Losartan+hydrochlorothiazide|
45468911|NCT05309070|Dietary Supplement|N-acetyl cysteine|Study group will receive N-acetyl cysteine in unmarked boxes, in a daily dose of 1200 mg during two months
45681418|NCT04021420|Drug|Nivolumab Injection|Nivolumab (flat dose: 240mg, 30 minutes infusion)
46108465|NCT00853580|Device|placebo|Starting at 20mg for 2 weeks, then increasing to 40mg for 14 additional weeks for a total duration of treatment of 16 weeks.
46108466|NCT00781924|Procedure|biopsy|ultrasound guided biopsy of tumors.
46108467|NCT00782002|Biological|IMC-18F1|Cohorts 1-4 will receive IMC-18F1 intravenously for 4 weekly infusions, followed by a 2-week observation period. Cohort 5 will receive IMC-18F1 intravenously every other week for the first 6 weeks of therapy. Cohort 6 will receive IMC-18F1 every 3 weeks for the first 6 weeks for therapy. The starting dose in Cohort 1 will be 2mg/kg. The maximum dose of IMC-18F1 will not exceed 16mg/kg administered every week, 15mg/kg administered every other week, and 20mg/kg administered every 3 weeks. Dose escalation of 100% (2 x previous dose) if no dose limiting toxicities (DLTs) are observed in the first three patients within a cohort during the initial 6-week therapy period. Dose escalation increment will be reduced to 50% (1.5 x previous dose) following the occurrence of either grade 2 or higher AEs in 2 or more patients that are possibly, probably, or definitely-related to study medication or one DLT during the initial 6-week therapy period. No intrapatient dose escalation is allowed.
46108468|NCT00688493|Drug|Dapagliflozin|3 x 50 mg tablets, single oral dose
46108469|NCT00688493|Drug|Dapagliflozin|2 x 10 mg capsules, single oral dose
46108470|NCT00688493|Drug|Moxifloxacin|Overencapsulated 400 mg capsule, single oral dose
46108471|NCT00688493|Drug|Placebo to match moxifloxacin and dapagliflozin|Overencapsulated 400 mg capsule, single oral dose
46108472|NCT00778414|Drug|Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension|
46108473|NCT00688571|Device|Melody Transcatheter Pulmonary Valve|Transcatheter valve implantation into a RV-PA conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs intervention
46108474|NCT00865514|Drug|Dichloroacetate|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
46108475|NCT00865514|Genetic|Genotyping|Subjects will have 5 mls of blood drawn for genotyping
46108476|NCT00865514|Other|Leucine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
45468912|NCT05309070|Other|placebo|Control group will receive a placebo, in unmarked boxes, during two months
45468913|NCT04243876|Diagnostic Test|paraoxanase enzyme level|presence of paraoxonase enzyme deficiency and associated troponin elevation
45681419|NCT03946072|Procedure|Transseptal Aortic Approach Catheter Ablation Procedure|The transseptal approach entails obtaining femoral venous access, and, guided by fluoroscopy and intra-cardiac ultrasound, starting with a transseptal needle or radio frequency (RF) device inside the dilator of a long sheath; pulling down until the fossa ovalis in the interatrial septum is engaged on both fluoroscopy and intracardiac echo imaging; once on the left side, the long sheath is advanced over the transseptal needle, the needle and dilator are removed, and the ablation catheter can then be advanced across the mitral valve into the left ventricle.
46022599|NCT05242783|Drug|Terlipressin|intramyometrial Terlipressin versus carbitocin versus saline(placebo) injection in women undergoing open myomectomy procedure using haemostatic tourniquets.
46022600|NCT04181944|Other|Exercise Treatment Group|be specific
46022601|NCT05336305|Dietary Supplement|Polydextrose|Administration of 3g polydextrose per day, for 2 months
45838337|NCT03651830|Device|Prosthetic Foot Emulator|Participants will walk in the laboratory with the Prosthetic Foot Emulator (PFE) in three foot modes corresponding to actual study feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.
46022602|NCT04214743|Device|Incident dark field videomicroscope from Braedius|It allows to look at conjunctival microcirculation
45468914|NCT05308992|Device|HydroGlyde Condom|The latex HydroGlyde condom has a hydrophilic coating which maintains its lubricity when in contact with water. Improved lubrication during intercourse may lead to improved user satisfaction and increased condom use which would help prevent the spread of Sexually Transmitted Infections and unwanted pregnancies.
45468915|NCT04239820|Radiation|Imaging|MRI and TSPO-PET imaging at baseline and 18 months after baseline
46022603|NCT04214743|Device|Fundus camera from Optomed|It allows to monitor retinal microvasculature
46022604|NCT02846467|Other|Informed consent trough a portable video media|Information provided to patients using the mobile application (iURO app)
46022605|NCT02846467|Other|Written informed consent|Information provided to patient trough the traditional informed consent (written IC) for transurethral resection of bladder or prostate.
46022606|NCT03987685|Drug|Oratopo|Oral topotecan will be supplied in topotecan capsules and oral HM30181A-US tablets
46022607|NCT00969436|Biological|GSK Biological's investigational MMRV vaccine 208136|Subcutaneous injection
46022608|NCT00969436|Biological|Priorix™|Subcutaneous injection
45838338|NCT03651830|Device|Commercially available prosthetic feet|"Participants will walk in the laboratory with three different commercially available prosthetic feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.~Additionally, participants will be fit with one of the actual feet and wear it at home and in the community for approximately two weeks. This will be followed by two-week periods in the community with each of the other two commercially available prosthetic feet."
46022609|NCT00969436|Biological|Varilrix™|Subcutaneous injection
46108477|NCT00865514|Other|tyrosine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
46022610|NCT00900757|Drug|Palonosetron (PALO)|Eligible patients should receive a planned total dose of 54-60 GY of radiation and 75 mg/m2 of daily temozolomide for a total of six weeks of treatment. For each week of radiation patients will receive a single 0.25 mg intravenous dose of palonosetron 30 minutes before each week of radiation fraction. This schedule will be repeated for each week of radiation for a total of 6 weeks.
46108478|NCT02556580|Drug|Albumin 20%|Intervention: intravenious infusion Drug: albumin
46022611|NCT03735238|Other|SMILE Computerized Decision-Aid|SMILE is a computerized decision-aid designed to give lupus patients information about lupus, treatments for lupus available to them, as well as side effects. This will be administered at every lupus clinic session. Every patient will see the SMILE Computerized Decision-Aid at their index baseline clinic visit.
46022612|NCT05242393|Other|No intervention is planned|No intervention is planned
46108479|NCT00688649|Dietary Supplement|Standard Oral Nutritional Supplement (ONS)|Standard energy, oral nutritional supplement (a milk style nutritional supplement (1.5kcal/ml, 200ml) containing protein, fat, carbohydrate and micronutrients)
46108480|NCT00688649|Dietary Supplement|High energy Oral Nutritional Supplement (ONS)|High Energy nutritional supplement (a milk style nutritional supplement (2.4kcal/ml, 125ml) containing protein, fat, carbohydrate and micronutrients)
46108481|NCT04136717|Other|Washout period|During this period the patients will breath spontaneously oxygen titrated using the FreeO2 device with a SpO2 target set at 90%. The period duration is 30 minutes.
46108482|NCT04136717|Device|NIV - FreeO2|"During this period the patients will receive NIV using FreeO2 device for oxygen titration with a SpO2 target set at 90%. Initially, the inspiratory pressure will be set to obtain a tidal volume between 6 to 8 mL/Kg of predictive body weight and positive end-expiratory end pressure (PEEP) at 5 centimeters of water (cmH2O).~After NIV initiation, the parameters can be adjusted to improve patient comfort. The period duration is 30 minutes."
46108483|NCT04136717|Device|Nasal High flow Oxygen therapy - FreeO2|During this period the patients will receive NHFOT using the FreeO2 device for oxygen titration with a SpO2 target set at 90%. The high flow device will be set at 30 lpm.The period duration is 30 minutes.
46108484|NCT04136717|Other|CPAP - Oxygen constant flow|During this period, the patients will have their own CPAP with oxygen adjusted by hospital staff according to hospital protocol. The period duration is 15 minutes.
46108485|NCT04136717|Other|CPAP - FreeO2|During this period, the patients will have their own CPAP with oxygen adjusted using the FreeO2 device. SpO2 target will be set at 90% The period duration is 60 minutes.
46108486|NCT00782080|Drug|Sedariston|St. John´s Wort (100 mg) Valerian Extract (50 mg)
46108487|NCT00782080|Drug|Placebo|Placebo
46108488|NCT00769288|Drug|2'-F-ara-deoxyuridine|Given IV
46108489|NCT00769288|Other|positron emission tomography|Correlative studies
46108490|NCT00769288|Other|laboratory biomarker analysis|Correlative studies
45681420|NCT03946072|Procedure|Retrograde Aortic Approach Catheter Ablation Procedure|The retrograde aortic approach entails obtaining femoral arterial access and leaving a sheath in the femoral artery. Under fluoroscopy, an ablation catheter is then advanced up the ascending aorta where the catheter tip is curved using an internal mechanism controlled on the handle of the catheter to form a large loop (to prevent the tip from traveling down a coronary artery and causing trauma such as a dissection); the curved loop is advanced around the aortic arch and down the ascending aorta. To cross the aortic valve with this loop, the catheter is typically torqued in various directions until it falls through the aortic valve and into the left ventricle.
45838339|NCT03635112|Drug|Placebo|Placebo will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating.
46022613|NCT02846311|Device|Flu Test|
46022614|NCT00969280|Device|Standardized Acupuncture|"Acupuncture treatment will be applied 3 times per week, total 9 times for 3 weeks.~According to the guideline of WHO standard acupuncture point locations in the western pacific region, acupuncture treatment will be offered in all 17 acupoints: both BL2, GB14, TE23, Extra-1(Taiyang), ST1 and GB 20, and GV23, and Left SP3, LU9, LU10 and HT8, which are located in periorbit, forehead or temple of the head and Lt. forearm and back of the Lt. foot by a disposable 20*30mm (Dongbang Co., korea) acupuncture needle.~All the acupuncture needles will be inserted, induced strong 'deqi' sensation and retained for 20 minutes."
46108491|NCT00769288|Other|pharmacological study|Correlative studies
46108492|NCT00769288|Other|pharmacogenomic studies|Correlative studies
46108493|NCT00688727|Behavioral|CBT|CBT, up to 12 sessions.
46108494|NCT00688727|Behavioral|Standard Care|Routine review by neuropsychiatrist in outpatient clinic
46108495|NCT04136561|Device|Midline catheter|Midline catheter placed in patients with existing standard of care CVC
46108496|NCT00912938|Drug|zoledronic acid|Intravenous zoledronic acid 4mg over a minimum of 15 minutes in at least 100mls of calcium free infusion solution (0.9% sodium chloride or 5% glucose solution) every 4 weeks.
46108497|NCT00912665|Device|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
46108498|NCT00912665|Device|Goldmann applanation tonometer|intraocular pressure measurements
45468916|NCT05176938|Procedure|Ultrasound guided Thoracic Interfascial plane Block (TIFB)|Patients of the group will be placed supine and elevate arm to the head, Serratus intercostal plane block will be with the probe in the midaxillary line, The subcutaneous tissue and serratus muscle will be identified in the superficial plane, whereas the external intercostal muscles will be identified in the intermediate plane and finally in the deep plane the ribs, pleura and lung will be identified. The needle will be advanced from caudal to cranial direction after giving 3 ml lidocaine locally. In-plane technique was used until the tip of the needle placed between the serratus anterior muscle and the external intercostals muscle a volume of 20 ml plain bupivacaine will be injected.
45468917|NCT05176938|Procedure|Ultrasound guided Erector Spinae plane Block (ESPB)|The patient will be placed in setting position and a superficial (5-12 MHz) ultrasound transducer will be placed in a longitudinal orientation, 3 cm lateral to the T4 spinous process. An 8-cm 22-gauge spinal needle will be inserted in cephalic direction after giving 3 ml lidocaine locally until the needle tip hit the transverse process of T4 under ultrasound image visualization, then the needle will be withdrawn slowly to be within the interfacial plane below the erector spinae muscle, then the anesthetic mixture will be injected here. Successful injection will be evidenced by visible linear free spread (cranially and caudally) of injectate below the muscle.
46022615|NCT00969280|Device|Non-acupuncture point shallow penetration acupuncture|"Acupuncture treatment will be applied 3 times per week, all 9 times for 3 weeks.~Acupuncture treatment will be offered in 17 non-acupuncture points by a disposable 20*30mm acupuncture needle. A strong 'deqi' sensation will not be induced, but inserted acupunctures will be leaved for 20 minutes."
46022616|NCT04136743|Device|Lipogems|The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the tendon lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications.
46022617|NCT04136743|Drug|Dexamethasone|Triamcinolone Acetonide is a corticosteroid, which is a class of drugs that are commonly prescribed for shoulder pain. They work to reduce pain by limiting inflammation. They are typically injected into the subacromial space with or without ultrasound guidance.
46022618|NCT03931057|Drug|ADV6209 (=gamma-cyclodextrin-Midazolam)|30 min. before anesthesia children have to swallow the anxiolytic drug (ADV6209)
46022619|NCT03931057|Drug|Midazolam|30 min. before anesthesia children have to swallow the anxiolytic drug Midazolam
46022620|NCT00969124|Device|Third Eye Retroscope|Third Eye Retroscope is used in conjunction with a standard colonoscope while performing colonoscopy
46022621|NCT02846155|Other|clear water|the patients just drink common clear water before Magnetic-controlled Capsule Endoscopy examination
46022622|NCT02846155|Drug|simethicone|the patients drink clear water and simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion) before Magnetic-controlled Capsule Endoscopy examination
46022623|NCT02846155|Drug|simethicone combined with pronase|the patients drink simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion)，pronase granules（Deyou；Beijing Tide Pharmaceutical Co，China,containing 20,000iu pronase），and clear water before Magnetic-controlled Capsule Endoscopy examination
46022624|NCT02846077|Other|No intervention. Observation only|No intervention. Observation only
46108499|NCT00912665|Other|squatting|Subjects will perform squatting for 6 minutes while either blood flow or intraocular pressure measurements
46108500|NCT00912665|Device|Suction cup|Experimental stepwise increase of intraocular pressure while either optic nerve head blood flow or intraocular pressure measurements
45468918|NCT03771235|Behavioral|Mindfulness-based Intervention for Tics|Psychological intervention that focuses on cultivating awareness of urges to tic and developing a different relationship to those urges through meditation and other mindfulness practices.
45468919|NCT03771235|Behavioral|Tic Information and Coping Strategies|Psychological Intervention that focuses on learning more about tics, practicing a range of strategies for coping with tics (e.g., relaxation, effective communication), and discussing challenges commonly experienced by individuals with tics.
45681421|NCT04144582|Drug|Sintilimab Combined With Docetaxel Monotherapy|Sintilimab 200mg i.v q3w , Docetaxel 75mg/m2 i.v q3w
46022625|NCT03825523|Other|iART|After group assignment, ART will be started within the first 48 hours after admission to the hospital. ART regimen will be decided according to each subject´s the clinical characteristics
46108501|NCT00782236|Device|Bone Graft Material|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of Straumann Bone Ceramic or Freeze Dried Allograft Bone (FDBA) with a resorbable collagen membrane (Bio-Gide) for preservation of the alveolar ridge following tooth extraction. Following 6 months of healing, a core of bone will be taken from the surgical site and a dental implant will be placed. The subjects will then be followed for 12 months following dental implant placement.
46108502|NCT00688805|Drug|Propranolol|40 mg given as a single oral administration in an opaque capsule
46108503|NCT00688805|Drug|Placebo|matching capsule containing no active medication
46108504|NCT00701480|Other|skin cleanser contained Hibiscus sabdariffa extract|face washing 2-3 times/day
46108505|NCT00701480|Other|marketed skin cleanser|face washing 2-3 times/day
46108506|NCT04136639|Other|Miswak|sticks
46108507|NCT04136639|Other|Grape Seed Extract Mouthwash|Mouthwash
46108508|NCT04136639|Other|fluoride|mouthwash
46108509|NCT02613026|Drug|Pirarubicin|
46108510|NCT02613026|Drug|Docetaxel|
46108511|NCT02613026|Drug|Cyclophosphamide|
45681422|NCT03658954|Behavioral|Advice|Once per week for two weeks, participants will come to in-person visits to receive brief web-based sleep hygiene advice.
45681423|NCT03658954|Behavioral|Self-monitoring|Participants will complete daily web-based sleep and alcohol diaries for two weeks.
45468920|NCT05308836|Combination Product|adipose-derived messenchymal stem cell|Collaborative research program between Vinmec Research Institute of Stem Cell and Gene Technology with the National Yang-Ming University in Taiwan The adipose mesenchymal stem cell line (GXIPC1) was collected from healthy donors who have screened for infectious diseases and then multiplied in large numbers. These products were produced following the GMP laboratory system and approved by Taiwan FDA for preclinical and clinical trials with completed certificates
45468921|NCT04949646|Other|Pelvic Intraoperative Neuromonitoring|Pelvic Intraoperative Neuromonitoring (pIONM) allows mapping of the pelvic autonomous plexus during total mesorectal excision (TME).
46022626|NCT03825523|Other|cART|After group assignment, ART is started at the discretion of the attending physician. ART regimen will be decided according to each subject´s the clinical characteristics
46108512|NCT04136483|Behavioral|CBT-I|The theoretical framework is cognitive-behavioral therapy that includes sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive interventions and relaxation. The intervention has been adapted to adolescents by reducing the amount of psychoeducational information and the interventions related to changing cognitions. It involves six weekly face-to-face individual sessions with a therapist, supported by a participant workbook that contains information, work- sheets, and at-home tasks. Clinical psychologists or graduate clinical psychologists in training delivered the intervention sessions under supervision by the first author. Parents/care-givers were given information about the components, but did not take active part of the intervention.
46108513|NCT00769366|Behavioral|Psychotherapy|humanistic-existential psychotherapy conducted in individual and group meetings
46108514|NCT00769366|Drug|Medical therapy|Optimal medical therapy after Acute myocardial infarction
46108515|NCT02614742|Drug|SFX-01|An intervention releasing sulforaphane.
46108516|NCT02614742|Drug|Placebo|Placebo otherwise identical to Active product
46108517|NCT00778726|Drug|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
46108518|NCT00688883|Drug|Fludarabine Phosphate (Fludara)|Patients received Fludarabine Phosphate orally for 5 consecutive days, followed by a 23-day observation period. Setting this as 1 treatment cycle, 6 cycles will be given.
46108519|NCT00769522|Biological|Rituximab|"cycle 1: 375 mg/m² i.v., day 0, q28d~cycle 2-6: 500 mg/m² i.v., day 1, q28d"
45468922|NCT03612856|Drug|AB023- Dose 1|Participants will receive a single dose of 0.25 mg/kg AB023.
45468923|NCT03612856|Drug|AB023-Dose 2|Participants will receive a single dose of 0.5 mg/kg AB023.
45468924|NCT03612856|Drug|placebo|Participants will receive a single dose of placebo.
45468925|NCT03768583|Other|Group TSM ICT sneakers|Sensory motor training with sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
45468926|NCT03768583|Other|Group TSM ICT barefoot|Sensory motor training without sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
45468927|NCT03768583|Other|Group TSM health sneaker|Sensory motor training with sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
45468928|NCT03768583|Other|Group TSM health barefoot|Sensory motor training without sneaker for volunteers with Chronic ankle instability, for five weeks, twice a week.
46022627|NCT03744403|Drug|CS1001|In the dose-escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose-expansion part, both dose levels will be expanded.
46108520|NCT00769522|Drug|Bendamustine|cycle 1-6: 90mg/m² i.v., day 1-2, q28d
46108521|NCT00769522|Drug|Cyclophosphamide|cycle 1-6: 250 mg/m² i.v., days 1-3, q28d
46108522|NCT00769522|Drug|Fludarabine|cycle 1-6: 25 mg/m² i.v., days 1-3, q28d
46108523|NCT04138511|Device|ECOFISIO|The ECOFISIO application is focused on sports pathologies and contains relevant written and digital information about ultrasound imaging and managing as well as diagnosis of sport injuries.
46108524|NCT00688961|Drug|Aspirin|generic aspirin
46108525|NCT00688961|Drug|omega-3 acid ethyl esters|4, 1 g capsules q.d.
46108526|NCT04138355|Other|Extracorporeal shock wave therapy|ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen,Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave. ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
46108527|NCT00778804|Behavioral|telemedicine|Weekly transmission of health status (weight, activity, BP etc.) via the Internet with feeedback and reinforcement
45468929|NCT04763928|Drug|Venetoclax+Decitabine|"Patients will receive treatment with a combination of decitabine and venetoclax as follows:~Decitabine 20 mg/sqm intravenously on days 1 to 5 of 28-days courses~Venetoclax 400 mg per day orally on days 1 to 28 of 28-days courses; a dose escalation period is provided at first cycle (ramp-up) in which VEN is administered as follows: 100 mg on day -2, 200 mg on day -1, and 400 mg on day 1, a dose that is continued subsequently, daily, for 28-day cycles.~In case of achievement of response, the treatment will be continued until disease progression or death by other causes."
46022628|NCT02845921|Other|leg elevation|A stand making an angle of 30 degree to the horizontal is used to elevate both the legs
46022629|NCT02845921|Other|leg wrapping|Esmarch bandage is used to wrap each lower limb
46022630|NCT02845921|Other|control|no intervention has been done
46022631|NCT05336149|Procedure|Alveolar ridge preservation using whole-tooth dentin graft|Minimally-traumatic extraction of non-restorable teeth then grafting with whole-tooth dentin graft
46108528|NCT00689039|Drug|AZD1305|ER tablet, administered as single and repeated doses.
46108529|NCT00689039|Drug|Placebo|Tablet, administered as single and repeated doses.
46022632|NCT05336149|Procedure|Alveolar ridge preservation using particulate dentin graft|Minimally-traumatic extraction of non-restorable teeth then grafting with particulate dentin graft
46022633|NCT02845843|Drug|Combination of Lopinavir /Ritonavir and Interferon beta-1b|Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days
46022634|NCT02845843|Drug|Placebo|Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding
46022635|NCT02845999|Biological|allogenic immunotherapy based on Natural Killer cells adoptive transfer|day -1 : donor NK cell purification ; day 0 : adoptive transfer (according to a dose escalation) ; Dose escalation protocol : 3.10^6 ; 8.10^6 and 12.10^6 cells/kg of recipient body weight
46022636|NCT02845999|Biological|cetuximab|day -8 : cetuximab 400 mg/m2 ; day -1 and every week (for 7 weeks) : cetuximab 250 mg/m2
46022637|NCT02845999|Drug|Cyclophosphamide|day -6 : cyclophosphamide 60 mg/Kg
46022638|NCT02845999|Drug|fludarabine|day -6 to day -2 : fludarabine 25 mg/m2
46022639|NCT02845999|Drug|interleukin-2|day -1 : addition of 1000 UI/ml of interleukin 2 to NK cells and overnight culture at 37°C, 5%CO2 ; day 0, hour +12 : 10 MUI of interleukin 2 injection, 2 times a week during 3 weeks.
46022640|NCT00900601|Procedure|Arthrodesis to the sacroiliac joint and symphysis|"Standard surgical procedures will be used. When the patient has isolated pain in the symphysis isolated fixation will be performed. A 2x2 cm large bone block will be removed and replaced with spongy bone. For fixation the Matta-plate will be applied.~To the sacroiliac joint we use an anterior approach. A 2x1,5 cm large bone block will be removed and replaced with spongy bone from the iliac crest. For joint fixation we either use 2 plates or sacroiliac screws. The same procedure will be used on the other side in the cases with bilateral symptoms. Only one side will be operated at a time. After one year it will be decided if it's necessary to perform contralateral surgery."
46022641|NCT03671239|Behavioral|Placebo rectal insert|Participants will be instructed to insert in the rectum a placebo insert prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
46022642|NCT03671239|Behavioral|Placebo rectal suppository|Participants will be instructed to insert in the rectum a placebo suppository prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
46022643|NCT03671239|Behavioral|Placebo rectal douche|Participants will be instructed to insert in the rectum a placebo douche (enema bottle with approximately 120 mL of clean tap water or bottled water) prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI, or if no other RAI activity occurs in that 7-day period, to take a dose in the absence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
46022644|NCT02845609|Drug|Sialic Acid-Extended Release|Oral drug of Sialic acid
46022645|NCT05177185|Radiation|Hippocampal-sparing|Dose constraint placed on hippocampi to minimize dose to hippocampi, while maintaining target coverage (at least 98% of brain metastasis volume must receive 100% of prescription dose).
46022646|NCT05177185|Radiation|Stereotactic radiosurgery|Stereotactic radiosurgery (SRS) with prescription dose determined based on size of brain metastasis; 21 or 24 Gy in a single fraction if less than or equal to 20 mm, 18Gy in a single fraction in 21 - 30 mm, 15 Gy in a single fraction or 30 Gy in 5 fractions if 31 - 40 mm (physician discretion).
46022647|NCT05176015|Device|Frenzel Lens|pair of magnifying glasses (+20 dioptres) that are worn by the patient and an illuminating system. On using Frenzel goggles, the nystagmus is better seen as a result of eyes being magnified and inhibition of visual fixation.
46022648|NCT05176015|Diagnostic Test|Diagnostic Algorithm|"A diagnostic algorithm using the Tittrate approach: continuous, Intermittant, trigger or spontaneous.~The diagnostic algorithm use the REDCap software that include different videos to illustrate diagnostic tests and nystagmus types. Different manoeuvres: HINTS+ battery, Dix-Hallpike test, Supine Head Roll test.~Different Particule Repositionning Techniques will be proposed according to specific tests: Epley and Gufoni maneuvres.~Risk Scrore is used to assess stroke risk for transient ischemic attack: ABCD2 and the Canandian TIA Risk Score"
46022649|NCT05337085|Drug|Dexmedetomidine|Inj dexmedetomidine and inj midazolam given to 2 groups of participants and sedative effects of both drugs will be observed during surgery
46022650|NCT05337085|Drug|Midazolam|Midazolam
46022651|NCT02845765|Device|Dynamic Vessel Analyzer (DVA)|
46022652|NCT02845765|Drug|Phosphodiesterase type 5 Inhibitor (PDE5I)|
46022653|NCT05097937|Other|Sham intervention|The needle will be inserted into the right common extensor tendon of the epicondyle for 90 seconds without galvanic current.
46022654|NCT05097937|Other|Low intensity percutaneous electrolysis|A single impact of galvanic current will be applied in the common extensor tendon of the epicondyle (right side) with an intensity of 0.3 mA for 90 seconds.
45468930|NCT01567501|Drug|Levocetirizine Dihydrochloride tablets 5 mg|5 mg tablet once in a day
45468931|NCT01567501|Drug|Levocetirizine Dihydrochloride|5 mg tablet once in a day
46022655|NCT05097937|Other|High intensity percutaneous electrolysis|Three impacts of galvanic current will be applied in the common extensor tendon of the epicondyle (right side) with an intensity of 3 mA and a duration of 3 seconds each.
46022656|NCT01723579|Drug|Nomegestrol acetate (NOMAC)|Oral tablet with daily release of 2.5 mg
46022657|NCT01723579|Drug|Estradiol (E2)|Daily release of 1.5 mg
46022658|NCT04525183|Behavioral|Enhanced Usual Care (EOC)|Educational materials
46022659|NCT04525183|Behavioral|REVITALIZE ACT Intervention|Six 60-75 minute telehealth sessions approximately once a week for 6-8 weeks
45468932|NCT05385978|Drug|APHD-012|Distal jejunal-release dextrose beads (Aphaia technology, AT)
45468933|NCT05385978|Drug|APHD-012P|Distal jejunal-release placebo beads
46022660|NCT03648931|Behavioral|Focus Group Discussion (FGD)|"No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures. In particular, the FGDs will focus on:~Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~Perceptions of HIV risk during pregnancy and breastfeeding~Perceived role of male partners during pregnancy and breastfeeding~Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~Willingness to join a VR and/or oral PrEP study during pregnancy and breastfeeding"
46108530|NCT00782470|Behavioral|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to stay on the prophylactic treatment (prospective)
46108531|NCT00782470|Behavioral|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to switch to on-demand treatment (prospective)
46108532|NCT00782470|Behavioral|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects remaining on-demand treatment (retrospective)
46108533|NCT00865280|Drug|PTK 0796|PTK 0796 100 mg for injection; PTK 0796 tablet 150 mg
45468934|NCT04374721|Diagnostic Test|circadian gene expression evaluation|patients and controls will undergo circadian gene expression (CLOCK, ARNTL) evaluation at baseline and after 1, 3 and 6 months
45468935|NCT03428542|Behavioral|Yin yoga|Yin yoga 2 times per week for 5 weeks. Daily breathing assignments.
45468936|NCT03428542|Behavioral|YOMI|"30 minutes of psychoeducation combined with mindfulness practice followed by 60 minutes of Yin yoga allowing the psychological theme to be further explored, aided by verbal instructions of the yoga teacher. 2 times per week for 5 weeks.~Daily breathing assignments."
45468937|NCT05384340|Dietary Supplement|Beetroot juice rich in nitrate|On the first day, an acute test will be carried out with beet juice rich in nitrate, in which two units of juice will be provided, totaling 140 ml (800 mg of nitrate) for each protocol. That is, each participant will receive 2 units of juice bottles. From the second to the seventh day, participants will receive 6 units of vials of the juice corresponding to the first intervention on the first visit to the laboratory and will drink one vial a day for a week. Of the 8 units (100%), six bottles (75%) will be provided for the participants to take home. On the seventh day of the intervention, the participants will return to the laboratory for the consumption of the seventh and last bottle of juice. Between one protocol and another, a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
45838340|NCT03635112|Drug|TD-1473|TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.
46108534|NCT00865280|Drug|linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution
46108535|NCT00865280|Drug|moxifloxacin|moxifloxacin 400 mg tablet; moxifloxacin 400 mg IV infusion solution
46108536|NCT04136327|Drug|GLPG1972 film-coated tablets|single oral dose of GLPG1972
46108537|NCT04136327|Drug|[14C]-GLPG1972 solution for infusion|a 15-minute IV infusion [14C]-GLPG1972
46108538|NCT04136327|Drug|[14C]-GLPG1972 oral solution|single oral dose of [14C]-GLPG1972
46108539|NCT00782548|Drug|KADIAN (morphine sulfate sustained-release) capsules|Capsules, 30 mg
46108540|NCT00782548|Drug|Avinza (morphine sulfate sustained-release) capsules|Capsules, 30 mg
46108541|NCT00689195|Dietary Supplement|Curcumin powder|oral capsules containing the investigational agent
46108542|NCT00689195|Dietary Supplement|Ashwagandha extract|4.5% extract of ashwagandha
46108543|NCT00769678|Device|Stimulation of the diaphragm|Stimulation of the diaphragm using an electrode
46108544|NCT00694811|Behavioral|Re-feeding duration|1 or 6 weeks of re-feeding after VLED-induced weight loss
46108545|NCT00778882|Drug|VM106|Autologous hematopoietic stem cells with MT-gp91 retroviral vector
46108546|NCT00865124|Drug|Spironolactone|25 mg capsule daily for 6 months
46108547|NCT00865124|Drug|Hydrochlorothiazide + potassium|hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 milliequivalents (mEq) capsule daily
46108548|NCT00865124|Other|Placebo|Placebo capsule daily
46108549|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
46108550|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
46108551|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
46108552|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
46108553|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
46022661|NCT03648931|Behavioral|In-depth Interview (IDI)|"No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures, focusing on the following topics:~Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~Perceptions of HIV risk during pregnancy and breastfeeding~Perceived role of male partners during pregnancy and breastfeeding~Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~How others in their professional and social networks and communities would view the VR and/or oral PrEP use by pregnant and breastfeeding women"
45468938|NCT01321957|Drug|Oxaliplatin, 5FU/LV, Bevacizumab|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
45468939|NCT01321957|Drug|5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
45468940|NCT04450030|Drug|Methyl Prednisolonate|2000mg intravenous methyl prednisolone per day for five consecutive days
45838341|NCT03617679|Drug|Rucaparib|Participants allocated to the active ingredient arm will receive Rucaparib twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Medication should be taken around the same time every day, with 8 or more ounces of water.
46108554|NCT00871715|Behavioral|Accelerated Skill Acquisition Program (ASAP)|A 30-hour dose is administered over 1-hour visits at a frequency of 3x/week for a 10-week duration. A 2-hour orientation/evaluation session precedes the first visit.
46108555|NCT00871715|Behavioral|Dose-Equivalent Usual & Customary Care - DEUCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting, adjusted for dose, but otherwise administered in accordance with usual and customary practices. This is a 30-hour dose equivalency group, administered over 1-hour visits at a frequency of 3x/week for a 10-week duration.
46022662|NCT01481935|Other|Enhanced cleaning of surfaces in ICU rooms|Using a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), the following surfaces will be wiped clean by a study investigator if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. Cleaning will occur once on the day of enrollment and follow-up.
46108556|NCT00871715|Behavioral|Usual and Customary Care - UCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting. This is an observation only group and treatment dose will be administered in accordance with usual and customary practices.
46108557|NCT00694889|Behavioral|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
46108558|NCT00694889|Behavioral|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 16 weeks.
46108559|NCT00691067|Drug|mifepristone|200 mg po per day x 6 weeks
46108560|NCT00691067|Drug|Placebos|placebo
46108561|NCT04139291|Other|Complex decongestive therapy phase 1|Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
46108562|NCT00691145|Drug|tacrolimus ointment|transdermal
46108563|NCT00694967|Procedure|McDonald cerclage placement|Transcervical McDonald cerclage placement
46108564|NCT00694967|Drug|17 hydroxyprogesterone caproate|Weekly 250mg intramuscular injections
46108565|NCT04136249|Dietary Supplement|Over physical activity|105/5000 resistance training combined with nutritional monitoring on maximum strength of knee extensors
46108566|NCT00695045|Drug|intra thecal morphine|100 mcg intrathecal morphine given once .
45468941|NCT04450030|Procedure|Immunoadsorption|6 courses of tryptophane-based immunoadsorption within up to 12 days
45681424|NCT03658954|Behavioral|Feedback|Participants will receive feedback once per week for two weeks on their sleep and alcohol consumption, using all possible data derived from Fitbit actigraphs and Milo Sensor blood-alcohol trackers.
45681425|NCT01611974|Drug|Maribavir|Tablet for oral administration
45681426|NCT04144972|Device|Medtronic Summit RC+S|The investigators will perform DBS versus sham (randomized) to evaluate efficacy of stimulation for analgesia. Closed-loop DBS will be compared to open-loop DBS in a patient blinded, randomized fashion after initial, efficacy evaluation.
45681427|NCT04147078|Biological|DC vaccine subcutaneous administration|subcutaneous administration
45468942|NCT05308758|Other|Game-based High-Intensity Interval Training|There will be two training sessions each week. In each training session, there will be four sets of training programs separated by 3 minutes of passive recovery in accordance with a previous study.Each set of activities will last for around 5 minutes; therefore, the total duration of each training session will be approximately 30 minutes. A small group size (4-6 children per group) will be adopted to facilitate individual supervision and adaption of the exercise program.
46108567|NCT00695045|Drug|intra thecal morphine|200 mcg intrathecal morphine given once
46108568|NCT00695045|Drug|intra thecal morphine|300 mcg intrathecal morphine given once
46108569|NCT02624453|Drug|Fluconazole|Pre-emptive fluconazole therapy at 800mg/day for two weeks, then 400mg/day for eight weeks, and then 200mg/day thereafter till CD4 count goes beyond 200cells/ml
46108570|NCT02624453|Drug|Antiretroviral therapy|First line anti-retroviral therapy according to Cameroon national guidelines for the management of HIV/AIDS
46108571|NCT00819234|Drug|Placebo|placebo pramlintide and placebo metreleptin twice daily
46022663|NCT01481935|Other|Sham enhanced cleaning of surfaces in ICU rooms|While holding a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), a study investigator will mime the action of wiping the following surfaces in the room clean if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. The sham cleaning will occur once on the day of enrollment and follow-up.
45838342|NCT03617679|Drug|Placebo Oral Tablet|Participants allocated to the placebo arm will receive a placebo tablet (that looks identical to the active ingredient tablet) twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Tablet should be taken around the same time every day, with 8 or more ounces of water.
45838343|NCT03591731|Drug|Nivolumab|Nivolumab 3 mg/kg every 2 weeks
46022664|NCT00901927|Drug|Bendamustine|Starting dose 90 mg/m^2 by vein over 30-60 minutes on Days 1 and 2 of each cycle.
45468943|NCT05308758|Other|GameSAE|Similar to GameHIIT, the intervention will comprise 8 weeks of structured aerobic exercise sessions, lasting one hour on average in each session and up to twice per week. Six to eight stations of multidimensional exercises will be set up for each session. Adopting the train-the-trainer (TTT) model, training will be provided by front-line healthcare providers or trained helpers. Children will be instructed to finish the exercises in all stations one after another in a predetermined order.
45468944|NCT04450420|Other|Simulation based curriculum|See arm/group description
45468945|NCT04450420|Other|Standard training|See arm/group description
45468946|NCT03763435|Behavioral|Antenatal pregnancy classes|At least three comprehensive full-day educational program covering all the stages of pregnancy.
45468947|NCT03428464|Drug|Sodium Bicarbonate|Participants will take ½ the daily dose of sodium bicarbonate in the morning and the other ½ in the evening.
45468948|NCT03428464|Other|Placebo|Participants will take ½ the daily dose of a placebo in the morning and the other ½ in the evening.
45838344|NCT03591731|Drug|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
46022665|NCT00901927|Drug|Mitoxantrone|10 mg/m^2 by vein over 15 minutes on Day 2 of each cycle.
45838345|NCT03588728|Other|Transcranial Direct Current Stimulation|Transcranial direct current stimulation targeting the right inferior frontal gyrus
45838346|NCT03588728|Behavioral|Cognitive Remediation (CR)|Cognitive exercises on a computer designed to increase attention, memory, and processing speed.
46022666|NCT00901927|Drug|Rituximab|375 mg/m^2 by vein over several hours on Day 1 of each cycle.
46022667|NCT01400269|Behavioral|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention
46022668|NCT02845141|Procedure|Actifuse|bone tunnel filled with Actifuse
46108572|NCT00819234|Drug|Pramlintide and Metreleptin|Subcutaneous injection, twice daily
46108573|NCT00689507|Biological|LY2127399|monoclonal antibody
46108574|NCT00695201|Drug|Floxuridine, Oxaliplatin, CPT-11|For patients on the 4-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin (which is used to prevent blood from clotting) and saline. Whether the pump contains drug or heparin and saline, it will need to be emptied and refilled about every two weeks. We will inject either the drugs or the saline and heparin into the pump through the skin using a needle and syringe. In summary, 2 weeks of drug in the pump is followed by 2 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day as the pump is filled and emptied, ie. Day 1 and Day 15 of each cycle.
45468949|NCT05681208|Behavioral|Motivational interview|"Information will be given about the motivational interviews to be held and the objectives and content of the motivational interviews will be explained clearly. Care will be taken to ensure that the content of the brochures and materials provided is not too dense. It was prepared according to the Health Behavior Interaction Model of motivational interview steps. The first meeting of the motivational interview will start in the 4th month and the meetings will continue to be held every week for the first month and a half, and every two weeks for the next month and a half.~Negotiations will end in nine weeks. After the last interview, the scales will be applied to the mother again. Motivational interviews are planned to last 60-90 minutes (first session 45-50 minutes) every week."
45468950|NCT04953078|Biological|Baiya SARS-CoV-2 Vax 1|Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 1 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
45468951|NCT03428386|Procedure|Gastric plication ileal bypass|laparoscopic plication of the greater curvature of the stomach then the duodeno-jejunal junction is identified and 300 cm is measured downwards. The selected loop will be ascended without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just 3 cm away from the pylorus with a linear stapler charged with a green cartridge, the diameter of ileal antrum anastomosis is not exceeding 3 cm in diameter. The staple defect is closed with a two-layer running 3/0 polyglactin suture
45468952|NCT05681130|Other|questionaire|two questionaires for each group
46022669|NCT02845141|Procedure|bone graft|bone graft to fill bone tunnel
46108575|NCT00695201|Drug|Floxuridine, Oxaliplatin, CPT-11|For patients on the 5-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin and saline. This is repeated on day 29 of each cycle). In summary, 2 weeks of drug in the pump are followed by 3 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day that the pump is emptied and filled with heparin and saline, i.e. Day 15 and Day 29 of each cycle.
46108576|NCT02625311|Procedure|surgery method using CR TKP|Operation through minimal invasive surgery or standard open surgery
46108577|NCT00689585|Drug|Placebo|250mg matching placebo capsules
46108578|NCT00689585|Drug|Ethosuximide|500-1500mg/day over a 1-5 week dose titration period until maximal tolerated dose (MTD) attained, followed by 1 week MTD plateau period.
46108579|NCT04136093|Other|the MED|The MED diet will be composed of the basis food items traditional for the Mediterranean region i.e. olive oil, nuts, vegetables, fruits, and fish and this diet will be given an ad libitum approach. The MED diet will be giving a higher proportion of fat, at least 40% of the total energy, with 20% of the total energy from MUFAs, and less proportion of carbohydrates. To ensure the assumed supply of MUFAs and polyunsaturated fatty acids (PUFAs), the participants will be asked to daily intake 60 g (6 spoons) of extra virgin olive oil and 30 g (6 pieces) walnuts.
45468953|NCT03433768|Genetic|Real time PCR|We take peripheral blood sample at day one, six and ten of ovarian stimulation and measure mRNA expression of androgen receptor.
45468954|NCT04950192|Device|ICE Image guidance|ICE image guidance will be used on all patients undergoing planned cardiac catheterization procedures
45468955|NCT05369208|Drug|Avatrombopag Oral Tablet|Avatrombopag 20 mg given once daily (initial dose). Dose adjustments will be determined by the physician and in accordance with the overseas Doptelet prescribing information.
46022670|NCT04612621|Diagnostic Test|combination of diagnostic tests|capsule endoscopy, MRE , intestinal ultrasound, fecal microbiota, blood and serum biomarkers as described
46022671|NCT04602871|Diagnostic Test|Breath Biopsy|Breath Biopsy sampling using the ReCIVA® Breath Sampler
46022672|NCT05335837|Procedure|Regional Anesthesia and Sedation|Preoperative ilioinguinal/iliohypogastric nerve block and moderate to deep intraoperative sedation.
46022673|NCT05336929|Other|Roy adaptation model-based nursing education|
46022674|NCT02845063|Behavioral|concentric cardiovascular training|Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of concentric type contractions on a softrobotic device.
46022675|NCT02845063|Behavioral|eccentric cardiovascular training|Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of eccentric type contractions on a softrobotic device.
46022676|NCT02845063|Genetic|ACE genotyping|Subjects will be genotyped for the ACE-I/D gene polymorphism.
46022677|NCT04451161|Behavioral|Beliefs and Attitudes for Successful Implementation in Schools (BASIS)|BASIS blended (i.e., multifaceted and protocolized) implementation strategy, which occurs at the beginning of active implementation. BASIS is designed to facilitate observable implementation outcomes, including EBP adoption and intervention fidelity, via strategic education, motivational Interviewing, and social influence strategies.
45468956|NCT04537416|Other|No intervention|No intervention
45468957|NCT04722276|Other|positive end expiratory pressure|7cmH2O of positive end expiratory pressure with fraction of inspired oxygen 80% applied during induction of anesthesia
45468958|NCT04722276|Other|fraction of inspired oxygen 80%|fraction of inspired oxygen 80% applied during induction of anesthesia
45468959|NCT05363592|Drug|CT-L01 12.5/500 mg|FDC tablet, 2 tablets at a time, oral administration
46022678|NCT04451161|Behavioral|Trauma-Focused Cognitive-Behavioral Therapy|TF-CBT is an evidence-based treatment that helps children from elementary to high school to address the negative effects of trauma and promote greater emotion and behavior regulation, including processing their traumatic memories, overcoming problematic thoughts and behaviors, and developing effective coping and interpersonal skills. It also includes a treatment component for parents or other caregivers. Parents can learn skills related to stress management, positive parenting, behavior management, and effective communication.
45468960|NCT05363592|Drug|Alogliptin Benzoate 12.5 mg|Alogliptin Benzoate 12.5 mg 2 tablets, at a time, oral administration
46022679|NCT04451161|Behavioral|Treatment as Usual|Scaffolded intervention as usual. Includes: initial assessment of trauma symptoms, psychoeducation, follow-up planning and support.
46022680|NCT04451161|Behavioral|Attention Control|Didactic presentation of implementation-related content (e.g., information about the importance of implementing, definitions of key terms, etc.) to control for facilitator, dose, information provided, and delivery platform
46022681|NCT00903721|Drug|mometasone furoate|"Metered-dose spray type suspension containing 50 μg mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 μg)~Duration: up to 6 months"
46022682|NCT02844985|Other|No Intervention|
45468961|NCT05363592|Drug|Metformin HCl XR 500 mg|Metformin HCl XR 500 mg 2 tablets, at a time, oral administration
46022683|NCT04900987|Device|Steri-strips|Pneumatic TR band compression with use of steri-strips
46022684|NCT02845219|Drug|semaglutide|Oral administration once daily alone or together with oral contraceptive.
46022685|NCT02845219|Drug|SNAC|Oral administration once daily together with oral contraceptive.
46022686|NCT02845219|Drug|Microgynon®|Oral administration once daily alone or together with oral semaglutide or SNAC.
46022687|NCT00968968|Drug|Lapatinib|Oral Lapatinib 1000 mg once daily. Lapatinib was a small molecule, reversible inhibitor targeting HER2 tyrosine kinase receptor.
45468962|NCT03428308|Other|Screening|Each individual general practitioner reviews his/her record system and detects patients who meet the inclusion criteria. Patients who meet these criteria will be invited to participate in the project.
46022688|NCT00968968|Biological|Trastuzumab|IV Trastuzumab 6 mg/kg every three weeks. Trastuzumab was a humanized, monoclonal antibody directed against the extracellular domain of the HER2 tyrosine kinase receptor.
46022689|NCT02842801|Other|Hip manipulation|High-amplitude and low-velocity thrust mobilization
46022690|NCT04819009|Other|the Enhanced Transtheoretical Model Intervention (ETMI)|"ETMI consists of a physical and functional examination, a discussion about the role of physical activity matched to the patient stage of change, and guided through motivational interviewing techniques, exposure to fast walking, and goal setting. The patient receives a postcard outlining the main messages about physical activity and four simple stretches.~The ETMI method consists of four parts:~Creating a therapeutic alliance (communication skills and reassurance)~Clear messages to the patient: Mandatory 3 sentences: (1. physical activity is the only thing that will help your back pain over time. 2. It's easy to reduce your pain now - but the important thing is to prevent the next episode, 3. Your body must be strong and flexible.)~Exposure to brisk walking (brisk walking in the corridor, hand by hand with the therapist) and graded activity.~Postcard with reminder messages on how to self manage the back."
46022691|NCT02862886|Other|myometrium biopsy|
46022692|NCT03879655|Drug|VTS-270|Administered IT via LP infusion of VTS-270
46022693|NCT00973102|Drug|Premarin IV|One time dose of Premarin IV
46022694|NCT00973102|Drug|Placebo|One time dose of placebo.
45838347|NCT03547947|Device|Medacta Shoulder System|Total Shoulder Arthroplasty
46022695|NCT04689061|Device|Arthrex FastThread Interference Screw|The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping. The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping
46022696|NCT04622605|Device|Trabecular bypass and Schlemm's canal stent|ab interno Microstent placement after cataract surgery
46022697|NCT05205070|Biological|Rosnilimab|humanized monoclonal antibody
46022698|NCT05205070|Biological|Placebo|Placebo solution
45838348|NCT03538691|Drug|Brexpiprazole|Tablet
45838349|NCT03538691|Drug|Placebo|Tablet
45838350|NCT03538691|Drug|Citalopram Hydrobromide|Tablet
46022699|NCT02863588|Biological|seropositive for Toxoplasma gondii|blood sample
46022700|NCT03691090|Drug|SHR-1210|SHR-1210 200mg
46022701|NCT03691090|Drug|Placebo|Placebo
46022702|NCT03691090|Drug|paclitaxel|paclitaxel 175mg/m2
46022703|NCT03691090|Drug|cisplatin|cisplatin 75mg/m2
46022704|NCT00783211|Drug|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
46022705|NCT00783211|Drug|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
45468963|NCT03428308|Other|Treatment|Patients who are diagnosed with one or more of the selected somatic diseases receive an individualized course of treatment in general practice, primarily focusing on initiation and maintenance of medical treatment, and complying with current clinical guidelines and course programmes. Treatment goals are set in active co-operation with the patient and his/her family and with supervision and support from the Mental Health Centre Copenhagen, clinical pharmacologists and relevant staff from the municipality in terms of contact/support persons.
46022706|NCT00783211|Drug|placebo|placebo, once daily for 15 days
46022707|NCT03679546|Drug|Infliximab|Infliximab : The treatment is infused at a dose of 5 mg/kg at week 0, 2 and 6 and then every 8 weeks.
46022708|NCT03679546|Drug|Vedolizumab Injection|Vedolizumab : The treatment is infused at a dose of 300 mg at week 0, 2 and 6 and then every 8 weeks.
46022709|NCT00779545|Drug|Placebo|One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
46022710|NCT00779545|Drug|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils in the morning, and one spray of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 100 mcg.
46022711|NCT00779545|Drug|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and two sprays of placebo to the left and right at night for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
46022712|NCT00779545|Drug|Mometasone furoate|Four sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and four sprays of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
45468964|NCT04903080|Biological|HER2 Specific CAR T Cell|HER2 CAR (Chimeric Antigen Receptor) T cells are T cells that have been genetically engineered to target the protein HER2 for the treatment of cancer.
45468965|NCT03433690|Behavioral|HIIT|High Intensity Interval Training for twelve weeks
46022713|NCT00779545|Drug|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
46022714|NCT00779545|Drug|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
46108580|NCT04136093|Other|the DASH|The DASH diet will be giving a higher proportion of carbohydrates, at least 60% of total energy and less fat. The DASH diet will be composed wholegrain cereal products, fruit, vegetables, low-fat dairy products, fish, seafood, poultry, beans, seeds and nuts and will be recommending eating of the traditional polish food items for example oatmeal, rye bread, barley groats, apples, plums, etc. and reducing the supply of salt, sweets, sugars, fats especially saturated fats and red meat. In our study, the DASH diet will be given an ad libitum approach. The sufficient supply of carbohydrates and β glucans in the DASH diet will be ensured by daily consumption at least 50g oatmeal and 50g of barley groats.
45468966|NCT03433690|Behavioral|Moderate training|Moderate training for twelve weeks
45468967|NCT05264298|Other|VIRTUAL|At the time of discharge, stroke survivors in the VIRTUAL arm will receive a package containing an iPad and a remote BP monitoring device that allows transmission of BP to the study team.The first telehealth visit will occur 7-14 days after discharge. Patient will be counseled on the importance of BP monitoring, salt reduction, and the importance of diet and exercise for stroke prevention. Medications, side effects and interactions will be reviewed. The social worker will refer the patient to specific resources according to social needs abd patient will be referred to a primary care provider if they do not have one. Subsequent video visits will be 1-month (30 days +/- 7) , 3 months (90 days +/- 14), and 5 months (150 days +/- 14) days after enrollment.
45468968|NCT05264298|Other|Standard care|Participants randomized to standard care will receive an educational packet and a blood pressure monitor prior to hospital discharge. They will be contacted by a social worker to determine if they received their medications and appointments. The stroke practitioner will evaluate the patients at 7-14 days and then follow up according to current standard of care. They will be seen over video or in-person, according to their preference and capabilities. The pharmacist will contact patients at 1-month (30 +/- 7 days) days over the telephone to review BP logs and will make recommendations to their primary care provider to adjust BP medications. Subsequent pharmacist calls will occur monthly until 6 months and recommendations for medication adjustments will be communicated to their primary care provider.
45468969|NCT03428074|Procedure|Surgeries|Minimally invasive surgeries of Ivor-Lewis and Mckeown
45681428|NCT04146688|Other|Music Balance Board|The SSM is measured with an innovative tool (Music Balance Board) developed at the University of Ghent (Belgium) and specially designed to record the movements of the elderly in a natural and comfortable position This chair is equipped with a tablet and sensors that record the movements of the hand and body during the SSM to a musical sequence. The analysis will focus on the difference between the participant's striking and the beat of the music measured using this chair.
45681429|NCT01848938|Behavioral|Smartphone treatment with PFMT|A smartphone application with information on SUI, life style information, different programmes of PFMT with increasing severity, possibility to save statistics on training. The treatment period is three months
45838351|NCT03538691|Drug|Escitalopram|Tablet
46022715|NCT03679312|Drug|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
46022716|NCT03679312|Drug|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
46022717|NCT00901459|Device|Active rTMS Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
45838352|NCT03538691|Drug|Fluoxetine|Capsules
45838353|NCT03538691|Drug|Paroxetine|Controlled-release tablets
46022718|NCT00901459|Device|rTMS Location Control Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the motor cortex (MC) during the presentation of smoking and control cues.
46022719|NCT00901459|Device|rTMS Frequency Control Condition|High frequency rTMS (90% Motor Threshold at 10 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
46022720|NCT02842567|Drug|Hydroxytyrosol plus Vitamin E|This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks
45468970|NCT04886934|Device|CS1 System|Placement of CS1, a temporary bipolar myocardial electrode (TME) with an integrated motion sensor (accelerometer), on the left ventricle and externalization of the associated leads through the chest wall during open-heart surgery. CS1 will remain in place for up to 7 days after surgery and closure of the chest wall.
45468971|NCT04209088|Other|Pulmonary ultrasounds|"Two ultrasounds will be performed by the same pediatrician for each child included: the first at nine days of life +/- two days, the second at fifteen days of life +/- two days.~A blind replay of ultrasound images to calculate the score will be performed by a another investigator."
46022721|NCT02842567|Drug|Placebo|This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
46022722|NCT02842489|Procedure|left lateral tilt-down position|patients will be positioned on their left side and at an angle of 20 degree
46022723|NCT02842489|Procedure|left lateral horizontal position|patients will be horizontally positioned on their left side
46022724|NCT02133703|Behavioral|Enhanced Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
46022725|NCT02133703|Behavioral|Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support. This intervention is designed to provide education regarding the available risk management options.
45681430|NCT04146454|Other|Smartphone-based balance exercises|A smartphone-based wearable telerehabilitation system will provide video and audio instructions on how to perform in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises).
46022726|NCT02133703|Behavioral|Enhanced Print DA|BRCA1/2 carriers randomized to this arm will receive print-based decision support materials which include a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
45681431|NCT03929926|Other|Best Practice|receive usual care
45681432|NCT03929926|Behavioral|Cancer Educational Materials|Receive educational materials via mail
45838354|NCT03538691|Drug|Sertraline|Tablet
45838355|NCT03538691|Drug|Duloxetine|Delayed-release capsule
45838356|NCT03538691|Drug|Venlafaxine Extended Release Oral Capsule|Extended-release capsule
46022727|NCT02133703|Behavioral|Print DA|BRCA1/2 carriers randomized to this arm will receive print education materials designed to provide information regarding the available risk management options.
46022728|NCT02133703|Behavioral|Inconclusive Results DA|Women who receive uninformative BRCA1/2 results randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
46022729|NCT00896233|Procedure|MRE|"Part 1: Participants will have a screening visit, followed ~1 month later by two imaging visits over ~14 days. Each imaging visit will consist of two liver MRE scans.~Part 2: Participants will have a screening visit, followed ~1~month later by one imaging visit. The imaging visit will consist~of two liver MRE scans."
46022730|NCT02840149|Drug|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan
46022731|NCT00705211|Drug|Ezetimibe|Ezetimibe, 10-mg tablets,
46108581|NCT04136093|Other|Control diet|"The control group will only receive oral dietary recommendations based on the Harvard model Healthy Eating Plate, that recommend to eat a half of plate of vegetables and fruit, a quarter of plate of whole grains products, and a quarter of plate of protein products for one meal."
46108582|NCT00667342|Biological|Bevacizumab|Monoclonal Antibody against vascular endothelial growth factor (VEGF). Given intravenously (IV).
46108583|NCT00667342|Drug|Cisplatin|Given IV.
46108584|NCT00667342|Drug|Doxorubicin|Given IV.
46108585|NCT00667342|Drug|Methotrexate|Given IV.
46108586|NCT00667342|Drug|Ifosfamide|Given IV.
46108587|NCT00667342|Drug|etoposide|Given IV.
45468972|NCT03333837|Behavioral|Dance Group|Active imagination refers to working with imagery and is crucial in improvisatory practice. Verbal auditory cues are used to create movement scenarios that cue or activate the motor imagination. Variability means the improvisational method does not aim to learn a specific movement pattern and habituate to it. Cues are delivered quickly, one after another. Within an average of two minutes, tasks requiring quicker decision-making are introduced. Pacing is the rate at which new movement prompts are presented. Quick changes in pace avoid defaulting to habitual responses, thereby facilitating new movement options. Participants cannot rely on copying another, memory, or anticipation to address the motor problem.
46108588|NCT00667342|Procedure|Surgery|Participants undergo definitive surgery and assessment of histologic response at week 10.
45468973|NCT03333837|Behavioral|Non-Group Dance|The caregiver will be asked to stay in the area while the subject is dancing. A video camera will be affixed in an upper corner of the room to record individual dance sessions. This recording will yield data that a trained student or staff member can view and code to document movement fidelity (e.g., that the person has responded to the dance prompts and for the purpose of comparing the amount of quality of movements that occur in individual vs. group dance settings). For the first two sessions, study staff would observe the full dance session from outside the room to be sure that instruction was clear and adherence was attained, and that no safety issues arise.
45468974|NCT03333837|Behavioral|Social Group|The social group will consist of improvisational party games to foster curiosity and playfulness, use imagery, and encourage non-judgment. Games that may be used include 'Balderdash', 'Wise and Otherwise', 'Charades', 'Pictionary', and 'Tell Me A Story' cards. These games will also use the same core strategies as the dance group. Games will be varied within an hour-long session to incorporate pacing and variability into the social group, akin to the dance group. The social group will occur 2x/week for 1 hour each time and be led by the same instructors who lead the Dance Group, to control for effects of personality of the group leader.
45468975|NCT03333837|Behavioral|No Contact|The condition of not receiving an intervention can have ethical implications and reduce retention rates. Therefore, these participants will be invited to join in a weekly community improvisational dance class after they complete the study, for as many sessions as they would like.
45468976|NCT03708211|Drug|TAK-931 PIC|TAK-931 PICs.
45468977|NCT03708211|Drug|TAK-931 Tablet|TAK-931 Tablets.
45468978|NCT03708211|Drug|Esomeprazole|Esomeprazole Tablets.
45468979|NCT02948634|Device|Sham Phoenix Laser Treatment|Sham treatment will be delivered via the same protocol in terms of time, application, and areas of treatment as stated above, except the laser unit will not discharge any photonic energy. Intervention will take place in the therapy room at the McDermott Center for Pain Management, which is appropriately equipped for laser administration. Application of therapeutic laser will be completed by licensed physical therapists who have completed safety training for therapeutic laser application including appropriate use of safety eyewear, room access, laser signage for laser use, and patient monitoring.
45468980|NCT02948634|Device|Active Phoenix Laser Treatment|The 30 min treatments will include multiple 60 sec applications to all tender points on the spine or extremities and a 10 minute application along the bilateral sympathetic ganglion in the paraspinous region. The treatment will be applied via a non-contact method, with the laser applicator held 12-18 inches above the participant's skin.
45468981|NCT04208230|Device|XtremeCT|HRpQCT technology provides information on bone microarchitecture, bone density and bone strength by measuring the cortical and trabecular bone structures with improved spatial resolution and defining the surfaces in three-dimensional manner.
46108589|NCT00667342|Radiation|Radiotherapy|Radiation therapy delivered for positive margins or intralesional resections.
46108590|NCT00769912|Drug|50% N2O- 50%O2 mixture|50% N2O- 50%O2 mixture administration
46108591|NCT00769912|Drug|Placebo (air)|Placebo administration during the intervention
46108592|NCT00783016|Drug|Morphine|
46108593|NCT02556502|Device|18F-Florbetaben PET|
46108594|NCT00778960|Behavioral|Slow Breathing|The slowed breathing group will be trained on a breathing device, RESPeRATE, designed to reduce respiratory rate.They will practice with RESPeRATE once a week (for 6 weeks) in the laboratory with the research staff.
46108595|NCT00778960|Behavioral|Meditation|The Mindfulness Body Scan meditation will be used for the mindfulness meditation group.Participants will be trained once a week (for six weeks) in the laboratory by the research staff.
46108596|NCT00778960|Behavioral|Meditation and slow breathing|A structured Mindfulness breathing will be guided by the research staff during the lab trainings. The participant will sit upright and attempt to focus attention on his or her own breath as it passes the opening of the nostrils or on the rising and falling of the abdomen or chest. Whenever attention wanders from the breath, the participant will simply notice the distracting thought and then let it go as attention is returned to the breath. Training will be given once every week for 6 weeks.
46108597|NCT00778960|Behavioral|Sitting Quietly|"The SQ control group's intervention will include sitting quietly and listening to a neutral-content book on tape to serve as a time and attention control at each laboratory session. They will also be asked to sit quietly at home daily."
46108598|NCT00769990|Dietary Supplement|genistein|Genistein will be taken orally once daily as 500 mg capsules throughout the study (60 days).
46022732|NCT00705211|Drug|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets, other lipid-lowering medication(s) as prescribed by attending physician
46022733|NCT05334901|Device|High intensity light cure|Bulk fill resin composite restoration cured with high intensity light curing (2200 mw/cm2)To achieve increased power and a wider spectrum for short exposure time (1 second) to overcome resin composite restoration techniques sensitivity and shorten the clinical procedure
46108599|NCT00769990|Radiation|radiation therapy|A course of palliative external beam radiation therapy -performed within 8 weeks prior to start of the study.
46108600|NCT00784420|Drug|UK-453,061|UK-453,061 1000 mg once daily for 10 days
46108601|NCT00784420|Drug|UK-453,061|UK-453,061 1000 mg once daily for 10 days
46108602|NCT00784420|Drug|Raltegravir|Raltegravir 400 mg twice daily for 10 days
46108603|NCT00784420|Drug|Raltegravir|Raltegravir 400 mg twice daily for 10 days
46108604|NCT02555800|Drug|Bevacizumab|Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
46108605|NCT02555800|Drug|Cidofovir|Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
46108606|NCT02555800|Other|Placebo|Saline solution
46108607|NCT00783172|Drug|Gemcitabine|1000mg/m2, IV (in the vein) over 30 minutes after treatment with OGF; first cycle is consecutive seven weeks and one week off; subsequent cycles are three weeks on and one week off.
46108608|NCT00783172|Biological|Opioid Growth Factor (OGF)|Initial treatment is 150ug/kg (based on body weight of the patient) in a volume of 50ml sterile saline, IV (in the vein) over 45 minutes; subsequent treatments at dose of 250ug/kg
46022734|NCT02839993|Device|tDCS|
46108609|NCT00783250|Drug|Salbutamol + Tiotropium|Salbutamol 400 micrograms + Tiotropium 18 micrograms
46108610|NCT00783250|Drug|Placebo + Tiotropium|Placebo via MDI + Tiotropium 18 micrograms
46108611|NCT00783328|Drug|PF-00299804|Dosage form: 5 mg and 20 mg tablet Dosage: 15 mg, 30 mg and 45 mg, orally, once daily Number of Cycles: until progression or unacceptable toxicity develops.
46022735|NCT02839993|Behavioral|training|
46022736|NCT02842255|Device|Calibrate the oximeter ALTITRAINER200®|During normoxic condition and four situations of hypoxia.
46108612|NCT04047082|Diagnostic Test|Quantitative aortogram (videodensitometry)|Patients that performed TAVR will have their aortogram analysed in the cath-lab by videodensitometry (quantitative aortogram)
46108613|NCT02555644|Drug|Prexasertib|Administered IV
46108614|NCT02555644|Drug|Cisplatin|Administered IV
46108615|NCT02555644|Drug|Cetuximab|Administered IV
46108616|NCT02555644|Radiation|Intensity Modulated Radiation Therapy|
46108617|NCT00871403|Drug|pazopanib and pemetrexed|oral pazopanib 600 mg once daily and pemetrexed intravenous (IV) 500mg/m^2 once every 3 weeks, then pazopanib 800 mg once daily
46108618|NCT00871403|Drug|pemetrexed and cisplatin|pemetrexed IV 500 mg/m^2 and cisplatin IV 75 mg/m^2 once every 3 weeks
46108619|NCT00689663|Procedure|Laparoscopic cholecystectomy|Randomized to three arm.
46108620|NCT00695513|Dietary Supplement|BENEO synergy1|50/50 v/v inulin/oligofructose 10 gram BID
46108621|NCT00691379|Drug|Carboplatin|Carboplatin (IV) 2 AUC on day 1,8,15. Treatment repeats every 4 weeks until progression
46108622|NCT00691379|Drug|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1,15. Treatment repeats every 4 weeks until progression
46108623|NCT00691379|Drug|Paclitaxel|Paclitaxel (IV) 90 mg/m2,on day 1,8,15. Treatment repeats every 4 weeks until progression
46022737|NCT02840071|Other|Psychological therapy|Acceptance and commitment therapy is a third-wave cognitive behavioural therapy. The aim of ACT intervention is to increase a person's psychological flexibility by enabling them to change their relationship with distressing cognitions (acceptance) and doing things that are personally meaningful to them (commitment). The ACT model does not focus on distress reduction, although this is a secondary consequence of acceptance and commitment. This is targeted through the six core processes: present moment awareness, cognitive defusion, acceptance, self-as-context, values and committed action which means taking effective action, guided by the identified values. The intervention will involve six 1.5 hourly individual sessions.
46108624|NCT00689741|Biological|Cervarix|3 doses of IM injection
46108625|NCT00689741|Biological|placebo|3 doses of IM injection of Al(OH)3 placebo
46022738|NCT02839837|Behavioral|Aerobic Exercise|Aerobic exercise will be performed on a stationary cycle ergometer for 15 minutes at an intensity of 35% heart rate reserve or 70% heart rate reserve. During the control condition the participant will remain seated on the stationary cycle for 15 minutes and will not perform exercise.
46022739|NCT02839837|Device|Paired Associative Stimulation|After aerobic exercise participants will receive a paired associative stimulation (PAS) paradigm. PAS consists of paired brain and peripheral nerve stimuli. Participants will receive 200 paired stimuli. Peripheral nerve stimulation will be delivered to the median nerve at the level of the wrist via electrical stimulation at 300% perceptual threshold. Brain stimulation will be delivered via transcranial magnetic stimulation (TMS) over the hand knob of the motor cortex at an intensity that elicits a 1mV response in the contralateral abductor pollicis brevis muscle. During each paired stimulation, peripheral nerve stimulation will precede the TMS stimulation by 25ms.
46108626|NCT00695591|Other|Evaluation for Nocturnal non invasive ventilation|Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 >6.0 Pa; and 2) nocturnal Sa,O2 <88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV
46108627|NCT02624531|Drug|Taxane|NACT and Fertility-sparing Treatment Strategy
46108628|NCT02624531|Procedure|radical trachelectomy|NACT and Fertility-sparing Treatment Strategy
46108629|NCT00689897|Procedure|acupuncture, Deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation.
46108630|NCT00689897|Procedure|acupuncture, Non-Deqi|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
46108631|NCT00691457|Device|Opti-Free contact lens solution|Solution
46108632|NCT00691457|Device|ReNu Multiplus contact lens solution|Solution
46108633|NCT00691457|Device|Clear Care contact lens solution|Solution
46108634|NCT00689975|Behavioral|behavioral dietary intervention|
46108635|NCT00689975|Behavioral|exercise intervention|
46108636|NCT00689975|Other|counseling intervention|
46108637|NCT00689975|Other|flow cytometry|
45468982|NCT04186390|Other|Simulation training in small bowel capsule endoscopy|Training in the evaluation of small bowel capsule endoscopies including evaluation, diagnostic and treatment in different cases.
46022740|NCT02839759|Other|TELLYHealth|Educational videos and questions.
46022741|NCT02839525|Dietary Supplement|Omega 3|3000mg of n-3 oil (2000mg EPA e 1000mg DHA)
46108638|NCT00689975|Other|immunoenzyme technique|
46108639|NCT00689975|Other|laboratory biomarker analysis|
46108640|NCT00689975|Procedure|complementary or alternative medicine procedure|
46108641|NCT00689975|Procedure|standard follow-up care|
45468983|NCT03433612|Other|Classic Intercristal Line Technique|"Researcher will use the classic technique to estimate the L4-L5 interspace. The classic technique begins by palpating both the right and left posterior iliac crests and following the imaginary line that intersects each (intercristal line) with the non-dominant hand to the spine where it is estimated to intersect the L4 spinous process or L4-L5 interspace. A marker pen will mark an X lateral to the estimation, opposite side from the estimation of the other technique."
45468984|NCT03433612|Other|Novel SAIL Technique|"Researcher will use the novel technique to estimate the L4-L5 interspace. The SAIL technique begins by palpating the sacrum and the researcher sliding the non-dominant hand up the dorsal surface of the sacrum to the first interspace (L5-S1) and then up one more interspace to estimate the L4-L5 interspace. A marker pen will mark an X lateral to the estimation, opposite side from the estimation of the other technique."
45468985|NCT03768193|Procedure|Deep serratus anterior plane block|Deposition of local anaesthetic in the space between the serratus anterior muscle and the external intercostal muscle, at the level of the 4th-5th rib, in the midaxillary line. Procedure performed under ultrasound guidance. Catheter - based infusion of local anaesthetic into this space for 48 hours.
46022742|NCT02839525|Dietary Supplement|Isolate whey protein|23g of protein of whey protein
46022743|NCT02839525|Dietary Supplement|Omega 3 and Isolate whey protein|3000mg of n-3 oil (2000mg EPA e 1000mg DHA) and 23g of protein of whey protein
46022744|NCT02839525|Other|Eccentric exercise|100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series
46022745|NCT02839213|Drug|Hyoscine Butyl bromide|
46022746|NCT02839213|Drug|Saline|
46022747|NCT02839447|Other|no intervention|
46022748|NCT05334043|Drug|CuminUP30|7 capsules, 500 mg / capsule
46108642|NCT00695747|Procedure|2 Site procedure- Phacoemulsification/IOL and Trabeculectomy|2 Site Combined Procedure: in which a temporal clear cornea approach would be used for the cataract/IOL part of the procedure, and immediately thereafter the superior limbus would be employed for a limbus-based trabeculectomy
46108643|NCT00690053|Procedure|Injection of HX-4|In step 1: 1 injection of HX-4 (max.6mCi (222MBq)) In step 2: 1 injection of HX-4 (max.12mCi 444MBq)
45468986|NCT03768193|Procedure|Surgically-placed paravertebral block|Surgically-placed paravertebral block catheters for continuous local anaesthetic infusion of 0.125% levobupivacaine at 8-12mls/ hr for 48 hours.
45468987|NCT05223816|Drug|VG161|"Name: VG161 (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) Concentration/Content: ≥1×107 PFU/mL; 1.0 mL/vial. Actual titer will be recorded on Certificate of Analysis.~Composition: VG161,50 mM Tris-HCl, 150mM NaCl, <5% glycerol Route of Administration: Intratumoral injection or image guided intratumoral injections."
45468988|NCT03770923|Drug|Rupatadine|Rupatadine 10 mg daily
45468989|NCT03770923|Drug|Montelukast|Montelukast 10 mg daily
46022749|NCT05334043|Drug|Curcumin capsules|5 capsules, 450 mg / capsule
46022750|NCT02839369|Other|walking under varies conditions|The children were asked to walk an electronic mat, three cycles for each one of the different trials as comfortable regular speed, walking as fast and as slow as possible, walking on straight line etc
46022751|NCT02839369|Other|walking under varies conditions|walking on electronic walkway under different conditions
46022752|NCT04250623|Other|Health care product (gel)|hyaluronic acid intimate moisturizing gel (to be applied on the subject's skin)
46022753|NCT04250701|Other|Body Posture Assessment|Application of three evaluations above at a one time.
46108644|NCT00695825|Dietary Supplement|Low GI+high GI|Consumption of low GI food product on day 1 Consumption of high GI food product on day 2
46108645|NCT00695825|Dietary Supplement|High GI+low GI|Consumption of high GI food product on day 1 Consumption of low GI food product on day 2
46108646|NCT00690131|Behavioral|BTSCS|BTSCS includes: (1) A behavioral group emphasizing motivational enhancement, skills training, education, and relapse prevention; (2) Contingency management with financial incentives to reinforce reductions in smoking; (3) Supported use of Bupropion or nicotine replacement therapy that is integrated with clients' psychiatric care in participants who are interested; and (4) Smoking cessation care coordination to increase treatment engagement and retention.
46108647|NCT04136015|Drug|Dasatinib 100 MG|The CML-CP patients with early(3m to 6m) molecular response failure on imatinib,Conversion dasatinib group or Imatinib group
46108648|NCT02624063|Drug|Daclatasvir + Sofosbuvir|Sofosbuvir 400 mg tablet + Daclatasvir 60 mg tablet oral dosing once daily for 12 weeks
46108649|NCT02624063|Drug|Simeprevir + Sofosbuvir|Sofosbuvir 400 mg tablet + Simeprevir 150 mg tablet oral dosing once daily for 12 weeks
46108650|NCT05298683|Drug|Isatuximab|Intravenous (IV) infusion. Dose regimen: Isatuximab will be given at a dose of 10 mg/kg QW by IV infusion on Days 1, 8, 15, and 22 in Cycle 1 and Days 1 and 15 in subsequent cycles. In patients with ≥VGPR who will be randomized to receive isatuximab once monthly from Cycle 7, isatuximab will be given on day 1 of each cycle.
46108651|NCT05298683|Drug|Pomalidomide|Route of administration: Oral (PO). Dose regimen: Pomalidomide will be given at 4 mg orally (PO) will be given on Days 1-21 of each cycle.
46108652|NCT05298683|Drug|Dexamethasone|Route of administration: PO or IV. Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) PO, or IV will be given on days 1, 8, 15, and 22 in each cycle.
45468990|NCT03433534|Other|Pharmacokinetic of Nivolumab|Nivolumab residual concentration is measured 14 days after administration of nivolumab 3 mg/kg as an intravenous infusion just before the new administration.
45468991|NCT04690218|Diagnostic Test|Hospital anxiety and depression scale|Self assessment scale suitable for hospital community as well as public community. Applying the scale does not require any psychopathologic training.
46022754|NCT02838823|Biological|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
46022755|NCT05333887|Behavioral|PFC+|Therapists instruct parents in ways to coach their children to display better friendship behaviours using skill teaching and home practice. The program includes 2 intake sessions, a group workshop where all strategies are reviewed, and 3 consultation sessions to work on implementing strategies with therapist support. Emphasis throughout the program is placed on parents' connection and engagement with the material and therapist.
46022756|NCT03362749|Other|RFA, MWA, cryo and IRE|local tumor ablation
46108653|NCT05298683|Drug|Acetaminophen (paracetamol)|Route of administration: PO. Dose regimen: Acetaminophen (paracetamol) will be given at 650-1000 mg PO 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion
46108654|NCT05298683|Drug|Ranitidine (or equivalent)|Route of administration: IV. Dose regimen: Ranitidine or equivalent will be given at 50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.
46108655|NCT05298683|Drug|Diphenhydramine (or equivalent)|Route of administration: IV. Dose regimen: Diphenhydramine or equivalent will be given at 25-50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.
46108656|NCT02624297|Other|Aerobic exercise training|The patients will be submitted to four months of aerobic exercise training, three time a week.
46108657|NCT02624219|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
45468992|NCT04690218|Diagnostic Test|Pittsburgh Sleep Quality Index|Self assessment scale for public community. Applying the scale does not require any specially trained personnel.
45468993|NCT04690218|Behavioral|Nutritional Status Questionnaire|It consists of 26 items, questioning the frequency and amount of certain nutritional elements (ones known to worsen and benefit mastalgia) consumed by the individual.
46108658|NCT02624219|Drug|MF59 adjuvant|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
46108659|NCT02624219|Biological|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
46108660|NCT00853112|Drug|PF-00489791|tablet form, 1 mg, single dose (Day 1)
46108661|NCT00853112|Drug|PF-00489791|tablet form, 2 mg, single dose (Day 1)
46108662|NCT00853112|Drug|PF-00489791|tablet form, 4 mg, single dose (Day 1)
46108663|NCT00853112|Drug|PF-00489791|tablet form, 10 mg, single dose (Day 1)
46108664|NCT00853112|Drug|PF-00489791|tablet form, 20 mg, single dose (Day 1)
46108665|NCT00853112|Drug|placebo|tablet form, single dose (Day 1)
46108666|NCT00853112|Drug|sildenafil|tablet form, 20 mg, single dose (Day 1)
45468994|NCT04080934|Behavioral|Swimming|Patients will participate in 8 weeks of the swimming program, which involves three weekly swimming sessions of 30 minutes minimum.
45468995|NCT05445895|Drug|Renexin CR 200/160mg|Renexin CR 200/160mg will be added to Aspirin 100mg
45468996|NCT05445895|Drug|Plavix 75mg|Plavix 75mg will be added to Aspirin 100mg
45468997|NCT04534309|Behavioral|Written Weight Loss Material|Participants will receive written weight loss material by email.
45468998|NCT04534309|Behavioral|Weight Loss App|Participants will receive written weight loss material as well as instructions for using a free weight loss app on their phone or computer.
45468999|NCT04534309|Behavioral|Behavioral Lifestyle Weight Loss Intervention (Coaching)|Participants will receive weekly coaching phone calls to encourage regular dietary, exercise, and self-monitoring practices which encourage gradual, healthy weight loss.
46022757|NCT03340207|Device|Pneumaglide|The device is designed to facilitate intubation and reduce the time to intubation. It works with traditional glidescope to make the process of intubation easier. In this study patients scheduled for surgery and intubation, will be randomized to two groups. The intervention group will be intubated with the help of the pneumaglide. Yet, the other group will receive standard intubation. We aim to evaluate the efficacy of the Pneumaglide to improve the ease of intubation in unskilled clinicians and skilled clinicians during difficult and routine intubations
46022758|NCT04201717|Procedure|laparoscopic assisted left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. The patients in the control group underwent with the traditional laparoscopic assisted technology. The free colon was taken out through a small incision in the middle of the abdomen or the outer edge of the left rectus abdominis. The mesentery was trimmed, the specimens were removed, and the anastomosis was completed. After the anastomosis, the whole surgical area was flushed and drainage tubes were left.
46108667|NCT02624141|Drug|Epoetin Beta|Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
46108668|NCT00691613|Drug|Epoetin alpha|The dosage (60.000 I/U Epoetin alpha) will be diluted in 10 ml of 0.9% sodium chloride solution and injected in a single dose intravenously in the dominant forearm (the non-dominant forearm will be used as ischemic model).
46108669|NCT00691613|Drug|NaCl|0.9% sodium chloride solution as placebo dosage is 10 ml, which will be administered in the same manner as the interventional medicinal product.
46108670|NCT00691691|Radiation|Stereotactic Body Radiation Therapy|Radiation Dose: 48 Gy in 4 fractions in 2 weeks. A minimum of 48 hours should separate each treatment (e.g. every Tuesday and Friday). The dose is prescribed to the marginal isodose (80-90%) that encompasses the entire target lesion (GTV). Treatment will be delivered using a linear accelerator. For verification of the accuracy of these external skin fiducial markers, 10 patients will also have implanted internal gold coil markers. The implantable gold coil markers will be implanted into the liver in the proximity of the target lesions via a percutaneous transhepatic route under fluoroscopy guidance.
46022759|NCT04201717|Procedure|total laparoscopic left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. In the experimental group, the mesentery was endoscopically trimmed, the specimens were excised and the anastomosis was completed under the laparoscope. The specimens were taken out through trocar incision in the navel or in the right lower abdomen. After the anastomosis, all surgical area was flushed and drainage tubes were left.
45469000|NCT03367299|Drug|Chemotherapy + Blinatumomab|Chemotherapy cycles are administered at 21-28 days intervals and each blinatumomab course is 28-day long.
46022760|NCT00156091|Drug|Olanzapine|5- 20 mg QD
46022761|NCT00156091|Drug|Asenapine|5 or 10 mg BID
46022762|NCT00156091|Other|Placebo|
46022763|NCT00140959|Drug|MK0954, losartan potassium/Duration of Treatment: 18 weeks|
46022764|NCT00140959|Drug|Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks|
46022765|NCT00095017|Drug|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
46022766|NCT00092755|Drug|MK0663, etoricoxib|
46022767|NCT00092755|Drug|Comparators: ibuprofen and placebo|
46022768|NCT00899431|Drug|Lenalidomide|Starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months
46022769|NCT00899431|Drug|Fludarabine|30 mg/m^2 intravenously daily on days -5, -4, -3.
46022770|NCT00899431|Drug|Rituximab|375 mg/m2 intravenously on day -13, and 1000 mg/m^2 on days -6, +1 and +8.
46022771|NCT00899431|Drug|Thymoglobulin|1.0 mg/kg intravenously over 4 hours (day -2 and -1).
46022772|NCT00899431|Procedure|Stem Cell Transplantation|On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes.
46022773|NCT00899431|Drug|Bendamustine|130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
46022774|NCT00899431|Drug|Allopurinol|300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
45681433|NCT03929926|Other|Behavioral, Psychological or Informational Intervention|Receive shared decision making and lung cancer screening information
45681434|NCT03929926|Other|Counseling|Undergo decision counseling session
46022775|NCT05335213|Diagnostic Test|16S rRNA gene sequencing|"DNA extraction and 16S rRNA gene sequencing DNA extraction, 16S rRNA gene amplification, and deep sequencing of the 16S rRNA amplicon performe.~The V4-V5 region of the 16S rRNA gene amplify with barcodes for multiplexing."
46022776|NCT02843971|Device|Intraocular pressure measurement with the Sensimed triggerfish Device|
46022777|NCT00899353|Dietary Supplement|Omega 3 Fatty Acid|Omega 3 supplementation will be initiated at three 1250 mg capsules daily for the first month. If dose is well tolerated, it will be increased to six 1250 mg capsules daily for 30 days, and finally to nine 1250 mg capsules daily. Treatment period is 12 months.
46022778|NCT02844127|Procedure|Implantable Cardioverter Defibrillator (ICD)|Patients will receive an Implantable Cardioverter Defibrillator (ICD), with the leads implanted in either the apex or the septum as the first location. After defibrillation threshold is determined, the leads position will be changed to the second location and DFT will be determined again.
46022779|NCT02843893|Device|Measure the minimum intensity of a painful stimulation|With Neurolight device.
46022780|NCT00898807|Drug|citalopram|target dose 30mg daily for 9 weeks
46022781|NCT00898807|Drug|placebo|daily for 9 weeks
46022782|NCT05335135|Other|TriageGO-MDW Clinical Decision Support|TriageGO-MDW is non-device clinical decision support that provides patient-level clinical risk estimates based on clinical data derived from the electronic health record
46022783|NCT05335135|Other|Usual Care|Clinical care without decision support provided by TriageGo-MDW
46022784|NCT02842177|Procedure|Classic group|The speculum was placed into the vagina and the cervix was cleansed with povidone iodine. After placement of single toothed vulsellum on the anterior lip of the cervix, for traction and fixation of the uterus, the uterine sound was inserted for determination of uterine length and uterine position followed by Cu-IUD insertion. The duration of IUD insertion were reported.
46022785|NCT02842177|Procedure|Uterine sounding sparing group|after bimanual examination, the same sonographer (Level II experience) performed transvaginal /US using a SonoAce X6 machine (Medison, Korea) with transvaginal probe (4-8 MHz frequency, using an average 6.5 MHz). Firstly, he evaluated the uterine position. Then, he measured the endometrial and cervical stripe lengths in the sagittal view of the uterus and summed to have the actual length of the uterus; by which the IUD tube was adjusted before insertion.The same speculum and vulsellum were used and the IUD was inserted directly into the uterine cavity.
46022786|NCT02842177|Radiation|Transvaginal ultrasound|
46022787|NCT02842177|Device|Cu-IUD|
46022788|NCT01229267|Biological|V212|V212 viral antigen for HZ. Participants will receive consistency Lot 1, 2, or 3 or the High Antigen Lot.
46108671|NCT05298527|Behavioral|Back Massage|The woman lies face down and a pillow is placed under her forehead. Massage begins with effleurage. Petrissage is started from the sacrum and the hands are lifted up to the nape and repeated 4 times. After the petrissage movement is completed, effusion is applied to the area once. Friction is applied. After rubbing, tapotement is applied to the entire back.
45838357|NCT03535584|Behavioral|Exercise Program|Participants will be asked to complete 2 1-hour exercise sessions per week for 8 weeks (16 total sessions) under the supervision of a licensed respiratory therapist on non-dialysis days. The exercise program will be based on pulmonary rehabilitation and will follow guidelines established by the American Thoracic Society. Exercise sessions will include endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training. Exercise sessions will be tailored to individual participants, and participant safety will be monitored during each session.
46022789|NCT01229267|Biological|Matching placebo|Vaccine stabilizer for V212 with no virus antigen
46022790|NCT02690779|Other|Educational intervention|2-3 minute video demonstrating video images of adequate and inadequate bowel preps, and reviewing instructions for split dose prep administration.
46022791|NCT02690779|Other|Routine Care Instructions|patients will follow routine care and instructions
46022792|NCT00897715|Drug|Rilonacept|160 mg of rilonacept administered subcutaneously once a week for 12 weeks
46108672|NCT04135625|Behavioral|Integrated nutrition and agricultural (INA) trainings|Monthly INA training session to help increase knowledge about nutrition and chicken husbandry and help to increase resiliency on a household level.
46108673|NCT04135625|Behavioral|Ceremonial Gifting of Livestock|Egg laying chickens will be presented as a gift to the child by a community champion (their religious leader or village chief)) during a gifting ceremony
46108674|NCT04135235|Drug|TAF|Propofol tenofovir fumarate
46108675|NCT04135235|Drug|TDF|Dipirofurate fumarate tenofovir
46108676|NCT00460603|Drug|bevacizumab|bevacizumab 5 mg/kg every 2 weeks
46022793|NCT00897715|Drug|Placebo|160 mg of placebo administered subcutaneously once a week for 12 weeks
46022794|NCT00633295|Drug|AMN107- NILOTINIB|The dose of nilotinib will be 400 mg bid.
46022795|NCT04205773|Device|CompuFlo|After priming with 5 mL saline, the catheter was connected to CompuFlo to record the occurrence of pulsatile waveforms and/or their disappearance during its removal
46022796|NCT02842099|Drug|TA or TAC|Taxol, Epirubincin, with or without Cyclophosphamide
46022797|NCT02842099|Drug|X|Capecitabine
46108677|NCT00460603|Drug|AG-013726|AG-013726 5 mg bid every 2 weeks
46022798|NCT02842021|Drug|S2G6T-1|Twice a day topical cream
46022799|NCT02842021|Drug|S2G6T-2|Twice a day topical cream
46022800|NCT02842021|Drug|S2G6T-3|Twice a day topical cream
46108678|NCT00460603|Drug|AG-013736 (axitinib)|AG-013736 5 mg bid starting dose
46108679|NCT00696059|Drug|Adalimumab (Humira)|Adalimumab (Humira) 40 mg subcutaneously every other week
46108680|NCT04131218|Drug|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
46108681|NCT00700388|Device|TPEP device (UNIKO)|This technique is mainly based on a continuous low-pressure insufflation in the airways, which is likely to reduce (or even avoid) the potential pressure-related damages of other commonly used devices. This device should be used only in those individuals who are showing a normal competence of their cough reflex, thus it should be considered as a means which may help those techniques normally adopted for the individual's bronchial hygiene.
46108682|NCT00700388|Procedure|MABT (Manually assisted breathing techniques)|Conventionally manually assisted breathing techniques
45681435|NCT04587908|Drug|TAS-205|・Treatment period：oral administration for 52 weeks, BID after meal
46022801|NCT02842021|Drug|S2G6T-4|Twice a day topical cream
46022802|NCT02839057|Procedure|Non-surgical treatment|Cervical collar immobilisation for 12 weeks.
46022803|NCT02839057|Procedure|Surgical treatment|Stabilisation of C2-fracture by posterior fusion C1-C2, posterior fusion C2-C3, anterior fusion C2-C3 (no postoperative collar) or anterior screw osteosynthesis C2 (postoperative collar for 6 weeks).
46022804|NCT01229111|Drug|cediranib maleate|Given PO
46108683|NCT02625155|Other|Urine diagnostic testing as SOC, drug regimen changes per SOC|
45681436|NCT04587908|Drug|Placebo|"Observation period：oral administration for 2 weeks, BID after meal~Treatment period：oral administration for 52 weeks, BID after meal"
45838358|NCT03534726|Device|7 T CMR|7 tesla MRI device
46022805|NCT01229111|Drug|oxaliplatin|Given IV
46022806|NCT01229111|Drug|leucovorin calcium|Given IV
46022807|NCT01229111|Drug|fluorouracil|Given IV
46022808|NCT00894361|Procedure|TKA surgery with the rotating platform mobile-bearing knee design|Depuy Sigma RP rotating platform design
46022809|NCT00894361|Procedure|TKA surgery with the all-polyethylene tibia knee design|Depuy Sigma fixed-bearing design with all-polyethylene tibia
46108684|NCT02625155|Other|Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results|
46022810|NCT02843815|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
46022811|NCT02843815|Biological|NK Immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
46022812|NCT01228175|Drug|Placebo|25mg look alike riboflavin tablets to match active study medication.
46022813|NCT01228175|Drug|Varenicline|Days 1-3 - .5mg tablet 1xdaily Days 4-7 - .5mg tablet 2xdaily Days 8-84 - 1mg tablet 2xdaily
45469001|NCT04071418|Radiation|3D-printing Template-assisted CT-guided I-125 Seeds Implantation|(1) positioning and preoperative plan design;(2) 3D printing template design and production;(3) reset and seeds implantation;(4) intraoperative optimization;Postoperative dose verification.Dosimetric parameters include: dose D90 and D100 reaching a certain percentage target volume; Target volume V100, V150 and V200 reaching a certain percentage of prescribed dose;And the dose of organs at risk: Dmean, D2cc, d0.5cc, d0.1cc. Regular follow-up was conducted after treatment.
46022814|NCT02843737|Other|Polysomnography under spontaneous breathing|Patient will come to the sleep laboratory to perform the polysomnography under spontaneous breathing prescribed by the clinician
46022815|NCT01228019|Drug|Niacin (+) laropiprant|Niacin (+) laropiprant (TREDAPTIVE) prescribed according to the current local label
46022816|NCT02987959|Drug|TAK-228|TAK-228 is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128) targets 2 distinct mTOR complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
46022817|NCT05335057|Behavioral|VR Close Other|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with the friend or family member who accompanied them to the lab
46022818|NCT05335057|Behavioral|VR Alone|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments alone
46022819|NCT05335057|Behavioral|VR Stranger|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with a stranger
46022820|NCT05335057|Behavioral|Video Close Other|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they chat with the friend or family member who accompanied them to the lab using a video-conferencing tool
46022821|NCT02841631|Genetic|HPV status and typing of tissue|HPV status and typing of tissue
46022822|NCT01227707|Drug|bevacizumab [Avastin]|5 mg/kg intravenously every 2 weeks, 4 cycles
46022823|NCT01227707|Drug|capecitabine [Xeloda]|825 mg/m2 twice daily orally, 38 days
46022824|NCT01227707|Radiation|Radiation therapy|Total dose of 45 Gy over 38 days
46108685|NCT00700466|Drug|i.v. beta-blocker infusion (metoprolol)|A beta-blocker (metoprolol) will be infused for treatment of hypertension and/or tachycardia prior to induction of anesthesia aiming at decrease of blood pressure and heart rate to normal limits
45469002|NCT04450186|Other|EEG/fMRI neurofeedback|EEG/fMRI neurofeedback
46022825|NCT01227707|Procedure|Mesorectal excision|6-8 weeks after completion of neoadjuvant treatment
46022826|NCT01227707|Drug|bevacizumab [Avastin]|Post-surgery adjuvant treatment at the discretion of the investigator: 5 mg/kg iv every 2 weeks for at least 6 months
46022827|NCT01227707|Drug|5-fluorouracil|Post-surgery adjuvant therapy: bolus of 400mg/m2 iv plus iv infusion of 600 mg/m2 on Days 1 and 2 of each 2-week cycle for 6 months
46022828|NCT01227707|Drug|leucovorin|Post-surgery adjuvant treatment: 100 mg/m2 iv on Days 1 and 2 of each 2-week cycle for 6 months
46108686|NCT00698282|Drug|AZD1981|Oral tablet, 250 mg single dose
46108687|NCT00698282|Drug|AZD1981|Suspension, 15, 75, 1000 and 2000 mg
46108688|NCT00698282|Drug|Placebo|
46108689|NCT02621645|Procedure|Early selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using an 18 Gauge to 20 Gauge needle
45469003|NCT02945046|Drug|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
45469004|NCT02945046|Drug|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
45681437|NCT04149418|Other|Yogurt|Low-fat flavored yogurt
46022829|NCT00633373|Drug|Cyclosporine Inhalation Solution|Cyclosporine USP Inhalation Solution (CIS) 300mg/4.8 mL delivered via a disposable nebulizer. A titration phase of 10 days is recommended starting with 100 mg and then increasing over the 10 days to a maximum of 300 mg or the highest tolerated dose.
46022830|NCT05334745|Other|Alvogyl|application of Alvogyl in the palatal wound with stent versus hyaluronic acid application
46108690|NCT02621645|Procedure|Late selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using a 17 Gauge to 20 Gauge needle OR fetoscopic laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber. The treating physician can decide which technique will be used for the selective reduction.
46108691|NCT02621645|Device|Ultrasound-guided intrafetal ablation using a 18 to 20 Gauge needle|
46108692|NCT02621645|Device|Ultrasound-guided intrafetal ablation using a 17 to 20 Gauge needle|
46108693|NCT02621645|Device|Laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber|
46022831|NCT04586179|Other|Aerobic (treadmill) Exercise|"Individuals begin walking at 5.8 km/hr. (3.6 mph) at a 0.0% incline (5.1 km/hr. [3.2 mph] if below 5' 10 tall), the treadmill incline is increased 1 degree each minute for the first 15 minutes, then speed increased 0.64 km/hr. (0.4 mph) each minute thereafter.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90*[{208-(.7*age)}-resting HR]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion (RPE) greater than 18.5."
46108694|NCT04117022|Dietary Supplement|DVS supplementation|Oral supplement. Each subject will be given the carotenoid supplement of DVS formula. The DVS formula consists of vitamins C, D3 and E (d-α tocopherol), zinc oxide, eicosapentaenoic acid, docosahexaenoic acid, α-lipoic acid (racemic mixture), coenzyme Q10, mixed tocotrienols/tocopherols, zeaxanthin, lutein, benfotiamine, N-acetyl cysteine, grape seed extract, resveratrol, turmeric root extract, green tea leaf, and Pycnogenol (patented French Maritime Pine Bark extract, sp Pinus pinaster, Horphag Research, Geneva, Switzerland). Supplements bottles will be labelled with a unique identification number for each subject and supplied by ZeaVision, LLC, Chesterfield, Missouri, USA. To assure that the participants do not have any issues with the vitamin supplement and to ensure adequate adherence to schedule of vitamin intake the participants will get regular phone calls from the study investigators (once every two weeks).
46108695|NCT00700544|Drug|chemotherapy treatment (see arm) + norethandrolone|"oral form~Dosage:~10 mg in patients with a weight < 60 kgs 20 mg in patients with a weight > 60 kgs frequency: every day Duration: 2 years"
46108696|NCT00700544|Drug|chemotherapy treatment (see arms)|Induction chemotherapy + maintenance chemotherapy
45469005|NCT04449952|Other|Listerine Cool Mint|Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing
46022832|NCT04586179|Other|Dynamic (Agility) Exercise|"Participants will begin in a center circle with equidistant cones 2.5 meters away. After the administrator presents a card, the participant touches a corresponding cone and returns to the starting position. Cards will be presented in increasing frequency in synchrony with a metronome application until exercise termination criteria are identified.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90*[{208-(.7*age)}-resting HR]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion greater than 18.5."
46108697|NCT02612792|Procedure|Open flap debridement (OFD)|Open flap debridement (OFD) alone
46108698|NCT02612792|Procedure|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
46108699|NCT02612792|Procedure|OFD with Platelet rich fibrin (PRF)+1.2% Atorvastatin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
46108700|NCT04138121|Device|Ultrasound|Ultrasound scan of the cricothyroid membrane
46108701|NCT00662038|Drug|pirfenidone|Pirfenidone, 2403 mg/d, administered as 801-mg doses, three times daily.
46108702|NCT00701792|Procedure|liver transplantation|liver transplantation
46108703|NCT00701792|Other|standard care for liver disease|"standard care for liver disease included therapy for ascitis (spironolactone, furosemide), portal hypertension (oesophageal varices ; propranolol), encephalopathy (lactulose), and bacterial infections whatever their localization (prophylaxis of spontaneous peritonitis with norfloxacin). All medical or instrumental procedures were allowed. Patients undergoing iterative paracentesis, variceal band ligation or sclerotherapy, peritoneojugular shunt (LeVeen), transjugular intrahepatic portosystemic shunt (TIPS) or surgical portocaval anastomosis were considered as receiving standard medical therapy."
46108704|NCT02621567|Device|Bright Light Therapy Lamp|TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps emit light of intensity 10,000 lux.
46108705|NCT02621567|Device|Modified Dim Lamp|TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps have been modified to emit light of intensity 500 lux.
46108706|NCT00784498|Drug|Ketamine/Midazolam|Intravenous bolus of midazolam 0.1mg/kg in titrated dose of 1 mg/min until spontaneous eye closure or up to 5mg (whichever comes first) followed by ketamine 0.5-1mg/kg (up to 100mg) in titrated dose of 10mg/30 seconds, to achieve the desired level of sedation
46108707|NCT00784498|Drug|Propofol|Intravenous bolus of propofol 0.5-1mg/kg in titrated dose of 10mg/30seconds (up to 100mg) to achieve the desired level of sedation
45469006|NCT04449952|Other|5% Hydroalcohol Mouth Rinse|Participants use 20 mL of 5% Hydroalcohol mouth rinse for 30 sec after brushing.
45469007|NCT04449952|Other|Colgate Cavity Protection Toothpaste|Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.
45681438|NCT04149418|Other|Control food|Low-fat flavored soy pudding
46022833|NCT02939755|Behavioral|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
46022834|NCT02939755|Behavioral|Enhanced Usual Care|usual care from health providers
46022835|NCT02821273|Other|Modified INSURE technique|modified INSURE means intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.
46022836|NCT02821273|Other|INSURE technique|INSURE means intubation-surfactant-extubation. Extubation and noninvasive ventilation is used after surfactant administration.
46022837|NCT02838589|Drug|Byetta|Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
46022838|NCT02838589|Drug|Isotonic saline|Single dose of subcutaneous injection of 20 μL isotonic saline (placebo).
46022839|NCT02841475|Other|Charlson comorbidity index|Charlson comorbidity index
46022840|NCT02838511|Other|Modified Frailty Index (MFI)|non-cardiac surgical patients will have frailty evaluated
46022841|NCT02838511|Other|Hopkins Frailty Score (HFS)|non-cardiac surgical patients will have frailty evaluated
46022842|NCT02839135|Drug|Reformulated scopolamine patch|Reformulated scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with deliver approximately 1.0 mg over 72 hours
46022843|NCT02839135|Drug|Marketed scopolamine patch|Marketed scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with delivery of approximately 1.0 mg over 72 hours.
46022844|NCT00895843|Drug|Brufen retard|Single dose 2 x 800mg tablets 2 hours prior to surgery
46022845|NCT00895843|Drug|ibuprofen|Single dose ibuprofen 2 x 200mg tablets 2 hours prior to surgery
46022846|NCT00895843|Drug|Bupivacaine|Up to 10ml of Bupivacaine 0.5% with 1:200,000 Adrenaline given prior to surgical incision as inferior alveolar nerve block and long buccal nerve infiltration.
46022847|NCT02838433|Other|biological samples|blood and tissue samples
46022848|NCT05333809|Drug|Pembrolizumab|an anti-PD-1 monoclonal antibody
46022849|NCT05333809|Drug|Disitamab vedotin|HER2-ADC
46022850|NCT02838667|Procedure|Standard of Care plus Nephrology Care|
46022851|NCT05333731|Drug|Oxytocin|In the two groups, if spontaneous labor does not occur after PROM, they all receive the oxytocin for up to 24h.
46022852|NCT02838355|Device|Respiratory Depression Monitoring with End Tidal Carbon Dioxide Nasal Cannula (ETCO2- NC)|The ETCO2-NC is a non-invasive device that monitors the amount of carbon dioxide that is exhaled with every breath.
46022853|NCT02838355|Other|Standard Non-invasive Respiratory Depression Monitoring|Standard non-invasive respiration monitoring includes telemetry of heart rate and rhythm, respiratory rate, blood pressure, CF-LVAD flow, and oxygen saturation (SpO2) via pulse oximetry.
45469008|NCT04449952|Other|Alcohol-Free Essential Oil Containing (AFEO) Mouth Rinse Lead Formula|Participants use 20 mL of AFEO mouth rinse lead formula for 30 sec after brushing.
45469009|NCT04449952|Device|Concept Curve Winter Series Toothbrush|Participants will brush teeth at least one minute with provided bristled toothbrush.
46022854|NCT02843581|Device|Cryosurgery|Argon-helium cryosurgical system
46022855|NCT02843581|Biological|NK immunotherapy|Nutral killer cell immunotherapy for more than 6 times
46022856|NCT02843503|Device|Arterialized-venous reference (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. The samples will be arterialized using a heated-hand-box (arterialized-venous reference (YSI). Blood will be drawn for the determination of glucose concentrations using arterialized-venous sampling techniques per YSI.
45469010|NCT04449952|Device|Listerine Cool Mint Floss|Participants will use marketed fluoride-containing dentifrice, floss.
45681439|NCT01871870|Device|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an outpatient automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm programmed into a smart phone.
45681440|NCT02080780|Drug|Clarithromycin XL|Clarithromycin XL administered once daily on Days 4 through 9 as 2 x 500 mg tablets, 1000 mg per day, for a total of 6000 mg
45681441|NCT02080780|Drug|2% Diltiazem|2% Diltiazem Hydrochloride Cream applied on Day 1 & Day 8 to the perianal area (~2.5 cm [1 inch]; ~8.5 mg)
46022857|NCT02843503|Device|Venous reference measurement (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. Blood will be drawn for the determination of glucose concentrations using venous sampling techniques measured per YSI.
46022858|NCT02843503|Device|Capillary reference (SMBG)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive vingerstick measurements to sample capillary blood measured per Self Monitoring of Blood Glucose (SMBG) device.
46108708|NCT01022983|Drug|Levosimendan|At least 2 hours before surgery: Infusion of Levosimendan (0,1 microgram/kg/min.). 24 hours of infusion without a bolus.
46108709|NCT01022983|Drug|Placebo|ml/kg/hours - same infusion rate as active comparator
46108710|NCT00912860|Drug|Interferon beta-1a|serum free Avonex given IM once a week
46108711|NCT00819156|Drug|degarelix|Degarelix was given as subcutaneous injections.
46108712|NCT02621333|Biological|CIK|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1. After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-induced killer cells are transfused into the vein of patients in one hour.
45469011|NCT03705793|Drug|Mometasone Furoate Nasal Irrigation|Participants will undergo an 8-week treatment course that includes nasal saline irrigation with mometasone powder and placebo nasal spray.
46108713|NCT02621333|Drug|chemotherapy|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1.
46108714|NCT04116086|Diagnostic Test|Prostate Biopsy Test|see earlier information
46108715|NCT02623673|Drug|simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg.|
46108716|NCT05021536|Other|Placebo|Matching Placebo Comparator
46108717|NCT05021536|Drug|AMX0035|Proprietary formulation of taurursodiol and sodium phenylbutyrate
45681442|NCT04142632|Procedure|clinical and paraclinical examination|Physical examination of the penis, ultrasonography of the bladder end the testis, Biological sample for endocrine assessment
45681443|NCT01871558|Drug|Vildagliptin|50 mg b.i.d
45681444|NCT01871558|Drug|Metformin|metformin is to be kept unchanged
45681445|NCT01871558|Drug|sulfonylurea (SU)|
45681446|NCT01871558|Drug|Basal Insulin|
45681447|NCT01711359|Drug|Baricitinib|Administered orally
46022859|NCT02815813|Behavioral|PeerFIT|The 12-month PeerFIT intervention consists of a 6-month intensive phase including: (a) once weekly 60-minute group weight management and exercise session led by a lifestyle coach; (b) once weekly one-hour physical activity session delivered in community settings; and (c) Facebook and mHealth technology (i.e., Fitbits, text messaging support) to increase motivation and facilitate self-monitoring and peer social support for health behavior change. Participants then transition to a 6-month lower intensity phase in which the 90-minute weight management sessions are discontinued. The groups will be conducted as open groups with a minimum of 4 and maximum of 18 participants at any given time.
46108718|NCT00701870|Drug|ezatiostat hydrochloride (Telintra®)|4500 mg orally per day in two divided doses
46108719|NCT00696839|Behavioral|Cognitive-behavioral therapy|3 sessions of CBT: introduction of CBT, training in relaxation and guided imagery, and troubleshooting/closure. 50 minute sessions with an HIV-experienced treating psychologist in Beck-type CBT. Participants will be given an audiorecording of the 2nd session to be used in private home practice, as desired.
45681448|NCT01711359|Drug|Methotrexate|Administered orally
45681449|NCT01711359|Drug|Baricitinib Placebo|Baricitinib placebo administered orally once daily.
45681450|NCT01711359|Drug|MTX Placebo|MTX placebo administered orally once weekly.
46108720|NCT02625077|Procedure|Laparoscopic gastroesophageal valvuloplasty|
46108721|NCT02625077|Procedure|Laparoscopic Toupet fundoplication|
46108722|NCT00784732|Drug|QAV680|
46108723|NCT00784732|Drug|QAV680|
46108724|NCT00784732|Drug|Mometasone Furoate|
46108725|NCT00459979|Drug|sunitinib malate|Sunitinib will be dosed at 50 mg p.o. daily
46108726|NCT00459979|Procedure|conventional surgery|nephrectomy
46108727|NCT04117256|Device|Direct Current Stimulation|20 minutes of direct current stimulation using an intensity of 1.5mA and electrode size of 6x4cm
46108728|NCT04117256|Device|Sham DCS|20 minutes of sham stimulation. Subjects will be stimulated during the first 30 seconds. After that, a ramp down of 10 seconds and then the stimulator is turned-off.
46108729|NCT02621411|Drug|Substance use|Patients are found use of substances by preoperative screen
46108730|NCT00783484|Drug|PF-03716539|PF-03716539 10 mg oral solution, single dose
46108731|NCT00783484|Drug|PF-03716539|PF-03716539 25 mg oral solution, single dose
46108732|NCT00783484|Drug|PF-03716539|PF-03716539 3 mg oral solution, single dose
46108733|NCT00783484|Other|Placebo|Placebo for 3 mg, 10 mg and 25 mg of PF-03716539 (single dose)
46108734|NCT00783484|Drug|PF-03716539|PF-03716539 100 mg oral solution, single dose
46108735|NCT00783484|Drug|PF-03716539|PF-03716539 200 mg oral solution, single dose
46108736|NCT00783484|Drug|PF-03716539|PF-03716539 50 mg oral solution, single dose
46108737|NCT00783484|Other|Placebo|Placebo for 50 mg, 100 mg and 200 mg of PF-03716539 (single dose)
46108738|NCT00783484|Drug|Midazolam|Midazolam 1 mg IV, single dose
46108739|NCT00783484|Drug|Midazolam + PF-03716539 (100 mg)|Midazolam 1 mg IV, single dose plus PF-03716539 100 mg oral solution, single dose
46108740|NCT00783484|Drug|Midazolam + PF-03716539 (50 mg)|Midazolam 1 mg IV, single dose plus PF-03716539 50 mg oral solution, single dose
46108741|NCT00783484|Drug|Darunavir|Darunavir 600 mg tablet twice daily for 9 days (Days 1-9)
46108742|NCT00783484|Drug|Darunavir + PF-03716539|Darunavir 600 mg tablet, single dose plus PF-03716539 50 mg oral solution, single dose (Day 10)
46108743|NCT00783484|Drug|Maraviroc|Maraviroc 150 mg tablet once daily for 6 days (Days 1-6)
46108744|NCT00783484|Drug|Maraviroc +PF-03716539|Maraviroc 150 mg tablet, single dose plus PF-03716539 100 mg oral solution, single dose (Day 7)
46108745|NCT00783484|Drug|Maraviroc|Maraviroc 225 mg tablet once daily for 6 days (Days 1-6)
46108746|NCT00783484|Drug|Maraviroc +PF-03716539|Maraviroc 225 mg tablet, single dose plus PF-03716539 200 mg oral solution, single dose (Day 7)
46108747|NCT00706290|Behavioral|Brief Cognitive Behavioral Therapy|The cognitive-behavioral intervention consists of 6-7 sessions lasting 60-90 minutes each focused on psycho-education; relaxation training; cognitive-restructuring and coping with cancer fears; and activity planning and pacing. Sessions are delivered by a licensed clinical psychologist or trained psychology fellow or graduate student.
46022860|NCT02815813|Behavioral|BEAT|Participants in BEAT will receive monthly individual lifestyle sessions delivered by a lifestyle coach including education, guidance, and support for self-monitoring behaviors (i.e., daily self-weighing and tracking daily steps) during the first six months of the study, plus text message reminders and encouragement for self-monitoring weight loss behaviors during the entire 12-month study period. Participants will receive materials with tips and strategies for healthy eating and increasing physical activity. They will also be given a wearable activity tracker (i.e., Fitbit Zip) to use with instructions for using the device. The first session with the lifestyle coach will be in person and thereafter by phone.
46022861|NCT02690857|Drug|Docosahexaenoic acid|
45469012|NCT03705793|Drug|Mometasone Nasal Spray|Participants will undergo an 8-week treatment course that includes placebo saline irrigation with mometasone nasal spray.
46022862|NCT02690857|Drug|Sunflower Oil|
46022863|NCT02843269|Behavioral|Multi-component lifestyle intervention|The exact same intervention was given to the three Stepped-wedge groups - but each of the three groups were started up three months apart. The waiting groups served as control groups. Thus, the intervention were for all three groups a multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
45469013|NCT03333057|Drug|NOV03|Perfluorohexyloctane
46022864|NCT02843347|Procedure|Blood draw|Three tubes of blood (28.5 mL in total) will be obtained at the Baseline Visit. The sample will be stored for future research.
46022865|NCT02843113|Behavioral|4 Your Child Program|Integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.
46022866|NCT02841319|Other|Virtual Reality Exercises using Hand Tutor|Virtual reality technology is rapidly becoming a popular application for physical rehabilitation and motor control research. The prototype, which includes a built-in movement sensor, allows the user to do controlled exercises as part of a rehabilitation program. The supervised intervention program consists of a forty-minute exercise session three times a week for 8 weeks. In addition, these patients will receive a home exercise program. The patients in the control group will receive only a home exercise program for 8 weeks. The home exercise program consists of different games and exercises such as range of motion, stretch, and strengthening exercises for hand.
46108748|NCT00700700|Device|Active Cardiac Resynchronization Therapy (CRT)|"Initiation of active biventricular pacing/cardiac resynchronization therapy~Devices by Medtronic:~Insync Sentry 7298 & 7299~Concerto C174 ASK (Most frequently implanted)~Insync III 8042 (PM)~Devices by Guidant/Boston Scientific:~Contak Renewal 4 H190 & H199~Contak Renewal 3 H127~Devices by ELA/Sorin:~1. Ovatio CRT 6750"
46108749|NCT04130750|Combination Product|treatment of drug screening|Patients in experimental group will receive a drug screening in vitro to select sensitive chemotherapy drug. And neoadjuvant chemotherapy will be performed according the results of drug screening.
46022867|NCT02841007|Device|geko neuromuscular electrostimulation device|
46022868|NCT02842957|Behavioral|Lifestyle Intervention|Patients randomized to the lifestyle group will be given individual counseling regarding the implementation of a plant based diet. They will also be given a home based exercise program to complete. Patients will be assisted with the optimal use of their prescription medications and they will receive specific counseling regarding strategies to help them successfully change their behavior.
45469014|NCT03333057|Drug|Placebo|Saline solution (0.9% sodium chloride solution)
45681451|NCT01711359|Drug|Folic Acid|Administered orally every day
45681452|NCT04149964|Drug|Acetaminophen 325 mg Oral Tablet|Standard of Care Acetaminophen 325 mg every 6 hours as needed for pain
45681453|NCT04149964|Drug|Acetaminophen 650 mg Oral Tablet|Acetaminophen 650 mg scheduled every 6 hours round the clock for pain
45681454|NCT04149964|Drug|OxyCODONE 5 mg Oral Tablet|Oxycodone 5 mg every 4 hours as needed for breakthrough pain
45681455|NCT04149964|Drug|Acetaminophen/Hydrocodone 325 mg/7.5 mg oral tablet|Acetaminophen 325 mg/ Hydrocodone 7.5 mg oral tablet every 4 hours as needed for breakthrough pain
45469015|NCT04449718|Dietary Supplement|Vitamin D|200,000 IU on admission
45469016|NCT04449718|Dietary Supplement|Placebo|200,000 IU on admission
45469017|NCT03763279|Combination Product|Triclosan-coated barbed suture|Use of Triclosan-coated Polydioxanone barbed suture
45469018|NCT03763279|Combination Product|Triclosan-coated monofilament suture|Use of Triclosan-coated Polydioxanone monofilament suture
45469019|NCT03763279|Device|Monofilament suture|Use of Polydioxanone monofilament suture
45469020|NCT03429478|Other|Preoperative application of a bluetooth enabled Headphones.|A Bluetooth enabled Headphones device which is worn overhead and music can be played through it.
45469021|NCT03638037|Diagnostic Test|Vitamin D measurement|Maternal serum 25- hydroxyl vitamin D level
46022869|NCT02615353|Behavioral|Intensive Lifestyle Intervention|6-months of lifestyle education
46022870|NCT02615353|Other|Usual Care Control|Medical visit and dietary counseling
46022871|NCT02842879|Other|Outpatient Foley cervix priming|Outpatient setting for cervix priming with Foley catheter
46022872|NCT05334667|Other|Routine management|Routine management
46022873|NCT05334667|Device|CRRT|Prisma-flex (Gambro-Swedan) machine will be used to carry out both CRRT and PPH sessions. Each CRRT session continue for 72 hours, while PPH session continue for 4 hours.
46022874|NCT05334667|Device|PPH|Prisma-flex (Gambro-Swedan) machine will be used to carry out both CRRT and PPH sessions. Each CRRT session continue for 72 hours, while PPH session continue for 4 hours.
46022875|NCT00895453|Drug|itraconazole|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid)
46022876|NCT00895453|Drug|lactobacillus gasseri|Lactobacillus vaginal tablets monthly given through 6 days
46022877|NCT00895453|Drug|classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)|CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
46022878|NCT00893971|Drug|PT001|Inhaled PT001, single dose
46022879|NCT00893971|Drug|PT005|Inhaled PT005, single dose
46022880|NCT00893971|Drug|PT003|Inhaled PT003, single dose
46022881|NCT00893971|Drug|PT001 + PT005|Inhaled PT001 + PT005, single dose
46022882|NCT00893737|Drug|sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)|Treximet 1 tablet as soon as the patient has headache indicative of migraine. May be repeated between 2 and 24 hours post-treatment for persistent or recurring headache. Subjects should not take more than 2 Treximet tablets in 24 hours.
46022883|NCT00893113|Drug|Placebo|Alfuzosin-matched One tablet once daily
46022884|NCT00893113|Drug|Alfuzosin|10 mg once daily
46108750|NCT00783562|Other|Extension-oriented exercise program|The exercise program was composed of six graded sessions, two per week for three consecutive weeks. Sessions, each of one hour length, were conducted after the working hours in a wide room of the nursery school, gathering together all the teachers from each school. The exercises were selected in order to reinforce lumbar extension and to strengthen the primary stabilizers of the spine (transversus abdominis, oblique abdominal, multifidus, quadratus lumborum and erector spinae muscles)
46108751|NCT00783562|Other|Informative Brochure|The brochure showed the correct way to lift loads, and provided ergonomic suggestions to prevent musculoskeletal complaints, according to the Italian legislation
46108752|NCT00783640|Drug|Lactic Acid|Drug: Lactic Acid (Dermacyd Femina)
46108753|NCT00851786|Biological|ZOSTAVAX|Subcutaneous injection of 0.65 mL of ZOSTAVAX at Day 0 and Week 6
45469022|NCT03763201|Diagnostic Test|measurement of GITR|serum and synovial fluid measurement of glucocorticoid-induced tumour necrosis factor receptor related protein
45681456|NCT04149496|Combination Product|in vitro maturation of oocytes|Immature oocytes (rather than mature oocytes) are harvested as in IVF. These oocytes are allowed to mature in the laboratory before fertilization
45681457|NCT04587752|Behavioral|CBT for Weight Bullying|Cognitive-behavioral therapy for weight-related bullying delivered by audio/video telehealth.
46022885|NCT05333653|Other|Continouse supportive care|"Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care parameters recommended by The Royal College of Midwives (2012) were applied to the women in the ICSC group in line with their preferences.~Participants in the control group, on the other hand, received routine care given in the hospital by other midwives in the clinic."
46022886|NCT05333653|Other|routine care|Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
46022887|NCT02838199|Device|SAPIEN 3|
46022888|NCT02838199|Procedure|SAVR|
46108754|NCT00851786|Biological|Placebo|Subcutaneous injection of 0.65 mL of placebo at Day 0 and Week 6
46108755|NCT00665626|Drug|Fostamatinib disodium (R935788)|R935788 100 mg tablet, orally, twice-a-day
45469023|NCT03763123|Drug|Sevacizumab|Drug: Sevacizumab escalating doses of Sevacizumab : 0.5mg/kg，1mg/kg，1.5mg/kg and 2mg/kg
46022889|NCT02840929|Procedure|Second-look OGD|Second-look OGD within 16 to 24 hours after primary OGD
46022890|NCT02840929|Drug|Esomeprazole|
46022891|NCT04201483|Other|DCE without RUSI feedback|Participants assigned to this group will perform an exercise known to selectively activate the semispinalis cervicis muscle
45469024|NCT03763123|Drug|Paclitaxel|paclitaxel 80mg/m2 as a > 3-hour IV infusion on days 1, 8,15, and 22 every 4 weeks;
46022892|NCT04201483|Other|DCE + RUSI feedback about performance|Participants in this group will perform the same exercise as the DCE group to selectively activate the semispinalis cervicis muscle but receiving RUSI feedback about correct performance
46022893|NCT02837887|Behavioral|Computerized Cognitive Behavior Therapy|Undergo computerized cognitive behavior therapy
46022894|NCT02840617|Drug|Indocyanine Green (ICG)|
46022895|NCT02838121|Drug|Aclasta|Aclasta once annually for 2 years
46022896|NCT02838121|Drug|Placebo|No IV aclasta
46022897|NCT02837965|Drug|treatment with topical superpotent corticosteroid therapy|
46022898|NCT02837965|Drug|treatment with systemic therapy (methotrexate)|
46022899|NCT02837965|Drug|treatment systemic therapy (prednisone)|
46022900|NCT02837965|Drug|treatment with systemic therapy (prednisone)|
46022901|NCT02837965|Drug|treatment with systemic therapy (doxycycline)|
46022902|NCT04250389|Other|Hemodynamic assessment (micro and macrocirculatory)|"Each of the variable related to macro- and microcirculatory will be evaluated before and one hour after start of MB infusion.~Macrocirculatory parameters will include :~Mean, systolic, diastolic arterial, heart rate (HR)~Cardiac output (CO), sequential vascular response (SVR) and stroke volume (obtained with transthoracic echocardiography or transpulmonary thermodilution catheter if available).~A passive leg raising (PLR) test will be performed before and one hour after MB infusion. Patients will be classified as fluid responder if they had a CO of at least 10% after PLR.~Microcirculatory parameters will include :~Cutaneous and gingival refill time~Tissue oxygen saturation combined with vascular occlusion test (VOT)~Video microscopy measurements of the sublingual microcirculation~Metabolic variables: Arterial blood gases including arterial lactate and central venous blood gases."
46022903|NCT02838043|Dietary Supplement|Probio'Stick|A combination of the probiotic strains Lactobacillus helveticus and Bifidobacterium longum
46022904|NCT00892957|Biological|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|The actual dose of FS VH S/D 500 s-apr will depend on the length of the suture line and the intensity of bleeding (but shall not exceed 4 mL FS VH S/D 500 s-apr).
46022905|NCT00892957|Other|Surgical gauze pads|Manual compression with surgical gauze pads
46022906|NCT02834611|Drug|Ceramide NanoLiposome|Intravenous administration of Ceramide NanoLiposome
46022907|NCT02834689|Behavioral|Walking|Walking on a treadmill at 3.5 METS for 50 minutes
46022908|NCT02834689|Behavioral|Seated Control|Sitting for 50 minutes
46022909|NCT05322733|Drug|Orelabrutinib|150 mg capsules administered orally once daily (28-day cycles). Until 12 or 24 cycles and following BM undetectable MRD, or disease progression, or intolerant toxicity.
46022910|NCT05322733|Drug|Obinutuzumab|1000 mg administered intravenously once on Day 1, 8, 15 of first cycle and on Day 1 of following cycles for maximal 12 cycles (28-day cycles).
46022911|NCT05322733|Drug|Fludarabine|25mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
46022912|NCT05322733|Drug|Cyclophosphamide|250mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
46022913|NCT00968812|Drug|Glimepiride|Glimepiride will be given orally (by mouth), as over-encapsulated tablets, starting at a dose of 1mg once daily and increasing to a maximum of 6 mg or 8 mg once daily for 104 weeks.
46022914|NCT00968812|Drug|Canagliflozin (JNJ-28431754)|Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.
45469025|NCT03763123|Drug|Topotecan|topotecan 4 mg/m2 as a >30 minute IV infusion on days 1, 8, and 15 every 4 weeks ;
45469026|NCT03429400|Drug|Morphine Sulfate|Morphine every 4 hours as needed for up to a maximum of 5 days
45469027|NCT04805307|Drug|CMG901|CMG901 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
45469028|NCT03429088|Behavioral|Motivational interviewing telephone counseling|
45469029|NCT02944968|Device|THERMOCOOL SMARTTOUCH® SF-5D catheter|
45469030|NCT03429010|Procedure|"New guideline anesthesia strategy team"|"New guideline anesthesia strategy team"
45469031|NCT03761797|Drug|TRADIANCE® Combination Tablets AP|Fixed dose combination
45469032|NCT03761797|Drug|TRADIANCE® Combination Tablets BP|Fixed dose combination
45681458|NCT04140136|Dietary Supplement|Tocotrienols|Tocotrienols as a potent antioxidant to modulate oxidative stress and inflammatory response
46022915|NCT00968812|Drug|Metformin|Metformin will be given orally at the protocol-specified dose for 104 weeks.
46022916|NCT02834767|Device|Genioglossis Strength Trainer|The genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. The device can be set to a specific pressure resistance ranging from 10 to 40 Newtons. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
46022917|NCT02834767|Device|Placebo Genioglossis Strength Trainer|The placebo genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. Whereas the pressure loaded spring in the active trainer can be set to a wide range of pressures, the placebo trainer has a maximum resistance of 5 Newtons. The device is set to a specific pressure resistance of 5 Newtons at all times. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
46022918|NCT02834845|Drug|Sevoflurane|Sevoflurane %2-3 for general anesthesia maintenance
46022919|NCT02834845|Drug|Desflurane|Desflurane %6-8 for general anesthesia maintenance
46022920|NCT02840851|Device|MRI|Participants will undergo a MRI scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory rate and PetCO2 will be measured.
46108756|NCT00665626|Drug|Placebo|Placebo, orally, twice-a-day
46022921|NCT02840851|Device|TCD|Participants will undergo a TCD scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory and PetCO2 will be measured.
46022922|NCT02834533|Device|Lokomat|Lokomat (Hocoma Inc., Zurich, Switzerland)includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . As compared to Lokomat-Nanos, the Pro device offers a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
46022923|NCT02834143|Other|No intervention|The is no intervention. This study is a descriptive one
46022924|NCT05197192|Drug|Obinutuzumab|"Obinutuzumab i.v. infusion:~Cycle 1 Day 1: Obinutuzumab 100 mg i.v.~Cycle 1 Day 1 (or 2): Obinutuzumab 900 mg i.v.~Cycle 1 Day 8: Obinutuzumab 1000 mg i.v.~Cycle 1 Day 15: Obinutuzumab 1000 mg i.v.~Cycles 2-6: Day 1: Obinutuzumab 1000 mg i.v."
46022925|NCT05197192|Drug|Venetoclax|"Venetoclax p.o.:~Cycle 1: Days 22-28: Venetoclax 20 mg (2 x 10 mg)~Cycle 2: Days 1-7: Venetoclax 50 mg (1 x 50 mg)~Cycle 2:Days 8-14: Venetoclax 100 mg (1 x 100 mg)~Cycle 2:Days: 15-21: Venetoclax 200 mg (2 x 100 mg)~Cycle 2:Days: 22-28: Venetoclax 400 mg (4 x 100 mg)~Cycles 3-12: Days 1-28: Venetoclax 400 mg (4 x 100 mg)"
46022926|NCT05197192|Drug|Acalabrutinib|"Cycles 15-24: Days 1-28:~100 mg acalabrutinib twice daily p.o. approx. every 12 hrs (corresponding to a total daily dose of 200 mg)."
46022927|NCT02834299|Behavioral|DBT Guided Self-Help|DBT self-help manual plus six 30-minute therapy sessions for 12 weeks
46022928|NCT02834299|Behavioral|DBT Unguided Self-Help|DBT self-help manual without any therapy sessions for 12 weeks
46022929|NCT02834299|Behavioral|Self-Esteem-Focused Unguided Self-Help|Self-esteem focused self-help manual without any therapy sessions for 12 weeks
46022930|NCT05333575|Behavioral|Lullaby|The mothers in this group were asked to sing a lullaby while their babies were fed with an orogastric tube. Mothers were released on lullabies. They were encouraged to sing the lullaby they knew or loved the most. The mother was given a sound decibel meter. Mothers were asked to do an application before going to the baby. It was taught that the number of sound decibels should not exceed 40 decibels while singing a lullaby. Later, the mother was taken to the baby's incubator at feeding time. She was seated in a chair. The working status of the decibel meter was checked and given to the mother. When the feeding started, the mother started singing lullabies and continued to sing until the feeding was finished. Attention was paid to aseptic techniques during all procedures. A single mother was asked to sing a lullaby at each feeding, and the baby of the mother who sang only a lullaby was included in the study.
46022931|NCT05333575|Behavioral|Classic music|The babies in this group were given classical music recitals during feeding. The classical music piece Mozart-Baby Smart was preferred because it was seen to be used in the literature (Keidar 2014). Mozart-Baby Smart was loaded into the music player by the researcher before the feeding process. Before feeding, the decibel meter was disinfected by surface disinfectant and placed on sterile sponge in an incubator 10 cm away from the baby's head. The music player was turned on, not exceeding 40 decibels, by adjusting the decibel meter at the time of starting the feeding, and classical music was continued during the feeding. When the feeding was finished, the music player was turned off and the incubator was taken out. Attention was paid to acetic techniques during all procedures. Ambient sounds were tried to be controlled as much as possible so that the baby would not be affected by different sounds when listening to classical music.
46022932|NCT02837809|Radiation|Low dose CT|annual CT vs biennial CT
46022933|NCT00992056|Drug|nebivolol|5 mg titrated to 10 mg daily versus matching placebo
46022934|NCT00992056|Drug|Metoprolol|Metoprolol 50 mg titrated to 100 mg
46022935|NCT02837653|Behavioral|Physical Activity Counselling|
46022936|NCT02837653|Other|Therapeutic Exercise for LBP|
46022937|NCT02837653|Other|Superficial Thermotherapy|
46022938|NCT04249999|Behavioral|ActivOnline|Access to online physical activity platform (www.activonline.com.au)
45469033|NCT03127930|Behavioral|Intervention|Participants receive 5 individualized contacts (home visits and phone calls) with either a social worker or a nurse to develop problem solving skills as applied to medication management.
46108757|NCT04116944|Behavioral|Resistance exercise training|The ecologically-valid resistance exercise training was designed according to World Health Organization and American College of Sports Medicine guidelines. The eight-week, twice-weekly intervention was designed to be performed at a moderate intensity. The resistance of each exercise was such that when participants could successfully complete 2 sets of 12 repetitions at a certain load, the resistance was increased incrementally up to 5% for the following session. Exercise sessions were scheduled with at least one day of rest between sessions. The eight exercises included the barbell squat, barbell bench press, hexagon bar deadlift, dumbbell shoulder lateral raise, barbell bent over rows, dumbbell lunges, dumbbell curls, and abdominal crunches.
46022939|NCT04286074|Other|50% resistance|Prior to training, the muscle training technique will be performed. The objective of applying the intervention using the Powerbreathe® device is to produce an increase in inspiratory force. The technique will be performed with the athlete standing, holding the device with his hand and his lips sealed on the mouthpiece. After a full expiration, you will make a quick and deep inspiration. The principal investigator of the study will ensure that the technique is performed correctly. There will be 2 series of 30 maximum inspirations. These interventions will be faced with a resistance of 50% of the maximum inspiratory pressure of each athlete
46108758|NCT04116944|Other|Wait-list|Participants randomized to the delayed-start wait-list condition completed questionnaires once-weekly. The investigator sent a weekly email to the participant providing links to the questionnaires. Participants that completed the eight-week wait-list condition were offered the eight weeks of RET either immediately upon completion, or later at a time of their convenience while the trial was ongoing. Each participant randomized to the eight-week wait-list also completed two 30-minute bouts of seated quiet rest in an empty room at weeks one and eight.
46108759|NCT00828672|Drug|Oxaliplatin|Administered on days 15,22,29,36 en 43; 50 mg/m2
46108760|NCT00828672|Drug|Bevacizumab|Administered on days 1,15,29 and 43 ; 5mg/kg
46108761|NCT00828672|Drug|Capecitabine|825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
46108762|NCT00828672|Radiation|radiotherapy|Total dose 45Gy
46108763|NCT04130984|Device|EZ-IO|The insertion site locates at 1 cm medial tibial tuberosity. EZ-IO (U.S. Teleflex® Corporation) will be used with an adult 15G needle. Pull out the needle when having a sense of frustration, withdraw the bone marrow with the syringe, bolus 20 mL of normal saline to open intramedullary path and begin drug resuscitation at the same time. The retention time of IO route should be less than 24 h, and venous access should be established after winning rescue time as soon as possible to continue treatment.
46108764|NCT02612870|Device|Sienna+ retro|Sentinel node marking with Sienna+ retro-mamillary 1 day before surgery
46108765|NCT02612870|Device|Sienna+ peri|Sentinel node marking with Sienna+ peri-tumorally 1 day before surgery
46108766|NCT02612870|Device|Sienna+ retro 4-6|Sentinel node marking with Sienna+ retro-mamillary 4-6 days before surgery
46108767|NCT02612870|Device|Sienna+ peri 4-6|Sentinel node marking with Sienna+ peri-tumorally 4-6 days before surgery
46108768|NCT02612870|Device|Technetium 1|Sentinel node marking with Technetium 1 day before surgery
46108769|NCT00784888|Other|Aromatase inhibitors|non-interventional study
46108770|NCT00706368|Device|Point of care tests|Several point-of-care tests are offered: OSOM TV rapid trichomonas test; OSOM BV Blue rapid test; pHEMalert vaginal pH test. All subjects receive the OSOM TV test, while the other two are optional.
46108771|NCT00873119|Drug|belinostat, carboplatin, paclitaxel|
46108772|NCT00873119|Drug|carboplatin, paclitaxel|
46108773|NCT00661726|Drug|Decitabine (USAN, INN)|Participants will receive 0.2 mg/kg of decitabine subcutaneously twice a week for 12 weeks. The dose will be reduced for toxicities as needed. The maximum dose of decitabine to be given will be 0.2 mg/kg.
46108774|NCT00865046|Other|Periosteal stimulation|Four acupuncture needles are placed around the knee to the level of the periosteum and two needles are placed pretibially in the soft tissue. All needles are stimulated with 100 Hz current. The stimulation of the needles in the soft tissue is discontinued after one minute.
46108775|NCT00865046|Other|Control-Periosteal Stimulation|Acupuncture needles are placed as per the PST intervention, but only the soft tissue needles receive electrical stimulation for one minute.
46108776|NCT00706680|Drug|Thymoglobulin|methyl prednisone intravenously pre-operatively, as per institutional practice. Thymoglobulin, initiated prior to completion of the anastomosis, or if not possible, within 24 hours of transplantation for a total dose of 6-7.5mg/kg given over 3-5 doses. Steroids initiated post-operatively at 1mg/kg/day for 2 days, then 0.5mg/kg/day for 2 days, then 0.25mg/kg/day for 2 days. Patients will be placed on 5mg daily for the remainder of the study. All patients will receive Mycophenolic acid at a dose of 2gm/day (Cellcept) or 1440mg/day (Myfortic) post-transplantation with dose adjustment as needed. Cyclosporine micro-emulsion will be initiated when renal function is established or no later than day 10 in a dose of 3mg/kg twice daily with adjustment to achieve a C2 target of 600-800 nanograms/ml.
46108777|NCT02624999|Biological|AlloVax™|AlloVax™ combines an anti-tumor effect of mini-transplant procedures with patient specific tumor antigens
46108778|NCT02624999|Drug|Cisplatin|Subjects in the chemotherapy arm will receive up to 6 cycles of cisplatin on day 0 of the 3-week cycle at dose of 80-100 mg/m2 IV and 1000 mg/m2 IV 5FU on days 1-4 of the cycle
46108779|NCT02612480|Drug|ticagrelor|7 day treatment of ticagrelor 2dd90mg after a loading dose of 180mg
46108780|NCT02612480|Drug|Clopidogrel|7 day treatment of clopidogrel 1d75mg after a loading dose of 300mg
46108781|NCT02612480|Drug|Acetylsalicylic acid lysinate|7 day treatment of acetylsalicyclic acid 1d80mg after a loading dose of 160mg
46108782|NCT02612480|Drug|Placebo|7 day treatment with placebo
46108783|NCT00784966|Drug|etanercept|Treatment option 'A'-Two weeks treatment with etanercept. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two weeks.
46022940|NCT04286074|Other|10% resistance|Prior to training, the muscle training technique will be performed. The objective of applying the intervention using the Powerbreathe® device is to produce an increase in inspiratory force. The technique will be performed with the athlete standing, holding the device with his hand and his lips sealed on the mouthpiece. After a full expiration, you will make a quick and deep inspiration. The principal investigator of the study will ensure that the technique is performed correctly. There will be 2 series of 30 maximum inspirations. These interventions will be faced with a resistance of 10% of the maximum inspiratory pressure of each athlete
45469034|NCT02944656|Drug|Gabapentin|Participants in this group will receive 600 mg of gabapentin given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion. Gabapentin is an FDA approved medication that is used to prevent seizures and to treat various forms of chronic and acute pain.
46022941|NCT02834221|Device|Real-time ultrasound-guided puncture|A 7 megahertz ultrasound linear probe will be used.
46022942|NCT02834221|Other|Anatomical landmark guided puncture|Anatomical landmark puncture
46022943|NCT00972322|Drug|MK-8245|MK-8245 50 mg twice daily for 28 days
46108784|NCT00784966|Drug|etanercept|Etanercept will be given for a total of 2 months. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two months.
46108785|NCT00828516|Other|Acupuncture and moxibustion|Acupuncture is a form of traditional east Asian medicine that uses needles inserted superficially under the skin to stimulate sites on the body known as acupuncture points. Traditional practice encompasses moxibustion, the application of heat (usually from the smouldering herb artemisia vulgaris or mugwort) to stimulate the points by warming them.
46022944|NCT00972322|Drug|Comparator: placebo|matching placebo to MK-8245 twice daily for 28 days
46022945|NCT02840773|Other|Peri-implanter sulcus fluid sampling|PISF sampling was made twice
46022946|NCT02840773|Other|Probing depth|The change of probing depth between baseline and 12 month after prosthetic loading. Probing depth was measured with a plastic periodontal probe (mm)
46022947|NCT02840773|Other|Crestal bone loss|Crestal bone loss was measured on digital radiographs at baseline and after 1 year of prosthetic loading with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
46022948|NCT02840773|Other|Presence of bleeding on probing|The change bleeding on probing of between baseline and 12 month after prosthetic loading. Presence of bleeding on probing were performed at four sites of implants.
46108786|NCT02623595|Radiation|Stereotactic body radiotherapy|A type of radiation therapy
46108787|NCT02623595|Drug|rhGM-CSF|Immune modulating agents
45469035|NCT02944656|Drug|Placebo|Participants in this group will receive 600 mg of gelatin capsules that are identical in appearance to gabapentin capsules. The placebo will be given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion.
45469036|NCT02713529|Biological|AMG820 and pembrolizumab|Treatment with AMG820 and pembrolizumab
45469037|NCT03763045|Drug|Sildenafil|Sildenafil 25 mg: Phosphodiesterase inhibitor to be taken once daily
45469038|NCT03763045|Drug|Sildenafil|Sildenafil 50 mg: Phosphodiesterase inhibitor to be taken once daily
45681459|NCT04140136|Dietary Supplement|Placebo|The placebo is similar in appearance, but does not contain tocotrienols and consist of palm oil
45681460|NCT04146532|Drug|Aspirin 500 MG|Single 500mg aspirin capsule.
46022949|NCT02840773|Other|Plaque index levels|The change of plaque index level between baseline and 12 month after prosthetic loading. Presence of plaque index was performed at four sites of implants.
46022950|NCT02863744|Procedure|coronally advanced flap with subepithelial connective tissue graft|"Under local anesthesia 2% lignocaine hydrochloride using a No. 15 BP (Bard Parker) blade full thickness flap will be elevated till the MGJ (mucogingival junction) using a small periosteal elevator and a partial-thickness flap will be raised beyond the mucogingival junction to allow a passive coronal displacement of the flap completely covering the CEJ without tension.~The donor site consisting of 2 mm thick palatal connective tissue graft will be harvested from the premolar to the first molar area using the 'trap door' technique.14 The connective tissue graft will be secured in position with 4-0 absorbable sutures in recipient sites.~The flaps will be stabilized with sling suture in a coronal position, followed by interrupted suture on releasing incisions in an apico-coronal direction using 4-0 absorbable sutures."
46022951|NCT02834377|Other|Treatment algorithm targeting individual cardiac output|
46022952|NCT02834455|Device|Contrast-enhanced CT|50% of patients with unilateral pleural effusion will have performed a CE-CT
46022953|NCT02834455|Device|PET-CT|50% of patients with unilateral pleural effusion will have performed a PET-CT
46022954|NCT02837575|Biological|VCL-HB01|Investigational Product
46022955|NCT02837575|Other|Phosphate-buffered saline|Placebo
46108788|NCT04135001|Behavioral|HBM Training|A computer-based training to reduce hostile bias and interpersonal conflict as a mechanism to improve trust and cohesion within an operational military unit across the deployment cycle. The computer training is based on the Go/No-Go task (Fillmore et al., 2006) and Lexical Decision Task (Lepore & Brown, 2002). The training reduces HAB by affecting two cognitive mechanisms: prime seeking non-hostile concepts when presented with ambiguous cues and conditioning inhibition in response to hostile cues. Thus, the training induces a non-hostile attribution bias while simultaneously training the inhibition of hostile attribution bias and aggressive behavior in response to ambiguous cues.
46108789|NCT04135001|Other|Placebo Training|Volunteers in the placebo condition will be told to complete the fragments with the first word that comes to mind. This placebo still exposes volunteers to the training stimuli and computer task, but does not train inhibition or selectively prime non-hostility, which are the hypothesized mechanisms of the training.
46022956|NCT04209361|Other|Questionnaire|Data will be obtained through a printed questionnaire for assessment of knowledge, attitude and practice of dentists at military hospitals regarding child abuse and neglect. The collected data will be saved and tabulated on a computer and finally will be statistically analyzed.
46022957|NCT04249765|Other|Assessing grasping force, pinch force,|"Grip Strength The participants sat upright on a chair with their feet supported. The tested arm was positioned on a table with the shoulders slightly abducted and neutrally rotated, the elbow in 90° of flexion, the forearm in 0° between pronation and supination, and the wrist in neutral resting position. The participants were instructed to maintain that position during the test. The grip strength of both hands was measured using the Hand Dynamometer.~3. Pinch Strength Participants were seated at a table on which the dynamometers were positioned. The subjects were told to keep their elbow flexed without resting their arm or the grip handle of the dynamometer on the table."
46022958|NCT05334355|Other|Family history of hypertension|Presence or absence of a family history of hypertension in a cross sectional study design.
46022959|NCT02840695|Drug|bDMARD treatment|Treatment with bDMARD includes registered ATC-codes: L04AA and L04AB.
46022960|NCT02837497|Other|ICU-RESUS CPR Improvement Bundle|"Point-of-care CPR training~Post-cardiac arrest educational debriefings"
46022961|NCT00967798|Drug|Sitagliptin|100 mg of sitagliptin is taken orally each morning with breakfast. Duration is 12 months or conversion to CF diabetes, whichever comes first.
46108790|NCT00665392|Drug|cisplatin|75 mg/m², day 1. 3 cycles
46108791|NCT00665392|Drug|docetaxel|75 mg/m² Day 1. 3 cycles
46022962|NCT02837419|Behavioral|Health related Quality of life EQ-5D|Quality of Care
46108792|NCT00665392|Drug|fluorouracil|750 mg/m² day 1 to day 5. 3 cycles
46108793|NCT00665392|Drug|Cetuximab|400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.
46108794|NCT00851630|Drug|Fixed dose combination zidovudine/lamivudine/abacavir|All subjects will receive fixed dose combination zidovudine(300 mg) / lamivudine (150 mg) / abacavir (300 mg) by mouth twice daily. Medications will be provided as long as deemed beneficial by the site investigator and study subject for up to two years. Toxicity substitutions are allowed per protocol.
46022963|NCT04248361|Diagnostic Test|TEM-PCR URI Panel|Target Enriched Multiplex Polymerase Chain Reaction (TEM-PCR™) is a breakthrough molecular multiplex technology that allows rapid DNA/RNA identification of multiple pathogens (i.e., bacteria and viruses) in a single sample, typically within one day of specimen receipt.
46022964|NCT04248361|Other|SOC/Empiric Diagnosis|The SOC for upper respiratory infection may include, but is not limited to, rapid strep testing, rapid influenza testing, and sputum cultures. In the event a lower respiratory infection is suspected a chest x-ray or CBC with differential may be performed.
46022965|NCT04248439|Biological|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene
46022966|NCT02863510|Device|Renal Sympathetic Denervation|Renal sympathetic denervation is a minimally invasive, endovascular catheter-based procedure using radiofrequency ablation of sympathetic nerves located in the walls of renal arteries, aimed at treating treatment-resistant hypertension.
46022967|NCT05291923|Other|no intervention|no intervention
46108795|NCT05298761|Drug|Lignocaine|Inj lignocain and inj nalbuphine given to two groups of participants and effects of both drugs
46108796|NCT04130594|Biological|BVRS-GamVac|a vector vaccine for the prevention of the Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration
46108797|NCT04130594|Other|placebo|placebo
46108798|NCT04135157|Procedure|Pectoralis nerve block II|PECS II block will be performed 30 min. before general anesthesia.
46108799|NCT04135157|Procedure|Erector spine plane block|ESP block will be performed 30 minutes before general anesthesia.
46108800|NCT04135157|Other|Control|Only general anesthesia will be performed.
45469039|NCT03763045|Other|Placebo|Placebo tablet.
45681461|NCT04146532|Drug|Placebo|Single 500mg placebo capsule.
45681462|NCT03929224|Drug|Medicinal honey|Treat healing surgical site with medicinal honey
46022968|NCT04286464|Other|No intervention|No intervention
46108801|NCT00784108|Device|Modulated Imaging (MI)|Modulated Imaging measure effect of Photodynamic therapy treatment
46108802|NCT00784108|Other|Photodynamic therapy|Modulated Imaging measure effect of Photodynamic therapy treatment
46108803|NCT00459667|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 250ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
45469040|NCT03127852|Device|Medly|
45681463|NCT03929224|Drug|Bacitracin|Treat healing surgical site with bacitracin
46108804|NCT00459667|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 500ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
46108805|NCT00459667|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|"Phase A: 250ug administrated s.c. every other day (open-label). For patients previously randomized in Bayer study 91162 to 20mg Copaxone® administrated s.c. once daily and patients with premature discontinuation of study medication during the study 91162.~Phase B: All patients will receive 500µg s.c.every other day (open-label)."
46108806|NCT05603000|Behavioral|Emotion Focused Family Therapy|"The Emotion Focused Family Therapy (EFFT) intervention for this study will be delivered to groups of four to ten parents over six weekly sessions of two hours each. The goal of EFFT is to teach and empower parents to coach their child to process the emotions at the source of their mental health symptoms, to increase their child's adaptive behaviours, and to repair emotional injuries within the parent-child relationship. EFFT also targets parents' own emotional challenges that may prevent them from feeling capable or being able to support their child's treatment.~Each EFFT session will include introductions, psychoeducation about emotion and psychopathology, introduction of skills, experiential activities (e.g., chair work), open discussion and feedback, and homework activities covering the foci of EFFT: emotion coaching, behaviour coaching, therapeutic apology, and parental emotion blocks."
46108807|NCT02621255|Drug|Sevoflurane|Anesthesia type of performed for patient which has femur fracture.
46108808|NCT02621255|Drug|Bupivacaine|Anesthesia type of performed for patient which has femur fracture.
46108809|NCT04047238|Other|Reminiscence Therapy|"Intervention group will receive two Reminiscence Therapy sessions per week for 3 months. Reminiscence therapy sessions will last approximately 50 minutes and will be developed according to the following structure:~Welcome to the patient and reality orientation therapy (7 minutes)~Conducting the main activity of reminiscence (40 minutes)~Closure, thank you for the participation and farewell until the next session (3 minutes) Reminiscence therapy sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of Reminiscence Therapy. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of Past and Present."
46108810|NCT00828204|Device|single-use autoinjector with a prefilled liquid Avonex syringe|
46108811|NCT00828204|Device|Avonex prefilled syringe via manual IM injection|
46108812|NCT00828204|Drug|BG9418 (interferon beta-1a)|
46108813|NCT00696215|Drug|placebo|Placebo 1 mg once a day
46108814|NCT00696215|Drug|rasagiline|1mg
46108815|NCT00784186|Drug|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
46108816|NCT00784186|Drug|misoprostol|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
46108817|NCT00784186|Drug|placebo|placebo resembling mifepristone taken 24 hours before 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
46108818|NCT02621099|Device|Hybrid optical-gamma imaging|Acquisition of images using the camera as additional steps to the standard SLNB procedures.
46108819|NCT00851552|Biological|rituximab|Given IV
46108820|NCT00851552|Drug|bortezomib|Given IV
46108821|NCT00851552|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
45469041|NCT01321489|Drug|Sildenafil Citrate 20mg Tablet Sublingual|Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
45469042|NCT01321489|Drug|Viagra ® 50mg tablet Coated|Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
45469043|NCT03427840|Procedure|Procedure/Surgery: superior hypogastric block|superior hypogastric blockade during surgery
46022969|NCT04248205|Drug|Ketamine|Standard general anesthesia PLUS ketamine will be given for post-operative analgesia
46022970|NCT02833831|Drug|ALS-008176|Participants will receive a single dose of ALS-008176 orally.
46022971|NCT02833831|Drug|Placebo|Matching Placebo will be administered.
46022972|NCT02833831|Drug|Moxifloxacin|Participants will receive a single dose of moxifloxacin 400 mg.
46022973|NCT02833987|Drug|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban in the 30 days following the date of an incident VTE diagnosis.
46108822|NCT00851552|Genetic|gene expression analysis|Correlative Study
46108823|NCT00851552|Genetic|polymerase chain reaction|Correlative Study
46022974|NCT02833987|Drug|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran in the 30 days following the date of an incident VTE diagnosis.
46022975|NCT02833987|Drug|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban in the 30 days following the date of an incident VTE diagnosis.
46108824|NCT00851552|Genetic|polymorphism analysis|Correlative Study
46108825|NCT00851552|Genetic|proteomic profiling|Correlative Study
45469044|NCT04800627|Biological|Pembrolizumab|Given IV
45469045|NCT04800627|Drug|Pevonedistat|Given IV
45469046|NCT05308680|Biological|BNT162b2|Administration of the fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19
45469047|NCT03771625|Radiation|radiotherapy|whole brain with/without spinal cord
45469048|NCT05308602|Biological|SCTV01C|Day 0; intramuscular injection
46108826|NCT00851552|Other|flow cytometry|Correlative Study
46108827|NCT00851552|Other|laboratory biomarker analysis|Correlative Study
46022976|NCT02833987|Drug|Warfarin (ATC B01AA03)|Exposure to warfarin (ATC B01AA03) will be defined as a new prescription for warfarin in the 30 days following the date of an incident VTE diagnosis.
46108828|NCT02611986|Device|the McGrath MAC|in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
46108829|NCT02611986|Device|the Macintosh Laryngoscope|in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
46108830|NCT02621177|Biological|NBP607|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
46108831|NCT02621177|Biological|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
45469049|NCT05308602|Biological|SCTV01C|Day 28; intramuscular injection
45469050|NCT05308602|Biological|SCTV01C|Day 180; intramuscular injection
45469051|NCT05308602|Biological|SCTV01E|Day 0; intramuscular injection
45469052|NCT05308602|Biological|SCTV01E|Day 28; intramuscular injection
45469053|NCT05308602|Biological|SCTV01E|Day 180; intramuscular injection
45469054|NCT05308602|Biological|mRNA vaccine manufactured by Pfizer or Moderna|Day 0; intramuscular injection
46022977|NCT02833909|Other|surgery|
46022978|NCT05283187|Behavioral|MBCT|Mindfulness Based Cognitive Therapy
46022979|NCT02833519|Behavioral|group exercise|"Group training supervised by Physiotherapists from Copenhagen University Hospital, Rigshospitalet. 70 minutes sessions twice a week for 12 weeks.~The training consists of 10 minutes of warm up (Borg scale 7-10), 20 minutes of fitness training on exercise bike, tread mill or cross-trainer (Borg scale 11-15), 25 minutes of muscle training and 15 minutes stretching/relaxation, (Borg scale 6).~The intensity of the training follows national recommendations on physical activity for pregnant women, which recommends moderate physical activity or more depending on the pregnant woman's fitness level prior to pregnancy.~The pregnant women´s general practitioners are informed about the intervention and who is participating in the project.~A weekly supportive email."
46108832|NCT00785122|Drug|Endoxana, Leukine, IMA910|a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90
46108833|NCT00785122|Drug|Endoxana, Leukine, IMA910, Aldara|a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90 followed by Aldara (Imiquimod)
46108834|NCT04116554|Drug|0.25% bupivacaine.|20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side
46108835|NCT04116554|Device|0.9%saline|20 ml of 0.9%saline will be injected on each side
46108836|NCT00459355|Behavioral|Home Safety Toolkit|Health literacy-verified booklet and home safety items to promote competence to make home safety modifications.
46108837|NCT00700856|Drug|add-on pioglitazone|participants randomised to this arm will add pioglitazone 15 mg/die to therapy with metformin (2 gr/die)
46108838|NCT00700856|Drug|add-on sulphonylurea|participants randomized to this arm will add a sulphonylurea (glibenclamide 5 mg/die; gliclazide 30 mg/die or glimepiride 2 mg/die)to monotherapy with metformin (2 gr/die)
46108839|NCT00790114|Drug|AZD7325|Oral, day 1-12
46108840|NCT00790114|Drug|Midazolam|single dose, twice during treatment
46108841|NCT00790114|Drug|Caffeine|single dose, twice during treatment
46108842|NCT01023139|Behavioral|Sibutramine|During phase 1, sibutramine is given to all participants, 10mg po q day. If they do not meet a change in BMI of at least 2.5%,then the dosage may be increased to 15mg po q day. The main intervention in the study during phase 1 and 2is the behavioral modification
45469055|NCT05308602|Biological|mRNA vaccine manufactured by Pfizer or Moderna|Day 28; intramuscular injection
45469056|NCT05308602|Biological|mRNA vaccine manufactured by Pfizer or Moderna|Day 180; intramuscular injection
45469057|NCT05308602|Biological|Sinopharm inactivated COVID-19 vaccine|Day 0; intramuscular injection
45469058|NCT05308602|Biological|Sinopharm inactivated COVID-19 vaccine|Day 28; intramuscular injection
45469059|NCT05308602|Biological|Sinopharm inactivated COVID-19 vaccine|Day 180; intramuscular injection
45469060|NCT03768037|Drug|Anlotinib plus Pemetrexed|"Anlotinib p.o, qd and it should be continued until disease progress or unacceptable toxic effects.~Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects"
45469061|NCT03768037|Drug|Pemetrexed|Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects
45469062|NCT01146977|Other|HDAC chemotherapy|If he/she decides not to participate, he/she will be treated with HDAC consolidation chemotherapy, which is the current standard treatment.
45469063|NCT01146977|Other|Autologous HCT|"After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information.~If he/she decides to participate, request of health insurance support on the autologous HCT will be submitted and further processes related to autologous HCT will continue."
46022980|NCT02833441|Behavioral|Peer Support|
45469065|NCT03762967|Biological|Lipoaspiration and SVF introduction.|Lipoaspiration, isolation of SVF and introduction into testis Interstitium.
45469066|NCT03762967|Drug|Standard therapy.|Standard therapy include to give up bad habits, to establish a healthy diet, to eliminate excessive physical exertion. eliminate. In the case of endocrine disorders, hormone therapy is prescribed.
45469067|NCT03929289|Behavioral|Social Facilitation|During the functional Magnetic Resonance Imaging (fMRI) scans, the subject will perform cognitive tasks measuring eye movements and attention alternatively observed by a familiar peer (in an adjacent room) or not.
45469068|NCT05055856|Diagnostic Test|urine sample|Each participant will give a urine sample for diagnose of asymptomatic bacteriuria
45469069|NCT05055856|Diagnostic Test|Blood and urine sample|Each participant will give a urine and blood sample for diagnose of SIADH
45469070|NCT03762889|Device|Eyeprotx™ General Anesthesia Protective Goggles|Eyeprotx™ Protective Goggles have been designed specifically for use in the operating room or in any scenario where general anesthesia must be used, such as intubation in an emergency. The integral function is to reduce intraocular pressure while in place, prevent operating room bright light penetration, facilitate a swift placement preventative measure with straps, form a barrier against bacterial invasion and mechanical damage. This study would seek to examine this goggles' effectiveness as a preventative measure as vs. other measures.
46108843|NCT02555176|Dietary Supplement|Dietary intervention|Follow a low-carbohydrate diet
46108844|NCT00459043|Drug|ZD6474|Taken orally once every morning
46108845|NCT00459043|Drug|Docetaxel|Given on the first day of every treatment cycle (every 3 weeks)
46108846|NCT00795262|Drug|Quinapril (Accupril) plus Alpha Lipoic Acid|Patients in Arm 2 (n=20) will receive quinapril 40 mg and Alpha Lipoic Acid (600 mg/day)for an 8-week treatment period (Treatment A).
46108847|NCT00795262|Drug|accupril, placebo|accupril 40 mg
46108848|NCT00795262|Drug|accupril, alpha lipoic acid|accupril (quinapril) 40 mg plus alpha lipoic acid 600 mg
45469071|NCT03762889|Device|Eyelid Tape|Taping the eyelids during intubation is one of the standard techniques used perioperatively under general anesthesia. This intervention would be used for the Eyelid Tape Group.
46108849|NCT00785200|Other|Chlorhexidine|Chlorhexidine-soaked disposable cloths will be distributed each Monday, Wednesday, and Friday to each enrolled detainee for a 6-month period.
46108850|NCT00785200|Other|Water|Water-soaked disposable wash cloths identical in appearance to the CHG cloths will be distributed to enrolled detainees on every Monday, Wednesday, and Friday for a 6-month period.
45469072|NCT03762889|Device|Eye Ointment|Another standard technique used perioperatively under general anesthesia is to apply an ointment to the eye for lubrication. This intervention would be applied to the Eye Ointment Group.
45469073|NCT05211414|Other|Yoga Based Daily Excercise|Subjects will be trained to perform 30 minutes of moderate level yoga daily, with instruction on breathing, self-awareness, and ways to modify poses to avoid pain. Subjects will be instructed in use of the email links to access the 30-minute instructive video. Subjects will attend weekly Zoom classes to learn additional postures and techniques, which will be reflected in their 30 minutes video (i.e. a new video for each week). At these weekly remote yoga classes, they will be asked about difficulties encountered and given advice about their personal home practice.
45598557|NCT02351973|Drug|Amiloride|"Amiloride 10mg to 20mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
46022981|NCT04248049|Other|Platelet rich fibrin|The roots of patients with diagnosis of gingival recessions will be covered with coronally advanced flap (CAF) and platelet rich fibrin (PRF) (CAF+PRF)
46022982|NCT04247893|Device|blood flow restriction|Occlusion training is an exercise approach whereby resistance exercise or aerobic exercise is performed whilst an occlusion cuff is applied to proximal aspect of the muscle.
46022983|NCT04247893|Device|Photobiomodulation|Photobiomodulation therapy is defined as the utilization of non-ionizing electromagnetic energy to trigger photochemical changes within cellular structures that are receptive to photons.
46022984|NCT04247893|Device|Placebo photobiomodulation|Placebo photobiomodulation - photobiomodulation device turned off.
46108851|NCT01023373|Drug|Medical treatment|hypotensive drugs, statins and anti-platelets
46108852|NCT01023373|Procedure|PTRS|Percutaneous transluminal renal artery stenting. The same medical therapy, as in group A, plus PTRS
46108853|NCT01023373|Device|renal artery stent|Non-drug intervention, percutaneous transluminal renal artery stent angioplasty
46108854|NCT01023373|Device|renal artery stent|Adding the renal artery stenting (in group B) to the optimal medical therapy (as in group A) that includes hypotensive drugs, statins and antiplatelet therapy
46108855|NCT00817206|Drug|LCP-Tacro|LCP-Tacro tablets will be administered orally QD, at the same time in the morning to maintain trough levels at 5-15 ng/ML. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels. LCP-Tarco (tacrolimus) tablets provided in 0.5 mg, 1 mg, 2 mg, and 5 mg tablets.
46108856|NCT00817206|Drug|Prograf|Oral prograf doses will be given BID (in the morning and evening), to maintain trough levels of 5- 15 ng/mL. Prograf capsules (tacrolimus) capsules, twice daily oral, provided in 0.5 mg, 1 mg, and 5 mg capsules.
46108857|NCT01023529|Radiation|Palliative pelvic soft-tissue radiation (external beam)|3 Gy x 10-13 (range 30 - 39 Gy total)
46108858|NCT02611518|Drug|Rosuvastatin|Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 14.
46108859|NCT02611518|Drug|JNJ-54861911|JNJ-54861911 will be administered at a dose of 25 mg once daily from Day 8 to Day 17 (in panel 1), Day 8 to 16 (in panel 2).
46108860|NCT02611518|Drug|Metformin|Metformin will be administered as a single oral 500 mg on Day 1 and Day 14.
46108861|NCT01023607|Drug|Atorvastatin|Atorvastatin 20mg/day
46022985|NCT02837341|Device|Philips®Vital Sign Device - Camera-based system (Prototype)|"Respiratory rates monitored via camera-based system and capnography simultaneously The Philips Vital Sign Device will record chest movements by camera. The program will use an algorithm to convert the chest movements into the respiratory rate"
46108862|NCT01023607|Drug|Atorvastatin|Atorvastatin, 60mg/day
46022986|NCT02837185|Procedure|Botulinum Toxin injection|Botulinum toxin injection for cervical dystonia subjects (as part of clinical care)
46022987|NCT02837185|Other|Physiological measures|These include TMS and EMG measurements
46022988|NCT00965458|Biological|Alefacept|Weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
45469074|NCT04555239|Procedure|Fascial Distortion Model (FDM)|"Only treatment of herniated trigger points, continuum distortions, and/or trigger bands will be performed.~Herniated trigger points are single areas of sharp pain within soft tissue.~Continuum distortions are single points of sharp pain overlying bony tissues.~Trigger bands are lines of pain overlying either soft or bony tissues.~Treatment with FDM is performed using firm, direct pressure over the area of the patient's pain with the provider's thumb. This pressure is applied at a single point or area indicated by the patient for herniated trigger points and continuum distortions, and along the indicated line of pain for trigger bands."
46108863|NCT01023607|Drug|Rosuvastatin|Rosuvastatin,10mg/day
45681464|NCT04601493|Behavioral|Choice Architecture Nudge|"During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient who has not had an opioid prescription within the past six months. The alert provides guidance language about opioid prescribing and prompts the PCP to open the SmartSet to order non-opioid treatment alternatives. PCPs can choose to ignore this, but opening the SmartSet is the default option. When the SmartSet is opened, PCPs can choose to click on a variety of treatment order options, including both non-opioid pharmacological options and non-pharmacological options (e.g., referral to physical therapy or pain clinic)."
46108864|NCT00706758|Behavioral|IBS school|Structured patient group education
46022989|NCT00965458|Drug|Placebo|Weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
46022990|NCT02837107|Dietary Supplement|Mind Master|80ml Mind Master / day for 8 weeks
46108865|NCT00706758|Behavioral|IBS-guidebook|Written information - IBS-guidebook
46022991|NCT02837107|Dietary Supplement|Placebo|80ml a look-alike Placebo / day for 8 weeks
46108866|NCT02609412|Other|Static compression of LMTRP|Static compression of most sensitive Triggerpoint with a foam roller (Blackroll Inc., Germany).
46108867|NCT02609412|Other|Dynamic self-myofascial release of calf|Dynamic self-massage of the calf with a foam roller (Blackroll Inc., Germany).
46108868|NCT02609412|Device|Placebo laser acupuncture of LMTRP|Used device: Laserneedle System (Laserneedle Systems GmbH, Glienicke/Nordbahn, Germany). Electrodes positioned on skin but device remains switched off.
46108869|NCT00665002|Biological|WT-1|Immune responses were to be evaluated at weeks 6 and 12 via delayed-type hypersensitivity, CD4 T cell proliferation, CD4 and CD8 T cell interferon release, as well as by bone marrow cytogenetics including polymerase chain reaction (PCR) to look for molecular evidence of disease. Patients who had an immunologic response and had not had disease progression could continue with up to 6 more vaccinations administered approximately every month. In that case, patients were to be reevaluated with bone marrows/immunologic studies after the 9th and 12th vaccination. In addition, patients would undergo evaluations for residual disease including immunohistochemistry and/or quantitative polymerase chain reaction (RQ-PCR) for WT-1 expression (on selected patients), and multiparameter flow cytometry (AML/ MDS).
46108870|NCT00665002|Drug|Montanide|The WT-1 vaccine is given with another substance, called Montanide, which clumps the WT-1 vaccine and thereby improves the immune response.
46108871|NCT00665002|Drug|Sargramostim (GM-CSF)|GM-CSF was administered at a dose 70 mcg (140ul) as a subcutaneous injection at the site of vaccination on day -2 and day 0.
46108872|NCT05757024|Device|high power laser therapy|m6 laser therapy of ASA company with multilocked wave system and synchronized emission wave lengths 808 and 905 wave lengths
46022992|NCT04249531|Drug|Amikacin Inhalation Dry Powder|Patient will inhale the weeks after iv amikacin, dry powder amikacin per inhalation once 400 mg, next week once 700 mg and the last week 1000 mg
46022993|NCT04249531|Drug|Amikacin Injectable Product|patient wil receive one dose of 400 mg amikacine intravenously in week 1
46022994|NCT02836951|Other|Withdrawal of blood|Withdrawal of blood
46022995|NCT02836639|Drug|Busulfan|Busulfan 0.8 mg/kg four times per day from day -7 to day -5
46022996|NCT02836639|Drug|Etoposide|Etoposide 400 mg/m2 from day -5 to day -4
46108873|NCT02554240|Drug|DA-5202 20mg|once a week, intra-articular injection, for 3 weeks
46108874|NCT02554240|Drug|DA-5202 10mg|once a week, intra-articular injection, for 3 weeks
45681465|NCT04601493|Behavioral|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration & nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
45681466|NCT03928288|Drug|Cabergoline 0.5 MG|Medication
45681467|NCT03928288|Drug|Placebo - Cap|Placebo capsule
46108875|NCT02554240|Drug|Na Hyaluronate 20mg|once a week, intra-articular injection, for 3 weeks
46108876|NCT05100810|Other|Natural History Study|Longitudinal assessment of disease progression of Angelman syndrome in patients
46108877|NCT05756868|Behavioral|Time restricted feeding|In the time-restricted nutrition intervention, the first meal is scheduled at 10:00 and the last meal at 18:00 (ad libitum). Eating for 8 hours and fasting for 16 hours are targeted.
46108878|NCT02611050|Behavioral|The Multi-vessel Coronary Artery Disease Option Grid|The Multi-vessel Coronary Artery Disease Option Grid is a patient decision aid used during the clinical visit. It is one page and contains a table a patient's frequently asked questions and the respective information for each treatment strategy. The Multi-vessel Coronary Artery Disease Option Grid was developed using patient and provider feedback and has been field-tested in clinic by cardiologists and surgeons.
46022997|NCT02836639|Drug|Bendamustine|Bendamustine 200 mg/m2 starting dose on day -3 and -2
46108879|NCT02611050|Behavioral|Usual Care|In usual care clinicians will discuss the patient diagnosis and treatment options typical to routine care for that clinician.
46108880|NCT03847987|Drug|RO7017773 Phase I Capsule|Participants will receive 1 single oral dose of RO7017773 Phase I Capsule.
46108881|NCT03847987|Drug|RO7017773 Phase II Tablet Unflavored|Participants will receive 3 single oral doses of unflavored RO7017773 Phase II tablet during Part 1, and 1 single oral dose of unflavored RO7017773 Phase II tablet during Part 2.
45681468|NCT04146610|Drug|an antibody drug conjugate|Multiple dose grouping
45681469|NCT02985034|Procedure|RFA|Radiofrequency ablation (RFA) is performed according to routine practice, and then safety margin is assessed by a) visual side-by-side comparison between pre-RFA MRI and post-RFA CT, and b) registration software for two modalities.
45681470|NCT03925870|Drug|KN046|Eligible subjects will be enrolled and receive KN046 (3 mg/kg) monotherapy treatment until progressive disease according to RECIST 1.1, unacceptable toxicity, completion of 2 years' KN046 treatment, or withdrawal of informed consent, whichever comes first
46108882|NCT03847987|Drug|RO7017773 Phase II Tablet Sweetened/Flavored|Participants will receive 1 single oral dose of sweetened/flavored RO7017773 Phase II tablet during Part 2.
45681471|NCT04146376|Other|Use of a postpartum diary and additional blood draws|"A diary will be used to capture postpartum hemorrhage (PPH), Wilate and tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken."
45681472|NCT04146376|Drug|VWF replacement therapy with Wilate|This study design uses on-label Wilate for VWF replacement therapy for delivery and the postpartum period in VWD patients whose VWF levels are <100% in the third trimester of pregnancy
45681473|NCT04146376|Drug|Tranexamic acid|This study design uses tranexamic acid for prophylaxis for postpartum hemorrhage for all women with VWD
45681474|NCT04146376|Other|Use of a postpartum diary and additional blood draws.|"A diary will be used to capture postpartum hemorrhage (PPH), tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken."
45681475|NCT01710657|Drug|Lacosamide 50 mg|"Active Substance: Lacosamide~Pharmaceutical Form: Film-coated tablet~Concentration: 50 mg~Route of Administration: Oral use"
46108883|NCT00660010|Drug|Lupron (leuprolide acetate)|Leuprolide acetate was administered monthly by intramuscular injection starting at 300 mcg/kg with adjustments of 3.75 mg upward, at subsequent clinic visits based on physical and laboratory parameters. Dosing continued until NDA was approved, or until subject no longer required leuprolide acetate to treat CPP.
46108884|NCT04015908|Drug|Celecoxib|Celecoxib 100mg
46108885|NCT04015908|Drug|Acetaminophen|Acetaminophen 325mg
46108886|NCT04015908|Drug|Pregabalin|Pregabalin 50 mg
46108887|NCT04015908|Drug|Oxycodone|oxycodone 5-10 mg
46108888|NCT04015908|Drug|Percocet|Percocet (oxycodone 5mg/acetaminophen 325 mg)
45681476|NCT01710657|Drug|Lacosamide 100 mg|"Active Substance: Lacosamide~Pharmaceutical Form: Film-coated tablet~Concentration: 100 mg~Route of Administration: Oral use"
46022998|NCT00972244|Drug|Dapagliflozin|once daily, 12 weeks
46022999|NCT00972244|Drug|Placebo|once daily, 12 weeks
46023000|NCT00892723|Drug|AZX100 Drug Product|Subjects were administered AZX100 0.3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
46108889|NCT00790816|Drug|Lapatinib in combination with an anti-cancer agent|Lapatinib in combination with paclitaxel, letrozole, capecitabine, capecitabine/oxaliplatin, gemcitabine, docetaxel, trastuzumab, FOLFOX4, or FOLFIRI
46108890|NCT00790816|Drug|Lapatinib|Lapatinib monotherapy
46108891|NCT00790816|Drug|Lapatinib in combination with an anti-cancer agent as specified by parent protocol|Lapatinib in combination with an anti-cancer agent as specified by parent protocol
46023001|NCT00892723|Drug|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
46108892|NCT00873041|Drug|deferasirox|Supplied as 125 mg, 250 mg and 500 mg tablets.
45469075|NCT04555239|Other|Standard Care|"The usual standard of care for extremity pain varies from provider to provider and varies from patient to patient depending upon their comorbidities but often includes some combination of the following:~X-rays, if suspicion for fracture exists~Venous duplex ultrasound, if suspicion for DVT/SVT exists~Computed tomography (CT) angiogram (CTA), if suspicion for arterial occlusion exists~C-reactive Protein (CRP)/erythrocyte sedimentation rate (ESR)/arthrocentesis is suspicion if suspicion for septic arthritis exists~Arthrocentesis if suspicion for gout exists~Splinting/casting/immobilization~NSAIDs, Tylenol, or opioids for pain control~Possibly trigger point injections~Possibly osteopathic manipulation~Recommendations to use RICE (rest, ice, compression, elevation) at home~Physical/occupational therapy referral~Orthopedic referral"
45469076|NCT03427762|Other|Rehabilitation|"Healthy cycling group: The group participates in 5 weeks of intensive cycling therapy.~Healthy xbox group: The group participates in 5 week intensive xbox therapy Healthy controll group: The group does not take any kind of therapy. PD group: We have already analyzed the results of our group, and we will compare their results with the results of healthy groups."
46108893|NCT00873041|Drug|placebo|Supplied as matching 125 mg, 250 mg and 500 mg tablets.
45469077|NCT03746041|Drug|abaloparatide|In cycle 1, patients will be treated with single-agent, subcutaneous (SQ) abaloparatide at a dose of 80 mcg/day for 28 days.
45469078|NCT03746041|Drug|bevacizumab|In cycles 2-4 (each cycle is 28 days), patients will be treated with SQ abaloparatide at a dose of 80 mcg/day and intravenous (IV) bevacizumab 5 mg/kg on days 1 and 15.
45469079|NCT01236989|Procedure|anatomical liver resection|anatomical liver resection by means of IOUS-finger compression
46108894|NCT05758506|Device|Primary Immunodeficiency (PID) Rapid Diagnostic Test (RDT)|We are evaluating the accuracy of a new rapid diagnostic screening test. There is no medical intervention with the participants in this study.
46108895|NCT00795496|Procedure|Histamine provocation|A dosimetric histamine challenge test in which the provocative dose of inhaled histamine producing a decrease of 15% in FEV1 is measured.
46108896|NCT00795496|Procedure|Skin prick tests|Skin prick testing will be performed for: birch, timothy, mugwort, alder, pine, cat, dog, horse, house dust mite, Cladosporium herbarum.
46108897|NCT00795496|Procedure|Serum IgE blood testing|One blood test to measure total serum IgE
46108898|NCT00795496|Procedure|Mantoux-testing|Tuberculin (2 TU) s.c. on the forearm. The test is read after 72 hours.
45469080|NCT01236989|Procedure|Non-anatomical liver resection|non-anatomical liver resection
45681477|NCT01710657|Drug|Placebo|Matching oral Placebo tablets twice daily for 16 weeks.
45681478|NCT04142710|Device|Telemedicine: tablet and possibly tools to perform measurements|Users of telemedicine can answer simple questions about their health condition and/or perform measurements related to their health (e.g., blood pressure, blood sugar, oxygen saturation, weight) via a tablet or a similar device. The results are transferred from the measuring devices to the tablet so that users can easily see them and track their own results over time. The results are transmitted digitally to a follow-up service. The follow-up service contacts the patient in case of signs of deterioration or when measurements lie outside what is normal values for the individual. The follow-up service provides medical support and guidance based on the patient's needs and plan for follow-up, and will, in consultation with the patient, assess whether this should contact their GP/emergency room.
46023002|NCT00892723|Drug|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
46108899|NCT00795574|Drug|infliximab|Dosing is 5mgs/kg at weeks 0,2 and 6 to complete loading dose of drug and then every 8 weeks thereafter until end of treatment phase.
46023003|NCT04286854|Diagnostic Test|Stress echocardiography with semi-supine bicycle|"The patient is accelerating against a workload that gradually increases at a constant rate, during the exercise the images will be obtained by echocardiography.~The patient begins with 25 Watts with increments of 25 Watts every 3 minutes, continuing the exercise until significant electrocardiographic changes occur or the patient starts with symptoms."
46108900|NCT00795574|Drug|Placebo Comparator|5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.
46108901|NCT05206864|Other|Medical Food: SBD111|One capsule administered twice daily with morning and evening meals for 28 days
46108902|NCT05206864|Other|Placebo|One capsule administered twice daily with morning and evening meals for 28 days
46023004|NCT02836717|Device|sacral nerve modulation|electric stimulation of the sacral nerve using an implanted electrode and stimulator
45469081|NCT03423472|Behavioral|Orange Fleshed Sweet Potato (OFSP) agriculture promotion and nutrition education on vitamin A intake|Support to farmers to grow and store OFSP in the form of agricultural extension, community based trainings and supplies, while simultaneously increasing community demand for OFSP through community-based Healthy Living Clubs. The Clubs promote OFSP, provide nutrition education, and conduct community mobilization events and social marketing of OFSP and OFSP-based processed products. Special emphasis is on women and children < 2y; especially diet diversity and vitamin A intake.
45469082|NCT03423472|Behavioral|Healthy Baby Toolkit|The toolkit consists of a demarcated bowl, a slotted spoon, and a counseling card. The demarcations on the bowl guide caregivers on age-specific meal volume and frequency. The slotted spoon promotes thicker food consistency - and therefore nutrient density - by cuing caregivers when food drips through the slots. The counseling card relies on images rather than text to reinforce messages of the previous two instruments, promote dietary diversity, and promote hygienic food preparation.
46108903|NCT02609256|Procedure|Stereotactic infarct tissue aspiration|The patient posed supine position to expose local skin and puncture point was located at 6.5 cm behind the hairline of the lesion side, and 5.0 cm lateral of midline. After routine skin preparation and disinfection, 5% lidocaine 2-5 ml was injected for local anesthesia. The skin was cut to expose periosteum by a scalpel. After skull was vertically drilled through with a 6mm diameter hole, a sterile tube with a needle in tube was put about 8 cm into centrum semiovale. The needle was put out and about 50ml necrosis brain tissue was aspirated by a 20 ml syringe. The tube was fixed into the skin about 2 cm after subcutaneous tunnel, and connected to the drainage bag. Surgical area was sterilized and wrapped by sterile gauze bandage.
46108904|NCT02609256|Other|Medical therapy|osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc
45681479|NCT04765930|Other|Q-switched nd:YAG laser toning|Q-switched nd:YAG laser toning for melasma.
45681480|NCT05582044|Other|Lower-body Negative Pressure (-25 mmHg)|The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -25mmHg LBNP.
45681481|NCT05582044|Other|Lower-body Negative Pressure (-15 mmHg)|The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -15mmHg LBNP.
45681482|NCT05582044|Other|Lower-body Neutral Pressure (0 mmHg)|In this placebo trial, the LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, but the chamber will be vented to atmosphere.
46023005|NCT03811912|Drug|CTP-543|CTP-543 administered as 8 mg tablet.
46023006|NCT03811912|Drug|CTP-543 Matching Placebo|Administered as tablets to aid treatment masking.
46108905|NCT00785434|Drug|escitalopram|Dose ranging up to 50mg
46108906|NCT02620709|Behavioral|Hula intervention|Hula and heart health education
46023007|NCT02836561|Other|Telephone message|A pre-visit telephone intervention describing availability of long-acting reversible contraceptives at time of uterine evacuation
46023008|NCT05333419|Drug|100ng/day PA5346 Latanoprost FA SR Ocular Implant|PA5346 ocular implant is a small, clear rod-shaped implant that is placed in the anterior (front) chamber of the eye, at a single timepoint, and slowly releases a drug called latanoprost free acid (100ng/day) over a period of approximately 30 weeks
46108907|NCT00785590|Drug|Dermacyd PH_DETINLYN (Lactic Acid)|
46108908|NCT00458341|Drug|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water, milk, or apple juice. Participants are to receive a total of 42 doses of ataluren during each cycle, for a total of 84 doses of ataluren in both cycles.
46108909|NCT00692081|Behavioral|Social competence training|8 group sessions multi-modal social competence training, 2-4 hours each, 2 trainers, 6-10 participants
46108910|NCT00692081|Behavioral|Special vocational training|as provided in German special centres for vocational training
46108911|NCT02610894|Other|mHealth application (PoCAH)|Participants will have unlimited access to the mHealth app via iPad Mini for 5 days post-operatively to aid in pain management
46023009|NCT04285996|Procedure|PET Scan|
46023010|NCT02836795|Biological|humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
46023011|NCT04285762|Other|LVEEA|lymphaticovenous end-to-end
46023012|NCT04285762|Other|LVESA|lymphaticovenous end-to-side
46023013|NCT04285762|Other|LVSEA|lymphaticovenous side-to-end
46108912|NCT02610894|Other|As usual standard discharge and care instructions|As usual standard discharge and care instructions are provided via iPad mini to orthopaedic ambulatory surgery patients.
46023014|NCT02836483|Drug|LCB01-0371 800mg, QD|Oral administration
46023015|NCT02836483|Drug|LCB01-0371 400mg, BID|Oral administration
46023016|NCT02836483|Drug|LCB01-0371 800mg, BID|Oral administration
46023017|NCT02836483|Drug|Tubes 3~5Tablet, QD|Oral administration
46023018|NCT02836483|Drug|Zyvox 600mg, BID|Oral administration
46023019|NCT02836483|Drug|LCB01-0371 1200mg, QD|Oral administration
46023020|NCT02836171|Drug|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
46108913|NCT00790894|Drug|ixabepilone|Arm A: ixabepilone will be given at a dose of 40 mg/m2 as a 3-hour intravenous infusion on Day 1 in a 21 days cycle.
45681483|NCT03906682|Behavioral|RAP Club|RAP Club was adapted from a trauma treatment program called Structured Psychotherapy for Adolescents Responding to Chronic Stress (SPARCS). Core program components include psychoeducation, mindfulness, and cognitive-behavioral strategies.
46108914|NCT00790894|Drug|ixabepilone|Arm B: ixabepilone will be given at a dose of 20 mg/m2 as a 3-hour intravenous infusion on Days 1, 8 and 15, then 1 week off in a 28-days cycle.
46108915|NCT02623283|Other|No intervention given|Participants will have a full dental examination but no operative intervention
46108916|NCT00785668|Drug|AER 001|10 mg dry powder administered using a handheld device
46108917|NCT02623127|Drug|Sunitinib|
46108918|NCT05263492|Drug|Lenvatinib|Lenvatinib once a day by mouth every day
46023021|NCT02836171|Drug|Itraconazole Capsules|rifampicin was administered in the morning 0.5 hours after breakfast
46023022|NCT00971932|Drug|Cetuximab|The initial dose of cetuximab will be 400 milligram per square meter (mg/m^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m^2 as an IV infusion over 60 minutes.
45683928|NCT01923142|Biological|Outer-Root-Sheath Melanocytes Suspension|The treatment consists in depositing a suspension of autologous outer-root-sheath melanocytes, derived from patient's plucked hair follicles, and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
46023023|NCT00971932|Drug|Cisplatin/Carboplatin|Subjects will receive 100 mg/m^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle. If subject developed non-hematological toxicities to cisplatin, carboplatin (area under curve 5 [AUC5]) will be administered as an IV infusion over 60 to 120 minutes on Day 1 of each 3-week treatment cycle.
46023024|NCT00971932|Drug|5-Fluorouracil|Subjects will receive 1000 mg/m^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 4 of each 3-week treatment cycle.
46023025|NCT02840305|Other|Evaluation of visual function|
46023026|NCT02840305|Other|Magnetic Resonance Imaging|
46023027|NCT00629746|Device|Medtronic Xomed Nerve Integrity Monitor (NIM)|"patients receive surgery will be intubated with Medtronic Xomed NIM EMG endotracheal tube and the device will be connected to the monitoring system~The channel leads from the NIM EMG reinforced endotracheal tube were connected to a NIM-response monitor~A Prass monopolar probe was used in direct contact with the vagus nerve and RLN for laryngeal nerve stimulation.~The stimuli were generated from the NIM-Response monitor for vagal and RLN stimulation.~The NIM-response monitor was set to run with a 50 millisecond time window and an amplitude scale at 0.2 mV/division. Event capture was activated with a threshold at 100 μV. Peak to peak amplitudes of evoked EMG activities were directly read on the monitor screen."
46023028|NCT04400929|Drug|Sargramostim|Dosage for IV Leukine® injection: 125mcg/m2/day over a 4-hour period for up to 5 days.
46023029|NCT04400929|Other|Normal Saline 0.9%|IV normal saline 0.9% for 5 days
46023030|NCT05170672|Biological|Abatacept|
46023031|NCT03640624|Combination Product|Multidisciplinary treatment|"Assessment by gynaecologist and dermatologist, resulting in tailored vulvar care, including daily topical lidocaine 5% ointment. Other topical or oral medication, such as oestradiol cream or oral antidepressants will be prescribed on individual basis.~Tailored physiotherapy targeting muscular dysfunction, utilizing: Patient education, pelvic floor muscle exercises (contraction and relaxation), EMG-biofeedback. Low frequent electrical stimulation, massage, stretching and myofascial release and trigger point treatment of the pelvic floor. Desensitization exercises (manually or vaginal dilator). Relaxation and body awareness. Minimum one visit per month.~Guided imagery sessions, minimum twice a week using a sound track that is developed for vulvodynia patients."
46108919|NCT05263492|Drug|Pembrolizumab|Pembrolizumab through a needle or tube in a vein (intravenously, IV) every 3 weeks.
46108920|NCT04134611|Device|Hyaluronic acid injection|Injection of Hyaluronic acid in knees of those who has degenerative changes after arthroscopic treatment of lateral patellar compression syndrome
46108921|NCT04134611|Device|No injection of Hyaluronic acid|No injection of Hyaluronic acid was done
46108922|NCT02620631|Drug|Morphine|Subjects receive intrathecal morphine pre-operatively to determine its level of efficacy in acute pain control post-operatively when used in conjunction with post-operative PCA morphine
46108923|NCT02620631|Drug|Placebo|Subjects receive intrathecal, preservative-free normal saline pre-operatively in conjunction with post-operative PCA morphine
45681484|NCT03906682|Behavioral|Healthy Topics|Co-investigator Dr. Sibinga developed the Healthy Topics curriculum to function as an active control condition for randomized controlled trials in both clinic-based and school-based studies of mindfulness instruction for urban youth. Adapted from the Glencoe Health Curriculum (McGraw Hill), it was designed to control for the effects of a positive adult, time and attention, a small group learning environment, engaged instruction, and interesting material. The Healthy Topics curriculum has been successfully implemented as an effective active control condition, with student engagement and participation comparable to the intervention arm. The curriculum includes information about nutrition, exercise, sleep, drug use, and other topics related to physical health.
45469083|NCT03423472|Behavioral|Standart of care|Government standard of care for nutrition education through the Health Development Army
45469084|NCT05188014|Behavioral|Luteal Phase Aerobic Exercise|Participants will perform 45 minutes of moderate (60% VO2peak) aerobic exercise on a cycle ergometer during the last week of active pill consumption.
45681485|NCT04145518|Drug|Naproxen Sodium|Participants will be randomized to take either a placebo pill or a single 550 mg naproxen sodium pill.
46108924|NCT00816036|Behavioral|Smoking Cessation Guideline Implementation|"1. Enhanced academic detailing of staff nurses (face-to-face training, feedback on group performance, and periodic check-ins with both nurse managers and peer leaders); 2. Adaptation of the computerized information system (modified nursing admission database that includes pertinent questions about smoking, computerized quick orders for smoking cessation medications), 3) Patient self-management support (self-help materials, fax referral of motivated patients to state quit line), and 4) nursing peer leaders on each study unit."
46108925|NCT00795652|Behavioral|Distance Treatment for postpartum depression|Evidence-based, cognitive behavioural intervention for women with postpartum depression
46108926|NCT02622971|Other|PBMT|Effects of phototherapy isolated and/or combined with cryotherapy in post-exercise skeletal muscle recovery.
46108927|NCT02622971|Other|Cryotherapy|Effects of cryotherapy isolated and/or combined with phototherapy in post-exercise skeletal muscle recovery.
46108928|NCT00795730|Drug|NSA-789|
46108929|NCT00795730|Other|placebo|
46108930|NCT04027920|Drug|Shenghua Decoction|Three days' shenghua decoction treatment
46108931|NCT04030572|Drug|Clonidine Pill|0.1 mg tabs, one by mouth daily at bedtime for one week
46108932|NCT00795808|Drug|Metformin|500mg tds for 6 months
45681486|NCT03021772|Drug|Neostigmine|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
46108933|NCT00795808|Drug|Placebo|One tablet tds for 6 months
46108934|NCT00795808|Drug|Metformin + Clomiphene|500mg tds + Ovulatory dose for 6 months
46108935|NCT00795808|Drug|Metformin|500mg tds for 6 months
46108936|NCT00795808|Drug|Clomiphene|Ovulatory dose for 6 months
46108937|NCT04135781|Drug|nab paclitaxel|nab paclitaxel （120mg/m2；iv；d1，8）
46108938|NCT04135781|Drug|Tegafur|S-1 （<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid）
46108939|NCT04135781|Drug|Oxaliplatin|Oxaliplatin（130mg/m2 , iv, d1）
46108940|NCT04135781|Drug|Capecitabine|Capetabine（1000 mg/m2 po, d1-14 bid ）
46108941|NCT04046692|Other|Hospital School Experience, point of view of the children|Operators of the PANAS-C, PH-C and VAS ask the children to answer the questionnaire before/after the school lesson; then they ask the children to make 2 paintings about hospital and not hospital school experience.
46108942|NCT04046692|Other|Hospital School Experience, point of view of the hospital teachers|operators interview hospital teachers and make them complete a questionnaire (CEESQ)
46108943|NCT04046692|Other|Hospital School Experience, point of view of the non hospital teachers|operators interview the teachers and make them complete a questionnaire (CEESQ)
46108944|NCT04046692|Other|Hospital School Experience, point of view of parents|Operators interview parents
46108945|NCT04135547|Device|intra-osseous access vs. intra-venous access|EZ-IO®: The Arrow® Intraosseous Vascular Access System from Teleflex IV-catheter: form local qualified manufactures
46108946|NCT05758350|Behavioral|home based IOPI swallow training|Use IOPI for tongue and labial muscle resistance training. Conventional training was the same as controlled group.
46108947|NCT00795964|Other|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 6 ml/kg predicted body weight
46108948|NCT00795964|Other|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 12 ml/kg predicted body weight
45469085|NCT05188014|Behavioral|Follicular Phase Aerobic Exercise|Participants will perform 45 minutes of moderate (60% VO2peak) aerobic exercise on a cycle ergometer within 5 days of starting their menses.
45469086|NCT03767959|Procedure|Chen's U-Suture|Chen's U-Suture is a new technique of the invaginated end-to-end pancreaticojejunostomy with transpancreatic transverse U-sutures
46108949|NCT04135313|Drug|Capecitabine|2000 mg/m2, bid, per os, days 1-14
46108950|NCT04135313|Drug|Oxaliplatin|130 mg/m2 iv day 1
45469087|NCT03767959|Procedure|Classic pancreatic duct to mucosa|A Classical anastomosis technique for Pancreaticojejunostomy
45469088|NCT01239563|Drug|antithymocyte globulin|Thymoglobulin 1.5mg/kg, 4 doses Thymoglobulin 6mg/kg, single dose
46108951|NCT04135313|Drug|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
46108952|NCT04135313|Radiation|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 54 Gy on primary tumor in 2 Gy fractions
46108953|NCT04135313|Procedure|Rectal cancer surgery|Laparoscopic or open total mesorectal excision or extralevator abdominoperineal resection
46108954|NCT05271864|Device|Apple Watch|Apple Watch
46108955|NCT00785746|Other|Core|We have devised a series of core strength training exercises that can be easily and safely performed under the supervision of trained staff. The exercises will be individualized depending on the participants' ability and health conditions. The majority, but not all, of exercises will be performed on or with exercise balls of different sizes and shapes, round for more advanced persons and oval for more frail persons.
46108956|NCT05262972|Other|Conservatory treatment|Personalized plantar orthosis
46108957|NCT05262972|Other|Innovate treatment|Personalized plantar orthosis + percutaneous electrolysis
46108958|NCT00692159|Drug|TRC102 + pemetrexed|Oral TRC102 solution + IV pemetrexed
46108959|NCT00692315|Drug|Methylcobalamin (methylB12)|75 ug/Kg methylB12 every 3 days by subcutaneous injection
46108960|NCT02609022|Biological|CV-MG01|"3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.~Two dose levels: low and high dose."
45469089|NCT01239563|Drug|Basiliximab|Intravenous 20mg, day 0&4
45469090|NCT03423394|Behavioral|Motivational Enhancement Therapy|The MET intervention will consist of three 45-90 minute telephone delivered sessions that will be staggered to occur 1 week, 1 month, and 2 months after the baseline assessment. The first MET session intervention will involve a counselor using motivational interviewing (MI) strategies to establish an empathic therapeutic relationship and focus learning about the PTSD symptoms the participant is experiencing and exploring ambivalence about seeking treatment services. MET sessions 2 and 3 will focus on identifying and responding to risk factors for dropping out of treatment (increases in ambivalence, avoidance behavior, concerns about stigma, life chaos), identifying and responding to barriers to participant's active engagement in treatment, and facilitating enrollment in alternate therapeutic resources if necessary.
45469091|NCT03423394|Behavioral|Treatment as Usual|TAU will include a written referral list comprised of PTSD resources including information on in-person treatments, self-help, web-based and bibliotherapy options. At the completion of the study, participants in the TAU condition will be offered the MET intervention.
45681487|NCT03021772|Drug|Dexamethasone|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
45681488|NCT04149886|Procedure|cardiac ganglion plexus ablation(cardioneuroablation)|Cardiac ganglion plexus ablation in the left atrium will be performed before implanting permanent pacemaker in patients with sick sinus syndrome.
45681489|NCT04149886|Device|Permanent pacemaker implantation|DDD permanent pacemaker will be implanted in the paticipants.
46108961|NCT02609022|Biological|Placebo|3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
46108962|NCT02623049|Other|New oral anticoagulant pharmacodynamic analysis (blood level assesment)|
46108963|NCT02608944|Drug|Adenosine|Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
46108964|NCT02608944|Drug|Regadenoson|Regadenoson: 0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
46108965|NCT02608944|Drug|O-15 labeled radioactive water|O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
46108966|NCT02608944|Device|MRI|Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
46108967|NCT02608944|Device|PET Imaging|Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day.
45681490|NCT05584774|Procedure|PELDAN|percutaneous endoscopic lumbar dissectomy and annuloplasty and nucleoplasty
45681491|NCT05581654|Procedure|Salpingectomy|Salpingectomy by vaginal natural orifice transluminal endoscopic surgery (v-NOTES).
46108968|NCT00696917|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection 3 different vaccine lots
46108969|NCT00696917|Biological|Engerix™-B|3-dose intramuscular injection
45681492|NCT05581576|Drug|Pitolisant|Pitolisant initial dose 8.9 mg, titrated depending on symptomatic response.
46108970|NCT00913614|Drug|Eplivanserin (SR46349)|Oral administration
46108971|NCT05755230|Other|No intervention|No intervention
46108972|NCT05756478|Other|Medication review|This is a feasibility study of implementing a pharmacist-led medication review using prescribing tools (e.g. STOPP/START, Beers Criteria)
46108973|NCT00664534|Drug|Insulin Glargine|patient glucose-level dependent, injection, as needed per patient glucose level, 48 weeks
46108974|NCT00664534|Drug|Insulin Lispro Premix (mid-mixture and low-mixture)|patient glucose level dependent, injection, as needed per patient glucose level, 48 weeks
46108975|NCT05758272|Behavioral|mobile phone-based simple physical exercise reminder to help quit smoking|Regular messages supporting participants in practicing simple physical exercises and assist in managing cravings will be sent to participants via IM apps and scheduled in a tapering manner for 3 months (twice per week in the first month to once per week in the third month). Images and videos explaining and demonstrating the simple physical exercises will be sent to the participants via IM apps, which serves as a reminder and supporting materials for participants. The benefits of exercise in SC will be explained. We will also encourage the practice of moderate/ vigorous exercises to further improve the physical activity and well-being of the participants. Various delivery formats of messages will be considered to attract participants' interest such as text, emojis, voice, image, animation, and video. The simple exercises consist of a) Zero-time exercises (ZTEx), b) handgrip exercises and c) resistance exercises.
46023032|NCT03640624|Combination Product|Treatment as usual|Treatment as usual in accordance with local guidelines by specialist in gynaecology, including a minimum of two visits (when diagnosis is made and after 3 - 6 months)
46023033|NCT02836405|Device|Transcranial Magnetic Stimulation|Single pulses of TMS as well as continuous theta burst stimulation (cTBS) will be applied to the motor cortex.
46023034|NCT04285138|Other|phantom limb exercise|phantom limb exercises (that is, active imaginal efforts to move the phantom), under the assumption that the neural pathways involved in performing actual movements are activated when using one's imagination to move the phantom extremity
46023035|NCT04285138|Other|conventional treatment|"Mirror therapy uses a flat mirror placed parasagittally in front of the patient's body with the reflective surface toward the sound limb so that the amputee sees the reflection of the sound limb in the mirror [Figure 1]. This reflection mimics the amputated limb, and with the movement of the intact limb, the mirror provides an optical illusion that the phantom limb is moving simultaneously.~Equipment:~Therapy mirror: A standing mirror (130 cm × 46 cm) with wooden frame and base (62 cm × 65 cm) Routine physiotherapy The general exercise programme consisted of strengthening, stretching, dynamic, and isometric exercises based on the level of amputation and their assessment results. Participants allocated to the control group were advised to continue rehabilitation at their respective physiotherapy out-patient departments as frequently as possible. Participants were given a diary and advised to record their activities, specifying the nature, frequency and duration of each activity"
46023036|NCT02862652|Other|Blood sample|Blood sample to quantify microparticles and to study expression and activity of the tissue factor on their surface
45681493|NCT04145752|Procedure|Nurse-led femoral nerve block|The nurse perform a femoral nerve block in the emergency department in patients diagnosed with a hip fracture (x-ray)
46023037|NCT04284982|Behavioral|16-week supervised heavy resistance training program with weekly undulating periodization|Participants trained a whole-body program consisting of squat, bench press, deadlift and pendlay row two times per week for 16 weeks
46023038|NCT00970684|Biological|bevacizumab|15 mg/kg on day 1 of a 21-day cycle
46023039|NCT00970684|Drug|docetaxel|75 mg/m2 on day 1
46023040|NCT00970684|Drug|gemcitabine hydrochloride|900 mg/m2 on days 1, and 8,
46023041|NCT00967330|Drug|bevacizumab [Avastin]|10mg/kg iv every 2 weeks
46023042|NCT00967330|Drug|irinotecan|125mg/m2 iv every 2 weeks
46023043|NCT00967330|Drug|temozolomide|75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
46023044|NCT02863276|Procedure|Intensified insulin therapy|
46023045|NCT00967018|Drug|Degarelix|
46023046|NCT00965146|Device|Scorpio® CR Total Knee System|All subjects will be implanted with a femoral component, a tibial insert, a tibial tray and a resurfaced patella.
46023047|NCT02863042|Procedure|Repair Deltoid Tendon|
46023048|NCT02863042|Other|Ankle Fracture Without Deltoid Tendon Repair|Standard of care
46023049|NCT04286152|Drug|Mirabegron 50 MG|The experimental drug is administered to patients PO once a day for 7 days from stent insertion until removal
46023050|NCT04286152|Drug|Placebo oral tablet|A sugar pill manufactured to mimic Mirabegron 50 mg tablet is administered to patients PO once a day for 7 days from stent insertion until removal
46023051|NCT00966940|Drug|Travoprost 0.004% ophthalmic solution (TRAVATAN)|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
46023052|NCT00966940|Drug|Tafluprost 0.0015% ophthalmic solution|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
46023053|NCT03631420|Biological|Human Umbilical Cord Derived-Mesenchymal Stem Cells|Cohort 1 : 3 million cells/kg ; Cohort 2 : 10 million cells/kg ; Cohort 3 : 30 million cells/kg
46023054|NCT03623464|Other|Mobile health application and Fitbit + standard of care|Mobility data will be generated using a mobile health tracker designed for smartphone devices, which allows the phone to automatically and passively (no patient input needed) capture information on the patient's activity; i.e. if the person is walking, remaining stationary, or moving at a rapid speed (eg. in a car). The app will prompt patients once daily to answer a series of questions that will collect patient reported symptoms and health status data. Physicians will be alerted to abnormal values within 24-48 hours and patients will be triggered to call their physicians immediately if the values are outside of normal parameters.
46023055|NCT03623464|Other|Standard of care|Post-operative standard of care information
46023056|NCT00965848|Drug|Doripenem|Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
46023057|NCT04284748|Other|Plyometric exercise with blood flow restriction|"Blood flow restriction training is an exercise protocol based on the method of limiting blood flow with external pressure by pneumatic tourniquet from the proximal of the muscle to be strengthened. Blood flow restriction (Occlusion) during pliometric exercises for 8 weeks, a pneumatic tourniquet (Kaatsu Master) proximal to the thigh will be applied to each patient within a safe pressure range. The pressure to be applied to the patient will be calculated with the following formula described in the literature.~Pressure = 0.5 x (systolic blood pressure) + 2 x (thigh circumference) + 5 Application will be done for a maximum of 15 minutes, then rest for 10-15 minutes and other exercises will continue.~Plyometric training with blood flow restriction. Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)"
46023058|NCT04284748|Other|Plyometric exercise|Plyometric training Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
46023059|NCT04284748|Other|Routine physiotherapy program|Anterior and lateral plan exercise (3x10 rep) Open kinetic quadriceps and hamstring strengthening exercise (3x10 rep) Lunge exercises on different ground (3x10 rep) Single leg squat exercise on different ground (3x10 rep) Anterior and lateral walking exercise in a squatting position with an exercise band (40 step) Balance and proprioceptive exercises
46023060|NCT03447574|Other|ethanol dilution|Ethanol has been validated against deuterium oxide, the invasive gold standard for determining totally body water
46108976|NCT05758272|Behavioral|regular text-based intervention|The control group will receive 6 regular messages via IM at twice per month within 3 months. These messages cover simple cessation advice and reminders for telephone follow-ups.
46108977|NCT00594035|Device|Spinal Sealant System|
46108978|NCT00594035|Device|Standard of care|Standard of care: devices intended to provide a watertight closure
46108979|NCT02620475|Device|SutureSafe|SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.
46108980|NCT00913848|Drug|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
46108981|NCT00913848|Drug|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
45681494|NCT04149262|Drug|Fiasp|Fiasp® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
46023061|NCT04284826|Procedure|Endoscopic injection of Mitomycin-C on bougie-dilated refractory benign esophageal stricture|
46108982|NCT00790972|Drug|Sinofresh|two sprays in each nostril three times daily for one week
46108983|NCT00790972|Drug|Placebo|two sprays in each nostril three times daily for one week
46108984|NCT00796042|Other|Usual care|Subjects will be encouraged to implement the standard wound care protocol that is consistent with the National (CAWC) and Provincial (RNAO) best practice guidelines for the treatment of pressures ulcers. This wound care program will be customized to subject's needs based on the results of the assessment performed by the wound care specialist. A registered dietitian will review blood values associated with nutritional status and make recommendations for dietary changes. Wherever possible, implementation of this wound care program will be coordinated with the subjects' current health care team and appropriate referrals to home care agencies or specialists will be initiated where needed. Subjects assigned to this group will continue their current level of activity (bed rest). Any equipment or services will be obtained through the usual provider agencies.
46108985|NCT00796042|Other|Pressure management and Mobility program|Subjects are provided with the same customized wound care program as the usual care group and a pressure management and mobility program that is customized to the individual's needs. This program is based on an in depth home assessment performed by a registered Occupational (OT) or Physical Therapist (PT). Pressure Management Program: A qualified OT or PT will examine the subject on all in-use surfaces and observe all transfers to identify sources of friction and shear, and any strength or balance deficits, identifying what equipment/services are required to manage pressure, improve mobility, and reduce friction and shear. Mobility Program: A qualified PT will assess strength, balance, range of motion, and functional independence with transfers and other ADLs and will develop a mobility program to optimize functional independence and improve strength and balance required for safe and effective transfers. Program to be implemented within one month of this evaluation.
46108986|NCT04135469|Other|Referral for tax preparation services|Printed materials will be provided with contact information for tax preparation services at BMC and other sites in the city.
46108987|NCT04135469|Other|Navigator assisted tax preparation services at BMC|A study navigator will assist the participant in accessing the BMC located tax preparation services.
45681495|NCT04149262|Drug|Novorapid|Novorapid® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
45681496|NCT04149262|Device|640G pump|MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link
45681497|NCT03647800|Biological|APVO436|APVO436
45681498|NCT04145908|Procedure|midline mesh reinforcement|augmentation of midline closure by nonabsorbsble mesh
46023062|NCT04284670|Other|EXERCISE|The intervention group will perform an 8 week program, 2 sessions a weak for a total of 16 sessions. training will be done on a designated negative gradient treadmill, first two session will be in -5% gradient. sessions 3,4 and 5 will be in -10% gradient, all of the following sessions will be in -15% gradient. exercise intensity will be 70%-80% out of maximal heart-rate. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. each training will start and end with a 2 minutes of warm up and calm down under neutral gradient. Every two minutes of training, Visual Analog Scale and Rating of Perceived Exertion data will be collected from the participants.
46023063|NCT03442192|Other|PrEP Care Anywhere Services|"PrEP Virtual Clinic Visits. PrEP clinical care will follow guidelines as established by the CDC for PrEP clinical evaluation and follow-up. Appointments will be set up in the same process as any practice visit and require the same clinical documentation and billing requirements, but will have a separate clinic designation for the visit type. At any time during the study, a patient can request a face-to-face visit with the provider. The provider may also request a face-to-face visit based on patient presentation and/or laboratory results.~The typical visit options will include:~On demand peer interim visits- participants can text, chat (via PrEPme app) or call to access an on demand virtual support visit with a peer Case Manager (CM).~HIV and Sexually Transmitted Infection (STI) at Home Self-Testing"
46108988|NCT04135391|Behavioral|Aerobic exercise training|All recruited subjects underwent 36 times of moderate-intensity continuous training (MICT) at 60% of peak oxygen consumption (VO2peak) for 30 mins, and 10or had high-intensity interval training (HIIT) at alternative 80% and 40% VO2peak with the same training times and duration.
45681499|NCT05581420|Drug|Ferrous fumarate|Patients randomized in the oral group, will all be prescribed ferrous fumarate 200 mg d.d. for the first 4 weeks. Then, depending on their iron status, 100 mg d.d. for the following 12 weeks or 4 more weeks 200 mg d.d. followed by 4 weeks 100 mg d.d.. If iron levels are still too low after 12 weeks, the intervention has failed.
46108989|NCT05756322|Drug|LBS-007|Open Label.
46108990|NCT02620163|Drug|telmisartan/amlodipine 40/5mg|
46023064|NCT04284904|Diagnostic Test|aGVHD biomarker|To verify the effectiveness of aGVHD biomarkers monitoring in predicting aGVHD risks
46108991|NCT02620163|Drug|YH22162 40/5/12.5 mg|
46108992|NCT02620163|Drug|telmisartan/amlodipine 80/5mg|
45681500|NCT05581420|Drug|MonoFer|Study patients will be treated with intravenous iron. The brand name of the iv iron is dependent on the hospital policy and the doses will be according to recommended guidelines (weight of patient). Iv iron is intramural medication without add-on status and needs infusion at daycare.
46108993|NCT02620163|Drug|YH22162 80/5/25 mg|
46108994|NCT02620163|Drug|telmisartan/amlodipine 40/5mg placebo|
45681501|NCT05581342|Diagnostic Test|Punch biopsy (3mm)|In case of suspicion of recurrence or a voluntary control biopsy; a punch biopsy (3mm) was obtained conform regular care.
45681502|NCT05581264|Behavioral|Diabetes Self-Management Education Program|diabetes self-management education and counseling program with follow-up via phone for the intervention group for 24 weeks
46108995|NCT02620163|Drug|YH22162 40/5/12.5 mg placebo|
46108996|NCT02620163|Drug|telmisartan/amlodipine 80/5mg placebo|
45683929|NCT01923142|Biological|Placebo|The treatment consists in depositing a solution made of saline and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
45683930|NCT05241184|Diagnostic Test|Multiparametric stress CMR protocol|Multiparametric stress CMR protocol
46108997|NCT02620163|Drug|YH22162 80/5/25 mg placebo|
46108998|NCT02620241|Other|sitting position|
46108999|NCT02622893|Drug|Transperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
46109000|NCT02622893|Drug|Retroperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
46109001|NCT05758116|Drug|Tislelizumab|Tislelizumab: 200mg d1,q21d*17
46109002|NCT00912821|Drug|6 L dialysate|6 L peritoneal dialysis solution
46109003|NCT00912821|Drug|8 L dialysate|8 L peritoneal dialysis solution
46109004|NCT00692393|Procedure|Hartmann intervention|sigmoid resection, peritoneal and rectal lavage, terminal stoma
46109005|NCT00692393|Procedure|Protected anastomosis resection|sigmoid resection , peritoneal and rectal lavage, anastomosis, diverting stoma
46109006|NCT02624921|Other|There was no intervention.|Participants were transported one day to a urban setting, one day to a green space, one day to a beach. No intervention was done.
46109007|NCT05758038|Procedure|Radiofrequency ablation/Microwave ablation|thermal ablation by radiofrequency and Microwave
45681503|NCT03022474|Behavioral|Healthy Lifestyles Intervention|The program included three major components. The first component consists of live lectures to kindergarten staff about basic nutrition and food concepts that attempted to correct false beliefs. The second component was a health curriculum for children that focused on promoting healthy nutrition habits and a healthy living style. Preschools were required to ensure that children received a health education lesson every two weeks. The third component was aimed at educating parents and consisted of lectures every two months, preschool-home communication every week and child growth monitoring every three months.
46023065|NCT04284592|Procedure|Remote ischemic post-conditioning (RIP)|The limb RIP was applied after leaving of cardiopulmonary bypass and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on an arm and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff.
46109008|NCT00922727|Biological|L. reuteri|The oil drops contains 10^8 CFU (colony forming units). As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10^8 CFU/ 5 drops. The dose given is within the release limit which is greater than 2 x 10^8 CFU/ 5 drops and less than 8 x 10^8 CFU/ 5 drops.
46023066|NCT04204564|Device|pactlitaxel PAD device|Peripheral vascular intervention on femoral-popliteal occlusive disease with paclitaxel and non-paclitaxel devices.
46023067|NCT04285528|Drug|General anesthetia Fentanyl and Propofol|Patients were anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Proper classic laryngeal mask airway was inserted afterwards.
46109009|NCT00922727|Biological|Sunflower Oil|As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10^8 CFU/ 5 drops.
46109010|NCT00570310|Drug|Comparator: pregabalin|pregabalin (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
46109011|NCT00570310|Drug|Comparator: Placebo (unspecified)|pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
46109012|NCT00696995|Drug|biphasic insulin aspart 30|Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
46109013|NCT00664066|Drug|DYNEPO (epoetin delta)|dose, dose frequency, route of administration (iv or sc) and duration will be determined by the investigator according to their normal prescribing habits, as this is an observational study
46109014|NCT02620085|Procedure|blood sampling|blood sampling
46109015|NCT02610738|Behavioral|Junior KICk-OFF education programme|The Junior KICk-OFF course is an age appropriate eduction course which aims to improve the understanding and knowledge of children with type 1 diabetes. It has been designed with school teachers and educationalists to meet the learning needs of children aged 4-11yrs
46109016|NCT02555020|Dietary Supplement|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
46109017|NCT02555020|Dietary Supplement|Allocated to Placebo group|Patients received 400 mL of oral free water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before.
46109018|NCT02555020|Dietary Supplement|Allocated to MN NPO group,|Patients received NPO from MN.
46109019|NCT04676958|Dietary Supplement|Vitamin K2|Vitamin K2
45681504|NCT03021070|Other|Conditional cash transfer|For each honoured and verified health visit that is made on time following enrollment, a woman receives a cash transfer. The value reduces by one quarter for each week of delayed visit, and no reward is offered for any visit made 3 weeks after the appointment date. Transportation cost by a local taxi to the health facility, and is a value that has been approved by the research ethics committee for many studies in the region as reasonable compensation for research participants.
46109020|NCT04676958|Dietary Supplement|Micro-crystalline cellulose|Micro-crystalline cellulose
46109021|NCT02619929|Drug|Vinorelbine oral|
46109022|NCT00785902|Device|AtriCure Bipolar System|
46109023|NCT00796198|Drug|Xalatan+Cosopt|Xalatan ophthalmic solution one drop at 10pm + Cosopt ophthalmic solution one drop at 8am and one drop at 8 pm
46109024|NCT00796198|Drug|Xalatan|Xalatan ophthalmic solution one drop at 10pm
46109025|NCT00692549|Device|ultrasound|
46109026|NCT00791050|Device|Allon Thermowrap. MTRE Advanced Technologies Ltd.|"Thermowrap set at 37 °C before induction of anesthesia and maintained until initiation of CPB; during CPB set to monitoring and set again to 37 °C from rewarming during CPB to end of surgery."
46109027|NCT02622503|Drug|Rituximab|This is an observational study. Patients with rheumatoid arthritis and having received treatment previously will be assessed for the treatment responses.
46109028|NCT00791206|Procedure|Real preconditioning|Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 15 mmHg greater than systolic arterial pressure.
46109029|NCT00791206|Procedure|Sham preconditioning|Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 10mmHg with the same cycling protocol as the real preconditioning.
46109030|NCT05326685|Other|video with korotkoff sounds|The State-Trait Anxiety Inventory short version (STAIS-5, STAIT-5) and the student introduction form were applied at the beginning of the study. Then Intervention participants were shown and listened visual video with korotkoff sounds before blood presssure measurement. Afterwards, blood pressure was measured to the students 3 times and 3 measurements were recorded. After the application about 2 hours later, the students State Anxiety Inventory short version (STAIS-5) form was filled again by students.
46109031|NCT00814710|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
46109032|NCT00814710|Biological|Tritanrix-HepB/Hib|Intramuscular injection, 3 doses
46109033|NCT00814710|Biological|Hiberix|Intramuscular injection, 3 doses
46109034|NCT00814710|Biological|Tritanrix-HepB|Intramuscular injection, 3 doses
46109035|NCT00796276|Drug|IR OROS paliperidone and ER OROS paliperidone|
46109036|NCT05298371|Behavioral|Corrected Sitting postures|Change after being in Corrected Sitting postures
46109037|NCT05298371|Behavioral|Natural / relaxed sitting postures|Change after being in relaxed sitting postures
46109038|NCT05298371|Behavioral|Corrected Standing posture|Change after being in Corrected Standing posture
46109039|NCT05298371|Behavioral|Natural / relaxed standing postures|Change after being in relaxed standing postures
46109040|NCT00796354|Drug|MOVICOL|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
46109041|NCT00796354|Drug|Sugar Pill|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
46109042|NCT00796432|Drug|OROS paliperidone|
46109043|NCT02555566|Procedure|Blood sampling|Blood sampling is done for Kidney transplant recipients for evaluation of the polymorphisms and EETs dosage
45469092|NCT05308524|Diagnostic Test|ICU scoring system in covid 19|The intensive care unit (ICU) at Assiut University Hospital, which is supervised by the staff members of the Chest Diseases Department and designated to deal with critically ill Covid 19 patients.
46109044|NCT02555566|Procedure|flow-mediated distal stimulation of the forearm radial artery by cutaneous heating|Flow-mediated distal stimulation of the forearm radial artery by cutaneous heating for Kidney transplant recipients
46109045|NCT05757960|Procedure|Physiotherapy|Various physiotherapeutic techniques are used in three defined sessions. Before the first session, a dental examination is performed and a clinical functional status is obtained to assess the extent of temporomandibular dysfunction. The results are recorded on validated questionnaires.
46109046|NCT05755074|Procedure|Ablation through left arm|Ablation through left arm
46109047|NCT05755074|Procedure|Ablation through femoral vein|Ablation through femoral vein
46109048|NCT00786058|Drug|OFF in experimental arm|OFF was given according to a six week cycle. FA (500 mg/m2 , 0.5h, i.v.) and 5-FU (2,600 mg/m2, 24-hour, i.v.) were administered on days 1, 8, 15, and 22. Oxaliplatin (85 mg/m2 , 2-4 h, i.v.) was administered directly before FA/ 5-FU on days 8 and 22.
46109049|NCT00871169|Drug|Irinotecan, oxaliplatin, and cetuximab|"Irinotecan at 90 mg/m2 intravenously every two weeks (administered over 60 minutes) + Oxaliplatin at 60 mg/m2 intravenously every two weeks(administered over 60 minutes) + Cetuximab at 250 mg/m2 intravenously every two weeks (administered over 90 minutes).~The treatment interval (one cycle) is every 14 days."
46109050|NCT02610114|Other|Z-Score and computer algorithm|In addition to the routine Z-score for zygote selection, if needed, the photographs of the zygotes already taken for quality and safety reasons are analysed using the new computer algorithm. Within a few minutes it generates a score, determining the quality of the cells. The two best cells upon Z-score result and new computer algorithm result are selected for first transfer.
46109051|NCT02610114|Other|Z-Score|After fertilisation pronuclei and nucleoli can be seen inside the cells by microscope. Routinely, the alignment of nucleoli can be used generating a score, the Z-score 1-4, established by Scott. Two zygotes getting the best Z-score are selected for cell culture and the cells that develop to embryo stage are used for first transfer.
46109052|NCT00791284|Drug|Intermediate release (IR) Paliperidone|
46109053|NCT00791362|Other|National programme for accreditation and improvement of GP|The national programme for accreditation and improvement of general practice. This procedure consists of a package of activities, including audit, feedback, improvement plans, and follow-up. It is partly based on new theories on quality improvement, including the use of market forces and pressure for accountability. For the purpose of the study, the intervention group will be requested to focus their improvement plans in the first year on cardiovascular diseases. The control group is requested to focus their improvement plans in the first year on other domains and to provide cardiovascular care as usual.
46109054|NCT02620319|Device|SX-ELLA Stent DV Tracheal (DV Stent)|The trachea is intubated with a rigid bronchoscope while participants are placed under total intravenous anesthesia and jet ventilation. The delivery apparatus containing the stent is introduced through a rigid tube to the desired depth under visual control. Then the stent is deployed and its position is determined and, if necessary, stent is repositioned using rigid forceps. In-stent balloon dilation is carried out. If needed, thoracic surgeon can secure the stent in place via external (percutaneous) fixation: one suture is passed through the stent, the tracheal wall, soft tissues, and skin; the suture is then knotted on the skin of the neck. The suture is removed two to three weeks after implantation.
46109055|NCT00814632|Drug|CC-10004|CC-10004 20 mg. twice a day for 12 weeks
46109056|NCT00786136|Drug|rosuvastatin|rosuvastatin
45469093|NCT03767803|Other|Non-interventional study|This is an observational, non-interventional study.
46109057|NCT02622737|Other|Functional training|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a functional training and 5 minutes of respiratory exercises.
46109058|NCT02622737|Device|Stationary bike|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Stationary Bike exercise and 5 minutes of respiratory exercises.
46109059|NCT02622737|Device|Exergaming|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Virtual Reality exercise (performed by Xbox360 with KinectTM sensor) and 5 minutes of respiratory exercises.
46109060|NCT00796588|Other|remote preconditioning|Three periods of 10 minute occlusion of blood supply to leg using a pneumatic tourniquet
46109061|NCT04031352|Other|implementation of CATCH scale|subject completed the CATCH scale
46109062|NCT02620007|Drug|Ciprofloxacin|oral Ciprofloxacin 500 mg bis in die (bid) for 12 weeks
46109063|NCT02620007|Drug|Rifaximin|oral Rifaximin 800 mg bid for 12 weeks
46109064|NCT02620007|Drug|Ciprofloxacin Placebo|a placebo of Ciprofloxacin bid for 12 weeks
46109065|NCT02620007|Drug|Rifaximin Placebo|a placebo of Rifaximin bid for 12 weeks
45681505|NCT04149340|Drug|Cataract surgery|Patient's satisfaction and surgeon's satisfaction was assessed by four Lickert's scales, ranging from one to four. hemodynamic parameters before incision, 10 min post-incision and at the end of the surgery
46109066|NCT02554942|Drug|Epoetin beta|Participants will receive weekly SC injections of epoetin beta beginning at 450 IU/kg, with doses adjusted according to hemoglobin level. Treatment will continue for a total of 16 weeks.
46109067|NCT02619851|Biological|ALLO-ASC-DFU|Dressing for Second Deep degree Burn injury
46109068|NCT02619851|Device|Conventional Therapy|Typical therapy conducted for burn injury patients
46109069|NCT00786214|Other|Acupuncture|Patients will be stimulated at specific acupuncture points as determined for treatment of the disease by certified acupuncturists
46109070|NCT00786214|Other|Sham acupuncture|Patients will be given sham acupuncture treatment at dummy acupuncture points
46109071|NCT02619773|Procedure|mupirocin ointment|Mupirocin ointment will be applied after skin closure. A standard island dressing will be placed over the incision.
45469094|NCT04982159|Other|There is no intervention. This is an observational study.|There is no intervention. This is an observational study.
45681506|NCT03021226|Behavioral|Fatherhood Development|Fatherhood Development is a curriculum based program provided by a facilitator through a skill-based education intervention.
45681507|NCT03021226|Behavioral|Relationship Enhancement|Relationship Enhancement is a curriculum based program provided by a facilitator through a skill-based education intervention.
46109072|NCT00791440|Behavioral|Cognitive-Behavior Therapy|Weekly individual Cognitive-Behavior Therapy (CBT) to target hallucinations and delusions in addition to standard psychiatric treatment.
45469095|NCT05308368|Device|Ultrasound Imaging|We will collect ultrasound images during the grasping motion for both groups
45469096|NCT05308368|Device|Electromyography|We will collect electromyography (EMG) signals of both the flexor and extensor muscles of the wrist during the grasping motion for both groups
45469097|NCT05308368|Device|Inertial Measurement Units (IMU)|We will use data from the ultrasound images and EMG to develop a tremor model. The model will be validated in comparison to joint angle measurements from an Inertial Measurement Unit (IMU) collected during the grasping motion
46109073|NCT00791440|Other|Standard Psychiatric Treatment|Standard psychiatric treatment.
46109074|NCT02622659|Drug|Fuganlin Oral Liquid|"less than 1 years old: 5mL each time and three times a day~1~3 years old: 10mL each time and three times a day~4~6 years old: 10mL each time and four times a day~7~12 years old: 10mL each time and five times a day"
46109075|NCT02622659|Drug|Xiaoer Jiebiao Oral Liquid|"1~2 years old: 5mL each time and twice a day~3~5 years old: 5mL each time and three times a day~6~14 years old: 10mL each time and twice a day"
46109076|NCT02555488|Device|diode laser|MB and diode
46109077|NCT02555488|Device|diode laser|diode laser
46109078|NCT02555488|Drug|Methylene blue|Methylene blue and diode laser was used
46109079|NCT02554864|Drug|lidocaine|Local anesthetic
46109080|NCT02554864|Drug|ropivacaine|Local anesthetic
46109081|NCT04134377|Other|Protein Food Snack|The intervention is 6-months using a food snack with control being three months prior to and three months after-study invention whereby serum albumin levels will be collected monthly. If patients are participating in a supplement program, they will be maintained throughout all ten months of the study so long as the criteria for the supplement program (enrollment and discontinuation) is still being met.
46109082|NCT02622425|Dietary Supplement|Placebo|maltodextrin
46109083|NCT02622425|Dietary Supplement|PD01|Carotenoid-producing Bacillus strain PD01
46109084|NCT00786292|Other|Assisted mechanical ventilation|Patients will be mechanically ventilated with noisy PSV and PSV in random sequence
46109085|NCT00851318|Drug|Certolizumab pegol|Subcutaneous (SC) injection
46109086|NCT00851318|Drug|Methotrexate|Methotrexate dose between 6 to 8 mg/week.
46109087|NCT00791596|Other|Ergonomic Intervention|The intervention used in this investigation was an ergonomic adjustment of the VDT workstation design
46109088|NCT00791752|Drug|AZD4017|ascending single doses (start dose 2 mg), oral suspension
46109089|NCT00791752|Drug|Placebo|Placebo
46109090|NCT00786370|Drug|dexmedetomidine|Propofol or dexmedetomidine infusion will be started according to the randomized treatment allocation. The propofol group will receive a bolus of 2mg midazolam and 100mcg fentanyl and then continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved. The dexmedetomidine group will receive a bolus of dexmedetomidine 1mcg/kg for 10 minutes and then a continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
46023068|NCT04285528|Combination Product|PFK|A mixture of 5 mcg/ml of Fentanyl, 5 mg/ml of Propofol, and 5 mg/ml of Ketamine was used. Each patient received an initial dose of 0.5 mg/kg from the solution, then after waiting for 60 seconds, another 0.5 mg/kg were given. Maintenance was given as boluses of 0.2- 0.33 mg/kg every three to five minutes. No Laryngeal mask airway nor endotracheal tube were inserted, and the patients were breathing spontaneously through a simple face mask on a support of 3 L/min O2.
46023069|NCT00629824|Drug|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
46023070|NCT00629824|Drug|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
45469098|NCT05308368|Device|Functional Electrical Stimulation (FES)|We will use the develop closed-loop control methods for tremor suppression using information from the ultrasound-image based tremor models. FES will be used to provide stimulation that will help with tremor suppression
46023071|NCT00629824|Drug|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 180 ug/week and ribavirin 1000-1200 mg/day for 24 weeks
46023072|NCT04285216|Other|Dry Needling|Hot pack 10 mints,stretching,Neck isometrics, dry needling(DN) and Strain counterstrain(SCS)
46023073|NCT04285216|Other|Strain counter strain|Hot pack 10 mints, stretchings,Neck isometrics, Strain counterstrain(SCS)
45681508|NCT03021226|Behavioral|Financial Literacy|Relationship Enhancement is a curriculum based program provided by a facilitator through skill-based education intervention.
45469099|NCT03427684|Radiation|Hypo-fractionated radiotherapy|Hypo-fractionated radiotherapy with fraction >2Gy .
45469100|NCT03427684|Drug|S1|S-1 80mg/m2/day, orally intake on radiotherapy days.
45681509|NCT02984956|Device|pleth variability index|
45469101|NCT03762811|Device|NanoFUSE® Bioactive Matrix|NanoFUSE® is placed into bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure.
45469102|NCT01321255|Drug|FDC|FDC includes a combination of 100 mg aspirin, 40 mg simvastatin, and 2.5;5;10 mg Ramipril
45469103|NCT01321255|Drug|Separately drugs, simvastatin, aspirin and ramipril|Aspirin 100 mg once a day Ramipril 2.5; 5; 10 mg once a day Simvastatin 40 mg once a day
45681510|NCT04148794|Behavioral|echo-assisted advanced life support|"Integrated point-of-care ultrasound skill in to the setting of resuscitation, and critical condition patients.~Educate the participants to use these protocols and monitoring if there were improvement of patient's outcomes"
45681511|NCT05580952|Device|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement system
45683931|NCT05241028|Drug|Ensartinib|Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity
46023074|NCT00961636|Drug|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks
46023075|NCT00961636|Drug|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks.
46023076|NCT00961636|Drug|Extended-release niacin (ERN)|Two 1g tablets ERN (2g total) once daily for 12 weeks.
46023077|NCT00961636|Drug|Placebo to ERN/LRPT|One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks
46023078|NCT04285060|Device|Samsung GEMS-H|Subjects will participate in 18 sessions of training in the outpatient clinic with a licensed physical therapist. Therapy sessions will include 30 minutes of task specific training and another 15 minutes of the session can be used to focus on patient specific goal areas related to functional mobility and balance. Training sessions will occur 2-3 times a week for 6-8 weeks to complete the training protocol.
46023079|NCT02862262|Device|ARIES Bordetella Assay|
46109091|NCT00786370|Drug|Propofol|continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved
46023080|NCT02862340|Genetic|Genetic test|
46109092|NCT00786370|Drug|Dexemedetomidine|continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
46109093|NCT02624609|Other|Control without pomegranate juice|Control meal of 109 g white bread and 200 ml water (containing the same amount and type of sugars naturally present in pomegranate juice) to which the response of the test meal with pomegranate juice will be compared to.
46109094|NCT02624609|Other|Test with pomegranate juice|The test meal will contain 109 g white bread and 200 ml of pomegranate juice whose response will be compared to that of the control meal.
46109095|NCT00796900|Drug|Dantrolene|Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
46109096|NCT00796900|Drug|Placebo|Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
46109097|NCT02619461|Other|Exercise|Exercise at 70%VO2max on a recumbent bicycle for 30 minutes to investigate the effects of exercise at high intensities on appetite and biomarkers of appetite and inflammation.
46109098|NCT00791830|Drug|Irbesartan|Tablets, 300 mg * 1 daily, 1 year
46109099|NCT00791830|Drug|Placebo matching irbesartan 150 mg|Tablets, 300 mg * 1 daily, 1 year
45838359|NCT03513081|Behavioral|Educative session|The experimental group receive nine educational sessions (one per week) about different vegetables and, at lunch time, they are exposed to a different vegetable. If they try it, they will receive a sticker. In each session, researcher will record their preference for the vegetable and the quantity that they consumed in a scale from one to three (1- the child prooved it; 2 - the child repeated it; 3 - the child ate all the quantity). In the end of 9 sessions, all children (experimental and control group) will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
45838360|NCT03500354|Dietary Supplement|Nutrient drink|High calorie drink with therapeutic supplements
45598558|NCT02351973|Drug|Hydrochlorthiazide and Amiloride|"HCTZ 12.5 to 25mg & + Amiloride 5mg to 10mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
45838361|NCT03489018|Biological|PCV10|Experimental arms will receive a lower dose of the intervention than the marketed dose.
45838362|NCT03489018|Biological|PCV13|Experimental arms will receive a lower dose of the intervention than the marketed dose.
45838363|NCT03483337|Other|MRI examinations|Patients will be imaged on a 1.5 T or 3 T MR scanner either from GE or Philips. Patients will receive a test-retest scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at main campus, will also be imaged weekly during their course of treatment.
45838364|NCT03483337|Other|MRI examinations|Patients will be imaged on a 1.5 T or 3T MR scanner within one week prior to treatment initiation and at two months and four months after treatment completion (+/- 1 week).
45838365|NCT03469960|Drug|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
46023081|NCT04283422|Diagnostic Test|Biofire filmarray|"Identification of microorganisms including:~Isolation of microorganisms:~The sample will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates,~Identification of the organism by Vitek2~Antibiotic sensitivity test of the organism by Vitek2~Identification of the organism by Biofire filmarray"
46023082|NCT00964678|Drug|Carvedilol|twice daily oral treatment in escalating dose
46023083|NCT00964366|Drug|clindamycin and benzoyl peroxide|Daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide
46023084|NCT00964366|Drug|Dapsone gel|Twice-daily applications of dapsone gel
46023085|NCT03545464|Drug|Placebo Oral Tablet|Placebo of cortancyl Oral Tablet 20mg
46023086|NCT03545464|Drug|Cortancyl Oral Tablet|Cortancyl oral Tablet 20 mg
46023087|NCT03545464|Drug|Levocetirizine Oral Tablet|Levocetirizine Oral Tablet 5 mg
46023088|NCT02861326|Device|Gracey Curettes|
46023089|NCT02861404|Genetic|skin flakes collection|viral status assessment of skin flakes
46023090|NCT03523702|Drug|PembroRT|Patients whose tumors are found to have high (≥ 50%) PD-L1 expression will automatically be placed in the PembroRT group. These patients will receive three intravenous treatments with pembrolizumab, followed by four weeks of daily radiotherapy, followed by up to 12 more treatments with pembrolizumab. Pembrolizumab is given as an intravenous infusion once every three weeks. This treatment course will last, in total, up to one year.
46023091|NCT03523702|Drug|ChemoRT|Patients whose tumors are found to have low (< 50%) PD-L1 expression will automatically be placed in the ChemoRT group. These patients will receive radiotherapy over a course of four to seven weeks. During radiotherapy, patients will also receive two standard chemotherapy agents (carboplatin and paclitaxel) once each week. Following completion of chemotherapy and radiotherapy, patients may receive additional treatments with chemotherapy or immunotherapy as part of routine care. These treatments are optional and are not required by this clinical trial.
46023092|NCT04284514|Drug|AKB-9778 Ophthalmic Solution|AKB-9778 Ophthalmic Solution
46023093|NCT04284514|Drug|Placebo Ophthalmic Solution|Matched vehicle-control
45469104|NCT04958837|Other|FIFA 11+ protocol with additional Core training exercises|Slow paced running exercises of 8 minutes' duration (2 rounds each), followed by Strength, plyometric and balance exercises including 3 sets of 20-30 sec of The Bench, Sideways Bench each side, Nordic Hamstring strengthening, single leg stance balance training, squatting and high speed running. The protocol will end with additional core training exercises including leg raises, crunches, superman, plank hip twist, and supine bridge. Each exercise plan will be progressively increased. Core training will be followed by 30 sec stretch of major muscle groups.
45469105|NCT04958837|Other|FIFA 11+ protocol|Slow paced running exercises of 8 minutes' duration including running straight, running with hip out, running hip in, running circling partner, running shoulder contact and running quickly forward and backwards (2 rounds each), followed by Strength, plyometric and balance exercises including The Bench, Sideways Bench each side, Nordic Hamstring strengthening and single leg stance balance training, squatting and jumping. All exercises will be progressively increased as per established protocol. The final phase of the study includes fast running for 2 minutes.
45469106|NCT03417310|Device|"H joystick"|A joystick that corrects lateral displacement and angulation for multi-direction reduction
45469107|NCT03417310|Procedure|Common reduction methods|Manual reduction methods without the assistance of any devices
45469108|NCT05016960|Behavioral|Sleep-SMART|Sleep-SMART will be a treatment for insomnia that will follow the standard 6 session 50-minute CBT-I format and will deliver CBT-I treatment along with training in select CogSMART strategies to enhance intervention learning and adherence. It will be delivered via video-based telehealth.
45469109|NCT01883297|Biological|Re-stimulated tumor-infiltrating lymphocytes (TILs)|Intravenous infusions: Dose level 1 (3 patients): 3x10^7 TILs (with maximum 3x10^6 autologous dendritic cells); Dose level 2 (3 patients): 1x10^8 TILs (with maximum 1x10^7 autologous dendritic cells); Dose level 3 (3 patients): 3x10^8 TILs (with maximum 3x10^8 autologous dendritic cells)
45469110|NCT01883297|Biological|Interleukin-2|Subcutaneous injections of IL-2 x 4 days during the first week and x 5 days the second week with 2 days of rest in between each week of dosing
45469111|NCT01883297|Drug|Cyclophosphamide|Intravenous infusion: 30 mg/kg/day for 2 days (Day -3 and -2 prior to infusion of TILs)
45469112|NCT03427606|Procedure|Continuous Locked Suture vs Traditional 5-points suture for Laparoscopic Sacral Colpopexy|To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using continuous locked suture vs traditional 5-points suture for mesh fixation
45469113|NCT03762577|Other|Ground-based walking training|Patients will attend a 2-day 30-minute ground-based walking training under the supervision of a physiotherapist. Patients will walk for 1-2 days in a week without supervision. According to the Modified Borg Scale, the dyspnea intensity will be 3-4 (medium to slightly difficult) and the heart rate will be completed to not exceed 120 min / pulse. Heart rate of patients will be followed by finger type pulse oximeter
45469114|NCT03638778|Drug|Semaglutide 3 mg|Semaglutide 3 mg will be administered once daily (OD) orally in the morning from day 1 to 5.
45469115|NCT03638778|Drug|Semaglutide 7 mg|Semaglutide 7 mg will be administered OD orally in the morning from day 6 to 10.
45469116|NCT03638778|Drug|Semaglutide B 3 mg|Semaglutide B 3 mg will be administered OD orally in the morning from day 1 to 5.
46109100|NCT04137809|Device|AMBLE|Treadmill walking while wearing AMBLE device; three times a week for two weeks; 45-60 minutes per session.
45469117|NCT03638778|Drug|Semaglutide B 7 mg|Semaglutide B 7 mg will be administered OD orally in the morning from day 6 to 10.
45469118|NCT03638778|Drug|Semaglutide C 3 mg|Semaglutide C 3 mg will be administered OD orally in the morning from day 1 to 5.
45469119|NCT03638778|Drug|Semaglutide C 7 mg|Semaglutide C 7 mg will be administered OD orally in the morning from day 6 to 10.
45469120|NCT03638778|Drug|Semaglutide D 3 mg|Semaglutide D 3 mg will be administered OD orally in the morning from day 1 to 5.
45469121|NCT03638778|Drug|Semaglutide D 7 mg|Semaglutide D 7 mg will be administered OD orally in the morning from day 6 to 10.
45469122|NCT01146119|Biological|Multimeric-001, 500 mcg|Adjuvanted Multimeric-001 was administered twice with an interval of 19-23 days.
45469123|NCT01146119|Biological|Adjuvanted PBS|Adjuvanted PBS was administered twice with an interval of 19-23 days.
46109101|NCT00786448|Drug|Darifenacin, Emselex (BAY79-4998)|Patients from routine practice
45469124|NCT01146119|Biological|PBS and TIV 15%|PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 15% dose of commercial seasonal trivalent vaccine (season 2011) was administered.
45469125|NCT01146119|Biological|PBS and TIV 50%|PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 50% dose of commercial seasonal trivalent vaccine (season 2011) was administered.
45598559|NCT03520621|Other|No intervention|no intervention
45598560|NCT04831619|Drug|PET scanner with injection of 18 FDG (18F-2-fluoro-2-deoxy-D-glucose) (radiolabel)|A PET scan will be performed in the patients included, in addition to the conventional imaging workup (MRI, endovaginal and pelvic ultrasound).
45598561|NCT02295397|Other|food|food provocation, skin testing, blood sampling
45598562|NCT02231411|Procedure|V-DCC|Ventilation with CPAP 5 cm H2O between inflations and Delayed clamping of the umbilical cord for 60 seconds
45598563|NCT02231411|Procedure|Delayed cord clamping|Delayed clamping of the umbilical cord for 60 seconds
45838366|NCT03469960|Drug|Nivolumab|Nivolumab 3 mg/kg every 2 weeks
45838367|NCT03455582|Other|Clinical assessment|Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
46109102|NCT00692705|Drug|Radioligand (11C)AZD2995|Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers.
45838368|NCT03455582|Other|Ecological evaluation|Virtual reality task and Actual reality
46109103|NCT00692705|Drug|Radioligand (11C)AZD2184|Single dose of i.v solution. Once for AD patients respective healthy volunteers.
46109104|NCT00791986|Device|ULB , LB|"ULB: The patients breath in slowly without resistance via the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks.~LB : The patients breath in slowly against resistance of 20 cmH2O provided by the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks."
45469126|NCT03417232|Procedure|CAF|The design of the flap consisted of two horizontal beveled incisions (3mm in length) and two slightly oblique beveled incisions. The resulting trapezoidal-shaped flap was elevated in the coronal-apical direction. The suture of the flap started with two interrupted periosteal sutures performed at the most apical extension of the vertical releasing incisions; afterwards, it proceeded coronally with other interrupted sutures, each of them directed, from the flap to the adjacent buccal soft tissue, in the apical-coronal direction. The last sling suture allowed for the stabilization of the surgical papillae over the inter-dental connective tissue bed and allowed for a precise adaptation of the flap margin over the underlying convexity of the crown.
45469127|NCT03707821|Device|senofilcon A TEST Lens|JJVC Investigational Contact Lens
45469128|NCT03707821|Device|senofilcon A CONTROL Lens|Acuvue Oasys
46109105|NCT04137653|Drug|nab-Paclitaxel+carboplatin|Nab-P (Abraxis BioScience, LLC., Mclrose Park, IL, USA; drug license No. H20091059), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; drug license No. Guoji Zhunzi H20020181), AUC=2 mg•min/mL, intravenous drip for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
46023094|NCT02861248|Procedure|Fractional micro-plasma radiofrequency treatment|After the patient's scars were subjected to a mild cleanser and 70% alcohol, a topical cream of 5% lidocaine hydrochloric acid (Beijing Ziguang Medication Manufacture Corporation Ltd, Beijing, China) was applied to the entire scar surface under occlusion for 60-90 min before treatment to achieve local anesthesia. Fractional micro-plasma radiofrequency treatment (Pixel RF, Accent XL; Alma Lasers, Caesarea, Israel) was applied using a roller tip at 50-80 watts. Three or four passes were made in different directions over each affected area. A high rolling speed of roughly 5 cm/s was manually controlled. This treatment was accompanied by an air cooler (Cryo 5; Zimmer, Warsaw, IN, USA) for pain control. All patients attended three to five treatment sessions at intervals of 8-16 weeks.
46109106|NCT04137653|Drug|Paclitaxel+carboplatin|Paclitaxel (Yangtze River Pharmaceutical Co., Ltd., Taizhou, Jiangsu Province, China; drug license No. Guoyao Zhunzi H20053001), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin, AUC=2 mg•min/mL, intravenous infusion for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
45469129|NCT03423316|Behavioral|Supervised exercise therapy|The therapy will be conducted three times each week for 12 weeks. Each session takes 1 hour, consisting of 5 minutes of warmup activities, 50 minutes of intermittent exercise, and 5 minutes of cool-down activities. Exercise consists of walking on a treadmill initiated at 2 mph and 0% grade, until claudication pain becomes moderately severe. After claudication pain subsides, the subject will restart the walk. At the end of the session, the total exercise duration will be recorded. After a patient is able to walk 8-10 minutes at the initial workload, the grade is increased by 1-2%, or the speed is increased by 0.5 mph as tolerated.
45469130|NCT04546581|Biological|Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is derived from the plasma of individuals who recover and develop neutralizing antibodies. Participants will receive a single infusion.
45469131|NCT04546581|Other|Placebo|Participants will receive a single infusion of the placebo (saline).
45469132|NCT04546581|Drug|Remdesivir|Remdesivir will be given to participants in both groups as standard of care (SOC).
45469133|NCT02204254|Device|Radiofrequence|Associated to arm radiofrequence
45469134|NCT02204254|Drug|Doxycycline|doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
45469135|NCT04609644|Other|Digital Tools for Asthma Self-Management|Please see description of active study arm.
46023095|NCT04283344|Other|KY Ticket to Healthy Food Benefits|Households in the treatment group received an extra monthly SNAP benefit amount through two new intervention-related deductions to the SNAP benefit formula
46023096|NCT02860078|Device|Ultrasound|Location and function of sacral epidural space with ultrasound
46023097|NCT02860078|Device|Radioscopy|Location and puncture of the sacral epidural space only with fluoroscopy
45598564|NCT02231411|Procedure|Dry and and if apneic initially can stimulate by gently rubbing the back for approximately 30 seconds with warm sterile towels|
45681512|NCT03905434|Genetic|miRNA sampling|Blood samples for miRNA testing will be collected from all subjects (control and patients diagnosed with acute ischemic stroke)
45598565|NCT02355405|Device|lung ultrasound|lung ultrasound investigations were performed right before and after the surgical procedure.
45598566|NCT02355405|Radiation|thoracic computed tomography|thoracic CT were performed within one hour after the LUS investigation
45681513|NCT03904498|Drug|Tolcapone|Tolcapone 100 mg tablets
45681514|NCT03904498|Drug|Placebo|Placebo tablets
45683932|NCT01572909|Drug|Bendavia (MTP-131)|0.05 mg/kg/hr
45683933|NCT01572909|Drug|Placebo|Identically appearing placebo
45683934|NCT01572675|Drug|etorocoxib|Administered as 30 mg or 60 mg oral film-coated tablets
45683935|NCT01572675|Drug|celecoxib|Administered as 100 mg or 200 mg oral hard capsules
46023098|NCT02859922|Device|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
45469136|NCT05302128|Other|Cold vapor|Before surgery, the socio-demographic data of the patients will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of nausea and vomiting before and 15 minutes after the cold vapor application in the recovery room and at the 2nd, 6th,12th, and 24th hours after the cold vapor application in the postoperative service.
45469137|NCT01312935|Drug|PMX-60056|investigational drug
45469138|NCT03707587|Drug|M7824|Patients will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week, for up to 12 weeks total treatment (6 cycles).
45469139|NCT03925077|Other|Movement-to-Music|The M2M program has been developed for onsite instruction and will be repurposed into an eHealth version. The program is based on the positive effects of exercise and music on both physiological and psychosocial outcomes in people with disabilities. Investigators aim to advance our current M2M program by enabling more robust personalization features, allowing people with SCI to individualize their M2M program. Movement and tempo-based adaptations will also be available. A typical M2M session will consist of tailored movement routines starting with a warmup using range of motion exercises, followed by muscle strengthening, cardiorespiratory, and/or balance routines, and ending with a cool down emphasizing breathing and mindfulness.
45469140|NCT03925077|Other|Standard Exercise Training|The SET program is based on the NCHPAD 14-Weeks to a Healthier You program launched in 2008. Exercise videos including range of motion, muscle strengthening, cardio and balance routines performed both seated and standing have been developed and will be restructured for use in this study. The SET program will be delivered through the same platform as M2M.
45469141|NCT03423004|Procedure|Biopsy|the sample will be taken by superficial cutaneous biopsy in psoriasic patients
45469142|NCT05299632|Diagnostic Test|99mTc-MIBI planar imaging and SPECT/CT.|Participants will undergo a Tc-MIBI scan and management will be as per the finding of the Tc MIBI scan which is the standard of care.
46023099|NCT02859922|Device|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
45469143|NCT05299632|Diagnostic Test|F- 18PSMA PET/CT imaging study|F-18 PSMA is an FDA-approved imaging agent used for PET/CT for evaluating metastatic prostate cancer. The findings of the images of F-18 PSMA will be shared with the referring /treating surgeon. However, the findings will not influence the management.
45681515|NCT04405960|Drug|Alfacalcidol 1 MCG Oral Capsule|The subjects in the intervention group were given 1 µg oral capsule alphacalcidol once daily Subjects in the control group were given placebo once daily with similar capsule shape and color to the capsule given to the intervention group. The process of alphacalcidol and placebo encapsulation were carried out by pharmacists in the pharmacy depot under the supervision of researchers and CRO Equilab. Alphacalcidol and placebo were put into plastic pots containing 30 capsules for every 4 weeks for each subject. The pot had an etiquette written explaining how to consume the drug (after breakfast between 7 - 10 a.m.). The drugs' packaging and code numbering were carried out by CRO Equilab to ensure a double-blind procedure. As a control, each subject was equipped with a monitoring card. Alphacalcidol and placebo were given for 12 weeks without interruption. Monitoring of compliance and side effects was performed by physicians every 2 weeks.
45683936|NCT01550289|Biological|Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
45683937|NCT01550289|Biological|Placebo: NaCl 0.9% solution|0.5 ml, Subcutaneous
46023100|NCT02860936|Drug|Lenvatinib|Lenvatinib will be self orally administered at 24 mg daily, on a continuous basis in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Study drug should be taken at approximately the same time each morning.
46023101|NCT04283266|Dietary Supplement|Synbiotic|Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of synbiotic (Bifidobaterium animalis lactis Vesalius 002 and Fructo-Oligosaccharrides) for 5 days, then they received daily 1 sachet for the next 25 days
46023102|NCT04283266|Dietary Supplement|Placebo|Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of placebo (maltodextrin and sucrose) for 5 days, then they received daily 1 sachet for the next 25 days
46023103|NCT04281550|Other|Think Drink|The Think Drink Guide that had three interacting components. The 'policy' component was directed at the governance of the care home, whereas 'practice' components were directed at hydration procedures and processes, and 'educational' components that provided learning resources for care home staff to develop knowledge and understanding of hydration care. Think Drink was implemented through a short awareness-raising educational programme and accompanying information booklet detailing a range of practices (including organisational, system and individual practice) designed to encourage hydration.
46023104|NCT00630214|Dietary Supplement|Oral calcium plus vitamin D|calcium supplementation took 3 g/day oral calcium (1 g every 8 h) plus 1 mcg/day vitamin D (0.5 mcg every 12 h), beginning on the night of surgery and continuing for 14 days.
46023105|NCT00630214|Dietary Supplement|Oral calcium alone|calcium carbonate (3 g/day, 1 g every 8 h)
46023106|NCT04204486|Behavioral|Exercise|Functional strength training, 1 hour, 3 times a week.
45469144|NCT01321567|Drug|rabeprazole sodium|Doses of 10 mg or 20 mg twice daily may be administered orally to reflux esophagitis patients for a further 8 weeks when proton pump inhibitor treatment is ineffective. However, a dose of 20 mg twice daily should only be administered to patients with severe mucosa injury.
45469145|NCT04289025|Other|Exercise|A set of exercises are provided to each patient.
45469146|NCT03417076|Drug|Bexagliflozin|Bexagliflozin tablets, 20 mg, and bexagliflozin by IV
45469147|NCT03901755|Drug|Alprolix|Extended half-life factor IX product
45469148|NCT05294172|Drug|KL-A167|KL-A167 4-6 cycles for combined therapy.KL-A167 maintenance.
45469149|NCT05294172|Drug|Gemcitabine|4-6 cycles for combined therapy
45469150|NCT05294172|Drug|Cisplatin|4-6 cycles for combined therapy.
45469151|NCT05294172|Drug|Placebo|4-6 cycles for combined therapy.Placebo maintenance.
45469152|NCT03416920|Other|Wellframe|Wellframe mobile phone app
45469153|NCT03638544|Dietary Supplement|Reduced gluten bread and Pasta compared o normal gluten bread and Pasta|Pasta with low gluten (50% of the normal) content achieved by optimization of techological parameters such as dough yield, time of fermentation and concentration of fungal proteases The gluten reduction is obtained without any other intervention of wheat breeding or the endogenous proteolytic enzymes of flours.
45469154|NCT02192008|Biological|Salmonella Typhi|
46109107|NCT04137497|Diagnostic Test|The Coma Recovery Scale-Revised and the Nociception Coma Scale-Revised (NCS-R)|All enrolled DOC patients were evaluated at least five times over one week by two trained professionals using the Chinese version of the CRS-R. During the evaluation of the patient's consciousness level, the NCS-R was used to evaluate the pain response of all patients in random order at least once, and the best behavioral response (i.e., the highest score) of each subscale was recorded during resting, noxious, and physiotherapy conditions, respectively, according to the NCS-R guidelines.
45469155|NCT02192008|Biological|Salmonella Paratyphi|
45469156|NCT03427372|Behavioral|anxiety scale, depression scale|post spinal puncture headache and backache will be assess by using visual analogue scale, anxiety will assess by beck anxiety scale, depression mood will assess by beck depression scale
45469157|NCT03416842|Device|Training with 4D Motion Capture Device|Participants will be given access to a tablet-based application and non-invasive sensors that will track movements of the upper extremity and will prompt daily exercise. Participants will be encouraged to use the device daily for 30 consecutive days, up to one hour per day.
45469158|NCT03164655|Drug|Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil|Oxaliplatin 100 mg/m² infusion in 2 hours, Cetuximab 500mg/m² infusion in 2 hours, Bevacizumab 5 mg/kg infusion in 30 minutes, Panitumumab 6 mg/kg, Irinotecan 180 mg/m² over 90 minutes to begin 30 minutes after folinic acid infusion is started, Leucovorin 400 mg/m² infusion in 2 hours, 5-Fluorouracil 2400 mg/m² infusion continuous in 46h
45469159|NCT04373694|Procedure|vaginoscopy|vaginal distension with hysteroscope for hysteroscopy morcellation (without speculum or tenaculum forceps)
45469160|NCT04373694|Procedure|standard hysteroscopy|speculum, paracervical block before hysteroscopy morcellation
45469161|NCT02561273|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
45469162|NCT02561273|Drug|Cyclophosphamide|Given IV
45469163|NCT02561273|Drug|Doxorubicin Hydrochloride|Given IV
45681516|NCT04405960|Drug|Sugar pill|The subjects in the control group were given placebo containing simple sugar oral capsule once daily with similar capsule shape and color to the capsule given to the intervention group. The process of alphacalcidol and placebo encapsulation were carried out by pharmacists in the pharmacy depot under the supervision of researchers and CRO Equilab. Alphacalcidol and placebo were put into plastic pots containing 30 capsules for every 4 weeks for each subject. The pot had an etiquette written explaining how to consume the drug (after breakfast between 7 - 10 a.m.). The drugs' packaging and code numbering were carried out by CRO Equilab to ensure a double-blind procedure. As a control, each subject was equipped with a monitoring card. Alphacalcidol and placebo were given for 12 weeks without interruption. Monitoring of compliance and side effects was performed by physicians every 2 weeks.
46109108|NCT00797056|Drug|G-CSF|G-CSF 5 mcg/kg/day SQ daily for 10 days
46109109|NCT00797056|Drug|Placebo|Saline SQ daily for 10 days
46109110|NCT00797056|Drug|Aspirin|Aspirin 75 mg/day for 14 days
46109111|NCT00797056|Drug|Clopidogrel|Clopidogrel 75mg/day daily for 14 days
46109112|NCT02622269|Device|Patient-regulated compression device|Compression of the abdomen with a patient-regulated compression device
46109113|NCT02622269|Device|Standard compression device|Compression of the abdomen with the standard compression device
46109114|NCT02554162|Other|Rye products with varying structures|The satiating effect of rye products with various structures will be studied
45469164|NCT02561273|Drug|Etoposide|Given IV
45469165|NCT02561273|Other|Laboratory Biomarker Analysis|Correlative studies
45469166|NCT02561273|Drug|Lenalidomide|Given PO
45469167|NCT02561273|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
45469168|NCT02561273|Drug|Prednisone|Given PO
46109115|NCT00593957|Drug|Dextromethorphan|Subjects will be randomized to receive one of three dosage groups either 0.25 mg/kg per day; or 2.5 mg/kg/day; or 5mg/kg/day of Dextromethorphan Polistirex (Delsym)oral syrup, which will be given exactly 12 hours apart in two divided doses during the 6 month trial.
46109116|NCT00593957|Drug|Dextromethorphan|Dextromethorphan polistirex. Doses are 0.25 mg/kg/day, 2.5mg/kg/day, and 5 mg/kg/day. The drug is given in two divided doses 12 hours apart for 6 months.
45469169|NCT02561273|Drug|Vincristine Sulfate|Given IV
45469170|NCT03422926|Behavioral|Social marketing campaign|Messaging campaign designed to help mothers in choosing healthful options when dining out.
45469171|NCT05304780|Behavioral|smart e-care needs tailored recovery program (NTRP)|Smart care technology will be adopted to establish the smart e-care Needs-Tailored Nurse-Led Recovery Program (NTRP) through the standardized process of platform goal (targeted actions) setting, development (content and format) and verification. By the way, the contents of NTRP were divided into five major stages of care:1. Build partnerships; 2. Conduct integrated needs assessment; 3. Set needs-based recovery goals and provide empowerment-oriented measures; 4. Conduct continuous monitoring of goals. 5. Conduct effectiveness evaluation: treat recovery as the primary outcome measure and other elements (needs, empowerment, hope, and medication adherence) as secondary outcome measures.
45469172|NCT03312543|Device|Active Mask|A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the active light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
46109117|NCT00697151|Drug|Warfarin|Warfarin once a day, titrated to obtain an INR of 1.4 to 2.8; placebo aspirin once a day
46109118|NCT00697151|Drug|Aspirin|Aspirin 325 mg once a day; placebo warfarin once a day
46109119|NCT04046770|Device|Drug administration and Flushing procedure using Double-Chamber Syringe|The new device will allow the professional to conduct all the procedure (assure the patency/enables the pre-flushing), drugs administration and flushing, using only one device.
46109120|NCT04046770|Device|Drug administration and Flushing procedure using Classic Syringe|To fully complete the intravenous drug administration with rigor, nurses should flush the catheter pre, post and inbetween drug administration. This implies the use of two or three syringes.
46109121|NCT00697229|Biological|Engerix™-B|Intramuscular injection, 1 or 3 doses
45469173|NCT03312543|Device|Sham Mask|A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the sham light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
45469174|NCT02521012|Dietary Supplement|Vitamin D 10 micrograms|Vitamin D supplementations of 10 micrograms/day will be given to depressed individuals for three months
46109122|NCT00697229|Biological|HBV-MPL vaccine|Intramuscular injection, 1 or 3 doses
45838369|NCT03455582|Other|Neuropsychological evaluation|cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
46109123|NCT00792220|Procedure|MSU|"In the Mobile Stroke Unit procedure: Conventional Emergency Medical Service together with the MSU will meet at the side, where the patient is found. The MSU is an ambulance, equipped with a neurologist and neuroradiologist and includes CT scanner and point of care laboratory unit. The patient's medical history and the physical examination will be directly performed by the neurologist. CT scan analysis will be performed by the neuroradiologist, while the neurologist will analyze the blood samples with the point of care laboratory unit. If the inclusion and exclusion criteria are fulfilled, the thrombolytic therapy will directly be started by the neurologist. A possible thrombolytic therapy will be performed under the current inclusion and exclusion criteria that are associated with the rt-PA drug approval in Europe. After performance of the acute therapy, the patient will be transported to the University Hospital of the Saarland."
45469175|NCT02521012|Dietary Supplement|Vitamin D 100 micrograms|Vitamin D supplementations of 100 micrograms/day will be given to depressed individuals for three months
45469176|NCT03416764|Device|EFP-NF training|Experimental groups (among participants with and without steady menstrual cycle) will receive a total of 10 training sessions during 10 weeks. In addition to EFP-NF training, participants in the experimental groups will continue to be treated as usual at Clinic for Sexual Assault.
45683938|NCT04277026|Behavioral|Mindful Walking|Eight weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals.
45838370|NCT03455582|Other|Psychological evaluation|questionnaires for depression, anxiety and fatigue
45838371|NCT03455582|Device|MRI Evaluation|morphological MRI and resting state functional MRI (fMRI)
45838372|NCT03453268|Other|STEP DOWN strategy|"reduction of the number of antihypertensive medication according to:~the systolic blood pressure levels,~co-morbidities"
45838373|NCT03453268|Other|Control|usual treatment
45838374|NCT03448926|Other|Treatment Recommendation Surveys|Treatment Recommendation Surveys are completed by the treating physicians before and after receiving results from the DCISionRT test, which is prognostic for risk of recurrence over 10 years and predictive for benefit from radiation therapy.
45838375|NCT03444701|Drug|E7130|Starting dose of 25 μg/m^2 on Day 1 and Day 15 of Cycle 1.
45838376|NCT03444701|Drug|E7130|Starting dose is lower than one at which the first DLT was observed in the 2-week regimen administered on Day 1 of Cycle 1.
45469177|NCT04756128|Drug|Colchicine 0.6 mg|"Colchicine is an oral anti-inflammatory agent that is relatively inexpensive, readily available, and has been used for generations. Approved for treatment and prophylaxis of gout flares and Mediterranean fever, it is also used in a variety of other inflammatory conditions (e.g. pericarditis and diffuse vascular inflammation such as Behcet syndrome). Colchicine binds to tubulin causing depolymerization, which interferes with neutrophil chemotaxis, adhesion, and mobilization to sites of inflammation, and contributes to reduction in superoxide production; through interference of the NLRP3 inflammasome protein complex, colchicine inhibits IL-1b, IL-6, and IL-18 production.~For this study, patients enrolled in a colchicine containing arm will receive 0.6mg of colchicine BID (unless renal function/gastrointestinal issues require adjustments described in the protocol)"
45469178|NCT04756128|Drug|Naltrexone|"Most well known as an opioid antagonist, or a treatment for alcohol dependence, naltrexone also possesses immunomodulatory effects. Seen exclusively at low doses, this attribute is being employed in the pain community as a novel anti-inflammatory agent that has been shown to reduce symptom severity in fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome.~For this study, patients enrolled in a naltrexone-containing arm will take their daily dose of the medication (4.5mg) by oral suspension."
45469179|NCT03427216|Drug|Baclofen/diazepam|Vaginal suppository placed once daily, patients will record pelvic pain daily on a VAS scale, sexual satisfaction and quality of life on a standardized questionnaire weekly
45469180|NCT03427216|Drug|Vaginal placebo|Vaginal suppository placed once daily, patient will record pelvic pain daily on a VAS scale, sexual satisfaction and quality of life on a standardized questionnaire weeky.
45469181|NCT01144091|Drug|pentoxyphylline|pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
45469182|NCT01144091|Drug|placebo|placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
45469183|NCT01144091|Drug|pentoxiphylline|pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
45838377|NCT03439033|Drug|PET/MRI with Gallium-68 labeled PSMA-HBED-CC|Subjects have one visit, during which they will undergo one PET/MRI with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
46023107|NCT04284358|Other|Technology integrated instruction neuromuscular training warm-up workshop|Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation. Participants will then attempt the exercise and assess their execution via a video on a peer learning tablet application. This occurs for every exercise and occurs in pairs in which participants can discuss and evaluate an exercise by an exercise's key execution components.
46023108|NCT02859766|Drug|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection.
46023109|NCT04282798|Other|Personalized Music Intervention|Participants will complete a series of questionnaires to identify participants' music preferences and participants' sensitivity to reward from musical engagement. The responses from the music preference questionnaires will be used to create a 1 hr playlist of songs by a member of the study team for the participant to be played daily for four weeks. After playlist is created and transmitted to MP3 device, participants will pick up the equipment and a compliance log will be given for the participant and participants' caregivers to confirm adherence to the protocol of daily listening. The platform will be Spotify, where the MP3 device given to participant at the start of the intervention will be preprogrammed with the participant's personal playlist on the platform. This trial is a supplementary treatment option for cognitive and neuropsychiatric assessments for AD, as such no alterations in the current treatment plans of any participant will be necessary.
46023110|NCT02862028|Biological|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
46023111|NCT02860858|Biological|Intravitreous aflibercept injection|
46023112|NCT00960154|Device|PEAK PlasmaBlade|The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade including the skin incision
46023113|NCT00960154|Procedure|Traditional Electrosurgery with scalpel|The skin incision will be performed using a standard scalpel; the subcutaneous dissection will be performed with traditional electrosurgery using the Cut and Coagulation modes.
46023114|NCT02861170|Behavioral|Brief Mindfulness-Based Intervention|In addition to the educational materials that will be provided to all participants, the participants in the intervention group will also receive a 10-minute mindfulness-based intervention called a body scan. The body scan is a guided meditation exercise where participants are lead through focusing their attention on their body while maintaining awareness and acceptance of their sensations, emotions, and thoughts without trying to control or change them. The goal of the intervention is to increase mindfulness (i.e., moment-to-moment, non-judgmental and non-reactive awareness of sensations, emotions and thoughts), to provide self-regulation strategies, and to promote healthy and adaptive responses to stress.
46023115|NCT00960076|Drug|Saxagliptin|5mg oral tablet once daily
46023116|NCT00960076|Drug|Metformin XR|500mg oral tablet once daily
46023117|NCT00960076|Drug|Metformin XR|750mg, 2 tablets once daily
46023118|NCT02859688|Genetic|pyrosequencing|
46023119|NCT02859688|Genetic|Methylome|
46023120|NCT04281082|Drug|ursofalk|To study the genetic polymorphisms in pregnant women with ICP treated with ursoflak and in their first degree relatives
46023121|NCT04284202|Drug|PD-1 plus Dasatinib|Toripalimub 240mg injection day1; Dasatinib 100mg po qd day1-day21. 3weeks is 1 cycle.
46023122|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
46023123|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
46023124|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
46023125|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
46023126|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
46109124|NCT00792220|Procedure|OCCM|In the optimized conventional clinical management: After patient's medical history, physical examination and emergency treatment by the emergency physician, the patient will be transported to the University Hospital of the Saarland. The delivery of the patient will directly take place at the CT scanner. The neurologist will perform a second medical history, physical examination, while the blood will be drawn by the assisting nurse. CT scan will be performed, while the blood will be analyzed by point of care technique, placed close to the CT scanner. Additionally the blood will be sent in parallel to the hospital central laboratory for conventional laboratory analysis. Depending on the results, a thrombolytic therapy will be initiated directly at the CT. Thereafter, the patient will be transported to the hospital Stroke Unit.
46109125|NCT00797368|Other|Manual Therapy and Exercise|Manual Therapy and Exercise
46109126|NCT00797368|Other|Home exercises|Home exercises
46109127|NCT02619539|Procedure|plasma fibrinogen measurement|plasma fibrinogen measurement
46109128|NCT02621957|Drug|GDC-0810|During Period 2 subjects will be administered an oral 600 mg dose GDC-0810 daily beginning on Day 5 for 4 consecutive days (from Days 5 to 8, inclusive).
45838378|NCT03439033|Drug|Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC|Subjects have two visits (the second visit being optional) within two years. During each visit, they will undergo one PET/MRI with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
46023127|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
46109129|NCT02621957|Drug|Pravastatin|Subjects will receive a single oral dose of 10 mg pravastatin on Day 1 in Period 1 and Day 7 in Period 2.
46023128|NCT01227629|Drug|warfarin|comparator
46023129|NCT01227629|Drug|dabigatran without ASA|dose comparison
46023130|NCT01227629|Drug|dabigatran without ASA|dose comparison
46109130|NCT00870233|Behavioral|online platform WEBCORE|Enrollees will be sent weekly email reminders to login to WEBCORE from home. Participants will be expected to complete the questionnaire once pre-operatively and then weekly starting 7 days after surgery until the 6-week post-operative period has ended.
46109131|NCT00696683|Other|None, this is an observational study|
46109132|NCT00851084|Drug|aflibercept|administration: IV infusion
46109133|NCT00851084|Drug|oxaliplatin|administration: IV infusion
46109134|NCT00851084|Drug|5-FU|administration: IV infusion
46109135|NCT00851084|Drug|Folinic Acid|administration: IV infusion
46109136|NCT04137419|Dietary Supplement|Probiotic lozenges|Probiotic strains
46109137|NCT04137419|Other|Placebo|Similar to ProlacSan lozenges in taste in colour
46109138|NCT02619695|Drug|Fastjel|2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
46109139|NCT02621879|Procedure|Bilateral Gluteal Advancement Flap|Dissection of both gluteus maximus muscles from their origin in the sacrum, advancement of both muscles is conducted to the midline after creating release incisions in their fascia.
46109140|NCT02619383|Device|Hyperbaric oxygen therapy|The treatment comprised 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression.
46109141|NCT02621801|Behavioral|Stress Management and Resiliency Training for Residents (SMART-R)|The Stress Management and Resiliency Training Program for residents (SMART-R) is a six-hour intervention delivered over 2 or 3 sessions that teaches residents mind-body skills to reduce stress and enhance coping strategies.
46109142|NCT00912587|Drug|ghrelin|0.1 microgram/kg/min, intravenous for 60 minutes
46109143|NCT02617199|Drug|Epidural anesthesia|Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours
46109144|NCT02617199|Drug|intravenous analgesia|ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
46109145|NCT02617433|Device|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours. After measurement, patient is induced anesthesia. Rocuronium dose is 12mg for male, and 9mg for female.
45469184|NCT01144091|Drug|placebo|placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
45838379|NCT03439033|Drug|PET/CT with Gallium-68 labeled PSMA-HBED-CC|Subjects have one visit, during which they will undergo one PET/CT with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
46023131|NCT01227629|Drug|dabigatran without ASA|dose comparison
46023132|NCT00963820|Drug|Ixazomib citrate|Ixazomib citrate capsules
46023133|NCT03241186|Drug|Ipilimumab|1mg/kg
46023134|NCT03241186|Drug|Nivolumab|3mg/kg
46023135|NCT03241186|Drug|Nivolumab|480mg
46023136|NCT01227395|Drug|Azithromycin|"Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults.~Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults."
46023137|NCT02859532|Radiation|elastography SWIRE|
46023138|NCT03237286|Drug|Intravenous ketamine|Intravenous ketamine is given at a subanesthetic dose, which previous research suggests is safe and efficacious for rapid relief from depression.
46023139|NCT03237286|Behavioral|Computer-based Cognitive Training|"Computer-based Cognitive Training will be delivered following intravenous ketamine to test whether learning during a post-ketamine window of opportunity might extend relief from depression."
46023140|NCT04319003|Behavioral|Sugar-reduction intervention|The intervention consisted of a) installation of a water filter at the school. b) each participant received a metal water bottle. c) a registered dietitian gave a 30-minute presentation on sugar reduction for the purposes of type 2 diabetes prevention
46023141|NCT04281238|Other|Yoga group|Yoga training 3 days a week for 8 weeks. In addition to this, home exercises 5 days a week for 8 weeks
46023142|NCT04281238|Other|Control group|Home exercises 5 days a week for 8 weeks
46023143|NCT02859376|Dietary Supplement|sucrose 24%|Premature neonates undergoing blood samples through skin breaking procedures, meeting inclusion criteria, will be randomized as soon as the doctor decision to drown the blood is made, to either sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE the skin breaking procedure or sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE and DURING the skin breaking procedure, according to a computer generated randomization list.
46023144|NCT04283032|Procedure|Multiparametric magnetic resonance|MRI uses a powerful magnetic field, pulsed radiofrequency and a computer to create detailed images of organs, soft tissues, bones, and practically the rest of the internal structures of the body. MRI does not use ionizing radiation (X-rays).
46109146|NCT02619227|Other|Livelihood intervention|Participants will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
46109147|NCT00845858|Drug|metoclopramide|30 minutes before meals and at bedtime for 4 weeks
46109148|NCT00845858|Drug|Placebo|30 minutes before meals and at bedtime
45469185|NCT01321333|Biological|HuCNS-SC cells|single dose intramedullary transplantation of HuCNS-SC cells in the thoracic spinal cord
45469186|NCT04934046|Other|Additional acquisition|Additional SPECT acquisition (30min added time approximately), with no added radiation
46109149|NCT02617043|Radiation|hypofractionated whole breast irradiation with simultaneously integrated boost|deliver 40Gy/15Fx to whole breast with 48Gy/15fx simultaneously integrated to tumor bed
46109150|NCT02616809|Other|Maintaining posture and energy expenditure|Participants will sit continuously for 8-hrs during a simulated office environment
46109151|NCT02616809|Other|Increasing energy expenditure|Participants will cycle slowly while seated in prescribed hourly intervals. This condition will increase energy expenditure while keeping a sitting posture
46109152|NCT02616809|Other|Changing posture|Participants will transition from sitting to standing in prescribed hourly intervals. This condition will change posture (sit to stand) while maintaining low energy expenditure
46109153|NCT02616809|Other|Increasing energy expenditure and changing posture|Participants will transition from sitting to a walking workstation in prescribed hourly intervals. This condition will both increase energy expenditure and change posture.
46109154|NCT02616653|Procedure|L3-L4 location: Palpation method confirmed by US|An anesthesiologist will locate the L3-L4 space using the palpation method (Tuffier's line). An investigator trained in US imaging will proceed to the US exam of the spine specifically aiming to identify the L3-L4 intervertebral space. The investigator will note if the same level was identified and if not, which one was according to the US exam.
46109155|NCT00850538|Radiation|MRI|1.5T MRI exam of signal knee with knee coil (estimated time: 35 minutes)
46109156|NCT00850538|Procedure|Primary Total Knee Replacement|Fluid, bone, and meniscus specimens obtained from total joint replacement will be collected.
46109157|NCT02619149|Drug|Piperacillin-tazobactam combination product|Piperacillin-Tazobactam (extended-spectrum, beta-lactamase inhibitor) iv peroperatively as prophylaxis
46109158|NCT02619149|Drug|Saline solution|Saline iv as placebo control
45469187|NCT03416686|Device|Radiofrequency (RF star electrode electrode_Fixed)|"The radiofrequency will be performed under ultrasound control after local anesthesia by a trained operator, after finding the lesion to be treated by the operator.~Medical device used: RF star electrode electrode_Fixed (Starmed Co,Gyeonggi-do, Korea, French representative Cosysmed)."
45469188|NCT05292846|Drug|Direct-acting oral anticoagulation|Apixaban Dabigatran Edoxaban Rivaroxaban
45469189|NCT01313013|Behavioral|question prompt sheet|
45469190|NCT05060328|Other|Medical Device Usage and Evaluation|"Use Google Translate Conversation Mode translation application."
45469191|NCT05060328|Other|Survey Administration|Complete survey
45469192|NCT02008552|Genetic|Sampling of blood|Sampling of blood was taken and analyse to research factor genetic
45469193|NCT03762499|Diagnostic Test|Echocardiography scan|Non-invasive ultrasound imaging of the heart.
45469194|NCT03767725|Biological|Treatment|Phase 1 Clinical Study of The patients undergo leukapheresis. The patients then receive fludarabine and cyclophosphamide on days-5 to-3. Subjects will receive (0.6-60)x10E8 transduced CART cells as a split dose over three days as follows: Day 0, 10% fraction: (0.06-6)x10E8 CART19 cells, Day 1, 30% fraction: (0.18-18)x10E8 CART19 cells, Day 2, 60% fraction: (0.36-36)x10E8 CART cells.
45469195|NCT02392559|Drug|Evolocumab|Dose of subcutaneous evolocumab every 4 weeks
46023145|NCT01226459|Drug|5% Minoxidil Topical Foam|Dosage Form: 5% Minoxidil Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
46023146|NCT01226459|Drug|Vehicle Topical Foam|Dosage Form: Vehicle Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
46109159|NCT04134065|Drug|Vitamin D|patients with refractory Crohn disease and a serum 25(OH)D concentration <75 nmol/L were prescribed oral liquid vitamin D supplementation over 12 weeks using a specific protocol with dose adjusted 4-weekly to aim for a target level of 100e125 nmol/L.
46109160|NCT04134065|Drug|Placebo oral capsule|the capsule contain nothing
46109161|NCT05602298|Other|Quality of Recovery 15 survey|QOR 15 is a patient reported outcomes measure (PROM) tool used as a global measure of patient recovery after surgery and anesthesia. It uses fifteen questions to assess various domains of patient health: pain, physical comfort, physical independence, psychological support, and emotional state.
46109162|NCT02616731|Drug|Tranexamic Acid|use tranexamic acid oral tablets 500 mg two tablets every six hour with the onset of the first day of menstrual cycle till the end of bleeding then The amount of menstrual flow will be calculated by the PBAC
45469196|NCT02392559|Drug|Placebo|Dose of subcutaneous placebo treatment every 4 weeks
45469197|NCT03422692|Biological|BioXclude amnion-chorion membrane|BioXclude will be used for the prevention of alveolar ridge resorption via socket bone graft and amnion-chorion membrane closure
45469198|NCT03422692|Biological|Mem-Lok collagenous membrane|Mem-Lok will be used for the prevention of alveolar ridge resorption via socket bone graft and collagenous membrane closure
45469199|NCT03767647|Behavioral|Emotional Intelligence lessons|6 lessons were given to the students in separated weeks by the same investigator. Lessons were 45-60 minutes long and each one was dedicated to one of the main aspects of emotional intelligence.
46109163|NCT02616731|Drug|Diosmin|use diosmin oral tablets 500 mg t.d.s (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.then The amount of menstrual flow will be calculated by the PBAC
45469200|NCT03422614|Diagnostic Test|Diagnostic Test|Characterisation of cellular and functional phenotype in different PIDs
46023147|NCT01225991|Drug|Milnacipran|All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day: Day 1: 12.5 mg once a day; Days 2-3: 25 mg/day (12.5 mg twice daily); Days 4-7: 50 mg/day (25 mg twice daily); After Day 7: 100 mg/day (50 mg twice daily). The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day).
46023148|NCT00959374|Device|V-Loc 180/90 Wound Closure Device|Barbed absorbable suture
46109164|NCT00850460|Drug|Statins|Subjects will be randomized to continue their statin dosage or placebo for 8 weeks. They will stay on the same dosage as prescribed by their physician. Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20 mg/tab once daily by mouth.
46109165|NCT00850460|Drug|Placebo|Placebo pills will consist of lactose and will be given one capsule once daily
46109166|NCT04137263|Other|DOSE formulation|over-the-counter topical
46109167|NCT00661492|Drug|cetuximab|Erbitux (cetuximab) IV over 2 hours (loading dose) on Day 1 (Cycle 1 only), followed by Erbitux (cetuximab) IV over 1 hour weekly thereafter
46109168|NCT00661492|Drug|Mitoxantrone|Novantrone (mitoxantrone) IV Day 1 + Prednisone QD for ten (10) 21-day cycles Standard androgen deprivation therapy (ADT) will be continued in all patients who enter study on LHRH agonists
46109169|NCT04116632|Drug|BMS-963272|Single dose with varying frequency among groups
46109170|NCT04116632|Drug|Placebo|Specified dose on specified days
46109171|NCT02619071|Procedure|Tumor sampling|Bone marrow aspirate, blood sampling
46109172|NCT02619071|Biological|Constiutional DNA sampling|Buccal swab or Hair follicles
46109173|NCT00693095|Biological|CMV-ALT + CMV-DCs|CMV-ALT (3 X 10e7) with CMV-DCs (2 X 10e7)
46109174|NCT00693095|Biological|CMV-ALT + Saline|CMV-ALT (3 X 10e7) with Saline
46109175|NCT02619305|Other|Social network tie|Participants will be social network ties of women receiving a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
46109176|NCT00850070|Drug|sapropterin|Patients will receive sapropterin 20 mg per kilogram per day for 16 weeks
46109177|NCT00850070|Drug|Placebo|Patients will receive a placebo identical in form and dosage to the active drug daily for 16 weeks.
46109178|NCT04134143|Biological|ExpressGraft-C9T1 Skin Tissue|A round patch of experimental skin tissue that the doctor applies over the ulcer
46109179|NCT00693251|Procedure|Crush technique|Crush technique
46109180|NCT00693251|Procedure|provisional T stenting|Provisional T stenting
46109181|NCT00797680|Other|72 hours hypothermia|72 hours mild hypothermia (33 +/1 1 degree Celsius)
46109182|NCT00797680|Other|24 hours hypothermia|24 hours mild hypothermia (33 +/1 1 degree Celsius)
46109183|NCT02618837|Procedure|Downstream strategy|"At diagnosis:~Subjects receive a loading dose of aspirin (150-300mg). Administration of clopidogrel is allowed only for patients already receiving clopidogrel~Pre-procedure:~Until PCI is performed, all subjects will be maintained at a minimum of 75mg of aspirin (Subjects with clopidogrel may be maintained at a minimum of 75mg of clopidogrel)~Peri- and post-procedure:~For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; choice based upon clinical judgement.~In this case, subject will be randomized in a 1:1 fashion to prasugrel vs ticagrelor~At the time of PCI, the loading doses required (according to randomization):~Ticagrelor 180mg, maintained at 90mg b.i.d. for at least 12 months~Prasugrel 60mg, maintained at a minimum of 75mg of aspirin for at least 12 months plus 10mg of prasugrel* daily for at least 12 months~If subject is >75 years old or <60 kg, daily dose of prasugrel should be 5mg"
46023149|NCT00959374|Device|3-0 Monocryl Absorbable Sutures|3-0 Monocryl Absorbable Suture (non-barbed)
46023150|NCT02859298|Device|Uterine Cervix Polarimetric Imaging|Polarimetric imaging is a promising optical technique that can provide information in large field and potentially in vivo about the abundance and 3D structure of collagen. Images will be taken with a polarimetric colposcope. As the imaging is realized with visible light from classical sources (lamps or LEDs, neither lasers or other high intensity sources, nor any ionizing UV radiation) and without any chemicals, it is totally innocuous, just like the intensity imaging used in conventional colposcopy.
46023151|NCT04283110|Drug|intrthecl midazolam|midazolm as as adjuvant in spinal anesthesia
46023152|NCT02859610|Other|research on interactions between portal hypertension and microparticles|
46023153|NCT02860780|Drug|prexasertib|Administered IV
46023154|NCT02860780|Drug|ralimetinib|Administered orally
46023155|NCT01225835|Drug|Menotrophin|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
46109184|NCT02618837|Procedure|Upstream strategy|"At the time of diagnosis:~Subjects randomized in this arm must receive a loading dose of aspirin (150-300 mg) and ticagrelor (180 mg) at admission as soon as possible.~Pre-procedure:~All subjects will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, until coronary angiography is performed.~Peri- and post-procedure:~For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; the choice of the anticoagulant at the time of PCI will be based upon clinical judgement.~All subjects randomized to the upstream strategy arm will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, for at least 12 months. If the subject develops hypersensitivity or intolerance to ticagrelor, clopidogrel may be used as a substitute at a dose in accordance with standard hospital practice (to be documented in the eCRF)."
45469201|NCT01561729|Device|RightSpot pH Indicator|The RightSpot pH Indicator device is used to confirm proper placement of all types of gastric tubes used for gastric rest, suction, or medicating/feeding by measuring the pH of stomach aspirate. This device is intended for 1 (one) SINGLE USE. The probability of proper placement is higher when the pH is less than or equal to 4.5 and if aspirate has a typical gastric fluid appearance (grassy green, brown, colorless- with possible shreds of off-white mucus or sediment).
45469202|NCT01561729|Radiation|Chest radiograph|Chest radiograph will be taken after tube placement to verify proper positioning of the nasogastric or orogastric tube.
46023156|NCT01225835|Drug|Follitrophin alpha|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
46109185|NCT00792376|Drug|etoricoxib|etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days
46109186|NCT00792376|Drug|diclofenac|diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
45469203|NCT04919070|Behavioral|Connect for Caregivers|The intervention being studied is a single session guided behavioral intervention to improve social connectedness in caregivers of individuals with ADRD. The intervention, Connect for Caregivers, provides psychoeducation on the importance of social connectedness for health and well-being, includes a card-sort process to identify and prioritize barriers to connectedness, and provides personalized resources and strategies for caregivers to use to increase their social connectedness.
45469204|NCT03332589|Drug|E6201|E6201 formulated in cyclodextrin for IV administration.
46109187|NCT00592358|Drug|paliperidone|tablet, 3mgQAM - 6mgQAM, taken daily for 8 weeks
46109188|NCT00814320|Biological|Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)|"Comprises subjects previously participating in Study 160601, who now only complete Study Epoch 2 (subcutaneous [SC] infusions) as bioavailability/exposure for intravenous (IV) treatment was already obtained in Study 160601.~Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up)."
46109189|NCT00814320|Biological|Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)|"Comprises all other subjects.~Study Epoch 1: IV infusion of IGIV, 10% (same dose and frequency as pre-study) to determine pharmacokinetics.~Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up)."
46109190|NCT00787072|Drug|AZD8075|Single dose, the starting dose will be 7 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits.
46109191|NCT00787072|Drug|Placebo|Oral suspension
46109192|NCT00869999|Drug|Everolimus|Taken orally once daily in the morning
46109193|NCT00869999|Drug|rituximab|Given intravenously on Days 1, 8, 15, and 22 of Cycle 1 then on Day 1 of cycles 2-6
45469205|NCT03332589|Drug|E6201 plus dabrafenib|E6201 formulated in cyclodextrin for IV administration. Dabrafenib capsules for oral administration.
46023157|NCT01225835|Drug|Cetrorelix|Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum. The last dose of Cetrorelix is given on the day of ovulation induction.
46023158|NCT01225835|Drug|Choriongonadotropin|10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13). The criterion for hCG administration is three follicles >+17 mm diameter as shown by pelvic ultrasound examination.
46023159|NCT01225835|Drug|Progesterone|Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).
46023160|NCT02923180|Drug|Enoblituzumab|Enoblituzumab 15mg/kg IV (in the vein) weekly for 6 doses beginning 50 days prior to radical prostatectomy.
46023161|NCT00962650|Device|Transgastric diagnostic peritoneoscopy with laparoscopic assistance|Device: Natural Orifice Transgastric Endoscopic (NOTES GEN 1 Toolbox): Articulating Hook Knife(IN2505), Articulating Snare (IN2503), Articulating Needle Knife(IN2504), Articulating Graspers(IN2501 or IN2506), Articulating Biopsy Forceps(IN2502), Steerable Flexible Trocar (IN0501) with Rotary Access Needle (IN0502), Flexible Bipolar Hemostasis Forceps (IN0301), and/or Flexible Maryland Dissector(IN1601)
46023162|NCT04282252|Drug|I.V. SOLUTIONS|All i.v. fluids used in an Intensive Care Unit.
46109194|NCT04030988|Drug|Oral dexamethasone minipulse|50 patients will receive mini pulse dexamethasone therapy in a dose of 3 mg/ day for adults or 1.5 mg/day for children on two consecutive days per week plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
46109195|NCT04030988|Drug|Placebo oral tablet|50 patients will receive placebo having the same color, form and packaging as the dexamethasone therapy for 6 months plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments
46109196|NCT00792454|Behavioral|exercise training|"Subjects will undergo renal rehabilitation in the form of guided exercises 2 times per week for 3 months. Subjects will be encouraged to walk for 1 hour on their own a third day of the week.Subjects will receive recommendations for cardiovascular, weight training and stretching exercises.~Cardiovascular and strength capabilities of all subjects will be evaluated at the initial session in order to prescribe the appropriate exercise regimen. An exercise physiologist will conduct these evaluations using the Perceived Level of Exertion Subjects will also receive education and practice in mindful meditation and a heart healthy diet.~Subjects will be encouraged to continue exercises, meditation, and healthy eating habits after the 3-month in-center program. Subjects will receive follow-up phone calls at 3-month intervals to encourage ongoing exercise, meditation, and healthy diet."
46109197|NCT00703352|Drug|Eplerenone|Eplerenone (coated tablet) 50mg daily during 12 months.
46109198|NCT05326607|Device|Prototype of adaptive eyeglasses|The tested investigational medical device is a prototype of semi-integrated eyeglasses.
46109199|NCT05326607|Device|Comparator|The comparator is either a pair of progressive lenses that provide clear vision at both distance and near vision, either, for wearers who have rejected progressive glasses, an alternative solution providing clear vision at both distance and near vision which can consist of bifocal glasses, multifocal or monovision lenses, multiple pairs of glasses or one pair for cases of emmetropia.
46109200|NCT00797758|Other|Cord blood transplantation|Umbilical cord blood transplantation after reduced intensity conditioning
46109201|NCT02618525|Other|Supraorbital pressure|Supraorbital pressure is applied by applying pressure over the notch on the inner aspect of eyebrow.
46109202|NCT02618525|Other|Jaw thrust maneuver|Jaw thrust is performed by placing the index and middle fingers to physically pull the posterior aspects of the mandible upwards while their thumbs push down on the chin to open the mouth.
46109203|NCT00703430|Drug|Memantine|Initially Memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day, which is maintained for the following 2 months.
46109204|NCT00797836|Procedure|Quantiferon Gold|"Interferon-gama release assay evaluating tuberculosis-specific T-lymphocytic response~Health Personnel Hospitals, General Occupational Diseases/*epidemiology/*statistics & numerical data Occupational Exposure/*statistics & numerical data~Tuberculosis/*diagnosis/*epidemiology/prevention & control Immunologic Tests/methods/*standards Disease Transmission, Horizontal/*statistics & numerical data Patient Isolation~Tuberculin Test/standards/*methods Immunoassay/methods/*standards T-Lymphocytes/immunology Interferon Type II/*blood/*analysis~*Reagent Kits, Diagnostic~Mass Screening/*methods Incidence Follow-Up Studies Comparative Study Sensitivity and Specificity Risk Assessment/*methods"
46023163|NCT04282096|Other|native and non native casein|selected participant will test the 3 treatments in a random order
46023164|NCT04284046|Other|CT score|CT score = normal lung tissue (%) ×1 + GGO (%) ×2 + consolidation (%) ×3
46023165|NCT00630136|Behavioral|interview|The parent/LAR who has consented to have their child undergo an outpatient endoscopy procedure will be interviewed prior to the procedure being performed.
46023166|NCT04280614|Behavioral|Dialectical behaviour therapy (DBT)|DBT is based on the behavioural therapy principals focusing on four main modules: mindfulness, interpersonal effectiveness, emotional regulation and distress tolerance. The therapy is taught in a group and individual therapy model with coaching during periods of crisis. CBT is a standard model of therapy similar to DBT but is more direct in focusing clients on changing maladaptive behaviours or thoughts to effectively manage difficult emtions.
46109205|NCT04046380|Diagnostic Test|work of breath measurement and calculation|The ventilator-imposed power at various tidal volume (6, 8, 10 ml/Kg) and positive end-expiratory pressure (5, 10 cmH 2 O) will be calculated by the formula.
46109206|NCT02618447|Device|4Dimensional Phase Contrast Magnetic Resonance Angiography|4D PC MRA is a new non-contrast MRA technique that can measure flow of blood within vessels of interest over time.
46023167|NCT04280770|Procedure|23 PARS PLANA VITRECTOMY|We performed a three-port vitrectomy: one infusion trocar and two instruments trocars. Non-contact wide-angle viewing systems (Resight- Biom) have a viewing field of 60-130° was used. Put 23 needle attached to the automated pump for silicone oil extraction. Strict examination of the retina to detect new breaks or untreated breaks. Closure of the sclerotomies.
46023168|NCT02899000|Drug|Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel|Topical acne therapy
46023169|NCT02899000|Drug|Oral doxycycline hyclate|Tetracycline-class oral antibacterial 200 mg daily (2 tablets [50 mg], twice daily)
46023170|NCT02858986|Procedure|3D laparoscopy|
46109207|NCT02618447|Procedure|Portal vein embolization|
46023171|NCT02858986|Procedure|4K laparoscopy|
46023172|NCT02859220|Other|Determination of PTH following|"Determination of PTH following:~in group 1: intact PTH Elecsys Roche"
45838380|NCT03412812|Radiation|Dose Escalated Five Fraction Stereotactic Radiosurgery|As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
46023173|NCT02859220|Other|Determination of PTH following:|"PTH 1-84 complete (PAC) report and CAP / CIP, the package Duo PTH IRMA Scantibodies. The CIP is obtained by calculating the difference between total intact PTH and PTH 1-84 in the kit used."
46023174|NCT04281862|Drug|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
46023175|NCT04281862|Drug|Topical Prednisolone|Standard of care topical drop treatment
45838381|NCT03405558|Other|No intervention|As this is an observational study, we will only supervise testing and training sessions which were performed anyway during first rehabilitation as daily therapeutic routine
46023176|NCT00958828|Device|Nelfilcon A contact lens|Spherical, soft contact lens for daily disposable wear
46023177|NCT00958828|Device|Narafilcon A contact lens|Spherical, soft contact lens for daily disposable wear
46023178|NCT03122002|Drug|Drug Therapy|For this observation research, anti platelet drugs, statins and ect. would be used as clinical guidelines as usal, and statical ananysis of the relationship between these drugs and the final outcomes
46023179|NCT03122002|Diagnostic Test|Routine Blood Test and Image Scan|Routine blood test(HCY, LDL and ect.) and image scan (DWI, DSA and ect.)
46023180|NCT03122002|Other|Intravascular therapy|Intravascular therapy including thrombectomy
46023181|NCT03122002|Other|Emergency Treatment|Emergency treatment including time to self-diagnosis of stroke, time to call for help, devices used to hospital and ect.
46023182|NCT03122002|Other|Medical history|Medical history including hypertension, diabetes, hyperlipemia and ect.
45838382|NCT03405311|Device|Rivanna Accuro 3D Ultrasound Device|The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device
45838383|NCT03405311|Other|Palpation|The control group (Group 2: Epidural) will receive the 'Blind approach/palpation', which is using palpation in administering labor epidural analgesia. Additionally, anesthesiologist will scan patient's back with Accuro device in turned off mode
46023183|NCT02858596|Dietary Supplement|Semi-solid feed (Terumo PG soft)|
46023184|NCT02858596|Dietary Supplement|Liquid feed (Meibalance)|
46023185|NCT02861482|Device|Bakri Balloon|Gradually increase the liquid volume inside Bakri Balloon to 250-500ml until bleeding is decreased or stopped
46023186|NCT02861482|Drug|Oxytocin|using oxytocin(usage:20IU oxytocin in 500ml lactated Ringer's, ivgtt to a maximum of 60IU) for the first step when dealing with PPH before laying Bakri Balloon
46023187|NCT02861482|Drug|Hemabate|using Hemabate (usage:250-500ug im) for the first step when dealing with PPH before laying Bakri Balloon
46023188|NCT02861482|Drug|Duratocin|using Duratocin (usage:100ug iv) for the first step when dealing with PPH before laying Bakri Balloon
46023189|NCT02861482|Procedure|Uterine Massage|continuous uterine massage for the first step when dealing with PPH before laying Bakri Balloon
46023190|NCT02861482|Procedure|B-lynch Suture|One of conservative surgical procedures if Bakri Balloon didn't work
46023191|NCT02861482|Procedure|Uterine Artery Embolization using sponges|One of conservative surgical procedures if Bakri Balloon didn't work
46023192|NCT02861482|Procedure|Cervical cerclage|One of conservative surgical procedures if Bakri Balloon didn't work
46023193|NCT02861482|Procedure|Hysterectomy|Hysterectomy with all the above measures not working
45838384|NCT03400982|Diagnostic Test|Bone densitometry measurement|Bone densitometry and measurement of body composition
45838385|NCT03380962|Drug|Clazakizumab|All patients will receive clazakizumab 25 mg subcutaneous injections (monthly) for a maximum of 18 injections.
46023194|NCT02861482|Drug|Blood Product|transfusion of blood product if necessary no matter which surgical procedure has been taken
46023195|NCT02861716|Drug|Bupivacaine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight in 2ml volume and it will be injected slowly over 20 seconds."
45838386|NCT03380377|Drug|Clazakizumab|Clazakizumab 25 mg subcutaneous monthly x 6 doses (or max of 12 doses) will be given to patients who are enrolled in this clinical trial.
45838387|NCT03330886|Drug|Atezolizumab|Atezolizumab will be administered via IV at a 1200-mg dose over 60 minutes every 3 weeks (to be reduced to 30 minutes every 3 weeks if the first dose is tolerated).
45838388|NCT03310424|Other|No active intervention.|No active intervention is undertaken. Collection of samples for bio-informatic analysis only
45838389|NCT03282799|Drug|etonogestrel implant|The etonogestrel implant is an contraceptive implant that is placed into the upper arm.
45838390|NCT03264261|Device|robotic training|robotic training, 3 times/week for 6 weeks
45838391|NCT03264261|Device|treadmill training|treadmill training only, 3 times/week for 6 weeks
46109208|NCT00693407|Procedure|gastric capsaicin with heterotopic stimulation/ distraction|The subjects are randomized to swallow either a capsaicin 0.50mg capsule or an identical placebo capsule with 100ml of water If after 15 minutes pain scores do not reach a minimum level of 30, a further double-blinded capsule of the same content will be swallowed with 100ml of water. This is repeated to a maximum of 8 capusles until pain with VAS >30 is reported.
46109209|NCT02616341|Behavioral|Team ERP (T-ERP) Intervention|
46109210|NCT02616341|Behavioral|Treatment as Usual (TAU)|
46109211|NCT00787306|Behavioral|Active risk factor surveillance|Cardiovascular risk status assessment followed by active surveillance and physician review where risk factor control is suboptimal
46023196|NCT02861716|Drug|Fentanyl|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus fentanyl 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
45469206|NCT03427138|Behavioral|Jasper|Families in the joint attention intervention will receive 10 weeks of the JASPER (Joint Attention Symbolic Play Engagement Regulation) protocol. JASPER is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari at the Center for Autism Research and Treatment, at University of California, Los Angeles. Our research staff will be trained on the specific techniques of JASPER guided by Connie Kasari (consultant on project) and her colleagues The study's intervention involves 2 days/week of 60-minute sessions with a trained experimenter (which may take place in the lab or home, depending on the needs of the family). The primary goal for the intervention will be to increase the frequency and range/variety of joint attention and to advance the child to higher levels (e.g., from requesting to initiating joint attention acts).
46023197|NCT02861716|Drug|Dexmedetomidine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus dexmedetomidine 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
46109212|NCT02618681|Other||
46109213|NCT00792532|Procedure|interventional MRI for implantation of DBS electrodes|DBS implantation will be performed entirely within a Phillips 3T MRI scanner
45469207|NCT03427138|Behavioral|Parent Education|Families in the parent education intervention. Parent education will be provided in group sessions. During the sessions information is presented about ASD, how to deal with behavioral difficulties and available services, and parents are given an opportunity to share experiences. Parents will attend a weekly session for 10 weeks. 10 different topics will be discussed, which include: causes and symptoms of autism, diagnosis process, treatment options, enhancing communicative abilities in children with autism, emotion regulation, dealing with distress, correcting behavior difficulties, applying structure and routines.
45469208|NCT03767569|Drug|Myo-inositol|Myo-inositol and Folic acid daily
46023198|NCT04265092|Drug|Incobotulinum toxin A|Treatment consisted of 200 IU of incobotulinum toxinA injected into the TS. Outcome measures were assessed before injection, at 6 weeks and 3 months post-injection, using the Goal Attainment Scale (GAS), Twelve Item MS Walking (MSWS-12) Scale, Timed Up and Go (TUG) Test, 6 Minute Walk Test (6MWT). Spatiotemporal gait data was obtained by GAITRite.
46023199|NCT00960934|Drug|MK-5442|MK-5442 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg tablet once daily for at least 6 months.
45469209|NCT03767569|Drug|Folic Acid|Folic Acid daily
45469210|NCT03416452|Device|vibratory cueing device|ankle brace with vibrator that provides electric stimulus
46023200|NCT00960934|Drug|Placebo|Dose-matched oral placebo to MK-5442
46023201|NCT00960934|Dietary Supplement|Vitamin D3|Vitamin D3, two 400 IU tablets daily throughout the study.
46109214|NCT00792532|Device|DBS electrodes|Deep brain stimulation (DBS) electrodes
46109215|NCT05755932|Drug|HFO MDI|"Dose formulation: MDI~Unit dose strength(s): Experimental (propellant only)~Dosage level(s): 6 inhalations, BID~Route of administration: Oral inhalation~Participants will receive treatment A in 1 of 2 possible treatment sequences: AB or BA"
46109216|NCT05755932|Drug|HFA MDI|"Dose formulation: MDI~Unit dose strength(s): Reference (propellant only)~Dosage level(s): 6 inhalations, BID~Route of administration: Oral inhalation~Participants will receive treatment B in 1 of 2 possible treatment sequences: AB or BA."
46109217|NCT02618603|Drug|Botulinum toxin A|
46109218|NCT02618603|Drug|Triamcinolone Acetonide|
46109219|NCT02616497|Drug|Aspirin|COX-1 inhibitor
46109220|NCT02616497|Drug|Triflusal|COX-1 inhibitor
46109221|NCT00570232|Drug|Erlotinib|150 mg per day by mouth for 12 months
46109222|NCT05755854|Biological|allogeneic γ9δ2 T Cells|dose escalation (3+3) : dose 1 (5 × 10^7cells/kg) ,dose 2 (1 × 10^8 cells/kg) ,dose 3 (2 × 10^8cells/kg)
46109223|NCT05755854|Drug|Fludarabine|Intravenous fludarabine on days-5 and -4,the infusion dose is adjusted according to the subject's condition
46023202|NCT00960934|Dietary Supplement|Calcium carbonate|Participants who had a calcium intake of less than 1200 mg/day at baseline received a daily 500 mg calcium supplement throughout the study.
46023203|NCT00892177|Biological|bevacizumab|Given intravenously
46023204|NCT00892177|Drug|dasatinib|Given orally
46109224|NCT05755854|Drug|Cyclophosphamide|Intravenous cyclophosphamide on days -5、-4、and -3, the infusion dose is adjusted according to the subject's condition
46109225|NCT05755854|Drug|Zoredronic acid|Intravenous zoredronic acid 50ug/kg 24 hours before cell infusion（or according to the dosage of the instruction）（If applicable）
46109226|NCT04133129|Behavioral|Low Volume-High Intensity Interval Training|On a treadmill, a 2 minute warm-up will be followed by 2 bouts of 4 minutes at an intensity between 85% and 95% of Maximum Heart Rate (HRmax) interspersed by a 2 minutes recovery bout at 70% of heart rate max, followed by a 3 minutes Cool Down
46109227|NCT04133129|Behavioral|Moderate Intensity Continuous Training|On a treadmill,a 2-minute warm-up will be followed by 45 minutes at 65%-75% of Heart Rate max followed by 3 minutes cool down.
46109228|NCT00787384|Drug|Imatinib|Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib wsa discontinued after 12 total weeks of therapy.
46109229|NCT04669002|Drug|EP0057|EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously
46109230|NCT04669002|Drug|Olaparib tablets|Olaparib is a PARP inhibitor (poly [adenosine diphosphate-ribose] polymerase inhibitor)
46109231|NCT02616419|Device|Buzzy® device|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
46109232|NCT02616419|Drug|Maxilene® (Lidocaine liposomal 4%)|Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
46109233|NCT00797992|Drug|Injection|Intravitreal injection of 1.25 mg bevacizumab
46109234|NCT02618369|Device|MR-Guided High Intensity Focused Ultrasound|Target treatment of bone lesion using High Intensity Focused Ultrasound
46109235|NCT04137341|Drug|GLPG1972 - A|Film-coated tablet, formulation A
46109236|NCT04137341|Drug|GLPG1972 - B|Film-coated tablet, formulation B
46109237|NCT04137341|Drug|GLPG1972 - C|Film-coated tablet, formulation C
46023205|NCT00892177|Other|placebo|Given orally
46109238|NCT00798070|Drug|dtEC→dtT|Individually tailored and two weekly dosed epirubicin (start dose 90mg/m2) + cyclophosphamide (start dose 600mg/m2) followed by a three weeks break followed by biweekly and tailored docetaxel (start dose 75mg/m2) given every second week. If toxicity measured by CTC-NCI criteria are grade 2 or less (except haematological toxicity) it will be possible to escalate doses
46109239|NCT00798070|Drug|FEC→T|Fixed dosed and three weekly epirubicin (100mg/m2), cyclophosphamide (500mg/m2) and 5-fluorouracil (500mg/m2), followed by fixed dosed and three weekly docetaxel (100mg/m2), no dose escalations.
46109240|NCT02618291|Other|Active Geriatric Evaluation (AGE tool)|Yearly administration of the brief assessment tool (BAT). Once the presence of one or more geriatric syndromes is suspected using the brief assessment tool, a management strategy is proposed. It is divided in two distinct steps: 1) perform additional tests to confirm or exclude the diagnosis and 2) to propose specific management attitudes. All proposed attitudes are based on literature review and geriatrician expertise. The FP remains free to follow the proposed attitudes.
46109241|NCT02618291|Other|Usual care|"No specific intervention will be provided to the patients, except what family practitioners (FPs) usually do. In this regard, it is possible that some FPs might use structured interventions similar to the AGE tool. This will be neither encouraged nor discouraged. FPs in the usual care arm will be asked to perform one BAT after 2 years of follow-up, at the final patient visit."
46109242|NCT00693563|Behavioral|Scheduled Telephone Intervention|Participants and their significant others will be contacted by telephone within 24 to 48 hours after discharge and 10 additional times at weeks 1, 2, 4, 6, and months 2, 3, 4, 6, 8, and 10. The frequent early telephone contacts are meant to address early concerns that frequently arise after discharge are expected to last between 30 and 45 minutes. Later phone calls may be brief if no concerns are raised and are expected to address resource needs as well as ongoing questions that arise through the first year after injury. Content of each phone call will be dependent on issues raised by each individual participant and their significant other and/or follow-up on concerns raised in prior phone contacts rather than a specific structured interview.
46109243|NCT00809328|Drug|Azithromycin|The intravenous formulation 500 mg is administered once daily for 2-5 days; followed by the oral formulation 500 mg will be given once daily to complete a 7 to 10-day course of therapy.
46109244|NCT00868517|Other|True group auricular acupuncture|Received true group auricular acupuncture
46109245|NCT00868517|Other|Sham group auricular acupuncture|Received sham auricular acupuncture.
45469211|NCT03416452|Device|Mobile Gait Trainer|standard rolling walker that has a battery operated sensor attached to the side, designed to detect footsteps
45469212|NCT03620916|Procedure|Intravenous morphine|Single dose of intravenous morphine (0,15 mg/kg body mass) immediately after the operation, patient controlled analgesia with morphine (2 mg intravenously, a least 20 min interval) over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale>4, at least 6 hour interval) over next two days
46023206|NCT00962104|Drug|Atomoxetine|40-120 milligrams (mg) taken by mouth, once daily for 10 weeks.
46023207|NCT00962104|Drug|Placebo|Taken by mouth, once daily for 10 weeks.
46023208|NCT02821000|Biological|Pembrolizumab|Intravenous infusion
46023209|NCT02836327|Other|Magnetic Resonance Imaging|Magnetic Resonance Imaging
46023210|NCT02860624|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) being taken orally each morning on an empty stomach for 8 weeks
46023211|NCT02860624|Drug|40mg esomeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) being taken orally each morning on an empty stomach for 8 weeks
46023212|NCT02831647|Dietary Supplement|AYMES PRAGUE|AYMES PRAGUE is a ready to drink, high energy, low volume oral nutritional supplement drink. It provides 300 kcal and 12g protein per 125ml serving. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision. It is not designed as a sole source of nutrition.
46023213|NCT02860468|Other|Cranberry juice|cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
46023214|NCT02860468|Other|Placebo juice|apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
46023215|NCT02858518|Other|questionnaires|scales : HEMORR2HAGES (hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...), HAS-Bled (arterial hypertension, renal function, liver function, cerebrovascular accident...), ATRIA (anemia, serious kidney diseases, hypertension, antecedent...), Shireman (gender, age, hemorrhage, diabetes, anemia...), Charlson (age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer) and standardised geriatric assessment (comorbidities, cognition, mobility, pain, nutrition, living environment...)
46023216|NCT00892099|Drug|Ergocalciferol|50,000 IU tablet given weekly
46023217|NCT00892099|Drug|Ergocalciferol|50,000 IU tablet given monthly
46023218|NCT00892099|Other|Placebo|Placebo equivalent of ergocalciferol, given weekly as one tablet
46023219|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
46023220|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a standard breakfast
46023221|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
46023222|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered after an overnight fast of at least 10 hours.
46023223|NCT04248907|Other|0 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
46023224|NCT04248907|Other|2 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
46023225|NCT04248907|Other|4 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
46023226|NCT02835937|Other|No-Transfuse|Patients will not receive an otherwise-indicated red blood cell transfusion
46023227|NCT02835781|Other|Acellular dermal matrix implantation|Acellular dermal matrix obtained from Central tissue bank, University Hospital Bratislava, will be used for acellular dermal matrix implantation.
46109246|NCT00868517|Other|Wait-List Control Group|Received conventional care only. Eligible to receive true group auricular acupuncture once study period completed.
46109247|NCT00798148|Drug|131I-MIBG , Etoposide, Melphalan, Carboplatin, Autologous Peripheral Stem Cell Transplantation|131I-MIBG 12mci/kg CEM(Etoposide)=1200mg/m2 Melphalan=210mg/m2 Carboplatin=1500mg/m2 Autologous Peripheral Stem Cell Transplantation
46109248|NCT00787462|Drug|Pregabalin|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
46023228|NCT02836015|Behavioral|Shared Medical Visit|The Shared Medical Visits are a replacement for standard diabetic visits with PCP, and will occur completely in Spanish, the patients' preferred primary language. An interdisciplinary group including behavioral health, social work, pharmacy, MD, and diabetic educator will be involved in the visit. The focal point of the meeting is a 30 minute session in which all members are seated around a large table in the Midtown SMV area and each patient's blood sugars, labs, and medications are discussed in front of the entire group. Pertinent labs and vaccines are drawn/administered.
46023229|NCT00958438|Drug|Placebo|Placebo loading dose followed by placebo subcutaneous (SC) injection (2 mL) once a week for 16 weeks.
46023230|NCT00958438|Drug|Rilonacept|Rilonacept 160 mg SC loading dose followed by Rilonacept 80 mg/2 mL SC injections once a week for 16 weeks.
46023231|NCT00958438|Drug|Rilonacept|Rilonacept 320 mg SC loading dose followed by Rilonacept 160 mg/2 mL SC injections once a week for 16 weeks.
46023232|NCT02835859|Other|Dietary: saccharin|Assess the glycemic and hormonal responses to an oral glucose load preceded by an oral solution of NCASs (saccharin).
46023233|NCT02835859|Other|Estimate glucose absorptions|Indirectly estimate the rate of glucose absorption and gastric emptying by using 3-O-methyglucose (3-OMG) and acetaminophen, respectively.
46023234|NCT02835703|Procedure|Surgical repair of coarctation of aorta|Surgical repair of coarctation of aorta with aortic arch hypoplasia under CPB
46023235|NCT05151172|Device|endovascular thrombectomy (EVT)|minimally invasive endovascular surgery for mechanical removal of occluding intracranial thrombus
46023236|NCT05151172|Other|Standarad medical care|Stanadard medical care wil involve use of thrombolytic drugs, Blood pressure management, use of antiplatelet or anti coagulant drugs
46023237|NCT02835469|Drug|Menotrophin|
46023238|NCT02858674|Other|Pop Up Interruption Alert|Traditional Pop Up Alert used in Epic
46023239|NCT02858674|Other|Side Bar Non Interruptive Provider Checklist|Noninterruptive alert that sits in the checklist
46109249|NCT00787462|Drug|Placebo|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
46109250|NCT02618135|Other|Intervention Group|Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology.
46109251|NCT02618135|Other|Control Group|"Participants will wait for 8 weeks before training intervention begins.~Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology."
46109252|NCT00792766|Drug|everolimus (RAD001)|Subjects will resume the dosing regimen that they were receiving at the completion of the initial RAD001 study.
46109253|NCT02617979|Other|SAFECARE at Home customized lessons|
46109254|NCT02616107|Other|Managing Cancer Care: A Caregiver's Guide|"MCC-CG is a set of 7 printed modules including information about caregiver-nominated SM topics, conversation starters to facilitate communication with patients and providers, and links to caregiver resources. The modules are as follows:~Becoming a Cancer Caregiver [role, changes, challenges, adjusting, self-care]~Basics of Cancer Caregiving [physical, functional, emotional, social, & spiritual support; treatment timeline worksheet]~Caregiver's Role in Managing Patient Care [who/what is involved; health care professionals worksheet]~Managing Cancer Symptoms and Side Effects [common symptoms/side effects; maintaining health; nutrition & exercise; medication management worksheet]~Care Options: [information on curative, palliative and hospice care]~Talking About Goals of Care [information on goals of care conversations]~Managing Transitions [defining transitions, transition examples, helping yourself and patient to manage transitions; transitions worksheet]"
46109255|NCT02616107|Other|Symptom Management Toolkit|Along with an overview of symptom management, the Toolkit provides concise information on commonly experienced symptoms, including fatigue, alopecia, cognitive dysfunction, nausea and vomiting, and sleep problems, among others. Each chapter uses a question-and-answer format to cover the topics of who is most likely to experience the symptom, when and why the symptom may occur, how the symptom can be managed, and when to call a provider. Drs. Schulman-Green and McCorkle have previously tested the Symptom Toolkit in an attention-control group.
46023240|NCT02860390|Other|Denver Health Asthma Management Program|text message (SMS) support including educational, motivational, and resource content.
46023241|NCT02860390|Other|Person of Support|Subjects in the adolescent cohort will designate a support person (e.g. parent) to receive messages from the Denver Health Asthma Management Program
46109256|NCT00787696|Behavioral|Cognitive-behavioral HIV/STD risk reduction|18 60-minute group sessions plus 1 individual health and safety planning session
46109257|NCT00798382|Other|soy protein formula|ad lib for 0-35 days of age
46109258|NCT00798382|Other|Commercially available soy formula|ad lib for 0-35 days of age
46109259|NCT00798382|Other|Soy formula experimental #2|ad lib for 0-35 days of age
46109260|NCT00868439|Drug|patiromer|Active investigational drug
46109261|NCT00868439|Drug|placebo|placebo
46109262|NCT00798460|Drug|adefovir|adefovir 10mg
46109263|NCT00798460|Drug|clevudine|clevudine 30mg
46109264|NCT00798460|Drug|lamivudine|lamivudine 100mg
46109265|NCT00798538|Other|Services will be provided at one site|Provision of buprenorphine induction and management, substance abuse counseling and HIV care will be provided at one clinic: the Waterbury Hospital Infectious Disease Clinic..
46109266|NCT00798538|Other|Services remain dispersed; i.e., not centralized to one-location or provider.|Buprenorphine induction, substance abuse counseling, and HIV care will be provided at separate locations: the Community Health Care Van (CHCV), the Yale AIDS Program, and patients' own HIV providers, respectively.
46109267|NCT02615873|Drug|Accordion Pill™ Carbidopa/Levodopa|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
46023242|NCT02832973|Drug|Spironolactone|Spironolactone 25 mg
46109268|NCT00814164|Drug|clofarabine|IV
46109269|NCT00814164|Drug|daunorubicin hydrochloride|IV
46109270|NCT00814164|Genetic|cytogenetic analysis|Correlative study
46109271|NCT00814164|Genetic|protein expression analysis|Correlative Study
46023243|NCT02832973|Drug|Furosemide,|Furosemide 20-40 mg
46023244|NCT02832973|Drug|Amiloride|Amiloride 5 mg
46023245|NCT02832973|Drug|Ramipril|Ramipril 5-10 mg
46023246|NCT02832973|Drug|Bisoprolol|Bisoprolol 5-10 mg
46023247|NCT02832739|Device|SENACA - ICT based self-management support system|SENACA - ICT based self-management support system is a structured self-management support system with several interacting components, combining tele-monitoring devices and a solution for personalised health plans. ==> www.senaca.ch
46023248|NCT00958360|Other|Interdisciplinary Low Vision Service|Services are provided by optometrist(s) and low vision therapist(s), and include low vision therapy to improve use of remaining vision and low vision devices, and structured homework to practice use of low vision devices that are prescribed and dispensed.
46109272|NCT00814164|Other|immunologic technique|Correlative Study
46109273|NCT00814164|Other|pharmacological study|Correlative Study
45469213|NCT03620916|Procedure|Intrathecal morphine|Single dose (0,4 mg) intrathecal morphine immediately before operation, patient-controlled analgesia with morphine (2 mg intravenously, a least 20 min interval) over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale>4, at least 6 hour interval) over next two days in the postoperative period
45469214|NCT03767413|Procedure|PNF|proprioceptive neuromuscular facilitation training
45469215|NCT03767413|Procedure|PNFMP|proprioceptive neuromuscular facilitation training and mental practice technique
45469216|NCT03427060|Drug|Coversin|Coversin - 22.5mg followed by 45mg for 6 months.
45469217|NCT01237067|Drug|Carboplatin|A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
45469218|NCT01237067|Drug|Olaparib|A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
45469219|NCT05282316|Dietary Supplement|EVOO polyphenols enriched|Addition of 40 ml daily of healthy polyphenols enriched EVOO to mediterranean diet for 6 months
45469220|NCT05282316|Dietary Supplement|EVOO standard|Addition of 40 ml daily of standard EVOO to mediterranean diet for 6 months
45469221|NCT03762187|Behavioral|Self-affirmation|Individuals select important values and then write about why that value is important to them.
46023249|NCT00958360|Other|Basic Low Vision Service|Service is provided by the optometrist alone and includes demonstration of low vision device use and maintenance of prescribed low vision devices, without low vision therapy or homework and with less contact time.
46023250|NCT02832895|Other|Transcranial doppler examination|Assessment of frontal bone window for transcranial doppler
46023251|NCT02832817|Device|Pulse oximeter|For each monitoring of Arterial Oxygen Saturation, measures of Arterial Pulsed Oxygen Saturation will be made for each pulse oximeter.
46023252|NCT02860312|Behavioral|Intradialytic exercise on stationary bicycles|Patients are exercising for 30-60 min during dialysis on an Rated Perceived Exertion (RPE) Scale between 12 and 14
46023253|NCT02860312|Behavioral|Non-exercising group|Patients are having their usual physical activity
46109274|NCT02609334|Drug|CRD007|One single dose given 3 hours prior to Mannitol challenge
46109275|NCT02609334|Other|Placebo|One single dose given 3 hours prior to Mannitol challenge
45469222|NCT03762187|Behavioral|Positive living counseling|Each of the clinics from which participants were recruited conducts positive living counseling as part of their treatment programs. This counseling is conducted by counselors who are trained and monitored by the Lesotho Network of AIDS Support Organizations (LENASO) and consistent with the positive prevention framework (see Bunnell et al., 2005 for description). Each counseling session focused on addressing positive living goals such as the importance of taking one's medications on time and every day, using protection with every partner, and the importance of maintaining a healthy lifestyle.
46023254|NCT02831491|Drug|Ramucirumab|Administered IV
46023255|NCT02831491|Drug|Docetaxel|Administered IV
46109276|NCT05757882|Other|4 hours of fasting time|Oral intake is not allowed for 4 hours before sedation including water.
45469223|NCT03422458|Device|Alveolar Ridge Preservation|Insertion of a bone substitute material (BioOss Collagen) within the bony envelope at least to the level of the palatal/ lingual bone plate. Adaptation of a collagen matrix (Mucograft Seal) to the soft tissue borders.
45469224|NCT05279352|Drug|FBR-002|Administration on D1 and D3
45469225|NCT05279352|Drug|Placebo|Administration on D1 and D3
45469226|NCT03426982|Drug|Unfractionated heparin|Infusion dose of unfractionated heparin was adjusted by APTT
45469227|NCT03426982|Drug|Unfractionated heparin|Infusion dose of unfractionated heparin was adjusted by anti-Xa
46023256|NCT02860234|Drug|Oxaliplatin|
46023257|NCT02860234|Drug|Capecitabine|
45469228|NCT03762031|Drug|GC4711 30mg|single dose given via a 15 minute intravenous infusion
46023258|NCT02860234|Radiation|intensity modulated radiotherapy|
46109277|NCT05757882|Other|2 hours of fasting time|Oral intake is not allowed for 2 hours before sedation including water.
46109278|NCT00693641|Other|Safe Sea sun lotion with jellyfish sting protection SPF 15|Prevent or significantly reduce jellyfish sting using sun lotion with a jellyfish sting inhibitor. The amount of lotion applied to the skin before spreading is the same as for regular sun lotion 2.00 mg.cm-²± 2.5%.
45469229|NCT03762031|Drug|GC4711 60mg|single dose given via a 15 minute intravenous infusion
46023259|NCT02860234|Procedure|DRE-Endoscopy-MRI-CEA|
46023260|NCT02860234|Procedure|Nonoperative Management|
46023261|NCT02860234|Procedure|Local Excision|
46023262|NCT02860234|Procedure|Total Mesorectal Excision|
46023263|NCT02860234|Behavioral|Quality of Life Questionnaires|
46023264|NCT02858752|Other|Experience 1 : Auditory and Visual Discrimination|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
46109279|NCT00693641|Other|Nivea sun, caring sun lotion SPF 15|The amount of lotion applied to the skin before spreading is 2.00 mg.cm-²± 2.5%.
46109280|NCT00659230|Drug|Nepicastat|100-800mg
46109281|NCT00659230|Drug|Placebo|100-800mg placebo
46109282|NCT04133831|Other|Total Survival|"The overall or total survival rate at each center is displayed in the table of outcome statistics.~Total survival is computed from survival rates of both transplant and waitlist patients: [(number of patients surviving after transplant at end of year + number of patients alive on waitlist at end of year)] / [number of patients alive on waitlist at start of year]."
45469230|NCT03762031|Drug|GC4711 90mg|single dose given via a 15 minute intravenous infusion
46023265|NCT02858752|Other|Experience 2 : Passive and Active Auditory Perception|Neuropsychological tests consist in listening to sounds under 2 conditions, an active or a passive one, during which different auditory stimuli will be presented: frequent stimuli (standard) and rare stimuli (deviants). These two stimuli differ in some of their feature (height, duration, …). A third, very rare (novel) stimulus will also be used (the subject's first name). Responses will be provided using a response-button and feedback will be given at each response. EEG will be recorded all along to measure Neurophysiological signals.
46109283|NCT04133831|Other|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = [number of patients surviving after transplant with excellent organ]/[number of patients for whom excellent organ was accepted for transplant] marginal transplant survival = [number of patients surviving after transplant with marginal organ]/[number of patients for whom marginal organ was accepted for transplant]"
46109284|NCT00792844|Dietary Supplement|Bio-K capsule formulation|Bio-K 1 capsule formulation daily for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
45469231|NCT03762031|Drug|GC4711 120mg|single dose given via a 15 minute intravenous infusion
45469232|NCT03762031|Drug|Placebo|single dose of normal saline given via a 15 minute intravenous infusion
45469233|NCT03762031|Drug|GC4711 75mg|single dose given via a 15 minute intravenous infusion
45469234|NCT03762031|Drug|GC4711 105mg|single dose given via a 15 minute intravenous infusion
45838392|NCT03263546|Behavioral|Internet-delivered cognitive behavioral therapy (ICBT)|"Participants will receive internet-delivered CBT with therapist support for 16 weeks. The treatment consists of 14 online chapters with interactive features as videos and illustrations. The treatment has the main focus on exposure with ritual prevention. The children and parents have regular contact with a personal assigned therapist via written text messages in the platform.~Participants that are classified as non-responders at 3 months follow-up will receive face-to-face CBT of up to 12 sessions over 12 weeks."
46023266|NCT02858752|Other|Experience 3 : Visual Attention Training|This experience aims at training visual attention through serious games. Children will play against an artificial intelligence and will focus their attention on one out of many possible targets (checkers, cards, boxes) presented on screen. Responses will be provided using a response-button, sometimes completed by an eye-tracking measure. Feedback will be given to the child after his response. EEG will be recorded all along to measure Neurophysiological signals.
45469235|NCT04983810|Drug|Fadraciclib|Fadraciclib is a highly selective, orally- and intravenously- available, 2nd generation amino-purine inhibitor of CDK2 and CDK9.
46109285|NCT00792844|Dietary Supplement|Bio-K drink|Bio-K 98 g of diary-free soy beverage formulation for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
45469236|NCT01239641|Procedure|High intensity focused ultrasound|The term 'high intensity focused ultrasound' means using ultrasound to causes coagulation necrosis to destroy the targeted tissue, in this case, uterine fibroids.
45469237|NCT03770533|Other|MR-proADM guided|MR-proADM value together with routine clinical evaluation identifies patients with a low 14 day mortality risk who do not need to be hospitalized
45469238|NCT01312584|Dietary Supplement|Processed High-flavanol|
45469239|NCT03416218|Behavioral|Prognosis|Prognosis will be a single-player 2D, digital simulation game and supporting multimedia website. Players are situated as a major official of Hexacago, and tasks them with managing the city's finances, education levels, and health concerns to lower rates of teenage pregnancy and sexually transmitted infections. In the game Prognosis, player dispatches professionals from a variety of fields to different neighborhoods around the city, observing the effects of their resource allocation decisions across multiple systems over many in-game months. The supporting multimedia website will house curriculum and learning tools to support the learning objectives of Prognosis.
46023267|NCT02858752|Other|Experience 4 : Attention and Distractibility|Neuropsychological tests consist in listening to sounds preceded by a visual cue indicating (or not) in which ear the sounds will be played. The subject Child should detect the target sound (e.g. a dog barking). In some trials, a distracting distraction will be introduced between the visual cue and the target sound. Responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
46023268|NCT02858752|Other|Experience 5 : Sustained Visual Attention|Neuropsychological tests consist in watching visual stimuli presented in 3 blocks of 3 minutes each, with a break of one minute between each block. The child has to detect the presence of a red letter in a pattern made of four letters (the three other letters are black). Behavioral responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
45681517|NCT04405804|Drug|Ivabradine 5Mg Tab|"Initial dose of ivabradine will be:~0.02 mg/kg/dose twice daily in patients between 6-12 months 0.05 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight < 40 kg 2.5 mg/day in patients between 3-18 years with weight > 40 kg During titration phase, the dose may be increased, maintained, reduced or discontinued in accordance with titration rules. The titration rules will be adjusted on the basis of age subset and of each patient's evaluation during the titration phase, whether or not the target heart rate is reached (HR ≥ 20% compared to baseline HR) and whether or not are present bradycardia (HR should be greater than predefined by a HR threshold per age subset) and/or bradycardia-related symptoms.~Maximum dose to be reached will be:~0.2 mg/kg/dose twice daily in patients between 6-12 months 0.3 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight < 40 kg 15 mg/day in patients between 3-18 years, weight > 40 kg"
45681518|NCT04145206|Behavioral|Flamenco dance|evaluation of ankle injuries in the flamenco dancers
46023269|NCT02832583|Device|Regenkit BCT-HA Cellular Matrix|To assess the efficacy of PRP-HA on skin rejuvenation, thirty one patients with chronological aging including wrinkles, dull and dry skin with loss of elasticity and firmness. The patients received three PRP-AH injection sessions 4 weeks apart into the cheeks.
45681519|NCT04145128|Drug|AG881|AG-881 tablets.
45681520|NCT03945604|Drug|SHR-1210 + Apatinib +Fluzoparib|SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity.
45681521|NCT03944434|Drug|Ribociclib|ribociclib 600 mg/day orally
45681522|NCT03944434|Drug|Aromatase Inhibitors, non steroideal|letrozole 2.5 mg/day orally or anastrozole 1 mg/day orally
45469240|NCT01561885|Other|Pathway-Based Care|Patients who are randomly allocated to Pathway Care will be treated by the Pathway Clinical Teaching Unit as well as other collaborative healthcare professionals (pharmacists, nurses, health educators, nutritionists, and social workers). The Pathway Care physicians will have access to the Clinical Care Plan on the QuadraMed, which is a detailed, organized, day-to-day treatment plan that includes pre-set orders and medications. Physicians for the patients on Usual Care will not have access to this information, and the collaborative healthcare will only be provided upon consultation.
45469241|NCT02129543|Procedure|Blood Draw|Whole blood samples will be collected from study subjects for immune cell and plasma analysis per protocol.
45469242|NCT03684343|Other|Filmed consultation with a dermatologist|"Patient will be seen by a dermatologist for a consultation which will be filmed. During the consult, a laterality test and a tactile sensitivity test will be performed.~After the consult, videos will be analysed by scientists to identify the frequency of occurrence of each behavior and the percentage of time passed to express each behavior."
45469243|NCT03767179|Diagnostic Test|study|procalcitonin, sedimentation, CRP, leukocyte identification
45469244|NCT01546948|Drug|Methadone|Patients in the methadone group will be administered 0.3 mg/kg of methadone intraoperatively: two-thirds of the dose (6 cc or 0.2 mg/kg of methadone) on induction of anesthesia as a bolus. The remainder of the dose (3 cc or 0.1 mg/kg of methadone) will be administered at approximately 1.5-2 hours before the end of the procedure.
45469245|NCT01546948|Drug|Hydromorphone|Patients in the hydromorphone group will receive 0.03 mg/kg of hydromorphone; two-thirds the dose (6 cc or 0.02 mg/kg) on induction of anesthesia, and the remainder of the hydromorphone (3 cc or 0.01 mg/kg) will be bolused 1.5-2 hours before surgery concludes.
45469246|NCT00458003|Drug|Ephedrine|Ephedrine concentration: 8 mg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP > 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP < 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
45469247|NCT00458003|Drug|Phenylephrine|Phenylephrine concentration: 100 mcg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP > 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP < 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
45469248|NCT04599972|Drug|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
45469249|NCT04599972|Drug|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
46023270|NCT04280380|Diagnostic Test|Real time PCR|At inclusion, serum samples will be collected to determine CMV serological status. Plasma samples will be collected weekly for CMV PCR analysis. Antibodies for CMV will be assessed using a commercial enzyme immunoassay kit for detection of total antibodies to CMV (LIAISON CMV IgG assay, DiaSorin S.p.A). DNA will be extracted in 200 μL of plasma eluted in 60 μL of elution buffer using a NucliSENS easyMAG system (bioMérieux, Boxtel, The Netherlands). Samples will be amplified using Affigene CMV Trender diagnostic assay (Cepheid AB, Bromma, Sweden), according to the manufacturer instructions. Amplification will be performed on a MX3000P instrument (Stratagene Instruments Systems, La Jolla, CA, USA). Samples with >500 copies/mL of plasma will be considered positive.
45469250|NCT03416140|Other|Therapeutic Exercise|30 minutes per day of therapeutic exercise
45681523|NCT03944434|Drug|LHRH agonist|Triptorelin 3,75 mg or Leuprolide 3,75 mg or goserelin 3,6 mg, as injectable.
45681524|NCT05580484|Procedure|Second surgery|The primary outcomes were adhesion severity and adhesion area in the lower ab-dominal cavity, as determined through direct visual observation of a laparotomy wound or laparoscopic observation from stoma closure wound.
45681525|NCT03944356|Drug|Dabrafenib and Trametinib|Dabrafenib and trametinib treatment under routine conditions according to the applying SmPC.
45681526|NCT04148716|Procedure|additional biopsies|additional biopsies during a fibroscopy planned in the care
46109286|NCT02615795|Device|Tele Monitoring, using Tunstall monitoring device|Monitoring of symptoms and physiological parameters at home, using Tunstall Healthcare telemedicine equipment. Patients perform physiological measurement. In addition, they correspond to a standardized questionnaire regarding disease specific symptoms. Data is assessed by the medical staff the same day. If the data indicates worsening in the patient's condition, the patient is contacted by phone. The assessment of the patient is made either on the specialist nurse level, or at a conference between the specialist nurse and a senior pulmonary doctor. There is no call center service.
46023271|NCT04280146|Behavioral|daily energy intake|Investigate daily energy intake according to eating rate and food processing
46023272|NCT05263141|Procedure|retro-auricular single-site endoscopic thyroidectomy|The strap muscles and the sternocleidomastoid muscle were separated. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified，A lobe of thyroid specimen and central lymph nodes were dissected.
46109287|NCT00809094|Drug|N-acetylcysteine (NAC)|
46109288|NCT00809094|Drug|Placebo|
46109289|NCT00658996|Device|SofLens DD Toric|daily disposable wear contact lens for 2 weeks
46109290|NCT00658996|Device|Ciba Vision Focus Dailies Toric Contact Lens|daily disposable wear contact lens for 2 weeks
46023273|NCT05263141|Procedure|traditional open surgery thyroidectomy|The strap muscles were separated in the midline to expose the thyroid gland. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified， a lobe of thyroid specimen and central lymph nodes were dissected.
46023274|NCT00630370|Drug|Placebo|2 Placebo tablets, TID, orally, 58 days
46109291|NCT02615639|Biological|HPDC-T cells & Entecavir|experimental groups will be given HPDC-T cells & Entecavir. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and entecavir 0.5mg tablet every night by mouth
46109292|NCT02615639|Drug|Entecavir|0.5mg tablet every night by mouth
46109293|NCT02615639|Drug|HPDC-T cells & IFN-a-2a|experimental groups will be given HPDC-T cells & IFN-a-2a. HPDC-T cells will be given for 24 weeks on the basis of anti-HBV therapy ,and IFN-a-2a 180ug subcutaneous injection every week
45469251|NCT03770611|Dietary Supplement|Probiotic|The probiotic supplement is composed of the following bacterial strains: Bacillus coagulans, Bacillus subtilis, Bifidobacterium (B) bifidum, B. breve, B. longum, Lactobacillus (L) acidophilus, L. brevis, L. casei, L. helveticus, L. Paracasei, L plantarum, L. rhamnosus, L. salivarus, Lactococcus lactis, Pediococcus acidilactici, Pediococcus parvulus, Weisella confusa, Weisella paramesenteroides
45469252|NCT03770611|Dietary Supplement|Prebiotic|The prebiotic fiber is Agave inulin
45681527|NCT03582436|Procedure|Kidney transplantation|"For the patients with the kidney transplantation, these parameters will be analysis:~Transcriptomics analysis Characteristics of anti HLA DSA analysis Non-HLA antibodies analysis Omics blood analysis Urine chemokines analysis"
45469253|NCT03770611|Dietary Supplement|Symbiotic|The supplement is a combination of the probiotic product + the prebiotic fiber
46109294|NCT02615639|Drug|IFN-a-2a|IFN-a-2a 180ug subcutaneous injection every week
46109295|NCT02615639|Drug|HPDC-T cells & Telbivudine|experimental groups will be given HPDC-T cells & Telbivudine. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and Telbivudine 600mg tablet every day by mouth
46109296|NCT02615639|Drug|Telbivudine|Telbivudine 600mg tablet every day by mouth
46109297|NCT00798616|Drug|prednisolone or methylprednisolone|either prednisolone 2mg/kg PO once daily or methylprednisolone 1.6mg/kg IV once daily (if IV access is present) for length of hospitalization, for a maximum of seven days
46109298|NCT00798616|Drug|placebo|oral or IV placebo
46109299|NCT02618057|Drug|Prednisolone|PO prednisolone, 1 mg/kg/day, for 5 days
46109300|NCT02618057|Drug|Levofloxacin|Levofloxacin, 10mg/kg/day, IV, for 5days
46109301|NCT02617823|Procedure|lateral position|patients placed on their left side after epidural catheter insertion
46109302|NCT04866004|Behavioral|Contingency Management - Cannabis|Participants in the contingency management program will be provided financial incentives for 28-days of cannabis abstinence. At every visit, participants will provide urine samples for the biochemical verification of cannabis abstinence). Participants with evidence of cannabis abstinence will be provided a financial incentive that increases across subsequent study visits.
46109303|NCT05098236|Device|Training in the Blind Field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. Subjects will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 3 and up to 12 months at a time.
45469254|NCT03770611|Dietary Supplement|Placebo|The supplement is a combination of probiotic placebo and prebiotic fiber placebo. Placebo will consist on maltodextrin for both cases.
45469255|NCT03008616|Biological|AMAG-423 (digoxin immune fab)|AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
45469256|NCT03008616|Other|Placebo|Normal saline, 30 minute IV infusion, every 6 hours x 4 days
45681528|NCT01701063|Drug|Telaprevir|100- and 250-mg chewable tablets or 375-mg film-coated tablets for oral administration
46023275|NCT00630370|Drug|20 mg ATI 7505|1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
46023276|NCT00630370|Drug|40 mg ATI 7505|1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days
46023277|NCT00630370|Drug|80 mg ATI 7505|2 ATI 40mg tablets, TID, orally, 58 days
46023278|NCT02832349|Other|Educational Actions|Individual educational session and 3 group educational sessions (5-6 patients per group) built around the epileptic disease, its treatment and daily life, will constitute the program of EA group.
46023279|NCT04280068|Behavioral|Clinician Guide (CG)|An evidence-based, intervention approach to reduce heavy drinking in primary care settings.
46023280|NCT04280068|Behavioral|Clinician Guide plus HealthCall|HealthCall is a smartphone application designed to help participants keep track of their daily alcohol use, medication adherence and a few other health behaviors through brief daily use.
46109304|NCT05098236|Device|Training in the Sighted Field|This training will take place in lab at the University of Rochester Medical Center. Subject will perform one daily training session, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the visual field. The computer program will automatically create a record of patient performance during each training session. Subjects will train daily (about 30-40 minutes total), 5 to 7 days per week for at 7 - 14 days.
46109305|NCT00867815|Drug|Diagnostic procedures|The patients will not receive any study drug in this study. The patients will have ophthalmological (eye) examinations, blood work and will complete an interview
46109306|NCT05755776|Drug|TMF|switch ETV to TMF
46109307|NCT04137029|Drug|Formoterol|The participants will receive inhalation of formoterol 12 micrograms
46109308|NCT04137029|Drug|Tiotropium Bromide|The participants will receive inhalation of tiotropium bromide 18 mkg once
46023281|NCT02835547|Other|Data collection|Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
46023282|NCT04281706|Drug|Etomidate vs Propofol as induction agent|Patients undergoing cardiac surgery were induced with Etomidate according to the standard operating procedure for induction until October 1st, 2013, afterwards a new SOP with Propofol as primary induction agent was introduced. After a washout period of 3 months, Propofol was used as sole induction agent. The rest of the standard operating procedure remained the same.
46023283|NCT02835391|Device|PerClot|Haemostatic device for the control of bleeding from capillary, venous or arteriolar vessels by pressure, ligature or other conventional means is either ineffective or impractical.
46023284|NCT02835391|Device|Floseal, Surgicel, Surgiflo, Arista|Haemostatic device for the control of bleeding
46023285|NCT02835391|Procedure|Electrocautery/Diatermy|Procedure for the control of bleeding
46023286|NCT02997826|Other|Infantil formula|
46023287|NCT02835001|Procedure|Bronchoscopy|Two sequences of 30 minutes are necessary by patient
46023288|NCT02835001|Device|Lung Volume Reduction Coil (HEAT-LVRC)|Bronchoscopy with Heat-LVRC
46023289|NCT02835235|Drug|NNC9204-0530|Administered daily subcutaneously (s.c., under the skin)
46023290|NCT02835235|Drug|placebo|Administered daily subcutaneously (s.c., under the skin)
46023291|NCT02831101|Drug|Sufentanil|To evaluate, in the elderly, the impact of a concomitant administration of sufentanil during a step-wise propofol induction of anaesthesia on the depth of sedation measured using BIS and clinical sedation score.
46109309|NCT04137029|Diagnostic Test|metacholine test|The participants will receive inhalation of metacholine once
46109310|NCT00787774|Drug|resume raltegravir|resume raltegravir after 16 weeks of stopping
46109311|NCT00452413|Drug|enzastaurin|Administered orally
46109312|NCT00452413|Drug|erlotinib|Administered orally
46109313|NCT00793000|Drug|PF-04287881|75 mg oral dose (prepared solution) given once
46109314|NCT00793000|Drug|Placebo|placebo to match 75 mg oral dose (prepared solution), given once
46109315|NCT00793000|Drug|PF-04287881|150 mg oral dose (prepared solution) given once
46109316|NCT00793000|Drug|Placebo|placebo to match 150 mg oral dose (prepared solution), given once
46109317|NCT00793000|Drug|PF-04287881|300 mg oral dose (prepared solution) given once
46109318|NCT00793000|Drug|Placebo|placebo to match 300 mg oral dose (prepared solution), given once
46109319|NCT00793000|Drug|PF-04287881|750 mg oral dose (prepared solution) given once
46109320|NCT00793000|Drug|Placebo|placebo to match 750 mg oral dose (prepared solution), given once
46109321|NCT00793000|Drug|PF-04287881|1000 mg oral dose (prepared solution) given once
45469257|NCT03422146|Other|Tea Tree Oil (TTO)|Participants will use the Cliradex® eyelid hygiene lid wipe / towelette for BID for 2 weeks
46023292|NCT02831101|Drug|Placebo|To evaluate presence or absence of strong opioid (sufentanil) on BIS values in the elderly during propofol induction until the loss of consciousness
46023293|NCT02834923|Behavioral|Enhanced Engagement Protocol for CTH (EE-CTH)|EE-CTH integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol.
46023294|NCT02834923|Behavioral|Connection to Health (CTH)|CTH is a comprehensive SMS program that focuses on behavior change.
46023295|NCT04247659|Drug|sodium aescinate|The main mechanism of sodium aescinate includes anti - inflammatory, anti - exudate anti - oxygen free radical ,anti - edema increased venous tension.The treatment course of sodium aescinate is 10 days,20mg/day, intravenous infusion.
46023296|NCT02831413|Behavioral|RS+|The curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making.
46023297|NCT02831413|Behavioral|Codeacademy|a computer programming curriculum, Codeacademy, that teaches students how to use HTML.
46023298|NCT04201327|Behavioral|Project Jumpstart|PrEP focused intervention to improve PrEP related health outcomes
46109322|NCT00793000|Drug|Placebo|placebo to match 1000 mg oral dose (prepared solution), given once
46109323|NCT00793000|Drug|PF-04287881|1250 mg oral dose (prepared solution) given once
46109324|NCT00793000|Drug|Placebo|placebo to match 1250 mg oral dose (prepared solution), given once
46109325|NCT00793000|Drug|PF-04287881|1500 mg oral dose (prepared solution) given once
46109326|NCT00793000|Drug|Placebo|placebo to match 1500 mg oral dose (prepared solution), given once
46023299|NCT04245787|Drug|Self assembling peptide with fluoride|peptide forms a 3D matrix within demineralized carious lesions areas, which enables novo hydroxyapatite crystal formation facilitating the so-called guided enamel regeneration of the lost enamel structure. The peptide has shown encouraging results as a scaffold for enamel regeneration
46023300|NCT04201171|Device|CSII and CGM|use of CSII as insulin delivery or CGM as glucose monitoring
46023301|NCT02831803|Dietary Supplement|Walnuts|28 gm/day in single-serve package
46023302|NCT02831803|Dietary Supplement|Extra Virgin Olive Oil|32 gm/day provided in 3, 34 ounce bottles
46023303|NCT00633451|Other|Manual Therapy and Exercise|Manual therapy to the thoracic spine and shoulder, and therapeutic exercise to the shoulder and spine applied in a prescribed progression of therapeutic exercise aimed at improving shoulder function.
46023304|NCT00633451|Other|Exercise Only|A prescribed progression of therapeutic exercise for the shoulder and spine aimed at improving shoulder function
46023305|NCT02828605|Device|Virtual Interactive Platform (VIP) Transplant|
46023306|NCT02831179|Drug|Capecitabine|Given PO
46023307|NCT02831179|Drug|Temozolomide|Given PI
46023308|NCT02831179|Drug|Veliparib|given PO
46023309|NCT02831179|Other|Pharmacological Study|Correlative studies
46023310|NCT02831179|Other|Laboratory Biomarker Analysis|Correlative studies
46023311|NCT04245553|Diagnostic Test|Abdominal Point of Care Ultrasound|Participants will be have their needle insertion site for a paracentesis land-marked using both the traditional anatomical method, and with a point of care ultrasound. Note that the current standard of care does not require the use of point of care ultrasound.
46023312|NCT04245631|Diagnostic Test|Recombinase aided amplification (RAA) assay|We established a real time reverse-transcription RAA (RT-RAA) assay for detection of 2019-nCoV. This assay was performed at 42°C within 30min using a portable real-time fluorescence detector, Recombinant plasmids containing conserved ORF1ab genes was used to analyze the specificity and sensitivity. Clinical specimens from patients who were suspected of being infected with 2019-nCoV were used to evaluate the performance of the assay. In parallel, we also used the commercial RT-qPCR assay kit for 2019-nCoV as a reference. Sample types include either of nasal swab, oral swab, bronchoalveolar-lavage fluid, urea, blood, fecal.
46023313|NCT02828683|Device|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST segment elevation myocardial infarction (STEMI)
46109327|NCT00793000|Drug|PF-04287881|300 mg oral dose (prepared solution) given once
46109328|NCT00793000|Drug|Placebo|placebo to match 300 mg oral dose (prepared solution), given once
45469258|NCT03422146|Other|I-Lid'n Lash® Hygiene|Patients will use the I-Lid'n Lash® Hygiene lid wipe / towelette for BID for 2 weeks
46023314|NCT02828683|Device|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST-segment elevatio myocardial infarction
46023315|NCT02828527|Other|Observational|
46109329|NCT00793000|Drug|PF-04287881|750 mg oral dose (prepared solution) given once
46109330|NCT00793000|Drug|Placebo|placebo to match 750 mg oral dose (prepared solution), given once
46109331|NCT00793000|Drug|PF-04287881|1000 mg based on safety and PK from previous cohorts; oral dose (prepared solution) given once
46109332|NCT00793000|Drug|Placebo|placebo to match 1000 mg oral dose (prepared solution), given once
46023316|NCT04245007|Behavioral|Fasting|Doing fasting 2 days a week within 8 weeks
46023317|NCT05097469|Device|Carbon dioxide laser|3 consecutive sessions of carbon dioxide laser treatment
46023318|NCT05097469|Device|Sham laser treatment|3 consecutive sessions of sham laser treatment
46023319|NCT02830789|Dietary Supplement|Calcium Carbonate|
46023320|NCT02830789|Dietary Supplement|Calcium Citrate|
46023321|NCT02830789|Dietary Supplement|Placebo|Tablet manufactured to mimic a calcium carbonate tablet
46023322|NCT02830789|Procedure|Roux-en-Y gastric bypass|Roux-en-Y gastric bypass surgery at least 12 months before study inclusion
46023323|NCT04243993|Other|Calcium silicate cement|Calcium silicate cement for using in endodontic treatments i.e. pulpotomy, orthograde MTA apical barrier, root perforation repair, and endodontic microsurgery.
46023324|NCT04243603|Behavioral|Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA-DK)|Please see description of experimental arm (arm one)
46023325|NCT02828293|Other|Dynamic videofluoroscopic analysis|Patients bearing 3 different prosthesis (3 groups) will be prospactively assessed with videofluoroscopy.
46023326|NCT04245163|Behavioral|Educational program|The intervention program will include 3 phases. At phase 1 a presentation on Microsoft PowerPoint in order to increase the general knowledge about glaucoma. At phase 2 a video and a one on one teaching to develop skills of administering the eye drops in a correct and systematic way. At phase 3, a discussion in order to identify cues to action that can easily be adopted by the patient in his/her daily routine, (such as, how to remember to put in drops) will take place.
45838393|NCT03263546|Behavioral|Cognitive behavioral therapy (CBT)|"Participants in the gold standard group will receive 14 individual face-to-face CBT sessions over 16 weeks. The treatment is based on current evidence based recommendations for OCD, and focuses on exposure with ritual prevention.~Participants that are classified as non-responders at 3 months follow-up will receive additional face-to-face CBT of up to 12 sessions over 12 weeks."
46023327|NCT04245319|Drug|Acitretin|The patients will receive the drug and the effect on repigmentation on vitiligo lesions will be observed
46023328|NCT04245319|Other|Narrow band ultraviolet B|Patients receive nbUVB session 3 times per week
46109333|NCT05091450|Behavioral|Couple-based I-BMS intervention for infertility|It is based on the previous I-BMS intervention for women undergoing IVF treatment, and aims to improve fertility quality of life and couple flourishing by (1) increasing awareness of the interconnectedness between physical and psychosocial well-being, (2) practicing body-mind-spirit techniques, (3) facilitating personal growth and partner empathy and compassion, and (3) creating the shared meaning of life, family, children. As a strength-focused and meaning-oriented approach, it utilizes experiential and self-reflective exercises to help participants reconstruct the meaning behind their ordeal and rediscover the strengths that keep them going.
46109334|NCT04134533|Other|Gross Motor Function Measurement|These instruments will be used for determine the gross motor functional level and quality of life of the children with cerebral palsy and anxiety, depression levels of caregivers.
46109335|NCT00798772|Dietary Supplement|Micronutrients and antioxidants|8 capsules twice daily for two years
46109336|NCT00798772|Dietary Supplement|Multivitamins and minerals|8 capsules twice daily for two years
46109337|NCT00867503|Drug|Bendamustine HCL|bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
46109338|NCT00788164|Biological|TA-HPV|Given intramuscularly
46109339|NCT00788164|Biological|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|Given intramuscularly
46109340|NCT00788164|Drug|imiquimod|Given topically
46109341|NCT05055648|Radiation|Photon Radiotherapy|nCXT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
46109342|NCT05055648|Radiation|Proton Radiotherapy|nCPT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
46109343|NCT04134299|Dietary Supplement|AXA4010|The study will initiate with approximately eight (8) adult subjects (≥18 y/o) with SCD (Cohort 1). Each subject will receive AXA4010 twice a day (BID) for 12 weeks. Safety and tolerability will be monitored, and study procedures will be performed. Analysis of safety, tolerability and laboratory assessments at week 12 would be performed. Based on the 12-week observations from at least three subjects in Cohort 1, subsequent Cohorts 2 and 3 in Part II may be initiated.
46109344|NCT00793156|Drug|Nalfurafine HCl 2.5 µg|Daily dose of 2.5 µg
46109345|NCT00793156|Drug|Nalfurafine HCl 5.0 µg|Daily dose of 5.0 µg
46109346|NCT00793156|Other|Placebo|Placebo daily dose
46109347|NCT04132739|Behavioral|Diet|The Nutrition Intervention will consider the participants' food preferences and concerns for managing glycemic control and maintaining muscle-mass. Each topic will be presented interactively and the participants will be encouraged to attend 2 times/week (attendance will be logged). The topics will be presented as a combination of evidenced-based materials for older adults with type 2 diabetes. We anticipate 3 sessions/topic during the 6-month intervention and will modify the topics and time to fit the needs of our audience. The lessons and materials will be offered in English and Spanish. The food quality change will be measured using a Food Frequency Questionnaire validated in Hispanic populations. The goals are to increase the participants' self-efficacy (belief and self-confidence) that they have the tools necessary to manage diabetes and reduce mobility impairments.
45681529|NCT01701063|Drug|Peginterferon alfa-2b|50 μg/0.5 mL, 80 μg/0.5 mL, 120 μg/0.5 mL, or 150 μg/0.5 mL for subcutaneous (SC) injection
46023329|NCT02828449|Behavioral|therapeutic education program|
46023330|NCT02828371|Device|stepping verticalization|After patient positioning, the slope of the tilt table was gradually increased from 0° to 20°, 40° and then 60° in a time span of nine minutes. The stepping frequency was set at 20 steps/min for the entire treatment. Cardiovascular and respiratory parameters were continuously monitored. The net time of the session was 30 minutes
45681530|NCT01701063|Drug|Ribavirin|200-mg capsules or 40-mg/mL solution for oral administration
45681531|NCT04406116|Device|Microwave coagulation using HS1 Instrument|Microwave therapy at 5.8 GHz
45681532|NCT04145050|Other|Carbohydrate dosing|The purpose of this study is to examine effects of different carbohydrate doses during marathon simulation in elite wheelchair racers.
45681533|NCT03941314|Device|Supera® Peripheral Stent System|The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
46023331|NCT02828371|Other|conventional mobilization|in-bed physiotherapy (mobilization exercises in supine and sitting position on bed, without out-of-bed mobilization nor verticalization)
46109348|NCT04132739|Behavioral|Exercise|The Exercise Intervention will involve 30-minute exercise sessions based on the Otago Exercise Program. The exercises involve lower and upper limb strengthening, balance training and a walking plan. The participants will receive illustrations of the exercises to do. Each participant will exercise for 30 minutes, 2x/week during supervised sessions in the facilities and be encouraged to do the exercises by themselves on days the group sessions are not offered. We will also teach self-monitoring for signs of low-blood glucose to ensure safety. Progression will be done every two weeks during the first 2 months, once at month 3, and once at month 6 by increasing intensity and/or difficulty and the walks by increasing continuous walking time and walking speed without compromising safety.
46109349|NCT04132739|Behavioral|Diet and exercise|A combination of the diet and exercise interventions following the same procedures previously described.
46109350|NCT00798850|Procedure|Percutaneous Transluminal Angioplasty (PTA)|PTA will be performed by a consultant interventional radiologist with no deviation from the standard protocol at Hull & East Yorshire Yospitals NHS Trust.
46109351|NCT00798850|Procedure|Supervised Exercise Programme (SEP)|"SEP: Conducted 3 times per week for 12 weeks.The session will be supervised by a physiotherapist and conducted in the cardiac gym.~Each session begins with gentle warming up exercises followed by an exercise circuit of 6 stations(2 minutes each).~Station 1-Step-ups(20-cm high step,alternating leg after 10 step-ups)~Station 2-Exercise bicycles~Station 3-Knee extensions with weights(2kg beanbag)~Station 4-Heel raises~Station 5-Knee bends(Alternating legs after 10 bends)~Station 6-Rest station(2Kg Biceps curls) Gentle walk for 2minutes in between the stations to recover.For first 6weeks patients complete one full circuit, followed by on extra station/week, thus by 12weeks patients will complete 2 full circuits.Finally patients perform a series of gentle stretching and cooling down exercises.~This exercise programme was designed to comply with suggested guidelines based on a meta-analysis assessing the effectiveness of SEP for claudicants."
46109352|NCT00798850|Procedure|Combined Treatment|PTA will be performed according to routine protocol followed by enrollment of patient in SEP. SEP will commence in the week following PTA.
46109353|NCT05757726|Device|Velocity pAVF system|A second generation percutaneous AVF device that creates an AVF between the proximal radial artery and cubital perforating vein.
46109354|NCT02613104|Other|emotion recognition modification - sad>happy|Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than sad. The intervention is completed three times.
46109355|NCT02613104|Other|emotion recognition modification - sad>happy control|Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
46109356|NCT02613104|Other|emotion recognition modification - angry>happy|Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than angry. The intervention is completed three times.
46109357|NCT02613104|Other|emotion recognition modification - angry>happy control|Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
46109358|NCT02615561|Device|Bepanthen Itch Relief Cream: Phoenix 2 (Bepanthen Sensiderm, BAY207543)|2-3 times daily using multiples of Finger Tip Units (FTUs) depending on size of the area of the flares
45469259|NCT03770377|Device|Intermittent Perturbation to Continuous Perturbation|Manipulate the Movement Planning Period (MPP), by interrupting sensory predictions by removing e-stim during the inter-trial interval (Intermittent Perturbation), followed by a washout/de-adaptation period.
45469260|NCT03770377|Device|Continuous Perturbation to Intermittent Perturbation|Manipulate the Movement Planning Period (MPP), by keep sensory input about the perturbation constant by maintaining e-stim during the inter-trial interval.
45469261|NCT03422068|Drug|BI 1015550|Tablet formulation
45681534|NCT03941314|Device|EverFlex™ Self-Expanding Peripheral Stent System|The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
45681535|NCT04144816|Other|Not applicable (no intervention)|Not applicable (no intervention)
45469262|NCT03422068|Drug|Placebo|Tablet formulation
45469263|NCT03623659|Procedure|Laser assisted hatching|After warming, blastocysts are subjected to laser assisted hatching (LAH) following the standard procedure.The LAH procedure lasts one minute per blastocyst.
45469264|NCT03767023|Other|cross sectional|
45469265|NCT03426670|Device|OraQuick HIV Self-Test|OraQuick® HIV Self-Test is an in-vitro diagnostic medical device that is used for self-testing of antibodies for HIV-1 and HIV-2 in oral fluid. This test is intended as an aid to detect antibodies to HIV-1 and HIV-2 from infected individuals.
45681536|NCT04144660|Device|Extracorporeal Membrane Oxygenation|Use of ECMO for circulatory / hemodynamic support of peripartum of pregnant patients who developed cardiogenic shock.
45681537|NCT01700985|Drug|122-0551|Applied twice daily for two weeks
45681538|NCT01700985|Drug|Vehicle|Applied twice daily for two weeks
46109359|NCT02615561|Other|New cosmetic Bepanthen product: Pumpkin (BAY207543)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
46109360|NCT02615561|Other|Stelatopia (cosmetic comparator)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
45469266|NCT03127462|Behavioral|Nurse-led educational intervention|Patients in the intervention group will receive an individual face-to-face conversation with a duration of 45 min. All patients will have access to telephone counselling by their primary nurse when needed and able to arrange a new face-to-face conversation. After 4-6 weeks the face-to-face the nurse will of conversation reach out to the patient by phone to follow up on the earlier conversation. Three months after the face-to-face conversation the nurse will offer the patient a closing face-to-face conversation of 15 min at the same time where the patient has a doctor appointment at the department. Those who are in the control group will continue standard care and not receive any conversation and be used as the control group.
45469267|NCT03770143|Other|Feeding with palm olein formula|
45469268|NCT04506736|Other|ARM|"The ARM is performed by setting the peak inspiratory pressure to 45 cmH₂O then changing the mode of ventilation to pressure controlled ventilation (PCV) with the inspiratory pressure set to give a tidal volume equal to that given during VCV, I:E ratio of 1:1 and a PEEP of 5 cmH₂O. The PEEP level is then increased in 5 cmH₂O steps every minute till it reaches 20 cmH₂O and inspiratory pressure is increased to get an airway opening pressure (inspiratory pressure + PEEP) of 40 cmH₂O which is maintained for one minute after which the ventilation returned to the original setting except for the PEEP level which is kept at 20 cmH₂O.~The titration of individualized PEEP is done by decremental reduction of the 20 cmH₂O PEEP level in 2 cmH₂O steps every 2 minutes and measuring static compliance of the respiratory system (CRS) at each step."
46109361|NCT00799006|Drug|Placebo|Subjects will be given placebo or PF-04620110
45681539|NCT04148404|Procedure|Normothermic group|"Normothermic group (NT group) included patients will undergo CABG under warm bypass using warm blood cardioplegia (Normothermic CBP).~Hypothermic group (HT group) included patients will undergo CABG under cold bypass using cold blood cardioplegia (Hypothermic CBP)."
45681540|NCT04144426|Behavioral|Normal diet|Participants will receive either a 2000 calorie or a 2500 calorie diet at normal meal times
46109362|NCT00799006|Drug|PF-04620110|A single oral dose of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned and the period of the cross-over for that cohort. Initial planned doses are 0.3-30 mg but may be modified based on emerging PK and safety data.
46109363|NCT00793234|Drug|TB-402|TB-402 administered as single bolus 18-24 post total knee replacement surgery.
46109364|NCT00793234|Drug|Enoxaparin|Enoxaparin 40mg/day sc injection for at least 10 days post-surgery
46109365|NCT04571112|Device|NBM stimulation using the Vercise device (Boston Scientific, Marlborough, Massachusetts, US)|This will either be turned on or off depending on the arm which the patient is randomized to. After 8-weeks, the subject will switch arms for another 8-weeks.
46109366|NCT04133597|Device|social media stimuli (Line app)|social media stimuli (Line app) with texting messages or calls
46109367|NCT00697775|Biological|HBV-MPL vaccine Formulation A|Single dose (when extemporaneously co-administered with Engerix™-B) or 2-dose (when administered alone) intramuscular injection
46109368|NCT00697775|Biological|HBV-MPL vaccine Formulation B|2-dose intramuscular injection
46109369|NCT00697775|Biological|Engerix™-B|Single dose (when extemporaneously co-administered with HBV-MPL) or 3-dose (when administered alone) intramuscular injection
46109370|NCT05754840|Drug|MPL-001|High-CBD arm (MPL-001) a cannabidiol-enriched cannabis herbal extract which contains a 1:25 ratio of THC:CBD. The MPL-001 oil is produced by MediPharm Labs, each ml contains 50mg CBD and 2mg THC.
46109371|NCT05754840|Drug|MPL-005|Medium-CBD arm (MPL-005) a cannabidiol-enriched cannabis herbal extract which contains a 1:5 ratio of THC:CBD. The MPL-005 oil is produced by MediPharm Labs, each ml contains 25mg CBD and 5mg THC.
46109372|NCT05754840|Drug|MPL-009|Balanced arm (MPL-009) a balanced 1:1 ratio of THC:CBD. The MPL-009 oil is produced by MediPharm Labs, each ml contains 25mg CBD and 25mg THC.
46109373|NCT00799084|Behavioral|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
46109374|NCT00799084|Behavioral|AVR|Receives 6 telephone calls over 8 weeks from an programmed automated telephone system to assist with symptom management
46109375|NCT02609958|Drug|Varlitinib|"varlitinib tablets with:~starting dose: 300mg BID~target dose: 400mg BID~dose modification by investigator allowed between 200mg BID to 500mg BID"
46023332|NCT02828215|Device|Swept-source optical coherence tomography (SS-OCT)|"The SD-OCT provides faster images and the ability to scan more of the central retina (macula). SD-OCT simultaneously measures multiple wavelengths of reflected light across a spectrum generating up to 40,000 A-Scans (axially sample points) per second. This allows the generation of 3 dimensional faster based volumetric images of the retina. The Spectralis OCT utilises real-time hardware eye tracking to resample lines scan enhancing the signal to noise ratio by improving the image quality.~The swept-source OCT (SS-OCT) uses a tuneable laser light source with a longer wavelength of light (typically 1040-1050 nm) that the light source seen in more conventional SD-OCT devices. The tissue penetration and resolution is greater with fast acquisition speeds and longer line scan lengths."
46109376|NCT04133051|Drug|Quadratus Lumborum Block Using Bupivacaine 0.2%|"Ultrasound guided transmuscular approach for quadratus lumborum block using an 18 gauge Touhy's epidural needle to insert the catheter. Normal saline 5 mL will be used to identify that plane. A volume of 20 ml of 0.25% of Bupivacaine bolus will be injected in that plane just over QL. This will be followed by epidural catheter insertion to facilitate continuous infusion. A similar procedure will be performed on the other side. A continuous infusion of 0.2% Bupivacaine at 5 ml/h will be administered to the patient.~This transmuscular quadratus lumborum (TQL) block, has been suggested to be a simple and perhaps safer alternative to the anterior approach as was described for the original QL block"
46109377|NCT04133051|Drug|Epidural Analgesia Using Bupivacaine 0.25%|"With Patients placed in sitting position, puncture site will be identified at (T8-9, T9-10, or T10-11) intervertebral spaces. Using aseptic conditions, an 18G Tuohy epidural needle will be used to insert epidural catheter as appropriate.~Induction of epidural analgesia with 10-15 ml bupivacaine 0.25% preoperatively with top up doses of 5-7 ml bupivacaine 0.25% or equivalent administered judiciously till we achieve analgesic level of T4 to L1. The calculated top up doses will be administered each hour using bupivacaine 0.25% or by using a continuous infusion syringe pump for equivalent doses"
46109378|NCT00788242|Drug|Glucose-insulin-potassium|20 IU of insulin and 10 mM of KCl mixed with 50 ml of 40% Glucose. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
46109379|NCT00788242|Drug|Placebo|60 ml of isotonic saline. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
46109380|NCT05039970|Other|WellQuest™|WellQuest™ is a mobile device-based serious health game.
46109381|NCT04031027|Drug|Apremilast|Apremilast is prescribed in accordance with the terms of the SmPC and the marketing authorizations.
46109382|NCT00694031|Procedure|Hemodialysis|3 times per week
46109383|NCT00694031|Procedure|On-line hemodiafiltration|3 times per week
46109384|NCT02609802|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
46109385|NCT02609802|Drug|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
46109386|NCT02617745|Other|Platelet level determination|evaluate the predictive value of a biological test performed in the radio-chemotherapy phase in patients suffering from glioblastoma. For this the platelet level will be determined each wek during the radiotherapy phase and each cycle during the chemotherapy phase
46109387|NCT02609646|Drug|Linezolid|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
46109388|NCT02609646|Drug|Meropenem|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
46109389|NCT02609646|Drug|Piperacillin-tazobactam combination product|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
45469269|NCT04506736|Other|spontanous ventilation|volume controlled ventilation (7ml/kg tidal volume) with addition of 5 cm H₂O fixed PEEP till the end of the surgery .
45681541|NCT04144426|Behavioral|Modified diet|Participants will receive either a 2000 calorie or a 2500 calorie diet with a single meal shift, breakfast is moved to an hour before bedtime.
45681542|NCT03920722|Drug|Rituximab|1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
46109390|NCT02609646|Drug|Vancomycin|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
46109391|NCT02617511|Dietary Supplement|Omega-3 Supplementation|
46109392|NCT02617511|Dietary Supplement|Placebo|
46109393|NCT02610504|Device|Durolane|single injection of 3ml
46109394|NCT04136873|Drug|CVL-231|CVL-231
46109395|NCT04136873|Drug|Matching Placebo|Placebo matching CVL-231
46109396|NCT04132583|Drug|Deflox®|Participants received a single oral dose of 50 mg Deflox® tablet in either treatment period 1 or 2 under fasting conditions.
46109397|NCT04132583|Drug|Cataflam DD®|Participants received a single oral dose of 50 mg Cataflam DD® tablet in either treatment period 1 or 2 under fasting conditions.
46023333|NCT05143099|Drug|TEC|tislelizumab（an anti-PD-1 monoclonal antibody）+cetuximab（monoclonal antibody against EGFR）+irinotecan
46109398|NCT05754762|Drug|Remifentanil|Advanced intravenous injection of remifentanil before the etomidate injection
46109399|NCT02608866|Radiation|SF-SSRS|Spine stereotactic radiosurgery/ablative radiotherapy (SSRS) with 16 Gy in single fraction to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
45469270|NCT03426592|Drug|Vitamin D3, 10000 Intl Units Oral Capsule|"Vitamin D capsule. Over-encapsulated to mimic placebo oral capsule.~Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.~Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.~Rectal swabs will be taken at 0, 24 and 36 weeks.~All participants will continue antiretroviral therapy throughout the study."
45469271|NCT03426592|Drug|Placebo oral capsule|"Capsule containing oleic acid. Over-encapsulated to mimic vitamin D3 capsule.~Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.~Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.~Rectal swabs will be taken at 0, 24 and 36 weeks.~All participants will continue antiretroviral therapy throughout the study."
45469272|NCT01567657|Drug|pethidin hydrochlorid, midazolam|Pethidin hydrochlorid: 25 mg iv. at the beginning of the examination Midazolam: 1-2 mg iv. at the beginning of the examination. Repetitive given in a dosis of 1 mg iv. until a total amount of 7 mg iv.
46023334|NCT02828059|Drug|Ropivacaine|Surgical wound Infiltration over 48 hours
46023335|NCT02827903|Drug|Metformin + Rosuvastatin|Group I: Metformin + Rosuvastatin,
46023336|NCT02827903|Drug|Metformin + placebo|Group II: Metformin + placebo,
46023337|NCT02827903|Drug|placebo + Rosuvastatin|Group III: placebo + Rosuvastatin
46023338|NCT05135923|Dietary Supplement|Randomized, controlled trial (RCT) with parallel arms and double blinded|Experiment group receive optimized gluten free products (high in fiber and whole grain) compared to comparable benchmark gluten free products (control group).
46023339|NCT02830945|Behavioral|Motivational Interviewing Intervention Arm|
46023340|NCT02830945|Other|Control Brochure Arm|
46023341|NCT04247113|Behavioral|Parent-based prevention following bariatric surgery|PBP-B is an adapted version of Parent-Based Prevention (PBP), an innovative approach with demonstrated efficacy in targeting the familial effects of parents with eating disorders on their young children's healthy behaviors. PBP-B addresses the parental cognitions and behaviors that putatively increase the risk for maladaptive outcomes in their children.
46023342|NCT00888433|Device|Renal Denervation (Symplicity® Renal Denervation System)|Catheter-based renal denervation
46023343|NCT01243424|Drug|linagliptin|linagliptin tablets 5mg QD
46023344|NCT01243424|Drug|glimepiride|glimepiride over-encapsulated tablet 1-4 mg QD
46023345|NCT01243424|Drug|linagliptin placebo|linagliptin placebo
46023346|NCT01243424|Drug|glimepiride placebo|glimepiride placebo
46109400|NCT02608866|Radiation|MF-SSRS|SSRS with 24 Gy in three fractions to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given on every other day. Treatment on the consecutive days to the same target volume is not allowed.
46109401|NCT05326152|Biological|hepatitis B vaccine immunotherapy of common warts (GeneVac-B 10 ml vial, Serum Institute of India Ltd., Pune, India)|Randomized placebo-controlled comparative effectiveness clinical trial
46109402|NCT05326152|Biological|Intralesional saline|Intralesional saline
46109403|NCT05757648|Drug|Non-buffered Anesthetic|non-buffered LA, 2% lidocaine with epinephrine 1:100,000
46023347|NCT02831023|Drug|Sulphadoxine-pyrimethamine|Each Fansidar tablet is scored containing 500mg sulphadoxine and 25 mg pyrimethamine. Doses will be administered by weight.
46109404|NCT05757648|Drug|Buffered Anesthetic|A cartridge of 2% lidocaine with epinephrine 1:100,000 alkalinized at 9:1 ratio with a resulting pH of 7.21 using 8.4% sodium bicarbonate solution per manufacturer.
46109405|NCT05757648|Device|Onset|"The test solution will be made by a mixing pen called Onset- This mixing pen Onset will deliver 0.18 mL of sodium bicarbonate solution into the anesthetic cartridge."
46109406|NCT00914004|Drug|Desipramine HCl 50 mg Tablets Cord Laboratories|
46109407|NCT00914004|Drug|Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc|
46109408|NCT00867113|Drug|imatinib mesylate|imatinib mesylate was supplied in 100 and 400 mg tablets
46109409|NCT02610270|Dietary Supplement|2 Gums|760 mg DHA
46109410|NCT02610270|Dietary Supplement|3 Gums|1140 mg DHA
46109411|NCT02608710|Drug|RDEA3170 4.5 mg|
46109412|NCT02608710|Drug|RDEA3170 6 mg|
46109413|NCT02608710|Drug|RDEA3170 12 mg|
46109414|NCT02615483|Other|Web-based platform|"The WP is based on a conducted literature review and results form a previous study conducted in the regional context of the study. Information on the WP is animated based on the current literature stating that educative animation video optimises patients' acquisition of knowledge. The intention is to offer the patients the advantages in gaining knowledge in familiar surroundings and at a pace matching their needs and wishes.~The WP contains animated and written information mirroring the course of treatment, frequently asked questions and answers, it contains animated training support, a diary in order to keep track of training and development of pain and finally a social feature, a web-café."
46109415|NCT04030260|Drug|Regorafenib and PD-1 antibody in Combination with Radiotherapy|Regorafenib will be given 3 weeks on/1 week off (80 mg od po.) and PD-1 antibody
46109416|NCT04030260|Radiation|Radiation therapy|Radiation therapy is believed to increase the likelihood of response of immunotherapy
46109417|NCT00697385|Drug|Cyclokapron|(2) 500mg tablets taken by mouth every 6-8 hours
46109418|NCT04133753|Behavioral|Facilitator-Based Intervention|Facilitators interact in person with patients, family, and clinicians both during and following the patient's ICU stay for 3 months. In-person contacts include visits to patients' homes and/or care facilities; phone contacts include calls to patients, families and clinicians. Patients and families have access to facilitators through phone and email. Facilitators may attend clinic visits with patients. In addition to checking directly with patients/families during regular contacts, facilitators also access the electronic health record to ensure they have accurate information about appointments and treatment plans and to document key points for the clinical team. Facilitators encourage referral to inpatient or outpatient palliative care services when needs are identified.
46109419|NCT00451555|Drug|enzastaurin|1125 milligram (mg) loading dose then 250 mg, oral, twice daily (for a total of 500 mg), until disease progression
46109420|NCT00451555|Drug|placebo|oral, daily
46109421|NCT00451555|Drug|fulvestrant|500 mg, intramuscular (IM), day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, every 28 days, until disease progression
46109422|NCT00808236|Device|RhinoChill|Nasal catheters are placed and cooling is begun during the resuscitation attempt
46109423|NCT00808236|Other|Control|Advanced cardiac life support according to American Heart Association & European Resuscitation Council 2005 Guidelines
46023348|NCT02831023|Drug|0.25 mg/kg primaquine|Primaquine will be administered in an aqueous solution according to weight-based dosing.
46109424|NCT00867035|Drug|Chlorine dioxide and scraper|20ml of mouthwash used for 30sec as adjunct to tongue scraper twice a day
46109425|NCT00867035|Drug|Chlorhexidine gluconate and scraper|The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.12% chlorhexidine gluconate rinse for 30sec, for one week.
46109426|NCT05012748|Other|Ketogenic diet|The ketogenic diet will consist of 75% fat, 20% protein and 5% carbohydrates. The diet will be standardised and matched to the energy consumption of each participant. The diet does not dictate time of consumptions. The food regime will be strictly followed every day for 3 weeks, where the investigator will contact the participants every day to secure adherence.
46109427|NCT05754684|Biological|Natural killer cell|Natural killer cells isolated from HLA-haploidentical relative donor
46023349|NCT02831023|Drug|Dihydroartemisinin-piperaquine|160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets will be used to administer weight-based doses.
46023350|NCT02831023|Drug|Methylene blue|Methylene blue will be given as minitablets in prepackaged sachets according to weight groups.
46109428|NCT05754684|Drug|Dinutuximab beta|Dinutuximab beta iv for 5 days
46109429|NCT05754684|Drug|Interleukin-2|Interleukin-2 sc alternate day for 6 doses
46109430|NCT05754684|Drug|Granulocyte-Macrophage Colony-Stimulating Factor|Granulocyte-macrophage colony-stimulating factor sc daily till ANC >2,000/mm3
46109431|NCT05754684|Drug|Spironolactone|Spironolactone po three time daily
46109432|NCT05298839|Diagnostic Test|Evaluation of core muscle endurance, hand grip strength, upper extremity functional performance, reaction time, agility performance and 3 minutes step test|"Core muscle endurance was evaluated with extensor muscle endurance test, flexor muscle endurance test and lateral muscle endurance test.~Hand Grip Strength was evaluated with Jamar hand dynamometer. Upper extremity functional performance was evaluated with health ball throwing test.~Reaction time was evaluated with Fitlight Trainer. Agility performance was evaluated with Pro-agility test. Cardiovascular endurance was evaluated with the 3-minute step test."
46109433|NCT00694187|Drug|Zaleplon|
45469273|NCT01567657|Drug|Propofol|"50 years and over: initial dose of 50-60 mg Propofol iv. Followed by bolus of 20-30 mg iv. until sedation is achieved.~< 50 years: initial dose 30-40 mg Propofol iv. Followed by bolus of 10-20 mg until sedation is achieved."
45469274|NCT03127618|Drug|Lorlatinib|
45469275|NCT03770065|Device|VML-0001|Medical device
46023351|NCT02831023|Drug|Amodiaquine|Amodiaquine will be administered once daily for 3 days, following weight-based dosing of 150 mg tablets.
46023352|NCT02830711|Other|Positive and Negative Affect Scale for Children|A 36-item instrument, including the Mood and Anxiety Symptom Questionnaire (MASQ)16 developed by Chang and Yeh and the Positive and Negative Affect Scale for Children developed by Watson and Clark
46023353|NCT02826967|Procedure|Colonic Irrigation|
46109434|NCT02617121|Drug|Gabapentin|oral gabapentin 300 mg 1 hour before induction of anesthesia
46109435|NCT02617121|Drug|Ramosetron|ramosetron 0.3 mg iv at end of surgery
46109436|NCT02617121|Drug|Gabapentin and Ramosetron|oral gabapentin 300 mg 1 hour before induction of anesthesia and ramosetron 0.3 mg iv at end of surgery
46109437|NCT05005572|Other|Payment adjustment for home dialysis and transplant|The ETC model makes two types of payment adjustments for facilities and managing clinicians, an adjustment to the reimbursement rate for home dialysis, and a performance adjustment. The first adjustment, Home Dialysis Payment Adjustment (HDPA), raises the reimbursement rate for home dialysis for the first three years of the program; the amount of increase is 3% in 2021, and reduces to 2% in 2022, and 1% in 2023. The second adjustment, Performance Payment Adjustment (PPA), is an increase or decrease in the reimbursement rate based on the home dialysis rate and the transplant rate attributable to the participating facility or clinician.
46109438|NCT00663208|Drug|Daclatasvir|Capsule, Oral, Approximately 182 days from initial dosing
45469276|NCT03416062|Drug|Remaxol®|Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle
45469277|NCT03416062|Drug|Ringer's Solution|Solution for intravenous infusion, 400 or 800 ml
46023354|NCT04244539|Device|high-intensity laser Device.|Twenty four treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 8 weeks in succession via HIRO® 3.0 device (ASAlaser, Arcugnano, Vicenza, Italy). The device gives pulsed emission (λ = 1064 nm), maximum power (3000 W), fluency range (360-1780 mJ/cm2), pulse duration (≤ 100 μs), frequency range (10-40 Hz), maximum energy per pulse (350 mJ), mean power (10.5 W), and power cycle of ~0.1%.
46023355|NCT02827825|Other|No intervention|No intervention. It's a study on retrospective Data
46109439|NCT00663208|Drug|Placebo|Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel
46109440|NCT02609490|Drug|Azilsartan tablets|20mg/tablet
46109441|NCT02609490|Drug|Azilsartan placebo tablets|placebo tablet
46109442|NCT02609490|Drug|Olmesartan medoxomil tablets|20mg/tablet
45469278|NCT03761485|Other|Use of Dentifrice Fluoride|Use of few of dentifrice on brushing during a year
45469279|NCT03426514|Procedure|Three-port Laparoscopic Surgery|Patients undergo three-port laparoscopic surgery. The surgery will be completed by a surgeon and a camera-person without another assistant. The surgeon will adjust surgical position to expose the operative field with the help of gravity. All the orther operative procedures are the same as conventional laparoscopic surgery.
46109443|NCT02609490|Drug|olmesartan medoxomil placebo tablets|placebo tablet
45469280|NCT03426514|Procedure|Conventional Laparoscopic Surgery|Patients undergo conventional laparoscopic surgery（4 or more ports）.The surgery will be routinely completed by a surgeon，a camera-person and another assistant to provide counter-traction.
45681543|NCT03920722|Drug|placebo|Placebo-Rituximab 1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
45469281|NCT03766867|Drug|Vortioxetine infusion 25 mg|1 mg/mL, concentrate for solution for infusion, 25 mL (25 mg) administered in 250 mL saline over 2 hours as single dose for 7 days
45681544|NCT05580094|Other|general anesthesia only.|induction of general anesthesia by propofol and maintenance sevoflurane.
45681545|NCT05580094|Other|general anesthesia plus supraclavicular block.|induction of general anesthesia by propofol and maintenance sevoflurane then the patients will receive the supraclavicular block with bupivacaine 0.5 ml per kg.
46023356|NCT02827669|Behavioral|One Drop Experts Program|
45469282|NCT03766867|Drug|Vortioxetine tablets 10 mg/day|10 mg, tablets, oral administration once daily
45681546|NCT05589766|Dietary Supplement|Nicotinamide Riboside|Nicotinamide Riboside supplementation up to 3000mg daily in total.
45681547|NCT05589766|Other|Placebo|Placebo tablet identical in taste, form and appearance to NR tablets, administered twice daily for a total of 12 weeks.
46023357|NCT02827669|Behavioral|One Drop Experts Program + Apple Watch|
46109444|NCT00810810|Biological|Standard blood components|Transfusion, if ordered by physician, with unfiltered red blood cells and apheresis platelets
46109445|NCT00810810|Biological|Leukoreduced blood components|Transfusion, if ordered by a physician, of leukoreduced red blood cells and apheresis platelets
46109446|NCT00810810|Biological|Leukoreduced and irradiated|Transfusion, if ordered by physician, of gamma irradiated leukoreduced red blood cells and gamma irradiated apheresis platelets
46109447|NCT00661258|Behavioral|Electronic drug monitoring feedback data|All patients were given electronic drug monitors that can monitor pill-taking behavior. In the intervention arm, patients and their attending doctors were given the electronic drug monitoring data on pill bottle openings at each monthly visit for use in adherence counseling sessions. Control arm patients were not given their electronic drug monitoring feedback data and their counseling sessions were based on self-reported adherence, as per standard of care in Dali.
46109448|NCT05754606|Diagnostic Test|Audio recordings|Automatica analysis of audio recordings
45469283|NCT03766867|Drug|Placebo infusion|concentrate for solution for infusion, 25 mL administered in 250 mL saline over 2 hours as single dose
45469284|NCT03766867|Drug|Placebo tablets|oral administration once daily
45469285|NCT03415984|Diagnostic Test|Color retinography|Color retinography
46023358|NCT04244695|Drug|Dexamethasone Oral|To compare oral dexamethasone 16 mg vs 8 mg vs placebo in pateints undergoing unilateral TKA
46023359|NCT00887809|Drug|gemcitabine|
46023360|NCT00887809|Drug|docetaxel|
46023361|NCT00887809|Drug|bevacizumab|
46023362|NCT02830399|Device|active rTMS-ECT|5 High Frequency (20Hz) rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
46023363|NCT02830399|Device|sham rTMS-ECT|5 sham rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
46109449|NCT05757414|Device|Tailored Lighting Intervention (LIT)|The lighting intervention will provide high circadian stimulation produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system.
46109450|NCT05757414|Device|Actigraph|An actigraph is a wrist worn device that measures rest and activity patterns
46109451|NCT05754528|Drug|Standard of care administration of Endocrine therapy|Standard daily dosing of endocrine therapy. Defined as taking endocrine therapy every day from the start.
46109452|NCT05754528|Drug|Dose-frequency escalation administration of Endocrine therapy|Endocrine therapy dose-frequency escalation. Defined as taking endocrine therapy every other day for 1 month and then daily.
46109453|NCT02610348|Biological|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
45838394|NCT03192020|Procedure|Percutaneous needle fasciotomy (PNF)|The division of the cord can be made under local anesthesia in the clinic and takes only a few minutes to perform. It can be performed whenever the cord is palpable. There are only puncture wounds left, and hence, the patient can start normal use of the hand the day after the procedure. If patient seeks for a treatment and the recurrence of the disease can not be treated by the PNF or patient is not willing to new PNF patient will be treated with LF.
46109454|NCT02610348|Biological|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
46109455|NCT05757336|Drug|Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab|Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab
46109456|NCT00871871|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 50 mg (two 25 mg capsules) once daily for 4 weeks per treatment period.
46109457|NCT00871871|Drug|Comparator: Placebo to HCTZ|Placebo to HCTZ two 0 mg capsules once daily for 4 weeks per treatment period
46023364|NCT02826889|Device|Philips Intelivue MP70 monitor|Philips Intelivue MP70 monitor (Intellivue MP70, Philips medical Systems, Suresnes, France) -a radial arterial cannula is inserted and arterial pressure waveforms are monitored through Philips Intelivue MP70 monitor. In the monitor, PPVauto is displayed in real-time. It is based on automatic detection algorithms, kernel smoothing, and rank-order filters.
46109458|NCT00871871|Drug|Isosorbide mononitrate (ISMN)|ISMN 60 mg extended release capsule once daily for 4 weeks per treatment period
46109459|NCT00871871|Drug|Comparator: Placebo to ISMN|Placebo to ISMN 0 mg capsule once daily for 4 weeks per treatment period
46109460|NCT02608788|Drug|S.L.®|"1.5mg/ml Benzydamine hydrochloride, S.L.® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
46109461|NCT02608788|Drug|Difflam Forte ®|"3.0mg/ml Benzydamine hydrochloride ,  Difflam Forte ® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
46023365|NCT02826889|Device|Pleth Variability Index (PVI)|PVI is the measure of the dynamic changes in the Perfusion Index (PI) that occur during one or more complete respiratory cycles. A rainbow Pulse CO-Oximetry sensor is attached to the patient's finger and the PVI is displayed in real-time on the Root monitor.
46109462|NCT02608788|Drug|Acular®|"5％ Ketorolac Tromethamine ,  Acular®  spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
46109463|NCT02608788|Drug|placebo|Distilled water spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
46109464|NCT05754372|Diagnostic Test|user-friendly and widely applicable algorithm to tailor the treatment of acute neonatal hyperammonemia|user-friendly and widely applicable algorithm to tailor the treatment of acute neonatal hyperammonemia, based on kinetic modelling
46109465|NCT04132349|Drug|Ulipristal Acetate 5 mg|Ulipristal acetate (from Cenexi manufacturer, France) at daily dose of 5mg in 3 consecutive months course
46109466|NCT00913926|Drug|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara according to local drug information.
46109467|NCT02617355|Device|Prototype surgical magnetic drape|New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax
46023366|NCT04244617|Behavioral|iCBT with addition of peer-support|Peer-supporters and participants, as well as psychologists and participants, interact in the treatment program via asynchronous secure messages. Peer-supporters are able to give support and feedback on exercises. A reconciliation call via telephone is entered into the middle of the treatment and a follow-up call after completion of treatment conducted by the peer-support. The interaction between peer-supporters and participants is tracked by the psychologist.
46023367|NCT02827747|Other|Antioxidants (Vitamins A,C,E) plus GSH|Study medication would contain 500 milligrams of vitamin C, 400 International Units of vitamin E, and 15 milligrams of beta-carotene (the equivalent to 25,000 International Units of vitamin A).The study medication would also contain 1000mg of Glutathione (GSH).
46023368|NCT02827747|Other|Placebo|Placebo pill
46109468|NCT02617355|Device|Green Covidien Magnetic Drape|Green Covidien Magnetic Drape applied to the patient's thorax
46109469|NCT02617355|Device|Jac-Cell Medic Reusable Magnetic Pad|Jaa-Cell Medic Reusable Magnetic Pad applied to the patient's thorax
46109470|NCT02617355|Device|"DeRoyal Magnetic Pad size 20 x 16"|"Magnetic Instrument Pad #25-002, size 20 x 16, DeRoyal Industries Inc applied to the patient's thorax"
46109471|NCT02617355|Device|"DeRoyal Magnetic Pad size 10 x 16"|"Magnetic Instrument Pad #25-001, size 10 x 16, DeRoyal Industries Inc applied to the patient's thorax"
46109472|NCT02615405|Dietary Supplement|EPA|A daily treatment of 5 identical capsules of EPA (3.5 g/d) for Studies 1 & 2.
46023369|NCT02827747|Dietary Supplement|Centrum|Centrum
46023370|NCT02827747|Combination Product|Dietary Sources|From dietary sources of vitamins.
46023371|NCT02830633|Procedure|LNTME|Patients in this group received laparoscopy-assisted nerve-preserved TME for treatment of rectal cancer
46023372|NCT02830633|Procedure|OTME|Patients in this group received traditional open TME for treatment of rectal cancer
46023373|NCT04244851|Other|Malnourished patients|"Data of included patients will be recorded during hospitalization using medical charts.~Every patient will be contacted by phone 3 months after hospital discharge. A sample of patients and their caregivers will be interviewed to better understand their perception of malnutrition and what they need to better take care of malnutrition."
46023374|NCT00958126|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free.
46023375|NCT00958126|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume).
46109473|NCT02615405|Dietary Supplement|DHA|A daily treatment of 5 identical capsules of DHA (1.75 g/d) for Studies 1 & 2.
46023376|NCT00958126|Biological|Placebo|Vaccine diluent, thimerosal 0.01% (weight/volume).
46023377|NCT02861560|Other|dHACM|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
46023378|NCT04281394|Device|Robot assisted gait training|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT group received RAGT 5 sessions per week at duration 30 minutes with 30 minutes conventional physical therapy in 12 weeks.
46023379|NCT04281394|Other|conventional gait training|even level gait training and range of motion exercises
46023380|NCT04281628|Drug|Ketamine group:|Ketamine group: will be administered ketamine in a loading dose of 0.2 mg/kg over 5 min pre incision followed-by an infusion at 0.2 mg/kg/h until the end of surgery.
46023381|NCT04281628|Drug|Control group|where normal saline was administered as a loading dose then infused with same rate of another group, throughout the whole surgery.
46023382|NCT02859844|Device|Transcutaneous Tibial Nerve Stimulation (TTNS)|
46023383|NCT04280302|Behavioral|Virtual Reality-based Rehabilitation|VR-based eye stabilization exercises and balance exercises
46023384|NCT04280302|Behavioral|Conventional Therapy|Conventional rehabilitation therapy based on eye stabilization exercises and balance exercises
46023385|NCT04279756|Other|Hip Mobilization with Movement, Self-Mobilization with Movement, Dynamic Stretch|Participants receive either a therapist performed mobilization with movement, a self-mobilization with movement, or a dynamic stretch.
46023386|NCT02861638|Device|Experimental group|Video of the exercises
46023387|NCT02861638|Device|Control group|video of nature scenes
46109474|NCT02615405|Dietary Supplement|Placebo|A daily treatment of 5 identical capsules of placebo (high oleic oil) in single or divided administration for Study 1.
46109475|NCT04961190|Behavioral|Prolonged Exposure Therapy|A form of cognitive-behavioral psychotherapy focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders
46109476|NCT04961190|Drug|Pharmacotherapy with paroxetine or venlafaxine XR|Standard dosing with paroxetine, a selectiveserotonin reuptake inhibitor that is FDA approved to treat PTSD and depression, or venlafaxine extended-release, a serotonin-norepinephrine reuptake inhibitor that is FDA approved to treat anxiety and depression
46109477|NCT04130789|Other|compare data patterns by data-driven algorithms to determine sepsis|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to reliably determine sepsis
46109478|NCT04130789|Other|compare data patterns by data-driven algorithms to predict sepsis-related mortality|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to to predict sepsis-related mortality
46109479|NCT00849680|Other|Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine|Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine.
45469286|NCT03415984|Diagnostic Test|Optical coherence tomography|Optical coherence tomography
46023388|NCT02861638|Device|Conventional physiotherapy|Mobilization, exercises and transfer practice.
46023389|NCT00887341|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; first infusion 1h duration, subsequent infusions 31 minutes duration
46023390|NCT00887341|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; each infusion 1h duration
46023391|NCT04279600|Dietary Supplement|Taurine|Taurine supplementation in capsules of 1 gram of taurine powder, total dosage: 3 grams/day
46023392|NCT04279600|Dietary Supplement|Placebo|Placebo supplementation in capsules of 1 gram of starch powder, total dosage: 3 grams/day
46023393|NCT04279600|Other|Exercise training|4 weeks of combined exercise training (alternating strength and aerobic exercise), with a frequency of 3 times/week with 55 min/day.
46023394|NCT05051995|Drug|Open-label placebo|Prior to the open-label placebo administration, an explanation why placebos without concealment might be effective is offered. Participants receive placebo pills with the instruction to take 2 pills daily for 2 weeks.
46023395|NCT05051995|Other|No-treatment|During the no-treatment phase, participants receive no treatment for 2 weeks.
46109480|NCT00849680|Biological|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)
46109481|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)
46109482|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)
46023396|NCT02830321|Other|helicopacter pylori stool antigen test (CER TEST BIOTEC)|Stool samples were tested by using one step H.pylori stool antigen test (CER TEST BIOTEC)for the detection of H. pylori antigen in pregnant women with hyperemesis gravidarum
46023397|NCT04246645|Other|CORE STABILITY EXERCISES|SELECTED CORE EXERCISES
46023398|NCT00886795|Drug|abatacept (Orencia ®)|4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.
46023399|NCT02783482|Biological|GC5107|GC5107 20g/200mL, intravenously, dose of 300 - 900 mg/kg (of body weight) every 21 or 28 days for 12 months, a follow-up (3 or 4 weeks)
46023400|NCT02827357|Other|No specific intervention|Clinical, drug and data collection : characteristics of patients (age, sex and histology), non HER 2-directed treatments including response and duration of response
46023401|NCT00889681|Device|Arctic Front Cardiac Cryoablation System|The CryoCath Arctic Front® Cardiac CryoAblation Catheter System, including the Freezor MAX Cardiac Cryoablation Catheter, is indicated for the treatment of patients with paroxysmal atrial fibrillation to reduce the likelihood of subsequent detectable atrial fibrillation.
46023402|NCT05048095|Other|AI cancer detection system|The use of AI as a third reader and as a decision support system during consensus meeting
46109483|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)
46023403|NCT00957658|Device|Accolade® TMZF® Hip Stem|Accolade® TMZF® Hip Stem
46109484|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)
46109485|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)
46109486|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)
46109487|NCT00849680|Biological|Comparator: Placebo to MRKAd5 HIV-1 gag vaccine|Placebo to the MRKAd5 HIV-1 gag vaccine.
46109488|NCT04045691|Drug|Encorafenib|Observation of real-life treatment with encorafenib and binimetinib
45681548|NCT05586100|Drug|Toripalimab+cetuximab|"Toripalimab administered by intravenous drip at a fixed dose of 240 mg for subjects weighing <50 kg at baseline, using 3 mg/kg. administered every 3 weeks, 2 preoperative and 6 postoperative doses.~The starting dose of cetuximab is 400 mg/m2, with a titration time of 120 min, and the titration rate should be controlled within 5 ml/min. The maintenance dose is 250 mg/m2 administered weekly for a total of 6 preoperative doses; patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional 6 cycles of postoperative cetuximab adjuvant therapy."
46023404|NCT00953680|Drug|losartan potassium (+) hydrochlorothiazide (HCTZ)|Single dose losartan 100 mg/HCTZ 12.5 mg combination tablet in one of two treatment periods.
46023405|NCT00953680|Drug|losartan potassium|Single dose losartan 100 mg tablet in one of two treatment periods.
46023406|NCT00953680|Drug|hydrochlorothiazide (HCTZ)|Single dose HCTZ 12.5 mg capsule in one of two treatment periods.
46023407|NCT00890929|Drug|Lenalidomide|5 mg, 10 mg, 25 mg, and/or 50 mg of lenalidomide administered PO from day 8 to Day 28 of each cycle
46023408|NCT00890929|Drug|Azacitidine|75 mg/m2 Azacitidine administered intravenously (IV) or subcutaneously (SC) for days 1 to 7 of each cycle
46023409|NCT04279366|Behavioral|Lifestyle intervention|The 14 week courses takes place at a Danish folk high school (Ubberup), specialized in lifestyle interventions targeting a 10% weight loss. Adult individuals with obesity sign up for the course. They stay at the School for the whole course period and the total cost amounts to 300-400 Euros per week plus loss of income.
46023410|NCT04246567|Procedure|Mean Blood Pressure (MBP)|Mean blood pressure (MBP) for patients 50-65 mmHg
46023411|NCT04246567|Drug|Add to 0.5 mcg / kg fentanyl.|When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl.
46023412|NCT04271566|Behavioral|Education program|A mobile application plus short message service (SMS) program to deliver disease-related health education and reinforcement to experimental group patients and see its impact on their health related quality of life, physical activity and Body mass index
46109489|NCT04045691|Drug|Binimetinib|Observation of real-life treatment with encorafenib and binimetinib
46109490|NCT00810342|Behavioral|physical activity tailored|tailored telephone counseling, email feedback, and website resources over 12 months
46109491|NCT00810342|Behavioral|physical activity standard|standard print and website information on how to become more active
46109492|NCT04130945|Other|erector spina plane block, cost analysis|in preopererative period, ESP block is going to utilise for postoperative analgesia for patients who undergo laparoscopic procedure and cost analysis will make after the end of 24 hour of operation
46109493|NCT00849524|Biological|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
46109494|NCT00808080|Biological|AMLCTL|Ex-vivo expanded cytotoxic autologous AML-reactive T cells (CTL)
45838395|NCT03192020|Drug|Collagenase Clostridium Histolyticum (CCH) 2.9 MG/ML [Xiaflex]|CCH chemically dissolves type I collagen of which the cord is composed of. It is injected inside the cord at least three different places in the outpatient clinic and the cord can be ruptured by gently force after one to three days. If patient seeks for a treatment and the recurrence of the disease can not be treated by the CCH or patient is not willing to new CCH patient will be treated with LF.
46023413|NCT04243681|Combination Product|CD 34 and MSC infusion|Combination of stem cells
46023414|NCT04243681|Drug|Standard of care for Cirrhosis management|Drugs used for Cirrhosis management such as Diuretics, Hepatoprotective agents and Lactulose
46023415|NCT00886639|Other|6MWT with oxygen|2 liter per minute as continuous-flow
46023416|NCT00886639|Other|6MWT with medical air|2 liters as continuous-flow
46023417|NCT04244383|Diagnostic Test|interleukin IL-1beta and interleukin IL-18|pro-inflammatory cytokines measured in the serum
46023418|NCT04244305|Other|Exercise Therapy|Endurance training in the form of treadmill/cycle-ergometry
46023419|NCT02830243|Drug|Sevoflurane|End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
46023420|NCT02830243|Drug|Desflurane|End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
46023421|NCT02830009|Other|Urines samples|24-hour urines will be collected
46023422|NCT02830009|Other|Blood sample|
46023423|NCT00889603|Drug|Aricept® Evess|"5 mg film-coated orodispersible tablets, 10 mg film-coated orodispersible tablets.~Treatment may be started with 5 mg donepezil/ day (once-a-day dosing) and after four weeks can be titrated to 10 mg/day (once-a-day dosing)."
46023424|NCT04244071|Device|Bair Paws Blanket 81003 and FOC device 87500|This study is a randomized, pretest - posttest controlled experimental design.
46023425|NCT04244071|Other|routine hospital care|routine hospital care
46023426|NCT04244149|Other|Prolonged Exercise session|After a standardized warm-up of 10 minutes of continuous running on a treadmill at 60% of their maximum heart rate (HRmax), subjects will perform a maximum oxygen consumption test (VO2max) with a gas analyzer (UltimaTM Series, MGC Diagnostic Corporation, St. Paul, MN, USA. The protocol will start with a slope of 1% at a speed of 10 km/h, with increments of 0.3 km/h every 30 s until volitional exhaustion. Finally, ten minutes after the treadmill test, volunteers will run 1 kilometer (t1km) as fast as possible and the time needed to cover the distance will be recorded.
46023427|NCT04243135|Device|ESWT|Extracorporeal shock wave therapy
45838396|NCT03192020|Procedure|Limited fasciectomy (LF)|LF is performed in general or regional anesthesia in operating room. Constricting cords will be excised under direct vision. LF has been the dominant technique of surgical treatment. If patient seeks for a treatment the recurrence of the disease will be treated with LF as long as needed.
46109495|NCT04036266|Procedure|medial open wedge high tibial osteotomy|opening of medial aspects of the proximal tibial metaphysis and change the coronal alignment of the tibia in order to shift the center of force passing axially through the knee from the arthritic region of the knee towards the unaffected side then fixation with a plate (the standard plate is the T-locked plate )
46109496|NCT00866723|Drug|bevacizumab|
46109497|NCT05757180|Behavioral|Positive Events Training (PET)|PET is a group-based training program combining Memory Specificity Training (MEST; Raes, 2007) and Future Event Specificity Training (FEST; Dutch version of Hallford et al. (2020): Changing the Future: An initial test of Future Specificity Training). It comprises four sessions of 50 minutes each. The training is delivered in a standardized manner, using the Positive Event Training Manual developed for this study (content adapted from our MEST and FEST manuals). Following brief psychoeducation on the rationale, participants practice generating detailed specific memories and future events using neutral and positive cue-words. Participants are maximally supported and challenged by the trainer and by the other group-members to generate very specific and highly detailed memories and future events using mental imagery and drawing upon visual, olfactory, auditory and emotional elements of the events, including both contextual and sensory-perceptual details.
46109498|NCT05757180|Behavioral|CREAtive writing Training (CREAT)|CREAT follows the exact same format and length as the PET training (i.e., delivered by a trainer in group over 4 x 50-minute sessions, including homework exercises). Following brief psychoeducation on the (bogus*) rationale behind PET, participants complete a series of creative writing exercises using funny and thought-provoking writing prompts. Just as in PET, participants are maximally supported and challenged by the trainer and by the other group-members, in this case to generate completions that are as creative and funny as possible. The investigators used CREAT successfully before in an online format as a bogus control training for a memory specificity training. (*) The investigators tell participants that these creative writing exercises have been found to be beneficial for mental wellbeing, as creative writing exercises cultivate creativity and stimulate participants' imagination skills.
46109499|NCT00697853|Biological|Engerix™-B|3-dose intramuscular injection
46109500|NCT00697853|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection
45838397|NCT03125928|Drug|Atezolizumab|Monoclonal antibody
45838398|NCT03125928|Drug|Paclitaxel|Chemotherapy
45838399|NCT03125928|Drug|Trastuzumab|Monoclonal antibody
45838400|NCT03125928|Drug|Pertuzumab|Monoclonal antibody
46023428|NCT02826577|Drug|Pregnenolone 175mg|Single Dose 175mg
46023429|NCT02826577|Drug|Pregnenolone 400mg|Single Dose 400mg
46023430|NCT02826577|Drug|Placebo|Single Dose
46023431|NCT00886483|Device|Active Neurofeedback|A comparison of active neurofeedback to sham neurofeedback and of two treatment schedules: twice weekly vs. three times a week, with the same amount of total treatment over 40 sessions, varying only in frequency.
46023432|NCT00886483|Device|Sham neurofeedback|Active neurofeedback vs. sham neurofeedback for 40 treatments, either twice or three times per week.
46023433|NCT00886015|Device|TT Clamp|trichiasis surgery performed with TT clamp
46023434|NCT00886015|Procedure|Standard BLTR Technique|bilamellar tarsal rotation procedure in trichiasis surgery
46109501|NCT00849290|Biological|APC8015F|APC8015F is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. APC8015F consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
46109502|NCT02615327|Dietary Supplement|8 g Polydextrose|8g of Polydextrose
46109503|NCT02615327|Dietary Supplement|12 g Polydextrose|12 g of Polydextrose
46109504|NCT02615327|Dietary Supplement|16 g Polydextrose|16 g of Polydextrose
46109505|NCT02615327|Dietary Supplement|Placebo|0 g of Polydextrose
46109506|NCT02613455|Procedure|extracorporeal shock wave therapy|Following clearance, patients will be booked for ESWT in the operating room either WRNMMC or Kimbrough Ambulatory Care Center (KACC), depending on availability. Under conscious sedation, patients will receive 2000 shocks at 18-24kV, which is the standard dose utilized by our clinic in treatment of this condition. The range is necessary to account for differing size of the soft tissue envelope depending on patient habitus. The final dose utilized will be at the surgeon's discretion.
46109507|NCT02613455|Drug|Kenalog (triamcinolone)|patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
46109508|NCT02613455|Drug|lidocaine 1% (lidocaine HCl 20mg)|patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
46109509|NCT00849212|Drug|E2007|The dose of E2007 will start from 2 mg and will be increased by 2 mg every week up to 12 mg (the maximum dose). The dose will be adjusted during 6 weeks (i.e., titration period). Subsequently, the dose will be fixed and maintained during 4 weeks (Maintenance period). Patients must visit study site at Weeks -4, 1, 2, 3, 4, 5, 6, 8, 10 and 14 to confirm.
46109510|NCT04119011|Biological|Probiotic|(Lactobacillus acidophilus, lactobacillus casei, lactobacillus lactis) and Bifidobacterium (Bifidobacterium bifidum, bifidobacterium longum, bifidobacterium infantis) lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
46109511|NCT04119011|Other|Placebo|lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
46109512|NCT00703586|Drug|Maraviroc|"ARM A:~Addition of maraviroc to baseline ARV medications for 24 weeks at one of the following doses:~150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor~600 mg orally BID when coadministered with efavirenz or nevirapine~ARM B:~Addition of an additional NRTI to baseline ARV medications for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:~Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc.~Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.~Addition of tenofovir 300 mg daily to an abacavir containing regimen for 12 weeks then replacing the tenofovir with maraviroc."
45469287|NCT03415984|Diagnostic Test|Fundus autofluorescence imaging|Fundus autofluorescence imaging
46109513|NCT04130399|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive 5 fractions of SBRT delivered over a five-day period. Treatment may be delivered over 2 weeks, provided that the patient receives at least 2 fractions per week.
46109514|NCT04130399|Drug|FOLFIRINOX|Participants in this trial will receive neoadjuvant and adjuvant FOLFIRINOX chemotherapy for 6 cycles (1 cycle = 14 days) per routine guidelines
46109515|NCT00810264|Device|CRT Therapy - LV Lead Registry|Collecting long-term safety and efficacy data on a market-released left ventricular lead.
46109516|NCT00849056|Biological|albiglutide|albiglutide weekly subcutaneous injection
46109517|NCT00849056|Drug|placebo|placebo weekly subcutaneous injection
45469288|NCT03761407|Drug|100 mg GRT0151Y|100 mg capsule (1 x 100 mg capsule)
46109518|NCT02612948|Drug|Quetiapine|escalating dose to prevent delerium.
46109519|NCT00706862|Drug|Talactoferrin|Oral, 1.5 grams twice per day
46109520|NCT00706862|Drug|Placebo|Oral, twice per day
46109521|NCT00707018|Device|External rotation shoulder sling|The external rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 10 to 15 degrees of external rotation at the shoulder.
46109522|NCT00707018|Device|Internal rotation shoulder sling|The internal rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 70 to 80 degrees of internal rotation at the shoulder.
46109523|NCT00913406|Other|Lutein fortification|
46109524|NCT00913406|Other|Standard formula|
46109525|NCT02612714|Drug|Rosuvastatin|All parameters were measured before statin treatment, after 6 months of statin treatment and 6 months after discontinuing statin treatment. Scores of the sexual health inventory for men (SHIM) were also evaluated.
46109526|NCT02612636|Other|ear plug|The patients will receive the intervention (ear plug) in the third night (N3) from 9 pm to 6 am.
46109527|NCT02612636|Other|eye mask|The patients will receive the intervention (eye mask) in the second night (N2) from 9 pm to 6 am.
45469289|NCT03761407|Drug|125 mg GRT0151Y|125 mg (1 x 100 mg capsule and 1 x 25 mg capsule)
45469290|NCT03761407|Drug|150 mg GRT0151Y|150 mg (1 x 100 mg capsule and 1 x 50 mg capsule)
45469291|NCT03761407|Drug|225 mg GRT0151Y|Day 1: 150 mg (1 x 100 mg capsule and 1 x 50 mg capsule) Day 2 - 5: 225 mg (2 x 100 mg capsules and 1 x 25 mg capsule)
45469292|NCT03761407|Drug|Matching placebo|Matching placebo capsules using the same dosing regimen as defined in the treatment groups.
45469293|NCT02061293|Drug|Psilocybin|
45469294|NCT02061293|Drug|Diphenhydramine|
45838401|NCT03085056|Drug|Trametinib|trametinib orally 2mg daily during each 4 week cycle
46023435|NCT02829853|Genetic|Genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING|Patients with sarcoidosis patients are monitored in the regular follow-up in one of 28 GSF clinical centers. Blood sampling was performed in two 5ml classical heparinized tube, as used for red/white/platelets blood cells analysis. The patients receive complete information on the SARCFAM protocol and sign an informed consent stating that the genetic study will be conducted on the BTNL2 gene and genes related to immunity, including loci other than BTNL2.DNA was extracted from a 1-5 ml sample of blood and stored in frozen conditions until analysis. Genomic DNA is captured using Agilent in-solution enrichment methodology (Human Clinical Research Exome, Agilent) with their biotinylated oligonucleotides probes library, followed by paired-end 75 bases massively parallel sequencing on Illumina HiSEQ 400. For each genomic position, the exomic frequencies (Homo & HTZ) are determined from all the exomes already sequenced and/or the exome results provided by 1000G, EVS, HapMap database.
46109528|NCT02612558|Drug|Fostamatinib 150 mg bid|Fostamatinib 150 mg bid. The dose of Fostamatinib may be reduced at any time to as low as 100 mg PO once daily (qd) if dose limiting adverse events are observed.
46109529|NCT00702026|Dietary Supplement|multispecies probiotic (Ecologic 801)|once daily, 5 gram [10e9 cfu/gram]
46109530|NCT00702026|Dietary Supplement|Placebo|once daily, 5 gram [10e9 cfu/gram]
46109531|NCT02612402|Device|messages generated by learning algorithm|THIS INTERVENTION HAS BEEN INCLUDED IN THE LEARNING ALGORITHM ARM The app measures physical activity by the phone accelerometer and sends SMS messages to encourage activity. An automatic learning algorithm for encouraging physical activity learns the patterns of response for each patient and chooses the best messages for the patient to encourage activity.
45838402|NCT03085056|Drug|Paclitaxel|paclitaxel 80mg/m^2 weekly for 3 out of 4 weeks
46109532|NCT02612402|Device|constant weekly message reminding patient to exercise|THIS INTERVENTION HAS BEEN INCLUDED IN THE CONTROL ARM The app measures physical activity by the phone accelerometer and sends a constant SMS messages to remind the patient to exercise.
46109533|NCT00837434|Drug|Etanercept|50 mg dose of etanercept by subcutaneous injection
46109534|NCT00837434|Drug|Adalimumab|40 mg dose of adalimumab by subcutaneous injection
46109535|NCT00703742|Drug|Escitalopram|A,1: Escitalopram, oral, 20 mg/day, 8 weeks
46109536|NCT00702104|Other|survey administration|
46109537|NCT00702182|Drug|Vinorelbine (Navelbine)|Conventional Schedule Oral Vinorelbine on day 1 and day 8 of a 21 day schedule
46109538|NCT00702182|Drug|Vinorelbine (Navelbine)|Metronomic Schedule Oral Vinorelbine 3 times a week
46109539|NCT00702182|Drug|Erlotinib|Daily Oral Erlotinib 100 mg
46109540|NCT00702260|Drug|Ramipril|10 mg capsule
45469295|NCT02061293|Behavioral|Motivational Enhancement and Taking Action (META)|Manualized psychosocial intervention based on motivational enhancement therapy, functional analysis, and implementation of a change plan.
45838403|NCT03006705|Drug|Nivolumab|Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
45838404|NCT03006705|Drug|Tegafur-gimeracil-oteracil potassium|Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
45838405|NCT03006705|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
46109541|NCT00702416|Procedure|Ultrasound-guided continuous interscalene brachial plexus block|"With patients in the supine position, a high-frequency (10-12 MHz) ultrasound transducer in a sterile sheath will be applied to explore the interscalene region and locate the brachial plexus. The transducer will be positioned so as to image the C5 and C6 roots in a single view. Visualization of the C7 root in the same scan will be sought, but will not be required.~A 50-mm, 20 G needle will be advanced in-plane from the postero-lateral side of the transducer. Injection of the local anesthetic will be performed in small aliquots while repositioning of the needle in order to optimize spread of the injectate around the nerve roots.~At the end of the injection, a catheter will be threaded through the needle. The catheter will be positioned to lie deep and close to the imaged nerve roots."
46109542|NCT00702416|Procedure|Continuous interscalene brachial plexus block using electrical nerve stimulation|"With patients in the supine position, the head will be rotated to the contralateral side. The interscalene groove will be palpated.~A 35-mm, 20 G needle will be inserted at the estimated C6 level (cricoid cartilage) with a 30-45° angle to the skin. The needle will be advanced along a line joining the insertion site to the axilla.~An electrical nerve stimulator will be used at an initial intensity of 1.0 mA (frequency: 2 Hz, pulse width: 0.2 ms). A musculocutaneous or axillary-nerve mediated twitch will be sought~Injection of the local anesthetic will start with a visible motor response at a current <0.5 mA. The catheter will be positioned to as to elicit a motor response at ≤0.4 mA."
46109543|NCT00702416|Drug|Ropivacaine|"Block induction [1% (wt/vol) solution]:~20 ml (200 mg)~Postoperative analgesia [0.2% (wt/vol) solution]:~Background infusion: 4 ml/h (8 mg/h)~Incremental on-demand dose: 2 ml (4 mg)~Lockout time: 15 min"
46109544|NCT00702416|Drug|Paracetamol|1 g iv q8h
46109545|NCT00702416|Drug|Morphine|5 mg im prn q1h (in the postoperative period)
46109546|NCT00702416|Drug|Fentanyl|50 µg iv prn (in the intraoperative period)
46109547|NCT00702416|Procedure|General anesthesia|"Will be given in case of block failure and/or patient discomfort intractable with fentanyl during the procedure.~The technique will be left at the discretion of the attending anesthesiologist. Monitored anesthesia care will also be acceptable; the block will be considered as failed in that case as well."
46109548|NCT00827918|Drug|MK-8998|MK-8998 6 mg capsules twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 8 mg capsules twice daily. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
46109549|NCT00827918|Drug|Comparator: Olanzapine|Olanzapine 5 mg tablets twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 5 mg tablets in the morning and 10 mg tablets in the evening. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
46109550|NCT00827918|Drug|Comparator: Placebo|Placebo tablets matching olanzapine tablets and MK-8998 capsules
46109551|NCT00813150|Drug|Dexamethasone|Type=exact number, number=20, unit=mg, form=tablet, route=oral. The patients will receive 20 mg of dexamethasone on days 1+2,4+5,8+9,11+12 for 21 days for 8 cycles.
45469296|NCT03426280|Device|Apple Watch Series 1|Clinic pharmacists will issue Apple Watches to study arm patients and teach them the usage of the Activity app. In addition to usual care, these patients will each receive an in-person 3-minute coaching session during clinic visit at 2, 4, 6 and 12 months.
46109552|NCT00813150|Drug|Bortezomib|Type=exact number, number=1.3, unit=mg, form=injection, route=intravenous. The patients will receive 1.3mg/m2 on days 1,4,8,11 for 21 days for 8 cycles.
46109553|NCT00813150|Drug|Cyclophosphamide|Type=exact number, number=50, unit=mg, form=tablet, route=oral. The patients will receive 50 mg of cyclophosphamide once daily continuously from cycle 1 to 8.
46109554|NCT05757102|Drug|FF/UMEC/VI|FF/UMEC/VI will be administered.
46109555|NCT05757102|Device|ELLIPTA|FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler
45681549|NCT05587270|Other|Web based surveys|A web-based survey will explain the purpose, aims, and ethical rights, as well as how to complete the questionnaire online. Further, information about, and an invitation to participate in the DXA-scan will be included with this information. Upon electronic consent by both parent and athlete (or just athlete if of consenting age (15 y o a)), access to the multi-section questionnaire will be granted. Contact details of the researchers will be available in case of difficulties comprehending the questions. Following completion, the participants' data will be sent to a secure database for analysis. Participants will be ensured of the confidentiality of the study and will be free to withdraw from the study. Parents will also be asked to provide their consent if participants age is under 14.
46109556|NCT05757102|Drug|FF/VI|FF/VI will be administered.
46109557|NCT00807846|Drug|Celecoxib|Celecoxib 50 mg or 100 mg PO BID for 6 weeks
45838406|NCT03006705|Drug|Capecitabine|Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
45838407|NCT03006705|Drug|Placebo|Placebo: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
46023436|NCT00890695|Dietary Supplement|Ready to use supplementary food (RUSF)|It is a strategy of detection of moderate malnutrition and providing advice and short term provision of a standard formulation of ready to use supplementary food (RUSF) for 4 weeks with appropriate counseling on its use.The amount supplied will be based on the child's weight; 100kcal per kg per day which is equivalent to 25g RUSF per kg per day.
46023437|NCT02826655|Device|WF-AO-OCT|WF-AO-OCT allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. This unit is being conducted under an abbreviated IDE.
46109558|NCT00807846|Drug|Naproxen|Naproxen 7.5 mg/kg PO BID [maximum of 500 mg BID] for 6 weeks
46109559|NCT05754138|Device|Sport SICD|Follow up
46109560|NCT05755386|Drug|Placebo|Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
46109561|NCT05755386|Drug|iptacopan|iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
46109562|NCT00810108|Drug|lopinavir/ritonavir (Kaletra®) tablets|The subject will bring their own prescription of lopinavir/ritonavir. The patient will take a witnessed dose of lopinavir/ritonavir with an 6 ounce glass of cool water (if taken whole) or mixed in 4 ounces of Jell-O brand pudding (if crushed).
46109563|NCT05297370|Behavioral|Mixed and match Intervention|Participants will receive a brief 15-minute counselling session based on the 5A's' and '5R's' models by our trained research assistant. Participants will be able to choose their smoking cessation treatment options from our menu.
46109564|NCT05297370|Other|Control|Participants in the control group will receive a self-help quitting leaflet issued by the TACO
46109565|NCT00827606|Drug|atorvastatin|Atorvastatin tablets or chewable tablets, 5, 10, 20, 40 mg strengths, once daily, for three years (an 80 mg maximum daily dose is delivered by taking two 40 mg strengths, once daily)
46109566|NCT04892082|Behavioral|Mindful Moment|The Mindful Moment program is a web-based self-guided cognitive-behavioral intervention to reduce parenting stress, targeting postpartum mothers. It consists of 6 weekly modules, each module targeting a specific thematic content, and providing mothers with both information and specific therapeutic strategies (with a strong focus on the third wave of cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
46109567|NCT04892082|Other|Waiting-List Control (WLC)|The control group only receive the intervention at the end of the intervention group.
46109568|NCT04016220|Drug|Budesonide|first nebulization of 0.5 mg of budesonide in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 0.5 mg of budesonide at 20, 40, 60 and 120 min.
46109569|NCT04016220|Drug|normal saline|first nebulization of 2ml of normal saline as placebo comparator in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 2 ml of normal saline at 20, 40, 60 and 120 min.
46109570|NCT04233606|Other|Hypertonic Saline|Infusion of hypertonic saline to induce an osmotic secretion of the hormone vasopressin
46109571|NCT04233606|Other|Normal Saline|Infusion of normal saline to inhibit the secretion of the hormone vasopressin
46109572|NCT05755308|Procedure|Autologous FMT|Autologous faecal microbiota transplantation by colonoscopy.
46109573|NCT05755308|Procedure|Placebo FMT|Placebo FMT will consist of 250 mL water. Placebo infusions will be delivered by colonoscopy.
46023438|NCT02826499|Device|Pediguard|It is a guide for the perforation of the pedicular channel, with a probe at its extremity. This probe allows a real time measurement of the electric conductivity of the tissues that are being crossed. The conductivity measure is translated in a sound signal. Because the cortical bone has a low conductivity, the probe will emit a low intensity sound signal. The cancellous bone has a medium conductivity. Therefore, the probe will emit a medium sound signal. However, in the event of a breach in the pedicular cortical, as blood and periost have a high conductibility, the probe will emit a intense, rapid pace, sound signal.The Pediguard technique helps thus to anticipate a cortical effraction, by detecting the proximity of the cortical wall.
46109574|NCT00663052|Drug|Etanercept|ETN 50 mg QW + PBO QW for 12 weeks followed by ETN 50 mg QW for 12 weeks.
46109575|NCT00663052|Drug|Etanercept|ETN 50 mg BIW for 12 weeks folowed ETN 50 mg QW for 12 weeks.
46109576|NCT00827372|Drug|Pazopanib|Pazopanib will be administered at a starting dose of 800 mg orally once each day.
46109577|NCT05599880|Drug|Bortezomib|Bortezomib is administered at 1.3mg/m2 iv or sc on each Cycly Day1, Days4, and Days8. Bortezomib is administered every 3 weeks for a total of 3 cycles. Thereafter, follow-up is scheduled for 12 months.
46109578|NCT00707252|Drug|Polyphenon E|Patients will be assigned to 3 sequential cohorts of three different dose levels of Polyphenon E (providing 200, 400 and 800mg of Polyphenon E given once daily) in a step-wise manner.
46109579|NCT00707252|Drug|Tarceva|All patients will also receive Erlotinib 150mg po/day from Day 1.
46109580|NCT00826748|Drug|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
46109581|NCT00922844|Drug|Sevoflurane and isoflurane|Patients will be randomized to a 10 minute treatment with isoflurane, followed by a wash-out period, followed by a 10 minute treatment with sevoflurane, or the other way round.
46109582|NCT00707330|Drug|Clarithromycin|Prolonged release tablet, 500 mg, 1 tablet a day for a week
46109583|NCT00707408|Drug|Imatinib|Daily dosing of imatinib 600 mg/day is planned for one month or until progression of disease. Dose increase to 800 mg/ day imatinib is permitted for 2 additional months in the event of response failure. Novartis provided supplies of imatinib for all patients included in the study.
46109584|NCT04041596|Device|Advanced Bionics' Acoustic Earhook|designed to deliver acoustic amplification through the modular attachment of the Naída CI Q90 AcoustiEarhook, while also delivering electrical stimulation along the full range of the implanted Advanced Bionics electrode.
45681550|NCT05587270|Radiation|DXA|All participants will be invited to complete a DXA scan at baseline. DXA is to date the most reliable way of examining the long-term physical consequences of RED-S.
45838408|NCT02991248|Device|robotic training|robotic training by applying pelvis force perturbation
46109585|NCT00806988|Procedure|Mitral Valve Repair|"Surgical techniques for mitral valve repair may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation. The common elements for mitral annuloplasty planned as part of this study include the following:~All procedures will be performed with cardiopulmonary bypass (CPB) and with moderate hypothermia. Cannulation will be central with aortic cannulation for arterial inflow from the cardiopulmonary bypass circuit. Right atrial or bicaval (inferior and superior vena cava) drainage cannulas will be employed.~The heart will be arrested with cardioplegia.~A complete annular ring shall be placed unless specifically contraindicated by intra-operative findings. Additional repair of the mitral apparatus itself will be based on intra-operative findings."
46109586|NCT00806988|Procedure|CABG|CABG will be performed using standard surgical techniques. Conduit selection and harvesting methods will not be prescribed, except that utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, within the judgment of the surgical investigator.
46109587|NCT05749770|Other|blood testing|blood testing for basal hormones and markers of inflammation
45681551|NCT04148248|Other|No intervention|There is no intervention for this study
45681552|NCT05585008|Device|two different denture manufacturing technique (heat cure pack and press technique(heat cure acrylic,Acrostone,Egypt)/3d printed dneture(HARZ lab,Russia))|retention for the two groups will be measured at 0,1 and 3months, patient satisfaction will be recorded, and accuracy of the denture base will be measured on the software.
45681553|NCT05584852|Other||no intervention
45838409|NCT02991248|Device|spinal cord electrical stimulation|Applying direct current electrical stimulation on spinal cord
45838410|NCT02991248|Device|treadmill|conventional treadmill training only
46109588|NCT00788320|Drug|Vitamin D3|Vitamin D3 50,000 IU three times a week for 8 weeks
46109589|NCT00788320|Drug|Placebo|Placebo three times a week for 8 weeks
46109590|NCT00799162|Other|Psychophysical testing, questionnaires, and genetics|pre-operative psychophysical testing of endogenous pain modulation, pre-operative questionnaires, peri- and post-operative data collection, long term follow-up assessing chronic pain, SNP association analysis, and whole genome scanning association studies
46109591|NCT00807144|Drug|Tacrolimus (Kidney transplant maintenance immunosuppression)|Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml
46109592|NCT00807144|Drug|Kidney transplant maintenance immunosuppression|Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml
46109593|NCT05753826|Drug|Adebrelimab|20mg/kg，D1，q3W
46023439|NCT02826499|Other|Fluoroscopy|The placing of pedicular screws under fluoroscopic control is the most common technique as it is both reproducible and accessible. It is a two dimensional imaging technique. The profile incidence at the level of the spine is mostly used to spot the vertebral pedicle and the direction of the screw in the sagittal plane. However, there is no real control of the direction of the pedicular screw in the horizontal or frontal plane and it is an irradiating imaging technique.
46109594|NCT05753826|Drug|Fuzuloparib|100 mg bid
46109595|NCT00799240|Drug|Arm A: Pemetrexed Cisplatin|Pemetrexed: 500mg/m2 IV on day 1 and Cisplatin: 75 mg/m2 IV on day 1 every 21 days x 6 cycles.
45838411|NCT02987543|Drug|olaparib|300 mg (2x 150 mg tablets) twice daily
45838412|NCT02987543|Drug|enzalutamide|160 mg (4 x 40 mg capsules) once daily
46109596|NCT00799240|Drug|Arm B Pemetrexed, Cisplatin and MK-0646|Pemetrexed 500 mg/m2 IV on Day 1 and Cisplatin 75 mg/m2 IV on Day 1 every 21 days for 6 cycles in combination with MK-0646 will be given IV, 10 mg/KG, Days 1, 8 and 15 weekly.
46109597|NCT02555410|Device|Brain Sentinel Seizure Detection and Warning System|A sEMG based automated seizure detection and warning system worn on the biceps
46109598|NCT02555332|Other|75g oral glucose tolerance test (OGTT)|All these women underwent the 75g oral glucose tolerance test (OGTT) at 24-28 weeks of gestation.
46109599|NCT00591006|Drug|Phenytoin (brand name Dilantin)|Three days prior to imaging, participants will take two capsules containing phenytoin tablets (100 mg) by mouth at 0900 hours and 2100 hours (400 mg/day) for a total of three days with the last dose at 0900 hours on the day of the imaging (7 doses total).
45838413|NCT02987543|Drug|abiraterone acetate|1,000 mg (4 x 250 mg tablets) once daily
45838414|NCT02987543|Drug|abiraterone acetate|1,000 mg (2 x 500 mg tablets) once daily
45838415|NCT02987543|Drug|enzalutamide|160 mg (4 x 40 mg tablets) once daily
45838416|NCT02983045|Drug|Dose Escalation Doublet: Combination of NKTR-214 + nivolumab|NKTR 214 + nivolumab at 5 dosage levels.
46023440|NCT04242979|Behavioral|Questionnaire about albumin use in liver cirrhosis|"Permission to carry out the study will be obtained from the Faculty's Ethics Committee.~To achieve validity and reliability of the tool. It will be reviewed by two experts in the field of the study and necessary modification will be done.~A pilot study will be 10% done to test the clarity and feasibility of developed tool.~Each participant involved in the study will be assessed for his or her knowledge using (tool I).~Data will be collected by personal interview with participants or via fulfilling online questionnaire taking in consideration data confidentiality.~Application of the designed evidence based indications for human albumin use supported by the international guidelines will be done by researcher using (tool II).~Evaluate the effect of the designed evidence based indications for human albumin use supported by the international guidelines on physicians' knowledge after 1 month using (tool I) in a random sample of those physicians"
46023441|NCT02829541|Drug|BIIB068|Administered as specified in the treatment arm.
46023442|NCT02829541|Drug|Placebo|Administered as specified in the treatment arm
45838417|NCT02983045|Drug|Dose Expansion Doublet: Combination of NKTR-214 + nivolumab|Select patient cohorts with select tumor types will be dosed with NKTR-214 + nivolumab at the RP2D + other anti-cancer therapies per institution standard.
45838418|NCT02983045|Drug|Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab|1L patients with RCC, NSCLC, UCC, and melanoma received NKTR-214 0.006 mg/kg q3w in combination with nivolumab and ipilimumab according to 3 dosing schedules.
46023443|NCT02827123|Device|McGrath MAC videolaryngoscopy|Orotracheal intubation with McGrath MAC videolaryngoscopy after anesthetic induction
46109600|NCT00591006|Drug|Hydrocortisone|Beginning two days prior to the imaging (the day after initiating the phenytoin or placebo), participants will begin taking 4 tablets containing hydrocortisone (20 mg) or placebo also at 0900 hours and 2100 hours (160 mg/day) with the last dose at 0900 hours on the day of the imaging (5 doses total). The doses were selected to achieve a low therapeutic blood level of phenytoin and stress level of cortisol. Newcomer et al. (1999) used this dose of hydrocortisone in healthy controls. The imaging will be performed at approximately 1300 hours.
46109601|NCT00591006|Drug|Placebo|Participants take two capsules of placebo 100 mg at 0900 hours and 2100 hours for a total of 3 days with the last dose at 0900 hours on the day of imaging (7 doses total). Beginning two days prior to the imaging (the day after initiating placebo), participants will being taking 4 tablets containing placebo (20 mg) also at 0900 hours and 2100 hours with the last dose at 0900 hours on the day of the imaging (5 doses total).
46109602|NCT00788398|Procedure|Saline Solution|Irrigation with Saline
46109603|NCT00788398|Procedure|Soap solution|Irrigation with Castile Soap Solution (80 ml per 3L bag of saline)
45838419|NCT02983045|Drug|Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab|Combination of NKTR-214 + nivolumab + ipilimumab was administered at RP2D dose/schedules in select tumor types
45838420|NCT02981407|Biological|Red Blood Cell Transfusion|Transfusion of packed red blood cell units
46109604|NCT00788398|Procedure|Gravity Flow Irrigation|Gravity flow irrigation will be standardized across participating centers as 3L bags of normal saline (alone or with soap solution) suspended 6-8 feet above floor level using an I.V. pole. Irrigation tubing (measuring 1/4 - 3/8 inch inner diameter) will be connected to the 3L bag and secured with a stopcock (or compressive device) until ready for use.
46109605|NCT00788398|Procedure|Low Pressure Irrigation|"Irrigation with the Stryker SurgiLav System. At the low pressure setting delivers 5.9 p.s.i. pressure. The high-flow irrigator tip will be held perpendicular to and 5cm above the wound.~Irrigation with the Zimmer PulsaVac. For low pressure delivery, the shower tip will be used at the low pressure setting which delivers a pressure of 5.8 p.s.i."
46109606|NCT00788398|Procedure|High Pressure|"Irrigation with the Stryker SurgiLav System. For the high pressure delivery, the multi-orifice tip will be used at the high setting which delivers a pressure of 30 p.s.i.~Irrigation with the Zimmer PulsaVac System: For the high pressure delivery the shower tip will be used at the high pressure setting which delivers a pressure of 23 p.s.i."
46109607|NCT02606916|Radiation|SMART|Once-daily simultaneous modulated accelerated radiotherapy(64Gy/30f )
46109608|NCT02606916|Drug|DDP|DDP(25 mg/m2.qw) for six weeks.
46109609|NCT02606916|Drug|S-1|S-1(40 mg/m2.Bid .po) on D1-14，D22-35 during radiotherapy
46109610|NCT00788476|Other|Survey|"Survey packets to adult (>18 years old) childhood cancer survivors who return to MDACC for follow-up appointments within the next 12-months and conduct a mailed survey with the remaining participants and their primary caregivers i.e. guardians of survivors who are currently under age 18."
46109611|NCT02554084|Other|Optical Coherence Tomography|Digital images of tear film
46109612|NCT05715918|Biological|Vaccine for intramuscular injection|Volunteers ( Group 1 - 150) will receive the vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
46023444|NCT02827123|Drug|Macintosh Laryngoscopy|Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
46023445|NCT00633607|Other|Research Registry|Information regarding medical and family history is stored in the registry to be used for potential future studies
46023446|NCT05041621|Device|Sensor augmented MDI therapy plus mobile application|"Participants will use the mobile application to calculate their basal dose and to calculate their meal bolus dose by entering their glucose value, carbs (if applicable), fat composition (high fat or not), and type and timing of postprandial exercises. Participants will receive their dosing parameters weekly upon adjustments made by the reinforcement learning algorithm. Participants will be contacted by telephone on Weeks 1, 3, 5, and 7 in case of any technical difficulties or questions.~All participants will be asked to complete the:~(i) Diabetes treatment satisfaction questionnaire (DTSQ) and hypoglycemia fear survey-II (HFS-II) at baseline, halfway through the intervention, and post-intervention.~(ii) mHealth usability questionnaire (MAUQ) at post-intervention."
46023447|NCT05041543|Drug|NTX-101|Eye drops, topical administration
46023448|NCT05041543|Drug|Placebo|Placebo as eye drops
46109613|NCT05715918|Other|Placebo comparator (without active ingredient) for intramuscular injection|Volunteers ( Group 2 - 150) will receive the vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
45681554|NCT05585086|Other|Peppermint Oil Inhalation|Peppermint oil will be given by diluting 1/10 in wheat oil so that it does not cause skin irritation. Application; by inhalation method, 2 cc lavender essential oil + 100 cc water (2%) will be in the form of two drops for 20 minutes. Since the effectiveness of essential oils decreases over time and the desired dose cannot be applied at the same time; Peppermint oil will be applied to the individual for a total of 5 times every 30 minutes.
45681555|NCT05583448|Device|ExploR Radial Head|Patient must have undergone primary or revision elbow arthroplasty with the ExploR Radial Head System according to a cleared indication.
45838421|NCT02944136|Behavioral|enhanced usual care|usual care from health providers
46109614|NCT00799630|Dietary Supplement|Carbohydrate drink|Maltodextrins, dextrose, fructose, amino acids (leucine, isoleucine, valine), natural flavors, sodium chloride, magnesium citrate, zinc, lactate, acid: malic acid, anti-caking agent: silicon dioxide; Curcumin (turmeric extract) , Thickener: xanthan gum, caffeine, vitamin C (Acerola extract), vitamin E - B1 - B2 - B3; piperine (black pepper extract).
46109615|NCT05753748|Procedure|Endoscopic Eradication Therapy|Endoscopic eradication therapy is a procedure performed to destroy the precancerous cells at the bottom of your esophagus, so that healthy cells can grow in their place. It involves procedures to either remove precancerous tissue or burn it. These procedures are performed through the endoscope.
46109616|NCT02554552|Drug|YY1201 2ml|YY1201 2ml
46023449|NCT05660863|Drug|MN-08 24 mg/day|Subjects in this cohort will receive 12 mg MN-08 tablets b.i.d. for a total daily dose of 24 mg or matching placebo for 6 consecutive days, and the last dose (12 mg) on the morning of Day 7.
46109617|NCT02554552|Drug|Placebo 2ml|phosphate buffered saline 2ml
46109618|NCT02554552|Drug|YY1201 3ml|YY1201 2ml
46109619|NCT02554552|Drug|Placebo 3ml|phosphate buffered saline 3ml
46109620|NCT03764124|Diagnostic Test|PET/CT imaging|The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events were applied.
46023450|NCT05660863|Drug|MN-08 60 mg/day|Subjects in this cohort will receive 30 mg MN-08 tablets b.i.d. for a total daily dose of 60 mg or matching placebo tablets for 6 consecutive days, and the last dose (30 mg) on the morning of Day 7.
46109621|NCT00788554|Procedure|Lichtenstein procedure|open surgical procedure for inguinal hernia correction
46109622|NCT00788554|Procedure|TEP|Total Exta Peritoneal procedure for inguinal hernia correction
46109623|NCT00799786|Behavioral|Building Better Caregivers Online Workshop|
46023451|NCT02826265|Device|multiple breath washout test (MBW)|
46023452|NCT02826265|Device|impulse oscillometry (IOS)|
46023453|NCT02826265|Device|body plethysmography (BP)|
46023454|NCT02826265|Device|quantitative computed tomography (qCT)|ultra-low-dose qCT
46023455|NCT04246411|Behavioral|Ultrasound-guided determination of cuffless RAE tube depth|"Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~Ultrasound-guided detection of endobronchial intubation depth by loss of lung sliding sign in the left lung field.~Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning"
46023456|NCT04246411|Behavioral|Auscultation-guided determination of cuffless RAE tube depth|"Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~Auscultation-guided detection of endobronchial intubation depth by loss of breathing sound in the left lung field~Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning"
46109624|NCT00844844|Drug|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
46109625|NCT04158882|Other|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
46109626|NCT05748054|Drug|Silver Diamine Fluoride|A colourless solution known with its alkaline nature; it simply consists of a union of silver, fluoride and ammonia. It can be applied on caries cavities using a micro-brush.
46109627|NCT00660790|Other|Intensified Treatment of risk factors|Patients received a target oriented, intensified treatment of risk factors according to current national treatment guidelines
45838422|NCT02944136|Behavioral|stepped collaborative care|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
46023457|NCT05109637|Device|Konectom NMD Application|Administered as specified in the treatment arm.
46023458|NCT02829385|Drug|Apatinib and XELOX combined treatment group|"Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)~Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs."
46109628|NCT00702572|Drug|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|This dose escalating phase will enroll sequential cohorts of 3-6 patients to be entered at the following dose levels: Level -1: Days 1-14, Vorinostat 100 mg po QD; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 175 mg/m2. Level 1: Days 1-14, Vorinostat 200 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 2: Days 1-14, Vorinostat 300 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 3: Days 1-14, Vorinostat 400 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Treatment cycles will be repeated every 3 weeks. The highest dose level which <2 out of 5 patients experience dose limiting toxicity will be defined as the recommended phase II dose.
46023459|NCT02826109|Device|PeriAcryl®90 HV|
46109629|NCT00702572|Drug|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|Once the recommended phase II dose has been established from Phase I, 12 additional patients will be treated to evaluate the toxicities and safety profile of the 4-drug regimen.
46109630|NCT00799942|Drug|Neramexane mesylate|open-label treatment of 36 months Neramexane mesylate up to 75 mg per day
46109631|NCT00913172|Other|Treatment|Directly observed treatment (DOT) by health extension workers (HEWs)
46109632|NCT00788632|Behavioral|Patient educational DVD and brochure|"Construct a tailored direct-to-patient intervention to educate and activate older women about osteoporosis testing and treatment and aimed at improving patient-provider communication and closing the loop between knowledge communication and action. The intervention will include risk assessment, will be delivered through culturally/ethnically tailored story-telling, and will be mailed-out as both a paper copy (Booklet) and an interactive DVD (allowing the patient to use the delivery mediums they are most comfortable with). A follow-up brochure will be sent as a booster."
46109633|NCT00788632|Behavioral|Physician web modules|Web based osteoporosis continuing medical education (CME) materials
46109634|NCT00788632|Behavioral|System|Create a practice redesign strategy to alert patients that they should receive a BMD test and provide them with direct patient access to schedule their own test
46109635|NCT00793468|Drug|GSK598809|GSK598809 once daily for 12 weeks
46109636|NCT00793468|Drug|Nicotine Replacement Transdermal Patch|All subjects will be treated during the 4 week open-label smoking cessation phase of the study. During Weeks 1-3, subjects will receive 21mg/day, and during Week 4, subjects will receive 14 mg/day. Those subjects who reached continuous abstinence on at least week 4 of the open-label phase will receive 7mg/day during Week 5 while taking GSK598809 or placebo.
46109637|NCT00793468|Drug|Placebo|Placebo once daily for 12 weeks
46109638|NCT00836810|Drug|Timed Release Tablet Prednisone|Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.
46109639|NCT00836810|Drug|Prednisolone|Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.
46109640|NCT00788788|Drug|HELIOX|HELIOX is a mixture of Helium in Oxygen with a low density and the ability to reduce the work of breathing in subjects with airway obstruction. The fractions of Helium was altered in a different order depending on the arm of the study
46109641|NCT00658684|Drug|fesoterodine fumarate|4 mg tablets OD for 4 weeks, then either 4 mg or 8 mg tablets OD for 48 weeks
46109642|NCT04046146|Drug|Indocyanine Green|A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
46109643|NCT04046146|Device|MultiSpectral Imaging System|Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
46109644|NCT00800098|Drug|herbal topical cream|
46109645|NCT00788866|Dietary Supplement|Pomegranate Juice|8 oz of pomegranate juice daily vs placebo juice identical in all respects except pomegranate
46109646|NCT00788866|Dietary Supplement|Placebo|Juice that matches the makeup of pomegranate in regards to sugar, vitamin C, etc. The only difference is that it lacks pomegranate juice.
45838423|NCT02933892|Procedure|Cardiac Catheterization|Cardiac catheterization is a diagnostic procedure used to treat and diagnose heart conditions.
45838424|NCT02923440|Biological|blood sample|
46109647|NCT00800332|Drug|CYT003-QbG10|subcutaneous injection
46109648|NCT00800332|Drug|Placebo|subcutaneous injection
45838425|NCT02894398|Drug|Palbociclib|"Capsules (commercially available, obtained from local pharmacies), 125mg daily, 21 days, 7 days off, cycles of 28 days.~Dose reductions: 100mg, 75mg (no change in administration schedule) Number of cycles: until disease progression, intolerable toxicity, death or any other reasons"
46023460|NCT02826343|Drug|Xenon129 MRI imaging|subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
46023461|NCT02826343|Drug|Gadolinium MRI|subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
46023462|NCT02826343|Drug|Advair (250mcg/50mcg) one puff twice a day|subjects will receive for 3 month duration between baseline and 3 month post Xenon129 MRI imaging and Gadolinium MRI.
46023463|NCT05660785|Drug|Herombopag|"Hetrombopag is a TPO receptor agonist approved in China in 2021 for idiopathic thrombocytopenic purpura (ITP) and second-line severe aplastic anemia (SAA). Indications of chemotherapy-induced thrombocytopenia (CIT), pediatric/juvenile ITP and naive severe aplastic anemia are under development. Hetrombopag was granted Orphan Drug Designation by FDA for the treatment of CIT.~Cyclosporine A is a calcineurin inhibitor, which has an effect on reducing T-cell proliferation and activation, can reverse pancytopenia and alleviate transfusion requirements in NSAA."
46023464|NCT04246255|Drug|Xylocaine 10% Oral|"50 ml of lidocaine solution maintained from xylocaine 10% oral that transferred to a bottle with a spray pump which pumps 0,1ml for each pump will be used for the experiment.~3 pumps of lidocaine will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted."
46109649|NCT00660400|Drug|5-azacitidine|Once enrolled, the patients will receive pre-transplant 5-azacitidine (Vidaza) 75 mg/M^2/day subcutaneously for 5-7 days every 28 days). Adjustments in dose and timing may occur based on clinical and hematological parameters.
46109650|NCT00660400|Procedure|Allogeneic Hematopoietic Cell Transplantation (HCT)|"Patients will receive transplantation if there is either a suitable sibling or an unrelated donor.~Response will be evaluated by bone marrow biopsy after 4 cycles of 5-azacitidine or prior to HCT whichever comes first. Due to the very high risk of progression to AML or death in this patient population, the HCT will be done as soon as possible.~The patients may have additional cycles of 5-azacitidine per standard hematology practice until scheduled for transplant or until progression of disease.~All patients will be followed until time to progression of MDS, AML or death or a maximum of 1 year. For patients that are transplanted, follow up will be to one year post-transplant."
46109651|NCT00800410|Behavioral|Community Health Worker (CHW) services|CHW services included access to an 11 week healthy lifestyle education curriculum, two home visits per month, two additional phone contacts per month, and accompanied participants to one clinic visit within the six month intervention period
46109652|NCT00788944|Procedure|blood draw|Test Article was not provided to subjects for this study.
46023465|NCT04246255|Drug|Placebo- Serum Fizyolojik Izotonik 0,9% 10 ml ampul|"50 ml of Serum physiologic in a bottle with a spray pump which pumps 0,1ml for each pump will be used for placebo.~3 pumps of placebo will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted."
46023466|NCT04246099|Other|Post-operative care|"Retrospective collection of clinical data recorded in the electronic medical record.~The following variables were continuously recorded in the institutional database: age, gender, body weight, height, personal medical history, American Society of Anesthesiologists (ASA) score, type of thoracic surgery, the duration of surgery, duration of anesthesia (from intubation to extubation), the duration of PACU stay, the need for morphine titration, epinephrine, norepinephrine.~For data at day 30, the vast majority of patients were included in the enhanced recovery program and as such benefited from a consultation at 1 month with a coordination nurse who collected data on post-operative pain in a standardized manner.~All data was extracted from investigators institutional database and collected by a physician who was not involved in the care of the study patients."
46023467|NCT02824861|Behavioral|Bemobile|
46109653|NCT00793702|Biological|rdESAT-6 + rCFP-10|rdESAT-6 + rCFP-10 skin test administered intradermally by the mantoux injection technique
46109654|NCT04854850|Device|Apollo|The Apollo System offers a convenient novel non-invasive, non-habit-forming solution to improve performance and recovery under stress in children and adults by delivering gentle wave-like vibrations to the body that improve autonomic nervous system balance in real time (Siegle & Rabin et al., under review). The gentle vibrations delivered by the Apollo System are extremely low intensity in that they are typically just barely noticeable or perceptible by the user. Additionally, the range of frequencies and intensities of the Apollo System have been safely used in numerous commercial products without adverse events reported, including sexual vibrators and massagers. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy.
46109655|NCT00826514|Drug|Tanezumab|Intravenous, 20 mg, single dose.
46109656|NCT00826514|Drug|Placebo|Intravenous placebo, single dose
46109657|NCT00800566|Drug|Oral Clofarabine|The starting dose will be 1 mg orally daily x 21 days every 4 weeks +/- 4 days.
46109658|NCT00793858|Drug|placebo, isotonic ciclesonide, hypotonic ciclesonide|200mcg/nostril
46109659|NCT00800644|Procedure|CT or MRI + Blood Test|"During routine visits, a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.~Blood (about 1 tablespoon) will be drawn to test for bone turnover."
46109660|NCT00800722|Drug|Rapamycin Treatment of Port Wine Stain|Treatment of Port Wine Stain
46023468|NCT02825953|Drug|surfactant|the investigators attempt to administer surfactant in a more gentle way, i.e. by nebulization, by minimally invasive surfactant therapy, and endotracheal bolus application of natural surfactant
46109661|NCT04046458|Behavioral|Nighttime Vital Sign EHR Alert|A pop-up window in the EHR will notify a physician that their patient has been judged by a predictive algorithm to be safe for reduced overnight vital sign checks.
46109662|NCT04046458|Other|No EHR alert|No change to EHR function; no alert visible to providers
45838426|NCT02894398|Drug|Letrozole|Letrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 2.5mg/daily, oral intake
46023469|NCT02825953|Device|nasal continuous positive airway pressure|each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
46109663|NCT04046068|Procedure|ComfortSafe Care|In most cases, sevoflurane, an inhalation anesthetic, will be used in higher-than-traditional concentrations to replace opioids and provide safe control of vital signs along with amnesia and analgesia. Intravenous (IV) propofol, esmolol, and other beta-blockers can also be administered to prevent increases in BP and HR during surgery. At the time of wound closure, the ComfortSafe Pyramid derived Preemergence Analgesic Checklist guides the anesthesia and surgical teams through collaborative decisions for implementation of a multimodal analgesic plan. Local anesthetics, including liposomal bupivacaine, can then be injected and IV non-opioid analgesics administered allowing the patient to awaken comfortably from anesthesia. Standardized kits for liposomal bupivacaine administration will be utilized. If the patient does have pain, IV opioids can be administered to provide immediate relief without hesitation since the non-opioid analgesics have already been given.
45469297|NCT03761329|Procedure|mini-Bier's block with lidocaine 0.5% 25ml|An intravenous catheter will be placed in the dorsal vein of the hand that will undergo surgery. Afterwards, a tourniquet will be placed on the forearm and inflated, after which the anesthetic can be administered via the dorsal vein catheter (25ml lidocaine 0.5%). The tourniquet remains inflated for 10 minutes to reduce systemic toxicity reactions postoperatively.
46109664|NCT00826280|Drug|regadenoson|IV
46109665|NCT00826280|Drug|overencapsulated caffeine|oral
46109666|NCT00826280|Radiation|technetium|IV
46109667|NCT00826280|Drug|placebo|oral
46109668|NCT00794014|Procedure|Conservative strategy|"Main vessel stenting was performed.~Side branch ballooning and kissing ballooning were done if Thrombolysis In Myocardial Infarction (TIMI) flow <3 in the side branch after main vessel stenting in non-left main bifurcation (non-LM) subgroup, and diameter stenosis (DS) >75% in LM subgroup.~Side branch stenting was performed if TIMI flow <3 in the Side branch after ballooning in non-LM subgroup, and DS >50% or dissection in the Side branch after ballooning in LM subgroup."
46109669|NCT00794014|Procedure|Aggressive strategy|"Main vessel was performed.~Side branch ballooning and kissing ballooning were done if DS >75% in the side branch after main vessel stenting in non-LM subgroup, and DS >50% in LM subgroup.~Side branch stenting was performed if DS >50% in the side branch after ballooning in non-LM subgroup, and DS >30% or dissection in the side branch after ballooning in LM subgroup."
46109670|NCT00800800|Drug|Rosuvastatin|40 mg, oral, single dose
46109671|NCT00800800|Drug|Placebo|oral, single dose
46109672|NCT00864851|Biological|Replagal|Intravenous (IV) infusion for 12 months
46109673|NCT00703898|Drug|nevirapine|200 mg/day twice a day
45469298|NCT03761329|Procedure|Conventional Bier's block with lidocaine 0.5% 40ml|An intravenous catheter will be placed in the dorsal vein of the hand that will undergo surgery. Afterwards, a tourniquet will be placed on the upper arm and inflated, after which the anesthetic can be administered via the dorsal vein catheter (40ml Lidocaine 0.5%). The tourniquet remains inflated for 25 minutes to reduce systemic toxicity reactions postoperatively.
46109674|NCT00794092|Drug|Sinerem administration|Single dose
46109675|NCT04030754|Combination Product|amniotic membrane|amniotic membrane is a biological dressing
46109676|NCT04030754|Combination Product|duoderm dressing|duoderm dressing is a synthetic dressing
46109677|NCT04030442|Drug|Immediate-release Oral Morphine Sulfate Tablets|0 mg Immediate release oral morphine; 15 mg Immediate release oral morphine; 30 mg Immediate release oral morphine; Randomized between sessions
46109678|NCT04030442|Other|Thermal and Pressure Nociceptive Sensitivity|Primary outcome measures of pain threshold and tolerance.
46109679|NCT00800956|Drug|[14C]-esreboxetine|Single oral dose of 6mg esreboxetine in solution containing approximately 100uCi [14C]-esreboxetine
46109680|NCT00857207|Behavioral|Goal Management Training|Enhanced Goal Management Training is a 10-week group therapy that teaches strategies to improve an individual's ability to complete everyday tasks.
46109681|NCT05603624|Procedure|Cervical examination to assess labor|Patients were randomized to receive cervical examinations to assess progression in labor with either sterile or clean gloves.
46109682|NCT00801034|Drug|Calcium|tablets, 1 tablet 2 times per day in 28 days
45469299|NCT03415906|Combination Product|sacubitril+valsartan|Combined angiotensin receptor + neprilysin inhibition
45469300|NCT03415906|Drug|valsartan|Angiotensin receptor inhibition alone
45469301|NCT03766789|Device|Cell phone application|cell phone to organize medications
46109683|NCT00801034|Drug|Potassium|Tablets, 5 tablets 2 times per day for 28 days
46109684|NCT04130477|Device|Tunnel attachments and light Nickel Titanium wire|Tunnel attachments planned virtually and light Nickel Titanium wire
46109685|NCT04130477|Device|Clear Aligner therapy|Clear Aligner therapy
46023470|NCT02825953|Device|non-invasive intermittent positive-pressure ventilation|each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
46023471|NCT02825953|Device|Neopuff|Fisher and Paykel, Auckland, New Zealand
46023472|NCT02825953|Device|neonatal ventilator|GE Healthcare, Madison, USA
46109686|NCT00794326|Drug|Solution for Peritoneal Dialysis|Treatment with one bag per day during 6 months
46109687|NCT00836498|Biological|Comparator: RotaTeq|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
46109688|NCT00836498|Biological|Comparator: Placebo|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
46109689|NCT00836498|Biological|Comparator: RotaTeq + Placebo|One 2.0 mL oral dose of RotaTeq and two 2.0 mL oral doses of placebo over an approximately 3-5 month treatment period
46109690|NCT04132037|Other|data record|At each protocol's visit, clinical and urinary data will be recorded and the answers of the questionnaires will be also reported
46109691|NCT02615015|Other|Blood draw|
46109692|NCT00801190|Other|HES (130/0.4)|33 ml/kg i.v. during surgery
46109693|NCT00801190|Other|Ringer's Lactate|33 ml/kg i.v.
46109694|NCT00702728|Drug|Furosemide and matched saline hydration|Subjects will begin treatment approximately 90 minutes prior to the start of catheterization procedure. After a pre-hydration bolus of 250 ml of normal saline solution over 30 minutes the patient will receive 0.5 mg/kg of furosemide intravenously. Then, a replacement solution (saline) is given in an amount matched (ml for ml) to the volume of urine produced. Matched hydration will occur prior, during, and 4 hours post procedure.
46109695|NCT00702728|Drug|isotonic saline solution|Subjects will receive 1 ml/Kg/hr of intravenous saline solution for a minimum of 12 hours prior to catheterization. Hydration will continue to occur during the catheterization, and for a minimum of 12 hours post catheterization.
46109696|NCT04132115|Drug|Piperacillin/tazobactam|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
46109697|NCT04132115|Drug|Meropenem|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
46109698|NCT04132115|Drug|Daptomycin|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
46109699|NCT04132115|Drug|Ceftobiprole|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
46109700|NCT04132115|Drug|Linezolid|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
46109701|NCT04132115|Drug|Vancomycin|Therapeutic drug monitoring(TDM) of this antibiotic plasma concentration
46109702|NCT04132115|Drug|Fluconazol|Therapeutic drug monitoring (TDM) of this antifungal plasma concentration
46109703|NCT04132115|Drug|Acyclovir|Therapeutic drug monitoring (TDM) of this antiviral plasma concentration
46109704|NCT04132115|Drug|Gentamicins|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
46109705|NCT04132115|Drug|Amikacin|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
46023473|NCT05217589|Other|Funny/Amusing Video Clips|Participants watch 5-7 minutes of video clips that are funny/amusing in nature
46023474|NCT05217589|Other|Horror/Scary Video Clips|Participants watch 5-7 minutes of video clips that are scary in nature
46023475|NCT05217589|Other|Thrilling/Suspenseful Video Clips|Participants watch 5-7 minutes of video clips that are thrilling/suspenseful in nature
46023476|NCT02826187|Other|Early complications data|"Early complications of interest are :~New arthroplasty for any reason~Related to the implant :~Wrong position of the implant~Early displacement of the implant~Related to the intervention :~Hematoma~Dislocation (or not causing the resumption of joint replacement)~Deep vein thrombosis~Pulmonary embolism~Acute Infection"
46023477|NCT02826187|Other|Late stage complications data|"Late complications taken into account are:~New arthroplasty for any reason~Aseptic loosening~Delayed hypersensitivity reaction type IV~Solid Tumors~Recurrent dislocation (causing or not the resumption of joint replacement)~Allergic reactions of any kind~Chronic infection"
46109706|NCT04132115|Drug|Ganciclovir|Therapeutic drug monitoring (TDM) of this antiviral plasma concentration
46109707|NCT00801268|Drug|tripterygium wilfordii|TW，60mg/d
46109708|NCT00801268|Drug|Emodin|100mg/d
46109709|NCT02611622|Behavioral|LUMA ENT™|
46109710|NCT02611622|Other|Survey|Demographic and Patient Satisfaction Survey
46109711|NCT02614937|Drug|ranibizumab|0.5 mg IVT ranibizumab
46109712|NCT02614937|Drug|Squalamine Lactate Ophthalmic Solution, 0.2%|Squalamine Lactate Ophthalmic Solution BID
46109713|NCT00707564|Device|HemCon Dental Dressing|The HemCon Dental Dressing is an oral wound dressing made of chitosan
46109714|NCT00707564|Device|Gauze with pressure|Gauze with pressure
46109715|NCT00789490|Dietary Supplement|Daminaide 995 - SuppleFem Sprinkles|The study agent SuppleFem will be a preblend manufactured by Acatris in Oakville Ontario and will be repackaged into 1 gram aliquots in white plastic Tamper Seal Vials.1 ram to be taken with test meal
46109716|NCT00789490|Dietary Supplement|Materna|Materna is a pregnancy supplement available on the Canadian market and is manufactured by Wyeth. Dose is 1 tablet per day
46109717|NCT00697931|Biological|Recombinant MPL- adjuvanted hepatitis B vaccine|Intramuscular injection, 3 doses
46109718|NCT00697931|Biological|Engerix™-B|Intramuscular injection, 3 doses
46109719|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [Low Dose of WN-80E API (5 µg) + Alhydrogel (3.5 mg)] given one month apart
46109720|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [Medium Dose WN-80E API (15 µg) + Alhydrogel (3.5 mg)] given one month apart
46109721|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [High Dose WN-80E API (50 µg) + Alhydrogel (3.5 mg)] given one month apart
46109722|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [High Dose WN-80E API (50 µg)] given one month apart
46109723|NCT00789568|Drug|sapropterin dihydrochloride|20 mg/kg and 100 mg/kg
46109724|NCT00789568|Drug|Moxifloxacin|Moxifloxacin is included as a positive control to demonstrate the assay sensitivity based on the expected increased QTc response.
46109725|NCT00789568|Drug|Moxifloxacin placebo|Moxifloxacin placebo tablet
46109726|NCT00789646|Procedure|Lidocaine/NSS|First injection: subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival NSS 0.4 ml. before antibiotic injection
46109727|NCT00789646|Procedure|NSS/Lidocaine|First injection: subconjunctival NSS 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection
46109728|NCT02554006|Behavioral|good clinical practice|education from physician regarding dual antiplatelet therapy as part of the routine discharge process
46109729|NCT02554006|Behavioral|bundle group|visits and materials describing advantages and side effects of dual antiplatelet therapy and their management
46109730|NCT00801346|Other|laboratory biomarker analysis|
46109731|NCT00801346|Other|metabolic assessment|
46109732|NCT00801346|Other|questionnaire administration|
46109733|NCT00801346|Procedure|assessment of therapy complications|
46023478|NCT02826187|Other|Patient Satisfaction|Patient satisfaction evaluated by Womac reduced Score
45469302|NCT03415750|Drug|Everolimus|Conversion from Mycophenolate mofetil to Everolimus
46109734|NCT00801346|Procedure|fatigue assessment and management|
46109735|NCT00801346|Procedure|quality-of-life assessment|
46109736|NCT00801424|Device|humidified warmed CO2|Additional insufflation of humidified carbon dioxide (approx. 36-37ºC, approx. 80-100% relative humidity) via a humidifier with a heated tube (Fisher&Paykel) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity
45469303|NCT03415750|Drug|Mycophenolate mofetil|Patients will remain in Tacrolimus + Mycophenolate mofetil
45469304|NCT03415750|Drug|Tacrolimus|
45469305|NCT01239719|Drug|Dexamethasone + clemastine|Dexamethasone 0.5 mg clemastine fumarate: 01 tablet every 12 hours.
45469306|NCT01239719|Drug|Dexamethasone|Dexamethasone 0.5 mg: 01 tablet every 12 hours.
45598567|NCT03520543|Drug|[11C]Yohimbine|Each subject will receive an intravenous (IV) bolus injection of [11C]Yohimbine at a dose of 370 MegaBecquerel (MBq) ± 10% with concomitant arterial blood sampling. The distribution of [11C]Yohimbine in brain will be measured by dynamic PET scans obtained from the time of injection for up to 90 minutes along with measurement of the tracer input function with arterial samples for intact tracer and metabolites to establish the total and regional compartmental kinetics of [11C]Yohimbine.
46023479|NCT02826187|Other|Efficacity|Efficacity as evaluated by Harris HIP score
46109737|NCT00856973|Drug|eszopiclone|1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
46109738|NCT00856973|Drug|eszopiclone|2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
46109739|NCT00856973|Drug|Placebo|1 tablet per day for 12 weeks
46109740|NCT00794482|Drug|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5 mL.
46109741|NCT00801502|Dietary Supplement|Oily fish consumption|Two portions of salmon per week from week 20 of pregnancy until giving birth
46109742|NCT00801502|Other|Control|No change to habitual diet from week 20 of pregnancy until giving birth
46023480|NCT02826187|Other|Radiographic evaluation|Bone reaction visible in radiography
46023481|NCT05210725|Drug|Rivaroxaban 2.5 Mg Oral Tablet|2.5 mg rivaroxaban twice a day in addition to acetylsalicylic acid (80-00mg once a day, standard care).
46023482|NCT02826031|Drug|Sodium Hyaluronate Injection|
46023483|NCT02826031|Drug|DICL-SR|
46023484|NCT02829697|Drug|Ropivacaine|Perineural injection.
46109743|NCT00794638|Drug|SyB L-0501|The administration of SyB L-0501 90 mg/m2 or 120 mg/m2/day on Day 2 and Day 3 will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
46109744|NCT00794638|Drug|Rituximab|The administration of rituximab 375 mg/m2 on Day 1 of each cycle will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
46109745|NCT00801580|Drug|doxorubicin liposomal|"Cyclophosphamide~Mesna~Methotrexate~Doxorubicin liposomal~Vincristine~Dexamethasone~Rituximab~Cytarabine"
46109746|NCT00699569|Dietary Supplement|hyperimmune colostrum|hyperimmune colostrum
46109747|NCT00699569|Dietary Supplement|Placebo|
46109748|NCT00794716|Drug|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5mL.
46109749|NCT04132271|Other|Personalized diet|Modified texture and volumen diet according to the OD specifications
46109750|NCT04132271|Other|Control|Nutritional Recommendations according to the OD specifications
46109751|NCT04951492|Drug|Olaparib|Given PO
46109752|NCT00794872|Other|blood sampling|
46109753|NCT00801658|Device|selective Laser Trabeculoplasty (SLT)|
46109754|NCT02553382|Dietary Supplement|Dietary, Herbal|Viscous fibre blend and Salba and American and Korean Red Ginseng capsules
46109755|NCT02553382|Dietary Supplement|Positive Control|Oat bran blend and wheat bran capsules
46109756|NCT00844532|Device|Absolute Pro™ Peripheral Self-Expanding Stent System|Absolute Pro™ Peripheral Self-Expanding Stent System: Devices include both Absolute Pro™ and Absolute Pro™ LL Peripheral Self-Expanding Stent Systems. It is indicated for the treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
46109757|NCT00805194|Drug|placebo plus docetaxel|placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
45469307|NCT03761251|Behavioral|Pet Fish|"Participants will be provided a fish tank with supplies to care for the fish and access to a fish (Betta splendens) from a local pet store. All participants will receive specific instructions for coupling the fish care and diabetes care:~feed fish one pellet in the morning after waking; check and record BG reading at that time~feed fish one pellet in the evening before dinner; check and record BG reading at that time~feed fish one pellet at night before bedtime; check and record BG reading at that time~every week clean the tank alternating with test the water quality in partnership with caregiver; review blood glucose readings with caregiver with each weekly fish care activity and problem solve any issues related to the blood glucose pattern.~Each child will also receive two books intended to supplement and enrich their pet fish experience."
45469308|NCT03916679|Biological|anti-MESO CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-MESO CARs
45469309|NCT04268173|Other|Community-Based, Client-Centered Prevention Home|Prevention Navigators at Vivent Helath offices will engage participants in risk assessments, goal planning, and treatment referrals based on their needs and desires.
45469310|NCT03421990|Procedure|General anesthesia|general anesthesia and regional anesthesia techniques are used
46023485|NCT04980469|Other|Vitex negundo + Zingiber officinale|200 mg/ Capsule
46023486|NCT04980469|Other|Placebo (MCC)|200 mg/ Capsule
46023487|NCT02829151|Drug|Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )|Combination antiplatelet therapy using aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) after the index angioplasty
46109758|NCT00805194|Drug|BIBF 1120 plus docetaxel|BIBF 1120 2 times daily along with standard therapy of docetaxel
46109759|NCT00836186|Radiation|Radiation therapy|Patients will receive whole breast radiation therapy at a dose of 180-200 centigray (cGy) per fraction for 23-27 fractions to a total dose of 4600 - 4860 cGy. Additional radiation to the lumpectomy bed (Boost) is at the discretion of the treating physician. The total dose to the tumor bed cannot exceed 6600 cGy.
46109760|NCT00657046|Drug|Droxidopa|Capsules containing 200 mg droxidopa
45469311|NCT01248143|Dietary Supplement|Green tea|9 gram per day
45469312|NCT01248143|Dietary Supplement|FPP|2 sachets twice daily
46109761|NCT00657046|Drug|Placebo|Capsules with mannitol substituted for droxidopa
46109762|NCT00707720|Device|TERIS procedure|The implantation of the restrictive implant
46109763|NCT00707798|Biological|Pneumococcal vaccine GSK2189242A|Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. Six different formulations of this vaccine will be tested
46109764|NCT00707798|Biological|Pneumo 23™|One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2
45469313|NCT03421912|Other|Cicaplast Balm B5|The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers
45469314|NCT03421912|Other|Dexeryl|The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers
45469315|NCT03766711|Other|Physical Therapy|Repetitive bimanual task training for upper limb motor function recovery.
46023488|NCT02829151|Drug|Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel|Combination antiplatelet therapy using aspirin (100 mg) and clopidogrel (75 mg) after the index angioplasty
46023489|NCT02829151|Drug|Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol|Combination antiplatelet therapy using aspirin (100 mg) and cilostazol (200 mg) after the index angioplasty
46023490|NCT05660395|Drug|Loncastuximab Tesirine|Intravenous (IV) Infusion
46023491|NCT05207137|Behavioral|Telephone call about vaccination|Participants receive phone call from their family physician, where they are invited to ask questions about the COVID-19 vaccine.
46109765|NCT00704054|Drug|ridaforolimus|Ridaforolimus is given as an IV infusion over 30 minutes on days 1-5 and 15-19 of each 28 day cycle. For children less than 10 kg body weight, dosing will be adjusted.
46109766|NCT00801736|Drug|Cisplatin, Paclitaxel|"Cisplatin 75mg/m2, Day 1~Paclitaxel 175mg/m2, Day 1"
46023492|NCT02825719|Drug|Ulipristal acetate|Ulipristal acetate 5mg daily will be prescribed
46109767|NCT05747196|Device|WhiteSwell eLym System|The WhiteSwell eLym™ System is designed to treat congestion in Acute Decompensated Heart Failure (ADHF) patients. The device comprises two endovascular components, a Catheter and a Sheath, that are used in combination with a Console. The device is designed to create a low-pressure zone at the Thoracic Duct Outflow which is located adjacent to the venous angle (junction of the left subclavian vein and left internal jugular vein). This low-pressure region facilitates movement of fluid (lymph) from the interstitial compartment through the lymphatic system and the Thoracic Duct and into the intravascular space, while removal of fluids from the intravascular space is enabled using diuretic therapy. The treatment duration will be up to 72 hours.
46109768|NCT04950244|Diagnostic Test|High-sensitivity cardiac troponin I (hs-cTnI)|"Capillary and veinous whole blood sampling for hs-cTnI was collected. The sample was tested at the bedside with a point-of-care device (Atellica VTLi, Siemens Healthineers).~The result of both hs-c TnI values obtained was blinded to the treating physician"
46023493|NCT02825719|Other|Placebo pills|Placebo pills will be prescribed
46023494|NCT02825719|Drug|Ferrous sulphate|Ferrous sulphate 300mg three times a day will be prescribed if haemoglobin level is less than 10g/dL.
46023495|NCT02825719|Drug|Tranexamic Acid|Tranexamic Acid 500mg four times a day on request basis will be prescribed if patient complained of menorrhagia.
46109769|NCT00856661|Drug|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 to 2 minutes on 1st day
46109770|NCT00856661|Drug|Placebo|IV, single bolus over 1 to 2 minutes on 1st day
46023496|NCT04241653|Procedure|Pressure Support Ventilation|Ventilator will be adjusted to administer pressure at 10 cmH2O.
46023497|NCT04241653|Procedure|Unparalyzed Pressure Control Ventilation|Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography.
46109771|NCT02606994|Drug|Oral Defense Toothpaste|Brush with a Oral Defense Toothpaste three times per day during the study
45469316|NCT04898855|Behavioral|Cognitive Behavioral Therapy for Insomnia|Treatment includes sleep hygiene, sleep restriction, stimulus control, and cognitive therapy.
45838427|NCT02894398|Drug|Anastrozole|Anastrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 1mg/daily, oral intake
46023498|NCT04241653|Procedure|Paralyzed Pressure Control Ventilation|Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography. Also, neuromuscular blockade will be achieved.
46023499|NCT04241653|Device|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation; its size is chosen according to the body weight of the child.
46023500|NCT04241653|Drug|Sevoflurane|Sevoflurane in air/oxygen mixture of 40% will be titrated to achieve adequate depth of anesthesia to maintain immobilization of the eye.
45469317|NCT02913612|Drug|0.25% Timolol Maleate Gel Forming Solution|50:50 Randomized 0.25% Timolol Maleate Gel Forming Solution
45469318|NCT02913612|Drug|0.5% Timolol Maleate Gel Forming Solution|50:50 Randomized 0.5% Timolol Maleate Gel Forming Solution
46109772|NCT02606994|Drug|Crest Toothpaste|Brush with Crest Toothpaste three times per day during the study
46109773|NCT02606994|Drug|Magic Mouth Rinse|Participants using Crest Toothpaste who require additional pain intervention for their oral mucositis will be provided Magic Mouth Rinse
46109774|NCT00844376|Drug|Atorvastatin suspension|A single dose of 80 mg Atorvastatin suspension
46109775|NCT00844376|Drug|Lipitor|A single dose of 80 mg Lipitor tablet
46109776|NCT04046302|Drug|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) self-inserted by participants 3 hours before scheduled IUD insertion appointment.
46109777|NCT04046302|Drug|placebo|one tablet of placebo self-inserted by participants 3 hours before scheduled IUD insertion appointment.
46109778|NCT00914394|Drug|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
45838428|NCT02894398|Drug|Exemestane|Exemestane will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 25mg/daily, oral intake
45838429|NCT02894398|Drug|Fulvestrant|Fulvestrant will be administered as basic therapy (commercially available injection, obtained from local pharmacies) as followed: 500mg/once monthly, intramuscular injection
45838430|NCT02871752|Behavioral|Health promotion|mindfulness-based stress reduction
46109779|NCT00914394|Drug|Phenylephrine|1µg/kg/min, infusion period 20 minutes
46109780|NCT00914394|Drug|Physiological saline solution (as placebo)|infusion period 20 minutes
46109781|NCT00914394|Device|Laser Doppler Flowmetry|Measurements will be performed at the neuroretinal rim to assess ONH blood flow.
46109782|NCT00914394|Device|Goldmann applanation tonometer|intraocular pressure measurements
46109783|NCT00914394|Device|Suction cup|Experimental stepwise increase of intraocular pressure while measurement of optic nerve head blood flow.
46109784|NCT04045678|Drug|LY03003 ( Rotigotine, extended-release microspheres)|"Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks."
46109785|NCT04045678|Drug|Placebo, extended-release microspheres|"Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks."
46109786|NCT00704210|Device|SpineMed Table, Cert HealthSciences LLC|For Group A (the treated group) the following tension adjustments will be used: starting treatment tension will equal 1/4 body weight minus 10 lbs. Incremental increases of 4 lbs. per session will be implemented until optimum tensions are reached, which would be a maximum of ¼ body weight plus 25 lbs, unless distraction tensions cause discomfort, which would require a reduction of the tensions applied.
46023501|NCT05199961|Behavioral|Digital Health Coaching|The digital health coaching program consists of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. The program is 6-months in duration and designed for engagement following CAR T cell infusion.
46109787|NCT00704210|Device|SpineMed Table, Cert HealthSciences LLC|Group B will receive sham decompression treatment (i.e. tension not exceeding 15 lbs) for 30 minutes and ice treatment for 15 minutes once a day during each treatment session. No incremental increases will be used for Group B.
46109788|NCT00801814|Dietary Supplement|PolyGlycopleX (PGX)|2.5 grams of PGX
46109789|NCT00801814|Dietary Supplement|PolyGlycopleX (PG)|5.0 grams of PGX
46109790|NCT00801814|Dietary Supplement|PolyGlycopleX|7.5 grams of PGX
46023502|NCT04241731|Drug|Raltitrexed|Raltitrexed 2.5mg / m2, intravenous infusion for 15min, d1,q2w.
46023503|NCT04241731|Drug|Cetuximab|Cetuximab 500mg / kg, intravenous drip over 120min, d1,q2w.
46109791|NCT00801814|Dietary Supplement|Control|0g of PGX
46109792|NCT00801814|Dietary Supplement|Second Control|0g of PGX
46023504|NCT02829073|Device|Neuromonics Tinnitus Treatment Program|The Neuromonics Oasis™ treatment device will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
46023505|NCT02829073|Device|Placebo Device|A placebo device, identical to the Neuromonics Oasis™ device with altered firmware will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
46023506|NCT04915027|Other|a usual follow-up with Rehabkompassen®|Rehabkompassen® is a patient-centered digital graphic tool for capturing the patient's rehabilitation needs in the follow-up after stroke.
46109793|NCT00658606|Drug|alefacept|IM
46109794|NCT00658606|Procedure|Narrow Band UVB Phototherapy|UVB Phototherapy
46109795|NCT00795106|Drug|Capsaicin|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
46023507|NCT04915027|Other|a usual follow-up with Post-Stroke Checklist, i.e. without Rehabkompassen®|Post-Stroke Checklist consists of eleven questions concerning common and treatable post-stroke problems affecting quality of life.
46023508|NCT02824159|Other|Blood samples for pharmacokinetics exploration|6 blood sample at regular intervals
46023509|NCT02824159|Other|Imagery|Efficacity will be assessed with 3 sessions of resonance magnetic imaging or positron emission tomography scan
46109796|NCT00795106|Drug|Placebo|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
46109797|NCT00809302|Drug|aplindore MR tablets or Placebo|aplindore MR tablets administered BID for about 13 weeks
46109798|NCT00589290|Drug|Belinostat (PDX101)|1000 mg/m^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.
46109799|NCT00801970|Behavioral|Psychological Treatment|15 weekly therapy sessions.
46109800|NCT00801970|Behavioral|Group Therapy|3 months of weekly group therapy sessions.
46109801|NCT02973594|Drug|Ivabradine|
46109802|NCT02973594|Drug|Placebo|
46023510|NCT02824159|Other|Quality of life scale|Quality of life will be evaluated with questionaries 5 times during the study
46109803|NCT00802048|Drug|Local anesthetic (Ropivacaine)|Local anesthetic infusion
46109804|NCT00802048|Drug|Saline|Saline serum infusion
46023511|NCT02824159|Other|Detection of adverse events|The detection will be assessed using the AMA (assistance des malades ambulatoires) system
46023512|NCT02824159|Genetic|Saliva samples|Saliva samples will be collected to explore genetic characteristics of germinal DNA (genes involved in drug pharmacokinetic)
46023513|NCT02824159|Genetic|Blood sample|A unique blood sample will be performed in order to determine characteristics of tumoral DNA (resistance to treatment mutation)
46109805|NCT00802126|Drug|"Combination therapy IVB + rf-PDT"|low-fluence photodynamic therapy combined with intravitreal bevacizumab
46109806|NCT02552680|Other|Exercise|Physical Exercise
46109807|NCT02552680|Other|Guideline|Guideline on care and prevention of Work-Related Musculoskeletal Disorders in activities of daily living, especially those relating work activities.
46109808|NCT02552680|Other|Brochure|Manual/brochure containing information about general health
46109809|NCT00809380|Behavioral|Parental presence|Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.
46023514|NCT02824159|Other|Biological statement|"The following parameters will be assessed :~Complete blood count~Hemoglobin~Hepatic enzymes~Creatinine clearance~Lactate dehydrogenase rate~Total bilirubin rate~Cluster of differentiation 4 T lymphocytes rate~Total gamma-globulins rate"
46023515|NCT02824159|Other|Clinical examination|"The clinical examination are composed by :~Weigh, Height and body mass index measurement~Clinical state of patient during examination~Stage of the disease (OMS grade, binet classification, Ahn Arbor classification)~Presence of B symptomatology~Prognostic factors (Genetic, Mantle Cell Lymphoma International Prognostic Index, Follicular Lymphoma International Prognostic Index, presence of lymph nodes, other target organs ...)"
46023516|NCT04241887|Procedure|thoracic paravertebral blockade|Anesthesia was performed under the ultrasound guidance: the Th8 spinous process was identified, then a probe was moved lateral to medial until two adjacent transverse processes and the pleura were visible. After anaesthetising the skin with 2ml of 1% lignocaine (Lignocainum hydrochlorici, WZF 1%), the Touhy needle 22G (Smith Medical)was introduced under the real time guidance. Once in the paravertebral space, 20ml of 0,25% bupivacaine (Bupivacainum hydrochloricum WZF 0,5%, Polfa Warsaw SA) was injected with an end point of a characteristic pleural displacement.
46109810|NCT00809380|Behavioral|Control|One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.
46023517|NCT04241887|Procedure|local anaesthesia|Local infiltration anaesthesia with 0.5% lignocaine 5ml (Lignocainum hydrochlorici, WZF 1%) was applied to the skin and the potential needle path of ablation.
46023518|NCT05660005|Other|Muscle Stretching|Stretching based on the FAIR (flexion, adduction and internal rotation) position, which provides the most effective stretching on the piriformis muscle, was demonstrated, and a illustrated brochure containing the explanatory information of the application was given to the group participants. With the ipsilateral hip flexion, adduction and internal rotation, the foot is positioned to the lateral side of the contralateral knee, thus long-term passive stretching is targeted in this position. Individuals were asked to leave a 2-days gap between the two stretching exercise sessions by performing 10 repetitions (minimum duration of 15 s stretching, 30 s rest period between repetitions) 3 sets and 3 days of a week.
46109811|NCT04830202|Drug|Telisotuzumab vedotin|Intravenous Infusion
46109812|NCT04820374|Procedure|pupil's light and pupil diameter|It is necessary to meet the requirement that the pupil's light reflection is slightly restored to the state of entering the room, and then the tube is extubated and the pupil diameter and the light reflection are restored to the state of entering the room, leaving the recovery room
46109813|NCT00843518|Drug|LY451395|3 mg LY451395 orally twice daily for 12 weeks; may have been reduced to 1 mg if participant was unable to tolerate
46109814|NCT00843518|Drug|Placebo|Placebo orally twice daily for 12 weeks
46109815|NCT02552524|Device|rTMS active then rTMS placebo|A 20 minute session of rTMS active at the frequency of 10 Hz then, 7 days later, a 20 minute session of rTMS placebo
46109816|NCT02552524|Device|rTMS placebo then rTMS active|A 20 minute session of rTMS placebo then, 7 days later, a 20 minute session of rTMS at the frequency of 10 Hz
46109817|NCT00809536|Drug|Metformin|225 mg q12, oral PD 0332334 immediate release formulation on Days 1 through 5; Single, oral, 500 mg dose of metformin immediate release
46109818|NCT00809536|Drug|Metformin|Single, oral, 500 mg of metformin immediate release
46109819|NCT00809536|Drug|PD 0332334|500 mg q12, oral metformin immediate release administered on Days 1 through Day 6 Single, oral, 300 mg dose of PD 0332334 immediate release formulation administered on Day 3
46109820|NCT00809536|Drug|PD 0332334|Single, oral, 300 mg dose of PD 0332334 immediate release formulation
46109821|NCT00809692|Procedure|validated techniques for histamine response|the prick test and iontophoresis technique (serial assessment of blood flow using validated Doppler technique)
46109822|NCT00809692|Procedure|new technique for histamine response|laser Dopper technique and genotyping
46109823|NCT00843284|Drug|Pregabalin|Capsules, 150 - 600 mg/day, 2-3 times/day, 8 weeks
46109824|NCT02972892|Device|Et Control Feature|Subjects using Et Control option; the investigator will use and initiate Et Control after the airway is secured and mechanical ventilation is initiated. Machine log data is collected when the investigator initiates the start of anesthesia case on the Aisys CS2. Adjustments to the anesthesia machine settings, discontinuation of use of the investigational Et Control option, and changes to treatment are based upon clinician judgment for the wellbeing of the subject. The clinician must continuously monitor measured inspired and end tidal oxygen and anesthetic concentrations to assess individual responses and compare to the target concentrations.
46109825|NCT02972892|Device|Conventional Fresh Gas|"Subjects to undergo a surgical procedure with inhaled anesthesia meeting the American Society of Anesthesiologists status classification system 1-3. Subjects using conventional option; the investigator will use their conventional means to adjust the vaporizer and mixer, and monitor the patient gas concentrations with the legally marketed Aisys CS2 anesthesia machine without the investigational Et Control feature. Machine log data collection will end, when an end case is confirmed on the Aisys CS2 at the end of the anesthesia case."
46109826|NCT00802282|Drug|psilocybin|dose manipulation as described in the protocol and to which volunteers are blinded
46109827|NCT00802282|Behavioral|Intensity of support for spiritual practice|Volunteers will be assigned to standard or high support, as described in the protocol
45469319|NCT03426202|Drug|Modafinil Oral Tablet|modafinil 200mg
45469320|NCT03426202|Drug|Placebo Oral Tablet|placebo 200mg
46109828|NCT00802282|Behavioral|Number of sessions|Volunteers will be assigned to either 2 or 3 sessions, as described in the protocol
46023519|NCT05660005|Other|Self Myofascial Release|The patient was presented with the anatomically localized area of the PiM on a visual anatomy map and they were encouraged to find this area on their body. They were asked to verify the trigger points along the PiM and then sat on the trigger points with the help of a tennis ball. Individuals were taught the PiM-SMR exercise, in which they would make forward-backward, right-left, diagonal and circular movements on the ball using their body weight. There was a continuation of the application with an interval of 2 days; 3 times a day with 10 repetitions (the application was for 1 min and 30s rest period between repetitions).
46023520|NCT05660005|Other|home exercises|The exercise brochure consists of 5 different exercises that include isometric and isotonic strengthening of the hip and surrounding muscles. Isometric contraction of gluteus maximus, hip march, external/internal rotation of hips with theraband, 4 sided straight leg raises were the exercises and prescribed 5 days a week, 10 repetitions, 3 sets. All participants were advised to use analgesics determined by the physician in case of unbearable pain and to apply a hot pack for 10-20 minutes before sessions.
46109829|NCT00802516|Dietary Supplement|stanol ester|enriched margarine
46109830|NCT00802516|Dietary Supplement|sterol ester|enriched margarine
46109831|NCT00802516|Dietary Supplement|No intervention|placebo margarine
46109832|NCT02606760|Drug|P-3073|
46109833|NCT02606760|Drug|Vehicle of P-3073|
46109834|NCT04106466|Device|Medtronic Summit RC+S DBS system|Open label active Deep Brain Stimulation (DBS)
46109835|NCT00652834|Procedure|Small bowel capsule endoscopy (SBCE)|SBCE will be performed at Day 2 and Day 30.
46109836|NCT00652834|Drug|myfortic|switching from mycophenolate mofetil to mycophenolic acid on equimolar basis
46109837|NCT02553148|Other|Need for children's palliative care|Need for children's palliative care
46109838|NCT00825812|Drug|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 2.0 mg/kg sugammadex was administered.
46109839|NCT00825812|Drug|neostigmine|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 50 µg/kg neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
46109840|NCT00802594|Drug|DB289|A single 100 mg DB289 capsule will be taken by mouth twice a day, morning and evening. Drug is to be taken with a glass of water within 15 minutes of the completion of meal.
46109841|NCT02606682|Drug|NPT200-11|Single doses of NPT200-11capsules, orally administered
46109842|NCT02606682|Drug|Placebo|Single doses of microcrystalline cellulose capsules, orally administered
46109843|NCT00707876|Drug|ferumoxytol|Dose 1 versus non-contrast MRA
46109844|NCT00707876|Drug|ferumoxytol|Dose 2 versus non-contrast MRA
46109845|NCT00707876|Drug|ferumoxytol|Dose 3 versus non-contrast MRA
46109846|NCT00809770|Behavioral|Contingency Management|Opportunities to earn rewards are given three times a week for 12 weeks contingent on negative urine analyses indicating drug abstinence
46109847|NCT00809770|Behavioral|Non Contingent Control Condition|Opportunities to draw for rewards are provided three times a week for 12 weeks for providing urine analysis. Opportunities to earn rewards are not based on urine analysis results.
46109848|NCT02606448|Drug|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
46109849|NCT02606448|Procedure|Femoral nerve block|Pre-operative femoral nerve block
46109850|NCT02606448|Drug|Ropivicaine|Ropivicaine was used in all femoral nerve blocks
46109851|NCT00810004|Drug|Ferinject|Intravenous infusion of iron
46109852|NCT05746962|Device|ScopeGuide Navigated Colonoscope|colonoscopes equipped with ScopeGuide
46109853|NCT05746962|Device|Navigation screen|ScopeGuide's 3D visualisation screen
46109854|NCT00802750|Device|LoFric POBE|"LoFric POBE, Nelaton 40 cm, CH 12 with new solvent. Each subject will use the reference catheter LoFric POBE, Nelaton 40 cm, CH 12 with current solvent before being catheterized with the test catheters."
46109855|NCT00802750|Device|LoFric POBE|"Unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with new solvent Each subject will use the reference catheter LoFric POBE, Nelaton 40 cm, CH 12 with current solvent before being catheterized with the test catheters."
46109856|NCT00802828|Drug|Famotidine Tablets, 40 mg|
46109857|NCT00824720|Drug|High Dose Device|inserted for 14 days
46109858|NCT00824720|Drug|Low Dose Device|inserted for 14 days
46109859|NCT00824720|Device|Placebo Device|inserted for 14 days
46109860|NCT00802906|Device|subthreshold micropulselaser|on demand if leakage is persistent or recurs after initial treatment
46109861|NCT00802906|Drug|bevacizumab|1.5 mg initial intravitreal injection
46109862|NCT00802984|Device|Endovascular thoracic aortic aneurysm repair using TALENT TAA Stent Graft System|
46109863|NCT00803140|Procedure|Cautery vs Active Control Arm (Scalpel)|"Interventions: The cautery used will be the standard operating room monopolar cautery used at our institution. The cautery will be used on a cut setting of 20 with a blend setting of zero (pure cut). A standard protected needle tip cautery will be used.~A #15 blade carbon steel scalpel blade will be used on ½ of the incision; a cautery device with the above-mentioned settings will be used on the other ½ of the wound. The patient will be randomly assigned to receive the cautery incision on the left or right side. The same surgeon will make all of the skin incisions and perform the skin closures in order to provide as much standardization as possible.~The closure will be standardized."
46109864|NCT00803218|Drug|Fluticasone Propionate 0.005% Ointment-Reference Product|Small amount applied and evaluated over the course of one day
46109865|NCT00803218|Drug|Fluticasone Propionate 0.005% Ointment-Test product|Small amount applied and evaluated over the course of one day
46109866|NCT00803296|Other|Oral glucose tolerance test (OGTT)|
46109867|NCT00803296|Other|Isoglycemic intravenous glucose infusion|
46109868|NCT03704064|Behavioral|Stigma-Reduction Intervention|Session topics will be based on those tested in a previous pilot study, including: psychoeducation about weight and weight stigma; challenging myths and cognitive distortions related to weight; strategies for coping with instances of stigma; and increasing empowerment and body esteem. The effects of weight stigma on health behaviors will be discussed, and sessions will focus specifically on helping participants overcome stigma-related barriers to physical activity. For example, they will be given strategies to cope with anticipated stigma while exercising in public spaces (e.g., while walking), as well as to challenge self-critical beliefs (e.g., that they are lazy) which may otherwise lead them to avoid exercising. These concrete strategies, along with reducing WBI and improving self-confidence, are intended to increase participants' self-efficacy for and engagement in physical activity.
46109869|NCT03704064|Behavioral|Behavioral Weight Loss (BWL)|This intervention will be based on the Diabetes Prevention Program. A diet of 1200-1499 calories per day will be prescribed for participants < 250 lb, and 1500-1800 for those ≥ 250 lb. Participants will be instructed to eat a balanced deficit diet. Session topics during the first 20 weeks will include self-monitoring, stimulus control, social support, portion sizes, and goal-setting. Those during weeks 21-72 will focus on skills required for weight loss maintenance and relapse prevention. Physical activity will be begin with a prescription of 60 min/wk, and will gradually progress by 10 minutes over 2-4 week intervals until achieving 150 min/wk by week 20, 200 min/wk by week 46, and 250 min/wk by week 72. Participants will be instructed to spread the activity equally across at least 5 days in bouts that are >10 minutes in duration. Moderate intensity will be prescribed with an emphasis on walking; the vast majority of our research participants self-select this form of activity.
46109870|NCT00824564|Drug|Tranexamic Acid plus standard of care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + Standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
46023521|NCT04242745|Behavioral|Intervention group|"The elderly in this group were trained using the For Your Health For Fluid training booklet and a projection device, and after training, all individuals were given a training booklet. The training was carried out individually in a room reserved for training and took an average of 25-30 minutes.~A Beyid wristwatch was used. This spoke the time in Turkish, every hour on the hour. In this way, the old people were reminded to drink a glass of liquid each hour. The watch had an alarm capability, and could be taken on to sleep mode at night in order not to wake the old people."
46023522|NCT04242745|Behavioral|Control group|"The elderly in this group were trained using the For Your Health For Fluid training booklet and a projection device, and after training, all individuals were given a training booklet. The training was carried out individually in a room reserved for training and took an average of 25-30 minutes."
46109871|NCT00824564|Procedure|Standard of care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
46109872|NCT00803374|Drug|AntiCD137|Infusion, IV, 0.1 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
46109873|NCT00803374|Drug|AntiCD137|Infusion, IV, 0.3 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
45469321|NCT04449016|Other|High intensity interval training|Repeated, brief, and intense exercise bouts separated by active recovery
45469322|NCT03916523|Procedure|Sustained lung inflation|"Preterm infants will receive a total of 15 sustained lung inflations during the first 4 days of life as follows:~On day 1 of life (a total of 6 sustained lung inflations, 20 cmH2O for 21 seconds each) once at enrollment and then once every 4 hours~On day 2 of life (a total of 3 sustained lung inflations, 15 cmH2O for 21 seconds each) once every 8 hours.~On day 3 of life (a total of 3 sustained lung inflations 10cmH2O for 21 seconds each) once every 8 hours.~On day 4 of life (a total of 3 sustained lung inflations 10cmH2O for 21 seconds each) once every 8 hours."
45469323|NCT03916523|Procedure|Continuous positive airway pressure (CPAP)|Preterm infants will receive CPAP for respiratory support.
45469324|NCT03916523|Procedure|Mechanical ventilation|Preterm infants in this group will receive mechanical ventilation for respiratory support
45469325|NCT03312231|Drug|AS03|Oil-in-water emulsion based adjuvant system.
45469326|NCT03312231|Biological|Inactivated influenza H7N9 vaccine|Monovalent 2017 H7N9 inactivated influenza vaccine
45469327|NCT03312231|Other|Phosphate Buffered Saline (PBS) diluent|Diluent for 2017 Monovalent Inactivated Influenza A/H7N9 virus vaccine (2017 H7N9 IIV)
45469328|NCT03421678|Diagnostic Test|Urine Sample|One to two home visits where tobacco use and medical history and biological samples will be collected including blood, buccal cells and urine
45469329|NCT04232280|Biological|mRNA-1647|Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
45469330|NCT04232280|Other|Placebo|0.9% sodium chloride (normal saline) injection
45469331|NCT03421600|Device|blue laser imaging|blue laser imaging
45469332|NCT03421600|Device|White light imaging|White light imaging
45469333|NCT04223310|Drug|Virtual AAD TEST group|"Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~Preselect drug with optimal antiarrhythmic effects in the patient.~Take an AAD selected by virtual AAD simulation in patients who recur AF after catheter resection~Drug selection should be decided according to the guidelines.~A follow-up of rhythm follow-up has to be conducted according to the above study design."
45469334|NCT04223310|Drug|Empirical AAD group|"Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~Selection of AAD based on the experience of the attending physician, independent of the results of the virtual AAD test in patients who recur AF after catheter resection~Drug selection should be decided according to the guidelines.~A follow-up of rhythm follow-up has to be conducted according to the above study design."
45469335|NCT01248299|Drug|FU-CDDP|"every 21 days:~Fluoro-uracil [800 mg/m2, day 1 to day 5]~CisPlatin [75 mg/m2, day 1 or day 2]"
45469336|NCT01248299|Drug|LV5FU2-CDDP|"every 14 days:~Elvorin [200 mg/m2, 2h IV, day 1 and day 2]~Fluoro-uracil [400 mg/m2 as a bolus, day 1 and day 2]~Fluoro-uracil [600 mg/m2, 22h continous infusion, day 1 and day 2]~CisPlatin [50 mg/m2, day 2]"
45469337|NCT01248299|Drug|FOLFOX|"every 14 days:~Oxaliplatin [85 mg/m2 by 2h infusion, day 1]~Fluoro-uracil [400 mg/m2 as a bolus, day 1 and day 2]~Fluoro-uracil [600 mg/m2, by 22h continous infusion, day 1 and day 2]~Elvorin [500 mg/m2, day 1 and day 2]"
46023523|NCT02825875|Drug|18F DCFPyL- Radiopharmaceutica|
46023524|NCT02828995|Other|Comprehensive Diabetes Stigma Survey|"The surveys to be administered in the ENDSTIGMA study are as follows:~The Adherence to Refills and Medications for Diabetes survey is a validated, diabetes-specific survey measure utilizing patient self-report to assess diabetes medication adherence.~The Demographics survey will be used to assess participant baseline characteristics, including body mass index (BMI). The questions contained in this survey have been validated by Dr. Kerri Cavanaugh's research group.~Comprehensive Diabetes Stigma Survey is a novel survey being developed and validated in the ENDSTIGMA study. The ENDSTIGMA study will also compare the results from this survey with the medication adherence results, to determine if there is an association between diabetes stigma and medication adherence."
46109874|NCT00803374|Drug|AntiCD137|Infusion, IV, 1.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
46023525|NCT02825485|Procedure|Voiding cystourethrogram|
46109875|NCT00803374|Drug|AntiCD137|Infusion, IV, 3.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
46109876|NCT00803374|Drug|AntiCD137|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
46109877|NCT00803374|Drug|Ipilimumab|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12, 12+ weeks depending on response
46109878|NCT00803530|Drug|ATO + Ascorbic acid|"ATO will be diluted in 250 ml of normal saline solution at a dosage of 0.3 mg/Kg during the first week of therapy and at a dosage of 0.25 mg/Kg during the subsequent weeks (week 2 to 16), and administered intravenously over a 1-2 hour period.~The dose of ascorbic acid will be 1000 mg in 100 cc D5W or normal saline solution (NaCl 0.9 %) (protected from light and air) administered as an IV infusion over 15 to 30 minutes. The dosing solution is not to be mixed with any alkaline solution."
46109879|NCT00704288|Drug|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing
46109880|NCT00803608|Device|TrueContour® Insole|Novel designed insole
46023526|NCT05660317|Other|Tip control score|Scoring of endoscopist's tip control performing snare tip soft coagulation to the margins of a endoscopic mucosal resection (EMR) defect
46109881|NCT00803608|Device|Current standard of care insole|Current Medicare approved A5513 insole
46109882|NCT00708188|Device|Multidetector raw CT|Multidetector raw CT
46109883|NCT00803764|Drug|Naproxen Tablets, 500 mg|
46023527|NCT02825563|Drug|Anlotinib|in the fasting state
46109884|NCT02611310|Other|No intervention|No intervention administered in this study.
46109885|NCT02553694|Other|Enhanced education|Investigator created video to help educate subject before the in-laboratory split night polysomnogram. The subject will watch the short video immediately prior to the initiation of the in-laboratory polysomnogram.
46109886|NCT02553694|Other|Usual education|Usual education by American Academy of Sleep Medicine (AASM)- created educational pamphlets
46023528|NCT02825563|Drug|Anlotinib|in the high fat diet
46023529|NCT02825797|Drug|3BNC117|Intravenous infusion of 3BNC117
46023530|NCT02825797|Drug|10-1074|Intravenous infusion of 10-1074
46109887|NCT02553694|Other|Usual follow up|MD will follow up by phone after the in-laboratory split night polysomnogram
46109888|NCT02553694|Other|Enhanced follow up|Sleep center non-MD staff member will follow up by phone after the in-laboratory split night polysomnogram
46109889|NCT00704366|Drug|AZD0530|oral, tablet, once daily, dose will be variable
46109890|NCT00708266|Device|Openflow microperfusion catheter|Macro-perforated, double lumen catheter used to withdraw interstitial fluid samples from different tissues.
46109891|NCT00708266|Dietary Supplement|Intralipid 20%|"Lipid emulsion used in clinical practice as supplementary intravenous nutrition. 28 hours venous infusion during the treatment study visits."
46109892|NCT00708266|Other|0.9% Saline Solution|"0.9% sodium chloride solution, used in clinical practice for venous hydration. 28 hours infusion during the control study visits."
46109893|NCT00803842|Drug|doxycycline|Doxycycline (the study drug) will be provided to all subjects as 100 mg tablets. They will be allocated enough doxycycline to last them until their next scheduled visit. The doxycycline tablets should be taken orally (only) at a dosage of 100 mg every 12 hours. Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. The doxycycline tablets should not be taken with foods that contain calcium. The absorption of doxycycline is reduced when taking bismuth subsalicylate. Duration of study period if 14 days
46109894|NCT03700554|Device|Pleuralvent™|Pneumothorax treatment with Pleuralvent™ device (Heimlich valve device)
46109895|NCT03700554|Procedure|Chest tube|Chest tube insertion
46109896|NCT00922246|Device|custom-made insoles (Thermo+Camel, cost for the military 20,50 euros)|The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length.
46109897|NCT00658528|Drug|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, taken orally, once daily for 4-8 weeks.
46109898|NCT00658528|Drug|Esomeprazole|Esomeprazole 40 mg capsule, taken orally, once daily for 4-8 weeks.
46023531|NCT02825797|Other|Analytical treatment interruption|Analytical treatment interruption
46023532|NCT02825797|Drug|Placebo|Intravenous infusion of placebo (sterile saline)
46023533|NCT04241497|Behavioral|Home-based rehabilitation|1 supervised exercise session at the hospital; 3 weeks of supervised home-based exercise training (3x/week); 9 weeks of unsupervised home-based exercise training (3x/week)
46023534|NCT02824315|Drug|AL-335|AL--335 800 mg once daily on Days 1--3, 24--26 and 34--36.
46023535|NCT02824315|Drug|Odalasvir (ODV)|ODV 150 mg on Day 14 and 50 mg once daily on Days 15--23, 24--26, 27--33 and 34--36.
46023536|NCT02824315|Drug|Simeprevir (SMV)|Simeprevir 75 mg once daily on Days 4-13, 27--33 and 34--36.
46109899|NCT02872974|Other|GDM|Exposure to GDM during fetal life
46109900|NCT03871426|Procedure|manual therapy|Manual Cervical Traction, Trunk Stabilization Maneuver
46109901|NCT00806104|Dietary Supplement|Fructo-oligosaccharides|Dietary supplementation for 4 weeks
46109902|NCT00806104|Dietary Supplement|Maltodextrins|Dietary supplementation for 4 weeks
46109903|NCT04710940|Behavioral|Diabetes BOOST|Participants will receive supportive care using technology for DSMT in addition to usual care.
46109904|NCT04710940|Behavioral|Usual Care|Participants will receive usual care for DSMT.
46109905|NCT00806338|Drug|Trodusquemine (MSI-1436)|A single dose of Trodusquemine (MSI-1436) will be administered every 72 hours on Days 0, 3, 6, 9, 12, 15, 18 and 21. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2 and 10mg/m2 in cohort 3.
46109906|NCT00806338|Drug|Placebo|
46109907|NCT04017052|Drug|FSME-IMMUN Vaccine|Booster with TBE vaccine (i.m.) FSME Immun
46109908|NCT00806572|Drug|hOKT3gamma1(Ala-Ala)|3 cycles, six months apart, each consisting of 12 daily infusions with 455-1818ug/m2 hOKT3g1(Ala-Ala)
46023537|NCT00633529|Drug|IMO-2055|0.08, 0.16, or 0.32 mg/kg SC (subcutaneous) on days 1,8,and 15 of every 21 day cycle until evidence of progressive disease, unacceptable treatment-related toxicities, withdrawal of patient consent and/or Investigator decision to withdraw study therapy with documented reason, whichever occurs first.
46109909|NCT02864394|Biological|Pembrolizumab|Pembrolizumab administered IV at 2 mg/kg on Day 1 of each 21-day cycle for up to 35 doses (approximately 24 months).
46109910|NCT02864394|Drug|Docetaxel|Docetaxel administered IV at 75 mg/m^2 on Day 1 of each 21-day cycle as per the approved product label.
46109911|NCT00856583|Drug|Sertindole|Sertindole was supplied as 4, 12, 16, and 20 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national Summary of Product Characteristics (SPC) for sertindole; in countries where sertindole was not marketed, the European Union (EU) SPC applied (all national and EU SPCs were essentially identical). Recommended dose range: 12 to 20 mg/day. The investigators were instructed to contact H. Lundbeck A/S if they deemed it necessary to increase the dose of sertindole to 24 mg/day, which was allowed in exceptional cases
45469338|NCT01248299|Drug|TPF|"every 21 days:~Docetaxel [30 mg/m2, day 1 and day 8]~CisPlatin [60 mg/m2, day 1]~Fluoro-uracil [200 mg/m2/day by continous infusion]~Or every 21 days:~Docetaxel [50 mg/m2, day 1]~CisPlatine [70 mg/m2, day 1]~Fluoro-uracile [700 mg/m2 /day, day 1 to day 5]"
45469339|NCT01248299|Other|Best Supportive Care|See European professionnal recommendations (ESMO 2009) Exemples : antalgic treatment, nutritional support, ...
46023538|NCT02823613|Dietary Supplement|High salt diet followed by low salt diet|High salt diet (250 mmol/day) in 5 days followed by low salt diet (60-70 mmol/day) in 5 days.
46023539|NCT02823613|Dietary Supplement|Low salt diet followed by high salt diet|Low salt diet (60-70 mmol/day) in 5 days followed by high salt diet (250 mmol/day) in 5 days.
46023540|NCT02824081|Biological|Blood sample|Blood sample in order to study inflammatory biomarkers and genetics purpose
46023541|NCT04242433|Drug|Direct Acting Antivirals|"All subjects with viremic chronic hepatitis C will be given DAAs based on the MMPHCRF Treatment algorithm. Patients will be assessed for cirrhosis, prior treatment exposure, high risk groups like dialysis patients, HIV-HCV coinfection, etc. Accordingly treatment will be provided at any of the 25 peripheral centres or at the apex nodal treatment centre (PGIMER) of the MMPHCRF.~Baseline and post treatment RAS samples will be collected with consent."
46023542|NCT02825407|Dietary Supplement|Oral physiology|
46023543|NCT04242511|Diagnostic Test|Measurement of tuberculosis medications level|Measurement of tuberculosis medication levels at 2 hours post-dose
46023544|NCT02825173|Device|Seal-G|"Intervention:~Device: Seal-G Seal-G is applied adjunctively to cover standard closure techniques"
46023545|NCT02825329|Device|TORAYMYXIN PMX-20R|Two (2) PMX cartridges will be administered approximately 24 hours apart. PMX Cartridge is an extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
46023546|NCT02823925|Drug|Pamidronate or Zoledronate|
46023547|NCT05659771|Behavioral|Food properties manipulation to alter eating behavior and food and energy intake|Food properties of commercially available food products
46023548|NCT04242589|Radiation|Radiotherapy|External beam radiation therapy is a type of radiation therapy used for cancer treatment. A machine is used to aim high-energy rays from outside the body into tumor
46109912|NCT00856583|Drug|Risperidone|Risperidone was supplied as 1, 2, 3, and 4 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national SPC for risperidone. Recommended dose range: 2 to 8 mg/day
46109913|NCT00856349|Behavioral|Therapy Programming Report (TPR)|Center-specific therapy programming reports (TPRs) illustrating physician usage of shock reduction programming are provided to each center approximately 9-12 months after their first enrollment and monthly thereafter throughout the study.
46109914|NCT00803244|Drug|300 IR|300 IR grass pollen allergen extract tablet starting 2 months before the grass pollen season and during the grass pollen season
46023549|NCT04242589|Procedure|Vertebropladty|Vertebroplasty is a procedure for stabilizing compression fractures in the spine. Bone cement is injected into vertebrae that have cracked or broken. The cement hardens, stabilizing the fractures and supporting your spine.
46023550|NCT04201249|Drug|Piroxicam, lidocaine|Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
46023551|NCT04201249|Device|Mesotherapy without drug administration|Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
46023552|NCT00633685|Drug|Fluoxetine|Fluoxetine will be administered at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
46109915|NCT00803244|Drug|Placebo|Placebo sublingual tablet starting 2 months before the grass pollen season and during the grass pollen season
46109916|NCT02608632|Device|Renal denervation guided by HFS|
46109917|NCT02608632|Device|Renal denervation as standard procedure|
46109918|NCT02614313|Procedure|Open breath test with fructose|Open randomised fructose 35g during breath test
46109919|NCT02614313|Procedure|Breath test with sweet placebo (Assugrin)|Double-blind randomised breath-testing with sweet placebo (Assugrin)
46109920|NCT02614313|Procedure|Breath test with neutral placebo (still water)|Double-blind randomised breath-testing with neutral placebo
46109921|NCT02614313|Procedure|Blinded breath test with fructose|Double-blind randomised fructose 35g during breath test
46109922|NCT02614391|Other|Active distraction using a tablet|Playing a videogame using a computer tablet
46109923|NCT02614391|Other|Passive distraction|A nurses singing a song, reading a book, blowing bubbles and playing a puppet show
46109924|NCT05706558|Procedure|Esophagectomy|Esophagectomy
46023553|NCT00633685|Drug|Placebo|Placebo will be empty gelatin capsules that are identical in size and shape to active treatment
46109925|NCT04131803|Drug|Bifico combined with chemotherapy plus targeted therapy|Bifico combined with chemotherapy plus targeted therapy
46109926|NCT04131803|Drug|chemotherapy plus targeted therapy|chemotherapy plus targeted therapy
46023554|NCT02823691|Drug|Lanreotide and Metformin|Lanreotide and Metformin
46109927|NCT04060212|Other|Tuna fish|Six meals of tunafish (~200gms) will be consumed. Three meals will be consumed in a period of 14 days, and a subsequent 3 meals will be consumed within a 14 day period six month after the first 3 meals.
46109928|NCT04060212|Dietary Supplement|prebiotic|Prebiotin brand prebiotic will be consumed at 8grms/day for a period of 75 days. The prebiotic administration will begin with the second grouping of 3 fish meals.
46109929|NCT02608008|Device|Data analysis|data parameters Analysis
46109930|NCT02608086|Behavioral|Psychoeducation|"Participants in Control Group will be delivered a flyer named What can I do facing a crisis?, containing information about normal reactions to crisis, what to do to return to normal life and which are the signals of an initial trauma."
46109931|NCT02608086|Behavioral|Psychological First Aid|"Psychology students (PFA Providers) will intervene according to an adapted protocol based on the WHO PFA Operation Guide 2012. Protocol for this study contemplates 4 steps: 1. Active Listening 2. Relaxing and Breathing Techniques 3. Help in prioritizing needs 4. Help in contacting network and services. Moreover, participants in this group will receive a brochure with full contact information of public network, and a flyer named What can I do facing a crisis?."
46109932|NCT02607852|Device|iPads|The current study will help determine if using Burn Outcomes Questionnaire and 17- item Pediatric Symptom Checklist (PSC-17) feedback data, collected on iPads or online, over the course of patient treatment will be useful for the physicians and ultimately impact the recovery of the patient.
46109933|NCT05753358|Other|Total Worker Health for Wildland Firefighters|The program is structured as 30-minute modules that can be done individually, with a partner, as a group or in a classroom setting. The six core modules are supplemented with eight elective modules. The program can be accessed on a smartphone, tablet or computer, and if needed can be downloaded as a pdf.
46109934|NCT04014114|Other|Digital Genetic Assistant|An end-to-end digital solution to the carrier screening process from participant registration to receipt of the test results and their interpretations. These steps are provided using personalized animated videos.
46109935|NCT04013100|Diagnostic Test|3D-VNE (virtual neck exploration)|The 3D-VNE model is obtained with VP Planning software (Visible Patient, Strasbourg, France), using DICOM (Digital Imaging and Communications in Medicine) images of contrasted Computed Tomography scan of the neck in operative positioning.
46109936|NCT05753280|Drug|Vitamin D|Patients take 800 mg vitamin D capsules daily during the whole treatment period
46109937|NCT02606370|Other|Unstable shoe|Wearing Unstable shoes during 1 month
46109938|NCT05753202|Device|transcranial current direct stimulation|Transcranial electrical stimulation over two different brain regions associated with cognitive training. 15 sesions in 3 weeks (5 days/week)
46109939|NCT02606214|Drug|TBA-354|
46109940|NCT02606214|Drug|TBA-354 Placebo|
46109941|NCT04022148|Biological|Gardasil|Experimental arm: Vaccine group VS Control arm: Non-Vaccine group
46109942|NCT00804570|Drug|LY2196044|250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
46109943|NCT00804570|Drug|placebo|once daily, orally, 16 weeks
46109944|NCT05753124|Other|Observational|This is an observational study
46023555|NCT04888195|Other|Questionnaire|Participants will complete a set of validated questionnaires (TRSC-C and demographic sheet) before chemotherapy. They also have to complete the same questionnaires (TRSC-C) again within 1 week after the 1st, 2nd, 3rd, 4th , 5th and 6th courses of chemotherapy via telephone interview by our research assistants.
46109945|NCT02606292|Procedure|Photoacoustic endoscopy|
46109946|NCT02606292|Procedure|Endoscopic ultrasound (standard of care)|
46109947|NCT02606292|Procedure|Endoscopic surgery (standard of care)|
46023556|NCT02825095|Procedure|Talc Pleurodesis|chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
46023557|NCT02825095|Procedure|Indwelling Pleural Catheter|Indwelling Pleural Catheter type PLEURAX will be inserted to the pleural space. the patients will be discharged with the pleural catheter.
46023558|NCT02825095|Procedure|chest ultrasound|All insertion of a chest drain will be guided by ultrasound
46109948|NCT00824408|Drug|pemetrexed|500 mg/m^2 i.v. on day 1 of 21 day cycle
46109949|NCT00824408|Drug|pemetrexed|500 mg/m^2 i.v. on day 1 of 21 day cycle
46109950|NCT00824408|Drug|BI 6727|BI 6727 i.v. on day 1 of a 21 day cycle
46109951|NCT02611700|Drug|Nimotuzumab|400mg,day1,weekly,until disease progression or toxicity
46109952|NCT02611700|Drug|Paclitaxel|175mg/m^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
46109953|NCT02611700|Drug|Cisplatin|60mg/m^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
46109954|NCT02611700|Drug|Placebo|400mg,day1,weekly,until disease progression or toxicity
46109955|NCT05429840|Drug|MT1980|single dose
46109956|NCT05429840|Drug|Placebo|single dose
46109957|NCT00708344|Drug|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Duration of treatment : 10 weeks
46109958|NCT00708344|Drug|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Treatment duration : 10 weeks
46109959|NCT00866333|Drug|Entinostat|Entinostat tablets
46109960|NCT00834080|Drug|Medisorb naltrexone 380 mg|Intramuscular (IM) injection administered once every 4 weeks for up to 2 years
46109961|NCT00823472|Drug|Mild stimulation|Fixed daily dose of 150 IU rFSH start cycle day 5 or day 2 depending on the Arm
46109962|NCT04131569|Diagnostic Test|ESBL-E fecal carriage screening according to routine care|ESBL-E fecal carriage screening according to routine care
46109963|NCT04118699|Drug|Rifaximin oral tablet|Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered investigational product (rifaximin) for 4 weeks
46109964|NCT04118699|Drug|Placebo oral tablet|Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered placebo for 4 weeks
46109965|NCT00856193|Drug|Placebo|Matching placebo capsules were supplied for inhalation once daily with Concept 1 device.
46109966|NCT00856193|Drug|NVA237|NVA237 50 μg capsules were supplied for inhalation once daily with Concept 1 device.
46109967|NCT00698087|Biological|MPL-Adjuvanted recombinant hepatitis B vaccine|Intramuscular injection, 2 or 3 doses, 2 different formulations
46109968|NCT00698087|Biological|Engerix™-B|Intramuscular injection, 2 or 3 doses
46109969|NCT04130087|Drug|Selegiline Hydrochloride 10 MG|Single 10mg tablet of Selegiline Hydrochloride
46023559|NCT02825095|Drug|Local anesthesia|Inserting a chest drain will be after local anesthesia with 10-20 mL of Lidocaine hydrochloride 20MG/ML - Esracain injection 2%
46023560|NCT02825095|Procedure|Chest Tube|chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
46109970|NCT04130087|Drug|Placebo|Single Placebo Tablet, identical appearance to experimental tablet.
46109971|NCT00652366|Drug|Erlotinib, escalating dose|100mg, PO, once daily, escalating to a maximum of 250mg, PO, once daily
46109972|NCT00652366|Drug|Erlotinib, standard dose|100mg, PO, once daily
46109973|NCT00652366|Drug|Gemcitabine|1000 mg/m2, IV, on days 1,8 and 15 of each 4 week cycle
46109974|NCT00841568|Drug|OPC-41061|orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years.
46109975|NCT00855959|Drug|Budesonide|Inhalation powder, inhalation, twice daily, 4 weeks followed by Suspension for nebulisation, inhalation, once or twice daily, 6 weeks
46109976|NCT00855959|Drug|Pulmicort Turbuhaler|Pulmicort Turbuhaler 200 µg, Dry powder inhaler, budesonide 200 µg/dose, 112 doses/Turbuhaler
45681556|NCT03904030|Other|Rehabilitation with or without Anti-Gravity Treadmill|The study will include patients with grade III-IV primary knee osteoarthritis. The investigators will take 27 patients to the both groups. The investigators will look after more specifically the anti-gravity treadmill rehabilitation and traditional rehabilitation after arthroplasty. Follow-up is one year. Functional tests will be made and questionnaires will be given to the patients before operation and after operation. After 6 to 8 weeks, 4 months and 12 months of operation questionnaires will be fil up again. After six month the investigators will send a questionnaire and there will be asked possible rehabilitation sessions, use of drugs and possible complications after knee arthroplasty.
46109977|NCT00704600|Drug|nelfinavir|"Phase I:~take nelfinavir tablets (minimum 6, maximum 10) starting 7 days before start of chemoradiotherapy, for 45 days~day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample~day 0: PET-CT~Phase II:~take nelfinavir tablets (MTD from phase 1) starting 7 days before start of chemoradiotherapy, for 45 days~day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample~day 7 biopsy~day 7, 21 and week 15 :PET-CT + perfusion CT"
46109978|NCT00699881|Drug|cetuximab|cetuximab 400mg/m2 as initial dose, subsequently at 250mg/m2 weekly dose. CPT-11 180 mg/m2 CF 200 mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
46109979|NCT00708578|Drug|Glimepiride|Once a day before breakfast
46109980|NCT00708578|Drug|Metformin|After breakfast and supper
46109981|NCT00708578|Drug|Insulin Glargine|Injection in the morning
46109982|NCT04130009|Procedure|Tourniquet use|Use of Tourniquet in The TKA
46109983|NCT00806650|Genetic|gene expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
46109984|NCT00806650|Genetic|protein expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
46109985|NCT00806650|Diagnostic Test|diagnostic laboratory biomarker analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
46109986|NCT00806650|Other|immunoenzyme technique|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
46109987|NCT00806650|Other|immunohistochemistry staining method|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
45681557|NCT03902938|Biological|Biodesign Otologic graft|Patient's mastoid cavity will be covered with porcine small intestine submucosa, Biodesign.
45681558|NCT03902938|Other|Autograft temporalis fascia|Patient's mastoid cavity will be covered with covered with autograft.
45681559|NCT05583136|Device|Parietal tACS combined with visuo-attentional training|Parietal tACS combined with visuo-attentional training
46023561|NCT04241263|Device|Wireless vital sign monitoring - comparative|Participants who currently have vital sign monitoring will, in addition, have the wireless system attached. We will then collect up to 24 hours of vital sign data from both systems, which will allow us to make direct comparisons between them.
46023562|NCT04241263|Device|Wireless vital sign monitoring - usability|Babies will be recruited who do not currently require vital sign monitoring. The wireless system will be attached to these babies by nurses who have been trained in its use. A parent will then be asked to perform Kangaroo Care for as long as they feel comfortable. After the baby is placed back in its cot, and the sensors have been removed, we will conduct (separate) interviews with the nurse and the parent on the neonatal intensive care unit (NICU).
46109988|NCT00841100|Drug|Kuvan|20mg/kg by mouth once daily
46109989|NCT00841100|Other|Diet|Phenylalanine-restricted diet (4-10 mg/kg/day phenylalanine) using the prescribed phenylalanine-free medical formula and low protein foods tested with the patients for taste and acceptance to lower blood phenylalanine levels below 600 umol/l.
45681560|NCT05583136|Device|Sham (placebo) tACS combined with visuo-attentional training|Sham (placebo) tACS combined with visuo-attentional training
46109990|NCT02614157|Procedure|LLND|advanced rectal cancer patients whose lymph nodes are suspiciously enlarged after neoadjuvant chemoradiation will undergo lateral lymph node dissection (LLND) and total mesorectal excision (TME)
46109991|NCT02614157|Device|labeled line|
46109992|NCT02552992|Behavioral|Yoga|
46109993|NCT02552992|Behavioral|Self-Directed Mind-Body Program|
46109994|NCT00704678|Drug|SBR759|1g tid
46109995|NCT00704678|Drug|Sevelamer HCl|1.6 g tid
46109996|NCT00704678|Drug|Sevelamer HCl|1.5 g tid
46109997|NCT00704678|Drug|Sevelamer HCl|0.8 g tid
46109998|NCT00804076|Biological|NP2|Intradermal injection of NP2 at doses ranging from 10e7 to 10e9 pfu at the site of pain.
46023563|NCT02823535|Behavioral|Iwin: Individual Well-Being Navigator|Immediately following the baseline assessment, the Intervention Group will receive a secure link to download the IWin app. The app provides three types of integrated interventions: 1) stage-matched feedback on the participant's risk behaviors as determined via the assessments; 2) up to two in app messages a day determined by a series of algorithms that control the timing, content, and cadence of the messages; and 3) up to two prompts a week to complete stage-matched activities that foster behavior change (e.g., quizzes, calculators, guided visualizations, info-graphics, testimonials, and more).
46109999|NCT00810160|Dietary Supplement|ProlactPlus|Group 1 infants will be fed a concentration of Permeate mixed with formula. The ProlactPlus will be increased each week as follows: week 1 95:5 (formula:ProlactPlus), week 2 90:10, week 3 85:15, week 4 80:20, and week 5 75:25. Caloric content is roughly as follows: week 1 21 cal/oz, week 2 22 cal/oz, week 3 23 cal/oz, week 4 24 cal/oz, and week 5 25 cal/oz.
46023564|NCT02823379|Behavioral|Physical Activity|A Smartphone delivered physical activity program
46110000|NCT00810160|Dietary Supplement|GOS galacto-oligosaccharides|Group 2 infants will have their formula supplemented with galacto-oligosaccharides (GOS) for each feeding as follows: week 1 0.25 g/dL, week 2 0.5 g/dL, week 3 1.0 g/dL, week 4 1.5 g/dL, and week 5 2.0 g/dL.
46110001|NCT00810160|Dietary Supplement|Bifidobacterium infantis|Group 3 infants will have their formula supplemented with B. infantis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
46110002|NCT00810160|Dietary Supplement|Bifidobacterium animalis|Group 4 infants will have their formula supplemented with B. animalis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
46110003|NCT00708656|Drug|mesalazine (Asacol®)|800 mg tablets
46110004|NCT00806728|Drug|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of normal saline on Days 16, 23, 30, and 37.
46110005|NCT00806728|Drug|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of MEDI-507 on Days 16, 23, 30, and 37.
46110006|NCT04118543|Other|Intervention Group|Each participant assigned to this intervention arm will start with a progressive cardiovascular warm-up for 10mins. The main exercise session will consist of resistance and cardiovascular based exercises targeting the whole body, which will last for 35-40mins. A cool-down period will follow lasting 5-10mins.
46110007|NCT04118543|Other|Sham-Exercise Group|Each participant assigned to this intervention arm will start with a warm-up for 10mins, which will be controlled in order to reduce any cardiovascular training effects. The sham-exercise sessions will consist of stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group. This will last for 35-40mins, followed by a 5-10min cool-down.
46023565|NCT02823379|Behavioral|Wellness|A Smartphone delivered wellness intervention focused on topics other than physical activity (e.g., skin care, oral health, and breast exams).
46023566|NCT02825017|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2mg/cm*2 test application.(Formulation-SR15-79_Y73-161)
46110008|NCT00913328|Drug|Montelukast (Singulair)|10 mg tablet once daily
46110009|NCT00913328|Drug|Placebo|Oral placebo once daily
46110010|NCT00651820|Drug|Collagenase Santyl|"Dermatome-induced skin wounds treated with drug active.~Each subject serves as his own control receiving both treatments in parallel."
46110011|NCT00651820|Drug|Collagenase Santyl Vehicle|Dermatome-induced skin wounds treated with Vehicle alone. Each subject serves as his own control receiving both treatments in parallel.
45681561|NCT05583136|Device|Sham (placebo) tACS combined with phonics training|Sham (placebo) tACS combined with phonics training
45681562|NCT01710501|Drug|Grazoprevir|Grazoprevir tablet, orally, once per day at assigned dose
46023567|NCT02824939|Other|Transversus Abdominis Plane (TAP) Block|0.5 ml/kg of 0.25 % Bupivacaine deposited in the transversus abdominis plane under ultrasound guidance postoperatively
46023568|NCT02824939|Other|Quadratus Lumborum (QL) Block|0.5 ml/kg of 0.25 % Bupivacaine deposited in the anterolateral aspect of the quadratus lumborum muscle under ultrasound guidance postoperatively
46023569|NCT04195009|Procedure|major surgery under opioid free anesthesia without regional anesthesia|measuring nociception in every patient but blinded for attending anesthesiologist
46110012|NCT02612168|Device|Melanoma Image Analysis Algorithm (MIAA)|The images will be analysed by MIAA (Melanoma Image Analysis Algorithm). The MIAA result for PLs that are biopsied will be compared to the diagnosis made from the biopsy. The MIAA result for PLs not biopsied will be compared to clinician diagnosis.
45469340|NCT03766633|Diagnostic Test|Liver volumetry of the graft on CT|Preoperative liver volumetry using the CT images of the potential living liver donors.
45681563|NCT01710501|Biological|pegylated interferon alfa-2b|1.5 mcg/kg/week, administered as a weekly subcutaneous (SC) injection
46110013|NCT04017208|Drug|ASP2713|Administered intravenously
46110014|NCT04017208|Drug|placebo|Administered intravenously
46110015|NCT00804232|Behavioral|childhood diabetes|the intervention compares three different regimes for children newly diagnosed with type 1 diabetes: (1) traditional hospital based care, (2) intensive psychological support to the family, and (3) home based family psychosocial support. A further aim is to identify families were the child runs the risk of decreased metabolic control and to give those families increased support.
46110016|NCT00866177|Other|Laboratory Biomarker Analysis|Correlative studies
46110017|NCT00866177|Drug|Selumetinib|Given orally
46110018|NCT00804310|Drug|ixabepilone|This intravenous treatment will be performed on an outpatient basis. Ixabepilone (15 - 20mg/m2) will be given weekly for 3 weeks, then one week off, every 28 days (4 weeks). The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
46110019|NCT00804310|Drug|lapatinib ditosylate|Lapatinib (1000-1500 mg) will be administered orally on a daily basis. The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
46110020|NCT04131101|Behavioral|Community Organizing|The intervention will be community organizing and will consist of engaging tenants, health providers, legal service staff, social service agencies and advocacy organizations (e.g. ACORN). Each building team will identify initial priorities and then invite all building members to discuss and to finalize, as well as a plan for change. Building teams will engage in advocacy to TCHC and its representatives, and other city departments as appropriate. Engaging in advocacy will consist of a wide range of activities but essentially means presenting evidence (e.g. personal experiences, data) to policymakers and decision makers to affect change.
46023570|NCT05660083|Drug|L-NMMA|Patients with HER2 negative metastatic or locally advanced MpBC, will receive a combination of an iNOS inhibitor, nab-paclitaxel and alpelisib . As prophylaxis against deep venous thrombosis and hypertension, patients will receive aspirin (81 mg po daily) and amlodipine (10 mg po Days 0-5 each cycle). Metformin will be initiated at 500 mg once daily starting one week prior to treatment to reduce risk of severe hyperglycemia. Based on tolerability and serial blood sugar assessments, metformin dose will be increased to 500 mg twice daily, followed by 500 mg with breakfast and 1000 mg with dinner, followed by further increase to 1000 mg twice daily if needed. Insulin sensitizers and/or SGLT2i will be used as second anti-diabetic agents, if necessary. For prophylaxis of alpelisib rash, patients will be treated with an anti-histamine (cetirizine 10 mg daily) along with alpelisib.
46023571|NCT02824549|Device|FreeStyle Libre Flash Glucose Monitoring|
46110021|NCT00833924|Device|Zenith(R) Low Profile AAA Endovascular Graft|The Zenith(R) Low Profile AAA Endovascular Graft and ancillary components are indicated for the endovascular treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair.
46110022|NCT04131257|Behavioral|Nurse-led Continuum of Care|This will be a nurse-led community level prevention program for individuals with diabetes and pre-diabetes, where participants in intervention group will receive nurse-led continuum of care while control group will receive usual diabetic care.
46110023|NCT02614235|Device|Pocket-ECG III system|Continuous cardiac telemetry until diagnosis or a maximum of two months
46110024|NCT00840086|Drug|turoctocog alfa|Subjects will receive bleeding preventive treatment (home treatment with self-injection i.v.) with turoctocog alfa at a dose of 20-40 IU/kg body weight every second day or 20-50 IU/kg body weight three times per week at the investigator's discretion.
46110025|NCT04118777|Drug|Ropivacaine|0.2 % Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr
46110026|NCT04129385|Procedure|20 degree Trendelenburg position|The patients in the intervention group will be placed in trendelenburg position postoperatively.
46110027|NCT00708812|Drug|Endostar(Recombinant Human Endostatin Injection)|Endostar 7.5mg/m2 on d8-d21 in each 21-day cycle
46110028|NCT00708812|Drug|paclitaxel-carboplatin|paclitaxel, 175mg/m2, iv, d1, q3w; carboplatin, AUC 5, iv, d1, q3w
46110029|NCT04127747|Drug|Standard dose of rituximab|Patients in this group will accept RTX 500mg treatment on the first day and on the 6th, 12th,18th and 24th month after that.
45681564|NCT01710501|Drug|Ribavirin|Ribavirin capsule, orally, twice daily, at a dose of 800 to 1400 mg based on participant weight
45681565|NCT01710501|Drug|Placebo|Placebo to match grazoprevir tablets to maintain dose blinding
45681566|NCT05583058|Other|Hormone Overdose and Misuse|This is an observational study. Hormone Overdose and Misuse is an exposure.
45681567|NCT04144270|Other|Evaluation of muscle mass and muscle function|Included patients have their muscle mass and muscle function evaluated before start on and after completion of oncological treatment.
45681568|NCT04144114|Dietary Supplement|ProHydrolase®|Subjects received 250mg of ProHydrolase® with 25g whey protein mixed together in a drink
45681569|NCT04144114|Dietary Supplement|Whey protein|Subjects received 25g of whey protein powder mixed to together in a drink
45681570|NCT04144114|Dietary Supplement|Placebo|Placebo
45681571|NCT01700829|Drug|Ketamine|Single dose of 0.5 mg/kg of ketamine given intravenously (in the vein) over 40 minutes
45681572|NCT01700829|Drug|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
45681573|NCT04143880|Drug|Progesterone|intramuscular injection intranasal administration
45681574|NCT04143880|Other|saline|intramuscular injection intranasal administration
45681575|NCT04144192|Drug|Lidocaine patch 1.8%|
46110030|NCT04127747|Drug|Individualized dose of rituximab|Patients in this group will accept RTX 500mg treatment on the first day of admission. Patients will be followed-up every 3 months, and will receive one RTX 500mg treatment, if CD19 B cell count ≥ 1%, or dsDNA titer increased (dsDNA antibody positive, and increased more than 100% compared with the previous time), or complement C3 level decreased (lower than normal value, and decreased more than 50% compared with the previous time).
46110031|NCT00822926|Drug|Botulinum Toxin Type A|Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue
46110032|NCT00822926|Drug|Saline|Subcutaneous injection of saline into scar tissue
45681576|NCT04144192|Drug|Lidocaine 5% patch|
45681577|NCT04144192|Drug|Lidocaine 2% Injectable Solution|
45681578|NCT01710345|Drug|Sufentanil NanoTab 20 mcg|
45681579|NCT01710345|Drug|Sufentanil NanoTab 30 mcg|
46110033|NCT00698555|Biological|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
46110034|NCT00698555|Biological|Engerix™-B|3-dose intramuscular injection
46110035|NCT00822770|Drug|Plerixafor|"Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.~Phase II: Maximum Tolerated Dose (MTD) as determined in Phase I"
46110036|NCT00822770|Drug|Filgrastim|Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.
46110037|NCT00822770|Drug|Fludarabine|Dose of 40 mg/m^2 beginning on Day -6 for four consecutive days.
46110038|NCT00822770|Drug|Busulfan|Dose of 130 mg/m^2 for four consecutive days, immediately after completion of Fludarabine.
46110039|NCT00822770|Procedure|Allogeneic blood stem cell transplant|Stem Cell Infusion (Bone marrow or PBPC)
46110040|NCT00822770|Drug|ATG (Thymoglobulin)|Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.
46110041|NCT02611388|Device|TEAS (transcutaneous electrical acupoint stimulation)|2/10HZ Electric stimulation was given through electrode attached to specific acupoints
46023572|NCT02824705|Procedure|Congenital Heart Disease Surgery|Stool and blood sample collected prior to surgical intervention for congenital heart disease; stool and blood samples then collected in days following cardiac intervention.
46110042|NCT02611388|Device|TEAS (transcutaneous electrical acupoint stimulation)|10/50HZ Electric stimulation was given through electrode attached to specific acupoints
46110043|NCT02611388|Device|fake stimulation|Patients were only attached electrodes without electric current
46110044|NCT02842086|Drug|F/TAF|200/25 mg tablet administered orally once daily
46110045|NCT02842086|Drug|F/TDF|200/300 mg tablet administered orally once daily
46110046|NCT02842086|Drug|F/TAF Placebo|Tablet administered orally once daily
46110047|NCT02842086|Drug|F/TDF Placebo|Tablet administered orally once daily
46023573|NCT02822443|Behavioral|Psychological therapy (PT) as TAU with integrated emotion focused components (TAU - EFT)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
46023574|NCT02822443|Behavioral|Psychological therapy (PT) as TAU with focus on self-regulation (TAU - SR)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions
46023575|NCT02824393|Biological|Autologous mesenchymal stem cell|Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
46023576|NCT02823769|Device|SI-R21204 resin composite|Primary caries of posterior teeth will be restored using SI-R21204 resin composite. Procedures will be done under local anesthesia if necessary. The preperation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
46023577|NCT02823769|Device|Nanohybrid resin composite|One of the cavities will be restored with a nanohybrid resin composite (Clearfil Majesty) as a control restoration wth ordinary restorative techniques.
46110048|NCT00822692|Drug|Trim/ Sulfa DS|bactrim DS (800/160) two tablets PO BID x 7 days
46110049|NCT00822692|Drug|placebo|matched placebo 2 pills PO BID x 7 days
46110050|NCT03284775|Device|Intraoperative ultrasound|Patients will undergo transsphenoidal surgery in the usual manner except that an intraoperative ultrasound device will be available for use to better visualise the tumour and surrounding neurovascular structures.
46110051|NCT02612012|Radiation|axillary radiotherapy|Whole breast irradiation and axillary level I-II areas radiotherapy. The prescription dose is 50Gy in 25 fractions in 5 weeks. Tumor bed boost is necessary with 10Gy in 5 fractions in one week.
46110052|NCT03260127|Behavioral|Computerized executive function training plus CPT (CEFT-CPT)|Participants randomized to the CEFT-CPT arm will receive 6 weeks of computerized executive function training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
46110053|NCT03260127|Behavioral|Word game training plus CPT (WT-CPT)|Participants randomized to the WT-CPT arm will receive 6 weeks of computerized word game training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
46110054|NCT05535062|Device|repetitive Transcranial Magnetic Stimulation|the administration of a series of magnetic stimuli to the brain for the purpose of altering brain function
46110055|NCT02607111|Drug|Dalteparin|
46023578|NCT02824003|Drug|ISIS-GCGRRx|once weekly dosing for 13 weeks
46110056|NCT00703196|Dietary Supplement|folic acid|Given orally once daily
46110057|NCT00703196|Other|placebo|Given orally once daily
46110058|NCT00913250|Drug|Serum containing Avonex|60mcg IM dose of serum containing Avonex on Day 1, followed by 60mcg IM dose of serum free Avonex on Day 15
46110059|NCT00913250|Drug|Serum Free Avonex|60mcg IM dose of serum free Avonex on Day 1, followed by 60mcg IM dose of serum containing Avonex on Day 15.
45681580|NCT01710345|Drug|Placebo NanoTab|
45681581|NCT04143568|Other|Observation|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
45681582|NCT03022006|Drug|elbasvir, grazoprevir|
45681583|NCT04148092|Drug|ripretinib|orally administered solid dosage form
46023579|NCT02824003|Drug|Placebo|once weekly dosing for 13 weeks
46023580|NCT04240951|Other|Sweat patch|Flexible, epidermal, wearable skin patch to collect and analyze sweat
46023581|NCT04241107|Procedure|Laparoscopic repair of Uterine niche|Repair of uterine niche through Laparoscopic approach.
46110060|NCT02608554|Behavioral|Taichi|The program of Taichi training consisted of 60 minutes exercise sessions, 3 days per week for 12 weeks, based on their original level of physical activity. Each session comprised 40 minutes of Taichi training plus a 10-minute warm-up and cool-down. The Taichi training was instructed by the same experienced Taichi instructors who were qualified in the teaching of Taichi. The 24 forms of simplified Taichi recommended as the popular health sport by the General Administration of Sport of China were applied.
46110061|NCT02608554|Behavioral|Self-monitored exercise|Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise for 60 mins. 3 days per week for 12 weeks.
46110062|NCT02612246|Drug|GLPG1972 single ascending doses|single dose, oral solution
45681584|NCT04143334|Diagnostic Test|Conventional survey|
45681585|NCT05582824|Other|Blood and urine test|Daily blood and urine samples
46110063|NCT02612246|Drug|Placebo single dose|single dose, oral solution, matching placebo
46110064|NCT02612246|Drug|GLPG1972 multiple ascending doses|multiple doses, daily for 14 days, oral solution
46110065|NCT02612246|Drug|Placebo multiple doses|multiple doses, daily for 14 days, oral solution
46110066|NCT00914277|Drug|SAR407899|Oral administration
46110067|NCT00914277|Drug|Placebo|Oral administration
46110068|NCT00914277|Drug|Sildenafil|Oral administration
46110069|NCT00708968|Behavioral|FOCUS Program|Supportive, educative sessions with patients and spouses.
46110070|NCT00704756|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at 1.5 μg/kg body weight/week subcutaneously for up to 24 wks (Genotype [G] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
46110071|NCT00704756|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered based on body weight 800-1200 mg/day (<65 kg : 800 mg, 65 - 85 kg : 1000 mg, >85 kg : 1200 mg) orally for up to 24 wks (Genotype [G] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
46110072|NCT00806442|Drug|Borage Seed Oil and Echium Seed Oil|2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
46110073|NCT00806442|Dietary Supplement|Corn Oil|9 g/day of corn oil
46023582|NCT04241107|Procedure|Transvaginal repair of Uterine niche|Repair of uterine niche through Transvaginal approach.
46023583|NCT02822365|Procedure|Computed Tomography|Undergo PET/CT scan as clinically indicated (Note: CT is for attenuation correction and not for diagnostic purposes).
46023584|NCT02822365|Device|Imaging Phantoms|Undergo limited field of view PET scan with the Pocket Phantom placed nearby to assist in scanner calibration. No additional PET tracer will be used.
46110074|NCT02606955|Device|BIA DW|All patients undergo a Clinical DW assessment. Then, they undergo a HD session in which BIA DW (injection of 800 microAmpere at 50 kilohertz alternating sinusoidal current with a standard tetrapolar technique) is determined. BIA DW is determined by performing the REsistance Stabilization Test (REST).
46110075|NCT00821678|Other|Telemedicine Outreach for PTSD|The intervention involves an off-site PTSD care team (tele-psychiatrist, tele-psychologist, tele-pharmacist, and tele-nurse care manager) and uses telemedicine technologies (telephone, interactive video and electronically shared medical records). A dedicated nurse telephone care manager educates/activates patients, identifies preferences, overcomes treatment barriers, monitors symptoms, side-effects and adherence, identifies psychiatric comorbidities, and encourages patient self-management. Tele-pharmacists provide medication management by phone. Tele-psychologists provide Cognitive Processing Therapy via interactive video. Tele-psychiatrists supervise the off-site care team as well as conduct consultations and provide medication management via interactive video.
46110076|NCT04112121|Behavioral|Meeting with a Chaplain coupled with Biblical Readings|
46110077|NCT02608242|Drug|YH22189|
46110078|NCT02608242|Drug|Twynsta 80/10mg|
46110079|NCT02608242|Drug|Crestor 20mg|
45681586|NCT02335216|Device|Implantation with the commercially available Axium neurostimulator|
46023585|NCT02822365|Procedure|Positron Emission Tomography|Undergo PET/CT scan as clinically indicated.
46110080|NCT04111653|Other|Mud therapy|Application of sludge poultice
46110081|NCT02607696|Drug|Zolpidem Hemitartarate|
46110082|NCT00915057|Drug|NRL972|Single dose of NRL972 administered at baseline, at 3-monthly intervals during treatment for up to 12 months (or the end of treatment) and at 3 and 6 months after the end of treatment.
46110083|NCT03556722|Device|Repetitive Transcranial Magnetic Stimulation.|High frequency rTMS on left dorsolateral prefrontal cortex.
46110084|NCT03556722|Device|Sham rTMS|Sham rTMS without active magnetic coil on left dorsolateral prefrontal cortex.
46110085|NCT00839852|Drug|Cariprazine|Cariprazine was supplied in capsules.
46110086|NCT02604849|Drug|Neomycin|
46110087|NCT02604849|Drug|Streptomycin|
46110088|NCT02604849|Drug|Gentamicins|
46110089|NCT05632107|Device|TOF-Watch®；DELSYS® Wireless surface EMG|TOF-Watch® is the most widely accepted AMG-based neuromuscular monitor; and DELSYS® Wireless surface EMG is a new technology that allows for the simultaneous acquisition of EMG and AMG signals in a wireless manner.
46110090|NCT00704834|Other|Blood Draw|35 cc of peripheral blood will be obtained by venipuncture from each subject.
46110091|NCT00709046|Drug|High dose pantoprazole infusion|Pantoprazole 80mg iv bolus, 8mg/hr infusion for 72hrs
46110092|NCT00709046|Drug|Standard dose pantoprazole infusion|Pantoprazole 40mg iv bolus qd x 3 days
46110093|NCT00833690|Drug|Placebo|500 mg of inactive substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing adjusted algorithmically to parallel that in the inosine arms
46110094|NCT00833690|Drug|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL
46110095|NCT00833690|Drug|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL
46110096|NCT00820898|Drug|Gemcitabine Hydrochloride|Given IV
46110097|NCT05370092|Other|Percutaneous needle electrolysis|Electrolysis is the process by which water (H2O) and sodium chloride (NaCl) molecules, which are present in the biological tissues and body compartments of our organism, are organically broken down into their constituent chemical elements, regrouping to create entirely new substances such as sodium hydroxide (NaOH), hydrogen gas (H2) and chlorine gas (Cl2). This process occurs thanks to the passage of a flow of direct electric current, also known as galvanic current, which is a totally athermal process. The passage of this current allows a local inflammatory response to occur (increase in lymphocytes and macrophages) as well as an increase in vasodilatation, inducing phagocytosis and biological stimulation of tendon repair.
46023586|NCT02823301|Behavioral|VAMOS Program|Active life improving health: all participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for five months. The VAMOS Program is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by 12 meetings (six weekly meetings and six fortnightly meetings), in group, lasting about 90 min. In each In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories.
46023587|NCT04806607|Procedure|19G FNB|Biopsy specimen adequacy using the 19G FNB
46110098|NCT05370092|Other|Therapeutic exercise|The first exercise they will perform will be the Short-Foot Exercise holding the position 5 seconds isometrically. The second exercise will be plantar flexion of the ankle with adduction of the foot and inversion with elastic band in its concentric and eccentric phase
46110099|NCT05370092|Other|Manual therapy|The manual therapy (TM) treatment for tendinopathies is mainly focused on soft tissue mobilization and deep transverse friction massage (Cyriax).
46110100|NCT00865709|Drug|Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Subjects will receive oral Sorafenib 400 mg twice daily (BID) continuously and intravenous (IV) mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease (PD)
46110101|NCT00865709|Drug|Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Subjects will receive oral matching placebo 2 tablets BID continuously and IV mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease
46110102|NCT00839306|Drug|Rabeprazole ER|50 mg capsule, taken orally, once daily for 26 weeks.
46110103|NCT00839306|Drug|Ranitidine|150 mg capsule, taken orally, twice daily for 26 weeks.
46110104|NCT02612090|Dietary Supplement|Active Treatment Beverage|Strawberry
46023588|NCT04806607|Procedure|22G FNB|Biopsy specimen adequacy using the 22G FNB.
46110105|NCT02612090|Dietary Supplement|Placebo Treatment Beverage|Placebo
46110106|NCT00698243|Drug|OSI-027|Administered orally
46110107|NCT04131335|Drug|AEONTM Repair|Lubricating eye drops
46110108|NCT04131335|Other|Routine post-operative eye drops used.|Dexamethasone 0.1% eye drops QDS for 4 weeks Chloramphenicol 0.5% eye drops QDS for 1 week
46110109|NCT04131023|Behavioral|Breezing Metabolic Rate Tracking|Metabolism (indirect calorimetry) data were collected every two weeks over 13 weeks of gestation across the second trimester (weeks 13-27) and the values obtained were provided to the participant without health education.
46110110|NCT00839072|Drug|Trazodone HCl|100 mg immediate-release tablet, dosing q8h
46110111|NCT00839072|Drug|Trazodone HCl|300 mg extended-release caplet, single dose
46110112|NCT02613845|Other|no intervention|
46110113|NCT04118465|Procedure|external cephalic version|external cephalic version
46110114|NCT00704990|Dietary Supplement|Zinc, Magnesium, Vitamin B6, Vitamin C (Compound Natural Health Product for ADHD)|Weight based dosing of a chewable natural health product containing 15-35 mg zinc citrate, 150-350 mg magnesium lactate, 30-70 mg pyridoxine hydrochloride and 150-350 mg calcium ascorbate. Participants will take weight based dose two times during the day with meals for a 10 week period
46110115|NCT00855803|Radiation|radiation|Given in 1 or 5 fractions
46110116|NCT02613923|Behavioral|GO! To Sleep|Controlled sleep intervention. Provide online education and reminder emails on improving sleep behavior
46110117|NCT02613923|Behavioral|Sleep information|Participants will receive weekly emails on the health benefits of sleep for 6 weeks
46110118|NCT02613923|Procedure|Blood Draw|blood sample measured for stress and sleep markers
46110119|NCT02613923|Other|Pittsburgh Sleep Quality Index (PSQI)|Assessment of sleep quality. This is a continuous measure from 0 (best) to 21 (worst). Sleep duration will be obtained directly from responses.
46110120|NCT02613923|Other|Insomnia Severity Index (ISI)|
46110121|NCT02613923|Other|SF-12 quality of life survey|
46110122|NCT02614001|Device|Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA|Patient will be trained daily, total 30 minutes or 15 minutes twice per day, at least 5 times a week, for 10 weeks
46110123|NCT02614001|Other|post-stroke rehabilitation program|
46110124|NCT03553836|Biological|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
46110125|NCT03553836|Other|Placebo|Administered as an IV infusion every 3 weeks (Q3W)
46110126|NCT02607774|Drug|Midazolam|midazolam administered to all patients Days -7, 1 and 35.
45681587|NCT04148326|Other|No Intervention|There is no intervention for this study.
45681588|NCT04147936|Dietary Supplement|AXA1665|Dietary supplement: AXA1665
45681589|NCT04147936|Dietary Supplement|Placebo|Placebo
46110127|NCT02607774|Drug|AIN457|secukinumab administered at Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24
46110128|NCT00838916|Biological|albiglutide|albiglutide weekly injection
46023589|NCT04800055|Other|Attractive Targeted Sugar Bait|ATSBs will be installed on all structures of consenting households in intervention areas for six months according to instructions from the manufacturer. Monitoring assistants will be responsible for providing individual level household orientation for the ATSB and seeking informed consent. Prior to ATSB deployment, community sensitization activities will be conducted to prepare communities for the intervention and research activities. Where appropriate, local media may be used to disseminate messages to sensitize the community to the intervention and the research.
46110129|NCT00838916|Drug|insulin glargine|insulin glargine
46110130|NCT00703274|Behavioral|PROTECT DC|PROTECT DC facilitates the initiation of secondary prevention behaviors in an attempt to prevent the recurrence of stroke among participants. The program trains a lay person, called a stroke navigator, to provide participants with education on secondary prevention behavior and to navigate the health and human service system, which will assist participants in obtaining the necessary services and programs to engage in secondary prevention behaviors.
46110131|NCT00838682|Drug|omeprazole sodium IV|Intravenous Omeprazole (brand name: Losec® injection 40 mg) 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
46110132|NCT00838682|Drug|Rabeprazole|Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
46110133|NCT02612324|Behavioral|Pono Choices|Medically accurate teen pregnancy and STI prevention education delivered through a place-based framework integrating Hawaiian cultural activities that draw upon both historical and local references.
46110134|NCT02612324|Behavioral|Business as Usual|Teen pregnancy and STI prevention education left to the discretion of the school.
46110135|NCT00913484|Drug|Disulfiram|Disulfiram 250 mg per day
46023590|NCT02822131|Dietary Supplement|sodium phosphate|
46110136|NCT00913484|Drug|Placebo|Placebo daily
46110137|NCT00709280|Drug|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
46110138|NCT00709280|Drug|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
46110139|NCT00820040|Device|acellular porcine dermal collagen mesh|porcine mesh for hernia repair/ abdominal wall reconstruction
46110140|NCT00709358|Other|Detection of microbial DNA in blood by SeptiFast®|"The LightCycler® SeptiFast Test, the innovative real-time PCR test from Roche Diagnostics, is designed to detect and identify the 25 most important bacterial and fungal species causing bloodstream infections within just a few hours. The LightCycler® SeptiFast Test detects the pathogenic bacteria and fungi directly from whole blood without the need for prior incubation or culture steps.~Rapid detection and identification of bacterial and fungal DNA, directly from a 1.5 ml whole blood sample, without prior incubation or culture steps in less than 6 hours."
45838431|NCT02869399|Dietary Supplement|dietary intervention in addition to standard recommendations|"The diet of the intervention group will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences (www.dietandcancerreport.org):~avoid or limit alcoholic drinks (2 drinks men, 1 drink women)~increase consumption of a variety of non-starchy vegetables, fruits (at least 400g per day) and dietary fibers (at least 25g per day)~eat mostly food of plant origin~eat lean meat, limit intake of red meat and avoid processed meat~increase consumption of anti-inflammatory foods, such as fish and whole grain cereals, f.e. brown rice and barley creams~avoid high glycaemic and high insulinemic foods, such as refined flours, white breads, and pastries"
45838432|NCT02855034|Other|Blood samples|Blood samples for dosage: copeptin and protein S100B
46023591|NCT02822131|Drug|sevelamer, sodium bicarbonate, sodium chloride|
46023592|NCT02820649|Other|Sleep deprivation|40 hours of continuous wakefullness
46110141|NCT00709358|Other|detection of microbial DNA in blood by blood culture|A blood culture is a test to find an infection in the blood. Most bacteria can be seen in the culture in 2 to 3 days, but some types can take 10 days or longer to show up. Fungus can take up to 30 days to show up in the culture.
46110142|NCT00705302|Behavioral|Group training with self-help group|Combined educational and exercise program for pulmonary rehabilitation, with (1) or without(2 a self-help group. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group. Patients will instead of five of the group training sessions, participate in a self-help group.
46110143|NCT00705302|Behavioral|Group training|Combined educational and exercise program for pulmonary rehabilitation. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group.
46110144|NCT05320952|Device|WellO2|The WellO2 breathing training device performs back-pressure steam breathing training during the inhalation and exhalation phases.
45838433|NCT02845505|Other|Intravascular Ultrasound, coronary computed tomography angiography|
46023593|NCT04240873|Biological|Catholic MASTER cell|Injection of CATHOLIC MASTER cells 1 x 10^8 cells/DMEM 5cc into knee of patents with osteoarthritis
46023594|NCT04240873|Other|Saline|Injection of saline 5cc into knee of patents with osteoarthritis
46023595|NCT02820805|Other|Meal Skipping|No meal
46023596|NCT02820805|Other|French fries|50g of available carbohydrates meal
46023597|NCT02820805|Other|Mashed potatoes|50g of available carbohydrates meal
46023598|NCT02820805|Other|Hash browns|50g of available carbohydrates meal
46110145|NCT05318612|Procedure|Laser Interstitial Thermal Therapy (LITT)|LITT is a minimally invasive neurosurgical procedure in which a laser catheter is placed into the tumor and warms the tumor to such an extent that tumor tissue is destroyed. LITT is performed under MR-guidance.
46110146|NCT05318612|Procedure|Biopsy|A sample of tissue from the tumor is obtained to confirm the diagnosis.
46110147|NCT00803712|Drug|Cinacalcet|Cinacalcet is a calcimimetic agent, which is synthesized as a hydrochloride salt.
46110148|NCT00803712|Drug|Vitamin D|Titration of active Vitamin D in accordance with treatment practice guidelines in order to treat Secondary Hyperparathyroidism.
46110149|NCT00591344|Behavioral|Progressive resistance training|Exercise twice a week for 2 years doing either progressive resistance training. The The PRE program consisted of 11 strengthening exercises: chest press, latissimus pull downs, reverse flys, double leg press, hip extension, shoulder press, biceps curl, rotary calf (ankle plantar flexion), triceps extension, seated quadriceps extension and back extension.
46110150|NCT00591344|Behavioral|Modified Fitness Counts|The modified Fitness Counts program was taken from Chapters 2 and 3 of the Parkinson's disease: Fitness Counts booklet and focused on non-progressive stretching, strengthening and balance exercises.
46110151|NCT05758610|Drug|ETH-155008|"ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form: 10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal."
46110152|NCT05757050|Dietary Supplement|"Re-Focus Verum Tablets"|The active intervention contains Scutellaria baicalensis (400 mg) and Crataegus (40 mg) and is in the form of a chewable tablet with a blood-orange flavour
46023599|NCT02820805|Other|Rice|50g of available carbohydrates meal
46110153|NCT05757050|Dietary Supplement|"Re-Focus Placebo Tablets"|The placebo will be a matched control.
46023600|NCT02820805|Other|Beans|50g of available carbohydrates meal
46110154|NCT00803634|Drug|Clevidipine|Clevidipine was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative IV antihypertensive agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Patients who received an alternative antihypertensive agent along with the study drug were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered approximately 1 hour prior to the termination of clevidipine with study drug down-titrated or terminated in order to maintain the desired blood pressure level.
46110155|NCT00803634|Drug|Standard of Care IV antihypertensive|SOC IV antihypertensive agent will be administered for a minimum of 30 min and, if medically warranted, may continue beyond 96 hours at the investigator's discretion. As with clevidipine, the SOC agent was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Higher dose titration rates were required to be attempted prior to making the decision to switch to or add on an alternative antihypertensive agent(s). Patients who received an alternative antihypertensive agent with SOC were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered per institutional practice.
46110156|NCT00838526|Drug|Rabeprazole ER|50 mg capsule, taken orally, once daily for 26 weeks.
46110157|NCT00838526|Drug|Ranitidine|150 mg capsule, taken orally, twice daily for 26 weeks.
46110158|NCT02611934|Procedure|Mild Therapeutic Hypothermia (MHT)|The induction with ice packs and infusion of 0.9% sodium chloride (NaCl) at the temperature of 4˚C. MHT will be maintained with a MTH-dedicated catheter introduced into the inferior vena cava through the femoral vein during PCI. MTH will be maintained for at least 12 hours at target temperature of 33˚C. The rewarming phase will be conducted in an actively controlled manner (0.3˚C per hour). The patient's core temperature will be independently measured in the urinary bladder as well as in the lower one third of the oesophagus using a dedicated catheter and tube. All patients treated with MTH will be mechanically ventilated with a concomitant continuous intravenous infusion of propofol and fentanyl for sedation and analgesia.
46110159|NCT00914472|Biological|heparin sodium - APP|Heparin 5000 IU / mL
46023601|NCT02821975|Other|Cognitive computer training|COGNIFIT is cognitive computer training. Its purpose is to improve cognitive function and is designed to accommodate each individual's cognitive strengths and weaknesses. The cognitive computer training last three months and must be done three times a week, in session lasting 10-20 minutes.
46023602|NCT04239625|Drug|ALK-001|Oral administration of a pill for up to 24 months
46110160|NCT00914472|Biological|Heparin sodium - Hipolabor|Heparin 5000 IU / mL
46110161|NCT02611466|Drug|ASP7962|Participants receive ASP7962 100 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
45681590|NCT03918382|Other|Electronic Patient-Reported Outcome|Weekly reporting of patient-reported outcomes on a tablet for closer contact between patient and clinic during radiotherapy.
46023603|NCT04239469|Drug|KL16-012|Standardized cannabis sativa extract of THC and CBD, with each drop containing 1 mg of THC and 0.45 mg of CBD
46023604|NCT04239469|Drug|Placebo|Placebo
46023605|NCT04240795|Dietary Supplement|Low lubricity (LL) hydrogels containing fibre-based beads|The preload is made from kappa-carrageenan and alginate beads of 450 μm size. It contains no additional macronutrient but has food-grade watermelon flavor, color, and non-nutritive sweetener.
46110162|NCT02611466|Drug|Naproxen|Participants receive naproxen 500 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
46110163|NCT02611466|Drug|Placebo|Participants receive matching placebo orally twice daily, in the morning and evening with or without food (approximately 12 hours).
46110164|NCT02688270|Drug|Vascana (0.9% nitroglycerin cream)|Study drug administered topically
46110165|NCT02688270|Drug|Vehicle Cream (placebo)|Vehicle administered topically
46023606|NCT02821897|Procedure|Target-controlled intravenous anaesthesia|
46023607|NCT02821897|Procedure|Total anaesthesia|
46023608|NCT04239547|Procedure|Alveolar Recruitment maneuver (ARM) +PEEP|Following anesthesia induction and intubation, alveolar recruitment maneuver followed by 5 mmHg PEEP
46023609|NCT04239547|Procedure|PEEP|Following anesthesia induction and intubation, only 5 mmHg PEEP
46023610|NCT02822209|Behavioral|EORTC QLQ-C30|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
46110166|NCT02610920|Procedure|Iron-tracer guided axillary ultrasound and biopsy|After ultrasound identifying sentinel lymph nodes, no more than two nodes will be core-needle biopsied and sent to pathology department for analysis of cancer involvement. The biopsied node(s) will be marked for later identification for the surgeons during the regularly scheduled intraoperative sentinel lymph node biopsy (standard of care).
46023611|NCT02822209|Behavioral|Satisfaction questionnaire - patient|The patient will fill in a satisfaction questionnaire three times : around the third, the sixth and the twelfth month after they started an anti-cancer therapy.
46023612|NCT02822209|Behavioral|Satisfaction questionnaire - general practitioner or home nurse|The general practitioner or the nurse in charge of the patient at home will fill in a satisfaction questionnaire six months after the patient started an anti-cancer therapy.
46110167|NCT02610920|Drug|Iron tracer|All participants will receive a 30mg injection of subcutaneous iron sucrose into the breast followed by an axillary ultrasound looking for lymph nodes with enhanced reflexivity.
46110168|NCT00913562|Drug|Rosuvastatin|one tablet rosuvastatin 10 mg per day for 12 weeks
46110169|NCT00913562|Drug|Placebo|one tablet a day for 12 weeks
46110170|NCT05687838|Other|Music|Music medicine
45469341|NCT03638154|Procedure|GF+GMSCs carried on β TCP|"surgical augmentation of GF+GMSCs carried on β TCP in intrabony periodontal defect and covered by collagen membrane(Bioresorb, Sybron, implant solutions GmbH Bremen, Germany) Cytoplast, RTM Collagen Cytoplast, Barrier Membranes, Osteogenics Biomedical, New Gersey, USA).~Ibuprofen"
46023613|NCT02822209|Behavioral|EORTC QLQ-LC13|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
46023614|NCT02690623|Other|Pediatric hospitalist program|In-house hospitalists available at all hours
46023615|NCT02690623|Other|General Pediatric Inpatient Services|Inpatient care by general pediatrics faculty
46023616|NCT02823067|Other|Blood sample|One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.
46023617|NCT02820493|Drug|vedolizumab|
46023618|NCT02820415|Other|chromosomal status of blastocysts from fresh and vitrified/warmed oocytes|
46110171|NCT05294978|Diagnostic Test|OCT|Macular optical coherence tomography (OCT)
46110172|NCT02661204|Device|Automated breast ultrasound examination (ABUS)|Automated breast ultrasound examination
46110173|NCT04010136|Other|Palliative care training|Intervention will consist on providing different types of palliative care training to identify the most accurate on improving GPs' identification of palliative care patients skills
45469342|NCT03638154|Procedure|β TCP bone substitute only|surgical augmentation by β TCP in intrabony periodontal defect(Bioresorb, Sybron, implant solutions GmbH Bremen, Germany) Ibuprofen
46023619|NCT02822053|Procedure|US-guided laser ablation for refractory neoplasms|
46023620|NCT02822989|Device|Vagus nerve stimulation|Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch.
46110174|NCT00818246|Device|Sham light|
46110175|NCT00818246|Device|LumiPhase-R™, OPUSMED Inc. Montreal, Canada|660 nm wavelength delivered in a sequential pulsing mode
46110176|NCT00705380|Behavioral|Cognitive behavioral therapy (CBT) with panic control treatment (PCT) for adolescents|CBT with PCT treatment will consist of 11 weekly sessions that are designed to be developmentally appropriate for a younger population. The primary aim of this treatment will be to directly influence three aspects of panic attacks and general anxiety: the cognitive/misinterpretational aspect, the hyperventilatory response, and the conditioned reactions to physical sensations. Throughout treatment, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks.
46110177|NCT00705380|Behavioral|Waitlist control|During the 12-week waitlist period, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks. Participants will also meet with a therapist every other week to discuss the nature of any panic attacks or address any concerns.
45469343|NCT03415672|Biological|HBVaxPro|Three doses of HBVaxPro-10μg at 0, 1, and 2 months. The HBVaxPro-10μg vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
46023621|NCT02822989|Device|Sham vagus nerve stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
46110178|NCT00818168|Biological|Infliximab|"Dosage and infusion intervals were employed in~accordance to the Summary of Product Characteristics (SmPC)"
46110179|NCT02607540|Other|2 cycles cisplatin-5-fluorouracil|2 cycles cisplatin-5-fluorouracil(PF 2 cycles): cisplatin: 75mg/m2 d1，29; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.
46110180|NCT02607540|Other|4 cycles cisplatin-5-fluorouracil|4 cycles cisplatin-5-fluoroura(PF 4 cycles): cilcisplatin: 75mg/m2 d1，29, 57, 85; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.
46110181|NCT02607540|Radiation|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
46110182|NCT02608398|Other|no intervention|NO intervention by the research group - this is an observational study. urine samples simply collected as children lose weight on their diet and exercise camp
46110183|NCT02496624|Other|Cone Beam CT localization and placement of microcoil|Cone Beam CT localization and placement of microcoil
46110184|NCT05753046|Drug|Early TAP Block|For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the initiation of the procedure (immediately following placement of the robotic / laparoscopic camera port). The TAP block will be performed with 15 mL 2 finger breadths subcostal at the mid-clavicular line and then 15 mL at the level of the umbilicus along the mid-axillary line on each side. Laparoscopic / robotic camera will be used as a visual aid to confirm positioning between the internal oblique and transversus abdominis muscles for the goal of pain relief.
46110185|NCT05753046|Drug|Late TAP Block|For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the conclusion of the procedure (immediately proceeding removal of the robotic / laparoscopic camera port). The TAP block will be performed with 15 mL 2 finger breadths subcostal at the mid-clavicular line and then 15 mL at the level of the umbilicus along the mid-axillary line on each side. Laparoscopic / robotic camera will be used as a visual aid to confirm positioning between the internal oblique and transversus abdominis muscles for the goal of pain relief.
46110186|NCT00817778|Drug|AZD1656|Subjects will be treated with tolerable dose twice daily for another 24 days.
46110187|NCT00817778|Drug|Placebo|Subjects will be treated with tolerable dose twice daily for another 24 days.
46023622|NCT05659459|Drug|KIN001|Oral tablet
46023623|NCT05659459|Drug|KIN001-Placebo|Comparator - Oral tablet with same appearance of KIN001
46110188|NCT05685264|Drug|Ponsegromab|Participants will receive one subcutaneous injection
46110189|NCT05685264|Drug|Ponsegromab|Participants will receive four subcutaneous injections
46110190|NCT05733780|Drug|Prolectin-M|"Prolectin-M~Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus"
45469344|NCT03415672|Biological|HBAI20|Three doses of HBAI20 at 0, 1, and 2 months. The HBAI20 vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
46023624|NCT04239391|Drug|Triferic|Ferric Pyrophosphate Citrate
46023625|NCT02820259|Drug|Tacrolimus|
46023626|NCT02823223|Device|Zephyr endobronchial valve placement|Patients will have ELVR (Endoscopic Lung Volume Reduction) with Zephyr valve inserted into the target lobe of the lung with the aim of complete lobar exclusion.
46023627|NCT02821663|Behavioral|vocal intervention|10 x 60 min. sessions of vocal intervention
46023628|NCT02822755|Other|Home Exercise Program and Adherence Logs|Both groups will receive physical therapy prescribed home exercises and be asked to record adherence to their program on an exercise log.
46023629|NCT02821585|Behavioral|Nutritional Counseling|Carbohydrate counting will be reviewed, as well as hypoglycemia management. The 9 following visits will focus on different aspects of each diets: types of fats, meat and alternatives, grain products, milk and alternatives, fruits and vegetables, salt intake, energy density and restaurants.
45469345|NCT03766399|Drug|AZD0449|Participants will receive single inhaled AZD0449 nebulizer suspension and single IV dose of AZD0449 solution.
45469346|NCT03766399|Drug|Placebo|Participants will receive single dose of placebo for AZD0449 (nebulizer suspension).
45469347|NCT01239875|Biological|dendritic cell vaccine therapy|Given intratumorally
45469348|NCT01239875|Procedure|cryotherapy|Undergo cryoablation
45469349|NCT01239875|Biological|pneumococcal polyvalent vaccine|Given intramuscularly
46023630|NCT02821351|Device|Radio frequency (RF) Cardiac ablation|Catheter based RF cardiac ablation to treat Paroxysmal Atrial Fibrillation
46023631|NCT02820103|Behavioral|Text+Visual BCT-based intervention|Participants in the visual intervention group will receive usual care specified below plus a specifically developed Text + Visual BCT-based intervention, comprising 12 BCTs identified from SR and expert consensus study. An animated video, just under 8 minutes in length is hosted online in the Intervention Modelling Experiment. The animation contains 9 of the 12 BCTs and tells the 'delay stories' of three different characters. It was not possible to deliver all of the 12 BCTs comprehensively in the relatively passive media of the animation as some techniques require active participation from participants (e.g. action planning). Thus, n=7 BCTs (1 2 Problem-solving; 1 4 Action planning; 5 2 Salience of consequences; 7 1 Prompts/cues; 9 3 Comparative imagining of future outcomes; 15 2 Mental rehearsal of successful performance) are also delivered via short web-based exercises which follow the animation.
46110191|NCT05758532|Biological|Measles-Mumps-Rubella vaccine (MMR)|0.5 ml of MMR vaccine injected intramuscularly in the deltoid region or in the anterolateral area of the thigh
46110192|NCT00705458|Procedure|Coronary Computed Tomography Angiography|64-detector, retrospectively EKG-gated, computed tomography angiography of the coronary arteries during heart rate control (intravenous metoprolol, when necessary)
46110193|NCT00705458|Procedure|Stress Nuclear Myocardial Perfusion Imaging|Usually dual-isotope perfusion imaging at rest (201-Thallium) and at stress (99m-Technetium-MIBI). Some patients will have a 2-day MIBI protocol. Gated SPECT and attenuation-correction images will be obtained. Treadmill stress will be performed. If a patient is unable to exercise, adenosine or dobutamine will be given.
46110194|NCT00813098|Drug|LX1031 High Dose|A high dose of LX1031; daily oral intake for 28 days
46110195|NCT00813098|Drug|LX1031 Low Dose|A low dose of LX1031; daily oral intake for 28 days.
46110196|NCT00813098|Drug|Placebo|Matching placebo dosing with daily oral intake
46110197|NCT00705692|Drug|Levamisole|
46110198|NCT00705692|Drug|Placebo|
46110199|NCT05756582|Diagnostic Test|Prevalence of Latent Tuberculosis Infection|The prevalence of Latent Tuberculosis Infection [LTBI] is defined as 1) tuberculin conversion after a documented negative-baseline tuberculin skin test (TST), 2) positive result of the QuantiFERON-TB Gold (QFT) test performed [higher response than the cut-off value of 0.35 IU / ml of INF-γ was detected in at least one test tube (TB1 or TB2)], 3) chest imaging excluding pleural and/or pulmonary lesions suggestive of active tuberculosis and 4) final medical evaluation done by a Specialist in Infectious Diseases which excluded active disease. All four criteria must be met.
46110200|NCT05297318|Device|hypotension prediction index guided|patients receiving hypotension prediction index monitoring and let the anesthesiologist' alerted the coming intraoperatiobe hypotension
46110201|NCT05297318|Other|without hypotesion prediction index guided|patients receiving usual care without hypotension prediction index monitoring but with usual arterial line care
46110202|NCT05758454|Behavioral|Caries and Obesity Prevention|A culturally adapted oral health education intervention to prevent development of ECC and to improve parental oral health related knowledge and attitudes.
46110203|NCT00705770|Drug|Anecortave Acetate|"Low dose~Sustained release depot suspension"
46110204|NCT00705770|Drug|Anecortave Acetate|"Middle dose~Sustained release depot suspension"
46110205|NCT00705770|Drug|Anecortave Acetate|"High dose~Sustained release depot suspension"
46110206|NCT00705770|Drug|Placebo|Placebo treatment with vehicle
45469350|NCT01239875|Other|laboratory biomarker analysis|Correlative studies
46110207|NCT02609906|Device|PhilosTM with augmentation (Depuy-Synthes)|"All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the angle stable plate fixation system PhilosTM with augmentation (Depuy-Synthes)."
46110208|NCT02609906|Device|MultiLoc®-Nail (Depuy-Synthes)|"All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the multiplanar proximal humeral nail MultiLoc® (Depuy-Synthes)."
46110209|NCT00796653|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
46110210|NCT00796653|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
46110211|NCT00796653|Drug|Formoterol|Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
46110212|NCT00796653|Drug|Placebo|Placebo devices for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
46023632|NCT02820103|Behavioral|Text-only BCT intervention|Participants in the text-only BCT-based intervention group will receive the usual care specified above plus a text-only BCT-based intervention. This was developed in the same way as the text + visual BCT-based intervention but does not include the visual elements (i.e. animation). Instead, the voiceover from the animated film is displayed in text on screen and narrated in audio. The BCTs which require active engagement are delivered via identical web-based exercises as the text + visual BCT-based intervention.
46110213|NCT00806286|Drug|CS7017 tablets|CS7017 tablets, strength 0.25 mg, two tablets, two times daily for twenty-five to thirty months
46110214|NCT00806286|Drug|Paclitaxel|Intravenous (IV), 200 mg/m^2, once every three weeks for up to 18 weeks
46110215|NCT00806286|Drug|Carboplatin|IV, area under the curve (AUC) of 6, once every three weeks for up to 18 weeks
46110216|NCT00806286|Drug|Placebo Tablets|Placebo tablets matching CS-7017 tablets
46110217|NCT03537924|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
46110218|NCT03537924|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
46110219|NCT02607384|Behavioral|Eyeglass wearing|Children found to require eyeglasses will be given two pairs free of charge
46110220|NCT02607384|Behavioral|Orthoptic exercises|Children found to have convergence insufficiency will be prescribed orthoptic exercises
45469351|NCT01239875|Other|immunoenzyme technique|Correlative studies
45469352|NCT01239875|Other|immunohistochemistry staining method|Correlative studies
45469353|NCT01239875|Biological|autologous dendritic cell-tumor fusion vaccine|Given intradermally
45469354|NCT03415594|Drug|FE203799 GLP-2 analogue|FE203799 5 mg subQ once weekly
45469355|NCT03415594|Drug|FE203799 Placebo GLP-2 analogue|Placebo subQ once weekly
45469356|NCT03415594|Drug|FE203799 GLP-2 analogue|FE203799 10 mg subQ once weekly
46023633|NCT02820103|Behavioral|Leaflet information (control)|Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge.
46023634|NCT05658991|Diagnostic Test|Retinal electrophysiology|Retinal electrophysiology to assess retinal function before and with fasting during ramadan in both groups.
46110221|NCT02607384|Other|Specialist referral|Children found to any other eye condition will be referred to a pediatric eye care specialist
46023635|NCT02822833|Procedure|Sentinel lymph node mapping|Before laparoscopic hysterectomy and lymphadenectomy procedure for endometrial cancer, Indocyanine green solution will be injected through cervix. Then the surgeon will look for sentinel lymph nodes under fluorescence visualization.
46110222|NCT02605980|Behavioral|Sedentary time|
46110223|NCT00590538|Drug|Sodium 4-Phenylbutyrate|The standard oral adult dose is 20 g/day (tablets) for 4 days.
45469357|NCT04219254|Drug|Pembrolizumab 25 MG/ML(MK-3475)|Pembrolizumab 200mg administrated IV every third week as a fixed dose will be used in Phase I and IIa
46110224|NCT00590538|Drug|Genistein (Unconjugated Isoflavones 100)|Every participant will be administered a perfusion of 50 MicroM of Genistein (Unconjugated Isoflavones 100) during the modified NPD procedure.
45469358|NCT01321411|Other|Near Infrared Spectroscopy|"Healthy Volunteers:~Study #1 (Abnormal Pulmonary Resistance) subjects will breathe through a Starling resistor simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV.~Study #2 (Abnormal Pulmonary Compliance) subjects will breathe while wearing a chest binder simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV."
45469359|NCT01321411|Other|Near Infrared Spectroscopy|"Clinical Volunteers:~Study #3 (Abnormal Pulmonary Resistance) subjects recovering from COPD exacerbations will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB.~Study #4 (Abnormal Pulmonary Compliance) subjects recovering from ARDS will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB."
46110225|NCT00590538|Drug|Placebo|The placebo is given to match the active comparator for four days.
45469360|NCT04448860|Behavioral|performance of behavioral locomotion tasks phase 1|The performance of behavioral locomotion tasks is performed on 4 visits on pilot phase (2 in real condition and 2 in virtual reality in D1 and M1)
46110226|NCT02608320|Drug|Duragesic (Fentanyl Transdermal System [TDS] Small Patches)|Duragesic 12.5 mcg/h (Treatment A) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
46110227|NCT02608320|Drug|New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches)|New JNJ-35685-AAA-G016 12.5 mcg/h (Treatment B) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
46110228|NCT02608320|Drug|Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches)|Aged JNJ-35685-AAA-G016 12.5 mcg/h (Treatment C) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
46110229|NCT02608320|Drug|Duragesic (Fentanyl TDS Large Patches)|Duragesic 100 mcg/h (Treatment D) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours, applied to the paraspinal region of the back for 72 hours.
45469361|NCT04448860|Behavioral|performance of behavioral locomotion tasks phase 2|The performance of behavioral locomotion tasks is performed on 6 visits on validation phase (3 in real condition and 2 in virtual reality in D1, M1 and M12)
46110230|NCT02608320|Drug|New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)|New JNJ-35685-AAA-G021 100 mcg/h (Treatment E) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
46110231|NCT02608320|Drug|Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)|Aged JNJ-35685-AAA-G021 100 mcg/h (Treatment F) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
46110232|NCT01731444|Drug|Phenylephrine|
46110233|NCT04111887|Behavioral|Group-based therapy|College students with depressive symptoms will be randomized to one of three conditions: 1) a cognitive behavioral prevention intervention, 2) a cognitive behavioral prevention intervention with counter-attitudinal elements or 3) an educational brochure control. We will test if the additional of counter attitudinal elements produces intervention effects when delivered to participants with sub threshold depressive symptoms.
46110234|NCT04111575|Behavioral|Music Therapy|Music Therapy
45469362|NCT01144169|Drug|Hydroxychloroquine (HC)|Subjects will receive HC orally for 14 days prior to surgery. The fixed dose of HC will be 400 mg/day in divided doses (200 mg bid). The final dose will be administered on the evening prior to nephrectomy.
46110235|NCT05728788|Drug|Antitumor drugs|Anthracyclines, immune checkpoint inhibitors, monoclonal antibodies, and tyrosine kinase inhibitors
46110236|NCT03991416|Behavioral|Understanding Your Baby|Research-based knowledge on the understanding and meeting of the baby's socioemotional needs is delivered to the parents systematically by public health visitors based on a manual, cue cards, and video clips at four time points from 1 to 10 months postpartum.
46110237|NCT03991416|Behavioral|Postnatal care as usual|In accordance with Danish national guidelines, health visitors visit families during the infants first year of life, where they weigh and measure the infant. Further, they offer individual guidance and support regarding for instance feeding, sleeping, how to stimulate the infant, and the developmental stages that the infant goes through.
46110238|NCT02604927|Dietary Supplement|Beta-alanine|
46110239|NCT02604927|Dietary Supplement|Dextrose|
46110240|NCT00914082|Behavioral|Self hypnosis|3 antenatal classes of 1 hour. 3 audio compact discs for reenforcement. 1 audio compact discs for support at birth
46110241|NCT04111341|Drug|TCM (Gan-Lu-Yin)GLY|TCM Gan-Lu-Yin 6g in the morning TCM Jia-Wei-Xiao-Yao-San, Ye-Jiao-Teng, Suan-Zao-Ren 8g in the evening for 12 weeks
46110242|NCT04111341|Drug|PLACEBO|TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks
46110243|NCT00914238|Behavioral|2 years OPUS treatment|2 years OPUS and transfer to standard treatment.
46110244|NCT00914238|Behavioral|OPUS 5 years|
46110245|NCT05681832|Behavioral|Intervention group|"The children in this group will participate in a 15-minute HIIT (High-intensity interval training) program twice a week for eight weeks. Motivational interviewing through presentations and Kahoot for the children and their parents will be done at the program's beginning, middle, and end.~The HIIT program will consist of 2.5 minutes of warm-up 12.5 exercises then a cool-down period of 5 minutes. The intensity of the exercise was increased based on each kid's performance and monitored during the sessions using a smartwatch."
46110246|NCT04110951|Behavioral|Pranayama Breathing Technique|Yogic Breathing Technique
46110247|NCT04110951|Behavioral|Relaxation technique|Progressive relaxation technique
46110248|NCT00914550|Other|Procalcitonin level, caregiver informed|Procalcitonin levels will be measured and known by investigator, only 1/2 of the patients' caregivers will know the results of serial Procalcitonin levels. We will analyze the rate of antibiotic discontinuation for the two arms
46110249|NCT02608164|Dietary Supplement|3000IU(75μg) vitamin D3|
46023636|NCT02819947|Other|This is an observational prospective study.|Investigators will get clinical information including gender, date of birth, height, weight, family history for systemic sclerosis, education, and symptoms of organ involvement of skin, lung, heart, gastrointestinal tract, kidney, musculoskeletal system and laboratory data. Investigators will evaluate nailbed capillary microscope, hand x-ray, 6 minute walk test, echocardiography, computed tomography of chest, pulmonary function test (FVC%, DLCO%), and electrocardiogram as baseline. Investigators permit replacement of previous results within one year from baseline. Participants in the cohort will be followed up annually and investigators will treat SSc patients according to their routine practice in the best interest of patents. Medications for other comorbid conditions are allowed.
46023637|NCT02821429|Other|Combined Thoracic Echography Record|This examination will be done to do the longitudinal follow-up of the patient
46110250|NCT02606058|Procedure|Deferred cord clamping|Deferred cord clamping (for 60 seconds or more with the baby held below or at the level of the placenta)
46110251|NCT02604693|Other|Nothing|No interventions will be administered.
46023638|NCT00633763|Drug|18F-fallypride|Single bolus i.v. injection 60 minutes before PET-CT scanning. Maximum activity per single administration 5 mCi; maximum amount of drug per administration <10 micrograms.
46110252|NCT00915135|Drug|Ramelteon and Placebo (25 possible combinations total)|"Randomized sequence over two consecutive nights for a total of five treatment periods to include the following:~Ramelteon 4 mg, tablets, orally over two nights~Ramelteon 8 mg, tablets, orally over two nights~Ramelteon 16 mg, tablets, orally over two nights~Ramelteon 32 mg, tablets, orally over two nights~Ramelteon placebo-matching tablets, orally over two nights"
46110253|NCT02607462|Biological|PRP|
45469363|NCT03769987|Other|observation|observe patients every 6 months
45838434|NCT02708810|Device|Unframed Virtual Cone|A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. This will allow for very precise targeting. During the procedure, the study doctor will also confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask (unframed) will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on the painful nerve in the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is in the range of 30 to 60 minutes. The face mask (unframed) will be removed after the treatment.
45838435|NCT02708810|Radiation|80 Gy Radiation|
46023639|NCT00633763|Drug|18F-fallypride|I.v. bolus maximum activity per single administration 5 mCi; maximum amount of drug per administration <10 micrograms.
46110254|NCT02607462|Other|Placebo|
46110255|NCT00796419|Drug|5% human albumin|Intravenous administration of 250 milliliters (mL) 5% human albumin every 8 hours for 5 days
45469364|NCT03415516|Device|Gluma Universal|Adhesive systems
45838436|NCT02678689|Biological|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|
45838437|NCT02678689|Device|Intraventricular access device|Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
45838438|NCT02678052|Drug|Vedolizumab|Vedolizumab exposure
45838439|NCT02678052|Biological|Other Biological Agent|Other Biological Agent exposure
45838440|NCT02576717|Drug|RPC1063|
45838441|NCT02564263|Biological|pembrolizumab|200 mg administered as IV infusion on Day 1 of every 21-day cycle
46110256|NCT00796419|Drug|6% hetastarch|Intravenous administration of 250mL 6% hetastarch every 8 hours for 5 days
46110257|NCT04110873|Drug|Antroquinonol Capsule 50mg|patients will receive Antroquinonol 50mg per day (QD) on Day 1 for 12 weeks
46110258|NCT04110873|Drug|Antroquinonol Capsule 100mg|patients will receive Antroquinonol 100mg per day (QD) on Day 1 for 12 weeks
46110259|NCT04110873|Drug|Placebo oral capsule|patients will receive placebo per day (QD) on Day 1 for 12 weeks
46110260|NCT04110717|Device|Vestal Device|Vestibular nerve stimulator
46110261|NCT04110717|Device|Control Device|Control Device
46110262|NCT04110717|Behavioral|Hypocaloric Diet|Hypocaloric diet
46110263|NCT05619939|Dietary Supplement|Protein isolate|The indicated protein isolates will be given to subjects as their major protein source
46110264|NCT02604615|Drug|Capecitabine(Aibin)|capecitabine(Aibin):625mg/m2,bid d1-5; q1w, po,5 or 10 weeks in total
46110265|NCT02604615|Drug|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,I.V. or Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,43,50,64,71,I.V.
46110266|NCT02604615|Radiation|Radiotherapy|concurrent radiotherapy:50Gy in total,2 Gy/d,5d/w,Until disease progression or unacceptable toxicity
46110267|NCT04110639|Device|Intracranial pressure (ICP) monitor|The investigators' hypothesis is that by utilizing an intracranial pressure (ICP) monitor to detect the presence or absence of waveforms in the femoral head, investigators could reliably assess the perfusion levels within the femoral head and possibly reduce the incidence of osteonecrosis.
46110268|NCT04110639|Other|Standard of Care|10 patients with minimally displaced femoral neck fractures (Garden 1) which will be pinned in situ without manipulation
46110269|NCT00796107|Drug|RG1507|R1507 was administered at a dose 16 mg/kg every 3 weeks.
46110270|NCT00796107|Drug|Letrozole|Letrozole was administered orally at a dose 2.5 mg daily.
46110271|NCT00795951|Biological|T.R.U.E. Test|48 hour application of 28 allergens and negative control
46110272|NCT04110483|Procedure|Thulium fiber laser en-bloc resection of non-muscle-invasive bladder cancer|After cystoscopy and determining tumor topography, a circumferential incision around the tumor is made in the visually intact bladder mucosa (approximately 10 mm from the edges of the tumor). It allows for accurate morphological evaluation of the surgical margin. After that, the incision is continued deeper into the muscular layer. Having identified the layer, the surgeon resects the base of the tumor with the muscular layer using traction and incisions of the muscle fibers. Making incisions in the muscular layer requires precision, a full bladder and adequate guidance with visualization techniques. Traction may be employed with the help of the tip of the resectoscope or working element. After complete tumor resection, local hemostasis was performed.
46023640|NCT02822911|Behavioral|Alcohol Used Disorders Identification Test (AUDIT C)|"The Audit-C questionnaire is a three item alcohol screen that can help identify persons who are hazardous drinkers or have active alcohol abuse disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument.~Score from 0 to 12. Each Audit-C question has a 5 answer choice, allotted points are from 0 to 4 points. In men, a score of 4 is considered as positive, optimal for identifying hazardous users or active alcohol abuse disorders. The same for 3 points in women."
46023641|NCT02822911|Procedure|Carbohydrate deficient transferrin|Blood sample to collect carbohydrate deficient transferrin (CDT) only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
46023642|NCT02822911|Procedure|Gamma glutamyl transpeptidase|Results of Gamma glutamyl transpeptidase (GGT) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reaches at least 1 point.
46023643|NCT02822911|Procedure|Mean Corpuscular Volume|Results of Mean Corpuscular Volume (MCV) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
45469365|NCT03415516|Device|All Bond Universal|Adhesive systems
46023644|NCT02820025|Drug|doxapram|
46023645|NCT02820025|Other|saline|
46110273|NCT04110483|Procedure|Transurethral resection of non-muscle-invasive bladder cancer|After cystoscopy and determining tumor topography, a step-by-step resection of a tumor is done. Firstly, visible tumor is resected, then resection continues to the apparently normal mucosa on the border of the tumor, than resection of the muscle layer at the base of the tumor is performed until normal muscle fibers are visible.
46110274|NCT04110561|Device|Use of the Atalante exoskeleton|A session basically includes a stand up, walks over a distance of 10 meters, exercises, U-turns and a sitting
46110275|NCT00795717|Drug|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.
46110276|NCT00795717|Drug|Placebo|2 capsules given twice daily
46110277|NCT00805740|Drug|Active anidulafungin|Subjects in this arm will receive active anidulafungin and placebo caspofungin
46110278|NCT00805740|Drug|Active Caspofungin|Subjects in this arm will receive active caspofungin and placebo anidulafungin
45469366|NCT03415516|Drug|Single Bond2|Adhesive systems
45469367|NCT05152979|Behavioral|Verb Network Strengthening Treatment (VNeST)|Participants are presented with a verb (representing an activity, for example, driving) orally and in writing. The participants are first asked to name someone who may perform the given activity (an agent, for example, a chauffeur), then to name an object which the given activity may be performed with (a patient, for example, a limousine). Several types of semantic clues and assistance are provided if the participant is having difficulties finding adequate nouns. This procedure is repeated for three different agents and objects related to the given verb. The participants are then asked to choose one of the three phrases participants have created and expand on it by telling where, when and why the agent is performing the activity. After this the participant are given sentences (with several foils) including the activity as well as agents and patients, and are asked to indicate whether the sentences are correct or not.
45469368|NCT02709954|Drug|Active inhaled delta-9-THC|"Low dose THC (~4 mg), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer."
46110279|NCT05613075|Procedure|tooth extraction and socket preservation with demineralized tooth graft|tooth extraction and socket preservation with demineralized tooth graft
46110280|NCT05613075|Procedure|tooth extraction and socket preservation with demineralized tooth graft with hyaluronic acid|tooth extraction and socket preservation with demineralized tooth graft with hyaluronic acid
46110281|NCT04110015|Device|virtual visual field|Patients with identified conditions will be invited to do a virtual visual field test with virtual reality headsets.
45469369|NCT02709954|Drug|Placebo|Control: Approximately 4 drinks of orange juice or ginger ale covered by a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
45469370|NCT02709954|Drug|Placebo|Control: No active THC. Administered over 20 minutes via a vaporizer. approximately 10 minutes.
45469371|NCT02709954|Drug|Active Oral Ethanol|0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to consuming approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
45838442|NCT02564263|Drug|paclitaxel|80-100 mg/m^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle
45838443|NCT02564263|Drug|docetaxel|75 mg/m^2 administered as IV infusion on Day 1 of every 21-day cycle
45838444|NCT02564263|Drug|irinotecan|180 mg/m^2 administered as IV infusion on Day 1 of every 14-day cycle
45838445|NCT02540018|Device|Transluminal Angioplasty with Paclitaxel-coated Luminor® Balloon Catheter in the Superficial Femoral and Popliteal Arteries|"Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure (DEB) is assigned by randomization.~Luminor35®-DEB PTA catheter is applied."
45838446|NCT02540018|Device|Transluminal Angioplasty with and non-coated (CE-marked) plain old angioplasty balloon (POBA) catheter|Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure is assigned by randomization. POBA catheter is applied.
46110282|NCT03954210|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I is an in-person, one-on-one program with a graduate psychology research assistant who is trained in providing a standardized CBT-I. Participants will maintain a sleep diary during the course of the program to aid in tailoring the program. Each session will begin with a summary and graphing of sleep diary data and will include an assessment of treatment gains and adherence.
46110283|NCT03954210|Behavioral|Sleep and Lifestyle Education|Participants in the sleep and lifestyle education group will attend six weekly, in-person, one-on-one, stretching, and thinking activity sessions with a graduate research assistant to control for socialization and contact with research personnel.
46110284|NCT02605902|Behavioral|(i)Comprehensive Behavioral Intervention for Tics|
45838447|NCT02522247|Procedure|UPP|surgery with cold steel in general anesthesia
46110285|NCT02605902|Behavioral|internet-delivered psychoeducation and relaxation training|
46110286|NCT01227876|Drug|Ster|prednisolone 1% ophthalmic suspension
46110287|NCT01227876|Drug|Pred Fort|prednisolone 1% ophthalmic suspension
46023646|NCT04824079|Drug|Keynatinib|The recommended dose is 20 mg Keynatinib twice a day until disease progression， unacceptable toxicity death occurs or withdraw from the study, whichever occurs first.
46023647|NCT02819869|Drug|Statin and Metformin use|
46023648|NCT02819713|Other|ultrasound gel|
46023649|NCT02819713|Other|Instillagel|
46110288|NCT00795639|Drug|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily
46023650|NCT02821117|Device|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days followed by 8 weeks unmasked wear.~During the 2 weeks of masked device wear participants will use the BG strip port for self-monitoring of blood glucose (SMBG). Scanning the sensor at least every 8 hours during this phase.~Followed by 8 weeks of unmasked device wear when participants will use the device (Sensor glucose and SMBG) according to labelling for their day to day management."
46023651|NCT02820883|Biological|Staphylococcus aureus vaccine (60µg/per protein)|two doses of 60µg/0.6ml per dose
46023652|NCT02820883|Biological|Staphylococcus aureus vaccine (30µg/per protein)|two doses of 30µg/0.6ml per dose
46023653|NCT02820883|Biological|Staphylococcus aureus vaccine (15µg/per protein)|two doses of 15µg/0.6ml per dose
46023654|NCT00633841|Biological|AFFITOPE AD02|4 subcutaneous injections of IP in 4-week intervals
46023655|NCT05659615|Other|Study will not have intervention|Study will not have intervention
46023656|NCT04811287|Device|Carpal Tunnel Release with Platelet-Rich Plasma|CTR is performed with adjuvant PRP placed intra-operatively.
46110289|NCT00795639|Drug|Placebo|Sitaxsentan Placebo = 1 tablet administered orally, once daily
46110290|NCT05297292|Drug|MW02|MW02 is a recombinant anti-VEGF humanized monoclonal antibody injection.
46110291|NCT05297292|Drug|Lucentis|a recombinant anti-VEGF humanized monoclonal antibody injection
46110292|NCT05674734|Behavioral|4FM Acceptance Training|4FM Acceptance Training, therapeutic intervention in the form of an additional to TAU module - 12 (1,5 hour) group meetings in the form of 4FM Acceptance Training at Day Care Units at IPIN Mental Health Centre for Mokotów and IPiN (1 meeting weekly).
46110293|NCT05612373|Behavioral|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
46110294|NCT00540774|Device|detection of oral pathology|detection of oral pathology
46110295|NCT02604459|Device|cerebral oximeter (Fore-Sight)|The cerebral oximeter will be monitored in the optimized care group and cerebral oxygenation will be maintained at 60% or higher.
45838448|NCT02513056|Other|MRI|MRI
45838449|NCT02423265|Drug|Ranolazine|Ranolazine: 500 mg twice day, up-titrated after 1 week to 1000 mg twice a day
45838450|NCT02423265|Drug|Placebo|Matching placebo: up-titration after 1 week
46023657|NCT04811287|Procedure|Carpal Tunnel Release without Platelet-Rich Plasma|CTR is performed without adjuvant PRP placed intra-operatively.
46023658|NCT02819401|Other|pediatric formula|high-fiber enteral formula
45838451|NCT02416050|Procedure|Brain MRI imagery|Brain MRI performed during the first week of inpatient cocaine cessation
45838452|NCT02379819|Device|Nucleus Hybrid L24 Implant|
45838453|NCT02368886|Drug|Clobetasol Propionate|Given topically
45838454|NCT02368886|Other|Pharmacological Study|Correlative studies
45838455|NCT02368886|Other|Quality-of-Life Assessment|Ancillary studies
45838456|NCT02368886|Drug|Regorafenib|Given PO
45838457|NCT02332369|Device|Capsular Tension Ring|
46023659|NCT04200859|Other|Cold application|cold application using ice pack/gel pad in the control of pain experienced during chest tube removal
46023660|NCT02819245|Procedure|posterior correction and fusion|
46110296|NCT02604459|Device|depth of anesthesia monitor (BIS)|The depth of anesthesia will be maintained between 40 and 60 in the optimized care group.
46110297|NCT02604459|Procedure|BP management|The systolic blood pressure will be maintained within 20% of preoperative levels in the optimized care group.
46110298|NCT02604459|Procedure|General anesthesia|General anesthesia will be used in both groups
46110299|NCT02604459|Drug|propofol|propofol per protocol
46110300|NCT02604459|Drug|fentanyl|fentanyl per protocol
46110301|NCT02604459|Drug|sevoflurane|maintenance of anesthesia with inhaled sevoflurane
46110302|NCT04012398|Diagnostic Test|Amsterdam IADL Questionnaire short, German version|Questionnaire to assess impairments in instrumental activities of daily living
46110303|NCT02604225|Drug|Methoxyflurane|Participants randomised to the experimental arm will inhale methoxyflurane administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
46110304|NCT02604225|Drug|Placebo|Participants randomised to the control arm will inhale 0.9% saline administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
46023661|NCT04200703|Other|Adult and Child Survivor Centered Approach|Child welfare workers and supervisors, and community partners will be trained in the Adult and Child Survivor Centered Approach, and supervisors will receive ongoing coaching and training.
46023662|NCT02819089|Drug|Dexmedetomidine|Demedetomidine infusion (2mcg/ml); loading 0.5 mcg/kg for 30 min (BW/2 ml/h for 30 min), then 0.5 mcg/kg (BW/4 ml/h) until 30 minutes before finish the operation.
45469372|NCT02785120|Drug|TF0023|TF0023 is a new Investigational drug as a topical spray as an anti thrombosis drug, indicated for relief of the signs and symptoms and functional improvement of patients with ischemic strokes.
45838458|NCT02301286|Drug|Acetylsalicylic acid|
45838459|NCT02301286|Drug|Placebo Acetylsalicylic acid|
46110305|NCT00537108|Behavioral|Home visiting and care management|Third trimester teens are assigned a Care Manager (CM) who establishes a continuity relationship and provides monthly visits until the index child is 2 years old. Core services for intervention group include: 1)Baseline and ongoing assessment of health, mental health, housing, daycare, and school needs; 2)Administration of a culturally sensitive, developmentally relevant parenting curriculum; 3)Computer Assisted Motivational Interviewing to promote healthy relationships, improve contraceptive practices, focus on goals, and promote school continuation; 4)Efforts to engage the young father; 5)Linkage and coordination with primary care for teen, child, young father; 6)Support & skills-building for school continuation, higher education, and job readiness.
46110306|NCT02604303|Other|No Intervention|No intervention; prospective observational study
45469373|NCT01248689|Other|concentration profile 1|"IOP will be measured under this order of sevoflurane concentrations:~7%, 5%, 2%, 0.5%"
45838460|NCT02262221|Other|Scheduled radiologic evaluations|Scheduled radiologic evaluations (CT or MRI scan) and PET scan in the case that patiets are ≥ 50 years old and with a smokink history ≥ 20 pack year
45838461|NCT02257853|Other|Stress reduction intervention|Gentle chair yoga and breath work
46023663|NCT02819089|Other|NSS|NSS infusion; loading BW/2 ml/h for 30 min, then BW/4 ml/h until 30 minutes before finish the operation.
46023664|NCT02818699|Dietary Supplement|Placebo|280mg placebo capsule containing only maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
46023665|NCT02818699|Dietary Supplement|EMIQ|280mg placebo capsule containing 180 mg EMIQ and 100mg maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
46023666|NCT02690311|Device|smartphone display|
46023667|NCT04191265|Diagnostic Test|serum tropinin, serum CKmb|early detection of myocardial injury, allowing application of acute cardiac shock and cardiogenic shock
46023668|NCT04238923|Drug|Topical vancomycin paste (1g vancomycin powder + 4mL sterile saline) and Collatamp G gentamicin-eluting sponge (Azralez Pharmaceuticals; 2.0mg gentamicin sulphate/cm2 to cover wound)|Topical vancomycin paste and gentamicin-eluting collagen sponge will be applied directly to the deep layers of the wound following reconstruction, prior to closure.
46023669|NCT02819167|Other|neurologic and neuropsychological evaluation|cognitive prognosis, cognitive reserve, brain volume will be studied on patients with scale, questionnaire, magnetic resonance imaging
46023670|NCT04239001|Drug|PEG-rhG-CSF|24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, patients with pancreatic cancer who met the input / discharge criteria were given secondary prophylactic administration of the tested drug PEG-rhG-CSF.
46023671|NCT04240015|Other|Oral-Dental Health-Related Quality of Life-United Kingdom (OHRQoL-UK) scale|It consists of 4 different categories and 16 questions evaluating the effects of OHRQoL in positive and negative areas. These categories are as follows; symptoms (2 questions), physical status (5 questions), psychological status (5 questions), social status (4 questions) ' Questions on the OHRQoL-UK scale were scored using the Likert-type scale as 'very bad effect-score 1, bad effect-score 2, no effect-score 3, good effect-score 4, very good effect-score 5. The scores obtained from all questions were summed to give the scores of the 4 sub-categories separately and the total OHRQoL score. A higher total score indicates a higher OHRQoL.
46023672|NCT02815657|Drug|SP2086|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
45838462|NCT02227238|Drug|DTG|DTG is supplied as 50 mg tablets
45838463|NCT02227238|Drug|LPV/RTV|LPV/RTV is supplied as the LPV/RTV oral tablet, which contains 200 mg of LPV and 50 mg of RTV
45838464|NCT02227238|Drug|Two NRTIs|Investigators will choose a dual NRTI background regimen for each subject . In consultation with the medical monitor, 3TC may be added as a third NRTI to a dual-NRTI background regimen in subjects with chronic HBV infection and evidence of HIV resistance to 3TC
45838465|NCT02225925|Radiation|Brachytherapy|
45838466|NCT02216305|Procedure|Hemorrhoidectomy|Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorrhoidal base with absorbable suture
46023673|NCT02815657|Drug|Valsartan|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
46023674|NCT04597333|Drug|Dinoprostone|Dinoprostone vaginal insert.
46023675|NCT04597333|Device|Cervical ripening balloon.|Double lumen cervical ripening balloon.
46023676|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg twice daily (BID) on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 60 mg BID, and 75 mg BID) until Maximum Tolerated Dose (MTD) is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
45469374|NCT01248689|Other|concentration profile 2|"IOP will be measured under this order of sevoflurane concentrations:~7%, 2%, 5%, 0.5%"
45469375|NCT01248689|Other|concentration profile 3|"IOP will be measured under this order of sevoflurane concentrations:~7%, 0.5%, 5%, 2%"
45469376|NCT05432167|Drug|CIN-107|Patients will take CIN-107 tablets by mouth once daily.
46110307|NCT03362970|Device|BioFire Gastrointestinal Panel FilmArray®|The BioFire Gastrointestinal Panel FilmArray® is a multiplexed nucleic acid (NA) based device that simultaneously identifies 22 enteric pathogens. It specifically tests for the presence of Shiga toxin and for O157. It requires 2 minutes of hands-on-time, returns results in ~2-3 hour, and is Health Canada and Food and Drug Administration approved. The device, which has been validated, hopefully will enable the early identification of infected children and initiation (or withholding) of interventions directed by previously unavailable clinical data. It will enable us to bring a precision medicine approach into ED care.
46110308|NCT03362970|Other|Standard of Care|Standard practices for children with hematochezia upon the discretion of the treating physician. If investigations are ordered, results have a turn-around time up to 72 hours.
46110309|NCT00589602|Procedure|peripheral blood lymphocyte therapy|T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be >0.5 x 105 but <1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be >2 x 106 cells/kg.
46023677|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg BID on Days 1 to 21 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 45 mg BID, 60 mg BID, 75 mg BID, and 90 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
46110310|NCT00589602|Procedure|allogeneic hematopoietic stem cell transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
46023678|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally at a dose of 60 mg BID on Days 1-28 of a 28-day cycle. The dose escalation will proceed to 75 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
46110311|NCT00589602|Procedure|peripheral blood stem cell transplantation|Peripheral blood stem cell transplantation
46110312|NCT00589602|Radiation|total-body irradiation (TBI)|Treatment will be delivered using 6MV photons twice daily for 3 days
46110313|NCT00794157|Drug|Indacaterol 150 μg capsules|Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
46110314|NCT00794157|Drug|Indacaterol 300 μg capsules|Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
46110315|NCT00794157|Drug|Placebo capsules|Placebo was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
46110316|NCT02607072|Drug|Acetylsalicylic acid (ASA)/aspirin 200 mg daily|
46110317|NCT02607072|Drug|Acetylsalicylic acid (ASA)/aspirin 100 mg daily|
46110318|NCT02607072|Drug|Placebo|
46110319|NCT03300648|Other|Mechanical ventilation|Intubation and mechanical ventilation for a maximum of 7 days
46110320|NCT03300648|Drug|Hypertonic saline|Intravenous 3 percent hypertonic saline for a maximum of 7 days
46110321|NCT04110093|Drug|Regorafenib and PD-1 inhibitor|All Colorectal cancer patients received regorafenib (80mg qd d1-d21,q4w) and PD-1 inhibitor. The patients could receive one type of PD-1 inhibitors according to oneself circumstance consideration including nivolumab (3mg/kg, ivgtt, q2w), Carelizumab (200mg, ivgtt, q3w), Sintilimab (200mg, ivgtt, q3w), Toripalimab(240mg ivgtt, q3w).
45469377|NCT05432167|Drug|Placebo|Patients will take placebo tablets by mouth once daily.
45838467|NCT02216305|Procedure|HAL-RAR|Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorrhoid. Other procedures will not be associated.
45838468|NCT02126969|Radiation|Low dose fractionated radiation - 80cGy with chemotherapy|Chemotherapy + 80 cGy of RT
45838469|NCT02126969|Drug|Docetaxel and Carboplatin AUC 6|Docetaxel 75 mg/m2 and Carboplatin AUC 6 without Radiation
46023679|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
46023680|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 21 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
46110322|NCT02607150|Other|Cerebral Oxygenation Changes|Monitor cerebral oxygenation changes in patients receiving blood transfusions who are undergoing spinal fusion surgery.
46110323|NCT03180918|Procedure|testicular tissue biopsy|testicular tissue biopsy during general anesthesia
45838470|NCT02121743|Device|strattice|use of a strattice
45838471|NCT02121743|Procedure|No strattice|no use of a strattice
46110324|NCT03161652|Drug|DME lactose pill|Patients with DME will take placebo orally 3 times a day (TID) for 8 weeks.The placebo is taken on top of standard therapy for diabetes and blood pressure control.
46110325|NCT03161652|Drug|DME levosulpiride|Patients with DME will take levosulpiride (75 mg/day) orally TID for 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
46110326|NCT03161652|Drug|DR lactose pill|Patients with non-proliferative DR will take a lactose pill (placebo) orally TID for 8 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
46110327|NCT03161652|Drug|DR levosulpiride|Patients with non-proliferative DR will take levosulpiride (75 mg/day) orally TIDfor 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
46110328|NCT03161652|Drug|DR vitrectomy lactose pill|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will have to take a lactose pill (placebo) orally TID for one week. The last placebo pill will be taken on the morning of the day vitrectomy is performed. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
46110329|NCT03161652|Drug|DR vitrectomy levosulpiride|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will take levosulpiride (75 mg/day) orally TID for one week. The last pill will be taken on the morning of the day vitrectomy is performed. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
46023681|NCT04496947|Behavioral|Stress Reduction|"The stress reduction program is a multimodal mind-body resiliency program that incorporates 3 core components into each session:~Elicitation of the Relaxation Response (RR) through mind-body techniques;~Discussion about stress awareness to learn how to identify personal stressors and experiences of stress; and~Coping strategies and adaptive perspective-taking to promote positive well-being."
46023682|NCT02817373|Other|Ultrasound scan performed through a vaginal probe|5-8 minute scan recording : endometrial thickness, endometrial pattern, endometrial -myometrial junction appearance, subendometrial wave contractions (presence and number), endometrial surface area
46110330|NCT03161652|Drug|DME plus ranibizumab lactose pill|Patients with DME with conventional intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a lactose pill (placebo) orally TID for 24 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
46110331|NCT03161652|Drug|DME plus ranibizumab levosulpiride|Patients with DME with receive intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a levosulpiride (75 mg/day) orally TID for 24 weeks. The study medication is taken on top of standard therapy for diabetes and blood pressure control.
46110332|NCT00588237|Drug|Paclitaxel,Cisplatin, Bevacizumab|IV paclitaxel, followed by IV Bevacizumab on Day 1. Bevacizumab treatment will begin cycle 2, day 1. IP cisplatin will be given on Day 2, and IP Paclitaxel on Day 8. Subjects will receive up to six cycles of therapy, or until disease progression or unacceptable toxicity.
46110333|NCT02605746|Drug|ceritinib 750mg|
46110334|NCT02604381|Dietary Supplement|Glucosamine Sulfate Potassium Chloride/Standardized Ginkgo Biloba Extract|
46110335|NCT02604381|Other|Placebo|
46110336|NCT04109781|Procedure|Microscope assisted discectomy|Microdiscectomy
46110337|NCT05610033|Device|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
46110338|NCT04109859|Drug|Saline|When using saline, if found mean arterial pressure <65mmHg, Cardic Output>4L/min, Sequential Vascular Response<800 (dyne×sec)/cm, starting dose of norepinephrine 0.04ug/min/kg
45598568|NCT03520543|Drug|[11C]Yohimbine (Part B1) and [11C]Yohimbine + clonidine (Part B2)|"Part B1 : Test Retest Variability will be assessed on percent difference in the binding potential following [11C]Yohimbine PET scan (IV bolus injection of [11C]Yohimbine at a dose of 370 MBq ± 10%) obtained at least 1 week after [11C]Yohimbine PET scan of part A.~Part B2 : Occupancy of alpha2-adrenergic receptors in brain by clonidine will be evaluated by comparing the binding potential of [11C]Yohimbine (IV bolus injection of [11C]Yohimbine at a dose of 370 MBq ± 10%) after single oral dose of clonidine (0,15mg) to the binding potential of [11C]Yohimbine obtained at baseline (part A)."
46023683|NCT04279210|Device|Platelet-rich plasma|The RegenKit-THT (RegenLab SA, Switzerland) was used to separation of plasma and blood cells. 3mL PRP was extracted from the bottom of the plasma. PRP was injected into anterior vaginal wall, near external urethral sphincter, and into endopelvic fascia.
46023684|NCT02817295|Other|clinical measurements|follow up on the number of complications, revisions, hospitalization and co-morbidities
45838472|NCT02099188|Drug|Cisplatin|80 mg/m2 or 33 mg/m2/day or 100 mg/m2 - Concentrate for solution for infusion
45838473|NCT02099188|Drug|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
46023685|NCT00957424|Behavioral|telephone-based intervention|10-15 minute web-based survey on a computer
46023686|NCT00957424|Drug|nicotine replacement therapy|One week supply
46023687|NCT00957424|Other|informational intervention|
46023688|NCT00957424|Other|internet-based intervention|
46023689|NCT00957424|Other|questionnaire administration|Given out week 2, 3 and 4.
46023690|NCT02817061|Device|Omnilux|The Omnilux LED array sources can be changed to emit different wavelength.
45838474|NCT02099188|Drug|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
45838475|NCT02099188|Drug|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
45838476|NCT02099188|Drug|Adriamycin|20 mg/m2/day - Powder for solution for infusion
45838477|NCT02099188|Drug|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
45838478|NCT02099188|Drug|Leucovorin|250 mg/m2/day - Powder for solution for infusion
46023691|NCT02818855|Procedure|Coronally advanced flap (CAF)|"The test group will be treated by means of the association of Collagen Matrix + Coronally Advanced Flap. As treatment, the control group will receive the association of a subepithelial Conjunctive Tissue Graft + Coronally Advanced Flap.~The aim of both procedures will be to obtain root coverage. All these procedures will be performed in a standardized manner."
46023692|NCT02818855|Drug|Collagen Matrix|A new collagen membrane
46110339|NCT04109859|Drug|Methylene Blue|Patients in the methylene blue group were given methylene blue before anesthesia and continued intraoperative pumping
46110340|NCT04010058|Device|LIDCO CNAP device|The LiDCO CNAP device (referred to as CNAP in this document) provides continuous cardiac output non-invasively, without the requirement for an arterial catheter. It uses a dual finger cuff in addition to a standard arm cuff (familiar to everyone who's had their blood pressure checked) and it transforms infrared plethysmographic signals into continuous blood pressure information. It uses an algorithm to derive cardiac output-related parameters. In recognition of the potential difference between the derived values and any measured values, it refers to some of its values as 'nominal' values. It has been evaluated in a range of surgical populations8-11 a post-operative cohort12, and a haemodynamically unstable critical care population13. In a population of patients undergoing endoscopy there was increased detection of episodes of hypotension compared with standard measures.
46110341|NCT00790023|Drug|80 mcg Ciclesonide|80 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
46110342|NCT00790023|Drug|160 mcg Ciclesonide|160 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
46110343|NCT00790023|Drug|Placebo|Placebo HFA Inhaler once daily (one actuation per nostril)
46110344|NCT00588822|Biological|Rituximab|Rituximab will be given as a 375 mg/m^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22).
46110345|NCT04115202|Procedure|lumbar arthrodesis|two approaches anterior versus posterior, optimally by leaving physicians free to use them as they do daily without modifying their procedures
45598569|NCT02227511|Dietary Supplement|Fruits|Randomization to extra fruit or nuts as snacks
45598570|NCT02227511|Dietary Supplement|Nuts|
46110346|NCT05563467|Drug|Pembrolizumab 25 MG/ML [Keytruda]|The treatment scheme will be based on pembrolizumab administered intravenously in cycles of every 3 weeks 200 mg, with supportive treatment with steroidogenesis inhibitor (metyrapone or ketoconazole) for adrenocortical carcinoma producing cortisol.
45838479|NCT02099188|Radiation|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~Particle boost with ENI:~HR-PTV: carbon ions 18 - 21 Gy (relative biological effectiveness, RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~Photons boost with ENI. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
46023693|NCT02818855|Procedure|Subepithelial connective tissue graft|Connective tissue graft
46023694|NCT04278976|Other|Implementation of CoBaTrICE|"The implemention of CoBaTrICE will include the three following essential elements:~Training the trainers. In order to provide high quality feedback to guide development of competence, tutors will receive a course in formative assessment, debriefing techniques, and effective feedback.~Workplace-based assessment (WbA) to promote learning and to guarantee that the predefined competences and skills are effectively acquired. Current Wb observation methods such as mini-clinical examination exercise, direct observation of procedural skills and multisource-feedback 360º will be used.~The use of an electronic portfolio specifically created as a personal collection of training documents that includes the record of formative assessments, activities, and the levels of competence achieved. The portfolio will help monitor progress of trainee's skills development and learning experiences contributing to an effective assessment, self-reflection and control of the learning process."
46110347|NCT03051984|Device|Neuromuscular electrical stimulation|NMES will be conducted on the quadriceps of the operative leg using a portable stimulation device, starting within 48-72 hrs of surgery. The operative leg will be immobilized at a neutral angle (~30º), with electrodes affixed to the anterior surface of the thigh. Symmetrical, biphasic pulses (400 µs duration at 50 Hz) will be used, with a duty cycle of 25% (10 s on, 30 s off), with patient-selected stimulation intensity to cause visible contractions below pain threshold. NMES sessions will occur 5 d/week, twice daily for 45 min (5 min warm-up) for 5 wks.
45838480|NCT02099188|Radiation|Radiotherapy - Patients not needing ENI|"Treatment with particles. IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
45838481|NCT02099188|Radiation|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~Particle boost. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
46110348|NCT00914706|Other|P-PROMPT|P-PROMPT is a web-based chronic disease management system. The system will help to ensure that all patients have up-to-date laboratory monitoring and visits as recommended by the Canadian Diabetes Association Guidelines.
46110349|NCT00589914|Drug|RISPERDAL CONSTA|RISPERDAL CONSTA: Type=exact number, unit=mg, number=25, 37.5, or 50, form=suspension for injection, route=Intramuscular use. One i.m. injection of RISPERDAL CONSTA 25-50 mg eq every 2 weeks at V4, V6, V7, V8, V9, and V10. PALIPERIDONE PALMITATE PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 2 weeks at Baseline and at V4, V7, and V9. RISPERIDONE: Type=up to, unit=mg, number=1 to 6, form=Tablet, route=Oral Use. One tablet for the first 4 weeks (28 days) of the DB treatment period.
45838482|NCT02099175|Drug|Cisplatin|80 mg/m2 or 33 mg/m2 or 100 mg/m2 - Concentrate for solution for infusion.
45838483|NCT02099175|Drug|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
45838484|NCT02099175|Drug|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
45838485|NCT02099175|Drug|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
45838486|NCT02099175|Drug|Adriamycin|20 mg/m2/day - Powder for solution for infusion
45838487|NCT02099175|Drug|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
46023695|NCT02818621|Drug|Group Dex (dexmedetomidine)|1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure
46023696|NCT04642651|Drug|Dexmedetomidine|Patients in the dexmedetomidine group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and 1.0 μg/kg dexmedetomidine, in a total volume of 20 ml.
46110350|NCT00589914|Drug|Paliperidone palmitate|PALIPERIDONE PALMITATE: Type=exact number, unit=mg, number=50, 100, or 150, form=suspension for injection, route=Intramuscular use. One i.m. injection of Paliperidone palmitate 50-150 mg eq every 4 wks at Baseline, V4, V7, and V9. RISPERDAL CONSTA PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 4 weeks at Baseline, V4, V7, and V9.
46110351|NCT00789555|Drug|Olopatadine hydrochloride 0.6% nasal spray (PATANASE)|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
46110352|NCT00789555|Other|Olopatadine nasal spray vehicle, pH 3.7|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
46110353|NCT00789555|Other|Olopatadine nasal spray vehicle, pH 7.0|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
46023697|NCT04642651|Drug|Placebo|Patients in the control group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and normal saline, in a total volume of 20 ml.
46110354|NCT04009902|Behavioral|Beck Depression Scale and Pittsburgh Sleep Quality Index|postoperative depression and sleep disorders in patients with endometriosis will be evaluated
46110355|NCT03905460|Diagnostic Test|Point-of-care ultrasound|Focused ultrasound of the heart, lungs and pleurae
46110356|NCT04112472|Device|EYESTAR 900|EYESTAR 900 is an optical biometry device used to create a geometrical representation of the eye by means of optical interferometry. The intervention are optical, non-contact examinations with the investigational device EYESTAR 900 and comparative device(s). Results of the examinations serve to compare the performance data of the investigational device with those of the comparative devices.
45838488|NCT02099175|Drug|Leucovorin|250 mg/m2/day - Powder for solution for infusion
45838489|NCT02099175|Radiation|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"Particle boost with ENI:~HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~Photons boost with ENI:~HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
46023698|NCT01061151|Drug|Zidovudine (ZDV)|300 mg twice daily
46023699|NCT01061151|Drug|Nevirapine (NVP): Antepartum Mothers|200 mg at onset of labor
46110357|NCT04115046|Device|ShearWave Elastography (SWE) in Endoscopic Ultrasound (EUS)|ShearWave Measurement is a software option available on the ARIETTA 850 that uses transient pulses to generate shear waves in the body. The tissue's elasticity is directly deduced by measuring the speed of wave propagation.
45598571|NCT02355483|Device|Unenhanced abdominal Computed Tomography|Systematic Unenhanced abdominal Computed tomography
45838490|NCT02099175|Radiation|Radiotherapy - Patients not needing ENI|"Treatment with particles IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 54-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
46023700|NCT01061151|Drug|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail|200 mg/300 mg x 2 tablets at onset of labor or as soon as possible thereafter; 200 mg/300 mg orally each day after delivery for 7 days or the date of the Week 1 visit (up to 14 days), whichever is later.
46110358|NCT04115046|Device|FibroScan|manufactured by Echosens
46023701|NCT01061151|Drug|Lamivudine-Zidovudine (3TC-ZDV)|150 mg/300 mg twice daily
46023702|NCT01061151|Drug|Lopinavir-ritonavir (LPV-RTV)|400 mg/100 mg twice daily beginning at >= 14 weeks gestation; 600 mg/150 mg twice daily beginning at >= 28 weeks gestation or at next visit (during third trimester) through delivery; 400 mg/100 mg twice daily after delivery up to 14 days postpartum.
46023703|NCT01061151|Drug|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])|200 mg/300 mg
46110359|NCT04115046|Device|ALOKA ARIETTA 850 -|manufactured by Hitachi Healthcare - included on the system is the ShearWave measurement software
46110360|NCT00451321|Drug|Otelixizumab|Infusion
46110361|NCT03770455|Drug|Avelumab|Avelumab 10mg/kg every 2 weeks (Q2W) + 2nd generation ADT
46023704|NCT01061151|Drug|Nevirapine (NVP): Infant short-course|Oral suspension (dosing according to birth weight) once a day through 42 days of age or through the week 6 visit, whichever is later.
46023705|NCT01061151|Drug|Nevirapine (NVP): Infant extended|Oral suspension (dosing according to birth weight) once a day from 6 (up to 14) days of age until there was no longer any risk of MTCT or until the end of follow-up (104 weeks), whichever came first.
46023706|NCT01061151|Other|No Intervention|"Women registered before/during labor received the full Antepartum Arm A regimen.~Women registered after labor, and who received nevirapine outside of the study, received the Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail."
46110362|NCT03770455|Drug|2nd generation ADT (abiraterone or enzalutamide)|2nd generation ADT (abiraterone or enzalutamide)
46110363|NCT01025869|Device|Cinatra™ Corolimus Eluting Coronary Stent System|Stent implantation
46110364|NCT01026025|Device|Duet TRS|This is a single arm study.
45598572|NCT02231489|Drug|JNJ-42756493 Tablet|Participants will receive 10 mg of JNJ-42756493 tablet as single oral dose on Day 1 of each treatment period.
45598573|NCT02231489|Drug|JNJ-42756493 Capsule|Participants will receive 10 mg of JNJ-42756493 capsule as single oral dose on Day 1 of each treatment period.
45469378|NCT02920866|Behavioral|Functional Strength Integration (FSI)|FSI intervention involves strengthening of the hip musculature combined with focused techniques emphasizing early initiation of hip muscle recruitment to stabilize the pelvis, integrating strength and movement pattern training to maximize functional recovery. The FSI program consists of therapeutic exercise in 3 domains: pelvic stability (PST) training, functional training (FT), and strength training (ST). PST includes early surgical-limb weight bearing and core muscle strengthening, progressively increasing in difficulty based on performance benchmarks and therapist monitoring. FT focuses on gait and stair climb exercise, progressing to higher level agility training. ST includes progressive, resistance exercise to improve lower extremity muscle strength. The ST exercises include use of weighted pulleys/weight-training machines. Therapists will determine an 8-rep max for muscle groups and weight will be increased by 10% every 2 weeks to maximize hypertrophy and strength gains.
45838491|NCT02099175|Radiation|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~Particle boost:~HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.~Concomitant chemotherapy will be administered only in case of radiotherapy with photon beams exclusively."
45838492|NCT01946074|Drug|paclitaxel|Paclitaxel will be administered by intravenous infusion.
45838493|NCT01946074|Drug|FOLFIRI|5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion.
46023707|NCT01061151|Other|Discontinue triple ARVs|ARVs were discontinued. When protocol specified criteria were met, mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
46110365|NCT01026259|Other|Warming of surgical incision|A warming pack (chemical activation) is applied to the dressing over the surgical incision, warming to 38 degrees C, for a period of 90 minutes times 6 treatments. The first treatment occurs in the PACU.
46023708|NCT01061151|Other|Continue triple ARVs|Mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
46110366|NCT01026259|Other|Warming dressing without actual warming|The same type of surgical incision dressing is used but no warming treatments are administered.
46110367|NCT03754465|Biological|ALLO-ASC-DFU|Application of ALLO-ASC-DFU Sheet to diabetic foot ulcer
46023709|NCT02818543|Drug|LYC-30937|
46023710|NCT02816047|Other|Registry|Observational study to describe WCD indications, event rates, inappropriate shock rates and follow up (including ICD rate, shock rate, morbidity and mortality) in all Austrian WCD patients
46110368|NCT03754465|Procedure|Hydrogel SHEET(Vehicle control)|Application of Hydrogel SHEET to diabetic foot ulcer
46110369|NCT03753997|Behavioral|Treatment by a diabetes educated psychologist|Patients will meet a diabetes educated psychologist. There will be a minimum of 5 meetings during the first 3 months and then in the following 6 months there will be a minimum of 2 meetings. More meetings will be scheduled if needed.
46110370|NCT01026337|Genetic|mutation analysis|Correlative study
46110371|NCT01026337|Other|pharmacological study|Correlative study
46110372|NCT01026337|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
46110373|NCT01026337|Drug|sunitinib malate|Given orally
46110374|NCT01026337|Other|immunohistochemistry staining method|Correlative study
46110375|NCT01026337|Other|laboratory biomarker analysis|Correlative study
46110376|NCT03746275|Drug|Rivaroxaban (BAY59-7939, Xarelto)|2.5 mg twice daily
45838494|NCT01946074|Drug|ABT-165|ABT-165 will be administered by intravenous infusion at escalating dose levels.
45838495|NCT01946074|Drug|ABBV-181|ABBV-181 will be administered by intravenous infusion.
45838496|NCT01898637|Other|Augmented pulse oximetry using incentive spirometer.|Augmented pulse oximetry using incentive spirometer.
45838497|NCT01898637|Device|Incentive spirometer.|The incentive spirometer is a simple passive device that measures the amount of air a person can inhale.
45838498|NCT01840150|Procedure|breath test|Undergo NA-NOSE breath test
45838499|NCT01840150|Other|laboratory biomarker analysis|Correlative studies
46110377|NCT03746275|Drug|Acetylsalicylic acid|75 - 100 mg once daily according to local label
46110378|NCT01026415|Drug|brentuximab vedotin|1.8 mg/kg IV every 21 days
46110379|NCT01026415|Drug|rifampin|600 mg/day PO
46110380|NCT01026415|Drug|midazolam|1 mg IV
46110381|NCT01026415|Drug|ketoconazole|400 mg/day PO
46110382|NCT01026415|Drug|brentuximab vedotin|1.2 mg/kg IV every 21 days
46110383|NCT03731611|Procedure|Umbilical Cord Milking|Umbilical cord milking (UCM) is typically performed by placing the infant below the level of the placenta. The cord is held at 20-25 cm distance from the baby and milked vigorously towards the umbilicus for 3 times at a speed of 10 cm/sec. After completion, the cord is clamped, and the neonate is handed to the resuscitation team.
46110384|NCT01026649|Procedure|Central venous catheterization|Approach the internal jugular vein in a traditional one stage fashion during central venous catheterization
46110385|NCT01026649|Procedure|Central venous catheterization|Approach the internal jugular vein in a 2 stage fashion during central venous catheterization
45469379|NCT02920866|Behavioral|Control Group (CON)|Observed practice patterns from previous investigations and discussion with physical therapists indicate that patients receive rehabilitation services during the 2-3 day hospital stay after THA, but not routinely after hospital discharge. Yet, to control for attention and volume of rehabilitation for the FSI group, patients in the control group will attend outpatient physical therapy for 14 visits (40 minute sessions) over 8 weeks. This control program will mimic the typical postoperative experience for patients in our community, in which patients independently manage their activity. This program will focus on patient education, functional ADL training, and therapeutic exercise. However, the activities in the exercise domain will be limited to low load exercise such as isometric muscle exercise, range of motion (ROM), and flexibility activities. These activities are specifically designed to mirror usual care activity.
45469380|NCT03415438|Diagnostic Test|Visual Analogue Scale|intensity of pain perception patients feel
45469381|NCT03415438|Diagnostic Test|posterior capsule tightness|tape measurement for posterior capsule tightness with patients lying at side and horizontally adducting their shoulder.
45469382|NCT03415438|Diagnostic Test|shortness tests for lumbar movements|tape measurement for lumbar movements
45469383|NCT03415438|Diagnostic Test|range of motion tests for lumbar movements|range of motion measurements for lumbar flexion, extension and lateral flexion with goniometer.
46110386|NCT01026727|Drug|MPC-4326 plus a 2-3 drug optimized background regimen (OBR)|For treatment arm #1: the MPC-4326 dose will be selected based on the inclusion of raltegravir (i.e., will be limited to 300 mg BID) or inclusion of darunavir (i.e., will be assigned 400 mg BID) in the OBR. If both raltegravir and darunavir are included in the OBR for a subject, the subject will be limited to 300 mg BID
45469384|NCT03415438|Diagnostic Test|The thoracolumbar fascia length test|patient sitting straight with shoulders at horizontal plane, both the arms are asked to rotated with primarily spinal rotation. the degree of rotation gives idea about the thoracolumbar fascia length
46110387|NCT01026727|Drug|3-4 commercially available antiretroviral drugs|For treatment arm #2: the antiretroviral regimen, dosage and frequency will be selected by the investigator.
46110388|NCT00802464|Biological|Herpes zoster vaccine GSK1437173A|2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)
46110389|NCT00802464|Biological|Placebo|2 vaccinations at Months 0 and 2 with placebo
45469385|NCT03415438|Diagnostic Test|Modify Schober test|tape measurement of spinal flexion between designated regions
45469386|NCT01144247|Drug|alloreactive CTL|cellular immunotherapy with alloCTL
46023711|NCT05649553|Behavioral|Digital Game Based Diabetes Education|While creating the digital diabetes game, an agreement is made with a software company, and this company will be responsible for the software, repair, design and development of the game.The digital diabetes game covers the basic education topics of Type 1 diabetes. Expert opinion was obtained from experts in the field of Child Health and Disease Nursing for the suitability of the content of the training material. The name of the game site and how it will be used will be explained to the children in the intervention group by the researcher. In addition, the user names and passwords will be given to the children in the intervention group to enter the site. Children will be given 1 month to play with the digital diabetes game. Game Sections; What is Diabetes?Medical Nutrition Therapy in Diabetes, Insulin Therapy and Administration, Exercise and Physical Activity in Diabetes, Complications of Type 1 Diabetes Mellitus, Diabetes management at school
46110390|NCT04112082|Behavioral|Mobile Neurofeedback|Home-based neurofeedback training (downtrain theta, uptrain beta; training site: Cz) 4 times weekly for a 40 of total sessions over the ten-week training period. Session duration of 21 minutes for the first 20 sessions to 30 minutes for the last 20 sessions. Positive visual and auditory feedback when brainwaves are within the desired range.
45469387|NCT03874767|Behavioral|Patient Mobility|A team of two mobility technicians will switch between two units on a monthly basis. The unit staffed by the mobility technician will be referred to as the intervention unit, while the other will be referred to as the control unit. One unit will start as the control unit and will switch to being the intervention unit after one month. Similarly, the other unit will start as the intervention unit and will switch to becoming the control unit after one month. All patients present on a unit during the intervention period will be provided mobility technician support according to standardized clinical guidelines that have been developed by the care team and described below. Patients who are present on a unit at the time of cross-over will not be included in the analysis, but will either no longer receive mobility technician support (if crossing from intervention to control) or will start to receive mobility technician support (if switching from control to intervention).
45469388|NCT03620838|Drug|oral contraceptive pill, oral progesterone|ovarian endometrioma cyst excision
46110391|NCT04112082|Other|Treatment as Usual|Treatment plan as part of regular care at the ADHD clinic, which may include pharmacological intervention, cognitive behavioral therapy (CBT), a combination of pharmacological intervention and CBT, or no intervention. Care will often include pharmacological intervention, with the specifics (e.g., type of medication, dosage) determined by psychiatrist recommendation considering such factors as response to previous interventions, participant characteristics, and practical constraints. Most pharmacological interventions will be stimulants (e.g., methylphenidate) with various release mechanisms. Each participant will receive an individualized dose titration and follow-up plan, including clinic visits as needed (generally 1-2 visits over the 10-week intervention period); interventions may be switched in accord with clinical judgment.
46110392|NCT05752656|Other|Clinical examinations|Clinical examinations and administration of clinical scales
46110393|NCT02604966|Drug|Artesunate (AS) group|Oral treatment with AS at 4mg/kg/day for 3 days followed by three days of DHA - PPQ in order to insure total parasite clearance. Randomization is done by blocks of ten.
46023712|NCT04472143|Drug|Granisetron Transdermal Delivery System|A total of 60 patients with HER2-positive advanced breast cancer who are scheduled to receive pirotinib combined with capecitabine will be enrolled. A single transdermal patch will be applied to the subject' upper outer arm 24-48 hours before chemotherapy for 7 days. The observation period will be from the time of enrollment to 14 days (± 7 days) after the removal of granisetron patch.
46023713|NCT04303923|Procedure|Ultrasonography|The diameters of both the radial artery and the distal radial artery were measured by ultrasonography.
46110394|NCT02604966|Drug|DHA - PPQ group|Oral treatment with 3-day course of DHA - PPQ. Randomization is done by blocks of ten.
45838500|NCT01754610|Behavioral|Strengthening Family Coping Resources (SFCR)|"Trauma Version (15 weeks) and High Risk Version (10 weeks) are 2 hour sessions. Dinner will be provided at the start of group for all participants.~Activities will be conducted at each group to encourage family involvement. The treatment modules focus on family rituals and routine, strengthening families' collaborative coping, and resolution of the trauma(s) bringing the families to treatment. Activities will be both family-based and age-based."
46023714|NCT00634075|Drug|omega-3-fatty acids (Omegaven)|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
46023715|NCT00634075|Drug|placebo|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
46110395|NCT02605668|Behavioral|Intensified psychological intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 6 weeks (2 sessions per week/week 1 and 2, 3 sessions per week/week 3 und 4, 1 session per week/week 5 and 6)
46110396|NCT02605668|Behavioral|Standard intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 10 weeks (2 sessions per week/week 1 and 2, 1 session per week/week 3 to 10)
46110397|NCT00914160|Drug|Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)|
45469389|NCT03916367|Radiation|CT-guided Radioactive I-125 Seeds Implantation|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring.
45838501|NCT01716026|Drug|Bevazizumab intravitreal injection|Intravitreal injection of bevacizumab
45838502|NCT01715285|Drug|Abiraterone acetate|Abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day until disease progression, withdrawal of consent or unacceptable toxicity.
46023716|NCT01241552|Biological|MK-3415|A single IV infusion of MK-3415 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A)
46023717|NCT01241552|Biological|MK-6072|A single infusion of MK-6072 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
46023718|NCT01241552|Biological|MK-3415A|A single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A and 10mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
46023719|NCT01241552|Biological|Placebo|A single IV infusion of normal saline (0.9% sodium chloride)
46110398|NCT00914160|Drug|Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)|
46110399|NCT00914160|Drug|Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
46110400|NCT02605590|Drug|AIR DNase|
46110401|NCT02605590|Drug|Placebo|
46110402|NCT00450619|Radiation|Samarium Sm 153 lexidronam pentasodium|1 mCi/Kg given intravenous (IV)over 1 minute on day 8.
46110403|NCT00450619|Biological|Sargramostim|100 mcg/injection x 4 days given subcutaneously
46110404|NCT00450619|Biological|Recombinant vaccinia-TRICOM vaccine|2 x 10^8 PFU given subcutaneously on day 1.
46110405|NCT00450619|Biological|Recombinant fowlpox-TRICOM vaccine|1 x 10^9 PFU given subcutaneously on days 15 and 29
45469390|NCT03415360|Procedure|cryoablation|cryoablation of nerve responsible for phantom limb pain
45838503|NCT01715285|Drug|Prednisone|Prednisone 5 mg capsule will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
46023720|NCT01241552|Drug|SOC|Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
46023721|NCT04748523|Drug|Mirtazapine|arm to receive 15 to 30 mg of Mirtazapine for a period of 8 weeks.
46023722|NCT04748523|Drug|Placebo Oral Tablet|arm to receive 15 to 30 mg of Placebo for a period of 8 weeks.
46023723|NCT02817217|Drug|SP2086|SP2086 will be administered orally (by mouth) as 100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
46023724|NCT02817217|Drug|Valsartan|SP2086 will be administered orally (by mouth) as100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
46023725|NCT00948922|Drug|Bortezomib|AUTOLOGOUS ARM: Day -3 bortezomib (1.3 mg/m^2) as an intravenous push over 3 to 5 seconds (follows Melphalan infusion). ALLOGENEIC ARM: Day -3 bortezomib (1.3 mg/m^2) as an intravenous push over 3 to 5 seconds (follows fludarabine and melphalan infusion).
46023726|NCT00948922|Drug|Melphalan|AUTOLOGOUS ARM: Day -4 and Day -3 Melphalan 100 mg/m^2/day IV over 30 minutes. ALLOGENEIC ARM: Day -4, Day -3 Melphalan 70 mg/m^2/day IV over 30 minutes.
46023727|NCT00948922|Procedure|Autologous Stem Cell Transplant|Autologous Stem Cell Transplant: Autologous Peripheral Blood Stem Cell Rescue. Stem cell mobilization with granulocyte colony-stimulating factor (GCSF) at a dose of 10 μg/kg/day as per institutional standards. CD34+ peripheral blood stem cells will be collected following the administration of G-CSF as per institutional standards. Day 0 Infusion of autologous stem cells.
46023728|NCT00948922|Drug|Fludarabine|Days -6,-5,-4,-3 Fludarabine 30 mg/m^2/day IV
46023729|NCT00948922|Procedure|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant: Allogeneic Peripheral Blood Stem Cell Rescue. Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with GCSF mobilization and infused fresh to the recipients. Allogeneic donor stem cells may also be cryopreserved if they cannot be infused fresh.
46023730|NCT02817139|Device|TDCS|
46023731|NCT02858128|Other|IMAGING STUDY|Choline-PET/CT versus NMRscan comparative study
46023732|NCT04238065|Device|Caterna Virtual Reality|"Vivid interactive games of perceptual learning content, with artificial intelligent sound and scores to feedback vision and actions results, which can be connected to the supervision of cellphone softwareWechat to upload vision acuity and choose 2 eyes' video output automaticly."
46023733|NCT04238065|Device|Spectacles(Best optical corrected distance vision)|Each eye has best corrected vision spectacles with best corrected optical lens.
46023734|NCT04238065|Device|Patch|2 hours patch to the non-amblyopia eye if the other amblyopia eye is mild or moderate amblyopia; 6 hours patch to the non-amblyopia eye if the other amblyopia eye is severe abmlyopia
46110406|NCT03704857|Other|Foraminal Enlargement / Irrigating solutions / Filling materials|"Instrumentation with foraminal enlargement and various irrigation solutions and filling materials will be performed according to the allocated group.~The foraminal enlargement provides better results in the bacterial removal of the apical portion of the root canal. This instrumentation will be done with the Reciproc 40 or 50 system in the apical foramen, determined by the apical locator.~To contribute to disinfection of the root canal, sodium hypochlorite and chlorhexidine are the most widely used irrigators. Sodium hypochlorite has a broad antimicrobial spectrum and an effective ability to dissolve organic matter and necrotic tissue; while chlorhexidine shows substantivity and antimicrobial residual activity when used as an irrigating substance.~Besides that, MTA Fillapex or AH Plus will be used and the recommended filling technique will be lateral condensation."
46110407|NCT03704857|Other|Photobiomodulation|aPDT will be performed with 0.01% methylene blue solution and it will be inserted into the root canal for 5 minutes. The excess will be removed and irradiation will be performed inside the root canal with the red laser of Índio Gálio Alumínio Fósforo (660nm, Laser Duo, MMOptics, São Paulo, SP, Brazil) for 90 seconds. Laser therapy with Gallium-Aluminum-Arsenic infrared laser (808nm, Laser Duo, MMOptics, São Paulo, SP, Brazil) will be performed on the gingiva from the vestibular face and on the palatal / lingual face, both located in the periapical region for 40 seconds.
46023735|NCT02620852|Other|Complete a health questionnaire|Complete a health history questionnaire.
46023736|NCT02620852|Device|Provide a saliva sample for genetic testing|Provide a saliva sample for testing of 9 genes and a panel of single nucleotide polymorphisms (SNPs) that influence breast cancer risk
46023737|NCT02620852|Other|Screening advice based on a comprehensive risk assessment|Receive a screening schedule recommendation
46023738|NCT02620852|Other|Screening advice based on a basic risk assessment|Receive a screening schedule recommendation
45469391|NCT03845751|Drug|HIFU hemi-ablation combined with ADT.|Hemi-ablation of the cancer-harbouring prostatic lobe will be carried out using HIFU energy. Short-term 3-month ADT will be administered concomitantly. Short-term ADT is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone [LHRH] agonist). The ADT protocol starts within 1 month prior to the scheduled HIFU session
45598574|NCT02231489|Drug|JNJ-61818549|Participants will JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, after 2 hours of administration of JNJ-42756493 tablet/capsule on Day 1 Treatment Period 1.
45838504|NCT01715285|Other|Androgen deprivation therapy (ADT)|All participants will receive stable regimen of ADT, that is, lutenizing hormone releasing hormone (LHRH) agonists or surgical castration according to local guidelines until disease progression, withdrawal of consent or unacceptable toxicity.
45838505|NCT01715285|Drug|Abiraterone acetate Placebo|Placebo matched to abiraterone acetate will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
45838506|NCT01715285|Drug|Prednisone Placebo|Placebo matched to prednisone will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
45469392|NCT03760861|Device|Prototype Microcapsule Treatment|The subject will be sedated and using an endoscope, a prototype microcapsule will be placed into the gastric corpus. Then, an external handheld magnet will be applied to inflate the balloon encapsulated in the microcapsule. Upon ascertaining the full inflation based on the endoscopic visualization, the investigator will wait another 10 minutes after that to observe how the subject feels before manually puncturing the balloon with needle knife, and retrieving the punctured balloon with the RothNet through the mouth.
45469393|NCT04890743|Other|Kinesiotherapy combined with electrotherapy (Convenctional TENS method).|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Conventional TENS method).
46023739|NCT04237909|Biological|PRP injection into at least one ovary|The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into at least one ovary using a 35 cm 17 G single lumen needle. The injection will be done underneath the ovarian cortex to the subcortical and stromal areas. Approximately 2-4cc of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30-40 minutes and also be discharged home on the same day.
46023740|NCT04237831|Drug|BMS-986259|Specified Dose on Specified Days
46023741|NCT00634309|Drug|Candesartan|
46023742|NCT00634309|Drug|Placebo|
46110408|NCT03704857|Other|Passive ultrasonic irrigation|PUI will be performed with Newtron P5 ultrasound (Satelec / Acteon Group, Bordeaux, France), at intensity 9 and with a 25mm (# 0.25, taper 0.00). The protocol of use will be 3 sequences of 20 seconds of ultrasonic activation with 2 ml of sodium hypochlorite 2.5% in each root canal.
45469394|NCT04890743|Other|Kinesiotherapy combined with electrotherapy (Pseudo-acupuncture TENS method).|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Pseudo-acupuncture TENS method).
46110409|NCT03704857|Other|OHIP-14|Patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
46023743|NCT01239992|Drug|Niacin/ Laropiprant|1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily
46023744|NCT02816905|Drug|0.1 % Dexamethasone|20 eyes are randomized to receive topical 0.1% Dexamethasone four times per day for 2 weeks.
46023745|NCT02816905|Drug|0.1% Fluorometholone|20 eyes are randomized to receive topical 0.1% Fluorometholone four times per day for 2 weeks.
46023746|NCT02816905|Drug|1% Rimexolone|40 eyes are randomized to receive topical 1% Rimexolone four times per day for 2 weeks. 20 of these eyes were the contralateral eyes of the patients who received 0.1% Dexamethasone in their first eye. The other 20 eyes were the contralateral eyes of the patients who received 0.1% Fluorometholone in their first eye
46023747|NCT02816827|Dietary Supplement|AG-01|Product to increase mental alertness
46023748|NCT02816827|Dietary Supplement|AG-05|Product to increase mental alertness
46023749|NCT02816827|Dietary Supplement|AG-06|Product to increase mental alertness
46023750|NCT02816827|Dietary Supplement|AG-07|Product to increase mental alertness
46023751|NCT01072539|Drug|tigecycline|As prescribed by physician in usual clinical practice
46023752|NCT01239680|Drug|Glutamine|Intravenous 25 grams once over 6 hours
46023753|NCT01239680|Drug|Ringer's Lactate|Intravenous 1 liter once over 6 hours
46023754|NCT01239680|Drug|Placebo (for Glutamine)|Given Intravenously in 1 liter Lactated Ringer's
46023755|NCT02816749|Procedure|Maggot debridement therapy|Participant will receive bio-bags treatment every 3 days until the wound heal completely, when wounds assessed.
46023756|NCT02816749|Procedure|Conventional Dressing Therapy|Participant will be disinfected by iodophor and dressed by gauze 3 days until the wound heal completely, when wounds assessed.
46023757|NCT05517590|Drug|Tranexamic acid|1 gram of tranexamic acid will be diluted into 100 ml of saline solution and administered at a rate of 100 ml/hr 10 minutes before the skin incision time.
46023758|NCT05517590|Drug|Saline|100 ml of saline solution will be administered at a rate of 100 ml/hr 10 minutes before the skin incision time.
46110410|NCT03704857|Other|Assessment of pain and edema|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
46110411|NCT03704857|Other|Assessment of periapical lesion|The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months.
46110412|NCT03704857|Other|Longevity of rehabilitations|The teeth will be rehabilitated with resin and glass fiber post. The longevity of rehabilitations will be performed clinically and radiographically for 24 months.
45469395|NCT04890743|Other|Kinesiotherapy combined with electrotherapy (Trabert ultrastimulation method)|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Trabert ultrastimulation method).
46110413|NCT03704857|Other|Cryotherapy|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
46110414|NCT03704857|Other|Ozone therapy|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
46110415|NCT00802074|Drug|Raltegravir|400mg BID
45469396|NCT04890743|Other|Kinesiotherapy combined with placebo electrotherapy|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and placebo electrotherapy.
45469397|NCT03415282|Drug|RVT-501 0.5% topical ointment|RVT-501 0.5% topical ointment twice daily (BID) for 4 weeks.
46023759|NCT04211857|Device|Round XTENDOBUTTON Fixation Device used in suture fixation of ligaments and tendons in conjunction with an ULTRABUTTON™ product or ENDOBUTTON™ device.|Round XTENDOBUTTON Fixation Device used in suture fixation of ligaments and tendons in conjunction with an ULTRABUTTON™ product or ENDOBUTTON™ device.
46023760|NCT02874885|Procedure|Biospecimen Collection|Undergo collection of blood sample
46023761|NCT05515094|Behavioral|Empowerment Counseling Intervention|The intervention entails case managers conducting first-line support (i.e., a brief psychosocial support session), and a safety and health assessment, adapted from current case management content and the Safe and Sound intervention.
46110416|NCT00802074|Drug|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
46110417|NCT00802074|Drug|Ritonavir|100 mg BID or QD
46110418|NCT03995719|Other|Preoperative education|65 patients were instructed to a preoperative stoma-education program
46110419|NCT03995719|Other|Postoperative education|73 patients, receiving the same information in postoperative period.
46110420|NCT04112004|Other|Collecting sodium reports and outcome measures|
45469398|NCT05276661|Dietary Supplement|TAC/Collagen gel|Apply it twice per day for 4 weeks
45469399|NCT05276661|Dietary Supplement|placebo lotion|Apply it twice per day for 4 weeks
45838507|NCT01705184|Drug|Cisplatin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles of each sequence
45838508|NCT01705184|Drug|Bevacizumab|7,5 mg/kg, IV (in the vein) on day 1 of each 21 day cycle until progression for each sequence
45838509|NCT01705184|Drug|Pemetrexed|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles for the 1st sequence and until progression for the 2nd sequence.
45838510|NCT01633502|Device|Conventional circulatory support|Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs.
45838511|NCT01633502|Device|Impella CP|Control group treated with Impella CP for a minimum of 48 hrs.
46023762|NCT05654077|Biological|CAR-T Cell Injection|intravenously once, and the dose group was 3.0 × 10^6cells/kg、9.0 × 10^6cells/kg、1.5 × 10^7cells/kg。
46023763|NCT05654077|Drug|Fludarabine|Fludarabine 25~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
46023764|NCT05654077|Drug|cyclophosphamide|250~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
46023765|NCT04303767|Drug|Casein phosphopeptide amorphous calcium phosphate|varnish containing calcium and phospate ions which act as a source for tooth remineralization
46023766|NCT04303767|Procedure|Atraumatic restorative treatment|excavation of dental caries and restoring with light cured Glass Ionomer Restoration
46023767|NCT02816671|Device|Surgical Stapler|Patients in whom the MicroCutter stapler was used during a thoracic surgical procedure.
46110421|NCT04112394|Other|local anesthetic injection|A linear ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. Local anesthetic mixture will be injected bilaterally into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS).
46110422|NCT04112394|Other|Standard perioperative and postoperative analgesia protocol.|Standard perioperative and postoperative analgesia protocol will be given consisting of paracetamol 1 gr IV and tenoxicam 20 mg IV initiated after induction of anesthesia. At the end of the operation patients will receive contramal 1 mg/kg IV before extubation. Postoperative pain levels will be determined by Numeric Rating Scale (NRS) system, 20 minutes intervals in the first hour and at 2th, 6th, 12th and 24 th hour. For the first hour in the postoperative care unit, tramadol 50 mg IV will be given for rescue analgesia with minimum 20 minutes between doses, in patients showing a NRS ≥ 4. Paracetamol 1 g / 12 hour will be given during ward follow-up. In the ward in patients showing a NRS ≥ 4 tramadol 50 mg IV will be given for analgesia.
46110423|NCT00450385|Drug|Rituximab|Rituximab 375 mg/m2 on day 1 for 6 to 8 cycles
46110424|NCT00450385|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV on day 1 for 6 to 8 cycles
46110425|NCT00450385|Drug|Doxorubicin|Doxorubicin 50 mg/m2 on day 1 for 6 to 8 cycles
46110426|NCT00450385|Drug|Prednisone|Prednisone 40 mg/m2 orally days 1-5, repeated every 21 days for 6 to 8 cycles.
45469400|NCT03766243|Behavioral|Brochure and DVD plus nursing training|"After recruitment for both groups of participants, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use.~The intervention consisted of stretching exercises and movements involving the mimic muscles to perform in front of a mirror. The control group could learn the standardized exercises for the mouth-opening through information brochure and the audio-visual DVD.~The experimental group was closely followed by the research nurse, an expert in Adult Education, who held 20-minute face to face meetings at baseline and at follow-up with the patients allocated to the experimental group. For both groups an information brochure and an audio-visual DVD were developed specifically for the study. The audio-visual DVD is available on the IDI-IRCCS institutional website."
45838512|NCT01599559|Other|observation|observation
46110427|NCT00450385|Drug|Vincristine|Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1 for 6 to 8 cycles
45469401|NCT03766243|Behavioral|Brochure and DVD only|"After recruitment for both groups of participants, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use.~The intervention consisted of stretching exercises and movements involving the mimic muscles to perform in front of a mirror. The control group could learn the standardized exercises for the mouth-opening through information brochure and the audio-visual DVD."
45469402|NCT01239953|Device|Coronary angioplasty using the paclitaxel-eluting balloon|Balloon angioplasty
45469403|NCT01239953|Device|Coronary angioplasty using the everolimus-eluting stent|Stent implantation
45469404|NCT03421522|Other|ICBN preservation surgery|"For participants randomized to the ICBN preserving technique, surgeons will perform axillary dissection in which the second ICBN, just inferior to the axillary vein, will be preserved. Surgeons will be asked to indicate whether the ICBN nerve was fully preserved, partially preserved, or sacrificed.~All study participants will receive anesthetic management at the discretion of the attending physician, which will be documented."
46023768|NCT01238900|Procedure|Endoscopic Retrograde Cholangiopancreatography (ERCP)|Endoscopic Retrograde Cholangiopancreatography (ERCP) with placement of metal stent in the bile duct
46023769|NCT04303299|Drug|Oral|Anti virus treatment
46023770|NCT02874963|Procedure|Surgical Periodontal Treatment|In the patient's with periodontal disease at least one tooth extraction will be performed.
46023771|NCT02874963|Device|Non Surgical Periodontal Treatment includes scaling root planing with UDS-J Ultrasonic Scaler.|Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included: full-mouth scaling and root planing (FM-SRP) with ultrasonic device (UDS-J Ultrasonic Scaler, Guilin Woodpecker Medical Instrument) and periodontal curets for mechanical debridement of the supra- and sub-gingival plaque and calculus.
46110428|NCT01026883|Other|Blood draw|A venous blood sample will be taken (15 ml). Blood will be collected in 5 tubes. To avoid hematocrit variations due to the blood draw procedure, the first tube will be discarded. After that, the tourniquet which is used for venipuncture will be removed and 4 EDTA tubes (each 3 ml) will be filled with blood for hematocrit determination, one tube will be sent to the Department of Laboratory Medicine, and the other ones will be processed at the Department of Clinical Pharmacology.
46110429|NCT01566019|Procedure|Tumoral biopsy|Every enrolled patient undergoes tumoral biopsy
46110430|NCT00588354|Drug|Clonidine|200 or 400 micrograms clonidine
46110431|NCT00588354|Drug|Triamcinolone hexacetonide|40 or 80 milligrams triamcinolone
46110432|NCT00588354|Drug|Lidocaine HCl|1 ml 2% lidocaine (20 mg/mL)
45838513|NCT01599559|Radiation|3D-Conformal Radiotherapy (3D-CRT)|Radiation treatment should start within 6-8 weeks after the end of chemotherapy.
45838514|NCT01285817|Drug|celecoxib, Vinblastine, Cyclophosphamide , methotrexate ,|
45838515|NCT01285479|Drug|Fingolimod|fingolimod 0.5 mg/day, including generic versions of fingolimod
45838516|NCT01250496|Drug|Aminophylline|75 mg of intravenous aminophylline
45838517|NCT01250496|Drug|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
46023772|NCT02874963|Drug|Non Surgical Periodontal Treatment includes post operative mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%)|Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%) for the 3 weeks after tooth extraction and cleaning.
46023773|NCT02818465|Other|Vascular calcifications by Xray|
46023774|NCT02818465|Other|Vascular calcifications by tomodentimetry|
46023775|NCT02818465|Biological|Blood sample withdrawn|
46023776|NCT02818309|Drug|Lesogaberan|120 mg bid
46023777|NCT02818309|Drug|Placebo|Placebo
46023778|NCT01238822|Drug|Methylphenidate|18 mg methylphenidate
46023779|NCT01238822|Drug|placebo|Placebo
46110433|NCT01566097|Device|Smoking Cessation Decision Aids|"The decision aids were developed through: 1) literature review; 2) qualitative interviews with Korean smokers from various backgrounds; 3) expert opinions. They were in the form of short educational videos (flash), displayed by Apple's iPad.~The decision aids contained the followings, in proper Korean social and cultural context:~Information on the risk of continued smoking and benefits of cessation~Messages that address common misbeliefs regarding smoking cessation services and medications~Information on possible smoking cessation options, their efficacy, side effects, costs, etc.~The choices given in the decisions aid were:~Behavioral only~Nicotine replacement therapy~Bupropion~Varenicline"
46110434|NCT04114968|Other|GP-based screening or HPV self-sampling|Women in the intervention group will receive an invitation for HPV-based cervical cancer screening by either 1) scheduling an appointment for a cervical cytology by the GP or 2) collect a cervico-vaginal sample themselves in their own home using a self-sampling kit.
46110435|NCT00449761|Drug|LBH589|
46110436|NCT00800982|Procedure|Narrow band (310-312 nm) ultraviolet light B phototherapy|Narrow band (310-312 nm) ultraviolet light B phototherapy 3 times a week during Weeks 12-24. NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff
46110437|NCT00800982|Drug|etanercept|Etanercept is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.
46023780|NCT01238822|Drug|Methylphenidate|36 mg methylphenidate
45469405|NCT01322191|Drug|Morphine|A single dose of morphine 0.1 mg/kg infused by syringe pump over 10 minutes; urine and blood sample frozen at -80 degrees Celsius
46023781|NCT01238822|Drug|Methylphenidate|54 mg methylphenidate
46023782|NCT04303455|Diagnostic Test|blood sampling|sampling serum renin
45469406|NCT03760705|Other|Data Collection|"Collection of data as detailed below:~Clinical data collected by SCDB~Clinical, administrative, pharmacy, financial data collected by each participating hospital~Administrative data collected by MOH~Data will be extracted and anonymized on a secure healthcare analytics platform~Collaboration with the MOH for collection of administrative and financial data~Analysis on how healthcare behavior is affected by education, socioeconomic level and other social or cultural factors.~Statistical Analysis by the bio statistical team. This team will be responsible for collecting and merging the collected data and will also ensure the quality of the data."
46023783|NCT02818387|Drug|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
46023784|NCT02818387|Drug|Remifentanil|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration.
46023785|NCT02818387|Drug|Midazolam|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.015 mg/kg administration 1 min after remifentanil infusion start.
46023786|NCT05296629|Drug|DFD-29|DFD-29 (40 mg) extended release capsules
45838518|NCT01134757|Biological|house dust mite and alternaria allergen bronchial challenge|2 ml of saline-dissolved lyophylised house dust mite or alternaria in concentration 5000 standard biological units (SBU/ml) The challenge is the only intervention. dosed in 6 steps of 5, 10, 20, 40, 80, and 160 SBU. 10 minutes after each step up a spirometry will be performed the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.
45838519|NCT01105975|Drug|LY2484595|Administered daily by mouth for 12 weeks
45838520|NCT01105975|Drug|Atorvastatin|Administered daily by mouth for 12 weeks
45838521|NCT01105975|Drug|Simvastatin|Administered daily by mouth for 12 weeks
45469407|NCT02776306|Other|Mirror Box therapy|In mirror box therapy the patient uses the reflection of their good arm to trick to brain into thinking that the effected arm is working.
45838522|NCT01105975|Drug|Rosuvastatin|Administered daily by mouth for 12 weeks
45838523|NCT01105975|Drug|Placebo for LY2484595|Administered daily by mouth for 12 weeks
45838524|NCT01105975|Drug|Placebo for Statins|Administered daily by mouth for 12 weeks
45838525|NCT00831623|Radiation|Proton Radiation|3 Cobalt Gray Equivalent (CGE) /Day to isocenter, one treatment per day, 5 days per week for 20 treatments (=60 CGE to isocenter/20 fractions)
45838526|NCT00831623|Radiation|Proton|As above
46023787|NCT05296629|Drug|Doxycycline|Doxycycline 40 mg capsules
46023788|NCT05296629|Drug|Placebo|Placebo capsules
46023789|NCT00634153|Other|Research Registry|We are asking for permission to allow us to place subject's past, current and future medical record information into a Surgical Gastrointestinal Disease Registry. By placing the medical record information of many subjects into a research registry, researchers will be able to conduct research studies directed at increasing our knowledge about Gastrointestinal Diseases.
46023790|NCT01238588|Drug|Sevelamer Carbonate (Renvela)|Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.
46023791|NCT04303143|Behavioral|Self-Hypnosis|Self-Hypnosis
46023792|NCT04303143|Behavioral|Direct Autonomic Experience Control|Direct Autonomic Experience Control. Use of learned mental tool/process to affect outcome measure of SUDS discomfort experience. (eg. Squeeze hand as pre-learned mental anchor to relieve discomfort in lower legs)
46110438|NCT01019395|Drug|Daptomycin|"Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion;~Group 2:Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion;~Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion."
45838527|NCT00651456|Drug|Standard Chemotherapy (Pemetrexed and Cisplatin)|"Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation Day 1 (D1=D22, 6 cycles)~Cisplatin 75 mg/m² Day 1 (D1=D22, 6 cycles)"
45838528|NCT00651456|Drug|Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab|"Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles)~Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles)~Bevacizumab 15 mg/kg D1 (D1=D22, until progression)"
46023793|NCT02818231|Other|Brushing of the olfactory cleft|Non invasive sampling of olfactory cleft cells, by brushing under local anesthesia during fiberendoscopy Form: survey of acceptability
46110439|NCT04115124|Behavioral|Participatory Action Research|The research will employ a Participatory Action research quasi-experimental pre-post test study design .
46110440|NCT00830960|Drug|Prasugrel|Oral, daily, 90 days
46110441|NCT00830960|Drug|Clopidogrel|Oral, daily, 90 days
46110442|NCT04114578|Other|Echocardiography|Echocardiography has become routinely used in the diagnosis, management, and follow-up of patients with any suspected or known heart diseases. It is one of the most widely used diagnostic tests in cardiology. It can provide a wealth of helpful information, including the size and shape of the heart (internal chamber size quantification), pumping capacity, and the location and extent of any tissue damage. An echocardiogram can also give physicians other estimates of heart function, such as a calculation of the cardiac output, ejection fraction, and diastolic function (how well the heart relaxes). The acquisition usually takes about 30 minutes.
46110443|NCT01026961|Drug|Phenylephrine HCL|Phenylephrine HCL 10mg
45838529|NCT00639639|Biological|tetanus toxoid|Given by injection
46023794|NCT00627003|Drug|Cabergoline|Cabergoline oral tablets administered once daily in the evening: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14, followed by a stable dose for an additional 3 weeks
45838530|NCT00639639|Biological|therapeutic autologous dendritic cells|Given intradermally
46023795|NCT00627003|Other|Placebo|Placebo oral tablets administered daily for 5 weeks
46023796|NCT04238611|Device|Microneedle|Lactate microneedle applied on the skin of participant
45838531|NCT00639639|Biological|therapeutic autologous lymphocytes|Given IV
45838532|NCT00591695|Procedure|Stent bridge to surgery + elective surgery|positioning in emergency of a metallic self-expanding stent followed, in case of successful colic decompression, by an elective surgical (laparoscopic or open) resection of the tumour
46023797|NCT04238611|Diagnostic Test|Blood lactate measurement|Serum lactate testing through conventional laboratory methods
46023798|NCT04238611|Other|Exercise regimen|Standardised aerobic exercise regimen
46023799|NCT02818153|Other|Self questionnaire for allergic rhinitis control|
46023800|NCT04238533|Other|eADAPT training|eADAPT training for myoelectric prosthesis users is the comparator training.
46023801|NCT04238533|Other|Conventional training|Conventional training with Myoboy has been the only training available to users.
45838533|NCT00591695|Procedure|Emergency Surgery|Emergency surgery performed in these ways: Resection followed by enterostomy (Hartmann procedure), 'On table' washing and primary anastomoses, Subtotal colectomy
45838534|NCT00280202|Procedure|Biopsy of the major carinal area|Biopsy performed intraoperatively
46023802|NCT05657509|Other|Functional training|Functional training Length: 12 weeks; Training duration: 60 minutes; Intensity: 50 to 70% in the last weeks' intensity will be 60 to 70%; 3 days per week. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes; Rest: 30 seconds rest between exercises and 1-minute rest between sets.
46110444|NCT01026961|Drug|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate|Phenylephrine HCL 10mg/Acetaminophen 500mg/Dimethindene Maleate 1mg
46110445|NCT05636982|Other|Telecare-based intervention program|A 3-month telecare-based intervention program
45838535|NCT00280202|Procedure|Biopsy of abnormal & suspicious areas of the bronchial tree|Biopsy performed intraoperatively
45838536|NCT00280202|Procedure|Evaluation of the tumor for DNA mutations|Tumor tissue is banked for future analysis.
46023803|NCT05657509|Other|No intervention|The Control group continues regular traditional training exercises for 12 weeks with a training duration of 60 minutes and three days per week.
46023804|NCT04238221|Drug|Doxofylline|Patients will receive a 4-week treatment with doxofylline 400 mg bid, in addition to their chronic usual inhalation therapy.
46023805|NCT02815423|Biological|UCMSCs|Transplatation of umbilical cord mesenchymal stem cells
46023806|NCT02815423|Biological|Percutaneous|Percutaneous injection
46023807|NCT01047501|Drug|AMR101 (ethyl icosapentate) - 4 g/day|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks
46110446|NCT01566253|Drug|Acetaminophen, ketoprofen, morphine|Acetaminophen 0.5g, maximum 4g by day, 48 hours ketoprofen 100 mg, twice a day, 48 hours Morphine 10 mg, maximum 90 mg by day, 36 hours
46110447|NCT01566253|Drug|Acetaminophen, ketoprofen,morphine|Acetaminophen 1g/100 ml IV, maximum 4g by 24 hours, 48 hours Ketoprofen IV, maximum 0,2 gram by 24 hours, 48 hours Morphine IV,maximum 60mg by 24 hours, 36 hours.
46110448|NCT01023763|Other|A structured training program|A structured training program in nursing homes in the intravenous treatment of dehydration and infections.
46023808|NCT01047501|Drug|AMR101 (ethyl icosapentate) - 2 g/day|AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks
46110449|NCT02604888|Other|MEXIS/M6S Patent - lotion against alopecia|For greatest problems 20 drops on the scalp per day for 6 months. For minor problems 10 drops on the scalp three times per week for 6 months.
46023809|NCT01047501|Drug|Placebo|Placebo 4 capsules/day for 12 weeks
46023810|NCT01238120|Drug|Ibuprofen|200 mg BID and 8 hours apart
46110450|NCT03849313|Drug|Adalimumab|"AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory diseases"
46110451|NCT04111614|Drug|Tofacitinib tablet|Single dose of tofacitinib 5 mg tablet
46110452|NCT04111614|Drug|Tofacitinib Oral Solution|Single 5 mL dose of tofacitinib oral solution (1 mg/mL)
46110453|NCT01019473|Drug|AFQ056|
45838537|NCT00280202|Procedure|Bronchoalveolar Lavage (BAL) for cytokine analysis|BAL performed intraoperatively
45469408|NCT03323736|Combination Product|Iontophoresis & tube placement|Subjects will receive active Tymbion iontophoresis and will have tubes placed in-office using the Tube Delivery System in all ears indicated for tube placement.
46023811|NCT01238120|Behavioral|Home-Based Exercise|A progressive walking and resistance band exercise program called Exercise for Cancer patient (EXCAP) for a 6 week period
46023812|NCT01238120|Drug|Placebo|200mg BID and 8 hours apart
45469409|NCT03323736|Device|Tube placement|Subjects will have tubes placed in the OR using the Tube Delivery System in all ears indicated for tube placement.
45469410|NCT03916289|Other|No intervention would be taken|No intervention would be taken. Patients enrolled would be managed by this tiered diagnosis and treatment system and receive standard treatment according to clinical guidelines of osteoporosis.
46023813|NCT05655481|Other|Aerobic and Resistance training with rehabilitation|Effects of home telerehabilitation program improve functional capacity variables
45469411|NCT03760549|Drug|Subjects were administered NasoVAX high dose|NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo
45838538|NCT00280202|Procedure|Correlation of flow cytometric & RT PCR for TNM stage|Tissues banked for future correlative studies
45838539|NCT00280202|Procedure|Analysis of lymph nodes|Tissues banked for future analysis
46023814|NCT05655481|Other|Health education|Telehealth and guidelines for the practice of physical activity and health education
46023815|NCT01237340|Drug|Saizen®|Single dose of Saizen® (recombinant human growth hormone, r-hGH) solution for injection will be administered subcutaneously for 26 weeks. Dosage regimen will be in accordance with marketed formulation of Saizen® (freeze-dried formulation), based on locally approved product labeling.
46023816|NCT02818075|Other|Mobile Phone Based Peer Support|Adolescents allocated to the experimental group will have access to all standard prenatal and postpartum community supports. In addition, mobile phone-based peer support (MPPS), which consists of support provided by a peer mentor via mobile phone (with both voice calling and Short Message Service text message capabilities) will be provided during pregnancy and for 12 weeks postpartum. Peer support is defined as a specific type of social support (informational, appraisal, and emotional support) that is provided by a peer mentor who possesses experiential knowledge of adolescent motherhood and is of similar age to the participant.
46023817|NCT02818075|Other|Usual Care|Participants allocated to the usual care group will not receive the peer support intervention but will have access to all standard community prenatal and postpartum support services such as 1) the Canada Prenatal Nutrition Program; 2) postpartum home visits / telephone support from a public health nurse; 3) postpartum appointments with midwives, obstetrician, family physician, and / or pediatricians, and 4) prenatal and postpartum support as needed from psychiatrists, psychologists, social workers, breastfeeding clinics, and community resources.
46110454|NCT01019473|Drug|Placebo|
46110455|NCT05633394|Device|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
46110456|NCT01023919|Device|Device: Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Cypher stent or YinYi stent randomly implanted in coronary artery disease
46110457|NCT04028622|Other|TCAD (telemedicine anesthesia consultation)|Patients in the TCAD (telemedicine anesthesia consultation) group, arrange their bookings on a website and realise their anesthesia consultation from a platform from home
45838540|NCT00079417|Drug|Carboplatin|Given IV
46023818|NCT04303533|Device|Neuro-Feedback EFP|Neurofeedback (NF) - is a treatment method based on learned self-modulation of neural activity in response to feedback of neural signal. Amygdala-EFP (EEG-finger-print, EFP) is an EEG-NF application that modulates amygdala response.
46110458|NCT03844087|Device|Multiplanar neuromuscular training|See arm description
46110459|NCT00830804|Drug|Raltegravir|400 mg tablet taken orally twice daily
46110460|NCT00830804|Drug|Darunavir/Ritonavir|800 mg Darunavir/100 mg Ritonavir tablet taken orally once daily
45838541|NCT00079417|Procedure|Cryosurgery|
46110461|NCT00789477|Procedure|Laser Photocoagulation|laser every 16 weeks as needed
46110462|NCT00789477|Drug|Intravitreal Aflibercept Injection|
46110463|NCT01024075|Drug|Dexamethasone|4cc of Dexamethasone and 4cc of Saline mixed with Sinufoam
46110464|NCT01024075|Drug|Saline|8cc of Saline mixed with Sinufoam
45469412|NCT03426046|Procedure|Partial Pulpotomy|Partial removal of inflamed pulp tissue in cariously exposed teeth
45469413|NCT03426046|Drug|Pulp Capping Agents|Biocompatible materials
45469414|NCT03769831|Drug|SHR2285|Ascending dose oral adminstration
46110465|NCT05756348|Device|Marathon® XL No Sting Cyanoacrylate Skin Protectant and 3M™ Cavilon™ Advanced Skin Protectant|All participants will receive both device interventions listed above.
45469415|NCT03769831|Drug|Placebo|Ascending dose oral adminstration
45469416|NCT01310530|Radiation|Proton Beam Radiotherapy|Daily proton beam radiotherapy is delivered to the site of the breast tumor in ten treatment sessions over two week as an outpatient.
46110466|NCT00913874|Drug|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
46110467|NCT00913874|Drug|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
46023819|NCT00634231|Biological|AdV-tk|
46023820|NCT00634231|Drug|valacyclovir|
46023821|NCT00634231|Radiation|Radiation|
46110468|NCT04106661|Other|Tai Chi|Physical activity requiring slow, controlled whole body movement and weight shifting.
46110469|NCT00796614|Drug|tamsulosin hydrochloride|Oral
46023822|NCT02816593|Drug|hydrogen peroxide 6%|Office; hydrogen peroxide 6%, 3 sessions of 20 minutes of application
46023823|NCT02816593|Drug|hydrogen peroxide 15%|Office; hydrogen peroxide 15%, 3 sessions of 20 minutes of application
46023824|NCT02816593|Drug|Carbamide Peroxide 10%|Homemade; Carbamide Peroxide 10%, 2 hours per day for 21 days
46023825|NCT04237987|Drug|Interleukin-2|Interleukin-2 was produced by Beijing Shuanglu Pharmaceutical Co., Ltd
46110470|NCT00796614|Drug|Placebo|Oral
46110471|NCT02603445|Drug|BCL201|
45838542|NCT00079417|Procedure|Infrared Laser Therapy|
46110472|NCT02603445|Drug|Idelalisib|
45838543|NCT00079417|Radiation|Iodine I-125|Undergo radioactive therapy
45838544|NCT00079417|Radiation|Radiation Therapy|Undergo radioactive therapy
45838545|NCT00079417|Radiation|Ruthenium Ru-106|Undergo radioactive therapy
46110473|NCT04106505|Behavioral|Biofeedback training via app on smartphone|Biofeedback training as described in biofeedback arm.
46110474|NCT04106505|Behavioral|Sham-biofeedback training via app on smartphone|Sham-biofeedback training as described in sham-biofeedback arm.
46110475|NCT00448747|Drug|AEZS-130 (formerly ARD-07)|A single oral administration of AEZS-130 as Growth Hormone Stimulation Test
46110476|NCT00448747|Drug|L-ARG+GHRH|A single administration of L-ARG+GHRH (iv bolus) followed by a 30min infusion of L-ARG as Growth Hormone Stimulation Test
46110477|NCT00830180|Biological|Anti-NGF AB|Solution for injection, 10 mg, one injection/8 weeks
46110478|NCT02605512|Other|Subclinical cardiac lesions and biomarkers|Functional myocardial dysfunction based on 2D-speckle tracking echocardiography, Anatomical coronary lesions based on Coronary computed tomography angiography, a panel of circulating biomarkers based on blood samples and plasma
46110479|NCT02603679|Drug|Paclitaxel|Any brand of paclitaxel may be used, excluding nab-paclitaxel
45838546|NCT00079417|Drug|Vincristine Sulfate|Given IV
45838547|NCT04387968|Diagnostic Test|Covid-19 presto test|Use an auto-test in 15 minutes get the results about covid-19 anticorps
45838548|NCT04387890|Diagnostic Test|Serologic SARS-CoV-2 screening|Quantitative Indirect Chemiluminescence Immunoassay (CLIA) to access SARS-CoV-2 specific IgM and IgG serum antibody level every 2 weeks during follow up
45838549|NCT04387578|Device|fixed orthodontic appliance and arch wires|leveling and aligning stages in orthodontics
45838550|NCT04387500|Drug|Sintilimab injection plus Inlyta treatment|Combined Sintilimab injection and Inlyta treatment in FH-deficient RCC
46023826|NCT04237987|Drug|ciclosporin and corticosteroid|ciclosporin and corticosteroid
46023827|NCT04551547|Biological|Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd., with a antigen content of 300SU/0.5ml
46023828|NCT04551547|Biological|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd., with a antigen content of 600SU/0.5ml
46023829|NCT04551547|Other|Two doses of placebo at the schedule of day 0,28|The placebo contains no active ingredient and manufactured by Sinovac Research & Development Co., Ltd.
46023830|NCT02815579|Other|Shamba Maisha Intervention|A) A microcredit loan (~$140) B) Agricultural implements to be purchased with the loan C) Education in financial management and sustainable farming practices
46023831|NCT01045707|Drug|insulin degludec/insulin aspart|Injected s.c. (under the skin) once daily with the breakfast meal. Dose was individually adjusted.
46023832|NCT01045707|Drug|insulin glargine|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
46110480|NCT02603679|Drug|Tamoxifen + Palbociclib|Any brand of tamoxifen may be used
46110481|NCT02603679|Drug|Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
46110482|NCT02603679|Drug|Goserelin + Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
46110483|NCT03995485|Drug|KW-136 capsule|KW-136 60 mg was provided in a single capsule of 60 mg.
46110484|NCT03995485|Drug|Sofosbuvir|Sofosbuvir was provided in a single tablet of 400 mg.
46110485|NCT02605434|Drug|Accordion Pill™ Carbidopa/Levodopa|AP-CD/LD capsule containing 50 mg carbidopa with 400 mg or 500 mg levodopa administered orally twice or 3 times a day
46110486|NCT02605434|Drug|Sinemet®|Sinemet® tables containing carbidopa and levodopa 25/100 mg will be administered orally at least 4 times a day according to patients need
45681591|NCT04148014|Behavioral|An Adjunctive Emotion Regulation Skills Training|The adjunctive emotion regulation skills training is delivered in a group format once a week during 5 weeks to young adults with eating disorders together with treatment as usual
46023833|NCT02816125|Dietary Supplement|omega-3 fatty acid|SEE YOURSELF WELLTM OMEGA-3 Dietary Supplement: See Yourself Well Inc., Leamington, Ontario) containinged 200 mg of EPA and 100 mg of DHA for a total of 1.2 g n-3/day.
46023834|NCT02816437|Biological|OpenBiome Fecal Microbiota Transplantation retention enema|Keep enema frozen until ready for administration. A single transfer of all 250mL of fecal material using universal precautions to a standard retention enema bag over 1 hour with material retained for at least 1 hour.
46023835|NCT04533997|Drug|Hypertonic saline solution plus intravenous furosemide|"Intravenous 60-minutes of hypertonic saline therapy plus furosemide:~Furosemide:~125 mg if home oral furosemide < 160 mg, 250 mg if home oral furosemide ≥ 160 mg~Hypertonic saline solution:~Na+ 125-134: 3.6%, Na+ 135-145: 2.4%"
46023836|NCT04533997|Drug|Intravenous furosemide|"Intravenous 60-minutes infusion of furosemide:~125 mg if home oral furosemide < 160 mg, 250 mg if home oral furosemide ≥ 160 mg"
46023837|NCT04303221|Other|Exercise|The exercises will be performed three times a week (Mondays, Wednesdays and Fridays), lasting 60 min, 10 minutes of warm-up, 40 min of multisensory exercises, and 10 min of final relaxation, for 12 weeks.
46023838|NCT04238377|Procedure|Stellate Ganglion Block|"Using US with a linear array transduce, subfascial-C6- Stellate Ganglion Block. Patients will be supine with the neck slightly hyper- extended. After aseptic preparation of the skin, the transducer is placed on the neck to enable cross sectional visualization of anatomical structures at the level of C6. The carotid artery, internal jugular vein, thyroid gland, trachea, longus colli covered with the prevertebral fascia, root of C6, and transverse process of C6 are all visualized. The transducer will then gently be pressed between the carotid artery and trachea to retract the carotid artery laterally and to position the transducer close to the longus colli.~A 1.0-inch, 25-gauge long-bevel needle were paratracheal inserted toward the middle of the longus colli. The endpoint for injection were the ultrasound image demonstrating the tip of needle penetrating the prevertebral fascia in the longus colli. After negative aspiration, 5 mL of 0.5% bupivacaine was injected"
46023839|NCT04238377|Drug|Multimodal Analgesia|Multimodal analgesia in the form of administering of IV paracetamol 1000 mg one hour prior to start of surgery in combination 30 mg ketorolac and Single preoperative 0.1 mg/kg dose dexamethasone has a combined action, anti-emetic and provides enhanced analgesia, with intra-operative fast acting opioid analgesics, Fentanyl 2 mic/kg
46023840|NCT04302831|Behavioral|Strength training|weight lifting to increase muscle strength
46023841|NCT04302831|Behavioral|Endurance training|treadmill walking to increase endurance
46023842|NCT04302831|Behavioral|Flexibility training|stretches to improve flexibility
46023843|NCT04302831|Behavioral|Physical activity behavioral intervention|Intervention to encourage participants to be more physically active
46023844|NCT04302831|Behavioral|Task Specific timing and coordination training|stepping and walking patterns to improve timing and coordination of gait
46023845|NCT02817685|Other|3 months|
46023846|NCT02817685|Other|6 months|
46023847|NCT02817685|Other|3 month ultrasound(US)+3 month CT/MRI+3 month US+3 month CT/MRI|
46023848|NCT02874807|Drug|Empagliflozin|
46023849|NCT02874807|Other|Placebo|
46023850|NCT02817529|Device|Pulmonica|The Pulmonica is a specially constructed and tuned Pulmonary Harmonica that produces deep, resonant, meditative sounds that can be felt vibrating in the lungs and sinuses. Participants who will be instructed to inhale and exhale through Pulmonica at least ten times daily for up to six months.
46023851|NCT02817529|Device|RC-Cornet|RC-Cornet is an oscillatory positive expiratory pressure device, which is designed to aid in the loosening and removal of mucus build-up in the lungs. Participants who will be instructed to inhale and exhale through RC-Cornet at least ten times daily for up to six months.
46023852|NCT02875431|Procedure|Patients undergo ACDF or cervical vertebral body replacement|
46023853|NCT02817607|Procedure|Sensory testing and Biopsy|"Semmes-Weinstein testing: Each breast will be subdivided into 5 regions. This will include the upper 1/3rd, the middle 1/3rd medial and lateral to the nipple areola complex, the lower 1/3rd and the nipple areola-complex. These regions are consistent with the dermatomes described for the breast innervation.~A cutaneous nerve/skin biopsy is a simple procedure commonly performed on an outpatient setting. The total procedure is expected to take 20 minutes and may be done at the time of surgery as well as 2 and 6 months post operatively either during a revision or at a follow up visit."
46110487|NCT02605434|Drug|Placebo -AP-CD/LD|Placebo for AP-CD/LD capsule
46110488|NCT02605434|Drug|Placebo- Sinemet|Placebo for Sinemet tables
46110489|NCT00863681|Drug|Riociguat (BAY63-2521)|BAY63-2521: 1mg tid -2.5 mg tid oral until end of study
46110490|NCT05758298|Other|Non-medicated gum|Non-medicated, regular chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
46023854|NCT00627159|Other|High risk assessment|For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All participants predicted to be at high risk are referred for assessment to a High Risk clinic in the community via the family doctor.
46023855|NCT00627159|Other|Low to moderate risk|For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All low to -moderate risk participants are directed to self-refer to the Calgary Health Region Multicultural education classes.
46110491|NCT05758298|Drug|NICOTINE 2MG GUM|Nicotine 2mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
46023856|NCT02814097|Drug|elamipretide|Subcutaneous injection of 40 mg elamipretide once daily for 28 consecutive days
46023857|NCT02814097|Drug|Placebo|Subcutaneous injection of placebo administered once daily for 28 consecutive days
46110492|NCT05758298|Drug|NICOTINE 4MG GUM|Nicotine 4mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
46110493|NCT00789321|Drug|Comparator: amlodipine besylate|Two 5 mg tablets amlodipine daily for 6 weeks.
46110494|NCT00789321|Drug|Comparator: Placebo|Two 5 mg tablets placebo to amlodipine daily for 6 weeks
46110495|NCT02603367|Other|Communication Intervention|Undergo communication coaching
46110496|NCT02603367|Other|Educational Intervention|Receive COMFORT communication curriculum
45469417|NCT01144325|Procedure|thoracoscopic esophagectomy|"In prone position group, patients are intubated with single lumen endotracheal tube. Surgeon and assistant stand on the right of the patient. A 10 mm camera port is placed 7th intercostals space in posterior axillary line, CO2 pneumothorax is created with pressure of 8mmHg. A 5 mm port is placed just posterior to the scapular tip. The last 10mm port is placed at 9th intercostals space in the scapular line for. The tumor and esophagus are dissected with cleaning of the lymph nodes along bilateral recurrent nerve.~In controlling group, The four chest ports were similar to that described by the University of Pittsburgh group. The left two ports are used for surgical exposure, the right two ports is to divide and dissect the esophagus. The dissection is similar to that of the prone position."
45469418|NCT03620760|Drug|Ticagrelor 90 mg|Ticagrelor (AZD6140) 90 mg twice daily dose
45469419|NCT03620760|Drug|Ticagrelor 45 mg|Ticagrelor (AZD6140) 45 mg twice daily dose
45469420|NCT03620760|Drug|Aspirin|Aspirin 100 mg once daily dose
45469421|NCT03765931|Drug|Doxycycline|The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged > 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature > 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature < 37.5°C.
46023858|NCT02874573|Drug|Tocilizumab|Investigational agent
46023859|NCT02874573|Drug|Normal saline|Placebo
46023860|NCT02814331|Device|multimodal high-resolution EEG-NIRS|
46110497|NCT02603367|Other|Psychosocial Support for Caregiver|Undergo communication coaching
46110498|NCT02603367|Other|Questionnaire Administration|Complete questionnaires
46110499|NCT03998553|Procedure|IN VITRO MATURATION AND OOCYTE ACTIVATION|This study aims to fine-tune the in vitro maturation (IVM) technique to achieve nuclear mature oocytes, i.e., to mature the oocytes up to the metaphase II stage. In addition, an artificial oocyte activation (AOA) will be carried out to check the cytoplasmic maturation of the oocytes, avoiding the generation of potentially viable embryos.
46110500|NCT04105959|Drug|RIST4721|RIST4721 oral solution
46110501|NCT04105959|Drug|Placebo|Placebo oral solution
46110502|NCT04126421|Device|Prosthesis component (acetabular cup) E1 cup|Semented acetabuar cup With E1 cup
46110503|NCT04126421|Device|Prosthesis component (acetabular cup) Marathon cup|Semented acetabuar cup With Marathon cup
46110504|NCT00811928|Drug|Posaconazole|"40 mg/mL; 200 mg (5 mL) TID~Treatment was continued with each cycle of chemotherapy until:~The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~3 chemotherapy cycles or~Total treatment duration up to 12 weeks (84 days)"
46110505|NCT00811928|Drug|Fluconazole|"50 mg/capsule (2 capsules), 150 mg/capsule (2 capsules);~400 mg QD~Treatment was continued with each cycle of chemotherapy until:~The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~3 chemotherapy cycles or~Total treatment duration up to 12 weeks (84 days)"
46023861|NCT02875275|Other|Glucose with grass jelly solution|50 g glucose and 3.12 g grass jelly dissolve in water (top up to 200g)
45469422|NCT03765931|Drug|Amoxicillin|The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged > 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature > 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature < 37.5°C.
46110506|NCT00698321|Behavioral|HIV/STD prevention curriculum|The curriculum will include eight 1-hour HIV prevention modules administered weekly for 8 weeks. The modules will educate youth about risky sexual behaviors and will provide them with knowledge and skills necessary to reduce their risk of STDs, HIV, and pregnancy by abstaining from sex or using condoms if they choose to have sex. The curriculum is based on cognitive behavioral theories, focus groups, and the researchers' experience working with youth.
46110507|NCT00698321|Behavioral|General health promotion curriculum|The curriculum will include eight 1-hour general health modules administered weekly for 8 weeks. The curriculum will focus on teaching students healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance abuse.
45838551|NCT04387266|Radiation|modified reduce-volume target IMRT|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.
45838552|NCT04386876|Drug|Lopinavir/Ritonavir 200 mg/50 mg Film Tablet|Lopinavir/Ritonavir film tablet containing 200 mg lopinavir and 50 mg ritonavir (World Medicine-Turkey).
45469423|NCT03916445|Other|Connor Davidson Resilience Scale (CD-RISC 10)|questionnaires about resilience (Connor Davidson Resilience Scale(CD-RISC 10)) and quality of life (EQ-5D-5L)
46110508|NCT02611544|Behavioral|Acceptance and Commitment Therapy|6-week ACT intervention group (n=33)
46110509|NCT02611544|Behavioral|Survivorship Education|6-week survivorship education group (SE; n=32)
46110510|NCT02611544|Behavioral|Enhanced Usual Care|enhanced usual care (EUC; n=26)
46110511|NCT00788775|Drug|Nilotinib|
46023862|NCT02875275|Other|Glucose with grass jelly (solid)|50 g glucose and 3.12 g grass jelly and 3.12g starch dissolve in hot water (top up to 200g)
45469424|NCT02365363|Other|Control|Non pulse ingredient bagel
45469425|NCT02365363|Other|Pea flour|Pulse ingredient bagel
46023863|NCT02875275|Other|Porridge and juice with coconut oil|Add instant porridge with hot water with oil. Consume with commercially available orange juice
46110512|NCT05756036|Other|None Observational study|Non interventional study
46110513|NCT00448669|Drug|Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg|
45469426|NCT02365363|Other|Pea fibre|Pulse ingredient bagel
45469427|NCT02365363|Other|Pea flour and pea fibre|Pulse ingredient bagel
45469428|NCT02365363|Other|Pea flour and pea protein|Pulse ingredient bagel
45469429|NCT02365363|Other|Pea flour + pea fibre + pea protein|Pulse ingredient bagel
45469430|NCT03415204|Other|acupuncture|acupuncture for post operative pain
45469431|NCT01240265|Dietary Supplement|Vitamin D3|150,000 IU orally given once
45469432|NCT01240265|Dietary Supplement|Vitamin D3|5000 IU given orally daily for 28 days
45838553|NCT04386876|Drug|Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet|Lopinavir/Ritonavir film coated tablet containing 200 mg lopinavir and 50 mg ritonavir(AbbVie Deutschland GmbH & Co.-Germany)
46023864|NCT02875275|Other|Porridge and juice with coconut oil gel|Add instant porridge with hot water with oleogel. Consume with commercially available orange juice
46023865|NCT05636605|Diagnostic Test|Multiomics analysis|Genome, proteomics, single cell RNA sequencing, and space transcriptome sequencing，etc
46110514|NCT00448669|Drug|Placebo Oral Tablet|
46110515|NCT00591734|Drug|Bevacizumab|15 mg/kg of bevacizumab intravenously (IV) once every 3 weeks.
46023866|NCT01054599|Drug|Memantine|All subjects in the treatment group will be placed on memantine. The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the first phase of the study. At the conclusion of the first 13 weeks, subjects will discontinue the treatment (memantine or placebo) and enter the open label phase.
46023867|NCT01054599|Other|Sugar Pill|In the control arm of the study, subjects will take one placebo sugar pill per day for one week, then increase to one tablet twice per day for the following 12 weeks. At the end of this phase of the study, subjects will enter the open-label phase (unblinded treatment with memantine).
46110516|NCT00591734|Drug|Everolimus|10 mg by mouth daily
46110517|NCT00788697|Drug|SonoVue-enhanced ultrasound|Contrast-enhanced ultrasound (CE-US) examination of the target lesion. Drug: SonoVue® Dose of 2.4 mL bolus injection administered intravenously. Maximum of 2 injections (4.8 mL)
46110518|NCT00788697|Other|Unenhanced ultrasound|-Unenhanced: Gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion. Drug: None
46110519|NCT05755880|Procedure|Intrathecal dexamethason|After general anesthesia intrathecal dexamthasone will be added
46110520|NCT00848549|Drug|Zonisamide|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 500 mg; the minimum daily dose allowable is 200 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events, respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 100 mg per week.
45838554|NCT04387032|Other|HVLA Manipulations|The procedure of experimental manipulation: the patient lay on the healthy side with the straight lower limb, and the torso turned towards the dysfunctional side, whose lower limb was bent in the hip and knee joint, and the hands rest on the lower ribs on the same side. The therapist allowed the initial loosening of the tissues and chose the movement barrier with his stabilizing hand. Then, with the treatment hand, he introduced the HVLA thrust through the iliac bone towards the bottom, while giving the iliac bone a posterior or anterior rotation - meaning, the opposite to the occurring dysfunction. If during the manipulation, no cavitation sound was heard, the HVLA thrust was repeated once.
45838555|NCT04387032|Other|Sham Manipulation|The sham procedure was the same, but no external force was introduced in the form of a therapeutic impulse.
46110521|NCT00848549|Drug|Carbamazepine|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 1200 mg; the minimum daily dose allowable is 400 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 200 mg per week.
46110522|NCT00788151|Biological|CYD Dengue Vaccine Serotypes 1, 2, 3, and 4|0.5 mL, Subcutaneous (SC)
46110523|NCT00788151|Biological|Pneumococcal polysaccharide vaccine|0.5 mL, SC
46110524|NCT04116359|Drug|Cisplatin|Given IV
46110525|NCT04116359|Drug|Etoposide|Given IV
46023868|NCT01054599|Drug|Memantine|Open label: When the blinded phase is complete (Weeks 1-13), all subjects will receive open-label treatment with memantine (Weeks 14-26). The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the study. At the conclusion of the study, subjects will discontinue the treatment.
46110526|NCT04116359|Drug|Etoposide Phosphate|Given IV
45838556|NCT04386486|Other|Bathe anamnesis method|BATHE anamnesis (BA) is applied to first group and preoperative examinations are completed.
45838557|NCT04386486|Other|standart anamnesis|standart anamnesis is applied to second group and preoperative examinations are completed.
45838558|NCT04386642|Drug|Tranexamic acid|Tranexamic acid 2000 mg dilute in normal saline solution 50 ml.
45838559|NCT04386642|Drug|Placebo|normal saline solution in a clear 50-ml syringe
45838560|NCT04386408|Combination Product|Combination of plant extracts (BSL_EP027)|Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
46110527|NCT04116359|Drug|Molibresib|Given PO
46110528|NCT04116359|Drug|Molibresib Besylate|Given PO
46110529|NCT00788073|Drug|STX209|Variable dose from 1 mg bid to 10 mg tid, Capsule, Oral, 4 weeks
46110530|NCT00788073|Drug|Placebo|variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
46110531|NCT04118153|Drug|Abatacept|Abatacept will be administered by subcutaneous injections weekly for 3 months. Dosing is according to body weight at screening visit and will be administered as follows: up to 25 kg receive 50 mg (0.4 mL); 25 to <50 kg receive 87.5 mg (0.7 mL), and > 50 kg receive 125 mg (1.0 mL) per dose.
46110532|NCT00848393|Drug|Fentanyl (High Dose)|Fentanyl (High Dose) 25 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
46110533|NCT00848393|Drug|Fentanyl (Low Dose)|Fentanyl (Low Dose) 10 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
46110534|NCT00848393|Drug|Fentanyl (Low Dose) + Dexmedetomidine|Fentanyl (Low Dose) + Dexmedetomidine. Dexmedetomidine at 1mcg/kg loading dose over 10 minutes, followed by an infusion at a rate of 0.5mcg/kg/hr. In addition, this group will receive a total of 10 mcg/kg Fentanyl (Low Dose). Half the dose will be given at induction and the second half before incision.
46110535|NCT00815516|Drug|micafungin|Administered by intravenous infusion
46110536|NCT00815516|Drug|amphotericin B deoxycholate|Administered by intravenous infusion
46110537|NCT04118309|Behavioral|Exercise|
46110538|NCT04118309|Other|Placebo|
46110539|NCT00705926|Drug|Highly Active Antiretroviral Therapy (HAART)|Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks. Their medications will not be provided by the study.
46110540|NCT00705926|Other|No treatment|Participants in this group will not receive treatment at this stage of their infection.
46023869|NCT05635201|Drug|Anesthesia induction with propofol|After a 10-minute-long acclimation, general anesthesia is induced with 2% propofol at the effect-site concentration of 4 μg/ml based on the Marsh Pharmacokinetic model. The effect-site concentration was maintained at 4 μg/ml until the trachea was intubated. Five minutes after the anesthesia induction, remifentanil was administered at the effect-site concentration of 4 ng/ml based on the Minto pharmacokinetic model until the trachea was intubated. With the initiation of remifentanil infusion, 1 mg/kg of rocuronium was administered following the calibration of the neuromuscular monitoring device. With the train-of-four count of 0, the trachea was intubated. Then, the effect-site concentrations of propofol and remifentanil were decreased to 3 μg/ml and 0 ng/ml, respectively, until the surgical incision was made.
46110541|NCT05755724|Other|3-D Teaching|Telesimulation using immersive VR technology. Briefly, students will have a 360° camera mounted to their head, which will broadcast their first-person perspective to their teachers. Teachers will be able to immerse themselves in the perspective of the trainee using a virtual reality HMD (Oculus Quest 2), which allows them to look around freely and view equipment, hand movements, etc. and offer instruction accordingly.
46110542|NCT05755724|Other|2-D Teaching|Telesimulation using standard teleconferencing software and equipment including 2D computer monitors, webcams, and an ultrasound machine linked to a computer (enabling ultrasound images to be transmitted).
46110543|NCT05087576|Behavioral|Expressive Helping|Expressive helping integrates two distinct areas of research showing that emotional disclosure over writing and support giving improves psychological well-being among healthy and clinical populations. Participants write 4 brief structured writing sessions.
46110544|NCT05087576|Behavioral|Caregiving Fact writing|Factual Writing has been used with in other writing-based interventions (e.g., expressive writing). It is also completed in 4 brief structured writing sessions.
46110545|NCT00787917|Drug|Omalizumab|Omalizumab subcutaneous injections of 600 mg daily.
46023870|NCT05635201|Drug|Anesthesia induction with remimazolam|After a 10-minute-long acclimation, general anesthesia is induced with a 2-minute-long infusion of remimazolam at a rate of 12 mg/kg/hr, after which the infusion rate was reduced to 1 mg/kg/hr and was maintained until the surgical incision was made. Five minutes after the anesthesia induction, remifentanil was administered at the effect-site concentration of 4 ng/ml based on the Minto pharmacokinetic model until the trachea was intubated. With the initiation of remifentanil infusion, 1 mg/kg of rocuronium was administered following the calibration of the neuromuscular monitoring device. With the train-of-four count of 0, the trachea was intubated. Then, the effect-site concentration of remifentanil was decreased to 0 ng/ml until the surgical incision was made.
46110546|NCT00787917|Drug|Placebo|Placebo subcutaneous injections blinded to match experimental arm dosing regimen.
46110547|NCT00787917|Drug|Itraconazole|Itraconazole twice daily with a maximum daily dose of 400 mg.
45469433|NCT02327455|Procedure|Stress Dobutamine Echocardiographic using 4DE System|Subjects will undergo their clinically indicated stress dobutamine echocardiographic studies using our standard clinical graded dobutamine stress imaging protcol, employing the iE33 4DE system.
45681592|NCT04143022|Device|acupuncture press needle|Press needle will be applied to acupoints at Jin's 3-tongue point ( EX-HN21 and the two extra channel points, 0.8 individual cun lateral to both sides of EX-HN21) and EX-HN25 in group A and at EX-CA1, EX-CA5 and EX-CA6 in group B. Each subject will start first course and receive the treatment 2 times a week for 4 weeks (8 times in total). Then, it takes 2-week washout period and make group A and group B crossover. Second course begins after 2-week washout period with the same treatment times as the first course.
46110548|NCT05038280|Behavioral|Let's Talk about Children intervention|The LTC -intervention includes two steps: Let´s Talk about Children discussion and Let´s Talk about Children network meeting. Students, students´ parents, and a teacher take part in the LTC -discussion. The LTC logbook is used as the framework for the discussions. The LTC discussion depicts the child's ordinary day in all developmental contexts and an action plan is made with parents to enhance the identified strengths and to give support in vulnerabilities. When the action plan is difficult to carry out without further participants, the LTC-Network meeting is planned with parents (and sometimes also the child). LTC-Network meeting provides a forum for case-based cross-sectoral collaboration, including also the families and their social network.
45469434|NCT03415126|Drug|ASN007: ascending doses|Oral drug for the treatment of advanced solid tumors
45681593|NCT04143256|Other|JUUL ENDS 5% Virginia Tobacco|JUUL ENDS Virginia Tobacco 5% nicotine strength
45469435|NCT03415126|Drug|ASN007 RD|Oral drug for the treatment of advanced solid tumors
45469436|NCT03638076|Drug|GLS4|Subject in group A will receive Mesilate Capsule 120mg twice daily. Subject in group B will receive Mesilate Capsule 120mg three times daily.
45469437|NCT03638076|Drug|RTV|Subject in group A will receive Ritonavir tablet 100mg twice daily.Subject in group B will receive Ritonavir tablet 100mg three times daily.
45838561|NCT04386408|Combination Product|Placebo|Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
45838562|NCT04386564|Diagnostic Test|mRNA in urine test|Assessment of renal function, expression of viral RNA in urine and assessment of radiological changes will be performed
45469438|NCT03916211|Biological|MSCs treatment|intramuscular injection of adipose stem cells treat diabetic foot
45469439|NCT03415048|Other|No Intervention|
45469440|NCT03614364|Drug|nanoxel|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
45681594|NCT04143256|Other|JUUL 3% Virginia Tobacco ENDS|JUUL ENDS Virginia Tobacco 3% nicotine strength
45469441|NCT03614364|Drug|herzuma|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
45681595|NCT04143256|Other|JUUL 5% Mint ENDS|JUUL ENDS Mint 5% nicotine strength
45681596|NCT04143256|Other|JUUL 3% Mint ENDS|JUUL ENDS Mint 3% nicotine strength
45681597|NCT04143256|Other|JUUL 5% Menthol ENDS|JUUL ENDS Menthol 5% nicotine strength
45681598|NCT04143256|Other|JUUL 3% Menthol ENDS|JUUL ENDS Menthol 3% nicotine strength
46023871|NCT02813863|Drug|SP2086|
46023872|NCT02813863|Drug|Metformin|
46023873|NCT02874729|Procedure|Venesection|Blood will be removed from the circulatory system through a cut (incision) or puncture for the purpose of analysis by qualified staff. Serum or plasma will be separated from the cellular fraction and stored for analyses.
45681599|NCT04143256|Other|JUUL 5% Mango ENDS|JUUL ENDS Mango 5% nicotine strength
45681600|NCT04143256|Other|JUUL 3% Mango ENDS|JUUL ENDS Mango 3% nicotine strength
45681601|NCT04143256|Other|US Cigarette, Non-menthol - Marlboro Gold King Size|US Cigarette, Non-menthol - Marlboro Gold King Size
45681602|NCT04143256|Other|US Cigarette, Menthol - Newport King Size|US Cigarette, Menthol - Newport King Size
45681603|NCT04143412|Drug|Tritace (Ramipril 10 mg)|Stratified randomized clinical trial
46023874|NCT02874729|Procedure|Urine collection|Urine will be collected in appropriate sterile holders provided.
46023875|NCT02874729|Procedure|Sputum collection|Saliva will be collected in appropriate sterile holders provided.
46110549|NCT04106271|Other|dyadic pain management program|a dyadic pain management program for older adults and their informal caregivers is developed as intervention. The program will be conducted at community activity center face-to-face combined with digital-based activities and the program will include 4 sessions, weekly 1 hours. Each session will be classified into three stages, including 10 minutes for watching videos and group discussion, 20 minutes for theoretical knowledge and coping skills and 20 minutes for exercising together. Last 10 minutes of each session is to wrap up and Q & A. There will be a brief introduction of program and self-introduction of participants at the beginning of the first session. One exercise book is given to each pair and researchers have a 4-week follow-up.
46110550|NCT05758064|Drug|Duphaston|10 mg tablet will be given twice
45469442|NCT03760393|Behavioral|(SB-related planning + daily text messages)|"Participants will receive a one-on-one behavioral counseling session, and planning sheet as reference for developing strategies as part of their Action/Coping Plan. Participants will be asked to form 3-4 actions plans specifying when, where, how, and for how long they would reduce occupational (student) sitting time; and anticipate potential barriers and identify ways they could be overcome. Strategies will explicitly focus on the ultimate objective of increasing break frequency to every 30-45 minutes, achieving a break duration of 2-3 minutes, and increasing time spent standing and engaged in light-intensity PA, in the occupational domain (i.e. as a student; during school-related activities).~Participants will also receive sedentary behaviour-related text messages twice daily, depending on their preferences and schedule, which will act as mini-booster interventions."
46110551|NCT05758064|Drug|prolutex|subcutaneous injection daily
46023876|NCT02874729|Procedure|Bronchoalveolar lavage|Bronchoscopy will be performed. Briefly, clinical care team will collect liquid after an instrument (bronchoscope) is passed through the nose or mouth into the lungs, and saline solution is squirted into a small part of the lung, then collected for analyses.
46110552|NCT00814892|Biological|allogeneic tumor cell vaccine|Given intradermally
46023877|NCT04275661|Procedure|Ultrasound (US) bi-level erector spinae block|nerve block
45469443|NCT01146197|Drug|TREATMENT|Patients with received in random order 75mg/day indometacin(chronoindocid®), 10-20 mg/day amiloride and 50-150 mg /day eplerenone (Inspra ®). The three 6 weeks-periods of treatment will be followed by six weeks washout period. 3-6 weeks before the first period of treatment, a supplementation with potassium and magnesium will be orally given, and maintained at the same dose throughout the study and stoped 6 weeks after the end of the third period of treatment.
45469444|NCT03414970|Radiation|Radiation Therapy|Undergo RT
45469445|NCT03414970|Other|Questionnaire Administration|Ancillary studies
46110553|NCT00814892|Biological|therapeutic autologous dendritic cells|Given intradermally
45469446|NCT03414970|Other|Quality-of-Life Assessment|Ancillary studies
46023878|NCT04275661|Drug|levobupivacaine|20 ml 0.25% levobupivacaine injected into fascial plane deep to erector spinae muscle
46023879|NCT04275661|Drug|Ketamine|2 mg /kg ketamine.injected into fascial plane deep to erector spinae muscle
46023880|NCT04275661|Drug|Magnesium Sulfate|2mg/kg Magnesium Sulfate .injected into fascial plane deep to erector spinae muscle
46110554|NCT00787839|Other|Glucose challenge test|At a first outpatient visit, at different times of the day and without a prior fast, subjects will have a 50 gram glucose drink followed by measurement of plasma and capillary glucose along with A1c one hour later. They will also fill out questionnaires. At a second outpatient visit, in the morning after fasting overnight, they will have a 75 gram oral glucose tolerance test.
45469447|NCT03414970|Other|Laboratory Biomarker Analysis|Correlative studies
45469448|NCT03414970|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
45469449|NCT03765775|Biological|Sintilimab|Participants receive Sintilimab(IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle
46110555|NCT00787839|Other|Glucose tolerance test|Subjects found to have diabetes or prediabetes on the initial glucose tolerance test may be requested to have a repeat glucose tolerance test and A1c.
46110556|NCT02610764|Procedure|Blood Test for CTC evaluation|
46110557|NCT04105647|Behavioral|Lifestyle-integrated exercise|The experimental group will receive a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise and physical activity. The lifestyle-integrated exercise is modified from Zero-time exercise. It focuses on four exercise domains that patients with lung cancer could be done at home, including breathing, balance, aerobic, strength, stretching exercises
46110558|NCT04105647|Behavioral|Healthy living information|The control group will receive a face-to-face group session and a package healthy living instant messages, but not related to lifestyle-integrated exercise and physical activity.
46110559|NCT02602977|Other|Multiple-dose Remote Ischemic Preconditioning|"A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Multiple-dose RIPC consists of a daily dose of 1 RIPC as described above for 7 consecutive days."
45469450|NCT03765775|Drug|Anlotinib Hydrochloride|Participants receive Anlotinib 10 mg, administered as PO on Day 1-14 of each 21-day cycle
46023881|NCT02813941|Other|Current GRADE SoF table|The current GRADE SoF table will be the common comparator for the other two SoF tables
46023882|NCT02813941|Other|Alternative GRADE SoF table|The alternative GRADE SoF table format will be developed from a user-testing survey.
46023883|NCT02813941|Other|EPC SoF table|For the EPC SoF table, the investigators will use one of their format which was recently published
46023884|NCT02875041|Device|Transcranial Magnetic Stimulation (TMS)|
46023885|NCT02875041|Device|MAGSTIM Rapid2|
46023886|NCT02813707|Other|QoL questionnaire regarding the long term complication|Micronutrients evaluation
46023887|NCT04187521|Other|Meal A|A breakfast meal with a specific macronutrient proportions.
45469451|NCT01240499|Other|Health-At-Every-Size (HAES)|"HAES group: 14 weekly sessions.~Focus on general well-being and positive ways of having a healthy and satisfying lifestyle. Supported by lectures, guided self-reflection, group discussions, as well as practical exercises, this intervention aims at enhancing awareness and knowledge about biological, psychological, and sociocultural aspects of body weight.~SS group: 14 weekly sessions.~The objective is to reproduce a structural social support provided by the group itself. Each participant offers their support to each other. Each theme discussed in the HAES group is repeated in the SS group but the health professionals in charge of the group (dietitian & psychologist) are not counselors (as in HAES group) but only facilitators.~Outcome measures: For all women under study."
46023888|NCT04187521|Other|Meal B|A breakfast meal with a specific macronutrient proportions.
46023889|NCT00948766|Drug|Rivastigmine 4.6 mg/24 h (5 cm^2)|Rivastigmine was supplied in a 5 cm^2 patch which released 4.6 mg/24 h. Patches were changed daily.
46023890|NCT00948766|Drug|Rivastigmine 9.5 mg/24 h (10 cm^2)|Rivastigmine was supplied in a 10 cm^2 patch which released 9.5 mg/24 h. Patches were changed daily.
45469452|NCT02255929|Radiation|Gamma Knife Radiosurgery|
45469453|NCT01329731|Drug|elmex® gelée|1.25% fluoride (elmex® gelée) Dosage: Weekly brushing with 0.5g of respective gel Route: Intraoral topical
45469454|NCT01329731|Drug|negative control (placebo)|0% fluoride (negative control) Dosage: Weekly brushing with 0.5g Route: Intraoral topical
45469455|NCT03765697|Drug|Lidocaine 5% medicated plaster|Topical application at the site of skin affected by painful PHN for up to 12 hours per day (plaster-free interval at least 12 hours).
45469456|NCT03765385|Other|High-intensity training|Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.
46023891|NCT00948766|Drug|Rivastigmine 13.3 mg/24 h (15 cm^2)|Rivastigmine was supplied in a 15 cm^2 patch which released 13.3 mg/24 h. Patches were changed daily.
46023892|NCT00948766|Drug|Placebo|Placebo patches were identical in size and composition to the corresponding rivastigmine patches, except that they did not contain rivastigmine. Patches were changed daily.
46023893|NCT02813629|Device|tDCS plus PES|"transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.~PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability."
46023894|NCT04206722|Device|Shock Wave Therapy|Shock Wave therapy - hip osteoarthritis program
45469457|NCT03765385|Other|Moderate-intensity continuous training|Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.
45469458|NCT01144559|Procedure|Continuous Infusion|Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered continuously every hour by a pain pump. Outcome measures will be tested.
45681604|NCT05582278|Drug|D-TACE|CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.
46023895|NCT04206722|Device|Ultrasound|Ultrasound 0.7W/cm2
46023896|NCT01053663|Drug|Tamiflu|10 doses over 5 or 6 days of which the first 5 or 6 doses must be intravenous, up to 5 days (10 doses) of additional intravenously or oral treatment if virus shedding continues at day 6
46023897|NCT00634387|Dietary Supplement|Anthocyans|Anthocyans
46023898|NCT00634387|Other|placebo|
46023899|NCT00634387|Dietary Supplement|Anthocyans|
46023900|NCT01235546|Drug|Azithromycin and standard of care|500 mg in 250 cc normal saline 1 time dose plus standard of care (cephazolin or clindamycin)
46023901|NCT01235546|Drug|Placebo and standard of care|250 cc normal saline, plus standard of care (cephazolin or clindamycin)
46023902|NCT02813395|Device|Low Level Laser Therapy|"Low Level Laser Therapy was applied at four points to the dominant upper limb of the volunteers on the muscle belly of the biceps. Delineation was done using a measuring tape from the elbow joint line to the acromion marked at points corresponding to 20%, 30%, 40% and 50% of this distance, focusing the application on the muscle belly region, thereby excluding the tendinous region.~An 808 nm equipment was used for applying laser therapy, with a power of 100 mW and total energy of 20 J."
46023903|NCT02813395|Device|Placebo Laser|Laser application simulation with a second pen of the laser device, which was disconnected and did not effectively irradiate energy.
46023904|NCT01053429|Drug|ziprasidone|This is a non-interventional, pharmacovigilance study, therefore patients are on ziprasidone as prescribed by their doctor.
46023905|NCT01233284|Drug|tiotropium bromide 2.5µg once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
46110560|NCT02602977|Other|Single-dose Remote Ischemic Preconditioning|"A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Single-dose RIPC consists of 1 dose of RIPC as described above"
46023906|NCT01233284|Drug|Tiotropium matching Placebo once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
46023907|NCT01233284|Drug|tiotropium bromide high dose once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
46023908|NCT01233284|Drug|tiotropium bromide 1.25µg once daily|IMP
46023909|NCT00627237|Behavioral|Immediate Start|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
46110561|NCT02602977|Biological|LPS infusion|To achieve a controlled inflammatory state, 30 subjects (multiple-dose RIPC group [n=10], single-dose RIPC group [n=10] and control group [n=10]) will receive LPS intravenously. The LPS at a dose of 2 ng/kg iv will be injected in 1 minute.
46110562|NCT00829244|Drug|GONAL f® prefilled pen|GONAL f® doses starting at minimum of 112.5 IU per day and a maximum of 450 IU per day for 1 cycle only
45469459|NCT01144559|Procedure|Bolus Administered|Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered using a bolus every hour by a pain pump. Outcome measures will be tested.
45838563|NCT04385628|Behavioral|the patient' relatives satisfaction questionnaire|The patient' relatives satisfaction questionnaire will be filled face to face during informing the patient's relatives after the 3rd, 10th, and 30th days of patient admission, and once a month. We will evaluate the most recent questionnaire.
45838564|NCT04385784|Other|Balance exercise program.|Multimodal exercise program that combines strength, mobility, elasticity and postural control exercises. It develops once a week for a total of 24 weeks. Each session lasts one hour and is carried out in small groups of 8 to 10 people maximum.
45469460|NCT01322503|Biological|Norovirus|Norovirus challenge pool administered to each subject
45469461|NCT03311841|Drug|Midazolam oral solution|Midazolam hydrochloride 10 μg (1 mL of 10 μg/mL oral solution), administered orally as part of a microdose cocktail
45469462|NCT03311841|Drug|Dabigatran and pitavastatin oral solution|375/10 μg dabigatran etexilate and pitavastatin (1 mL of 375/10 μg/mL oral solution), administered orally as part of a microdose cocktail
45469463|NCT03311841|Drug|Atorvastatin and rosuvastatin oral solution|100/50 μg atorvastatin and rosuvastatin (2 mL of 50/25 μg/mL oral solution), administered orally as part of a microdose cocktail
45838565|NCT04385784|Other|Home-based exercise program.|Exercises based on the OTAGO program that are carried out at home without supervision. Participants are explained to carry out the program three or four times a week in a safely way.
45838566|NCT04385550|Drug|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
45838567|NCT04385550|Drug|AK105 injection|AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.
45469464|NCT03311841|Drug|Rifampin|Rifampin 600 mg single dose (two 300 mg capsules) administered orally
45469465|NCT03915821|Device|ECT|"Electroconvulsive therapy was administered by using bidirectional constant current, brief-pulse devices. During the procedure, the patients were sedated using propofol or thiopenthal. Succinylcholine (1 mg/kg) was used as muscle relaxant, and glycopyrrolate (0.2 mg) or atropine was used as an anticholinergic agent when necessary. The mean charges were 351 (SD, 143) mC for the unilateral electrode placement group, 417 (SD, 192) mC for the bitemporal electrode placement group and 260 (SD, 76) mC for the bifrontal electrode placement group, (Brus, Ole MSc, 2017).~The average course of treatment for depression is 6 to 12 treatments, but some patients may require as many as 20 treatments,"
46023910|NCT00627237|Behavioral|Waitlist|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
46110563|NCT00829244|Drug|GONAL f® prefilled pen|GONAL f® standard treatment arm (150 IU of GONAL f® per day) up to Day 5 of stimulation after which the dose can be adjusted based upon the subject's ovarian response and according to the center's standard practice.
46110564|NCT00787605|Drug|Amlodipine|Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
46110565|NCT00787605|Drug|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide 12.5 mg for 1 week followed by Hydrochlorothiazide 25 mg for 7 weeks
45469466|NCT01249469|Other|skin whitening cosmetic product|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand
45469467|NCT03915743|Other|palliative care|complex and multi-faceted individualized palliative care
46023911|NCT00948688|Radiation|Radiation therapy|Once per day, 5 days a week for 6 weeks
46110566|NCT00787605|Drug|Aliskiren|Aliskiren 150 mg for 1 week followed by Aliskiren 300 mg for 7 weeks
46110567|NCT00448591|Drug|bevacizumab [Avastin]|10mg/kg iv on day 1 of each 3 week cycle, or 15mg/kg iv on day 1 of each 2 week cycle
46110568|NCT00448591|Drug|Taxane-based chemotherapy|As prescribed
46110569|NCT00651664|Drug|alisertib|Alisertib (MLN8237) capsules
45469468|NCT03760159|Device|Kinocardiography unintrusive recording|"The Kinocardiography (Kino) is a device which records the electric and mechanic function of the heart. The device comprises a combination of ECG recording, (6 degrees of freedom), accelerometer and gyroscope sensors. The Kino device consists of a back and a chest housing in contact with the patient. The back housing is placed in the middle of the lower back of the patient, and the chest housing is placed on the chest (either on the sternum or on the costal grill at the apex of the heart). The housings are connected by two cables. Data obtained from the device are visualized on a digital application via a Bluetooth connection.~For the group A, the KCG records the cardiac signals while the patient performs specific respiratory manoevres, as describe above.~For group B, C, D, the KCG records the cardiac contraction during sleep along with the PSG recording."
46023912|NCT00948688|Drug|5-FU|Intravenously over 24 hours, 7 days per week during each week of radiation therapy
46023913|NCT00948688|Drug|Vorinostat|Taken orally. Dose will depend upon time of enrollment and how well previous participants tolerated the drug
46023914|NCT02188264|Drug|Cyclosporine|Given PO
46023915|NCT02188264|Other|Laboratory Biomarker Analysis|Correlative studies
46110570|NCT00787527|Drug|Zolinza (vorinostat)|Up to two 100 mg capsules of Vorinostat (dosage will vary from 100 mg orally (PO) twice daily (BID), 300 mg PO every evening and 200 mg PO BID with the starting dose at 300 mg PO every evening for the phase I trial) are to be administered orally twice daily (once in the morning and once in the evening, or if in the daily dosing cohort once in the evening) in repeated 21-day cycles consisting of 10 days dosing starting on days 5 through 14 followed by a 7-day rest period, during which no vorinostat will be administered.
46110571|NCT00787527|Drug|Cyclophosphamide|750 mg/m^2 by vein over 1 hour on Day 1 of 21 day cycle
46110572|NCT00787527|Drug|Doxorubicin|50 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle
46110573|NCT00787527|Drug|Vincristine|1.4 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle
46110574|NCT00787527|Drug|Prednisone|100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
46110575|NCT04105881|Dietary Supplement|Investigation|Cross sectional intervention
46110576|NCT00804388|Procedure|Total hip arthroplasty|32 mm versus 36 mm caput of ceramics Vitamin E stabilized polyethylene
46110577|NCT04025151|Behavioral|Alcohol brief intervention|At baseline, subjects will receive face-to-face or online alcohol brief intervention developed based on the guideline by the World Health Organisation in 5-10 minutes
46110578|NCT04025151|Behavioral|12-page health warning leaflet|Nurses will provide information about the consequences of drinking using a 12-page health warning booklet. Benefits of reducing and quit drinking will be emphasized by focusing on improving their perception towards the impacts on health, social problems, risky behaviors, academic performance and financial issues.
46110579|NCT04025151|Behavioral|Regular messages through Instant Messaging (IM)|A total of 26 e-messages will be scheduled: once daily for the first week, 3 time/week for subsequent 4 weeks and 1 time/week for the remaining 7 weeks. The frequency will be adjusted according to IM Apps conversation and subject's requests.
46023916|NCT02188264|Other|Pharmacological Study|Correlative studies
46023917|NCT02188264|Drug|Selumetinib|Given PO
46023918|NCT02857114|Other|massage|
46023919|NCT01233050|Drug|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol|Preoperative skin antisepsis preparation
46023920|NCT01233050|Drug|Iodine Povacrylex/74% Isopropyl Alcohol|preoperative skin antisepsis preparation
46023921|NCT01232894|Drug|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
46023922|NCT01232894|Drug|Long-acting beta2-agonist|Long-acting beta2-agonist (LABA) bronchodilator monotherapy via inhaler twice daily
46023923|NCT01049217|Drug|pregabalin|Pregabalin 75 mg-300mg twice daily during the course of the study.
46110580|NCT04025151|Behavioral|Real-time chat-based support through IM Apps|The chat-based IM support is the extension of baseline ABI and regular e-messages, which aims to provide real-time behavioral and psychosocial support to reduce or quit drinking. It will be personalized according to the subjects' characteristics (gender, drinking pattern and alcoholic drinks preferences), intention to drink and specific questions regarding drinking. Through real-time chatting (text and/or voice), drinkers can acquire information on consequences of drinking and gain social support immediately to reduce intention to drink and alcohol consumption.
46110581|NCT04025151|Behavioral|General health through SMS|After baseline, they will receive regular e-message through SMS with similar frequency to Intervention group with content on general health and the reminding the importance of participating in the follow-up surveys.
46110582|NCT04025151|Behavioral|AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong|"a diagram explaining drinking behaviour and potential health risks, definitions of alcohol unit and binge drinking, and advise on limiting daily drinking to 2 alcohol units for men and 1 unit for women"
46110583|NCT00804466|Device|OncoE6|HPV oncoprotein assay
46110584|NCT00804466|Device|EVA System|low-cost colposcope
46110585|NCT00806884|Other|Physiotherapy Musculoskeletal Treatment|Other: Physiotherapy Musculoskeletal Treatment Specific, gentle oscillatory mobilisations to the rib cage and thoracic spine of the subjects to improve joint alignment and mobility, and to reduce pain. Treatment of specific muscle dysfunction or tight muscle groups to further optimise muscle length and biomechanical relationships in the area , leading to improved efficiency of recruitment and improved power output. Postural education and awareness discussions to improve the subject's own joint alignment and ability in a functional manner. A short programme to reinforce the progress during the treatment sessions may be given.
46110586|NCT00806884|Other|Control group measurements|None other than control group measurements
45838568|NCT04385550|Drug|Paclitaxel injection|Paclitaxel injection 80mg / m² IV on Days 1, 8 and 15 of each 28-day cycle.
45838569|NCT04385550|Drug|Docetaxel injection|Docetaxel injection 75mg / m² IV every 3 weeks of each 21-day cycle.
46023924|NCT01049217|Drug|placebo|Subjects may be assigned to placebo during this study. The study duration is approximately 19 weeks.
46023925|NCT01232738|Drug|rasagiline|rasagiline 2 mg daily for 12 months
46110587|NCT04025073|Other|Dietary Approaches to Stop Hypertension|The DASH diet will have a reduced caloric intake by 400 kcal/day, when compared to the standard hospital diet. The DASH diet will be planned according to the following: total daily energy intake 1,900 kcal; total daily fat intake 27%; daily intake of saturated fatty acids 6%; total daily protein intake 18%; total daily carbohydrates intake 55%; cholesterol 150 mg/day; sodium 2,300 mg/day; potassium 4,700 mg/day; calcium 1,250 mg/day; magnesium 500 mg/day; and fiber 30 g/day.
46023926|NCT04206644|Other|biological analysis|biological analysis of the Concentration of CCL18
46023927|NCT00957268|Drug|Alogliptin|Alogliptin tablets
46023928|NCT02888444|Drug|Varenicline|Two 0.5mg tablets taken twice daily
45681605|NCT05582278|Drug|HAIC|FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 100 mg/m2 infusion for 2 hours; calcium levofolinate, 200 mg/m2 infusion for 1 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
46023929|NCT02888444|Behavioral|Behavioural support|Consisting of the study-specific doctor delivering relapse prevention orientated behavioural support at the time of consultation, plus six 10-15 minute calls over the 12 weeks delivered by a research assistant.
45681606|NCT05582278|Drug|Lenvatinib|12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight <60 kg
45681607|NCT05582278|Drug|tislelizumab|tislelizumab 200 mg, every 3 weeks.
45681608|NCT05582122|Biological|HPV16 Ct-DNA dosing|"Droplet based digital PCR (ddPCR) technology is a novel method for performing digital PCR. A sample is fractionated into 20,000 droplets, PCR amplification of the template molecules occurs in each individual droplet.~ddPCR allows to generate quantitative and accurate data without standard curves and also present higher sensitivity compared to conventional quantitative PCR (qPCR). Indeed, this method is based on the realization of millions of single-molecule PCRs in parallel in independent compartment (here droplets of an emulsion) and consequently avoids the bias seen in conventional PCR.~ddPCR offers an optimized approach for the sensitive detection and quantification of low-target-abundance biological samples.~DNA extraction will be planned on 1 mL of plasma, which will further increase the sensitivity of our technique initially based on only 200µL of DNA extracted plasma."
45681609|NCT04147702|Other|Balance analysis|Balance analysis is assessment method to estimate deterioration of postural control.
45681610|NCT03902080|Drug|Vibegron|oral administration
46023930|NCT02888444|Drug|Placebo|Two 0.5mg tablets taken twice daily
46023931|NCT02888132|Procedure|Echocardiography-guided transthoracic radio frequency ablation for HOCM ventricular septum|
46023932|NCT02888132|Procedure|Echocardiography-guided transthoracic laser ablation for HOCM ventricular septum|
46023933|NCT02158858|Drug|Pelabresib (CPI-0610)|
46023934|NCT02158858|Drug|Ruxolitinib|
46110588|NCT04025073|Other|Nutrition education program|The nutrition education program will consist of four lectures intended to improve the overall participants' dietary habits. The lectures will be interactive and will be organized in smaller groups (up to 10 participants) covering the following themes: My Plate dietary guidelines; Principles of a balanced diet; Reading and understanding food nutrition labels; Dietary recommendations for elevated blood pressure, dyslipidemia, and diabetes mellitus.
46023935|NCT01230788|Drug|rituximab|375 mg/m2/dose on days 8, 15, 22, and 29 (diluted in NS to a final concentration of 1 mg/ml for ease of administration). (Premedicate with Acetaminophen 15 mg/kg po (max 650 mg) and Diphenhydramine 1 mg/kg IV/PO (max 50 mg)).
46110589|NCT00810238|Biological|C-Cure|Intraventricular injection
46110590|NCT03998007|Device|IRIS System|A QEEG based pain biomarker that scales with the patient reported NRS
46110591|NCT00806962|Drug|Adjuvant/Excipients|intranasal,14 mg chitosan, 3 mg mannitol, 3 mg sucrose and 50 mcg of MPL, 2 doses 21 days apart
46110592|NCT00806962|Device|placebo|intranasal, puff of air, 2 doses, 21 days apart
46110593|NCT00806962|Biological|Norwalk VLP Vaccine|intranasal, 50mcg, 2 doses--21 days apart
46110594|NCT00806962|Biological|Norwalk VLP Vaccine|Intranasal, 100 mcg, 2 doses, 21 days apart
46023936|NCT04269694|Drug|Medihoney dressing|Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
46023937|NCT04269694|Device|Medihoney dressing|Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
46023938|NCT01230710|Drug|Erlotinib|Erlotinib was supplied as tablets.
46023939|NCT04269616|Behavioral|Order of pictographs provided to participants|The pictographs presented to participants about survival and disability were varied in the order in which they were presented (i.e. survival or disability information first).
46023940|NCT04269616|Behavioral|Level of description in survival pictograph|The pictographs presented to participants about survival and disability were varied in the level of description provided in the survival pictograph (i.e. only numerical data, or also a description of course of NICU stay).
46023941|NCT00627081|Drug|remifentanil|dosage
46110595|NCT04105569|Procedure|Stent-Induced Biofilm Overgrowth|Customized acrylic dental (sextant) stent will be used during brushing for 21 days to influence reversible gingival tissue inflammation.
46110596|NCT00804544|Device|SPECT/CT|SPECT/Low-Dose MultiSclice CT
45469469|NCT03687047|Device|New complete dentures|Preliminary impressions using stock trays and impression compound; primary casts fabricated to make custom trays for definitive impressions; definitive impressions using zinc oxide eugenol impression paste; definitive impressions poured with type III dental stone to obtain mastercasts; jaw relations will be recorded, and the casts will be mounted on the articulator; the artificial acrylic resin teeth will be arranged, esthetics will be verified, and the trial dentures will be flasked and polymerized (72°C per 12 hours). The dentures will be finished and polished for insertion and follow-up.
45469470|NCT03760003|Drug|ABX464 25mg|ABX464 25mg (One capsule of ABX464 25 mg + One capsule of placebo) once daily for 16 weeks
45681611|NCT03902080|Drug|Placebo|oral administration
46110597|NCT01019551|Drug|ART Intensification|Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks
46110598|NCT01019551|Biological|Immunomodulation|Starting at Week 8, 1 cycle of 3 injections (1 per week) of recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose.
46110599|NCT00787137|Drug|PG102|A single intravenous infusion
46110600|NCT00787137|Drug|Placebo comparator|Phosphate-buffered saline
45469471|NCT03760003|Drug|ABX464 50mg|ABX464 50mg (One capsule of ABX464 50 mg + One capsule of placebo) once daily for 16 weeks
45681612|NCT01710033|Drug|Placebo|Placebo tables twice daily (BID) for 28 days
45681613|NCT01710033|Drug|CP-690,550 5 mg BID|CP-690,550 5 mg BID for 28 days
45681614|NCT01710033|Drug|CP-690,550 15 mg BID|CP-690,550 15 mg BID for 28 days
45681615|NCT01710033|Drug|CP-690,550 30 mg BID|CP-690,550 30 mg BID for 28 days
46023942|NCT01230554|Device|Daily disposable cosmetic tint lens|Bausch & Lomb daily disposable cosmetic tint contact lens worn on a daily disposable basis for 1 week.
46023943|NCT04302909|Other|focused extracorporeal shock wave therapy|40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
46023944|NCT04302909|Other|sham focused extracorporeal shock wave therapy|40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
46023945|NCT04302909|Other|night splint|40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
45469472|NCT03760003|Drug|ABX464 100mg|ABX464 100mg (two capsules of ABX464 50 mg) once daily for 16 weeks
45469473|NCT03760003|Drug|Placebo|Two capsules of placebo once daily for 16 weeks
46110601|NCT02553226|Drug|Oxytocin|Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
46110602|NCT02553226|Drug|Placebo|Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
46110603|NCT00810316|Drug|Alprazolam|Administration of a single oral dose tablet of 1 mg of alprazolam immediate release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
46110604|NCT00810316|Drug|Alprazolam XR|Administration of a single oral dose tablet of 1 mg of alprazolam modified release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
46023946|NCT02888054|Drug|lesinurad/allopurinol 200/300 FDC tablet|
46110605|NCT00810316|Drug|Clonazepam|Administration of a single oral dose of two tablets of 0.5 mg of clonazepam on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
46110606|NCT00448435|Drug|GW815SF HFA MDI|salmeterol and fluticasone propionate combination
46110607|NCT00448435|Drug|salmeterol and fluticasone propionate|salmeterol + fluticasone propionate
45469474|NCT04822493|Other|Counseling Aid|Women will watch an educational video regarding expectations for delivery and postpartum care in addition to receiving standard care and counseling.
45469475|NCT01249937|Drug|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
46023947|NCT02888054|Drug|lesinurad 200 mg|
46023948|NCT02888054|Drug|allopurinol 300 mg|
46023949|NCT02816359|Other|head-bed position|Head-bed position at 0° for 30 minutes then head-bed position at 30° for 30 minutes
45469476|NCT01249937|Drug|Triamcinolone Acetonide|Sub-tenon injection of 40mg/mL dosage at months 0 and 2 with follow up for a total of 6 months.
45469477|NCT05138783|Device|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
45469478|NCT05138783|Device|Nesofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
45469479|NCT01321645|Drug|Azadirachta Indica|To start with subjects will be prescribed Azadirachta Indica in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
45469480|NCT03915353|Other|No Intervention|No Intervention
45469481|NCT03765151|Device|low-level laser therapy|LLLT will be performed by a diode gallium-aluminum-arsenide (Ga-Al-As) laser with a 940-nm wavelength (Ezlase; Biolase Technology Inc., Irvine, CA) and delivered by a quadrant-sized probe which cover the region from the central incisor to the first molar on the test side. The laser probe will be 1 cm from the soft tissue around the test tooth at the gingival margin and alveolar mucosa covering the root area using a setting of 800 milliwatt in a continuous wave. Each tooth will receive 30 seconds of exposure, with no more than 8.6 J/cm2 of energy delivered. In addition, a spot-size laser probe will be applied for 30 seconds 5 mm from the cervical dentin with an output power of 700 milliwatt to reduce tooth sensitivity.
45681616|NCT04148170|Procedure|Endodiathermy Probe and Intubation Versus Intubation|children suffer from congenital nasolacrimal duct obstruction will have probing with endodiathermy probe and then intubation with bicanlicular silicon tube
46023950|NCT05477810|Drug|Treatment A (investigational drug) followed by Treatment B (reference drug)|Two drug administration periods (1 and 2), each consisting of administration of Treatment A (investigational drug) followed by Treatment B (reference drug) on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
46110608|NCT00804622|Drug|telbivudine|daily oral administration,600mg,over 12 weeks
46110609|NCT00804622|Drug|tenofovir disproxil fumarate|daily oral administration,300mg,over 12 weeks
46110610|NCT00804622|Drug|telbivudine plus tenofovir disproxil fumarate|daily oral administration of telbivudine 600 mg and tenofovir disproxil fumarate 300 mg in combination given over 12 weeks
46110611|NCT02603055|Biological|30μg/0.5ml Hepatitis E vaccine|three doses, 30μg/0.5ml per dose
46023951|NCT05477810|Drug|Treatment B (reference drug) followed by Treatment A (investigational drug)|Two drug administration periods (1 and 2), each consisting of administration of Treatment B (reference drug) followed by Treatment A (investigational drug) or on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
46110612|NCT02603055|Biological|30μg/0.5ml Recombinant Hepatitis E vaccine|30μg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co.,Ltd.,three doses, 30μg/0.5ml per dose
46110613|NCT00810472|Other|HLA Matching|HLA matching is exerted by selecting the donor with least-most additional HLA alleles. We will predict the waiting time for such a donor in order to assess eligibility for the trial [8]. In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method [6]) is accepted if the patient is waiting less than half of his predicted waiting time. The next available donor exerting a 2/6 match (or better) is assigned thereafter. The next graft will be assigned, regardless of HLA matching after 6 months.
46110614|NCT00810472|Procedure|Penetrating keratoplasty|Corneal transplantation.
46023952|NCT02815969|Other|vena punction|vena punction and urine collection
46110615|NCT02603289|Device|Invisalign|
45469482|NCT03765151|Other|orthodontic retention|All participants included will wear fixed lingual retainer and removable retainers in the post-orthodontic retention period and their previous orthodontic treatment will be carried out by one operator using preadjusted appliances with bonded 0.022×0.028-inch2 brackets/buccal tubes and 0.014-inch Nickel Titanium (NiTi) archwires as the first archwires.
45469483|NCT02528201|Drug|Celecoxib 200 milligrams|Celecoxib 200 milligrams once a day
46023953|NCT02811367|Device|HPV test|Women will perform the HPV self-test and will also undergo a physician-performed HPV test.
45469484|NCT02528201|Drug|Celecoxib 400 milligrams|Celecoxib 400 milligrams once a day
46023954|NCT01040793|Drug|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
46023955|NCT01040793|Drug|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
46023956|NCT01040793|Drug|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
46023957|NCT01040793|Drug|Olodaterol (BI1744)|Comparison of low and high dose on exercise endurance time in COPD patients
46023958|NCT01040793|Drug|Olodaterol (BI 1744) placebo|Placebo that represents olodaterol
46023959|NCT04204447|Other|Hepatitis C Educational Brochure|Subjects will receive information about Hepatitis C through a brochure
46023960|NCT04204447|Other|Hepatitis C Educational Video|Subjects will receive information about Hepatitis C through a video
46023961|NCT04155151|Other|6 minute walk test|A test of fitness that requests the participant to walk as far as they can at their own pace in 6 minutes, the distance walked in those 6 minutes is recorded.
46023962|NCT02690233|Procedure|Elective Surgery|Elective laparoscopic inguinal hernia repair
46023963|NCT02811055|Biological|Blood sampling|Blood sampling for Plasma aldosterone, Plasma cortisol, plasma renin, plasma electrolytes after before and after administration of Aprepitant 80 mg once per day during 14 days or Administration of placebo once per day during 14 days
45469485|NCT02528201|Drug|diclofenac 50 milligrams|diclofenac 50 milligrams three times a day
46023964|NCT02811055|Procedure|Blood Pressure Measurement|Blood Pressure Measurement before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
46023965|NCT02811055|Device|electrocardiogram|Electrocardiogram before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
46023966|NCT02811055|Procedure|orthostatic test|Orthostatic test after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
46023967|NCT02811055|Drug|Administration of Aprepitant|Administration of Aprepitant 80 mg once per day during 14 days
46023968|NCT02811055|Drug|Administration of placebo|Administration of placebo once per day during 14 days
46023969|NCT02810977|Device|Ultrasound|Ultrasound assessment of gastric content and volume
46110616|NCT00804700|Behavioral|Active teaching in synchronous listening to music while exercising|Subjects will be instructed to exercise while listening to four audio tutorials that are stored on their MP-3 player. These tutorials guide the subject on how to synchronize his or her body movements to the beat of the music.
46110617|NCT02602899|Procedure|PINS'Deep Brain Stimulator device|deep brain stimulation of the PINS'IPG function to anterior nucleus of the thalamus is off in a short time
46110618|NCT02553070|Other|Survey|Pharmacy students will be asked to participate in a short (5-7 minutes) survey (see below) that contains 21-short cases involving an exposure to a pharmaceutical or non-pharmaceutical agent. All cases involve children less than 19 years of age. Participants will be asked to indicate their year in pharmacy school (1st or 2nd) and their gender (female/male).
45681617|NCT01822496|Radiation|Radiation Therapy|30 once-daily 2 Gy fractions over 6 weeks totaling 60 Gy of intensity-modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3D-CRT).
46110619|NCT02602743|Drug|Remifentanyl|0,25 µg/kg remifentanyl will be administered for induction in 1 minute. Then 0,1 µg/kg/h remifentanyl infusion will be started.
46110620|NCT02602743|Drug|Propofol|1 mg/kg propofol will be administered for induction and then 1 mg/kg/h propofol infusion will be started.
46110621|NCT02602743|Drug|Ketamine|2 mg/kg ketamine will be administered for induction in 1 minute.
46110622|NCT00810550|Other|Carotid ultrasound|Measurement of intima-media thickness
46110623|NCT00807118|Drug|Fesoterodine|Single dose of 2 x 4 mg tab in formulation F under fed condition
46110624|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fed condition
46110625|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation E(1) under fed condition
46110626|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fed condition
45681618|NCT01822496|Drug|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, AUC=6, IV, days 1 and 22."
45838570|NCT04385316|Diagnostic Test|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of gastric tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of gastric tumor."
46023970|NCT04192903|Drug|Chidamide combined with Cisplatin|Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 75mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off
46023971|NCT02810899|Drug|dexmedetomidine|A loading dose dexmedetomidine (0.5 ug/kg IV infused in 15 minutes) will be administered after anesthesia induction, followed by a continuous infusion at a rate of 0.5 ug/kg/h until the closure of the brain duramater at the end of surgery.
46023972|NCT02810899|Drug|normal saline|Normal saline will be administered in the same rate, volume and duration as that in the dexmedetomidine group
45469486|NCT03764839|Behavioral|"Perioperative Digital Behavioral Pian Medicine My Surgical Success"|"The My Surgical Success website include 45 minutes of psychoeducation material developed and delivered by Beth Darnall, PhD. Viewers learn basic skills to improve regulation of pain-related distress. Treatment includes an app and a personalized plan for surgical success."
45681619|NCT01822496|Drug|Cisplatin|50 mg/m2, IV (intravenous), on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, cisplatin will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
46110627|NCT00807118|Drug|Fesoterodine|Single dose of 2 x 4 mg tab in formulation F under fasted condition
46110628|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fasted condition
46110629|NCT00810628|Behavioral|Cognitive Behavioral Therapy|Individual interviews and group discussion/training.
46110630|NCT00448279|Drug|trastuzumab|2mg/kg i.v. weekly, or 6mg/kg i.v. every 3 weeks
46110631|NCT00448279|Drug|Chemotherapy|Schedule and dose at the investigator's discretion
46110632|NCT00804856|Drug|BI 6727 (d1 and 15)|BI 6727 (d1 and 15 - one hour iv.v)
46110633|NCT00804856|Drug|BI 6727 (d1 and 15)|BI 6727 (d1 and 15 - one hour iv.v)
45681620|NCT01822496|Drug|Crizotinib|250 mg, orally, twice daily for four 3-week cycles (12 weeks in total)
45681621|NCT01822496|Drug|Erlotinib|150 mg, orally, once daily for four 3-week cycles (12 weeks in total)
45681622|NCT01822496|Drug|Etoposide|50 mg/m2, IV, on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, etoposide will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
46023973|NCT02810665|Behavioral|Visual acuity measurement by ETDRS chart|All participants must complete VA measurement of the study eye using 3 charts including the original ETDRS alphabet, ETDRS Landolt C, and ETDRS numeric charts for 2 times, at least 30 minutes apart.
46023974|NCT04237129|Drug|Gan & Lee Insulin Aspart|All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area.
45469487|NCT05276583|Behavioral|Motivated Learning Task|"The Motivated Learning Task is split into two parts, the learning phase, and the test phase. During the learning phase participants are presented with 72 landscape images (targets) which they must memorise. Each image which participants are shown is associated with a reward amount. During the test phase participants are shown the 72 images they saw during the learning phase, known as targets, intermixed with 72 new images they did not see during the learning phase, known as lures. Participants must decide whether the image is old (i.e., they saw it during the learning phase) or new (i.e. they did not see it during the learning phase). After they have made their old/new decision, participants rate their confidence in their decision on a 3-point scale (i.e., guess, sure, very sure)."
46110634|NCT00804856|Drug|Cytarabine|Cytarabine 2 x 20 mg/d s.c.
46110635|NCT00804856|Drug|Cytarabine|Cytarabine 2 x 20 mg/d s.c.
46110636|NCT01024153|Behavioral|Active video game play|Children will get a Wii video game console and one game at week one and another at week 7. We will monitor their video game play and physical activity during this time.
46023975|NCT02810587|Drug|Topical antibiotics following injection|Either receive or not receive topical antibiotics following intravitreous injection
46023976|NCT02810353|Device|Differential rapid maxillary expansion|Twenty-five patients will be submitted to rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be provided by bands adapted either on the maxillary first permanent molars or on the second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. If the maxillary second deciduous molars will be banded, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars. Both anterior and posterior screws will be activated with a complete turn a day during 6 days. Then, only the anterior screw will be additionally activated for 4 more days. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
46110637|NCT00810706|Drug|exemestane|Patients randomised to receive exemestane (25 mg/day) for 5 years.
46023977|NCT02810353|Device|Conventional rapid maxillary expansion|Twenty-five patients will undergo rapid maxillary expansion using conventional Hyrax expander. Bands will be adapted either on the maxillary first permanent molars or on second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. Similarly to the experimental group, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars if the maxillary second deciduous molars will be banded. The expander screw will be activated with a complete turn a day during 6 days. After the expansion active phase, the screw will be fixed with acrylic resin and the appliance will be kept in the dental arch as a retainer for 6 months.
46110638|NCT00807196|Drug|Rituximab|250mg/m2 day -21 and day -14 of preparative regimen
45469488|NCT03759769|Other|Wheelchair simulator|Computer application providing 3D first person view of a wheelchair, with six different activities: street crossing, entering an elevator, entering an adapted van, bathroom, shopping mall and supermarket
45469489|NCT03759769|Other|Video game|'Kart' driving video game
45469490|NCT01241747|Behavioral|Walking Exercise|3 times per week for 3 months
45469491|NCT01241747|Behavioral|Control|Resistance training 3 times per week for 3 months
46110639|NCT00807196|Drug|90Y ibritumomab tiuxetan (Zevalin)|0.4 mCi/kg IV on day -14 of preparative regimen
46110640|NCT00807196|Drug|Cyclophosphamide|300mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
46110641|NCT00807196|Drug|Fludarabine|30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
46110642|NCT00807196|Other|Non myeloablative allogeneic stem cell transplantation|Blood stem cell infusion on day 0
46110643|NCT00448123|Drug|Tamsulosin|Study Drug
46110644|NCT00448123|Drug|Placebo|Placebo
45469492|NCT05276427|Other|Non Clinical procedure|Non clinical procedure- Informed consent completion and interview session
45469493|NCT01205815|Other|Tissue and blood collection|Tissue will be obtained from a previous biopsy if available, or if unavailable, tissue will be collected from a scheduled biopsy. About3-4 teaspoons of blood will be collected.
45469494|NCT03638193|Biological|CART-meso cells|CART-meso is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m^2 of cyclophosphamide, which will be administered according to standard procedures, Thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects.
46023978|NCT04187365|Other|Duration of Indwelling Catheter|Foley catheter
46110645|NCT00810784|Behavioral|Education|(1) a risk-assessment tool completed at the time of a hospital admission, (2) structured educational sessions on VTE prevention, and (3) audit-feedback where institutional data was reviewed during the educational sessions. These sessions were given once to the clinical pharmacists and on three separate occasions to the medicine house officers.
46110646|NCT00804934|Drug|Lucentis|0.5mg Lucentis every four months
46110647|NCT00805012|Drug|docetaxel+CDDP|docetaxel+CDDP
46110648|NCT00805012|Drug|docetaxel+S-1|docetaxel+S-1
46110649|NCT00922324|Drug|STP206 or vehicle control|STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days
46110650|NCT00447499|Drug|Somatuline Autogel (lanreotide acetate)|Injections
46110651|NCT00447499|Behavioral|Home administration|Questionnaire
46110652|NCT00805090|Drug|Sporanox|200 mg
46110653|NCT00805090|Drug|Diclofenac Sodium|37.5 mg
46023979|NCT02810275|Drug|Folinic Acid|Folinic acid 5 mg, taking in the morning, daily, during four weeks
46110654|NCT02552758|Biological|omega-3 fatty acid|omega-3 fatty acid
46110655|NCT02552758|Biological|placebo|placebo
46110656|NCT02552758|Device|positron emission tomography (PET)|
46110657|NCT00810862|Drug|pimecrolimus active cream|Pimecrolimus 1% cream apply to affected study area twice daily for 21 days
46023980|NCT02810275|Drug|Placebo|Placebo capsule received 1 tablet, taking in the morning, during four weeks
46110658|NCT00810862|Other|placebo base cream|apply to affected study area twice daily for 21 days
46110659|NCT00800436|Drug|Herceptin|Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.
46110660|NCT00810940|Drug|AbelaDrug200|IV 200 ml 28%drug in D5W every six hours, 10 min. duration, until ICP < 20 mmHg, then IV 100 ml same schedule for 24 hours
46110661|NCT00810940|Drug|mannitol|mannitol plus standard treatment
46110662|NCT04109508|Drug|Oral semaglutide|Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
46110663|NCT00655564|Drug|Alefacept|"Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.~Alefacept is supplied as a lyophilized powder. Alefacept contains LFA3-IgG1 Fusion Protein and excipient materials (citrate, glycine and sucrose)."
46110664|NCT00447421|Drug|pemetrexed|"Phase 1: 500 mg/m2 then 400 mg/m2, intravenous (IV), every 21 days x 4 cycles (dose escalation)~Phase 2: 500 mg/m2 then phase 1 determined dose, IV, every 21 days x 4 cycles"
46110665|NCT00447421|Drug|cisplatin|Phase 1 and Phase 2: 75 mg/m2, intravenous (IV), every 21 days x 4 cycles
46110666|NCT00447421|Radiation|radiation|Phase 1 and Phase 2: 50-62 Gy, 25-31 days, cycles 2-4
46110667|NCT00651118|Drug|Placebo|placebo
46110668|NCT00651118|Drug|azelastine Hcl|azelastine Hcl 548 mcg
46110669|NCT00651118|Drug|azelastineHcl / fluticasone propionate|azelastine Hcl 548 mcg / fluticasone propionate 200 mcg
46110670|NCT00651118|Drug|fluticasone propionate|fluticasone propionate 200 mcg
46110671|NCT00447265|Drug|Etanercept|1.) Immune suppressant. 2.) Tumor necrosis factor (TNF) inhibitor.
46110672|NCT00447265|Drug|Lupus Treatment- Standard of Care|Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)
46110673|NCT00447265|Drug|Placebo|
46110674|NCT03641755|Drug|Sapacitabine|Sapacitabine may help to stop the growth of some types of cancers
46110675|NCT03641755|Drug|Olaparib|Olaparib is an inhibitor of PARP (poly [adenosine diphosphate-ribose] polymerase), which means that it stops PARP from working
46110676|NCT00657358|Drug|Lidocaine|Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.
46110677|NCT00457639|Drug|Cholic Acid|Capsules of active Cholic Acid or matching placebo, total dose is 15 mg/kg per day, maximum dose of 1500 mg per day, taken PO, BID.
46110678|NCT00800202|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
46110679|NCT00800202|Drug|carboplatin|AUC6 iv every 3 weeks for 6 cycles
46110680|NCT00800202|Drug|erlotinib [Tarceva]|150mg/day po
46110681|NCT00800202|Drug|paclitaxel|200mg/m2 iv every 3 weeks for 6 cycles
46023981|NCT05646745|Procedure|Autologous Transobturator Fascia Lata Sling|"Hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through incision in the lower lateral aspect of the thigh, 4 cm above the knee, ~1 cm× ~5 cm fascial strip is isolated from the fascia lata. Two stay sutures are secured to the corners of the fascial segment on each side.~About 1cm skin incision is performed at the thigh fold on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration of the fascial strip."
46110682|NCT00811096|Drug|Tinidazole|2gms, p.o. q.d. for 5 days
46110683|NCT00811096|Drug|chloroquine|
46110684|NCT00805402|Other|flow cytometry|flow cytometry
46110685|NCT04045756|Device|Procedure/Surgery: Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates 1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bollous of i.v. corticosteriods () is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Cirpofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
46110686|NCT05608278|Behavioral|Bergen 4-Day Treatment (B4DT)|Novel CBT treatment
46110687|NCT05608278|Behavioral|Gold standard cognitive behavioral therapy (gold standard CBT)|Gold standard CBT treatment
46023982|NCT02809807|Other|measurement of the work of breathing|We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Comfort has also been assessed. FreeO2 System has been used and pre-programmed in accordance with the patient SpO2 target zone for potential correction of the hypoxemia occurrences. Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
46110688|NCT05146804|Other|BroccoCress|BroccoCress® is a brand name for an edible plant, broccoli sprouts. BroccoCress® is a product within the group of vegetable sprouts.
46110689|NCT05146804|Other|Affilla Cress|Pea sprouts commercially available as Affilla Cress® will be used as placebo in this study since these sprouts do not contain Glucoraphanin/Sulforaphane.
45681623|NCT01822496|Drug|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
45681624|NCT03937726|Other|Boiled peanut|Desensitisation using boiled peanut for induction and initial updosing
46023983|NCT02809807|Device|Gas Mask|Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
46023984|NCT00948064|Drug|Vorinostat|200 mg by mouth three (3) times per day with food for 5 days (Days 1 - 5)
46110690|NCT00655486|Drug|lacosamide|Subjects' dose of lacosamide may be increased or decreased as needed to maintain a subject's effective and tolerable dose during the study. Tablets are 50 mg or 100 mg each; Dose is 100 mg/day up to 800 mg/day administered twice daily throughout the study (up to 2 years).
46023985|NCT00948064|Drug|Azacitidine|75 mg/m^2/day given intravenously over 15 - 30 minutes daily for 5 days (Days 1 - 5)
46023986|NCT02813239|Other|hCG|Oocyte maturation with hCG
46023987|NCT02813239|Other|hCG + GnRH agonist|Oocyte maturation with hCG + GnRH agonist
46023988|NCT02815501|Biological|blood samples|for the determination of thyroid hormones (TSH, FT3, FT4 ) and antibodies against the thyroid (anti TPO antibodies and anti thyroglobulin)
46023989|NCT02854930|Other|questioning|
46023990|NCT02813161|Biological|cellular and tissue based therapy|
46023991|NCT02813161|Device|negative pressure wound therapy|
46023992|NCT02813161|Procedure|debridement|
46023993|NCT02813161|Procedure|advanced wound therapy|
46023994|NCT02813161|Dietary Supplement|Nutritional screening|
46023995|NCT02813161|Device|off-loading|
46023996|NCT02813161|Device|Hyperbaric oxygen Therapy|
46110691|NCT04111302|Other|IV-PCA|IV-PCA contains dezocine 10mg, sufentanil 100ug, metoclopramide 20mg and normal saline are prepared into 100ml solution and pumped evenly at the speed of 2ml/h.
45681625|NCT03937726|Other|Defatted roasted peanut flour|Desensitisation using defatted peanut flour for induction and initial updosing
46023997|NCT04271098|Procedure|Open-Heart Surgery for nine months duration|In a single group of patients including 340 patients undergoing open-heart surgery during a period of nine months, the collected parameters include; alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), total bilirubin (TBIL), and gamma-glutamyl transpeptidase (GGT) and albumin preoperatively and on postoperative days of 1, 3 and 7. All patients were divided into two groups as with or without hyperbilirubinemia, and this was defined by the occurrence of a plasma total bilirubin concentration of more than 34 µmol/L (2 mg/dL) in any measurement during the postoperative period. For each diagnostic test, a comparison within the group for different time points was statistically evaluated by analysis of variance tests.
46110692|NCT04111302|Other|IV-dezocine|IV-dezocine contains dezocine 5mg and 250ml normal saline are made into solution and injected intravenously twice a day for 3 consecutive days after surgery.
46023998|NCT04271098|Other|Relation between possible risk factors and hyperbilirubinemia|Possible preoperative, intraoperative, and postoperative risk factors were investigated. The relations between hyperbilirubinemia and possible risk factors are sought by the use of the statistical analysis methods including logistic regression analysis.
46023999|NCT04271098|Other|Follow-up period|All patients were investigated for a period of ten days postoperatively. During this period, intensive care unit (ICU) stay, in-hospital stay, and all adverse events were recorded.
46024000|NCT02813005|Procedure|Jet ventilation group|MONSOON III™ (Acutronic Medical System AG®, SEBAC) with Double lumen catheter 12CH (Acutronic Medical System AG®, SEBAC)
45469495|NCT03758677|Drug|Apatinib|30 patients who progressed after EGFR-TKI treatment without T790M mutation will receive apatinib 250mg qd orally combine with chemotherapy , if the patient has a grade 3/4 adverse reaction during such treatment, apatinib should be reduced to 250mg orally once per two days. Chemotherapeutic agents are limited to platinum-based double drugs(Pemetrexed,Gemcitabine,Docetaxel).
45469496|NCT03915509|Device|Evaluation of the effect of surface properties on the stability of the different implants with resonance frequency analysis|Lasak Impladent Implants (sandblasted)
46024001|NCT02813005|Procedure|Standard ventilation group|apnea made by the anesthesiologist to the request of the radiologist
45469497|NCT05276271|Diagnostic Test|the blood sample test results|Retrospectively the fasting blood samples results were obtained for serum thyroid-stimulating hormone (TSH), free triiodothyronine, free thyroxine, total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, Triglyceride/HDL Index, uric acid, CRP, and transaminases at the administration.
45469498|NCT03758599|Procedure|Climbing|All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
46024002|NCT02858206|Radiation|IMRT simultaneous integrated boost|To achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively
45469499|NCT03758599|Procedure|Nordic Walking|All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
46024003|NCT02858206|Drug|Nimotuzumab|nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks
46024004|NCT02858206|Drug|Paclitaxel|Paclitaxel from 45 to 60 mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
46024005|NCT02858206|Drug|Nedaplatin|Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
46024006|NCT02858206|Procedure|Esophagectomy|Radical esophagectomy 4-6 weeks after neoadjuvant therapy
45469500|NCT03758599|Procedure|Social Contact|All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
46110693|NCT04111302|Other|IV-PCA+AA|IV-PCA contains dezocine 10mg, sufentanil 100ug, metoclopramide 20mg and normal saline are prepared into 100ml solution and pumped evenly at the speed of 2ml/h. And selecting the auricular points TF4, AH6a, HX2, HX5, CO4, AT4 and cowherb seeds will be attached to each auricular point after the auricle skin is disinfected. The participants will be asked to press the cowherb seeds against the auricular points every 2 hours during waking hours; each point is stimulated for one minute. Auricular points are pressed unilaterally, and the cowherb seeds will be replaced with new ones every 2 days, alternating from left to right.
45469501|NCT03764683|Drug|Suvorexant (Belsomra)|Suvorexant (Belsomra) is approved by the U.S. Food and Drug Administration (FDA) to treat insomnia. It has not yet been studied in people with bipolar disorder who have problems sleeping.
45469502|NCT03764683|Drug|Placebo|Subjects will take placebo capsules (containing no active substance) identical in appearance to those containing Suvorexant
46024007|NCT05581615|Other|Inulin|Each intervention provided 10 g/d inulin split into two dosages of 5 g.
46024008|NCT02810119|Drug|LO2A|
46024009|NCT02810119|Drug|Placebo|
46024010|NCT02810041|Dietary Supplement|yoghurts enriched with XXS|
46024011|NCT02810041|Dietary Supplement|yoghurts non enriched with XXS|
46024012|NCT02809885|Biological|Hepatitis E serology|
46024013|NCT02815189|Procedure|Ibuprofen for post operative pain|All treatment sessions were approximately 50 minutes in length to allow for acceptable time for completion of treatment and retreatment in one or two visits. All the clinical procedures were performed by the author. Following local anesthesia with 2% lidocaine with 1:100,000 epinephrine (Septodont Saint-Maur des Fossés, France) and rubber dam isolation the tooth was disinfected with 5.25% NaOCl (Ultra bleach, Bentonville, AR, USA).
46024014|NCT02815189|Drug|Acetaminophen 325 mg for Flare up|Each patient will be evaluated a week after completion the clinical procedures.
46024015|NCT02809963|Drug|Eplerenone|50 mg tablets, oral use.
46024016|NCT02809963|Drug|Placebo|50 mg tablets, oral use
46024017|NCT05628337|Other|Motivational texting|Health related information relevant to a subject's diagnosis and ongoing treatment
45469504|NCT03414892|Drug|Globalagliatin Hydrochloride|once daily, oral
46024018|NCT05628337|Other|Control|Non-motivational text messages containing no specific health information
46024019|NCT02815111|Drug|Ketamine|Receive an analgesic regimen that involves Ketamine infusions
46110694|NCT04111302|Other|IV-dezocine+AA|IV-dezocine contains dezocine 5mg and 250ml normal saline are made into solution and injected intravenously twice a day for 3 consecutive days after surgery.And selecting the auricular points TF4, AH6a, HX2, HX5, CO4, AT4 and cowherb seeds will be attached to each auricular point after the auricle skin is disinfected. The participants will be asked to press the cowherb seeds against the auricular points every 2 hours during waking hours; each point is stimulated for one minute. Auricular points are pressed unilaterally, and the cowherb seeds will be replaced with new ones every 2 days, alternating from left to right.
46024020|NCT02815111|Drug|Lidocaine|Receive an analgesic regimen that involves Lidocaine infusions
45469505|NCT03414892|Drug|Placebo|once daily, oral
46024021|NCT02815111|Drug|Acetaminophen|May be administered Acetaminophen rectally, by mouth, or intravenously in patients not suitable for either of the other methods of administration
46024022|NCT02815111|Drug|Neurontin|May be given Neurontin by mouth as an approved medication for pain control
46024023|NCT04236817|Behavioral|Pre-packed blisters for distribution of medications|
46110695|NCT00457249|Biological|ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
46024024|NCT04236817|Behavioral|Routine distribution of medications|
46110696|NCT00457249|Biological|DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed|0.5 mL, IM
46110697|NCT02552290|Other|Upper Trapezius Stretch|Sustained stretch of upper trapezius muscle
46110698|NCT02552290|Other|Cervicothoracic manipulation|Manipulation to the cervicothoracic spine
46110699|NCT02552290|Other|No intervention|Wait
46024025|NCT04236895|Drug|Gan & Lee Insulin Glargine Injection|All IMPs will be administered as a 0.5 U/kg single subcutaneous dose by a pre-filled pen.
46110700|NCT04111848|Drug|Ketamine|"Patients will be assigned into 2 groups (each of 45):~Ketamine group (group K): will receive a bolus of 0.5 mg/kg ketamine during induction of anaesthesia diluted in 100 ml normal saline, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. The infusion pump concentration will be 0.6mg/ml and the rate of infusion will be 0.2 ml/kg/hour."
46110701|NCT04111848|Drug|ketamine and magnesium|Ketamine and magnesium group (group KM): will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate diluted in 100 ml normal saline over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery. Each ml of the administered infusion will contain 0.6mg ketamine and 40mg magnesium and the rate of infusion will be 0.2 ml/kg/hour.
46110702|NCT05656482|Other|Cats fed with PRO PLAN® LIVECLEAT®|Patient with domestic cats fed with an egg product containing anti-Fel d1 IgY (PRO PLAN® LIVECLEAT®)
46110703|NCT00457015|Drug|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
46110704|NCT00457015|Drug|Phosphate Buffer Saline (PBS), pH 7.0|given as three 1mL subcutaneous injections.
46024026|NCT02809651|Device|Infrascanner|bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.
46024027|NCT02809729|Drug|Cefazolin|2 g of cefazolin diluted in 0.9% saline by endovenous, once, at the moment of anesthetic induction
46024028|NCT02809729|Drug|sterile saline|0.9% saline sterile by endovenous, once, at the moment of anesthetic induction
46024029|NCT02809729|Procedure|oncologic breast surgery|The patient will be submitted to a conservative oncologic breast surgery
46024030|NCT02809729|Other|Microbiology|Samples for quantitative cultures will be obtained in the operating room before antisepsis and the end of surgery. A sample is also collected with the same patterning, on the first postoperative day, immediately after the removal of the dressing placed in the operating room. Will be passed in a standardized manner, a sterile swab soaked in saline over a standard 5cm by 10cm area determined by a field fenestrated sterile filter paper.
46110705|NCT05606328|Behavioral|Emergency Department Delirium Screening and Detection Program (ED-DDP)|Champions will participate in a 1-day workshop, consisting of patient testimonials, small group discussions, delirium and screening tool use (didactics), and role-playing. Following the workshop, champions will receive 3 tele-training sessions; 2 to provide direct observation/feedback while the champion performs a bedside delirium screen, and 1 to provide direct observation/feedback of the champion providing training to the nurse. Once delirium champions complete training, they will provide bedside delirium training for all ED nurses. No adaptations to the ED-DDP will occur between implementation sites and no data will be collected during implementation phases.
46110706|NCT00654940|Drug|Pregabalin (Lyrica)|Oral, 75mg or 150mg capsules, BID
46110707|NCT00654940|Drug|Placebo|Oral, matched capsules, BID
46110708|NCT00588666|Drug|Bevacizumab|
46110709|NCT00588666|Drug|Carboplatin|
46110710|NCT00588666|Drug|Gemcitabine|
46110711|NCT03835351|Device|Urinary Catheter|An intraoperative urinary catheter will be inserted which will be taken out at the end of the case
46110712|NCT00807430|Device|Grindcare (Active)|Active treatment
46110713|NCT00807430|Device|Grindcare (Placebo - the device is not activated)|Placebo treatment
45469506|NCT03311373|Drug|Regimen A|2 inhalations BGF MDI; no spacer device; no oral charcoal - reference formulation/total systemic exposure
45469507|NCT03311373|Drug|Regimen B|2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; no oral charcoal - test formulation/total systemic exposure
46110714|NCT00805558|Drug|moxifloxacin|400 mg moxifloxacin once daily for 7 days
45469508|NCT03311373|Drug|Regimen C|2 inhalations BGF MDI; no spacer device; with oral charcoal - reference formulation/lung exposure
45469509|NCT03311373|Drug|Regimen D|2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; with oral charcoal - test formulation/lung exposure
45681626|NCT03936088|Device|"Intervention -- Headspace mindfulness application"|"Patients will be provided with a pre-paid 12-week subscription to the mindfulness application, and provided an in-person demonstration on how to use it, and the subscription license code will be recorded for the purposes of tracking use after the conclusion of the study. The intervention group will be asked to use the mindfulness app 10 minutes per day/5 days per week. To standardize Pack usage across all participants, users will be asked to complete the Headspace Essentials, Pain Management, and Physical Health Session Packs."
45681627|NCT03936088|Device|"Control -- My Water Balance application"|My Water Balance calculates an individual's recommended daily water requirements and assists users in tracking their daily fluid intake. The control group will be asked to log their water intake for the duration of the study, with requested use of 5 days per week to create an equal control. This application is free to download and use. There are options for in-app purchases and application upgrades, though users will be advised against doing so. Information logged in the application may be stored on a third party server; however, no application data will be extracted by the study team. Application use will be reported via weekly surveys, alone.
46024031|NCT04303377|Biological|Evolocumab|Evolocumab 140 mg every 2 weeks plus Standard of Care, including optimal lipid lowering treatment (high dose of statin ± ezetimibe)
46024032|NCT00953524|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)|0.5 mL, Intramuscular on Day 0 and on Day 21
46024033|NCT00953524|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)|0.5 mL, Intramuscular on Day 0 and Day 21
46024034|NCT00953524|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)|0.5 mL, Intramuscular on Day 0 and day 21
46024035|NCT00953524|Biological|Normal saline solution (placebo)|0.5 mL, Intramuscular on Day 0 and Day 21
46024036|NCT02809573|Drug|Chidamide|In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle.
46024037|NCT02809573|Drug|cyclophosphamide|On Day 1, cyclophosphamide is given in a 20-minute intravenous (IV) infusion at 750 mg/m^2 in 5 minutes after chidamide administration
46110715|NCT00805558|Drug|Ciprofloxacin plus metronidazole|Ciprofloxacin 1000 mg once daily for 7 days; Metronidazole 500 mg twice daily for 7 days
45469510|NCT03759691|Behavioral|Structured interview|Interview contains questions about stroke knowledge and help-seeking behaviour on the day the stroke occured.
45469511|NCT01242605|Drug|selumetinib|The starting dose of selumetinib will depend on the cohort. The first dose of selumetinib to be studied will be 75 mg twice daily (bd). Selumetinib will be taken every day (continuously) either once or twice a day, depending on the dose. Treatment with selumetinib may continue until disease progression.
45469512|NCT01242605|Drug|gemcitabine|gemcitabine: taken in combination with cisplatin will be given at 1000 mg/m*2 in 250 - 500 ml 0.9% saline over 30 minutes by intravenous infusion on days 1, and 8 of each 21-day cycle for eight cycles in total
45469513|NCT01242605|Drug|cisplatin|cisplatin: 25 mg/m*2 in 1000 ml 0.9% saline given over 1 hour followed by 500mls 0.9% saline over 30 minutes followed by gemcitabine on days 1, and 8 of each 21-day cycle for eight cycles in total
46024038|NCT02809573|Drug|adriacin|On Day 1, Adriacin is given in a 20-minute IV infusion at 50 mg/m^2 soon after cyclophosphamide administration.
46024039|NCT02809573|Drug|vincristine|On Day 1, vincristine is given in IV infusion at 1.4 mg/m^2 after adriacin administration.
46024040|NCT02809573|Drug|prednisone|On Day 1 to 5, prednisone is given orally at 100 mg once a day
46024041|NCT02812927|Device|Edelvaiss Multiline-8|Optimised infusion line
46024042|NCT02812927|Device|Standard infusion line|
46024043|NCT04388683|Drug|Nitric Oxide|"Subjects will receive iNO using the INO pulse device at a dose of 125 mcg/kg IBW/hr (equivalent to approximately 20 ppm). The clinical disease severity will be assessed pre-randomization as the worse of 2 scores measured 2 hours apart. Patients eligible for randomization will be those with scores of 1 or 2 (below), and randomization will be stratified according to score (1 or 2). Study drug will begin within 1 hour of randomization. Beginning on the day following randomization (day 1), we will be calculate clinical score, daily, as the average of 3 measurements taken within 2 hour windows centered at 6AM, 2PM, and 10PM."
46024044|NCT02809261|Procedure|Ultrasound-guided perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
46110716|NCT01019785|Dietary Supplement|Ergocalciferol|100 000 U drops is given once
46110717|NCT01019785|Dietary Supplement|Ergocalciferol|500 U drops given once
45469514|NCT04448470|Other|Questionnaire for recording daytime sleepiness over the course of the day|Questionnaire for recording daytime sleepiness over the course of the day
46110718|NCT02604186|Other|Botulinum Toxin Injections|Each patient in the treatment group will receive 400 units of botulinum toxin. 100 units will be injected at adductors at each leg and 100 units will be applied in each triceps surae bilaterally.
46024045|NCT02809261|Procedure|Ultrasound-guided perineural injection with normal saline|Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
46024046|NCT02809261|Drug|Normal Saline|Normal saline is safe for perineural injection.
46024047|NCT02809261|Drug|5% Dextrose|5% Dextrose could decrease the release of CGRP and substance P to reduce the nerve inflamation.
46024048|NCT05644639|Device|StimRouter Neuromodulation System|The StimRouter device is indicated for pain management in adults who have severe, intractable chronic pain of peripheral nerve origin and as an adjunct to other modes of therapy (e.g., medications). The StimRouter device is not intended to treat pain of craniofacial nerve origin.
46024049|NCT01040403|Drug|olodaterol (BI 1744) low|olodaterol (BI 1744) low
46024050|NCT01040403|Drug|low tiotropium bromide|low tiotropium bromide
46024051|NCT01040403|Drug|olodaterol (BI 1744) high|olodaterol (BI 1744) high
46024052|NCT01040403|Drug|medium tiotropium bromide|medium tiotropium bromide
46024053|NCT01040403|Drug|high tiotropium bromide|high tiotropium bromide
46024054|NCT01040403|Drug|Placebo|Placebo
45469515|NCT04448470|Other|Anamnesis and physicial examination|Anamnesis and physical examination, e.g. medication, comorbidities, complaints
45469516|NCT04448470|Other|Questionnaire for quantifying daytime sleepiness|the Epworth Sleepiness Scale (ESS) questionnaire and the STOP BANG Questionnaire
45469517|NCT04448470|Diagnostic Test|Pulmonary function test|The measured values of spirometry/body plethysmography, CO diffusion and blood gas analysis are documented, if available.
46110719|NCT02604186|Other|Placebo Injections|Each patient in the placebo group will receive sterile sodium chloride injections at adductors and triceps surae muscles bilaterally.
46110720|NCT01024543|Drug|Angiotensin II|Angiotensin II
46110721|NCT01024543|Drug|Phenylephrine|Phenylephrine
46110722|NCT01024543|Drug|Placebo|
46110723|NCT00805636|Drug|2-(5-fluoro-pentyl)-2-methyl-malonic-acid ([18F]-ML-10)|[18F]-ML-10 will be radiolabeled at the PET Radioactive Drug Production (RDP) facility at or in close proximity to each clinical site, and will be administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The dose concentration selected for [18F]-ML-10 will be 7 MBq/Kg or 0.19 mCi/Kg. The radioactivity dosage of [18F]-ML-10 administered at each PET/CT session will be at least 300 MBq (8.1 mCi) and not more than 500 MBq (13.5 mCi).
46110724|NCT00805636|Radiation|Stereotactic Radio-Surgery (SRS) therapy|SRS will be administered according to the standard of care using a radiation dose of 14-24 Gy to each lesion.
45469518|NCT04448470|Diagnostic Test|Polygraphy|Polygraphy is a non-invasive portable examination method that the patient uses in the home environment at night to measure possible sleep-related breathing disorders. Typically, the following measurement signals are recorded: nasal airflow, thoracic and abdominal breathing excursions, snoring and breathing sounds via a microphone, pulse, oxygen saturation and position. The evaluation results and the findings are checked by a physician. Essential parameters include the apnoea-hypopnoea index, the number of obstructive, central and mixed apnoea/hypopnoea, the number and duration of desaturation, snoring or the association with a certain position.
45469519|NCT03759613|Other|Gait Analysis|"Gait Analysis: Gait analysis is not a routine assessment tool for upper extremity burn injuries. This analysis is an assessment method to estimate gait symmetry.~Restriction arm swing: Participants in group will be restricted for arm swing using a bandage. Thus, the reciprocal arm swing will be prevented."
45469520|NCT03414814|Drug|Osimertinib 80 MG [Tagrisso]|Osimertinib 80mg once daily until disease progression
45469521|NCT03840525|Behavioral|The Qigong Intervention|Qigong is a low-impact, slow-movement, meditative form of exercise that has helped relieve mental and physical stressors.
45469522|NCT03840525|Behavioral|Sham Qigong|This intervention includes similar body movements to qigong; however, it does not have the meditative or breath work.
46024055|NCT01040403|Device|Respimat|Respimat inhaler
46024056|NCT02809339|Other|Questionnaires|
46024057|NCT00957034|Drug|placebo|placebo patch
46024058|NCT00957034|Drug|testosterone|300 or 450 micrograms/day transdermal testosterone patch
46024059|NCT02812693|Drug|Imatinib Mesylate|Given PO
46024060|NCT02812693|Other|Laboratory Biomarker Analysis|Correlative studies
46024061|NCT02812693|Biological|Pembrolizumab|Given IV
46024062|NCT02812459|Other|Kinesio taping|Kinesio taping is a new taping modality which act diminishing pain.
46024063|NCT02812459|Other|Electrical Stimulation|Electrical stimulation therapy is a electrical current that allow patients diminish pain.
46024064|NCT02857972|Device|Wondaleaf®|Use of Wondaleaf® during menstruation every night in one menstrual cycle.
46110725|NCT00805636|Procedure|Positron Emission Tomography|Each patient will undergo 2 PET/CT sessions, each following intravenous administration of [18F]-ML-10, to assess tracer uptake by the brain metastases treated by SRS. The PET/CT scan will be directed to the brain and will include one bed position. The PET/CT sessions will be performed at baseline, i.e., before the radiation treatment, and on the day after, within 24h after SRS treatment.
46024065|NCT04270552|Drug|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
46110726|NCT00793182|Drug|Ioversol 320 mgI/mL|125 mL of Ioversol administered in the vein
46110727|NCT00793182|Drug|Iodixanol 320 mgI/mL|125 mL of Iodixanol administered in the vein
46110728|NCT01024621|Device|Endomicroscope|Pentax EC3870K, Tokyo, Japan
46110729|NCT01024621|Device|Standard endoscopy|Pentax EG-2931 gastroscope
46110730|NCT00811330|Drug|Atorvastatin 80 mg|Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.
46110731|NCT04110912|Other|This is a registry and no interventions are taking place.|
46110732|NCT00811408|Drug|carboplatin|
46110733|NCT00811408|Drug|cidofovir|
46110734|NCT00811408|Genetic|protein expression analysis|
46110735|NCT00811408|Other|laboratory biomarker analysis|
46110736|NCT00811408|Radiation|brachytherapy|
46110737|NCT00811408|Radiation|radiation therapy|
46110738|NCT00813514|Genetic|VEGF genotyping|blood sample for gene analysis
46110739|NCT00793104|Procedure|Placement of allograft CR Plug in primary injury site|Core defect and implant allograft CR plug
46110740|NCT00807508|Dietary Supplement|placebo|wheat meal capsules with each main meal
46110741|NCT00807508|Dietary Supplement|leucine|daily leucine capsules with each main meal
45681628|NCT01867047|Drug|ACE-I Cessation group|"Subjects stop ACE-I 48 hours prior to surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)"
46110742|NCT00446797|Drug|Non-selective NSAIDS|Non-selective NSAIDs administered at usual (standard) doses.
46110743|NCT00446797|Drug|Celecoxib|celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days.
46110744|NCT00855335|Drug|Darunavir|TMC114 (darunavir) two 300 mg or one 600 mg tablet twice daily up to 12 weeks postpartum in Group 1. TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum in Group 2.
46110745|NCT00855335|Drug|Ritonavir|100 mg tablet twice daily up to 12 weeks postpartum.
46110746|NCT00855335|Drug|Etravirine|200 mg (1*200 mg/2*100 mg) tablets twice daily up to 12 weeks postpartum.
46110747|NCT00855335|Drug|Rilpivirine|One 25 mg tablet once daily up to 12 weeks postpartum.
46110748|NCT00855335|Drug|Darunavir/Cobicistat (FDC)|Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
46110749|NCT00811486|Drug|Spironolactone and conivaptan|Tablet, 50 mg to 200 mg, daily, orally 20 mg intravenously one time over 30 minutes
46110750|NCT00813670|Drug|XPF-001|Single oral dose, or 6 days of repeated oral doses.
46110751|NCT04114188|Drug|Antithymocyte Immunoglobulin (Rabbit)|1st kidney transplant recipients (low risk: PRA/cPRA < 20%, no DSA) will receive short rATG induction (2x1.5 mg/kg) given perioperatively and on first postoperative day. All patients will receive one shot Infliximab mAb at day 2. Since POD1, maintenance IS consists of Tac and tapered steroids therapy.
46024066|NCT04270552|Drug|Placebo|Matched tablets without any active substance.
46024067|NCT04237597|Drug|K-877|K-877 tablets
46024068|NCT04237597|Drug|CSG452|CSG452 tablets
46024069|NCT02854462|Behavioral|Language comprehension intervention|
46024070|NCT02854462|Behavioral|Counting intervention|
46024071|NCT02812381|Procedure|KT|to aplicate neuromuscular bandage technique(KT)
46110752|NCT00811876|Other|Data Collection on Depo-Eligard exposure|Retrospective, Non-interventional
46110753|NCT00915252|Drug|azacitidine|"Starting dose has been determined during run-in dose finding part of the study. Starting dose of the interventional drug is 75 mg/m²/d. Application form:~During induction therapy phase: i.v. on days -5--1 before standard chemotherapy for 1 or 2 cycles, During consolidation therapy: s.c. on days -5--1 before standard chemotherapy (2 cycles).~During maintenance therapy: s.c. on days 1-5 on a 28day cycle till maximum one year after start of first induction therapy."
46110754|NCT00915252|Drug|standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine|"Induction therapy:~Daunorubicin 60mg/m²/d i.v.on days 3,4,5 AraC 100mg/m²/d i.v. on days 1-7~Consolidation therapy:~AraC 1g/m² twice a day on day 1,3,5"
46110755|NCT04125017|Device|ICSI with laser pulse|Using laser pulse before ICSI
46110756|NCT04125017|Device|ICSI with micro needle technique|Using micro needle technique before ICSI
46110757|NCT00813826|Drug|SLC022|SLC022 150 mg capsule, 900mg daily dose
46110758|NCT00813826|Drug|Placebo|Placebo capsule, TID
46110759|NCT00799422|Device|Complete Easy Rub|Commercially marketed contact lens solution for contact lens care
46110760|NCT00799422|Device|ReNu MultiPlus|Commercially marketed contact lens solution for contact lens care
46110761|NCT00799422|Device|Clear Care|Commercially marketed contact lens solution for contact lens care
46110762|NCT00799422|Device|Contact lenses|Acuvue Oasys silicone hydrogel contact lenses per participant's habitual prescription worn 8-10 hours per day for one week.
46110763|NCT00593489|Other|Basal Insulin Initiation Strategy|This multifaceted intervention consists of (1) Diabetes Specialist Consultation Support which entails specialists and educators providing consultation for insulin initiation and titration for the 12 months following the Workshop. Support will consist of prearranged and scheduled communications to review and advise for the first 2 months and will continue on an ad hoc basis for the remaining 10 months, with communication initiated by the physician (2)Community Pharmacy Insulin Initiation consists of trained community pharmacists providing patient education insulin initiation. Education will consist of one individual teaching session, one hour in duration, to review the insulin prescription protocol, insulin injection method, management of hypoglycemia, and self-monitoring of blood glucose.
45469523|NCT03759535|Diagnostic Test|Acute rejection|Donor derived cell free DNA
45469524|NCT03421444|Other|No intervention|No intervention
45469525|NCT03759457|Device|High Flow Nasal Cannula (AIRVO2)|High-flow nasal cannula (HFNC) delivers oxygen flows of up to 60 L/min. The gas source (air/oxygen blender, ventilator, or turbine flow-generator) is connected via an active heated humidifier to a nasal cannula and allows FiO2 adjustment independently from the flow
45469526|NCT03660657|Drug|Ozone|Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 µg/ml; 40 sessions in 16 weeks.
46110764|NCT02551900|Other|Warm water exercise|Warm water based cycling exercise training program will be based on cycling in warm water (temperature 34◦C ). Warm water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
46024072|NCT02812381|Procedure|SCS|To aplicate strain-counterstrain above trigger point
46024073|NCT02854774|Behavioral|Muscle activation exercises|Activation of either muscles activating the knee or hip.
46024074|NCT02812849|Drug|Cu-64 DOTATATE|
46024075|NCT04117594|Diagnostic Test|WB-MRI|Whole body MRI with diffusion-weighted imaging (DWI)
46024076|NCT02812303|Other|Centralized support for population health management activities|
46024077|NCT02809495|Other|use of app in smartphone|
46024078|NCT04236973|Device|Molbio Truenat™ HCV assay (the investigational product)|The Molbio Truenat™ HCV assay (the investigational product) is a quantitative chip-based Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) tests for the detection of HCV genomic RNA from human whole blood, EDTA plasma and serum. The Truenat™ HCV assay runs on the Truelab™ Uno, Truelab™ Duo or Truelab™ Quadro Dx. Results of testing by Truenat™ HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
46024079|NCT04236973|Other|Abbott RealTime HCV assay|Plasma specimens will be also tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities. Only the results of Abbott RealTime HCV assay may be used to make clinical decisions.
46024080|NCT02689999|Drug|Dexrabeprazole 10 mg Enteric-Coated Tablets|
45469527|NCT03660657|Drug|Oxygen|Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 µg/ml (only O2); 40 sessions in 16 weeks.
45469528|NCT03421366|Drug|Posaconazole|A triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients
45469529|NCT03764605|Drug|Metformin|Patieny will be treated by using Metformin from 500 mg a day to 500 mg thrice a day.
45469530|NCT03764605|Drug|Tolvaptan|Patients will be treated with tolvaptan from 45 mg + 15 mg a day to 90 mg + 30 mg a day
45469531|NCT05276193|Other|Observational health care register - no applicable intervention at present|Observational health care register - no applicable intervention at present
45469532|NCT03425890|Behavioral|SURE program|SURE program is a self-exercise program which aims to empower people with stroke and their caregivers to increase early UL practice outside therapy
46024081|NCT02808793|Drug|AK002|
46024082|NCT02809105|Drug|linaclotide|Oral administration once daily
46024083|NCT02809105|Drug|Placebo|Oral administration once daily
46024084|NCT00953056|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|"Single 2.0 mL dose V260 (RotaTeq™) administered orally at enrollment.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses."
46024085|NCT00953056|Biological|Comparator: Placebo|Single 2.0 mL dose of matching placebo to RotaTeq™ administered orally at enrollment.
46024086|NCT00953056|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|"Three 2.0 mL doses of RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses."
46024087|NCT00953056|Biological|Comparator: Placebo|Three 2.0 mL doses of matching placebo to RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.
46024088|NCT02811289|Drug|Mirbetriq (Mirabegron)|50mg of Mirabegron will be administered orally at time 0 in protocol A.
46110765|NCT02551900|Other|Cold water exercise|Cold water based cycling exercise training will be based on cycling in cold water (temperature 20◦C ). Cold water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
46024089|NCT02811289|Other|cold exposure|Acute cold exposure protocol using a water-conditioned cooling suit will be applied from time 120 to 300 min in protocol B
46110766|NCT02551900|Other|Land based cycling exercise|Land based cycling exercise training will be based on ride a bicycle ergometer (Monark 894e, Sweden). Land based cycling exercise training will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
46110767|NCT00446641|Drug|Cilostazol|cilostazol 100mg twice a day for 4 weeks
46110768|NCT00446641|Drug|placebo|placebo 1 tablet twice a day matching for cilostazol
46110769|NCT00646282|Drug|doxercalciferol|The study drug dosage will be initiated according to baseline iPTH levels. For patients with iPTH>300 pg/ml, oral Doxercalciferol will be given at 1 mcg/day; for patients with iPTH <300 pg/ml, oral Doxercalciferol will be initiated at 0.5 mcg/day.
46110770|NCT02551588|Procedure|Valvular aortic stenosis surgery|Dilatation of Valvular aortic stenosis
46024090|NCT02811289|Radiation|injection of 18FDG|I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed at time 270 min, followed by 30 min dynamic PET/CT scanning
46024091|NCT02811289|Radiation|injection of 11C-acetate|i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
46024092|NCT02811289|Radiation|[3-3H]-glucose|i.v. administration of 1.5 uCi/min of [3-3H]-glucose
46024093|NCT02811289|Other|[U-13C]-palmitate|i.v. administration of 0.08 umol/kg/min of [U-13C]-palmitate
46110771|NCT00814060|Drug|neratinib|HKI-272
46110772|NCT00792636|Drug|sumatriptan and naproxen sodium combination tablet|sumatriptan 85mg and naproxen sodium 500mg
46110773|NCT00792636|Drug|sumatriptan tablet|sumatriptan 85mg
46024094|NCT02811289|Other|2H-Glycerol|i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
46110774|NCT00792636|Drug|naproxen sodium tablet|Naproxen sodium 500mg
46110775|NCT00446563|Drug|Valsartan|160 mg film coated tablets taken orally once daily in the morning.
46110776|NCT00446563|Drug|Amlodipine|5 mg or 10 mg tablets taken orally once daily in the morning.
45681629|NCT01867047|Drug|ACE-I Continuation group|"Subjects take ACE-I through day of surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)"
46110777|NCT00446563|Drug|Hydrochlorothiazide|12.5 mg or 25 mg tablets taken orally once daily in the morning.
46110778|NCT00446563|Drug|Losartan|100 mg tablets taken orally once daily in the morning.
45469533|NCT03764527|Drug|Artemether-lumefantrine|Two doses a day for 3 days, under supervision
46024095|NCT02809027|Drug|Ginger|
46024096|NCT02809027|Drug|Placebo|
46024097|NCT02857660|Other|Whole body Electromyostimulation (exercise)|1.5 x 20 min/week (e.g. each Tuesday and every second Friday) with bipolar current, 85 Hz, 360 µs, rectangular mode, intermittent with 4 sec of current and 4 s of rest.
46024098|NCT02857660|Dietary Supplement|Protein|up to 1.5-1.7 g/kg bodymass/d of protein (whey protein)
46024099|NCT02874495|Behavioral|Psychological tests|Related to affective and cognitive dimensions of pain.
46024100|NCT02874495|Device|Magnetic Resonance Imaging|"With a certain or uncertain anticipation phase of distension (warning light) followed or not by a rectal distension at the pain threshold previously determined, and then a retrospective quotation of pain during distension and the fear of pain induced by anticipation. Structural MRI and rest of functional connectivity measure MRI.~With measure of heart rate variability."
46024101|NCT02874495|Behavioral|Heart Rate Variability|During MRI session, from the electrocardiographic signal. (measure of variations on R-R interval in milliseconds ms).
46024102|NCT02808949|Drug|Dapivirine|Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to wear for approximately 14 continuous days. Participants age 18 and over, at least 6 weeks postpartum, able to produce and express breast milk for 14 consecutive days.
46110779|NCT00650806|Drug|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
46110780|NCT00650806|Drug|Placebo|One matching placebo capsule orally once daily for 12 weeks.
46024103|NCT02854306|Procedure|Bariatric surgery|With mindfulness programm
46024104|NCT02854306|Procedure|Bariatric surgery|Without mindfulness programm
45469534|NCT03764527|Drug|Coadministered Artesunate plus Amodiaquine|One dose a day for 3 days, under supervision
45469535|NCT04662489|Procedure|Pulmonary vein electrical isolation|Electrical isolation of the pulmonary veins from the left atrium with cryoablation therapy
46024105|NCT04207177|Drug|Mycophenolate Mofetil 500 mg Tab|Twice daily dosing of MMF only for a week before transplantation in this subgroup. All patients will get maintenance treatment With MMF in combination With tacrolimus and steroids after transplantation.
46024106|NCT04207177|Drug|Tacrolimus capsule|Twice daily dosing of tacrolimus only for a week before transplantation in this subgroup. All patients will get maintenance treatment With tacrolimus in combination With MMF and steroids after transplantation.
45469536|NCT04662489|Procedure|Radial ablation|Electrical isolation of the pulmonary veins from the left atrium plus radial ablation of rotational activity sites with radiofrequency ablation.
45469537|NCT05668975|Device|Inspiratory Muscle Training|A mechanical pressure threshold loading device (POWERbreathe, POWERbreathe International Ltd, UK) will be used for the training.
46024107|NCT02812147|Drug|L-DOPS|Added as described in the Arm/Group Descriptions.
46024108|NCT02812147|Drug|Placebo|Added as described in the Arm/Group Descriptions.dded as described in the Arm/Group Descriptions.
46024109|NCT02854150|Genetic|characterization of variants in new genes using high throughput sequencing either on a panel of targeted genes or on exome in families.|
45469538|NCT04788693|Other|Physical rehabilitation of gait with motor imagery|Physical rehabilitation of gait is a type of non-invasive treatment that seeks to change the way of performing a task or motor function (in this case, gait) through movement modification and corrected repeated practice, taking into account the alterations, limitations and considerations related to the disease suffered by the person. In this intervention, in addition to physical exercise to correct gait, mental exercises will be included in which the patient visualizes himself performing the exercises that he will then develop with the body.
45469539|NCT04788693|Other|Physical rehabilitation of gait without motor imagery|Physical rehabilitation of gait is a type of non-invasive treatment that seeks to change the way of performing a task or motor function (in this case, gait) through movement modification and corrected repeated practice, taking into account the alterations, limitations and considerations related to the disease suffered by the person. Motor imagery exercises are not included in this program.
45469540|NCT03421054|Dietary Supplement|patients assuming nutraceutical containing HA|pain reduction of the affected knee in the patients assuming nutraceutical containing HA
46024110|NCT04303065|Drug|Dexamethasone Oral|It will be a short and descending course of oral dexamethasone: 4mg/6 hours (2 days); 4 mg/8 hours (2 days); 2 mg/6 hours (2 days); 2 mg/8 hours (2 days); 1 mg/8 hours (2 days); 1 mg/12 hours (2 days).
46024111|NCT04303065|Drug|Placebo oral tablet|The preparation and conditioning of the placebo capsules will be carried out following the standardized work procedures of the pharmaceutical laboratory and its quality controls, previously authorized by the Agencia Española del Medicamento (AEMPS).
46024112|NCT02874417|Behavioral|CAST psychoeducation|
46024113|NCT02874417|Behavioral|PHET|
46024114|NCT02081248|Other|Consent Form Specific Format 1|The Consent Form Specific Format 1 is the 'Standard Consent'. The standard consent does not have the format of two-columns with changes in layout readability, organization of content, typography and use of plain language. Standard consents are already used by sites for the BMT CTN 0901, 1101, 1203, and 1301 clinical trials.
46024115|NCT02081248|Other|Consent Form Specific Format 2|The Consent Form Specific Format 2 is the 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent is two-columns with changes in layout readability, organization of content, typography and use of plain language.
46024116|NCT02808715|Other|Blood Sample Collection|Blood draw #1 Site of blood draw: IMU Volume of blood: 20mL Purpose of blood draw: Isolation of genomic DNA Site of storage: NHRIS biobank Coding: Specimens will be identified using a research ID that will be affixed to samples using bar-coding. After the blood is collected, stored the blood at 4 degree Celsius and contact the NHCS biobank coordinator to collect the blood samples. The blood samples must be collected within 1 hour of collection.
46024117|NCT04302129|Procedure|Erector spinae plane block|20 ml local anaesthetic are injected bilaterally on each side of the surgical incision underneath the erector spinae muscle where the dorsal rami pass around the bases of the transverse processes.
46110781|NCT00863057|Drug|Duloxetine|During each treatment period, participants will take duloxetine in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
46110782|NCT00863057|Drug|Duloxetine placebo|During each treatment period, participants will take duloxetine placebo in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
46024118|NCT04302129|Drug|Multimodal analgesia|Ketorolac 0.75 mg/ Kg and paracetamol 10 mg/ Kg intravenously
46024119|NCT02814877|Other|promotion of appropriate use of antibiotics in hospital|promotion of appropriate use of antibiotics in hospital by visiting physicians
46024120|NCT02856958|Procedure|Nerve decompression|
46110783|NCT00863057|Drug|Methadone|During each treatment period, participants will take methadone in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
46110784|NCT00863057|Drug|Methadone placebo|During each treatment period, participants will take methadone placebo in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
46110785|NCT02552602|Dietary Supplement|Multivitamin A|Multivitamin containing 7 micronutrients at recommended daily allowance (RDA)
46024121|NCT02856958|Other|Non-operative|Physical therapy
46024122|NCT00952822|Biological|Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)|Subjects are randomized to receive an infusion of rAHF-PFM reconstituted in 2 mL sterile water for infusion (SWFI) followed (after a wash-out period) by rAHF-PFM reconstituted in 5 mL SWFI or in 5 mL then 2 mL SWFI(cross-over design). Each subject will receive 2 infusions.
46024123|NCT02857738|Drug|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
46110786|NCT02552602|Dietary Supplement|Multivitamin B|Multivitamin containing 22 micronutrients at RDA
46110787|NCT02552602|Dietary Supplement|Multivitamin C|Multivitamin containing 22 micronutrients at three times the RDA
46110788|NCT00814216|Drug|QAV680|
46110789|NCT00814216|Drug|Matching placebo for QAV680|
46110790|NCT00814216|Drug|Fluticasone Propionate|
46110791|NCT00829166|Drug|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
46110792|NCT00829166|Drug|Lapatinib|Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
46110793|NCT00829166|Drug|Capecitabine|Capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
46110794|NCT00799266|Drug|Zoledronic acid|intravenous infusion
46110795|NCT00799266|Drug|Placebo|intravenous infusion
46110796|NCT00650104|Drug|Ropinirole XL (formerly CR)|Active Ropinirole CR tablets of 2.0mg, 4.0mg, 8.0mg where subjects can tritrate to an stable optimum dose level of either 2.0mg, 4.0mg, 6.0mg, 8.0mg, 12mg, 16mg, 20mg, or 24mg per day.
46110797|NCT05231642|Other|Nutritional Interventional|Individualised postprandial glucose and vascular risk responses
46110798|NCT00808054|Drug|EMLA|0.5g topical EMLA
46110799|NCT05030948|Behavioral|Tiempo Juntos Intervention|"If assigned to this group, participants will take part in weekly 1-hour group sessions twice a week for 3 months. The sessions will be with a trained Community Health Worker that will involve group (5-6 participants) moderate-intensity walking. Upon completing the 3 months of physical activity sessions, for the next 3 months, they will receive motivational booster sessions delivered every other week via phone calls/text messaging."
46110800|NCT02552134|Other|exercise training|
46110801|NCT02552134|Other|recommendation to be active|
46110802|NCT04108806|Procedure|Endovascular therapy|Ballon dialtation of the diseased artery
46110803|NCT00814450|Device|Biopsy needle guidance system (ActiSight™)|The ActiSight system assists in guiding an aspiration or biopsy needle, to a designated point within the body by means of CT visualization.
46110804|NCT05102734|Drug|Nitroglycerin Topical Product|Topical nitroglycerin solution
45469541|NCT01321801|Drug|Pregabalin|Preoperative administration of pregabalin 600mg
45469542|NCT01321801|Drug|placebo|Preoperative administration of a matching placebo
46024124|NCT02857738|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
46024125|NCT02854072|Drug|GV1001|At week 1, GV1001 will be administered intradermally on day 1, day 3 and day 5. This will be followed by a once weekly schedule for weeks 2, 3, 4 and 6. After that, GV1001 will be administered once monthly until withdrawal from trial treatment due to patient choice, intolerable toxicity or disease progression. GM-CSF will be used as an adjuvant, given 10-15 minutes prior to each administration of GV1001.
46024126|NCT02854072|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 will be intravenously administered on day 1,8 and 15 followed by 7 days' rest.
46024127|NCT02854072|Drug|Capecitabine|Capecitabine 830 mg/m^2 will be orally given in the morning and evening (total dose of 1660 mg/m^2) for 21 days followed by 7 days' rest.
46024128|NCT01038297|Drug|EXC 001|Intradermal injections of EXC 001 and placebo given on various schedules.
46024129|NCT01038297|Drug|Placebo|Intradermal injections of EXC 001 and placebo given on various schedules.
46024130|NCT02537314|Drug|benzocaine|0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
46024131|NCT02537314|Other|placebo|Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
46024132|NCT04111705|Drug|Lorlatinib|100 mg once daily
46024133|NCT00631150|Drug|Levetiracetam (Keppra)|
46024134|NCT02808559|Device|Bodystudio ATBM (Automatic Total Body Mapping)|The mapping of the entire body is automatically done using a high-resolution apparatus (20 photographs of the patient in 8 positions (face, back, lateral left and right, specific extremities) The photographs will be done with a standardized procedure established by FotoFinder. Every lesion is completely evaluated and the PASI score can be calculated.
46024135|NCT04278040|Drug|Melphalan|Inhalations with low doses of Melphalan for 5 consequent days
46110805|NCT05621226|Behavioral|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
46024136|NCT02812069|Device|ThermaZone® Device|The device will be used to intraoperatively warm patients having minor-to moderate surgical procedures
46024137|NCT05641675|Diagnostic Test|right heart catheterization|Connect to a heart monitor to record heart rate, blood pressure and blood oxygen levels Place sterile sheets on chest and neck (or groin area) Clean the skin over the neck or groin Give local anaesthetic to numb the area (this may sting a little when it is given) Gently pass a catheter into a vein to the heart Record pressure readings from the heart chambers and lungs Give medication, depending on heart's pressure readings Remove the catheter and apply pressure where it was inserted
46024138|NCT00955708|Device|ACUITY Spiral Left Ventricular Lead|The implant of the ACUITY Spiral Lead
46024139|NCT02811757|Procedure|tenotomy|
46024140|NCT02811757|Procedure|tenodesis|
46024141|NCT04237519|Behavioral|SFL training|"The SFL training program comprises:~Physical exercises: 50 video exercises to improve balance, muscle strength and physical capabilities in older adults;~Cognitive exercises: Four ludic activities targeting problem solving (4 Images/ 1 word), memory (Quiz and Recall me), speed processing and divided attention (Attention!).~In addition, the SFL program includes a series of unique components:~Chat rooms: to share views about topics of interest and tips for common real-life problems;~Psycho-education content: to improve self-management and promoting cognitive transfer though 22 different topics (provide recommendations usually given in psychotherapy sessions);~Virtual coach: to guide participants along the proposed exercises by giving them instructions, reminding them regularly to practice a variety of available activities repeatedly, providing appropriate and timely feedback on participant's performances and rewarding assiduity, perseverance and performance."
46024142|NCT04237519|Behavioral|Active controlled training|"The active control training program is structured in the same manner as the SFL training program and will also offer different physical and cognitive activities:~Physical exercises: 12 different exercises trains upper and lower extremity strength, mobility and balance offered through a computerized version of a health insurance company physical training program;~Cognitive activities: Four commercially available leisure activities (Sudoku. Cross Words, Pac-Man and Countdown activities) that are appreciated by older adults but do not teach cognitive strategies and are were not designed to improve cognition per se.~No chat room, psycho-educational content or virtual coach were included in the active control training program."
46024143|NCT02814799|Other|bone removal|
46024144|NCT02856724|Drug|PGE2|10 mg PGE2 vaginal ovul(Propess)
46024145|NCT02808637|Other|Manual Pressure|First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered in accordance with the conventional injection technique.
46024146|NCT02808637|Other|Rapid Injection without Aspiration|First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using rapid injection without aspiration technique.
46110806|NCT00812188|Other|Medium Dose UVA-1|UVA-1 phototherapy treatment (60 J/cm2) three times per week for 12 weeks.
46110807|NCT00812188|Other|High Dose UVA-1|High dose (120 J/cm2)UVA-1 phototherapy three times per week for 12 weeks.
46110808|NCT00814528|Drug|5-ALA plus Blu-Light|20% 5-ALA ampoules will be crushed and prepared for application after shaking for 3 minutes. Topical ALA will be applied liberally on skin with extra pressure on lesions. Incubation of ALA will take place for 0-3 hours. Exposure to Blue U light source (417 nm) (DUSA), will be performed for Actinic Keratosis for 15 minutes. Application of combination light sources will be performed when lesions are traced with one pass of Pulsed dye laser (595 nm) (Candela) followed by exposure to Blue U light source for 5-8 minutes pending response.
46110809|NCT00814528|Drug|5-FU, Imiquimod or treatment with cryotherapy|Cryotherapy will be performed on lesions only every 2 week intervals. Application of Imiquimod will be done on the treated skin area 5 days weekly for 4-6 weeks. 5-FU will be once daily on the treated areas 4- 6 weeks. Responses will be monitored every 2 weeks.
46110810|NCT00915174|Drug|Neramexane|25 mg q.d., 3 days 2 x 25 mg b.i.d., 11 days
46110811|NCT00814606|Drug|Fluvastatin|Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily
46110812|NCT00814606|Drug|Peginterferon alfa2a|180 mcg/ml SQ injection once a week for 48 weeks (starting at week 9)
46110813|NCT00814606|Drug|ribavirin|1000-1200 mg daily orally in two divided doses for 48 weeks (starting at week 9)
46024147|NCT02808637|Other|Manual Pressure + Rapid Injection without Aspiration|First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered by using the rapid injection without aspiration technique.
46024148|NCT02808637|Other|Control|First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using the conventional injection technique.
46110814|NCT04114422|Other|Seven-day preoperative exercise training program|The preoperative exercise training program will be supervised by a physiotherapist and will comprise aerobic exercise on a treadmill as well as strengthening exercises for the upper and lower limbs. The protocol will include 7 daily sessions of 60 minutes in duration. The treadmill exercise will start with a 5-minute warm-up and will progress to 30 minutes of exercise with a speed corresponding to 70% of the maximum speed reached in the incremental shuttle walk test. It will finish with a 5-minute cool down period. Participants will also perform three strengthening exercises for the lower limbs (hip flexion, knee flexion and extension) and three for the upper limbs (shoulder flexion, elbow flexion and extension). The initial strengthening exercises intensity will be set at 60% of 1RM and will be progressively increased. Patients will perform 3 sets of 8 to 12 repetitions for each exercise.
46024149|NCT02808325|Drug|Gelaspan 4%|Gelaspan 4% combined with Sterofundin ISO
46024150|NCT02808325|Drug|Gelofusine 4%|Gelofusine 4% combined with Sodium Chloride
46110815|NCT00814762|Biological|HIV Vaccine 732462|Two doses reconstituted adjuvanted vaccine, injected intramuscularly, at an interval of approximately one month.
46110816|NCT00814762|Biological|Placebo vaccine|Two doses of placebo, injected intramuscularly, at an interval of approximately one month
46110817|NCT00654238|Drug|sorafenib|400mg PO BID daily
46110818|NCT00862979|Drug|Everolimus (EVR)|Everolimus 0.25mg, 0.75mg or 1.0mg based on blood levels (5-10 ng/mL)
46110819|NCT00862979|Drug|cyclosporine A (CyA)|10 mg, 25 mg, 50 mg or 100 mg capsule according to blood levels for CNI-regimen group. For CNI-free-regimen dispense on month 6 to 9 only
46110820|NCT00862979|Drug|tacrolimus (TAC)|0.5 mg, 1 mg, or 5 mg capsule given according to blood levels for CNI-regimen. For CNI-free-regimen give on month 6 to 9 only
46110821|NCT00862979|Drug|Enteric coated mycophenolate sodium (EC-MPS)|180 mg or 360 mg tablet dosed 1440-2280 mg per day
46110822|NCT00862979|Drug|mycophenolate mofetil (MMF)|250 mg or 500 mg tablets with a dose of 1500-3000 mg per day
46110823|NCT00862979|Drug|Corticosteroids|according to local standard: 0.05-0.3 mg/kg of prednisolone or equivalent
46110824|NCT02605356|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|
46110825|NCT02605356|Drug|Placebo|
46110826|NCT02605356|Drug|Bortezomib|
46024151|NCT01037985|Drug|EXC 001|Multiple intradermal injections of EXC 001 and placebo
46024152|NCT01037985|Drug|Placebo|Multiple intradermal injections of EXC 001 and placebo
46110827|NCT02605356|Drug|Dexamethasone|
46110828|NCT00812266|Drug|topotecan + cisplatin|topotecan IV 2 mg/sqm d1-3 + cisplatin IV 50 mg/sqm d3 q3W
46110829|NCT00812266|Drug|Etoposide + carboplatin|Etoposide 120 mg/sqm IV d 1-3 + carboplatin AUC 5 d1 q3W
46110830|NCT00814840|Device|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with two intracardiac leads|Cardiac resynchronization with two intraventricular leads: one in the right ventricle and one in the left ventricle (via the coronary sinus)
46110831|NCT00814840|Device|Triple-site cardiac resynchronization|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with three intraventricular leads: one in the right ventricle and two in the left ventricle (via the coronary sinus). Two left ventricular leads connected with Y-connector (Lead Adaptor 2827, Medtronic, Minneapolis, MN, USA)
46110832|NCT00483379|Biological|alglucosidase alfa|intravenous infusion
46110833|NCT00814918|Drug|5-ALA with Blu-U Light|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to DUSA Blu-U light (417nm).
46110834|NCT00814918|Drug|5-ALA with Candela V-beam Pulse Dye Laser|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to Candela V-beam Pulsed Dye Laser (595 nm).
46110835|NCT04113954|Drug|Mepivacaine Injection|Injection of 0.375% mepivacaine in nerve block
46110836|NCT04113954|Drug|Mepivacaine Injection|Injection of 1.5% mepivacaine in nerve block
46110837|NCT00812344|Drug|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
46110838|NCT00812344|Drug|Ketoconazole|tablets, orally, once daily for 3 days
46110839|NCT00812344|Drug|ketoconazole|dissolved tablets, dosing through the Loc-I-Gut catheter, single dose
46110840|NCT00446251|Drug|Rituximab|Rituximab dose is 1,000 mg given as an IV infusion every two weeks for 2 doses (days 1 and 15).
46110841|NCT00446251|Drug|Mycophenolate mofetil (MMF)|Cellcept is continued from prior study, taken 500 - 1,000 mg BID, P.O.
46110842|NCT00812422|Drug|Dexibuprofen|one dose of Dexibuprofen 2.5 or 5 mg/kg
46110843|NCT00812422|Drug|Dexibuprofen|one dose of Dexibuprofen 3.5 or 7 mg/kg
46110844|NCT00812422|Drug|Ibuprofen|one dose of Ibuprofen 5 or 10 mg/kg
46024153|NCT00955474|Drug|Quetiapine|Quetiapine XR 100 mg/h.s. will be the starting dose and increased by 100 mg q h.s. q day to a target dose of 300 mg/h.s. by day three and continued on 300 mg/h.s. through week three. Between weeks four and eight, there will be flexible dosing up to 800 mg/h.s. or reductions in doses to no lower than 200 mg/h.s. Incremental increases or decreases in dose will be no more than 100 mg/h.s. over a minimum of one week, unless a patient is unable to tolerate the current dose. Patients unable to tolerate at least 200 mg/h.s. will be discontinued from the study.
46024154|NCT00955474|Drug|escitalopram|"Active comparator arm:~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
46024155|NCT00955474|Drug|Sertraline|"Active comparator arm:~Sertraline 50 mg/a.m. starting dose; increased to 100 mg/a.m. at week 2; continued on 100 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 200 mg/a.m. or reductions in doses to no lower than 50 mg/a.m.~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m.~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
46024156|NCT00955474|Drug|Citalopram|"Active comparator arm:~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m."
46024157|NCT02808247|Drug|Nintedanib|Pharmaceutical form: Soft gelatine capsule Pharmaceutical code: Nintedanib (BIBF1120) Source: Boehringer Ingelheim Pharma GmbH & Co. KG Unit strength: 100 mg and 150 mg capsules Daily dose: 400 mg (200 mg twice daily p.o.) Route of administration: oral
46024158|NCT02808247|Drug|Ifosfamide|Ifosfamide will be given at a dose of 3 g/m2 intravenously on days 1, 2 and 3 every 21 days. The total dose per cycle is 9 g/m2
46024159|NCT02037334|Device|Pregnolia System|No intervention is done except for measuring the stiffness of the cervix in pregnant women
46024160|NCT02808091|Drug|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for 4 cycles
46110845|NCT03995407|Dietary Supplement|Peptamen®|Participants in the intervention arm will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements. Those who are not currently taking oral nutritional supplement will be started on Peptamen® while those who are currently on oral nutritional supplements will have to convert to Peptamen® solely. The dietician will determine the amount of Peptamen® required per day based on the recommendations of the product information. Should the participant's daily protein requirement not be met be Peptamen® alone, the dietician will recommend additional whey protein to be added in the form of Beneprotein® Instant Protein Powder. Beneprotein® is a concentrated source of high-quality whey protein that can be added to most foods, liquids or enteral formulas.
46024161|NCT02808091|Drug|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for a total of 6 cycles.
46024162|NCT02808091|Radiation|IMRT|a minimum of 50 Gy of IMRT to tumor bed and neck (5 weeks)
46024163|NCT02807935|Device|Optical coherence tomography imaging|
46110846|NCT03995407|Other|Usual Care|"Participants receive usual care. They will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements (non-100% whey i.e. not on Peptamen® or Beneprotein®). They will consume their regular diet in accordance with the dietician's recommendations."
46110847|NCT04110834|Drug|itraconazole gel once daily|itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
46110848|NCT04110834|Drug|itraconazole gel twice daily|itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
46110849|NCT04110834|Drug|placebo|the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, itraconazole, is not added then applied twice daily in the same manner
46110850|NCT00812500|Other|Lower Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a lower protein diet.
46110851|NCT00812500|Other|Medium Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a medium protein diet.
46110852|NCT00812500|Other|Higher Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a higher protein diet.
46110853|NCT04108494|Procedure|Type of omentectomy|Partial omentectomy with preservation of the greater omentum at >3 cm from the gastroepiploic arcade.Control group with total omentectomy.
46110854|NCT04045444|Other|walking|Every participants will performed a set of tasks of 2 min. Each task will be separated by a 2 min resting period. The tasks will be walking at 3 km/h, walking while doing the cognitive task, walking at the preferred speed, walking at the preferred speed while doing the cognitive task.
46110855|NCT04045444|Other|cognitive task|Every participants will performed a set of tasks of 2 min. Each task will be separated by a 2 min resting period. The tasks will be a cognitive task, a control cognitive task.
46110856|NCT04108572|Behavioral|Infant feeding|Verbally delivered pre-specified infant feeding message. The messages focus on appropriate milk feeding and establishing complementary feeding and solid food introduction in relation to timing and practical guidance around processes of feeding and provision of additional infant-feeding resources including information leaflet, a magnet, an infant bib and access to an informational website.
45469543|NCT03420976|Dietary Supplement|Novel Supplement Based Therapy|"Supplements and Dosage:~Detox Support: Liver-G.I. Detox BID for 30 days GI Support: L-Glutamine Powder 2 scoops QD for 35 days Microbial Balance: MicroDefense 1 capsule QD for 49 days Microbial Balance: A.C. Formula II 2 capsules BID for 49 days Probiotic: Probiotic-5 1 capsule QD for 49 days Digestive Enzymes: Digestive Enzymes Ultra with Betaine HCl As needed up to 6 longer term"
46024164|NCT02874183|Behavioral|Pharmacist intervention|Pharmacist counseling and follow-up phone calls
46024165|NCT02808013|Drug|NDS-446|
46024166|NCT02808013|Drug|Placebo|
46024167|NCT04302519|Biological|Dental pulp mesenchymal stem cells|On the basis of clinical standard treatment, the injection of dental mesenchymal stem cells was increased on day 1, 3 and 7 of the trial.
46024168|NCT02811991|Drug|Paracetamol injection|325mg(32.5mL) or 500mg(50mL) iv q6h,4 doses in 24h.Infushion time≥15min.
46024169|NCT02811991|Drug|Normal Saline injection|32.5mL or 50mL iv q6h,4 doses in 24h.Infushion time≥15min.
46024170|NCT02811991|Drug|Morhpine PCA|Morphine PCA will be connected upon the first dose of study drug(roughly 30min prior to the completion of would suture). Morphine PCA is set as follows:1mg bolus every 5min with background infusion of 0.25mg/h and maximal dose<25mg/4h.
46024171|NCT02873793|Genetic|Extraction of total RNA from healthy and tumour tissues|
46110857|NCT00815074|Other|No intervention|no intervention
46024172|NCT02873637|Device|under sartorial catheter|
46024173|NCT02873637|Device|femoral catheter|
46024174|NCT04237675|Procedure|surgery and anesthesia|patients with MS who received general or regional anesthesia for a surgery or labor
46024175|NCT02807701|Procedure|Laparoscopic pancreaticoduodenectomy|"Laparoscopic pancreaticoduodenectomy~dissection~reconstruction"
46024176|NCT02807701|Procedure|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy
46024177|NCT05638165|Drug|NCP112|The first two subjects for sentinel dosing are randomly assigned to either the test drug or placebo in a 1:1 ratio. After safety and tolerability were reviewed for sentinel participants up to 24 hours after dosing, the subsequent 7 subjects are randomized to the remaining treatment allocations, with 5 subjects to the test drug and 2 to the placebo.
46024178|NCT05598853|Drug|intrathecal nivolumab and intrathecal ipilimumab|Patients shall be treated with a fixed dose of intrathecal nivolumab and increasing doses of intrathecal ipilimumab. From cycle 2, patients will receive systemic nivolumab/ipilimumab in addition to intrathecal treatment. Systemic nivolumab/ipilimumab corresponds to the current standard of care for non-small cell lung cancer and for melanoma patients.
46024179|NCT04237285|Other|Inhalation aromatherapy|Besides routine care, the Control Group was treated with jojoba oil (Simmondsia Chinensis- produced by Arifoğlu, obtained from jojoba fruits by cold squeezing method) inhalation aromatherapy 15 minutes before Hydrotherapy. Jojoba oil was used as a placebo because it had no specific odor. Besides routine care Intervention-15 Group received lavender oil (Lavandula angustifolia Miller Oleum-produced by Arifoğlu, obtained from lavender flowers by water vapor distillation method) inhalation aromatherapy 15 minutes before Hydrotherapy and besides routine care Intervention-60 Group received lavender oil inhalation aromatherapy 60 minutes before Hydrotherapy.
46110858|NCT04110678|Drug|NeuroEPO|NeuroEPO [CIMAB S.A, Havana, Cuba]
46110859|NCT00812578|Drug|Cholecalciferol|8 tablets equivalent to 280 micrograms for 2 weeks and 4 tablets equivalent to 140 micrograms for 10 weeks
46110860|NCT00815152|Behavioral|coping skills intervention training|The strategies will include ways to improve problem solving, communication skills, and managing activities.
46110861|NCT00815152|Behavioral|usual care|The ususal care at the Preston Robert Tisch Brain Tumor Center
46110862|NCT00796224|Drug|60 mg/kg azithromycin ER|subjects taken 60 mg/kg azithromycin ER
46110863|NCT00796224|Drug|30 mg/kg azithromycin IR|subjects taken 30 mg/kg azithromycin IR (Immediate Release)
46110864|NCT00808366|Drug|Keratolytic/Antifungal|Intial treatment with RV4104A ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
46110865|NCT00808366|Drug|Keratolytic/Antifungal|Initial treatment with bifonazole-urea ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
46110866|NCT04113798|Other|Day 1 Assessments|Structured clinical interview to assess trauma history and mental health diagnoses, as well as a screening EKG to assess safety to engage in exercise testing (lasts 3-4 hours)
46110867|NCT04113798|Other|Day 2 Fear Learning|Participants undergo a standard fear conditioning procedure, in which they learn that one of two geometric shapes (circles or triangles) predict the occurrence of a noxious stimulus (mild electrotactile stimulation). Day 2 lasts about 1 hour.
46110868|NCT04113798|Other|Day 3 Fear Extinction|Participants undergo a fear extinction procedure, in which participants learn that the geometric shapes no longer predict a noxious stimulus (i.e., safety learning). Blood samples will be drawn immediately before exercise, and immediately following.
46110869|NCT04113798|Behavioral|Moderate Intensity Exercise|The moderate-intensity aerobic exercise session will consist of a 5 minute warm-up of light intensity activity (40-60% maximum heart rate; MHR) on a treadmill followed by walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes on Day 3
46110870|NCT04113798|Behavioral|Low Intensity Exercise|Control participants will maintain light-intensity activity (i.e., walking at ~50% of MHR) for the full duration of 30 minutes.
46110871|NCT04113798|Other|Day 4 Recall of Fear Extinction|During Day 4, recall of the fear extinction memory is tested. Visits on Day 4 occur ~24 hours following Day 3, and lasts about 30 minutes.
46110872|NCT00812734|Procedure|Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)|Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)
46110873|NCT04113486|Other|Blood test|About 4 ml of blood draw
46024180|NCT04237363|Behavioral|Exercise|Underwater treadmill training and supplemental overground walk training
46024181|NCT01229150|Drug|AZD6244|For KRAS mutant patients randomized to the single agent arm, AZD6244 75 mg bid (twice a day).
46024182|NCT01229150|Drug|Erlotinib|For Wild-Type KRAS patients randomized to the single agent arm, Erlotinib 150 mg qd (every day)
46024183|NCT01229150|Drug|AZD6244 + Erlotinib|For KRAS mutant patients and Wild-Type KRAS patients randomized to the combination arm (arms are stratified based on KRAS mutational status), AZD6244 150 mg qd (every day) + erl (erlotinib) mg qd.
46024184|NCT02804815|Drug|Aspirin 100mg|Aspirin 100mg
46024185|NCT02804815|Drug|Aspirin 300mg|Aspirin 300mg
46024186|NCT02804815|Drug|Placebo 100mg|Placebo 100mg
46110874|NCT04045522|Drug|Zoledronic Acid|Based on routine treatment, 4 mg zoledronic acid (Novartis Pharma Stein AG, Switzerland, registration No. H20140218) was intravenously administered, once every 3-4 weeks, for 1-2 years.
46110875|NCT04113564|Drug|Remimazolam|
46110876|NCT04108650|Other|Fit & Strong! group|Consistent with the original format of F&S!, the classes met three times per week for 90 minutes each for 8 weeks (24 sessions in total). Each class session consisted of 60 minutes of exercise and 30 minutes of health education. The exercise protocol included 10 minutes of warm-up and cool-down exercises, 20 minutes of low-intensity aerobic exercises, and 20 minutes of lower extremity strengthening exercises. The health education program focused on symptom management and behavioral strategies to increase physical activity and commitment to lifestyle change.
46110877|NCT02551276|Drug|Salbutamol|
46110878|NCT02551276|Drug|Placebo|
46024187|NCT02804815|Drug|Placebo 300mg|Placebo 300mg
46024188|NCT04017247|Drug|Oxytocin|Intermittent oxytocin Infusion
46024189|NCT04017247|Drug|Oxytocin|Continous oxytocin Infusion
46024190|NCT00634465|Device|RSA Beads|Radiostereometric Analysis, or RSA, is an accurate in vivo measurement technique using two simultaneous radiographs. It provides researchers with three dimensional motion analyses to look not only at routine flexion/extension, but also other rotational and translational changes
46024191|NCT02807389|Drug|MSC Fistula Plug|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
46024192|NCT02804737|Device|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
46110879|NCT02551276|Other|Resistance training|
46110880|NCT00815386|Device|Percutaneous transvenous mitral annuloplasty|Catheterization procedure with anesthesia requiring subclavicular puncture, catheterization of the right atrium and coronary sinus vein, placement and optimization of the PTMA device with access hub remaining subcutaneous at the clavicle.
46110881|NCT00791934|Device|Stratus Microflow Ethmoid Spacer|The Spacer is inserted surgically into the ethmoid complex through the use of a sinus access system. Triamcinolone acetonide will be administered into the Spacer for this investigational study. The Spacer will be left in the ethmoid sinus for a period of 28 days. At the end of the implant period, the device is removed with standard instrumentation, during a follow-up office visit.
46110882|NCT00848081|Drug|Tadalafil|5 mg taken by mouth once daily for 12 weeks
46110883|NCT00848081|Drug|Placebo|By mouth once daily for 12 weeks
46024193|NCT00952588|Drug|AZD1152|1200 mg, iv, 7 day infusion
46110884|NCT02551978|Other|The serious game KOP|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
46110885|NCT02605278|Other|Clinical program for pain and depression|Already described
46110886|NCT02605278|Other|Control|Care as usual
46110887|NCT00815464|Device|Liquid Acupuncture (Herb Acupoint Injection)|Each 4 weeks per one circle.The first 3 weeks for treatment practice(one per week)and the last week for test collection.
46110888|NCT04111380|Drug|cisplatin and nab-paclitaxel|Nab-paclitaxel, 130mg/m2, d1,d8, Cisplatin, 20mg/m2, d1-3 ,3week, 4-6 cycles.
46110889|NCT02552056|Other|CAMH training|Training of PHC workers included in the study for 5 days to screen children and adolescents for CAMH conditions, based in the mhGAP curriculum for non-specialist health providers.
46110890|NCT04117919|Drug|paper mulberry leaf|Topical steroids+paper mulberry leaf The botanical origin of paper mulberry leaf is Broussonetia papyrifera (L.) Vent.
46024194|NCT00952588|Drug|LDAC|20 mg, sc, bd, 10 days
46024195|NCT02814409|Drug|Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase|
46110891|NCT04117919|Drug|Triamcinolone (Encort-A) 0.1%15g/Tube|only Topical steroids
46024196|NCT02814409|Drug|Intravenous Tenecteplase|
46024197|NCT02804893|Procedure|VATS|Thorax thoracoscopic surgery (lobectomy)
46024198|NCT02804893|Procedure|RATS|Thorax robotic surgery (lobectomy)
46024199|NCT02853916|Dietary Supplement|500 mg InSea2®|
46024200|NCT02853916|Dietary Supplement|250 mg InSea2®|
46024201|NCT02853916|Dietary Supplement|Placebo|
46024202|NCT02853838|Other|Prolonged slow expiration+provoked coughing|"Five cycles of prolonged slow expiration and provoked coughing, which will be repeated five times.~During the prolonged slow expiration, the infant will be in supine while the therapist applies pressure at the same time on the rib cage and abdomen during spontaneous expiration. The pressure is applied slowly during two o three respiratory cycles, only during the final phase of expiration."
46024203|NCT02853838|Other|Manual chest wall vibration|"Five cycles of manual chest wall vibrations during 20 seconds each, being repeated five times.~The manual chest wall vibrations are oscillatory maneuvers applied on the thorax to improve mucociliary clearance of bronchial mucus and ease its removal."
46024204|NCT02853838|Other|Standard Therapy|Standard therapy (ST): nasopharyngeal suction, oxygen therapy, fluids administration, 0.5% adrenaline nebulization, and chest physiotherapy.
46024205|NCT05527717|Procedure|Culprit lesion only PCI|"Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio.~This group will be taken culprit-lesion only PCI during primary PCI."
46110892|NCT04108338|Other|Trial setting|Study results from clinical trials usually have been found not work efficiently in clinical practice. This outcome disparity may be caused by different pragmatic features of medical environment, also known as study setting such as trial setting and real-world setting, in which biases inherent to clinical trial design restrict its applicability even though all confounding factors are avoided.
46110893|NCT02551510|Procedure|Suture|Skin incision closure with standard subcuticular technique
45838571|NCT04385316|Diagnostic Test|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of colorectal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of colorectal tumor."
46110894|NCT02551510|Device|Experimental: Histoacryl®|Skin incision closure with topic skin adhesive Histoacryl® Flexible (n-Butyl-2-Cyanoacrylate Monomer)
46110895|NCT00701285|Drug|pitavastatin|pitavastatin 4mg once daily
46110896|NCT00701285|Drug|pravastatin|pravastatin 10mg once daily
46110897|NCT05617638|Behavioral|Intervention|Participants will watch nature images in virtual reality from the e-Natureza VR Database for 20 minutes for 2 consecutive days.
46110898|NCT02613767|Other|Protein meal|Ingestion of protein
46024206|NCT05527717|Procedure|Immediate multi-vessel PCI|"Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio.~This group will be taken immediate multi-vesesl PCI during primary PCI."
46110899|NCT02613767|Other|L-[ring 13C6]Phenylalanine infusion|experimental method for determining protein synthesis rates
46110900|NCT04001166|Other|Non-interventional study|This is a non-interventional study. Patients will be treated with any treatment deemed appropriate by the patient's physician.
46110901|NCT00812890|Device|semi-quantitative pregnancy test|
46110902|NCT02604498|Drug|Nemonoxacin|Single dose 500mg oral
46110903|NCT00700037|Drug|high-dose atorvastatin|20mg/day
46110904|NCT00700037|Drug|low-dose atorvastatin|5mg/day
46110905|NCT00808522|Drug|hCG|recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.
46110906|NCT00815542|Device|double balloon catheter|cervical ripening using double balloon catheter
46110907|NCT00815542|Drug|prostaglandins E2|prostaglandins E2 - Intravaginal Propess for 24 hours
46110908|NCT00791778|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients in Sorafenib arm will receive 2 Sorafenib tablets (200 mg each) twice a day and in continuous administration.
46110909|NCT00791778|Drug|Placebo|Patients in Placebo arm will receive 2 matching placebo tablets twice a day and in continuous administration.
46110910|NCT04108260|Drug|Albutrepenonacog Alfa 1 UNT [IDELVION]|Clinical data will be collected from patients who suffered from hemophilia B, and switch from other FIX products to Idelvion as prophylaxis, prevention of bleeding (e.g. surgery) or treatment of bleeding.
46110911|NCT05595018|Other|End user|Participants will provide their opinions in two rounds to reach consensus
46110912|NCT05595018|Other|Demand side- management|Participants will provide their opinions in two rounds to reach consensus
46110913|NCT05595018|Other|Supply side|Participants will provide their opinions in two rounds to reach consensus
45469544|NCT03054727|Other|Villalta phone score > or = to 5|"Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score > or = 5 will have a visit with clinical and CUS assessments of PTS/ venous insufficiency.~All patients will have self administered-questionnaires. For Grenoble Center, the 200 first patients with clinical follow-up will have an Echo-Doppler examination."
46024207|NCT04236505|Behavioral|Acceptance and Commitment Therapy (ACT) group based intervention|4 week ACT psychological intervention group based on Flaxman and McIntosh's ACT in the work place group format
46024208|NCT04236505|Behavioral|Mindfulness based stress reduction (MBSR) informed brief mindfulness skills group intervention|4 week Mindfulness based stress reduction (MBSR) informed brief mindfulness skills group intervention
46024209|NCT04236505|Behavioral|Wait list Control group|this group are placed on a wait list for group treatment whilst the other experimental groups run. This group are offered the MBSR based mindfulness skills once the follow up data has been collected from the other two experimental groups
46110914|NCT05595018|Other|Funder|Participants will provide their opinions in two rounds to reach consensus
46110915|NCT05595018|Other|Academia|Participants will provide their opinions in two rounds to reach consensus
46110916|NCT00798174|Device|Standard configuration vs. azygos coil|Addition of an azygos vein defibrillation coil instead of a standard SVC coil.
46110917|NCT04113642|Other|ultrasonographic measurement of abdominal muscle thickness at four positions|Thickness of transversus abdominis, internal oblique and external oblique muscles were evaluated using ultrasound at rest and during abdominal hollowing, bridge, and bridge with isometric arm extension.
46110918|NCT04113174|Other|Decision Analytic Modelling|Prognostic models will be translated into a framework to guide clinical decision making by identifying relevant thresholds of predicted risk, above which implementation of our stated interventions is warranted.
46110919|NCT02604576|Drug|FDC Bromopride 10 mg and Simethicone 80 mg|Fixed-dose combination of Bromopride 10 mg and Simethicone 80 mg
46110920|NCT02604576|Drug|Bromopride 10 mg|Bromopride 10 mg
46110921|NCT04110600|Other|Coffee effect on early gastric motility|this group 100ml coffee after two hours
46110922|NCT04110600|Other|Efficacy pepper mint oil on motility|This group 100me pepper mint oil after 2 hours
46024210|NCT02804581|Dietary Supplement|Gum Arabic|Oral intake of GA in powder from30 grams per day
46024211|NCT01227902|Drug|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
46110923|NCT05615610|Device|spine TENS|The participants in Group A will receive TENS (Burst mode, 9 pulses per burst, pulse frequency = 160 Hz, burst frequency = 2 Hz) with upper limb exercises. The electrical stimulation will be generated by the neurostimulator (MH8000P; MEDIHIGHTEC MEDICAL CO., LTD., Taiwan). Two 7.5 × 12.6 cm electrodes will be attached between C6 and T5 level on each side of spinal column and with 2 cm from the spine. Intensity of TENS will be individually selected by the participants according to tolerance levels.
45681630|NCT03588988|Drug|Dexmedetomidine IV infusion|Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The DEX group injects DEX at 0.2 ug / kg / hr from 9 pm to 7 am. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
46024212|NCT02804659|Other|microRNA|Extraction of the microRNA using the mirVana miRNA isolation kit and quantification using real-time PCRs
46110924|NCT05615610|Device|tVNS|The participants in Group B will receive tVNS (pulse frequency = 25Hz, pulse duration = 0.3 ms) on the cymba conchae of left outer ear with upper limb exercises.The electrical stimulation will be generated by the neurostimulator (MH8000P; MEDIHIGHTEC MEDICAL CO., LTD., Taiwan). Intensity of tVNS will be individually selected by the participants according to tolerance levels. Previous studies showed that it was effective to improve the upper limb motor function in people with stroke and cognitive function in people with mild cognitive function.
46110925|NCT05615610|Device|Control|The participants in Group C will receive placebo tVNS with upper limb exercises, where the stimulation will be delivered by placebo-TENS device with disconnected electrical circuit.
45469545|NCT03054727|Other|Villalta phone score < 5|"Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score < 5, will don't have a clinical follow up.~All patients will have self administered-questionnaires."
46110926|NCT02604654|Drug|Yiqitongluo granule|administered after dissolved
45469546|NCT03414580|Procedure|Breath sampling for volatile organic compounds|Acquisition of exhaled breath sample in exhaled air to be analysed by gas chromatography-mass spectrometry
45469547|NCT01155375|Drug|Ferumoxytol|Experimental: Ferumoxytol
45469548|NCT01155375|Drug|Oral Iron|Active Comparator: Oral iron
46024213|NCT00946192|Drug|Transdermal 17Beta-estradiol, progesterone|100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
46024214|NCT00946192|Drug|Ethinyl Estradiol + Desogestrel|Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily
45469549|NCT02613754|Behavioral|Contingency Management|See arm description.
45469550|NCT02613754|Behavioral|Treatment as Usual|See arm description
45469551|NCT03759301|Drug|Growth Hormones Somatropin Recombinant|Growth Hormones Somatropin Recombinant 4 IU/day subcutaneous from the 2nd day of the cycle and stopped 1 day before ovum pickup
46024215|NCT00946192|Dietary Supplement|Sham Comparator|Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
46024216|NCT01037127|Drug|GSK1120212|Daily oral dosing
46024217|NCT02806999|Drug|Berberine; Insulin|Participants will receive 500mg Berberine twice a day for 8 days; Meanwhile，participants will also continue to receive intensive insulin therapy.
46024218|NCT02806999|Drug|Insulin|Participants will continue to receive intensive insulin therapy; Meanwhile, Participants will also receive a placebo twice a day for 8 days.
46024219|NCT02874261|Device|Whole Body Periodic Acceleration|oscillating bed that the subject will lie on 3 days a week for 45 minutes at 140 cycles per minute.
45469552|NCT03759301|Drug|Placebo saline solution|same volume as growth hormone ampule used
45469553|NCT03109132|Device|Oridion Smart CapnoLine® H Plus with Wedge cannula|The subjects will assess the comfort level of the different cannulas
45469554|NCT03109132|Device|Oridion Smart CapnoLine® Plus with Non-Wedge cannula|The subjects will assess the comfort level of the different cannulas
46110927|NCT04110132|Procedure|Ganglion impar block with Bupivacaine.|"Bupivacaine group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Bupivacaine 0.5% 10ml.~Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative."
46110928|NCT04110132|Procedure|Ganglion impar block with normal saline|Saline group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Normal Saline 10ml Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative.
46110929|NCT04107792|Behavioral|parental sense of competence workshop|The intervention will be a two-hour parent education workshop that provides education and teaches parent-mediated strategies for managing children's behaviours associated with SPIs.
46110930|NCT00798096|Drug|Fostamatinib Disodium|200 mg PO BID
46110931|NCT05297214|Diagnostic Test|serum creatinine and Other investigations will be done according to the case|following up AKI patients with serum creatinine,Urine out put, CBC,Serum electrolytes,renal functin test,Liver function test,urine analysisand specific investigations according to case
46110932|NCT04113096|Drug|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
46110933|NCT04113096|Drug|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
45681631|NCT03588988|Drug|Normal saline|Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The control group is inoculated with saline solution. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
45469555|NCT03109132|Device|Experimental sample line Model 3|The subjects will assess the comfort level of the different cannulas
45469556|NCT03109132|Device|Experimental sample line Model 4|The subjects will assess the comfort level of the different cannulas
46024220|NCT02806921|Device|ZenLens|The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
46110934|NCT04113096|Drug|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
46110935|NCT04113096|Drug|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
46110936|NCT04113096|Drug|Stage IV Breast Cancer Placebo|20 mg once daily for 6 months
46110937|NCT04113096|Drug|Stage IV: Colon Cancer Placebo|20 mg once daily for 6 months
46024221|NCT04292613|Other|"The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"|"The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"
46024222|NCT02807077|Drug|Pacritinib|Group 1, 2, 3, and 5 will be administered single oral 400-mg dose of pacritinib. Subjects in the Group 4 received a single 400-mg dose of pacritinib during two different treatment periods: Dialysis and Inter-Dialysis
45469557|NCT03109132|Device|Experimental sample line Model 5|The subjects will assess the comfort level of the different cannulas
45469558|NCT03109132|Device|O2/CO2 cannula w/female luer (Westmed comfort plus #0504)|The subjects will assess the comfort level of the different cannulas
45469559|NCT03759145|Other|Exergame|Participants use exergame with the therapist in the rehabilitation center. Several games are available, the therapist adjusts the choice of game and level of difficulty according to the participant's abilities and interests.
45681632|NCT05581888|Device|trifocal intraocular lens|Binocular implantation of two different trifocal intraocular lens in high myopic cataracts
46110938|NCT04113096|Drug|Cervical Cancer Stage IV Placebo|20 mg once daily for 6 months
45469560|NCT03759145|Other|usual care|participants continued their planned rehabilitation sessions
45469561|NCT03764215|Drug|Nilotinib 150 MG|10 participants will receive an oral dose of 150mg Nilotinib once daily for 3 months (group 1). If this dose is tolerated another 10 participants will receive an oral dose of 300mg Nilotinib once daily (group 2) for 3 months.
46110939|NCT04113096|Drug|Cancer of the Prostate Placebo|20 mg once daily for 6 months
46110940|NCT00795600|Drug|insulin detemir|Insulin detemir once daily plus insulin aspart at mealtime
46110941|NCT00795600|Drug|insulin NPH|Insulin NPH once daily plus insulin aspart at mealtime
46110942|NCT00795132|Drug|Busulfan|This drug is a bifunctional alkylating agent. Busulfan is highly toxic to noncycling or slowly-cycling cells. Pharmacokinetic studies of the IV formulation in pediatrics have shown that using a dose of 0.8mg/kg IV q6 hours most patients will achieve AUC levels between 800 and 1300 uM/min, representing steady state levels between 600-900ug/ml. The manufacturer recommends higher doses, 1.1mg/kg for children less than 12kg. Because this is a reduced intensity study and infants on the study will be very heavily pretreated we will use the lower dose of 0.8mg/kg q6 hours for a total of 8 doses for all patients.
46110943|NCT00795132|Drug|Anti-Thymocyte Globulin|"Thymoglobulin will be administered at a dose of 2.5 mg/kg recipient body weight intravenously on each of 4 successive mornings (Days -4, -3,-2,-1) for patients receiving unrelated grafts and at a dose of 2.5mg/kg as a single dose on d-1 for patients receiving related marrow grafts. ATG is infused over a minimum of 4 hours, but is generally better tolerated over 6-8 hours. Suggested premedications are acetaminophen (10 mg/kg/dose), diphenhydramine (1 mg/kg/dose), and methylprednisolone. The methylprednisolone should be given at a dose of~1mg/kg 30 minutes prior to the ATG, with another 1mg /kg four hours into the infusion (total 2mg/kg/d). Patients are observed continuously for possible allergic reactions throughout the infusion."
46110944|NCT00795132|Drug|Fludarabine|Administration and Dosage: Fludarabine will be administered at a dose of 30 mg/m2 in 100 ml of D5W intravenously over one hour on each of six consecutive days -10 through -5 for unrelated grafts or d-7 through d-2 for related grafts. Fludarabine is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-beta-D-arabinofuranosyladenine. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. The half-life of 2-fluoro-ara-A is approximately 10 hours. The mean total plasma clearance is 8.9 L/hr/m2 and the mean volume of distribution is 98 L/m2. Approximately 23% is excreted unchanged. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
46110945|NCT00795132|Drug|Cyclosporine|"Cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. The effectiveness of cyclosporine results from specific and reversible inhibition of immunocompetent lymphocytes in the G 0 - and G~1 -phase of the cell cycle. Administration and Dosage: Cyclosporin start on day -3 initially at a dose of 2.5mg/kg IV q12 hours or 3mg/kg/dose (neoral equivalent) PO q12 hours targeting suggested troughs of 250 to 350 ng/ml. Continuous infusion cyclosporin may be allowed per institutional preference. 3x daily dosing may be used for younger children to achieve therapeutic levels. PBMTC Protocol #ONC0313 19 Continuous infusion cyclosporin may be allowed per institutional preference."
46110946|NCT00795132|Drug|Mycophenolate mofetil|MMF is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Administration and Dosage: Initial dosage will be IV or PO with switch to PO when tolerated. Starting doses will be 15 mg/kg/day bid (total dose 30mg/kg/d, IV same as PO dose) beginning day 0 with the first dose given approximately 4-6 hours after the stem cell infusion. This dose will stop on day +30 for patients receiving matched sibling BM/PBSC and UCB grafts, but will continue until day +40 and then taper at approximately 11%/wk over 8 weeks until patients are off at day +96.
46110947|NCT02604420|Drug|eculizumab|
46110948|NCT04110210|Drug|Bilateral Ultrasound-Guided Erector Spinae Plane Block|Following skin sterilization and local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivacaine 0.25% are then injected into the ESP. The procedure is repeated on the contralateral side.
46110949|NCT04110210|Drug|Morphine Consumption|After operation, patients will be transferred to post anesthesia care unit (PACU) for complete recovery and monitoring. The pain VAS scores between the studied groups will be registered every 4 hours for 24 hours postoperatively. A standard postoperative analgesia regimen will be prescribed as paracetamol 1gm every 6 hours and ketorolac 30mg every 8 hours in the first 24 hours postoperatively. Morphine 2.5 mg will be given as a rescue analgesic dose if visual analogue score was ≥ 3 or when patient suffering from pain between the assessment intervals in both groups not exceeding 0.1 mg/kg in a period of 6 hours. Metoclopramide 0.15 mg/kg IV will be prescribed for patients complaining of nausea or vomiting.
46024223|NCT04302363|Other|Fecal microbiota detection and exfoliated cell gene detection|Fecal microbiota detection and exfoliated cell gene detection
46110950|NCT00647296|Drug|Placebo|Placebo: 2 tablets taken orally twice daily
46110951|NCT00647296|Drug|Dexpramipexole 50 mg/day|Dexpramipexole: 2 x 12.5 mg tablets taken orally twice daily
46110952|NCT00647296|Drug|Dexpramipexole 150 mg/day|Dexpramipexole: 2 x 37.5 mg tablets taken orally twice daily
46110953|NCT00647296|Drug|Dexpramipexole 300 mg/day|Dexpramipexole: 2 x 75 mg tablets taken orally twice daily
46110954|NCT00644878|Drug|Nilotinib|Nilotinib 300 mg is taken by mouth twice a day at 12 hour intervals. Nilotinib is to be taken with water on an empty stomach. No food two hours prior to the dose of nilotinib and for one hour following the dose.
46110955|NCT04045288|Behavioral|Standard Implementation|Schools in the Standard implementation model received web-based training, access to on online education / tracking system and programming resources (modules, posters, trinkets) to facilitate wellness programming in their school. They completed audit tools at the beginning to facilitate goal setting and received weekly emails during the 12-week implementation process.
45681633|NCT04414137|Other|Description of eosinophilic pneumonia due to daptomycine|Description of eosinophilic pneumonia in patients treated by daptomycin for an osteoarticular infection
45681634|NCT05580172|Drug|RH324|polymolecular
45681635|NCT05587582|Other|Survey Administration|Complete a survey
45681636|NCT05586178|Behavioral|Reminder that facilitates action|Patients will receive a text message reminding them that they can now get the bivalent COVID-19 booster and facilitating action. The message will contain a link to schedule a booster appointment at UCLA Health and a link to vaccine.gov (where people can find local pharmacies that carry the bivalent booster).
46024224|NCT00946114|Drug|sildenafil|tablets, 20mg, TID, 112 weeks at the maximum
46024225|NCT00946114|Drug|sildenafil|tablets, 20mg x 4 (80mg), TID, approximately 70 weeks
46024226|NCT02804503|Behavioral|Calorie Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
46024227|NCT02804503|Behavioral|Exercise Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
46024228|NCT02804503|Behavioral|No Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
46110956|NCT04045288|Behavioral|Enhanced Implementation|Schools in the Enhanced implementation model received the same training, web-access, and programming resources as those in the Standard implementation, but also received enhanced monthly support during implementation from the project team. The supplemental web calls (completed jointly by Extension leaders and SWITCH staff) utilized motivational interviewing to help schools build capacity and to enhance motivation for wellness programming.
46110957|NCT00813046|Biological|gpASIT+TM|oral administration of entero-coated capsules containing increasing doses of gpASIT+TM (25 to 1600µg), one dose per day for 4 days
46110958|NCT00813202|Drug|Nesiritide|Nesiritide 0.01 mcg/kg/min intravenous (IV) infusion (with or without 2 mcg/kg bolus) for 24 to 168 hours (hrs)
46110959|NCT00646906|Drug|Aspirin First|Crossover period Aspirin First: Subjects will receive 81 mg aspirin at approximately 8 am followed by acetaminophen at approximately 10 am.
46110960|NCT00646906|Drug|Aspirin Last|Crossover period Aspirin Last: Subjects will receive acetaminophen at approximately 8 am followed by 81 mg aspirin at approximately 10 am.
46110961|NCT00646906|Drug|Acetaminophen 1000 mg/d|Subjects will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM.
46024229|NCT04302285|Other|PKU type meal and Exercise|"Exercise was conducted prior to PKU type meal.~PKU type meal was based on PKU special low protein foods (50% of total energy intake), natural free protein foods (37%) and protein substitute (13%). Calories provided in breakfast were 600 kcal and were not based on individual dietary requirement. 65% of total energy intake was provided from carbohydrate, 13% from protein and 22% from fat."
46024230|NCT04302285|Other|PKU type meal|PKU type meal was based on PKU special low protein foods (50% of total energy intake), natural free protein foods (37%) and protein substitute (13%). Calories provided in breakfast were 600 kcal and were not based on individual dietary requirement. 65% of total energy intake was provided from carbohydrate, 13% from protein and 22% from fat.
46024231|NCT02804425|Other|actor-spectator|"actor-spectator group : actor at least once during the simulation session"
46024232|NCT00627471|Drug|Insulin Glargine|For the control group (following the physician's standard practice) a minimum of 4 visits to the clinic is required. Insulin titration and concomitant medications will be done at the discretion of the physician. Strips will be distributed among patients in this group, but there will not be a requirement in frequency or type of SMBG.
46110962|NCT00646906|Drug|Acetaminophen 4000 mg/d|Crossover period Acetaminophen 4000 mg/d: Acetaminophen (1000 mg p.o.) orally at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.
46110963|NCT00646906|Drug|Ibuprofen 800 mg/d|Crossover period Ibuprofen 800 mg/d: Ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.
46024233|NCT00627471|Drug|Insulin Glargine|"In the group following the algorithm, fasting SMBG will be asked 3 times a week until FBG<100 mg/dl is achieved. Afterwards, 1 fasting SMBG will be asked weekly. Pre-prandial SMBG will be performed at the discretion of the physician.~For the group following the algorithm, during the titration period, weekly telephone contacts will be required and a minimum of 4 visits to the clinic."
46110964|NCT00808600|Behavioral|resource-activating behavioural training programme|"Stepwise intervention based on the principles of resource-activating training (RAT) applied to the needs of patients in the process after lung transplantation.~Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Continued resource-activation and transfer by means of internet-based interventions (1 per 2 weeks) as well as personal interventions by trained nurses and a clinical psychologist during regular out-patient visits (approx. 4 times per year) over one year immediately following rehabilitation. Interventions focus on strengthening individual and interpersonal resources for well-being, psychoeducation, stress management and coping with illness. Phase 3: Termination and transfer, including a detailed medical report."
46110965|NCT00808600|Behavioral|Relaxation training|Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Regular relaxation training after rehabilitation by self-guided relaxation compact disk and accompanying worksheets.
46110966|NCT00808600|Behavioral|Intensified anaerobic exercise training|Phase 1: Recruitment and initiation of intensified and individualised aerobic/anaerobic exercise training based on determination of aerobic/anaerobic threshold during rehabilitation in the rehabilitation centre Fallingbostel. During rehabilitation daily training sessions with a duration of 30 minutes each are performed under medical supervision. Phase 2: Home training on an IT-assisted ergometer 3.5 times a week with interval exercise intensity above the anaerobic threshold. Work load and heart rate are stored by an ergometer-chip, lung function analyses are performed and should be transferred via phone-based telemetry. Exercise training intensities will be adapted monthly, corresponding to training results. At regular 3 months visits to the outpatient clinic a medical examination is carried out. Moreover, according to the actual functional state of the patient estimated 3 monthly training work load will be adjusted. Phase 3: Termination, evaluation after a period of 12 months.
46110967|NCT00808600|Behavioral|Moderate aerobic exercise training|Phase 1: Recruitment and initiation of moderate aerobic exercise training based on 40 percent of maximal oxygen consumption in Watt during rehabilitation in the rehabilitation centre Fallingbostel. Phase 2: Moderate aerobic endurance training with the target intensity of 40 percent of the individual maximum exercise capacity will be performed 3.5 times a week with a duration of 30 minutes per session, work load will be adapted continuously according to the measures that are assessed during the repeated control examinations after periods of 3 months in the outpatient clinic of the pulmonary department of Hanover Medical School.
46110968|NCT00813436|Drug|Oxytocin (also: syntocinon, pitocin)|24 IU for each subject (3 puffs in each nostril, 4 IU in each puff). each subject will receive a single administration, 40 minuets before task start time.
46110969|NCT00813436|Drug|Placebo|saline liquid, intranasally administered
45681637|NCT05586178|Behavioral|Consistency framing|The message will leverage the psychological principle of consistency. It will highlight to patients that based on medical records, they have completed a COVID-19 vaccine primary series, have done a great job protecting their health, and can now get the bivalent booster.
45681638|NCT05586178|Behavioral|Information provision about the uniqueness of the bivalent booster|The message will contain information about how the bivalent booster differs from previous doses patients have received and why it is valuable.
46024234|NCT04269382|Device|Combined non-invasive intermittent (oscillometric arm cuff), non-invasive continuous (finger cuff and ClearSight device), and invasive continuous (intra-arterial catheter) BP measurements|Continuous (finger cuff) noninvasive and invasive BP measurements, over a 30-min period. Pairs of noninvasive/invasive BP recorded each minute). In the same time, 3 pairs of oscillometric NIBP (cuff placed around a calf), and invasive BP measurements, at 30-sec intervals. The cuff is then placed around an arm and triplets of BP (arm cuff, finger cuff, intra-arterial catheter) will be taken over a 20-min period, at 3-min intervals and every time the invasive and/or the continuous finger cuff measurements cross the threshold of 65 mmHg for the mean BP. If clinically indicated, a cardiovascular intervention that can be either vascular volume expansion or initiation of vasoactive drug therapy, can be administered during this period. Finally, the cuff placed around the arm will be once again placed around the calf to take 3 pairs of oscillometric NIBP measurement with cuff placed around a calf, and simultaneous invasive BP measurement, at 30-second intervals.
46024235|NCT02814721|Device|Sonic Window ultrasound device|
46110970|NCT00642772|Other|Group Physical Therapy|12-week group-based program of physical therapy. Participants will meet approximately every other week for a total of 6 visits. The group sessions will include education about appropriate self-care for knee osteoarthritis and instructions and participation in group exercises. Participants will also be instructed in a home exercise program.
46110971|NCT00808678|Drug|ABT-143|once, see arm description for more information
46024236|NCT04302441|Drug|Vinorelbine|vinorelbine 25mg/m2 on day 1 and 8,every 3 weeks
46110972|NCT00808678|Drug|ABT-335|once, see arm description for more information
46024237|NCT04302441|Drug|Capecitabine|Capecitabine 1000mg/m2, po, bid, d1-d14, 21 days per cycle
46110973|NCT00808678|Drug|rosuvastatin|once, see arm description for more detail
46024238|NCT04236427|Drug|Angong Niuhuang Wan|Angong Niuhuang Wan 3g
46024239|NCT04236427|Drug|Angong Niuhuang Wan Placebo|Angong Niuhuang Wan Placebo 3g
46024240|NCT02853682|Biological|plasma|assesment of glycocalyx protein
46024241|NCT02874027|Other|The TBI patients with depression|The study is to investigate whether exist the relationship between depression and circadian rhythm of patients with TBI or not.
46024242|NCT02800447|Drug|Natulan|Each baseline BEACOPP regimen lasts 21 days, and each cycle consists of： Cyclophosphamide injection: 650mg/m2, IV infusion, day 1； Doxorubicin hydrochloride injection: 25mg/m2, IV infusion, day 1； Etoposide injection: 100mg/m2, IV infusion, day 1~3; Natulan (procarbazine hydrochloride capsule): 100mg/m2，po, day 1~7; Bleomycin hydrochloride injection: 10mg/m2, IV or IM, day 8; Vincristine: 1.4mg/m2 (single maximum dose is 2mg), IV infusion, day 8; Prednisone tablet: 40mg/m2, po, day 1~14
46110974|NCT04045366|Other|Sample collection|Plasma and BAL sample collection
46110975|NCT00815854|Dietary Supplement|Folic Acid|5 mg of folic acid taken daily for 3 months in an open label fashion
46024243|NCT02800447|Drug|ABVD|Each ABVD cycle lasts 28 days1 cycle of the ABVD regimen consists of： Doxorubicin hydrochloride injection：25mg/m2，IV infusion，day 1 and 15; Dacarbazine injection：375mg/m2，IV infusion，day 1 and 15； Bleomycin injection：10mg/m2，IV or IM，day 1 and 15； Vincristine injection：1.4mg/m2 (single maximum dose is 2mg), IV infusion，day 1 and 15;
46024244|NCT01104220|Other|Weight loss|Bariatric surgery-induced weight loss to achieve ~20%-30% reduction in initial body weight
46024245|NCT05520619|Drug|Paclitaxel, Cisplatin|Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135-175mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will receive paclitaxel 45mg/m2 and cisplatin 25 mg/m2 once weekly for 5 weeks during radiotherapy.
46024246|NCT05520619|Drug|tislelizumab|Patients received tislelizumab 200 mg every 3 weeks for 16 cycles in Arm A and 4 cycles in Arm B.
46024247|NCT05520619|Radiation|Radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
46024248|NCT01038921|Drug|Melatonin|8 mg dose of Melatonin
46024249|NCT01038921|Drug|Placebo|Placebo
46024250|NCT01088542|Behavioral|Communities That Care|The Communities That Care (CTC) system provides communities training and ongoing technical assistance in a structured process for conducting prevention needs assessments using epidemiological data on levels of risk and protective factors for adolescent problem behaviors, selection of tested and effective preventive interventions shown to address community-prioritized factors, implementation of these interventions with fidelity, and evaluation of the community's progress toward its goals. The CTC system is designed to produce a plan for prevention services that is tailored to the needs of each community. CTC is installed in five phases through a manualized series of training events designed to build the capacity of communities to install and sustain the system over time.
46024251|NCT02804347|Device|Cognitive Function Imaging and Battery|Individuals will be placed in the fMRI scanner and complete the NBACK Cognitive Task
46110976|NCT00815854|Other|Placebo|Subjects may receive placebo (a sugar pill) for 4 months
46110977|NCT02551354|Device|Portable video pupillometer|Portable video pupillometer measures pupil diameter (PD) in patient during obstetrical labor
46110978|NCT02551198|Drug|HAPREP®|"Arm1: HAPREP® (2L polyethylene glycol with ascorbic acid; PEG-Asc)~: : PEG-Asc(500mLx2 times q30min)[PM 7-9, the day before colonoscopy] + PEG-Asc(500mLx2 times q30min)[AM 5-7, the day of colonoscopy]"
46110979|NCT02551198|Drug|SUCLEAR®|Arm2: SUCLEAR® (oral sulfate solution; OSS): OSS(1b/177mL)[PM 7-9, the day before colonoscopy] + OSS(1b/177mL)[AM 5-7, the day of colonoscopy]
46110980|NCT00446095|Drug|fostamatinib|200 mg PO BID
46110981|NCT00815932|Device|TDCS/sham procedure on five consecutive days|The latency and amplitude of P300, subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined at before and 15 min and 120 min after the 1st and 5th tDCS/sham procedure, To receive tDCS/sham treatment, two electrodes will be placed on the patient´s skull (for details see section Methods) and the patient will rest for 5 min. After that, the patient will receive 20 minutes of 2 mA tDCS/sham. Subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined before-, 15 min after and 120 min after each tDCS/Sham procedure. At the 1st and 5th tDCS/Sham session, the latency and amplitude of P300 will be determined before-, 15 min after and 120 min after the tDCS/sham procedure.
45469562|NCT03414346|Other|Exclusively ice pack|Each subject will receive an experimental intervention of exclusively 500 grams of crushed ice. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
46024252|NCT02804347|Device|Sniffin Sticks|Using Sniffin Sticks, olfactory functioning will be assessed using three tests: identification, discrimination, and threshold.
46024253|NCT02804347|Other|Cognitive Batteries|Participants will conduct the following cognitive batteries: DSST, TMT A & B, RAVLT
46024254|NCT02804191|Drug|LO2A|eye drop solution.
46024255|NCT02804191|Drug|Saline|Placebo
46024256|NCT02804113|Device|Supera Peripheral Stent System|
46024257|NCT02374372|Device|conventional hemodialysis|
46024258|NCT02374372|Device|hemodiafiltration On-line|
46110982|NCT00817648|Drug|Quetiapine|Quetiapine fumarate, 25mg/200 mg, the dose titration is carried in week 1. flexible doses(600-750 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
46110983|NCT00817648|Drug|risperidone|risperidone, 1mg/tablet, the dose titration is carried in week 1. flexible doses(3-6 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
46110984|NCT03633643|Drug|oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets)|"five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day~1 and 2 after surgery while the patient is in hospital."
46110985|NCT03633643|Drug|oral applications of Placebo|five oral applications of Placebo at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
46024259|NCT04236349|Genetic|immunogenetics|blood samples at day 0, week 2, month 2; at the end of treatment (month 6 or month 9 or month 12 depend on treatment duration)
46024260|NCT01038687|Drug|A3309|A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets
46024261|NCT01038687|Drug|placebo|placebo
46024262|NCT02803957|Device|NeoChord DS1000|Trans-apical, beating heart repair of degenerative mitral valve insufficiency with artificial chordae implanted with the NeoChord DS1000
46110986|NCT00808756|Dietary Supplement|Fermentable carbohydrates.|Infant formula enriched with fermentable carbohydrates.
46110987|NCT00808756|Other|Standard infant formula.|Standard infant formula.
46110988|NCT04045054|Behavioral|Link Team|A VA home care Link Team (clinical pharmacist, social worker, physical activity trainer) provides the intervention based on a conceptual model of home care as a bridge between hospital and home, in which three interconnected domains determine short-term and long-term outcomes: medical complexity (e.g., medication management), social complexity (e.g., caregiving, environment), and functional impairment (e.g., mobility, physical activity). The Link Team provides support and assessment for each domain, and will use tablet technology and wearable sensors in the home to gather patient data and facilitate communication. At the end of formal home care services, the Link Team provides patient-centered care in: 1) support for the the Veteran and caregiver in the event of changes in medical condition or medications and social or caregiver stressors; and 2) coaching to the Veteran and the caregiver during this transition period to optimize functional mobility and physical activity.
46110989|NCT00829010|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as 3 or 4 doses
45469563|NCT03414346|Other|Ice pack added 10% of water|Each subject will receive an experimental intervention of ice pack added to 50 mL of water. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
45469564|NCT03414346|Other|Ice pack added 100% of water|Each subject will receive an experimental intervention of ice pack added to 500 mL of water. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
46024263|NCT02803957|Device|Surgical Mitral Valve Repair|Surgical repair of degenerative mitral valve insufficiency with cardiopulmonary bypass, and annuloplasty ring and some form of leaflet repair or artificial chordae.
46024264|NCT02856568|Drug|Cisplatin|Given IV
46024265|NCT02856568|Drug|Gemcitabine Hydrochloride|Given IV
46024266|NCT02856568|Other|Laboratory Biomarker Analysis|Correlative studies
46024267|NCT02856568|Other|Pharmacological Study|Correlative studies
46024268|NCT02856568|Drug|Ricolinostat|Given PO
46024269|NCT02804269|Other|Cardiovascular Magnetic Resonance|For the evaluation of heart function and structure of the cardiovascular system.
46024270|NCT02804269|Other|Fatmass measurement|It utilizes a scale machine to measure the body fat and skeletal muscle percentage
46024271|NCT04236583|Other|Telehealth|Post-discharge virtual visit
46024272|NCT02874105|Other|Group C: physiotherapy protocol with Conventional physiotherapy.|
46024273|NCT02874105|Other|Group S: physiotherapy protocol with Dynamic Humeral Centering.|
46024274|NCT04081831|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Follow clinical administration
46110990|NCT00829010|Biological|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
46110991|NCT00829010|Biological|measles|Intramuscular injection, 2 doses
45469565|NCT03420898|Other|Quality Improvement Intervention, prescription reduction|The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
45469566|NCT03420820|Biological|Bacterial Culture Swab|Culture swabs will be obtained before application of PI and after injection.
45469567|NCT03764059|Device|Filtek bulk fill posterior restoration|"The subjects will be assigned to either the investigational product (Filtek Bulk ) or the control product (Z350XT) per web-based randomization system.~Immediately after restoration placement, at 1 week and 1 year postoperative, two evaluators from each site will perform an independent clinical assessment."
45469568|NCT03764059|Device|Filtek™ Z350XT Universal Restorative|Filtek™ Z350XT Universal Restorative (Z350 XT) will serve as the control in this study.
45469569|NCT02294968|Other|Family Startup (in Danish: Familieiværksætterne)|Manualized parenting support program; see Center for Socialt Ansvar (2013)
45469570|NCT03771469|Other|Sleep study|Sleep study
45469571|NCT03420664|Device|Orthosis VACOped|Orthosis for lower limb immobilisation
46024275|NCT02807155|Behavioral|Transition Empowerment Program|Participants will receive the 1-year transition empowerment program/curriculum (TEP-CG) alone.
45469572|NCT03420664|Device|Below knee cast|Below knee cast for lower limb immobilisation
45469573|NCT03414190|Behavioral|Mobile phone text message|The treatment group will receive the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the text-messaging intervention. The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living habits texts. There will be four streams: one for patients who are non-smokers and are free of diabetes; one for current/recent smokers; one for diabetic patients; and one for smoker and diabetic patients. Texts will be sent out 4 times per week for 180 days. All participants in the same stream will receive the same texts in the same order. The usual care group will receive standard discharge treatment, instructions, and information for patients with acute coronary syndrome. They will also receive simple and short text messages related to the importance of trial participation.
46024276|NCT02807155|Behavioral|Transition Empowerment Program (TEP) + Diabetes Wellness Council (DWC)|Participants will receive the identical 1-year Transition Empowerment Program, plus the innovative wellness-based group process (council).
46024277|NCT02807155|Behavioral|Online Transition Empowement Program Access|Participants assigned to an outside medical home would be followed according to the clinical needs as assessed by their medical provider. They would be given access to the TEP website curriculum, but would not participate in other aspects of the 1-year TEP.
46024278|NCT01081912|Drug|Placebo|Capsules, no active substance, shells identical to active comparator capsules
46024279|NCT01081912|Drug|Hydrocodone bitartrate|"dosage form: capsule~Strengths 10mg, 20mg, 30mg, 40mg, 50mg"
46024280|NCT02800525|Device|Picosecond laser|Picosecond 532 and 1064 nm laser Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesions.
46110992|NCT00829010|Biological|Rotarix|Oral, 2 doses
46110993|NCT00829010|Biological|Local OPV|Oral 4 doses. Given at any time during the study, routinely given concurrently with DTPw-HBV/Hib vaccine
46110994|NCT00817882|Other|individually targeted vocational rehabilitation|"individually targeted vocational rehabilitation over 4 month period, maximum of 10 sessions, in addition to routine back pain rehabilitation.~Maximum of 25 participants with low back pain"
45469574|NCT02718001|Device|Edwards EVOQUE Eos Mitral Valve Replacement System|Replacement of the mitral valve through a transcatheter approach
45469575|NCT02260102|Drug|Temocillin|Venous blood will be drawn (as per the protocol) for assay of temocillin on day 1 and day 4 of treatment. This is not part of our standard of care and is, therefore, an intervention. Patients are enrolled only if receiving temocillin as part of their normal standard of care (and the drug will be administered based on current recommendations [no change due to enrollment in the study]).
45469576|NCT03425734|Drug|Dexmedetomidine|The drug will be prepared in 50 ml saline 0.5 ml DEX (100mc/ml +49.5 cc saline 1ml=1mg), and the dose will be calculated according to body weight.
46110995|NCT00817882|Other|routine back pain rehabilitation|routine back pain rehabilitation Maximum of 25 patients with low back pain
46110996|NCT04632784|Device|Artiflex Presbyopic implantation|Implantation of iris-fixated multifocal Artiflex Presbyopic IOL
46110997|NCT00706316|Biological|EBV-Specific CTLs and CD45 Mab|"One time infusion (IV) at one of the following dose levels:~Dose level I: 5 x 107 cells/m2~Dose level II: 1 x 108 cells/m2~Dose level III: 2 x 108 cells/m2"
46110998|NCT00644332|Drug|Ranolazine|Oral dosage form.
46110999|NCT00808912|Drug|sildenafil|sildenafil 50 mg ingested orally 1 hour prior to exercise testing
45469578|NCT03127072|Device|Radiofrequency Ablation (RFA)|The radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue
46024281|NCT02800525|Device|Q-switched Nd:YAG laser|Q-switched Nd-YAG 532 and 1064 nm laser. Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesion.
46111000|NCT00808912|Other|placebo|matching placebo for sildenafil 50 mg to be ingested orally 1 hour prior to exercise testing.
46111001|NCT02551042|Drug|Fibrogammin®P, coagulation factor XIII concentrate (Human)|IV infusion
46111002|NCT02551042|Drug|0.9% sodium chloride|IV infusion
46111003|NCT00808990|Dietary Supplement|BioFemale|BioFemale 6 months.
46111004|NCT00445939|Biological|adalimumab|160 mg at Week 0, 80 mg at Week 2
46111005|NCT00445939|Biological|adalimumab|80 mg at Week 0, 40 mg at Week 2
46111006|NCT00445939|Biological|placebo|Placebo at Week 0 and Week 2
46111007|NCT00816244|Drug|Atorvastatin|Atorvastatin 80 mg daily for two weeks, ending at the day of operation for breast cancer.
46111008|NCT00817960|Drug|Methylphenidate|The effect of ritalin on postural stability of old adults (65 years old and over) will be measured using RCT study design
46111009|NCT00816322|Dietary Supplement|Omega-3 fatty acids|EPA 2.1 g/d+DHA 1.1 g/d
46111010|NCT00816322|Dietary Supplement|Placebo|high oleic oil
46111011|NCT01565785|Behavioral|The FSM-DPI.|Nurses will assess key elements of family self-management (home care, child's care, practice, medications, watching child, recovery, development, family adjustment and parental support) and address any deficits to facilitate effective discharge and family management of child at home after hospitalization.
46111012|NCT00818038|Drug|BG0002 (natalizumab)|Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.
46111013|NCT03995953|Behavioral|SHIELD intervention (Support for HIV Integrated Education, Linkages to care, and Destigmatization)|The SHIELD intervention includes a three-session, six-module program for AGYW that increases knowledge, skills, and self-efficacy to engage along the HIV prevention and care continuum, and a two-session, four-module program for family members to increase social support. In addition, the SHIELD intervention includes youth clubs to foster peer support.
46111014|NCT03995953|Other|Integrated wellness care (IWC) clinics|IWC clinics will be created within health facilities where AGYWs can receive sexual and reproductive health services, including HIV testing and treatment, family planning, sexually transmitted disease screening and treatment, and HPV vaccination in a youth-friendly environment.
45469579|NCT03127072|Drug|chemotherapy ± target therapy|chemotherapy ± target therapy
45469580|NCT03420586|Drug|Nitrous Oxide|The nitrous oxide group (GN2O) will receive 70% N2O in 30% O2 at the end of surgery.
46024282|NCT01038609|Drug|Hydrocodone/Acetaminophen Extended Release|
46024283|NCT01038609|Drug|Acetaminophen|
46024284|NCT01038609|Drug|Morphine Extended Release|
46024285|NCT01038609|Drug|Placebo|
46024286|NCT02803879|Device|Cardiogoniometry|
46024287|NCT02800759|Dietary Supplement|JOINTRUS®|100% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
46111015|NCT00482053|Procedure|Autologous hematopoietic stem cell transplantation (auto-HSCT)|Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents
46111016|NCT00482053|Procedure|Allogeneic hematopoietic stem cell transplantation (allo-HSCT)|Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)
46111017|NCT00482053|Procedure|Total lymphoid irradiation (TLI)|TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT
46111018|NCT00482053|Drug|Rituximab|375 mg/m2 IV days 1 and 7 over 4 to 8 hours
46111019|NCT00482053|Drug|Carmustine|"Based on body weight, unless its more than 15 kg greater than the idal body 15mg/kg (max dose 550 mg/m2) day -6 over 2 hours.~Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)"
46111020|NCT00482053|Drug|Etoposide|60 mg/kg over 4 hours day -4 and alternatively VP-16 2 Gm/m² may be used (for mobilization)
46111021|NCT00482053|Drug|Filgrastim|10 µg/kg/day subcutaneous starting Day 9 until last day of apheresis. 5 ug/kg actual body weight per day will be started at Day +6 after allo-HCT until hematologic recovery
46111022|NCT00482053|Drug|Anti-thymocyte globulin (ATG)|1.5 mg/kg/day for 5 days
45469581|NCT03763981|Procedure|prolene seton treatment|patients with perianal fistulas will treated with seton placement by prolene thread
45469582|NCT03763981|Procedure|silk seton treatment|patients with perianal fistulas will treated with seton placement by silk thread
46024288|NCT02800759|Dietary Supplement|80% dose of JOINTRUS®|80% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
46024289|NCT02800759|Dietary Supplement|62.4% dose of JOINTRUS®|62.4% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
46111023|NCT00482053|Drug|Cyclosporine|5.0 mg/kg twice daily from day -3 until after day +56
46111024|NCT00482053|Drug|Mycophenolate mofetil (MMF)|"250 mg (total) twice daily, oral~15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. On day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor."
46111025|NCT00482053|Drug|Cyclophosphamide|100 mg/kg will be administered over 2 hours on day -2
45469583|NCT03759067|Drug|clopidogrel 75mg|clopidogrel once daily 75mg
45469584|NCT03759067|Drug|Clopidogrel 300 mg|clopidogrel 300mg reloading
45469585|NCT03759067|Drug|clopidogrel 600mg|clopidogrel 600mg loading
46111026|NCT00482053|Drug|Acetaminophen|Pre-medication for rituximab and PBPC infusion. Administered at 650 mg by mouth 1 hour prior to infusion
46111027|NCT00482053|Drug|Diphenhydramine|Pre-medication for rituximab and PBPC infusion. Administered at 50 mg intravenous 1 hour prior to infusion
46111028|NCT00482053|Drug|Hydrocortisone|Pre-medication for the PBPC infusion. Administered at 100 mg intravenous 1 hour prior to infusion
45469586|NCT03425656|Drug|Trastuzumab plus docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide|Trastuzumab (8 mg/kg IV loading dose at cycle 1, followed by 6 mg/kg at subsequent cycles) is given concomitantly with docetaxel (100 mg/m2 IV) for four 21-day cycles after four 14-day cycles of Doxorubicin (60 mg/m2 IV) plus cyclophosphamide (600 mg/m2 IV)
45469587|NCT03420430|Biological|GL-ONC1|
45469588|NCT00628095|Drug|CE-224,535|500 mg po BID
45469589|NCT00628095|Drug|Placebo|no active ingredient
45469590|NCT03420352|Diagnostic Test|Thromboelastography|paired TEG analysis undertaken from participants with the two different needles
45469591|NCT03413956|Procedure|Surgeries|Surgeries
46024290|NCT02800759|Dietary Supplement|Starch 100%|0% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
46024291|NCT02857582|Biological|Cultured human intestinal microbiota|Secondary treatment for C diff in replacement for regular vancomycin.
45469592|NCT03413878|Other|Breathing in the simulated avalanche snow|Breathing in the simulated wet or dry avalanche snow with a small or large air pocket
45469593|NCT03745677|Behavioral|Advanced and Integrated MicroSystems (AIMS) interventions|Each of 4 sites is receiving mentorship from nurse and physician with expertise in implementing similar interventions. The AIMS interventions consist of 1) unit-based physician teams, 2) unit nurse-physician co-leadership, 3) enhanced interprofessional rounds, 4) unit-level performance reports, and 5) patient engagement activities.
45469594|NCT03425578|Dietary Supplement|MSG|150 mg/kg body mass monosodium glutamate (MSG).
45469595|NCT03425578|Dietary Supplement|CHO|75g CHO (i.e. dextrose)
45469596|NCT03425578|Dietary Supplement|Placebo A|A non-caloric placebo composed of table salt (NaCl) and sucralose (Splenda).
45469597|NCT03425578|Dietary Supplement|Placebo B|A non-caloric placebo composed of flavoured water.
46024292|NCT02857582|Drug|Vancomycin|Active comparator to treatment with ACHIM
46024293|NCT02857582|Drug|Metronidazole|Primary treatment for C diff in all treatment arms
46024294|NCT04301973|Other|Stool collection|There is no intervention with a product in this study. The healthy subject has just to come 2 times in the clinical trial unit for clinical exam including urinary pregnancy test, fill life habits and diet questionnaires, and provide one stool sample for the 2nd visit, after 2 weeks of alimentary restrictions.
46024295|NCT02803801|Behavioral|Build Your Parenting Toolkit Program|Ten session program, with a mix of parents-only lectures and parent and child Cooking Clubs.
45469598|NCT03425344|Diagnostic Test|Diagnostic|No traditionally intervention will be given but participants will be exposed to shoulder- MRI, ultrasound and sonoelastography..
45469599|NCT03413722|Drug|Tacrolimus|The patient's physician will prescribe drug according to standard practice.
45469600|NCT03413722|Drug|Everolimus|The patient's physician will prescribe drug according to standard practice.
46024296|NCT04301895|Behavioral|Continuous conversational interaction|Maintaining continuous conversation, requiring that the subject answer questions and engage in discussion without interruption.
46024297|NCT04301895|Drug|Remifentanil infusion|10 minute remifentanil infusion
46024298|NCT02357134|Procedure|Oxygen Therapy|Receive high-flow oxygen
46024299|NCT02357134|Procedure|Oxygen Therapy|Receive high-flow air
46024300|NCT02357134|Other|Quality-of-Life Assessment|Ancillary studies
46024301|NCT02357134|Other|Questionnaire Administration|Ancillary studies
46024302|NCT02357134|Procedure|Respiratory Therapy|Receive low-flow oxygen
46111029|NCT00482053|Drug|Methylprednisolone|Anti-reaction medication for the ATG infusion. Administered at 1 mg/kg, Day-11 to Day-7
46111030|NCT00455923|Drug|Seretide|Seretide
46111031|NCT00455923|Drug|Flixotide|Flixotide
46111032|NCT00642616|Drug|Technosphere® Insulin|Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents
46111033|NCT00642616|Drug|Usual Care|Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin
46111034|NCT00816478|Drug|Galactose|Oral galactose, 0.2 g/kg/dose twice daily for 28 days
46111035|NCT00809068|Drug|fenofibrate and tibolone|fenofibrate 160mg daily 8 weeks tibolone 2.5mg daily 23 weeks
46111036|NCT00809068|Drug|tibolone|tibolone 2.5 mg daily 23 weeks
46111037|NCT03844945|Drug|Netarsudil Ophthalmic Solution 0.01%|Topical sterile ophthalmic solution
46111038|NCT03844945|Drug|Netarsudil Ophthalmic Solution 0.02%|Topical sterile ophthalmic solution
46024303|NCT02357134|Procedure|Respiratory Therapy|Receive low-flow air
46111039|NCT03844945|Drug|Netarsudil Ophthalmic Solution 0.04%|Topical sterile ophthalmic solution
46111040|NCT03844945|Other|Netarsudil Ophthalmic Solution Placebo|Topical sterile ophthalmic solution
45469601|NCT03413644|Diagnostic Test|Flow Cytometry|Immunophenotyping of residual clinical samples tested with ClearLLab diagnostic reagent on a specified Flow Cytometer
45469602|NCT04787757|Procedure|Percutaneous cardiac procedure|Collection and analysis of intraprocedural information to provide artificial intelligence algorithms
45469603|NCT03420196|Other|Supervised exercise program|"It will consist in a supervised exercise program, including the following exercises:~Diaphragmatic breathing.~Transverse abdomLateral leg raise for gluteus mediuminis muscle activation.~Pelvic swing.~Gluteus bridge.~Spinal mobility.~Spinal extensor muscles strengthening~Frontal plank~Side plank.~Lateral leg raise for gluteus medium"
45469604|NCT03420196|Other|Non supervised exercise program|"It will consist in a non supervised exercise program, including the following exercises:~Diaphragmatic breathing.~Transverse abdomLateral leg raise for gluteus mediuminis muscle activation.~Pelvic swing.~Gluteus bridge.~Spinal mobility.~Spinal extensor muscles strengthening~Frontal plank~Side plank.~Lateral leg raise for gluteus medium"
45469605|NCT02889861|Drug|IMCgp100|Bispecific soluble human leukocyte antigen-A2 (HLA-A2) restricted gp100-specific TCR fused to anti-CD3
45469606|NCT00454948|Behavioral|Home-based nutrition sessions and play group exercise|
45469607|NCT00454948|Behavioral|Group-based nutrition sessions and mail-out activities|
45681639|NCT05586178|Behavioral|Information provision about bivalent booster eligibility|The message will clarify to patients that regardless of whether they are at high risk, received the original boosters, or previously got COVID-19, they are eligible for the bivalent booster based on their medical records, and the updated booster will be valuable for them.
46024304|NCT04200781|Drug|Granules of Shengdi Dahuang Decoction|Shengdi Dahuang Decoction contains Shengdi (rehmannia) and Dahuang ( rhubarb). Each pack of the granules of Shengdi Dahuang Decoction contains 15 grams of rehmannia and 5 grams of rhubarb.
46024305|NCT04200781|Drug|Placebo|Placebo granules has the same appearence, weight, shape and color as the experimental drug.
46111041|NCT03842995|Behavioral|Genetic Counselor|Standard of Care
46024306|NCT04302675|Behavioral|Prevention, Maternal Immunization|"This intervention will be focused on behavior change, both through providers gaining context, knowledge, confidence, and skills in talking to pregnant mothers about vaccination during pregnancy, but also with patients having increased knowledge about immunization issues, and decreased anxiety about getting vaccinated.~There is only one intervention arm in this study, and this study is looking at prevention in a pre-post feasibility study."
46024307|NCT02806765|Dietary Supplement|(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol|25 micrograms of (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol every day for 6 months
46024308|NCT02806765|Other|Control|Placebo in Softgel form
46024309|NCT02853526|Procedure|TIPS|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach (p-TIPS). Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction.
45681640|NCT05586178|Behavioral|Information provision about the severity of COVID-19 symptoms|The message will contain information about the often underestimated chances of people developing severe or long-lasting COVID-19 symptoms. The message will also mention that the bivalent booster can reduce such chances.
45681641|NCT01821560|Drug|Baclofen|
46024310|NCT02853526|Drug|Propranolol|Propranolol is a kind of non-selective beta blockers, and is used for reducing the portal pressure.
46111042|NCT03842995|Behavioral|Trained Healthcare Provider|Neonatologists and Neonatology Nurse Practitioners that receive training to deliver whole genome sequencing results
46111043|NCT01027117|Drug|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
46111044|NCT01027117|Drug|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
46111045|NCT01027117|Drug|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
46111046|NCT03995563|Drug|Dexamethasone|"Continous epidural injection will be done during 10 days. D group will be injected a 0.19% ropivacaine 8mL and dexametasone 1mg every other day during 10 days.~."
46111047|NCT03995563|Drug|Ropivacaine|Continous epidural injection will be done during 10 days Both group will be injected a 0.19% ropivacaine 8mL every other day during 10 days
46111048|NCT00445549|Drug|Vandetanib|300 mg daily dose, 28 day cycle
46111049|NCT00445003|Drug|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab at baseline and 4 weeks
46111050|NCT00445003|Drug|Triamcinolone Acetonide|Intravitreal injection of 4 mg triamcinolone acetonide at baseline and sham injection at 4 weeks
46111051|NCT00445003|Behavioral|Sham injection|Sham injection at baseline and 4 weeks
46111052|NCT00445003|Procedure|Focal/grid laser|Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
45838572|NCT04385316|Diagnostic Test|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of bladder tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples ,urine sample，blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the three types of samples of the patients respectively, and the DNA sequencing results of the three types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA ,urine ctDNAand tissue gDNA for the gene detection of bladder tumor."
45838573|NCT04384926|Procedure|Elective Cancer Surgery|Planned, curative cancer surgery
46024311|NCT02853526|Procedure|Endoscopic therapy|Endoscopic therapy includes the endoscopic variceal band ligation and sclerotherapy.
46111053|NCT00811070|Drug|SKI-606 (Bosutinib)|"Formulation: 100 mg Capsule for Part 1, 100 mg tablet for Part1 and Part 2.~SKI-606 (Bosutinib) will be taken by mouth with water and food as continuous once-daily dosing."
46111054|NCT02609594|Other|Weekly application of Amnioband|Weekly application of Amnioband.
46111055|NCT02609594|Other|Biweekly application of Amnioband|Biweekly application (every two weeks) of Amnioband.
45838574|NCT04384614|Diagnostic Test|Test PCR|Viral load (COVID+) testing by PCR
46111056|NCT02609594|Other|Standard of Care|Standard of care for this study is weekly multi-layer compression bandaging.
46111057|NCT04029896|Biological|HB-adMSCs|intravenous infusion of Hope Biosciences autologous adipose-derived stem cells
46111058|NCT00642460|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg (patients>=30kg) or 12mg/kg (patients <30kg) iv every 2 weeks. In Part III, administration frequency may be reduced to every 3 and every 4 weeks, respectively, according to an optional alternative dosing schedule.
45838575|NCT04384614|Genetic|TDR|IDR and blood sampling for testing DNA Cheque
45469608|NCT04843462|Device|edupression.com®|"Edupression.com® is an evidence-based self-help program that was developed for the treatment of mild to moderate unipolar depression. It is based on two core foundations, psychoeducation with elements of cognitive behavior therapy (CBT) and a mood chart. Both foundations are registered as a medical product. As such, detailed risk management documentation includes probability and severity of adverse events. Moreover, detailed strategies such as warnings were implemented in the software and documented accordingly.~It can be used on a PC as well as on mobile devices (browser, app) at any time."
46111059|NCT00642460|Drug|Placebo|iv every 2 weeks for 12 weeks
46111060|NCT00642460|Drug|Non-steroidal anti-inflammatory drugs (NSAIDs)|as prescribed
46111061|NCT00642460|Drug|methotrexate|as prescribed
46111062|NCT00642460|Drug|corticosteroids|orally, as prescribed
46111063|NCT00814658|Drug|Galantamine|Galantamine 8 mg/day for one month, followed by 4 weeks of galantamine 16 mg/day. If necessary and well tolerated, dosage of galantamine will be increased to 24 mg/day.
45681642|NCT01821560|Drug|placebo|
45681643|NCT05585164|Behavioral|Engage & Connect|"Engage & Connect, is a remotely-delivered extension of Engage psychotherapy. It is aimed to increase engagement in rewarding social activities and in turn, reduce suicidality. In Engage & Connect, depressed middle-aged and older adults with suicidal ideation work with a therapist to develop action plans to pursue rewarding social activities of their choice."
45681644|NCT01871402|Drug|000-0551 Lotion|
45681645|NCT01871402|Drug|Vehicle Lotion|
45838576|NCT04384614|Other|Clinical Examination|COVID 19 symptoms and Physical Examination
45838577|NCT04384536|Procedure|Neural therapy application|Local injections, C5-T8 segmental injections, trigger point injections of the forearm muscles and stellate ganglion injections are applied in each session, using a 27-gauge, 4-6 cm needle. The local injection is applied first in the first extensor compartment at the point of maximal tenderness and is directed proximally toward the radial styloid.trigger point is detected, approximately 5 mL lidocaine was injected to that point. C5-T8 segmental injections are applied intradermally to each spinous process and to 0.5-2 cm lateral of each process on the affected side. Finally, the stellate ganglion injection is applied using Fischer's modified technique.
46024312|NCT02853526|Drug|Warfarin|Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal.
46024313|NCT04200469|Diagnostic Test|Quantitative Flow Ratio (QFR) measurement|Quantitative flow ratio (QFR) is a novel approach enabling rapid computation of FFR pullbacks from three-dimensional quantitative coronary angiography (3D-QCA) without using a pressure wire.
46111064|NCT00814658|Drug|Nimodipine|Nimodipine 30 mg 3 times a day (tid).
46111065|NCT00814658|Drug|Placebo|Matching placebo three times a day (tid).
46111066|NCT00816634|Drug|Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)|"3.2 Overview of Study Design This study is a prospective, randomized, phase II study comparing response rate between patients with XP chemotherapy versus XG chemotherapy for patients with metastatic squamous cell carcinoma.~Chemotherapy regimen (XP):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr every 3 weeks~Chemotherapy regimen (XT):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs every 3 weeks"
46111067|NCT00642304|Drug|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Methoxy polyethylene glycol-epoetin beta is administered SC every four week up to Week 20.The starting dose is 120, 200 or 300 mcg based on the dose of darbepoetin alfa or epoetin beta participants shall be receiving in the week preceding the study start. Further dose adjustment during the study depending on the hemoglobin (Hb) values.
46111068|NCT00814580|Drug|Tapentadol IR|First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1, if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
46111069|NCT00814580|Drug|Oxycodone IR|First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1, if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
46111070|NCT00643162|Drug|Lexapro|5mg-10mg of lexapro, daily, for 9 weeks for all study participants.
46111071|NCT00643162|Behavioral|Light touch|Light touch twice a week, for 8 weeks
46024314|NCT03898531|Procedure|hip prosthesis removed metal / polyethylene, simple mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a simple mobility The aim is to define the types of particles that cause the most tissue inflammation"
46024315|NCT03898531|Procedure|hip prosthesis removed metal / polyethylene, double mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation"
46024316|NCT03898531|Procedure|hip prosthesis removed ceramic/ polyethylene, simple mobility|"Patients are hospitalized in order to change for their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a simple mobility.~The aim is to define the types of particles that cause the most tissue inflammation"
46024317|NCT03898531|Procedure|hip prosthesis removed ceramic/ polyethylene, double mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation."
46024318|NCT03898531|Procedure|Primary implanted hip prosthesis|"Patients are hospitalized in order to have a first hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The patients will be received a first prosthesis."
46024319|NCT03898531|Procedure|hip prosthesis removed metal/metal|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/metal. The aim is to define the types of particles that cause the most tissue inflammation"
46024320|NCT03898531|Procedure|hip prosthesis removed ceramic/ceramic|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/ceramic. The aim is to define the types of particles that cause the most tissue inflammation"
46024321|NCT02806531|Biological|two doses enterovirus 71 vaccine|Two doses of enterovirus 71 vaccine will be given in children aged 6-35 months old, 28 days interval.
46024322|NCT00630682|Drug|Dextroamphetamine|1 week placebo and 8 weeks 60mg d-AMP QD.
46024323|NCT00630682|Drug|Placebo|9 weeks of placebo 60mg capsules QD.
46024324|NCT04236193|Diagnostic Test|Ultrasound Shoulder and Immunological Phenotyping by FACS|Cross-sectional Ultrasound exam of the affected shoulder. Peripheral blood measurements of the T and B cell subsets. Anti-Influenza Antibody measurements
46111072|NCT00643162|Behavioral|Massage|Massage twice a week, for 8 weeks.
46111073|NCT00643006|Behavioral|Physical exercise|Supervised walks with poles twice a week at moderate-high intensity
46111074|NCT00643006|Behavioral|Active comparator: low intensive exercise|Supervised walks once a week at low-intensity.
45469609|NCT04843462|Drug|Esketamine nasal spray|All patients included in this study are receiving esketamine nasal spray as treatment-as-usual
46111075|NCT00814502|Drug|Zolpidem CR|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
45469610|NCT05275257|Device|Use of Uricap Female, a New Urine Collecting Device|The uridome is changed daily by trained staff
45469611|NCT03420040|Device|QS-M Needle Free Injector|The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection
45469612|NCT03420040|Device|Glargine pen|The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection
46111076|NCT00814502|Drug|Placebo|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
46111077|NCT00653224|Drug|levocetirizine dihydrochloride|5 mg daily (oral tablet) for 14 days
46024325|NCT00745420|Biological|Hematopoietic Stem Cell Transplantation|"The stem cell transplant preparative regimen is listed below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~Alemtuzumab: Children weighing 10 kg or more will receive 10 mg, 15 mg, and 20 mg intravenously (IV) on Days -21, -20, and -19, respectively~Fludarabine: 30 mg/m^2/day IV on Days -8 through -4~Melphalan: 140 mg/m^2 IV on Day -3~Rest on Days -2 and -1~Transplant occurs on Day 0~GVHD prophylaxis: Tacrolimus or cyclosporine beginning Day -3, methotrexate (7.5 mg/m2/day) Day 1, 3 and 6 and methylprednisolone/prednisone on Day +7 to +28 followed by a taper if there is no GVHD"
46024326|NCT02800681|Other|Expert panel evaluation|"From the medical records, described social and psychiatric history and observed psychiatric symptoms will be summarized and presented to two senior psychiatric consultants. The panels evaluation ensures the identification of subjects with typical symptoms, according to a best estimate clinical consensus.~The panel divides the participants into 4 groups: 'participant with symptoms typical of AS', 'participant with symptoms typical of SD', 'participant with inconclusive/non typical symptoms' and 'non eligible participant'."
46111078|NCT00653224|Drug|placebo|0 mg daily (matching oral tablet) for 14 days
46111079|NCT00444925|Drug|fesoterodine fumarate|4 mg once daily (OD) for 1 week followed by a forced dose-escalation to 8 mg once daily (OD) for 11 weeks
45469613|NCT01313169|Other|EMR Reminder|EMR reminders displayed
46024327|NCT02800681|Other|Semi-structured psychopathological interviews|Included participants are asked for a detailed social and developmental history and interviewed with 3 semi-structured interviews: 1. Schedules for Assessment in Neuropsychiatry (SCAN); Covering psychopathology and behaviour associated with the major psychiatric disorders. 2. Autism Diagnostic Observation Schedule (ADOS), module 4; An assessment to identify symptoms within the autism spectrum. 3. Examination of anomalous self-experience (EASE); A checklist for exploration of experiential anomalies. The Ph.D.-student will obtain social and developmental history and carry out SCAN and EASE interviews. ADOS will be carried out by a consultant psychologist at The Danish Autism Centre.
46024328|NCT02800681|Other|Self-administered rating scales|1.The Autism Quotient (AQ), a 50 question scale, for the assessment of autistic traits, 2. The Schizotypal Personality Questionnaire (SPQ), a 74 item scale, for the assessment of schizotypal personality, 3. The WHO-5 Well-Being Index (WHO-5), a 5 item scale, for the assessment of subjective psychological well-being.
46024329|NCT02800681|Other|Other general interviewer ratings|1. Global Assessment of Functioning (GAF), a numeric scale (1 through 100) for assessing social, occupational, and psychological functioning, 2. The Clinical Global Impressions scale (CGI-Severity), an assessment of the clinician's global view of the patient's severity of psychopathology on a 7 point scale.
46024330|NCT02806609|Other|Cold water immersion, with 10 degrees, for 10 minutes|cold water immersion
45469614|NCT01313169|Other|EMR Reminder + Panel management|EMR Reminder + Panel management
45469615|NCT03413566|Other|Clinical diagnosis|A clinical diagnosis of cerebral palsy given by a pediatrician at a habilitation center in Norway.
46024331|NCT02806609|Other|immersion in water at room temperature|immersion in water at room temperature
46024332|NCT02806609|Other|active recovery - running|active recovery
46111080|NCT00444925|Drug|placebo|once daily (OD)for 12 weeks
46111081|NCT00444925|Drug|tolterodine tartrate|4 mg once daily (OD) for 12 weeks
46111082|NCT00641056|Drug|Exenatide Once Weekly|subcutaneous injection, 2.0mcg, once weekly
46111083|NCT00641056|Drug|Insulin Glargine|subcutaneous injection, variable dose, QD
46111084|NCT00814346|Drug|EGb761®|Four weeks for AD patients, 18 months for MC and CNE patients
45469616|NCT05274945|Radiation|Radiotherapy|radiotherapy 45 Gy/ 25 fractions then boost 5.4 Gy/3 fractions with concurrent bolus 5-fluorouracil
46111085|NCT00814346|Drug|Placebo|Placebo 1 tablet BID
46111086|NCT00569374|Drug|Modafinil|subjects attend clinic for the first week in order to receive meds; oral, 200mg/day doses for three days for initiation doses; increased to oral 400mg/day for the remainder of the trial (weeks 2-6); washout period during week 7
46111087|NCT00828464|Drug|clobetasol propionate|Clobetasol propionate. The study product will be applied topically twice a day (morning and evening) for 14 days of treatment.
46111088|NCT00816712|Drug|Comparator: Testosterone 300 mg, intramuscular injection|"Day 1 & 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 & 7 - Testosterone 300 mg, Intramuscular injection."
45838578|NCT04384380|Drug|Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Hydroxychloroquine Sulfate is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
46024333|NCT02806609|Other|rest in the chair|rest in the chair
46024334|NCT02857348|Behavioral|Night Shift|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
45469617|NCT05274945|Drug|consolidation chemotherapy|6 cycles of FOLFOX or CAPOX
46024335|NCT02857348|Behavioral|Educational Module|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then complete questions in the Trauma Life Support MCQ Review, spending at least 1 hour on the combined tasks.
46111089|NCT00816712|Drug|Comparator: Testosterone 100 mg, Intramuscular injection|"Day 1 & 7- Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 & 7 - Testosterone 100 mg, Intramuscular injection."
45469618|NCT05274945|Procedure|TME or APR|total mesorectal excision or abdominoperineal resection
46024336|NCT03989869|Other|Immediate treatment|Early Medical Abortion treatment, when ultrasound does not yet have conclusive signs of intrauterine pregnancy
46024337|NCT05095870|Other|No intervention|Pure observational study
46111090|NCT00816712|Drug|Comparator: Placebo given by Intramuscular Injection|"Day 1 & 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 & 7 - Placebo given as intramuscular injection."
45469619|NCT03413488|Other|kinesio taping|Apply exercise and kinesio taping for intervention
45469620|NCT03413488|Other|exercise|Apply only exercise intervention
45469621|NCT02520856|Other|blood sample|
45469622|NCT04728958|Behavioral|Gratitude|A positive psychology intervention using expressions of gratitude
46111091|NCT00818194|Drug|extended release tacrolimus|oral
45469623|NCT03413410|Drug|Metoprolol|Patients with acute coronary syndrome take metoprolol during hospital and after discharge in the optimal dosing pathway.
45469624|NCT03661827|Diagnostic Test|Stress Cardiac MRI|Dobutamine and adenosine stress MRI
46111092|NCT00818194|Drug|cyclosporine A microemulsion|oral
45469625|NCT03413332|Other|E-Talkcare|Women in the intervention group will receive the E-Talkcare web address, a user name, and a temporary password. The participant will be able to read or listen (through audio narration) to instructions on how to complete the intervention in order, though she can freely navigate between web modules. Each module will have an ever-present indicator (showing users' progress) and a link to for users to continue navigating through modules.We will ask participants to complete the full intervention within 3 months after intervention delivery and then complete a 3-month post-randomization interview (T1). The website will remain open for six months after intervention delivery to allow participants to use QPL if they wish. A 6-month post-randomization interview (T2) will then be administered.
45469626|NCT03413332|Other|Usual Care|Survivors randomized to the usual care group will receive care from their doctors as usual, allowing us to compare the intervention against real-world practice to inform next steps. Since we do not know if the intervention will be efficacious, we decided not to provide a delayed intervention to control participants.
46111093|NCT00816010|Behavioral|telephone contact|for lifestyle and compliance counseling
46111094|NCT02552914|Device|Colli-Pee|Participants will be asked to use the colli-pee to collect first-void urine and to send it back to the Institute of Tropical Medicine by regular mail.
45469627|NCT03620721|Behavioral|mindfulness|8-week mindfulness based group intervention
45469628|NCT03425110|Other|Modified Ketogenic Diet|
45469629|NCT03548961|Drug|FOLFOX regimen|FOLFOX regimen will be administered for 6 cycles. Each cycle is 14 days followed by restaging, local surgery and concurrent chemo radiation therapy
45469630|NCT03419806|Drug|Infudopa i.v.|"Infudopa i.v. infusion will be given through an indwelling catheter placed in the arm. Infudopa i.v. will be delivered in 75% of the subject's individual pre-study dosing of Duodopa.~From patient 6 and onwards:~Infudopa IntraV, at 81% of the subject's individual pre-study daily Duodopa dose, will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The i.v. morning bolus is 110% of the hourly continuous dose delivered at the rate of 60 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer IntraV). The morning dose will not exceed 24 mL, corresponding to 240 mg levodopa. The maximum daily dose levodopa during i.v. administration is not allowed to exceed 3240mg (equal to 81% of the maximum allowed daily dosage for Duodopa that is 4000 mg)."
46111095|NCT02610686|Drug|Chloroquine|efficacy of chloroquine for the treatment of Plasmodium vivax infections
46111096|NCT00816790|Drug|Piperacillin/Tazobactam|eGFR 20-40 mls/min: Piperacillin/Tazobactam 3.375g IV q6h x 24 hours eGFR < 20 mls/min: Piperacillin/Tazobactam 2.25g IV q6h x 24 hours
46111097|NCT00816790|Drug|Piperacillin/Tazobactam|Piperacillin/Tazobactam 4.5g IV q 6h x 24 hours
46111098|NCT00818350|Drug|SUNITINIB|50 MG ORAL, DAYS 1-28 FOLLOWED BY 2 WEEKS RESTING
46024338|NCT04269460|Drug|Bupivacaine Hydrochloride 0.25% Injection Solution [MARCAINE]|preoperative ultrasound guided subcostal TAP block and Quadratus lumborum block using 1 ml/kg of Bupivacaine Hydrochloride 0.25%in pediatric patients undergoing pyeloplasty surgeries.
46024339|NCT04236037|Procedure|ultrasound-guided pleural biopsy|Using ultrasound the optimal point of entry for thoracentesis is located. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site . Again, the area is wiped with disinfectant and a millimeter small skin incision is made with a pointed scalpel. Six US-guided biopsies of 1.2 millimetres using closed needle biopsies (Quick-core Biopsy Needle 18G, COOK Medical, Bloomington, Indiana, USA or Bard Max Core needle 18G, Temple, Arizona, USA). ) are taken from the parietal pleura. Thoracentesis is performed as described above using the same incision as the pleural biopsy.
46024340|NCT04236037|Procedure|Thoracentesis|The optimal point of entry (the largest distance between parietal and visceral pleura) is identified using ultrasound. This is usually on the lower, dorsal side of the chest. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site. The area is wiped with disinfectant and a millimeter skin incision is made with a pointed scalpel. A 7 French (or up to 16 French, to the choice of the clinician) pigtail catheter is inserted and connected to sealed bag. Fluid is aspirated via a 3-way valve, and transferred to relevant bottles for culture, analysis of albumin and LDH, protein, and for cytology.
45681646|NCT03588832|Diagnostic Test|Evaluation Upper Extremity patterns.|The procedure involves evaluating subjects who meet the eligibility criteria and agree to participate in the study by signing informed consent. The study includes a measurement, applying a registration form, the Barthel scale and the FIM scale.
45683939|NCT03144232|Device|Active rTMS|rTMS will be delivered via a MagPro double blinded rTMS Research System (MagVenture, Denmark) with a Cool-B65 Butterfly Coil (a combined active and sham coil). We will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Study-treatment will be delivered at 120% rMT. Each active rTMS study-treatment will consist of a total of 4000 pulses of 10Hz stimulation (5s-on,10s-off). Study-treatments will be delivered at the EEG coordinate for F3 (which approximates the left DLPFC), and will be found using the Beam-F3 method.
45838579|NCT04384458|Drug|Hydroxychloroquine|Oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with 66 mg of zinc sulfate.
45838580|NCT04384458|Drug|Ivermectin|Oral ivermectin dosage guidelines based on participant body weight, once on day for 2 consecutive days. This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.
46024341|NCT04236115|Drug|Articaine 4%|Articaine 4% is dental local anaesthetic agent
45838581|NCT04383990|Other|Timing of taking insulin|To take insulin Glargine early (6-7pm) or late (bedtime-10-12pm)
45838582|NCT04384224|Other|acupuncture|use disposable sterile steel needles to insert to the acupuncture point
46024342|NCT04236115|Drug|Prilocain 3%|prilocaine is dental local anaesthetic agent
46024343|NCT04236115|Drug|Adrenalin|adrenaline is a vasoconstrictor
46024344|NCT04236115|Drug|Felypressin|Felypressin is a vasoconstrictor
46024345|NCT02853370|Drug|Bendamustine and Rituximab|
46111099|NCT00810602|Procedure|reduced intensity, related donor stem cell transplant|"Fludarabine /Busulfan(FluBu2)regimen~Fludarabine: 40 mg/m2/day in 0.9 NS, administered IV on days -5 to day -2 pre-transplant for a total of 4 doses. Busulfan: 3.2 mg/kg in 0.9 NS administered IV on days -5 and -4 for a total of 2 doses. Total body irradiation 200 cGy delivered in a single fraction will be given on day 0 for patients receiving an HLA-mismatched transplant."
46111100|NCT00810602|Drug|tacrolimus (standard GVHD prophylaxis)|Tacrolimus will begin on day -3, IV or oral. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant
46111101|NCT00810602|Drug|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
45838583|NCT04383834|Device|NobelActive® TiUltra™ implants and On1™ Base/Xeal™ along with On1 components|"The NobelActive® TiUltra™ implant is an ultra-hydrophilic multi-zone anodized implant surface. NobelActive® TiUltra™ features a gradual change in topography, from a minimally rough non-porous nanostructured implant collar to a moderately rough porous apex: more than roughness. NobelActive® TiUltra™ collar features surface chemistry and topography that promote early osseointegration and are designed to support bone stability. In addition, the Protective Layer preserves the pristine surface chemistry and hydrophilicity.~The second new product is the Base/Xeal™ new surface, which is covered by a titanium oxide layer, created by electrochemical anodization of a titanium machined component, resulting in a yellow hue nano-structured surface."
45838584|NCT04383678|Device|Extracorporeal membrane oxygenation|Veno-venous or veno-arterial extracorporeal oxygenation
46111102|NCT00810602|Drug|vorinostat|"Vorinostat given at a dose 100 mg PO BID starting day -10. If tolerated, vorinostat will be continued until day 100 post-transplant,whether or not acute GVHD develops.~Dose escalation/ de-escalation~Ten subjects treated at a dose of 100 mg PO BID. If dosing modifications are not required, during the pre-engraftment period in more than 4 patients, AND no more than two observed drug related toxicities CTC grade 4 or higher [probably or definitely related to the drug] then vorinostat dose will be escalated to 200 mg PO BID.~If dose escalation does not occur due to failure to meet the above criteria,then the study will enroll at the 100 mg PO BID dosing, subject to the protocol stopping rules.~If dose escalation occurs, subjects will be treated at 200 mg PO BID dosing level. If the probability of unacceptable toxicity exceeds the rules in protocol, then the dose of vorinostat will be de-escalated to 100 mg PO BID for the remainder of study."
46111103|NCT00816868|Drug|erlotinib in combination with capecitabine|Erlotinib 150 mg Q.D. orally for 21 days plus Capecitabine 1000 mg/m2 twice daily for 2 weeks followed by 1 week break every 21 days Until PD, unacceptable toxicity or death.
46024346|NCT04044625|Device|High-intensity NPPV|In the high-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) at a higher IPAP level. IPAP is initially set at 10 cmH2O and continuously adjusted by increments and decrements of 1-2 cmH2O (typically ranging between 20 and 30 cmH2O), according to patients' tolerance, to obtain a tidal volume (VT) of 10-15 mL/kg. IPAP should be increased as much as possible to decrease PaCO2 to a normal level. However, if PaCO2 decreases to less than 35 mmHg, IPAP should be decreased to achieve normocapnia.
46024347|NCT04044625|Device|Low-intensity NPPV|In the low-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) with a conventional IPAP level. IPAP is initially set to 10 cmH2O and is continuously adjusted by increments and decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT of 6-10 mL/kg.
46024348|NCT02806219|Device|Prefilled syringe (PFS)|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By prefilled syringe (PFS)
46111104|NCT05500586|Drug|Glucagon response study|Please see information in group descriptions
46111105|NCT00791700|Drug|Maraviroc|Maraviroc will be administered twice daily either as a liquid or tablet formulation, depending on the age of the subject. The dosage administered will be dependent upon the subject's body surface area as well as the background therapy.
45683940|NCT03144232|Device|Sham rTMS|Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of rTMS, combined with a TENS device which produces a small electric shock mimicking the feeling of active rTMS. This type of sham has been demonstrated to be indistinguishable from active rTMS.
45683941|NCT04108143|Device|MonitorMe|MonitorMe replaces the users existing telephone and for the majority of time is used as their ordinary telephone. At a known and set time of day for 4 weeks, participants will receive an automated MonitorMe telephone call. The participant answers a health and well-being automated script by pressing key pad numbers. At the same time vital signs data are collected. The responses and vital signs data, together with confidence values are then transmitted via telephone lines to an electronic patient record.
45838585|NCT04383600|Procedure|Micro-osteoperforation|three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.
45838586|NCT04383366|Device|Pentacam® (Oculus, Inc., Wetzlar, Germany)|Scheimpflug imaging
45838587|NCT04383366|Device|Casia II (Tomey Germany, Nürnberg)|Anterior segment optical coherence tomography
45838588|NCT04383366|Device|Spectralis Anterion (Heidelberg Engineering, Heidelberg, Germany)|Anterior segment optical coherence tomography
45838589|NCT04383054|Behavioral|'More minutes' conversation (Moving medicine)|For the interventions in this study we have chosen to use the Moving Medicine conversation tools because they are an evidence-based PA intervention tool. The Moving Medicine 'more minutes' conversation tool initially involves the investigator exploring the participant's understanding of PA. Improving patients' knowledge of the benefits of PA may empower them to increase their PAL because knowledge of the benefits of PA may motivate patients to increase their PAL. The division of the Moving Medicine conversation tools into chronic health conditions is important because it will allow the investigator to explore topics relating to PA which are specific to the participant's own medical co-morbidities. For example, in a patient with known ischaemic heart disease the investigator could discuss how PA helps to prevent the risk of further heart attacks and the development of heart failure (Moving Medicine).
46111106|NCT00816946|Behavioral|Enhanced education|"Enhanced Nutritional education/counseling to mothers on the following topics:~During Pregnancy: diet during pregnancy; antenatal care; iron tablets; colostrum Postpartum period: difficulties during lactation; diet during lactation; EBF; childhood vaccination; newborn care Complementary Feeding General Health: vitamin A; diarrhea management; iodine; hygiene for health; protection from malaria; ARI & protection against ARI"
46024349|NCT02806219|Device|e-Device|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By e-Device
46024350|NCT04068727|Other|Clinical Pharmacist Intervention|After randomization, the pharmacist calls patients to assess drug choice and dose. Staff distribute manufacturer coupons and help patients apply for medication payment assistance. Pharmacist discusses DOAC alternatives with prescribe and provides DOAC education by discussing potential adverse effects, medication interactions, alarm symptoms, and lab work. Staff mail educational materials. Pharmacist documents concerns in the electronic health record and messages prescriber about missing lab work. Patients share medication-related concerns. Patients are provided with a phone number for non-education calls to discuss their medications from 6 AM - 10 PM on any day. The pharmacist offers dose de-escalation instructions based on the DOAC prescription. The pharmacist advises the continuity provider on DOAC duration and monitoring. For follow-up/perioperative support, the pharmacist reviews and recommends lab monitoring and gives DOAC interruption/resumption recommendations.
46111107|NCT00810368|Drug|Carnosine|500mg Carnosine x2 daily
46111108|NCT00810368|Drug|Placebo|Microcrystalline cellulose placebo tablets x2 daily
46111109|NCT02610608|Other|ovarian stimulation|evaluation of clincal practice regarding prevention of arterial and venous thrombosis following ovarian stimulation
46111110|NCT02605200|Behavioral|Psychologist Support|Participants will complete several psychological questionnaires that are intended to cover a broad spectrum of physical, mental, and emotional aspects of the health of participants; the Behavior Assessment System for Children (BASC) ,the Children Depression Inventory (CDI 2), the Pediatric Quality of Life Inventory Transplant Module (PedsQL), and the Wechsler Abbreviated Scale of Intelligence II (WASI-II). Data gathered from this testing will be used to guide the provision of psychological care to address psychosocial challenges inherent to the care of children with transplant related diabetes.
46111111|NCT02605200|Behavioral|Pediatric Certified Diabetes Educators (CDEs) Support|Pediatric Certified Diabetes Educators (CDEs) are specially trained to teach diabetes self-management to children and their families. Participants who are diagnosed with diabetes will receive individualized support from a CDE in conjunction with their routine transplant care.
46111112|NCT00628108|Drug|Levocetirizine 1.25 mg|Levocetirizine dihydrochloride 1.25 mg (5 drops containing 5 mg/mL) dosed once a day for 2 weeks
46111113|NCT00628108|Other|Placebo|Placebo oral liquid once a day for two weeks
46111114|NCT00915330|Procedure|Rapid on-site cytopathologic evaluation (ROSE)|ROSE: examination in the endoscopy suite, by a pathologist, during the bronchoscopic procedure, of samples obtained with transbronchial needle aspiration.
46111115|NCT00915330|Procedure|TBNA|transbronchial needle aspiration
46111116|NCT00628030|Behavioral|NOURISH|Participants in the NOURISH intervention will have 6 weekly face-to-face parent group sessions regarding healthy eating and physical activity.
46111117|NCT00628030|Other|Wellness Group|Participants in the Wellness Group will have one face-to-face group meeting and information regarding healthy eating and physical activity will be provided on a regular basis via mail.
46111118|NCT02550964|Procedure|Composite Examination|First, patients will get the baseline ophthalmologic exam and medical evaluation by physicians. As a diagnostic method, the composite examination including fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography will be tested once every year.
46111119|NCT00821392|Drug|Febuxostat|
46111120|NCT00591578|Drug|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 40 mg, tablets, orally, once daily for up to 22 weeks.
46111121|NCT00591578|Drug|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 80 mg, tablets, orally, once daily for up to 22 weeks.
46111122|NCT00591578|Drug|Valsartan|Valsartan 80 mg, tablets, orally, once daily for 2 weeks; titrated to 320 mg, tablets, orally, once daily for up to 22 weeks.
46111123|NCT00817024|Drug|Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules,|3# XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
46111124|NCT00817024|Drug|Sheng Mai Capsules Plus Placebo of Xuefu Zhuyu Capsules|3# SM capsules plus 3# placebo of XFZY capsules, po, Tid, for 4 weeks
46111125|NCT00817024|Drug|Placebo of Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules|3# Placebo of XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
46111126|NCT00797862|Drug|Amlodipine|Amlodipine (5 mg and 10 mg) was provided as capsules taken orally once daily.
46111127|NCT00797862|Drug|hydrochlorothiazide|Hydrochlorothiazide 12.5 mg capsules were taken orally once daily
46111128|NCT00797862|Drug|Aliskiren|Aliskiren 150 mg and aliskiren 300 mg were provided as film-coated tablets, taken orally once daily.
46111129|NCT00817102|Procedure|FFR, IVUS, VH, or combination of the three|Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Virtual Histology (VH) or some combination of these three procedures will be completed during the cardiac catheterization procedure.
46111130|NCT00818428|Behavioral|Speech Production Intervention|Individual speech therapy directed at teaching the child to articulation specific speech sounds or word shapes accurately using traditional procedures such as phonetic placement and imitated and spontaneous speech production practice with feedback from the clinician about accuracy of articulatory gestures and knowledge of results.
46111131|NCT00818428|Behavioral|Speech Perception Intervention|Individualized intervention in which the Speech Assessment and Interactive Learning System is used to teach the child to identify recordings of words as either correct or incorrect pronunciations of the target word. In the event that the child is completely unable to pronounce the target speech sounds or word shapes focused stimulation activities are used to provide the child with further auditory exposure to the target forms. If the child stimulable for the target forms, the child is given opportunities the produce the target speech sounds or word shapes in the context of minimal pair games in which the child receives feedback about the communicative effectiveness of his or her attempts to produce the target words.
46111132|NCT00818428|Behavioral|Articulation Parent Group|Parents are taught to carry out home practice activities that focus on the child's ability to correctly articulate target speech sounds and word shapes.
46024351|NCT05491837|Other|Device induce acute intermittent hypoxia 9 % of Oxygen|Interventional group will be provided a brief sequence of mild hypoxia consisting of 9% oxygen for one minute followed by normoxia 21% of oxygen for a total of 15 episodes
46111133|NCT00818428|Behavioral|Dialogic Reading Parent Group|Parents are taught to read to their children using interactive techniques that help their children acquire new vocabulary, verbal reasoning abilities, and preliteracy skills.
46111134|NCT04025970|Genetic|Circulating tumor cell and circulating tumor DNA test|Patient stratification based on presence or absence of suspicious findings of cells and DNA
46111135|NCT00817180|Other|Positive Expiratory Pressure (PEP)|Physiotherapy technique for airway clearance
46111136|NCT00817180|Other|High Frequency Chest Wall Oscillation (HFCWO) using InCourage Vest System|Physiotherapy technique for airway clearance.
46111137|NCT00817258|Drug|cisplatin|Cisplatin 40mg/m2,weekly
46111138|NCT00817258|Radiation|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|3D-CRT or IMRT
46111139|NCT00794820|Drug|Fludarabine Phosphate|25 mg/m^2 by vein over 5-30 minutes daily for 3 days (days 2-4)
46111140|NCT00794820|Drug|Cyclophosphamide|250 mg/m^2 by vein over 60 minutes daily for 3 days (days 2-4)
46111141|NCT00794820|Drug|Rituximab|375 mg/m^2 by vein for dose 1 (given 1 day prior to chemotherapy) and then 500 mg/m^2 on days 2-3
46111142|NCT00455533|Drug|Ixabepilone|Intravenous Solution, intravenous (IV), 40mg/m², Day 1 every 21 days, 12 Weeks
46024352|NCT05491837|Other|Normoxia 21% of oxygen|SHAM group will be provided normoxia 21% of Oxygen
46111143|NCT00455533|Drug|Paclitaxel|Intravenous Solution, IV, 80mg/m², Weekly, 12 Weeks
46111144|NCT00455533|Drug|Cyclophosphamide|Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks
46111145|NCT00455533|Drug|Doxorubicin|Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks
46111146|NCT04037930|Behavioral|multiple implant surgery|Patients older than 30 years who will undergo elective dental implant surgery.
46111147|NCT04030208|Device|Umbulizer|Umbulizer is a reliable, user-friendly, and portable system that provides consistent air to the patient by quantitatively delivering a pre-determined tidal volume, inhale/exhale (I/E) ratio, peak pressure, and breathing rate (BPM). It can be configured to deliver either controlled ventilation or assist-controlled ventilation.
46111148|NCT04030208|Device|Traditional Mechanical Ventilator|A medical device designed to artificially perform breathing functions for patients who are unable to adequately perform these functions on their own.
46111149|NCT00818584|Drug|Micafungin|IV Administration
46111150|NCT02609516|Other|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
46111151|NCT00821470|Procedure|core decompression|core decompression procedure only
46111152|NCT00821470|Procedure|Bone marrow implantation into the necrotic lesion|
46024353|NCT00954538|Drug|[18F]MK-3328|IV dose of ~150 megabecquerel (MBq) [18F]MK-3328
46024354|NCT02690155|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
46024355|NCT02690155|Drug|VKA (Vitamin K antagonist)|As prescribed by treating physicians
46024356|NCT00630760|Drug|NRX 194204|NRX 194204 capsules given 3mg/m2 daily x 28 days. Repeated until PD
46024357|NCT02806375|Procedure|Allogeneic hematopoietic stem cell transplantation|Day 0: Infusion of unmanipulated graft
46111153|NCT05755490|Behavioral|PROWESS|Structured, culturally sensitive behavior change intervention comprised of six video-based or in-person sessions with psychologist or social worker. FitBit is provided by study.
46111154|NCT00818740|Drug|ORM-12741|i.v., oral solution and oral capsule forms. Oral capsule given with and without food.
46111155|NCT00821548|Procedure|electrostimulation|Electrostimulation of shoulder girdle and quadriceps muscles in facioscapulohumeral muscular dystrophy patients
46024358|NCT02806375|Drug|Busulfan|Days -5 through -3: Busulfan 1 mg/kg po qid №10
46024359|NCT02806375|Drug|Fludarabine monophosphate|Days -7 through -2: 30 mg/m2/day iv qd x 6 days
46024360|NCT02806375|Drug|Cyclophosphamide|Day +3 and +4: 50 mg/kg/day iv qd
46024361|NCT02806375|Drug|Ruxolitinib|Days -8 through -2 15 mg tid
46024362|NCT02806375|Drug|Ruxolitinib|Days +5 through +100: 7.5 mg bid
46024363|NCT02856256|Dietary Supplement|RedBull® energy drink|Subjects consume 25 mL of RedBull® energy drink
46024364|NCT02803489|Device|medical device intervention|
46024365|NCT02800603|Behavioral|Family Check Up|"The FCU is an ecologically sensitive, evidence-based, targeted intervention that aims to reduce child EBP. Features of the FCU: 1) Assessment-driven: a multi-method, multi-informant assessment in which the consultant reviews strengths and difficulties across domains of contextual risk, family functioning and child health. A tailored intervention plan is then created based on results 2) Motivational interviewing: Caregivers engage in self-assessment about motivation and barriers to addressing factors that may perpetuate risk. The consultant and caregiver work to establish a menu of services 3) The family may be offered up to 6 sessions of the Everyday Parenting curriculum. The FCU has demonstrated effectiveness and cultural sensitivity across multiple US settings."
46024366|NCT04269148|Other|Measurement of Quality of Life|Quality of life will be measured using McMaster University Head and Neck Radiotherapy Questionnaire and The Functional Assessment of Cancer Therapy - Head and Neck Cancer Version 4
46024367|NCT04269226|Procedure|Recruitment maneuver|Following intubation, patients will be ventilated according to the ideal weight within the scope of intraoperative protective ventilation strategy and in pressure-controlled ventilation (PCV) mode. Then, automatic recruitment maneuver will be applied to the recruitment group twice, after insufflation and desufflation. It will not be applied to the control group. During recruitment maneuver, PEEP (Positive end-expiratory pressure), where dynamic compliance is measured highest, will be the ideal peep for the patient, and PEEP will be adjusted at this value after recruitment.
46024368|NCT04269226|Procedure|No recruitment maneuver|Usual ventilation procedures will be applied.
46024369|NCT02803567|Behavioral|Brief psycho-educational intervention|Participants in the intervention arm will receive a computerized brief intervention composed of tailored feedback and psycho-education specific to their chronic condition.
46024370|NCT04273984|Drug|Misoprostol|Tablets will be inserted digitally by an experienced gynecologist 3hours before IUD insertion with taking care not inserting the medication into the cervix.
46024371|NCT02806297|Procedure|Early cholecystectomy with IOC|The intervention will be laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) on admission within 24 hours of presentation regardless of whether pain or tenderness are present or laboratory values are elevated.
46024372|NCT02806297|Procedure|Late cholecystectomy with IOC|The control will be laparoscopic cholecystectomy with IOC once the patient has met the following criteria: (a) a score of less than 2 on the Visual Analogue Pain Scale, (b) no tenderness on physical exam, and (c) decreased lipase to either less than half of the peak value or within normal range (73-393 U/L).
46024373|NCT02857504|Device|double lumen tube with a hook|The tube with the hook (after passing the bronchial cuff trough the vocal cords) was rotated for 180 degrees to the left and removed the stylet and when the hook passed the vocal cords, the tube was rotated for 90 degrees back to the right and push it into the bronchus. Following formula was used for the right depth (height (cm)/10 + 12 (cm)) of the tube without the hook. The tube with hook was inserted into the bronchus so that hook was placed on the carina and stopped.
46024374|NCT02857504|Device|double lumen tube without a hook|Tube without the hook was inserted with the following technique: after the bronchial cuff was passed the vocal cords, the stylet was removed and the tube was rotated 90 st towards left.
46024375|NCT02806453|Dietary Supplement|thickened formula|
46024376|NCT02806453|Dietary Supplement|Mg alginate|
46024377|NCT02806453|Behavioral|reassurance with lifestyle changes|
46024378|NCT04235803|Other|Telemedicine follow-up|A telemedicine follow-up form based in REDCap that collects information from the patient including: history, photographs, vision measurement, and questions.
46024379|NCT05555173|Device|Buzzy|Buzzy is a small vibrating bee with ice-pack wings.
46024380|NCT00943852|Drug|losartan potassium|Single dose losartan 100 mg in one of five treatment periods
46024381|NCT00943852|Drug|Comparator: isosorbide mononitrate (ISMN)|Single dose ISMN 60 mg in one of five treatment periods
46024382|NCT00943852|Drug|Comparator: losartan + ISMN|Single dose losartan 100 mg and ISMN 15 mg in one of five treatment periods
46024383|NCT00943852|Drug|Comparator: losartan + ISMN|Single dose losartan 100 mg and ISMN 60 mg in one of five treatment periods
46024384|NCT00943852|Drug|Comparator: Placebo|Single dose placebo only in one of five treatment periods
46024385|NCT02803645|Biological|blood sample|
46024386|NCT02853136|Drug|Fluvoxamine|single dose
46024387|NCT02853136|Drug|BI 409306|low single dose
46024388|NCT02853136|Drug|BI 409306|medium or high dose
46024389|NCT02800369|Biological|ZFN-603 and ZFN-758|Each suppository contain 500 µg of ZFN-603 or ZFN-758
46024390|NCT02803723|Procedure|Holding-cuddling|"The Holding-cuddling is started 5 minutes before veinipuncture."
46024391|NCT02803723|Procedure|Sucrose|The sucrose adminstration is started 2 minutes before veinipuncture.
46024392|NCT02803255|Device|MAHI Exo-II|
46024393|NCT02803099|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number-SR15-63-Z13-084).
46024394|NCT02803177|Biological|BMC2012|
46024395|NCT02803177|Device|beta-TCP Chronos® Synthes|
46024396|NCT04236661|Device|chilipad|Chilipad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
46024397|NCT02806141|Drug|Aerosolized plus intravenous colistin|Aerosolized colistin at the dose of 4 mg colistin base activity (CBA)/kg twice daily (8 mg/kg/day) plus intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
46024398|NCT02806141|Drug|Intravenous colistin|Intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
46024399|NCT02805985|Device|FLXfit™ TLIF Interbody Fusion Device|The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
46024400|NCT04037917|Device|CorNeat EverPatch|Covering Ophthalmic Implants
46024401|NCT02806063|Procedure|intraoperative samples|
46024402|NCT02805751|Device|Early loading on a training pedal|The patients will perform early loading by using a special training pedal for 5 weeks, starting 2 weeks after the rupture. The patients will remove the walker and train twice a day on this pedal.
46024403|NCT02805751|Other|Tendon strain exercises|The patients will perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
46024404|NCT02805751|Other|Early weight bearing|The patients are allowed to bear weight as much as tolerated in the walker from day 1.
46024405|NCT02803021|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation Number - SR15-47-Z13-076)
46024406|NCT02802787|Other|Camp Discovery|Activities will include physical, social, emotional, sensory and spiritual activities.
46024407|NCT04235881|Behavioral|Mindfulness-based stress reduction program|Mindfulness training through an adaptation of the standardized MBSR program. This program was conducted in person and in a group, with a maximum of 25 participants per group and a total duration of 8 weeks. The training was carried out in 8 sessions, one each week, with a duration of 2 h each session.
46024408|NCT04235881|Behavioral|App REM volver a casa|"The intervention was carried out through the computer application for mobile phone REM volver a casa. This application has been developed to carry out training in the emotional regulation program based on mindfulness, autonomously. The application is designed to carry out the program in 8 weeks."
46024409|NCT02805673|Procedure|Osteopathy|
46024410|NCT04235959|Drug|Tirzepatide|Administered SC
46024411|NCT04235959|Drug|Placebo|Administered SC
46024412|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
46024413|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
46024414|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
46024415|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
46024416|NCT00952276|Biological|Normal saline solution|0.5 mL, Intramuscular on Day 0
46024417|NCT02802709|Device|SB-061|delivered via intra-articular injection
46024418|NCT02802709|Other|Placebo|Placebo
46024419|NCT02805829|Drug|Trastuzumab + NK cells|NK cellular therapy conduct 2 cycles per year. Herceptin initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks till to disease progress.
46024420|NCT02856178|Drug|F901318|F901318 treatment starting after completion of chemotherapy. Max. 14 days of intravenous F901318 b.i.d. treatment, followed by one oral dose of F901318. Loading doses 4 mg/kg b.i.d. , maintenance doses 2 mg/kg b.i.d.
46024421|NCT02856178|Drug|Caspofungin|Intravenous Caspofungin treatment starting during chemotherapy for concomitant prophylaxis of fungal infection. Loading dose 70 mg q.d., maintenance doses 50 mg q.d.
46024422|NCT02852980|Other|gestational diabetes women|No intervention.
46024423|NCT02800135|Drug|Furosemide|1.0 mg/kg of intravenous furosemide. In order to minimize the risk of hypovolemia, urine output will be replaced ml for ml with either Ringers lactate or normal saline for six hours after the furosemide stress test.
46024424|NCT02853058|Radiation|normal PI|measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
46024425|NCT02853058|Radiation|pathological PI|measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
46024426|NCT02799901|Biological|Nivolumab|Injection of nivolumab
46024427|NCT02799901|Radiation|hypofractionned radiotherapy|radiation
46024428|NCT00943384|Device|chronOS Strip|chronOS strip combined with bone marrow aspirate plus local bone
46024429|NCT04235647|Other|Nurse led tutorial on lifestyle management and pedometer hand-out|Individual 10-minute nurse-led tutorial with distributed handouts on the health benefits of regular physical activity and pedometer hand-out
46024430|NCT04235647|Other|Steps goal setting and supporting phone calls|A goal of minimum 7000 steps per day, phone calls to assess the goal meeting and to support goal achievement every 2 weeks
46024431|NCT02805205|Drug|PEG-rhG-CSF|
46024432|NCT02799979|Device|3D right ventricular imaging echocardiographic|Echocardiographic data (3D right ventricular imaging echocardiographic) will be collected at baseline and after 6months.
46024433|NCT02805439|Drug|S47445 15mg|One tablet of S47445 15 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
46024434|NCT02805439|Drug|S47445 50mg|One tablet of S47445 50 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
45469631|NCT03419806|Drug|Infudopa s.c.|"A suitable infusion needle will be placed laterally on the abdomen for the s.c. infusion of Infudopa. Infudopa s.c. will be delivered in the same dosage as the subject's individual pre-study dosing of Duodopa, as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion up to 16 h.~From patient 6 and onwards:~Two infusion needles will be placed on the abdomen for the s.c. infusion of Infudopa SubC in 86% of the the subject's individual pre-study daily Duodopa dose. The intervention is given as a continuous fixed infusion rate for 16h preceded by a morning bolus dose. The s.c. morning bolus is 155% of the hourly continuous dose delivered at the rate of 80 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer SubC). The morning dose will not exceed 30 mL. The maximum daily dose levodopa during s.c. administration is not allowed to exceed 3440mg (equal to 86% of the maximum allowed daily dosage for Duodopa that is 4000 mg)."
45838590|NCT04383054|Behavioral|'one minute' conversation (Moving medicine)|For the interventions in this study we have chosen to use the Moving Medicine conversation tools because they are an evidence-based PA intervention tool. The Moving Medicine 'more minutes' conversation tool initially involves the investigator exploring the participant's understanding of PA. Improving patients' knowledge of the benefits of PA may empower them to increase their PAL because knowledge of the benefits of PA may motivate patients to increase their PAL. The division of the Moving Medicine conversation tools into chronic health conditions is important because it will allow the investigator to explore topics relating to PA which are specific to the participant's own medical co-morbidities. For example, in a patient with known ischaemic heart disease the investigator could discuss how PA helps to prevent the risk of further heart attacks and the development of heart failure (Moving Medicine).
46024435|NCT02805439|Drug|Placebo|One tablet of placebo taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
46024436|NCT02802163|Drug|Panobinostat|"Induction Phase: Panobinostat (dose escalation beginning at 10 mg) will be administered 3 times a week (TIW) by mouth every other week starting on day 1 of each cycle.~Maintenance Phase: Panobinostat will be administered TIW by mouth every other week starting on day 1 of each cycle. The dose of panobinostat during maintenance phase will be the same dose taken during cyce 8 of induction phase."
46024437|NCT02802163|Drug|Carfilzomib|Induction Phase: Carfilzomib will be administered at 20 mg/m^2 on Cycle 1 Day 1. Beginning on Cycle 1 Day 2 the carfilzomib dose will be according to the assigned level of 27 mg/m^2 or 36 mg/m^2. Carfilzomib will be administered twice weekly IV on Days 1,2, 8,9,15, and 16.
46024438|NCT02802163|Drug|Lenalidomide|"Induction Phase: Lenalidomide (25 mg) will be administered once-daily by mouth on Days 1-21, 25.~Maintenance Phase: Lenalidomide (10 mg) will be administered once-daily by mouth on days 1-21."
46024439|NCT02802163|Drug|Dexamethasone|Induction Phase: Dexamethasone (20 mg) will be administered twice weekly by mouth or by IV on Days 1,2, 8, 9, 15, and 16.
46024440|NCT02799511|Biological|protein expression|Differential protein expression between the period of acute cerebral ischemia and the control period
46024441|NCT02802007|Device|Elipse Intragastric Balloon|
46024442|NCT02801773|Dietary Supplement|Treatment Gingivitis with Probiotic|Gingivitis Treatment (scaling and coronary polish) and one lozenge containing Lactobacillus reuteri per day during 3 months
46024443|NCT02801773|Other|Treatment Gingivitis conventional|gingivis treatment (scaling and coronary polish) and and one lozenge containing Placebo (mint lozenge) per day during 3 months
46024444|NCT02802085|Device|VEGA Knee|TKA
46024445|NCT02801851|Behavioral|SCREEN-ED|SCREEN-ED will have 4 key components: systematic screening for delirium using the CAM; informing providers of the screening result; a checklist protocol for initial delirium management based on clinical guidelines tailored to the ED, which includes identification of cause, risk factor modification, and behavioral interventions; documentation in the Electronic Health Record (EHR) and communication with inpatient providers of delirium screening results.
46024446|NCT02801929|Drug|Coppertone (BAY987518)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number - SR15-72_V27-010).
46024447|NCT02801461|Device|extracorporeal shock wave therapy|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs).
46024448|NCT00943306|Drug|lomitapide|5-60 mg po every day
45838591|NCT04382742|Behavioral|Dynamic Resistance Exercises|Modified Wingate protocol that incorprates 20 minutes of training on a cycle ergometer; included one minute of cycling with resistance to be performed at 85% to 90% of Maximal Heart Rate (MHR) followed by one minute of cycling with no resistance. The protocol will be performed for 10 times for a duration of 20 minute of workout.
46024449|NCT02805049|Drug|Echinocandins|The patients included in this protocol require routine treatment with caspofungin or micafungin. Though this intervention is under study, it is not modified by this protocol.
46111156|NCT02609438|Behavioral|Short breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take a 1-minute active break every 30 minutes during the workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
46024450|NCT02799589|Drug|Remifentanil|1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min)
45838592|NCT04382274|Procedure|Quadratus Lumborum Block|transducer will be placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border will be visualized leaving underneath the internal oblique muscle, like a roof over the QL muscle. The probe will be tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip will be placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine will be applied
46024451|NCT02799589|Drug|Dexmedetomidine|1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr)
46024452|NCT02799589|Drug|Ropivacaine|Caudal anesthesia block with Ropivicaine 0.2% 1ml/kg injected into the caudal space
46024453|NCT02235610|Procedure|EVLP Group|"EVLP technique (Lund Protocol): open left atrium, Steen solution mixed with red blood cells and perfusion 100% of the donor predicted cardiac output.~Lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice."
46024454|NCT02801695|Drug|Citrulline|Citrulline supplementation
46024455|NCT02801695|Drug|Placebo|Placebo
46024456|NCT02856100|Drug|18F DCFPyL- Radiopharmaceutical|
46024457|NCT02801539|Device|RMT therapy using modified RMT device|The exercises provided by the RMT device is intended to strengthen breathing muscles.
46024458|NCT02801539|Device|Sham-RMT therapy using modified RMT device|The exercises provided by the Sham-RMT modified device is not intended to strengthen breathing muscles.
46024459|NCT04272970|Diagnostic Test|Validation of a new gene / protein variant implicated in familial CT|Realize a blood sample to perform functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to prove the pathogenicity of variants of new genes potentially involved in constitutional thrombocytopenia.
46024460|NCT02801383|Drug|Yallaferon®， the recombinant human interferon α-2b gel|
46024461|NCT02801383|Other|gel without active ingredient|
46024462|NCT02799355|Drug|Sofosbuvir, Ribavirin, With or Without Pegylated Interferon|Retrospective will carried out to find percentage of patients with sustained virologic response at 12 weeks after the end of treatment
46024463|NCT02856022|Device|Electrical ilioinguinal nerve stimulation|"Four abdominal points are selected. The upper two points are located 2.5 cun bilateral to Guanyuan (Ren 4). The lower two points are located 1.5 cun bilateral to Zhongji (Ren 3). Four long needles are punctured obliquely 1~2 cun in depth (depending on the fat layer thickness of the patient) to the four points to make the needling sensation reaching the urethra or vulva.~After the needling sensation reach the above regions, each of two pairs of electrodes from a device are connected with the two ipsilaterally inserted needles. The parameters are continuous waves, a frequency of 2.5 Hz and intensity that the patient feels comfortable for 60 min, three times a week for at least four weeks."
46024464|NCT02856022|Procedure|Intravesical Irrigation|The patient was asked to lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine drained. The Cystistat 50mL 40mg (sodium hyaluronate, Bioniche Teoranta, Ireland) solution is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the Cystistat inside the bladder coating the lining. It was recommended the solution was retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at least four weeks.
46024465|NCT02801305|Drug|Diltiazem Gel 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
46111157|NCT02609438|Behavioral|Long breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take two 15-minute activity breaks during each workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
46111158|NCT00627094|Device|Biatain|A standard polyurethane foam dressing Biatain non-adhesive (Coloplast A/S) with an elastic semi-permeable backing film, size 15x15 cm. The product is CE marked.
46111159|NCT00627094|Device|Biatain Ibu|Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
46111160|NCT02610530|Procedure|Sleeve Gastrectomy with Ileal Transposition|Type 2 diabetic patients who underwent ileal transposition surgery within the last 2 years.
46111161|NCT02610530|Procedure|Sleeve Gastrectomy with Transit Bipartition|Type 2 diabetic patients who underwent transit bipartition surgery within the last 2 years.
46111162|NCT02610530|Other|Medical Treatment|Conventional Non-Surgical Treatment for Glycemic Control group consisted of patients who did not undergo any kind of surgery, and are on medical treatment for type 2 diabetes.
46111163|NCT00923000|Drug|Nalbuphine|Nalbuphine 10mg with oral administration
46111164|NCT00923000|Drug|Morphine|Morphine 10mg with oral administration
46111165|NCT00923000|Drug|Morphine with Long dan xie gan tang|Morphine 10mg with oral administration
46024466|NCT02801305|Drug|Nitroglycerin Ointment 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
46024467|NCT02801305|Drug|Vaseline|This is used as the topical placebo agent.
46024468|NCT02795845|Dietary Supplement|Probiotic Capsule containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus and Bifidobacterium bifidum|Probiotic
46111166|NCT00923000|Drug|Nalbuphine with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g tid with oral administration
46111167|NCT00923000|Drug|Nubian with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g with oral administration
46024469|NCT02795845|Other|Placebo|capsule without active ingredient
46024470|NCT00637975|Drug|oxycodone|"Arm A - 20 mg/day~Arm B - increasing dose startnig at 20 mg/day~For 15 days or until unacceptable toxicity develops."
46111168|NCT04534972|Other|Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)|Post-implementation of targeted normoxemia through oxygen titration for individual patients. Intervention for treatment of hypoxemia will follow usual local practice. Interventions for treatment of hyperoxemia (SpO2 >96% or PaO2 > 100 mmHg) will involve down titration of FiO2 (or supplemental oxygen for non-mechanically ventilated patients) within a time frame based on local site preferences-typically in increments of no greater than 0.10 until goal oxygenation in the normoxemia range is achieved (including room air [no supplemental oxygen] for non-mechanically ventilated patients).
46024471|NCT00637975|Drug|pregabalin|"Arm A - pregabalin at increasing dose starting from 50 mg/day~Arm B - pregabalin 50 mg/day~For 15 days or until unacceptable toxicity develops."
46024472|NCT02799433|Behavioral|Usual services + HAP|The HAP process includes child care center providers completing a self-assessment(s), setting improvement goals, receiving technical assistance materials, attending topic-specific workshops, improving best practices, re-self-assessment and qualification for a HAP award.
46024473|NCT02799433|Behavioral|Usual services|Control condition
46024474|NCT02801149|Procedure|Wrist Magnetic Resonance Imaging (MRI)|Patients that enter this group are randomised to receive non-standard care with a 3-sequence MRI scan of the scaphoid following the initial conventional radiography.
46024475|NCT02801227|Drug|Oxytocin|Intravenous oxytocin: 2.5 mIU per minute with increments of 2.5 mIU every 20 minutes until achieving 4-5 contractions during 10 minutes or 20 mIU. Then after continuous infusion without increasing oxytocin dose will be continued. In case of lack of painful contraction/active labor after 24 hours with oxytocin a trial with PGE2 will be initiated (as described for PGE2)
46024476|NCT02801227|Drug|Prostaglandin E2|PGE2 2 mg wil be inserted to the posterior fornix, this will be repeated every 6 hours until achieving painful contractions or up to 4 doses (24 hours). In case of lack of painful contraction/active labor after the fourth dose of PGE2 a trial with oxytocin will be initiated (as described for Oxytocin).
46024477|NCT02795611|Behavioral|Family-centered occupational therapy|Caregivers will be equipped with the skills of guiding children with ASD in play and participation in their daily life.
46024478|NCT02795611|Behavioral|regular occupational therapy|regular occupational therapy
46111169|NCT05218382|Device|Virtual reality|immersive virtual reality technology
46111170|NCT05218382|Device|No virtual reality|Virtual reality with blank screen
46111171|NCT04946084|Procedure|Tympanocentesis|When acute otitis media is diagnosed, local anesthetic applied, small hole placed in eardrum, middle ear fluid extracted.
46111172|NCT04946084|Other|Nasal Phalangeal Swab and Wash|Nasal phalangeal swab used to retrieve sample. Nasal wash used to retrieve sample.
46111173|NCT04946084|Other|Blood Draw|Venipuncture
46111174|NCT04944992|Drug|Efinopegdutide 20 mg/mL|Subcutaneous injection in a dose-escalation administration of 2.4 mg, 5.0 mg, and 10.0 mg
46111175|NCT04944992|Drug|Semaglutide 1.34 mg/mL|Subcutaneous injection in a dose-escalation administration of 0.25 mg, 0.5 mg, and 1.0 mg
46111176|NCT01019863|Drug|oxaliplatin|oxaliplatin 100mg/m2 + Rituxan 375 mg/m2 + Gemcitabine 1000mg/m2 every 2 weeks for 8 cycles
46024479|NCT02795611|Other|intervention done outside our hospital|intervention done outside our hospital
46024480|NCT02799121|Device|ReGenerCell™ Autologous Cell Harvesting Device|
46024481|NCT02795455|Behavioral|Interoceptive Exposure (IE)|Participants are provided with a meal replacement shake of 'unknown' Kcal or macronutrient content and are asked to mindfully observe the sensations (aversive taste, texture, bloating, icky feeling, etc.) and associated emotional states (i.e., disgust) with the empathetic support of parents/therapist in session, without expectation of habituation. Sessions occur on a weekly basis with session one lasting 2 hrs. The remaining 5 sessions last one hour, and participants eat a meal replacement shake over 30-minutes, identical to the first session. All sessions include debriefing and development of IE homework that includes daily practice of IE.
46024482|NCT02795455|Behavioral|Family Based Therapy-Weight Gain Control (FBT-WG)|Participants and families randomized to FBT-WG will receive 6-weeks of FBT treatment for AN. Sessions occur weekly, with the first session lasting two hours and the remaining 5 sessions one hour. FBT is atheoretical in terms of the etiology, but uses parent-enforced contingencies to increase value of eating and decrease the value of food avoidance.
46024483|NCT02795455|Dietary Supplement|meal replacement shake|
46024484|NCT02795299|Drug|Gerilimzumab|Either Gerilimzumab 5 mg followed by 2 mg, or Gerilimzumab 10 mg followed by 5 mg or Gerilimzumab 20 mg followed by 10 mg are to be administered once every 8 weeks during the treatment period of the study.
46024485|NCT02795299|Drug|Methotrexate|Methotrexate (MTX) to be administered once a week every week during the treatment period.
46024486|NCT02795299|Drug|Folic Acid|Acid folic (folate) 1mg to be administered once daily during the treatment period.
46024487|NCT02795299|Drug|Placebo|10 mM acetate, 9% (w/v) sucrose, and 0.006% (w/v) polysorbate 20 at pH 5.2 ± 0.3
46111177|NCT00642850|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
46111178|NCT00455455|Drug|Optifree RepleniSH Multipurpose Disinfecting Solution|lens care system
46024488|NCT03930277|Diagnostic Test|Electroencephalogram|Electroencephalogram for fetal brain activity monitoring.
46111179|NCT00455455|Drug|ReNu Multiplus Multipurpose Solution|lens care system
46111180|NCT00913952|Drug|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions|
46024489|NCT02799043|Procedure|Standard PVI|Standard PVI procedure without FIRMap.
46024490|NCT02799043|Procedure|FIRM-Guided Procedure and PVI|
46111181|NCT00913952|Drug|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions|
46111182|NCT00913952|Drug|Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions|
46111183|NCT04581382|Biological|Nivolumab|Given IV
46111184|NCT04581382|Biological|Pembrolizumab|Given IV
46024491|NCT02801071|Drug|15g L-citrulline daily p.o.|
46111185|NCT04581382|Radiation|Radiation Therapy|Undergo radiation therapy
46111186|NCT04581382|Biological|Therapeutic Exchange Plasma|Undergo therapeutic plasma exchange
46111187|NCT00818818|Drug|Meglumine antimoniate|5mg/kg/d of pentavalent antimony, IV, for 20 consecutive days
46024492|NCT02801071|Drug|Placebo|
46024493|NCT02790619|Device|tDCS via Chattanooga Ionto Iontophoresis System-Phoresor|Small electrical current delivered non-invasively to the scalp. 1mA electrical current to Meditation and Active Stimulation 1 condition. 2mA to Meditation and Active 2 Stimulation condition.
46024494|NCT02790619|Device|Sham tDCS Chattanooga Ionto Iontophoresis System-Phoresor|Blinds participants to meditation condition by applying 30 seconds of real stimulation and then turning the device off.
46024495|NCT04233931|Behavioral|PrEP medication adherence mobile app|Participants use a PrEP medication adherence mobile app for six weeks.
46024496|NCT03981757|Device|NeurOS|NeurOS system pads will be placed on patients' head for monitoring.
46024497|NCT02799277|Drug|Testosterone|Effect of testosterone on moral decision making
46024498|NCT02799277|Drug|Placebo|Effect of testosterone on moral decision making
46024499|NCT04235179|Radiation|SABR|SABR to a dose of 30Gy/5 to the pelvis (vaginal and paravaginal tissues as well as regional lymph nodes)
46024500|NCT01198002|Drug|LY2127399|Administered Subcutaneously (SC)
46111188|NCT02609282|Behavioral|Hourly prompts to stand delivered by Microsoft Outlook|
46111189|NCT03840811|Drug|Cefixime|Mandatory rescue therapy consisting of cefixime 400 mg orally in a single dose: on patient request, at the onset of symptoms or on the 5th study day after inoculation.
46111190|NCT03840811|Drug|Ceftriaxone|Mandatory rescue therapy consisting of ceftriaxone 250 mg intramuscularly in a single dose: on patient request, at the onset of symptoms or on the 5th study day after inoculation.
46111191|NCT03840811|Drug|Ciprofloxacin|Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose: if the subject has a positie test of cure 1 week post initial antibiotic treatment
46111192|NCT03840811|Biological|Neisseria gonorrhoeae strain FA1090 A26|0.4 mL of a suspension containing 10^5 - 10^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
46024501|NCT01198002|Drug|Placebo Q2W|Administered SC
46024502|NCT01198002|Drug|Placebo Q4W|Administered SC
46024503|NCT01198002|Drug|Methotrexate|Methotrexate is a background therapy.
46024504|NCT02790307|Device|The Geko|transcutaneous tibial nerve stimulation (stick on patch)
46024505|NCT02790151|Behavioral|Standard Therapy|Learning and practicing Memory strategies
46024506|NCT02790151|Behavioral|Experimental Intervention|Computerbased Working Memory Training in Combination with a Recollection Training
46024507|NCT02794909|Device|Cardiopulmonary ultrasound exam|The cardiopulmonary ultrasound exam consists of a point-of-care ultrasound scan of the heart, lungs, peritoneal cavity, aorta, and femoral veins.
46024508|NCT02798887|Procedure|Ridge preservation|Ridge preservation comparing the clinical and histologic healing with or without a barrier membrane
46024509|NCT02795065|Drug|Enoxaparin|Use of enoxaparin 40 mg subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
46024510|NCT02795065|Drug|Bemiparin|Use of bemiparin 3500 IU subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
45838593|NCT04382274|Procedure|Dual Transversus Abdominis Plane and Ilioinguinal/Iliohypogastric Nerve blocks|the probe will be located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall will be identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique will be used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine will be injected. Then abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualised between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side.
46111193|NCT03840811|Biological|Neisseria gonorrhoeae strain FA7537|0.4 mL of a suspension containing 10^5 - 10^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter
46024511|NCT02794987|Device|SpyGlass® choledoscopy|Stage 1: patients included were evaluated using a standard duodenoscope and both SpyGlass® cholangioscopes: First generation, SpyGlass® Direct Visualization System and Second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA) Procedures were performed by one experienced endoscopists with more than 300 ERCP/year (C.R.M). Biopsies were taken in order to correlate to histopathology. Stage 2: patients will be evaluated using a standard duodenoscope and second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA). Procedures will be performed by two experienced endoscopists with more than 300 ERCP/year (C.R.M and M.S.A). Biopsies will be taken in order to correlate to histopathology.
46024512|NCT02789995|Procedure|Human biological samples|Blood sample - Muscle biopsy - Bone marrow sample (mesenchymal stem cells)
46024513|NCT02790229|Other|anti-gravity treadmill (alter G®)|Patients in the experimental arm will be treated with manual lymphatic drainage, cryotherapy and a fixed protocol of training in an anti-gravity treadmill (alter G®). The protocol is designed parallel to standard physiotherapy with a frequency of two to three times a week with duration of about 20 minutes for six weeks.
46024514|NCT02790229|Other|standardized physiotherapy|Patients in the control arm will be treated with manual lymphatic drainage, cryotherapy and 20 minutes of physiotherapy two to three times a week for six weeks. Physiotherapy will be done according to a standardized protocol.
46024515|NCT02798965|Biological|serodiagnosis|
46024516|NCT02798809|Other|Clinical dental examination|Clinical dental examination and a questionnaire that was filled out by the parents before each clinical examination.
46111194|NCT00640510|Drug|Rapid Acting Intramuscular Olanzapine|10mg/injection, IM. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
46111195|NCT00640510|Drug|Isotonic sodium chloride solution|0.9% sodium chloride (NaCl) solution. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
46111196|NCT04889378|Other|prehabilitation|very low calories diet (800-1000kcal/day) with moderate intensive aerobic exercise (1 hour per section; 3 sections per day)
46111197|NCT01323127|Procedure|Sagital xrays|5 xrays will be taken: (1) Upright standing position; (2) Upright, straight chair position; (3) Slouching, straight chair position; (4) Upright, ergonomic chair position; (5) Slouching, ergonomic chair position.
46111198|NCT04882982|Behavioral|Caria app|App to improve symptoms of menopause
45838594|NCT04382040|Drug|ArtemiC|Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
46024517|NCT04233697|Drug|Copanlisib|Novel, pan-class phosphatidylinositol 3-kinase (PI3K) inhibitor with potent activity against both the δ and α isoforms9. Copanlisib has been evaluated for the treatment of a wide variety of malignancies, including lymphoma, either as a single agent or in combination with other investigational agents.
46024518|NCT04233697|Drug|Romidepsin|Indicated for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
46024519|NCT04234009|Other|Healthy Lifestyle|"The physical activity guidelines for older consist of 150 minutes per week moderate-to-high intensity exercise, two times per week muscle and bone strengthening exercises, which are combined with balance exercises. Additional health benefits can be achieved with a longer exercise duration, frequency and/or intensity. Furthermore, the amount of time sitting should be minimised. The dietary guidelines are described in detail in the so-called The Wheel of Five. In brief, the circle is divided into four food groups and one beverage group. More than half of the circle is covered by fruits, vegetables, whole grain (containing) breads, cereals and potatoes. A much smaller part is compromised by animal source foods, spreads and cooking fats. Water, tea and coffee without sugar complete the circle."
46024520|NCT02857036|Other|rhythmic parameter recording|the following rhythmic parameters are recording during 48 hours: temperature, heart rate and actimetry
46024521|NCT02857036|Behavioral|psychiatric assessment|different psychometric scales are filled in: Montgomery and Asberg depression rating scale (MADRS), Quick inventory depression scale (QIDS-C16) and Beck depression inventory (BDI)
46024522|NCT04234087|Other|Additional balance and resistance training|Additional exercise program with balance and resistance training three times per week. After completion participants are encouraged to continue exercise training at home according to recommendations and will receive control calls every two weeks.
46024523|NCT05470699|Procedure|Computed Tomography|Undergo PET/CT
46024524|NCT05470699|Other|Fluorine F 18 Piflufolastat|Given IV
46024525|NCT05470699|Device|Positron Emission Tomography|Undergo PET/CT
46024526|NCT04233619|Diagnostic Test|optical coherence tomography|non-invasive test performed by an Ophthalmologist that allows three-dimensional imaging of the retinal vasculature
46024527|NCT02794753|Behavioral|Working memory training|
46024528|NCT02794753|Behavioral|Game|
46024529|NCT02794519|Drug|Sirukumab|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
46024530|NCT02794519|Drug|Placebo|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
46024531|NCT02794519|Drug|Rescue medication|Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.
46024532|NCT05463523|Device|A Real-time Augmented Reality Device with Artificial Intelligence Integration|Patients are diagnosed and treated with the assistance of artificial intelligence, augmented reality and new optical imaging technology, which is different from traditional model.
46024533|NCT03826303|Other|E-cigarette liquid with ethanol, 1 puff|E-cigarette liquid with ethanol, 1 puff
46024534|NCT03826303|Other|E-cigarette liquid without ethanol, 1 puff|E-cigarette liquid without ethanol, 1 puff
46024535|NCT03826303|Other|E-cigarette liquid with ethanol, 10 puffs|E-cigarette liquid with ethanol, 10 puffs
46024536|NCT03826303|Other|E-cigarette liquid without ethanol, 10 puffs|E-cigarette liquid without ethanol, 10 puffs
46024537|NCT02794675|Drug|Cesium 131|The number sources and activity will be based on the target volume to deliver total radiation dose, this will vary per patient.
46111199|NCT04882982|Behavioral|Menopause Education|Educational materials about symptoms of menopause
46111200|NCT00825838|Dietary Supplement|Chronic consumption of chili pepper extract|6mg chili pepper extract per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
46111201|NCT00825838|Dietary Supplement|Chronic consumption of matching placebo|0mg chili pepper extract (matching placebo) per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
46111202|NCT00913718|Drug|Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)|
46111203|NCT00913718|Drug|Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)|
46111204|NCT00813800|Drug|Varenicline|Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.
45598575|NCT04026295|Behavioral|Short Burst Interval Treadmill Training (SBLTT)|SBLTT will consist of short-bursts (30 seconds) of high speed walking alternating with 30 seconds of low/moderate speed walking. Total duration of walking per session will be up to 30 minutes of the 30 second alternating intervals (30sec high / 30sec low/moderate) with rests as needed. Both groups will receive 40 sessions delivered 5x/week for 8 weeks. Initial speeds for high speed walking will be 75-80% of each participant's over ground baseline fast walking speed, and low/moderate speed will be 75-80% of self-selected speed calculated from the 10-Meter Walk Test.
46024538|NCT02798653|Drug|Choriomon® injection|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
46024539|NCT02798653|Drug|Choriomon® injection+Endometrin ®|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
46024540|NCT02798653|Drug|Endometrin ® vaginal tablets|Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
46111205|NCT00627016|Drug|Dexlansoprazole|30 mg capsule, orally, once daily for 4 weeks
46024541|NCT02794363|Biological|Autologous platelet rich plasma|5cc of autologous platelet rich plasma derived from 50cc of whole blood will be injected into vulvar skin.
46024542|NCT04234789|Diagnostic Test|cardiopulmonary exercise testing with dynamic hyperinflation maneuver|test performed as recommended by ATS guidelines
46024543|NCT04234789|Diagnostic Test|spirometry|test performed as recommended by ATS guidelines
46024544|NCT04234789|Diagnostic Test|pletysmography|test performed as recommended by ATS guidelines
46024545|NCT04234789|Diagnostic Test|forced oscillometry technique|test performed as recommended by ATS guidelines
46111206|NCT00627016|Drug|Placebo|1 capsule, orally, once daily for 4 weeks
46111207|NCT00794664|Drug|Mipomersen|200 mg (1 mL), weekly subcutaneous injections for 26 weeks
46111208|NCT00794664|Drug|Placebo|1 mL weekly subcutaneous injections for 26 weeks
46111209|NCT02610452|Other|Clown therapy|"The clowns intervene by twos: a game takes place.~The game requires the active presence of a number of potential players in the room (patient, family, caregivers) and takes into account body position, emotional state, the general atmosphere.~The clowns initiate a game proposal: provisional staging of clown characters based on imagination/improvisation which engages a physicality and a basic emotional state.~The original game proposal is adjusted according to mutual empathy with those present.~The game is developed on the model of theatrical improvisation: an original creation that has scenic quality comparable to that of a complete representation. Improvisation time varies depending on the condition of the person, his/her desire to participate, choosing the main theme.~The final stage of the game is preparing all actors for separation: restitution of roles, revisiting the paths traveled."
45838595|NCT04382040|Drug|Placebo|Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
46024546|NCT02794051|Behavioral|Group Therapy|Participating children and their caregivers will attend 90-minute weekly group therapy sessions for 10 consecutive weeks.
46111210|NCT02609360|Other|Priming of ECMO circuit with 0.9% NaCl|0.9% NaCl as priming crystalloid solution
46111211|NCT02609360|Other|Priming of ECMO circuit with Ringer Lactate|Ringer Lactate as priming crystalloid solution
46111212|NCT02609360|Other|Priming of ECMO circuit with Balanced Solution|Balanced Solution as priming crystalloid solution
46111213|NCT00444535|Drug|lapatinib|1500 mg oral lapatinib (once daily)
45469632|NCT03419806|Drug|LCIG (Duodopa)|"Duodopa will be administered directly to the proximal small intestine via a PEG-J tube connected to a portable infusion pump. Individually optimized dosing of Duodopa will be administered as a morning rapid constant rate administration followed by continuous infusion and, if needed, intermittent extra doses (subject-initiated based on symptom experience). The maximum daily dose levodopa during Duodopa administration should normally not exceed 3350 mg, and is not allowed to exceed 4000 mg.~From patient 6 and onwards:~The pre-study daily Duodopa dose will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The morning bolus is 110% of the hourly continuous dose delivered at the rate of 40 ml/h. The morning dose will not exceed 15 mL, corresponding to 300 mg levodopa. The maximum daily dose levodopa is not allowed to exceed 4000mg."
46024547|NCT02789683|Other|Fine emulsion|Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
46024548|NCT02789683|Other|Coarse emulsion|Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
46024549|NCT02789683|Other|Control|Beverage is made up of distilled water and olive oil. Beverage will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
46024550|NCT02789761|Dietary Supplement|High-flavanol milk choocolate|
46024551|NCT02789761|Dietary Supplement|Low-flavanol milk chocolate|
45838596|NCT04381884|Drug|IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.|IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
45469633|NCT04229901|Drug|HepaStem|HepaStem will be administered as an intravenous (IV) infusion
45469634|NCT04229901|Drug|Placebo|Placebo will be administered as an intravenous (IV) infusion
45469635|NCT03425032|Device|CT scanner|Regular CT imaging of the abdomen and pelvis
45469636|NCT04179591|Other|Exercise|Intrinsic foot muscles and tibialis posterior strengthening exercises
45469637|NCT04179591|Other|Orthesis|Customized arch support insoles
45469638|NCT03419728|Behavioral|Healthy Families, Healthy Futures|Home visiting program for pregnant and parenting teens
45469639|NCT03424954|Behavioral|EpxOstomy|A 30-day post-operative automated text-messaging intervention for home monitoring of ileostomy output
45838597|NCT04381962|Drug|Azithromycin Capsule|Azithromycin 500 mg OD PO 14 days
45469640|NCT03424876|Drug|Imatinib 400mg|exposure 400 mg/day or 600mg/day,
45469641|NCT03424876|Drug|Sunitinib 37.5Mg Oral Capsule|exposure 37.5 mg/day, continuous taking, or 50 mg/day (4/2)
45469642|NCT04448236|Device|Blood flow restriction resistance exercise|"Application the Blood flow restriction device over the proximal thigh to have 80% of the limb occlusion pressure to accumulate the metabolite generated during knee extension"
45469643|NCT03325881|Drug|SHP465|SHP465 capsule 6.25 mg orally once daily for 4 weeks
45469644|NCT03325881|Drug|Placebo|Placebo matching to SHP465 capsule orally once daily for 4 weeks
45838598|NCT04382430|Procedure|Ultrasound guided venous access|Each physician/ provider will perform 2 assisted ultrasound (US) guided venous access and pocket creation for cardiac device implant and 10 solo ultrasound guided cardiac device implant.
45838599|NCT04382430|Procedure|Conventional technique|Physician will perform 5 cardiac device implant using conventional technique of venous access and pocket creation
46024552|NCT02798497|Other|Serum and Blood samples|
46024553|NCT02789917|Other|Dual Therapy|Combination of Apixaban 5mg/dl (or in reduced dosing of 2.5 mg/d depending on age, renal function and body weight) in combination with Clopidogrel 75 mg/d for 6 months.
46024554|NCT02789917|Other|Triple Therapy|"HAS-BLED-Score <3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 6 months.~HAS-BLED-Score ≥ 3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 1 month followed by Phrenprocoumon (INR 2.0-3.0) and Clopidogrel (75mg/d) for 5 months."
46024555|NCT03863587|Biological|HLX12|healthy volunters receive HLX12 (8mg/kg) once
46024556|NCT03863587|Biological|Cyramza (Ramucirumab)|healthy volunters receive Cyramza (Ramucirumab) 8mg/kg once
46111214|NCT00444535|Drug|bevacizumab|10 mg/kg intravenous bevacizumab (every two weeks)
46111215|NCT05757752|Behavioral|Problem Solving Therapy and Integrated Care|The intervention, will consist of problem solving therapy techniques to promote PAD self-management behaviors and depression/distress management.
46111216|NCT04110288|Drug|Paclitaxel|Paclitaxel to treat peripheral arterial disease
46111217|NCT04110288|Device|Non-drug coated Device Treatment|
46111218|NCT03863158|Other|No intervention|No intervention / medical records only
46024557|NCT02789605|Drug|Bacilor|Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months. Then all patients will be then followed up for 3 additional months without treatment.
46111219|NCT00826306|Other|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on sunscreen. In the active comparison arm (control arm), the comparison intervention is written patient educational material on sunscreen.
46111220|NCT04832360|Behavioral|Financial Incentives|Financial incentives may be offered to participants based on their behavioral outcomes (smoking cessation and participation in online psychoeducation about smoking)
46024558|NCT02789605|Drug|Placebo|Patients of group B will took the placebo similarly at the Lactobacillus rhamnosus Lcr35® orally . All patients will be then followed up for 3 additional months without treatment.
46024559|NCT02789839|Procedure|Blood test|Blood test of 30mL
46024560|NCT02789839|Procedure|Medullar test|Medullar test for 2-5mL and a smear
46024561|NCT04233463|Dietary Supplement|Modulen|Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet
46024562|NCT04233463|Drug|Budesonide|Standard treatment for mild Crohn Disease patients
46111221|NCT04025502|Device|Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System|The testing protocol consists of an auditory oddball Event-Related Potential (ERP) paradigm, 40Hz ASSR, and the collection of 6 minutes of resting electroencephalogram (EEG). During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 6 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 60-75 minutes.
46111222|NCT00826384|Procedure|balloon catheter|transcatheter arterial chemoembolization therapy with balloon catheter
46111223|NCT04107714|Behavioral|STC|"The peer-led and web-based group program contains four lessons plus one booster session:~Lesson 1: Consider the pros and cons of disclosing: Participants reflect on their experience of self-stigma and weight their pros and cons of (non-)disclosing their child's mental illness.~Lesson 2: Different ways to disclose: Participants learn about different ways to disclose and their respective pros and cons. Afterwards participants discuss possible responses they might experience and develop strategies to cope with.~Lesson 3: Communication about disclosure between parents and their child: Participants discuss pros and cons of (non-)disclosure for their children and how to negotiate whether to disclose or not.~Lesson 4: Telling your story: Participants learn how to tell their own story.~In a booster session, participants discuss their experiences with disclosure or non-disclosure."
46111224|NCT05753852|Drug|Tauroursodeoxycholic Acid|Tauroursodeoxycholic acid (TUDCA) 250 mg capsules Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal Mode of administration: orally Duration: 18 months
46024563|NCT02794129|Other|Functional Magnetic Resonance Imaging|
46024564|NCT02793973|Device|shoe lifts|
46111225|NCT00821782|Drug|Levofloxacin; Azithromycin|
46111226|NCT00847613|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
46024565|NCT02793895|Device|Medtronic SEEQ™ mobile cardiac telemetry system|The SEEQ™ system consists of a wearable sensor which is a single-lead, low-profile, peel-and-stick device applied over the anterior left chest wall of the subject. The wearable patch is designed for one-time use only and cannot be re-applied if removed. Each sensor provides up to 7.5 days of monitoring. Subjects randomized to the intervention group will undergo 30 days of continuous cardiac rhythm monitoring with the SEEQ™ device at the time of randomization. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device.
46111227|NCT00847613|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
46111228|NCT00847613|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
46111229|NCT00847613|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
46111230|NCT00847613|Drug|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
46111231|NCT00847613|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
46111232|NCT00847613|Drug|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
46111233|NCT00847613|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
46111234|NCT00821860|Other|talc|Talc pleurodesis
46111235|NCT00821860|Procedure|therapeutic thoracoscopy|Talc pleurodesis via thoracoscopy
46111236|NCT00821860|Procedure|therapeutic videothoracoscopy|Video-assisted thoracoscopic pleurectomy
46111237|NCT00794196|Behavioral|Pharmaceutical care program for antidepressant treatment|The pharmaceutical care program is a support program for patients starting and maintaining antidepressant treatment.
46111238|NCT00821938|Procedure|LV dp/dt pressure measurement|Assessment of response to bi-ventricular pacing. Responder-arm, will be permanently paced bi-ventricularly
46111239|NCT00821938|Procedure|LV dp/dt pressure measurement|Assessment of response to bi-ventricular pacing. Non-esponder-arm, will be treated with standard ICD-treatment
46024566|NCT02793895|Other|Usual Care|For subjects randomized to the usual care group, no protocol-mandated cardiac rhythm monitoring will be performed. However, subjects in the control group may undergo rhythm monitoring during the study period if their treating physicians deem that there is a clinical indication to so do. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia. Inc) cardiac rhythm monitoring device.
46111240|NCT00807092|Drug|biphasic insulin aspart 30|The initial doses for BIAsp 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 U/kg body weight and to be equally divided (1/2:1/2) between pre-breakfast and pre-dinner
46111241|NCT00807092|Drug|biphasic human insulin 30|The initial doses for BHI 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 IU/kg body weight and to be divided in the ratio of 2/3:1/3 between pre-breakfast and pre-dinner
46111242|NCT00807092|Drug|metformin|Metformin dose must remain the same as that used prior to the trial.
46024567|NCT02793895|Device|CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device|The CardioSTAT device is a wearable adhesive cardiac rhythm monitoring system which is low-profile, water-resistant, and is adhered onto the skin surface with 2 electrodes. This wearable adhesive device is designed for one-time use only. Each CardioSTAT device will provide 14 days of cardiac rhythm monitoring. For subjects randomized to the intervention group who will be monitored by the CardioSTAT device, they will receive 28 days of continuous cardiac rhythm monitoring.
46111243|NCT00794118|Other|As per clinical practice|As per clinical practice
46111244|NCT02549872|Other|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
46024568|NCT04234711|Procedure|Surgical strategy|To compare the efficacy between conventional repair and sutureless technique for total anomalous pulmonary venous connection
46024569|NCT02793427|Biological|blood sample collection|
46024570|NCT02793739|Procedure|Hyaluronic acid filler injection|Hyaluronic acid filler will be injected into the dorsal fingers at day 0 and at day 14 if a touch-up is necessary.
46111245|NCT04112550|Drug|Methadone Hydrochloride|FDA approved medication to treat pain
46111246|NCT04112550|Drug|Oxycodone-Acetaminophen|FDA approved medication to treat pain
46111247|NCT00640042|Drug|morphine sulfate extended release capsules|30 mg, 60 mg, 90 mg, 120 mg morphine will be prescribed by the Investigator in accordance with the AVINZA prescribing information.
46111248|NCT00807014|Drug|Duac Gel|Duac® Gel will be applied to the face once daily at night, for 12 weeks.
46111249|NCT00807014|Drug|Differin gel|Differin Gel will be applied to the face once daily at night, for 12 weeks.
46111250|NCT00847535|Biological|autologous muscle cell injection|Injection of autologous muscle cells
46111251|NCT04830566|Other|Myofascial release technique|Myofascial technique on the thoracolumbar fascia and lumbar paraspinal muscles
45469645|NCT04687852|Other|Conservative and Non-conservative treatments|This program includes Focused Pelvic Floor with Motor Imagery Technique Group ,Nonsteroidal Anti-Inflammatory Drug Group, Diosmin Group, Acupressure Group (LI-4 (Bilateral), CV-6, CV-4, SP-6 (Bilateral). It is aimed to determine the most effective treatment among these groups.
45469646|NCT04678180|Behavioral|Combined HRT and ERP|tic training using the principles of HRT and ERP as to reduce tic intensity
46024571|NCT02793661|Device|RenalGuard|Replacement of urine output by infusion of a matched volume of sterile replacement solution to maintain a patient's intravascular fluid volume. Diuretic is administered to reach an optimum urine flow and protect efficiently the patients' kidneys.
46024572|NCT02793661|Other|Control|Hydration protocol following ESC Guidelines 2014
46024573|NCT03874039|Device|Gas sensor|The gas sensor is an airtight gas capsule attached with a floating solid phase microextraction (SPME) tube. SPME uses a fiber coated with a nontoxic liquid (polymer), and a nontoxic solid (sorbent). The fiber coating extracts the compounds from the gas being released from the skin. Only the glass sample is in contact with the skin.
46111252|NCT04830566|Other|Simulated Myofascial Release technique|Superficial hands contact on the lumbar area
46111253|NCT04809272|Behavioral|ParentChat for parents of children ages 2-17|The programme will include text/audio messages, illustrated comics, videos, and activity assignments for parents to do with their children. Parents will be prompted to give feedback regarding successes and challenges applying these parenting skills via audio or text messages during the week.
46111254|NCT00592631|Device|CPAP-Continuous Positive Airway Pressure|Cpap will be worn at night by subjects 6 to 7 days duration.
46111255|NCT00592631|Device|SHAM|SHAM will be worn at night by subjects 6 to 7 days duration.
46111256|NCT05753774|Biological|FMT|FMT is a technique in which intestinal microbiota are transferred from a healthy screened donor to a patient, with the goal being to introduce or restore a stable microbial community in the gut. FMT was given 2courses, 3 times per courses
46111257|NCT05757674|Other|Sample examination|No intervention will be performed
46111258|NCT04116125|Procedure|Radiotherapy|Adjuvant radiotherapy on axillary region
46111259|NCT04805918|Behavioral|VIPP-SD|Parenting program
46111260|NCT05757596|Drug|VSA001 injection|The active drug is VSA001 injection. The active pharmaceutical ingredient (API) contained in VSA001 is a synthetic, double-stranded, hepatocyte targeted NAG-conjugated RNAi.
46111261|NCT05757596|Drug|Placebo|0.9% Saline, volume matched
46111262|NCT00791388|Drug|Placebo|oral capsule, 2x/day for 14 days
46111263|NCT00791388|Drug|PG-760564|oral capsule, 50 mg, 2x/day for 14 days
46111264|NCT00791388|Drug|PG-760564|oral capsule, 100mg, 2x/day for 14 days
46111265|NCT00791388|Drug|PG-760564|oral capsule, 200 mg, 2x/day for 14 days
46111266|NCT00791388|Drug|PG-760564|oral capsule, 400 mg, 2x/day for 14 days
46024574|NCT03874039|Device|Sweat Sensor|The sweat sensor is a soft, flexible device that rests on the skin and collects secreted sweat through capillary action. The device is held in place by medical-grade acrylic adhesive film.
46024575|NCT02798419|Drug|DFD05 Cream|
46024576|NCT02798419|Drug|Active01 Cream|
46024577|NCT02793505|Drug|metformin|This is not an intervention but an observed exposure.
46111267|NCT00794040|Drug|Add-on citalopram following optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
46024578|NCT02793505|Drug|any drug not known as a major teratogen or major fetotoxicant|This is not an intervention but an observed exposure.
46024579|NCT02789371|Procedure|the first pass is made with 5ml suction technique|the first pass is made with 5ml suction technique, then modified wet suction technique / 5ml suction technique/ modified wet suction technique is operated successively.
46024580|NCT02789371|Procedure|the first pass is made with modified wet suction technique|the first pass is made with modified wet suction technique, then 5ml suction technique/ modified wet suction technique/ 5ml suction technique is operated successively.
46024581|NCT02798575|Device|Astral 150 ventilator|Patients indicative for invasive ventilation will receive the Astral 150 ventilator at the weaning station of the hospital. The ventilator will be set by the physician. Afterwards patients will be transferred into home care.
46024582|NCT02789293|Device|EyeOP1 device|Ultrasound Ciliary Plasty (UCP procedure) using Focused Ultrasound
46024583|NCT02797873|Other|fMRI - Stroop task|2 x 10 minutes Stroop task (2 x 5 minutes emotional blocks, 2 x 5 minutes non-emotional blocks, order balanced across participants) performed during fMRI scan. See Detailed Study Description.
46024584|NCT02797873|Other|fMRI - MID task|2 x 10 minutes MID task performed during fMRI scan. See Detailed Study Description.
46024585|NCT02797873|Behavioral|Stop Signal Task|Performed at a computer at first visit, 10 minutes divided into 3 blocks. See Detailed Study Description.
46024586|NCT02797873|Other|SCID-II|See Detailed Study Description.
46024587|NCT02797873|Other|SDQ|See Detailed Study Description.
46024588|NCT02797873|Other|ASRS|See Detailed Study Description.
46024589|NCT02797873|Other|AQ|See Detailed Study Description.
46024590|NCT02797873|Other|TAS-20|See Detailed Study Description.
46024591|NCT02797873|Other|Raven's SPM|See Detailed Study Description.
46024592|NCT02797873|Other|Reading ability|See Detailed Study Description.
46111268|NCT00794040|Drug|Add-on placebo following optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
46111269|NCT02603796|Other|3D Scan of nares|3D scan of subjects nose prior to implementation of ncpap and upon discontinuation of ncpap.
46024593|NCT02797873|Other|Ishihara's tests for colour deficiency|See Detailed Study Description.
46111270|NCT04109742|Drug|phosphatidylcholine-curcumin complex supplement|a dietary curcumin supplement given at two different doses
46111271|NCT04109742|Drug|Placebo curcumin capsule|matching placebo to active curcumin capsules
46111272|NCT00813488|Drug|Fentanyl Buccal Tablet|"FBT dose strengths = 200, 400, 600, or 800 mcg (1, 2, 3, or 4 tablets) taken prn (as needed) in the event of breakthrough pain.~The maximum dose of FBT permitted during the titration and double-blind periods in this study is 800 mcg (4 tablets).~For the subsequent 12-week open-label treatment period, patients will either continue with FBT treatment or begin treatment with an alternative short-acting opioid deemed appropriate for each patient by the clinician."
46111273|NCT00813488|Drug|Immediate release oxycodone|"Immediate release oxycodone dosage strength: 15, 30, 45, and 60 mg doses (1, 2, 3 or 4 capsules) to be taken prn (as needed) for breakthrough pain.~The maximum single dose would be 60 mg (4 capsules)."
46111274|NCT02604030|Other|Upper limb function|Physical therapy program will be done in two steps, with 8 sessions each one (twice a week for four weeks). First, 8 sessions of passive mobilization in glenohumeral joint and scapular, scar massage, lymphatic drainage, stretching exercises will be completed. Second, 8 sessions of upper limb strengthening and stretching exercises for upper limb. Each session will be completed in 1 hour (twice a week) during two months.
46111275|NCT02603874|Device|Target Tape|Comparing procedures using Target Tape against procedures not using Target Tape
46024594|NCT02797873|Other|Additional questionnaire|including questions about somatic disease, current medication, BMI, smoking habits, first menstruation, last menstruation's first day, days without active oral contraceptive pill during last month, claustrophobia, vision impairment.
46024595|NCT02797873|Other|Brown-ADD|See Detailed Study Description.
46024596|NCT02797873|Other|MFQ|See Detailed Study Description.
46024597|NCT02797873|Other|STAI-T|See Detailed Study Description.
46024598|NCT02797873|Other|BIS|See Detailed Study Description.
46024599|NCT02797873|Other|DAWBA|See Detailed Study Description.
46024600|NCT02797873|Other|STAI-S|See Detailed Study Description.
46024601|NCT02797873|Other|Sleepiness rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
46024602|NCT02797873|Other|Motivation rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
46024603|NCT02797873|Behavioral|FEFA2|Assessing ability to recognise emotional face, performed at a computer at first visit. See Detailed Study Description.
46024604|NCT02797873|Other|Structural T1 MRI scan|See Detailed Study Description and Outcome Measures.
46024605|NCT02797873|Other|Structural T2 MRI scan|See Detailed Study Description.
46024606|NCT02797873|Other|DTI MRI scan|See Detailed Study Description and Outcome Measures.
46024607|NCT02797873|Other|Resting state MRI scan|See Detailed Study Description and Outcome Measures.
46024608|NCT02793193|Dietary Supplement|Probiotic|Probiotic B.longum 1714 will be donated by Alimentary Health Ltd. (Cork, Ireland) and each sachet contains 10 billion CFU
46024609|NCT02793193|Dietary Supplement|Placebo for antibiotic|The placebo supplementation is identical-looking to the antibiotic Xifaxan ®
46024610|NCT02793193|Drug|Antibiotic|Antibiotic Xifaxan ® will be 200mg per tablet
46024611|NCT02793193|Dietary Supplement|Placebo for probiotic|The placebo identical-looking to the probiotic B.longum 1714
46111276|NCT04109664|Procedure|laparoscopic sleeve gastrectomy|The greater omentum is carefully dissected from the stomach at a distance of 2cm for the patients with AR, and 6cm for patients with AP. The omental dissection was performed using 5mm-abdominal ligature (Ligasure®, Metronic-Covidien, Minneapolis, USA), from the antrum towards the angle of His. Transection from the omentum is continued until the left crus has been identified. All sleeves are transected using 36 French orogastric tubes. Green cartridges (4.8 mm staple height) are used for the first firing and blue cartridges (3.5 mm) for the rest. Neither oversewing sutures to the staple line nor staple line reinforcement products are used. Homeostatic metallic clips are used for bleeding at the staple line. If bleeding persists and cannot be controlled, an interrupted suture is performed at the point of bleeding. A leak test with methylene blue is performed to the gastric remnant to assess the integrity of the suture line.
46111277|NCT00797316|Drug|Aliskiren|Aliskiren 150 mg or 300 mg taken once daily in oral form
46024612|NCT02793271|Behavioral|RESHAPE|Mental health services users and primary care workers who have previously completed the training are trained using PhotoVoice and other techniques to participate as co-facilitators. They participate in introductions to the intervention, myth busting, recovery stories, psychosocial communication role plays, and collaborative activities addressing challenges and barriers to task sharing/ task shifting mental health services in primary care.
46024613|NCT02793271|Behavioral|PRIME/mhGAP|"Primary care workers are trained using the mental health Global Action Programme (mhGAP) to identify and treat mental disorders in primary care. Primary care prescribers (those who can administer psychotropic medication) are trained to treat disorders including depression, alcohol use disorder, psychosis / schizophrenia, and epilepsy. Non-prescribers (primary care workers not authorized to dispense medications) are trained to deliver psychosocial and psychological interventions."
46024614|NCT02793349|Device|Absorb Bioresorbable Vascular Scaffold|Absorb Bioresorbable Vascular Scaffold
46024615|NCT01197534|Drug|fostamatinib|fostamatinib 100 mg twice daily
46024616|NCT01197534|Drug|fostamatinib|fostamatinib 100 mg twice daily/ 150 mg once daily
46024617|NCT01197534|Drug|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily.
46024618|NCT04234321|Drug|basic fibroblast growth factor|Basic fibroblast growth factor,100ml/ bottle, (35000IU / 8ml) / 100cm2 / time,three times a day.
46024619|NCT04234321|Drug|Kangfuxin Liquid|Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.
46024620|NCT04234321|Drug|0.9% Normal saline|0.9% Normal saline,20ml / 100cm2 / time,three times a day.
46024621|NCT02793115|Behavioral|Disclosure Letter-RISKS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
46024622|NCT02793115|Behavioral|Disclosure Letter-BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
46024623|NCT02793115|Behavioral|Disclosure Letter-RISKS AND BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS AND BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
46024624|NCT02793115|Behavioral|Disclosure Letter-NO RISKS OR BENEFITS|This letter includes a standard statement reminding the patient about the appointment and the location of the appointment.and DOES NOT provide any information on the physicians' financial relationships with industry nor information regarding the potential risks and benefits of physicians' conflicts of interest with for-profit industry.
46024625|NCT02793115|Behavioral|Letter-APPOINTMENT REMINDER|This letter only includes a standard statement reminding the patient about the appointment and the location of the appointment.
46024626|NCT03832933|Behavioral|High Protein Diet|16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%.
46024627|NCT03832933|Behavioral|Standard Protein Diet|16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:21%:25%.
46024628|NCT02797717|Radiation|Radiotherapy:|"All patients will have 2 OPEAcycles(chemotherapy cycle:Vincristine,Etoposide,Prednisone,doxorubicin) ,After assignment ( by randomization) to one of the arms the patient will be treated accordingly . response assessment will be done after OPEA cycles (ERA) and after cycles of copdac 28 or DECOPDAC 21(LRA).according to the assessments results patients will have radiotherapy or not."
46024629|NCT02797717|Drug|Vincristine|ARM A and ARM B
46024630|NCT02797717|Drug|Etoposide|ARM B , 100mg/m2/day
46024631|NCT02797717|Drug|Prednisone|ARM A and ARM B , 40mg/m2/day p.o
46024632|NCT02797717|Drug|Doxorubicin|ARM B , 25mg/m2
46111278|NCT00797316|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg or 25 mg taken once daily in oral form.
46024633|NCT02797717|Drug|Dacarbazine|ARM A and ARM B , 250mg/m2 i.v
46024634|NCT02797717|Drug|Cyclophosphamide|ARM A and ARM B , 625mg/m2 i.v
45469647|NCT03476577|Drug|Ibuprofen|Patients are tested for their normal prescription ibuprofen medication
46024635|NCT02793037|Device|Zirconia resin bonded bridge|
46024636|NCT02792725|Drug|Abemaciclib|Administered orally
46024637|NCT02792881|Procedure|Laparoscopic total gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent.For carcinomas arising in the remnant stomach with a gastrojejunostomy, jejunal lymph nodes adjacent to the anastomosis are included as regional lymph nodes. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
46024638|NCT04235569|Drug|Warfarin Sodium 5 MG|warfarin sodium 5mg tablets
46024639|NCT04235569|Drug|Warfarin Sodium 3 MG|warfarin sodium 3mg tablets
46024640|NCT04235569|Drug|Enoxaparin Sodium 100 MG/ML Prefilled Syringe|"Clexane® Syringes 2,000 IU (20 mg)/0.2 ml solution for injection in pre-filled syringes.~Clexane® Syringes 4,000 IU (40 mg)/0.4 ml solution for injection in pre-filled syringes.~Clexane® Syringes 6,000 IU (60 mg)/0.6 ml solution for injection in pre-filled syringes.~Clexane® Syringes 8,000 IU (80 mg)/0.8 ml solution for injection in pre-filled syringes.~Dose was determined individually for each patient as 1mg/kg every 12 hours."
46111279|NCT00587964|Radiation|Stereotactic Radiosurgery|"All patients would undergo craniotomy and the goal of surgery in all cases would be total removal of the metastases. The patient will initially receive premedication with 0.5- 1mg of Ativan orally prior to SRS procedure. Subsequently, the patient will have the stereotactic head ring placement under local anesthesia. A peripheral IV will be placed for administration of the intravenous contrast. Thin-section CT images will be obtained with intravenous contrast with head ring in place for the purpose of treatment planning.~A fusion program will be used to combine the recently obtained MRI images along with the CT scans. The target volume as well as the critical structures will be contoured. SRS would be delivered using either the Brain Lab or Radionics Radiosurgery planning and delivery system. Patients would receive a single treatment ranging from 15-22 GY."
46111280|NCT02608580|Other|Survey|
46111281|NCT05640336|Procedure|Single Debridement, Antibiotics and Implant Retention|Surgical debridement and wash out of infected joint. The polyethylene (plastic) insert, which acts as the articulating surface (modular component) of the prosthesis, will be removed and the exposed surfaces scrubbed, sterilized, and soaked. A new modular component will be placed with additional irrigation and antiseptic soak. Tissue cultures will be sent to the lab for further evaluation and antibiotic guidance. After the operation subjects will continue six weeks of IV antibiotics followed by oral antibiotic suppression for the life of the implant or at least two years after operation.
46111282|NCT05640336|Procedure|Planned Double Debridement, Antibiotics and Implant Retention|Surgical debridement and wash out of infected joint with an additional irrigation and debridement scheduled for approximately 5 days after the initial DAIR. During the first washout, antibiotic cement beads will be placed in the joint and these will remain in the interim until they are removed during the second washout. During the second DAIR, the antibiotic beads are removed, and the modular components are once again removed and replaced with new components. Exposed surfaces are again irrigated and debrided following a standardized protocol. A six-week course of IV antibiotics will follow the DAIR with additional oral antibiotics for the life of the component (standard of care) or at least a minimum of two years.
46111283|NCT05753696|Drug|Azilsartan|Azilsartan initial dose 20mg/d, if not reached the goal of hypertension; azilsartan dose 40mg/d
46111284|NCT05753696|Drug|Losartan|losartan initial dose 40mg/d, if not reached the goal of hypertension; losartan 100mg/d
46111285|NCT04109898|Device|Supraglottic airway device (I-gel) insertion|Modified I-gel insertion technique believed to be easier and non traumatic in anaesthetised patients.
46111286|NCT04788992|Other|Intervention group|Dementia care training consists of dementia care e-books, dementia virtual reality activity and peer support program.
46111287|NCT04788992|Other|Control group|Dementia care training consists of dementia care e-books and peer support program without dementia virtual reality activity
45838600|NCT04381572|Behavioral|High fidelity simulation training|At the beginning of scheduled classes in the simulation center, students were placed sitting at rest for 30 min. In each team a leader was chosen. Other team members were also assigned detailed functions. Before starting the scenario, participants were oriented for 10 -15 minutes by a physician instructor about the simulation room setup and manikin features. The simulated scenarios were performed using a high fidelity computer-based manikin simulator, with the possibility of remote control of vital signs. All medications and equipment required during the clinical scenarios were available. The scenario used was prepared and validated by experienced simulation instructors. All student groups were given the same standardized scenario.
45838601|NCT04381338|Other|Pulmonary and Motor Rehabilitation|Pulmonary and Motor Rehabilitation in ICU
46024641|NCT02789449|Other|assessment of DLNO and DLCO|
45838602|NCT04381026|Dietary Supplement|Botanical dry extracts combination|Aframomum melgueta dry extract (50mg), Glycine max bean dry extract (100mg) and Punica granatum skin extract (100mg)
45838603|NCT04381026|Dietary Supplement|Placebo|Filler agent
45838604|NCT04381104|Drug|Paracetamol|The intervention arm will receive 2 capsules of paracetamols of 500mg.
46024642|NCT01197378|Drug|Cysteamine Bitartrate Delayed-release Capsules|"Participants who entered the trial from the RP103-03 study continued treatment with cysteamine bitartrate every 12 hours at the last dose level prescribed during their participation in that study.~Participants not entering the trial from Study RP103-03 were started on twice a day administration of cysteamine bitartrate at a total daily RP103 dose of 70% of their pre-study total daily stable Cystagon® dose."
46024643|NCT02797639|Other|Co-PID|"The program was carried out by the school occupational therapist and homeroom teachers. The Co-PID had two phases. The first phase was a 1.5 hour in-service meeting that focused on the concept of Participation.~In the second phase of the Co-PID intervention, a collaborative consultation model was used. It included eight 45-minute consultation meetings, which took place every other week over a 3-months period. The meetings took place between the occupational therapist and each teacher, with the purpose of brainstorming; thinking of activities that the teacher could implement during the lessons for enhancing participation among the students."
46024644|NCT02797639|Other|IS|IS group included three meetings, a 1.5 hour in-service meeting focusing on the concept of participation, and two more workshop meetings aimed at sharing teachers' experience.
46024645|NCT02789527|Drug|Phenotyping|finger-tip blood drop : enzymatic activities assessed by specific single point concentration ratios after oral intake of the Geneva micrococktail made of : CYP1A2: paraxanthine/caffeine CYP2B6: 4-hydroxybupropion/bupropion CYP2C9: 4-hydroxyflurbiprofen/flurbiprofen CYP2C19: 5-hydroxyomeprazole/omeprazole CYP2D6: dextrorphan/dextromethorphan CYP3A4: 1-hydroxymidazolam/midazolam
46024646|NCT02789527|Genetic|Genotyping|DNA sampling from a saliva sample
46111288|NCT04107480|Procedure|Endoscopic trans-sphenoidal adenoma resection|"Neurosurgical consultation consists of at least one consult with a neurosurgeon and at least one consult with an endocrinologist with relevant experience. If the multidisciplinary team (MDT) agrees the patient is a good surgical candidate, the patient is asked consent for surgery, as is a custom part of preoperative requirements. When the patient decides not to have the surgery, (s)he will receive standard medical treatment, but will continue study follow up in the intervention group.~Surgery only takes place if both the MDT and the patient agree to it and should then be planned within three months after randomization. Surgery is performed by one or two trained neurosurgeons in the hospital where the counseling took place. A standard, semi-protocolled, endoscopic trans-sphenoidal surgical resection of the prolactinoma is performed according to standard practice."
46024647|NCT03735199|Device|PCL-TCP scaffold|During the surgery, the scaffold will be shaped by cutting and shaving with a scalpel so as to fit the extraction socket snugly at the crestal half to two-thirds aspect. A collagen membrane will be placed over the scaffold at the crestal aspect of the socket. The periosteum of the buccal flap will then be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
46024648|NCT03735199|Device|Geistlich Bio-Gide collagen membrane|A collagen membrane will be placed over the crestal aspect of the socket and the periosteum of the buccal flap will be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
45838605|NCT04380870|Dietary Supplement|Chinese Herbal Medicine|Chinese Herbal Medicine (CHM) has been used in the prevention and treatment of epidemic diseases dating back to the Han, Ming and Qing Dynasties and extending al the way through modern times. CHM formulas may contain plant elements of root, seed, back, stem or leaf in addition to minerals and other natural substances. All herbs dispensed in this trial will be from Spring Wind Herb Company.
46024649|NCT04233307|Diagnostic Test|Telethermographic images|Infrared digital thermography photographs of fracture wound and contralateral limb before and after propofol infusion.
46024650|NCT02789215|Behavioral|Proposed Meal Changes for CACFP: Impact on Child Food Intake and Costs|
46024651|NCT02792647|Drug|Placebo|Administered orally
46024652|NCT02792647|Drug|IX-01|Administered orally
46024653|NCT02792491|Drug|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone|Reduced dose of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
46111289|NCT04107480|Drug|Dopamine Agonists|"The treating physician adheres to the treatment protocol in general, but has freedom to choose treatment to his/her ideas how to deliver best care.~Current first line treatment consists of a dopamine agonists: cabergoline (currently the most used), bromocriptine or quinagolide. All dopamine agonists are taken orally, and the dosage may be raised based on its effect. It is usually titrated to achieve a normal or suppressed prolactin level and restoration of the gonadal axis. Dopamine agonist treatment is discontinued after 2 years of treatment, unless a normal prolactin level cannot be achieved. The dopamine agonist is restarted when prolactin levels rise after the medication is discontinued.~In standard care, surgical treatment is reserved for patients who don't tolerate medication, or whose adenoma fails to show a sufficient response. Patients in the control group with an intolerance for dopamine agonists or an insufficient response may be offered surgery as part of standard care."
46024654|NCT02792803|Drug|Xalatan|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
46111290|NCT05564130|Drug|Sodium bicarbonate|Sodium bicarbonate 1 mmol/ml
46111291|NCT05564130|Drug|Sodium chloride|Sodium chloride 9 mg/mL
46024655|NCT02792803|Drug|Apo-Latanoprost|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
46111292|NCT00915408|Drug|Lenalidomide|Oral lenalidomide 25mg daily on Days 1-21 every 28 days cycles for up to 9 cycles. From Cycle 10 Lenalidomide 25mg orally on days 1-21, every 28 days.
46111293|NCT00915408|Drug|Dexamethasone|Dexamethasone 20mgs orally, daily on Days 1-4 and 8-11 repeated every 28 day cycles for up to 9 cycles.
46111294|NCT00915408|Drug|Cyclophosphamide|Oral Cyclophosphamide will be added to the regime starting on days 1 and 8. The dose of Cyclophosphamide will be escalated in cohorts rising in 100mg increments from 300 to 700mgs days 1,and 8 every 28 day cycles for up to 9 cycles.
46024656|NCT02792803|Drug|Co-Latanoprost|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
46024657|NCT02792569|Procedure|Biopsy of ovarian cortical tissue|Biopsies will be taken from either right or left side. The cortical tissue will be isolated and fragmented in 1x1 mm2 pieces, followed by auto-transplantation to a peritoneal pocket.
46024658|NCT02797795|Drug|NEV801|Dose Escalation
46111295|NCT05573724|Drug|AZD5305|"In Part A, the participants will receive a single dose of AZD5305 on Day 1 and Day 7.~In Part B, the participants will receive AZD5305 once daily."
46024659|NCT02789059|Other|muscle oxygenation|Subjects will be invited to perform an isokinetic effort of the knee extensors against an isokinetic dynamometer. During this effort, muscle oxygenation and oxygen consumption will be assessed with a near infrared spectroscopy device and a gas exchange measurement device. Patients affected by Becker muscular dystrophy and healthy controls will be invited to have a muscle biopsy of the vastus lateralis.
46024660|NCT02797249|Drug|Aspirin|Low dose aspirin（100mg）per day starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy,taking at night.
46024661|NCT02797249|Other|Blank|Routine examination during pregnancy.
46111296|NCT05573724|Drug|Itraconazole|In Part A, the participants will receive Itraconazole twice daily on Day 4 and once daily on Days 5-12
46111297|NCT00590954|Drug|Perifosine|"Dosing will be continuous, and for the purpose of this trial a cycle will be defined as 28 days. Perifosine will be given as a 600 mg loading dose on day 1. The loading dose will be divided into 4 equal doses of 150 mg each. The first 3 doses should be given with food in the adult day hospital to allow intravenous antiemetic prophylaxis, and 4th dose at bedtime at home. The interval between doses of perifosine should be no less than 4 hours. On day 2, patients will start the maintenance dose of 100 mg daily at bedtime at home.~In addition to baseline serum, all patients will have weekly serum drawn during weeks 2-4."
46024662|NCT02792335|Drug|apixaban|
46024663|NCT02792335|Drug|dabigatran|
46024664|NCT02792335|Drug|rivaroxaban|
46024665|NCT02792335|Drug|warfarin|
46024666|NCT02792023|Other|Immunochemical fecal occult blood test|Participants will be provided with a single immunochemical fecal occult blood test. Participants will introduce a small sample of feces inside and bring the test to the hospital
46024667|NCT02792023|Device|Colonoscopy|A colonoscopy (procedure performed using a scope design to examine the large bowel) will be offered to the participants
46024668|NCT02792023|Device|Upper endoscopy|An upper endoscopy (procedure performed using a scope to examine the upper digestive tract) will be offered to the participants
46024669|NCT02792179|Drug|[18F]RO6958948|Radiolabeled low molecular weight compound, administered as single IV injection. The mass dose of [18F]RO6958948 injected will be less than or equal to (</=) 10 micrograms (µg), injection volume </=20 mL. Target injected activity for [18F]RO6958948 will be 370 megaBecquerel (MBq) (10 millicurie [mCi]).
46024670|NCT01197300|Drug|Zoledronic acid|intravenous infusion
46024671|NCT02797405|Radiation|Standard treatment|Sarcoma patients will undergo radiotherapy followed by surgery Rectum cancer patients will undergo radio-chemotherapy followed by surgery Esophagus cancer patients will undergo radio-chemotherapy followed by surgery
45838606|NCT04380558|Other|Pulmonary rehabilitation|"Patients will be asked to answer two questionnaires about urinary incontinence symptoms (see outcomes) to assess the prevalence and the type of these symptoms.~They will subsequently participate in their usual pulmonary rehabilitation program consisting in 90min sessions (including endurance training, muscle strengthening and self-management), 3x/week for 8weeks (centre 1) or 2x60min sessions (including the same components), 3x/week for 8weeks (centre 2)."
46024672|NCT02791867|Drug|AphoelineBrake|The study is proposed as a placebo controlled randomized controlled trial with an intervention (AphoelineBrake) in addition to their standard treatment in comparison to a standard treatment control arm receiving an identical placebo. Prior to the commencement of any study procedures, participants will document informed consent and acknowledgement of privacy rights. Participants will be seen for initial consenting procedures, initial study procedures, and follow-up procedures at the Dasman Diabetes Institute clinic.Scheduled study visits will occur at Day 0, Day 7, Months: 1, 3, 6, 9, and 12 months in accordance with standards of medical care.
46024673|NCT04234243|Procedure|cytoreduction and HIPEC|cytoreduction CCR 0-1, and HIPEC close technique
46111298|NCT04104750|Other|assessment scales (BFI, QLQ, TESS)|the patient's Fatigue will be measured during the treatment period with antiblastic drugs and part of the followup period. To this end the BFI scale validated in Italian will be used (Mendoza et al 1999; Catania et al, 2013) which includes 9 items with a score for each of 0 to 10 and a consequent total score from 0 to 90. The measurement will take place in 4 times: the day of enrollment, 6 months, 12 months and 24 months after enrollment.the quality of life of patients measured by the EORTC QLQ C-30 scale (Aaronson et al, 1993) and the level of autonomy measured by the TESS scale (Davis et al, 1996) in 4 steps: the enrollment day , at 6 months, at 12 months and at 24 months from enrollment.
46111299|NCT04030286|Other|Observation|Evaluation of Malondialdehyde level and correlation of Malondialdehyde level with periodontal and cardiovascular disease
46111300|NCT05753540|Other|Laser therapy|Multiwave locked system laser therapy
46024674|NCT04200235|Drug|Dexmedetomidine hydrochloride nasal spray|"In the low weight group, 18 subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, 18 subjects will receive a high dose of dexmedetomidine nasal spray."
46024675|NCT04200235|Drug|Dexmedetomidine hydrochloride nasal spray blank preparation.|"In the low weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation."
46024676|NCT02791789|Other|Autism Spectrum Disorder|Training to the serious game sematic, clinical exam, speech and language therapy and neuropsychological evaluations
46024677|NCT02791711|Other|High Flow Nasal Cannula|Evaluation of the use of High Flow Nasal Cannula by biological markers, questionary of quality of use of HFNC by the physician, questionary of evaluation of adverse events with HFNC
46024678|NCT02791243|Drug|Finasteride 0.25%|Cutaneous solution of finasteride 0.25%
46024679|NCT02791243|Drug|Placebo for Finasteride 0.25%|vehicle cutaneous solution of P-3074
46024680|NCT02791243|Drug|Negative Control|0.9% aqueous NaCl
46024681|NCT02791477|Device|Attune FB PS knee arthroplasty|
46024682|NCT04234165|Device|TURBT|different power sources ( bipolar vs monopolar)
46024683|NCT05393635|Biological|ITIL-168|"ITIL-168 is a cell therapy product derived from a participant's own TILs. A portion of tumor is resected to make a personalized ITIL-168 product. If appropriate, participants may receive bridging therapy after recovering from the tumor resection during ITIL-168 manufacturing. Once ITIL-168 has been made, the participant is treated with up to 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.~Drug: Pembrolizumab Participants will receive 1 dose of pembrolizumab following tumor resection prior to receiving ITIL-168, and additional doses for up to a year after ITIL-168 infusion."
46024684|NCT02788825|Procedure|Targeted biopsies using Magnetic Resonance Imaging guiding|Prostate biopsies targeted by findings on MRI where findings are classified according to PI-RADS v2.
46024685|NCT02797483|Other|Test Fat Blue|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Blue which incorporated into daily snacks (~50g of test fats, 2 experimental cupcakes (~15g test fat each) for breakfast and 4 pieces experimental cookies (~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
46111301|NCT05753540|Other|Sham laser therapy|Sham laser therapy
46111302|NCT02602548|Other|Culture|Specimens will be obtained and sent to the lab for cultures.
46111303|NCT00791076|Drug|Placebo|2pmol/kg-1/min-1 placebo infused continuously over 72 hours.
46111304|NCT00791076|Drug|Pancreatic Polypeptide (PP)|2pmol/kg-1/min-1 PP infused continuously over 72 hours.
46111305|NCT05757518|Other|Cryosauna|The intervention was Cryosauna - cryostimulation at -110°C for 1.5 minutes, for four consecutive days.
46111306|NCT04785560|Device|Initial shunt setting post-operatively of the Certas Plus shunt valve.|The setting/resistance of the Certas Plus Shunt valve implanted is set according to randomisation and is not changed until the first post-operative MRI is performed 36-48 hours after surgery.
46111307|NCT05757440|Other|Icon resin application|Application of the low-viscosity resin infiltration (Icon) to the white spot enamel lesions
46111308|NCT02609126|Drug|EP-104IAR|Single, ultrasound-guided injection of EP-104IAR into the knee
46111309|NCT02609126|Drug|Vehicle|Single, ultrasound-guided injection of vehicle placebo into the knee
46111310|NCT04107402|Other|Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay|Blood sample Urine Sample Pulmonary, hepatic and cardiac tissue from biopsy and autopsy
46111311|NCT02603718|Other|Rehabilitation treatment|
45838607|NCT04380402|Drug|Atorvastatin|Atorvastatin 40 mg tablet
45838608|NCT04380324|Drug|LY3471851|LY3471851 drug product is a sterile liquid for SC injection that may be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
45838609|NCT04380324|Drug|Placebo|The placebo dosing solution is 0.9% sodium chloride for injection (USP).
45838610|NCT04380246|Other|Qualitative Interview|There is no intervention as part of this study. Clinicians will participate in a qualitative interview.
45681647|NCT04607174|Other|Pathologic group|"Voluntary Activation level will be determined according to the interpolate twitch technique (ITT).~During isometric contractions (knee at 40° flexion), three electric shocks (doublets) will be delivered. The first shock will be delivered at rest before contraction. The second one will be delivered 3-4 s after the beginning of the effort. The third one will be delivered at rest 2-3 s after the contraction has ended. Two isometric contractions will be performed, with a 3-minute break.~Then, 3 consecutive continuous passive motion (CPM) extension-flexions of the knee joint (range 105-0°), and 3 isokinetic concentric contractions (ISOK) will be performed. During both CPM and ISOK an electric shock will be delivered during each repetition. The instant of stimulation will be determined in a way allowing the twitch moments to peak at exactly 40° of knee flexion during extension. The same procedure will be administered first to the affected limb, and then to the non-affected limb."
46111312|NCT02610062|Drug|AGS67E|Intravenous (IV) infusion
46111313|NCT05757284|Diagnostic Test|Lower Limb Lymhedema assessment|assessessment with the selected measurement methods showing sufficient reliability and feasibility in the patient group with LLL from aim 1:NCT05269264. Measurement will occur at the genital/midline region, and on both legs/ feet.
46111314|NCT05757206|Diagnostic Test|Syn-One Test|Participating subjects will have three small skin punch biopsies.
46111315|NCT02610218|Other|CTC and cfDNA analysis|The enumeration of CTCs as well as the detection of HER2 expression will be achieved via the integrated subtraction enrichment (SET) and immunostaining-fluorescence in situ hybridization (iFISH) platform. Further, for the geneomic analysis, the enriched single CTC will be isolated for single-cell targeted sequencing. While for cfDNA analysis, extracted DNA from plasma will be directly subjected to targeted sequencing. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
46111316|NCT00590720|Biological|MEDI528 50 mg|MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
46111317|NCT00590720|Other|PLACEBO|Placebo administered as a subcutaneous injection twice weekly for 4 weeks
46111318|NCT00625378|Drug|Sorafenib (Nexavar, BAY43-9006)|At the same dose and schedule as in the participants' original clinical trials
46111319|NCT00822250|Other|analysis of pigmentation|cutting hair, skin description, skin biopsy for only 4 patients
46111320|NCT00819364|Behavioral|BCRI intervention program|"Phase 1: The parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.~Phase 2: BCRI model intervention.Parents and children will take part in a 24-halfday workshop to learn practical teaching skills in BCRI model. Then Home-based intervention using BCRI model for 11 months. At least 28 hours of BCRI intervention per week is acquired. Doctors or therapists will meet the parents and children once per month, each for 30 minutes, totally 10 times, to monitor and give advice on the interventions."
46111321|NCT00819364|Behavioral|Standard community care|"Phase 1: the parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.~Phase 2:Any treatment and interventions available chosen by families for children with autism and ASD, for at least one and a half years.~Phase 3:One and a half years after enrollment, parents and children will be free to take part in the BCRI model intervention which is the same as Phase 2 for experimental group lasting for one year."
46111322|NCT00806624|Drug|DU-176b tablets|DU-176b tablets taken once daily for up to 3 months
46111323|NCT00806624|Drug|DU-176b tablets|DU-176b tablets taken once daily for up to 3 months
46111324|NCT00806624|Drug|Warfarin tablets|Warfarin tablets taken once daily for up to 3 months
46111325|NCT05753228|Other|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS)|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS) to assess metabolic and mitochondrial perturbations in post-COVID fatigue or cancer fatigue.
46111326|NCT05753228|Other|Chalder Fatigue Scale|The Chalder Fatigue Scale is used for measuring the extent and severity of fatigue within both clinical and non-clinical, epidemiological populations.
46111327|NCT05753228|Other|Health Questionnaire (EQ-5D-5L)|"The Health Questionnaire (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from no problems through extreme problems."
46111328|NCT05753228|Other|Hamilton Depression Rating Scale|The Hamilton Depression Rating Scale is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.
46111329|NCT00806546|Drug|NP101|NP101 study patch four hour application
45681648|NCT05580328|Drug|Hematoporphyrin Injection actived by photodynamic therapy combined with Sonodynamic Therapy|Hematoporphyrin in tumor tissue will be greatly enhanced by the combination of Sonodynamic Therapy and Photodynamic Therapy and achieve better treatment effect.
46111330|NCT00624832|Drug|Xolair|Xolair (Omalizumab) dose: 2 x 450 mg, 2 x 525 mg or 2 x 600 mg; subcutaneous injection;
46111331|NCT00624832|Drug|Placebo|Matching placebo of Xolair (omalizumab), by subcutaneous injection of a solution with a concentration of 125 mg/mL in a supine position.
45838611|NCT04380012|Drug|Pyrotinib|Pyrotinib as interventions were used in patients with HER2-positive advanced colorectal cancer
45838612|NCT04380012|Drug|Pyrotinib in combination with trastuzumab|Pyrotinib in combination with trastuzumab as interventions were used in patients with HER2-positive advanced colorectal cancer
46111332|NCT04029662|Behavioral|Valsalva Maneuver|Performing Valsalva maneuver will reduce the pain intensity during spinal needle insertion.
46111333|NCT05753150|Drug|Tafenoquine|Tafenoquine 300 mg (2x150 mg tablets)
45469648|NCT03957213|Device|Acute Intermittent Hypoxia|Acute intermittent hypoxia is a safe, non-invasive technique. All sessions will be monitored by research study staff trained in delivering acute intermittent hypoxia. Hypoxic intervals will be delivered with a commercially available sports performance hypoxicator. A unit capable of delivering a fraction of inspired oxygen ranging from 21%-9% will be used. Air will be delivered into a mask that will be secured comfortably over the subject's nose and mouth. Intervention sessions will occur for 10 days over a 2 week period.
46111334|NCT05753150|Drug|Primaquine|Daily primaquine adjusted by weight (0.25 mg/kg/day for 14 days)
46111335|NCT05753150|Drug|Primaquine|Weekly primaquine adjusted by weight (0.75mg/kg/week for 8 weeks)
45469649|NCT03957213|Behavioral|Computerized Cognitive Training|60 minutes of Double Decision cognitive training for 10 days over a 2 week period.
45469650|NCT03424798|Device|Inspiwave|patients are monitored with the Inspiwave device. A low dose inert tracer gas is added to the inspred air
46111336|NCT00826774|Behavioral|Usual Care|Participants in this group will receive usual medical care, provided by their own primary care providers (PCPs). PCPs also will provide participants recommendations for weight management at quarterly-scheduled visits.
46111337|NCT00826774|Behavioral|Brief Lifestyle Counseling|These participants, like those in the Usual Care group, will receive the same PCP visits, plus monthly brief counseling sessions with an auxiliary health care provider (e.g., a medical assistant), on-site or by phone.
46111338|NCT00826774|Behavioral|Enhanced Brief Lifestyle Counseling|These participants will receive the same intervention as those in the Brief Lifestyle Counseling condition, including quarterly PCP visits and monthly sessions with a medical assistant who will instruct them in lifestyle modification. These individuals also will select, in consultation with their PCP, the use of either meal replacements or weight loss medication, to facilitate the induction and maintenance of weight loss
46111339|NCT05757128|Behavioral|Optimal Health Program|The OHP intervention will comprise a psychosocial management program that will be adapted to the CHR population and will be accompanied by a structured workbook, all accessed virtually through a web based digital portal. Sessions are approximately 1 hour in duration and held weekly for 6 weeks, and every two weeks for the remaining 6 weeks. The OHP has three components: 1) assessment and engagement; 2) therapy sessions, and 3) maintenance integration.
46111340|NCT02550730|Behavioral|Birth Sisters Best Beginnings for Babies|Birth Sisters Best Beginnings for Babies support during Pregnancy, Labor and Delivery and six weeks postpartum. Participants assigned to the Birth Sister group receive community doula services with consultation from the Medical Legal Partnership when indicated beginning at 24 weeks. Participants receive up to 8 two-hour prenatal home visits; continuous support through labor and birth, and up to 4 two-hour postpartum home visits through 6-8 weeks postpartum.
45838613|NCT04380168|Procedure|Modified pec11 trunk block|Ultrasound guided modified pec 11 block injecting local anesthetic with or without adjuvant between pectoralis minor and serratus anterior muscles
45469651|NCT03939351|Diagnostic Test|OCT-angiography and SD-OCT|Performing an OCT-angiography and SD-OCT examination
46111341|NCT02550730|Other|Usual maternity care|Usual prenatal, intrapartum and postpartum maternity care
46111342|NCT00826852|Drug|docetaxel and carboplatin|weekly docetaxel 30mg/m2 and four weekly carboplatin AUC (Area under curve) 5
46111343|NCT04734392|Procedure|TAVR|TAVR implantation in cusp overlay technique
45469652|NCT03413176|Drug|Cardiac complication induced by VEGF/VEGFR inhibitor|Case reported in the World Health Organization (WHO) of cardiac complication of patient treated by AAs, with a chronology compatible with the drug toxicity
45469653|NCT03885765|Diagnostic Test|Predictive data|"The novel predictive data in this study includes 5 predefined variables derived from thoracic CT scans:~(i) Expiratory to inspiratory ratio of mean lung density (MLDe/i), total; (ii) MLDe/i of the section to be excised / MLDe/i total; (iii) Percentage of emphysema according to voxel thresholding at -950 HU (PVOX-950), total; (iv) PVOX-950 for the section to be excised; (v) Iodine concentration [I] of the section to be excised / [I] total."
45838614|NCT04379934|Dietary Supplement|3-hydroxybuturate|3-hydroxybuturate will be administered directly as a modified Krebs Henseleit buffer in a super perfused atrial strips model
46111344|NCT00826930|Drug|Trans Sodium Crocetinate (TSC)|Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.
46111345|NCT00913796|Drug|Potassium citrate|2.41 gram of citrate b.i.d. for 12 months. Dosage to be adjusted according to serum potassium concentration.
46111346|NCT00913796|Drug|Potassium chloride|370 mg potassium t.i.d. for 12 months. Dosage to be adjusted according to serum postassium concentration.
46111347|NCT00822406|Drug|homeopathic medicine|individualized homeopathic medicine
46111348|NCT00822406|Drug|placebo|placebo - 6 months
46111349|NCT02550574|Procedure|Wound Closure with 2-octylcyanoacrylate|
45838615|NCT04379856|Drug|NM-002|NM-002 is a fusion protein, of which the pharmacological active portion is the glucagon-like peptide-1 (GLP-1) analog domain with the same amino acid sequence as the active pharmaceutical ingredient (exenatide)
45838616|NCT04379778|Other|Aerobic exercise|Progressive moderate to high intensity aerobic exercise.
45838617|NCT04379388|Behavioral|Web + text smoking cessation intervention|Participants will receive referral to a quit smoking hotline and 12-week web and text-based smoking cessation intervention
45838618|NCT04379310|Drug|ACE Inhibitors and Calcium Channel Blockers|effect of drugs on patients with covid-19 pneumonia
46111350|NCT02550574|Procedure|Wound Closure with 5-0 Vicryl Sutures|
45838619|NCT04378998|Other|Acupuncture|The intervention group received usual care plus acupuncture for three days. The acupuncture spots: Pericardium-6, Stomach-36, Liver-3 and Yin Tang were used. The control group received usual care.
46024686|NCT02797483|Other|Test Fat Green|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Green which incorporated into daily snacks (~50g of test fats, 2 experimental cupcakes (~15g test fat each) for breakfast and 4 pieces experimental cookies (~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
46111351|NCT04723784|Other|Initial Assessment|In this phase the evaluation of the participants will be done, with the application of the instrument presented in outcome measures' section. According to the age of the person, specific questionnaires will be used to gather information more concrete about the skills for mobility. This assessment will allow determining the specific needs, demands and capabilities of participants. The assessment process will be done by professionals of research groups in rooms of collaborators centers.
46111352|NCT04723784|Other|Implementation of assistive technology in the daily life of participants|The professionals of collaborator centers, supported by the research groups, will carry on the training in the use of AT by the participants, facilitating its incorporation during the performance of activities of daily living.
46111353|NCT04723784|Other|Application of outcome measures|After the process of implementation of AT (the next 2 and 6 months), members of the research group and the professionals of collaborators centers will apply the measurement instruments to determine the possible improvements in the level of functional independence (FIM scale) of people with disabilities, the impact that the AT has had on their lifes (PIADS scale) and the level of matching between person and AT (ATD PA - MPT model).
45838620|NCT04378686|Other|dialysis|treatment with dialysis. This can be hemodialysis, hemodiafiltration, peritoneal dialysis
46111354|NCT02550340|Other|acute alcohol intake|Smart phone based ECG recording
45469654|NCT03885765|Procedure|Lung resection|Surgical resection will be characterised by type (pneumonectomy, bi-lobectomy, lobectomy, or lobectomy with anastomosis resection), whether or not lymph node dissection was performed, and whether or not the resection was atypical.
45469655|NCT03424720|Device|PLE and BIS|Investigators attach the PLE and BIS sensors on the forehead of the patients undergoing facial nerve integrity monitoring during general anesthesia using total intravenous anesthetics
45469656|NCT03413098|Device|Nasal CPAP mask|Investigative Nasal Mask to be used for OSA therapy
45681649|NCT04415450|Behavioral|Nutrition Education counseling|In the context of health education program, an educational intervention was developed by the research team based on a training module. The nutrition education contained introductory messages and focused on meanings of healthy diet, eating a variety of food, eating well with the locally available food, hazards of maternal malnutrition, important supplements to be taken during pregnancy, harmful substances to be avoided, and measures of alleviating common discomforts associated with nutrition during pregnancy. The training program was carried out in the form of counseling using printed materials and flip charts for pictorial representation. Self-reading of leaflets containing the core messages for every topic prepared in the native language of the participants was also employed as the women in the study had one each.
45838621|NCT04378608|Drug|OBV/PTV/r) ± ribavirin (RBV)|
45838622|NCT04378452|Behavioral|COM-COVID anonimous survey|Anonimous e-survey administered to the general population by sharing it through social and mass media, including questions on sociodemographic data, physical symptoms in the past 14 days compatible with SARS-CoV-2 infection, socio-economic impact of the COVID-19 outbreak and psychological impact of the COVID-19 outbreak and mental health status.
45469657|NCT03720561|Drug|Ibrutinib|Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 3 years.
45469658|NCT03419650|Drug|ACTHar|Acthar™ 80 units twice a week for 4 weeks followed by 40 units twice a week until week 12.
46024687|NCT02797483|Other|Test Fat Red|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Red which incorporated into daily snacks (~50g of test fats, 2 experimental cupcakes (~15g test fat each) for breakfast and 4 pieces experimental cookies (~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
46024688|NCT02791087|Other|Computed Tomography Angiography|The CTA is non-invasive and is used commonly for patients who have chest pain to assess the coronary artery disease, prior to the more invasive coronary angiogram.
46024689|NCT02791087|Other|Intra-operative graft flow rate measurement|This procedure involves the insertion of a Medistim Ultrasound Transit Time Flow Probe into the graft vessel to measure its flow rate. This technique is commonly used for evaluating graft opening during CABG surgery.
46111355|NCT05123768|Diagnostic Test|NGS|A genetic panel of more than 100 genes, associated with CP spectrum disorders, will be assessed using NGS
46111356|NCT00819442|Procedure|cardiobiopsy|5 samples will be taken from right ventricle by Cordis bioptome
45469659|NCT03424642|Behavioral|Interactive 4D-ultrasound examination|Randomized controlled trial
45469660|NCT04893915|Biological|Cytokine-induced memory-like NK cells|Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core or another FACT-accredited cellular therapy production facility that can manufacture the product per the IND CMC.
45469661|NCT04893915|Drug|Fludarabine|-Lymphodepleting regimen
45469662|NCT04893915|Drug|Cyclophosphamide|-Lymphodepleting regimen
46111357|NCT04704986|Device|PVI using the Arctic Front Cryoballoon (Medtronic)|"Patients randomized to the Arctic Front cryoballoon group will undergo PVI using the Arctic Front Cryoballoon (Medtronic).~At the end of the procedure, an implantable cardiac monitor (Medtronic Reveal LINQ) will be implanted for the purpose of continuous arrhythmia monitoring."
46111358|NCT04704986|Drug|PVI using the PolarX Cryoballoon (Boston Scientific)|"Patients randomized to PolarX cryoballoon group will undergo PVI using the PolarX Cryoballoon (Boston Scientific).~At the end of the procedure, an implantable cardiac monitor (Medtronic Reveal LINQ) will be implanted for the purpose of continuous arrhythmia monitoring."
46111359|NCT00822484|Biological|ILV-095|
46111360|NCT00822484|Other|Placebo|
46111361|NCT02608814|Procedure|Pleural biopsy sampling|6 - 8 pleural biopsy samples will be taken before the insertion of the chest drain. These samples will be sent to microbiology for examination.
45838623|NCT04378218|Behavioral|High Intensity Interval Training (HIIT)|A 16 week, 3 sessions per week HIIT program from the subject's personal wheelchair, positioned near an adjustable table with an arm-ergometer affixed.
46111362|NCT02608814|Other|Ultrasound|
46111363|NCT00633880|Drug|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
46111364|NCT00633880|Drug|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
45681650|NCT03901300|Behavioral|Fundamental Motor Skills App|Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized experimental group.
46024690|NCT05423743|Other|Arm 1: Routine Care|Routine Antibiotic Stewardship Arm - Continuation of antibiotic stewardship activities in accordance with national standards.
46024691|NCT05423743|Other|Arm 2: INSPIRE Stewardship Bundle for Abdominal Infection|Quality improvement intervention that includes (1) computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimates for having an abdominal infection due to a multidrug-resistant organism (MDRO) and recommends standard spectrum antibiotics for low risk patients in the first 3 days of hospitalization; (2) clinician feedback reports, and (3) activities to support CPOE adoption (including education and alignment of CPOE workflows). Other antibiotic stewardship activities to continue in accordance with national standards.
46024692|NCT05422573|Behavioral|post-test cardiovascular genetic counseling with pre-test education by video|post-test cardiovascular genetic counseling with pre-test education by video
46111365|NCT04029428|Drug|90Y-DOTATATE|Total activity of 90Y DOTATATE, 4x3.7GBq (14.8 GBq). Single session of i.v. infusion of 90Y DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
46111366|NCT04029428|Drug|(177Lu-DOTAOTyr3)Octreotate|Total activity of 177Lu DOTATATE, 4x5.55GBq (22.2 GBq). Single session of i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
46111367|NCT04029428|Drug|90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)|Total activity of 90Y DOTATATE and 177Lu DOTATATE, 4x3.7GBq (14.8 GBq 50% each 90Y and 177Lu). Single session of i.v. infusion of 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
46111368|NCT02608424|Device|Foot Mechanical Stimulation (Gondola®, CE marking n° 0476)|The feet mechanical stimulation will be performed by Gondola (Gondola®, CE marking n° 0476).
46111369|NCT00819520|Drug|ivermectin|Two single doses of oral ivermectin 400 mcg/kg (Days 1 and 8) plus 2 single applications of placebo lotion
46111370|NCT00819520|Drug|malathion|Two single applications of malathion 0.5% lotion (Days 1 and 8) plus 2 single doses of placebo tablets
45681651|NCT03901300|Behavioral|Unstructured Physical Activity App|Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized active comparator group.
45681652|NCT03588676|Other|Melatonin|5mg Melatonin
45681653|NCT03588676|Other|Placebo|5mg Placebo capsule
45681654|NCT03467542|Device|PHIL® Liquid Embolic System|The PHIL Embolic System is indicated in the treatment of dural arteriovenous fistulas (DAVF)
45681655|NCT01846442|Drug|Placebo|Placebo vaginal suppository containing 0.0% (0 mg) DHEA; daily dosing with one suppository for 12 weeks.
45681656|NCT01846442|Drug|DHEA (0.25%)|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
45681657|NCT01846442|Drug|DHEA (0.5%)|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
46024693|NCT05422573|Behavioral|required phone call with genetic counselor pre-test|REQUIRED phone call with genetic counselor pre-test.
46024694|NCT05422573|Behavioral|optional phone call with genetic counselor pre-test|OPTIONAL phone call with genetic counselor pre-test
46024695|NCT02797015|Drug|RPC1063|Oral capsule daily
46024696|NCT02791009|Other|Cardiovascular Magnetic Resonance Imaging (CMRI)|CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
46024697|NCT02791009|Other|Electrocardiogram (ECG)|ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
46024698|NCT02791009|Other|Blood Sample Collection|Blood will be drawn for circulating biomarkers, which are measurable indicators of the severity or presence of the heart failure condition.
46024699|NCT02791009|Other|Clinical Assessment|Check health status, blood pressure, heart rate, height and weight measured. In addition, subject will undergo a heart examination.
46024700|NCT02791009|Other|Cardiovascular Ultrasound (CVUS)|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help the investigators understand the type and severity of heart failure.
46024701|NCT02791009|Other|Cognitive Test|To relate the presence and severity of cognitive impairment (CI) with simultaneously acquired advanced cardiovascular imaging characteristics and circulating biomarkers of cardiovascular function, inflammation and coagulation.
46024702|NCT03700567|Other|low temperature contrast|UAP patients undergoing PCI were performed with low temperature contrast. The investigators used thermal insulation equipment to keep contrast at 5℃. The EKG and blood pressure were monitored during the PCI procedure. After PCI, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
45838624|NCT04378062|Procedure|Digital nerve procedure|The type of procedure performed on the digital nerve at the time of amputation
46024703|NCT02790775|Drug|Anti-VEGF in quadrant 1|
46111371|NCT00590564|Drug|Sho-saiko-to|All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal. Patients will be seen for clinical follow-up at three month intervals: at 3, 6, 9, and 12 months, and assessed for compliance and asked about side effects and pulmonary symptoms. At each clinic visit, a comprehensive metabolic profile will be performed. At the 6-month clinic visit, a CBC will be performed. At the 12-month clinic visit, quantitative HCV-RNA by PCR will be obtained (Viromed Labs, Inc., 6101 Blue Circle Drive, Minneapolis, MN 5534). Within 4 weeks after the 12-month clinic visit (after 52 weeks of SST therapy), the second liver biopsy will be scheduled and performed.
46111372|NCT00827164|Behavioral|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
46111373|NCT00827164|Behavioral|Resistance Training|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
45838625|NCT04377906|Behavioral|Modification Lifesyle|high protein-fiber and exercise
45838626|NCT04377828|Device|Pigment laser|one to two session of pigment laser (532 nm)
45838627|NCT04377750|Drug|Tocilizumab|The placebo treatment arm will include 100 ml of normal saline administered along 60 min
45469663|NCT04893915|Procedure|Donor Leukapheresis|-Apheresis will be performed via peripheral IVs or central line, as determined by the apheresis team.
45838628|NCT04377516|Other|pelvic floor muscle training|pelvic floor muscle training
45838629|NCT04377516|Other|pelvic floor muscle combined global muscle exercise training|pelvic floor muscle combined global muscle exercise training
45838630|NCT04377516|Other|education of pelvic girdle|education of pelvic girdle
45838631|NCT04377282|Other|Food-1|Cooked buckwheat
45838632|NCT04377282|Other|Food-2|Cooked couscous
46024704|NCT02790775|Drug|Anti-VEGF in quadrant 2|
46024705|NCT02790775|Drug|Anti-VEGF in quadrant 3|
46024706|NCT02790775|Drug|Anti-VEGF in quadrant 4|
46024707|NCT04010695|Diagnostic Test|SD Biosensor G6PD Analyzer|The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.
46111374|NCT05755178|Behavioral|Music, feelings and relationships - music group for children at shelters|"A music group intervention, offered to children 3-10 years who live or have lived at a shelter.~6 group sessions with musicians and music therapist and a group of 4-8 children.~Focus on improving recognition and regulation of emotions, and on relational capacity with adults and peers."
46024708|NCT04010695|Diagnostic Test|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
46111375|NCT05755100|Behavioral|I MOVE!+UP|An individual psychotherapy that integrates behavioral weight management with evidence-based psychotherapy for PTSD (Cognitive Processing Therapy) for up to 6 months, augmented with evidence-based psychiatric and weight management medication management.
46111376|NCT04029740|Behavioral|CBT- both internet and face to face|There are a few common psychotherapies for treating PD, with Cognitive Behavioral Therapy (CBT) as the most common. The most known type of CBT for treating PD consists of two major strategies: cognitive restructuring, and interoceptive and structured exposure to bodily sensations that have become associated with panic attacks (D H Barlow, 1997). The ICBT therapy is based on Barlow and Craske's (2007) protocol for treating PD with elaborations (Huppert & Baker-Morissette, 2003). It includes six modules containing psychoeducation, cognitive restructuring, exposures, acceptance, and consolidation of gains and relapse prevention. The online modules include reading passages, worksheets, videos, and homework assignments. After completing each module, participants practice related skills and complete homework assignments. The treatment is up to 16 weeks long; participants are encouraged to complete the treatment within this time period, and reminders are sent to monitor their progress.
46111377|NCT04029740|Other|No intervention|Healthy controls will not receive any intervention.
46111378|NCT00631696|Drug|Pregabalin|pregabalin 600 mg given twice a day
46024709|NCT04010695|Diagnostic Test|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
46111379|NCT00631696|Drug|Placebo|Placebo
46111380|NCT05752994|Other|Training in the multisensory room environment|The children will start with the swing follow with the scheduled activities and tabletop activity. The session will end in the relaxation room such as bubble tube, fiberoptic cascade, fiberoptic carpet and aurora projector bundle while the therapist has the interactive communication with children
46111381|NCT05752994|Other|Home program|Home program
46024710|NCT02790931|Other|Intervention Group|Patients will receive a physical therapy intervention in groups twice/wk, and using a software twice/ wk for 3 months, for foot and ankle strengthening, stretching and functional training. They must continue to exercise at home twice a week with the software supervision for one year.
46111382|NCT04021628|Other|No intervention- not applicable|No intervention - not applicable
46111383|NCT04021004|Other|Survey Questionnaire|Survey Questionnaire
46111384|NCT04430140|Device|CT Scan|"CT Scan~Number of research exams: 1 Effective Dose (mSv) for 1 exam: 0.6 Total Effective Dose (mSv)*: 0.6"
46111385|NCT05326100|Other|Conventional Therapy (CPT)|The exercises may include traditional vestibulo-ocular reflex (VOR) exercises, cervical musculoskeletal exercises, somatosensory exercises, habituation, gait exercises, and aerobic conditioning. The treating PT will modify specific exercises as appropriate based on the participant's symptoms.
46111386|NCT05326100|Device|CAREN Therapy|The CAREN, an FDA-registered exempted Class I device, is a VR-based system which includes a six degree-of-freedom motion platform with an embedded, instrumented treadmill surrounded by an immersive 180-degree screen. The CAREN can display a variety of virtual environments (VEs), where the difficulty level and task requirements can be easily modified by the treating clinician to target patient-specific needs.
46111387|NCT05326100|Device|Augmented Reality (AR) Therapy|AR head-mounted displays are designed to provide immersive virtual environments similar to the CAREN, but with the portability to be used in most outpatient clinical settings and potentially for at-home therapy as well as significantly reduced cost compared to the CAREN. AR devices have integrated eye-tracking and inertial measurement units (IMUs) which can be used to objectively quantify characteristics of eye, head and body movement.
46111388|NCT00822562|Other|PRFA or PMCT|PRFA or PMCT 30-35W for 10-15minutes one cycle,three cycles
45838633|NCT04377282|Other|Food-3|Water
46024711|NCT02796859|Drug|Siltuximab|Investigational agent
46024712|NCT02796859|Drug|normal saline|Placebo
46024713|NCT02790697|Other|Indirect calorimetry|Indirect calorimetry will be conducted using the new calorimeter and mixing chamber method using the mass spectrometer.
46024714|NCT02790385|Device|Negative Pressure Wound Therapy|
46024715|NCT02790385|Other|Standard Gauze Treatment|
46024716|NCT03803761|Drug|Copanlisib|Given IV
46024717|NCT03803761|Drug|Fulvestrant|Given IM
46024718|NCT02788435|Behavioral|Absolute Voice Rest|Patients will be instructed to not use their voice and minimize any voice-use activities such as coughing or throat-clearing for a period of 7 days following surgery.
46111389|NCT00822562|Procedure|surgery|only surgery
46111390|NCT05749172|Other|Strength group|4 sets of strength training exercises with 10 repetitions determined from ACSM two days a week, with a minimum of 72 hours between these days. In this exercise protocol, the movements of back squat, seated leg extension, seated leg curls, machine hip adductions, machine hip abductions, standing calf raises, back lat pulldowns, seated rows, bench press, incline bench press, biceps curls, triceps pushdowns, back press, back extension, pushup, pullup, squats and sit-ups will be performed.
46111391|NCT05749172|Other|Controlled group|Two hours of parkour training for two days a week.
46111392|NCT00631540|Device|Formula Balloon-Expandable Stent|renal artery stenting
46111393|NCT02608112|Drug|Methotrexate|Administered as per investigator's discretion. Investigator could also suggest any other csDMARDs instead of methotrexate.
46111394|NCT02608112|Drug|Tocilizumab|Tocilizumab treatment will be administered SC at the discretion of the investigator in accordance with local clinical practice and local labelling.
46111395|NCT00630916|Device|Mitroflow Aortic Heart Valve|Replacement of the native aortic valve or a previously implanted prosthetic aortic valve
46111396|NCT04375384|Drug|Cetuximab|"A loading dose of Cetuximab will be administered intravenously in the first day of treatment. The dose is 400 mg/m2 and will be infused over 2h followed by 1h observation.~The maintenance dose of Cetuximab is 250 mg/m2 and will be infused over 1h. No further observation time needed.~The maintenance dose of cetuximab will be given every 7 days (+/- 2 days) starting 7 days (+/- 2 days) after the loading dose of cetuximab.~Pre-medicate with 50 mg Diphenhydramine IV before the loading dose of Cetuximab and as per standard of care before the maintenance treatment."
46111397|NCT04375384|Other|Questionnaire administration|Ancillary studies
46111398|NCT04375384|Other|Quality of life assessment|Ancillary studies
46111399|NCT02549326|Dietary Supplement|vitamin D|
46111400|NCT02549326|Dietary Supplement|Placebo|
46111401|NCT02549404|Drug|KHK7580|Oral administration
46111402|NCT00819598|Procedure|BLOOD PRESSURE MEASURMENT|Blood pressures using Doppler and oscillometric methods will be obtained at each limb and on one toe from each foot.
46111403|NCT00819598|Procedure|BLOOD PRESSURE MEASUREMENT|Blood pressure measurements will be taken at each limb (arm and ankle) with Doppler and oscillometric based methods.
46024719|NCT04233151|Drug|QL1203|6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
46024720|NCT04233151|Drug|Placebo|6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
46024721|NCT04233151|Drug|mFOLFOX6 regimen|The mFOLFOX6 regimen is consist of oxaliplatin 85 mg/m^2 intravenous (IV) infusion on Day 1;leucovorin, 200 mg/m^2 on Days 1 and 5-fluorouracil 400 mg/m^2 IV bolus on day 1, then 1200 mg/m^2/dx2days(total 2400 mg/m^2 over 46-48 hours) IV continuous infusion. Each cycle was 14 days.
46024722|NCT04233541|Diagnostic Test|Fall assessment|Through a comprehensive geriatric assessment carried out by our geriatrician led multidisciplinary team we gather information about fall recalls consistent with the definition of landing on the floor or ground.
46024723|NCT02796703|Dietary Supplement|Heat Inactivated probiotics|Biotikid, a probiotic mixture, will be heated to 100 degrees Centigrade for 10 minutes to inactivate and then 1 tsp will be diluted in milk and give with feeds to treatment group
46111404|NCT02549248|Other|BAL|Patients with idiopathic and non idiopathic interstitial lung diseases
46111405|NCT02549248|Other|BW|Patients with idiopathic and non idiopathic interstitial lung diseases
46111406|NCT02549248|Other|EAC|Patients with idiopathic and non idiopathic interstitial lung diseases
46111407|NCT02549248|Other|blood specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
46024724|NCT02796703|Dietary Supplement|Placebo|2 cc of milk will be given to control group
46024725|NCT02796547|Drug|Levobupivacaine|Infiltration of the banks of the episiotomy done with Levobupivacaine
46024726|NCT02796547|Other|Physiological serum|Infiltration of the banks of the episiotomy done with physiological serum
46111408|NCT02549248|Other|Urine specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
46111409|NCT00630292|Other|Magnetic Resonance Angiography (MRA) of the Breast|Magnetic Resonance Angiography (MRA) of the breast will be performed before or after pre-treatment magnetic resonance imaging (MRI) and then once again before or after the post-treatment MRI.
46111410|NCT00822640|Device|Total Knee Arthroplasty|All patients receive the same posterior cruciate retaining implant but the tibial tray and bearing (B. Braun Aesculap Columbus CR and RP) by two experienced surgeons and will follow an identical rehabilitation regime.
46111411|NCT00819676|Other|analysis of exhaled breath by biosensors|
46111412|NCT00819676|Other|measurement of exhaled nitric oxide|
46111413|NCT00827320|Drug|Levetiracetam|1000 mg tablet
46111414|NCT00827398|Biological|MSC (hPPL)|Treatment with MSCs (hPPL) is indicated as soon as steroid refractory acute GVHD is diagnosed
46024727|NCT01196988|Biological|Influenza vaccine GSK2321138A|intramuscular injections
46024728|NCT01196988|Biological|FluarixTM|intramuscular injections
46024729|NCT01196988|Biological|Influenza vaccine GSK2604409A|intramuscular injections
46024730|NCT02790541|Device|Hyperbaric Oxygen Therapy|60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 3 months.
46024731|NCT02796469|Drug|Pentoxifylline|
46024732|NCT02796469|Drug|Corticosteroid|
46024733|NCT02796469|Drug|Placebo|
46111415|NCT00626548|Drug|ZD4054|10 mg once daily oral dose
46111416|NCT00626548|Drug|Palcebo|Matching Plcebo oral tablet once daily
46111417|NCT00819754|Drug|IXO regimen + bevacizumab|"Phase I study - identifies the safety of IXO with bevacizumab and recommended phase II dose~Phase II study - assesses efficacy and safety of IXO with bevacizumab"
46024734|NCT02796157|Device|PCI with Absorb everolimus-eluting bioresorbable vascular scaffold|Patients allocated to this arm will undergone PCI with Absorb everolimus-eluting bioresorbable vascular scaffold. It will be allowed to used multiple stents for a long coronary lesion.
46111418|NCT00827476|Procedure|ovarian transplantation|ovarian xenotransplantation or in vitro culture
46024735|NCT02796157|Device|PCI with Xience everolimus-eluting metallic stent|Patients allocated to this arm will undergone PCI with Xience everolimus-eluting metallic stent. It will be allowed to used multiple stents for a long coronary lesion.
46024736|NCT03328741|Behavioral|Online Osteoarthritis treatment|6 week online-program
46024737|NCT03328741|Behavioral|Face-to-face osteoarthritis treatment|3 months face-to-face program
46024738|NCT02786797|Behavioral|MBSR(BC) 6 Week Program|The MBSR(BC) is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. It incorporates simple yoga, sitting meditation, body scan, and walking meditation in this program. Classes for this intervention occur on a weekly basis for 2 hours for 6 weeks. The participants will be asked to record their informal/formal practices in a daily diary during the program and from 6 weeks to 6 months after the intervention.
46024739|NCT02786797|Behavioral|BCES 6 Week Program|"The BCES is an education support program. This 6-week program is based on the published NIH program, Support for People with Cancer: Taking Time Education Support Group. In addition the class sessions consist of group discussion of educational materials and homework assignments; and group processes related to sharing supportive care situations. The participants will record their feelings, coping mechanisms, and questions related to survivorship in a daily diary during the program and from 6 weeks to 6 months after the intervention."
46024740|NCT04200001|Other|Quality of life|"The patient will receive the following questionnaires to be completed :~EORTC QLQ-C30~EORTC QLQ-BR23~EORTC SHQ-C22~CUPIDON 2 specific questionnaire"
46024741|NCT01196052|Drug|Trastuzumab emtansine|Trastuzumab emtansine was provided as a single-use lyophilized formulation in a glass vial.
46024742|NCT02689921|Drug|Exemestane|Aromatase inhibitor
46024743|NCT02689921|Drug|Letrozole|Aromatase inhibitor
46111419|NCT00819988|Drug|Pregabalin|Pregabalin capsule 75 mg given preoperatively, then eith 50 mg or 25 mg given every 8 hours for 3 days postoperatively based on renal function
46111420|NCT00819988|Other|Sugar pill|Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
46111421|NCT02549482|Other|Respiratory resistor|The volunteers are breathing through the four respiratory resistors (inspiratory, expiratory, combined in- and expiratory and no resistor) in order to increase the intrathoracic pressure svings
46111422|NCT00827554|Drug|LMWH|Nadroparin Ca 4100 AXa iu twice daily lasted for 6 weeks
46111423|NCT00827554|Procedure|TACE|transarterial chemoembolization with lipiodol 1-1.5ml/cm tumor diametres，pharmorubicin 20mg，5-Fu 1g and Carboplatin 150mg。
46111424|NCT00822796|Device|Thermogard™|Those who have a Thermogard™ central venous warming catheter placed prior to surgery
46111425|NCT00822796|Device|Standard central venous catheter|Those who have a standard central venous catheter placed prior to surgery
46111426|NCT00822874|Procedure|prematuration culture|"The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos."
46024744|NCT02689921|Drug|Anastrozole|Aromatase inhibitor
46024745|NCT02689921|Drug|Leuprolide Acetate|Luteinizing Hormone-Releasing Hormone agonist
46024746|NCT02689921|Drug|Pertuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
46024747|NCT02689921|Drug|Trastuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
46111427|NCT00847379|Drug|Ataluren|Ataluren oral powder for suspension will be administered as per dose and schedule specified in the arm.
46111428|NCT02549560|Device|tDCS|Application of two daily sessions of cerebral stimulation starting from the first day after de surgery, for 4 consecutive days, with each session having 20 minutes, having an 8 hour minimum break between them. Will be applied a direct current stimulus of 2 milliampere (mA) (right anode/left cathode) in the prefrontal right region.
46111429|NCT00820144|Biological|CTB by nasal way|
46111430|NCT00820144|Biological|absorption of CTB by oral way|absorption of CTB by oral way
46111431|NCT00820144|Biological|absorption of dukoral by oral way|absorption of dukoral by oral way
46111432|NCT00820144|Biological|absorption of CTB by sublingual way|absorption of CTB by sublingual way
46111433|NCT00820144|Biological|absorption of CTB by sublingual way|absorption of CTB by sublingual way
46111434|NCT00827710|Behavioral|point of care patient report cards|gives patient feedback on performance on glycemic, lipid, and blood pressure control relative to expert recommended goals
46111435|NCT00827710|Behavioral|Provider performance report card|Gives provider feedback on performance on their diabetes panel of patients and includes patient level data
46111436|NCT00624520|Behavioral|Cognitive Behavioral Stress Management (CBSM)|10 week program of weekly CBSM therapy group sessions
46111437|NCT00624520|Other|Patient Education|"10 week program of Patient Education group sessions, involving presentations of educational materials relating to heart disease."
46111438|NCT04118075|Drug|PT-CY-FK +/-ATG|GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
45681658|NCT01846442|Drug|DHEA (1.0%)|Vaginal suppository containing 1.0% (13 mg) DHEA; daily dosing with one suppository for 12 weeks.
46111439|NCT00698711|Biological|MUC-2-KLH|"The MUC-2-KLH conjugate will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4 week break and then a fourth vaccination during week 7, and 3 months later during week 19. Booster vaccinations may be given at or after week 50 and 100, and every 6 months thereafter to select patients who show no evidence of radiographic disease progression.~After 5 patients have been enrolled and completed two vaccinations without Grade II or greater toxicity, we will proceed to the next higher dose level. No dose escalations will be performed in the same patient."
46111440|NCT04122209|Other|HIIE-First|Multiple exercise bout during the same day; HIIE first followed by continuous exercise
45681659|NCT03586570|Drug|Aprocitentan 25mg|Oral tablets in strength of 25 mg
45681660|NCT03586570|Drug|Placebo|Oral tablets matching aprocitentan tablets
46024748|NCT03116425|Device|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
46024749|NCT03116425|Device|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
46024750|NCT03116425|Device|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
46111441|NCT04122209|Other|Continuous-First|Multiple exercise bout during the same day; Continuous exercise first followed by HIIE
46111442|NCT00847145|Biological|1a - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and routine vaccine at study month 12.
46111443|NCT00847145|Biological|1b - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine at study month 12 and routine vaccine at study month 13.
46111444|NCT00847145|Biological|2a - Routine and rMenB+OMV NZ vaccines|One dose of routine vaccine at study month 12 and two doses of rMenB vaccine at study months 13 and 15.
46111445|NCT00847145|Biological|2b - rMenB+OMV NZ and routine vaccines|Two doses of rMenB vaccine at study months 12 and 14 and one dose of routine vaccine at study month 12.
46111446|NCT00847145|Biological|3a - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
45681661|NCT03588598|Drug|SHC014748M|a selective PI3Kδ inhibitor
45681662|NCT03588364|Other|Osteopathic Manipulation|Osteopathic manipulation involves a number of different manual techniques. These include muscle inhibition; myofascial release; muscle energy stretch; counterstrain; facilitated positional release ; osteopathy in the cranial field ; balanced ligamentous tension/ligamentous articular strain; one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
45681663|NCT03584932|Behavioral|LINK2 Youth Services Navigation Intervention|There will be 6 in-person sessions delivered by a youth services navigator, plus weekly check-in calls after session 2 for a total of six months. As part of the learning sessions, the participant will learn important information about HIV and how to get the most out of his/her HIV care.
46111447|NCT00847145|Biological|3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations|One dose of rMenB vaccine at study month 12 and one dose of routine vaccine study month 13.
46111448|NCT00847145|Biological|4a- rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
46024751|NCT03116425|Procedure|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
46111449|NCT00847145|Biological|4b - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
46024752|NCT03116425|Procedure|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
46111450|NCT00701597|Drug|bosentan|Bosentan (Tracleer 125mg Tabletts), peroral, dose: 500mg for 8 days
46111451|NCT00700193|Biological|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.25mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
46111452|NCT00700193|Biological|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.50mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
46111453|NCT04117529|Other|Blood sample|Collection of 2 blood sample : The first one at the inclusion in the study, the second one between 6 months and 9 months after the inclusion. The sample consists of 2 tubes of EthyleneDiamineTetraAcetic (EDTA) of 7 mL.
46111454|NCT02612987|Behavioral|Internet-based Cognitive Behaviour Therapy (iCBT)|
46111455|NCT02612831|Procedure|Early bariatric surgery|
46111456|NCT02612831|Procedure|Delayed bariatric surgery|
46111457|NCT00846521|Drug|Acarbose|At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
46111458|NCT00698945|Drug|Istalol and Optive|Istalol: one drop a day for 28 days Optive: one drop a day for 28 days
46111459|NCT00698945|Drug|Alphagan|Alphagan: two drops a day for 28 days
46111460|NCT00862823|Drug|tenofovir, emtricitabine and efavirenz fixed dose tablet|Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
45681664|NCT03588208|Other|Progressive resistance training program|Progressive resistance training program were performed twice a week for 12 weeks. The charge intensity was progressively increased from 40% to 80% of 1 repetition maximum. The following muscle groups were worked: trunk flexors and extensors, elbow flexors and extensors, knee flexors and extensors, hip abductors and adductors and shoulder abductors. In addition to strength training.
46111461|NCT00862823|Drug|tenofovir, emtricitabine and efavirenz tablet added to solution|Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
46111462|NCT00790842|Drug|Lenalidomide|Given by mouth days 1-21 of a 28-day cycle. There is a 7 day rest (days 22-28). Continue until disease progression or unacceptable toxicity.
46111463|NCT00790842|Drug|Dexamethasone|40 mg given by mouth days 1, 8, 15 and 22 of a 28-day cycle. Continue until disease progression or unacceptable toxicity.
46111464|NCT00790842|Drug|Anticoagulants|Anticoagulation consisted of aspirin at either 81 mg/day or 325 mg/day at the physician's discretion. Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.
46111465|NCT04107012|Device|Orthodontic treatment with clear aligner|Included orthodontic treatment with clear aligner (eon Aligners)
46111466|NCT04104204|Drug|Intrathecal morphine|0.5% Iso/Hyperbaric bupivacaine 2-3 ml add morphine 0.1 mg for spinal anesthesia
46111467|NCT04104204|Drug|Ultrasound guided supra-inguinal fascia iliaca block|Ultrasound guided supra-inguinal fascia iliaca block with 0.25% bupivacaine 40 ml and 0.5% Iso/Hyperbaric bupivacaine 2-3 ml without spinal morphine for spinal anesthesia
45681665|NCT03588208|Other|Educational Program|Structured education program were performed during one hour class once a week for five weeks
46024753|NCT03116425|Procedure|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
46024754|NCT02887638|Other|Individual Profile Analysis (Physical therapy Intervention)|"The Individual Profile Analysis consists of the following components:~Analysis of the sitting-posture profile:~o cervical spine, thoracic spine, lumbar spine and pelvis during a longitudinal provoking task (working at a laptop).~Analysis of the dural profile before and after the provoking task:~o Determination of the dural sensitivity by the use of the slump-test~Analysis of the pain profile before and after the provoking task:~Determination of pressure pain sensitivity by the use of pressure algometry~Determination of the influence of pain on the quality of life by the use of the HIT-6 questionnaire"
46024755|NCT02786485|Biological|rivogenlecleucel|T cells transduced with iCasp safety switch
46111468|NCT04107324|Procedure|ARAPS|In a previous experimental study on rats, the investigators have shown that PVE combined with radiofrequency ablation (RFA), hereafter called Associated Radiofrequency Ablation and Portal Vein Ligation for Staged Hepatectomy (ARAPS), can induce accelerated growth of the FLR
46111469|NCT04107324|Procedure|PVE|Portal vein embolisation
46111470|NCT05572476|Drug|Association of lurbinectedin and durvalumab|"A treatment cycles consists of 3 weeks (i.e. 21 days). Lurbinectedin will be administered by intravenous infusion on Day 1 every 3 weeks.~Durvalumab will be administered by intravenous infusion on Day 1 every 3 weeks."
46111471|NCT05572476|Drug|Association of carboplatin and etoposide|"Treatment will be administered on a 21-days cycle basis up to a maximum of 6 cycles.~Carboplatin will be administered by intravenous infusion on Day 1 every 3 weeks.~Etoposide will be administered by intravenous infusion on Day 1-3 every 3 weeks"
46024756|NCT02786485|Drug|Rimiducid|administered to treat GVHD
46024757|NCT04198753|Diagnostic Test|Skin tape stripping|Adhesive skin sampling discs will be firmly pressed against the skin in a hairless location (not the face) followed by lifting it free of the skin. Tape stripping will be collected from non-lesional skin up to 30 times. These discs will then be used to evaluate proteins and lipids. With every 5 tape strips collected, transepidermal water loss measurements will be performed.
46111472|NCT00915486|Procedure|Good Standard of Care (GSoC)|Procedural treatment twice per week
46111473|NCT00915486|Biological|Vehicle|Topical fibrin as an adjunct to GSoC twice per week
46111474|NCT00915486|Biological|I-020201|Topical treatment with 3 different concentrations as an adjunct to GSoC twice per week
46111475|NCT05533866|Combination Product|APR-TD011|APR-TD011 wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician. Based on its product profile, APR-TD011 has been granted an FDA Orphan Drug Designation for epidermolysis bullosa.
46024758|NCT04198753|Device|Skin barrier assessment|A small device will be used to measure transepidermal water loss (TEWL), which is the quantity of water that passes from inside the body through the skin to the surrounding atmosphere via diffusion and evaporation process. The device, a probe, is simply placed against the skin surface making superficial contact and kept there for a few seconds until the measurement terminates. This will be performed at baseline and after every 5 tape strips.
46024759|NCT04198753|Diagnostic Test|Blood draw|Subjects will undergo genetic testing of FLG mutation status (5mL of whole blood in lavender top tube) and vitamin D level (2mL of whole blood in red top tube) via blood draw.
46111476|NCT02602392|Behavioral|Lungtropolis|A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents
46111477|NCT02602392|Behavioral|Asthma educational booklet|Text-based asthma education booklet for parents and children in PDF format
46024760|NCT01195662|Drug|Dapagliflozin|Tablets, Oral, 10 mg, once daily, Up to 12 weeks
46024761|NCT01195662|Drug|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, Up to 12 weeks
46024762|NCT02786407|Drug|Botulinum Toxin Type A for Injection|In these studies,patients received a minimum intramuscular(IM) dose of 100U of Botulinum Toxin Type A administered to 20 injection sites
46024763|NCT02786407|Drug|Placebo|In these studies,patients received placebo administered to 20 injection sites
46024764|NCT03028519|Drug|Vitamin D3|Vitamin D3
46024765|NCT02786641|Drug|Docetaxel|Docetaxel 65mg/m2 in induction chemotherapy
46024766|NCT02786641|Drug|Cisplatin 1|Cisplatin 75mg/m2 in induction chemotherapy
45681668|NCT01709721|Drug|Hydromorphone Hydrochloride|Opioid for chronic pain
46111478|NCT00574288|Drug|Part 1: Daratumumab|First participant will receive intravenous (injection of a substance into a vein) 0.005 milligram per kilogram (mg/kg) (planned dose) infusion of daratumumab and other participants will receive different doses. The participants will receive 7 full infusions of daratumumab and 2 predose infusions every 2 weeks. The dose of daratumumab will be escalated sequentially and considering the safety and efficacy of dose in Part 1, dose for Part 2 of the study will be decided. A predose infusion of 10% of the full dose of daratumumab will be administered a day before the first 2 full infusions.
46111479|NCT00574288|Drug|Part 2: Daratumumab|In Part 2, the participants will receive dose of daratumumab as determined in part 1 (16 mg/kg) of the study. Participants will receive 8 full infusions at weekly intervals followed by biweekly (every 2 weeks) infusions for 16 additional weeks and monthly infusions until disease progression or unmanageable toxicity, whichever comes first. Predose was dropped at some point in Part 2. A predose infusion of 10 mg daratumumab will be administered on the day before the first full infusion in select cohorts.
45681669|NCT01709721|Device|Programmable Implantable pump|Programmable Implantable pump delivering intrathecal hydromorphone
46024767|NCT02786641|Drug|Xeloda|Xeloda 2000mg/m2 D1-14 in induction chemotherapy
46024768|NCT02786641|Radiation|IMRT|IMRT for all patients
46024769|NCT02786641|Drug|Cisplatin 2|Cisplatin 100mg/m2 in concurrent chemotherapy
46024770|NCT02787967|Drug|CHF 1535 35/4µg NEXThaler®|4 (four) inhalations (total dose: BDP/FF 140/16 µg)
46024771|NCT02787967|Drug|free comb. beclomethasone DPI and formoterol DPI|2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
46024772|NCT02788123|Drug|bismuth tripotassium dicitrate|oral
46024773|NCT02788123|Drug|pantoprazole|oral
46111480|NCT00574288|Other|Methylprednisolone|"Pre-dose: Participants (part 1) will receive methylprednisolone 80 mg intravenous (IV) injection 30 minutes to 2 hours before treatment. Participants (part 2) will receive 100 mg methylprednisolone IV 60 minutes to 2 hours before treatment; if a patient experiences no significant infusion-related reactions, the dose of methylprednisolone may be decreased to 50 mg after Visit 4.~Post-dose: All participants (part 1) will receive 40 mg methylprednisolone orally on the first and the second day after all full infusions. During Part 2, all participants will receive 20-25 mg methylprednisolone orally or equivalent on the first and second days after all full-dose infusions."
46024774|NCT03631771|Drug|Iohexol|Iohexol administered intravascularly
46111481|NCT00574288|Other|Dexamethasone|Participants (Part 2) will receive 20 mg dexamethasone intravenous (IV) injection pre-dose, on the first and second days after every full-dose infusions.
46111482|NCT02603562|Biological|ATYR1940|ATYR1940 will be administered as an IV infusion at doses of 0.3, 1.0, and 3.0 mg/kg using intrapatient dose escalation. The dose level in this study will not exceed 3.0 mg/kg
45469664|NCT04893915|Drug|Interleukin-2|-IL-2 will start approximately 2-4 hours after the NK cell infusions.
46111483|NCT02603562|Biological|Placebo|An initial IV infusion of placebo will be supplied as normal saline, and administered over a 30-minute period at Week 1.
46111484|NCT05568654|Diagnostic Test|Rapid Diagnostic Testing|Eligible patients in hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT testing. A CDSS-based alert will be generated in real time. If the patient is not being admitted to the intensive care unit, the form will append orders for viral pathogen and UAT testing.
46111485|NCT05568654|Other|Pharmacist-led de-escalation|A CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for greater than 48 hours and generate a list for the antimicrobial stewardship pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. The validated measures of clinical stability in patients with CAP are a) resolved vital sign abnormalities (temperature, heart rate, oxygen saturation, blood pressure and respiratory rate) b) normal mental status and c) ability to eat. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page. The de-escalation recommendations made by the pharmacist will be based on a protocol developed by the research team.
46111486|NCT00827788|Drug|Iodixanol|Iso-osmolar contrast medium (Iodixanol) will be administered during PCI
46111487|NCT00827788|Drug|Iopromide|Low-osmolar contrast medium (Iopromide) will be administered during PCI
46111488|NCT00827866|Other|Counselor-Initiated Tobacco Quit Line|The proposed active intervention will be a the Counselor-Initiated QL which includes provision of 8 weeks of nicotine replacement therapy (NRT) and six scheduled telephone sessions of a behavioral intervention.
46111489|NCT00827866|Other|Self-Paced Tobacco Quit Line|The comparison condition will be the Self-Paced QL with provision of 2 weeks of NRT and encouraged obtainment of additional NRT. If participants in the Self-Paced condition make all six calls, they will receive the same behavioral intervention as in the Counselor-Initiated condition.
46111490|NCT00790452|Drug|Aspirin|325 mg daily by mouth
46111491|NCT00790452|Drug|Placebo|Tablet daily by mouth
46024775|NCT03631771|Drug|Iodixanol|Iodixanol administered intravascularly
46024776|NCT03631771|Drug|Iopromide|Iopromide administered intravascularly
46024777|NCT03631771|Drug|Ioversol|Ioversol administered intravascularly
45469665|NCT03419494|Drug|PLD|PLD36mg/m2.d d1、d15，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
45469666|NCT03419494|Drug|DNR|DNR 45mg/m2.d d1～3，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
45469667|NCT04986189|Diagnostic Test|Low dose CT thorax|A low dose CT scan of the thorax to screen for lung cancer
45469668|NCT03419416|Other|Kangaroo mother care (KMC)|Skin to skin contact of newborns with mothers and exclusive breast feeding
45469669|NCT04985409|Behavioral|Feedback|The system uses Sonifi health (TV content and visualizations) and Fitabase (3rd party server to process Fitbit data and export to Sonifi). The system utilizes the patient's TVs to engage the patient and multidisciplinary team in monitoring ambulation status.
45469670|NCT03413020|Drug|esomeprazole|proton pump inhibitor
46024778|NCT04317768|Behavioral|Basic oral health education and motivation|Subjects will receive verbal oral hygiene instructions using a model to demonstrate only once at the beginning of the study, no further motivation or educational seminars will be done.
46024779|NCT04317768|Behavioral|Intensive oral health education and motivation|Subjects will be educated and motivated by an intensive program consisting of verbal instructions, PowerPoint lectures, posters and live demonstrations about oral hygiene instructions and teaching the proper way to brush the teeth. These will be reinforced by the investigator at intervals of 1 week, 1 month, 3 months, 6 months and 1 year.
46024780|NCT02787889|Other|Uneven Protein intake pattern|Each participant will consume 15%/2-%/65% of total protein in breakfast, lunch, and dinner, respectively)] on net protein synthesis over 8 weeks.
46024781|NCT02787889|Other|Even Protein Intake Pattern|Each participant will consume 33% of total protein consumed each meal
46024782|NCT04232995|Other|Balance Training|Balance enhancing exercises
46111492|NCT00823030|Procedure|Urodynamic study|A small catheter will be inserted into the bladder and water will slowly be instilled through the catheter and into your bladder. A series of measurements will then be taken to assess your bladder's capacity to hold liquid, the average and maximum urine flow rates, as well as bladder filling and leak point pressure readings.
46111493|NCT00823030|Drug|Lidocaine|20 cc of alkalinized lidocaine will be injected after the first UDS
45469671|NCT03413020|Drug|bismuth Potassium Citrate|gastric mucosal protective drug with anti-H. pylori effect
46024783|NCT04232995|Other|General Exercises|General Exercises
46024784|NCT02796235|Other|Venous Doppler ultrasound of the lower limbs|Venous Doppler ultrasound of the lower limbs at 6, 9 and 12 months of the initial injury
46024785|NCT02787733|Dietary Supplement|Citrus flavonoid|Daily dose of 500mg divided over two capsules
46024786|NCT02787733|Dietary Supplement|Placebo|Daily dose of 500mg divided over two capsules
46024787|NCT02787811|Device|Intrauterine insemenation|Semen preparation processing hen intrauterine transfer after 24 hours of HCG triggering of ovulation
46024788|NCT02787577|Behavioral|Sleep Lengthening|Behaviour change techniques targeting sleep hygiene
46024789|NCT01195272|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 52 weeks
46024790|NCT02796079|Biological|mesenchymal stem cells|stem cell acquisition, processing and reinfection, to evaluate the efficacy by using autologous bone marrow stem cell
45681670|NCT03588520|Diagnostic Test|Home Blood Pressure Monitoring|Patients randomly assigned to the HBP-guided management group will perform home BP monitoring for 7 days with the use of a validated self-inflating automatic oscillometric device (HEM 705 CP, Omron Healthcare). Home BP monitoring will be performed according to the currently available European Society of Hypertension guidelines at the baseline visit and will be repeated 1 week before the prespecified follow-up visits (at Month 1, Month 2 and Month 4). Patients randomly assigned to the control group will receive conventional management of hypertension based on office BP recordings obtained with the same BP monitor (HEM 705 CP, Omron Healthcare) during the same prespecified follow-up visits.
46024791|NCT02796079|Biological|saline|saline injections
46024792|NCT01194804|Drug|Eculizumab|Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 days.
46024793|NCT02785627|Other|Comprehensive bone health assessment|Blood sample taken for biomarkers of bone turnover, anthropometric measurements, assessments of physical function, DXA scan, HR CT T12 vertebra, Xtreme pQCT radius
45469672|NCT03413020|Drug|amoxicillin|antibiotic for H. pylori eradication
46024794|NCT04232605|Other|GLP-1 peptide|Receive intravenous infusion of GLP-1. The dosage will be determined after a dose finding pilot study.
46111494|NCT00823030|Other|Normal Saline|20 cc of normal saline will be injected into the bladder after the first UDS
45469673|NCT03413020|Drug|clarithromycin|antibiotic for H. pylori eradication
45469674|NCT03413020|Drug|metronidazole|antibiotic for H. pylori eradication
45469675|NCT03413020|Drug|levofloxacin|antibiotic for H. pylori eradication
45469676|NCT03424564|Drug|Perampanel|Oral Tablet
45469677|NCT03412942|Device|FISH SP|The device will be used to close the femoral artery after angiogram and/or endovascular procedure.
45469678|NCT02887989|Device|Virtual Reality|A menu of VR experiences, lasting from 3-30 minutes each. For example, patients may watch a soothing virtual campfire, or fly over a scenic landscape, or play an interactive game.
45469679|NCT02887989|Device|Health and Wellness Channel|Relaxing content broadcast passively on the patient in-room television channel.
45469680|NCT03419338|Procedure|Sinus lift|Using a lateral access, the Schneider membrane will be elevated using curettes allowing the insertion of graft material.
46024795|NCT04232605|Other|Placebo|Receive intravenous infusion saline
46024796|NCT00638053|Genetic|somatropin|Somatropin will be administered as a daily subcutaneous injection; Fixed doses starting with 0.1 mg/day in patients older than 55 years or patients weighing less than 50 kg; all other patients: 0.1 mg/day or 0.2 mg/day (these doses should all be lower than 0.04 mg/kg/week); all patients starting at 0.1 mg/day will have their dose progressively increased in 0.1 mg/day increments to a maximum clinically- and pharmacologically- tolerated plateau dose; all patients starting at 0.2 mg/day will increase in 0.2 mg/day increments; all incremented dose changes will occur at monthly intervals based on IGF-I levels; treatment will continue for 12 months
46024797|NCT02787421|Device|Breathe-Rite Nasal Dilator Strip|During the pre-operative clinic visit, participants will be given a Breathe-Rite Nasal Dilator Strip
46111495|NCT00823186|Drug|Phyxol(Paclitaxel)|"Paclitaxel is 5ß,20-Epoxyl-1,2α,4,7,β 10 β,13 α-hexahydroxytax-11-en-9-one 4,10~-diacetae 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisocerine"
46111496|NCT00820378|Other|No special interventioin|Comprehensive transthoracic M-mode, 2-dimensional, and Doppler echocardiographic studies will be performed using commercially available equipment. The aortic dimensions were assessed at end-diastole at the different levels:
46111497|NCT02550496|Device|Dermoscopy|
46111498|NCT00820456|Other|DCE-MRI|Participants will receive two (2) dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) prior to chemotherapy and one (1) DCE-MRI after the first cycle of chemotherapy. Participants will be followed for up to 2 years after the initiation of chemotherapy or until disease progression.
46111499|NCT00626392|Drug|niacin extended-release (NER)|Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period
46111500|NCT00626392|Drug|aspirin (ASA)|325 mg tablets administered once daily
46024798|NCT03560635|Behavioral|Weight Loss Maintenance (Control vs. Reverse Diet)|Participants in both groups will receive a 12-week comprehensive, individually delivered behavioral weight loss maintenance intervention, adapted from the Diabetes Prevention Program (DPP) Post-CORE program. This program focuses on utilization of tools and strategies to maintain a healthy lifestyle and prevent weight regain, and is therefore most appropriate for the weight-reduced population we will enroll. While the DPP Post-CORE program includes 15 sessions delivered over 15-months, we will deliver sessions #1-12 and 15 over a 12-week period. Content for sessions 13 and 14 from the DPP Post-CORE curriculum focus specifically on Type 2 Diabetes Mellitus and Heart Disease. The informational handouts will be provided to participants, but not specifically covered in weekly meetings. Groups will differ only in specific caloric prescriptions (described in the Arms section).
46024799|NCT02771353|Radiation|WT_vDIBH|
45469681|NCT03419338|Procedure|Surgical alveolus|Using a round diamond bur, a surgical alveolus will be created on an toothless ridge region.
45681671|NCT03588052|Procedure|VISTA using PRF|"Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Freshly prepared platelet-rich fibrin will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured"
46024800|NCT02771353|Radiation|VMAT_FB|
46024801|NCT02785861|Behavioral|supervision of physical activity|
46024802|NCT02785861|Behavioral|distance supervised physical activity|
46111501|NCT00626392|Drug|aspirin placebo (ASA Pbo)|Tablets administered once daily
46024803|NCT05333107|Drug|NNC0385-0434 G|Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
46024804|NCT05333107|Drug|NNC0385-0434 F|Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
46024805|NCT05333107|Drug|NNC0385-0434 B|Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
46024806|NCT02786017|Biological|Conventional therapy|Patients will receive the conventional therapy.
46024807|NCT02786017|Biological|Injectable Collagen Scaffold + HUC-MSCs|Injectable collagen scaffold combined with HUC-MSCs was injected into left lateral segment, left medial segment, right anterior segment, right posterior segment and caudate lobe under B-mode ultrasound supervision, respectively. The total amount of HUC-MSCs was 5*10^8.
46024808|NCT05331625|Behavioral|Offering Additional Resources to Promote Symptom Management|Participants will be offered additional resources to promote symptom management.
46024809|NCT02785549|Drug|Ibuprofen|600 mg/8hours
46024810|NCT02785549|Drug|Acetaminophen|1 g/8 hours
46024811|NCT02785549|Drug|Amoxicillin/clavulanic acid|875mg/125mg/8 hours
46111502|NCT00828022|Biological|attenuated measles vaccine|4-week apart, two vaccines starting 4 weeks after last chemotherapy
46111503|NCT00828100|Device|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC) setting.
45681672|NCT03588052|Procedure|VISTA using SCTG|"Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Subepithelial connective tissue graft will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured"
46024812|NCT02720653|Procedure|Endoscopic sinus surgery|
46024813|NCT03429829|Device|Flairesse varnish|"Flairesse is applied to enamel and dentine as protective varnish to prevent caries formation and to promote remineralization of initial caries. It is also used in the treatment of hypersensitive teeth by sealing dentin tubules and hypersensitive areas at the neck of the tooth and exposed root dentine. Flairesse varnish contains xylitol and fluoride (22,600 ppm). Both components have been well established for oral health by reducing caries prevalence and incidences.~During the application, children sat upright; their teeth were first cleaned and dried with cotton wool rolls. After mixing the fluoride varnish, it was applied as a thin layer to all surfaces of the lower and upper dentition, including proximal surfaces (using floss in case of tight contact points) as well as pits and fissures (using a small brush that was provided together with the varnish by the manufacturer). Children were advised not to drink or eat directly after the application, while this could not be controlled."
46024814|NCT02785705|Biological|poliovirus vaccine|Different vaccination schedules with bOPV, tOPV and cIPV would be provided for 6 arms respectively.
46024815|NCT02785783|Device|Standard colonoscopy|
46024816|NCT02785783|Device|EndoRings™|Colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
46024817|NCT02821507|Drug|sirolimus and cyclophosphamide|
46024818|NCT02787265|Device|spinal cord stimulation|
46024819|NCT02785393|Drug|Sugar Pill|The administration of a sugar pill
46024820|NCT02785393|Drug|Doxazosin|The administration of the Doxazosin medication
46024821|NCT02787109|Biological|CTH522-CAF01|CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration
46024822|NCT02787109|Biological|CTH522-Al(OH)3|CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration
46024823|NCT02787109|Biological|Placebo|Saline
46024824|NCT03427255|Behavioral|CBT group treatment-plus|The CBT group program-plus consists of 3 1- hr CBT couple sessions and 10 2-hr CBT group sessions over a period of 6 months. The manualized treatment comprise, pain- and sexual education, relaxation and gradual exposure exercises as well as sensate focus and sexual communication exercises for the couple. 6-8 women participate in each group. Two psychologists conduct the couple and group sessions.
46024825|NCT03427255|Other|Waiting-list control condition|Waiting-list control condition during length of active treatment (6 months).
46024826|NCT04232527|Diagnostic Test|Y Balance Test|The footballer will place one foot on the stationary platform of the test set during the test so that the top of the sneaker does not exceed the starting line. The second foot, or the tip of the foot, will push the movable part of the platform down the measuring tube, which is marked by half-inch intervals. Any lifting of the standing leg on the heel, on the toes or loss of balance will be considered a mistake and the attempt will be repeated. Mobility will be tested through 3 trial and 3 valid measurements of the lower limbs in the anterior, posteromedial, and posterolateral directions. The arms should rest on the hips.
46024827|NCT04232527|Diagnostic Test|Sit and Reach Test|This test involves sitting on the floor with your legs stretched straight forward. Shoes should be removed. The feet themselves are set straight against the box. Both knees must be stretched. With the palms facing down and the palms side-by-side or side-by-side, the subject approaches the measurement line as far as possible. It is important to keep your hands in the same position level, not that one reaches further than the other. Once the subject has reached the maximum distance, hold this position for one to two seconds and record the distance.
46024828|NCT04232527|Diagnostic Test|"Maximum Legs Abduction Test"|Seated legs abduction is a test to assess the flexibility of the groin region. Respondent without the shoe sits with its back and head resting against the wall. As a sign, the subject extends the legs (stretches) to the maximum extent. During the test, the legs should not be bent at the knee joint.
46024829|NCT04232527|Diagnostic Test|"S_RAG (reactive agility) Test"|The test consist of fast-moving forward, and a change of direction conditioned by visual stimuli.
45681673|NCT01866657|Drug|Vasoconstrictor Agents|cerebral desaturations may be treated with IV vasoactives to increase blood pressure or cardiac output at attending physician's descretion.
45681674|NCT01866657|Other|Head/neck repositioning|Assure that arterial and venous neck blood flow is not obstructed related to patient positioning
46024830|NCT04232527|Diagnostic Test|S_CODS (change of direction speed) Test|S_CODS (change of direction speed) is a test that allows athletes to outperform their opponents in situations where they can pre-define a movement pattern.
46111504|NCT00828100|Device|BinaxNOW® Influenza A & B|The BinaxNOW Influenza A & B Test is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal wash/aspirate specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results should be confirmed by culture.
46024831|NCT02787031|Procedure|Neuraxial anesthesia|
46024832|NCT02787031|Procedure|General anesthesia|
46111505|NCT00820690|Drug|doxorubicin|4 cycles AC: doxorubicin 60mg/m2
46111506|NCT00820690|Drug|cyclophosphamide|4 cycles AC: cyclophosphamide 600mg/m2
46024833|NCT03398395|Procedure|endocrown restoration|a cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
46024834|NCT03398395|Procedure|90° shoulder endocrown restoration|a 90°cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
46024835|NCT02784301|Device|Belly breathing with biofeedback app|This intervention consists of learning how to belly breathe using a smartphone biofeedback application that coaches children how to breathe slowly and deeply. The app consists of a cartoon avatar in a hot air balloon that inhales and exhales bubbles. The goal of the biofeedback game is to a) teach a voluntary deep breathing protocol, b) detect compliance to the breathing protocol using the attached audio-based pulse oximeter sensor and c) to raise the hot air balloon in accordance to this compliance in order to motivate the children. Scenery changes as the balloon rises, driven by biofeedback, until it eventually reaches outer space.
46024836|NCT02784301|Behavioral|Belly breathing without biofeedback app|This intervention consists of learning how to belly breathe without the biofeedback application prior to the blood collection and continuing with self-directed belly breathing during the procedure itself.
46111507|NCT00820690|Drug|paclitaxel|4 cycles T: paclitaxel 175mg/m2 after 4 AC
46111508|NCT00820690|Procedure|Surgery|"The surgery will be performed 30 days after the chemotherapy. The correlation between clinical, radiologic and pathologic response will be reported.~The oncoplastic surgery rate will be reported"
46111509|NCT00828256|Procedure|arthroscopy of shoulder|arthroscopic repair of chronic rotator cuff tears
46111510|NCT00828334|Device|Transcatheter PDA Coil|The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter < 4 mm.
46111511|NCT00624286|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
46111512|NCT00624286|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
46111513|NCT00823420|Procedure|prematuration culture|"The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos."
46111514|NCT00820768|Drug|ABI-010|17-AAG and ABI-007
46111515|NCT00624052|Drug|fixed-dose combination of telmisartan 40mg+amlodipine 10mg|
46111516|NCT00624052|Drug|fixed-dose combination of telmisartan 80mg+amlodipine10mg|
46111517|NCT00821080|Drug|Sirolimus|Taken orally at different dose levels depending upon enrollment time period
46111518|NCT00821080|Drug|Vandetanib|Taken orally at different dose levels depending upon enrollment time period
46111519|NCT00828490|Behavioral|provider feedback|The provider-level intervention includes a targeted review of trigger-flagged beneficiaries' drug utilization history and an information packet sent to providers which includes patient-specific pharmacy and medical claims history, patient specific recommendations, and provider comparative profiling.
45681675|NCT01866657|Other|Increase ETCO2|Allow normalization or slight increase in end tidal CO2 to cause selective cerebral vasodilation and increased tissue blood flow/O2 delivery
46111520|NCT00828490|Behavioral|patient intervention|The patient intervention arm includes the provider-level intervention mentioned above in addition to Medication Therapy Management Services (MTMS), a program that provides patients one-on-one therapy counseling administered by community pharmacists who have completed an MTMS certificate program.
46111521|NCT00828490|Behavioral|Process-level|The process-level intervention includes the provider-level intervention plus in-clinic evidence-based quality improvement workshops with opportunity for CME credit
46111522|NCT00823498|Behavioral|Focus Group|6 Focus Groups asked how living in public housing effects physical activity and feelings about neighborhood.
46111523|NCT00823498|Behavioral|Interview|Interview with a member of study staff at housing development site.
45469682|NCT03419338|Procedure|Inorganic bovine bone + newly forming bone|Maxillary sinus lift will be done with inorganic bovine bone associated with newly forming bone. The newly forming bone will be collected from surgical alveolus previous prepared.
46024837|NCT02784301|Behavioral|Belly breathing + visual distraction|This intervention consists of learning how to belly breathe without the application plus receiving visual distraction by watching a cartoon avatar in the hot air balloon rising through space. The avatar will not coach the child to breathe as the visual cues for breathing (words and bubbles) will not be present and the avatar will not rise in response to correct belly breathing. Participants will be instructed to continue with self-directed breathing while also watching the visual distraction during the blood collection procedure.
45469683|NCT03419338|Procedure|Inorganic bovine bone|Maxillary sinus lift will be done with inorganic bovine bone.
45469684|NCT03419338|Device|Collagen membrane|At the end of the sinus lift, a collagen membrane will be used to obliterate the graft inside the maxillary sinus.
46111524|NCT00823498|Other|Photovoice Project|Activity allowing expression of thoughts and feelings about neighborhood through neighborhood pictures taken by youth and parent(s).
46111525|NCT04044430|Drug|Binimetinib|Given PO
46111526|NCT04044430|Drug|Encorafenib|Given PO
46111527|NCT04044430|Biological|Nivolumab|Given IV
46111528|NCT04044430|Other|Questionnaire Administration|Ancillary studies
46111529|NCT00821158|Drug|Antioxidant|Antioxidant iv bolus
45681676|NCT01866657|Other|IV fluid bolus|Administer IV fluids to increase preload and cardiac output
45681677|NCT01866657|Drug|Additional anesthesia|By deepening anesthetic there will be a decrease in cerebral metabolic oxygen consumption.
45681678|NCT01866657|Biological|RBC transfusion|By administering RBCs there will be a increase in intravascular volume and cardiac preload and an increase in oxygen carrying capacity
46111530|NCT00821158|Other|Placebo|Placebo tablet and iv
46111531|NCT00821158|Drug|Anti-inflammatory drug|Anti-inflammatory tablet
46111532|NCT00830674|Drug|Placebo|single dose IV or SC administration
46024838|NCT02784223|Device|Radiation : PET-CT with F18-choline examination|PET-CT with F18-choline examination will be performed before surgery
46024839|NCT05262751|Drug|Ofev®|Ofev®
46111533|NCT00830674|Drug|KRN23|Single IV administration on day 1: 0.003, 0.01, 0.03, 0.1 and 0.3 mg/kg and Single SC administration on day 1: 0.1, 0.3, 0.6 and 1.0 mg/kg
45469685|NCT04559685|Combination Product|SONALA-001(ALA) and MR-Guided Focused Ultrasound device (MRgFUS)|SONALA-001(ALA) given 5-7 hours prior to receiving the MRgFUS.
45681679|NCT01866657|Drug|Increase FiO2|Increase FiO2 to improve oxygen delivery to tissue
46024840|NCT05262751|Drug|Nintedanib formulation 1|Nintedanib formulation 1
46111534|NCT00823732|Other|educational intervention|Undergo individualized interdisciplinary palliative care intervention
46111535|NCT00823732|Other|medical chart review|Ancillary studies
45681680|NCT03587350|Device|Shimmer monitoring|The shimmer monitor, monitors movement and the range of movement.
45681681|NCT03581344|Diagnostic Test|Repetition of Re-staging|Second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy if major or complete response at 7-8 weeks
46111536|NCT00823732|Other|questionnaire administration|Ancillary studies
46111537|NCT00823732|Procedure|end-of-life treatment/management|Undergo end-of-life treatment/management
45469686|NCT04559685|Device|MR-Guided Focused Ultrasound device (MRgFUS)|MR-Guided Focused Ultrasound device (MRgFUS) alone
45469687|NCT03424486|Other|Questionnaires|Evaluation of the prevalence of anxiety, depression and quality of life
45469688|NCT01313481|Behavioral|Group exercise|Otago exercise performed in groups of 4-8 patients, 2 times a week over 12 weeks
45469689|NCT01313481|Behavioral|Home exercise|Otago exercise performed as home exercise 3 times a weeks over 12 weeks. Individually tailored physical balance and muscle strength exercise
45469690|NCT03424408|Drug|Aspirin 81 mg|Healthy volunteers will receive 5 days of aspirin 81 mg daily. Following cessation of aspirin, daily blood samples will be collected for serum thromboxane B2 measurement
45681682|NCT03584152|Drug|Norco 5Mg-325Mg Tablet|Opioid Analgesics
45681683|NCT03584152|Drug|Tylenol 325Mg Caplet|Non opioid analgesics
45681684|NCT03584152|Drug|Ibuprofen 200 mg|Non opioid analgesics
45681685|NCT03020836|Behavioral|Referral to primary care physician for hypertension control|Referral to primary care physician for hypertension control
45681686|NCT03020836|Behavioral|Referral to smoking quit line|Referral to Maryland Tobacco/Smoking quit line for help with smoking cessation
45681687|NCT01700205|Other|Type of Formula|infant formula
45681688|NCT03589690|Dietary Supplement|Alpha lipoic acid|22 Patients will consume 600 mg Alpha lipoic acid for 12 weeks .
45681689|NCT03589690|Dietary Supplement|Placebo|Participants will be supplemented with 600 mg/day placebo (Starch).
46024841|NCT05262751|Drug|Nintedanib formulation 2|Nintedanib formulation 2
46024842|NCT02785315|Behavioral|rehabilitation & remediation approach|The rehabilitation & remediation approach group will receive 12 weekly 90-minute combined cognition interventions in a group. The first half of each session will be cognitive training which focus on teaching various cognitive strategies to enhance the attention, memory, processing speed, and executive functions. The second half of the session will apply rehabilitation intervention by discussing everyday situations with memory problem and specific strategies related to real-life situations. Investigators will also include one individual session in the 12 group sessions.
46024843|NCT02785315|Behavioral|remediation approach|The remediation approach will receive 12 weekly 90-minute cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions.
46024844|NCT02785237|Device|Coroflex® ISAR Drug-eluting stent|Coroflex® ISAR Drug-eluting stent and an Ultimaster® Drug-eluting stent in the second lesion.
46111538|NCT00823732|Procedure|psychosocial assessment and care|Undergo psychosocial assessment and care
46111539|NCT00823732|Procedure|quality-of-life assessment|Ancillary studies
46111540|NCT00823732|Procedure|management of therapy complications|Undergo management of therapy complications
46024845|NCT02785237|Device|Ultimaster® Drug-eluting stent|Ultimaster® Drug-eluting stent and a Coroflex® ISAR Drug-eluting stent in the second lesion.
46111541|NCT00823732|Procedure|assessment of therapy complications|Undergo assessment of therapy complications
46111542|NCT04018456|Other|Biodentine|Biodentine is calcium silicate based cement which is bioactive and inductive material. Biodentine will be applied as coronal plug material.
45681690|NCT03589534|Diagnostic Test|home pregnancy test|Each participant will use 4 different home pregnancy tests
45681691|NCT03589456|Other|No intervention|There are no interventions associated with this registry as it is purely observational.
46024846|NCT04231123|Procedure|PENG Block with local anesthetic|After induction of general anesthesia, PENG block with 20 ml of a mixture of 1% Lidocaine with 0,5% Ropivacaine and 1/400.000 Epinephrine will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
46024847|NCT04231123|Procedure|PENG Block with 0,9% saline|After induction of general anesthesia, PENG block with 20 ml of 0,9% saline will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
46024848|NCT04231279|Drug|synthetic human secretin|Secretin is a gastrointestinal peptide hormone, indicated for the stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction.
46024849|NCT02782585|Other|Cervical manipulation|The therapist cradled the subject´s head with the other hand. Gentle ipsilateral side flexion and contralateral rotation to the targeted side were introduced until slight tension was perceived in the tissues at the contact point. The High velocity, low amplitude (HVLA) manipulation was directed upward and medially in the direction of the subject´s contralateral eye. The therapist monitored for cavitation or 'popping sound' accompanying the manipulations. If an audible popping sound was not heard during the first manipulative attempt, the procedure was repeated in the second time.
46024850|NCT02782585|Other|Cervical lateral glide|The upper limb of the right side of subjects was maintained in rest, with the arm along the trunk and the hand over the abdominal wall. The right hand of the treating therapist was positioned over scapula region, to depress the scapula while left hand cradled the occiput and neck above C5-C6 and left hand produced a passive lateral movement of the occipital and neck region.
46024851|NCT02782585|Other|Cervical mobilisation|The patients received a passive cervical mobilization that involved a grade III oscillatory unilateral posteroanterior mobilization to the right articular pillar of C5/C6 segment as described Maitland at a frequency of 2Hz. All the subjects were positioned in prone position as the protocol described by Sterling et al. for 3 sets of 2 minutes with 1 minute rest between sets.
46024852|NCT02605759|Device|CryoBalloon Focal Ablation System|Positioned within the esophagus at the target location, the Balloon is simultaneously inflated and cooled with nitrous oxide. The nitrous oxide cools the inner Balloon surface. The Balloon remains stationary during the delivery of the nitrous oxide for the Cryoablation of Dysplastic Squamous Tissue in Patients with Esophageal Squamous Cell Dysplasia
46024853|NCT02782273|Drug|Ketorolac|The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
46024854|NCT02782273|Drug|Morphine|The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
46024855|NCT02782507|Behavioral|CBT for Distressing visual hallucinations|"Eight to ten sessions of manualised CBT for distressing visual hallucinations based on existing treatment manuals (ie. Kingdon & Turkington, 2004, Morrison et al., 2005), delivered over 8 to 12 weeks by CBT therapists.~Subjects will continue to receive treatment as usual throughout the therapy period and will receive appropriate prescription of medication if requested or clinically indicated."
46111543|NCT04018456|Other|White MTA|MTA is calcium silicate based cement which is bioactive and inductive material. MTA is used in most cases of regenerative endodontics and it will be applied as coronal plug material.
46111544|NCT00828646|Drug|BMS-708163|Capsules, Oral, 50 mg, once daily, 14 days
46111545|NCT00828646|Drug|BMS-708163|Capsules, Oral, 100 mg/day, once daily, 14 days
46111546|NCT00828646|Drug|BMS-708163|Capsules, Oral, 75 or 100 mg/day, once daily, 14 days
46111547|NCT00828646|Drug|Placebo|Capsules, Oral, once daily, 14 days
46111548|NCT02548936|Drug|Ezetimibe+Simvastatin Drug Combination|The patients in Ezetimibe+Simvastatin Drug Combination group received simvastatin (10mg/day) + ezetimibe (20 mg/day) by oral administration for 12 month.
46111549|NCT02548858|Procedure|Perineorrhaphy|Those patients who are randomized to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
46111550|NCT02548858|Procedure|No Perineorrhaphy|Those patients who are randomized not to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
46111551|NCT00828724|Drug|Lorcaserin 10mg|
45681692|NCT01700049|Drug|vismodegib (150 mg PO daily)|Biopsies will be performed on all participants at baseline, week 12 and week 24.
45681693|NCT03587194|Drug|Otezla|Otezla 30mg BID
46111552|NCT00828802|Drug|Lenalidomide, Decitabine|Decitabine 20mg/m2 over one hour IV for 5 days, with cycles repeated every 28 days. Lenalidomide given orally on Days 1-21 followed by 7 days of rest at various dose escalated cohorts (5 mg, 10mg, 15mg, 20 mg, 25 mg)
46111553|NCT00823810|Other|PET/CT|18F-FDG PET/CT
46024856|NCT05179135|Other|Postprandial exercise of different modalities|Physical exercise performed 60 minutes after a standardized meal, of different modalities (4 different modalities will be examined, as described in the Arms)
46111554|NCT00823888|Device|pneumatic brace|pneumatic knee brace with three trial conditions: air bladders inflated at 0psi, 7 psi, and 12 psi
46111555|NCT00785577|Drug|Placebo|"LY545694 placebo BID po for 5 weeks~Pregabalin placebo capsules TID po for 6 weeks"
46111556|NCT00785577|Drug|Pregabalin|"Pregabalin TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6~LY545694 placebo BID po for 5 weeks"
46024857|NCT05342545|Other|Alert-based computerized decision support|For patients randomly assigned to the BPA intervention group (alert group), an on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the responsible provider that his or her T2DM patient should be evaluated for CKD with UACR assessment. The provider then will be given on-screen options to either order a UACR assessment or follow a link to learn more about CKD assessment in T2DM. Should the alert-recipient elect to omit an order for UACR assessment and decline to follow a link to learn more about CKD assessment in T2DM, the provider will be able to continue on with clinic visit-related EHR documentation but will need to select an acknowledge reason (rationale) for not following the evidence-based clinical practice recommendation highlighted in the alert.
46024858|NCT05342389|Drug|Camrelizumab|a PD-1 antibody
46024859|NCT05342389|Drug|Apatinib Mesylate|an oral tyrosine kinase inhibitor
46024860|NCT04230655|Dietary Supplement|Low energy diet using meal replacements|The LED phase (from baseline to 24 weeks) consists of 12 weeks with 4 portions/day of liquid meal replacements, for a total of 800-880 kcal/day, followed by a 12-week slow phasing out to a regular diet. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended.
46024861|NCT04230655|Behavioral|CBT-based group treatment|All participants (control and intervention) receive 2.5-hour sessions of CBT-based group treatment every 4 weeks for 1 year. Participants are randomly assigned to groups of 8-16 participants.
46111557|NCT00785577|Drug|LY545694 21 mg|"LY545694 21 mg BID po for 1 week~Pregabalin placebo TID po for 6 weeks"
46111558|NCT00785577|Drug|LY545694 49 mg|"LY545694 escalated to 49 mg BID po for 1 week during Week 2.~Pregabalin placebo TID po for 6 weeks."
46111559|NCT00785577|Drug|LY545694 105 mg|"LY545694 105 mg BID po for 5 weeks~Pregabalin placebo TID po for 6 weeks"
46111560|NCT00830830|Drug|Hyalgan (sodium hyaluronate)|
46111561|NCT00828880|Device|DRX9000|DRX9000 - non-invasive spinal decompression. Treatments 28 min 5 x/wk x 2wks, 3x/wk x 2 wks, 2x/wk x 2 wks for a total of 20 treatments in a 6-week period
46111562|NCT02548390|Drug|RXDX-107|Subjects in this study will receive RXDX-107 intravenously at dose levels specified for their respective dose cohorts. Dosing will begin at 25 mg/m2 on Day 1 and Day 2 of a 28-day cycle and will escalate until the maximum tolerated dose (MTD) or (RP2D) is determined. An additional schedule of administration of RXDX-107 on Day 1 of a 28 day cycle may be assessed. Cycles will be repeated in four-week (28 day) intervals for up to 6 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
46111563|NCT00830908|Device|HairMax LaserComb|LaserComb to be used 3 times weekly on non-consecutive days, according to User Manual instructions. Use is preferably following a shower, prior to using any styling products on the hair or scalp. Hair may be wet or dry during treatment.
46111564|NCT00828958|Drug|Risperidone long-acting injectable|
46111565|NCT04105101|Device|Industrial passive shoulder exoskeleton|Both exoskeleton types are passive shoulder exoskeletons. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions.
46111566|NCT00830986|Device|Total Knee Arthroplasty Implant (Scorpio®)|Implantation of a Total Knee Arthroplasty using Conventional Intramedullary Instrumentation
46111567|NCT00830986|Device|Total Knee Arthroplasty Implant (Scorpio®)|Implantation of a Total Knee Arthroplasty using a Computer Assisted Software, without Intramedullary Instrumentation
46111568|NCT02548780|Device|Chemoembolization|"First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.~Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of LifePearl beads used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved and confirmed with angiography of the whole liver."
46111569|NCT02548780|Other|Pharmacokinetics|Pharmacokinetic analysis will be performed in cohort I and II after the first treatment only. In addition to blood samples taken for biochemistry and haematology analysis, blood will be taken for pharmacokinetic assessment: Whole venous blood samples (6 ml in 2 tubes) will be taken from peripheral blood into ethylenediaminetetraacetic acid (EDTA) tubes prior to and at 5mins, 20mins, 40mins, 1h, 2h, 6h, 24h, 48h and 7 days after the procedure, and if needed (i.e. value at d7 is detectable) at 1 month (for safety assessment visit) either during hospital stay or in the outpatient clinic.
46111570|NCT04105023|Dietary Supplement|genistein|Administered orally once every 12 hours
46024862|NCT04230655|Device|Intragastric balloon|An IGB (Orbera IGB, Apollo Endosurgery Inc., Austin, Texas, (CE certified)) is set in place endoscopically by a gastroenterologist at Örebro University Hospital, Region Örebro county, and is left in the stomach for 6 months. A proton-pump inhibitor is prescribed to counteract an increased risk to develop a gastric ulcer. During the first 2 weeks, dietary adjustments are necessary to adapt to the IGB. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended identical to the control group. The IGB is removed endoscopically after 6 months IGB treatment.
46024863|NCT02784067|Drug|Sucraid|Study drug
45469691|NCT03412708|Other|Vestibular Rehabilitation supported with Virtual Reality|Patients will perform the supervised vestibular exercises in virtual reality environment using a virtual reality goggle (Samsung Gear VR SM323) and a smartphone (Samsung Galaxy S7). The virtual environments consist of 2 media provided by the videos taken with a 360 camera (Samsung Gear 360). 1) A square with people moving, noise and traffic and 2) A supermarket where the shelves are full.
46024864|NCT02784067|Drug|Placebo|Sucraid placebo
46024865|NCT05260099|Device|LPS Adsorber|LPS Adsorber, binding endotoxin caused by suspected or verified gram-negative bacteria.
46024866|NCT02268175|Drug|Enzalutamide|160 mg (four 40 mg capsules), oral, once daily, 28 days (4 weeks) 6 cycles maximum. Can be taken with or without food.
46024867|NCT02268175|Drug|Abiraterone Acetate|1000 mg (four 250 mg tablets), oral, once daily, 28 days (4 weeks) 6 cycles maximum. No food should be consumed for at least two hours before the dose and for at least one hour after the dose.
46024868|NCT02268175|Drug|Prednisone|5 mg, oral, once daily, 28 days (4 weeks) 6 cycles maximum.Take with food, preferred to be taken in the morning .
46024869|NCT02268175|Drug|Leuprolide Acetate|Either 7.5 mg monthly or 22.5 mg every three months, Intramuscular, monthly or every three months.
45838634|NCT04376970|Drug|FLUCON®|"The drug was prescribed monthly according to the predefined regimen. It was not namely specefied in the prescription and was delivered by the hospital pharmacy according to the randomisation list.The subjects were masked to the contents and were instructed to return the empty tubes on monthly visit, wherein 1 pack of topical treatment was provided to them. Neither the patient nor the ophthalmologist knew the allocated treatment. No other medication was allowed during the trial. Duration of the whole regimen was six months. The study included an extra month after the end of the regimen. It was called  wash-out . Patients who had less than one month of treatment or an uncontrolled treatment side effect or who presented a degenerative iron line were excluded from the rest of the regimen."
46024870|NCT02207647|Other|no intervention|
46024871|NCT02783989|Other|white wine|A dietary beverage: a market white wine, 13º alcohol
46024872|NCT02783989|Dietary Supplement|tyrosol|tyrosol in capsules
46024873|NCT02783833|Drug|MMV390048 40mg|
46024874|NCT02783833|Drug|MMV390048 dose to be determined mg|Cohort 2 will receive a single dose of MMV390048. Depending on the data obtained from the 40mg cohort, the dose in Cohort 2 will be determined.
46024875|NCT02783755|Behavioral|Device: smartphone|Coping Skills Training for pain will be delivered to participants using video-conferencing
46024876|NCT02783677|Procedure|Percutaneous balloon angioplasty|
46024877|NCT02782429|Drug|Ketamine|
46111571|NCT04105023|Dietary Supplement|Placebo|Administered orally once every 12 hours
46111572|NCT00831064|Procedure|colonoscopy bowel prep|PEG, bisacodyl, NaP, PSMC and Mg-citrate
46024878|NCT02782429|Other|Saline|
46024879|NCT04229719|Drug|N-acetyl-5-methoxytryptamine|1.2 mg of melatonin powder will place in the osteotomy site before the insertion of the implant.
46024880|NCT02782351|Biological|CAR-T|Patients will be infused with autologous CAR-T infusion in a dose escalating manner.
46024881|NCT04231903|Device|Aortic clamp|In the firs group an endo-aortic clamp is used and in the second group an external clamp is used.
46111573|NCT04104867|Drug|Itopride|the patients are instructed to take one pill of Itopride at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
46024882|NCT02784847|Drug|Triheptanoin|Triheptanoin oil administered three times per day during meals at a total dose 1mg/kg/day for 3 months
46024883|NCT04230889|Other|Usual Diet Group|three main meals and two snacks
46024884|NCT04230889|Other|Group 1 Nutritional Shake|2 servings per day
45469692|NCT02887521|Other|education|pulmonary rehabilitation participant manual
45469693|NCT02887521|Procedure|rehabilitation|pulmonary rehabilitation
45469694|NCT02887521|Device|pedometer|receive a pedometer
46111574|NCT04104867|Drug|Domperidone|the patients are instructed to take one pill of Domperidone at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
46024885|NCT04230889|Other|Group 2 Nutritional Shake|2 servings per day
46111575|NCT04104867|Other|Placebo|the patients are instructed to take one pill of placebo at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
46111576|NCT04024605|Dietary Supplement|Sunflower|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
46024886|NCT01855867|Drug|Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)|
46111577|NCT04024605|Dietary Supplement|Rapeseed|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
46024887|NCT02689843|Drug|Cyproterone compound + Spironolactone|Cyproterone compound (Cyproterone Acetate 2mg-Ethinyl estradiol 35mcg) 1 tablet daily + Spironolactone 50 mg twice daily
46111578|NCT04024605|Dietary Supplement|Flaxseed|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
46024888|NCT02689843|Drug|Metformin|Metformin 500mg three times daily
46024889|NCT02689843|Drug|Pioglitazone|Pioglitazone 30mg once daily
46024890|NCT02783365|Behavioral|Photo-elicitation and online group support|See above information.
46024891|NCT02783521|Behavioral|Counseling sessions|During the first 12 weeks, intervention participants will attend weekly 30-45-minute individual counseling sessions guided by a trained bilingual Hispanic male lifestyle coach. Counseling sessions will be tailored to the needs of the participants (e.g., evening/weekend sessions, waiting/childcare area). After 12 weeks, intervention group participants will receive bi-weekly phone calls across a 12-week follow-up. Phone calls will last approximately 10 minutes in duration and study staff will follow a script to review current body weight, eating and activity behaviors, and specific barriers for weight loss/maintenance or diet/physical activity behaviors.
46111579|NCT04024605|Dietary Supplement|Lupin|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
46024892|NCT02783521|Behavioral|Wait List Control|After 12 weeks, the wait list control will receive the weight loss intervention plus mHealth technology support. It will include tailored, targeted text messaging and real-time self-monitoring support including beverage tracking cups, which provide the amount of calories users are consuming through beverages on a daily basis, and wearable activity monitors.Behavioral constructs used for the intervention group will be maintained during this intervention delivery thereby ensuring all participants have the appropriate tools to continue weight loss efforts regardless of mHealth use.
46024893|NCT02781961|Other|cellvizio|pCLE during gastroscopy
46024894|NCT05171725|Diagnostic Test|EEG,PSG|concurrent overnight sleep study with full electroencephalography (in-lab or at home)
46024895|NCT05171725|Diagnostic Test|biosample collection (blood and CSF)|blood or CSF collection for analyses of neurodegenerative, inflammatory, and, per condition, genetic information
46024896|NCT05171725|Diagnostic Test|neuropsychological testing|paper and pencil, as well as tablet based cognitive testing
46111580|NCT00789828|Drug|Everolimus|Everolimus was formulated as tablets of 1.0-mg strength and was blisterpacked under aluminum foil in units of 10 tablets.
46111581|NCT00789828|Drug|Placebo|Placebo was provided as a matching tablet and was blisterpacked under aluminum foil in units of 10.
46111582|NCT04044118|Behavioral|Low Calorie Diet|Low Calorie Diet consisted of ~50% calories of a normal-calorie diet (female, 1000kcal/day; male, 1200kcal/day)
46111583|NCT04024839|Other|Active Isolated Stretch|In supine position, participant was asked to lock the knee and slowly lift leg using the quadriceps muscles. gentle assistance was given by the rope at the end of the movement, as the quadriceps muscles continue to move the leg. strech was applied for 2 sec and then release to starting position. two sets of 10 repetitions were performed.
46111584|NCT04024839|Other|Post Isometric Relaxation|In supine line, participant was asked to do SLR until resistance was met in hamstring muscles and then was asked to do isometric contraction (10-20% of maximum) for 5 - 10 sec and inhale. After this, patient was asked to exhale while doing so gentle stretch was applied till the new barrier. Starting from this new barrier, the procedure was repeated 2 - 3 times.
46111585|NCT02550262|Drug|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
46024897|NCT05171725|Diagnostic Test|actigraphy|week long actigraphy assessment with concurrent sleep diary acquisition
46024898|NCT05171725|Diagnostic Test|clinician assessment|standard clinical assessment by an expert clinician in the respective field of brain disorders
46024899|NCT05166577|Drug|Nanatinostat|Nanatinostat dose escalation starting at 20 mg orally daily, 4 days per week
46024900|NCT05166577|Drug|Pembrolizumab|Pembrolizumab (anti-PD-1) dosed at 200 mg intravenous (IV) every 3 weeks
46024901|NCT05166577|Drug|Valganciclovir|Valganciclovir starting at 900 mg orally daily
46024902|NCT05341999|Other|cold saline (cryotherapy)|using 20ml of 2.5°C cold saline for 5 min
46024903|NCT05341999|Drug|Ibuprofen 400 mg|patients will be prescribed ibuprofen medication as a single dose immediately after completion of root canal treatment.
46024904|NCT05341999|Other|Final irrigation with normal saline|final irrigation will be done using normal saline at room temperature.
46024905|NCT02781805|Drug|Alendronate|10 mg (1 tablet) once daily for 1-3 weeks before breast surgery; drug will be discontinued the day before surgery.
46024906|NCT02781493|Drug|2 mg Prucalopride plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Prucalopride group will recieve 2 mg Linaclotide plus 2 L Polyethylene Glycol regimen before colonoscopy.
46111586|NCT02550262|Drug|Fentanyl|0.0625% Bupivacaine plus fentanyl 2mcg/ml
46024907|NCT02781493|Drug|2 mg Placebo plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Placebo group will recieve 2 mg Placebo plus 2 L Polyethylene Glycol regimen before colonoscopy.
45681694|NCT03893500|Device|Home-based 6 minute walk test|Participants will receive a loaner Apple Watch with the Walk.Talk.Track. (WTT, produced by PHaware) app downloaded. Participants will perform a daily 6MWT at home using the Apple Watch and WTT app. They will undergo a history and physical, blood draw, echocardiogram and in-clinic 6MWT at the baseline and 12-week follow up visit.
46024908|NCT02783287|Behavioral|Text message reminder for medication adherence|Patients randomized to this arm receive one text message per day (at the scheduled time) reminding them to take their medication.
46024909|NCT02783287|Behavioral|Text message reminder for exercise regimen|Patients randomized to this arm receive 4 daily text messages reminding them to exercise for 30 minutes per day.
46024910|NCT02783053|Drug|Metformin|Metformin vs no metformin
46024911|NCT05230615|Drug|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
46024912|NCT04230343|Behavioral|Self-benefit message|A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine and included a figure of one smiley face.
46111587|NCT02550262|Device|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
46024913|NCT04230343|Behavioral|Other-benefit message|A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine, and gaining immunity would lower the chances of transmitting the disease to others. The figure included one smiley face surrounded by three other smiley faces.
46024914|NCT02783209|Procedure|Cataract surgery|
46024915|NCT02689609|Radiation|Intensity-modulated radiation therapy|All patients will receive intensity-modulated radiation therapy with or without chemotherapy as usual standard of care in our institution.
46111588|NCT04024449|Other|Group A|ovarian function test in control group
46111589|NCT02550418|Drug|Budesonide|
46111590|NCT00829114|Drug|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
46111591|NCT00829114|Drug|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
46111592|NCT00790296|Drug|Thyrotropin releasing hormone (TRH)|0.5mg and 1.5mg
46111593|NCT00790296|Drug|Placebo|Saline
46111594|NCT02548702|Behavioral|Fit4Life|Fit4Life is a programme whereby patients with type 2 diabetes are counselled and then allocated to a community-based sport programme based on their interests and perceived barriers to participation
45469695|NCT02887521|Other|education|receive a pamphlet with exercises plus the standard course of care
45469696|NCT02887521|Procedure|surgery|patients undergo surgery
45681695|NCT01699815|Drug|Acetaminophen|
45681696|NCT03586960|Device|Peak Force Measurement|Force will be measured at 5,10, and 30 minutes
45681697|NCT03589222|Drug|Selinexor|Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle
45681698|NCT03589222|Drug|Daratumumab|daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter
46024916|NCT02783131|Device|MedNav|MedNav is a tablet based platform device that acts to help teams manage emergencies. In the way that satellite navigation devices have replaced maps on journeys mednav has replaced paper based checklist and guidelines to give teams real-time guidance as the emergency happens. In supports teams by deligating, prompting and scribing as the emergency unfolds. The intervention arm will be taught how to use this device over 30 minutes and then use it in a simulated scenario managing a post partum haemorrhage.
46024917|NCT02782975|Drug|aducanumab|
46024918|NCT01324531|Procedure|Bankart repair and remplissage|Bankart repair may be completed before or after remplissage. While maintaining camera in anterior-superior portal drill guide and anchor cannula is placed through the posterior portal into remplissage site. Anchor cannula with obturator is passed through infraspinatus tendon and posterior capsule via pre-existing portal, and first anchor is placed in inferior aspect of Hill-Sachs lesion.Once anchor is inserted, penetrating grasper is passed through tendon and posterior capsule, 1 cm inferior to the initial portal entry site, to grasp and pull 1 suture limb.Second anchor is placed in superior aspect of Hill-Sachs lesion and grasper penetrator is used in same fashion to pass 1 suture limb 1 cm superior to initial portal entry site. The inferior suture is tied first with knots remaining extraarticular in the subdeltoid space. The superior suture is tied to complete remplissage.
46024919|NCT01324531|Procedure|Bankart repair|Bankart repair based on surgeon's preference
46024920|NCT02782819|Drug|Isotonic crystalloid solution resuscitation|Patient will receive normal saline or Ringer lactate or other balance salt solution during fluid resuscitation for shock reversal.
46111595|NCT00829192|Drug|Afamelanotide (CUV1647)|16 mg subcutaneous implant administered every 60 days
46024921|NCT02782819|Drug|Colloid solution resuscitation|Patient will receive 5% albumin or gelatin solution during shock resuscitation
46111596|NCT00829192|Drug|Placebo|Placebo subcutaneous implant administered every 60 days
46111597|NCT00623194|Drug|insulin detemir|Treat-to-target dose titration scheme (individually adjusted), injection s.c. (under the skin), once or twice daily.
46111598|NCT00623194|Drug|insulin aspart|Treat-to target dose titration scheme (individually adjusted), injection s.c. (under the skin), at larger meals.
46111599|NCT00829348|Other|No intervention|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
46111600|NCT00829348|Behavioral|Short Message Service (SMS)|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
46111601|NCT02548000|Other|Resistance training|The resistance training will be compound by 12 exercises for all body muscles, performed three times per week. The intensity of training will be measure by maximum repetitions from 12 until 8 repetitions with 2-3 series. The loads will increase for keep the maximum strength as the capacity of patients. The blood pressure and the casual glycemic will be measure before and after the training in each session. Before to start the exercises, patients will perform a warming on treadmill for 10 minutes and after the training will perform some stretching exercises for muscles groups trained.
46111602|NCT02548000|Other|Stretching control|The stretching session will be composed by stretching and joint mobilization exercises for all body muscles and will happen only one time per week.
46111603|NCT00829582|Drug|"ETI-204, Anthim"|single intravenous infusion of 120, 240 or 360 mg of ETI-204
46111604|NCT00829582|Other|placebo|single intravenous infusion
46111605|NCT00831298|Other|Analysis of sleep disturbance|Behavioral Questionnaire Sleep Recordings Genetic analysis
46111606|NCT00784368|Drug|ITCZ Oral Solution|ITCZ syrup product containing ITCZ 10 mg per ml in dose range of 20 ml to 40 ml daily for 7 days up to 12 weeks
46111607|NCT00784368|Drug|ITCZ-IV|200 mg IV twice daily for 2 days and once daily for the next 1 to 12 days
46111608|NCT02548468|Drug|Fludarabine|Given IV
46111609|NCT02548468|Radiation|Total-Body Irradiation|Undergo TBI
46111610|NCT02548468|Biological|T Cell-Depleted Donor Lymphocyte Infusion|Undergo donor CD3+ enriched T lymphocyte infusion
46111611|NCT02548468|Drug|Cyclophosphamide|Given IV
46111612|NCT02548468|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSC transplant
46111613|NCT02548468|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
46111614|NCT02548468|Drug|Mycophenolate mofetil|Given IV
46111615|NCT02548468|Drug|Tacrolimus|Given IV
46111616|NCT00829660|Drug|Acarbose|The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
46111617|NCT00829660|Drug|Matching Placebo|The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
46111618|NCT00915564|Drug|TMC435|Participants will receive 150 mg dose of TMC435 orally (by mouth) once daily for 7 days of treatment (from Day 1 to Day 7).
46111619|NCT00915564|Other|Methadone|Participants will receive supervised individualized methadone dose (dose of methadone will be adjusted for each participant between a range of 30 and 150 mg daily [extremes included]) from Day -14 untill Day 8. Participants will continue to receive individualized methadone during follow up of 30 to 32 days.
46111620|NCT02603406|Drug|erythropoietin|
46024922|NCT04182217|Other|Epidemiological description|Description of the characteristics of Peritonitis in Haiti
46111621|NCT04106700|Drug|Apixaban 2.5 MG|Apixaban will be started simultaneously with anti myeloma treatment on day 1 of cycle 1 of VTD, and continues for 4 to 6 months depending on the number of induction cycles administered to the patient
46111622|NCT04107090|Other|lung recruitment maneuver|Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome
46111623|NCT04107090|Other|tracheal IL-6 level|tracheal IL-6 level was measured before and after recruitment maneuver
45838635|NCT04376970|Drug|Cyclosporine A eye drops 0.5%|The same regimen was prescribed for both treatments in order to preserve the double-blind characteristic. Cyclosporine eye drops 0.5%, was prepared from an oral solution of cyclosporine (Sandimmun®) and combined with castor oil, both sterilized by filtration. The preparation was carried out in a pharmacotechnical laboratory where a controlled atmosphere area was dedicated to ophthalmic preparations. The castor oil-Sandimmun® solution mixture is made in a sterile receptacle. After stirring, the mixture is distributed into sterile low density polyethylene bottles. A sterile insert and cap including a tamper-evident seal were placed on each bottle. A content control was then carried out on each batch produced. A sterility test was done on a batch of each day of preparation. Each bottle of each batch is then cleaned, polished, labeled and then packaged in a pre-printed box with an adapted notice. The stability was fixed at 6 months before opening and at 15 days after opening.
45838636|NCT04377048|Drug|Nivolumab|"as described in NGS Arm"
46111624|NCT04107090|Other|US guided lung recruitment maneuver|Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome guided by lung ultrasound
46111625|NCT00831376|Drug|levosalbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
46111626|NCT00831376|Drug|racemic salbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
46111627|NCT00831376|Drug|placebo|Patients will be asked to take two puffs four times a day for 2 weeks
46111628|NCT02602470|Drug|Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)|Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser & Moisturizing
46111629|NCT02602470|Drug|Azelaic Acid Cream|Azelaic Acid Cream 20%
45838637|NCT04377048|Drug|Gemcitabine|"as described in NGS Arm"
45838638|NCT04377048|Drug|Tegafur-Gimeracil-Oteracil|"as described in NGS Arm"
46024923|NCT02781415|Procedure|Traditional Acupuncture Session|"Skin disinfection was made by an antiseptic solution in the sites of insertion and sterile acupuncture needles were used (0.25 x 0.5 mm).~Patients were installed in a seated position and needles were inserted perpendicularly through the skin to a depth of 1 - 2 cm until the De Qi was achieved.~The DeQi corresponds to a feeling of numbness and tingling within the range of acupoint, The insertion sites are represented by the urinary bladder meridian points to the side of the pain (UB21, UB22, UB23, UB24, UB26, UB45, UB46, UB47, UB48 and UB49)."
45838639|NCT04376892|Other|Quality of life measurement|Quality of life measurement by St. George Respiratory questionnaire
45838640|NCT04376814|Drug|Favipiravir|Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days
46111630|NCT02602470|Drug|Metronidazole gel|Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser
46111631|NCT02602470|Drug|Metronidazole cream|Metronidazole Cream 1%, Metronidazole Cream 0.75%, Metronidazole Cream 0.75% w/ Cleanser
46111632|NCT02602470|Drug|Metronidazole Emulsion|Metronidazole Emulsion 0.75%
46111633|NCT02602470|Drug|Metronidazole Lotion|Metronidazole Lotion 0,75%
46111634|NCT02602470|Drug|Brimonidine Tartrate Gel|Brimonidine Tartrate Gel 0.33%
46111635|NCT00829816|Drug|Dimebon|
46111636|NCT00829816|Drug|Placebo|
46111637|NCT00824200|Behavioral|Behavioral|Multicomponent Behavioral and Exercise Therapy (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene & non-pharmacological management of peripheral edema.
46111638|NCT00824200|Drug|tamsulosin (alpha-adrenergic antagonist medication)|0.4 mg given daily
46111639|NCT00824200|Drug|placebo|tamsulosin placebo
46111640|NCT00824200|Behavioral|placebo|placebo behavioral intervention
46111641|NCT04043884|Other|sEmg biofeedback training|Volunteers will perform scapular strengthening and stabilization exercises added to sEMG biofeedback in the upper trapezius (TS), Trapezius (TM), Lower Trapezius (TI), and Serratil Anterior (AS) muscles in real time displayed in a Computer screen.
46111642|NCT04043884|Other|Strength training|The volunteers will perform a strengthening protocol with elbow flexion exercises, medial and lateral shoulder rotation, scapular retraction and push up plus.
46111643|NCT04103736|Dietary Supplement|Beet It Sport Shot|Source of naturally occurring dietary nitrates
46024924|NCT02781415|Drug|Morphine Titration|"Morphine was previously prepared by a study nurse by diluting a 10 mg / 1 ml flakon of morphine chlorhydrate in a 9 ml solution of serum saline to obtain a 10 ml preparation (1 ml = 1 mg).~An initial bolus of 0.1 mg per Kg of actual body weight of morphine chlorhydrate solution is administered.~A titration dose of 0.1 mg / Kg of body weight was repeated every 5 minutes' interval until reaching the therapeutic goal."
46024925|NCT02785003|Drug|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
46024926|NCT02785003|Drug|Ketamine|All individuals randomized to the experimental arm of the trial will receive ketamine therapy at a rate of 2 mcg/kg/hr dosed based on ideal body weight.
46024927|NCT02785003|Drug|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance < 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
46024928|NCT02785003|Drug|Opioid|"All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment."
46111644|NCT04103736|Dietary Supplement|Nitrate-depleted placebo|Placebo
46111645|NCT00829894|Drug|Risperidone|1 mg Tablet
46111646|NCT00829894|Drug|Risperidone|1 mg Tablet
46111647|NCT00622726|Drug|Bevacizumab|Anti-angiogenic drug: intravitreal injection of 0.625 mg (0.025 ml) once into each eye.
46024929|NCT02785003|Drug|Alvimopan|All patients enrolled into the trial will be screened for eligibility for alvimopan utilization. Only in circumstances where patients are not on outpatient opioid medications and where they have not received any at time of arrival will alvimopan be administered. It will be given at least 30 minutes prior to surgery.
46024930|NCT02781259|Procedure|Axillary lymph node dissection|Lymph node dissection is performed in axillary lymph node level I and II. In case of palpable nodes in level II, additional lymph node dissection in level III is done.
46111648|NCT00622726|Procedure|Conventional Laser for ROP|Conventional Laser is applied to the Avascular Peripheral Retina (Anterior to the Vascularized Posterior Retina)
46024931|NCT02781259|Drug|Indocyanine green|10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery
46024932|NCT02781259|Device|Imaging devices|Near-infrared fluorescence is collected by imaging lenses and digital camera.
46024933|NCT05341531|Other|elderly patients undergoing non-cardiac surgery|Elderly patients 60 years and older undergoing major non-cardiac surgery > 2 hours
46111649|NCT00831610|Procedure|Bariatric surgery (Roux-en-Y Gastric Bypass) + Post-bariatric abdominoplasty.|Surgical removal of the exceeding skin and adiposity of the abdominal wall by one midline vertical fuse and one supra-pubic horizontal fuse. Skin suture without flap undermining and with low tension.
45838641|NCT04376814|Drug|Hydroxychloroquine|200mg of Hydroxychloroquine two times per day will be given to patients for seven days in Test group, and Patients in Control group will be given a stat dose of 400mg Hydroxychloroquine tablets two times per day.
45838642|NCT04376814|Drug|Lopinavir / Ritonavir|Patients will be given 200/50 mg of Lopinavir / Ritonavir two times per day for seven days.
46024934|NCT05297617|Drug|Anti-aromatase inhibitor|"Treatment will be either:~Letrozole, given per os, 2.5 mg daily~Anastrozole, given per os, 1 mg daily~Exemestane, given per os, 25 mg daily"
46024935|NCT02782897|Drug|Immunoglobulin Therapy|Immunoglobulin is given intravenously 0.4 g/kg per day for five consecutive days.
46024936|NCT02782897|Other|Standard management|Standard management includes: the use of mild sedation, blood pressure control, management of elevated intracranial pressure, glucose management, temperature management, airway maintenance, and management of medical complications.
46024937|NCT04229953|Device|US scan with 3D/4D VRU software|"Every patient will be evaluated by grayscale 2D-ultrasound and color Doppler. Then, a Samsung WS 80A Elite US scanner with 3D/4D VRU software will be used to assess the placental invasion by applying the two modes (crystal vue and realistic vue). The image analysis will be performed after obtaining the volume dataset. Data will be compared with the intraoperative findings and histopathological confirmation if hysterectomy will be done."
46024938|NCT05280847|Procedure|Erector spinae plane block|fascial plane injection using ultrasound and fluoroscopic guidance
46024939|NCT00638131|Drug|bosentan|62.5mg bid x4 weeks, up-titrate to 125mg bid x12 weeks
46024940|NCT05142475|Biological|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10^9-5x10^10 autologous TILs to patients i.v. in 30-120 minutes.
46111650|NCT00831610|Procedure|Roux-en-Y gastric bypass (bariatric surgery) + Post-bariatric abdominoplasty (without flap undermining)|Bariatric surgery Plastic surgery Abdominoplasty
46111651|NCT00830050|Drug|Naproxen|500 mg BID 7 days
46111652|NCT00830050|Drug|Placebo|BID 7 days
46111653|NCT00623428|Drug|peginterferon alfa-2a|
46111654|NCT00623428|Drug|Ribavirin|
46111655|NCT00831688|Device|Meniett(C) device by MedTronic|pulsed pressure application, up to 12 cm H20 column, 3 times daily for 5 minutes, generated by Meniett device and conducted to middle ear cavity via tympanostomy tube
46111656|NCT00831688|Device|placebo treatment|device seemingly identical to active device, manufactured by Medtronic. 3 times daily for 5 minutes.Produces similar sound effect, but without pulsed pressure elevation.
46111657|NCT00824356|Drug|GSK1004723 (200mg)|Intranasal antihistamine.
45469697|NCT03419182|Procedure|Open Reduction internal Fixation|A surgeon uses hardware, such as plates and screws, to restore structural integrity and alignment of an acetabular fracture.
45469698|NCT03419182|Procedure|Open Reduction Internal Fixation with Total Hip Arthroscopy|A surgeon uses hardware, such as plates and screws, to restore structural integrity and alignment of an acetabular fracture, and replaces the cartilage and bone of the greater trochanter with prosthetic components.
46111658|NCT00824356|Other|Placebo|Equivalent to GSK1004723 in presentation etc.
46111659|NCT00824356|Drug|GSK1004723 (1000mg)|Intranasal antihistamine.
46111660|NCT00831922|Drug|masitinib (AB1010)|3 mg/kg/day
45469699|NCT03424330|Device|ReX-C intervention|Patients receive medication by the ReX-C device
45469700|NCT03424330|Other|Standard of Care|Patients receive medication as usual
45469701|NCT03419104|Diagnostic Test|preoperative walk test|Patients undergoing bariatric surgery who will complete a preoperative 60 meters 60 seconds walk test.
45469702|NCT03305055|Drug|ketamine|Information included in arm descriptions
45469703|NCT03305055|Drug|Fentanyl|Information included in arm descriptions
45469704|NCT03424252|Drug|FDL169|Cystic Fibrosis Transmembrane Regulator (CFTR) corrector
45838643|NCT04376034|Biological|Convalescent Plasma 1 Unit|"Each adult recipient will receive 1 units of plasma, each unit will consist of about 200 to 250 mL.~Each pediatric recipient will receive 10mL/kg up to 1 unit of plasma."
45469705|NCT04547985|Drug|Naltrexone HCl 50 MG Oral Tablet|Generic, oral tablet.
45469706|NCT04547985|Drug|Placebo|Composed of filler material and encapsulated to appear identical to naltrexone.
46024941|NCT02781181|Device|CAS with CPD|using a neuroprotection device
46024942|NCT02781181|Other|CAS without CPD|No Neuroprotection
46024943|NCT05341297|Behavioral|ParentKIT|The intervention is structured in 9 modules through which parents learn to identify and manage their children's anxiety and depressive symptoms. The Internet intervention is guided by two psychotherapists under supervision training in Cognitive Behavioral Therapy, trained by the first author on the treatment protocol.
46024944|NCT02781103|Other|Guided imagery plus active tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have tDCS for 20 minutes concurrently with Guided Imagery.
46111661|NCT00831922|Drug|masitinib (AB1010)|6 mg/kg/day
46111662|NCT00824590|Drug|Dimebon|a single oral dose of 20 mg Dimebon
46111663|NCT00824590|Drug|Dimebon|a single oral dose of 20 mg Dimebon
46111664|NCT02548624|Device|Zephyr BioPatch|"The ZephyrLIFE Hospital System includes the BioPatch™ device (consisting of the BioModule™ sensor, BioModule™ holder, and snap ECG electrodes), the ECHO radio system, and a software monitoring interface. The BioModule™ sensor is a Class II device, 510(k) cleared by the FDA, and commercially available.~The ZephyrLIFE Hospital System stores, transmits and displays vital sign data including ECG, HR, RR, body orientation, and activity to caregivers via a central station."
46111665|NCT00837304|Device|PillCam Colon Capsule|PillCam Colon Capsule: The PillCam Colon capsule has two cameras that enable the device to take video images from both ends. It is 31.11 mm in size and takes pictures at a rate of 4 frames per second. The delay mode allows recording of images from the esophagus and the stomach for 5 minutes before the capsule switches into sleep mode for 2 hours to save energy.
46111666|NCT00837304|Procedure|Standard Colonoscopy|Standard Colonoscopy: Pts. undergo colonoscopy with a video colonoscope (CF H180 AI; Olympus, Tokyo, Japan).
46024945|NCT02781103|Other|Guided imagery plus Sham tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The sham arm will have 30 seconds of tDCS, but after 30 seconds the device will be turned off. The device will remain in place until the subject has listened to 20 minutes of the guided imagery CD.
46024946|NCT04229251|Behavioral|Online Mindfulness-based Intervention|The iMBI starts with psychoeducation about ADHD and defining mindfulness. Participants were then encouraged to discuss their experience of living with ADHD via a series of guided questions. Upon orientated to the program, the participants will be introduced to various topics of mindfulness and ADHD, as well as a wide range of in-session online mindfulness exercises. Offline assignments that correspond to each week's theme will be assigned to participants at the end of each session. Downloadable audio tracks for offline practices will be provided to the participants. Participants are expected to spend around 15 to 30 minutes each day to complete the weekly iMBI assignment.
46024947|NCT04229251|Behavioral|Online Introductory Psychology Program|The online introductory psychology program is a mass online open course program, providing comprehensive overview about psychology as an academic discipline. Each week, participants will be presented with approximately 2-hours pre-recorded lecture. Offline assignments that correspond to each week's theme will be assigned to participants at the end of each session.Downloadable handouts for revision will be provided to the participants. Participants are encouraged to spend around 15 to 30 minutes each day to complete the weekly assignment.
46024948|NCT02462239|Other|Whole-body FDG PET-CT|
46024949|NCT02780245|Drug|Tranexamic Acid|At 20 minutes preoperatively, TXA of 20 mg/kg was administered in Z Solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g).
46024950|NCT02780245|Procedure|Intraoperative Uterine Cooling|Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
46024951|NCT00634699|Procedure|Active Comparator, ischemic compressions|Ischemic Compressions,3 times a week,5 weeks.
46111667|NCT00832156|Biological|Cultured autologous keratinocytes|The experimental wound site will be covered with cultured keratinocytes on a collagen/elastin carrier after the application of a meshed split skin autograft. The control wound site will be covered with a meshed split skin autograft alone.
46111668|NCT00837382|Behavioral|MEDVAMC Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting
46111669|NCT00837382|Behavioral|Telepsychiatry Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting Through Videoconferencing
45469707|NCT05121675|Behavioral|Neuroflow app: Mental health and wellbeing resources for adults|"The NeuroFlow app delivers resources on resilience training, mindfulness-based strategies and cognitive behavioral therapy to adults looking to support their mental health and wellbeing. The specific journey (i.e., content such as activities, videos, trackers, and journaling) is tailored to individuals based on depression and anxiety screeners administered upon signing up to the app."
45469708|NCT03412552|Drug|MgSO4|Loading dose of magensium sulphate (4-6g I.V), given over 20 minutes in 100 ml of dextrose, Maintenance dose (4-6g) magensium sulphate in 500 cc dextrose given over 8 hours using continuous IV drip
45469709|NCT02763189|Other|Expert mentoring|Experts will provide personalized instructional review on how to use the new device for changing endotracheal tubes.
45469710|NCT02763189|Other|Self-study|All subjects will receive self-study
45469711|NCT02521168|Drug|Oral triiodothyronine|Oral triiodothyronine is given peri-operatively through naso-gastric tube
45681699|NCT03589222|Drug|Bortezomib|bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9
45681700|NCT03589222|Drug|Dexamethasone|dexamethasone is 20mg (IV) when given on days that daratumumab is administered (as pre-infusion medication) plus 20 mg of dexamethasone (VO) the day after and the dose of dexamethasone is 40mg (VO) on days when daratumumab is not administered
45681701|NCT01866423|Drug|orteronel|Given PO
45681702|NCT01866423|Other|laboratory biomarker analysis|Correlative studies
45681703|NCT01846208|Drug|Egg Oral Immunotherapy|Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
45469712|NCT02521168|Drug|Placebo|Placebo consist of saccharin lactis that has the same appearance as Tetronine
46024952|NCT05341063|Behavioral|Online Education|"Diabetes education presentations prepared beforehand were explained in two parts in each training. Training interventions were carried out weekly over Zoom for 4 weeks, lasting approximately 40 minutes. Patients' questions were answered.~Two months after the training was completed, the current routine analysis results of the participants were taken again, and height and weight measurements were made with the same measurement tools. Participants were allowed to fill in the data collection forms again."
46111670|NCT00837460|Other|rehabilitation|4 weeks of bilateral followed or preceded by 4 weeks of unilateral similar prehension oriented repeated rehabilitation tasks. About 45 minutes 3 times a week, the subject is coached by a physiotherapist to enhance his prehension habilities.
46111671|NCT04043338|Drug|XC130-A10H|XC130-A10H supplied as a 0.2, 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules or tablets
46024953|NCT05341063|Other|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
45681704|NCT01846208|Drug|Baked Egg|Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.
45681705|NCT03020758|Dietary Supplement|Dried Fruit|Mixture of equal parts 4 dried fruits (figs, raisins, dates, plums) totaling 3/4 cup daily.
46111672|NCT04043338|Drug|Placebo|Placebo supplied as matching capsules or tablets
46111673|NCT00824668|Drug|biphasic insulin aspart 30|
45469713|NCT03412474|Drug|Bupivacaine|"The study drugs will be prepared by an anesthesiologist not involved in performing the block, patient care or in data collection. Patients will be randomly allocated into two groups of 40 patients each:~Group A: will receive 0.2 ml/kg/side of bupivacaine (0.125%)."
46111674|NCT00824668|Drug|insulin glargine|
46111675|NCT00824668|Drug|insulin glulisine|
46111676|NCT00832234|Drug|Bortezomib, Dexamethasone, Rituximab|The combination of bortezomib, dexamethasone and rituximab will be administered in five treatment cycles. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle one. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of bortezomib, dexamethasone 40mg IV and rituximab 375mg/m2 IV will be administered. A total of 8 infusions of rituximab will be administered. The administration of bortezomib before rituximab may abrogate the IgM flare phenomenon that occurs frequently after the first course of rituximab.
46111677|NCT05036980|Drug|Trans Sodium Crocetinate|Single IV bolus
45469714|NCT03412474|Drug|Dexmedetomidine|Group B: will receive 0.2 ml/kg/side of bupivacaine (0.125%) + 0.5 µ/kg of dexmedetomidine.
45681706|NCT03020758|Other|High Carbohydrate Snack|Calorie-matched carbohydrate-rich snack.
46024954|NCT05340985|Dietary Supplement|25(OH)D3|calcifediol
46024955|NCT05340985|Dietary Supplement|vitamin D3|Cholecalciferol
45469715|NCT03412474|Drug|paracetamol|paracetamol
45469716|NCT03273387|Drug|Trimetazidine|The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.
45681707|NCT04166799|Device|Mepitel Film|Mepitel® Film is a thin, soft and conformable transparent film dressing with Safetac®, offering protection for vulnerable skin.
46024956|NCT05340829|Biological|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with lymphoma and lympholeukemia
46024957|NCT02780791|Other|Transplantation into pelvic wall|Ovarian tissue will be transplanted subperitoneal into the loge of the adnexa of Uterus.
46024958|NCT02780791|Other|Transplantation into the ovary|Ovarian tissue will be transplanted contralateral into the ovary.
46024959|NCT02780947|Procedure|Ventricular tachycardia substrate ablation|"Study protocol~Baseline programmed ventricular stimulation performed from the LV~High density endocardial LV mapping using CARTO® 3 System~Randomized substrate ablation in half patients. Ablation end-point is considered the elimination of all endocardial late and early potentials (LPs and EPs)~Final programmed ventricular stimulation performed from the LV~Programmed ventricular stimulation with up to 4 extrastimuli from LV is performed and repeated at the end of the procedure in patients undergoing substrate ablation."
46024960|NCT02784457|Drug|Cetrorelix|
46111678|NCT00837772|Device|Standard cutting guide for TKA|Use of the usual cutting guide for surgical replacement of a diseased knee
46111679|NCT00837772|Device|Otismed MRI generated cutting guide for TKA|Use of the customized MRI generated cutting guide for surgical replacement of a diseased knee
46111680|NCT00832312|Other|ozone-oxygen mixture|10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml)
45469717|NCT03273387|Drug|Placebo oral capsule|The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
45469718|NCT03418948|Device|CC followed by EC|CC = conventional colonoscopy EC = endocuff assisted colonoscopy
45469719|NCT03418948|Device|EC followed by CC|CC = conventional colonoscopy EC = endocuff assisted colonoscopy
45469720|NCT03418948|Device|2x EC|EC = endocuff assisted colonoscopy
46111681|NCT00832312|Other|placebo (saline)|Injection of 1cc of saline into the knee joint
45681708|NCT03586804|Other|dual task|mental and motor tasks will be performed while standing. Motor task: holding mini blocks Mental task: Counting the numbers from 200 to 1
45681709|NCT03589066|Drug|LY03003|28 mg intramuscular suspension
46024961|NCT05338177|Other|Immunosuppression reduction|participants stop mycophenolate or azathioprine one week before additional vaccine dose. Overall medication is stopped for two weeks.
46024962|NCT05338177|Other|No immunosuppression reduction|participants do not alter immunosuppresion
46024963|NCT02780323|Drug|CELBESTA®|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
46024964|NCT02780323|Drug|CELEBREX®|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
46024965|NCT02780323|Drug|CELEBREX® placebo|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
46111682|NCT02547532|Other|collection of sputum|
46111683|NCT00837850|Device|Bone cement 1|Bone cement SmartSet® HV
46111684|NCT00837850|Device|Bone cement 2|Bone cement Palacos R
46111685|NCT00784134|Drug|Alteplase|1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses
46111686|NCT00784134|Other|Normal saline|1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses
46111687|NCT00832468|Other|ear acupressure|The ear acupressure that is used involved a 0.3 cm-sized magnetic pellet on a 1 cm size sticky patch (Ching-Ming Co., Taiwan), which was placed on the bilateral ear Shenmen points; each of the points were pressed once a second for one minute (60 times) before sleep every night. The time period of the treatment course was four weeks.
46024966|NCT02780323|Drug|CELBESTA® placebo|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
46111688|NCT00832468|Other|sham ear acupressure|The sham ear acupressure that was used involved a 1 cm size sticky patch placed on the bilateral ear Shenmen points. There was no magnetic pellet attached to the sticker and no need to press it.
46024967|NCT05331859|Drug|Insulin|Topical insulin drops will be prepared by diluting 1 unit of rapid-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops will be preserved at low temperature (2ºC) and applied four times a day.
46024968|NCT05331859|Drug|autologous serum (AS)|Whole blood (20 ml) wll be procured by venipuncture, centrifuged at 1,500 revolutions per minute (relative centrifugal force of 25.15 × g) for 10 minutes. AS drops will be carefully prepared under a laminar airflow cabinet, and diluted with artificial tears (Systane ultra; Alcon) to 20%. AS drops will be prepared on the day of surgery and patients will be asked to keep AS drops refrigerated at about 4C.
45469721|NCT03418948|Device|2x CC|CC = conventional colonoscopy
46024969|NCT05331859|Drug|conventional|Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon Laboratories) four times daily for one month then fluorometholone 0.1% (Efemyo; Orchidia Laboratories) four times daily for another two to four weeks depending on refraction and haze level.
46024970|NCT02784691|Device|Feeligreen patch|
46111689|NCT00832546|Drug|Placebo|
46111690|NCT00832546|Drug|Oral NGX426 (Powder in solution)|
46111691|NCT00837928|Drug|bendamustine|40 mg/m2 will be administered IV on days 1,2,and 3 prior to surgery.on each day of SRT.
46111692|NCT00837928|Other|laboratory biomarker analysis|samples will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. PK samples will not be collected from patients who begin SRT on day 1).
46111693|NCT00837928|Procedure|Surgical Resection of Brain Metastases|Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine)
46111694|NCT00837928|Radiation|Stereotactic body radiation therapy|Starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri)
46111695|NCT02550184|Other|Focused ultrasonographic examination.|Focused ultrasonographic examination of the lungs and the heart of patients who fulfill the inclusion criteria and who have given their informed and written consent for participation.
45469722|NCT03423784|Device|HA BPX V3.3|medical device containing HA
45681710|NCT01845974|Device|ThermoCool® SF NAV Catheter|The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
46111696|NCT03996174|Other|Interview|Interview bases on the use of an interview guide, during one hour maximum
46111697|NCT04106622|Procedure|electrophysiological study|"To assess whether the AP is of high risk or not, for all patients the AERP of the AP will be determined by one of the following ways:~The cycle length at which abrupt and complete loss of pre-excitation occurs during exercise test. If this didn't happen, the patient will be subjected to invasive electrophysiologic study..~The Antegrade refractory period of the AP is measured during EPS as the shortest cycle length with one-to-one conduction over the AP by incremental atrial stimulation after which the QRS becomes narrow or no conduction occurs due to block of the impulse in the AP.~The shortest pre-excited R-R interval during spontaneous or induced AF."
45681711|NCT01845974|Device|ThermoCool® catheter|The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
45681712|NCT03020368|Biological|Leeches|
46111698|NCT04102566|Drug|Ibuprofen 600 mg|We'll be adding ibuprofen while trying to limit oxycodone use while hospitalized. Patients will not be discharged with a narcotic.
46111699|NCT04102566|Behavioral|Education|We'll be adding education to patient's post-operative instructions to aid in their pain control management.
46111700|NCT04106778|Drug|DMT310|Topical Powder
46111701|NCT04106778|Drug|Placebo|Placebo Topical Powder
46111702|NCT00916110|Drug|ATN-103|1.5 mg solution, single subcutaneous injection
46111703|NCT00916110|Drug|ATN-103|4 mg solution, single subcutaneous injection
46111704|NCT00916110|Drug|ATN-103|10 mg solution, single subcutaneous injection
46111705|NCT00916110|Drug|ATN-103|25 mg solution, single subcutaneous injection
46111706|NCT00916110|Drug|ATN-103|25 mg solution, single intravenous injection
45469723|NCT03423784|Other|Dentinox-Gel N|Anaesthetic gel
45681713|NCT03020368|Drug|Diclofenac|
45681714|NCT03020290|Device|Endovascular treatment for PAD during medical care (SuperA stent (Abbott))|Long femoropopliteal stenting with SuperA devices during medical care. The endovascular treatment for PAD will be done during the usual medical treatment of patient. The intervention is not carried out within the framework of the research protocol
46111707|NCT00916110|Drug|ATN-103|50 mg solution, single subcutaneous injection
46024971|NCT04229407|Dietary Supplement|Dietary supplement|MRI eligibility evaluation Dietary supplement drink powder dissolved in 150 c.c. warm water oral intake twice daily at every morning and night (30 minutes after exercise if do exercise) for 12 weeks subjects will be instructed to do 45-minute exercise once a week following the training program of the study trainer at gym, and 30-minute exercise (per exercise manual) at least twice a week at home.
46111708|NCT00916110|Drug|ATN-103|100 mg solution, single subcutaneous injection
46111709|NCT00916110|Drug|ATN-103|200 mg solution, single subcutaneous injection
46111710|NCT00916110|Drug|ATN-103|200 mg solution, single intravenous injection
46111711|NCT00776100|Other|clinical observation|Patients undergo observation for 6 weeks.
46024972|NCT04229407|Dietary Supplement|vitamin B|MRI eligibility evaluation vitamin B drink powder dissolved in 150 c.c. warm water oral intake twice daily at every morning and night (30 minutes after exercise if do exercise)for 12 weeks subjects will be instructed to do 45-minute exercise once a week following the training program of the study trainer at gym, and 30-minute exercise (per exercise manual) at least twice a week at home.
46111712|NCT00776100|Radiation|radiation therapy|Patients undergo radiotherapy 5 days a week for 6 weeks.
46024973|NCT05340595|Other|Orthodontic retainer bonding|Self-etch primer (Transbond XT Primer; 3M Unitek, California) was administered to the teeth's lingual surfaces.
46111713|NCT04103658|Radiation|Near-infrared heating|Same as the arm/group description. The NIR heating group will have the non-melanoma skin cancer lesion excised based on the lesion borders established from application of NIR heat at a distance of 20cm for 10 minutes.
46111714|NCT02602236|Device|AOS-C2000-B|1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day
46111715|NCT04102176|Other|stopping nucleos(t)ide therapy|patients taking nucleoside(t)ide therapy will stop treatment
46111716|NCT04102176|Other|Continue nucleos(t)ide analogue|Continue nucleos(t)ide analogue
45681715|NCT03442582|Biological|Afluria Influenza Vaccine|"Afluria is a seasonal influenza vaccine~Vaccine exposure in routine care (no vaccination per protocol)"
46024974|NCT04231435|Drug|Fedratinib|Oral
46024975|NCT04231435|Drug|Digoxin|Oral
46024976|NCT04231435|Drug|Rosuvastatin|Oral
46111717|NCT04101864|Procedure|Electromagnetic navigation|Acetabular component placement in total hip arthroplasty will be performed wit the help of electromagnetic image-less navigation system.
46111718|NCT04101864|Procedure|Freehand|In the control group acetabular components in total hip arthroplasty will be placed with the help of the freehand technique.
46111719|NCT00783432|Drug|Astepro Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
46111720|NCT00783432|Drug|Astelin Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
46111721|NCT00783198|Biological|SCH 39641 6 Amb a 1-U|SCH 39641 6 Amb a 1-U sublingual tablets administered once daily
46111722|NCT00783198|Biological|SCH 39641 12 Amb a 1-U|SCH 39641 12 Amb a 1-U sublingual tablets administered once daily
45681716|NCT03891706|Drug|tumor-specific TCR-T cells|On day 0 and day 14, 0.5-5x10^9 TCR-T cells will be infused intravenously (IV) over 1 hour,patients may choose to receive more cell infusions if they benefit from the treatment.
46024977|NCT04231435|Drug|Metformin|Oral
46024978|NCT05262907|Device|Transthoracic Echocardiogram or Cardiac MRI|Non-invasive imaging of the heart to evaluate structure and function.
46111723|NCT00783198|Biological|Placebo|matching placebo sublingual tablets administered once daily
46111724|NCT00789360|Drug|Inhaled Placebo|Inhaled Staccato Placebo, 2 inhalations, 8 hours apart
46111725|NCT00789360|Drug|Inhaled Loxapine|Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart
46111726|NCT04022538|Procedure|Anterior maxillary vertical segmental sandwich osteotomy with simultaneous implant placement|"Following the Sandwich Osteotomy procedure described in the study description, the following steps will be done:~The first implant osteotomy will be prepared and placed while a chisel is placed between the down fractured segment and the basal bone, and then the second implant will be installed.~The gap between the transported segment and the basal bone will be filled with xenograft particulate bone substitute.~Finally, periosteal scoring will be done to allow tension-free interrupted closure using 3-0 vicryl suturing material."
46111727|NCT04022538|Procedure|Anterior maxillary vertical segmental sandwich osteotomy using micro-plates fixation|"Following the Sandwich Osteotomy procedure described in the study description, the following steps will be done:~The created gap between the transported segment and the basal bone will be filled with xenograft particulate bone substitute.~The mobilized segment is to be fixed to the basal bone using micro-plates and micro-screws.~Finally, periosteal scoring will be done to allow tension-free interrupted closure using 3-0 vicryl suturing material."
46111728|NCT05526924|Radiation|Chemoradiation|A combination of chemotherapy and radiation given at the same time to treat cancer.
46111729|NCT05526924|Drug|Pamiparib|An anti-cancer drug that targets specific cells to help fight cancer given by IV (through a needle inserted into a vein).
45681717|NCT03891706|Drug|Interleukin-2|Aldesleukin 3,000,000 IU. IV.QD beginning within 24 hours of cell infusion and continuing for up to 5 days .
45681718|NCT03581422|Drug|hCG administration before embryo transfer|Thawed embryo transfer with ovulation triggered by hCG
45681719|NCT03581266|Other|Rye/Wheat|Mechanistic study of glucose kinetics after ingestion two kinds of bread
46024979|NCT05262907|Device|Ventripoint Echocardiogram|Non-invasive ultrasound of the heart to evaluate structure and function through 3D imaging.
46111730|NCT05526924|Drug|Hydroxyurea|A chemotherapy drug given in pill form; used to treat leukemia and head and neck cancer.
46111731|NCT05526924|Drug|Fluorouracil (5FU)|A chemotherapy drug used to treat different types of cancer.
46111732|NCT05526924|Drug|Tislelizumab|An anti-cancer drug.
46111733|NCT05526300|Device|Intelligent Hypertension Management System|The intelligent hypertension management system is used to remotely detect the blood pressure of hypertensive patients
46111734|NCT05526300|Other|The standard care|The standard care
46111735|NCT00782496|Device|Education + new meter|Diabetes education and a new meter with basic features
46111736|NCT00782496|Device|Education + new meter + feature activation|Diabetes education and a new meter with advanced features
46111737|NCT00782418|Drug|Comparator: exenatide|exenatide in two 5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 5mcg doses will be administered, followed by HCG or GGI.
46111738|NCT00782418|Drug|Comparator: exenatide|exenatide in two 1.5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 1.5mcg doses will be administered, followed by HCG or GGI.
46024980|NCT05340517|Procedure|video-assisted rib planting|Give the patient intercostal nerve block and laryngeal mask anesthesia, after that, put the patient in lateral position. Make a 4-6cm posterolateral incision along the lower edge of the scapula，sever latissimus dorsi and serratus anterior and reach the rib surface. Lift the scapula with the abdominal retractor (or xiphoid retractor), Free adhesion tissue inside the scapula and put in the thoracoscopic lens. Free the tissue of the upper and lower edges of the ribs carefully, reset ribs and insert rib plate, which is fixed by 90° electric drill and locking screw.
46111739|NCT00782418|Drug|Comparator: Placebo|5% osmitrol in two 60 mcL subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 60 mcL doses will be administered, followed by HCG or GGI.
46111740|NCT00782340|Drug|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
46111741|NCT00782340|Drug|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
46111742|NCT00916188|Dietary Supplement|Black Tea Extract|Amount/dose depends on Arm assignment.
46111743|NCT00774852|Drug|abatacept|Intravenous infusion (500-1000 mg, dep on weight) at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
46111744|NCT00774852|Drug|cyclophosphamide|500 mg intravenous infusion every 2 weeks for 12 weeks
46111745|NCT00774852|Drug|azathioprine|2 mg/kg/day orally from weeks 12-28; continue until week 52 if only partial response observed at week 24
46111746|NCT00774852|Drug|prednisone|60 mg/day for 2 weeks, then taper to 10 mg/day by 12 weeks, then continue on stable dose
45681720|NCT05702944|Drug|Phenoxybenzamine|Patients in sham comparator group take a phenoxybenzamine at least 2 to 5 weeks before surgery. If blood pressure is more than 130/80 mmHg in the sitting position, the patient will take a more amount of phenoxybenzamine. If blood pressure is less than 90 mmHg in the standing position, the patient will take a less amount of phenoxybenzamine. In active comparator group, there is no drug to be taken.
45681721|NCT05702866|Diagnostic Test|Transcutaneous oximetry|Comparison of the TcpO2 values recorded during dynamic maneuver with the estimated rate of compression of the subclavian and axillary vessels determined on dynamic angiography.
45681722|NCT03581110|Diagnostic Test|computed tomography|noncontrast-enhanced chest computed tomography
45681723|NCT04765618|Procedure|bariatric surgery|laparoscopic sleeve gastrectomy,or gastric bypass
45681724|NCT03586180|Behavioral|Medical Clowning for children|Clowns in clinical setting have been found to be effective in reducing children's experiences of these effects during hospitalization and before procedures.
45681725|NCT03580876|Drug|addition of azathioprine|impact of addition of azathioprine after a switch of a second anti-TNF agent
46111747|NCT00774852|Drug|abatacept placebo|Intravenous infusion at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
46111748|NCT00774852|Drug|azathioprine placebo|Oral capsule, daily from weeks 28 to 52, only if complete response observed at week 24
46111749|NCT02602158|Dietary Supplement|Octanoic acid (1-13C, 99%)|"13C-marker will be mixed with emulsions. 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm"
46111750|NCT02602158|Dietary Supplement|TRIOCTANOIN (1,1,1-13C3, 99%)|"13C-marker will be mixed with emulsions 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm"
46111751|NCT02603016|Drug|GLSE compound|
46111752|NCT02603016|Drug|Maitake mushroom extract compound|
46111753|NCT02603016|Drug|Ginseng compound|
46111754|NCT04101942|Behavioral|Internet-based CBT|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 36 hours.
45469724|NCT04527003|Drug|Cannabidiol (CBD) Extract|Cannabis is a well-known plant that contains more than 500 identified phytochemicals of which over 100 are cannabinoids. The most widely studied is 9-tetrahydrocannabinol (9-THC), which is the major psychoactive component of Cannabis, but Cannabidiol (CBD) has been increasingly favored for its reduced side effect profile and potential health benefits. CBD was first isolated from Cannabis in the 1940s. CBD, unlike 9-THC, does not bind to CB1 and CB2 receptors, which accounts for its lack of typical psychotropic effects, but is still appears to work via alternative mechanisms via the endocannabinoid system.
45469725|NCT04527003|Drug|Norethindrone Acetate|Norethindrone is a form of progesterone, a female hormone important for regulating ovulation and menstruation.
45681726|NCT03580876|Drug|Switch to a second anti-TNF drug alone|Switch to a second anti-TNF drug alone without addition of azathioprine
46024981|NCT05340439|Drug|IncobotulinumtoxinA 100 UNT [Xeomin]|"In cycle 1, a total body dose of 16U/kg (maximum 400U) of IncobotulinumtoxinA will be injected into the spastic muscles of the affected limbs.~In cycle 2, a total body dose of 19U/kg (maximum 475U) of IncobotulinumtoxinA will be injected. If a dose of 19U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 1 (16U/Kg; maximum 400U) may be administered in the cycle 2.~In cycle 3, a total body dose of 22U/kg (maximum 550U) of IncobotulinumtoxinA will be injected. If a dose of 22U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 2 (19U/Kg; maximum 600U) may be administered in the cycle 3 (if the patient has been treated with 16U/kg in cycle 2, a dose of 19U/kg may be injected in cycle 3)."
46024982|NCT05340361|Device|Optical coherence tomography-guided percutaneous coronary intervention|OCT examination is performed using a frequency-domain OCT system (C7 Dragonfly OPTIS Imaging Catheter, Abbott Vascular, Santa Clara, CA, USA) with a 5.4 or 7.5 cm total pullback length according to a non-occlusive technique. The procedure is performed via radial or femoral access with a ≥6 Fr guiding catheter. The OCT catheter is advanced over the 0.014-inch PCI wire and the implanted stent was crossed after administration of intracoronary nitrates of 200 µg. For blood clearing, contrast media was injected through the guiding catheter with an automated power injector. The standard infusion rate was 4 mL/s for 4 seconds with 250 PSI. Follow-up OCT image acquisition was achieved with the same method. After post-PCI OCT, we evaluate the factor regarding post-PCI optimization target by European Expert Consensus.
46111755|NCT04106310|Device|High-flux dialyzer|a dialyzer meeting the definition of high-flux
46111756|NCT04106310|Device|Theranova dialyzer|a middle cut-off dialyzer
46111757|NCT04106076|Biological|UCART123|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor
46111758|NCT00774306|Drug|phenytoin|Phenytoin is a anti-seizure medication. Participants will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
46111759|NCT00774306|Drug|valproate|Valproate is an anti-seizure medication. Participants will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses.
46111760|NCT00774306|Drug|levetiracetam|Levetiracetam is an anti-seizure medication. Participants will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
46111761|NCT04105920|Device|Hyaluronic acid arm|Patients included in this arm, will have, before insertion of brachytherapy seeds in the prostate, an injection of hyaluronic acid between the prostate, rectum, and pudendal arteries
46111762|NCT04105764|Drug|Rocuronium|DEEP block to PTC 1-3
46111763|NCT04105764|Drug|Rocuronium bromide|MODERATE block to TOF1-2
46111764|NCT04105608|Dietary Supplement|High-fiber vegetarian meal|The intervention consisted in the administration of a high fiber vegetarian meal prepared by our research group staff.
45469726|NCT04527003|Other|Placebo|a substance or treatment which is designed to have no therapeutic value
45469727|NCT03412318|Device|Twisted file|Use of twisted file during cleaning and shaping of root canals
45469728|NCT03412318|Device|Mpro|Use of Mpro during cleaning and shaping of root canals
45681727|NCT03580798|Procedure|Delayed graft|8 weeks post-extraction 15 test patients will receive implant placement plus osseous grafting.
45681728|NCT03580798|Procedure|Simultaneous graft|At the time of extraction osseous graft will be placed in the socket and implant placed 4 months later.
46111765|NCT04105608|Dietary Supplement|Mediterranean-like meal|The intervention consisted in the administration of a Mediterranean-like meal prepared by our research group staff.
46111766|NCT04105686|Other|Control Infant Formula|Ready to feed infant formula, feed ad libitum
46111767|NCT04105686|Other|Experimental Infant Formula|Ready to feed infant formula, feed ad libitum
46111768|NCT00781326|Drug|Nimodipine|Nimodipine will be initiated at one, 30-mg tablet three times a day for 1 week, increased to 2 tablets three times a day for 1 week, and then increased to three tablets three times a day for the remaining 30 weeks of the study. Participants who cannot tolerate the maximum dose of 270 mg/day will be maintained at the highest tolerable dose.
46111769|NCT00781326|Drug|Placebo|Placebo will be given in doses matching those of nimodipine.
46111770|NCT02603094|Procedure|clear fluid ingestion|drinking of clear fluid in preoperative period
46111771|NCT00916266|Procedure|Stem cell transplantation|Transplantations with autologous bone marrow mononuclear stem cells by selective posterior cerebral artery angiography
46111772|NCT00787800|Device|Dual Chamber ICD|Dual Chamber ICD: Atrial therapies and minimized ventricular pacing will be programmed on along with VT/VF detection and therapies with detection enhancements; remote monitoring set to alert for sustained atrial fibrillation Dual Chamber ICD Atrial prevention and termination therapies, Managed Ventricular Pacing (MVP)along with VT/VF detection and therapies for dual chamber device.
46111773|NCT00787800|Device|Single Chamber ICD|"Single Chamber: Optimally programmed VT/VF detection and therapies will be programmed on including use of detection enhancements.~VT/VF detection and therapies with discrimination criteria for single chamber device."
46111774|NCT00773838|Drug|Vorinostat|Four 100 mg vorinostat capsules orally, once daily (QD) by mouth on Days 1-14 of each 21-day treatment cycle.
46024983|NCT05340361|Device|Optical coherence tomography-guided Onyx expansion|"Expansion of 2.25, 3.0, and 4.0 mm Resolute Onyx @ nominal pressure~OCT pullback~Expansion with over 0.5mm sized non-compliant balloon of each stent~OCT pullback~Expansion with over 1.0mm sized non-compliant balloon of each stent~OCT pullback~Expansion with over 1.25~1.5mm sized non-compliant balloon of each stent~OCT pullback~Evaluation of polymer status with overexpansion assessed by an electric microscope"
46024984|NCT01194414|Drug|tocilizumab SC|Tocilizumab supplied in a single-use pre-filled syringe, with a needle safety device, delivering 162 mg/0.9 mL solution for subcutaneous injection once a week.
46024985|NCT01194414|Drug|tocilizumab IV|Tocilizumab supplied in vials as a sterile solution for 8 mg/kg intravenous infusion every 4 weeks.
46024986|NCT01194414|Drug|placebo to tocilizumab SC|Placebo tocilizumab supplied as a single-use pre-filled syringe with a needle safety device, delivering 0.9 mL sodium chloride for subcutaneous injection once a week for 24 weeks in the double-blind period.
46024987|NCT01194414|Drug|placebo to tocilizumab IV|Placebo to tocilizumab supplied as a solution in 10 mL vials containing polysorbate 80 and sucrose in water for infusion every 4 weeks for a total of 24 weeks in the double-blind period.
46111775|NCT00773838|Drug|Bortezomib|Bortezomib 1.3 mg/m^2, IV injection QD on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
46111776|NCT00773838|Drug|Dexamethasone|Five 4 mg Dexamethasone tablets orally, QD on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day treatment cycle if PD is observed after 2 treatment cycles or if NC to disease is observed after 4 treatment cycles.
46111777|NCT00787644|Drug|Pioglitazone|Pioglitazone tablets; 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
46111778|NCT00787644|Drug|Placebo|Matching placebo (inert tablet)
45681729|NCT03889834|Procedure|Autologous Blood Transfusion|Autotransfusion of packed red blood cells (200 ml) stored at 4 or -80°C for 31 days
46111779|NCT02602002|Drug|Remifentanil|IV
46111780|NCT02602002|Drug|Placebo|Placebo
46111781|NCT00787566|Drug|Intranasal granisetron|0.5 mg, 1.0 mg or 2.0 mg dose of TRG prior to the administration of a highly-emetogenic chemotherapy regimen
45681730|NCT03889834|Other|No transfusion|no transfusion
45681731|NCT03586024|Drug|Pembrolizumab|dose of pembrolizumab will be 200 mg IV every 3 weeks
46024988|NCT01194414|Drug|Disease-modifying antirheumatic drugs (DMARDs)|stable dose as prescribed
46024989|NCT05340283|Procedure|physiotherapy|Patients received physiotherapy treatment at home for a certain period of time. Data were collected on the assessments made at the beginning and at the end of the physiotherapy treatment.
46111782|NCT04103112|Device|Graduated compression stocking|"Compression stockings have been used safely in the UK for about 50 years. They contain an elastic fibre designed to fit tightly around the legs. These specialist stockings are tighter around the ankle, with the level of compression gradually decreasing up the garment.~The pressure created by the stockings helps blood flow up the leg, allowing blood to flow freely to the heart and not pool in the leg which can result in pain and swelling."
46111783|NCT04101552|Procedure|socket shield technique with xenophobic graft particulate and without the use of graft|the jumping gap between the implant and the shield is grafted by xenograft particulate and the control group is not grafted
45469729|NCT03423706|Procedure|the new model of haplo-HSCT for r/r B-ALL|take advantage of high-dose CTX、CD19-CART、donor CD34+HSC and Tregs to create a new model of haplo-HSCT for the patients in r/r B-ALL,to improve the quality of HSCT.
45681732|NCT05702632|Device|1- Reciprocal electrical stimulation|A specialized programmable electrical stimulation device was used (Uniphy is the manufacturer of Phyaction787; Uniphy, Eindhoven, the Netherlands). The device has two channels that can alternatively stimulate two opposing groups of muscles (reciprocate).
46024990|NCT02686411|Other|Survey Administration|Complete survey
46024991|NCT05340127|Device|CEREBO®|Usability Study
46024992|NCT05327413|Other|CT and MRI|CT and MRI were conducted to measure the femoral external rotation
46024993|NCT05028829|Drug|Atorvastatin 20mg|Oral administration of atorvastatin 20 mg
46024994|NCT05028829|Drug|Placebo|Oral administration of placebo
46024995|NCT02784769|Other|measurement of skin autofluorescence|
46111784|NCT04017234|Other|frequency following response, eye exercise, and transcutaneous|frequency following response, eye exercise, and TENS for 3 times per week during 4 weeks
46111785|NCT02602938|Drug|Aspirin|Take aspirin (100mg) orally once a day for 2 months
46111786|NCT00787254|Drug|Lansoprazole|Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 6 to 24 months.
46111787|NCT00787254|Drug|Gefarnate|Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 6 to 24 months.
46111788|NCT00625846|Other|Laboratory Biomarker Analysis|Correlative studies
46024996|NCT02784769|Other|skin biopsy collection|
46024997|NCT02173405|Drug|OnabotulinumtoxinA|comparison of OnabotulinumtoxinA with placebo
46024998|NCT02173405|Drug|Placebo|comparison of placebo with investigational drug OnabotulinumtoxinA
46111789|NCT00625846|Drug|Pazopanib Hydrochloride|Given PO
46111790|NCT00824902|Procedure|Tissue Elastography Imaging|Using special elastography software, probe pressed gently against prostate during routine ultrasound before prostate surgery, 10-15 minutes process.
46111791|NCT00922402|Procedure|Intensive insulin infusion|"The intensive control of glycemia is obtained with a shared in-hospital insulin infusion protocol, supported by the use of a continuous glucose monitoring system (Medtronic Guardian REAL Time). Any sudden variation of glycemia levels and/or alarms, as indicated by the device, has to be confirmed with a finger-stick before any therapy modification.~In-hospital management is subdivided in a 2-day intensive and a 3-day post-intensive phase."
46111792|NCT04101786|Other|Hip adductors exercise variations|The participants will perform different exercise variations targeting hip adductors in randomized order.
46111793|NCT00824980|Drug|IP10.C8|IP10.C8 Gel 1%
46111794|NCT02550028|Drug|Oral levetiracetam|Oral load of levetiracetam (50 mg/kg) following identification of EEG confirmed neonatal seizure.
46111795|NCT02550028|Drug|Intravenous phenobarbital|Intravenous load of phenobarbital (20 mg/kg)following EEG confirmation of seizure activity load.
46111796|NCT04105374|Drug|Extended Release Flucytosine|Given PO
46024999|NCT02120365|Drug|Perampanel|Perampanel is a noncompetitive (allosteric) antagonist of the AMPA-R that is well-absorbed (100% bioavailability), has good blood-brain-barrier penetration, and rapidly reaches peak plasma concentrations (1 hour). To date, there have been no clinical trials of AMPA-R antagonists (e.g., perampanel) for the treatment of alcoholism.
46025000|NCT02120365|Drug|Placebo|Placebo given in place of perampanel during the pre-treatment period and lab session days.
46025001|NCT04228939|Behavioral|Recovery Record aftercare|"Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of Recovery Record at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 4-8, every other week in weeks 8-12 and once in week 16."
46111797|NCT04105374|Device|NovoTTF-100A Device|Receive Optune device
46111798|NCT04105374|Other|Quality-of-Life Assessment|Ancillary studies
46111799|NCT04105374|Other|Questionnaire Administration|Ancillary studies
46111800|NCT04105374|Radiation|Radiation Therapy|Undergo radiation
46111801|NCT04105374|Drug|Temozolomide|Given PO
46111802|NCT04105374|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
46111803|NCT04105374|Biological|Vocimagene Amiretrorepvec|Given via intracranial injection
46111804|NCT04102722|Device|MUST device|Imaging with MUST device
46111805|NCT02601846|Other|No intervention|This is an observational study, without any specific intervention.
46111806|NCT04102878|Drug|Topical Anesthetic|Topical anaesthetic drops (proxymetacaine 0.5% and tetracaine 1%) applied
46111807|NCT04102878|Procedure|Transconjunctival anaesthetic|Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transconjunctival route
46111808|NCT04102878|Procedure|Transcutaneous anaesthetic|Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transcutaneous route
46111809|NCT04102878|Other|Patient comfort questionnaire|The patient will be asked to rate the level of pain during each local anaesthetic injection on a 0-10 scale
46111810|NCT04102878|Other|Facial photograph|The patient will have a photograph taken following the anaesthetic injections to document the presence or absence of bruising
46111811|NCT04102878|Procedure|Eyelid surgery|Eyelid surgery will be performed as per the plan from their preoperative appointment
46111812|NCT00825136|Behavioral|relaxation|Participants were asked to log in the system to keep the muscle relaxation program every day and complete some self-rating scales on browser every week.
46111813|NCT00825136|Behavioral|biofeedback (finger temperature biofeedback)|Participants were asked to log in the system to keep the muscle relaxation program plus finger temperature biofeedback every day and complete some self-rating scales on browser every week.
46111814|NCT00838084|Drug|LY2811376|Oral capsules
45469730|NCT04447612|Drug|Durvalumab|Intravenous infusion of durvalumab 1500mg every 4 weeks for 13 cycles (1 year), starting 1 week before start of induction chemotherapy
45469731|NCT04447612|Drug|Cisplatin|Induction phase: cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles Concurrent phase: cisplatin 100mg/m2 starting on day 1 of radiation therapy via intravenous infusion every 3 weeks for 3 cycles
46111815|NCT00838084|Drug|Placebo|Oral capsules
46111816|NCT05548764|Procedure|Prevention Bundles for SSIs|10 preoperative, intraoperative and postoperative bundles that aim to decrease SSIs rate after their implementation in patients that underwent abdominal surgery.
46025002|NCT04228939|Behavioral|Treatment as usual (TAU)|Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2.
46025003|NCT05017051|Behavioral|Chocolate cake|The participants will have to make a chocolate cake following an imposed recipe at 4 visits (initially (M0), after 12 months (M12), after 24 months (M24) and after 36 months (M36)).
46111817|NCT00838240|Drug|clofarabine|Given IV
46111818|NCT00838240|Drug|cytarabine|Given IV
46111819|NCT00838240|Drug|idarubicin|Given IV
46111820|NCT00773292|Drug|ciclosporin|Ciclosporin 2.5 - 5mg/kg/day in two equally divided doses. dose adjusted according to trough ciclosporin concentration
46111821|NCT00838318|Behavioral|Interview|Audiotaped Phone Interview/Survey, 30 - 45 minutes.
46111822|NCT00786864|Other|exercise programme|Specific low back pain exercise programme for children
46111823|NCT00838396|Drug|XP19986 CR|
46111824|NCT00838396|Drug|Placebo for XP19986 CR|
46111825|NCT00838474|Other|music|Each infant was randomized to receive music therapy or no music over 2 consecutive days
46111826|NCT00838708|Drug|SRD174 Cream|topical SRD174 Cream
46111827|NCT00838708|Other|vehicle cream|topical vehicle cream
46111828|NCT00833014|Device|Dynamic Annuloplasty Ring (with option to adjust off-pump)|Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant.
46111829|NCT00838864|Drug|ceftrioxone|500 mg iv q12h for 3 days
46111830|NCT00838864|Drug|ceftrioxone|500 mg q12h for 7 days
46111831|NCT00838942|Behavioral|Questionaries|MMS (Mini Mental Status), ADAS-cog Alzheimer Disease Assessment Scale for cognitive functions, NPI (Neuropsychiatric Inventory) for behavior troubles, IADL (Instrumental Activities of Daily) for autonomy evaluation, GDS (Geriatric Depression Scale) or Cornell Scale (Cornell Scale for Depression in Dementia) for mood troubles.
46111832|NCT03855748|Other|Healthy group|"Subjects undergo the following activities:~Walking~Jogging (8-11 km/h)~Maximal 5 meters sprint acceleration~Single leg drop jump from 35 cm height~Horizontal jump with single leg landing with a distance of 100% and 150% of leg length~Maximal change of direction at 45, 135, 180 degrees~Single-leg cross-country skiing exercise"
46111833|NCT00825214|Device|Zapperclick|Device deliveres small piezoelectrical discharge to bite site (forearm)
45469732|NCT04447612|Drug|Gemcitabine|Induction phase: gemcitabine 1000mg/m2 on day 1 and day 8 via intravenous infusion every 3 weeks for 3 cycles
45469733|NCT03412240|Procedure|Induced pacing of the heart|Once the defibrillator leads have been inserted or, in the case of a box change, the old leads have been tested as per routine procedure, these pacing leads will be connected to an external pacing stimulator. The test involves electrically pacing your heart at different rates and we will be constantly monitoring you under close clinical supervision. During the test, your heart will be electrically stimulated to beat at a faster rate.
45469734|NCT01328080|Radiation|Targeted UV-B|Daavlin Lumera phototherapy device (290-320 nm), dosed by patients' individual minimal erythema dose (MED)
45469735|NCT05171140|Procedure|Triangular Nail Placement of Femoral Neck|Triangular Nail Placement of Femoral Neck in arm A Femoral Neck Inverted Triangle Nail Surgery in arm B
46111834|NCT00825214|Device|Inactivated zapperclick device|placebo
46025004|NCT05017051|Behavioral|Lego model|The participants will have to build a Lego model at 4 visits (M0, M12, M24 and M36).
46111835|NCT00839020|Procedure|Navigated TKA with a minimally invasive approach|Navigated total knee arthroplasty with a minimally invasive approach
46111836|NCT00839020|Procedure|Navigated TKA with a conventional approach|A navigated total knee arthroplasty is performed using the Orthopilot navigation system. A conventional approach is performed
46111837|NCT00833326|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
45469736|NCT03418870|Behavioral|Family Integrated Care|Parents of infants assigned to mFI-Care will be trained and treated as primary caregivers for their infants and participate in daily medical rounds, with mFI-Care-trained nurses serving as teachers and coaches.
46111838|NCT00833326|Drug|Docetaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
46111839|NCT00833326|Drug|Prophylactic growth factors; subcutaneous|standard of care
46111840|NCT00839176|Drug|RX-10100|Extended-release tablet, 5~15mg, twice day (morning & evening) at least 30 min before meal, 8 weeks
45469737|NCT03418636|Behavioral|Staying Safe (Ssafe)|Staying Safe motivates and teaches young people who inject drugs (PWID) planning skills and drug use management strategies to enable long-term risk avoidance and the implementation of healthy protective behaviors. Content is presented through guided discussions and role playing exercises, and relies heavily on interactive participation by group members to foster peer-based learning and social reinforcement processes.
46111841|NCT00825292|Procedure|Polp removal and identification|Identify polyp during colonoscopy then remove polyp
46111842|NCT00825292|Procedure|colon polyp removal|identify and remove polyp
45469738|NCT03418636|Behavioral|Healthy Living|The content of the Healthy Living intervention is based on the DHHS' Eat Healthy, Be Active Community Workshop curriculum, supplemented with basic sleep hygiene education. Science-based dietary and light physical activity guidelines are demonstrated and promoted to help participants develop and maintain a healthy lifestyle.
46111843|NCT00825292|Procedure|ETMI colonoscope (ETMI scope is a FDA approved device)|ETMI colonoscope used to identify colon polyps as compared to HD white light colonoscope identifying colon polyps.
46025005|NCT05017051|Device|Measurement of sensorimotor abilities|The measurement of sensorimotor abilities is based on a multi-sensor device called Smart Flat specifically designed for this study at 4 visits (M0, M12, M24 and M36).
46025006|NCT05017051|Other|Measurement of facial expression of emotions|Participants will have to evoke an emotionally charged autobiographical story by modulating facial expressions through a mirror at 4 visits (M0, M12, M24 and M36).
46025007|NCT05339971|Other|block perforation|The bone block used for lateral bone augmentation will be perforated several times.
46111844|NCT00833404|Drug|Nicotine transdermal patch|8-week nicotine patch regimen (21mg/day during week 1-4, 14mg/day during week 5-6, and 7mg/day during week 7-8).
46111845|NCT00833716|Drug|semaglutide|10 mg/mL of semaglutide solution for s.c. injection, single dose
46111846|NCT02549794|Procedure|CT angiography with high concentration contrast agent|Standard concentration of iodine contrast agent for CT
46111847|NCT02549794|Procedure|CT angiography with low concentration contrast agent (320)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
46111848|NCT02549794|Procedure|CT angiography with low concentration contrast agent (270)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
46111849|NCT00825448|Procedure|Hospitalization for a week|Patient in hospital a week before the date of surgery for the treatment of their addiction to alcohol (alcohol weaning)
46111850|NCT00621322|Biological|GSK Biologicals' AS01B adjuvant|Intramuscular injection, 2 doses
46111851|NCT00621322|Biological|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1|Intramuscular injection, 2 doses
46111852|NCT00621322|Biological|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2|Intramuscular injection, 2 doses
46111853|NCT00621322|Biological|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 3|Intramuscular injection, 2 doses
46111854|NCT00621322|Biological|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 1|Intramuscular injection, 2 doses
46111855|NCT00621322|Biological|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 2|Intramuscular injection, 2 doses
46111856|NCT00833872|Drug|LEO 22811|First-in-man
46111857|NCT00833872|Drug|placebo solution|
46111858|NCT00839488|Drug|pantoprazole 40 mg iv|pnatoprazole 40 mg iv qd
46025008|NCT02780557|Behavioral|Contingent Reading Intervention|Caregivers will be provided with 6 picture books. They will be trained to use contingent talk when looking at picture books with their infants. They will be asked to spend 10 mintues each day engaging in contingent talk while looking at picture books. The intervention will run for 4 months. Parents will be asked to keep a daily reading diary.
46025009|NCT02780557|Behavioral|Book Provision Control|Caregivers will be provided with 6 picture books. They will not be trained to read with their child. They will receive information from other sources (e.g. health visitors and Book Start schemes) as normal.
46025010|NCT04231045|Device|PiCCO device cardiac monitoring|"PiCCO is a cardiac output monitor that combines pulse contour analysis and transpulmonary thermodilution technique.Haemodynamic monitoring~especially if complex mixed forms of shock (e.g. septic and cardiogenic) PAC unavailable or contra-indicated"
46025011|NCT04228627|Drug|Parentral Iron|Correction of Iron stores without anaemia
46025012|NCT04228471|Procedure|spontaneous breathing activity during APRV|Allowing spontaneous breathing activity with APRV throughout the first 48 hours.
46025013|NCT04228471|Procedure|No spontaneous breathing activity|No spontaneous breathing activity will be allowed with pressure controlled ventilation throughout the first 48 hours.
46025014|NCT02784145|Dietary Supplement|Resistant starch|
46025015|NCT02784145|Other|Recommendation with regard to nutrition|Subjects in this arm will receive General recommendations with regard to nutrition based on the guidlines of the German Society for nutrition
46025016|NCT05322031|Drug|Aripiprazole|Patiens who underwent a a period of stabilization with aripiprazole in oral formulation that begin therapy with long-acting aripiprazole, or already in therapy with long-acting aripiprazole from no more than two weeks.
46025017|NCT02779621|Procedure|Self-collecting a vaginal sample with a swab for HPV testing|The vaginal sample self-collected with the Floq swab will be tested for Human Papillomavirus (HPV) using Abbott RealTime PCR assay.
46025018|NCT02779621|Procedure|Collection of cervical sample for routine cervical screening|This is the routine cervical screening test available to the public through the NHS. This sample is collected by a clinician (usually a Practice Nurse)
46111859|NCT00839488|Drug|famotidine 20 mg iv|famotidine 20 mg q12h
46111860|NCT00839566|Procedure|Ablation|AV-node ablation
46111861|NCT00839566|Other|Rate Control|Rate control by drug
46025019|NCT02780011|Drug|Brentuximab Vedotin|Antibody-drug conjugate composed of the anti-CD30 chimeric immunoglobulin G1 monoclonal antibody cAC10 and the antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker.
46025020|NCT02780011|Drug|Alsertib|Aurora A kinase inhibitor
46025021|NCT02780479|Drug|Dexamethasone|at 24 hours from the first Dexamethasone dose given in ED.
46025022|NCT02780479|Drug|Prednisone|at 24 hours from the first Dexamethasone dose given in ED.
46025023|NCT05252923|Drug|Sulodexide|Sulodexide 250 LSU 1 oral capsule twice daily for 8 weeks
46025024|NCT00634777|Other|pet scan|pet scan
46025025|NCT05097079|Drug|MYOBLOC Low Dose|Weight-based dose; 5.0 units/kg for submandibular gland and 25.0 units/kg for parotid gland
46111862|NCT00833950|Device|Phase Out treatment in pure tone tinnitus patients|Phase Out treatment: 30 min 3x/w during 6 weeks
46111863|NCT00825526|Behavioral|Mindfulness Based Stress Reduction (MBSR) Therapy|The objectives of MBSR therapy are to 1) understand their personal response to stress and 2) develop techniques to change the way these patients respond and cope with stress
46025026|NCT05097079|Drug|MYOBLOC High Dose|Weight-based dose; 10.0 units/kg for submandibular gland and 40.0 units/kg for parotid gland
46025027|NCT05097079|Drug|Placebo|volume-matched placebo
46025028|NCT05339737|Device|Nociception Level (NOL) Index|The NOL integrates multiple physiologic parameters that are captured through a finger probe with disposable sensor. These parameters include heart rate, heart rate variability, photoplethysmography pulse wave amplitude, skin conductance and temperature, and their time derivatives. All these parameters are analyzed simultaneously to provide the NOL index which can range from 0 to 100. Values >25 were found to be indicative of nociception and related-pain in the field of anesthesia. The investigators will use the Pain Monitoring Device-200 (PMD-200)TM, which offers the multi-parametric NOL index (0-100) (Medasense Biometrics Ltd., Ramat Gan, Israel), and was approved by Health Canada for clinical use in September 2017.
46025029|NCT02779309|Procedure|Home Care/RAI-HC Assessment|Home care recipients who have received a comprehensive health assessment using the Resident Assessment Instrument for Home Care (RAI-HC).
46111864|NCT00839644|Device|High frequency chest wall oscillation|Therapy prescribed twce daily for twenty minute sessions. High frequency chest wall oscillation (HFCWO) applies sharp compression pulses via an air-pulse generator and inflatable vest. HFCWO generates transient increases in airflow at low lung volumes, cough-like shear forces, and alterations in the consistency of secretions.
46111865|NCT00839644|Device|Oscillatory Positive Expiratory Pressure|Therapy was prescribed twice daily for 20 minute sessions and included airway vibration, oscillating PEP, and forced expiratory technique (FET) with coughing.
46111866|NCT00839644|Other|PD&P: Postural drainage and percussion|Each of the six positions are to be clapped or vibrated for 4 minutes. After each position the patient is to do three forced expiratory techniques (FET) and cough, continue with FET and coughing until all mobilized mucus has been cleared.
46111867|NCT00834184|Drug|nikkomycin Z|"Multiple rising doses. Doses packaged on a unit dose basis in 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.~250 mg BID (n=6) vs Placebo capsule BID (n=2), 500 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg TID (n=6) vs Placebo capsule TID (n=2) At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos."
46111868|NCT00839722|Procedure|embolization|fertility after embolization
46111869|NCT00825604|Procedure|Percutaneous coronary angioplasty (PCI)|optimized medical treatment, physical training and smoking cessation with complimentary treatment with coronary angioplasty (PCI):
46111870|NCT02549950|Procedure|Peizocorticision|Peizocorticision a non invasive procedure used in/ to accelerate orthodontic tooth movement
46111871|NCT02549950|Procedure|Conventional Orthodontic Mechanics|Full Fixed Orthodontic Appliance with conventional orthodontic Mechanics
46025030|NCT02780635|Behavioral|Mobile App + Mailed Materials for managing stress associated with PTSD|"PTSD Coach and PTSD Family Coach mobile apps plus mailed Couples Coach intervention materials and discussion board added to PTSD Family Coach app"
46111872|NCT00834262|Drug|biphasic insulin aspart 30|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46111873|NCT00834262|Drug|biphasic insulin aspart 50|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46111874|NCT00834262|Drug|biphasic insulin aspart 70|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46111875|NCT00853385|Drug|CP 690,550|tablets 5 mg BID PO plus q2 week placebo SC injections for 12 months
46111876|NCT00853385|Drug|CP-690,550|tablets 10 mg BID PO plus q2 week placebo SC injections for 12 months
46111877|NCT00853385|Other|Placebo|placebo tablets BID PO advance to 5mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
46111878|NCT00853385|Other|Placebo|tablets BID PO advance tablets to10mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
46111879|NCT00853385|Biological|Biologic TNFi|placebo tablets BID PO plus adalimumab 40 mg q2 week SC injections for 12 months
46111880|NCT00622336|Drug|CC-5013|Oral 25mg daily on Days 1-21 every 28 days.
46111881|NCT00622336|Drug|Lenalidomide|Oral Lenalidomide 25mg daily on Days 1-21 every 28 days.
46025031|NCT02780635|Behavioral|Mobile App for managing stress associated with PTSD|PTSD Coach and PTSD Family Coach mobile apps
46025032|NCT02779387|Drug|Goserelin Acetate|
46111882|NCT00779766|Biological|HPV GSK 580299 vaccine|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
46111883|NCT00779766|Biological|Placebo control|Subjects were planned to receive three doses of the placebo control administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
46111884|NCT00846365|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
46111885|NCT00846365|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
46111886|NCT00846365|Drug|Olmesartan medoxomil-hydrochlorothiazide|"Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg, tablets, orally, once daily for the remaining 4 weeks."
46111887|NCT00839878|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
46111888|NCT04307992|Device|Prophylactic sac filling with AneuFix|ANEUFIX is administered through translumbar injection into the AAA using imaging techniques to guide the place of injection.
46111889|NCT00834496|Procedure|Liver biopsy|percutaneous liver biopsy
46111890|NCT00834730|Drug|N2O gas vs ketamine|Ketamine : 2mg/kg IV N2O : 50%-70% N2O gas
46111891|NCT02601924|Drug|20% Benzocain (Master-Dent, Monroe, NC)|Two topical anesthetic gel groups will receive anesthetic gel at the site of injection with massage on treating tooth.
46111892|NCT02601924|Other|Topical pressure massage|Two topical pressure massage groups will receive topical placebo gel with pressure massage at the site of injection.
46111893|NCT00840112|Dietary Supplement|Vitamin E supplement|400 IU (268 mg) capsules of will be provided for the subjects. Subjects will be instructed to take one capsule with meals 2 times per day.
46111894|NCT04101474|Drug|Ketamine|Ketamine is a high-affinity, noncompetitive N-methyl-D- aspartate (NMDA) glutamate receptor antagonist it has been used in anesthesiology for more than 50 years the time course of antidepressant response to ketamine is characterized by an initial reduction in depressive symptoms within 2 h
46025033|NCT04228315|Drug|Primaquine|radical cure dosing
46025034|NCT04228393|Drug|6-mercaptopurine|6-mercaptopurine was administered orally to patients once daily.
46025035|NCT04228393|Procedure|Standard treatment|The initial dose is 50mg/m2. The dose was adjusted according to white blood cells.
46025036|NCT04228393|Procedure|Individualized treatment|The initial dose is determined according to the genotypes of patients combined with Clinical Pharmacogenetics Implementation Consortium (CPIC). The dose was adjusted according to white blood cells, genotypes and the concentrations of 6-TGN in red blood cells.
46025037|NCT04976179|Drug|Ferric carboxymaltose|Ferric carboxymaltose to be given as an intravenous infusion
46025038|NCT04976179|Drug|Ferrous sulfate|Ferrous sulphate tablet to be taken orally
46111895|NCT00840190|Drug|P1446A-05|P1446A-05 available as 25mg,50mg,100mg capsule. Subjects will be enrolled at at different dose levels of P1446A-05 to be taken once a day for 14 days followed by 7 days rest.This constitutes one cycle of P1446A-05. Four such cycles will be administered.
46111896|NCT04101708|Drug|Lansoprazole, Amoxicillin|high dose dual regimen
46111897|NCT04101708|Drug|Lansoprazole, Amoxicillin,Clarithromycin and Bismuth subcitrate|half-dose clarithromycin-containing bismuth quadruple regimen
46111898|NCT00825760|Drug|Topical PPA904 gel and light|
46111899|NCT00825760|Drug|Topical placebo gel plus light|
46025039|NCT05246761|Device|Balloon catheter|In the two groups, if their bishop score <6, they will receive the cervical riening by the balloon catheter, and then the oxytocin if necessary.
45838644|NCT04376034|Biological|Convalescent Plasma 2 Units|"Those that meet severe or critical criteria will be given 2 units if available or 1 unit if 2 units are not available.~Those that are given 1 unit may receive the second unit (or the remainder of the maximum pediatric weight calculated amount of plasma up to 1 additional unit) if they progress to severe or critical condition or if already in severe or critical condition but only received 1 unit secondary to shortages.~Each pediatric recipient will receive 10mL/kg up to 2 units of plasma."
46111900|NCT00779142|Drug|Methotrexate intravenous 25mg/ml|Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose. Statistical analysis would not be applicable in this small sample.
46025040|NCT02779777|Drug|Tipifarnib|900 mg b.i.d. Days 1 -7, 15-21 in 28-day cycle
46025041|NCT05296915|Device|tVNS|An electric current with a frequency of 25 Hz (Figure 2) will be applied to the cymba conca of the left ear through a specific device (VITOS, Cerbomed, Germany; CE marking). The stimulation intensity will be customized between 0.1 and 5 mA according to the sensitivity threshold of each participant. Patients will be instructed to perform tVNS at home for 4 non-consecutive hours per day for 12 weeks, in accordance with the protocol reported in the literature for the treatment of major depression.
46111901|NCT00840346|Drug|panobinostat|20 mg, 30 mg, 40 mg in combination with idarubicin and cytarabine, according to the classical 3+3 schedule.
45681733|NCT05702632|Device|TheraTogs orthotic treatment|A sleeveless top vest and two pairs of shorts with two thigh cuffs and limb cuffs each make up the TheraTogs strapping system which is applied to the children in the TheraTogs group. The TheraTogs suit is providing breathable, comfortable- Latex over the torso and thigh, as well as free toileting. For infection control and size fitting problems, participants are not allowed to share their TheraTogs with other patients. TheraTog's orthotic undergarment and strapping system were worn under their regular clothes, so it was neither distracting nor irritating.
45681734|NCT05702632|Procedure|traditional physical therapy program|Facilitation of balance and gait training
45838645|NCT04376034|Other|Standard of Care|Those that meet mild severity will be allowed to enroll in the study, but will not receive plasma unless there is progression of illness into the moderate/rapid progression or greater category.
45681735|NCT03354520|Behavioral|Tailored Videos|web-based OSA messages (videos featuring role models and coaching advice using motivational enhancement) addressing OSA barriers within a health literacy framework--to decrease cognitive load and render messages understandable and actionable. OSA messages were tailored based on focus group data in the previous study (group tailoring).
45838646|NCT04376190|Radiation|low level laser therapy|In the laser group, patients received LLLT from a semiconductor Gallium Aluminum Arsenide diode laser (SMARTMPRO, LASOTRONIX, Poland) with the following set parameters; 635 nm wavelength in continuous-wave mode, 50 mw power output, 4.5 J/cm2 energy density, 11.25 J total dose per side, 45 seconds/ point, and 8 mm fiber optic tip diameter. Laser was applied (Fig.2) at five points located within TMJ region on both right and left sides in contact with skin as follows: lateral, superior, anterior, posterior, and posterior- inferior points.
45838647|NCT04375566|Other|Patient Decision Aid|More than 20 IT specialists, 15 doctors and 15 patients
46111902|NCT04105140|Drug|Oxytocin|intranasal administration of oxytocin (24 IU)
46111903|NCT04105140|Drug|Placebo|intranasal administration of placebo (24 IU)
46111904|NCT00622180|Device|NBUVB|NBUVB hand foot box
46111905|NCT00622180|Device|Monochromacitc Excimer light|Treatment with Monochromacitc Excimer light
45838648|NCT04375488|Other|Resistance Exercise Training|60 minutes resistance exercise training for 8 major muscle groups (quadriceps, hamstring, biceps, triceps, pectoralis major, gluteus medius , gluteus maximus, middle part of deltoid) for 8 weeks, 3 times per week
46025042|NCT05296915|Device|rTMS|"The stimulation will be carried out with a TMS STM9000 system (Ates, Medica Device s.r.l., Italy) equipped with a 70 mm butterfly cooled coil. The stimulation protocol followed will be the one approved by the FDA for major depression, that is, a stimulation at the level of the left dorsolateral prefrontal cortex at an intensity equal to 120% of the motor threshold, at the frequency of 10hz. Each stimulation session will last 37.5 minutes, and will consist of 75 trains lasting 4 seconds, with a 26-second break between each train. During each session, a total of 3000 stimuli will be administered. The sessions will take place 5 days a week, from Monday to Friday, for 4 weeks, and for a total of 20 sessions of stimulation."
46111906|NCT02601768|Device|Transcatheter closure of ASD II|Transcatheter closure of ASD II performed in our center.
46025043|NCT05296915|Behavioral|CBT-E|Targeted cognitive-behavioral therapy following the CBT-E protocol (CG Fairburn - 2010. La terapia cognitivo-comportamentale dei disturbi dell'alimentazione. Firenze, Eclipsi; 2010.)
46025044|NCT02779933|Other|Epidemiology od HAP|no intervention
46111907|NCT00840580|Drug|Moxifloxacin 0.5% ophthalmic solution (Vigamox)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
46111908|NCT00840580|Drug|Levofloxacin 0.5% ophthalmic solution (Cravit)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
46025045|NCT05286697|Diagnostic Test|measuring optic nerve diameter|During the measurement of the optic nerve diameter, a layer of sterile water-soluble gel will be applied on the closed eyelid with a linear 10-5 MHz ultrasound probe.
46111909|NCT00773136|Drug|Bimatoprost Suspension|see prior
46111910|NCT00843388|Drug|Spironolacton (hexalacton(R))|Tablet Spironolacton 25 mg OD
45469739|NCT02790034|Drug|Sarizotan low dose|2 mg or 5 mg bid based on age and weight criteria for 24 wks DB 2 mg bid (4 to <13 years; ≥13 years of age and weighing <25 kg; 5 mg bid (≥13 years of age and weighing ≥25 kg). Assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
45469740|NCT02790034|Drug|Sarizotan high dose|5 mg or 10 mg bid based on age and weight criteria for 24 wks DB 5 mg bid (4 to <13 years; ≥13 years of age and weighing <25 kg; 10 mg bid (≥13 years of age and weighing ≥25 kg) Assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients
45838649|NCT04375488|Other|Inspiratory Muscle Training|with % 30 of MIP, 20 minutes inspiratory muscle training for 8 weeks, 3 times per week
45838650|NCT04375098|Biological|COVID-19 convalescent plasma|COVID-19 convalescent plasma
45838651|NCT04375176|Diagnostic Test|Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2|Phenotypic and functional analysis of monocytes and NK cells
46025046|NCT05339425|Other|No additional intervention will be administered.|No additional intervention will be administered.
46025047|NCT05340049|Diagnostic Test|Online questionnaire of children's backgrounds|A series of questions were asked to the children's parents in a virtual questionnaire on physical characteristics, previous health assessments and observations of their balance and coordination in front of their children.
46025048|NCT05340049|Other|Academic behavioral intervention of teachers|"the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-49%), normal (50-79%) and high (80-100%). Low and high values are considered impairments in one or more of the areas evaluated. Evaluation of the Battelle scale was carried out before and after the therapy sessions."
46111911|NCT00843388|Drug|placebo tablet|placebo tablet 25 mg OD
46111912|NCT04101084|Other|Therapy|Rocking sessions in a safe rocking chair for 2 hours daily for six weeks
46111913|NCT00843544|Behavioral|Integrative Medicine|"Participants assigned to the treatment group will begin in groups of ten. The treatment protocol will consist of six 1-2 hour sessions over a six-week period as follows:~Subjects will attend a two-session class on healthy eating focused on reducing inflammation-promoting foods in the diet. All subjects will also be started on fish oil and vitamin C supplements, as well as on a supplement called Kaprex, which is an extract from hops and rosemary with anti-inflammatory action. Supplements willl be provided free of charge. Subjects will be provided with a take home supply to begin using.~Subjects will attend two classes at CCHH in yoga breathing techniques and will then be provided with a CD for home study and practice~Subjects will attend two guided journaling sessions at CCHH in which subjects will be asked to write for a 30-minute period about the most traumatic or stressful life experience to date."
46111914|NCT02548234|Other|Mirror therapy|Mirror therapy group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
46111915|NCT02548234|Other|Bilateral arm training|Bilateral arm training group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
46111916|NCT02602860|Radiation|[11C]UCB-J|"Pharmaceutical form: Sterile solution for intravenous infusion~Concentration: 20 mCi~Route of Administration: iv"
46111917|NCT02602860|Drug|Brivaracetam|"Pharmaceutical form: Sterile solution for intravenous infusion~Concentration: 10 mg/ml~Route of Administration: iv"
46111918|NCT02602860|Drug|Levetiracetam|"Pharmaceutical form: Sterile solution for intravenous infusion~Concentration: 100 mg/ml~Route of Administration: iv"
46111919|NCT02602860|Drug|Brivaracetam|"Pharmaceutical form: Tablets for oral intake~Concentration: 25 mg~Route of Administration: oral"
46111920|NCT00840736|Procedure|Laparoscopic adjustable gastric banding|Laparoscopic adjustable gastric banding
46111921|NCT00840736|Procedure|vertical banded gastroplasty|vertical banded gastroplasty
46111922|NCT05546268|Drug|Oral MRT-2359|Orally administered tablets of MRT-2359 taken once a day on Days 1 through 5 and Days 15 through 19 of a 28-day cycle (5 days of dosing followed by 9 days of no dose)
46111923|NCT05546268|Drug|Oral MRT-2359|Orally administered tablets of MRT-2359 taken once a day on Days 1 through 5 and Days 15 through 19 of a 28-day cycle (5 days of dosing followed by 9 days of no dose)
45469741|NCT02790034|Drug|Placebo|Placebo BID followed by assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
46111924|NCT05546268|Drug|Oral MRT-2359|Orally administered tablets of MRT-2359 taken once a day on Days 1 through 5 and Days 15 through 19 of a 28-day cycle (5 days of dosing followed by 9 days of no dose)
46025049|NCT05340049|Procedure|Therapy sessions|"Seven sessions were given to each of the three groups according to their classification (placebo, TMR, TCS), being able to obtain a stable value in each of the treatments carried out. Before each session, the effect of the previous session was explored in order to evaluate its efficacy (from the second session onwards). Each of the therapies had the same number of sessions (1 per week for 7 weeks) in order to have equality in all the parameters evaluated.~The effectiveness values of the therapies were expressed as percentages of satisfaction with the classifications of 25% (apparent changes less than half of the sample in each therapy group), 50% (apparent changes in half of the sample plus one in each therapy group) and 75-100% (apparent changes in all or almost all of the sample in each therapy group)."
46111925|NCT05546268|Drug|Oral MRT-2359|Orally administered tablets of MRT-2359 taken once a day on Days 1 through 5 and Days 15 through 19 of a 28-day cycle (5 days of dosing followed by 9 days of no dose)
46111926|NCT00853307|Drug|Alisertib|Alisertib capsules
46111927|NCT00835432|Device|Ossix|Test group
46111928|NCT00835432|Device|Biogide|controls
46111929|NCT05514834|Device|Cellular Matrix TM BCT-HA Kit (ref. BCT-HA-3)|Injections with platelet-rich plasma and hyaluronic acid
46111930|NCT05514834|Other|PRP Only|platelet rich plasma without hyaluronic acid
46111931|NCT05514834|Other|Placebo|Neither PRP nor hyaluronic acid
45469742|NCT05170360|Diagnostic Test|Assessment of smoking ,heavy metal, organophosphorus exposure and d) Mutational analysis of the KRAS and BRAF genes:|"Assessment of smoking exposure:~Serum cotinine will be measured by using serum cotinine ELISA kits~Assessment of heavy metal exposure:~Lead and cadmium will be measured using Graphite Tube Atomizer.~Assessment of organophosphorus exposure:~By measuring pseudocholinesterase level by spectrophotometer~Mutational analysis of the KRAS and BRAF genes:~the tissue samples will be used to determine the mutation in k-ras and BRAF genes by RCR"
46111932|NCT00825058|Drug|amibegron (SR58611A)|oral administration 2 X 350mg/day at 12 hours intervals
46111933|NCT00825058|Drug|placebo|oral administration 12 hours intervals
46111934|NCT00825058|Drug|paroxetine|oral 20 mg/day
46111935|NCT00701831|Drug|Insulin glargine|The dose is titrated according to patient needs
45469743|NCT03418558|Drug|Trastuzumab emtansine|
45469744|NCT05170828|Drug|Cyclophosphamide|pre-transplant conditioning treatment
45469745|NCT05170828|Drug|Fludarabine|pre-transplant conditioning treatment
45838652|NCT04375254|Other|NbB psychopharmacology training|a two part course in psychopharmacology based on Neuroscience based Nomenclature
46111936|NCT00840892|Other|INTERdisciplinary COMmunity-based COPD management (INTERCOM)|The INTERCOM program consisted of exercise training, education, nutritional therapy and smoking cessation support offered by local physiotherapists and dieticians in the proximity of the patient's home and by respiratory nurses in the hospital. The program was divided in a 4-month intensive intervention phase, followed by a 20-month maintenance phase.
46111937|NCT00835744|Drug|clomiphene citrate|ovulation induction
46111938|NCT00835744|Drug|gonadotropins|ovulation induction
46111939|NCT00841048|Drug|AZD4017|ascending multiple doses(start dose 75mg od), oral suspension
46111940|NCT00841048|Drug|Placebo|
46111941|NCT00778830|Drug|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m^2) biweekly on Day 1 of 14 days treatment cycle until disease progression, occurrence of unacceptable toxicity, or withdrawal of consent.
45469746|NCT05170828|Radiation|Total Body Irradiation|pre-transplant conditioning treatment
45469747|NCT05170828|Drug|Busulfan|pre-transplant conditioning treatment
45469748|NCT05170828|Drug|Mesna|given with cyclophosphamide
45469749|NCT05170828|Drug|Sirolimus|post-transplant treatment for GVHD
45469750|NCT05170828|Drug|Mycophenolate Mofetil|post-transplant treatment for GVHD
45469751|NCT05170828|Drug|Filgrastim|post-transplant treatment for GVHD
45469752|NCT05170828|Drug|Cyclophosphamide|post-transplant treatment for GVHD
45469753|NCT05170828|Procedure|Bone Marrow Transplant|Transplant with investigational bone marrow product
45469754|NCT05170750|Other|Foams|Every subject will perform 24 randomized trials on force platform.
45469755|NCT05170750|Other|Foam / Orthopedic insole|3/5 of the initial population will perform static and locomotion task, with randomized conditions.
45469756|NCT05170282|Diagnostic Test|Radiomic Algorithm|Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.
45469757|NCT05169892|Procedure|Aquablation|Aquablation
46025050|NCT05339347|Device|Photoneuromodulation|Treatments were administered daily for a period of 2 weeks (10 sessions) with a Light-Aid (Bright Photomedicine, SP, Brazil), continuous wave, 300 LED wavelength 850 nm) or with a placebo probe of the same appearance and display. The irradiation parameters created will be based on the disease, pain intensity and skin phototype. Each session has from 10 to 15 min, depending on skin phototype
46025051|NCT05339269|Procedure|Laparoscopic splenectomy|The laparoscopic splenectomy is performed by the same surgical team.
46025052|NCT05069545|Drug|Insulin degludec|Introducing a NovoPen® 6 to patients with type 1 diabetes mellitus (T1DM), who are already being treated with Tresiba® and Fiasp®
45469758|NCT03412006|Drug|Fulacimstat (BAY1142524)|25 mg BAY1142524 are given twice daily over a treatment period of 6 months
46025053|NCT05069545|Drug|Fast-acting insulin aspart|Introducing a NovoPen® 6 to patients with type 1 diabetes mellitus (T1DM), who are already being treated with Tresiba® and Fiasp®
46025054|NCT05044975|Behavioral|Sleep restriction|Participants will receive sleep restriction intervention
45469759|NCT03412006|Drug|Placebo|Matching placebo tablets are given twice daily over a treatment period of 6 months
45469760|NCT02734108|Device|Transcranial direct current stimulation|Anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
45838653|NCT04375020|Drug|GABA|GABA nutritional supplement 750mg per day for 6 months
45838654|NCT04374942|Drug|Hydroxychloroquine|Oral Hydroxychloroquine, 400 mg taken once daily, for three months as pre-exposure prophylaxis to prevent COVID-19 in health care workers in the emergency department.
46025055|NCT05044975|Behavioral|Stimulus control|Participants will receive stimulus control intervention
46025056|NCT05044975|Behavioral|Systematic light exposure|Participants will receive systematic light exposure intervention
46025057|NCT05339191|Behavioral|Compassionate image workshop|Participants attend a workshop through which they will be supported to develop and use their own compassionate image.
46025058|NCT05279833|Drug|dronedarone|Pharmaceutical form is tablet and route of administration is oral
46025059|NCT05279833|Drug|sotalol|Pharmaceutical form is tablet and route of administration is oral
46025060|NCT04987957|Other|Music Therapy|Classical Music, Turkish Classical Music, Turkish Folk Music and Sufi Music
46025061|NCT05339035|Behavioral|Training based on IMB model, motivational interview technique, hippotherapy program|"In the first stage of the research, the Digital Game Addiction Scale for Children will be applied to the entire universe and participants with a digital game addiction score of 73 and above will be determined. According to the criteria of inclusion in the research, students will be informed and those who volunteer to participate in the study will be determined and listed. After the experimental and control groups are determined, the participants will be contacted and data collection forms will be applied. The students in the experimental group will be trained according to the IMB model, the students in the experimental group will be given a 6-session motivational interview program and the students will be taken to the hippotherapy program, which lasts 1 hour once a week for 8 weeks. Hippotherapy applications will be carried out at the horse farm in Amasya, accompanied by expert horsemen."
46025062|NCT01880359|Drug|Cisplatin|
46025063|NCT01880359|Radiation|Radiotherapy|
45469761|NCT02649946|Device|Covera Vascular Covered Stent following PTA|Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.
45838655|NCT04374942|Drug|Placebo oral tablet|Placebo pill (same formula as Hydroxychloroquine without active ingredient) taken once daily, for three months.
46025064|NCT01880359|Drug|Placebo|
46025065|NCT01880359|Drug|Nimorazole|
46025066|NCT04975555|Drug|Siltuximab|Siltuximab is administered at the dose of 11mg/kg via intravenous infusion over 1 hour. If no resolution of CRS is achieved then a repeat dose of siltuximab at the dose of 11mg/kg via intravenous infusion over 1 hour will be given.
46025067|NCT04967833|Biological|Tumor Infiltrating Lymphocytes (TIL)|Biological: Tumor Infiltrating Lymphocytes (TIL) Adoptive transfer of 1x10^9-5x10^10 autologous TILs to patients i.v. in 30-120 minutes.
46025068|NCT05338489|Drug|Selpercatinib|Administered orally.
46025069|NCT05338489|Drug|Itraconazole|Administered orally.
45469762|NCT02649946|Procedure|Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon|Treatment of stenoses with PTA only
46025070|NCT05338489|Drug|Rifampin|Administered orally.
46025071|NCT02779699|Drug|AL2846|AL2846 p.o. qd
46025072|NCT05266417|Drug|INS-GSH|Intranasal INS-GSH Twice Daily
46025073|NCT05266417|Drug|Matched Placebos|Intranasal Matched Placebos Twice Daily
45469763|NCT03418246|Device|GIC|tooth colored filling
45469764|NCT03418246|Device|Biodentine|White filling -Biodentine
45469765|NCT03411928|Device|Tracheolator|'Tracheolator' non-occlusive tracheal dilation balloon manufactured by Disa Life Sciences, Cape Town, South Africa.
45469766|NCT03411850|Biological|Orencia|FDA approved biologic
45469767|NCT03411850|Other|Placebo|
45469768|NCT05170594|Drug|Bevacizumab|Bevacizumab will be administered at 15mg/kg IV, every 3 weeks
45469769|NCT05170594|Drug|chemotherapy|The non-platinum chemotherapy regimen will be determined by the investigator.
46025074|NCT04985773|Device|Lacrosse NSE ALPHA coronary dilatation catheter|The Lacrosse NSE ALPHA is a rapid exchange percutaneous transluminal coronary angioplasty balloon catheter with non-slip element nylon threads that focus dilatation force to reduce balloon slippage during inflation.
46111942|NCT00778830|Drug|FOLFIRI|Irinotecan will be administered intravenously at a dose of 180 mg/m^2 along with folinic acid administration intravenously at a dose of 400 mg/m^2 (racemic) or 200 mg/m^2 (L-form) and 5-fluorouracil will be administered intravenously at a dose of 400 mg/m^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m^2 given biweekly until disease progression, death, or consent withdrawal.
46111943|NCT00778830|Drug|FOLFOX|Oxaliplatin will be administered intravenously at a dose of 100 mg/m^2 along with folinic acid administration intravenously at a dose of 400 mg/m^2 (racemic) or 200 mg/m^2 (L-form) and 5-fluorouracil administration intravenously at a dose of 400 mg/m^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m^2 given biweekly until disease progression, death, or consent withdrawal.
46025075|NCT02779465|Drug|Vitamin D3|Participants with chronic hepatitis B will take 800 IU of vitamin D3 per day by mouth besides the anti-virus treatment with nucleos(t)ide medicine
46025076|NCT04985305|Behavioral|Teaching material|The GPs receive a power-point slide show to use at the nursing home. The slide show includes a description of BPSD symptoms, what the mechanism, effect and adverse events of antidepressants and a rationale for deprescribing.
46025077|NCT04985305|Behavioral|Pre-visit reflection tool|The GPs receive a checklist and an email template to ensure; 1) The home visit is planned on a day where the staff at the nursing home that knows the patient best is at work. 2) The staff at the nursing home contacts the relevant relatives and informs about the home visit. 3) The symptom assessment scale is complete by the nursing home staff and returned to the GP prior to the home visit
46025078|NCT04985305|Behavioral|Dialogue tool|The dialogue tool includes a list of questions to help the GP explore the nursing home staffs', patients' and relatives' concerns and views on deprescribing antidepressants, as well as information on when to contact the GP. The intervention has been developed during a tailoring process involving GPs, nursing home staff, interviews with patients and other experts in the field.
46025079|NCT04985305|Behavioral|Educational session for GPs|Before randomization all participating GPs receive a ½-day course on the evaluation and treatment of neuropsychiatric symptoms that occur in patients with dementia. Elaborate information about antidepressants to this population and reasons to discontinue use. A sSpecialists in general practice, pharmacology and geriatrics/gerontopsychiatrics teaches the course. The course is mandatory for the participating GPs, but voluntary for the staff at the GPs office. The course is preferably held with actual attendance, but may be converted to an online meeting due to the COVID-19 pandemic.
46111944|NCT04102332|Device|Safe Infusion Device|Safe infusion device is a different method than usual infusion practices (neutral solvent-purged infusers)
46111945|NCT00772668|Drug|Rituximab|Administered intravenously during induction and maintenance therapy per protocol.
46025080|NCT04985305|Behavioral|Symptom assessment scale|An email template containing 12 screening questions from the Neuropsychiatric Inventory Nursing Home Edition is given to the GPs to distribute to the nursing home prior to the home visit and 1 month after the home visit
46111946|NCT00772668|Drug|Bortezomib|Administered intravenously per protocol.
46111947|NCT00772668|Drug|Cyclophosphamide|Administered intravenously per protocol.
46111948|NCT00772668|Drug|Prednisone|Administered orally (PO) per protocol.
46111949|NCT04101318|Device|New Stoma Baseplat based on the Sensuro Mio product line.|New Stoma Baseplate based on the Sensuro Mio product line. New Baseplate is not named at this point, but has a new protective layer.
46111950|NCT00786474|Drug|Placebo|Normal saline solution, dosage determined by weight, self-administered by patient twice a day
46111951|NCT00786474|Drug|Dalteparin|Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day
46111952|NCT00784875|Drug|LY2624803|1 mg, oral capsule, once nightly before bedtime
46111953|NCT00784875|Drug|LY2624803|3 mg, oral capsule, once nightly before bedtime
46111954|NCT00784875|Drug|Placebo|matching placebo (capsule or tablet), once nightly before bedtime
46111955|NCT00784875|Drug|zolpidem|5 or 10 mg, oral tablet, once nightly before bedtime
46111956|NCT04104711|Other|Home visits, health education|
46111957|NCT02602665|Procedure|Shallow catheter tip placement|for shallow placement tip of catheter placed 1 vertebral body above to even with the carina
46111958|NCT02602665|Procedure|Deep catheter tip placement|deep placement catheter tip is placed 1.5 to 2.5 vertebral bodies below the carina
46111959|NCT02602431|Device|Extra-oral laser irradiation|Irradiation will be employed extra oral by infra-red wave laser, 660nm, 100mW, and 107J/cm2 in four points of Masseter muscle for 30 seconds in each
46111960|NCT02602431|Device|Intra-oral laser irradiation|Irradiation will be employed intra oral by red wave laser, 660nm, 100mW, and 107J/cm2 in four points for 30 seconds in each : 1. Superficial face of dental socket, 2. Lingual face; 3. buccal face and 4. Retromolar region
46111961|NCT02602431|Device|Extra-oral placebo|Laser point will be placed over the same extra-oral points for 30 seconds in each point without irradiation on
46111962|NCT02602431|Device|Intra-oral Placebo|Laser point will be placed over the same intra-oral points for 30 seconds in each point without irradiation on
46111963|NCT00592553|Drug|Ataluren|Ataluren will be administered as per the dose and schedule specified in the respective arms.
46111964|NCT00592553|Drug|Placebo|Placebo matching to ataluren will be administered as the schedule specified in the respective arm.
46025081|NCT02779231|Other|Bi-directional texting|
46025082|NCT02776189|Drug|Dexmedetomidine|intravenous dexmedetomidine 1 mcg per kg body weight over 10 minutes followed by infusion of dexmedetomidine at dose of 1 mcg per kg body weight per hour till end of procedure
46025083|NCT02776189|Drug|propofol|intravenous propofol 2mg per kg body weight followed by infusion of propofol at a dose of 100 mcg per kg body weight per min till end of procedure
46025084|NCT02776189|Drug|Midazolam|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation
46025085|NCT04841707|Device|uEXPLORER/mCT|Each participant will undergo two 18F-FDG PET/CT scans, one at baseline and one at 4- month (+/- 2 weeks) follow-up.
46025086|NCT04226287|Device|Monterey Pneumatic Compression Device|The MontereyInvestigational System is a compact pneumatic compression device used for the treatment of either primary or secondary lymphedema. The primary intention in this study is to gather usability design feedback. This will be done by observing how a patient uses the device after a brief demonstration from the clinician. Errors and difficulties will be noted by the ResMed representative observing the trial. The qualitative interview with the patient at the end of the trial will yield additional understanding of the patient experience with the device.
46025087|NCT04228003|Dietary Supplement|Pendulum Glucose Control formulation for T2D|"All bacteria contained in the study product formulation are commensal organisms that have been repeatedly documented to inhabit the human GI tract under normal circumstances. Pendulum's Glucose Control Formulation consists of five human commensal microbial strains including butyrate producing and mucin-degrading strains. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS).~The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃."
46025088|NCT02776267|Device|Angiolite stent|Following index PCI, patients will be followed via scheduled clinic and/or phone contact at 1-, 3-, 6-, 12- and 24-month. Patient will be randomized to undergo a scheduled repeat coronary angiogram and OCT evaluation at either at 3- or 6-month post index PCI.
46025089|NCT04225975|Diagnostic Test|electroencephalogram|Within the 5 min after birth the electroencephalogram of the neonates will be recorded with the aid of a patch on the scalp
46025090|NCT04225975|Diagnostic Test|oxymetry|Within the 5 min after birth the cerebral oxymetry of the neonates will be recorded with the aid of a patch on the scalp
46025091|NCT02776345|Other|Ultrasound guided Needle Fragmentation|Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudocapsule. The needle tip will be retracted into the subacromial bursa and 3 ml of 0.5% sensorcaine and 1 ml of steroid ( Depomedrol- 40mg/ml) will be injected into the bursa. The needle will then be removed.
46111965|NCT00701909|Drug|morphine plus saline|During the first wound care procedure, some patients will receive morphine 0.1 mg/kg (maximum dose of 8 mg) plus saline (MS), according to randomization, while other patients will receive morphine 0.05 mg/kg (maximum dose of 4 mg) plus ketamine 0.25 mg/kg
46111966|NCT00701909|Drug|morphine plus ketamine|Patients who received morphine 0.1 mg/kg (maximum dose of 8 mg)plus saline during the first wound care procedure will now receive ketamine 0.25 mg/kg IV plus morphine 0.05 mg/kg
46111967|NCT00699023|Drug|ezetimibe tablets|ezetimibe tablets 10 mg/die
46111968|NCT00699023|Drug|simvastatin tablets|simvastatin tablets 20 mg/die
46111969|NCT00699023|Drug|placebo|placebo
46111970|NCT00853229|Drug|pregabalin|pregabalin 150mg twice daily for 4 weeks
46111971|NCT02612753|Procedure|improvement of language for aphasics patients|Aphasics patients receive active stimulation during SLT
46111972|NCT02612753|Device|Sham tDCS|Aphasics patients control receive sham stimulation during SLT
46111973|NCT02612753|Device|tDCs|
46111974|NCT00853151|Drug|LY2428757|14 mg subcutaneous injection 1 time a week for 5 weeks
46111975|NCT00853151|Drug|TT223|subcutaneous injection once a day for 4 weeks
46111976|NCT00853151|Drug|Placebo for LY2428757|subcutaneous injection 1 time a week for 5 weeks
46111977|NCT00853151|Drug|Placebo for TT223|subcutaneous injection once a day for 4 weeks
46111978|NCT00700349|Other|Small loan|Applicants in the treatment group were offered an interest rate, loan size, and maturity per the lender's standard underwriting criteria, involving a 4-month maturity at 11.75% per month, charged on the original balance (200% annual percentage rate).
46111979|NCT02612675|Other|ONS|
45469770|NCT05170594|Drug|Fluzoparib|Fluzoparib will be administered orally continuously at 150mg bid until disease progression and toxicity becomes intolerable
46111980|NCT00853073|Drug|bevacizumab|1.0mg (0.04 cc of 25 mg/ml subconjunctival bevacizumab following bleb needling procedure
46111981|NCT00853073|Other|balanced salt solution|0.04 cc of balanced salt solution injected to the bleb following bleb needling procedure
46111982|NCT00846053|Diagnostic Test|FDG-PET|All subjects underwent FDG-PET and low-dose volumetric CT imaging. After completing a transmission scan, [18F]FDG was injected intravenously at the start of dynamic scan acquisition. Regions of interest were drawn over multiple tomographic slices to determine average whole-lung and regional lung tissue [18F] FDG uptake. Patlak graphical analysis was used to determine the rate of [18F]FDG uptake from the blood input function and lung tissue activity curves, measured as the influx constant Ki (slope of the linear regression from the Patlak plot). Corrected Ki (i.e., Ki divided by the initial volume of distribution). Lung density was calculated from the attenuation image by standard methods.
46111983|NCT00700505|Device|FlowPants(R) Garment|"The garment is shaped like a pair of boxer briefs. Garment heating is battery-powered.~The garment is activated and begins to heat up 5-15 minutes prior to voiding."
46111984|NCT00845897|Drug|Botulinum Toxin|200 units of botulinum toxin, and 300 units of botulinum toxin. Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
46025092|NCT02776345|Other|US guided needle fragmentation & Lavage|Using local anesthetic and strict aseptic precautions, the tip of the 18-20 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 2ml. of local anesthetic ( 1% xylocaine) will be injected into the bursa. The needle tip will be advanced into the supraspinatus tendon and ½ ml or less of 0.5% Sensorcaine will be injected into the pseudo capsule around the calcification. Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudo capsule. During this procedure, or after the fragmentation, using a syringe of saline or local anesthetic( 1% xylocaine) and with pumping action of the syringe the calcification with be sucked into the syringe.
46111985|NCT00845897|Drug|Saline|Placebo (saline) (3cc). Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
46111986|NCT04115891|Other|Anxiety scale|Anxiety Face Image Scale (FIS) assessment in a separate room with face to face interview.
46025093|NCT02776345|Other|Ultrasound guided subacromial injection|Using local anesthetic and strict aseptic precautions, the tip of the 22 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 4 ml. of local anesthetic ( 0.5% xylocaine) and 1 ml of steroid( Depomedrol 40 mg/ml) will be injected into the bursa. The needle will then be removed. Post procedure US images in the short and long axis planes will be obtained and documented. The patient's post procedure pain on a scale of 10 and their range of shoulder movement (abduction) will be assessed and documented.
46025094|NCT02776111|Other|Blood Sample|A one time blood sample will be provided.
46025095|NCT02775955|Drug|RX0041|Active
46025096|NCT04931407|Other|A 12-week interdisciplinary complex intervention|"The intervention will last for 12 weeks and includes four components; patient education, physical exercise, cognitive behavioral program and nutritional counseling.~The patient education will include an online 2-hours group-based patient-education sessions in week 1.~The physical exercise program includes two weekly exercise sessions, one supervised by a physiotherapist and one unsupervised, including aerobic exercise, resistance exercise and psychometric physiotherapy. Half of the intervention group (N=7) will perform the supervised exercise session individually with a physiotherapist in the municipality, while the other half (n=8) will exercise in online groups lead by physiotherapists.~The cognitive behavioral program will begin in week 3 and include six group-based online sessions every week lead by a clinical psychologist.~The nutritional counseling will include three individual digital nutrition counselling sessions in week 2, 6 and 10 by a clinical dietitian."
46025097|NCT04947163|Device|Inspiratory Muscle Training|Participants will perform home-based IMT twice daily [once in the morning (between 7:00 and 12:00 am) and once in the evening (between 16:00 and 21:00 pm)], for 8 consecutive weeks, using a mechanical pressure threshold loading device. In addition, participants in this group will try to increase the inspiratory resistance when the participants feel that 30 breaths are achievable with ease or if the participants could reach 35 consecutive breaths.
46025098|NCT04947163|Device|Sham IMT|Participants will perform 60 slow breaths once daily at a load setting of 0 (corresponding to ~15% [baseline] MIP), using the same device as the IMT group. For the sham group, the ability to adjust the training load will be prevented using sticky tape applied to the device's load adjuster.
45469771|NCT03411772|Procedure|TAP block|Injection of 20 mL of 0.25% bupivacaine in the transversus abdominis plane under ultrasound guidance after performing bariatric surgery
46025099|NCT05045833|Drug|SYN-020 Delayed Release Capsule|Oral administration (by mouth)
46025100|NCT02778217|Procedure|Culture media renwal|
45469772|NCT03411772|Procedure|Bariatric surgery|Bariatric surgery will be conducted
45469773|NCT03410836|Drug|intravenous lidocaine (IVL)|lidocaine 2% will be used for induction (1 syringe of 5 ml, administered dose of 1.5 mg / kg) and for intra-operative infusion (1 syringe of 30 ml, infusion dose of 1.5 mg / kg / h). Lidocaine syringes and placebo will be prepared on a blinded manner so that the investigating anesthesiologist in charge of the patient in the operating room, as well as the respiratory therapist and the recovery room nurse and the floors do not know what the patient received during the anesthesia (whether IVL or placebo).
45469774|NCT03410836|Other|Placebo|Group Control will receive (double blinded) an infusion of saline at the same volume and regimen than the lidocaine 2% group (IVL).
45838656|NCT04374786|Device|Calm Meditation App|"Meditation is a self-management strategy that can be utilized by anyone to assist with the management of stress. Meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time."
45838657|NCT04374864|Drug|Trelagliptin|Anti diabetic
46111987|NCT04115891|Other|Pain scale - 1|Face, Legs, Activity, Cry, Consolability (FLACC), to assess objective operational pain after anesthesia injection and tooth extraction
46111988|NCT04115891|Other|Pain scale - 2|Wong Baker Pain Rating scale (WBS), to assess subjective operational pain after anesthesia injection and tooth extraction
46111989|NCT04115891|Behavioral|Inhalation|lavender oil inhalation in a separate room for 3 minutes prior to interventions
46111990|NCT04115657|Other|Starch 1|Consumption of milk tea with sucrose and boba pearls made from tapioca starch
46111991|NCT04115657|Other|Starch 2|Consumption of milk tea with sucrose and boba pearls made from high amylose
46111992|NCT04115657|Other|Starch 3|Consumption of milk tea with sucrose and boba pearls made from kithul flour
46111993|NCT04115657|Other|Starch 4|Consumption of milk tea with sucrose and boba pearls made from sago flour
46111994|NCT04115657|Other|Sugar 1|Consumption of milk tea with pure palatinose and boba pearls made from tapioca starch
46111995|NCT04115657|Other|Sugar 2|Consumption of milk tea with blend of sucrose and palatinose and boba pearls made from tapioca starch
46025101|NCT02777983|Behavioral|Educational Video App|The content of the app will be grounded in a biopsychosocial model and modeled on the Back Book, a booklet developed to help modify beliefs and behavior of patients with LBP. Essentially this will take the primary concepts and ideas often given in print or verbal form, and present it in a more engaging and dynamic fashion.
46111996|NCT00862277|Biological|Menactra®|0.5 mL, Intramuscular (from a previous study)
46111997|NCT00862277|Biological|Menomune®|0.5 mL, Intramuscular (from a previous study)
45681736|NCT03354520|Behavioral|OSA Treatment|Web-based platform delivering messages promoting OSA self-efficacy. . All patients will view the introductory video, followed by the video cluster: Sleep, Health, and Well-Being; Sleep-Heart Health; Lifestyle Changes; and Sleep Hygiene.
46111998|NCT04120337|Device|RemovAid device + lidocaine patch|The RemovAid device incises the skin and grasps the implant for removal. A lidocaine patch will be used prior to incision.
46111999|NCT04120337|Procedure|Standard technique + lidocaine injection|Using scalpel, tweezers, and forceps to remove a subdermal implant. A lidocaine injection will be used prior to incision.
46112000|NCT04120337|Device|RemovAid device + lidocaine injection|The RemovAid device incises the skin and grasps the implant for removal. A lidocaine injection will be used prior to incision.
45681737|NCT03354520|Behavioral|Standard Videos|Patients in the control arm will also receive an iPad, providing access to standard online OSA health information (e.g., National Sleep Foundation) in an equivalent dose as in the intervention arm using pre-selected automatic alerts to access the website
46112001|NCT00852995|Biological|HP802-247|One dose of HP802-247 consists of 260 microliters (uL) containing keratinocytes and fibroblasts totaling 0.5 x 10-6 power or 5.0 x 10-6 power cells per mL, plus fibrin.
46112002|NCT00852995|Biological|Placebo (Vehicle)|"Placebo (Vehicle) consisting of:~Component 1 - acellular fibrinogen solution; Component 2 - acellular thrombin solution"
46112003|NCT00701987|Drug|ALS-357|Topical application of ALS-357
45681738|NCT03580642|Device|eHealth Technologies|The controls will get a conventional treatment from the acute to the chronic phase of stroke and the cases will get a conventional treatment till the end of the subacute phase. However, in the chronic period they will use the developed STARR App and DSS, as well as commercial wearables.
45681739|NCT03585868|Other|Placebo|Beverage with no flavonoids
46112004|NCT04117061|Procedure|Observation|Patient after primary investigation is observed for 8-12 hours, (instead of being send directly to CT scan), after observation repeated clinical evaluation, laboratory tests and ultrasound examination are done , if final diagnosis stays unclear the patient is refered to CT scan.
46112005|NCT00592319|Drug|Celebrex|oral taking of Celebrex (100 mg, BID) for 9 months
46112006|NCT00592319|Device|PDL|once time radiation on laryngeal papilloma with PDL , at 6.0-8.0 J
46112007|NCT00592319|Procedure|CO2 laser or microsurgery|once-time surgery to remove laryngeal papilloma
46112008|NCT04115813|Behavioral|Project YES! Youth Engaging for Success|Participants in the intervention were offered once a month one-on-one meetings and group meetings with their assigned youth peer mentors over approximately six months. The participant's caregiver could also attend up to 3 caregiver support groups held at the clinic (every other month). In addition, intervention participants in the children's hospital were assessed (clinical and psycho social factors) for physical transition to an adult clinic. After midline data collection, the intervention arm went into a maintenance phase, meeting with the youth peer mentor every other month (3 times). Participants in the comparison arm after midline started the Project YES! intervention as described above. Primary analysis was conducted using midline data.
46112009|NCT00862121|Drug|Pentasa|6 g/day orally, 2 g in the morning and 4 g in the evening
45469775|NCT03411694|Other|Survey|Survey in patients from the Jessa Hospital that are planned for elective surgery, both ambulatory and inpatient.
45681740|NCT03585868|Other|Flavonoids|Flavonoids-enriched cacao beverage
45681741|NCT03585868|Dietary Supplement|No Flavonoids|Beverage with alkalinized cocoa which eliminates flavonoid content
45681742|NCT03580564|Drug|KL-A167|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
46112010|NCT00862121|Drug|Placebo|6 g/day orally, 2 g in the morning and 4 g in the evening
46112011|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, low dose, dosed at least once/day, 8 weeks
46112012|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks
46112013|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, intermediate dose, dosed at least once/day, 8 weeks
46025102|NCT05214937|Behavioral|Intervention|During the first two weeks (baseline), participants will be asked to maintain their regular movement routine to set a baseline daily average step count. Phases I-III will involve self-regulatory strategies (e.g., action planning), address reducing/interrupting sedentary time, and step counts. Participants will be encouraged to increase their steps by 1000 steps/day from the baseline phase during each subsequent phase (i.e., 3000 steps above baseline by Phase III). Phases IV-V will be a maintenance phase through which participants will be encouraged to maintain 3000 steps per day above baseline. The sessions will be grounded within the Multi-Process Action Control Framework and address perceived capability/opportunity and instrumental/affective attitudes. The 1-on-1 sessions will focus on regulation (action & coping planning, social support, goal setting) and reflexive processing (self-regulation, habit). The final one on one session will be a booster session to revisit previous topics.
46112014|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, high dose, dosed at least once/day, 8 weeks
46112015|NCT00784719|Drug|Cyclosporine|Ophthalmic topical solution, 0.05%, dosed at least once/day, 8 weeks
46112016|NCT00784719|Drug|CP-690,550 Vehicle|Ophthalmic topical solution, dosed at least once/day, 8 weeks
46112017|NCT04120103|Behavioral|Doll therapy|The patient will then be given the doll to be used in the research by the caregiver and the researcher. Intervention group (accepting the baby) will be evaluated in terms of interaction with the baby, communication with employees and other patients and participation in daily life activities for 60 days. In addition, the agitation symptoms of the patients during the 60 days they spend with the baby will be evaluated by CMAI and cognitive level by MMSE.
46025103|NCT05214937|Behavioral|FitBit Only|Participants will be provided with a FitBit Inspire 2 and access to publicly available resources about active living. They will receive a FitBit orientation session with a movement specialist prior to the 12-week control period.
46112018|NCT04120103|Other|Routine nursing care|The nursing care provided by the institution was applied to the dementia patients in the routine nursing care group. Routine nursing care group interventions in the institution; Monitoring of life signs, application of drug treatments, participation in social activities such as listening to music, reading prayer, initiatives such as assisting patients in performing daily living activities.
46112019|NCT00852917|Drug|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
46112020|NCT00852917|Drug|Placebo|One Placebo tablet daily.
46112021|NCT00700583|Drug|combination therapy of terazosin and hydrochlorothiazide|25 mg of hydrochlorothiazide eight hours before bedtime and 4 mg of terazosin at bedtime for 4 weeks
46112022|NCT00913055|Drug|octreotide acetate|subcutaneous implant
46025104|NCT01194258|Drug|Insulin lispro|
46112023|NCT04117139|Diagnostic Test|PET/MRI|A PET/MRI of the Head and Neck region is done for all patients included in the project.
46112024|NCT02612597|Other|Bedrest|
46112025|NCT02612597|Other|Exercise Training|
46025105|NCT01194258|Drug|Insulin aspart|
46112026|NCT00845429|Biological|Influenza virus vaccine - cell based (2007-2008 Formulation)|0.5 mL, Intramuscular
46025106|NCT01194258|Drug|Recombinant human hyaluronidase PH20|
46025107|NCT01194258|Drug|Insulin glulisine|
46025108|NCT01194258|Drug|Insulin glargine|
46112027|NCT00845429|Biological|Influenza virus vaccine - cell-based (2007-2008 Formulation)|1.0 mL, Intramuscular
45681743|NCT03585634|Behavioral|Dads in Gear Program|
45681744|NCT03163264|Behavioral|Peer Assisted Lifestyle|Patients will use PAL online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals.
45681745|NCT03163264|Behavioral|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
45681746|NCT03886324|Combination Product|GIE Medical Drug Coated Balloon|Stricture patients treated by DCB
46112028|NCT00845429|Biological|Influenza virus vaccine (2007-2008 Formulation)|0.5 mL, Intramuscular
46112029|NCT00699101|Device|Conture Multi-Lumen Balloon|Placement of the balloon in a separate procedure using ultrasound guidance after surgery for breast cancer.
46112030|NCT00593333|Device|Antegrade Intramedullary Nail|Use of an antegrade intramedullary nail implanted through the Piriformis fossa of the femur. The use of these nails has yielded a union rate of 97 - 99%, and has clearly become the most commonly utilized implant for femur fractures.
46112031|NCT00593333|Device|Trigen Trochanteric Femoral Nail|Antegrade intramedullary nails developed with a proximal lateral bend that allows implantation through the greater trochanter rather than the piriformis fossa. This start portal is remarkably easier to locate and may be associated with decreased risk of abductor muscle weakness and pain.
46112032|NCT04117217|Diagnostic Test|Labs drawn|We will collect blood samples/biomarkers at the time of enrollment.
46112033|NCT02613533|Other|Intra-ocular pressure measurement (IOP)|Subjects will be given 10ml/kg of water over 15 min prior to laser peripheral iridotomy (LPI) surgery and Intra-ocular pressure (IOP) is tested every 15 min before and after surgical procedure
46025109|NCT04883437|Drug|Acalabrutinib|Given PO
46025110|NCT04883437|Biological|Obinutuzumab|Given IV
46025111|NCT04883437|Other|Quality-of-Life Assessment|Ancillary studies
46025112|NCT04883437|Other|Questionnaire Administration|Ancillary studies
46112034|NCT00844883|Drug|sorafenib|sorafenib: given 400 mg twice per day for as long as it is beneficial
46112035|NCT00844883|Procedure|LC Bead-TACE|"LC Beads loaded with doxorubicin~Doxorubicin loaded LC Beads: given intra-arterially into the liver, up to fours times in a 6 month period"
46112036|NCT00851903|Drug|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a prefilled SoloStar® pen (3 mL).
46112037|NCT00851903|Drug|Sitagliptin|Oral administration. 100mg film-coated tablets.
46112038|NCT00851903|Drug|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
46112039|NCT02612441|Device|real Acupuncture Needles|Acupuncture needles
46025113|NCT02777905|Behavioral|Mindfulness Based Cognitive Therapy|
46025114|NCT01193556|Device|PEAK PlasmaBlade TnA|The PEAK PlasmaBlade will be used for the tonsillectomy.
46025115|NCT01193556|Device|Traditional Electrosurgery with scalpel|Traditional electrosurgery for the tonsillectomy.
46025116|NCT05035459|Diagnostic Test|lung ultrasound|drug adjustment based on lung ultrasound results
46025117|NCT05035459|Diagnostic Test|Lung ultrasound|drug adjustment independent on lung ultrasound results
46025118|NCT02775877|Drug|Letrozole|
46025119|NCT02775877|Drug|clomiphene|
46025120|NCT02775877|Drug|HMG|
46025121|NCT02775799|Other|Registration|Registration according to approved data sets
46025122|NCT02778763|Drug|CBLB612|4 μg CBLB612 SQ
46025123|NCT02778763|Drug|Placebo|
46025124|NCT04228159|Device|Balance Tutor Biofeedback Rehabilitation System|Balance Tutor system is a unique technology which allows for several postural control ability assessments as well as reactive response training in both standing and walking using controlled perturbation in simple task or multitask performance. Together with proactive training the system allows for optimal rehabilitation outcome and recovery
46025125|NCT04228159|Other|Balance and strengthening exercise|exercise training programs for fall prevention including walking and balance exercises, functional tasks, strength, flexibility and endurance
46112040|NCT02612441|Device|sham Acupuncture Needles|sham Acupuncture Needles
46112041|NCT00587457|Drug|CAT-8015 5 mcg/kg|Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
46112042|NCT00587457|Drug|CAT-8015 10 mcg/kg|Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
46112043|NCT00587457|Drug|CAT-8015 20 mcg/kg|Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
46112044|NCT00851747|Drug|Phosphatidylcholine Deoxycholate|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
46112045|NCT00851747|Drug|Saline|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
46112046|NCT04099875|Diagnostic Test|ultrasound|Ultrasound is a type of imaging. It uses high-frequency sound waves to look at organs and structures inside the body.
46112047|NCT04100031|Device|bandage contact lenses|wear bandage contact lensesfor a week after cataract surgery.
46112048|NCT04100031|Procedure|phacoemulsification|underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
46112049|NCT02612519|Device|Alfapump|Implantation of Alfapump
46112050|NCT02612519|Device|TIPS|Implantation of TIPS
46112051|NCT04099563|Drug|PF-04965842|"For this study, the investigational product is PF-04965842 (provided as 100 mg tablet).~PF-04965842 100 mg tablets will be provided by Pfizer. Investigational product will be presented to the participants in individual dosing containers"
46025126|NCT04226989|Biological|CT-RD06|CT-RD06 cell injection by intravenous infusion
46112052|NCT02613689|Behavioral|Scheduled Gradual Reduction (SGR)|Participants in this group will group will receive the Scheduled Gradual Reduction (SGR) smokeless tobacco cessation reduction intervention via text message over a period of four weeks. Participants will initially report their smokeless tobacco use according to their usual habit, and over the course of the intervention be directed via text message precise times to start and stop each instance of smokeless tobacco use, gradually reducing the occurrences of use. In addition, this group will also receive the support messages that are sent to the control group.
46112053|NCT02613689|Behavioral|Text Messages|Participants in this group will receive text messages about smokeless tobacco cessation in the form of counseling messages at various times throughout the day over a period of four weeks.
46112054|NCT00767325|Drug|Abatacept|Abatacept, 10 mg/kg, solution given intravenously on Days 1, 15, 29,57, 85, 113, 141, and 169
45469776|NCT03411538|Other|Collect data on clinical history|Collect data on clinical history, clinical manifestation, comorbidity, admission data, use of invasive medical intervention, history of antibiotic treatment and antibiotic susceptibility test results
46112055|NCT00767325|Drug|Methotrexate|Methotrexate administered in a dose of 15 mg/week or higher for at least 3 months and at a stable dose for at least 28 days prior to baseline
46025127|NCT04941157|Procedure|Cerebrospinal Fluid Drain Placement|Prophylactic CSF Spinal Drain to be placed prior to surgery in patients randomized to the experimental arm of the study
46112056|NCT00851591|Drug|fenugreek|3 capsules 3 times per day with a full glass of water each dose for 7 days
46112057|NCT00851591|Drug|Placebo (Psyllium)|3 capsules 3 times a day with a full glass of water each dose for 7 days
45469777|NCT03411460|Device|FreeStyle Libre™ system|Measured non-invasively via scanner
45469778|NCT03411460|Procedure|Finger prick|Blood test
45469779|NCT03418168|Drug|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
45469780|NCT03127306|Diagnostic Test|Assessment of Polish version of BPS|Validation of Polish Version of BPS.
45469781|NCT02521090|Biological|EGFRBi-Armed Autologous T Cells|Given IT and IV
45469782|NCT02521090|Other|Laboratory Biomarker Analysis|Correlative studies
45469783|NCT03273153|Drug|Cobimetinib|Cobimetinib 60 mg tablets orally once daily on a 21 days on, 7 days off schedule.
45469784|NCT03273153|Drug|Atezolizumab|Atezolizumab 840 mg as IV infusion once in every 2 weeks.
45469785|NCT03273153|Drug|Pembrolizumab|Pembrolizumab 200 mg as IV infusion once in every 3 weeks.
46112058|NCT04119947|Drug|SY-009|The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) . Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 2,5, 10, 20, 40mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
46112059|NCT04115579|Other|Biscuit 1 Control|Consumption of control biscuit of a higher glycaemic index at one session during breakfast and afternoon snack
46112060|NCT04115579|Other|Biscuit 2 Test|Consumption of test biscuit of a lower glycaemic index at one session during breakfast and afternoon snack
45469786|NCT03418090|Drug|129Xe MRI|Evaluation of pulmonary function
45469787|NCT03418090|Drug|133XE scintigraphy|Evaluation of pulmonary function
45469788|NCT03323034|Drug|Irinotecan|Given IV
45469789|NCT03323034|Drug|Pevonedistat|Given IV
45469790|NCT03323034|Drug|Temozolomide|Given PO
45469791|NCT03410680|Behavioral|FUERTES|The intervention focuses on antiretroviral therapy habit-formation among MSM living with HIV
45469792|NCT03418012|Device|cervical pessary|Intervention: Device: Cervical pessary: After Having excluded a vaginal infection insertion of the cervical pessary (silicone ring) directly after enrollment. After insertion verification of correct fit of the cervical pessary by transvaginal ultrasound. Removal of the pessary at 37+0 weeks of gestation, or before if any unexpected event occurs. Except for the insertion of the pessary the obstetrical management during the remainder of the pregnancy will be usual management.
46025128|NCT04875013|Device|Vestibular rehabilitation with dynamic posturography|Rehabilitation exercises guided by an interactive display and measured by a footplate sensor
46025129|NCT05021107|Other|FDM with isometrics|FDM with isometrics will be done
46025130|NCT05021107|Other|FDM without isometrics|FDM without isometrics will be done
46025131|NCT02777359|Procedure|the transcatheter closure of PFO|the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA,clopidogrel(50mg/d, 3mon) , aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
46025132|NCT02777671|Drug|BIA 2-093|
45469793|NCT03418012|Other|Control-Group|Intervention: Other: expectant management: expectant management is usual care; interventions only in terms of a tertiary prevention of PTB according to guidelines for premature rupture of membranes, premature labour or other pregnancy complications
46112061|NCT00702455|Behavioral|Self-Directed (weight loss maintenance)|Self- Directed participants will receive a core set of print materials describing key behaviors and skills necessary for successful weight loss maintenance and will review these materials with an intervention coach in two sessions.
46025133|NCT02777671|Drug|Gliclazide|tablets containing gliclazide 80 mg (Diamicron® 80 mg)
46025134|NCT02777515|Behavioral|using electronic cigarette|"Assesment of patients, using electronic cigarette, presenting to the Rhythm of consultation for a cardiovascular evaluation by:~A compendium of history, a general physical examination (weight, height) and cardiovascular with measurement of oxygen saturation, an assessment of past and current smoking (with documentation of the concentration of nicotine in the electronic cigarette and the product brand used)~measurement of blood pressure~An electrocardiogram~A Holter-ECG 10 minutes~A transthoracic echocardiogram"
46112062|NCT00702455|Behavioral|Guided (weight loss maintenance)|Guided participants will receive 8 monthly check in calls and then bimonthly calls for the rest of the study. Guided participants are also asked to report their weight weekly, either via the Keep It Off website, email or voicemail. Those who experience weight gain will receive outreach calls to assist them in reversing their weight gain.
46112063|NCT04116905|Behavioral|Intensive Lifestyle Intervention|The lifestyle intervention is implemented with individual supervision sessions and is aimed at achieving and maintaining at least a 15% decrease in weight from baseline. It is implemented during a 12-month period with the most intensive application during the first 4 months. To help participants achieve and maintain weight loss, partial diet replacement with very low calorie diet, strengthend exercise strategies. Mobile phone applications (apps) will be used to manage metabolic syndrome during weight loss program. Optional medications on metabolic syndrome will be utilized based on a preset algorithm and participant progress.
46112064|NCT04116905|Behavioral|Conventional Treatment|Participants assigned to conventional treatment and education are offered metabolic syndrome management and social support every 1 month, aimed at achieving and maintaining a 5% decrease in weight in 1 year. Mobile phone applications (apps) will also be used in the weight loss program.
45469794|NCT03417934|Procedure|Hip Arthroscopy Procedure|The purpose of this pilot study is to evaluate the effects of hip distraction without a perineal post on the lower extremity during hip arthroscopic procedures by peri-operative monitoring of various prognostic markers for venous, nerve and tissue injury.
45469795|NCT02473536|Radiation|Stereotactic ablative radiation therapy|SABR
45681747|NCT01865487|Biological|H56ug/IC31nmol|H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
46025135|NCT02777437|Drug|XELOX or FOLFOX chemotherapy|4 cycles of XELOX or FOLFOX neoadjuvant chemotherapy before surgery
46025136|NCT04226521|Procedure|Extracoropreal photopheresis|Patients who sign informed consent form undergo prophylactic extracorporeal photopheresis after heart transplant according to predetermined protocol
46112065|NCT02612363|Drug|Dexmedetomidine for sedation|"Dexmedetomidine or control drug for sedation~Analgesia~Propofol at lowest dosage.~Dose range: 0.1- 0.7 u/kg/hour~Target RASS score of -2 to +1~Supplemental other sedatives at lowest effective dose"
46112066|NCT00913211|Device|rTMS|600 pulses of 6 hz priming rTMS at 90% of threshold followed by 600 pulses of low-frequency rTMS at 90% of threshold.
45681748|NCT01865487|Biological|Placebo|Sterile buffer consisting of 10mM Tris and 169mM NaCl at pH 7.4
45681749|NCT03585556|Drug|Intravitreal anti-VEGF|Intravitreal injection of anti-VEGF at Day 0 then monthly as needed
45681750|NCT03585556|Biological|Intravitreal AAVCAGsCD59|An intravitreal injection of AAVCAGsCD59 will occur at Day 7 once
45681751|NCT03585556|Drug|Oral prednisolone|A 7 day tapering dose of oral prednisone will be taken at Day 30 by all patients
45681752|NCT05702398|Drug|Vitamin A|1,000 μg retinyl palmitate twice a day for 6 months
46025137|NCT04817839|Behavioral|3-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 3-weeks post operation.
46112067|NCT00913211|Procedure|Motor learning training|one hour of repeated finger tracking movements toward a changing target.
46112068|NCT00913211|Procedure|rTMS and Tracking|Combination of rTMS and finger tracking
45681753|NCT05702398|Drug|Nicotinamide|500 mg NAM twice a day for 6 months
46025138|NCT04817839|Behavioral|6-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 6-weeks post operation.
46025139|NCT02775721|Other|Nursing Education related to Gastrostomy Tube Care|The research nurse will provide educational intervention at each study visit utilizing the nursing process.
46112069|NCT00913211|Device|Sham rTMS|Sham treatment of rTMS
46112070|NCT00702611|Device|Granulocyte Monocyte Apheresis (GMA-Apheresis)|GMA Apheresis will be performed in a once per week during seven weeks only in experimental arm. Each apheresis will last 60 minutes at a blood flow rate of 30 ml/min.
45681754|NCT05702398|Other|Other: Placebo|Identical placebo pills twice a day
46112071|NCT00702767|Drug|INTRALIPIDS|INTRAVENOUS FAT EMULSIONS
46112072|NCT04119869|Other|iaya|The iaya app is a smartphone application intervention that -through a variety of approaches, such as exercises aimed at identifying and changing thoughts and behaviors, imagery, and relaxation- seeks to enhance coping with the emotional impact of cancer.
46025140|NCT02775721|Other|Speech Therapy Education and Evaluation|Speech therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Speech therapy and evaluation is assessed per the attending speech therapist. The study team will collect all data related to speech therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
46112073|NCT00912899|Drug|Noscapine HCl|Escalating doses given twice per day
46112074|NCT00700895|Drug|Warfarin Sodium|All predicted warfarin dose will be administered by rounding down to the nearest 0.5 mg. Warfarin (Marevan®) is available as 1mg (brown), 3 mg (blue) and 5 mg (pink) oral tablets from GlaxoSmithKline Pte. Ltd.
46112075|NCT00861341|Drug|Aspirin|81 mg
45469796|NCT04410783|Behavioral|Education|Nurses and physicians will be engaged regarding the clinical outcome data on the importance of ED-based sedation, and the objectives of the research. Education will include in-services and lectures focused on the importance of sedation protocols on patient outcome. The use of sedation will be evaluated throughout the study in order to better understand providers' perception of and experience with ED-based sedation protocols.
45469797|NCT04410783|Other|Standard post intubation sedation practices|Usual care sedation provide in the ED
45469798|NCT02520934|Drug|Miglustat|combine miglustat and ERT to see if neurologic manifestations can be improved
45469799|NCT02520934|Drug|ERT|enzyme replacement therapy
45469800|NCT02749968|Drug|Liposomal bupivacaine|1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
45469801|NCT02749968|Drug|0.9% sodium chloride|1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
45469802|NCT03270657|Device|IPG; RC+S|We will measure the effects of varying stimulation parameters on the neural activity in subjects with Parkinson's disease (PD).
46112076|NCT00861341|Drug|Pioglitazone|30mg Pioglitazone x1
46112077|NCT00766467|Drug|Armodafinil|Taken orally once a day in the morning. Dose will change depending upon level of fatigue
46112078|NCT00766467|Other|Placebo|Placebo taken once a day in the morning
46112079|NCT00850499|Drug|fludarabine|fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
46112080|NCT00850499|Drug|rituximab|rituximab 375mg/m2 on Day 1 of every 35-day cycle
46112081|NCT00850499|Drug|VELCADE|1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 of every 35-day cycle
45469803|NCT03410602|Procedure|Full-mouth supragingival scaling|Control group comprised of 15 patients who were treated with routine full-mouth supragingival scaling.
45681755|NCT01699503|Behavioral|Collaborative Dementia Care Program|Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.
45681756|NCT01709409|Drug|Curosurf-Group1|Maximum of 3 doses are administered to infants diagnosed with RDS.
45681757|NCT01709409|Drug|BLES-group 2|Maximum of 3 doses are administered to infants with RDS
46112082|NCT00860951|Device|Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
46112083|NCT03123549|Device|Simplify Disc|Simplify Disc at two levels of the cervical spine
46112084|NCT00844805|Drug|Infliximab|
46112085|NCT00844805|Drug|Placebo|
46112086|NCT00844805|Drug|Naproxen|
46112087|NCT04022265|Device|implant placement|Full-thickness muco-periosteal flaps will be elevated, and the alveolar bone exposed to prepare the bed for the implant installation
46112088|NCT03043209|Genetic|Genomic sequencing|Genomic sequencing of DNA in Blood sample and myectomy tissue
46112089|NCT00765999|Drug|Linaclotide|Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.
46112090|NCT00765843|Device|orthoses|orthoses are provided for use in standardized shoes that all subjects receive
46112091|NCT04099407|Drug|Pirfenidone|Treatment consist of 600 mg tablets of a prolonged-released formulation of Pirfenidone. Patients are instructed to take medication orally, every 12 h, after breakfast and dinner.
46112092|NCT04099407|Other|Standard of care|All participants will require to adhere to a standard of care including nutritional support, quarterly medical evaluation to review lab results and adjust medications, bi-annual Fibrotest, FibroScan and liver ultrasound, and annual upper-gastrointestinal endoscopy.
46025141|NCT02775721|Other|Nutritional Therapy Education and Evaluation|Nutritional therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Nutritional therapy and evaluation is assessed per the attending dietitian. The study team will collect all data related to nutritional therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
46025142|NCT02775721|Other|Quality of Life Questionnaire C30 version 3|30-item instrument that measures the Health Related Quality of Life (HRQoL) in a wide range of cancer patient populations.
46025143|NCT02775721|Other|Quality of Life Questionnaire EORTC QLO - H&N35|35-item instrument that measures the Health Related Quality of Life specific to Head and Neck cancer patient populations.
46025144|NCT04903951|Device|Adaptive Servoventilation (ASV) therapy|Patients assigned to the active group will receive ventilatory support with ASV (DreamStation BiPAP autoSV®) during diurnal and nocturnal sleep, from study randomization until clinically indicated
46025145|NCT04903951|Other|Best medical treatment|Best medical treatment for stroke, including rehabilitation
46025146|NCT02775565|Device|AngioVac|
46025147|NCT04811677|Other|radiology|image analysis
46025148|NCT04225741|Behavioral|Training group|The single-session training lasted for approximately 40-45 minutes and was conducted in the training room of Sıtmapınarı family health center, as a suitable environment. The health belief model predicts the determinants of preventive health behaviors and explains inadequate participation in disease prevention and screening programs. Furthermore, this model not only explains behavior regarding screening, but also evaluates the cognitive factors that facilitate health-promoting behaviors.
46025149|NCT02775253|Other|Chronic cold acclimation|
46025150|NCT04227691|Device|Long-pulsed Nd Yag laser treatment|One treatment of the assigned axilla with long-pulsed Nd YAG laser treatment in ten patients
46112093|NCT00765063|Drug|Fragmin|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium
46112094|NCT04098939|Diagnostic Test|Diaphragm evaluation|Ultrasound and radiographic evaluation of diaphragm function
46112095|NCT00764751|Drug|LEO 19123 Cream (calcipotriol plus LEO 80122)|Once daily application
46112096|NCT00764751|Drug|Dovonex® cream|Twice daily application
46112097|NCT00764751|Drug|Cream vehicle|Twice daily application
46112098|NCT02601495|Behavioral|Women in a court diversion program|Women in Recovery (WIR) is an intensive outpatient alternative for eligible women facing long prison sentences for non-violent, drug-related offenses in Oklahoma.
46112099|NCT00764673|Device|3DKnee|Subjects with knee osteoarthritis and willing to participate in the study
45469804|NCT03410602|Procedure|Subgingival scaling|Test group comprised of 15 patients who were treated with subgingival scaling only around all banded first molars.
46025151|NCT04227691|Device|IPL treatment|One treatment of the assigned axilla with IPL treatment in ten patients
46025152|NCT02775175|Behavioral|Modified Ramadan Fasting|The intervention aims to provide knowledge about fasting and its effects on the body/mind, and health advice around nutrition to support health and well-being of participants during Ramadan.
46112100|NCT00764517|Drug|Cladribine|Given IV
46112101|NCT00764517|Other|Laboratory Biomarker Analysis|Correlative studies
46112102|NCT00764517|Biological|Rituximab|Given IV
46112103|NCT00764517|Drug|Vorinostat|Given PO
46112104|NCT00764361|Drug|doxycycline|1.0% doxycycline gel applied topically to the wound once daily for 20 weeks
46112105|NCT00764361|Drug|placebo gel|placebo gel applied topically to the wound once daily for 20 weeks
46112106|NCT00763971|Drug|Lisdexamfetamine Dimesylate (LDX)|30, 50 or 70mg capsule once per day (Overencapsulated)
46112107|NCT00763971|Drug|Methylphenidate Hydrochloride|18, 36, or 54mg tablet one per day (Overencapsulated)
46112108|NCT00763971|Drug|Placebo|Placebo capsule once per day (Overencapsulated)
46112109|NCT00763815|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
46112110|NCT00763815|Drug|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
46112111|NCT00763815|Device|Pen auto-injector|
46112112|NCT00763815|Drug|Pioglitazone|Dose to be kept stable.
46112113|NCT00763815|Drug|Metformin|Metformin, if given to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
46025153|NCT02777203|Device|EcoSac 400 ECO-T|Laparoscopy will be performed in the standard multi-port technique. The specimen will be morcellated in the EcoSac400 ECO-T bag.
46025154|NCT02778841|Other|Exercise|This study is designed to examine and comparing there intervention program on balance, mobility and knee proprioception among male elderly
46025155|NCT02775097|Device|OCT|OCT for all Arms
46025156|NCT01129687|Procedure|Microsurgery|Patient would under to total, near-total, or subtotal resection of tumor
46025157|NCT01129687|Procedure|Stereotactic radiation therapy|Patient who has sign of growth of tumor remnant would undergo this treatment
46025158|NCT02775019|Dietary Supplement|Lactobacillus reuteri|2 x daily repeated consumption of a lozenge containing 10E9 CFU Lactobacillus reuteri for 42 days
46025159|NCT02775019|Dietary Supplement|Placebo|2 x daily repeated consumption of a lozenge being void of Lactobacillus reuteri for 42 days
46025160|NCT02778997|Procedure|CSF Shunt treatment for hydrocephalus|State after CSF shunt implantation
46112114|NCT00763269|Drug|Triclosan, Silicon dioxide, fluoride|Brush twice daily
46112115|NCT00763269|Drug|Triclosan, fluoride|Brush twice daily
46112116|NCT00763035|Drug|Regadenoson|Each participant will receive regadenoson 0.4mg (5ml) one time bolus dose at one visit.
46112117|NCT00763035|Drug|Dobutamine|Each participant will receive dobutamine infusion (as per protocol to achieve a target heart rate of 85% of predicted for age) at another visit.
46112118|NCT00844649|Drug|Albumin-bound paclitaxel (ABI-007)|ABI-007 125 mg/m^2 administered by intravenous infusion
46025161|NCT04194853|Device|Electromyographic Biofeedback|Surface EMG biofeedback is an adjunct therapy to standard exercise regime for increasing muscle strength .Electromyographic (EMG) biofeedback is a specific form of biofeedback. The biofeedback device records muscle activity through the application of electrodes superficially or subcutaneously when targeting specific muscles
46112119|NCT00844649|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).
46025162|NCT04194853|Other|Quadriceps Isometric exercises|In supine lying or sitting, Patient is asked to press down knee while contracting Quadriceps muscles.
46025163|NCT02774863|Other|Home passages|Three home passages between the 2nd and 3rd months of follow up.
46025164|NCT02778919|Drug|KLH-2109|
46025165|NCT02778919|Drug|Placebo|
46112120|NCT04098861|Drug|Latanoprost/Timolol|Latanoprost/Timolol Fixed Combination
46025166|NCT02778919|Drug|Leuprorelin acetate|
46025167|NCT02774629|Other|prick and patch test|The cases are pricked and patched with local food allergen extract at different storage times (0, 3 and 6 months after preparation)
46025168|NCT00635011|Behavioral|psychotherapy|Cognitive Behavioral therapy
46025169|NCT02779153|Drug|Acthar low dose (40 U)|The 40U group will administer 0.5 mL of study medication once a day. Patients will taper study medication during Week 2 through the remainder of the study and will administer 0.5 mL of study medication twice a week. The stable Acthar regimen should be maintained for the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
46025170|NCT02779153|Drug|Acthar high dose (80 U)|The 80U group will administer 1.0 mL of study medication every day. If a patient meets dose reduction criteria, their assigned volume will be adjusted from 1.0 mL to 0.5 mL. Patients will taper study medication during Week 2 through the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
46025171|NCT04226443|Drug|Midazolam intravenous injection|The midazolam was prepared as 5 mg midazolam in 20 mL syringe of 5% dextrose water solution (0.25 mg/mL) in both arms. Both groups of patients received an intravenous bolus dose of midazolam was administered before the start of the surgery. In Group 1, continuous infusion of intravenous midazolam was started and in Group 2, intravenous bolus doses of midazolam were administered. The doses were adjusted depending on pain level and sedation level using appropriate scales for monitoring during the surgical time period. The drip rate was adjusted according to pain intensity. The infusion of drugs was discontinued at the end of the procedure.
46112121|NCT00762723|Device|Trinica Anterior Lumbar Plate System|Trinica Anterior Lumbar Plate System accommodates the use of either fixed- or variable-angle screws. This study is a comparison of clinical outcomes from anterior lumbar interbody fusion patients receiving the Trinica Anterior Lumbar Plate system with either all fixed-angle screws, variable-angle screws, or a hybrid configuration.
46025172|NCT04226443|Drug|Remifentanil intravenous bolus dose|A remifentanil infusion was prepared as follows; 0.5 mg remifentanil was added into 100 mL of 0.9% saline at a concentration of 5 μg/mL. The preparation of remifentanil solution and installation of the device was done by an anesthesiologist who was blinded for the study groups. The dose and number of patients that required remifentanil were recorded. The infusion of drugs was discontinued at the end of the procedure. A rescue medication of intravenous remifentanil bolus dose was used as 1 to 3 mL (5 μg or 15 μg) every 5 minutes if necessary for pain scores greater than 3. This infusion was prepared prior to the use during the study and was discontinued at the end of the procedure.
46025173|NCT02776891|Drug|Gallium citrate|Ga-68 citrate will be administered on an outpatient basis at the Center for Molecular and Functional Imaging at China Basin. It will be administered a single time point intravenously prior to PET imaging. The one-time nominal injected dose will be up to 15 mCi containing 10 - 25 μg Ga-68. A simultaneous MRI (PET/MRI) of the head will be used for attenuation correction and anatomic localization of gallium-68 citrate uptake and standardized uptake value (SUV) calculation.
46025174|NCT02776813|Biological|ACTR087|
46025175|NCT02776813|Biological|rituximab|
46025176|NCT02776657|Other|Magnetic Resonance Imaging|Each participant will undergo at least one MRI scan. A small number will be asked to undergo repeat MRI scanning at one and three months following the initial scan.
46025177|NCT02776657|Device|Optical Coherence Tomography|Participants may undergo Optical Coherence Tomography (OCT) during the angiogram procedure in order to detect thrombus within the coronary arteries.
46112122|NCT04098705|Other|Introduction of the World Health Organization Triage Scale|"The intervention will comprise implementation of a new triage and patient flow system facilitated through staff training and clinical redesign.~The three-tier World Health Organization Triage Scale (WHOTS) will be used as the triage instrument. This tool, developed collaboratively by the WHO, International Committee of the Red Cross (ICRC) and Médecins Sans Frontières (MSF), incorporates features of the South African Triage Scale but has been modified for application in a wide variety of RL settings. WHOTS documents are provided in the research protocol."
46112123|NCT00850343|Drug|Certolizumab pegol|Subcutaneous (SC) injection
46112124|NCT00849875|Biological|Immunotherapeutic GSK2132231A|Intramuscular administration
46112125|NCT00849875|Drug|Dacarbazine|Intravenous administration Chemotherapy
46112126|NCT00844415|Drug|dabigatran etexilate|2.14 mg/kg BID to a max 150 mg BID
46112127|NCT00843635|Drug|Tadalafil|Given orally
46112128|NCT00843635|Other|Placebo|Given orally
45469805|NCT03410602|Drug|Subgingival irrigation|Test group comprised of 15 patients who were treated with subgingival irrigation only around all banded first molars with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent.
45681758|NCT01698879|Drug|Mylotarg|"Cohort 1 version 1.0. GO: 6mg/m^2 (maximum 10 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m^2 IV days 1 to 7, to begin 4 hours after the administration of GO.~Cohort 1.0 version 2.0: GO: 3 mg/m^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m^2 IV days 1 to 7, to begin 4 hours after the administration of GO.~Cohort 2: G-CSF: 150 mcg/m^2, SC, days 0 to 7. GO: 3 mg/m^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m^2 IV continuous infusion on days 1 to 7, to begin 4 hours later after the administration of GO."
46025178|NCT02776657|Procedure|Invasive Coronary Angiography|This will be performed as part of usual care and does not constitute part of the research project.
46025179|NCT02774551|Behavioral|Physical activity intervention group|150 minutes of minimum intensity activity during a week (e.g. walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week.
46025180|NCT02774317|Biological|Plasma|FFP (plasma frozen within 8 hrs of collection) or FP24 (plasma frozen within 24 hrs of collection)
46025181|NCT02774161|Other|Ultrasound Tomography|Undergo B-mode ultrasound imaging
46025182|NCT04936243|Behavioral|FOLLOW UP VISIT-TELEMEDICINE|Routine follow up care conducted remotely with video-conferencing tools
46025183|NCT04936243|Behavioral|FOLLOW UP VISIT-FACE TO FACE|Routine follow up care conducted in person
46025184|NCT02774083|Behavioral|Feuerstein Program|Mediated learning cognitive enhancement program
46025185|NCT02774083|Behavioral|Adler Program|Social and emotional group program
46025186|NCT04175821|Radiation|Hypofractionated radiotherapy|35Gy/ 15#/3weeks to chest wall and 40Gy/15#/3 weeks to supraclavicular fossa
46112129|NCT00699179|Drug|biphasic insulin aspart 30|There is no intervention in this trial. The trial is prepared to be non-interventional one. Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation.
46112130|NCT04119557|Drug|LY3471851|Administered SC
46112131|NCT04119557|Drug|Placebo|Administered SC
46112132|NCT04116827|Drug|Tamoxifen Oral Tablet|Patients who are scheduled for application of tamoxifen and goserelin
45681759|NCT02335294|Drug|TRV130|Rescue: Ibuprofen, oxycodone
45681760|NCT02335294|Drug|Morphine|Rescue: Ibuprofen, oxycodone
46112133|NCT00843167|Dietary Supplement|broccoli sprout extract|Given orally
46112134|NCT00843167|Other|placebo|Given orally
46112135|NCT00849017|Biological|albiglutide|albiglutide weekly injection
46112136|NCT00849017|Biological|albiglutide uptitration|albiglutide uptitration at week 12
46112137|NCT00849017|Biological|placebo|matching albiglutide placebo weekly injection
46112138|NCT00842543|Dietary Supplement|Fruit and Vegetable Juice Concentrate (FVJC)|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
46112139|NCT00842543|Dietary Supplement|Placebo|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
46112140|NCT00785928|Biological|LY2127399|Administered SC every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
46112141|NCT00785928|Drug|Placebo|Administered subcutaneously (SC) every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
46112142|NCT00842309|Drug|d-cycloserine|100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
45681761|NCT02335294|Drug|Placebo|Rescue: Ibuprofen, oxycodone
45681762|NCT01698801|Drug|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 of each 28-day cycle
45681763|NCT01698801|Drug|dexamethasone|40 mg oral dexamethasone once daily on Days 1, 8, 15 and 22 of each 28-day cycle
46025187|NCT05157997|Drug|Casirivimab and Imdevimab Antibody Cocktail|The study will utilize REGEN-COV 8,000mg (4,000 mg of each monoclonal antibody) given as IV infusion on day of transplant and 2400mg (1,200 mg of each monoclonal antibody) on post-operative day 1.
46025188|NCT00635245|Biological|figitumumab|
46025189|NCT00635245|Other|imaging biomarker analysis|
46025190|NCT00635245|Other|laboratory biomarker analysis|
46025191|NCT00635245|Other|pharmacological study|
46025192|NCT00635245|Procedure|conventional surgery|
46025193|NCT00635245|Procedure|magnetic resonance spectroscopic imaging|
46025194|NCT00635245|Procedure|neoadjuvant therapy|
46025195|NCT02776501|Drug|Coppertone (BAY987521)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: Y49-103)
46025196|NCT02776423|Procedure|Bulkamid|The procedure was standardized, identical for all patients, and entirely performed in an outpatient setting. All injections were performed by a single urogynecologist. Before injection all patients received a single dose trimethoprim (Idotrim®, Orion Pharma). The patient was placed in a supine position and given intraurethral topical 2% lidocaine hydrochloride gel (Xylocain®, Astra Zeneca) for anesthetic. Using a video-urethroscope and a 23-gauge needle, polyacrylamide hydrogel deposits of 0.3-0.4 mL were injected at 12, 4 and 8 o´clock into the submucosa approximately 1 cm from the bladder neck. Patients were discharged after successful voiding.
46025197|NCT02776579|Other|Girls-only resistance training|
46025198|NCT02778373|Dietary Supplement|Vitargo ®, Swecarb AB, Karlskrona, Sweden|
45469806|NCT04787250|Biological|Phage Therapy|Phage will be administered based on patient's matching results.
45469807|NCT04787250|Procedure|Two-Stage Exchange Arthroplasty|Performed per the study center's standard of care. No investigational products are used.
46112143|NCT00842309|Drug|Placebo|Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
46025199|NCT02778373|Dietary Supplement|DE15 maltodextrin, Matrin® M160, Grain Processing Corporation, Muscatine, IA|
46025200|NCT02778373|Other|Placebo: Water|
46025201|NCT02772835|Device|Medin-cno|Medin-cno is a noninvasive ventilator. With this device we can practice either nCPAP and nHFOV ventilation.
45469808|NCT03303417|Diagnostic Test|MRI Scan|Participants will undergo hourly MRI scans on day 3 to assess bowel fluid content
46112144|NCT04119401|Procedure|doppler-guided hemorrhoidal artery ligation|"Ligation: a lubricating gel is applied to the tip of the Transanal Hemorrhoidal Dearterialization device and, with the patient in the lithotomy position, the proctoscope is introduced into the anal canal. The terminal branches of the superior rectal artery are detected by the doppler signal 2-3 cm above the dentate line. The tip of the instrument is gently tilted and the arteries are ligated with a Z-shaped stitch using 2:0 braided polyglycolic acid suture inserted using a special needle-holder through an aperture in the operating proctoscope.~Mucopexy: after the haemorrhoid artery ligation, the suture is continued with three to five sutures applied 5 mm apart, making sure that the last is at least 5 mm above the dentate line. The suture is then tied to create a hemorrhoidopexy. The procedure is repeated after all detected artery ligations."
46112145|NCT04119401|Procedure|Finger-guided hemorrhoidal artery ligation|"Ligation: the exact placement of all terminal branches of the superior rectal artery are found by intraoperative palpation at anal clock 2-3cm above the anorectal junction. Then arteries are ligated with Z-shaped suture using 2:0 braided polyglycolic suture.~Mucopexy is then performed in the same technique as in comparative group"
46112146|NCT02613065|Dietary Supplement|Consumption of NOW Foods eggwhite protein shake|Consumption of NOW Foods egg white protein shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
46112147|NCT02613065|Dietary Supplement|Consumption of NOW Foods maltodextrin shake|Consumption of NOW Foods maltodextrin shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
45469809|NCT03303417|Other|Kiwifruit|Kiwifruit
45469810|NCT03303417|Other|calorie-matched sugar drink|calorie-matched sugar drink
46112148|NCT00842153|Drug|Clobetasol propionate foam|Topical Clobetasol propionate foam
46112149|NCT00842153|Drug|Vehicle foam|Vehicle foam does not include the active drug.
45469811|NCT03411226|Procedure|re-TREPP|repeated hernia repair via the TREPP technique
46025202|NCT02773147|Drug|Cyanocobalamin|
46025203|NCT02773147|Drug|Folate|
45469812|NCT03637569|Other|Measurement of triceps skinfold thickness|By using skin thickness caliper, measure triceps skinfold thickness on the half of forearm (Rt side). In every 3 weeks, triceps skinfold thickness will be measured.
45681764|NCT03735628|Drug|Copanlisib|Copanlisib: lyophilisate for reconstitution and further dilution for infusion
45681765|NCT03735628|Drug|Nivolumab|Nivolumab: concentrate for solution for infusion
46112150|NCT00762411|Drug|LY450139|Administered orally once daily.
45681766|NCT03580252|Other|Correlation analyses for the outcomes|No medical intervention would be done. The single arm would receive regular practice of Hammersmith Assessment and MRI / Ultrasound
45681767|NCT04548297|Other|Assessment|Assessments of foot sole sensation, joint position sensation, attention, fatigue, body awareness, and physical activity level
45681768|NCT03585166|Procedure|lpaparoscopic hepatectomy|laparoscopic hepatectomy： laparoscopic hepatectomy for hepatocellular carcinoma.
45681769|NCT03585166|Procedure|open hepatectomy|open hepatectomy: open hepatectomy for hepatocellular carcinoma
45681770|NCT05702242|Procedure|IUD removal with no visible strings|Removal with either alligator forceps or MVA
45681771|NCT05702242|Device|Alligator forceps|IUD removal with alligator forceps
46025204|NCT02773147|Drug|Pyridoxine|
46025205|NCT02773927|Drug|Metformin|Metformin in tablet presentation of 500 mg
46112151|NCT00762411|Drug|Placebo|Administered orally once daily.
46112152|NCT00761865|Device|Air Cast Stirrup Brace & High Tide Fracture Boot|Subjects will be randomly assigned to one of two treatment braces. All patients will be given instructions to use fracture boot or air cell brace at all times of ambulatory activity until follow-up until 2 week post-strain follow-up.
45681772|NCT05702242|Device|Manual Vacuum Aspirator|IUD removal with MVA
46025206|NCT02773927|Dietary Supplement|Agave inulin|Inulin in powder obtained from agave plant, it was given to each patient a full 10 mg container.
46025207|NCT02773927|Other|Placebo of agave inulin|Calcinated magnesia powder
46025208|NCT02773927|Other|Metformin placebo|Calcinated magnesia tablet
46025209|NCT02773771|Dietary Supplement|beta-hydroxy-beta-methylbutyrate|HMB is a leucine metabolite that may also be a potent mediator of anabolic processes in skeletal muscle; subjects will not receive >3g of HMB/ day.
46025210|NCT02773771|Dietary Supplement|Placebo|The placebo is cornstarch and will be mixed in with Vital HP. The solution will look identical to the intervention arm.
46025211|NCT02773771|Dietary Supplement|Vital HP®|Vital HP® is a form of enteral nutrition a part of the Massachusetts General enteral formulary
46025212|NCT02773615|Procedure|Cardiac computed tomography|Non-invasive CT scan of the heart
45838658|NCT04374396|Procedure|Real ultrasound-guided single shot erector spinae plane block (ESP B)|"ESP block will be performed with the patient lying in the lateral position and the surgical side at the top. After skin disinfection, sterile draping will be placed, and ultrasound probe will be sheathed. The level of the block will be at the transverse process of L2, using a 9-12 MHz linear probe and placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) will be identified and a 22 Gauge 50 mm insulated needle will be inserted craniocaudally in plane between the transverse process and the fascia of the ESM.~After negative aspiration, 0.3 mL/kg- of bupivacaine 0.25% will be injected confirming correct position by visualizing the solution lifting the ESM off the transverse process .Spread of LA between the L1 and L4 transverse processes will be thereafter visually tracked with the transducer. In the control group, no local anesthetics will be injected."
45681773|NCT01682811|Drug|Part 1 Levulan injection|Control or treatment lesions will be injected with Levulan vehicle only or active drug and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
46112153|NCT00841763|Biological|Placebo (PL)|One dose of 0.5 ml IM injection of isotonic saline solution was administered in the deltoid muscle, preferably of the non-dominant arm.
46112154|NCT00841763|Biological|Trivalent influenza virus vaccine (TIV)|A single IM injection of a 0.5 ml dose of non-adjuvanted trivalent influenza virus vaccine administered in the deltoid muscle, preferably of the non-dominant arm.
46112155|NCT00841763|Biological|Adjuvanted monovalent influenza virus vaccine (aH5N1)|Two intramuscular (IM) injections of a 0.5 ml dose administered three weeks apart in the deltoid muscle.
46112156|NCT00841763|Biological|Adjuvanted trivalent influenza virus vaccine (aTIV)|Two IM injections of a 0.5 ml dose of adjuvanted trivalent influenza virus vaccine administered three weeks apart, in the deltoid muscle.
46112157|NCT00838331|Biological|Fresh blood|For fresh transfusions, a whole blood unit will be drawn from volunteers, processed, and then reinfused on the same day during the study. For impaired and repaired transfusions, the volunteers will be brought to the blood bank to donate; then, after processing and the appropriate length of storage (eg, 28 days), they will return for the FBF studies. Since recipients of fresh transfusions are relatively anemic after donation and before reinfusion, recipients of impaired/repaired transfusions should also be mildly anemic for the study. Thus, they will donate another whole blood unit prior to beginning the study course, they will be transfused with their stored unit during the study, and then the autologous unit collected at the beginning of the day will be reinfused at the end of the day after the study is complete.
46025213|NCT04175275|Other|Interview patient|Interview patient without scoring about the reasons for the implant, the complications, the reasons for abandonment, the evaluation of the satisfaction
46112158|NCT00838331|Biological|Aged blood|"In a separate aim, the FMD assay will be used to investigate NO-mediated vasodilation in patients with CVD who are receiving transfusions. Over 60% of blood orders for cardiology patients at Emory are for 2 units or more. Therefore, when a 2-unit order is placed on a consented patient, they will be issued both fresh (< 7 days) and impaired (> 28 days) compatible units from inventory. Prior to starting transfusions, the patient will be randomized to either receive the fresh or the older unit first. All RBC units will be ACD/AS1. Units will also be leukoreduced and/or irradiated, if either of those modifications were found to impair NO bioavailability in prior studies. If washing or rejuvenation were found to be successful in significantly repairing NO bioavailability in previous aims, some patients may also receive impaired and repaired (> 28 days; washed or rejuvenated) RBC transfusions."
46112159|NCT05603429|Diagnostic Test|Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status|Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status measurements for determining Endothelial Damage and Oxidative Stress
46112160|NCT00703001|Behavioral|Educational Intervention|students in this arm will receive several oral health educational modules in class
46112161|NCT00703001|Behavioral|Referral Intervention|Parents of enrolled children will receive assistance in accessing oral health care for their child
46112162|NCT00785538|Biological|IMC-A12|"Cohort 1~3 milligrams/kilogram (mg/kg), I.V. once a week, for 4 weeks, followed by a 2-week observation period."
46025214|NCT04927663|Procedure|Computed Tomography|Undergo CT imaging
46025215|NCT04927663|Procedure|Magnetic Resonance Imaging|Undergo MRI
46025216|NCT04927663|Procedure|Positron Emission Tomography|Undergo PET imaging
46025217|NCT04927663|Drug|11C-YJH08|Given IV
46025218|NCT02773693|Behavioral|Cognitive Processing Therapy-Cognitive Only (CPT)|Twice weekly CPT over 6 weeks.
46025219|NCT02773693|Behavioral|Cognitive Behavioral Therapy of Insomnia and Nightmares (CBTin)|Cognitive behavioral therapy of insomnia and nightmares weekly over 6 weeks.
46112163|NCT00785538|Biological|IMC-A12|"Cohort 2~6 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
46112164|NCT00785538|Biological|IMC-A12|"Cohort 3~10 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
46112165|NCT00785538|Biological|IMC-A12|"Cohort 4~15 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
46112166|NCT00785538|Biological|IMC-A12|"Cohort 5~21 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
46112167|NCT00785538|Biological|IMC-A12|"Cohort 6~27 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
46112168|NCT04102488|Procedure|Six-step hand hygiene technique with an application time of 30 seconds|Six-step hand hygiene technique with an application time of 30 seconds
46112169|NCT04102488|Procedure|Six-step hand hygiene technique with an application time of 15 seconds|Six-step hand hygiene technique with an application time of 15 seconds
46025220|NCT02773693|Behavioral|Continuation Cognitive Processing Therapy-Cognitive Only (CPT)|Once weekly continuation CPT over 6 weeks.
46025221|NCT02773459|Drug|MEK162+capecitabine|In phase 1 part: capecitabine(mg/m2) will be given twice a day, 2 week on/1week off Q 3weeks + MEK162 twice a day, continuously, starting at 1000mg/m2 and 30mg/m2 respectively. Expansion part will be treated with the dose found at phase 1 part.
46025222|NCT02773303|Device|Mente Autism™|A portable headband records EEG activity, and specialized algorithms convert the EEG activity into sonified binaural signals feeding them back to the user
46025223|NCT02773303|Device|Sham|a device externally identical to Mente Autism™, providing binaural beats but not tailor-made neurofeedback binaural beats
45838659|NCT04374396|Radiation|Sham ultrasound-guided single shot erector spinae plane block (ESP B)|"EESP block will be performed with the patient lying in the lateral position and the surgical side at the top. After skin disinfection, sterile draping will be placed, and ultrasound probe will be sheathed. The level of the block will be at the transverse process of L2, using a 9-12 MHz linear probe and placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) will be identified and a 22 Gauge 50 mm insulated needle will be inserted craniocaudally in plane between the transverse process and the fascia of the ESM.~No local anesthetics will be injected"
45469813|NCT04908748|Drug|Esflurbiprofen Hydrogel Patch|Esflurbiprofen is a cyclooxygenase (COX) inhibitor indicated for the treatment of osteoarthritis pain and inflammation
46112170|NCT04102488|Procedure|Three-step hand hygiene technique with an application time of 30 seconds|Three-step hand hygiene technique with an application time of 30 seconds
46025224|NCT02773225|Drug|Eltrombopag|"CSA + Eltrombopag, evaluation after three month therapy start regarding dose escalation~6 month after therapy start --> evaluation and report of remission status of the study office --> unblinding by study office --> partial or complete remission Eltrombopag and slow tapering of CSA~12 month after therapy start --> evaluation and report of remission status --> complete and partial remission --> tapering/end of study treatment"
46025225|NCT02773225|Drug|Placebo (for Eltrombopag)|"CSA + Placebo, evaluation after three month therapy start regarding dose escalation~6 month after therapy start --> evaluation and report of remission status of the study office --> unblinding by study office --> no complete remission: CSA + Eltrombopag and evaluation 3 months after therapy start --> dose escalation~12 month after start of eltrombopag --> evaluation and report of remission status --> complete and partial remission --> tapering/end of study treatment"
46025226|NCT02773381|Drug|semaglutide|Oral administration once-daily.
46025227|NCT02773381|Drug|placebo|Oral administration once-daily.
46025228|NCT04818229|Drug|CBP-307|CBP-307 capsules oral administration.
46025229|NCT04818229|Drug|Placebo-matched CBP-307|Placebo-matched CBP-307 capsules oral administration.
46025230|NCT04818229|Drug|Moxifloxacin (Avelox)|Moxifloxacin tablets oral administration。
46025231|NCT04818229|Drug|Placebo-matched Moxifloxacin|Placebo-matched Moxifloxacin tablets oral administration.
46025232|NCT02772991|Other|troponin measurement|Cardiac catheterization (for patients with >50% lesions) or discharge or in patients with intermediate risk.
46112171|NCT04102488|Procedure|Three-step hand hygiene technique with an application time of 15 seconds|Three-step hand hygiene technique with an application time of 15 seconds
45469814|NCT04261413|Drug|RS-0139|RS-0139 will be administered for the indication of NSCLC.
45469815|NCT02943564|Drug|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
45469816|NCT02943564|Drug|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
45838660|NCT04374318|Drug|Dexmedetomidine|INTRATHECAL AND INTRAVENOUS
46112172|NCT04101162|Diagnostic Test|shear waves elastography; liver biopsy|Diagnostic accuracy in a new ultrasound software compared to histology for Non Alcoholic Fatty liver disease (NAFLD) and Non Alcoholic Steato Hepatitis (NASH)
46112173|NCT02602704|Drug|Bazedoxifene|Bazedoxifene 20mg/day (Viviant) for 48 weeks
46112174|NCT02602704|Drug|Calcium/Vit D|Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day) for 48 weeks
46112175|NCT02601690|Other|Blood Sampling|
46112176|NCT04105296|Device|EKSO+ES|6 months of exoskeleton training with epidural stimulation.
46112177|NCT00916422|Biological|Allergen extract (Phleum pratense)|Subcutaneous immunotherapy with modified extract of Phleum pratense. A subcutaneous monthly treatment.
46112178|NCT00916422|Biological|Placebo|Subcutaneous monthly treatment
46112179|NCT00860405|Drug|HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion), Human serum albumin (HSA 50g/L)|Study medication will be given as part of the priming of the ECC and for plasma volume replacement after start of ECC up to the maximum dosage of 50 mL/kg body weight/day.
46112180|NCT00860405|Drug|Human serum albumin (HSA 50g/L)|Human serum albumin (HSA 50g/L)
46025233|NCT02773069|Behavioral|Church Bridge Project|Community-based participatory research combining efforts of academic researchers, church leaders, primary care providers and community stakeholders.
46025234|NCT02772523|Other|Lifestyle recommendations|Dietary, and physical, cognitive and social activity recommendations
46112181|NCT04104906|Other|motor control training|The volunteers of the motor control group will initiate the exercises on a stable and rigid basis. These will be progressed with adding an unstable base as the volunteer gains motor learning (between the fourth and fifth week of the protocol). For the motor control group, two sets of 10 repetitions will be performed keeping in isometry for ten seconds each repetition.
46112182|NCT04104906|Other|The exercise group|the protocol of strengthening and will have five elastic bands with different resistances available (extra-light, light, moderate, strong and extra-strong) for elbow flexion exercises progression, medial rotation and lateral rotation of the shoulder and scapular retraction.
46112183|NCT05542290|Procedure|Capsular tension ring implantation|Capsular tension ring implantation during phacoemulsification lens extraction and intraocular lens implantation combined with goniosynechialysis in included angle closure patients.
45681774|NCT01682811|Drug|Part 1 Levulan surface application|Control or treatment lesions will be painted with Levulan vehicle only or active drug, allowed to dry, and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
46112184|NCT05542290|Procedure|No capsular tension ring implantation|No capsular tension ring implantation during phacoemulsification lens extraction and intraocular lens implantation combined with goniosynechialysis in included angle closure patients.
46112185|NCT04099758|Behavioral|Mindfulness of the breath meditation|A 10-minute mindfulness of the breath meditation practice
46112186|NCT04099758|Behavioral|Audio-recording control|10 minute non-fiction audio-recording delivered online
46112187|NCT05491434|Dietary Supplement|Protein supplement|One líquid brick every day during 3 weeks
46112188|NCT05603351|Diagnostic Test|magnetic resonance|biparametric MRI with protocol including anatomical T2 sequence and diffusion-weighted images (DWI), according to the standards
46112189|NCT05603351|Diagnostic Test|serum PSA examination|testing of prostate-specific antigen (PSA) in serum
46112190|NCT05603351|Procedure|Biopsy|"Men with a positive MR test are planned for a targeted MRI/US fusion and systematic prostate biopsy.~Men with a positive blood marker (either PSA, PSAD, or PHI) are planned for a systematic 12 core biopsy. Positive test results are PSA ≥ 3, integrated marker PSAD ≥ 0.15, and PHI ≥ 35."
46112191|NCT00703313|Drug|1.5% levofloxacin ophthalmic solution|1 drop instilled at each visit
46112192|NCT00703313|Drug|0.5% moxifloxacin hydrochloride ophthalmic solution|1 drop instilled at each visit
46025235|NCT04771741|Drug|Acetominophen|1,000 mg every 6 hours
46112193|NCT00703313|Drug|0.3% gatifloxacin ophthalmic solution|1 drop instilled at each visit
46112194|NCT00703079|Drug|Octreotide-LAR or lanreotide|Treated with octreotide-LAR will be given at dosages of 10-40 mg/q28d and treatment with lanreotide-SR at dosages of 60-120 mg/q28d. The dosages are up-titrated to control GH and IGF-I levels
46112195|NCT00703079|Procedure|Transsphenoidal adenomectomy|Removal of pituitary adenomas via one-nostril transsphenoidal approach and endoscopy-assisted.
46112196|NCT00840827|Drug|lenalidomide|Lenalidomide 10mg po daily
46112197|NCT00840827|Drug|cyclosporine A|CSA 250mg orally twice daily
45681775|NCT01682811|Drug|Part 1 Levulan surface application twice|Control or treatment lesions will be painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 3 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
45838661|NCT04374552|Drug|Hydroxychloroquine sulfate &Azithromycin|Drug - Hydroxychloroquine sulfate &Azithromycin
46025236|NCT04771741|Drug|Toradol|10 mg every 6 hours, days 0-3
46112198|NCT00860249|Behavioral|Letter Only|Prior to a scheduled upcoming appointment, participants will get a letter signed by their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening.
46112199|NCT00860249|Behavioral|Letter and Educational DVD|Participants will get a letter from their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening. It will be accompanied by an educational DVD about the screening. The participants will receive this prior to a scheduled upcoming appointment with their physician.
46025237|NCT04771741|Drug|Meloxicam|15 mg once daily, beginning post-op day 4
46025238|NCT04771741|Drug|Cyclobenzaprine|10 mg every 8 hours
46025239|NCT04771741|Drug|Lyrica|75 mg every 12 hours
46025240|NCT02772445|Behavioral|STROKE-CARE|In STROKE-CARE, caregivers will learn a problem-solving strategy. They will (1) identify barriers to performance, (2) generate strategies to address barriers, and (3) apply these strategies to support care-recipients in occupations.
46025241|NCT02772601|Drug|Caffeine|
46025242|NCT02772601|Drug|Warfarin|
46025243|NCT02772601|Drug|Omeprazole|
46025244|NCT02772601|Drug|Metoprolol|
46025245|NCT02772601|Drug|Midazolam|
46025246|NCT02772601|Drug|Risankizumab|
46025247|NCT02772055|Other|Moxibustion|Moxibustion at three acupuncture point(EX-LE04,ST35,ST36).12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
46112200|NCT00840749|Radiation|CyberKnife Stereotactic Radiotherapy|Central lesion dose/fractionation: 15 Gy x 4 fractions = 60 Gy; Peripheral lesion dose/fractionation: 20 Gy x 3 fractions = 60 Gy
46112201|NCT00840749|Procedure|Surgery|Both open thoracotomy and video assisted thoracotomy (VATS) are acceptable procedures. Surgery may consist of a lobectomy, sleeve resection, bilobectomy or pneumonectomy as determined by the attending surgeon based on the operative findings
46112202|NCT00703469|Drug|MDX1106-02|Single dose
46025248|NCT02772055|Other|Moxa smoke purification device|Investigators place a purification device(Shenzhen Conyson Electronic Technology Co, Ltd,C200 moxa smoke purification device,Shenzhen,China) at the top of the moxibustion to remove the moxa smoke.
46025249|NCT02772133|Procedure|Primary PCI|
46025250|NCT02772211|Drug|Ketamine|"Patients will undergo 6 ketamine infusions within a 3-week period. Intravenous ketamine will be administrated by a senior anesthesiologist and under the supervision of a senior psychiatrist hence ensuring patient safety. The procedure will be explained in detail to each patient, and written consent will be obtained.~After a psychiatric and medical evaluation by a senior psychiatrist and a senior anesthesiologist, patients will be given ketamine infusion added on to their antidepressant therapy. A slow ketamine infusion of 0.5mg/kg over 40 minutes will be given to the patients. Patients will be monitored by the experienced staff which includes a senior anesthesiologist and a nurse as well as a psychiatrist who will be available nearby. All patients will be monitored continuously for heart rate and rhythm and oxygen saturation, and blood pressure will be measured at 10 minutes intervals."
46025251|NCT02772211|Drug|D-cycloserine|"Following completion of Ketamine infusions. patients in the experimental group will start receiving D-cycloserine pills titrated slowly up to 1000mg/d over the next 8 weeks [2] in the following manner:~Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~Week 7: Day 43-49 - 750mg/d, three pills per day~Weeks 8-11: Days 50-77 - 1000mg/d four pills per day"
46025252|NCT02772211|Drug|Placebo|"Following completion of Ketamine infusions. patients in the experimental group will start receiving placebo titrated slowly up to 1000mg/d over the next 8 weeks [2] in the following manner:~Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~Week 7: Day 43-49 - 750mg/d, three pills per day~Weeks 8-11: Days 50-77 - 1000mg/d four pills per day"
46112203|NCT00703469|Drug|Placebo|Placebo single dose
46112204|NCT02612207|Device|Bilirubin Binding Capacity by Hematofluorometry Validation|Observation study
46112205|NCT00859937|Drug|Dasatinib|Given PO
46112206|NCT00859937|Other|Laboratory Biomarker Analysis|Correlative studies
46112207|NCT04030715|Drug|bismuth-containing quadral therapy based on antibiotic susceptibility|the different mucosal pathology graded by New Sydney System
46112208|NCT00592007|Drug|Fulvestrant and Erlotinib|Upon enrollment, patients will continue to receive erlotinib daily orally at 150 mg/day or at 100 mg/day if 150 mg was associated with adverse events requiring dose reduction before enrollment in this study. Doses less than 100 mg/day will not be allowed. Fulvestrant will be added intramuscularly 500 mg Day 0, 250 mg Days 14 and 28. In cycles 2 and up, fulvestrant will be given 250 mg on day 28. Patients will receive this therapy until they progress.
46112209|NCT00591851|Drug|AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)|No Intervention
46112210|NCT00913289|Biological|adipose tissue derived stromal cells|dosage
46112211|NCT00837473|Device|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures
45469817|NCT04900402|Other|Survey|International Physical Activity Questionnaire Short Form (IPAQ) and Quality of Life Scale for Children (PedsQL)
46112212|NCT00703547|Drug|GSK586529 capsules|GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams.
46112213|NCT00703547|Drug|GSK586529 tablets|GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams.
46112214|NCT00703547|Drug|Placebo|Placebo tablets and capsules will be provided to subjects.
46112215|NCT04030793|Device|Individualized transcranial direct current stimulation|Based on tDCS stimulation, individualized stimulation during 30 minutes with sitting position.
46112216|NCT04030793|Device|Conventional transcranial direct current stimulation|Conventional tDCS stimulation during 30 minutes with sitting position.
46112217|NCT00839423|Drug|Placebo|capsules, daily, orally
46112218|NCT00839423|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
46112219|NCT00839423|Drug|Venlafaxine XL|capsules, daily, orally
46112220|NCT00837161|Device|Philips MR guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis
46112221|NCT00859547|Biological|rThrombin, 1000 IU/mL|rThrombin,1000 IU/mL, 1000 IU/mL, applied topically to the bleeding site during a single surgery procedure on Day 1.
46112222|NCT00859469|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV infusion for 2 hours
46112223|NCT00859469|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV infusion for 90 minutes
46112224|NCT00703625|Drug|Temsirolimus|
46112225|NCT00703625|Drug|Docetaxel|
46112226|NCT00703703|Drug|Darifenacin|Darifenacin tablets 15 mg once daily
45469818|NCT03417700|Dietary Supplement|NW training|NW training
46025253|NCT02767687|Other|Noninvasive ventilation|Twenty minutes after extubation all subjects will receive noninvasive ventilation delivered through a facial mask with an ICU ventilator with NIV option for 60 minutes. NIV associates pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O).
45469819|NCT03417700|Dietary Supplement|Placebo|training with placebo
45469820|NCT03417700|Dietary Supplement|HICT|Training and vitamin D
46025254|NCT04722445|Diagnostic Test|Early ultrasound measurement of quadriceps shortening during neuromuscular electrical stimulation (NMES)|NMES will be applied to the quadriceps muscle to generate muscle contraction. Ultrasound measurement of the quadriceps thickness will be provided during contraction and rest, and the shortening of the quadriceps muscle will be measured. A second measurement using Shear-wave elastography measurement will also be undertaken. The measures will be undertaken at day 1 of neuromuscular blockers liberation (if any) as well as at day 3 and day 7 for the patients that will still be received mechanical ventilation at that time.
46025255|NCT02767297|Drug|FDL169|
46025256|NCT02772289|Biological|Mesenchyme Stem Cells low-dose group|Participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.
46025257|NCT02772289|Biological|Mesenchyme Stem Cells high-dose group|Participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
46025258|NCT02772289|Biological|Placebo|Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
46025259|NCT04225195|Drug|Amphotericin B cholesteryl sulfate complex for injection(ABCD)|"IC patients will only receive intravenous treatment with ABCD, with the longest course of treatment up to 42 days. ABCD will be administered once a day at a dose of 3-4 mg/kg. Visit plan: screening period (D-4 to D-1), baseline period (D1), treatment period and follow-up period (14±3days after the end of the last dose of ABCD).~IA patients will be treated with ABCD for 4 weeks first, followed by oral administration of voriconazole. The total course of treatment should be at least 6 to 12 weeks. ABCD dosing regimen will be the same as that for IC patients. Visiting plan: screening period (D-4to D-1), baseline period (D1), treatment period and follow-up period."
46025260|NCT02771821|Other|Operative groups based on methodology of problematization|"The educational intervention based on the methodology of problematization consisted of the survey prior knowledge on the subject; planning; Implementation and Evaluation through verbalization solutions applicable to the reality of the elderlies.~Each operative group was composed of an average of 12 to 15 elderlies diabetics who participated in monthly activities lasting 2 hours, for six consecutive months."
46025261|NCT02771899|Device|spineEOS software|During a full-length exam from head to feet in the standing position, 3D reconstructions of the spine, the pelvis and lower extremities using spine workflow and global postural assessment workflow on spineEOS software will be performed.
46025262|NCT02771899|Device|EOS|The system performs a full-length exam from head to feet in the standing position. 2D parameters will be obtained per standard of care.
45469821|NCT03410524|Drug|Simethicone Solution|200 mg of Simethicone in 3 mL of Simethicone Solution Formulation
46025263|NCT04227223|Diagnostic Test|biochemical measurements|TOC,TAC, and BDNF measurements are performed using ImAnOx , PerOx and BDNF tests (Immundiagnostik, Germany)
45469822|NCT03410524|Drug|Water|3 mL of water as placebo added to the bowel preparation
45469823|NCT04756440|Behavioral|Education Program and Music Therapy|After the intervention, it is expected that their awareness of Romana cervical cancer will increase, their perception of obstacle towards screening tests will decrease and they will be tested.
45469824|NCT03417622|Procedure|Bracketing|At the beginning of therapy, ultrasonographic examination is used to measure the tumor in three dimensions and bracket the tumor using 4-6 metal clips which will serve as markers for the initial tumor extent in case of tumor shrinkage in response to systemic treatment.
45681776|NCT01682811|Drug|Part 1 Levulan surface application twice with microneedling|Control or treatment lesions will be prepared with microneedling, painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 24 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
45681777|NCT01682811|Drug|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 8 minutes to achieve a dose of 50 J/cm^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
46025264|NCT02771509|Drug|ANG-3777|6 mg/mL BB3, IV, 4 days in a row, first dose must be within 4 hours after surgery, the next three doses will be approx. 24 hours after the last dose
46025265|NCT02771509|Drug|Placebo|Normal saline
46025266|NCT02697019|Behavioral|Internet-delivered Emotion Regulation Individual Therapy for Adolescents|
46112227|NCT00703703|Drug|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
46025267|NCT02696941|Drug|Metformin|Metformin 500mg once daily and titrated weekly to a dose of 1000mg twice daily for 3 months
46025268|NCT02696941|Drug|SGLT2 inhibitor|SGLT2 inhibitor has been recommended to be started as part of routine clinical care
46112228|NCT00703703|Drug|Placebo|Placebo tablet once daily
46025269|NCT02771665|Other|Mammographic breast density at diagnosis|Mammographic breast density at diagnosis
46112229|NCT00859313|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
46112230|NCT02611973|Other|Aspirin therapy interruption|Stop the treatment by aspirin 100mg/d in the experimental arm.
46112231|NCT02611973|Other|Usual treatment by aspirin 100 mg/d in the active comparator arm|HU+ aspirin maintenance
46025270|NCT02767375|Drug|Oxaliplatin(OXA), 5-fluorouracil (5-FU)|for the HAIC treatment group OXA 85mg/m2, d1，0-4h 5-FU 1500mg/m2 d1, 4-24h 24 hours in d1 & 2 , IA，q4-6 Weeks
46025271|NCT02767375|Procedure|Hepatic arterial catheter implantation|for the the HAIC treatment group: Hepatic arterial catheter implantation for HAIC
46112232|NCT02611973|Other|No interruption of aspirin in the Observational arm|patient with Contre indication to aspirin or required antithrombotic therapy
46025272|NCT02767453|Procedure|Wound drainage|Experimental portion removing/draining blood/fluid from a space created during a surgical procedure. Typically, surgeons place a plastic tube in the shoulder joint to drain fluids that may accumulate after surgery. Hemovac drain is a FDA-approved device routinely used or wound drainage; however, there is no known evidence whether this improves outcomes of surgery.
46025273|NCT02767453|Procedure|Total Shoulder Arthroplasty|"Standard procedure for treating the severe pain and stiffness that often result at the end stage of various forms of arthritis or degenerative joint disease of the shoulder joint. The primary goal of shoulder replacement surgery is pain relief, with a secondary benefit of restoring motion, strength, function, and assisting with returning patients to an activity level as near to normal as possible. Shoulder prosthesis is a standard artificial device to replace both components of the ball and socket joint during TSA."
46025274|NCT02767141|Behavioral|Coping Strategies|Coping strategies for households in the US with food insecurity
46025275|NCT02767219|Drug|bevacizumab|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 2 will receive a subconjunctival injection of bevacizumab and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given for 4 consecutive weeks from time of entry into trial.
46025276|NCT02767219|Drug|5-fluorouracil|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 1 will receive a subconjunctival injection of 5-fluorouracil and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given as required for 4 consecutive weeks from time of entry into trial. This is current standard practice.
46112233|NCT02611973|Drug|Hydroxyurea treatment (HU)|HU maintenance
46112234|NCT00771810|Drug|TXA127|Once daily subcutaneous injection of 100 ug/kg
46112235|NCT00771810|Drug|TXA127|Once daily subcutaneous injection of 300 ug/kg
46112236|NCT00771810|Drug|Placebo|Once daily subcutaneous injection of placebo
46112237|NCT00836927|Drug|Ridaforolimus Tablet|Ridaforolimus 10 mg oral tablet
46112238|NCT00836927|Drug|Ridaforolimus Intravenous (IV) Infusion|Ridaforolimus IV infusion administered once daily for 5 days every 2 weeks in a 28-day cycle (two 2-week courses equals 1 cycle).
46112239|NCT00703235|Drug|Bevacizumab|
46112240|NCT02612051|Drug|GSK3008348 Nebuliser solution|Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.
46112241|NCT02612051|Drug|Placebo Nebuliser solution|5% mannitol nebuliser solution. 4 ml of solution will be administered by nebulisation
45838662|NCT04374552|Drug|Placebo|Drug - placebo
45838663|NCT04374162|Procedure|PEEP|different PEEP set on the anesthetic machine
46112242|NCT02612051|Radiation|GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion|Formulated in 0.9% saline. The maximum amount of radioactivity injected during each PET scan will be 150 Megabecquerel (MBq) and maximum mass of [18F]-FBA-A20FMDV2 administered across all three administrations will be 100 mcg. Intravenous bolus infusion of 20 ml will be administered over about 30 seconds.
46112243|NCT00771030|Biological|Brodalumab|Solution for subcutaneous or intravenous administration
46112244|NCT00771030|Other|Placebo|Solution for subcutaneous or intravenous administration
46112245|NCT00768300|Drug|Ambrisentan|Ambrisentan (5mg or 10 mg tablet) was administered orally once daily.
46112246|NCT00768300|Drug|Placebo|Placebo to match ambrisentan was administered orally once daily.
46112247|NCT00768222|Device|silk suture|skin closure
46112248|NCT00768222|Device|VICRYL* Plus suture|skin closure
46025277|NCT02767219|Drug|Dexamethasone|Both intervention groups will be given a subconjunctival injection of dexamethasone at the time of injection of either bevacizumab or 5-fluorouracil
46025278|NCT02766829|Procedure|Cross leg sitting position|Subjects were set on cross leg sitting position before spinal anesthesia begun.
46025279|NCT02766829|Procedure|Traditional sitting position|Subjects were set on traditional sitting position before spinal anesthesia begun.
46025280|NCT04711993|Other|Aerobic exercise|"Patients will do aerobic exercise three days a week for 40 minutes during 8 weeks. Aerobic exercise protocol will consist of warm up, loading and cooling periods. . Exercise prescription will be prepared in line with the recommendations of The American College of Sports Medicine."
46025281|NCT04711993|Other|Stretchin exercise|Patients will do stretching exercise three days a week for 40 minutes during 8 weeks. Stretching exercises will start with active warm-up activities. Static stretching method will be used.
46112249|NCT00768144|Drug|Sunitinib|
46025282|NCT02771587|Dietary Supplement|Alcohol and energy drink|Multiple oral dose of alcohol Multiple oral dose of energy drink
46025283|NCT02771587|Dietary Supplement|Alcohol|Multiple oral dose of alcohol
46112250|NCT03996330|Diagnostic Test|taqman array card|The array card contains multiple PCR reactions for microbial pathogens, extracted microbial nuclear material from lavage or blood is run on the card to detect pathogen specific sequences by polymerase chain reaction.
46112251|NCT00784836|Drug|BG9418 (interferon beta 1-a)|
46112252|NCT04104984|Device|transvaginal ultrasound|a transvaginal ultrasound is done to patient to determine cervical length
46112253|NCT04104984|Drug|Progesterone Vaginal Suppository|a progesterone vaginal suppository to prevent preterm labour
46112254|NCT04104984|Procedure|cervical cercalage|Mcdonald's cervical cercalage . a stitch taken around the cervix to prevent preterm labour
46112255|NCT04104984|Other|digital vaginal exam|vaginal examination to detect short cervix
46112256|NCT04104984|Device|abdominal ultrasound|use abdominal ultrasound to measure cervical length
46112257|NCT04104984|Drug|Tocolytic Agents|a medication is given to prevent uterine contraction
46112258|NCT00784758|Device|Fenzian Device|Three 20-minute treatments with the Fenzian Device per week for 5 weeks (for a total of 15 treatments)
46112259|NCT00784758|Device|Sham Device|Three 20-minute treatments with the sham device per week for 5 weeks (for a total of 15 treatments) (NOTE: This arm is similar to a placebo arm in a drug trial.)
46112260|NCT00768066|Biological|Autologous human mesenchymal cells (hMSCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hMSCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
45469825|NCT03417622|Drug|Neoadjuvant therapy|All patients will receive primary systemic therapy according to the current institutional guidelines. Drugs include cytotoxic chemotherapy, hormonal therapy and/or anti-HER2/neu therapy as indicated.
45469826|NCT03417622|Procedure|Post-treatment volume margin resection|The lumpectomy resection margin is planned according to the identifiable tumor at operation. The initial extent of the tumor at diagnosis is not taken in account. If there is complete clinical response to systemic therapy (i.e. no identifiable tumor), the center of the bracketed tissue is biopsied.
45469827|NCT03417622|Procedure|Pre-treatment volume margin resection|The lumpectomy includes the whole bracketed tissue to take in account the initial tumor extent before systemic therapy.
46025284|NCT02771587|Dietary Supplement|Energy drink|Multiple oral dose of energy drink
46025285|NCT02771587|Dietary Supplement|Placebo|Multiple oral dose of water Multiple oral dose of non-caffeinated soft drink
46025286|NCT04742725|Drug|Placebo|Placebo
46025287|NCT04742725|Drug|Prothione™ (6g)|Prothione is a pro-Glutathione compound includes free-form amino acids
46025288|NCT02778451|Other|Measurement of competence|This study is a psychometric validation of a generic assessment tool to evaluate ultrasonography competence among surgeons
46025289|NCT02771743|Drug|Cisplatin|
46112261|NCT00768066|Biological|Autologous human bone marrow cells (hBMCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hBMCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
45469828|NCT02713776|Drug|Pasireotide|Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.
46025290|NCT02771743|Drug|Doxorubicin|
46025291|NCT02771743|Drug|Etoposide|
46025292|NCT02771743|Drug|Cyclophosphamide|
46025293|NCT02771743|Drug|Ifosfamide|
46025294|NCT02771743|Drug|Carboplatin|
46025295|NCT02771743|Procedure|Tandem HDCT/auto-SCT|
46025296|NCT02771743|Radiation|Radiotherapy|
46025297|NCT02771743|Drug|Interleukin-2|
46025298|NCT02771743|Drug|Isotretinoin|
46112262|NCT00768066|Biological|Placebo|Participants will receive 0.5 mL injections of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
46112263|NCT00767676|Device|HP828-101|Nine topical patch applications over 3 weeks, rest period of 2 weeks and challenge after 48 hours.
46112264|NCT00767520|Drug|Exemestane + Dasatinib|Tablets, Oral, Exemestane 25 mg + Dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity
46112265|NCT00767520|Drug|Exemestane + Placebo|Tablets, Oral, Exemestane 25 mg + Placebo 100 mg, once daily, until disease progression or unacceptable toxicity
46112266|NCT02601612|Biological|D46cpΔM2-2 vaccine|Delivered as nose drops
46112267|NCT02601612|Biological|Placebo|Delivered as nose drops
45838664|NCT04373850|Behavioral|Home Visit|Physical exam, medication dose titration
46025299|NCT02771743|Radiation|MIBG|
46025300|NCT02762851|Other|Sterile saline|0.5 ml dose injected intramuscularly
46025301|NCT02762851|Drug|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
46025302|NCT02771431|Other|Tele-rounding in post operative care|Both groups will receive standard of care. The only difference between these groups would be the physical presence of the attending in the room. Both groups will receive a physical exam with supervision of the attending, one group will have attending in the room and the other will have the attending present via I-pad. In both cases if there was something of concern the attending would step in for the physical exam if needed, regardless of which group they were randomized for.
46025303|NCT02770963|Procedure|Acupuncture|"Shenshu (BL23) on bilateral sides and Dachangshu (BL25), Weizhong (BL40), and Chengshan (BL57) on the affected side will be applied.~A Huatuo Brand needle (0.3*75 mm) for BL25 will be inserted at a depth of 40-70 mm vertically until the patient feels soreness and a distension sensation that radiates to the leg. The needle will be lifted 1-2 mm without rotating or lifting. Huatuo Brand needles (0.3*40 mm) at the other acupoints (BL23, BL40 and BL57) will be inserted 30 mm and manipulated by lifting, thrusting, twirling evenly until the Deqi sensation is achieved. The needles in these acupoints will be manipulated by small evenly applied lifting, thrusting, and twirling movements 3 times every 10 minutes."
46112268|NCT00838565|Drug|Placebo|intravenous infusion on three consecutive months
46112269|NCT00838565|Drug|dose level 1|intravenous infusion on three consecutive months
46112270|NCT00838565|Drug|dose level 2|intravenous infusion on three consecutive months
46112271|NCT00838565|Drug|dose level 3|intravenous infusion on three consecutive months
46112272|NCT00838565|Drug|dose level 4|intravenous infusion on 3 consecutive months
46112273|NCT00858845|Drug|Clonidine Patch|A clonidine patch (0.1 mg/week) to be worn for a period of 3 months.
46112274|NCT00858845|Other|Matching Placebo Patch|A matching placebo patch to be worn for a period of 3 months.
46112275|NCT00703859|Drug|Dichloroacetate (DCA)|DCA starting at an initial dose of 3mg/kg twice daily PO for consecutive days (days 1-5) on a 28 days cycle up to 6 cycles unless evidence of tumour progression. Each dose to be administered with food at the same time everyday 12 hours apart.
46112276|NCT05591339|Biological|BCG vaccine (two doses, 4 weeks apart)|BCG vaccine provided intradermally at the upper arm.
46112277|NCT05591339|Biological|Saline placebo (Two doses, 4 weeks apart)|Participants randomized to the control group (placebo) will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
46112278|NCT04030949|Other|No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants|No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants
46112279|NCT05565287|Combination Product|ultra early physiotherapy intervention|"NBAS / NBO and GMs based guidelines in explaining neonatal signs into the NICU (lasting 15-30 minutes)~NBAS / NBO and GMs based guidelines in explaining neonatal signs to parents, 1st neonatal assessment and intervention upon hospital discharge (lasting one hour)~NBAS / NBO and GMs based guidelines in explaining neonatal signs to parents, 1st neonatal assessment and intervention every 15 to 20 days until the 3rd month of life (corrected age)."
46112280|NCT00770562|Drug|rituximab|
46112281|NCT00770562|Drug|Dexamethasone|
46112282|NCT00836693|Drug|tadalafil|5 milligrams (mg) administered orally once a day for 12 weeks
46112283|NCT00836693|Drug|placebo|tablet administered orally once a day for 12 weeks.
46112284|NCT00770484|Drug|Propranolol then Placebo|Propanolol 20 mg, given orally within 1 hour prior to exercising
46112285|NCT00770484|Drug|Placebo then Propranolol|Placebo, matching pill given orally within 1 hour prior to exercising
46112286|NCT04099602|Other|Baby Massage|Received baby massage and bilirubin levels were measured twice daily by the transcutaneous bilirubin meter for 5 days
46112287|NCT04098042|Device|Scaffold|implantation of a Magmaris scaffold
46112288|NCT00835679|Biological|cetuximab|Given IV
46112289|NCT00835679|Drug|dasatinib|Given orally
46112290|NCT00835679|Procedure|therapeutic conventional surgery|Undergo surgery
46112291|NCT00835679|Other|laboratory biomarker analysis|Correlative studies
46112292|NCT04100070|Behavioral|Monitoring of the patients|"Follow-up of the patients during the 12 months study periods including :~visits with the diabetologist/pediatrician~contacts with the service provider (nurses' visits) (more in intensive group)~personalized monitoring of glycemic data transferred to the diabetologist/pediatrician for each visit (only in intensive group)"
46112293|NCT04119245|Device|I-gel supraglottic airway device|After induction of general anesthesia, we will measure the Oropharyngeal leak airway pressure during controlled ventilation in supine and in positions after insertion of I-gel.
46112294|NCT00766506|Device|Fentanyl IONSYS|Participants will receive 40 mcg of fentanyl dose up to a maximum of 240mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).
46112295|NCT00766506|Device|Morphine IV PCA|Morphine sulphate solution will be administered intravenously (IV) by a patient-controlled analgesia (PCA) pump using set bolus doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.
46112296|NCT04097886|Other|Morning Exercise|moderate intensity exercise (70% VO2 max) each morning for 5 days
45838665|NCT04374006|Drug|Dienogest|1mg/kg BW/day based on the study by Katayama et al. A DNG in 0,5% carboxymethylcellulose suspension was given orally with metal sound daily 0,2-0,4 mL per day
46025304|NCT02770963|Procedure|Sham acupuncture|"Specially designed sham needles (0.3*25 mm) will be used. The sham needle consists of a needle handle, needle body, blunt tip and a sterile polyethylene cylindrical foam pad (identical to the pads in the acupuncture group).~The acupoints will be the same as the acupuncture group. The needle will be inserted vertically until pressed against the skin without penetration. The manipulation will be consistent with the acupuncture group and blind to the patients."
46025305|NCT02771041|Procedure|medical consultation 8 days before surgery|"This consultation would serve to explain to the patient the early course of care, give advice and help to anticipate acts for its release post-operative as, for example, contact a physical therapist and a nurse or check to their community pharmacy if their heparin stock is enough and to answer any questions."
46025306|NCT04224805|Device|Bone-borne CAD/CAM splint|3D printed splint that repositions the maxilla with the zygomatic buttress as a reference.
46025307|NCT04224805|Device|3D interocclusal conventional splint|Interocclusal splint that relies on the centric relation of the condyle as well as occlusion.
46025308|NCT04710433|Device|Non-invasive Neuromodulation|Sacral nerve stimulation via two adhesive electrodes (single current).
46112297|NCT04097886|Other|Evening Exercise|moderate intensity exercise (70% VO2 max) each evening for 5 days
46025309|NCT04710433|Other|Medical and Behavioral Therapy|Behavioral Therapy consists of toilet training, an active and healthy lifestyle. Doses of medical options are applied weight-adjusted.
46025310|NCT02767063|Drug|Pioglitazone|PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade >1 related AE.
46112298|NCT00770328|Drug|Pentoxifylline|400mg PO TID x 8 weeks
46112299|NCT00770328|Drug|Placebo|PO TID x 8 weeks
46112300|NCT05500092|Drug|Nivolumab|Patients randomized to the Nivolumab + Platinum Doublet Chemotherapy only arm will receive three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) with sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor
45838666|NCT04374006|Drug|Propolis|The propolis contains 20 mg in each ml. So, each rat we given 0,2 ml for 50mg/kg propolis treatment and 0,4 ml for 100mg/kg propolis treatment
45838667|NCT04374006|Other|placebo|we gave 0,2 ml to each rat everyday to negative control groups, and we gave no treatment to sham groups
46025311|NCT02767063|Drug|Avelumab|10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period. (If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)
46025312|NCT02766751|Behavioral|HIVPASS|The 7-session HIVPASS intervention is provided to individuals randomized to the HIVPASS study arm.
46025313|NCT02766751|Behavioral|Health Education|The 7-sessions of Health Education is provided to individuals randomized to the Health Education study arm.
46025314|NCT02766595|Other|hyperventilation while sitting up during routine EEG|Child will be asked to perform hyperventilation while lying down as well as while sitting up
46112301|NCT05500092|Radiation|(8gy x 3)|sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor
46112302|NCT05500092|Drug|Platinum Doublet|Standard of care doublet platinum therapy
46112303|NCT04097496|Behavioral|Act Out! Intervention|Data included in the description of the intervention arm.
46112304|NCT00916500|Drug|CONCURRENT CHEMORADIATION (CISPLATIN)|Cisplatin IV 75mg/m2 Every 3 Week For 3 Cycles; External Pelvic Radiation 40Gy; Brachytherapy Up To 85-90 Gy To Point A
46112305|NCT04100928|Other|dental students|WEMWBS and a questionnaire included demographic details and social background, lifestyle behaviors was applied to the participants.
46112306|NCT03110094|Other|Adalimumab|It will be an interventional study with minimal risks and constraints, prospective, mono-centric, in current care. Patient management will not be changed during the study. It will be taken at two different tracking points (M0 and M3) 4 additional tubes and use of surplus articular fluid (M0 and M3).
46112307|NCT03110094|Other|Healthy volunteers|Collection of 2 tubes of blood. The values of the quantitative study of lymphocyte subpopulations will be compared to those obtained from healthy blood donors to define the standards used in this study.
46112308|NCT02600988|Drug|1000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
46112309|NCT02600988|Drug|5000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
46112310|NCT05499078|Device|SULFEX 13081.22|Patients with dry or irritated nose treated with SULFEX 13081.22 nasal spray for 6 days (with at least 1 spray use a day). Severity of the nasal symptoms will be compared before and 6 days after spray use on a 7-point nasal symptoms scale basis.
46112311|NCT04097574|Drug|NPO-13: l-menthol|20 mL/site
46112312|NCT04099680|Procedure|Partial thickness recipient bed|Flap will be separated by sharp dissection and elevated toward apical direction, leaving the periosteum covering the bone, and the elevated pedicle flap will be incised and removed.
46112313|NCT04099680|Procedure|Full thickness recipient bed|Full-thickness (mucoperiosteal) flap will be raised on the recipient bed to establish a denuded bone area. Two bone screws will be placed at the most apical border of the denuded bone.
46112314|NCT04099680|Device|Bone screw (FDA approved bone screw)|Two bone screws placed at the most apical border of the denuded bone after osteotomy.
46112315|NCT04099680|Procedure|Periosteal sutures|Interrupted periosteal sutures placed at the 4 corners of each graft, and mesial and distal surfaces to engage the graft at an equidistance from the graft corners.
46112316|NCT04099680|Procedure|Sling sutures|Crossed sling sutures placed over the graft engaging the fixed crestal/lingual KT coronally and the periosteum apically.
46112317|NCT04099680|Procedure|Sling sutures around screws|Crossed sling sutures placed over the graft engaging the fixed crestal/lingual KT coronally and each is apically looped around the corresponding apically positioned screw.
46112318|NCT00766038|Drug|Recombinant human Growth Hormone|400 micrograms/day SC for 6 months. Dose adjusted based on serum IGF-1 measurements
46112319|NCT00766038|Drug|Placebo|SC injection daily
46112320|NCT04100304|Diagnostic Test|resection|CT volumetry,liver function,biopsy before resection
46112321|NCT00765882|Drug|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
46112322|NCT00765882|Drug|Linaclotide 145 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
45469829|NCT02713776|Drug|Placebo|Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
45469830|NCT04813510|Device|electroacupuncture treatment|"Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at Zusanli(ST36), Xiajuxu(ST39), Hegu(LI4), Neiguan(PC6) once a day for seven days. AfterDeqi, electroacupuncture stimulation apparatus(HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 ~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of treatment."
45469831|NCT04813510|Device|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at nonacupoints (located 1 inch beside acupoints).. Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle for the same time as treatment group"
45469832|NCT05168878|Behavioral|30-second BeSMART video|30 second video focused on education about child gun deaths and responsible gun storage
46112323|NCT00765882|Drug|Placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
46112324|NCT04097418|Behavioral|Aerobic training compared to conventional motor training|"Aerobic training: aerobic training by treadmill at moderate intensity. Each treatment will consists of 35 minutes of training, administered 3 times per week, for 8 weeks.~Conventional motor training: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training, administered 3 times per week, for 8 weeks."
45469833|NCT05168878|Behavioral|3-minute BeSMART video|3-minute video focused on education about child gun deaths and responsible gun storage
45469834|NCT03397810|Radiation|low dose radiotherapy|10 Gy in 5 fractions of 2 Gy on 5 consecutive days
45469835|NCT03397732|Procedure|aorto-bifemoral bypass and aorta stentgraft|Surgical implantation of aorto-bifemoral bypass or aorta stentgraft under general and/or regional anaesthesia.
45469836|NCT05215990|Drug|MetFORMIN 500 Mg Oral Tablet|studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients receive metformin with pulmonary tuberculosis standard treatment group in second week, second, fifth, and sixth month.
45469837|NCT05215990|Drug|Placebo|studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients receive placebo drug with pulmonary tuberculosis standard treatment group in second week, second, fifth, and sixth month.
45469838|NCT03126058|Procedure|enhanced recovery after surgery|Patients will undergo enhanced recovery after surgery programs.
45838668|NCT04373772|Other|abdominal massage|the patients in the AM group were given a total of 30 minutes of AM by the nurses (HD, OM) everyday for 15 minutes in the morning and evening.In this study AM, which included effleurage, strokes, petrissage and vibration techniques, was applied to the patients for 15 minutes in each session at 9:00 am and 9:00 pm.
45838669|NCT04373538|Behavioral|Trans-C for sleep and circadian function + Memory Support|The Memory Support Intervention will be delivered interwoven with Trans-C. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. The memory support strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
46025315|NCT04224103|Drug|Inhaled nitric oxide|"Stage 1: Patients in whom VA ECMO is being initiated will be invited to participate. Hemodynamic, echocardiographic, and biochemical parameters will be measured immediately prior to iNO administration, and thirty minutes after initiation. After six hours, hemodynamic, echocardiographic, and biochemical parameters will be re-assessed after which iNO will be weaned. All parameters will be re-evaluated 30 minutes after iNO discontinuation.~Stage 2: iNO will be re-initiated 30 minutes prior to the ECMO weaning trial. Hemodynamic, echocardiographic, and biochemical parameter will be recorded immediately prior to iNO administration and then at 30 minutes prior to the ECMO weaning trial. When ECMO weaning is unsuccessful, these parameters will be recorded immediately prior to re-initiation of full flow VA ECMO and 30 minutes thereafter. If successful, data will be collected after the wean and after iNO discontinuation."
46025316|NCT02766439|Drug|etanercept|25-mg etanercept injection subcutaneously twice a week
46025317|NCT04701307|Biological|Dostarlimab|Given IV
46025318|NCT04701307|Drug|Niraparib|Given PO
46025319|NCT04651075|Other|music listening|The music selected by the participants was played to the music listening group.
46025320|NCT04651075|Other|individual training|Individual training group was trained on coronary angiography.
46025321|NCT04223869|Other|non-surgical periodontal treatment|scaling and root planing were performed
46025322|NCT02766361|Behavioral|Cognitive Behavioral Rehabilitation|12 weekly sessions of Combined intervention lasting 90 minutes
46112325|NCT05297136|Procedure|Pancreatic Stenting|Pancreatic stent of appropriate size and length is inserted to the pancreatic duct before distal pancreatectomy
46112326|NCT05297136|Procedure|No Stent|No preoperative stenting with distal pancreatectomy alone
46112327|NCT00769860|Drug|Arimoclomol|Arimoclomol 100 mg TID for 4 months
46112328|NCT00769860|Other|Placebo|Placebo for 4 months
46112329|NCT02600754|Behavioral|IT-PST|5 sessions of problem-solving therapy by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More)
46112330|NCT02600754|Behavioral|IT-SCM|5 sessions of self-care management support by trained lay advisers co-located in an aging-service agency (Meals on Wheels and More)
45469839|NCT03268941|Drug|TAK-906 Maleate|TAK-906 Maleate Capsules
45469840|NCT03268941|Drug|Metaclopramide|Metaclopramide Tablets
46112331|NCT00858143|Other|Non Interventional Observation|Post marketing surveillance study = prospective, non-interventional observation of the use of Somavert®
46112332|NCT04118933|Drug|JS001|JS001 240mg, Q3W
46112333|NCT00913367|Drug|glimepiride + insulin glargine (Amaryl + Lantus)|"Amaryl® 4 mg at breakfast + Lantus® at dinner~The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast"
46112334|NCT00913367|Drug|glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)|"Amaryl® M 1/500 mg at breakfast + Amaryl® M 1/500 mg at dinner + Lantus® at dinner~The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast"
46112335|NCT00922805|Dietary Supplement|guar gum|guar gum (20 g/l of formula) for one week
46025323|NCT02766361|Other|Treatment as Usual|standard out-patient treatment offered in our clinic, which involves psychopharmacological mood stabilization and regular contacts with mental health nurses.
45469841|NCT03268941|Drug|TAK-906 Maleate Placebo|TAK-906 placebo-matching Capsules
46025324|NCT02766127|Other|Veritise Flow|Self-adhering composite
46025325|NCT02766127|Other|Universal Dentin Sealant|non-polymerizable, high molecular weight resin sealant
46025326|NCT02766127|Other|Clearfil Protect Bond|methacrylate-based resin, self-etching adhesive system
46025327|NCT02766127|Other|Flor-Opal® Varnish|fluoride-based varnish
46025328|NCT02766049|Biological|DC|Autologous dendritic cells (3x10e7)
46025329|NCT02766049|Biological|DC10e6+HIV-AT2|Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV
46025330|NCT02766049|Biological|DC10e7+HIV-AT2|Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV
46025331|NCT02765971|Other|gums|Group A, 180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval.
46025332|NCT02765971|Drug|picolax drops|Group B, 180 women will receive laxatives after their operating room discharge by 3 hours.
46112336|NCT00704015|Behavioral|Smoking cessation|Nurses, specifically trained for smoking cession program, contacted the patients at the orthopedic wards and initiated the intervention (stop smoking) within 1-2 days after acute hospitalization. The intervention included one or two personal meetings and weekly phone contacts during 6 weeks with a trained nurse. A phone number to a non-smoking hotline was provided for all patients. The patients were continuously encouraged not to smoke and free nicotine substitution (Nicorette®) was offered those who needed it. No other drug therapy was used.
46112337|NCT00828113|Drug|varenicline|Extension of 1 mg twice daily treatment to 52 weeks
45469842|NCT05215834|Drug|Remifentanil|"Remimazolm and Remifentanil (RR group): anesthesia was induced with remimazolam 6 mg/kg/h by continuous intravenous (IV) infusion and with the effect-site concentration of remifentanil 4 ng/ml and until the loss of consciousness (LoC), followed by remimazolam 1-2 mg/kg/h and remifentanil 3 ng/ml until the end of surgery.~Propofol and Remifentanil (PR group), anesthesia was induced with the effect-site concentration of propofol of 6.0 μg/ml and remifentanil 4 ng/ml, and until the loss of consciousness (LoC), followed by the effect-site concentration of propofol of 2-4 μg/ml and remifentanil 3 ng/ml until the end of surgery."
46025333|NCT02765971|Drug|normal saline|Group C received 500 cc of normal saline, Intravenous fluid
46025334|NCT02765815|Drug|Liposomal bupivacaine, 266mg|
46025335|NCT02765815|Drug|Bupivacaine 0.5 % with Epinephrine|
46025336|NCT02765815|Drug|Ketorolac 30mg|
46025337|NCT02765815|Drug|Morphine 10mg|
46025338|NCT02765815|Drug|Bupivacaine 0.25% with Epinephrine|
46025339|NCT02765893|Other|No Foley|Patients will have Foley catheter removed 6 hours post-op.
46112338|NCT00828113|Drug|varenicline|Double-blind switch to placebo after 12 weeks of open-label therapy
45469843|NCT03410368|Biological|NK cells|Autologous peripheral blood mononuclear cells (PBMCs) are collected by apheresis on D0, then induced into NK cells and infused into the patients 14 days later (D14) as the initial transfusion. There are 3 consecutive transfusion days (D14-D16). The second course of PBMCs collection started D14 before infusion. A total of 6 courses will be completed unless progression or unacceptable adverse events.
46025340|NCT02765581|Device|Verum acupuncture|"The main acupuncture points are bilateral Hegu (L14) and Taichong (LR3), unilateral Taiyang(EX-HN5), Fengchi (GB20) and Shuaigu (GB8). Additional points can be chosen according to individual syndrome differentiation of meridians: (1) Yangming headache: Touwei (ST8); (2) Taiyang headache: Tianzhu (BL10); (3) Jueying: Baihui (GV20). The NO.16 special type of acupuncture (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
46025341|NCT02765581|Device|Sham acupuncture|"We use a non-insertive sham control produced by Asia-med Company in Germany-the streitberger placebo-needle. Sham points are described as follows: 1) Bilateral of midpoint between acupoint Jianjin(GB21) and Jugu(LI16); 2) 5 cun lateral to the seventh thoracic spine; 3) 5 cun lateral to the eighth thoracic spine; 4) 5 cun lateral to the ninth thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun."
46025342|NCT02765581|Behavioral|Usual care|Health education is provided in three aspects: lifestyle changes, behavioral therapies and migraine self-management.
46025343|NCT02765347|Drug|Metformin|For arm 1, accept MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g tid) for 24 weeks.
46112339|NCT00828113|Behavioral|Individual smoking cessation counseling|Brief (<10 minutes) smoking cessation counseling delivered at clinic visits
46112340|NCT00704093|Device|Right ventricular pacing|Right ventricular pacing vs. sinus rhythm or atrial pacing at the same rate
46112341|NCT00707135|Drug|Rapamycin|Rapamycin given once weekly in escalating doses. Higher dose levels will be split with the half the dose given on day 1 and half the dose on day 2 (24 hours later).
46025344|NCT02765347|Drug|Insulin|For arm 2, just accept insulin for 24 weeks
46025345|NCT02765425|Device|AMES|Subjects will be trained while seated on the AMES device. As the footplate of the device rotates the ankle ±15 deg in dorsiflexion and plantarflexion, the participant will assist that motion. Vibration (2-3 mm at 60 pulses/s) will be applied to the tibialis anterior tendon during plantarflexion and to the Achilles tendon during dorsiflexion. To assist participants in the assisted movement task, the AMES biofeedback screen will provide real-time visual feedback of the volitional ankle torque that the participants actively apply to the AMES device. Each training session will include 15 min of training of each ankle; training sessions will be conducted 3 times/week over a 12-week period, for a total of 9 hours of training on each ankle.
46112342|NCT00769704|Biological|Talimogene laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
46112343|NCT00769704|Biological|GM-CSF|125 µg/m² subcutaneous injection
46112344|NCT00818753|Drug|dabigatran 110 mg|comparison of different dabigatran dosages with unfractionated heparin
46025346|NCT04223713|Procedure|TriRec|Trileaflet Reconstruction of the Aortic Valve
46025347|NCT04223713|Procedure|Aortic valve replacement|Biological Prosthesis, Device: Edwards Perimount
46025348|NCT02764957|Dietary Supplement|green coffee extract|
45469844|NCT03394144|Drug|AZD9150, Durvalumab|After confirmed safety with Cohort 1, Cohort 2 will open. Patients allocated in each cohort will be evaluated for DLT
46025349|NCT02764957|Dietary Supplement|placebo|
46025350|NCT02765113|Procedure|Facial nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
45469845|NCT02346825|Behavioral|Neurorehabilitation therapy with cast|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a full-arm cast on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
45469846|NCT02346825|Behavioral|Neurorehabilitation therapy with splint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing part-time splint on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
46025351|NCT02765113|Procedure|Facial and Trigeminal nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~Trigeminal nerve combing:To sort out the trigeminal nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
45469847|NCT02346825|Behavioral|Neurorehabilitation bimanual|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks will not wear a constraint. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
46025352|NCT04686175|Drug|INZ-701|INZ701-101 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
46112345|NCT00818753|Drug|dabigatran 150 mg|comparison of different dabigatran dosages with unfractionated heparin
46112346|NCT00818753|Drug|unfractionated heparin|comparison of different dosages dabigatran with unfractionated heparin
46112347|NCT00704249|Drug|nevirapine|Full-dose nevirapine from baseline (200 mg bid).
45469848|NCT05011149|Drug|Ibuprofen|"Pharmacotherapy, when indicated (ie, for severe PDA on echocardiography, irrespective of clinical symptoms, or a moderate PDA on echocardiography with at least moderate clinical illness), will be provided in the form of ibuprofen as first line agent at a standard dosing of 10 mg/kg followed by 2 doses of 5mg/kg every 24 h. The route of administration may be intravenous or enteral, as determined by the treating team.~For treated infants, follow-up echocardiography will be conducted at the end of the 3-day course and second course of treatment will be initiated if they still fulfill study treatment criteria as mentioned above. If any treatment-eligible infant has a contraindication to ibuprofen, use of acetaminophen will be permitted as an alternative agent."
45469849|NCT03397498|Behavioral|CogniFit™|The program utilizes 21 tasks, which may develop 14 cognitive domains: awareness, inhibition, spatial perception, visual short term memory, working memory, hand-eye coordination, visual scanning, response time, divided attention, time estimation, visual perception, shifting, naming, and planning.
45469850|NCT03397498|Behavioral|Control-games|The program utilizes classic computer games, which may develop cognitive domains. Games will be used over 8 weeks. The participants will use the program 3 days a week, with one rest day between each session. Each session lasts approximately 20 minutes. The participant will use the program for a total number of 24 sessions.
46025353|NCT02764879|Dietary Supplement|Omega 3 fatty acids|omega3 received 2 times daily-for 6 months
45469851|NCT03126994|Device|PhysioWave Cardiovascular Analyzer|Measurement of Pulse Wave Velocity, Pulse Rate, Body Weight and BMI
45469852|NCT03126994|Device|AtCor XCEL PWA & PWV|Measurement of Pulse Wave Velocity and Pulse Rate
46025354|NCT02764879|Procedure|scaling and root planing|
46025355|NCT02764879|Other|placebo soft gelatin capsules|placebo soft gelatin capsules received 2 times daily-for 6 months
46112348|NCT00704249|Drug|nevirapine|Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
46112349|NCT00765726|Biological|Moroctocog alfa(AF-CC)|Dosing is at the discretion of the investigator during the study
46112350|NCT00765726|Procedure|Blood draw for laboratory testing|Hematology and Chemistry panels, Factor VIII inhibitor and recovery studies
46112351|NCT04100226|Dietary Supplement|Vitamin D3 (1.25 (OH)2 cholecalciferol)|"Vitamin D 3 in a dose of 200.000 IU intramuscular injection every 2 weeks for 3 months for Vitamin D deficient interstitial lung disease patients and every month for 3 months for vitamin D insufficient interstitial lung disease patients.~calcium supplementation in form of ca carbonate 600 mg oral capsule once daily for 3 months for all patients."
46112352|NCT00765336|Drug|minocycline extended release|1 mg/kg extended release minocycline HCL, once daily for 84 days.
46112353|NCT00765336|Drug|Placebo|placebo comparator for 1 mg/kg extended release minocycline HCL, once daily for 84 days.
46025356|NCT02764645|Device|CardioGard Cannula|"CardioGard Cannula is a specially designed arterial (aortic) cannula for use in cardiac surgery for the purpose of removal of gaseous and solid embolic material emanating during the CPB procedure.~The CardioGard cannula is a double lumen cannula where the primary lumen provides blood from the heart-lung machine similar to ordinary cannulas and the secondary lumen performs suction of blood and embolic matter away from the aortic arch and back to the cardiopulmonary bypass machine for filtration."
46112354|NCT00818519|Drug|EE20/Drospirenone (YAZ, BAY86-5300)|20µg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
46112355|NCT00818519|Drug|Placebo|Inert tablet
46112356|NCT00827567|Drug|RAD 001|RAD 001-10 mg by mouth once everyday
45469853|NCT03126994|Device|Detecto SOLO|Measurement of Body Weight and BMI
46025357|NCT02764645|Device|22Fr curved Cannula|arterial cannula for use in cardiac surgery
46025358|NCT02770885|Drug|Dulaglutide|Treatment with dulaglutide for 3 weeks.
46025359|NCT02770885|Drug|Placebo|Treatment with Sodium Chloride 0.9% (Placebo) for 3 weeks.
46025360|NCT02770651|Device|Everolimus-Eluting stent|Everolimus-Eluting stent with bioabsorbable polymer
46025361|NCT02770651|Device|Zotarolimus-Eluting stent|Zotarolimus-Eluting stent with permanent polymer
45469854|NCT03410290|Other|Online Questionnaire|The online questionnaire includes questions about factors that impacted a patients diagnosis of vasculitis.
45681778|NCT01682811|Drug|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 16 minutes to achieve a dose of 100 J/cm^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
45838670|NCT04373304|Other|low FODMAP diet|A diet specifically developed for the management of IBS is the low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols (FODMAP) diet. FODMAP is a collective term that includes fructose in excess of glucose, oligosaccharides including fructans/fructo-oligosaccharides (FOS), galacto-oligosaccharides, sugar polyols such as sorbitol and mannitol, and lactose. Controlled studies have established efficacy of the low FODMAP in managing IBS symptoms, but this diet is complex, associated with low calorie intake, and requires individualized explanation and follow-up by an experienced dietician.
46112357|NCT00765102|Drug|Bortezomib|"Bortezomib was administered at a dose of 1.0 mg/m^2 as an intravenous (IV) push over 3 to 5 seconds twice weekly for 2 consecutive weeks (Days 1, 4, 8 and 11) of each 28-day cycle. On days that bortezomib and romidepsin were administered together, bortezomib was administered prior to the romidepsin infusion.~Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles."
46112358|NCT00765102|Drug|Romidepsin|Romidepsin initially was administered at a dose of 10 mg/m^2 as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. Based on the occurrence of Grade 3 thrombocytopenia at this dose level, the dose was reduced by protocol amendment to 8 mg/m^2.
46112359|NCT00809354|Drug|NSAID|IV doses of placebo (to match tanezumab) every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
46025362|NCT02770573|Other|Cavex Bite&White ExSense|a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
46112360|NCT00809354|Biological|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48) and oral placebo for NSAID BID from Weeks 2 through 56
46112361|NCT00809354|Biological|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 56) and oral placebo for NSAID BID from Weeks 2 through 56
46112362|NCT00809354|Biological|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48)
46025363|NCT02770573|Other|Kuraray Teethmate™ Desensitizer|Calcium-Phosphate-based powder and a liquid mainly water-based.
46025364|NCT02770573|Other|Ghimas Dentin Desensitizer|a fluid desensitizing gel with 30% of nano-hydroxyapatite, added to 70:100 thousandths of micron-sized crystals of nano- hydroxyapatite.
46025365|NCT02770729|Drug|Moxifloxacin|Intracameral injection of moxifloxacin at conclusion of cataract surgery
46025366|NCT02770729|Drug|No injection of moxifloxacin|No intracameral injection of moxifloxacin at conclusion of cataract surgery
46025367|NCT02770807|Drug|EDS-EP dose range of ~5-10 mg DSP/infusion|infusion
46025368|NCT02770807|Drug|EDS-EP dose range of ~14-22 mg DSP/infusion|infusion
46112363|NCT00809354|Drug|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
46112364|NCT00809354|Biological|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 48)
46112365|NCT00809354|Drug|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
46025369|NCT02770807|Drug|Placebo|infusion
46025370|NCT02770495|Other|blood sample|
46025371|NCT02770417|Dietary Supplement|beta-alanine|Patients receive beta-alanine
46025372|NCT02770417|Dietary Supplement|placebo|Patients receive placebo
46025373|NCT02770417|Other|control|Healthy controls will be assessed to compare baseline muscle carnosine levels
46112366|NCT00834899|Drug|Eptifibatide|Patients randomized to eptifibatide will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
45469855|NCT03397420|Other|FAM-CARE|Family-centered care, where all HIV-positive family members are seen together as a unit and receive HIV care and treatment services together, for HIV-positive children and their caregivers
45469856|NCT03393988|Drug|Fentanyl infusion|After induction of general anesthesia; Fentanyl infusion (0.5 µg/kg/hr) will be started (which will be afterwards adjusted intraoperatively according to the hemodynamics and Bispectral Index (BIS) reading).
45469857|NCT03393988|Procedure|Ultrasound guided TAP block|After induction of general anesthesia; Patients will receive ultrasound guided subcostal oblique TAP block with 0.25 % bupivacaine 40 ml on each side resulting in a total volume of 80 ml, subcostal TAP block was given twice, at the beginning and at the end of the surgery.
46025374|NCT02770105|Other|Theanine|Oral administration of 200mg of L-theanine powder dissolved in 200ml of distilled water
46025375|NCT02770105|Other|Caffeine|Oral administration of 160mg of anhydrous caffeine powder dissolved in 200ml of distilled water
45838671|NCT04373070|Combination Product|CAir|The CAir desk is a custom-built home disease monitoring device. The device consists of a smartphone (A320 [2017], Samsung Group, Seoul, Korea), home spirometer (Air Next Spirometer, NuvoAir, Stockholm, Sweden), physical activity tracker (Charge 3, Fitbit Inc., San Francisco CA, USA), and an air-quality monitor (Foobot, Airboxlab, Esch sur Alzette, Luxembourg). The components of the CAir desk are CE-certified.
46025376|NCT02770105|Other|Theanine-Caffeine Combination|Oral administration of 200mg of L-theanine and 160mg of anhydrous caffeine powder, dissolved in 200ml of distilled water
46025377|NCT02770105|Other|Placebo|Oral administration of 200ml of distilled water
46025378|NCT02770027|Drug|Intravenous Crystalloid|Crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
46112367|NCT00834899|Drug|Placebo|Patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.
46112368|NCT04100460|Dietary Supplement|7.25 grams of Arabinoxylan leaf fiber extract|Participants are given 7.25 grams of Arabinoxylan daily
45838672|NCT04372836|Procedure|Vasopressin injection|The intervention consists of five steps: rupture the ovarian endometrial cyst and remove the ''chocolate fluid;'' inject diluted vasopressin solution into the interface between endometrioma and ovarian parenchyma; stop injecting until the solution overflow; separate the endometrioma away from the ovarian parenchyma; and coagulate bleeding spots and suture the ovary.
46112369|NCT04100460|Dietary Supplement|14.5 grams of Arabinoxylan leaf fiber extract|Participants are given 14.5 grams of Arabinoxylan daily
46112370|NCT04100460|Dietary Supplement|Control - No Arabinoxylan|Participants are given no Arabinoxylan
46112371|NCT00764946|Drug|Comparator: raltegravir|400 mg tablets taken twice daily. Total treatment period is 48 weeks.
46112372|NCT00764868|Drug|Lisdexamfetamine Dimesylate (LDX)|optimal dose of 30, 50 or 70 mg once daily
45838673|NCT04372290|Other|Product A|Usual brand (UB) filtered, combustible cigarette
45838674|NCT04372290|Other|Product B|Nicorette® White Ice Mint 2 mg nicotine gum
45838675|NCT04372290|Other|Product C|CSD1904-01, a nicotine pouch, 2 mg nicotine
45838676|NCT04372290|Other|Product D|CSD1904-02, a nicotine pouch, 4 mg nicotine
45838677|NCT04372290|Other|Product E|CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)
46025379|NCT02770027|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
46112373|NCT00764790|Biological|Fluarix|One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection. Two different doses are tested.
46112374|NCT00764790|Biological|Fluzone|One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
46112375|NCT05748548|Other|Thoracic kyphosis- Lumbal Lordosis angle measurement|In order to determine the kyphosis, the degrees determined by measuring the spinous processes of the T12 T1, T2 and L1 vertebrae with an inclinometer while the individuals are standing will be collected. In order to determine the degree of lumbar lordosis, the measurement between the spinous processes of the T12L1 and S2S3 vertebrae will be made and the degree of lordosis will be determined by adding the degrees found. While the reference values for thoracic kyphosis are 20-45 degrees, this value is 20-40 degrees for lordosis. These measurements will be made with an inclinometer. Measurements will be repeated 3 times and the results will be recorded by taking the average of the measurements.
46112376|NCT05748548|Other|Back Muscle Endurance Test - Sorenson Test|The endurance of the back muscles will be evaluated with the Biering Sorensen Test (Static Back Endurance Test).
46112377|NCT05748548|Other|Surface EMG activation|We will try to find out which of the exercises such as pressing back the back, waist extension on the balance ball, lumbar extension while in the active prone position, Superman exercises have better lumbar extensor muscle activations.Muscle activations of individuals will be evaluated using superficial EMG. An 8-channel EMG Noraxon MiniDTS system (Noraxon, USA, Inc, Scottsdale, AZ) will be used to measure signals from the muscles.
46025380|NCT02769871|Behavioral|Neuroimages of stroke|Participants in the intervention group will be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes. Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed. Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep. In comparison, patients will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking. Patients will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
46025381|NCT02769871|Behavioral|standardized smoking cessation counseling|Standardized smoking cessation counseling will be provided at their initial interview. They will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction. Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit. Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009). Counseling will be scripted and standardized to ensure similar language with all participants.
46025382|NCT02769637|Drug|PPI treatment|PPI treatment or no PPI treatment
46025383|NCT02769559|Procedure|Reduction mammaplasty|Surgical removal of excess breast tissue
46025384|NCT02696707|Procedure|LVEF 3 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
46112378|NCT05752916|Drug|rhTNK-tPA|Recombinant human TNK tissue-type plasminogen activator. Patients will receive intravenous rhTNK-tPA (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).
46025385|NCT02696707|Procedure|LVEF 4 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
46112379|NCT05752916|Drug|Antiplatelet Agents|Patients will receive single antiplatelet therapy-choice at the discretion of the clinician. Aspirin will be the choice of most physicians, some will choose clopidogrel.
46025386|NCT02769715|Device|Laser-sintered removable partial denture|The master cast was scanned using 3D scanner. In the digital file, the path of insertion was determined using a special software. The survey line was drawn and all undesirable undercuts were eliminated. After that, the entire framework design was built virtually 3 dimensionally using a special software (3Shape Software) according to the specified design in three steps: deciding the contour of the component, building the tissue surface then creating the polished surface. The file was saved in STL file and was transferred to rapid prototyping machine. Framework was produced by selective laser sintering technique using the alloy powder (Sintech Metal).
46112380|NCT03990896|Drug|Talazoparib|"Talazoparib is a study drug that inhibits (stops) the normal activity of certain proteins called poly (ADP-ribose) polymerases also called PARPs. PARPs are proteins (made from genes which are part of DNA) that are found in all normal and cancer cells that are involved in the repair of DNA. PARPs are needed to repair mistakes that can happen in DNA when cells divide. If the mistakes are not repaired, the defective cell will usually die and be replaced. Cells with mistakes in their DNA that do not die can become cancer cells."
46025387|NCT02769715|Other|cast removable partial dentures|The denture was fabricated traditionally using lost-wax casting technique.
46025388|NCT02769793|Drug|Levodopa dispersible|Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
46112381|NCT00756444|Drug|Panitumumab|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
46025389|NCT02769793|Drug|Levodopa|Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
46025390|NCT02769325|Drug|Atropine|IV atropine 0.1%, 10 ml
46025391|NCT02769325|Drug|Placebo|IV saline, 10 ml
46025392|NCT02769325|Drug|Sevoflurane|All patients will receive anaesthesia based on sevoflurane, titrated to a bis of 45-60
46025393|NCT02769325|Drug|sugammadex|Patients will receive sugamadex for neuromuscular reversion, if necessary
46025394|NCT02769325|Drug|Ketorolac|60 mg IV ketorolac will be administered at induction, and patients will receive 30mg/8h on the postoperative period
46112382|NCT00756444|Drug|Cisplatin|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
46025395|NCT02769325|Drug|Morphine PCA|Patients will receive a PCA of morphine with a program of 0 (continuous infusion), 1 mg bolus and 8 minutes lockout
46025396|NCT02769325|Drug|rocuronium|general anaesthesia will use rocuronium 0.6 mg/kg to facilitate intubation
46025397|NCT02769325|Drug|propofol|for anaesthesia induction, patients will receive 2-3 mg/kg iv propofol
46025398|NCT02770261|Drug|DP-R208|DP-R208 + Candesartan 32mg placebo + Rosuvastatin 20mg placebo
46025399|NCT02770261|Drug|Candesartan32mg|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
46112383|NCT00756444|Drug|5FU|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
46112384|NCT04099368|Behavioral|Musical pitch training|Crossover design with one group receiving musical training as rehabilitation, second group receiving visual training first as a control rehabilitation.
46025400|NCT02770261|Drug|Rosuvastatin 20mg|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
46025401|NCT02770261|Drug|DP-R208 Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
46025402|NCT02770261|Drug|Candesartan32mg Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
46025403|NCT02770261|Drug|Rosuvastatin 20mg Placebo|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
46025404|NCT02769403|Device|HeartMath EmWAVE Pro|"The following information will be recorded about HeartMath use:~Self-report: adherence (whether the daily session was completed), coherence score, any comments/notes about the daily session From the application: coherence ratio, coherence score, achievement score, session time, average heart rate"
46112385|NCT04100616|Other|No intervention|There is no intervention for this study
46112386|NCT00769002|Biological|FluShield|Flu vaccine
46025405|NCT02769403|Other|Questionnaires|All participants will complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance.
46025406|NCT02769403|Other|Blood Pressure and Heart Rate|All participants will have blood pressure and heart rate collected at baseline, week 6, and week 12.
45838678|NCT04372212|Device|Hernia sac inversion and Snaring|"Vertical trans umbilical 5-mm incision [Point A] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
45469858|NCT03393988|Drug|Dexmedetomidine|Dexmedetomidine (200 µg in 2 ml diluted in 48 ml of saline) will be started in a dose of 1 μg/kg over 10 min then maintenance dose as continuous infusion between 0.2 and 0.8 μg/ kg/h through infusion pump (which will be adjusted according to the hemodynamics and BIS reading)
45469859|NCT05168410|Other|Alvarado Score|The Alvarado Score assesses patient symptoms to enable optimal triage and management of cases with suspected acute appendicitis.a
46025407|NCT02769403|Other|Sick Days|Sick days during the 12 week study period will be collected
46025408|NCT02769403|Other|Patient Satisfaction|This will include patients who complete the satisfaction survey for the 12 weeks prior to the study and during the 12 week study period. Each patient satisfaction survey is tied to a specific healthcare provider (physicians, Advanced Registered Nurse Practitioner (ARNP) & Physician Assistants [advance practice clinicians], and nurses) and will be linked to the consented research participant.
46025409|NCT04224649|Device|HARA Filler(Hyaluronic acid Filler)|The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
46025410|NCT04224649|Device|Restylane® Lidocaine|The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
46025411|NCT02769169|Drug|Lucentis® (Raibizumab) double-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 1mg of Lucentis® (Raibizumab). Intervention 'double-dose: Ranibizumab 1mg, 3 injection plus prn' has not been included in any Arm/Group Descriptions.
46025412|NCT02769169|Drug|Lucentis® (Raibizumab) regular-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 0.5mg of Lucentis® (Raibizumab). regular-dose: Ranibizumab 0.5mg, 3 injection plus prn
45469860|NCT04447300|Procedure|high power application|Radiofrequency delivery was performed in a point-by point fashion and continuously (an inter-lesion distance of 6 mm) with 50 W and 70 W and the ablation time for each point is limited to 7s and repeated if needed till the Unipolar signal modification turn to complete positive R wave.
45469861|NCT04447300|Procedure|Standard power application|Standard power application
46112387|NCT00769002|Biological|FluShield - same arm|Flu vaccine
46112388|NCT00769002|Biological|FluShield - opposite arm|Flu vaccine
45469862|NCT03410212|Drug|Ketorolac Tromethamine|The 30mg/mL vial of Ketorolac will be injected as second inferior alveolar nerve block and the success of anesthesia will be evaluated using visual analog scale.
45469863|NCT03410212|Behavioral|Sham injection|In the control group, the sham injection will be provided at the same place of the first inferior alveolar nerve block but any injection would be done.
45469864|NCT04447924|Dietary Supplement|Bif195|Daily intake of Bif195 dietary supplement
45469865|NCT04447924|Other|Placebo|Daily intake of Placebo
46025413|NCT02768857|Behavioral|Sensorimotor reeducation programs|
46025414|NCT02769013|Other|Pre-treatment follow up|No active intervention; medical support provided if needed
46025415|NCT02769013|Other|S. haematobium treatment|Praziquantel-treatment for S. haematobium positive volunteers
46025416|NCT02769013|Other|Post treatment follow up|No active intervention; medical support provided if needed.
46025417|NCT02769013|Other|Olfactometer experiment|No active intervention; medical support provided if needed.
46112389|NCT00769002|Procedure|Blood Draws|50 cc of heparinized blood and 10 cc of serum at study entry and at 10-12 week post vaccination
46112390|NCT00769002|Procedure|FDG PET-CT Scan|PET scan
46112391|NCT00769002|Genetic|Cytokine Profiling|Blood draw for Cytokine Profiling Draw at 2,4 and 6 weeks post vaccination
46112392|NCT04100382|Device|Laser and SLA|Patients will be randomized into two groups, control group for SLA implants, and study group will receive the Laser treated implants. Implants will be placed classically in the posterior maxillary region and their stability will be measured by ISQ device at the placement. Measurements will be taken again at 2, 4, 6, 8 , 10 and 12 weeks.
46112393|NCT00753012|Drug|Lisdexamfetamine|Lisdexamfetamine daily until the completion of participation in the clinical trial (up to Week 11 or final study visit). Subjects will start on 30 mg of LDX per day for the first week of treatment. The dose will be increased weekly in 20 mg increments, up to a 70 mg daily (maximum). If significant adverse effects (AE) occur, the daily dose may be reduced by 20 mg. At subsequent visits, a higher dose may be resumed if tolerated. Both cohorts of the study will follow the same treatment plan.
46025418|NCT02768779|Other|Hair analysis|Within the laboratory, experimental factors controlling IR-MALDESI response to key ARVs representing various drug classes will be systematically evaluated using the design of experiments (DOE) statistical approach (41,127) for an unbiased optimization of IRMALDESI response to each of the ARVs and their major metabolites. The goal will be to achieve a lower limit of quantification (LLOQ) below clinically relevant hair strand concentrations.
46025419|NCT02765503|Radiation|External beam radiotherapy|External beam radiotherapy using megavoltage radiotherapy with radical intent.
46112394|NCT00806156|Drug|NKTR-102 q14d|NKTR-102 given on a q14 day schedule
46112395|NCT00806156|Drug|NKTR-102 q21d|NKTR-102 given on a q21 day schedule
45469866|NCT03393910|Diagnostic Test|Experimental Pelvic Exam|"The pelvic exam will be completed in the following order: external, speculum, bimanual exam in the standard group. In the Experimental group the pelvic exam will be done with external xam, bimanual exam then speculum exam."
45469867|NCT03410134|Device|NeoMTA|NeoMTA™ Plus® root and pulp treatment material is a powder/gel system with no resin. The components are an extremely fine powder primarily tricalcium and dicalcium silicate plus a water-based gel.
45469868|NCT02520700|Device|Daylight and Maquet Power 500 LED surgery light|Comparing the use of daylight and a surgical light (Maquet Power 500 LED surgery light) to activate ALA cream for treatment of actinic keratoses
45469869|NCT03397264|Biological|Aflibercept|Intravitreal injection
45469870|NCT03397264|Biological|OPT-302|Intravitreal Injection
45838679|NCT04372134|Device|repetitive transcranial magnetic stimulation therapy|A sham-controlled double-blind randomized study was undertaken. 28 patients with chronic (>1 year) motor incomplete traumatic SCI were randomized into real rTMS group (n=14) or sham rTMS group (n=14). Real rTMS (20 Hz, a total of 1600 stimuli) or sham r TMS were applied in the motor cortex area of lower extremities during 3 weeks (15 sessions). In addition to rTMS sessions, patients underwent a rehabilitation program including exercises for strengthening, walking and balance.
45838680|NCT04371978|Drug|Linagliptin 5 MG|Linagliptin 5 mg PO once daily
46112396|NCT00764478|Drug|Asenapine|asenapine tablet, 5 mg sublingually BID for 21 days
46112397|NCT00764478|Drug|Asenapine|asenapine tablet, 10 mg sublingually BID for 21 days
46112398|NCT00764478|Drug|Placebo|placebo sublingual tablet, administered BID for 21 days
46112399|NCT05755022|Procedure|Maxillary Segment Repositioning|"Le-Fort I osteotomy will be made using the cutting guide.~Mobilization of the maxilla will be done.~The osteotomized segment will be positioned using the positioning guide that will be fabricated utilizing the reverse engineering technology using 3D photogrammetry technique.~While the guide in place, the plates will be fixed into their intended position.~After fixation of the plates, the guide will be removed."
46112400|NCT05755022|Procedure|Maxillary Segment Repositioning|"Le-Fort I osteotomy will be made using the cutting guide.~Mobilization of the maxilla will be done.~The osteotomized segment will be positioned using the positioning guide that will be fabricated utilizing the reverse engineering technology using the commercial scanners.~While the guide in place, the plates will be fixed into their intended position.~After fixation of the plates, the guide will be removed."
45838681|NCT04371822|Drug|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin plus Sunlight exposure
45838682|NCT04371822|Drug|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin and Sunlight exposure
45469871|NCT03397264|Other|Sham intravitreal injection|Sham (mock) intravitreal injection
45469872|NCT03397186|Procedure|Biopsy|Undergo biopsy
45469873|NCT03397186|Other|Laboratory Biomarker Analysis|Correlative studies
45838683|NCT04371822|Drug|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin plus Sunlight exposure
45838684|NCT04371822|Drug|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.
45838685|NCT04371822|Other|placebo|No Intervention
46025420|NCT02768545|Drug|Ezetimibe|Ezetimibe 10 mg per day before and after transplant
46025421|NCT02768623|Other|Pharmacist led Asthma Management|
46025422|NCT02768623|Other|Pharmacist Intervention (when requested by patient)|
46025423|NCT04224259|Procedure|Ultrasound pre-scan|Before cannulation, use ultrasound to mark the position of right internal jugular vein
45469874|NCT03397186|Drug|Trabectedin|Given as standard of care
46112401|NCT03968276|Other|use of digital tablet|"At the end of hospitalization, the patient has an educational tablet at his disposal for 1 month at home. Throughout its use, the patient may contact the investigating physician via a telephone number available within the application if he/she encounters a problem related to the study. At the end of this month, the patient must complete two questionnaires through the application to assess his or her knowledge of his or her condition and treatment, as well as his or her satisfaction with the use of the tablet.~In this research, 1 month after inclusion, the patient will have an additional follow-up visit corresponding to a dedicated consultation in the vascular medicine department. It will allow the patient to review the use of the tablet and his or her satisfaction with the use of such a tool."
46112402|NCT00805766|Drug|TA-650|(1) Screening Period: 5 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at week 0. If patients do not meet the Eligibility Criteria at week 8, they will be administered 5 mg/kg of TA-650 at week 8. (2) Increased Dose Period: 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours every 8 weeks for 32 weeks.
46112403|NCT02608970|Drug|BMS-986177|
46112404|NCT02608970|Other|Placebo|
46112405|NCT00805532|Behavioral|Behavioral Activation treatment|Behavioral Activation (BA) is a present-focused psychotherapy based on behavioral theory and principles of change, that aims to re-engage individuals with meaningful and pleasurable life activities by targeting and problem-solving patterns of avoidance. It is well-established as a treatment for depression and has been modified for the current study to address PTSD-related problems.
45838686|NCT04371510|Other|blood sample|a blood sample is taken on Covid-19 chronic haemodialysis patients with moderate symptoms
46112406|NCT00805532|Other|Treatment as Usual|Usual Care for PTSD (UC)-that is provided in the VA PTSD Specialty clinics. Actual clinical practice varies between sites and between providers within sites, as is typical of the VA health care system. Subjects assigned to Usual Care will be permitted to receive medical intervention (i.e., pharmacotherapy) and any additional psychotherapy deemed appropriate by the provider. They will also be offered a minimum of 6 sessions of individual therapy.
46112407|NCT05752838|Other|No intervention|This is a survey study, and there were no intervention
46112408|NCT04634084|Procedure|Experimental group(Bursa Implantation)|Prior to all rotator cuff repairs, a subacromial bursectomy is performed with an oscillating shaver so that the rotator cuff can be visualized and repaired.In the experimental group, instead of being discarded, this minced bursal tissue will be collected via a sterile filtration device attached to the oscillating shaver. The bursal tissue is then placed into a sterile syringe, and reimplanted back onto the bursal surface of the rotator cuff repair at the completion of the case. The arthroscopic fluid is turned off, and fluid is evacuated from the shoulder prior to reimplantation of the bursa.. Nothing is added to the bursa prior to reimplantation. There are no reagents. The bursa tissue is purely the minced bursa tissue removed from the patient, and never leaves the sterile field.
46112409|NCT04634084|Procedure|Control Group(Standard of Care)|Prior to all rotator cuff repairs, a subacromial bursectomy is performed with an oscillating shaver so that the rotator cuff can be visualized and repaired.The current standard of care procedure is to discard this tissue, and then proceed with the rotator cuff repair
46112410|NCT03947138|Biological|GC3107|BCG Vaccine
46112411|NCT03947138|Biological|Intradermal BCG SSI inj.|BCG Vaccine
46112412|NCT05752760|Other|Lactobacillus Plantarum 299v Freeze Dried Capsule|The intervention is a probiotic lactobacillus that is contained in food products in the US
46112413|NCT05752760|Other|Freeze Dried Potato Starch Capsule|The intervention is potato starch that is freeze dried designed to mimic the lp299v capsule.
46112414|NCT00764322|Drug|tamoxifen citrate|Women found to be IM or PM will undergo increased tamoxifen to 40 mg/day (20 mg bid). Drug is given orally on a daily basis.
46112415|NCT00764322|Genetic|gene expression analysis|Genetic analysis of blood sample.
46112416|NCT00764322|Other|pharmacogenomic studies|Genetic analysis of blood sample.
45838687|NCT04370886|Behavioral|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
46025424|NCT04224259|Procedure|Landmark guidance|The traditional landmark-guided technique for internal jugular vein cannulation, including recognizing the sternocleidomastoid muscle and palpating the carotid artery
46025425|NCT02764723|Drug|Hyperbaric bupivacaine|12.5 mg of hyperbaric bupivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
46025426|NCT02764723|Drug|Isobaric ropivacaine|15 mg of isobaric ropivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
46025427|NCT02764567|Other|Essential Oil|Participants in this arm will be offered one of three essential oils: ginger, lavender or calming
46112417|NCT00764322|Other|questionnaire administration|Questionnaire called the survey of participants. Questionnaires is self administered on paper documents and given pre-study, and at 4 months
45469875|NCT02520466|Dietary Supplement|flavanol-rich drink vs flavanol-free drink|Patients will be randomized to either a flavanol-rich drink or a flavanol-free drink of similar volume, taste and calory and sugar content
45469876|NCT03397030|Other|Home-Based Exercise Program|The intervention will include a combination of both aerobic and body-weight based exercises. The aerobic portion of the intervention will include 5 days of light to moderate intensity walking for 30 mins. Intensity will be set at 40-60% of the individual's heart rate reserve. The body-weight based exercises will be done 3 times a week and will consist of 3 sets of 15 reps of bodyweight squats, incline push-ups, and hip thrusts. If these exercises cannot be performed, lower intensity exercises such as sit-to-stand, wall push up and pelvic tilt can be replaced. Individuals in this group will be given a pocket guide with instructions on how to safely perform the exercises and document their completion.
45469877|NCT03393442|Diagnostic Test|Brain MRI scan|Diagnostic brain MRI scan with the purpose to detect signal changes due to brain deposits of Gd.
45469878|NCT03393364|Drug|Oxycodone|Patients receive oxycodone for pain control after outpatient urologic surgery.
45469879|NCT03393364|Drug|Ketorolac|Patients receive ketorolac for pain control after outpatient urologic surgery
45469880|NCT03405922|Drug|Placebo 40 mL Saline 0.9%|Injection of 40 mL 0.9% saline
45469881|NCT03405922|Drug|40 mL Ropivacain 0.5%|Ropivacaine Hcl 0.5% Injection 40 mL
45469882|NCT04632706|Drug|Ivermectin|Ivermectin: Investigation of the safety, tolerability and the pharmacokinetic profile of the active IMP in an exploratory study
45469883|NCT04632706|Drug|Placebo|Matching Placebo to the Active IMP.
45469884|NCT03396796|Procedure|Vagus nerve-preserving group|The modified vagus nerve-preserving procedure was performed in the following order: (1) left gastroepiploic vein along greater curvature; (2) the posterior surface of stomach, including the posterior gastric veins; (3) the left lateral surface of the distal esophagus; (4) the left inferior phrenic veins; (5) the posterior surface of the distal esophagus;(6) the anterior surface of the distal esophagus; and (7) the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved. the adherent junction between visceral peritoneum and the right crural diaphragm, and divided it into the lesser omental sac. The left gastric artery and vein and the posterior gastric veins were transected en bloc using a linear laparoscopic vascular stapler.
46025428|NCT04664959|Drug|SB16 (Proposed Denosumab Biosimilar)|"Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months.~At Month 12, subjects transited from Prolia® group to SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously."
46112418|NCT00764322|Procedure|quality-of-life assessment|Self administration of a multiquestion questionnaire called the Functional Assessment of Cancer Therapy -Breast (FACT-B). Given pre-study, at 4 months and at 8-10 months.
45469885|NCT03405454|Drug|durvalumab|Durvalumab will be given at 1500mg fixed dose every 4 weeks for 24 months or until the appearance of significant treatment-related toxicity or disease progression
45469886|NCT03405454|Drug|standard chemotherapy|chemotherapy treatment will be administered as per local institutional guidelines
45469887|NCT02520622|Behavioral|Digital photographs loaded onto a mobile device|
45469888|NCT02520622|Behavioral|Skin exam reminders|
45469889|NCT02520622|Behavioral|Social support network|
45469890|NCT05035264|Device|Laryngeal mask insertion|Laryngeal mask insertion in neutral position
45469891|NCT05035264|Device|Laryngeal mask insertion|Laryngeal mask insertion in sniffing position
45469892|NCT05035264|Device|Laryngeal mask insertion|Laryngeal mask insertion in beyond sniffing position
45469893|NCT04609930|Drug|Anti-PD-1 or anti-PD-L1|Immunotherapy treatment via anti programmed death 1 and/or anti-programmed death ligand 1.
45469894|NCT04569604|Diagnostic Test|MRI scans|Contrast-enhanced, magnetic resonance imaging (MRI) based method to detect disturbances in microvascular flow patterns in the human brain
45469895|NCT04569604|Diagnostic Test|Neuro cognitive tests|Standard neuropsychological test battery consists of validated tests to assess cognitive domains including verbal and visual memory, attention, language, visuospatial and executive functioning.
45469896|NCT04569604|Diagnostic Test|Questionnaires on Quality of Life|SF36v2, WHO-5 well-being index, HPQ28, Symptom questionnaire, and a general questionnaire on background information, medication and diet.
45469897|NCT04569604|Diagnostic Test|Blood samples|Markers of calcium homeostasis, inflammatory markers and hematology.
45469898|NCT04569604|Diagnostic Test|24 hr urine samples|24 hr urine content of calcium, phosphate, magnesium, and creatinine.
46025429|NCT04664959|Drug|Prolia® (Denosumab)|Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months.
46112419|NCT00914108|Behavioral|Newborn Individualized Developmental Care|The developmental care model aims to create a relationship-based developmentally supportive care environment for the preterm infant and family. The theory proposes that care implementation that takes into account infants' thresholds of disorganization is most supportive of long term outcome. Specifically, the intervention consisted of weekly neurobehavioral observations and reports of the experimental group infants' behavior with suggestions for parents and staff in ways to support each infant's development. The developmental specialists observed each infant's behavior throughout hospitalization and to 2 weeks corrected age and formulated descriptive neurobehavioral reports with suggestions to structure caregiving procedures adapted to the infant's sleep/wake cycle and in support of the infant's well-regulated behavioral balance. Parents were supported to care for their infant, encouraged to nurse and hold their infant skin-to-skin, and to cradle them during stressful procedures.
46025430|NCT02762695|Other|Case Management|"A model of health care for chronic patients, based on Case Management and guided by a nurse which targets the patient´s risk.~The core elements of this strategy are: a. processes to identify specific population and their risk; b. evidence-based practice guidelines according to risk (higher risk, more interventions and monitoring by a nurse, lower risk, higher emphasis on self-care); c. Practice models based on collaboration between health team members leaded by a nurse; d. self-management education for patients; e. monitoring patients face to face or by telephone to ensure to follow the care program (blood test, medical consultation, for example); e. measurement of process and outcomes."
46112420|NCT03908060|Drug|Methadone|One intravenous administration of methadone (0.2 mg/kg ideal body weight)
46112421|NCT03908060|Drug|Morphine|One intravenous administration of morphine (0.2 mg/kg ideal body weight)
45469899|NCT04446520|Procedure|autogenic drainage|breathing control using expiratory airflow to mobilize secretions from smaller to larger airways. Secretions are cleared independently by adjusting the depth and speed of respiration in a sequence of controlled breathing techniques during exhalation in addition to traditional physiotherapy (deep breathing exercise, diaphragmatic breathing and splinted coughing)
45469900|NCT05168176|Drug|Dotilavir sodium tablet|The subjects randomly received single oral administration of Dotilavir sodium tablet 50mg.
45469901|NCT05168176|Drug|Dotilavir sodium tablet(Tivicay@)|The subjects randomly received single oral administration of Dotilavir sodium tablet 50mg.
45469902|NCT04872088|Behavioral|Strengthened SBCC|Social and Behavioral Change Communication related to prenatal, postnatal, IYCF practices as well as on the care of young children at several specific ages, hygiene, and health will be delivered during monthly home visits by pairs of NASG members.
45469903|NCT04872088|Dietary Supplement|Preventive nutritional supplement|"Monthly delivery by NAGS pairs of a nutritional supplement: SQ-LNS, at a dose of 28 bags of 20g per month per beneficiary child. The nutritional supplement is limited to :~- [6-17]months old children diagnosed as non-wasted (MUAC>=125mm)"
45469904|NCT04872088|Behavioral|Family MUAC|"MUAC screening of children 6 to 59 months of age by family members will be introduced. This will involve distributing Shakir MUAC tapes to all intervention households and training mothers/guardians, or any other family member expressing an interest, in the screening of wasting with the MUAC criterion.~The training will be carried out by the members of the NASGs and during each home visit, they will be able to ensure that the MUAC measurement technique is well mastered by the mother (or another member) and correct the technique if necessary. They will also explain the procedure to be followed if the child is diagnosed as wasted by a family."
45469905|NCT04872088|Behavioral|Active screening by NASGs|"Monthly screening by the NASG members of the children they follow, using the MUAC.~Referral to the health center of [6-17] months old children screened as malnourished (result of MUAC orange or red), and follow-up on referral to confirm child was enrolled."
45838688|NCT04370964|Other|Lausanne Trilogy Play|"Trilogical game of Lausanne (Lausanne Trilogue Play in English abbreviated LTP), which allows an evaluation of the family alliance. This systematic observation provides a snapshot of the family structure and its adaptive abilities. It is based on the assumption that the ability to solve small tasks is representative of the ability to solve more important tasks.The LTP consists of modelling the different possibilities of interaction in a triad according to a four-part scenario: 1) one parent plays with the child, the other parent is simply present; 2) the parents switch roles; 3) both parents play together with the child; and 4) both parents have to talk together."
46112422|NCT00752856|Drug|Kaletra + Isentress|kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day
46112423|NCT00752856|Drug|Atripla|Atripla 1 tab once a day
46112424|NCT03727568|Procedure|Cryobiopsy|"In this study the investigators want to evaluate the diagnostic yield comparing 2 different techniques of performing cryobiopsy. A shorter freezing time and more number of biopsies vs a longer freezing time and less number of biopsies would be compared. Patients are randomised to the groups 1 or 2 immediate before the bronchoscopy.~Group 1: a total of 3 samples with a freezing time of 7 seconds at least for the first biopsy and freezing time for 5 seconds or more for the followings biopsies Group 2: a total of 8 samples with a freezing time of 3 seconds at least for the first biopsy and freezing time for less than 5 seconds for the followings biopsies"
46112425|NCT05745740|Drug|RC48-ADC|RC48-ADC 1.5/2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
46112426|NCT05745740|Drug|Pyrotinib|Pyrotinib 400 mg by oral once a day.
46112427|NCT04096404|Genetic|Genotype- based personalised advice|Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their genotype via email
46112428|NCT04096404|Behavioral|Non genetic personalised advice|Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their reported intake, BMI and activity via email
46112429|NCT02600832|Behavioral|AABM Training|The investigators will use a training version of the Alcohol Approach-Avoidance Task (AAT), in which patients are asked to respond to the format of presented pictures, irrespective of the pictures' content. Pushing a presented picture away will decrease picture size, whereas pulling a picture closer will increase size. There are 2 categories of pictures; 20 different alcoholic and 20 different non-alcoholic beverages. Training effect is achieved by presenting alcohol pictures in push format only and non-alcoholic drinks in pull format only. Two hundred training trials are presented per session.
46112430|NCT02600832|Behavioral|Sham Training|Sham training is identical to AABM training, except pictures are presented randomly in both formats.
46112431|NCT02600676|Device|Transcutaneous Electric Nerve Stimulation (TENS) - active|TENS is a non-invasive method using surface electrodes. Except a few cases with local skin irritation in the area where the electrodes are applied, there is no evidence of side effects of TENS treatment.
46112432|NCT02600676|Device|Transcutaneous Electric Nerve Stimulation (TENS) - placebo|
46112433|NCT00755196|Drug|AN2728|AN2728 Ointment, 5%, twice daily for 12 weeks
46112434|NCT00755196|Drug|Ointment vehicle|Ointment vehicle, twice daily for 12 weeks
46112435|NCT04020510|Drug|onaBoNT-A|Intradetrusor onabotulinumtoxinA in either the standard number of injections or a reduced number of injections
46112436|NCT00805142|Drug|Tapentadol PR|Tapentadol PR tablets will be administered orally twice daily initiated at dose of 25 mg. Dose will be adjusted as per Investigator's discretion. Maximum dose limit is 500 mg per day. Total duration of treatment is 19 days.
45838689|NCT04370964|Other|Lausanne Family Play|Lausanne Family Play (LFP) is a game situation adapted to families with more than one child. Thus, like the LTP, the LFP takes place in four phases:1) one parent plays with siblings while the other is in a third-observer position; 2) the parents reverse their roles;3) children play while parents are talking and 4) family members play together.
45469906|NCT04872088|Behavioral|Intensified followup of children with wasting referred to and enrolled in CMAM treatment|NASG members will conduct biweekly follow-up visits in the households of children with wasting referred to and enrolled in CMAM treatment programs to ensure adherence to the outpatient treatment schedule.
46112437|NCT00761631|Biological|13 valent pneumococcal conjugate vaccine|Intramuscular injection of 0.5mL at visit 1 and visit 2 for group 1 and and visit 1 for groups 2, 3, and 4.
46025431|NCT02762695|Other|Usual Care|Usual Care at Primary Health Care Center
45469907|NCT04872088|Behavioral|Relapse prevention|NASG members will conduct biweekly home visits to monitor the nutritional status of children aged 9 to 17 months who were discharged from CMAM treatment after recovery. NASGs members will provide additional counseling to prevent relapse and screen these children for wasting to detect possible relapse.
45469908|NCT04872088|Behavioral|Cooking demonstrations|NASGs members will also be supported by the IRAM project in the organization of cooking demonstrations with nutrient-rich foods in the community, during which passive screening of children will be carried out.
45469909|NCT03393130|Diagnostic Test|APOE genotyping|APOE genotyping and broad cognitive assessment expressed as a median T-score of the following tests (with cognitive domains assessed in brackets) Trail Making Part A (processing speed), Trail Making Part B (executive function), One Back test (working memory), List Learning Task (Immediate recall, visual learning, delayed recall and recognition discrimination).
45469910|NCT04539730|Drug|Liposomal bupivacaine|266 mg or 20 ml Liposomal Bupivacaine injectable solution
45838690|NCT04370808|Other|Exposure|Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
46025432|NCT00951496|Biological|Bevacizumab|Given IV
46025433|NCT00951496|Drug|Carboplatin|Given IV
46025434|NCT00951496|Drug|Carboplatin|Given IP
46025435|NCT00951496|Drug|Cisplatin|Given IP
46112438|NCT00763698|Device|QuickFlex Micro Model 1258T Left Heart Lead|Implantation of QuickFlex Micro 1258T left heart lead in combination with a CRT-D system.
46025436|NCT00951496|Other|Laboratory Biomarker Analysis|Correlative studies
46025437|NCT00951496|Drug|Paclitaxel|Given IV
45838691|NCT04370262|Drug|SOC + Intravenous Famotidine|Standard of Care treatment plus IV famotidine
45838692|NCT04370262|Drug|SOC + Placebo|Standard of Care treatment plus IV placebo
45838693|NCT04370340|Device|BabySlide|Application of BabySlide during vacuum-assisted births for perineal protection
45838694|NCT04369872|Procedure|Microwave ablation|Microwave ablation of lung lesion using Solero Microwave Tissue Ablation system.
46025438|NCT00951496|Drug|Paclitaxel|Given IP
46025439|NCT00951496|Other|Quality-of-Life Assessment|Ancillary studies
46025440|NCT02764177|Dietary Supplement|Protein drink|The protein drink was administered during this trial
46025441|NCT02764177|Dietary Supplement|Carbohydrate drink|The carbohydrate drink was administered in this trial
46025442|NCT02696629|Procedure|upper airway surgery|Uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery
46025443|NCT02696629|Device|Continues positive airway pressure|Participants who are treated with continues positive airway pressure during sleep.
46025444|NCT02696629|Behavioral|education and follow up|Patients education and follow up:The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
46025445|NCT02696551|Other|Medical education|
45469911|NCT04539730|Procedure|Drug: SoC Ropivacaine|0.5% (5mg/mL) 20 mL single dose SOC anesthetic Ropivacaine.
46025446|NCT02764411|Drug|Brimonidine 0.33% gel|Topical application of Brimonidine 0.33% gel on Capillary Malformation (CM) lesion once daily for 12 weeks
46025447|NCT02764099|Behavioral|Life Skills Training|The Life Skills Training (LST) program is a comprehensive competence enhancement prevention approach that teaches resistance skills while also emphasizing generic personal and social skills training. The LST program content and skills training is delivered to youth participants by trained providers through instruction, demonstration, behavioral rehearsal with feedback and social reinforcement, extended practice through homework assignments, and didactic teaching methods.
46025448|NCT02768077|Drug|Melatonin(Circadin®)|
46025449|NCT02768077|Drug|Placebo|
45469912|NCT05168098|Other|board game comparison|The group used 24 board games popular among the elderly population in Taiwan, including Noah's Ark, Splash Attack, Pengoloo, Speedy, and Zingo. Because some games were too complicated for the participants to play, some game rules were modified into more simple and directive thinking.
46025450|NCT01193244|Drug|Orteronel|Orteronel will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of <50 ng/dL.
46025451|NCT01193244|Drug|Placebo|Placebo will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of <50 ng/dL.
46025452|NCT01193244|Drug|Prednisone|Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of <50 ng/dL.
46025453|NCT02768467|Procedure|Tissue Matrix Graft Placement|Subject will receive a covering for the wound post buccal mucosa removal.
46025454|NCT02768467|Procedure|No Stitches|Subject will not receive stitches post buccal mucosa removal.
45469913|NCT05168098|Other|olfactory stimulation intervention|The group used 15 flavors of essential oil (i.e., lavender, rosemary, sweet orange, lemongrass, mint, and hinoki) and essence (i.e., lemon, coffee, peach, magnolia, chocolate, jasmine, strawberry, pomelo, and passion fruit), purposefully selecting two to three flavors for each session. Because some flavors are familiar to the participants and some are not, the familiar flavors were initially used to trigger memory. The unfamiliar flavors (i.e., lavender, rosemary, sweet orange, and lemon) were used in later sessions because those were recognized as having potential effects on cognitive function
45469914|NCT03396484|Drug|Methyldopa|Tablet for oral dosing
45469915|NCT03396484|Drug|Placebo|Tablet for oral dosing
46025455|NCT04224337|Drug|Durvalumab + doxorubicin + ifosfamide|Durvalumab: 1500mg via IV infusion on day 1 Q3W for 4 cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W for up to a maximum 12 months Doxorubicin 20mg/m2 via IV infusion on day 1 to day 3 Q3W (up to 4 cycles) Ifosfamide: 1.5g/m2 (with mesna) via IV infusion on day 2 to day 4 Q3W (up to 4cycles)
46025456|NCT02768311|Procedure|neolix rotary system (continuous rotation system)|Procedure: neolix rotary system
46025457|NCT02768311|Procedure|waveone rotary system (reciprocating system)|Procedure: waveone rotary system
46025458|NCT02768311|Procedure|hand files k-files|Procedure: hand files k-files
46025459|NCT02768233|Behavioral|Educational programme|The 6-session educational programme is based on theory of motivational interviewing, and patients can choose between individualized education or education in groups. The standard treatment consists of withdrawal and consultations by neurologist.
45469916|NCT03245619|Drug|GSK3335065|GSK3335065 is being developed as a treatment for acute pancreatitis with the intent of reducing 3-hydroxykynurenine (3HK) levels to the normal range (or lower) and maintaining them at this level. GSK3335065 is a solution and will be administered as intravenous injection and infusion with dose strength of 5 milligram (mg)/mL that may be diluted in 0.9% weight by volume (w/v) sodium chloride.
45469917|NCT03245619|Drug|Placebo|Placebo solution to match GSK3335065 will be given as intravenous injection and infusion.
45469918|NCT05167942|Device|deep transcranial magnetic stimulation with H1 coil|Sham deep transcranial magnetic stimulation on PFC .Duration:40 days.
45469919|NCT05167942|Device|High frequency deep transcranial magnetic stimulation with H1 coil|high frequency(20Hz) deep transcranial magnetic stimulation on PFC .Duration:40 days.
45469920|NCT05167942|Device|iTBS deep transcranial magnetic stimulation with H1 coil|iTBS deep transcranial magnetic stimulation on PFC .Duration:40 days.
45469921|NCT04483882|Device|Tactile Labels for Drug identity and dose frequency|The tactile labeling proposed in this protocol is rigid labeling. A ring-clip has an inner diameter of 12.5cm, an outer diameter of 16 cm, and a height of 1.5 cm. The ring is cut at 2 cm to form a semi-circle allowing it to be clipped onto the bottleneck. The ring clip fits most if not all prescription eye drop bottles. The individual protrusions with shapes at the end can be cut off by the pharmacist to match the frequency of administration prescribed.
45469922|NCT03396406|Device|Pulsed radiofrequency (PRF)|received PRF at 42°C for 8 minutes followed by CRF at 60°C for 270s
45469923|NCT03396406|Device|thermocoagulation|received sole CRF at 70°C for 270 s
45469924|NCT05000463|Drug|Ozone|The participants will lay flat and the area of injection will be prepared with antiseptic. Maintenance of ultrasonography probe sterility was also guaranteed using a sterile barrier. Under sonographic guidance, superficial peroneal nerve, deep peroneal, sural , asphenous, and tibila nerves will be injected An ozone/oxygen mixture ( 25μg/ml) will be injected in each nerev
45469925|NCT05000463|Drug|Convtrol group|The medical treatment included optimal glycemic control, vitamin B complex, a lipoic acid, selective serotonin reuptake inhibitors, and pregabalin.
45469926|NCT04472650|Drug|Sitravatinib|Administered orally as a free base capsule
46112439|NCT04620668|Device|Wysa|Wysa is an AI-based mental health chatbot. It uses evidence-based techniques to help users build mental resilience skills and improve their mental health.
46025460|NCT02767999|Drug|Fluoxetine|20 mg of fluoxetine capsule per day from D0 to D90
46112440|NCT03684980|Drug|Methotrexate|(Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m^2
46112441|NCT03684980|Drug|Rituximab|Patients will be treated with rituximab 500 mg/m^2.
46112442|NCT03684980|Drug|leucovorin|Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
46112443|NCT03684980|Drug|Glucarpidase|Glucarpidase 2000 units
46112444|NCT04098627|Behavioral|Laughter Therapy|Once weekly 30-minute long group laughter therapy session for 8 weeks
46112445|NCT00763386|Device|NexGen LPS-Flex Fixed Bearing Knee|NexGen LPS-Flex Fixed Bearing femoral component
45469927|NCT04472650|Drug|Sitravatinib|Administered orally as a malate salt capsule
45469928|NCT02606461|Drug|Selinexor|Selinexor 60mg
45469929|NCT02606461|Drug|Placebo|
45469930|NCT03321396|Device|sodium alginate mixed with calcium lactate|"The product is used in Endoscopic submucosal dissection which is accomplished by steps listed as follows: lesion marking, submucosal injection, mucosal incision, submucosal dissection, then en-bloc resection. It's a new submucosal injection regimen, sodium alginate mixed with calcium lactate, which turned to calcium-alginate gel, we called it as Gut Guarding Gel."
46112446|NCT00763386|Device|NexGen Legacy Posterior Stabilized Knee|NexGen Legacy Posterior Stabilized femoral component
46112447|NCT03901274|Behavioral|Clinical Services Support|The CSS framework packages together evidence-based practices of family engagement, modular evidence-based practice, quality assurance, and implementation support. Depending on their time of enrollment, participants can be involved in this condition for one to three years. They will be asked to complete assessments during their therapy sessions periodically throughout the trial.
46112448|NCT03901274|Behavioral|Patient Centered Enhancements|The two PCEs are: enhancing mental health literacy and stigma reduction, and improving family-school-mental health partnerships. Depending on their time of enrollment, participants can be involved in this condition for one to three years. They will be asked to complete assessments during their therapy sessions periodically throughout the trial.
45681779|NCT01682811|Drug|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 32 minutes to achieve a dose of 200 J/cm^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
46025461|NCT02767999|Drug|Placebo|cellulose placebo per day from D0 to D90
45469931|NCT03244917|Behavioral|TRAIN-AD|The study intervention is a multi-component training and education program targeting direct care providers and healthcare proxies for advanced dementia NH residents, intended to improve the management of urinary and lower respiratory tract infections in advanced dementia patients. There are two components to this practice intervention: 1. Provider Training, and 2. Proxy Education. Intervention components aimed at the provider include: Professionally led infection management training seminars, online infection management course, and infection management guidance algorithms. Additionally participating prescribing providers will be sent bimonthly infection management feedback reports. Proxy Education is completed by providing an infection management in Advanced Dementia booklet to proxies of patients with AD upon resident enrollment in study.
45469932|NCT04809376|Drug|Pentosan Polysulfate Sodium twice weekly|Subcutaneous Injection, 1.5mg/kg Ideal body Weight (IBW)
45838695|NCT04369716|Other|Whole oranges|Navel oranges (227 g total)
46112449|NCT00761319|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
45838696|NCT04369716|Other|Whole Apples|Red Delicious apple with skin (230 g)
46025462|NCT02767999|Radiation|fMRI|functional resting state MRI
46025463|NCT02768155|Other|Amniotic Fluid 4.0ml dose|Injection of Amniotic Fluid
46025464|NCT02768155|Other|Amniotic Fluid 2.0ml dose|Injection of Amniotic Fluid
46025465|NCT02768155|Other|Placebo Control|Normal Saline
46112450|NCT00761319|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanoprost.
46112451|NCT00762996|Device|etafilcon A|contact lens
46112452|NCT00762996|Device|omafilcon A|contact lens
46112453|NCT04599296|Device|Hip brace|Hip brace
46112454|NCT02601534|Behavioral|Zero-time Exercise|a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months (not a part of cRCT, for the collection of feedback only) as well as biweekly/monthly mobile messages to improve physical activity habit.
45469933|NCT04809376|Drug|Placebo (Sodium Chloride Injection, 0.9%)|Placebo to match PPS
46112455|NCT02601534|Behavioral|Healthy Eating|a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months (not a part of cRCT, for the collection of feedback only) as well as biweekly/monthly mobile messages to improve dietary habit.
46112456|NCT00762606|Procedure|Phacoemulsification cataract extraction surgery|Surgical removal of cataract using phacoemulsification followed by implantation of an AcrySof Intraocular Lens (Model SN60WF)
46112457|NCT00762606|Procedure|Small incision cataract surgery|Surgical removal of cataract using small incision cataract surgery (SICS) followed by implantation of a Polymethyl methacrylate(PMMA) Intraocular Lens (Model MZ60BD).
46112458|NCT00818441|Drug|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) at 45 mg daily or 30 mg daily by continuous oral dosing, to be escalated in tolerating patients to 45mg after at least 8 weeks of therapy (30 patients in Cohort A started at the lower dose).
46112459|NCT00818441|Drug|Dacomitinib (PF-00299804)|In Cohort B, patients getting Dacomitinib for first line therapy started at 30 mg, but those who had prior anti-cancer therapy started at 45 mg.
46112460|NCT00704639|Drug|Cetuximab|Patients will receive weekly intravenous cetuximab (initial dose 400mg/m2 in the week prior to commencing radiotherapy, then weekly 250mg/m2)for the duration of the radiotherapy
45469934|NCT04809376|Drug|Pentosan Polysulfate Sodium Fixed Dose|Subcutaneous Injection, 100/150/180 mg if <65kg/ ≥ 65 kg and ≤ 90kg/ >90 kg IBW
45469935|NCT04809376|Drug|Pentosan Polysulfate Sodium once weekly|Subcutaneous Injection, 2.0mg/kg Ideal body Weight (IBW)
46025466|NCT04696471|Device|Continuous Theta Burst Stimulation (cTBS)|cTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions
46025467|NCT04696471|Device|Sham Continuous Theta Burst Stimulation (Sham cTBS)|Sham cTBS goes through the motions of applying cTBS to the brain but administers very low current so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
46025468|NCT04223167|Dietary Supplement|Red Bull Energy Drink|473 ml Reb Bull Energy Drink
46025469|NCT04223167|Dietary Supplement|Water|473 ml Water
46025470|NCT02763943|Behavioral|Pharmacist-led, technology enabled education intervention|Prospective, non-randomized, pilot study assessing the feasibility and potential efficacy of a 6-month, pharmacist-led, technology enabled education intervention on improving medication safety and cardiovascular risk factor control in adult solitary kidney transplant recipients with a secondary aim of assessing if the impact of the intervention varies by race.
46025471|NCT02764021|Dietary Supplement|Carbohydrate-Restricted Diet|Macronutritional composition: Carbohydrate 30 E%, Protein 30 E%, Fat 40 E%
46025472|NCT02764021|Dietary Supplement|Standard Antidiabetic Diet|Macronutritional composition: Carbohydrate 50 E%, Protein 13 E%, Fat 17 E%
46112461|NCT00704639|Drug|Carboplatin|Weekly intravenous carboplatin (AUC 2) for the duration of the RT
45469936|NCT03321006|Device|Phonak Audeo B-R 90 hearing aid device (Active)|Hearing aids will be the latest Audeo B-R 90 devices manufactured by Phonak. Full amplification hearing aids will have their gain determined by audiometric profile as per standard clinical practice
45469937|NCT03321006|Drug|Duloxetine or escitalopram|We opted to allow two potential medication choices so that study participation could be offered to individuals who had previously taken one medication and either not responded or not tolerated it. After 4 weeks if subjects do not meet remission criteria (HRSD≤10), the dose of study medication will be increased to escitalopram 20mg or duloxetine 60mg for the remaining 8 weeks of the study.
45469938|NCT03321006|Device|Audeo B-R 90 hearing aid device (Sham)|Hearing aids will be the latest Audeo B-R 90 devices manufactured by Phonak. Low amplification hearing aids will be programmed to a hearing threshold of 10dB across all frequencies
46112462|NCT00704639|Radiation|Radiotherapy|"The radiotherapy schedule will be the infield boost (IFB) regimen, that is 66 Gy in 35 fractions over 5 weeks: daily for 3 weeks, then twice daily for 2 weeks (or 70 Gy in 35 fractions over 7 weeks for a specific subgroup of patients where IFB is not recommended)."
45469939|NCT04507347|Drug|TRC041266|TRC041266 sachet 1500 mg strengths
45469940|NCT04507347|Drug|Placebo|TRC041266 sachet 1500 mg matching placebo
45469941|NCT04760626|Drug|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 52 weeks.
45469942|NCT04760626|Drug|Insulin Glargine 100U/mL|Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
45469943|NCT04760626|Drug|Insulin Degludec|Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
46112463|NCT05305235|Device|RISE Guide|Smartphone-based intervention that uses Cognitive Bias Modification to change perceptions of stress.
46025473|NCT02762617|Drug|Tenofovir disoproxil fumarate intravaginal ring|The TDF IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of 86% (w/w) TDF and 14% (w/w) sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
46112464|NCT05305235|Device|Relaxation Control|Guides users through relaxation techniques.
46112465|NCT00826943|Drug|Cetirizine|Cetirizine 10 mg tab daily x 7 days
46112466|NCT00826943|Drug|Levocetirizine|5 mg tab daily x 7 days
45469944|NCT04760626|Drug|Insulin Glargine 300U/mL|Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
45469945|NCT03572244|Device|Laser-Lok|A microgrooved abutment will be placed
45469946|NCT03572244|Device|Machined|A machined transmucosal healing abutment will be placed
45469947|NCT04238247|Behavioral|Tiny Cargo, Big Deal/Abróchame Bien, Cuídame Bien (TCBD/ABCB) Basic Intervention|"A bilingual emergency department (ED)-based precision prevention intervention grounded in Self-Determination Theory. The Basic TCBD/ABCB intervention integrates one personalized counseling session based on principles of motivational interviewing (MI) and eHealth components including a tailored mobile-friendly educational website and short message service (SMS) text message communications with the goal of improving child passenger safety.~Participants receive monthly text message requests to submit photographs depicting the child as they usually travel. Feedback is provided via text message to correct any observed errors or misuse. Tailored informational and motivational text messages are sent twice each month."
45469948|NCT04238247|Behavioral|Tiny Cargo, Big Deal/Abróchame Bien, Cuídame Bien (TCBD/ABCB) Enhanced Intervention|The Enhanced TBDC/ABCB Intervention includes a second motivational interviewing session. Basic Intervention text messages continue with an additional 1-2 tailored text messages per month.
45469949|NCT01974609|Drug|Narcotic|Hydrocodone 5mg + acetaminophen 325 mg
45469950|NCT01974609|Drug|non-narcotic|ibuprofen 600mg + acetaminophen 325 mg
45469951|NCT04741386|Biological|SARS-CoV-2 vaccination|All participants will receive two vaccinations against COVID-19 according to the manufacturer's instructions.
46025474|NCT02762617|Drug|Placebo intravaginal ring (IVR)|The Placebo IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
45469952|NCT04706208|Behavioral|Cognitive Multisensory Therapy|Cognitive multisensory rehabilitation (CMR) is a type of physical therapy that incorporates conscious perception of body positions and movements during (multi)sensory discrimination exercises. The treating therapists will give 40 minutes of discrimination exercises embedded in functional movements followed by 5 minutes of applying the learned strategies during activities of daily living. CMR uses several types of discrimination exercises: Participants discriminated shapes, length, weight, distance, resistance, textures or compare kinesthetic information with visual information for integration of multisensory information. Solving the discrimination task is combined with reflection and a learning process, prompted by the therapist on how the limb (was) moved or was positioned.
45469953|NCT04706208|Other|Usual Care|Standard of care treatment for neuropathic pain after spinal cord injury
45469954|NCT04706208|Behavioral|Clinical Assessment|Clinical assessments are detailed below. Screening will include demographic and general health data; mini mental state evaluation (MMSE)-short version; Edinburgh handedness inventory; and the kinesthetic and visual imagery questionnaire (KVIQ).
45469955|NCT04706208|Behavioral|Magnetic Resonance Imaging (MRI)|The MRI scanning will include structural scans, resting-state functional MRI, and 4 task-based functional MRI.
46025475|NCT02696473|Dietary Supplement|Carrot|
46025476|NCT02696395|Device|DePuy Tri-Lock® femoral stem + Deltamotion® acetabular component|
46025477|NCT02696395|Device|DePuy Corail® femoral stem + Deltamotion® acetabular component|
46112467|NCT00826943|Drug|Placebo|Placebo tablet daily x 7 days
46112468|NCT00707369|Drug|Amoxicillin and Metronidazole|tablets: Amoxicillin 3H2O 574 mg and 400 mg metronidazole three times daily for 7 days
46112469|NCT00707369|Drug|Placebo|Placebo tablets (cellulose powder, lactose monohydrate, magnesium stearate, microcrystalline cellulose): three times daily for 7 days
46112470|NCT02611661|Device|PET/MRI|
46112471|NCT02611661|Radiation|Percutaneous ablation|
46112472|NCT02611661|Radiation|Stereotactic body radiotherapy|
46112473|NCT02611739|Device|Medi-Port|Treatment
46112474|NCT02611739|Device|Medi-Port|Control
46112475|NCT00834041|Drug|Aliskiren 3.125 mini-tablets|Oral mini-tablets (3.125 mg) of aliskiren once each morning
46112476|NCT00760929|Drug|Placebo|iv 9mg/kg weekly
46112477|NCT00760929|Drug|Placebo|iv 16mg/kg every 3 weeks
46112478|NCT00760929|Drug|RG1507|iv 9mg/kg weekly
46112479|NCT00760929|Drug|RG1507|iv 16mg/kg every 3 weeks
46112480|NCT00760929|Drug|erlotinib [Tarceva]|150mg oral daily
46112481|NCT00818207|Other|Full Smoking Cessation Treatment Coverage (100%)|This is a pragmatic study in which the intervention is a health policy (SCT reimbursement). Champix (varenicline), Zyban (bupropion) and NRTs (nicotine replacement therapies; patches, gums) are SCT eligible for reimbursement. Prescriptions will be issued as per the most recent version of the Product Monograph of the prescribed SCT or equivalent.
46025478|NCT01192152|Drug|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
46112482|NCT00818207|Other|No Smoking Cessation Treatment Coverage (0%)|None of the subjects recruited in the study have access to SCT reimbursement in real-life. As such, subjects randomized to the control group represent lack of SCT coverage in real-life and are considered to receive standard of care for smoking cessation.
46112483|NCT00704795|Other|Oral glucose tolerance test|50 g of waterfree glucose dissolved in 300 ml water is ingested over 5 minutes following a 10-h fast including liquids and medication (if any).
46112484|NCT00704795|Other|Isoglycemic iv glucose infusion|The plasma glucose curve obtained during a 50 g-OGTT (performed on a separate day) is copied using an adjustable iv glucose infusion (20% w/v) performed following a 10-h fast including liquids and medication (if any). The iv catheter is inserted into a peripheral vein in the hand/forearm.
46112485|NCT04039295|Procedure|ultrasound guided caudal epidural block|dynamic ultrasound imaging of the spread of local anesthetics
46112486|NCT00707525|Procedure|Preimplantation Genetic Diagnosis|Preimplantation Genetic Diagnosis (PGD) is performed on the embryos resulting from these natural and stimulated cycles.
46112487|NCT00704951|Drug|Posaconazole or alternative fungal treatment|"Dosage of Posaconazole:~Prophylactic dosing: 200mg tid (600mg/day) Treatment dosing: 400mg bid (800mg/day)"
46112488|NCT00760617|Biological|GSK Bio's influenza vaccine GSK2186877A|Intramuscular (IM) administration, 1 dose
46112489|NCT00760617|Biological|Fluarix|Intramuscular (IM) administration, 1 dose
46112490|NCT04098783|Other|Home visit, health education|
46112491|NCT04098549|Other|Rapid lowering of plasma glucose|Rapid lowering of plasma glucose using hypoglycemic clamp technique
46112492|NCT04098549|Other|Slow lowering of plasma glucose|Slow lowering of plasma glucose using hypoglycemic clamp technique
46112493|NCT04098159|Device|duplex ultrasound|regular duplex follow up every three months with subsequent intervention either diagnostic venography , angioplasty or surgery according to the type of the lesion
46112494|NCT00760383|Dietary Supplement|Essential amino acids|Subjects will ingest 20 grams of essential amino acids (EAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the EAA supplement 30 minutes after the end of each PT rehabilitation session.
46112495|NCT00760383|Dietary Supplement|Alanine|Subjects will ingest 20 grams of non-essential amino acid (NEAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the NEAA supplement 30 minutes after the end of each PT rehabilitation session.
46112496|NCT04098471|Procedure|transanal local excision following radiotherapy|transanal local excision following radiotherapy
46025479|NCT01192152|Drug|Glucophage XR|Tablets, Oral, 500 mg, once daily, Single dose
46025480|NCT01192152|Drug|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 1000 mg), once daily, 4 days
45469956|NCT04706208|Other|OPTIONAL: blood draw|This part is OPTIONAL: 38ml of blood will be taken one time (for able body adults) or at 3 time points (for adults with spinal cord injury and neuropathic pain.
45469957|NCT04492293|Drug|ICP-192|ICP-192 is a white, round, uncoated table
45469958|NCT05167708|Procedure|Micro-osteoperforation|flapless small punctures in the bone at direction of tooth movement to accelerate the movement.
45469959|NCT03396328|Behavioral|conventional low salt education|conventional low salt education
45681780|NCT03585088|Device|surgical pleth index|All patients applied surgical pleth index after recovery of spontaneous breathing at the time of peritoneum and skin closure under Bispectral index score <=60.
45838697|NCT04369716|Other|Orange juice + orange pomace|Orange Juice (149 g) + orange pomace (100g) [40% pomace by weight]
45838698|NCT04369716|Other|Apple juice + apple pomace|Apple Juice (129 g) + apple pomace (106 g) [45% pomace by weight]
45838699|NCT04369716|Other|Orange juice|Orange Juice (250 g)
46025481|NCT02763553|Dietary Supplement|Ketogenic Feed|A low-carbohydrate, high-fat feed designed to induce a ketotic state.
46025482|NCT02763553|Dietary Supplement|Standard Feed|Standard enteral feed used in critical care patients requiring nutrition via a nasogastric tube
46025483|NCT04572451|Drug|nivolumab|"Nivolumab (BMS-936558-01), 480 mg intravenous (every 4 weeks)~Treatment must be within 7 days of the last dose of radiation."
46112497|NCT00759915|Drug|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
46112498|NCT00759915|Drug|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
45838700|NCT04369716|Other|Apple juice|Apple Juice (235 g)
45838701|NCT04369404|Behavioral|Pelvic organ prolapse decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of pelvic organ prolapse
45838702|NCT04369404|Behavioral|Stress urinary incontinence decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of stress urinary incontinence.
46112499|NCT00759759|Drug|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
45469960|NCT03396328|Behavioral|Intensive low salt dietary education by smartphone application|Participants are provided with information on food and recipe, which allows them to record daily meals in their applications. Through the mobile application, the participants receive information on daily salt intake. Based on this information, the clinical nutritionist coach sets a goal for low salt diet and provides feedback to the patients through the mobile application. The clinical nutritionist coach checks the activity of the user more than twice a week and sends in-app messages to maintain compliance.
46112500|NCT00759759|Drug|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
45469961|NCT01868373|Biological|Microbiota Transplantation (FMT)|Active therapy
45469962|NCT02593123|Drug|mycophenolate mofetil|Given PO, by mouth, orally or IV, intravenous medication administration.
46112501|NCT00759681|Device|ArterX Surgical Sealant|Apply at the suture site.
45469963|NCT02593123|Biological|Sargramostim|"GM-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-15 cohort will receive sargramostim (GM-CSF) 250 mcg/m2/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.~Patients receiving GM-CSF will also receive inhaled corticosteroids, fluticasone (Flovent) 2 puffs twice daily, starting on post-transplant day 4 and stopping after cessation of GM-CSF, to diminish the risk of pneumonitis.~Note: At investigator discretion, patients in the MMF-15 cohort who have preexisting pulmonary risk factors, will be permitted to receive G-CSF."
45469964|NCT02593123|Biological|Filgrastim|G-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-30 cohort will receive filgrastim (G-CSF) 5 mcg/kg/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.
45469965|NCT03396250|Drug|Naproxen sodium and diphenhydramine hydrochloride soft capsules|Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)
45469966|NCT03396250|Drug|Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)|Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
46112502|NCT00759681|Device|Gelfoam and Thrombin|Apply at the suture site.
46112503|NCT00826241|Drug|Temozolomide|Starting dose 125 mg/m^2 daily by mouth on days 1-7 & 15-21 of a 28 day cycle.
45469967|NCT04697290|Biological|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 2E6、6E6、1E7、3E7 cells/kg.
45469968|NCT03302559|Other|Retinol Complex 0.5|Retinol Complex 0.5 topically in the evening.
45469969|NCT03302559|Other|Facial cleanser|Facial cleanser in the morning and in the evening.
45469970|NCT03302559|Other|Moisturizing lotion|Fragrance free moisturizing lotion in the morning and in the evening.
45469971|NCT03302559|Other|Sunscreen|Sunscreen broad spectrum sun protection factor (SPF) 35 topically in the morning and as needed.
46025484|NCT04572451|Drug|BMS-986253|"BMS-986253 (Anti-IL-8), 2,400 mg intravenous (every 2 weeks)~Treatment must be within 7 days of the last dose of radiation."
46025485|NCT04572451|Radiation|Stereotactic Body Radiotherapy (SBRT)|"Stereotactic Body Radiotherapy (SBRT) (varying doses)~SBRT: Initial Dose fractionation of 3 or 5 fractions of radiation as determined by the location of the metastases to be irradiated, to at least 1 but no more than 4 metastatic lesions. There will be a minimum of 40 hours between treatments for an individual metastasis.~SBRT must be completed within a 14-day window, separate from the screening phase. Treatment with nivolumab and BMS-986253 must be within 7 days of the last dose of radiation."
46112504|NCT00826241|Drug|Lapatinib|Starting dose 1250 mg daily by mouth.
46112505|NCT00707681|Drug|MS-20|4 ml/vial
46112506|NCT00707681|Drug|Placebo|4ml/vial
46112507|NCT04097847|Drug|Pentoxifylline-Tocopherol-Clodronate|the aim of this retrospective study is to analyze from patient records the impact of the PENTOCLO protocol on maxillofacial osteoradionecrosis at Brest Hospital University, France.
46112508|NCT05467371|Behavioral|Parenting Action Plan|The parenting action plan a booklet with information that focuses on sleep hygiene, soothing a crying baby, what to do when the baby's crying is overwhelming, identifying safe caregivers in case of emergency, and issues surrounding feeding and bonding with the baby.
46112509|NCT05467371|Behavioral|Safe Kids Home Safety Checklist|Safe Kids created a home safety checklist to help keep kids safe, room by room.
46112510|NCT00758589|Drug|AZD1981|Oral tablet, 50 mg twice daily
46112511|NCT00758589|Drug|AZD1981|Oral tablet, 400 mg twice daily
46112512|NCT00758589|Drug|AZD1981|Oral tablet, 1000 mg twice daily
46112513|NCT00758589|Drug|Placebo|
46112514|NCT00833417|Drug|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
46112515|NCT00762372|Drug|desflurane|volatile liquid for inhalation
46112516|NCT00762372|Drug|desflurane/nitrous oxide|volatile liquid for inhalation with gas for inhalation
46112517|NCT00762372|Drug|sevoflurane/nitrous oxide|volatile liquid for inhalation and gas for inhalation
46112518|NCT00833261|Drug|cetuximab|cetuximab
46112519|NCT00833261|Drug|cisplatin|cisplatin
46112520|NCT00833261|Radiation|intensity-modulated radiation therapy|IMRT
46112521|NCT00833261|Drug|Nab-Paclitaxel|Nab-Paclitaxel
45469972|NCT03302559|Device|Skin Imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight Dx Optical Coherence Tomography (OCT) and VivaScope 1500
45469973|NCT05061745|Device|Guided Meditation VR for Wellness|"Selected Modules of Commercially Available Guided Meditation VR presented on Valve Index Headset"
45469974|NCT05061745|Device|Accelerated Transcranial Magnetic Stimulation: Treatment A|Either MagVenture Transcranial Magnetic Stimulation (Treatment Coil Cool B70 AP) or The NeuroStar® System will be used.
46112522|NCT00833105|Device|AMES treatment|The AMES device rotates the fingers-thumb or the wrist in the flexion-extension directions over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that are lengthened by the thumb-finger or hand movement. A treatment consists of 20 minutes of fingers-thumb movement, followed by 10 minutes of wrist movement. The subject's task is to assist the motion of the device.
46112523|NCT02600598|Drug|LEO 43204 Gel, 0.037%|
46112524|NCT02600598|Drug|LEO 43204 Gel, 0.037%|
46112525|NCT00833027|Drug|sitagliptin phosphate|Sitagliptin 100 mg/day - tablet for 24 weeks
46112526|NCT05758493|Diagnostic Test|124I-Evuzamitide|Amyloid reactive protein used as imaging agent to detect systemic amyloidosis
45469975|NCT05061745|Device|Accelerated Transcranial Magnetic Stimulation: Treatment B|Either MagVenture Transcranial Magnetic Stimulation (Cool D-B80 AP) or The NeuroStar® System will be used.
45469976|NCT03396172|Other|Control|The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria
45469977|NCT03396172|Device|FreeDom|Early return home, patients using an innovative device that automatically adjusts and wean the oxygen flow (FreeO2 system) coupled to telemedicine and tele-rehabilitation
45469978|NCT05167630|Other|prognostic marker|prognostic marker
45469979|NCT03763903|Other|3D training|Skills (FLS tasks) training using 3D visualization
45469980|NCT03763903|Other|2D training|Skills (FLS tasks) training using 2D visualization
45469981|NCT05167474|Other|breast milk smell|yenidoğanlara fototerapi tedavisi esnasında anne sütü kokusu uygulanmıştır.
45469982|NCT03763825|Behavioral|Mini-AFTERc|Structured 30-45 minute telephone discussion based on health psychology theory and CBT principles.
45469983|NCT03393052|Procedure|Coronary Angiography|Comparison of left radial versus femoral access during coronary angiography of patients who have undergone coronary artery bypass grafting surgery
45469984|NCT03763669|Dietary Supplement|Myoinositol|myo-inositol (2 g. twice a day)
45469985|NCT03763669|Dietary Supplement|Placebo (for myoinositol)|(twice a day)
45469986|NCT03302247|Biological|Nivolumab|Monoclonal antibody against non small cell lung cancer
46025486|NCT04317924|Device|Polyglycolic acid felt|Neoveil is a polyglycolic acid felt that has been shown to decrease the incidence of prolonged air leak after lung resection in Japan.
46025487|NCT04317924|Other|Standard of care|Standard of care after air leak post lung resection
46025488|NCT04692181|Biological|SYN-004, Ribaxamase or Placebo|SYN-004 is an oral formulation of a recombinant class-A beta-lactamase that hydrolyzes the beta-lactam ring of susceptible antibiotics that are excreted into the intestines
46025489|NCT04222933|Device|Motorized cryotherapy|application of motorized cryotherapy after ACL reconstruction
46025490|NCT04222933|Device|Classical cryotherapy|application of an ice bag
46025491|NCT02758249|Drug|Sevoflurane|patients are anesthetized by using sevoflurane inhalation
46112527|NCT00752622|Biological|Infliximab 5 mg/kg|Participants received Infliximab 5 mg/kg intravenously (IV) at weeks 0, 2 and 6 during the induction phase. At Week 10, those who were in clinical response received further treatment every 8 weeks during the observational phase
46112528|NCT00752622|Biological|Infliximab 5 mg/kg every 6 weeks|Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 5 mg/kg IV every 6 weeks (shortened interval group)
46112529|NCT00752622|Biological|Infliximab 7 mg/kg every 8 weeks|Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 7 mg/kg IV every 8 weeks (increased dose group)
46112530|NCT04038827|Diagnostic Test|D-CEC counting|By means of preliminary bulk separation step with the CellSearch system, single CEC will be sorted
46112531|NCT00913601|Device|Medtronic INTERSIM II - 3058|Medtronic INTERSIM II - 3058 Impuls Generator
46112532|NCT00754650|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in single-use vials.
45681781|NCT03321760|Radiation|Stereotactic Ablative Radiation Therapy (SABR)|SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.
45469987|NCT03302247|Drug|Nivolumab+Gemcitabine|Gemcitabine is added to the Nivolumab treatment
45469988|NCT04993339|Drug|OOC|The OOC will be mixed with autologous 5cc of platelet rich plasma (PRP), and then injected using a syringe into both tibia and femoral tunnels
45469989|NCT03404830|Other|HIIT group, MICT group|"The HIIT program training:~5 minutes of heating will be done. The intervention will consist of a training in suspension (TRX) performing squats. The session will be divided into four four-minute intervals at an intensity of 90-95% of the maximum heart rate, followed by three-minute active rest intervals of 50-70%. This intensity will be assigned to each subject individually. After the training, there will be a return to calm of 10 minutes of exercises of joint range. There will be 2 weekly training, with three days between both training, for a period of 12 weeks.~The training of the MICT program:~5 minutes of heating will be done. Subsequently, participants will perform a squat training with the Suspension Training System (TRX) with an intensity close to 70% of their maximum heart rate maintained for 40 minutes. The session will conclude with a return to calm of 10 min of joint width and stretching."
45681782|NCT03580096|Other|Core stability|Core stability intervention will be done with different stages and increasing gradually. The training program starts with exercises that isolate specific core muscles but progressing to include complex movements and incorporate core stability in dynamic tasks.
45681783|NCT03580096|Other|Standard intervention|Standard intervention will include active exercises based on active joint mobilizations, muscle stretching and motor coordination.
46025492|NCT02758249|Drug|propofol|patients are anesthetized by using propofol infusion
46025493|NCT02758405|Drug|Bupivacaine|0.125% Bupivacaine plus fentanyl 2mcg/ml
46025494|NCT02758405|Drug|Fentanyl|0.125% Bupivacaine plus fentanyl 2mcg/ml
46025495|NCT02758405|Device|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
46025496|NCT02763787|Drug|BIA 3-202|single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)
46025497|NCT02763787|Drug|Placebo|Identical placebo
46025498|NCT02763631|Other|Experimental: Treatment|Participants will be established on portable CPAP during the day with nasal pillows as an interface and requested to use it at least 8 hours/day.
46025499|NCT02763631|Other|Experimental: Run In Phase|Participants will undergo a run-in phase during which they will undergo baseline assessments. If they tolerate the portable CPAP and if their 6-MWT improves by more than 30m when performed on CPAP, they will be randomised into the trial.
46025500|NCT02763631|Other|Sham Comparator: Stand Care Arm|No change will be made to participants care
45681784|NCT03580018|Drug|Tranexamic Acid Powder|Ten mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation.
45681785|NCT03580018|Procedure|Post-anterior cruciate ligament reconstruction (ACLR)|Post-anterior cruciate ligament reconstruction (ACLR)
46025501|NCT02762305|Other|RSVP Bone Builders Group Exercise|
46112533|NCT00707837|Other|Preterm infant formulas and discharge formulas|Preterm infant formulas to be consumed per health care provider orders
46112534|NCT00707837|Other|Preterm infant formula with added soluble lipids|Preterm infant formula to be fed per healthcare provider instructions
46112535|NCT02611271|Other|Monitoring of antibiotic drug removal|No study specific intervention will be performed
46112536|NCT04093440|Other|lifestyle modification|nutrition counselling, diet and physical exercise monitoring, smoking cessation, and medication optimization
46025502|NCT04223011|Behavioral|In-Hospital Recovery Coach Intervention|The recovery coach will meet with the patient at least once during the hospital admission, during which he/she will reinforce the importance of continuing medication treatments, if initiated, as well as community and social supports for recovery and will discuss the plan for engaging in these services. This will include recommendations for suitable community resources for recovery services, or for housing, transportation, or other external barriers that may make it more difficult to engage in outpatient treatment. The recovery coach will encourage the participant to complete a relapse prevention plan, and help the patient organize post-discharge appointments and review medications. If applicable, family members and significant others will be encouraged to be present for these encounters.
46025503|NCT02758327|Drug|TheraTears Lubricating Eye Drops|Sodium Carboxy-methylcellulose 0.25% eye Lubricant
46025504|NCT02758093|Behavioral|Speed of Processing Training|These are specific computerized exercises that are designed to increase the rate in which people can process visual information.
46025505|NCT02758093|Other|Internet Navigational|This is a sham condition in which participants will receive the same amount of social and computer contact as those randomized to receive the 10 hours of speed of processing training. In this condition, participants will learn how to do various activities on the internet.
46025506|NCT02763475|Drug|cyclophosphamide|60mg/kg by vein on day -6
46025507|NCT02763475|Drug|Fludarabine|25mg/m2 iv daily on day -5 to -1
46025508|NCT02763475|Procedure|NK cell infusion|"First allogeneic haploidentical NK cell iv. infusion: 5x10e7/kg, NK CD3-CD56+ immunophenotype, 24-48h after chemotherapy~Second allogeneic haploidentical NK cell iv. infusion: up to 5x10e8/kg, NK CD3-CD56+immunophenotype, 7 days after the first infusion."
45469990|NCT01758081|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
45469991|NCT01758081|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
45469992|NCT01758081|Dietary Supplement|Vitamin D3 placebo|
45469993|NCT01758081|Dietary Supplement|fish oil placebo|
46025509|NCT02763475|Drug|IL-2|1x10^6 UI/m2 three times a week for two weeks from first NK infusion (day 0)
46025510|NCT02762383|Drug|Peginterferon Alfa-2|Peginterferon alfa-2a will be administered as 90 micrograms (mcg) via subcutaneous (SC) injection once weekly.
46025511|NCT02763163|Behavioral|Sun exposure routine|
46025512|NCT02763241|Drug|Cleanoze®|Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.
46025513|NCT02763241|Drug|Saline (Syringe irrigation)|Nasal irrigation using 250 ml normal saline pushing into the nostril by 20 ml syringe
46025514|NCT02763397|Device|NBM-DBS|DBS which has already been implanted aiming initially to stimulate the GPi will be reprogrammed in order to stimulate more distal structure, the NBM.
46025515|NCT02763397|Device|DBS|DBS will be switched off
46025516|NCT04223245|Behavioral|exercise+multi-modal sensory feedback (MMSF)|home program of 3 stepping exercises and 3 balance exercises with progression of speed, step distance and reduced vision. Real-time sensory feedback during ex. using ankle, wrist wts., laser on chest and mat with footpads and clickers (auditory feedback during stepping)
46025517|NCT04223245|Behavioral|Exercise only|3 stepping and 3 balance exercises which are to progress in speed and distance of movement as well as progress to eyes closed while performing.
46025518|NCT02758015|Other|Standardized Meal|
46025519|NCT02758015|Dietary Supplement|Betaine Hydrochloride 1500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
46025520|NCT02758015|Dietary Supplement|Betaine Hydrochloride 3000mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
46112537|NCT00761748|Device|Convatec Uro 2-piece|"Specific name of the device: 'Combihesive Natura® with a Durahesive Convex-It® base plate, 45 mm coupling, moldable (13-22 and 22-33 mm) hole size with boarder tape'.~The subjects are asked to test each of the two products for 21 days plus/minus 3 days in a randomised order and in accordance with their normal frequency of change and normal use pattern. The duration of the clinical investigation should be enough time to identify any difference in user-preference. If the subject is in the middle of testing an urostomy base plate when the test period is turning into the next period, the urostomy base plate can be worn until it needs to be changed. It is not possible to blind the investigation as the appearance of the test- and refer-ence products are very different in the look."
46112538|NCT00761748|Device|SenSura Uro 2-piece|SenSura URO 2-piece Extended Wear, convex light, 50 mm coupling, cuttable (15-33 mm)
46112539|NCT00825305|Biological|Abbreviated Zagreb 2-1-1 schedule|Subjects received the abbreviated Zagreb 2-1-1 schedule in a safety-lead-in phase.
45469994|NCT03392896|Drug|DCR-PHXC|DCR-PHXC is a novel, potent, and long-acting small interference ribonucleic acid (siRNA) molecule conjugated to N-acteylgalactosamine (GalNAc) that is designed to decrease liver oxalate production. DCR-PHXC is delivered via subcutaneous (SC) injection.
45469995|NCT03392896|Drug|Placebo|Single SC administration of placebo, which will be a sterile, preservative-free normal saline 0.9% solution for SC injection, which is of similar osmolality to the DCR-PHXC formulation.
45469996|NCT03758209|Procedure|Prehabilitation + ERAS|Prehabilitation will cover a range preoperative education and exercises (weekly) on diet, physical activity (daily walking), respiratory training (forced deep inspiration with spirometer device), as well as anxiolytic group psychotherapy.
45469997|NCT03758209|Procedure|ERAS|Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.
45469998|NCT01665573|Drug|PF-04457845|Acquisition of conditioning Administration of drug Extinction of conditioning
45469999|NCT01665573|Drug|Placebo|Acquisition of conditioning Administration of placebo Extinction of conditioning
45470000|NCT04363840|Drug|Aspirin 81 mg|Aspirin 81 mg to be taken orally once daily for 14 days.
45470001|NCT04363840|Dietary Supplement|Vitamin D|Vitamin D 50,000 IU to be taken orally once weekly for 2 weeks
46025521|NCT02758015|Dietary Supplement|Betaine Hydrochloride 4500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
46025522|NCT02757937|Behavioral|Health & Wellness Website|Educational website for patients with chronic disease (i.e., Type 2 diabetes, asthma, high blood pressure, high cholesterol). The website is a free interactive resource to help patients manage their health condition(s) each day and to help them achieve their goals. It is a multichannel health and wellness platform to help patients adhere to their treatment and care plans between office visits.
46112540|NCT00825305|Biological|Standard Essen 1-1-1-1-1 schedule|Subjects received the standard Essen regimen.
46112541|NCT05469971|Genetic|KIR genotyping|DNA extraction and KIR genotyping by KIR SSO Genotyping Test (One Lambda, Thermo Fisher, Monza, Italy).
46112542|NCT05454839|Other|Survey|Interviewer-administered survey
45838703|NCT04369404|Behavioral|Overactive bladder decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of overactive bladder.
46112543|NCT05454839|Other|Focus group|Focus group for selected participants
46112544|NCT00754572|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv, every 4 weeks
46112545|NCT00754572|Drug|methotrexate|10-25mg oral or parenteral weekly.
45470002|NCT03758131|Behavioral|Peer-enhanced Motivational Interviewing|"In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the peer of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use."
46112546|NCT00824993|Drug|Ibandronate|Infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant.
45681786|NCT03584854|Drug|15-methyl prostaglandin F2α|"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the carboprost study group will receive an intramuscular dose of 0.25mg (1mL) carboprost. If another second-line uterotonic is requested, the patients will receive 0.2mg (1mL) intramuscular methylergonovine."
46112547|NCT00824993|Drug|Vitamin Supplements|"Calcium 500 mg by mouth everyday for 12 months~Vitamin D 400 units by mouth 2 times a day for 12 months"
46025523|NCT02757937|Other|Control Arm|Continue with standard diabetes care without getting access to the intervention website.
46112548|NCT05758415|Drug|Secukinumab|The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
45681787|NCT03584854|Drug|Methylergonovine Maleate|"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the methergine study group will receive an intramuscular dose of 0.2mg (1mL) methylergonovine. If another second-line uterotonic is requested, the patients will receive 0.25mg (1mL) intramuscular carboprost."
45681788|NCT04765540|Behavioral|Low Intensity Nudges|"A bundle of 'low-intensity' passive interventions, including:~Large Mirrors & hand-shaped sign posts pointing to the station"
46025524|NCT04221685|Other|Artpharma|ArtPharma is a unique amide local anesthetic that is currently Used in dentistry Amides has taken over their predecessors esters with their enhanced performance.Each ml Articaine (D.C.I) 40.00 mg hydrochloride, Epinephrine (D.C.I) (tartrate) 0.01 mg
46025525|NCT04221685|Other|Artinibsa|"Powerful local anaesthetic with a short latency time.~Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains:~Articaine (D.C.I) 40.00 mg hydrochloride, Epinephrine (D.C.I) (tartrate) 0.01 mg"
46025526|NCT02762461|Procedure|IVF or ICSI|
45838704|NCT04369248|Other|hepassocin|hepassocin levels in polycystic ovary syndrome
46112549|NCT05758415|Drug|Placebo|The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
45681789|NCT04765540|Behavioral|High Intensity Activities|"A bundle of 'high-intensity' active interventions delivered for three weeks, including:~Free soap and free facemasks for handwashing station users, a community message board & general encouragement"
45681790|NCT04765540|Behavioral|BRAC's business-as-usual|A set of community activities to increase awareness of public handwashing stations and the need to use them. This includes in-person group sessions demonstrating hand hygiene as well as stickers and posters placed in the community to alert people to the handwashing stations.
46025527|NCT02762539|Drug|omega-3 enriched SMOF lipid emusion|
46025528|NCT02757703|Drug|Somatostatin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
46112550|NCT04095312|Procedure|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general HBP surgery
46112551|NCT04095312|Procedure|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general Uro surgery
46112552|NCT04095312|Procedure|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general colorectal surgery
46112553|NCT04093674|Procedure|de-epithelized (DE) SCTG|subepithelial connective tissue grafts
45838705|NCT04369092|Other|DYMUS|DYsphagia in MUltiple Sclerosis (DYMUS) that was questionnare and Eating Assessment Tool (EAT-10) were used for assess swallowing problem. All individuals were classified according to DYMUS. The DYMUS Score was 1 or 2 was taken as mild swallowing problems, 3 or more was taken as severe swallowing problems. Patients were divided into three groups; first group that include patients without swallowing problems, second group that include patients with mild swallowing problems, third group that include severe swallowing problems.
45838706|NCT04369170|Device|prosthesis connected directly to the implants|dental prostheses connected directly to the dental implants
46112554|NCT04095390|Drug|Pyrotinib|400 mg
46112555|NCT04095390|Drug|SHR6390|125mg
46112556|NCT04095390|Drug|Letrozole|2.5mg
46112557|NCT04095390|Drug|Capecitabine|500mg
46025529|NCT02757703|Drug|Terlipressin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
46112558|NCT02599818|Behavioral|NavSTAR|Participants in the NavSTAR program will work with a team of case workers who will provide motivational intervention and proactive barrier resolution services using patient navigation
46112559|NCT04095468|Radiation|Preoperative Radio(Chemo)Therapy|Preoperative radiotherapy +/- chemotherapy, then surgery (total mesorectal excision) or watch-and-wait
46112560|NCT00832091|Drug|Thymosin Beta 4|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were three concentrations of gel used for topical administration to the active groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days
46112561|NCT00832091|Drug|Placebo|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
46112562|NCT00754338|Drug|Alcon Opti-Free® RepleniSH® with Supraclens®|Marketed Multipurpose Disinfecting Care System + Marketed contact lens protein remover
46112563|NCT00754338|Drug|Alcon Opti-Free® RepleniSH®|Marketed Multipurpose Disinfecting Care System
45681791|NCT03586336|Device|ReDS-Guided|ReDS measurements will be shared with the treating clinicians who can use the information to guide diuresis and determine the appropriate timing of discharge
45681792|NCT03586336|Device|Usual Care|ReDS measurements will not be shared with the treating clinicians, who will guide diuresis using standard clinical criteria
45681793|NCT03584698|Drug|Misoprostol 100Mcg Tab|women will receive misoprostol 100 mcg (Misotac, Sigma Pharmaceuticals, Egypt) vaginally applied every 6 hours till cervical dilatation.
45681794|NCT03584698|Drug|Evening Primrose Oil 1000 MG|women will receive 4 capsules evening primrose oil 1000 mg (Primrose plus, Ema Pharm, Egypt) vaginally applied every 6 hours till cervical dilatation.
45681795|NCT03588130|Drug|EscharEx (5% EX-02 formulation)|Active arm
46025530|NCT02757703|Drug|Pantoprazole|Both study groups were administered with 40mg pantoprazole intravenously after EVL for 3 days, and following oral form for 12 days to hasten the process of healing of ulcers induced by ligation.
46025531|NCT02757703|Device|Endoscopic variceal ligation|Two experienced endoscopists performed emergent EVL for the enrolled patients with acute EVB. Pneumoactive ligation device (Sumitomo Bakelite Co., Ltd, Tokyo, Japan) and endoscopes (GIF XQ260; Olympus Co. Ltd, Tokyo, Japan) were applied. The targeted varix was suctioned and entrapped by a cap on endoscope. Ligation was aimed at active bleeding sites, red color spots or white nipple signs during the procedure.
46112564|NCT00754338|Drug|B&L ReNu MultiPlus™|Marketed Multipurpose Disinfecting Care Systems
46112565|NCT00708149|Drug|lansoprazole OD|arm 1: lansprazole 30 mg qd from NG route or orally for 14 days
46112566|NCT00708149|Drug|placebo|takepron placebo
46112567|NCT00916734|Procedure|MDT (McKenzie Method)|Subjects who perform exercises in their direction of preference.
46112568|NCT00916734|Procedure|Spinal thrust manipulation|Subjects who receive spinal thrust manipulation as an intervention.
46112569|NCT04016051|Drug|Clarithromycin DST (125 mg)|Clarithromycin DST (125.0 mg clarithromycin / straw).
46112570|NCT04016051|Drug|Clarithromycin DST (187.5 mg)|Clarithromycin DST (187.5 mg clarithromycin / straw).
46112571|NCT04016051|Drug|Clarithromycin DST (250 mg)|Clarithromycin DST (250.0 mg clarithromycin / straw).
46112572|NCT04016051|Drug|Clarithromycin Syrup (125 mg)|Clarithromycin Syrup 2.5 ml (125 mg).
46112573|NCT04016051|Drug|Clarithromycin Syrup (187.5 mg)|Clarithromycin Syrup 3.75 ml (187.5 mg).
46112574|NCT04016051|Drug|Clarithromycin Syrup (250 mg)|Clarithromycin Syrup 5 ml (250 mg).
46112575|NCT00761514|Drug|Humira (adalimumab)|40 mg eow
46112576|NCT00831779|Drug|Dapagliflozin|Tablets, Oral, 5 mg, once daily, 12 weeks
46112577|NCT00831779|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks
46112578|NCT04098510|Dietary Supplement|MitoQ|Subjects ingest 8x20 mg MitoQ capsules
46112579|NCT05441891|Other|Auditory intervention filter-modulated group|"Intervention consisted of listening to classical music modulated by an equalizer for 30 minutes, 2 sessions a day separated by at least 3 hours, for 10 days (Monday to Friday for 2 weeks).~The musical intervention was always performed with the same songs and in the same order using original CDs, heard through headphones (Beyerdynamic, DT 250 / 80 ohm. GMBH & Co. KG, Theresienstr. 8 D-74072 Heilbronn, Germany). The music was played with a sound system (Panasonic MASH, No. SA-PM24. Hamburg, Germany). and filtered through an equalizer called Earducator (Hollagen Designs, PÍO. Box 43 7864 Bergvliet W.Cape - South Africa) that modulates music by alternating low and high tones with an unpredictable cadence, preventing habituation. It also allows very narrow band complementary filters to attenuate (by about 40 dB) abnormally perceived frequencies (hyper-hearing peaks): filters in: 1 kHz - 1,5 kHz - 2kHz - 3 kHz - 4 kHz - 8kHz."
46025532|NCT02757781|Behavioral|Community of Practice|The intervention group will be offered participation for 12 months in a virtual CdP based on a web 2.0 platform. The control group will receive usual training.
46025533|NCT02763007|Drug|alogliptin+pioglitazone|alogliptin and pioglitazone add on metformin
46025534|NCT02763007|Drug|alogliptin|nesina add on metformin
46112580|NCT00758043|Drug|telaprevir|750 mg every 8 hours (q8h) for 12 weeks
46112581|NCT00758043|Drug|ribavirin|1000 - 1200 mg/day based on body weight for either 24 or 48 weeks
46112582|NCT00758043|Biological|peginterferon alfa-2a|180 mcg/week for either 24 or 48 weeks
45681796|NCT03588130|Drug|Gel Vehicle|Control arm
45681797|NCT03588130|Drug|Non-surgical standard of care (NSSOC)|Santyl (Enzymatic debridement) or commercially approved Hydrogel
45838707|NCT04369170|Device|Intermediate abutment|dental prostheses connected with an intermediate abutment to the implant
46025535|NCT02763007|Drug|pioglitazone|actos add on metformin
46025536|NCT02753101|Drug|[18F]-FTC-146|10 mCi± 1 mCi of [18F]FTC-146 intravenously
46025537|NCT02762227|Device|Abdominal high resolution CT|CT examinations were performed using a 64-slice CT scanner. Arterial phase scanning was triggered by bolus tracking technique after 100 to 120 mL nonionic contrast material was injected through the antecubital vein. With a delay of 60 and 140 s after the beginning of contrast medium injection, portal venous and equilibrium phase image scanning were followed.
46112583|NCT00831701|Drug|Tamsulosin|0.4 mg Tamsulosin once daily for 21 days
46112584|NCT00831701|Drug|Placebo|One placebo pill per day for 21 days or until stone expulsion
46112585|NCT00705419|Drug|Vicriviroc maleate|Follow-up for subjects who previously received 30 mg tablet administered once daily according to the parent protocol.
46112586|NCT00705419|Drug|Vicriviroc maleate|Follow-up for subjects who previously received 20 mg tablet administered once daily according to the parent protocol.
46112587|NCT00705419|Drug|Placebo|Follow-up for subjects who previously received placebo tablet administered once daily according to the parent protocol.
46112588|NCT00705419|Drug|Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg|Follow-up for subjects who previously received active control consisting of emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg combination tablet administered once daily according to the parent protocol.
46112589|NCT02599935|Dietary Supplement|Hypercaloric beverages|Nutritional supplement: Hypercaloric beverages
46112590|NCT02599935|Other|standard treatment|No other than standard treatment
46112591|NCT02599935|Other|educational structured counseling|Nutritional counseling leaded to patient and caregivers
46112592|NCT05426837|Behavioral|Combatting Social Isolation|A brief, computerized psychoeducational intervention designed to target ways to cope with and address loneliness and social isolation in older adults modeled after our group's previous Building Stronger Allies (BSA) intervention.
46112593|NCT05426837|Behavioral|Health Education Training|Control condition where participants learn about healthy lifestyle behaviors.
46112594|NCT05425355|Drug|Intravenous (IV) acetaminophen + oral placebo|Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group, the IV study drug will be IV acetaminophen and the oral study drug will be a placebo tablet.
46025538|NCT02762227|Device|Contrast-enhanced ultrasonography (CEUS)|CEUS examinations were performed using a Philips iU 22 scanner with a 1-5 MHz（Mega Hertz, MHz）vector transducer. Traditional transabdominal ultrasound and CEUS were performed by the same investigator, one with more than 3 years experiences in CEUS. Traditional ultrasound was used initially to locate the lesion. The plane with the bottom of the lesion was selected for further examination. When multiple lesions were existed, the largest one was selected to evaluate. The target was placed in the center of the screen and was kept stable. Pulse inversion harmonic imaging with an index of 0.06 was used in CEUS examination. SonoVue, which contained sulfur hexafluoride microbubbles, was used as the contrast agent.
46025539|NCT02762227|Procedure|Cholecystectomy|Cholecystectomy is performed by method of either laparoscopic cholecystectomy or open cholecystectomy.
45838708|NCT04368624|Other|Skin Tape|Skin sample collection: samples of human stratum corneum will be obtained with squame adhesive tape disks typically at the time of their clinic appointment. The tape will be placed on the inside of the forearm and the procedure will be repeated up to five times per patient to have sufficient corneocytes for analysis. This type of sampling is non-invasive.
45838709|NCT04368624|Diagnostic Test|Blood Draw|Blood specimens: blood will be obtained for serum amino acids/phenylalanine levels. This sample is obtained for disease monitoring as part of routine standard of care. Results from up to three clinic visits will be correlated with the tape sample obtained on the same day.
46025540|NCT00635323|Drug|Irinotecan plus capecitabine|Irinotecan 200-250 mg/m2 intravenous infusion over 30 to 90 minutes on day 1 of a 3-week cycle. Capecitabine 1000 mg/m2 oral tablet twice daily for 14 days followed by a 7 day rest throughout the treatment period for
46025541|NCT01191840|Drug|Vancomycin|Duration
46025542|NCT01191840|Drug|Vancomycin|Duration
45838710|NCT04368546|Drug|Sunitinib|
45838711|NCT04368312|Other|No intervention|No intervention, just of questionnaire including validated tests
45838712|NCT04368000|Behavioral|Intermittent prone positioning instructions|Participants will be given instructions to lie in the prone position for a duration of 1-2 hours, every 4 hours while awake.
46025543|NCT02752711|Procedure|the PECARN clinical decision rule|the PECARN clinical decision rule for the detection of clinically-important traumatic brain injuries in children with minor head trauma
46025544|NCT04534543|Radiation|MRI/Spectroscopy|Participants will undergo multiple 7T MR imaging sessions which include advanced 31P MRSI techniques, before start of palliative chemotherapy and during treatment until progression of disease or until week 54.
46025545|NCT05656950|Procedure|Assessment|Oral health of the patient was evaluated by the researcher using a flashlight, tongue depressor and Oral Evaluation Guide.
46112595|NCT05425355|Drug|Intravenous (IV) placebo plus oral acetaminophen|Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group the IV study drug will be normal saline and the pill will be acetaminophen
46112596|NCT00705497|Procedure|Radiofrequency Tumor Ablation|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
46112597|NCT00752895|Dietary Supplement|American ginseng|Given orally
45470003|NCT03758131|Behavioral|Motivational Interviewing|In the Motivational Interviewing (PMI) condition, target clients only will receive one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change.
45838713|NCT04368000|Behavioral|Usual care positioning with no instructions|Participants will not be given instructions to lie in the prone position for any duration.
45838714|NCT04367532|Other|Foam rolling|Foam rolling performed on cuff muscles in 3 sets of 30 seconds per each muscle part in duration with a 15-second rest between sets. The first sets on the central part of the cuff muscles, the second on the medial and third on the lateral side of the cuff.
45838715|NCT04367532|Other|Tissue flossing|A standard cuff muscle bandaging technique on cuff muscle. After the application, each participant is asked to perform a 2 min ankle-exercise program.
46112598|NCT00752895|Dietary Supplement|Placebo|Given orally
46112599|NCT00831389|Device|Closed Loop|Insulin pump controlled by closed loop unit and algorithm
46112600|NCT04093713|Procedure|A novel technique to block the inferior alveolar nerve block using Mepivecaine with Levonordefrin|blocking the inferior alveolar nerve using extroral landmarks
46112601|NCT04093635|Device|Negative Pressure Wound Therapy|VAC was applied by placing sterile pads in two layers with a 16Fr Ryle's tube placed between the two layers and then the wound was sealed by a sterile transparent polyurethane sheet. The tube was connected to a wall-mounted suction device and the pressure will be set at -125 mmHg Mode of NPWT. This dressing will be changed every 72 hrs
46112602|NCT00831311|Biological|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular
46112603|NCT00831311|Biological|DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine|0.5 mL, Intramuscular (right and left thighs, respectively)
46112604|NCT04093479|Other|blood samples|blood samples will be taken repeatedly
45470004|NCT03758131|Other|Waitlist Control|Dyads randomized to this intervention will have no contact with study personnel until 2 months after the PMI group has completed the PMI intervention. Then those in the Waitlist Control condition will receive the full PMI protocol.
45470005|NCT04985331|Device|W-GenZD|"W-GenZD is a program that delivers evidence based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent."
45470006|NCT03403270|Other|ENCOURAGE App|Users will have an opportunity to engage with the app as described for the duration of the study period.
45838716|NCT04367376|Other|mobilization|central postroanterion mobilization on the most painful vertebral level at the lumbar spine
45838717|NCT04367376|Other|manual therapy|manual therapy
45838718|NCT04367376|Other|instrumental manual therapy|instrumental manual therapy
45838719|NCT04367454|Other|Use of Personal Protective Equipment|As described in the arm descriptions
46112605|NCT03980301|Diagnostic Test|ultrasound|screening of pregnant women with hepatitis c virus received treatment in first trimester for congenital anomalies
46112606|NCT00831233|Drug|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
46112607|NCT00831233|Drug|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
46112608|NCT00831233|Drug|Bicalutamide|On Day 0, three days before the first dose of goserelin on Day 3, patients began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
46112609|NCT05438277|Drug|Methylprednisolone (MPA)|injection into subacromial or glenohumeral space with MPA
46112610|NCT05438277|Drug|Triamcinolone Acetonide (TA)|injection into subacromial or glenohumeral space with TA
46112611|NCT00761280|Drug|trabedersen|
46112612|NCT00761280|Drug|temozolomide|
46112613|NCT00761280|Device|Drug delivery system for administration of AP 12009|Drug delivery system for Convection Enhanced Delivery consists of a portable pump (Pegasus vario or Pega vario) with drug reservoir (Pega Bag) and infusion line (Pega Line). Main implanted parts are the port access system (PORT-A-CATH) and the intratumoral catheter (Medtronic ventricular catheter).
46112614|NCT00761280|Procedure|Placement of Drug Delivery System|Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
46112615|NCT00761280|Drug|carmustine|
46112616|NCT00761280|Drug|lomustine|
46025546|NCT02752555|Other|Antioxidant (l-cratinine) + modifiable lifestyle factors|All participants were subjected to the same three-month period treatment protocol, which included 1) antioxidant treatment with L-Carnitine (2g daily); 2) frequent ejaculation every 2 days; and 3) minimizing adverse lifestyle factors.
46025547|NCT04472377|Device|Self sampling kit for collecting discharge from vaginal fornix|A device to collect exfoliative cells from vaginal fornix that can self-operated with ease and comfort.
46112617|NCT04093089|Device|Bionode IOP Lowering System|Patients wearing Bionode spectacles and customized contact lens and will receive stimulation at 50 Hz, 100 µs, up to 150 µA for 2 hours.
46112618|NCT04093089|Device|Bionode IOP Lowering System|Control: No stimulation
46112619|NCT00916890|Drug|Morphine|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral sustained-release morphine will be randomly assigned to a patient.
45470007|NCT04974697|Device|JJVC Investigational Multifocal Toric Contact Lens|TEST
45470008|NCT03265119|Drug|AEVI-001|Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily during the treatment period.
45470009|NCT03265119|Drug|Placebo|Oral doses of 100 mg, 200 mg or 400 mg of Placebo will be administered twice daily during the treatment period.
45470010|NCT03396094|Device|High-flow nasal cannulae (HFNC) oxygenation|Delivery of 60L/min of supplemental oxygen for pre-oxygenation and apnoeic oxygenation during rapid sequence intubation using the AIRVO™ 2 Humidifier with Integrated Flow Generator (Fisher & Paykel Healthcare, Auckland, New Zealand)
45470011|NCT03396094|Device|Non-rebreather mask and standard nasal cannula|Pre-oxygenation using non-rebreather mask and apnoeic oxygenation via nasal cannulae at 15L/min
45470012|NCT03758053|Other|No intervention|No intervention
45470013|NCT04981665|Drug|Tislelizumab|Tislelizumab 200mg IV Q3W
45470014|NCT04981665|Drug|TACE|TACE will be performed after curative resection (4±1w)
45470015|NCT03392818|Other|The measured distance|To measure the distance between the upper edge of the thyroid cartilage to the upper edge of the sternum add the distance from the upper edge of the sternum to the carina calculated according to the chest CT scans as a guide to the placement of Uniblocker without the aid of Fiberoptic bronchoscope.
46112620|NCT00916890|Drug|Oxycodone|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral extended-release oxycodone will be randomly assigned to a patient.
46112621|NCT00916890|Drug|Fentanyl|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal fentanyl will be randomly assigned to a patient.
46112622|NCT00916890|Drug|Buprenorphine|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal buprenorphine will be randomly assigned to a patient.
46112623|NCT02599701|Drug|Gabapentin|A single dose Gabapentin 300mg at bedtime.
45470016|NCT03392818|Other|formula|Calculate the depth of intubation according to the formula of 0.1977* patient's height - 4.2423
45470017|NCT03392818|Device|Fiberoptic bronchoscope|The intubation of Uniblocker under the guidance of Fiberoptic bronchoscope
45470018|NCT04952701|Device|Control lenses|Control Multifocal lenses
45470019|NCT04952701|Device|Test lenses|Test Multifocal lenses
45470020|NCT05166928|Device|carriere motion appliance|after finished treatment with carrirere motion appliance in the two group (group 1 have upper wisdom teeth ,group 2 have not upper wisdom teeth ) the pre and post casts will be scanned and superimposed to determine amount upper molar distalization
46025548|NCT00624546|Drug|Prevacid Solutabs|BID Prevacid Solutabs
45470021|NCT03392740|Drug|Lisinopril|Patients will be given lisinopril once a day prior to starting an anthracycline chemotherapy regimen and titrated up in a stepwise fashion, as allowed by patients blood pressure, to a target dose of 20mg daily.
45470022|NCT03392740|Drug|Placebo Oral Tablet|Patients will be given a look-alike placebo medication once a day prior to starting an anthracycline chemotherapy regimen. They will be given a new placebo medication in a step-wise fashion over period of 1 to 3 weeks.
45470023|NCT04723173|Device|Feature for noise reduction (on)|The noise reduction feature shall support the hearing aid user in noisy situations and shall reduce the listening effort.
45470024|NCT04723173|Device|Feature for noise reduction (off)|To show the advantage of the noise reduction feature there is a comparison without the feature necessary.
45470025|NCT04919317|Drug|Dexamethasone 4mg|The experimental group received 4mg dexamethasone added to their bupivacaine block preoperatively just prior to bilateral reduction mammaplasty.
45470026|NCT04919317|Drug|Saline|The control group received 1mL of 0.9% saline added to their bupivacaine block preoperatively just prior to bilateral reduction mammaplasty.
46112624|NCT02599701|Drug|Placebo|A single placebo dose with the same physical characteristics of the active intervention.
46112625|NCT04093401|Other|individualized risk assessment|Individualized risk assessment of developing a second basal cell carcinoma
46112626|NCT04093245|Behavioral|GEM nurse|hospital-based geriatric emergency nurse (GEM nurse) specialist to support patients during the post-discharge transition period
46112627|NCT04093245|Behavioral|pre- and post-hospitalization medication list reconciliation|pre- and post-hospitalization medication list reconciliation for elderly
46112628|NCT04093245|Behavioral|systematic discharge summaries|systematic discharge summaries given to patients and/or caregiver, and sent to their family physician
46112629|NCT04093245|Behavioral|medical follow-up appointment|a planned follow-up appointment with their family physician
45838720|NCT04367220|Diagnostic Test|Diagnostic testing performed as per routine care|
45470027|NCT02938689|Other|Exercise|
45838721|NCT04366986|Other|Tested for SARS-CoV-2 (regardless of the result)|This is an observational study with no intervention
46025549|NCT00624546|Procedure|Antireflux surgery|Lap Nissen
46025550|NCT05656872|Procedure|Transverse Abdominis Plane Block|Group T, will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed in the transverse plane to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest. The abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized. A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. Separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in-between will be observed. The procedure will be repeated following the same steps on the other side.
46112630|NCT04093245|Behavioral|follow-up phone call|a systematic follow-up phone call for discharged patients
46112631|NCT04093245|Other|Wiki-based Knowledge tools|access to wiki-based patient-oriented KT tools
46112632|NCT04093245|Other|Telemonitoring service|access to a community-based telemonitoring service
46112633|NCT02599896|Biological|VRC-HIVMAB080-00-AB (VRC01LS)|VRC01LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
46112634|NCT02599896|Biological|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
46112635|NCT04094922|Behavioral|Swedish PTSD Coach smartphone app|Self-help smartphone app targeted towards posttraumatic stress that includes psychoeducation, rating/monitoring of distress, lists of support and treatment resources, and strategies for coping with distress.
46112636|NCT04095000|Behavioral|FACE-TC SP|The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction.
46112637|NCT04095000|Behavioral|Treatment as Usual|Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals.
46112638|NCT00824369|Drug|No drug will be administered|No drug will be administered.
46112639|NCT00824291|Drug|desvenlafaxine succinate sustained release|50 mg/day oral tablet for 12 weeks
46025551|NCT05656872|Procedure|Ilioinguinal-iliohypogastric block|Group I, will receive an Ultrasound-guided IIIH block that will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed on the line between the anterior superior iliac spine and the umbilicus, where 3 layers of muscles (extra-abdominal oblique, intra-abdominal oblique, and transverse abdominis) will be visible on the inner side of the anterior superior iliac spine.A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle next to the iliohypogastric/ilioinguinal nerve. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. The procedure will be repeated following the same steps on the other side.
46112640|NCT00824291|Genetic|Genotyping|CYP2D6 genotyping at randomization
46112641|NCT05297747|Diagnostic Test|Apical periodontitis|Radiography of the patients were taken. Blood samples were collected from those patients.
46112642|NCT05297747|Diagnostic Test|Chronic periodontitis|Radiography of the patients were taken. Blood samples were collected from those patient
46112643|NCT05239871|Diagnostic Test|Ultrasound|Preoperative transvaginal/transabdominal ultrasonography done according to IDEA criteria.
46112644|NCT00804986|Drug|LY2428757|Once weekly for 12 weeks as a subcutaneous injection.
45470028|NCT03126526|Behavioral|Food specific Inhibitory control training|It involves a go/no-go task in which participants are requested to respond by clicking a particular button when a specific stimulus appears and requested to withhold their response when another particular stimulus appears. Stimuli in this intervention include photos of food and non-food.
45838722|NCT04366986|Other|Clinical diagnosis of COVID-19 by a health care professional|This is an observational study with no intervention
45838723|NCT04366674|Procedure|cleft palate repair|restoration of tensor veli palatini for the purpose of the muscle function recovery.
46025552|NCT02757469|Drug|Drospirenone and ethinyl estradiol combination (Yasmin)|Female oral combined contraceptive containing 30 mcg (0.030 mg) Ethinyl Estradiol and 3 mg drospirenone (Androstenes)
46112645|NCT00804986|Drug|Placebo|1 of 5 volumes of placebo given once weekly for 12 weeks as a subcutaneous injection.
46112646|NCT00752232|Biological|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
46112647|NCT00752232|Other|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
46112648|NCT00752232|Biological|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
46112649|NCT00752232|Other|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
46112650|NCT00752232|Other|PBS|IM injection, Day 1, month 3, 6, 9, 12
46112651|NCT02600520|Drug|SRP with RSV gel LDD|After SRP, 1.2% Rosuvastatin (RSV) gel was delivered subgingivally into the pocket
46112652|NCT02600520|Drug|SRP with ATV gel LDD|After SRP, 1.2% Atorvastatin (ATV) gel was delivered subgingivally into the pocket
46112653|NCT02600520|Drug|SRP with placebo gel LDD|After SRP, placebo gel was delivered subgingivally into the pocket
46112654|NCT02600442|Other|non interventional study|
46112655|NCT00760266|Drug|Aliskiren|Aliskiren 150 mg for 1 week, Aliskiren 300 mg (with or without amlodipine)for 7 weeks
46112656|NCT00760266|Drug|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg for week 1; Hydrochlorothiazide (HCTZ) 25 mg (with or without amlodipine)for 7 weeks
46112657|NCT00753714|Drug|ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
46112658|NCT00753714|Drug|Placebo to Match ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
45838724|NCT04366596|Device|Angioplasty with paclitaxel eluting balloon|The patients will be treated with renal artery angioplasty using paclitaxel eluting balloon
45838725|NCT04366596|Device|Angioplasty with plain old balloon|Angioplasty with plain old balloon
46112659|NCT00753714|Drug|Gemcitabine|administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle UP to 6 cycles or UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
46112660|NCT00759954|Drug|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
46112661|NCT00759954|Drug|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
45681798|NCT05702008|Other|Rabies Information Education and Communication Material|The test group was administered the rabies IEC material available on the National Center for Disease Control (NCDC) website (https://ncdc.gov.in/index1.php?page=1&ipp=All&lang=1&level=2&sublinkid=502&lid=428) in English and Hindi languages using a WhatsApp broadcast every 3 days for 30 days, in a cyclical manner. This material includes brochures, posters, short films, and informative documents designed to educate the general public about rabies prevention and post-exposure prophylaxis practices. Text messages, encouraging the participants to go through the material, were also a part of this intervention.
46025553|NCT05656716|Behavioral|Nutritional intervention|The nutritional intervention will be based on a nutritional education program adapted for patients with breast cancer in active treatment. The nutritional intervention program will be based on the practical guidelines for nutrition in the oncology patient. The main objectives of the nutritional intervention will focus on preventing malnutrition, maintaining an adequate nutritional status and dietary adaptation to secondary symptomatology. To this end, an adequate energy and protein intake will be ensured and the consumption of plant-based foods will be promoted to ensure an adequate intake of vitamins, minerals and antioxidants
46025554|NCT05656716|Behavioral|Physical exercise intervention|Weekly physical exercise guidelines will be given following the published Canadian clinical guideline recommendations combining moderate and vigorous aerobic activity. Walking will be performed 3 days a week for 30 minutes at a modified Borg scale intensity of 4-5/10, and 2 days a week for 15 minutes at a modified Borg scale intensity of 7-8/10. There will also be 5 minutes of warm-up and 5 minutes of recovery, in moderate activity at 3/10, and in vigorous activity at 4/10. In addition, 3 days per week (not coinciding with vigorous aerobic activity) of strength training at a modified Borg scale intensity of 7/10 will be included. Two sets of 8-10 repetitions will be performed, adaptable to that intensity according to the progression of the subjec
46112662|NCT00804908|Drug|temozolomide|temozolomide capsule administered orally once daily for 5 days every 28 days
46112663|NCT00804908|Drug|ABT-888|ABT-888 capsule administered orally twice daily for 7 days every 28 days
46112664|NCT00804908|Other|Placebo|Placebo for ABT-888 capsule administered orally twice daily for 7 days every 28 days
46112665|NCT05433948|Diagnostic Test|Simultaneous EEG and CRT|"EEG is recorded with 32 electrodes and commercial recording equipment.10 min EEG is recorded in idle mode with eyes closed prior to continuous EEG recording during the CRT examination, see below.~The test is performed via a laptop using EKHO software. The software generates 150 sound stimuli of 90 dB, which the patient hears in sound-insulated headphones. Via a push button in the dominant hand, the patient must respond as quickly as possible as soon as sounds are perceived.~PSE test: Duration 20 min. Includes 5 tasks: Digit-symbol Test, Number Connecting Test A, Number Connecting Test B, Serial Dotting Test and Line Tracing Test. Exits in 4 versions, which are used in repeated tests to avoid the learning effect. Scores range from -18 t0 6 and less -4 is abnormal."
46112666|NCT00808808|Biological|Choice of TIV or FluMist with baseline advertisement|An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist
46112667|NCT00808808|Other|Choice of TIV or FluMist with enhanced advertisement and incentives|An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination
46112668|NCT00808808|Biological|Control - Usual care offering TIV only with baseline advertisement|A control arm of usual care offering TIV with baseline advertisement
46112669|NCT02608034|Drug|Itraconazole|Itraconazole will be administered as a 200 mg oral solution QD during Part 1 only for 20 consecutive days.
46112670|NCT02608034|Drug|Rifampin|Rifampin will be administered as a 600 mg oral solution QD during Part 2 only for 20 consecutive days.
46112671|NCT02608034|Drug|Vemurafenib|Vemurafenib will be administered in both Part 1 and Part 2 at a dose of 960 mg BID for at least 40 conseutive days.
46112672|NCT05751278|Device|ERBECRYO® 2 Cryosurgical Unit and Accessories - K190651|ERBE 1.1mm flexible single-use cryoprobe with oversheath
46112673|NCT05751278|Device|Radial Jaw 4 Pulmonary Biopsy Forceps|Radial Jaw 4 Pulmonary Biopsy Forceps Standard Capacity for 2mm endoscope
46112674|NCT02608190|Behavioral|Working memory training|See protocol
46112675|NCT00589784|Drug|Sunitinib|The study drug will be administered on an outpatient basis. The starting dose will be 50 mg daily for 28 days (4 consecutive weeks) followed by 14 days off for patients not on CYP3A4 inducers or inhibitors. A cycle equals 42 days.
46112676|NCT05754944|Diagnostic Test|ABI/TBI|ABI/TBI to be performed after surgery while patient is still admitted at the hospital.
46112677|NCT05754944|Other|Questionnaires|PAD symptoms questionnaire to be administered at baseline before surgery. mLEFS (included in PAD symptoms questionnaire) and WIQ to be administered at baseline before surgery. mLEFS and WIQ will be administered 1 month, 3 months, 6 months after surgery and every 6 months after that for a goal of at least 1 year.
46112678|NCT00759876|Drug|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with milk. Dosing based on participant body weight
46112679|NCT04569344|Other|Laboratory test positive for SARS-CoV-2 virus|Exposure/intervention: diagnosis of Covid-19, defined as positive laboratory test for SARS-CoV-2
46112680|NCT05750264|Drug|Ibuprofen|800 mg of IV ibuprofen
45470029|NCT03126526|Behavioral|Implementation intentions|"It involves designing if-then strategies of behaviour. Participants will be asked to describe situations in which they feel they are more prone to behave in a way that is not congruent to their long term goals, and then to plan strategies to behave differently when faced with this situation in the future."
45470030|NCT03126526|Behavioral|General inhibitory control training|It involves a go/no-go task in which participants are requested to respond by clicking a particular button when a specific stimulus appears and requested to withhold their response when another particular stimulus appears. Stimuli in this intervention include only non-food pictures.
45681799|NCT03584620|Other|Inspiratory muscle training|Inspiratory Muscle Training was performed with an exercise tool (Powerbreath®) with a resistance range of 0-90. The training intensity was started with 30% of the Maximum Inspiratory Pressure (MIP) value obtained as a result of the mouth pressure measurement, training was progressively increased from 30% to 60% considering that they were terminal-stage pulmonary disease patients. Patients were asked to perform IMT for 15 minutes, twice a day, 7 days a week, for 3 months.
46025555|NCT02762149|Device|Nerve stimulator|The nerve stimulator (Stimpod NMS 450: Xavant technology (PTY) Ltd; Pretoria, South Africa or similar nerve stimulator) will be connected to the epidural catheter through an adapter (Johans ECG Adapter, Arrow International Inc., Reading). The epidural catheter and the adapter will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. Secured connections and avoidance of any air within in the system must be ensured to avoid high impedance in the circuit, which could result in false negatives. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle.
46112681|NCT05716724|Drug|Semaglutide|Participants will receive oral semaglutide with or without other OADs as per local label at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study.
46112682|NCT03981588|Other|Imaging studies|Patients will undergo different imaging and clinical follow-up procedures to run out cardiotoxicity
46112683|NCT05742854|Procedure|C-sections operations|Immediately after the delivery of the baby, uterotonic agents will be applied before the placenta is removed and by a manual check of the fundus of the uterus and the anterior wall, followed by an examination of the uterine tone by the surgeon
46112684|NCT05742854|Drug|Oxytocin|Oxytocin
46112685|NCT05742854|Drug|Carbetocin|Carbetocin
46025556|NCT05656560|Behavioral|Clinical decision support (CDS)-Commitment nudge|EHR clinical decision support alerts-clinician commitment to discuss high risk polypharmacy
46112686|NCT00823979|Drug|UK-453,061 Dose 1|UK 453,061 750 mg QD + one optimized NRTI + darunavir/ritonavir.
46112687|NCT00823979|Drug|UK-453,061 Dose 2|UK 453,061 1000 mg QD + one optimized NRTI + darunavir/ritonavir.
46112688|NCT00823979|Drug|Etravirine|Etravirine 200 mg BID + one optimized NRTI + darunavir/ritonavir.
46112689|NCT04093284|Device|The needle-free jet injector|Continuous insulin therapy for 9 days
46112690|NCT05754866|Procedure|Transbronchial lung cryobiopsy|Lung tissue was obtained by transbronchial lung cryobiopsy for subsequent pathology and clinical diagnosis.
46112691|NCT05754866|Procedure|Transbronchial lung biopsy|Lung tissue was obtained by transbronchial lung biopsy for subsequent pathology and clinical diagnosis.
46112692|NCT02599584|Behavioral|precritical staff|free pre critical scenario team staff
46112693|NCT04094766|Drug|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
46112694|NCT02606786|Other|Lumbopelvic stabilization exercises|The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine.
46112695|NCT05428722|Behavioral|deep breathing exercises with a incentive spirometer|Deep breathing exercise will be explained to the patients with an incentive spirometer (IS), it will be demonstrated in practice and it will be applied from the first day of hospitalization in addition to routine treatment and care. The patient will be informed about whether they are doing it right and their questions will be answered. It will be ensured that the patients start after breakfast in the morning and make 5-10 inspirations, hold her/his breath for 3 seconds and 5-10 expirations per hour with IS until they fall asleep. The research nurse will warn the patients that they should do the exercise every hour, and the alarms of the patients' mobile phones will be set to ring every hour to be a warning. The start and end time of the exercise will be decided together with the patient, and usually the time of waking and going to bed will be taken into account.
46112696|NCT00708383|Other|10% SSS embryo culture medium protein supplementation|10% SSS in addition to the 0.5% HSA already in the culture medium.
46112697|NCT00708383|Other|0.5% HSA embryo culture medium protein supplementation|0.5% HSA in the culture medium
46112698|NCT02606864|Drug|Nifurtimox (BAYa2502)|Oral Intake of 4 x 30 mg nifurtimox tablets
45838726|NCT04366284|Other|No Facilitation Support|Clinicians will have full use of the NOCTEM platform. They will not have scheduled and/or structured contacts with the facilitation teams, however can reach out to the NOCTEM team or their local point of contact and coordinator with questions or technical issues that may arise.
46025557|NCT05656560|Other|Clinician education|Brief, online education module for primary care clinicians
46112699|NCT02606942|Other|Questionnaires, physical exam, US of the knee|Function and pain questioners, physical findings and sonographic study of the knee joint
46112700|NCT05521607|Device|Picterus Jaundice Pro (JP)|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
46112701|NCT00823901|Drug|Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel|Applied on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
46112702|NCT00823901|Drug|Placebo gel|Applied placebo gel with no active medication to entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
46112703|NCT00823823|Other|Bivalved cast|Circumferential cast will be applied following closed reduction and then bivalved using a cast saw
46112704|NCT00823823|Other|Circumferential cast|Circumferential cast will be applied following closed reduction
46025558|NCT05656560|Behavioral|Clinical decision support (CDS)-Justification nudge|EHR clinical decision support alerts-clinician rational for high risk polypharmacy
46112705|NCT05740592|Procedure|micro-osteoperforations ,microincision|Patients in MOPs group will be subjected to minimal 6 MOPs 2mm apart and corticoperforation will be conducted by using drilling bure and only 1 or 2mm bicortical in the mid-palatal suture area. Patients with the piezocision group will be subjected to minimal 3 micro incisions spaced 4mm apart and a piezoelectric device with diamond surgical tip (size: 4 mm, thickness: 0.5mm) will be used.. The MARPE technique comprises the insertion of four bicortical miniscrews adjacent to the mid-palatal suture, being two mesial and two distal to the expanding screw. Each MARPE have two arms and will be fixed to molar band by soldering.
46025559|NCT02757391|Biological|Adoptive Immunotherapy|Undergo CD8 +T cell therapy
46112706|NCT05714072|Drug|Ruxolitinib|10mg BID or 15mg BID
46112707|NCT05714072|Drug|Abemaciclib|50, 100 and 150 mg
46112708|NCT04540094|Drug|Human albumin|Any preparation of 5% Human Albumin Solution which has marketing authorisation in the UK to be used for this indication and is stocked by local hospital pharmacies at the participating sites, may be prescribed in this study
46112709|NCT04540094|Drug|Balanced crystalloid solution|"Any preparation of intravenous balanced crystalloid which has marketing authorisation in the UK to be used for this indication and is stocked by local hospital pharmacies at the participating sites, may be prescribed in this study."
46112710|NCT02926898|Drug|ZX008 (Fenfluramine Hydrochloride)|"ZX008 0.5 mg/kg/day (maximum 20 mg/day). ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL.~*Note: The 0.5 mg/kg/day dose of ZX008 fenfluramine hydrochloride in this study is equivalent to 0.4 mg/kg/day (maximum 17 mg/day) dose of fenfluramine base."
46112711|NCT02926898|Drug|Matching Placebo|Matching Placebo
46112712|NCT02606630|Drug|ABT-555|ABT-555 will be administered on Visit 4 in Part 2 only
46025560|NCT02757391|Biological|Aldesleukin|Given SC
46112713|NCT03633032|Diagnostic Test|Acquiring of ultrashort echo time (UTE) MRI sequences|Modern MRI sequences (ultrashort echo time (UTE)) for a better depiction of bone anatomy
46112714|NCT00759564|Drug|CP-70,429 and PF-03709270|Study Periods 1 and 2 will be separated by a minimum of 14 days. In Period 1, subjects will receive a single dose of CP-70429 (800 mg given as a 1.5 hour intravenous infusion), while in Period 2, subjects will receive a single oral dose of PF-03709270 (1000 mg).
46112715|NCT00816023|Drug|ecallantide|infusion administered IV over the duration of the surgical procedure
46112716|NCT00816023|Drug|placebo|solution for IV infusion over the duration of the surgical>> procedure
46112717|NCT00759174|Drug|No intervention|No intervention occurs in this observational study.
46112718|NCT00815633|Drug|Alefacept|15mg intramuscular injection weekly for 12 weeks
46112719|NCT02610881|Dietary Supplement|Iron and Folic Acid (IFA)|1 mg of IFA syrup (containing 20 mg of elemental iron and 100 mcg of folic acid) will be taken twice per week for one month.
46112720|NCT02610881|Dietary Supplement|Micronutrient Powders (MNP)|"One sachet of micronutrient powder will be mixed into food to be taken once daily for a total of one month. One sachet of micronutrient powders includes the following:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin Base"
46112721|NCT02610881|Behavioral|Iron Plus Strategy Counseling|Mothers of participants will receive counseling on the benefits of regular iron intake, side effects associated with IFA administration, and the preservation of the IFA bottle and MNP sachets.
46112722|NCT00830765|Drug|Progesterone (OHP17)|100mg of OHP17 or comparable amount of placebo administered by IM injection weekly until either 34 weeks' gestation or delivery has been achieved, whichever occurs first.
46112723|NCT00830765|Drug|Placebo|2cc of placebo liquid formulated by pharmacy personnel at the University of Mississippi Medical Center injected IM weekly until 34 weeks' gestation has been reached or delivery, whichever occurs first.
46112724|NCT04093206|Dietary Supplement|EpiCor and Vitamin C|One daily dose
46112725|NCT04093206|Dietary Supplement|Vitamin C|One daily dose
46112726|NCT00705887|Behavioral|Brief Motivational Enhancement Intervention|The motivational enhancement intervention lasted 5-8 minutes and consisted of gaining the client's permission to address the topic of skin cancer prevention, exchanging information through the elicit-provide-elicit strategy of information exchange, and summarization/ conclusion based on verbal and nonverbal cues from the participant.
46025561|NCT02757391|Drug|Cyclophosphamide|Given IV
46025562|NCT02757391|Other|Laboratory Biomarker Analysis|Correlative studies
46025563|NCT02757391|Biological|Pembrolizumab|Given IV
46025564|NCT05656404|Device|TorEx Lung Perfusion System|When donor lungs with clinical indication for EVLP are allocated to consented recipients, the lungs will be assessed using the second generation TorEx Lung Perfusion System rather than the first generation Toronto EVLP technique (standard of care).
46025565|NCT04564417|Biological|W0180|Participants will receive W0180 in a 21-day cycle.
46112727|NCT00830375|Drug|Memantine|10-30mg, by mouth, daily
46112728|NCT04094454|Device|special tampon with a diameter of 28mm|patients will use a special tampon with extended vaginal dilatation (diameter 28mm) during radiotherapy
46112729|NCT04094454|Device|standard tampon with a diameter of 12-13mm|patients in Arm B will use a normal commercially available tampon (diameter 12-13mm) during radiotherapy
46025566|NCT04564417|Drug|Pembrolizumab|Participants will receive Pembrolizumab 200 mg flat dose as IV infusion every three weeks (Q3W) in a 21-day cycle.
46025567|NCT02757157|Behavioral|Water-based walking|"Participants will walk in the water for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking in water, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured."
46112730|NCT00803270|Drug|Non-Surgical Intervention|Both oral urge incontinence medication and behavioral treatment
46025568|NCT02757157|Behavioral|Land-based walking|"Participants will walk on land for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking on land, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured."
46025569|NCT02757079|Drug|NPC-15|NPC-15, Melatonin granule 1 mg, 2 mg or 4 mg, once a day, is administered orally before going to bed for 26 weeks after a screening phase of 2 weeks with placebo administration.
46112731|NCT00803270|Procedure|Surgical|Initial surgical (stress incontinence surgery) treatment approach.
46112732|NCT00708539|Drug|progesterone|90 mg, vaginal, once daily
46112733|NCT00708539|Drug|Progesterone|200 mg, vaginal, three times daily used in Denmark, 400 mg, vaginal, three times daily used in Sweden
46025570|NCT04221217|Drug|Icosapent|Icosapent (MND-2119) capsules.
46025571|NCT02696161|Other|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
46025572|NCT02696161|Other|5% dextrose|Ultrasound-guided 3cc 5% dextrose injection between proximal carpal tunnel and median nerve.
45470031|NCT02839551|Procedure|simplified drug provocation test|Assessment of the Hypersensitivity to betalactams by simplified drug provocation test
46112734|NCT05516537|Behavioral|Guidelines for Exercise in Multiple Sclerosis (GEMS)|Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on aerobic fitness and muscle strength as a mode of training.
46112735|NCT05516537|Behavioral|FLEX Stretching and Toning Program|Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on stretching and range of motion as the mode of training.
46112736|NCT00751998|Device|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
46112737|NCT00914420|Device|Intrepide Trapidil eluting stent|"The INTREPIDE coronary stent system consists of a balloon expandable stent coated with two layers of Trapidil and parylene. The Trapidil eluting stent is pre-mounted on a Nimbus PCTA balloon and is intended for use in the treatment of CAD.~The controlled release of Trapidil is achieved through the parylene barrier, locally delivering the drug to the target lesion, inhibiting smooth muscle cell proliferation and hence neointimal hyperplasia."
45470032|NCT03392506|Device|EBUS-TBNA-RTE|Every patient will do CT、 PETCT and EBUS-TBNA-RTE.These three kind of examination will have their own result.The three methods of inspection will be compared by diagnostic rate
46025573|NCT02887560|Procedure|transoesophageal echocardiography|
46025574|NCT04220749|Radiation|Radiation|Standard of Care: Radiation +/- Chemotherapy
45470033|NCT05166772|Drug|Donafenib|200 mg BID，oral administration will start before the first HAIC treatment.
45470034|NCT05166772|Drug|Sintilimab|200 mg，Q3W，Intravenous infusion will performe before HAIC treatment.
45470035|NCT05166772|Other|HAIC|Q3W. The total number of HAIC treatments was determined by the investigator based on patient needs. Dose: Oxaliplatin 85 mg / m2 for 2h, Calcium folinate 400 mg / m2 for 2h, 5-FU 400 mg / m2 for 10min, followed by 5-FU 1200 mg / m2 for 23 hours);
45470036|NCT02818023|Drug|Pembrolizumab|"Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ). Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
46025575|NCT04220749|Procedure|Trans-Oral Surgery (TOS) + Neck Dissection|Trans-Oral Surgery (TOS) + Neck Dissection (plus radiation, if required)
46025576|NCT05655858|Other|Management of allergic rhinitis|Collection of patient data in real-life
46025577|NCT05655702|Other|Community based TB intervention|"3 bi-annual RDSS (RDSS1, 2 and 3), for TB screening~A PWID-specific Information and communication (I&C) TB module to improve PWID awareness about TB,~Peer group support to facilitate TB treatment initiation and retention,~Implementation of a peer support contact tracing and screening for active TB in contacts."
46025578|NCT02752321|Device|eDischarge|Patients will be enrolled in the eDischarge technology during their inpatient hospital stay. A completed electronic discharge packet (EDP) will be given to patients on the day of hospital discharge.
46025579|NCT02768389|Drug|Bevacizumab|Subjects receive Bevacizumab as standard of care
46112738|NCT00914420|Device|Taxus drug eluting stent|Paclitaxel Drug eluting stent manufactured by Boston Scientific
46112739|NCT04094532|Drug|Bupivacaine|Ultrasound guided 20 ml % 0.250 bupivacaine injection to transverse thoracic muscle plane bilaterally
46112740|NCT04094532|Drug|Saline|Ultrasound guided 20 ml % 0.9 saline injection to transverse thoracic muscle plane bilaterally
46112741|NCT00708773|Drug|Irinotecan|"90 minute IV infusion once every 3 weeks.~Dose will be based on sex and genotype determination."
46112742|NCT05758259|Drug|combination oral and topical vitamin D|combination vitamin D 2000 IU 1x1 and topical 7-Dehydrocholesterol 5000 mcg 2x1
45470037|NCT02818023|Drug|Vemurafenib|"Vemurafenib will be given at 480 mg twice daily, 720 mg twice daily, or 960 mg twice daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
46112743|NCT05758259|Drug|oral placebo and topical cholecalciferol|oral placebo and topical 7-Dehydrocholesterol 5000 mcg 2x1
46112744|NCT05758259|Drug|oral placebo and basic ingredient placebo topical vitamin D|oral placebo and basic ingredient placebo topical vitamin D similar to the ointment
46112745|NCT02607644|Device|Laryngeal Mask Airway (LMA)|Laryngeal Mask Airway (LMA) for Control group
46025580|NCT02768389|Behavioral|Modified Atkins Diet|The modified Atkins diet (MAD) includes high fat, unlimited protein, and restricted carbohydrates (< 20gm/day).
46025581|NCT05381766|Other|CSA model|Community-supported agriculture (CSA) involves a community of individuals who support a farm and in return receive distributions of the farm's produce throughout the growing season. Culturally appropriate produce will be provided in subsidized weekly boxes for 20 weeks to community members at Brooklyn Grange Farm in Sunset Park at a fee of $5, which was determined to be acceptable by community members. Participants that receive SNAP benefits can use their EBT card to cover their $5. Education will be offered in the form of nutrition education, cooking tutorials, and farming information provided by staff at Brooklyn Grange.
46112746|NCT02607644|Device|Laryngeal Tube (LT)|Laryngeal Tube (LT) for Intervention group
46112747|NCT02601066|Device|Electrophysiological Study and ECG holter monitor|Electrophysiological Study and ECG holter monitor implantation
46112748|NCT00803738|Drug|Terconazole Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
46112749|NCT00803738|Drug|Terazol Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
46112750|NCT00758706|Drug|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
46112751|NCT00758706|Drug|Placebo|Dosing to match AZD1236
45470038|NCT02818023|Drug|Cobimetinib|Cobimetinib will be given at 20 mg once daily, 40 mg once daily, or 60 mg once daily. Treatment with cobimetinib will commence on the same day. Cobimetinib will be given daily for 21 days, then held for 7 days.
46112752|NCT04097808|Dietary Supplement|collagen peptides|Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.
46112753|NCT00591266|Drug|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 40 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
46112754|NCT00591266|Drug|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 80 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
46112755|NCT00591266|Drug|Amlodipine|Azilsartan medoxomil placebo-matching tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
45470039|NCT04919161|Device|Body weight support system control group|The BWSS control group interventions consisted of various balance activities, including: marching, side-stepping, retro-ambulation, step-taps, and step-ups. The BWSS control group also practiced various gait tasks, including: ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions.
45470040|NCT04919161|Device|Body weight support system with balance perturbations|"The BWSS with balance perturbations group conducted the same balance and gait activities as the control group, including: marching, side-stepping, retro-ambulation, step-taps, step-ups, ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions.In addition, this arm will receive eight balance perturbations, two in each direction (lateral, anterior, and posterior) each session. BWSS-P participants will start at perturbation level one and progress up to level ten as appropriate. Each session, the perturbation level will be set based on the participant's progress."
45838727|NCT04366284|Other|External Facilitation Support|Clinicians will have full use of the NOCTEM platform and the NOCTEM team will provide external facilitation via bi-weekly consult or supervision teleconference, or via telephone. The NOCTEM team will also be available by email and text messaging on an as needed basis.
45838728|NCT04366284|Other|External and Internal Facilitation Support|Clinicians will have full use of the NOCTEM platform and external facilitation support. In addition to external facilitation by the NOCTEM team a local point of contact and coordinator will serve as a more proximal facilitator.
45838729|NCT04366128|Drug|CAPA indution immunotherapy|"Camelirumab 200mg Intravenous injection on day 1.~Apatinib 250mg taken orally once daily.~Pegaspargase 2000U/m2 Intramuscular injection on day 1."
46112756|NCT04094376|Other|receiving operation during the day or at night|eighty-four patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00) and the Night Group (18:00-22:00)
46112757|NCT04093128|Other|herbal tea intervention|herbal tea intervention for 7 weeks
46112758|NCT04093050|Drug|Vasostrict Injectable Product|Vasostrict® (vasopressin injection, USP)
46112759|NCT04092972|Other|Atherectomy|Straub Rotarex S atherectomy and drug-coated balloon DCB. Predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA).
46112760|NCT04092972|Other|POBA and DCB|Standard predilation (POBA) and DCB. Predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA).
46112761|NCT05450640|Other|satisfaction survey|1 eQuestionnaire per patient completed during study
46112762|NCT02601144|Device|Deep Brain Stimulation|Deep Brain Stimulation
46112763|NCT04093908|Other|Prediction of motor outcome after STN DBS based on preoperative variables|Generating individual probabilities for motor response based on preoperative variables
46025582|NCT04529005|Drug|Angiotensin II|If intraoperative or postoperative hypotension occurs (e.g. SBP < 120 mmHg) and the attending surgeon and/or attending anesthesiologist deems vasopressor therapy to be necessary, angiotensin II (Giapreza) will be the first vasopressor used for management.
45470041|NCT03402256|Behavioral|Text Message|In addition to the SC interventions, participants in the Text Message condition received text messages. Participants received 3 text messages per day for the first four weeks of the study and 3 messages per week for the last four weeks. Participants will receive messages targeting known predictors of alcohol abstinence and relapse, including (1) craving, (2) identification of high-risk situations, (3) identification of triggers, (4) stress level, (5) coping skills, and (5) quality of life. The text messages will include motivational messages and behavior-change techniques (e.g. coping with cravings and urges to drink, trigger identification, high-risk situation identification). Messages will encourage participants to continue with sobriety and focus on the success they have achieved so far.
46112764|NCT02599662|Radiation|10 Gy Low-KV IORT|: intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
46112765|NCT02599662|Radiation|15 Gy Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
46025583|NCT05357040|Drug|Nitrous oxide gas for inhalation|"60-minute sessions of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) or 25% nitrous oxide in oxygen (FiO2 0.75), administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide."
46112766|NCT02599662|Radiation|20 GY Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
46112767|NCT00758394|Drug|Fluoride|Brush two times a day for 4 days.
46112768|NCT00758394|Drug|Triclosan/Fluoride|Brush two times daily for 4 days
45470042|NCT03262389|Drug|Fludeoxyglucose PET CT|Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).
45470043|NCT03262389|Drug|Sodium Acetate C11 PET CT|Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).
46112769|NCT00758394|Drug|Triclosan/Fluoride|Brush twice daily for 4 days
46112770|NCT00758394|Drug|Triclosan/Fluoride|Brush twice daily for 4 days
46112771|NCT04092738|Behavioral|Walk@WorkApp-Diab|The intervention (Walk@WorkApp-Diab), based on an mHealth program, consists on replacing sedentary job tasks for active ones, during 13 weeks. The intervention group will download the mHealth program into their personal cellphones
46112772|NCT04450394|Drug|LY3209590|Administered SC
45470044|NCT03262389|Drug|Fludeoxyglucose PET MRI|Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).
45470045|NCT03262389|Drug|Sodium Acetate C11 PET MRI|Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).
45470046|NCT03400930|Other|Severe Acute Malnutrition|
45838730|NCT04365972|Behavioral|Attention Bias Modification (ABM)|A home-delivered version of ABM will be administered in this open trial. ABM will be comprised of 5 sessions with a variation of the dot-probe task in which the target probe always replaces the neutral stimuli to induce diversion of attention away from threat. This condition was found effective in reducing anxiety symptoms.
46112773|NCT04450394|Drug|Insulin Degludec|Administered SC
46112774|NCT00758160|Drug|OROS Methylphenidate|Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.
46112775|NCT05699564|Other|Early biomarker-based cardiological assessment|We will perform cardiac biomarker testing with NT-proBNP and hs-cTnT measurements on emergency department admission in all participants, regardless of randomization status. The results will be provided in the patient's EHR, regardless of randomization status. For patients randomized to the intervention group, we will provide a note in the patient's EHR that includes assessment of probability that myocardial injury or dysfunction are the underlying pathophysiology responsible for tachypnea, as evaluated by the cardiac biomarker algorithm of the study. We will inform on general recommendations for work up and treatment.
46112776|NCT02599740|Other|Natural fruit extract|Natural fruit extract consumed with rice
45470047|NCT04460313|Other|nasopharyngeal sample|Nasopharyngeal swabs from children with acute otitis media aged 6 to 24 months. The swabs were analyzed by the French National Reference Centre for Pneumococci.
45838731|NCT04366050|Drug|Ramipril 2.5 MG Oral Capsule|Include description or ramipril from protocol
45838732|NCT04366050|Drug|Placebo oral capsule|Placebo
46112777|NCT02599740|Other|Assumed active|Assumed key active consumed with rice
46025584|NCT05357040|Drug|Placebo|"60-minute sessions of inhaled oxygen-air mixture (FiO2 ≈0.3) to be administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide."
46112778|NCT02599740|Other|Placebo|Rice only
46112779|NCT02606552|Drug|Dabigatrain plus aspirin|Dabigatran (Pradaxa®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with atrial fibrillation. Aspirin is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop clopidogrel (maintain dabigatran + aspirin) at 3 months after PCI.
45470048|NCT04460313|Other|Stools collection or anorectal swab samples|For a subgroup of children stools samples or anorectal swab samples were collected for assessment of E. coli (ESBL) resistance
45470049|NCT04631536|Drug|Atorvastatin + L-arginine + Folic acid + Nicorandil + Nebivolol|active Comparator: Endothelial dysfunction protocol + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc). Treatment to be continued until 14 days or discharge/death whichever occurs first. It includes: Nebivolol 5 mg PO daily, Sigmart 10 mg PO twice daily, Atorvastatin 40 mg PO daily, Folic Acid 5 mg PO daily, L-arginine 1000 mg PO 3 times daily.
45470050|NCT04631536|Drug|Placebo|Placebo + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc)
46112780|NCT02606552|Drug|Dabigatrain plus clopidogrel|Clopidogrel is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop aspirin (maintain dabigatran + clopidogrel) at 3 months after PCI.
46112781|NCT02606552|Device|Amplazter Cardiac Plug (ACP)|Patients allocated to the intervention group should be received percutaneous closure of the LAA by use of the ACP device (St. Jude Medical, St Paul, MN, USA).
46112782|NCT04094220|Procedure|Lateral lumbar interbody fusion|LLIF is an indirect decompression technique, and does not directly remove the disc or osteophyte protruding into the spinal canal. Its decompression effect is not as thorough as traditional posterior decompression surgery. Usually, posterior decompression is required for patients who have unsuccessful indirect decompression.
45470051|NCT03758911|Other|Semi-structured Interview|
45681800|NCT03584620|Other|Pulmonary rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band"
45470052|NCT03262233|Combination Product|nicotine|
45470053|NCT03262233|Other|placebo|
45470054|NCT03261531|Device|Transcutaneous electrical nerve stimulation (TENS)|Participants will be treated before and after two meals of the day with T6 dermatomal electrical stimulation delivered by a TENS unit.
45470055|NCT04151290|Diagnostic Test|Cognoa ASD diagnostic device|Cognoa device is intended to aid healthcare providers in diagnosing Autism Spectrum Disorder (ASD)
45470056|NCT03400540|Diagnostic Test|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
46112783|NCT05695898|Drug|XmAb22841|Given intravenously (IV)
46112784|NCT05695898|Drug|XmAb23104|Given intravenously (IV)
46112785|NCT02852486|Drug|Pioglitazone|30 mg/day, orally, for 3 months, before imatinib discontinuation
46112786|NCT02852486|Other|imatinib discontinuation|imatinib discontinuation after 3 months of pioglitazone
46112787|NCT00757848|Drug|AZD9668|60 mg, oral tablet, twice daily for 28 days
46112788|NCT00757848|Drug|AZD9668 Placebo equivalent|Match placebo to 60 mg, oral tablet, twice daily for 28 days
46112789|NCT05695742|Other|Active Smoking|Being active smoker
46112790|NCT05695742|Other|Passive smoker|Being exposed to secondhand smoke
46112791|NCT05695742|Other|Non-smoker|Not being an active or passive smoker.
46112792|NCT02606396|Procedure|Cryotherapy|Cryotherapy employs thermal ablation to treat esophageal cancer and BE. Ablation is achieved by intracellular disruption and ischemia that is produced by freeze-thaw cycles using liquid nitrogen or carbon dioxide
46112793|NCT02606396|Procedure|Esophagogastroduodenoscopy (EGD)|EGD is a diagnostic procedure that allows the physician to diagnose and treat problems in the upper gastrointestinal (UGI) tract. The doctor uses a long, flexible, lighted tube called an endoscope.
46112794|NCT02606396|Procedure|Endoscopic ultrasound (EUS)|EUS is a procedure that allows a doctor to obtain images and information about the digestive tract and the surrounding tissue and organs, including the lungs. Ultrasound testing uses sound waves to make a picture of internal organs.
46112795|NCT02601222|Drug|Runzao zhiyang capsule|Runzao zhiyang capsule：4 pills each time, 3 times a day, oral. Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
46112796|NCT02601222|Drug|Runzaozhiyang capsule agent simulation|Runzaozhiyang capsule agent simulation：4 pills each time, 3 times a day, oral， Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
45470057|NCT04389333|Device|non-contact magnetically-controlled capsule endoscopy|The novel non-contact magnetically-controlled capsule endoscopy (MCE) system (Ankon Technologies, Wuhan, China) (Figure 1) added a remote control workstation and an audio-visual exchange system to the original well-establish MCE system, which consisted of a robotic magnetic arm, a workstation (currently bypassed) and a capsule endoscope.
46112797|NCT02601222|Drug|Urea cream|Topical application, apply to the affected area and gently rub, 2 times a day.Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
46112798|NCT02608736|Drug|Valproic Acid|Half of the participants will receive valproic acid orally for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in placebo arm.
46112799|NCT02608736|Drug|Placebo|The other half of the participants will receive placebo for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in valproic acid arm.
46112800|NCT04015986|Dietary Supplement|Microbiota Directed Complementary Food-2|MDCF prototype with four complimentary food ingredients without powdered milk (rationale: lead with evidence from the recently completed pre-POC clinical trial of promoting growth promoting microbiota and positive effects on growth
46025585|NCT05655390|Behavioral|Safety Intervention Planning|The therapy is based on the iFightDepression platform implemented by the European Alliance against Depression. The aim of this specific therapy is to help individuals to acquire strategies to regulate emotions and learn to tolerate discomfort preventing the imminent risk for suicidal behavior. The safety planning intervention will be conducted by identifying warning signs and provide each individual with personal and individualized coping strategies and sources of support. Main skills to be acquired and integrated for the individual are as it follows: 1) Contingency plan by five steps (identification of warning signs; applying internal coping strategies; network as distraction; safe environment; reasons for living and contact professionals), 2) Mindfulness, 3) Discomfort tolerance, and 4) Regulating emotions.
46112801|NCT04015986|Dietary Supplement|Ready to Use Supplementary Food|Rice-lentil based RUSF (rationale: reference standard of care for post-SAM, MAM; based on knowledge of its effects on child growth and the gut microbiota)
46112802|NCT05734898|Biological|NKG2D CAR-NK|Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion
46112803|NCT05424510|Drug|Ringer's Lactate|500 ml of Ringer's Lactate
46112804|NCT05424510|Other|IV line|Placing of an IV line before surgery
46112805|NCT02607566|Behavioral|Yoga|
46112806|NCT02607566|Behavioral|Standard Exercise Program|twice weekly aerobic exercise program, 60 minutes for 12 weeks
46112807|NCT02607410|Drug|sitagliptin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
45470058|NCT04099498|Behavioral|Online Program: Healthy Eating Promotion with Self-regulation|Online-Intervention group
45470059|NCT04099498|Behavioral|Enhanced Online Program: Healthy Eating Promotion with Self-regulation|Enhanced-online-Intervention Group
45470060|NCT05166538|Drug|Ticagrelor|direct-acting oral P2Y12-receptor antagonist
46025586|NCT00943072|Biological|VEGF Trap-Eye 2.0mg|Monthly intravitreal injection out to the Week 24 Primary endpoint
45470061|NCT05166538|Drug|Clopidogrel|platelet aggregation inhibitor
45470062|NCT03399916|Behavioral|Prompt sent|
45470063|NCT04055740|Device|IVUS Imaging|IVUS or radial-ICE (intracardiac echocardiography) is a visualization tool used in many cardiac procedures including electrophysiology procedures (catheter ablation). Its utility in identifying ILA will be assessed in this study.
45470064|NCT04459546|Behavioral|patient education, training booklet, 3 months tele health|Patient education includes general disease information, COPD self-management and symptom control. The education face-to-face and practical training was provided by the researcher. The training booklet was prepared by the researcher. The readability of the booklet was very easy and its comprehensibility was tested by pre-application. Tele monitoring was done by the researcher for support and motivation. The participants were called 4 times by phone.
45470065|NCT03399760|Biological|i-PRF|i-PRF (injectable platelet rich fibrin) assisted upper canine retraction
46025587|NCT00943072|Drug|Sham|Monthly sham intravitreal injection out to Week 24 Primary Endpoint
45470066|NCT03399760|Procedure|canine retraction|upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
45470067|NCT03392350|Behavioral|Physician Body Scan Consultation with Behavioral Intervention|The RENEW™ program consisted of 7 bi-monthly face-to-face web sessions over 16-18 weeks followed by an average of 15 monthly check-in sessions (maintenance) over 80 weeks.This included modules on responding to stress, enhancing effects of relaxation, nourishing theimmune system, physical activity, and social support.
45470068|NCT03395938|Behavioral|Proactive engagement|The engagements would include (1) a sealed envelope containing a cancer information sheet and an invitation letter directed towards siblings for them to contact the research team, (2) weekly phone reminders to the participants for a total of 4 weeks in a bid to remind participants of the need to convey the screening message to their siblings. The envelope will contain information on the various means for the siblings to contact the research team. These include communication means such as electronic mails (emails), telephone, hard copy returned mails through pre-paid envelopes, short messaging services (SMSs) or clinic consult.
46025588|NCT05655234|Behavioral|Music Breathing|"The MB programme consists of four stages: 1. Silent breathing for grounding (SB), 2. Music breathing for grounding (MBG), 3. Music breathing for modulation (MM), 4. Music breathing for working (MW).~After completing the silent breathing and music breathing practices, the participants will draw pictures of their body images of breathing space and centre. The form of the imagined breathing space expressed in the drawing and the meaning and content of the experience will be explored through a process facilitated by the therapist. The therapist's understanding of the participants' difficulties and progress will guide the next step, particularly the selection of music for the next sessions. The whole session takes about 2 hours. Weekly home practice is advised."
46112808|NCT02607410|Drug|NPH insulin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
45470069|NCT03395938|Behavioral|Current practice|This intervention depicts current practices by having the research team educate the participants on the Ministry of Health Singapore screening guidelines akin to counselling sessions carried out during the patient's clinical consultation. The research team would highlight that we would be happy to assist if necessary. The research team would then contact the patients in 4 weeks to check if they have communicated with their siblings and if they have gone for screening. We would also find out which method did they adopt to communicate with their siblings.
46025589|NCT05655234|Behavioral|Control condition|The control condition consists of 30-min mental health education programme with topics on stress management, music playing, and breathing exercise provided in the first and 6th weeks. A take-home kit which consists of the fact sheet information of the health talk and the video link of the breathing exercise and musical pieces will be provided to the participants after the first meeting. They are instructed to practice the breathing exercise and listening to the musical pieces at home.
46112809|NCT02599038|Dietary Supplement|Serine supplementation|Serine supplementation (200 mg/kg/day)
45838733|NCT04365894|Other|Transformative learning theory|According to the transformative learning theory, learning methods in education should include four activities as investigate, collaborative, higher-order thinking and interactive learning activities
45470070|NCT03260205|Drug|Placebo|Placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.
45470071|NCT03260205|Drug|SPD489 (Lisdexamfetamine dimesylate)|SPD489 capsule in a 5:5:5:5:6 ratio to 5, 10, 20, 30 mg orally once daily for 6 weeks.
45470072|NCT03260205|Drug|SPD489|SPD489
45838734|NCT04365816|Other|Interview|A survey was created, aiming to collect information about prior history of chronic disease, the Self-Evaluation of Food Intake, dysregulations (anosmia, ageusia...), anthropometric data, food data during and after hospitalisation, healthcare consumption since the discharge from hospital
45838735|NCT04365738|Other|Rehabilitation|Chest and diaphragm respiration, in-house mobilization, joint range of motion exercises was performed to the patients as breathing exercises.
45838736|NCT04365582|Drug|Azithromycin|500 mg day 1 ; 250 mg/day for 4 days
46112810|NCT05423964|Diagnostic Test|AI use in Endoscopy Room|The use of AI versus no AI in comparing the detection of adenomas during Endoscopy procedures.
46112811|NCT05423964|Other|Non-AI use Standard of Care endoscopy room|Non-AI use in comparing the detection of adenomas during Endoscopy procedures.
46112812|NCT05693090|Drug|Tipifarnib|Oral administration
46112813|NCT05693090|Drug|Osimertinib|Oral administration
45470073|NCT03395860|Drug|ATG|group A:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3 group B:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
45470074|NCT03399682|Diagnostic Test|cystography|observationnal study
45470075|NCT04666441|Drug|REGN10933+REGN10987 combination therapy|Administered IV or SC single dose
45838737|NCT04365582|Drug|Hydroxychloroquine|200 mg x 3/day for 10 days
45838738|NCT04365582|Drug|Lopinavir 200Mg/Ritonavir 50Mg Tab|400/100 mg (2 tablets) x 2/day for 15 days
46112814|NCT04092426|Other|opthalmologic examination|opthalmologic examination : Refraction Best corrected visual acuity Intraocular pressure Slit lamp examination
46112815|NCT05692466|Diagnostic Test|Comprehensive molecular panel test|Lab test
46112816|NCT05692466|Other|EORTC QLQ-30|Quality of life questionnaire
46112817|NCT05692388|Other|Patient and Community Stakeholder Interviews|Thirty in-depth face-to-face patient interviews, and ten in-depth structured stakeholder interviews will be conducted to explore and identify facilitators and barriers to self-care in African American adults with DKD experiencing MDA and living in the inner-city.
45838739|NCT04365270|Drug|Glass Ionomer|Glass ionomer filling material would be modified accordingly or used as is
46112818|NCT05692388|Other|Cross-sectional Study Participants|Three hundred African American adults with DKD experiencing MDA and living in the inner-city will be recruited to participate in a cross-sectional study. All participants will complete a one-time survey, and blood samples and blood pressure readings will be obtained to assess clinical outcomes.
46112819|NCT05692388|Other|Focus Groups and Intervention Mapping|A subsample of patient interview/cross-sectional study participants will be invited back to participate in four focus groups (five participants/group) to review components of the intervention, give feedback on appropriateness, feasibility, acceptability, and likelihood of having an impact based on their lived experiences.
46112820|NCT02598804|Other|5 educational workshop|
46112821|NCT02598804|Other|written information booklet|
45838740|NCT04365270|Drug|Chitosan Low Molecular Weight (20-200 Mpa.S)|deacetylated chitin, poly(D-glucosamine) purified by dissolving in 0.1 mol/L acetic acid, then precipitated in 0.1 mol/L sodium hydroxide and the precipitate will be washed with ethanol/water (70/30 v/v) mixture followed by freeze drying
45838741|NCT04365270|Drug|Chlorhexidine Diacetate|Chlorhexidine antibacterial effect to be compared by Sigma-aldrich PHR 1222 , lot#LRAB3716
45838742|NCT04365270|Drug|Titanium Dioxide|Titanium(IV) oxide,nanopowder, 21 nm primary particle size (TEM), >99.5% trace metals basis cat#718467 Lot#MKCB6332 Lot #MKCB6332
45838743|NCT04365504|Diagnostic Test|Dual energy X ray absorbtiometry|The primary clinical application of dual-energy x-ray absorptiometry (DXA or DEXA) is the measurement of bone mineral content (BMC, g) and bone mineral density (BMD, g/cm2) of the lumbar spine and proximal femur to assess risk for osteoporosis.
46112822|NCT00917202|Drug|Methylenblue|
46112823|NCT02606240|Device|CO2 removal with PRISMALUNG in ARDS|Observational study of patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS) submitted to Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device to allow ultraprotective mechanical ventilation with tidal volume reduction (from 6 to 4 ml/kg, predicted body weight) and plateau pressure reduction from 28-30 to 23-25 cmH2O.
46112824|NCT02600052|Other|PNF|RESPIRATORY PATTERN PROPRIOCEPTIVE NEUROMUSCULAR FACILITATION
46112825|NCT02600052|Device|treadmill|AEROBIC TRAINING
45470076|NCT04666441|Drug|Placebo|Administered IV or SC single dose to match
45470077|NCT03320850|Drug|OnabotulinumtoxinA and Hydrogel admixture|BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation
45838744|NCT04365192|Device|I-gel|"The i-gel airway is a supraglottic airway management device made of thermoplastic elastomer, which is soft, gel-like, and transparent.~The i-gel has evolved as a device that accurately positions itself over the laryngeal framework, providing a reliable perilaryngeal seal, and therefore no cuff inflation is necessary."
45838745|NCT04365192|Device|Self-pressurized air-Q|The self-pressured air-Q is a supraglottic airway management device The intracuff pressure of air-Q dynamically equilibrates with the airway pressure and adjusts to the patient's pharyngeal and periglottic anatomy, potentially providing improved airway fit and seal.
45838746|NCT04365426|Device|Mechanical stimulus|Electrical dynamometer to measure mechanical pressure
46025590|NCT02757001|Other|Inferior vena cava filter placement and retrieval|"There are really no interventions in this study. This is an prospective observational study of patients that have been implanted a inferior vena cava filter with intention to be retrieved.~Patients are recruited when the filter is implanted, and the investigators observe when is it finally retrieved, and if there is any complication at the retrieval of the filter."
46112826|NCT05754476|Other|Low-dose GBCA levels|MRI examinations for patients at two dose levels: low-dose (10% or 25%）can be chosen.
46112827|NCT05690516|Behavioral|Wearing face masks|Participants are asked to wear face masks in public spaces.
46112828|NCT02606318|Other|Adjusted the challenge-skill balance|In the first session of occupational therapy, the therapist assessed the client's problems in daily living using the Canadian Occupational Performance Measure. Based on the problems identified, an activity that could be supported in day care was selected. In the second session, the client performed the selected activity, and then the challenge and skill levels of the activity were evaluated. Based on these levels, adjustment of the challenge-skill balance in the activity was attempted. Occupational therapy consisted of 10 sessions of 20 minutes held over about 10 weeks
45838747|NCT04365426|Procedure|Thermal (cold) stimulus|Water cold bath
45838748|NCT04365426|Other|Oral contraceptive (OC)|Oral contraceptive (OC)
46025591|NCT04220515|Biological|Inactivated Poliomyelitis Vaccine Made From Sabin Strain|Type I D antigen 30DU;Type II D antigen 32DU;Type III D antigen 45 DU
46025592|NCT04222855|Drug|Diltiazem|Puerperal patients was administered (60 mg) orally every 8 hours with diltiazem (tables).
46025593|NCT00942994|Drug|Aliskiren/Amlodipine|"Amlodipine capsule (5 mg)~Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)"
46025594|NCT00942994|Drug|Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)|"Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)~HCTZ capsule (12.5 mg, 25mg)"
46025595|NCT02756767|Other|Survey|
46025596|NCT05658432|Other|Exercise via telehealth|Same as arm/group description
46025597|NCT05658432|Other|Exercise unsupervised|Same as arm/group description
46025598|NCT02761525|Other|silver nanoparticles|Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into an innocuous gel and dished in oral mucosa surface to then compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential.
46025599|NCT02761525|Other|placebo|Compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential using the same procedure to dished the gel.
46112829|NCT02606318|Other|Non-adjusted the challenge-skill balance|The first and second sessions were conducted in the same way as for the experimental group, except that the therapists were not informed of the client's subjective perception of the challenge and skill levels for the activity. From the third session, the therapists simply assessed the client's performance and conducted the therapy in the normal manner for the day care center, following the general guidelines for occupational therapy practice
46112830|NCT00751296|Drug|Lenalidomide|Subjects will receive lenalidomide, starting at 2.5 mg daily x 3 weeks (days 1-21) and escalating up to a target dose of 10 mg daily X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28 day cycle.Patients will be treated with lenalidomide until disease progression or 2 cycles past CR. (no maximum of cycles).
46112831|NCT04339166|Diagnostic Test|Non-invasive chromosome screening（NICS）|NICS is noninvasive chromosome screening approach to analysis the euploidy by free DNA in embryo culture medium
46112832|NCT04093830|Device|hearing aid|hearing aid can be used in their non- implanted ear with residual hearing
46112833|NCT05689658|Behavioral|Brazilian Diabetes Prevention Program|A Program structured in 7 visits (in group and individual) to guide the improvement of diet quality, self-care, and practice of physical activity
46112834|NCT05689658|Behavioral|Diet|Hypocaloric diet prescription
46112835|NCT04093518|Drug|Estradiol|2 transdermal patches to be changed twice a week for the duration of 16 weeks
46112836|NCT04093518|Drug|Placebo|2 transdermal patches to be changed twice a week for the duration of 16 weeks
46025600|NCT04317222|Device|eCRRT|"eCRRT was define as:~Initiated within the first 24 post-transplant hours;~High volume (35-50ml/kg) hemofiltration;~Continuous at least 12 hours per day for 3 days;~Standard treatment"
46025601|NCT04268602|Other|local anesthetic injection|1% lidocaine
46112837|NCT02606084|Drug|Esketamine|Participants will self-administer esketamine solution intranasally 28 milligram (mg) on Day 1.
46112838|NCT05733260|Behavioral|Exercise|10 weeks of resistance training.
46112839|NCT00751140|Procedure|Lymph Node Dissection|The lymph nodes will be sent to pathology for review.
46112840|NCT05732168|Diagnostic Test|A test battery for evaluation of muscle strength, balance and functional performance|Subjects with chronic ankle instability (CAI) were evaluated with five tests of strength, balance and functional performance.
46112841|NCT05754398|Behavioral|six independent and interconnected educational training sessions|"Each of the six components will be offered each month for six consecutive months. Each session will last approximately 30 to 40 minutes.~All the six sessions will be delivered through a face-to-face approach."
46112842|NCT02599272|Other|Rice with tomatoes and peeled aubergine (no spice)|Dose 0
46112843|NCT02599272|Other|Rice with vegetables and low spice|Dose 1, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, peeled aubergine, onion, ginger and garlic
46112844|NCT02599272|Other|Rice with vegetables and high spice|Dose 2, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, onion, ginger and garlic
46112845|NCT02607488|Drug|Placebo|"Participants will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight-IBW)]"
45470078|NCT03320850|Drug|Placebo and Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation
45838749|NCT04365426|Other|No oral contraceptive (No OC)|No oral contraceptive (No OC)
46112846|NCT02607488|Drug|Lidocaine 1%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight-IBW)]"
46112847|NCT02607488|Drug|Lidocaine 1.5%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1.5% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight-IBW)]"
46025602|NCT05658354|Other|Computerized cognitive program|BrainHQ was developed by Posit Science and includes computer-based brain-training exercises organized into six categories: Attention, Brain Speed, Memory, People Skills, Intelligence, and Navigation. Participants were instructed to perform a total of 24 sessions of computerized cognitive training at home, consisting of 45 minutes of training, twice per week, over a 3-month period.
45470079|NCT03923920|Procedure|Biopsy|During clinically-scheduled spinal stenosis surgery, ligamentum flavum tissue (which may contain surrounding tissue and subcutaneous fat) that is removed during the procedure will be sent to pathology to be analyzed with amyloid-specific staining.
46112848|NCT02607488|Drug|Lidocaine 2%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight-IBW)]"
45470080|NCT04447378|Drug|Fondaparinux 2.5Mg/0.5Ml Inj Syr|post natal thromboprophylaxis
45470081|NCT03125980|Drug|capecitabine plus oxaliplatin before and after surgery|"Subjects will receive systemic CapeOX chemotherapy both before and after the radical surgery for at most 4 cycles respectively. They shall have rest after the surgery for at least four weeks before the post-operative chemotherapy. CapOX regimen will be administered as follows:~Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~Repeat every 3 weeks (Q3W)"
46112849|NCT00914498|Drug|Local, pre-incisional injection of 20 ml 1% xylocaine|Local, pre-incisional injection of 20 ml 1% xylocaine
46112850|NCT02558582|Behavioral|respiratory and exercise therapy|The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
46025603|NCT02756455|Other|gastric cancer pts undergoing surgery|Measure PCT (procalcitonin), CRP (C-reactive protein) and WBC (white blood cell count) in 3rd and 5th postoperative day and registration of all intra and postoperative complications
46025604|NCT00942604|Drug|PEP005 (ingenol mebutate) Gel|two day treatment
46025605|NCT00942604|Drug|Vehicle gel|two day treatment
46025606|NCT04314336|Drug|Public procurement|Cost minimisation study through public procurement
46112851|NCT02558582|Behavioral|respiratory and exercise therapy with supplemental oxygen|"The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
46112852|NCT00914030|Other|Neuropsychological evaluation|Study one: global/local processing, with a neutral prime (stimulus influencing the processing of the subsequent stimulus)Study two: global/ local processing with a prime whose elements are collinear.Study three: global/local processing with a prime whose elements are not collinear
46112853|NCT02605850|Other|Water|All subjects will consume ground beef patty meal with water at the baseline visit.
46112854|NCT02605850|Dietary Supplement|Pomegranate Juice|Pomegranate Juice will be taken 1/day for 4 weeks.
46112855|NCT02605850|Dietary Supplement|Pomegranate extract|Pomegranate extract will be taken 1/day for 4 weeks.
45470082|NCT03125980|Drug|capecitabine plus oxaliplatin after surgery|"Subjects will first receive radical surgery, then have rest for at least four weeks. Thereafter, subjects will receive systemic CapeOX chemotherapy for at most 8 cycles. CapOX regimen will be administered as follows:~Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~Q3W"
45470083|NCT03529344|Dietary Supplement|Blue whiting protein hydrolysate|Dietary Supplement: Blue whiting protein hydrolysate 6g protein per day for 6wk
45470084|NCT03529344|Dietary Supplement|Placebo Comparator: Control|Control group will receive non-caloric juice without protein supplementation
45470085|NCT03399604|Drug|LIQ861 Inhaled Treprostinil|LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
46112856|NCT05754320|Device|Tension band wire fixation|Tension band wire fixation
46112857|NCT05754320|Device|Plate fixation|Tension band wire fixation
46112858|NCT00751881|Drug|Placebo|"Film-coated tablet~Oral administration"
46112859|NCT00751881|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
45470086|NCT04082520|Radiation|Gallium Ga 68-DOTATATE|Given IV
45470087|NCT04082520|Drug|Lutetium Lu 177 Dotatate|Given IV
45470088|NCT04082520|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
45470089|NCT04082520|Procedure|Positron Emission Tomography|Undergo PET/MRI
45470090|NCT04082520|Other|Quality-of-Life Assessment|Ancillary studies
46025607|NCT04314336|Drug|Drug and Therapeutics Committee|Cost minimisation analysis of results of the drug and therapeutics committee before and after clinical pharmacist involvement
46112860|NCT02386826|Drug|INC280|"Dose Escalation: INC280 by mouth (PO) twice daily for 28 days according to the following schedule until the maximum tolerated dose (MTD) is determined:~Dose Level 1 (starting dose): 200 mg (divided dose of 100 mg twice per day) Dose Level 2: 400 mg (divided dose of 200 mg twice per day) Dose Level 3: 800 mg (divided dose of 400 mg twice per day)~Dose Expansion: INC280 PO twice daily at the MTD determined in the dose escalation phase"
46112861|NCT02386826|Biological|bevacizumab|bevacizumab: 10 mg/kg IV every 2 weeks. Patients with unresectable GBM will be given 15 mg/kg IV every 4 weeks.
46112862|NCT00747474|Drug|Lipotecan|Lipotecan IV day 1, 8, 15
46112863|NCT04091802|Procedure|interdental papilla reconstruction with L-PRF|interdental papilla reconstruction with single layer of L-PRF versus multiple layers of L-PRF
46112864|NCT02598570|Drug|duvelisib|Duvelisib will be administered orally as a fixed dose in 28-day cycles.
46112865|NCT04089462|Behavioral|"Five sessions per period - Two sessions per period"|"Period 1: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)~Period 2: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)"
45838750|NCT04364724|Other|CT-based finite element analysis|"CTFEA is a computerized analysis of CT-scans which simulates stress testing of finite element models of various bones (in this study - femurs and vertebrae).~No intervention is planned - the study is observational. CT scans are performed for follow-up as an accepted standard of care. Secondary use of CT scans for CTFEA is in addition to the standard of care.~In a case when CTFEA analysis detects a high risk of pathologic fracture, the treating hematologist will be informed and will refer the patient for evaluation at the National Unit of Orthopedic Oncology."
46112866|NCT04089462|Behavioral|"Two sessions per period - Five sessions per period"|"Period 1: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)~Period 2: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)"
46112867|NCT02599779|Drug|Pembrolizumab|200mg given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria
46112868|NCT02599779|Radiation|Stereotactic Body Radiation Therapy|Dose and duration dependent on body site. In Arm A: SBRT given at the time of progression on pembrolizumab. In Arm B: SBRT given before the 2nd course of pembrolizumab.
46112869|NCT04093011|Procedure|Congenital Heart Disease Surgery|Patients with congenital heart disease will undergo congenital heart disease surgery.
46112870|NCT02597556|Drug|Albendazole|A single 400mg dose of Albendazole administered at 0, 3, 6, 9, and 12 months.
46112871|NCT02597556|Drug|Placebo|Matching placebo tablet administered at 0, 3, 6, and 9 months. At month 12, all participants will receive a single dose of 400mg Albendazole.
46112872|NCT02599857|Device|CONCOR smartphone application|
45838751|NCT04365036|Drug|Toripalimab|toripalimab 240mg, d1, intravenous drip
46112873|NCT04091958|Procedure|Pectoralis myo-glandular flap reconstruction.|Tumorectomy with surgical margin will be evaluated with frozen-section examination. Reconstruction starts with mobilization of skin flaps. The sternal head of the pectoralis major muscle will be disconnected from its insertion at the humerus. The muscle fibers will be mobilized off the chest wall. The pectoralis major receives dual blood supply. The pectoral branches of the thoraco-acromial artery enter the superior part of the muscle and the perforator branches of the internal mammary artery enter the medial part of the muscle. According to the location of the defect in the breast, the muscle will be mobilized based on one vascular pedicle. The muscle flap may consist of all or some segmental fibres of the sternal head of the pectoralis major muscle. In all cases, the muscle flap connection to the overlying breast parenchyma is kept intact and the clavicular head of the pectoralis major muscle is undisturbed. Closure of the cavity in layers over suction drain will follow.
46112874|NCT05406726|Dietary Supplement|palmitoylethanolamide|palmitoylethanolamide is an lipid based endocannabinoid naturally made by the body and is present in several common foods such as eggs
46112875|NCT05406726|Dietary Supplement|Placebo|a capsule filled only with maltodextrin will be used as a placebo
46112876|NCT02599623|Procedure|Local Anesthesia|Patients in LA group received the local infiltration technique. A mixture of 2% lidocaine 20ml and 0.9%NS 30ml was used as the local anesthetic. Patients required extra analgesia during the surgery were given 20-40mg parecoxib sodium intravenously. Conversion to GA was performed if LA was intolerant for patient, which was evaluated by both anesthetists and surgeons.
46112877|NCT02599623|Procedure|General Anesthesia|In group GA, anesthesia was induced with propofol 2mg/kg and fentanyl 0.1-0.2mg intravenously. Inhalation anesthesia was given at the same time with a mixture of oxygen and isoflurane 1-2% through an intubation.
46112878|NCT02599467|Other|ULNT 1 and EMG recording|While the ULNT 1 was performing, EMG muscle activity form biceps brachii and triceps brachii were recorded. The maneuver was stopped to measure abduction, external rotation and elbow flexion range of motion (ROM) with a goniometer. Three measurements were performed: measure 1) when the first sense of tightness perceived by the subject appeared; measure 2) when evoked muscle activity increased on EMG record; measure 3) when sense of final resistance perceived by the investigator appeared. Considering the increase of symptoms with contralateral or decrease of symptoms with ipsilateral cervical side bending as mandatory positivity criterion.
45838752|NCT04365036|Drug|Pegaspargase|pegaspargase, 2000U/m2, d1, intravenous drip
45838753|NCT04365036|Drug|Gemcitabine|gemcitabine, 1000mg/m2, d1,d8, intravenous drip
45838754|NCT04365036|Drug|Oxaliplatin|oxaliplatin, 130mg/m2, d1, intravenous drip,
45838755|NCT04365036|Radiation|Definitive intensity-modulated radiotherapy (IMRT)|Definitive intensity-modulated radiotherapy (IMRT) of 54-56Gy will be given in 25~26 days
46025608|NCT02756221|Dietary Supplement|Probiotics|One capsule per day for 90 days. Containing 8 x 109 CFU of bacteria /capsule Lactobacillus heleveticus Lafti L10 Bifidobacterium animalis ssp lactis Lafti B94 Enterococcus faecium Rosell-26 Bifidobacterium longum RO175 Bacillus subtills Rosell-179 Inactive ingredients: potato starch, magnesium stearate, ascorbic acid White vegetable capsule size 1
46025609|NCT02756221|Other|Placebo|Placebo capsules identical in shape and color to the probiotics capsules, one capsule per day for 90 days
46112879|NCT00916968|Device|Standard CR-Flex total knee|total knee implant used for joint replacement surgery of the knee
46112880|NCT00916968|Device|Gender specific CR-Flex|TKA by Gender specific Nexgen CR-Flex
46112881|NCT02599389|Device|Drug-coated balloons|
46112882|NCT02599389|Device|Excimer Laser|
46112883|NCT04019886|Other|Neurophysiological Facilitation of Respiration|Six neuro-facilitation techniques will be given to experimental group. Each technique will be given for 5 seconds hold with 5 repetitions and two sets.
46112884|NCT02597400|Drug|Metformin|"Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;~Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals"
46112885|NCT02597400|Drug|HMS5552|"Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;~HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals."
46112886|NCT00830063|Biological|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
46112887|NCT00830063|Biological|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
45838756|NCT04364490|Device|Copernicus noVF|Advanced gait training sessions by the computerized BWS system, named Copernicus®, without visual feedback.
45838757|NCT04364490|Device|Copernicis VF-Plus|Advanced gait training session with the addition of visual feedback ensuring a real-time interactive control of locomotor performance.
45838758|NCT04364490|Other|Control group|Usual care
45838759|NCT04363944|Device|mRehab|mRehab (mobile Rehab) was created to better support in-home upper limb rehabilitation programs. It incorporates a task-oriented approach and immediate performance-based feedback. mRehab consists of 3D-printed household items (a mug, bowl, key, and doorknob) integrated with a smartphone and an app. The app guides participants through practice of activities of daily living (ADL), for example, sipping from a mug. It can also consistently measure time to complete an activity and quality of movement (smoothness/accuracy) during the performance of ADLs. In each session of exercise participants receive feedback on the number of repetitions they complete for each activity, the average time to complete the activity and the average smoothness to perform the activity. Participants were trained in use of mRehab in lab visits and then took mRehab home to use the system. mRehab recorded longitudinal data.
45838760|NCT04364022|Drug|Lopinavir/ritonavir|2x 200mg/50mg, twice daily for 5 days (bid, PO)
45838761|NCT04363710|Other|Low Calorie Diet|800-1000 Kcal/day
45838762|NCT04363866|Drug|Hydroxychloroquine|Hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes than the parent compound, chloroquine. These characteristics result in hydroxychloroquine having a longer half-life, comparatively lower toxicity to chloroquine, as well as fewer concerns pertaining to drug-drug interactions
45838763|NCT04363866|Drug|Placebo|A placebo is a pill that looks like the study drug but has no real medicine in it.
46025610|NCT00624702|Drug|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
46025611|NCT00624702|Drug|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
46112888|NCT00830063|Drug|naproxen|naproxen 1000 mg daily for 16 weeks
46112889|NCT00830063|Other|placebo|placebo to match tanezumab and naproxen dosing
46112890|NCT02599233|Other|Telephone conctact at 3 months|Patients will be contacted at 3 months post-surgery for pain questionnaires.
46112891|NCT02599233|Other|In hospital pain evaluation|Patients will evaluate their pain levels via a verbal numerical scale on days 1(or-1), 2, 3, 4, 5, 6 & 7.
46112892|NCT02599233|Other|In hospital questionnaires|Patients are required to fill out the HADS and PCS questionnaires between on day -1 or +1.
46112893|NCT04092621|Drug|Amiodarone in Parenteral Dosage Form|Amiodarone IV
46112894|NCT04092621|Drug|Amiodarone Pill|Amiodarone tablet
46112895|NCT04092621|Procedure|Direct Current Cardioversion (DCC)|Convert arrhythmia back to sinus rhythm
46112896|NCT04092621|Drug|Rate-control therapy|one or combination of the following: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin
46112897|NCT00750438|Dietary Supplement|Propionate ester|The subject will take propionate ester at the dose specified by the dose finding study, three times a day for 24 weeks
46112898|NCT00750438|Dietary Supplement|Inulin|The subjects in this group will take inulin at a comparable dose, three times a day for 24 weeks
46112899|NCT00750438|Dietary Supplement|Cellulose|The subjects in this group will take the non fermentable carbohydrate, cellulose, at a comparable dose for 24 weeks.
46112900|NCT04092699|Device|semiautomatic software|semiautomatic segmentation is as accurate as the direct volume of maxillary sinus and as well as the manual segmentation.
46112901|NCT04092465|Procedure|Pulmonary parenchyma resection, lobectomy, pneumonectomy, sleeve lobectomy, extended lobectomy/pneumonectomy|Resection of the downstaged locally advanced NSCLC through formal thoracotomy
46112902|NCT00586326|Device|MammoSite Radiation Therapy System|The MammoSite is a balloon catheter that is designed to position a radioactive source inside the lumpectomy cavity. The MammoSite applicator is inserted into the cavity created by the tumor removal surgery. The MammoSite applicator is then inflated and expands to fill the cavity.
45681801|NCT05703178|Behavioral|Online Pain Coping Skills Training|The intervention is completed online, using a personal computer, tablet computer, or smartphone. It includes 8 interactive sessions, each of which teaches users a different pain coping skill. Participants are asked to practice these skills in their daily lives to manage pain and pain-related symptoms and problems. Each session takes 35 to 45 minutes to complete. Participants can take breaks during the sessions and review them at any time after completing them.
46025612|NCT00624702|Drug|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
46025613|NCT00624702|Drug|Placebo|
46025614|NCT02857192|Biological|Blood samples|
46112903|NCT00751101|Drug|Nicotine patch|Nicotine patch applied prior to and concurrently with capecitabine chemotherapy or beginning during the first course of capecitabine after the onset of hand-foot syndrome symptoms
46112904|NCT00750204|Device|APRV|"APRV Protocol~Set fraction of inspired oxygen (FiO2) at 0.1 higher than the setting on conventional MV currently used~Tlow = 1.0 second (this setting shall remain unchanged throughout the trial).~Respiratory rate (RR) to equal 60-65% of RR on conventional MV.~P high = the inspiratory plateau pressure. Maximum P high = 30 cm H20.~Plow = 5 cm water (H2O). Adjust Plow to achieve pressure release volumes 5.5-6.5 ml/kg of percent body weight (PBW).~If release volumes on APRV are greater than desired, increase Plow by 2-4 cm H2O increments to a maximum of Plow = 12 cm H2O. If release volumes are larger than desired despite raising Plow to 12 cm H20, decrease P high in increments of 2-4 cm H20 to achieve desired release volumes (minimum P high = 12 cm H20). If release volumes on APRV still remain larger than desired,the participant will be excluded from the study and placed on conventional MV."
46112905|NCT00750204|Device|Conventional MV|Low tidal-volume mechanical ventilation
46025615|NCT02756377|Drug|cetylpyridinium chloride mouthwash|cetylpyridinium chloride mouthwash, 10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
46112906|NCT04092309|Drug|ACE inhibitor, Sacubitril-Valsartan|Search for Protective effect after chemotherapy and bone marrow transplantation
46025616|NCT02756377|Drug|Chlorhexidine mouthwash|Chlorhexidine mouthwash,10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
46025617|NCT02852824|Drug|BI 655130|
46025618|NCT02852824|Drug|Placebo|
45470091|NCT04082520|Other|Questionnaire Administration|Ancillary studies
46025619|NCT02752009|Procedure|Axillary Lymph Node Sampling Clip|
46025620|NCT02199184|Drug|Cyclophosphamide|Given IV
46025621|NCT02199184|Drug|Doxorubicin Hydrochloride|Given IV
46025622|NCT02199184|Drug|Etoposide|Given IV
46025623|NCT02199184|Biological|Ofatumumab|Given IV
46025624|NCT02199184|Drug|Prednisone|Given PO
46112907|NCT02598414|Procedure|Near-infrared ICG fluorescence imaging|Patient will have their bowel anastomosis assessed intraoperatively by near-infrared technology after indocyanine green has been injected intravenously at a concentration of 2.5 mg/ml. This procedure will be repeated twice during surgery, the first time before and the second time after the anastomosis has been done. The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
45470092|NCT04447066|Other|No intervention|No intervention - VHIT will be used but without intervention
46025625|NCT02199184|Biological|Rituximab|Given IV
46025626|NCT02199184|Drug|Vincristine Sulfate|Given IV
45470093|NCT03301623|Other|Clinical Decision Support|The CDS intervention will test the use of existing guideline-based EHR alerts related to the prescription of opioids. CDS alerts employ computer algorithms that account for patient characteristics and diagnoses to deliver reminders of appropriate use when a provider enters an order for a medication.
46112908|NCT02598414|Procedure|Traditional bowel anastomosis|Traditional bowel anastomosis will be performed without ICG fluorescence imaging.
46112909|NCT02598414|Device|FireFly™|The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
46112910|NCT04020003|Drug|Levosimendan|General treatment group: control the infection, remove or control the original disease, mechanical ventilation, small tidal volume, high PEEP mechanical ventilation strategy, strictly control the capacity, strengthen the airway management, timely nutrition support and intensive rehabilitation treatment. Levosimendan group: on the basis of routine group treatment, 12.5 mg of levosimendan 5% GS 50ml was given on the same day, and the micro-pump was continuously pumped for 24 hours. The initial dose was 0.5 ml/ h, and if the blood pressure was not significantly decreased, the blood pressure was gradually increased to 2.4 ml/ h at the maximum dose, until the pump was over. The above treatment is repeated every 7 days until the offline success or the patient leaves the ICU.
46112911|NCT03977142|Diagnostic Test|Radical 7 Masimo Hemoglobin pulse co-oximeter non invasive monitor|Measure hemoglobin levels non invasively by pulse co-oximeter
45470094|NCT03301623|Other|Patient Education and Activation Tools|"The patient education materials selected for this study: Pain Management: Which Treatment is Right for You, Preparing for Your Health Care Visit, and a video from the American Chronic Pain Association (ACPA) named A Car with Four Flat Tires, which helps to give patients a better understanding of how multi-modal treatment can be more effective than relying on one source of treatment (e.g., pain medication)."
45838764|NCT04363788|Procedure|double gloves|The study was based on dying gloves used during resuscitation. The gloves were secured with disposable hermetically sealed pouches and described by one of the EMS team members - each time after resuscitation was completed.
46112912|NCT04091334|Device|Focused ultrasound of the lungs (FLUS) and focused cardiac ultrasound (FoCUS)|"FLUS: Scanning 8 zones of the front and lateral of the thorax. Record number of B-lines, consolidations, pneumothorax, pleural effusions.~FoCUS: Scan the heart in different views and record the ejection fraction, size of the right side of the heart, pericardial effusion, tricuspid annular plane systolic excursion (TAPSE), inferior vena cava (IVC) diameter, and IVC collapsibility Index (IVC-CI)."
46112913|NCT04091334|Other|Standard care|Standard care and evaluation and monitoring
46112914|NCT00751023|Drug|Modafinil|400 mg daily for four weeks
46112915|NCT00751023|Drug|Placebo|Placebo 2 tablets daily for 4 weeks
46112916|NCT00917592|Drug|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid 1 gr every 8 hours 48 hours followed by oral amoxicillin plus clavulanic acid 1 gr every 8 hours for 10 days
45470095|NCT03399526|Drug|Mapracorat (ZK 245186, BAY 86-5319)|0.1% (1 mg/g) of the active ingredient mapracorat plus excipients as ointment
46025627|NCT05658198|Behavioral|Counseling|Patients who first decline HPV vaccination receive a 3-5 minute counseling session on HPV and the benefits of the vaccine.
46025628|NCT04220437|Other|no interventin|Our stusy analysed the images obtained from ISR patients, no extra intervention was given based on this study.
46025629|NCT05378100|Drug|Ketamine|Infusion of ketamine 0.5 mg/kg over 40 minutes
46025630|NCT05378100|Drug|Midazolam|Infusion of midazolam 0.05 mg/kg over 40 minutes
46025631|NCT02752477|Drug|Opioid-free general anesthetic|An opioid-free general anesthetic technique utilizing dexmedetomidine, ketamine, and lidocaine infusions
46025632|NCT02752477|Drug|Traditional general anesthetic|Traditional general anesthetic technique utilizing sufentanil, fentanyl or remifentanil
46025633|NCT02761681|Behavioral|ACT-CL Web-based guided self-help|
46025634|NCT02761681|Behavioral|Control Web-based guided self-help|
46112917|NCT00917592|Drug|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid for 7 days followed by oral antibiotic for 5 days
46112918|NCT04092231|Behavioral|Early speech perception test|The early speech test is one of the closed-set response speech discrimination tests,using object identification technique.It was carefully designed for estimation of speech perception abilities in very young children who have extremely low verbal abilities
46112919|NCT04091412|Drug|Butylphthalide Soft Capsules|The first class national new drug for the Treatment of Mild to Moderate Acute Ischemic Stroke; Long-term application can improve collateral circulation.
46112920|NCT04092075|Device|RF-utilizing powered toothbrush|RF-utilizing Powered toothbrush
46112921|NCT04092075|Device|Control placebo with no RF|Placebo control, toothbrush with no RF
46112922|NCT02599311|Device|transvaginal synthetic mesh|transvaginal synthetic mesh
46112923|NCT02599311|Drug|Tolterodine|Tolterodine tartrate can improve patients' LUTS.
46112924|NCT00591773|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily; and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
46112925|NCT00591773|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg, tablets, orally, once daily; azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
46112926|NCT00591773|Drug|Chlorthalidone|Chlorthalidone 25 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily and azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
46112927|NCT04091919|Diagnostic Test|2D- Transthoracic Echocardiography (TTE)|2D- Transthoracic Echocardiography (TTE) derived Tissue Doppler and Strain imaging
46112928|NCT04091997|Diagnostic Test|serum Eliza assay|laparoscopy and biopsy of lesions in endometriotic patients and seum ELIZA assay of microphage migration inhibitory factor
46112929|NCT00750867|Drug|intravenous immunoglobulin (IVIg)|The intravenous immunoglobulin (brand Privigen) will be infused intravenously, monthly, 6 times, for 6 months the dose will be 0.4 gram/kg for each infusion.
46112930|NCT04091841|Drug|protein supplement|Three sachet of protein supplement to be mixed in with water used daily.
46112931|NCT04091841|Other|Carbo Mass|Three sachet of Carbo Mass supplement to be mixed in with water used daily.
46112932|NCT00744042|Biological|asfotase alfa|
46112933|NCT04091763|Drug|Polidocanol Injectable Foam|"Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery."
45470096|NCT03399526|Drug|Prednicarbate 0.25% ointment|0.25% (2.5 mg/g) of the active ingredient prednicarbate as ointment
46025635|NCT04220593|Other|tDCS associated with Tcog|2mA-intensity aETCC will be applied to the left dorsolateral prefrontal cortex (CPFDL) region for 20 min, three times a week (every other day) over a one-month period, totaling 12 sessions. In each session activities aimed at stimulating cognition will be applied over the 20 minutes.
46025636|NCT04204096|Biological|Vi-DT (Multi-dose formulation)|"Manufacturer: SK bioscience Co., Ltd.~Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (multi dose Vi-DT with preservative 2 PE)~Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2 to 45 years~Storage Conditions: +2 to +8°C"
46025637|NCT04204096|Biological|Vi-DT (Single dose formulation)|"Manufacturer: SK bioscience Co., Ltd.~Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (single dose Vi-DT without any preservative)~Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2-45 years~Storage Conditions: +2 to +8°C"
46112934|NCT04091763|Device|Rubber band ligation|"Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery."
46112935|NCT00829829|Other|Placebo|Placebo loading dose followed by placebo injections (2 mL) qw for 16 weeks.
46112936|NCT00829829|Drug|Rilonacept 80 mg|Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 16 weeks.
46112937|NCT00829829|Drug|Rilonacept 160 mg|Rilonacept 320 mg loading dose followed by Rilonacept 160 mg/2 mL injections qw for 16 weeks.
45470097|NCT03399526|Drug|Clobetasol 0.05% ointment|0.05% (0.5 mg/g) of the active ingredient clobetasol as ointment
45838765|NCT04363554|Other|Fluid intake|The participants will intake fluid
45838766|NCT04363554|Other|Thirsting|The participants will thirst
45681802|NCT05703178|Other|Education|Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects.
45838767|NCT04363476|Other|SHRED Osteoarthritis program|Combined exercise and education intervention
45838768|NCT04363086|Behavioral|iFightDepression online self-help tool|Computerized cognitive behavior therapy
45838769|NCT04363086|Behavioral|Treatment as Usual|TAU
46025638|NCT04204096|Biological|Control Vaccine|"For participant ≥ 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered~For participants 6 months to 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered during the study and the next dose will be provided after the study unblinding at the completion of 6 months follow up of last subject."
46025639|NCT05376852|Combination Product|based decitabine and olverembatinib（HQP1351)chemotherapy|"AP-CML treated with decitabine 10mg/m2 d1-5 intravenously (IV) over 60 minutes on days 1-5 and HQP1351 40mg qod every 28 days.After completion of HQP1351 lead-in, patients will receive HQP1351 PO qod on days 1-28 of subsequent cycles.~BC-CML:treated with decitabine 20mg/m2 d1-5 IV on days 1-5 and HQP1351 40mg qod every 28 days,with or without other chemotherapy Drugs"
46025640|NCT02756143|Behavioral|Exercise|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
46025641|NCT05657730|Dietary Supplement|Water Kefir beverage|Participants will consume the water kefir beverage for two weeks.
46112938|NCT04092036|Device|Optic Nerve Sheath Diameter (ONSD) measurement by ultrasound|"ONSD measurements will be performed in the supine patient. Ultrasound gel will be applied over the closed upper eyelid. The ultrasound probe will be placed on the temporal area of the eyelid. Then the probe will be angled in order to display the entry of the optic nerve into the globe.~ONSD will be measured 3 mm behind the globe in the transverse plane perpendicular to the optic nerve. For each optic nerve three measurements will be made. The ONSD corresponds to the mean of the six values which will be obtained from each patient (three measurements for each eye)."
46112939|NCT04091529|Device|RADIOFREQUENCY ABLATION OF UTERINE MYOMAS|The ablation device consisted of an radiofrequency (RF) energy generator (STARmed, RF generator VRS01) and an electric pump for the continuous cooling of the electrode tip. The RF generator to which the electrode (STARmed Gyeonggi-Do, Korea) is connected displays simultaneously the temperature of the electrode tip, the tissue impedance characteristics, the power and the ablation time. A 35 cm long 18Gauge internally cooled electrode with an exposed tip of 10 mm or a variable exposed tip was used
46112940|NCT02599155|Drug|Crystalloid|normal saline administration for volume expansion in hypovolemic status
45681803|NCT03587038|Drug|OKN 007|400 mg OKN-007/mL in a phosphate buffer
45681804|NCT03587038|Drug|Temozolomide|75 mg/m2
45681805|NCT03587038|Radiation|Photon/Proton IMRT|standard of care treatment to be given 1 to 2 hours after OKN-007
45681806|NCT03582124|Procedure|Near-Infrared Fluorescence Imaging|Undergo imaging
45681807|NCT03582124|Drug|Panitumumab-IRDye800|Given IV
45681808|NCT03582124|Other|Pharmacokinetic Study|Correlative studies
46025642|NCT02756299|Other|Educational Support|General information about OSA and PAP treatment at baseline and additional polysomnography chart viewing from both diagnostic and titration nights
46025643|NCT02756299|Other|Standard Support|General information about OSA and PAP treatment at baseline
46025644|NCT05657574|Drug|D377|oral, once daily, 8 weeks
46025645|NCT05657574|Drug|CKD-331|oral, once daily, 8 weeks
46025646|NCT05657574|Drug|D086|oral, once daily, 8 weeks
46025647|NCT05657574|Drug|Placebo (for D377)|oral, once daily, 8 weeks
46025648|NCT05657574|Drug|Placebo (for CKD-331)|oral, once daily, 8 weeks
46025649|NCT05657574|Drug|Placebo (for D086)|oral, once daily, 8 weeks
46112941|NCT02599155|Drug|Colloid|HES 130/0.4 administration for volume expansion in hypovolemic status
46112942|NCT00823199|Drug|Allopurinal|300mg once daily by mouth for four weeks
45681809|NCT03582124|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45681810|NCT03584308|Dietary Supplement|Viusid®|The VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner.
45681811|NCT03584308|Dietary Supplement|Glizigen®|The GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
45838770|NCT04363086|Behavioral|phone call|phone call
45838771|NCT04363398|Other|Comprehensive Follow-up|Trained research staff members will provide weekly support to coaches on the NMT warm-up.
45838772|NCT04363398|Other|Standard Follow-up|Research staff will monitor teams weekly, however no additional support for warm-up will be provided.
46112943|NCT04091373|Combination Product|cotadutide multidose pen injection|SC injection in the upper arm
46112944|NCT04091373|Combination Product|cotadutide multidose pen injection|SC injection in the lower abdomen
45681812|NCT03584308|Dietary Supplement|Viusid Placebo|The placebo of VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner .
46112945|NCT04091373|Combination Product|cotadutide multidose pen injection|SC injection in the thigh
46112946|NCT02611583|Device|TENS|Transcutaneous Electrical Nerve Stimulation
46112947|NCT00829439|Drug|Levodopa/Carbidopa (4:1)|"Dosages are based on levodopa.~Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
45470098|NCT03399526|Drug|Calcipotriene 0.005% ointment|0.005% (0.05 mg/g) of the active ingredient calcipotriene as ointment
46112948|NCT00749775|Drug|Selara|Treatment should be initiated at 25 mg once daily and titrated to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. Selara may be administered with or without food.
46112949|NCT00705965|Behavioral|Psychotherapy|Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
46112950|NCT00705965|Behavioral|Information session|One information session about living with heart disease.
45470099|NCT03399526|Drug|Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment|0.005% (0.05 mg/g) of the active ingredient calcipotriene/0.05% (0.5 mg/g) of the active ingredient betamethasone dipropionate as ointment
45470100|NCT03392272|Device|Using of Tisseel fibrin glue|Using of Tisseel fibrin glue instead of sutures in Müller's Muscle-Conjunctival Resection (MMCR) surgeries
45470101|NCT03392272|Other|Using sutures|Using sutures in Müller's Muscle-Conjunctival Resection (MMCR) surgeries
45470102|NCT03756493|Procedure|Periodontal Surgery with OFD+ABG+L-PRF|Patients will be treated by periodontal surgical flaps with the addition of L-PRF+ Autogenous Bone Graft filling material.
45470103|NCT03756493|Procedure|Periodontal Surgery with OFD+ABG|Patients will be treated by periodontal surgical flaps with the addition of Autogenous Bone Graft filling material.
45470104|NCT03756493|Procedure|Periodontal Surgery OFD|Patients will be treated by Open Flap Debridement without use of filling material.
45470105|NCT03319212|Device|senofilcon A contact lenses|Senofilcon A Daily Disposable Contact Lenses
45470106|NCT03392116|Biological|NGM120|Subcutaneous Injection
45470107|NCT03392116|Other|Placebo|Subcutaneous Injection
45470108|NCT03756415|Device|"DiMax Zero Total face mask R,"|a non-CO2 rebreathing device included directly in the full face mask
45470109|NCT03756415|Device|traditional face mask|a traditional mask without a non-CO2 rebreathing device included directly in the full face mask
46025650|NCT02761447|Other|Treatment Traditional and Imaginary Motor Program|Amputees patients also conservative protocol will undergo physiotherapy techniques work Imaginary Motor. The first video will include two sequences of a harmonic gear that will allow the patient to examine, with the physiotherapist, the characteristics of the different body segments involved in locomotion and place the member in space. The second video include an analysis in five phases: a) relaxation of Benson, b) phase external imagination where cycles of normal running on a video provided by the physiotherapist, c) phase internal imagination where the patient will identify the problem discussed compared with the normal course presented in the video, d) recreation of images in the first person made an e normalized locomotion) closing his eyes, prompted the patient to mentally recreate sequences normal gait and analyzed and subsequently verbalize differences of these with respect to their own way of getting around.
46112951|NCT00705965|Other|Usual cardiological care|Usual cardiological care
46112952|NCT05758103|Dietary Supplement|Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains)|Non-surgical professional mechanical debridement and probiotic supplement Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains)
46112953|NCT02599077|Drug|Dienogest|patients assigned to this treatment receive 2 milligrams per day
45470110|NCT03905902|Biological|DCVAC/OvCa|activated autologous dendritic cells
45470111|NCT03905902|Biological|DCVAC/OvCa placebo|placebo for activated autologous cells
45470112|NCT03638310|Procedure|intratympanic application of gentamicin|under local anesthesia is gentamicin instilled through tympanic membrane to tympanic cavity
46112954|NCT02599077|Drug|Levonorgestrel|patients assigned to this treatment receive (0.10 mg levonorgestrel + ethinyl estradiol - 0.02 milligrams daily)
46112955|NCT00829283|Behavioral|Behavioral Weight Loss|weekly individual sessions for 6 months
46112956|NCT00829283|Behavioral|Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy|weekly BWL sessions for 4 weeks and 6-8 CBT sessions for 5 months
46112957|NCT00829283|Drug|Placebo|One pill daily
45470113|NCT03638310|Procedure|microsurgical removal of vestibular schwannoma|surgery under general anesthesia
45470114|NCT04656691|Drug|bamlanivimab|Participants that test positive for COVID-19 may be eligible to receive an in-home infusion of bamlanivimab by a registered nurse. This infusion will last approximately 1 hour followed by 1 hour of observation.
45470115|NCT04016532|Dietary Supplement|Personalized dietary management at home|"Personalized dietary management at home to improve nutritional status.~Four (J7, J30, J60 and J90 for non-undernutrition patients) or five Home visits (J7, J15, J30 and J90 for undernutrition patients or at risk of undernutrition) by professional dietitians from Saveurs & Vie over a period of 3 months after discharge from the hospital: personalized dietary advice and recipe sheet.~There will be no change in medical prescriptions"
45470116|NCT02520232|Behavioral|Combination of aerobic and strength exercises|Combination of aerobic and strength exercises
46025651|NCT02761447|Other|Treatment Traditional and Mirror Therapy|Amputees patients also conservative protocol will undergo physiotherapy techniques mirror therapy work. The protocol will consist of mirror therapy sessions three days a week (25-30 minutes) for a month, where participants will move the intact limb looking in the mirror and imagining the movement of the limb with phantom sensation.
46025652|NCT00061282|Drug|Clotrimazole|One retention enema, administered nightly
46025653|NCT05657496|Drug|Triamcinolone Acetonide 40 mg/ml Inj, Susp|Prepared in clinic by physician or medical staff
46112958|NCT00829283|Drug|Sibutramine/Orlistat|Sibutramine 15 mg daily or Orlistat 120mg TID
46112959|NCT04091139|Behavioral|Unified protocol for adolescents (UP-A)|"The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. The goal of the UP is to help patients to cultivate a greater willingness to experience uncomfortable emotions and to reduce maladaptive emotion response tendencies, so as to lessen the intensity and frequency of uncomfortable emotions. Ehrenreich and colleagues modified from the original UP and developed the UP for adolescents (UP-A).~A Chinese treatment protocol would be developed based on the UP-A. Contents of the treatment includes motivational enhancement, psychoeducation of emotion, avoidance and emotion driven behaviours, interoceptive exposure, cognitive reappraisal, emotion awareness training and emotion exposure. It consists of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardians."
46112960|NCT04091139|Behavioral|Treatment as usual (TAU)|TAU participants will receive usual clinical psychological service provided in the clinic (i.e. treatment as usual) in the first 12 weeks, before they start receiving same individual treatment program based on UP-A.
46025654|NCT05657496|Biological|Platelet-rich plasma Inj|Produced from participant's whole blood venous draw of approximately 15 mL. Prepared by centrifuge in clinical office
46025655|NCT02756065|Other|no intervention|no intervention is used
46025656|NCT04268524|Combination Product|drug: miltefosine with thermotherapy|see previous
45470117|NCT02520232|Behavioral|Stretching and balance exercise program|Stretching and balance exercise program
46025657|NCT05657418|Drug|JS107|JS107, i.v., q3w
46025658|NCT05657418|Combination Product|JS107 combination with Toripalimab|JS107 i.v., q3w combine with Toripalimab
46112961|NCT05394623|Diagnostic Test|HDV-Ab (IgG), HDV-RNA, RNA genotype|Anti-HDV was evaluated semiquantitatively by means of end-point dilutions. Quantitative HDV-RNA was performed by means of LightCycler 2.0. Genotyping of HDV was performed by direct sequencing of the delta antigen region.
46112962|NCT05758025|Procedure|"Resection based on thymus-vascular-inferior parathyroid complex"|"Before clearing the central lymph nodes, looking for the thyro-thymic ligament first, looking for the inferior parathyroid along the thyro-thymic ligament. Dissect and leave the thymus-vascular-inferior parathyroid complex laterally; the inner side of this layer is the tissue of the central area. Then remove the central lymph nodes. Check for parathyroids in the removed specimen, transplant the parathyroids which are removed by accident."
46112963|NCT00706199|Procedure|Bone marrow aspiration|Collection of a 2 ml bone marrow sample from an aspirate carried out for medical purposes.
46112964|NCT00708929|Procedure|Squatting|Squatting for 6 minutes
46112965|NCT00821873|Other|CR Plug|CR Plug will be placed in the harvest site
46112966|NCT00706277|Drug|propofol|propofol 2mg/kg for induction of anesthesia; followed by propofol 6 mg/kg/hour
46112967|NCT00706277|Drug|propofol|propofol 2mg
46112968|NCT00706277|Drug|remifentanil|remifentanil 0,25mcg/kg/hour
46112969|NCT00706277|Drug|fentanyl|fentanyl 100mcg
46112970|NCT00706277|Drug|Sevoflurane/Nitrous Oxide|maintenance of anesthesia with sevoflurane and nitrous oxide
45681813|NCT03584308|Dietary Supplement|Glizigen Placebo|The placebo of GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
46025659|NCT02695693|Behavioral|TeachTown|TeachTown is an online program for students with autism that uses an applied behavior analysis framework to provide intervention in academic and pre-academic areas
46025660|NCT02695693|Behavioral|Discrete Trial Training|Discrete trial training is a one-on-one didactic behavioral intervention in which the teacher or therapist uses specific behavioral methods based on principles of operant conditioning, to help students gain skills
46025661|NCT02695693|Behavioral|Pivotal Response Training|Pivotal response training is a one-on-one child-lead behavioral intervention in which the teacher or therapist uses specific behavioral methods, leveraging the students interests, to help students gain skills
46025662|NCT02695693|Behavioral|Teaching in Functional Routines|Functional routines are sets of chained behaviors that students are taught that help them complete and manage specific activities in the classroom
46025663|NCT02855632|Drug|G-CSF|7 days after first hysteroscopic adhesiolysis, G-CSF will be injected into the uterine cavity after balloon removing.
46025664|NCT02855632|Drug|Normal saline|7 days after first hysteroscopic adhesiolysis, normal saline will be injected into the uterine cavity after balloon removing.
46025665|NCT02855632|Drug|hormone therapy|In all cases hormone therapy was commenced shortly after the operation, consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of the oestrogen therapy. Following the withdrawal bleed, the hormone therapy was repeated for another cycle.
46025666|NCT02855632|Other|Cook balloon|At the end of the procedure, the Cook balloon were placed in the uterine cavity of each patient.the device was removed after 7 days.
45838773|NCT04362540|Diagnostic Test|MRI scan|On attendance to antenatal clinic with confirmed diagnosis of gestational diabetes based on OGTT and following informed consent: Ultrasound scan: Those with positive OGTT results (i.e. GDM positive) will attend an appointment for an ultrasound scan, as per routine practice. These women will,at that appointment, be assessed for presence/absence of NAFLD as well as undergoing their routine foetal assessment. This is a simple addendum to the existing scan, taking no more than 5 minutes. Participants will have been informed during the consent process that the results (regarding the presence / absence of NAFLD) will be compared to MRI after delivery.
46112971|NCT00749463|Drug|Nicotine Gum|2 mg or 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
46112972|NCT00749463|Drug|Nicotine Patch|Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
45838774|NCT04362384|Drug|Vitamin E ovules|Endoanal vitamin E ovules will be prescribed
46025667|NCT05657340|Diagnostic Test|Video-head impulse testing|Video-head impulse testing is a recent diagnostic bed-side test for evaluation of semi-circular canal function.
46112973|NCT00821327|Drug|Gemcitabine, Cisplatin, Sunitinib|"Patients will receive gemcitabine 800 mg/m2 IV (Days 1 and 8), cisplatin 60 mg/m2 IV (Day 1), and sunitinib 37.5 mg PO daily (Days 1-14) of each 21-day cycle.~2. One cycle of treatment is defined as 21 days (3 weeks). Restaging studies will be performed after every 3 cycles of therapy.~3. Successive cycles will be initiated every 3 weeks, and will be continued through 6 cycles unless a patient shows evidence of disease progression or intolerable toxicity."
46025668|NCT02761213|Drug|Oral sulfate solution (OSS)|Oral sulfate solution (OSS)
46025669|NCT02761213|Drug|2-L PEG/Asc|Low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc) COOLPREP is a proprietary name of 2-L PEG/Asc.
46112974|NCT05412459|Drug|99mTc-DARPinG3|Diagnostic test (99mTc-DARPinG3-based SPECT) is used for the assessment of the effect of anticancer therapy.
46112975|NCT05412069|Device|Fecobionics|Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry, balloon expulsion test, and anal ultrasonography will be used as reference.
46112976|NCT04038281|Other|Sensory tests|Fat, bitter taste sensitivity and food preference measurement
46112977|NCT04090671|Diagnostic Test|Multidimensional Dyspnea Profile|The Multidimensional Dyspnea Profile measures the intensity of dyspneic breathing discomforts. It tests five sensory qualities that describe the patient's dyspnea in its respective intensity. Additionally it includes five potential reactions. The MDP is designed to refer to a specific event of time.
46112978|NCT00706667|Drug|Ferinject ®|iv administration in Arm 1 placebo NaCl 0.9% In arm 2 iv administration of Ferinject ® and subcutaneous NaCl 0.9 % as an EPO placebo In arm 3 iv administration of Ferinject ® and subcutaneous EPO
46112979|NCT04090437|Procedure|Catheter ablation procedure|Catheter ablation procedure using Acutus mapping system
46112980|NCT04090593|Other|Patient Education 101: Mobile Health Education Tool|Intervention is interactive, mobile (tablet-or-smart-phone delivered), educational module that patients engage with during hospital admission.
46112981|NCT04015973|Dietary Supplement|High energy diet|An overfeeding regime of 135% required energy intake per day, set from baseline energy requirements consisting of high (saturated) fat snacks, added to the usual diet, supervised by a dietitian.
46112982|NCT00917085|Behavioral|Skin-to-Skin contact|Infants in the Skin-to-Skin group also had standard care provided by hospital staff. In addition, the researchers facilitated skin-to-skin contact by placing diaper-clad infants prone between their mothers' breasts as soon as possible after birth. Thereafter the infants and their mothers experienced skin-to-skin contact as often as possible and for as long as possible each time throughout the protocol.
46112983|NCT00709007|Behavioral|Directly Administered Antiretroviral Therapy (DAART)|Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
46112984|NCT00709007|Behavioral|SAT|Participants take their HIV medications by themselves.
46112985|NCT00821093|Drug|Indacaterol 150 µg|Indacaterol 150 μg was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
45681814|NCT01682031|Dietary Supplement|selenomethionine|Given PO
45838775|NCT04362384|Drug|Prednisolone ointment|Endoanal Prednisolone ointment will be prescribed
46025670|NCT02852746|Behavioral|Performance measures of the upper extremity|Athletes will perform the unilateral seated shot put test (USSPT) and the upper quarter Y balance test (UQYBT) bilaterally.
46025671|NCT05657262|Other|Pre-post test|Personal Information Form, Vas Scale, Undesirable Symptoms Form and General Comfort Scale Questions will be asked to immunotherapy patients with this research.
45681815|NCT01682031|Other|placebo|Given PO
45681816|NCT01682031|Drug|cisplatin|Given IV
45681817|NCT01682031|Radiation|radiation therapy|Undergo radiotherapy
45681818|NCT01682031|Procedure|quality-of-life assessment|Ancillary studies
45681819|NCT03584230|Behavioral|Assigned to positive group|See arm description
45681820|NCT03584230|Behavioral|Assigned to negative group|See arm description
46112986|NCT00821093|Drug|Salmeterol 50 µg|Salmeterol 50 μg was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]).
46112987|NCT00821093|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
46025672|NCT00635635|Behavioral|Guided Imagery Audio|Guided Imagery Audio listened to 5x per week
46025673|NCT00635635|Behavioral|Music Audio|Music only audio to be listened to 5x per week
46025674|NCT02852668|Other|Power Training|This experimental groups underwent an intervention period of power training
46025675|NCT02852668|Other|Strength Training|This experimental groups underwent an intervention period of strength training
46025676|NCT04220281|Drug|Propofol|propofol infusion during surgery
46025677|NCT04220281|Drug|Nitroglycerin|nitroglycerin infusion during surgery
46025678|NCT02852512|Procedure|sacrocolpopexy|Peritoneal incision from the sacral promontory to the Pouch of Douglas. After careful dissection of the inter-rectovaginal space, a two-piece Y-shaped polypropylene mesh was fixed posteriorly to the levator ani muscles using a absorbable suture. The midpoint of the mesh is anchored to the posterior wall of the vagina. The anterior portion of mesh was then introduced and fixed within the intervesico- vaginal space to the anterior/apical vaginal wall with a running suture. The tails of both meshes were fixed to the sacral promontory with a strong non-absorbable polypropylene suture. The peritoneal incision was re- approximated with a running absorbable suture
46112988|NCT00821093|Drug|Placebo to salmeterol|Placebo to salmeterol was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]).
46112989|NCT00821015|Device|Pulmonary vein isolation with cryoballoon catheter|For each patient, the balloon catheter will be advanced to the ostium of each pulmonary vein. Once location has been optimized, the balloon will be inflated, and cryoenergy delivery will be initiated. Because the entire surface of the balloon acts as an ablative surface, circumferential ablation of each pulmonary vein will be achieved concurrently. This will be completed for each pulmonary vein for each patient.
46112990|NCT00814463|Behavioral|MMSE|Neurocognitive function via MMSE done every 3 months for length of study.
46112991|NCT00814463|Behavioral|QOL via FACT-Br|Quality of Life via FACT-BR every 3 months for length of study.
45838776|NCT04361916|Other|home care monitoring|home care active monitoring of patients with suspected of confirmed COVID-19
46112992|NCT00814463|Procedure|MRI|MRI done every 3 months for the length of the study.
46112993|NCT00814463|Radiation|Post-operative SRS|Single fraction SRS is currently a viable treatment option of intracranial metastatic lesions.
46112994|NCT00706745|Dietary Supplement|oil rich in cis9, trans11 conjugated linoleic acid|An oil rich in cis9, trans11 conjugated linoleic acid (cis9,trans11-CLA). Of the total amount of CLA in the oil, 80% is cis9, trans11-CLA and 20% trans10, cis12-CLA. In total 4 grams of oil will be given daily. The oil will be taken in the form of soft gel capsules. Two capsules will be taken in the morning and two in the evening.
45838777|NCT04361760|Device|single-puls TMS|Medical Device (MD): MagPro X100
45838778|NCT04361760|Device|sham stimulation|Sham stimulation is delivered with a dedicated coil, which is magnetically shielded and thus produces only approx. 20% of the nominal magnetic field. This is not enough to reach and stimulate the cortex, but the produced sound and scalp sensation are the same as with a real TMS coil.
46112995|NCT00706745|Dietary Supplement|placebo|identical placebo capsules.
46025679|NCT05657184|Drug|REGEND001 Autologous Therapy Product|Transplantation of REGEND001 Autologous Therapy Product for dosage re-escalation.
46112996|NCT05229809|Drug|Yiqi Wenyang Jiedu prescription|The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
46112997|NCT05229809|Drug|Simulation agent of Yiqi Wenyang Jiedu prescription|It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
46112998|NCT00709163|Drug|Nesiritide|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
46112999|NCT00709163|Drug|5% Dextrose|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
46113000|NCT00913445|Procedure|appendicectomy|Wound healing after absorbable and nonabsorbable stitches are compared
46113001|NCT02611505|Drug|Esketamine|Esketamine 28 mg will be self-administered by participants as intranasal spray at 0 hour (h) on Day 1.
46113002|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|4 doses of 13vPnC (0.5ml, IM) will be administered. (3 doses infant series, and 1 toddler dose)
46025680|NCT02751619|Drug|Lidocaine patch 5%|Lidocaine patch 5% was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
46025681|NCT02751619|Drug|Placebo patch|A patch without lidocaine was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
46025682|NCT04316988|Diagnostic Test|Ultrasonography|A real time 2D ultrasound evaluation was done over the trachea of the patient.
46025683|NCT02751541|Drug|Sunscreen Sport Spray (BAY987519)|50 μl/cm*2 or 0.05 gm/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB#Y51-002)
46113003|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|3 doses of 13vPnC (0.5ml, IM) will be administered. (2 doses for infant series catch-up, and 1 toddler dose)
46025684|NCT02751541|Other|Untreated Skin|This site is patched without treatment as irradiated control.
46113004|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (1 dose infant series catch-up, and 1 toddler dose)
46113005|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (2 catch-up dose(s) greater than 60 days apart )
46025685|NCT02755753|Drug|Lansoprazole|Oral administration of Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
46113006|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose of 13vPnC (0.5ml, IM) will be administered. (1 catch-up dose)
46113007|NCT00748215|Drug|calcium aluminosilicate anti-diarrheal|Given orally
46113008|NCT00748215|Other|placebo|Given orally
46113009|NCT04089384|Other|Control Group|Will receive individualized dietary plan - alimentary reeducation and micropore containing a point made with a black gel pen that will be placed in the ear
46113010|NCT04089384|Other|Auriculotherapy Group|Will receive individualized diet plan - diet reeducation and auricular therapy method with strategic points for obesity
46025686|NCT02755753|Drug|Rebamipide|Oral administration of Mucosta (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch, and dinner
46113011|NCT04089384|Other|Placebo group|Will receive individualized diet plan - diet reeducation and sham points, points not indicative for the proposed treatment).
46113012|NCT04089540|Procedure|New intubation method|
46113013|NCT04089540|Procedure|Conventional intubation method|
46113014|NCT02598843|Other|Standard treatment protocol|"Cast Protocol 4 weeks in Full Equinus cast - Non Weight Bearing (NWB) with axillary crutches; 4 weeks in Semi-Equinus cast NWB with axillary crutches; 2 weeks in neutral cast - Full Weight Bearing (FWB); 2 weeks FWB out of cast, with shoe insert heel raise.~Followed by course of physiotherapy"
46113015|NCT02598843|Other|Accelerated Rehabilitation|"4 weeks in Ossur Rebound walking boot with 3cm heel raise, worn continuously including in bed. Weight bearing as tolerated (WBAT)/FWB - crutches for balance; 2 weeks in Rebound walking boot with 1.5cm heel raise (WBAT/FWB - crutches for balance; 2 weeks in Rebound walking boot with foot in neutral. At 8 weeks, remove boot and allow FWB out of boot.~At 8 weeks after initiation of treatment, physiotherapy is commenced."
46113016|NCT04089228|Other|Kinesiotaping|Total of 4 sessions on upper trapezius trigger points on alternate days.
46113017|NCT04089228|Other|Integrated Neuromuscular Inhibition Technique|Sustain Pressure. Strain Counter-strain (for 90 sec) Passive Isometric Relaxation (PIR) (6-10 sec hold, 4 reps)
46113018|NCT00917163|Device|Supralimus(R) Sirolimus-Eluting Coronary Stent System|Drug eluting stent implantation in the treatment of coronary artery disease.
46113019|NCT00917163|Device|Xience V™ Everolimus Eluting Coronary Stent|Drug eluting stent implantation in the treatment of coronary artery disease
46113020|NCT04090086|Drug|JNJ-53718678|JNJ-53718678 suspension will be administered orally as per assigned treatment sequence.
46113021|NCT04090086|Drug|JNJ-64417184|JNJ-64417184 tablet will be administered orally as per assigned treatment sequence.
46113022|NCT00749892|Drug|Erlotinib Hydrochloride|Given PO
46113023|NCT04088487|Behavioral|New in Town-Interner Intervention for Migrants|New in Town is an internet intervention for migrants that aims at increasing social self-efficacy. Exercises in the intervention are based on the principles of Cognitive Behavioral Therapy and relate to four sources of self-efficacy beliefs-mastery experiences, vicarious experiences, verbal persuasions, and emotional and physiological states (Bandura, 1997).
46113024|NCT04091256|Other|Single arm clinical study|Participants will be treated with desensitizing toothpaste containing zinc-carbonate hydroxyapatite nanocrystals (Zn-CHA) for 8 weeks.
46113025|NCT02595645|Genetic|Polypectomy and NGS|NGS of 38 cancer-related genes, systems biological analyses, correlation genetics to pathology and clinical data
46113026|NCT02595333|Drug|Group SF1|primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
45838779|NCT04361526|Device|Cytokine Adsorption|Cytokine adsorption will be performed through a venous hemodialysis catheter, preferably jugular or femoral. The filtration system will be established with a cytokine adsorption cartridge in an hemoperfusion system using a blood flow rate of 150 - 200 ml/min. Adsorbent therapy will last 72 hours, changing cartridges every 24 hours. Prior to start, heparinization will be stablished by a 1mg/Kg iv Na heparin bolus plus iv perfusion. Activated Partial Thromboplastin Time (aPTT) control will be performed every 6 hours, with a goal range between 60 and 80 seconds.
46025687|NCT02755753|Drug|Rebamipide-placebo|Oral administration of Mucosta®-placebo, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner
46113027|NCT02595333|Drug|Group S1|sufentanil was administered for analgesia in primary cesarean section
46113028|NCT02595333|Drug|Group SF2|sufentanil and flurbiprofen was administered for analgesia in repeated cesarean section
46113029|NCT02595333|Drug|Group S2|sufentanil was administered for analgesia in repeated cesarean section
46025688|NCT02755987|Drug|ANG1005|
46025689|NCT01188564|Drug|rhC1INH|One i.v. injection of rhC1INH at the dose of 50 U/kg, for patients up to 84 kg; one i.v. injection of rhC1INH at the dose of 4200U (2 vials) for patients of 84 kg body weight or greater.
46025690|NCT01188564|Drug|Placebo (Saline)|One i.v. injection of saline (NaCl 0.9% w/v), equivalent in volume to the active treatment
46025691|NCT02755909|Behavioral|Pre-anesthetic Education|Education was done before the anesthetic procedure, using a flip chart made by the researchers.
46025692|NCT04222777|Diagnostic Test|Cinematographic Recording|A cinematographic recording during the second half of extension of the cervical spine will be made during 16 seconds at two timepoints with an interval of two weeks.
46025693|NCT04316598|Drug|Cannabis Sativa|"Subjects will receive a total of 4 inhaled doses of 20 mg of tetrahydrocannabinol (THC) in 3 days.~Cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing THC 22% and cannabidiol <1%, supplied by Bedrocan®.~To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of Cannabis flos, equivalent to 20 mg of THC."
45838780|NCT04361604|Biological|Biological collection (patients co infected HIV Sras-CoV-2)|Biological sampling (blood,saliva, tear urine, stool, respiratory tract, semen only for 20 patients, or other samples if indicated.)
46025694|NCT04316598|Drug|Cannabis placebo|"Subjects will receive a total of 4 inhaled doses of cannabis placebo (THC <0,2%) in 3 days.~Placebo cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing cannabinoids <0.2%. To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of cannabis placebo."
46113030|NCT00749580|Drug|Switch NRTIs as a Backbone to Raltegravir|This is a multicenter, pilot randomized, controlled study to evaluate the safety and efficacy of raltegravir in patients switched from a stable boosted PI-based regimen with a NRTI backbone to raltegravir instead of their current NRTIs. A stable boosted PI-based regimen is defined as having a documented HIV RNA <75 copies/mL for ≥ 3 months prior to study entry, while receiving a boosted PI-based with NRTI backbone. Additionally, patients must not have had HIV RNA ≥ 75 copies/mL during the three months prior to study entry. Approximately 25 patients will be enrolled in the raltegravir treatment arm (Group 1) and approximately 25 patients in the continuation of the current NRTI backbone regimen treatment arm (Group 2). Patients will be randomly assigned 1:1 to a treatment group.
46113031|NCT02595177|Procedure|Cataract surgery with intraocular lens implantation.|Phacoemulsification under topical anesthesia with intraocular lens implantation.
46113032|NCT02595255|Other|No intervention|No intervention
46113033|NCT02595021|Procedure|Total or Subtotal Colectomy|Resect all or most parts of the colon: with total or subtotal colectomy as a part of optimal cytoreductive surgery(residual disease <=0.5cm)
46113034|NCT02595021|Procedure|Other Bowel Resection|Resect part of the colon or small intestine: with other types of bowel resection as a part of optimal cytoreductive surgery(residual disease <=0.5cm)
46025695|NCT02761369|Device|A multi-channel deep TMS device with an H-coil (Brainsway Ltd)|A 3-week long treatment (15 days). Treatment session consist of 300 rapidly occurring pairs of pulses over the dorsolateral prefrontal cortex (at a frequency of 10 Hz and intensity of 110% of individual's motor threshold), with a 5-seconds interval, for a duration of 1800 seconds in total.
46113035|NCT02595099|Other|Mindfulness training|group-based training programme, 2.5 hours delivered weekly for 8 weeks
46113036|NCT00747006|Drug|TI Inhalation Powder and Humalog (Amendment 1)|Subcutaneous (sc) rapid acting analog to be administered at one half of the meal challenge visits 15 minutes before a meal. Only the last 5 - 10 patients (Type 2) will be undergoing this amendment to the protocol.
46113037|NCT00747006|Drug|TI Inhalation Powder (original protocol)|Inhaled insulin technology to be administered immediately before a meal (prandially) for glucose control in Type 1 or Type 2 diabetics
46113038|NCT04091100|Procedure|Electroacupuncture|An electrical current of 2 mA and 60 Hz was administered using the Enraf Nonius Sonoplus 492 (OPTOMED) device for 20 minutes. All the treatments were performed for 2 sessions per week for 3 weeks. Both groups were given a home program involving neck stretching and posture exercises. The exercises were to be performed at least two times a day in two sets of fifteen repetitions.
45838781|NCT04361604|Other|Auto-questionnaires (patients co infected HIV Sras-CoV-2)|4 autoquestionnaires will be collected : HADS Hospital anxiety and depression scale, PCL-5 (post-traumatic stress disorder checklist version DSM-5), symptoms with the modified Justice Symptom Index PROQOL-HIV
46113039|NCT04091100|Procedure|Myofascial Release|longitudinal stretching, friction massage and pinching technique, All the treatments were performed for 2 sessions per week for 3 weeks. Both groups were given a home program involving neck stretching and posture exercises. The exercises were to be performed at least two times a day in two sets of fifteen repetitions.
46113040|NCT04091178|Dietary Supplement|VITAMIN D|ORAL SOLUTION (2 ml) at 100.000 UI
46113041|NCT04090008|Drug|PRP gel|The PRP gel is applied on the ulcer twice per week
46113042|NCT04090008|Drug|Saline dressing|Normal saline is used for dressing of the ulcer twice a week
46113043|NCT00917358|Drug|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a 135 ug/week for 24 weeks
46113044|NCT02597244|Device|Percutaneous Extraforaminotomy|percutaneous dissecting of the lumbar extraforaminal and foraminal region with BS extraforamonotomy kit(BioSpine Co.,Ltd, Seoul, South Korea) under fluoroscopy
46113045|NCT00743340|Drug|Emtricitabine|6 mg/kg capsule once daily, up to a maximum dose of 200 mg once daily, or 10 mg/mL oral solution once daily, up to a maximum of 240 mg once daily
46113046|NCT00917046|Behavioral|high-intensity interval training|3 weekly sessions of high-intensity interval training in 12 weeks
46113047|NCT00917046|Behavioral|Moderate continuous training|3 weekly sessions of moderate continuous training for 12 weeks
46113048|NCT00917046|Behavioral|Recommendation of regular moderate exercise|Recommendation of regular exercise at moderate intensity at individual choice. In addition patients will meet for treadmill walking in order to motivate for post intervention testing
46113049|NCT04090944|Procedure|the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) for confirmation of LMA position|-The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading licensed by Aoyama et al.
45470118|NCT03756181|Behavioral|Five-week MSC program (MSC5wk)|This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator may discuss the student's experience and encourage group sharing within the course of the session. These discussions will reinforce the guiding principles of mindfulness meditation. There will also be sessions dedicated to incorporating or mindfulness in daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
45470119|NCT03301155|Drug|Anaferon for children|Tablet for oral use.
46113050|NCT00749190|Drug|BI 10773|
46113051|NCT00749190|Drug|placebo|
46113052|NCT00749190|Drug|sitagliptin|
46113053|NCT00748566|Drug|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40 to 160 mg total daily dose) for up to 1 year.
46113054|NCT02597166|Drug|Ledipasvir/Sofosbuvir|Each tablet of Harvoni contains 90 mg ledipasvir and 400 mg sofosbuvir.
46113055|NCT03976440|Other|Renal Replacement Therapy (RRT) start|At the discretion of the nephrologist, treatment modality will be selected among CVVH, CVVHDF or SLED. Whatever the RRT modality, the investigators will adopt RCA as the standard anticoagulation strategy
46113056|NCT04090788|Dietary Supplement|dried bitter-gourd supplements|intervention with 2.4g/d dried bitter-gourd supplements
46113057|NCT04090788|Dietary Supplement|dried cucumber supplements|reference intervention with 2.4g/d dried cucumber supplements
46113058|NCT02597088|Other|Laboratory studies of the effect of human milk handling using a rage surface area bottle (study device)|Using laboratory studies of the effect of storage and heating on expressed human milk, the investigators will compare milk handled in regular bottle and bottle warmer and milk handled using the study device (large surface area bottle)
46113059|NCT00743106|Drug|Fenoldopam|Fenoldopam (0.1 ~g/kg/min)started during surgery and lasting for a total of 24 hours
45470120|NCT03301155|Drug|Placebo|Tablet for oral use.
45470121|NCT03763513|Device|ESWT|Extracorporeal Shock Wave Therapy=ESWT
45838782|NCT04361604|Other|Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19)|Qualitative interviews will be realized in 40 patients (20 with COVID-19 and 20 without COVID-19)
45838783|NCT04361448|Other|samling of oropharynx and nasopharynx|Three different swabs will be taken of each participant: 1 oropharyngeal swab and 2 nasopharyngeal swabs
46113060|NCT00743106|Drug|Placebo|Placebo infusion(0.9% Nacl) beginning during surgery and lasting for up 24 hours post surgery
45470122|NCT03763513|Other|Kinesiotaping Application|Kinesiotaping=KT (CT)
45470123|NCT03392038|Procedure|Thin ADM|Use of soft tissue allograft for root coverage
46025696|NCT02761291|Drug|Gemcitabine|Gemcitabine will be administrated 600~1250 mg/m^2 intravenously according to the body surface area at day 1 and day 8 in a 28 day-treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times. The first dose level of gemcitabine will be started at 800 mg/m^2. If no subject suffered the dose limit toxicity, 1000 mg/m^2 and even 1250 mg/m^2 will be started by order. If subjects suffered the dose limit toxicity in 800 mg/m^2, the 600 mg/m^2 will be started.
46025697|NCT02761291|Drug|Valproic acid|Valproic acid will be administrated orally by the fixed dose 12.5 mg/kg/day according to instructions from day 1 to day 14 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
46025698|NCT02761291|Drug|Valganciclovir|Valganciclovir will be administrated orally by the fixed dose 1350 mg/day (creatinine clearance rate ≥ 60 mL/min) or 900 mg/day (creatinine clearance rate ≥ 40 mL/min and < 60 mL/min) from day 9 to day 15 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
46025699|NCT01187550|Drug|Recombinant human growth hormone (r-hGH)|Recombinant human growth hormone (r-hGH) administered at dose of 0.033 milligram/kilogram (mg/kg) body weight (0.1 International Unit [IU]/kg body weight) per day by subcutaneous injection.
46025700|NCT02755363|Other|osteopathic manual therapy|"suboccipital decompression - atlanto-occipital joint relaxation technique.~deep cervical fascia release - the technique aims to improve mobility of the first and second ribs during expiration and to relaxation of the vagus and phrenic nerve course area.~thoracic lymphatic pump with activation is designed to reduce the tension of mediastinal structures, improve lymphatic flow, and thus reduce the breathing resistance.~stretching the diaphragm in order to relax and reduce adhesion within the fascial system between the diaphragm and abdominal organs."
46113061|NCT04090632|Diagnostic Test|Closed Kinetic Chain Upper Extremity Stability Test|Each patient receive the same intervention, the CKCUEST. The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
46113062|NCT04090554|Device|Cytosponge™|The device consists of a spherical mesh enclosed in a gelatine capsule and attached to a string. The capsule is swallowed and allowed to reach the stomach . In the stomach the capsule is left for up to 5 minutes where it dissolves allowing the sponge to expand to its full size. It is then withdrawn using the suture, and as it does so collects cells from the lining of the oesophagus.
45470124|NCT03392038|Procedure|Thick ADM|Periodontal surgical procedure to coronally position the tissue over the ADM allograft
45470125|NCT01952730|Biological|GVAX|
46113063|NCT02597322|Drug|AXITINIB|Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, 3 It will be supplied as 1 mg and 5 mg film coated tablets for oral administration in light protecting bottles of 60 tablets.
45470126|NCT03753529|Other|Deep friction massage|Submitted to three session weekly 30-minute sessions of therapy will performed by the administration of sliding and kneading maneuvers of the masseter and temporalis muscles, bilaterally,lateral pterygoid and digastric over four consecutive weeks (total:12 sessions) Sliding consisted of a unidirectional movement in which part of the therapist's hand (mainly the fingertips) will used, moving from the proximal to the distal portion of the face with constant, progressive pressure compatible with the status of each tissue. The degree of pressure varied depending on the level of pain, sensitivity and tension in each individual. Kneading consisted of a gripping maneuver of a muscle group or portion of a muscle.Then follow-up with a passive stretch to the muscle. This will repeated for three to five times for three sessions per week for 4 weeks.
46113064|NCT04090320|Device|CATERPILLAR™ Arterial Embolization Device|Placement of the CATERPILLAR™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.
46025701|NCT02755363|Other|control group|"manual mobilization techniques of the slides in the shoulder joint toward the front, rear and bottom.~manual techniques to increase range of motion in the shoulder joints using the patient's breathing manoeuvres."
46113065|NCT00738699|Drug|MORAb-003 (farletuzumab)|Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
46025702|NCT00602368|Other|histological technique|
46113066|NCT00738699|Drug|0.9% Saline|Placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
46025703|NCT00602368|Other|laboratory biomarker analysis|
46025704|NCT00602368|Procedure|colposcopic biopsy|
46025705|NCT00602368|Procedure|colposcopy|
46025706|NCT00602368|Procedure|light-scattering spectroscopy|
46113067|NCT00738699|Drug|Paclitaxel|
46025707|NCT00602368|Procedure|loop electrosurgical excision procedure|
46113068|NCT02596932|Other|Standard Protocol for intrapartum glucose management|Tight glucose control protocol: Goal maternal blood glucose 70-100, q 1 hour blood glucose checks, insulin treatment started with single maternal blood glucose level > 100mg/dL or < 60mg/dL
46113069|NCT02596932|Other|Experimental Protocol for intrapartum glucose management|Less Tight: Goal maternal blood glucose 70-120, q 4 hour blood glucose checks (unless symptomatic), insulin treatment started with single maternal blood glucose > 120 mg/dL or < 60 mg/dL
46025708|NCT00602212|Behavioral|relaxation with virtual reality (VR)|VR relaxing environment and audio-visual mobile narratives will be used to teach patients how to relax themselves
46025709|NCT00602212|Behavioral|relaxation and biofeedback virtual reality|The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
46025710|NCT02755675|Other|68Ga-NOTA-AE105 PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/CT
46025711|NCT02855866|Procedure|thyroidectomy|
46113070|NCT00814307|Drug|CP-690,550|5mg CP-690,550 BID PO for 6 months
46113071|NCT00814307|Drug|CP-690,550|10 mg CP-690,550 BID PO for 6 months
46113072|NCT00814307|Drug|Placebo|Placebo patients advance to 5mg CP-690,550 BID at Month 3 visit
46113073|NCT00814307|Drug|Placebo|Placebo patients advance to 10mg CP-690,550 BID at Month 3 visit
46113074|NCT02597010|Dietary Supplement|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
46113075|NCT02597010|Dietary Supplement|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
46025712|NCT02855866|Other|cryotherapy|
46025713|NCT02855866|Drug|cortisone aerosol|
46025714|NCT02855866|Drug|Dexamethasone acetate|
46025715|NCT02855866|Drug|paracetamol|
46025716|NCT02751463|Drug|Sunscreening Sport Spray Rest (BAY987519)|50 μl/ cm*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.(Formulation Number - RB# Y51-002 )
46025717|NCT02751463|Other|Untreated skin|One site is patched without treatment as control
46025718|NCT04316520|Dietary Supplement|Ketogenic diet|Ketogenic diet 2:1
46025719|NCT02751307|Drug|metformin 500 mg|metformin 500 mg QAM for metformin 500 mg/d group; metformin 500 mg 1 BID for metformin 1000 mg/d
46113076|NCT02594943|Device|Boston Scientific Large Capacity with needle Biopsy|The investigators will use a conventional biopsy forceps for taking tissue biopsies in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the conventional biopsy forceps from the tumor tissue.
46113077|NCT02594943|Device|Endodrill 1A (BIBBInstruments, Lund, Sweden)|The investigators will use the Endodrill, a new device for endoscopic tissue sampling in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the Endodrill instrument from the tumor tissue.
46025720|NCT02751307|Drug|clozapine 100 mg|Clozapine dose remained unchanged during metformin intervention period in recruited patients.
45838784|NCT04361292|Procedure|INTRAUTERINE INSEMINATION|Intrauterine insemination (IUI) combined with ovarian stimulation, has been an extensively used procedure for the treatment of patients with unexplained infertility. The fact that IUI is less expensive, less invasive, and easier to perform than other assisted reproductive techniques makes it the first-line treatment option in infertility treatments. Sperm that have been washed and concentrated are placed directly into the uterus around the time of ovulation. All patients had ovulation induction with gonadotropins and ovulation was triggered by recombinant hcg.
45838785|NCT04361214|Drug|Leflunomide|Tolerability study of leflunomide 100 mg administered once daily for 3 days followed by 30 mg administered once daily for the duration of 2 - 7 days.
46113078|NCT02596776|Procedure|Fat biopsy|up to 16 biopsy samples will be taken from each subject
46113079|NCT02596776|Drug|Propranolol and fat biopsy|subset of subjects will receive propranolol and have fat biopsy performed
46113080|NCT02596776|Other|heavy water and fat biopsy|subset of subjects will be given heavy water and have fat biopsy performed
46113081|NCT02594631|Procedure|ESWL|Patients in this arm will receive ESWL for treatment of acute calcular urinary retention
46113082|NCT02594631|Procedure|Endoscopic treatment|Patients in this arm will receive endoscopic treatment of acute calcular urinary retention
46113083|NCT02598180|Device|VergenixTM Flowable Gel|The VergenixTM Flowable Gel is supplied as powder contained in a syringe that will be hydrated with saline.
46113084|NCT02598336|Device|Structured Light Plethysmography|Non contact device that uses light to record displacement of the anterior thorax and abdomen region
46113085|NCT02598336|Device|Pneumotachograph Spirometry|Device that measures airflow at the mouth using a mouthpiece
46113086|NCT02611895|Biological|HIV DNA|Quantitate the amount of HIV DNA harbored in the cytoplasm of peripheral blood CD4+ T cells
46113087|NCT00748098|Drug|GSK1838262 Extended Release Tablets|GSK1838262 extended release tablets
46113088|NCT00748098|Drug|Placebo|Placebo
46113089|NCT00813995|Drug|Comparator: Sitagliptin phosphate|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate 100 mg tablets once daily (q.d.) and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
46113090|NCT00813995|Drug|Comparator: Placebo|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate placebo tablets q.d. and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
46113091|NCT02598882|Device|videogame|Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute guided activity through an active video game
45838786|NCT04361370|Drug|Olaparib-Pembrolizumab-Bevacizumab|"Olaparib 300mg (twice daily [BID])~Pembrolizumab 200mg every 3 weeks (Q3W) from 2nd infusion for up to 35 infusions~Bevacizumab 15mg/kg or 7.5mg/kg every 3 weeks (Q3W)"
46025721|NCT05356494|Other|Postural drainage|(Group A will be treated with postural drainage)
46113092|NCT02598882|Device|treadmill|Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute activity in treadmill.
46113093|NCT00737529|Drug|lenalidomide|25mg oral capsules continuous days 1-21 each of a 28 day cycle
45838787|NCT04361136|Drug|Delgocitinib cream|Cream for topical application
46025722|NCT05356494|Other|Positive expiratory pressure|(Group B will be treated with positive expiratory pressure technique).
46025723|NCT04220359|Device|non-invasive monitoring|Prospective monitoring with retrospective big-data analysis
46025724|NCT00638209|Drug|Human insulin|
46025725|NCT00638209|Drug|Saline|
46113094|NCT03971526|Other|MRI images review|MR images were reviewed by one junior radiologist and one senior neuroradiologist, both blinded to clinical, therapeutic and follow-up data.
46025726|NCT02760745|Other|Ancillary tests|Blood culture, complete blood count, crp, urinalysis for all patients. If clinically indicated: Urine culture, chest x ray, csf culture, stool culture, joint fluid culture
46025727|NCT04220047|Procedure|Left Atrial Appendage Resection and Marshall Ligament Amputation|Left Atrial Appendage Resection and Marshall Ligament Amputation during the cardiac surgery
46025728|NCT05429749|Drug|Ferinject|Intravenous ferinject 1000mg is administered between the admission day and the surgery day.
46025729|NCT05429749|Drug|Normal saline|Normal saline 250ml is administered between the admission day and the surgery day.
46025730|NCT05429671|Procedure|total knee arthroplasty|Participants will have total knee arthroplasty
46113095|NCT02596542|Other|Water immersion|Different temperatures of cold water immersion will be assessed
46113096|NCT00813917|Drug|varenicline|12 weeks of varenicline 1 mg by mouth twice per day
46025731|NCT05429671|Drug|Tobramycin|Total knee arthroplasty using Stryker Surgical Simplex P with tobramycin
46025732|NCT05429671|Drug|Gentamicin|Total knee arthroplasty using Huraeus Palacos R+G cement containing gentamicin
46025733|NCT05429671|Device|Antibiotic cement spacer|participants getting an antibiotic-loaded cement spacer during surgery comprised of vancomycin and tobramycin.
46113097|NCT00813917|Drug|placebo|12 weeks of placebo (double blinded) by mouth twice per day
46113098|NCT02611193|Procedure|Manipulative treatment|Manipulative treatment as described by the GBMOIM (Grupo Barcelona de Medicina Ortopédica y Manual) will be perform with extension of the transverse carpal ligament maneuver and fascia release maneuver
46113099|NCT02611193|Procedure|Simulated manipulative treatment|Simulated Manipulative Treatment
46113100|NCT02594709|Radiation|Multisession Radiosurgery|Patients will undergo multisession radiosurgery as clinical practice.
46113101|NCT02598102|Drug|Diclofenac sodium|Diclofenac for pain relief
46113102|NCT02598102|Drug|Placebo|Placebo for comparison
46113103|NCT05757947|Procedure|Сoronary bypass surgery according to the I-graft method|"Revascularization of the right coronary artery basin will be performed using no-touch SVG and the formation of an anastomosis of the stump of the right internal mammary artery and end-to-end saphenous vein graft."
45681821|NCT04116723|Device|Flexible brace|Participants will be invited to undergo a fitting session of a flexible brace. After the fitting session, participants will join a two-hours wear trial of the flexible brace. Participants are required to wear the brace for two-hours and undergo assessments before and after the wear trial. The measurement outcomes of the assessment include 1) X-ray scan, 2) 3D body scan, 3) garment pressure, and 4) questionnaire.
45681822|NCT03020134|Drug|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
45681823|NCT03020134|Drug|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
45681824|NCT03020134|Drug|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
45681825|NCT03020134|Drug|Placebo|Placebo
46113104|NCT05757947|Procedure|Сoronary bypass surgery by the method of free conduit|"Revascularization of the right coronary artery basin will be performed using no-touch SVG and anastomosis of the saphenous vein graft to aorta."
45681826|NCT03020056|Drug|Phacolin eye drops|After enrollment, the participants will be provided antioxidant eye drops, Phacolin (Zhongshan ophthalmic center, China) for free.The eye drops will be administered 4 times per day for 1 year.Then either phacoemulsification or manual small incision cataract surgery will be performed.
45681827|NCT03020056|Procedure|cataract surgery|After enrollment,either phacoemulsification or manual small incision cataract surgery will be performed within 4 weeks.
45681828|NCT03026062|Biological|Durvalumab|Given IV
45681829|NCT03026062|Biological|Tremelimumab|Given IV
46025734|NCT02754973|Behavioral|an integrated experiential training program with coaching|The intervention will be implemented to each participant by a designated coach who is a trained nursing student during 28 home visits throughout a 6-month period (24 weeks) and each visit will last for about 1 hour. The 1-hour program consists of a 30-minute English tutorial session, and a 30-minute physical activity session with the coach. The same coach will pay a visit to a participant at twice a week for the first 4 weeks and then once a week for the subsequent 20 weeks. 4 levels of physical activity will be taught to the participants gradually according to their ability.
46113105|NCT02598024|Behavioral|Narrative Exposure Therapy|In Narrative Exposure Therapy the patient constructs a narration of his or her life, focusing on the detailed context of the traumatic experiences as well as on the important elements of the emotional networks and how they go together. This process allows the majority of persons to recognise that the fear/trauma structure results from past experiences and that its activation is just a memory. They thus lose the emotional response to the recollection of the traumatic events, which consequently leads to a remission of PTSD symptoms. Thus, they gain access to 'lost' past memories and develop a sense of coherence, control, and integration. Revised Narrative Exposure Therapy (NET-R, Zang et al, 2013) is a 4-session treatment delivered within a week.
45598576|NCT04026295|Behavioral|Traditional Locomotor Treadmill Training (TLTT)|TLTT group will receive the same number of sessions (40) delivered 5x/week for 8 weeks with a total duration of walking per session up to 30 minutes with rests as needed. TLTT will consist of walking at steady-state speeds. Initial treadmill speed will be 75-80% of over ground self-selected walking speed. The overall goal will be to achieve 30 minutes of walking at a steady-state walking speed within each session. Speed will be increased on the next session by .1 to .4mph when the subject can walk for 30 minutes on the treadmill at the current speed with an OMNI score of < 6/10.
45598577|NCT02355639|Drug|Clobetasol propionate 0.05 % ointment|
45598578|NCT02355639|Drug|Betamethasone dipropionate 0.064 % ointment|
45598579|NCT02355639|Drug|Petrolatum ointment|
45598580|NCT02355249|Procedure|MIE|Minimally invasive thoracol-laparoscopic esophagectomy will be performed in this group.
45598581|NCT02355249|Procedure|OE|Patients will be treated with traditional three incisions esophagectomy.
45598582|NCT03520465|Device|DynaMesh®-CICAT longitudinal measure 10x35 cm|
45598583|NCT02227589|Behavioral|MET/CBT-12|Two sessions of motivation enhancement therapy followed by 10 sessions of cognitive behavior therapy targeting alcohol or cannabis abuse. These 12 sessions will be delivered over 12 to 14 weeks.
45681830|NCT05701774|Drug|DCCR|Once daily oral administration
45681831|NCT03584074|Drug|Pregabalin 75mg|Orally taken twice daily for 8 weeks
45681832|NCT03584074|Drug|Celebrex 200Mg Capsule|Orally taken once daily for 8 weeks
45681833|NCT03584386|Device|V-CAMS (aka Jaspr)|V-CAMS is an integrated software system for use on any device by suicidal patients.
45681834|NCT03581188|Behavioral|Self-examination of the skin|Participants will use a dermatoscope device to conduct self-examination of the skin.
46113106|NCT02598024|Behavioral|Control Focused Behavioural Treatment|The Control-focused Behavioural Treatment (CFBT, Başoğlu et al 2005) for earthquake survivors was designed after 1999 Turkey earthquake as an intervention to facilitate natural recovery processes by restoring sense of control over anxiety, fear, or distress. Its underlying principle is to reduce helplessness responses by encouraging behaviours that are likely to enhance sense of control over stressor events and life in general. Its primary aim is to reverse traumatic stress processes by increasing anxiety or distress tolerance. In earthquake survivors, CFBT involves a single session in most cases and an additional few sessions in cases that do not respond to the initial session.
46113107|NCT02610647|Drug|Wrist anesthesia|Prior to the tapping test, regional anesthesia is performed in the form of sensory blocks distal to the wrist: injection of ropivacaine 7.5mg / ml is carried out successively in contact with three nerves (ulnar, median and radial) with a volume of 2 ml for nerve, for a total of 45mg.
46113108|NCT02610647|Other|Blinding mask|Patients will don a mask that prevents them from seeing during the tapping test.
46113109|NCT02610647|Other|Anti-noise helmet|Patients will don a helmet that prevents them from hearing during the tapping test.
45838788|NCT04361136|Drug|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
46025735|NCT02754973|Behavioral|Placebo Control|When discharged home, participants will receive an amount of time and attention (home visits by research assistants) that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. The placebo activities during the home visits may include playing cards or chess games, health advice on the prevention of influenza and healthy diet which will be conducted for 30 minutes.The participants will also receive a 30-minute English tutorial session with the research assistants in each home visit.
46025736|NCT04222621|Other|Pregnant women without intervention|Pregnant women with those exposures of interest determined in specific research based on the registry
46025737|NCT01186770|Drug|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
46025738|NCT01186770|Drug|Placebo|Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.
46025739|NCT02754817|Drug|insulin degludec/liraglutide|This is a non-interventional, chart review study and the patients are treated according to current clinical practice and local licenses upon the treating physicians' decision.
46025740|NCT02755051|Behavioral|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy for children with Chronic Insomnia and Autism Spectrum Disorder involves 8, one-hour sessions of a non-drug cognitive behavioral intervention. Session content listed below:~Sleep education~Sleep scheduling, limit setting, and stimulus control~Teaching relaxation strategies and other adaptive coping skills~Parenting strategies (differential attention, rewards, consequences)~Identification of maladaptive & adaptive cognitions~Problem solving & communication skills~Sleep restriction; bright light to change circadian rhythms~Review gains and plan for long-term maintenance"
46025741|NCT05429515|Procedure|HFR-SUPRA|HFR-SUPRA everyday for 3 days, then 3 times/week until patients do not require dialysis.
46025742|NCT05429515|Procedure|hemodialysis|hemodialysis everyday for 3 days, then 3 times/week until patients do not require dialysis.
46025743|NCT05429515|Drug|Chemotherapy|chemotherapy protocol will be made by hematologists.
46025744|NCT01186692|Device|Melody® Transcatheter Pulmonary Valve|Transcatheter Pulmonary Valve replacement Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
46025745|NCT04230031|Drug|Daratumumab|Experimental
46025746|NCT01186458|Drug|Fludarabine|Fludarabine 25 mg/m2 IV over 30 minutes on days 1, 2, 4. Cycle = 28 days; maximum of 6 cycles of therapy.
46025747|NCT01186458|Drug|Velcade|Velcade (given after fludarabine)1.3 mg/m2 IV push over 3 to 5 seconds on days 1, 4, 8, 11. Cycle = 28 days; maximum of 6 cycles of therapy.
46025748|NCT01186458|Drug|Rituximab|Rituximab given after Velcade) 375 mg/m2 IV piggyback on day 1. Cycle = 28 days; maximum of 6 cycles of therapy.
46025749|NCT01185834|Device|Lotrafilcon A upgrade soft contact lens|Silicone hydrogel contact lens approved for daily wear and extended wear up to 30 consecutive nights.
46025750|NCT01185600|Biological|Washed RBC|There is no pre-set dosage, frequency and duration for transfusion with washed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed washed RBC for the subject.
45598584|NCT02227589|Behavioral|CBT-D|CBT-D consists of seven weekly sessions of cognitive behavior therapy targeting depression.
46113110|NCT02610647|Other|Tapping test|"Subjects will be placed at a table in a sitting position where they will perform a rhythmic finger tapping test. The seat height is adjusted so that the front dominant arm rests comfortably on the table. Subjects will be equipped with headphones to receive auditory signals during a first synchronized phase of tapping.~After the last auditory signal, participants will continue the tapping task by themselves as directed: after the metronome stops,continue tapping the prescribed tempo as accurately and consistently as possible throughout the test. The movements of the index finger will be measured by a single-axis accelerometer (15 × 15 mm) attached to the nail."
46113111|NCT02595918|Procedure|Metastasectomy|Undergo metastasectomy
46113112|NCT02595918|Procedure|Nephrectomy|Undergo nephrectomy
46113113|NCT02595918|Biological|Nivolumab|Given IV
46113114|NCT02610569|Device|standard endoscopy|standard endoscopy will be either colonoscopy or rectosigmoidoscopy
46113115|NCT02610569|Device|PillCamCOLON (C2)|PillCamCOLON (C2) is a colon video-capsule
46113116|NCT02595840|Drug|Afatinib|
46113117|NCT02595840|Drug|Pemetrexed|
46113118|NCT05756855|Behavioral|adapted behavioral intervention|cognitive behavioral therapy based intervention that focuses on anger, violence, and psychosis
46025751|NCT01185600|Biological|Unwashed RBC|There is no pre-set dosage, frequency and duration for transfusion with unwashed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed unwashed RBC for the subject.
46113119|NCT04089774|Behavioral|Adapted Physical Activity (APA)|Supported by an Adapted Physical Activity (APA), at the rate of 3 sessions per week supervised by the association SCO STE MARGUERITE, spread over 12 months
46113120|NCT00737061|Device|Adiana Transcervical Sterilization System|Implantation of silicone matrix in fallopian tubes
45470127|NCT03753529|Other|Pressure release|First, using a pincer grasp moved throughout the fibers of the pterygoid, masseter, digastric and temporalis muscles to palpate the muscle aiming to locate a trigger point . A common location is detected according to Simon and Travell book. Once located on the trigger point, apply an IC by gradually applying pressure to the trigger point with your thumb. Keep in communication with the patient, checking to ensure that in staying within the limits of his pain tolerance. Hold this technique for approximately 20 seconds to 1 minute, patient tells you that pain has diminished, or until feels the muscle fibers begin to relax under your pressure. Once feel this release, gradually release pressure. All identified trigger points were treated. Then follow-up with a passive stretch to the muscle. This will repeated for three to five times for three sessions per week for 4 weeks.
46025752|NCT02754895|Other|Positive Psychology (PP)|Positive psychology (PP) interventions aim to improve the frequency and intensity of positive emotional experiences. This positive psychology intervention focuses on targeted activities in several domains, including altruism (e.g., performing acts of kindness), gratitude (e.g., systematically recalling positive life events), using one's personal strengths in a deliberate manner, and optimism (e.g., thinking about past successes and applying these skills to the future).
46025753|NCT02754895|Other|Motivational Interviewing (MI)|"MI is a goal-oriented, patient-centered approach to helping patients resolve their ambivalence to change their health behaviors.~Each session follows the same structure. Study trainers will: (a) ask participants about their health goals, (b) advise them about current health guidelines and/or refer them to their treatment team, (c) assess readiness to set a goal by identifying how important participants feel the goal is, how confident participants are about making a change, and what the participants' pros and cons for making a change, (d) assist participants in clarifying their goals and problem-solving barriers to reaching those goals, and (e) arrange for the next session by summarizing the participant's plan and scheduling the next session."
46025754|NCT01185366|Drug|Everolimus|10 mg by mouth once a day.
46025755|NCT01185366|Drug|Sunitinib|50 mg by mouth daily for 4 weeks on / 2 weeks off
46025756|NCT01185288|Biological|Adalimumab|Adalimumab in pre-filled syringes
46025757|NCT01185288|Drug|Methotrexate|Methotrexate capsule
46025758|NCT01184508|Drug|Placebo|Administered orally, once daily, for 12 weeks
46025759|NCT01184508|Drug|LY2300559|300 milligrams (mg) administered orally, once daily, for 12 weeks
46025760|NCT02887014|Procedure|SPECIFIC VERBAL INSTRUCTIONS|Participants will be randomized either to get detailed instructions verbally by the medico-paramedical staff of the participating centers (physicians or nurses) before starting bowel preparation (Group A) or to get ordinary instructions as usual in each of the participating centers (Group B). Instructions provided to Group A will include details about the procedure of bowel preparation, its potential side effects and the importance of the adequate preparation (Appendix)
46113121|NCT02594865|Dietary Supplement|Glucerna|Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.
46113122|NCT02594865|Dietary Supplement|Fresubin|Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
46113123|NCT02594787|Dietary Supplement|Phosphorus|
46113124|NCT02594787|Dietary Supplement|Placebo|
46113125|NCT02594553|Behavioral|GP-parent information-exchange tool|The booklet incorporates already existing information about fever, alarm symptoms, advices use of medication and specific infectious diseases that frequently occur in childhood in combination with fever such as upper respiratory tract infections, and otitis media. The difference with these existing sources of information is the fact that they until now, were not incorporated into one booklet which can be physically handed over to parents.
46113126|NCT02594397|Other|acupoints combination 1|
46113127|NCT02594397|Other|acupoints combination 2|
46113128|NCT02594397|Other|sham acupoints combination|
46113129|NCT00917943|Behavioral|Tailored Counseling Intervention Arm|Study staff contact women when they are between 28 and 34 weeks pregnant, confirm their non-smoking status, and make an appointment to explain the study further, obtain written informed consent, conduct the risk assessment, and collect baseline data. Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
46025761|NCT01184118|Drug|FP 220 mcg 2 puffs BID|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
46025762|NCT01183884|Biological|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid|"3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles .Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage.~Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles. The patients are in > or = to 2nd CR/VGPR and at high risk for additional relapse. Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started after cycle 2."
46025763|NCT05344248|Biological|JS005 (recombinant humanized monoclonal antibody against IL-17A)|Subcutaneous injection
46113130|NCT02594241|Drug|Methyl-Prednisolone|Single-shot 125 mg infusion given immediately after induction of anesthesia.
46025764|NCT05344248|Biological|JS005 placebo|Subcutaneous injection
46025765|NCT01183260|Device|Trabecular Metal Revision Cup|Revision of the acetabular cup
46025766|NCT01183260|Device|Trabecular Metal Modular Cup|Revision of the acetabular cup
46025767|NCT01191762|Drug|sevelamer carbonate|2400 mg with each meal for 4 weeks
46025768|NCT01191762|Drug|placebo|3 tablets with each meal
46025769|NCT04315974|Drug|Rivaroxaban|Rivaroxaban therapy for at least 4 weeks.
46113131|NCT02594241|Drug|Physiological saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
46113132|NCT02594475|Procedure|Endoscopic retrograde cholangiopancreatography|"Endoscopic retrograde cholangiopancreatography is started using conventional duodenoscope (TJF 240 or 260V, Olympus Optical Co., Ltd, Tokyo, Japan) in randomly assigned left lateral position or prone position.~Selective bile duct cannulation is performed using wire-guided cannulation.~In case of difficult cannulation, precut is performed using a needle-knife.~After selective cannulation, cholangiogram is obtained using ERCP catheter, and endoscopic sphincterotomy and/or endoscopic papillary balloon dilation is performed."
46025770|NCT04315974|Procedure|Catheter ablation|Radiofrequency catheter ablation or cryoballoon ablation.
46113133|NCT00585975|Drug|bromfenac ophthalmic solution|sterile opthalmic solution
46113134|NCT02594319|Behavioral|Monetary incentives|
46113135|NCT02594319|Behavioral|Self monitoring|
46113136|NCT04088253|Procedure|umbilical herneal repair|reduction of the herneal content an repair of the defect with IPOM
46113137|NCT00918021|Drug|olanzapine|normal dosage of olanzapine (the same dosage as on hospital ward)
46113138|NCT00918021|Drug|placebo|placebo
46113139|NCT02594007|Device|SEEQ|Mobile cardiac telemetry system worn externally for a total of 28 days.
46113140|NCT02594007|Device|Cardiocom|Patient-based interface tool that includes a blood pressure cuff and blue-tooth enabled scale for daily recordings. The patient will also answer a series of behavioral and symptomatic questions daily through 30 days.
46113141|NCT02594007|Device|DocView|Patient-based interface tool that analyzes state of wellness. The patient will answer a series of questions daily through day 30.
46113142|NCT00585585|Drug|betahistine dihydrochloride|oral, 50-300 mg, daily
46113143|NCT02594085|Other|Patch 1|Patch 1 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 1 contains the subjects own feces. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
46113144|NCT02594085|Other|Patch 2|Patch 2 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve Patch 2 contains the subjects own feces and filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
45470128|NCT03753529|Other|control group|Stretching and transcutaneous electrical nerve stimulation
45470129|NCT04893577|Drug|EDTA|Patients will treat their cold sore with EDTA eye drops based upon their randomization.
46025771|NCT04316208|Procedure|PEEP variations|Patients will be ventilated with a PEEP of 5 cmH2O during induction of anesthesia. After craniotomy, the PEEP will be reduced to 0 cmH2O for 5 minutes and data will be collected at the end of 5 minutes. Next, PEEP will be increased to 5 cmH2O for 5 minutes and data will be collected at the end of 5 minutes. Finally, PEEP will be increased to 10 cmH2O for 5 minutes and data will be collected at the end of 5 minutes.
46025772|NCT01723774|Drug|PD0332991|
46025773|NCT01723774|Drug|Anastrozole|
46025774|NCT01723774|Drug|Goserelin|
46113145|NCT02594085|Other|Patch 3|Patch 3 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 3 contains simulated output. The Patch is placed over the adhesive strip to invesitgate the impact of output on the adhesive strip
46113146|NCT02594085|Other|Patch 4|Patch 4 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 4 contains simulated output with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
46113147|NCT02594085|Other|patch 5|Patch 5 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 5 contains buffer. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
46113148|NCT02594085|Other|Patch 6|Patch 6 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 6 contains buffer with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
46113149|NCT02593929|Drug|ruxolitinib|
46113150|NCT02593851|Drug|JNJ-53718678|JNJ-53718678 oral solution will be administered once or twice daily for 7 days.
46025775|NCT01723774|Procedure|Surgery (standard of care)|-Breast and axillary lymph node surgery
46025776|NCT01723774|Procedure|Tumor biopsy|
45470130|NCT04893577|Drug|Abreva|Patients will treat their cold sore with Abreva based upon their randomization
46113151|NCT02593851|Drug|Placebo|Placebo oral solution will be administered once or twice daily for 7 days.
46025777|NCT02855788|Drug|Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly|metronomic chemotherapy
46025778|NCT02852278|Other|Web-based Survey|This is a prospective 12-month study of patients with motor neuron disease enrolled in CReATe Connect, an RDCRN Contact Registry.
46113152|NCT02593695|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
46113153|NCT02593695|Other|Fluoxetine|Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
46113154|NCT00734097|Drug|Esomeprazole 40 mg|Once a day
45470131|NCT03638232|Other|Administrative data|Gender Birthdate Department and town of residence Date of death Affiliation to french Universal Health Coverage
46113155|NCT00734097|Procedure|Physical Exam|every visit
45470132|NCT03638232|Other|Medical data|Long term affection code, number and medical codification Date of onset and end of care Codification of medical acts and consultation (With common classification of medical acts)
45470133|NCT03638232|Other|Drug exposition data|Speciality of prescribing physician CIP code of drug Name of speciality prescribed Date of deliverance Date of prescription Number of treatment box delivered
45470134|NCT03395626|Dietary Supplement|ID-JPL934|probiotics
45470135|NCT03395626|Dietary Supplement|Placebo|corn starch
45470136|NCT03757975|Procedure|urethral length measure|measure of urethral length, distribution of questionnaires before and after operation
45681835|NCT03583996|Combination Product|HepQuant SHUNT Liver Diagnostic Test|One time testing using the HepQuant SHUNT Liver Diagnostic Test kit (the combination product) in subjects with CLD and undergoing a standard of care EGD. The SHUNT test will be completed prior to the EGD. Each subject will receive an IV push dose of 13C Cholate mixed with Albumin simultaneously with an oral dose of d4 Cholate
45681836|NCT03583918|Device|HighThroughput Micro Coring Device|Assess Safety and Efficacy for skin treatments through micro-excisional skin removal with micro-coring device
46025779|NCT01190514|Drug|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fed condition
46113156|NCT00734097|Other|Quality of Life Questionnaires|every visit
46113157|NCT00734097|Procedure|pregnancy test, if applicable|as needed
45470137|NCT03399448|Biological|NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1|Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRα, TCRβ and PD-1 (NYCE T Cells).
45681837|NCT03583762|Diagnostic Test|Mass spectrometry|Molecular diagnostic test for bacterial identification from bacterial colony
46025780|NCT01190514|Drug|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fed condition
46025781|NCT01190514|Drug|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fast condition
46025782|NCT01190514|Drug|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fast condition
46025783|NCT02852356|Device|MIRI-TL Incubator|MIRI-TL Timelapse incubator
46025784|NCT02886858|Device|Device : Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
46025785|NCT02886858|Device|Device : sham Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
46113158|NCT05756699|Diagnostic Test|multiple reaction monitoring (MRM)-based multimarker panel|multiple reaction monitoring (MRM)-based multimarker panel test to detect hepatocellular carcinoma
46113159|NCT00819767|Drug|Aliskiren|Aliskiren was supplied in 150 mg tablets.
46113160|NCT00819767|Drug|Valsartan|Valsartan was supplied in 160 mg capsules.
46113161|NCT00819767|Drug|Placebo to aliskiren|Placebo to aliskiren was supplied in tablets matching aliskiren 150 mg.
46113162|NCT00819767|Drug|Placebo to valsartan|Placebo to valsartan was supplied in capsules matching valsartan 160 mg.
46113163|NCT02593617|Other|Addiction Profile Index|
46113164|NCT02593617|Other|Alcohol Use Disorders Identification Test|
46113165|NCT02593617|Other|Barratt Impulsiveness Scale|
46113166|NCT02593617|Other|Zuckerman Sensation Seeking Scale|
46113167|NCT02593617|Other|Energy Drink Consumption Questionnaire|
46113168|NCT00922961|Biological|Blood sample|Blood sample taken for the analysis of the rate of CD8 T-Lymphocyte Apoptosis
46113169|NCT00922961|Procedure|Clinical exam|Assessment of the esthetic score, and the late cutaneous side effect by 2 physicians
45470138|NCT03399448|Drug|Cyclophosphamide|a cytotoxic chemotherapy agent used for lymphodepletion prior to NYCE T cells.
46025786|NCT04268290|Combination Product|Single incision plus one port laparoscopic surgery|SILS plus one port surgery and enhanced recovery after surgery protocol both are methods taking the minimally invasive benefits for the patients including faster recovery, reduced postoperative pain and shorter hospital stay.
46113170|NCT00918099|Procedure|Avaulta mesh|Insertion of a mesh vs conventional repair
46025787|NCT00604318|Drug|rhTSH|The patients will be randomised to either T3 (Liothyronine) pause related to the first radioiodine treatment and Thyrogen injection with continuing Liothyronine treatment related to the second treatment/uptake - or Thyrogen related to the first treatment and T3 pause related to the second treatment /uptake.
46113171|NCT00918099|Procedure|Anterior repair|Conventional repair
46113172|NCT05297357|Dietary Supplement|Mediterranean Diet weaning scheme|Kids in experimental group were weaned by using fresh foods traditionally used in MD and appropriately adapted to infants including seasonal fruit and vegetables, various kinds of fresh blue fish, spices and herbs. No salt was used while a small amount of Parmesan cheese was added. No sugar was added to any meal.
46113173|NCT04088175|Other|JUUL ENDS - Virginia Tobacco 5% nicotine strength|JUUL ENDS - Virginia Tobacco 5% nicotine strength
46113174|NCT04088175|Other|JUUL ENDS - Virginia Tobacco 3% nicotine strength|JUUL ENDS - Virginia Tobacco 3% nicotine strength
46113175|NCT04088175|Other|JUUL ENDS - Menthol 5% nicotine strength|JUUL ENDS - Menthol 5% nicotine strength
46113176|NCT04088175|Other|JUUL ENDS - Menthol 3% nicotine strength|JUUL ENDS - Menthol 3% nicotine strength
46113177|NCT04088175|Other|JUUL ENDS - Mint 5% nicotine strength|JUUL ENDS - Mint 5% nicotine strength
46113178|NCT04088175|Other|JUUL ENDS - Mint 3% nicotine strength|JUUL ENDS - Mint 3% nicotine strength
46113179|NCT04088175|Other|JUUL ENDS - Mango 5% nicotine strength|JUUL ENDS - Mango 5% nicotine strength
46113180|NCT04088175|Other|JUUL ENDS - Mango 3% nicotine strength|JUUL ENDS - Mango 3% nicotine strength
46113181|NCT00733005|Drug|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
46113182|NCT00733005|Drug|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
46113183|NCT00812981|Biological|GSK1562902A|new-processed (NP), administered intramuscularly in the deltoid region of the non-dominant arm
46113184|NCT00812981|Biological|GSK1562902A|comparative-processed (CP), administered intramuscularly in the deltoid region of the non-dominant arm
46113185|NCT05756621|Drug|Ketamine|"Dual anti-glutamatergic therapy (DUAL) intervention group: patients who received ketamine as a continuous i.v. for 3 days (induction dose 1.5-3 mg/kg, followed by maintenance dose 2-10 mg/kg/h; dose adjustment according to EEG target of ketamine pattern) + oral perampanel via nasogastric tube for 5 days (12 mg if weight > 60 kg; 9 mg if weight 50-60 kg; 6 mg if weight < 50 kg), followed by gradual reduction according to clinical evolution."
46113186|NCT05756621|Drug|Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel|Any antiseizure and anesthetic therapy according to usual clinical practice, excluding the two anti-glutamate drugs Ketamine and Perampanel
46113187|NCT00732615|Drug|Placebo|Placebo for subcutaneous injection
46113188|NCT00732615|Drug|NPSP558|Parathyroid hormone 50, 75, or 100 mcg injectable subcutaneously daily
46025788|NCT01190436|Drug|Bisoprolol|Bisoprolol will be administered at an initial dose of 5 milligram (mg) once daily for 2 weeks. If the blood pressure would be greater than or equal to 130/80 mmHg after 2 weeks, then dose will be adjusted to 10 mg once daily. Total duration of study treatment will be 12 weeks.
46025789|NCT02852122|Drug|C-11 choline|This is an uncontrolled, open-labeled, non-randomized, prospective study. The study duration is expected to be completed in a period of 2 years. Up to 54 patients with primary prostate cancer and stratified as high risk group (PSA > 20 ng/mL, or Gleason score 8-10, or clinical stage >T2c) would be included.
46113189|NCT00732381|Drug|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
46113190|NCT00732381|Drug|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
46113191|NCT04871711|Drug|Delgocitinib cream|Cream for topical application
45470139|NCT03399448|Drug|Fludarabine|a chemotherapy agent used for lymphodepletion prior to NYCE T cells.
45470140|NCT03399448|Device|NY-ESO-1 expression testing|Testing to determine if NY-ESO-1 is expressed on tumor tissue.
46025790|NCT01035255|Drug|LCZ696 200 mg BID|LCZ696 200 mg BID
46025791|NCT01035255|Drug|Enalapril 10 mg BID|Enalapril 10 mg BID
46113192|NCT04871711|Drug|Cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
46113193|NCT05756543|Behavioral|Counterfactual Inference Test|All participants were asked to complete the Counterfactual Inference Test - CIT (McNamara et al., 2003), a neuropsychological test that measures the ability to produce counterfactual-derived inferences. Moreover, the decision-making ability will be specifically tested through ad-hoc questionnaire (i.e., the Decision-Making Questionnaire). Finally, all participants will be screened with an extensive neuropsychological assessment, particularly on executive functioning.
46113194|NCT00913991|Behavioral|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
46113195|NCT00913991|Behavioral|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
45470141|NCT05370625|Dietary Supplement|Totum-854|To compare Totum-854 with Placebo on blood pressure
45470142|NCT05370625|Dietary Supplement|Placebo|Five capsules per day to consume orally in two intakes
46025792|NCT04268056|Diagnostic Test|Collection of skin culture samples|Collection of skin culture samples using a sterile swab. the swab will gently rubbed on the skin on the 3 different skin areas. The target areas are i) regions surrounding the RT treatment area (if possible, not from the scar area or from skin folds areas), ii) a control site of the normal (healthy) breast , iii) a control area on the forehead.
46025793|NCT00631072|Biological|INKT|Administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.
46113196|NCT04037033|Behavioral|Everyday Meaningful Activities (EMA) intervention|"The EMA intervention will include 6 intervention sessions. At session 1, the interventionist and participant will identify 2 meaningful active lifestyle behavior goals using COPM. Last, an action plan will be created for behavior 1. Participants will be asked to implement the action plan everyday.~At session 2, the interventionist and participants will review the daily activity log and the action plan.~At session 3, the interventionist and the participants will review the daily activity log and the action plan.~At session 4, an action plan will be created for behavior 2. Participants will be asked to implement the action plan for behavior 2 everyday.~At session 5, the participants and interventionists will discuss the participant's daily activity log and action plan.~At session 6, the participants and interventionists will discuss the participant's daily activity log and action plan."
46113197|NCT00732303|Drug|Pemetrexed|Pemetrexed (Alimta) 500mg/^2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles
46113198|NCT00732303|Radiation|Radiation Therapy|"Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy must be a Monday, Tuesday, or Wednesday.~The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks."
46113199|NCT02593461|Device|Daifert|
46113200|NCT02593461|Other|Control Group|
46113201|NCT00813761|Device|O2Optix contact lens|control contact lens to be worn daily for approximately 7 months for entire length of study.
46113202|NCT00813761|Device|Proclear contact lens|control contact lens to be worn for entire length of study.
46113203|NCT00813761|Device|ReNu MultiPlus Multi-Purpose Solution|lens solution for overnight lens disinfection
46113204|NCT00813761|Device|Clear Care Cleaning and Disinfecting Solution|lens solution for overnight lens disinfection
46113205|NCT00732069|Drug|Placebo|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
46113206|NCT00732069|Drug|Ramipril|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
46113207|NCT00732069|Drug|Valsartan|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
46113208|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.1% Adapalene + 1% Clindamycin Hydrochloride
46113209|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.1% Adapalene + 2% Clindamycin Hydrochloride
46113210|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.05% Adapalene + 0.5% Clindamycin Hydrochloride
46113211|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.05% Adapalene + 1% Clindamycin Hydrochloride
46113212|NCT02593383|Drug|Placebo|
46113213|NCT02609321|Procedure|Thoracic Paravertebral Block|Thoracic paravertebral block at T3 level with bupivacaine 0.5%, dosis 1.5mg/Kg
46113214|NCT02609321|Procedure|Surgical Wound Infiltration|Surgical wound infiltration on the skin and subcutaneous tissue in surgical area with bipivacaine 0.5%, dosis 1.5mg/kg
46113215|NCT04856813|Other|Manual therapy active|massage or ischemic compression with active contraction, tha will be isometric or concentric.
46025794|NCT00631072|Drug|GM-CSF|Given subcutaneously once daily for 10 days beginning the second day of the second and third infusion
46025795|NCT00602524|Drug|Pilocarpine|
46025796|NCT01189890|Drug|sitagliptin phosphate|Sitagliptin tablets, orally, at a dose of 100 mg or 50 mg QD for 30 weeks. The dose level to be administered will depend on the participant's estimated glomerular filtration rate (eGFR), calculated at Visit 3 and may be adjusted as medically indicated during the study.
46025797|NCT01189890|Drug|Glimepiride|Glimepiride tablets, orally, starting at a dose of 1 mg QD, which may be gradually increased, as needed, to maximum dose of 6 mg QD for 30 weeks. The dose may also be decreased as medically indicated during the study.
46025798|NCT01189890|Drug|Placebo to Sitagliptin|Matching placebo tablets to sitagliptin to allow for blinding.
46113216|NCT04856813|Other|Manual therapy|massage or isquemic compression without contraction
46025799|NCT01189890|Drug|Placebo to Glimepiride|Matching placebo tablets to glimepiride to allow for blinding.
46025800|NCT01189812|Drug|Lithium Carbonate|300 mg one time per day for 4 weeks
46113217|NCT02609243|Behavioral|dietary consulting|dietary consulting implies specific dietary advice based on pre-interventional self-report regarding food intake; consulting focuses on nutrient content, calory intake, weight loss; with regard to randomisation consulting intensity and content varies
46113218|NCT05756387|Device|Non-invasive ventilation|NIV as in standard care
46113219|NCT00731679|Drug|Rifaximin|
46113220|NCT00731679|Drug|Placebo|
45838789|NCT04361058|Drug|Nivolumab|At Day +50 (±10 days) post-allogeneic SCT, participants will be treated with Nivolumab. Nivolumab will be administered intravenously once every two weeks for a total of 4 treatments. Participants will initially receive nivolumab at a significantly reduced starting dose of 0.25 mg/kg. This dose was determined based on the incidence of increased aGVHD, which was noted after treatment post-SCT in previous studies. Nivolumab IV will be given every 2 weeks for 4 cycles. One dose of nivolumab is equivalent to one cycle. The first administration will be at Day +50 (±10 days), assuming the participant has not had any evidence of Grade II-IV aGVHD after allogeneic SCT and does not have any current evidence of any grade of aGVHD at the day of first application of nivolumab. Depending on emerging safety data, dose escalation cohorts will explore higher dose levels of nivolumab at 0.5 mg/kg and 1 mg/kg.
46113221|NCT02609087|Drug|Sevoflurane|
46113222|NCT02609087|Drug|Propofol|
46113223|NCT04812119|Diagnostic Test|The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F)|The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F; Robins, Fein, & Barton, 2009) is a 2-stage parent-report screening tool to assess risk for Autism Spectrum Disorder (ASD). It is valid for children 16-30 months old.
46025801|NCT01189812|Drug|Placebo|Take one time daily for 4 weeks
45470143|NCT03883282|Other|Not Provided|Not Provided
46025802|NCT01189812|Drug|Citalopram|All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)
46113224|NCT04812119|Diagnostic Test|The Autism Spectrum Quotient-Children's Version (AQ-Child)|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright & Allison, 2008) is a parent-report questionnaire that aims to quantify autistic traits in children 4-11 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
46113225|NCT04812119|Diagnostic Test|The Autism-Spectrum Quotient (AQ)-Adolescent Version (AQ-Adolescent)|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright & Allison, 2008) is a parent-report questionnaire that aims to quantify autistic traits in children 12-15 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
46113226|NCT04812119|Diagnostic Test|The Viking's Speech Scale|The Viking Speech Scale (Pennington, Virella, Mjøen, da Graça Andrada, Murray, Colver, … & Andersen, 2013) is used to classify children's speech production, specifically the ease at which children can make themselves understood using different methods of communication. The scale has four levels and is ordinal. The four levels include: (1) speech is not affected by motor disorder (2) speech is imprecise but usually understandable to unfamiliar listeners (3) speech is unclear and not usually understandable to unfamiliar listeners out of context (3) no understandable speech. It is intended for children above the age of 4 years.
46113227|NCT04812119|Diagnostic Test|The Functional Communication Classification System (FCCS)|The Functional Communication Classification System (Barty, Caynes & Johnston, 2016) was designed to classify how children with cerebral palsy communicate on a daily basis. The tool focuses on how children typically communicate with familiar and unfamiliar communication partners. There are five classifications a child can be categorized in: (1) effective communicator in most situations (2) effective communicator in most situations, but does need some help (3) an effective communicator in most situations and can communicate small ranges of messages and topics to most familiar people (4) assistance is required in most situations, especially with unfamiliar people and environments. Communicates daily needs and wants to familiar people (5) communicates using undirected movement, vocalisation and/or behaviour, for interpretation by familiar people. The FCCS is valid for use in children up to 13 years.
46113228|NCT04812119|Diagnostic Test|Brief Infant Sleeping Questionnaire (BISQ)|The Brief Infant Sleep Questionnaire (BISQ; Sadeh, 2004) is used to assess sleep patterns, parent perception, and sleep-related behaviors in young children (0-36 months). The BISQ has been validated against actigraphy, daily logs, and has high sensitivity in documenting expected developmental trends in sleep.
46113229|NCT04812119|Diagnostic Test|Pediatric Sleep Questionnaire (PSQ)|Pediatric Sleep Questionnaire (PSQ; Chervin, Hedger, Dillon, Pituch, 2000) has been designed to screen for sleep problems in children. The scale consists of 22 parent-reported items examining snoring and breathing problems, daytime sleepiness, inattention, hyperactivity, and other signs and symptoms of apnea including obesity and nocturnal enuresis. Those questions specifically relate to sleep-disordered breathing (SDB) in children. PSQ has been validated for children 2-18 years old.
46025803|NCT00950950|Drug|Romosozumab|Administered by subcutaneous injection
46025804|NCT00950950|Drug|Placebo|Administered by subcutaneous injection
46025805|NCT00950872|Device|Duet TRS|Patients will have their gastric pouch created with ENDO GIA staplers with Single Use Loading Units with Duet TRS.
46025806|NCT04302597|Procedure|Staples|Skin closure using surgical stapler.
46025807|NCT04302597|Procedure|Tissue adhesive|Skin closure using 2-octylcyanoacrylate tissue adhesive.
46025808|NCT01189500|Drug|Tamoxifen|Period 1-Tamoxifen 40mg on study day 1.
46025809|NCT01189500|Drug|Tamoxifen and Desvenlafaxine Succinate Sustained Release|Period 2-Desvenlafaxine SR 100mg on days 1-28 with coadministration of Tamoxifen 40mg on day 7.
46025810|NCT02874339|Device|High flow nasal oxygen therapy|In the optiflow group, oxygen will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs. Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance.
46113230|NCT04812119|Diagnostic Test|The Eating and Drinking Ability Classification System (EDACS)|The Eating and Drinking Ability Classification System (EDACS; Sellers, Mandy, Pennington, Hankins, Morris, 2013) has been developed for people with cerebral palsy to describe five distinct levels of ability using the key features of safety and efficiency. The patient can be categorized in: (1) eats and drinks safely and efficiently, (2) eats and drinks safely but with some limitations to efficiency, (3) eats and drinks with some limitations to safety; maybe limitations to efficiency, (4) eats and drinks with significant limitations to safety or (5) unable to eat or drink safely - tube feeding may be considered to provide nutrition. The EDACS is valid for use in children above the age of 36 months.
46025811|NCT02874339|Device|Non invasive ventilation|In the NIV group, NIV will be delivered through a face mask connected to a ventilator with pressure support applied in a noninvasive ventilation mode. The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort.
46025812|NCT00627315|Procedure|Gastric bypass|NOTE: Surgery will not be paid by the study
46025813|NCT00627315|Procedure|Gastric banding|NOTE: Surgery will not be paid by the study
46025814|NCT00938860|Drug|cyclosporin (Neoral)|Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
46025815|NCT00938860|Drug|tacrolimus (Prograf)|Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
46025816|NCT05381584|Procedure|laparoscopy|laparoscopy will be done under anesthesia for management for cases with blind vagina
46113231|NCT04812119|Diagnostic Test|Mini Manual Ability Classification System (Mini-MACS)|The Mini Manual Ability Classification System (Mini-MACS; Eliasson, Krumlinde-Sundholm, 2013) describes how children with cerebral palsy use their hands to handle objects in daily activities. MACS describes five levels. The levels are based on the children's self-initiated ability to handle objects and their need for assistance or adaptation to perform manual activities in everyday life. It has been validated for children 1-4 years of age.
46113232|NCT04812119|Diagnostic Test|Manual Ability Classification System (MACS)|The Manual Ability Classification System (MACS; Eliasson, Krumlinde Sundholm, Rösblad, Beckung, Arner, Öhrvall, Rosenbaum, 2006) describes how children with cerebral palsy use their hands to handle objects in daily activities. MACS describes five levels. The levels are based on the children's self-initiated ability to handle objects and their need for assistance or adaptation to perform manual activities in everyday life. It has been validated for children 4-18 years.
46113233|NCT04812119|Diagnostic Test|The Gross Motor Function Classification System - Expanded and Revised (GMFCS - E&R)|The Gross Motor Function Classification System - Expanded & Revised (GMFCS - E&R; Palisano, Rosenbaum, Bartlett, Livingston, 2007) is a 5-level classification system that describes the gross motor function of children and youth with cerebral palsy on the basis of their self-initiated movement with particular emphasis on sitting, walking, and wheeled mobility. Distinctions between levels are based on functional abilities, the need for assistive technology, including hand-held mobility devices (walkers, crutches, or canes) or wheeled mobility, and to a much lesser extent, quality of movement. The questionnaire is available for four age groups of children and youth: 2 to < 4 years, 4 to < 6 years, 6 to < 12 years, and 12 to 18 years.
45598585|NCT02227589|Other|D-TAU|D-TAU is treatment as usual in the community, targeting depression. It may consist of medication and/or behavioral intervention.
46025817|NCT00604396|Drug|insulin detemir|
46025818|NCT00604396|Drug|insulin NPH|
46025819|NCT00938470|Drug|capecitabine|Given PO
46025820|NCT00938470|Drug|docetaxel|Given IV
46025821|NCT00938470|Drug|fluorouracil|Given IV
46025822|NCT00938470|Drug|oxaliplatin|Given IV
46025823|NCT00938470|Radiation|radiation therapy|Undergo radiation therapy
46025824|NCT00938470|Procedure|therapeutic conventional surgery|Undergo surgery
46025825|NCT00602680|Drug|SSR180711C|duration of treatment: 4 weeks
45598586|NCT02259101|Behavioral|CBT-I Treatment Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
46025826|NCT00602680|Drug|donepezil|duration of treatment: 4 weeks
46025827|NCT00602680|Drug|placebo|duration of treatment: 4 weeks
46025828|NCT02852200|Other|SEGAm|
45598587|NCT02259101|Behavioral|SH Comparison Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
46025829|NCT00938392|Biological|GSK investigational FluNG vaccine GSK2186877A, aged lot|Single dose, intramuscular injection
46025830|NCT00938392|Biological|GSK investigational FluNG vaccine GSK2186877A, fresh lot|Single dose, intramuscular injection
46113234|NCT04812119|Diagnostic Test|The Visual Function Classification System (VFCS)|The Visual Function Classification System (Baranello et al, 2019) is a valid and reliable 5-level classification system of visual functioning for children with Cerebral Palsy. It describes the use of visual abilities in daily life, focusing on activity and participation.
45470144|NCT03756025|Procedure|Atraumatic Restorative Treatment (ART)|The atraumatic restorations were performed in the dental office by a single operator trained in the ART Technique [20], who received the restorative material already prepared by a trained auxiliary, ensuring blinding of the study. The restorative procedure performed in relative isolation and without the use of anesthesia consisted of removal of the carious tissue using hand instrument excavators and dentin spoons, with subsequent conditioning of the cavity with a polyacrylic acid solution at 11.5% (DFL) applied with a microbrush for 10 seconds. Immediately after, the cavity was washed and dried with cotton balls. In this step, according to the randomization, the respective GIC was inserted and subsequent digital compression was performed for 30 seconds. After occlusal adjustment, the ARTs were protected with finish gloss Alfa Bond® (DFL).
45470145|NCT04202757|Biological|[21CFR640.30] Plasma from 18 - 25 year old volunteer donors|12.5 ml/kg intravenous Spectrum Plasma yFFP, per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
46113235|NCT04812119|Diagnostic Test|The Early Childhood Oral Health Impact Scale (ECOHIS)|The ECOHIS measures the impact of oral problems and/or experience of dental treatment on the quality of life in children under 5 years old and their parents or other family members. It has 13 questions divided into two domains: one related to impact on the child (9 questions), and another to impact on the family (4 questions), measured using the Likert scale. In children with cerebral palsy and/or the ECOHIS has been validated for ages up to 6,5 years, in children with intellectual disability for ages up to 5 years and in children with special need for ages up to 9 years.
46113236|NCT04812119|Diagnostic Test|The Family Impact Scale (FIS)|The FIS evaluates the impact of a child's oral condition on family life. It consists of 14 items divided into three subscales: parental/family activity (PA), parental emotions (PE), and family conflict (FC). The financial burden subscale (FB) is the only one that is evaluated separately, since it comprises a single item and addresses economic rather than psychosocial or behavioural impact. It has been validated for children above the age of 12 years.
46113237|NCT04812119|Diagnostic Test|The Achenbach System of Empirically Based Assessment (ASEBA)|The Achenbach System of Empirically Based Assessment (ASEBA; Achenbach) is a collection of questionnaires used to assess adaptive and maladaptive behavior and overall functioning in individuals. The system includes report forms for multiple informants - the Child Behavior Checklist (CBCL) is used for caregivers to fill out ratings of their child's behavior, the Youth Self Report Form (YSR) is used for children to rate their own behavior, and the Teacher Report Form (TRF) is used for teachers to rate their pupil's behavior. The ASEBA seeks to capture consistencies or variations in behavior across different situations and with different interaction partners. The ASEBA exists for multiple age groups, including preschool-aged children, school-aged children, adults, and older adults. Scores for individuals in each age group are norm-referenced.
46113238|NCT04812119|Diagnostic Test|Adaptive Behavior Assessment System Third Edition (ABAS-3)|The ABAS-3 (Harrison, Oakland, 2015) is a rating scale useful for assessing skills of daily living in individuals with developmental delays, autism spectrum disorder, intellectual disability, learning disabilities, neuropsychological disorders, and sensory or physical impairments. Rating forms are filled out by the parent and a teacher. The ABAS-3 covers three broad domains: conceptual, social, and practical, using 11 skill areas within these domains. Tasks focus on everyday activities required to function, meet environmental demands, care for oneself, and interact with others effectively and independently. On a 4-point response scale, raters indicate whether, and how frequently, the individual performs each activity.
46113239|NCT00731133|Drug|Disulfiram|250 mg/day
46113240|NCT05326451|Device|active tDCS|Participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with HD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down. Sessions will be remotely supervised by trained research staff (RA), and will run from Monday through Friday for four consecutive weeks.
46025831|NCT00602758|Behavioral|Motivational interviewing with cognitive behavioral therapy|Counseling sessions are completed face-to-face or by telephone at baseline and Weeks 1, 2, 4, 6, 9, 11, 15, 19, and 23. Counselors are trained in motivational interview technique and focus on ART medication adherence.
46025832|NCT00602758|Behavioral|Modified directly observed therapy|From baseline to Week 16, Monday through Friday, study staff meet the participants daily to observe one dose of their ART and to leave with the participants all other doses needed until the next observed dose. The frequency of observed doses begins to taper at Week 17 through to Week 24.
46113241|NCT03964077|Diagnostic Test|Neurogenic Bladder Symptom Score Questionnaire|Neurogenic Bladder Symptom Score Questionnaire is a self-reported 24 item questionnaire.
46025833|NCT02851888|Drug|Ropivacaine|Iliac fascia block was performed in the experimental group with a single shot of Ropavicaine.
46025834|NCT02851888|Other|Normal Saline Sham Injection|Sham block using normal saline instead of iliac fascia block but otherwise employing the equivalent technique.
46025835|NCT02851888|Procedure|General Anesthesia|Patients were induced and maintained in a fashion consistent with standard practices.
46025836|NCT05381428|Drug|Indomethacin suppository|Control Group: Patients will be randomized to receive a 100 mg indomethacin suppository will be administered immediately before the endoscopic procedure (20-30 minutes) and saline infusion will be given as needed.
46113242|NCT05756309|Device|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
46113243|NCT00730275|Drug|Sitagliptin phosphate|Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of sitagliptin 50 mg tablet, sitagliptin 100 mg tablet, or sitagliptin 200 mg.
46025837|NCT05381428|Combination Product|Indomethacin suppository and high-flow lactated ringer infusion combination|Interventional group: Patients will be randomized to receive an indomethacin suppository that will be administered immediately before (20-30 minutes) the endoscopic procedure in combination with a lactated Ringer's infusion that will be administered with the following weight-based schedule: 3 cc/kg/h during ERCP, a bolus of 20 cc/kg after ERCP, and again 3 cc/kg/h for 8 hours after ERCP.
46113244|NCT00730275|Drug|Comparator: matching placebo|Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.
45681838|NCT03583762|Diagnostic Test|Microarray assay|Bacterial identification by Microarray assay from positive blood culture and confirmed by Mass spectrometry technique from bacterial colony. Adjusted antibiotic therapy according to AST Re-evaluation after treatment
46025838|NCT00604474|Device|HiResolution Bionic Ear System (Cochlear Implant)|Subjects are required to have bilateral implantation of the Advanced Bionics HiResolution Bionic Ear System (Cochlear Implant)
46113245|NCT04793711|Device|EpiCeram|Barrier cream
46113246|NCT02609009|Other|Spinal Manipulation Therapy|Intervention will consist of Diversified type adjustments. Patients will be assigned to the nearest participating chiropractic clinic and will have a complete standardized examination on their first visit. Patient will then receive a maximum of 12 treatments (3x per week for a period of 4 weeks).
46113247|NCT02609009|Other|Usual Medical Care|Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises. If recommended, physical therapy will be provided by the hospital physical therapy services. Physical therapy might include treatments such as massage, different electrotherapy, postural repositioning, exercises, etc
46113248|NCT00730041|Device|Pillar Palatal Implant System|The Pillar system is intended as an initial treatment option for mild to moderate OSA. It consists of a delivery system and an implant. The delivery system is comprised of a disposable handle and needle assembly that allows for positioning and placement of the implant within the soft palate of the mouth. The 18mm x 2mm implant is a cylindrical shaped segment of braided polyester filaments that is intended for permanent implantation into the soft palate. The implant is pre-loaded into the needle. Three implants are placed in each subject under local anesthesia. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
46113249|NCT00730041|Device|Sham system|The Pillar system consists of a delivery system and an implant. The only difference between the treatment and sham arm in this study is that the sham delivery device is not pre-loaded with the implant. Otherwise the appearance, manufacturing and function of the delivery devices are identical. Three insertions are made, but no implants are actually deployed during the procedure. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
46113250|NCT04031495|Device|central vein cannulation|central vein cannulation
46025839|NCT02852044|Behavioral|Rest|Allowed to watch television or read for one hour prior to oral glucose tolerance test
45470146|NCT04202757|Other|Saline|12.5 ml/kg intravenous 0.9% sodium chloride with 0.1% riboflavin , per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
45681839|NCT03583294|Other|MRI pelvic|Pelvic MRI
45681840|NCT05701696|Diagnostic Test|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
45681841|NCT05701696|Diagnostic Test|Widespread pain index|Total the number of painful body areas
46025840|NCT02852044|Behavioral|Exercise|One hour of cycling at 50% of maximal power output
46025841|NCT02852044|Other|Dorsal Hand Vein Cannulation (heated hand technique)|
46025842|NCT02852044|Other|Venous Cannulation|
46025843|NCT02851654|Device|Infrared oculography|The infrared oculography provides binocular recordings and allows simultaneous measurement of horizontal and vertical eye movements.
46025844|NCT02851966|Procedure|mTESE|mTESE time may be postponed or advanced.
46025845|NCT02851732|Behavioral|Quality Improvement Intervention|The quality improvement intervention includes case management, reminders, check lists, educational materials, and audit and feedback reports
45681842|NCT05701696|Diagnostic Test|Symptom severity scale|The sum of the fatigue, waking unrefreshed and cognitive symptoms and the extent of somatic symptoms
46113251|NCT04026893|Procedure|Uterine Transplant from Deceased Donor|The recipient will be started on anti-rejection medications (as is routine for transplant recipients) prior to the OR. Standard of care anesthesia and line placement will take place. The recipient will be appropriately identified as an organ recipient and the donor organ identified per required transplant protocols already in place. The recipient team will then connect the vasculature and appropriate supporting structures for the uterus transplant. Once the organ has been re-perfused, the remainder of the operation will take place and the patient will be moved to the Intensive Care Unit and later to the transplant patient floor for standard monitoring.
46113252|NCT05756231|Behavioral|SIHT-16|a pencil-paper assessment tool.
46113253|NCT04790825|Procedure|Full mouth scaling and root planing (FMSRP)|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets completed within 48 hours
46113254|NCT02610257|Device|Mechanical stimulus (vibration) applied on the forearm|"Local vibration will be applied using a custom-made vibratory system (named Vibrators) consisted of small vibratory devices (constructed using DC micro motors (Faulhaber® - Switzerland) bearing an eccentric load, enclosure on a PVC involucre). Vibrators measure 4.5cm x 2cm x 2cm and weight 27-31g each. Vibrators were custom-made especially for this study and therefore do not have a trade name.~Vibrators will be positioned either on the extensor carpi radialis brevis (ECRB) muscle belly or on the olecranon region. Devices will be kept in place using regular elbow elastic supports."
46113255|NCT00729651|Drug|alendronate sodium (+) cholecalciferol|Alendronate sodium/Cholecalciferol; tablet, once weekly, for 16 weeks
45470147|NCT03316170|Behavioral|Social Support|A brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs, and a written directory of a range of social support resources delivered via mail.
46113256|NCT00729651|Drug|Comparator: Alendronate sodium (Fosamax)|Alendronate sodium; tablet, once weekly, for 16 weeks
46113257|NCT00729651|Dietary Supplement|Comparator: Calcium|500 mg oral tablet calcium once daily, for 16 weeks
45470148|NCT03316170|Drug|NRT Sampling|"A brief phone consult (10-15 minutes via phone) germane to smoking cessation akin to brief advice, a written summary of the benefits of smoking cessation, evidence-based approaches to quit, and the basics of nicotine replacement therapy (NRT) delivered via mail, and a free, 2-week supply of nicotine patches and lozenges delivered via mail."
46025846|NCT02855320|Other|Nurse-led self-management education intervention|A nurse education consultation at M 0 and M3 in addition to the usual care by the rheumatologist. The nurse will assess the patients' health beliefs and educational needs, focusing on safety skills, self-injections and motivation. The control group will have usual care by the rheumatologist.
45470149|NCT03395548|Drug|Macrogol|Used drug: Macrogol (osmotic laxative)
45470150|NCT03753451|Procedure|treatment of periodontal disease|Patients with periodontal disease received treatment of periodontal disease through ultrasound or manual scaling of dental calculations. In addition to receiving instructions to improve oral health, such as the correct use of dental floss, adequate time and the correct way to brush.
45470151|NCT03399214|Drug|IOP Injection|T1 and T2
45470152|NCT03638388|Procedure|Dry needling (DN)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the tender area of my muscle. The needles will be repositioned a few times to make the muscle twitch. After several twitches occur, the researcher will leave the needles as they are, and the subject will sit in a chair without moving my arms or head, for 10 minutes. After 10 minutes the needles are removed and discarded.
45470153|NCT03638388|Procedure|Dry needling with intramuscular electrical stimulation (DNES)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the tender area of the muscle. The needles will be repositioned a few times to make the muscle twitch. After several twitches occur, the researcher will leave the needles as they are, and attach alligator clips to the needles to provide electrical stimulus for 10 minutes while the subject sits in a chair without moving arms or head. After 10 minutes, the electrical stimulus will be turned off and detached, and the needles removed and discarded.
46025847|NCT04204174|Dietary Supplement|Tyrosine, brand name: myprotein|tyrosine at a dose of 100 mg/kg is then administered orally to the participants once
46025848|NCT05100004|Device|Accelerated Theta Burst Stimulation|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
46025849|NCT05100004|Device|Sham Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system."
46025850|NCT01022853|Drug|BI 6727|intravenous each 21 days
45470154|NCT03755947|Drug|Ibrutinib|Ibrutinib Oral Capsule [Imbruvica] Tablets 120 mg. Oral. 420mg/day, day 1 to 28, every 28 days. 3 cycles.
46025851|NCT01022853|Drug|BIBF 1120|oral continuously
45470155|NCT03755947|Drug|Obinutuzumab|Obinutuzumab Injection. Intravenous Solution [Gazyva] Parenteral. 1000 mg, day 1 of every cycle, every 28 days. 6 cycles.
46025852|NCT00937768|Drug|Goserelin Acetate|Given SC
46025853|NCT00937768|Other|Laboratory Biomarker Analysis|Correlative studies
46025854|NCT00937768|Drug|Leuprolide Acetate|Given IM
46025855|NCT00937768|Other|Quality-of-Life Assessment|Ancillary studies
45470156|NCT03755947|Drug|Venetoclax|Venetoclax Oral Tablets [Venclexta] Tablets 100 mg. Oral. 400 mg/day. Day 1 to 28, every 28 days. 12 cycles.
46025856|NCT04204018|Other|Experimental Arm|"First, these providers will receive educational materials (e.g. a slide deck) meant to mimic what physicians will receive in the real-world market as they learn about the Progenity technology.~Second, within each of their four cases, intervention-arm physicians only will receive simulated test results from the Progenity PE test at the clinically-appropriate point in each case."
46025857|NCT02851810|Behavioral|oculomotor parameter recording|visual scanning behavior is assessed during visualization of emotional pictures
46025858|NCT02851810|Behavioral|attachment scale interview (ASI)|ASI is used to determine the attachment style of each participant
46025859|NCT02851810|Behavioral|psychophysiological recording|this consists of the measurement of the skin conductance reactivity (SCR) during the picture visualization
46025860|NCT02851810|Behavioral|psychometric assessment|self administered questionnaires are used to assess anxiety, depression and alexithymia.
45470157|NCT03395470|Drug|PXL770|MAD
45470158|NCT03395470|Drug|Placebo|MAD
45470159|NCT03395470|Drug|Rosuvastatin|DDI
45470160|NCT03257865|Drug|Brexpiprazole|Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.
45470161|NCT03257865|Drug|Placebo|Administered orally daily for 3 weeks.
45681843|NCT05701696|Other|Fibromyalgia impact questionnaire|A tool to assess health status in fibromyalgia
45470162|NCT04620330|Drug|avutometinib (VS-6766)|Monotherapy
45470163|NCT04620330|Drug|avutometinib (VS-6766) and Defactinib|Combination therapy
45470164|NCT04104412|Biological|human umbilical cord mesenchymal stem cell|2*10^7
45470165|NCT05056129|Behavioral|Sensor-controlled digital game (SCDG)|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid rehospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal HF health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback (e.g., reduce fluid intake or call doctor for weight gain) to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
45681844|NCT05701696|Diagnostic Test|Hospital Anxiety and Depression Scale|An instrument for detecting depression and anxiety
45838790|NCT04360902|Other|Anemia Controller|"Model Predictive Controller software (called Anemia Controller) that utilizes our physiology-based erythropoiesis model to provide ESA dosing recommendations in order to guide a patient's Hgb level towards a predefined target value."
46025861|NCT02851810|Behavioral|parent interview|an interview of the adolescent parent is performed in order to assess the confusion of the parent-child role and the interaction between the child and its parent.
46025862|NCT00602914|Device|MicronJet|The micronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the skin). In this study the MicronJet will be used to inject insulin vs. a convention needle injection.
46025863|NCT00602914|Device|MicronJet|MicronJet, Intradermal Injection
46025864|NCT00940888|Device|SJ4 connector and RV high voltage SJ4 lead|Standard of care implantation of SJ4 device system
46025865|NCT05381116|Device|Avation System|Subjects will perform therapy with active Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, eligible Subjects from the Active Arm will be offered the opportunity to participate in the additional twenty one (21) month Open-Label Phase.
46025866|NCT05381116|Device|Sham Avation System|Subjects will perform therapy with sham Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, all Subjects from the Sham Arm will be offered the opportunity to crossover and participate in the additional twenty one (21) month Open-Label Phase.
46025867|NCT00631228|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
46025868|NCT02851576|Other|Infusion of ADV specific T cells|Cell engineering
46025869|NCT05381038|Device|QPOP|QPOP is a mechanism-agnostic platform for optimizing drug selection. QPOP uses a quadratic equation to describe the patient-specific drug-drug interaction space based solely on experimentally derived drug-response data on individual patient's tissue sample, from which optimal drug combinations can be identified. Drug selection via QPOP allows for identification of an optimal combination therapy without the need for exhaustive testing of every combination. The first stage of the trial aims to generate a personalised QPOP drugs list for each participant based on experimentally derived data from ex vivo testing in the participant's tissue sample. Optimal drugs from a pre-specified drug pool will be recommended by the QPOP team.
45470166|NCT05056129|Behavioral|Sensor Only|Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). This group will also be provided with standardized evidence-based HF educational material.However, the data from the Withings sensors will not be routed to the SCDG.
46113258|NCT04088019|Drug|Fixed drug combination (FDC) of ATT and Oral steroid|"In the first two week, patients receive FDC of ATT only. Oral steroid start to be given in week three.~The ATT regiment is continued for up to 6 months or more, in accordance with WHO guidelines. In the first two months the antibiotic combination given consisted of isoniazid (INH), rifampicin, pyrazinamide, and ethambutol. The next four months or continuation phases, the ATT given is rifampicin and isoniazid.~The following dosage and administration of oral steroids will be given to patients, according to guidelines from the American Journal of Ophthalmologists (Douglas A. Jabs et al, 2000):~Initial dose: 1mg/kg/day, with maximum adult oral dose 60-80 mg/kg and maintenance dose less than or equal to 10 mg/day. The tapering schedule: Over 40 mg/day, decrease by 10 mg/day every 1-2 weeks, 40-20 mg/day, decrease by 5 mg/day every 1-2 weeks, 20-10 mg/day, decrease by 2.5 mg/day every 1-2 weeks, 10-0 mg/day, decrease by 1 to 2.5 mg/day every 1-4 weeks."
46113259|NCT00729183|Drug|Odanacatib|Odanacatib 50 mg tablets, taken orally once weekly for 24 months.
46113260|NCT00729183|Drug|Placebo|Matching placebo tablets to odanacatib taken orally once weekly for 24 months.
46113261|NCT00729183|Drug|Vitamin D3|Vitamin D3 tablets (5600 IU) taken orally once weekly for 24 months.
46113262|NCT00729183|Drug|Calcium supplement|Calcium supplement 500 mg tablet taken orally once daily (up to ~1200 mg total) for 24 months.
46113263|NCT00811733|Biological|Ofatumumab|Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.
46113264|NCT00728949|Biological|IMC-A12 (cixutumumab)|10 mg/kg I.V.
46113265|NCT00728949|Drug|tamoxifen|Daily 20 mg, oral
46113266|NCT00728949|Drug|Anastrozole|Daily 1 mg, oral
46113267|NCT00728949|Drug|Letrozole|Daily 2.5 mg, oral
46113268|NCT00728949|Drug|Exemestane|Daily 25 mg, oral
45470167|NCT03399058|Other|Group 1 5+5+5 (Control)|The standard of care in Cambodia is known as the basic health and nutrition service package or 5+5+5. The participants in the first group will be the control group and will only be implementing the standard of care, 5+5+5 package (Group 1).
45470168|NCT03399058|Behavioral|Group 2: 5+5+5 & PDH|The participants in the second group will receive contextualized Hearth messages through on-going PDH programs in addition to the basic standard of care (Group 2).
46113269|NCT00728949|Drug|Fulvestrant|Monthly 250 mg, intramuscularly
46113270|NCT00918177|Drug|AP09004|
46113271|NCT00918177|Drug|Carbidopa/Levodopa, immediate release|
46113272|NCT00728481|Drug|Esomeprazole|Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks
46113273|NCT00728481|Drug|Budesonide|Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose [Splenda-registered trademark]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
45470169|NCT03399058|Behavioral|Group 3: 5+5+5 & PDH lite+mHealth|The participants in the third group will receive a PDH lite program and receive follow-up through mobile support phone calls (Group 3).
46113274|NCT00811655|Procedure|therapeutic conventional surgery|Surgery of a single brain metastasis.
46113275|NCT00811655|Radiation|stereotactic radiosurgery|Pre-operative single fraction SRS
46113276|NCT03963609|Radiation|multisclice CT|assessment of the remodeling index by multisclice CT in patients with chronic stable angina
46025870|NCT05381038|Device|CURATE.AI|"CURATE.AI - a small data, AI-derived technology platform based on this discovery - allows personalised guidance of an individual's dose modulations based only on that individual's data. Additionally, CURATE.AI is mechanism-independent, and dynamically adapts to changes experienced by the participant, providing dynamic dose optimisation throughout the duration of the participant's treatment.~The second stage of the trial aims to obtain a personalised CURATE.AI profile for each participant, based on their phenotypic response to a set of drug doses from the drug combinations with azacitidine identified and recommended by the QPOP team. The doses will be recommended by the CURATE.AI team, when relevant to the clinical decision-making process. Once an actionable profile is obtained, dose recommendations are based on the profile and aimed to treat the participant.~The maximum period of involvement with this study when azacitidine may be adjusted by CURATE.AI is 18 months."
46025871|NCT05381038|Drug|Azacitidine + docetaxel|"Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 30 mg/m2 docetaxel intravenously Day 1 and 8~Each chemotherapy cycle will be 21 days."
46113277|NCT02592993|Device|PicoWay device|The PicoWay base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier.
46113278|NCT04087941|Biological|VM-202|VM202 is a DNA plasmid that contains novel genomic cDNA hybrid human hepatocyte growth factor (HGF) coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723.
46113279|NCT02593227|Biological|Low dose FRα vaccine|165ug per peptide ID injection
46113280|NCT02593227|Drug|Cyclophosphamide|IV infusion over 1 hour
46113281|NCT02593227|Biological|High dose FRα vaccine|500ug per peptide ID injection
46113282|NCT04030481|Other|inhalation anesthesia|sevoflurane was used to maintain anesthesia
46113283|NCT04030481|Other|Total intravenous anesthesia|propofol was used to maintain anesthesia
46113284|NCT04748861|Other|Indoor Cycling (IC)|Participants will ride a Peloton bike 3x/week for 18 months.
46113285|NCT04087863|Other|Not applicable(observational study)|Not applicable(observational study)
46113286|NCT05755217|Dietary Supplement|70% cocoa,|see above
46025872|NCT05381038|Drug|Azacitidine + paclitaxel|"Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 80 mg/m2 paclitaxel intravenously Day 1 and 8~Each chemotherapy cycle will be 21 days."
46025873|NCT05381038|Drug|Azacitidine + irinotecan|"Azacitidine intravenously subcutaneous injection Day 1, 2 and Day 8, 9 + 100 mg/m2 irinotecan intravenously Day 1 and 8.~Each chemotherapy cycle will be 21 days."
46025874|NCT00603070|Other|E-prescribing system|Transition from home-grown to vendor-based ambulatory e-prescribing systems
46113287|NCT02592915|Drug|Clonidine hydrochloride|Single bolus of clonidine hydrochloride 0.3µg/kg (max 150 µg/kg) administered IV after induction and obtaining a stable anaesthetic level
46113288|NCT02592915|Other|Single bolus of physiologic sodium chloride serum administered IV after induction and obtaining a stable anaesthetic level|
46113289|NCT00727311|Biological|PegIntron (peginterferon alfa-2b; SCH 54031) injector|PegIntron administered at a dose 1.5 μg/kg/week, according to the Summary of Product Characteristics (SPC) and approved European labeling
46113290|NCT00727311|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered at a dose of 800-1200 mg/day (on a weight-basis) according to the SPC and approved European labeling
46113291|NCT04087551|Other|Developing the list of items for BRFES|The finalized list of items will be discussed by two researchers who will combine similar items generated by the two focus groups to complete the Balance Recovery Falls-Efficacy Scale. The list of items has been developed by a group of community-dwelling older adults who had demonstrated an understanding of near-falls and will be able to articulate the use of balance recovery strategies used in near-fall experiences.
46113292|NCT02592759|Device|Smart Glove Treatment|Smart glove is digital motion-based treatment device for stroke rehabilitation. The stroke patients wear this glove and hand motion is displayed on the computer monitor. They play games with this glove and are motivated to rehabilitation treatment because of fun.
46113293|NCT02592837|Device|Flexible 19G EBUS-TBNA needle|
46113294|NCT02592837|Device|21G EBUS-TBNA needle|
46113295|NCT00726999|Drug|Gabapentin|oral gabapentin in load pre-op (15mg/kg) and maintenance 5mg/kg TID for 5 days or discharge
46113296|NCT00726999|Drug|Placebo|
46113297|NCT00726999|Drug|Morphine|Administered as needed
46113298|NCT00585351|Drug|Ranitidine|50 mg single dose injection of Ranitidine
46113299|NCT00585351|Drug|Placebo|50 mg single dose injection of normal saline (placebo)
46113300|NCT00585351|Other|Advanced notification|Advanced notification of study via faxed consent to local Emergency Room (ER)
46113301|NCT00585351|Other|No advanced notification|No advanced notification of study via faxed consent to local Emergency Room (ER)
46113302|NCT02592603|Device|Endocuff-assisted Colonoscopy|Colonic examination with Endocuff-assisted Colonoscopy
46113303|NCT02592681|Procedure|verum acupuncture|"Participants will receive real needle insertion. Sterile needles will be used on all acupoints. The depth of insertion will vary from 15 mm to 20 mm depending on the exact locations. An initial manual stimulation will be given at insertion by rotation methods to produce a specific sensation described as de-qi in TCM. Then the needles will be left in the acupoint for 20 min, with a manual rotation at 4-8 Hz and an amplitude of approximately 0.5-2 rotations at a ten-min interval to maintain the sensation of de-qi. Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian)."
46113304|NCT02592681|Procedure|acupressure|"The acupoints and the number of the sessions will be exactly the same as for the verum acupuncture group. Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Finger pressure will be applied to each acupoint for eight seconds followed by two-seconds rest, repeated for 3 min. The strength of the pressure depends on individual participant's sensation of de-qi. Duration of each session will be 15 min."
46113305|NCT02592681|Procedure|control acupuncture|The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. Sterile needles will be used on acupoints that have no therapeutic effect on either menstruation or migraines, based on the acupuncture text books and acupuncture research literature. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan). The depth of needle insertion will be as superficial as 3 mm, and without manual rotation, in order to minimize stimulation of the needle.
46113306|NCT04031651|Drug|Pudilan Xiaoyan Oral Liquid|In the respiratory and emergency departments of the hospitals under surveillance, the medication of Pudilan Xiaoyan Oral Liquid is observed for those aged 18-80 years who strictly follow the prescription of the instructions.
46025875|NCT00603070|Other|Electronic transmission of medication discharge lists|Patient discharge medication lists will be transmitted upon discharge from their inpatient medical record to their outpatient medical record and their outpatient provider will be notified of this transmission.
46025876|NCT05380960|Device|cbc coaglation profile|The Demographic, clinical, and laboratory data for the enrolled subjects will be collected. To assess the coagulability state in the participants, we will measure the levels of certain markers in the blood that are thought to be associated with an increased coagulability. A comparison will be made between the different included groups regarding the level of these markers. These markers included complete blood count (CBC) indices (hematocrit, red cell distribution width, platelets count, mean platelet volume and platelet distribution width), C - reactive protein, d dimer, and blood coagulation tests (prothrombin time, international normalized ratio and partial thromboplastin time).
46025877|NCT02851498|Other|Food product: high-protein pasta and cereal|
46025878|NCT02690272|Behavioral|Psychic processes|Quantitative and qualitative aprroche of the psychic process
46025879|NCT02851420|Other|spectroscopy|
46025880|NCT00604630|Drug|recombinant human erythropoietin alfa|40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
46113307|NCT05755919|Procedure|Epilepsy surgery|Epilepsy surgery will be performed as a part of the clinical management of patients with drug-resistant epilepsy.
46025881|NCT00604630|Drug|0.9% NaCl|50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
46025882|NCT05380882|Drug|TQB2930 injection|TQB2930 is an anti-HER2 bispecific antibody.
46025883|NCT01189266|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
46113308|NCT05757479|Procedure|Steroid-eluting stent implantation|The sinus cavity with inflammation receives one bioabsorbable steroid-eluting sinus stent.
46113309|NCT05757479|Drug|Steroid nasal spray|1 spray into each nostril once a day.
46113310|NCT05757479|Procedure|nasal saline rinses|The saltwater runs through nasal passages and drains out of the nostril.
46113311|NCT00726609|Drug|Posaconazole|The usual dose of NOXAFIL® is 400 mg twice daily (10 mL) at meals or with 240 mL of a food supplement. For patients unable to take meals or food supplements, NOXAFIL® is administered at a dose of 200 mg (5 mL) four times daily.
46113312|NCT00726453|Device|Resolute Zotarolimus-Eluting Coronary Stent|Implantation of a Resolute Zotarolimus-Eluting Coronary Stent
46113313|NCT00726063|Device|Nanotite dental implant|Nanotite root form titanium dental implant
46113314|NCT00726063|Device|Osseotite dental implant|Osseotite Root form titanium dental implant
46113315|NCT03960567|Device|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
46113316|NCT04019457|Other|Dietary intervention|Dietary intervention: Participants receive dietary fibers for a defined number of days.
46113317|NCT00808028|Biological|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
46025884|NCT01189266|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
46113318|NCT00808028|Biological|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
45470170|NCT03395158|Diagnostic Test|Implementation of new alert criteria|The intervention is when the prior alert criteria are replaced by the present alert criteria
46025885|NCT01189266|Other|Laboratory Biomarker Analysis|Correlative studies
46025886|NCT01189266|Drug|Vorinostat|Given PO
46025887|NCT01189032|Drug|DE-089 ophthalmic solution|
46025888|NCT01189032|Drug|DE-089 ophthalmic solution|
46025889|NCT01189032|Drug|Placebo ophthalmic solution|
46113319|NCT00808028|Biological|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
46113320|NCT00808028|Other|normal saline (placebo)|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
46025890|NCT01188798|Drug|Methotrexate|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
46025891|NCT01188798|Drug|Pentostatin|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
46025892|NCT04316052|Other|Aerobic training|After the baseline assessment, Following randomization into the exercise group, participants will undergo an exercise program orientation, which will be conducted individually.At the visit, participants will be first instructed in the use of the treadmill, which included heart rate assessment capability. Walking intensity and duration prescriptions will be accordance with recommendations of the American College of Sports Medicine. Participants will be instructed to walk for 45 minutes, including a 5-minute warm-up and 5 min cool-down, at 50% to 80% of their age-predicted maximum heart rate.Over the course of 4 months, each patient will complete 48 sessions. The morning after the 24th and 48nd sessions of aerobic physical exercise, each participant will be assessed completely
46113321|NCT03466346|Drug|Fluoxetine|Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.
46113322|NCT03466346|Behavioral|Interpersonal Psychotherapy|PT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.
46113323|NCT05754242|Drug|Ascorbic acid|1.5 gr of ascorbic acid
46113324|NCT05754242|Drug|0.9% Saline solution|100 ml of 0.9% saline solution
46113325|NCT04030364|Behavioral|CrossFit group exercise classes|"The group classes will occur at a local CrossFit gym facility. Participants will be free to attend up to 6 regularly-scheduled, free, 1-hr group classes per week at the local exercise facility for a period of 3-months. The recommendation will be to aim to attend at least three classes/week but there will no prescribed minimum. Classes will be supervised by experienced trainers.~Trainers will work collaboratively with participants to adapt the skill and workout of the day within each group class to the individual participant's physical limitations and needs. As such, each participant may complete a slightly different movement or workout on any given day based on their functional status at that time. However, all participants will be actively included in the community of the group class and will experience a relative stimulus that is moderately challenging for them."
46113326|NCT02606006|Behavioral|Canine Animal-Assisted Therapy|Canine Animal-Assisted Therapy is the inclusion of a certified therapy canine in the standard of care physical therapy session, such as for walking, fetching balls, standing/petting, etc.
46113327|NCT02606006|Behavioral|Standard of Care Physical Therapy|This intervention is the standard of care physical therapy currently offered. No canine is present.
46113328|NCT00809783|Biological|tanezumab|Tanezumab 10 mg
46113329|NCT00809783|Biological|tanezumab|Tanezumab 5 mg
46113330|NCT00809783|Biological|tanezumab|Tanezumab 2.5 mg
46113331|NCT05675462|Drug|Oncorine|a modified human recombinant type 5 adenovirus with genetic modifications
46113332|NCT05675462|Drug|Tislelizumab|PD-1inhibitor
46113333|NCT05675462|Drug|Lenvatinib|TKI
46113334|NCT05727800|Drug|VX-668|Suspension for oral administration.
46113335|NCT05727800|Drug|Placebo|Suspension for oral administration.
46113336|NCT00914264|Device|continuous positive airway pressure|CPAP with adequate pressure for 1 day, 3 & 12 months
46113337|NCT05754164|Behavioral|Attention Control Training|Mobile app-based attention control training is an effective training method that can help people improve their ability to control attention. It is generally recommended to undergo 4 weeks of training, with 3-4 sessions per week and one day between each session. The specific operational method of this training may vary depending on different applications, but generally, training is presented in the form of a series of tasks. These tasks may involve aspects such as focusing attention, inhibiting interference, and reacting quickly.
46113338|NCT02608658|Other|Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin)|"Visit 1, screening (Day 0): At this visit, the investigators of the study will:~Obtain demographic information, as will past medical history and medications.~Perform a physical examination.~Collect samples for labs~Administer the Chronic Liver Disease Questionnaire (CLDQ)~Perform a lactulose breath test~From Day 0 to 8 weeks: subjects will take the medical food twice daily~Visit 2, Week 4 (Day 28 +/- 3): At this visit, the investigators of the study will:~Perform a physical examination~Collect and record returned investigational product~Dispense investigational product and instruct again regarding use~Record any adverse events~Visit 3, Week 8 (Day 56 +/- 3): At this visit, the investigators of the study will:~Perform a physical examination.~Collect samples for labs~Administer the Chronic Liver Disease Questionnaire (CLDQ)~Perform a lactulose breath test"
46113339|NCT00809471|Drug|placebo|30 minutes orally prior to initiation of sexual activity
46113340|NCT00809471|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
46113341|NCT00809471|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
46113342|NCT00807248|Drug|Escitalopram placebo|Once daily before bedtime for 8 weeks
46113343|NCT00807248|Drug|Gaboxadol placebo|Once daily before bedtime for 8 weeks
46113344|NCT00807248|Drug|Escitalopram 20 mg|Once daily before bedtime for 8 weeks
46113345|NCT00807248|Drug|Gaboxadol 5 mg|Once daily before bedtime for 8 weeks
46113346|NCT00807248|Drug|Gaboxadol 10 mg|Once daily before bedtime for 8 weeks
46113347|NCT05755061|Behavioral|GEMS Plus|12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that exceed the published physical activity guidelines for adults with MS
46113348|NCT05755061|Behavioral|GEMS|12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that meet the published physical activity guidelines for adults with MS
46113349|NCT05326295|Diagnostic Test|CTC detection|CTCs separation and enrichment technology. Combined with the prognosis of patients with recurrence and survival time, we explored the evaluation of CTC number, cell phenotype distribution, PDL1 and FOXC2 expression on the prognosis of early stage breast cancer patients. The research results are expected to provide a new effective index and theoretical basis for evaluating the treatment efficacy of breast cancer patients.
46113350|NCT02610491|Dietary Supplement|Hesperidin|Citrus peel extract
45470171|NCT04848727|Other|Detecting asymmetric lung disease like atelectasis or pneumothorax with electrical impedance tomography (EIT)|"The EIT system will be placed at the subject's bedside to collect EIT measurements: Ventilation distribution%, changes in regional aeration in arbitrary units (AU), dependent and non-dependent silent spaces. A data acquisition cart will also be placed at the subject's bedside to collect hemodynamic and respiratory parameters measurements including: Heart rate (HR), blood pressure (BP), respiratory rate (RR), fraction of inspired oxygen (FiO2), transcutaneous carbon dioxide (TcCO2), and peripheral oxygen saturation (SpO2) via bedside monitoring devices.~The LuMon belts for neonates are disposable single-patient use belts that are adhesive-free. EIT measurements and data will be collected on each timeperiods (t1 and t2) for approximately 15-30 minutes on invasive or non-invasive ventilatory support."
46025893|NCT04316052|Other|strength training|After the baseline assessment, participants will undergo exercise program orientation, which will be conducted individually. Participants will be instructed to perform 45 min session, two sets of 8 to 12 repetitions of each exercise (2 second hold each up and down hold) for the first 2 weeks to provide an introductory period. In the first session, muscular strength will be assessed using a standardized 10-repetition maximum approach, from which one repetition maximum (1-RM) will be estimated. The exercise prescription for strength training will be made at approximately 50% of the estimated 1-RM.The strength training activities included horizontal leg press, leg extension, leg curl, hip adduction, hip abduction, and seated rotary calf press.
46025894|NCT01183104|Drug|Sitagliptin|Starting dose for sitagliptin is 50mg per day, can be increased up to 100mg (25-50mg; estimate glomerular filtration rate (eGFR) 30=< <50).
46025895|NCT01183104|Drug|Glimepiride|Starting dose for glimepiride is 0.5mg per day, can be increased up to 6.0mg
46025896|NCT02886468|Other|skin ultrasound|
46025897|NCT05302908|Behavioral|NuestraSaludSegura|It blends peer navigation and mHealth
46113351|NCT02610491|Dietary Supplement|Placebo|Cellulose
46113352|NCT05720936|Procedure|Percutaneous stellate ganglion block (PSGB)|"Both the two approaches present in literature and commonly used for this technique are allowed for the study:~The anatomical approach which consist in the identification of the Chassaignac's tubercle that represents the point of needle insertion~The echo-guided approach"
46113353|NCT02610335|Other|Control group (C)|"kyphosis reeducation on Huber platform during 2 weeks,~patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),~flexibility exercises, stretching exercises and abdominal muscles exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),~exercises on cycle ergometer or walking on treadmill : to continue at home."
46113354|NCT02610335|Other|Test group|"spinal mobility reeducation on Huber platform during 2 weeks,~patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),~flexibility exercises and mobilization exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),~exercises on cycle ergometer or walking on treadmill : to continue at home."
46025898|NCT04188132|Other|EEG -BCI based Feedback for rehabilitation|Subjects will undergo EEG based BCI as feedback for rehabilitation
46025899|NCT04187664|Behavioral|Postoperative Monitoring|Nursing and medical staff will monitor patients vital signs and clinical deterioration triggers twice as often as in previous ward care.
46113355|NCT02607332|Drug|Paclitaxel|
46113356|NCT03356756|Diagnostic Test|simultaneous combined 18F-FDG PET and cardiac MRI imaging|Patients will undergo a research study performed with an integrated whole-body PET/MRI imaging system designed for simultaneous PET and MRI acquisition, immediately after standard of care PET/CT exam.
46113357|NCT05297669|Drug|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min)..~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at 30±5 minutes before the end of the operation (Skin suture completes the last stitch).The drug was given 3 times,3 times/day, once every 8 hours."
45470172|NCT01686906|Procedure|Bowman layer graft implantation|For patients with progressive advanced keratoconus, a mid-stromal manual dissection is made and a donor isolated Bowman layer is positioned into the stromal pocket.
45470173|NCT04617847|Drug|WVE-120101|WVE-120101 is a stereopure antisense oligonucleotide (ASO). It is administered monthly via intrathecal injection.
46025900|NCT04187664|Diagnostic Test|High-sensitivity cardiac troponin testing|High-risk patients will have their high-sensitivity cardiac troponin tested preoperatively and daily for the first 48h postoperatively
45470174|NCT04615507|Device|JJVC Investigational Multifocal Contact Lens|TEST Lens
45470175|NCT04615507|Device|Dailies Total 1® Multifocal Contact Lens|CONTROL Lens
46113358|NCT05297669|Drug|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection. Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min).~One dose at 8h and 16h after the start of the first dose, the first intravenous infusion was started at 30±5 minutes before the end of the operation (Skin suture completes the last stitch).The drug was given 3 times,3 times/day, once every 8 hours."
46113359|NCT05180513|Behavioral|Teleconference Mindfulness Intervention|The teleconference intervention is administered by a trained interventionist via Zoom and is based on a manual adapted from a traditional MBSR version. Practices and activities include meditations, mindful breathing exercises and movements, discussions, and reflections, which participants learn at weekly sessions and practice on their own throughout the week. To adapt the traditional MBSR program for the target community population, intervention materials were reviewed for feedback from community stakeholders, and modified according to their feedback.
46113360|NCT05180513|Behavioral|Smartphone App Mindfulness Intervention|The smartphone app intervention is administered through the app. The smartphone app aligns with the traditional MBSR format, but training and practice is done individually and independently by members of this group. To adapt the traditional MBSR program for the target community population, the app was tested by community stakeholders and modified according to their feedback.
45681845|NCT05701696|Diagnostic Test|Self-Leeds Assessment of Neuropathic Symptoms and Signs|An instrument used to identify pain of neuropathic origin
46113361|NCT05757323|Other|infant formula based on hydrolyzed protein|infant formula based on hydrolysed protein
46113362|NCT05757323|Other|infant formula based on intact protein|infant formula based on intact protein
46113363|NCT00589628|Drug|infliximab|5mg/kg/dose IV at 4 week intervals
46113364|NCT00589628|Drug|infliximab|10mg/kg/dose IV at 4 week intervals
46113365|NCT05754983|Drug|Solid tumor patients receiving immunotherapy for the first time were included in the study|Solid tumor patients receiving immunotherapy were included in the study. Baseline information before treatment (including demographic characteristics, basic diseases and their medication history, tumor and anti-tumor history, quality of life scores, etc.) and follow-up information after treatment (PFS, OS, etc.) were collected to summarize factors that may affect the efficacy and prognosis of patients receiving immunotherapy
46113366|NCT05720546|Other|Baseline Survey|A survey that measures participant satisfaction will be offered to participants during infusion at baseline.
46113367|NCT05720546|Other|Semi-structured interviews|Semi-structured interviews will be conducted in the same infusion spaces.
46113368|NCT05720546|Other|Follow-up Survey|A survey that measures participant satisfaction will be offered to participants during following infusion.
46113369|NCT04660955|Other|No Intervention - Observational study with MRI|90 minute MRI of the knees
46113370|NCT00914576|Drug|Vitamin and mineral supplement|1 capsule/day in the morning for 14 days, containing: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, Ginko Biloba 10mg, Flavonoids 25mg, Fish oil 300mg
46113371|NCT00914576|Drug|Vitamin and mineral supplement|1 capsule/day in the evening for 14 days, containing: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selene 20µg, Ginko Biloba 10mg, Flavonoids 25mg, Alpha Lipon acid: 150mg
46113372|NCT00914576|Drug|Placebo|2 capsules/day for 14 days
46113373|NCT00914576|Drug|100% Oxygen|breathing of 100% O2 for 30 minutes on both study days
46113374|NCT00914576|Drug|Escherichia coli Endotoxin|Escherichia coli Endotoxin (LPS, US Standard Reference Endotoxin, dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
46113375|NCT00914654|Drug|inhaled formoterol|Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.
46113376|NCT04115618|Radiation|Simultaneous integrated boost intensity-modulated chemoradiotherapy|Using IMRT technology, two fields are irradiated synchronously, prescription radiation dose: 50.4 Gy/28F in PTV-C, 1.8 Gy per fraction; 63 Gy/28F in PTV-G, 2.25 Gy per fraction. Six times of concurrent DP week regimen chemotherapy: cisplatin 20mg/m2 qw plus docetaxel 20mg/m2 qw.
46113377|NCT02605772|Drug|Acarbose|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
46113378|NCT02605772|Drug|Metformin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
46113379|NCT02605772|Drug|Saxagliptin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
46113380|NCT00588848|Device|Autoadjusting CPAP (VPAP Auto)|An autoadjusting CPAP unit is used in place of subject's own CPAP unit during the night of the polysomnography study (the first night after surgery).
46113381|NCT00588848|Device|CPAP|Subject's own CPAP unit is applied to the subject during the polysomnography study night (the first night after surgery)
46025901|NCT02885532|Other|University of California, San Diego Brief Assessment of Capacity to Consent Tool|Non-pregnant, English speaking patients older than 18 with evidence of acute alcohol intoxication were considered eligible for participation. Patients were asked to complete the 10 question tool on arrival to the emergency department. Patie
46113382|NCT04115462|Drug|Morphine|A 20 mg tablet of morphine
46113383|NCT04115462|Drug|Placebo oral tablet|Matching tablet of placebo
46113384|NCT04115462|Drug|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
46113385|NCT04115462|Drug|Cowhage (Mucuna Pruriens)|25 spicules will be inserted in the centre of the predefined skin area on the forearm. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
46113386|NCT04115462|Drug|isotonic saline|A droplet of saline (0.9%) as vehicle control will be placed on the predetermined area on the forearm and the lancet will be pierced through the droplet.
45598588|NCT02351895|Other|Copper impregnated linen|Copper impregnated linen was used in place of regular linen on one ward (out of two) for each period of the study. Each study period lasted for 23 weeks. After the washout period (3 weeks) the wards were switched.
46025902|NCT05304078|Behavioral|Telehealth Assessment and Skill-Building Kit (TASK III) Group|The TASK III group will receive a TASK III Resource Guide (mailed hard copy, USB drive, eBook, and Website access) and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The TASK III nurse will train caregivers how to assess their needs and concerns, and how to use the TASK III Resource Guide containing content and skill-building tip sheets to address their needs and concerns. Caregivers will also receive an American Heart Association brochure about family caregiving, as well as information, support, and referral to community resources.
46113387|NCT04115462|Drug|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the mandibular area, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
46113388|NCT04115462|Drug|Cowhage (Mucuna Pruriens)|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
46025903|NCT05304078|Behavioral|Information Support and Referral (ISR) Group|The ISR group will receive an American Heart Association brochure about family caregiving and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The ISR nurse will provide information, support, and referral to community resources.
46025904|NCT02885688|Dietary Supplement|Liquid Nutrition|Participants receive liquid nutrition by vein non-stop for up to 7 days.
46113389|NCT04010474|Procedure|Modified Surgical APGAR Score|"Four intraoperative factors~Lowest heart rate (HR),~Lowest mean arterial pressure (MAP)~Estimated blood loss~Operation time"
46025905|NCT02885688|Procedure|Insulin Drip|"Insulin drip by vein to keep serum glucose level between 140 and 180 mg/dL as per ICU protocol.~The interventions required in the current standard management of patients with septic shock is based on the MD Anderson Evidence-Based Protocol (EBP) for management of Severe Sepsis initiated on admission to the ICU."
46025906|NCT00950248|Drug|Idebenone|idebenone, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium povidone, magnesium stearate, silicon dioxide, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
46025907|NCT00950248|Other|placebo|lactose monohydrate, microcrystalline cellulose, magnesium stearate, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
46025908|NCT04269928|Procedure|Endovascular chemical ablation of adrenal gland|Patients in this group will be treated with ablation of adrenal gland by endovascular injection of dehydrated alcohol
46025909|NCT00950170|Procedure|Laboratory Tests|Blood draws to determine the level of factor VIII activity before and after dosing at appropriate visits, and blood draws to determine levels of factor VIII inhibitor (antibody to factor VIII).
46025910|NCT05380804|Diagnostic Test|cutaneous silent period (CSP) measurement|CSP recordings are performed in the upper extremities using the same surface bar recording electrodes. Filters are set at 2 Hertz (Hz) to 10 kilo Hz, sensitivity is 200 microVolts (µV) and sweep speed is set at 200 milliseconds (ms). Stimulating electrode is placed on the index finger and recording bar electrode is placed on the abductor pollicis brevis (APB) muscle. During steady submaximal (50% of the maximal contraction) thumb abduction, 10 consecutive painful electrical stimuli of standard 80-milli Ampere (mA) intensity and 0.5-ms duration are applied to the index finger and responses are superimposed. CSP latency and duration are calculated and recorded. CSP latency is defined as the time between the stimulation and the onset of the silent period. CSP duration is calculated as the time interval between the beginning and end of the CSP.
46113390|NCT04026932|Other|Listening to unmodified music|Listening to unmodified music for at least 2 hours a day
46113391|NCT04026932|Other|Listening to modified tinnitus relieving sound|Listening to modified tinnitus relieving sound for at least 2 hours a day
46113392|NCT02605460|Drug|Busulfan|12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7, -6, -5 y -4.
46113393|NCT02605460|Drug|Cyclophosphamide|80mg/kg, Intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 y -2.
46113394|NCT02605460|Drug|CXCR4 Antagonist|24mg, Subcutaneous (SC), in one day, 24mg/day SC, during day -4.
46113395|NCT02605460|Procedure|Hematopoietic Stem Cell Transplantation|Peripheral blood HSC (autologous HSCT) or Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
46113396|NCT04115930|Device|Physical Activity measurement:|7 days measurement with Active style Pro HJA-350IT device
46113397|NCT00797108|Drug|sulopenem and PF-03709270|Sulopenem - 600 mg infused over 1 hour, single loading dose and switch to oral PF-03709270 - 1000 mg twice a day
46113398|NCT00797108|Drug|Sulopenem and PF-03709270|Sulopenem - 600 mg infused over 1 hour twice daily for a minimum of 2 days and switch to oral PF-03709270 - 1000 mg twice a day
46113399|NCT00797108|Drug|Ceftriaxone and amoxicillin/clavulanate|IV ceftriaxone (2g) infused over 30 minutes QD (once daily) for minimum of 2 days Step down oral amoxicillin/clavulanate potassium suspension (400 mg/5 ml) BID (every 12 hours)
46113400|NCT04112420|Diagnostic Test|Trans-esophageal echocardiography|"The department registers an unplanned admission of a patient to the intensive care unit. The indication is verified again by the intensive care physician.~In this case, the patient is then admitted to the intensive care unit, supervised by an intensive care physician, orientated and initiated therapeutic and diagnostic measures.~As part of the planned transthoracic cardiac ultrasound examination, it is then selected whether the patient is suitable according to the patient's will and the inclusion or exclusion criteria.~After clarification, time to think and consent, the examination is then carried out according to the protocol by approved doctors of the Clinic for Anesthesia, intensive care and pain therapy. Followed by digital storage for the finding.~After the subsequent operation, the investigator determines whether knowledge of detected pathologies would have an effective influence on the anesthesiological procedure or not."
45598589|NCT00503035|Drug|Celecoxib|400 mg by mouth twice daily x 6 months
46025911|NCT02851030|Behavioral|Move, Play, Learn!|Participants will attend a 4 hour workshop at the beginning of the intervention and the midpoint, covering project information, physical activity for young children, and distribution of project materials. Teachers will focus on one area of their child care day for 2 weeks each: indoor structured PA, outdoor structured PA, transitions between activities, and circle time. Participants will receive an email newsletter introducing the topic and will implement short (10 minutes) classroom activities. Teachers will also be educated about teacher PA practices, focusing on 1 behavior during each segment. Research staff will contact the teachers weekly to provide technical assistance, help teachers troubleshoot any issues that participants have with the activities, and provide encouragement.
46113401|NCT04112264|Procedure|Monopolar radiofrequency ablation|a radiofrequency cannula is advanced under USG guidance towards the nerve. The final position will be confirmed by using nerve stimulator with elicitation of paraesthesia along the area of knee joint supplied by that respected genicular nerve by stimulation at 50 Hz current of <0.5 mV. The motor stimulation will be negative at all instances. For each genicular nerve, two conventional RF lesions are done for 120s at 80° of temperature using the Neurotherm 1100 RF generator.
46113402|NCT04112264|Procedure|Bipolar radiofrequency ablation|Two radiofrequency cannula are advanced under USG guidance towards the nerve. The final position will be confirmed by using nerve stimulator with elicitation of paraesthesia by stimulation at 50 Hz current of <0.5 mV. The motor stimulation will be negative at all instances. For each genicular nerve, two conventional RF lesions are done for 120s at 80° of temperature using the Neurotherm 1100 RF generator.
46113403|NCT03244826|Other|Shared Care|Shared Care involves four specific strategies to allow patients to have a portion of their care locally after HCT, where clinic and laboratory visits are equally shared between the local oncologist and primary HCT team
46113404|NCT03244826|Other|Standard Care|The usual care provided by the transplant center at DFCI.
46113405|NCT02607176|Drug|Heweizhixie capsule|3 #, Tid, Oral for 3 days
46113406|NCT04112108|Procedure|PTMC|percutaneous mitral ballooning with Inoue balloon
46113407|NCT04111718|Biological|Platelet-rich plasma (PRP)|Autologous platelet-rich plasma which will be derived from blood drawn from the patient.
46113408|NCT04111718|Behavioral|Viewing of preparation|The patient will receive a description of the preparation process and will view the preparation in the centrifuge.
46113409|NCT04111640|Other|CoRe software|Computer-supported cognitive training (CT)
46113410|NCT04111640|Other|Control Group|Paper and pencil cognitive training (paper-and-pencil CoRe version)
46113411|NCT04025996|Diagnostic Test|Cardiac Assessments and Eye Assessments|"Cardiac Assessments, include the following:~transthoracic echocardiography~computed tomography of coronary arteries~position emission tomography computed tomography or single photon emission tomography computed tomography~Eye examinations, include the following:~pupil dilation~retinal photography~dynamic vessel analyser~IOL master"
46113412|NCT00742560|Biological|elotuzumab|Humanized Anti-CS1 Monoclonal IgG1 Antibody (HuLuc63) administered as an intravenous infusion once a week during Cycles 1 and 2, and every other week beginning with Cycle 3.
46113413|NCT00742560|Drug|lenalidomide|Lenalidomide 25 mg administered orally once daily on Days 1 to 21 of each 28-day cycle
46113414|NCT00742560|Drug|dexamethasone oral|Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
46113415|NCT00742560|Drug|dexamethasone injection|Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
46113416|NCT02604914|Drug|ND0612|Subcutaneous solution
46113417|NCT02604914|Drug|LCIG|Intrajejunal Gel
46113418|NCT05637866|Other|Soy milk|Soya milk or soymilk, a plant-based beverage that can be sweetened or unsweetened.
46113419|NCT00796718|Radiation|Standard radiotherapy|Administered as prescribed according to normal clinical practice.
46113420|NCT00796718|Drug|Capecitabine [Xeloda]|825 milligrams per meter square (mg/m^2) orally twice daily for 5 weeks.
46113421|NCT00809159|Biological|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
46113422|NCT00809159|Drug|Placebo|Placebo to AIN457
45470176|NCT03753295|Diagnostic Test|Hand Grip Force|"For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation.~The test will be performed twice, and the higher value between the two measurements will be selected.~The subjects will be allowed a rest time of more than 5 minutes after the first measurement to avoid examiner bias and to decrease physical stress"
45470177|NCT04120233|Drug|Placebo|Matched placebo administered orally
45470178|NCT04120233|Drug|MW151, 10mg|10 mg MW151, 1 x 10mg capsule administered orally
46113423|NCT02596386|Procedure|sialometry|potassium evaluation
46113424|NCT02596386|Procedure|blood test|potassium evaluation
46113425|NCT04111796|Other|nature based solution for stress reduction|participation in nature activities: 30 min stress management in nature and group activity (walking, cycling)
46113426|NCT00745368|Drug|Raltegravir|400 mg tablets twice daily during duration of trial
46113427|NCT04111562|Procedure|Cranioplasty|Bone grafts
46113428|NCT04025840|Other|Epidural block|Epidural block (with 0.375% ropivacaine) is performed during surgery. Patient-controlled epidural analgesia (with a mixture of 0.12% ropivacaine and 0.5 microgram/ml sufentanyl) is provided after surgery.
46113429|NCT04025840|Drug|Dexamethasone|Dexamethasone (10 mg) is administered intravenously before anesthesia induction.
46113430|NCT00589472|Drug|Bicalutamide|Given PO
46113431|NCT00589472|Drug|Goserelin Acetate|Given SC
46113432|NCT00589472|Other|Laboratory Biomarker Analysis|Correlative studies
46113433|NCT00589472|Drug|Leuprolide Acetate|Given IM
46113434|NCT00589472|Procedure|Therapeutic Conventional Surgery|Undergo radical prostatectomy
46113435|NCT00589472|Drug|Vorinostat|Given PO
46113436|NCT00811577|Drug|Placebo|Patients in the Placebo-only arm were dosed intradermally with placebo (saline) in three trocar sites on Day 9 (plus/minus 2 days) and Day 21 (plus/minus 2 days) after arthroscopic shoulder surgery. In the AZX100-placebo arm, 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
46113437|NCT00811577|Drug|AZX100|AZX100 Drug Product 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
45470179|NCT04120233|Drug|MW151, 20mg|20 mg MW151, 1 x 20mg capsule administered orally
46113438|NCT02607020|Other|Physical exercises in an self-management setting|"Workout sessions will be based on the principle of self-management, without direct supervision of a therapist. Sessions will include:~1. Twenty minutes of aerobic exercises 1.2. Five to ten minutes of stretching exercises. 2.3. Fifteen to twenty minutes of resistance exercises to improve muscle strength of lower limbs. The targeted muscles will be the hip flexors, the knee extensors and flexors, and the foot extensors and plantar flexors. These exercises will comply with the recommendations of the American College of Sports Medicine (ACSM, 2011). Patients will be asked to perform muscle contractions against the gravity (about 15 repeats). There will be on average 5 to 6 series per session. Several muscle groups of the lower limbs will be trained during the same session."
46025912|NCT04267666|Device|incentive spirometer|Patient had to produce a high inspiratory pressure. The ball serves as visible feedback of the inspiratory flow and indicates the obtained flow on a calibrated scale on the transparent cylinder of the spirometer. If the patient flows greater than 300 milliliters per second, the float ball in first chamber will rise. As patient flow increases to 600 milliliters per second the second ball float will rise. If the patient flow exceeds 900 milliliters per second all three will be suspended. Patient should encourage holding the balls up for a few seconds
46025913|NCT04267666|Other|Inspiratory muscle trainer device|The threshold trainer is a small plastic handheld device supplied by respironics. It includes a mouthpiece and a calibrated spring loaded valve. The valve controls a constant inspiratory pressure training load and the patient must generate the inspiratory pressure in order for the inspiratory valve to be opened and allow inhalation of air.
46113439|NCT02607020|Other|Relaxation|The relaxation sessions of the control group will be carried out with the help of soothing music. Patients will receive a Compact Disc (CD) of soothing music at the inclusion. Patients will also have an electronic training logbook that will be reviewed each week by a therapist. They will have a phone contact with the therapist every two weeks, to discuss about the treatment and adapt it if necessary. They will also have a reminder session every four weeks.
46113440|NCT02608931|Drug|Dronabinol|
46113441|NCT02608931|Other|Placebo|placebo
46113442|NCT04619225|Device|TetraGraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
46025914|NCT00604864|Drug|anti TNFa monoclonal antibody - Infliximab|Chimeric A2 (infliximab, RemicadeTM) IgG ; 100 mg infliximab IgG, Infliximab was freshly prepared immediately before each administration. Infliximab or placebo was administered as a slow infusion of 250mL on weeks 0, 2 and 6. Women were closely observed during, and for 1 hour after, the infusion in the event of any serious adverse reactions.
46025915|NCT00604864|Drug|placebo|Placebo
45470180|NCT04120233|Drug|MW151, 40mg|40 mg MW151, 2 x 20mg capsule administered orally
46025916|NCT05380648|Procedure|Total knee arthroplasty|Total knee arthroplasty surgery will be performed by different orthopedist.
46025917|NCT01227824|Drug|GSK1349572 (dolutegravir)|GSK1349572 50 mg taken once daily with or without food
46025918|NCT01227824|Drug|raltegravir|raltegravir 400mg taken twice daily
46025919|NCT01227824|Other|GSK1349572 Placebo|GSK1349572 placebo taken once daily
46113443|NCT00744978|Drug|Varenicline|0.5 mg once daily for 1 week followed by 0.5 mg twice daily for 1 week followed by 1 mg twice daily for 4 weeks
46113444|NCT00744978|Drug|Placebo|Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.
45470181|NCT04120233|Drug|MW151, 80mg|80 mg MW151, 1 x 80mg capsule administered orally
46025920|NCT01227824|Other|ABC/3TC|Abacavir/Lamivudine background therapy once daily
45470182|NCT04120233|Drug|MW151, 160mg|160 mg MW151, 2 x 80mg capsule administered orally
46025921|NCT01227824|Other|TDF/FTC|Tenofovir/emtricitabine background therapy once daily
46025922|NCT01227824|Other|raltegravir Placebo|raltegravir placebo taken twice daily
45470183|NCT01610700|Drug|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
46113445|NCT02608775|Device|Metrodoloris Medical System|Application of a skin electrode
45470184|NCT01610700|Drug|Placebo|Each actuation of placebo delivered the excipients only.
45470185|NCT03753217|Device|qCON Monitor|supervision by qCON monitor of the depth of anesthesia
45470186|NCT03755869|Drug|Anlotinib|Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
45470187|NCT04595851|Other|Patient Reported Outcome Measure (PROM)|Participants will complete a PROM (Michigan Oncology Quality Consortium, Patient Assessment Tool for Oral Chemotherapy) for their oral anticancer agent (OAA) at two timepoints over 2 months, to assess patient symptoms and adherence to OAA.
46113446|NCT02608775|Device|Aisys® care station, Acertys|Standard photoplethysmography
45598590|NCT00503035|Procedure|Colonoscopy Biopsy|Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure
46025923|NCT00949702|Drug|vemurafenib|960 mg b.i.d. continuous oral dosing
46113447|NCT05326217|Other|Aerobic exercise|The aerobic exercise :In this study, the exercise intensity is set based on the subject's maximum heart rate, and the target heart rate is adjusted according to the literature to reach 60-90% of the maximum heart rate. A gradual increase of intermittent exercise will be designed for current exercise prescription. In terms of exercise frequency and time, there will be two times interventions per week for at least 60 minutes per time (including warm-up and cool down exercises).
46113448|NCT05326217|Other|Resistant exercise|The resistant exercise : muscular endurance (15-20RM) and muscular hypertrophy (8-12RM) are applied to main exercise intensity. The intensity is gradually adjusted according to the state of each subject, and the intervention is performed twice a week (50 minutes per time).The target muscles of resistance training include quadriceps femoris, biceps femoris, calf muscles, core muscles (including pelvic floor muscles), back muscles, pectoralis major, biceps/triceps and other muscle groups.
46025924|NCT01034631|Drug|Everolimus|Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals
46025925|NCT01034631|Drug|BNC105P|BNC105P, up to 16 mg/m^2
46025926|NCT01227668|Drug|Aripiprazole|Tablets, Oral, 2-15 mg, once daily, 13-42 weeks
46025927|NCT01227668|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks
46113449|NCT02610101|Other|Traditional SCD Diet|Traditional SCD includes removal of all processed foods as well as all grains, sweetners except for honey and all diary except for yogurt fermented for over 24hrs and some hard cheeses
46113450|NCT02610101|Other|Modified SCD Diet|Food components of the traditional SCD with the addition of rice and oats.
46113451|NCT02610101|Other|Whole foods diet|A whole foods diet with removal of processed foods. Removal of corn, wheat, sugar and milk are also apart of this dietary regime.
46113452|NCT04089618|Behavioral|MBLM|Complex 8 week Mind-Body program.
46113453|NCT04034303|Genetic|analysis of genetic and epigenetic risk factors|analysis of gene, methylation and expression, microbiome
46113454|NCT02595606|Drug|0.3% Sodium Hyaluronate|five times per day for the intervention of eye drop
46025928|NCT00603460|Biological|DCVax-L and T Cells|"Arm A~Optional DCVax-L prior to chemotherapy~Apheresis~Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~Infusion of activated T cells~DCVax-L vaccine~End of study visit~Arm B~Optional DCVax-L prior to chemotherapy~Apheresis~Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~Infusion of activated T cells~DCVax-L vaccine~Oral cyclophosphamide (one week on/one week off) for a total for a total of 6 weeks~End of study visit"
46025929|NCT02851186|Device|Acupuncture|
46113455|NCT05755685|Drug|Hyperthermic intraperitoneal treatment of recombinant modified human tumor necrosis factor (rmhTNF)|5 million IUrmhTNF, dissolved in 30-50ml normal saline, was intraperitoneal heat perfusion into the surgical focus after the operation;
46025930|NCT02851186|Device|Sham acupuncture|
46025931|NCT04319432|Behavioral|Voice rest|The first days will take place in hospitalization to assess patient complience to voice rest. Patients will be instructed to continue voice rest at home up to 7 days accourding to group allocation in the study. The confirmation of voice rest will relay on patient report (telephonic approval), after the voice rest period will end.
46113456|NCT00917436|Drug|Thiocolchicoside|
46025932|NCT01227512|Drug|tolvaptan|15 mg titrated to 30 mg then 60 mg once daily as oral tablet for up to 7 days based on response.
45838791|NCT04360668|Other|Muscle Energy Technique (MET)|The Contract-Relax Agonist-Contract (CRAC) technique will be used, which belongs to the broad MET group. The participant will be in the supine position. The therapist will set the cervical segment in the lateral flexion until a slight soft tissue tension is felt. The technique will consist of two stages. In the first phase (contraction phase), the upper trapezius will be activated against the therapist's resistance (shoulder girdle elevation) - 10 seconds. Then the person undergoing the procedure breathes in and out deeply. Then 10 seconds of antagonist group contraction (shoulder girdle depression) will be performed. Next, the therapist will passively move the participant's shoulder girdle towards the depression. Then the second phase will follow (stretching phase), during which the participant will passively lie in the back position for 30 seconds. Both phases will make up the therapeutic cycle. Each participant will have 5 cycles on each side of the upper trapezius.
46025933|NCT01227512|Other|Fluid Restriction|"Placebo tablet once daily with prescribed daily fluid intake of 1500 mL, then intensifying to 2 lower volumes of fluid intake for up to 7 days based on response.~Since all particpants were blinded to treatment, titration to stricter fluid restriction followed the same algorithm as tolvaptan, increasing both the level of fluid restriction and increasing the placebo dose"
46113457|NCT04088838|Other|Pain tracking app|In this study no clinical interventions are made. Patients scheduled for surgery will be treated according to the standard of care. All patients enrolled will have an application installed to track their pain symptoms through short daily and weekly questionnaires.
46025934|NCT01227278|Other|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
46025935|NCT01227278|Biological|Benralizumab 100 mg|Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
46025936|NCT01034397|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg (minimal dose 480mg, maximum dose 800mg) iv infusion every 4 weeks for 24 weeks
46113458|NCT02609945|Drug|zolmitriptan|Oral Tablet and Nasal Spray
46113459|NCT02609945|Drug|CVT-427 (zolmitriptan inhalation powder),|Capsules containing zolmitriptan; dose levels equivalent to estimated fine particle dose (i.e., lung-delivered) zolmitriptan.
46113460|NCT00739908|Drug|CX157 (TriRima)|Six capsules administered three times a day for six weeks.
45470188|NCT04595851|Other|Comprehensive Medication Review (CMR)|Following the first PROM, participants will be contacted by the primary care pharmacist for a Comprehensive Medication Review (CMR) for their chronic medications. If warranted, a follow-up CMR will take place after the second PROM.
45470189|NCT04595851|Other|Communications between oncology and primary care pharmacists|Throughout the study, the oncology and primary care pharmacists will communicate about medications through the electronic medical record.
45470190|NCT04632459|Drug|pembrolizumab plus ramucirumab|"Patients will continue to receive study treatment, until they demonstrate objective disease progression (determined by modified RECIST 1.1) or until they meet any other discontinuation criteria.~Ramucirumab 8mg/kg on q2W~Pembrolizumab 200mg on q3W (pembrolizumab first followed by ramucirumab when concurrently administered on the same day)~If ramucirumab had to be stopped due to intolerable toxicity, pembrolizumab will be continued until unacceptable toxicity, disease progression or upto 35 cycles."
45470191|NCT04663932|Procedure|immediate stenting group(one-step strategy)|Patients assigned to the immediate stenting group will undergo appropriate stent implantation based on characteristics of the lesions.
45470192|NCT04663932|Procedure|deferred stenting group (two-step strategy)|Patients assigned to the deferred stenting group will be sent back to the ward after PCI to receive standard anticoagulant and antiplatelet therapies, and the CAG will be repeated 5 to 7 days after initial intervention, followed by treatment with stent implantation.
45470193|NCT03256851|Behavioral|Telephone-Delivered Exercise Therapy|"A combination of aerobic and resistance training has been shown to be most effective for reducing fatigue in persons with MS.~Aerobic training will consist of: 30 minutes of either cycling, treadmill walking or overground walking, 2x/week. Participants will be given a wrist-worn pedometer with heart-rate monitor to track their heart rate during training. Participants will be progressed to reach 60-70% of their maximal heart rate during aerobic training over the course of the study.~Strength training will consist of hip extension, hip flexion, hip abduction, knee extension and knee flexion movements with resistance bands performed 3x/week.~This home exercise program will be paired with a 1x/week telephone call with an investigator."
46025937|NCT01034397|Drug|placebo|iv every 4 weeks for 24 weeks
46025938|NCT01034397|Drug|non-biological DMARDs|stable dose at investigator's prescription
46025939|NCT01227044|Drug|Naltrexone|NTX arm will receive monthly extended release NTX doses at 380mg (4 mL), administered as an intramuscular gluteal injection at 4-week intervals.
46025940|NCT01227044|Other|Placebo + Medication Management/Medication Coaching|Placebo + Medication Management/Medication Coaching
46025941|NCT02872779|Procedure|Blood sampling for free mutant DNA analysis|Blood sampling for Patients Treated for Metastatic Colorectal cancer
46025942|NCT01225952|Device|Crystalens AO|Bausch & Lomb model silicone multi-piece accommodating IOL.
46025943|NCT01225952|Device|ReSTOR 3.0|An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.
46025944|NCT01225952|Device|AMO Tecnis Multifocal|The Tecnis Multifocal foldable hydrophobic acrylic IOL, Model ZMA00 (Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL.
46025945|NCT01034163|Drug|Panobinostat|
46025946|NCT01034163|Drug|Placebo|Placebo
46025947|NCT05035641|Drug|AND017|Orally, 3 times per week in Period 1 and randomize to TIW or QW group at the same dose in Period 2
46025948|NCT05035641|Drug|Placebo|Orally, 3 times per week
46025949|NCT01033851|Behavioral|Mindfulness Based Stress Reduction|8 week course
46025950|NCT01033851|Behavioral|Stress Management Education|8 week course
46025951|NCT01162122|Biological|MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)|one dose 0.5 mL administered IM in the deltoid muscle of (preferably) the non-dominant arm
46113461|NCT00739908|Drug|Placebo|Six capsules administered three times a day for six weeks.
46113462|NCT05297435|Diagnostic Test|Questionnaires|Questionnaire study
46113463|NCT04578431|Dietary Supplement|Artificial sweeteners (acesulfame-potassium, sucralose, saccharine, cyclamate)|The intervention is found in light products ingested by millions of people on a daily basis worldwide
46113464|NCT02596308|Biological|Plague vaccine|Plague vaccine is comrised by native fraction 1 capsule (F1) and recombine virulence-associated (V) antigens.
46113465|NCT04570475|Drug|Vitamin D|Participants will receive vitamin D+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
46113466|NCT04570475|Drug|multivitamin|Participants will receive placebo+multivitamin or vitamin D+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
46113467|NCT04570475|Drug|Placebo|Participants will receive placebo+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
46113468|NCT02609165|Drug|rhNGF 180 µg/ml eye drops solution|eye drops
46025952|NCT01162122|Biological|Non-adjuvanted trivalent subunit influenza vaccine (TIV)|one 0.5 mL dose administered IM in the deltoid muscle of (preferably) the non-dominant arm
46113469|NCT02609165|Drug|vehicle eye drops|placebo
46113470|NCT05052125|Drug|Oxygen|Administering oxygen to achieve the desired peripheral oxygen saturation
46113471|NCT00739596|Drug|Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks|Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks
46113472|NCT00739596|Drug|Amlodipine: 8 weeks|Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks
46113473|NCT05754905|Other|Magnetic resonance examination|the two groups are underwent magnetic resonance examination including enhanced 3D-WATSc sequence
46113474|NCT04549493|Behavioral|Exposure Therapy|Exposure Therapy is used to reduce the symptoms of PTSD
46113475|NCT00742326|Drug|Pioglitazone|45 mg/daily
46113476|NCT00742326|Drug|Placebo|one capsule daily
46113477|NCT05757089|Dietary Supplement|ALCOFILTRUM|ALCOFILTRUM helps alleviate alcohol hangover symptoms after a single intake for 30 minutes before alcohol consumption.
46113478|NCT04088760|Drug|TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT)|The majority of TCRαβ+ T cells and CD19+ B cells will be removed from the allogeneic graft utilizing the CliniMACS® immunomagnetic selection device (Miltenyi Biotec). The depletion process involves two phases; cell labeling (phase 1) and the automated immunomagnetic depletion process (phase 2). The CD34+ dose may be adjusted by the need to not exceed the TCRαβ+CD3+ dose threshold.
46113479|NCT05755607|Procedure|laparoscopic pancreaticoduodenectomy|The laparoscopic group will perform the surgical procedure using laparoscopic instruments, with three surgeons involved throughout the procedure.
46113480|NCT05755607|Procedure|Robot Pancreaticoduodenectomy|The robotic team will perform the surgery using the latest generation Da Vinci robotic surgical system, with an additional surgeon assisting in the procedure.
46113481|NCT00741936|Drug|MaZiRenWan (MZRW)|MZRW granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
46025953|NCT01033071|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
46025954|NCT01033071|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
46113482|NCT00741936|Drug|Placebo|Placebo granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
46113483|NCT05754749|Drug|Iohexol 350 Mg/mL Injectable Solution|Participants will be scanned with the digital breast tomosynthesis (DBT) system before and after the intravenous administration of iodinated contrast agent, iohexol 350mg I/mL at a dose of 1.5 mL/kg body weight. Images will be acquired of the breast of interest prior to the administration of contrast, followed by at approximately 2 minutes and 5 minutes after administration. For the purposes of this study, imaging will focus on a single breast to simplify data acquisition.
46113484|NCT02608853|Other|No treatment given|No treatment is actively administered. Patients are treated according to routine clinical practice at the discretion of their treating physicians.
46113485|NCT02597868|Drug|Capecitabine|Capecitabine is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment.
46113486|NCT02597868|Procedure|endocrine therapy|endocrine therapy is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment,the medicine will be confirmed by the patient's past-treatment.
46113487|NCT05754671|Other|perceptual assessment of the recorded voice sample|perceptual assessment of the recorded voice samples
46113488|NCT05754671|Other|voice recording|voice recording
46113489|NCT02595294|Procedure|Cervical Lateral Glide neural mobilization|Non-surgical non-invasive Cervical Lateral Glide neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The correct linear alignment of patient's cervical spine was determined through the baseline use of a Universal Goniometer Device in each application of Cervical Lateral Glide neural mobilization.
46025955|NCT01033071|Drug|Olmesartan medoxomil and hydrochlorothiazide|"Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks."
46025956|NCT04313946|Diagnostic Test|Scanning Chest X-rays and performing AI algorithms on images|Chest X-Rays; AI CNNs; Results
46113490|NCT02609867|Device|Flowise Cerebral Flow Diverter|Flowise Cerebral Flow Diverter Placement
46113491|NCT00811187|Drug|Lidocaine paracervical block|5cc 1% lidocaine injection in each paracervical region
46113492|NCT00811187|Drug|Normal Saline|5cc Normal Saline injection in each paracervical region
46113493|NCT02593812|Behavioral|Stepping training|Participants will step rapidly to one of four cued targets. Each trial will consist of 24 steps. Participants will perform 6 blocks of 6 trials per day for 3 consecutive days.
46025957|NCT04125030|Other|Validation of questionnaires|Participants will complete i) the RAS (24 items, 5-point Likert scale), ii) the CM (23 items, 5-point Likert scale), and the iii) the RSA for consumers (32 items, 5-point Likert scale). These participants have already completed these other measures (clinical recovery): iv-Anxiety: Anxiety State-Trait Anxiety Inventory Form Y6 (STAI-Y6) (6 items); v- Depression: Depression Patient Health Questionnaire (PHQ-9) (9 items) ; vi- Alcohol Dependence: Alcohol Use Disorders Identification Test (AUDIT-10) (10 items) ; vii- Drug Dependence: Drug Abuse Screening Test (DAST-10) (10 items) ; viii- Psychosis : Psychosis Screening Questionnaire (PSQ 12 items) ; ix- Social functioning : World Health Organization Disability Assessment Schedule (WHODAS 2.0) (12 items).
46113494|NCT04421729|Behavioral|Group sessions over 3 weeks|Informational and educational group-mediated program for family members caring for a person living with dementia; 6 sessions.
46113495|NCT04421729|Behavioral|Group sessions over 6 weeks|Informational and educational group-mediated program for family members caring for a person living with dementia; 3 sessions.
46113496|NCT02596074|Drug|Omiganan (CLS001) topical gel|
46113497|NCT02596074|Drug|Vehicle topical gel|
46113498|NCT05754515|Procedure|target controlled infusion (TCI) group|"Patients in the TCI group will be anesthetized with propofol and remifentanil throughout the operation.~Patients included in the inhalation anesthesia group will be anesthetized with desflurane and remifentanil with a bispectral index of 40-60 throughout the operation."
46113499|NCT00917748|Drug|DOCETAXEL(XRP6976) + MODAFINIL|arm 1: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily arm 2: best supportive care (docetaxel chemotherapy) plus placebo of modafinil 200mg mane daily
46113500|NCT00917748|Drug|Modafinil|best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily
46113501|NCT00917748|Drug|Placebo of Modafinil|Best supportive care (docetaxel chemotherapy) + placebo capsules one daily-mane (before noon)
45470194|NCT03256851|Behavioral|In-Person Delivered Exercise Therapy|"A combination of aerobic and resistance training has been shown to be most effective for reducing fatigue in persons with MS.~Aerobic training will consist of: 30 minutes of either cycling, treadmill walking or overground walking, 2x/week. Participants will be given a wrist-worn pedometer with heart-rate monitor to track their heart rate during training. Participants will be progressed to reach 60-70% of their maximal heart rate during aerobic training over the course of the study.~Strength training will consist of hip extension, hip flexion, hip abduction, knee extension and knee flexion movements with resistance bands performed 3x/week.~This home exercise program will be paired with a 1x/week visit to the laboratory to work with a physical therapist or trained team member."
46025958|NCT01032915|Biological|AIN457|AIN457 300mg s.c weekly for 3 weeks then every 2 weeks
46113502|NCT02596152|Other|mini-trampoline|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
46025959|NCT01032915|Biological|AIN457|AIN457 300mg s.c at baseline and Week 2 then every 4 weeks
46025960|NCT01032915|Biological|AIN457|AIN457 150mg s.c at baseline and Week 2 then every 4 weeks
46113503|NCT02596152|Other|Nordic Walking|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
46113504|NCT02595138|Drug|Zoledronic acid|
46113505|NCT00591149|Drug|Oxaliplatin|130 MG/M2 IV over 2 hours on day 1 of 21 day cycle over a period of 4 cycles
46113506|NCT00591149|Drug|Docetaxel|60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle for a period of 4 cycles
46113507|NCT00591149|Drug|Cetuximab|400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks
46113508|NCT00735072|Drug|Placebo|Dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
45470195|NCT03757663|Behavioral|UV Counseling|Participants will self-report their knowledge and attitudes related to UV exposure. They will then wear a dosimeter for 3 weeks. After, the study team will counsel the participants on their UV levels and exposure, creating a personal plan and advice for avoiding sun exposure before letting the participants wear the dosimeter for an additional 3 weeks.
45470196|NCT01050504|Other|Cytology Specimen Collection Procedure|Correlative studies
46113509|NCT00735072|Drug|Maraviroc|Dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
46025961|NCT01032915|Drug|Placebo|Placebo s.c weekly for 3 weeks then every 2 weeks
46025962|NCT04589325|Drug|Ixekizumab|"Ixekizumab will be available at a concentration of 80 mg solution for injection in pre-filled syringes.~Ixekizumab will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months."
46025963|NCT04589325|Drug|Placebo|"Placebo will be available at a concentration of 80 mg solution for injection in pre-filled syringes.~Placebo will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months."
45470197|NCT01050504|Other|Laboratory Biomarker Analysis|Correlative studies
45470198|NCT03393078|Device|transcranial magnetic stimulation with real coil|TMS with real coil is a noninvasive technique to activate and modify the activity of the neurons
45470199|NCT03393078|Device|transcranial magnetic stimulation with sham coil|TMS with sham coil is a placebo
45470200|NCT04837807|Drug|Systane Hydration PF|This is an over-the-counter preservative free artificial tear that can be purchased at most retail stores and pharmacies.
45470201|NCT04103931|Behavioral|"Treatment Choices for Aortic Stenosis Decision Aid"|"A decision aid, titled Treatment Choices for Aortic Stenosis, produced by the American College of Cardiology that contains information for patients deciding between TAVR and surgery to treat their aortic stenosis."
45470202|NCT03974022|Drug|DZD9008|Daily dose of DZD9008
45470203|NCT03985371|Drug|EDTA Eye Drops|One drop in the Band Keratopathy affected eye only, two times per day for six months.
45470204|NCT03753139|Device|Heart rhythm monitoring with portable device|"The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.~Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.~Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.~Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel.~Samsung Gear S3 wearable (Samsung Electronics, Co., Soul, South Korea) which is CE cleared consumer device. Gear S3 is a photopletysmogram, which measures optically the amount of blood circulating in the blood vessel."
45470205|NCT04111965|Drug|Nanodrop®|minimum to meet 1 drop 4 times a day, both eyes
46025964|NCT00627783|Other|a bicycle exercise test|
46025965|NCT01161498|Biological|Talimogene Laherparepvec|Administered by intratumoral injection
46025966|NCT01161498|Radiation|Radiation|70 grays of radiation administered in 35 fractions over 7 weeks
46025967|NCT01161498|Drug|Cisplatin|Administered by intravenous infusion
46025968|NCT02873559|Drug|testosterone|Testosterone supplemented in 5 months
46025969|NCT02873559|Other|Progressive muscle training|Progressive muscle training during 4 months
46025970|NCT01180998|Device|Senofilcon A Toric (AOfA)|Soft toric contact lenses for astigmatism
46025971|NCT01180998|Device|Etafilcon A Toric (1DAMfA)|Soft toric contact lenses for astigmatism
46025972|NCT01029795|Drug|LY2599506|Administered orally (po), twice daily (BID) prior to morning and evening meals for 12 weeks
46025973|NCT01029795|Drug|Glyburide|Administered po, BID daily prior to morning and evening meals for 12 weeks
46113510|NCT00810641|Procedure|Gufoni maneuver|For Gufoni maneuver,16,18 the patient was quickly brought down to the side-lying position on the affected ear from the sitting position. After one minute in this position, the head of the patient was quickly turned 45O upward, so that the nose directed upward. Approximately 2 minutes later, the patient was returned to the upright position (Figure 2A).
46113511|NCT00810641|Procedure|Head-shaking maneuver|For head-shaking maneuver,15 patients were brought into a sitting position. After pitching the head forward by approximately 30O, we moved the head sideways in a sinusoidal fashion at an approximate rate of 3 Hz for 15 seconds.
45470206|NCT04111965|Drug|Systane Balance|minimum to meet 1 drop 4 times a day, both eyes
46025974|NCT01029795|Drug|Placebo|Matching placebo capsules administered po, BID prior to morning and evening meals for 12 weeks
46113512|NCT00810641|Procedure|sham maneuver|For the sham maneuver, patients quickly lied on the unaffected side, and returned to the sitting position after one minute.
46113513|NCT05753813|Drug|Phexxi|intravaginal gel twice weekly for 4 weeks.
46113514|NCT04181723|Drug|Trofinetide|Trofinetide solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
46113515|NCT04181723|Other|Placebo|Trofinetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
46113516|NCT00793598|Drug|Placebo|
46113517|NCT00793598|Drug|Brincidofovir|
46113518|NCT04115072|Drug|Praziquantel 600Mg Oral Tablet x 5|Five doses of Praziquantel 40 mg/kg
46025975|NCT04124874|Other|There will be no intervention|There will be no intervention
46025976|NCT02885766|Drug|PF-114|
46025977|NCT02885454|Drug|Drospirenone/ethinylestradiol|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol to be taken orally on Days 1, 6, 25, and 32.
45470207|NCT03753061|Device|Aspiration Catheter|Patients will be treated for mechanical recanalization with Aspiration Catheter within 8 hours after stroke onset plus standard medical management.
45470208|NCT03753061|Device|Solitaire FR|Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
45470209|NCT03316872|Drug|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
46025978|NCT02885454|Drug|AL-335|AL-335 (800 mg) tablet once daily on Days 5-7 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
46025979|NCT02885454|Drug|Odalasvir (ODV)|ODV 25 mg tablet once daily on Days 12-25 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
46025980|NCT02885454|Drug|Simeprevir (SMV)|SMV 75 mg capsule as a component of 3-DAA combination to be taken orally on Days 26-32.
46025981|NCT02885610|Biological|Placebo plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
46025982|NCT02885610|Biological|RC18 80 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
46113519|NCT04115072|Drug|Praziquantel 600Mg Oral Tablet x 1|Single dose of Praziquantel 40 mg/kg
46113520|NCT04025294|Device|videogame|A videogame intervention that is interactive and engaging that teaches adolescents how to restructure negative automatic thoughts through an adapted thought record (a technique used in cognitive behavioral therapy to improve moods) by modeling how to do so and then empower them through real-life activities to improve their school climate. The videogame intervention is comprised of five mini-games, each containing a short narrative that models how to restructure negative automatic thoughts and navigate through challenging situations that often take place in school settings. The topics of each mini-game are informed by the constructs of school climate according to the National School Climate Center. Students using the videogame intervention will be prompted to think deeply and reflect on the narratives presented in each mini-game.
46113521|NCT04025294|Behavioral|School Climate Assessment Survey|A school climate assessment survey will include items adapted from questions developed by the National School Climate Center. Items will assess various dimensions of school climate including safety, social media, relationships, support for learning, and environment.
46113522|NCT04005482|Other|Rate control|Rate control according to the Atrial fibrillation - ESC Guidelines 2016
46113523|NCT05631548|Device|iTBS to dmPFC|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. Approximately 25% of the nasion-inion distance, or Talairah coordinates X 0 Y+60 Z+60 will be measured.The first session will begin with the acquisition of the resting motor threshold (rMT; lowest stimulus intensity that elicits a visible twitch on 50% of the trials) on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last about 3 minutes. Each participant will receive 2 sessions with a 15-20 minute interval between sessions.
45470210|NCT03316872|Radiation|Stereotactic Body Radiotherapy (SBRT)|SBRT involves delivery of high doses of radiation therapy in smaller fractions
45470211|NCT03256695|Drug|Albuterol sulfate (ABS)|ABS will be administered via eMDPI as per the dose and schedule specified in the arm.
45470212|NCT03752983|Diagnostic Test|blood samples|blood samples
46113524|NCT05631548|Device|Sham iTBS|Sham TMS will be delivered with the sham side of the MagVenture Cool B70 A/P coil. The software will be pre-programmed by a staff member that will not be involved in data analysis or collection for blinding purposes. The sham stimulation will match the number of pulses and length of time as the active condition and each participant will receive 2 sessions with a 15-20 min interval between sessions.
46113525|NCT00796562|Drug|Busulfan|Participant will receive Busulfan injections, 4 times a day for 4 days with dilantin prophylaxis (in patients 10 years of age or older). Busulfan levels in the blood will be measured and dose adjusted, if needed.
45838792|NCT04360668|Other|Trigger Point Therapy (TPT)|The technique of Positional Release (PR) will be used, which is one of the broadly understood Trigger Point Therapy. It will consist in compressing the trigger point with a simultaneous shortening of muscle attachments (slight lateral flexion towards the relaxed muscle). The muscle on both sides will be treated. The pressure exerted by the therapist's pincer grip will be acceptable to the patient. The duration of the technique will be 2 minutes for each muscle. While performing this technique, the participant will passively lie on his back.
46025983|NCT02885610|Biological|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
46113526|NCT00796562|Drug|Cyclophosphamide|Patient will receive Cy by IV once a day for 2 days.
46113527|NCT00796562|Radiation|Total body irradiation|Patients will receive TBI once a day for 4 days.
46113528|NCT00801632|Procedure|Kidney Transplantation|Surgical transplantation of donor kidney
46113529|NCT00801632|Procedure|Bone marrow transplantation|During kidney transplant, bone marrow cells donated by the same donor as the kidney are given through a plastic tube placed in a vein in the chest, underneath the collarbone
46113530|NCT00801632|Biological|MEDI-507|0.1 mg/kg on day -2; 0.6 mg/kg on days -1,0,1
46025984|NCT02885610|Biological|RC18 240 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
46025985|NCT04314180|Device|Taking slit-lamp images|The participant only needs to take several slit-lamp images as usual.
46113531|NCT00801632|Drug|cyclophosphamide|60 mg/kg infusion on days -5, -4
46113532|NCT00801632|Biological|rituximab|375 mg/m^2 infusion on days -7, -2, 5, and 12
46113533|NCT00801632|Drug|Tacrolimus|0.05 mg/kg intravenously twice daily starting on day -1, adjusted to trough level of 10-15ng/ml, then tapered (if eligible) on days 1, 7, 14, 21, 28, 42, and 56
46025986|NCT01032837|Drug|Oseltamivir|Oseltamivir capsules for participants ≥ 13 years.
46113534|NCT00801632|Drug|corticosteroids|2 mg/kg prednisone on day 4, with an additional 500-mg pulse of methylprednisolone given on days 10, 11, and 12, and then tapered off by day 20
46113535|NCT00801632|Radiation|thymic irradiation|700 cGy of thymic irradiation administered in a single dose on day -1
46113536|NCT04111484|Other|Adrenomedullin|Adrenomedullin is a naturally found in the human body and has strong vasoactive properties.
46113537|NCT04111484|Other|Saline|Placebo
46113538|NCT05630690|Device|IPL with smart diagnostic handpiece|treatment with IPL following diagnostic with SMART system
46113539|NCT04109300|Genetic|HLADQA1*05A>G screening|DNA will be extracted from whole blood collected from subjects in both arms using the MagNA Pure Compact instrument (Roche, Laval, Quebec, Canada). A custom TaqMan allelic discrimination assay (Applied Biosystems, Carlsbad, CA) will be used to determine the presence of wild-type and/or variant alleles in the class II HLA gene region at rs2097432 mapped to the HLA-DQA1*05 region in infliximab-exposed IBD subjects. Genetic data will be used to determine whether or not one of methotrexate or azathioprine should be applied to the patient in the experimental arm.
46113540|NCT04109300|Other|Standard of Care|The treating physician will use clinical judgement to determine need for the addition of one of methotrexate or azathioprine to infliximab therapy.
45470213|NCT04623684|Drug|Microdrop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 6-7 μL)]|1 drop (6-7 μL) for 3 doses, 5 minutes' intervals
46025987|NCT01032837|Drug|Oseltamivir|Pediatric suspension for participants aged ≤ 12 years.
46025988|NCT01032837|Drug|Placebo|Matching placebo provided as capsules and as a suspension.
46113541|NCT02604290|Device|Kinesio Taping method|"The tape is applied depending on the physical examination:~Muscular technique is placed along paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied in the direction of paravertebral muscle fibers; the base is placed up or down if the mobilisation direction is up or down respectively.~Space technique is placed horizontally over the painful spinal segmental level if back pain in flexion or extension improves when skin/fascial mobilisation is applied approaching to a central point.~Fascia technique is placed horizontally over the painful area in paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied transverse to the paravertebral muscle fibers."
46113542|NCT02604290|Device|Kinesio Taping sham|The tape is applied with 0% tension, horizontally over two non-tender to palpation spinal segmental levels. The patient is kept in neutral position.
46113543|NCT04111328|Drug|intravenous sufentanil|The PCA pumps contain sufentanil . And the pump is connected to participants intravenously .
46113544|NCT04111328|Drug|subcutaneous sufentanil|The PCA pumps contain sufentanil. And the pump is connected to participants subcutaneously.
46113545|NCT04111328|Drug|intravenous hydromorphone|The PCA pumps contain hydromorphone. And the pump is connected to participants intravenously .
46113546|NCT04111328|Drug|subcutaneous hydromorphone|The PCA pumps contain hydromorphone. And the pump is connected to participants subcutaneously.
45470214|NCT04623684|Drug|Standard drop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 28-34 μL)]|1 drop (28-34 μL) for 3 doses, 5 minutes' intervals
46113547|NCT04111328|Drug|intravenous sufentanil and dexmedetomidine|The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants intravenously .
46025989|NCT04314102|Other|No intervention will be made.|No intervention will be made. Only checks will be made
46113548|NCT04111328|Drug|subcutaneous sufentanil and dexmedetomidine|The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants subcutaneously.
46113549|NCT04111328|Drug|intravenous hydromorphone and dexmedetomidine|The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants intravenously.
46113550|NCT04111328|Drug|subcutaneous hydromorphone and dexmedetomidine|The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants subcutaneously
46113551|NCT00806819|Drug|Nintedanib (BIBF1120)|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
46113552|NCT00806819|Drug|Pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
46113553|NCT00806819|Drug|pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
46025990|NCT04206072|Drug|D-0316 Capsule|"The initial dose of D-0316 is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD until disease progression or meet the discontinuation criteria. A cycle of treatment is defined as 21 days of once daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were confirmed T790M mutation positive may have the option to continuously receive D-0316."
46113554|NCT00806819|Drug|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
46113555|NCT00806819|Drug|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
46113556|NCT00806819|Drug|placebo|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
46113557|NCT00806819|Drug|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
46113558|NCT00806819|Drug|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
46113559|NCT00806819|Drug|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
46113560|NCT00806819|Drug|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
46113561|NCT00806819|Drug|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
46113562|NCT00806819|Drug|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
46113563|NCT00806819|Drug|placebo|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
46113564|NCT00806819|Drug|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
46113565|NCT00806819|Drug|Nintedanib (BIBF1120)|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
46113566|NCT00806819|Drug|Pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
46113567|NCT00801242|Drug|Degarelix 240 mg / 80 mg|For each treatment cycle, a starting dose of 240 mg of degarelix was administered on Day 0 as two 120 mg subcutaneous (s.c.) injections in the abdominal region. Thereafter, 6 doses of 80 mg degarelix were administered 28 days apart via single s.c. injections.
45838793|NCT04360668|Other|Muscle Energy Technique (MET) combined with Trigger Point Therapy (TPT)|For this type of intervention, TPT will first be performed on both sides of the upper trapezius muscle, followed by MET, which will also be performed bilaterally. The detailed method of performing the applied therapeutic techniques for the combined procedure will be identical as in the case of isolated (single) methods.
46025991|NCT04206072|Drug|Icotinib Hydrochloride Tablets|"Icotinib (125 mg three times daily, orally), treatment should continue until disease progression or meet the withdrawal criteria. A cycle of treatment is defined as 21 days of three times daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Icotinib arm and confirmed T790M mutation positive have the option to receive D-0316 (crossover to active D-0316)."
46025992|NCT01180296|Drug|oral micronized progesterone|oral micronized progesterone = 400 mg oral micronized progesterone nightly from 16 to 34 weeks
46113568|NCT04109534|Diagnostic Test|Bronchial allergen provocation (BAP)|Nebulized Dermatophagoides farina administered at following doses: 10AE, 20 AE, 40 AE, 80 160 AE, etc… until the FEV1 decreases 20% below the initial FEV1-value
46113569|NCT04109534|Diagnostic Test|Nasal provocation test (NPT)|Dermatophagoides farina will be administered in both nostrils
46113570|NCT04109534|Diagnostic Test|Methacholine test|Nebulized metacholine will be administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg until the FEV1 decreases 20% below the initial FEV1-value
46113571|NCT04109534|Diagnostic Test|Peak nasal expiratory flow (PNIF)|Comparison of peak nasal expiratory flow (PNIF) after NPT between groups
46113572|NCT04108910|Diagnostic Test|Guidance UTI|
46113573|NCT05754437|Device|Low Level Light Therapy|light-emitting diodes (LED), λ = 633 ± 10 nm; power of 100 mW/cm2, 15 minutes
46113574|NCT04377659|Drug|Tocilizumab|Participants will receive Tocilizumab 8 mg/kg i.v. at enrollment. Dose will be capped at 800 mg per infusion. If there is no improvement or toxicity, a second dose can be given 24 hrs to 5 days later.
46113575|NCT04024709|Procedure|Gastric Peroral Endoscopic Myotomy|Creation by submucosal dissection of a tunnel in the gastric wall at the level of the antrum, then of a pyloric and antral myotomy, before closing the mucosal access by clips.
46113576|NCT04111250|Procedure|Maxillary sinus augmentation|Raise the sinus membrane to graft bone substitute to augment the sinus cavity allowing implants placement.
45838794|NCT04360512|Procedure|Posteriorization of the talus|Three sets of a 30-s grade IV mobilization
46025993|NCT01180296|Drug|Identical Placebo tablet|Identical Placebo tablet = placebo taking nightly from 16 to 34 weeks
46025994|NCT01160640|Drug|Ceftriaxone|ceftrixone 250mg IM single dose
46025995|NCT01160640|Drug|Doxycycline|Doxycycline 100 mg PO bid x 14 days
46025996|NCT01160640|Drug|Metronidazole|metronidazole 500 mg PO bid x 14 days
46113577|NCT05326139|Drug|Tranexamic acid|TA-soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
45470215|NCT03757507|Device|MultiSpectral Optoacoustic Tomography|Multispectral Optoacoustic Tomography is a new emerging imaging technique which uses laser light to heat up molecules with a high pulsed laser. The molecules undergo thermal expansion and produces sound waves, which can be detected by special transducers. The device can pick up different signals in different wavelength to produce images with anatomic and biological information.
46113578|NCT05326139|Other|Isotonic saline|Isotonic saline -soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
46025997|NCT01160640|Drug|Placebo Oral Capsule|placebo oral capsule PO bid x 14 days
46025998|NCT01160484|Drug|DVD-R|40 mg dexamethasone will be administered IV on Days 1, 4, 8, and 11 of each cycle. 1.0 mg/m2 Bortezomib will be administered IV over 3 to 5 seconds followed by a standard saline flush, on Days 1, 4, 8, and 11 immediately following the dexamethasone infusion. 4.0 mg/m2 PLD will be given as a 90 minute infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle, following the bortezomib administration. 10 mg/day lenalidomide will be administered PO on days 1-14 of a 28-day treatment cycle, followed by a 14-day rest period, following the PLD administration.
46113579|NCT04110782|Other|Radium223|55 kBq/ Kg
46113580|NCT05754359|Behavioral|I'm an Active Hero (IAAH) Intervention Program|"The I'm an Active Hero (IAAH) programme is a 10-week intervention aimed at increasing physical activity and decreasing sedentary behaviour in preschool-aged (aged 3-5 years) children. It is anticipated to begin in February 2023 to May 2023. Assessments will be conducted at baseline and immediately following the intervention. The IAAH-intervention will be implemented by the preschool teachers, who will have two teacher training sessions with the main researcher (myself). The IAAH-intervention involves environmental modifications (a classroom) to create areas with sufficient space for active play; classroom sessions these will be implemented for 10 weeks (a minimum of one hour per week); and parent involvement, such as the provision of parental-child interaction homework activities and written information (tip cards, posters, and newsletters). for parents on how to encourage their children to be active."
46113581|NCT02605694|Drug|Duvelisib|25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity
46113582|NCT02605694|Drug|Rituximab|375 mg/m2 will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
46113583|NCT02605694|Drug|R-CHOP|"IV infusion on Day 1 of Cycles 1-6 (21-day cycles)~Cyclophosphamide (750 mg/m2)~Doxorubicin hydrochloride (50 mg/m2)~Vincristine sulfate (1.4 mg/m2) (2 mg maximum)~Rituximab (375 mg/m2)"
46113584|NCT02605694|Drug|Prednisone|100 mg orally on Days 1-5 of Cycles 1-6 (21-day cycles)
46113585|NCT02604134|Procedure|Prophylaxis|A dental prophylaxis is a cleaning procedure performed to thoroughly clean the teeth. Prophylaxis is an important dental treatment for halting the progression of periodontal disease and gingivitis.
46113586|NCT02604134|Drug|Fluoride varnish|Fluoride varnish is a highly concentrated form of fluoride which is applied to the tooth's surface, by a dentist, dental hygienist or other health care professional, as a type of topical fluoride therapy.
45470216|NCT03305016|Drug|TransCon hGH|Once weekly subcutaneous injection at a starting dose of 0.24 mg/kg/week
45838795|NCT04359966|Drug|Esomeprazole 40mg, Clarithromycin 500 mg, Metronidazole 400 mg,|First line therapy
46025999|NCT01032291|Drug|cetuximab|Intravenous infusions of cetuximab (400 mg/m^2 Cycle 1 Day 1, thereafter 250 mg/m^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.
46026000|NCT01032291|Drug|lenalidomide|Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle
46113587|NCT02604134|Drug|Silver Nitrate|a small amount will be applied to the tooth via a cotton applicator. Silver nitrate is a colorless, odorless, transparent solution used as an escharotic, dehydrating and sclerosing agent.
46113588|NCT00800540|Drug|Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension|Fixed combination ophthalmic suspension
46113589|NCT00800540|Drug|Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution|Fixed combination ophthalmic solution
46113590|NCT00800384|Device|Implantable defibrillator|Implantable defibrillator to detect and terminate ventricular arrhythmias
46113591|NCT04108832|Drug|TCM OA2|Usage: 3g twice daily
45838796|NCT04359966|Drug|Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg|First line therapy second arm
45838797|NCT04359966|Drug|Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg|Second line therapy for Helicobacter pylori infection
46113592|NCT04108832|Drug|PLACEBO|Usage: 3g twice daily
46113593|NCT00796328|Drug|Phenylephrine infusion|Up-down, biased coin design
45470217|NCT03808311|Other|Treatment strategy regarding different systolic BP goals|The trial will test a treatment strategy question regarding different systolic BP goals and not test specific medications. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of anti-hypertensive medications as long as systolic BP levels are within targets (<120 mmHg in the intensive arm and <140 mmHg in the standard arm).
45470218|NCT04585243|Device|Evalyn Brush|The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.
45470219|NCT03752905|Drug|PTR-01|Recombinant human collagen 7 (rC7)
45838798|NCT04359966|Drug|Esomeprazole 40mg, Amoxicillin 500 mg, Levofloxacin 500 mg|Second line therapy for Helicobacter pylori infection second arm
45470220|NCT03752905|Drug|Normal saline|Saline control
45838799|NCT04360122|Drug|Levamisole|Levamisole (150 mg/day for two days per week for 2 months
46026001|NCT01159938|Drug|Lispro|Dosage based on participants with type 2 diabetes mellitus (T2DM) normal morning insulin dose and energy content of participant's normal breakfast. Subcutaneous injection given on one occasion. Administered once on low post prandial day.
46026002|NCT02873871|Device|Standardized compressive dressing|Standardized compressive dressing
45838800|NCT04360122|Drug|Isoprinosine|Isoprinosine (1 g 3 times per day daily) for two months
46113594|NCT02604758|Behavioral|The Psychiatric Nursing Approach Based On The Tidal Model|To provide individualized care for patients in the experimental group, the One-to-One Sessions were initiated and interventions were performed in line with the goals of the persons and the aims of the research. The interventions were selected from interventions regarding with coping and self-esteem from the Nursing Interventions Classification(NIC) system.The One-to-One sessions help the person recognize change and focus the person on achievement and goals.Taking into account the basic process of the Tidal Model, care stages, the following interview plan was drawn up, containing the details of the interviews to be carried out with people with alcohol dependency, and the One-to-One Sessions were held in line with this plan two times per week.
46113595|NCT02605382|Drug|Chlorhexidine gluconate|
46026003|NCT02873871|Device|Hemostasis with TerumoBand®|Hemostasis with TerumoBand®
46026004|NCT04300335|Other|Individual Exercise|Supervised body weight & resistance band resistance exercises in a one-on-one personal training setting plus home based aerobic exercise
46113596|NCT02605382|Drug|placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
46113597|NCT04114916|Dietary Supplement|Apigenin, luteonin, grapefruit extract and citrolive|Two capsules daily at breakfast and dinner.
46113598|NCT04114916|Dietary Supplement|maltodextrina|Two capsules daily at breakfast and dinner.
46113599|NCT04110860|Drug|voriconazole gel once daily|voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
46113600|NCT04110860|Drug|voriconazole gel twice daily|voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
46113601|NCT04110860|Drug|placebo|the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, voriconazole, is not added then applied twice daily in the same manner
45470221|NCT03297021|Drug|Ondansetron 4 MG|dose as per arm selection
46026005|NCT04300335|Other|Group Exercise|Supervised body weight & resistance band resistance exercises in a Group setting plus home based aerobic exercise
46113602|NCT04114760|Device|patchy-type wireless ECG|This device consists of a single patchy and save the ECG result as a Potable Document Format. Also can transfer to hospital using wifi-network.
46113603|NCT04114760|Device|defibrillator ECG|This device is essential equipment in ambulance. For 12-lead ECG examination the connector need to replace for specific cable.
46113604|NCT02604836|Drug|Ibandronate|Film-coated oral ibandronate tablet (150 mg) once-monthly
45470222|NCT03297021|Drug|Ondansetron 8mg|dose as per arm selection
45470223|NCT03755635|Combination Product|The WHO multimodal hand hygiene strategy|Comprises five essential elements; system change-availability of alcohol-based hand rub at the point of care and/ or access to safe continuous water supply and soap and towels; training and education of healthcare professionals; monitoring of hand hygiene practices and performance feedback; reminders in the workplace; and the creation of a hand hygiene safety culture with the participation of both individual healthcare workers and senior hospital managers.
46113605|NCT00588692|Device|SphygmoCor|The SphygmoCor, a hand-held tonometer will assess central blood pressure noninvasively. This pencil-like device is applied over the radial artery, and uses a validated mathematical transformation to derive central aortic pressure.
46113606|NCT02604524|Device|Closed-Loop Control|Subjects will use the CLC during 5 nights/6 days at a ski camp.
46113607|NCT02604524|Other|Sensor Augmented Pump Therapy|Subjects using their personal pumps with study CGM.
45470224|NCT04820491|Diagnostic Test|X-Ray|Shoulder x-rays as felt necessary for standard of care of diagnosis of shoulder dislocation and reduction
45838801|NCT04360122|Drug|Levamisole and Isoprinosine|Levamisole (150 mg/day for two days per week for 2 months and Isoprinosine (1 g 3 times per day daily) for two months
45838802|NCT04360356|Combination Product|Ivermectin plus Nitazoxanide|Ivermectin 200 mcg/kg once orally on empty stomach plus Nitazoxanide 500 mg twice daily orally with meal for 6 days
45838803|NCT04360356|Other|Standard Care|Oxygen via Ventilators
46026006|NCT04301739|Drug|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
46026007|NCT04301739|Drug|nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide|chemotherapeutics
46026008|NCT04301739|Drug|Placebo|Placebo
46026009|NCT04301583|Dietary Supplement|procyanidin B2 enriched cocoa|Volunteers will intake 5 grams per day of dietary supplement for 10 weeks
46026010|NCT01029405|Drug|AN2728|Ointment B, 2% or 0.5% applied once or twice daily
46026011|NCT01029405|Drug|Placebo|Ointment B Vehicle applied once or twice daily
46026012|NCT02872623|Radiation|Enterography-MRI without enteroclysis|
46026013|NCT02872623|Radiation|enteroCT with enteroclysis|
46113608|NCT04114526|Other|Nicotine Replacement Therapy|"CHAs meet with all interested residents to discuss taking steps towards quitting. The CHAs follow a four step program with all participant 1) get to know the resident and their smoking, 2) Assess what the resident is ready to do to take steps towards quitting, 3) discuss using nicotine replacement therapy (NRT) in the form of patches, gum or lozenges, 4) set one goal for taking steps towards quitting. CHAs will attempt to follow up with participants after the initial encounter. There is no limit on the number of times the CHA may talk with the participants. Some follow interactions will be brief encounters in the neighborhood, while others will be at scheduled. All contacts with each participant will be tracked.~We will provide up to 6 weeks of NRT patches, gum and lozenges to participants who are interested in using NRT to help them quit."
46026014|NCT01021683|Drug|Itraconazole|Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
46026015|NCT01021293|Biological|Poliorix™|3 doses, intramuscular administration
46113609|NCT04110704|Procedure|Insertion of transvaginal cerclage|Transvaginal cerclage is inserted in women with a high risk of preterm birth. However it is unknown whether this alongside cervical length monitoring improves the incidence of preterm birth. The cerclage is inserted under regional analgesia.
46113610|NCT04110548|Procedure|Emotion Regulation Task|"Participants are instructed to complete the emotion assessment after Look or Decrease the neutral or negative pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of emotion, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Then, a neutral or negative picture is presented on the screen for 7s. Finally, participants will rate the intensity of their emotion for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand."
46026016|NCT01021293|Biological|Oral Poliovirus vaccine|3 doses, oral administration
46113611|NCT04110548|Procedure|Craving Regulation Task|"Participants are instructed to complete the craving assessment after Look or Decrease the neutral or gaming pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of craving, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Second, a neutral or gaming picture is presented on the screen for 7s. Third, participants rate the intensity of their craving for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand."
46113612|NCT05616104|Device|FLEX Vessel Prep System|"The FLEX Vessel Prep System to create circumferential, continuous micro-incisions along the length of the stenosis by performing a retrograde pullback through the lesion.~Following FLEX, standard balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding Instructions for Use. Once advanced into the lesion, the balloon should be inflated according to the site's standard of care."
46113613|NCT00915200|Dietary Supplement|N-acetylcysteine|600 mg orally twice daily for three months
46113614|NCT00915200|Dietary Supplement|silibin|480 mg orally twice daily for three months
46113615|NCT00915200|Dietary Supplement|high-dose silibin|960 mg orally twice daily for three months
46113616|NCT00915200|Dietary Supplement|N-acetylcysteine placebo|excipient orally twice daily for three months
45470225|NCT04820491|Diagnostic Test|Ultrasound|Initial evaluation with ultrasound; may also evaluate nearby areas for concern of fracture. Order x- rays after ultrasound as seen fit for other injuries of diagnostic uncertainty.
45838804|NCT04359576|Diagnostic Test|Primary and secondary hemostasis|Focus on platelet aggregation, primary and secondary hemostasis parameters
46026017|NCT04625725|Drug|AZD7442|"Single dose (× 2IM injections) of 300 mg of AZD7442 on parent study Day 1.~Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 1.~Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 183.~Single dose (x 2IM injections) of 600mg of AZD7442 on sub-study Day 183 and Day 366"
46026018|NCT04625725|Drug|Placebo|Single dose (× 2IM injections) of saline placebo on parent study Day 1.
46026019|NCT01021215|Drug|Zileuton|1200 mg twice daily given orally (PO) for 6 days
46026020|NCT01021215|Drug|Celecoxib|200 mg twice daily given orally for 6 days
45470226|NCT03752749|Other|Prednisolone + Acute Intermittent Hypoxia|Administration of oral prednisolone followed by 15, 60-second bouts of mild hypoxia
45470227|NCT03752749|Other|Placebo + Acute Intermittent Hypoxia|Administration of oral matching placebo followed by 15, 60-second bouts of mild hypoxia
45470228|NCT01988571|Drug|Atorvastatin|40 mg tablet taken by mouth each morning for 24 months.
45470229|NCT01988571|Drug|Placebo|One placebo tablet taken each morning orally for 24 months.
45838805|NCT04359810|Biological|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Convalescent Plasma that contains antibody titers against SARS-CoV-2
45838806|NCT04359810|Biological|Non-convalescent Plasma (control plasma)|Non-convalescent plasma (does not contain antibody titers against SARS-CoV-2)
45838807|NCT04359264|Other|Cash transfer|Cash transfer of $1000
46026021|NCT01021215|Other|laboratory biomarker analysis|Correlative studies
46026022|NCT02696239|Device|V-lock suture|
46026023|NCT02696239|Device|Vicryl Suture|
46026024|NCT02696239|Device|Lapra-Ty II|
46026025|NCT02760979|Drug|Denosumab|Denosumab treatment one year after surgery
46026026|NCT02760979|Drug|Placebo|Serum one year after surgery
46026027|NCT04301115|Other|attachment|unilateral attachment from rehine 83
46026028|NCT04301115|Other|bridge|tooth implant supported bridge
46113617|NCT00915200|Dietary Supplement|silibin placebo|excipient orally twice daily for three months
46113618|NCT04108754|Other|microangiopathic burden|to determine the value of the global microangiopathic burden on the prediction of early stroke risk in a homogeneous cohort of TIA.
46113619|NCT05654402|Diagnostic Test|Non-invasive measurement of carotid-femoral transit time by Doppler velocimetry (Athys Medical©) - WAKIe R3 2TC®) (PWV in cm/s)|"Measurement of the carotid-femoral transit time (ms) (recorded on Data Warehouse Connect).~Measurement of the distance between the carotid and femoral points with a tape measure (m).~Calculation of the propagation speed of the wave PWV (expressed in m/s).~For all patients PWV in (m/s=) will be collected over three distinct periods:~Before induction (awake without premedication)~During general anesthesia or loco-regional anesthesia~Upon awakening from general anesthesia or lifting of the loco-regional anaesthesia"
46113620|NCT00588146|Drug|Pegylated Interferon Alpha2b|Weekly subcutaneous injection of 1 microgram/kg/week
46113621|NCT00588146|Other|Standard care|Standard care
46113622|NCT02604602|Other|blood exam|laboratory test
46113623|NCT05653622|Procedure|Integrated boost technique (SIB) guided by PET FDOPA|intensity-modulated irradiation scheme with integrated boost technique (SIB) guided by PET FDOPA during the chemo-radiotherapy
46113624|NCT05613764|Behavioral|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms
46113625|NCT04110470|Diagnostic Test|X-ray|Patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks.
45470230|NCT04794751|Device|JJVC Investigational Multifocal Contact Lens|senofilcon A C3
46113626|NCT04110470|Diagnostic Test|No-Xray|These patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks, unless clinically indicated.
46113627|NCT04110002|Behavioral|Injury Prevention Program|
46113628|NCT00795704|Drug|Mulberry Leaf Extract|Mulberry Leaf Extract 1000 mg by mouth three times daily for 3 months
46113629|NCT00795704|Drug|Placebo|Placebo 500 mg #2 capsules by mouth three times daily
46113630|NCT02604368|Drug|SC411|Soft gelatin capsule
46026029|NCT04301115|Other|CONVENTIONAL|conventional metalic partial denture
46026030|NCT05429281|Other|Pilates-based Core Strengthening Exercises|The PsCS group performed eight Pilates exercises over 45 minutes, three times per week for 12 successive weeks. The training was conducted under the supervision of a physical therapist who had more than 5 years of experience in Pilates.
46026031|NCT05429281|Other|Plyometric-based Muscle Loading Exercises|The PlyoML group performed 10 plyometric exercises over 45 minutes, three times per week for 12 successive weeks. The training was conducted under the close supervision of a licensed pediatric physical therapist. The safety and performance guidelines, defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association, were considered during training.
46026032|NCT05429281|Other|Combined Pilates and Plyometrics|The combined training group performed the same exercises as the PsCS and PlyoML groups, although with half the number of sets/repetitions over 45 minutes, three times per week for 12 successive weeks. The PsCS and PlyoML were executed within the same session, with a 10-to-15-minute rest interval. The training was conducted under the close supervision of a licensed pediatric physical therapist. The safety and performance guidelines, defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association, were considered during training.
46026033|NCT02873325|Other|antiviral therapies for CMV and/or ADV|salvage antiviral treatments for ADV and/or CMV
45470231|NCT04794751|Device|Dailies Total 1® Multifocal Contact Lens|delefilcon A
46026034|NCT05429125|Device|Endotracheal Tube with Stylet|Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with an endotracheal tube + stylet.
46026035|NCT05429125|Device|Flexible Tip Bougie|Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
46026036|NCT02873403|Device|KNEEMO knee brace|Bespoke knee brace made by additive manufacturing
45470232|NCT00536172|Drug|Escitalopram|Participants take 10 mg for 1 week and then 20 mg for 15 weeks.
46026037|NCT02873403|Device|Popular knee brace|Customized knee brace used in the management of medial knee ostearthritis
46113631|NCT02604368|Drug|Placebo|Soft gelatin capsule
46113632|NCT04110392|Dietary Supplement|Chaya (Cnidoscolus chayamansa)|Chaya Water Beverage of Chaya will be prepared as follows: 40 g of Chaya leaves will be treated with a commercial brand disinfectant following the manufacturer's instructions for use, then added 1L of purified water and mixed in blender. Finally, 500 mL of it will be placed in bottles. Participants will be instructed to consume 1 bottle per day for 6 weeks. 7 bottles will be delivered at each visit, which will be consumed during the week; participants will be instructed to keep the water refrigerated until it is consumed.
46113633|NCT04108520|Other|Exercise|Exercise with respiratory training
46113634|NCT04108442|Behavioral|Traditional|Surgeons (rather than individual subjects) will be randomized to traditional Postoperative follow-up modality groups. They will adhere to this form of postoperative follow-up for all of their surgical patients (subjects) for one month.
46113635|NCT04108442|Behavioral|Virtual|Surgeons (rather than individual subjects) will be randomized to virtual postoperative follow-up modality group. They will adhere to that form of postoperative follow-up for all of their surgical patients (subjects) for one month.
46026038|NCT02754505|Other|Early rehabilitation|The early rehabilitation program consisted of a coordinated exercise therapy and neuromuscular electrical stimulation, for two hours and five days a week until discharge from the acute hospital. Exercise therapy included strength training (three days/week, one to three sets of 12-15 repetitions, 8-10 exercises involving the major muscle groups: thighs, calves, buttocks, trunk, shoulder girdle), aerobic exercise (large muscle activities five days/week, 10-30 min/session, 50-80% maximal heart rate) and active breathing techniques. For neuromuscular electrical stimulation we applied Compex-P© devices producing biphasic symmetric impulses with a frequency of 50 Hz and a pulse width of 0.35 ms (stimulus regime: 8 s on/24 s off) five days/week, 30 min/session involving the anterior thighs and buttocks.
46113636|NCT04108598|Other|Quality of life questionnaire|No intervention will be administered, select sites will administer a quality of life questionnaire
46026039|NCT02754505|Other|Usual care|exercise therapy, respiratory therapy, neuromuscular electrical stimulation (as described above).
46113637|NCT00444457|Biological|13-valent Pneumococcal Conjugate Vaccine|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
46113638|NCT00444457|Biological|7vPnC|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
46026040|NCT04301193|Device|Quantra Analyzer|Subjects blood will be manipulated in the lab and will be tested with the Quantra Analyzer
46026041|NCT02760901|Drug|Acetazolamide|patients received acetazolamide 250 mg half an hour before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity
46026042|NCT02760901|Drug|Acetylcysteine|patients received NAC (600 mg every 12 hours) for 4 doses beginning 24 hours before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity
46113639|NCT05612360|Behavioral|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
46113640|NCT00799058|Drug|dapivirine 4789|dapivirine gel 4789, 0.05%, 2.5g applied once daily
46113641|NCT00799058|Drug|dapivirine gel 4759|dapivirine gel 4759, 0.05%, 2.5g applied once daily
46113642|NCT00799058|Drug|Drug placebo|HEC-based universal placebo gel, 2.5g applied once daily
46113643|NCT00725985|Drug|Cladribine|Cladribine tablets were administered until CDMS conversion, whichever occur first.
46113644|NCT00725985|Drug|Placebo|Placebo matched to cladribine tablets were administered.
45681846|NCT03153826|Other|Comparison of clinical and biological characteristics of patients|Comparison of clinical and biological characteristics of patients with less variation in muscle mass (evaluated by CSARF) compared to patients with greater variation during an hospitalization for COPD exacerbation
46026043|NCT02760901|Drug|Mannitol|patients received mannitol 20 % 100 ml half an hour before cisplatin and saline hydration.
46026044|NCT02760901|Drug|saline|saline hydration 2500 ml before cisplatin therapy
46026045|NCT02760901|Drug|Cisplatin|patients with tumours already prescribed cisplatin
46113645|NCT00725985|Drug|Rebif® new formulation (RNF)|Participants who converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received RNF subcutaneously at a dose of 44 microgram (mcg) three times a week. Participants who converted to CDMS during long-term follow-up (LTFU) period, received RNF subcutaneously at a dose of 44 mcg three times a week.
46113646|NCT04107974|Device|Gastropexy.|Two T-fasteners for G-tube insertion (gastropexy).
46113647|NCT04107974|Procedure|Non-Gastropexy|Insertion of G-tube in absence of T-fasteners.
45470233|NCT00536172|Drug|Placebo|Placebo distribution matches the active medication.
46026046|NCT04301427|Other|Bone mineral density|Bone mineral density will be measured twice in all included patients.
45681847|NCT03158818|Other|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
45681848|NCT03156556|Behavioral|Mood Mechanic Course|French-Canadian version of the Mood Mechanic Course. Performed by a professional translator (Bourret Translation Inc.) and reviewed by the research supervisor, Professor France Talbot, clinical psychologist as well with expertise in CBT.
45681849|NCT04405336|Drug|tab block|injection of tab block to women who are doing cs
46113648|NCT04113824|Procedure|trapezuis motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
46113649|NCT04113824|Procedure|other Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
46113650|NCT04113980|Other|music group|The children in the groups were distracted by music 2 minutes before venipuncture, until the process was over
46113651|NCT04113980|Other|kaleidoscope group|The children in the groups were distracted by kaleidoscope 2 minutes before venipuncture, until the process was over
46113652|NCT04113980|Other|video group|The children in the groups were distracted by watching video 2 minutes before venipuncture, until the process was over
46113653|NCT04109768|Behavioral|nutrition and activity|16 sessions; nutrition 8; activity 8- 45 minutes to improve health and nutrition literacy
46113654|NCT00793910|Drug|Gabapentin|Gabapentin 300 mg taken by mouth thrice daily for 7 days
46113655|NCT00793910|Drug|placebo|placebo (sugar pill) taken by mouth thrice daily for 7 days
46113656|NCT04113902|Behavioral|Health Education|the adolescent girls and their mothers who participated in the intervention group were given health education twice in the first interview and in the fifth week. Follow-up continued for 12 weeks. The adolescent girls and their mothers in the control group received routine clinical practice. The effects of health education were evaluated with Human Papilloma Virus Knowledge Scale and Health Belief Model Scale for Human Papilloma Virus and its Vaccination.
46113657|NCT02592525|Behavioral|IP-SDM training for health professionals|Multifaceted SDM training program for providers: i) 1.5-hour online tutorial, ii) 3.5-hour skills building workshop; iii) video-clip demonstrating SDM in the context of an IP home care team with an aging adult making a decision about location of care (to be used with clients and providers as well); and iv) performance feedback to providers (role play during the workshop).
45681850|NCT04405336|Drug|PCA|giving women PCA
45681851|NCT04405336|Drug|women who will not receive tab block or PCA|no tab block or PCA will be given
45681852|NCT03583138|Drug|buprenorphine|To provide buprenorphine for 12 months for those who are interested in receiving it.
46113658|NCT05589818|Drug|Pembrolizumab|Patients will be treated with the standard dose of pembrolizumab for the first 12 weeks of the study. After week 12 assessments, patients without objective progression of disease are eligible to transition to Q6W dosing of pembrolizumab 400mg IV. Patients will be offered this schedule, also an FDA-approved option, at the discretion of the treating physician, based on tolerability of the q3week regimen and clinician assessment of need for closer follow up intervals. Pembrolizumab will be continued until disease progression, unacceptable toxicity, withdrawal of consent, or death.
46113659|NCT01019941|Drug|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, CKD-810 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
46113660|NCT01019941|Drug|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, Taxotere inj. 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
46113661|NCT04113668|Drug|BMS-986165|Specified Dose on Specified Days
46113662|NCT04113668|Drug|diflunisal|Specified Dose on Specified Days
46113663|NCT00444145|Drug|Prevacid|30 mg bid for 3 months
46113664|NCT00444145|Procedure|Esophageal and Laryngeal Biopsies|repeat egd with biopsy after Prevacid 30 mg bid for 3 months
46113665|NCT04108286|Device|1-DAY ACUVUE MOIST|TEST
46113666|NCT04108286|Device|DAILIES AQUA COMFORT PLUS|CONTROL
46113667|NCT04107896|Drug|Silodosin|Cap silodosin
46113668|NCT04107896|Drug|Tamsulosin|Cap tamsulosin
46113669|NCT05582720|Behavioral|Conventional burger|Participants initially randomized to this intervention arm will be provided with a total of 8 conventional burgers and will be asked to consume them twice weekly for 4 weeks. Conventional burgers will be produced by Hellenic Catering S.A. using standard procedures. Participants will also be instructed to maintain their usual dietary intake, physical activity level, prescribed medications and dietary supplements, as well as to refrain from any weight loss effort during the intervention. After a 2-week wash-out period (no burger consumption), participants will cross over to the other intervention arm.
46026047|NCT04629963|Other|Pain Evaluation and BPISF|Current diagnostic approaches guide evaluators to use the United Nations Istanbul Protocol (UNIP) for the assessment of torture survivors. The proposed investigation offers a novel diagnostic paradigm by which patients are evaluated by the UNIP and a validated pain screen (Brief Pain Inventory Short Form).
46026048|NCT00635713|Drug|Fulvestrant|125mg
46113670|NCT05582720|Behavioral|Vegan burger|Participants initially randomized to this intervention arm will be provided with a total of 8 vegan burgers and will be asked to consume them twice weekly for 4 weeks. Vegan burgers will be produced by Hellenic Catering S.A. using novel technologies. Participants will also be instructed to maintain their usual dietary intake, physical activity level, prescribed medications and dietary supplements, as well as to refrain from any weight loss effort during the intervention. After a 2-week wash-out period (no burger consumption), participants will cross over to the other intervention arm.
46113671|NCT04103983|Device|Sensory retraining device|All participants will be given a device to keep at home and will be asked to use it for 60 minutes each day, as one block, or as multiple shorter sessions of 20 minutes minimum duration. Participants will be asked to use their device on 15 of the 21 days. They will be asked to spread out the use of the device over the 21 days. Participants are asked to record device use in a diary.
46113672|NCT01024777|Drug|Cholecalciferol|Cholecalciferol (Vitamin D3) 10,000 IU in tablet form will be taken once daily for the duration of the trial (6 months)
46113673|NCT01024777|Drug|Cholecalciferol|Cholecalciferol (Vitamin D3) 400 IU in tablet form will be taken once daily for the duration of the trial (6 months)
46113674|NCT04113590|Procedure|Laparoscopic Assisted Transvaginal Cholecystectomy|Perform transvaginal cholecystectomy while obtaining safe access under laparoscopic visualization
46113675|NCT04106882|Drug|Ketones|Supplement administered mid-scan.
46113676|NCT04106882|Drug|Glucose|Supplement administered mid-scan.
45470234|NCT04578457|Device|Hearing Aid without NR enabled|Each participant will be fitted with noise reduction disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
45470235|NCT04578457|Device|Hearing Aid with NR(1)|Each participant will be fitted with the noise reduction program on the same hearing aid. The principle of the noise reduction algorithm is to remove noise from a speech signal with the aim of improving the speech intelligibility and comfort.
46026049|NCT00635713|Drug|Anastrozole|ARIMIDEX
46026050|NCT00635713|Drug|Fulvestrant|250mg
46026051|NCT02760823|Drug|Alpha Lipoic Acid (Thioctacid)|600 mg/12 hours, IV (in the vein)
46026052|NCT02760823|Drug|Placebo (for Alpha Lipoic Acid)|Normal saline in syringe simulating Alpha Lipoic Acid 600mg
46026053|NCT04222543|Combination Product|RGD PET/CT|Patients will receive an RGD PET/CT and a CT perfusion scan prior to treatment and during chemoradiotherapy
46113677|NCT00725283|Biological|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)|Intramuscular administration
46113678|NCT00444067|Device|Spinal Sealant|Spinal Sealant System
46113679|NCT00444067|Other|Standard of Care|Standard of Care
46113680|NCT01323283|Dietary Supplement|Omega-3|This group will receive capsules containing omega-3, omega-6 and vitamin E. The dosage is six capsules per day containing a total of 558 mg of eico-pentaenoic acid (EPA), 174 mg of docosahexaeonic acid (DHA), 60 mg of gamma-linolenic acid (GLA) and 9,6 mg vitamin E in natural form (alfa-tocopherol), gelatine, glycerol. Participants will be instructed to eat three capsules each morning and evening.
46113681|NCT01323283|Dietary Supplement|Placebo|This group will receive capsules containing rape seed oil. Participants will be instructed to eat three capsules each morning and evening.
46113682|NCT00789854|Drug|Quetiapine XR|300 mg once daily (od)
46113683|NCT00789854|Drug|Lithium carbonate|900 mg once daily (od)
46113684|NCT00789854|Drug|SSRI/Venlafaxine|SSRI - doses within label, Venlafaxine dose up to 225 mg/day
46026054|NCT01020747|Drug|Avastin® (bevacizumab)|Bevacizumab injections (~7.5-12.5mg in 0.3 - 0.5 c.c.) into diseased vocal folds in conjunction with 532 nm pulsed-KTP laser photoangiolysis, administered every 6 ±1 weeks, for a total of 5 treatments. No patient will have an injection volume exceed 0.5 cc. for any single treatment. If initial results indicate a benefit, as described below, an extension of the active treatment period will be permitted up to a total treatment duration of 18 months.
45470236|NCT04578457|Device|Hearing Aid with NR(2)|Each participant will be fitted with a second noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1).
46026055|NCT01020747|Drug|Saline|A sham injection with saline (0.3-0.5 cc) has been administered to the other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the initial treatment always getting the drug injection.
46026056|NCT02760511|Dietary Supplement|Anthocyanin|Capsules with different anthocyanin content
46026057|NCT02760511|Dietary Supplement|Placebo|Placebo capsules
46113685|NCT00725205|Biological|PegIntron (Peginterferon alfa-2b)|Peginterferon alfa-2b (injection pen) administered according to the product's labeling and current practice in Hungary (1.5 micrograms [mcg]/killogram [kg]) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
46113686|NCT00725205|Drug|Rebetol (Ribavirin)|Ribavirin capsules administered according to the product's labeling and current practice in Hungary (weight based daily) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
46113687|NCT01323361|Procedure|Laparoscopic ventral hernia repair|Patients operated with laparoscopic repair of ventral or incisional hernia
46113688|NCT00443755|Drug|metformin|To minimize side effects the metformin will be initiated at 500 mg twice daily with meals and increased to 1 gm twice daily with meals after two weeks and continue to a total of 3 months of dosing.
46113689|NCT00443755|Drug|pioglitazone|To minimize side effects, the pioglitazone will be initiated at 30 mg daily and increased to 45 mg daily after two weeks, and continue to a total of 3 months of dosing.
45470237|NCT04578457|Device|Hearing Aid with NR(3)|Each participant will be fitted with a third noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1) and NR(2).
45470238|NCT04673331|Other|exercise capacity|3minute step test and 1minute sit to stand test used assessment of exercise capacity.
45470239|NCT03334188|Behavioral|Patient engagement materials|The intervention is a brief, animated video designed to engage and activate patients around their HFrEF medication prescribing, as well as a HFrEF medication checklist.
45470240|NCT03334188|Behavioral|No Intervention--Usual Care|Control for intervention--patient receives care as usual from provider to contrast against intervention arm.
45470241|NCT04374669|Procedure|Neuroplasty with Racz catheter|The patient is placed in the prone position with a pillow placed under the abdomen to correct the lumbar lordosis. After sterile preparation and draping, the epidural space via the sacral hiatus using a 16 gauge needle is accessed. Then, the Racz catheter is advanced to the site of adhesions under the fluoroscopic guidance. The target site is determined by the location of pathology on lumbar MRI, preprocedural epidurography, and clinical symptoms before the adhesiolysis. Adhesiolysis is performed through the high-volume administration of medications, which consist of a combination of a steroid, local anesthetics, hyaluronidase, and 5% hypertonic saline. As needed, the catheter remains in the epidural space for two days, with the additional injection on each of the days.
45470242|NCT05460403|Radiation|Adjuvant Radiotherapy|Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.
46113690|NCT00443755|Drug|Placebo|Placebo tablets matching the metformin and pioglitazone tablets are given in the same regimen as the active drug arm for 3 months.
46113691|NCT04107740|Drug|C-Trelin OD Tab(5mg Taltirelin Hydrate)|BID, 10mg per day, for 24 weeks
46113692|NCT04107740|Drug|Placebo|BID for 24 weeks
45470243|NCT01325805|Behavioral|Structured Weight Loss Program|Those patients randomized to the structured weight loss group will have a formal evaluation and counseling a medical endocrinologist specializing in weight management. The structured weight loss program will consist of meeting with a dietician who will guide them on following a hypocaloric diet with a calorie deficit of 750kcal/day. The weight loss goal will be to lose 1-1.5 pounds/week. The participants will receive teaching utilizing the American Diabetes Association Exchange Lists and will receive sample meal plans. In addition, participants will be seen by the dietitian once a week for a month, then every 2 weeks for 2 months, then once per month for 3 months. Patients randomized to the study group will continue in the structured weight loss program for 6 months.
45681853|NCT03153514|Biological|Obinutuzumab|"Obinutuzumab i.v.~[Day 0 = day of stem cell transplant]~Cycle 1: 100 mg (d -8), 900 mg (d -7), 1000 mg (d -1, +7, +14)~Cycle 2: 1000 mg (d +1, +8, +15, +22)"
45681854|NCT03583060|Behavioral|Mindful Awareness in body-oriented therapy|teaches interoceptive awareness skills for self care
46113693|NCT00724971|Drug|Inotuzumab Ozogamicin (CMC-544)|1.8 mg/m2, IV on day 2 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
46113694|NCT00724971|Drug|Rituximab (Rituxan)|375 mg/m2, IV on day 1 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
46113695|NCT00443599|Drug|Insulin|Study drug is continuously infused intravenous insulin. Suggested dose is calculated by a computerized infusion algorithm using the participant's blood sugar concentration. The insulin infusion rate is titrated to maintain normal blood sugar. Participants are eligible to receive insulin while they have an in-dwelling arterial catheter.
46113696|NCT00443599|Other|Usual Care|Participants receive standard Cardiac ICU care without tight blood glucose control.
46026058|NCT04628013|Device|Noxious Electrical Stimulation (NxES)|The NxES intervention will be applied with a pair of 2x3 inch electrodes placed orthogonally to the knee joint line with one electrode on the medial and lateral sides of the knee. The device is a commercially available unit(Chattanooga Continuum, DJO Global, Vista CA) and the parameters of the NxES include: 400 μs biphasic square wave pulses delivered at 50-100 pulses/second, using a cycle time of 10-seconds on, with a 2-second ramp-up in intensity, followed by a 10-second off period. The current intensity will be dosed over the first 2-minutes of stimulation to find the sensory perception threshold and the threshold for the first perception of a sharp, prickly buzzing sensation that they would identify as painful. Next, the current intensity will gradually be increased until the participant reports a sharp or prickly buzzing sensation that achieves a pain rating of not more than a 5/10 using a numeric pain rating scale.
46026059|NCT05428579|Procedure|Retroperitoneal Liposarcoma resection|Retroperitoneal Liposarcoma resection
45470244|NCT01325805|Behavioral|Routine Weight Loss Counseling|Participants randomized to the routine weight loss counseling group will receive the ACOG Patient Education pamphlets on obesity.
45470245|NCT03752671|Device|Insertion of INTRASPINE device|"The surgical technique for excision of the disc hernia is the surgeon's usual technique: patient positioning (lying on his/her back or front or in the knee to chest position) the approach to the lumbar disc hernia (interlaminar or interspinous), closure and drainage of the operation site are performed by the surgeon's usual practice.~IntraSPINE® is positioned once surgery for the disc hernia has been performed. The implant bed is prepared with the assistance of the distractor provided. The choice of implant size is made after positioning the trial device corresponding to the anatomical bed. Once the size has been established the corresponding implant is placed in a cup of physiological saline prior to implantation. Implantation is performed using the appropriate implant holder."
45470246|NCT03752671|Procedure|Discectomy|The surgical technique for excision of the disc hernia is the surgeon's usual technique: patient positioning (lying prone or supine or in the knee to chest position). The approach to the lumbar disc hernia (interlaminar or interspinous), closure and drainage of the operation site are performed using the surgeon's normal practice.
46113697|NCT02604056|Behavioral|Audit + Feedback|Online Audit + Feedback practice reports detailing prescribing performance for this class of medication for each prescriber in the nursing home. (Details: http://www.hqontario.ca/Quality-Improvement/Practice-Reports/Primary-Care)
46113698|NCT02604056|Behavioral|Audit + Feedback + Educational Outreach|"The Educational Outreach program will be delivered by academic detailers, health professionals (often nurses or pharmacists) who have received specific intensive training to support prescribing providers in a particular environment, in this case long-term care homes, to make the best or appropriate clinical decisions as possible. It is defined as: an innovative method of service-oriented educational outreach for front-line clinicians. It combines the interactive, one-on-one communication approach of industry detailers with the evidence-based, non-commercial information of academia. The Educational Outreach will be delivered in addition to online Audit + Feedback practice reports, which detail prescribing performance for this class of medication for each prescriber in the nursing home."
45470247|NCT03333876|Device|Nasal Dilator|Mute is a pair of nasal dilators that fit snugly in the nose of the snorer dilating the nostrils to help reduce or eliminate snoring. This is an over-the-counter (OTC) product and is cleared by FDA for use in the United States. The introduction video for Mute is located at http://mutesnoring.com/how-to-use/.
45470248|NCT03333876|Device|Mandibular Advancement|"For purposes of this trial, we will be using an investigational myTAP V, which is not available for commercial use. The changes from the released product are: a vertical offset (+3mm) has been added to the design of the adjustment post and mechanism to improve overall comfort.~myTAPTM is a mandibular advancement device used for snoring relief. The product requires a prescription and is cleared by FDA for use in the United States."
45470249|NCT03333876|Device|Positional Therapy|Sleep Positional Trainer (SPT) is a small device worn around the chest with an ergonomic band that continuously monitors the sleep position of the snorer. When the snorer is supine, it emits a gentle vibration to remind them to turn to the side to help reduce or eliminate their snoring.
45470250|NCT03755557|Drug|Rhinocort|Application of a nasal spray
45470251|NCT03755557|Drug|Budesolv|Application of a nasal spray
45470252|NCT03755557|Other|Placebo|Application of a nasal spray
46026060|NCT02754739|Drug|Pravastatin|Pravastatin 40mg once daily for 24 weeks and nutritional education by a nutritionist
46026061|NCT02754739|Drug|Placebo (for Pravastatin)|Pill manufactured to mimic pravastatin 40mg tablet once daily for 24 weeks and nutritional education by a nutritionist
46026062|NCT02754739|Behavioral|Nutritional education only|Only nutritional education by a nutritionist
46113699|NCT04113512|Other|Jalaneti|Sterilised and lukewarm isotonic salt water using neti pot was poured into one nostril, so that it leaves through the other. The procedure is then repeated on the other side, and the nose is dried by bending forward and by rapid yoga breathing
45470253|NCT03511599|Drug|Cycloserine|Cycloserine 100mg
45470254|NCT03511599|Device|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
45470255|NCT03511599|Drug|Placebo Oral Tablet|Placebo tablet matched to cycloserine tab
45470256|NCT03294681|Device|Objective measures with CSEP|Objective measures to be conducted with Custom SoundTM EP 5 software and the CP900 series sound processor in CI532 and CI512 Cochlear Implant recipients
46026063|NCT04300101|Other|molecular characterization|"immunohistochemical determinations: Cell of Origin (COO) (according with Hans algorithm), evaluation of Cluster of Differentiation (CD) (CD20, CD5, CD10), Bcl6, Bcl2 (cut off>50%), MUM1/IRF4, c-myc (cut off>40%) and Ki67, FISH for c-myc and if rearranged for Bcl2 e Bcl6.~mRNA expression by Nanostring Single cell analysis Immune checkpoint expression Proteomic analysis Metabolic analysis"
46026064|NCT02754583|Behavioral|Water, sanitation, and hygiene (WASH) intervention|WASH arm: Communities will receive the water, sanitation, and hygiene (WASH) intervention including water point construction and maintenance, hygiene and sanitation education and promotion, community-based hygiene promotion workers, household wash stations, household WASH education books, household soap distribution, and a hygiene curriculum for primary schools.
46113700|NCT02592369|Device|Medtronic CoreValve™ Evolut R™ System|The Evolut R System is intended for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, to be at high or extreme risk for open heart surgery. The Evolut R TAV treats aortic stenosis by displacing and functionally replacing the dysfunctional native valve with a bioprosthetic valve delivered on a catheter while the heart is still beating, thus avoiding the risks of cardiopulmonary bypass. Its intended performance is to relieve aortic valve stenosis without inducing significant regurgitation, thereby restoring effective aortic valve function.
46113701|NCT04107428|Drug|Somatostatin|A bolus of 5cc of saline containing 500 mcg of somatostatin will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 250 mcg per hour of somatostatin (infusion rate 2.5 cc/hour) for 10 days.
46113702|NCT04107428|Drug|Placebo|A bolus of 5cc of saline will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 2.5 cc of saline/hour for 10 days.
46113703|NCT02603978|Behavioral|BASICS|A 2-hour group intervention focused on reducing alcohol use with the use of motivational interviewing
46113704|NCT02603978|Behavioral|Bystander and Social Norms|A 2-hour group intervention focused on increasing healthy sexual behaviors and prosocial bystander behavior
46113705|NCT02603978|Behavioral|Combined BASICS and Bystander|A 2-session, 4-hour group that consists of both BASICS and the Bystander intervention
46113706|NCT00455143|Drug|Precedex (Dexmedetomidine)|Dexmedetomidine started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.
46113707|NCT00455143|Drug|Placebo|Matching placebo given prior to surgery and continued for 24 hours postoperatively
46113708|NCT00454987|Biological|Menitorix|Menitorix was only administered to subjects of the group Meningitic+Hiberix group at 40 to 43 months of age.
46113709|NCT00454987|Biological|Infanrix IPV|Infanrix IPV was administered according to the manufacturer's instructions to UK subjects at 40 to 43 months of age.
46113710|NCT00724893|Biological|PegIFN-2b|PegIFN-2b powder for solution adminstered subcutaneously using the newly approved Redipen. Dosing per approved labeling
46113711|NCT00724893|Drug|Ribavirin|Ribavirin capsules administered orally. Dosing in accordance with approved labelling.
46113712|NCT00789698|Drug|Lurasidone HC1|Lurasidone 40-160 mg/day flexibly dosed.
46113713|NCT00789698|Drug|Quetiapine XR|Quetiapine XR 200-800 mg/day flexibly dosed.
46113714|NCT00724815|Drug|NP101 - Sumatriptan iontophoretic transdermal patch|Sumatriptan iontophoretic transdermal patch
46113715|NCT00724815|Drug|Placebo|NP101 Placebo iontophoretic transdermal patch
46113716|NCT00454909|Biological|Meningococcal vaccine 134612|Single dose intramuscular injection.
45470257|NCT04989426|Other|the state of health of newly arrived migrant patients in the year following their arrival in France|the state of health of newly arrived migrant patients in the year following their arrival in France
46113717|NCT00454909|Biological|Menactra®|Single dose intramuscular injection.
46113718|NCT00798590|Drug|Glucagon-Like Peptide-1|5ng/kg-1/min-1 GLP-1 infused in 3 ml continuously over 72 hours.
46113719|NCT00798590|Drug|Saline|5ng/kg-1/min-1 placebo infused in 3 ml continuously over 72 hours.
46113720|NCT05368155|Behavioral|Brief ACT for Pelvic Pain|The Brief ACT for Pelvic Pain treatment will include three weekly, 90-minute group sessions that teach Veterans new ways to respond to difficult thoughts and emotions related to pain (Acceptance and Mindfulness Training) and encourage behavioral (re)engagement in meaningful life activities (Behavioral Change Training). The overall goal is to cultivate psychological flexibility by helping Veterans learn to respond to life events in ways which do not exacerbate difficulties or restrict engagement in meaningful activities. Workshop content is integrated with education on pelvic pain (its diagnostic criteria, etiology, and associated health outcomes) to increase alignment of the treatment with patient needs.
46026065|NCT02754583|Behavioral|Standard of care WASH intervention|Stand of care WASH arm
46026066|NCT02754583|Drug|Azithromycin|20mg/kg
46026067|NCT02754583|Drug|Tetracycline|Tetracycline will be administered in lieu of azithromycin if individual is under 6 months, has a known azithromycin allergy, or is severely ill.
46113721|NCT05366673|Other|massage|Perform a 10-minute back massage every day for a week
46113722|NCT01020175|Procedure|Bone marrow transplantation|Patients received bone marrow transplantation
46113723|NCT01020175|Procedure|Peripheral blood stem cell transplantation|Patients received filgrastim-mobilized peripheral blood stem cell transplantation
46026068|NCT02754583|Other|Control|The control group will receive no intervention during the trial. They will be enrolled in mass antibiotic treatment at the conclusion of the trial.
46113724|NCT01024933|Behavioral|Positive Affect/Self-Affirmation/Motivational Interviewing|The PASA group-intervention will receive small gifts one week prior to their scheduled follow up. The PASA intervention involves reminding participants to think about their proud and positive moments. The motivational interviewing intervention includes assessing the patient's motivation and confidence; elicit barriers and concerns; summarize in a non-threatening manner the 'pros' and 'cons' of patient's concerns, thereby eliciting positive self-motivational statements about the behavior. Follow up will be every two months.
46113725|NCT01024933|Behavioral|Educational and Behavioral|The Education and Behavioral Contract (Control group)will receive an educational workbook and behavioral contract. In addition, each patient will receive a home blood pressure device for self-monitoring, and will be called every two months.
46113726|NCT00481195|Drug|Armodafinil|Patients were randomly assigned to begin oral treatment with armodafinil, which was titrated to 150 mg/day (3 tablets). Armodafinil was titrated up to the target dosage of 150 mg/day (daily dose was administered each morning). Patients began taking blinded armodafinil at a dose of 50 mg/day (1 tablet) on the day following the baseline visit. Doses were increased by 50 mg/day (1 tablet) to a dose of 100 mg/day on Day 2 and 3, and then again by 50 mg /day on day 4 for a target dose of 150 mg/day. Following titration, patients continued taking 150 mg/day of armodafinil for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 100 mg/day [2 tablets]) was allowed. The dosage could not be increased after it was decreased.
46026069|NCT01020435|Other|Spinal Manipulation|The procedure in its broadest definition describes the application of a load (force or displacement) to specific body tissues (usually vertebral joints) with therapeutic intent. The mechanical characteristics of SM can vary in terms of its duration and amplitude, (hence, the rate at which it is applied), as well as its anatomical location, choice of levers, direction of force application, and the vehicle used to apply the force (manually or mechanically assisted).
45470258|NCT04822818|Drug|BEVA+SOC|Bevacizumab : 7.5 mg / kg (with a maximum of 750 mg) on day 1 (D1) SOC : patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
46026070|NCT01020435|Other|Sham Spinal Manipulation|The sham assessment procedures will be the same as those in the high velocity treatment group. The sham intervention is identical to this treatment protocol except for the placement of the treating clinicians pisiform contact. The force and vector applied will be the same.
46026071|NCT02754349|Device|SphygmoCor version 7, AtCor Medical, Sydney, Australia|Pulse wave velocity, augmentation index and central blood pressure measurement with applanation tonometry before and after electrical cardioversion
46026072|NCT02873949|Biological|Crevicular samples (1-10µl)|"In periodontitis patients: from 2 sites affected by periodontitis and 1 healthy site, 2 samples/site, before and after treatment~In non-periodontitis individuals: 2 samples from 1 site"
45838808|NCT04359342|Dietary Supplement|HIIT + protein|"8-week supervised exercise program consisting of high-intensity interval training (HIIT).~HIIT: 10x1 min at 85-95% HRmax divided by low intensity recovery periods. Three exercise sessions per week. Participants receive 40 g of a commercially available protein supplement administered as a shake after every exercise session."
46026073|NCT02873949|Biological|Saliva samples (1ml)|
46026074|NCT02873949|Other|Etiologic treatment|education on oral hygiene, scaling and root planing
46026075|NCT02873949|Other|Psychometric tests|Spielberger State-Trait Anxiety Inventory and Cohen Perceived Stress Scale
46026076|NCT02754271|Other|Fit for Dialysis|A 15-minute research-based film that explores the barriers and facilitators regarding exercise participation by older hemodialysis patients and support by nephrology staff and family caregivers, and a 16-week exercise program involving activities during dialysis, at home, and in the community.
46026077|NCT01031979|Drug|Yohimbine|alpha-2 adrenergic receptor antagonist
46026078|NCT01031979|Drug|Placebo|Placebo
45470259|NCT04822818|Drug|SOC|patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
45470260|NCT01140867|Drug|zonisamide|zonisamide 100 mg tablet
46026079|NCT04502173|Device|Ellavi UBT|The study team will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers, clinical officers) involved in PPH management at the participating healthcare facilities on use of the Ellavi UBT. This will be done to gather feedback from the healthcare workers (post-training and post-PPH) to understand the barriers to and facilitators of use in order to evaluate acceptability and feasibility among facilities providing different levels of care (level 4, level 5 (county), level 6 (tertiary)).
46026080|NCT04624633|Drug|Acalabrutinib|Oral, twice a day, predetermined dosage
45598591|NCT02227745|Drug|Dorzolamide hydrochloride (2%)|"Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed"
45598592|NCT02227745|Drug|Placebo Sodium hyaluronate 4mg|"Intervention: Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed."
46026081|NCT04624633|Drug|Umbralisib|Oral, once a day, predetermined dosage, each 28 day cycle up to 24 cycles
45470261|NCT04572997|Drug|Apremilast|Apremilast was taken orally twice daily (except Day 1). Patients received tablets in blister/bottles sufficient for one month. To mitigate potential gastrointestinal side effects (primarily mild-to-moderate nausea and diarrhoea), dose titration was implemented in this study in accordance with the Summary of Product Characteristics (SmPC). A titration pack included tablets of 10, 20 and 30 mg for a period of one month. During the first 5 days, the dosage was up-titrated. The initial dose on day 1 was 10 mg in the morning; this was increased to 10 mg in the morning and evening on day 2. The evening dose was further increased by 10 mg (to 20 mg) on day 3. On day 4, the morning dose was increased to 20 mg, so that 20 mg was taken twice daily, and on day 5 the evening dose was increased to 30 mg. From Day 6 onwards, patients received the 30 mg dose twice a day. Subsequent packs included only tablets of 30 mg strength.
46026082|NCT04624633|Drug|Ublituximab|28 day cycle, starting cycle 7 via iv, on at predetermined dosage and timepoints in each cycle
46026083|NCT04614025|Biological|PLX-PAD|PLX-PAD - allogeneic ex-vivo expanded placental mesenchymal-like adherent stromal cells
46026084|NCT02754193|Other|moderate hypothermia|moderate hypothermia will be induced using the heat controller of the VA-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 24 hours ± 1h followed by a progressive reheating (0.2±0.1°C/h) to reach 37 °C. Temperature at 37°C ± 0.3°C will be maintained during 48 hours ± 4h after having reached 37 °C.
46026085|NCT02753803|Drug|Evogliptin, Pioglitazone, Evogliptin+Pioglitazone|Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
46026086|NCT02753803|Drug|Pioglitazone, Evogliptin, Evogliptin+Pioglitazone|Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
46026087|NCT02753803|Drug|Evogliptin, Evogliptin+Pioglitazone, Pioglitazone|Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD
46026088|NCT02753803|Drug|Pioglitazone, Evogliptin+Pioglitazone, Evogliptin|Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
46026089|NCT02753803|Drug|Evogliptin+Pioglitazone, Evogliptin, Pioglitazone|Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD
46026090|NCT02753803|Drug|Evogliptin+Pioglitazone, Pioglitazone, Evogliptin|Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
46026091|NCT04219579|Drug|Antithrombin III, continuous infusion|Antithrombin-III is administered continuously
46026092|NCT04219579|Drug|Antithrombin III, Intermittent infusion|Antithrombin-III is administered intermittently
46026093|NCT04613947|Behavioral|Informed consent|The style of informing patients about the procedure they will undergo
46026094|NCT04613947|Procedure|Third molar surgery|Surgical extraction of the third molar tooth
46026095|NCT00635401|Drug|Varenicline|0.5 mg BID for 7 weeks
46026096|NCT04199065|Other|Good Practice Guidelines implementation|Implementation of Good Practice Guidelines on the framework of the Best Practice Spotlight Organization in Spain (CCEC® / BPSO®), that allows a standardized methodology for providing care and registering indicators.
46026097|NCT05424055|Behavioral|Multicomponent exercise|The intervention will consist of a multicomponent exercise training programme, which will include supervised progressive resistance exercise training, balance-training and walking for 3 consecutive days. During the training period, patients will be trained in 20-minute sessions twice a day (morning and evening). The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM (Matrix, Johnson Health Tech, Ibérica, S.L., Madrid, Spain) combined with balance and gait retraining exercises that will progress in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.
46026098|NCT02753959|Other|Acute Intervention|"Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:~Electrical impedance tomography (EIT)~EMGpara~SpO2~tcCO2~Respiratory inductance plethysmography~EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention~Interventions will be set as follows with a 30 minute washout period between modes:~Manual techniques only~MIE at low pressure (+30 to -30)~MIE at high pressure (+60 to -60)"
46113727|NCT00481195|Drug|Placebo|Patients were randomly assigned to begin oral treatment with placebo, which was titrated to 3 tablets. Placebo tablets matching the 50 mg armodafinil tablet were used in a manner identical to that of the armodafinil tablets. Study drug was titrated up to the target dosage of 3 tablets / day (daily dose was administered each morning). Patients began taking blinded study drug at a dose of 1 tablet daily on the day following the baseline visit. Doses were increased by 1 tablet to a dose of 2 tablets/day on Day 2 and 3, and then again by 1 tablet /day on day 4 for a target dose of 3 tablets/day. Following titration, patients continued taking 3 tablets/day of study drug for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 2 tablets/day) was allowed. The dosage could not be increased after it was decreased.
46113728|NCT03604549|Drug|Lipiodol UF|Up to 10cc of Lipiodol Ultra Fluid will be infused via intrauterine catheter
46113729|NCT03604549|Drug|Saline|Up to 10cc of saline will be infused via intrauterine catheter
46113730|NCT01027429|Drug|procaine penicillin and gentamicin|procaine penicillin 50,000 units/kg by intramuscular injection once daily for 7 days; gentamicin, 5 mg/kg once daily by intramuscular injection for 7 days
46113731|NCT01027429|Drug|amoxicillin and gentamicin|oral amoxicillin 80-90 mg/kg divided in two doses for 7 days intramuscular gentamicin, 5 mg/kg once daily for 7 days
46113732|NCT01027429|Drug|procaine penicillin, gentamicin, amoxicillin|procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
46113733|NCT00454363|Other|Laboratory Biomarker Analysis|Correlative studies
46113734|NCT00454363|Drug|Pazopanib Hydrochloride|Given PO
46026099|NCT02753959|Other|Stable Intervention|"Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:~Electrical impedance tomography (EIT)~EMGpara~SpO2~tcCO2~Respiratory inductance plethysmography~EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention~Interventions will be set as follows with a 30 minute washout period between modes:~Manual techniques only~MIE at low pressure (+30 to -30)~MIE at high pressure (+60 to -60)"
46026100|NCT02753725|Drug|Fentanyl|The intervention arm will comprise Fentanyl given at a dose of one microgram per kilogramme body weight administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed.
46026101|NCT02753725|Drug|Normal saline|the placebo arm will be given normal saline at a volume equivalent to Fentanyl dose per body weight,administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed
46026102|NCT01020123|Drug|AZD1656|Different doses of AZD1656 administered to 5 groups of patients
46026103|NCT01020123|Drug|Placebo|AZD1656 placebo and glipizide placebo administered to 1 group of patients
46026104|NCT01020123|Drug|Glipizide|Glipizide administered to 1 group of patients
46026105|NCT04603027|Drug|EDP1815|EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
46026106|NCT04603027|Drug|Placebo|Placebo oral capsule
45838809|NCT04359342|Dietary Supplement|HIIT + placebo|"8-week supervised exercise program consisting of high-intensity interval training (HIIT).~HIIT: 10x1 min at 85-95% HRmax divided by low intensity recovery periods. Three exercise sessions per week. Participants receive 40 g of a commercially available iso-caloric placebo (Maltodextrin) administered as a shake after every exercise session."
46026107|NCT04300959|Drug|Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin|"Gemcitabine:1000mg/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8； Anlotinib : 10mg po qd, days 1-14; Sintilimab: 200mg IV, day 1；~1 cycle = 3 weeks."
46026108|NCT04300959|Drug|Gemcitabine Plus(+)Cisplatin|"Gemcitabine:1g/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8；~1 cycle = 3 weeks."
46026109|NCT04299711|Other|Exposed to the novel coronavirus disease 2019|Exposed to the novel coronavirus disease 2019
46026110|NCT02753569|Other|Imaging - DW-MRI|
46026111|NCT02753569|Radiation|FDG PET-CT|
46026112|NCT02760355|Drug|Ledipasvir 90 mg/Sofosbuvir 400 mg|Oral administration on one fixed dose combination tablet for 12 weeks
46026113|NCT02760355|Drug|Ribavirin|Oral administration of body weight-dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients <75 Kg of body weight, or 1,200 mg in two administrations for those >75 Kg) for 12 weeks.
46026114|NCT01028391|Drug|Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.|Patients will receive combination therapy with blinded sitagliptin 100 mg q.d. (q.d. = once daily) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. Sitagliptin 100 mg q.d. and pioglitazone 45 mg q.d. will be administered as oral tablets.
46026115|NCT01028391|Drug|Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. The placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. will be administered as oral tablets.
46026116|NCT01028391|Drug|Metformin|Patients not meeting specific glycemic goals during the 30-week extension study will receive open-label metformin at a dose determined by the investigator.
46026117|NCT02753491|Behavioral|Motivational short interview|New designed motivational short interview model
46026118|NCT01179672|Drug|Duloxetine|30 mg administered orally (po), QD for 1 week; 60 mg administered po, QD for remaining 11 weeks; 30 mg administered po, QD for 1 week during taper period
46026119|NCT01179672|Drug|Placebo|Administered po, QD for 12 weeks; administered po, QD for 1 week during taper period
46026120|NCT02872545|Procedure|Rest tomoscintigraphy in forward tilted|Rest tomoscintigraphy in forward tilted position
46026121|NCT02872545|Procedure|Rest tomoscintigraphy in semi sitting position|Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
46026122|NCT02872545|Procedure|Rest tomoscintigraphy in dorsal decubitus position|Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
46026123|NCT04321915|Other|Analysis of intestinal microbiota in autism spectrum desorder|This analysis permit to describe the diversity and composition of microbiota and the factors that may influence them. In fact, the gut microbiota plays a key role in regulating the gut-brain axis
46026124|NCT04321915|Other|Analysis of neuroinflammation markers in autism spectrum desorder|This analysis permit to reveal the integrity of the blood-brain barrier (BBB) which is affected in autism spectrum desorder.
46026125|NCT04301349|Drug|vaginal dinoprostone|two tablets of vaginal dinoprostone (6 mg) 3 hours prior to IUD insertion
46026126|NCT04301349|Drug|vaginal misoprostol|two tablets of vaginal misoprostol (400 mcg) 3 hours prior to IUD insertion
46026127|NCT04301349|Drug|placebo|two tablets of placebo given 3 hours prior to IUD insertion
46026128|NCT02753647|Drug|Rituximab|
46026129|NCT02753647|Drug|Cyclophosphamide|
46026130|NCT02753647|Drug|Doxorubicin|
46026131|NCT02753647|Drug|Vincristine|
46026132|NCT02753647|Drug|Prednisone|
46026133|NCT02753647|Drug|Chidamide|
46026134|NCT02872389|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
46026135|NCT02872389|Drug|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
46026136|NCT02760199|Drug|89Zr-AMG211|Injection of 89Zr-AMG211 for imaging.
46026137|NCT02760199|Device|89-ZrAMG211 PET|89Zr-AMG211 PET scan(s).
46026138|NCT02695927|Device|Computer rehabilitation glasses|
46113735|NCT00454363|Other|Pharmacological Study|Correlative studies
46113736|NCT01020253|Drug|alendronate, alfacalcidol|Alendronate: 5mg per day, Tablet, Duration is 48 weeks. Alfacalcidol: 1μg per day, Tablet, Duration is 48 weeks.
46113737|NCT00454207|Drug|sildenafil citrate (UK-92,480)|sildenafil citrate (UK-92,480)
46026139|NCT04307251|Device|Navio™ Robotics-assisted Surgical System, LEGION Total Knee System|Robotic TKA uses computer software to convert anatomical information into a virtual patient-specific 3D reconstruction of the knee joint.The surgeon uses this virtual model to plan optimal bone resection, implant positioning, bone coverage, and limb alignment based on the patient's unique anatomy.
46113738|NCT01020331|Drug|Memantine|
46113739|NCT01030939|Drug|SB-649868|In each of all cohorts, 18 subjects will be randomised in a 2:1 ratio to receive either SB-649868 or placebo
46113740|NCT00738894|Device|Septal Occluder Device|PFO closure with study septal occluder device
46113741|NCT00738894|Drug|Antiplatelet Medical Therapy|Investigator's choice of one of three regimen options specified in protocol
46113742|NCT00480493|Behavioral|STEP|Experimental: Minutes of parent mentor-parent participant interactions Control: Minutes of parent contact-parent participant interactions
46113743|NCT01027663|Dietary Supplement|Iron Supplement|Iron supplementation (325 mg of ferrous sulfate) once daily for the 2 month duration of the study.
46113744|NCT01020409|Procedure|cardiac surgery with CPB use|cardiac surgery with CPB use or ascending aorta surgery performed with use of cardiopulmonary bypass with or without aortic cross clamping.
46113745|NCT00734994|Device|Hyperthermia System|Hyperthermia applied to heat the bladder to a temperature of 42 degrees Celsius for 40-60 minutes concurrent with mitomycin Treatment Schedule: 6 Weekly Sessions (Induction) followed by 4 Monthly Sessions (Maintenance) until documented second recurrence
46113746|NCT00734994|Drug|Mitomycin C|40 mg in 40 ml sterile water instilled into bladder
46113747|NCT02593734|Drug|olanzapine|oral antipsychotic drug therapy
46113748|NCT02593734|Drug|risperidone|oral antipsychotic drug therapy
46113749|NCT02593734|Drug|amitryptaline|oral antidepressant drug therapy
46113750|NCT02593734|Drug|fluoxetine|oral drug therapy for depression
46026140|NCT04307251|Device|Conventional, LEGION Total Knee System|Total Knee Arthroplasty (TKA) is a widespread orthopaedic procedure for restoring functionality and minimizing pain due to end stage osteoarthritis. Conventional TKA, well-accepted as the standard of care, is performed with manual instrumentation guided by intramedullary or extramedullary alignment rods, as well as rotational guides that are not patient-specific.
45470262|NCT02943096|Dietary Supplement|CocoaVia|Flavanols represent a specific group of plant derived nutrients that are found in cocoa beans, grapes, tea, berries and various other fruits and vegetables. The specific flavanols investigated in this study come from cocoa.
46026141|NCT01030965|Drug|GSK573719 125mcg|125mcg once-daily
46026142|NCT01030965|Drug|GSK573719 250mcg|250mcg once-daily
46026143|NCT01030965|Drug|GSK573719 500mcg|500mcg once-daily
46026144|NCT01030965|Drug|Placebo|once-daily
46026145|NCT02753179|Other|Head Impulse Tests|Head Impulse Tests are performed by the clinician who holds the patient's head in his hands, while he is looking straight at an earth-fixed target; then by turning the patient's head abruptly and unpredictably to the left or right, up or down through a small angle (only 10-20 degrees - not a large angle). 20 impulses in each directions (6) will be performed.
46113751|NCT04088526|Combination Product|intervention group|Through effective intervention combined with drugs and dietary guidance within 3 to 6 months, all the observation markers including blood pressure and laboratory results will reach the target target value.
46113752|NCT00798434|Drug|Placebo|placebo administered orally in the morning or evening.
46113753|NCT00798434|Drug|Fesoterodine fumarate|Fesoterodine fumarate is an antimuscarinic drug recently approved by the European Medicines Evaluation Agency for treatment of symptoms of overactive bladder syndrome.
46113754|NCT04106804|Drug|Abatacept 125 MG/ML|Patients will receive weekly abatacept (Orencia®) s.c. Abatacept in the dose regimen given in the label for RA and PsA for six months
46113755|NCT00724503|Device|SIR-Spheres yttrium-90 microspheres|"SIR-Spheres microspheres (yttrium-90 [Y-90] labelled resin microspheres), hepatic artery injection administered on Day 3 or 4 of cycle 1.~mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2."
46113756|NCT00724503|Drug|Systemic chemotherapy (FOLFOX)|"mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2."
46113757|NCT00791648|Drug|atorvastatin|"Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.~Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1."
46113758|NCT00791648|Drug|placebo|"Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.~Aim 2 control: placebo the day of cardiac surgery and postop day 1."
46113759|NCT05366595|Drug|oral zinc sulfate|Oral zinc sulfate at dose 10 to 20 mg daily for 10 days
46113760|NCT02592213|Procedure|Cell-assisted lipotransfer|Stromal vascular fraction, autologous. Isolated using Celution System (Cytori)
46113761|NCT04006886|Dietary Supplement|Gluten-free diet|After run-in phase with normal diet under Observation, patients will be on a gluten-free diet for two months.
46113762|NCT03956511|Other|Spontaneous Breathing Trial|It involves placing an infant from invasive mechanical pressure limited time cycled ventilation ventilation to endotracheal continuous positive end-expiratory pressure (ET-CPAP) for a period of 5 minutes during which saturation and heart rate are closely monitored. The infant would pass the test if there is no hypoxia or bradycardia during the test. If the infant has either bradycardia for more than 15 seconds and/or a fall in SpO2 below 85% despite a 15% increase in FIO2, the study will be stopped and ventilation will be restarted.
46113763|NCT04087239|Other|HIV|
46113764|NCT04113356|Diagnostic Test|Cardiovascular Magnetic Resonance Imaging|Cardiovascular magnetic resonance imaging will be performed within the first week after ST-elevation myocardial infarction and in a defined subgroup 4 months, 12 months and 10 years thereafter.
46113765|NCT04017260|Procedure|open and closed approach|"The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.~Group A:The wound was closed with 0 polypropylene u-shaped sutures ."
46113766|NCT04017260|Procedure|Rhomboid flap technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.Rhomboid flap technique: involve closure of the defect after excision of all sinuses with Rhomboid flap of skin and subcutaneous tissue
46113767|NCT04017260|Procedure|Karydakis technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.the long axis of the ellipse is parallel to the midline and 2cm from it.undercutting incision is made along the whole length 1cm below the skin surface then unrolling the flap over the midline.
46026146|NCT02753179|Other|Dynamic visual acuity Test (DVAT)|Dynamic visual acuity Test (DVAT) assesses visual acuity during head movement relative to baseline static visual acuity. DVA will be assessed actively during self-generated rotations of the head in different directions.
46026147|NCT02753179|Other|VEMPs & VEMPo|VEMPs & VEMPo are sound evoked muscular contractions of the neck or eye. They are recorded using an evoked response computer, a sound generator, and surface electrodes to pick up neck or eye muscle activation.
46113768|NCT04017260|Procedure|open technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.Open procedure involved a wide excision of the pilonidal sinus tract and healing by secondary intention.
46113769|NCT02592135|Other|hsTnT level|hsTnT and NTproBNP levels at baseline and baseline plus 3 hours.
45470263|NCT02943096|Other|Placebo|"The placebo looks like the other intervention pills, but does not contain any flavanols (it is sometimes called a sugar pill)."
45681855|NCT03020524|Biological|Autologous CD4 T-Cells|all participants will receive a single infusion of C34-CXCR4-modified CD4+ T-cells at one of 3 dose levels. The first 3 subjects will receive dose level 1 of 0.8-1x109 transduced CD4+T-cells. Provided no dose limiting toxicity (DLT) is seen at the first dose level, the next 3 subjects will receive infusion at the 2nd dose level of 2.4-3x109 transduced CD4+ T-cells. If no DLT occurs at that dose, the final 3 subjects will receive the 3rd dose level of 0.8-1x1010 transduced CD4+ T-cells. In the event of a DLT (grade 3 or higher unexpected, related AE) recruitment will be paused pending DSMB decision
46026148|NCT02753179|Other|Dizziness Handicap Inventory|Dizziness Handicap Inventory is a questionnaire that identify difficulties that patient may be experiencing because of dizziness, yielding to a score ranging from 0 to 100
46026149|NCT02753179|Other|Oscillopsia severity questionnaire|Oscillopsia severity questionnaire is a 9 items questionnaires that identify oscillopsia in different circumstances.
46026150|NCT02753257|Other|Non-Interventional|Non-Interventional
46026151|NCT02752867|Drug|Jianpi Yishen Huatan Granules|Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
45470264|NCT04571515|Drug|MR-107A-01|Oral tablet
45470265|NCT04571515|Drug|Placebo|Oral tablet
45470266|NCT03292653|Drug|Sotagliflozin|Pharmaceutical form: Tablet; Route of administration: Oral
45470267|NCT03292653|Drug|Placebo|Pharmaceutical form: Tablet; Route of administration: Oral
45681856|NCT03020602|Other|Laboratory Biomarker Analysis|Correlative studies
45681857|NCT03020602|Other|Pharmacological Study|Correlative studies
45681858|NCT03020602|Drug|Ubidecarenone Injectable Nanosuspension|Given IV
46026152|NCT02752867|Other|the placebo|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
46026153|NCT01179516|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
46026154|NCT01179516|Drug|Placebo|Vortioxetine placebo-matching capsules
46026155|NCT02752945|Other|One-day CBT workshop|One-day long CBT workshop, with between 4-15 participants, facilitated by clinical psychologists. Following introductions, ice breakers and an explanation of the CBT model, CBT techniques are then introduced and practised using a variety of methods. One week after the workshop, any personal goals set during the workshop are reviewed with one of the workshop facilitators in a 'telephone goal review.'
46026156|NCT02752945|Other|Usual care|Usual care afforded by local CAMHS services
46026157|NCT01018953|Drug|BIM 23A760|BIM 23A760 is a solution at a concentration of 5 mg/mL ready for subcutaneous injection. BIM 23A760 dose of 1, 2, 4, 6 and 8 mg can be given to the patient according to a dose escalation and titration process. Patients will receive 24 weekly injections of BIM 23A760 during the treatment period. Patients eligible to continue the extension phase will be administered BIM 23A760 for further 52 weekly injections.
46026158|NCT04219657|Biological|mesenchymal stem cell application|
45470268|NCT03858634|Drug|KPL-716|A loading dose of KPL-716 720 mg (2x maintenance dose) administered via 2 subcutaneous (SC) injections within 30 minutes on Day 1. All subsequent doses of KPL-716 (360 mg maintenance dose) administered via a single SC injection.
46113770|NCT00791492|Drug|Fx-1006A|Fx-1006A 20mg soft gelatin capsule administered orally once daily (at the same time each day) for 12 months.
46113771|NCT04017338|Drug|Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet|A potent and effective antiviral medication that has recently been approved for use in Canada with over 99% cure rates.
46026159|NCT04315740|Other|Particles from candles|Generating fine and ultrafine particles from lit candles
46026160|NCT04315740|Other|Particles from cooking|Generating fine and ultrafine particles from frying pork in an oven
46113772|NCT04017338|Drug|Ezetimibe 10Mg Oral Tablet|A cholesterol-lowering medication that also blocks entry of HCV into liver cells.
46113773|NCT04017338|Device|Ex Vivo Lung Perfusion|A technology that allows for the assessment and treatment of lungs prior to transplant.
46113774|NCT04106726|Drug|Soolantra® Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
46026161|NCT04315740|Other|Clean Air|Nothing but clean air
46026162|NCT04314024|Drug|Evobrutinib|Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A and Treatment B), or under fed conditions that is within 30 minutes after start of high-fat meal (Treatment C) in period 1, 2 and 3.
46026163|NCT00635791|Drug|Sorafenib|Given by mouth
46113775|NCT04106726|Drug|Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
46113776|NCT04106726|Drug|Placebo for Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
46026164|NCT00635791|Drug|Vorinostat|Given by mouth
46026165|NCT04219501|Other|VIVO|Non-invasive mapping system software product that combines patient-specific images (MRI or CT) of the torso and cardiac structures and a 3D image of the torso that identifies precise ECG lead placement to generate a 3D model of the patient's heart.
46026166|NCT02753023|Other|no intervention|No intervention related
46026167|NCT01158924|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
45470269|NCT03858634|Drug|Placebo|Placebo dose administered via 2 SC injections within 30 minutes on Day 1. All subsequent doses of placebo administered via a single SC injection.
45470270|NCT03752593|Other|ET Tube|Patients with a BMI of greater than 30 or less than who are presenting to the hospital for any surgical procedure requiring general anesthesia
45470271|NCT02891070|Drug|FS VH S/D 500 s-apr|
45470272|NCT02891070|Device|DuraSeal Dural Sealant|
46026168|NCT02760121|Drug|Acetazolamide|
46113777|NCT03998774|Behavioral|Evaluate the anxiolytic effect during dental care with MEOPA in children|"Primary Purpose: The main objective of this study is to evaluate the anxiolytic effect of EMONO in children during dental care.~Enrollment: 30"
46113778|NCT04106336|Device|rTMS|Repetitive transcranial magnetic stimulation (rTMS) will be done for cannabis addict
46113779|NCT02603354|Drug|peroxide gel tooth bleaching 6%|gel of hygrogen peroxide for teeth bleaching in a low concentration (6%)
46113780|NCT00723957|Drug|Ixabepilone, 32 mg/m^2|Intravenous (IV) solutions, ixabepilone, 32 mg/m^2
46113781|NCT00723957|Drug|Paclitaxel, 200 mg/m^2|IV solutions, paclitaxel, 200 mg/m^2
46113782|NCT00723957|Drug|Carboplatin (area under the concentration curve [AUC] 6)|Carboplatin (AUC 6) day 1, every 21 days, 6 cycles
46113783|NCT04106180|Drug|GM-CSF|Patients will receive GM-CSF 125μg/m2 daily for 14 consecutive days after completing SBRT treatment.
46113784|NCT04106180|Drug|Sintilimab|Patients will receive Sintilimab 200 mg every 3 weeks up to 2 years after completing SBRT treatment.
46026169|NCT02760121|Drug|Methazolamide|
46026170|NCT02760121|Drug|Placebo|
46026171|NCT05218447|Device|Robotic Gait Training|"Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting.~Subjects will wear an exoskeleton device and receive robotic gait training (RGT) with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will complete 24 robotic gait training sessions over different durations during outpatient rehabilitation. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity."
46026172|NCT05218447|Other|Usual Care (UC) Gait Training|"Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting.~Subjects will complete gait training with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity."
46113785|NCT04106180|Radiation|SBRT|Patients will receive SBRT for one previously unirradiated primary or metastatic lesion (size: 1-5cm). 24 Gy in 3 fractions (8Gy/Fx) administered once-daily for 3 consecutive days.
46113786|NCT02603822|Dietary Supplement|12C mannitol|12C mannitol 100 mg
46026173|NCT00635869|Behavioral|ARCC standard information|EBP didactic education sessions, EBP toolkit, environmental prompts, identification of an EBP champion among unit staff RNs
46026174|NCT00635869|Behavioral|ARCC enhanced|same as ARCC standard plus EBP mentor on-site twice each week plus available by e-mail for consultation
46113787|NCT02603822|Drug|Indomethacin|Subjects will receive six 25 mg capsules of Indomethacin (immediate release). The subjects will take 3 capsules 8 hours before the timing of visit 5 (before fasting), and 3 additional capsules 30 minutes before visit 5.
45470273|NCT05399953|Other|Myofascial Release Technique|"Sternocleidomastoid, Upper trapezius, Suboccipital region, Scalenes, Pectoral release, Scapular and hyoid mobilization techniques.~Duration: 6 weeks, 1 supervised session per week, and the session lasted 30 minutes."
46026175|NCT00635869|Behavioral|Placebo|didactic education sessions on physical assessment
46026176|NCT05215873|Drug|Misoprostol|a synthetic prostaglandin E1 analogue
46113788|NCT02603822|Dietary Supplement|13C mannitol|13C mannitol 100 mg
46026177|NCT05215873|Drug|Syntocinon|synthetic oxytocin
46113789|NCT02603822|Dietary Supplement|Lactulose|lactulose 1 g
46113790|NCT04087005|Other|hominis placental pharmacopuncture|Hominis placental pharmacopuncture is human placental extract, which has been used in traditional Korean medicine to treat chronic diseases, including frailty, cough, anorexia, and fatigue, by enhancing the body's resistance.
46026178|NCT02759887|Procedure|biospecimen collection|Blood: ApoE genotyping, comprehensive metabolic panel, RNA sequencing. Urine: beta-hCG (human corionic gonadotropin) testing.
46026179|NCT02759887|Other|cognitive assessments|Dementia Questionnaire for People with Learning Disabilities; Mini-Mental State Examination; Severe Impairment Battery; Vineland Adaptive Behavior Scale; Arizona Memory Assessment for Intellectual Disability; Kaufman Brief Intelligence Test; Nepsy Mazes; and, Timed Up and Go.
46026180|NCT02759887|Other|caregiver questionnaire|
46026181|NCT02759887|Procedure|Florbetapir F18 imaging|Used in small doses to image brain amyloid-beta deposits in human beings. Radioactivity necessary to create the positron emission tomography (PET) images. Radiation exposure is slightly more than a person would receive from a routine clinical head computed tomography scan.
46026182|NCT02759887|Procedure|MRI|Magnetic resonance imaging of the head and brain.
45681859|NCT03582982|Behavioral|Eccentric overload exercise|12 weeks of 2x per week of the following eccentric exercises: squat, shoulder press, row, and bicep curl.
46113791|NCT02592057|Drug|SOF|SOF tablets administered orally once daily based on approved prescribing information
46026183|NCT02759887|Procedure|Fludeoxyglucose F18 (FDG)|Injected intravenously during a PET scan and is a marker for the tissue uptake of glucose; a radiopharmaceutical compound.
46113792|NCT00723801|Drug|Atenolol|Atenolol 50mg PO QD
46026184|NCT02759887|Procedure|Tau Pet|Administered during a PET, in small amounts, necessary to create the scan images. Radioactive. The total amount of radiation is about the same that a patient receives from a routine abdominal/pelvis computerized tomography.
46026185|NCT02759887|Procedure|Actigraphy|A non-invasive method of monitoring human rest and activity cycles. A small actigraph unit is worn to measure gross motor activity. The unit is usually worn on the wrist.
46026186|NCT05146765|Device|Mobile application|Device: Use of mobile application Participants will be instructed to use the speech therapy app for 30 minutes to one hour per day over a 4-week period.
46113793|NCT00723801|Drug|Losartan|Losartan 100mg PO QD
46113794|NCT04087083|Other|Technological intervention arm|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training (G-EO system, Reha Technology, Switzerland), an end-effector technology that simulates floor walking and stairs climbing (up and down)
46113795|NCT04087083|Other|Control arm|Each session will include 50 minutes of traditional physical rehabilitation therapy
46113796|NCT04086927|Device|Unna Boot|The unna boot is a zinc coated compression dressing
46113797|NCT00797966|Drug|OPC-34712|Tablets, Oral, 1 - 4 mg OPC-34712 variable dose once daily, 14 weeks
46113798|NCT00797966|Drug|Placebo|Tablets, Oral, 1- 4 mg OPC-34712 once daily, 14 weeks
46113799|NCT00797966|Drug|ADT|Tablets, 10 - 225 mgs, dose once daily, 14 weeks
46113800|NCT00723489|Biological|Live Yellow Fever Vaccine (YFV-17D)|
46113801|NCT00723489|Drug|YFV-17D Placebo|
46113802|NCT02591901|Drug|Uro vaxom|Prevention of recurrent symptomatic lower urinary tract infections
45470274|NCT05399953|Other|Exercise|"Therapeutic exercise: passive and active range of motion, strengthening and postural exercise in order to improve shoulder and cervical mobility, muscle flexibility, strength and endurance, postural control and movement patterns; 2) stretching of pectoral muscles and serratus anterior; 3) scar tissue massage to reduce scar tissue's stiffness.~Duration of the intervention: 6 weeks (1 supervised session and 2 individual per week). Each exercise will be done 1-3 sets and 5-10 repetitions.The session lasted 30 minutes.~Exercise diary will be utilized in order to follow the exercise program."
45470275|NCT05399953|Other|Scar Tissue Massage|Circular, Up and Down, Side to Side technique
46113803|NCT02591901|Other|Placebo comparator|Placebo comparator
46113804|NCT05362695|Drug|IW-3300|A dose of IW-3300 administered rectally (as a low-volume [20 mL] enema).
46113805|NCT05362695|Drug|Placebo|A dose of placebo administered rectally (as a low-volume [20 mL] enema).
46113806|NCT05361837|Procedure|Single level serratus anterior plane block|Serratus anterior plane block with local anesthetics at the third rib
45470276|NCT03349593|Diagnostic Test|Echocardiography|Preoperative transthoracic echocardiography
45470277|NCT04671693|Other|PASCA intervention|"At each study visit (T1 = 1 month, T2 = 6 months, T3 = 24 months, T4 = 60 months), an exhaustive screening of complications as well as associated sub-clinical abnormalities and risk factors previously identified as such in the literature, will be conducted.~Management of complications consists of referring the patient to a healthcare professional belonging to the PASCA network based on the test results. Referral is defined by referring to pre-established decision trees. It is made to a specialist physician, a health professional from the paramedical field or the patient's general practitioner who confirms the diagnosis if necessary and initiates the patient's care and follow-up. These patients also receive their usual follow-up in the context of their tumor pathology in oncology and onco-hematology."
45470278|NCT03255291|Behavioral|Risk Assessment App|The App provides participants with personalized risk results for colon cancer, breast cancer (women), heart disease, diabetes, and stroke.
45470279|NCT03255291|Behavioral|Audio Recording - Sleep|-Participants imagine themselves improving sleep hygiene
45681860|NCT03153670|Other|fMRI|DBS patients will undergo fMRI scanning. For each patient, scans will be performed using a selection of DBS settings. fMRI responses will be analysed to evaluate brain responses on different DBS settings. These results will be provided to the programming clinician to guide them choose the optimal setting for each patient at the clinician's discretion.
45681861|NCT03582904|Procedure|tDCS|real or sham tDCS delivered to primary motor cortex
46026187|NCT05146765|Other|Treatment as usual|The patients will follow the treatment as usual, including conventional stroke therapy if needed based on the medical guidelines.
46026188|NCT02750917|Drug|Lornoxicam|At the end of surgery patients in group LORNOXICAM received one pill of 8 mg lornoxicam every 12 hours in the surgery day and first postoperative day.
46026189|NCT02750917|Drug|Etoricoxib|At the end of surgery patients in the ETORICOXIB group received one pill of 120 mg etoricoxib at the end of surgery and a second one after 24 hours. This group also received placebo pills at 12 h, between the active pills.
46026190|NCT02750839|Procedure|proximal humerus fracture fixation|Mini-invasive proximal humerus fixation with plate, patient in beach chair position, general anesthesia, a small incision lateral to shoulder is made to insert the plate under scope control
46026191|NCT02759809|Other|Pasteurized donor human breastmilk|
46026192|NCT02759809|Other|Preterm formula|
46026193|NCT02750995|Biological|NPMW-peptide vaccine|Peptide vaccine against long peptide sequences from NY-ESO-1, PRAME, MAGE-A3, WT-1.
46113807|NCT05361837|Procedure|Single level serratus anterior plane block with dexmedetomidine|Serratus anterior plane block with local anesthetics and dexmedetomidine at the third rib
46113808|NCT05361837|Procedure|Bilevel serratus anterior plane block|Serratus anterior plane block with local anesthetics at the third and fifth rib
46113809|NCT05361837|Procedure|Bilevel serratus anterior plane block with dexmedetomidine|Serratus anterior plane block with local anesthetics and dexmedetomidine at the third and fifth rib
46113810|NCT00587990|Biological|Lower dose mesenchymal stem cell (MSC) injection|Participants will receive between 10 and 20 intramyocardial injections of 2 million MSCs per 0.25-0.5 cubic centimeter (cc) for a total of 2 x 10^7 cells. The injections will be administered following completion of CABG surgery.
46113811|NCT00587990|Genetic|Placebo|Participants will receive between 10 and 20 placebo injections that consist of phosphate buffered saline (PBS) and 1% human serum albumin (HSA).
46113812|NCT00587990|Biological|Higher dose MSC injection|Participants will receive between 10 and 20 intramyocardial injections of 20 million MSCs per 0.25-0.5 cc for a total of 2 x 10^8 cells. The injections will be administered following completion of CABG surgery.
46113813|NCT02603744|Biological|Intraovarian injection of Adipose derived Stromal cells (ADSCs)|Intra-ovarian injection of Adipose derived mesenchymal stem cells.
46113814|NCT00723255|Biological|bevacizumab|Given IV
46113815|NCT00723255|Drug|temsirolimus|Given IV
46113816|NCT00791258|Drug|amlodipine and olmesartan medoxomil tablets|amlodipine and olmesartan medoxomil tablets administered orally, once daily for up to 20 weeks
46113817|NCT00791258|Drug|hydrochlorothiazide tablets|hydrochlorothiazide tablets may be administered orally, if necessary once daily, for up to 8 weeks
46113818|NCT00808067|Drug|dabigatran dose 1|dabigatran high dose twice daily
45681862|NCT01567527|Drug|Intramuscular (IM) Depot Aripiprazole|Formulation: Intramuscular (IM) Depot Aripiprazole Formulation 400 mg or 300 mg, once a month injection
46026194|NCT02750995|Drug|Azacitidine|Standard therapy. All participants receive azacitidine 6 months prior to inclusion, which continues during the study period.
46026195|NCT01027845|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 4 doses
46026196|NCT01027845|Biological|DTPa|Subcutaneous injection, 4 doses
46113819|NCT00808067|Drug|dabigatran dose 2|dabigatran low dose twice daily
46113820|NCT00723021|Drug|PF-04191834|30mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets.
46113821|NCT00723021|Drug|PF-04191834|100mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets, single dose.
46113822|NCT00723021|Drug|PF-04191834|2000mg PF-04191834, single dose, oral dispersion + 2 x placebo tables, single dose
46113823|NCT00723021|Drug|zileuton|1200mg, 2 x 600mg tablets, single dose + placebo oral dispersion, single dose.
46113824|NCT00723021|Drug|Placebo|2 x placebo tablets + placebo oral dispersion, single dose.
46113825|NCT04087317|Drug|Paracetamol 500 Mg Oral Tablet|The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
46113826|NCT04087317|Drug|Ibuprofen 400Mg Tab|The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
46113827|NCT04087317|Drug|Paracetamol 500 Mg Oral Tablet|The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
46113828|NCT04087317|Drug|Ibuprofen 400 mg|The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
45470280|NCT03255291|Other|Surveys|Assesses information comprehension, intentions, perceived risk and severity worry, self- efficacy, response efficacy, affect, race, education, age, numeracy, graph literacy, and exercise and sleep behaviors.
46026197|NCT04219345|Device|Transcranial direct current stimulation|Both groups will undergo the same protocol of twelve sessions of twenty minutes of tDCS associated with mindfulness, where only the type of received electric current is varied (active or simulated sham type). The twelve sessions will be performed in three sessions per week for four weeks, and mindfulness practice at home will be encouraged on days when the intervention is not administered.
45470281|NCT03255291|Behavioral|Audio Recording - Exercise|Participants imagine themselves improving exercise
45470282|NCT03255291|Other|Text message reminders|-Reminders to practice mental imagery
45470283|NCT03255291|Other|Text Message Survey|-Assesses exercise behavior, intentions, actions plans, self-efficacy, affect, imagery vividness, and practice.
46026198|NCT05113225|Procedure|Micro-swim up technique|processing and selection of the sperm for ICSI in the same dish
46026199|NCT04221919|Drug|β -Blockers|Target doses of carvedilol, bisoprolol, metoprolol tartrate, or metroprolol succinate
46113829|NCT05754281|Device|2nd Gen LabPatch Glucose Sensing System|"I. The 2nd Gen LabPatch chip which lies in the center of a clasp unit. The chip measures approximately 15.7 mm [0.618] x 15.7 mm [0.618]. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact~II. A LabPatch clasp device~III. A wire that connects the clasp unit to a Windows tablet which will communicate with the clasp via an application. Each data point will be viewed on the tablet and the application will also have some limited graphing capabilities to view trends of previous measurements"
45470284|NCT00381381|Drug|Donepezil|2.5mg once daily for the first 7 days, 5mg once daily for the next 3 weeks, after then the dose can be increased 10mg once daily under the investigator's decision.
45470285|NCT02927691|Device|EMST|
46113830|NCT04087161|Other|Nephrocheck bed side testing of AKI|Usage of Nephrocheck system to assess AKI after open TAAA repair
46113831|NCT04309409|Drug|Nivolumab|480 mg nivolumab fixed dose given as 60-minute iv infusion every 4 weeks for 12 doses over 1 year
46113832|NCT04086537|Diagnostic Test|hepcidin levels and BMPR2 expression|Samples will be collected in the three groups. Hepcidin levels will be measured in serum using ELISA and BMPR2 expression will be assessed as previously described using real time-qPCR
46113833|NCT02608619|Radiation|F-choline PET Scan|
46113834|NCT02608619|Device|FDG-PET|
46113835|NCT02608619|Procedure|biopsy|
46113836|NCT02591589|Other|Normoxic oxygenation|FiO2 set at 0.35 to maintain PaO2 > 70 mmHg or oxygen saturation greater than or equal to 92%.
46113837|NCT02591589|Other|Hyperoxic oxygenation|FiO2 set at 1.0 throughout the procedure
46113838|NCT05754203|Radiation|Super-hyperfractionation Pulse Radiotherapy|Radiotherapy design: a single dose of 0.5Gy, 16 consecutive pulses with an interval of 3 minutes (0.5Gy * 16F), total dose DT: 8Gy; Immunotherapy: PD-1/PD-L1 monoclonal antibodies conforming to CSCO guidelines for lung cancer indications, including Carrilizumab, Tirelizumab, Teripril, Paborizumab, etc., conventional therapeutic dose, Q3W, until progression or the investigator judges that there is no longer clinical benefit or intolerable side effects.
46113839|NCT02591667|Procedure|Upfront staging laparoscopy + peritoneal biopsy|Upfront staging laparoscopy with biopsy of peritoneal tumor deposits, assessment of peritoneal cancer index and resectability.
46113840|NCT02591667|Drug|Neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab|"Patients will receive 4 cycles of FOLFOXIRI + bevacizumab; the last cycle will be given w/o bevacizumab~Dosage: Bevacizumab: 5 mg/kg via 30 min. IV infusion, day 1; Oxaliplatin: 85 mg/m2 via 2-hour IV infusion, day 1; Irinotecan: 165 mg/m2 via 1-hour IV infusion, day 1; Leucovorin: 200 mg/m2 via 2-hour IV infusion, day 1; 5-Fluorouracil: 3200 mg/m2 via 48-hour IV infusion, day 1;"
46113841|NCT02591667|Procedure|Surgical re-exploration|Three to 5 weeks after completion of FOLFOXIRI + bevacizumab chemotherapy, patients will undergo surgical re-exploration with the intent to perform a complete surgical cytoreduction. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, may be given at the discretion of the investigator. Systemic chemotherapy may be started beginning 4 weeks post-surgery and after complete wound healing.
45470286|NCT02927691|Behavioral|smTAP|
45470287|NCT03637335|Combination Product|irradiation + carboplatin|30 Gy en 10 fractions de 3 Gy + 10 injections of carboplatin
46026200|NCT04299633|Drug|Vadadustat|2 x 150 mg oral tablets
46026201|NCT04299633|Drug|Sevelamer carbonate|2 x 800 mg oral tablets
46026202|NCT04299633|Drug|Calcium acetate|2 x 667 mg oral gelcaps
46026203|NCT04299633|Drug|Auryxia®|2 x 1 gram tablets (210 mg ferric iron equivalent to 1000 mg ferric citrate)
46026204|NCT02695459|Drug|cisplatinum and everolimus|Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
46026205|NCT04288713|Drug|Eculizumab|A distal complement inhibitor.
46026206|NCT02759497|Other|serum amyloid A level|serum amyloid A level (SAA)
45681863|NCT01567527|Drug|Intramuscular (IM) Depot Placebo|Formulation: Intramuscular (IM) Depot Placebo 400 mg or 300 mg, once a month injection
46026207|NCT00627549|Procedure|Avaulta (surgical procedure using a mesh implant)|The use of Avaulta
46026208|NCT00627549|Procedure|Conventional surgery (anterior repair)|Anterior repair surgery
46113842|NCT00721227|Procedure|Reduction Gastroplasty|"Subjects will undergo reduction gastroplasty by gastric plication~Subjects are followed for 12 months to evaluate outcomes and potential complications."
46113843|NCT00807599|Procedure|Stem cell transplant x 1 or x 2|"After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.~On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L."
46113844|NCT00807599|Drug|lenalidomide and dexamethasone|Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.
46113845|NCT00721149|Device|Radiofrequency Ablation|The Biosense Webster® NAVISTAR THERMOCOOL Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
46113846|NCT00788372|Drug|Fentanyl|Fentanyl transdermal patch will be applied daily starting at a dose of 12.5 mcg/hr, and up to 52 weeks. Dose will be increased as per Investigator's discretion.
46113847|NCT04086459|Device|Repetitive transcranial magnetic stimulation|Those receiving experimental treatment will receive 20 sessions of rTMS, stimulation protocol included 20 sessions within 30 days (once a day, 5 days/week, 4 weeks, 10 Hz frequency, pulse intensity 100% of the resting motor threshold, 50 pulses per train, inter train pause of 10 s, 40 stimulation trains, 2000 pulses/ session)
46113848|NCT05754125|Dietary Supplement|Di-Leucine Supplement|Participants will consume a amino acid supplement containing Di-Leucine following resistance exercise and their whole body anabolism will be determined over the subsequent 6 hours
46113849|NCT05754125|Dietary Supplement|BCAA Supplement|Participants will consume a amino acid supplement containing branched chain amino acids (BCAA) following resistance exercise and their whole body anabolism will be determined over the subsequent hours
46113850|NCT05754125|Dietary Supplement|Collagen Supplement|Participants will consume a amino acid supplement containing Collagen protein following resistance exercise and their whole body anabolism will be determined over the subsequent hours
45681864|NCT03582670|Behavioral|Strategy Training|Participants will attend four strategy training sessions total. In sessions 1 and 2, in addition to teaching about event- and time-based tasks, the trainer teaches the participant specific strategies for each type of task (implementation intentions for event-based and strategic clock-checking for time-based). In sessions 3 and 4, the trainer tells the participant s/he will be practicing both types of tasks in the training games and can support the participant's strategy use if needed. Feedback on accuracy and strategy use are provided after each training game. At the end of each session after completing the training games, the trainer and participant discuss how the strategies can be applied to the participant's real-life prospective memory goals, and the trainer helps the participant develop written action plans to do so. Plans are reviewed (and modified if necessary) at each session.
45838810|NCT04359342|Dietary Supplement|HIIT and resistance training + protein|"8-week supervised exercise program consisting of high-intensity interval training (HIIT) and resistance training (RST).~HIIT: 5x1 min at 85-95% HRmax divided by low intensity recovery periods. RST: 3-set resistance training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum. Two exercise sessions per week. Participants receive 40 g of a commercially available protein supplement administered as a shake after every exercise session."
46113851|NCT00915668|Drug|JNJ-31001074|
46113852|NCT05754047|Diagnostic Test|immunohistochemistry (IHC) and in situ hybridization (ISH) Test|These tests are usually applied for breast cancer patients to assist the surgeon to better understand the clinicopathological characteristics and survival features of tumors
46113853|NCT00738582|Drug|MORAb-009 (Amatuximab)|MORAb-009 (Amatuximab) by IV on Days 1 and 8 every 21 days for 6 cycles.
46113854|NCT00738582|Drug|Pemetrexed|Pemetrexed 500 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
46113855|NCT00738582|Drug|Cisplatin|Cisplatin 75 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
46026209|NCT04299789|Other|Validating the Military Service Identification Tool|This study seeks to validate the Military Service Identification Tool in its ability to accurately determine military service status.
46113856|NCT05753657|Drug|Pioglitazone|hyperinsulinemia and hyperglycemia
46113857|NCT04106024|Drug|Anlotinib|Anlotinib 12mg.qd ,taken for 2 weeks and discontinued for 1 week, namely 3 weeks (21 days).
46113858|NCT00720759|Drug|D-cycloserine + distributed treatment|Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
46113859|NCT00720759|Behavioral|D-cycloserine + condensed treatment|Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
46113860|NCT00720759|Drug|Placebo + distributed treatment|Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with placebo administered before each treatment session
46026210|NCT04217863|Behavioral|GDP|Guided Disclosure Protocol
46026211|NCT02872233|Drug|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
46026212|NCT02872233|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
46026213|NCT04219423|Behavioral|Multimodal physical therapy|see description in arm/group description
46026214|NCT04599231|Diagnostic Test|Quality of Recovery -15|The investigators plan to evaluate patients' quality of recovery at postoperative day (POD) 1, 2, and 3.
46113861|NCT00720759|Behavioral|Placebo + condensed treatment|Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with placebo administered before each treatment session
46113862|NCT04017494|Diagnostic Test|Cardiac Magnetic Resonance Imaging|Cardiac Magnetic Resonance Imaging (non-invasive, with i.v. application of contrast), awake or (if clinically indicated) in general anesthesia
46113863|NCT04017494|Diagnostic Test|Blood draw for hematocrit and heart failure biomarkers|Approximately 10 ml of blood will be drawn before administration of contrast medium.
46113864|NCT04017494|Diagnostic Test|Cardiopulmonary exercise test|In patients 8 years of age or older: on a cycle ergometer with breath-by-breath analysis, continuous ECG and SpO2 monitoring during exercise, after a baseline spirometry and bodyplethysmography
46026215|NCT04219267|Behavioral|character strengths-based intervention|"Character strengths-based intervention (CSI) is one kind of positive psychology interventions. It specifically focuses on character strengths, related activities and exercises assisting individuals to reconnect with their characters and promote self-conceptualization.~The researcher will develop an education module on CSI based on the previous literatures conducted in China and other countries. Before the RCT, this module will be adapted to Chinese participants. During the intervention, participants in the intervention group will be offered the educational module to learn about strengths, comments around the definition of character strengths and examples of specific strengths."
46113865|NCT04017494|Diagnostic Test|Exhalomics|Measurement of exhaled molecules by mass spectrometry; patients breathe into a mouthpiece for 15 seconds 6 times (total time requirement: about 5 minutes)
46113866|NCT04017494|Diagnostic Test|Quality of life questionnaire|Questionnaire to be filled out by the Patient regarding quality of life perception
46113867|NCT03998228|Diagnostic Test|Dual X-ray absorptiometry (DMO) densitometry.|"Simple clinical examination with forearm inspection and palpation;~Radiological examination of BMD;~Calculation of the FRAX® score;~Fact sheet on patients with dermatoporosis, proposal of a topical treatment (cosmetic cream) and completion of the questionnaire specific to dermatoporosis"
46113868|NCT00918060|Drug|Camella sinensis gel|clinical effect of locally-delivered gel between Camella sinensis and placebo
46113869|NCT00918411|Drug|Ramosetron|oral
46113870|NCT00918411|Drug|Placebo|oral
46113871|NCT00720213|Device|Respironics BiPAP autoSV2|Respironics BiPAP autoSV2 is an Auto Servo Ventilation Device. This will be used on a randomized night.
46026216|NCT04219267|Behavioral|early memories|In early memories, participants will be instructed to write down something from their early memories every day. The memories could be the things happened several days or many years before the writing day. The memories could be participant' travel experiences or food for a day. There are no strict restrictions on the timing or content of these early events.
46026217|NCT01017549|Radiation|Electronic brachytherapy (Axxent System)|3.4 Gy per fraction for 10 fractions for a total of 34 Gy.
46113872|NCT00720213|Device|Respironics BiPAP autoSV3|Respironics BiPAP autoSV3 is an Auto Servo Ventilation Device. This will be used on a randomized night.
46113873|NCT05353647|Biological|Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a|A single infusion of autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
46113874|NCT00915434|Drug|JNJ-31001074|
46113875|NCT04000802|Behavioral|response to questionnary|No intervention. Observational study
45470288|NCT03637335|Combination Product|irradiation + placebo|30 Gy en 10 fractions de 3 Gy + 10 injections of placebo
46113876|NCT04086303|Other|LSST test|LSST test: Scapular mobility testing Upper Extremity test: Upper extremity agility and endurance testing Y Balance test: Balance and Coordination testing Sit and Reach Test: Assessment of flexibility
46113877|NCT04112966|Procedure|14 sessions of manual lymphatic drainage technique|Early manual lymph drainage including 14 sessions of manual lymphatic drainage technique in the three months following surgery and health education for lymphedema prevention including verbal instructions and written materials.
46113878|NCT04112966|Other|the health education|The health education for lymphedema prevention.
46113879|NCT04086381|Dietary Supplement|Creatine monohydrate|5 grams of creatine monohydrate, four times daily, for 9 consecutive days.
46113880|NCT04086381|Dietary Supplement|placebo cellulose|oral ingestion of placebo containing 20 gram cellulose daily
45470289|NCT03637257|Device|modified Guedel airway|Monitoring of breathing
45470290|NCT04670991|Radiation|EXATRAC imaging|Exatrac imaging performed before the standard CBCT imaging prior to each chemotherapy session
45754400|NCT04186767|Dietary Supplement|Very Low Carb Ketogenic Diet|Patients will be submitted to very low-calorie ketogenic dietary intervention (VLCK) according to the recommendations of the Pronokal® Method program including lifestyle and physical activity guidelines. The ketogenic stage (phase 1-3) consists of a VLCD diet (600-800 kcal / d), with low carbohydrate intake and lipids. The amount of high biological value proteins ranges from 0.8 to 1.2 g / kg of body weight / day. This first stage (ketogenic) is maintained until the patient reaches the goal of reducing the target weight by 80% to be reduced, being variable in time, according to the response of each patient. After this period, it evolved to a non-ketogenic stage, initiating the hypocaloric diet (800 to 1500 Kcal), with progressive introduction of other food groups, reducing weight more slowly. The maintenance stage consists of a balanced diet, ranging from 1500 to 2000 Kcal.
46113881|NCT04107350|Device|whole-body vibration|10 minutes WBV exercise in standing position; amplitude 2mm,; frequency 4-10Hz; resting interval: 3 minutes rest.
46026218|NCT00635947|Other|isotonic solution|1.5 L- during 2-4hours
46026219|NCT00635947|Other|water|1.5 L- during 2-4hours
46113882|NCT00810407|Drug|rifabutin|"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily."
46113883|NCT00720057|Drug|Naproxen Sodium ER (BAYH6689)|Analgesic efficacy in dental pain; per oral; 1 tablet extended release Naproxen Sodium; with a full glass of water within 4 hours post surgery
46113884|NCT00720057|Drug|Placebo|Inactive ingredient; per oral; 1 lactose based tablet; with a full glass of water within 4 hours post surgery
46113885|NCT04134689|Device|DOT Selfie Intervention|This comprises a smart phone, the VDOT App, a prepaid weekly internet bundle and text message medication reminders
46026220|NCT00635947|Other|water|200mL- during 2-4hours
46026221|NCT04299243|Device|Contact Lenses|Contact lenses for vision correction
46026222|NCT05112991|Drug|Envafolimab+Lenvatinib|"Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.~Lenvatinib: the recommended Phase 2 dose (RP2D) orally 20mg QD during each 28-day cycle."
46113886|NCT04134689|Other|In-person DOT|Directly observed TB treatment by a health-worker either in a patient's home or at an agreed upon location within the community.
46026223|NCT05112991|Drug|Envafolimab|Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.
46026224|NCT01030341|Device|CGMS and insulin pump|Use of continuous glucose monitoring system and insulin pump
46026225|NCT02750449|Drug|Sun screening Sport Lotion, (BAY987516)|50 μl/ cm*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3 μl/ cm*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation Number - RB# Y65-110)
46113887|NCT00790868|Drug|d-cycloserine|50mg
46113888|NCT00790868|Drug|placebo|50mg
46113889|NCT04105556|Other|Nursing Care Based on Kolcaba's Comfort Theory|In this study, nursing care based on Kolcaba's Comfort Theory, which continues throughout the perioperative period, was applied to children and their parents.
46113890|NCT00719901|Drug|obatoclax mesylate|Given IV
46113891|NCT00719901|Drug|bortezomib|Given IV
45470291|NCT02939937|Drug|Phenytoin|100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.
45681865|NCT03582670|Behavioral|Process Training|Participants will attend four process training sessions in this group. In sessions 1 and 2, the trainer teaches the participant about event- and time-based prospective memory tasks, respectively. In sessions 3 and 4, the trainer simply tells the participant that s/he will be practicing both types of tasks in the training games. In all sessions, the participant completes the training games with no strategy instruction from the trainer. Feedback on accuracy is provided after each training game. At the end of each session after completing both training games, the trainer reminds the participant of his/her real-life prospective memory goals, provides a handout that lists the goals, and instructs the participant to try to complete them as intended. Of note, even this minimal level of discussion of real-life cognitive tasks is not typical of process training interventions, but we include it to control for that which is occurring in the strategy training group.
46026226|NCT02750449|Other|Untreated skin|This site is patched without treatment as control
46026227|NCT04301037|Procedure|Tension band wires|medial malleolus fracture fixed with tension band wiring): 2 k.wires (1.6 mm) are inserted perpendicular to the fracture site. Again the position is checked under image intensification for the correct direction and length. We drilled a 2.5mm hole with a protection sleeve, 2-3cm above the level of the horizontal joint line, aiming the drill bit slightly inferiorly to avoid screw pullout. We inserted a 3.5mm unicortical screw about 30 mm in length (with or without washer), 2-3mm is left for the wire between the bone and screw head before full tightening. A steel wire is constructed into a figure of eight between the screw the reduction k. wires, then twisted to achieve interfragmentary compression
46026228|NCT04301037|Procedure|Cannulated screws|In group 2 (15 patients with medial malleolus fixed by 2 cannulated screws): Two guide wires (1.6mm) are inserted perpendicular to the fracture site, the appropriate length, proper insertion site including the distance from the articular surface is checked fluoroscopically .the length is measured .drilling of the bone through the threaded guide wire with a cannulated drill bit (3.2mm). A two 4.5mm partially threaded cannulated screws (with or two washers) are inserted through the guide to achieve Compression, the guide wires are then removed
46113892|NCT00719901|Other|laboratory biomarker analysis|Correlative studies
46113893|NCT02603276|Dietary Supplement|Plant sterols|Plant sterols 800 mg/dose, 1 liquid stick per day, for 8 weeks
46113894|NCT02603276|Dietary Supplement|Red Yeast Rice|Red Yeast Rice titrated in 5 mg monacolin K per daily dose, 1 liquid stick per day, for 8 weeks
46113895|NCT02603276|Dietary Supplement|Red Yeast Rice plus Plant sterols|Red Yeast Rice titrated in 5 mg monacolin K per daily dose plus Plant sterols 800 mg/dose, together in 1 liquid stick per day, for 8 weeks
46113896|NCT02591277|Drug|Harvoni|Harvoni (90/400 mg) FDC tablet administered orally once daily
46113897|NCT02609555|Procedure|TEM perineal rectopexy|perineal rectopexy using polyprolene mesh assisted by TEM technique and special proctoscope postanal repair in two layers to narrow the postanal space anal cerclage with absorbable sutures
45470292|NCT02939937|Drug|placebo|100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.
45470293|NCT02939079|Drug|Fingolimod|Produced by Osveh ® Pharm Company in Iran
45470294|NCT02939079|Dietary Supplement|Fish Oil|produced by Zahravi ® Pharm Company in Iran
46026229|NCT02750293|Drug|Cholecalciferol|Vitamin D preparation
46113898|NCT00807365|Drug|GHRH|GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 Post Meridian (PM), 1:00 Ante Meridian (AM), 3:00 AM, & 5:00 AM for 6 months.
46113899|NCT02609789|Drug|JNJ-55920839|JNJ-55920839 will be administered as either IV infusion or subcutaneous injection.
46113900|NCT02609789|Drug|Placebo|0.9 percent (%) normal saline.
46113901|NCT02591355|Device|Autologous Platelet Rich Plasma|Autologous Platelet Rich Plasma a novel therapeutic modality used in numerous applications. In dermatology, its uses have included treatment of chronic wounds and facial rejuvenation. More recently, anecdotal reports have suggested some efficacy in the treatment of hair loss.
45470295|NCT02939079|Drug|Placebo (for Fish Oil)|placebo capsules to mimic Fish Oil 1 g capsules
46113902|NCT02591355|Device|Saline solution injection|Placebo is a saline solution
46113903|NCT05753969|Device|MT1 Device|Pre-and post-evaluation in MT1 device following stimulant treatment or placebo control
46113904|NCT03781427|Device|Cardiac resynchronization therapy|Left ventricular pacing
45470296|NCT04562155|Drug|BAY1817080|Study drug BAY1817080 will be administered orally as tablet.
46113905|NCT00719355|Behavioral|Walking with poles|Patients walked with poles, 20-45 minutes, 3 times/week for 24 weeks.
45470297|NCT04562155|Drug|Placebo|Matching Placebo for BAY1817080 will be administered orally as tablet.
45470298|NCT02896257|Other|Guideline treatment recommendations|Patient-tailored E-consult, orders and rationale to discontinue inhaled corticosteroids and discontinue or receive other COPD related care.
45470299|NCT03313050|Biological|Multivalent|Pneumococcal conjugate vaccine
45470300|NCT03313050|Biological|Tdap|Tetanus, diphtheria, acellular pertussis vaccine
45470301|NCT03313050|Biological|polysaccharide|23-valent pneumococcal polysaccharide vaccine
45681866|NCT03582670|Behavioral|Control Group|Participants in this group do not attend any sessions during the time the other groups are participating in the Strategy or Process Training
46026230|NCT02750293|Drug|Placebo|placebo
46026231|NCT04217785|Drug|Optive, Ophthalmic Solution|6 drops per day, for 8 weeks
46113906|NCT00719355|Behavioral|Walking exercise|Patients walked for 20-45 minutes, 3 times/week for 24 weeks.
46113907|NCT05753579|Behavioral|Spinal Mobilization|Mobilization applications are passive movements that do not involve pushing or stimuli, applied within the range of motion or up to the physiological range of motion.
45470302|NCT02774265|Drug|VTE prophylaxis with Enoxaparin 30mg BID|Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
45470303|NCT02774265|Drug|VTE prophylaxis with Aspirin 81mg BID|Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
45470304|NCT04595058|Device|Double pigtail plastic stent through lumen-apposing metal stent|Biliary drainage guided by endoscopic ultrasound: Addition or not, of a axis-orienting plastic stent, mostly, double-pigtail stent through the lumen of a lumen-apposing metal stent
45470305|NCT04595058|Device|Lumen-apposing metal stent without double pigtail plastic stent|Endoscopic ultrasound-guided transmural biliary drainage is with lumen-apposing metal stent is a formal indication according to the instruction forms of the manufacturer.
45470306|NCT04755595|Drug|Botox Cosmetic Injectable Product|Acetylcholine release inhibitor and a neuromuscular blocking agent
45470307|NCT04755595|Device|Juvéderm Voluma XC|Gel implants consisting of cross-linked hyaluronic acid
45681867|NCT03159988|Drug|Angiotensin-(1-7)|Angiotensin-(1-7) 100mcg/kg/day for 12 weeks
46026232|NCT04217785|Biological|Umbilical Cord Serum eye drops|UCS eye drops (6 drops per day, for 8 weeks)
46026233|NCT04217785|Drug|Genteal lubricant gel|Genteal lubricant gel (2 drops per day, for 8 weeks)
46026234|NCT01026831|Drug|Preservative-Free Tafluprost|One drop of preservative-free vehicle per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for 12 weeks
46113908|NCT05753579|Behavioral|Stabilization Exercise|Diyafragmatik solunum ile kombine edilen, pasif-aktif kas iskelet sistemi ve nöral sistemi aktive eden bir yaklaşımdır. Bu yaklaşımda derin çekirdek kaslar olarak transversus abdominis, multifudus kasları aktive edilmektedir
46113909|NCT02591433|Other|Tobacco Cessation Counseling|Undergo JeffQuit group therapy
46113910|NCT02591433|Other|Support Group Therapy|Undergo JeffQuit group therapy
46113911|NCT02591433|Other|Quality-of-Life Assessment|Ancillary studies
46026235|NCT01026831|Drug|Comparator: timolol|One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks
46026236|NCT04299165|Device|Kaia COPD Application|The study intervention consists of training sessions conducted daily by the patient via the COPD-App.
46026237|NCT04299165|Other|Usual Care|The control group will also be an active control as participants receive a leaflet to convey an active lifestyle and a list of exercises to do at home.
46026238|NCT05103943|Other|SPECT MPI|SPECT MPI including dynamic acquisitions for stress, rest MBF and MFR
46026239|NCT02759341|Other|Manual for the Assessment and Documentation of Psychopathology (AMDP 8)|
46026240|NCT02759341|Other|Million Clinical Multiaxial Inventory 3 (MCMI-III)|
46026241|NCT02759341|Other|State-Trait Anxiety Inventory form Y (STAI-Y)|
46026242|NCT02759341|Other|SF-36 Health-Related Quality of Life|
46026243|NCT02759341|Other|Blood oxygenation level dependent- functional Magnetic Resonance Imaging (BOLD-fMRI)|
46026244|NCT05052385|Drug|Ruxolitinib|As per treating physician's decision - non interventional study
46113912|NCT02609711|Drug|Candesartan cilexetil|
46113913|NCT04973657|Drug|VK0214|API in capsule
46113914|NCT04973657|Other|Placebo|API in capsule
46113915|NCT05749601|Other|Influence of the metabolic syndrome (MetS) parameters on knee osteoarthritis (KOA) severity, the assesment of the reactive oxygen species and reactive nitrogen species in knee synovial fluid|Highlighting the influence of environment of origin on KOA incidence and corelated impact of high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol, triglycerides and body mass index (BMI). The analytes from synovial fluid were determined by fluorometric method.
46113916|NCT05749601|Other|The influence of patellofemoral morphology in the radiological severity of knee osteoarthritis|Highlighting the influence of distal femoral torsion angle, patellofemoral congruence angle and sulcus angle, in KOA severity under the influence of sex and age.
45470308|NCT04755595|Device|Juvéderm Volbella XC|Gel implants consisting of cross-linked hyaluronic acid
46113917|NCT05749601|Other|The influence of ROS from the synovial fluid on the severity of KOA|Highlighting the influence of ROS from the synovial fluid in KOA severity under the influence of some biochemicals blood constants.
46113918|NCT05748821|Device|Delfi Personal Tourniquet Systems|Measure within & between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.
46113919|NCT04967807|Diagnostic Test|Cardiac PET/MRI|An imaging technique that combines the strengths of both MRI and PET into one comprehensive study. This technique allows for detailed myocardial tissue characterization with MRI (including assessment of myocardial edema and fibrosis) and metabolic changes (including myocardial inflammation).
46113920|NCT04967807|Diagnostic Test|Blood Biomarkers|Markers of cardiac damage, inflammation, circulating microRNA profiles, and COVID antibody levels will be evaluated in patients after COVID-19 vaccination.
45470309|NCT02697279|Procedure|Traditional Incision and Drainage.|Control Group- Standard treatment of a simple cutaneous abscess with traditional I&D technique with or without packing utilizing a standard I&D kit.
45470310|NCT02697279|Procedure|Loop drainage|Study Group- Treatment of a simple cutaneous abscess with the loop drainage technique utilizing an standard I&D kit and the cuff of a sterile glove for a loop device.
45470311|NCT04822272|Device|MRI thermometry|MRI sequence of 5 to 10 minutes to measure the variation of temprerature in the prostate
45470312|NCT03755479|Device|Hybrid Closed Loop Insulin Pump Minimed 670G|Five Day Group Education on Minimed 670G
45681868|NCT03159988|Behavioral|Memory Training|50% of the treatment arm will receive 2 session per week for 2 weeks of memory training
46026245|NCT05052385|Device|Extracorporeal photopheresis|As per treating physician's decision - non interventional study
46026246|NCT05052385|Drug|Ibrutinib|As per treating physician's decision - non interventional study
46026247|NCT04956757|Other|Exercise Intervention|Scapula retraction exercises at varying shoulder abduction angles will be applied
46113921|NCT04016207|Drug|Guanfacine|regular treatment
46113922|NCT00590759|Device|GORE TAG® Thoracic Endoprosthesis|implant
46113923|NCT05753423|Diagnostic Test|Interview-based questionnaires & Clinical examination|Interview-based questionnaires will be conducted among Egyptian mothers attending Pediatric Dentistry and Dental Public Health outpatient clinic at Faculty of Dentistry, Ain Shams University by the principal investigator. Clinical examination of the oral health status of their preschool children aged 3-5 years will be conducted by the principal investigator.
46026248|NCT01016067|Device|INFUSE/MASTERGRAFT|INFUSE® (rhBMP-2) on an absorbable collagen sponge (ACS) and MASTERGRAFT® granules with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
46026249|NCT01016067|Procedure|Autograft bone|Autogenous bone graft with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
46026250|NCT04905511|Biological|natural human collagen arteriovenous graft for hemodialysis access|The True Vascular Graft will be implanted in the forearm or upper arm in a straight or curved configuration.
46026251|NCT04843891|Drug|[64]Cu Macrin|Up to 15 mCi of [68Ga]CBP8 will be administered to each subject.
46026252|NCT04830475|Device|Non invasive ventilation (NIV)|Patients allocated in NIV Group fulfilled a 120-minute cycle of PSV + PEEP with full-face mask. Ventilation was performed with a Draeger Ventilator with the following basic settings: DeltaPInsp 10 mmHg + PEEP 5 mmHg + Fio2 60%.
46026253|NCT04830475|Device|Conventional Venturi Mask|Patients were offered VenturiMask with Fio2 60% at 15 l / m.
46026254|NCT00636103|Drug|CUF2|"0.619g of dried aqueous extract of equal weights of 5 herbs (Astragalus mongholius Bunge, Cordyceps sinensis Sacc., Radix Stemonae, Bulbus Fritillariae Cirrhosae, Radix scutellariae).~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
46113924|NCT04030091|Drug|3 hours humulin R 100 IU/mL PIT|PIT procedure: a venous catheter will be placed into one superficial vein at one arm, which will be connected to the insulin infusion pump and a glucose infusion pump via a three-way connector. Endothelial function will be measured by means of the Vendys 2 device. The blood glucose will be tested by means of a POCT meter and the CGM, and the PIT procedure will be started (10 pulses of 3 U of regular human insulin per hour). Blood glucose will be tested every 5 to 10 min and glucose infusion will be started once a drop in blood glucose is detected. Adjustment of glucose administration will be performed until a stable glucose value between 80 mg/dL to 160 mg/dL is reached. In parallel, endothelial function will be measured every 30 min. At the end of the PIT procedure, the venous catheter will be removed and the patient will be discharged until the next visit.
46113925|NCT04030091|Drug|2 hours humulin R 100 IU/mL PIT|"As described for the Intervention 3 hours of pulsatile insulin infusion (PIT) with humulin R 100 IU/mL, the treatment duration is just one hour less."
45470313|NCT04573296|Device|Vitadio|A 6-month digitally administered behavioral change program Vitadio focus on lifestyle change and self-management. The program aims for strengthening patients autonomy with the goal to promote weight loss and improve metabolic health. The program includes personalized education, adaptive daily tasks and weekly goals, automated motivational and educational messaging, monitoring tools, recipes, peer-support group and remote coaching.
46026255|NCT00636103|Other|Placebo|"Dark coloured corn starch~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
46026256|NCT04423393|Biological|VIR-3434|VIR-3434 given by subcutaneous injection or intravenous infusion.
46026257|NCT04423393|Other|Placebo|Sterile normal saline (0.9% NaCl) given by subcutaneous injection or intravenous infusion.
46113926|NCT05753345|Behavioral|Aquatic therapy|Children receive aquatic occupational therapy twice a week for 10 weeks. 30 minutes of aquatic therapy in a warm water pool to increase upper extremity function and swim skills; 15 minutes of self care training to increase independence with dressing and showering.
46113927|NCT04030013|Other|group education|All patients of group 1 and 2 will receive intensive education for 3-4 months, then refreshment session every 3 months for 2 years. Initially, patient data will be collected through 3 types of forms: patient identification form, metabolic control parameters form and diabetes self-care scale questionnaire; then every 6 months metabolic parameters and diabetes self-care scale questionnaire will be reassessed.
46113928|NCT00734604|Drug|tadalafil once a day [T(OaD)]|5 mg tablet taken once a day (OaD) by mouth for 8 weeks
46026258|NCT04217395|Behavioral|Obese or overweight health subjects involved in the X-Ailes program (at least one contact with the health system navigator)|"The X-Ailes program is a face-to-face or telephone-based support program by health-system navigators and developed by a patients and public association to support overweight or obese care users.~The main objective of the study is to evaluate the efficacy of the X-ailes program on quality of life of overweight and obese people involved in the program.~Secondary objectives are to assess their overall health status, their health literacy level and their empowerment. The implementation study is guided by the RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance; Glasgow, Vogt, & Boles, 1999) theoretical framework to determine whether the intervention objectives are being met and to understand the mechanisms of action of the device."
46026259|NCT02750137|Drug|Tetracaine|Application of Ametop prior to intravenous cannulation
46113929|NCT00734604|Drug|sildenafil citrate as needed [S(PRN)]|100 mg tablet taken as needed (PRN) by mouth for 8 weeks
46113930|NCT00734604|Drug|tadalafil as needed [T(PRN)]|20 mg tablet taken as needed (PRN) by mouth for 8 weeks
46113931|NCT00590681|Drug|Bevacizumab and Temozolomide|This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
46113932|NCT05748509|Other|Surface EMG activations|We will try to find out which of the exercises such as pressing the back back, waist extension on the balance ball, lumbar extension in the active prone position, Superman exercises have better lumbar extensor muscle activations. Muscle activations of individuals will be evaluated using superficial EMG. An 8-channel EMG Noraxon MiniDTS system (Noraxon, USA, Inc, Scottsdale, AZ) will be used to measure signals from the muscles.
46113933|NCT02607917|Other|Mass Media plus clinic intervention.|
46113934|NCT02607917|Other|Media|
45470314|NCT04573296|Behavioral|Conventional high-intensity lifestyle intervention program|A 6-month high-intensity lifestyle intervention program consisting of 5 face-to-face nutrition/lifestyle education sessions. Participants can use an online diary tool for recording meals with an option to receive remote feedback on their diet from the educator.
45470315|NCT04588428|Drug|INO-4700|INO-4700 will be administered ID.
46026260|NCT04687735|Other|Intervention after nerve block|Brachial plexus block + Physical therapy
46026261|NCT02760043|Drug|Dexamethasone|8mg (2mL) of Dexamethasone added to standard LIA mixture
46113935|NCT04939415|Drug|mQFPD|The dosage of mQFPD is 8 capsules three times a day for 14 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary.
45470316|NCT04588428|Drug|Placebo|Sterile saline sodium citrate (SSC) buffer (SSC-0001) will be administered ID.
45470317|NCT04588428|Device|CELLECTRA™ 2000|EP using the CELLECTRA™ 2000 device will be administered following ID drug administration
45470318|NCT01322659|Device|Helmet|Weaning from mechanical ventilation with noninvasive positive pressure ventilation delivered by means of the helmet
45754401|NCT03586076|Biological|JHL1922|Single doses of JHL1922 2.5 mg and then 10 mg per eRapid nebulizer
45754402|NCT03586076|Biological|dornase alfa|Single doses of Pulmozyme® 2.5 mg and then 10 mg per eRapid nebulizer
45754403|NCT04167579|Device|Transcutaneous Valve Therapy|Any patient who undergoes an attempted transcutaneous aortic or mitral valve therapy procedure, with an FDA approved device.
46026262|NCT02760043|Other|0.9% NaCl Placebo|2mL of 0.9% NaCl placebo (saline) added to standard LIA mixture
46026263|NCT02760043|Drug|LIA Combination Mixture|150mL 2% Ropivacaine, 30mg Ketorolac and 0.6mg of Epinephrine
46113936|NCT04939415|Drug|organic brown rice|The dosage of mQFPD is 8 capsules three times a day for 14 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary.
46113937|NCT04088682|Behavioral|Quality improvement strategies and tools|Quality improvement strategies and tools
46113938|NCT02594982|Other|intervention bundle (sedation, pain, mobilization and sleep)|"Sedation: Sedation after target RASS Pain: Implementing a pain guideline and CPOT for pain assessment. Mobilization: Implementing a guideline on early mobilization and a daily prescribed mobilization level.~Sleep: Implementing a daily quite time and changing procedures to minimize noise during the night"
46113939|NCT02607839|Biological|glucose or normal saline|20% glucose solution or normal saline, intravenous infusion
46113940|NCT00727272|Drug|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered after an overnight fast of at least 10 hours.
46113941|NCT00727272|Drug|Quinine Sulphate Tablets 300 mg|One 300 mg tablet administered after an overnight fast of at least 10 hours.
46113942|NCT00727272|Drug|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered thirty minutes after the initiation of a standardized, high-fat breakfast.
46113943|NCT00805025|Drug|AZLI|75 mg aztreonam for inhalation solution (AZLI), administered 3 times daily using the PARI Investigational eFlow® Nebulizer System (with a minimum of 4 hours between doses) following administration of a short-acting bronchodilator
46113944|NCT00734214|Drug|0.9% NaCl|"Intravenous Fluid~Isotonic Parenteral Fluid"
46113945|NCT00734214|Drug|0.45%NaCl|"Intravenous Fluid~Hypotonic Parenteral Fluid"
46113946|NCT03669653|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.
46026264|NCT02696005|Other|Exercise- Based Cardiac Rehabilitation Programme|Exercise- Based Cardiac Rehabilitation Programme for patients suffering from Heart Failure.
46113947|NCT03669653|Procedure|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days.
45838811|NCT04359342|Dietary Supplement|HIIT and resistance training + placebo|"8-week supervised exercise program consisting of high-intensity interval training (HIIT) and resistance training (RST).~HIIT: 5x1 min at 85-95% HRmax divided by low intensity recovery periods. RST: 3-set resistance training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum. Two exercise sessions per week. Participants receive 40 g of a commercially available iso-caloric placebo (Maltodextrin) administered as a shake after every exercise session."
46026265|NCT02750059|Drug|TDF/3TC/EFV + Telmisartan|The subject will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily
46026266|NCT02750059|Drug|TDF/3TC/EFV only|Starting from the first visit, all participants will be placed on an ART regimen to treat HIV. This is the standard route of care for HIV patients.
46113948|NCT03656315|Other|Airway Assessment|All patients recruited to this study will have an ultrasound of their cricothyroid membrane
46113949|NCT05247372|Other|The effect of Iyengar yoga practice on patients with multiple sclerosis|The study will be conducted as a longitudinal follow-up - at first patients will fbe examined 2 months before the start of the exercise, than they will be examined at the beginning and end of the exercise, which they will attend for 3 months. Patients will be re-examined 2 months after the end of the exercise to clarify the continuing effect of the exercise. The examination will include a basic kinesiological analysis and a neurological examination,TUG test, 6MWT along with the Borg Subjective Weight Rating Scale and T25FWT, BBS, NHPT and stable sitting time in wheelchairs. To evaluate the development of the chest, the respiratory amplitude will be examined and the position of the spine in statics and dynamics will be evaluated using a spinal mouse. Quality of life will be assessed through the MFIS, MSIS-29, MSQOL 54 questionares and Beck's anxiety inventory.
46026267|NCT02759029|Drug|eradication of Helicobacter pylori|"clarithromycin-based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk~concomitant therapy group Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk~bismuth based quadraple therapy Pantoloc 40mg, PO, BID, 1wk Bismuth, 300mg, PO, QID, 1wk Tetracycline, 500mg, PO, QID, 1wk Metronidazole, 500mg, PO, TID, 1wk~levofloxacine based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Levofloxacin 500mg, PO, QD, 1wk"
46026268|NCT03893617|Drug|Propranolol|A single oral dose (80mg) of propranolol will be administered in a blinded capsule at the start of the baseline monitoring period of the acute stress study visit.
46113950|NCT02607995|Behavioral|Behavioral standardized manual-based multidisciplinary routine care|Behavioral standardized manual-based multidisciplinary routine care (lifestyle intervention). Six sessions offered over the course of three to six months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media will be covered.
46113951|NCT02595216|Device|Profound System|The Profound system is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of submental laxity
46113952|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
46113953|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
46113954|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
46113955|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
46113956|NCT00787202|Other|placebo|Administration via oral route twice daily for the duration of treatment
46113957|NCT02609477|Drug|Istradefylline|Istradefylline 40, 80, 160 mg
46113958|NCT02609477|Drug|Phentermine 45 mg|Phentermine 45 or 90 mg
46113959|NCT02609477|Other|Placebo|Placebo
46113960|NCT05744999|Procedure|Coconut technique|We recently developed a simple but effective laparoscopic technique to approach and ligate the cystic duct in cases of difficult acute cholecystitis. Three to four centimeters of the inflamed gallbladder wall was then cut using an electrocautery hook. An incision was made in a safe zone at the junction of the infundibulum and the body of the gallbladder. The separation between the outer layer and inner layer was searched. This clear identification of the confluence between the cystic duct and the body of the gallbladder represents the way to determine if the procedure was safely completed using the current technique. After successful identification, the cystic duct was clipped. The gallbladder can then be lifted and turned over, leaving the unidentified CBD untouched, and cholecystectomy can be carefully performed as usual. The inflamed posterior wall remained attached to the gallbladder bed of the liver.
46113961|NCT02592720|Drug|cocktail|Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
45838812|NCT04358952|Diagnostic Test|Global Longitudinal Strain|Electrocardiogram with measure of the Global Longitudinal Strain to evaluate myocardiac dysfunction
46113962|NCT02592720|Device|FFR|Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
46113963|NCT02592720|Device|QCA guided group|Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
45838813|NCT04358796|Device|Hyperbaric oxygent treatment|Subjects will enter the oxygen chamber. ATA will be elevated to 2 ATA. They will breath 100% oxygen while solving cognitive tests designed to assess their cognitive capacities
46113964|NCT02608073|Drug|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m^2 BID on Days 1 to 14 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
46113965|NCT02608073|Drug|Cisplatin|Participants will receive cisplatin, 100 mg/m^2 via IV infusion on Day 1 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
46026269|NCT03893617|Drug|Placebo oral capsule|A single blinded capsule containing no active medication will be administered at the start of the baseline monitoring period of the acute stress study visit.
46113966|NCT02594904|Drug|Yinzhihuang Oral Liquid|All the four groups will be given same treatment as being described in arm description.
46113967|NCT02605070|Drug|Bravelle|"Bravelle will be provided to all patients in the treatment group by the principal investigator (PI) or another member of the research team.~From week nine on, the patients will undergo a physical examination on three different occasions to assess the appearance of any adverse reactions during treatment. It will be up to the patient to communicate the appearance of signs or symptoms which could be associated with the use of the drug.~At week 12 the patient will be scheduled for another visit to perform a semen study and to measure new hormone levels. To this end, a blood test will be carried out (FSH, LH, estradiol, total testosterone, SHBG, and albumin to calculate the amount of bioavailable testosterone). A semen sample will also be obtained to carry out a spermiogram according to WHO guidelines; part of this sample will be used for epigenetic analysis."
46113968|NCT04041791|Drug|Benzyl penicillin|Benzyl penicillin is a penicillin antibiotic.
46113969|NCT04041791|Drug|Gentamicin Sulfate|Gentamicin is an aminoglycoside antibiotic.
46113970|NCT04041791|Drug|Ceftriaxone|Ceftriaxone is a third generation cephalosporin antibiotic active against a wide range of gram negative and positive bacteria.
46113971|NCT04041791|Drug|Amoxicillin Clavulanate|Amoxicillin Clavulanate is a combination of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor.
46113972|NCT04041791|Other|Intravenous fluid|Maintenance fluids administered for at least 24 hours.
46113973|NCT04041791|Other|Nasogastric feeds|Feeds given via nasogastric tube. Feeds may include cow's milk, breast milk, porridge, formula among others.
46113974|NCT04041791|Drug|Ampicillin|Ampicillin is a penicillin-type antibiotic.
46113975|NCT05572502|Behavioral|plant-based diet|For the duration of the study, this arm will: follow a low-fat vegan diet; weigh themselves weekly, and get fasting bloodwork before, during and after the study
46113976|NCT02605226|Procedure|Cryoablation therapy|Cryoablation therapy
46113977|NCT02605226|Radiation|External beam radiation therapy|External beam radiation therapy
46113978|NCT02605226|Drug|bicalutamide|bicalutamide
46113979|NCT02605226|Drug|luteinizing-hormone releasing-hormone (LHRH) agonist|luteinizing-hormone releasing-hormone (LHRH) agonist
46113980|NCT05571878|Drug|Humalog|All participants will be given an intranasal insulin challenge (80 IU) to assess brain insulin signalling via MRI based assay
46113981|NCT05571878|Drug|Saline nasal spray|All participants will be given an intranasal saline placebo (0.8 mL) in order to establish baseline brain insulin signalling via MRI based assay
46113982|NCT04033367|Drug|Dupilumab|Pharmaceutical form: solution for injection Route of administration: subcutaneous
46113983|NCT04033367|Drug|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
46113984|NCT00733980|Drug|GSK561679|GSK561679
46113985|NCT00733980|Other|Placebo|Placebo
46113986|NCT05755295|Other|horse therapy|equitherapy and hippotherapy once a week during 16 weeks
46113987|NCT04088448|Drug|Placebo oral tablet|Fluoxetine 20 mg capsule plus Placebo tablet administered once daily after food
46113988|NCT04088448|Drug|Metformin|Fluoxetine 20 mg capsule plus Metformin 1000 mg extended release tablet administered once daily after food
46113989|NCT00806585|Drug|MK-0736|
46113990|NCT00806585|Drug|Comparator: Placebo|
46113991|NCT00806585|Drug|Comparator: HCTZ|
46113992|NCT02607761|Other|Video|Video-Audio Media
46026270|NCT03893617|Behavioral|Acute stress task|Participants will complete speech and arithmetic tasks, performed in front of an audience (e.g., researcher staff members) and recorded by a video camera to assess non-verbal behaviors and evaluate performance. The task will be initiated following completion of baseline sample collection during the acute stress study visit and will take approximately 15 minutes.
46113993|NCT05740553|Device|ReTrieve Automated Stereognosis System|An automated tactile training system that may help patients recover lost tactile function after brain injury.
46113994|NCT05753111|Dietary Supplement|PEA|PEA supplementation
46113995|NCT05753111|Dietary Supplement|PLACEBO|Maltodextrin supplementation
46113996|NCT00480025|Biological|GSK1572932A Antigen-Specific Cancer Immunotherapeutic|Intramuscular administration, 13 doses
46113997|NCT00480025|Biological|Placebo Control|Intramuscular administration, 13 doses
46026271|NCT03893617|Behavioral|No stress task|Participants will sit quietly for 5 minutes, read a short passage aloud for 5 minutes, and read a list of numbers aloud for 5 minutes. The task will be initiated following completion of baseline sample collection during the no stress study visit and will take approximately 15 minutes.
46113998|NCT00806351|Drug|Active Anidulafungin|Subjects in this arm will receive active anidulafungin and placebo caspofungin
46113999|NCT00806351|Drug|Active Caspofungin|Subjects in this arm will receive active caspofungin and placebo anidulafungin
46114000|NCT03589963|Behavioral|Postnatal Lactation Support|In-home breastfeeding support delivered by professional lactation consultants and provision of a high-quality breast pump
46114001|NCT03995251|Drug|Testosterone Supplementation|Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations
46114002|NCT03995251|Drug|Standard Medical Treatment|Standard Medical Treatment
46114003|NCT03995251|Other|Exercise|Exercise
46114004|NCT02606825|Other|Registry of AML patients > 60 years|
46114005|NCT01031017|Drug|progesterone|ovules, 200mg per vagina, once a day from 18 weeks
46114006|NCT01031017|Drug|placebo|placebo
46114007|NCT03635177|Procedure|Remote ischemic conditioning|Four weeks of daily ischemic conditioning and four weeks of sham ischemic conditioning in a cross over design
45470319|NCT01322659|Device|Endotracheal tube|Weaning from mechanical ventilation with invasive mechanical ventilation delivered by means of the endotracheal tube
46114008|NCT03742531|Drug|oxytocin|one group will be treated with low dose oxytocin and the other group will be treated with high dose oxytocin for augmentation of labor induction.
46114009|NCT05738135|Drug|Aminophylline group|Patients will receive 4 mg/kg aminophylline diluted in 50 ml normal saline over 30 minutes.
46114010|NCT05738135|Drug|normal saline|Patients will receive 50 ml normal saline over 30 minutes.
46114011|NCT00733902|Biological|tanezumab|IV tanezumab 10 mg at 1 dose every 8 weeks
46114012|NCT00733902|Biological|tanezumab|IV tanezumab 5 mg at 1 dose every 8 weeks
46114013|NCT00733902|Biological|tanezumab|IV tanezumab 2.5 mg at 1 dose every 8 weeks
46114014|NCT00733902|Biological|Placebo|IV placebo to match tanezumab at 1 dose every 8 weeks
46114015|NCT01027741|Behavioral|Phone Referral|Participants receive phone referral to cancer control and prevention services.
46114016|NCT01027741|Behavioral|Tailored Cancer Communication|Mailed material with messages tailored to participant's age, gender, race/ethnicity, whether he or she has kids in the home, reason for calling 211, and cancer control need.
46114017|NCT01027741|Behavioral|Cancer Control Navigator|A cancer control navigator is assigned to each participant. This navigator helps the participant make and keep cancer control and prevention appointments, as well as providing resources and guidance to help address participant barriers to use of needed cancer control and prevention services. Intervention is phone-based.
46114018|NCT05737355|Dietary Supplement|ANKASCIN 568-P Red yeast rice capsules|Product ingredients: ANKASCIN 568-P red yeast rice product 440 mg,microcrystalline ,cellulose,Maltodextrin; capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
46114019|NCT05737355|Dietary Supplement|Placebo Capsules|Maltodextrin was used as a placebo
46026272|NCT02759263|Behavioral|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will receive a link for downloading a web-based software program. The program will be installed on a computer at a family's home by a research assistant. Parents and adolescents will be actively involved, and during the installation session, adolescents will complete several practice trials. The 25 sessions will be completed individually by the adolescent with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the adolescent can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
45838814|NCT04358796|Device|Control hyperbaric oxygen treatment|Subjects will enter the oxygen chamber. ATA will be elevated to 1.2 ATA for a short while and the decreased back to 1 ATA. They will breath air while solving cognitive tests designed to assess their cognitive capacities
46026273|NCT02749825|Drug|Trelstar|As labeled
46114020|NCT00914225|Other|Bednets and Water Purification|Individuals in the intervention cohort will be provided with a LLIN and water filtration device. Subjects are followed for 24 months and have serial measurements of HIV disease progression. Data are collected every 3 months on the frequency of malaria, diarrhea and other co-morbidities, as well as compliance with LLIN and water filter use.
46026274|NCT02749825|Drug|Lupron|As labeled
46114021|NCT02608541|Other|rib fracture fixation|Use of MatrixRib, where indicated, according to departmental protocol
46026275|NCT02749825|Drug|Zoladex|As labeled
46026276|NCT02759107|Drug|LY3298176|Administered SC
46026277|NCT02759107|Drug|Placebo|Administered SC
46026278|NCT02759107|Drug|Dulaglutide|Administered SC
46114022|NCT00914381|Behavioral|Behavioral therapy|
46026279|NCT04412629|Drug|Cabozantinib|Cabozantinib should be taken on an empty stomach (at least 1 hour before or 2 hours after eating) at the same time every day.
46114023|NCT04008173|Other|Non-interventional patient registry|Non-interventional patient registry
46114024|NCT04002167|Behavioral|Neurofeedback|The Neurofeedback group will receive the proposed intervention which integrates computerized working memory training with neuromonitoring and neurofeedback.
46114025|NCT04002167|Behavioral|Cognitive training|The Cognitive training group will receive computerized working memory training with performance feedback.
46114026|NCT02607527|Device|Mitral Valve IRIS Ring|Transcatheter implantation of the IRIS
46114027|NCT05714033|Procedure|Ventilatory Strategy To Prevent Atelectasis|Given
46114028|NCT05714033|Procedure|Lateral Decubitus Strategy (LADS)|Given
46114029|NCT03540017|Drug|Cisplatin|Heated Intraperitoneal Chemotherapy will be administered after the completion of interval cytoreductive surgery after three cycles of neoadjuvant chemotherapy.
45838815|NCT04358718|Procedure|general anesthesia|Patients will receive intraoperative and postoperative intravenous opioid-based analgesia for robot-assisted laparoscopic radical cystectomy.
45838816|NCT04358718|Procedure|general anesthesia combined with epidural analgesia|Patients will receive epidural ropivacaine-based analgesia for robot-assisted laparoscopic radical cystectomy.
46026280|NCT04412629|Procedure|Blood for plasma biomarkers|Baseline, cycle 1 day 8, cycle 1 day 15, and day 1 of every cycle thereafter
46026281|NCT04412629|Procedure|Tissue biopsy|Baseline, before start of cycle 2, and time of progression
46026282|NCT02758873|Genetic|Personalised medicine (Salmeterol)|If participants require add-on medication and have the Gly/Gly variant on the ADRB2, salmeterol will be prescribed.
46114030|NCT05753033|Drug|SR750 tablet|Ascending single and multiple doses of SR750 orally
46114031|NCT05753033|Drug|Placebo|Ascending single and multiple doses of placebo orally
46114032|NCT02606747|Other||routine blood sugar control
45838817|NCT04358562|Drug|Gefitinib|If persistence of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
45838818|NCT04358562|Drug|Anlotinib|If clearance of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
46026283|NCT02758873|Genetic|Personalised medicine (Montelukast)|If participants require add-on medication and have the Arg/Arg or Arg/Gly variant on the ADRB2, montelukast will be prescribed.
46114033|NCT02606981|Device|Water chlorination by the Flogenic|The chlorine doser delivers a constant amount of chlorine into water as it flows into a holding tank. The water is then piped to public and private taps.
46114034|NCT02606981|Device|Active control, vitamin C dosing into water|The control group will receive a vitamin C dosing device that looks identical to the intervention chlorine doser installed in the holding tank that feeds their shared water access point.
46114035|NCT02606435|Procedure|percutaneous coronary intervention (PCI)|percutaneous coronary intervention (PCI) by stent implantation
46114036|NCT02606435|Device|thrombus aspiration|thrombus aspiration with export catheter
46114037|NCT03519347|Other|Potassium Removal Maximization|This intervention will test whether prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia reduces the incidence of clinically significant arrhythmias compared to an approach minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.
45470320|NCT05239390|Drug|SCI -110|"Dronabinol - Manufactured by Pharmaceutics International, Inc., Hunt Valley, MD 21031, USA. Dronabinol Capsules (dronabinol solution in sesame oil in soft gelatin capsules) are 2.5 mg - cream, oblong, soft-gel capsules. In an NDC 49884-867-02 Bottle of 60 capsules packaged in a well-closed container and stored in a locked refrigerator, 2° to 8°C. Protect from freezing, in accordance with the Israeli legal requirements (Israel Narcotic Drugs Act). Storage conditions should be monitored on a daily basis.~PEA - Manufactured by Pharmacies Inc. 767 Front st. Suite 202. Catasauqua, PA 18032 www.pharmacures.com. 1-888-334-3130. 400 mg PEA tablets, in a 60 mL barrier bottle, 30/400 mm, Bottle of 30 capsules packaged in a well-closed container and stored in RT (20° to 25°C). Storage conditions should be monitored on a daily basis."
45838819|NCT04358094|Other|Conversational hypnosis script|Conversational hypnosis during peripherical veinous catheter set up
46114038|NCT03519347|Other|Potassium Gradient Minimization|This intervention will test whether minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients reduces the incidence of clinically significant arrhythmias compared to an approach prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.
46114039|NCT03519347|Other|Alkalosis Avoidance|The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing alkalosis avoidance by use of lower dialysate HCO3 concentrations.
46114040|NCT03519347|Other|Acidosis avoidance|The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing acidosis avoidance by use of higher dialysate HCO3 concentrations.
46114041|NCT04015349|Diagnostic Test|Polysomnography|The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)
46114042|NCT03518723|Other|Non-linear Periodized Resistance Training|8 week non-linear periodized resistance training intervention, 3 sessions per week, 60 minutes per session
46114043|NCT03518723|Other|Resistance training|8 week resistance training intervention, 3 sessions per week, 60 minutes per session
46114044|NCT05752955|Other|SMARThealth Pregnancy|"At each visit, the CHW will:~Update history and contact details~Check haemoglobin with a point of care device.~Check BP~Check iron folic acid (IFA) supply and compliance~Brief screen for mental health problems~An electronic decision support platform will provide advice if referral is needed. At the Primary Health Centre, doctor/s will be issued a tablet computer with a version of the SMARThealth Pregnancy App to:~Generate an automated list of all patients in the community who require review, with the dates of testing and referral, and with two-way communication back to the CHW.~Suggest management based on current Indian guidelines for the diagnosis and management of anaemia, hypertension and diabetes in pregnant and non-pregnant adults."
46114045|NCT00790790|Drug|Placebo|LY545694 placebo BID po for 5 weeks
46114046|NCT00790790|Drug|LY545694 49 mg|LY545694 49 mg BID po for 5 weeks.
46114047|NCT00790790|Drug|LY545694 105 mg|LY545694 105 mg BID po for 5 weeks.
45470321|NCT03752437|Diagnostic Test|ACT (Activated Clotting Time)|Measure of ACT in the two arms in order to determine if injection of heparin based on ideal weight is better or not than those one on real weight.
46114048|NCT02602964|Other|Deep neuromsucular block|Deep or standard neuromuscular block
45681869|NCT03582592|Behavioral|Fluid Distribution Timetable|It is a scheduled distribution of pre-determined amounts of fluid intake on a daily basis depicted via a 5x6 table. The timetable includes three major columns. The first column has six timepoints of a day with a four-hour interval. The second column, which was further divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intakes in a day, usual level of activity, time of medication intake, and common time they encounter thirst in a day. Lastly, the third column indicates the converted percentages of fluid allotment in milliliters.
45838820|NCT04358094|Other|Standard script|Standard script during peripherical veinous catheter set up
46026284|NCT02758873|Other|Standard care|If participants require add-on medication in the arm, they will be prescribed either salmeterol or montelukast according to health professional's choice based on current guidelines.
46026285|NCT02749747|Drug|Sulpiride use|50mg sulpiride once a day use for 60 days
46114049|NCT00914888|Drug|Tigecycline|"Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered."
45470322|NCT03752437|Drug|Heparin|300 IU of heparin
46026286|NCT02749747|Drug|Placebo|50mg placebo once a day use for 60 days
46026287|NCT02749591|Drug|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity upper extremity for stroke patients.Doses and muscles selected for BoNT-A injection are individualized on the basis of a number of factors, including the spasticity patterns, severity of spasticity, and treatment goals
46114050|NCT00914888|Drug|Tigecycline|"Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
46026288|NCT02749591|Other|Robot-assisted therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the RT group will receive a 45 minutes of robotic training and 30 minutes of training in functional training.
46114051|NCT00914888|Drug|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|"Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given."
46114052|NCT00914888|Drug|CAP: Ceftriaxone, plus if applicable oral clarithromycin|"Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
46114053|NCT02603198|Drug|mepivacaine chloridrato epinephrine|local anesthesia for tooth removal
46114054|NCT02603198|Drug|mepivacaine chloridrato levonordefrin|local anesthesia for tooth removal
46114055|NCT04105790|Behavioral|Cognitive Behavioural Therapy with Mindfulness classes|The standard CBTm protocol is comprised of four 90-minute classes offered virtually via videoconferencing once a week for four consecutive weeks. The classes cover topics including mindfulness, cognitive therapy principles, behaviour therapy principles, managing anger, assertiveness, problem solving, goal setting, and evidence-based self-help resources. They are lecture-based but also involve experiential elements, such as mindfulness activities and practice of cognitive therapy strategies. Participants are assigned daily homework between each class to practice the strategies taught in session.
46114056|NCT02602886|Behavioral|Exposure and Response Prevention Therapy|The treatment includes both therapist-supervised and self-controlled exposure and ritual prevention exercises. 2 sessions per week, up to 15 sessions in total. Session time is 90 minutes. The majority of in-session time is spent conducting in vivo exposures. When engaging in E/RP tasks, patients are instructed to refrain from ritual engagement. Between-session homework is given the patient practicing the within-session E/RP task up to 90 minutes each day. Clinicians supplement E/RP with other cognitive-behavioral interventions including motivational strategies for resistant patients, Socratic dialogue, and behavioral experiments to test the validity of erroneous cognitions.
46114057|NCT04105478|Procedure|Shoulder arthroplasty|Patients suffering from severe glenohumeral osteoarthritis are treated surgically by a total shoulder arthroplasty
46114058|NCT04105322|Other|Kinesio Taping|The kinesio tape is adhesive and it does not contain drug substance. After the patients were randomized to the groups, kinesio tape will be applied to the relevant region.
46026289|NCT02749591|Other|Mirror therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
46026290|NCT02749591|Other|Control intervention|After injecting Botulinum toxin type A on the spasticity upper extremity, the CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
46026291|NCT04467853|Biological|LCAR-C18S cells|Before treatment with LCAR-C18S cells, subjects will receive a conditioning regimen
46026292|NCT04460833|Device|Feedback modalities given through an augmented reality headset|All children wear the augmented reality headset. After a habituation period to the holograms, they start the protocol. It consists of a warm-up session, training session (which three feedback modalities are presented), calibration session (to get the maximal speed and spontaneous speed of the child), and test session. During test session, all the children walk on the 30m corridor. They have 6 feedback modalities + the control, given randomly. On the way out, they have to walk fast as possible ; on the return they have to walk at intermediate speed.
46026293|NCT04359979|Drug|Tamsulosin|selective alpha1 receptor antagonist
46026294|NCT04218955|Combination Product|Silver Diamine Flouride|Material used to arrest caries in children
46114059|NCT00719043|Biological|A/turkey H5N1 vaccine|Administered as an intramuscular (IM) injection
46114060|NCT00719043|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|Administered as an intramuscular (IM) injection
45470323|NCT05239312|Drug|Antimicrobial|Implementation of antimicrobial protocol for empirical treatment which will be done according to the results of antibiotic susceptibility
45598593|NCT02348073|Drug|Vayarin®, supplementation of n-3 PUFA|"Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.~At the end of this period, active product will be continued, at the same dose, for a 12 week-open label period. All patients will be administered the active product."
46026295|NCT04180813|Drug|Linagliptin|drug
46026296|NCT04180813|Drug|Acarbose|drug
46026297|NCT04221607|Other|Sensate Focus exercise|Structured exercise to enhance intimacy
46026298|NCT04148443|Other|Preoxygenation|participants will receive 3 minutes of preoxygenation before intubation
46026299|NCT04148443|Other|Preoxygenation (longer)|participants will receive 5 minutes of preoxygenation before intubation
46114061|NCT00719043|Biological|Placebo|Administered as an intramuscular (IM) injection
46114062|NCT04105166|Biological|RP-L301|Autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKD gene
46114063|NCT00786422|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 30 mg rivaroxaban bid (twice-daily) orally for the first 3 weeks followed by 20 mg rivaroxaban bid for the remainder of the 3-month treatment period.
46114064|NCT00718887|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily (QD), 52 weeks
46114065|NCT00718887|Drug|Adefovir/Entecavir|Tablets, Oral, 10-mg adefovir QD for 12 weeks followed by 0.5-mg entecavir QD for a maximum of 52 weeks
46114066|NCT00786188|Drug|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive Brisdelle™ (paroxetine mesylate) Capsules 7.5 mg.
46114067|NCT00786188|Drug|Sugar pill|Subjects will receive a sugar pill.
46114068|NCT00790556|Drug|MK8245|MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
46114069|NCT00790556|Drug|Comparator: Placebo|MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
46114070|NCT04112732|Dietary Supplement|Multivitamin|Multivitamin
46026300|NCT04116775|Biological|Fecal microbiota transplant|A total of 100 mL of a mixture of stool and saline will be transplanted via endoscopy once.
46114071|NCT04112732|Other|Placebo|Placebo
45598594|NCT02348073|Drug|PLACEBO|Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.
46026301|NCT04116775|Drug|Pembrolizumab|Pembrolizumab 200 mg administered as a 30 minute infusion every 3 weeks.
46026302|NCT04116775|Drug|Enzalutamide|Daily oral dose.
46114072|NCT00733824|Drug|AMD3100|
46114073|NCT00733824|Drug|G-CSF|
46114074|NCT00733824|Procedure|Apheresis|
46114075|NCT00718809|Drug|saracatinib|Given orally
46114076|NCT04086069|Device|Sit-to-stand trainer|The sit-to-stand trainer device is an exoskeleton that enables standing-up movement resembling the movement of a healthy person. It consists of three sub-systems: a foldable chair, a lever for body orientation and a triggering mechanism. It includes a support for feet with adjustable height. The device offers partial support to the patient while standing up. The patient will exercise with the device for 10 sessions (one per day), standing up for up to 30 times per session.
46114077|NCT00585039|Drug|xopenex|will receive xopenex rather than albuterol to treat acute exacerbation
46114078|NCT04085913|Drug|Lidocaine Epinephrine|Preincision injection, as is current practice
46114079|NCT04085913|Drug|Bupivacaine Hydrochloride-EPINEPHrine|Preincision injection
45681870|NCT03582358|Other|Food weighing|Quantification of food intake over three consecutive days (D5, D6 and D7 then D26, D27 and D28) by weighing the food served and the leftovers at and after mealtimes.
45681871|NCT05701540|Drug|Tegoprazan|Tegoprazan 50mg tablet
46026303|NCT04172857|Procedure|anterior vitrectomy combined with hyaloidotomy, zonulectomy and iridectomy|First, a 23-G incision was made at the peripheral inferior temporal sector of the cornea and connected with an anterior chamber infusion cannula. Another corneal incision was made at the superior temporal sector or superior nasal sector, and Viscoat® (Bausch & Lomb, Shandong, China) was infused though the incision to fill the anterior chamber. Iridotomy was performed through the incision using Wescott scissors and toothed forceps. Hyaloidectomy and zonulectomy were performed through a peripheral iris defect using an anterior chamber approach to set up a pathway between the anterior chamber and the vitreous cavity. We repeatedly carried out vitrectomy around the pathway to reduce the risk of postoperative re-obstruction of the tunnel created.
46114080|NCT04085913|Drug|Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine|Preincison injection of lidocaine and epinephrine and a postincision injection of Exparel
46114081|NCT00806195|Biological|MenACWY-CRM197|Four 0.5mL vaccinations of MenACWY-CRM197 conjugate vaccine was administered by intramuscular injection at 2, 4, 6 and 12 months of age.
46114082|NCT00806195|Biological|DTaP (Diptheria, Tetanus, Pertussis) Vaccine|Four vaccinations of DTaP (Diptheria, Tetanus, Pertussis) was administered at 2, 4, 6, and 15 months of age.
46114083|NCT00806195|Biological|Hib (Haemophilus influenza b) Vaccine|Four vaccinations of Hib (Haemophilus influenza b) vaccine was administered at 2, 4, 6 and 15 months of age.
46114084|NCT00806195|Biological|IPV (Inactivated Polio Vaccine) Vaccine|Three vaccinations of IPV (Inactivated Polio Vaccine) was administered at 2, 4, and 6 months of age.
46114085|NCT00806195|Biological|Pneumococcal conjugate Vaccine|Four vaccinations of Pneumococcal conjugate vaccine was administered at 2, 4, 6 and 12 months of age.
46114086|NCT00806195|Biological|MMR (Measles, Mumps, and Rubella) Vaccine|One vaccination of MMR (Measles, Mumps, and Rubella) was administered at 12 months of age.
46114087|NCT00806195|Biological|Varicella Vaccine|One vaccination of Varicella vaccine was administered at 12 months of age.
46114088|NCT00806195|Biological|Hepatitis A Virus|One vaccination of Hepatitis A Virus vaccine was administered at 12 months of age.
45598595|NCT02223767|Device|Experimental: Verum TMS|Intensity of 100 % of the resting motor threshold with 10 Hz and ITI of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
45681872|NCT05701540|Drug|Esomeprazole|"Esomeprazole 20mg tablet~For patients with ERD: two Esomeprazole 20mg tablets~For patients with NERD: one Esomeprazole 20mg tablet"
45681873|NCT03159598|Device|Tissue Glu|Once adequate hemostasis has been achieved during surgery and the abdominal fascia and flaps have been irrigated, Tissue Glu will be applied. Tissue Glu is applied at approximately one centimeter intervals while remaining one centimeter away from the umbilicus and inferior incisions.
45838821|NCT04358484|Behavioral|Incredible Years - ASD and Language Delay®|"The IY - ASLD Program will consist of 22 weekly online group sessions for parents of children between 2-5 years of age with symptoms or a diagnosis of ASD or delayed language acquisition. The program will be conducted by a therapist and a co-therapist, trained in the model.~Fidelity to the intervention will be assessed in accordance with the regulations of the program. All of the therapists and co-therapists will be trained in the intervention by accredited trainers. The three main therapists will be supervised by accredited supervisors of the IY Program, seeking accreditation in the intervention. As the intervention IY - ASLD has not been translated into Spanish, the English materials will be used with simultaneous translation into Spanish language."
46026304|NCT02749435|Other|Use of digital disease management tool in participants with T2DM|The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control. The impact of the tool will be assessed in comparison to a Control group who will receive standard care alone. All participants will complete the PRO assessments. This is a real-world study carried out at the point of care intended to assist health care practitioners and managed care providers to make evidence-based decisions about how to improve participant self-management of their diabetes.
46026305|NCT04217083|Diagnostic Test|Breath sampling|The alveolar fraction of Colorectal cancer patients and Healthy controls will be sampled using a breath sampler able to fix the volatile organic compound on absorbable tubes
46026306|NCT04216849|Biological|human umbilical cord mesenchymal stem cells|human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
46026307|NCT04216849|Other|saline|Saline solution containing human serum albumin will be infused to the control group
46026308|NCT02749357|Device|30 minutes Lokomat|"30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 30 minutes.~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen (20). The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
46026309|NCT02749357|Device|60 minutes Lokomat|30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 60 minutes.
46026310|NCT03933553|Other|Aromatherapy with essential oil|the aromatherapy by fragrance inhalation
46114089|NCT02922335|Behavioral|Multisystemic Therapy for Emerging Adults|MST-EA is a home-based therapy in which therapists work closely with each young adult. Therapists often also work with the young person's family, as appropriate. MST-EA is designed to help young people work on their own behavior. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
46114090|NCT02922335|Behavioral|Enhanced Treatment as Usual|Standard services that a young person would receive if they have been in trouble with the law and also have a mental illness.
46114091|NCT05752877|Biological|Targeted IL-13 Rα2 UCAR-T cell injection|local administration (intracranial cavity or intravertebral injection after surgery): 1 ampoule (about 2-5 ml, 1-5×10^7 cells) for 1-2 minutes each time.
46114092|NCT05752877|Biological|Targeted B7-H3 UCAR-T cell injection|local administration (intracranial cavity or intravertebral injection after surgery): 1 ampoule (about 2-5 ml, 1-5×10^7 cells) for 1-2 minutes each time.
46114093|NCT03462329|Drug|Antibiotics (preferentially oral doxycycline 100 mg bid)|Patients will be treated with antibiotics for Lyme disease.
46114094|NCT05728151|Drug|Articaine and Epinephrine Only Product|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
45681874|NCT03159598|Device|Drain|Drains will be placed during surgery to allow for the drainage of seroma which may develop after surgery
45838822|NCT04358172|Other|'Oral and Denture Guide' mobile application|'Oral and Denture Guide' mobile application provides evidence-based information about cleaning aids and material for dentures, denture care and oral hygiene instructions.
45838823|NCT04357860|Drug|Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Best available treatment up to 14 days plus Sarilumab 200 mg
45838824|NCT04357860|Drug|Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Best available treatment up to 14 days plus Sarilumab 400 mg
46114095|NCT05728151|Drug|levobupivacaine|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
46114096|NCT05728151|Drug|mepivacaine|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and in peribulbar block on postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
46114097|NCT02919137|Other|Visible light exposure|Subjects will be exposed to visible colored light for 45 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
46114098|NCT00733746|Drug|erlotinib hydrochloride|oral administration
46114099|NCT00733746|Drug|gemcitabine hydrochloride|Intravenous administration
46114100|NCT00733746|Procedure|therapeutic conventional surgery|
46114101|NCT04028375|Other|No intervention|No intervention
46114102|NCT03422705|Device|Optimised programming|Optimised programming to avoid RV pacing when possible.
46114103|NCT03422705|Drug|Lisinopril|Uptitration of lisinopril
46114104|NCT03422705|Other|Standard care|No pacemaker adjustment or medical therapy
45681875|NCT03159598|Other|Questionnaires|Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers
46026311|NCT02758561|Behavioral|Workshop|"The first 15 minutes will be an information session on either Urinary Incontinence (UI) or Pelvic Organ Prolapse (PO) led by a Nurse Continence Advisor.~The following 60 minutes will comprise a psychologist-led group discussion. The structured discussion will encourage participants to share experiences, thoughts, and feelings on pelvic floor disorders. Resistances and barriers to seeking treatment will be discussed. Decision-making processes will be explored.~During the final 15 minutes, participants will be asked to complete a survey to evaluate the workshop. The survey will assess satisfaction with the information provided, quality of group discussion, comfort level with the group experience, and their satisfaction with the roles of the nurse continence advisor and psychologist."
46026312|NCT03913741|Drug|tisotumab vedotin|Tisotumab vedotin will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial
46026313|NCT02758639|Behavioral|Wonders & Worries Psychosocial Intervention|Session 1: Getting to Know Each Other The goal is to create a sense of safety within the group so that the children feel comfortable discussing difficult topics. Session 2: Cancer Education to provide developmentally appropriate education about the illness, treatment, and side effects. Session 3: Cancer Treatment Center Tour: This session consists of a treatment center tour and education about treatment plan involved in family's care in a safe environment. Session 4: Feelings: The focus of this session is expression and validation of all feelings the children may experience. Session 5: Stress and Coping: Goal is to emphasize the different ways individuals cope and differentiate positive vs. negative coping strategies. Session 6: Hopes for the Future/Closure: An emphasis is made on the idea that positive things may evolve from the most difficult circumstances.
46114105|NCT00918216|Genetic|fluorescence in situ hybridization|Additional histochemical, immunohistochemical, and fluorescence in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
45838825|NCT04357860|Drug|Best available treatment|Best available treatment up to 14 days
46026314|NCT02749669|Other|Qualitative research|Semi-structured Interviews
46026315|NCT02758795|Dietary Supplement|CONTROL|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
46026316|NCT02758795|Dietary Supplement|NUTRIENT|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
46026317|NCT02749123|Drug|lidocaine 5% patch|10cmx 14 cm transdermal patch sealed in its own pouch
46026318|NCT02749123|Drug|lidocaine 3.6%, menthol 1.25%|10cmx 14 cm transdermal patch sealed in its own pouch
46026319|NCT02749123|Drug|Placebo|patch with no active manufactured to have the same look and feel as Lidoderm 10cmx 14 cm transdermal patch sealed in its own pouch
46026320|NCT02758483|Other|Control diet|Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).
46026321|NCT02758483|Other|Test Diet|Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).
46026322|NCT04172545|Procedure|stapling|staples are fired through the gastric wall after waiting several seconds for compression without attention to blood pressure, fluids given or intra abdominal pressure, but these might have an impact on quality of stapling. therefore the conditions during stapling will be recorded during stapling.
46026323|NCT04218253|Dietary Supplement|300 calories or 500 calories nutrient rich in branched chain amino acids and dietary fiber|300 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for Mild malnutrition, or 500 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for moderate to severe malnutrition. The degree of malnutrition is determined by Patient-Generated Subjective Global Assessment (PG-SGA).
46026324|NCT04218253|Behavioral|Dietary mission|Dietary education was conducted according to preoperative nutritional requirements
46026325|NCT02748811|Other|Intervention group|The intervention group also receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change of treatment or progression. The participants will simultaneously receive full geriatric assessement and intervention. The clinical examination includes laboratory parameters, review of medication list, psycho-cognitive assessement, screening for malnutrition and need of physiotherapy, optimizing social support. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
46114106|NCT00918216|Other|immunohistochemistry staining method|Additional histochemical, immunohistochemical, and fluorescence in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
46114107|NCT00918216|Other|medical chart review|Patients' medical charts are reviewed to obtain clinical information
46114108|NCT00918216|Procedure|fluorescence spectroscopy|The freshly excised breast tissue samples are analyzed ex vivo by fluorescence, reflectance, and/or Raman spectroscopy.
46114109|NCT00918216|Procedure|histopathologic examination|Hematoxylin and eosin stained sections of the tissue samples are examined by light microscopy for histopathological analysis.
46114110|NCT00918216|Procedure|light-scattering spectroscopy|The freshly excised breast tissue samples are analyzed ex vivo by fluorescence, reflectance, and/or Raman spectroscopy.
46114111|NCT02607293|Drug|Gonal-f®|Recombinant human follicle stimulating hormone (r-FSH) will be administered subcutaneously (SC) for about 10 to 20 days along with the ART regimen as routinely practiced by Investigators and according to licensed summary of product characteristics (SmPC label) for the ovarian stimulation.
46114112|NCT02607293|Drug|Long GnRH agonist|As a part of the ART regimen GnRH-agonist will be administered for about 14 to 20 days until down regulation is satisfied as judged by investigator.
45838826|NCT04358016|Drug|Terlipressin|Evaluate the effect of Terlipression on the occurance of acute kidney injury in patients with upper-gastroentestinal bleeding
45838827|NCT04358016|Drug|Somatostatin|Somatostatin
45838828|NCT04357548|Device|FEEDBACK|Once the sample was selected, a test was performed in which the professionals performed 2 minutes of CPR on the dummy without any feedback system, after 5 minutes they performed 2 minutes of CPR with feedback system through the Zoll® monitor with CPR patch -D padz training, to later compare the pretest-posttest results.
46114113|NCT02607293|Drug|GnRH antagonist|As a part of ART regimen GnRH-antagonist will be initiated and regimen will be as routinely practiced by Investigators and according to licensed SmPC label.
45470324|NCT03757273|Procedure|FFF with CAD/CAM customized cutting guide|This began with the acquisition of a high-resolution CT scan of the craniofacial skeleton and lower legs. the CT scan will be sent to the modeling company for producing autoclavable 3D models and cutting guides of the mandible and fibula to be used during the workflow as well as a model of the final reconstructed mandible. Surgery will be performed by two surgical teams, one for cervicofacial resection and the other harvesting the flap. access to the mandible is obtained, osteotomy guides secured; cuts then accomplished as planned virtually. fibular flap is harvested and cutting guides secured to replicate osteotomies and reshaping as planned to conform with remaining mandible. fixation and pedicle anastomosis is performed. Finally, the operation completed with soft tissue reconstruction.
46114114|NCT02607371|Other|VKAs|VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
46026326|NCT02748733|Other|Adapted double mini PET|The modified double mini PET mimics the treatment of adapted PD and thus allows its validation
46026327|NCT02748733|Other|Standard double mini PET|The standard double mini PET reflects the routine PD treatment in children and is used for standardized comparison
46026328|NCT02748967|Drug|ExPEC4V|Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.
46114115|NCT02607371|Other|NOACs including Rivaroxaban (Xarelto, BAY59-7939)|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
46114116|NCT02607371|Other|Edoxaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
46114117|NCT02607371|Other|Apixaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
46114118|NCT02607371|Other|Dabigatran-etexilate|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
46114119|NCT00718419|Drug|Enzastaurin|"Enzastaurin: Cycle 1 Day 1 only: 3, 125-milligrams (mg) tablets three times on Day 1 (Day 1 total dose = 1125 mg)~Day 2 onwards and subsequent Cycles: 2, 125-mg tablets orally twice a day (500 mg total per day).~Cycle length (all cycles): 28 days. Patients may stay on drug past 8 cycles, (until the study is closed) or until disease progression."
46114120|NCT02590965|Drug|Fruquintinib|After checking eligibility criteria, subjects will be randomized into Fruquintinib plus best supportive care group (treatment group) or placebo plus best supportive care group (control group) in a ration of 2:1.
46114121|NCT02590965|Drug|Placebo|Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/1 week off
46114122|NCT02591043|Procedure|Outcome after surgery|Functional outcome after surgical treatment of pelvic ring fractures Measurements: TUG-test score, ADLs index, maximal pain (VAS 1-10) at rest and experienced during TUG-test. One-year mortality, signs of healing, dislocation or other complications on anterior-posterior radiographs of the pelvis, living situation before and after the injury (at home/institutional placement)
46114123|NCT03948711|Device|Near-infrared spectroscopy (NIRS) monitoring of cerebral oxygenation|Monitoring before anesthesia to hospital admission. No treatment decisions made based on monitoring.
46026329|NCT02748967|Drug|Placebo|Participant will receive single dose of Placebo on Day 1.
46026330|NCT02748655|Other|Alkaline ionized water|
46026331|NCT02748655|Other|Tap water|
46026332|NCT00635557|Drug|MPC-6827 + Carboplatin|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Carboplatin at AUC4 administered by intravenous infusion over 1 hour on Day 1 of each 4 week cycle.
46026333|NCT02748499|Other|Healthy Beat Accupunch (HBA) exercise program|HBA has three phases and takes 40 minutes to complete.
46026334|NCT02748499|Other|Control|Participants maintain their daily acitvities.
46026335|NCT02748577|Other|Questionnaires|Before the experimental session, participants will use REDCap to complete several questionnaires used to assess outcomes.
46026336|NCT02748577|Other|Quantitative Sensory Testing (QST) Pain Measurements|Investigators will administer noxious thermal stimulation to assess pain threshold temperatures and assess responses to pain on measures of pain intensity and pain unpleasantness
46026337|NCT02748187|Other|CBASP|Interpersonal psychotherapy for chronic depression
46026338|NCT02748421|Procedure|Lumera Microscope with OCT RESCAN|macular membrane dissection with OCT RESCAN
46114124|NCT04085757|Drug|long interval dinoprostone|A small envelope including two labeled plastic bags (A & B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
46114125|NCT04085757|Drug|short interval dinoprostone|A small envelope including two labeled plastic bags (A& B) (each bag containing either 1 dinoprostone tablet(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
46114126|NCT04085679|Other|Multidisciplinary Mobile Unit (MMU)|MMU is called in case of urgent clinical situations involving patients residing in nursing home
46114127|NCT02590887|Dietary Supplement|Drink manufactured from lupine peptides|Comparison of blood levels of immune, oxidative stress, biochemical markers and haemogram before and after (14, and 28 days) drinking the beverage.
46114128|NCT00717249|Device|galyifilcon A control lens|Marketed daily wear contact lens
46114129|NCT00717249|Device|galyfilcon A with a silver additive|Investigational daily wear contact lens
46114130|NCT00727194|Drug|eculizumab|eculizumab 600 mg IV weekly for 4 doses followed by eculizumab 900 mg IV every two weeks for 7 doses
46114131|NCT00727194|Drug|Placebo|Placebo IV weekly for 4 doses then every two weeks for 7 doses
46114132|NCT00717093|Drug|Varenicline Tartrate|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
46114133|NCT00717093|Drug|Placebo|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
46114134|NCT02592642|Behavioral|Self-management Program, Workbook, Video, Pedometer|Participants will attend 12 sessions over a six week period. The following therapies will be provided by licensed chiropractors: instruction on self-management strategies, cognitive behavioural techniques; exercise instruction, manual therapy. An instructional workbook and video will provide education and instruction on how to perform exercises, and reinforce instructions received during the sessions. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
46114135|NCT02592642|Behavioral|Instructional Workbook, Video, and Pedometer|Participants will attend one session with a chiropractor at the beginning of the six week treatment period. The chiropractor will provide and explain the instructional workbook and video. The workbook and video will provide education and instruction on how to perform exercises all aimed at improving overall fitness in the back and lower extremity and facilitate lumbar flexion. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
45598596|NCT02223767|Device|Experimental: Sham TMS|Sham stimulation with 10 Hz and ITI of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
45681876|NCT01818752|Drug|Carfilzomib|Carfilzomib was administered over 30 minutes on days 1, 2, 8, 9, 22, 23, 29, and 30 for nine 42-day cycles. Carfilzomib 20 mg/m² IV was administered on days 1 and 2 of cycle 1, followed by escalation to 36 mg/m² IV starting on day 8 of cycle 1.
45681877|NCT01818752|Drug|Bortezomib|Bortezomib 1.3 mg/m² was administered as a bolus IV injection or as a subcutaneous injection (per investigator's choice, dose modification, or regulatory approval) on days 1, 4, 8, 11, 22, 25, 29, and 32 of cycles 1 to 4, and on days 1, 8, 22, and 29 of cycles 5 to 9.
46026339|NCT02748421|Procedure|Conventional Microscope|macular membrane dissection without OCT RESCAN
46026340|NCT02748265|Drug|Inhaled Epoprostenol and phenylephrine|After 30 minutes of one-lung ventilation, Epoprostenol 50 ng/kg/min is administered via nebuliser in the anesthesia circuit with phenylephrine administered intravenously
45681878|NCT01818752|Drug|Melphalan|Melphalan 9 mg/m² was taken orally on days 1 to 4 of all cycles.
46026341|NCT02748265|Drug|Sevoflurane|Volatile maintenance anesthesia
46026342|NCT02748265|Drug|Propofol|Intravenous maintenance anesthesia
46026343|NCT01015833|Drug|Doxorubicin Hydrochloride|Given IV
46026344|NCT01015833|Other|Laboratory Biomarker Analysis|Correlative studies
46026345|NCT01015833|Other|Pharmacogenomic Study|Correlative studies
46026346|NCT01015833|Drug|Sorafenib Tosylate|Given PO
46026347|NCT04218175|Other|neuromobilization exercises|Median nerve neuromobilization (stretching and shifting) was performed. For median nerve stretching; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, median nerve stretching was performed by extending the participant's head to the opposite side while flexing the wrist and finger. After waiting for 30 seconds in this position, the wrist and head were moved to the neutral position and the participants relaxed. For median nerve shift; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, the participant flexed his wrist and fingers while lateral flexion of his head to the opposite side, and flexed his wrist and fingers while lateral flexion of the head to the same side.
46026348|NCT03523273|Drug|Liraglutide|Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
46026349|NCT03523273|Drug|Placebo|Placebo administration will match the study drug.
46114136|NCT02592642|Device|Para-spinal TENS|Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal musculature from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine (NeuroTrac TENS from Verity Medical Ltd U.K.) which will be worn by the subject concealed within a waist pouch. The TENS will be programmed for a frequency of 65-100 Hz modulated over 3-second intervals with a pulse width of 100-200 usec, and turned on 2 minutes before the start and during the SPWT. Current intensity will be set to the level of comfort of the patient, approximately 3 milliamps in pilot experiments, and below the level causing muscle twitch.
46114137|NCT02592642|Device|Para-spinal Placebo TENS|Group b: Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal muscular from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine [NeuroTrac TENS from Verity Medical Ltd (U.K.)] which will be worn by the subject concealed within a waist pouch. The TENS will be programmed using a transient placebo frequency and intensity (45) i.e. the unit will be active for the first 30 seconds then ramping down to zero stimulus over 15 seconds and worn from 2 minutes before the start and during the Self-Paced Walk Test (SPWT).
46114138|NCT02592642|Device|Prototype Spinal Stenosis Belt|Participants randomized to this subgroup will be fitted with the prototype spinal stenosis belt by a licensed chiropractor. The belt is designed as garment that will snugly fit over the sacrum and pelvic girdle with a pump that place pressure over the sacrum aimed at reducing lordosis.
46114139|NCT02592642|Device|Sham Spinal Stenosis Belt|Participants randomized to this subgroup will have a standard lumbar support belt (Tensor Adjustable Back Brace from 3M, 207744) fitted around the lumbar spine above the iliac crest comfortably according the manufacturer's instructions for wear. We speculate that the placement of the stenosis belt around the lumbar spine should not have any impact on the lumbar lordosis.
46114140|NCT00716859|Drug|Timolol|Timolol 0.5% dosed twice-daily
46114141|NCT00716859|Drug|latanoprost|Latanoprost 0.005% ophthalmic solution dosed once-daily
46114142|NCT00589121|Drug|Chemotherapy|Up to 6 courses of investigator's choice of neoadjuvant, adjuvant, concurrent, or interdigitated chemotherapy
46114143|NCT00589121|Radiation|Radiation therapy|Preoperative IGRT (3D-CRT or IMRT): If receiving neoadjuvant or adjuvant chemotherapy or no chemotherapy: 50 Gy (2 Gy once a day, 5 times a week). If receiving concurrent or interdigitated chemotherapy: 44 Gy (2 Gy once a day, 5 times a week). Postoperative radiotherapy boost for patients with positive margins following surgery: 16 Gy (2 Gy once a day, 5 times a week) external beam radiation therapy or 16 Gy at ≤ 80 cGy per hour brachytherapy or 3.4 Gy/fraction in 4 fractions brachytherapy or 10-12.5 Gy in a single fraction intraoperative radiation therapy boost.
46114144|NCT00589121|Procedure|Surgery|Resection of the sarcoma with the goal of having negative pathologic margins. Every effort should be made to have limb preservation surgery unless there is documented evidence of tumor progression that would require amputation for an appropriate negative margin resection. All lesions of the extremities should be treated with wide excision.
46114145|NCT00590135|Drug|atorvastatin (Lipitor)|atorvastatin 40 mg by mouth once daily
46114146|NCT03957161|Other|Continuation of ACEi and/or ARBs|Patients will continue or start taking ACEi and/or ARBs
46114147|NCT00589667|Drug|Pemetrexed plus Gemcitabine|"Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle. Vitamin supplementation will be as follows: Vitamin B12: 1000 µg IM injection no less than 1 week prior to the first dose of pemetrexed, and continuing approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.~Folic acid: The preferred oral daily dose of folic acid is 350 to 1000 µg. Daily folate supplementation begins no less than 1 week prior to the first dose of pemetrexed and continues until 3 weeks after the last dose of pemetrexed.~For rash prophylaxis, dexamethasone (4 mg po twice per day) should be taken on the day before, the day of, and the day after each dose of pemetrexed unless clinical contraindications exist."
46114148|NCT00737568|Drug|TDF|Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily
46114149|NCT00737568|Drug|FTC/TDF|Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily
46114150|NCT00737568|Drug|TDF Placebo|TDF placebo tablet administered orally once daily
46114151|NCT00737568|Drug|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
46114152|NCT02607137|Behavioral|Health Education|Information on healthy living style in relation to physical activity
46026350|NCT02746939|Behavioral|InSciEd Out Fitness and Nutrition Curriculum|Science curriculum is designed in partnership with 3rd and 4th grade teachers and InSciEd Out scientists. The curriculum is designed to focus on inquiry driven science, and also aims to decrease high risk behaviors that can lead to obesity in the students.
46026351|NCT04217941|Procedure|Health education with practical demonstration of nasal ointment|Health education with practical demonstration of medicine was compared to health education without practical demonstration
46114153|NCT03964584|Other|assessment of neurological and psychiatric disorders by self-administered questionnaires|Patients will be included on the day dolutegravir or bictegravir is prescribed. Neurological and psychiatric disorders will be assessed using self-administered questionnaires, at inclusion, one month, three months and six months.
46114154|NCT05752799|Drug|Opioid Free Anaesthesia|"40 mg/kg magnesium sulfate in 100 ml N/S infusion~0.4 mcg/kg dexmedetomidine, max total dose 50mcg in 50 ml N/S infusion~0.3 mg/kg ketamine in 10 ml volume~0.2 ml/kg of the Multimix regimen in 100 ml N/S infusion as a bolus (The Multimix regimen consists of 50mcg dexmedetomidine, 500 mg lidocaine and 50mg ketamine).~0.2 ml/kg/h of the Multimix regimen in 100 ml N/S infusion as a continuous infusion. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value > 25 or elevation of Heart Rate and/or Blood Pressure >20%.~Placebo infusions of normal saline will be prepared to enable blinding."
46114155|NCT05752799|Drug|Opioid based anesthesia|"2 mcg/kg fentanyl in 10 ml volume~0.2 mL/kg/h remifentanil infusion~0.1 mg/kg morphine. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value > 25 or elevation of Heart Rate and/or Blood Pressure >20%.~Placebo infusions of normal saline will be prepared to enable blinding."
46114156|NCT03945305|Device|Remote Ischemic Conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 30±2 days.
45838829|NCT04358250|Procedure|Direct Superior Approach|GROUP II :Patients positioned in lateral decubitus.landmark for incision is the apex of the greater trochanter,and skin, subcutaneous tissue except fascia are incised accordingly. Fibers of gluteus will be separated and not incised.posterior capsulotomy is performed,;femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach. Acetabulum is prepared with burs of increasing diameter, and acetabular cup is impacted. A polyethylene insert and a femoral rasp are subsequently introduced.All remaining definitive implants can be positioned.
46026352|NCT04217941|Drug|Health Education and practical demonstration of Nasal spray and intranasal ointment|We compared the effect of Health education and practical demonstration for using nasal spray and apply intranasal ointment compared to health education without practical demonstration
46114157|NCT02606591|Procedure|Electroencephalograph|EEG performed at beginning and end of school year.
46114158|NCT02606591|Behavioral|Cognitive Tests|During the EEG, participant asked to wear headphones and do some simple tests on the computer that measure their abilities to see, hear, and understand information.
46026353|NCT04217629|Drug|SY-005|This single-dose group will be initiated in healthy subjects at a 0.75mg dose that is the maximum recommended starting dose(MRSD). Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are2.5mg, 5mg, 10mg, 15mg, 20mg successively. The dose of multiple-doses groups are depending on the results of single-dose groups.
46026354|NCT02748343|Device|allograft bone|Use of the allograft bone to treat the bone defect in patients
46026355|NCT02748343|Device|tissue-engineered bone|Use of the tissue-engineered bone to treat the bone defect in patients
46114159|NCT02606591|Other|Hair Sample|Participants provide a sample of hair at baseline (near the beginning of school), and follow-up (near the end of school). Sample tested to measure cortisol levels.
46114160|NCT00737100|Drug|Placebo Respimat|patient to receive placebo matching active drug once daily
46114161|NCT00737100|Drug|Tiotropium bromide 5 mcg|patient to recieve high dose tiotropium once daily
46114162|NCT00737100|Drug|tiotropium bromide-low dose-2.5mcg|patient to receive low dose tiotropium once daily
46114163|NCT00732498|Drug|Methylprednisolone|250 mg/m2/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
46114164|NCT00732498|Drug|Etoposide|40 mg/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
46114165|NCT00732498|Drug|Cytarabine|2000 mg/m2 IV over 2 hours days 4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
46026356|NCT02695381|Drug|Etodolac-lidocaine topical patch|Once daily
46114166|NCT00732498|Drug|Cisplatin|25 mg/m2/day IV at 1mg/min days 1,2,3,4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
46114167|NCT00732498|Drug|Rituximab|250 mg/m2 slow IV over days 1, then 7,8 or 9 prior to In Zevalin. Rituximab + Zevalin regimen is given 4-6 weeks after completion of 2 cycles of ESHAP. Treatment can be completed within 7-9 days in an outpatient setting.
46114168|NCT00732498|Drug|In-Zevalin|5 mCi slow IV push over 10 minutes days 1. Given within 4 hours after Rituximab.
46114169|NCT00732498|Drug|Y-Zevalin|Platelet counts from 100,000/mm3 to 149,000/mm3 will receive 0.3 mCi/kg. Platelet counts from >/= 150,000/mm3 will receive 0.4 mCi/kg, not to exceed 32 mCi Y Zevalin. Slow IV push over 10 minutes, days 7,8 or 9 given within 4 hours after Rituximab.
46114170|NCT00726882|Procedure|Blood sample collection only|Approximately monthly collection of blood samples.
46114171|NCT00726882|Drug|ABT-333|Previous treatment in prior ABT-333 studies.
46114172|NCT00790400|Drug|Everolimus (RAD001)|Everolimus is used in 5 mg strength tablets, blister-packed under aluminum foil in units of ten tablets and dosed on a daily basis. 10mg daily dosing throughout the trial.
46114173|NCT00790400|Drug|Everolimus Placebo|Matching placebo was provided as a matching tablet and was also blister-packed under aluminum foil in units of ten.
46026357|NCT02695381|Drug|Placebo|Once daily
46026358|NCT02748109|Behavioral|Vestibular Rehabilitation + audio biofeedback|Vestibular rehabilitation paired with audio biofeedback for balance control 2 times per week with a physical therapist for 6 weeks.
46026359|NCT02748109|Behavioral|Vestibular Rehabilitation|Standard vestibular rehabilitation 2 times per week with a physical therapist for 6 weeks.
45598597|NCT03517033|Drug|Torrent's Nebivolol Tablets|
45598598|NCT03517033|Drug|Forest Pharmaceuticals Inc.'s Bystolic Tablets|
46114174|NCT04087434|Device|Brain Gauge Prospective and Healthy Control|The Brain Gauge is a brain health assessment system that takes advantage of the well-documented relationship between the sensory nerves in the fingers and the projection of those nerves to corresponding regions in the brain. The system is composed of a test device (the Brain Gauge) that uses novel fingertip vibration patterns to probe cortical complexity and utilize that complexity to gain more sensitive and specific detection of compromised neural function.
46114175|NCT00918294|Device|QuickOpt|The QuickOpt algorithm will suggest values for programming AV, PV and VV delay.
46026360|NCT02746861|Behavioral|Peer-Supported DSMS|Phone, SMS/text, and smartphone-based intervention.
46026361|NCT02746783|Drug|Single dose MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
46026362|NCT02746783|Drug|Double dose of MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
46026363|NCT02748031|Procedure|slit-lamp-adapted anterior segmental photography|The eligible patients underwent pupil dilation and slit-lamp-adapted anterior segmental photography to electronically record and monitor the morphology of their cataractous lens.
46026364|NCT02747953|Drug|Gilotrif|50 mg with an option to reduce the dose to 40mg or 30 mg once a day Continuous daily dosing, one course consists of 28 days. Patients are eligible for repeated treatment courses in the absence of disease progression and undue toxicity.
46026365|NCT02747797|Drug|Lucitanib|10 mg orally daily
46026366|NCT02747719|Behavioral|Light and exercise|Exposure to light and exercise
46026367|NCT02747641|Procedure|Pixel CO2 Laser System|
46026368|NCT02747563|Other|Blood test (PSA)|Measurement of blood PSA levels
46026369|NCT02735239|Drug|Durvalumab|
46026370|NCT02735239|Drug|Tremelimumab|
46114176|NCT00915512|Drug|Paliperidone extended-release (ER)|Paliperidone ER tablets will be administered orally once daily as flexible dose ranging from 3 to 12 milligram (mg) per day for 12 months. The recommended dose will be 6 mg once daily.
46114177|NCT02594670|Other|DU20 and HT7 combination|acupoints combination includes Baihui (DU20) and Shenmen(HT7),which was considered as the optimal clinical efficay among various combinations of acupoints.
46114178|NCT02594670|Other|DU20 and SP6 combination|acupoints combination of Baihui (DU20) and Sanyinjiao (SP6), which should have some clinical efficay among various combinations of acupoints.
46114179|NCT02594670|Other|DU20 and SA combination|Combination of Baihui (DU20) and a Sham acupoint (SA), which should have least clinical efficacy among these three types of acupoints combinations.
46114180|NCT04106960|Other|No Intevention Used|N/A as in the study does not have intervention in place. It is exploring the relationships between the social and physical features of the environment and participation through using standardized outcome measures.
46114181|NCT02594748|Behavioral|Self-management education|The intervention group will receive diabetes self-management education based on the idea of extended theory of planned behavior .
46114182|NCT02594748|Behavioral|Routine care|They will attend the routine lecture in hospital sit and listen, usually 1-2 times during one week in hospital
46114183|NCT04088214|Procedure|Arthroscopic lateral soft tissue release|The arthroscopic lateral soft tissue release is performed using an inside-out approach via the 1MTPJ arthroscopy.
46114184|NCT00786032|Device|BCI Device|A Brain Computer interface or BCI records brain signals and analyzes them to derive device commands. BCIs give their users communication and control channels that do not depend on peripheral nerves and muscles.
46114185|NCT02602652|Biological|a live attenuated chimeric JE vaccine|"The study included 2 visits (D0 and D28). At the first visit (D0), children were enrolled, collected the blood sample for evaluate the baseline immune status and given a JE-CV as a booster dose. After vaccination, children were observed for 30 minutes to monitor any immediate adverse events. Parents were given a digital thermometer for axillary temperature measurement, a ruler for measuring injection site reactions and a diary card for recording a solicited injection site and systemic reactions.~At the second visit (D28), blood samples were collected for evaluate the immunogenicity."
46114186|NCT02593500|Drug|Budesonida Pulmictan® 200 µg|
46114187|NCT02593500|Drug|Budesonide 200 µg|
46026371|NCT02735239|Drug|Oxaliplatin|IV administered Chemotherapy
46026372|NCT02735239|Drug|Capecitabine|orally-administered chemotherapy
46026373|NCT02735239|Radiation|Radiotherapy|
46026374|NCT02735239|Drug|Paclitaxel|IV administered Chemotherapy
46026375|NCT02735239|Drug|Carboplatin|IV administered Chemotherapy
46026376|NCT02735239|Drug|5-fluorouracil (5-FU)|IV administered Chemotherapy
46026377|NCT02735239|Drug|Leucovorin|orally-administered chemo-protective agent
46114188|NCT02594592|Other|questionaire|Arm: Experimental :questionaire medium risk, and high risk.(more than one positive answer about questionaire) Arm:Active Comparator: questionaire low risk (none of positive answer about questionaire)
46114189|NCT02594358|Drug|Caffeine|20 MG OR 40 MG ONCE DAILY ALONG WITH PATCHING
46026378|NCT02735239|Drug|docetaxel|IV administered Chemotherapy
46026379|NCT02655523|Drug|Triamcinolone|1 mL of 40 mg of Triamcinolone
46026380|NCT02655523|Drug|Dexamethasone|1 mL of 4mg of Dexamethasone
46026381|NCT02655523|Drug|Normal Saline|1 mL of preservative free normal saline
46026382|NCT02655523|Drug|Bupivacaine|2 mL of 0.5% bupivacaine
46026383|NCT02644291|Drug|Mebendazole|chewable mebendazole tablets that can also be crushed and mixed with food or drink to be taken daily with meals
46026384|NCT01015677|Drug|MK-6913|
46026385|NCT01015677|Drug|17-β estradiol|
46026386|NCT01015677|Drug|Placebo to MK-6913|
46026387|NCT01015677|Drug|Placebo to 17-β estradiol|
46026388|NCT01015677|Drug|MK-6913 25 mg|
46026389|NCT02281981|Dietary Supplement|Curcumin|333mg CurcuWin OAHTCUR002-2014
46026390|NCT02281981|Dietary Supplement|Placebo|OAHTCUR005-2014
46114190|NCT00785486|Drug|Midazolam Alone|Midazolam 2 mg syrup was given orally after a fast of at least 10 hours.
46114191|NCT00785486|Drug|Qualaquin (quinine) alone steady state|Qualaquin (quinine) 324 mg capsules were given orally every 8 hours for 7 days ( 21 doses total). On day 9 after taking Qualaquin (quinine) for 5 days according to the stated regimen and fasting for at least 10 hours, all participants took their usual dose of Qualaquin (quinine). Blood was drawn at times sufficient to characterize the pharmacokinetics of quinine at steady state
46114192|NCT00785486|Drug|Midazolam and Qualaquin at steady state|On the morning of day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen (324 mg every 8 hours), all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg after a fast of at least 10 hours
46026391|NCT00628017|Dietary Supplement|omega-3 polyunsaturated fatty acids ( EPA+DHA)|Group 1 received omega-3 PUFAs as 3 capsules twice daily (total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA). Group 2 received three identical placebo capsules twice daily which contained olive oil esters. Identical gelatin capsules were used. Both treatment and placebo capsules were vacuum deodorized and supplemented with tertiary-butyl hydroquinone, 0.2 mg/g, and tocopherols, 2 mg/g, as antioxidants. The source of the omega-3 fatty acids was menhaden fish body oil concentrate.
46026392|NCT04298619|Diagnostic Test|Standard cohort: Clinical lab follow-up|
46114193|NCT00917904|Drug|dapivirine|"dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks"
46114194|NCT00917904|Drug|placebo|"dosage form: vaginal gel~frequency: once daily~duration: 6 weeks"
46026393|NCT04298619|Diagnostic Test|Imaging cohort: integrated imaging follow-up|
46026394|NCT05266911|Behavioral|high-intensity functional strength training|HIFST is an exercise program using an interval format: alternating periods of high intensity/'hard' exercise using everyday lower-extremity based strength-building movements (e.g., sit to stand) with periods of light/'easy' activity. High-intensity is individualized based on the use of a rating of perceived exertion (RPE) scale. The program includes a warm-up and cool-down and will be completed in participant's homes 3 days per week.
46114195|NCT00589979|Drug|Lidoderm (Lidocaine 5% Patch)|Topical Patch
46114196|NCT00589979|Drug|Placebo Patch|Topical Patch
46114197|NCT03997136|Procedure|Supratentorial high grade gliomas resection.|Total, near total or subtotal/debulking resection of the brain supratentorial high grade gliomas
46114198|NCT02590653|Drug|Atorvastatin|Lipid-lowering therapy
46114199|NCT02590497|Procedure|Diffusion Weighted Imaging|Undergo diffusion weighted MRI
46114200|NCT02590497|Drug|Gadolinium|Undergo gadolinium-enhanced MRI
46114201|NCT02590497|Other|Laboratory Biomarker Analysis|Tissue genetic analysis
46114202|NCT02590497|Procedure|Magnetic Resonance Imaging|Undergo gadolinium-enhanced MRI
46114203|NCT02590497|Procedure|Magnetic Resonance Imaging|Undergo 3D volumetric T1-weighted sequence
46026395|NCT05266911|Behavioral|Lower extremity stretching|Lower extremity stretching program to be completed by participants at home 3 days per week.
46026396|NCT04297839|Drug|Citrate Anticoagulation Solution|Regional citrate anticoagulation in extended hemodialysis sessions compared to the standard of care actually performed in these therapies (heparin or continuous saline infusion)
46114204|NCT02590497|Procedure|Magnetic Resonance Imaging|Undergo FLAIR sequence
46114205|NCT02590497|Procedure|Perfusion Magnetic Resonance Imaging|Undergo perfusion MRI
46114206|NCT00797732|Device|Acupuncture|
46114207|NCT00915746|Drug|JNJ-31001074; ketoconazole|
46114208|NCT04085055|Diagnostic Test|Solid pancreatic mass lesion biopsy|The needle will be used to puncture the lesion and remove a piece of tissue from the mass for histological diagnosis.
46026397|NCT04297839|Drug|Control Group (heparin or continuous saline)|Use of heparin in hemodialysis sessions. If there is any contraindication against the use of heparina, the investigators will perform saline flush of the dialysis system
46026398|NCT02746549|Other|renal perfusion|measurement of renal perfusion with MRI arterial spin labelling technique
46114209|NCT05541614|Other|Emdogain® FL (flapless Emdogain®) - Enamel Matrix Derivative|Emdogain® FL has been shown to enhance the early healing of periodontal soft tissue wounds resulting from the instrumentation of periodontal pockets.
46114210|NCT05541614|Other|Emdogain® - Enamel Matrix Derivative|Enamel matrix derivative (EMD) has been widely used in the surgical treatment of periodontal disease and in furcation defects.
46114211|NCT02608151|Other|massage with oil|Application or not of an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil) during the massage. This oil was chosen due to its composition of essential fatty acids (60%) including: linoleic acid (omega 6,25g 100 g)), linolenic acid (omega 3 5.3g to 100 g) and tocopherol (vitamin E) .
46114212|NCT02608151|Other|massage without oil|
46114213|NCT02590575|Device|Extracorporeal CO2 removal with the Prismalung(R) gas exchanger on the Prismaflex(R) renal replacement platform|"With ongoing continuous hemofiltration and mechanical ventilation additional membrane gas exchange device (Prismalung®) in the renal replacement circulation; measurements of the effects on PaCO2 under varying blood and sweep gas flows~Afterwards, reduction of the tidal volume (VT) / plateau pressure until reaching the initial PaCO2value"
46114214|NCT00736944|Drug|Abraxane|100 mg/m2 IVPB, Day 1, 8 and 15 of cycles 1, 2, and 3
45681879|NCT01818752|Drug|Prednisone|Prednisone 60 mg/m² was taken orally on days 1 to 4 of all cycles.
46114215|NCT00736944|Drug|Cetuximab|400 mg/m2 IVPB, Day 1, cycle 1
46114216|NCT00736944|Drug|Cetuximab|250 mg IVPB, Day 8 and 15 cycle 1, Day 1, 8 and 15 of cycles 2 and 3
46114217|NCT00736944|Drug|Cisplatin|75 mg/m2 IVPB Day 1, cycles 1, 2 and 3
46114218|NCT00736944|Drug|5-FU|750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
46114219|NCT00736944|Radiation|Radiation (Post induction)|Monday-Friday, weeks 1-7
45681880|NCT03582280|Drug|Amorphous Calcium Carbonate (ACC) - Amor|Amor Powder is composed of Amorphous Calcium Carbonate and is administered oral Amor Inhaled Double Pack is composed of 1% ACC in solution and is administered by inhalation
45681881|NCT03159754|Procedure|Early Appendectomy|Removal of the appendix within 24 hours of admission
46114220|NCT00736944|Drug|Cisplatin|(Post induction) Cisplatin 100 mg/m2 IVPB on radiation day 1, 22 and 42
46114221|NCT00736944|Drug|Cetuximab|(Post-induction) Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB
46026399|NCT02751229|Behavioral|Honest Open Proud (HOP)|"five lessons in three modules, two for each two-hour session~Considering pros and cons of disclosing:~hurtful and helpful attitudes about mental illness~identify beliefs participants hold about themselves~explore five-step process to challenge their personally hurtful beliefs~weigh pros and cons of coming out in order to facilitate a decision on whether to disclose~Different ways to disclose:~different levels of (non-) disclosure and how to weigh the cons and pros~disclosure via social media versus disclosing face to face~how to find people that are better to disclose to than others and how to 'test them out'~participants will discuss how others might respond to their disclosure and how that will affect them~Telling your story:~how to tell one's story in a personally meaningful way, how to identify peers who might help with the coming out process, to review how telling one's story felt"
46114222|NCT03195959|Other|Hypoxia and Hyperoxia|10 minutes of breathing a gas mixture with FiO2 0.16 via a tight fitting mask. After 10 minutes of breathing ambient air (normoxia), patients were exposed to hyperoxia (FiO2 1.0) for 10 minutes.
45470325|NCT03757273|Procedure|FFF without customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the craniofacial skeleton. the C.T scan will be sent to the modeling company for planning three-dimensional model of the mandible. autoclavable model will be prepared for mandible to be used during the workflow for plate reshaping and positioning to conform with the remaining mandible.~Surgery will be performed by two surgical teams, one in charge of cervicofacial resection and the other harvesting the flap. access to the mandible is obtained, and resection/ reconstruction then performed in conventional surgical manner with microvascular anastomosis. Finally, the operation will be completed with soft tissue reconstruction."
46026400|NCT02751151|Other|have Levulan Kerastick (aminolevulinic acid) solution|Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
46026401|NCT02747251|Other|Strengthen your Shoulder|A simple home-based elastic band strengthening exercise intervention. This program consists of progressive high volume resistance training exercises with an elastic band.
46114223|NCT02590419|Device|BrightMatter™ products|"BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.~BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.~BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively."
46114224|NCT02606669|Dietary Supplement|Meal Replacement|Using a Meal Replacement product, supplemented by protein powder and multivitamin
46114225|NCT03943719|Diagnostic Test|FilmArray blood culture identification panel|FilmArray blood culture identification panel is performed 24 hours on 24hours and 7 days a week on positive blood cultures to accelerate pathogens detection
46114226|NCT02603510|Drug|SAR342434|"Pharmaceutical form:solution~Route of administration: subcutaneous"
46114227|NCT02603510|Drug|insulin lispro|"Pharmaceutical form:solution~Route of administration: subcutaneous"
46114228|NCT04084977|Diagnostic Test|Antibody detection|detecting anti bodies against D1, D2 receptor, tubolin Lysoganglioside
46114229|NCT02594436|Drug|Ingenol mebutate|Non-Interventional study enrolling patients already planned to be treated with ingenol mebutate according to approved labelling
46114230|NCT04107194|Drug|Pantoprazole 40mg|Proton pump inhibitor
46114231|NCT04107194|Drug|Amoxicillin 1000 MG|Antibiotic
46114232|NCT04107194|Drug|Clarithromycin 500mg|Antibiotic
46114233|NCT04107194|Drug|Metronidazole|Antibiotic
46114234|NCT04107194|Drug|Tetracycline 125 MG|Antibiotic
46114235|NCT04107194|Drug|Bismuth Subcitrate|Antibiotic adjuvant
46114236|NCT04107194|Drug|Rifabutin 150 MG|Antibiotic
46114237|NCT04107194|Drug|Levofloxacin 500mg|Antibiotic
45681882|NCT03159754|Procedure|Interval Appendectomy|Removal of the appendix after initial antibiotic treatment and at least 6 weeks of recovery.
46026402|NCT02747251|Other|Usual Care|"Usual care, consisting of a referral to general rehabilitation in the municipal under the Danish Health Act § 140, most often with the alternative option to choose a private physiotherapeutic clinic, partly at their own expense. Also includes any additional treatment the patient receives between baseline and follow-up, except that included in Strengthen your Shoulder."
46114238|NCT03180827|Procedure|ovarian tissue biopsy|ovarian tissue biopsy during general anesthesia
46114239|NCT02590263|Radiation|Whole Brain Radiation|Whole Brain Radiation will be administered in over 30 fractions as per the procedure in each study site.
46114240|NCT02590263|Drug|Temozolomide|Temozolomide will be administered per label.
45681883|NCT03159754|Drug|Antibiotics|Zosyn will be administered unless the patient has a penicillin allergy, in which case patients will receive both ciprofloxacin and metronidazole.
46114241|NCT02590263|Drug|ABT-414|ABT-414 will be administered by intravenous infusion
46114242|NCT02603588|Procedure|active sphenopalatine ganglion acupuncture|"The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process and temporal process. The needle was rotated until the participant felt de-qi sensations."
46026403|NCT04216537|Diagnostic Test|Glioma groups based on molecular pathology or genetic variation|Patients with newly diagnosed glioma that receive tumor resection
46114243|NCT02603588|Procedure|sham sphenopalatine ganglion acupuncture|The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
46114244|NCT00914303|Drug|AZD3241|Oral Tablet, Repeated Administration
46114245|NCT00914303|Drug|Placebo Tablet|Oral Tablet. Repeated Administration
46114246|NCT02590185|Drug|cocktail probe drugs|"For the assessment of drug-metabolizing enzyme activity, the patients will be given the cocktail probe drugs, by oral route, one time during the study:~A capsule of omeprazole ABBOTT® 10mg~10 mg of an oral liquid formulation of Dextrométhorphane bromhydrate (Drill Pierre FABRE MEDICAMENT® 5mg/5mL, syrup)~1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)~A tablet of fexofenadine Zentiva® 120mg"
46026404|NCT02695303|Drug|Coppertone (BAY 987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
46114247|NCT04104698|Diagnostic Test|Quantitative EEG|"Both groups will undergo evaluation of depression severity using Beck Depression Inventory Scale-II (Arabic Version)~Both groups will be assessed for psychological & cognitive contributes respectively using:~A. Connor and Davidson Scale for resilience (Arabic Version) B. The scale of Islamic Religiosity Attitude (SIRA)~Both groups will do Quantitative EEG (qEEG) to detect electrical, functional and brain mapping changes {Using Neurovirtual BW III, Florida, USA)~The quantitative analysis of EEG will focus on the following functions:~Histogram, Topography, Spectrum Analysis, Spectral Differences, Propagation, Positional Diagram, Medium Amplitude, Ranges of Absolute Frequencies, Ranges of Relative Frequencies, CSA, Spectrum, and CSA Compressed."
46114248|NCT00736476|Biological|H.pylori vaccines|1 dose of H.pylori vaccine at 0, 1, and 2 months
46114249|NCT00736476|Biological|Placebo Vaccine|Placebo Vaccine at 0, 1, and 2 months
46114250|NCT02590107|Dietary Supplement|Boost Plus|Receive nutritional supplementation twice daily to provide 28g of protein
46114251|NCT02590107|Dietary Supplement|Pro-Stat 101|Receive nutritional supplementation twice daily to provide 30g of protein
46114252|NCT02590107|Dietary Supplement|Milkshake|Receive alternate nutritional supplementation once daily to provide 28g protein
46114253|NCT02590107|Other|daily food diaries|Participants will be given a food intake form, clipboard, and pen to record specific foods, as well as amounts of foods that are consumed from outside sources. In addition, the specific food items that each participant consumes will be recorded by the participant on his or her meal tickets which are included with each meal tray
46114254|NCT04104932|Procedure|Open reduction and internal fixation|Open reduction and internal fixation
46114255|NCT02606357|Drug|INSULIN GLARGINE|"Pharmaceutical form:Solution~Route of administration: Subcutaneous"
46114256|NCT04019496|Drug|antibodies against calcitonin-gene related peptide or its receptor|the study is observational and does not interfere with clinical routine. In lin with this notion, the intervention is chosen by the treating physician in a shared decision making process involving the patient
46114257|NCT02607059|Other|Registry|
46114258|NCT04104386|Other|Telomere Disclosure Impact|Participants were either provided or not provided information about their personal telomere length and how they compared to the rest of the sample.
46114259|NCT05717153|Procedure|Biospecimen Collection|Undergo collection of blood
46026405|NCT04216459|Drug|oral lactobacillus probiotics plus intramuscular cholecalciferol|According to leukocyte anti- sedimentation rate (LAR) result on day 1 patients will be classified into high risk for sepsis patients (LAR < 15 %) and low risk for sepsis patients (LAR ≥ 15%) High risk sepsis patients will be randomly allocated into one of the 3 groups (sealed opaque envelops) to vitamin D plus probiotics intervention group (HR-DP) group. to vitamin C plus vitamin B intervention group (HR-CB) group. to control group (HR-C) group that does not receive any supplement
46026406|NCT04216459|Drug|intravenous vitamin C plus thiamine|starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours
46026407|NCT02747485|Device|Cardiac MRI|
46026408|NCT02747485|Biological|blood samples|Serum levels of biomarkers of myocardial fibrosis (galectine-3 and ST2) will be measured
46026409|NCT02747485|Procedure|myocardial biopsy|
46114260|NCT05717153|Procedure|Computed Tomography|Undergo CT
46114261|NCT05717153|Drug|Eflornithine|Given PO
46114262|NCT05717153|Procedure|Magnetic Resonance Imaging|Undergo MRI
46114263|NCT05717153|Drug|Polyamine Transport Inhibitor AMXT-1501 Dicaprate|Given PO
46114264|NCT05717153|Procedure|Resection|Undergo surgical resection
46114265|NCT05717153|Device|Post-operative Microdialysis|Post-operative Microdialysis
46114266|NCT00715299|Behavioral|locomotor training|Persons will train 3 times a week for 12 weeks. The training sessions will each last about an hour to an hour and a half. Therapists will manipulate the participant's body to generate stepping and walking that is more consistent with normal walking. Someone will manipulate the trunk by standing at the waist and helping with weight shift and proper upper body mechanics. The other two therapists will sit at the legs and bend and extend them as they should in a more normal gait pattern.
46026410|NCT02747485|Genetic|blood samples|extract DNA to look for genomic mutations associated with the disease.
46026411|NCT04216771|Drug|Idarubicin|Idarubicin 10mg/m²/day, D1 (IV)
46026412|NCT04216771|Drug|ID cytarabine|Cytarabine 1.5g/m² /12h, D1-D3 (IV)
46026413|NCT02747095|Device|IQon Spectral CT|Using IQon Spectral CT, Assess the added diagnostic value and impact on workflow of spectral images
46114267|NCT02602730|Behavioral|Break the Chain|Internet-based smoking cessation intervention designed for general population smokers with targeted materials for pregnant women. The program included a digital coaching component delivered via email at specific points as the user progresses through his/her quit process. Program content is based on Department of Health and Human Services Clinical Practice Guidelines for Treating Tobacco Use and Dependence.
46026414|NCT00636259|Drug|Bicalutamide (Casodex)|150mg
46026415|NCT02737033|Drug|Rhodiola|Rhodiola rosea 800mg
46114268|NCT02602730|Behavioral|Clearing the Air|PDF version of smoking cessation booklet from National Cancer Institute.
46026416|NCT02737033|Drug|Placebo|innocuous pill manufactured to mimic Rhodiola
46114269|NCT00918489|Drug|Vorinostat|Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
46114270|NCT04112888|Combination Product|Collagen|Patients will receive 3 to 5 collagen infiltrations in the scar once per week. Patients with episiotomy will receive 3 collagen infiltrations while patients who underwent a cesarean section will receive 5 collagen infiltrations. The infiltration will be done by tunneling technique, that is, it will be applied along the scar, placing the needle almost tangential to the entire length of the area, then it will be injected and at the same time the needle will be removed. Infiltrations will be carried out intradermally, previously performing asepsis in the area to be infiltrated. 2 ml syringes will be used to infiltrate the episiotomy scars (we will use 1 vial of 2 ml ) and 5 ml for cesarean scars (2 vials of 2 ml ) and sterile needles of 30G, 13mm.
46026417|NCT02736799|Device|Sham vibrating capsule|Sham device without vibration
46114271|NCT04112888|Procedure|Rehabilitation sessions|Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. There will be two sessions per week for four weeks. The sessions will last 45 minutes.
46114272|NCT05690087|Drug|Lidocaine|intravenous lidocaine 2% bolus of 1.5 mg/kg over 5 min before induction of anesthesia followed by lidocaine infusion at 1.5 mg/kg/h intraoperatively until desufflation
46114273|NCT05690087|Drug|sodium chloride 0.9% solution|intravenous sodium chloride 0.9% solution volume matched bolus and infusion.
46114274|NCT02604992|Drug|Treatment A|Dronabinol oral solution, under fed conditions
46114275|NCT02604992|Drug|Treatment B|Dronabinol oral capsule, under fed conditions
46114276|NCT02604992|Drug|Treatment C|Dronabinol oral capsule, under fasted conditions
46026418|NCT02736799|Device|Vibrant Capsule (1 vibration)|1 vibration/min
46026419|NCT02736799|Device|Vibrant Capsule (3 vibration)|3 vibration/min
46114277|NCT00730236|Drug|AEGR-733|5-80 mg daily by mouth for 1.5 yrs
46114278|NCT04084899|Device|Continuous Positive Airway Pressure therapy|Standard treatment with continuous positive airway pressure
45838830|NCT04358250|Procedure|posterolateral approach|GROUP I:patients are positioned in lateral decubitus.Landmark for incision is the apex of the greater trochanter.posterior capsulotomy is performed, femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach.Acetabulum is prepared with burs of increasing diameter,and acetabular cup is then impacted.All definitive implants can be positioned.
46026420|NCT02736799|Device|Vibrant Capsule (5 vibration)|5 vibration/min
46026421|NCT02736487|Device|True-Washout-Sham Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of true air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of sham air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
46114279|NCT00915824|Other|STOPP/START criteria|Application of STOPP/START criteria to the patient's prescription and diagnostic information with subsequent written recommendation on pharmaceutical care to the patient's medical team
45838831|NCT04357626|Other|Inpatient Rehabilitation|Observational electronic records review study during inpatient rehabilitation
45838832|NCT04357704|Other|S0N0|(no ITD)
45838833|NCT04357704|Other|S0N500|(ITD +500µs on noise)
45838834|NCT04357704|Other|S-500N500|(ITD -500µs on signal and +500 µs on noise)
45838835|NCT04357704|Other|S0N1000|(ITD + 1000 µs on noise)
45838836|NCT04357704|Other|S0Nuncorr|(no ITD cue, with uncorrelated stimulation frame)
46026422|NCT02736487|Device|Sham-Washout-True Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of sham air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of true air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
46026423|NCT03565939|Biological|Trichuris suis ova|Eggs from the pig whipworm
46026424|NCT03565939|Biological|Placebo|Solution without TSO
46026425|NCT02736331|Dietary Supplement|Treatment 1|Treatment 1 Beverage
46026426|NCT02736331|Dietary Supplement|Treatment 2|Treatment 2 Beverage
46026427|NCT02736019|Drug|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
46114280|NCT04084743|Other|Virtual reality intervention|Virtual reality intervention includes: Maze game software
46114281|NCT04084743|Other|Dual task intervention|The intervention combined both motor and cognitive training which includes, walking 10 meter (1) Free walking (2) Walking carrying an emptying tray (3) Walking carrying a tray with 4 empty glasses (4) Digit calculations (Counting forward and backward, addition, subtraction, multiplication and division) during walking.
46114282|NCT04084743|Other|Conventional physiotherapy|"Gait training in parallel bar~Balance activities which includes, a. Forward direction activity b. Backward direction activity c. Sideways direction activity"
46114283|NCT03899597|Drug|Oxytocin|The intervention group (ARTCON) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery oxytocin exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
46114284|NCT03899597|Other|Normal saline|The control group (SA) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery placebo exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
46114285|NCT05752097|Device|[18F]AlF-NOTA-FAPI-04 PET/CT examination|The intravenous radiotracer dose is 1.85-2.59 MBq/kg, and imaging will be performed 50-60 min after radiotracer injection. All patients are required to urinate as much as possible for imaging preparations, which reduces the influence of the residual radiotracer in the renal pelvis and calyces. Some patients with poor renal function (GFR<60 mL/min, urine volume < 1000 mL/24 h) will be given diuretics (Furosemide, 0.57 mg/kg). The scope of the whole-body inspection is from the base of the skull to the base of the thigh, using five to six beds (3 min/bed). The matrix was 128×128, the PET layer thickness was 3 mm, and all PET images are reconstructed iteratively.
46114286|NCT05752097|Procedure|Renal puncture biopsy|The patients undergo renal puncture biopsy one day after PET/CT examination. Pathological results of renal biopsy will be collected after surgery, including but not limited to: pathological diagnosis, proportion of glomerulosclerosis, extent of inflammatory cell infiltration, and degree of renal interstitial fibrosis.
46114287|NCT00714285|Biological|GSK Biologicals' quadrivalent influenza vaccine|Single intramuscular dose on Day 0.
46114288|NCT00714285|Biological|GSK Biologicals' trivalent influenza vaccine|Single intramuscular dose on Day 0.
46114289|NCT02823665|Drug|Exendin-(9-39)|A physiological study to evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.
46114290|NCT02823665|Drug|Atropine|A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism.
46114291|NCT02728115|Biological|Cellavita HD Lower Dose|The first three participants enrolled in the study will be assigned to the lower dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.
46114292|NCT02728115|Biological|Cellavita HD Higher dose|The last three participants enrolled in the study will be assigned to the higher dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.
46114293|NCT02590029|Behavioral|Mindfulness|The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
46114294|NCT02590029|Behavioral|Suggestion|The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
46114295|NCT02590029|Behavioral|Psychoeducation|The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
46114296|NCT04084665|Drug|Guselkumab|Guselkumab
46114297|NCT00776984|Drug|tiotropium 5mcg/day|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
46114298|NCT00776984|Drug|placebo|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
46114299|NCT05751239|Other|Questionaire|All participants answered an online questionaire. Out of the 837 participants 641 were included
46114300|NCT00714051|Behavioral|fall prevention training|Training on a specialized treadmill that produced trip-simulating perturbations (movements.
46114301|NCT00714051|Behavioral|Attention Control|Participants walked on a treadmill at a self-selected speed once per week for four weeks.
46026428|NCT02736019|Drug|Tramadol|Women will receive oral Tramadol 100 mg 2 hours before the procedure
46026429|NCT02736019|Drug|Placebo 1|Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
46026430|NCT02736019|Drug|Placebo 2|Women will receive an oral placebo similar to celecoxib 2 hours before the procedure
46026431|NCT02735863|Drug|ABX464|50 mg or 150mg once daily for 28 days
46026432|NCT02735863|Drug|Placebo|ABX464 matching placebo
46026433|NCT02735785|Behavioral|Harnessing Online Peer Education (HOPE) Social Media Intervention|
46026434|NCT04286581|Device|I-Gel Laryngeal Mask Airway|The I-Gel Laryngeal Mask Airway is a medical device that keeps a patient's airway open during anaesthesia or unconsciousness.
46026435|NCT04286581|Device|Ambu Auragain Laryngeal Mask Airway|The Ambu Auragain Laryngeal Mask Airway is a medical device that keeps a patient's airway open during anaesthesia or unconsciousness.
46114302|NCT00914147|Procedure|pulmonary function testing|After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization.
46026436|NCT04284397|Drug|Low dose ASA|A sub-group of older adults will be re-tested after 7 days of treatment with low-dose aspirin.
46114303|NCT05685147|Genetic|Non-invasive Preimplantation genetic testing for aneuploidy status|In the intervention group, comprehensive chromosome screening using NGS will be performed according to the recommendations of the company in all SCM samples. Sequence of replacement shall be altered by the NiPGT result after morpholgy.
46114304|NCT02605499|Other|UV-C light disinfection|UV-C light disinfection will be used in hospital patient rooms as an adjunct to routine daily and discharge cleaning.
46114305|NCT04026659|Other|Multi-modal exercise|A combination of aerobic, resistance, balance and flexibility exercises will be included. Aerobic exercise will consist of 20 to 30 min of moderate intensity exercise using a variety of modalities. Heart rate will be monitored using Polar hear rate monitors (target intensity 40-70% heart rate reserve) and the BORG Rating of Perceived Exertion (12-15). Resistance exercise will target the large muscle groups of the upper and lower extremities, be performed at 40% to 70% of the one repetition maximum (1-RM) and consist of two sets of 10-15 repetitions. Flexibility and balance exercise will also be included in the twice weekly programme. A home exercise programme will encourage participants to be moderately physically active for at least 30 minutes, three times per week in addition to the supervised programme.
46114306|NCT02606513|Other|MR Urography; CT Urography|
46114307|NCT04015557|Drug|Acetaminophen|Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
46114308|NCT04015557|Drug|N-acetylcysteine|Patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive again a normal dose of acetaminophen (1.5g) orally and one hour later oral N-acetylcysteine (70 mg per kilogram of body weight). Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
46114309|NCT02702765|Procedure|Fibroscan|Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver. The fibroscan is a non-invasive procedure
46114310|NCT02702765|Procedure|Ultrasound|Ultrasound is a non-invasive procedure
46114311|NCT02702765|Drug|Galactose|"Galactose elimination capacity is performed to evaluate metabolic liver function.~The metabolic liver function test galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours."
46114312|NCT02702765|Procedure|Liver biopsy|Histological disease activity at time of diagnosis evaluating if any liver fibrosis
46114313|NCT02702765|Procedure|Functional hepatic nitrogen clearance|Functional hepatic nitrogen clearance to evaluate metabolic liver function Functional hepatic nitrogen clearance requires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours
46114314|NCT02589951|Other|admission to non-psychiatric service|
46114315|NCT05534282|Behavioral|Interaction-focused Music Therapy with Children and Significant Others (INMUT-KB) (exp. group)|Interaction-focused music therapy with children with cancer and their significant others, delivered by trained music therapists.
46114316|NCT05534282|Behavioral|Music Therapy with Children (MUT-K) (exp. group)|Interaction-focused music therapy with children with cancer without the involvement of significant others, delivered by trained music therapists.
46114317|NCT05534282|Behavioral|Interaction-focused Music Therapy with Children and Significant Others (WG-KB) (control group)|Study participants randomized to this group receive the intervention INMUT 10 weeks after the experimental groups.
46114318|NCT02568605|Dietary Supplement|Prebiotic fibre|Oligofructose-enriched inulin (Synergy1)
46114319|NCT02568605|Dietary Supplement|Placebo|Maltodextrin
45838837|NCT04357938|Device|CT-imaging|Chest CT to rule out pneumonia in PCR negative, nonspecific symptomatic patients to prevent the spread of SARS-CoV-2 within the hospital.
45681884|NCT03582202|Procedure|Nutritional assessment and therapy|Nutritional screening, nutritional plan, follow-up and instructions on discharge
45681885|NCT03582202|Procedure|Standard care|Nutritional handling by nurse
45681886|NCT03159520|Behavioral|Advice sheet|Advice on management of post orthodontic pain
45681887|NCT03159832|Drug|SHR3824|All subjects were given SHR3824 20mg only one time.
45681888|NCT03582046|Device|Abdominal Perfusion Pressure (APP)|Intra-abdominal Pressure (IAP) actively measured and recorded every four hours, and mean arterial pressure (MAP) adjusted to maintain abdominal perfusion pressure (APP) levels ≥ 60 mmHg.
45681889|NCT03582046|Device|Mean Arterial Pressure (MAP)|Intra-abdominal Pressure (IAP) recorded passively in device, but not measured or reviewed by physician. Patient will be treated with sepsis standard of care, maintaining mean arterial pressure (MAP) of ≥ 65 mmHg.
45681890|NCT05701462|Diagnostic Test|biopsy under sonographic gidance|pleural biopsy under sonographic guidance
45838838|NCT04357470|Other|Hand Therapy|The patients were admitted to 12-weeks rehabilitation program and were called up once a week for follow-up appointments. Hand therapy continued as home program between 12th week and 6th month.
45838839|NCT04357392|Drug|Prednisone|Prednisone 10mg, TID * 2 weeks, decreasing 5mg per week, continuous treatment for 8 weeks
46026437|NCT04284397|Other|Control|All participants will be tested with no treatment.
46026438|NCT05595889|Drug|Surufatinib|250 mg/day p.o. QD
46026439|NCT05595889|Drug|Irinotecan|Participants will receive irinotecan，100 mg/m2，Intravenous drip, day 1 and day 8 of every 3 weeks
46026440|NCT02735629|Drug|CX1739 - 300 mg|Ampakine CX1739 - 300 mg
46026441|NCT02735629|Drug|CX1739 - 600 mg|CX1739 - 600 mg
46026442|NCT02735629|Drug|CX1739 - 900 mg|CX1739 - 900 mg
46026443|NCT02735629|Drug|Placebo|Placebo to 300 mg CX1739
46114320|NCT02568605|Behavioral|Weight Loss|All participants will receive 10 one-on-one sessions with a Registered Dietitian designed to achieve 10% weight loss over 6 months. The sessions will focus on nutrition education and behavior counseling to reduce food intake and improve dietary quality.
46114321|NCT00784784|Biological|Fluviral|One dose
46114322|NCT00784784|Drug|Zanamivir|10 mg, OD, for duration of influenza season (10-23 weeks)
45838840|NCT04357002|Drug|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
46026444|NCT02735395|Procedure|Scaling and root planing (SRP)|SRP performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
46114323|NCT00801983|Device|Alternative Keyboard|Subjects use either a typical or alternative keyboard
46114324|NCT05490368|Device|Bed mattress sensor system|The new sensor pad can detect any bed-exit activities, including stirring, sitting up, leaving, and out-of-bed. Audible message and alert to care staff can be customised in each participant. Whenever the system detects a change of bed-exit activity, an audible message will be played in the control box next to the resident's bed reminding the resident not to leave and that a care staff shall arrive shortly. Care staff at the nurse station will simultaneously receive the alert, as a sound and a visual figure on the dashboard, with the location and body position of the resident, and be prompted for a rapid and appropriate response. Care staff are allowed to customise each resident's alert settings, including time to alert and notification method.
46114325|NCT04114799|Procedure|Hemodynamic management based on invasive fluid responsiveness parameters|In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the SPV value more than 8% will be used as a trigger for the bolus of 2 ml/kg of Plasmalyte (Baxter)
46114326|NCT04114799|Procedure|Hemodynamic management based on noninvasive cardiac output and SVV measurement|In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the systemic vascular resistance (SVR) value will be used to trigger norepinephrine infusion. In patients with low SVR norepinephrine infusion will be started. In patients with high SVR value either fluid bolus (in patient with SVV value above 8%), or dobutamine infusion (in patients with SVV value below or equal 8%) will be used.
46026445|NCT02735395|Drug|Metronidazole 250 (7 days)|Subjects will intake Metronidazole 250 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
46114327|NCT05684991|Dietary Supplement|KMS-66 Ashwagandha 300mg|One capsule is taken by mouth twice daily with water
46114328|NCT05684991|Dietary Supplement|placebo capsule|One capsule is taken by mouth twice daily with water
46114329|NCT00587288|Biological|Reslizumab|
46026446|NCT02735395|Drug|Metronidazole 400 (7 days)|Subjects will intake Metronidazole 400 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
46114330|NCT00587288|Other|Saline|
46026447|NCT02735395|Drug|Metronidazole 250 (14 days)|Subjects will intake Metronidazole 250 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
46114331|NCT00800735|Drug|Pegylated-interferon alfa-2a|Pegylated-interferon alfa-2a was administered subcutaneously once weekly.
46114332|NCT00800735|Drug|Ribavirin|Participants received ribavirin with food, as the bioavailability of ribavirin is increased when taken with food. Ribavirin was administered as split doses, that is, 2 doses were given 12 hours apart, 1 in the morning and 1 in the evening. Participants received either 1000 or 1200 mg ribavirin per day according to body weight: 400 mg (2 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing < 75 kg or 600 mg (3 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing ≥ 75 kg.
46114333|NCT05324163|Drug|X0002 Spray|X0002 spray 17.5mg, twice a day; Celecoxib placebo 200mg, once a day
46114334|NCT05324163|Drug|Celecoxib capsules|X0002 spray placebo 17.5 mg, twice a day; Celecoxib capsule 200mg, once a day
45838841|NCT04357002|Drug|vaginal dinoprostone|patients will be given one vaginal dinoprostone tablet (3mg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
45838842|NCT04357002|Drug|vaginal placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
45838843|NCT04357080|Procedure|Urethroplasty|Augmentation Anterior Urethroplasty Using Dorsal Onlay Buccal Mucosal Graft
45838844|NCT04356846|Drug|LP-108 tablet|Taken orally within 30 minutes after a meal at the designated dose, once daily.
46026448|NCT02735395|Drug|Metronidazole 400 (14 days)|Subjects will intake Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
46114335|NCT05324163|Drug|placebo|X0002 spray placebo 17.5 mg, twice a day; Celecoxibplacebo 200mg, once a day
46114336|NCT00730158|Drug|KD018|Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
46114337|NCT00730158|Drug|Irinotecan|Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
46026449|NCT02735395|Drug|Amoxicillin|Subjects will intake Amoxicillin 500 mg. for 14 days, starting immediately after and the first session of Scaling and Root Planing.
46026450|NCT02735395|Other|Placebo 250 (7 days)|Subjects will intake placebo of Metronidazole 250 mg. for 7 days, starting immediately after to intake Metronidazole 250 mg.
46026451|NCT02735395|Other|Placebo 400 (7 days)|Subjects will intake placebo of Metronidazole 400 mg. for 7 days, starting immediately after to intake Metronidazole 400 mg.
46026452|NCT02735395|Other|Placebo 400 (14 days)|Subjects will intake placebo of Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
46026453|NCT02735395|Other|Placebo 500|Subjects will intake placebo of Amoxicillin 500 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
46114338|NCT00730158|Drug|Placebo|Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.
46114339|NCT04104074|Radiation|Radiotherapy|"Arm 1: The single radiotherapy dose was 200cGy, once a day, and the total dose was 5000cGy.~Arm 2: the single dose of radiotherapy was 300 cGy, once a day, and the total dose was 3000 cGy."
46114340|NCT04104074|Drug|Sintilimab|Sintilimab is a PD-1 inhibitor, intravenously, at a dose of 200 mg, once every 3 weeks
46114341|NCT04114643|Biological|Prothrombin Complex Concentrate|Octaplex will be administered when the blood bank receives an order for coagulation factor replacement
46114342|NCT04114643|Biological|Frozen Plasma|Frozen Plasma will be administered when the blood bank receives an order for coagulation factor replacement
46114343|NCT04114487|Other|dual task balance training|The studies were planned to be 2 times a week for 12 weeks. The 20-minute Dual Task balance training program is planned to be composed of two sections of 10 minutes. In the first 10 min section, the individual will exercise with the multi-task mode of CogniBoard on the balance ball. . Stroop study will be performed on the balance ball in the second 10 minutes of the exercise.
45470326|NCT04749745|Drug|L-theanine|The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with placebo in two separate sessions at least 72 hours apart.
45681891|NCT04405492|Device|Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.|"After inclusion, demographic and medical data will be collected. Evaluated point-of-care devices will be tested immediately. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Clinical samples will be stored in a dedicated biobank. Other SARS-CoV-2 diagnostic tests will be evaluated in the laboratory on the different clinical samples retrieved from the biobank.~For all antigenic, molecular and serological tests evaluated, the reference method will be real-time RT-PCR as well as the result of medical imaging carried out as part of patient care."
45838845|NCT04356378|Other|Data record|Data record
45838846|NCT04356222|Drug|Durvalumab|Intravenous infusion once every two weeks ,once 10mg/kg.
45838847|NCT04356222|Drug|methotrexate|Intrathecal chemotherapy specified dose on specified days
46026454|NCT02741947|Drug|Levodopa Benserazide Madopar|Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
46026455|NCT02741947|Drug|Levodopa Benserazide Teva Italia|Levodopa benserazide Teva 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
46114344|NCT02989662|Drug|Mifepristone|Participants receive 6 doses.
46114345|NCT02989662|Drug|Placebo - Cap|Participants receive 6 doses
46114346|NCT05750849|Procedure|BLOOD COLLECTION FOR P4 DETERMINATION|Serum progesterone levels on the pregnancy test day
46114347|NCT04084587|Device|Retimax Vision Trainer|The Retimax Vision Trainer is an innovative method that aims to increase visual function in patients with eye diseases of various origins and nature, allowing the patient to exploit and optimize their residual visual potential. It is aimed at patients with visual impairments of different origins and severity, such as campimetric deficits, low vision of central origin, degenerative retinal diseases, amblyopia. (1,2) It consists of a device for recording bioelectrical responses evoked during the perception of structured visual stimuli and the control of the same by the patient through a sound biofeedback mechanism. This results in an increase in visual capacity, exploiting neuronal plasticity through the activation of alternative neuronal circuits.
46114348|NCT05305443|Behavioral|Navigation Services|Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services
46114349|NCT05305443|Behavioral|Brief Counseling|Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
46114350|NCT05305443|Behavioral|Critical Dialogue|Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.
46026456|NCT05629195|Device|tunneled PICC|PICC catheter is inserted into the superior vena cava through the upper brachial vein by establishing a subcutaneous tunnel
46114351|NCT05305443|Behavioral|Referral and Digital Brochure|Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing IL recommendations is e-mailed or texted to participants.
46114352|NCT04112459|Other|prolonged mechanical ventilation|No intervention will be applied in this study
46114353|NCT00784550|Drug|Tiotropium Bromide|Long-acting muscarinic antagonist
45838848|NCT04356144|Diagnostic Test|Thrombin Generation Assay (TGA)|"TGA via a fluorimetric module. Coagulation cascade is activated upon addition of different concentrations of tissue factor and phospholipids. The fluorogenic substrate Z-Gly-Gly-Arg-AMC (ZGGR-AMC) is cleaved by formed thrombin over time. By plotting the changes in fluorescence as a function of time (cnt/min), it depicts the Thrombin Generation Curve (thrombin generated - plotted against time). The area under the thrombin curve is defined as the endogenous thrombin potential (ETP)."
46026457|NCT02741869|Device|photodynamic therapy (Ondine: MRSAid™)|Photodisinfection using MRSAid™ for the decolonization of S. aureus in hemodialysis patients
46026458|NCT02741557|Drug|DTG|DTG is provided as a white, film-coated, round tablet containing DTG 50 mg, debossed with SV 572 on one side and 50 on the other side. Subjects will receive a single oral dose of DTG 50 mg tablet with 240 mL of water.
46114354|NCT00784550|Drug|Fluticasone Propionate/Salmeterol|Inhaled corticosteroid plus long-acting bronchodilator
46114355|NCT02592564|Behavioral|Internet-delivered cognitive behavior therapy|Internet-delivered cognitive behavior therapy for social anxiety disorder. Similar to previous studies in our research group, the treatment will be delivered during 9 weeks. Each week the participant will be introduced to a module containing text material and homework assignments. The participants will receive feedback via text by a clinical psychologist once a week.
46114356|NCT05659121|Device|robotic exoskeleton training|robotic exoskeleton training using EksoGT will be incorporated into subject's conventional physiotherapy training.
46114357|NCT00729690|Drug|Pregabalin|"Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.~Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.~Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2."
46026459|NCT02741557|Drug|RPV|RPV is provided as a white to off-white, film-coated, round, biconvex tablet containing RPV 25 mg, debossed with TMC on one side and 25 on the other side. Subjects will receive a single oral dose of RPV 25 mg tablet with 240 mL of water.
46114358|NCT00729690|Drug|Pregabalin|Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
46114359|NCT00729690|Drug|Placebo|Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
46114360|NCT04027829|Drug|Dexmedetomidine Hydrochloride|Intravenous infusion of dexmedetomidine at the rate of 0.5mcg/kg for 10 min, then 0.5mcg/kg/hr for 50 min.
46114361|NCT02593344|Device|Endopat|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (Endopat)
46114362|NCT00784238|Drug|Paliperidone|Paliperidone ER oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.
46114363|NCT00917982|Other|vision therapy|
46114364|NCT02589873|Behavioral|In-Person Diabetes Prevention Program|Lifestyle intervention program involving group-based educational sessions, diet and physical activity tracking, and weekly weigh ins. Participants complete the intervention over 12 months.
46114365|NCT02589873|Behavioral|Online Diabetes Prevention Program|Lifestyle intervention program involving web-based educational videos, diet and physical activity tracking, and recording weight. Participants complete the intervention over 12 months.
46114366|NCT00729612|Drug|carboplatin|
46114367|NCT00729612|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
46114368|NCT00729612|Genetic|protein expression analysis|
46114369|NCT00729612|Other|immunoenzyme technique|
46114370|NCT00729612|Other|immunohistochemistry staining method|
46114371|NCT00729612|Other|laboratory biomarker analysis|
46026460|NCT02741557|Drug|DTG/RPV FDC|DTG/RPV FDC is provided as a pink, film coated, oval biconvex tablet containing FDC of DTG 50 mg and RPV 25 mg, debossed with SV J3T on one face. Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet with 240 mL of water.
46114372|NCT05684913|Procedure|Zn granulate stent after FGG surgery|Immediately after FGG harvesting from the palatal tissue, homeostasis was achieved by sterile wet gauzes and the ZnG was prepared according to the manufacturer guidelines. Briefly, approximately 10 grams of granulate was poured into hot water and then manually shaped to cover the surgical area. The retention was achieved from the palatal, occlusal and buccal surfaces of the teeth. The patient was asked to wear the ZnG for 7 days except for eating.(
46114373|NCT05684913|Procedure|Hemostatic agent suturing|Immediately after FGG harvesting from the palatal tissue, homeostasis was achieved by sterile wet gauzes. Then hemostatic agent containing cellulose were sutured on the palatal wound area with 4.0 vicryl sutures in this group. Sutures were removed after 7 days.
46114374|NCT04102202|Drug|BOL-DP-o-05|BOL-DP-o-05
46114375|NCT04102202|Drug|Placebo|Placebo
46114376|NCT02589795|Biological|DNA-C CN54ENV|DNA plasmid containing the Clade C gp140 envelope gene from HIV-1 isolate CN54
46114377|NCT02589795|Biological|CN54gp140|Recombinant protein expressed from the Clade C gp140 envelope gene from HIV-1 isolate CN54
46114378|NCT02589795|Device|Trigrid Delivery System - Intramuscular|Electroporation
46114379|NCT02589795|Device|Trigrid Delivery System - Intradermal|Electroporation
46114380|NCT02602418|Other|Adaptive WM CogMed Training|"12 different computerized visual and spatial Working Memory tasks will be presented at each sessoin. Each session will involve 8 of the 12 tasks, and each subject is required to complete 25 training sessions, 30-40 minutes per day, 4-5 days per week over a 5-8 week period (minimum 20 sessions). The tasks will become more difficult in an adaptive manner, which is hypothesized as optimal for learning and training effects."
45470327|NCT04749745|Drug|Placebo|The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with L-theanine in two separate sessions at least 72 hours apart.
45838849|NCT04356144|Diagnostic Test|Thrombomodulin Modified Thrombin Generation Assay (TGA-TM)|Recombinant Human Thrombomodulin (TM) is added to the conventional TGA. When recombinant TM is added, the protein C system is fully activated and therefore the ETP obtained reflects both the anti- and procoagulant factors.
46026461|NCT02741479|Other|Airplane Test|"The airplane test requires the subject to bend forward, bringing the upper body and one leg horizontal, making a T position with the body with the arms out to the sides while in single-leg stance; they then bend the supporting leg, bringing the finger tips towards the floor, followed by straightening the supporting leg and bringing the arms back out to the sides. This motion is repeated five times on each leg per trial. The airplane will be performed to a metronome to standardize performance time"
46114381|NCT02602418|Other|Nonadaptive WM CogMed Training|"The same 12 computerized visual and spatial working memory tasks will be presented, but at a fixed (non-adaptive) and low difficulty level. 5 sessions per week x 5 weeks fora total of 25 sessions (minimum 20 sessions)."
46114382|NCT05325801|Biological|BMCA and GPRC5D dual target CAR-T cells(OriC321)|Patients will receive lymphodepleting chemotherapy followed by a single infusion of OriC321
46114383|NCT05489510|Combination Product|Pulsed or continuous lighting|The cross-linking procedures will be performed on an outpatient basis using the PXL Platinum 330 System (UVA light source and riboflavin solution).
46114384|NCT00585546|Drug|clenbuterol|Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months.
46114385|NCT00768248|Drug|perineural ropivacaine|ropivacaine 0.4%; the basal rate will be set at 7 mL/h
46114386|NCT00768248|Drug|normal saline (placebo)|the basal rate will be set at 7 mL/h
46114387|NCT02589717|Drug|Atezolizumab [TECENTRIQ]|Atezolizumab 1200 mg will be administered by IV infusion q3w. Initial IV infusion will be given over 60 minutes and subsequent infusions will be given over 30 minutes.
46114388|NCT04099550|Device|RT-CGM|The group was monitored blood glucose initial 1-week with a RT-CGM.
46114389|NCT04099550|Other|SMBG|The group was monitored self-monitoring blood glucose (SMBG) at least 2 times a day for initial 1-week.
46114390|NCT02602028|Drug|colchicine|to compare once daily dosage schema of colchicine and twice daily dosage schema of colchicine
46114391|NCT05684757|Behavioral|Dietary Advice|Dietary Advice
46114392|NCT05486390|Behavioral|Nudge, health coaching and shared decision-making|"The EMPOWER app aims to nudge the participant towards successful self-management of their diabetes condition by encouraging and reinforcing positive lifestyle behaviors in 3 main aspects - diet, physical activity, medication adherence. Notifications included content based on behavioural change technique including feedback on performance, positive reinforcement, and prompts to self-monitor. Each notification focused on a single behaviour (physical activity, medication adherence or diet).~The participants in the intervention group will also interact with health coach throughout the study duration. In this study, the health coach will be responsible for the following roles :~Goal setting and action plan~After-visit summary~A report card summarizing the lifestyle behaviour, goals will be made available to facilitate shared decision making."
46114393|NCT04084431|Radiation|Radiation|WBRT will be applied in 10 fractions with single doses of 2 Gy (Arm 1) to the whole brain
46114394|NCT04084431|Other|OSC|optimal supportive Care (OSC) alone
46114395|NCT04103684|Drug|Methylprednisolone|30mg per kg per day for 5 days followed by course of oral prednisolone
46026462|NCT02741401|Other|Usual post-operative care|Usual post-operative care concerning patients who underwent surgery because of gastrointestinal malignancy
46114396|NCT04103684|Drug|Dexamethasone|0.6mg per kg perday for 5 days
45470328|NCT03257436|Device|CRT-D|Left Ventricular MultiSite Pacing
46114397|NCT04084275|Behavioral|breastfeeding education|
46114398|NCT04084275|Behavioral|personal hygiene education|In this training, the puerpera was informed about personal hygiene to prevent infection.
46114399|NCT04084275|Behavioral|nutrition education|In this training, the amount of nutrients that breastfeeding women should take daily was explained.
46114400|NCT04084275|Behavioral|fatigue education|In this training, suggestions were made to prevent the negative effects of fatigue
46114401|NCT04084275|Behavioral|sleep education|In this training, suggestions were offered the puerperants for better sleep. Strategies to improve sleep quality were explained.
46114402|NCT04084275|Behavioral|pilates exercises education|In this study, pilates exercises exclusively for postpartum women were selected from two reference books, Fitness Professional's Handbook and Guide Women's and Fitness Health, which include 13 movements: Bridging, Hundred, Roll Up, One Leg Circle (both ways), Rocker with close legs,Single Straight Leg Stretch, Double Leg Stretch, Spine Stretch Forward, Single Leg Kick, Side Kick up and down, Side Kick circles, Rest position (stretch and relaxation) and Curling. The trainings were provided by the investigator during home visits to the puerpera in the intervention group and the pilates exercises by the investigator who was also a pilates trainer. An appropriate setting was prepared at the homes of puerpera so that they could do the pilates exercises easily.
46026463|NCT02741401|Other|Hand-foot massage|Hand-foot massage administered during 5 consecutive days postoperatively by trained volunteers, concerning patients who underwent surgery because of gastrointestinal malignancy
46026464|NCT02695225|Behavioral|Lay-led tobacco abstinence|Lay-led tobacco abstinence: Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.
45470329|NCT04748341|Other|Pedagogical Framework (Learn, See, Practice, Prove, Do, and Maintain)|"The Learn, See, Practice, Prove, Do, and Maintain (LSPPDM) pedagogy is acting as a guiding path for educators in teaching and learning procedural skills. It is synthesized after intensely reviewing the literature comprises steps. In the 1st step, learners learn through didactic lectures, further proceeding to see procedural videos. The 3rd step, Practice expose learners to perform the skill on a simulator. In the 4th step Prove the learner proves the skill. The 5th step Do comprise real-life exposure through the clinical rotation. Then, finally the 6th stepMaintain the learner maintains skill supplemented with simulation as needed."
46026465|NCT02695225|Behavioral|Lay-led promotion of Ohio Quit Line|Lay-led promotion of Ohio Quit Line (control condition): Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
46026466|NCT02741167|Procedure|CRS and HIPEC|During CRS, all visible peritoneal tumors are removed. Consequently micrometastasis are removed with hyperthermic intraperitoneal chemotherapy
46114403|NCT02602184|Drug|AR/101|
46114404|NCT02602184|Drug|Placebo|
46114405|NCT00775268|Procedure|Biopsy|Biopsy taken
46114406|NCT00775268|Diagnostic Test|fluorodeoxyglucose F 18 Positron Emission Tomography and computed tomography|Imaging
45470330|NCT04748341|Other|Traditional Method|"The traditional method group learns through 2-step method.~didactic lectures on neonatal resuscitation were delivered.~Practice skill on mannequins"
45470331|NCT01328002|Drug|Milnacipran|"Maximum tolerated dose (50, 75, or 100 mg/day tablets) was determined during the open label phase of the study.~Oral administration, twice daily dosing"
45470332|NCT01328002|Drug|Placebo|matching placebo tablets daily
45838850|NCT04356300|Biological|Exosome of MSC|Exosome of MSC at a dose of 150mg will be given intravenously to patients once a day for 14 times.
46026467|NCT02740933|Drug|Demeclocycline|
46026468|NCT02741089|Procedure|Indication for a flexible bronchoscopy|"The data of patients are collected within the hospital routine documentation during the flexible bronchoscopy. The bronchoscopy is performed regardless of this study. Following the bronchoscopy the patients are asked a few questions about their health and their perception.~The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient."
46026469|NCT02740855|Device|Alcomed 3011®|Endtidal ethanol measurement
46114407|NCT00775268|Other|[3'-deoxy-3'-[F-18] fluorothymidine|Undergo scans
45470333|NCT02086578|Device|Breast MRI|
46114408|NCT00775268|Procedure|computed tomography|Undergo scans
46114409|NCT00775268|Procedure|fine-needle aspiration|sample collected
46114410|NCT00775190|Drug|ortho tricyclen|brand name oral contraceptive
46114411|NCT00775190|Drug|Trinessa|generic oral contraceptive
46114412|NCT00479557|Biological|ACC-001 + QS-21|Vanutide Cridificar (3, 10, 30µg) + QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
46114413|NCT00479557|Biological|ACC-001|Vanutide Cridificar (10, 30µg), IM on day 1, month 1, month 3, month 6 and month 12
46114414|NCT00479557|Biological|QS-21|QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
46114415|NCT00479557|Drug|Placebo: Phosphate buffered saline|Phosphate buffered Saline (pH : 7.4), IM on day 1, month 1, month 3, month 6 and month 12
46114416|NCT04099472|Behavioral|Delirium Education, Prevention, and Management|"Patients and families will have a choice of either watching a 6-minute video or reading an educational booklet with a competent research assistant on the signs of delirium, risk factors, and prevention and management strategies.~Caregivers will practice identifying delirium with the Sour Seven questionnaire, using previously validated case vignettes of hypothetical ICU patients. Family members will also complete a daily checklist of non-pharmacological interventions (ie. orientation, mobility, and environmental cues).~Delirium detection by family caregivers will be assessed by the Sour Seven Questionnaire and communicated to the bedside nurse."
46114417|NCT04099472|Behavioral|Standard Care|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission.
46114418|NCT00774800|Drug|Humalog|
45838851|NCT04356456|Dietary Supplement|Lumenato|tomato oleoresin obtained from yellow dry tomato pulp
45470334|NCT02086578|Behavioral|Breast-Q© questionnaire|
46114419|NCT00774800|Drug|Humulin-R|
46026470|NCT02694991|Other|Osteopathic Manipulative Treatment|The thoracic wall is gently manipulated in conscious subjects in a supine position in order to facilitate greater diaphragmatic excursion. The thorax is palpated by applying a low pressure load directly on the skin in the direction of resistance, without any sliding over the skin or forcing of the subcutaneous tissue until it begins to yield and there is a sensation of softening. Sterile procedures are used when touching the patients near the surgical site. The treatment consists of a fixed and preordained sequence of three sessions, beginning with the costal arch on the diaphragm and then moving to the sternal area and, finally, the region of the thoracic outlet. The first two phases are performed from the right side, and the third from the head of the bed.
46114420|NCT00774800|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
46114421|NCT00774800|Other|Liquid meal|
46114422|NCT00439309|Device|Gelfoam/Thrombin|Gelfoam/Thrombin
46026471|NCT02741011|Other|Radiological examination|During the period of two years, mentally handicapped patients were enrolled in this study. First a radiological examination was performed under sedation anesthesia and then an oral examination was performed when patient underwent general anesthesia for dental treatments. Oral and radiological examinations were compared with each other and also with treatment results to define the necessity of the radiological examination of mentally handicapped patients.
46114423|NCT00439309|Device|VascuSeal|VascuSeal
46114424|NCT00479167|Drug|Bortezomib and Tositumomab I-131|
46114425|NCT00725712|Drug|GSK1363089 (formerly XL880)|c-MET tyrosine kinase inhibitor
45470335|NCT02086578|Radiation|Multi-Beam IMRT|The radiation dose (50-50.4 Gy/25-28 fractions in approximately 5-6 weeks), treatment-planning and delivery aspects are according to departmental guidelines for breast IMRT.
45470336|NCT04537650|Diagnostic Test|Videofluoroscopic Swallowing Study (VFSS)|A standardized dynamic radiographic examination of oropharyngeal swallowing
45470337|NCT04009213|Device|LiquiBand FIX8®|An n-butyl-2-cyanoacrylate adhesive monomer and D&C Violet #2 dye
46026472|NCT02740465|Behavioral|Anxiety Inventory for Respiratory Disease (AIR)|An initial version of the AIR was developed through a mixed-methods approach to item development, incorporating both emic and etic perspectives. This included an extensive review of extant anxiety scales (etic perspectives) and in-depth qualitative interviews with patients with COPD and self-reported anxiety (emic perspectives). AIR has ten items on a scale from 0 to 3. It provides a score of 0-30. High score indicates elevated level of clinically relevant anxiety symptoms.
46114426|NCT02594046|Other|stem cell component extract|The Allogeneic Human adipose derived stem cell component extract
46114427|NCT05251701|Device|Personal KinetiGraph® (PKG®) System|The PKG® System includes a wrist-worn device that records and measures movement patterns in conditions such as Parkinson's disease.
46114428|NCT00729378|Other|Skeletal loading|Impact activities, 3 times per week, increasing the number of jumps (up to 40) and increasing height (from 6 inches to 24 inches per repetition) over the initial 8-weeks (2 months). New activities will be introduced approximately every 2-3 months in order to continually stress the skeleton over 2 years.
46114429|NCT05246787|Behavioral|breastfeeding|nonphamacological methods
46114430|NCT05246787|Combination Product|Breastfeeding and Shotblocker|combined Breastfeeding and Shotblocker device
46114431|NCT05246787|Device|shotblocker|it is a small plastic tool
46114432|NCT00478933|Device|Defibrillator, Dual Chamber ; Implantable|Patient must wear a dual chamber ICD to remain in study. Can be enrolled 10 days prior to implant. Is excluded if device type changes.
46114433|NCT00478933|Procedure|Blood sampling|Blood sampling
46114434|NCT03967860|Diagnostic Test|CT scan|Post surgical standard CT Scan as predictor of complication
46114435|NCT04084353|Other|Intrapartum fetal monitoring training and quality improvement project|Intrapartum fetal monitoring training
46114436|NCT04087824|Device|AI assisted recognition of colonic segments|After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. The whole withdrawal process is monitored by AI associated recognition system. Key colonic segments include ileocecal valve, ascending colon, transverse colon, descending colon, sigmoid colon and rectum. When typical anatomic sites are detected, the AI device will automatically captured relevant images and report the name of each segment on the screen. The operating endoscopy expert will give the final answer and judge the performance of AI, which is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
46114437|NCT00725322|Drug|Botulinum Toxin A|Subcutaneous injection of Botulinum Toxin Type A into the patient's scar tissue
46114438|NCT00725322|Drug|Placebo - Saline|Subcutaneous Saline injection given at site of scar neuroma
46114439|NCT04084197|Drug|HIP1402|Tamsulosin (HanmiTams Capsule) 0.4mg
46114440|NCT04084197|Drug|HIP1801|Tamsulosin 0.4mg
45470338|NCT04009213|Device|AbsorbaTack™|An absorbable synthetic polyester copolymer derived from lactic and glycolic acid and is dyed with D&C Violet No. 2.
45470339|NCT05239078|Drug|local anaesthetic injection|Inferior alveolar nerve block
45470340|NCT05238610|Procedure|PFO closure|PFO-closure will be performed after 3-6 month of observation and monitoring for paroxysmal atrial fibrillation
46114441|NCT02593890|Device|THEYA Recovery Range|Post-operative Lingerie made from viscose derived bamboo
46114442|NCT02589483|Procedure|The rectal anastomosis will be reinforced with HemoPatch.|Associated with the making of the anastomosis stapled or hand sewed, the device HemoPatch will be wrapped all the way around the anastomotic circumference.
46114443|NCT02589483|Device|Hemopatch|The rectal anastomosis reinforced with Hemopatch
45470341|NCT02579265|Drug|Smoflipid 20% (investigational lipid for parenteral nutrition)|"Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Smoflipid 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~Smoflipid 20% will be infused into a central or a peripheral vein."
45470342|NCT02579265|Drug|Intralipid® 20%|"Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Intralipid® 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~Intralipid® 20% will be infused into a central or peripheral vein."
46114444|NCT00725010|Drug|Temozolomide|Temozolomide will be administered orally at 75 mg/m^2 with radiotherapy during the concomitant treatment phase. After four weeks, temozolomide will be administered at 150 mg/m^2 to 200 mg/m^2 from Day 1 to Day 5 of six therapy cycles during the monotherapy phase.
46114445|NCT00725010|Radiation|Radiotherapy|Radiotherapy will consist of fractionated focal irradiation at a dose of 2 Gy per fraction given Monday through Friday for a total dose of 60 Gy, administered with temozolomide during the concomitant treatment phase.
45470343|NCT03752359|Dietary Supplement|whey protein|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 16 weeks. At the beginning and end of the experiment, two weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
45470344|NCT03752359|Dietary Supplement|placebo|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 16 weeks. At the beginning and end of the experiment, two weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
45470345|NCT05238220|Drug|Valganciclovir|continuation of valganciclovir prophylaxis up to 12 months with absence of demonstrated anti-CMV immunity
46026473|NCT02740465|Behavioral|Hospital Anxiety and Depression Scale (HADS)|The Hospital Anxiety and Depression Scale (HADS), a self-assessment scale, was developed to detect states of depression, anxiety and emotional distress amongst patients who were being treated for a variety of clinical problems.
46114446|NCT05228457|Device|Intensive intermittent theta-burst stimulation (iTBS)|Intensive iTBS is intermittent theta-burst stimulation (iTBS), a patterned form of repetitive transcranial magnetic stimulation (rTMS) over a specific brain region.
46026474|NCT00636337|Behavioral|Attention Training|Computer program training for attention difficulties.
46114447|NCT02589561|Device|Remote fitting|remote fitting of hearing aids
46114448|NCT02589561|Device|Face to face fitting|face to face fitting of hearing aids
46114449|NCT05684601|Device|Third molar surgery|It was extracted one impacted mandibular third molar per patient with piezoelectric or rotating drills device
46026475|NCT00636337|Behavioral|Placebo|Comparison computer program
46026476|NCT02740387|Drug|OTO-104|
46114450|NCT05216055|Combination Product|Ropivacaine, Dexmedetomidine, Dexamethasone sodium phosphate, Normal saline|Ropivacaine 0.5% HCl, 40 mL (5 mg per mL) (200 mg) Dexmedetomidine HCl, 0.50 ml (100 ug per mL) (50 ug) Dexamethasone sodium phosphate, 1 mL (10 mg per mL) (10 mg) Normal saline 0.9%, 18.5mL
46114451|NCT05216055|Drug|Liposomal bupivacaine|Liposomal bupivacaine, 20 mL (13.3 mg/ml) (266 mg) Normal saline 0.9%, 40mL
46114452|NCT02592408|Drug|ASP|3 days of artesunate sulfadoxine/pyrimethamine on days 0-2
46114453|NCT02592408|Drug|SDPQ|single dose primaquine on day 2
46114454|NCT02592408|Drug|14DPQ|14 day primaquine starting on day 2
46114455|NCT02592408|Drug|14DPQ on Day 42|14 day primaquine starting on day 42
46026477|NCT03699163|Diagnostic Test|Breath sample|Patients will be asked to give a sample of their breath, using the ReCIVA breath testing device. This involves performing tidal breathing whilst wearing a face mask for approximately 5 minutes. Breath (500mls at a flow rate of 200mls/min) is passed over thermal desorption tubes which absorb compounds of interest.
46026478|NCT02746393|Other|Health Advocates Program|Provided services and support to address identified social needs from health advocate navigators.
46114456|NCT03939195|Other|Follow-up|4 follow-up visits with OCT Angiography and Structural OCT B
46026479|NCT02746393|Other|211 Information Sheet|Receive a printed list of community resources to address social needs.
46026480|NCT04273555|Drug|[18F]-FDG|[18F]-FDG will be injected prior to PET/MRI imaging up to three times over the course of six months.
46114457|NCT00767000|Drug|MK-0941|MK-0941 tablets three times daily
46114458|NCT00767000|Drug|Comparator: Placebo|Matching placebo to MK-0941 three times daily
46114459|NCT00767000|Biological|Lantus|Lantus injection once daily
46114460|NCT00767000|Drug|Metformin|Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.
46114461|NCT05194449|Other|Comfort Talk® App|Patients will receive a tablet preloaded with the Comfort Talk® app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment. Upon departure, they will receive a download coupon for the app for home use.
46114462|NCT05194449|Other|Placebo App|Patients will receive a tablet preloaded with a white noise app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment.
46114463|NCT00724932|Drug|Rocuronium|Participants will receive an intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After this dose, maintenance doses of 0.1-0.2 mg.kg-1 rocuronium may be given.
46114464|NCT00724932|Drug|Sugammadex|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, a single bolus dose of 4.0 mg.kg-1 sugammadex at 1-2 PTC.
46026481|NCT02740309|Behavioral|Integrated Brief Behavior Therapy (IBBT) Intervention|The 4 sessions will empower and support families and youth to continue treatment autonomously with home practice
46114465|NCT00724932|Drug|Neostigmine|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, 50 μg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
46114466|NCT00724932|Drug|Atropine|After the last dose of rocuronium has been administered, participants will receive, according to randomization, 10 μg.kg-1 atropine (with neostigmine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
46114467|NCT00766532|Drug|Aromatase Inhibitor|Any aromatase inhibitor started as initial adjuvant therapy
46114468|NCT05684445|Other|Distant reiki group|According to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced every day for 10 days by researchers who have completed the Phase 1 training. The time of remote reiki application will be planned by talking with the patient.
46114469|NCT02602340|Behavioral|Behavioral Activation therapy|Behavioral Activation therapy
46114470|NCT02589093|Device|Stimulation|
46114471|NCT04083807|Biological|TISSEEL Lyo|The dose to be applied is governed by variables including the type of surgical intervention, the size of the affected area and the mode of intended application, and the number of applications.. The guideline for sealing surfaces is one package of Tisseel Lyo 2 ml (i.e. 1 ml sealer protein solution plus 1 ml thrombin solution) is sufficient for a surface of at least 10 cm2.
46114472|NCT04083807|Procedure|Manual compression with surgical gauze pads|Surgical 4x4 inches gauze pads
46114473|NCT02601794|Behavioral|App-based Mindfulness Training|A commercially available mindfulness training app delivered to smartphone or tablet.
46114474|NCT05188989|Drug|TPN171H 2.5mg group|TPN171H 2.5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
45470346|NCT04446598|Device|non-ablative SMOOTH mode Erbium YAG laser|Erbium:YAG (Er:YAG) laser with non-ablative SMOOTH™ mode
46114475|NCT05188989|Drug|TPN171H 5mg group|TPN171H 5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
46114476|NCT05188989|Drug|TPN171H 10mg group|TPN171H 10mg taken orally on demand 0.5-4 hour prior to sexual intercourse
46114477|NCT05188989|Drug|Placebo group|Placebo taken orally on demand 0.5-4 hour prior to sexual intercourse
46114478|NCT00774566|Procedure|PV-Isolation RF|Radiofrequency
46114479|NCT00774566|Procedure|PV-Isolation Cryo|Cryo-Balloon
46114480|NCT02589249|Dietary Supplement|AyuFlex|Active product
46114481|NCT02589249|Dietary Supplement|Placebo|Placebo
46114482|NCT02589327|Other|Exercise Intervention|The intervention will consist of 3 weeks of whole body circuit training (resistance training) where participants in the intervention group will perform 7 different exercises. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round. Intensity will be 6-7 of RPE at the first set, and 9-10 at the third set.
45470347|NCT04446598|Drug|Tadalafil 5mg|oral tadalafil 5 mg was administered daily over a period of two months
45470348|NCT01322737|Procedure|Tissue Access and Resection System|This feasibility trial will assess the effectiveness of SuMO System to create a submucosal pocket and resect the overlying mucosa in excised human colonic or gastric tissue
45470349|NCT03391804|Drug|ALLN-177|ALLN-177 7,500 units (2 capsules) with each meal/snack by mouth 5 times per day for 12 weeks
45470350|NCT05572593|Genetic|Pharmacogenomics (PGx) genetic testing|A buccal swab to collect cells from the inside the cheek
45470351|NCT03757195|Procedure|Augmentation|combination product
45470352|NCT03391726|Other|CART-19 cells|CART-19 cells treat
45470353|NCT04469907|Drug|AZD9977|Participants will receive a single oral dose of AZD9977 under fasted conditions.
45470354|NCT03391648|Other|Observation|Observation only
46026482|NCT02740309|Behavioral|Treatment as usual|Facilitated community referral for mental health treatment
46026483|NCT02746237|Drug|KAR5585 Capsules|Single and multiple ascending doses of KAR5585 (100 mg initial dose)
46026484|NCT02746237|Drug|Placebo Capsules|Single and multiple ascending doses of placebo (100 mg initial dose)
46026485|NCT02739841|Other|Ventilator hyperinflation|4 sets of 6 hyperinflation breath were applied by mechanical ventilator at 150% of tidal volume (VT) at initial.
46026486|NCT02739841|Other|Chest physical therapy|The patient will be received vibration and passive of the both upper extremity.
46026487|NCT02739763|Biological|Plasmodium falciparum sporozoite (PfSPZ)|Plasmodium falciparum sporozoites
46026488|NCT02739685|Device|Everolimus-eluting bioresorbable vascular scaffold|Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion
46026489|NCT02739685|Device|Everolimus-eluting stent|Implantation of everolimus-eluting stent in chronic total occlusion
46114483|NCT04103918|Device|Jalucomplex|Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
46114484|NCT05183685|Procedure|telecare consultation|Participants will use zoom to communicate with the doctors in clinic.
46114485|NCT05183685|Procedure|Usual face to face consultation|Participants will have face-to-face communication with the doctors in clinic.
46114486|NCT04022018|Radiation|Adaptive radiotherapy|CT repositioning will be performed after 15fractions of external radiotherapy, then new target volume will be contoured and new radiotherapy plan will be formulated with the assistance of artificial intelligence program. New radiotherapy plan will be performed from the 17th fraction external radiotherapy.
46114487|NCT04022018|Radiation|no adaptive radiotherapy|Concurrent external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of control group patients
46114488|NCT04084041|Device|Simeox|Airway clearance device
46114489|NCT04084041|Other|CCPT|Conventional chest physiotherapy
46114490|NCT00916214|Other|Pharmaceutical care program|The pharmaceutical care program consists of 2 elements, that includes individualized medication education and regular follow up
46114491|NCT04101968|Diagnostic Test|PET scan|3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.
46114492|NCT04101968|Diagnostic Test|neuroQWERTY|Analysis of free-text typing in a computer and/or a touch-screen device.
46114493|NCT00766376|Device|Erbium laser|Erbium laser treatment. Each subject will undergo up to 6 treatment sessions
46114494|NCT05163483|Drug|Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab|"Tucidinostat (chidamide), 30mg, po., biw, q3w Toripalimab, 240mg, ivgtt., d1, q3w Bevacizumab, 7.5mg/kg, ivgtt., d1, q3w~approximately 2 years"
46114495|NCT00587054|Drug|cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant|"Myeloablative and will consist of hyperfractionated TBI - 1375 cGy administered in 11 doses of 125 cGy each over a total of four days, with three doses on three days and two doses on the last day, fludarabine 25 mg/m2 IV x 5 days, and thiotepa 5mg/kg IV x 2 days. Recipients of HLA identical related transplants will not receive ATG to promote engraftment. Recipients of HLA mismatched related or unrelated stem cells will receive ATG for two days prior to the transplant. G-CSF mobilized CD34+E- PBSCs obtained from the HLA compatible donor will be infused on day 0. Post transplantation G-CSF will be administered only if clinically indicated and should begin on or after d+7.~Patients will be clinically evaluated at each clinic visit for incidence and severity of acute and chronic GVHD and transplant associated morbidity. Sequential evaluation of functional reconstitution of hematopoiesis and immunity will be made as per the BMT Service guidelines."
46114496|NCT04083729|Procedure|Percutaneous Mitral Commissurotomy|Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon or multitrack technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area > 1.5 square cm with less than moderate to severe mitral regurgitation.
46114497|NCT00766142|Biological|cetuximab|
46114498|NCT00766142|Drug|fluorouracil|
46114499|NCT00766142|Drug|leucovorin calcium|
46114500|NCT00766142|Drug|oxaliplatin|
46114501|NCT00766142|Procedure|adjuvant therapy|
46114502|NCT00766142|Procedure|therapeutic conventional surgery|
46114503|NCT05152563|Drug|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8
46114504|NCT05152563|Other|Placebo|Placebo
46114505|NCT00916526|Procedure|bronchial provocation test with mannitol|"Bronchial provocation test with mannitol: Aridol is supplied in kit form containing sufficient capsules to complete one complete challenge, and the inhalation device.~Apply nose clip and subject should be directed to breathe through the mouth~Insert 0 mg capsule into inhalation device. Puncture capsule by depressing buttons on side of device slowly, and once only (a second puncture may fragment the capsules)~The patient should exhale completely, before inhaling from device in a controlled rapid deep inspiration~At the end of deep inspiration, start 60 second timer, subject should hold breath for 5 seconds and exhale through mouth before removal of nose clip~At the end of 60 seconds, measure the FEV1 in duplicate (this becomes baseline FEV1)~Insert 5 mg capsule into inhalation device, and proceed as above~Repeat steps 1 - 4 following the dose steps in the table below until the patient has a positive response or 635 mg has been administered."
46114506|NCT03983486|Other|Imaging flow cytometry in multiple myeloma|Combination of immunophenotyping by flow cytometry and FISH in suspension (IS-FISH) may provide both cytogenetic and phenotypic information for a large number of cells in a single test. In this scope, a recent study demonstrated a proof of concept for IS-FISH to detect non pathological signals with the new ImageStream X technology (ISX).1
46114507|NCT05147649|Diagnostic Test|functional magnetic resonance imaging|functional magnetic resonance imaging
45470355|NCT03755167|Drug|IPL344|IPL344 will be administered by intravenously (IV) infusion once a day (every 24±6 hours), using a Peripherally Inserted Central Catheter (PICC) line or a permanent port. IPL344 will be administered using an electronic pump at a flow rate that will be determined in protocol 101/2. The dose will be fixed as MTD as established in protocol 101/2 (up to 3.2 mg/kg).
46114508|NCT00724854|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling
46114509|NCT00724854|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
46114510|NCT04023734|Behavioral|Reminders, habit-based strategies and/or involvement of family member|"Strategies to cope with forgetfulness include reminders, habit-based strategies and/or involvement of family members. The use of a reminder tool and pill boxes will be encouraged and a reminder app can be implemented if patients own a mobile phone. The habit-based strategy will be delivered through a printed worksheet which is tailored to patient's daily routine. Patients will be asked to identify the appropriate place and time to take their medication, and an action they conduct every day that could serve as a prompt or cue to take their medication. Patients will be asked to write coping plans to formulate their own if-then plans for all daily doses of their antihypertensive drug(s). Moreover, patients will be asked to choose a family member to become their treatment supporter. This individual will be asked to support patients to take the antihypertensive drugs. Pharmacists will remind patients to take his/her completed worksheet to the next visit."
45470356|NCT03391570|Drug|COX-2 inhibitor|Celebrex 200mg/1cap 2 tablets, take medication an hour before surgery
45470357|NCT03391570|Drug|Placebo Oral Tablet|Ramnos 250mg/1cap 2 tablets, take medication an hour before surgery
45470358|NCT03391570|Procedure|Preoperative peritoneal biopsy|Preoperative peritoneal biopsy (1x1cm sized peritoneal tissue)
45470359|NCT03391570|Procedure|Single-port laparoscopic surgery|Single-port laparoscopic surgery with CO2 gas
45470360|NCT03391570|Procedure|Postoperative peritoneal biopsy|Postoperative peritoneal biopsy (1x1cm sized peritoneal tissue)
46114511|NCT04023734|Behavioral|Counselling to increase knowledge|The content of the counselling to cope with lack of knowledge will focus on educating patients about the purpose of the medication, when and how to take the medication, the need for long-term use, the importance of medication adherence, and how to deal with possible side effects. To explore which education is needed, the patient will be asked whether they know why and how to take their medication. The teach-back method will be used, where the patient is asked to explain the pharmacist what he/she has understood after receiving the education.
46114512|NCT04023734|Behavioral|Counselling to increase motivation|The content of the counselling to cope with lack of motivation will focus on exploring and discussing their concerns and necessity beliefs. This method is called motivational interviewing. This is done by asking a first question about whether the medication bothers the patient. Follow-up on this question can focus on any concerns or low necessity beliefs (e.g., when patients are bothered by the medication because they think the medication is not needed or are afraid of side-effects).
45838852|NCT04355988|Procedure|Nonsurgical root canal therapy|After administration of LA and rubber dam isolation, acess cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with protaper rotary instruments in which Sx to S2 will be used to shape the canals and F1 and F2 will be used to finish until the apex. 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
46026490|NCT02735317|Drug|Oral Ulcer Gargle (FORRAD®)|Oral Ulcer Gargle (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of Oral Ulcer Gargle (FORRAD®) at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade > 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
46026491|NCT02735317|Drug|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine|Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade > 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
46114513|NCT04023734|Behavioral|Explore/address other drug related problems|The content of the counselling to address other drug related problems will focus on exploring these other problems underlying the non-adherence, for example experiencing side effects, costs, polypharmacy, difficulty to refill antihypertensive drugs in time, or medication intake problems, and offering solutions/alternatives when possible.
46114514|NCT04023734|Behavioral|Usual care based on the Indonesian guideline|Patients in five CHCs randomized to the control group will receive pharmacist counselling based on the Indonesian guideline of pharmacy practice. At each visit, they will receive information about the quantity and dose of the dispensed drugs, when and how to use and store the drugs, side effects and how to deal with them, the importance of medication adherence, and confirming if the patient understands how to take medications correctly.
46114515|NCT00919347|Other|ANSAR ANX 3.0 Software|"Three values are calculated by the ANSAR ANX 3.0® software of the spectral analysis of HRV and respiration:~RFa an indicator of parasympathetic function with normal values between 0.5 and 10 bpm2;~LFa an indicator of sympathetic function also with normal values between 0.5 and 10 bpm2;~SB or the ratio of LFa/RFa with normal reference values of 0.4 to 3.0.~The ANSAR ANX 3.0® software defines three different levels of autonomic neuropathy (autonomic dysfunction) as follows (see Figure 1):~Cardiovascular Autonomic Neuropathy (CAN): resting parasympathetic insufficiency (not enough parasympathetic protection for the heart) or RFa < 0.1 bpm2.~Diabetic Autonomic Neuropathy (DAN), or advanced autonomic dysfunction in non-diabetics, is defined as low autonomics: LFa < 0.5 bpm2 or 0.1 < RFa < 0.5 bpm2.~Autonomic Dysfunction: normal resting LFa and RFa, but low LFa response to Valsalva or low RFa response to deep breathing."
46114516|NCT04083651|Drug|Methylnaltrexone bromide|Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
46114517|NCT04083651|Drug|Placebo|Placebo matching to methylnaltrexone bromide will be administered as mentioned in the respective arm.
46114518|NCT00728988|Drug|Atorvastatin|80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days.
45838853|NCT04356066|Diagnostic Test|serum cxcl10 by ELISA|serum sample
45838854|NCT04355754|Device|Ventil - a gas flow divider|Checking ventilation parameters set and obtained and clinical parameters while ventilating the patient and an artificial lung simultaneously, using inspiratory flow divider.
46026492|NCT02735161|Other|Muscle strength training|Two different muscle strength training protocols will be compared; one exercise session with high load/low repetitions (4 sets x 5RM) versus one exercise session with low load/high repetitions (2 sets x 25RM). Both session will be conducted at four different exercises; seated leg press, chest press, cable lat pull down and seated rowing.
46026493|NCT02735161|Other|Endurance exercise training|Two different endurance exercise training protocols will be compared; one exercise sessions is interval training with high intensity (85-95% of HRmax) versus one of moderate intensity (70-75% of HRmax) with longer duration.
46026494|NCT02746315|Drug|HS-20004|
46026495|NCT02746315|Drug|Placebo|
45470361|NCT03752281|Other|Investigation of health and activity|During a six months multidisciplinary investigation of health status, activity and working ability for individuals receiving long-term social assistance, the health and activity status as well as function will be described using established questionnaires and the International Classification of Functioning
46026496|NCT05548621|Other|Decision aid|Online interactive decision aid for RCC
46026497|NCT02739529|Drug|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
46026498|NCT02739607|Behavioral|Transdiagnostic program|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
46026499|NCT05629975|Dietary Supplement|Oral Nutritional Supplements|"Each package contained L-arginine (750 mg), methionine (300 mg), glutamine (5 g), plant protein (10 g), vitamin B12 (1 ug), vitamin C (50 mg), vitamin D (2000 IU), vitamin A (300 mg), folic acid (5 mg), omega-3 fatty acid (1 g), zinc (20 mg), magnesium (400 mg), selenium (100 mcg), whole wheat fiber (5 g), carotenoid (3 mg), curcumin supplement (500 mg).~Probiotics included orally administration of clostridium butyricum& bifidobacterium (500 mg) every day for 7 days."
46114519|NCT00728988|Drug|Atorvastatin|40mg daily after PCI for 30 days.
46114520|NCT05133531|Drug|Ravulizumab|Administered Intravenous (IV) per the protocol
46114521|NCT05133531|Drug|Pozelimab|Administered IV and subcutaneous (SC) per the protocol
46026500|NCT02739451|Procedure|standard oxygen|"Devices used to treat spontaneously ventilating patients in the ICU who require supplemental oxygen. They deliver either~low-flow oxygen [including nasal cannula, Ventimask® without Venturi effect, and non-rebreather mask]~or medium-flow oxygen [Venturi masks and medium-flow facemasks]"
46026501|NCT02739451|Procedure|HFNO|The intervention is the use of a device that allows to deliver high flow humidified and warmed oxygen. The device used is the Optiflow™ (Fisher&Paykel, Courtaboeuf, France).
46114522|NCT05133531|Drug|Cemdisiran|Administered SC per the protocol
46114523|NCT05130957|Other|Massage Application with clove oil|The experimental group is given a massage with clove oil,
46114524|NCT05130957|Other|Massage Application without any oil|The control group is given a massage without any oil as a standard midwifery care.
46114525|NCT04087746|Drug|Aflibercept|Intra-vitreal injection of AVEGF AFLIBERCEPT in group I
46114526|NCT04087746|Drug|Ranibizumab|Intra-vitreal injection of AVEGF Ranibizumab in group 2
46026502|NCT02734927|Other|realization of computerized exercises|
46114527|NCT05128929|Drug|Hymecromone (H01)|800 mg oral H01 two times a day (total dose: 1600 mg/day).
46114528|NCT05128929|Drug|Placebo|Oral tablet placebo (inactive ingredients) two times a day.
46114529|NCT00728754|Device|Dental implant Osseotite Prevail|Root form titanium dental implant
46114530|NCT00728754|Device|Dental implant Osseotite|root form titanium dental implant
46114531|NCT04083417|Drug|Phenoxymethylpenicillin|tablet PcV 1000 mg x 3 for 10 days
46114532|NCT04083417|Other|No antibiotic treatment|No prescription of antibiotics
46114533|NCT00728130|Procedure|neck dissection of at least the ipsilateral sub-level 1B|neck dissection of at least the ipsilateral sub-level 1B
46114534|NCT02588937|Drug|EntecaBell ODT. 0.5mg|
46114535|NCT02588937|Drug|Baraclude Tab. 0.5mg|
46114536|NCT03938025|Procedure|Gastric volume resected in sleeve gastrectomy|Misure of resected gastric volume and outcome
46114537|NCT04083105|Drug|Nitrous Oxide|Nitrous oxide will be given prior to determine if it reduces pain from intranasal midazolam administration. Nitrous oxide is a minimal sedation drug used as an inhaled gas to reduce anxiety and produce anxiolysis and analgesia during dental procedures.
46114538|NCT04083105|Drug|Midazolam|Intranasal midazolam will be given after nitrous oxide administration.
46114539|NCT05112003|Device|Translingual neurostimulation|The device will be placed into and held in the participant's mouth for 20 minutes while the participant undergoes breathing and awareness training
46114540|NCT00735696|Biological|Ramucirumab|10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, on Day 1 of each 21-day cycle.
46114541|NCT00735696|Drug|Paclitaxel|200 milligrams per meter squared (mg/m^2), administered intravenously (IV) following the ramucirumab infusion, on day 1 of each 21-day cycle, for up to six cycles.
46114542|NCT00735696|Drug|Carboplatin|Administered after paclitaxel, as an intravenous infusion (IV), over 30 minutes on day 1 of each 21-day cycle, for up to six cycles. The dose to be administered is calculated based on the participant's actual body weight at time of treatment and the area under the curve (AUC) dosing. The target AUC for carboplatin treatment is AUC=6.
46114543|NCT02593968|Drug|Recombinant Human Interferon a-2b Gel|
46114544|NCT02593968|Drug|Placebo|
46114545|NCT02591862|Drug|Coversin|Patients enrolled in this protocol will initially be treated with an ablating dose of Coversin and daily repeat maintenance doses calculated according to body weight, the ablating dose to be 0.57mg/kg. Thereafter the daily repeat dose will be titrated according to clinical response and complement inhibition determined by CH50 ELISA. The initial repeat dose will be 25% of the ablating dose and this will be adjusted up or down if necessary once steady state is reached (5 days).
46114546|NCT02588547|Drug|Granisetron|IV granisetron 1 mg before spinal anethesia
46114547|NCT02588547|Drug|Granisetron|IV granisetron 0.7 mg before spinal anethesia
46114548|NCT02588547|Drug|Sodium chloride|IV 2 ml 0.9 sodium chloride before spinal anethesia
46114549|NCT00478231|Drug|Maraviroc|Maraviroc should be dosed BID with total dose adjusted according to the other drugs the patient is taking. Maraviroc may be taken with or without food. The subject should only take missed doses if it is not within 6 hours prior to the planned next dose. No dose adjustment of OBT is required due to the presence of maraviroc.
46114550|NCT04083261|Other|DNA Genotek Oragene 600|Saliva-based DNA sample collection kit
45470362|NCT03755089|Drug|Phenazopyridine|200mg PO Phenazopyridine taken 1-2 hours prior to the Botox® injection procedure
46114551|NCT05095233|Behavioral|Young Adults Culturally Adapted Manual Assisted Psychological Therapy (YA-CMAP)|"YA-CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behavior Therapy (CBT), including 8-10 sessions delivered over three months.~This intervention includes evaluation of the suicide risk mainly suicidal ideation, psycho education, crisis skills, problem solving and simple cognitive techniques to manage emotions, negative thinking, relapse prevention strategies, training on interoceptive awareness, mood management and behavior."
46026503|NCT05544721|Drug|Ropivacaine|0.5% 3-4 mL per level, with levels T1 and T2 will be used as the block injectate
46026504|NCT05629819|Device|Non-invasive phrenic nerve stimulation|Some studies have shown that PNS can relieve diaphragmatic atrophy and reverse diaphragmatic dysfunction.
46114552|NCT05095233|Device|Min Plan Tool|Self-help Tool are common evidence-based methods to help deal with mental health problems.The 'MIN PLAN APP' aims to support people at risk of suicide by letting them create a safety plan based on cognitive therapeutic intervention and behavioral techniques.
46114553|NCT02588703|Behavioral|Cognitive Behavioral Therapy|Coping Skills Treatment
46114554|NCT02588703|Behavioral|Usual Care|Existing DUI program group counseling
46026505|NCT02735005|Other|SMAF assessment|"After written information and non opposition expression, each enrolled patient will be assessed with the Functional Autonomy Measurement System (SMAF) tool during a 1 hour interview.~The French authority has considered this study as an interventional study with minimal risk because we use a tool (SMAF) that was not developped nor validated in this specific population (disabled people older than 40y). The SMAF assessment is not made in routine in this specific population (ID RCB : 2015-A00642-47)"
46026506|NCT04257097|Device|RPM - Osteogenics Lubbock Texas USA|25 patients will undergo bone regeneration with a reinforced PTFE mesh, manually shaped and modelled by the operator during surgery (traditional technique), covered with collagen membranes of medium-rapid resorption
46026507|NCT04257097|Device|Yxoss CBR - Reoss Filderstadt Germany|25 patients undergo bone regeneration with a custom-made titanium mesh, digitally designed by an operator before the surgery (digital technique), covered by collagen membranes with medium-rapid resorption
46114555|NCT02588625|Drug|BMS-986020|
46114556|NCT02588625|Other|Placebo|
46114557|NCT02588469|Other|Interventional group|"Venous compression leads to beneficial fluid regulation in OSA participants and appears as an efficient tool in OSA management.~To the investigators knowledge no study assess the impact of the cumulative effect of physical and venous compression program on upper airway resistances in obese teenager with OSA."
46114558|NCT02588469|Other|Control group|Standard obesity care with physical activity program
46114559|NCT00474175|Drug|Placebo gel|single dose (less than 1g) of a matching placebo gel
46114560|NCT00474175|Drug|benzocaine|single dose (less than 1g) of 10% benzocaine gel formulation
46114561|NCT00474175|Drug|benzocaine|single dose (less than 1g) of 20% benzocaine gel formulation
46114562|NCT00919425|Other|biologic sample preservation procedure|
46114563|NCT03002389|Drug|Anoro Ellipta|inhaler approved by FDA (strength umeclidinium 65 microgram + vilanterol 25 microgram) One puff once a day for 30 days
46114564|NCT03002389|Drug|Arnuity Ellipta|inhaler approved by FDA (strength 250 microgram) One puff twice a day for 30 days
46114565|NCT05075577|Drug|Enzalutamide|Daily oral dose of enzalutamide
46114566|NCT05075577|Drug|EPI-7386 with Enzalutamide|Daily oral dose of EPI-7386 in combination of enzalutamide
46114567|NCT02979379|Other|Pain|
46114568|NCT04082949|Biological|autologous fibrin glue application as an adjunct to nonsurgical periodontal treatment of chronic periodontitis|The purpose of this study was to investigate effects of autologous fibrin glue (AFG) which was an injectable platelet concentration, on clinical parameters in the nonsurgical treatment of chronic periodontitis.Seventy-two quadrants from 18 patients included in the study and divided into 2 random split-mouth groups. Control group included 631 sites (SRP+Placebo) and AFG group included 682 sites (SRP+AFG). Both groups divided into two subgroups according to initial pocket depth (PD:5-6mm and PD≥7mm).The test group was administered AFG using a blunt dental injector in the subgingival region, as an adjunct to SRP Clinical periodontal parameters including PD, clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were collected at the 1st, 3rd, and 6th months.
46114569|NCT04082949|Other|placebo application as an adjunct to nonsurgical periodontal treatment of chronic periodontitis|Seventy-two quadrants from 18 patients included in the study and divided into 2 random split-mouth groups. Control group included 631 sites (SRP+Placebo) and AFG group included 682 sites (SRP+AFG). Both groups divided into two subgroups according to initial pocket depth (PD:5-6mm and PD≥7mm).The control group was administered placebo as an adjunct to SRP.Clinical periodontal parameters including PD, clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were collected at the 1st, 3rd, and 6th months.
46114570|NCT03574129|Behavioral|Adolescent Transition Package|Clinic level intervention composed of an adolescent transition package with tools to support health care workers to disclose HIV status to adolescents and to track transition to adult care.
46026508|NCT04245943|Behavioral|Exercise training|18 weeks supervised strength and aerobic exercise training.
46026509|NCT05628805|Device|iTBS|intermittent theta burst stimulation with TMS
46026510|NCT02739217|Drug|PBI-4050|Four 200 mg capsules (800 mg total) administered orally, once daily.
46026511|NCT02739373|Drug|BMS-986189|
46026512|NCT02739373|Other|Placebo|
46026513|NCT02738983|Drug|Erlotinib (trade name: Tarceva®) or Icotinib (trade name: Conmana®)|Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day).
46026514|NCT02738983|Radiation|Radiotherapy|Concurrent radiotherapy total dose 60-66 Gy in 2 Gy fractions. One fraction per day, and 5 fractions per week.
46114571|NCT01020643|Drug|controlled administration of propofol|comparison of propofol sedation
46114572|NCT05062161|Behavioral|Sleep hygiene/extension intervention|The 60-minute sleep hygiene/extension educational session include the following: This session will consist of questionnaires, handouts, videos, and a discussion. Topic examples include information on establishing a comfortable sleep environment, including strategies on how to extend sleep duration by a maximum of 1 hour over the duration of the 8-week trial for an average of 7.5 minutes per week, not to exceed 15 minutes per week. Participants will also receive educational brochures and a sleep diary.
46114573|NCT05062161|Behavioral|Control care|The 60-minute educational session will address sleep physiology but not sleep hygiene. This session will consist of questionnaires, handouts, videos, and a discussion. Participants will receive an educational brochure.
46114574|NCT03537391|Diagnostic Test|Whole body contrast enhanced computer tomography|Computed tomography of the thorax, abdomen and pelvis will be performed as a part of routine clinical evaluation protocol. The imaging will be done with contrast agent if there are no clinical contraindications for the use of contrast agent.
46026515|NCT02739139|Dietary Supplement|AlphaBrain|Alpha BRAIN® (Onnit Labs LLC) is a multi-ingredient nutritional supplement that purports to enhance cognitive function in healthy adults. The commercially available product contains 12 naturally occurring compounds
46026516|NCT02739061|Behavioral|cognitive behavioral group therapy|"Establish closed every collection of six or so patients structured group. Each group patients were treated for 12 times, once a week, 120 minutes at a time.~Treatment for 1 to 3 times to obsessive-compulsive disorder and cognitive behavioral therapy as the theme of psychological education; 4 to 6, 8 to 10 times exposed step by step and reaction treatment and prevention of training;7 and 11 times invite patients family members or other caregivers, make education about obsessive-compulsive disorder cognitive behavioural therapy, to promote patients exposed response prevention homework completion and social support; The 12th time treatment is self assessment and treatment guidelines for a long time."
46026517|NCT02739061|Drug|sertraline, fluvoxamine|Select specified drugs (sertraline, fluvoxamine)
46026518|NCT02739061|Other|cognitive behavioral group therapy and drug therapy|Select specified drugs (sertraline, fluvoxamine) and start group cognitive behavior therapy for 12 weeks at the same time
46026519|NCT02746003|Other|Managed Aquifer Recharge water|Rain water will be recharged through slow sand filter and recharge wells into the confined underground aquifer and the surrounding community will abstract the water for drinking and cooking purposes
46026520|NCT02745925|Drug|Ibuprofen|
46026521|NCT04374253|Drug|Gantenerumab|Group 1 participants who were in the active arm in the double blind part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W. Participants who are naive to gantenerumab treatment will be required to undergo the 3 step uptitration scheme before receiving target dose of open label gantenerumab, 510 mg SC, Q2W.
46026522|NCT04374253|Drug|Gantenerumab|Group 2 participants who have completed OLE part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W
46026523|NCT02738905|Drug|Rifaximin|One 550 mg tablet taken orally two times a day.
46026524|NCT02738827|Procedure|Laser treatment|Intervention is diode laser treatment of bladder cancer through a cystoscope in the outpatient department
46026525|NCT02738749|Device|Implantable cardioverter-defibrillator (ICD)|Patients with newly implanted implantable cardioverter-defibrillators (ICDs) for primary prevention will be enrolled.
46026526|NCT02738671|Behavioral|Cognitive assessment|
46026527|NCT02738671|Other|functional magnetic resonance imaging|
46026528|NCT02738671|Other|olfactory function measurement|
46026529|NCT02738671|Procedure|bariatric surgery|Only a subgroup of the subjects will have the bariatric surgery.
46026530|NCT02738437|Device|Kryptonite-bone cement|
46026531|NCT02734459|Drug|cataract surgery|"the patient will be dosed with the study drug into the V pocket is formed between the eye ball and the lower eyelid during cataract surgery."
46026532|NCT05518825|Dietary Supplement|Fortimel/Nutridrink Compact Protein|Twice daily serving of the study product
46026533|NCT02745613|Other|8 weeks of combined exercise intervention|The subjects will undergo an 8 week combined exercise intervention
46026534|NCT02745691|Other|Surgery|Thoracic surgery for lung cancer
46114575|NCT03537391|Diagnostic Test|99mTC-HMDP planar bone scintigraphy (BS)|Planar bone scintigraphy will be performed as a part of routine clinical evaluation protocol. The subjects will be positioned supine on a Discovery NM/CT 670 CZT, a digital SPECT/CT scanner (General Electric Healthcare). The scanner includes a dual-detector, free-geometry integrated nuclear imaging camera with the advanced digital CZT detector technology combined with the high-performance Optima CT540 subsystem. Whole-body planar images will be scanned from the anterior and posterior views three hours after the intravenous injection of 670 MBq of 99mTc-HMDP. A wide-energy high-resolution (WEHR) collimator, a scan speed of 13 cm/min, a zoom of 1.0 and a matrix size of 256 x 1024 are used in the scintigraphy.
46026535|NCT02745691|Other|Radiochemotherapy|Either chemotherapy or radiotherapy alone or combination of both (either subsequent or concurrent)
46026536|NCT02745691|Other|Targeted therapy|New targeted therapies for lung cancer
46026537|NCT02745691|Other|Immunotherapy|New immunotherapies for lung cancer
46026538|NCT02734381|Other|Elderly patients|Elderly patients who visited the Emergency Department
45470363|NCT03755089|Drug|Lidocaine 2% Injectable Solution|30mL 2% lidocaine instilled into the bladder lumen 20 via a urinary catheter 20 minutes prior to the Botox® injection procedure
45470364|NCT03391414|Drug|hypertonic bicarbonate|8.4% sodium bicarbonate inhaled
45470365|NCT03391414|Drug|sodium chloride|7% sodium chloride inhaled
45470366|NCT03757117|Drug|Feminizing hormone therapy|"Estradiol valerate was initiated at 2 mg PO daily and increased to 4 mg after 4 to 12 weeks~Antiandrogen therapy with spironolactone started at a dose of 50 mg PO daily and increased every 4 weeks to 200 mg daily"
46114576|NCT03537391|Diagnostic Test|99mTc-HMDP single photon emission computer tomography/computer tomography|SPECT/CT imaging will be carried out after acquisition of the planar images with the same scanner. Three bed positions of SPECT data will be acquired from the top of the head to mid femoral level using WEHR collimators. A non-circular orbit, 60 views with 15-s scanning time per view will be acquired during 180 degrees of rotation. A 128 x 128 matrix size, a zoom of 1.0 and 15% photopeak and lower scatter energy windows are used. After SPECT a CT topogram and a low-dose tomogram with a modulated mAs (noise index ~ 70), 120 kVp, a pitch of 1.35 and a 2.5-mm slice thickness are scanned. The co-registration of SPECT and CT data is verified after which the SPECT images are reconstructed using modern iterative ordered subsets expectation (OSEM) reconstruction algorithm from General Electric or Hermes Medical Solutions, which includes, e.g., 10 iterations and 5 subsets and attenuation, collimator and scatter corrections.
46026539|NCT05628415|Procedure|Non-powered AeonTM Endostapler (according to manufacturer medical device classification IIb)|Closure of the left and/or right side of the lung after bilateral or unilateral lung-volume-reduction- surgery is performed with the non-powered Aeon™ Endostapler (Lexington medical) 60-mm and 45-mm. At the end of the operation, two 24F apical chest tubes are placed on each side and are systematically set at -10 cm H2O suction via the Medela- Topaz™ system. Air leak will be measured quantitatively in ml per minute by use of a Medela-Topaz™ system. Cessation of air leak is the case when a value of 0ml/min or two consecutive values under 30 ml/min by use of thoracic drainage Medela- Topaz™ system are read.
45470367|NCT03757117|Behavioral|Peer navigation|Transgender women community peer navigation
45470368|NCT03752125|Dietary Supplement|Flavonoid, caffeine|2 flavonoid/caffeine capsules before breakfast, 2 capsules before lunch
45470369|NCT03752125|Dietary Supplement|Placebo|2 placebo capsules before breakfast, 2 capsules before lunch
45470370|NCT03398980|Radiation|survivors treated with CRT|Radiotherapy technology included conventional radiotherapy (CRT) and intensity-modulated radiotherapy (IMRT).
45470371|NCT03289533|Drug|Avelumab (MSB0010718C)|Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
45470372|NCT03289533|Drug|Axitinib (AG-013736)|Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
45470373|NCT04727749|Behavioral|Therapy Dog Team Visit|For the intervention group, patient interacts with the therapy dog, handler shares information about the therapy dog, asks about patient's pets, and offers a trading card of the therapy dog at the conclusion of the visit.
45470374|NCT03391258|Procedure|Bone Regeneration with GLAM technique|Bone regeneration with GLAM technique in full arch implant supported rehabilitation
45470375|NCT03391180|Drug|ICON Remineralization|A material used for the Remineralization of white spot lesions.
45470376|NCT03391180|Drug|CPP-ACPF|Casein phosphopeptide-Amorphous calcium phosphate fluoride used for the remineralization of white spot lesions.
45470377|NCT04553107|Behavioral|Deprescribing Intervention|An individualized deprescribing intervention will be created by a pharmacist working with a patient to identify harmful, costly, and unnecessary medications to be reduced. The intervention will include a plan and monitoring for up to 3 months to reduce medication use.
45470378|NCT04553107|Behavioral|Usual Care|The usual care arm will receive the current standard of care, which includes medication reconciliation by a clinic nurse at the time of their appointment. Nurses review all medications and answer medication-related questions, and refer medication questions to the healthcare provider for further discussion when necessary.
45470379|NCT03395002|Drug|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder (1 puff) twice daily via Discair® for two days.
45470380|NCT03395002|Drug|Tiotropium 18 mcg Inhalation Powder|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler® for two days.
45470381|NCT03395002|Drug|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for two days
45470382|NCT05460091|Device|PTech Device|High-frequency vibration device used on regular basis in orthodontics
45470383|NCT05460091|Device|PTech Sham Device|sham device (does not vibrate)
45598599|NCT02355327|Device|Laselle Kegel Exerciser|Participants use a vibrating pelvic floor muscle training ball for 12 weeks. The ball is inserted into the vagina and left for 15 minutes daily in the first week, and if well tolerated 30 minutes daily from the second week onwards. To achieve the vibrating effect, the balls are worn while moving - performing everyday tasks or going for a walk.
46114577|NCT03537391|Diagnostic Test|Whole-body magnetic resonance imaging|Magnetic resonance imaging examination will be performed using a 1.5T (Philips 1.5T Ingenia, Best, Netherlands and/or Siemens 1.5T Aera/Avant, Erlangen, Germany) or 3T (Philips 3T Ingenia, Best, Netherlands and/or Siemens 3T Skyra fit, Erlangen, German) MR system. The body matrix coil in combination with a spinal coil will be used for image acquisition. T1-weighted anatomic imaging, STIR fat suppressed images and DWI will be performed in axial and coronal directions. DWI will be obtained with single-shot 2D spin-echo echo-planar imaging. The total scan time will be approximately 50 minutes.
46114578|NCT03537391|Diagnostic Test|Fluorine-18-prostate specific membrane antigen-1007- positron emission tomography/computer tomography|18F-PSMA-1007 is produced by radiolabelling with fluorine-18 produced by irradiating oxygen-18. Administration of the formulated solution is done shortly (<10h) after production. Imaging is carried out with digital PET/CT scanner (Discovery MI;General Electric Medical Systems, Milwaukee, WI, USA). The patients receive intravenous injection of 200-300 MBq (3 MB/kg) of 18F-PSMA-1007 diluted in 3-5 ml of saline as a 60-sec bolus which will be promptly flushed with saline. Before data acquisition patients will be asked to void. A static emission scan will be acquired 60-min from tracer injection over whole body. The sinogram data will be corrected for deadtime, decay and photon attenuation and reconstructed in a 256x256 matrix. Image reconstruction follows a fully 3D maximum likelihood ordered subsets expectation maximization algorithm incorporating random and scatter correction with two iterations and 28 subsets.The final in-plane full-width half-maximum of the systems is < 6 mm.
46114579|NCT05683665|Device|scintigraphy DaTSCAN|DaTSCAN™ (123I-ioflupnae) tomoscintigraphy assesses the density of dopamine transporters (DATs) on the pre-synaptic membrane of dopaminergic neurons
46026540|NCT05628415|Procedure|Echelon FLEX™ Powered plus Stapler (according to manufacturer medical device classification IIb)|Closure of the left and/or right side of the lung after bilateral or unilateral lung-volume-reduction- surgery is performed with the Echelon FLEX™ Powered plus Stapler (Ethicon) 60-mm and 45-mm. At the end of the operation, two 24F apical chest tubes are placed on each side and are systematically set at -10 cm H2O suction via the Medela- Topaz™ system. Air leak will be measured quantitatively in ml per minute by use of a Medela-Topaz™ system. Cessation of air leak is the case when a value of 0ml/min or two consecutive values under 30 ml/min by use of thoracic drainage Medela- Topaz™ system are read.
46114580|NCT03529591|Device|Selective laser trabeculoplasty (SLT)|In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.
45681892|NCT04405492|Device|Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.|"After inclusion, demographic and medical data will be collected. Point-of-care devices will be tested immediately. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken (D0). A follow-up at D15, M1, M3, M6, M9 will be done. At each visit, participants will be asked information about their health status and their contacts with COVID-19 patients. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Point-of-care devices will be tested during the visit.~Cinical samples will be stored in a dedicated biobank. Other SARS-CoV-2 diagnostic tests will be evaluated in the laboratory on the different samples retrieved from the biobank.~For all antigenic, molecular and serological tests evaluated, the reference method will be real-time RT-PCR as well as the result of medical imaging carried out as part of patient care."
46026541|NCT02745769|Drug|Ramucirumab|Administered IV
46114581|NCT03529591|Procedure|Selective laser trabeculoplasty|In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.
46114582|NCT05053191|Behavioral|Partnership, Assessment, Care and Transition training intervention|Partnership, Assessment, Care and Transition to psychosocial resources. Nurses who participate in PACT will receive 8 hours of training in a single, full-day workshop. We will train nurses in clusters of 10-12 nurses at one time, which will allow for cross-coverage with minimal disruption to workflow, and provide a more intimate, small-group learning environment.
46114583|NCT01027975|Procedure|laparoscopic Nissen/laparoscopic Thal|
46114584|NCT02588391|Behavioral|Brain Training (Active)|Online computer games targeting attention, EF, and problem-solving match the child's skill level.
46114585|NCT02588391|Behavioral|Brain Training (Passive)|Online computer games targeting attention, EF, and problem solving are set to a consistent level.
45470384|NCT05238064|Drug|Parsaclisib|"Phase Ib: Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day. This stage follows the traditional 3+3 model. Parsaclisib is set at 10 mg/day, 15 mg/day, 20 mg/day 3 dose groups, starting from 10 mg/day, each group included 3 subjects. The final dose determined at this stage will be used in the Phase II study.~Phase II:~Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib.~Maintain treatment: 2.5mg orally every day continuously, once a day until disease progression, death or unacceptable toxicity developments. The maximum treatment time of Parsaclisib is no more than 2 years."
45470385|NCT05238064|Drug|CHOP|Cyclophosphamide: 750mg/m2, IV, d1 Doxorubicin: 50mg/m2, IV, d1 Vincristine: 1.4mg/m2, IV, d1 (maximum 2mg) Prednison: 100mg, po, d1-5 21 days per cycle
45681893|NCT04405492|Device|Capillary and salivary sampling|Two rapid tests (NG Biotech) allowing anti-SRAS-CoV-2 antibodies detection from a fingerpick blood sample and antigen detection from a salivary sample will be provided in 3 pharmacies of Ile de France. The inclusion of lay persons will be carried out in pharmacies by investigators of the recruiting centers (Bacteriology and Virology departments). After inclusion, one of the tests will be given to the participant for self-testing. After performing the test, the participant will complete a questionnaire to give a feedback on the test usability and the result obtained.
45681894|NCT05701384|Drug|Lazertinib|160mg po qd
46114586|NCT02588391|Behavioral|Brain Training (Active or Passive)|Online computer games targeting attention, EF, and problem-solving either match the child's level or are set to a consistent level depending on which version the child has already completed.
45681895|NCT04142554|Drug|Parsaclisib|Parsaclisib tablets (1.0, 2.5 or 5 mg) are administered orally daily for up to 14 days
46114587|NCT02588313|Dietary Supplement|Mango fruit powder|Investigation of long-term effects of CarelessTM on microcirculation in healthy volunteers - a randomized, double-blind, placebo-controlled study with parallel design
46114588|NCT02968537|Behavioral|Alc-IT (50/50) (morning)|This alcohol-specific inhibition-training (Alc-IT) training group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In the morning group, this training will be administered within the first 2 hours after awakening.
46114589|NCT02968537|Behavioral|Alc-IT (75/25) (morning)|This version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In the morning group, this training will be administered within the first 2 hours after awakening.
46114590|NCT02968537|Behavioral|Control-training (morning)|This group will receive an unspecific inhibition training. this training is of the same length and difficulty as the two Alc-inhibition-trainings. In the morning group, this training will be administered within the first 2 hours after awakening.
46114591|NCT02968537|Behavioral|Alc-IT (50/50) (afternoon)|"As in the arm Alc-IT (50/50) (morning), this alcohol-specific inhibition-training (Alc-IT) group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
46114592|NCT02968537|Behavioral|Alc-IT (75/25) (afternoon)|"As in the arm Alc-IT (75/25) (morning), this version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
46114593|NCT02968537|Behavioral|Control-training (afternoon)|"As in the arm Control-training (morning), this group will receive an unspecific inhibition training. This training is of the same length and difficulty as the two Alc-inhibition-trainings. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
46114594|NCT05045391|Diagnostic Test|Aspergillus IgG detection|Aspergillus IgG will be detected among pulmonary tuberculosis patients. 5 ml of vein blood will be collected for ELISA.
45470386|NCT05460013|Dietary Supplement|Traditional Control|Placebo control is a compounded made-up shake that is traditionally used by the Hematology ward to supplement patients receiving HSCT. The control provides an equivalent of 500kcals and 20.6g protein, 3.4g fiber per day. The participants will be asked to consume the control twice daily in whole admission.
45470387|NCT05460013|Dietary Supplement|Oral Nutritional Supplement|The product to be studied is a standard polymeric formula. It is intended to provide 500cals, 18.4g protein, and 5g fiber per day. The fiber contained is mostly presented in the form of soluble fiber (inulin, fructo-oligosaccharide). The participants will be asked to consume the intervention twice a day throughout their admission.
45470388|NCT05009368|Drug|Drug: Treatment A|CTL0901, single dose, daily, repeated oral administration for 4 days
46026542|NCT02745769|Drug|Merestinib|Administered orally
45470389|NCT05009368|Drug|Drug: Treatment B|CTL0902, single dose, daily, repeated oral administration for 7 days
45681896|NCT01362608|Drug|Canakinumab, ACZ885|Canakinumab and placebo matching to triamcinolone acetonide
45681897|NCT01362608|Drug|Triamcinolone acetonide|Triamcinolone acetonide 40 mg and placebo matching to canakinumab
45754404|NCT05582252|Other|Non-Invasive saliva sampling|"There are two types of intervention in this ambidirectional study.~Non-Invasive Saliva Sampling will be done for DNA extraction for the purpose of genetic analysis. This would be the prospective sampling and it's not part of the related medical centre's clinical routine.~ICD that is already implanted in the patients and had been indicated by related medical centre's clinical routine approach. This is not a prospective approach to this study since the study would be retrospectively gathered phenotypic parameters from the hospital data records."
46026543|NCT02745769|Drug|Abemaciclib|Administered orally
46026544|NCT04370041|Device|Dokimos Plus aortic valve|Dokimos Plus aortic valve
46026545|NCT05629663|Device|AR guidance with Hololens 2|The AR instructions were developed as a step-by-step guide, utilizing the dynamic 365 Guide (Software, Microsoft Corporation, Redmond, WA, USA). The AR instructions were delivered using the Microsoft HoloLens 2.
46026546|NCT03636607|Diagnostic Test|PET/CT dynamic scan|The purpose of this study is to carry out 18F-FDG PET/CT dynamic scans and biopsy of primary or primary and metastatic lesions in newly diagnosed patients with primary liver cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of 18F-FDG PET/CT dynamic imaging in primary liver cancer metastases are discussed.
46114595|NCT01031329|Procedure|Tympanocenthesis and urine collection|Fluid using needle aspiration is obtained from middle ear fluid. Urine is collected using a urine bag.
46114596|NCT05034939|Device|FLEX Vessel Prep System|"The FLEX Vessel Prep System™ is an over-the-wire sheathed catheter with a three-strut treatment element near the distal tip. As the device is pulled back in a retrograde fashion through the target lesion, the Treatment Element flexes providing continuous engagement along the lesion to create controlled depth micro-incisions."
46114597|NCT05034939|Device|Angioplasty|The brand and type of PTA balloon(s) used will be at the discretion of the treating physician and used according to its Instructions for Use (IFU). PTA balloons consist of an over-the-wire catheter with a balloon fixed at the distal tip. Within the lesion the balloon is inflated to a pressure that allows full effacement.
46114598|NCT05030649|Device|Smart glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
46114599|NCT05030649|Device|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
45838855|NCT04355910|Behavioral|Calorie restriction|"Participants randomized to IFD were asked to restrict energy and carbohydrate on two non-consecutive days each week (75% energy restriction) and to consume a plant foods-based diet that met their estimated energy requirements for the remaining 5 d of the week.~The CCR group was prescribed a daily plant foods-based diet that was relatively low in fat with moderate energy-restriction (25% energy restriction).~The plant foods-based diet included adequate fruit and vegetable, nuts and seeds, whole-grain cereals, olive oil, fish and seafood, a moderate consumption of dairy products, poultry, eggs, and lean red meat."
46114600|NCT04082715|Drug|carbidopa/levodopa and celecoxib|Every patient of this arm will get one bottle of carbidopa/levodopa and one bottle of celecoxib. At treatment initiation, Carbidopa/Levodopa will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with carbidopa/levodopa twice daily for 3 days and then once daily for 3 days before discontinuing it completely.Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
46114601|NCT04082715|Drug|placebo1 and celecoxib|Every patient of this arm will get one bottle of placebo1 and one bottle of celecoxib. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
46114602|NCT04082715|Drug|placebo1 and placebo2|Every patient of this arm will get one bottle of placebo1 and one bottle of placebo2. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. placebo2 will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
46114603|NCT00443209|Drug|Telcagepant 300 mg soft gel capsules|One capsule taken orally at onset of migraine
46114604|NCT00443209|Drug|Telcagepant 280 mg tablets|One tablet taken orally at onset of migraine
46114605|NCT00443209|Drug|Rizatriptan 10 mg tablets|One tablet taken orally at onset of migraine
46114606|NCT00443209|Drug|Placebo to telcagepant capsules|One capsule taken orally at onset of migraine
46114607|NCT00443209|Drug|Placebo to telcagepant tablets|One tablet taken orally at onset of migraine
45470390|NCT05009368|Drug|Drug: Treatment C|CTL0901 and CTL0902, single dose, daily, repeated oral administration for 7 days
45470391|NCT03751891|Device|Phonak Audéo B90-Direct|The Phonak Audéo B90-Direct is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
46114608|NCT00443209|Drug|Placebo to rizatriptan tablets|One tablet taken orally at onset of migraine
46114609|NCT02588235|Drug|Ezetimibe and Atorvastatin|atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）
46114610|NCT02588235|Drug|Atorvastatin|atorvastatin (20 mg/day）
45470392|NCT03751891|Device|HearingAid_A|HearingAid_A is the most recent Receiver-in-the-canal Hearing aid from manufacturer_A which will be fitted to the participants individual Hearing loss.
45838856|NCT04355676|Drug|Selinexor|20 mg selinexor oral tablet.
45838857|NCT04355598|Drug|Lidocaine-Prilocaine cream|2 mL of the Lidocaine-Prilocaine cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
46114611|NCT01020955|Drug|NutropinAq (GH) and Increlex (IGF-I)|NutropinAq (GH)(0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and Increlex (IGF-I) (15 µg/kg/d for 1 month, 30 µg/kg/d for 5 months)
46114612|NCT01020955|Drug|NutropinAq and placebo|NutropinAq (0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and placebo for 6 months.
46114613|NCT05025267|Other|Medical Food: Peptide-Based Enteral Formula|Will be fed exclusively the study peptide-based, high protein enteral formula via a feeding tube
46114614|NCT01028209|Drug|[18F] PBR06|Subjects will be injected with 5mCi, not to exceed >10% of 5mCI, of [18F]PBR06, followed by PET imaging.
46114615|NCT05023551|Drug|DSP-0390|DSP-0390 administered orally
46114616|NCT05015985|Other|Music-Care|music relaxation by a specific hardware and software program application (MUSIC-CARE)
45470393|NCT03751891|Device|HearingAid_B|HearingAid_B is the most recent Receiver-in-the-canal Hearing aid from manufacturer_B which will be fitted to the participants individual Hearing loss.
46026547|NCT02737969|Device|Transesophageal Echocardiography/angiography (TEE/Angio)|"The TEE probe will be inserted into the patient's esophagus, after anesthetic induction or conscious sedation is administered, and removed after the completion of the procedure. Once the TEE probe is placed, the interventional cardiologist will acquire 2 fluoroscopic images with the TEE probe. These images will be used to co-register the ultrasound and fluoroscopy systems. As part of routine care, TEE and fluoroscopy images will be acquired throughout the procedure for clinical purposes. As new fluoroscopy images are acquired, the prototype software will automatically track the location of the TEE probe. When the echocardiographer has an image of a cardiac structure of interest, he may use the prototype software to place landmarks.~The echocardiographer may then press a button to have the landmarks displayed on the fluoroscopy image that is only visible on an assist monitor and will not interfere with the standard fluoroscopy imaging monitor."
46026548|NCT02734225|Other|Functional Recovery|Rehabilitation protocol based on muscle strengthening with isometric, isotonic and counter-resistance with progressive load exercises. Intervention consisted of warm-up phase with passive, active-assisted and active movements, and a work-out phase
46026549|NCT02734225|Other|Balance Training|Balance and proprioception training using parallel bars, unstable plates, ramps and stairs
46026550|NCT02734225|Other|Dynamometric Platform Training|Stability tests, weight changes and stability limits, performing both anterior-posterior and medial-lateral movements simultaneously in some cases
46114617|NCT05015985|Other|control group|music relaxation using a music playlist supply (control group)
46114618|NCT04082793|Combination Product|Photobiomodulation therapy with mandibular exercises|Low-level laser therapy (BMI 1005 Laser 2200) Wavelength: 658 nm Power: 100 MW Energy density: 4J/cm2 Dose administered: 4J Mode: Pulsed Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions/week on alternating days for 12 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement of the jaw Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetitions X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day
46114619|NCT04082793|Combination Product|Sonophoresis with mandibular exercises|"Ultrasound (BM1-1039) Ultrasonic massage with Diclofenac gel Frequency: 1.0 MHz Mode: Continuous Intensity: 0.8 to 1.5 W/cm2~Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions per week on alternating days for 8 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetition X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day"
46114620|NCT00439231|Drug|Lenalidomide|Lenalidomide (Revlimid) regimen testing to determine efficacy for SLL/ CLL subjects
46114621|NCT01021189|Drug|AZD1446|Oral solution Dose single and followed by 7-day multiple dosing.Specific doses depend on panel.
45470394|NCT03391102|Other|Observational study|
45470395|NCT03755011|Device|white noise|Patients in the interventional arm will have white noise (through in-room workstations- on-wheels and publicly-available white noise websites) playing overnight at a standardized volume to be determined.
45470396|NCT03755011|Behavioral|usual care|normal ICU activity noise
45470397|NCT03391024|Device|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system while navigated with clinically approved system.
46026551|NCT02734069|Drug|Carboplatin|Patients will receive carboplatin according to the carboplatin area under the curve dose calculation for 2 cycles to evaluate toxicity.
46026552|NCT02745223|Drug|PresbiDrops (CSF-1)|PresbiDrops (CSF-1) is a topical ophthalmic drug.
46026553|NCT02745223|Drug|Placebo|Placebo drops contains the same ingredients as PresbiDrops except for the active ingredients.
45754405|NCT04157985|Drug|Continue PD-1/PD-L1 Inhibitors treatment|Continued treatment with PD-1/PD-L1-1 inhibitor
45754406|NCT04157985|Other|Discontinue PD-1/PD-L1-1 inhibitor|Discontinued treatment with PD-1/PD-L1-1 inhibitor
46026554|NCT02737813|Drug|Isobaric marcaine|Isobaric marcaine 2.2 mL for spinal block
46114622|NCT01021189|Drug|Placebo|Oral solution Dose single and followed by 7-day multiple dosing.
46114623|NCT04993755|Drug|TPN-101, 400 mg/day|400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
46114624|NCT04993755|Drug|Placebo|Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
46114625|NCT01031485|Dietary Supplement|Milk peptides and plant sterols|
46114626|NCT01031485|Other|Placebo|
46114627|NCT00437983|Dietary Supplement|PS-Omega3|Phosphatidylserine-Omega3 capsules 3x100mg/day 15 wk. Next, follow up phase, open label,1x100mg/day, 15 wk
46114628|NCT00437983|Dietary Supplement|Placebo|Placebo cellulose tainted with fishy odor capsules 3x100mg/day 15 wk
46114629|NCT00783692|Drug|vedolizumab|Vedolizumab for intravenous infusion
46114630|NCT00783692|Other|Placebo|Placebo intravenous infusion
46114631|NCT04992273|Drug|casirivimab+imdevimab|Single dose administered based on weight
46114632|NCT05683509|Procedure|deep collagen layer, xenograft and collagen membrane|Alveolar ridge preservation is done using deep collagen layer, xenograft and collagen membrane
45470398|NCT04547023|Behavioral|Fasting before gestational diabetes screen|Fasting for at least 6 hours before 1-hour gestational diabetes screen.
45470399|NCT04547023|Behavioral|Per oral intake of food and drink|Per oral intake of food and drink within 2 hours of gestational diabetes screen
45470400|NCT05008120|Other|No intervention|No intervention
45470401|NCT03398746|Procedure|LOOP Technique|Placement of subcutaneous loop drain
45470402|NCT03398746|Procedure|Standard incision and drainage|Incise and drain with placement of packing
45754407|NCT03021122|Device|PedAMINES™ / Conventional Method|"Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• PedAMINES™ (Period 1) and then Conventional Method (Period 2)"
46114633|NCT05683509|Procedure|xenograft and collagen membrane|Alveolar ridge preservation is done using xenograft and collagen membrane only
46114634|NCT02588157|Device|Macintosh|Direct laryngoscopy
46026555|NCT02737813|Drug|Hyperbaric marcaine|Hyperbaric marcaine 2.2 mL for spinal block
46114635|NCT02588157|Device|Glidescope|Glidescope videolaryngoscope
45470403|NCT03390946|Drug|Poor responder group adjuvant chemotherapy|"Poor responder group (necrosis ≤ 90%)~: week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20~B. Resection of tumor~C. Adjuvant chemotherapy~Poor responder group (necrosis ≤ 90%)~week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20~Good responder group (necrosis > 90%)~week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin"
45470404|NCT03390946|Drug|Good responder group adjuvant chemotherapy|"Good responder group (necrosis > 90%)~: week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin"
46026556|NCT03630913|Procedure|Tagged axillary metastatic node|"First, initially metastatic lymph node is tagged with a metal clip under sonography. Then, patients receive NAC before surgery.~Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC.~SLN isotope detection is performed with or without blue dye. All patients undergo the resection of the tagged axillary node, SLN biopsy and a complementary axillary lymphadenectomy."
46026557|NCT02745379|Procedure|BFPSCs+ DFDBA+ PRF|
46026558|NCT02745379|Procedure|DFDBA + PRF|
46026559|NCT02745301|Other|Collection of urine and bladder tumor specimens|Voided urine (pre- and post surgical) and intraoperative bladder tumor specimens to be processed for the presence of specific biomarkers.
46026560|NCT02737735|Drug|standard chemotherapy medicine combined with Chinese herbs|
46026561|NCT02737735|Drug|standard chemotherapy medicine|
46026562|NCT02738515|Drug|0.75 % Boric Acid|After Scaling and Root Planing placement of 0.75% Boric Acid gel in Mandibular degree 2 Furcation defect.
46026563|NCT02738515|Drug|placebo|After Scaling and Root Planing placement of Placebo gel in Mandibular degree 2 Furcation defect.
46114636|NCT02588157|Device|McGrath MAC X-Blade|McGrath MAC X-Blade videolaryngoscope
46114637|NCT02588079|Behavioral|Internet-based cognitive behavioral therapy|
46114638|NCT01031173|Biological|agalsidase alfa|0.2 mg/kg body weight, administered by an intravenous infusion over 40 minutes, every other week.
46114639|NCT04082871|Other|Medication management review|The researcher screened each completed an MMR template and verified that all information in each patient template was complete. A classification system was then used to identify the TRPs which either actually or potentially interfered with the clinical outcomes for each patient.[19] This system was explained in detail and applied successfully in many previous studies.[10, 14, 20] The researcher then identified TRPs for each patient in both groups using evidence-based medicine. The TRPs including unneeded drug treatment, untreated condition/s, efficacy/effectiveness issues, safety issues, inadequate knowledge, inappropriate adherence to pharmacological therapy, inappropriate adherence to self-care activities and miscellaneous problems.
46114640|NCT04959903|Biological|Allogeneic T cell progenitors, cultured ex-vivo|Injection of T cell progenitors at [Day 4-Day 10] after T cell depleted allogeneic HSCT
46114641|NCT00783224|Drug|Placebo for MF|Placebo to mometasone furoate nasal spray, indistinguishable from mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
46114642|NCT00783224|Drug|Placebo for FP|Placebo to fluticasone nasal spray, indistinguishable from fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
46026564|NCT05497219|Diagnostic Test|Videofluoroscopic Swallowing Study (VF)|A videofluoroscopy (VF) is a dynamic radiological evaluation of swallowing in which the participant swallows liquid or food boluses of different consistencies prepared with barium contrast. The x-rays are recorded at 30 frames per second.
46026565|NCT02744599|Device|Prompting breaths via recorded voice, vibrating massager, and/or muscle tetany|Prompt volunteer to breathe using device to play recorded voice, massage the body, and/or apply muscle tetany
46026566|NCT00636415|Drug|morphine|1 mg (1 ml) morphine diluted in 9 ml saline by the intra-articular route, and 25 mg (10 ml) 0.25% bupivacaine without epinephrine.
46026567|NCT02733835|Drug|Remifentanil|Vital signs-controlled, patient assisted intravenous analgesia using remifentanil
46026568|NCT02737423|Drug|cholecalciferol|Effect of Vitamin D on the symptoms of diabetic neuropathy
46026569|NCT02694913|Other|Non Interventional|This is a non therapeutic, pilot study.
46026570|NCT02737345|Other|Rotem|
46114643|NCT00783224|Drug|Mometasone|Mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
46114644|NCT00783224|Drug|Fluticasone|Fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
46114645|NCT04102124|Drug|SHR3680|Tablet. Specifications of 80mg
46114646|NCT04102124|Drug|SHR3162|Tablet. Specifications of 10mg、40mg、50mg and 100mg
46114647|NCT04102124|Drug|SHR3680(Placebo)|Tablet. Specifications of 80mg
46114648|NCT04102124|Drug|SHR3162(Placebo)|Tablet. Specifications of 10mg、40mg、50mg and 100mg
46114649|NCT04015479|Dietary Supplement|Peanut Protein Powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
45470405|NCT03390868|Behavioral|Web-based training for staff|This web-based training program is focusing on strengthening the carers' communication skills. Video lectures on the definitions, characteristics and causes of challenging behavior will be given. Video lectures will also be given on the importance of the carers' views on their values, emotions, abilities and attitude towards people with intellectual disabilities and on the impact that workplace culture and environmental factors have on the quality of interactions. The program also includes written cases that gives the participants opportunities to reflect upon approaches supporting a successful interaction. It also covers factors to consider when mental illness and challenging behavior occur. The time to complete the web-based training program is estimated at approximately ten hours.
46026571|NCT05629507|Device|Virtual Reality|"The Virtual Reality intervention will administer through the use of a Virtual Reality headset. The multimedia contents in VR, will have a video quality from 4K to 8K, 360 degrees, and HD audio stereo.~The scenarios are classified into 12 categories: 1) Artistic cities (60 scenarios); 2) Africa (17 scenarios); 3) Hills (26 scenarios); 4) Rivers, lakes and waterfalls (43 scenarios); 5) Sardinia (13 scenarios); 6) Deserts (21 scenarios); 7) Beaches (20 scenarios); 8) Animals (20 scenarios); 9) Mountains (25 scenarios); 10) Concerts (21 scenarios); 11) Sea (24 scenarios); 12) submarine (20 scenarios)."
46114650|NCT04015479|Behavioral|Full body resistance training|Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
46114651|NCT04082559|Other|Arm 1- Antibiotics treatment|Patients with active disease will be randomized and will receive a prescription antibiotic regimens
46114652|NCT04082559|Other|Arm 2- Antibiotics treatment|Patients with active disease will be randomized and will receive a prescription antibiotic regimens
46114653|NCT04082559|Other|Arm 1- Combination therapy (Antibiotics + diet)|Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
46114654|NCT04082559|Other|Arm 2- Combination therapy (Antibiotics + diet)|Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
46114655|NCT04082559|Other|Arm 1- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
46114656|NCT04082559|Other|Arm 2- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
46026572|NCT02737267|Behavioral|Moderately high protein diet|"After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction."
46026573|NCT02737267|Behavioral|Low fat diet|"After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction.the energy derived from fat"
46114657|NCT04082559|Other|Arm 3- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
46114658|NCT04082325|Drug|Lu AF88434|Lu AF88434, single oral solution Starting dose will be 0.2 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).
45754408|NCT03021122|Device|Conventional Method / PedAMINES™|"Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• Conventional Method (Period 1) and then PedAMINES™ (Period 2)"
46114659|NCT04082325|Drug|Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434)|Oral solution
46114660|NCT04082325|Drug|Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434)|Oral solution
46114661|NCT04082325|Drug|Placebo|Placebo to Lu AF88434 oral solution, single dose
45470406|NCT03390790|Drug|Lidocaine gel 2%|If assigned to this intervention via randomization, participants will receive lidocaine (numbing) gel prior to their urodynamics procedure.
45470407|NCT03390790|Other|Standard lubricant gel|If assigned to this intervention via randomization, participants will receive standard lubricant gel prior to their urodynamics procedure.
46114662|NCT00782834|Drug|Nilotinib|400 mg orally twice daily until disease progression, intolerability or withdrawal of consent
46114663|NCT02587845|Drug|Tranexamic Acid (IV)|IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
46114664|NCT02587845|Drug|Tranexamic Acid (Topical)|Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
46114665|NCT04103528|Other|morning surgery|31 patients will be operated on between 8:00 and 12:00 in the morning.
46114666|NCT04103528|Other|afternoon surgery|31 patients will be operated on between 14:00 and 18:00 in the afternoon.
45470408|NCT03697993|Drug|Fosfomycin tromethamine|Administered orally as 3-gram single-dose sachet into 3-4 ounces (1 / 2 cup) of cool water; each dose must be taken immediately after dissolving in water. Hot water should not be used to dissolve fosfomycin. It may be taken either with or without food for normal kidney function. If Creatinine Clearance (CrCl) is less than 20 mL/min, fosfomycin should be taken as 3 grams every other day.
46026574|NCT02744911|Device|SpeechVive device|The SpeechVive is a wearable device that plays multi-talker babble noise in one ear while the person wearing it is talking. The noise is voice-activated (only present when the person speaks). The noise does not interfere with the ability to hear communication partners. The noise coming from the device functions as a natural external cue for people with Parkinson's disease to talk more loudly and clearly. Treatment will involve asking the participants to wear the device daily during the treatment period.
45470409|NCT03697993|Drug|Levofloxacin|750 mg is administered orally as one tablet once daily with or without food for normal kidney function. If Creatinine Clearance (CrCl) is 20-49 mL/min, 750 mg should be taken every other day. If on subsequent testing post-randomization, the Creatinine Clearance (CrCl) is less than 20 mL/min, followed by the dose is 500 mg every other day.
46026575|NCT02744911|Behavioral|Telemedicine interaction|Participants will interact with the speech-language pathologist using the telemedicine platform from their home.
45470410|NCT04446988|Device|Sacroiliac joint injection|Injection of sacroiliac joint with local anesthetic and steroid
45470411|NCT05393245|Drug|Tiotropium+Olodaterol|Tiotropium+Olodaterol
45470412|NCT05393245|Device|Spiolto Respimat|Spiolto Respimat Inhaler device
46026576|NCT02744911|Behavioral|In person interaction|Participants will interact with the speech-language pathologist in-person at the speech pathologist's office
46114667|NCT05683431|Behavioral|Cognitive Control of Emotion (CCE) Training|Training consists of game-like exercises using a software program developed in collaboration with PositScience Corporation (using BrainHQ platform ) - which has exercises targeting cognition and social cognition. The CCE training program incorporates characteristics that optimize learning-induced neuroplasticity - most importantly, exercises are short & rewarding, adapt to individual skill-level, and become increasingly difficult as performance improves. There are 5 CCE exercises that are organized in half-hour sessions and proceed in a predetermined sequence.
46114668|NCT04103840|Other|Testing stool mycobiota|Both cohorts of SAH and their family controls will be tested for fecal mycobiota
46114669|NCT02601404|Device|Bioresorbable scaffold (BRS)|The implantation procedure of an Absorb™ is similar to a metallic stent.
46114670|NCT04099394|Behavioral|Behavioral Health|Ten, group-based classes lasting one hour each that teaches symptom management and promotes physical activity.
46114671|NCT04099394|Behavioral|Health Education|Ten, group-based classes lasting one hour each that teaches topics related to aging and health (e.g., blood pressure control, maintaining healthy bones, cancer screening, immunizations).
46114672|NCT00584805|Biological|Inactivated, Dried, TSI-GSD 104, EEE|Subjects will receive 0.5ml SQ, as a two-dose primary series (days 0 and 28) and 0.1ml, as a mandatory booster dose at 6 months. A booster dose may be administered before 6 months if PRNT80 is < 1:40 after day 28. Up to four booster doses may be given in any 1-year period.
46114673|NCT04934163|Other|Flow rate setting of high-flow nasal cannula (initially 60L/min)|"The flow rates of HFNC(high-flow nasal cannula) is set as 60L/min(temperature:34°C).~Initial FiO2 is 100%, which would be titrated down to the minimal level to keep SpO2 ≥ 92% within 30 minutes after extubation.~After that, the flow rate setting is fixed for 24hrs +/- 6 hrs; then, is tapered to 30 L/min and kept for 12 more hours. Afterwards, HFNC would be changed to conventional oxygen therapy to keep SpO2≥ 92%."
46114674|NCT04934163|Other|Flow rate setting of high-flow nasal cannula (initially 40L/min)|"The flow rates of HFNC(high-flow nasal cannula) is set as 40L/min(temperature:34°C).~Initial FiO2 is 100%, which would be titrated down to the minimal level to keep SpO2 ≥ 92% within 30 minutes after extubation.~After that, the flow rate setting is fixed for 24hrs +/- 6 hrs; then, is tapered to 30 L/min and kept for 12 more hours. Afterwards, HFNC would be changed to conventional oxygen therapy to keep SpO2≥ 92%."
46114675|NCT00765674|Drug|Aliskiren|150 and 300 mg tablets
46114676|NCT00765674|Drug|Amlodipine|5 and 10 mg capsules
46114677|NCT00765674|Drug|Hydrochlorothiazide (HCTZ)|12.5 and 25 mg capsules
46114678|NCT00765674|Drug|Placebo|tablet
46114679|NCT00765674|Drug|Placebo|capsules
46114680|NCT04932291|Drug|vafidemstat|1.2mg capsule
45470413|NCT05393245|Drug|Long-acting muscarinic antagonists (LAMAs)|Long-acting muscarinic antagonists (LAMAs)
45470414|NCT05393245|Drug|Long-acting β2-agonists (LABAs)|Long-acting β2-agonists (LABAs)
45470415|NCT03394690|Dietary Supplement|green coffee|2 capsuls
45470416|NCT03394690|Other|control|2 capsuls
45470417|NCT03754855|Behavioral|Questionnaire|Questionnaire
45470418|NCT05237830|Procedure|Use of Cell Salvage in revision of total hip arthroplasty|The effective use of the cell saver was defined as the ability to re-transfuse at least 125 mL of re-suspended red blood cells with a hematocrit of 60 %.
46114681|NCT04932291|Drug|Placebo|placebo capsule
45470419|NCT04544995|Drug|Niraparib|Niraparib will be administered as tablet
46114682|NCT00765362|Device|Encore Mobile-Bearing Knee|Used for primary total knee replacement
46114683|NCT04231929|Device|Chemoembolization|"First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.~Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of BioPearl™ microspheres used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved."
46114684|NCT00586898|Drug|GnRH|leuprolide and goserelin are gonadotropin-releasing hormone analogues
46114685|NCT00586898|Drug|Ketoconazole|An imidazole antifungal agent. reduces adrenal and testicular androgen production in men
46026577|NCT02737111|Behavioral|Initial Screening Process|The doctor who meets with the family to share the diagnosis will give the participants a flyer about the research study at the end of their consultation and will briefly explain the study aim and purpose. Following this, the ICC Service Clinical Nurse Specialists (CNS) and the primary researcher will identify patients who meet the inclusion and exclusion criteria and all patients who are eligible to take part will be contact by a CNS shortly after a child receives a diagnosis to follow up with the family, and ask permission for the primary researcher to contact the child's parents to discuss the study.
45470420|NCT04544995|Drug|Dostarlimab|Dostarlimab will be administered as IV infusion
45754409|NCT04141514|Other|therapeutic fasting|fasting limited to daily 250 kcal during 3 days (day before chemotherapy, the D day of the chemotherapy and the day after chemotherapy)
46026578|NCT02737111|Behavioral|Information and Informed Consent|The researcher will contact parents of patients who agreed some weeks after receiving the diagnosis, check inclusion criteria, and information sheets will be provided. Individuals who consent to participate will arrange to meet with the researcher in their family home or at the hospital. When they meet, the researcher will go through the participant information sheet with the individuals, and gain written consent for participation
46026579|NCT02737111|Behavioral|Interview|Families who wish to take part will be invited to participate in an interview 2-3 months after they received the diagnosis from the hospital. At least ten families (and therefore at least 30 individuals including children with the diagnosis, parents and siblings) will be interviewed separately, about their experiences of the communication about the diagnosis to them, their child or their siblings. Younger children may do some drawings with the researcher about their experiences, and the researcher will ask questions about these drawings.Participants can be included even if not all family members wish to take part.
46114686|NCT00586898|Drug|Bicalutamide|A pure nonsteroidal antiandrogen
46026580|NCT02737111|Behavioral|Validated Questionnaires|Each member of the family will complete the mood and quality of life questionnaires.
46026581|NCT02737111|Behavioral|Debrief|At the end of each interview the research will explore with the individual to discuss how they found the experience and answer any questions they might have and review the questionnaires that they completed. The researcher will then meet with children and parents together to discuss the experience as a family.Information will be shared with families about options for accessing support including the paediatric psychology service at the hospital or local support services, if they wish. After the interviews, the researcher will send a letter to participants GP and medical team to inform them that they are taking part.
46114687|NCT00586898|Drug|Testosterone transdermal gel|an androgenic anabolic steroid
46114688|NCT00586898|Drug|Estrogen transdermal patch|Estradiol is the primary and most potent estrogen
46114689|NCT02587455|Drug|Pembrolizumab|Pembrolizumab - Trial Treatment
46114690|NCT02587455|Radiation|Radiotherapy|Radiotherapy - Standard Treatment
46114691|NCT04099238|Drug|Oral anticoagulant|Oral anticoagulants may comprise vitamin K antagonists (VKA) and non-vitamin K antagonist oral antagonists (NOAC).
46114692|NCT04932135|Diagnostic Test|Continuous heart rate monitoring|Continuous heart rate monitoring with a wrist worn fitnesstracker
46026582|NCT02733679|Drug|Metformin|Metformin will be given orally, regularly for eight weeks. Dose starts at 500mg once daily for one week, increasing by 500mg per week, to final dose of 1000mg twice daily.
46114693|NCT04099082|Other|samples|blood sample nasal swab
46114694|NCT00919659|Dietary Supplement|parenteral nutrition|25kcal/kg bw with parenteral nutrition
46114695|NCT04099316|Device|Eccentric exercise|Eccentric exercise with Eccentron electronic device. Exercise intervention: The exercise intervention is performed to twice a week (Total 8 weeks). Exercise intensity is gradually increased to the number of times by divided into two stages (1-4 weeks; 1st stage),(5-8 weeks; 2nd stage).
46114696|NCT04099316|Device|Conventional resistance exercise|Leg press exercise with leg press machine. Exercise intervention: The exercise intervention is performed to twice a week (total 8 weeks). Exercise intensity is gradually increased to the number of times by divided into two stages (1-4 weeks; 1st stage), (5-8 weeks; 2nd stage).
46114697|NCT04098926|Radiation|Dose-integrated accelerated EBRT in pN0 breast cancer|WBI: 5 x 5.7Gy Thoracic wall: 5 x 5.7Gy R0 boost: 5 x 6.5Gy R1 boost: 5 x 6.9Gy
46114698|NCT04098926|Radiation|Dose-integrated accelerated EBRT in pN+ breast cancer|WBI: 5 x 5.7Gy Thoracic wall: 5 x 5.7Gy R0 boost: 5 x 6.5Gy R1 boost: 5 x 6.9Gy Lymph node region: 5 x 5.4Gy
46114699|NCT04101812|Drug|pegylated liposomal doxorubicin (PLD)|PLD is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous use.
46114700|NCT04101812|Drug|PD-1|PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands and PD-L1.
46114701|NCT04923867|Device|Suturable DuraGen™|Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.
46114702|NCT02587533|Other|Hypoxia without dopamine|Target hemoglobin oxygen saturation (SpO2) 80%.
46114703|NCT02587533|Other|Hypoxia with dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. Dopamine dose 3 µg/kg/min.
46114704|NCT02587533|Other|Hyperoxia without dopamine|Nearly complete hemoglobin oxygen saturation.
45470421|NCT04544995|Drug|Niraparib|Niraparib will be administered as AAOLF (once available)
45470422|NCT03398668|Device|Relievion device- Treatment stimulation|1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation
45470423|NCT03398668|Device|Relievion Device- Sham stimulation|1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation
45470424|NCT03289455|Biological|AUTO3 (CD19/22 CAR T cells|Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 1 to 5.0 x 10⁶/kg CD19/CD22 Chimeric Antigen Receptor (CAR) positive T cells as a single or split dose.
45754410|NCT04141436|Behavioral|Interventions Based on Hypnofertility|Affirmation Visualization Imagination Relaxation
45470425|NCT03390712|Drug|Paliperidone Palmitate|Monthly injections
45470426|NCT03390712|Drug|Risperidal Consta|Bi-weekly injection
45470427|NCT03390712|Drug|Antipsychotic|Any oral antipsychotic prescribed to be taken on a regular basis prior to the initiation of a long-acting injectable antipsychotic.
45754411|NCT04141436|Other|Routine clinical procedure|Routine clinical procedure
46026583|NCT02733679|Drug|Pioglitazone|Pioglitazone will be given orally, regularly for eight weeks. Dose starts at 15mg once daily and after one week increases to 30mg once daily.
46026584|NCT02736877|Procedure|Lumera Microscope with OCT RESCAN|corneal transplantation guided by Lumera Microscope with OCT RESCAN
46026585|NCT02736877|Procedure|Conventional Microscope|corneal transplantation guided by Conventional Microscope
46114705|NCT02587533|Other|Hyperoxia with dopamine|Nearly complete hemoglobin oxygen saturation. Dopamine dose 3 µg/kg/min.
46114706|NCT04916847|Other|blood collection|"Depending on the weight of the child, between 5ml and 15ml of blood will be collected during a blood test necessary for the conventional care of the patient. A second blood sample will be taken one year later. The volume of blood taken does not exceed the volume allowed by the guideline Ethical considerations for clinical trials of medicinal products conducted in the paediatric population.~We will analyse:~Specific antibody responses (IgM, IgG, and immunoglobulin A (IgA) anti SARS-Cov-2) by quantitative chemiluminescence analysis.~Protective neutralizing capacity of these antibodies (neutralizing antibodies against SARS-cOV-2) by neutralization test.~SARS-Cov-2 specific memory T cell responses by multiparametric flow cytometry in order to characterize their maturation, differentiation, senescence, activation, secretion of interleukin (cytokines 2) , IFN-g, TNF) or Interferon-gamma (IFN-g) ELISPOT assay."
46114707|NCT04912245|Behavioral|Telehealth visit|Patients with either MCI or unrecognized dementia and their care partners (if available) will be approached to participate in a telehealth Advance Care Planning (ACP) visit with a member of the patient's primary care team via either telephone or video. Patients without willing or available care partners are still eligible to participate in the study.
46114708|NCT04884945|Procedure|Open Pyeloplasty (OP)|Open approach for the surgical correction of UPJ obstruction
46114709|NCT04884945|Procedure|Robotic-Assisted Laparoscopic Pyeloplasty (RALP|Robotic approach for the surgical correction of UPJ obstruction
46114710|NCT04870905|Drug|Tis-U-Sol|Tislelizumab 200mg will be given every 3 weeks for 12 cycles
46114711|NCT02587689|Biological|anti-MUC1 CAR T Cells|
46114712|NCT04082403|Procedure|Training on Suction Assisted Laryngoscopy and Airway Decontamination|Education on Suction Assisted Laryngoscopy and Airway Decontamination, via 30 minute teaching session, followed by practical demonstration of techniques.
46114713|NCT04082403|Procedure|No Training on Suction Assisted Laryngoscopy and Airway Decontamination Provided|No Training on Suction Assisted Laryngoscopy and Airway Decontamination provided to trainees
46114714|NCT04862325|Other|Multimodal Prehabilitation|"High-intensity endurance exercise training program and physical activity promotion remotely controlled with ICT (information and communications technologies).~Nutritional counselling to achieve protein intake of 1.5-1.8 g/kg and whey protein supplements.~Psychological intervention including motivational interview, mindfulness meditation and cognitive behavioral therapy"
46114715|NCT00919737|Drug|NPC-08|Polifeprosan 20 with Carmustine 3.85%
46114716|NCT03936231|Other|NO Intervention|"Given the observational nature of this study, we consider that no intervention is required.~Participation in concomitant studies: given the observational condition of this study, patiens that are included in other observational and/or experimental researches, can be included in the current study."
46114717|NCT02587611|Other|Elemental liquid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg [13C]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
46114718|NCT02587611|Other|Standard semi-solid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg [13C]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
46114719|NCT04848051|Behavioral|CRC screening reminder|Participants randomized to the CRC Reminder arm will receive reminder that they are due/overdue for CRC screening
46114720|NCT04848051|Behavioral|CRC Reminder & Short message|Participants randomized to the CRC Reminder & short message arm will receive reminder that they are due/overdue for CRC screening and short message to encourage screening
46114721|NCT04848051|Behavioral|CRC Reminder and Navigation Program|Participants randomized to the CRC reminder and navigation program arm will receive reminder that they are due/overdue for CRC screening and short message to participate in the health navigation program that will connect participants to individually tailored resources and assistance
45598600|NCT02355327|Behavioral|Pelvic floor muscle exercises|Participants get standard care after childbirth, which is the routine recommendation of pelvic floor muscle exercises. Participants will be asked to continue/start the pelvic floor muscle exercises they routinely were recommended by customary written instructions from their health professionals after birth. Intervention duration for this study is 12 weeks.
45598601|NCT02223845|Other|Music|Self-selected music played via headphones
46114722|NCT04848051|Behavioral|CRC Reminder & CRC education|Participants randomized to the CRC reminder and CRC education program arm will receive reminder that they are due/overdue for CRC screening and offered short educational program conducted online
45598602|NCT03516955|Drug|Rosuvastatin|Superstat ® Tablets 10mg, 20mg
45598603|NCT02348151|Other|Treadmill|The volunteers will perform the shuttle walk test on the treadmill
46026586|NCT02695147|Procedure|TAVI|
46026587|NCT02744443|Dietary Supplement|Leucine|
46026588|NCT02744443|Dietary Supplement|Placebo|
46026589|NCT02732353|Dietary Supplement|Minced beef|Cow meat protein supplement
46026590|NCT02732353|Dietary Supplement|Hydrolyzed beef|Cow meat protein supplement
46026591|NCT02731963|Drug|Polyethylene glycol|Patients with colorectal pathology who underwent elective colorectal anastomosis, that were randomized into two groups; one of them received mechanical bowel preparation with polyethylene glycol (study group), and the other one received clear liquid diet(control group) .
46026592|NCT03289741|Drug|Octreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Octreotide LAR for 3 injections followed by lanreotide for 3 injections
46026593|NCT03289741|Drug|LAR Lanreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
45598604|NCT02348151|Other|Corridor|The volunteers will perform the shuttle walk test on the corridor
46026594|NCT03289741|Behavioral|Questionnaires|Baseline questionnaire, Post-treatment questionnaire (after the first 3 injections), Preference questionnaire and Pain Score Diary.
46026595|NCT03865927|Other|Placebo Oral Tablet|see Arm/Group description
46026596|NCT03865927|Drug|GKT137831|GKT137831 is a NOX enzyme inhibitor
46114723|NCT04847661|Drug|Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed cases|Mefloquine hydrochloride will be given in a dose of 1100-1650 mg, according to body weight (BW), splitted into two to three doses.
46114724|NCT00919815|Drug|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
46114725|NCT00919815|Drug|Prednisolone|prednisolone 40mg daily then reducing regimen over 24 weeks
46114726|NCT02587377|Other|Non Standard of Care blood samples collection|According to Belgian Law of 07MAY2004, if non standard of care interventions are performed as per protocol, the study must be classified as Interventional Study.
46114727|NCT00796991|Drug|Ipilimumab|Solution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks
46114728|NCT00796991|Drug|Carboplatin|Solution, intravenous, Area Under the Concentration Time Curve=6, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
46114729|NCT00796991|Drug|Paclitaxel|Solution, intravenous, 175 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
46114730|NCT00796991|Drug|Dacarbazine|Solution, intravenous, 850 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
46114731|NCT05682183|Behavioral|Multi-domain Psychoeducation Self-management Programme|The MPSP is a 5-weeks psychoeducation programme aimed at improving the biopsychosocial health of people with MDD (PMDD). It will be conducted on every Saturday in the morning, afternoon and evening. Specific time of each session will be further discussed with the centre. Each session will last for approximately 45 minutes to 60 minutes and will be capped at 10 participants. The mode of session will be face-to-face (F2F) session conducted at MindCare.
46114732|NCT05682183|Other|Treatment as usual|Care management from assigned care manager
46114733|NCT04082247|Behavioral|The education and training of early childhood educators and their intervention on children|"A 24-week cluster randomized trial will be developed, with the childcare being the randomization unit. Training sessions will be conducted for all early childhood educators in the intervention group. The control group will receive the Portuguese standard education and at the end of the intervention this group will also receive the initial training given to the intervention group, so that they can later also implement the intervention. At the end of the intervention, all early childhood educators and parents/guardians will have access to the intervention outcomes."
46114734|NCT05681949|Other|ADBoard|Utilizing the clinical decision support system 'ADBoard' for therapy selection in participants with hepatobiliary tumors
46026597|NCT02731807|Dietary Supplement|Dose A: TA-65 24mg, powder|
46114735|NCT04112225|Behavioral|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
46114736|NCT04787211|Drug|BRII-196 and BRII-198|BRII-196 and BRII-198 given by intravenous administration
46114737|NCT04787211|Drug|Placebo|Placebo given by intravenous administration
46114738|NCT04112147|Drug|Antroquinonol capsule 100mg|Patients will receive 12-week of 50mg BID Antroquinonol
46114739|NCT04112147|Drug|Antroquinonol capsule 200mg|Patients will receive 12-week of 100mg BID Antroquinonol
46114740|NCT04112147|Drug|Placebo oral capsule|Patients will receive 12-week of 100mg BID Antroquinonol placebo
46114741|NCT04081857|Drug|HGP1810|HGP1810: Vildagliptin/Metformin
46114742|NCT04081857|Drug|HCP1704|HCP1704: Vildagliptin/Metformin
45598605|NCT02259179|Drug|Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)|
46114743|NCT02604953|Diagnostic Test|Short Duration Transient Visual Evoked Potential (SDtVEP)|Short duration transient visual evoked potentials (VEPs) detect disruption of electrical signals at any point along the visual pathway, from the retinal ganglion cells (RGCs) to the primary visual cortex. As an objective measure of visual function, VEP may have advantage over traditional visual field tests, by reducing confounded factors such as age, fatigue, and mental status.
46114744|NCT02604953|Diagnostic Test|Pattern electroretinogram (PERG)|Pattern electroretinogram (PERG), an objective test, is used for evaluating early damage to retinal ganglion cells (RGC). In PERG, retinal response is recorded while patterns are viewed in the visual field on a computer monitor.
46114745|NCT04773171|Other|Computer-assisted Cognitive Remediation|Drill practice and bridging activities
46114746|NCT04773171|Other|Conventional training programmes|Existing conventional activities in the settings
45598606|NCT02259179|Drug|Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)|
46114747|NCT02605109|Other|Risk of MERS infection|HCPs, patients and layperson to closely or indirectly contact a case-patients
46114748|NCT00914771|Biological|H5N1 pandemic Influenza vaccine 3.75µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 3.75µg H5N1 antigen
46114749|NCT00914771|Biological|H5N1 pandemic Influenza vaccine 7.5µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 7.5µg H5N1 antigen
46026598|NCT02731807|Dietary Supplement|Dose B: TA-65, 8mg, powder|
46026599|NCT02731807|Dietary Supplement|Dose C: TA-65 3.2mg, capsule|
46026600|NCT02731807|Dietary Supplement|Dose D: TA-65 8mg, capsule|
46026601|NCT02731807|Dietary Supplement|Dose E: TA-65 32mg, capsule|
46114750|NCT04114331|Other|Manual therapy and exercise|Manual therapy consisting of soft tissue and joint mobilization to gain mobility. Therapeutic exercise was active motion and resisted motion to gain motor control and motor coordination in the new range.
46114751|NCT02586987|Drug|Selumetinib|Selumetinib oral
46026602|NCT02744521|Other|Symptom-based screening intervention|The objective of this study is to evaluate whether empowering and involving inmate peer educators in TB control has an impact on increasing TB case detection rate and improving treatment success in resource-limited prison settings. In this interventional study, inmate peer educators will be trained about TB, its prevention, and control. Once tested for their capability, peer educators will then provide education about TB, its prevention and control for their fellows every two weeks on a regular basis for one year. They will also undertake routine TB screening using a standardized TB screening protocol to identify presumptive TB cases for a referral.
46026603|NCT05473585|Other|very low nicotine content cigarettes|Investigational combusted cigarettes with very low nicotine content
46114752|NCT02586987|Drug|MEDI4736|MEDI4736 IV
46026604|NCT05473585|Other|normal nicotine content cigarettes|Investigational combusted cigarettes with normal nicotine content
46114753|NCT02586987|Drug|Tremelimumab|Tremelimumab, IV
46114754|NCT04114253|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
46114755|NCT02586753|Other|Paclitaxel plus Cisplatin with radiotherapy|"we want to compare which regime is better with radiotherapy, PT regime (paclitaxel and cisplatine ) Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PT regimen (cisplatin of 20 mg/m2/d, d1-3; PTX(paclitaxel)of 135mg/m2/d, d1) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.~Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
46114756|NCT02586753|Other|S1 plus Cisplatin with radiotherapy|"we want to compare which regime is better with radiotherapy,SP regime (Tegafur Gimeracil Oteracil Potassium Capsule and cisplatine).~Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PS regimen (cisplatin of 20 mg/m2/d, d1-3; S1(Tegafur Gimeracil Oteracil Potassium Capsule)of 50mg/m2/d, d1-14) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.~Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
46114757|NCT00920049|Behavioral|Persuasion|
46114758|NCT00799487|Drug|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
46114759|NCT00799487|Drug|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
46114760|NCT00584727|Device|senofilcon A toric contact lens|contact lens
46114761|NCT00584727|Device|alphafilcon A toric|contact lens
46114762|NCT00584727|Device|etafilcon A sphere|contact lens
46114763|NCT04081935|Device|Virtual Reality|virtual reality (VR) as a distracting intervention could reduce pain and fear during an IV placement for school-age children in the emergent department.
46026605|NCT05473585|Other|Study e-cigarette|E-cigarette provided by study
46026606|NCT04189705|Drug|MCT-SR|Rebamipide 150mg
46026607|NCT04189705|Drug|Mucosta Tab.|Rebamipide 100mg
46026608|NCT02731651|Procedure|open hysterectomy|Hysterectomy with laparotomy incision.
46114764|NCT05616195|Other|3D printed bone prosthesis replacement surgery|To report the postoperative complications and limb function of patients who underwent 3D-printed bone prosthesis replacement in Henan Cancer Hospital.
46114765|NCT00799409|Drug|Placebo/ CONCERTA (methylphenidate HCl)|Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
46114766|NCT00799409|Drug|CONCERTA (methylphenidate HCl) / Placebo|Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
46114767|NCT00782210|Drug|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
46114768|NCT00782210|Drug|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
46114769|NCT00782210|Drug|placebo|Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
46114770|NCT04691739|Other|occupational therapy|occupational therapy sessions include a set of standardized test exercises plus additional modalities that are optimized to each patient's needs according to the clinical judgement of the treating therapist
46114771|NCT04111679|Other|Music|Participant selected music, applied using noise cancelling headphones
45598607|NCT03520153|Procedure|Hyperinsulinemic Euglycemic Clamp and 2H20|Test is used to assess insulin effects on hepatic glucose production.
45598608|NCT03520153|Procedure|Hyperglycemic Clamp|Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.
46114772|NCT05678153|Diagnostic Test|Nordic Orofacial Test-Screen (NOT-S)|screening tool to detect orofacial dysfunction
46114773|NCT00920127|Dietary Supplement|AKL1|"Each dose of AKL1 or placebo will consist of two capsules which will be swallowed twice daily for 8 weeks.~The morning dose of study medication should be taken at approximately the same time each morning between 7:00 am and 10:00 am and should consist of two 500 mg capsules and then repeated between 7.00 pm and 10 pm."
46114774|NCT05607771|Device|Manual Vitrification|Oocytes will be vitrified using the manual protocol
46114775|NCT05607771|Device|Automated Vitrification|Oocytes will be vitrified using the DaVitri device
46026609|NCT02731651|Procedure|laparoscopic assisted vaginal hysterectomy|Hysterectomy with laparoscopic assisstance.
46026610|NCT05629429|Drug|Olaparib|Olaparib 300mg BID PO
46026611|NCT05629429|Drug|Chemotherapy drug|Continue platinum based chemotherapy
46026612|NCT02744131|Drug|Oral contraceptive pill combination of ethyl estradiol and Cyproterone acetate|
46026613|NCT02744131|Drug|Metformin 1500mgs per day|
46114776|NCT01558115|Drug|Denosumab|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study"
46114777|NCT01558115|Other|Placebo|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection. The placebo group will receive vehicle injections at the same time interval.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study"
45470428|NCT03754777|Procedure|Laparoscopic appendectomy|"Preoperative care in both arms. Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~Surgery. General anesthesia with strict control of fluid therapy and hemodynamic changes during surgery. Appendectomy with the use of monopolar coagulation by experienced surgeons following appendix stump ligation by two Roeder knots.~Postoperative care. Antibiotics for 3-5 days for patients with complicated appendicitis (Gomez ≥ 3A). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 2, 6, 12 and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery."
45470429|NCT03390634|Other|Gastroesophageal reflux symptoms questionnaires|Reflux Disease Questionnaire (RDQ) Reflux Symptoms Index (RSI) Gastroesophageal Reflux Disease Health-Related Quality of Life (GORD-HRQL)
46114778|NCT01294007|Biological|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft with posterior transpedicular fixation.
46026614|NCT02731885|Drug|ABX464 Single dose|Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
46026615|NCT02731885|Drug|ABX464 Repeated dose|Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
46114779|NCT01294007|Procedure|Autograft bone|Iliac Crest and Local Autograft Bone
45470430|NCT03756805|Device|upper airway stimulation|One group of patients with UAS
45470431|NCT03756805|Device|continuous positive airway pressure|One group of patients with CPAP
45470432|NCT03126604|Diagnostic Test|female sexual function index|evaluation of sexual functions questionnaire about Desire, Arousal, Orgasm,pain , lubrications, satisfactions
45470433|NCT03756727|Drug|Ascorbic Acid|Patients in Ascorbic acid group received 2g of intravenous Ascorbic acid at the night before surgery, during the surgery and five days after surgery (once a day).
45470434|NCT03756727|Drug|Saline|Patients in Control Comparator group received saline 10ml at the night before surgery, during the surgery and five days after surgery (once a day).
45470435|NCT04962724|Drug|Radiolabelled Xevinapant 200 mg (Oral Solution)|[14C]-Xevinapant 200 mg administered as an oral solution on Day 1 of Part 1, containing approximately 100 microcurie (μCi) [3.7 megabecquerel (MBq)] in fasted conditions.
45754412|NCT03890900|Other|T2DXcel mobile application|T2DXcel is a mobile application (patient-facing) that delivers guideline-based diabetes education.
45754413|NCT00609271|Behavioral|low carbohydrate diet|<40 grams carbohydrate/day
45754414|NCT00609271|Behavioral|low fat diet|<30% fat, <7% saturated fat
46026616|NCT05468749|Drug|CTP-543|Single 12 mg oral dose administered on Day 1
46026617|NCT02731495|Dietary Supplement|EGCG|EGCG (Epigallocatechin -3-gallate)
46026618|NCT02731495|Dietary Supplement|Placebo (deionized water)|
46026619|NCT02731573|Drug|D-PLEX|D-PLEX will be administered as a single application during the open heart surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.
46026620|NCT02731573|Procedure|Open heart surgery|Subject will undergo open heart surgery according to standard of care
46026621|NCT02733523|Behavioral|"Program Sentirnos bien (Feeling well)"|"Group-based intervention delivered face-to face and held once a week during 3 months. It comprises:~Promoting the uptake of self-care healthy habits: providing information, setting personal goals and sharing experiences to facilitate behavioural change, specially on physical activity and healthy dietary habits.~Promoting social capital at individual level: facilitating mutual knowledge and mutual support among participants and fostering participation in sociocultural and community activities in the neighbourhood through visits to the community assets accompanied by volunteers.~Promoting health literacy: improving navigation through the health care system, communication with health professionals, as well as the understanding and decision making when buying food."
46026622|NCT03326791|Drug|Acetylsalicylic acid|Trombyl 160 mg once daily
46026623|NCT03326791|Drug|Placebo Oral Tablet|Placebo one tablet daily
46026624|NCT02743975|Drug|Bevacizumab-800CW|dose finding: 4.5mg; 10mg; 25mg; 50mg
46026625|NCT02743663|Procedure|Bronchodilator response|Bronchodilator (Salbutamol - dose dependent on participant prescription) to wheezing subjects. 15 minutes after bronchodilator, spirometry and FOT repeated.
46026626|NCT02743663|Procedure|Allergy Skin Test|Child will be tested for allergies to 17 different allergens, and positive (histamine) and negative (glycerin) controls, for a total of 19 allergens.
46026627|NCT02743663|Procedure|Multiple-Breath Washout|Facemask in children 3-5 yrs, Wash-in phase: medical air inhaled during tidal breathing until steady state. Bias flow switched to 100% oxygen. Wash-out phase: patient breathes in 100% oxygen until nitrogen levels reach ~2%. Each test in duplicate and average is calculated.
46114780|NCT02606123|Drug|EPI-506|"Patients will receive EPI-506 as an oral softgel capsule.~Part 1:~Approximately six dose levels of EPI-506 will be studied, beginning at 80 mg/day. During the Single-Dose Period, patients will first receive a dose of EPI-506 in the fasted state followed by 2 days of washout, and then patients will receive a second dose of EPI-506 in the fed state followed by 2 days of washout. Patients will then enter the Multiple Dosing and Long-term Dosing Period where they will receive once or twice daily dosing in a fed or fasted state until they meet discontinuation criteria.~Part 2:~The dose in Part 2 will be determined in Part 1 of the study. Patients will receive the Part 2 dose daily until they meet discontinuation criteria."
45470436|NCT04962724|Drug|Radiolabelled Xevinapant 100 μg (IV Solution)|100 μg [14C]-xevinapant single dose administered as an IV bolus on Day 1, containing approximately 0.2 μCi [7.4 kilobecquerel (kBq)].
46114781|NCT04684641|Drug|Standard Dose YPT-01|Participants will be randomized to receive the standard dose of phage therapy YPT-01.
46026628|NCT02743663|Procedure|Forced Oscillation Technique|Sterile mouthpiece attached to FOT device. Patient is tested seated with noseclips and mouthpiece. FOT device produces oscillations at different frequencies (from that flow into lungs. Device measures resistance and reactance in lungs.
46026629|NCT02743663|Procedure|Spirometry|Forced exhale manoeuvre completed by participant into flow meter, measuring forced exhale volumes and speed.
46114782|NCT04684641|Other|Placebo|Participants will be randomized to receive the placebo.
46114783|NCT05677763|Drug|OM-85|Subjects will be administered OM-85 3.5 mg capsules by mouth once daily. (10 days per month)
46114784|NCT05677763|Drug|Placebo|Subjects will be administered Placebo once daily. (10 days per month)
46114785|NCT04684485|Drug|Placebo|Placebo Tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.
45470437|NCT04962724|Drug|Xevinapant 200 mg (Oral Solution)|Xevinapant 200 mg administered as an oral solution on Day 1 of Part 2 in fasted conditions
45470438|NCT03398590|Behavioral|self-regulation theory-based mHealth behavior intervention|Participants will receive a self-regulation theory-based mHealth behavior intervention (5 biweekly group sessions, 60 minutes /session). An experienced Certified Diabetes Educator from the Joslin Diabetes Center and PI (Dr. Zheng) who has been trained using self-regulation for weight loss will co-facilitate group sessions. The intervention combines diet modification and increased physical activity with a weekly weight loss goal as well as focuses on improving participants' three typical self-regulation strategies - self-monitoring, self-evaluation and self-reinforcement. Intervention duration will last 2 months with subsequent 1-month follow.
45598609|NCT03520153|Diagnostic Test|Oral Glucose Tolerance Test|The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.
45838858|NCT04355598|Drug|glyceryl trinitrate cream|2 mL of the glyceryl trinitrate cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
46026630|NCT02743663|Drug|salbutamol|Given during bronchodilator response.
46026631|NCT02743663|Procedure|Nasal Brush|Nasal brush of 1 inferior turbinate to collect epithelial cells. Collected on either nare, choice dependent on how clear the nare is (i.e. no mucous, no nasal mucosal edema, no major structural impediments).
46026632|NCT02743663|Procedure|Blood sample|8mLs of venous blood collected using a butterfly needle of appropriate gauge. Blood sample used to collect CBC values, total IgE, serum, DNA, plasma, and whole blood.
46026633|NCT02743663|Procedure|Basophil activation test|Collect basophils from whole blood sample, and expose cells to food allergens in flow cytometry machine to measure allergic response, if any.
46026634|NCT02743663|Procedure|Nasal swab|Gentle swabbing of both nasal openings to collect mucous sample for analysis of microbial contents (i.e. bacteria, virus, fungi).
46026635|NCT02731417|Other|acupuncture|Acupuncture for women with post partum urinary retention
46114786|NCT04684485|Drug|SCD-044_Dose 1|SCD-044 tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.
46114787|NCT04684485|Drug|SCD-044_Dose 2|SCD-044 tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.
46114788|NCT04684485|Drug|SCD-044_Dose 3|SCD-044 tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.
46114789|NCT04111913|Drug|Anlotinib Hydrochloride|anlotinib once daily on days 1-14 of 21days cycle.
46114790|NCT04081467|Other|Bed rest|10-day of complete bed rest
46114791|NCT02605265|Radiation|Radiation|Pelvic Radiation: 50Gy/25Fx
46114792|NCT02605265|Drug|Capecitabine|
46114793|NCT02605265|Drug|Irinotecan|
46114794|NCT02605265|Drug|Oxaliplatin|
46026636|NCT02731417|Device|Foley catheter|Foley catheter insertion for women with post partum urinary retention.
46026637|NCT02731339|Device|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
46114795|NCT04682769|Other|Other|Patients with Coronary Heart Disease and Depressive Disorder are receiving routine treatment by their physician.
46114796|NCT02604875|Other|observation|blood sampling during 24 hours
46114797|NCT04081623|Device|Raydiant Oximetry Sensing System|The investigational device is used to record fetal pulse signals.
46114798|NCT04101500|Drug|Compound Ipratropium Bromide Solution(C1) for Inhalation|The patient's condition and basic condition were the same in the experimental group and the control group.
46114799|NCT04101500|Drug|Compound Sodium Chlolate and Aminophylline Tablets(C2)|Applied only to the experimental group.
46026638|NCT02731339|Behavioral|Low back pain intensity measurement|Low back pain intensity of the patients was questioned by Visual Analogue Scale
46026639|NCT02731339|Behavioral|Urogenital symptoms measurement|The presence and severity of various urogenital symptoms was assessed with the Urogenital Distress Inventory-6
46114800|NCT04101500|Drug|Placebo Tablets|Applied only to the control group.
46114801|NCT05676515|Other|culture media|spliting of biological material and use of three culture media
46114802|NCT04103060|Drug|Cerdulatinib 0.37% gel|Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks
46114803|NCT04103060|Drug|Vehicle gel|Vehicle gel applied topically twice daily for 6 weeks
46114804|NCT02586441|Device|Electroencephalography|Raw EEG signals were acquired at a sampling rate of 128Hz using a BIS-VISTATM monitor and was measured during all anesthetic period.
46026640|NCT02731339|Behavioral|Disability caused by low back pain|Disability caused by low back pain was assessed with the Oswestry Disability Index
46026641|NCT02733211|Device|MD- Logic Closed Loop System|Closed Loop System
46114805|NCT02586441|Drug|Propofol|intravenous 1% propofol (1.5-2.5 mg/kg)
46114806|NCT02586441|Drug|Rocuronium bromide|intravenous rocuronium bromide (0.6 mg/kg)
46114807|NCT05558241|Device|High-resolution micro-ultrasound|In a single biopsy session, first, a microUS-guided biopsy of regions of interest (ROIs) will be performed. The MRI fusion software will then be turned on, the clinician unblinded to the MRI results, and biopsy cores from within the boundaries of the MRI-fused lesion will be sampled from ROIs. Up to two ROIs identified on microUS or MRI will be targeted with up to 3 cores per ROI. If the MRI ROIs overlap with the microUS ROIs after unblinding, then the cores taken during the microUS-guided biopsy will be counted as both microUS and MRI-guided. Finally, a standard 12-core systematic biopsy will be performed.
46114808|NCT02586363|Drug|Baraclude Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
46114809|NCT02586363|Drug|Cavir Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
46114810|NCT02586363|Drug|Cavir Tab. 0.5mg, high fatty meal|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
45754441|NCT00610987|Drug|Placebo|Patients will be randomly assigned to one of two groups. Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group II will receive no additional antibiotic. Instead, they will receive normal saline injection every eight hours as a placebo.
46026642|NCT02733211|Device|sensor augmented pump therapy|Sensor augmented pump therapy
46026643|NCT02743585|Device|Filmarray Blood Culture ID (BCID) panel|The BCID panel is an FDA-approved nucleic acid amplification test (based on nested polymerase chain reaction) which detects Gram positive, Gram negative, the major Candida species and antimicrobial resistance markers (mecA for methicillin resistance, van A/B for vancomycin resistance, blaKPC for KPC carbapenemase) directly from positive blood cultures in < 1 - 1.5 hours
46114811|NCT00920205|Drug|MPC-3100 (an Hsp90 inhibitor)|oral daily dose for 21 days in a 28-day cycle
46114812|NCT00764660|Drug|SCH 900435|tablets
46114813|NCT00764660|Drug|Placebo|tablets
46114814|NCT02586285|Drug|S-Adenosyl Methionine|500mg-1000mg,iv,qd
46114815|NCT00584415|Device|GP ablation + PV isolation|All patients underwent GP ablation and PV isolation using the NaviStar ThermoCool ablation catheter
46114816|NCT05326022|Device|Microcurrent therapy|Microcurrent therapy
46114817|NCT05326022|Device|Low Level Laser Therapy|Laser therapy
46114818|NCT05326022|Other|Medical therapy|Medical therapy
46114819|NCT02586129|Drug|YH14755|20/1500mg, QD
46114820|NCT02586129|Drug|Metformin|1500mg, QD
46026644|NCT02743585|Device|Rosco Diagnostica ESBL/carbapenemase screen kit|These kits are CE-marked (Approved in the European Union) rapid chromogenic tests for extended-spectrum beta-lactamase / carbapenemase detection from both blood cultures and cultured bacterial colonies.
46114821|NCT02586129|Drug|Rosuvastatin|20mg, QD
46114822|NCT00916604|Drug|AZD1656|Three increasing dose-steps with oral suspension, 8 days treatment
46114823|NCT00916604|Drug|Placebo|Placebo oral suspension, 8 days treatment
46026645|NCT02733445|Drug|dasatinib|
46026646|NCT02733445|Drug|nilotinib|
46026647|NCT02731261|Other|Motor memory consolidation|Subjects were divided in two groups: a control group and an experimental group. Before the intervention of a physical exercise program, subjects performed a Finger Tapping Sequence to measure baseline performance. After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training.
46026648|NCT02731105|Drug|Acnatac® Gel left face|topical application
46026649|NCT02731105|Drug|Epiduo® Gel right face|topical application
46026650|NCT02731105|Drug|Acnatac® Gel right face|topical application
46026651|NCT02731105|Drug|Epiduo® Gel left face|topical application
46026652|NCT02743429|Drug|dinutuximab beta|"Up to 5 cycles of continuous infusion of ch14.18/CHO is administered at a dose of 10 mg/m2/day over 10 days (total dose 100 mg/m2/cycle).~Cycle duration: 35-days."
46114824|NCT04081077|Drug|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
46114825|NCT04081077|Drug|Pretomanid|Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
46114826|NCT04081077|Drug|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
46026653|NCT05454553|Other|myocardial perfusion SPECT|"For all participants, myocardial perfusion SPECT will be performed :~at 3, 6 and 12 months (post irradiation)"
46026654|NCT02730949|Dietary Supplement|D-chiro-inositol|Treated group
46114827|NCT04081077|Drug|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
46026655|NCT02730949|Dietary Supplement|Folic Acid|Control group
46026656|NCT04205929|Drug|Placebo|Placebo (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
46026657|NCT04205929|Drug|Curcumin|Curcumin 600 mg (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
46026658|NCT03856645|Drug|OKG-0301|OKG-0301 is an experimental ophthalmic antiviral and immunomodulatory therapeutic
46026659|NCT03259867|Drug|Nivolumab Injectable Product|a PD-1 immune check inhibitor
46026660|NCT03259867|Combination Product|Trans-arterial tirapazamine embolization|Embolization with Lipiodol and Gelfoam
45754442|NCT04140578|Drug|Ertapenem|inject from iv drip before endoscopic cyanoacrylateinjection obliteration
46026661|NCT02695069|Procedure|Random Placenta Margin Incision|A random hysterotomy incision is done in the placenta margin. To precisely determine the placental location and the edge of the placenta, preoperative ultrasonography is used in determining the optimal place for the uterine incision.
46026662|NCT04190797|Device|Photobiomodulation + patiente controled anaethesia (PCA)|Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device connected, 24h and 48h after the peripheral nerve block (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
46026663|NCT04190797|Device|Placebo + patiente controled anaethesia (PCA)|Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device switched off, in 24h and 48h after peripheral nerve bloc (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
46026664|NCT02743195|Dietary Supplement|Polyphenol/prebiotic blend|
46026665|NCT02743039|Behavioral|CareerAdvance®|CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
46026666|NCT03308773|Other|Lifestyle modification in routine care of patients|Diabetes Prevention Program Lifestyle recommendations and non-investigational pharmacotherapy in routine care of patients
46026667|NCT02731183|Procedure|fecal microbiota transplantation|Patients received frozen FMT on 6 consecutive days through nasojejunal tubes.
46114828|NCT04081077|Drug|Clofazimine|Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
46114829|NCT04669665|Drug|SLS-002|Intranasal racemic ketamine hydrochloride 90 milligrams (mg)
46114830|NCT04669665|Drug|Placebo|Intranasal placebo
45754443|NCT00574171|Drug|lapatinib|1250mg by mouth daily one hour before or after breakfast on a continuous basis.
46026668|NCT00636493|Device|fluocinolone acetonide (Retisert Implant)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
46026669|NCT02742961|Other|Peripheral nerve block|A physician billing code for deposition of a local anesthetic solution around an anatomically defined nerve or nerve plexus
46026670|NCT02730637|Other|Early nephrologist consultation|
46026671|NCT02730559|Other|Motivational Interviewing/Counselling|Motivational Interviewing/Counselling
46026672|NCT02730481|Drug|Oraxol|Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
46026673|NCT05423353|Device|Paraffin Bath Therapy|Device named 'Fizyowax 1300' (Fizyomed, Turkey).
46026674|NCT05423353|Device|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
46114831|NCT04669665|Other|Standard of care|Standard of care treatment will be determined by the treating physician(s) based on clinical judgement and practice guidelines
46114832|NCT04669665|Device|Intranasal device|Device to deliver intranasal solution
46114833|NCT00764504|Device|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and no previous shoulder device implanted.
46114834|NCT00764504|Device|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and a failed hemi or total shoulder implant.
46114835|NCT02586051|Drug|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) IV infusion.
46026675|NCT02733055|Other|posturographic evaluation|subjects will undergo CDP testing using one of the ext_mCTSIB tests without (baseline) and with oculomotor task
46114836|NCT02586051|Drug|Intravenous Immunoglobulin|High dose (2 grams per kilogram [g/kg]) IVIG (maximum 140 grams).
46114837|NCT02601326|Procedure|Laparoscopic ventral mesh Rectopexy|Laparoscopic fixation of rectum to sacral promontory using mesh
46026676|NCT02732977|Other|expert system development|data collection (imaging, biology physiology ... ) of patients with systolic heart failure complicated by mitral regurgitation and / or cardiac synchronization before and after implementation of the recommended standard treatments and modeling using mathematical and statistical models fed all data .
45470439|NCT03390556|Other|Nurse-delivered education|"The nurse will:~Give the caregiver and child an overview of asthma, and discuss asthma control, triggers, and medications.~Give caregivers information about asthma management written at or below 6th grade reading levels.~Provide colored medication labels to distinguish controller from rescue medications following the action plan color scheme (green for controller medications, red for rescue medications). Teach-back methods will be used to elicit understanding of correct indications of use.~Demonstrate MDI/spacer technique with teach-back.~Discuss age-appropriate caregiver and child responsibility for asthma management within the family, with an overview of transitioning responsibility.~Ask patients to make a 1 month follow-up appointment for asthma care."
46114838|NCT02601326|Procedure|Delorme's procedure|Transanal excision of rectal mucosa and plication of muscle layer
46114839|NCT04101734|Device|Double Lumen Endotracheal Tube.|Intubation was performed with Double Lumen Endotracheal Tube.
45470440|NCT03390478|Other|Combined Intervention Group|Experimental: Combined Intervention Program is composed by a Cognitive Stimulation Program (CSP), a Physical Activity Program (PAP) and Animal Assisted Therapy (AAT). During the PAP participants that use rolling-walkers, will do PAP using the Auto-Blocking kit mechanism for rolling walkers (ABMRW).
45470441|NCT03398512|Procedure|exploratory laparoscopy or laparotomy|Exploratory laparoscopy or laparotomy, for PCI score or radical colorectal resection and cytoreductive surgery
45470442|NCT03398512|Procedure|HIPEC|Normal saline 3000ml-4000ml, Raltitrexed 4mg, 43°C, 60min.
45470443|NCT03398512|Drug|Systemic chemotherapy|Oxaliplatin: 130mg/m2, day 1. Capecitabine: 1500mg, twice daily for two weeks, and then suspend for one week
45470444|NCT03390400|Device|Femtosecondlaser-assisted|Femtosecondlaser-assisted Cataract Surgery will be performed bilateral on the same day with different laser settings.
46026677|NCT02732821|Procedure|Gastric Per Oral Endoscopic Myotomy|Patients will receive Per Oral Endoscopic Gastric Myotomy for Gastroparesis.
46026678|NCT02742727|Biological|anti-CD7 CAR-pNK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD7 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD7.
45470445|NCT03390400|Procedure|Anterior Capsulotomy|Cataract Surgery
45470446|NCT03390400|Procedure|Lens Fragmentation|Cataract Surgery
45470447|NCT04484857|Drug|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm description.
46026679|NCT02730091|Drug|Letrozole|Letrozole 2.5 mg daily
46114840|NCT04101734|Device|Double Lumen Video Endotracheal Tube.|Intubation was performed with Double Lumen Video Endotracheal Tube.
46114841|NCT04099160|Other|Evaluation|The Turkish version of the Revised Neurophysiology of Pain Questionnaire will be applied to patients with chronic spinal pain at the beginning of the study and a week later. The Visual Analogue Scale and the Short Form-36 (SF-36) questionnaire will be applied to patients only at the beginning of the stuy.
46114842|NCT02601638|Other|Demographics and Health History Questionnaire|
46114843|NCT02601638|Other|Pre-Class Laryngectomy Survey|
46114844|NCT02601638|Behavioral|Counseling session with speech pathologist|
46114845|NCT02601638|Behavioral|Total Laryngectomy Preoperative Education Class|
46114846|NCT02601638|Other|Day of Hospital Discharge Laryngectomy Survey|
46114847|NCT02601638|Other|Day of Discharge Practicum|
46114848|NCT02601638|Other|Laryngectomy Education Study Exit Survey|
46114849|NCT00763958|Drug|Placebo|Placebo to match buprenorphine administered for 3 months
46114850|NCT00763958|Drug|Buprenorphine|Buprenorphine provided for 3 months; dosing was as clinically indicated up to 32 mg daily.
46114851|NCT02601482|Behavioral|CON|
46114852|NCT02601482|Behavioral|IW-60|
46114853|NCT02601482|Behavioral|IW-45|
46114854|NCT04101578|Drug|Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)|Treatment regimens are determined according to the physician's judgment and preferences of the patients.
46114855|NCT00763256|Drug|Triclosan, Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned treatment period.
46026680|NCT02730091|Drug|Anastrozole|anastrozole 1 mg daily
46026681|NCT02730091|Drug|Vinorelbine|50 mg three times a week (Monday Wednesday and Friday)
46114856|NCT00763256|Drug|Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned study treatment period.
45470448|NCT03398434|Drug|MAA868|3 MAA868 doses, single administration, subcutaneous,
46114857|NCT02585973|Drug|AZD1775|AZD1775 given twice daily (BID) for three consecutive days (M-W) concomitantly with standard of care cisplatin and radiation. AZD1775 doses will be escalated in 50 mg increments up to 200 mg BID (M-W) in subsequent cohorts to determine the MTD.
46114858|NCT02585973|Drug|Cisplatin|40 mg/m2 IV infused over 1 hour D1 of each week of radiation
46114859|NCT02585973|Radiation|Intensity Modulated Radiotherapy Treatments|Total dose will be 70 Gy at 2Gy/fx, 35 fractions, M to Fri, for 7 weeks
46114860|NCT00920283|Device|Chrono Carbostent Carbofilm™ Coated Coronary Stent|
46026682|NCT02730013|Behavioral|Square Stepping Exercise|"Square Stepping Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids.~In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged."
46114861|NCT00920283|Device|Driver Cobalt Alloy Coronary Stent|
46026683|NCT02742805|Dietary Supplement|Vitamin D (4,000 IU/day)|High Dose of 4,000 IU/day.
46114862|NCT04081311|Device|comparing interdental floss to water flosser around dental implants|to determine the effectiveness in reducing the bleeding on probing (BOP) index around dental implants
46114863|NCT04080921|Combination Product|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear Cells
46114864|NCT00762788|Device|senofilcon A|1 week extended wear contact lens
46114865|NCT00762788|Device|lotrafilcon A|1 week extended wear contact lens
46114866|NCT00762788|Device|lotrafilcon B|1 week extended wear contact lens
46114867|NCT00762788|Device|balafilcon A|1 week extended wear contact lens
46114868|NCT00762788|Device|comfilcon A|1 week extended wear contact lens
45470449|NCT03398434|Drug|Apixaban|Apixaban 5 mg b.i.d
45470450|NCT03398122|Procedure|TACE|epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
45470451|NCT03398122|Drug|Apatinib|a molecular targeted anti-tumor drugs,small molecule vascular endothelial growth factor receptor 2 inhibitor
45470452|NCT03750799|Device|Whole body vibration|Whole body vibration was applied on the right lower extremity in the experimental group.
45470453|NCT03750799|Device|Sham vibration|Sham vibration was applied on the right lower extremity in the Control sham group
45470454|NCT03754621|Diagnostic Test|Serum thyroid functions tests|Serum TSH, fT3, fT4 and anti-TPO
45470455|NCT03394300|Other|iol power calculation|iol power calculation in high myopia
45838859|NCT04355598|Drug|placebo cream|2 mL of the placebo cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
45838860|NCT04355286|Drug|Bemotrizinol|Market-image topical sunscreen formulation containing BEMT (6%)
46114869|NCT00762788|Device|etafilcon A|1 week extended wear contact lens
46114870|NCT04080609|Drug|Dorzagliatin|GKA currently under clinical development
46114871|NCT04080687|Device|Ankle-foot orthosis|Ankle-foot orthosis of any type (unilateral or bilateral, standard or carbon fiber, for support or correction)
46114872|NCT00583947|Drug|arformoterol|Arformoterol is given at a 7.5 ug per dosing during the cross-over phase and 15 ug per dosing during the open-label phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
46114873|NCT00583947|Drug|levalbuterol|Levalbuterol is given at a 0.63 mg per dosing during the cross-over phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
46114874|NCT00772928|Biological|Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®|0.5 mL, Intramuscular
46114875|NCT00772928|Biological|Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®|0.5 mL, Intramuscular
46114876|NCT00762476|Drug|3804-250A|"topical product~apply 2 pumps~apply at least every 4 hours or after hand washing"
46114877|NCT00762476|Drug|3804-291|"topical~apply 2 pumps~apply at least every 4 hours or after hand washing"
46114878|NCT02585661|Dietary Supplement|Dairy product fortified with enriched Fe-54 salt (1)|2.5mg of Fe per 100g of product
45470456|NCT05459857|Other|Heated tobacco device Intense (Product A)|Heated Tobacco device Intense, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
46114879|NCT02585661|Dietary Supplement|Dairy product fortified with enriched Fe-57 salt (2)|2.5mg of Fe per 100g of product
46114880|NCT00762164|Drug|Vytorin|Vytorin 10/80 split into 4
46114881|NCT00762164|Drug|Simvastatin|Simvastatin 20 milligrams
46114882|NCT02585817|Device|Remote CIED Management|Information Technology
46114883|NCT00762086|Device|AngioPress Intermittent pneumatic compression (IPC) Device|Treatment with Intermittent pneumatic compression (IPC) for PAD
46114884|NCT00762086|Other|Medications and Standard walking exercises|Aspirin/Clopidegrol and Standard walking exercises
45470457|NCT05459857|Other|Heated tobacco device Regular (Product B)|Heated Tobacco device Regular, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
45470458|NCT05459857|Other|Heated tobacco device Menthol (Product C)|Heated Tobacco device Menthol, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
45838861|NCT04355520|Drug|TQ-B3525|TQ-B3525 tablets were taken orally, once daily in 28-day cycle; The doses were 20 mg and 30 mg.
45838862|NCT04355520|Drug|Fulvestrant injection|Fulvestrant injection 500mg administered intravenously (IV) on day 1, day 15 of first cycle and on day 1 of follow-up treatment cycle. Each cycle is 28 days.
45838863|NCT04355442|Procedure|Facial fractures reduction or osteosynthesis|Facial fractures reduction or osteosynthesis
45838864|NCT04355208|Other|(3M™ Filtek™ Universal )|universal nanofillers resin composite (3M™ Filtek™ Universal )
46114885|NCT04098614|Behavioral|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
46026684|NCT02742805|Dietary Supplement|Vitamin D (400 IU/day)|Low Dose of 400 IU/day.
46026685|NCT02742805|Drug|Omalizumab|Standard of care dose.
45470459|NCT05459857|Other|Combustible cigarette (Product D)|Subject's own brand combustible cigarette, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
46026686|NCT02742571|Other|non applicable|
46114886|NCT00761774|Drug|Brivaracetam|Subjects will begin at a recommended dose of Brivaracetam 100 mg/day. Subjects will continue treatment at a dose up to a maximum of 200 mg/day with a twice per day administration. Up- and down-titration steps may be performed in steps of a maximum of 50 mg/day on a weekly basis. Full down-titration should include a one week step on 20 mg/day. The study medication will come in 10 mg and 25 mg tablet strengths.
46026687|NCT03204643|Behavioral|BH-VPN|A bundle of usual care components, applied consistently and completely, along with access to behavioral health specific patient navigators and navigation services.
46026688|NCT02729779|Other|Pilates Group|Elderly will be submitted to a specific exercise program of modified Pilates method performed in the mat and apparatus. In the first session, participants will receive basic guidance on the Pilates training and activation of the power house. The session will be divided in: global warming and stretching (5 minutes), Pilates exercises for upper and lower limbs, abdomen and spine (45 minutes), global stretching (5 minutes) and local relaxing massage (5 minutes).The session will consist of a minimum of 5 exercises and a maximum of 15 Pilates exercises. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
46026689|NCT02729779|Other|Aerobic Group|Elderly will be submitted to an exercise program with global stretching (for lower and upper limbs and column with two repetitions and 30 seconds of maintenance in each segment) for 10 minutes, walking on a treadmill for 20 to 40 minutes, and relaxing massage for 5 minutes. The intensity of the effort during walking on a treadmill will be based on a combination of heart rate (based on the percentage of maximum heart rate: 208 - (0.7 x age)) and rate of perceived effort assessed by the Borg scale. Exercise will be performed respecting the fraction of 50-75% of maximum heart rate and levels between 12 to 13 (moderate intensity) of the Borg scale. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
46026690|NCT02729857|Dietary Supplement|SFA muffin|Muffin rich in saturated fat.
46026691|NCT02729857|Dietary Supplement|PUFA muffin|Muffin rich in polyunsaturated fat.
45470460|NCT03394222|Drug|preoperative budesonide inhalation|
45470461|NCT03394222|Drug|preoperative normal saline inhalation|
45470462|NCT05216302|Behavioral|Group-based Nordic Walking Exercise Program|An exercise intervention based on nordic walking and health education of one hour and 15 minutes per session. Each session includes 10 min of health education followed by 15 minutes of warm-up exercises, 30 minutes of nordic walking and finally 15 min to cool-down. The intervention is meant to last during two months (last round of chemotherapy and one month pre-surgery), twice weekly for approximately a total of 16 sessions.
45838865|NCT04355052|Drug|hydroxychloroquine in combination with camostat mesylate|Two drugs which may act as antivirals against SARS CoVid 2 (Hydroxychloroquine may also act as an immunomodulator, Camostat mesylate is a protease inhibitor)
45838866|NCT04355052|Drug|Hydroxychloroquine in combination of Azithromycin|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2-5
46026692|NCT02732743|Dietary Supplement|Physiomanna® Baby|Dosage 1g/kg body, 2 cycles (if applicable)
46026693|NCT02732431|Other|Sleep Symptom|Questionnaires, skin allergy test, overnight polysomnography
46114887|NCT00583791|Device|Device closure with the AMPLATZER Muscular VSD Occluder|Device: AMPLATZER Muscular VSD Occluder
46114888|NCT04080453|Other|Septic shock|Plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha, HMGB-1, monocyte Dnases signal, circulating free DNA and DNase1 and DNase1L3 activities will be studied and compared at inclusion (Day 0), Day 1 and Day 5.
45470463|NCT03398044|Drug|Dexamethasone|Dexamethasone will be administered to patients randomised into the active treatment arm, in order to determine the influence upon PONV incidence.
46114889|NCT04080453|Other|Systemic Inflammatory Response Syndrome|Plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha, HMGB-1, monocyte Dnases signal, circulating free DNA and DNase1 and DNase1L3 activities will be studied and compared at inclusion (Day 0), Day 1 and Day 5.
46114890|NCT04080375|Drug|Dinoprostone 3 mg|the patient will take one vaginal tablet of 3 mg dinoprostone 1 hour before surgery
46114891|NCT04080375|Drug|placebo|the patient will take one vaginal tablet of placebo 1 hour before surgery
45470464|NCT03398044|Drug|Placebo|Placebo will be administered to patients randomised into the control group arm.
45470465|NCT04095793|Drug|ampreloxetine|Oral tablet, QD
45470466|NCT03848260|Device|Magnetic device prototype|The device prototype comprises a near-infrared light-emitting diode (SMT910, Epitex Inc, Kyoto, Japan) and receiver (PD15-22C TR8, Everlight Electronics Corporation, New Taipei City, Taiwan), a permanent electromagnetic actuator (JNP-12/12, Joint Magnetic Technology Corporation, Shenzhen, China), an iron sheet affixed to the paralytic upper eyelid, and a bio-signal acquisition module. The efficacy and safety of the device prototype was assessed using the device prototype.
45470467|NCT04914520|Biological|VN-0200|VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
45470468|NCT04914520|Biological|Placebo|Placebo administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
45470469|NCT04482439|Device|Vivity Extended Depth of Focus intraocular lens (IOL)|Bilateral implantation of the Vivity lens after cataract surgery, with slight myopia planned in the non-dominant eye.
45838867|NCT04354974|Behavioral|Evaluation|Evaluation of a cognitive remediation program for mood disorders
45838868|NCT04354662|Drug|Toripalimab|240mg d1
45838869|NCT04354662|Drug|Docetaxel|50mg/m2, d1;
45838870|NCT04354662|Drug|Fluorouracil|2600 mg/m², d1
45838871|NCT04354662|Drug|Leucovorin|200 mg/m², d1
45838872|NCT04354662|Drug|Oxaliplatin|85 mg/m², d1
46026694|NCT02742259|Device|Blood Draw|Blood draws only - non-diagnostic, non-treatment
46026695|NCT02729623|Drug|Kite Systems cannaHALER cannabis Inhaler.|
46026696|NCT04189549|Diagnostic Test|CNA Rapid Sepsis Dx|Novel biomarker based on circulating cell-free DNA (cfDNA) in the human blood stream
46026697|NCT04190719|Other|multimodal prehabilitation|"Paprika prehabilitation program content: patients will have choices for each activity. Messages and motivation will be reinforced by using a mobile app or leaflet advices, according to patient's preferences.~Physical activity promotion by discovering ebike, personalised gymnastics and encouragement to increase the number of daily steps of patients, measured by a wristband and a mobile App~An individualized nutritional optimization plan with dietary advices and protein supplementation (if necessary).~Psychological support will be proposed through auto-hypnosis sensibilisation or management of stress with Cognitive Behavior Stress Management technics"
46026698|NCT02690389|Drug|Flumazenil|used alone or with acupuncture
46026699|NCT02690389|Procedure|Acupuncture|used alone or with flumazenil
46114892|NCT00781274|Drug|MP-424|750 mg every 8 hours for 12 weeks
46114893|NCT00781274|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
46114894|NCT00781274|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
46114895|NCT02585739|Genetic|blood sample|
45470470|NCT03785236|Radiation|68Ga-NODAGA-exendin PET/CT|68Ga-NODAGA-exendin PET/CT
45598610|NCT02355093|Procedure|adductor canal block (ACB)|We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.
45754444|NCT00574171|Drug|Capecitabine|2000mg/m2 of body surface area (BSA), by mouth, divided into twice daily dosing. Capecitabine will be given for days 1 through 14 of a 21 day cycle.
45754445|NCT05581862|Behavioral|3 meals+3 snacks|All of the 20 subjects consumed an energy restricted weight loos plan with 3 main meals and 3 snacks for 3 months
45754446|NCT05581862|Behavioral|3 meals|All of the 20 subjects consumed an energy restricted weight loos plan with 3 main meals for 3 months
45754447|NCT03585998|Drug|Durvalumab|Concurrent radiotherapy Maintenance therapy
46114896|NCT02585583|Radiation|Thalamotomy|VoA-Vop complex of the thalamous or VIM nucleus will be targeted. 100 Gy, 120 Gy, 130 Gy, 140 Gy will be the foreseen prescription dose. CyberKnife will be always used to perform the procedure.
46114897|NCT04103294|Dietary Supplement|cowpea variety #1|two most popular varieties of cowpea currently consumed in the selected geographic area
46114898|NCT04103294|Dietary Supplement|cowpea variety #2|two most popular varieties of cowpea currently consumed in the selected geographic area
46114899|NCT02585505|Procedure|stem cells|stem cell will be injected
46114900|NCT03995576|Other|thoracic sympathetic ganglion block|thoracic sympathetic ganglion block which needle reaches posterolateral vertebral body
46114901|NCT04080765|Behavioral|HIV-ASSIST|HIV-ASSIST is an online interactive patient-based tool that allows for individualized HIV treatment recommendations through the synthesis of patient-specific factors with existing guidelines and evidence.
45470471|NCT03750682|Other|Physical Activity (PA) Intervention|The PA intervention will consist of a twice per week group- based moderate-intensity multimodal program that includes aerobic, strength, flexibility, and balance training, as previously described. The Community Health Promoter will be trained and certified by Dr. Reid to deliver the PA intervention. PA will be conducted at the Holland Street Senior Center in Somerville, MA. The center is equipped with a large dining hall and corridors which will be utilized to perform the various components of the PA intervention for ENGAGE-B. This real-world approach was shown to be safe, feasible and effective in the initial ENGAGE study among older adults with severe mobility-limitations. Throughout PA, walking will be the primary mode of exercise, given its widespread applicabilityThe study staff will administer an Adverse Event/Concomitant Medication Questionnaire biweekly to all PA subjects.
45754448|NCT00612235|Drug|Lamotrigine|Subjects had at least 3 months on a stable dosage of lamotrigine monotherapy.
45754449|NCT00612235|Drug|Levetiracetam|Subjects had at least 3 months on a stable dosage of levetiracetam monotherapy.
46026700|NCT03838861|Behavioral|NEMO: NEw MOdel of follow-up|The nurse led model is built upon phone contacts with content and intervals individually planned by the nurse and the patient. The individual contacts will be supported by graphic visualisation of ePROMs in REDCap filled out by the patient before each contact including DGCG's disease specific symptom list and the generic European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (24) supplemented with the relevant disease-specific add-on module (25, 26). The sum scores are visualised with colours to indicate severe problems (red), no problems (green) and mild or moderate problems (yellow and orange), respectively. Hence, alarm symptoms and problem areas are clearly presented to the project nurse and changes can be visualised over time enhancing the interpretation. The patient will be given access to own scoring results to obtain an understanding of the meaning of changes in health status.
46114902|NCT04080765|Behavioral|DHHS guidelines|This is the Department of Health and Human Services HIV/AIDS Treatment Guidelines.
46114903|NCT04103372|Other|Surveillance 6 monthly|6 monthly surveillance
46114904|NCT04103372|Other|Radiotherapy and surveillance|as per local policy
46114905|NCT04103372|Other|surveillance 3 montly|3 monthly surveillance
46114906|NCT00916292|Drug|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.
46114907|NCT00916292|Drug|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.
46114908|NCT02585427|Dietary Supplement|low glycemic index rice, high glycemic index rice, butter, olive oil and grapeseed oil|
46026701|NCT02732197|Drug|Sedation|Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
46026702|NCT02732197|Drug|No sedation|Parturients did not receive any type of sedation after spinal anesthesia.
46026703|NCT02729935|Drug|Parecoxib|40 mg of intravenous parecoxib 30 min before surgery
45754450|NCT00612235|Drug|Carbamazepine|Subjects had at least 3 months on a stable dosage of carbamazepine monotherapy.
45838873|NCT04354350|Drug|Ramipril|Ramipril dispensing claim is used as the reference
45838874|NCT04354350|Drug|Telmisartan|Telmisartan dispensing claim is used as the exposure
46114909|NCT02585193|Behavioral|Weight Watchers Intervention|All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
46114910|NCT02585271|Device|Transanal decompression tube|22 Fr transanal decompression tube
46114911|NCT02585271|Device|Stent|self-expandable colorectal nitinol alloys stent
46114912|NCT05520177|Drug|601 1.25mg|loading phase (6 months): 601 1.25mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
46114913|NCT05520177|Drug|ranibizumab 0.5mg|loading phase (6 months): ranibizumab 0.5mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
46114914|NCT04625517|Procedure|Digital Mammography|Digital Mammography enhanced with an iodinated contrast agent
46114915|NCT04625517|Drug|Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml|Injection of low osmolar contrast material during the digital mammography exam
46114916|NCT00780416|Drug|MP-424|750 mg every 8 hours for 12 weeks
46114917|NCT00780416|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
46114918|NCT00780416|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
45754451|NCT00612235|Other|No Intervention|No intervention was given
45754452|NCT03585842|Other|No intervention|No intervention
46114919|NCT00780416|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 48 weeks
46026704|NCT02729935|Drug|Placebo|An equal volume of saline
46026705|NCT02742415|Behavioral|Caring Hand Massage|Caring Hand Massage is a hand massage therapy program with several steps and techniques.
46114920|NCT00780416|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 48 weeks
46114921|NCT02585037|Other|Kinesio Taping® bandage|"The Kinesio Taping® bandage will be applied in an I format in the wrist flexor muscles of a dominant and non-dominant limb in G1 and G2 groups."
46114922|NCT02585037|Other|Dynamometer Jamar® pressure|The Jamar® dynamometer will be adjusted to the second position for measurement of maximal voluntary strength of handgrip. A muscle contraction period of three seconds will be performed in order to record handgrip strength.
46114923|NCT02585037|Other|Placebo|For the control group (G3) the Kinesio Taping® bandage will be placed from the lateral extremity to the medial axis.
46114924|NCT02584881|Other|safe opioid prescription protocol|When indicated a prescription for naloxone will be given to patients discharged with prescription opioids from the trauma services. All patients will receive information on safe opioid use and storage and methods for pain management.
46114925|NCT04098692|Drug|Derazantinib capsule|300 mg derazantinib oral administration (3x100 mg capsules)
46114926|NCT04098692|Drug|[14C]-Derazantinib solution for infusion|100 μg [14C]-derazantinib intravenous administration
46114927|NCT04098692|Drug|[14C]-Derazantinib capsule|300 mg [14C]-derazantinib oral administration (3x100 mg capsules)
45681898|NCT03581968|Device|Artificial Pancreas|"The system is composed of 3 main components:~Insulin infusion pump to infuse insulin. The pump model used in the study is t:slim, Tandem Diabetes Care.~Continuous glucose monitor (CGM) to continuously measure glucose levels in the interstitial fluid. Glucose levels will be measured by Dexcom G5® CGM.~MAP application (iMAP) that computes insulin infusion based on the glucose values. The application also alarms the user when glucose sensor values are approaching the hypoglycemic or hyperglycemic range. The iMAP runs on an android smartphone.~Every 10 minutes, iMAP retrieves the glucose values from the Dexcom G5 CGM via Bluetooth. The application computes an optimal insulin infusion rate based on i) the current glucose reading, ii) the glucose trend (i.e. how quickly the glucose level is rising or falling) and iii) the open-loop basal rates (study parameters). The insulin recommendations are then sent wirelessly via Bluetooth to the insulin pump."
46114928|NCT04080063|Other|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
46114929|NCT04098536|Behavioral|Diesel exhaust|Exposure to diesel exhaust fumes
46114930|NCT02584803|Radiation|Ultrasound|"Evaluating the feasibility and efficacy of IVC ultrasound imaging through the RUQ and subxiphoid view in term parturients.~Patient Acceptability of procedure~Patient Comfort:~Ease of exam for the examiner"
45681899|NCT03159286|Behavioral|Abstainer|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use.
45681900|NCT03159286|Behavioral|Abstainer + User|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use and using alcohol.
45681901|NCT03159286|Behavioral|Control|Participants view social networking site profiles with no alcohol content.
46114931|NCT04079985|Other|Animal-assisted therapy|The sessions were held in the primary care centre, and had specific objectives agreed in advance by the research team. The sessions had the following schedule: Session 1, lower extremities in sitting position; Session 2, upper extremities in sitting position; Session 3, cervical spine in sitting position; Session 4, dorsal spine in sitting position; Session 5, lumbar spine in sitting position; Session 6, Static Standing and Upper Extremities; Session 7, Static Standing; Sessions 8, 9, 10 and 11, Dynamic Standing; and Session 12, Safety Reinforcement.
46114932|NCT05506059|Diagnostic Test|Ultrasound|Participants will have ultrasounds of the heart by two different emergency medicine doctors.
45838875|NCT04354740|Procedure|with percutaneous coronary intervention (PCI) are with new-generation drug-eluting stents (DES)|"II-PCI:~-Coronary angiography and intervention will be done according to the European guidelines of ACS revascularization.~III-CABG:"
46026706|NCT02721667|Device|Telemonitoring|Secure, wireless transmission of home blood pressure measurements that are summarized in a secure health portal for healthcare providers use for clinical management decisions, including calculation of mean BP and graphing of temporal trends.
46026707|NCT02721667|Other|Case Management|Case managers work collaboratively with patients and physicians to optimize health behaviours, monitor risk factors, implement therapeutic adjustments, encourage adherence, and coordinate follow-up care.
46026708|NCT02729389|Behavioral|High Social Status Condition|Participants will be provided with a high degree of privilege in a game of Monopoly.
46026709|NCT02729389|Behavioral|Low Social Status Condition|Participants will be provided with a low degree of privilege in a game of Monopoly.
45470472|NCT03750682|Other|Healthy Aging Education (HE) Intervention|"The HE intervention will also be conducted at the Holland Street Senior Center in Somerville, MA. Participants will receive bimonthly lifestyle counseling workshops in a group setting. Participants will receive information on a variety of topics of relevance to older adults (e.g., nutrition for brain health, effective negotiation of the health care system, dietary guidelines for older adults, safe travel, age-appropriate preventive services and screenings, resources for reliable health information, etc.). All intervention materials will be submitted for IRB approval prior to the presentation. In addition to educational offerings, an instructor led program (5-10 minutes) of gentle upper extremity stretching exercises and relaxation techniques are to be performed during each class.~The study staff will administer an Adverse Event/Concomitant Medication Questionnaire biweekly to all HE subjects."
46026710|NCT02729233|Other|patients receiving biopsies|Six mucosal biopsies will be collected from each site (terminal ileum and rectum) for histologic verification of pCLE findings at baseline, and again at month 12 for a total of 12 research samples per colonoscopy, or 24 research biopsy samples during the course of the study. The study subjects will be followed for a total of 1 year after initial colonoscopy with pCLE. The primary study end-point is clinical response at 3 months following initiation of golimumab.
46026711|NCT02729467|Drug|JNJ-53718678|JNJ-53718678 will be applied twice at doses of 250 mg (in Panel 1, Day 1 and Day 9) and 3 times at 500 mg (Panel 2, Day 1, 4 and 9).
46114933|NCT04080141|Diagnostic Test|Multiple psychometric questionnaire|At the time of first contact (T0) only women were subjected to Hamilton's rating scale for depression (HRSD or HAM-D), Hamilton's rating scale for anxiety (HRSA or HAM-A), Beck Depression Inventory (BDI-II). At the follow up after 1 year from the first examination (T1) they were subjected to a questionnaire with multiple psychometric tests for mother and her partner. The female version included Post-traumatic stress disorder checklist (PCL-5), Iowa Personality Disorder Screen (IPDS), Beck Depression Inventory (BDI-II), Connor-Davidson Resilience Scale 10 (CD-RISC 10) and Short-Form Questionnaire on childhood trauma (CTQ-SF). The male version included Post-traumatic stress disorder checklist (PCL-5), Iowa Personality Disorder Screen (IPDS), Connor-Davidson Resilience Scale 10 (CD-RISC 10) and Short-Form Questionnaire on childhood trauma (CTQ-SF).
46114934|NCT04080141|Procedure|Clinical psychiatric examination|At the time of first contact (T0) only women were subjected to psychiatric clinical examination
46026712|NCT02729467|Drug|Itraconazole|Participants will receive itraconazole 200 mg (2 capsules of 100 mg) from Day 4-11.
46026713|NCT02729467|Drug|Rifampicin|Participants will receive 600 mg rifampicin (2 capsules of 300 mg) from Day 4-11.
46114935|NCT00920517|Biological|rDEN2/4delta30(ME) vaccine|10^3 PFU dose
46114936|NCT00920517|Biological|Placebo|placebo for rDEN2/4delta30(ME) vaccine
46114937|NCT02584569|Drug|TAK-915|TAK-915 oral suspension
45470473|NCT03751813|Dietary Supplement|Supplement|Supplement will be given to this group to take daily for 8 weeks
45470474|NCT03741790|Procedure|Ventilation|The difficult mask ventilation is defined as A) It is not possible for unassisted anesthesiologist to maintain the SpO2 > 90% using 100% oxygen and positive pressure mask ventilation in a patient whose SpO2 > 90% before anesthetic intervention; and/or B) It is not possible for unassisted anesthesiologist to prevent or reverse signs of inadequate ventilation during positive mask ventilation.
45681902|NCT03581890|Other|Socioeconomic position|"Socioeconomic position is the exposure in both study 1 and 2. Four different socioeconomic measures will be tested. The primary socioeconomic position measure is highest attained education the year before surgery (short/medium/long). Secondary measures are:~age- and sex-adjusted available income the year before surgery~Cohabitation status at the year of surgery (living alone/living with a partner) at the year of surgery.~Urbanicity (in four officially, predefined categories)."
45681903|NCT03159364|Biological|pathogen-specific CTLs|Patients will receive approximately 1x10^5~1x10^6 CTLs/kg as a single infusion via IV injection and may receive additional infusions.
45681904|NCT01871090|Device|Unpaired remote monitoring transmitter|Unpaired remote monitoring transmitter
46026714|NCT02727205|Drug|Rotigotine Transdermal System|
46114938|NCT00761462|Drug|Ciprofloxacin|Either as oral suspension, oral tablets or sequential intravenous (IV) - oral therapy or purely IV therapy according to label
45681905|NCT03158974|Drug|East Indian Sandalwood Oil Cream|Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
46026715|NCT02878915|Device|Ultrasound guided femoral puncture|
46026716|NCT02721433|Drug|Pamidronate|Bone-targeted agent as standard of care
46026717|NCT02721433|Drug|Denosumab|Bone-targeted agent as standard of care
46026718|NCT02721433|Drug|Zoledronate|Bone-targeted agent as standard of care
46026719|NCT02726893|Other|no intervention|
46026720|NCT02729155|Procedure|RIPre|Preconditioning 200 mmHg x 5 minutes before procedure
46026721|NCT02729155|Procedure|RIPost|Postconditioning 200 mmHg x 5 minutes after procedure
46026722|NCT02729155|Procedure|Sham-Pre|Sham 10 mmHg x 5 minutes before procedure
46026723|NCT02729155|Procedure|Sham-Post|Sham 10 mmHg x 5 minutes after procedure
46114939|NCT00761462|Drug|Non-quinolone antibiotic|Common used dose and route
46114940|NCT04101032|Behavioral|eBEfree|Contextual interventions based on promoting acceptance,mindfulness and self-compassion abilities
46114941|NCT00761306|Drug|Vortioxetine (Lu AA21004)|5 or 10 mg/day; tablets; orally
45470475|NCT03741790|Procedure|Intubation|"The difficult endotracheal intubation is defined as  It is not possible to visualize any portion of the vocal cords with conventional laryngoscopy or when proper insertion of the endotracheal tube with conventional laryngoscopy requires more than three attempts or more than ten minutes."
46114942|NCT02584491|Behavioral|Functional gait-related training|The motor learning (ML)-based functional gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Scheduling flexibility will promote adherence, with a minimum one day between sessions to provide opportunity for rest. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined active/imagery) will be five per week.
46026724|NCT02721199|Other|Neural Respiratory Drive Automated EMGpara assessment|Neural respiratory drive will be measured using surface electrodes and nasal cannula . The 2nd intercostal space will be identified by bony landmarks and skin preparation will be performed using detergent wipes, followed by EMG preparation gel with final cleaning to remove exfoliated skin. Wet gel electrodes will be placed immediately adjacent to the sternal border in the 2nd intercostal space and will be connected to the automated EMG analysis system. Electrodes will remain in place for the duration of the study. A nasal cannula will be placed in the nose and detect pressure changes during respiration in order to ensure accurate detection of inspiratory cycle. In addition, an accelerometer will be attached to the thorax of the patient
46114943|NCT04079595|Device|Head immobilization mask|Immobilization
46026725|NCT02721043|Biological|Peptides|Each subject will receive ten (10) total doses of PGV001. PGV001 will be administered on study visit: v4, v6, v8, v10, v12, v14, v16, v18, v20 and v22.
46114944|NCT00772538|Drug|tiotropium 5mcg/day|Intervention = randomisation: Patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo
45838876|NCT04354194|Procedure|Conventional Physiotherapy|Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in sitting and supported with a pillow under the head, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the cervical region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
46114945|NCT00772538|Drug|placebo|Matching placebo
46114946|NCT04079517|Drug|Tamoxifen|A registered SERM drug, Tamoxifen.
46114947|NCT02584413|Device|Magnetic resonance imaging|-Standard of care
46114948|NCT02584413|Drug|Gadolinium contrast|-Standard of care
46114949|NCT05493189|Other|Additional autonomous training sessions|The duration of the autonomous training will be 30 minutes, using a feedback CPR training simulator (eg Laerdal Little Anne QCPR).
46114950|NCT00761150|Drug|ABT-712|ABT-712 extended-release tablet
46114951|NCT00761150|Drug|Placebo|Placebo tablet
45470476|NCT03389776|Procedure|Anesthesia|Occurrence and severity of postoperative sore throat could be determined by various factors other than the pressure of the cuff alone. In particular, cuff pressure measurement, duration of anaesthesia, airway manipulations e.g. multiple insertion attempts, could all be factors determining the occurrence of postoperative sore throat.
46026726|NCT02721043|Drug|Poly-ICLC|Each subject will receive ten additional (10) total doses of the Poly-ICLC. The additional Poly-ICLC dose will be administered on study visit: v5, v7, v9, v11, v13, v15, v17, v19, v21 and v23.
46026727|NCT02721043|Drug|Lenalidomide|10mg once daily oral dose for maintenance therapy in multiple myeloma patients.
46114952|NCT00760994|Behavioral|Experiential acceptance|The experiential acceptance coping condition will focus on changing one's relationship to one's internal events by learning to remain in contact with negative and positive thoughts and feelings and cravings as they are, without defense or judgment or attempting to cling to them (Eifert & Forsyth, 2005; Hayes, Strosahl, & Wilson, 1999; Kadden et al., 1992; Levitt, Brown, Orsillo, & Barlow, 2004).
46026728|NCT02721121|Procedure|circumferential pulmonary vein isolation|
46026729|NCT02721121|Procedure|Linear ablation in addiction to circumferential pulmonary vein isolation|
46114953|NCT00760994|Behavioral|Cognitive restructuring|The cognitive restructuring coping condition will focus on how to change the content and frequency of internal events by changing one's thinking patterns (Kadden et al., 1992).
46114954|NCT00760994|Other|No-intervention control: Nutrition information|The no-intervention condition will be taught the plate method, a nutritional servings guideline, which will have no content related to AUD or PTSD, in order to control for time and contact with a research assistant.
46114955|NCT00583557|Drug|belimumab|IV 10mg/kg Q28 days
46114956|NCT00586820|Drug|BQ-123|BQ-123 is a cyclic peptide consisting of five amino acids. BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).
46114957|NCT00586820|Drug|Placebo|Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
46114958|NCT04581681|Behavioral|Group Cognitive Behaviour Therapy for Perinatal Anxiety (CBT-PA)|"The 6-session group CBT intervention for perinatal anxiety has been formalized with session guides for the facilitators and a workbook, Overcoming Anxiety in Pregnancy and Postpartum (Furer & Reynolds, 2015), developed by members of our Anxiety Disorders Clinic. There are 6 core modules covered over the 6 treatment sessions, including: (1) Understanding anxiety during pregnancy and postpartum, (2) self-care, (3) setting goals and facing fears, (4) nurturing the developing relationship with baby, (5) coping with negative thoughts and worries, and (6) relapse prevention. Content is based on general principles of CBT for anxiety but specific themes and examples are geared towards the pregnancy and postpartum periods. Distorted cognitions are also explored, with an additional focus on beliefs about motherhood and perfectionism. Due to the COVID-19 pandemic, the intervention will be conducted via a hospital-approved video-conferencing platform."
46026730|NCT02729311|Behavioral|Paired PLIÉ Program|The Paired PLIÉ Program is a novel, multimodal, movement program that focuses on abilities that are well maintained in people with dementia, including training procedural ('muscle') memory for basic daily movements, in-the-moment mindful body awareness, and social engagement. Group classes are held with affected individuals, care partners and instructors together. A monthly home visit also is provided.
46026731|NCT02729077|Device|Pulse Oximetry|Use of pulse oximetry device for 48 hours after surgery.
46114959|NCT04581681|Other|No treatment (waitlist control)|Patients in this condition are randomly assigned to a waitlist control condition before receiving treatment.
46114960|NCT04578093|Behavioral|LARC peer-based curriculum|Peer-based educational videos and supplemental activities
46114961|NCT00760838|Drug|Azithromycin 250 mg|Azithromycin 250 mg three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
46114962|NCT00760838|Drug|Placebo|Placebo three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
46114963|NCT00920595|Drug|CEP-9722|Starting dose of CEP-9722 is 150 mg/day (total dose). The study consists of a 14-day cycle of CEP-9722 alone, and at least one 28-day cycle of CEP-9722 plus temozolomide (150 mg/m2/day on Days 1-5). Patients who are receiving clinical benefit may receive subsequent cycles of study drug treatment.
46114964|NCT00586664|Drug|Bepreve (bepotastine besilate ophthalmic solution) 1.5%|sterile ophthalmic solution
46114965|NCT00586664|Drug|placebo comparator|sterile ophthalmic solution
46114966|NCT00586664|Drug|Bepotastine Besilate Ophthalmic Solution 1.0%|sterile ophthalmic solution
46114967|NCT02584335|Drug|"Lidocaine solution (A)"|"Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is A, the nurse will receive the syringes number 2 and 3 containing lidocaine solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception."
46114968|NCT02584335|Drug|"Saline solution (B)"|"Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is B, the nurse will receive the syringes number 2 and 3 containing saline solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception."
46114969|NCT00437281|Drug|Placebo|Placebo
46114970|NCT00437281|Drug|Pregabalin|Orally-administered pregabalin
45838877|NCT04354194|Procedure|Osteopathic Manupilative Treatment|Osteopathic Manupilative Treatment consist of stretching the fascia to the cervical region, soft tissue mobilization to the surrounding muscles, cervical manual traction, passive joint mobilization to the 7 cervical spine, passive joint mobilization to the 1st costa, passive joint mobilization to the clavicle and passive joint mobilization to the sternum mobilization in supine and prome positions.
46026732|NCT02728999|Procedure|Steep Trendelenburg|"•Subjects who undergo steep Trendelenburg will remain in 30 degrees of Trendelenburg, and the da Vinci robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
46114971|NCT02584023|Device|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
45470477|NCT02813200|Drug|Seretide® Diskus® 500/550 μg|Every day during 7 days
45470478|NCT02813200|Drug|Ultibro® Breezhaler® 110/50 μg|Every day during 7 days
45470479|NCT02813200|Drug|Spiriva® Respimat® 2,5 μg|Every day during 7 days
45470480|NCT04535947|Drug|Vehicle|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 8 weeks (56 days). Both eyes will be treated.
45470481|NCT04535947|Drug|SDP-4 Ophthalmic Solution (1.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 8 weeks (56 days). Both eyes will be treated.
46114972|NCT05475236|Behavioral|Experimental: Locomotor Learning|Participants will undergo four sessions of locomotor and turn learning. Locomotor learning will involve practicing walking over different terrains (i.e., soft and firm mats) and obstacles at different walking speeds (slow or fast) and turning practice at each end of the walking course. The full cohort will undergo either transcranial direct current stimulation or sham stimulation.
46114973|NCT02602106|Behavioral|Aquatic activities intervention|Women were suggested to exercise regularly through aquatic activities. A professional in physical exercise and sports designed and conducted the aquatic exercise program.
46026733|NCT02728999|Procedure|Decreased Trendelenburg|"•Subjects who undergo decreased Trendelenburg will be taken out of Trendelenburg to the minimal angle possible that enables adequate visualization, as determined by the primary surgeon, at which time robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
46026734|NCT02727049|Other|Osteopathic manipulative medicine (OMM)|Osteopathic manipulative medicine includes all types of manual therapies to gently restore and/or optimize one's natural joint, muscle, and other soft tissue balance.
46114974|NCT04556487|Other|evaluation|we will evaluate the home environment of the children asking by parents
46114975|NCT04102904|Other|Observational|Patients will be asked to donate a semen sample which will be analysed and compared with their eventual diagnosis.
46114976|NCT02584179|Device|Biparametric MRI before biopsy|All included men with suspicious lesions on bpMRI will have bpMRI targeted biopsies in addition to standard TRUS-bx.
46114977|NCT04102982|Drug|Camrelizumab|Patients will be treated with camrelizumab alone.
46114978|NCT04102982|Other|Camrelizumab plus microwave ablation|In the group, microwave ablation will be administrated to the primary tumors, followed by camrelizumab.
46114979|NCT04548609|Device|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
46026735|NCT02842723|Radiation|Protontherapy|59,5 Gy (1,7 Gy daily, 5 fractions per week).
46026736|NCT02720887|Procedure|Nanoparticles load|Pregnant women will have a sampling of amniotic fluid to measure load and composition of nanoparticles.
45470482|NCT03389542|Procedure|Surgery|Early mitral valve repair
46026737|NCT02728921|Drug|5% Albumin infusion 30 min|Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 30 minutes. Dose is based on ideal weight.
46114980|NCT04544007|Drug|Poly ICLC|Enrolled participants will receive poly-ICLC 20 mcg/kg/dose twice weekly IM (using Monday/Thursday or Tuesday/Friday schedule if possible).
46114981|NCT05468073|Drug|Proleukin|Sub-cutaneous injections of Interleukin-2 (PROLEUKIN ®) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks
46114982|NCT05468073|Drug|Placebo|Sub-cutaneous injections of placebo (NaCl) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks.
46114983|NCT04526847|Behavioral|Intermittent energy restriction (IER) : 5:2 diet pattern|Participants in the IER group will be provided menus on fasting day that provide ~25% of the individual energy requirement (400 kcal/day for females and 600 kcal/day for males) that means ~75% energy restriction per week (Sundfør et al., 2018; Svendsen, 2018; Templeman, Gonzalez, Thompson, & Betts, 2020). The recommended fasting day may be on two non-consecutive days (Mondays and Thursdays) per week and remaining five days of the week will be based on the usual diet plan. All participants will be instructed to complete all food by 12 pm and then fast until 8 am the following day (Svendsen, 2018).Thus, the weekly average calorie intake will correspond to ~75% of the normal energy requirements. They will receive a diet plan that recommended ~50 gm protein/day from chicken breast, lean meat, lean fish, fat-free yogurt, cottage cheese, egg or legumes, and vegetables to increase satiety on fasting days.
46026738|NCT02728921|Drug|5% Albumin infusion 3 hours|Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 3 hours. Dose is based on ideal weight.
46026739|NCT02728843|Drug|Deferiprone|600 mg tablets
46026740|NCT02728843|Drug|Placebo|Tablets that match the deferiprone tablets in appearance
46026741|NCT02726503|Drug|Lenvatinib|"All patients will receive lenvatinib 24 mg orally once daily at almost the same time. The treatment will be started within 1 week after enrollment. 1 cycle consists of 4 weeks.~The administration will be continued until patients meet withdrawal criteria. If any toxicity manifested that cannot be ruled out causal association with the study drug, drug withdrawal or dosage reduction will be conducted in accordance with drug withdrawal/dosage reduction criteria."
46026742|NCT02720965|Other|Remote-controlled perineural local anesthetics delivery|Remote-controlled perineural local anesthetics delivery
46026743|NCT02792413|Drug|Denosumab|Patients will receive a subcutaneous injection of Denosumab every 6 months for the duration of the study. In addition, they will receive vitamin D and calcium (which is the normal treatment) for the duration of the study.
45470483|NCT03389542|Other|Clinical interview and echocardiography|Clinical interview and echocardiography every 6 months.
45470484|NCT03750721|Other|Role of rifampin in staphylococcal PJI|the aim is to determine if the dose and the duration of rifampin influenced the prognosis
45470485|NCT01481272|Drug|Ofatumumab|1000 IV, according to detailed instruction included in the protocol, on day 1 of each 21-day cycle, maximum 6 cycles
45470486|NCT01481272|Drug|Etoposide|60mg/m2 IV, daily over 1 hour, on days 1-5 of 21-day cycle, maximum 6 cycles
45470487|NCT01481272|Drug|Ifosfamid|1500mg/m2 or 1000mg/m2 (patients >/=60 years), IV, daily over 1 hour, on 1-5 days of each 21-day cycle, maximum 6 cycles
46026744|NCT02792413|Drug|NaCl (placebo)|Patients will receive a subcutaneous injection of NaCl every 6 months for the duration of the study. In addition, they will receive vitamin D and calcium (which is the normal treatment) for the duration of the study.
46026745|NCT02726815|Other|Questionnaire|Questionnaire based study using a symptom assessment tool
46114984|NCT04526847|Behavioral|Continuous energy restricted (CER) group|Participants in the CER group will be advised to reduce total energy intake to 1200-1550 kcal in all seven days a week. They will be provided diet plan calculated in relation to each person's estimated energy requirements. Menus will be divided into breakfast, lunch, dinner, and snacks in line with their individualized energy recommendations. They will be requested to consume ~75% of the individual energy requirements daily (25% energy restriction of calculated baseline energy requirements daily) over six months. Thus, the overall energy restriction will similar between the groups at an estimated reduction of 25% of requirements. Participants will be randomized in a 1:1 ratio, and assigned to an intermittent or continuous energy restriction group randomly.
46114985|NCT00920673|Procedure|MRI|MRI during 35 to 65 minutes
46114986|NCT04520061|Behavioral|Health Insurance Navigation Program|The program will be delivered via videoconferencing by a navigator over a 2-month period and will consist of 4 sessions. The navigation intervention sessions will be as follows: Session 1- Learning About Survivorship Healthcare Needs; Session 2- Learning About Your Plan in Relation to Policy; Session 3- Navigating One's Own Plan and Overcoming Obstacles; Session 4- Managing Care Costs.
46114987|NCT02584101|Behavioral|ACT|ACT therapy administered in 3 sessions over a 4 week period
46114988|NCT02584101|Behavioral|Enhanced Treatment as Usual|2 group discussion sessions over a 4 week period
46114989|NCT02583945|Procedure|kidney treatment bundle (KDIGO)|Application of the measures of the kidney treatment bundle.
46114990|NCT05442255|Other|Toxicological analysis|Automated enzymatic assays Automated Immunoassay Urine Screening High Resolution Toxicological Screening
46114991|NCT05674773|Procedure|Endoscopic or surgical resection|endoscopic or surgical (partial, (sub)total, proctocolectomy) resection
46114992|NCT04079205|Device|Wearable Device(exoRehab)|rehabilitation program for patients after Anterior Cruciate Ligament Reconstruction using Wearable Device (exoRehab)
46114993|NCT04079205|Behavioral|Home rehabilitation program|rehabilitation program for patients after Anterior Cruciate Ligament Reconstruction
46114994|NCT04079283|Diagnostic Test|Clinical|Clinical: A diagnostic model incorporating clinical variables (Age, Pathological diagnosis, level of serum tumor biomarkers etc.)
46114995|NCT04079283|Diagnostic Test|Semantic|Semantic: A diagnostic model incorporating semantic radiological features (shape, location, border, density etc.)
46114996|NCT04079283|Diagnostic Test|Radiomic|Radiomic: A diagnostic model incorporating quantitative radiomic features (histogram, texture, morphology etc.)
46114997|NCT05674695|Drug|Ciclosporin|Any systemic drug used for atopic dermatitis in clinical practice
46114998|NCT04079049|Procedure|Surgical intervention|Surgical intervention by liver resection, ablation or stereotactic body radiotherapy as complement to oncological treatment
46114999|NCT04079049|Drug|Control|Oncological treatment in control group
46115000|NCT04078971|Other|Western diet|Subjects in this intervention will follow a normal western diet
46115001|NCT04078971|Other|ketogenic diet|Subjects in this group will follow a low carbohydrate ketogenic diet
46115002|NCT02596269|Drug|Nefopam|120 mg of nefopam is included in the i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time was set, without any background continuous infusion. After the end of surgery, and if the goal VRS score was achieved at PACU, PCA device was turned on and the patient was encouraged to use the pre-set bolus dose, until 24h after the end of surgery.
46115003|NCT02596269|Drug|Saline|i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time
45470488|NCT01481272|Drug|Mesna|300mg/m2 or 200mg/m2 (patients >/=60 years), IV, over 1 hour, mixed with ifosfamid then 900mg/m2 or 600mg/m2 (patients >/=60 years)over 12 hour or by local practice, on 1-5 days of each 21 day cycle, maximum 6 cycles
45470489|NCT01481272|Drug|Cytarabine|2g/m2 or 0,5-1g/m2 (patients >/= 60 years), IV, over 3 hours, 12 hourly (total of 4 doses), on days 1-2 of each 21 day cycle, maximum 6 cycles
45470490|NCT01481272|Drug|Methotrexate|12mg, it, on day 5 of each 21 days cycle, maximum 6 cycles
45470491|NCT01481272|Drug|Leukovorin|15mg, po 24 hours after methotrexate it
45470492|NCT01481272|Drug|Granulocyte-Colony Stimulating Factor|5 microgram/kg or 263 microgram ampoule, sc, daily, starting on day 7 of each 21 day cycle, until ANC>1.0x109/l
45470493|NCT03751735|Biological|Wharton Jelly Mesenchymal stem cells|Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
45470494|NCT03389464|Behavioral|computer-based confrontation with dysfunctional beliefs|"Patients will be presented with a virtual agent confronting them with their dysfunctional core beliefs (e.g. You are worthless). Participants will be instructed to contradict these virtual agents (e.g. That's not true, I'm a wonderful person)."
45470495|NCT04478695|Drug|AMG 330|Continuous intravenous (IV) infusion.
46026746|NCT05373043|Dietary Supplement|Mitoquinone|Mito-Q is a supplement that targets mitochondrial function. Linking a triphenyl-phosphonium cation to coenzyme-Q, to produce Mito-Q, results in a lipophilic compound, which, due to the large mitochondrial membrane potential, selectively accumulates within mitochondria. This targeted antioxidant approach results in 50- to 100-fold more Mito-Q accumulation compared to non-targeted antioxidant delivery.
46026747|NCT05373043|Dietary Supplement|Placebo|A placebo will be used in combination with exercise rehabilitation allowing for a double blinded placebo controlled design.
46026748|NCT02728765|Device|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard treatment for patients with obstructive sleep apnea (OSA). In a previous trials comparing therapeutic CPAP vs subtherapeutic CPAP, CPAP could reduce 24-hour mean blood pressure in mildly sleepy patients with OSA over 3 months whereas our one-year prospective study has shown that reduction of carotid artery intima-media thickness of OSA patients occurred mostly in the first 6 months and was sustained at 12 months in patients with CPAP compliance about 4.7 hours per night.
46026749|NCT02720497|Behavioral|60-minute Prolonged Exposure Therapy|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of weekly weekly 60-minute sessions, with 20 minutes imaginal exposure.
46026750|NCT02720497|Behavioral|90-minute Prolonged Exposure Therapy|Prolonged Exposure Therapy for PTSD consists of weekly 90-minute sessions, with 40 minutes imaginal exposure.
46115004|NCT00741039|Biological|inactivated influenza vaccine and the 23- valent pneumococcal vaccine|Patients >65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23-valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured, as will serum IgG levels and IgG subtypes. At 8-16 weeks after vaccination, post vaccine titers, CBC, lymphoid phenotype and function will be assessed.
46026751|NCT05372107|Drug|AG-80308|AG-80308 Eye Drop Solution
46115005|NCT00741039|Biological|inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)|MSKCC employee volunteer controls > or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly)and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured. At approximately 8-16 weeks after vaccination, post vaccine titers will be measured again.
46115006|NCT02595801|Other|Surgery in early childhood|Surgical interventions in early childhood (prior to completion of Early Development Instrument)
46115007|NCT04019769|Drug|L-glutamine|product will be obtained by Endari and administered by NIH pharmacy. Patient will take supplement as prescribed
46115008|NCT02583555|Behavioral|Interview followed by frequent telephone support|Interview followed by telephone support
46115009|NCT02583321|Device|Endotracheal tubes not allowing SSD|In the participating center, a bundle of Ventilator-Associated Pneumonia (VAP) prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
46115010|NCT02583321|Device|Endotracheal tubes allowing SSD|"In the participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
46115011|NCT04454229|Other|Direct oral penicillin challenge|The patient will receive a single dose of oral penicillin, following baseline vital signs.
45470496|NCT04478695|Drug|Pembrolizumab|Intravenous (IV) infusion.
45470497|NCT03125590|Other|Testing the PEQ (Personalized Exercise Questionnaire)|Administer the questionnaire to 114 participants to classify their facilitators, barriers and preferences to exercise
45470498|NCT03389386|Diagnostic Test|Blood withdrawal for laboratory analysis|"Participants in this study will have their peripheral blood sampled from the cubital vein and the total volume withdrawn for the purposes of this study will be no more than 22 mL per person.~Parameters of interest in the laboratory analysis will include serum catestatin levels, NT-proBNP levels, hs-cTnI, parameters of inflammation and renal function as well as standard biochemistry and complete blood count (CBC) panels."
45470499|NCT03389386|Other|Standard-of-care treatment|Patients diagnosed with chronic heart failure will receive optimal standards of care in terms of pharmacologic management, according to their current clinical condition.
45470500|NCT03389386|Diagnostic Test|Transthoracic echocardiography (TTE)|Participants from both groups will undergo transthoracic echocardiography examination that will measure established hemodynamic parameters of systolic and diastolic cardiac function as well as parameters of LV and RV strain in the selected subset of patients.
45470501|NCT04474405|Drug|Flortaucipir F18|IV injection, 370 MBq (10 mCi), single dose
46115012|NCT04454229|Other|Standard of care|Routine management as per the treating clinicians that include skin prick and intradermal beta-lactam testing, followed by oral penicillin challenge in the setting of negative skin testing.
46115013|NCT02583087|Procedure|endoscopic submucosal dissection|Endoscopic resection of a superficial neoplastic lesion of the esophagus, including the mucosal and the submucosa resected en bloc.
45470502|NCT04474405|Procedure|Brain PET Scan|positron emission tomography (PET) scan of the brain starting immediately after administration (60 minute dynamic imaging plus 4 frames x 5 minutes at approximately 80 minutes post-dose).
45470503|NCT04474405|Procedure|Whole body PET scan|positron emission tomography (PET) scan of the body from the vertex of the head to the thighs starting immediately following injection and repeated over 6 hours
45838878|NCT04354116|Device|Rapid maxillary expansion|Palatal expanders of the HYRAX type, with bands on the first permanent molars will be used for patients in both groups. In the experimental group, the expander will be anchored mesially and bilaterally in mini-implants, in a technique known as rapid maxillary expansion assisted by mini-implants (MARPE). The control active group will be with conventional HYRAX expanders. The maxillary expansion protocol will be once a day for 2 weeks.
46026752|NCT02726737|Drug|sodium bicarbonate|
46026753|NCT02726737|Drug|Lidocaine|
46026754|NCT02726737|Drug|sterile distilled water|
46026755|NCT02720575|Other|Consumption of capsule/bread with vitamin D|
46026756|NCT02720341|Device|ARMin|single sessions of about one hour each
46115014|NCT04436055|Other|No Intervention will be used|Since this is an observational study, there are no interventions.
46026757|NCT02726425|Behavioral|Diabetes Self Management Medical Group Visits|The Women in Control DSM intervention involves: (1) 8-wk series of interactive, educational medical group visit sessions with groups of 10-12 participants, led by clinicians & peer leaders lasting ~100'' in length conducted either in Spanish or English and (2) Individual consultation with a clinician lasting 10-15 minutes. Group visits will consist of experiential and discussion based learning of topics including the importance of diet, physical activity, medications, mindfulness and stress reduction to diabetes self management.
46026758|NCT02726191|Behavioral|Spatial Match Exercise|
46026759|NCT02726191|Behavioral|Temporal Sequence Reconstruction Exercise|
46026760|NCT02726191|Behavioral|Token Task Exercise|
46115015|NCT02583165|Biological|MEDI1873|Subjects will receive MEDI1873 by intravenous administration
46115016|NCT00772382|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 52 weeks of flexible dose
46026761|NCT02726191|Behavioral|Story Recall Exercise|
46115017|NCT02582931|Device|MRI-guided SBRT|
45838879|NCT04354116|Device|Maxillary Protraction|Protraction hooks will be projected around the upper canine area. In the experimental group (MARPE), the appliance will be anchored mesially and bilaterally in mini-implants. The control active group will be anchored with conventional HYRAX expanders. Both groups will be treated with maxillary protraction with a Petit-type face mask at night (12 hours a day).
46026762|NCT02726191|Behavioral|Sample-Match (Within Modality) Exercise|
46026763|NCT02726191|Behavioral|Pair-Match (Across-Modality) Exercise|
46115018|NCT02582931|Behavioral|EORTC QLQ-C30 Questionnaire|30 questions with 28 questions having answers that range from 1 (not at all) to 4 (very much) and the other 2 questions have answers that range from 1 (very poor) to 7 (excellent)
46115019|NCT02582931|Behavioral|EORTC QLQ-OV28 Questionnaire|28 questions having answers that range from 1 (not at all) to 4 (very much)
46115020|NCT04078581|Other|Questionnaire and fecal sample collection|Questionnaire and fecal sample collection in order to select donors for FMT.
46115021|NCT04102748|Procedure|I-incision, M-flap and conventional implant exposure techniques|Implant uncovering in the second stage using 3 different exposure techniques
46115022|NCT04078659|Drug|Propofol infusion|Following induction of anaesthesia, propofol infusion will be started 75 mcg/kg/min for the first 10-15 minutes, then a maintenance infusion of propofol (50 mcg/kg /min)
46115023|NCT04078659|Drug|Magnesium Sulfate infusion|Before induction of anaesthesia, Magnesium Sulfate infusion will be started at 40 mg/kg in 100 ml saline over 10 minutes as the loading dose then Magnesium sulfate infusion 10-15 mg/kg/hr started immediately after induction of anaesthesia
46115024|NCT04078659|Drug|Lidocaine|Patients will receive iv lidocaine 1.5 mg/kg before induction of anaesthesia
46115025|NCT04078659|Drug|Fentanyl|Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia
46115026|NCT04078659|Drug|Propofol|Patients will receive propofol in a dose of 1-2 mg /kg
46115027|NCT04078659|Drug|Atracurium|Patients will receive 0.6 mg /kg iv atracurium over 60 sec, to facilitate tracheal intubation
46115028|NCT04078659|Procedure|Mechanical Ventilation|Patients lungs will be ventilated using the volume controlled mechanically ventilated with 40% oxygen in the air with positive end-expiratory pressure (PEEP) of 5 cmH2O, tidal volume 500 ml and Respiratory Rate of 12 per minute
46115029|NCT02583243|Behavioral|MET/CBT based individualized counseling|Manualized counseling with the first four week being MET followed by 8 weeks of CBT
46115030|NCT02583243|Drug|Buprenorphine|Target dose in stabilization is 16 mg of buprenorphine to be taken sublingually once daily.
46115031|NCT02583009|Drug|PAC-14028 cream 0.1%|Topical application
46115032|NCT02583009|Drug|PAC-14028 cream 0.3%|Topical application
46115033|NCT02583009|Drug|PAC-14028 cream 1.0%|Topical application
46115034|NCT02583009|Drug|PAC-14028 cream vehicle|Topical application
46115035|NCT00798707|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|25 mg tablet, once daily dosing for 8 weeks
46026764|NCT02726191|Behavioral|Triad-FiguresExercise|
46026765|NCT02726191|Behavioral|Monster Garden Exercise|
46026766|NCT02726191|Behavioral|Memory Match Exercise|
46026767|NCT02726191|Behavioral|Memory Matrix Exercise|
46026768|NCT02726191|Behavioral|Familiar Faces Exercises|
46026769|NCT02726191|Behavioral|Lost in Migration Exercise|
46026770|NCT02726191|Behavioral|Playing Koi Exercise|
46115036|NCT00798707|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
46115037|NCT00798707|Drug|placebo|Matching placebo tablets (25 or 50 mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
46115038|NCT02582853|Procedure|Lumbar puncture|Lumbar puncture for spinal fluid
46115039|NCT02582853|Procedure|Blood Sample|Blood sample
46115040|NCT00760214|Drug|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.
46115041|NCT00760214|Drug|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.
45470504|NCT04474405|Drug|Florbetapir F 18|IV injection, 370 MBq (10 mCi), single dose
45470505|NCT04474405|Procedure|Brain MRI|Volume-based T1-weighted Magnetic Resonance Imaging (MRI) of the brain
46115042|NCT00760214|Drug|Ramipril|Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.
46115043|NCT04078425|Drug|Aldosterone Antagonists|aldosterone antagonist will be applied to patients of heart failure with preserved ejection fraction, level of the drug will be sampled before administration of the drug and follow up will be sampled after one month
45470506|NCT02687386|Drug|Mitoxantrone packaged EDV (EnGeneIC Delivery Vehicle)|EnGeneIC Delivery Vehicles (EDVs) are nanocells which can be loaded with anti-cancer drugs (mitoxantrone in this study) and targeted to tumor cells. These bacterially-derived nanocells are coated in bispecific antibodies (BsAb) that recognize oncogenic receptors on the tumor cell surface. Once bound to the tumour cell, the targeted and drug-loaded EDVs are endocytosed and release their toxic payload to destroy the tumor cell.
45470507|NCT03389932|Behavioral|Patient-Guided|Patients in the ET@Home study condition will receive four modules of video and print transplant education over a 6-month period. After each module is mailed, 3 postcards are mailed weekly that recap important transplant educational content covered within the videos. Patients will have the opportunity to participate in a texting component of ET@Home that also sends small pieces of educational content and learning reminders by phone each week.
45470508|NCT04531813|Drug|Butenafine HCl 1% (BAY1896425)|Approximately 0.2 g of cream containing butenafine HCl 1% daily (excluding weekends) was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the skin test site. The total dose applied to each participant completing the trial was 3 g.
45470509|NCT04531813|Drug|Positive Control-Sodium lauryl sulfate (SLS)|Approximately 0.2 mL of 0.3% solution of sodium lauryl sulfate was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the Positive Control test site.
46115044|NCT04098380|Procedure|Small Bite|the bites will be applied with a bite width of 5 mm and inter-suture spacing of 5 mm
45470510|NCT04531813|Other|Negative Control|A blank patch was applied to the Negative Control test site.
45470511|NCT03612544|Other|ENDS (Vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
45470512|NCT03612544|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
45470513|NCT05354869|Device|Urostym|electric pelvic floor muscle stimulator
45681906|NCT04142476|Other|interview|interviews with patient's pharmacist to motivate in the hormonotherapy's compliance.
45681907|NCT04142008|Device|Walk with Me app|For 10 weeks the subjects will use a mobile application (Walk with Me). The aim of this study is to investigate the usability of the mobile application, as well as investigating if the mobile application effects walking
45754453|NCT05580614|Device|Sham|MRI (Magnetic Resonance Imaging) paired ERP/Sham YBOCs(Yale-Brown Obsessive Compulsive Scale) (4,8,12) OCI-R (every other session). YBOCs and OCI-R will also be administered at intake and 4 weeks post treatment.
46026771|NCT02728609|Device|ABThera vacuum device|This intervention uses a commercially available vacuum device to temporarily close the abdomen following surgery.
46026772|NCT02728609|Device|Blue towel: vacuum pack device|This intervention uses operating room towels and the application of suction to temporarily close the abdomen following surgery.
46026773|NCT02728453|Drug|Empagliflozin|Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
46115045|NCT04098380|Procedure|Larger bite|the bites will be applied with a width of 10 mm and inter-suture spacing of 10 mm
46026774|NCT02728453|Drug|Glimepiride|Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
46026775|NCT02728687|Drug|Mannitol|Apply cream as needed up to 4 times daily to the painful foot and leg
46026776|NCT02728687|Drug|Menthol|Apply cream as needed up to 4 times daily to the painful foot and leg
46026777|NCT00636571|Behavioral|Exercise|Upright bike intervention for post-surgical lung cancer survivors.
46026778|NCT02720263|Drug|ASP4345|Oral
46026779|NCT02720263|Drug|Matching Placebo|Oral
46115046|NCT02582541|Procedure|SEMS alone|The SEMS (Wallstent, Boston Scientific, USA) would be placed.
46115047|NCT02582541|Procedure|SEMS plus radiofrequency ablation|The RFA catheter has an 8 F bipolar probe and two ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5 cm length. The catheter is compatible with standard side-viewing endoscopes (3.2 mm working channel), and could be passed over 0.035 inch guidewires. Ablation was performed by using an RFA generator (1500 RF generator; RITA Medical Systems, Fremont, Calif) delivering electrical energy at 400 kHz set at 7-10 W for 90-120 seconds. The RFA energy can be delivered repetitively at different tumor sites within one procedure. After the RFA application is completed, SEMS (Wallstent, Boston Scientific, USA) can be deployed.
46026780|NCT02726269|Drug|CLA (Clarithro+Lanso+Amoxi)|Tablets of oral administration administered to subjects randomized to this group twice daily for 10 days.
46026781|NCT02726269|Drug|PLA (Panto+Levoflox+Azithro)|Tablets of oral administration to subjects randomized to this group once daily for 10 days.
46115048|NCT00638391|Drug|Anastrozole|
46115049|NCT02583867|Behavioral|Exercise|Subjects will engage in supervised exercise sessions for 12 weeks. Each week will consist of at least three exercise sessions with a total duration of weekly exercise of approximately 150 minutes.
46115050|NCT02583633|Drug|Transdermal nitroglycerin|
46115051|NCT02583633|Drug|nifedipine|
46115052|NCT04447833|Drug|Mesenchymal Stromal Stem Cells - KI-MSC-PL-205|Allogeneic bone marrow derived mesenchymal stromal stem cells (MSCs).
46115053|NCT04487067|Drug|Atezolizumab|Atezolizumab 1200 mg IV infusion q3w
45838880|NCT04353882|Other|Assess the difference in MOR-1 expression between healthy and tumor tissue|Assess the difference in the quantitative expression of MOR-1 (by means of RT-qPCR) between healthy tissue and tumor tissue, in patients with stage II and III colorectal cancer undergoing scheduled surgery.
46026782|NCT02720029|Device|pH/impedance monitor|Placement of pH/impedance monitor via the nasogastric route with monitoring for 24 hours, followed by removal.
46115054|NCT04487067|Drug|Bevacizumab|Bevacizumab 15 mg/kg IV Q3W
46115055|NCT02582385|Other|in-situ cytokine expression|
46115056|NCT05353257|Drug|HLX10|"HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W"
46115057|NCT05353257|Drug|carboplatin/cisplatin-etoposide|"Etoposide: 100 mg/m2, IV, on Days 1, 2, and 3 of each cycle. Carboplatin: AUC = 5, IV, on Day 1 of each cycle up to a dose of 750 mg. investigator's choice.~Cisplatin: 75mg/m2, IV, on Days 1 of each cycle. investigator's choice."
46115058|NCT05353257|Radiation|Thoracic radiotherapy|Standard Thoracic Radiotherapy
46115059|NCT05353257|Drug|Placebo|Placebo Q3W
46115060|NCT05353257|Radiation|Prophylactic Cranial Irradiation (PCI)|PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
46115061|NCT04186689|Other|Routine Dental Examination|Routine dental examination for the pre-school children Questionnaire for their mothers
45838881|NCT04353570|Other|clinical interview|This interview can be carried out face to face or remotely. In the latter case, it is part of telemedicine, which is recognised by the health authorities in France.
45838882|NCT04353336|Drug|Chloroquine or Hydroxychloroquine|Chloroquine or Hydroxychloroquine
46115062|NCT00638469|Radiation|UVB-311nm|UVB-311nm radiation given 3 times a week to one randomized body half
46115063|NCT00638469|Other|No treatment|no UV exposure
46115064|NCT02689011|Procedure|Femoral Nerve Block|For patients in Femoral nerve Block Group (Group F), ultrasound guided Femoral nerve block was performed using 0.375% bupivacaine, 20 ml for femoral nerve
46115065|NCT02689011|Procedure|Epidural|Patients in Epidural Group (Group E) were turned in lateral position for epidural catheter placement in lumbar region. Epidural was loaded with 0.25% bupivacaine and infusion of M2 (Bupivacaine 0.1% + Fentanyl 2mcg/ml) was started at 8 - 12 ml per hour.
46115066|NCT02582307|Drug|Acetaminophen, Analgesics, Non-Narcotic|Oral single dose
46115067|NCT02582307|Drug|Hyoscine butylbromide, Analgesics, Non-Narcotic|Oral single dose
46115068|NCT02689245|Drug|Tenofovir|
46115069|NCT02689245|Drug|Fecal Microbiota Transplantation (FMT)|
46026783|NCT02728375|Other|computer game based rehabilitation protocol|Participants who consent to take part in the study will be asked to use objects instrumented with the miniature motion mouse to play various therapeutic yet entertaining games while handling and moving the test therapeutic objects as a part of experimental therapy protocol. The objects used will be everyday items; a) lifting/rotating a sports ball small beach ball which requires bimanual handling, b) rolling a cylinder object (diameter 6-10 cm with fingers extended and using elbow and shoulder motion, c) grasping grasp small glass and then a sponge ball with whole hand and rotating (supination- pronation motion) d) motion of a small wand (pencil) with 3-finger pinch grip and using hand-wrist motion, and e) turning of a key with 2-finger pinch fine finger control. These objects represent a wide range of physical properties requiring different modes of manipulation and functional demands sufficient to test the assessment tool.
46026784|NCT02728375|Other|Conventional therapy protocol|In control group: 1) Stretching of Biceps, Lattisimusdorsi, Pronators, Thumb muscles. 2) Weight Bearing Exercises. 3) CIMT for 20 min per day for 3-4 weeks, repeat each task 15-20 times. Pegboard activities, Rings: reaching- removing and putting back, Ball throw (under and over arm) - at basket which is kept 10 to 15 meter distance, opening bottle cap (large size bottle), Opening and closing door handle activity, Holding water bottle, bag in hand and transfer to 10 to 20 meter distance, Crumbling paper, Clay activities, Picking marbles from sand 4)Hand arm bimanual activities: Throwing ball with both hands, Holding ball with both hands and transfer, Holding bolster and keeping at place, Holding notebook in both hands, Holding rack with both hands, Holding plate in one hand and spoon in other hand, Pushing door or wall both hands.
46026785|NCT02719951|Drug|[18F]FPEB PET imaging|PET exam
46026786|NCT02719951|Other|Biological samples|blood sample and urine sample
46026787|NCT02719951|Other|MRI|MRI exam
46026788|NCT05357443|Procedure|Gastric bypass with transection of vagal nerves|Vagal nerve interruption above the level of the stomach is a known treatment for complicated peptic ulcer disease. It is not commonly performed during routine gastric bypass. The vagi are, however, interrupted part-way down the stomach to create the gastric pouch. This is the pars flaccida technique.
46026789|NCT05357443|Procedure|Gastric bypass without transection of vagal nerves|Dissection between the neurovascular bundle and the stomach, spareing the vagus nerves. This is the perigastric technique.
46115070|NCT04187001|Other|Content Validity|Use Delphi technique for achieve consensus
46115071|NCT04187001|Other|Cultural adaptation|Adapt the content to the target population
46026790|NCT02719717|Device|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
46115072|NCT00802841|Drug|nilotinib|Supplied as 200 mg tablets
46115073|NCT00802841|Drug|imatinib|Supplied as 100 mg and 400 mg tablets
46115074|NCT00772148|Drug|LCP -Tacro|"LCP-Tacro tablets will be administered orally once daily in the morning starting at 0.07 - 0.11 mg/kg. The starting dose for African-American patients will be 0.09 - 0.13 mg/kg. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other Names:Tacrolimus modified-release LCP-Tacro™ tablets (0.5 mg, 1 mg, 2 mg, 5 mg)"
46026791|NCT02728219|Procedure|TACE|In this study we prospectively select some early diagnosed recurrent HCC patients after radical resection with AFP conversion, then they will be treated with transcatheter arterial chemoembolization (TACE)
46115075|NCT00772148|Drug|Prograf|"Oral Prograf capsules will be administered starting at 0.10 - 0.15 mg/kg per day in two equally divided morning and evening doses. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other name: tacrolimus Prograf® capsules (0.5 mg, 1 mg, 5 mg)"
46115076|NCT02582229|Device|Endomina|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
46026792|NCT02728219|Procedure|Hepatectomy|Repeat Hepatectomy after postoperation recurrence
46026793|NCT02728297|Procedure|Staged ETS|Thoracoscopic approach of sympathetic ganglia T3-T12 on one side, retraction of the diaphragm and lung laterally to expose the ganglia then ablation of each ganglion using electrocauterization.
46026794|NCT02694289|Drug|Metformin|Treatment/continuation of metformin therapy during admission
46026795|NCT02694289|Drug|Subcutaneous (sliding scale) Insulin|Discontinue Metformin and be placed on subcutaneous sliding scale insulin during admission
46026796|NCT02728063|Dietary Supplement|Lactibiane Tolerance|probiotics
46026797|NCT02719873|Other|The impact of maternal obesity on pregnancy outcomes|observation of maternal obesity effect in foetal and maternal outcome
46026798|NCT02727985|Procedure|Pharmacist weaning schedule|individualized weaning schedule for each patient taking into account the amount of opioid, duration of opioid use, other adjunctive medications, and specific variables related to the patient.
46026799|NCT02728141|Other|Water|2 ml distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
46026800|NCT02728141|Other|Sucrose|2 ml 25% sucrose in distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
46115077|NCT02689089|Drug|3HP|An interrupted time series study design will be used to determine if the introduction of the 3HP regimen will result in more people completing LTBI treatment compared to the standard of 9 months INH twice weekly.
46115078|NCT01257269|Other|Observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
46115079|NCT00638547|Drug|IRT Laronidase|"Laronidase belongs to a class of drugs called enzyme replacement therapies or ERT that provides people with sufficient quantities of an important enzyme that they cannot create on their own. The main ingredient in laronidase is a protein that is identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. Laronidase replaces the missing enzyme alpha-L-iduronidase and restores sufficient enzyme activity to break down GAG buildup.~Subjects will receive an infusion of Laronidase into his/her spinal fluid approximately 12 weeks before, 2 weeks before, 100 days after and 6 months after transplant. This procedure is done by lumbar puncture"
46115080|NCT02605889|Other|Laser acupuncture|Laser acupuncture
46115081|NCT00759902|Drug|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
46115082|NCT00759902|Drug|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
46115083|NCT04077957|Drug|Methotrexate|Methotrexate 10mg per week will be the background therapy in participants in Group 1. Experimental.
46115084|NCT04077957|Drug|Sulfasalazine|Sulfasalazine 2.25g per day will be the background therapy in participants in Group 1. Experimental.
46115085|NCT04077957|Drug|Hydroxychloroquine|Hydroxychloroquine 0.2g per day will be the background therapy in participants in Group 1. Experimental.
46115086|NCT04077957|Drug|Etanercept (50mg per week, for 4 weeks)|Participants in Group 1. Experimental who satisfied the criteria for high disease activity (ASDAS≥2.1) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 4 weeks.
46115087|NCT04077957|Drug|Etanercept (50mg per week, for 2 weeks)|Participants in Group 1. Experimental who satisfied the criteria for low disease activity (2.1>ASDAS≥1.3) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 2 weeks.
46115088|NCT04077957|Drug|Etanercept (50mg per week)|Participants in Group 2. Positive Control will receive etanercept (50mg per week, for 12 weeks) for 48 weeks.
46115089|NCT04114019|Diagnostic Test|Vaginal tactile imager|Vaginal elasticity evaluation using a vaginal tactile imager
46115090|NCT04102670|Device|Ultherapy|Subjects will be treated with Ultherapy, which is a microfocused ultrasound, on the lower face, neck, and chest.
46115091|NCT04102670|Device|Xeomin|Vertical neckbands, also known as platysma bands, will be injected with Xeomin to relax the bands.
46115092|NCT04102670|Device|Belotero Balance|Horizontal necklace lines will be filled using Beletero Balance.
46115093|NCT04102670|Device|Dilute Radiesse|The chest area will be injected with dilute Radiesse to stimulate collagen.
46115094|NCT04102670|Other|Neocutis Micro Firm Face and Neck Cream|Neocutis Micro Firm Face and Neck Cream will be provided to subjects for topical use at home.
46115095|NCT04114097|Drug|Betnovate, betamethasone dipropionate ointment 0.1% and placebo|Explore the systemic effects of Betnovate
46026801|NCT02719795|Drug|Ropivacaine|Local injection of local anesthetic into the fascial spaces
46026802|NCT02719795|Drug|Normal saline|Sodium chloride solution commonly used in clinical which equal to human plasma osmotic pressure.
46026803|NCT02719561|Behavioral|Fatigue Intervention|The Fatigue Intervention will include education, energy conservation and activity promotion
46026804|NCT02727829|Device|pefusion index measurement|perfusion index measurement using massimo radical 7 device
46026805|NCT02726347|Biological|PPV-23|one hundred forty subjects will have pre-vaccination titers checked. All will be given vaccination as standard of care. Approximately 4 weeks later subjects will have post-vaccination titers checked for the same serotypes.
46026806|NCT02726035|Drug|Naltrexone|oral naltrexone 50 mg daily
46026807|NCT02726035|Other|Placebo|oral placebo (appearing identical to naltrexone) once daily
46026808|NCT02719405|Dietary Supplement|Lactobacillus GG|Lactobacillus GG
46026809|NCT02719405|Dietary Supplement|Extensively Hydrolyzed Casein Formula|Extensively Hydrolyzed Casein Formula
46026810|NCT02719405|Dietary Supplement|Amino Acid Formula|Amino Acid Formula
46115096|NCT04114097|Drug|Protopic, tacrolimus ointment 0.1%|Compare the systemic effects of Betnovate to Protopic
46115097|NCT04323189|Drug|Sitagliptin 100mg|Sitagliptin will be administered daily for 7 days, with a study day on day 7.
46115098|NCT04323189|Drug|Placebo Oral Tablet|Placebo will be administered daily for 7 days, with a study day on day 7.
46115099|NCT00772070|Biological|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
46115100|NCT00772070|Biological|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
46115101|NCT00796757|Drug|bevacizumab [Avastin]|10mg/kg iv infusion every 2 weeks
46026811|NCT02725957|Drug|Trehalose for IV Infusion|
46026812|NCT02725957|Drug|Saline 0.9% IV|
46026813|NCT02725879|Other||
46115102|NCT00796757|Drug|interferon alfa-2a|3 MIU sc t.i.w.
46115103|NCT00759356|Drug|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
46115104|NCT00759356|Drug|KADIAN|2 x 100 mg, single-dose capsule
46026814|NCT02719483|Device|Swiss DolorClast|"Radial (blue) handpiece; one rESWT session per week for three months, with 1500 radial shock waves per session and leg, i.e., a total of 3000 radial shock waves per session or a total of 36.000 radial shock waves within twelve weeks; radial shock waves evenly distributed over the gastrocnemius and soleus muscles; air pressure of the device set at 0.6 bar, resulting in a positive energy flux density (EFD+) of 0.03 mJ/mm2; radial shock waves applied at a frequency of 8 Hz; local or general anesthesia not applied."
46115105|NCT00900419|Other|immunohistochemistry staining method|Laboratory test
46115106|NCT00900419|Other|laboratory biomarker analysis|Laboratory Test
46026815|NCT02719483|Procedure|Traditional conservative therapy|Physical therapy, Chinese massage, meridian mediation and muscle stimulation for three months (six days per week, 30 min per type of therapy).
46115107|NCT00900419|Other|sputum cytology|Laboratory Test
46115108|NCT00900419|Procedure|biopsy|Laboratory Test
46115109|NCT04101266|Other|Interscalene block|30 minutes before anaesthesia induction interscalene nerve block will be applied with ultrasound guidance with %0,25 bupivacain 20 cc .The sham block consisted of after patients were placed in the lateral decubitus position skin preparation, ultrasound scanning of the suprascapular region, and a dry-needling, all performed to preserve patient blinding in the ISB group patients.
46115110|NCT04101266|Other|suprascapular and infraclavicular nerve block|30 minutes before anaesthesia induction suprascapular with %0,25 bupivacain 10 cc .and infraclavicular nerve block with %0,25 bupivacain 10 cc will be applied with ultrasound guidance
46115111|NCT05637515|Biological|Humira 40 MG in Prefilled Syringe|Humira (40 mg every other week)
46115112|NCT05637515|Biological|Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe|"• Subjects will receive Humira (initial dose of 80 mg [2 × 40 mg]; Day 1 administered subcutaneously (SC), followed by 40 mg SC given every other week starting 1 week after the initial dose (last dose at Week 10).~Hulio (40 mg every other week) at Week 12 and Week 14~Humira (40 mg every other week) at Week 16 and Week 18, and~Hulio (40 mg every other week) at Week 20, Week 22, Week 24 and Week 26."
46115113|NCT04113941|Drug|Neuronox|intradetrusor injection
46026816|NCT02719249|Other|Dried blood spot test|
46026817|NCT05130385|Device|High-resolution optical coherence tomography (High-Res-OCT)|Imaging with high-resolution optical coherence tomography
46115114|NCT04113941|Drug|Placebo|intradetrusor injection
46115115|NCT04102592|Other|Permethrin-treated Lesu (baby wrap)|0.5% permethrin application
46115116|NCT04102592|Other|Untreated Lesu (baby wrap)|Matching untreated lesu
46115117|NCT04113473|Other|Yoga Therapy|"An hour of yoga therapy included loosening exercise (sukshma vyayama), yoga postures (asana), yoga breathing (pranayama), relaxation (shavasana) and meditation.~Each participant were given handouts to follow home practice sessions everyday for twice a day for at least 15 minutes."
46026818|NCT05130385|Device|Standard spectral domain OCT (SD-OCT)|Imaging with standard spectral domain OCT
46026819|NCT02725723|Device|Therm-AppTM TH, thermographic camera|
46026820|NCT02725723|Drug|epidural injection|
46026821|NCT02727595|Device|CyclaPlex Implant|Button and suture type implant that will be implanted between the first and second metatarsal
46026822|NCT02727517|Procedure|Early (≤ 60 seconds) cord clamping|If the infant don't breathe, the umbilical cord is clamped (≤ 60 seconds) and cut and resuscitation will be provided at a resuscitation table
46026823|NCT02727517|Procedure|Delayed (≥ 180 seconds) cord clamping|If the infant don't breathe, the umbilical cord is not clamped and cut until after 180 seconds. Initial resuscitation will be provided bedside to the mother
46115118|NCT00721734|Drug|Carfilzomib|Carfilzomib was administered intravenously (IV) at a rate of approximately 10 mL/minute.
46115119|NCT04113551|Drug|MPH (Concerta)|MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from Japan medical data center (JDMC) database.
46115120|NCT04113551|Drug|MPH (Ritalin)|MPH (Ritalin) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
46115121|NCT04113551|Drug|Atomoxetine (ATO)|Atomoxetine (ATO) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
46115122|NCT04113551|Drug|Guanfacine (GFC)|Guanfacine (GFC) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
46115123|NCT02592954|Drug|Jojoba oil with broccoli sprout extract|500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
46026824|NCT02719093|Drug|recombinant FSH|Subcutaneous injection
46115124|NCT02592954|Drug|Jojoba oil (placebo)|1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
46115125|NCT02605343|Other|NeuroIDgenetix Test Panel|The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
46115126|NCT00544427|Device|Optical coherence tomography|Optical coherence tomography imaging
46115127|NCT00914615|Radiation|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver (up to an hour including all imaging and set-up procedures). You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment. Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
46115128|NCT05631197|Other|Biorepair Total Protective + desensitizing enamel-repair shock treatment|Domiciliary use twice a day
46115129|NCT05631197|Other|Sensodyne Repair & Protect + topical application of fluoridated gel|Domiciliary use twice a day
46115130|NCT00798317|Drug|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
46115131|NCT00798317|Drug|Placebo|Intravitreal injection placebo.
46115132|NCT04113629|Device|HCV point of care machine|Xpert HCV Assay performed on the GeneXpert point of care machine
46115133|NCT00077285|Biological|filgrastim|
46115134|NCT00077285|Drug|carboplatin|
46115135|NCT00077285|Drug|cyclophosphamide|
46115136|NCT00077285|Drug|dexrazoxane hydrochloride|
46115137|NCT00077285|Drug|doxorubicin hydrochloride|
46115138|NCT00077285|Drug|etoposide|
46115139|NCT00077285|Drug|ifosfamide|
46115140|NCT00077285|Drug|irinotecan hydrochloride|
45470514|NCT05354869|Behavioral|Standard care|patient education on home exercises and stretching
46026825|NCT02727439|Other|Acute Exhausting Exercise (AE)|A single progressive rowing training to maximal exhaustion (AE).
46026826|NCT02725255|Dietary Supplement|Ujiplus|Maize flour fortified with micronutrients and dried ground papaya (Carica papaya) seeds. The flour was used to prepare porridge and each child given a serving of 300 ml every school day for 60 days.
46026827|NCT02725255|Drug|Albendazole|400mg of albendazole given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300ml per day for 60 days.
46026828|NCT02725255|Dietary Supplement|uji|maize flour porridge fortified only with micronutrients, cooked and served to each child 300ml per day for 60 days.
46115141|NCT00077285|Drug|vincristine sulfate|
46115142|NCT00077285|Procedure|conventional surgery|
46115143|NCT00077285|Radiation|radiation therapy|
46115144|NCT00779402|Other|Control|Autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen.
46115145|NCT00779402|Biological|Sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
46115146|NCT00771914|Drug|Aspirin|Aspirin 81mg tablet
46115147|NCT00771914|Drug|Lovaza|Lovaza 4 grams
46115148|NCT00771914|Drug|Both Aspirin and Lovaza|Lovaza 4 grams plus aspirin 81 mg
46115149|NCT00771914|Other|Placebo|Capsule resembling fish oil and a tablet resembling aspirin
46115150|NCT04307511|Drug|Ticagrelor|60mg ticagrelor based DAPT vs 90mg ticagrelor based DAPT vs 90mg ticagrelor monotherapy
46115151|NCT04307511|Drug|Aspirin|Aspirin
46115152|NCT04078893|Other|telephone recruitment|using telephone to recruit inactive donors on two different methods
46115153|NCT04347759|Other|Symptom Care at Home-Heart Failure|When participants call, the IVR system will ask them about each of the selected symptoms, and the patient will report symptom presence and severity numerically with the touchtone keypad. Based on symptom severity, intervention group will receive automated coaching messages. There will be a toll-free number for participants to call and a password to log into the system which will be stored on a secure and HIPPA-compliant sever. Calls can be personalized to allow the voice to greet the patient by name.
46115154|NCT00779324|Drug|Amantadine Hydrochloride|100 mg every morning and noon
46115155|NCT00779324|Drug|Placebo|one placebo tablet every morning and 12 Noon
46115156|NCT04078347|Procedure|Paravertebral block at T4 and T5 level|Paravertebral block is performed at T4 and T5 level under realtime ultrasound guidenance with 10ml of 0.5% ropivacaine for each block, respectively.
46026829|NCT02718859|Biological|NK cells|The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd
46115157|NCT04300023|Behavioral|Social Cycling Group|engaged with a research staff member for 30 minutes of cycling
46115158|NCT04300023|Behavioral|Solo Cycling Group|Exercise without a partner for a target period of time and intensity.
46115159|NCT00779246|Other|Nasal swabs for MRSA culture|Patients will have nasal swabs performed upon ICU admission, upon discharge, and every 2 weeks while they remain in the ICU.
46115160|NCT00779246|Drug|Chlorhexidine gluconate|CHG-impregnated cloths (2%) will be used to bathe patients at least daily during the duration of their medical ICU stay. Surveillance cultures will be obtained on admission, discharge and every 2 weeks while in the ICU, but results will be blinded until conclusion of the study.
46115161|NCT00779246|Other|Contact isolation|All patients will be placed in contact isolation until the results of their active surveillance cultures are negative; if positive, they will remain in isolation.
46115162|NCT04078113|Other|Pupillometer|Measurements of pupillary dilatation with pupillometer to administer or not analgesia
46115163|NCT04097990|Other|blood sample|a 5 cc blood sample will be taken after a 12-hour fast for separation of triglycerides from the serum and for checking fatty acid levels
46115164|NCT04186533|Behavioral|Default Option|The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up). Participants in the default condition were presented with a prefilled online shopping cart containing groceries that met nutritional requirements based on participants' gender and age.
46115165|NCT04186533|Behavioral|Nutrition Education|The nutrition education materials were adapted from materials currently utilized by the Supplemental Nutrition Assistance Education Program
46115166|NCT02581761|Drug|CYTOTEC|synthetic prostaglandin E1
46115167|NCT02581761|Other|Placebo|no active material
46115168|NCT04101344|Other|Two fiber-blend snack and four fiber-blend snack|All subjects will complete a 47-day, multi-phase feeding study to evaluate the effect of two snack prototypes containing two different fiber blends on gut community structure and features of host biological state (plasma proteome/ metabolome).
46115169|NCT04119999|Device|Mandibular Advancement Device|Mandibular advancement device (MAD) has been a novel method in the management of snoring and OSA. For mild to moderate sleep apnea, MADs have been a boon. A guideline published by American Academy of Sleep Medicine stated that MAD was indicated as first-line therapy for mild OSA and a second-line therapy for moderate to severe OSA
46115170|NCT04119999|Device|Continuous Positive Airway Pressure|Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in people with OSA
46115171|NCT00771758|Drug|oxycodone IR|maximum daily dose 450 mg
46115172|NCT00771758|Drug|placebo|5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days
46115173|NCT00771758|Drug|tapentadol IR|50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days
46115174|NCT05293821|Diagnostic Test|TriQuik IVD|TriQuik Invitro Diagnostic Device Cassettes. TriQuik Invitro Diagnostic Device Cassettes.
46115175|NCT02581371|Drug|Cerebrolysin infusion|Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
46115176|NCT02581371|Other|Placebo infusion|Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval
46115177|NCT02688465|Drug|Apomorphine|
46026830|NCT02718859|Procedure|irreversible electroporation (IRE )|The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )
46026831|NCT00636727|Procedure|arthrocentesis|Irrigate the TMJ with lactated ringers
46026832|NCT00636727|Procedure|arthroscopy|The TMJ will be inspected with an arthroscope and the joint irrigated with lactated ringers
46026833|NCT00636727|Procedure|arthroplasty|The disc will be surgically repositioned with open surgery
46026834|NCT02727361|Radiation|PET (Positron Emission Tomography) imaging|Molecular imaging using a PET radiotracer of the vesicular acetylcholine transporter.
46115178|NCT04186611|Other|early occupational therapy|"The intervention will be the one usually carried out but earlier and on a daily basis. It will consist of the initial assessment and then positioning and/or carrying out activities of daily living.~The daily duration of the intervention will be about 45 minutes to 1 hour. The overall duration of the intervention will be determined according to the objectives and will be at most equal to the time of stay in the intensive care unit."
46115179|NCT02688543|Procedure|RF treatment|the genicular nerves are identified with the help of landmarks, ultrasound and nerve stimulation. Once the needle is correctly placed high frequency current is passed through the probe during 90 seconds at 20 V with tip temperature put to 80°C.
46026835|NCT02727361|Other|MRI : Magnetic Resonance Imaging|Multimodal MRI, MRI diffusion tensor (to study the microscopic structure of white matter) and functional MRI of the resting state (to study the functional organization of cerebral cholinergic networks at rest).
46115180|NCT02688543|Radiation|radiofrequency ablation|
46115181|NCT02688543|Device|ultrasound|
46115182|NCT00758498|Drug|armodafinil|50 mg/day orally, once daily in the morning for 3 days
46115183|NCT00758498|Drug|armodafinil|150 mg/day orally, once daily in the morning for 3 days
46115184|NCT00758498|Drug|placebo|placebo tablets, once daily in the morning for 3 days
46115185|NCT00798161|Drug|BI 1356|BI 1356 high dose tablet, once daily
46115186|NCT00798161|Drug|BI 1356 + metformin|BI 1356 low dose tablet + Metformin 500 mg tablet, twice daily
46115187|NCT00798161|Drug|Bi 1356 + metformin|BI 1356 low dose tablet + Metformin 1000 mg tablet, twice daily
46115188|NCT00798161|Drug|Metformin|Metformin 500 mg tablet, twice daily
46115189|NCT00798161|Drug|metformin|metformin 1000 mg tablet, twice daily
46115190|NCT00798161|Drug|matching placebo|matching placebo
46115191|NCT02688231|Other|Task-oriented upper limb training|"Participants in the experimental groups (high-intensity and low-intensity) receive for 8 weeks, 60 min/day, 5 days/week a task-oriented upper limb rehabilitation training at a high or low intensity, respectively, instead of their regular occupational therapy hours provided in the conventional multidisciplinary rehabilitation program.~The task-oriented training involves practicing of functional daily tasks, with the intention to acquire or reacquire a skill. Most functional upper limb tasks require following essential movement components: reaching, moving, positioning, transporting, lifting the upper limb and/or an object and grasping, releasing, stabilizing, manipulating an object.~The Tagtrainer of SymbioTherapy is used to support the independent training of tasks with real objects with different sizes and weights. The Diego of Tyromotion is used in patients who require assistance (gravity support) during the performance of different upper limb tasks."
46115192|NCT02688231|Other|Control intervention|"The participants in the control group receive for 8 weeks the conventional multidisciplinary rehabilitation program (physiotherapy, occupational therapy and speech or cognitive therapy if needed).~The training sessions are scheduled for 60 min/day, 5 days/week for the duration of 8 weeks."
45470515|NCT03603340|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
46115193|NCT02581683|Drug|Magnesium Sulfate|Given via adductor canal block
45470516|NCT03603340|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
45470517|NCT03750643|Drug|LY3454738|Administered IV
46115194|NCT02581683|Drug|Ropivacaine|Given via adductor canal block
46115195|NCT02581683|Other|Sham|Sham adductor canal block
46115196|NCT02688075|Other|No Intervention|Participants who are receiving Canagliflozin +/- other AHA as per usual clinical practice will be observed for effectiveness, safety and PRO.
45470518|NCT03750643|Drug|LY3454738|Administered SC
46115197|NCT04170855|Drug|Furosemide Injection|"We will measure kidney sodium content in patient with cardiorenal syndrome. we will inject within the week of this first measurement furosemide only in patient who will be resistant to diuretics (Based on these parameters, diuretic response will be defined as:~A reduction in fractional spot urinary sodium~An increase in urinary volume~A >1 kg reduction in body weight within 24 hours from diuretic administration (extrapolation of guidance on management of acute HF) and we will do another measurement of kidney sodium content after furosemide injection."
46115198|NCT04076709|Procedure|goal directed anaesthesia|Deep neuromuscular blockade (PTC 1-2) Nociception level index (NOL) target 10-25
46026836|NCT02719015|Drug|rAd.CD40L|"Dose Escalation Phase Starting Dose: 5x10^10 vp per tumor as an injection directly into 1-3 tumors every 3 weeks. Same tumors injected for each of the 4 injections at week 0, 3, 6 and 9. If the dose well tolerated, the rAd.CD40L escalated to 1x10^11 vp. Subsequently enrolled patients injected at the same dose of 1x10^11 vp. Number of injected sites/tumors increased to two sites/lesions if patients have >/=2 injectable lesions, at the same injection dose of 1x10^10 up to three separate sites/lesions if patients have > 3 injectable lesions.~Dose Expansion Phase Starting Dose: MTD from Dose Escalation Phase."
45470519|NCT03750643|Drug|Placebo|Administered IV
45470520|NCT03538444|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique which is currently FDA-approved as a treatment for major depressive disorder
45470521|NCT03538444|Device|Sham rTMS|Participants will undergo procedures that mimic rTMS, but that are inactive.
45470522|NCT05220397|Biological|Janssen Ad26.CoV2.S Vaccine|Single dose vaccine of 0.5 mL administered via intramuscular injection, typically in the deltoid muscle
45470523|NCT05220397|Other|Reduction in Immunosuppression Medication|Reduction in immunosuppression medication dosage
46026837|NCT02719015|Drug|Pembrolizumab|Dose Escalation and Expansion Phases: 2 mg/kg by vein every 3 weeks.
45470524|NCT05220397|Other|Maintenance in Immunosuppression Medication|Maintain current immunosuppression medication dosage
45470525|NCT03125824|Device|Soliton Acoustic Wave Device|Treatment of tattoos with Soliton Acoustic Wave Device as an accessory to laser
45470526|NCT01380028|Drug|oral corticosteroids|Active treatment is prednisone establishment within 72 hours after the end of surgery at the dose of 1 mg / kg (rounded to the nearest 10 mg) once daily orally for one week . The daily dose then decreases in increments of 10 mg weekly, by the second week. Once the level of 10 mg / day reached the daily dose by one level lower than 5 mg weekly. Treatment is stopped after this week to 5 mg / day (average 2 months of treatment)
45470527|NCT01380028|Drug|placebo|placebo
46026838|NCT02727283|Drug|GSK3179106|GSK3179106 will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength of 5 mg, 25 mg and 100 mg
46026839|NCT02727283|Drug|Placebo|Placebo will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength to match actives across all strengths
46115199|NCT04111523|Drug|SY-007|A single dose of SY-007 or placebo injection(1mg-45mg)
46115200|NCT00638781|Drug|Desmoteplase|Desmoteplase 62.5 µg/kg BW
46115201|NCT00638781|Drug|Desmoteplase|Desmoteplase 90 µg/kg BW
46115202|NCT00638781|Drug|Desmoteplase|Desmoteplase 125 µg/kg BW
46115203|NCT00638781|Drug|Placebo|Placebo
46026840|NCT02725333|Procedure|Shoulder Stabilization|Open Latarjet was performed as the standard and well-described Latarjet-Patte procedure with subscapularis split and triple locking mechanism.14 The graft was intra-articular in every case, the capsule was systematically reattached to glenoid according to Favard's modification,15 and a capsular shift was added. Arthroscopic Latarjet was carried out in one case according to a modified Lafosse technique.16 In the latter treatment option, no reattachment of the capsule was realized. The arthroscopic Bankart repair consisted in a mobilization of the anteroinferior capsule and the labrum with an arthroscopic elevator. The glenoid rim and neck were then prepared with a mechanical shaver device. Two loaded anchors were inserted at the 5 and 3 o'clock position, and sutures were shuttled across the inferior glenohumeral ligament and labrum, starting at the inferior position and progressing in a superior direction.
46026841|NCT02718937|Drug|BTA-C585 oral capsule|
46026842|NCT02718937|Drug|Matching placebo capsules|
46115204|NCT04115423|Drug|Tocilizumab|A humanized monoclonal antibody against the interleukin-6 receptor, which is mainly for the treatment of rheumatoid arthritis.
46115205|NCT04115423|Drug|Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)|Tumor Necrosis Factor inhibitors (TNFi) are a group of medicines that suppresses the physiologic response to TNF, a protein involved in early inflammatory events. We will include etanercept, infliximab, adalimumab, and golimumab as TNFis since these drugs are commercialized in Korea.
46115206|NCT04113005|Drug|Desmopressin|To evaluate the safety and tolerability of Desmopressin in CRPC subjects starting Docetaxel treatment. Additionally, CTCs will be collected before and after Desmopressin/Docetaxel treatment to evaluate therapeutic efficacy.
45470528|NCT03750565|Drug|TD-1473 - Dose A|oral capsule/tablet, QD
45470529|NCT03750565|Drug|TD-1473 - Dose B|oral capsule/tablet, QD
45470530|NCT03750565|Drug|TD-1473 - Dose C|oral capsule/tablet, QD
45470531|NCT03750565|Drug|Placebo|oral capsule/tablet, QD
45470532|NCT01305460|Drug|Azacitidine|"Treatment will consist of azacitidine 75mg/m2/d for 5 days every 14 days for 4 cycles.~Patients achieving CR or PR will be then treated with 4 cycles of azacitidine 75mg/m2/d for 5 days every 21 days followed by cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 9 and beyond), to be continued until progression/relapse or toxicity arises.~Patients not obtaining CR or PR after the initial 4 cycles of azacitidine-14 will continue to receive azacitidine 75mg/m2/d for 5 days every 14 days for 4 additional cycles (cycles 5 to 8). If they achieve CR, PR or HI after 8 cycles, they will then be treated with azacitidine 75mg/m2/d for 5 days every 21 days (cycles 9 to 12) and subsequently cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 13 and beyond) until progression/relapse or toxicity arises.~Patients not obtaining CR, PR or HI after 8 cycles of azacitidine-14 will go off-study."
45470533|NCT03750487|Behavioral|e-screening & brief intervention (e-SBI)|Computer-delivered screening and brief motivational intervention targeting alcohol and drug use + goal-setting and content reinforcement
45470534|NCT03750487|Behavioral|Control e-SBI|Computer-delivered screening and brief motivational intervention targeting healthy eating and exercise
45470535|NCT03754543|Other|Labeled iron salt Fe54|Ferrous fumarate enriched with Fe 54 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
45470536|NCT03754543|Other|Labeled iron salt Fe57|Ferrous fumarate enriched with Fe 57 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
45470537|NCT03754543|Other|Labeled iron salt Fe58|Ferrous bisglycinate enriched with Fe 58 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
45470538|NCT05177809|Other|Clinical rating scale to measure ataxia disease severity and progression|SARA is a clinical scale developed by Schmitz-Hübsch et al which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.
45470539|NCT01199302|Biological|Brodalumab|Administered intravenously once every 4 weeks
46026843|NCT04189237|Other|Electroacupuncture|needles were inserted to Taixi (KI3), Taichong (LR3), Zusanli(ST36), Yanglingquan (GB34), contralateral to the operated leg and deqi sensation elicited at acupoints.
46115207|NCT00588341|Drug|Temozolomide|"At the start of the trial a core needle biopsy of a palpable tumor will be obtained percutaneously in the office after administration of local anesthesia. Patients will then be treated with TMZ according to the extended dosing schedule of 75mg/m2/day x 6 weeks every 8 weeks. After each cycle, patients will be re-evaluated for response.~Responding patients will be offered another cycle of treatment. Patients will be treated until best response, progression of disease, or 6 cycles, whichever comes first.~After completing temozolomide treatment, patients will be evaluated for surgical resection. It is expected that, unless there is progression of disease, patients will undergo resection (i.e. therapeutic lymph node dissection). In patients who have a complete clinical response to temozolomide, whether or not to do a subsequent lymph node dissection will be left up to the discretion of the surgeon and the patient."
46115208|NCT00914693|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
46115209|NCT00915083|Drug|Amrubicin|40mg/m^2 5 minute IV infusion for 3 consecutive days (21 day cycle)
46115210|NCT00802529|Drug|Methylprednisolone|2 transtympanic injections at interval of two weeks.
46115211|NCT00802529|Drug|Gentamicin|2 transtympanic injections at an interval of two weeks. If there is significant hearing loss before second injection, it will be replaced by normal saline in double blinded fashion.
45470540|NCT05337163|Diagnostic Test|Diagnostic Test: Sputum DNA methylation analysis|Diagnostic Test: sputum specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)
45470541|NCT05337163|Procedure|chest CT or pathological examination|Subjects will undergo chest CT or pathological examination.
46026844|NCT02725489|Biological|Vigil|Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
46026845|NCT02725489|Drug|Durvalumab|A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
46115212|NCT02605811|Drug|temozolomide|
46115213|NCT02605811|Radiation|prophylaxis cranial radiotherapy|2
46115214|NCT00758264|Biological|Meningococcal vaccine GSK134612|Single dose intramuscular injection.
46115215|NCT00758264|Biological|Pneumococcal vaccine GSK1024850A|Single dose intramuscular injection.
46115216|NCT05670743|Drug|38% silver diamine fluoride|Topical application of 38% silver diamine fluoride to dental caries lesions
46026846|NCT02693899|Other|Non Interventional study|The samples of the study were made in conjunction with blood tests done routinely, no additional venipuncture is provided by the study. Flt3L plasma concentration will be measured at different time monitoring of patients according to their pathology (Acute lymphoblastic leukemia or acute myeloid leukemia). The exact number of samples will vary for each patient depending on the course of the illness, it is expected up to 15 blood tubes 9mL.
46115217|NCT04027517|Drug|JTZ-951|"Oral tablet~Dose adjustments as maintenance dose is allowed according to the result of Hb level."
45470542|NCT05459623|Other|Manual myofascial release|will receive Manual myofascial release to iliotibial band by having the subject to lie in the side lying position on the unaffected side. The upper leg to be tested was rested on the table with hip and knee flexion. Then the therapist applied a few kilograms of force weight along the iliotibial band course proximally to distally. The therapist will repeat this for 6 minutes.
45598611|NCT02355093|Procedure|Femoral nerve block (FNB)|the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.
45598612|NCT02355093|Drug|ropivacaine|
46115218|NCT04027517|Drug|Darbepoetin Alfa|"Intravenous administration~Dose adjustments as maintenance dose is allowed according to the result of Hb level."
46115219|NCT02601092|Procedure|Mini Gastric Bypass|"The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.~No drugs or devices will be used."
46115220|NCT02601092|Procedure|Roux-en-Y Gastric Bypass|"This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a Roux limb. In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.~No drugs or devices will be used."
46115221|NCT02605655|Drug|AMP-1915|A traditional Chinese Formula extract from Astragalus, Radix Puerariae and Cortex Mori is mixed into instant noodles. Patients are treated with AMP-1915 as meal.
46115222|NCT02605655|Other|Placebo|Instant noodles without drug
46115223|NCT00588731|Drug|Cannabidiol|Active Cannabidiol daily over 6 weeks
46115224|NCT00588731|Drug|Placebo|Placebo
46115225|NCT04111367|Drug|Seraprevir|Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12，the other group will receive the same dose for 24 weeks.
46115226|NCT04111367|Drug|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12,the other group will receive the same dose for 24 weeks.
46115227|NCT05629949|Drug|QL1701|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
46115228|NCT05629949|Drug|Herceptin®|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
45598613|NCT02223923|Drug|AZD6738|
45598614|NCT02223923|Radiation|Palliative radiotherapy|
46026847|NCT02718781|Behavioral|Health talk|Health talk on zero-time exercise.
46026848|NCT02718781|Behavioral|Regular contact with community leaders|Regular contact with community leaders to remind them do zero-time exercise.
46026849|NCT02718781|Device|Handgrip|This is a home-based equipment
46115229|NCT05629949|Drug|Docetaxel|The recommended dose is 75mg/m2 and the infusion time is approximately 70min (±20min) (or adjusted according to clinical experience at each study center). The drug was administered once every 3 weeks for a treatment cycle of 3 weeks, with the exception of the second day of the first cycle, followed by the first day of each cycle for at least 8 cycles
46115230|NCT04111445|Drug|ADG116|IV infusion at Day 1 of each cycle
46115231|NCT04112771|Drug|Penehyclidine hydrochloride|Penehyclidine hydrochloride was administered before anesthesia induction.
46115232|NCT04112771|Other|No penehyclidine hydrochloride|Penehyclidine hydrochloride was not administered before anesthesia induction.
46026850|NCT02716519|Biological|Santyl|Collagenase ointment applied topically once per day for up to six weeks
46026851|NCT02716519|Other|Standard Care|Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
46026852|NCT02716831|Behavioral|Nutritional Counseling & Acceptance-based Therapy|
46026853|NCT02716831|Behavioral|Cognitive Behavioral Therapy for Eating Disorders|
46026854|NCT02339233|Device|Standing and Stepping with spinal cord Epidural Stimulation|Standing and Stepping with support from trainers as needed, overground or in a harness with body weight support on a treadmill. Epidural stimulation with specific configurations will be administered to generate standing and stepping.
46026855|NCT02716753|Biological|seminal plasma|
46026856|NCT02716753|Biological|Physiological NaCL solution|
46115233|NCT02605577|Procedure|new systemic nutrition management protocol|a new established systemic nutrition management protocol
46115234|NCT05629481|Procedure|Fractional carbon dioxide laser treatment|Participants underwent three vaginal fractional CO2 laser (AcuPulse, Lumenis, Yokneam Illit, Israel) treatment sessions with 4-6 weeks intervals. The same laser device parameters (10 mJ, 10% density, spot diameter of 12×12 mm2) were used in participants. A special laser probe was inserted into the patient's vagina after cleaning and disinfection. The laser procedure was performed at the 0, 2, 4, 6, 8, and 10 o'clock positions by rotating the laser probe from the proximal vagina to the distal, and additional procedures were performed at the 11 and 1 o'clock positions 5 mm above the introitus vaginae.
46115235|NCT05629481|Procedure|Fractional carbon dioxide laser sham treatment|Participants underwent three vaginal fractional CO2 laser (AcuPulse, Lumenis, Yokneam Illit, Israel) sham treatment sessions with 4-6 weeks intervals. A special laser probe was inserted into the patient's vagina after cleaning and disinfection. The sham procedure was performed at the 0, 2, 4, 6, 8, and 10 o'clock positions by rotating the laser probe from the proximal vagina to the distal, and additional sham procedures were performed at the 11 and 1 o'clock positions 5 mm above the introitus vaginae.
46115236|NCT05628857|Drug|RC108|RC108 is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.
46115237|NCT04109573|Procedure|high resolution anal manometry|functional studies before and after anal laser ablation
46115238|NCT04112615|Device|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
46115239|NCT04017533|Procedure|GMK Sphere TKR|Se earlier
46115240|NCT05642273|Device|oXiris membrane|oXiris membrane for 24h
46115241|NCT05642273|Diagnostic Test|Blood tests|Blood tests just after randomization (H0) and at H24, H48 and 7 days
46115242|NCT05628233|Drug|SENS-401 (R-Azasetron Besylate)|Patients will receive SENS-401 ((R)-azasetron besylate) B.I.D. up to 23 weeks: 1 week prior to the initiation of the cisplatin treatment, during the whole duration of the chemotherapy treatment (estimated to last up to 18 weeks) and 4 weeks after stopping chemotherapy.
46115243|NCT04109261|Drug|Palbociclib|Palbociclib administration in breast cancer patients included in a compassionate use programme. Patients were treated according to the standard of care
46115244|NCT04109339|Drug|Oxytocin|During the laparoscopic hysteromyomectomia operation, different doses of oxytocin was used with different routs.
46115245|NCT05628077|Other|No intervention|No intervention
46115246|NCT04109495|Other|Smart phone application(NOOM)|The study population included first diagnosis of pancreatic cancer patients within 3 months of pancreatic cancer center visit, and randomly assigned to the use of Noom user group and non-use group. A total of 40 patients, 20 from each group, were used to examine nutritional status(PG-SGA), blood index analysis, and quality of life(EORTC QLQ) at 0, 4, 8, and 12 weeks. At the same time, the patients voluntarily record meals and receive feedback using Noom. The purpose and contents of this study are explained in detail to the subjects, and written consent is obtained. The questionnaire items included gender, age, weight, type of diagnosed digestive disease, treatment method, nutritional supplement, oral status and intake of oral supplement foods, and past medical history. To assess the nutritional status using laboratory data, blood(about 8ml) is collected for each visit.
46115247|NCT04109495|Other|Non-user|The patients dose not use Noom application. A total of 40 patients, 20 from each group, were used to examine nutritional status (PG-SGA), blood index analysis, and quality of life (EORTC QLQ) at 0, 4, 8, and 12 weeks. The purpose and contents of this study are explained in detail to the subjects, and written consent is obtained. The questionnaire items included gender, age, weight, type of diagnosed digestive disease, treatment method, nutritional supplement, oral status and intake of oral supplement foods, and past medical history. To assess the nutritional status using laboratory data, blood (about 8ml) is collected for each visit. At each visit, you will be assessed nutritional status and quality of life through the PG-SGA and EORTC QLQ.
46115248|NCT04109417|Procedure|osteotomy filled with PRP-gel and covered with PRP-biomembrane|
46115249|NCT04109417|Procedure|osteotomy site following the surgical intervention was left empty|
46115250|NCT00757172|Biological|panitumumab|
46115251|NCT00757172|Drug|cisplatin|
46115252|NCT00757172|Drug|docetaxel|
46115253|NCT00757172|Procedure|neoadjuvant therapy|
46115254|NCT00757172|Procedure|therapeutic conventional surgery|
46115255|NCT00757172|Radiation|radiation therapy|
46026857|NCT04124263|Other|Educational short message texts|Educational messages for patient engagement
46026858|NCT04124263|Other|Adherence short message texts|Reminder messages of medication use time
46026859|NCT02718547|Drug|Combigan|Each Participant will be instructed to instill Combigan eye drops twice daily in one of his eyes (randomly chosen)
46026860|NCT02725099|Drug|Chewing Ticagrelor|180 mg Chewing Ticagrelor
46026861|NCT02725099|Drug|Oral Ticagrelor|180 mg oral Ticagrelor
46026862|NCT02718703|Device|Blood Glucose Monitoring System.|In vitro diagnostic medical device
46026863|NCT02325427|Device|tDCS|tDCS could deliver either real or sham stimulation.
46026864|NCT02724865|Device|Somnodent® (Oral appliance therapy)|
46026865|NCT02724865|Device|Herbst® (Oral appliance therapy)|
46026866|NCT01225211|Drug|Lumacaftor|Tablet
45838883|NCT04353726|Other|Weight management|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating.
46026867|NCT01225211|Drug|Ivacaftor|Tablet.
46026868|NCT01225211|Drug|Lumacaftor Placebo|Matching placebo tablet.
46115256|NCT04097678|Other|Retained Surgical Sponge|A surgical sponge will be intentionally placed in the surgical field prior to final imaging and then removed. Postoperatively, images will be assessed for the presence or absence of a retained surgical sponge.
46115257|NCT00797225|Drug|Leuprorelin Acetate Depot|Leuprorelin acetate depot injection 3.75 mg administered as an intramuscular injection
46115258|NCT00797225|Drug|Elagolix|Elagolix tablets administered orally
46115259|NCT00797225|Drug|Placebo to Elagolix|Placebo tablet administered orally
46115260|NCT00797225|Drug|Placebo to Leuprorelin Acetate|Saline solution administered as an intramuscular injection
46115261|NCT04258605|Device|ASHCOM Shoulder System|Reverse Shoulder Arthroplasty
46115262|NCT05277285|Drug|Sodium Thiosulfate 25% Solution for Injection|The drug will be administered via continuous infusion after being diluted to a concentration 12.5 gr/100ml
46115263|NCT04069143|Diagnostic Test|18F-BMS-986327|Imaging Agent
46115264|NCT04033731|Behavioral|Attention Network Task|The Attention Network Test (ANT) is a computerized cognitive task designed to efficiently probe three independent but interactive attentional networks (alerting, orienting, executive control) in a single task paradigm.
46115265|NCT04085523|Drug|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
46026869|NCT01225211|Drug|Ivacaftor Placebo|Matching placebo tablet.
46115266|NCT04085523|Drug|Placebo for TransCon CNP|Weekly subcutaneously injection of placebo.
46115267|NCT04085523|Drug|sWfI Placebo for TransCon CNP|Weekly subcutaneously injection of placebo.
46115268|NCT04110665|Drug|Tramadol|Tramadol 100 mg tablet
46115269|NCT04110665|Drug|Nefopam 20 MG/ML|120 mg for 24 hours
46115270|NCT04110665|Drug|Morphine Sulfate|Tablet 10mg
46115271|NCT04110665|Drug|Oxycodone 20mg|release
46115272|NCT04077333|Procedure|Minimal Invasive surfactant administration|Participants enrolled spontaneously breathing preterm infants born between 26.1 and 31.9 weeks' gestational age with signs of respiratory distress syndrome. Preterm infants of the MISA (Minimal invasive surfactant administration) group were assigned to receive surfactant (Calf pulmonary surfactant, Double-Crane Pharmaceutical Co., China) via a 5Fr nasogastric tube with an ophthalmic surgery straight forceps during CPAP/NIPPV-assisted spontaneous breathing.
46115273|NCT00778700|Other|Placebo Cream|Cream with no active drug
46115274|NCT00778700|Drug|Ruxolitinib Phosphate|Ruxolitinib phosphate cream
46115275|NCT04077489|Procedure|cataract surgery|To measure the MT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
46115276|NCT00793403|Other|As per routinary clinical care|As per routine clinical care
46115277|NCT02687763|Biological|ProQuad|"2) Patients 6 months to 24 months of age who are being considered and/or evaluated for any solid organ transplant within the next five (5) years who are willing:~to receive two doses of ProQuad® at least 30 days but no more than 365 days apart.~to participate in the three (3) antibody titer blood draws."
46115278|NCT04077411|Other|Observational|This is an observational study with no interventions.
46115279|NCT03995030|Diagnostic Test|massively paralleled sequencing|Whole genome sequencing libraries will be generated and sequenced in batches on the Illumina MiSeq. FASTQ files will be demultiplexed and then aligned to microbial genomes using Phylosift.
46115280|NCT04110899|Other|Application of paratracheal force|An esophageal stethoscope is inserted into the upper esophagus under the application of different paratracheal force in anesthetized and paralyzed patients.
46026870|NCT02685709|Drug|Octreotide capsules|
46026871|NCT02265367|Drug|Levomilnacipran|
46026872|NCT02265367|Drug|Placebo|
46026873|NCT02718469|Biological|Ebola Vaccine - low dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
46026874|NCT02718469|Biological|Ebola Vaccine - mid dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
46026875|NCT02718469|Biological|Ebola Vaccine - high dose|2 x 1.0ml vaccine will be given as intramuscular injections on each of day 1 and day 28
46026876|NCT02718469|Biological|Placebo|2 x 0.5ml or 2 x 1.0ml placebo will be given as intramuscular injections on each of day 1 and day 28 depending on cohort
46026877|NCT02716363|Device|Rotational Atherectomy by Rotablator|
46026878|NCT02716285|Drug|Ileocolonic release peppermint oil|Peppermint oil, menthae piperitae aetheroleum
46115281|NCT04100876|Genetic|Global DNA methylation will be quantified in the DNA samples by colorimetry|Global DNA methylation will be quantified in the DNA samples by colorimetry
46115282|NCT02581293|Procedure|Group 1: Only visceral peritoneum will be closed|
46115283|NCT02581293|Procedure|Group 2 : Only parietal peritoneum will be closed|
46115284|NCT02581293|Procedure|Group 3 : Both of them will be closed|
46115285|NCT02581293|Procedure|Group 4: None of them will be closed|
46115286|NCT04109105|Other|NHS-PEG coated collagen patch|Analysis of the number and seriousness of leaks in the ileocolic anastomosis after using a NHS-PEG coated collagen patch reinforcement.
46115287|NCT02687997|Other|poligraphy|Sleep study
46115288|NCT04109183|Drug|The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.|The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
46115289|NCT04055883|Drug|DA-1229|All participants are administered one tablet per day for 96 weeks
46115290|NCT04244565|Behavioral|Self-directed model of clinical learning for nurses|the instructors play a facilitating role while, learners actively participate in identifying their own learning needs, learning goals, allocating resources & decide whether learning method can be used, and engaging in self-reflection & evaluation.
46115291|NCT04036695|Device|Reveal LINQ insertable cardiac monitoring system|A small implantable cardiac monitor (Reveal LINQ device) will be inserted under local anaesthetic in an outpatient procedure. The Reveal LINQ device is composed of two electrodes and is used to continuously monitor electric activity temporally. It can detect arrhythmic episode and record up to 27 minutes of electrocardiographic (ECG) activity. This device is capable of continuous monitoring of patient's ECG activity for up to three years and will be utilized in this study to obtain initial information on the timing and nature of the arrhythmia suffered by hemodialysis patients leading to SCD.
46026879|NCT02716285|Drug|Placebo|Placebo capsule, containing microcrystalline cellulose
46115292|NCT00638859|Drug|Telithromycin (HMR3647)|
46115293|NCT00793325|Drug|Somatropin|"Genotropin® 5.3mg, Genotropin®inj.12mg, Genotropin®MiniQuick s.c. inj.0.6mg・1.0mg・1.4mg, depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows.  Normally, the dosage is 0.021 mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. If efficacy is insufficient, the dose may be increased up to 0.47 mg/kg/week in 6-7 divided doses in a week by s.c. route."
46115294|NCT02537847|Drug|Sitafloxacin|The patients in intervention group will receive carbapenem for the first 3 days then sitafloxacin for 7 days. Total of treatment duration is 10 days.
46115295|NCT02537847|Drug|Ertapenem|Control group will be given ertapenem only for 10 days.
46026880|NCT02716285|Drug|Small intestinal release peppermint oil|Peppermint oil, menthae piperitae aetheroleum
46026881|NCT02725021|Behavioral|Education Against Tobacco school-based intervention by medical students|
46115296|NCT04033029|Device|Continuous venovenous hemodiafiltration with high adsorption membrane (oXiris®)|CRRT initiation will be determined by the treating physician on charge, according with the current recommendations of clinical practice and prescriptions of CRRT and local management protocols. The CVVHDF mode will be performed by using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).
46115297|NCT04033029|Drug|Antibiotics|Antibiotic concentration-time data will be collected and analyzed.
46115298|NCT04076553|Behavioral|CBT|Participants will complete 12 sessions of CBT
46115299|NCT04076553|Behavioral|ICT|"Participants will complete 4 weeks of daily inhibitory control trainings and booster ICT trainings following CBT treatment in weeks 5-12"
46115300|NCT04077645|Behavioral|Sun salutations|This group will be asked to participate in 25 minutes of low-to-moderate intensity Yoga. This acute session will include engaging in sun salutations, breathing exercises and relaxation. Sun salutations involves performing 10 postures in a particular sequence, and then repeating that sequence. Some of the positions include bending over and touching one's toes, and lying belly-down on the ground and pushing up from ground while arching backwards. The activity will begin as a low intensity activity for the first 5 minutes, and the intensity will be gradually increased. Participants' heart rate will be measured before and after the intervention. The intervention will be delivered by a video displayed on a tablet device. An orientation session in the beginning will familiarize participants with the activity.
46115301|NCT04077645|Behavioral|Aerobic exercise|This group will be asked to walk on the treadmill for the same amount of time (i.e. 25 minutes) at a moderate intensity (50-70% of their maximum heart rate). Participants will receive an initial 5-minute orientation and then begin at a self-selected speed for the first 5 minutes. Heart rate will be measured and monitored by an undergraduate research assistant. Speed will be increased after 5 minutes if participants have not reached the moderate zone. If participants still have not reached the target heart rate zone by the 10-min mark, the incline of the treadmill will be increased by a 5% grade until the zone is reached.
46115302|NCT04077645|Behavioral|Seated rest|This group will be watching educational videos for the same amount of time as the intervention groups. An orientation session of 5 minutes will be held in the beginning. Participants will be watching videos on general health related topics, such as healthy eating, while being seated in a quiet room, free of distractions.
46115303|NCT02687841|Drug|AST-120and pentoxyphylline (PTX)|AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days pentoxyphylline 400mg QD PO x 10 days.
46115304|NCT02687841|Drug|pentoxyphylline (PTX)|pentoxyphylline 400mg QD PO x 10 days.
46115305|NCT04076475|Device|neuromuscular electrical stimulation|Participants will receive muscular electrical stimulation on quadriceps muscle and abdominal muscles for 30 min/day for 10 days
46115306|NCT05121441|Drug|ARD-101|Twice daily, oral administration
46115307|NCT05121441|Drug|Placebo|Twice daily, oral administration
46115308|NCT04011267|Other|Physical therapy by foot-ankle segmental and functional exercises|The physiotherapeutic foot-ankle exercise protocol is based on previous clinical trials. It was designed following three criteria established in a supervised, face-to-face intervention: muscle stretching; strengthening of the intrinsic muscles; and strengthening of the extrinsic foot-ankle muscles and functional exercises, such as balance and gait training. To avoid monotony, game principles were inserted to reward the exercise execution and enhance motivation. The exercises change from session to session, and the maximum duration is no longer than 20 minutes. The exercises should only be done 3 times/week; no more than eight exercises each day; and the individual difficulty is regulated by the effort scale to manage the customized progression. In total, 39 different exercises were chosen, and when including their sublevels of progression, a total of 104 different exercises can be completed.
46026882|NCT01224821|Biological|Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab|Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
46026883|NCT02684851|Drug|Tranexamic Acid|Tranexamic acid: anti-fibrinolytic agents
46115309|NCT00778622|Drug|Metformin XR|Tablets, Oral, 500mg tid, 1500 mg/day, 16 weeks
46115310|NCT00915980|Procedure|gastric bypass surgery and testing|The patients will be tested with OGTT and meal testing before and after undergoing gastric bypass surgery.
46115311|NCT00777920|Drug|Ambrisentan|Tablet administered orally once daily
46115312|NCT04236141|Drug|Polatuzumab Vedotin|Participants will receive a total of 6 cycles (a cycle being 21 days) of 1.8mg/kg Polatuzumab Vedotin (IV infusion) on Day 2 of Cycle 1 and Day 1 of Cycles 2-6.
46026884|NCT02684851|Drug|Placebo|Placebo
46026885|NCT01224431|Drug|Buffered Lidocaine J-tip|All patients were administered the J-tip and randomized to either treatment with 1% lidocaine or an equivalent amount of sterile normal saline prior to lumbar puncture. Vital signs were recorded during the procedure. Facial expressions were video recorded
46026886|NCT02724943|Behavioral|BMI screening|Physician screening of patients to identify patients who are overweight or obese.
45598615|NCT03516799|Other|Acupuncture|Acupuncture is a method of Traditional Chinese Medicine that consists of the insertion of thin, sterile, FDA-approved disposable needles on specific acupuncture points (acupoints).
45598616|NCT02227823|Drug|Pyridostigmine Bromide|
45598617|NCT02295475|Drug|Apixaban|
45598618|NCT02295475|Drug|Warfarin|
46026887|NCT02724943|Behavioral|Next Steps brief clinical intervention|This intervention included identification of children who were overweight or obese, and Next Steps brief counseling materials for the healthcare provider (prior to enrollment in the intervention).
46026888|NCT02724943|Behavioral|MEND/CATCH|MEND 2-5 and MEND/CATCH 6-12 programs are multi-component interventions including behavioral, nutrition, and physical activity sessions. In the intensive (first 3 months) phase, MEND 2-5 entailed nine weekly sessions and MEND 6-12 entailed 18 twice weekly sessions.
46026889|NCT02724943|Behavioral|MEND/CATCH Transition Phase|The transition phase (next 9 months of the 12-month program) included monthly 90-minute sessions for parents and children included MEND reviews, cooking classes, Being Well book, CATCH activities and MEND World activities. Children were enrolled in YMCA sports teams or programs offered twice weekly to encourage physical activity. Weekly text messages were sent to parents to reinforce behavioral objectives of the intervention.
46026890|NCT02724943|Behavioral|Next Steps Self-Paced Booklet|Next Steps booklet for parents and children to work on nutrition and physical activity targets in a self-directed manner. Families were encouraged to seek repeated clinical visits to address child obesity as a follow up to the self-paced booklet.
46026891|NCT02716129|Drug|Morphine|38 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.2 mg morphine (Infumorph - Injection 10 mg/mL) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
46026892|NCT02716129|Drug|Morphine plus Nalbuphine|39 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.5 mg morphine (Infumorph - Injection 10 mg/mL) plus 0.2 mg nalbuphine (NALUFIN 20MG/ML AMP) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
46115313|NCT04236141|Drug|Bendamustine|Participants will receive a total of 6 cycles (a cycle being 21 days) of 90 mg/m2 Bendamustine (IV infusion) on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.
46115314|NCT04236141|Drug|Rituximab|Participants will receive a total of 6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab (IV infusion) on Day 1 of each cycle.
46115315|NCT04236141|Drug|Placebo|Participants will receive a total of 6 cycles (a cycle being 21 days) of Placebo (IV infusion) on Day 2 of Cycle 1 and Day 1 of Cycles 2-6.
46115316|NCT02601248|Drug|Theliatinib|Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
46115317|NCT04097522|Other|Neurofeedback|During the neurofeedback intervention, participants will be shown visual representations of their own brain activity in real-time. Over a number of sessions participants will teach themselves to increase this brain activity, in order to increase their own pain resilience levels.
46115318|NCT04233099|Procedure|Raman analysis of saliva with data collection and analysis|Saliva collection and processing to all the enrolled subjects and consecutive Raman analysis of the biological fluid. Statistical processing of the collected data.
46115319|NCT04097444|Biological|Bevacizumab|Given IV
46115320|NCT04097444|Drug|5-fluorouracil|Given IV
46026893|NCT01223183|Drug|hypertonic saline (7%)|single treatment by inhalation
46026894|NCT01223183|Drug|isotonic saline|single treatment by inhalation
46115321|NCT04097444|Drug|Leucovorin calcium|Given IV
46115322|NCT04097444|Drug|Irinotecan hydrochloride|Given IV
46115323|NCT04097444|Drug|Oxaliplatin|Given IV
46115324|NCT04097444|Drug|Capecitabine|Given PO
46115325|NCT04097288|Drug|Citalopram 40mg|Single dose
46115326|NCT04097288|Drug|Reboxetine 8 mg|Single dose
46115327|NCT04097288|Drug|Placebo oral tablet|Single dose
46115328|NCT04097288|Drug|Placebo oral tablet|Single dose
46115329|NCT04102358|Procedure|Medial approach infraclavicular block with single injection|infraclavicular blocks performed with single injection
46115330|NCT04102358|Procedure|Medial approach infraclavicular block with triple injection|infraclavicular blocks performed with triple injection
46115331|NCT03994094|Other|Telephone interview|Structured, directive, telephone interview, in order to collect the outcome measures in addition to the patients electronic health record.
46115332|NCT04076007|Dietary Supplement|Beetroot juice|
46115333|NCT04076007|Dietary Supplement|Nitrate depleted beetroot juice|
46115334|NCT04005105|Behavioral|Intensive management|Management based on premorbid MAP and MPP
46115335|NCT03997305|Device|AltaValve|Transcatheter Mitral Valve Replacement
46026895|NCT02718391|Biological|Autologous Dendritic Cell vaccine|The Dendritic Cells vaccine is given intradermally with 5 injections in sites close to inguinal or axillary lymphnode stations that had not site of previous surgical exeresis; as a rule, vaccine administrations should be performed by alternating injections sites. Two days after each vaccine administration, daily 3 MU Interleukin 2 will be administered subcutaneously for 5 days.
46115336|NCT03995901|Biological|FCR001|FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood of the kidney donor that is delivered as a single dose with a non- myeloablative conditioning regimen. FCR001 contains the donor's CD34+ cells, facilitating cells, and αβ T cells.
46115337|NCT04076085|Other|exercise|Stretching exercise for warmup, All arm exercise with and without weights as tolerated by the patients. Similarly lower limb exercise in different positions like lying standing as tolerated by the patients
46115338|NCT02581059|Drug|Regorafenib|All subjects will receive regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle for 2 cycles.
46115339|NCT02581059|Dietary Supplement|Ginseng|Subjects randomized to ginseng will receive 1,000 mg orally twice every day of each 28-day cycle for 2 cycles.
46115340|NCT04228419|Procedure|Total Shoulder Arthroplasty|Replacement of the shoulder joint (ball and socket, or humeral head and glenoid) using prosthetic components.
46026896|NCT02718235|Other|Overall survival|Observation of overall and disease free survival
46115341|NCT04228419|Procedure|Reverse Shoulder Arthroplasty|Replacement of the shoulder joint like the TSA, however the orientation of the ball and socket is reversed.
46115342|NCT05247957|Biological|CAR-NK cells|NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7
46115343|NCT02581605|Device|Custom-made 'cutting block'|To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
46115344|NCT00796445|Drug|GSK 2132231A|IM solution, a course of 13 injections administered over 27 months
46115345|NCT00796445|Drug|Placebo|IM solution, a course of 13 injections administered over 27 months
46115346|NCT04075773|Behavioral|Expressive Writing|The participants are asked to write for a period of time about specific concepts so that they think carefully and cognitively process the information they are generating.
46115347|NCT03799341|Behavioral|Prize-Based Contingency Management|"Participants assigned to Prize-based Contingency~Management (PBCM) conditions will receive PBCM as an adjunct to TAU. PBCM will involve twice weekly one-on-one sessions with a provider for 12-weeks. During each session, a urine specimen provided by the patient will be tested for cocaine using a point-of-care dip-test. Results of point-of-care testing will be shared with the patient and negative results will be reinforced with draws from a fish bowl containing 500 paper slips, 250 of which award small, large, or jumbo prizes (remaining slips deliver words of encouragement). Patients will be reinforced with a single prize draw for their first negative specimen; an additional prize draw will be added for each consecutive negative result (up to 8~prize draws per session). Abstinence-contingent prize draws will be reset to one upon either a positive test result or unexcused, missed appointment."
46115348|NCT03799341|Behavioral|Treatment As Usual Outpatient Substance Use Treatment|All participants will receive treatment as usual outpatient substance use services during the 12-week treatment interval. TAU will specifically entail recommended participation in at least two outpatient group and/or individual psychotherapy encounters per week within the Center for Treatment of Addictive Disorders (CTAD) at VA Pittsburgh Healthcare System. Participants will additionally continue any previously prescribed pharmacotherapy for substance use and/or other mental health conditions, if applicable.
45838884|NCT04353180|Drug|Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment|"After three days of randomization and standard treatment , 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days.+standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection"
46026897|NCT02724709|Procedure|Three-dimensional transoesophageal echocardiography|Three-dimensional transoesophageal echocardiography, analysed by eSie valve software (Siemens)
46115349|NCT04108871|Procedure|Prostate Biopsy|Samples of tissue are removed from the prostate for histopathological diagnosis of prostate cancer through the use of a needle with the assistance of transrectal ultrasound.
46115350|NCT03799263|Procedure|evaluation group|Recordings Pneumologic assessment Severity grades (I-IV: old GOLD and A-D: new GOLD) Smoke History Drug therapy Comorbidities 6MWT performed within previous 10-14 months, if available. Measurements Standard exams usually performed at Rehab Center Lung Function tests and diffusing capacity of the lung for carbon monoxide Arterial Blood Gases Dyspnoea Health Status and Health Related Quality of Life Daily activity Lower limb muscle strength Exercise capacity
46115351|NCT03999047|Diagnostic Test|PRISMA score|Screening for frailty using PRISMA-7
46115352|NCT02580513|Behavioral|Circadian Misalignment|
46115353|NCT03939819|Device|ViSiGi® 3D suction calibration device|ViSiGi 3D®is a non-sterile, single patient use device. The device comprises a tube with a closed, rounded tip, and holes at the distal end. The proximal end of ViSiGi 3D® includes an integral suction regulator and vented On/Off valve.
46115354|NCT03939819|Device|Esophagogastroduodenoscopy (EGD) calibration|Gastroscope is an illuminated optical, slender and tubular instrument (a type of borescope) used in esophagogastroduodenoscopy.
46115355|NCT05674383|Procedure|Axillary plexus nerve block|Axillary plexus nerve block: an ultrasound-guided axillary plexus nerve block with a single injection of lidocaïne 1%.
46115356|NCT05674383|Procedure|Fracture hematoma block|Fracture hematoma block: a blinded single injection into the fracture with lidocaïne 1%.
46115357|NCT04219449|Diagnostic Test|PT|measuring PT drawn on citrated blood sample
46115358|NCT04219449|Diagnostic Test|Protein C|measuring protein C drawn on citrated blood sample
46115359|NCT04219449|Diagnostic Test|Platelet aggregation by ADP and arachidonic acid|measuring platelet aggregation drawn on citrated blood sample
46026898|NCT02724709|Procedure|Computed tomography|Computed tomography, analysed by Synovia Workstation (Siemens)
46026899|NCT02920333|Procedure|conventional rehab training|Conventional rehab training will be conducted daily for 10 days, after NIBS intervention.
46115360|NCT04209855|Drug|Mirvetuximab Soravtansine|Mirvetuximab soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
46115361|NCT04209855|Drug|Paclitaxel|Paclitaxel is a taxane that can stabilize microtubules to inhibit cell division. It was approved for treatment of recurrent epithelial ovarian cancer.
46026900|NCT02920333|Device|tDCS|tDCS will be applied 10 days, followed by conventional rehab training. Stimulation will be conducted at the intensity of 2 mA and last for 20 minutes. anode will be placed over the affected primary motor cortex (M1) of cortical representation of the tibialis anterior muscle (TA), while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.
45838885|NCT04353180|Drug|Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment|"Drug: After three days of randomization and standard treatment , Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days +standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection"
45838886|NCT04353180|Drug|Isotretinoin (13 cis retinoic acid ) capsules|13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
45838887|NCT04353180|Drug|Aerosolized 13 cis retinoic acid|Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
46026901|NCT02920333|Device|rTMS|rTMS will be applied 10 days, followed by conventional rehab training. Subjects will receive 10 Hz rTMS, and a total of 1200 pulses will be delivered for one treatment session.
46026902|NCT02920333|Device|sham tDCS|The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
46026903|NCT02724553|Device|Acrylic lens implantation|
46026904|NCT02718079|Biological|Plasma Exchange|
46026905|NCT02718079|Other|Management of cerebral edema/intracranial hypertension:|
46026906|NCT02718079|Other|Transfer to Intensive Care Unit|
46026907|NCT02718079|Drug|Prophylactic Antibiotics|
46115362|NCT04209855|Drug|Topotecan|Topotecan induces irreversible DNA damage. It inhibits topoisomerase 1, leading to both single and double strand DNA break that eventually promote apoptosis. Topotecan was approved for treatment of epithelial ovarian cancer after failure of initial or subsequent chemotherapy.
46115363|NCT04209855|Drug|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin is a standard chemotherapy regimen used for treating platinum-resistant ovarian cancer. The active component doxorubicin is an anthracycline that intercalates DNA, leading to inhibition of replication and subsequently, the inhibition of proper cell division.
45838888|NCT04353180|Drug|Standard treatment|Standard treatment is according to the protocol of treatment of 2019-nCoV infection
45838889|NCT04352868|Device|Intelliwave multifocal, toric, soft contact lens|This is a quarterly disposable, multifocal, toric soft contact lens commercially available from Art Optical Contact Lens, Inc.
45838890|NCT04352868|Device|Intelliwave toric, soft contact lens|This is a quarterly disposable toric soft contact lens commercially available from Art Optical Contact Lens, Inc.
46026908|NCT02718079|Other|Intubation of trachea|
46026909|NCT02718079|Other|Administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure|
46026910|NCT02718079|Other|Volume Replacement|
46026911|NCT02718079|Other|Pressor Support|
46026912|NCT02718079|Drug|N-acetyl-L-cysteine|
46026913|NCT02718079|Other|Correction of metabolic parameters|
46026914|NCT02718079|Dietary Supplement|Correction of nutrition|
46026915|NCT02717923|Other|maintenance treatment with capecitabine plus cetuximab|Using a maintenance treatment strategy of capecitabine plus cetuximab as a treatment option in mCRC after first-line 5-FU-based chemotherapy plus cetuximab
46026916|NCT02724475|Procedure|LA|Ultrasound-guided puncture to the front of the thrombus with a power of 30 watts and pulse time of 0.3-0.4 seconds with 1 second interval until the thrombus was totally eliminated
46026917|NCT02724475|Procedure|3D-CRT|γ-knife treatment with radiation dose of 48-63 Gy/6-9 times
46026918|NCT02716207|Device|CyberKnife|Radiation Therapy
46026919|NCT02716051|Device|MRI|Whole body MRI with cardiac and pulmonary synchronization
46026920|NCT02716051|Device|PET|
45470543|NCT05459623|Other|Emmett intervention|"will receive manual myofascial release and the Emmett intervention with the subject sitting upright on a 45cm wooden chair; light, constant pressure via the middle finger (at a perpendicular angle to the skin) will be applied at both points, three times for 10-20s with 5-10s breaks between. A light sweeping action over the sensory area that will treated will be performed once, using the back of the fingers. The rationale for this is that the light brushing action disperses the sensory awareness to move without being too heavy or specific enough to create muscular response. The sequence performed on one side will then repeated on the opposite leg. In Ross Emmett's teachings of the technique he insists on treatment of both sides when focusing on the lower body (for balance). Once both sides will be completed, the subject will be instructed to walk around the room for a minute."
45470544|NCT03754387|Drug|Ceftazidime|Patients choosing AT group were admitted to the hospital for observation and to receive intravenous antibiotics Intravenous Ceftazidime sodium (50mg/kg/dose every 12 hours) was administered for 3 days.
46115364|NCT04075929|Other|Training effects on aerobic output|The cyclists were allowed to perform ad libitum low intensity (LIT) in addition to high intensity (HIT) sessions that were determined to each group. The cyclists completed 12 supervised HIT sessions during the intervention period, three HIT sessions per week with at least 48 hours between each HIT-session. All HIT sessions were performed as supervised group training sessions. Each HIT session started with an individual 30 minutes' warm up at low intensity (55-70% HRmax) interspersed by freely chosen progressive sprints. For all groups the power output during the recovery periods was 50 % of the power output used during work intervals. The cyclists in all groups were instructed to perform each interval session at their maximal sustainable intensity. Each session ended with 15-20 minutes' cool down (55-70% HRmax). All HIT sessions were supervised and performed in groups on the University of Agder's (UiA) premises at Spicheren fitness center in Kristiansand.
46115365|NCT00756938|Drug|losartan potassium|losartan potassium, dry powder, to be suspended in liquid and given orally, once daily; doses will start at 0.1 mg/kg, 0.3 mg/kg, and 0.7 mg/kg, respectively, in the three study arms and can be escalated up to 1.4 mg/kg (maximum dose 100 mg) until target blood pressure is reached.
45470545|NCT03754387|Procedure|appendectomy|APPT group consisted of admission to the hospital with promptinitiation of intravenous antibiotics and appendectomy
46026921|NCT02717845|Device|Ellipse|diagnostic CT scan imaging
45470546|NCT03332784|Drug|TAK-925|TAK-925 Intravenous Infusion
45470547|NCT03332784|Drug|Placebo|TAK-925 Placebo Intravenous Infusion
45470548|NCT05317741|Drug|IA-14069|Subjects received IA-14069 tablet orally on Day 1.
45470549|NCT05317741|Drug|Placebo|Subjects received matching placebo tablet orally on Day 1.
45470550|NCT03751501|Procedure|Indocyanine green-Guided Targeted Laser photocoagulation|Detection of macro-aneurysms by ICG angiography, laser photocoagulation and optional post-laser verification of the effectiveness of the photothrombosis by OCT.
45470551|NCT03751501|Procedure|Sham laser|Therapeutic procedure used in ophthalmology
45470552|NCT03248154|Device|Procellera|burn dressing
45598619|NCT03146949|Device|Sorin Inspire Oxygenator|This is an oxygenator manufactured by the Sorin group. It is a hollow fibre polypropylene oxygenator.
46026922|NCT02717845|Device|Tomofix|diagnostic CT scan imaging
46026923|NCT02715973|Dietary Supplement|Nutritional Supplement|Energy dense supplement appox. 2 kcal/mL, prepared from locally available, affordable, socially acceptable food items - milk, sugar, edible coconut oil, egg and custard powder as base) in addition to standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age.
46026924|NCT02715973|Dietary Supplement|Standard Nutritional Treatment|Standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age
46026925|NCT02724397|Device|LCI/BLI then white endoscopy|First use of Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) and then White Light Endoscopy to detect colonic adenomas.
46026926|NCT02724397|Device|White endoscopy and then LCI/BLI|First use of White Light Endoscopy and then Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) to detect colonic adenomas.
46026927|NCT02717533|Other|dry weight adjustment|dry weight change to match ideal blood volume obtained by blood volume measurement.
46026928|NCT02715817|Other|Virtual Rehabilitation|It is the use of the NW games for rehabilitation of balance and gaite in post-stroke patients.
46026929|NCT02715817|Other|Conventional therapeutic exercises|It is the use of the conventional therapeutic exercises for rehabilitation of balance and gait in post-stroke patients.
46026930|NCT02715817|Other|Virtual Rehabilitation and Conventional Therapeutic Exercise|It is the use of the conventional exercises and of the NW for rehabilitation of balance and gait in post-stroke patients.
46026931|NCT05051761|Drug|Jaktinib|Administered orally.
46115366|NCT04076865|Drug|EMLA (lidocaine) +Itch (Histamine and cowhage)|"Cutaneous anaesthesia: will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine, AstraZeneca A/S, Albertslund, Denmark).~Histamine: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied.~Cowhage: Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip, once inserted into the epidermis, the spicules evoke a moderate sensation of itch and to a lesser extent sensations of burning and stinging pain."
46115367|NCT00796367|Drug|VI-0521|7.5 mg phentermine and 46 mg topiramate
46026932|NCT05051761|Drug|placebo|Administered orally.
46026933|NCT02717689|Other|Biomarker based adjustment of corticosteroid dose|The subject's corticosteroid dose will be adjusted based upon biomarker results (FeNO, eosinophils and periostin)
46115368|NCT00796367|Drug|Placebo|placebo
46026934|NCT02717065|Other|Tone|Band-limited white noise stimulus or frequency-matched tone presented at a comfortable loudness level via headphones or earphones.
46115369|NCT00796367|Drug|VI-0521|15 mg phentermine and 92 mg topiramate
46115370|NCT02580825|Behavioral|Biofeedback gait retraining|Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). During the meeting, participant will receive biofeedback that will displayed on a computer screen that shows the forces that develop in the knee joint so that the patient can see graphically the forces that develop around the knee joint and will be guided / try to reduce the values of the graph by changing the intensity of his landing on the tracks. In all training the time that the biofeedback is shown will be reduced.
46026935|NCT02717065|Other|Video|Silent video recording of a person speaking or a still face with an expanding circle over the mouth presented on a computer or tablet screen.
46026936|NCT02694367|Other|Investigate the MAP kinase signaling pathways through ERK and p-ERK proteins|
45470553|NCT05668897|Drug|GST-HG171|This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
46115371|NCT02580825|Behavioral|Exercise|Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section).
45470554|NCT05668897|Drug|placebo of GST-HG171|This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
45470555|NCT03171480|Drug|Monoket Pill|Intra-vaginal application of Monoket as a cervical ripening agent for pregnant women undergoing induction of labor
45470556|NCT03171480|Drug|Placebo|The pharmacy has compounded an identical appearing placebo
45470557|NCT04465357|Drug|Erenumab-Aooe 140 MG/ML [Aimovig]|140 mg/mL administered subcutaneously
45470558|NCT03160794|Diagnostic Test|[18F]DCFPyL PET/MRI scan|PET/MRI imaging using the radiotracer, [18F]DCFPyL
46026937|NCT04864171|Device|near-infrared spectroscopy|Near-infrared spectroscopy is an intravascular imaging device to visualize lipid-rich plaque of coronary artery.
46115372|NCT00770588|Drug|Gefitinib|Dose form: 250 mg/tablet; Route: oral; Frequency: 1 tablet per day; Duration: until to objective PD
46115373|NCT00770588|Drug|Placebo|To match Gefitinib
46115374|NCT02604719|Drug|Tranexamic Acid and Ethamsylate|The intervention will be the intravenous administration of 10 ml blinded vial of the study drugs (either 1 gmTranexamic acid and 1 gm Ethamsylate or placebo according to randomization group) slowly (over 30-60 sec ) in the 2 minutes after birth and the routine prophylactic oxytocin and after the cord has been clamped , all generally by the anesthesiologist or obstetrician then a pad will be placed under women buttocks then weighting the pads to allow objective measurement of blood loss.
46115375|NCT03788343|Dietary Supplement|Phenylalanine|The study product Phenylalanine, a dietary supplement, is authorized in Switzerland, but not designated for this patient group.
46115376|NCT03788343|Drug|Placebo|Placebo capsules are indistinguishable in their appearance from Phe capsules
46115377|NCT02604797|Drug|Nalbuphine|patient-controlled intravenous analgesia
46115378|NCT02604797|Drug|Sufentanil|patient-controlled intravenous analgesia
45470559|NCT03160794|Radiation|Stereotactic Ablative Radiotherapy|SABR as treatment for lesions identified using [18F]DCFPyL PET/MRI
45598620|NCT03146949|Device|Medtronic Affinity Fusion|This is an oxygenator manufactured by the Medtronic group. It is a hollow fibre polypropylene oxygenator.
45598621|NCT02227901|Drug|Tipifarnib|Given PO
46026938|NCT02715739|Other|No intervention|
46026939|NCT02715661|Other|exercise|six-month interval of exercise
46026940|NCT04860817|Biological|Target CD7 CAR-T cells|"Enrolled participants are allocated to one of three different dose levels of target CD7 CAR-T cells. The infusion dose of CAR-T cells will start at low dose and then rise to higher dose after completion of low dose group.~Dose level one: 0.6×10^7 cells/kg;~Dose level two: 1×10^7 cells/kg;~Dose level three: 1.5×10^7 cells/kg. Before CAR-T infusion, all participants will receive a preconditioning therapy suggested as: Fludarabine 30 mg/m^2×6d, Cyclophosphamide 300 mg/m^2×6d or Cyclophosphamide 600 mg/m^2×6d. After completion of preconditioning therapy, infusion of CAR-T cells needs to start within 1 week. Participants will receive one infusion of CAR-T cells which will take between 15 and 30 mins."
46026941|NCT02717221|Other|18F-MPG|N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-[18F] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)
46026942|NCT02715895|Dietary Supplement|Friso|Friso formula feeding on demand for 3 months
46026943|NCT02715895|Dietary Supplement|Wyeth|Wyeth formula feeding on demand for 3 months
46115379|NCT02604797|Drug|flurbiprofen axetil|patient-controlled intravenous analgesia
46026944|NCT02715895|Dietary Supplement|Breast milk|Breast milk feeding on demand
46115380|NCT02604797|Drug|ramosetron|patient-controlled intravenous analgesia
46115381|NCT03778827|Behavioral|Intensive Center-Based Pivotal Response Treatment (PRT-C)|Intensive Center-Based Pivotal Response Treatment (PRT-C) will consist of a combination of weekly individual parent training sessions and center-based therapy for a total of 13 weekly treatment hours.
46115382|NCT04107233|Behavioral|Audit and Feedback|Charts for enrolled physicians will be audited and they will receive feedback, consisting of tailored reports and one-on-one meeting with colleague to review at baseline, 3 months and 6 months
46115383|NCT03773523|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
46115384|NCT00777608|Drug|Comparator: Placebo 5mg (run in)|Matching placebo to donepezil - 5 mg capsules orally for 14 day run in prior to randomization.
46026945|NCT02717299|Device|Verasense|Verasense will collect balancing data on all patients in this trial.
46026946|NCT04189315|Drug|asfotase alfa|Asfotase alfa is administered subcutaneously.
46026947|NCT02724163|Drug|Gemtuzumab ozogamicin|Antibody-conjugated chemotherapy agent.
46115385|NCT00777608|Drug|Donepezil 5 - 10 mg|"Donepezil 1 capsule (5 mg) orally, once daily for 14 days.~Donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84)."
46115386|NCT00777608|Drug|Comparator: Placebo 5-10 mg|"Matching placebo to donepezil, 1 capsule (5 mg) orally, once daily for 14 days.~Matching placebo to donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84)."
46115387|NCT00777608|Drug|Donepezil 10 mg|Donepezil 2 capsules (total 10 mg) orally, once daily for 24 weeks, from day 85 (optional).
46115388|NCT05604989|Drug|Probiotic Combination Cap/Tab|The Perfect Probiotics® capsule will be given as an intervention, which is composed of mostly Lactobacillus acidophilus & Bifidobacterium lactis.
46115389|NCT05604989|Drug|intravitreal Anti-VEGF injection|Intravitreal anti-VEGF injection treatment in the neovascular AMD patients.
46115390|NCT03905031|Device|InfraScanner 2000|The InfraScanner is a portable screening device that measures lateralized differences in optical density (OD) to determine the presence of intracranial hematoma. A difference in OD>0.2 is abnormal and suggestive of intracranial hematoma.
46115391|NCT02580903|Radiation|Radiology|Only a small subsample will require CT and right heart catherisation
46115392|NCT00792935|Drug|MK-0941|MK-0941 will be taken three times a day (TID), within 15 minutes before each meal. MK-0941 will be titrated to a maximally effective dose. The treatment period will be 6 weeks.
46115393|NCT00792935|Drug|Glimepiride|Glimepiride will be taken once a day (QD) in the morning, within 15 minutes before the breakfast meal. Glimepiride will be titrated to a maximally effective dose. The treatment period is 6 weeks.
46115394|NCT00792935|Drug|Metformin|The study will include an up to 4-week metformin dose titration/dose stabilization period. Once a participant has reached the maximum tolerated dose of metformin [(i.e., ≥1500 mg/day and ≤2550 mg/day (or ≤3000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)], the participant should remain on the same metformin dose throughout the study.
46115395|NCT03904563|Drug|Bevacizumab|Patients are treated with Bevacizumab 1-2 months after the chemoradiotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for up to 1 year.
45598622|NCT02227901|Radiation|External Beam Radiation Therapy|Undergo EBRT
46026948|NCT02724163|Drug|Liposomal daunorubicin|"Anthracycline~(Randomisation 1 (R1)) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug."
45598623|NCT02227901|Drug|Temozolomide|Given PO
45838891|NCT04352946|Drug|Hydroxychloroquine Pre-Exposure Prophylaxis|HCQ PreP 400mg daily
45598624|NCT02227901|Other|Laboratory Biomarker Analysis|Correlative studies
45598625|NCT03146715|Other|Feeding trial|Children were asked to eat the designated portion of the assigned food once a day for six weeks.
45838892|NCT04352946|Drug|Placebo oral tablet|Placebo tablets 400mg daily
46026949|NCT02724163|Drug|Mitoxantrone|DNA-reactive agent
46026950|NCT02724163|Drug|Fludarabine|A water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine.
46026951|NCT02724163|Drug|Cytarabine|Pyrimidine nucleoside analogue, an antineoplastic agent.
46026952|NCT02724163|Drug|Busulfan|Alkylsulfonate
46026953|NCT02724163|Drug|Cyclophosphamide|A nitrogen mustard alkylating agent from the oxazaphosphorine group
46026954|NCT02723851|Device|Corsens|Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index [MCI] and isovolumetric contraction (IVCT). Measurements will not affect the treatment provided to the patients.
46026955|NCT02717377|Behavioral|physical activity|
46026956|NCT02486965|Device|thermode (TSA-II model)|thermal stimulation with test thermode
46026957|NCT02486965|Other|Adapted Physical Activity|
46026958|NCT02486965|Other|Physical activity|
45470560|NCT03912324|Procedure|Unipolar voltage subtraction map guided PV isolation group|"Pulmonary vein isolation will be performed using a radiofrequency catheter~Esophageal temperature will be monitored to prevent esophageal injury~Mapping of echocardiographic unipolar voltage subtraction after atrial septal puncture~the electrode map data is transferred to the core lab by network to calculate the unipolar voltage subtraction color map (within 10 minutes)~Increase radiofrequency ablation time by 2 to 5 seconds in areas with high potential in unipolar voltage subtraction color map~Decrease radiofrequency ablation time by 2 to 5 seconds in areas with low potential in unipolar voltage subtraction color map~Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~Evaluate time to complete isolation after additional ablation~Evaluation of Procedure and Ablation time, and perfusion saline dose~Rhythm follow-up after the procedure in accordance with the study design."
45754454|NCT05580614|Device|tVNS|MRI (Magnetic Resonance Imaging) paired ERP/tVNS YBOC's (Yale-Brown Obsessive Compulsive Scale) (4, 8, 12) OCI-R (every other session). YBOCs and OCI-R will also be administered at intake and 4 weeks post treatment.
46026959|NCT02723539|Drug|MBN-101|Topical application
45838893|NCT04352712|Other|blood sampling|blood sampling
45838894|NCT04352634|Other|Exposure to the SARS-CoV-2 and its consequences|This is an observational design. Participants are exposed to the SARS-CoV-2, the Covid-19 pandemic, and/or its consequences
45838895|NCT04352322|Dietary Supplement|A+HA(tm)|oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin
45838896|NCT04352322|Dietary Supplement|Placebo|oral solution with no active ingredients
46026960|NCT02723539|Drug|Placebo|Topical application
46026961|NCT02723617|Other|MED 0.5|Participants will be fed a Mediterranean diet providing 0.5 oz. per day of lean beef.
46026962|NCT02723617|Other|MED 2.5|Participants will be fed a Mediterranean diet providing 2.5 oz. per day of lean beef.
46026963|NCT02723617|Other|MED 5.5|Participants will be fed a Mediterranean diet providing 5.5 oz. per day of lean beef.
46026964|NCT02723617|Other|AAD 2.5|Participants will be fed an average American diet providing 2.5 oz. per day of lean beef.
46115396|NCT03904563|Radiation|chest radiation|split-course chest radiation
46115397|NCT03904563|Drug|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
46115398|NCT00770510|Drug|Eszopiclone 1 mg|Eszopiclone 1 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
46115399|NCT00770510|Drug|Eszopiclone 2 mg|Eszopiclone 2 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
46115400|NCT00770510|Drug|Eszopiclone 3 mg|Eszopiclone 3 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
46115401|NCT00770510|Drug|Placebo|Placebo tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
46115402|NCT00770510|Drug|Zolpidem Tartrate 10 mg|Zolpidem Tartrate 10 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
46115403|NCT02580747|Biological|anti-meso-CAR vector transduced T cells|genetically engineered lymphocyte therapy
45838897|NCT04352400|Drug|Nafamostat Mesilate|administered intravenously as a continuous infusion
46115404|NCT04077177|Behavioral|Male Athlete Body Project|Participants who meet eligibility criteria and consent to the study will be randomized to one of two conditions: intervention condition (i.e., Male Athlete Body Project) or an assessment only control condition. The intervention groups will take place at IIT. Participants who accept randomization to condition will complete baseline questionnaires after randomization (immediately prior to Session 1 in the intervention condition and after being randomized to the assessment only control condition). Questionnaires will be repeated immediately post-intervention (intervention condition)/after a 3-week interval (control). All participants will be asked to complete the questionnaires again, 4 weeks after the previous round of questionnaires. The 3, 80-minute group sessions will be separated by 1 week.
46115405|NCT04077255|Drug|Anti-EGFR antibody in combination with weekly paclitaxel|Intravenous GC-1118 in combination with weekly paclitaxel for EGFR-amplified cancer cancers as a second-line therapy
46115406|NCT00770432|Drug|Polyethylene glycol 3350|Polyethylene glycol 3350 powder for solution. Single dose (17 grams in 4 to 8 ounces of beverage) for 7 days.
46115407|NCT00770432|Other|Placebo, maltodextrin 500 powder for solution|Maltodextrin 500 powder for solution, One single dose (one capful) in any 4 - 8 ounces beverage for 7 days.
46026965|NCT02902003|Behavioral|Empowering Families|A program that integrates the healthy relationship curriculum, Family Wellness, into a comprehensive set of services that includes case management, employment services, and financial coaching. The program will have four core components: (1) 20 hours of core workshop sessions using the Family Wellness curriculum; (2) case management; (3) employment services; and (4) financial coaching. The core component of Empowering Families will be a 20-hour group workshop, organized into eight two-and-a-half-hour weekly sessions (Table 1). The main content of these sessions will be based on the Family Wellness relationship education curriculum which will be covered in six sessions. These six sessions will be led by two trained facilitators employed by The Parenting Center. The core workshops will be supplemented with two additional sessions on financial planning and employment topics that will designed to be useful to all participants, regardless of their level of financial and employment needs.
46026966|NCT02715427|Other|Conventional care|
46115408|NCT00792701|Drug|cisplatin|Given IV
46115409|NCT00792701|Drug|gemcitabine hydrochloride|Given IV
46026967|NCT02715427|Other|Enhanced recovery|
46026968|NCT02715349|Behavioral|Psychoeducation|3 session psychoeducation program with the family, and 3 session psychoeducation program with the patient, after psychosis is controlled. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
46115410|NCT03772353|Drug|Dalpiciclib|Dalpiciclib (SHR6390) is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
46115411|NCT03772353|Drug|Pyrotinib|Pyrotinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor, showed promising anti-tumour activity and acceptable tolerability in patients with HER2+ metastatic breast cancer (MBC)
46115412|NCT03772353|Drug|Letrozole|Letrozole, a third-generation aromatase inhibitor, is the principal drug used in the treatment of postmenopausal patients with both early- and advanced-stage endocrine-responsive breast cancer (BC).
46115413|NCT03772353|Drug|Fulvestrant|Fulvestrant is a selective oestrogen receptor (ER) degrader used in postmenopausal women with hormone receptor-positive advanced breast cancer
46115414|NCT03771105|Drug|phosphate|The target daily phosphate (Pi) intake is 3,500 mg/day (dietary intake plus our supplementation) for this study. Subjects will take a supplement of Pi (as KPhos Neutral 250 mg/tablet) to reach this target. Subjects will receive treatment for 30 days.
45838898|NCT04352400|Drug|Placebo|administered intravenously as a continuous infusion
45838899|NCT04352478|Diagnostic Test|Histopathological result|Incidental gallbladder cancer and other pathology
46115415|NCT05559983|Biological|OSP:rTTHc Cholera Conjugate Vaccine Cohort A|OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 5 µg of OSP:rTTHc
46115416|NCT05559983|Biological|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort A|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 5 µg of OSP:rTTHc
46115417|NCT05559983|Other|Placebo Cohort A|Sterile 0.9% sodium chloride
46115418|NCT05559983|Biological|OSP:rTTHc Cholera Conjugate Vaccine Cohort B|OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 10 µg of OSP:rTTHc
46115419|NCT05559983|Biological|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort B|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 10 µg of OSP:rTTHc
46115420|NCT05559983|Other|Placebo Cohort B|Sterile 0.9% sodium chloride
46115421|NCT05559983|Biological|OSP:rTTHc Cholera Conjugate Vaccine Cohort C|OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 25 µg of OSP:rTTHc
46115422|NCT05559983|Biological|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort C|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 25 µg of OSP:rTTHc
45754455|NCT00613405|Other|Stress + cue exposure|Trier Social Stress Task(TSST): subject is asked to give a talk and perform a math task in front of an audience, follwed by neutral and marijuana cue exposure.
45754456|NCT00613405|Other|No stress + cue exposure|Neutral and marijuana-associated cue exposure (scripted imagery, in vivo cues).
45754457|NCT05245435|Diagnostic Test|FDHT-PET Scan|[18F]-fluoro-5α-dihydrotestosterone (FDHT)- positron emission tomography (PET)
45838900|NCT04351932|Biological|bone marrow mesenchymal stem cells|intrarticular bone marrow mesenchymal stem cells injection
46115423|NCT05559983|Other|Placebo Cohort C|Sterile 0.9% sodium chloride
46115424|NCT03765567|Drug|Vancomycin|2 vials of Vancomycin 1g powder will be applied topically to the open fracture wound site.
46026969|NCT02715505|Drug|Umbilical cord blood transplantation with HSC835|Hematopoietic Stem cell transplantation will be done with the cell therapy product HSC835
46026970|NCT02716909|Device|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
46115425|NCT02580669|Other|Neuropsychological assessment|A neuropsychological assessment is done
46115426|NCT02580669|Other|Neurologic consultation|A neurologic consultation is done
46115427|NCT02580669|Other|MRIs (with vasoreactivity testing)|MRIs (with vasoreactivity testing) is done
46115428|NCT00777296|Drug|ARIKACE™|Study start date is before Jan 18, 2017.
46115429|NCT00777296|Drug|Placebo|Study start date is before Jan 18, 2017.
46115430|NCT05186805|Drug|Tapinarof cream, 1%|Tapinarof cream, 1% applied topically once daily
46115431|NCT04106609|Other|Supervised, individualized exercise oncology program|The study intervention is a supervised, individualized exercise oncology program described in previous literature2,3,12 and provided by Maple Tree Cancer Alliance, a non-profit organization providing exercise training to individuals with cancer (https://www.mapletreecanceralliance.org/). This organization was founded in 2011 and currently operates in 9 hospitals serving Ohio and Pennsylvania, offering free exercise programs and nutritional guidance to approximately 500 patients annually to help relieve side effects related to cancer treatment.
46115432|NCT04106609|Other|Current standard of care|Resource guide with various options available to cancer survivor. Within this guide are tips for healthy eating and pictures of standard exercises to improve fitness.
46115433|NCT02603549|Other|Pituitary panel will be drawn pre-op and post-op for all patients.|
46115434|NCT05084547|Other|No intervention|No intervention
46115435|NCT04097132|Device|echocardiography|echocardiography for left atrial diameter, size ,Ejection Fraction Holter for detection of paroxusmal AF
46115436|NCT04076163|Other|serious game|a serious game was performed by the investigators in order to enhance the critical appraisal practice of students
46115437|NCT00756470|Drug|Lapatinib|1000 mg taken by every day by mouth (PO) weeks 1 and 2; then starting day 15 for 12 weeks (weeks 3 to 14) daily 750 mg PO. Week 15, second combination treatment consisting of lapatinib (1,000 mg orally once daily) combined with FEC7.
46115438|NCT00756470|Drug|Paclitaxel|80 mg/m^2 intravenously over 1 hour weekly for 4 cycles administered on Day 1, Day 8, and Day 15 of each cycle then weekly starting day 15 for 12 weeks.
46115439|NCT00756470|Drug|5-Fluorouracil (5-FU)|500 mg/m^2 intravenously over 3-5 minutes every three weeks of Weeks 13-24.
46115440|NCT00756470|Drug|Epirubicin|75 mg/m^2 intravenously over 5-10 minutes every three weeks of Weeks 13-24.
46115441|NCT00756470|Drug|Cyclophosphamide|500 mg/m^2 intravenously over 45-60 minutes every three weeks of Weeks 13-24.
46115442|NCT00792623|Biological|VarilrixTM|Subcutaneous injection, 2 doses, in the deltoid region of the non-dominant upper arm.
46115443|NCT03862599|Device|Extra-corporeal shockwave therapy (ESWT)|low-intensity extra-corporeal shockwave therapy
45838901|NCT04351932|Biological|Adipose Mesenchymal stem cells|intrarticular adipose mesenchymal stem cells injection
45838902|NCT04351932|Biological|bone marrow & adipose mesenchymal stem cells injection|intrarticular bone marrow and adipose stem cells injection.
45838903|NCT04352088|Procedure|Nasal provocation test|Allergen extract under controlled conditions will be applied into nasal mucous.
46115444|NCT03862599|Other|Standard care|Cialis and vacuum pump
46026971|NCT02723695|Other|Evaluation of postural performances|Postural tests
46026972|NCT02723461|Drug|Pulsatile Oxytocin|Using a programmable syringe pump, oxytocin will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
46026973|NCT02723461|Drug|Continuous Oxytocin|Oxytocin will be administered at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
46026974|NCT02715037|Other|Throat swabbing|
46026975|NCT02723227|Behavioral|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
46026976|NCT02723227|Behavioral|Referral to Social Services|
46026977|NCT02716597|Drug|25% Albumin|
46026978|NCT02716597|Drug|Placebo|
46115445|NCT04096898|Device|Senofilcon A contact lens|Senofilcon lenses will be tested in moderate to severe dry eye patients to determine their efficacy in reducing discomfort associated with dry eye.
46026979|NCT04857619|Other|None (Observational study)|The data on different types of treatment received by the patients, socio-demographics, and clinico-pathological characteristics and healthcare resource utilisation will be extracted from patients' medical records (both alive and deceased).
46026980|NCT02715193|Biological|REMD-477|
46026981|NCT02715193|Biological|Placebo Comparator|
46026982|NCT04855435|Drug|MBS8(1V270)|The investigational medicinal product will be administered IV by infusion. Subjects will be treated in cycles.
46026983|NCT04851535|Drug|Jaktinib Hydrochloride Tablets|Jaktinib 100mg Bid
46026984|NCT01223027|Drug|Dovitinib|Dovitinib is formulated as an oral gelatin capsule of 100 mg strength and was dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule. Medication labels complied withthe legal requirements of each country and were printed in the local language.
46026985|NCT01223027|Drug|Sorafenib|Sorafenib is formulated as a round, oral, biconvex, red film-coated tablet that contains 200 mg of sorafenib (tosylate). Sorafenib was administered twice daily without food at least 1 hour before or 2 hours after a meal. Sorafenib was supplied according to local practice.
46026986|NCT02714959|Drug|Proleukin|
46115446|NCT04106921|Other|Universal Health Coverage Mode|"In the intervention arm, the CHW's household list will appear differently within the app in the following ways:~The CHW will be able to filter and order households by the date of the most recent home visit.~A color-coded visual icon will display the number of home visits in the past month for each household.~A red exclamation mark will be displayed for every household that has not reached 2 visits in the past month (default at the start of every month).~Text displayed below each household showing the date of last visit will turn red if more than 30 days have passed since last visit. When more than 60 days have passed since the most recent visit, the text displayed below each household showing the date of last visit will be changed to date of last visit is unknown in red.~The family profile will also contain the date of last visit, and the visits they have received in that month"
46115447|NCT05052567|Drug|CEND-1|The dose is specified according to the protocol. CEND-1+paclitaxel (albumin-bound type)+gemcitabine
46115448|NCT00756314|Behavioral|Personalized contraceptive counseling|The intervention comprised a personalized and comprehensive (face-to-face) contraceptive counseling regarding to individual contraceptive history and needs. The counseling intervention was conducted by three trained gynecologists according to standard one day training.
46115449|NCT04108793|Other|Physiotherapy exercises|The intervention group will receive an extended home-based rehabilitation program twice a week continued for 3 months (12 weeks) after discharge funded by the study.
46115450|NCT00727506|Drug|BIBW 2992|BIBW 2992 once daily
46115451|NCT00727506|Drug|TMZ|TMZ 21/28
46115452|NCT00727506|Drug|BIBW 2992 plus TMZ|BIBW 2992 once daily plus TMZ 21/28 days
46115453|NCT04108715|Procedure|Erector spina plain block for mastectomy analgesia|After giving general anesthesia, patient is positioned in lateral decubitus with the surgical side up, An erector Spina plain block is performed with inserting block needle (Pajunk, Geisingen, Germany) in-plane under ultrasound control until needle tip hits the transverse process, a volume of 0.3 ml/kg of bupivacaine 0.25% (Marcaine, Astra Zeneca Pharmaceuticals) is injected. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia (PCA) for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10) and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to post-anesthesia care unit PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
46026987|NCT04805671|Drug|ADG20|Single dose of ADG20
46026988|NCT04805671|Drug|Normal saline|Single dose of normal saline
46026989|NCT02714647|Behavioral|Attentional prime|
46026990|NCT02714647|Behavioral|Sham prime|
46026991|NCT02714725|Drug|Dexmedetomidine|During bypass, patients will receive dexmedetomidine infusion 0.5 mcg/kg/hr
46026992|NCT02714725|Drug|Placebo for Dexmedetomidine normal saline infusion|During bypass, patients will receive normal saline infusion
46026993|NCT02714725|Drug|Propofol infusion|During bypass, patients will receive propofol infusion 50 - 70 mcg/kg/min
46026994|NCT01015287|Drug|Placebo|Administered once orally
46026995|NCT01015287|Drug|Prasugrel|Administered orally
46026996|NCT02714803|Behavioral|"Connective tissue massage and Conservative applications"|Connective tissue massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
46026997|NCT02714803|Behavioral|"Classic massage group and Conservative applications"|Classic massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
46026998|NCT02714803|Behavioral|"Sham massage group and Conservative applications"|Sham massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
46026999|NCT04028713|Procedure|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab.
46027000|NCT04028713|Procedure|Dried blood spot|A subset of patients will sample additionally by using the dried blood sampling technique.
46027001|NCT04028713|Drug|Dose reduction|Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.
46027002|NCT04772365|Drug|SHR-1819|SHR-1819 will be subcutaneously administered with different dose levels;
46027003|NCT04772365|Drug|Placebo|Placebo will be subcutaneously administered with different dose levels;
46027004|NCT02714491|Other|Erigo + Music|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and musical stimulation."
46115454|NCT04108715|Procedure|Deep serratus anterior plane block|After giving general anesthesia, the patient is positioned in lateral decubitus, with the surgical side up. The upper arm is abducted and elevated above the head level. A block needle is introduced in-plane, targeting the plane deep to the serratus anterior muscle, and a bolus of 0.3 ml/kg bupivacaine 0.25% is injected through ultrasound guidance. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia PCA for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10), and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
46115455|NCT03862131|Device|MyoStrain®|MyoStrain® SENC software receives image data from MRI storage archives and performs viewing, image manipulation, communication, printing, and quantification of images.
46027005|NCT02714491|Other|Erigo + Metronome|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and metronome stimulation."
46115456|NCT03860883|Procedure|Wide Local Excision = 1cm Margin|"A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed."
46115457|NCT03860883|Procedure|Wide Local Excision = 2cm Margin|"A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed."
46115458|NCT00789815|Device|Bispectral index guide propofol infusion|"Induction:~Alfentanil: 5μg/kg slowly push. Propofol: 0.5-1.5mg/kg slowly push till BIS value 70.~Maintenance:~Propofol infusion (3~12 mg/kg/hour) to maintain BIS around 65~75. Alfentanil: 5μg/kg slowly push Q15min prn if severe cough."
46115459|NCT00789815|Drug|Clinical-judged midazolam administration|"Induction:~Alfentanil: 5μg/kg slowly push. Midazolam: 2 mg slowly push followed by increments of 2 mg/ 2min till OAA/S* 2~3.~Maintenance:~Midazolam: 2 mg/ 2min prn to keep OAA/S* 2~3 or if intolerance of procedure. Alfentanil as study arm.~*Observer's assessment of alertness/sedation (OAA/S):~Class 5: Responds readily to name spoken in normal tone.~Class 4: Lethargic response to name called in normal tone.~Class 3: Responds only to name called loudly.~Class 2: Responds only to shaking.~Class 1: No response to shaking."
46115460|NCT02592174|Other|Health related quality of life and social and demographic informations|At the inclusion visit with a self-assessment questionnaire
46115461|NCT02592174|Other|Neurocognitive assessment|At the neurocognitive visit, with standard test as CONSTANCES cohort
45681908|NCT05703022|Other|Aerobic interval training|The intervention will start between 7 and 21 days after heart valve surgery. While hospitalized the participants will perform supervised aerobic interval training comprised 4x4 minute, 3 times per week. Intensity will start at 60% of maximum heart rate in the first week, around 13-14 in Borg RPE-Scale. The workload will be gradually increased as the participant tolerance improves, but not above 85% of maximum heart rate or 16-17 in Borg RPE Scale.
46115462|NCT02592174|Radiation|cerebral images sub-study|Standard magnetic resonance imaging
46115463|NCT04019730|Other|diet|low carbohydrate diet (< 10 EN% carbs) vs high carbohydrate diet (>50 EN% carbs)
46115464|NCT05042583|Procedure|Stellate ganglion block|The probe direction was 30-45 degrees from the sagittal plane of the neck. The anterior nodules of the transverse process of the sixth cervical vertebra were displayed. The important anatomical structures were distinguished, and the internal carotid artery and longus cervical muscle were observed. A 25G, 6cm puncture needle was used with the tip beveled downward, and the needle path and tip were shown under ultrasound. The tip reached the high-echo sieve structure between the carotid artery and longus cervical muscle, and the drug solution was injected after withdrawal without blood and gas . The experimental group was injected with 6ml 0.5% ropivacaine.
45681909|NCT03159052|Drug|SHR3824|Once daily, 52 weeks
45681910|NCT03159052|Drug|Placebo|Once daily, 24 weeks
45681911|NCT03158584|Drug|Intrathecal Morphine|Intrathecal administration of Morphine in children undergoing major abdominal surgeries
45681912|NCT03265366|Device|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.
45681913|NCT03265366|Device|CT scan (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
45681914|NCT03158506|Drug|HMS5552|[14C]-labelled HMS5552
45681915|NCT03156712|Dietary Supplement|Ferrous sulfate|The intervention is the ASP, a natural form of iron supplement and compared to a widely used dietary iron supplement ferrous sulfate in terms of serum iron response over a 4h period.
45681916|NCT03158662|Other|Survey|Survey Study
45681917|NCT04765228|Drug|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2~4 cycles
45681918|NCT04765228|Drug|Anlotinib|Anlotinib
46027006|NCT02714491|Other|Erigo + Silence|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks), without auditory stimulation."
46027007|NCT02714179|Drug|Paracetamol was given intravenously in both group at different times|
46115465|NCT00721578|Drug|voriconazole|Patients must have received (in the Intensive Care Unit [ICU] at study entry) at least 1 day therapy with systemic antifungal agent for treatment of a proven or suspected fungal infection. The decision regarding choice of antifungal agent would lie with the treating physician and will necessarily precede and be independent of the decision to enroll a patient into the study.
46115466|NCT00789737|Drug|Welchol|Welchol 625mg tablets
46115467|NCT00789737|Drug|Placebo|placebo
46115468|NCT03854721|Drug|VAX014|Solution for intravesical infusion, 3.33x10^10 rBMCs per vial
45470561|NCT03912324|Procedure|CT myocardial thickness map guided PV isolation group|"Pulmonary vein isolation will be performed using a radiofrequency catheter~Esophageal temperature will be monitored to prevent esophageal injury.~Prepared myocardial thickness map with CT DICOM images conducted prior to procedure.~Increase radiofrequency ablation time by 2 to 5 seconds in thick areas in CT myocardial thickness map~Decrease radiofrequency ablation time by 2 to 5 seconds in thin areas in CT myocardial thickness map~Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~Evaluate time to complete isolation after additional ablation~Evaluation of Procedure time, Ablation time, and perfusion saline dose~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
46115469|NCT04075617|Device|electronic habit reminder|Habit reminder in the form of wrist watch with music that display as reminder is one of recent innovations for cessation of the habit in short time and the child accepts it and it's comfortable
46115470|NCT04075617|Other|palatal crib|Fixed palatal crib is commonly used and recommended for treating thumb/finger sucking habit.
46027008|NCT02714413|Dietary Supplement|D-allulose|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
46115471|NCT02592252|Behavioral|Participatory gender training|10 sessions of participatory gender training
46027009|NCT02714413|Dietary Supplement|sucrose|All subjects will receive a standardized oral sucrose load of 50 gms
46027010|NCT02714413|Other|Placebo|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
46027011|NCT01015131|Radiation|18F-FLT-PET/CT Imaging|Participants receive the investigational radiotracer 18F-FLT intravenously and undergo Positron Emission Tomography (PET)/Computed Tomography (CT) scans at the following three times: prior to initiation of chemotherapy, at the end of the first cycle of treatment, and at the conclusion of chemotherapy.
46115472|NCT02592252|Other|Microfinance|Microfinance loan
45681919|NCT04141540|Genetic|Molecular analyses|Comparaison of the molecular profil between two monozygotic twins carrying a deletion 22q11.2
45681920|NCT04141462|Genetic|blood sample|blood test
45681921|NCT04141384|Device|Modular Interactive Tiles System, MITS|The modular robotic brick system was developed by Danish scholar Prof. Henrik Hautop Lund in collaboration with the University of Siena in Italy to develop a new tool. The system uses the design principles of different levels of daily life activities, combined with the way of cognitive games, Lego toys can combine different game concepts, with a set of individual or multi-person activity programs with hands or feet, provide a set Modular floor tiles for stroke patients and the elderly.
45681922|NCT04140994|Device|rTMS device|Participants will participate in 1 session of neuronavigated (TMS Navigator, Localite, Schloss Birlinghoven, D-53757, Sankt Augustin, Germany ) iTBS (patterned form of TMS) coupled with motor learning.
46027012|NCT02714101|Other|Equine assisted occupational therapy|Intervention was one 40 to 60 minute session per week. Half of the session was spent riding a horse and half was spent doing horse related activities. Children had 9 to 12 sessions
46027013|NCT02714023|Procedure|Normal Saline|Intra-operative irrigation with normal saline
46027014|NCT02714023|Procedure|Sterile Water|Intra-operative irrigation with sterile water
46027015|NCT02713633|Other|internal Double-J stents|internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy
46115473|NCT04019574|Drug|CR845 0.5 mcg/kg IV|0.5 mcg/kg IV CR845
46115474|NCT04019574|Drug|CR845 3 mcg/kg IV|3 mcg/kg IV CR845
46115475|NCT04019574|Drug|Moxifloxacin 400 mg Oral Tablet|400 mg Oral Moxifloxacin
46115476|NCT04019574|Other|Placebo|IV Placebo as a bolus injection
46115477|NCT02593266|Behavioral|Preventive Intervention Program (PIP) for depression|"Manualized intervention designed by Beardslee and colleagues (Beardslee et al., 2003) It is a program based on cognitive behavioural therapy, narrative therapy and systemic therapy. It is divided in 7 modules which are imparted weekly in the family home by 2 'preventionists' (therapists trained to deliver the intervention)~Module 1: Depression and family~Module 2: Psychoeducation about depression~Module 3:The child's perspective on their parent's depression~Module 4: Skills development~Module 5: Preparation for the family session~Module 6: Family session~Module 7: Revision and future planning~Follow-up"
46115478|NCT04106687|Procedure|Ultrasound Guided Caudal Block|Postoperative pain procedure
46115479|NCT04106687|Procedure|Sacral Erector Spinae Block|Postoperative pain procedure
46115480|NCT05374122|Diagnostic Test|DSOC with AI biopsy guidance|Patients with a presumptive diagnosis of biliary malignancy will undergo DSOC + Artificial intelligence model (AIWorks) guidance for detection of neoplastic lesion during real-time procedure, tissue sampling acquisition, and histopathological analysis.
46115481|NCT05374122|Diagnostic Test|DSOC biopsy without AI guidance|"Patients with lesions suggestive of malignancy will undergo DSOC without AI guidance for sampling.~Based on the observer´s criteria regarding areas suggestive of malignancy, the collected tissue sample will be sent for histopathological studies."
46115482|NCT02581449|Dietary Supplement|omega-3|dietary supplement
46115483|NCT02581449|Other|empty soft gelatin capsules|empty softgels of matched size, shape and color
46115484|NCT04110977|Device|mobile application (reminder app)|This app will remind the patients four times a day to perform skin and mouth care. Instructions are given how to properly perform skin and mouth care. The patients may postpone each required care procedure for up to 2 hours. Finally, the patients are asked to state for each procedure whether or not they performed it. To increase the patients' motivation, they will earn points for each successfully performed care procedure.
46027016|NCT02713633|Other|External Stent|we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
46027017|NCT02723383|Drug|BACLOFEN|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
46115485|NCT04086498|Other|Mediterranean diet|The group received a plan for a isocaloric Mediterranean Diet
46115486|NCT04086498|Other|KEMEPHY|The group received a plan for a ketogenic mediterranean with herbal extracts diet
46115487|NCT04086498|Other|KD|The group received a plan for a low carbohydrate ketogenic diet
46115488|NCT00792467|Drug|ITF2357|ITF2357, supplied as hard gelatine capsules for oral administration at the strength of 50 mg each.
45681923|NCT05696626|Drug|Lasofoxifene in combination with abemaciclib|5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day
45681924|NCT05696626|Drug|Fulvestrant in combination with abemaciclib|Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day
45681925|NCT03158350|Other|Instructed Brushing Method|Stationary Bristle Technique
45681926|NCT03158428|Other|CSD170202AA|A moist snuff product
46115489|NCT00585468|Drug|Myfortic|Myfortic 720 mg orally twice daily
46115490|NCT03962946|Other|Questionnaires to assess Patient reported Outcomes|Adolfsson-Score questionnaire quantifies the patient's utility of the hand. Suhm Score questionnaire quantifies the independency of a patient in his daily life.
46115491|NCT03962946|Other|wrist function test|wrist function assessed by the range of motion (ROM) for both the affected and the unaffected side.
46115492|NCT02604641|Dietary Supplement|Placebo group|Subjects will take 5 mL of placebo syrup (0 mg CoQ10/day) once per day for 12 weeks.
46115493|NCT02604641|Dietary Supplement|Quvital LD group|Subjects will take 5 mL of LD syrup (50 mg CoQ10/day) once per day for 12 weeks.
46115494|NCT02604641|Dietary Supplement|Quvital HD group|Subjects will take 5 mL of LD syrup (150 mg CoQ10/day) once per day for 12 weeks.
46115495|NCT04087356|Genetic|Blood draw|Blood samples are collected for genetic analysis, looking specifically at serum lipids and the inflammatory biomarker hs-CRP.
46115496|NCT05600387|Drug|Empagliflozin 10 MG|subjects in Empagliflozin group take 10mg Empagliflozin per day
46115497|NCT04075305|Radiation|Radiation therapy|Radiation therapy on the CE marked and FDA approved MR-Linac
46115498|NCT04087044|Device|Computerized Rotational Head Impulse Test ( crHIT)-Vertical|"Oculo-Motility and Positional Testing,~Caloric Testing"
46115499|NCT05557409|Drug|AXS-05|AXS-05 tablets, taken twice daily
46115500|NCT05557409|Drug|Placebo|Placebo tablets, taken twice daily
45681927|NCT03158428|Other|CSD170202AB|A moist snuff product
45681928|NCT04140916|Device|Midline catheter|Peripherally inserted short intravenous catheter
46115501|NCT00724152|Behavioral|Cognitive Behavioral Therapy|A psychotherapeutic approach to tinnitus management which includes tinnitus education
46115502|NCT00724152|Behavioral|Tinnitus Education|An audiologic rehabilitative approach to tinnitus education.
46115503|NCT02591940|Procedure|Surgery or Treatment by Heart Catheter|
46027018|NCT02723383|Drug|PLACEBO|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
45470562|NCT03912324|Procedure|Empirical PV isolation group|"Pulmonary vein isolation will be performed using a radiofrequency catheter~Esophageal temperature will be monitored to prevent esophageal injury.~The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner.~Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~Evaluate time to complete isolation after additional ablation~Evaluation of Procedure time, Ablation time, and perfusion saline dose~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
45470563|NCT03750409|Device|Helmet|The portable device covers the head and weighs about 3.5 lb., and is made of light-weight, durable plastic, it is placed on the head with eye panels facing forward. Elastic straps holding the arrays together easily expand to conform to each subjects' head. Patients may notice slight warming of scalp after usage. This warming effect is similar to wearing a regular motorcycle helmet for a similar duration.
46027019|NCT02723149|Behavioral|Marijuana Approach Avoidance Training|Approach Avoidance Training (AAT) is a novel computerized procedure that modifies implicit approach tendencies by training individuals to selectively avoid drug- related stimuli, thereby overriding habitual approach tendencies. Participants are randomized to either the treatment or sham condition. Treatment duration involves 6 training sessions of approximately 15 minutes each (400 trials). AAT requires minimal training and involves only a computer and a joystick, in which participants are either pulling or pushing the joystick when different marijuana or non-marijuana images are displayed with either yellow (pull) or blue (push) border.
46027020|NCT02722915|Procedure|fMRI|collection of functional brain data for 1 hour per day
46027021|NCT02722915|Behavioral|Neurofeedback|Task of the participants is to increase or decrease the connectivity between selected brain regions in double-blind, randomized order. After the regulation they will get a feedback about the regulation success. (Patients and controls with AVH: days 3 & 4; controls without AVH: Days 2 & 3)
45470564|NCT01313052|Behavioral|Forensic Assertive Community Treatment (FACT)|Individuals in this arm will receive the services of an Assertive Community Treatment team and close supervision of a judge trained in the FACT model.
45838904|NCT04351542|Dietary Supplement|Ayurveda|Based on individual constitution (ayurveda based assessment) and symptoms an individual has, ayurveda herbal supplement and self managed practices were advised along with usual care recommendation.
45838905|NCT04351542|Other|Usual Care|Usual care recommended by National Health Services, self isolation, plenty fluid, rest and Paracetamol. During the Covid 19 outbreak, additional recommendation were followed given by health services.
46027022|NCT02722915|Other|PANAS|to assess the mood before and after the fMRI and after 1 week during a telephone interview
46115504|NCT00721110|Drug|Lidocaine|Upon general anesthesia induction, lidocaine (1.5 mg/kg) will be given. Lidocaine infusion of 2 mg/kg/hour, to a maximum of 200 mg/hour during The lidocaine infusion will be reduced to 1.3 mg/kg/hour, to a maximum of 133 mg/hour, at skin closure and discontinued 24 hours postoperatively.
46115505|NCT00721110|Drug|Placebo|Placebo boluses and infusions will be substituted
46115506|NCT00721110|Drug|Ketamine|Ketamine (0.25 mg/kg) will be given followed by an infusion of ketamine (0.25 mg/kg/hour) up to 25 mg/hour. The ketamine infusion will be reduced to 0.12 mg/kg/hour up to a maximum of 12 mg/hour at skin closure and discontinued 24 hours postoperatively.
46115507|NCT00721110|Drug|Ketamine + Lidocaine|both Ketamine and Lidocaine will be given
46115508|NCT02580279|Drug|EGCG|
46115509|NCT02580279|Drug|placebo|
45470565|NCT01313052|Behavioral|Enhanced Treatment as Usual|Individuals in this arm of the study will receive an expedited appointment at a clinic specializing in the treatment of psychotic disorders. These individuals will receive the services of a therapist, psychiatrist, and case manager.
45681929|NCT04140916|Device|PICC-line catheter|Peripherally inserted long intravenous catheter
45838906|NCT04351464|Other|physical therapy and reflexology|
45838907|NCT04351308|Drug|MAPI chemotherapy|"AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day * 2day (total/cycle 75 mg/m²)~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²) ; M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue; I = Ifosfamide 2400 mg/m2/day *5day (total/cycle 12000 mg/m²)"
46027023|NCT02722915|Other|AVHRS|to assess the intensity and quality of the hallucinations before and after the fMRI and after 1 week during a telephone interview
46027024|NCT02722915|Other|SF36|questionnaire about life quality after 1 week during a telephone interview
46027025|NCT05269537|Radiation|Transthoracic Echocardiography|Measurement of cardiac output in supine position with left lateral tilt at baseline, at 10 minutes after intrathecal injection, immediately after delivery, and at 1 hour after intrathecal injection
46115510|NCT05073237|Other|Placebo|Daily placebo tablet
46115511|NCT05073237|Drug|conjugated estrogens/bazedoxifene (CE/BZA)|Participants assigned to CE/BZA will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20mg.
45838908|NCT04351308|Drug|Apatinib Mesylate|anti-angiogenesis tyrosine kinase inhibitors 500 mg orally daily
45838909|NCT04351308|Drug|Camrelizumab|anti-PD-1 antibody 200mg ivgtt. Q2W
46027026|NCT05269537|Procedure|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 25-gauge spinal needle
46027027|NCT05269537|Drug|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
46027028|NCT05269537|Drug|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
46027029|NCT05269537|Drug|Crystalloid Coload 1000 mL|Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection
46115512|NCT02592096|Drug|0.1% Pazufloxacin Mesilate Ear Drops|
46115513|NCT02592096|Drug|0.3% Pazufloxacin Mesilate Ear Drops|
45838910|NCT04351152|Biological|Lenzilumab|Administered as an intravenous (IV) infusion
45838911|NCT04351152|Drug|Standard of Care|Standard of care therapy can include remdesivir and/or dexamethasone per institutional treatment guidelines or written policies
45838912|NCT04351074|Procedure|LIFT|ligation of the intersphincteric fistula track
45838913|NCT04351074|Procedure|fistulectomy|excision of the fistulous track with its internal and external orifices
45838914|NCT04350918|Device|Muscle Enery Techniques|Group of patients that underwent muscle energy technique as a mean of treatment for the complaint
46027030|NCT05269537|Procedure|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision and uterine exteriorization
46027031|NCT05269537|Drug|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
46115514|NCT02592096|Drug|0.5% Pazufloxacin Mesilate Ear Drops|
46115515|NCT02592096|Drug|Pazufloxacin mesilate injection|
46115516|NCT00791999|Drug|CDP870 400mg|400mg CDP870 given every 2 weeks until Week22 (SC)
46115517|NCT00791999|Drug|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week22 (SC)
46115518|NCT00791999|Drug|CDP870 100mg|200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks until Week22 subcutaneously(SC)
46115519|NCT00791999|Drug|Placebo of CDP870|given every 2 weeks until Week22 (SC)
46115520|NCT04085484|Dietary Supplement|More concentrated parenteral nutrition solution|This study is a single-center retrospective observational study comparing two cohorts of very low birth weight (VLBW, birth weight < 1500 grams) infants who received parenteral nutrition (PN) either before or after a concentrated PN regime was implemented into clinical use. Both PN regimes were based on standardized PN solutions.
46115521|NCT04033263|Other|Mouth rinse 1|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
46115522|NCT04033263|Other|Mouth rinse 2|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
46115523|NCT04033263|Other|Mouth rinse 3|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
46115524|NCT04033263|Other|Mouth rinse 4|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
45838915|NCT04350918|Device|Static Stretching|Set of patients that had static stretching technique for the treatment for the complaint
46115525|NCT04033263|Other|Mouth rinse 5|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
46115526|NCT04033263|Other|Mouth rinse 6|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
46115527|NCT04033263|Other|Mouth rinse 7|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
46115528|NCT04033263|Other|Mouth rinse 8|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
45838916|NCT04350996|Other|Wearable alcohol sensor|BACtrack Skyn, is a novel transdermal blood alcohol sensor developed by BACtrack, a company established for police-grade breathalyzers, and winner of the Wearable Alcohol Biosensor Challenge sponsored National Institute on Alcohol Abuse and Alcoholism.
46115529|NCT04033263|Other|Mouth rinse 9|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
45838917|NCT04350528|Drug|Chlorpromazine or Pentobarbital|Sedation
45838918|NCT04350684|Drug|Umifenovir|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Umifenovir in COVID-19 patients.
45838919|NCT04350684|Drug|Interferon-β 1a|This Drug will be used in all arms as we discovered its benefits in our previous randomized clinical trial.
45838920|NCT04350684|Drug|Lopinavir / Ritonavir|This Drug will be used in all arms as mandated by our governmental guidelines.
46115530|NCT04075227|Drug|0.2% loteprednol etabonate|Use topical 0.2% loteprednol etabonate eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
46115531|NCT04075227|Drug|0.1% dexamethasone|Use topical 0.1% dexamethasone eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
46115532|NCT03499821|Device|EDOF ICL|The Visian ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens. It offers an intraocular alternative for the correction of refractive error in those who currently utilize spectacle and/or contact lenses correction.
46115533|NCT00585078|Drug|Capecitabine|
46115534|NCT00585078|Drug|Oxaliplatin|
46115535|NCT00720876|Biological|rituximab|Rituximab will be administered at a dose of 375 mg/m2 on day 1 of every cycle, every 3 weeks.
46115536|NCT00720876|Drug|vorinostat|200 mg twice daily, orally for 14 days followed by a seven day break on a 21 day cycle.
46115537|NCT00723840|Other|Observational Studies: participants treated according to the real clinical practice.|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
46115538|NCT03956316|Device|Titan Modular Total Shoulder System|total shoulder arthroplasty using the Titan Modular Total Shoulder System
46115539|NCT00789581|Drug|Doxorubicin|Doxorubicin 60 mg/m2
45838921|NCT04350684|Drug|Single Dose of Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
46115540|NCT00789581|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2
46115541|NCT00789581|Drug|Ixabepilone (Ixempra)|Ixabepilone 40 mg/m2
46115542|NCT00789581|Drug|Paclitaxel (Taxol)|Paclitaxel 80 mg/m2
46115543|NCT04075071|Behavioral|Teacher-Child Interaction Training - Universal|Teacher-Child Interaction Training - Universal (TCIT-U) is an empirically-supported classroom-based intervention designed to strengthen teacher-child relationships, reduce and prevent child behavior problems, and promote social-emotional skills. TCIT-U is based in behavioral and attachment principles and was developed as a modification of Parent-Child Interaction Therapy (PCIT), an evidence-based treatment with well-established support for decreasing disruptive child behaviors and parental stress with children ages two to seven years old. In TCIT-U, teachers of children, preschool through second grade, are taught and coached in skills to manage challenging classroom behaviors and improve the quality of relationships. TCIT-U is delivered to teachers through group didactic training and live individualized coaching.
46115544|NCT00717756|Drug|lenalidomide|25 mg po qd x 21 days then 1 week off equals one cycle
46115545|NCT00915629|Dietary Supplement|Lactibiane candisis 5M|2 gelules per day for 2 months then 1 gelule per day for 4 months
46027032|NCT05269537|Drug|Oxytocin|Intravenous oxytocin 10 U in 500 mL Ringer acetate will be administered over 30 minutes starting immediately after delivery of the fetus
46115546|NCT04111289|Drug|-Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)|"After consenting for primary PCI ,the patient will be assigned to one arm ( either upstream high bolus dose IV before going to cath lab or selective downstream administration according to operator discretion )~Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)~Randomization will be performed by Microsoft Excel where random order will be generated for the study population"
46115547|NCT04108637|Procedure|penicillin allergy assessment pathway|"Summary of penicillin allergy assessment pathway :~Stage-1 PAAP in Primary Care - Clinical History. Screening, questionnaire and antimicrobial history will be undertaken in primary care Stage-2 Skin Test(ST) in hospital clinic (this may not be needed for all participants) Stage 3 Oral Challenge Test (OCT) in hospital clinic Testing will involve half a day in clinic and then a three-day post clinic course of oral antimicrobial therapy, without a reaction"
46115548|NCT05674539|Drug|Fludarabine and Busulfan|Fludarabine with total dose of 150 mg/m^2 in combination with Busulfan with total dose of 6.4 mg/kg
46115549|NCT05674539|Drug|Fludarabine and Melphalan|Fludarabine with total dose of 150 mg/m^2 in combination with Melphalan with total dose of 140 mg/m^2
46115550|NCT04108559|Procedure|Kinesiologic Tape Group|A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures.The kinesiologic tape will be prepared individually for each patient; it will be cut into three equal strips (approximately 1.6 cm in width) and placed between the clavicle and the tragus-commissura line. The patients will be invited after one week for removing the sutures.
46115551|NCT04108559|Procedure|Drain Group|A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures. A plastic non-customised drain tube (2-cm long, 2-mm diameter) will be inserted into a vertical incision between the first and second molars and sutured to the vestibular mucosa. The patients will be invited after one week for removing the sutures.
46115552|NCT04108559|Other|Control Group|Routine third molar extraction will be performed. No extra procedures will be done after surgery.
46115553|NCT00717522|Drug|Pomalidomide|
46115554|NCT04128189|Biological|Shingrix|Both arms receive standard 2 doses of Shingrix. Transplanted subjects may receive 3rd dose.
46115555|NCT05014659|Dietary Supplement|Creatine monohydrate|4 x 5g doses daily for 5 days, followed by 1 x 5g dose daily for 23 days.
46115556|NCT05014659|Dietary Supplement|Placebo|4 x 5g doses daily for 5 days, followed by 1 x 5g dose daily for 23 days.
45681930|NCT04140760|Other|Symprove|A liquid probiotic
45838922|NCT04350684|Drug|Standards of Care|This Drug will be used in all arms as mandated by our governmental guidelines.
45838923|NCT04350450|Drug|Hydroxychloroquine|400 mg tablet
46027033|NCT02722993|Dietary Supplement|Probiotics|
46027034|NCT02722993|Dietary Supplement|Placebo|
46027035|NCT01222715|Biological|Bevacizumab|Given IV
46027036|NCT01222715|Drug|Cyclophosphamide|Given IV
46027037|NCT01222715|Other|Laboratory Biomarker Analysis|Correlative studies
46027038|NCT01222715|Drug|Temsirolimus|Given IV
46027039|NCT01222715|Drug|Vinorelbine Tartrate|Given IV
46115557|NCT00791921|Drug|CDP870|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks until Week22 subcutaneously(SC)
46027040|NCT02723071|Drug|Ocrelizumab|Participants will receive a total of 8 intravenous (IV) infusions of ocrelizumab given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
46027041|NCT02722759|Other|hemoglobin measurement|
46027042|NCT02722681|Procedure|Blood and urine sampling|Collection of blood and urine samples taken during usual clinical management
46027043|NCT02722681|Procedure|Cerebrospinal fluid sampling|Collection of cerebrospinal fluid samples taken during usual clinical management
46027044|NCT02722447|Drug|rivaroxaban|Rivaroxaban 20 mg for 6 weeks
46027045|NCT02722447|Drug|Placebo|Placebo for 6 weeks
46027046|NCT01222403|Biological|Fluad_MF59-adjuvanted trivalent influenza subunit vaccine|
46027047|NCT01222403|Biological|Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine|
46115558|NCT00791921|Drug|Placebo of CDP870|Placebo given every 2 weeks until Week22 (SC)
45470566|NCT03750253|Other|Extracorporeal Shock Wave Therapy|Extracorporeal Shock Wave Therapy will be used for pain-relief after arthroscopy for osteochondral lesions of the talus
46115559|NCT05003115|Behavioral|Motivational interviewing|In this trial, motivational interviewing (MI) is the intervention. The MI sessions will embody the spirit of MI (PACE - Partnership, Acceptance, Compassion and Evocation) and the use of MI strategies (OARS - Open-ended questions, Affirmations, Reflections and Summaries) and MI communication processes (engagement, focusing, evoking and planning).
46115560|NCT04111055|Device|Closed-loop system|the CLV system will correct hypotension by automated adjustment of norepinephrine.
46115561|NCT02580123|Behavioral|Intervention taught by trained educators|
46115562|NCT04106843|Drug|Lutetium Lu 177 Dotatate|Given IV
46115563|NCT03657693|Diagnostic Test|NICU MRI|MRI device that is not FDA approved.
46027048|NCT02722369|Drug|Gemcitabine|Chemotherapy
46027049|NCT02722369|Drug|Carboplatin|Chemotherapy
46027050|NCT02722369|Drug|Etoposide|Chemotherapy
46027051|NCT02722369|Drug|Hydroxychloroquine|Maintenance Agent
46027052|NCT04657393|Procedure|mechanical ventilation|change of ventilation frequency
46115564|NCT03657693|Diagnostic Test|Polysomnography|Polysomnography to better determine obstruction index in the airway.
46115565|NCT04106453|Procedure|navigated microwave ablation|the laparoscopic microwave ablation in the pig liver is performed with the CasOne-Spot system
46115566|NCT04106453|Procedure|ultrasound guided navigation|the laparoscopic microwave ablation iin the pic liver is performed with ultrasound guidance
46115567|NCT03475953|Drug|Phase 1 : Regorafenib|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Patients will be allocated 3 dose levels of Regorafenib following a 3 + 3 design.
46115568|NCT03475953|Drug|Phase 1 : Avelumab|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Avelumab will be administered on cycle 1 Day 15 as a 1-hour intravenous (IV) infusion (10mg/kg), repeated every two weeks thereafter (ie. Day 1 and Day 15 of each subsequent cycle, as a 1-hour intravenous infusion).
46027053|NCT02722291|Device|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|
46027054|NCT02694211|Behavioral|ProMES|Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
46027055|NCT02694133|Procedure|Smart Phone Based Assistive Speech Therapeutic System|use the mobile device, which with the camera and speaker, for patients to practice the naming training at home, and assess the speech ability every 2-4weeks by speech therapist via telerehabilitation platform. Concise Chinese Aphasia Test (CCAT) will be used as the assessment tool for evaluation speech ability and functional ability.
46027056|NCT02694133|Procedure|Mobile phone-based tele rehabilitation program|Mobile phone-based tele rehabilitation program
46115569|NCT03475953|Drug|Phase 2 : Regorafenib|Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.
46115570|NCT03475953|Drug|Phase 2 : Avelumab|Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.
46115571|NCT03475953|Drug|Phase 2: low-dose Regorafenib|Phase 2 : Regorafenib - All patients will be treated at a fixed low-dose of regorafenib of 80 mg/day
45470567|NCT04901221|Device|Extrusion arch|one couple force system is applied; a custom-made extrusion wire from 0.016x0.022 stainless steel wire with helical bends placed 2-5 mm mesial to the molar tube placed in the upper and lower arches and tied distal to the lateral incisors
45470568|NCT03332628|Device|Microneedle patch|Each patch contains 50 microneedles.
45470569|NCT05459467|Other|Exercise|12 weeks high intensity exercise programme
45681931|NCT04140760|Other|Symprove placebo product|An inert placebo
45681932|NCT01818596|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
46027057|NCT01222247|Drug|Betamethasone|The active study drug, betamethasone. 3 mg per ml betamethasone sodium phosphate 3 mg per milliliter betamethasone acetate The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later.
46027058|NCT01222247|Drug|Placebo|Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.
46027059|NCT01014975|Biological|Plasmin (Human)|Plasmin (Human), 20 mg, delivered through a catheter into a thrombus
46027060|NCT01014975|Biological|Plasmin (Human)|Plasmin (Human), 40 mg, delivered through a catheter into a thrombus
46027061|NCT01014975|Biological|Plasmin (Human)|Plasmin (Human), 80 mg, delivered through a catheter into a thrombus
46027062|NCT02713555|Procedure|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass surgery entails the formation of a small gastric pouch and the division of the small intestine 60 cm from the duodenum. Formation of a gastrojejunal anastomosis with the distal segment and the formation of a jejuno-jejunal anastomosis 150 cm from the gastrojejunal anastomosis with the biliary segment.
46027063|NCT02713555|Procedure|Gastric Sleeve|Gastric Sleeve entails a vertical division of the stomach with a stapler.
46027064|NCT00628173|Procedure|AGV implantation|
46027065|NCT00611065|Device|magnetic resonance imaging|MR contrast agent (0.1 mmol/kg)
46027066|NCT04299477|Procedure|non-surgical periodontal treatment|supra- and subgingival scaling, and root planning
46027067|NCT03982537|Drug|N-Acetyl-L-Cysteine dietary supplement|Treatment will be administered on an outpatient basis, either twice daily or 48 hours prior to starting chemotherapy radiation. Eligible participants will start NAC at least 9 days before definitive or adjuvant radiation therapy.
46027068|NCT03982537|Radiation|Chemotherapy and Radiation|Participants will receive definitive or adjuvant concurrent chemotherapy and radiotherapy s per standard of care.
46027069|NCT05260593|Device|Vitamin B12 phonophoresis|Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of vitamin B12 gel will be applied over the wrist. The following parameters will be used: intensity of 1.0 W/cm2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the vitamin B12 gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
46027070|NCT05260593|Device|Placebo Vitamin B12 phonophoresis|Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of Vitamin B12 will be applied over the wrist. The ultrasound probe will be held over the wrist using topical gel containing Vitamin B12 which was the same as in group A. Ultrasound device will seem to be working for 5 min period with light-off position. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
46027071|NCT05260593|Device|Wrist splint|Patients were instructed to wear a neutral volar splint at night and while performing strenuous activities during the day for 5 weeks. Patients were given forms in order to check if they won't be compliant to the splint application and will be asked to bring the forms at the post treatment evaluation. Patients who won't check the form more than once a week will be regarded as non-compliant to splinting.
46027072|NCT05260593|Other|tendon and nerve gliding exercises|During tendon-gliding exercises, the fingers will be placed in five discrete positions (straight, hook, fist, tabletop, and straight fist). During the median nerve-gliding exercise, six different hand and wrist positions will be used to mobilize the median nerve. During these exercises, the patient must maintain the neck and the shoulder in neutral position with a supinated forearm and elbow flexed 90 degrees. Each position must be maintained for 5 seconds. Each exercise will be repeated 10 times at each session and patients will be encouraged to apply exercise 3-5 times per day for 5 weeks.
46027073|NCT02713477|Drug|Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010|"Pharmaceutical form: solution~Route of administration: subcutaneous"
46027074|NCT02713477|Drug|Insulin glargine HOE901|"Pharmaceutical form: solution~Route of administration: subcutaneous"
46027075|NCT02713477|Drug|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
46027076|NCT00611299|Dietary Supplement|BB-12 and CRL 431|
46027077|NCT01221623|Biological|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
46027078|NCT01221623|Biological|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
46027079|NCT02722213|Behavioral|Mindfulness-Based Stress Reduction (MBSR).|MBSR is a combination of mindfulness meditation, breathing practices, gentle yoga, and other relaxation techniques; it is taught in a manualized 8-week program, does not require special equipment, and can be practiced safely by people of all abilities
46027080|NCT02693587|Drug|Misodel and Angusta|
46027081|NCT01014585|Drug|Placebo|Placebo tablets administered orally twice daily
46027082|NCT01014585|Drug|Milnacipran|Milnacipran tablets administered orally twice daily
46027083|NCT02722135|Drug|Volasertib|
46115572|NCT04106375|Behavioral|Online mindfulness based cognitive therapy intervention|MBCT is based on Mindfulness-Based Stress Reduction (MBSR), combining principles of cognitive therapy (CT) with those of mindfulness meditation to prevent depression relapse. Both MBSR and MBCT use contemplative practices, including sitting meditation, body scan and walking meditation, as core methods to teach awareness of negative thoughts and emotions with the aim of disengaging from pervasive patterns of ruminative self-centered mentation. Participants will be given an initial orientation session and then complete an online 8-week MBCT program. Each week participants will take part in one 2-hour online group session and will complete homework assignments anticipated to take 15-30 minutes per day to complete. Additionally, weekly phone coaching will be offered based on the modified tele-coach manual developed by Mohr and colleagues (Duffecy et al. 2010).
46115573|NCT04108325|Drug|YY-20394|Each treatment cycle is comprised of 28-day consecutive of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if there are benefit from the treatment and the toxicity is tolerable.
45838924|NCT04350216|Drug|Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|"The treatment of sarilumab 200mg will be administered every two weeks subcutaneously.~Each patient will be followed for 6 months from the start of treatment. The last administration of Sarilumab will be 2 weeks before the end of the study."
46027084|NCT00611143|Drug|atorvastatin|atorvastatin 20 mg/d, started 3 days before surgery
45681933|NCT03156400|Other|Exercise Stress Test|Gradual increase in treadmill grade while collecting respiratory gases.
45838925|NCT04349592|Drug|Hydroxychloroquine|Hydroxychloroquine 200 mg tablet oral, one tablet three times a day for 7 days
46027085|NCT01221233|Other|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) to the low back muscles (i.e. spinal extensors) will be applied at the parameters previously used in the knee muscles at the maximal tolerable intensity, which results in a full, sustained isometric contraction of the back muscles. Pad placement will be just below the waist line, with 2, 2X2 inch pads, on either side of the spine. Participants will be positioned on their belly with 2 pillows under their stomach to level the spine and secured to a table using a belt that crosses the buttock.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees)."
46115574|NCT00582933|Drug|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25 mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (thymoglobulin®) prior to transplant to promote engraftment.All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
46115575|NCT00582933|Drug|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
46115576|NCT00582933|Drug|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
46115577|NCT00791765|Biological|Etanercept|Etanercept for subcutaneous injection.
46115578|NCT00791765|Biological|Placebo|Placebo for subcutaneous injection.
46115579|NCT03648021|Drug|Paracetamol|">50kg: Paracetamol 1 gramme in a solution of 10mg/mL administred intravenously. 1 dose~>50kg: Paracetamol 15mg/kg/dose in a solution 10mg/mL administred intravenously. 1 dose"
46115580|NCT03648021|Drug|Placebo|100mL of chlorure de sodium 0.9% administred intravenously. 1 dose
46115581|NCT03646227|Other|Standard of Care|There is no prescribed intervention for this study. Standard of care will be captured in the eCRF.
46115582|NCT00789191|Drug|insulin detemir|The detemir insulin dose is injected subcutaneously (under the skin) once daily in the evening and will be titrated (individually adjusted) weekly throughout the trial.
46115583|NCT00789191|Drug|sitagliptin|The sitagliptin dose is 100 mg/ day and should be kept stable throughout the trial. Frequency of sitagliptin is once daily.
46115584|NCT00789191|Drug|metformin|Metformin treatment with at least 1000 mg/ day. Dose and dosing frequency should remain unchanged throughout the trial.
46115585|NCT00789191|Drug|sulphonylurea|Sulphonylurea (SU) dose and dosing frequency should initially remain unchanged. In case of hypoglycaemia SU dose may be reduced at the discretion of the investigator.
46115586|NCT04968405|Device|Catalyst CSR Total Shoulder System|The Catalyst CSR Shoulder System is a bone preserving total shoulder prosthesis designed for use in patients where the humeral head, neck and glenoid vault are of sufficient bone stock and there is an intact or reconstructable rotator cuff. The design requires minimal bone resection, thus giving the patient an alternative to other total shoulder designs where more bone is removed.
46115587|NCT04967235|Other|Conventional Exercise-based Cardiac Rehabilitation Session|"This session will be composed of:~I.10 minutes of initial rest in the supine position; II. 15 minutes of warm-up through stretching and global exercises; III. 30 minutes of treadmill aerobic exercise at an intensity of 60-80% of the heart rate reserve for those without diabetes Mellitus and 40-70% of the heart rate reserve for those diagnosed with diabetes mellitus; IV. 1 minute passive recovery in orthostatic position; V. 30 minutes of passive recovery in the supine position."
45838926|NCT04349592|Drug|Azithromycin|Azithromycin 250 mg capsules oral, 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
46027086|NCT01221233|Other|Moist Heat|"For participants who do not receive NMES, moist heat will be applied for 15 minutes in a position of comfort for the participant.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees)."
46027087|NCT04300569|Other|Non-interventional|No intervention will be administered.
45838927|NCT04349592|Other|Placebo Tablet|Oral, one tablet three times a day for 7 days
46027088|NCT04488393|Device|MaterniT21 PLUS and GENOME Laboratory-Developed Tests|Both the MaterniT21 PLUS and GENOME are intended for use as laboratory developed test that analyze ccfDNA extracted from a maternal blood sample utilizing Massively Parallel Sequencing (MPS) technology.
46027089|NCT02713165|Other|Raisins|Participants will consume 84g of raisins per day for 14 days.
46027090|NCT02712619|Drug|Metformin|
46027091|NCT00611221|Procedure|Massage|Massage therapy by an RMT during labour
45681934|NCT04140448|Drug|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|Intravitreal injection of Ranibizumab 0.5 MG/0.05 ML
45681935|NCT04140448|Device|Ultra-wide Fluorescein Angiography|Ultra-wide-field Fluorescein Angiography can clearly observe the peripheral retina
46027092|NCT00611221|Procedure|Massage|Massage by anyone else, eg. husband, nurse, doula
46027093|NCT01220609|Drug|Ixabepilone|Given IV
46027094|NCT01220609|Other|Laboratory Biomarker Analysis|Correlative studies
46027095|NCT02713087|Drug|Ephedrine|Infusion of Ephedrine 2mg/ml until MAP above 60 mmHg or until MAP has raised 20%
46027096|NCT02713087|Drug|Phenylephrine|Infusion of Phenylephrine 0,1mg/ml until MAP above 60 mmHg or until MAP has raised 20%
46027097|NCT02722603|Drug|gabapentin|75 mg/ml gabapentin syrup
46027098|NCT02722603|Drug|tramadol|100 mg/ml tramadol oral drops
46027099|NCT02722603|Other|placebo tramadol|placebo tramadol oral drops
46027100|NCT02722603|Other|placebo gabapentin|placebo gabapentin syrup
46027101|NCT03975517|Behavioral|PrEP|Define the behavioral characteristics of the active file of patients using PrEP in Strasbourg in 2019.
46027102|NCT02712853|Other|Saliva collection|Collection of saliva via swab for miRNA processing
46027103|NCT02712853|Other|Vineland Adaptive Behavior Scale-II Assessment|
46027104|NCT02712697|Drug|WM (Shentong Granules)|Shentong Granules with Prednisone
46027105|NCT02712697|Drug|Hormone (prednisone)|Oral prednisone
46027106|NCT02708563|Procedure|Immediate intubation|Infants that are not vigorous at delivery will receive immediate tracheal suctioning
46027107|NCT02708563|Procedure|Immediate resuscitation|Infants that are not vigorous at delivery will receive immediate initial steps of resuscitation and PPV if needed
46027108|NCT02708797|Other|Magnetic resonance imaging|Patients and controls will first be studied with MRI. The total duration of MRI is about 60mn. These technic is not invasive.
46027109|NCT02708797|Other|Transcranial Doppler|Patients and controls will first be studied with TCD. The total duration of TCD is about 60mn. These technic is not invasive.
46027110|NCT02708719|Procedure|Pulmonary rehabilitation|Inpatient pulmonary rehabilitation has a duration of 3 weeks. This multimodal program consists of exercise training, breathing therapy, medical council, education and psychological support.
46027111|NCT01220297|Drug|Sirolimus|"Immunosuppressant administered orally to:~Adults (age 14 and older), beginning on Day -3 with 12 mg loading dose, followed by 4 mg/day.~Children < 13 years or weighing 40 kg, beginning on Day -3 with 3 mg/m² loading dose, followed by 1 mg/ m², rounded to the nearest full milligram.~Daily dosage may be adjusted to maintain a target serum trough level of 3 to 12 ng/ml. Sirolimus dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months."
46027112|NCT01220297|Drug|Mycophenolate mofetil (MMF)|Immunosuppressant given intravenously (IV) at 15 mg/kg 3 times daily, starting on Day 0 ≥ 2 hr after the completion of the HSCT infusion. Dose of MMF will be based on actual body weight, but limited to 15 kg above ideal body weight. MMF dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months.
46027113|NCT01220297|Drug|Carmustine|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -6 at the lesser of 15 mg/kg or 550 mg/m².
46027114|NCT01220297|Drug|Etoposide|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -4 at 60 mg/kg
46115588|NCT04967235|Other|Dance-based Cardiac Rehabilitation Session|I.10 minutes of initial rest in the supine position; II. 15 minutes of warm-up through stretching and global exercises; III. 30 minutes of dance therapy. The intensity of the choreography will be set at the same range as the conventional exercise-based session. (60-80% of the heart rate reserve for those without diabetes Mellitus and 40-70% of the heart rate reserve for those diagnosed with diabetes mellitus); IV. 1 minute passive recovery in orthostatic position; V. 30 minutes of passive recovery in the supine position.
45681936|NCT03158194|Behavioral|CBT for anxiety-related asthma|The specific assignments in the intervention will be based on individual behavior analysis for each participant.
46027115|NCT01220297|Drug|Cyclophosphamide (Cyclo, CY)|"Cyclophosphamide is a chemotherapy agent.~For FTBI + Cyclophosphamide cohort, administered IV on Day -3 and -2 at 60 mg/kg.~For Carmustine + Etoposide + Cyclophosphamide cohort, administered IV on Day -2 at 100 mg/kg"
46027116|NCT01220297|Drug|FTBI|For FTBI + Cyclophosphamide cohort, administered as 1320 cGy delivered in 11 120 cGy fractions over 4 days starting on Day -7.
46027117|NCT02721901|Behavioral|iEAT Manual Intervention|The iEAT manual guides caretakers in increasing the volume of food consumed by the child. The manual involves a touch screen application that collects and stores data on key behaviors and provides the feeder with direction for structuring treatment meals. Sessions will be 45 minutes long and occur biweekly for 10 sessions over 5 months. Two meals each day will be completed at home as part of the treatment of the feeding problems.
46027118|NCT02721901|Behavioral|Control group|The psychoeducation condition will involve 6 appointments (once monthly for 5 months and 1 session during the post-treatment assessment). Each appointment will include curriculum related to feeding concerns such as the etiology of feeding problems, meal structure, appropriate food selection, mealtime problem behaviors, and generalization of appropriate feeding behaviors. Each session will last approximately 45 minutes.
46027119|NCT02888015|Other|upper extremity exercise program|five exercises to improve upper extremity strength and endurance will be provided to patients, shoulder flexion, abduction/adduction, elbow flexion/extension, internal/external rotation
46027120|NCT02712775|Drug|Minocycline (yes/no)|
46115589|NCT02603315|Other|marker CD74 and vascular endothelial growth factor VEGF|correlate the result of vascularity test done on paraffin blocks on both types of malignant pleural mesothelioma patients diagnosed and receive treatment and evaluated after treatment
45681937|NCT03156634|Other|PALS|PALS is a web based patient education system that uses text and audiovisual formats to deliver patient education materials.
45681938|NCT03156634|Other|WebMD|WebMD is an internet based health information source.
46027121|NCT02712775|Drug|Placebo|Saline
45681939|NCT04415216|Device|percutaneous coronary intervention|Percutaneous coronary intervention with drug eluting balloon (DEB) vs. thin struts drug eluting stents (thin-DES) for treating in-stent restenosis (ISR)
45754458|NCT05245435|Diagnostic Test|liquid biopsies|circulating tumor cell count and circulating tumor DNA abundance in blood of prostate cancer patients
46027122|NCT01219985|Other|standard and respiratory-gated PET acquisitions|"After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations."
45470570|NCT03754075|Procedure|Complete mesocolic excision|The resection was based on the principles of CME. The superior mesenteric vein was exposed to perform central vessel ligation and lymph nodes dissection. Extended right hemicolectomies for tumors located from the ascending colon close to the hepatic flexure and distally were performed openly as standard during the study period. These resections included the prepyloric and gastroepiploic lymph nodes dissection.
46027123|NCT04318847|Drug|Ondansetron 4 MG|Administration of ondansetron 4 mg or 8 mg according to weight
46027124|NCT02721823|Behavioral|lifestyle-modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of colitis patients.
46027125|NCT02721823|Behavioral|Control group|Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
46027126|NCT02691221|Behavioral|Relief Link Application Daily Tasks|Participants will complete daily mood tracking and completion of a minimum of one stress management activity per day. Relaxation exercises to choose from on the current version of RL are audio files (i.e., no visuals), and consist of: Guided Meditation, Energizing Breath, Guided Visualization for Relaxation, Progressive Relaxation, Mindfulness Meditation Body Scan, and Mindfulness of Breathing.
46027127|NCT02721745|Behavioral|Natural Fatigue|Experimental: EEG Indirect Calorimetry Pupillometry
46027128|NCT02721745|Device|tDCS|Experimental: EEG Indirect Calorimetry Pupillometry
46027129|NCT02721745|Device|TMS|Experimental: EEG Indirect Calorimetry Pupillometry
46027130|NCT02721511|Drug|Furosemide Injection Solution 8mg/mL|Furosemide Injection Solution, 8 mg/mL, (total dose =80 mg) administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours by means of the B. Braun Perfusor® Space Infusion Pump System.
46027131|NCT02708329|Procedure|T-provisional stenting|Standard endovascular T-provisional stenting technique
46027132|NCT02708329|Procedure|Mini-crush stenting|Standard endovascular Mini-crush stenting technique
46027133|NCT02708329|Procedure|CTO coronary angioplasty|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
46027134|NCT02708407|Procedure|Peritoneal Dialysis|One week after insertion of a PD catheter the intervention group will received a single nightly exchange, using dialysis fluid containing icodextrin; a variable proportion of participants may require a second exchange as directed by the consultant nephrologist as part of routine care. The second exchange would use dialysis fluid containing glucose, not icodextrin. Support and training will be given to each participant by the PD specialist team.
46027135|NCT02712307|Drug|Phenoxymethylpenicillin|
46027136|NCT02708251|Drug|glyceryl trinitrate cream|
46027137|NCT02708251|Drug|lidocaine cream|
46027138|NCT02708251|Drug|placebo cream|
46027139|NCT02708173|Biological|One dose of Quadrivalent Influenza Virus Vaccine|
46027140|NCT02708173|Biological|One dose of Quadrivalent Influenza Virus Vaccine|
46027141|NCT00611611|Biological|fluzone|once
46027142|NCT00611611|Biological|pneumovax|once
46115590|NCT03923595|Other|Adherence intervention research|dedicated management
46115591|NCT00789035|Drug|BI 10773|
46115592|NCT00789035|Drug|placebo|
46115593|NCT00789035|Drug|metformin|
46115594|NCT02579577|Other|Observation|Observation of clinic appointments and ward rounds if the child is admitted to hospital during the study period.
46115595|NCT02579577|Other|Interviews|Semi-structured interviews will be conducted approximately 3 times during the study period with each participant.
46115596|NCT02579577|Other|Medical notes review|The child's electronic medical record will be accessed periodically to identify any planned appointments or periods of hospitalisation and their medical notes will also be reviewed at the end of the study.
45470571|NCT03754075|Procedure|Conventional colon resections|The patients underwent what was considered standard colon cancer resections in Denmark during the study period.
45754459|NCT05582408|Device|Measures of Standard Noise Reduction NR1|Each participant will be fitted with the Standard Noise Reduction (NR1)
45754460|NCT05582408|Device|Measures of Noise Reduction Principle NR2|Each participant will be fitted with the novel Noise Reduction principle NR2 on the same hearing aid
46115597|NCT05016843|Behavioral|Treatment condition: Internet-administered Unified protocol|"Treatment condition:~The cognitive, behavioral treatment Unified protocol is a transdiagnostic treatment for anxiety and depression. Participants are taught five techniques in order to find new and more helpful ways to react to hindering thoughts and feelings: mindfulness, cognitive flexibility, identify and reduce behavioral avoidance, increase willingness to experience physiological sensations and exposure. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week."
46115598|NCT05016843|Behavioral|Treatment condition: Internet-administered Affect phobia treatment|The aim of psychodynamic Affect phobia treatment is for the patient to reach an intellectual and emotional understanding of his/hers problems. The goal of the treatment is for participants to decrease emotional avoidance and start to approach emotions and increase emotional awareness. Participants are taught this through linking their symptoms to their emotional avoidance, observe frequent and maladaptive patterns in relationships and see how these are linked to emotional avoidance. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week.
46027143|NCT04188925|Device|Laser Acupuncture|"The LA is using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.03cm2; power density, 5W/cm2; pulsed wave; RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany). The LA treatment will be applied to EX-LE5, ST35, and BL40 for 80 seconds, under power 150mW, to deliver a total treatment dose of 6 Joule/ cm2.~The EA is the combination of acupuncture and transcutaneous electrical nerve stimulator. The transcutaneous electrical nerve stimulator is produced by Ching Ming Medical Device Company. This machine is verified by Department of Health in Taiwan, with the ID number 001147. We perform acupuncture on GB33, GB34, SP9, SP10, and ST36."
46115599|NCT05016843|Other|Treatment condition: Waitlist control|The waitlist condition is a control condition without any intervention.
46027144|NCT04188925|Device|Sham Laser Acupuncture|Sham LA is using the same appearance of LaserPen without energy output to perform the same acupoint as above description. Both of the LaserPen in two groups are labeled with A and B, one of them is revised by the company to become the sham LA. The outward of both LaserPen are the same and our physician does not know which one is the real.
46027145|NCT03906643|Drug|HS-201|HS-201 will be administered intravenously as a single dose
46027146|NCT01218659|Drug|migalastat hydrochloride|150-mg capsule administered orally QOD
46027147|NCT01218659|Biological|agalsidase|Agalsidase via intravenous infusion as prescribed by the participant's treating physician and in accordance with the approved prescribing information
46027148|NCT02712229|Behavioral|CONNECT|"Primary palliative care, care management intervention led by existing oncology nurses. Deployed through a series of nurse-led encounters before or after regularly scheduled oncology visits. Based on best practices in palliative oncology care, the first visit focuses on establishing rapport, addressing symptom needs and choosing a surrogate decision maker. Subsequent visits include additional focus on treatment preferences and future goals.~Visits are guided by patient-reported outcomes. During all encounters, the nurse works with patients/caregivers to complete/update individualized Shared Care Plans. After all visits, the nurse discusses patients' symptoms, preferences and goals with their oncologists via a mandatory check-in session and a follow-up call with the patient and/or caregiver."
46027149|NCT05172037|Biological|Novaferon|a novel recombinant antiviral protein drug
46027150|NCT05172037|Biological|Placebo|Saline
46027151|NCT02708017|Procedure|Ultrasound guided bilateral subcostal TAP block|ultrasound guided bilateral subcostal TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray,with the help of portable ultrasound machine using probe frequency of 11 Mega Hertz,ultrasound probe was positioned parallel to the costal margin near the midline,the rectus abdominis muscle was identified ,probe was gradually moved laterally and obliquely along the subcostal margin and the transversus abdominis muscle identified lying posterior to the rectus muscle.the 20Gauge,100millimeter long needle was introduced at the lateral edge of the rectus muscle ,from medial to lateral,in plane of the ultrasound beam.After confirmation of the plane with saline, 20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
46027152|NCT02708017|Procedure|Ultrasound guided bilateral posterior TAP block|ultrasound guided bilateral posterior TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray.with the help of portable ultrasound machine using probe frequency of 11Mega Hertz,ultrasound probe was positioned transversely to the abdominal wall in the midaxillary line between the iliac crest and coastal margin,and carefully moved posteriolaterally for optimal identification of plane.the 20G,100mm long needle was introduced anteriorly and in line with the probe,from medial to lateral,and advanced until it reached the fascial plane between the internal oblique and transversus abdominis muscle.upon reaching the plane ,20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
46115600|NCT05016843|Other|Treatment length: 8 weeks|Participants will partake in their treatment condition for 8 weeks.
46115601|NCT05016843|Other|Treatment length: 16 weeks|Participants will partake in their treatment condition for 16 weeks.
46115602|NCT05016843|Other|Access to a moderated forum|During their treatment, participants will have access to a discussion forum moderated by a clinician. Participants are encouraged to discuss questions and experiences related to their treatment condition.
45681940|NCT04405882|Procedure|topographic guided trans epithelial excimer laser|In this retrospective study 8 eyes affected by cornea ectasia of 8 patients (mean age 31.50±14.73 years) underwent simultaneous CCR and CXL. Preoperative and 6 month postoperative uncorrected distance visual acuity (UDVC) and distance corrected visual acuity (DCVA) were measured using the Efficacy and Safety index. Objective and subjective quality of vision were respectively evaluated through preoperative and 6 month postoperative corneal morphological irregularity index (CMI), National Eye Institute Visual Function NEI-VFQ25 and NEI-VFQ39 questionnaires.
45681941|NCT03157570|Behavioral|Exercise|7-min High Intensity Interval Training with 12 different exercises (each exercise 30 seconds continuously with 10 seconds rest interval)
46027153|NCT00612625|Drug|glucagon-like peptide-1|continuous infusion of GLP-1 (1½ pmol/kg/min)
46027154|NCT00612625|Drug|Saline|continuous infusion of saline
46027155|NCT02712073|Other|Questionnaire|Self administered questionnaire to evaluate the preparation quality of colonoscopy
46027156|NCT00612001|Biological|glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine|
46027157|NCT02711761|Device|central venous catheterization|"15 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 15 cm.~17.5 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 17.5 cm.~20 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 20 cm."
46027158|NCT02711917|Drug|MAC 0.5|0.5 MAC Sevoflurane
46027159|NCT02711917|Drug|MAC 0.75|0.75 MAC Sevoflurane
46027160|NCT02711917|Drug|MAC 1.0|1.0 MAC Sevoflurane
46027161|NCT02711917|Drug|Propofol|Propofol consumption
46027162|NCT02711917|Drug|Etomidate|Etomidate consumption
46027163|NCT02711917|Drug|Rocuronium|Consumption of Rocuronium
46027164|NCT02707783|Device|Bioresorbable vascular scaffold (BVS) implantation|
46027165|NCT02711449|Drug|Methylprednisolone|125 mg methylprednisolone as an intravenously bolus injection approximately 30 minutes prior to skin incision.
46027166|NCT02711449|Drug|0.9% Saline|0,9% Saline as an intravenously bolus injection approximately 30 minutes prior to skin incision.
46027167|NCT04419103|Other|no intervention|Natural exposure of iodine.
46027168|NCT02707705|Device|Apply an auricular acupuncture protocol by stimulating specific points of the ear with needles inserted on adhesive tape (Pyonex®).|"Intervention Description :~The auricular acupuncture protocol is based on an anxiolytic triad of three points selected according to the World Health Organization classification. These points are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear. The detected points are treated by application of adhesive tape with needles of diameter 0.2 mm and length 0.9 mm.~Data collected :~T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency~T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects~T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects~T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
46027169|NCT02707705|Device|Apply a device having no real effect|"The three points of the protocol are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear.The detected points are treated by application of adhesive tape without needle.~Data collected :~T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency~T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects~T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects~T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
46027170|NCT02707705|Procedure|Disinfection|The ear is disinfected by applying Chlorhexidine®.
46027171|NCT00612079|Drug|Sertindole|oral 3 x 4mg
46027172|NCT00612079|Drug|Placebo|3 x 4mg Placebo
46027173|NCT00940498|Drug|PF-05212384 (also known as PKI-587)|Intravenous dosing once weekly infusion
46027174|NCT05125783|Other|questionnaire|Completion of the questionnaire by the patient after consultation with the practitioner.
46027175|NCT03820531|Diagnostic Test|Next Generation Sequencing|DNA Mutational Analysis in pancreas cyst fluid concerning KRAS/GNAS-mutations and mutations in tumor supressor genes
46027176|NCT03820531|Diagnostic Test|CEA and lipase|"Measuring CEA and lipase level in pancreas cyst fluid:~CEA > 192 ng/ml and lipase > 200 U/l = mucinous cyst"
46027177|NCT03820531|Diagnostic Test|Cytology|"Cytology in pancreas cyst fluid:~mucinous versus non-mucinous cyst; LGD versus HGD/Carcinoma"
46027178|NCT03820531|Diagnostic Test|Histology of resected pancreas cyst|Histology of resected pancreas cyst concerning mucinous versus non-mucinous cyst, IPMN versus non-IPMN and LGD versus HGD/Carcinoma
46027179|NCT02711527|Other|Acupunture group A|"Subjects in Group A will receive 14 needles based on the TCM theory Soothing liver-qi stagnation, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), Ligou蠡沟 (LR 5), Zhongdu 中都(LR6), Xiguan膝關 (LR 7), Ququan曲泉 (LR 8), Zhangmen章門(LR13), Qimen期門 (LR14)."
46027180|NCT02711527|Other|Acupunture group B|"Subjects in Group B will receive 14 needles based on the TCM theory Soothing liver-qi stagnation and Tonifying the heart and the spleenand Invigorating the Yang Qi, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), , Sanyinjiao 三陰交 (SP 6), Xuanzhong懸鐘 (GB 39), Shenmen 神門 (HT 7), Zusanli 足三里(ST 36), Baihui 百會(DU 20), Shenting神庭(DU24), Qihai 氣海(RN6), Guanyuan 關元(RN4). Teding Diancibo Pu (abbreviation: TDP) 特定電磁波譜 will be applied to Group B immediately after the needle insertion."
46027181|NCT05115721|Other|no intervention|It's only observational study. No interventions.
46027182|NCT02850718|Drug|Sublingual Sildenafil|50 mg sildenafil sublingual wafer.
46027183|NCT02850718|Drug|Oral Sildenafil|50 mg oral sildenafil (Viagra)
46027184|NCT02707393|Drug|Fludarabine|infusion
46027185|NCT02707393|Drug|Thiotepa|infusion
46027186|NCT02707393|Drug|Melphalan|infusion
46027187|NCT02707393|Drug|ATG|infusion
46027188|NCT02707393|Drug|Cyclosporine A|infusion, orally if possible
46027189|NCT02707393|Drug|Mycophenolate mofetil|infusion
46027190|NCT02707393|Biological|bone marrow or peripheral blood stem cells|infusion
46027191|NCT02711605|Device|UltraShape focused ultrasound device|3 biweekly focused ultrasound treatments to the male chest with UltraShape.
46027192|NCT00940342|Drug|GM-CSF (Sargramostim)|250 mcg injection under the skin, three times a week for eight weeks.
46027193|NCT00940342|Drug|Rituximab|375 mg/m^2 administered intravenously once weekly for four weeks
46027194|NCT02707549|Drug|balanced crystalloid solution (components: sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride)|
46027195|NCT02707549|Drug|0.9% sodium chloride|
46027196|NCT00936910|Drug|amphotericin B liposomal (Ambisome)|After enrollment, antifungal therapy will be instituted consisting of both systemic and antifungal lock therapy. Systemic therapy will be amphotericin B liposomal (Ambisome) administered IV in a dose of 3-5 mg/kg/day (or other antifungal based upon standard of care) combined with antifungal lock therapy. The antifungal lock therapy consists of placing sufficient amphotericin B liposomal (Ambisome [2 mg/ml]) lock solution into the infected central venous catheter (CVC) and allowing it to dwell uninterruptedly for 8 to 12 hours per day for 10-14 days (largest CVC = 2.3 mL).
46027197|NCT02707627|Device|Laser Therapy|Laser therapy is a technology that can be used to treat hypertrophic burn scars.
46027198|NCT02707315|Drug|Gemcitabine|
46027199|NCT02707315|Radiation|Stereotactic Radiosurgery|
46027200|NCT00604942|Procedure|Heller's Myotomy|Long vs Short Heller's Myotomy for Achalasia
46027201|NCT00604942|Procedure|Nissen Fundoplication|Partial vs Full Fundoplication for GORD
46027202|NCT00604942|Drug|domperidone or esomeprazole (Conservative management)|Conservative management for dysphagia not referred for surgery. Conservative management: balloon dilatation or drugs such as domperidone 10 mg or esomeprazole 40 mg
46027203|NCT00604942|Drug|Esomeprazole 40 mg|Esomeprazole vs no esomeprazole for GORD not referred for surgery
46027204|NCT02711683|Drug|DL-3-n-butylphthalide|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
46027205|NCT02711683|Drug|Donepezil|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
46115603|NCT05016843|Other|No access to a moderated forum|Participants will not have access to a moderated forum, hence their treatment is self-guided.
46115604|NCT04108013|Drug|SHR-1210|In the experimental group, 200mg SHR-1210 was given in the first day of each cycle, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
46115605|NCT04108013|Drug|Carboplatin and Paclitaxel-albumin|In the control group, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
45681942|NCT05688280|Drug|1.0% IP-001 for Injection|4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.
45754461|NCT05582408|Device|Measure of Noise Reduction Principle NR3|Each participant will be fitted with the novel Noise Reduction principle NR3 on the same hearing aid
46027206|NCT02854618|Other|additional blood sample|
46027207|NCT04266808|Device|An interactive telehealth monitoring and biofeedback system|A pressure sensitive mat located under the user's wheelchair seat cushion and a wheelchair propulsion monitoring device attached to the chair which are interfaced with a phone App based user interface to provide feed back to promote physical activity and pressure relief maneuver performance among wheelchair users.
46027208|NCT04266808|Behavioral|Education Control|Participants will receive education on importance of pressure relief maneuvers and physical activity and the recommended amounts of each for prevention of pressure ulcer/injury and for physical health.
46027209|NCT05079061|Drug|Misoprostol|sublingual misoprostol 600 micrograms in addition routine uterotonics at third stage of labour
46027210|NCT00605800|Other|blood drawn|Baseline levels of bone marrow derived liver stem cells from normal healthy volunteers, which will be drawn once Two 5ml blue tubes).
46027211|NCT00605800|Other|blood drawn|At the time of preoperative testing, patients will have two extra test tubes (5cc blue top) of blood drawn for determination of pre-operative base line levels of bone marrow derived liver stem cells in peripheral blood. Intraoperatively, blood will be drawn after liver resection (two tubes of 5cc blue top). Two extra tube of blood will be drawn at the same time of routine postoperative blood drawing to determine levels of bone marrow derived liver stem cells in peripheral blood on post-operative days #1, and #3.
46115606|NCT04105985|Drug|Kovanaze Nasal Spray|Intra-nasal local anesthetic
46115607|NCT04105985|Drug|Articaine Injection|Local anesthetic
46115608|NCT04074213|Drug|Clozapine|Clozapine treatment
46115609|NCT04110587|Biological|Hyaluronic Acid|1 mL Hyaluronic Acid Injection (20 mg/mL, 7000 KDa) at the end of arthroscopy .
46115610|NCT04110587|Procedure|Temporomandibular Joint Arthroscopy|Lysis and Lavage
46027212|NCT02693431|Other|Non interventional Study|"Parents and children will be informed at the inclusion visit (V0) that is a normal consultation under the care of the child.~The children included will be followed for 18 months with a maximum of 6 months without meeting art therapy sessions and 12 months with art therapy. The art therapy sessions will be scheduled during the usual consultations conducted as part of the care of children.~At each visit, clinical, paraclinical and external factors of anxiety will be collected and anxiety of parents and children will be measured using specific questionnaires."
46027213|NCT00605020|Drug|insulin detemir|
46027214|NCT00605020|Drug|insulin aspart|
46027215|NCT00605020|Device|biphasic insulin aspart|
46027216|NCT02707081|Drug|Intravenous normal saline|Normal saline in a volume equivalent to that used in intravenous lidocaine group
46027217|NCT02707081|Drug|Intraperitoneal normal saline|Patients received 00 ml of saline intraperitoneally
46027218|NCT02707081|Drug|Intraperitoneal Lidocaine|Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure.
46027219|NCT02707081|Drug|Intravenous Lidocaine|Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery.
46027220|NCT02711371|Other|fMRI|
46027221|NCT02707237|Other|Verbal counseling|Verbal counseling done by physician
46027222|NCT02707237|Other|Verbal, pictorial, written counseling|verbal counseling in addition to gestational age specific written information and pictures will be given to parents
46027223|NCT00605098|Drug|Lopinavir / ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation and maintained for at least 6 weeks after delivery.
46027224|NCT00605098|Drug|Lopinavir/ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation, increase the lopinavir/r dosage (200/50 mg, 3 tablets every 12 hours) in the third trimester (from 25 weeks on), and return to standard dose(200/50 mg, 2 tablets every 12 hours)for at least 6 weeks after delivery.
46027225|NCT02711215|Diagnostic Test|PET/MR [11C]DASB|2 PET/MR scans will be performed (placebo/citalopram - double-blind randomized cross-over)
46027226|NCT02711215|Drug|Citalopram|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
46027227|NCT02711215|Drug|Escitalopram (Mirtazapine/Duloxetine/Venlafaxine)|After completion of imaging procedures, patients will receive treatment with escitalopram 10-20mg. In case of non-response, after 6 weeks, treatment will be switched to either Mirtazapine, Duloxetine or Venlafaxine
46027228|NCT02711215|Drug|Placebo|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
46027229|NCT04254406|Other|Descriptive study|Evaluation of routine treatment
46027230|NCT04310215|Biological|CARTISTEM®|"*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~Procedure: Microfracture~Biological: CARTISTEM®(Human Umbilical Cord Blood-derived Mesenchymal Stem Cell product)"
46027231|NCT04310215|Procedure|Microfracture|"*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~1. Procedure: Microfracture"
46027232|NCT00603772|Drug|Atralin (tretinoin) gel, 0.05%|Assess photoallergic reactions for tretinoin 0.05% and vehicle, measured as skin reactions following induction and challenge.
46115611|NCT04110587|Drug|Antibiotic therapy|Amoxicillin / Clavulanic Acid, 1g I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth (Post-operative).
46115612|NCT04110587|Drug|corticosteroid|Dexamethasone, 4 mg I.V. (Intraoperative)
46115613|NCT04110587|Drug|Antiinflammatories|Diclofenac 100 mg / 12h / 5 days by mouth (Post-operatively).
46115614|NCT04110587|Drug|Analgesics|Metamizol 575 mg / 8h by mouth (Post-operatively)
45754462|NCT00575029|Drug|megestrol acetate|600 mg by mouth daily
46027233|NCT02706613|Behavioral|Face to Face Pulmonary Rehabilitaton|6 week face to face, incremental exercise and education programme for people with COPD
46115615|NCT04110587|Other|Exercise program|Home exercise program
46115616|NCT03625869|Device|PiCSO|After blood flow restoration, the subjects meeting all inclusion and none exclusion criterial will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes (at minimum 30 minutes) whereas the treatment should be continued during and post stent insertion, but should not exceed a maximum duration of 90 minutes. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
46115617|NCT03616587|Drug|AZD9833|Part A: AZD9833 monotherapy dose escalation.
45754463|NCT03912584|Device|P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
46027234|NCT02706613|Behavioral|Online Pulmonary Rehab|6 week online, incremental exercise and education programme for people with COPD
46027235|NCT00605332|Device|inferior vena cava filter|Crux Biomedical IVC Filter
46027236|NCT02706769|Drug|Placebo|Study medication contains blinded placebo
46027237|NCT02706769|Drug|Paracetamol|Study medication contains blinded paracetamol
46115618|NCT03616587|Drug|AZD9833|Part B: AZD9833 monotherapy expansion.
46115619|NCT03616587|Drug|AZD9833 with palbociclib|Part C: AZD9833 in combination with palbociclib dose escalation
46115620|NCT03616587|Drug|AZD9833 with palbociclib|Part D: AZD9833 in combination with palbociclib expansion
46115621|NCT03616587|Drug|AZD9833 with everolimus|Part E: AZD9833 in combination with everolimus dose escalation
46115622|NCT03616587|Drug|AZD9833 with everolimus|Part F: AZD9833 in combination with everolimus dose expansion
46027238|NCT05044117|Drug|Capecitabine|Metronomic capecitabine (650 mg/m2 bid, d1-21, q3w) for 1 year
46027239|NCT05031715|Dietary Supplement|Berberine Phytosome|2 tablets of 550 mg per day (1 before lunch and 1 before dinner)
46115623|NCT03616587|Drug|AZD9833 with abemaciclib|Part G: AZD9833 in combination with abemaciclib (± anastrozole) dose escalation
46115624|NCT03616587|Drug|AZD9833 with abemaciclib|Part H: AZD9833 in combination with abemaciclib (± anastrozole) dose expansion
45838928|NCT04349592|Other|Placebo capsules|Oral 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
46027240|NCT05029609|Drug|Intranasal Foralumab Solution|The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.
46027241|NCT05029609|Drug|Placebo|The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.
46027242|NCT02693197|Drug|T-817MA|A single oral dose of 448 mg
46027243|NCT02711293|Other|ART home delivery|Community health workers visit participants who are clinically stable on antiretroviral therapy (ART) at home (maintaining patients' prior clinic visit frequency) to deliver ART. Clinically stable on ART was defined as 1) taking ART for at least six months, 2) having had a CD4-cell count >350 cells/μL or a suppressed viral load at six or more months after ART initiation, and 3) the patient's most current CD4-cell count must have been >350 cells/μL or the most current viral load must have shown viral suppression, with the last measurement not taken more than 12 months ago.
46027244|NCT02711293|Other|Enhanced nutrition counseling|Community health workers visit participants at home to provide standard counseling (focusing on family planning, prevention of HIV transmission, and ART adherence) plus enhanced nutrition counseling (covering food production and dietary advice). In addition, participants who state that they have access to a plot of land or garden to grow vegetables receive a pack of seeds (amaranth, cowpea, or pumpkin) at enrolment.
46027245|NCT03961165|Drug|Butylscopolamine Bromide 20 MG/ML|1 mL Butylscopolamine Bromide 20 mg/mL i.v. Single dose.
46027246|NCT03961165|Drug|Sodium Chloride 9mg/mL|1 mL Sodium Chloride 9 mg/mL i.v. Single dose.
46027247|NCT03807973|Drug|[Zr-89]Oxine-labeled leukocytes PET/MRI|All study participants will undergo an investigational imaging study using autologous [Zr-89]-labeled leukocytes and brain PET/MRI. Participants will undergo a venous blood draw, and the leukocytes in the blood sample will be isolated for labeling using [Zr-89]oxine. The labeled leukocytes (7.4- 18.5 megabecquerel (MBq), 200-500 uCi) will be re-injected into the participant followed by brain PET/MRI at 24-48 hours after injection. Participants will be asked to have a second brain imaging study 3-6 days after this injection, but this second imaging study is optional.
46027248|NCT02706457|Other|Barthel index for functionality|The Barthel Index for functionality is done standard in all patients after intensive care admission
46027249|NCT02706535|Drug|GSK525762 Besylate Tablets|GSK525762 is available as a film-coated, white to slightly colored round, biconvex tablets with no markings. It is available in unit dose strength of 5 mg.
46027250|NCT02706535|Drug|Itraconazole 200 mg|Itraconazole is available as a clear yellow solution with unit dose strength of 10 mg/mL
46027251|NCT02706535|Drug|Rifampicin 300 mg|Rifampicin is available as a red capsule with printed markings and as a 300 mg unit dose strength.
46027252|NCT02711059|Procedure|parathyroidectomy|surgical treatment of hyperparathyroidism
46027253|NCT02706223|Other|Pharmacist Led|Trial of administering established, licensed treatments by a novel pathway, ie Community Pharmacists, which is hypothesized to improve treatment and retention in treatment of difficult to engage subjects
46027254|NCT02706223|Other|Nurse led|Trial of administering established, licensed treatments by the conventional clinical care pathway, ie Specialist nurses
46027255|NCT02706379|Other|Local cerebral oxygen saturation|take blood culture before antibiotic use;measure the blood lactate;liquid rescisutation as 20ml/kg
46027256|NCT03960073|Dietary Supplement|MitoQ|4 week 20mg oral daily dose of Mito Q
46027257|NCT03960073|Dietary Supplement|Placebo|4 week oral daily dose of TTP placebo
46027258|NCT02706301|Behavioral|Telephone-Based Coping Skills Training (CST)|
46027259|NCT02710825|Other|Osteopathy|"The treatment begins, if possible, on the body part of the child whose osteopathic score is the highest , with the least elasticity and mobility. Then the other restricted joints will be treated. The set of techniques will be carried out after palpation and appropriate tensioning. The various actions will be carried out on the tissues and joints who have been particularly affected by the operation.~When a joint or tissue has a restricted mobility in a direction or a specific movement, it will require appropriate and gently manual correction, in order to reduce and improve its functionality."
46115625|NCT03616587|Drug|AZD9833 with capivasertib|Part I: AZD9833 in combination with capivasertib dose escalation
46115626|NCT03616587|Drug|AZD9833 with capivasertib|Part J: AZD9833 in combination with capivasertib dose expansion
46027260|NCT02710825|Other|superficial palpatory agreement|The simulated treatment also begins with the body part of the child whose osteopathic score is the highest. Then the other restricted joints will be treated. The set of techniques will be carried out with the same investments as the tests , with a superficial palpatory agreement and without tensioning so that the restricted articulation or tissue will not be corrected
46027261|NCT00612703|Drug|ARQ 197|Treatment with ARQ 197 in combination with erlotinib
46115627|NCT03616587|Drug|AZD9833 with ribociclib|Part K: AZD9833 in combination with ribociclib (± anastrozole) dose escalation
46115628|NCT03616587|Drug|AZD9833 with ribociclib|Part L: AZD9833 in combination with ribociclib (± anastrozole) dose expansion
46027262|NCT00612781|Procedure|cataract surgery (Hoya AF-1 [UY] YA-60BB)|implantation of a yellow Hoya AF-1 (UY) YA-60BB intraocular lens
46027263|NCT00612781|Procedure|cataract surgery (Hoya AF-1 [UV] VA-60BB lens)|implantation of an uncoloured Hoya AF-1 (UV) VA-60BB
46027264|NCT00612157|Drug|Eszopiclone|Eszopiclone 3mg orally at bedtime for 14 nights
46027265|NCT00612157|Drug|Placebo control|Matching placebo
46115629|NCT03616587|Drug|AZD9833 with anastrozole|Part M: AZD9833 in combination with anastrozole dose escalation
46115630|NCT03616587|Drug|AZD9833 with anastrozole|Part N: AZD9833 in combination with anastrozole dose expansion
46115631|NCT03386253|Device|active tDCS|two 13 minute tDCS sessions separated by 20 minutes in between
45681943|NCT03157726|Procedure|Transurethral plasmakinetic enucleation of prostate|Transurethral plasmakinetic enucleation of prostate(PAKEP),an operation mode devised by Liu Chunxiao Team in southern medical university urology department. The theory of the operation is using transurethral resectoscope instead of the finger in the open operation, to find the surgical capsule of prostate and to peel the hyperplastic prostate gland visually in a antidromic way.
45838929|NCT04349748|Behavioral|Health education, and regular HIV and STDs testing prompting service|Health education through app for once a week, and regular HIV and STDs testing prompting service (every month through app) are given to the participants at the beginning of the study and last for the whole five observation periods.
45838930|NCT04349748|Behavioral|Health status inquiry through app (partner notification)|The permission to query health status through app (partner notification) is given to participants (participants can query their potential sexual partner's status of HIV, syphilis, hepatitis B, and hepatitis C respectively through app) at the specific observation period,and the permission is retained until the end of study.
46027266|NCT05265559|Procedure|Partial Indirect Restoration|Dental restorative treatment
46027267|NCT00940108|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
46027268|NCT00940108|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
46027269|NCT02710903|Procedure|Stent-induced biofilm overgrowth|Customized stents will be fabricated for each subject. Stents will be fabricated to resemble an acrylic mouth-guard but extended to cover approximately 2mm over gingival margins. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will abstained from brushing and flossing teeth in one maxillary and one mandibular posterior sextant during a three- week period. Patients will be monitored for safety every week and after the induction of experimental biofilm overgrowth through 21 days
46027270|NCT05265403|Drug|Commercially-available energy storage and return prosthetic foot|Each patient will walk in the Freedom Highlander, a commercially-available energy storage and return prosthetic foot. The foot will be sized based on the patient's foot size and weight.
46027271|NCT05265403|Device|MIT-Lower Leg Trajectory Error (LLTE) customized prosthetic feet|Each patient will walk in prosthetic feet designed by the researchers at MIT. These feet will be customized for the user based on their body size (ie, height, foot length) and weight.
46027272|NCT04971655|Other|Music therapy|Music therapy will be applied throughout diabetes education. Turkish Folk, Classical, Turkish Art and Sufi Music genres will be offered to individuals as an option and will be listened to throughout the process. Instrumental works will be uploaded to the computer by the researchers and will be played on the loudspeaker during the training.
46027273|NCT04612699|Drug|Jaktinib|Administered orally
46027274|NCT04612699|Drug|Placebo|Administered orally
46027275|NCT04267432|Dietary Supplement|Placebo|Blank
46027276|NCT04267432|Dietary Supplement|TCI633|Probiotics
46027277|NCT04267432|Drug|Type 2 collagen|Positive control group
46115632|NCT03386253|Device|sham tDCS|sham tDCS session given for same length of time as active
46115633|NCT02658279|Drug|Pembrolizumab|
46115634|NCT02633163|Drug|Low Dose Mesenchymal Stem Cells (MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.
45681944|NCT03157726|Procedure|transurethral resection of prostate|"Transurethral resection of prostate(TURP), a kind of mature minimally invasive surgery of prostate , taking the place of the traditional open surgery in 1930s , still is the gold standard operation for surgical treatment of BPH."
46027278|NCT04970173|Other|use of a very low-volume 1L-PEG plus ascorbate (plenvu) or low-volume 2L-PEG plus ascorbate (moviprep) for bowel preparation in open access colonoscopy|Patients are free to choice the kind of BP in an open access booking system colonoscopy. The safety of BPs was assessed by reviewing the clinical and laboratory data of patients who attended the Emergency Department (ED) of the five Hospitals of our Digestive Endoscopy Unit in the 7 days following the colonoscopy. This was feasible since the electronic reporting system is the same across our five Hospitals.
46027279|NCT04267354|Other|Arm cycling|The arm cycle will be placed on table with height adjusted to be the same as the acromion (highest point on shoulder). Participants will start arm cycling at a low intensity and increase as per tolerance. They will exercise for a maximum of two minutes at a time, followed by a rest period for 30 seconds. In this manner 5 cycles of exercise and rest will be performed. The exercise sessions are anticipated to last a maximum of 20 minutes, depending on the patient's abilities.
46115635|NCT02633163|Drug|High Dose Mesenchymal Stem Cells (MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells MSCs 5 x 10^6 cells/kg in Plasma-Lyte A solution.
46115636|NCT02633163|Drug|Placebo Infusion|Participants will receive a placebo infusion that does not contain any mesenchymal stem cells.The placebo infusion will consist of Plasma-Lyte A, which is the same vehicle used to deliver the MSCs in the experimental groups.
45681945|NCT03156322|Drug|5 mL epidural initiation volume (bupivacaine + fentanyl)|5 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
45681946|NCT03156322|Drug|10 mL epidural initiation volume (bupivacaine + fentanyl)|10 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
45838931|NCT04349202|Diagnostic Test|EUROIMMUN assay|Serology testing to detect SARS-CoV-2 antibodies
45838932|NCT04348812|Behavioral|ABMT|mobile attention bias modification training for anxiety, using the app Personal Zen
45838933|NCT04348812|Other|Transcranial direct current stimulation|Soterix 1X1 tDCS Limited Total Energy (LTE) Stimulator
45838934|NCT04348890|Drug|Vamorolone 4% suspension for oral dosing|vamorolone 6 mg/kg/day orally once daily for 8 weeks.
46027280|NCT05382988|Drug|Sodium zirconium cyclosilicate|The experimental group was required to take SZC 10g at 6 am on the day of surgery.
46027281|NCT05379868|Procedure|Posterior column osteotomy|Apical full facet joint resection. Study intervention does not involve a device.
46115637|NCT03534453|Drug|Olaparib 300mg tablets|300mg Olaparib tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
46027282|NCT05379868|Procedure|No osteotomies|Standard treatment
46027283|NCT02710747|Genetic|CYP2C9;VKORC1|
46115638|NCT02609685|Other|Active Surveillance|Subjects will be actively observed for disease progression (condition worsens) instead of receiving immediate surgery, considered standard of care.
46115639|NCT04074915|Other|Placebo mouth rinse|Normal saline
46115640|NCT04074915|Drug|Chlorhexidine mouth rinse|Chlorhexidine gluconate
46027284|NCT05382832|Combination Product|SCS|SCS-experimental treatment
46027285|NCT05382832|Combination Product|SCS|SCS-placebo
46027286|NCT00936598|Drug|zolpidem|Participants will receive the FDA approved dose of zolpidem, (10 mg for women <65; 5 mg for women = or > 65 years) during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
46027287|NCT00936598|Drug|sugar pill|Participants will receive placebo (sugar) pills during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
46115641|NCT04074915|Drug|Test group|Chamomile mouth rinse
46115642|NCT05673525|Device|Transcatheter Aortic Valve Implantation (KOKA-VALVE)|Transcatheter Aortic Valve Implantation
46115643|NCT02579733|Drug|Azathioprine|
46115644|NCT02579733|Drug|Placebo|
46115645|NCT03326193|Drug|Niraparib|Niraparib will be administered orally once a day continuously throughout each 21 day cycle (84-day cycle after amendment 2). The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count. Participants with a Baseline actual body weight of greater than equal to (>=) 77 kg and Baseline platelet count of >=150,000/ microliter (μL) will take 300 mg/day (3X100mg) at each dose administration. Participants with a Baseline actual body weight of less than (<) 77 kg and/or Baseline platelet count of <150,000/μL will take 200 mg (2X100 mg) at each dose administration.
46115646|NCT03326193|Biological|Bevacizumab|Maintenance bevacizumab 15 mg/kg will be administered via a 30-minute IV infusion on Day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death. Bevacizumab will be administered for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of approximately 5 months of bevacizumab received with chemotherapy.
46027288|NCT04159441|Other|None intervetion|None intervetion
46027289|NCT00936364|Other|Short-term fasting|No calories will be consumed during periods of fasting. Good oral hydration will be encouraged. Water may be consumed, as well as non-caloric beverages (i.e. zero calorie soft drinks, black coffee or tea).
46115647|NCT03287193|Biological|Blood sample|for patient and its parents
46115648|NCT03287193|Genetic|high-throughput sequencing|exome or whole genome sequencing
46115649|NCT02517099|Drug|Beclometasone|Beclometasone dipropionate 200mcg bd for 4 months
46115650|NCT02517099|Drug|Co-amoxiclav|Co-amoxiclav 0.3ml/kg bd for 4 weeks
46027290|NCT00936364|Other|Modified fast|Minimal caloric intake on days -2 and -1
46115651|NCT02517099|Drug|Azithromycin|Azithromycin 10mg/kg od for 4 weeks
46027291|NCT00936364|Other|Fasting|Day -1
46027292|NCT00936364|Other|Fasting|Days -2 and -1
46027293|NCT00936364|Other|Fasting|Days -3, -2, and -1
46027294|NCT00936364|Other|Fasting|48-hour fast with minimal caloric intake on days -2 and -1
46027295|NCT01025817|Drug|Everolimus and tacrolimus|"Everolimus:~Dosage form: 0.75 mg, 0.25 mg, and 0.5 mg tablets~Dose: 1.5 mg per day~Frequency: 0.75 mg twice daily~Tacrolimus:~Dose adjusted to maintain specific blood levels"
46027296|NCT01025817|Drug|mycophenolate mofetil and tacrolimus|Mycophenolate mofetil: - Dose form: 250 mg capsule - Dose: 2g per day - Frequency: 1g twice daily Tacrolimus: - Dose adjusted to maintain specific blood levels
46027297|NCT02710513|Dietary Supplement|Beta-glucans|2 months Mediterranean Diet-based free diet (run-in) + 2 months Mediterranean Diet-based free diet with a daily supplementation of 100 g of beta-glucans pasta (intervention). Medical visits, dietary counselling with food frequency questionnaires administration, blood, urine and feces collection were performed before (T0) and after (T2) the two months of beta-glucans intervention.
46115652|NCT04073199|Procedure|Long Lever Group|"the physiotherapist wears the limb passively towards flexion, external rotation and abduction until the physiotherapist has perception of stretch of the tissues (sensation terminal elastic firm according to the concept of Orthopaedic Manual Therapy for the soft tissue treatment) The patient's own weight stabilizes the proximal segment, in case that the scapula is not stable, the physiotherapist fixes with his free hand the scapula.~The technique will be performed two days a week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate)."
46115653|NCT04073199|Procedure|Short Lever Group|"It consists of a stretch made by the physiotherapist, with the patient in supine position, with the extremity to be treated in a submaximal position of flexion and external rotation (fixed by the arm and body of the physiotherapist) and realizing the stretch a through the scapula in the medial and caudal dorsal direction.~The technique will be performed two days per week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate)"
46115654|NCT02478099|Drug|MPDL3280A|Anti-PD-L1 antibody
46027298|NCT00939640|Behavioral|DASH/sodium-restricted diet (SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.
46027299|NCT05264545|Device|PrimeTaper EV|The PrimeTaper EV Implant is a screw shaped dental implant with a defined surface achieved through grit blasting, followed by a process involving a treatment in diluted hydrofluoric acid. There is a conical connection between the implants and the abutments for a tight and stable connection.
46115655|NCT02473263|Drug|Ceftriaxone|Ceftriaxone 2g IV will be infused in the first 60 minutes, for non nosocomial severe septic syndrome
46115656|NCT02473263|Drug|Piperacillin tazobactam|Piperacillin/tazobactam 4g IV will be infused in the first 60 minutes, for nosocomial severe septic syndrome
46115657|NCT02473263|Drug|Norepinephrine|Norepinephrine will be infused after failure of hemodynamic optimization using vascular fluid loading
46027300|NCT00636883|Drug|Gemcitabine|GEMOX-Erlotinib consists of erlotinib 100 mg orally daily starting day 1, Gemcitabine 1000 mg/m2 in 10 mg/m2/min (100 minutes) infusion on day 1 followed on day 2 by oxaliplatin 100 mg/m2 in a 2-hour infusion. Treatment will be repeated every 2 weeks. Each two weeks is a cycle.If at end of 12 cycles response continues, will administer Gemox and erlotinib till achieve maximum response. Then start Erlotinib maintenance therapy.
46027301|NCT02872155|Other|Oral hydratation|500 mL of water two hours before computed tomography and 2000 milliliters 24 hours after performing computed tomography
46115658|NCT02473263|Drug|Hydrocortisone|Hydrocortisone 100mg IV will be infused after failure of hemodynamic optimization using norepinephrine with at least 1.5mg/h
46115659|NCT03249831|Drug|Cyclophosphamide|Orally daily
46027302|NCT02872155|Drug|Bicarbonate endovenous hydratation|Intravenous hydration: sodium (1.6 molar) Bicarbonate 3 mL / kg / h starting one hour before the computed tomography and sodium bicarbonate (1/6 M) 1 mL / kg / h during the hour after computed tomography.
46115660|NCT03249831|Drug|Pentostatin|Intravenous
46115661|NCT03249831|Drug|Rabbit anti-thymocyte globulin|Intravenous
46115662|NCT03249831|Drug|Tacrolimus|Initially IV. If patient tolerates, convert to oral.
46115663|NCT03249831|Drug|Mycophenolate mofetil|IV or oral
45681947|NCT03156322|Drug|20 mL epidural initiation volume (bupivacaine + fentanyl)|20 mL 0.625% bupivacaine + + 2 μg/mL fentanyl solution is administered from epidural catheter
45681948|NCT05682664|Other|Luchtbrug Junior (online monitoring)|Online monitoring via Luchtbrug Junior will replace 50% of the outpatient visits. Children in the intervention group will be monitored online monthly by a digital version of TRACK.
46115664|NCT03249831|Biological|CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant|Infusion
46115665|NCT03222609|Drug|Ruxolitinib|Tablet; Oral
46115666|NCT03222609|Drug|Navitoclax|Tablet; Oral
46115667|NCT02578485|Device|AVideogame|Participants active video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
46115668|NCT02578485|Device|SVideogame|Participants sedentary video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
46115669|NCT02578485|Device|EMIntensity|Participants performed walking on a treadmill at moderate intensity by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
46115670|NCT02578485|Device|EISVideogame|Participants performed walking on a treadmill in intensity similar to the game by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
46027303|NCT02872155|Drug|Saline endovenous hydratation|If there is contraindication for administration of bicarbonate the pattern of intravenous hydration is performed with saline solution: 3 ml / kg / h for 1 hour before the procedure and normal saline 1 mL / kg / hour for hour after computed tomography.
46115671|NCT02578485|Device|Control|participants remained at rest for a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
46027304|NCT00605956|Drug|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse - 1% spinosad
46115672|NCT04074369|Diagnostic Test|CRISPR-based Test|CRISPR-based Test performed on sputum or BALF in TB suspects.
46115673|NCT00437203|Drug|PF-00477736|"Escalating doses of PF-00477736 will be administered intravenously on Days 2 and 9 and gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).~If a patient is administered Cycle 0 - only PF-0047736 will be administered intravenously on Days 1 and 8 of a 21-day cycle for patients who have a 3-hour infusion and Days 1 and 8 of a 14-day cycle for patients who have a 24-hour infusion."
46115674|NCT00437203|Drug|gemcitabine|gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).
46115675|NCT02466321|Procedure|Inverse/Reverse Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Inverse/Reverse System
46115676|NCT04072653|Procedure|SLNB is spared|SLNB is spared in patients with negative preoperative axillary assessment(including LymphPET and other imaging examinations)
46115677|NCT00753272|Biological|GSK Bio's influenza vaccine GSK2186877A|IM administration, two times one annual dose, 3 different lots will be tested
46115678|NCT00753272|Biological|Fluarix TM|IM administration, two times one annual dose
46115679|NCT02419287|Drug|crizotinib|
46115680|NCT00437125|Drug|Duloxetine hydrochloride|Duloxetine 30 milligram (mg) once daily (QD) orally (PO) for 1 week, then duloxetine 60 mg QD PO for 11 weeks
46115681|NCT03173001|Diagnostic Test|Parasitological examination|Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.
46115682|NCT02578407|Other|accommodative/vergence therapy|12 weekly accommodative/vergence therapies
46115683|NCT03511027|Device|SME + Karie Device|For the duration of the study, participants will use the Karie device to promote medication adherence. The Karie device prompts users to take their medication in the right amount at the right time.
45681949|NCT05682664|Other|Usual care|Routine outpatient clinical visits every 3 months.
45681950|NCT04140682|Device|PAV+ mode|PAV+ mode by using Puritan-Bennett 840 ventilator
45681951|NCT04140682|Device|PSV mode|PSV mode by using Puritan-Bennett 840 ventilator
45681952|NCT03156088|Device|"Sacral Neuromodulator InterStim"|
45681953|NCT03021382|Other|data collection, non-intervention|
45681954|NCT03156166|Procedure|fiberoptic bronchoscope|Distance from grille (the end of shaft in supraglottic airway) to glottis is measured using FOB
45681955|NCT04140058|Drug|Ondansetron|ondansetron was administered 20 minutes prior to spinal anesthesia.
46027305|NCT00605956|Drug|NatrOVA Creme Rinse Vehicle Only|NatrOVA Creme Rinse Vehicle - no spinosad
46027306|NCT00605956|Drug|Blank Patch|Blank Patch
46027307|NCT02710357|Procedure|Mandibular Overdenture|Placement of an implant in the mandibular midline.
46027308|NCT02710357|Procedure|Mandibular complete denture|No intervention. Maintenance of the dentures will be done when needed.
46115684|NCT03511027|Other|SME only|At discharge, participants will be provided with self-medication education.
46115685|NCT02578329|Behavioral|Intensively advised Mediterranean diet|Mediterranean Diet: fatty fish 3 times/week; legumes 2-3 times/week; vegetables twice/day; fresh fruits twice/day; 30 to 45g olive oil/day; 1-2 glasses red wine/day; less than 150g red meat/week
46115686|NCT02578329|Behavioral|usual low-fat dietary advice|usual low-fat dietary advice for cardiovascular disease
46115687|NCT01028287|Drug|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
46115688|NCT01028287|Drug|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
46115689|NCT02578173|Device|AVERT PLUS|
46115690|NCT01028365|Other|No intervention|Study participants will not be asked to make any changes to their daily lifestyle or existing health care routine. Participants also will not be asked to take any medications or change their diet.
46115691|NCT04698135|Other|Biological samples collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
46115692|NCT04698135|Other|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
46115693|NCT04698135|Other|Medical/laboratory examinations|Blood pressure measurement, abdominal and thoracic physical examination, body composition through bioimpedance analysis and metabolic, cardiovascular and respiratory variables; OGTT 75gr for blood glucose and insulin at times 0, 30, 60, 90 and 120', and a nocturnal oximetry and subsequently, if necessary, overnight polysomnography for the diagnosis of obstructive sleep
46115694|NCT01028443|Drug|Sandimmune|
46115695|NCT01028443|Drug|Artelose|
46115696|NCT05440214|Behavioral|Dialectical Behavior Therapy Skills Training|Dialectical Behavior Therapy Skills Training (DBT-ST) is a group-based intervention focused on teaching skills for improving emotion regulation. The sessions will be offered in-person or via approved telehealth services.
46027309|NCT02871999|Device|Acupuncture therapy|
46115697|NCT04096976|Other|logistic regression|To identify associations between factors listed in Table 1 and hospital survival, we used logistic regression
46115698|NCT03116997|Drug|Neostigmine+glycopyrrolate|At the conclusion of surgery neuromuscular blockade reversed with neostigmine/glycopyrrolate
46115699|NCT03116997|Drug|Sugammadex|At the conclusion of surgery neuromuscular blockade reversed with sugammadex
46115700|NCT02600780|Drug|Febuxostat|Comparison of two anti-hyperuricemic molecules
46115701|NCT02600780|Drug|Allopurinol|Comparison of two anti-hyperuricemic molecules
46115702|NCT00582309|Procedure|Glucommander-Guided Intravenous Insulin Infusion|"Glucommander-Guided Intravenous Insulin Infusion.~Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.~During the infusion, enter glucose levels into the Glucommander and follow recommendations regarding infusion rate and time to measure next blood glucose levels."
46115703|NCT00582309|Procedure|Standard Intravenous Insulin Infusion|"Standard Intravenous Insulin Infusion Standard Intravenous Insulin Infusion in the ICU setting Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.~Algorithm 1: Start here for most patients. Algorithm 2: For patients not controlled with Algorithm 1, or receiving glucocorticoids, or patient with diabetes receiving >80 units/day of insulin as an outpatient.~Algorithm 3: For patients not controlled on Algorithm 2.No Patients Start Here."
46115704|NCT00582309|Procedure|Simple Calculated Intravenous Insulin Infusion|If the patient was on insulin prior to this admission, 1/2 of the total insulin dose divided by 24 will be the initial insulin infusion rate. The amount of insulin given will be dependant upon blood sugar levels ( BG levels 80-120= 0.5 units/hr, 121-160=1.0 units/hr, 161-200= 2.0 units/hr, 201-240= 3.0 units/hr, 241-280= 4.0 units/hr, 281-320= 5.0 units/hr, 321-360=6.0 units, 361-400= 7.0 units, greater than 400= 8.0 units.
46115705|NCT00443053|Drug|Fondaparinux 2.5mg or placebo|Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day
46115706|NCT01977183|Dietary Supplement|MSPrebiotic|Potato Resistant Starch
46115707|NCT01977183|Dietary Supplement|Placebo|Placebo - Corn Starch
46115708|NCT00720798|Drug|Tocilizumab|For participants weighing > 100 kg, the maximum dose of tocilizumab was 800 mg. Tocilizumab was supplied as a sterile solution in vials.
46115709|NCT00720798|Drug|Disease-modifying anti-rheumatic drugs|Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These drugs could be used alone or in combination, except for the combination of methotrexate and leflunomide, which was not allowed.
46115710|NCT00720798|Drug|Non-steroidal anti-inflammatory drugs|Participants could be treated with non-steroidal anti-inflammatory drugs up to the maximum recommended dose throughout the study. The choice and doses of non-steroidal anti-inflammatory drugs were at the discretion of the investigator.
45681956|NCT04140058|Drug|Normal saline|Placebo of 10 mL normal saline was administered.
46115711|NCT00720798|Drug|Oral corticosteroids|Oral corticosteroids (≤ 10 mg/day) were permitted during the study.
46115712|NCT01816971|Drug|dexamethasone|Given IV or PO
46115713|NCT01816971|Drug|carfilzomib|Given IV
46115714|NCT01816971|Drug|lenalidomide|Given PO
46115715|NCT01816971|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplant
46115716|NCT01816971|Other|laboratory biomarker analysis|Correlative studies
46115717|NCT03995095|Other|Therapeutic interview: kibo protocol|The kibo protocol is a therapeutic interview designed to address the spiritual needs of patients at the end of life.
46115718|NCT03995329|Other|IQOS|Acute effects of IQOS on pulmonary function, oxygen saturation, exhaled CO, heart rate and arterial blood pressure.
46115719|NCT03489187|Device|Visualase Thermal Therapy System|Patients who have previously received treatment with VTTS when used as intended.
46115720|NCT04936893|Behavioral|Mindfulness Practice|10-15 mins of daily mindfulness practice using HeadSpace, for 3 weeks
45598626|NCT03160053|Device|NB-UVB|NB-UVB has an emission spectrum in the ultraviolet B range of 290-320 nm. The system consists of a light source, a spot handpiece, and a light guide that connects the handpiece to the light source. The light source has a Start/Stop switch for light beam activation. Activation can also be controlled remotely with a foot switch. The light source has a timer and an output level control to adjust the intensity of the ultraviolet light. This will be calibrated using a manufacturer-provided UV meter prior to every treatment to ensure accurate doses of ultraviolet light.
46027310|NCT02871999|Procedure|Laparoscopic Surgery|
46027311|NCT05382676|Device|Eyeswift Pro|assessment of visual function parameters
46027312|NCT01218113|Biological|GSK Biologicals HIV Vaccine 732462|2 or 3 doses according to protocol schedule
46027313|NCT01218113|Drug|Placebo|1 or 3 doses according to protocol schedule
46027314|NCT05264467|Biological|Platelet rich fibrin on colorectal anastomosis|Platelet rich fibrin on colorectal anastomosis
46115721|NCT04936893|Behavioral|Cognitive training|10-15 mins of cognitive games using Lumosity, for 3 weeks
46115722|NCT01021267|Drug|Saw palmetto berry extract|1x daily 1 capsule containing 320mg lipophilic extract
46115723|NCT04072965|Other|balance training|Thirty five females with CAI will be recruited from the Faculty of Physical Therapy, Cairo University by announcements to participate in this study. The participants will be randomly assigned into three groups; (A) Cross Education will receive single leg balance training for the non affected side (n=10), (B) Traditional training will receive single leg balance training for the affected side (n=10), (C) control group will receive no intervention (n=15).
46115724|NCT04072731|Other|pathologic|All the enrolled patients were treated with whole resection and diagnosed by the Pathology Department based on the pathological evidence.
46115725|NCT03478267|Diagnostic Test|AChE levels|AChE levels in peripheral blood tests from maternal blood, fetal umbilical cord and placenta.
46027315|NCT02871453|Device|Scalp Acupuncture Treatment|The Motor Area of the scalp acupuncture is located over the anterior central convolution of the cerebral cortex, being a line starting from a point 0.5cm posterior to the midpoint of the anterior-posterior midline of the head and stretching diagonally to the juncture between the eyebrow-occipital line and the anterior border of the corner of temporal hairline is indistinct, draw a vertical line upward from the middle point of the zygomatic arch to the eyebrow-occipital line, the intersection of the two lines is the projection of the Motor Area. Needles will be inserted in an about 15 degree angle to a depth of 1.0-1.5cm. Needles are rotated at least 200 revolutions per minute for 1 minute every 10 minutes for a total of 60 minutes. five times a week, 8 weeks in total.
46027316|NCT02871453|Other|Rehabilitation treatment|The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists.
46027317|NCT00605410|Drug|ipratropium bromide|2 puffs (40 micrograms) 2 puffs (0micrograms)
46027318|NCT00605410|Drug|placebo|Matched placebo
45681957|NCT03157648|Other|observing for shivering symptom|In the PACU investigators measure body temperature of all patients at tympanic membrane, forehead, and dorsal of hand. Investigators calculate the difference between body temperature measure at tympanic membrane and forehead/dorsal of hand. Investigators observe the shivering symptom and grading for severity.
46027319|NCT02710201|Behavioral|Descriptive Social Norm|
46027320|NCT02710201|Behavioral|Descriptive-plus-Injunctive Social Norm|
46027321|NCT04300881|Drug|Eplerenone|Following intravitreal ocriplasmin therapy
46027322|NCT05382520|Diagnostic Test|Questionares and practice|Questionares and practice
46027323|NCT04203940|Procedure|Cyanoacryale|mesh fixation was done using dots of N-butyl 2-cyanoacrylate tissue glue
46027324|NCT04203940|Procedure|Suture|mesh fixation was done with polypropylene 2/0 sutures
46027325|NCT00603850|Device|ForeseeHome|human factor
46027326|NCT03873493|Drug|Venetoclax|Venetoclax tablets taken orally once a day (QD). Initially, venetoclax was administered utilizing a 5-step dose ramp-up over 5 days. Subjects were hospitalized and closely monitored for 7 days. The venetoclax ramp-up was administered in a daily manner: 20 mg on Week 1 Day 1, 50 mg on Week 1 Day 2, 100 mg on Week 1 Day 3, 200 mg on Week 1 Day 4, and 400 mg on Week 1 Day 5 and thereafter, once daily, until the end-of-treatment. The dose of venetoclax may have been increased to 600 mg QD at Week 8 or thereafter.
46027327|NCT03873493|Drug|Ibrutinib|Ibrutinib capsules taken orally once a day, 420 mg/day until the end-of-treatment.
46027328|NCT05264311|Other|Pilates exercise program|"The Pilates Exercise Program (PEP) (1 h x 2 sessions per week x 2 months) was delivered by one Pilates professional (with a mean of 6.5 years of experience in Pilates). The PEP carried out by Pilates instructor has been published in a previous study [31]. The exercises focused on core stability, posture, breathing, flexibility, strength, and muscle control, being the active awareness of the use of trunk muscles to stabilize the pelvic-lumbar region the main approach. The exercises performed were: the hundred, the rolled up, single leg circles with bent leg, spine stretch, rolling like a ball and single leg stretch. Each exercise was performed as follows: 4 repetitions of 30 seconds with 2 minutes of recovery between repetitions. In order to complete the 60 minutes session two exercises: the superman and the double leg bridge were added to the mentioned PEP."
46027329|NCT02710123|Other|Sub-Threshold exercise prescription|Participants will be given a prescription to exercise at 80% of their threshold HR for symptom exacerbation. HR Threshold will be monitored weekly and exercise level increased accordingly.
46027330|NCT02710123|Other|Structured stretching prescription|Participants will be given a prescription for daily stretching lasting approximately 20 minutes.
46115726|NCT04086420|Behavioral|Mindfulness|Received instructions to exercise at moderate intensity while listening to an audio-recorded mindfulness-based physical activity intervention
46115727|NCT04086420|Behavioral|Heart-Rate|Given a heart rate monitor, told to exercise within the moderate intensity range (64-76% of estimated maximum heart rate)
46115728|NCT00756002|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
46115729|NCT00756002|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
46115730|NCT04017403|Drug|Bifidobacterium triple live capsule|Bifidobacterium triple live capsules, indications for acute and chronic diarrhea and constipation caused by intestinal flora imbalance, can also be used for the treatment of mild to moderate acute diarrhea, chronic diarrhea and indigestion, bloating, and adjuvant treatment of intestinal flora Endotoxemia caused by disorders.
45470572|NCT05397860|Procedure|Radiofrequency ablation using gradual radiofrequency energy delivery with Octopus electrodes|Radiofrequency ablation (RFA) will be performed by using multi-VIVA generator and Octopus electrodes. Three electrodes will be placed on the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF) will be applied to two of three electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C. The RF energy will starts at 60 watts and increase by 10 watts every 30 seconds for the first 3 minutes, and then increases gradually by 10 watts per minute after reaching 100 watts.
45681958|NCT03156010|Device|Neuro Kinetics IPAS|Testing with PAS device
45681959|NCT03156010|Device|Oculogica EyeBox|Testing with Oculogica EyeBox device
45681960|NCT03156010|Device|SyncThink EyeSync Device|Testing with SyncThink EyeSync device
45681961|NCT04142320|Device|closed-loop rTMS|Delivers patterned magnetic stimulation in closed-loop fashion
45681962|NCT04142320|Device|open-loop rTMS|Delivers patterned magnetic stimulation in open-loop fashion
45681963|NCT04142320|Device|sham rTMS|Delivers placebo magnetic stimulation
46027331|NCT04300309|Drug|artemether:lumefantrine (2.5 mg:30 mg)|artemether:lumefantrine (2.5 mg:30 mg)
46027332|NCT05264233|Dietary Supplement|Coconut oil|50 g of coconut oil will be added to the test meal for breakfast and 30 g of coconut oil will be added to the test meal for lunch
46115731|NCT04017403|Drug|Placebos|Placebos were administrated as same as the bifidobacterium live capsule
46115732|NCT00717366|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|Will be administered IV, every 4 weeks.
46027333|NCT05264233|Dietary Supplement|Butter|50 g of butter will be added to the test meal for breakfast and 30 g of butter will be added to the test meal for lunch
46027334|NCT05264233|Dietary Supplement|Vegetable oil|50 g of vegetable oil will be added to the test meal for breakfast and 30 g of vegetable oil will be added to the test meal for lunch
46115733|NCT04096664|Device|SIMEOX|Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX
46027335|NCT00611689|Drug|Imatinib and PTK/ZK222584|Imatinib and PTK/ZK will each be administered orally daily. Two dose levels of imatinib (400 mg and 600 mg) will be tested with 4 dose levels of PTK/ZK (250 mg, 500 mg, 750 mg, and 1000 mg). 3 patients will be accrued at each individual dose level. If dose-limiting toxicities are reported in ≤ 1/3 patients, the dose level will be expanded to 6 patients. If dose-limiting toxicities are reported in < 2/6 patients, then dose escalation will continue. If ≥ 2/6 patients experience dose-limiting toxicity, the next lower dose will be considered the maximum tolerated dose and will be expanded to a total of 12 patients. There will be no intrapatient dose escalations. Patients may continue to receive treatment until unacceptable toxicity or disease progression is encountered.
46115734|NCT02939989|Drug|Sofosbuvir|Tablet for oral administration
46115735|NCT02939989|Drug|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
46115736|NCT02939989|Drug|Ribavirin|Tablet for oral administration
46115737|NCT04096742|Drug|tretinoin 0.05% lotion (Altreno)|Altreno topical lotion
46115738|NCT04096742|Other|Vehicle|Lotion not containing active ingredient (tretinoin)
46115739|NCT04085640|Other|Obturator nerve block with ropivacaine 0.2%.|20 milliliters of ropivacaine 2 mg/mL will be injected in the interfacial plane between the pectineus and external obturator muscles.
46115740|NCT04085640|Other|Obturator nerve block with isotonic saline|20 milliliters of isotonic saline will be injected in the interfacial plane between the pectineus and external obturator muscles.
46115741|NCT02600858|Behavioral|Upper limb feeding training|"Participants will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90° and 135° around the start cup as fast as possible using their non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition; each trial will consist of 15 repetitions. Participants will perform 50 trials per day for 3 consecutive days."
46115742|NCT03994315|Other|B. infantis EVC001|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)"
46027336|NCT05264077|Drug|Dexmedetomidine Hydrochloride|Inj dexmedetomidine and inj midazolam given to two groups of participants and effects of both drugs will be observed for 24 hrs
46027337|NCT04892641|Drug|Epetraborole|Epetraborole hydrochloride 250 mg tablets for oral administration
46115743|NCT03994315|Other|Lacto-N-tetraose (LNT)|LNT is a human milk oligosaccharide (HMO) found in human breast milk and is a selective prebiotic for B. infantis.
46115744|NCT02590926|Procedure|Fractional Flow Reserve, Myocardial|The ratio of maximum blood flow to the myocardium with coronary stenosis present, to the maximum equivalent blood flow without stenosis.
46115745|NCT04100642|Drug|Hemay808|topical apply
46115746|NCT04100642|Drug|Placebo|topical apply
46115747|NCT01031719|Biological|adjuvanted A(H1N1) influenza vaccine|7.5 ug of HA antigen; adjuvanted; monovalent
46115748|NCT01031719|Biological|non-adjuvanted A(H1N1) influenza vaccine|15ug of HA antigen, non-adjuvanted; trivalent
45681964|NCT04146298|Drug|Cyclophosphamide|Cyclophosphamide will be administered prior to cell infusion.
45681965|NCT04146298|Drug|Fludarabine|Fludarabine will be administered prior to cell infusion.
46027338|NCT04892641|Drug|Placebo|Matching placebo for 250 mg epetraborole hydrochloride tablets for oral administration
46027339|NCT03757819|Device|tDCS|Brain Stimulation
46027340|NCT03757819|Device|SHAM|Placebo device
46027341|NCT04160845|Procedure|cardiac surgery|cardiac surgery with hypothermic cardiopulmonary bypass
46115749|NCT01031719|Biological|non-adjuvanted A(H1N1) influenza vaccine|15 mcg of antigen; non-adjuvanted; trivalent
46115750|NCT00723606|Drug|Intramuscular ziprasidone mesylate|The recommended dose is 10 to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day for 3 days.
46115751|NCT00723606|Drug|Intramuscular haloperidol|The haloperidol group will receive an initial intramuscular injection of haloperidol 5mg, following on which 5mg haloperidol may be repeated every 4-8 hours to a maximum of 20 mg /day for 3 days.
45470573|NCT04516759|Drug|AZD1656|50mg film-coated tablets (at daily dose of 100mg BID)
45470574|NCT04516759|Other|Placebo|Matched placebo tablets
45681966|NCT04146298|Biological|Mutant KRAS G12V-specific TCR transduced autologous T cells|After preconditioning regimen, T cells will be infused to the patient intravenously in the Patient Care Unit over approximately 30 to 50 minutes.
45681967|NCT04146298|Drug|Anti-PD-1 monoclonal antibody|During the treatment, anti-PD-1 monoclonal antibody will be administered if needed.
45681968|NCT02899078|Drug|Ibrutinib|Given PO
45681969|NCT02899078|Drug|Nivolumab|Given IV
46027342|NCT00612859|Drug|levetiracetam|
46027343|NCT04866901|Behavioral|Slow-Paced Breathing (SPB)|see arm description
46027344|NCT04866901|Behavioral|Mindfulness (M)|see arm description
46027345|NCT04866901|Behavioral|Yogic Breathing (SPB+M)|see arm description
46027346|NCT00612391|Procedure|Lateral minimally invasive approach (plate fixation)|A longitudinally oriented, 4-cm incision will be made laterally starting at the acromion. The deltoid will be split proximally at the most strategic location (vis-à-vis the fracture), and after the deltoid is bluntly elevated from the humerus more distally the axillary nerve will be identified by digital palpation. The nerve is easily identified posteriorly as it emerges from the quadrilateral space. With a finger maintained on the nerve for protection, the plate will be inserted onto the lateral side of the proximal humerus and fixed according to the described technique. A second, 2-cm longitudinal incision will then be made further distally for diaphyseal screw placement. This incision is well distal to the course of the axillary nerve.
46115752|NCT01028521|Drug|CM3.1-AC100|Solution for sc injection, single ascending doses
46115753|NCT01028521|Drug|Placebo|Solution for sc injection
45681970|NCT03156946|Behavioral|breastfeeding mother-to-mother support|The mother-infant dyads in the intervention arm will receive breastfeeding mother-to-mother support from the hospitalization in the maternity and NICU up to 1 month after discharge. The intervention will be in addition to the usual or routine care. Breastfeeding counselors will be voluntary mothers who breastfed their own preterm infant (aged between 6 months and 5 years at the time of the study) for a minimum of 2 months, and who have had a positive personal breastfeeding experience, and who have undertaken a training course.
46115754|NCT01021501|Drug|nifedipine controlled release tablets|nifedipine controlled release tablets 60mg/day for at least 4 weeks
46115755|NCT01028599|Other|Intensive physical exercise|Intensive physical exercise 1 hour three times per week
46115756|NCT02921581|Radiation|FDG-PET guided dose painting|
46115757|NCT04009057|Other|B/F/TAF|B/F/TAF administered in accordance with the approved product monograph
46115758|NCT04005001|Other|HindSight|HindSight will examine the dynamic trends of clinical measurements taken from a patient's EHR and analyzes correlations between vital signs to alert for the onset of sepsis.This machine learning based tool is optimized by encoder and utilizes periodic retraining to improve its performance over time.
46115759|NCT04005001|Other|InSight|Compared to the ability of the InSight software's recognition of sepsis onset to HindSight's performance. The study determines if the HindSight software has equivalent or better performance than the InSight software.
46115760|NCT01021579|Drug|Metformin plus Placebo|PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)
46115761|NCT01021579|Drug|Metfomin plus Simvastatin|
46115762|NCT01031875|Drug|pazopanib hydrochloride|
46115763|NCT01031875|Radiation|fludeoxyglucose F 18|
46115764|NCT01021657|Procedure|trabeculectomies, non penetrating deep sclerectomies|
46115765|NCT01021735|Drug|etanercept or adalimumab|etanercept 50mg/week by s/c injection adalimumab 40mg eow by s/c/ injection
46115766|NCT01021735|Drug|Rituximab|1g x2 by IV infusion repeated every 5 months or more
46115767|NCT03378271|Device|Simultanious CGM/FGM|Patients will use both CGM and FGM and document their values as well as documenting a capillary blood glucose value.
46115768|NCT00442351|Drug|Asmanex twisthaler|Asmanex Twisthaler 220 mcg provided once daily in the evening for 12 weeks
46115769|NCT00442351|Other|Placebo for Asmanex twisthaler|Placebo for Asmanex Twisthaler 220 mcg, once daily in the evening for 12 weeks
46115770|NCT00436501|Drug|docetaxel|25 mg/m^2 given intravenously (IV) over 1 hour (+/- 10 minutes) following VEGF Trap every 3 weeks starting cycle 1 (21 day cycles)
46115771|NCT00436501|Biological|ziv-aflibercept|Starting dose 2 mg/kg given IV Cycle 0. Phase I Group: Every 3 weeks beginning with Cycle 0 (Completed 03/14/2008); Phase II Group: Every 3 weeks starting cycle 1 (Opened 05/09/2008).
46115772|NCT00436501|Other|laboratory biomarker analysis|Correlative studies
46115773|NCT00436501|Other|pharmacological study|Correlative studies
46115774|NCT00755846|Drug|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
46115775|NCT00755846|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
46115776|NCT00755846|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
46115777|NCT00755846|Drug|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks.
46115778|NCT00755846|Drug|Alogliptin|Alogliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
46115779|NCT00755846|Drug|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
46115780|NCT03850093|Drug|Gabapentin1200 mg|patients received 1200mg gabapentin 2 hrs preoperative
46115781|NCT03850093|Drug|bisoprolol 2.5mg|patients received 2.5mg bisoprolol 2 hrs preoperative
46115782|NCT03850093|Drug|placebo|patients received oral placebo 2 hrs preoperative
46115783|NCT00442117|Drug|mometasone furoate dry powder inhaler|MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day) for 12 weeks.
45470575|NCT03332160|Device|Flexitouch head and neck lymphedema treatment system|Pneumatic compression device cleared for use by medical professionals and patients who are under medical supervision, for the treatment of many conditions such as: lymphedema; primary lymphedema; post mastectomy edema; edema following trauma and sports injuries; post immobilization edema; venous insufficiency; reducing wound healing time; treatment and assistance in healing stasis dermatitis, venous stasis ulcers, or arterial and diabetic leg ulcers. The Flexitouch system and garments for head and neck are intended for use by medical professionals and patients who are under medical supervision for the treatment of head and neck lymphedema.
46115784|NCT00442117|Drug|Budesonide DPI|Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day) for 12 weeks.
46115785|NCT04096508|Behavioral|Music listening|Patients sit comfortably in a chair for 20 min listening music before the procedure.
46115786|NCT04096352|Behavioral|Direct Method|Learning effective vocal skills using speech therapy exercises and virtual reality simulations.
46115787|NCT04096352|Behavioral|Indirect Method|Information on voice function and voice hygiene.
46115788|NCT02600702|Other|Siriraj knee exercise|Siriraj knee exercise, 12 position of exercise protocol
46115789|NCT02600702|Other|Physical modalities|
46115790|NCT01796145|Other|Fibroscan|
46115791|NCT04095962|Other|Exercise|The MT program will be conducted for 6 months, twice a week in 60 minutes sessions. Sessions will be divided in warm-up (10 minutes, including slow walk, postural and mobility exercises for general activation, and stretching exercises), specific training (35-45 minutes, including balance/coordination training, strength and aerobic exercises) and cool down (5 minutes with breathing and stretching exercises for the main worked joints and muscles) following the main guidelines recommended by the American College of Sports Medicine [18] and the WHO [19].
46115792|NCT03070119|Drug|Tofersen|Participants will receive a loading dose regimen followed by maintenance dosing.
46115793|NCT04095884|Procedure|blood sampling|observational study and no intervention will be given. only blood samples collected and treated with iron supplements
46115794|NCT02578017|Behavioral|Mobile DOT|Mobile DOT is a multi-dimensional tool that uses automated reminders, adherence feedback messages, incentives, and video observation of medication administration.
46115795|NCT03917355|Behavioral|Nonverbal synchrony, therapeutic alliance|Association between motor synchronisation in psychiatrist/patient dyad and patient therapeutic adherence in patients with a first psychotic episode will be measured, 6 months after the first post hospitalisation consultation, using video without sound. Nonverbal synchrony, therapeutic alliance and treatment will evaluated.In this purpose, videos of patients and psychiatrist will be made (for all patients included), and the images will be analyzed.
46115796|NCT03014817|Procedure|Ultrasonically activated scalpel|Dissection with ultrasonically activated scalpel
46115797|NCT03014817|Procedure|Electrocautery|Dissection with electrocautery
46115798|NCT00752726|Drug|Orlistat|Weight loss treatment
46027347|NCT00612391|Procedure|Deltopectoral approach (plate fixation)|Anterior, Delto-Pectoral Approach - A 10-cm incision will be made over the deltopectoral groove, starting at the coracoid process proximally. As the clavipectoral fascia is incised, the cephalic vein will be identified and retracted laterally with the deltoid muscle. The pectoralis major as well as the conjoint tendon will be retracted medially, and the long head of the biceps tendon will be identified and used as a guide for achieving an anatomic reduction of the different fracture parts. Next, internally rotating the humerus will allow access to the lateral side of the proximal humerus, on which the plate will then be fixed according to the described technique.
45470576|NCT03332160|Other|Standard home lymphedema care|May include daily self manual lymphatic drainage, exercise, skin care, compression garments (as appropriate).
45470577|NCT01380236|Drug|ASM8|
46027348|NCT02709811|Drug|Electrochemotherapy|
46027349|NCT04216147|Other|PNE|Percutaneous Needle Electrolysis: the application of galvanic current through an acupuncture needle.
46027350|NCT04216147|Procedure|Surgery for CTS|Median nerve release
46027351|NCT05263765|Procedure|utilization of AO in the acute resuscitation of trauma and acute care surgery patients in shock.|AO to facilitate the acute resuscitation of trauma and acute care surgery patients in shock.
46115799|NCT00752726|Drug|Placebo|Inactive
46115800|NCT03012243|Procedure|Gallbladder aspiration|Percutaneous ultrasound-guided aspiration of bile from the gallbladder. This is performed without leaving a drain in the gallbladder. The aspiration is performed with the intention to relief the pressure in the gallbladder, without drain.
46115801|NCT03012243|Procedure|Cholecystostomy|Ultrasound-guided insertion of drain in the gallbladder. The drain is left in the gallbladder until clinical assessment and laboratory analyses show that the acute cholecystitis has been successfully treated.
46115802|NCT03918525|Other|Sindhi families|It is an observational study and no intervention is involved
46115803|NCT04093544|Device|Deep brain stimulation|Steered stimulation using directional leads
46115804|NCT04072497|Biological|One shot of the zoster vaccine|One shot of the zoster vaccine (with live virus >=4.3 LgPFU per dose)
46115805|NCT04072497|Biological|One shot of the varicella vaccine|One shot of the varicella vaccine (with live virus >=3.3 LgPFU per dose)
46115806|NCT04072497|Biological|one shot of placebo|one shot of placebo with no live virus
46115807|NCT02600000|Radiation|Myocardial scintigraphy|Myocardial scintigraphy with Iodo123-Metaiodobenzylguanidine (MIBG) to assess the Sympathetic myocardial activity
46115808|NCT02600000|Device|Cardiopulmonary test|Assessment of maximal functional capacity
46115809|NCT02600000|Device|AVD-Glittre Test|Evaluation of submaximal functional capacity after inspiratory muscle training.
46115810|NCT02600000|Device|Diaphragm ultrasound|Evaluation of thickness and diaphragmatic mobility
46115811|NCT04072263|Biological|Tumor Infiltrating Lymphocytes (TIL)|Adoptive cell therapy using Tumor-Infiltrating Lymphocytes (TIL) i.v.
46115812|NCT04072263|Drug|Interferon Alfa 2A|Interferon alpha (IFNα) s.c., may work as a low toxic preconditioning regimens that creates the space required for the infused TIL but that it also supports the TIL by sustaining their persistence and indirectly their function, by upregulation of HLA class I on tumor cells and decreasing the numbers of regulatory T cells.
46115813|NCT04072263|Drug|Carboplatin|chemotherapy i.v.
46115814|NCT04072263|Drug|Paclitaxel|Chemotherapy i.v.
46115815|NCT00755222|Biological|AA4500|2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series was separated by 6 weeks.
46115816|NCT00755222|Biological|Placebo|2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series is separated by 6 weeks.
46115817|NCT02956239|Procedure|Thermocoagulation (device)|Thermocoagulation uses heat injury to destroy the abnormal dysplastic cells of the cervix
46115818|NCT02956239|Procedure|Cryotherapy (device)|Cryotherapy uses cold injury to destroy the abnormal dysplastic cells of the cervix
46115819|NCT02956239|Procedure|LEEP (device)|The abnormal area of the cervix is excised with a thin metallic loop driven by electrosurgical unit
46115820|NCT00441727|Drug|Esomeprazole 40 mg|Esomeprazole 40 mg once daily
46115821|NCT00441727|Drug|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
46115822|NCT00441727|Drug|Placebo|Placebo once daily
46115823|NCT04095728|Dietary Supplement|Brain Octane Oil|Participants will complete a 7-day dose escalation period, and then consume 2 servings of the study product (1 serving = 1 tablespoon) for 21 days.
46115824|NCT04095728|Other|Placebo|Participants will complete a 7-day dose escalation period, and then consume 2 servings of the study product (1 serving = 1 tablespoon) for 21 days.
46115825|NCT02955225|Device|Active Moticon OpenGO insole|A Moticon OpenGO insole measures shoe pressure and connects/sends data to a ANT+ enabled smartphone.
46115826|NCT02955225|Device|Passive shoe insole|A deactivated insole measures shoe pressure only.
46115827|NCT04074057|Other|Conventional Cardiac Rehab Classes|conventional weekly CR programme lasting 8-12 sessions.
45470578|NCT02680106|Device|SPINNER|The SPINNER device is aimed at the DSW from a distance of 20 cm and activated for 1 minute. A nano-fibrous matrix is thus created.
46027352|NCT05261035|Behavioral|stretching exercises|For the stretching exercises group; the researchers explained to the women how to perform the stretching exercises through different visual materials like videos & pictures, provided a demonstration of each step, and emphasized that they could perform this exercise at any comfortable position, standing, sitting, or dorsal.
46027353|NCT05261035|Other|thermotherapy|women were instructed to warm the water to 43-47 C° using a water thermometer or test it with the inner aspect of their wrists. They are also advised to avoid using too hot or too cold water. Then immerse their legs for 20 minutes in the warm water at a h
46027354|NCT04848805|Procedure|liver transplantation|total hepatectomy material was examined by pathology laboratory
46115828|NCT04074057|Device|Heart Track|"Key components of Heart-Track are a heart rate sensor, a mobile app and a remote monitoring portal. The Heart-Track mobile app is synchronized/ connected to Polar heart rate sensor through bluetooth in order to provide continous heart rate monitoring when subjects are exercising. This is to ensure safety and exercise effectiveness."
45470579|NCT02680106|Device|JELONET / IBU Biatain|The patient's DSW will be dressed by JELONET/IBU Biatain
45470580|NCT05396690|Drug|Remimazolam Injection [Byfavo]|Induction dose: 6 mg/kg/h with sufentanil Maintenance dose: 1~2 mg/kg/h with sufentanil If arousal occurs during surgery, rapidly increase the infusion rate of remimazolam to 12 mg/kg/h and infuse for 1 minute. If the patient's arousal persists after these measures, stop remimazolam infusion and replace with another drug.
46115829|NCT04072185|Other|Physical activity|TThe intervention group will participate in a group physical activity program for 4 months. It will consist of 60 minutes of walking sessions 2 days a week. The sessions will be directed by two referents of each primary care center. Also once a month, coinciding with the walk, you will visit some sociocultural municipal equipment to promote a community connection.
46115830|NCT05673447|Biological|anti-CD19 CAR NK cells|"Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Doses of 6×10^8, 1×10^9, 1.5×10^9 Anti-CD19 CAR NK cells will infused in each group using the 3 + 3 dose-escalation strategy."
46115831|NCT00770120|Drug|everolimus|
46115832|NCT03996655|Drug|Sugammadex Injection [Bridion]|Reversal of neuromuscular blockers
45470581|NCT05396690|Drug|Sevoflurane|Induction dose: 2~3 mg midazolam with sufentanil Maintenance: Adjust the concentration to be BIS 35-65 based on 0.5 mac If arousal occurs during surgery, raise the concentration of sevoflurane to 1.5 MAC (increase the total gas flow rate to 8 l/min) and if arousal persists after 1 minute, administer midazolam 2-3 mg.
45470582|NCT05276856|Drug|Levothyroxine|"Step 1:~Reduce the dose of T4 therapy by 50% and recheck serum T4 after 2 weeks.~If serum T4 is normal, go to step 2.~If serum T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure).~Step 2:~Discontinue T4 therapy altogether and recheck serum TSH and T4 after 2 weeks.~If serum T4 is normal, go to step 3.~If serum T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure).~Step 3:~Recheck serum TSH and T4 after 8 weeks.~If serum TSH and T4 levels are normal, these patients will be regarded as having successful T4 withdrawal.~If T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure)."
45470583|NCT01384058|Drug|ezetimibe|ezetimibe 10 mg per day for six weeks
45470584|NCT01384058|Drug|simvastatin|Simvastatin 20 mg per day for six weeks
45470585|NCT01384058|Drug|Ezetimibe 10/Simvastatin 20|Ezetimibe 10mg/Simvastatin 20mg per day for six weeks
46115833|NCT03996655|Drug|Neostigmine|Reversal of neuromuscular blockers
46115834|NCT01032031|Dietary Supplement|Green tea + vitamin C high dose|One green tea capsule (1250mg catechin) and one vitamin C tablet (100mg) daily for 3 months
45470586|NCT04401384|Drug|Diclectin|Diclectin (combination of 10 mg doxylamine and 10 mg pyridoxine hydrochloride in a delayed release tablet) During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of Diclectin or placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.
46115835|NCT01032031|Dietary Supplement|Placebo capsule|One capsule daily for 3 months
46115836|NCT01032109|Drug|Bevacizumab|A single intravitreal injection of 1.25 mg of bevacizumab (0.05 mL of solution prepared from Avastin, 100 mg/4 mL vial) was performed within 2 weeks after PDT treatment.
45470587|NCT04401384|Drug|Diclectin placebo|Diclectin placebo will be packed and tested by a commercial pharmacy supply company specifically for this study. It have the same appearance, size, batch, odor, and taste compared with Diclectin. During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.
46115837|NCT04100330|Biological|Ficlatuzumab|Ficlatuzumab is a selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
46115838|NCT04100330|Drug|Cytarabine|Cytarabine is a chemotherapy agent. Chemotherapy agents are medications that kill cancer cells.
46115839|NCT04100252|Other|AFI via transabdominal ultrasonography|AFI via transabdominal ultrasonography was performed at the time of diagnosis.
46115840|NCT00436345|Drug|Remifentanil|analgesia in medical and post-surgical Intensive Care Unit subjects requiring mechanical ventilation
46115841|NCT00436345|Drug|Propofol|conventional sedation in medical and post-surgical Intensive Care Unit subjects requiring mechanical
46115842|NCT00916448|Drug|Atazanavir|capsules of 150 mg, 2 capsules, twice daily on 4 consecutive days
46115843|NCT00916448|Drug|E. coli endotoxin|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
46115844|NCT04095650|Behavioral|STEPS (Seniors using Technology to Engage in Pain Self-management)|Participants will meet with a community health worker (CHW) at a one-hour in-person study orientation session. At this session, they will be introduced to the program, learn how to use the online modules and associated materials, and schedule six weekly telephone sessions with the CHW. Participants will be given a wearable physical activity tracker to use throughout the course of the program. They can choose to report daily step counts by automatically syncing to an app or via text message. Each week during the study period, participants will engage with content on the website, have a session with the community health worker, track their daily steps, and set and work toward pain-management goals.
46115845|NCT02601716|Biological|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation-attenuated, Plasmodium falciparum (Pf) sporozoites
46115846|NCT02601716|Biological|CHMI (7G8)|CHMI is conducted by exposure to the bites of five mosquitoes infected with heterologous (7G8) Pf parasites.
46027355|NCT04841005|Other|The Square-Step Exercise Training|The Square-Step Exercise is instructed to walk according to the step pattern shown on a 100 * 250 cm mat, divided into 40 squares of 25 cm each. It includes forward, backward, lateral and diagonal steps, and step patterns are progressively made more complex. Each pattern consists of two to 16 steps; Individuals are asked to repeat the step pattern until they reach the end of the mat. Each step pattern is repeated 4-10 times to ensure that individuals can complete the pattern. The individuals included in the study will exercise in easy-difficulty patterns for the first 2 weeks, medium-difficulty patterns in the 3rd and 4th weeks, medium and advanced patterns in the 5th and 6th weeks, and advanced patterns in the 7th and 8th weeks. The square-step exercise group will perform 15 minutes of warm-up exercise, 30 minutes of progressive square-step exercise, and 10 minutes of cool-down exercise accompanied by a physiotherapist, 3 days a week.
46115847|NCT02601716|Biological|CHMI (NF135.C10)|CHMI is conducted by exposure to the bites of three to five mosquitoes infected with heterologous (NF135.C10) Pf parasites.
46115848|NCT01032187|Drug|Meglumine antimoniate|20mg/kg/day IV for 20 days
46115849|NCT01032187|Drug|Amphotericin B-deoxycholate|Amphotericin B-deoxycholate 1 mg/kg/day IV for 14 days
46115850|NCT04095338|Other|traditional rehabilitation|Each session will include 50 minutes of traditional physical rehabilitation therapy
46115851|NCT04095338|Other|virtual reality games intervention|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training by Tymo system (Tyromotion, Austria), a wireless platform for the balance and the postural control training that simulates floor walking and stairs climbing. Tymo system is connected to a screen and provides virtual reality games, adaptable to the functional capacity of the patient. Through the games proposed, the physiotherapist will decide to work in a dimension (antero-posterior or medio-lateral dimension) or in two dimensions (combining the antero-posterior and medio-lateral movements).
46115852|NCT04095338|Other|robotic treadmill intervention|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training by Walker view (TecnoBody, Italy), a treadmill equipped with a sensorized belt with eight load cells and a 3D camera.to detect length, speed and symmetry of the pace and load, range of the trunk, hips and knees. Patients will be asked to walk at a comfortable speed, while the physiotherapist will be able to work on different parameters such as step length, load distribution, and step height. The setting will take place taking into account the clinical conditions of each patient, customizing the intervention. The Walker View will offer visual and auditory feedback to the patient, so as to correct gait in real time.
46115853|NCT01028755|Drug|BAY79-4620|BAY79-4620 will be administered as 1 hour IV infusion. Dose escalation will be dependent on any dose limiting toxicities
46115854|NCT00769184|Drug|Corticosteroid|"One side of body:~clobetasol: 2 applications / day along with LCD application 2 applications/day"
46115855|NCT00769184|Other|Placebo|"One side of body:~Placebo Solution: 2 applications / day along with clobetasol 2 applications/day"
46115856|NCT00769184|Drug|LCD|"One side of body:~LCD Solution: 2 applications / day along with clobetasol 2 applications/day"
46115857|NCT01028833|Other|Power mobility|Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
46115858|NCT00768560|Drug|Nifedipine (Adalat CR, BAYA1040) 80mg OD|Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
46115859|NCT00768560|Drug|Nifedipine (Adalat CR, BAYA1040) 40mg BID|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
46115860|NCT00768560|Drug|Nifedipine (Adalat CR, BAYA1040) 40mg OD|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
45470588|NCT04401384|Device|Active acupuncture|Participants will receive active acupuncture every day for 2 consecutive weeks, a total of 14 sessions. The needle will be left for 30 minutes. After de qi induced by acupuncture, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6).
45598627|NCT02227979|Behavioral|The Purple Cry Intervention|This intervention consists of an 11-page booklet and 12-minute DVD produced by the National Center on Shaken Infant Syndrome.
45681971|NCT03156946|Behavioral|Control|The mother-infant dyads in the control arm will continue to receive the usual/routine care provided by participating centers during the hospitalization and Mother and Infant Protection service after discharge.
45598628|NCT02227979|Behavioral|Control Intervention|This intervention consist of 1 brochure and a DVD on infant safety excerpted from the Safe Start video on infant safety.
45598629|NCT03146793|Drug|Sodium Thiosulfate|25g intravenously 3 times per week
45598630|NCT03133195|Drug|Teriparatide|Teriparatide 20 μg subcutaneous once daily for 12 weeks (Patient self administration at home by pen injector)
45598631|NCT03133195|Drug|Placebo|Placebo subcutaneous once daily for 12 weeks. (Patient self administration at home by pen injector)
45598632|NCT03133195|Dietary Supplement|Calcium supplement|1000 mg/day of elemental calcium
45598633|NCT03133195|Dietary Supplement|Vitamin D|20,000 IU/week of vitamin D2
46027356|NCT04841005|Other|Strengthening Exercise Training|Thera-Band brand elastic bands will be used to apply resistance in strengthening training. To determine the intensity of the exercise, the perceived difficulty level after 15 repetitions with the elastic band will be evaluated with the Borg scale. If the perceived difficulty level is at the level of 12-14 (slightly difficult), it will be considered as the starting difficulty level.In the strengthening exercise group will perform, shoulder abduction, shoulder press after elbow flexion, horizontal abduction, punching with an elastic band, triceps strengthening, external rotation of the shoulder, hip abduction with external rotation and sit-to-stand exercises for 8 weeks, 3 days / week , 3 sets / sessions, 8-12 repetitions. For each exercise, it will be applied as 8 repetitions in the initial workload. In the next exercise sessions, the number of repetitions will be increased until the patient can comfortably perform 12 repetitions with the same load.
46027357|NCT02709733|Behavioral|VR Motivation Training|Computerized treatment with a virtual reality-based motivation training program, administered for 1 hour per week for 8 weeks.
46115861|NCT00468559|Drug|Open Label Run In Esomeprazole|Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)
46115862|NCT00468559|Drug|Double Blind Esomeprazole|Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)
46115863|NCT00468559|Drug|Double Blind Placebo|Double Blind Placebo
46115864|NCT00754442|Drug|Teriparatide|"Teriparatide will be given by continuous intravenous infusion at a rate of 12 pmol/kg/hr for 8 hours to both patients and controls"
46115865|NCT02600390|Biological|SANGUINATE|A two-hour infusion provided once a week over a 4-week or 6-week period.
46115866|NCT00754052|Drug|Aricept (donepezil hydrochloride)|All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalation will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil. All doses will be administered orally.
46027358|NCT04179409|Drug|Casimersen|This drug is used to target skipping of exon 45 of the dystrophin gene.
46115867|NCT00754052|Drug|Aricept (donepezil hydrochloride)|All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) donepezil. All doses will be administered orally.
46115868|NCT00754052|Drug|Placebo|All participants will start with a dose of 2.5 mg/day (2.5 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) placebo. All doses will be administered orally.
46115869|NCT04095182|Drug|Zebinix 400mg|Zebinix 400mg group is administered with two Zebinix 200mg tablets per day. (Single dose: Day 1, Multiple dose: Day5~11)
46115870|NCT04095182|Drug|Placebo for Zebinix 400mg|"Placebo for Zebinix 400mg group is administered with two placebo for Zebinix 200mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5~11)"
45681972|NCT01670344|Procedure|Treatment with investigational method (virtual implant positioning system)|
45681973|NCT01670344|Procedure|Treatment with surgical standard of care|
45681974|NCT04747444|Other|Anti-Gravity Treadmill|Treadmill in which the body weight percent placed on the lower extremities can be controlled
46115871|NCT04095182|Drug|Zebinix 800mg|Zebinix 800mg group is administered with a Zebinix 800mg tablet per day. (Single dose: Day 1, Multiple dose: Day5~11)
46115872|NCT04095182|Drug|Placebo for Zebinix 800mg|"Placebo for Zebinix 800mg group is administered with a placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5~11)"
46115873|NCT04095182|Drug|Zebinix 1600mg|Zebinix 1600mg group is administered with two Zebinix 800mg tablets per day. (Single dose: Day 1, Multiple dose: Day5~11)
46115874|NCT04095182|Drug|Placebo for Zebinix 1600mg|"Placebo for Zebinix 1600mg group is administered with two placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5~11)"
46115875|NCT00916916|Other|Blood draw|A blood draw will occur to take 10cc of blood to measure lanreotide levels.
46115876|NCT04093232|Drug|Hymovis|All subjects will receive 2 ultrasound guided Hymovis injections and the goal of the study is to correlate responsiveness to subjects unique SF biomarker panel results before the first Hymovis injection and identify potential mechanism of action of those OA patients who receive the greatest benefit.
46115877|NCT04093154|Device|wearing the virtual headset|watching the application by wearing virtual glasses to the child/adolescent
45681975|NCT04764760|Device|Wing shaped Tensiflex prosthesis|Curative inguinal hernia repair techniqque
45754464|NCT03912584|Device|P200TxE|The P200TxE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
46115878|NCT02599844|Drug|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
45681976|NCT01670734|Drug|alirocumab SAR236553 (REGN727)|"alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)~Pharmaceutical form:Solution for injection Route of administration: subcutaneous"
45681977|NCT03155776|Diagnostic Test|GUS|gastric volume estimation using gastric ultrasound was performed immediately after anesthetic induction, and after aspirating the residual gastric contents using nasogastric tube
46115879|NCT02599844|Procedure|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
46115880|NCT02599844|Procedure|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
46027359|NCT04179409|Drug|Eteplirsen|This drug is used to target skipping of exon 51 of the dystrophin gene.
46027360|NCT04179409|Drug|Golodirsen|This drug is used to target skipping of exon 53 of the dystrophin gene.
46115881|NCT02599844|Procedure|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
46115882|NCT02599844|Drug|Gadolinium|Magnevist Gadolinium (GD)-diethylene-triamine-pentaacetic acid-bis-oleate (0.07 to 0.14 mL/kg) will be used to determine GFR.
46115883|NCT02600312|Device|oXiris|oXiris CRRT filter which adsorbs cytokines, toxins.
46027361|NCT03872401|Drug|Evolocumab|Administered subcutaneously using an autoinjector pen.
46027362|NCT03872401|Drug|Placebo|Administered subcutaneously using an autoinjector pen.
45681978|NCT03155464|Procedure|Order of two elements of surgical procedure|Please see the arm/group descriptions for the order of elements of the surgical procedure in group 1 and group 2.
46027363|NCT00939484|Other|Pharmacological Study|Correlative studies
46027364|NCT00939484|Drug|Vismodegib|Given PO
46027365|NCT01010217|Drug|Cyclophosphamide|50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.
46115884|NCT04099784|Other|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages & Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
46027366|NCT01010217|Drug|Fludarabine|40 mg/m^2 IV over 1 hour on Days -6, -5, -4, and -3.
45598634|NCT02258789|Other|VR-method|Neglect rehabilitation by intense scanning training and multi sensory stimuli using Virtual Reality
46027367|NCT01010217|Drug|Melphalan|140 mg/m^2 IV (or 100 mg/m^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.
46027368|NCT01010217|Drug|Mesna|10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.
46027369|NCT01010217|Drug|Rituximab|CD20+ lymphoid malignancies: 375 mg/m2 on Day -13 followed by 1000 mg/m2 on Day -6, +1, and +8.
46027370|NCT01010217|Procedure|Stem Cell Transplantation|Infusion of donor's stem cells by vein on Day 0, may last anywhere from 15 minutes to several hours.
46027371|NCT01010217|Drug|Thiotepa|5 mg/kg Regimen 1 (or 5 mg/kg with reduced intensity Regimen 2) IV over 4 hours on Day -7.
46027372|NCT01010217|Drug|Tacrolimus|0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months
46115885|NCT04099784|Other|Physical development and General Health|Physical development and General health examination
46115886|NCT04099784|Other|Developmental Red flags|Developmental Red flags Questionnaires
46115887|NCT05430152|Drug|Low-Dose Naltrexone|"Study drug dosing schedule (LDN):~Week 1: 1 mg/day (1 mg cap)~Week 2: 2 mg/day (two 1 mg caps)~Week 3: 3 mg/day (three 1mg caps)~Weeks 4-6: 4.5 mg/day (three 1 mg caps, plus one 1.5 mg cap = 4.5 mg/day)~Weeks 7-16: 4.5 mg/day (one 4.5 mg cap) OR based on self-titration dosage (one 1mg, 2mg, or 3mg cap)"
46115888|NCT05430152|Other|Placebo|"Study drug dosing schedule (Placebo; capsules made to match LDN doses):~Week 1: 1 mg/day (1 mg cap)~Week 2: 2 mg/day (two 1 mg caps)~Week 3: 3 mg/day (three 1mg caps)~Weeks 4-6: 4.5 mg/day (three 1 mg caps, plus one 1.5 mg cap = 4.5 mg/day)~Weeks 7-16: 4.5 mg/day (one 4.5 mg cap) OR based on self-titration dosage (one 1mg, 2mg, or 3mg cap)"
46115889|NCT00747812|Device|Precision|Implantable Neurostimulator
46115890|NCT04092920|Device|laser and SLA|"ligible patients will be randomized to 2 groups control group will receive SLA surface treated implant to replace badly broken tooth immediately after extraction and a study group will receive laser surface treated implant to replace badly broken tooth immediately after extraction.~atraumatic extraction will be performed and socket will be examined for presence of bone dehesince or fenestration if no, implant will be placed immediately and a implant primary stability will be measured using an ISQ unit and recorded as base Line reading .~gingival former will be attached to the implant and removed at 2 ,4,8,12 week intervals to record ISQ readings."
46027373|NCT01010217|Drug|Mycofenolate mofetil|15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated
46027374|NCT01010217|Drug|G-CSF|5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery > 1000/mcl.
45598635|NCT02292199|Device|TENS High Frequency|TENS high frequency (100 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
46027375|NCT00605488|Procedure|novel PET tracer FACBC|Two IV catheters (heplock) will be placed in your forearms for injection of the dye-like material (FACBC) and blood sampling. An IV blood sample and a urine sample will be taken for testing. These samples will be used to measure the dye, FACBC, in blood and urine. You will be placed in the PET machine, where FACBC will be injected slowly over 30 seconds. Pictures of one region of your body will be taken for up to 60 minutes. Depending on your condition, your actual picture time may be shorter. You will come out of the scanner to stretch, walk around or sit in a chair. An optional urine sample and an IV blood sample will also be taken at this time. Again, these samples will be used to measure the dye, FACBC, in blood and urine. This will be followed by a picture of your body from the neck to the upper thighs. This picture will take about 30 minutes.
46115891|NCT02927067|Drug|Maribavir|Participants will receive 400 mg of maribavir BID orally.
46115892|NCT02927067|Drug|Valganciclovir|Participants will receive valganciclovir tablets orally.
46115893|NCT02927067|Other|Placebo|Participants will receive placebo tablets matched to either maribavir or valganciclovir.
46115894|NCT02600468|Drug|Orencia|
46115895|NCT04094636|Behavioral|In-bed cycling|Patients will daily perform 30 min of supervised in-bed cycling
46115896|NCT04094636|Behavioral|Exercise booklet|Patients will daily perform 30 min of supervised physical training with exercises from the exercise booklet
45838935|NCT04347330|Drug|Intensive BP Control|Participants in the Intensive group have a goal of home SBP <120 mm Hg. The CRAFT BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications, but there should be preferences among the drug classes, based on CVD outcome trials results and current guidelines. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. Combination of different classes of agents are encouraged to achieve the home SBP goal. Medications will not be provided by the CRAFT study.
45838936|NCT04347330|Drug|Standard BP Control|Participants in the Standard group has a goal of home SBP <135 mmHg. The same principle of BP treatment in the Intensive BP arm will be used for the Standard BP arm. Medications will not be provided by the CRAFT study.
46115897|NCT04094324|Behavioral|Questionnaires|4 questionnaires will be answered via iPads
46115898|NCT04094402|Other|None. It is an observational study|None. It is an observational study
45838937|NCT04347642|Procedure|Umbilical port placement|The port will be inserted in the midline at the level of the umbilicus.
46115899|NCT02577939|Behavioral|Interval Exercise Training (IET)|This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
46115900|NCT04094480|Device|polymeric non absorbable clips|a method to secure appendicular stump
46115901|NCT04094480|Other|endoloops|a method to secure appendicular stump
46115902|NCT04073901|Other|Endocrowns|Adhesive monoblock restoration for pulpotomized primary molars
46115903|NCT05447312|Other|Adaptive Music Intervention|Music that has been enhanced by frequencies that are associated with positive feelings as measured by EEG data. Music will be delivered through the Pi Electronic Inc.'s Venus Speaker that aims to promote psychosocial and cognitive functioning over and above traditional music therapy.
46115904|NCT05447312|Other|Traditional Music Intervention|Music that has not been enhanced by frequencies. Music is delivered through the Pi Electronic Inc.'s Venus Speaker that aims to promote psychosocial and cognitive functioning.
46115905|NCT02598596|Biological|Pegloticase|Pegloticase, IV
45838938|NCT04347642|Procedure|Paraumbilical port placement|The port will be inserted 3-4cm laterally to the midline at the level of the umbilicus.
45838939|NCT04347252|Drug|Glucagon|Intravenous infusion of glucagon at fasting or elevated glycemia. Blockade of the GLP-1 receptor during hyperglycemia with and without glucagon.
46115906|NCT02598596|Drug|Azathioprine|Azathioprine (1.25 mg/kg, followed by 2.5 mg/kg) oral, daily
46115907|NCT01771107|Drug|Brentuximab Vedotin|Given IV
46115908|NCT01771107|Drug|Dacarbazine|Given IV
46115909|NCT01771107|Drug|Doxorubicin Hydrochloride|Given IV
46115910|NCT01771107|Other|Pharmacological Study|Correlative studies
45838940|NCT04346940|Other|Telerehabilitation|15 volunteers aged 65 and over will be included in this group. An online exercise program has been created for individuals who will participate in the study. It is planned that this program will continue for 3 days a week, 6 weeks, and the duration of exercise will reach 45 minutes in the last week due to the increase in the number of repetitions about 30 minutes at the beginning. The treatment sessions will start with warm-up exercises, complete with posture exercises, joint range of motion exercises, stretching exercises, and cool-down exercises in the main program.
45838941|NCT04346940|Other|Exercise brochure|The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.
46115911|NCT01771107|Drug|Vinblastine|Given IV
46115912|NCT01751685|Behavioral|Kyphosis-specific spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis-specific spinal strengthening exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
46027376|NCT05379556|Diagnostic Test|Assessment of andrological profile of LO-COCO-ANDRO male patients|"Assessment of serum prolactin (PRL), luteininzing hormone (LH), follicle stimulating hormone (FSH), 17β-estradiol, testosterone. Physical examination with measurement of body weight, height, body mass index, waist and hip circumference. Andrological physical examination with evaluation of testis volume with Prader orchidometer, testicular consistency and lesions, varicocele. Scrotal ultrasound performed in longitudinal, transverse and oblique scans using a high frequency linear probe with grayscale and color-doppler; transrectal prostate ultrasound performed with transverse, longitudinal and oblique scans using an end fire probe; basal penile ultrasound will be performed in longitudinal and transverse scans using a high frequency linear probe with grayscale and color-doppler; dynamic penile ultrasound performed as described for basal penile ultrasound after intra-cavernous infiltration of 10 mcg of prostaglandin-E1 (PGE1)."
46027377|NCT05379556|Diagnostic Test|Assessment of reproductive function of LO-COCO-ANDRO male patients|Semen samples will be collected on site by masturbation directly into a sterile plastic container after 3-5 days of sexual abstinence. The sample will be analyzed according to World Health Organization (WHO) 2010 guidelines. Semen samples will be stored for biochemical and molecular evaluations.
46027378|NCT05379556|Diagnostic Test|Assessment of sexual function of LO-COCO-ANDRO male patients|Validated questionnaires to assess the prevalence of male sexual disorders, namely erectile dysfunction with International Index of Erectile function 15 (IIEF-15), premature ejaculation with premature ejaculation diagnostic tool (PEDT), hypoactive sexual desire disorder with andrological structured interview on erectile dysfunction (ANDRO-SIEDY). Patients will be also interviewed to evaluate lifestyle habits.
46027379|NCT05379556|Diagnostic Test|Assessment of olfactory function of LO-COCO-ANDRO male and female patients|"Brief interview to collect patient's anamnesis relative to olfactory function, with particular reference to hypo / anosmia and hypo/ageusia onset timeline, duration and regression.~Interview for the self-assessment of chemosensory skills and for the evaluation of quality of life in relation to olfactory dysfunction.~Sniffin 'Sticks test for the evaluation of odor threshold (T), odor discrimination (D) and odor identification (I) (TDI score)."
46027380|NCT04558359|Other|Standard of Care|These patients will receive standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.
46027381|NCT04558359|Drug|Angiotensin II|These patients will receive angiotensin II in addition to standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.
46027382|NCT04268212|Dietary Supplement|Bitter melon juice (100 ml)|Fresh bitter melon fruits were purchased from certified local groceries. The seeds of bitter melon were removed, and the juice was obtained from the raw fruit using a blender. Every 140 g of bitter melon fruit produced approximately 100 ml bitter melon juice.
46027383|NCT04268212|Behavioral|Exercise|The walking exercise was started 15 minutes after the glucose load. Walking speed was determined to elicit 65% of the maximum heart rate (HRmax) during exercise for each participant. HRmax was estimated using the America College of Cardiology prediction model, HRmax=208 - 0.7 × age. All participants wore a heart rate monitor (Polar, Vantage, XL) around the chest to assess exercise intensity. A rate of perceived exertion was assessed every 2 minutes based on the Borg's scale.
46027384|NCT00604006|Drug|Spironolactone|25 mg tablets (placed in capsules for blinding) once daily.
46027385|NCT00604006|Drug|Placebo|Placebo (lactose in capsules for blinding) once daily
46027386|NCT00604084|Drug|Ivermectin|Ivermectin 200ug/kg, 1 dose Q 6 months x 2, total duration = 12 months
46027387|NCT00604084|Drug|Permethrin 5% lotion|apply lotion to entire body, excluding head, at bedtime, rinse off following morning, wait one week, repeat application for a total of 2 applications, PRN frequency, NMT 6 applications in 12 months, total duration = 12 months.
46115913|NCT01751685|Other|Control|monthly educational lectures on various topics
45754521|NCT03585140|Other|Low glycemic diet|The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. A list of foods classified as having low index and glycemic load was used according to the mexican equivalent food system. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins. Milk and vitamin supplements will be eliminated from the diet.
46027388|NCT02691052|Other|Quality of Life questionnaire|EORTC QLQ-C30 questionnaire
46027389|NCT05379478|Diagnostic Test|Laboratory assessment of antibody profiles|Antibody profiles will be determined on submitted plasma samples
46027390|NCT04267042|Drug|Budesonide|Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.
46115914|NCT00586508|Drug|enzastaurin|1125 milligrams (mg) loading dose then 500 or 875 mg, orally, daily, 4-week cycles with participants evaluated after each cycle. The dose difference is for participants who are on enzyme-inducing antiepileptic drugs (EIAED) versus non-enzyme inducing antiepileptic drugs (NEIAED).
46115915|NCT00586508|Drug|bevacizumab|10 milligrams per kilogram (mg/kg), intravenously (IV), every 2 weeks, participants are evaluated after each cycle (4-week cycles).
46115916|NCT00586508|Drug|Enzyme-inducing antiepileptic drugs (EIAED)|Administered orally
46115917|NCT00586508|Drug|Non-enzyme inducing antiepileptic drugs (NEIAED)|Administered orally
45470589|NCT04401384|Device|Sham acupuncture|Blunt-tipped placebo needles will be used. Participants will receive sham acupuncture every day for 2 consecutive weeks, a total of 14 sessions. The needle will be left for 30 minutes. After de qi induced by acupuncture, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6). Then, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6).
46115918|NCT00581919|Drug|Bort, Dex, and Dox with ALCAR|Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long
46115919|NCT04094168|Drug|DEL NIDO CARDIOPLEGIA|"Del Nido components: Plasmalyte 148 (1000 ml), NaHCO3 8.4% 1M (13 ml), MgSO4 0,5 M (16,5 ml), Mannitol 20% (16,3 ml), KCl 2 M (13 ml), Lidocaine 2% (6,5 ml).~Electrolytic composition (l000 ml): Na+ 153 mEq, K+ 31 mEq, Cl - 124 mEq, Mg2+ 19,5 mEq, NaHCO3 13 mEq, Acetate 27 mEq, Sulfate 16,5 mEq, Gluconate 23 mEq."
46115920|NCT04094168|Drug|COLD BLOOD BASED CARDIOPLEGIA|Cardibraun components: Electrolytic composition (1000 ml): Na+ 185,8 mmol, K+ 24,1 mmol, Cl- 192,8 mmol, Acetate 23 mmol, Fosfate 0,97 mmol, Citrate 6,32 mmol.
46115921|NCT00723528|Drug|Placebo (CP)|Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12).
45681979|NCT03155464|Drug|Indocyanine Green|Intraoperative ICG has been validated to correlate to postoperative outcomes. ICG is administered by means of peripheral or central intravenous access, is excreted exclusively by the liver into the bile, and is not associated with risk for nephrotoxicity. We will be using a concentration of 2.5mg/cc. 12.5mg will be administered at each injection of ICG. Complete washout of the ICG occurs after 15 minutes, plenty of time considering the interval surgery that must occur. As per the protocol, ICG will be administered 3 times during the surgery. The patients will receive a total of 37.5mg of ICG, well below the recommended threshold of 2mg/kg. No significant toxic effects have been observed in humans with the high dose of 5 mg/kg of body weight.
46115922|NCT00723528|Drug|Ustekinumab 45 mg (CP)|Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
46115923|NCT00723528|Drug|Ustekinumab 90 mg (CP)|Ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
46115924|NCT00723528|Drug|Placebo A (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
46115925|NCT00723528|Drug|Placebo B (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
46115926|NCT00723528|Drug|Ustekinumab 45 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 45 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) SC at Weeks 16, 28, 40 and 52.
46115927|NCT00723528|Drug|Ustekinumab 90 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 90 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) SC at Weeks 16, 28, 40 and 52.
46115928|NCT02892123|Drug|ZW25 (Zanidatamab)|ZW25 administered IV once weekly, once every 2 weeks, or once every 3 weeks. Part 1: in multiple increasing doses; Part 2: ZW25 given at the MTD, OBD, or an RD identified in Part 1; Part 3: ZW25 given at the MTD, OBD, or an RD combined with one of the following selected drug combination:
46115929|NCT02892123|Drug|Paclitaxel|Combination therapy with ZW25 - Part 3 Treatment Groups 1 and 4
46115930|NCT02892123|Drug|Capecitabine|Combination therapy with ZW25 - Part 3 Treatment Groups 2 and 5
46115931|NCT02892123|Drug|Vinorelbine|Combination therapy with ZW25 - Part 3 Treatment Groups 3 and 6
46115932|NCT02892123|Drug|Tucatinib|Combination therapy with ZW25 and Capecitabine - Part 3 Treatment Group 7
46115933|NCT02892123|Drug|Tucatinib|Combination therapy with ZW25 - Part 3 Treatment Group 8 (may be opened if recommended by the Safety Monitoring Committee and/or the sponsor)
46115934|NCT00751790|Drug|triptorelin embonate (INN)|Triptorelin embonate 22.5 mg 6 month formulation to be injected every 24 weeks
46115935|NCT04092998|Procedure|Thermocautery circumcision|Histopathological changes from thermocautery circumcision
46115936|NCT04086810|Drug|DCCR|Once daily oral administration
46115937|NCT02598674|Drug|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
46115938|NCT02598674|Procedure|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
46115939|NCT02598674|Procedure|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
46115940|NCT02598674|Procedure|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
46115941|NCT02598674|Drug|Gadolinium|Dotarem Gadolinium (GD)- Gadoterate Meglumine (0.07 to 0.14 mL/kg) will be used to determine GFR.
46115942|NCT04020536|Drug|Antibiotics|Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition
46115943|NCT00917228|Device|recordings with device equipped|
46115944|NCT00917228|Device|Control|Recording without device equipped
46115945|NCT02598518|Behavioral|Integrating Combined Therapies|Individual Integrating Combined Therapies, approximately 10 sessions, one session per week
46115946|NCT02598518|Behavioral|Standard Care|Standard Care, individual or group therapy, approximately 9 hours per week for 3 months.
46115947|NCT00916760|Biological|Depigoid Parietaria judaica 1000DPP/ml|Subcutaneous monthly treatment
46115948|NCT00916760|Biological|Placebo|Subcutaneous monthly treatment
46115949|NCT05444192|Device|CAD/CAM insoles|computer-aided-design computer-aided-manufacture (CAD/CAM) insoles
46115950|NCT02600078|Device|AMS Monitor App|Participants will complete a novel coordination task performed on an android phone.
46115951|NCT02600078|Other|Lake Louise Score|Participants will complete a questionnaire to assess acclimatization to hypoxia.
46115952|NCT02600078|Other|Balance Error Scoring System|Participants will complete a series of static stance positions to evaluate their ability to maintain balance.
46115953|NCT02600078|Other|Heart Rate & Pulse Oxygen Saturation|Participants will have their heart rate and pulse oxygen saturation continuously monitored throughout the entire exposure.
46115954|NCT05442554|Drug|Brentuximab vedotin|Brentuximab vedotin IV infusion.
46115955|NCT00723450|Drug|lamictal|Flexible Dosing
46115956|NCT02599610|Other|Digital vaginal examination|Patients will be subject to digital vaginal examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
46115957|NCT02599610|Device|Transperineal ultrasound examination|Patients will be subject to transperineal ultrasound examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
46115958|NCT02599532|Drug|apixaban|Study subjects will be given a single-dose of apixaban 10 mg.
46115959|NCT02598752|Other|Symptom-limited cardiopulmonary exercise test (CPET)|
45470590|NCT04835701|Behavioral|Music|Music may be played through a portable speaker in close proximity to the patient or through the patient's own headphones, if preferred. Music will be played at a low enough volume for subjects to hear standard anticipatory guidance during the procedure.
45470591|NCT03631082|Other|Slump stretching|Slump stretching will be provided to this group along with standardized exercises.
45470592|NCT03631082|Other|Lumbar mobilization|Lumbar mobilizations will be provided to this group along with standardized exercises.
45681980|NCT01670890|Drug|TMZ|patients were treated with TMZ alone,Oral TMZ 50mg/m2/day,day 1 to 28,for 6 cycles
46027391|NCT04267042|Device|Mucosal Atomization Device|MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
46027392|NCT04267042|Device|NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation|INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
46027393|NCT04266496|Other|Questionnaires|ICIQ FLUTS (women) or MLUTS (mannen) CIVIQ 2 PSQI
46027394|NCT04266496|Diagnostic Test|Frequency Volume Chart|Collect a frequency volume chart for 3 days: measure the amount of voids and volume urinated.
46115960|NCT02598752|Other|Resting assessment of cardiac function by echocardiography|
46115961|NCT02598752|Other|Post-exercise assessment of cardiac function by echocardiography|
46115962|NCT02598752|Other|Pulmonary function|
46115963|NCT02598752|Behavioral|Patient-reported outcomes questionnaire|
46115964|NCT04085094|Dietary Supplement|high-salt diet (V1) and low salt diet (V2)|Before the first visit, the participant will follow a five-day high salt diet (addition of 6g/day of salt to their regular diet followed at home). Before the second visit (V2), the participant will follow for five days a low-salt diet, according to dietary instructions followed provided during the screening visit.
46115965|NCT04085094|Diagnostic Test|Contrast-enhanced ultrasound (CEUS)|Renal ultrasound with use of a contrast product (SonoVue®), perfusion rate 0.015ml/kg/min. Four destruction-reperfusion sequences are performed in order to measure the Perfusion Index (PI) of the renal cortex.
46115966|NCT04085094|Diagnostic Test|functional MRI|Measurement of renal oxygenation with the Blood Oxygenation Level Dependant-MRI technique (BOLD-MRI) on Siemens Prisma 3T scanner before and 15minutes after 0.03mg/kg of IV furosemide. Assessment of the amount of salt stored in the skin and muscles with the 23Na MRI technique.
46115967|NCT04085094|Other|Pilocarpine test|Assessment of sweat salt and potassium concentrations in healthy volunteers according to slat intake. Two electrodes are placed on the forearm. The electric current between the two electrodes will induce perspiration which will be collected with the Macroduct system.
46115968|NCT00751400|Drug|Naproxen Sodium ER (BAYH6689)|Consumer use of Extended Release Naproxen Sodium
46115969|NCT04086342|Drug|CHI-902|A standardized cannabis extract in MCT oil administered in oral liquid (oil) form.
46115970|NCT04086342|Drug|Placebo|Placebo is a vehicle oil that will match CHI-902.
46115971|NCT05341362|Procedure|LiDCOrapid|According to the illustration of the patient's hemodynamic figures shown on the LiDCOrapid monitor, we decide on the timing of the vasopressor administration. This group aims to maintain the cardiac output within a baseline range.
46115972|NCT05420948|Drug|Pembrolizumab|A drug that binds to a protein called programmed cell death 1 (PD-1) to help immune cells kill cancer cells better. Pembrolizumab is used to treat many different types of cancer.
46115973|NCT05420948|Drug|Carboplatin|A chemotherapy drug used to treat cancer.
46115974|NCT05420948|Drug|Paclitaxel|A chemotherapy drug used to treat cancer.
46115975|NCT04093778|Other|Low dose high frequency training and Safe Delivery Phone Application|The intervention period is a 9-month period where we will facilitate a quality improvement cycle using Low Dose High Frequency training with the Safe Delivery App as an anchor point and facilitate the integration into clinical practice through our Safe Delivery Focal Points at each hospital. All staff in maternity, paediatric wards and outpatient clinics will receive training and be encouraged to use the Safe Delivery App on a weekly basis.
46115976|NCT00585312|Drug|Celecoxib|celecoxib, 16 mg/kg/day, for 5 years
46115977|NCT00585312|Drug|Placebo|Masked, placebo comparator
46115978|NCT00753506|Dietary Supplement|Artemisinin|100 mg of artemisinin twice per day for 10 weeks
46027395|NCT04266496|Diagnostic Test|Collect urine during 1 day|Volunteers are asked to collected their urine during the last day of the frequency volume chart. Volunteers get 2 jars: One for collection during the day, and 1 for overnight collection of urine. Osmolality and sodium of urine is tested
46115979|NCT00753506|Dietary Supplement|Identical looking placebo capsule|Identical looking placebo twice per day for 10 weeks
46115980|NCT03980912|Diagnostic Test|LiverFASt|LiverFASt™ is a blood based diagnostic test utilizing a patented algorithm to determine presence and the progression of liver disease. The test is non-invasive, simple, and less expensive than liver biopsy or liver imaging.
46115981|NCT05406440|Drug|MK-8189|MK-8189 4 mg and/or 12 mg tablet(s) will be administered orally QD for a total daily dose of 48 mg, 60 mg, 80 mg.
46115982|NCT05406440|Drug|Placebo|MK-8189 dose-matching placebo tablets will be administered orally QD.
46115983|NCT00720096|Drug|Liposomal Doxorubicin|Liposomal Doxorubicin 40 mg/m2 q 28 days
45470593|NCT03312114|Drug|Avelumab|Avelumab* (MSB0010718C; anti-PD-L1 is a fully human anti-PD- L1 IgG1 antibody)
46027396|NCT04266496|Diagnostic Test|Blood sample|Blood collection to measure plasma sodium and osmolality.
46027397|NCT04266496|Diagnostic Test|Measurement of the circumference of the lower legs|"Circumference of the lower legs wil be measured twice:~After awakening, when still laying dowing in bed~Before goin to sleep~Circumference should be measured 2 cm above the medial malleolus"
46115984|NCT00720096|Drug|Topotecan|"Topotecan (daily x 5 days of a 21 day cycle)~Per amendment #15: Topotecan (days 1, 8, 15 of a 28 day cycle)"
46115985|NCT04086108|Dietary Supplement|Tomato|A maximum of 1 kilo pureed tomatoes, containing 1 gram of GABA.
46115986|NCT04086108|Dietary Supplement|GABA supplement|1 gram of GABA dissolved in water.
46115987|NCT04086108|Dietary Supplement|Glutamate supplement|A maximum of 8 grams glutamate, adjusted to amount of glutamate given in the tomato arm. Dissolved in water.
46115988|NCT02577783|Drug|PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone|doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)
46027398|NCT04266652|Procedure|tooth block|tooth root blocks were used to increase the bone width
46027399|NCT04266652|Procedure|autogenous bone block|autogenous bone block were used to increase the bone width
46115989|NCT02577783|Drug|PAD regimen: bortizomib, dexamethasone and doxorubicin|doxorubicin (duoroubixing) plus bortizomib (velcade) and dexamethasone (disaimisong)
46115990|NCT04089410|Device|Hyperthermic Fitness Treatment (HFT)|The Hyperthermic Fitness Treatment uses Alfa Basic capsule, an ergonomic camera in which a participant may take a lying position and undergo hyperthermia procedures (infrared heating with intracapsule temperature increase up to 80 degrees C◦), the head being outside the camera blown by cool air with a built-in ventilator. HFT is comparable to dry sauna bathing. Core body temperatures will be raised to 37.5-38.5°C◦. Recommended duration of one HFT session is 40 min. All the HFT group participants while undergoing sessions in the Cocoon will be dressed in bathing suits.
46115991|NCT04089410|Device|Placebo Hyperthermic Fitness Treatment|Attenuated heating with less heat set (20-30 degrees C◦). This results in no increase of core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual HFT, and will be in the capsule for the same period of time.
45470594|NCT03694327|Device|CT-101-M|Mobile Application
45470595|NCT03694327|Device|QuitGuide|Mobile Application
45470596|NCT01380158|Device|Cup pessary (Bioteque America, Inc)|Placement of cup pessary in the vagina after randomization
45470597|NCT04239222|Device|Revo-M|Investigational energy storage and return prosthetic foot with using novel elastic elements.
45470598|NCT04239222|Device|Taleo|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transfemoral amputee subjects
45470599|NCT04239222|Device|Proflex XC|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transtibial amputee subjects
45470600|NCT02566304|Drug|Fludarabine|Given IV
46027400|NCT01217957|Drug|Ixazomib|Ixazomib capsules
46027401|NCT01217957|Drug|Lenalidomide|Lenalidomide capsules
46027402|NCT01217957|Drug|Dexamethasone|Dexamethasone tablets
46027403|NCT05260879|Behavioral|Diabetes prevention program|Adaptation of the Centers for Disease Control and Prevention (CDC) Diabetes Prevention Program Power to Prevent for use in low income neighborhoods in Bamako, Mali
46027404|NCT00939094|Drug|AZD2066|Capsule, once daily
46115992|NCT04089410|Other|Physical Examination|"Resting hearth rate (HR), Systolic and Diastolic blood pressure (SBP and DBP) values are measured twice in supine position using an automatic tonometer after 5 min of rest.~Body mass (BM) and height are measured to calculate Body Mass Index. Body composition is assessed with the use of portable body-impedance-meter for the whole body impedance-analysis.~Body core temperature, Blood pressure (BP) and Heart rate (HR) are measured before and right after each session. Arterial oxygen saturation (SpO2) and HR is monitored continuously by the use of a pulse oximeter, attached to the index fingertip of non dominant hand."
46115993|NCT04089410|Other|Assessment of Cardiorespiratory Fitness|An assessment of exercise tolerance and cardiorespiratory fitness (ET, CRF) is carried out with the use of Cardiopulmonary Exercise Test - CPET). Testing is carried out using a gas analyzer and an Intertrack treadmill. Evaluation of gas exchange parameters conducted according to a given program - Cardiopulmonary load testing.
46115994|NCT04089410|Other|Autonomic Balance, Orthostatic and Hypoxic tolerance|"Evaluation of Autonomic balance is assesed using Heart Rate Variability (HRV) analysis. The HRV test relies on a 5-min RR interval (time in milliseconds between two R waves of the electrocardiogram complex) recorded at rest for 5 min supine (SU) followed of 5 min resting time. Measurement of the interval duration between two R waves of the cardiac electrical activity are performed with a HR monitor.~Orthostatic tolerance is assessed after ANS balance assessment by HRV analysis to continue RR intervals registration for 3 min after participant was asked to stand up taking a vertical position near the couch.~The individual sensitivity to hypoxia is determined by conducting a 10-minute hypoxic test (HT) - breathing through a facial mask by a gas mixture with 11% of O2, with minute-by-minute monitoring of HR and hemoglobin saturation by oxygen (SaO2). Arterial blood pressure is recorded before and after HT."
45470601|NCT02566304|Radiation|Total-Body Irradiation|Undergo TBI
45470602|NCT02566304|Biological|T Cell-Depleted Donor Lymphocyte Infusion|Undergo DLI
45470603|NCT02566304|Drug|Cyclophosphamide|Given IV
45470604|NCT02566304|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
46027405|NCT00939094|Drug|Placebo|Capsule, once daily
46027406|NCT04297371|Diagnostic Test|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
46027407|NCT05260801|Other|Bright Lighting|The bright lighting condition will administer the light intensity as determined from the finding of Study 1. Bright lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day.
46027408|NCT05260801|Other|Placebo Lighting|The placebo condition will expose participants to 150 lux, a light level that is equivalent to average room lighting. Placebo lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The placebo lighting condition will be applied to minimize the bias and false improvements that might occur due to experiencing new lighting conditions and devices.
45470605|NCT02566304|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC transplant
45470606|NCT02566304|Drug|Tacrolimus|Given PO
45470607|NCT02566304|Drug|Mycophenolate mofetil|Given IV
45470608|NCT02566304|Other|Laboratory Biomarker Analysis|Correlative studies
45470609|NCT03750097|Behavioral|Comfortable walking velocity (CWV)|Walking for 250 Steps with self-selected comfortable walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT)
45470610|NCT03750097|Behavioral|Slow walking velocity (SWV: CWV - 20%)|Walking for 250 Steps with slow walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT). Slow walking consists of walking with 20% slower than the self-selected comfortable walking velocity by following a researcher who controls the walking velocity with a measuring wheel.
46027409|NCT01217801|Drug|Ondansetron (ODFS)|Ondansetron Orally Dissolving Filmstrip Ondansetron (ODFS)
46027410|NCT01217801|Drug|Ondansetron (ODT)|Ondansetron Orally Disintegrating Tablet Ondanestron (ODT)
46027411|NCT02693509|Other|GWTG Heart Failure program|Evidence based guideline recommended therapies and counseling prior to hospital discharge
46027412|NCT04318769|Behavioral|AFFIRM|AFFIRM is an 8-session manualized group coping skills intervention focused on reducing sexual risk behaviours and psychosocial distress among SGMY. AFFIRM is delivered by two facilitators (primarily social workers and peers) through a combination of education and rehearsal (i.e., simulation of real-life experiences) in a manner that affirms participants' sexual and gender minority identities and experiences.
46027413|NCT00935818|Drug|Varenicline|varenicline - 1 mg bid for 12 weeks
46027414|NCT00935818|Drug|placebo|placebo for 12 weeks
46115995|NCT04089410|Other|Psychological Testing|"Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36), which is a self-completed quantity of health-related QoL.~Participants are asked to complete the Pittsburgh Sleep Quality Index (PSQI), a retrospective self-report measure assessing their quality of sleep during the last three weeks preceding the study.~Anxiety level is estimated by using State and Trait Anxiety Scales (SA and TA) developed by Ch. Spielberger~Subjective Ratings of Thermosensation and Pain.Participants rate their comfort, thermosensation, and pain by fixing results in visual-analogous scale (VAS) while passing each of HFT treatment."
46115996|NCT04089410|Other|Measurement of Blood Markers|Periferal venous blood (10 ml) sumples of the fastest (overnight fast) study subjects are withdrawn by a qualified laboratory technician via aseptic technique from the antecubital vein in the sitting position, using sterile needles and are collected. Serum BDNF, HGH, HSPs (60, 70, 90) concentrations are determined.
45838942|NCT04347096|Behavioral|mHealth Intervention|"The mHealth Intervention will provide sedentary workers with evidence-based information on diet, physical activity and sedentary behavior, and tailored feedback on their responses to daily records. Key features of this intervention will include individualized feedback and multimedia presentation in the form of web app. The intervention group will also receive a reliable device for wireless physical activity tracking for monitoring step counts.~The web app will consist of seven major components: (1) daily healthy eating goals and records; (2) daily physical activity goals and records; (3) daily stand-up goals and records; (4) advice and reminder; (5) educational and motivational tools; (6) personal and team health ranking; and (7) online social network. In addition, the intervention will be enhanced with follow-up booster coaching calls bi-monthly at 2, 4, 6, 8 months after the 12-week intervention."
46027415|NCT00935818|Drug|bupropion SR|bupropion sr - 150 mg bid for 12 weeks
46115997|NCT03953040|Diagnostic Test|intracoronary imaging (IVUS, OCT)|Patients presenting with non STE-ACS will be subjected after performing PCI of the culprit lesion to intracoronary imaging with the help of IVUS and OCT of the non-culprit lesions to detect and image the so-called vulnerable plaques
46115998|NCT04092608|Procedure|GDFT|The titration of fluid will be based on stroke volume variation. The goal is to maintain this variable < 13% during surgery with multiple mini fluid challenge of 100 ml of balanced crystalloid.
46115999|NCT04092608|Procedure|LOW CVP (restrictive group)|Goal = CVP < 7mmHg and only 2 ml/kg/h max during surgery.
46027416|NCT05260567|Behavioral|Exercise and Lifestyle Change|"Patients will undergo to weekly phone call/videoconference for 12 weeks and discuss the behaviour change.~They also will undergo to home-based exercise training will be performed twice a week for 12 weeks via Zoom (up to 5 patients per session). Each session will be comprised of warm-up (10 min), the main part (15 to 20 min), and cooldown (5 to 10 min). The training aims to develop resistance, aerobic and functional capacity such as getting up, walking, pulling, pushing, throwing, transferring body weight or external loads. In addition, patients will be encouraged to increase their physical activity. Patients will be provided with a Fitbit device to monitor their step count and will be recommended to increase their previous week's average step count by 10%."
46027417|NCT01216319|Device|Nipple reconstruction|Biodesign® Nipple Reconstruction Cylinder
46027418|NCT00607516|Procedure|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
46027419|NCT00607516|Procedure|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
46027420|NCT04804345|Other|standard of care|retrospective study: standard of care
46027421|NCT02709265|Drug|amikacin/fosfomycin|single aerosolized dose
46027422|NCT00611845|Drug|Aprotinin (Trasylol, BAYA0128)|Trasylol at either 1,000,000 KIU or 2,000,000 KIU
46027423|NCT02709499|Device|0J LLLT|perform with the machine off
46027424|NCT02709499|Device|6J LLLT|irradiation will be perform with 4J
46027425|NCT01216163|Drug|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
46027426|NCT01216163|Drug|Acetaminophen|Single-dose of acetaminophen (1000mg)
46027427|NCT01216163|Drug|Placebo|Single-dose of placebo
46027428|NCT05260411|Biological|AK102|Administered AK102 450 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
46027429|NCT05260411|Biological|AK102|Administered AK102 600 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
46027430|NCT05260411|Drug|Placebo|Administered placebo by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
45754522|NCT03585140|Drug|Adapalene 0.1% Gel|Adapalene 0.1% gel daily at night for 12 weeks, applied on the face, chest and back.
45754523|NCT03585140|Drug|Doxycycline|Doxycycline 100 mg per day orally, before breakfast
45754524|NCT03584984|Procedure|Mixture of Autogenous bone & Anorganic Bovine Bone (ABB)|Filling the socket with Mixing of autogenous bone graft and anorganic bovine bone in a 50:50 ratio
46027431|NCT05260255|Drug|vitamin D2 ( calciferol )|add on vitamin D2( calciferol ) 40,000 IU/wk ( 2 cap) for 12 weeks
45754525|NCT03584984|Procedure|Anorganic Bovine Bone (ABB)|Filling the socket with Anorganic bovine bone graft material only
45754526|NCT03584984|Procedure|Absorbable gelatin sponge|Filling the socket with an absorbable gelatin sponge foam pack
45754527|NCT00575887|Drug|Temozolomide|100 mg/m2/day, (PO) orally, on days between 1 and 21 of each 28 day cycles. Number of cycles: Until progression or unacceptable toxicity
46116000|NCT00723294|Procedure|cryosurgery|
46116001|NCT00723294|Procedure|therapeutic conventional surgery|
45681981|NCT01670890|Drug|TMZ plus CDDP|patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1 to 28,for 6 cycles
46116002|NCT04072029|Procedure|Phacoemulsification with intraocular lens implantation|Phacoemulsification (2.2mm coaxial, viscoelastic shield, experienced surgeon) with intraocular lens implantation (acrylic hidrophobic)
46116003|NCT04092140|Device|ultrasound|easy new non invasive tool
46116004|NCT04092296|Other|resin infiltration|using infiltrant resin intervene proximal caries
46027432|NCT05260255|Drug|Placebo|add on placebo ( 2 cap ) for 12 weeks
46116005|NCT04092296|Other|remineralization|using fluoride to remineralize proximal caries
46116006|NCT04092296|Other|sham|replace resin with water
46116007|NCT02577705|Behavioral|Self Empowerment Groups|The Self Empowerment Groups (SEG) curriculum draws key components from the S.E.L.F. tool within Sanctuary, focusing the four domains: creating personal, emotional, moral and physical safety (S), processing and managing emotions (E), recognizing loss and letting go (L), and developing goals for a sense of future (F). S.E.L.F. establishes a common language that all people who have experienced adversity can use to organize their lives and work towards building stable foundations to support their goals and invest in their potential.
46116008|NCT02577705|Behavioral|Financial Empowerment|The Financial Empowerment curriculum developed for this study consisted of interactive exercises, worksheets, and journal assignments that fostered understanding and practice of banking, building credit and debt management, making the most of one's money, and setting financial goals for oneself and one's family. Content focused on identifying and harnessing the internal and external resources that participants can leverage to begin taking steps towards financial self-sufficiency.
45470611|NCT03750097|Behavioral|Fast walking velocity (FWV: CWV + 20%)|Walking for 250 Steps with fast walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT). Fast walking consists of walking with 20% faster than the self-selected comfortable walking velocity by following a researcher who controls the walking velocity with a measuring wheel.
45470612|NCT04732260|Drug|Letermovir|"Each patient will receive 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP.~5 women will receive 240 mg. 5 women will receive 480 mg."
45681982|NCT01676428|Radiation|Radiotherapy|"The investigational treatment will be prescribed as a 2-tiered dose scheduled dependant on target size.~For lesions <5cm, a single fraction of 26Gy will be prescribed. For lesions ≥5cm a fractionated course of 14Gy by 3 fractions will be prescribed, delivered at least 48 hours apart."
45681983|NCT04577794|Drug|GLPG3970|GLPG3970 powder and solvent for oral solution reconstituted prior to use.
45681984|NCT04577794|Drug|Placebo|Placebo powder and solvent for oral solution reconstituted prior to use.
45681985|NCT04551196|Drug|Alternating Acetaminophen and Ibuprofen|Subjects will alternate their post-operative acetaminophen and ibuprofen every 3 hours.
46027433|NCT00612469|Drug|Sodium Fluoride|Topical application of 1.23% sodium fluoride to the dentition, every 24 hours, during 6 consecutive days
45838943|NCT04347096|Behavioral|Control Intervention|The control intervention group will receive educational tools, which will provide knowledge on benefits of physical activity and healthy eating, health risks of sitting and unhealthy diets, and recommendations on physical activity and a balanced healthy diet for good health.
46027434|NCT00612469|Drug|vancomycin hydrochloride|Topical application of 3% vancomycin hydrochloride to the dentition, every 24 hours, during 6 consecutive days
46027435|NCT00612469|Drug|vancomycin hydrochloride|Topical application of 10% vancomycin hydrochloride to the primary dentition, every 24 hours, during 6 consecutive days
46027436|NCT00612469|Drug|chlorhexidine digluconate|Topical application of 1% chlorhexidine digluconate to the dentition, every 24 hours, during 6 consecutive days
46116009|NCT02577705|Behavioral|Matched Savings|Participants were assisted with opening a savings accounts at a local non-profit federal credit union (with 1:1 matches of up to twenty dollars per month) over the course of 12 months.
46116010|NCT00918450|Drug|ABT-263|"Continuous dosing until disease progression using one of the following formulations:~25 mg/mL oral solution OR 50 mg/mL oral solution OR 2.0 grams/bottle powder for oral solution of 25 mg/mL when mixed OR 2.0 grams/bottle powder for oral solution of 50 mg/mL when mixed"
46116011|NCT04092374|Procedure|Locking compression plates|Fixation of sternal fracture using locking compression mechanism
46116012|NCT02591628|Behavioral|HCTZ prescription conversion to chlorthalidone|The intervention is simply a prescription conversion and the main outcome is whether or not patients accept the conversion and treatment with chlorthalidone.
46116013|NCT04090112|Drug|10% lidocaine sprayed|four puffs of 10% lidocaine sprayed at the cuff of ETT and four puffs at laryngeal inlet
46116014|NCT04090112|Drug|2% lidocaine intravenous|15 mg/kg of 2% lidocaine intravenous injection prior to extubation
46027437|NCT00933244|Dietary Supplement|High Dose Vitamin D3|Yellow gel-cap vitamin D3 at 50,000 International Units daily for 15 days then two times a month for 350 days. Daily white placebo pills.
46027438|NCT00933244|Dietary Supplement|Low Dose Vitamin D3|White gel-cap vitamin D3 at 800 International Units to take orally, daily for 365 days. Intermittent yellow placebo pills.
46027439|NCT00933244|Dietary Supplement|Placebo|Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days. White gel-cap placebo pills once daily for 365 days.
46027440|NCT02709187|Drug|DP-R208|Investigational product is prescribed to all of randomized subjects
46027441|NCT02709187|Drug|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
46027442|NCT02709187|Drug|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
46116015|NCT02590770|Behavioral|attention modification|participants will receive gaze-continent feedback according to their viewing patterns
46116016|NCT02590770|Other|Placebo|participants will receive non-gaze-continent feedback unrelated to their viewing patterns
46116017|NCT04091906|Device|Peripheral blood mononuclear cell apheresis|Peripheral blood mononuclear cell donation for tumor immunotherapy study of UCAR-T cells
45470613|NCT04799964|Device|Flow Diverter (Tonbridge)|The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introducer sheath. The stent and the delivery guide wire are pre-installed in the introducer sheath.
46116018|NCT03951948|Other|retrospective analysis of surgical performance, clinical and radiologic outcome|retrospective analysis of surgical performance, clinical and radiologic outcome
46116019|NCT04071717|Behavioral|NIRS neurofeedback|Neurofeedback as a treatment for people which can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
46116020|NCT04071717|Behavioral|Sham NIRS neurofeedback|Sham NIRS neurofeedback
46116021|NCT02597504|Other|Pen and paper neuropsychological test|Will be administered for Construct Validity to determine agreement with Quick Test
46116022|NCT02597504|Device|Quick Test|Quick Test, computerized test will be administered to all subjects.
46116023|NCT00747344|Drug|Placebo - Controlled Period (CP)|Placebo, Weeks 0-12
45470614|NCT04799964|Device|Tubridge (MicroPort)|Tubridge consists of a stent system and a microcatheter system. The stent system consists of a stent and a conveyor, the stent is self-expanding as well.
46116024|NCT00747344|Drug|Ustekinumab 45 mg - CP|Ustekinumab 45 mg, Weeks 0-12
45838944|NCT04346862|Drug|Acetyl-L-carnitine hydrochloride 500mg|The participants will receive treatment of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
45838945|NCT04346862|Drug|Placebo|The participants will receive treatment of placebo of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
46116025|NCT00747344|Drug|Placebo to ustekinumab 45 mg - after CP|Placebo at Weeks 0 and 4, then ustekinumab 45 mg at Week 12 and Week 16
46027443|NCT02708953|Procedure|Thoracic manipulation (Manipulation Group)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
46027444|NCT02708953|Procedure|Thoracic Manipulation (Control wait-list)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
46027445|NCT04262830|Diagnostic Test|Cardiac magnetic resonance imaging (MRI)|Cardiac magnetic resonance imaging will be performed to evaluate cardiac remodeling, function, and tissue characteristics
45470615|NCT02517398|Drug|MSB0011359C|Subjects will receive intravenous infusion of MSB0011359C once every 2 weeks in a dose escalation fashion until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
45470616|NCT03330288|Drug|Theraflex, BAY 874017|The first three weeks which do have a different posology (3 capsules a day) according to the label should be entered as a distinct period to the treatment period with a recommended posology of 2 capsules a day
45838946|NCT04347174|Drug|Suspension of heat killed (autoclaved) Mycobacterium w|Patients will be randomized to receive either Mycobacterium w in combination with standard care as per hospital practice or standard care alone in COVID-19 as per hospital practice.
46027446|NCT04262830|Diagnostic Test|Echocardiography|Echocardiography, heart ultrasound, will be performed in conjunction with cardiac MRI.
46027447|NCT04262830|Diagnostic Test|Electrocardiogram|Measuring conduction abnormalities
46027448|NCT05258929|Other|Data collection (Prior and planned treatments, allograft)|MHLC questionnaire (Multidimensional Health Locus of Control) when a novel therapeutic strategy is set up
46116026|NCT00747344|Drug|Ustekinumab 45 mg - after CP|Ustekinumab 45 mg at Weeks 0 and 4, then placebo at Week 12 and ustekinumab 45 mg at Week 16
46116027|NCT00580983|Radiation|IMRT|
46116028|NCT00580983|Drug|Paclitaxel|
46116029|NCT00580983|Drug|Carboplatin|
46116030|NCT00580983|Drug|Cisplatin|
46116031|NCT00580983|Drug|5-Fluorouracil|
46116032|NCT02576223|Drug|Ropivacaine hydrochloride|Ropivacaine injected perineural at the suprascapular nerve.
46116033|NCT02576223|Drug|Isotonic Saline|Saline injected perineural at the suprascapular nerve.
46116034|NCT04089878|Procedure|Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration|Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration
46116035|NCT04089878|Other|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
46116036|NCT00917618|Other|Exercise|Patients randomized to treatment arm attended 2-3 Spinning classes per week for 12 weeks.
46116037|NCT00917618|Other|Control|Patients randomized to the control arm were instructed not to change their baseline exercise programs
46116038|NCT02309931|Procedure|antiperistaltic side-to-side ileocecal anastomosis|Right laparoscopic hemicolectomy + antiperistaltic side-to-side ileocecal anastomosis
46027449|NCT00930046|Device|Ropivacaine wound catheter|19 gauge fenestrated wound catheter inserted into the fascial planes of the surgical site prior to skin closure with a separate exit site.
46027450|NCT00930046|Device|Saline wound catheter|19 gauge fenestrated wound catheter will be inserted into the fascial planes of the surgical site prior to wound closure
46027451|NCT05244031|Procedure|superficial erector spina plane block|The investigators performed superficial erector spina plane block to that patient group for postoperative analgesia
46116039|NCT02309931|Procedure|isoperistaltic side-to-side ileocecal anastomosis|Right laparoscopic hemicolectomy+isoperistaltic side-to-side ileocecal anastomosis
46116040|NCT04071873|Diagnostic Test|Point-of-care HIV testing|Participants will undergo an HIV 1/2 antibody point of care test (Oraquick) and receive pre- and post-test counselling.Participants with positive tests will be referred to the HIV clinic for Western Blot confirmation, and linkage to care.
46027452|NCT05244031|Procedure|Standard (opioid-based) analgesia|The investigators performed intravenous opioid infusion with PCA to that patient group for postoperative analgesia
46116041|NCT04071873|Behavioral|HIV testing education|Participants will be provided with education on community based HIV resources.
46116042|NCT02577627|Device|PrediCare|
46116043|NCT02599376|Device|LiDCOrapid|Cardiac output will be non invasively monitored by using 2 cuffs on fingers.
46116044|NCT02577393|Drug|EGCG|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Immediately at the beginning of radiotherapy, the EGCG solution is given until two weeks after radiotherapy completed. Steroids, non-steroidal anti-inflammatory drugs, narcotics, local anesthetics, or other antibiotic/antifungal therapy are not given unless esophagitis progressed to grade 4.
46116045|NCT02577393|Drug|EGCG|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Patients begin medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
46116046|NCT02577393|Drug|mLDG|mLDG (lidocaine 0.16mg/mL, dexamethasone 0.02mg/mL, and gentamycin 0.16mg/mL) dissolved in 0.9% saline solution was administered three times a day. Patients were given oral mLDG solution, and began medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
46116047|NCT02599298|Device|Continuous Positive Airway Therapy|
46116048|NCT02599298|Behavioral|Sleep-Study Guided Multidisciplinary Therapy|
46116049|NCT02241291|Procedure|Percutaneous coronary intervention|Non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. A deflated balloon or other device on a catheter is fed from an artery (such as the inguinal femoral artery or radial artery) up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery
45470617|NCT01383278|Behavioral|Computer-directed 5 A's intervention for smoking|Computer-directed 5 A's intervention for smoking
45470618|NCT01383278|Behavioral|Screening and resource provision|Screening and resource provision
46027453|NCT05155306|Drug|BI 1358894, intended Commercial Formulation (iCF) (T)|Test Treatment (T)
46116050|NCT00753896|Drug|exenatide|subcutaneous injection, 2.0mcg, once weekly
46116051|NCT02597114|Drug|AGT-181|intravenous infusion over 3-4 hours
46116052|NCT00716976|Drug|sodium thiosulfate|Given IV
46116053|NCT00716976|Procedure|examination|Patients undergo audiological assessments periodically
45838947|NCT04347174|Drug|Placebo|All patients will continue to receive standard therapy as per hospital practice till considered requisite by the treating physician
46027454|NCT05155306|Drug|BI 1358894, Trial Formulation 2 (TFII) (R)|Reference Treatment (R)
46027455|NCT05240677|Procedure|Upper GIT endoscopy|Upper gastrointestinal endoscpy for all participants and gastric biopsy for histopathological examination for suspicious lesions
46116054|NCT04852107|Other|Spinal Cord Stimulation, association of both (DUAL), Dorsal Root Ganglion stimulation|"Lead Implantation which will be conducted in 2 steps:~Lead implantation: 8-contact SCS percutaneous lead on SC and 8-contact lead on DRG.~Neurostimulation trial phase (Mode DUAL). IPG implantation + Randomization + 1st leads programming (SC, DRG or DUAL stimulation according to randomization sequence).~2nd leads programming (SC, DRG or DUAL stimulation according to randomization sequence). 3rd leads programming (SC, DRG or DUAL stimulation according to randomization sequence). All patients will be switched to Burst waveform for a 1- month follow-up period while keeping the last allocated stimulation type in the randomized crossover arm."
46116055|NCT00743444|Drug|AZD3355|65 mg capsules, oral, 3 single doses
46027456|NCT04262752|Device|intermittent colonic exo-peristaltic massage treatment with the MOWOOT medical device|"The MOWOOT massager belt is connected to the desktop device and is the component which is in contact with the subject giving the abdominal massage action.~The massager belt, which is placed on the user's abdominal area, administers a specific abdominal massage on the ascendant and descendent segments of the colon. This massage emulates the techniques used by professional therapists through a series of pneumatic actuators operating like the movement of a wave transmitting movement through the colon. The type and speed of the massage can usually be regulated by an algorithm that controls the operation from the desktop device.~For the present clinical trial, time and force will stay fixed on 20 minutes and force 3 (0'6-0'7 bar). Subjects will not be able to choose other massage options. Subjects should use the MOWOOT device once a day for 20 min (1 complete treatment) ideally at the same hour every day for the 4 weeks of the interventional treatment period."
46027457|NCT03823651|Behavioral|Interval training|Patients will be asked to complete up to 3 x 30-minute structured high intensity interval training aerobic exercise sessions/week. For the first session, patients will come to the Duke Center for Living for in person evaluation and training. After the initial training session in person, a subsequent training session will take place at the patient's home via iPad/iPhone videoconference using a device provided to the patient to provide additional support and the opportunity to answer questions. Subsequent sessions will be done independently by patients, but study staff will be available via iPad/iPhone if questions arise.
46027458|NCT03823651|Behavioral|Psychiatric consult|Subjects who score below threshold on the PHQ2/PHQ9, PC-PTSD/PCL-5, PROMIS-Depression and/or PROMIS-Anxiety assessments will be referred to a psychiatrist for follow up.
46027459|NCT03823651|Behavioral|Nutrition/diet evaluation|PG-SGA, ASA24, food group tracking Assessments and Vit D, Vit A, albumin, prealbumin, lipids, A1c levels will be used to provide weekly feedback for one month
46027460|NCT03823651|Behavioral|Referral to Social Worker|Subjects who score below threshold on the PROMIS-Emotional Support and/or PROMIS-Social Isolation assessments will be referred to a social worker for follow up
46116056|NCT00743444|Drug|Placebo|capsules, oral, 3 single doses
46116057|NCT02598284|Other|Point of Care|Practice facilitators will work with practices to implement strategies to improve ABCS care during the patient encounter. Some examples of these types of quality improvement initiatives are electronic reminders and clinical decision support to prescribe aspirin or a statin at the time of a visit, improving how your practice collects blood pressure measures to increase clinicians' willingness to act on readings, or electronic reminders for nursing staff that there is no lipid panel in record and have a standing order to act on this.
46116058|NCT02598284|Other|Population Management|"Practice Facilitators will work with practices to both implement Point of Care strategies as well as population management strategies. These practices will use their EHR and/or receive training to use the popHealth software package, which works with data from the EHR, to generate lists of high-risk patients that need outreach for one of the ABCS domains (such as conducting outreach to patients who are not on aspirin who would benefit from this therapy).~Practices in this arm will receive the opportunity to link to community resources such as pharmacists who could assist patients with medication management or tobacco quit lines through the HealtheRx program."
46027461|NCT04712071|Drug|Ketamine Hydrochloride|Patients with a diagnosis of Gulf War Illness using Kansas Criteria will be enrolled to receive a single 40 minute infusion of 0.5 mg/kg ketamine.
46116059|NCT00616395|Device|No intervention|
46116060|NCT05673369|Drug|CKD-387|1 Tablet
46116061|NCT05673369|Drug|D484|1 Tablet
46116062|NCT00743366|Drug|Marijuana|0,6.2% THC
46116063|NCT00743366|Drug|Quetiapine|200 mg/day
46116064|NCT00743366|Drug|Placebo oral capsule|
46116065|NCT01760655|Drug|Fludarabine phosphate|Given IV
46116066|NCT01760655|Drug|Busulfan|Given IV
46116067|NCT01760655|Radiation|Total-Body Irradiation|Undergo TBI
46116068|NCT01760655|Biological|Therapeutic Allogeneic Lymphocytes|Undergo DLI
45838948|NCT04346784|Behavioral|maintaining positive working memory training|Participants complete 10 sessions of maintaining positive working memory training during a two-week period. Each session consists of 15 blocks.
45838949|NCT04346784|Behavioral|repressing negative working memory training|Participants complete 10 sessions of repressing negative working memory training during a two-week period. Each session consists of 15 blocks.
45838950|NCT04346784|Behavioral|Positive ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes.
46116069|NCT01760655|Drug|Cyclophosphamide|Given IV
46116070|NCT01760655|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
46027462|NCT05151328|Drug|Plecanatide|Plecanatide or Placebo; Route of Plecanatide/placebo administration: tablet; dosage: 30mg, dosage form oral; Frequency of administration: QD
46027463|NCT02708875|Other|Mixed Meal Challenge|Liquid mixed meal (300 calories - fat, carbohydrate, and protein).
46116071|NCT01760655|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
46116072|NCT01760655|Drug|Tacrolimus|Given IV
46027464|NCT02708875|Other|Glucose Challenge|Glucose drink (50g glucose)
46027465|NCT00609388|Drug|Tacrolimus|Immunosuppression, intraoperative intraportal infusion of 1ml Tacrolimus with a concentration of 20 ug/mL
46116073|NCT01760655|Drug|Mycophenolate Mofetil|Given IV
45470619|NCT04685226|Drug|ICP-723|ICP-723 is a white, round, uncoated table
46116074|NCT01760655|Other|Laboratory Biomarker Analysis|Correlative studies
46116075|NCT02597348|Procedure|Liver Transplantation|The patient of the arm LT+C are treated by experimental liver transplantation preceding the Non experimental standard chemotherapy (according to usual practices) .
46027466|NCT00609388|Other|Saline solution 0.9% (250mL)|intraoperative intraportal infusion of Saline solution 0.9% (250mL)
46027467|NCT02709031|Drug|Cicletanine + magnesium|"Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD (once daily); it was well tolerated at that dose. The drug has had an excellent safety profile in its ~1.8 million patient-years of post-launch experience,~Magnesium is being added to cicletanine in order to decrease losses of potassium and sodium, thereby enhancing cicletanine's safety at higher doses."
46116076|NCT00721968|Device|Glaucoma Stent Surgery (GTS400 Stent)|ab interno trabecular bypass stent surgery
46116077|NCT00721968|Procedure|cataract surgery alone|Cataract surgery alone
46116078|NCT00743288|Drug|Melphalan|Same as above
46116079|NCT00743288|Drug|Panobinostat|
46116080|NCT04073511|Drug|Eungyosan|This drug is a commercially available drug, manufactured according to the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. Dosage is 1 packet, 2.3g, 3 times daily, 6.9g total daily dose. The total duration of administration is up to 8 days.
45470620|NCT02463500|Other|DFU|Standard care.
45470621|NCT04680156|Drug|Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies|No treatment to be administered - Observational only
45470622|NCT01383980|Dietary Supplement|Continuous Tube Feedings|Tube feeds continued up until elective surgery.
46116081|NCT04073511|Drug|Samsoeum|This drug is a commercially available drug, manufactured according to MFDS regulations and the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. 3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.
45470623|NCT03178370|Device|Gastric Electrical Stimulation|Temporary and permanent gastric electrical stimulation
45470624|NCT01383902|Other|Food type|1ml, 1ml, 5ml, 50ml, 6ml, 20ml, 60ml and 200ml of chocolate dessert or 1 g, 1 segment (5 segments to a bar) repeated 6 times, 2 bars repeated twice of chocolate bars
46116082|NCT04073511|Drug|Placebo|It is composed of lactose carb, corn starch, caramel pigment, and ginseng flavor powder. It is brown granule and made to be recognized as Korean medicine. Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.
46116083|NCT02591394|Behavioral|STEP Clinic|Patients will visit with STEP clinic staff (including a stroke nurse practitioner or stroke doctor) to receive personalized goals, stroke education (including diet and exercise), instructions to self-monitor using blood pressure cuff, and prescription medications Patient will be scheduled for additional clinic follow-up or be contacted for telephone follow-up for management of your blood pressure. Questionnaires will be administered to determine medication adherence and persistence (following instructions for prescribed medication), disability, depression, cognition, self-efficacy, and sleep apnea. The care plan determined by the STEP clinic will be shared with the patient's primary care provider.
46116084|NCT02591394|Behavioral|Usual Care|"Patients will complete questionnaires related to medical history and health behaviors prior to initial visit.~After being seen by the stroke neurologist, patients may be scheduled to return to the stroke clinic according the doctor's recommendations.~Recommendations for blood pressure and risk factor monitoring will be sent to primary care providers."
46116085|NCT04089254|Behavioral|Inpatient Psychiatry|Inpatient hospitalization to treat and stabilize suicidal thoughts and behavior.
46116086|NCT04089254|Behavioral|Outpatient Crisis Intervention Clinic|Outpatient psychiatric clinic that provides crisis intervention to treat and stabilize suicidal thoughts and behavior.
46116087|NCT02579187|Procedure|tooth extraction|The study tooth will be removed
45470625|NCT01383824|Device|Silent™ Hip|A short cementless, femoral component for use in total hip arthroplasty
45470626|NCT03084536|Drug|Bupivacaine|-Given after general anesthesia
46116088|NCT02579187|Radiation|CBCT scan|a CBCT scan limited to the dental arch that includes the study side will be obtained
46116089|NCT02579187|Drug|Anesthesia|all subjects will receive local infiltrative anesthesia, prior to extraction of the tooth
46116090|NCT02579187|Other|clinical measurements|After tooth extraction, clinical measurements of the site will be obtained and recorded (keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness
46116091|NCT02579187|Drug|Biodegradable sponge (type I bovine collagen)|control group subjects will receive a biodegradable sponge (type I bovine collagen) to stabilize the clot
46027468|NCT02709031|Drug|Cicletanine|Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD; it was well tolerated at that dose. The drug has had an excellent safety profile in its ~1.8 million patient-years of post-launch experience,
45681986|NCT04551196|Drug|Combined Acetaminophen and Ibuprofen|Subjects will take their post-operative acetaminophen and ibuprofen together every 6 hours.
45681987|NCT04510168|Drug|11C-ER176|PET imaging to measure 18kDa translocator protein; target imaging dose of up to 20 millicurie (mCi)
46027469|NCT05233111|Behavioral|Brief Prolonged Exposure Therapy|Brief PE will include 3 therapy sessions, each lasting approximately 60 minutes.
46116092|NCT02579187|Drug|10µg of pSil-miR200c|subjects in the experimental group will receive a 10µg of pSil-miR200c plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
46116093|NCT02579187|Procedure|cross mattress suture|The site will be stabilized with a simplet external, cross mattress suture
46116094|NCT02579187|Drug|10µg of PMIS miR200a plasmids|subjects in the experimental group will receive a 10µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
46116095|NCT02579187|Drug|5µg of pSil-miR200c and 5µg of PMIS miR200a|subjects in the experimental group will receive a 5µg of pSil-miR200c and 5µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
45470627|NCT03084536|Drug|Gabapentin|"As per routine care~Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years."
46027470|NCT05233111|Behavioral|Treatment as Usual|This may include an evaluation by a licensed psychologist and continued follow-up psychotherapy as needed. Treatment as usual participants will have follow-up assessments at 1, 3, and 6 months.
46027471|NCT04262674|Other|Cognitive-motor training|Simultaneous cognitive-motor training and strength training
46027472|NCT02887937|Drug|Definity|The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein. Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study. The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl). Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied. During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.
46027473|NCT00606112|Drug|Trodusquemine (MSI-1436)|A single dose will be administered on Day 0. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2, 10mg/m2 in cohort 3 and 15mg/m2 in cohort 4/
46116096|NCT02579187|Procedure|Blood|Subjects will have venipuncture performed to obtain a small blood sample (approx. 2 ml) to assess for miR-200c and PMIS-miR-200a expression and liver function (AST, ALT, bilirubin levels)
46116097|NCT02579187|Other|Photos/videos|subjects will have photos and/or videos of the extraction site and/or implant taken at each visit.
46116098|NCT02579187|Procedure|Wound fluid|a small sample of wound fluid will be obtained from the extraction site in a minimally invasive manner using a paper point at 1, 2, 3 & 4 weeks post extraction
46116099|NCT02579187|Procedure|saliva|approximately 2 mls of saliva will be obtained in a minimally invasive manner at the time of extraction and at 14 weeks post extraction.
46116100|NCT02579187|Radiation|periapical xray|periapical xrays will be obtained at screening, 16 weeks and at 12 month followup time point
46116101|NCT02579187|Other|PVS impression|PVS impressions will be taken to plan the implant placement surgery. This will be done at the screening visit and also at 14 weeks post extraction.
46116102|NCT04092062|Device|ToothWave|RF-utilizing powered toothbrush for teeth whitening
46116103|NCT04092062|Device|powered toothbrush|regular powered toothbrush with no RF
46116104|NCT02590692|Biological|CPCB-RPE1|Patients will receive one CPCB-RPE1 implant of approximately 100,000 differentiated RPE cells attached to a small parylene membrane. The density of cells on the membrane represents the approximate density of RPE cells in the human eye. The membrane size was chosen to cover a substantial portion of the macular region of the retina.
45470628|NCT03084536|Drug|Celecoxib|"As per routine care~Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years.~Naproxen will be substituted for celecoxib in patients with sulfa allergies."
45470629|NCT03084536|Drug|Acetaminophen|-As per routine care
45470630|NCT03084536|Drug|Midazolam|-As per routine care
45681988|NCT04510168|Drug|[F-18]MK-6240|PET imaging to measure tau; target imaging dose of 4 to 5 mCi
45681989|NCT04510168|Drug|Florbetaben|PET radioligand that binds to amyloid plaques; target-imaging dose of up to 8.1 mCi
45681990|NCT04510168|Other|Magnetic Resonance Imaging|Brain MRI
45681991|NCT03155152|Other|DECT|The DECT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is imposed in a decremental fashion.
46116105|NCT04019912|Other|Gait Training plus music|GaitTrainer3 is a platform that integrates gait training via a treadmill and RAS. The device is indeed equipped with an instrumented deck that issues acoustic cues to determine the exact tempo and rhythm during gait training and visual real-time biofeedback to prompt patients to follow their gait pattern. In fact, the device provides online feedback, including step length, speed, and symmetry, to encourage patient progress and monitor patient performance. Patient footfalls were compared in real-time to the desired footfalls step by step and documented in a histogram.
46116106|NCT04019912|Other|Traditional Gait Training|The traditional training will be provided by a conventional treadmill.
46116107|NCT02579109|Other|memory test|
46116108|NCT02598440|Drug|Alendronate|Participants wil receive once-weekly oral alendronate (70 mg tablet)
46116109|NCT02598440|Drug|Ibandronate|Participants wil receive once-monthly oral ibandronate (150 mg tablet)
46116110|NCT02575989|Other|1: control group|Classic - current management of trauma patients by French medical teams
46027474|NCT05232955|Device|PET/MR scanner|Simultaneous PET and 3T MR scanning; protocol duration of approx. 100 min
46027475|NCT00606190|Procedure|Retrograde brain perfusion|observational
46116111|NCT02575989|Other|2: interventional group|"Intervention Name : monitoring, treatment, control and prevention of hypothermia~Continuous monitoring of body temperature~Ambulance warming (target : 30°C)~Patient warming with dedicated blanket~Infusion fluid warming (and temperature control)"
46116112|NCT04091594|Device|Flexible orthotic|Participants will receive the SIAFO to wear
46116113|NCT04091594|Device|Standard orthotic|Participants will received the standard AFO to wear
46116114|NCT02184663|Other|without APA program|Control Arm : chemotherapy alone
46116115|NCT02184663|Other|APA program|Experimental Arm : chemotherapy + APA program during 16 weeks (aerobic and muscular strength exercises)
46116116|NCT00750308|Drug|Ramipril|Ramipril 10 mg per day for three weeks
46116117|NCT00750308|Drug|Tadalafil|tadalafil 10 mg every other day for three weeks
45838951|NCT04346784|Behavioral|Positive placebo ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes
46116118|NCT00750308|Drug|placebo|placebo matching ramipril
45470631|NCT03084536|Drug|Fentanyl|-As per routine care
45470632|NCT05291936|Device|PRECISION1® for Astigmatism Contact Lenses|TEST
45470633|NCT05291936|Device|MyDay® Toric Soft Contact Lenses|CONTROL
45470634|NCT03289143|Drug|Semorinemab|Participants will receive Semorinemab intravenously (IV).
45470635|NCT03289143|Drug|Placebo|Matching placebo doses of Semorinemab given intravenously (IV).
45470636|NCT03289143|Drug|[18F]GTP1|[18F]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
46116119|NCT00750308|Drug|placebo|placebo matching tadalafil
46116120|NCT02577237|Behavioral|In-person education sessions|The intervention will be delivered by a radiation oncology nurse. Each of the four in-person sessions consists of approximately 30 minutes of educational content/simulation that addresses a specific caregiving topic and any issues or concerns that the caregiver may be experiencing.
46116121|NCT02577237|Behavioral|NCI Booklet|Radiation Oncology Nurse will hand participant the NCI booklet
45470637|NCT03311724|Drug|Tirzepatide|Administered SC
45470638|NCT03311724|Drug|Placebo|Administered SC
45470639|NCT05213312|Drug|Nivolumab|Nivolumab, 360mg intravenous infusion (ivgtt.), on DAY1, Q3W for two cycles;
45470640|NCT05213312|Drug|Cisplatin|80 mg/m2 on DAY2 with paclitaxel, Q3W or 80 mg/m2 on DAY1, Q3W ivgtt for two cycles
45470641|NCT05213312|Drug|Paclitaxel|175 mg/m2 on DAY2, with cisplatin Q3W, ivgtt for two cycles
45470642|NCT05213312|Drug|5Fluorouracil|800 mg/m2 on DAYS1-5 with cisplatin, Q3W for two cycles
45470643|NCT05213312|Procedure|Esophagectomy (minimally invasive)|4-6 weeks after neoadjuvant therapy.
45470644|NCT01379378|Device|Artificial urinary sphincter|Standard of care
45470645|NCT01379378|Device|InVance Sling|Standard of care
45470646|NCT01379378|Device|AdVance Sling|Standard of care
45470647|NCT01379378|Device|Virtue Sling|Standard of care
45470648|NCT01379378|Drug|Contigen|2.5-10 cc
45470649|NCT05276388|Other|biological bank|biological bank of subjects vaccinated against SARS-CoV-2 infection
45598636|NCT02292199|Device|TENS Low Frequency|TENS low frequency (4 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
45838952|NCT04346550|Other|Suction drain|Post operatively, in both arms including drain group and no drain group, parameters of pain was assessed by visual analog scale (VAS) from 0 (no pain) to 10 (worst pain), assessed at 1st postoperative day by the duty doctor or the nurse. VAS > 3 was considered as post surgical pain. The total number of hospital stay was noted from the day of operation till the day of discharge and discharge criteria was taken as a patient having pain as per VAS<3, no fever and tolerating oral intake
45838953|NCT04345848|Drug|Enoxaparin|Two different doses of anticoagulation
45838954|NCT04345770|Procedure|D2 radical gastrectomy|radical gastrectomy with D2 lymphadenectomy
46027476|NCT00606190|Procedure|Antegrade brain perfusion|observational
46027477|NCT05379010|Procedure|Endodontic Microsurgery|Surgical removal of 3 millimeters of the root-end, removal of the apical pathology, Root-end preparation and retrograde filling. The entire procedure is done under magnification.
46027478|NCT05225545|Drug|Sucrosomial Iron|Experimental Arm
46027479|NCT05225545|Drug|Oral Iron|Active Comparator
46027480|NCT05378932|Other|Actigraphy|Sleep efficiency recording at home by means of actigraphy during 10 consecutive days.
46027481|NCT05378932|Other|Recording of proximal and distal skin temperature and temperature of the bedroom|"Recording of proximal and distal skin temperature at home by data loggers placed on the skin during 10 consecutive days.~Recording of temperature of the bedroom by a data logger during 10 consecutive days."
45838955|NCT04345770|Drug|SOX neoadjuvant or postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.
46116122|NCT02577237|Other|Survey|written, qualitative assessments of areas including depression and anxiety, caregiver self-efficacy, care-giver self efficacy for head and neck cancer, health-related quality of life, patient performance status, demographics, and medical history.
46116123|NCT02577237|Other|Interview|A structured series of open-ended questions will be used during a telephone interview with participants at four weeks post radiation treatment.
46027482|NCT05378932|Other|Questionnaires assessing subjective sleep quality|"One-off questionnaires assessing subjective sleep quality. The Pittsburgh Sleep Quality Index (PSQI) evaluates sleep quality with questions about sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction during the last month.~The Epworth Sleepiness Scale evaluates daytime sleepiness and comprises 8 items (situations) during which individuals assess how likely they would fall asleep."
46027483|NCT05378932|Other|Sweat test|One-off measurement of sweating by a sweat test at the hospital.
46027484|NCT05378932|Other|Urine melatonin assay|Two urine melatonin at home during 24 hours, one during a week day and one during the weekend
46116124|NCT04091438|Drug|TAK-925|TAK-925 IV infusion.
46027485|NCT05378932|Other|Polysomnography|Sleep architecture assessed by a polysomnography during one night at home.
46116125|NCT04091438|Drug|TAK-925 Placebo|TAK-925 placebo-matching IV infusion.
46116126|NCT02579031|Device|Orsiro|Novel biodegradable-polymer sirolimus-eluting stent used during primary percutaneous coronary intervention
45598637|NCT02292199|Device|TENS Placebo|TENS was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
45838956|NCT04345770|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.
46027486|NCT05378932|Other|Standardized psychological and neuropsychological assessment|One-off psychological and neuropsychological assessment of patients with HED during a hospital visit
46027487|NCT05222971|Drug|Durvalumab|"Durvalumab 1,500 mg IV on Day 1~Every 4 weeks"
46116127|NCT02579031|Device|Xience|Durable-polymer everolimus-eluting stent used during primary percutaneous coronary intervention
46116128|NCT00750152|Drug|NAFT-500|topical cream application up to 4 weeks
46116129|NCT00750152|Drug|Placebo|placebo cream applied for up to 4 weeks
46116130|NCT02597192|Other|probiotic oral hygiene products with Bacillus (PIP, Chrisal)|products with Bacillus probiotics
46116131|NCT02597192|Other|oral hygiene products without Bacillus|products without Bacillus
46116132|NCT05392790|Other|Progressive resisted exercise training|Progressive resisted exercises will be started with the 8 maximum repetition test (8 RM) performed at progressive intensities. The subject will perform the 8 RM test at the beginning and the end of each cycle over the two-month training period. Each training session lasts sixty minutes and will be performed three times per week on alternate days.
46116133|NCT05392790|Drug|Calcium and Vit D|Traditional medical treatment in the form of Calcium, Vit D and Bi phosphnate.
45838957|NCT04345692|Drug|Hydroxychloroquine|oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet
45838958|NCT04345380|Other|Implantation of an Alcon Acrysof SN60WF intraocular lens|Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
45838959|NCT04345380|Other|Implantation of an AMO Tecnis ZCB00 intraocular lens|Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
45838960|NCT04345380|Other|Implantation of an Envista MX60 intraocular lens|Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
45838961|NCT04345458|Drug|prefilled liquid etanercept(Yisaipu)|
45838962|NCT04345458|Drug|lyophilized etanercept powder(Yisaipu)|
46027488|NCT05222971|Drug|Olaparib|"Olaparib 300 mg twice daily~Every 4 weeks"
46027489|NCT04168957|Drug|Oraxol|"Oraxol (oral paclitaxel + oral HM30181AK-US)~Paclitaxel: supplied as capsules HM30181 methanesulfonate monohydrate: supplied as HM30181AK-US tablets"
46027490|NCT00935584|Behavioral|Physician training in patient-centered emr use|This intervention was performed in between the pre-intervention (Baseline) clinic visit and post intervention clinic visit.
46116134|NCT05392790|Other|Aerobic exercises|Aerobic exercises will be applied at 70 - 80% of their maximum heart rate. Trained health professionals supervised the exercise program. Each exercise session will begin with a 5-10-minute warm-up, will be followed by 20 -30 minutes of aerobic activity, and will be concluded with a 5-10-minute cool-down period.
46116135|NCT04071483|Procedure|Cervical transforaminal epidural steroid injection|Cervical transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of cervical radicular pain.
46027491|NCT05201443|Device|Diode laser|Diode Laser is applied to one group as an adjunctive therapy.
46116136|NCT05404802|Device|Experimental group intervention|"Training session~Facilitators will facilitate participants' interaction with PARO for 7 main activities, namely: (1) hugging PARO; (2) expressing emotions to PARO: (3) remembering PARO; (4) feeding PARO; (5) sleeping PARO; (6) bathing PARO; (7) decorating PARO.~Free-play session~In these sessions, every participant can interact with one PARO without instructions but are under the safety supervision of a PARO facilitator."
45838963|NCT04345614|Drug|Auxora|Auxora will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Auxora will be administered intravenously (IV) over 4 hours.
46116137|NCT05404802|Device|Control group intervention|Facilitators will facilitate participants' interaction with PARO for 7 main activities, namely: (1) hugging PARO; (2) expressing emotions to PARO: (3) remembering PARO; (4) feeding PARO; (5) sleeping PARO; (6) bathing PARO; (7) decorating PARO.
46116138|NCT01387113|Other|Computed tomography perfusion imaging|As per standard of care at CPMC
46116139|NCT02597036|Drug|LY3127804|Administered IV
46116140|NCT02597036|Drug|Ramucirumab|Administered IV
45470650|NCT03846024|Device|RibFx Orthosis Belt|Each patient in the interventional arm will be fitted with a RibFx orthosis belt, which is to be worn during the majority of their day (excluding showering/bathing). It will be encouraged (though not mandatory) to wear at night. Patients in both the control and interventional arm will be expected to participate in pulmonary hygiene / toilet exercises with guided and independent incentive spirometry as per our normal routine and standard of care. There are no other interventions or procedures that the patients will be subjected to for the research trial- other procedures/interventions will be performed only if the clinical care team feels they are indicated.
45470651|NCT03311646|Other|Normal nicotine content cigarettes (NNC, Baseline)|Participants will exclusively smoke research cigarettes that have a normal nicotine content for five days/four nights while staying in a hotel.
45838964|NCT04345614|Drug|Placebo|Placebo will be given at 1.25 mL/kg on Day 1 and then 1.0 mL/kg on Days 2 and 3. All doses of placebo will be administered intravenously over 4 hours.
45838965|NCT04344912|Other|Data collection|Diagnostic and prognostic evaluation of cardiac patients hospitalized in CCU during the COVID-19 outbreak; patient's immune status regarding the presence of SARS-CoV-2 specific antibodies
45838966|NCT04344990|Procedure|Epidural analgesia - Group E|Postoperative analgesia with continuous epidural infusion (control group) with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min)
45838967|NCT04344990|Procedure|Femoral blockade - Group F|Postoperative analgesia with continuous femoral nerve blockade infusion with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min) .
46027492|NCT05201443|Device|Titanium curettes|Non-surgical treatment with titanium curettes were administrated to both groups.
46027493|NCT00612547|Drug|Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam)|"Tablet:~Children aged between 2 and 11 months: Artesunate 25 mg + Amodiaquine 67.5 mg et Children aged between 12 and 59 months: Artesunate 50 mg + Amodiaquine 135 mg Per os one intake per day/3 day"
46027494|NCT04266262|Behavioral|High-intensity interval training (HIIT)|"Supervised HIIT sessions (2x/week) will comprise cycling 10 x 60 secs at 85-95% maximum heart rate (HRmax) interspersed by 60 secs of low-intensity recovery.~Unsupervised HIIT sessions (1x/week) will involve 10 x 60 secs of walking or alternative (intensity of 7-9 on the 0-10 RPE) interspersed by 60 secs of walking or cycling at low intensity recovery (RPE 3-5)."
46116141|NCT02597036|Drug|Paclitaxel|Administered IV
46116142|NCT04073355|Behavioral|Physical Activity|Smartphone-delivered physical activity intervention
46116143|NCT04071639|Drug|Haloperidol 2Mg Tab|Haloperidol take 0.5mg~2mg three time a day.
46116144|NCT04071639|Drug|Risperidone 1Mg Tab|Risperidone take 1mg once at night.
46116145|NCT04071639|Drug|Zoloft 50Mg Tablet|Zoloft take 50mg once in the morning.
46116146|NCT04071639|Drug|Idebenone|Idebebone take 30mg three times a day.
46116147|NCT04071639|Drug|Deutetrabenazine Oral Tablet [Austedo]|The recommended starting dose of Austedo is 6 mg administered orally once daily, and dose may be increased at weekly intervals in increments of 6 mg per day to a maximum recommended daily dosage of 48 mg.
46116148|NCT04089176|Drug|Carbetocin|carbetocin 100 mcg + RLS solution 10 ml injected directly into the vein over 2 min
46116149|NCT04089176|Drug|oxytocin|oxytocin 20 IU diluted in 1000 ml of RLS solution administered intravenously at rate 120 ml/hr x 8 hr
46116150|NCT05388032|Behavioral|Sodium Reduction Intervention|The sodium reduction intervention is a dietician-led behavioral intervention consisting of two phases, first a 3-month intensive intervention phase, followed by a 9-month maintenance phase. The overall goal of the intervention is to reduce sodium intake to <2,300 mg per day based on the most recent guideline from the National Academies of Medicine. Both phases will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake.
46116151|NCT02577081|Other|CAT scan (CT scan)|all patients will pass a CAT scan of ths pelvis and the 2 femurs. No other interventions are required.
46116152|NCT03971786|Behavioral|Quality of life|Assessment of quality of life through measuring scales
46116153|NCT02596724|Other|Genomic and/or molecular testing of blood or tissue|Genomic and/or molecular testing of blood or tissue
46116154|NCT02596646|Procedure|Early Precut|Early precut was performed during ERCP with difficult biliary cannulation
45838968|NCT04344990|Procedure|Intraarticular infusion - Group I|Postoperative analgesia with continuous intraarticular infusion with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min)
46116155|NCT02596646|Procedure|Prolonged cannulation attempts|Prolonged cannulation attempts was performed during ERCP with difficult biliary cannulation
46116156|NCT04089020|Behavioral|Support for walking to school|5 modules that address psychosocial skills, with ongoing text messaging.
46116157|NCT04818255|Behavioral|PET Biomarker Disclosure|Participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging conducted as part of an affiliated research study (no additional imaging is required for this project). Participants meet with a licensed clinical neuropsychologist to discuss their biomarker status, the meaning of this information, and potential next steps to consider based of their status. Participants receive written summaries of this information, as well as resources as deemed necessary or as requested.
45470652|NCT03311646|Other|Very low nicotine content (VLNC)|Participants will exclusively smoke research cigarettes that have a very low nicotine content for five days/four nights while staying in a hotel.
45470653|NCT05276232|Drug|Cannabis(THC) inhaled|Cannabis vapor is produced from 500mg, approximately 5-10% High dose bulk cannabis plant material, 30-37.5 mg THC
45470654|NCT01672892|Radiation|Standard radiation therapy|Patients treated once a day, 5 days a week with a daily fraction size of 1.8 Gy. Whole pelvis treated with a four-field technique (AP/PA/R lateral/L lateral) to 45 or 50.4 Gy at 1.8 Gy/fraction. The dose is prescribed to the isocenter which is defined as the intersection of the four beams and can be normalized to an isodose line between 97-100%. The decision to deliver 45 or 50.4 Gy is at the physician's discretion and must be reported at the time of enrollment.
45470655|NCT01672892|Radiation|intensity-modulated radiation therapy|Patients treated once a day, 5 days a week with a daily fraction size of 1.8 Gy. All targets treated simultaneously. The vaginal planning target volume (PTV) (ITV with 7.0 mm margin) and nodal PTV receives 45 Gy in 25 fractions or 50.4 Gy in 28 fractions. The decision to deliver 45 or 50.4 Gy is at the physician's discretion and must be reported at the time of enrollment.
45470656|NCT03680274|Drug|Vitamin C|Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
45470657|NCT03680274|Other|Control|Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.
45470658|NCT05276076|Biological|VM-001 1X10^6 cells/kg|Administration: Inject intravenously single dose
45470659|NCT05276076|Biological|VM-001 3X10^6 cells/kg|Administration: Inject intravenously single dose
45470660|NCT05276076|Biological|VM-001 5X10^6 cells/kg|Administration: Inject intravenously single dose
45470661|NCT05276076|Biological|VM-001 1X10^6 cells/kg two dose|"Administration: Inject intravenously~1X10^6 cells/kg per dose, two dose in total, weekly"
45470662|NCT05276076|Biological|VM-001 1X10^6 cells/kg four dose|"Administration: Inject intravenously~1X10^6 cells/kg per dose, four dose in total, weekly"
45838969|NCT04344834|Diagnostic Test|A questionnaire or scales|A questionnaire or scale to assess the participants mental health.
46116158|NCT00749996|Device|DIAM™ Spinal Stabilization System|The DIAM™ Spinal Stabilization System is a spacer that is inserted between adjoining spinous processes after doing a standard herniectomy procedure using a posterior surgical approach.
46116159|NCT00749996|Procedure|Herniectomy|"Herniectomy is defined as the removal of the extruded/protruded/sequestrated disc material. This is done by probing the annulus and disc space and removing all mobile disc fragments."
46116160|NCT02577159|Drug|Dapagliflozin|Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day by adding the conventional treatment if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.
46116161|NCT00916994|Device|SpaceGuard Balloon|Positioning of the balloon into the subacromial space between the humerus head and the acromion
46116162|NCT02143245|Diagnostic Test|Synovial Biopsy|Synovial biopsy is a procedure using a guided needle, where 6 to 8 small tissue samples with be extracted from the shoulder using an x-ray guided needle.
46116163|NCT02143245|Diagnostic Test|Open Tissue Biopsy|During the standard of care revision surgery, 6 to 8 small tissue samples will be taken in order to test for infection. This is standard of care treatment. As part of this study, an additional 1 to 2 samples of tissue would be taken in order to develop a test to determine more precisely what type of infection there may be.
46116164|NCT00749684|Biological|Interferon α-2b|20 mio IU/m² interferon-α-2b 5x/week intravenously (IV) over the course of 1 month, followed by 10 mio IU/m² interferon-α-2b 3x/week subcutaneously (SC) for 11 months.
46027495|NCT04266262|Behavioral|High-Intensity resistance training (HIRT)|"Supervised HIRT sessions (2x/week) will comprise 2-3 sets of 6-8 repetitions progressively achieving 85% of 1RM.~Unsupervised HIRT sessions (1x/week) will involve 2-3 sets of 15-20 repetitions using a resistance exercise band when necessary."
46116165|NCT02575755|Drug|Azithromycin plus piperaquine phosphate|
46116166|NCT02575755|Drug|Sulfadoxine-pyrimethamine|
46116167|NCT02576769|Other|No intervention|
46116168|NCT04071561|Other|Posterior retroperitoneal adrenalectomy (PRA)|Minimally invasive adrenalectomy procedure
46116169|NCT04071561|Other|Lateral transperitoneal adrenalectomy (LTA)|During posterior retroperitoneal adrenalectomy, the failure to progress or the difficulty of creating or maintaining a pneumoperitoneum are reasons why conversion occurs.
45598638|NCT02231567|Other|Neurocognitive Rehabilitation|The patients will be treated in inpatient clinic with a neurocognitive rehabilitation approach. The frequency will be two times a day for six days a week for four consecutive weeks. Followed by outpatient treatment three times a week for four weeks. Each session lasts about one hour.
46027496|NCT00606268|Drug|Micafungin|IV
45754528|NCT03219125|Device|Dixon Magnetic Resonance Imaging|MRI of the lumbar spine (L1 to L4) and hip (non-dominant) for the measurement of Ad Med. (In%) by the DIXON sequence.
46027497|NCT05194189|Drug|Vitamin C|12 g vitamin C (48 ml) will be intravenously injected by a infusion pump every 12 h for 4 days or at ICU discharge
46027498|NCT05194189|Drug|5% glucose injection|5% glucose solution 48 ml every 12 h for 4 days or at ICU discharge.
45754529|NCT03219125|Device|dual-energy X-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
46027499|NCT05342935|Device|Inteligent Dialysis Assistant (IDA)|The IDA is a small dialysis system that allows a higher level of freedom to the patients, permitting them to perform the PD exchange while continuing to do their everyday activities
45754530|NCT04147052|Behavioral|iSLEEPms|Participants randomized to iSLEEPms complete daily online sleep diary forms and weekly online educational modules. Modules focus on typical elements of CBT-I, adapted for individuals with MS: education about sleep in MS, sleep restriction, and stimulus control; sleep hygiene and relaxation; and cognitive restructuring around sleep and coping with MS. Sleep diaries are scored each week, and feedback is provided to participants to guide adjustments to their recommended bedtimes and wake times. Telephone support is available to provide clarification around module content.
45754531|NCT00575965|Drug|Simvastatin|Oral tablets taken daily
46027500|NCT04262518|Device|Outcomes4Me Mobile App|A mobile app that provides patient navigation and treatment and clinical trial options to people with breast cancer
46027501|NCT05342857|Drug|Aflibercept Injection [Eylea]|Aflibercept 2.0 mg with the T&E criteria in Taiwan local consensus
46027502|NCT04264624|Device|Perioflow and Erythritol powder and ultrasonic debridement|Airflow and Perioflow combined with Erythritol powder will be used as an adjunct therapy
46116170|NCT04073277|Device|SCF-N-treated needles|The SCF-N-treated needles were used for acupuncture at LI 4 (Hegu) and LI 11 (Quchi) acupoints in the experimental groups..
46116171|NCT04073277|Device|Untreated needles|he untreated needles were used for acupuncture at LI 4 (Hegu) and LI 11 (Quchi) acupoints in the control groups.
46116172|NCT04073121|Device|Luminor DCB and Angiolite DES|Patient to undergo angioplasty with Luminor DCB and Angiolite DES
46116173|NCT00746798|Biological|ChimeriVax-WN02 vaccine|low dose, approximately 4 x 3log10, given one time subcutaneously
46116174|NCT00746798|Biological|ChimeriVax-WN02 vaccine|medium dose, approximately 4 x 4log10, given one time
46116175|NCT00746798|Biological|ChimeriVax-WN02 vaccine|high dose, approximately 4 x 5log10, given one time subcutaneously
46116176|NCT00746798|Biological|Placebo|0.9%Normal Saline for Injection, given one time subcutaneously
46116177|NCT00716274|Drug|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks
46116178|NCT00716274|Drug|Placebo|oral, daily, for 16 weeks
46116179|NCT02125149|Other|Exercise Intervention|
46116180|NCT00746564|Device|SJM Confirm|All patients in this study will receive the SJM Confirm device.
46116181|NCT02598908|Diagnostic Test|Quality control - enzyme activity|A blood sample will be collected from patients and staff donors, no more than twice per year.
46116182|NCT01298193|Drug|Aprepitant|Efficacy phase (second cycle)
46116183|NCT04090970|Device|Briagen|Natural complex carbohydrate wound dressing for skin wounds
46116184|NCT02590536|Drug|Sildenafil citrate|"In patients with Fetal Growth Restriction (FGR)and abnormal umbilical artery Doppler, will be randomly assigned and divided to 2 groups which will be treated with sildenafil citrate either placebo.~This study will compare the change in Resistance Index (RI) and the Pulsatility Index (PI) of the umbilical artery and fetal middle cerebral artery, for patients who receive 25 mg of oral sildenafil citrate 8 hourly starting at diagnosis of FGR until delivery against those who will receive placebo of the same color and shape of sildenafil citrate tablet."
46116185|NCT02590536|Drug|placebo|
46116186|NCT02576691|Device|percutaneous coronary intervention|
46116187|NCT03944928|Other|Lung ultrasound|"For each usual consultation every 3 months, the patient will have clinical examination and pulmonary function tests (CPI score). Thoracic ultrasound will be made during the consultation (M0, M3, M6, M9 and M12). The presence, gravity and localisation of each ultrasound sign will be described. CT-scan data will be collected in the 3 months before the start of the study and during the study. To be enrolled in the study does not change to the usual follow-up.~For the thoracic ultrasound, a convex probe will be used (1 to 5 MHz). Patient will be layed down in a right lateral prone position then left. Thoracic ultrasound will be timed, saved and anonymized. 14 intercostal spaces will be explored by experimented operator.~The records will be seen a second time by same operator then a second operator. this will measured interoperator and intraoperator variability."
46027503|NCT04264624|Device|Airflow and Erythritol powder and ultrasonic debridement|Airflow combined with Erythritol powder will be used as an adjunct therapy
46027504|NCT05342779|Procedure|stripping of great saphenous vein|"I will make 2 or 3 small cuts in your leg. The cuts are near the top, middle, and bottom of your damaged vein. One is in your groin. The other will be farther down your leg, either in your calf or ankle.~I will then thread a thin, flexible plastic wire into the vein through your groin and guide the wire through the vein toward the other cut farther down your leg.~The wire is then tied to the vein and pulled out through the lower cut, which pulls the vein out with it.~I will close the cuts with stitches. Patient will wear bandages and compression stockings on leg after the procedure."
46116188|NCT00719862|Drug|Placebo nasal spray|Placebo
46116189|NCT00719862|Drug|0.15% azelastine hydrochloride Nasal Spray|0.15% azelastine hydrochloride 822 mcg
46116190|NCT02578953|Drug|Dutasteride-Test product|Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by GSK, Poznan.
46116191|NCT02578953|Drug|Dutasteride-Reference product|Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Glycerin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by Catalent, Beinheim.
46116192|NCT04073589|Biological|ARGX-113 with rHuPH20|subcutaneous administration of efgartigimod with recombinant human hyaluronidase PH20 (rHuPH20)
46116193|NCT02591472|Procedure|Integrated care (ICare)|The Integrated Care approach provides Usual Care processes plus simultaneous psychosocial support via the Transform-10 Program. The Transform-10 Program will include information regarding emotional well-being, social support, and provides opportunity for the patient to openly discuss their thoughts and concerns regarding their recovery. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
46116194|NCT02591472|Procedure|Usual Care (UsCare)|Usual Care includes radiographic imaging and administration of pain medication and antibiotics, skin care and range of motion of the injured area. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit. At the end of the study all of the materials that make up the Transform-10 Program will be provided.
46116195|NCT02591472|Other|Patient-Reported Outcomes Measurement Information System|Questionnaires of Physical Functional quality of life and Emotional Well-being will be performed during the hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
46116196|NCT02591472|Other|Lower Extremity Gain Scale (LEGS)|LEGS consists of a 3-meter walk, putting on a sock, putting on a shoe, rising from an armless chair, stepping up and down stairs, getting on and off the toilet, reaching from a sitting position to an object on the ground. In people with traumatic fractures, LEGS has high internal consistency and the content, concurrent and construct validity are high. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
45470663|NCT03288987|Drug|Bevacizumab + FOLFIRI-3|Bevacizumab 5 mg/kg will be administered at day 1 every 2 weeks. Initially, it will be administered as a 90-min infusion. If the first infusion is well tolerated, the second will be delivered as a 60-min infusion, and if the 60-min infusion is well tolerated, all subsequent infusions will be given over 30 minutes. FOLFIRI-3 regimen consists of irinotecan 100 mg/m2 over 1 hour at day 1, leucovorin 400 mg/m2 at day 1 followed by a 46 hour 5-FU continuous infusion (2000 mg/m2) and irinotecan 100 mg/m2 over 1 hour on day 3 will administer. Induction treatment was administrated every 2 weeks until disease progression, unacceptable toxicities, surgical intervention, or withdrawal of consent.
45754532|NCT04142060|Drug|Enzalutamide|Patients will be dispensed with oral enzalutamide 160 mg (four 40 mg capsules) as a self-administered single oral daily dose, continuously.
46116197|NCT02591472|Other|Dynamometer|Isometric handgrip strength will be measured using a hand-held hydraulic dynamometer. Handgrip strength is clinically important as it strongly predicts long-term function capability after orthopedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
46116198|NCT02591472|Other|Active Range of Motion (AROM)|The use of goniometer and a digital inclinometer will be used to assess AROM. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
46116199|NCT02591472|Other|Posttraumatic Stress Disorder (PTSD)|The Posttraumatic Stress Disorder (PTSD) Checklist will be administered to measure posttraumatic stress levels. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
46027505|NCT00606424|Drug|20 mCi dose for a 50 kg individual of [F-18]HX4|All subjects, normal volunteers and cancer subjects will receive HX4 administered through a previously placed suitably sized angiocatheter or a butterfly needle. Prior to injection, qualified site personnel will assay the dose in the dose calibrator and document the activity of the dose and time of assay. After injection, the line will be flushed with saline (approximately 10 mL).
46116200|NCT02591472|Other|Beck Depression Inventory-II|The Beck Depression Inventory-II is a broadly-applicable, clinically relevant psychometric instrument with high reliability and consistency which notes depression. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
46116201|NCT02591472|Other|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) will be used to measure state anxiety (anxiety about an event) and trait anxiety (anxiety level as a personal characteristic). This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
46116202|NCT02591472|Other|Tampa Scale of Kinesiophobia-11 (TSK-11)|Tampa Scale of Kinesiophobia-11 (TSK-11) will be used to assess pain-related fear in orthopaedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
46116203|NCT02578719|Drug|bupivacaine|marcaine %0.5 20 ml flacon
46116204|NCT02578719|Drug|saline|%0.9 sodium chloride
46116205|NCT00742508|Drug|SK&F-105517-D 10 mg capsule|1 capsule once a day
46116206|NCT00742508|Drug|Carvedilol-immediate release (IR) 2.5 mg tablet|1 or 2 tablet(s) twice a day
46027506|NCT04266184|Other|Kinesio tape (KT)|"For abdominal taping, four I-shaped tapes will be used. Two of them will start from the superior symphisis pubis, follow the rectus abdominis muscle, and finish at the xiphoid process. Other two I-shaped tapes will start from the mid-symphisis pubis, follow the external oblique abdominals, and finish at the spina iliaca anterior superiors.~Symphisis pubis taping will be applied with two I-shaped tapes, by forming a X shape.~For lumbopelvic taping, three I-shaped KTs will be used. Two tapes will be applied bilaterally and longitudinally on the lumbar erector spinal muscles. The third tape will start from one sacroiliac joint and end at the other, vertically to the previous two tapes, forming a H-shape.~All tapings will be applied with 15-25% tension (tape-off tension). KTs will stay three days. They will be removed from the site, and the skin will be checked and cleaned. Then, they will be reapplied for the next three days."
46116207|NCT00742508|Drug|SK&F-105517-D 20 mg capsule|1 capsule once a day
46116208|NCT00742508|Drug|SK&F-105517-D 40 mg capsule|1 or 2 capsule(s) once a day
45838970|NCT04344756|Drug|Tinzaparin or unfractionated heparin|Tinzaparin INNOHEP ® 175 IU/kg/24h for 14 days if creatinine clearance Cockcroft ≥ 20mL/min, Otherwise unfractionated heparin (Calciparine®, Héparine Sodique Choay®) subcutaneously or intravenous with an anti-Xa target between 0.5 and 0.7 IU/mL for 14 days
46116209|NCT00742508|Drug|Carvedilol-IR 10 mg tablet|1 tablet twice a day
46116210|NCT04720911|Behavioral|In-person TASCS|In-person clinician delivery of the intervention, including the Safety Planning Intervention, connection to best-match behavioral health resources, and development of an outpatient treatment plan by a research clinician, facilitated by the TASCS Clinician App.
46116211|NCT04720911|Behavioral|Telehealth TASCS|Telehealth clinician delivery of the intervention, including the Safety Planning Intervention, connection to best-match behavioral health resources, and development of an outpatient treatment plan by a research clinician, facilitated by the TASCS Clinician App.
46116212|NCT04720911|Behavioral|Self-administered TASCS|Self-administration of the intervention, including the Safety Planning Intervention, facilitated by the TASCS ED Patient App.
46116213|NCT04720911|Behavioral|Follow-up care|Counseling calls and access to the Post-ED Patient and Family App for three months after the index presentation. These resources allow the patient and family to review their safety plan, life plan, and outpatient care plan
46116214|NCT04085016|Device|Keratograph 5M, Oculus, Wetzlar, Germany|
46116215|NCT02590614|Dietary Supplement|800 IU Vitamin D|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the intervention group.
46116216|NCT02590614|Dietary Supplement|Placebo|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the placebo group
46116217|NCT02575443|Drug|Rocuronium (MB group)|Count of train-of-four: 1-2 Titration of rocuronium dose
46027507|NCT04266184|Other|Pelvic belt (PB)|The women in this group will use the belts, after adjusting them at a comfortable tension, after getting up the bed in the mornings, during daily activities and walking. Evaluation will be made three days after the first application and they will be asked to continue using it for the second three-day period.
46027508|NCT04266184|Other|Educational program|This program will include pain neuroscience education and ergonomic education, and will approximately last one hour.
46116218|NCT02575443|Drug|Rocuronium (DB group)|Post-tetanic count: 1-2 Titration of rocuronium dose
46116219|NCT05382650|Biological|Human rabies immune globulin 300 IU/mL|All participants in this single-cohort observational study will receive human rabies immune globulin 300 IU/mL at a dose of 20 IU/kg per standard of care.
46116220|NCT03975842|Other|Sinonasal and otologic evaluation|"At onset, each participant had:~sinonasal evaluation (several nasal signs and symptoms were evaluated, bilateral endoscopic nasal examination, computed tomography (CT) of the sinuses when sinus surgery became necessary).~otologic evaluation (evaluation of middle ear status, documentations of personal history of otologic disease, otoscopic examination, pure-tone audiometry and tympanometry)"
46027509|NCT04188691|Biological|Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
46027510|NCT04188691|Biological|Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
46116221|NCT02589912|Device|Nucleus Profile ABI541 Auditory Brainstem Implant|
46116222|NCT04071093|Other|Home Telemonitoring System (HTS)|The HTS consists of an App that daily collects measurements of weight, blood pressure, heart rate and symptoms (checklist of symptoms questions). The HTS processes the data and generates and sends an alert to the physicians if a risk situation occurs (measurements are outside of normal ranges). The App has also an educational functionality that allows learning about lifestyle, self-care and healthy habits for HF patients. For this purpose, the application: a) has a section that answers frequent questions, b) has a question and answer game about HF, and c) sends educational messages to the patients every day.
46116223|NCT02596334|Drug|dolutegravir 50mg +abacavir 600mg +lamivudine 300mg|
46027511|NCT04188691|Biological|Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）administered intramuscularly according to a 0, 28，（56）day vaccination schedule
46116224|NCT02596334|Drug|dolutegravir|
46116225|NCT00719706|Drug|acetyl-l-carnitine PLUS alpha-lipoic acide|1000-3000 mg/day of acetyl-l-carnitine in addition to 600-1800 mg/day of alpha-lipoic acid.
46116226|NCT00719706|Drug|Placebo|Placebo
46027512|NCT04188691|Biological|Normal saline|Normal saline administered intramuscularly according to a 0, 28 ，（56）day vaccination schedule
45838971|NCT04344288|Drug|Prednisone|The experimental group will receive oral prednisone during 10 days (0.75 mg/kg/day during 5 days then 20 mg/day during 5 more days)
46116227|NCT02575599|Behavioral|Guided self-determination programme (GSD)|The GSD intervention consist of four e-consultations with structured reflection sheets. Reflection sheets are intended to increase patients' ability to express their views and prepare them for active participation in the care process. Through the web-based platform, the subsequent four e-consultations will allow for communication between patients and nurses. The platform allows the participants to fill in the reflection sheets using their own words and drawings to express their own experiences with self-management as well as to formulate behavioral goals and plans to achieve their goals. It also permits feedback from the nurses on these reflections sheets via secure emails. Each person will be able to access the web-based program from his or her own computers or other electronic devices.
45838972|NCT04344288|Other|Control group|The control group will receive standard of care according to the international recommendations and practices of the investigational site. No corticosteroid therapy can be prescribed in this group.
45838973|NCT04344522|Procedure|Descemet membrane endothelial keratoplasty DMEK|DMEK : it involves separating the Descemet membrane from a corneal donor graft , doing a descematorhexis in the recepient cornea , loading and injection of the graft into the anterior chamber , unfolding and fixing the graft to the recepient cornea by intracameral air bubble.
46027513|NCT04188691|Biological|Aluminum adjuvant|Aluminum adjuvant administered intramuscularly according to a 0, 28，（56） day vaccination schedule
45681992|NCT03155152|Other|HIIT|The HIIT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is kept constant.
45681993|NCT01671124|Other|Soline capsule|
45681994|NCT03155230|Other|no intervention|no intervention
45681995|NCT04764838|Other|Yoga|"Breath Awareness Training (5 minutes) Asanas (20 minutes)~Bending sideways in Mountain Stance~Standing Pelvic Shaking Warrior Stance II Squatting and malasana (wreath pose) Breath awareness in lotus pose (sitting) Cane pose Fixed Butterfly / Angel Pose~Sitting wide in Angel Pose Cat Pose Tiger Breath Mudra and meditation (10 minutes)"
45681996|NCT04457674|Behavioral|Cognitive Behavioral Therapy for insomnia (CBTi)|CBTi consists of six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.
46116228|NCT02575521|Drug|Propofol-Dexmedetomidine group|Porofol (1.5-2 mg/kg/h) infusion, Dexmedetomidine (0.2-1µg/kg/h) infusion and Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value). Maintenance infusions will start immediately after induction.
46027514|NCT04264546|Biological|sIPV|The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU. The vaccine was in liquid form, 0.5 ml per dose.
46116229|NCT02575521|Drug|Sevoflurane group|Sevoflurane at a concentration of 2-2.5%., Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value).
46027515|NCT02691208|Other|Kinesiotherapy|Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
46027516|NCT02691208|Other|Acupuncture|Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes plus 30 minutes of classical acupuncture using predefined points.
46116230|NCT02576613|Other|MPP-S|> 30 weekly sessions of modified psychodynamic psychotherapy in addition to standard treatment
46116231|NCT02576613|Other|TAU|standard medical treatment without structured psychotherapeutic intervention
46116232|NCT00742274|Device|Gore TAG Endoprosthesis|Implant Gore TAG device with Best Medical therapy per physician discretion
46116233|NCT00742274|Other|Best Medical Therapy|Best Medical therapy is regimen of antihypertensive medications used to maintain blood pressure below 125/80 mm/Hg throughout the entire follow-up period. Because BMT is assessed by blood pressure response to medication, specific medication regimens for each patient will differ. The typical regimen consists of 1 to 4 concomitant antihypertensive medications that may include angiotensin converting enzyme (ACE) inhibitors, alpha blockers, beta blockers, calcium channel blockers, diuretics, and/or vasodilators.
46116234|NCT04711473|Behavioral|Colonoscopy Only|Mailed letter asking participants to complete CRC screening by colonoscopy
46116235|NCT04711473|Behavioral|Choice|Mailed letter and FIT test asking participants to complete CRC screening by their choice of either colonoscopy or mailed FIT
46116236|NCT04711473|Behavioral|FIT Only|Mailed letter and FIT test asking participants to complete CRC screening by mailed FIT
46116237|NCT00917696|Procedure|Comparator: Iontophoresis and Laser Doppler with ATP|Iontophoresis treatments with 10 mM ATP (adenosine triphosphate) solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
46027517|NCT01215851|Drug|PA-824|200 mg tablet, once daily for 14 days
46027518|NCT01215851|Drug|Pyrazinamide|Dosed by Weight
46027519|NCT01215851|Drug|TMC207|TMC207 700 mg Day 1; 500mg Day 2; 400mg Days 3-14
46027520|NCT01215851|Drug|Rifafour|Rifafour e-275
46116238|NCT00917696|Procedure|Comparator: Iontophoresis and Laser Doppler with Saline|Iontophoresis treatments with 20 mM saline solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
45838974|NCT04344522|Procedure|IOL exchange|IOL exchange : it involves performing a corneoscleral tunnel , freeing the AC IOL from any adhesions and explanting it through the tunnel , then implanting a posterior chamber PMMA lens or iris claw lens if there is no adequate capsular support.
45838975|NCT04344522|Procedure|iridoplasty|iridoplasty : repairing any iris defect by using 10/0 prolene.
45838976|NCT04344522|Procedure|Inferior peripheral iridectomy|Inferior peripheral iridectomy : performed by vannus scissor to avoid postoperative pupillary block due to the intracameral air .
46116239|NCT02576457|Biological|BMS-936559|
46027521|NCT01215851|Drug|Moxifloxacin|moxifloxacin 400 mg
46027522|NCT05378698|Drug|Application of Tralokinumab|2 Arms 20 patients 5 healthy controls
46116240|NCT02576457|Other|Placebo|
46116241|NCT05276102|Other|Emollient cream|Commercially available emollient cream
46116242|NCT02596100|Drug|Betrixaban|
46116243|NCT01192971|Drug|Apatinib|apatinib p.o. once daily for 4 weeks
45470664|NCT01379846|Biological|TAK-816+ DPT-TAKEDA|TAK-816 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
45838977|NCT04344210|Behavioral|Tele-interventions related to diabetes management and mental well-being|Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
45838978|NCT04343820|Procedure|Breast reconstruction|Breast reconstruction by prepectoral positioned implant after lipo-preparation of the wall.
46027523|NCT00613093|Drug|Temodar and O6-Benzylguanine (BG)|"Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).~BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle."
46027524|NCT00933166|Device|Lotrafilcon A contact lens|Investigational silicone hydrogel, single vision, soft contact lens worn on a daily wear basis, flexible wear basis, or extended wear basis for three months
46116244|NCT04090814|Device|HeatTens (HV-F311-E)|(1) 2~108 Hertz (modulation program inside); (2) 100 microseconds (pulse duration)
46027525|NCT03696277|Radiation|Stereotactic ablative body radiation (SABR)|SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
46116245|NCT01918215|Device|ICD|
46116246|NCT01918215|Device|ILR|
46116247|NCT04090892|Procedure|selective percutaneous muscle release|Children will be evaluated before and two times after they undergo a selective percutaneous myofascial release. Investigators make no determination about the need for the surgery or which muscles are released, nor do they participate in the surgery. The investigators are assess outcomes on gait and motor function.
46116248|NCT05412836|Device|AqueousJoint|AqueousJoint is a liposomal boundary lubricant, which coats the cartilage surface and protects it from further damage and degradation.
45681997|NCT04457674|Behavioral|Sleep Hygiene Education (SHE)|SHE participants receive six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.
46027526|NCT04262362|Procedure|Root canal treatment|Incidence of pain that may occur due to sodium hypochlorite extrusion
46027527|NCT00607750|Drug|ATG003 (mecamylamine)|1% Ophthalmic solution, eyedrop BID, 48 weeks
46027528|NCT00607750|Drug|Placebo|Placebo eyedrops, BID, 48 weeks
46027529|NCT04262050|Device|transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS)|
46027530|NCT05271955|Device|"e-GOLIAH"|"Usual care plus electronic tablet with games application e-GOLIAH (Gaming Open Library for Intervention in Autism at Home)"
46027531|NCT05271955|Behavioral|Usual care|Usual care which combines speech therapy, psychomotor, educational or psychological care with a developmental and / or behavioral orientation and a school life support during schooling.
46027532|NCT00609544|Drug|Rilonacept|Loading dose of 320 mg Rilonacept or placebo followed by 160 mg Rilonacept or placebo once a week for 11 weeks
46027533|NCT04908475|Drug|Risankizumab|Subcutaneous injection
46027534|NCT04908475|Drug|Apremilast|Oral Tablets
46027535|NCT04261816|Procedure|extubation in the operating room|Patients who underwent liver transplantation early extubation in the operating room immediately following liver transplantation
46116249|NCT00719472|Drug|Rituximab|During Cycle 1 rituximab was administered at an initial rate of 50 mg/hour. In the absence of infusion toxicity during Cycle 1, the infusion rate was escalated by 50 mg/h increments every 30 minutes to a maximum rate of 400 mg/hour. In case of infusion-related reactions, the infusion was interrupted or the infusion rate reduced. In case of Grade 3/4 infusion reactions, the rituximab infusion was discontinued and medical treatment provided. If the rituximab infusion in Cycle 1 was tolerated without a serious adverse event (AE) or Grade 3/4 infusion-related AE, as judged by the investigator, infusions in Cycle 2 onwards were administered as follows: 20% of the total dose was given over 30 minutes and the remaining 80% of the dose was given over the next 60 minutes, for a total infusion time of 90 minutes. Commercial preparations of rituximab were used.
46027536|NCT04261816|Procedure|extubation in the ICU|Patients who underwent liver transplantation extubation in the ICU following liver transplantation
46027537|NCT05127070|Device|Neotree|The Neotree is a digital app, data collection and quality improvement system. collecting and collating routine health data at the bedside for babies on admission and discharge and for laboratory results. it provides point of care education and clinical decision support to optimise the clinical care of sick and vulnerable newborns according to approved and best available clinical guidelines.
45681998|NCT01923298|Drug|Estradiol|
45681999|NCT03155386|Other|Angiommamography|"A blinded central re-reading of the acquisition technique will be carried out by 3 radiologists (2 seniors and 1 junior) who will evaluate:~The intensity of lesion enhancement~The presence and type of artefacts on the recombined images.~The quality of low-energy images according to recognized criteria for mammography.~The gold standard will be histology (biopsies or surgery) or follow-up to 1 year for non-biopsied benign lesions"
45682000|NCT04417192|Drug|Olaparib|Olaparib will be administered at a dose of 300mg as oral dose, twice a day.
45682001|NCT04417192|Drug|Pembrolizumab|Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
45682002|NCT01671436|Behavioral|Central Meditation and Imagery Therapy|
45682003|NCT05629156|Other|No intervention implemented. Observational study only|Observational study only. Injuries and illnesses and exposure is registered using standardized paper forms.
45754533|NCT01797887|Behavioral|Diet and Lifestyle Counseling|Diet and Lifestyle Counseling
46027538|NCT05267041|Other|Quality of life questionnaire|One questionnaire between diagnostic annoucement and first line treatement
46027539|NCT05267041|Biological|Blood sample|One optional veinous blood sampling (24 ML) between the first diagnostic annoucement and before the first treatment for lung cancer
46027540|NCT05267041|Other|Quality of life questionnaire|One questionnaire 6 months later after first line treatment
46116250|NCT00719472|Drug|CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)|Commercial preparations of CHOP were used. Prednisone was administered prior to rituximab infusion.
46116251|NCT00719472|Drug|CVP (cyclophosphamide, vincristine, prednisone)|Commercial preparations of CVP were used. Prednisone was administered prior to rituximab infusion.
46116252|NCT00719472|Drug|Analgesic/antipyretic and antihistamine drugs|An analgesic/antipyretic (eg, acetaminophen) and an antihistamine (eg, diphenhydramine) were administered 30 minutes before each infusion of rituximab.
46027541|NCT05267041|Other|Quality of life questionnaire|One questionnaire before second line treatment
45470665|NCT01379846|Biological|ActHIB+ DPT-TAKEDA|ActHIB 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
46027542|NCT05267041|Other|Quality of life questionnaire|One questionnaire 6 months later after second line treatment
46027543|NCT03513211|Drug|SUBA-itraconazole|150mg PO BD
46027544|NCT03513211|Drug|Hydroxychloroquine|Escalating doses in Rolling 6 Phase I
46027545|NCT04611139|Drug|SP-2577|Daily oral doses
46027546|NCT04611139|Drug|Pembrolizumab|200mg Q3W by IV infusion
46027547|NCT00935272|Device|Restylane®|Restylane® injections in the lips
46116253|NCT02599064|Drug|RXI-109|RXI-109 dosed intravitreally to subjects with NVAMD
46116254|NCT05293158|Drug|Hepatect CP 50 I.E./ml infusion solution|"Application of i.v. (intravenously) HBIGs for ≥6-weeks:~Day (D) 0-7: 10.000 IU D14 until end-of-treatment: 10.000 IU once per week HBIGs will be given until LT/liver resection."
45682004|NCT01671514|Dietary Supplement|Epicatechin-enriched dark chocolate|For experimental purposes, subjects will take one square of epicatechin-enriched dark chocolate per day for 90 days.
45682005|NCT01671514|Other|Low-epicatechin dark chocolate|As a placebo control, subjects will take 1 square of low-epicatechin chocolate per day for 90 days.
45838979|NCT04343742|Drug|chlorine dioxide 3000 ppm|"Each patient will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions.~: 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots)."
45838980|NCT04343508|Other|Fortified rice|100 g of rice was fortified with 150 µg vitamin A (Vitamin A palmitate), 0.5 mg vitamin B1 (thiamin mononitrate), 7 mg vitamin B3 (niacin amide), 0.6 mg vitamin B6 (pyrodoxine hydrochloride), 1 µg vitamin B12 (cyanocobalamin), 130 µg folic acid, 4 mg iron (ferric pyrosphosphate), and 6 mg zinc (zinc oxide).
46027548|NCT00935272|Device|Non-Treatment|Non- Treatment
46027549|NCT04570501|Drug|Angiotensin-(1-7)|Ang (1-7) administered by continuous intravenous (IV) infusion
45470666|NCT02939781|Device|Indirect calorimetry|Indirect calorimetry measurement at baseline (stable state), at onset of fever and continued till fever dehiscence
45598639|NCT02231567|Other|Traditional Rehabilitation|The patients will be treated in inpatient clinic with a traditional rehabilitation approach. The frequency will be two times a day for six days a week for four consecutive weeks. Followed by outpatient treatment three times a week for four weeks. Each session lasts about one hour.
45682006|NCT05212246|Drug|5% Imiquimod cream|Topical 5% Imiquimod cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
45754534|NCT03217097|Drug|Oxaliplatin-based chemotherapy|"The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
46027550|NCT04570501|Drug|Placebo|Placebo (normal saline) administered by continuous intravenous (IV) infusion
46027551|NCT04570423|Drug|Eflapegrastim|Eflapegrastim supplied in prefilled, single-use syringes for SC injection.
46027552|NCT04570423|Drug|Chemotherapy|Chemotherapy agents may include doxorubicin, ifosfamide, docetaxel, CHOP regimen, etoposide, cyclophosphamide and vincristine which will be administered as per standard of care per the Primary Care physician's treatment plan.
46027553|NCT00607828|Radiation|stereotactic body radiation therapy|Undergo radiotherapy
46027554|NCT04114747|Other|Starting at high or low blood pressure|Using norepinephrine, patients will receive high or low blood pressure to start with and after measurements cross to receive the other blood pressure target
46027555|NCT00607906|Drug|SB-756050 immediate release capsule|SB-756050 immediate release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white drug layered pellets. Each capsule will contain 5, 25 or 100 milligrams of SB-756050.
46116255|NCT05410262|Other|Evaluation of CT images|A helicoidal CT scanner will be used (Aquilion CXL, Toshiba, Japan), with AIDR 3D technique (Adaptive Iterative Dose Reduction 3D) in order to minimize exposure to X-rays. Two complete thorax CT scans will be performed, one of them in expiratory pause (PEEP) and the other in inspiratory pause (PPlat). Esophageal pressure shall be measured (FluxMed GrT, Argentina) and transpulmonary pressure will be calculated at the end of inspiration (Ppl-insp) and expiration (Ppl-exp).
46116256|NCT00579501|Drug|Trabectedin|Trabectedin 1.5 mg/m^2 over a 24-hour iv infusion every 3 weeks for a minimum of 3 and a maximum of 6 cycles of trabectedin.
46116257|NCT00579501|Drug|Dexamethasone|Dexamethasone 20 mg iv will be administered within 30 minutes before start of each trabectedin iv infusion
46116258|NCT02590458|Procedure|Short Breast MRI (SBMRI)|One day after routine MRI, short breast MRI (SBMRI) with contrast performed. Scan will take about 10 minutes to complete.
46116259|NCT02590458|Behavioral|Questionnaire|After SBMRI, participant completes a questionnaire about their comfort level and experience of the research scan. It should take about 10 minutes to complete the questionnaire.
46116260|NCT02596178|Device|Electrical Impedance Tomography|Electrical impedance tomography capitalizes on changes in electrical impendence between air-filled versus tissue or fluid-filled spaces in order to characterize and quantify regional distribution of lung volume at the bedside.
46027556|NCT00607906|Drug|SB-756050 modified release capsule|SB-756050 modified release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white enteric coated drug layered pellets. Each capsule will contain either 25or 100 milligrams of SB-756050.
46116261|NCT04085952|Procedure|dermal graft (ARCUS repliform) for anterior colporrhaphy|At the time of surgery patients were randomized to anterior colporrhaphy with dermal graft augmentation
46116262|NCT04085952|Procedure|suture based anterior colporrhaphy|At the time of surgery patients were randomized to anterior colporrhaphy with a suture based repair
46116263|NCT02598362|Drug|ciprofloxacin|Serum and urine concentrations after ciprofloxacin administration. pharmacokinetic testing after ciprofloxacin administration
46116264|NCT02589834|Other|Quran group|
46116265|NCT02576301|Drug|Phase 1 - OXi4503|Determination of MTD of OXi4503
46027557|NCT00607906|Drug|Placebo|Subjects will also receive placebo capsules.
46027558|NCT04569331|Procedure|Stimulation of efferent loop|"Stimulation of efferent loop: 3 weeks before the ileostomy closure surgery, efferent loop will be stimulated with 250 ml of water and thickened.~This procedure consists of introducing through the light efferent loop ileostomy 250 ml of water with thickener every 48-hours during the first two weeks and once daily the thrid week with a Foley catheter. Patient will be provided with all the material and the procedure sheet for all the stimulation of the efferent loop sessions. This technique will be performed at patient's home until the day before the ostomy patient closure surgery."
45470667|NCT05175794|Diagnostic Test|Xpert® MTB/XDR|The Xpert MTB/XDR Assay, performed on the GeneXpert Instrument Systems, is a nested real-time polymerase chain reaction(PCR) in vitro diagnostic test for the detection of extensively drug resistant (XDR) Mycobacterium tuberculosis (MTB) complex DNA in unprocessed sputum samples or concentrated sediments prepared from sputum. In specimens where MTB is detected, the Xpert MTB/XDR Assay can also detect isoniazid (INH) resistance associated mutations in the katG and fabG1 genes, oxyRahpC intergenic region and inhA promoter; ethionamide (ETH) resistance associated with inhA promoter mutations only; fluoroquinolone (FLQ) resistance associated mutations in the gyrA and gyrB quinolone resistance determining regions (QRDR); and second line injectable drug (SLID) associated mutations in the rrs gene and the eis promoter region.
45470668|NCT05275764|Procedure|primary or secondary intraocular lens implantation surgery|primary or secondary intraocular lens implantation surgery
45470669|NCT05179161|Device|Prone crawl positioning|Breast cancer patients are placed in a prone position with the ipsilateral arm besides the body rather than extended besides the head on a dedicated couch that provides the required support for maintaining this position.
45470670|NCT01379690|Other|HBA1C|Used level of HBA1C as a reflection of glycaemic control of the cases and controls
45682007|NCT05212246|Drug|Placebo Vehicle Control Cream|The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
45682008|NCT05196022|Other|Cochlear implant|G2 will receive a cochlear implant during the study
46116266|NCT02576301|Drug|Phase 1 - OXi4503 + cytarabine|Determination of MTD of the combination of OXi4503 + cytarabine
46116267|NCT02576301|Drug|Phase 2 - OXi4503 + cytarabine|Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with AML
46116268|NCT02576301|Drug|Phase 2 - OXi4503 + cytarabine|Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with MDS
45470671|NCT03728166|Behavioral|Electronic alert|"On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a Extended-Duration VTE Prevention order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis."
45470672|NCT01379612|Other|Ultrasonic Elastography|Non-invasive
45838981|NCT04343196|Radiation|Diagnostic Angiography (DSA or DVA based on randomization result)|After radial/brachial/femoral artery puncture using Seldinger technique, the investigators first position a pigtail catheter above the level of the renal arteries. With Siemens Artis Zee Pure DSA machine the examiner will use a postero-anterior X-ray view for the first image, which is an aortography of some part of the iliac system. Then, the catheter will be repositioned to the aortic bifurcation and 15-18 mL contrast media (CM) with 9-10 mL/s flow for the ilio-femoral region will be injected. All of the following image series will be made from this catheter position, with a 9 mL/s flow rate. In cases for when the recorded image series will be inconclusive, image series with left/right oblique position will be recorded. All femoro-popliteal images will be recorded with 10-16 ml CM and crural regions with 12-22mml. DSA images will be calculated from all series on a dedicated Syngo workstation and used for diagnosis. DVA images will be calculated by the Kinepict Medical Imaging Tool
46027559|NCT04569331|Procedure|Rehabilitation pelvic floor|3 months after the closure of the ileostomy, you will be referred to the pelvic floor rehabilitation unit,where will start 15 individual sessions, 2 days a week (8 weeks of sessions), with reeducation of defecatory habits and hygienic-dietary measures, defecation record where assess stool consistency using the Bristol Scale and number of bowel movements that take place in 24 hours, muscle toning exercises (Exercises Kegel), Biofeedback (BF), rectal balloon work to improve sensitivity and accommodation, reeducation of the expulsive maneuver, and perineal block in situations hyperpressive.
46027560|NCT02692963|Biological|BCG vaccination|BCG vaccine InterVax
46027561|NCT04266106|Drug|SuperBio probiotic|One capsule po BID for 28 days
46027562|NCT04266106|Drug|Placebo|One capsule po BID for 28 days
46116269|NCT02589756|Other|The fatty fish group|At inclusion demographic information recorded, including length of breastfeeding for women. Thereafter, participants will start with a run-in period of two weeks where they will be asked not to consume salmon, mackerel, sardines or other fatty fish or nuts providing a dietary baseline. At baseline, subjects will be randomized to a fish, nuts or control group. The fish group will be asked to consume three to four portions weekly. The fish will be eaten at the main meal and in sandwiches for a total of 600 grams weekly for 6 months. This group will avoid eating nuts. The nut group will consume equal amount of energy (~1400 kcal ) for weekly use for 6 months. This group will avoid eating fatty fish. The control group will consume their usual diet, but asked to avoid fatty fish and nuts.
45470673|NCT05275452|Other|No intervention|No intervention
45470674|NCT04339920|Diagnostic Test|Spermine Measuring Device|The Spermine Measuring Device (SMD) is a simple device, with automatic urine aspiration and also spermine level assessment. First about 30 cc urine will be freshly collected by a prepared collection device. Then the cap of the SMD will be removed and the aspiration tip of the device will be immersed into the urine specimen. After firmly pressed on the device, a small sample of urine will be aspirated into the SMD. The device will then automatically assess the urine spermine level. The result will then be read at a indicator window after about 5 minutes. If the level was below a pre-set cutoff, i.e. suggestive of having increase risk of prostate cancer, the indicator window will turn into red colour. However, if the spermine level is higher than the cutoff value, i.e. low risk of having cancer, the indicator window will turn blue.
45470675|NCT01379456|Procedure|physiotherapy|exercises, 20 sessions over 10 weeks
45470676|NCT04079361|Diagnostic Test|Blood samples|Bood samples during prenatal and postnatal visits
45470677|NCT01379300|Drug|dabigatran etexilate|dabigatran etexilate, orally, as 2 x 75-mg capsules (150 mg), single administration
45470678|NCT01379300|Drug|rivaroxaban|rivaroxaban, orally, as 2 x 10-mg tablets (20 mg), single administration
45470679|NCT04316130|Device|Uincare Homeplus|Interactive digital healthcare system
45470680|NCT04316130|Other|Brochure|Brochure
45470681|NCT05572359|Device|cryo-and compression brace|patients in the intervention groups are instructed to use the cryo- and compression brace during the six postoperative weeks five times a day, for a maximum of 20 minutes. The amount of compression is dependent on a patients' own preference.
45470682|NCT01383122|Device|Pulsed electromagnetic field device (ActiPatch TM)|Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
45470683|NCT01383122|Device|Inactive pulsed electromagnetic field device (ActiPatch TM)|Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
45470684|NCT05572281|Drug|Tasimelteon Oral Capsule|No additional information
45470685|NCT05572281|Drug|Tasimelteon Oral Suspension|No additional information
45470686|NCT05422196|Procedure|Platelet-rich fibrin|Addition of platelet-rich fibrin into the cleft site.
45470687|NCT03682224|Drug|Liposomal Bupivacaine|Liposomal Bupivacaine 1.3% (Exparel), 20 ml vial for injection, administered subcutaneously at port site
45470688|NCT03682224|Drug|Bupivacaine-Epinephrine|Bupivacaine-Epinephrine 0.25%, 1:200,000 (Marcaine with epinephrine), administered subcutaneously at port site
45470689|NCT04061733|Device|Hydrogel injection|Hydrogel injection
46116270|NCT02589756|Other|The nut group|At baseline (conditions for baseline are the same in all three groups) the nut group will consume equal amount of energy (~1400 kcal ~100 grams walnuts, ~50 grams hazelnuts and ~50 grams almonds/week).The nuts will be provided free of charge for the six months. This group will avoid eating fatty fish.
46027563|NCT04264468|Combination Product|neoadjuvant chemotherapy|This study prospectively included 150 breast cancer patients (30 patients in the first stage and 120 patients in the second stage) who were treated with the commonly used neoadjuvant chemotherapy recommended by NCCN, received surgical treatment after neoadjuvant chemotherapy, and evaluated the efficacy according to the surgical pathological response.Based on the Mammaprint technology analysis of patients with pathologic complete response (pCR), partial response and no response, we analyzed the characteristic genes related to breast cancer in the tumor tissues and evaluated the accuracy and sensitivity of the Mammaprint test for the efficacy of neoadjuvant chemotherapy
46027564|NCT05198791|Drug|Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets|Stratified medicine including interventional diagnostic procedure (IDP) and linked treatment with eplerenone. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
46116271|NCT02589756|Other|The control group|After the baseline the control group will consume their usual diet, asked to avoid fatty fish and nuts.
46116272|NCT00918762|Procedure|assessment of therapy complications|
46116273|NCT00918762|Procedure|diagnostic endoscopic surgery|
46116274|NCT00918762|Procedure|quality-of-life assessment|
46116275|NCT00918762|Procedure|therapeutic conventional surgery|
46116276|NCT00918762|Procedure|therapeutic endoscopic surgery|
46116277|NCT00918762|Procedure|transoral robotic surgery|
46116278|NCT00918762|Procedure|video-assisted surgery|
46116279|NCT04019067|Diagnostic Test|MCE first|"Patients randomized to the MCE first group will have a MCE deployed as soon as possible once confirmed to fast for at least 8 hours."
46116280|NCT05684874|Radiation|Neoadjuvant RT|"Dosimetric CT scan with contrast injection for treatment planning. Radiation therapy at a dose of 50Gy in 25 fractions, 5 fractions per week. Daily pre-treatment positioning tomographic imaging (either high energy (MVCT) or cone beam computed tomography (CBCT)).~Delineation of the tumor volume and evaluation of its evolution. In case of change of volume and if medically relevant, new dosimetric scan and collection of the tumor volume."
46116281|NCT05684874|Other|Pre-radiotherapy mpMRI|"Performed less than 14 days before the dosimetric scan. Conventional morphological T1-weighted, T2-weighted, and T1-weighted imaging sequences after injection of contrast agent.~Quantitative imaging sequences including multiple b-value diffusion imaging. Chemical shift sensitized sequences."
46116282|NCT05684874|Other|Post-radiotherapy mpMRI|"Performed 4 to 6 weeks after the end of the radiotherapy. Conventional morphological T1-weighted, T2-weighted, and T1-weighted imaging sequences after injection of contrast agent.~Quantitative imaging sequences including multiple b-value diffusion imaging. Chemical shift sensitized sequences."
46116283|NCT05684874|Procedure|Tumor resection|Performed 6 to 8 weeks after the end of radiotherapy. An anatomopathological observation of the surgical specimen will be performed.
46116284|NCT02575287|Device|Optical Enhancement|A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement (Pentax Video Processor EPK-i7010; HOYA Co. Tokyo, Japan)
46116285|NCT02575287|Device|Optical Enhancement with optical magnification|A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement associated with an optical magnification using the scope called magniview (PENTAX Medical EG-2990Zi)
46116286|NCT02575287|Device|Optical magnification without Optical enhancement|A endoscopic visualization of the mucosa using optical magnification without the use of the pre-processor filter called Optical enhancement
46116287|NCT04086186|Procedure|Liposomal Bupivacaine Peri-articular Injection|A 20mL solution of 266mg of liposomal bupivacaine (Exparel) was mixed with 40mL of normal saline, which was then infiltrated consistently in the posterior capsule, medial and lateral side of the arthrotomy, patella tendon, quadriceps tendon, quadriceps musculature, and subcutaneous soft tissue.
46116288|NCT04086186|Procedure|Adductor canal block|Anesthesiologist performs preoperative adductor canal block using 15mL of 0.5% Bupivacaine HCl
45682009|NCT01671592|Biological|DC Vaccine|Alpha-type-1-polarized dendritic cells (αDC1) pulsed with apoptotic autologous tumor.
46116289|NCT00741338|Biological|Laronidase|0.058 mg/kg - 0.58 mg/kg IV infusion weekly.
46116290|NCT00741338|Drug|Cyclosporine A (CsA)|Orally three times daily.
46116291|NCT00741338|Drug|Azathioprine (Aza)|Orally either every day for Cohort 1 or every other day for Cohort 2.
46116292|NCT03971396|Other|Physiotherapists working in intensive care|Physiotherapists working in intensive care will be reached by mail or telephone. Physiotherapists will be asked to complete the prepared questionnaire.
46116293|NCT00917072|Behavioral|Didactic|Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
45838982|NCT04343118|Procedure|Hardware Removal|elective removal of plate osteosynthesis at the clavicle
45470690|NCT01377818|Procedure|ventilation|"positive-pressure breathing bilevel (BiPAP ® Respironics, Inc.) Parameters initially programmed be: IPAP 10 cm H2O, EPAP 4 cmH2O, method ST setting yourself respirations 12 breaths minute. The IPAP was progressively increased to a maximum of 20 cm H2O, depending on patient tolerability, clinical response and arterial oxygen saturation was continuously monitored by pulse oximetry, trying to avoid possible leaks through the mask. It can also supply oxygen through a cannula connected to the mask at a flow rate of 2-4 liters per minute to maintain oxygen saturation at around 85-90%.~Patients aired uninterruptedly during nighttime (minimal between 6-8 hours night)."
45470691|NCT01377818|Procedure|excecise training|"The training program (trained group) was carried out for 12 weeks and sessions of 40 minutes duration:~20 minutes of bicycle ergometer with an initial charge of about 70% of initial maximal oxygen consumption, increasing the load every two weeks as tolerated.~Weightlifting in 2 sets of 6 replicates of 5 simple exercises. These are held at a station multigimnástica (CLASSIC Fitness Center, KETTLER)"
45682010|NCT04402606|Other|Evaluation on skin toxicities|Measurements will be carried out using specific tools, such as the cutaneous ultrasound system (measurement of the skin layers thicknesses, the cutometer (measurement of the elasticity of the skin), the corneometer (measurement of the hydration of the skin), the pH meter (measuring the pH of the skin), the colorimeter (measuring the color of the skin), the tewameter (measuring the insensible loss of water), the sebometer (measuring sebum).
45682011|NCT01671670|Other|acupuncture|In this group, acupuncture is given according to traditional acupuncture theories.
45682012|NCT01671670|Other|sham acupuncture|Sham acupuncture points will be used in this trial, with needle penetration.
45838983|NCT04342728|Dietary Supplement|Ascorbic Acid|Readily available marketed open label ascorbic acid
45838984|NCT04342728|Dietary Supplement|Zinc Gluconate|Readily available marketed open label zinc gluconate
46027565|NCT05198791|Other|Stratification and standard care|Interventional diagnostic procedure (IDP) without linked treatment i.e., standard care. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. In the standard care group, the IDP is performed but the results are not disclosed. The IDP is therefore a sham procedure. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
46027566|NCT04261660|Other|NO intervention|NO INTERVENTION
46027567|NCT01010061|Drug|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
46027568|NCT01010061|Drug|rituximab|375 mg/m^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6.
46027569|NCT01010061|Drug|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
46116294|NCT00917072|Behavioral|Didactic+Simulation|Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center
46116295|NCT00917072|Behavioral|Control|The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
46116296|NCT02575131|Other|whole wheat bread yeast basis|
45682013|NCT03154840|Drug|Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU|Investigate the Relative Bioavailability among Different Eutropin Formulations
45682014|NCT04404790|Drug|Anfibatide 5 IU/60kg|5 IU/60kg IV administration of Anfibatide with 5 minutes
45838985|NCT04342728|Dietary Supplement|Ascorbic Acid and Zinc Gluconate|Readily available marketed open label ascorbic acid and zinc gluconate
46116297|NCT02575131|Other|Oatmeal|
46116298|NCT02575131|Other|Cheerios|
46116299|NCT02575131|Other|whole wheat sourdough bread|
46116300|NCT02575131|Other|standard breakfast|
46116301|NCT02598830|Dietary Supplement|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
45682015|NCT04404790|Drug|Anfibatide 5 IU/60kg +0.002 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
45682016|NCT04404790|Drug|Anfibatide 5 IU/60kg +0.004 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
45682017|NCT04404790|Drug|Anfibatide 5 IU/60kg +0.008 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
45838986|NCT04342728|Other|Standard of Care|Readily available prescribed medications/ supplements- None study supplements
45838987|NCT04342650|Drug|Chloroquine Diphosphate|150mg tablets Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
45838988|NCT04342650|Drug|Placebo oral tablet|150mg placebo tablets
46116302|NCT02598830|Dietary Supplement|Placebo|Olive oil, encapsuled
46116303|NCT05285670|Behavioral|Digital counseling plus interactive two-way SMS dialogue|We will utilize a digital counseling tool on a tablet to provide initial reproductive life planning counseling while waiting for an HIV care provider. We will then use Mobile WACh, a human-computer hybrid system that enables seamless two-way SMS communication and patient tracking, to provide consistent support to women following enrollment and for up to 2 years. Women will receive automated theoretically grounded SMS messages targeting the appropriate reproductive health needs and will have the capability to respond and spontaneously message a nurse based at the clinic. . Automated SMS will be delivered at times and in languages based on patient preferences, weekly the first 3 months, every other week in months 4-12, and monthly during the last year of the trial. If there is a change in the reproductive health needs, more frequent messaging will be re-initiated at the same frequency as enrollment.
46116304|NCT02578251|Drug|Paracetamol|
46027570|NCT03502603|Diagnostic Test|Railroad Test|This is a test designed to evaluate visual perception capacities and requires the participant to match photographs with railroads as a central theme. The participant is presented with a photograph image at the top of the screen and is asked to match it to one of the two, three or four choices in the lower portion of the display.
46027571|NCT03502603|Diagnostic Test|Swamp Test|This is a test of immediate visual memory/attention for photographs with swamp wetlands as a central theme. The participant is briefly presented with a photograph which is replaced by two, three or four choices, one of which the participant is asked to select as the initially presented image.
46116305|NCT02578251|Drug|Pethidine|
46116306|NCT03971552|Procedure|gadolinium-enhanced extracranial magnetic resonance angiogram|288 of the 912 acute ischemic stroke patients received gadolinium-enhanced extracranial MRA additionally to the standardized stroke MRI imaging protocol.
46116307|NCT05285358|Drug|Cisplatin|Given IV
46116308|NCT05285358|Drug|Gemcitabine|Given IV
46116309|NCT05285358|Drug|Nab-paclitaxel|Given via PIPAC
46116310|NCT05285358|Other|Quality-of-Life Assessment|Ancillary studies
46116311|NCT05285358|Other|Questionnaire Administration|Ancillary studies
45470692|NCT01377818|Procedure|Both|both types of intervention
45470693|NCT01377740|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
45470694|NCT04345965|Procedure|Endovascular procedure|Endovascular therapies for erectile dysfunction
45682018|NCT04404790|Drug|Anfibatide 7 IU/60kg|7 IU/60kg IV administration of Anfibatide with 5 minutes
45682019|NCT04404790|Drug|Anfibatide 7 IU/60kg +0.002 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
46116312|NCT00746330|Drug|Mometasone furoate/formoterol fumarate (MFF)|Formoterol fumarate dihydrate / mometasone furoate combination product 10 μg / 100 μg delivered via Pressurized Metered Dose Inhaler (pMDI). One dose consisted of 2 puffs x 5 μg / 50 μg.
46116313|NCT00746330|Drug|Formoterol fumarate 12 μg pMDI (F12M)|Formoterol fumarate dihydrate 12 μg delivered via Pressurized Metered Dose Inhaler (pMDI) (1 dose = 2 puffs x 6 μg).
46116314|NCT00746330|Drug|Formoterol fumarate 12 μg DPI (F12D)|Formoterol fumarate dihydrate 12 μg delivered via Dry Powder Inhaler (DPI).
46116315|NCT00746330|Drug|Placebo to F12D|Placebo to formoterol fumarate DPI delivered via DPI
46116316|NCT00746330|Drug|Placebo to F12M/MFF|Placebo to formoterol fumarate pMDI and formoterol fumarate / mometasone furoate delivered via pMDI
46116317|NCT00714207|Behavioral|NOT program|Students in this arm of the study received the reformatted NOT intervention
46116318|NCT00714207|Behavioral|NOT controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
46116319|NCT00714207|Behavioral|Kicking Butts intervention|Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
46116320|NCT00714207|Behavioral|KB controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
46116321|NCT02590224|Drug|Ferrous bis-glycinate|
46116322|NCT02590224|Drug|Ferrous glycine sulphate|
46116323|NCT00709449|Drug|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
46116324|NCT00709449|Drug|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
46116325|NCT00709449|Drug|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
45470695|NCT04018508|Other|Massage|Massage intervention including effleurage, petrissage and energy work/Reiki at a pressure of 2 or less (Walton Pressure Scale)
46116326|NCT05340816|Other|Manual Lymphatic Drainage|Manual lymphatic drainage will apply to the neck, abdominal, bilateral inguinal lymph nodes, bilateral anterior/posterior thighs, and lumbal area. Treatment duration will be approximately 30 minutes for 5 days.
46116327|NCT05340816|Device|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation will be apply to abdominal and lumbal area as 100 Hz and 100 msn. Treatment duration will be approximately 20 minutes for 5 days.
46116328|NCT00746252|Drug|risperidone|Children will have a flexible dose titration based on their unique response to the medication (assessed using clinical global improvement scores). Children will be treated for six months using daily, bid dosing.
45470696|NCT05421884|Behavioral|5 Love Languages|Emotional support will be given through utilizing the patient/partners specific Love Language (physical touch, words of affirmation, gifts, quality time, and acts of service).
45470697|NCT05178615|Other|preoperative education|Education about knee anatomy, patophysiology, total knee arthroplasty surgery, pain neurophysiology, management of pain, the importance of exercise
45470698|NCT01383044|Procedure|EVL + carvedilol|EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day
45470699|NCT01383044|Drug|carvedilol|carvedilol 6.25mg-12.5 mg per day
45470700|NCT05421572|Diagnostic Test|Fibrotouch|Fibrotouch will be performed showing the stiffness and fat content of liver
45470701|NCT01377506|Behavioral|lifestyle counseling|21 session group-based behavioral weight management program delivered in senior center over 12 months by lay health educators
45470702|NCT01377506|Behavioral|Cognitive Training|21 session group-based cognitive training program delivered in senior center over 12 months by lay health educators
45470703|NCT03727802|Drug|TRK-250|single and multiple doses (4 weeks)
45470704|NCT03727802|Drug|Placebo|single and multiple doses (4 weeks)
45470705|NCT01377428|Drug|Indacaterol|Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)
46027572|NCT03502603|Diagnostic Test|Presidents Recognition Test|This is a test of history knowledge and facial recognition using pictures of US presidents and non-president distractors. The participant is presented with two photographs and is asked to identify which is the picture of a US president
46027573|NCT03502603|Diagnostic Test|Judgment of Line Orientation|This test requires participants to visually match the orientation of line segments. This is a test of visual perception and was included as a relative equivalent of the Railroad Test.
46027574|NCT03502603|Diagnostic Test|Symbol Span subtest of the Wechsler Memory Scale-IV|This test requires participants to immediately recall a sequence of designs after a brief presentation. This is a test of immediate visual memory/attention and was included as a relative equivalent of the Swamp Test
46027575|NCT03502603|Diagnostic Test|Information subtest of the Wechsler Adult Intelligence Scale-IV:|This test requires participants to answer factual knowledge questions. This is a test of fund of knowledge and was included as a verbal equivalent for the non-verbal Presidents Recognition Test.
46116329|NCT00746252|Drug|aripiprazole|children will have a flexible dosing titration based on their unique response (assessed using clinical global improvement scores). Children will be treated with daily medication for six months.
46116330|NCT02574975|Drug|methacholine|Methacholine,inhaled cumulative dosage 2.5mg
46116331|NCT02574975|Drug|adenosine monophosphate|Adenosine monophosphate ,inhaled cumulative dosage 40mg
46116332|NCT02574975|Drug|leukotriene D4|Leukotriene D4,inhaled cumulative dosage 2.4 μg
46116333|NCT02574975|Device|Astograph Jupiter-21 airway reaction testing apparatus|Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus
46116334|NCT02574975|Drug|budesonide /formoterol|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three months in all participants (80 Anticipated)
46116335|NCT00718770|Drug|Bexarotene|Bexarotene will be given by mouth once a day every day for 1 year. The dose to be used will be 300 mg/m2.
46116336|NCT00714363|Procedure|LASIK|Refractive surgery
46116337|NCT00714363|Procedure|SBK|Refractive surgery
45470706|NCT01377428|Drug|Formoterol|Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)
45470707|NCT03508622|Behavioral|Telehealth group sessions|Telehealth sessions will utilize an online meeting platform and will be conducted by RDs, PTs, psychologists, and MDs, to deliver weight management information/counseling, to group of 5-6 14-18 yos with obesity.
45470708|NCT03508622|Behavioral|Empower clinic|Empower visits for the retrospective control group were multi-disciplinary in nature, occurred at CHLA outpatient clinic, and were intended to be monthly (though actual adherence to recommended attendance was variable). Teen and minimum of one family member were asked to attend monthly visits, as per our standard clinical care.
46116338|NCT02599142|Device|Group A: Closed-face shell|As for arm description
45470709|NCT03083990|Biological|IBI305(Bevacizumab Biosimilar)|3mg/kg, infusion in 90minutes
45470710|NCT03083990|Drug|Avastin(Bevacizumab)|3mg/kg, infusion in 90minutes
46027576|NCT03502603|Diagnostic Test|Digit Span subtest of the Wechsler Adult Intelligence Scale-I|This test requires the participant to repeat sets of digits forward, backward, and to sequence digits in ascending order. This is a test of immediate memory/attention and was included to investigate possible attentional correlates of the Swamp Test. This test includes a performance validity indicator that will permit analyses of validity indicators included with the experimental tests
46027577|NCT03502603|Diagnostic Test|Reading subtest of the Wide Range Achievement Test|This test requires participants to read words printed on a card. This is a test of word knowledge/academic achievement and was included to investigate the academic achievement concomitants of the Presidents Recognition Test.
46116339|NCT02599142|Device|Group B: Open-face shell|As for arm description
46116340|NCT02590302|Other|Implementation Phase|"Core Components of the implementation intervention include:~Hospital and CMHA project commitment~Site champion teams (from hospital and CMHA)~Memorandum of Agreement between Hospital and CMHA~Pre-intervention site visits~Education sessions~Posters/reminders~Instructional videos (HEADS ED video)~Completed pathway implementation includes EDMHCP site-customization and committee approvals, consequent planning and agreements among ED-CMHA partners, delivery of at least two educational workshops, and EDMHCP availability in the ED. An 8-month period for EDMHCP implementation, with negotiated interim target dates was set for each site."
46116341|NCT04561791|Device|Tethered Capsule Endomicroscopy|Participants will be asked to swallow the TCE device. Participants may use mild numbing spray, and lubrication spray to help swallowing. Imaging will be conducted once the TCE device is past the pharynx. The TCE device will be advanced until the stomach and then slowly pull the TCE back up the esophagus. This may be repeated twice.
46116342|NCT04084158|Drug|Toripalimab injection (JS001)|Toripalimab injection (JS001) is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies.
46116343|NCT04084158|Drug|Paclitaxel, Albumin-Bound|Paclitaxel
46116344|NCT04084158|Radiation|Radiotherapy|PTV 50.4Gy/28 fractions, PGTV 61.6Gy/28 fractions, once a day, 5 days a week.
46116345|NCT04084158|Drug|Platinum-Based Drug|carboplatin
46116346|NCT00714441|Behavioral|Lifestyle and Activities Education Program (LEAP-AHEAD)|Patients in the LEAP-AHEAD Program arm will be shown a 40-minute interactional DVD and given the Healthy Habits Health Risk Appraisal, at baseline and 20 weeks that asks questions about diabetes self care practices and other health behaviors and gives recommendations in those areas. A score sheet based on the participant's responses will be left with the participant. At intervals from 0 to 44 weeks, patients will receive emailed informational pamphlets on diabetes and its complications, along with live telephone calls to answer any questions and check-in.
46116347|NCT00714441|Behavioral|Computer Automated Self-Management (CASM)|CASM is a live and computer-assisted, low intensity, automated web and telephony based program that is directed at enhancing and sustaining diabetes self-management behavior over time. It provides education on the importance of healthy eating, physical activity and medication taking, and then asks patients to select an area for behavior change. At baseline patients will have a 45 minutes home visit to help them set goals and familiarize them with the website. A booster session is given at 20 weeks. Patients receive 8 ive phone calls over 12 months to support behavior change efforts.
45470711|NCT04950998|Behavioral|Moving Up - A|Moving Up - A is a physical activity smartphone app for persons with mild cognitive impairment or mild forms of dementia. The app includes a personally tailored set of messages, tips, strategies, and tasks designed to increase physical activity levels and disrupt extended periods of sedentary time. Users also have the ability to track their steps and and sedentary behavior time as well as their progress towards activity goals.
45470712|NCT03252015|Drug|Probe Drug Cocktail|Administered orally
45838989|NCT04342416|Behavioral|Visiospatial Interference|Behavioral: Brief cognitive intervention. A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) with instructions to engage in the task self-guided in the subsequent weeks.
46027578|NCT03502603|Diagnostic Test|Symbol Digit Modalities Test:|This test requires participants to visually match abstract symbols with numbers within a certain time period. The participant either verbalizes or writes the response on an answer sheet. This is a test of speed of information processing and was included to assess speed of response factors pertaining to all of the experimental tests as reflecting speed of information processing.
45470713|NCT03252015|Drug|Lasmiditan|Administered orally
45470714|NCT03252015|Drug|Placebo|Administered orally
45470715|NCT01314027|Drug|Neoadjuvant Chemotherapy with gemcitabine/oxaliplatin|"Patients with resectable cytologically proven adenocarinoma of the pancreatic head are randomized to arm A or B.~Patients randomized to arm A receive an 8-week neoadjuvant chemotherapy with gemcitabine/oxaliplatin. Thereafter, surgery is performed if the restaging does not reveal a contraindication. Finally, all patients receive adjuvant gemcitabine for six months."
45470716|NCT01314027|Drug|adjuvant chemotherapy with gemcitabine|Patients randomized to arm B undergo surgery and receive the same adjuvant treatment as in arm A.
45470717|NCT03708003|Drug|Ibrutinib|"Patients receive 6 cycles (cycle = 28 days) of ibrutinib monotherapy at the daily dose of 420 mg (3x 140 mg).~Venetoclax is added on ibrutinib treatment starting from cycle 7 as weekly dose ramp-up (20 mg, C7 day 1-7; 50 mg, C7 day 8-14; 100 mg, C7 day 15-21; 200 mg, C7 day 22-28; 400 mg, C8-31 day 1-28).~Venetoclax (400 mg d1-28) and ibrutinib (420 mg d1-28) continue until cycle 31. Depending on MRD-neg CR/CRi patients will continue the combination treatment (maintenance) or stop treatment (observation) up to 5 years after cycle 31."
45470718|NCT03708003|Drug|Venetoclax|"Venetoclax is added on ibrutinib treatment starting from cycle 7 as weekly dose ramp-up (20 mg, C7 day 1-7; 50 mg, C7 day 8-14; 100 mg, C7 day 15-21; 200 mg, C7 day 22-28; 400 mg, C8-31 day 1-28).~Venetoclax (400 mg d1-28) and ibrutinib (420 mg d1-28) continue until cycle 31. Depending on MRD-neg CR/CRi patients will continue the combination treatment (maintenance) or stop treatment (observation) up to 5 years after cycle 31."
45838990|NCT04342104|Other|Monitoring for aggravation|"Monitor patients on CPAP or NIV and analyzing possible variables that may predict failure, namely:~lymphopenia~thrombocytopenia~CRP~ferritin~LDH~troponin I~NT-ProBNP~Liver enzymes~D-dimers~radiologic aggravation  1 day and 1 week after starting NIV or CPAP"
45838991|NCT04342104|Other|Evaluate HACOR score effectivity in this patients|Apply the HACOR score after starting NIV and CPAP and later verify if it was effective in predicting NIV/CPAP failure
45470719|NCT05178303|Drug|SB-1121(1)|The daily maintenance, SB-1121(1) dose is to take 2 times a day, 1 tablet each time.
46027579|NCT03502603|Diagnostic Test|Dot Counting Test|This test requires participants to count arrays of dots presented on a card while being timed. This is a performance validity test and was included to ascertain validity factors pertaining to each of the experimental tests.
46027580|NCT00607984|Drug|thiotepa melphalan|thiotepa 900 mg per meter squared total, on days -11,-10,-4,-3 melphalan 140 mg per meter squared total on days -11,-10,-4,-3 autologous stem cell transplant in day 0
46116348|NCT00714441|Behavioral|Computer Automated Self-Management and Problem Solving Therapy (CAPS)|Patients in the CAPS program receive all of the protocol included in the CASM program, and in addition receive a Problem Solving program. Problem solving is a process by which an individual attempts an adaptive solution to stressful, real life problem(s). At baseline there is a 45 minute home visit where the Counselor will introduce the patient to CASM and will go on to teach the patient about diabetes distress and PST. They will then generate a list of distress-related problems to teach the steps of PST. The steps of PST are: problem definition, goal setting, brain storming, decision making, action planning, and solution review. At 20 weeks there will be a booster session. Patients receive 8 live phone calls over 12 months to support behavior change efforts.
46116349|NCT00746096|Drug|IKH-01|ethinyl estradiol 0.035mg and norethisterone 1mg
45470720|NCT05178303|Drug|SB-1121(2)|The daily maintenance, SB-1121(2) dose is to take 2 times a day, 1 tablet each time.
45470721|NCT05178147|Device|Compression bandaging without reference to GraduCheck pressure measurements|To apply compression bandages to legs of volunteers without guidance from the Graducheck device (that lies below the bandages) to assess use of the device.
45470722|NCT05178147|Device|Compression bandaging using GraduCheck pressure measurements to monitor compression pressure|To apply compression bandages to legs of volunteers using the guidance from the Graducheck device (that lies below the bandages) to assess use of the device.
45470723|NCT03083132|Drug|modafinil 50mg|1 capsule oral daily
45470724|NCT03083132|Drug|Placebo oral capsule|1 capsule oral daily
45470725|NCT03683823|Behavioral|Attention guidance|Explicitly guiding attention towards faces during public speaking exposures
45470726|NCT03683823|Behavioral|Control intervention|Public speaking exposures
45470727|NCT03476018|Drug|Z-100|Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
45682020|NCT04404790|Drug|Anfibatide 7 IU/60kg +0.004 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
45682021|NCT04404790|Drug|Anfibatide 7 IU/60kg +0.008 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
45682022|NCT03154762|Device|NIPPV|Application of chronic distension of the airway through NIPPV to produce a reduction in bronchial hyperreactivity.
45682023|NCT03154762|Device|CPAP|4 cmH2O CPAP as the minimum pressure necessary to mobilize the air flow and avoid the space death with no effect on the ventilation.
45682024|NCT04297618|Drug|Xiidra|Xiidra (lifitegrast 5% ophthalmic solution)
45682025|NCT03154918|Drug|GLIDE|The dose and schedule of GLIDE chemotherapy was as follows: gemcitabine 800 mg/m 2 days 1, 8; Peg-ASP 2500 U/m 2 days 4; ifosfamide 1000 mg/m 2 days 1 - 3; dexamethasone 20 mg days 1 - 4; etoposide 100 mg/m 2 days 1 - 3.
45682026|NCT01671904|Drug|Bendamustine|Participants will receive intravenous (IV) infusion of bendamustine (90 or 70 milligrams per square meter [mg/m^2]) on Days 2-3 of Cycle 1 and Days 1-2 of Cycles 2-6.
45838992|NCT04341714|Other|Satisfaction evaluation|Assessement of satisfaction of the telephone consultation
46116350|NCT00746096|Drug|Placebo|Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
46116351|NCT04084236|Device|electrical stimulation|electrical stimulation
46116352|NCT04084236|Device|Sham|no stimulation
46116353|NCT00714519|Drug|Xenaderm® Ointment|Topical, BID or as needed
46116354|NCT00714519|Drug|Placebo Comparator|Topical, BID or as needed
46116355|NCT03950934|Other|no intervention, observational study, perioperative survey|no intervention
46116356|NCT04070859|Procedure|Internal Fixation of Glenoid Fractures|Internal Fixation via (Paltes & Screws, Tension bands. etc)
46116357|NCT00709527|Drug|ARC1905|intravitreal injection
46116358|NCT00715026|Device|Trilogy AB Acetabular Hip Implant System|Total hip replacement with ceramic on ceramic treatment surfaces.
46116359|NCT00714675|Dietary Supplement|Citrulline|1 unit of 10 g L-Citrulline, 1 time on morning during 21 days
46116360|NCT00714675|Dietary Supplement|Amino acids|1 unit of an equivalent quantity of iso nitrogenous of non-essential amino acids(alanine, aspartate, glycine, serine, histidine, proline), 1 time on morning during 21 days.
46116361|NCT00714948|Drug|gemcitabine and cisplatin plus sorafenib|Gemcitabine 1000 mg/m 2 will be administered on days 1 and 8 and cisplatin 35 mg/m 2 will be administered on days 1 and 8. A total of six cycles of therapy will be administered at 21day intervals. Sorafenib 400 mg PO twice daily will be initiated on day 1 of cycle 1 and continued, as tolerated, until the time of disease progression or a maximum of 12 months. The total chemotherapy dose for gemcitabine and cisplatin (GC) may be modified for patients with severe obesity (e.g. body surface area (BSA) > 2.1), after consultation with the Principal Investigator.
46116362|NCT02575053|Procedure|assessment of a new latex protocol|"All powdered latex surgical gloves are removed from the operating theatres, recovery room and surroundings starting from 01-07-2015 in order to create a latex safe environment.~Steps 2 and 3 remain unchanged in respect to ASA( American Society of Anesthesiologists) protocol.~Removal of all materials containing latex from the resuscitation carts.~Further requirements in case of latex allergic patients:~Identification of patients with (suspected) latex allergy.~All materials used during the procedure (catheters, drains, monitoring equipment,…) should be checked for latex.~All latex containing materials should be removed from the room and latex free alternatives should be available.~All staff present in the room should use latex free synthetic gloves.~Operating tables and supports should be made of latex free material or should be covered with blankets.~The entire OR staff is thoroughly educated concerning the latex safe protocol."
46116363|NCT00714831|Behavioral|Physical activity intervention|3-months physical activity intervention
45838993|NCT04341402|Drug|Antifungal Nail Gel Study|Daily Application antifungal gel of miconazole 3% and diclofenac sodium 1% and urea 40% to infected nails.
46027581|NCT04019353|Genetic|cf-DNA Collection|"For all consenting recipients undergoing kidney biopsy between 1 and 12 months post-transplant, a single tube of blood will be drawn (at the time of other blood draws so that there is no additional needle stick) to measure cf-DNA. The tube will be shipped to the California lab for determination of donor cf-DNA. For recipients whose biopsy shows AR, a tube of blood will be drawn at 2, 4, 6, and 8 weeks after initiation of anti-rejection treatment and similarly will be shipped to the California lab for determination of cf-DNA.~Recipients whose exit biopsy shows ongoing inflammation and receiving additional anti-rejection therapy will have an additional exit biopsy additional cf-DNA determinations."
46027582|NCT00609778|Device|LUCAS|Mechanical chest compression
46116364|NCT00714831|Behavioral|Health educational program|Health education sessions and stretching sessions
46116365|NCT00714870|Behavioral|Behavioral nutrition and exercise program|The intervention consists of a behavioral nutrition and exercise program. Meetings occur monthly on a Saturday afternoon and last 4 hours. During this time we cover: 1)registration: monitoring of sedentary activities and liquid choices, motivational interviewing, exercise testing;2)exercise: includes strength training; 3) educational lectures; 4) didactic games and projects.
45470728|NCT03476018|Drug|Placebos|Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
45470729|NCT03466814|Other|Non-Interventional|Non-Interventional
45682027|NCT01671904|Drug|Obinutuzumab|Participants will receive IV infusion of obinutuzumab (100 milligrams [mg]) on Day 1 of Cycle 1; 900 mg administered on Day 2 of Cycle 1; and 1000 mg administered on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
46116366|NCT02575209|Other|GENDER|
46116367|NCT00714714|Drug|Adapalene Gel|adapalene gel 0.3% topically applied daily in a split-face model for two weeks
46116368|NCT00714714|Drug|Tretinoin Gel|Tretinoin 0.1% topically applied daily in a split face model for two weeks
46116369|NCT00441337|Biological|MDX-1106|patients will receive a single dose of MDX-1106 as a 60 minute infusion.
46116370|NCT00709605|Drug|VRC-HIVADV014-00-VP|
46116371|NCT04084938|Procedure|Prostate operation or prostate artery embolization|As described above.
46116372|NCT00578877|Device|SILCS Diaphragm|SILCS Diaphragm used with 5 ml gel
46116373|NCT00578877|Combination Product|Nonoxynol-9 Gel|Gynol II (2% N-9 gel)
46116374|NCT00578877|Combination Product|Buffer Gel|Buffer Gel
46116375|NCT02590146|Behavioral|Non-pharmacologic pain control adjuncts|
46116376|NCT01032343|Dietary Supplement|Omega-3 PUFA|One capsule (4g omega-3 PUFA) daily for 3 months
46116377|NCT01032343|Dietary Supplement|Gelatine|One capsule daily for 3 months
46027583|NCT00609778|Other|Conventional manual resuscitation method|Manual compression
46027584|NCT05143801|Device|High-intensity interval exercise with surgical face mask in a temperate environment|Participants performed high-intensity interval exercise in a temperate environmental condition while wearing surgical face mask
45470730|NCT04121468|Drug|Metformin|Each tablet contains 500mg of metformin hydrochloride
45470731|NCT04121468|Other|Placebo|Each tablet contains no active drug ingredient
45682028|NCT01671904|Drug|Rituximab|Participants will receive IV infusion of rituximab (375 mg/m^2) on Day 1 of Cycle 1 and 500 mg/m^2 administered on Day 1 of Cycles 2-6.
45682029|NCT01671904|Drug|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
45682030|NCT01671982|Other|Tenofovir Dose Adjustment|In subjects with a confirmed CLcr 30 to <50 mL/min, switch tenofovir 300 mg every 48 hours, to 150 mg once daily for 2 weeks.
46116378|NCT05263050|Drug|Cabozantinib|Cabozantinib initiated at 40 mg daily. Dose-escalate or de-escalate based on pre-specified criteria and at set dosing schedules
46116379|NCT02573727|Drug|Nor adrenaline + albumin|
46116380|NCT02573727|Drug|Terlipressin + albumin|
46116381|NCT00709683|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46116382|NCT04085874|Behavioral|Promotion of Food-based recommendations|Prolonged contact through weekly home visits and monthly group meeting for 12 weeks
46116383|NCT04085874|Behavioral|Nutrition counseling from standard health services care|once nutrition counselling from health services
45470732|NCT01377350|Device|"Pneumedicares monitoring system."|50 patients hospitalized due to the decompensated HF are considered for entry. 3 patches will be attached to the patients' thorax that include motion sensors. The system will be attached to the patients at the start of treatment. Patient's signals will be recorded during the entire treatment in the hospital, to the point that there is an improvement in their health condition.
45470733|NCT01377350|Device|"Pneumedicares monitoring system"|Non invasive clinical follow-up of patients with HF deterioration and improvement, by a device-based algorithm. The system comprises of patches attached to the patients' thorax that include motion sensors (Accelerometers) that measure the chest wall dynamics and the mechanics of lung inflation and deflation.
45470734|NCT03285711|Drug|Filgotinib|200 mg tablet administered orally once daily
45470735|NCT03285711|Drug|Lanraplenib|30 mg tablet administered orally once daily
45470736|NCT03285711|Drug|Filgotinib placebo|Tablet administered orally once daily
45470737|NCT03285711|Drug|Lanraplenib placebo|Tablet administered orally once daily
45470738|NCT03648489|Drug|Paclitaxel|Please refer to arm/group description
46027585|NCT05143801|Device|High-intensity interval exercise with surgical face mask in a hot environment|Participants performed high-intensity interval exercise in a hot environmental condition while wearing surgical face mask
46116384|NCT00918840|Biological|DermaVir|DermaVir is a synthetic nanomedicine. The active pharmaceutical ingredient is a single plasmid DNA expressing 15 HIV proteins that assemble to HIV-like particles. DermaVir is topically administered with DermaPrep medical device to target the nanomedicine to Langerhans cells of the skin.These Langerhans cells migrate to the lymph node to induce cytotoxic T cells that can kill HIV-infected cells
46027586|NCT05143801|Other|High-intensity interval exercise without using a surgical face mask in a hot environment|Participants performed high-intensity interval exercise in a hot environmental condition without wearing a surgical face mask
46116385|NCT00918840|Biological|Placebo|Dextrose/glucose solution
46116386|NCT00918840|Drug|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
46116387|NCT02574897|Other|Electronic symptom survey|Standard of care plus daily electronic symptom surveys, the results of which are sent to clinicians electronically.
45470739|NCT03648489|Drug|TAK228|Please refer to arm/group description
45470740|NCT03284606|Device|TAPING|Taping in conjunction with common rehabilitation for hemiplegic patients
45470741|NCT03284606|Procedure|Common rehabilitation|Common rehabilitation for hemiplegic patients
45470742|NCT01382888|Drug|Heparin 2,400 IU /ml Cutaneous Spray|Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication twice daily. Patients will get adequate training before first administration.
45470743|NCT01382888|Drug|Placebo Cutaneous Spray|Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication (placebo) twice daily. Patients will get adequate training before first administration.
45754535|NCT03217097|Drug|Alkylating-based chemotherapy|"The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
46027587|NCT05143801|Other|High-intensity interval exercise without using a surgical face mask in a temperate environment|Participants performed high-intensity interval exercise in a temperate environmental condition without wearing a surgical face mask
46027588|NCT00929734|Drug|Rosuvastatin|10mg tablets, once daily in three months
46116388|NCT02574897|Other|Blinded Electronic Symptom Survey|Standard of care daily clinician interviews with blinded symptom surveys
46116389|NCT00918528|Procedure|Internal urethrotomy|
46116390|NCT00918528|Drug|Mitomycin C - local injection|
46116391|NCT00468481|Drug|Drospirenone/Ethinylestradiol/Methyltetrahydrofolate|0.020 mg ethinylestradiol with 3.0 mg drospirenone and 0.451 mg L-5-methyltetrahydrofolate (L-5-MTHF)
46116392|NCT00468481|Drug|Drospirenone/Ethinylestradiol (Yaz)|0.020 mg ethinylestradiol with 3.0 mg drospirenone
46116393|NCT00714168|Behavioral|Standard Behavioral Weight Loss Program|This program will include group sessions that will focus on modifying eating and physical activity behaviors to improve weight loss.
46116394|NCT00714168|Behavioral|Stepped-Care Weight Loss Program|In this program, increases in the intensity of treatment will be based on participants' abilities to achieve predetermined weight loss goals. Participants will initially receive less contact with program staff. The intensity and/or frequency of contact will then increase at 12-week intervals, based on weight loss progress until a 10% weight loss is attained and maintained. The program will stay constant, unless weight loss drops below the 10% level.
46116395|NCT02574819|Drug|Methylnaltrexone (MNTX)|MNTX nearly 0.15mg/kg administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
46027589|NCT00929734|Drug|Placebo|1 tablet, once daily in three months
45470744|NCT01313949|Other|Training program|These diabetes patients will undergo a 32-hour 'Train the trainer' program (4 workshops, 8-hours each) led by health care experts in nutrition, physical activity, psychology and neuro-linguistic program [NLP] trainer to ensure the adequacy of knowledge and skills of these mentors.
45470745|NCT04045041|Behavioral|Acceptance and commitment therapy|An acceptance based intervention with focus on exposure.
45470746|NCT02927366|Drug|QCC374|0.03 mg (2 capsules of 0.015 mg) BID 0.06 mg (1 capsule of 0.06 mg) BID 0.12 mg (2 capsules of 0.06 mg) BID
45470747|NCT02927366|Drug|Placebo Matching|"Placebo matching to QCC374:~0.03 mg BID, 0.06 mg BID and 0.12 mg BID"
46116396|NCT02574819|Drug|Placebo|Placebo administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
46116397|NCT00709839|Drug|Hydrocortisone|0.6 mg/kg body weight, intravenous bolus given at time-point minus 4'
46116398|NCT00709839|Drug|Glucose 33%|1ml/kg body weight, intravenous bolus given at time-point 0'
46116399|NCT02591316|Other|no intervention|
46116400|NCT00715065|Procedure|fMRI Scan|Subjects will undergo a functional MRI scan of the head lasting ~45 minutes. They will be repeatedly shown video clips of blood, other disgusting things, or are neutral.
46116401|NCT00713700|Device|AMPLATZER Duct Occluder II|AMPLATZER Duct Occluder II
45470748|NCT03249909|Device|Exufiber Ag+|gelling fibre dressing with silver
45470749|NCT03249909|Device|Exufiber|gelling fibre without silver
45470750|NCT03249909|Device|Aquacel Ag Extra|gelling fibre with silver
45470751|NCT01382810|Drug|Altaire Gel forming solution|Three times a day for two months
45470752|NCT01382810|Drug|Refresh Tears|Three times a day for two months
45470753|NCT04809116|Drug|Pimavanserin|open-label, fixed-dose pimavanserin 34mg at bedtime for 6 weeks
45470754|NCT03081884|Drug|FACBC PET-CT Imaging|"Participants will fast for 4 hours to normalize their neutral amino acid levels. One hour prior to the scan, participants will drink up to 450ml of standard oral contrast. Participants will lie on the scanning bed while the bed moves through the PET/CT scanner for the CT portion of the exam. After completion of the CT scan, approximately 10 units of FACBC will be injected for the PET scan portion of the exam. The bed will move through the scanner again and the PET portion of the exam will take 30 minutes. The entire visit will take about two hours.~Standard of care procedures include conventional imaging (CT and/or MRI; bone scan and/or NaF PET per institutional standards) and radical prostatectomy with extended pelvic lymph node dissection."
46116402|NCT03949153|Drug|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|Single Nivolumab 240 mg infusion at D0
46116403|NCT03949153|Procedure|Cryotherapy|Cryotherapy using interventional radiology of metastatic lymphadenopathy at D1
46116404|NCT03949153|Drug|Ipilimumab Injection|In situ injection with ipilimumab at D2.
46116405|NCT00709917|Drug|repaglinide|Start dose and freqency to be prescribed by the physician at his discretion following clinical practice
46116406|NCT02574741|Behavioral|Behavioral Therapy|Thrice-weekly individually based language JAE-EMT intervention will be provided by a trained therapist and taught to the child and their caregivers. A total of 36 sessions will be provided over 12 weeks, with 2 per week at UCLA, and one session per week in the home.
46116407|NCT02574741|Drug|Aripiprazole|50% of the subjects will be randomized to aripiprazole (active study medication)
45470755|NCT02726360|Behavioral|survey|The ILR Scale, a non-English language proficiency self-assessment.
46116408|NCT02574741|Drug|Placebo|50% of the subjects will be randomized to placebo (inactive study medication).
46116409|NCT00468169|Drug|Cetuximab|250mg/m2(day 1, weekly x 10);
46116410|NCT00468169|Drug|5-FU|600 mg/m2/day; days 0-5 (120 h total) every other week x 5
46116411|NCT00468169|Drug|Hydroxyurea|500 mg PO BID, days 0-5 every other week x 5
45470756|NCT02726360|Behavioral|Audio record|Audio record the initial visits between patients and their treating physician
45470757|NCT02410850|Device|Oral Appliance|Mandibular Advancement Splints
45470758|NCT01377038|Other|Phenotype assessment|Quantitative sensory testing and patient reported outcome measures used to assess patient pain phenotype
45470759|NCT03077438|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate|0.5 milliliter (mL), Intramuscular
45470760|NCT03077438|Biological|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|0.5 mL, Intramuscular
46116412|NCT00468169|Radiation|Twice-daily radiation|150 cGy per fraction, days 1-5, every other week x 5 (total duration 10 weeks)
46116413|NCT00468169|Drug|Cisplatin|100 mg/m2, week 1 and 4 on day 1 (or 2)
46116414|NCT00468169|Radiation|Accelerated fraction radiotherapy with concomitant boost|72 Gy/42 F/6 W (3-D or IMRT based). Total duration 7 weeks.
46116415|NCT02589990|Behavioral|Strength training|see arm description
46027590|NCT05378542|Behavioral|Mobile application usage|The implementation of the research was carried out in two stages. In the first stage, a mobile application was created, in the second stage, training and counseling was given to the experimental group with the mobile application, and no attempt was made to the control group.
46027591|NCT04251676|Other|Observational study|Observational study
46116416|NCT04015830|Other|electroencephalography (EEG) and event related potentials (ERP)|This is an exploratory study of EEG/ERP measures in older African American and Whites with HIV
46116417|NCT00918606|Drug|LIPO-102|LIPO-102
46027592|NCT04248634|Procedure|Delayed colo-anal anastomosis|"Colo-anal anastomosis performed in two surgical steps:~- Step one: the colon is exteriorized transanally and 5 cm of the colon is left outside without anastomosis creation.~Step two: after 7 days, the excess colon is resected and the colo-anal anastomosis is created."
45470761|NCT01382732|Drug|Carbetocin|Protocol A (carbetocin + placebo) Carbetocin: 100ug (1mL) + Ringer's Lactate 10mL directly into the vein in no less than two minutes.
46116418|NCT05685030|Dietary Supplement|Placebo|product vehicle (sunflower oil)
46116419|NCT05685030|Dietary Supplement|Limosilactobacillus reuteri CCT 7862|Limosilactobacillus reuteri CCT 7862 - 1 x 10e9 UFC/ day.
45470762|NCT01382732|Drug|Oxytocin|Oxytocin 20 U (4mL) diluted in a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr
46027593|NCT00609856|Drug|pioglitazone|tablet, 30 mg, once daily, 26 weeks
45470763|NCT02183870|Drug|Crizotinib|250mg crizotinib bid until end of treatment
46027594|NCT00609856|Drug|insulin glargine|subcutaneous injection, start dose 6-10 units, once daily, 26 weeks
46116420|NCT05685030|Dietary Supplement|Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863|Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863 - 1 x 10e9 UFC/ day
46116421|NCT05334576|Other|Crizanlizumab|Crizanlizumab 5.0 mg/kg infusions will be administered over 24 months
45470764|NCT03076970|Drug|lasmiditan 200 mg|drug including single placebo tablet
45470765|NCT03076970|Drug|Sumatriptan|drug including single placebo tablet
46116422|NCT02959320|Procedure|Hip Hemiarthroplasty|This single-institution, prospective, randomized clinical trial will be performed on consecutive elderly patients admitted for surgical treatment of displaced femoral neck fractures with hemiarthroplasty (HA).
45470766|NCT03076970|Drug|matching placebo|single oral tablet -given with single lasmiditan tablet and with single sumatriptan tablet.
46116423|NCT05251974|Diagnostic Test|Quest beta blocker assay|Blood assay to detect presence of beta blocker medications
46116424|NCT02589444|Dietary Supplement|High-Dose Vitamin D3|50,000 IU of oral vitamin D3 once a week (the standard of care for repletion of vitamin D status by the Cystic fibrosis Foundation)
46116425|NCT02589444|Other|Stool Sample|Participants will be asked to provide a stool sample in a collection container for analysis of stool microbiota. This will be done upon enrollment (baseline) and at 3 month follow-up.
46116426|NCT02589444|Other|Sputum Sample|"Participants will be asked to collect their sputum (the thick mucus or phlegm that is expelled from the lower respiratory tract through coughing) into a kit.~This will be done upon enrollment (baseline) and at 3 month follow-up."
46116427|NCT02589444|Other|Sham Comparator|A placebo capsule taken once a week (manufactured by the same company that makes the Vitamin D supplement).
46116428|NCT02589444|Procedure|Blood draw|Participants will be asked to provide 30 ml of blood collected via a blood draw to measure 25 (OH)D serum concentration and other nutrient markers related to vitamin D including Parathyroid hormone, fibroblast growth factor-23, vitamin D binding protein and markers of immune system/inflammation. This will be done at baseline and at 3 months follow up.
46116429|NCT05325684|Drug|PD-L1 inhibitor|Enrolled patients received durvalumab/ Atezolizumab plus chemotherapy or target therapy treatment (durvalumab,1000mg，iv, d1, 21day as a cycle; Atezolizumab,1200mg iv, d1, 21day as a cycle.)
46116430|NCT00435487|Drug|Dalteparin ( Fragmin)|Dalteparin will be administered at a dose of 120 IU/kg (international units per kilogram) total body weight subcutaneously (SC) every 12 hours up to a maximum dose of 10,000 IU/12 hours.
46116431|NCT00435487|Drug|Unfractionated heparin|Unfractionated heparin will be given intravenously according to a weight-adjusted nomogram (bolus of 60 U/kg [units per kilogram] and initial infusion of 12 U/kg/h [units per kilogram per hour]).
46116432|NCT00918918|Dietary Supplement|Alcohol + orange juice|100 mL Vodka (37.5 vol%; 30 gram of alcohol/day) + 200 mL orange juice
46116433|NCT00918918|Dietary Supplement|Orange juice|200 mL orange juice
45470767|NCT05416346|Behavioral|Digital Cognitive Behavioral Therapy|Cognitive behavioral therapy for insomnia (CBT-i) has been showed to be effective in reducing insomnia symptoms and insomnia-related symptoms, including sleepiness, dysfunctional beliefs and attitudes about sleep, anxiety and depressive symptoms
45470768|NCT05416346|Behavioral|Sleep Hygiene Education (SHE)|The SHE group received sleep hygiene education delivered in text form, and the same intervention as the dCBT-i group did after four weeks.
45470769|NCT04801394|Procedure|hernioplastic and insertion of FLaPp® composite mesh|"After the reduction of the large incisional hernia, the polypropylene transparent film of this mesh (lower flap) was sutured to the margins of the residual peritoneum and posterior rectus sheath as a neo-peritoneum; the macroporous light polypropylene layer (upper flap) was then sutured circumferentially with full-thickness transabdominal stitches in the retromuscular space."
45470770|NCT04784312|Combination Product|9MW1411 injection|9MW1411 injection
45470771|NCT04784312|Combination Product|9MW1411 injection placebo|9MW1411 injection placebo
45754536|NCT04147988|Other|screening and diagnostic assessment DONALD T unit list|Screening and diagnostic assessment of the group of people awaiting assessment, and thus test the feasibility of a screening and diagnosis procedure for autism in adults without intellectual disabilities
46027595|NCT02873169|Other|Implantable cardioverter-defibrillator|Collection of clinical, biological, hemodynamic and rhythmic data
46027596|NCT05116813|Drug|Dipraglurant|Oral 50 mg and 100 mg tablet
46027597|NCT04877197|Behavioral|BA-HT|Behavioral Activation for depression delivered via home-based telehealth (BA-HT) will be implemented over 12, weekly 50-minute sessions via VA approved telehealth software.
46116434|NCT02589678|Biological|Tdap - IPV Vaccine|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, combined with inactivated poliomyelitis vaccine (0.5 ml) will be administered intramuscularly.
45682031|NCT03154684|Other|STARK intervention|"The STARK Intervention is a new care concept for hip fracture patients that enable hip fracture patient to return to their home directly after discharge from acute care. The STARK comprehensive autonomy health care package includes following services;~Multidisciplinary collaboration of geriatricians, nurses and Spitex (ambulant nursing service at home) starting already during acute care~Inspection of the environment at the patient's home~Care and autonomy support~Social life support~Secondary prevention strategies:~Home exercise program (3x/weeks)~Protein enriched food preparation (20g whey protein/day)~Support to take vitamin D supplementation (2000 IU/day)~Recommendation and support to eat calcium rich foods~Motivation to be physically active"
46116435|NCT02589678|Biological|MMR Vaccine|A live attenuated virus vaccine against measles, mumps and rubella (0.5 ml) will be administered intramuscularly.
46116436|NCT02590848|Dietary Supplement|Walnut intake|Nutritional intervention: 30g walnut kernels per day
46116437|NCT05234970|Other|Wysa|Participants in the intervention arm will be able to log into the Wysa app at any time of day. They can chat with the AI-based bot, Wysa, or choose to complete different self-care exercises. These exercises are grouped into tool packs, which include dealing with relationships, overcoming loneliness, managing mood, among many others. Users can engage in simple, therapeutic exercises including mindfulness and cognitive re-structuring for negative thinking.
46116438|NCT05234970|Other|Harvard College App|Participants in the control arm will be given instructions on how to download and utilize the Harvard College App. Students assigned to this app receive instructions on how to utilize the app to navigate resources on campus to support their mental health including professional and peer support groups and how to make an appointment at the Counseling and Mental Health Services. Participants cannot send messages or share any information through the app.
46027598|NCT04877197|Other|Standard Care|Best practices standard care delivery for post-CVD hospitalization as regularly implemented at the RHJ VAMC. Standard care may include all or some of the following: post-operative follow up, referral to VA primary care clinic at 1 month post-procedure, primary care visit with VA mandated assessments of pain and depression with referral for these conditions, referral to facility-based or home-based cardiac rehabilitation program as appropriate. All participants in this condition will be referred to mental health care. In addition, these participants will receive a weekly telephone call from project staff during which time supportive questioning about patient progress and general mood and recovery.
46027599|NCT04527757|Procedure|Inhalation induction|For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O).
46116439|NCT05328258|Drug|Triptorelin Embonate|"11.25 mg will be given for subjects having at least 3 months gonadotoxic treatment, one injection of 11.25 mg will compensate for 3 months' effect of the study drug.~3.75 mg will be given for subjects during one-month of gonadotoxic treatment, one injection of 3.75 mg will compensate for 1 month' effect of the study drug."
46116440|NCT05328258|Drug|Sodium Chloride solution 0.9%|One injection compensating for 3 months' effect OR one injection compensating for 1 month' effect to maintain the study blind.
46027600|NCT04527757|Procedure|Intravenous induction|For the intravenous induction, commonly used induction anaesthetics will be used (propofol, etomidate, ketamine, midazolam).
45682032|NCT03154684|Other|Standard of Care|Standard of Care involves inpatient rehabilitation or home-based or inpatient transitional nursing care
46027601|NCT00613249|Drug|Dapivirine Gel 4750, 0.05%, 2.5g|intravaginal gel, dosed daily
46027602|NCT00613249|Drug|Dapivirine Gel 4789, 0.05%, 2.5g|intravaginal gel, dosed daily
46027603|NCT00613249|Drug|HEC-based Placebo Gel|intravaginal gel, dosed daily
46116441|NCT05319288|Device|Acupuncture|In DPOG, motion style acupuncture would be used; in LPMG, Traditional Chinese Medicine acupuncture is used.
46116442|NCT04084782|Device|Fungal Nail Treatment Kit|The treatment kit consists of 5 disposable nail files to be used to remove the top layer of the infected nail at various times throughout the use of the product and a liquid formulation and brush applicator.
46116443|NCT02591004|Drug|Magesium sulphate|*Experimental: Group A: Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins & 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first)
46116444|NCT02591004|Drug|Nifedipine|*Active Comparator: Group B Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses
45682033|NCT03732118|Device|Eye-tracker Mobile EBT|Use of the eye-tracker for the diagnosis of minimal HE by studying the characteristics of saccades and anti-saccades during a day hospitalization.
46027604|NCT00613561|Drug|Fludarabine, Busulfan, and Anti-Thymocyte Globulin|Patients on this study will receive 5 days of Fludarabine, 1 day of Busulfan Test Dose, 2 Days of Busulfan Regimen Dose, and 4 days of Anti-Thymocyte Globulin
46116445|NCT02591004|Radiation|Doppler on fetal middle cerebral artery|both group A and group B: ultrasound doppler to measure the mean pulsility index (PI) and resistance index (PI) of the middle cerebral artery in the fetus twice, once before giving them the drug, and the other after 4 hours of starting the loading dose.
46116446|NCT05310786|Other|Pharmacist-integrated Medication Treatment for Opioid Use Disorder (PrIMO)|This is not a true intervention, but rather a clinical model of care established at an FQHC in Maine.
46116447|NCT04085562|Drug|Bisoprolol Fumarate 5-10 mg|Bisoprolol as antihypertensive drug in patients on hemodialysis
46116448|NCT04085562|Drug|Amlodipine 5-10 mg|Amlodipine as antihypertensive drug in patients on hemodialysis
46027605|NCT01009983|Biological|panitumumab|Given IV
46116449|NCT05343000|Behavioral|Home-based pulmonary rehabilitation (PR) system|Technology to facilitate remote health coaching through PAP management, sleep scheduling, sleep duration, diet, exercise, medication and more. The tablet and sensors upload the patient's activities, physiological data, and answers to the daily self-report questions to a secure website. This website also allows health coaches to view patient data via overview, weekly, daily, and trend reports. Health coaches call patients regularly to celebrate progress, assist with any issues, and set new goals.
46116450|NCT02591160|Procedure|HCTZ cessation|Patients will stop taking their HCTZ for 3 months
45682034|NCT01672138|Procedure|Pulmonary Vein Antrum Isolation|Radio-frequency catheter ablation of pulmonary vein antrum extended to the left atrial posterior wall
45682035|NCT01672138|Procedure|scar homogenization|PVAI + RF energy will be delivered until all abnormal potentials in the low-voltage areas are eliminated.
46116451|NCT05307978|Drug|ALXN1910|Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.
46116452|NCT05307978|Drug|Placebo|Participants will receive Placebo IV or Placebo SC according to their assigned cohort.
46116453|NCT04084002|Other|physical activity measurement|Physical activity will be measured via accelerometer and self reported questionnaire (Physical activity scale for elderly)
46027606|NCT01009983|Drug|paclitaxel|Given IV
46027607|NCT01009983|Drug|carboplatin|Given IV
46116454|NCT05048238|Drug|Tofacitinib|10 participants with Cutaneous lupus erythematosus (CLE). Consenting individuals meeting all entry criteria will undergo 25 days of treatment with tofacitinib (11 mg orally (PO) daily) with evaluation of UVB-mediated cutaneous apoptosis
46116455|NCT05047536|Drug|KZR-261|KZR-261 for Injection is a lyophilized drug product supplied in single-use vials delivering 75 mg of KZR-261.
46116456|NCT05683626|Drug|Humira|subcutaneous injection
46116457|NCT04082832|Drug|Cu(II)ATSM|oral suspension
46116458|NCT04082832|Drug|Placebos|oral suspension
46116459|NCT05038488|Drug|MIB-626|Fifty participants will be randomized, stratified by sex, remdesivir use, and trial site, in a 3:2 ratio to receive either MIB-626 1.0 g orally or matching placebo twice daily for 14 days.
46116460|NCT05038488|Drug|Placebo|Subjects will be randomized to receive either the placebo or 1000-mg MIB-626 twice daily orally.
45682036|NCT01672138|Procedure|Non-PV triggers ablation|PVAI + Isolation of LA posterior wall + Catheter ablation of triggers originating from extra-PV sites
45682037|NCT04040452|Drug|Continuous ketorolac|Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte) for 48 hours.
45682038|NCT03154450|Device|EncoreAnywhere with data available to review|Encore Anywhere will be installed and available for review by the clinical team
46027608|NCT01009983|Procedure|laboratory biomarker analysis|Correlative study
46027609|NCT01009983|Procedure|immunohistochemistry staining method|Correlative study
46116461|NCT05038488|Other|Home Treatment|Participants, who are discharged from the hospital before the completion of the 14-day intervention period, will be provided sufficient study medication to take home with them so they can continue to take the medication twice daily for the remaining duration of the 14-day intervention period.
46116462|NCT04082988|Diagnostic Test|18F-FDG PET-CT|18F-FDG PET-CT scan
46116463|NCT05038098|Procedure|Gastrectomy|Undergo surgery
46116464|NCT05038098|Drug|Indocyanine Green|Given peritumorally
45470772|NCT04737512|Behavioral|Mindfulness-Based ADHD Treatment for Children|MBAT-C is derived from Mindfulness-Based Stress Reduction (MBSR), a well-known and extensively-studied mindfulness intervention. Unlike all other mindfulness-based interventions, however, MBAT-C is tailored to the needs, abilities, and vulnerabilities of children with ADHD through the use of age-appropriate class length, homework assignments, contemplative practices, and discussion topics.
45470773|NCT04737512|Biological|Goal-Standard Medication (Treatment as Usual)|"Participants will receive gold-standard, non-experimental medication. This treatment arm relies on a step-by-step approach that is designed to mimic pharmacologic treatment-as-usual in the community. The treatment algorithm is as follows:~All participants will start with Concerta; Ritalin may be started if the effect of Concerta wears off mid-day;~If Concerta +/- Ritalin is ineffective or not tolerated, participants will progress to Vyvanse; Adderall may be started if the effect of Vyvanse wears off mid-day;~If Vyvanse +/- Adderall is also ineffective or not tolerated, participants will progress to Kapvay;~If Kapvay is ineffective or not tolerated, participants will progress to Intuniv.~Alternative combinations of the above medications will be considered if the above combinations are ineffective or otherwise not tolerated."
45470774|NCT00726596|Drug|hydroxychloroquine|Hydroxychloroquine will be taken at a dose of 200 mg twice per day in the first 27 patients (cohort A). Once cohort A completed, the dose of hydroxychloroquine will then be increased to 600mg per day (200mg three times per day)(cohort B).
46116465|NCT05038098|Other|Iron Conjugated Polymers in Saline Suspension|Given peritumorally
45470775|NCT01376960|Procedure|elective forefoot surgery|Includes both soft-tissue and osseous procedures.
45470776|NCT04897880|Drug|Panobinostat|Panobinostat capsules, 10mg, starting at a de-escalated dose of 8mg/m2 per day
45470777|NCT03630458|Other|Pearl millet couscous - made in Senegal|Pearl millet couscous (made in Senegal) was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
45470778|NCT03630458|Other|Pearl millet couscous - made in USA|Pearl millet couscous (made in USA) was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
45470779|NCT03630458|Other|Pearl millet thick porridge|Pearl millet thick porridge was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
46116466|NCT02589366|Drug|Lymphoseek plus Vital Blue Dye|intrapatient comparison of Lymphoseek with Vital Blue Dye in detecting lymph node metastases
46116467|NCT05218044|Procedure|Cryoablation|The cryoprobe tip will be inserted into the breast and directed under ultrasound guidance to the location where the ultrasound visible marker is located. Next, the cryoprobe will be used to freeze a 4 X 3 X 3 cm diameter area of DCIS using two separate 10-minute freeze cycles separated by a single 10-minute thaw cycle. The cryoprobe will remain in place the entire time. After the second freeze, the cryoprobe will be withdrawn from the breast and a bandage will be applied to the skin.
46116468|NCT00919230|Drug|Ferrous sulphate tablets|200mg twice daily for four weeks
46116469|NCT02589132|Other|Mobile-Thrive application|Families receive standard of care plus the Mobile-Thrive application
46116470|NCT05684562|Other|Cardiopulmonary exercise test|CPET, the gold standard, will be used in the assessment of cardiorespiratory fitness. The cardiopulmonary exercise test system (Cosmed Quark CPET, Rome, Italy) is a safe method in which the patient can be monitored via ECG during the execution of the individual on a treadmill, and simultaneously lactate measurement, maximal O2 consumption, and CO2 production are evaluated. The Bruce protocol is the most commonly used method for KPET applied with a treadmill. However, since the Bruce protocol prefers high workload preferences, the Modified Bruce/half Bruce protocol with intermediate increments will be used. In addition, dyspnea, leg fatigue, and general fatigue at rest, during the test, and during the recovery phases after the test will be recorded with a sphygmomanometer using the Modified Borg Scale.
46116471|NCT05684562|Other|Pulmonary function test|Pulmonary function testing will be performed with a spirometer (Cosmed Quark CPET, Rome, Italy) connected to the CPET system using standard procedures. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC, peak expiratory volume measured at 25% and 75% of forced expiratory time (FEF 25-75%), and peak expiratory volume (PEF) parameters will be saved.
46027610|NCT04474795|Behavioral|Staff -Educational training|Nurses and community health workers will complete 4 hours of online modules on gestational diabetes - Module 1: GDM Disease, Diagnosis and Complications; Module 2: Nutrition and Physical Activity Management; Module 3: Monitoring, Medications, and Avoiding Hypoglycemia; Module 4: Future Diabetes Risk and Prevention. Effectiveness of the training will be evaluated with pre/post evaluation of diabetes knowledge, attitudes, and self efficacy.
46116472|NCT05684562|Other|Respiratory muscle strength test|Intraoral maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) will be used as indicators of respiratory muscle strength. A portable intraoral pressure gauge (MicroRPM, Micromedical, Kent, UK) and nose clip will be used during MIP and MEP assessments. MIP and MEP measurements will be obtained using standard procedures. 3 measurements will be made where the difference between each measurement is not more than 10% and the maximum value of MIP and MEP will be recorded.
46116473|NCT00918996|Procedure|Omission of Bladder Flap Creation|Omission of bladder flap creation by making uterine incision 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
46116474|NCT00919308|Other|Competency based simulation training|Completion of a hands-on ultrasound guided simulation training protocol on a partial task training simulator until competence is achieved as measured by the ability to cannulate a simulated vein under ultrasound guidance on first pass in five consecutive attempts and correct insertion of a central venous catheter on a partial task training simulator with no technical errors.
46116475|NCT05168202|Drug|CC-95251|Specified dose on specified days
46116476|NCT05168202|Drug|Azacitidine|Specified dose on specified days
46116477|NCT02588196|Drug|Dexamethasone acetate|
46116478|NCT02588274|Device|Acupuncture|Acupuncture is one of the oldest standardized neuromodulatory therapies. The method of acupuncture treatment involves the insertion of needles in acupuncture points according to a system of channels and meridians. The needles are stimulated by manual manipulation, electrical stimulation or heat. The general theory of acupuncture is based on the premise that there are patterns of energy flow through the body that are essential for health. Disruptions of this flow are believed to be responsible for disease. Acupuncture may correct imbalances of flow at identifiable points close to the skin.
46116479|NCT02588274|Device|placebo needle|Placebo needle is a type of control without skin penetration based on the application of placebo needles with blunt needle tips.
46116480|NCT02588820|Drug|Antiretroviral Therapy (Experimental)|"Initial ART until HLA-B5701 results became available (48 hours):~Tenofovir 245 mg once a day~Emtricitabine 200 mg once a day~Dolutegravir 50 mg once a day~Darunavir 800 mg once a day~Ritonavir 100 mg once a day~Maraviroc 150 mg twice a day~Three months continuation treatment (after HLA-B5701 confirmed as negative):~Dolutegravir 50 mg once a day.~Abacavir 600 mg once a day~Lamivudine 300 mg once a day~Darunavir 800 mg once a day~Ritonavir 100 mg once a day~Maraviroc 150 mg twice a day The whole treatment schedule comprises 7 pills per day (in a single dose), except for maraviroc, which will be given twice daily.~Nine months continuation treatment (till complete 12 months treatment):~Abacavir, 600mg once a day~Lamivudine, 300 mg once a day~Dolutegravir, 50 mg once a day"
46116481|NCT04083768|Device|15° and 30° wedge sponges|After the spinal anesthesia is completed, the wedge sponge is placed between the patient's pelvis and ribs and the wedge is removed before the skin is cut.
46116482|NCT00579345|Biological|Cell culture derived seasonal trivalent influenza vaccine (cTIV)|cell cultured trivalent influenza vaccine (cTIV) vaccine administered as 0.5 mL single dose in the deltoid muscle, preferably of the non-dominant arm.
45470780|NCT03630458|Other|Wheat couscous|Wheat couscous was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
45470781|NCT03630458|Other|White rice|White rice was tested as a comparator for gastric emptying rate, glycemic response, fermentability, and appetitive response.
45470782|NCT04460690|Device|Rapid Onsite COVID-19 Detection|saliva assay test for high concentrations of SARS-CoV-2
45470783|NCT04456244|Other|Evaluation of the static posture|Photographing from the back, front and side with ADIBAS posturography in standing position
45470784|NCT02890992|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form: solution Route of administration: subcutaneous injection
45470785|NCT02890992|Drug|statins|Pharmaceutical form: tablet Route of administration: oral
45470786|NCT02890992|Drug|ezetimibe|Pharmaceutical form:tablet Route of administration: oral
45470787|NCT02890992|Drug|cholestyramine|Pharmaceutical form:tablet Route of administration: oral
45470788|NCT02890992|Drug|fenofibrate|Pharmaceutical form: tablet Route of administration: oral
45470789|NCT02890992|Drug|omega-3 fatty acids|Pharmaceutical form: tablet Route of administration: oral
45470790|NCT02890992|Drug|nicotinic acid|Pharmaceutical form: tablet Route of administration: oral
45470791|NCT04268628|Other|Serum and plasma samples analysis|This is a non-interventional study and no drug will be given as part of this study. Serum and plasma samples will be collected from the participants with metastatic castration-resistant prostate cancer to evaluate genetic polymorphism and pharmacodynamic parameters.
45470792|NCT05275296|Device|Intracranial stent for wide-necked aneurysms|Intracranial stent for wide-necked aneurysms
45682039|NCT03154450|Device|EncoreAnywhere with no data available to review|Encore Anywhere will be installed but not available for review by the clinical team
46116483|NCT00579345|Biological|Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).|egg based trivalent influenza vaccine (eTIV_a) administered as 0.5 mL single dose in the deltoid muscle, preferably of the non-dominant arm.
45682040|NCT04027894|Drug|Rifamycin SV MMX|200 mg Rifamycin SV-MMX® (CB-01-11)
45682041|NCT04027894|Drug|Placebo to Rifamycin SV-MMX|Placebo to Rifamycin SV-MMX® Placebo tablets correspond to active tablets with respect to size, taste, and appearance.
46027611|NCT00628485|Device|BION|"The second group will have a High Stimulation paradigm at a frequency that produces strong, fused contractions (20-30pps) for a total of 1h/d, also in two spaced sessions. Stimulation intensity will be adjusted to produce the strongest contractions that are tolerated."
46027612|NCT00628485|Device|BION|"The first group will have a stimulation paradigm employing low-frequency (1-5 pps), supramaximal twitch stimulation. The period of the stimulation will probably be short for the first sessions as the muscles gain strength and fatigue resistance, but will eventually be 60 minutes per day in two spaced sessions of about 30 minutes each."
46027613|NCT00628485|Device|BION|A third group of experimental subjects will have a standardized program of voluntary swallowing exercises. Their BIONs will not be activated until they have worsening of dysphagia, and thus are considered to have failed conventional therapy.
46027614|NCT04471363|Behavioral|Cancer-Specific Exercise education|An audio-recorded PowerPoint presentation created by the study team on the benefits of exercise for survivors, caregivers and romantic couples.
46027615|NCT04297215|Device|DermaCura® Chitosan based antimicrobial therapeutic clothing|"DermaCura® antimicrobial therapeutic clothing (D&M) consists of 98% TENCEL® and 2% elastane. 1% chitosan has been added to TENCEL®~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes."
46027616|NCT04297215|Device|Binamed® silver based antimicrobial therapeutic clothing|"The Binamed® antimicrobial therapeutic clothing (BAP Medical) consists of micro-modal, lycra and woven silver filaments as antibacterial agent.~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes."
46027617|NCT04297215|Device|Binamed® therapeutic clothing without antimicrobial agents|"The Binamed® therapeutic clothing without antimicriobial agents (BAP Medical) is therapeutic clothing made of micro-modal and lycra. Micro-madal is a semi-synthetic wood cellulose fiber. This fiber has a high strength hand elasticity, a high moisture-permeability and feels soft. Lycra ensures an optimal fit on the skin.~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes."
46116484|NCT00579345|Biological|cTIV or eTIV_a|0.5 mL, Single dose of either cell cultured trivalent influenza vaccine (cTIV) or egg based trivalent influenza vaccine eTIV_a administered.
46116485|NCT00579345|Biological|cTIV+PV OR eTIV_a+PV|0.5 mL, Single dose of either cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) administered concomitantly with 23-valent pneumococcal polysaccharide vaccine (PV).
46116486|NCT00715377|Drug|Benztropine|Patients aged ≥ 50 years suffering from a primary psychotic disorder treated with a SGA and benztropine concomittantly at any dose steadily for at least 3 months will be eligible to participate in this study. The dose of benztropine will be reduced by 0.5mg per week. During this 8-week study period, extrapyramidal symptoms will be assessed on a weekly basis. The clinical assessments will be repeated 8 weeks after the initial assessments.
45682042|NCT01672216|Device|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|
45682043|NCT01672216|Device|EMG-biofeedback alone|
45682044|NCT03154216|Behavioral|Exercise|90 minutes of moderate-intensity walking exercise on a treadmill
45682045|NCT03154216|Other|Drink|Beverage to be consumed after exercise
45754537|NCT03623828|Drug|Apomorphine Hydrochloride 50Mg/10mL Prefilled Syringe|Product administered using an external continuous subcutaneous infusion pump.
45754538|NCT03704207|Other|nNO testing|Collection of already performed clinical data and nNO testing
45470793|NCT03603912|Drug|Metformin|Metformin ER 500 mg daily, titrated at 1 month intervals to 500 mg twice daily, then 750 mg twice daily, as tolerated, for 2 years.
46027618|NCT04850989|Device|Pico Goblin VR headset|We worked with Limbix to tailor content on a Pico Goblin VR headset by creating two exposure therapy themes (general social skills training/dinner party or job interview) based on CBT principles and literature. The Pico Goblin VR headset projected a 5.5-inch diagonal screen size (depth: 139.7 mm; height: 122mm; width: 68mm) with 2560 x 1440-pixel resolution, 3 degrees of freedom, 92° field of view, a refresh rate of 70Hz, and 54-71mm interpupillary distance (Kyoto, 2017). It was chosen because displays of the pre-recorded VRE videos could be smoothly operated wirelessly with a tablet that showed the selected scenes in real-time. Further, the headset could be conveniently switched on and off, and dovetailed the participant's head motion. These scenes were filmed with a 360° stereoscopic camera, each lasting between 1.5 to 10 min.
46027619|NCT02873091|Procedure|Epidural analgesia|
46027620|NCT02873091|Procedure|Continuous epidural infusion|
46027621|NCT02873091|Procedure|Intermittent epidural bolus|
46027622|NCT02873091|Drug|ropivacaine|
46027623|NCT02873091|Drug|sufentanil|
46027624|NCT03905083|Other|Exercise Rehab|Participants who do the Exercise Rehab will engage in up to four center-based exercise rehab sessions each week for approximately 12 weeks; each session lasting roughly 1-hour with a stimulus (exercise) phase and a mix of warm up and cool down. Cycle ergometer and treadmill exercise may be used.
46027625|NCT04298775|Procedure|spinal anesthesia with morphine|
46027626|NCT04298775|Procedure|spinal anesthesia without morphine + peripheral nerve block|
46027627|NCT04285359|Procedure|Intracranial Interventions|Neurosurgical elective intracranial interventions: supra- and infratentorial craniotomies, transnasal endoscopic interventions.
46027628|NCT01215227|Drug|Preladenant|Daily for 40 weeks: 2, 5, or 10 mg preladenant tablet each morning; 2, 5, or 10 mg preladenant tablet each evening (approximately 8 hours after the morning dose)
46027629|NCT01215227|Drug|Rasagiline|Daily for 40 weeks: 1 mg rasagiline capsule each morning
46027630|NCT01215227|Drug|Placebo to preladenant|Placebo to match preladenant given daily for 40 weeks: placebo tablet each morning; placebo tablet each evening (approximately 8 hours after the morning dose)
46027631|NCT01215227|Drug|Placebo to rasagiline|Placebo to match rasagiline given daily for 40 weeks: placebo capsule each morning
46116487|NCT04083924|Other|Basic cardiac ultrasound training with Butterfly iQ handheld ultrasound|Pre-training online module of the American society of Echocardiography and hands-on training of basic cardiac ultrasound with Butterfly iQ handheld ultrasound.
45470794|NCT03603912|Behavioral|Lifestyle/Risk Factor Modification|Diet/nutrition counseling and exercise prescription with follow-up visits, sleep apnea screening and treatment if detected, optimization of guideline-directed medical therapies for hypertension, coronary artery disease (CAD), hyperlipidemia and heart failure (HF).
46027632|NCT04206371|Diagnostic Test|Defibrillator threshold testing|Under general or local anesthesia. Induction of Ventricular Fibrillation or R-wave synchronized shock
46027633|NCT05429957|Other|Muscle Energy Technique|"Muscle energy technique (Post Isometric relaxation) three times per week for 8 weeks.~MET of the Iliopsoas~MET of Piriformis muscle~MET of Quadratus Lumborum muscle~MET of Erector Spinae muscle"
46027634|NCT05429957|Other|Aerobic Exercises|"Aerobic exercise (treadmill walking) three times per week for 8 weeks~Warm-up phase: in which each patient alternately steps their legs forward, backward, and sideways in each direction for 5 min~Active phase: Treadmill speed was 3km/hour for 5 weeks and progress to 4km/hour after 5 weeks for 20 min.~Cool down phase: During a cool down period take a deep breath with both arms overhead and exhale while bringing the arms down, shaking out the legs and arms for 5 min."
46027635|NCT01009515|Drug|Paclitaxel, carboplatin, temozolomide|Combination chemotherapy was administered for up to 6 cycles
45470795|NCT05275062|Drug|IM92 CAR-T cells|2.5×10^8 CAR-T cells
46027636|NCT04550481|Procedure|Biospecimen Collection|Undergo blood sample collection
46027637|NCT04550481|Drug|Lisinopril|Given PO
46027638|NCT04550481|Procedure|Liver Ultrasonographic Elastography|Undergo transient elastography (Fibroscan)
46027639|NCT04550481|Procedure|Magnetic Resonance Elastography|Undergo PDFF MRE
46027640|NCT04550481|Procedure|Magnetic Resonance Imaging|Undergo PDFF MRI
46027641|NCT04550481|Procedure|Proton Density Fat Fraction|Undergo PDFF MRI/MRE
46027642|NCT04550481|Other|Questionnaire Administration|Ancillary studies
46027643|NCT01214915|Drug|Anagrelide Hydrochloride|Subjects will be started at 1.0 mg per day and titrated as necessary.
46027644|NCT04297527|Procedure|Conventional Physiotherapy|Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in prone and supported with a pillow under the abdomen, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the lumbar region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
46116488|NCT05023980|Drug|Pirtobrutinib|Oral
46116489|NCT05023980|Drug|Bendamustine|IV
46116490|NCT05023980|Drug|Rituximab|IV
46027645|NCT04297527|Procedure|Mulligan Mobilization|Extension SNAGS in prone, SNAGS in lion position and Lumbar flexion SNAGS in sitting, techniques were used. The techniques were applied in 3 sets with 10 repetitions and 60 seconds rest between sets.
46116491|NCT00718575|Procedure|Glucose/Ischemic Preconditioning Pre-treatment|A 20% dextrose+insulin infusion is administered to the liver via the mesenteric vein beginning after cannulation of the mesenteric vein and ending immediately prior to flushing with cold preservation fluid. Also, after completion of the visceral dissection but prior to cross-clamping, ischemic precondition will occur. This involves occluding the portal vein and hepatic artery to stop blood flow for 10 minutes, then restoring blood flow for 10 minutes.
46027646|NCT01009281|Drug|AIN457|
46116492|NCT02572713|Procedure|Biofluid samplings|Biofluid samplings (blood, saliva, and cerebrospinal fluid (CSF)
46116493|NCT02572713|Procedure|Tissue samplings|Tissue samplings (skin, colon, submandibular gland)
46027647|NCT01009203|Drug|Erlotinib|Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
45470796|NCT01313364|Device|"25G x 1 Needle Autoinjector"|All subjects will self-administer 4 IM injections using single-use autoinjectors.
45470797|NCT04357730|Drug|Alteplase 50 MG [Activase]|Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours, given as a 10 mg push followed by the remaining 40 mgs over a total time of 2 hrs. Immediately following the Alteplase infusion, 5000 units (U) of unfractionated heparin (UFH) will be delivered and the heparin drip will be continued to maintain the activated partial thromboplastin time (aPTT) at 60-80sec (2.0 to 2.5 times the upper limit of normal). Re-bolusing of Alteplase, at the same dose, is permitted in the Alteplase-50 intervention group in those patients who show an initial transient response (>20% improvement of PaO2/FiO2 over pre-infusion of Alteplase at any of the measurements at 2, 6, 12 or 18 hours, but <50% improvement of PaO2/FiO2 at 24 hours after randomization); the repeat dose will be given between 24 and 36 hours after the initial Alteplase administration.
45470798|NCT04357730|Drug|Alteplase 50 MG [Activase]|wed by the remaining 40 mgs over a total time of 2 hrs. Immediately following this initial Alteplase infusion, we will initiate a drip of 2 mg/hr Alteplase over the ensuing 24 hours (total 48 mg infusion) accompanied by an infusion of 500 units per hour (U/hr) heparin during the Alteplase drip. After this, heparin dose will be increased slowly to maintain aPTT between 60 and 80 sec, titrated per attending's discretion.
46027648|NCT01009203|Drug|Temsirolimus|In the absence of Grade 3 or higher toxicity, a single, intra-patient dose increase of temsirolims to 20 mg intravenously weekly is permitted after the first 28 day cycle. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
46027649|NCT01009047|Drug|Paliperidone extended release (ER)|Paliperidone ER will be administered as oral capsule at a dose of 6 mg for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
46027650|NCT01009047|Drug|Aripiprazole|Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
46027651|NCT04205097|Drug|Neostigmine + glycopyrate|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
46027652|NCT04205097|Drug|Sugammadex|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 2-4 mg/kg
46027653|NCT04285047|Other|Advancing Patient Experience (APEX) in COPD|Involves both EMR and PRIO data
46027654|NCT04283955|Drug|High-dose MTX based chemotherapy|Patients received MTX therapy at the dose of 5g/m2 for 24 hours. Each dose of HD-MTX therapy was followed by 6~7 times of leucovorin rescue 12 hours after the end of MTX infusion, at the dose of 15 mg/ m2 every 6 hours. The plasma MTX levels were monitored at 0, 24, 48, 72 hours from the initiation of HD-MTX infusion. To maintain the urine pH at approximately 7~8, intravenous hydration and alkalization at the dose of 1,500ml/ m2 per day were achieved 12 hours prior to the initiation of HD-MTX administration (D0) and 3,000ml/ m2 per day lasted for the following 3 days (D1 to D3). CF was used to rinse mouth to prevent oral mucositis from D1 to D3. We closely monitored the volume and pH of the urine via routine test from D0 to D4.
46116494|NCT02572713|Drug|DaTSCAN™|
46116495|NCT00710073|Device|sono-electro-magnetic therapy (Sonodyn Medico Star)|twice a day for 10 minutes during 6 or 12 weeks
46116496|NCT04070937|Diagnostic Test|vestibular test 1|videonystagmography
46116497|NCT04070937|Diagnostic Test|vestibular test 2|video head impulse test
45682046|NCT02564068|Drug|Oxytocin|"To test that intranasal oxytocin administration blunts the deleterious hypoxia/hypercapnia induced changes in heart rate that occur during nocturnal apnea in patients with OSA, we will examine the changes in heart rate in a group of patients that have recently been diagnosed with OSA. Ten subjects that have recently undergone a standard in the sleep-lab diagnostic polysomnography (per standard of care medical guidelines, and not for research purposes) and have been diagnosed with OSA will be recruited into a study to assess the beneficial effects of oxytocin treatment."
46027655|NCT04205565|Drug|High dose group: L-oxiracetam Injection|L-oxiracetam injection, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
45682047|NCT02564068|Drug|Placebo|Group B is a crossover study, where subjects will be randomized to receive either placebo or active drug on their first visit, and then the opposite intervention on their second visit.
46027656|NCT04205565|Drug|Low dose group: L-oxiracetam Injection|L-oxiracetam injection, 3 vials, once a day, IV. Placebo injection of l-oxiracetam, 1 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
46027657|NCT04205565|Drug|Control group: Oxiracetam Injection|Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Oxiracetam injection, 6 vials, once a day, IV.
46116498|NCT04070937|Diagnostic Test|vestibular evoked myogenic potentials|vestibular evoked myogenic potentials to measure the function of otolith organs
46116499|NCT04070937|Diagnostic Test|audiometry|tonal liminar audiometric thresholds
46116500|NCT04070937|Diagnostic Test|CT and MR imaging of temporal bone|Ct and MR imaging of temporal bone
46116501|NCT04070937|Genetic|p.P51S mutation|analysis of presence of p.P51S mutation in COCH
46116502|NCT00715455|Drug|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at approximately 10% the total reversal dose followed by the remaining dose several hours later to counteract RB006 induced anticoagulation.
46027658|NCT04205565|Drug|Placebo group: Placebo Injection|Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
46027659|NCT04205253|Diagnostic Test|Ultrasonography imaging|This study aimed to evaluate the tongue areas and compare the tongue areas before the implementation of rigid direct laryngoscope and after the rigid direct laryngoscope.
46027660|NCT04297059|Other|Ajyal Salima|It comprises in class-activities, meetings with parents and improvement of school foodservice
46027661|NCT04300725|Other|Video Counseling|Patients in the other study arm receive verbal + video counseling prior to their induction of labor.
46027662|NCT04300491|Other|Suspension walking training|Physiotherapy session, objective wlaking with body weight support using a specific device
46027663|NCT04296669|Device|Ergotron LearnFit Sit-Stand desk|An adjustable sit-stand desk design for children
46116503|NCT00715455|Drug|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at 100% of the total reversal dose to counteract RB006 induced anticoagulation.
46116504|NCT00715455|Drug|Unfractionated Heparin|Heparin will be administered per standard of care at sites
46116505|NCT02574663|Drug|TGR-1202|TGR-1202 oral daily dose
46116506|NCT02574663|Drug|nab-paclitaxel + gemcitabine|IV infusion
46116507|NCT02574663|Drug|Oxaliplatin + Folinic acid + Fluorouracil|IV infusion
46116508|NCT02574663|Drug|Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab|IV Infusion
46116509|NCT04417959|Procedure|Phaco-DSAEK|The intervention will be performed as a DSAEK triple-procedure with phacoemulsification and intraocular lens implantation prior to DSAEK.
46116510|NCT04417959|Procedure|Phaco-DMEK|The intervention will be performed as a DMEK triple-procedure with phacoemulsification and intraocular lens implantation prior to DMEK.
46116511|NCT00718653|Dietary Supplement|Lutein|Lutein (12 mg/d)
46116512|NCT00718653|Dietary Supplement|Lutein plus green tea extract|lutein (12 mg/d) plus green tea extract (200 mg/d)
46116513|NCT00718731|Drug|GSI-136|
46116514|NCT00718731|Other|Placebo|
46116515|NCT04083846|Drug|Reference drug|D744 Cap. 1 Cap., single oral administration under fed condition
46116516|NCT04083846|Drug|Test drug 1|CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fed condition
46116517|NCT04083846|Drug|Test drug 2|CKD-385 64 mg formulation II Tab. 1 Tab., single oral administration under fed condition
46027664|NCT01025193|Drug|Belimumab|Belimumab is a fully human monoclonal antibody that recognizes and inhibits BLyS ®. BLyS ® is a B-lymphocyte stimulator protein which plays a role in the development of B lymphocyte cells into plasma B cells, which then produce antibodies that can sensitize a potential transplant recipient. At the time of this trial, belimumab was not yet FDA approved and was being studied in clinical trials for the treatment of systemic lupus erythematosus. Until this trial, it had not yet been used in the transplant setting.
46027665|NCT01025037|Device|Conexa Reconstructive Tissue Matrix|Conexa will be placed as a soft tissue reinforcement in primary open or mini-open rotator cuff repair procedures
46116518|NCT02574507|Behavioral|Couples-Based Behavioral Weight and Symptom Management|Investigators anticipate that the intervention developed in phase I will consist of a total of 12 sessions 90 minutes in length (18 therapy hours) spaced across approximately 5 months. Sessions are spaced to provide participants sufficient time to complete home practice exercises and adequately examine change in weight and maintenance of weight loss. Sessions will be conducted individually for each day. The first 6 sessions will occur weekly and the final 6 sessions will occur biweekly.
46116519|NCT04069845|Drug|liposomal doxorubicin|intravenous liposomal doxorubicin
46027666|NCT01214837|Biological|MenACWY-CRM|This group received a 3-dose primary series at 2, 4, and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
46116520|NCT04070625|Other|Communication book group|Communication book
45470799|NCT05274984|Drug|Placebo|the control group will be given the same volume of saline.
45470800|NCT05274984|Drug|Lidocaine|the experimental group will be given 1.5mg/kg lidocaine and then 2mg/kg/h
46116521|NCT04070625|Other|Control group|Simple speech therapy
46116522|NCT05158140|Biological|V110|Single intramuscular (IM) dose of 0.5 mL V110 a pneumococcal polysaccharide vaccine containing the 23 serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F
46116523|NCT05158140|Biological|V114|Single IM dose of 0.5 mL V114 a 15-valent PCV containing the 15 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F
45470801|NCT05274672|Drug|Nitrofurantoin|Prophylactic postoperative antibiotic use
45470802|NCT05274672|Drug|Cephalexin|Prophylactic postoperative antibiotic use
45470803|NCT05274672|Drug|Sulfamethoxazole Trimethoprim Combination|Prophylactic postoperative antibiotic use
45682048|NCT03985150|Other|Biomechanical analysis of femoralis superficialis atherosclerotic tissue|Tissue collection during above-knee amputation; mechanical testing of tissue; microstructural testing of tissue
46116524|NCT05158140|Biological|mRNA-1273|Single IM dose of 50 μg/0.5 mL mRNA-1273
46116525|NCT05158140|Biological|Placebo for V110|Single IM dose of 0.5 mL placebo for V110
46116526|NCT05158140|Biological|Placebo for V114|Single IM dose of 0.5 mL placebo for V114
46116527|NCT02573805|Device|Rigiscan test|Rigiscan tests are performed in enrolled subjects for consecutive two nights.
46116528|NCT04068987|Diagnostic Test|MRI parametric mapping|Magnetic resonance (MR) sequences (T1 mapping, T2 mapping, T2* mapping, ECV mapping) to determine the MR signal characteristics of the body
46116529|NCT02574585|Biological|Autologous mesenchymal cells transplantation|Two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.
45470804|NCT05274672|Drug|Ciprofloxacin|Prophylactic postoperative antibiotic use
46027667|NCT01214837|Biological|MenACWY-CRM|This group received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
46027668|NCT01214837|Biological|Routine Vaccines|Each 0.5 mL dose of the pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) is formulated to contain approximately 2.2 μg of each of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
46027669|NCT01024959|Other|PCA3 Assay|Post-Digital Rectal Exam (DRE) urine collected prior to prostate biopsy
46027670|NCT02871921|Behavioral|Conversational Engagement|Examine whether increasing social interaction through face-to-face (video chat) conversations could improve cognitive function and whether the efficacy is mediated by improved psychological well-being, targeting older adults aged 75 and older who are socially isolated
45470805|NCT05274672|Procedure|Holmium Laser Enucleation of prostate|Endoscopic transurethral Holmium Laser enucleation of enlarged prostate followed by morcellation of prostatic tissue
45470806|NCT04308434|Other|CSD190601-11|Flavor variant CSD190601-11 of a 1.5% nicotine ENDS product
45470807|NCT04308434|Other|CSD190601-12|Flavor variant CSD190601-12 of a 1.5% nicotine ENDS product
45470808|NCT04308434|Other|CSD190601-13|Flavor variant CSD190601-13 of a 1.5% nicotine ENDS product
45470809|NCT04308434|Other|CSD190601-14|Flavor variant CSD190601-14 of a 1.5% nicotine ENDS product
45470810|NCT04308434|Other|CSD190601-15|Flavor variant CSD190601-15 of a 1.5% nicotine ENDS product
45470811|NCT04308434|Other|CSD190601-16|Flavor variant CSD190601-16 of a 1.5% nicotine ENDS product
45470812|NCT04308434|Other|CSD190601-17|Flavor variant CSD190601-17 of a 1.5% nicotine ENDS product
45470813|NCT04308434|Other|CSD190601-21|Flavor variant CSD190601-21 of a 3.0% nicotine ENDS product
45470814|NCT04308434|Other|CSD190601-22|Flavor variant CSD190601-22 of a 3.0% nicotine ENDS product
45470815|NCT04308434|Other|CSD190601-23|Flavor variant CSD190601-23 of a 3.0% nicotine ENDS product
45470816|NCT04308434|Other|CSD190601-24|Flavor variant CSD190601-24 of a 3.0% nicotine ENDS product
45470817|NCT04308434|Other|CSD190601-25|Flavor variant CSD190601-25 of a 3.0% nicotine ENDS product
46116530|NCT05198466|Device|Electrical Stimulation|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
46116531|NCT05198466|Device|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
46116532|NCT00919074|Procedure|Pancreatic duct stent|Placement of a pancreatic duct stent to facilitate bile duct cannulation
46027671|NCT03672175|Drug|SAGE-217|SAGE-217 hard gelatin capsules.
46027672|NCT03672175|Drug|Placebo|SAGE-217 matched placebo hard gelatin capsules.
46116533|NCT00919074|Procedure|Pancreatic wire placement|Placement of a pancreatic wire to facilitate bile duct cannulation
46116534|NCT05196126|Procedure|Permament pacemaker implantation|PM implantation
46116535|NCT05196126|Procedure|Cardioneuroablation|Biatrial, binodal CNA procedure with anatomical approach will be performed with pre- and post procedural extracardiac vagal nerve stimulation in general anesthesia.
46116536|NCT00710307|Procedure|Blood sampling|Blood samples will be collected at visit 1 (day 1) and at visit 2 (day 14 to 45).
46116537|NCT00710307|Genetic|Genetic analysis|The sample for genetic analyses may be taken at Visit 1. The blood sample volume will be 6 mL.
46116538|NCT05012592|Behavioral|Health Awareness Program TO Reduce Malnutrition and Helminth Infestation among Primary School children|This interventional study period started from September 2021 up to September 2022 (13 months) by school nurses to implement HAPSC. After completing four to five months of the educational session the school nurse will collect midline follow-up data and the endline data will be collected at the end of the interventional study. In this period a total of nine months (except annual leave) will be considered an interventional education period. The intervention group will receive one educational session per week every month. School nurses will be assigned for each class to provide health education. Each session will be conducted for a maximum of 45 minutes. The community worker will be assigned to assist the school nurse and they will communicate with the child's parents about their child's healthy nutrition and good hygiene practice. The significance of healthy eating and hygiene behavior for the children will be shared with the child's parents or guardians properly.
46116539|NCT00715689|Drug|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
46116540|NCT00715689|Drug|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
45470818|NCT04308434|Other|CSD190601-26|Flavor variant CSD190601-26 of a 3.0% nicotine ENDS product
46116541|NCT00715689|Drug|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
46116542|NCT00715689|Drug|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
46116543|NCT00715689|Drug|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
46116544|NCT00715689|Drug|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
45470819|NCT04308434|Other|CSD190601-27|Flavor variant CSD190601-27 of a 3.0% nicotine ENDS product
45470820|NCT03630848|Other|Effect of Protein on Blastocyst Development|Embryo Development Related to The Protein Concentration
45682049|NCT03985150|Radiation|CT or MR angiogram|Obtaining in vivo geometry of diseased artery
46116545|NCT00715689|Drug|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
46116546|NCT00715689|Drug|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
46116547|NCT05012046|Other|Orange juice|Matched for volume (240 mL/ 8 oz) of other test beverages. 100% orange juice.
46116548|NCT05012046|Other|Orange flavoured drink|Matched for volume (240 mL/ 8 oz) of other test beverages. Orange flavoured drink
46116549|NCT05012046|Other|Water|Matched for volume (240 mL/ 8 oz) of other test beverages. Water control
45470821|NCT03630692|Drug|observance of oral drug treatment|Completion of questionnaires at 4 times during patient's oral route drug treatment
45682050|NCT03977272|Drug|Combination drug|Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly
45682051|NCT03977272|Drug|Chemotherapy|modified-FOLFIRINOX
45682052|NCT03154528|Diagnostic Test|serum vitamin D level by ELISA|The study will include 60 patients with androgenetic alopecia (30 males & 30 females) and 30 age and sex-matched healthy volunteers. Study subjects will be recruited from the Dermatology Outpatients' Clinic, Assiut University Hospitals, Assiut, Egypt. Informed consent will be obtained from all subjects
45682053|NCT03947398|Device|BLIMP balloon|Using BLIMP balloon to cross lesion
45682054|NCT03947398|Device|Low profile balloon|using low profile balloon to cross lesion
45682055|NCT01672372|Dietary Supplement|Max Stress B|Participants are to mix one vial per day of either placebo or actual supplement in 1 liter of water and drink over the course of the day
45682056|NCT01672372|Dietary Supplement|Placebo Max Stress B|
45682057|NCT03154372|Other|Expert supervised practice with validated metrics|
45682058|NCT03154372|Other|self guided practice with validated metrics|
45682059|NCT01676506|Drug|Ranibizumab|Intravitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2.
45682060|NCT01676506|Procedure|Ranibizumab Injection|
46027673|NCT01008423|Drug|Budesonide|Budesonide will be administered as per the dose and schedule specified in the respective arm.
46027674|NCT01008423|Drug|Placebo|Placebo matching to budesonide will be administered as per the dose and schedule specified in the respective arm.
46027675|NCT02872077|Other|Auricular acupuncture|
46027676|NCT04296825|Dietary Supplement|Camel milk containing Bifidobacterium animalis A6|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
46027677|NCT04296825|Dietary Supplement|Camel milk|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
46027678|NCT04296825|Dietary Supplement|Bifidobacterium animalis A6|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
45470822|NCT01379144|Drug|latanoprost 75 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
45470823|NCT01379144|Drug|latanoprost 100 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
45470824|NCT01379144|Drug|latanoprost 125 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
46116550|NCT00715767|Behavioral|Assessment|"Cognitive Assessment:~Knowledge base and critical thinking will be evaluated by a 50-question BLS multiple-choice examination. At the designated 4 cognitive assessments in the study (pre-course, immediately post course, 3 months and 6 months) 50 equivalent questions will be used to cover all core BLS objectives. Technical Skills Assessment:~Primary outcome measures of adequacy of chest compressions and ventilations as well as key actions for each of the 3standardized basic life support skill tests during 3-minute testing scenarios. Video review by 2independent experts will be utilized for objective assessment of time and order dependent skills, and manikin output will be utilized to assess qualitative effectiveness of skills (adequate ventilation, compression, and defibrillation).~Survey Instrument for Barriers to Acute Medicine Education:~A survey tool will be used to identify barriers to acute medicine education implementation and efficacy."
46116551|NCT00919542|Drug|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
46116552|NCT00919542|Drug|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
45682061|NCT03154294|Drug|paclitaxel|Paclitaxel will be diluted prior to infusion in 0.9% Sodium Chloride for Injection, USP; 5% Dextrose Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP; or 5% Dextrose in Ringer's Injection to a final concentration of 0.3 to 1.2mg/mL. At ambient temperature (approximately 25°C) and room lighting conditions the solution is physically and chemically stable for up to 27 hours. The diluted product will be prepared and stored in glass, polypropylene, or polyolefin containers; DEHP-containing (polyvinyl chloride (PCV)) containers should not be used. Paclitaxel will be administered using a vented Paclitaxel set with in-line 0.22-micron filter and run over 1 hour.
45754539|NCT03581006|Dietary Supplement|Low-Calorie Mediterranean Diet|Participants in the intervention group will receive 6 months of education and behavioral counseling with self-monitoring to help them adopt a Mediterranean-style, calorie-restricted diet, and engage in physical activity
46116553|NCT00715845|Procedure|Carbon dioxide insufflation|For baseline evaluations, all patients will undergo a battery of neuropsychological testing after obtaining written informed consent and before cardiac surgery. A transesophageal echocardiography and a transcranial doppler will be performed for intraoperative evaluations. For post-operative evaluations, patients will undergo a diffusion-weighted magnetic resonance imaging three to seven days after surgery and have a repeat neuropsychological assessment at six to eight weeks post cardiac surgery. All patients will undergo cardiopulmonary bypass using the same equipment and technique. Patients in both groups will receive a jackson-pratt drain as a gas diffuser. The jackson-pratt drain will be placed 5 cm below the cardiothoracic wound opening adjacent to the diaphragm and if the patient is randomized to carbon dioxide, the flow will be set at 2 litre/min.
46116554|NCT04240626|Drug|Neurontin|600 mg on-call prior to surgery, post surgery 100 mg liquid q 8-12 hours post surgery with Tylenol every 6 hours
46116555|NCT04240626|Drug|Dilaudid Injectable Product|.5-1 mg IV Q3 hours and IV Tylenol 1000mg every 6 hours post surgery transitioning to oral pain control medications (Hycet 7.5/325mg/5 ml, 5-10 ml every 4 hours
46116556|NCT04240626|Drug|Marcaine Injectable Product|0.25% local injectable anesthetic agent infiltrated at all laparoscopic incision sites for both groups.
46116557|NCT04240626|Drug|Oxycodone Hydrochloride|1 mg/ml oral solution, dosage 5-10mg q4h prn for pain control
46116558|NCT04240626|Drug|Hycet 7.5Mg-325Mg/15Ml Solution|Dosage: 10-15ml q4h prn for pain control
46116559|NCT04240626|Drug|Zofran Injection|4 mg IV for nausea control while inpatient, prn
46027679|NCT04296825|Dietary Supplement|Cow milk|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
45754540|NCT03581006|Combination Product|Technology based monitoring and behavioral participation|Intervention participants will use smart phones to connect to intervention applications, WebEx, MyNetDiary
46027680|NCT01012947|Behavioral|Lifestyle Counseling Usual Care|Usual care participants in the group A received no additional services.
46027681|NCT01012947|Behavioral|Lifestyle Counseling Telephone, Bimonth|Participants in the group B received bimonthly telephonic care management based on manual.
46027682|NCT01012947|Behavioral|Lifestyle Counseling Telephone, Month|Participants in the group C received monthly the same telephonic care management and educational materials as those in the group B.
46027683|NCT01012947|Behavioral|Lifestyle Counseling Visit, Bimonth|Participants in the group D received health educator-initiated visit counseling bimonthly.
46027684|NCT01012947|Behavioral|Lifestyle Counseling Visit, Reward|Participants in the group E received health educator-initiated visit counseling bimonthly and reward.
46116560|NCT04240626|Drug|Scopolamine patch|Topical application patch for nausea control, used with/without Ativan.
46116561|NCT04240626|Drug|Ativan|0.5mg IV as needed in conjunction with/without Scopolamine and Zofran for Nausea control
46116562|NCT04240626|Drug|Flexeril Oral Product|5 mg orally q8h prn for muscle spasms.
46027685|NCT00627627|Drug|IPI-504|dose of 400 mg/m2 as a 30-60 minute IV infusion as part of a 21-day treatment cycle
46027686|NCT03665077|Diagnostic Test|Initial blood draw|At baseline, patients will undergo a blood draw.
46116563|NCT04240626|Drug|Tylenol Suspension|1000 mg q6h PRN for pain control.
46116564|NCT00719121|Drug|Talarozole|Topical Application (20 mg)
46116565|NCT00719121|Drug|Differin™, 0.1% adapalene gel|Topical Application (20 mg)
46116566|NCT00715923|Other|Modified consent form|modified consent form used
46116567|NCT00715923|Other|Standard consent form|standard consent form used
46116568|NCT00719199|Drug|IMO-2055|SC weekly injections
46116569|NCT00719199|Drug|Cetuximab|given weekly through intravenous administration. Cycle 1 Day 1 dose given at 400mg/m2, all subsequent doses given at 250 mg/m2.
46027687|NCT03665077|Diagnostic Test|Initial SWE ultrasound|At baseline, patients will undergo a sheer wave elastrography (SWE) ultrasound of their hands including wrists.
46027688|NCT03665077|Diagnostic Test|Blood draw at three months|Blood drawn at three months to evaluate oxylipins.
46027689|NCT03665077|Diagnostic Test|Blood draw at six months|Blood drawn at six months to evaluate oxylipins.
46027690|NCT03665077|Diagnostic Test|SWE ultrasound at six months|SWE ultrasound at six months to evaluate tendon stiffness.
46027691|NCT04296513|Diagnostic Test|High-Definition white light endoscopy.|evaluation of the gastric mucosa with high-definition white light endoscopy (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by
46116570|NCT00719199|Drug|FOLFIRI|Given day 1 of each cycle
46027692|NCT04296513|Diagnostic Test|High-definition magnification with digital chromoendoscopy.|Subject will be evaluated by upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves the use of a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode 1 and mode 2 without optical magnification, to obtain an overview of the gastric body and identify any gross changes in the mucosa, then optical magnification will be implemented.
46116571|NCT00719277|Device|Sleuth Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
46116572|NCT04068675|Behavioral|Group pre-operative counseling|Enrolled patients will participate in a group pre-operative counseling session on the online conferencing platform BlueJeans® prior to their surgery. The sessions will not replace any portion of the pre-operative standard counseling and is designed to review and re-enforce the counseling already provided. The sessions will not review or discuss the specifics of any one individual's cancer or surgery. Rather the counseling session will focus on the universal instructions provided to all patients undergoing major surgery for a known or suspected gynecologic malignancy. The sessions will be led by a physician on a weekly basis with a minimal of three (3) enrolled patients per session and last approximately one (1) hour.
46116573|NCT02589288|Procedure|Continuous Infusion of ropivacaine 0.2%|Postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
46116574|NCT02589288|Procedure|Automatic Intermittent Bolus of ropivacaine 0.2%|Postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% every hour and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
46116575|NCT00710463|Device|non invasive ventilation (Resmed VPAP III ST-A, Respironics Harmony)|non invasive ventilation was performed with commercially available ventilators from the manufacturers Resmed and Respironics.
46116576|NCT00716001|Drug|N-acetylcysteine|
46116577|NCT05136846|Drug|Carboplatin|Given IV
46116578|NCT05136846|Biological|Durvalumab|Given IV
46116579|NCT05136846|Drug|Paclitaxel|Given IV
46116580|NCT05136846|Drug|Papaverine|Given IV or SC
46116581|NCT05136846|Radiation|Radiation Therapy|Undergo RT
46027693|NCT03832153|Procedure|thrombus aspiration|Thrombus aspiration will be performed by experienced interventional cardiologists according to standard practices, as previously described. The intracoronary blood samples will be collected as well during the same procedure and- along with peripheral blood samples- they will be analyzed for the presence of specific miRNAs. The aspirated thrombi will be preserved in 10% formalin solution and will be analyzed using the micro/nano-CT scanners.
46027694|NCT04735861|Drug|Sintilimab|Sintilimab 200mg iv. q3w, up to 2 years.
46027695|NCT04735861|Drug|Bevacizumab Biosimilar IBI305|Bevacizumab 15mg/kg iv. q3w, up to 22 cycles
46116582|NCT02574429|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidenced-based treatment for PTSD. The investigators are offering CPT group over 13 weeks (12 group sessions & 1 individual session). CPT focuses on challenging beliefs that developed or were reinforced following the trauma(s).
46116583|NCT00710229|Drug|Ranibizumab|intravitreal injection
46116584|NCT00710229|Drug|Bevacizumab|intravitreal injection
46116585|NCT05684406|Genetic|Genotyping|Genotyping by Real Time PCR
46116586|NCT00710541|Device|ventilators designed for non invasive ventilation|Patients are advised to use the ventilator for non invasive ventilation as long term treatment for at least 6 hours per day over one year.
46116587|NCT00710619|Drug|activated recombinant human factor VII|This is an observation of how patients/caregivers dose bypassing agents at home for haemophilia with inhibitors
46116588|NCT00710619|Drug|Feiba VH|This is an observation of how patients/caregivers dose bypassing agents at home for hemophilia with inhibitors
46116589|NCT00710697|Drug|Picoplatin|IV 150 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
46116590|NCT05684250|Behavioral|Auditory biofeedback training|For the auditory biofeedback training, subjects are provided with two tones while fixating a target, one tone related to their accommodative response and the second to the target distance. Their task is to match these tones.
46116591|NCT00710775|Procedure|surgical replacement of the aortic stenotic valve|Prior to surgical removal of the aortic valve, the native valve will be dilated under direct vision of the surgeon using a standard valve dilation balloon. The HLT valve will be loaded into a short version of the delivery catheter system and the catheter will be passed across the native valve.Measurements will be taken of the device relative to the anatomic structures of the heart. Once complete, the implant is removed from the native valve and the surgical valve replacement procedure is completed.
46116592|NCT02572245|Device|PF-06410293 PFS|PF-06410293 40 mg administered subcutaneously by Prefilled syringe
46027696|NCT04395859|Procedure|Questionnaire|At inclusion : Questionnaire collecting data concerning the interruption of IVT treatment
46116593|NCT02572245|Device|PF-06410293 PFP|PF-06410293 40 mg administered subcutaneously by prefilled pen
46116594|NCT05192460|Biological|neoantigen tumor vaccine with or without PD-1/L1|In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with PD-1/L1.
46027697|NCT04395859|Other|Data collection up to 1 year|Data collection up to 1 year after resumption of follow-up: visual acuity, OCT : optical coherence tomography, IVT treatment, complications
46116595|NCT00719433|Device|robot therapy (ARMin)|therapy of the affected arm with a robot for eight weeks, three times weekly for one hour
46116596|NCT00719433|Other|conventional therapy|physical and occupational therapy of the affected arm for eight weeks, three times weekly for one hour
46116597|NCT02589054|Other|Monitoring|
46116598|NCT03897699|Device|Transcranial Direct Current Stimulation|A non-invasive neuromodulation technique that can modulate neural activity. Weak electrical current (~2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively.
46027698|NCT02693275|Device|Quotient® System iPad Test|See arm/group description
46027699|NCT04152031|Other|Prompting|Participants receive medication reminders on a smartphone. The reminders are generated through machine learning algorithms that automate the process of medication prompting according to successful medication contexts that occurred in the past.
46027700|NCT03717571|Diagnostic Test|Glenohumeral translation assessment|amount of glenohumeral translation under load
46027701|NCT03685747|Drug|Vancomycin|Vancomycin one-time 20 mg/kg intraperitoneal dose.
46027702|NCT00614341|Device|MedRelief SE 55|4150 Hz signal continuous or pulse, high intensity, high modulation for 6 hours each night during treatment phase
46116599|NCT03897699|Behavioral|Mindful Breathing|MBT is a mindfulness-based intervention that guides participants to pay attention to the present experience. Participants will be trained to become aware of mind-wandering, disengage, and shift attention back to the present experience. Participants will practice mindful breathing using a computerized application that they will be able to access on the web.
46116600|NCT03897699|Other|Sham|Weak electrical current (~2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively. Sham stimulation will serve as a control condition with current applied only for the first and last 30 seconds of the 20-minute session.
46116601|NCT02589210|Other|EpiFix Mesh|Weekly application of EpiFix Mesh and standard of care (moist wound therapy and offloading)
46116602|NCT04069689|Drug|EPX-100 (Clemizole Hydrochloride)|EPX-100 (Clemizole Hydrochloride)
46116603|NCT04069689|Drug|Placebos|Placebo to match EPX-100
45470825|NCT01379144|Drug|latanoprost 50 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
46027703|NCT03651271|Biological|Nivolumab Monotherapy|Single-agent nivolumab will be administered at 360 mg IV Q3W. Participants who continue to show clinical benefit after the first disease assessment will receive nivolumab 480 mg IV Q4W until PD or intolerable toxicity.
46027704|NCT03651271|Biological|Nivolumab and Ipilimumab and Combination for Metastatic Cancer|For nivolumab and ipilimumab combination therapy, nivolumab will be administered at 360 mg IV Q3W, and ipilimumab will be administered at 1 mg/kg IV Q3W for the first 2 doses and then Q6W for the 3rd and 4th doses, followed by single-agent nivolumab 480 mg IV Q4W until PD or intolerable toxicity.
46027705|NCT03651271|Biological|Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate Cancer|For nivolumab and ipilimumab combination therapy, CD8 low arm, approximately 10 participants will be randomly allocated into 1 of 2 cohorts, using different doses of ipilimumab administered in 6-week cycles. Participants assigned to Prostate Cohort A will receive nivolumab 1 mg/kg Q3W and ipilimumab 3 mg/kg every 6 weeks (Q6W) for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity. If the safety profile of Prostate Cohort B is deemed unacceptable, an additional 10 participants will be enrolled in Prostate Cohort A.
46116604|NCT00719511|Drug|Purified allergen dose 1 integrated in a Patch system|Epicutaneous application of a patch
46027706|NCT03651271|Biological|Nivolumab and Ipilimumab (5 mg/kg) Combination for Prostate Cancer|For nivolumab and ipilimumab combination therapy, CD8 low arm, approximately 10 participants will be randomly allocated into 1 of 2 cohorts, using different doses of ipilimumab administered in 6-week cycles. Participants assigned to Prostate Cohort B will receive nivolumab 1 mg/kg Q3W and ipilimumab 5 mg/kg Q6W for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity. If Prostate Cohort B is determined to have a tolerable safety profile, an additional 10 participants will be enrolled to receive nivolumab 1 mg/kg Q3W and ipilimumab 5 mg/kg Q6W for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity.
46116605|NCT00719511|Drug|Purified allergen dose 2 integrated in a Patch system|Epicutaneous application of a patch
46027707|NCT02692573|Other|positioning|prone positioning for the initial 5 minutes of life
46027708|NCT02692573|Other|positioning|supine positioning for the initial 5 minutes of life
46116606|NCT00719511|Drug|Purified allergen dose 3 integrated in a Patch system|Epicutaneous application of a patch
46116607|NCT00719511|Drug|Purified allergen integrated in a Patch system|Epicutaneous application of a patch
46116608|NCT04984122|Procedure|LEEP|According to the size of the cervix, a loop electrode size was selected. The electrical power for the loop electrode was set to 50 W cut and 45 W coagulation in blended mode. LEEP was performed by carefully passing the loop around the transformation zone from 12 o'clock to 6 o'clock. An additional top-hat excision was performed in patients with a lesion deep in the cervical canal. After completion of the excision, hemostasis was exclusively obtained using the ball electrode in spray coagulation mode. No suturing or other methods were used for hemostasis.
46116609|NCT00795821|Drug|LY2216684|Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks
46116610|NCT00795821|Drug|Placebo|Dose: 3 tablets QD for 10 weeks
46116611|NCT04068441|Other|no intervention|No intervention
46116612|NCT04068519|Drug|Tislelizumab|200 milligrams intravenously on Day 1 during each 21-day cycle
46116613|NCT04978272|Drug|Dihydroartemisinin-piperaquine (DP)|Duo-Cotecxin 20mg/160mg tabs by Holley-Cotec, Beijing, China Each treatment with DP will consist of half-strength tablets given once a day for 3 consecutive days according to weight-based guidelines.
46116614|NCT04978272|Other|DP Placebo|Placebos will be identical appearance to DP.
46116615|NCT00719667|Other|coronary artery bypass grafting|on pump off pump
46116616|NCT00710853|Other|YiRen Qi gong|One hour weekly class for 8 week duration
46116617|NCT00710853|Other|Tai Chi|One hour weekly class for 8 week duration
46116618|NCT00710853|Other|Hatha yoga|One hour weekly class for 8 week duration
46116619|NCT04973124|Drug|Dexmedetomidine|These participants will receive intraoperative dexmedetomidine.
46116620|NCT04973124|Drug|Placebo|These participants will not receive intraoperative dexmedetomidine.
46116621|NCT04971720|Drug|Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet|The subject will be randomized, in a double-blind manner to sacubitril/valsartan 49/51 mg once in the morning or once in the evening for a period of 28 days.
46116622|NCT04971720|Drug|Valsartan 80 mg Oral Tablet|The subject will be randomized, in a double-blind manner to valsartan 80 mg once in the morning or once in the evening for a period of 28 days.
46116623|NCT00711165|Drug|Placebo|2 puffs, qd
46116624|NCT00711165|Drug|Mometasone Furoate|400 mcg, qd for 8 weeks
46116625|NCT05683470|Drug|RBS2418|RBS2418 will be administered orally at 200 mg two times per day (BID).
46116626|NCT02588040|Biological|Leukocyte- and Platelet-Rich Plasma (L-PRP)|The Recover L-PRP Mini Platelet Separation Kit aids in the separation of the patient's own blood components by density through the use of a Biomet Biologics centrifuge.
46027709|NCT04327921|Behavioral|Peer navigation social support for smoking cessation|Standard guidelines will be used for brief advice for smoking cessation based on the 5A's. Also, motivational interviewing/guidance will also be used to determine whether enhanced treatment (using a Peer Navigator to navigate smoking cessation, obtain medication and treatment, improve adherence to treatment, and provide social support for quitting) will increase participant's quit attempts and smoking cessation rates.
46116627|NCT00719745|Drug|Prograf|oral
46116628|NCT00719745|Drug|MR4|oral
46116629|NCT02587416|Drug|Gemcabene 300 mg|1x300 mg gemcabene tablets orally once daily (QD) for 11 days
46116630|NCT02587416|Drug|Gemcabene 900 mg|3x300 mg Gemcabene tablets orally once daily (QD) for 11 days
46116631|NCT02587416|Drug|Atorvastatin|2x40 mg Atorvastatin tablets orally once daily (QD)
46027710|NCT04327921|Behavioral|Standard Condition|Standard guidelines will be used for brief advice for smoking cessation based on the 5A's.
46116632|NCT00719823|Drug|Maraviroc|Maraviroc 150mg, 300 mg or 600 mg twice daily administered orally with or without food in combination with other antiretroviral agents. The recommended dose of Maraviroc differs based on concomitant medications due to drug interactions as outlined in the Prescribing Information.
46116633|NCT00919776|Drug|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
46116634|NCT00919776|Drug|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
46116635|NCT00719979|Behavioral|Behavioral intervention (iCBT + TeleCoach)|TABI will include 12 weeks of Internet-based cognitive behavioral therapy (iCBT) combined with brief telephone and email support from a coach.
46116636|NCT00719979|Behavioral|Internet-based cognitive behavioral therapy (I-CBT)|I-CBT will include access to an interactive Web-based intervention designed to teach and facilitate the use of cognitive behavioral skills. The intervention will last 12 weeks.
45470826|NCT05341466|Other|Acute Intermittent Hypoxia|5 consecutive days of 15, 1.5 min episodes at 9% O2 (AIH) alternating with 21% O2 at 1 min intervals
45470827|NCT05341466|Other|SHAM Acute Intermittent Hypoxia|5 consecutive days of 15, 1.5 min episodes at 21% O2 (SHAM AIH) alternating with 21% O2 at 1 min intervals
46116637|NCT00719979|Behavioral|Treatment as usual / Wait-list control|TAU will include standard treatment from participants' primary care physicians. Participants will be able to choose between TABI and I-CBT treatment options after a 6-week wait-list period.
46116638|NCT00720135|Biological|DI-Leu16-IL2 immunocytokine|Given IV
46116639|NCT00720135|Biological|rituximab|Given IV
46116640|NCT00720135|Other|flow cytometry|Correlative studies
45682062|NCT03154294|Drug|TAK-228|TAK-228 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-228 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
46027711|NCT04154761|Procedure|Resection of inferior vena cava and reconstruction|Resection of inferior vena cava and reconstruction with primary repair, resection with autologous or prosthetic patch repair, and circumferential resection with graft replacement
46027712|NCT03586687|Drug|Triamcinolone|Ultrasound guided glenohumeral shoulder joint injection
46027713|NCT04324099|Other|neuroimaging session (with simultaneously acquired eye-tracking)|neuroimaging session, including two functional neuroimaging paradigms (ca. 15-20 minutes each) and a short structural image acquisition (mprage) for coregistration. Functional Magnetic Brain Imaging (fMRI) and simultaneous eye-tracking data will be collected during the paradigms: 1) an emotion processing paradigm (adapted from Passamonti et al., 2010); and 2) an emotional Go/noGo paradigm (adapted from Hare et al., 2008).
46116641|NCT00720135|Other|immunohistochemistry staining method|Correlative studies
46116642|NCT00720135|Other|pharmacological study|Correlative studies
46116643|NCT00720135|Other|laboratory biomarker analysis|Correlative studies
46116644|NCT00720135|Other|enzyme-linked immunosorbent assay|Correlative studies
46116645|NCT00720135|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
46116646|NCT04850274|Behavioral|Remote Therapy Intervention (RTI)|A single ED session followed by 5 remote therapy sessions
46116647|NCT04850274|Behavioral|Artificial Intelligence Remote Therapy Intervention|Optimized by reinforcement learning to step up or down the intensity of treatment between three levels based on patient response to daily assessments.
46116648|NCT02574273|Behavioral|Secret Agent Society (SAS) Program|The Secret Agent Society (SAS) intervention involves subjects participating in 9 weekly two-hour therapy groups ('Club meetings') with 3 to 6 other children. The SAS intervention includes a number of components to help children apply the skills that they learn in the session to home.
46116649|NCT02574273|Other|Waitlist Group / Treatment As Usual|The wait list control condition includes the treatment participants are already receiving (which may include but is not limited to: individual therapy, group therapy, and/or medication management). Therefore, the wait list control condition consists of treatment which is individually tailored for each participant. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits. The wait-list group will then be given the opportunity to participate in the SAS intervention at their treating clinic.
46116650|NCT02588118|Drug|propofol|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
46116651|NCT02588118|Drug|Cisatracurium|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
45682063|NCT03154294|Drug|TAK-117|TAK-117 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-117 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
45682064|NCT03154606|Other|Micellar Casein (#1)|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
45754541|NCT03581006|Other|Usual care group|Control group, who will receive no dietary or behavioral intervention during the trial
46116652|NCT00716391|Other|TPF, radiotherapy and cisplatin.|3 cycles of: cisplatin: 75 mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracil: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy, divided into daily doses of 2 Gray (total days: 35) Cisplatin: 100 mg/m2, i.v., 1 hour, 3 days
46116653|NCT00716391|Other|TPF, radiotherapy and cetuximab.|3 cycles of: cisplatin: 75 mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracil: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy, divided into daily doses of 2 Gray (total days: 35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
46116654|NCT02588898|Device|Blood collection and electrophysiological tests|Blood collected using a conventional method. Electrophysiology was tested after nerve Stimulation. Medical history and symptoms were collected after a standardized interview.
46116655|NCT04068129|Device|photoscreen|Determine amblyopia risk factors
46116656|NCT00716469|Drug|LS11|LS11 will be given as a one-time IV infusion over 3-5 minutes.
46116657|NCT04082598|Drug|Amoxicillin Clavulanate|tooth extractions are performed for all groups and antibiotics prescribed according to the allocation to the different arms
46027714|NCT04324099|Other|Questionnaire (for children) assessing traumatic experiences (Childhood trauma questionnaire (CTQ))|The Childhood Trauma Questionnaire is a brief survey of six early traumatic experiences (death, divorce, violence, sexual abuse, illness or other), and assesses individual's understanding of their childhood trauma.
46116658|NCT04082598|Dietary Supplement|Bifidobacterium longum and Lactoferrin|
46027715|NCT04324099|Other|Social and Health Assessment (SAHA) questionnaire (for children)|Self reported survey assessing social and mental health with four aspects of parenting determined (parental involvement, parental warmth, parental control, and inconsistency of parenting).
46027716|NCT04324099|Other|Massachusetts Youth Screening Instrument (MAYSI-2) (for children)|"The Massachusetts Youth Screening Instrument (MAYSI-2) is a screening instrument developed for detecting mental health needs in youth aged 12-17. Designed as a low-cost, easily administered tool, it screens for multiple issues and can be administered in 10-15 minutes. It is divided into seven scales composed of 52 questions that are designed to detect alcohol/drug use, angryirritable behavior, depression-anxiety, somatic complaints, suicide ideation, thought disturbance, and traumatic experience. Youths answer YES or NO concerning whether each item has been true for them within the past few months."
46116659|NCT03895203|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
46116660|NCT03895203|Drug|Adalimumab|Adalimumab will be administered according to the labeling recommendations.
46116661|NCT03895203|Other|Placebo|Subjects will receive placebo at pre-specified time-points.
46116662|NCT04958226|Drug|Capivasertib|Capivasertib (tablet) will be given as an intermittent schedule (4 days on/3 days off) from Cycle 1 Day 2 until discontinuation. Capivasertib will be administrated in both Part A and Part B.
46116663|NCT04958226|Drug|Midazolam|Single doses of midazolam (syrup, 1 mg) will be given on cycle 1 Days 1, 8, and 12.
46116664|NCT02587494|Procedure|Cardiac catheterization|Cardiac catheterization / coronary angiography is a diagnostic procedure used to define the coronary anatomy and presence of obstructive coronary lesions or culprit lesions. According to the findings, it may lead to percutaneous coronary intervention (PCI) using stents
45682065|NCT03154606|Other|Micellar Casein (#2)|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
45470828|NCT03076190|Behavioral|Psychoeducational My Surgical Success Video|The 90-minute video includes instruction by Dr. Beth Darnall, PhD, a pain psychologist at the Stanford Pain Management Center. She teaches the viewer about the relationship between stress, pain, and catastrophizing and provides instruction and skills to reduce catastrophizing, decrease stress, and increase relaxation.
45754542|NCT00501995|Drug|IV Cyclophosphamide|Cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total 200 mg/kg) followed by granulocyte colony-stimulating factor (5 µg/kg/day)
46116665|NCT04095195|Radiation|MRCP|"Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription"
46116666|NCT04095195|Procedure|Endoultrasonography|"Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription"
46116667|NCT00716547|Drug|ketoprofen in Diractin®|50 mg (b.i.d.)
46116668|NCT00716547|Drug|ketoprofen in Diractin®|100 mg (b.i.d.)
46116669|NCT00716547|Drug|Placebo|b.i.d.
46116670|NCT00716547|Drug|celecoxib|100 mg (b.i.d.)
46116671|NCT02573025|Drug|PEG-IFN alfa-2a BA-free formulation (Test)|Participants will receive single injection of 180 micrograms (mcg) of PEG-IFN alfa-2a BA-free formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
46116672|NCT02573025|Drug|PEG-IFN alfa-2a market formulation (Reference)|Participants will receive single injection of 180 mcg of PEG-IFN alfa-2a market formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
46116673|NCT00720291|Drug|Metronidazole|Patients who are randomly assigned to receive Metronidazole will receive 500 mg po bid Metronidazole for 7 days
46116674|NCT00720291|Drug|Placebo|Patients who are randomly assigned to receive a placebo will receive a placebo pill po bid for 7 days.
46116675|NCT00711399|Device|PulmoTrack® 2010 with WIM-PC™ and WIM-CC™ Technologies|wheeze and cough detection in hospitalized patients.
45470829|NCT01376882|Dietary Supplement|Placebo|Inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH. 1 Size 0 capsule 3 times a day for 14 days and 1 size 0 capsule on day 15.
45682066|NCT03154606|Other|Calcium Caseinate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from calcium casein. All ingredients are GRAS listed and approved.
46027717|NCT04324099|Other|Interpersonal Reactivity Index (IRI) (for children)|The Interpersonal Reactivity Index is a measure of dispositional empathy that takes as its starting point the notion that empathy consists of a set of separate but related constructs. The instrument contains four seven-item subscales (seven Likert items each), each tapping a separate facet of empathy (Empathic Concern, Perspective Taking, Personal Distress, and Fantasy). The 28-item IRI contains four subscales
46116676|NCT00711633|Dietary Supplement|Milk with probiotic and prebiotic activities|Comparison of two different formula for preterm infants
45470830|NCT01376882|Dietary Supplement|Caffeine and Placebo|100 mg Caffeine capsules 3 times per day for 14 days and 1 size 0 capsule of inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH on day 15.
46116677|NCT00711633|Dietary Supplement|Milk without probiotic and prebiotic activities|Comparison of formula for preterm infants
46116678|NCT05684016|Other|NeuroQuant|Reliably defines the volume of those parts of the brain that are important for memory and thinking.
46116679|NCT05684016|Other|Automated Neuropsychological Assessment Matrices|This is like an IQ test.
46116680|NCT05684016|Other|EDSS|Extended Disability Status Score
46116681|NCT05684016|Other|Physical Examination|Physical Examination
46116682|NCT02587338|Device|Verum tDCS|Neuropsychological (Working memory) training for 30 minutes, 6 sessions tDCS during training with 2000 microampere left anadal, right cathodal
46116683|NCT02587338|Device|Sham tDCS|Neuropsychological (Working memory) training for 30 minutes, 6 sessions tDCS during training with 0 microampere
46116684|NCT04842006|Drug|Total neoadjuvant therapy (TNT)|Short radiotherapy (5X5 Gy) and capecitabine/oxaliplatin
46116685|NCT04842006|Diagnostic Test|Minimal residual disease (MRD)|Postoperative MRD on circulating cell-free DNA
46116686|NCT04842006|Radiation|Long radiation therapy|Long-course 50.4 Gy radiation with capecitabine
46116687|NCT00578643|Drug|Busulfan|"Days -9 through -6~1 mg/kg initially (based on weight)"
46116688|NCT00578643|Biological|Alemtuzumab|"Day -5 through Day -2~Dose is based on weight:~Less than 15 kg: 3 mg~More than 15 kg to 30 kg: 5 mg~More than 30 kg: 15 mg"
46116689|NCT00578643|Drug|Cyclophosphamide|"Days -5 through -2~50 mg/kg"
46116690|NCT00578643|Drug|Fludarabine|"Day -5 through Day -2~30 mg/m^2"
46116691|NCT00578643|Drug|Cyclosporine|Cyclosporine will be administered beginning Day -2. Initial dose will 5 mg/kg infused over 24 hours.
46116692|NCT00578643|Procedure|Stem Cell Infusion|Stem Cell: Either bone marrow, cord blood, or peripheral blood stem cells may be used for stem cell transplantation. It is desired to infuse: for bone marrow, nucleated cells ≥ 4 X 10^8/kg recipient weight; for cord blood ≥ 3 X 10^7/kg nucleated cells; for peripheral blood stem cells ≥ 1 X 10^/kg CD34+ cells.
46116693|NCT04082286|Other|Yttrium-90 labelled monoclonal antibody against CD66|
46027718|NCT04324099|Other|Youth Psychopathic Traits Inventory (YPI) (for children)|self-report screening measures to assess psychopathic traits in youth assessing 10 core personality traits associated with the construct (grandiosity, lying, manipulation, callousness, unemotionality, impulsivity, irresponsibility, dishonest charm, remorselessness, and thrill seeking). Each item is scored on an ordinal 4-point Likert scale (1 = Does not apply at all, to 4 = Applies very well). Higher scores reflect an increased presence of psychopathic traits.
46027719|NCT04324099|Other|Reactive Proactive Questionnaire (RPQ) (for children)|The Reactive-Proactive Questionnaire (RPQ) scores (0 (never), 1 sometimes, 2 (often)) for proactive aggression items and reactive items. Proactive and reactive scale scores are summated to obtain total aggression scores.
46116694|NCT02587884|Procedure|TACE|Patients will treated by TACE in 4 or 8 weeks after operation.
46116695|NCT00716703|Other|CT Scan using IV contrast alone|CT scan using IV contrast alone
45682067|NCT03154606|Other|Sodium Caseinate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from sodium caseinate. All ingredients are GRAS listed and approved.
46116696|NCT02588508|Procedure|Warm packs|: The warm packs are held in the mother's perineum during birth. The warm packs are changed as needed to maintain warmth.
46116697|NCT02588508|Procedure|Perineal massage|"The perineal massage will be gently held in the longitudinal direction of the muscle fibers, with movements of the thumb and forefinger, like count coins."
46116698|NCT00720447|Biological|alemtuzumab|
46116699|NCT00720447|Biological|donor lymphocytes|
46116700|NCT00720447|Drug|carmustine|
46116701|NCT00720447|Drug|cytarabine|
46116702|NCT00720447|Drug|etoposide|
46116703|NCT00720447|Drug|melphalan|
45470831|NCT01376882|Dietary Supplement|Placebo and Caffeine|Inert placebo capsules containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH, 1 Size 0 capsule 3 times a day for 14 days and a 100mg caffeine capsule on day 15.
45754543|NCT03589898|Drug|Gabapentin|Single dose of gabapentin 900 mg
46116704|NCT00720447|Procedure|allogeneic bone marrow transplantation|
46116705|NCT00720447|Procedure|peripheral blood stem cell transplantation|
46116706|NCT02587806|Biological|Autologous Bone Marrow-Derived Mononuclear Stem Cells|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
46116707|NCT02587806|Other|Liberation therapy|
46116708|NCT04828824|Drug|Ethinyl Estradiol / Norgestimate Oral Tablet|Those who desire COCs as an intervention are prescribed (over the phone) or given (in person) 3 packs of COCs. They are told to take one pill per day until the first pack is complete and save the remaining 2 packs for possible future use.
46116709|NCT00578565|Drug|Rituximab|Rituximab 1000 mg. I.V.on each days 1 and 15 with repeat dosing at 6 months.
46116710|NCT04082208|Device|High Flow nasal cannula|Administration of high flow nasal cannula during ERCP procedure
46116711|NCT04082208|Device|Low Flow nasal cannula|Administration of low flow nasal cannula during ERCP procedure: standard care
46116712|NCT00716937|Procedure|karydakis flap|Karydakis flap is a type of primary repair of the wound, after complete excision of sacral pilonidal cyst with 2 characteristics 1)lateralization of final scar 2)flattening of natal cleft
46116713|NCT00716937|Procedure|laying open|laying open the site of excision of sinus or cyst without any flap
46116714|NCT02572089|Drug|Naloxone|
46116715|NCT04819386|Other|Active vision therapy sessions with the NEIVATECH Virtual Reality-based system|The active visual therapy sessions with the NEIVATECH Virtual Reality-based system will be 18 in total, will have an average duration of half an hour and will be distributed over a month as follows: 5 sessions in the first two weeks after enrollment (Monday to Friday) and 4 sessions in the next two weeks (Monday to Thursday).
46116716|NCT00919620|Behavioral|stage-specific case-management|Stage-specific case-management for psychosis by designated key-workers according to specified protocol
46027720|NCT04324099|Other|Emotion Regulation Questionnaire (for children)|10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree)
46116717|NCT04069377|Device|LUCAS™ 2 Chest Compression System|LUCAS is a portable device designed to rule out the problems encountered during manual chest compression, capable of performing standard and continuous chest compressions at a depth of 4-5 cm and at least 100 times per minute.
46116718|NCT04069377|Other|Manuel chest compressions by human efforts|In this way chest compressions will be handled by humans themselves.
46027721|NCT04324099|Other|Basic Empathy Scale (BES) (for children)|The Basic Empathy Scale (BES) measures 20 items (affective and cognitive empathy) on a Five-point Likert-type scale.
46116719|NCT02588742|Dietary Supplement|Melatonin|Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
46116720|NCT02588742|Dietary Supplement|Placebo|Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
46116721|NCT00720603|Drug|Plerixafor|Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
46116722|NCT04936854|Drug|Sirolimus 1 mg Oral Tablet|2 mg Sirolimus (two 1 mg tablets) on the first day, followed by 0,5 mg Sirolimus (half 1 mg tablet) per day for 12 weeks.
46116723|NCT04936854|Drug|Methylprednisolone|500 mg Methylprednisolone intravenously once a week for 6 weeks, followed by 250 mg once a week for 6 weeks. Total period of treatment 12 weeks.
46027722|NCT04324099|Other|Pubertal Development Scale (PDS) (for children)|self-report measure of physical development which has been shown to be correlated with measures of pubertal development derived from physical examination. Responses are coded on 4-point scales (1 = no development and 4 = completed development). For girls, a yes-no question about onset of menarche is weighted more heavily (1 = no and 4 = yes). For both genders, ratings are then averaged to create an overall score for physical maturation.
46027723|NCT04324099|Other|Alabama Parenting Questionnaire (APQ) (for parents)|The APQ measures five dimensions of parenting that are relevant to the etiology and treatment of child externalizing problems: (1) positive involvement with children, (2) supervision and monitoring, (3) use of positive discipline techniques, (4) consistency in the use of such discipline and (5) use of corporal punishment (42 self-reported responses, rated on a 5-point Likert scale- 1 (never) to 5 (always) for both child and parent forms)
46027724|NCT04324099|Other|Inventory of Callous Unemotional Traits (ICU) (for parents)|24-item questionnaire designed to provide a comprehensive assessment of callous and unemotional traits.The ICU has three subscales: Callousness, Uncaring, and Unemotional. The ICU is made up of statements with a 4-point Likert scale, ranging from 0 (Not at all true) to 3 (Definitely True), with higher scores indicating greater CU traits.
46116724|NCT00711789|Drug|Angiotensin II|Angiotensin II will be given by continuous infusion for 24 hours starting at a dose of 5ng/kg/min and then titrated to a maximum dose of 15 ng/kg/min according to a blood pressure based protocol
46116725|NCT00711789|Drug|Saline placebo|Saline placebo will be given by continuous infusion according to a blood-pressure base protocol. This protocol will also incorporate noradrenaline for blood pressure control (as is true in the active drug arm), such that blood pressure targets will be rapidly achieved in both arms of the study; the only difference being that in the active drug arm, at least part of the pressor effect will be provided by angiotensin II.
46027725|NCT04324099|Other|Child Behavior Checklist (CBCL) (for parents)|"The eight empirically-based syndrome scales are:~Aggressive Behavior~Anxious/Depressed~Attention Problems~Rule-Breaking Behavior~Somatic Complaints~Social Problems~Thought Problems~Withdrawn/Depressed. Higher scores indicate greater Problems."
46027726|NCT04324099|Other|Griffith Empathy Measure (GEM) (for parents)|self-report 23-item measure of empathy in which the respondent answers each item on a nine-point Likert scale from strongly disagree to strongly agree
46116726|NCT04082052|Behavioral|Single Session Interventions|A single session intervention either active (for self-dislike) or placebo (feelings disclosure)
46116727|NCT00717171|Device|SurgiStim3|Electrical stimulation device that provides interferential, high voltage pulsed current and neuromuscular waveforms in sequence. The device runs continuously for the first 2 days following surgery, then runs 3 times a day for 1 hour on days 3 through 42.
45470832|NCT01376882|Dietary Supplement|Caffeine|Capsule containing 100 mg caffeine, one 3 times a day for 14 days and then one capsule on day 15.
45470833|NCT03329196|Drug|MT-6548|Oral tablet
45470834|NCT03329196|Drug|Darbepoetin alfa|Subcutaneous
46116728|NCT00717171|Device|SurgiStim3|The placebo device is programmed to run for the same amount of time, at the same schedule, using the same waveforms as the functional device over the course of the 42 days. The placebo device, however, will only increase to 80% of the patient-set amplitude after a one minute set-up period and will only turn on for 6 seconds of every minute (3s ramp up, 1s on time, 2s ramp down).
46116729|NCT05683938|Device|Intermittent self-catheterisation|GentleCath™ Air intermittent catheter
46116730|NCT00717327|Other|Counseling for subjects who do not know their medications|Physician interviewer will provide counseling to subjects who indicate through answers that they do not know their medication names.
46116731|NCT00741260|Drug|Neratinib|Neratinib orally once daily continually
46116732|NCT00741260|Drug|Capecitabine|Capecitabine orally on days 1-14 of each 21 day cycle
46116733|NCT02587260|Drug|Ticagrelor|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
46116734|NCT02587260|Drug|Prasugrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
46116735|NCT02587260|Drug|Clopidogrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
46027727|NCT04324099|Other|Social Responsiveness Scale (SRS) (for parents)|Social Responsiveness Scale (SRS) measures social ability of children from 4 years to 18 years old. It is used primarily with individuals with Autism Spectrum Disorder (ASD), family members of individuals with ASD, and others who have social impairments. Parent or teacher questionnaire (65 items on a 4-point Likert scale). High scores are associated with more severe social impairments.
46116736|NCT02572011|Other|Home-based Games Console Balance Training|The balance training intervention involves completing prescribed balance tasks for a minimum of 60 minutes per session, three times a week for 12 weeks (minimum intervention time of 2160 minutes) in their own home. Participants will perform the balance related Wii Fit games that have been suggested previously by professional bodies and amputee therapists (BACPAR Ossur Wii Fit Exercise Recommendations).
46116737|NCT04231344|Device|Laryngoscopy|Laryngoscopic examination of patients with GERD by two physicians
46116738|NCT02596256|Drug|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
45470835|NCT03630380|Other|Clinical History|We will collect clinical history for each patient (days of illness, history of fever, cough, difficulty breathing, vomiting, chest pain).
46027728|NCT03584737|Diagnostic Test|rapid in vitro diagnostic test|IVD for qualitative detection of 3 bacterial pathogens (Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae)
46116739|NCT02596256|Drug|Docetaxel|Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity
46116740|NCT04934358|Behavioral|Physical and motivational follow-up treatment|Physical and motivational follow-up treatment
46116741|NCT04934358|Behavioral|Usual care|Usual rehabilitation program
46116742|NCT04090580|Diagnostic Test|Continuous glucose monitoring|"Subjects enrolled will be randomized 1:1 to either receive a daily dosage of dapagliflozin 10 mg and 2000 mg metformin for 12 weeks (n=18) or 2000 mg metformin (n=18). Patients who do not tolerate metformin at 2000mg dose will be downtitrated to 1500 mg daily. In case patients do not tolerate 1500 mg daily, they will be excluded.~Both groups will be monitored for 7 days using either iPro™ CGM system (Medtronic, Northridge, CA) or Dexcom G6 CGM (Dexcom Inc, San Diego, CA). Basal continuous glucose monitoring will start at week 1 (first visit), and removed at day 7 and final continuous glucose monitoring will start at week 11 and removed 7 days after (final visit)."
46116743|NCT02571933|Other|Pre-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised as an assessment of pain prior to standard analgesia dosing.
46116744|NCT02571933|Other|Post-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised 1-2 hours after receiving standard analgesia as an assessment of pain.
46116745|NCT02571933|Other|Cognitive interview|Patients will answer a series of questions pertaining to the pain scale's ease of use, intuitive nature, and cultural appropriateness.
46116746|NCT04089722|Drug|Deoxycholic Acid|The active ingredient in KYBELLA® is synthetic deoxycholic acid. Deoxycholic acid is a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat.
46116747|NCT05093166|Drug|"Ex vivo expanded autologous human oral epithelium containing stem cells"|The treatment includes a single administration of investigational product through a dedicated surgical procedure of penis wound bed preparation, epithelial surface adaption and product application followed by urethra tubularization and penis reconstruction.
46116748|NCT00720837|Procedure|Visualase® Thermal Therapy System|An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
46116749|NCT03973892|Diagnostic Test|Cere|Magnetic Rseonance imaging for brain tumour follow-up
45470836|NCT03630380|Other|Physical Exam Findings|We will collect physical exam findings including vital signs, WHO criteria for diagnosing pneumonia, and lung auscultation findings.
45682068|NCT03154606|Other|Milk Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from milk protein caseinate. All ingredients are GRAS listed and approved.
45470837|NCT03630380|Other|Laboratory Findings|We will collect laboratory findings (white blood cell counts, differential, and c-reactive protein) if ordered by the clinician.
45470838|NCT03630380|Other|Lung Ultrasound|We will perform lung ultrasound on all patients.
45470839|NCT04656002|Drug|Vactosertib|Take Baektoseotip (TEW-7197) twice a day for 5 days and take a break for 2 days (5D on/2D off). With this method, progression up to the 28th day is taken as one cycle. Take it with or without food every twelve hours
46027729|NCT03584737|Diagnostic Test|bacterial culture|Quantitative bacterial culture assay with isolate identification by MALDI-TOF.
46027730|NCT03584737|Diagnostic Test|PCR assay|Semiquantitative real-time PCR assay
46116750|NCT03977948|Other|semi-structured systemic interview|Semi-structured systemic interviews will be conducted with families who have benefited from the preparation for surgery through play. Other tools such as the logbook and the socio-demographic questionnaire will also be used. The themes that will emerge from these interviews will provide a better understanding of what these families are going through, how the proposed intervention may or may not have met their expectations, and provide insights so that health care services can build their own surgical preparation programs.
46027731|NCT01214603|Drug|LY2090314|Administered intravenously
46116751|NCT00712023|Device|warming device (a reusable, custom-made forced- air warming mattress)|"2=forced-air warming mattress~1=circulating-water mattress"
46116752|NCT05683314|Procedure|Tranditional open reduction and internal fixation|Under navigation and bone desity projecting method assisted 3D simulation and printing for minimal invasive surgrey
46116753|NCT02598986|Dietary Supplement|Macronutrient supplementation|adding of phosphorus, potassium and magnesium
46116754|NCT00717561|Drug|Avelox (Moxifloxacin, BAY12-8039)|IV therapy: every 24 hours, patients will be administered a 400 mg moxifloxacin infusion over 60 minutes. Oral therapy: patients will be administered a single moxifloxacin 400 mg tablet, every 24 hours
46027732|NCT02692729|Procedure|transverse supraumbilical|transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis
46027733|NCT02692729|Procedure|pfannenstiel incision|Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
46027734|NCT02692807|Procedure|Arthroscopic surgical procedures|See arm/group description of Arthroscopic surgery and sham surgery (HIPARTI). HARP: only arthroscopic surgery
46027735|NCT04308889|Drug|Lovaza|Lovaza contains ethyl esters of omega-3 fatty acids (EPA and DHA) obtained from the oil of several fish sources.
46116755|NCT00717561|Drug|Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin|IV therapy: every 24 hours patients will be administered a 2 g ceftriaxone infusion over 30 minutes. Following the infusion with ceftriaxone, patients will be administered a 500 mg azithromycin infusion over 180 minutes.Oral therapy: every 8 hours patients will be administered a 1000 mg amoxicillin/clavulanic acid tablet. Every 12 hours patients will be administered a 500 mg clarithromycin tablet.
45470840|NCT03328182|Device|New oral endotracheal tube holder|The single arm study product is designed to hold a standard or subglottic ET tube.
45470841|NCT01382498|Drug|Calcium dobesilate (Doxium)|500 mg, Tablet, Daily, 3 months
46027736|NCT04308889|Other|Cantharone|Cantharone is a clinical blistering agent for topical use to remove warts and molluscum contagiosum. We plan to use the drug to elicit a small skin blister and inflammatory response. This is a well described clinical inflammation research experimental model with multiple publications of its safety and utility in tracking the host inflammatory response.
46116756|NCT00720915|Other|Discontinue anticoagulant therapy (Negative d-dimer)|Patients with negative d-dimer discontinue long-term anticoagulant therapy.
45470842|NCT01382498|Drug|Placebo drug|Similar to the that of the Experimental arm, Daily, Three months
46027737|NCT04308889|Other|Phlebotomy|Subjects will have blood drawn from the antecubital vein for not more than 15mL at each visit.
46027738|NCT01212185|Drug|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily for 3 days
46027739|NCT01212185|Other|intranasal spray without oxytocin|6 insufflations (0.1 metered dose/insufflation) twice daily
46027740|NCT00613717|Dietary Supplement|folic acid + iron prenatally, vits A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
46027741|NCT00613717|Dietary Supplement|folic acid + iron prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
46027742|NCT00613717|Dietary Supplement|folic acid prenatally, vitamins A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
46116757|NCT00720915|Other|Continue on anticoagulant therapy (positive d-dimer)|Patients with positive d-dimer continue or re-start on anticoagulant therapy
46116758|NCT00717639|Procedure|Diagnostic MR-Angiography|Single MR-Angiography of the lower extremity after the bolus injection 0.03mmol/kg BW Vasovist
46116759|NCT02571699|Other|Subgluteal Nerve Block|ultrasound-guided subgluteal sciatic nerve block.
46116760|NCT02571855|Drug|ACT-541468 (hydrochloride salt)|Hard-gelatin capsules (strength: 5 mg and 25 mg)
46116761|NCT02571855|Drug|ACT-541468 (free base)|Soft capsules (strength: 25 mg)
46116762|NCT02571855|Drug|Placebo|Placebo capsules matching the ACT-541468 formulations
46116763|NCT00740870|Device|Transcatheter Pulmonary Valve replacement|Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
46116764|NCT00712101|Drug|abciximab intracoronary|administer abciximab bolus intracoronary during primary percutaneous coronary intervention
46116765|NCT00712101|Drug|abciximab intravenously|administer abciximab bolus intravenously during primary percutaneous coronary intervention
46116766|NCT00717717|Behavioral|Intervention|One-year rehabilitation program including weekly supervised and group-based physical exercise, home-based physical activity, individual and group-based coaching (narrative therapy), and expert educational talks/lectures
46116767|NCT04082130|Procedure|(XCM)+(CAF)|The description of this intervention has been already given before.
46116768|NCT04082130|Procedure|(SCTG)+(CAF)|The description of this intervention has been already given before.
46116769|NCT02574351|Biological|blood draw, breathing test|A blood draw,breathing test will be performed on every participant
46027743|NCT00613717|Dietary Supplement|folic acid prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
46027744|NCT04477759|Radiation|50 Gy Radiation Therapy|Ionizing radiation
46027745|NCT04477759|Radiation|55 Gy Radiation Therapy|Ionizing radiation
46027746|NCT04477759|Radiation|60 Gy Radiation Therapy|Ionizing radiation
46116770|NCT02587182|Device|Deep Dry needling|The muscles were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the myofascial trigger point, eliciting local twitch responses in some insertions
46116771|NCT00712257|Device|Spectranetics Laser with adjunct PTA and Gore VIABAHN Endoprosthesis with Heparin Bioactive Surface|treatment for superficial femoral artery instent re-stenosis
46116772|NCT00740792|Drug|azelastine HCl/fluticasone propionate|azelastine HCl 548 mcg/ fluticasone propionate 200 mcg one spray per nostril BID
46116773|NCT00740792|Drug|azelastine Hcl|azelastine Hcl 548 mcg one spray per nostril BID
46116774|NCT00740792|Drug|fluticasone propionate|fluticasone propionate 200 mcg one spray per nostril BID
46116775|NCT00740792|Drug|placebo|placebo one spray per nostril BID
46116776|NCT03728049|Diagnostic Test|CT-ADP performed during TAVI procedure|The CT-ADP will be performed in the catheterization laboratory and revealed to the operator. The decision to undertake corrective procedure will be based on CT-ADP on top of standard methods of PVR assessment.
46116777|NCT03728049|Other|No CT-ADP performed during TAVI procedure|PVR assessment with the standard methods only (TTE and/or angiography and/or hemodynamics but excluding TEE and CT-ADP). The decision to undertake corrective procedure will be left at the discretion of the operator.
46116778|NCT02595788|Other|Change from supine to prone position|Change from supine to prone position
46116779|NCT00721071|Drug|Hypertonic Saline|After each subject has performed post-bronchodilator spirometry, he/she will inhale increasing concentrations of 3, 4, and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
46116780|NCT00917774|Device|Standard LPS flex TKA|TKA by Standard LPS flex TKA
46116781|NCT00917774|Device|Gender specific LPS -Flex TKA|Total knee design created specific for female patients
46116782|NCT00721305|Drug|Lovastatin|Lovastatin 40 mg daily (2 tablets of 20 mg each, p.o.), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
46116783|NCT00721305|Other|placebo|Placebo will be administered daily (2 tablets which will look externally identical to intervention: wrapped in the same way, with the same size, shape and color), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
46116784|NCT00717951|Drug|docetaxol, cisplatin, capecitabine|docetaxol(75mg/m2 d1 every 21 days) combined with cisplatin(75mg/m2 d1 every 21 days) VS docetaxol( 75mg/m2 d1 every 21 days) combined with capecitabine(2000mg/m2 d1-14 every 21 days)
46116785|NCT00721383|Behavioral|Enhancing Physical Activity Intervention|Physical activity and caregiver skill-building
46116786|NCT00721383|Behavioral|CSBI|Caregiver skill-building
46027747|NCT04477759|Drug|Atezolizumab|Atezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 4 weeks following the initiation of radiation treatment up to 1 year from radiation fraction 1.
46027748|NCT03626233|Other|collect of placenta, blood and urinary samples at delivery|collect of placenta, blood and urinary samples at delivery
46027749|NCT04460131|Diagnostic Test|soluble ST2|Serum sST2 was measured on a monoclonal electrochemiluminescence immunoassay. Samples were exposed to two freeze cycles before analysed. Samples were exposed to two thawfreeze cycles before analysed.
46116787|NCT00721461|Biological|V930|Intramuscular injection of phosphate buffered saline solution will be given and within 2 - 5 minutes will be followed by an electrostimulation pulse with the MedPulser DDS in the deltoid muscle of the right arm. 15 days later, the same procedure will take place using the left arm.
46027750|NCT04424797|Other|Prone Positioning|Intervention is patient in prone positioning
46027751|NCT04424797|Other|Supine Positioning|Intervention is patient in supine positioning
46027752|NCT03369301|Drug|Gammanorm|Gammanorm given per standard of care
46027753|NCT03369301|Drug|Other Subcutaneous Immunoglobulins|Other Subcutaneous Immunoglobulins given per standard of care
46027754|NCT04865887|Drug|Pembrolizumab|200mg, every 3 weeks, IV infusion
46027755|NCT04865887|Drug|Lenvatinib|20 mg (2 capsules x10mg), daily, orally
46116788|NCT00712413|Drug|OBMT|Omeprazole 20 mg twice daily, in combination with bismuth subcitrate potassium (40 mg), metronidazole 125 mg and tetracycline 125 mg HCl. All patients must take 6 capsules of Pylera, in addition to 1 omeprazole twice daily
46027756|NCT00614419|Device|Prolene Polypropylene Mesh|The Lichtenstein tension-free hernioplasty consists of a swatch of polypropylene mesh, partway slit 1 cm from its inferior edge to accommodate the spermatic cord. The mesh is sutured circumferentially to the internal oblique abdominal muscle, the rectus sheath and the shelving edge of the inguinal ligament. The tails of the mesh are drawn around the cord and the inferior edge of each tail is sutured to the inguinal ligament. In case of direct hernias, no effort is made to repair the hernia itself. In indirect hernias the sac is excised, except for sliding hernias. The polypropylene mesh group: in this group of patients the polypropylene mesh will be fixed by the above mentioned sutures in Prolene 3/0.
46116789|NCT02574117|Procedure|flap with corticotomy and bone allograft|A maxillary expansion with quad helix appliance was placed on the posterior teeth with cross bite. A Luebke buccal flap was opened in the area of maxillary 1st premolar, 2nd premolar and first molar with a no. 15 scalpel. Corticotomy procedure was performed using low speed round bur size 3, holes to create a 0.5 mm deep hole penetrating the cortical bone. Multiple holes were performed leaving 1.5 mm distance in between. The defects were covered with demineralized freeze-dried bone allograft and the flap was sutured in its original position with 3-0 black silk suture.
46116790|NCT02572947|Drug|Dolutegravir|
46116791|NCT00712491|Drug|Sirolimus|Three subconjunctival injections of 1320 micrograms sirolimus each.
46116792|NCT00712491|Drug|Sirolimus|Three intravitreal injections of 352 micrograms sirolimus each.
46116793|NCT04083066|Drug|rituximab in combination with methotrexate, cytarabine and dexamethasone|"Rituximab 375mg/m2D0 is soluble in 0.9% NS concentration 1mg/ml, micro pump is pumped in 4h HD-methotrexate 3.5g/m2 D1 dissolved in 0.9% NS intravenous drip HD-cytarabine 1g/m2 Q12H D2-3 Dissolved in 250ml 5% GS intravenously~Dexamethasone 40mg D1-5 is dissolved in 100ml 5% GS intravenous drip (21 days is a cycle)"
46116794|NCT04070547|Device|Transcutaneous vagal nerve stimulation|Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device 4hours a day at 25Hz, 250 μs pulse width placed on tragus.
46116795|NCT04070547|Device|Sham stimulation|Sham stimulation will be performed using electrodes 4 hours a day placed on earlobe.
46116796|NCT05082402|Diagnostic Test|Swept Source Optical Coherence Tomography Angiography|The PLEX Elite 9000 is an FDA cleared research device for use in ocular imaging obtained by Northwestern University by way of a purchase agreement with the manufacturer, Carl Zeiss Meditec, Inc. It is currently unavailable outside of participation in the ARI Network, a cloudbased storage and image processing platform using deidentified information shared between academic institutions. The ARI Network is managed by a group of physicians and scientists from around the world that are working to better understand eye diseases.
46116797|NCT04069455|Other|Electronic Patients Reported Outcomes|ePRO is a application which is web based and accessible from home or mobile device, for patients to complete symptom reports and receive severity-based advice
46116798|NCT05683782|Drug|Split thickness Apically positioned flap with Chitosan based Erythropoietin Gel application|Split thickness Apically positioned flap will be performed to increase width of attached gingiva .1 mL of EPO-loaded with chitosan 5% and β-glycerophosphate disodium salt (GP) 20% gel will be used by the patient two times daily for 14 days.
46116799|NCT05683782|Drug|Split thickness Apically positioned flap without Erythropoietin application|Split thickness Apically positioned flap will be performed to increase width of attached gingiva.The patient will use a Chitosan gel without being loaded with erythropoietin two times daily for 14 days
46116800|NCT00712569|Behavioral|questionnaires|Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information. The coding of these patients' consultations with their physicians and analysis of their pre- and post-consultation questionnaires will address Aims 1 and 2.
45470843|NCT01272050|Radiation|radiation therapy|"RT in the standard arm A will be administered to a total dose of 64 Gy in 32 fractions of 2 Gy over 6.4 weeks. RT in the experimental arm B will be administered to a total dose of 70 Gy in 35 fractions of 2 Gy over 7 weeks.~Megavoltage equipments with nominal photon energies ≥ 6 MV are required. Rotational techniques such as Tomotherapy®, Rapidarc®, intensity-modulated arc technique (IMAT) and volumetric-modulated arc therapy (VMAT) will also be eligible. The patient will be treated in an isocentric setting and all fields will be applied for 5 days per week for the total RT duration."
45470844|NCT05322902|Drug|remimazolam group|Remimazolam 6 mg/kg/hr is administered as an intravenous infusion until the patient loses consciousness. Anesthesia is maintained at 1 mg/kg/hr of remimazolam. After confirming that the eyelash reflex disappears, rocuronium 0.8 mg/kg is administered, and SGA insertion is performed. During maintenance of general anesthesia, the concentration of remifentanil is continuously adjusted so that the ANI is above 50.
45470845|NCT05322902|Drug|propofol group|Propofol intravenous infusion is initiated by the application of a target concentration infusion (TCI) pump to cause the patient to lose consciousness. After confirming that the eyelash reflex disappears, rocuronium 0.8 mg/kg is administered, and SGA insertion is performed. During maintenance of general anesthesia, the concentration of remifentanil is continuously adjusted so that the ANI is above 50.
45470846|NCT05297942|Other|Expansion of Abbreviations and Acronyms|Expansion of Abbreviations and Acronyms
46027757|NCT00614419|Device|Surgisis Inguinal Hernia Matrix|The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
46027758|NCT03229915|Behavioral|cognitive processing therapy|Group therapy for PTSD patients
45470847|NCT03539796|Procedure|Dural puncture epidurals (DPE)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. A 26g Gertie Marx needle will be inserted through the Touhy epidural needle and used to puncture the dura; clear, free flowing CSF will return in the needle, but no medications will be injected. The 26g spinal needle will be removed, and the epidural catheter inserted through the epidural needle 3-5cm in the epidural space. A test dose with 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine in 5mL increments until a T4 dermatome level is reached. Epidural fentanyl 100mcg will be administered during initial dosing, and morphine-PF 3mg will be given via epidural after delivery of the fetus.
45682069|NCT03154606|Other|Pure Protein Blend|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pure protein blend. All ingredients are GRAS listed and approved.
45682070|NCT03154606|Other|Whey Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from whey protein blend. All ingredients are GRAS listed and approved.
45682071|NCT03154606|Other|Native Whey Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from Native Whey Protein Isolate. All ingredients are GRAS listed and approved.
45682072|NCT03154606|Other|Soy Protein|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from soy protein. All ingredients are GRAS listed and approved.
45682073|NCT03154606|Other|Pea Protein|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pea protein. All ingredients are GRAS listed and approved.
45682074|NCT03154606|Other|Native Whey: Micellar Casein (50:50) blend|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from native whey: micellar casein (50:50) blend. All ingredients are GRAS listed and approved.
46027759|NCT05345431|Device|endovascular denervation|Treating with EDN at the site of the iliac artery distal to the superficial femoral artery proximal before balloon dilation or stent implantation
46027760|NCT05345431|Device|PTA|Treating with balloon dilation or stent implantation
46027761|NCT05345275|Other|The facial expressions analyzed|The facial expressions associated with pain were analyzed by the researchers in the OpenFace program. The patient's pain scores were estimated in the Python program by combining the numerical outputs of facial expression analyses with machine learning algorithms.
45682075|NCT03154606|Other|Carbohydrate Control|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain predominantly carbohydrates as a control. All ingredients are GRAS listed and approved.
46027762|NCT01995175|Procedure|Nasal swab sampling|Nasal swab samples will be collected from subjects at each examination visit, if they develop respiratory tract infection symptoms with difficulty in breathing and are called for an examination visit in the study.
46027763|NCT01995175|Procedure|Blood sampling|A single blood sample will be collected from a sub-cohort consisting of the first 2000 enrolled subjects when they are either 2, 4, 6, 12, 18 or 24 months old.
46027764|NCT01995175|Other|Diary cards|Diary cards will be provided to parents or LARs of the subjects to record RTI/LRTI, wheeze and asthma symptoms.
46027765|NCT03611101|Combination Product|¹³C-Methacetin Breath Test|A breath analyzer will be used to measure changes in 12C (carbon 12) to 13C (carbon 13) ratio as a result of metabolism of the Methacetin substrate before and after treatment.
46027766|NCT03611101|Drug|BMS-986036|Investigational drug for NASH treatment in Main BMS protocol
46027767|NCT03611101|Device|BreathID MCS device|The BreathID MCS device is a breath analyzer specifically used for measuring changes in the ratio of 13CO2 and 12CO2 isotopes of carbon dioxide. The device is connected to the subject via a nasal cannula and breath is passively collected before and after ingestion of labelled 13C- Methacetin substrate.
46027768|NCT05345119|Drug|Sirolimus|2 mg orally on the first day followed by 0.5 mg per day for 12 weeks
46027769|NCT05345119|Drug|Methylprednisolone|500 mg/weekly (6 weeks) intravenously, 250 mg/weekly (6 weeks) (cumulative dose 4.5 g).
46027770|NCT03529123|Drug|INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
46027771|NCT03529123|Drug|INSULIN GLARGINE (HOE901)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
46027772|NCT03529123|Drug|Metformin|"Pharmaceutical form: Tablet~Route of administration: Oral"
46027773|NCT03529123|Drug|Insulin Glulisine (HMR1964)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
46027774|NCT04074187|Drug|Caplacizumab (ALX-0081)|Pharmaceutical form:Lyophilized powder for solution for injection Route of administration: IV (first dose), SC (all subsequent doses)
46027775|NCT04074187|Drug|Plasma exchange (PE)|Pharmaceutical form:Plasma (e.g. fresh frozen plasma) Route of administration: Plasma exchange
46027776|NCT04074187|Drug|Corticosteroid treatment (Methylprednisolone or prednisolone)|Pharmaceutical form:Solution for injection or Tablet Route of administration: IV or Oral
45682076|NCT01672450|Drug|Intratumoral Ipilimumab and Interleukin-2|Only 1 lesion, 0.5 -2 cm, will be treated. Interleukin-2, 3 mIU IT TIW x 2 weeks (days 1, 3 and 5), then BIW x 6 weeks (days 1 and 4). Escalating doses of Ipilimumab (0.1, 0.25, 0.5, 1, 2, mg) IT weekly x 8 weeks
46027777|NCT04074187|Drug|Immunosuppressive treatment (eg, rituximab)|Pharmaceutical form:Solution for injection (depending on product) Route of administration: IV (depending on product)
46027778|NCT02670031|Other|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
46027779|NCT02670031|Other|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
46027780|NCT02670031|Other|Electrocardiogram|To examine specific function of the heart.
45682077|NCT01672528|Other|Interview|Patient participates in a face-to-face interview to facilitate development of the new disease specific questionnaire
46027781|NCT02670031|Device|Ambulatory Blood Pressure Monitoring|A 24-hour test.
45682078|NCT01672528|Other|Questionnaires|Patients will be sent questionnaires before their procedure, 8 - 12 after their procedure and at 1 and 5 years post procedure
46027782|NCT02670031|Other|Retinal Photography (Optional)|The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
46027783|NCT03128905|Drug|Colchicine opocalcium 1mg|"International non-proprietary name: Colchicine~Molecule owner: Mayoly-Spindler Laboratory, 1mg scored tablet for oral administration, authorized 03/02/1995.~Composition :~Active principle : Crystallized colchicine Excipients: Erythrosine aluminium lake, lactose, saccharose, magnesium stearate and povidone."
45470848|NCT03539796|Procedure|Traditional epidurals (EPI)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. The catheter will be inserted 3-5cm in the epidural space. A test dose with 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine in 5mL increments until a T4 dermatome level is reached. Epidural fentanyl 100mcg will be administered during initial dosing, and morphine-preservative free (PF) 3mg will be given via epidural after delivery of the fetus.
46027784|NCT03128905|Drug|Prednisone : Cortancyl 20mg|"International non-proprietary name: Prednisone~Molecule owner : SANOFI AVENTIS France 20 mg scored tablet for oral administration, authorized since 02/05/1990, generic drug available.~Composition :~Active principle : Prednisone Excipients: Maize starch, lactose, talc, magnesium stearate."
46027785|NCT00613795|Dietary Supplement|Lactobacillus GG|Every 12 hours, the contents of a single capsule containing Lactobacillus GG will be suspended in 3 ml of water-soluble jelly. The suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second capsule will be suspended in 10 ml of sterile water and pushed through the NG tub followed by 10 mL of air to ensure complete administration.
46027786|NCT00613795|Dietary Supplement|placebo|Every 12 hours, the contents of a single identical placebo capsule containing the inert plant carbohydrate inulin will be suspended in 3 ml of water-soluble jelly. This suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second placebo capsule will be suspended in 10 ml of sterile water and pushed through eh NG tube followed by 10 mL of air to ensure complete administration
46027787|NCT02430181|Drug|lonafarnib|antiviral farnesyl transferase inhibitor
46027788|NCT02430181|Drug|peginterferon alfa-2a|immunomodulator
46027789|NCT02430181|Drug|ritonavir|CYP 3A4 inhibitor, lonafarnib booster
46027790|NCT03100591|Drug|14C-radiolabeled ACT-132577|Single oral dose of 3.7 megabecquerel (MBq) (100 microcurie [μCi]) 14C-radiolabeled ACT-132577 administered as 1 capsule of 25 mg
46116801|NCT00712569|Behavioral|audio recordings , questionnaires|"Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information. This category is important as our previous research indicates that sometimes patients do not discuss information because they feel there is not enough time or because the information is irrelevant or repetitive. These patients' audio recordings will be checked to verify that there was no internet information discussion. These audio recordings will not be coded.~However, assessment of these patients' questionnaires will aid in addressing Aim 3 and may provide some pilot data on why patients who initially intend to discuss internet information do not."
45598640|NCT03153033|Behavioral|Fatigue protocol|The figure 8 protocol (fatigue intervention) requires the participants to propel three times as many laps as possible for four minutes each with their wheelchair. The protocol has been developed and used previously. Every bout of four minutes is separated by 90 seconds of rest. Each lap consists of a right and left turn and two complete stops after half a lap. Measurements during the protocol include the Rate of Perceived Exertion (RPE) scale, heart rate, and propulsion kinetics.
46027791|NCT00613873|Procedure|Colonoscopy and Questionnaire|Pt is asked to complete attitude and belief questionnaire then have a Colonoscopy. Then within 6 weeks post colonoscopy a final telephone interview.
46027792|NCT02359825|Drug|Polyethylene glycol (PEG)|For the control groups, epineural repair or interposition grafting will be undertaken in the standard end-to-end fashion using interrupted nylon suture after irrigation of the wound with normal saline as deemed necessary by the operating surgeon. For the experimental group, the nerve(s) will be repaired using standard suture neurorrhaphy techniques and a 149.25 mM (50%) solution of PEG 3.35 kD in sterile water will then be irrigated onto the neurorrhaphy site for one minute. Following this, the approximated nerve ends will be irrigated with sterile water gently for 2 minutes. All wounds will be closed in the fashion deemed appropriate by the operating surgeon.
46027793|NCT00614653|Drug|Bevacizumab|5 mg/kg IV Over 90 Minutes Every 2 Weeks
46027794|NCT00614653|Drug|Erlotinib|100 mg by mouth Once Daily on days with radiation.
46027795|NCT00614653|Drug|Capecitabine|400 mg/m^2 PO Twice Daily on days with radiation.
46116802|NCT00712569|Behavioral|audio recorded questionnaires|Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it. Assessment of these patients' questionnaires will aid in addressing Aim 3. These audio recordings will not be coded. It is important, however, that these consultations be audio recorded for two reasons: First, it allows the physician to remain blinded to the intent of the patient to discuss internet information. Second, it provides a method of verifying that the patient really did not discuss internet information. Although not expected, it is possible for a patient to go into a consultation without intending to discuss internet information, but does end up discussing it. We will note if this occurs.
46027796|NCT00614653|Radiation|Radiation Therapy|Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy
46116803|NCT04877184|Device|Transcranial ultrasound stimulation and rehabilitation|"The participants in experimental group would received transcranial ultrasound stimulation and rehabilitation therapy.~transcranial ultrasound stimulation: during 4 weeks~rehabilitation: physiotherapy and occupational therapy (may combine with speech therapy and psychological therapy if needed)"
46116804|NCT04877184|Device|Rehabilitation|"The participants in control group would received rehabilitation therapy.~- rehabilitation: physiotherapy and occupational therapy (may combine with speech therapy and psychological therapy if needed)"
46116805|NCT00740714|Drug|Coenzyme Q10 with vitamin E|2400 mg dose - eight 300 mg Coenzyme Q10 chewable wafers taken orally four times a day; 1200 mg dose - four 300 mg Coenzyme Q10 and four placebo chewable wafers taken orally four times a day.
45682079|NCT03154060|Device|Abbott FreeStyle Libre Flash Glucose Monitoring sensors|Three FGM sensors will be inserted simultaneously (one on the back of the upper arm, abdomen and thigh) and will be worn for a consecutive 14 days. Throughout the study, patients should measure capillary blood glucose (BG) with the built-in BG meter of the Freestyle Libre at least 7 times per day (before and 1-2 hours after every meal and before bedtime). Additionally, patients should scan each sensor at least every 8 hours to obtain every measured interstitial glucose value. At the end visit (after 14 days), patients will come back to the hospital to download FGM and SMBG data.
45682080|NCT01854268|Drug|Healthy adults who receive capsaicin|Participants will be seated in a comfortable chair and fitted with cotton elastic bands designed to measure changes in chest wall and abdominal movement during cough. The participant will hold a facemask attached to a pneumotachograph, nebulized, and dosimeter. The participant will receive 3 nebulized doses of 200 microMolar capsaicin through the facemask. The participants will have a minute in between each presentation and water will be available at all times.
45682081|NCT01672606|Drug|Rocuronium|Partial neuromuscular blockade with rocuronium with a TOF 0.70
45682082|NCT05067244|Drug|MDMA|MDMA assisted psychotherapy
46027797|NCT05344807|Diagnostic Test|Renal DMSA Scintigraphy|patient injected with Tc99mDMSA then imaged after 2-4 hours by gamma camera
46027798|NCT05344729|Drug|TQB3616 Capsule|It inhibits the proliferation of tumor cells by reducing the level of retinoblastoma protein (Rb) phosphorylation in cancer cells and blocking the progression of cells from G1 to S phase.
46027799|NCT03909451|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
46027800|NCT03909451|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
46027801|NCT03463135|Drug|Glucopyranosyl Lipid A (GLA)|Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
46027802|NCT03463135|Drug|Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)|Pharmaceutical form:Solution Route of administration: Sublingual
46027803|NCT03463135|Drug|Placebo for GLA|Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
46027804|NCT03463135|Drug|Placebo for SLIT PE|Pharmaceutical form:Solution Route of administration: Sublingual
46027805|NCT03859765|Behavioral|HCT Symptoms and Steps|HCT Symptoms and Steps will provide patients with cognitive behavioral coping skills training and activity coaching sessions to enhance their ability to manage symptoms that interfere with activity.
46027806|NCT03596125|Drug|N-acetylcysteine|N-acetylcysteine supplementation
46027807|NCT03596125|Drug|Placebo|per os: jelly tablets Intravenous Route: Glucidion G5
46027808|NCT02315521|Procedure|Fetal Intervention for LUTO|"Fetal vesico-amniotic shunting placement consists in placing a shunt (stent) percutaneously from fetal bladder to the amniotic cavity under ultrasound guidance.~Fetal cystoscopy will be performed using a thin scope that will be introduced to the fetal bladder for evaluation of the cause of the obstruction and ablation of the posterior urethral valves."
46027809|NCT02243605|Drug|Cabozantinib S-malate|Given PO
46027810|NCT02243605|Other|Laboratory Biomarker Analysis|Correlative studies
46027811|NCT02118727|Drug|Memantine|All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
46027812|NCT02118727|Drug|Placebo (for Memantine)|All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
45682083|NCT01594281|Drug|Ranibizumab 0.5 mg|Pre-filled syringe for intravitreal injection
45682084|NCT01594281|Procedure|Panretinal laser photocoagulation|PRP treatment following DRS guidelines
46116806|NCT00740714|Drug|placebo with vitamin E|placebo or an inactive substance (with vitamin E 1200 IU/day); Placebo - eight chewable wafers taken orally four times a day.
46116807|NCT04068285|Other|Aerobic Exercise|Participants will be making aerobic exercise
46116808|NCT02587026|Other|Blood sample collection|
46116809|NCT02587026|Other|Tumor tissue sample collection|
46116810|NCT02588352|Dietary Supplement|Salt tablet|Subjects will be given salt tablets and instructed to take 4 grams of sale three times a day (total of 12 grams of salt/day) for one week
46027813|NCT03592771|Behavioral|Prompts to report adherence and symptoms via study app|Text message prompts to report medication adherence and symptoms via the web-enabled study app Weekly prompts to report AET use in the previous 7 days and treatment-related adverse symptoms via the web-enabled study app. All participant-reported data will be automatically entered into the patient's electronic health record and easily available to the care team for review. Any concerning symptoms or changes will trigger an email alert to the patient's oncology team.
46027814|NCT03592771|Behavioral|Feedback messages|Participants will receive weekly tailored feedback messages and/or images.
46116811|NCT00721773|Drug|Benazepril|Patients with hypertension will take 10-20mg benazepril per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
46116812|NCT00721773|Drug|Valsartan|Patients with hypertension will take 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
46116813|NCT00721773|Drug|Benazepril+Valsartan|Patients with hypertension will take 10-20mg benazepril plus 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
46116814|NCT00721773|Drug|Control|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
46116815|NCT05676684|Drug|Dapagliflozin|A: Dapagliflozin 10 mg once daily
45682085|NCT05025124|Device|Entia Liberty|Home monitoring system
45682086|NCT04764526|Other|Protein-enriched ice cream|Offering two protein-enriched ice creams
45682087|NCT05565820|Other|Vamousse Spray 'n' Go|Pediculicide for topical application, active ingredient Natrum Muriaticum 2X (HPUS).
45682088|NCT05565820|Drug|Nix Creme Rinse Lice Treatment|1% permethrin lotion for topical application.
46027815|NCT05343637|Combination Product|Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)|RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.
46027816|NCT03776227|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
46027817|NCT03369613|Device|transcranial electrical stimulation|The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.
46116816|NCT05676684|Drug|Spironolactone|B: Spironolactone 25 mg once daily (can be adjusted according to potassium and renal function)
46116817|NCT05676684|Drug|Spironolactone + Dapagliflozin|C: Dapagliflozin 10 mg once daily plus Spironolactone 25 mg once daily (can be adjusted according to potassium and renal function)
46116818|NCT02572869|Other|physical exam|Patients will be examined by the treating physician or his/her designee (Fellow). The examining physician will complete an 11-item clinical examination form about the patient's clinical function. This examination assesses lip competence, tongue movement, oral mucosa, dental state, mouth opening, speech, drooling, diet, appearance, oral sensation, and shoulder movement. Where appropriate, the physician will ask the patient questions regarding items on the questionnaire to ensure the completeness and accuracy of the outcome assessment.
46116819|NCT02572869|Behavioral|questionnaires|"The participating patients will be asked to complete three questionnaires:~(1) The European Organization for Research and Treatment of Cancer (EORTC) Head and Neck questionnaire (EORTC H&N 35) to assess their quality of life as it relates to their mandible function and aesthetic appearance (2) The EORTC QLQ-C30, which assesses overall health-related quality of life (3) The FACE-Q Oncology Module: Mandibulectomy, which contains questions regarding both functional and aesthetic outcomes."
46116820|NCT04377945|Drug|Part 1, JM-010 component Group A|JM-010 component Group A
46116821|NCT04377945|Drug|Part 1, JM-010 component Group B|JM-010 component Group B
46116822|NCT04377945|Drug|Part 1, JM-010 component Group C|JM-010 component Group C
46116823|NCT04377945|Drug|Part 1, Placebo Group|Placebo Group
46116824|NCT04377945|Drug|Part 2, JM-010 combination Group A|JM-010 combination Group A
46116825|NCT04377945|Drug|Part 2, JM-010 combination Group B|JM-010 combination Group B
46027818|NCT00614809|Drug|gefitinib|gefitinib 250mg qd until disease progression or unacceptable toxicity.
46027819|NCT02964013|Biological|vibostolimab|Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35
46027820|NCT02964013|Biological|pembrolizumab|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
46027821|NCT02964013|Drug|pemetrexed|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
46116826|NCT04377945|Drug|Part 2, JM-010 component Group C|JM-010 component Group C
46116827|NCT04377945|Drug|Part 2, Placebo Group|Placebo Group
45470849|NCT03539796|Procedure|Combined-spinal epidural technique (CSE)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. A 26g Gertie Marx needle will be inserted through the Touhy epidural needle and used to puncture the dura; clear, free flowing CSF will return in the needle and 12mg bupivacaine, 10mcg fentanyl, 200mcg morphine-PF. The 26g spinal needle will be removed, and the epidural catheter inserted through the epidural needle 3-5cm in the epidural space. No epidural test dose will be given immediately compared to the above procedures secondary to intrathecal injection of local anesthetic with this CSE technique. Only after approximately 1 hour after intrathecal injection will a test dose of 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine for the remainder of the procedure if necessary.
45470850|NCT04139798|Drug|NOV03|100% Perfluorohexyloctane
45470851|NCT04139798|Drug|Placebo|Saline solution (0.6% sodium chloride solution)
46027822|NCT02964013|Drug|carboplatin|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4
46027823|NCT02964013|Biological|pembrolizumab/vibostolimab coformulation|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
46027824|NCT02964013|Drug|cisplatin|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4
46027825|NCT02964013|Drug|etoposide|Administered as an IV infusion on Days 1-3 of 21-day infusion Cycles 1-4
46027826|NCT03562741|Procedure|Fecal Microbiota Transplantation|Transplantation of Screened donor stool as part of Fecal Microbiota Transplantation
46027827|NCT01752907|Other|General Education DVD|A general chemotherapy side effects education DVD
46027828|NCT01752907|Other|Bone Pain Education DVD|
46027829|NCT05343169|Behavioral|Overdose Education and Naloxone Distribution|"Education on OD risk behaviors and methods for responding to an OD, including naloxone use.~Duration and dose: Single 20-minute training at time of enrollment, provided to all participants in both arms"
46027830|NCT05343169|Behavioral|Advanced Education in Safer Substance Use, Treatment, and Self-Care|Education about misinformation about OAT, self-care, SEP services, HIV/HCV treatment Duration/dose: 9 mos., monthly ~2 hr. group sessions + ongoing access to video archive of recorded trainings.
46027831|NCT05343169|Behavioral|Social Service and Health Navigation|Help navigate access and barriers to healthcare, motivation and health goals Duration/dose: 9 mos., monthly face-to-face sessions to set goals and schedule appts, phone calls between sessions > 1x/wk.
46027832|NCT05343169|Behavioral|Peer Social Support|Support with social (re)integration, isolation, relationship building Duration/dose: 9 mos., monthly face-to-face events and phone calls/texts between sessions > 1x/wk.
46027833|NCT00614731|Biological|KLH carrier-protein|KLH carrier-protein vaccination containing no other protein or antibodies
46027834|NCT02692261|Procedure|Maxillary Sinus Augmentation|Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution
46027835|NCT02692261|Procedure|Maxillary Sinus Augmentation|Control group sinuses filled with heterolog bone graft alone
46027836|NCT03181087|Other|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1*10^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
46116828|NCT00718185|Procedure|Obtain blood specimens|Obtain blood samples at multiple timepoints.
46027837|NCT02704663|Procedure|Transumbilical removal of specimen via laparoscopy|Transumbilical removal of a benign adnexal mass from the abdominal cavity in laparoscopy
46116829|NCT04070469|Drug|Amoxicillin|dosage of plasma concentration of amoxicillin
46116830|NCT00712647|Drug|Beta Carotene and Retinol|"Pilot participants (ppts):~Asbestos-Exposed--15 mg/day beta-carotene + 25,000 IU/day retinol Heavy Smokers--30 mg/day beta-carotene + 25,000 IU/day retinol~Vanguard & Efficacy ppts:~Asbestos-exposed AND heavy smokers--30 mg/day beta-carotene + 25,000 IU/day retinol"
46116831|NCT00712647|Other|Placebo|Two placebos, one each/day
46116832|NCT00788957|Drug|Panitumumab|Panitumumab for intravenous infusion
46116833|NCT00788957|Drug|Ganitumab|Ganitumab for intravenous infusion
46116834|NCT00788957|Drug|Rilotumumab|Rilotumumab for intravenous infusion
46116835|NCT00788957|Drug|Placebo|Placebo intravenous infusion
46116836|NCT04067817|Drug|norepinephrine|patient who was received the treatment of norepinephrine
46116837|NCT04067817|Drug|Phenylephrine|patient who was received the treatment of phenylephrine
46116838|NCT00740636|Drug|Temozolomide|Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 75 mg/m2/day.
46116839|NCT00740636|Drug|Temozolomide|Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 200mg/m2/day.
46116840|NCT00718341|Drug|AF056|
46116841|NCT00718341|Drug|Placebo|
46027838|NCT02704663|Procedure|Lateral transabdominal removal of specimen via laparoscopy|Lateral transabdominal removal of a benign adnexal mass from the abdominal cavity in laparoscopy
46116842|NCT00721929|Procedure|MRI|Magnetic Resonance Imaging
46027839|NCT02552953|Drug|CYC065|
46027840|NCT02526355|Behavioral|Mobile based intervention|Learning through Play Plus Intervention delivered through mobile phone
45470852|NCT04615052|Other|Exercise training|A 16 weeks parallel-group randomised controlled trial will be performed, in which covid-19 survivors patients will complete a telemonitored home-based exercise training program, 3 times per week. The training program will involve strength, aerobic, balance and flexibility exercises.
46027841|NCT02480803|Drug|Continuous intrajejunal infusion of levodopa-carbidopa|Continuous delivery of levodopa-carbidopa intestinal gel through an intrajejunal percutaneous tube (Duodopa, CLI, CILI)
46027842|NCT02480803|Device|deep brain stimulation|Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
46027843|NCT03439189|Combination Product|Methacetin Breath Test|A breath analyzer will be used to measure changes in carbon-12 to carbon-13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.
46027844|NCT03439189|Drug|Emricasan|Investigational drug for NASH treatment in Main Conatus protocol
46027845|NCT03439189|Drug|Placebo oral capsule|Placebo versus emricasan in Conatus NASH treatment trial
46027846|NCT02699437|Other|Testing for antiphospholipid antibodies|Blood samples will be tested for anticardiolipin antibodies and lupus anticoagulant
46027847|NCT01211483|Drug|U3-1287|Liquid 70 mg/mL for IV infusion at high dose or low dose
46027848|NCT01211483|Drug|Erlotinib|Tablet 150 mg for oral administration
46027849|NCT01211483|Drug|Placebo|Placebo liquid matching U3-1287 for IV infusion
46027850|NCT00615823|Drug|Atorvastatin|Patients were assigned to receive 10 mg of atorvastatin for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
46027851|NCT00615823|Drug|Placebo|Patients were assigned to receive 10 mg of placebo for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
46027852|NCT02704195|Procedure|Unilateral reduction of stimulation|30% unilateral reduction of Subthalamic nucleus stimulation
46027853|NCT02704195|Procedure|Chronic Subthalamic nucleus stimulation|This arm is the reference, with the best stimulation parameters
46116843|NCT05592665|Other|Survey Questionnaire|Study participants will complete several questionnaires/assessments via PRO-Core standardized email communication or via telephone with a study team member.
45470853|NCT03327402|Drug|SHP465|SHP465 capsule will be administered at a dose of 6.25 mg, orally once daily for 4 weeks. SHP465 is comprised of sulfate salts of dextroamphetamine and amphetamine, with dextroamphetamine saccharate and amphetamine aspartate monohydrate, which provide a composite enantiomer ratio of 3:1 d-amphetamine to l-amphetamine.
46027854|NCT02699281|Drug|ultra-micronized palmitoylethanolamide|ultra-micronized palmitoylethanolamide 600 mg twice a day
46027855|NCT02699281|Drug|Placebo|um-PEA like placebo twice a day
46116844|NCT02595632|Other|No intervention|
46116845|NCT02572635|Biological|PnuBioVax|Three administrations (by intramuscular injection) given 28 days apart to 9 subjects.
46116846|NCT02572635|Biological|Placebo|Placebo administered by intramuscular injection to 3 subjects in each cohort. Three administrations given 28 days apart.
46116847|NCT02603159|Drug|Capecitabine(Aibin)|Capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 or 10 weeks in total
46116848|NCT02603159|Radiation|radiotherapy|Concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
46116849|NCT02595554|Radiation|Concurrent chemoirradiation|External beam radiation therapy (EBRT) with concurrent weekly platinum chemotherapy followed by brachytherapy
46116850|NCT02595554|Drug|Paclitaxel|New adjuvant chemotherapy 3 cycles with Paclitaxel 150mg/m2 over 3 hours and Cisplatin
46116851|NCT02595554|Procedure|Radical Surgery|Radical hysterectomy (Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
46116852|NCT02595554|Drug|Cisplatin|New adjuvant chemotherapy 3 cycles with Paclitaxel and Cisplatin 70mg/m2
46116853|NCT04069065|Drug|Conversion to Once-daily Tacrolimus|"Orally, once-daily in the morning~The first dose is converted to approximately 100% of the existing daily dose, taking into account the subject's blood concentration, after which the investigator check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3~10ng/ml."
46116854|NCT00735254|Device|pulsed dye laser|patient will have scar treated with pulsed dye laser
46116855|NCT00735254|Device|Affirm Laser|patient will have scar treated with Affirm laser
46116856|NCT00735254|Device|combined PDL and Affirm Lasers|patient will have scar treated with Affirm and pulsed dye lasers
46116857|NCT00735254|Other|Placebo|patient will receive no treatment
46116858|NCT04067583|Other|Physician questionnaire|This is a one-time cross-sectional survey of physicians, conducted electronically; there are no in person visits
46116859|NCT05615363|Drug|OPC 131461 10mg group|OPC-131461 5 mg tablet x 2，once-daily oral administration for 14 days
46116860|NCT05615363|Drug|OPC 131461 5mg group|OPC-131461 5 mg tablet and placebo tablet，once-daily oral administration for 14 days
46116861|NCT05615363|Drug|OPC 131461 2mg group|OPC-131461 1 mg tablet x 2，once-daily oral administration for 14 days
46116862|NCT05615363|Drug|OPC 131461 1mg group|OPC-131461 1 mg tablet and placebo tablet，once-daily oral administration for 14 days
46027856|NCT04320485|Diagnostic Test|Active Anthrax Detect™ Plus (AAD Plus)|A lateral flow immunoassay rapid test (AAD Plus) for early and presumptive diagnosis of inhalational anthrax.
46027857|NCT02699359|Device|HS-1000 recording|
46116863|NCT05615363|Drug|Placebo|Placebo tablet，once-daily oral administration for 14 days
46116864|NCT04070391|Dietary Supplement|vitamin B6|oral administration
46027858|NCT00615979|Device|Miniature echo machine|Images captured and real-time and store-and-forward file transfers performed
46027859|NCT01140373|Biological|engineered autologous T cells|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10^7 CAR+ T cells/kg, 3 x 10^7 CAR+ T cells/kg, and 1 x 108 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
46116865|NCT04070391|Other|control|oral administration
46116866|NCT04089800|Other|Mobile phone based multimedia application|The investigators shall develop a multimedia mobile health application using Java programming language, while the database that hosts multimedia messages shall be developed using SQlite. It shall be an offline (stand-alone) application following user-centered design approaches that involve incorporating input from pregnant women as prospective users. Pregnant women shall be provided with solar chargers to supplement electricity charging. The application has three major functionalities, appointment reminder function, calling function and the multimedia (Video and audio) function.
46116867|NCT05615051|Device|Surface decontamination procedure aiming at reconstructive therapy|Surface decontamination of infected implants followed by reconstructive therapy to manage peri-implantitis
46116868|NCT04070235|Drug|SH229 tablets|SH229 400 mg was provided in 4 tablets, 100mg each；SH229 600 mg was provided in 6 tablets , 100mg each；SH229 800 mg in was provided in 8tablets , 100mg each。
46116869|NCT04070235|Drug|Daclatasvir dihydrochloride|Daclatasvir dihydrochloride was provided in a single tablet of 60 mg.
46116870|NCT02593760|Other|Placebo|Placebo will be administered PO QD for up to 48 weeks.
46116871|NCT02593760|Drug|Ruxolitinib|Ruxolitinib will be administered PO BID at a starting dose depending on the participants's baseline platelet count for up to 48 weeks.
46116872|NCT02593760|Drug|Vismodegib|Vismodegib will be administered at a dose of 150 mg PO QD for up to 48 weeks.
46116873|NCT02604329|Device|"Oncolase Digi therapy laser diode"|"The athermic phototherapy laser diode will be used by scanning the entire oral mucosa, including cheek and lip mucosa, gums, palate, tongue and floor of the mouth. It will be applied uniformly every two days as long as the grade of mucositis is 2 or more, with a fluence of 4J/cm², under two wavelengths (635 nm and 815 nm).~Cheeks will be scanned extra-orally with laser fiber during 50 seconds, at the fluence of 4J/cm², associating two wavelengths : infra-red (815 nm, 3850mW) and red (635 nm, 150mW).~Intra-orally, the fiber will be used to scan each area of mucositis during 30 seconds per area of 2 cm2, at 1cm from the mucosa; the power at 635 nm will be 150 milliwatts and 150 milliwatts at 815 nm."
46116874|NCT00712803|Biological|rDEN3-3'D4delta30|Live attenuated 10^3 dose of rDEN3-3'D4delta30 vaccine.
46116875|NCT00712803|Biological|rDEN3-3'D4delta30|Live attenuated 10^5 dose of rDEN3-3'D4delta30 vaccine.
46116876|NCT00712803|Biological|rDEN3-3'D4delta30|Live attenuated 10^1 dose of rDEN3-3'D4delta30 vaccine.
45470854|NCT05262920|Behavioral|The BSM Intervention|The BSM intervention entailed a daily electronic journal for monitoring BF and BNP with feedings, bi-weekly texting for 6 weeks from a research nurse for informational support and to promote personalized goal-setting and problem-solving, and hyperlinks to eight uniform BNP educational modules (knowledge and skills) and online resources. 1. Fundamentals of BF (FBF), 2. Deep breathing (DB), 3. BNP non-pharmacological strategies (BNPS), 4. Guided imagery (GI), 5. Pain neurophysiology specifically related to BF (PN-BF), 6. Catastrophizing, 7. Stress reactivity, and 8. Common pumping issues and interventions (CPI).
45470855|NCT05262920|Behavioral|Attention Control|The Attention Control and Intervention groups both receive fourth-trimester care videos. The educational modules are the following: Urgent maternal warning signs, caring for the maternal body after birth; infant care; COVID-19 and infant health prevention; maternal and infant immunization; infant safety in the home; maternal and infant dietary recommendations; and national and health resources to support BF in the workplace
45470856|NCT03476538|Drug|Gabapentin|Patients are tested for their normal prescription gabapentin medication
46116877|NCT00795509|Drug|Tolterodine tartrate|"Detrusitol® Capsule 2mg and 4mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dosage for oral administration is 4 mg of tolterodine tartrate once daily. Occasionally dose reduction might be needed due to individual tolerability."
45470857|NCT03075878|Drug|ALXN1830|Administered via IV infusion.
45470858|NCT03326856|Biological|botulinum toxin, Type A|topical liniment
46027860|NCT01140373|Drug|cyclophosphamide|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10^7 CAR+ T cells/kg, 3 x 10^7 CAR+ T cells/kg, and 1 x 10^8 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
46116878|NCT03615573|Other|Quality of Life Surveys|Patients with breast cancer diagnosis complete questionnaires over 20-30 minutes at baseline and at 3, 6, and 12 months after enrollment.
45470859|NCT03326856|Biological|Vehicle|Vehicle Formulation
45470860|NCT01382420|Procedure|surgery|adrenalectomy
45470861|NCT04095078|Device|SIMEOX|Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX
45470862|NCT03819842|Diagnostic Test|Pseudophakic Measurement|standard aphakic measurements will be taken and then pseudophakic measurements will be taken after toric iol implantation. The data produced will aid the surgeon in proper placement of toric iol orientation
45470863|NCT04088136|Behavioral|Everyday Metacognitive Memory Intervention|Provides training in use of techniques and procedures to enhance proactive self-regulatory control over everyday memory demands, including strategies for learning information, planning for meeting everyday goals, and monitoring of efficacy of goal pursuit.
45470864|NCT04088136|Behavioral|Memory Strategy Control Intervention|Trains use of standard mnemonic techniques such as imagery and sentence generation for learning new associations and organizational and distinctiveness-based strategies for learning sets of items (e.g., word lists).
45470865|NCT00000116|Dietary Supplement|Vitamin A|15000 IU/d as retinyl palmitate
46116879|NCT02603003|Drug|JinFuKang|po.tid.30ml
46116880|NCT02603003|Drug|Cisplatin|According to the individual patient's condition
46116881|NCT02603003|Drug|Pemetrexed|According to the individual patient's condition
46116882|NCT00722163|Other|Cognitive Behavioural Therapy|
45470866|NCT00000116|Dietary Supplement|Docosahexaenoic acid|1200 mg/d
45470867|NCT00000116|Dietary Supplement|Control fatty acid|
45470868|NCT05232396|Biological|IL-6R Monoclonal Antibody Injection 4mg/kg|IL-6R Monoclonal Antibody Injection 4mg/kg i.v.,single use
45470869|NCT05232396|Biological|IL-6R Monoclonal Antibody Injection 6mg/kg|IL-6R Monoclonal Antibody Injection 6mg/kg i.v. , single use
46116883|NCT00722163|Other|befriending|
46116884|NCT04106141|Other|6 weeks changing of archwire|changing the archwire after 6 weeks instead of 4 weeks
46116885|NCT04106141|Other|4 weeks changing of archwire|changing the archwire every 4 weeks
46116886|NCT04106297|Drug|GLPG3970 oral solution|GLPG3970 for oral administration
46116887|NCT04106297|Drug|Placebo oral solution|Placebo for oral administration
46116888|NCT04106297|Drug|GLPG3970 capsule|GLPG3970 for oral administration
46116889|NCT02571621|Device|Combitube|Intubation with Combitube
45470870|NCT05232396|Biological|IL-6R Monoclonal Antibody Injection 8mg/kg|IL-6R Monoclonal Antibody Injection 8mg/kg i.v. , single use
46027861|NCT02704507|Drug|Triamcinolone|topical application nightly to half the face for 4 weeks
46116890|NCT04105673|Other|Clinical examination and survey|Children will be seen during an one consultation. A clinical examination and survey are realized.
45470871|NCT05232396|Biological|Tocilizumab Injection 8mg/kg|Tocilizumab Injection 8mg/kg i.v., single use
45470872|NCT05222724|Drug|Tachifene|paracetamol 500 mg/ibuprofen 150 mg FDC, film-coated tablets. Two tablets 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
45470873|NCT05222724|Drug|Brufen|ibuprofen 600 mg, film coated tablets. One tablet 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
45470874|NCT04581356|Drug|Voxelotor|daily voxelotor 1500mg oral medication
45470875|NCT03389802|Biological|APX005M treatment for recurrent or refractory primary malignant CNS tumor patients|"APX005M dosing will begin at 0.1 mg/kg, the APX005M dose may be increased (0.3, 0.45, 0.6 mg/kg) or decreased (0.03 mg/kg) in subsequent cohorts until the MTD is reached or until dose level 3 (0.6 mg/kg) is complete without MTD being defined.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first."
45682089|NCT03153904|Behavioral|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC (Chorpita & Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
46027862|NCT02704507|Drug|Tretinoin|topical application nightly for 8 weeks
46027863|NCT02704507|Drug|Emollient|topical application nightly to half the face for 4 weeks
46027864|NCT02699203|Behavioral|High-carbohydrate meal|Participants will consume a high-carbohydrate low fat meal. The macronutrients content will be 55% carbohydrate, 25% protein and 20% fat providing 400-500 kcal. Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
46027865|NCT02699203|Behavioral|Low-carbohydrate meal|Participants will consume a low-carbohydrate high fat meal. The macronutrients content will be 10% carbohydrate, 25% protein and 65% fat and will provide 400-500 kcal (matched to the high carbohydrate meal). Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
46027866|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 low dose
46027867|NCT01210001|Drug|BI 10773|BI 10773 tablets once daily
46116891|NCT04067193|Other|usability survey|usability survey composed of subpart: System Usability Scale, questions about ergonomic, questions about design, question about global satisfaction.
46116892|NCT02603081|Drug|SPI-1005|Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.
46116893|NCT04105829|Other|Bond-a braid|Stainless steel lingual retainer application
46116894|NCT04105829|Other|EverStick-Ortho|Fiber reinforced lingual retainer
46116895|NCT04105829|Other|Ribbond|Fiber reinforced lingual retainer
46116896|NCT00787787|Drug|sunitinib malate|Given PO
46116897|NCT00787787|Drug|capecitabine|Given PO
46116898|NCT02571387|Behavioral|Mindfulness-based intervention|
46116899|NCT02571387|Behavioral|Sham meditation|
46116900|NCT02571309|Device|Asthmatuner|Asthmatuner is an app for self-management of asthma.
46116901|NCT00722475|Drug|Intravenous immunoglobulin|Intravenous infusions, 25-35 g each time, 4th to 15th gestational week
45470876|NCT03389802|Biological|APX005M treatment for newly diagnosed DIPG patients|"The starting dose of APX005M for the DIPG patients will be one dose level below the RP2D determined in Stratum 1 patients. The dose may be decreased or increased to the RP2D established in Stratum 1.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first."
45470877|NCT01382342|Drug|Rasagiline|1 mg daily
45470878|NCT01382342|Drug|Placebo|1 mg daily
46116902|NCT00722475|Drug|Human albumin|Repeated infusions of Human Albumin 5%, 250-350 ml between 4th and 15th gestational week
46116903|NCT04108169|Procedure|Left atrial appendage occlusion surgery|CABG according to indications in the current guidelines on myocardial revascularization including surgical closure of left atrial appendage
46116904|NCT05549297|Drug|Tebentafusp|soluble gp100-specific T cell receptor with anti-CD3 scFV
46116905|NCT05549297|Drug|Tebentafusp with Pembrolizumab|soluble gp100-specific T cell receptor with anti-CD3 scFV in combination with Pembrolizumab
46116906|NCT05549297|Drug|Investigators Choice|Investigators choice of therapy
46116907|NCT00713037|Procedure|Fluoromisonidazole-PET/CT|2 scans at different time intervals: 2 weeks before and 3 weeks after the participants first proton radiation treatment.
46116908|NCT04067349|Other|Ergometry|"Patients underwent a preoperative ergometry to assess their physical fitness prior to their planned liver resection.~Bicycle stress testing was performed preoperatively and 1 and 6 months postoperatively."
46116909|NCT00787319|Other|no intervention|Outpatients with age-related macular degeneration (AMD)
46116910|NCT00713115|Procedure|needlescopic adrenalectomy and laparoscopic adrenalectomy|Needlescopic instruments, defined as those with a diameter of no more than 3 mm. They result in smaller incisions than conventional 5- to 12-mm instruments.
46116911|NCT02571465|Other|Passive leg raising test and fluid challenge|
46116912|NCT02571231|Device|HFV + and - VG|High frequency ventilation with and without volume guarantuee
46116913|NCT00915239|Drug|Pantoprazole|40 mg pantoprazole once daily for 28 days
45470879|NCT03471728|Drug|linaclotide|Oral
45470880|NCT03309696|Device|sham tDCS and sham rTMS|Both combinations of tDCS and rTMS in this intervention are sham.
45470881|NCT03309696|Device|sham tDCS and active rTMS|tDCS in this intervention is sham and rTMS is active
45470882|NCT03309696|Device|active tDCS and active rTMS|Both combinations of tDCS and rTMS in this intervention are active
45682090|NCT03153904|Other|Monitoring and Feedback System|For each child, the web-based MFS provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Brief Problem Monitor (BPM) and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all weeks of treatment.
46116914|NCT00915239|Drug|Placebo|identical placebo once daily for 28 days
46116915|NCT03481569|Other|Blood and cerebrospinal fluid pharmacocinetic samples on one of the nine antibiotics prescribed in routine use|Blood and cerebrospinal fluid pharmacocinetic samples at different time point
46116916|NCT02604485|Drug|Cohort 1|XOMA 358 single dose level A administered by an intravenous infusion
46116917|NCT02604485|Drug|Cohort 2|XOMA 358 single dose level B administered by an intravenous infusion
46116918|NCT02604485|Drug|Cohort 3|XOMA 358 single dose level C administered by an intravenous infusion
46116919|NCT02604485|Drug|Cohort 4|XOMA 358 single dose level D administered by an intravenous infusion
46116920|NCT00722631|Drug|Pioglitazone|Subjects who meet eligibility criteria will be titrated up to a maximum of 30 mg/day pioglitazone.
46116921|NCT00722631|Drug|Glimepiride|Subjects who meet eligibility criteria will be titrated up to a maximum of 4 mg/day glimepiride.
46116922|NCT02604095|Dietary Supplement|melatonin|Take one tablet (containing melatonin 3mg, calcium 52mg, vitamin B6 5mg) at bedtime everyday for 12 weeks.
46116923|NCT02571543|Drug|Ibuprofen|Beginning with 400mg Ibuprofen, 5 times. Depending on the outcome of stage 1 the treatment dose will increase to 800mg, 5 times.
46116924|NCT02574039|Dietary Supplement|Oat bran|66g oat bran made up in 350ml skimmed milk
46116925|NCT02574039|Dietary Supplement|refined grain|refined grain product and 350ml skimmed milk
46116926|NCT05580653|Other|Controlled feeding study of beef and/or pinto beans|Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (beef, pinto beans, and half beef/half pinto beans) completed in random order.
46027868|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 high dose
46116927|NCT05580653|Other|Controlled feeding study of eggs and/or black beans|Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (eggs, black beans, and half eggs/half black beans) completed in random order.
46116928|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 5% Virginia Tobacco ENDS|JUUL 5%, ENDS for 6-days in confinement
45470883|NCT01382264|Other|Computer Assisted Decision Support|Program to provide recommendations for achieving glycemic control in poorly controlled patients with T2 diabetes.
45470884|NCT03294330|Drug|IC-Green KIT|fluorescence lymphangiography with the use of IC-Green
46027869|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 high dose
46116929|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 3% Virginia Tobacco ENDS|JUUL 3%, ENDS for 6-days in confinement
46116930|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 5% Mint ENDS|JUUL 5%, ENDS for 6-days in confinement
46116931|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 3% Mint ENDS|JUUL 3%, ENDS for 6-days in confinement
46116932|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 5% Menthol ENDS|JUUL 5%, ENDS for 6-days in confinement
46116933|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 3% Menthol ENDS|JUUL 3%, ENDS for 6-days in confinement
46116934|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 5% Mango ENDS|JUUL 5%, ENDS for 6-days in confinement
46116935|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 3% Mango ENDS|JUUL 3%, ENDS for 6-days in confinement
46116936|NCT04107779|Other|Switch to Dual-use of JUUL 5% and UB of Combustible Cigarette|Combination use of JUUL 5% (Virginia Tobacco, Mint, Menthol or Mango flavored) and usual brand combustible cigarettes for 6-days in confinement
46116937|NCT04107779|Other|Tobacco/Nicotine Abstention|No smoking for 6-days in confinement.
46116938|NCT04107779|Other|Usual Brand of cigarettes|Continue smoking UB for 6-days in confinement.
46116939|NCT04067505|Drug|Rivaroxaban|Dose: 15mg twice daily for three weeks, then 20mg once daily until six months after the operation. Application: oral
46116940|NCT04067505|Drug|Warfarin|Dose: 3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until 6 months Duration: 6 months Frequency: once daily Application: oral
46116941|NCT04067505|Drug|Nadroparin|Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
46116942|NCT00794963|Drug|Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan|The intervention in the 4 patients consisted in dietary recommendations, advice regarding increasing physical activity, and use of Orlistat 60 mg three times daily. No other drugs were prescribed.
46116943|NCT00794963|Other|As selected by community physician|As selected by community physician
46116944|NCT00713271|Drug|AZD3199|"Low dose~Dry powder for inhalation, o.d., 1+12 days"
46116945|NCT00713271|Drug|Placebo|
46116946|NCT00713271|Drug|AZD3199|"intermediate dose~Dry powder for inhalation, o.d., 1+12 days"
46116947|NCT00713271|Drug|AZD3199|"high dose~Dry powder for inhalation, o.d., 1+12 days"
46116948|NCT02573961|Device|Laser acupuncture|GaAlAs semiconductor diode Laser Phototherapy Device
46116949|NCT02573961|Behavioral|high protein low carbohydrate diet|A tailored high protein/low carbohydrate/low caloric diet
46116950|NCT02573961|Behavioral|low caloric diet|Tailored balanced low caloric diet
46116951|NCT04105361|Procedure|Posterior neurectomy|Cut of posterior nasal nerve
46116952|NCT05673135|Drug|Anti-Hypertensive|For control of the blood pressure
46116953|NCT05673135|Radiation|Ultrasound|For assessment of gestational age and fetal weight
45470885|NCT05764616|Procedure|PARASTERNAL BLOCK|After induction of general anesthesia, an ultrasound-guided Parasternal Block will be performed with 20 mL of ropivacaine 0.5 % per side.
45470886|NCT05764616|Procedure|LOCAL INFILTRATION OF DRAINAGE EXIT SITES|At the end of surgery, a local infiltration of drainage exit sites will be performed with 10 mL of ropivacaine 0.25% per side
45470887|NCT05764616|Procedure|RECTUS SHEATH BLOCK|At the end of surgery, a rectus sheath block will be performed with 10 mL of ropivacaine 0.25% per side.
45470888|NCT05196984|Device|GENUS device (Active Settings)|Participants in the active condition within the Down Syndrome participant group and the Cognitively Normal Control group will use the GENUS device configured to active 40Hz settings for 30-60 minutes.
45470889|NCT05196984|Device|GENUS device (Sham Settings)|Participants in the control condition within the Down Syndrome participant group and the Cognitively Normal Control group will use the GENUS device configured to sham settings for 30-60 minutes.
45682091|NCT01566981|Procedure|Computerised support to the Diabetes type II patients|The randomly selected group of patients with diabetes type II will get software application and web based support to their usual healthcare process.
46027870|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 high dose
46027871|NCT01210001|Drug|BI 10773|BI 10773 tablets once daily
46027872|NCT03426865|Drug|Axumin PET scan|PET scan prior to RPLND
46027873|NCT04764331|Device|Revian Red All LED cap|Cap that uses two wavelengths of light, 620 nm and 660 nm will be used once a day for 10 minutes.for treatment
46116954|NCT05673135|Radiation|Doppler ultrasound|Umbilical artery Doppler assessment
46116955|NCT05673135|Diagnostic Test|complete blood count|For assessment of platelet count
46027874|NCT02699047|Dietary Supplement|Encapsuled fish oil|Fish oil extracted from sardine, mackerel and anchovy. Nutritional information per capsule: Kcal: 13; protein: 0.35g; Total Fats: 1.25g; Saturated fat: 0g; polyunsaturated fat: 0.75g; EPA: 0.5g; DHA: 0.25g; Cholesterol: 0g. The supplement was provided in gelatinous capsule with antioxidant (tocopherols).
46116956|NCT05673135|Diagnostic Test|Body mass index|for assessment of maternal weight during pregnancy
46116957|NCT02602925|Other|Dose decrease|Treatment strategy change: dose decrease based on PASI and DLQI
46116958|NCT02602925|Other|Usual care|Usual care
45682092|NCT01672684|Procedure|support group therapy|Complete at-home group video calling support sessions
46027875|NCT02699047|Dietary Supplement|Encapsulated Olive oil|Extra virgin olive oil. Nutritional information per capsule: Kcal: 10; protein: 0.35g; Total Fats: 1g; Saturated fat: 0.1 g; monounsaturated fat: 0.75g; polyunsaturated fat: 0.1g; EPA: 0g; DHA: 0g; oleic acid: 0.65g; Cholesterol: 0g. The supplement was provided in gelatinous capsule without antioxidants.
46027876|NCT00624455|Drug|Gabapentin|One dose of oral premedication of Gabapentin 10 mg kg-1 given at least 30 but not more than 90 minutes before surgery. Max dose is 600mg.
46116959|NCT00722709|Drug|Ropivacaine|"In the treatment arm patients will receive 10mls 0.75% ropivacaine diluted to 50mls with saline immediately before closure.~At closure, two small 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump (On-Q pain buster). This pump will contain 270mls of 0.2% ropivacaine. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal."
46116960|NCT00722709|Drug|0.9% Saline|"In the placebo arm patients will receive 50 ml 0.9% saline into the peritoneum soon after the creation of the laparotomy.~At closure, two 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump on-Q pain buster). This pump will contain 0.9% saline. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal."
46116961|NCT00722943|Other|Developmental Massage Therapy|Tactile stimulation and massage will be done by a licensed therapist
46116962|NCT00722943|Other|no intervention|The infant will not be touched by the therapist.
46116963|NCT04105205|Drug|Apramycin injection|30-min infusion
46116964|NCT04105205|Drug|Placebo injection|30-min infusion
46116965|NCT00794573|Drug|varenicline|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
46116966|NCT00794573|Other|placebo|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
46116967|NCT00584844|Biological|Live F tularensis Vaccine|Subjects will receive one drop of reconstituted F tularensis vaccine (approximately 0.0025 ml), applied with a bifurcated needle to the volar surface of the forearm, and the skin will be pricked 15 times over the prepared area. A booster dose will be given at the same dose volume and route of administration if the titer (days 56-84) is inadequate (< 1:20).
46116968|NCT05675748|Drug|Azvudine|Azvudine tablets are taken orally 5mg daily for a maximum of 14 days
46116969|NCT02587104|Other|EpiFix|Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
46116970|NCT00919464|Device|Pressure monitoring device|monitoring device inserted to measure thigh compartment pressures
45682093|NCT01672684|Other|educational intervention|Receive an educational workbook journal
45682094|NCT01870778|Drug|RLX030|1 mg/mL solution in 6 mL vials
45682095|NCT01870778|Drug|Placebo|Matching placebo solution to serelaxin
45682096|NCT05496322|Device|Continuous Non Invasive Blood Pressure Monitoring|Continuous non-invasive arterial pressure monitoring
45682097|NCT05496322|Device|Intermittent Non Invasive Blood Pressure Monitoring|Intermittent non-invasive arterial pressure monitoring
45682098|NCT04964050|Drug|Capozide|Capozide will be administered as per the treatment sequence.
45682099|NCT04964050|Drug|ACE-Hemmer-Ratiopharm|ACE-Hemmer-Ratiopharm will be administered as per the treatment sequence.
45682100|NCT03541330|Other|semi-directive interview|semi-structured interview conducted by a clinical psychologist
46027877|NCT00624455|Drug|Placebo|Placebo
46027878|NCT01127659|Drug|testosterone|intramuscular every 2 weeks
46027879|NCT01127659|Drug|placebo|saline intramuscular every 2 weeks
46027880|NCT01209689|Drug|Tocilizumab|
46027881|NCT01209689|Drug|Placebo|
46027882|NCT02698969|Drug|Sugammadex|
46116971|NCT00919464|Device|Compartmental fracture pressure monitoring|
46116972|NCT00919464|Device|This small project is designed to be a non-randomized, investigational prospective trial of compartment pressures in the thigh following femoral fracture|
46116973|NCT05683704|Drug|AK105，Anrotinib hydrochloride|AK105 administered IV at day 1 every 3 weeks for 8-12 cycles Anrotinib administered PO at day 1-14 every 3 weeks for 8-12 cycles
46116974|NCT04857372|Drug|IAG933|Capsule
46116975|NCT00723333|Procedure|Reduced Intensity Conditioning (RIC) Allogenic Transplant|Reduced Intensity Conditioning (RIC) Regimen Allogenic Stem Cell Transplant
46116976|NCT05373693|Device|Single vision lens|Wear single vision lens
46116977|NCT05373693|Device|+2D PDL|Wear Peripheral defocus lense with +2D
46027883|NCT02698969|Device|Diaphragm Ultrasonography|Prior to induction of anesthesia each enrolled patients, ultrasonography diaphragm evaluation will be performed using an ESAOTE ultrasound machine (ESAOTE MyLab, Genova, Italy) by assessing the TF and amplitude of excursion.
46116978|NCT05373693|Device|+3D PDL|Wear Peripheral defocus lense with +3D
46116979|NCT05373693|Device|+4D PDL|Wear Peripheral defocus lense with +4D
46116980|NCT02570451|Other|Patient Survey|This survey will assess patients' perspective about the importance of preoperative cognitive screening, information about living situation, information about who accompanied them to the preoperative visit, and level of perceived stress.
46116981|NCT02570451|Other|Mini Cog|The MiniCog is a simple cognitive screening tool that takes just 2-4 min to complete and has little or no education, language, or race bias. This is a well-validated tool to assess mild cognitive impairment.
46116982|NCT02570451|Other|Independent Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for instrumental activities of daily living using standardized scales
46116983|NCT02570451|Other|Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for basic activities of daily living using standardized scores
46116984|NCT02570451|Other|Geriatric Depression Scale Short Form|Questionnaire used to measure self-reported mood
46116985|NCT02570451|Other|Confusion Assessment Method (CAM)|This well-validated measure of post-operative delirium will be utilized up to 3 days after surgery
46116986|NCT02570451|Other|RAND 36-Item Short Form Health Survey|This measure is a generic, coherent, and easily administered health survey used to assess self-reported quality of life
46116987|NCT02570451|Other|Grip Strength|Measured using the JAMAR dynamometer
46116988|NCT05667792|Device|Microsoft Kinect 360|Balance and trunk proprioception games will be selected and played for the children to be included in the treatment. Children will play these games with their own body movements.
45838994|NCT04341636|Radiation|Bitewing X ray|"Each patients will be exposed to 4 horizontal bitewing for posterior teeth ( standard of care ) and 4 vertical bitewing for the same area ( experimental ) . X ray will be taken using a film holder and a steel wire (3mm ) on the film holders. This steel wire will help to adjust for magnification later on. The x ray tube will be in the same distance (4mm from the x ray).~The bitewing radiographs will be taken with double-packed Ekta speed Plus films on a radiograph machine operating at 0 kilovolt peak and 8 milliampere, having 2.5 aluminium filtration and a 0.860.8 mm focal spot, according to the manufacturer's exposure recommendations, with the parallel technique to obtain an accurate x ray as much as possible . The radiographs will be processed digitally. All the x ray will be taken using the standard protection protocol ."
45838995|NCT04341480|Drug|Chemotherapy|Routine chemotherapy for individual tumor type.
46027884|NCT02698969|Drug|Neostigmine|
46116989|NCT05667792|Other|Pediatric Rehabilitation|Bobath therapy
46116990|NCT04018911|Device|Hearing Aid with standard Noise Reduction (NR_1)|Hearing Aid with standard Noise Reduction (NR) Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs (ensures exact same hearing loss compensation for each intervention). Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The active comparator condition is the state of the art Noise Reduction principle.
46116991|NCT04018911|Device|Hearing Aid with NR_2|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions (novel NR principle) vary in their parametrization to result in different degrees of noise suppression and good speech quality.
46116992|NCT04018911|Device|Hearing Aid with NR_3|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions (novel NR principle) vary in their parametrization to result in different degrees of noise suppression and good speech quality.
46027885|NCT02698969|Drug|Atropine|
46027886|NCT02698969|Device|Neurumuscual monitoring|Neuromuscular monitoring assesses muscle recovery after deep neuromuscular block through trainf of four and post tetanic count method
46027887|NCT02698969|Drug|Rocuronium|Rocuronium will be administered 0.6 mg*kg-1 to reach neuromuscular block at the induction of general anesthesia and 0.15 mg*kg-1 when PTC elicits more than 5 twitches in order to maintain a deep neuromuscular block
46027888|NCT02698969|Drug|Fentanyl|Fentanest will be administered 2 mcg*kg-1 at the induction of general anesthesia and titrated 0.5 mcg*kg-1 every 30 minutes
46116993|NCT04018911|Drug|Hearing Aid with NR_4|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. This experimental condition combines standard NR and novel NR principle to result in different degrees of noise suppression and good speech quality.
46116994|NCT05061654|Drug|Ceftolozane-tazobactam IV|Empiric Ceftolozane-tazobactam IV 3g over 1 hour every 8 hours. The dose will be reduced to 1.5g 8 hourly in patients with CrCl of 30-50 ml/min, and to 750mg every 8 hours in those with CrCl of 15-29 ml/min. Patients on hemodialysis will receive 2.25g loading dose followed by 450mg every 8 hours.
46027889|NCT02698969|Drug|Propofol|Propofol will be administered 2 mg*kg-1 at the induction of general anesthesia
46116995|NCT04070079|Drug|Tenofovir Alafenamide|TAF 25mg once daily orally, for 48 weeks
46027890|NCT02698969|Drug|Sevoflurane|Sevoflurane will be administered at 1.0 MAC in an air/oxygen mixture
46116996|NCT00739934|Drug|voriconazole (Vfend)|"Study Days 1 to 7: IV voriconazole 7 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
46116997|NCT00713505|Other|educational intervention|Parents receive face-to-face training sessions with a therapist over approximately 2-3 months. Phone support/assistance is provided by the therapist within 2-3 days following each training session and then every 2 weeks for up to 6 months after completion of the training sessions.
45470890|NCT03630614|Drug|Electronic cigarette without nicotine (ECwN) plus active varenicline tablets|"The ECwN group use EC liquids containing 0 mg/mL of nicotine. Because nicotine delivery can be adjusted according to the user's need, all participants are able to adjust their individual nicotine dose by varying the wattage of their EC, by varying puff frequency and puff volume similarly as they are doing (or used to do) with conventional cigarettes.~EC device:~Mini iStick kit (20 W) Eleaf Clearomiser :GS Air M with resistance of 1.5 ohm, the clearomiser's Pyrex window is of blue colour not allowing to distinguish an eventual coloration of the e-liquid containing nicotine. Liquids for EC use are delivered in white opaque 10 mL vials not allowing to distinguish the color of the liquid.~Varenicline, Champix® 0.50 mg tablets Posology of vareniclin follows varenicline's monograph."
45470891|NCT03630614|Drug|Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline|"The ECwoN group receives EC liquids with 0 mg/mL of nicotine on a double blind manner (in identical non-transparent refill bottles of 10 mL).~Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph."
45470892|NCT03630614|Drug|Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline|The ECwN group use EC liquids containing 12 mg/mL of nicotine. Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph.
46116998|NCT00713505|Procedure|psychosocial assessment and care|Child participants and their families may access multidisciplinary psychosocial services (i.e., usual care).
45682101|NCT03526900|Drug|Atezolizumab|"Induction (four or six 21-day cycles) : Atezolizumab 1200 mg / iv + carboplatin 5 AUCs + pemetrexed 500 mg/m2~Maintenance (21-day cycles): atezolizumab 1200 mg/iv + pemetrexed 500 mg/m2."
45682102|NCT03427294|Other|Delphi study|Delphi study on the optimal rehabilitation pathway following lumbar arthrodesis
45682103|NCT05428696|Drug|ALXN2080|Powder-in-capsule
46027891|NCT00848731|Drug|nitric oxide|nitric oxide gas is delivered by facemask
45838996|NCT04341168|Other|this study is non- interventional|this study is non- interventional
45682104|NCT05428696|Drug|Placebo|Powder-in-capsule
45682105|NCT03420742|Drug|Midazolam|Midazolam syrup.
45682106|NCT03420742|Drug|Brigatinib|Brigatinib tablets.
46027892|NCT00537589|Procedure|Ultrasound guided arthrocentesis|Guidance of joint aspiration by ultrasound guidance
46027893|NCT01209143|Drug|Vismodegib|Vismodegib was supplied in hard gelatin capsules.
46116999|NCT02586948|Device|extracorporeal CO2 removal (Hemolung device)|ECCO2R in severe exacerbation of COPD patients, requiring invasive mechanical ventilation with persistent respiratory acidosis and dynamic hyperinflation
46117000|NCT00723411|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
46117001|NCT00723411|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
46117002|NCT00723411|Drug|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270
46117003|NCT02586558|Other|Experimental Infant formula|Ready-to-feed infant formula to be fed ad libitum
46117004|NCT02586558|Other|Reference group|Ready-to-feed infant formula to be fed ad libitum
46117005|NCT02586636|Drug|Metformin|Metformin is given alongside omeprazole / placebo. Started at low dose and titrated gradually over four weeks according to the individual's tolerance of metformin. We anticipate that their tolerance of metformin will be reduced by loss of function variants in OCT1, and by concurrent use of OCT1 inhibiting drugs (in our study this is omeprazole).
45838997|NCT04341324|Other|It is an observational study.|
46027894|NCT01209143|Drug|Rosiglitazone|Rosiglitazone was supplied in tablets.
46117006|NCT02586636|Drug|Omeprazole|Given as concurrent treatment in one of the two treatment periods. Omeprazole treatment dose is fixed at 20mg twice daily for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
46117007|NCT02586636|Drug|Placebo|Given as concurrent treatment in one of the two treatment periods. Placebo treatment dose is fixed at one tablet twice daily (to match the dosing pattern of omeprazole) for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
46117008|NCT00739310|Device|Vest Treatment (high frequency chest wall oscillation)|twice daily for 15-20 minutes
46117009|NCT04089644|Device|closed-loop system|"Hypotension will be corrected by an automated system for vasopressor administration.~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)"
46117010|NCT04089644|Device|Manual adjustment|"Vasopressor agents will be manually adjusted (standard practice).~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)"
46117011|NCT00713739|Drug|Alfuzosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
46117012|NCT00713739|Drug|nifedipine|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
46117013|NCT00713739|Drug|doxazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
45682107|NCT03372460|Device|Active stimulation|For active tDCS, the investigators will use a 1x1 configuration with the anode placed over EEG coordinate AF7 (using the 10-20 EEG convention) and the cathode over Fz. The investigators will use 3x3 cm sponge covered electrodes and a 2mA current for 25 minutes per session.
46027895|NCT01209143|Drug|Norethindrone/ethinyl estradiol|Norethindrone/ethinyl estradiol was supplied in tablets.
45682108|NCT03372460|Device|Sham stimulation|For sham tDCS, the investigators will use the same configuration of active tDCS, with the anode over AF7 and the cathode over Fz. The investigators will use 3x3 cm sponge covered electrodes and 1mA for 30 seconds, with a ramp up/down over 30 seconds per session.
45682109|NCT03372460|Other|Virtual Reality (VR)|Participants will undergo VR exposure to trauma-related context.
45682110|NCT01672840|Dietary Supplement|5g Cocoa Consumption|Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
45682111|NCT01672840|Dietary Supplement|10g Cocoa Consumption|Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
45470893|NCT05192694|Procedure|Computed tomography|Positron Emission Tomography
45682112|NCT02370706|Drug|PIM447|pan-pim inhibitor
46027896|NCT00454285|Drug|Effect of Amoxicillin on bacteremia following a single-tooth extraction|Administer Amoxicillin 1 hour prior to single-tooth extraction.
46027897|NCT00614965|Drug|Irinotecan|Irinotecan at the dose of 110 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
46027898|NCT00614965|Drug|Cisplatin|Cisplatin at the dose of 80 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
46027899|NCT00614965|Drug|Pemetrexed|Pemetrexed at the dose of 500mg/m2 IV every 3 weeks for 6 consecutive cycles
46027900|NCT00390325|Drug|Sorafenib Tosylate|Given PO
46027901|NCT00405613|Drug|Aspirin|
46027902|NCT02703883|Device|BWST|BWST (six weeks, 3 times/week)
46027903|NCT02703805|Other|Fit For Function Program|A 12-week YMCA-based wellness program for persons with stroke, consisting of 2 group exercise sessions, one gym exercise session and one education session per week with trained instructors
46027904|NCT02703805|Other|Standard YMCA membership|A 12 week standard YMCA membership.
46027905|NCT02703961|Drug|concurrent chemotherapy with cisplatin|in experimental group: cisplatin 60mg/m2, d1,d22;
45470894|NCT03630926|Diagnostic Test|NV-VPAC1 PCa Urine Diagnostic Test|The NV-VPAC1 PCa Urine Diagnostic Test is intended for use by clinicians to detect the presence of prostate cancer cells shed in voided urine of men at risk for prostate cancer.
46117014|NCT00713739|Drug|prazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
46117015|NCT04081662|Behavioral|compACT Intervention|"The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of distress, depressive symptoms, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments."
46117016|NCT05379920|Behavioral|High Volume Aerobic Exercise|Aerobic exercise is completed for 30 minutes, 5 days a week. Exercise intensity is adjusted weekly to 90% of the heart rate threshold. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT.
46117017|NCT05379920|Behavioral|Low Volume Aerobic Exercise|Aerobic exercise is completed for 20 minutes, 3 days a week. Exercise intensity is adjusted weekly to 90% of the heart rate threshold. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT.
46117018|NCT03908151|Device|CMK21 Hip system|Total hip arthroplasty
46117019|NCT05566704|Device|Modulus ALIF System|The Modulus ALIF System is designed to address lumbar pathologies utilizing interbody placement through an anterior or anterolateral surgical approach. The Modulus ALIF System is an interfixated interbody system available in various shapes and sizes to suit the individual pathology and anatomical conditions of the patient.
46117020|NCT05373069|Procedure|Mechanical ischemic preconditioning of diep-type flap|"Mechanical ischemic preconditioning: Performing series of reperfusion ischemia on the flap pedicle, before cold ischemia of the flap (flap harvesting before vascular mechanical anastomoses at the recipient site)~10 min of clamping with single-use microvascular forceps~10 min declamping~10 min of tightening with pliers~10 min declamping Either preconditioning for 40 minutes, simulating 2 cycles of ischemia reperfusion prior to flap harvesting and cold ischemia before revascularization."
46117021|NCT02595476|Drug|Remifentanil|
46117022|NCT02595476|Drug|propofol|
46117023|NCT02595476|Device|TCI|
46117024|NCT02595476|Procedure|Tetanic stimulation|
46117025|NCT02595476|Device|Algiscan|Pupillometry
45470895|NCT05190042|Device|Cotinuous suture|Cotinuous suture using surgery thread
45470896|NCT05190042|Device|Clips|Hemostatic clips
45470897|NCT01378910|Drug|Unique|Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)
45470898|NCT03946098|Behavioral|iCBT|A newly developed iCBT protocol targeting problem gambling.
45470899|NCT03922698|Other|No interventions|No interventions - observational study
45470900|NCT04899102|Behavioral|Time-Restricted, Intermittent Fasting|A special type of diet for 6 weeks, called time-restricted, intermittent fasting.
45682113|NCT02370706|Drug|Ruxolitinib|JAK1/JAK2 inhibitor
45682114|NCT02370706|Drug|LEE011|CDK4/6 inhibitor
45682115|NCT01818284|Drug|Filgrastim|5 µg/kg in the morning daily for 4 days.
46027906|NCT02703961|Drug|concurrent chemotherapy with docetaxel|in experimental group: docetaxel 60mg/m2, d1,d22;
46027907|NCT02703961|Radiation|pelvic radiotherapy|external beam radiotherapy for whole pelvix with 50Gy/25f boost radiotherapy for pelvic lymph node metastasis with 12-14Gy/4-7f.
46027908|NCT02703961|Radiation|brachytherapy|CT/MRI guided brachytherapy or x-ray guided brachytherapy
46027909|NCT02703961|Drug|adjuvant chemotherapy with cisplatin and docetaxel|cisplatin 75mg/m2, d43,d64; docetaxel 75mg/m2, d43,d64
45470901|NCT03902028|Other|Reinforced multidisciplinary follow-up|Reinforced multidisciplinary follow-up
46027910|NCT02703649|Drug|Letrozole|After the decision to use Letrozole for induction of ovulation, we will obtain informed consent and randomize the patents into 2 groups Single 20 mg dose of Letrozole on day 3 of the cycle Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
45470902|NCT04847778|Device|Use of Insulclock system, both Insulclock device and Insulclock 360 app.|"Visit 5, during week 4.~Randomization will be applied:~Active group will use all functionalities of Insulclock 360. They will have reminders, all their information and statistics at the disposition of the patient and healthcare providers, they have the assistance if desired of an ally or caregiver, a bolus calculator and the rest of functionalities described in the protocol."
45470903|NCT04847778|Device|Use of Insulclock system, both Insulclock device and Insulclock app on masked mode.|"Visit 5, during week 4.~Randomization will be applied:~Masked group will remain with the masked system, without functionalities."
45470904|NCT04570488|Other|EPIC risk score display|Display of risk score/ colored flag in Epic patient list column
45470905|NCT04543734|Device|HemoScreen hematology analyzer|The use of HemoScreen for self-testing of blood values
45470906|NCT03075644|Drug|somapacitan|Once weekly subcutaneous injections (s.c., under the skin)
45470907|NCT03075644|Drug|Norditropin|Daily subcutaneous injections (s.c., under the skin)
45470908|NCT04521296|Other|Part 1|- DWJ1248 600mg PO (100mg 2 tab, TID)
45470909|NCT04521296|Other|Part 2|- DWJ1248 600mg PO (200mg 1 tab, TID)
45470910|NCT05017818|Other|Observational retrospective data|Non-intervention
45470911|NCT05764538|Drug|DAOIB|The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation
45470912|NCT03689478|Other|Hyperthermic intravesical chemotherapy|Intravesical instillation of 40mg mitomycin C at 43 degrees for 60 minutes immediately after transurethral resection of bladder tumour
45470913|NCT01378832|Procedure|Intra-peritoneal antibiotic lavage|The lavage was performed immediately prior to closure of the abdominal wall. Prior to the lavage, a microbiological sample from the peritoneal surface (parietal and visceral) was obtained with a swab (sample 1), followed by a lavage with 500 ml normal saline, similar to the one performed in Group 1. After this lavage, a new microbiological sample was obtained from the peritoneal surface (sample 2), and a second lavage with an antibiotic solution, including gentamicin (240 mg) and clindamycin (600 mg) dissolved in 500 ml normal saline was performed. During this lavage, the solution was allowed to sit in the abdominal cavity for 3 minutes. After aspirating the lavage, a third microbiological sample was obtained in the same way as the two previous ones (sample 3).
46027911|NCT02703571|Drug|ribociclib|Combination treatment with LEE and TMT
45470914|NCT05060432|Drug|EOS-448|Anti-TIGIT monoclonal antibody
46027912|NCT02703571|Drug|Trametinib|Combination treatment with LEE and TMT
45470915|NCT05060432|Drug|pembrolizumab|Anti-PD-1 monoclonal antibody
45470916|NCT05060432|Drug|inupadenant|A2A receptor antagonist
45470917|NCT05060432|Drug|Dostarlimab|Anti-PD-1 monoclonal antibody
45470918|NCT05060432|Drug|SOC chemotherapies|SOC chemotherapies in 1L NSCLC
45470919|NCT01378754|Drug|Fospropofol (Lusedra®) 6.5|Group 1 will receive 6.5 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
45470920|NCT01378754|Drug|Fospropofol (Lusedra®) 10|Group 2 will receive 10 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
45470921|NCT01378754|Drug|Fospropofol (Lusedra®) 12|Group 3 will receive 12 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
45682116|NCT01818284|Drug|Plerixafor|240 µg/kg subcutaneously in the evening on the fourth day of Filgrastim mobilization.
45682117|NCT01818284|Procedure|Apheresis Procedure|"The apheresis procedure will start in the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor.~The apheresis procedure may continue beyond day 1 until the target dose of 4x106 CD34+ cells/kg (recipient's weight) is obtained."
45682118|NCT02081014|Drug|G-Pen Mini™ (glucagon injection)|stable, pre-mixed, liquid glucagon for subcutaneous injection
45682119|NCT01673074|Drug|(PDT) Photodynamic therapy|photosensitizer
45682120|NCT01673152|Dietary Supplement|Oligofructose|Dosing: children aged 7 to 12 years: 8g/day, children aged 12 to18 years: 15g/day Duration: 12 weeks
46027913|NCT00615355|Radiation|UVB 311 nm radiation|UVB 311 nm radiation randomized to one half of the transplanted vitiligo lesion given 2 times a week for 3 months; the other half of the transplanted lesion remains UV-non-irradiated
46027914|NCT00615355|Device|UVB 311nm|Repeated UVB 311nm narrowband irradiation (24 exposures)
46117026|NCT02586402|Drug|pegol-Sihematide|
46117027|NCT02586402|Drug|Epoetin Alfa|
46117028|NCT00713895|Behavioral|Expert System|an expert system intervention provided the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.
46117029|NCT00713895|Behavioral|Standard Self-Help|standard smoking cessation self-help manual
46117030|NCT00734630|Drug|nebivolol|"Encapsulated Nebivolol 5mg, 10mg, 20mg, or 40mg total daily dosage, oral administration once daily~Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration"
46117031|NCT00734630|Drug|Placebo|Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration
46117032|NCT02570997|Drug|CT1812|Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.
46117033|NCT02570997|Drug|Placebo|Matching placebo administered.
46117034|NCT05636514|Drug|Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET|Fixed dose treatment cycles 1 to 6. Cycle 1 is monotherapy, cycles 2 to 6 combination therapy with defactinib.
46117035|NCT05636514|Drug|Defactinib|"Defactinib treatment will commence with at the starting dose (dose level 1) from cycle 2 to 6.~Dose escalation/de-escalation will proceed based on the MTD determination.~Dose Level 1: 200mg Defactinib twice daily (starting dose level)~Dose Level 2: 400mg defactinib twice daily~Dose Level -1: 200mg Defactinib daily"
46117036|NCT05635032|Other|Comprehensive clinical assessment and biological samples collection|To establish the first Portuguese registry and biobank of PF-ILDs, comprising both extensive patient-level data, and systematic biological sampling (DNA, RNA, plasma, serum, bronchoalveolar lavage, lung tissue) at baseline and repeated biological sampling of blood and pharyngeal swabs performed at 6, 12 and 18 months, or whenever progression criteria are met or an acute exacerbation occurs. Participants will have regular visits at maximum intervals of 6 months, when their clinical condition and lung function tests are reassessed. A high resolution computed tomography (HRCT) scan of the lung will be performed every 12 months. Progressive fibrosis will be diagnosed based on meeting at least two of the following three criteria, occurring within the last year: (i) worsening of symptoms; (ii) absolute decline in FVC ≥5% predicted or absolute decline in DLCO (corrected for Hb) ≥10% predicted; (iii) increased extent of fibrotic changes on HRCT.
46117037|NCT02570529|Drug|Albis®|The patients take Albis® 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
46117038|NCT02570529|Drug|Placebo|The patients take placebo 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
46117039|NCT05372835|Other|La Chlogen mouthwash|Patients with periodontal disease were randomized into mouthwash group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the intervention was asked participants to rinse the commercially available La Chlogen mouthwash in mouth without spitting. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
46117040|NCT05372835|Other|water|Patients without periodontal disease were selected as a control group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the intervention was asked participants to rinse the pure water in mouth without spitting. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
46117041|NCT05372835|Other|La Chlogen mouthwash and La Chlogen periodontal flosser|Patients with periodontal disease were randomized into mouthwash and periodontal flosser group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the La Chlogen mouthwash in conjunction with the La Chlogen periodontal flosser were applied in mouth without spitting for interventions. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
46117042|NCT02586480|Device|dual chamber pacemaker with SafeR algorithm|SafeR is an AVB management algorithm: it provides AAI pacing while continuously monitoring AV conduction, it switches to DDD when detecting AVB I, II or III, according to the following criteria: (1) AVB I: 6 long PR intervals, (2) AVB II: 3 blocked atrial events/12 cycles, (3) AVB III: 2 consecutive blocked atrial events. It switches back to AAI mode when needed.
46117043|NCT02570607|Biological|BNP dosage|
46117044|NCT02570763|Device|Active tDCS stimulation|
46117045|NCT02570763|Device|Sham tDCS stimulation|
46027915|NCT02703727|Behavioral|Extended polymedication check|"Behavioral: Medication review~Patients on oral anticoagulants and polypharmacy will receive extended polymedication check to identify Pharmaceutical Care Issues, Adherence Issues, Drug related problems and Knowledge Gaps~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n>3 drugs) on long term conditions (> 3 months) and is reimbursed by swiss health insurance. The semi-structured interview contains questions about knowledge on oral anticoagulation therapy. This extended PMC follows a structured predefined protocol.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer."
46027916|NCT02703415|Drug|Bupivacaine|caudal block with bupivacaine (0.25%) 1mg/kg
46027917|NCT02703415|Drug|Tramadol|caudal block with tramadol 1 mg/kg
45682121|NCT01673152|Dietary Supplement|Maltodextrin|Dosing: children aged 7 to 12 years: 4g/day, children aged 12 to18 years: 6g/day, Duration: 12 weeks
45754544|NCT03584828|Behavioral|Tele Cardiac Rehabilitation|"A multidisciplinary intervention that aims to optimize structured exercise performed in the community as prescribed by rehabilitation cardiologist, cardiac care nurse, and exercise physiologist.~Additionally, in the intervention arm, we will provide psychological support, dietary intervention and disease management services that complement the structured physical activity - all by innovative smartphone applications and smart wearable devices, thus complementing the comprehensive secondary prevention program."
46117046|NCT04079556|Behavioral|Tobacco LHW|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
46117047|NCT00584454|Biological|Q Fever Vaccine (NDBR 105|Each volunteer will receive an intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase I, MNLBR 110) in the volar aspect of the arm on Day -7 of the study.Volunteers with skin test reactions that are considered negative may be vaccinated with Q Fever Vaccine, Phase I, Inactivated, Freeze-Dried, NDBR 105 (subcutaneously, 0.5 ml) in the upper outer aspect of the arm on Day 0 of the study.
45470922|NCT05764382|Behavioral|T'ai Chi and Qigong Rehabilitation|T'ai chi/Qigong is a multidimensional (mind, body, and spirit integrative) and multimodal (strength, flexibility, balance, posture, and light to moderate aerobic) form of exercise that is safe for persons of all ages and physical abilities. The 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation program proposed to be studied is adapted from the WaQi program, a curriculum developed by Master Yang Yang, PhD. Master Yang developed this course based on his own healing journey from severe back pain following a bike accident in 2014.
46117048|NCT02586324|Biological|global medium|
46027918|NCT02703181|Drug|Epelsiban (GSK557296)|White to off-white 0.270 inches x 0.700 inches oblong film coated tablet containing 25 mg or 100 mg epelsiban. To be swallowed whole with water, not to be chewed.
46027919|NCT02703181|Drug|Placebo to match GSK557296|White to off-white 0.270 inches x 0.700 inches oblong film coated Tablet containing placebo. To be swallowed whole with water, not to be chewed.
46117049|NCT02586324|Biological|SSM|
46117050|NCT04081272|Drug|Sodium Chromate Cr51|Sodium Chromate Cr 51 will be used to perform a red blood cell recovered study 24 hours post-transfusion.
46027920|NCT03297697|Procedure|Tumor biopsy|Biopsy specimen can be from bone marrow, blood, or lymph node. This specimen should have a high disease load
46117051|NCT02586246|Drug|CDP870|Self-injection
46117052|NCT00920244|Procedure|Cardiopulmonary resuscitation (CPR)|CPR is performed according to international and national guidelines on all patients.
46117053|NCT00920244|Drug|Epinephrine|According to guidelines epinephrine 1 mg i.v. is administered every 3 minutes during cardiopulmonary resuscitation.
46117054|NCT00920244|Drug|Atropine|According to CPR guidelines atropine 3 mg i.v. is administered if asystole og PEA with frequency < 60 beat/min.
46117055|NCT00920244|Drug|Amiodarone|According to guidelines amiodarone 300 mg i.v. is administered if recurrent ventricular fibrillation/tachycardia (VF/VT) during CPR.
46117056|NCT00920244|Device|External defibrillator|According to CPR guidelines patients with shockable rhythms may receive DC shocks. The defibrillator also stores physiological information regarding cardiac rhythm, pulse-oximetry, and end-tidal carbon dioxide (CO2) from endotracheal tube.
45470923|NCT05764382|Other|Usual care|Usual care as per primary care physican, physical therapist.
45470924|NCT05462678|Behavioral|Cognitive Rehabilitation|Each patient performed two weekly sessions of 45 minutes each, for 12 weeks
45470925|NCT05462678|Behavioral|Combined Rehabilitation|Each patient performed one session per week (45 minutes) of CR and one session per week of traditional MR training for 12 weeks.
46117057|NCT00920010|Other|biologic sample preservation procedure|
46117058|NCT00578175|Biological|Priorix-Tetra™ (MMRV vaccine 208136)|One subcutaneous injection.
46117059|NCT00578175|Biological|ProQuad®|One subcutaneous injection.
46117060|NCT00578175|Biological|Havrix®|Two intramuscular injections.
46117061|NCT00578175|Biological|Prevnar®|One intramuscular injection.
46117062|NCT00723879|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
46117063|NCT00723879|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
46117064|NCT00723879|Behavioral|Patient assistance program|"Patient assistance programs will be classified as follows:~medications, including psychiatric medications (antidepressants);~other interventions, including nurse telephone calls and nurse support in the office: and~educational literature about hepatitis C containing information about the disease, mode of transmission, complications, and treatment and treatment drawbacks that will be given to each patient at the start of treatment."
46117065|NCT03907605|Other|anti- mullerian hormone|All patients belong to the same group. The blood samples will be collected at the time of surgery and 3 months after surgery from the patients who need uterine artery ligation for PPH. The blood samples will be centrifuged within 2 hours after being obtained and assessed on the same day. AMH concentrations will be measured with an enzymatically amplified two-sided immunoassay
45470926|NCT05462678|Behavioral|Motor Rehabilitation|Each patient performed two weekly sessions45 minutes each, for a total of 12 weeks.
45470927|NCT05462366|Other|Sample collection|Collect breaskmilk and feces from mother-infant-pairs.
45470928|NCT05764304|Drug|Sinomenine|Participants will receive one intra-articular injection every 4 months
46027921|NCT03297697|Procedure|Peripheral blood draw|-Baseline, C1D1, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1, end of treatment, 3 month follow-up (optional), 6 month follow-up, 9 month follow-up (optional), 12 month follow-up, 15 month follow-up (optional), 18 month follow-up, 21 month follow-up (optional), 24 month follow-up, and at relapse
46027922|NCT03297697|Procedure|Lymphotrack TCR clonality assay|-Assay with high sensitivity that can be performed with peripheral blood
45470929|NCT05764304|Drug|Glucocorticoid|Participants will receive one intra-articular injection every 4 months
46027923|NCT04215835|Drug|letrozole then misoprostol|"Drug: Letrozole 2.5mg total dose 7.5 mg per day for 3 days~Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion"
46117066|NCT00435409|Drug|Sunitinib + Capecitabine|"Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen.~Capecitabine administered orally at a starting dose of 2000 mg/m^2 per day [1000 mg/m^2 bid (twice daily)] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons."
46117067|NCT00435409|Drug|Capecitabine|Capecitabine administered orally at a starting dose of 2500 mg/m^2 per day [1250 mg/m^2 bid (twice daily)] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons. At the time of progression, patients may be eligible to crossover to single agent sunitinib, administered orally at a starting dose of 37.5 mg daily.
46117068|NCT00724035|Drug|Midazolam|"Procedural sedation before the execution of the block.~0.03 mg/kg iv bolus"
46117069|NCT00724035|Drug|Ropivacaine|0.75% (wt/vol) solution, 20 ml perineural injection
46117070|NCT00724035|Drug|Fentanyl|50 µg iv bolus prn for pain during surgery, up to 150 µg
46117071|NCT00724035|Procedure|General anesthesia|General anesthesia will be induced if pain during surgery develops which is intractable with iv fentanyl ≤150 µg.
46117072|NCT00724035|Procedure|Axillary brachial plexus nerve block|"Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. With the abducted arm flexed 90° at the elbow, the transducer will scan for the axillary artery in its short-axis. Individual nerves will be sought for around the artery.~A 22G, 17°-bevel needle will be advanced in-plane to inject aliquots of local anesthetic around each nerve structure up to the prescribed dose."
46117073|NCT00724035|Procedure|Infraclavicular brachial plexus block|"Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. The linear transducer will be initially positioned between the middle and lateral third of the clavicle, scanning on a parasagittal plane.~The axillary artery and veins will then be sought for. We will try to visualize the three cords of the brachial plexus separately, and to inject local anesthetic around each of them. If this is not possible, the needle will be positioned cranially and posteriorly to the artery, and the injection will be made from there. A 20 G, 17°-bevel needle will be used for all blocks."
46117074|NCT04335591|Drug|75 mg linzagolix tablet|For oral administration once daily
46117075|NCT04335591|Drug|200 mg linzagolix tablet|For oral administration once daily
46117076|NCT04335591|Drug|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
46117077|NCT04335591|Drug|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
46117078|NCT04335591|Drug|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
46117079|NCT04335591|Drug|Placebo capsule to match Add-back capsule|For oral administration once daily
45470930|NCT03075410|Drug|GSK3036656|GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.
45470931|NCT03075410|Drug|Placebo|Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.
45470932|NCT05763290|Other|Affective Response to Exercise|Participants will perform a total of three trials of a cognitive task before and after their scheduled SJLIFE cardiovascular stress testing. Participants will then be asked to participate in a qualitative interview about the cognitive task tool and body sensations and emotions experienced during exercise.
45754545|NCT03666377|Other|Gum chewing|1 piece of sugarless gum to be chewed three times daily for 1 hour each.
46027924|NCT04215835|Drug|placebo then misoprostol|"Drug: Placebo placebo for 3 days~Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion"
46027925|NCT01023789|Device|ABSORB BVS|Absorb Bioresorbable Vascular Scaffold (BVS) System implantation
46027926|NCT02702947|Dietary Supplement|Prunus domestica extract|Prosman 1 capsule twice a day
46027927|NCT00637039|Drug|AZD8931|Tolerability and Pharmacokinetics of AZD8931 in Patients with Advanced Solid Malignancies.
46027928|NCT02703103|Other|Manual chest compressions|2 min of Chest compressions without mechanical chest compression system
46027929|NCT02703103|Device|ARM chest compressions|2 min of Chest compressions with mechanical chest compression system LifeLine ARM
45470933|NCT04084964|Other|Home-hospitalisation platform for heart failure|The primary objective of the INTERREG NWE-Chance project is the development of an integrated home-hospitalisation platform and the assessment of the feasibility of a home hospitalisation strategy for heart failure patients.
46027930|NCT01208207|Drug|Part I - etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 6 weeks
46117080|NCT04126824|Drug|Triamcinolone|40 mg triamcinolone administered as a Superior Hypogastric Nerve Block (SHNB)
46117081|NCT04126824|Drug|Bupivacaine|0.5% bupivacaine (20 mL) administered as a Superior Hypogastric Nerve Block (SHNB).
45754546|NCT00577135|Drug|Furosemide-Q12 hour bolus|Q12 hours bolus
45754547|NCT00577135|Drug|Furosemide-Continuous Infusion|Continuous infusion
45754548|NCT00577135|Drug|Furosemide-Low Intensification|1x oral dose
45754549|NCT00577135|Drug|Furosemide-High Intensification|2.5x oral dose
46027931|NCT01208207|Drug|Part I - etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 6 weeks
46027932|NCT01208207|Drug|Part I- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 6 weeks
46027933|NCT01208207|Drug|Part I - Placebo to naproxen 500 mg|Placebo to naproxen 500 mg oral tablet twice daily for 6 weeks
46027934|NCT01208207|Drug|Part II- etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 20 weeks
46117082|NCT04126824|Other|Iohexol contrast|The appropriate amount of contrast to enable visualization of the nerve block under fluoroscopy given as a Superior Hypogastric Nerve Block (SHNB) will be administered.
46117083|NCT00724113|Procedure|infiltration intra articular|infiltration intra articular at inclusion with XYLOCAINE 1%
45470934|NCT04832984|Behavioral|Mobile health|Participants will be issued a fitness tracker, Bluetooth enabled glucometer, and a custom developed app which they can communicate digitally to the study investigators either as a group or individually. In the beginning of the study, participants will be taught on how to use the program, how to interact with their coach, and the importance of maintaining motivation throughout the program. Participants will have access to a pharmacist-participant messaging, group messaging, daily challenges for behavior change, education articles (biweekly bite-sized content over 24 weeks), food logging, steps and exercise logging, and feedback. They will be asked to log their weight, meals, and physical activity within the program on a weekly basis. Pharmacist will monitor participant progress through a web-based dashboard. Community pharmacist will be assisting users in setting specific, measurable, attainable, realistic, and time-based goals on a weekly basis.
46117084|NCT00724113|Procedure|ARTHRO distension plus intensive mobilisation|ARTHRO distension plus intensive mobilisation
46027935|NCT01208207|Drug|Part II- etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 20 weeks
46117085|NCT04581330|Device|DEKA SmartXide C02 laser|One pass with a 1-mm spot density and a 60 micron depth will be performed followed by a 1-mm spot density and a 200 micron depth will be used
46117086|NCT05683236|Other|Health education|Doctors carried out health education for patients to avoid patients giving up their lives, encouraged them to actively cooperate with medical staff, and instructed patients on how to face the disease with a brave and strong attitude and actively fight the disease. Nurses conducted daily psychological counselling for patients, learnt their inner thoughts through communication with patients, and provided timely comfort and encouragement. An attention-shifting method can be used to alleviate the patient's attention to the disease, effectively improving internal depression and avoiding depression. For patients with anxiety and loneliness, family members were instructed to accompany and care.
46117087|NCT05683236|Other|Comfort care|Reasonable control of indoor temperature and humidity is necessary to ensure that warm, light conditions permit properly dressed patients to feel warm. Nurses need to ensure that patients are kept clean and tidy in personal hygiene. They would regularly assist patients in turning over while giving patients sufficient respect.
46117088|NCT05683236|Other|Pain care|Clinicians should regularly evaluate the patient's physical pain and give reasonable analgesic drugs to patients. Nurses should closely observe the medication response of patients. At the same time, it is necessary to observe and record patients' physical pain daily and take effective pain control measures.
45754550|NCT03583580|Radiation|Accelerated Partial Breast Irradiation|Patients are irradiated to the region of tumour bed using intensity modulated radiation therapy (IMRT)
45754551|NCT00502853|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
46027936|NCT01208207|Drug|Part II- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 20 weeks
45754552|NCT00502853|Drug|Methotrexate|10-25mg/week
45754553|NCT00617539|Drug|irinotecan hydrochloride|
46027937|NCT01208207|Drug|Part I - Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.
46027938|NCT01208207|Drug|Part I - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.
46027939|NCT01208207|Drug|Part II- Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.
46027940|NCT01208207|Drug|Part II - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.
46117089|NCT05683236|Other|Dietary care|The clinical nutritionist formulated appropriate nutritional diets according to the nutritional status and personal preferences of patients, provided nutritional support for patients, and followed up with patients once a week after discharge to improve their nutritional status.
46117090|NCT05683236|Other|Psychological and social support care|"Two nurses with psychological counselling qualifications in the team used the anxiety and depression scale to evaluate the psychological and emotional status of patients and referred to The Questionnaire Survey on Awareness of Palliative Care by the Department of Elderly Section of the union medical college hospital. The content mainly included the patient's medical history and general situation, the needs and awareness of patients and their families for palliative care, the choice of patients and their families for the final treatment plan, and the needs of families for grief counselling. Timely professional counselling and intervention were undertaken to alleviate the patient's adverse emotions."
46117091|NCT05683236|Other|routine nursing intervention|The control group was given routine nursing intervention, strictly in accordance with a routine treatment process, monitoring the vital signs of patients, giving basic nursing, health education, diet guidance and so on.
46027941|NCT01208207|Drug|Part II- Placebo to naproxen 500 mg|Placebo to naproxen 500 mg orally twice daily for 20 weeks.
45470935|NCT04832984|Behavioral|Usual care|Participants will be issued a fitness tracker and Bluetooth enabled glucometer but these functions will not be enabled or linked to any app. All participants will be given physical tracking sheets to log in their food intake, blood glucose levels and food diary but will not have access to a personal coaching. Participants are free to seek any assistance for their medical care during the study period.
46117092|NCT02584374|Other|Venography with balloon occlusion test|First, regular venography of the venous iliac tract will be performed. Second, a 16mm diameter balloon will be inflated in the common iliac vein and venography will be repeated.
46117093|NCT04070001|Drug|400 Mg Ibuprofen|1-dose 400-mg ibuprofen 1-hour before elastomeric separator placement
46117094|NCT04070001|Device|laser application|A single irradiation of laser after elastomeric separator placement
46117095|NCT04070001|Other|placebo tablets|Placebo lactose tablets 1-hour before elastomeric separator placement
46117096|NCT04081506|Other|Individualized perfusion targets|Targeting +/-5mmHg of the optimal mean arterial pressure
46117097|NCT00724191|Procedure|MRI|New MRI methods which measure information related to water, blood, and chemical makeup in the brain.
46117098|NCT02573649|Device|Closed-loop Stimulation on first|Closed-loop Stimulation algorithm is turned on in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned off and the patient performs a second head up tilt test.
46117099|NCT02573649|Device|Closed-loop Stimulation off first|Closed-loop Stimulation algorithm is turned off in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned on and the patient performs a second head up tilt test.
46117100|NCT00467857|Procedure|InteguSeal* skin sealant and standard surgical preparation|Surgical skin preparation prior to incision using InteguSeal* skin sealant following standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
46117101|NCT00467857|Other|Standard preoperative skin preparation|Surgical skin preparation prior to incision using standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
46117102|NCT02573571|Other|Development of biomarkers|Blood sampling
46027942|NCT02703025|Dietary Supplement|GCB-70|green coffee bean extract
46027943|NCT03292471|Device|Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique in which a focal, time-varying magnetic field is applied to a specific brain area to induce neuronal depolarization. rTMS can be used to selectively target a given brain region with a resolution as focal as 0.5 cm3 .Typically, administering a slow (1 Hz) sequence of magnetic pulses via rTMS temporarily reduces cortical excitability in the targeted brain region.
46117103|NCT05328219|Other|Chewing gums with PEG solution|"Patients undergoing colonoscopy under experimental group was advised to take 2L of PEG solution and packets of sugarless sweet mint flavored chewing gums.~The patients are advised to Chew one stick of sugarless gum for at least 10 min after taking each glass of PEG solution and discard the chewing gum before taking next glass."
46117104|NCT05328219|Other|Standard of care|Standard of care
46117105|NCT00724269|Device|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
45470936|NCT03630068|Procedure|Stereotactic percutaneous image-guided microwave ablation|Stereotactic percutaneous image-guided microwave ablation implies the use of computer-assisted navigation technology for 3D trajectory planning and stereotactic placement of ablation probes, before applying local microwave ablation therapy
45754554|NCT00617539|Drug|temozolomide|
45754555|NCT03584750|Other|Floating|Floating in specialized tank with full floatation and sensory deprivation.
46027944|NCT05420285|Drug|Dapagliflozin|Dapagliflozin (Forxiga) is a very potent selective and reversible inhibitor of SGLT2.
46027945|NCT04147663|Other|describe the management of the adult population suffering from suspected seizure by the emergency structures|For 3 consecutive days, all patients with suspected epileptic seizures (assessed by the Emergency medical assistance service ( SAMU), paramedical team and the emergency unit) will be included in the study. With the use of questionnaries, information will be collected from patients or witnesses by the SAMU, the paramedical team or physicians of the emergency unit. A 7-day follow-up will be carried out by the principal investigator (PI) of each center.
46027946|NCT01012713|Drug|Clobex Spray|Clobex Spray BID for Weeks 1-4 and weeks 9-12
46027947|NCT01012713|Drug|Vectical Ointment|Vectical ointment BID for weeks 5-8 and 9-12
46027948|NCT01012713|Procedure|Excimer Laser|Laser treatment for weeks 1-6 study and as needed for patients with less than PASI-75 response thereafter.
46117106|NCT00724269|Device|ReNu MultiPlus MPS|Multi-Purpose Solution for soft contact lenses
46117107|NCT05315661|Drug|ET-STEM|mesenchymal stem cells preconditioned with ethionamide
46117108|NCT00435019|Drug|insulin detemir|s.c. injection, once or twice daily.
46117109|NCT00435019|Drug|insulin NPH|s.c. injection, once or twice daily.
46117110|NCT00435019|Drug|insulin aspart|s.c. injection, at main meals.
46117111|NCT00714129|Other|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is the similar composition of their current diet.
46117112|NCT00714129|Other|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is lower in simple sugars, specifically fructose.
46117113|NCT00724425|Drug|IPI-493|Capsules, Multiple Schedules
46117114|NCT01028989|Dietary Supplement|Reduced Glycemic Load Diet|"36-40% fat; 40-42% carbohydrate; 18-22% protein~Glycemic Load <=46 per 1000 calories"
46117115|NCT01028989|Dietary Supplement|Standard Diet|"25-27% fat; 55-57% carbohydrate; 18-22% protein~Glycemic Load >=77 per 1000 calories"
46117116|NCT01029067|Behavioral|Metacognitive training|Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
45754556|NCT03584750|Other|Placebo floating|Floating in specialized tank with reduced floatation and sensory deprivation.
46117117|NCT01029067|Behavioral|Cognitive Remediation|Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
46117118|NCT05188599|Diagnostic Test|İsokinetic assessment|Isokinetic assessments of hip flexor and extensor muscle strength and proprioception wiill be performed
46117119|NCT00724581|Drug|Amiodarone|intravenous bolus of 300 mg oral treatment og 600 mg twice a day for five days
46117120|NCT02570841|Drug|Topical High dose Capsaicin|Topical High dose Capsaicin exposure within an area of 3x3 cm for 60 minutes
46117121|NCT02570841|Drug|Topical Placebo|Placebo exposure within an area of 3x3 cm for 60 minutes
46117122|NCT05079009|Device|ECCO2R pulsatile configuration|Use of the pulsatile extracorporeal blood flow configuration.
46117123|NCT03534531|Procedure|Intra-articular cervical zygapophyseal joint injection|Fluoroscopically-guided intra-articular cervical zygapophyseal steroid injection
46117124|NCT02570919|Radiation|IGRT 45 Gy in 5 fractions of 9 Gy|Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
46117125|NCT02570919|Radiation|IGRT 24 Gy single dose|Administration of a single dose of 24 Gy in one session
46027949|NCT02702713|Dietary Supplement|Dairy BEF|Dairy BEF: Milkshake powder enriched with 250 mg of DHA and 3g beta-glucans
46027950|NCT02702713|Dietary Supplement|Egg BEF|Egg BEF: Frozen pancakes enriched with 250 mg of DHA and 320 mg of anthocyanins
46027951|NCT02702713|Dietary Supplement|Bakery BEF|Bakery BEF: Biscuits enriched with 250 mg of DHA and 320 mg of anthocyanins
45754557|NCT05214625|Other|Questionnaire|Questionnaire concerning artificial intelligence and its implementation in healthcare. GI patients and GI physicians will be provided with slightly different questionnaires.
46027952|NCT02702713|Dietary Supplement|Bakery placebo|Bakery placebo: Biscuits without enrichment
46027953|NCT02702713|Dietary Supplement|Dairy placebo|Dairy placebo: Milkshake powder without enrichment
46027954|NCT02702713|Dietary Supplement|Egg placebo|Egg placebo: Frozen pancakes without enrichment
46027955|NCT05414747|Device|ABV-1701|ABV-1701 is an injectable, in-situ-forming hydrogel, composed of oxidized hyaluronic acid (oxi-HA) and adipic acid dihydrazide (ADH)
46027956|NCT05414747|Device|SF6 Gas|SF6 is a commercial gas tamponade as a vitreous substitute in pars-plana vitrectomy surgery (PPV)
46027957|NCT02698813|Biological|umbilical cord mesenchymal stem cells and hyaluronic acid|
46117126|NCT04732416|Drug|HM15136|Low dose of HM15136/ High dose of HM15136, SC injection, weekly
46117127|NCT00724659|Procedure|Ultrasound|Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
46117128|NCT00724659|Procedure|Ultrasound|Ultrasound of the joint(s) after a clinically scheduled arthrogram is performed. Ultrasound images will then be compared to the arthrogram findings, other imaging findings such as MRI and surgical pathological findings such as arthroscopy (if any.)
46117129|NCT05021757|Device|Shockwave C2 Coronary IVL|PCI procedure using a Shockwave C2 coronary IVL catheter
46117130|NCT02586168|Drug|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
46117131|NCT02586168|Drug|Placebo|Placebo
46117132|NCT04079478|Other|AI|Artificial intellignece colonoscopy
46117133|NCT04081116|Other|Symmetric settings (high pressures/fast rate)|Describes settings on the MI-E device
46117134|NCT04081116|Other|Asymmetric settings (Pi<Pe/Ti>Te)|Lower insufflation pressures at longer times
46117135|NCT04081116|Other|Preinclusion settings|Settings in use at start of study
46117136|NCT00577863|Drug|teriparatide|Subcutaneous injection of teriparatide 20 micrograms once daily using the Forteo B Pen. The primary phase of the study is 8 weeks after which time patients may participate in a study extension until the patient completes their maximum duration of teriparatide therapy or the Forteo B Pen becomes commercially available.
46027958|NCT02698813|Drug|hyaluronic acid|
46117137|NCT00724737|Procedure|Presurgical MRI|"People who are scheduled to have brain surgery with undergo a fMRI of the brain before surgery. This is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan."
46027959|NCT04205331|Device|Assessing validity of ultrasound as regards correlation to Cormack-Lehane grading in obese patients|Assessing validity of ultrasound as regards correlation to Cormack-Lehane grading in obese patients
46027960|NCT02702635|Procedure|DCE MRI of the brain|An MRI of the brain including a DCE sequence
46117138|NCT00724737|Procedure|functional MRI (fMRI) of the brain|"Healthy subjects will be undergo a brain fMRI of the brain. fMRI is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan."
46117139|NCT04019223|Diagnostic Test|anti-tissue transglutaminase group|Determination of anti-tissue transglutaminase IgA antibodies serum level.
46117140|NCT04019223|Diagnostic Test|biopsy group|Intestinal biopsy for histopathology study the jejunal histopathological
46117141|NCT04962789|Diagnostic Test|transvaginal ultrasound on the uterus|"Transvaginal ultrasound measurement to record endometrial thickness 2 times in each cycle:~In case of fresh cycles: 1)Day of ovulation triggering 2)Day of embryo transfer In case of frozen thawed cycles : 1)End of estrogen phase 2)Day of embryo transfer"
46117142|NCT04956627|Drug|BMS-986166|Specified dose on specified days
46117143|NCT04956627|Drug|Itraconazole|Specified dose on specified days
46117144|NCT04956627|Drug|Extended Phenytoin Sodium|Specified dose on specified days
46117145|NCT04956627|Drug|Gemfibrozil|Specified dose on specified days
46117146|NCT00920088|Drug|darunavir/ritonavir|DRV/RTV 600/100mg
46117147|NCT00920088|Drug|lopinavir/ritonavir|LPV/RTV 400/100mg
46117148|NCT00920088|Drug|Midazolam|Midazolam 3mg
46117149|NCT00920088|Drug|Dextromethorphan|Dextromethorphan 30mg
46117150|NCT00920088|Drug|Flurbiprofen|Flurbiprofen 50mg
46117151|NCT00920088|Drug|GSK2248761|NNRTI under investigation
46117152|NCT02570685|Behavioral|Reflective Interpersonal Gratitude|Participants were given the following instructions in their journal: Writing is a great way to reflect on your daily events, helping to look back and focus on the good things in our lives. There are many things in our lives, big and small, which we might be grateful for. For the next three weeks, 3 times a week (9 days in total), reflect back on your day and think of the people you met and interacted with and are grateful for. Please write down in the space provided a number of positive social interactions over the day or friendships/relationships you are grateful for…..
46117153|NCT02570685|Behavioral|Reflective-Behavioral Gratitude|"Participants were given the following identical instructions as the reflective journal in addition to this At the end of each week, express this gratitude to a friend of your choice face-to-face or through e-mail, facebook, a kind note, tell him/her how much you appreciate something specific that he/she does and reflect on how your friend's reaction and how you feel."
46117154|NCT02570685|Behavioral|Neutral Control Journal|Writing is a great way to reflect on your daily events, helping to look back and reflect on our lives. For the next three weeks, 3 times a week (9 days in total), please write in the spaces provided things that happened during the day.
46117155|NCT04018833|Drug|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|
46117156|NCT04018833|Drug|Aflibercept 40 MG/ML Intraocular Solution [EYLEA]|
46117157|NCT04066803|Drug|MTX|MTX group would be intervened by incremental MTX and folic acid，while the control group would be intervened by incremental original DMARDs they already used（including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony)
46117158|NCT04066803|Drug|Folic Acid|MTX group would be intervened by folic acid，while the control group would be not intervened by folic acid
45598641|NCT02224001|Procedure|The Flag Technique|"A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage without Septal Extension Grafts~The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result."
46027961|NCT02871531|Procedure|Pneumatic retinopexy|
46027962|NCT02871531|Procedure|Vitrectomy|
46117159|NCT04066803|Drug|DMARDs|including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony
46117160|NCT02570373|Drug|Guselkumab|Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
46117161|NCT04921371|Other|Colgate® Cavity Protection Toothpaste|Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.
46117162|NCT04921371|Other|Listerine® Cool Mint®|Participants will use 20 mL of Listerine® Cool Mint® mouth rinse for 30 seconds after brushing twice daily.
46117163|NCT04921371|Other|Concept Curve Winter Series Toothbrush|Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
46117164|NCT04921371|Other|5% Hydroalcohol Mouthrinse|Participants will use 20 mL of 5% Hydroalcohol Mouthrinse for 30 seconds after brushing twice daily.
46027963|NCT02702791|Behavioral|Telecoaching|Pedeometer based goals and telecoaching support
46027964|NCT02702791|Other|pulmonary rehabilitation|Conventional pulmonary rehabilitation along the ATS-ERS guidelines, total duration 6 months.
46027965|NCT04446585|Device|Automated External Defibrillator (AED)|Deployment of AEDs
46117165|NCT04921371|Other|Mouthrinse Prototype 1|Participants will use 20 mL of Mouthrinse Prototype 1 for 30 seconds after brushing twice daily.
46117166|NCT04921371|Other|Mouthrinse Prototype 2|Participants will use 20 mL of Mouthrinse Prototype 2 for 30 seconds after brushing twice daily.
46117167|NCT02569827|Drug|Celgosivir|Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg celgosivir total).
46117168|NCT02569827|Drug|Modipafant 50mg|Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg modipafant)
46117169|NCT02569827|Drug|Placebo|Placebo Q6H for 5 days
46117170|NCT02569827|Drug|Modipafant 100mg|Modipafant 100 mg Q12H alternating with placebo Q12H for 5 days (total of modipafant 10 doses = 1000 mg modipafant)
46027966|NCT04446585|Other|Training in cardiopulmonary resuscitation and AED use|Residents will undergo 30-minute courses at study start and if needed during the trial period. During the course they will also be recruited as citizen responders
46117171|NCT05648565|Device|Radiofrequency ablation (RFA)|The NEUROMARK device is an in-office, disposable bipolar RFA device with a treatment tip consisting of micro electrodes which delivers RF energy while monitoring appropriate tissue contact to maximize delivery to posterior nasal nerve and its variable branching. After topical anesthesia consisting of oxymetazoline and 1% lido followed by 4% lidocaine, the device will be placed in the posterior inferior turbinate under endoscopic visualization. The device will be activated per manufacturer's instructions
46117172|NCT03907761|Procedure|Hydrodissection|high velocity stream of normal saline is given to the dissection area by help of 10 ml syringe
46117173|NCT00725439|Drug|Talarozole|Oral Dose 1.0 mg once daily
46117174|NCT00920166|Dietary Supplement|Pétunia 1|Infant formula used for non breastfed children
46117175|NCT00920166|Dietary Supplement|Regular formula|Infant formula used for non breastfed children
46117176|NCT02570217|Device|HHHFNC|infants receive non-invasive respiratory support by mean of HHHFNC
46117177|NCT02570217|Device|NCPAP|infants receive non-invasive respiratory support by mean of NCPAP
46117178|NCT03205761|Drug|Olaparib|see information in arm description
46117179|NCT02584218|Procedure|Non-invasive resin based caries sealing|The dentists use resin based sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
46117180|NCT02584218|Procedure|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
46117181|NCT03204513|Device|Vanderbilt Powered Knee-Ankle Prosthesis|The Vanderbilt powered prosthesis is a transfemoral prosthesis with powered and coordinated knee and ankle joints. The Generation 3 prosthesis is actuated by two brushless direct current (DC) motors, providing up to 100 Nm of torque at the knee joint, and with the assistance of a parallel stiffness, up to 200 Nm in plantar flexion at the ankle. Sensors measure knee and ankle joint angles, axial load in the shank, and position and orientation of the prosthesis in space (via a 6-axis inertial measurement unit). An onboard lithium-ion battery provides sufficient energy for approximately 10,000 steps between battery charges. The prosthesis prototype weighs approximately 4.3 kg (9.5 lb), the mass of which is approximately equivalent to the intact limb of a 48 kg (105 lb) person.
46117182|NCT03204513|Device|Microprocessor (MP) Knee Prosthesis|Participants enrolled will already have their own microprocessor controlled (MP) non-powered knee prostheses as per inclusion criteria. Examples: OttoBock's C-Leg, Ossur's Rheo, Freedom Plie, Endolite Orion,etc.
46117183|NCT00725517|Drug|Icodextrin|Icodextrin was used instead of Dianeal for long dwell time every day for 5 weeks.
46117184|NCT00920751|Procedure|Water infusion|Water infusion in lieu of air insufflation during colonoscope insertion
46117185|NCT00920751|Procedure|Air insufflation|Conventional air insufflation colonoscopy
46117186|NCT04066881|Biological|Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48)|"DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef.~AIDSVAX® B/E is a bivalent HIV gp120 glycoprotein encompassing both subtype B (MN) and subtype E (A244) proteins that are adsorbed onto 600mcg of aluminum hydroxide gel suspension as adjuvant."
46117187|NCT04066881|Biological|Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48)|"DNA-HIV-PT123 (see above)~CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity.~MVA-CMDR (Modified Vaccinia Ankara-Chiang Mai Double Recombinant) is a non-replicating, highly attenuated strain of Vaccina virus that has been genetically engineered to express the HIV-1 genes envgp160 CM235 Subtype E and gag and pol CM240 Subtype A (integrase-deleted and reverse transcriptase non-functional)."
46117188|NCT04066881|Biological|Vaccine Group C: Saline placebo (weeks 0,4,24,48)|Sodium Chloride (NaCl) for injection, 0.9%
45598642|NCT02039037|Device|Acupuncture|Acupuncture Group, which will hold acupuncture needles brand Dong Bang 20x15 in specific spots for the treatment of low back pain.
45598643|NCT02039037|Device|Electroacupuncture (device 585)|Electro will be added through the use of electrical stimulation to the Electro Accurate use of the device 585 at the same points Pulse.
46027967|NCT04446585|Other|Activation of citizen responders|Citizen responders will be activated in case of suspected cardiac arrest through the heart runner app.
46027968|NCT02702557|Other|Elastic Band Exercises|
46027969|NCT02702479|Other|High Fructose Corn Syrup|An intervention in which calories from HFCS are substituted isocalorically for sucrose in the diet
46027970|NCT02702479|Other|Sucrose|An intervention in which calories from sucrose are substituted isocalorically for HFCS in the diet
46027971|NCT04422093|Device|OrthoKontrol|Fixing OrthoKontrol Sensor on multibracket appliance to measure cooperation
46027972|NCT02702323|Drug|Apatinib|apatinib 500mg/day for 6 weeks began taking 4-7 days after TACE
46027973|NCT02702323|Procedure|TACE|one times every 4-6 weeks.
46027974|NCT01007253|Drug|PL nasal spray|2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week
46027975|NCT01007253|Drug|fluticasone furoate (FF)|2 puffs of FF nasal spray in each nostril once a day for 1 week
46027976|NCT01007253|Drug|PL eye drops|1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week
46117189|NCT04066881|Drug|Control PrEP:TDF/FTC once daily (weeks 0-26)|Each tablet of Truvada contains 245mg of tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
46117190|NCT04066881|Drug|Experimental PrEP:TAF/FTC once daily (weeks 0-26)|Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
46117191|NCT00572481|Procedure|Axillary Reverse Mapping|During surgery, the technetium-99m sulfur colloid will be injected into the breast and the blue dye injected (if the patient is not allergic and it is not required to locate the SLN) in the patient's ipsilateral upper arm. The lymph node biopsy and/or dissection will be performed by the surgeon, according to standard practice.
46117192|NCT04620291|Biological|UB-421 SC|The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.
46117193|NCT04657068|Drug|ART0380|Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.
46117194|NCT04657068|Drug|Gemcitabine|Gemcitabine will be administered on Days 1 and 8 of a 21-day cycle.
46117195|NCT04657068|Drug|Irinotecan|Irinotecan will be administered as a 90-minute infusion on Days 1 and 8 of a 21 day cycle.
46117196|NCT04434417|Device|2019-nCoV IgG/IgM Rapid Test Cassette|The specimen (whole blood, serum, plasma) will be loaded into the cassette and will migrate via capillary action along the membrane to react with the gold conjugate. The result will be available in 10 minutes
46117197|NCT02298465|Procedure|Supine ESWL|ESWL to distal ureteric stone is performed in the supine position with the shockwave generator placed in the patient's buttock area. The aim is to direct the shockwaves through the greater and lesser sciatic foramina to reach the distal ureter.
46117198|NCT02298465|Procedure|Prone ESWL|ESWL to the distal ureteric stone is performed in the traditional prone position. The shockwave generator is placed on the patient's abdomen
46117199|NCT02298465|Device|Extracorporeal Shockwave Lithotripsy (ESWL)|The ESWL machine we use is the Dornier S2 lithotriptor. ESWL is performed without any sedation or anesthesia under fluoroscopy. Painkillers are given upon request.
46117200|NCT02586714|Other|No intervention|Observation only
46117201|NCT04562688|Other|CICADAS and then PEERS|Participants will complete sensory processing assessments and neuroplasticity-based social cognitive training (NB-SCT) exercises on a digital device for a total of 40 hours. The CICADAS app captures user-specific sensory processing abnormalities (SPA) through 10 brief computerized assessments. The data from these assessments guide and personalize the delivery of 10 NB-SCT exercises. After 16 weeks, participants will then crossover to PEERS, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians.
45598644|NCT02295631|Device|Standard tracheal tube|ETI with standard tracheal tube and Macintosh laryngoscope
45598645|NCT02295631|Device|ETView VivaSight SL|ETI with ETView VivaSight SL
45598646|NCT02224079|Drug|BIIB 722 CL|
46027977|NCT01007253|Drug|olopatadine (OLO)|1 drop of OLO eye drops in each eye once a day for 1 week
46027978|NCT02702167|Device|High-frequency rTMS|10 Hz active stimulation, once daily
46027979|NCT02702167|Device|Low-frequency rTMS|1 Hz active stimulation, once daily
46027980|NCT02702167|Device|Sham rTMS|Sham stimulation, once daily
46027981|NCT02691949|Drug|Mycophenolate mofetil|mycophenolate mofetil 1# BID-2# BID
46027982|NCT04146961|Device|Alcon PanOptix or PanOptix Toric IOL|Patients who previously underwent cataract surgery with the Alcon PanOptix or PanOptix Toric IOL in both eyes.
46027983|NCT02698501|Drug|MEDI9929|MEDI9929 700mg (3 doses in total, 4-week intervals), administered intravenously
46027984|NCT02698501|Drug|Placebo|Placebo (3 doses in total, 4-week intervals), administered intravenously
46027985|NCT04444479|Other|ECG verification|The correct positioning of the PICC catheter tip will be verified using ECG.
46027986|NCT04444479|Other|X-ray verification|The correct positioning of the PICC catheter tip will be verified using X-ray imaging.
46027987|NCT02702245|Dietary Supplement|Experimental: Thylakoids 5 g|75 g pure glucose + 5 g chloroplast membranes from spinach leaves in a dried powder.
46117202|NCT04562688|Other|PEERS + CICADAS and then no-contact|Participants will complete both PEERS and CICADAS study activities. Participants will complete sensory processing assessments and neuroplasticity-based social cognitive training (NB-SCT) exercises on a digital device for a total of 40 hours. The CICADAS app captures user-specific sensory processing abnormalities (SPA) through 10 brief computerized assessments. The data from these assessments guide and personalize the delivery of 10 NB-SCT exercises. In addition, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians. After 16 weeks, participant will crossover to No-Contact with no active intervention.
46117203|NCT04562688|Other|PEERS + Active Comparator and then no-contact|Participants will complete both PEERS and Active Comparator study activities. Participants will engage in computerized, casual video games for a total of 40 hours. Participants will also complete the 10 sensory processing abnormalities (SPA) computerized assessments. In addition, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians. After 16 weeks, participant will crossover to No-Contact with no active intervention.
46117204|NCT05596344|Other|Hospital Anxiety and Depression Scale|The basic information, anxiety and depression, treatment and prognosis of these patients were collected.
46117205|NCT02059551|Procedure|MRI combined with venous ultrasonography of the legs|In case of positive D-dimer testing or in patients with a high probability of PE, MRI and a venous ultrasonography of the legs are done.MRI protocol includes 2 sequences: 1-Unenhanced steady-state-free precession sequences (SSFP) are acquired first without ECG-gating or breath-holding in the axial plane in the multiphase cine mode, with 6 phases per location.The acquisition is repeated to cover 2-3 of the thorax, from the roof of the aorta to the diaphragm. 2- A pulmonary gradient recalled echo (GRE) sequence is performed in the axial plane.The acquisition is triggered to start when contrast enhancement occurred in the right ventricle.Two acquisitions are necessary to cover the anatomy. For each acquisition, 0.15 mL kg-1 body weight of DOTAREM Gadolinium is injected at a rate of 3 mL s-1 followed by an injection of 15 mL of normal saline at 3 mL s-1.Venous ultrasonography of the legs: the examination consists of a real-time B-mode examination of the common femoral and popliteal veins.
45598647|NCT02224079|Drug|Placebo|Hydroxypropyl-beta-cyclodextrin (HPβCD)
45598648|NCT03159741|Other|Inhibitor + GLP-2|Inhibitor and GLP-2 are used as study tools.
45598649|NCT03159741|Other|Placebo + GLP-2|Placebo and GLP-2 are used as study tools.
46027988|NCT02702245|Dietary Supplement|Experimental: Thylakoids 10 g|75 g pure glucose + 10 g chloroplast membranes from spinach leaves in a dried powder.
46027989|NCT02702245|Other|Placebo Comparator: Control|75 g pure glucose.
46027990|NCT04296747|Drug|induction chemotherapy|Toripalimab 240mg, d1; docetaxel 75mg/m2 d1; cisplatin 75mg/m2 d1, q21d, for 2 cycles
46027991|NCT04296747|Procedure|surgery|After induction chemotherapy, patients with resectable hypopharyngeal cancer would accept surgery within 2-4 weeks and investigator-selected postoperative treatment
46027992|NCT04296747|Radiation|chemoradiotherapy|After induction chemotherapy, patients with unresectable hypopharyngeal cancer who achieved CR/PR/SD in the tumor evaluation according to RECIST1.1 would accept another cycle of chemotherapy, and then radical chemoradiotherapy with cisplatin 100mg/m2, q21d
45598650|NCT03159741|Other|Placebo + GIP|Placebo and GIP are used as study tools.
45598651|NCT03159741|Other|Placebo + Saline|Placebo
45754558|NCT03584672|Other|Static Balance Test|Balance control is assessed by the Static Balance Test.
46027993|NCT02777281|Behavioral|Shoulder pain and SCI|Shoulder pain and SCI
46027994|NCT02777281|Behavioral|Shoulder pain and able bodies|
46027995|NCT04298931|Other|Series of ventilator settings|"Before a planned fluid administration, the investigators will apply a series of 10 ventilator settings for 30 seconds each.~The settings are the following combinations of respiratory rate (RR) and tidal volume (TV):~RR (min^-1), TV (ml/kg predicted body weight)~31, 6~31, 8~24, 6~24, 8~17, 6~17, 8~10, 4~10, 6~10, 8~10, 10~(the order of the respiratory rates: 17 to 31, will be randomized. 10/min will always be last. Tidal volume is always applied from lowest to highest for each respiratory rate)."
46027996|NCT02686879|Device|Multifocal contact lenses|
46027997|NCT02686879|Device|Single vision contact lenses|
46027998|NCT04296591|Diagnostic Test|fetal heart doppler findings|Doppler data of main pulmonary artery and right pulmonary artery, mitral valve e/a wave ratio and lamellar body count were determined as the main research parameters. In both groups, fetal thorax and heart circumference ratio, mitral e/a wave ratio, right pulmonary artery and main pulmonary doppler indexes (PI, RI, S / D, AT / ET) were evaluated before cesarean section.
45470937|NCT03246698|Other|Isolytic Stretching group|In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Isolytic stretching exercises will perform four times a week for four weeks. It's obligatory to receive at least 15 sessions in total. They will also receive standard physiotherapy program four times a week for four week, 15 sessions in total.
45470938|NCT03246698|Other|Static Stretching group|In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Static stretching exercises will perform four times a week for four weeks. It's obligatory to receive at least 15 sessions in total. They will also receive standard physiotherapy program four times a week for four week, 15 sessions in total.
46117206|NCT02585856|Device|PDT|"Patients with unresectable CCA are performed PDT with ERCP after porfimer sodium （chongqing ray high medical instrument co., LTD，Chongqing, China) i.v. at a dose of 2 mg/kg at 48 h.~PDT procedure: for light distribution, flexible cylindrical diffuser probes mounted on 400-mm quartz fibres with an active distal tip length of 2 cm （chongqing ray high medical instrument co., LTD，Chongqing, China) is used. The light source was a diode laser system with a maximum power output of 2 Wand a wavelength of 633.3 nm. The power emitted by the diffuser tip was calibrated to 400 mW/cm before PDT was administered using an integrating sphere power meter. The mean irradiation time was 452 s (range: 400-600 s), using a power density of 300-400 mW/cm and an energy dose of 180-200 J/cm (of diffuser length)."
46117207|NCT02585856|Device|stent|Patients with unresectable CCA are performed with ERCP, one or several plastic biliary stents (Boston Scientific Corporation, MA,USA) are inserted to ensure adequate decompression and bile drainage.
46117208|NCT00794417|Drug|Aflibercept|Administered in combination with the other two interventions via intravenous infusion.
46117209|NCT00794417|Drug|Pemetrexed|Administered in combination with the other two interventions via intravenous infusion.
46117210|NCT00794417|Drug|Cisplatin|Administered in combination with the other two interventions via intravenous infusion.
46117211|NCT04066101|Genetic|high caries risk|DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit Genotyping for a variant was carried out on a Roche Applied Science LightCycler® 480 (Roche Diagnostics GmbH, Mannheim, Germany) with real-time polymerase reaction of Taqman
45470939|NCT03246698|Other|Control group|They will receive only standard physiotherapy program, four times a week for four weeks, 15 sessions in total.
46027999|NCT04738123|Drug|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.
46028000|NCT04738123|Drug|Placebo|Placebo Capsules
46117212|NCT04066101|Other|caries activity|"Dental caries lesions of all patient scored as initial, moderate or advanced caries~Initial lesion; clinically detectable lesion Moderate; visible signs of enamel breakdown Advanced; enamel was fully cavitaed"
46117213|NCT04559256|Diagnostic Test|Cardiopulmonary Exercise Testing|Patients will receive a cardiopulmonary exercise testing before and 3-month after tricuspid intervention
45470940|NCT04731818|Biological|ZB-06|ZB-06 is a polyvinyl alcohol-based film containing 20 mg of human contraceptive antibody (HCA) for topical intravaginal administration.
46028001|NCT01006707|Drug|Ondansetron|In this cross-over study, the blinded patient will receive saline placebo in one session and ondansetron in the other. The order is decided with a randomization table. If ondansetron is randomly chosen, an 8mg IV Bolus will be given at the start of the study for 30 minutes by the unblinded investigator.
46028002|NCT02698657|Drug|ASP5094|Intravenous (IV)
46028003|NCT02698657|Drug|Placebo|Intravenous (IV)
46028004|NCT04298385|Other|Traction orthosis|Traction applied to a finger using elastic thread and sports tape and attached to an orthosis
46028005|NCT04216615|Behavioral|preoperative anxiety|patients who are anxious
46028006|NCT04296279|Drug|FMP014|Falciparum Malaria Protein-14
46117214|NCT01459107|Procedure|Deceased donor hand transplantation|Deceased donor hand is surgically attached to recipient arm's stump.
46117215|NCT01459107|Drug|Bone marrow cell-based therapy & single-drug immunosuppression.|This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human upper extremities under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
46028007|NCT04296279|Drug|ALFQ|ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
45470941|NCT05763212|Other|Traditional physical therapy|received Whole Body Vibration including three vibration sessions per week for three months. The participants have to carry out each set of vibration for 2 min in the first month, and then it was increased to 3 min in the second and 5 min in the third month. The rest period between each set was 1 min in the first month, then it became half a minute in the second and third month. Total training duration is 30 min/day, 3 days/week for 3 successive months.
46117216|NCT04557618|Device|Auricular Vagus Nerve Stimulation|Transcutaneous auricular vagal nerve stimulation
46117217|NCT04557618|Device|Sham Auricular Vagus nerve Stimulation|Transcutaneous auricular vagal nerve ear clip applied without current
46028008|NCT00616057|Dietary Supplement|Synergy 1|8 grams/day during the first week and then 8 grams twice a day during 3 months
46028009|NCT00616057|Dietary Supplement|maltodextrin|8 grams/day during the first week and then 8 grams twice a day during 3 months
46028010|NCT04296201|Device|DMA treatment|Each arm will receive the DMA treatment in a specific area on the body to observe immediate effect.
46028011|NCT00615511|Dietary Supplement|placebo pregnenolone|Sugar pill, taken twice a day
46117218|NCT02602847|Biological|cccDNA assay on liver biopsy|cccDNA assay will be performed on liver biopsies at different times : During transplantation : Liver biopsy of explant and graft and virological biology Between M1 to M3 after transplantation : Liver biopsy between 1 to 3 months after transplantation M12 : Liver biopsy 12 months after transplantation
46117219|NCT04391907|Procedure|IPL|Intense pulse light (IPL) laser is used for the treatment of dry eye originated from meibomian gland dysfunction. IPL laser will be performed to patients who are planned to cataract surgery to improve dry eye.
46117220|NCT04483206|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
45682122|NCT05405842|Device|Transauricular Vagal Nerve Stimulation|TENS 7000 is a handheld device used to deliver electrical impulses for nerve stimulation to help modulate and treat chronic pain. The manufacturer, Roscoe, has regulatory approval for the use of nerve stimulator therapy in the acute and/or prophylactic treatment of headaches, migraines, sciatica, muscle spasms, acute and chronic pain, and improve circulation. It is FDA approved in the USA for the above indications, but has not been approved for use in gastrointestinal diseases such as gastroparesis or functional dyspepsia. It has been registered as an investigational new device in various clinical trials. The purpose of this protocol is to provide vagal nerve stimulation to patients with gastroparesis, functional dyspepsia, and healthy controls as a comparison.
46117221|NCT04483206|Drug|Melphalan|Given IV
46117222|NCT04483206|Other|Questionnaire Administration|Ancillary studies
45754559|NCT03584672|Other|Berg Balance Scale|Functional balance is assessed by the Berg Balance Scale.
46117223|NCT04107545|Behavioral|athletes|Control of body temperature using the bodyCap temperature monitor that records body temperature for up to 48h (three times)
45470942|NCT05764226|Drug|HA35(L20200708MP07707, Ministry of Health, Mongolia)was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)|One hundred milligrams of the freshly made 35 kDa low molecular weight HA fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds once a day for 10 days.
45470943|NCT02826512|Drug|Niraparib|niraparib 300 mg QD continuously
45470944|NCT02674100|Other|Registry|
45754560|NCT03584672|Other|Timed Up an Go Test|Functional mobility is assessed by the Timed Up and Go test.
46028012|NCT00615511|Dietary Supplement|pregnenolone|500mg in tablet form taken orally twice a day
46028013|NCT04215133|Other|exercise therapy|inspiratory muscle training consists of strengthening exercise with threshold Inspiratory muscle training device and calf muscle training consist of isotonic and isometric strengthening exercise for calf muscle. All groups will receive compression therapy at the same time.
46028014|NCT02702089|Procedure|Rectal cancer surgery|Rectal cancer resection
46028015|NCT01006629|Biological|palivizumab|palivizumab 15 mg/kg intramuscularly
46028016|NCT04215055|Device|vibraject|VibraJect; is a small battery-operated attachment that snaps on to the standard dental syringe. It delivers a high-frequency vibration to the needle which is strong enough for the patient to feel.
46028017|NCT04214977|Procedure|Spinal Anesthesia for Anorectal Surgeries in Prone Position|Spinal anesthesia in sitting position was done under complete aseptic technique through a standard midline approach. One and a half millilitres of 0.5% bupivacaine (7.5 mg) was injected through a 25 Gauge pencil-point needle into the subarachnoid space at L3-L4 or L4-L5 interspace. All patients were kept in a head-up position for 3 minutes. The patient was then asked to turn him- or herself into the prone position on the surgical table with the help of the surgical and anesthetic teams.
46117224|NCT00725829|Drug|simvastatin|Simvastatin 40mg/d
46117225|NCT00725829|Drug|ezetimibe|ezetimibe 10mg/d
45470945|NCT04614662|Behavioral|SPARK Symptom Screening Linked to Feedback to Providers|Symptom screening three times weekly via SPARK, feedback of symptoms to healthcare providers and development of care pathways for symptom management.
45470946|NCT01569386|Behavioral|Daily low intensity physical activity by the half squat|They take a meal three times daily. They are a time to do the manual work every day. They watch the TV for two hours every day. And they do a walk of 30 minutes every day. They do a specific exercise. They were trained to conduct 40kcal period(about 20 min.) for adding to the amount of energy consumption of low-intensity physical activity at baseline.Specific exercise that was done the half squat(max knee flexion 70 degree). This squat is carried out in two seconds round trip. This squat is carried out in two seconds round trip. They grab the edge of the table. They put half the weight of the lower limbs paralyzed side. This observer once a week, to record their behavior over 24 hours. Intervention period is up to a maximum of 12 weeks.
45470947|NCT01569386|Behavioral|stretch exercise and usual activity|They take a meal three times daily.They are a time to do the manual work every day.They watch the TV for two hours every day.And they do a walk of 30 minutes every day.They do whole body stretch exercise for 20 minute in a day. An observer once a week, to record their behavior over 24 hours.Their behavior was used to calculate the amount of energy consumption.They are informed of the kcal a day from the viewer.
45470948|NCT05461196|Behavioral|CPMRx|Patients use a mobile application to track pain medication usage and pain scores.
45470949|NCT05391230|Other|Permethrin-treated lesu|0.5% permethrin soaked baby wraps (lesus)
45754561|NCT03584672|Other|Four Square Step Test|Dynamic balance is assessed by the Four Square Step Test.
45754562|NCT03584672|Other|Functional Reach Test|Limits of stability is assessed by the Functional Reach Test.
46117226|NCT00725829|Drug|placebo|placebo
46117227|NCT02603939|Procedure|Joint replacement surgery|We are assessing pain responses in participants with osteoarthritis before an after joint replacement surgery
46117228|NCT02584296|Behavioral|BSMA|Biobehavioral self-management approach (BSMA) intervention is aligned with information-motivation-behavioral skills (IMB) model and is guided physical activity (PA). Collects demographic, medical, disease, treatment data, blood specimens and the battery of measures. Includes PA self-assessment, 6 minute walk test(6MWT) and chair squat test (CST) with Physical Therapist (PT); provides PA handouts based on American Cancer Society (ACS) guidelines, discusses known benefits, beliefs and goals of PA (IMB health behavior motivation); assess/discuss perceived barriers to PA. PT or Exercise physiologist (EP) works with subject on various exercises (both strength and aerobic, ~30 minutes; IMB behavioral skills);PT or EP reviews exercises, subject practices, and provides a BSMA program (including strength/aerobic training) for subject to begin upon discharge. Subject keeps journal of PA and wears accelerometer (TAA) to record PA levels. 3-weeks at home study nurse calls subjects each week.
46117229|NCT04321317|Other|Measure of body composition by Air Displacement Plethysmography (ADP)|Each patient included will have one measure of body composition by Air Displacement Plethysmography (ADP) during the initial consultation in the referent center for food disorders of Lyon and one year later.
46117230|NCT04079322|Other|Meal|Participants will consume a meal containing a stable iron isotope following exercise or rest.
45470950|NCT05391230|Other|Untreated lesu|Water soaked baby wraps (lesus)
45470951|NCT01378598|Other|Nursing Educational Intervention|Four educational sessions with the direct care nurse (DCN)
46117231|NCT03316053|Other|Tissue sample for genetic testing|Tissue sample to be obtained during routine endoscopy
46117232|NCT00794339|Drug|64Cu-ATSM|
46117233|NCT00794339|Drug|FDG|
46117234|NCT02583438|Drug|Saxagliptin (Bristol-Myers Squibb Company)|6-month treatment of Saxagliptin 5mg Qd
46117235|NCT02570061|Behavioral|telephone|information given at the primary contact by phone, or at a scheduled later time
46117236|NCT02570061|Behavioral|consultation face-to-face|information given at a scheduled consultation at the hospital
46117237|NCT00725907|Biological|PGRF|injection of 6cc into injured area
46117238|NCT00725907|Biological|placebo saline|injection of 6cc into injured area
46117239|NCT04476654|Behavioral|YouTube Video Arm|Participants (n=25) will watch a 20 minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a culturally relevant format. Participants will complete pre and post assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to a patient navigator who will navigate participants to identified no cost or low cost services.
46117240|NCT00726141|Behavioral|Brief intervention, Motivational Interviewing, Expert System|Motivational Interviewing, stage-tailored self-help manual, physician letter, expert system feedback letter
46117241|NCT02583750|Behavioral|OGTT after deprived sleep first|Participants slept 1-3 hours less than their normal amount for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept as much as they wanted for three nights.
46117242|NCT02583750|Behavioral|OGTT after sufficient sleep first|Participants slept as much as they wanted for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept 1-3 hours less than normal for three nights.
46117243|NCT02603861|Drug|LY3154207|LY3154207 administered orally.
46117244|NCT02603861|Drug|Placebo|Placebo administered orally.
46117245|NCT02603861|Drug|Modafinil|Modafinil administered orally.
46117246|NCT02569905|Drug|parecoxib sodium|parecoxib sodium 40mg
46117247|NCT02569905|Drug|flurbiprofen|flurbiprofen 50mg
46117248|NCT02569905|Drug|saline|normal saline
46117249|NCT02603783|Other|Capsaicin|capsaicin 1,5 mg
45470952|NCT04428944|Procedure|Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI)|Standard PVI
45838998|NCT04340544|Drug|Hydroxychloroquine|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.
45838999|NCT04340544|Drug|Placebo|Placebo capsules
46028018|NCT04214977|Procedure|General Anesthesia Using Laryngeal Mask Airway for Anorectal Surgeries in Prone Position|General anesthesia was induced using fentanyl 2 mcg/kg and Propofol 2-3 mg/kg. Any stomach contents were then suctioned through an oro-gastric tube to reduce the risk of regurgitation. Proper (weight-based) classic laryngeal mask airway was then blindly inserted. laryngeal mask airway was then properly fixed to the face and anesthesia was maintained with isoflurane 1-2% in 50% Oxygen/air mixture.
46028019|NCT04428177|Device|Intravascular lithotripsy|Intravascular lithotripsy uses sonic pressure waves to disrupt calcium with minimal impact to soft tissue of coronary vessel
46028020|NCT04428177|Device|Standart therapy|conventional preparation of calcified lesion: non-compliant, cutting or scoring ballons predilatation or rotational atherectomy
46117250|NCT02603783|Other|Placebo|0,9% saline 75 ml
46117251|NCT04110275|Drug|Recombinant human tissue-type plasminogen activator derivative|Recombinant human tissue-type plasminogen activator derivative(rPA,chemical name: Reteplase,brand name:Ruitongli) 18mg/10ml/stick, provided by AngDe Biotech Pharmaceutical Co.,LIMITED(LTD)
46117252|NCT04110275|Drug|Recombinant human tissue-type plasminogen activator|Recombinant human tissue-type plasminogen activator(rt-PA,chemical name:Alteplase,brand name: Actilyse)50mg/stick,provided by Boehringer Ingelheim Pharma Gesellschaft mit beschrankter Haftung(GmbH)&Co,
46117253|NCT04250883|Other|Low intra-abdominal pressure|8 mmHg
46117254|NCT04250883|Other|Deep neuromuscular blockade (NMB)|Deep NMB (PTC1-2)
46117255|NCT04250883|Other|Standard intra-abdominal pressure|14 mmHg
46117256|NCT04250883|Other|Moderate neuromuscular blockade (NMB)|Moderate NMB (TOF 1-2)
46117257|NCT04469634|Diagnostic Test|Assessing antibody responses, neutralizing capacity and memory B-cell function|Assessing antibody responses, neutralizing capacity and memory B-cell function and their contribution to protection against re-infection
46117258|NCT04209543|Drug|Estetrol oral tablet|Estetrol oral tablet will be administered orally once daily
46117259|NCT04209543|Drug|Placebo oral tablet|Placebo oral tablet will be administered orally once daily
45470953|NCT04428944|Procedure|Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers)|Standard PVI + Ablation of drivers in LA and RA
45470954|NCT04428944|Procedure|Pulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box)|Standard PVI + Electrical isolation of the posterior wall of the left atrium
45839000|NCT04340622|Device|supra-luminous LED|810 nm light-emitting diode for the delivery of 2.1 J/cm2 to the brain.
45839001|NCT04340622|Device|Sham|Light-emitting diode covered with aluminium foil
46117260|NCT04209543|Drug|Progesterone oral tablet|Progesterone oral tablet will be administered orally once daily
46028021|NCT02701933|Drug|Ketamine|Racemic ketamine, intravenous, at a concentration of 10mg ketamine per 50ml infusion
46117261|NCT04465500|Radiation|External Beam Radiation|EBRT will be administered every 5 consecutive days for 5 consecutive weeks. This is standard of care practice for this therapy. This may be revised as applicable per treating physician discretion. The dose of radiation will be in accordance with standard clinical practice guidelines for the treatment of prostate cancer.
46117262|NCT04465500|Radiation|HDR Brachytherapy|HDR brachytherapy will be administered per standard clinical practice (per NCCN guidelines version 1.2020 for prostate cancer), however standard clinical practice may vary between clinicians. Therefore, the dose of 15Gy in 1 fraction and a set of dosimetry guidelines are to be followed for the purposes of this study. A diagnostic MRI will be co-registered with Transrectal Ultrasound (TRUS) to perform the HDR brachytherapy.
46028022|NCT02701933|Drug|Saline|Saline, intravenous infusion
46117263|NCT04465500|Drug|Androgen Deprivation Therapy|The dosing and administration of ADT will be in accordance with the drug label for the drug(s) used for this purpose. Participants may receive ADT before and/or during the course of this study.
46117264|NCT05432076|Device|Sleep Band and White Noise|"Not taking any sedative or anesthetic drug in the last 12 hours (Such duration of action) An average of 12 hours of sleepiness at the patient's departure and travel hindrance will.)~Being extubated~A Glasgow coma scale of 15 (to be investigated by the Glasgow coma scale).~Baby dreams of boredom~Besides pain (to the Wong Baker Face Scale used in the Pediatric Intensive Care Unit) evaluation)."
46117265|NCT04080726|Drug|HIP1601|Oral esomeprazole
46117266|NCT04080726|Drug|HGP1705|Oral Nexium Tab
45598652|NCT03516721|Other|the prevalence of chronotropic incompetence CI during maximal cardiopulmonary exercise testing, CPET|
46028023|NCT04295967|Other|formalin fixed paraffin embedded blocks|The study will be conducted using formalin fixed paraffin embedded blocks of seventy cases of urothelial carcinomas .CD31-PAS dual-staining will be performed to confirm the presence of VM.
46028024|NCT01012323|Biological|NewGam|The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as minimum trough levels of serum immunoglobulin G (IgG) was above 5 g/L. If serum IgG trough levels dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
46117267|NCT04080726|Drug|HIP1601 Placebo|Oral Placebo
46117268|NCT04080726|Drug|HGP1705 Placebo|Oral Placebo
46117269|NCT04646226|Device|AV graft|The purpose of the surgery is to connect a large vein in the arm to a nearby artery indirectly by inserting a graft material (graft surgery)
46117270|NCT04646226|Procedure|surgical intervention for creation of a fistula|The purpose of the surgery is to connect a large vein in the arm to a nearby artery directly (fistula surgery)
46117271|NCT04080570|Other|Remote Visit|After an initial in-home visit, the physician will see home hospitalized patients by facilitated video.
46117272|NCT02585544|Procedure|day-care surgery|day-care surgery
46117273|NCT04639986|Drug|Sacituzumab Govitecan-hziy|Sacituzumab govitecan 10 mg/kg via IV injection administered on Days 1 and 8 of a 21-day cycle. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.
45598653|NCT02231645|Device|STN DBS|The DBS device is turned on and off by the physician.
45754563|NCT03584672|Other|One-leg Stance Test|Postural steadiness is assessed by the One-leg Stance Test.
46028025|NCT02871765|Other|Patient education related Warfarin|Patient education related Warfarin: each subject in the experimental group was taught individually according to investigator's brochure in the outpatient department (OPD) by researchers. Three months later, participants received a follow-up phone call in order to clarify any questions related to the brochure. The contents of the brochure consisted of: the purpose of taking Warfarin, side effects, adjustments to daily diet, and precautions (i.e. how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure after pretest and routine care only in the OPD. All participants completed posttest at 6-month follow-up.
46028026|NCT02870751|Biological|TW11681 or TW10722|
46028027|NCT01011933|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
46028028|NCT01011933|Drug|Selumetinib|Given PO
46028029|NCT02549209|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered every 3 weeks for all subjects
46028030|NCT02549209|Drug|Paclitaxel|"For subjects with no prior therapy, paclitaxel will be dosed at 175mg/m2 and be administered as a 3-hour continuous IV infusion.~Subjects with prior XRT/platinum-based chemotherapy must initiate paclitaxel at 135mg/m2 and be administered as a 3-hour continuous IV infusion."
46028031|NCT02549209|Drug|Carboplatin|"For subjects with no prior therapy, carboplatin will be dosed at an AUC of 6 and given as an IV infusion in 250ml of D5W over 30 minutes.~Subjects with prior XRT/platinum-based chemotherapy must initiate carboplatin at an AUC of 5 given as an IV infusion in 250ml of D5W over 30 minutes."
46028032|NCT03405883|Other|Vaginal swab + endometrial biopsy|In the midluteal phase of the cycle, a vaginal swab (E swab) and endometrial biopsy (TAO brush) will be obtained.
46028033|NCT03278587|Other|Community-based screening program|In communities randomized to receive the screening program, all adults aged 50 and older will be eligible to receive screening for ocular disease. Screening assessments include visual acuity, refraction, intra-ocular pressure, fundus photography, and anterior segment photography. Participants meeting criteria for referral based on screening assessments will be referred to the nearest eye care center or eye hospital for further evaluation.
45470955|NCT05763056|Procedure|McGrath videolaryngoscopy|The McGrath video laryngoscope has a thin, disposable, clear, regularly shaped blade similar to a Macintosh blade and a large LCD display attached to the arm. It is lighter in weight and the Mc VL has a small camera at the tip, with a more compact screen and handle that can make tracheal intubation easier and faster in normal or difficult airway. The smaller volume, thinner and portrait screen helps reduce blind spots
45839002|NCT04340934|Device|REZUM system|Rezūm is a system uses water steam energy to remove the particular part of the prostate that enlarges and causes symptoms due to BPH. Rezum involves a radiofrequency (RF) generator system and an endoscopic device that is introduced into the body via the urethra.
46117274|NCT04639986|Drug|Eribulin Mesylate Injection|Eribulin is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
45839003|NCT04340778|Drug|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before copper IUD insertion plus inert placebo cream will be applied on the cervix at the time of IUD insertion
45598654|NCT03159585|Drug|TAEST16001|After completion of Lymphodepleting regimen pretreatment, the subject will receive an infusion of TAEST16001
45598655|NCT02292277|Drug|Ticagrelor|Oral loading dose of 180 mg ticagrelor.
45598656|NCT02292355|Other|Pilates|The intervention group will perform Pilates exercises for 15 weeks with frequency of twice weekly
45598657|NCT03152799|Procedure|RIPC Remote Ischaemic Pre-Conditioning|intermittent limb ischaemia via a peripheral blood pressure cuff inflation and deflation
45598658|NCT03152799|Other|Sham Control|intermittent peripheral blood pressure cuff inflation and deflation which does not induce a protective cellular response
45839004|NCT04340778|Drug|Lidocaine-prilocaine Cream|Lidocaine-prilocaine Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
46028034|NCT03278587|Other|Cataract camp program|In communities randomized to receive the cataract camp program, all adults aged 50 and older will be eligible to participate in a routine cataract camp run by Bharatpur Eye Hospital. Trained ophthalmic personnel and assistants will perform case detection for cataract via visual acuity, pen light exam, and indirect ophthalmoscope exam per Bharatpur Eye Hospital's standard cataract camp program. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
46028035|NCT03278587|Other|Community health worker program|In communities randomized to receive the community health worker program, all adults aged 50 and older will be eligible to participate. Existing community health workers will be trained to perform case detection for cataract via visual acuity assessment. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
45839005|NCT04340778|Drug|placebo|inert placebo Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
45839006|NCT04340466|Other|No intervention|No intervention
45839007|NCT04340388|Drug|Dolutegravir 50 MG|15 participants will be randomized to remain on fully suppressive background antiretroviral therapy. The third agent will be switched to dolutegravir at the dose of 50 mg daily.
45839008|NCT04340388|Drug|Antiretroviral/Anti HIV|15 participants with suppressed HIV disease for greater than or equal to 3 months will be randomized to remain on their current 2 or 3 drug fully suppressive antiretroviral regimen.
45839009|NCT04340310|Diagnostic Test|Home respiratory polygraphy|Home respiratory polygraphy or Polysomnography to stablish a therapeutic decission
45839010|NCT04340232|Drug|Baricitinib|Subjects will receive a 2 mg oral dose of baricitinib.
46028036|NCT02698267|Drug|BIIB074|Administered as specified in the treatment arm
46028037|NCT02698267|Drug|Itraconazole|200 mg twice daily [BID] on Day 8 and once daily (QD) from Day 9 to Day 15 inclusive
46117275|NCT04639986|Drug|Capecitabine Oral Product|Capecitabine is administered orally (PO) following recommended doses and regimens as per approved package inserts.
46117276|NCT04639986|Drug|Gemcitabine Injection|Gemcitabine is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
46117277|NCT04639986|Drug|Vinorelbine injection|Vinorelbine is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
46117278|NCT00726219|Other|Femoral perineural catheter|Comparison of 2 insertion distances (3 vs 7 cm) for a femoral perineural catheter in the context of major knee surgery.
46117279|NCT04126317|Drug|aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
46117280|NCT04126317|Drug|High-dose aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
46117281|NCT00920322|Device|rTMS 5 x weekly|Patients will receive rTMS five times weekly for 4 weeks
46117282|NCT00920322|Device|rTMS 3 times weekly|Patients will receive rTMS 3 times weekly for 4 weeks
46117283|NCT00726843|Other|8 weeks of Iyengar Yoga|Participants will attend 8 weekly, 75 min. yoga sessions, followed by 8 weeks of follow-up (will provide headache frequency/intensity)
46117284|NCT00726843|Other|8 weeks of Iyengar Yoga|Participants will provide headache frequency/intensity for 8 weeks, followed by 8 weekly, 75 min. yoga sessions
46028038|NCT01011465|Drug|intranasal oxytocin|The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after 24 IUs of oxytocin have been administered. Duration of administration is anticipated to be 2-5 minutes
46028039|NCT01011465|Drug|Placebo|Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after the full amount in the spray bottle has been used. Duration of administration is anticipated to be 2-5 minutes
46028040|NCT01011465|Behavioral|Social support|Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. If instructed to bring a same-sex close friend (excluding spouses, participants are joined by their support partners join participants at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.
46117285|NCT05539326|Other|Performance Clinical Outcome Test|Patients will be asked to perform a fast 4-meter walk test (4mWT) and the Timed up and Go (TUG) test in the clinic during their post-operative follow-up visit. Both performance exams will be performed in a controlled environment within the physician's clinic.
46117286|NCT00726531|Behavioral|Otago Exercise Programme|Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require
46117287|NCT00726531|Behavioral|Fame|Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.
46117288|NCT00726531|Other|Treatment As Usual|Treatment as usual by the general practitioner
46117289|NCT02583516|Drug|vemurafenib and cobimetinib|Comparison between different treatment regimens
46117290|NCT00790907|Drug|fondaparinux background and standard dose UFH|Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded standard dose UFH (based on planned glycoprotein [GP] IIb/IIIa inhibitor use: 60 units/kilogram (U/kg); no planned use: 85 U/kg and adjusted based on activated clotting time (ACT) [maximum two additional bolus doses]). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
46117291|NCT00790907|Drug|Fondaparinux background and low dose heparin|Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded low-dose UFH (50 U/kg), which was not adjusted for planned GPIIb/IIIa inhibitor use or ACT). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
46117292|NCT00790907|Drug|Open label fondaparinux|Open-label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier, for those participants not indicated for PCI and not randomized
46117293|NCT02569983|Other|Observational cohort|No intervention - observational study
46117294|NCT05472714|Other|Educational Video|We will develop an informational video to be presented within one week of diagnosis of a tumor to those referred for tumor normal paired genetic testing.
45598659|NCT02231801|Behavioral|Mother-Infant Dyad|Skin-to-skin holding of preterm infants by their mothers
45598660|NCT03516643|Other|Extracorporeal Shockwave Myocardial Revascularization|extracorporeal shockwave in ischemic area evaluated by SPECT
45598661|NCT02228135|Drug|Dexamethasone|
45598662|NCT03152877|Drug|Bupivacaine Liposome Injectable Product|20cc of liposomal bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.
45598663|NCT03152877|Drug|0.25% plain bupivacaine|20cc of 0.25% plain bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.
45598664|NCT02295709|Procedure|SNR steroid (dexamethasone) injection|"deliver steroids (dexamethasone) into spinal nerve root with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)"
45682123|NCT01673230|Procedure|cardiac surgery for ventricular dysfunction|For each included patient during the immediate post operative period, hemodynamic variables will be recorded (continuous arterial pressure, ECG, photoplethysmographic curve, CVP, wedge pressure, respiratory pressure), at rest (proclive 45°), during fluid expansion (physiological saline).
45682124|NCT03153358|Drug|Icotinib|icotinib 125 milligram three times a day
45682125|NCT03153358|Radiation|SBRT|given radiation for the primary lesion
46117295|NCT03109353|Drug|ECP with 5-aminolevulinic acid|extracorporeal photopheresis (ALA-ECP) using 5-aminolevulinic acid instead of psoralen (8-MOP) in a maximum of 10 treatment cycles
46028041|NCT01011465|Behavioral|No Social Support|Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. They are then instructed to bring a same-sex close friend (excluding spouses) with them, or to come alone. If they come to the laboratory without a friend, they engage in all the laboratory procedures without a friend present.
46117296|NCT04066569|Other|Performed 3 diagnostic tests (2 OGTT tests with 75 g of Glucose and 1 placebo test with 375 mg of Aspartam|"After inclusion, the study will include the sequential realization of 3 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water) and a placebo test (oral administration of 375 mg of aspartame in 100 mL of water). The order of the three tests (2 OGTT and 1 placebo) in acromegalic patients will be randomized.~The tests will be performed under the same conditions"
46028042|NCT02701855|Behavioral|Cognitive tests|"Cognitive tests include:~The MMSE (Mini Mental State Examination)~Free and Cued Selective Recall Reminding Test (FCSRT).~Executive functions (fluencies, TMT A and B, span).~Tests of verbal fluency (literal and category)~Digit symbol substitution test or Wechsler adult intelligence scale (W.A.I.S)~The Clinical Dementia Rating Scale~The IADL scale evaluates autonomy.~Geriatric Depression screening Scale (GDS)"
46028043|NCT02701855|Biological|Blood test|A blood test will be performed in order to collect following parameters: Urea, BUN, Creatinine, Potassium, Sodium, hematocrit, hsCRP, NFS, Pq, LDL-C, HDL-C, Triglycerides, Lp(a), Lp-PLA2 as well as fasting glucose, HbA1C and microalbuminuria
45682126|NCT03025594|Drug|Gonyautoxins|Periarticular infiltration of 40mcg of Gonyautoxin diluted in 30cc of Sodium Chloride 0.9%, with pH 6.2 and isosmotic. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue just before wound closure of total knee arhroplasty
45470956|NCT05763056|Procedure|C-MAC videolaryngoscopy|The Macintosh blade is attached to the handle and the light beam is passed through the blade tip into a small metal guide tube indented 40 mm. The camera cable is connected to the control unit and the optical cable is connected to the light source. The video macintosh system is installed in a small trolley for easy portability of the device. The trolley supports an 8-inch monitor mounted on a rotating arm on the patient's left side. C-MAC VL devices can create continuous video recordings or static images on a secure removable digital card. The electronic module includes 2 buttons for photo and video shooting. In addition, the image of the C-MAC VL device can be viewed on other devices or recorded via a standard video output port. 3 C-MAC VL reusable metal macintosh blades (sizes 2 to 4) can be used for adult patients. These non-disposable knives have a closed design without gaps in terms of hygiene and have beveled edges to prevent tissue damage.
45682127|NCT03025594|Drug|Chirocaine ketorolac epinephrine|Periarticular infiltration of 150ml of Chirocaine 2%, 60mg of ketorolac and 0.75mg of epinephrine. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue jbefore wound closure of total knee arhroplasty.
45682128|NCT04884256|Drug|CBT-004|Dose response study
45682129|NCT04404946|Other|phenylephrine infusion|in parturients allocated to the phenylephrine group, a phenylephrine infusion will be started as soon as spinal anesthesia is initiated
45682130|NCT04404946|Other|norepinephrine infusion|in parturients allocated to the norepinephrine group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated
45682131|NCT04404946|Other|placebo infusion|in parturients allocated to the placebo group, a normal saline infusion will be started as soon as spinal anesthesia is initiated
45682132|NCT01673542|Drug|Lidocaine-Prilocaine 5%|
46117297|NCT04066569|Other|Performed 2 diagnostic tests (2 OGTT tests with 75g of Glucose)|"After inclusion, the study will include the sequential realization of 2 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water).~The tests will be performed under the same conditions (fasting, semi-recumbent position, start of the test at 9 am) and will include a measurement of blood glucose, GH, insulinemia at -15, 0, 30, 60, 90, 120 min after ingestion of glucose or placebo."
46117298|NCT04071795|Behavioral|Opt-Out Reminder|half will receive a clinical reminder that includes a standing NRT order and a referral to cessation counseling that will automatically generate unless the provider actively opts-out
46028044|NCT02701855|Radiation|Brain and aorta RMI|A magnetic resonance imaging exam will be performed at the Neuroimaging Research Center of the Pitié-Salpêtrière Hospital. This exam will be optimized to fit in 30 minutes. Indeed brain 3D T1 and T2 FLAIR imaging lasts 15 minutes while cine and velocity encoded imaging of the aorta lasts 15 minutes.
46028045|NCT02701855|Other|Adaptative optics|"The retina adaptative optic imaging will be performed at the Unité de prevention des maladies cardiovasculaires Pitié Salpetrière Hospital. This exam lasts 10 minutes including patient positioning and imaging."
46117299|NCT04071795|Behavioral|Opt-In Reminder|Half of the psychiatrists will receive a reminder that encourages the psychiatrist to offer cessation medications and referral to cessation counseling to patients interested in quitting
46117300|NCT05413434|Other|exercise|high-intensity interval training will be performed on the treadmill.
46117301|NCT05413434|Device|inspiratory muscle training|Respiratory muscle strength exercise will be performed with the respiratory muscle strengthening device 'POWERbreathe Classic Light Resistance'.
45470957|NCT05763056|Device|Direct laryngoscopy|During intubation with a direct laryngoscope (DL), the laryngoscope is inserted into the oral cavity from the right side of the mouth, the tongue is pushed to the left, and after advancing up to the vallecula, it hangs up and forward. In this way, the floor of the mouth and the epiglottis structure are removed from the field of view. If a straight blade laryngoscope is to be used, it is advanced so that the epiglottis remains under the blade after viewing the epiglottis (1). In DL, manipulations such as head extension, sniffing position, and compression of the cricoid cartilage may be required to facilitate visualization of the vocal folds. In 10-15% of the complications experienced during intubation with DL, there are problems related to the angle of view.
45470958|NCT01663844|Behavioral|Therapist guided Internet-CBT for insomnia w. extra support|(Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia plus extra therapist support.
46028046|NCT04294485|Behavioral|Physical therapy|Electrostimulation combined with exercise
45470959|NCT01663844|Behavioral|Therapist guided Internet-CBT for insomnia|(Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia. Regular therapist support.
45682133|NCT01673542|Drug|DEXERYL|
45682134|NCT04804540|Drug|Vedolizumab IV|Vedolizumab IV infusion
46028047|NCT02494141|Drug|Curcumin|Dietary Supplement
46117302|NCT04066179|Drug|Gcsf|Granulocytes-Colony Stimulating Factor 300 mcg for 7 days followed by 300 mcg every 3 days
46117303|NCT04066179|Drug|Prednisolone|Prednisolone 40 mg for initial 7 days
46117304|NCT04110119|Drug|diclophenac sodium (75 mg, IM) and thiocolchicoside (4 mg, IM)|Single intramuscular injection of mixture of two commercial drugs (Analgesic-anti-inflammatory and myorelaxant) at the specified dosages
46117305|NCT04110119|Other|Chiropractic Treatment|High speed and low amplitude spinal manipulation techniques are applied to the case group.
45682135|NCT03724318|Procedure|closure of the left atrium appendage|closure of the left atrium appendage in addition to the planned Heart operation
45682136|NCT03713710|Behavioral|Pap testing|Women will be approached in the community by a Peer Health Educator and scheduled an appointment for a Pap testing at the local health department
45682137|NCT03713710|Behavioral|Choice|Women will be approached in the community by a Peer Health Educator and they will be given a choice between scheduling an appointment for a Pap testing at the local health department or engage in self-sampling for HPV testing at home
46028048|NCT02494141|Other|Placebo|
46028049|NCT01011387|Procedure|NPWT System|Dressing change 3 times per week
46028050|NCT01011387|Device|NPWT system|3 dressing changes/week for maximum 4 weeks.
46028051|NCT02701621|Other|MIRT-AT|Aquatic therapy
46028052|NCT02701621|Other|MIRT|Land-based Therapy
46028053|NCT02698345|Device|drug-eluting balloon (In.PACT Admiral, Medtronic)|
46028054|NCT04215211|Diagnostic Test|Survival prediction for glioma patients|Survival prediction of glioma patients in the frame of molecular pathology by leveraging AI
46117306|NCT04052061|Biological|CD19 t-haNK|CD19 t-haNK Suspension for Infusion
46117307|NCT02604251|Device|KLOX BioPhotonic WoundGel System|Patients will then be re-randomized to one of the three comparisons: treatment starting on day 7 post-surgery, treatment starting on Day 21 post-surgery, or two consecutive treatments applied once weekly.
46117308|NCT02604251|Device|Silicone sheets|Treatment of the surgical wounds with silicone sheets.
46117309|NCT02585310|Other|Packed red blood cell transfusion|Record number of PRBC transfusion during perioperative period.
46117310|NCT04630392|Other|Treadmill Training|Ten minutes of treadmill walking at 110% self-selected overground walking speed
46117311|NCT04630392|Other|Whole Body Vibration & Treadmill Training|Eight bouts of 90 seconds of vibration at 20 Hz and an amplitude of 2 mm on a Galileo Med-L side-to-side-alternating WBV plate (StimDesigns LLC, Carmel, CA, USA) followed by ten minutes of treadmill walking at 110% self selected overground walking speed.
46117312|NCT04019691|Device|Mix-and-Match|Phacoemulsification and implantation of Tecnis ZKB00 multifocal IOL with +2.75 D add power (Abbott Medical Optic Inc., Santa Ana, CA) in the dominant eye, and a Tecnis ZLB00 multifocal IOL with +3.25 D add power (Abbott Medical Optics Inc.) in the non-dominant eye.
46117313|NCT04019691|Device|EDOF|Phacoemulsification and implantation of Tecnis Symfony ZXR00 trifocal IOLs (Abbot Medical Optics Inc.) in both eyes.
46028055|NCT02701465|Other|Exercise: local high intensity interval exercise|The subjects in this arm will receive four high intensity (80% of peak work rate) four-minute interval exercises for the abduction movement in the plane of the scapula (m. supraspinatus), supervised three times per week. In addition they will perform the exercise program described for the control group.
46028056|NCT02701465|Other|Exercise: best clinical practice|The control group will receive a best clinical practice home-exercise program, with regular follow-ups at the shoulder clinic every other week. The details are described in Granviken et al. (2015).
46028057|NCT00616135|Procedure|ADRC-Enhanced Autologous Fat Transplant|Autologous fat harvested from the patient is enhanced with ADRCs derived from a portion of the harvested fat and transplanted into the breast(s) that have a volume deficit post lumpectomy. This is a single arm study with no control. All patients receive cell therapy.
46117314|NCT04019691|Device|Trifocal|Phacoemulsification and implantation of FineVision PodFT IOLs (PhysIOL SA) in both eyes.
46117315|NCT00726687|Drug|indibulin|indibulin, dose escalation, 400-600 mg taken twice every day
46117316|NCT00726687|Drug|capecitabine|capecitabine, dose escalation, 875 mg/m2- 1250 mg/m2, taken twice daily for 14 days per 21 day cycle
46117317|NCT04101396|Dietary Supplement|diabetic diet|Patients with gestational diabetes will be seen by the dietitian to be taught diet modification
46117318|NCT03950115|Device|Intense Pulsed Light (IPL)|IPL therapy will be performed with the M22® (Lumenis, Dreieich, Germany). IPL treatment is going to be administered to the skin below the lower eyelid. Before treatment, the eyes will be protected with opaque goggles. Ultrasound gel is going to be applied to the patient's face from tragus to tragus including the nose in order to conduct the light, help to spread the energy evenly, and provide a degree of protection. The intensity of the IPL treatment will range from 9.8J/cm2 to 13J/cm2 according to Fitzpatrick Skin Type Grading.
46117319|NCT04532424|Device|Transcranial magnetic stimulation|Non-invasive brain stimulation technique that is FDA-approved for the treatment of refractory depression, OCD and migraine.
46117320|NCT00727077|Biological|IntronA (interferon alfa-2b; SCH 30500)|IntronA (3 Mio I.E./m2, 3 times per week) administered in accordance with the SPC and approved European labeling
46117321|NCT00727077|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol (15 mg/kg/day) administered in accordance with the SPC and approved European labeling
46117322|NCT02585388|Drug|Vinorelbine|Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week. One dose level reduction is authorized at 30 mg per day.when stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued
46117323|NCT02585388|Drug|Letrozole|Lestrozole at 2,5 mg every day , per oral
46117324|NCT02585388|Drug|Anastrozole|Anastrozole at 1 mg every day, per oral
46028058|NCT01011309|Biological|LEISH-F2 + MPL-SE|10 μg LEISH-F2 + 25 μg MPL-SE on Days 0, 28 and 56
46028059|NCT01011309|Drug|Sodium stibogluconate|20 mg/kg/day IV daily for 20 days
46117325|NCT02653287|Behavioral|Experimental|The experimental intervention includes 4 individual coaching sessions (initial 1 hour in-person and remaining 10-15 minutes per telephone) designed to identify barriers and supports for physical activity and nutrition using motivational interviewing. They occur shortly after randomization, 1.5, 3, and 6 months. Daily participants monitor their physical activity via the Fitbit Flex and their dietary behavior on a paper diary.
46028060|NCT04214821|Drug|Levofloxacin Ophthalmic Solution|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
46028061|NCT04214821|Drug|Moxifloxacin Ophthalmic Solution|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
46028062|NCT00616213|Biological|filgrastim|filgrastim will be administered at a standard dose and schedule
46028063|NCT00616213|Drug|PR104|PR104 is administered intravenously once every 21 days
46028064|NCT00616213|Other|F-18-fluoromisonidazole|F-18-fluoromisonidazole is administered intravenously prior to performance of PET scan
46028065|NCT00615667|Drug|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
46117326|NCT02653287|Other|Control|The control group will receive four individual phone calls focusing on education for SLE disease management, as well as answering any questions the participants have about the study. Topics include: what is lupus, laboratory tests, medications, taking charge of your health care and managing stress (2 sessions). Each call will last about 10-15 minutes, and occur shortly after randomization, then at 1.5, 3, and 6 months.
46117327|NCT04080336|Drug|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3hours before IUD insertion.
46117328|NCT04080336|Drug|Misoprostol|1 vaginal tablet of misoprostol (200mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
46117329|NCT04080336|Drug|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
46117330|NCT00727155|Behavioral|Adjusting to Chronic Conditions Using Education Support and Skills|This psychosocial intervention uses a combination of cognitive-behavioral therapy and disease self-management techniques.
46117331|NCT00793871|Drug|Sunitinib Malate (SU011248)|Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
46028066|NCT00615043|Procedure|Bladder biopsy|provision of bladder tissue via cystoscopic biopsy during planned TURBT
46028067|NCT04295655|Other|Global Exercise intervention|The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises
46117332|NCT05466474|Biological|Tislelizumab Injection|Efficacy of tislelizumab or tislelizumab combined with dacarbazine in the treatment of advanced malignant melanoma.
46117333|NCT04065945|Other|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes questionnaires and provides biological samples at each scheduled study visit.
46117334|NCT02585154|Procedure|Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|'Classical' high-frequency Deep Brain Stimulation, which is applied irrespective of ongoing brain activity.
46117335|NCT02585154|Procedure|closed-loop Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|Deep Brain Stimulation, which is applied depending on ongoing brain activity.
46117336|NCT02585154|Procedure|Deep Brain Stimulation off|Deep Brain Stimulation is turned off.
46117337|NCT02585154|Device|local field potentials and electroencephalography recordings|Simultaneous recordings of local field potentials from subthalamic nucleus and electroencephalography
46117338|NCT00727233|Drug|Nexavar (BAY 43-9006) (Sorafenib)|
46117339|NCT00727233|Drug|Toxicity, Pharmacokinetics|
46117340|NCT00727233|Drug|Pharmacodynamics|
46117341|NCT00727233|Drug|Radiographic Evaluation|
46117342|NCT00727233|Drug|QOL assessment, Neuropsychological|
46117343|NCT00727233|Drug|Bony Toxicity|
46117344|NCT04105283|Biological|Tc99m-MAA|Tc99m-MAA is a particle that is used to assess blood flow distribution and has a similar size to the particles that are utilized for arterial delivery of radiation therapy, also called radioembolization. Tc99m-MAA is currently used to estimate radiation dosimetry prior to arterial radiotherapy administration for liver malignancies.
46117345|NCT02584062|Procedure|no-touch fluid-air exchange|
46117346|NCT02584062|Procedure|vitrectomy metrectomy and internal membrane peeling and gas tamponed|
46117347|NCT02947971|Device|Experimental OFDI Imaging|Imaging of the esophagus with a compact OFDI system and distal scanning catheter
46117348|NCT04105127|Device|orthodontic - Anterior resin builds-ups|After lower brackets placement, resin builds-ups are added on the palatal aspect of the upper central incisors. Both central incisors are customarily bonded to broadly distribute the occlusal forces. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
46117349|NCT04105127|Device|orthodontic - Posterior resin builds-ups|After lower brackets placement, resin builds-ups are added on the supporting cusps of first or second upper/lower molars. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
46117350|NCT02583906|Device|CPAP|Treatment with CPAP for six months in the CPAP arm.
46117351|NCT04066257|Drug|Tegoprazan|Tegoprazan 50 mg tablet
46117352|NCT04066257|Drug|Metronidazole|Metronidazole 250 mg tablet
46117353|NCT04066257|Drug|Tetracycline|Tetracycline hydrochloride 250 mg capsule
46117354|NCT04066257|Drug|Bismuth|Tripotassium bismuth dicitrate 300 mg tablet
45470960|NCT01663844|Behavioral|Therapist guided Internet-CBT for insomnia and depression|(Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia and depression.
46028068|NCT04295655|Other|Functional Electrostimulation Group|"The program included a neuromuscular stimulation therapy on quadriceps accompanied by lower limb exercises. The intervention was performed following the protocol described by Valenza et al (2017).~Valenza MC, Torres-Sánchez I, López-López L, Cabrera-Martos I, Ortiz-Rubio A, Valenza-Demet G. Effects of home-based neuromuscular electrical stimulation in severe chronic obstructive pulmonary disease patients: a randomized controlled clinical trial. Eur J Phys Rehabil Med. 2018 Jun;54(3):323-332. doi: 10.23736/S1973-9087.17.04745-1. Epub 2017 Nov 16. PubMed PMID: 29144103."
46117355|NCT00915707|Other|Baseline|Subjects are allowed time in bed for sleep as their usual time at home.
46117356|NCT00915707|Other|Sleep restriction|Subjects sleep is reduced to 4.5 hours in bed for 4 nights.
46117357|NCT00915707|Other|Reduced Sleep Quality|Subjects sleep quality is reduced for 4 nights.
46117358|NCT04080102|Other|High Intensity Interval Training|Exercise
46117359|NCT04080102|Dietary Supplement|Essential Amino Acid|Oral ingestion of a powdered dietary supplement
46117360|NCT04080102|Other|High intensity interval training and essential amino acid supplement|Exercise and dietary supplement
46117361|NCT02602691|Other|AlloMap®|
46117362|NCT02602691|Procedure|Endomyocardial biopsies|
46117363|NCT02583126|Behavioral|Guided Imagery and Music|Modified and resource-oriented form of the Bonny Method of Guided Imagery and Music (BM-GIM)
46117364|NCT05571839|Drug|SGN-BB228|Given into the vein (IV; intravenous)
46117365|NCT00920712|Drug|Weiqi decotion|Decoction ,two times a day
46117366|NCT03655821|Drug|Pemetrexed|Dosing is either based on BSA or renal function
46117367|NCT04104971|Diagnostic Test|blood tests , abdominal US and doppler|
46117368|NCT02585076|Other|Standard of care|As prescribed by treated physician
46117369|NCT00733863|Biological|Placebo|
46117370|NCT00733863|Biological|CAD106|
46117371|NCT04524702|Drug|Gemcitabine|Given IV
46117372|NCT04524702|Drug|Hydroxychloroquine|Given PO
46117373|NCT04524702|Drug|Nab-paclitaxel|Given IV
46028069|NCT04295655|Other|Standard treatment|Patients received standard medical and pharmacological care that consisted in systemic steroids, inhaled bronchodilators, oxygen, and a regimen of oral prednisone or its equivalent in doses of 40 to 60 mg per day for the duration of therapy as well as anti-biotic therapy
46117374|NCT04524702|Drug|Paricalcitol|Given IV
46028070|NCT02697955|Drug|Bupivacaine-epinephrine|50 mg bupivacaine and 50 μg adrenalin
46117375|NCT00727389|Behavioral|Physiotherapy|Exercise two days a week for six month
45682138|NCT02634268|Behavioral|Lifestyle Intervention|Behavioral lifestyle intervention focused on healthy eating and physical activity
46028071|NCT02697955|Other|Placebo|9 mg sodium chloride pr. ml (0,9 %)
45682139|NCT01610492|Drug|belimumab|10mg/kg administered intravenously
46028072|NCT04294329|Procedure|US-guided Quadratus lumborum block.|Performance of quadratus lumborum block using ultrasound machine to relieve pain after bariatric surgery
46117376|NCT00727467|Device|Auditory Cueing Device|Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks.
46117377|NCT00733941|Behavioral|High frequency training|24 training sessions, 8x weekly, followed by detraining phase 8 weeks, and retraining
46117378|NCT00733941|Behavioral|normal frequence training|24 training sessions, 3x weekly, followed by detraining phase 8 weeks, and retraining
46117379|NCT04080258|Other|Osteopathic manipulative therapy (OMTh)|"The Osteopathic Manipulative Therapy includes both evaluation and treatment. The evaluation is semi-structured, two osteopaths will assess the presence of somatic dysfunctions which have to include the hyoid-pharyngeal, laryngeal, temporo-mandibular and lingual areas.~The therapy is based on the treatment of somatic dysfunctions with different approaches that include: the balanced ligamentous tension technique, the myofascial release, the visceral manipulation, and the balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 of evaluation and 30 of treatment."
46117380|NCT04080258|Other|Light Touch Therapy (LTT)|The Light Touch Therapy is a sham treatment consistent with the OMTh one during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body by moving the hands every few seconds and by flattening and softening the surface of the hands in order to minimize focal areas of force.
45682140|NCT02738866|Drug|Palbociclib|Palbociclib will be given orally, continued at the same dose as was received previously; the maximum starting dose will be per the approved label, a dose of 125 mg once daily. Palbociclib will be taken days 1-21, then seven days off treatment to complete one 28 day cycle.
45754564|NCT03620123|Drug|Nivolumab and Ipilimumab|Nivolumab 3 mg/kg of body weight intravenous infusion every two weeks and ipilimumab 1 mg/kg of body weight intravenous infusion every six weeks
46028073|NCT04294329|Drug|Bupivacaine|Bupivacaine
46028074|NCT04294329|Drug|Saline|normal saline
46028075|NCT02871609|Other|Stent examination, urinary analysis, USSQ questionnaire|
46117381|NCT04018443|Diagnostic Test|common carotid artery diameter measurement|measurement of common carotid artery diameter will be carried out two times: the initial measurement (pre-infusion) which is followed by infusion of crystalloid solution (Ringer lactate) 30 ml/min till reaching a total infusion volume of 7 ml/kg body weight then another ultrasound measurement will be taken (prost-infusion). Between these sequential measurements, the patient position will not be changed. The percentage increase in CCA diameter will be calculated using the formula: [(dia-mpost/dia-mpre) × 100] - 100 [11].
46117382|NCT02583984|Procedure|Thoracic Surgery with Lung Resection|General anesthesia and lung separation Thoracic surgery with lung resection, such as lobectomy, segmentectomy
46117383|NCT02583984|Procedure|Thoracic Surgery without Lung Resection|General anesthesia and lung separation Thoracic surgery without lung resection, such as esophageal surgery, mediastinal surgery
46028076|NCT02701309|Device|Non-invasive Iron detection device via Zinc-Protoporphyrin|In this study the feasability, sensitivity and specifity of a non-invasive detection method of zinc-protoporphyrin in children is evaluated. It´s a one-arm study, without control Group. Children are aged between 9m and 5y and have a clinical blood sampling indicated.
46028077|NCT05235633|Diagnostic Test|Assessment of the accomplishment regarding Activities of Daily Living at the end of acute treatment|Participants perform a test battery to assess the capability to accomplish Activities of Daily Living that includes a standardized and validated questionnaire, a parcour with tasks based on Activities of Daily Living and a motor performance test.
46028078|NCT03250507|Drug|Bupivacaine|0.25% bupivacaine for TAP block
46117384|NCT02569203|Dietary Supplement|standard enteral nutrition|standard enteral nutrition
46117385|NCT02569203|Dietary Supplement|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
46028079|NCT03250507|Drug|Liposomal bupivacaine|Exparel for TAP block
45682141|NCT02738866|Drug|Fulvestrant|Fulvestrant 500 mg should be administered intramuscularly into the buttocks slowly (1-2 minutes per injection) as two 5 mL injections, one in each buttock, on days 1, 15, and 29 (i.e., Cycle 2 Day 1) and once monthly thereafter (i.e., day 1 of each cycle).
45682142|NCT02612662|Drug|AZD4076|Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
46028080|NCT03250507|Drug|Saline|Saline for TAP block that will be mixed with liposomal bupivacaine to bring the liposomal bupivacaine group to 60 mL total volume.
46028081|NCT00997893|Dietary Supplement|Soy Phytoestrogen|Novasoy® pill (55 mg)
45682143|NCT02612662|Drug|Placebo|Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
45682144|NCT02369770|Device|stretching and active movement training|A portable rehabilitation robot will be used to strongly or gently move the impaired ankle joint back and forth. Then subjects will be asked to use muscles to move the ankle with or without the robotic guidance depending on which group the subjects are in.
46028082|NCT00997893|Drug|Estradiol|Estradiol pill (1 mg)
46028083|NCT00997893|Drug|Medroxyprogesterone Acetate (MPA)|medroxyprogesterone acetate (MPA) (10mg)
46028084|NCT00997893|Drug|Soy Placebo|oral placebo pill (0mg Soy Phytoestrogen)
46117386|NCT02569203|Dietary Supplement|high-protein enteral nutrition of immune modulating nutrients without β-glucan|high-protein enteral nutrition of immune modulating nutrients without β-glucan
46028085|NCT00997893|Drug|MPA Placebo|oral placebo pill (0mg MPA)
45682145|NCT01673776|Device|PulsioFlex® Monitoring|"goal directed therapy according to PulsioFlex® Monitoring- measurements~femoral catheter~extended perioperative monitoring~nutritional supplementation, (if necessary)"
46028086|NCT02697877|Drug|Regadenoson|
46028087|NCT04214665|Drug|Alpha Lipoic acid 600 mg HR film coated tablets|
46028088|NCT02870673|Drug|SHINCORT|triamcinolone Acetonide (10mg/ml) 0.5 ml
46028089|NCT02870673|Drug|XYLOCAINE|xylocaine(20mg/ml) 0.5 ml
46028090|NCT02870673|Device|sham electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
46028091|NCT02870673|Device|electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
46028092|NCT02701231|Device|Low-frequency Rotating Magnetic Therapy System|Two pairs of fan-shaped NdFeB permanent magnets were attached to a circular iron plate and arranged to establish magnetic field. The bottom two magnets rotated at certain frequency driven by a step motor, which was controlled using a functional signal generator. The top two magnets rotated synchronously due to the strong magnetic interaction. Magnetic flux density was measured at the target site using a gauss meter. The entire magnetic apparatus was located in a hood with humidity and temperature controller.
46117387|NCT00920478|Other|Musculoskeletal Ultrasound|Gray scale and power doppler - to identify the presence of synovitis
46117388|NCT00920478|Other|28 Joint Disease Activity Score|Clinical assessment of synovitis - composite score incorporating 28 tender joint count, 28 swollen joint count, erythrocyte sedimentation rate and patient global VAS
46117389|NCT00730197|Drug|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
46117390|NCT00730197|Drug|VoSpire® ER Tablets 8 mg|8mg, single dose fed
46117391|NCT00727545|Other|iron bisglycine chelate|
46117392|NCT00727545|Other|placebo|
46028093|NCT02701231|Drug|Systemic anti-tumor therapy|Systemic anti-tumor therapy includes targeted therapies, chemotherapy and best supportive care, according to NCCN non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) guidelines. SCLC patients will receive six cycles of cisplatin and etoposide. NSCLC patients will receive EGFR and ALK test. With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib. If insensitive, the patient will receive six cycles of cisplatin and pemetrexed. Then the patient will receive tumor response evaluation. The patient with response or stable disease will receive maintenance therapy with one or some of the drugs including bevacizumab, pemetrexed, gemcitabine and docetaxel until disease progression. During experience all patients will receive clinical observation. Once proven for disease progression the patient will finish the experiment.
46117393|NCT00730431|Drug|IDX184|IDX184 supplied as size 3, white opaque capsules containing either 5 mg or 25 mg.
46117394|NCT00730431|Drug|Placebo|Placebo supplied as size 3, white opaque capsules matching IDX184 capsules.
46117395|NCT02583204|Device|Onicolife nail drops|The prescription free, CE (Conformité Européenne) marked product is for local application, and has a novel mode of action involving the modulation of mast cell action with the fatty acid amide, Adelmidrol ®. Mast cells are known to have a key role in the ability of the body to promote healing /repair and control tissue damage caused by chemo and radiotherapy. This includes damage to the nail and/ or nail matrix. OnicoLife ® thus helps to control inflammation and pain whilst antimicrobial action also provides antibacterial and antifungal support.
46117396|NCT02583204|Other|Nail polish|One dark colour of nail polish (deep burgundy/red) will be used in this study since this colour is considered more acceptable to many more women than a pure black coloured nail polish and hence, more likely to ensure compliance. No nail polish containing hardeners will be used since there is some evidence to suggest they can induce nail changes. As dark nail polish can stain the nail plate (and therefore mask any changes in nail pigmentation induced by chemotherapy), one clear base coat, two coats of coloured, and one clear top coat of polish will be required for each application. This standard of application is proposed as a gold standard for the prevention of nail staining and hypersensitivity reactions by an eminent podiatrist (Spalding, 2008).
46117397|NCT04517370|Device|Fractional/Pixel CO2 laser|"The treatment is done with a specialized vaginal applicator which allows treatment of vagina, using the Femilift fractional micro ablative CO2 laser system (Alma Lasers, Israel), according to the usual protocol (Laser mode: Pulse, Energy: 40-80 mj/pulse).~Before treatment, 5ml of topical anesthetic ointment (10% lidocaine in Vaseline base) will be spread in the vagina and on the vestibule for 30 minutes in both groups to avoid pain from the laser, as well as to allow the comparison between the groups (patients in both groups will not experience pain and therefore will remain blinded to their allocation)."
46117398|NCT00727701|Behavioral|Aftercare summary|A personalized, targeted set of self-care instructions for venous ulcer prevention, including a graphical depiction of patient adherence to self-care goals.
46117399|NCT02582892|Drug|Vit D|20 mg/day
46117400|NCT00734175|Biological|H6N1 Teal HK 97/AA ca recombinant vaccine|Approximately 0.2 ml of 10^7 TCID50 doses of vaccine administered intranasally
46117401|NCT04079946|Procedure|Total Mesocolic Excision with Central Vessel Ligation|sharp dissection of the anatomical layers and the dissection of the visceral plane from the parietal one . In addition a central division of the feeding arteries at their origins is performed at the level of superior mesenteric artery for tumors of the right colon and at the level of inferior mesenteric artery or the aorta for tumors of the left colon .this allows for removal of the maximum number of lymph nodes possible.
46117402|NCT04079946|Procedure|conventional surgery of cancer colon|removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
46117403|NCT00730509|Dietary Supplement|5-methyltetrahydrofolate and vitamin B12|children with cystic fibrosis were supplementated for 6 months with 5-MTHF, 7,5 mg/day ; vitamin B12, 0,5 mg/day
46117404|NCT04512456|Behavioral|Exercise training|Exercise training performed during 12 weeks, 3 sessions per week of 60 minutes of strength and aerobic exercises.
46117405|NCT02584764|Behavioral|Cognitive behavior therapy|
46117406|NCT02584764|Behavioral|Internet support|
46117407|NCT04764513|Biological|Ex-vivo expanded γδ T cell infusion|"Phase 1: Patients receive ex-vivo expanded γδ T cell (Dose escalation, 3 cohorts, x5 dose increments between cohorts, 2×10^6、 1×10^7 and 5×10^7 of cells per kg of body weight).~Phase 2: Patients receive ex-vivo expanded γδ T cell at the maximum tolerated dose determined in Phase 1."
46117408|NCT02584530|Procedure|Ultrasound guidance for PICC line placement|Apply ultrasound guidance for PICC line placement and positioning in newborns
46117409|NCT00727779|Behavioral|strength training|eight weeks of progressively increasing resistance training will be done in both groups side-by-side
46117410|NCT02582736|Drug|Olanzapine|Exposure to olanzapine (ATC N05AH03) will be defined as a prescription for olanzapine on the date of cohort entry.
46117411|NCT02582736|Drug|Risperidone|Exposure to risperidone (ATC N05AX08) will be defined will be defined as a prescription for risperidone on the date of cohort entry.
46117412|NCT02582736|Drug|atypical antipsychotics (other)|Exposure to other atypitical antipsychotics (ATC N05AH02, N05AH04, N05AE04, N05AX13, N05AX12) will be defined will be defined as a prescription for an atypical antipsychotic other than olanzapine on the date of cohort entry.
45470961|NCT01663844|Behavioral|Therapist Guided Internet-CBT for depression plus insomnia placebo|(Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. A placebo intervention for insomnia is added.
45470962|NCT05762978|Device|In-Check Dial|Patient will have their NIF measured with In-Check Dial
45470963|NCT05762978|Device|Inhaler Device|Children will use inhaler per standard of care.
45470964|NCT05762900|Radiation|Ultra-fractionated radiation therapy|5.2Gy per fraction for 5 fractions with an integrated boost of 6Gy per fraction.
45470965|NCT05764148|Behavioral|behavioral activation|"Behavioral Activation (BA) is a specific CBT skill. It can be a treatment all by itself, or can be used alongside other CBT skills such as cognitive restructuring.~Behavioral activation helps us understand how behaviors influence emotions, just like cognitive work helps us understand the connection between thoughts and emotions."
45682146|NCT01817582|Drug|Lotemax|Lotemax gel will be administered as per the dose and schedule specified in the arms.
46028094|NCT02701231|Device|Sham Low-frequency Rotating Magnetic Therapy System|Sham Low-frequency Rotating Magnetic Therapy System is a similar apparatus except that there were two rotating iron plates instead of magnets, thus lacking a magnetic field.
46028095|NCT02701075|Device|MC5-A Scrambler Therapy|up to 10 sessions, each session lasting 30 minutes
46117413|NCT02582736|Drug|typical antipsychotics|Exposure to typical antipsychotics (M03BB02, N05AA01, N05AF03, N05AF01, N05AB02, N05AG01, N05AD01, N05AA02, N05AH01, N05AC03, N05AB03, N05AG02, N05AC04, N07XX06, N05AB05, N05AB08, N05AC02, N05AF04, N05AB06, N05AF05) will be defined as a prescription for a typical antipsychotic on the date of cohort entry.
46117414|NCT04512144|Behavioral|Headspace Smartphone Application|Headspace is a smartphone application used for mindfulness, meditation, and stress reduction. It has been utilized in other behavioral and quality of life studies.
46117415|NCT00734565|Biological|Haemophilus influenzae type b|1 dose monovalent conjugated vaccine against Haemophilus influenzae type b in children aged 16 - 20 months and infants aged 2 - 4 months
46117416|NCT04503564|Device|coil-reinforced soft polymer indwelling cannula|This is a prospective, non-randomized, home-use feasibility study of device performance, usability, tolerability, and safety of the Capillary Biomedical, Inc. (CapBio) Achilles infusion set for continuous subcutaneous insulin infusion (CSII or insulin pump therapy) in up to 20 participants diagnosed with type 1 diabetes mellitus (T1DM).
46117417|NCT04019652|Drug|CS-3150|Single, oral administration; 10-mg or 40-mg dose
46117418|NCT04019652|Drug|Moxifloxacin|Single, oral administration; 400 mg-tablet
46117419|NCT04019652|Drug|Placebo matching moxifloxacin tablet|Placebo tablets matching moxifloxacin tablets
46117420|NCT04019652|Drug|Placebo matching CS-3150|Placebo tablets matching CS-3150 tablets
46117421|NCT00734721|Behavioral|Preoperative information and perioperative care|Patients receive different information and care in addition to the basic medical consultation.
46117422|NCT04400370|Device|Diaphragm ultrasound|"Diaphragm ultrasound is performed at the following three time points.~At the entrance of the operating room before induction of anesthesia~1 hour after surgery~24 hours after surgery"
46117423|NCT00734955|Device|49-channel optical spectrometer|
46117424|NCT04078464|Other|Mindfulness Training Alone|Participants will lie down and listen to a pre-recorded guided mindfulness meditation for 36 minutes.
46117425|NCT04078464|Other|Acute Physical Activity Alone|Physical activity will include a 6 minute stretching session, 1 minute transition to treadmill, 3 minute warm up at a participant chosen pace on the treadmill, 20 minutes of walking at a moderate pace at target heart rate, 3 minute cool down at 2.0-2.5 mph, 1 minute transition off treadmill and 2 minutes of stretching.
45470966|NCT02815124|Other|Standard of Care|Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Standard of Care
45470967|NCT02815124|Other|Image-Guided Cochlear Implant Programming|Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Image-Guided Cochlear Implant Programming
45470968|NCT01378442|Other|fitness training program|"Experimental: high level training group. The experimental group received training for 40 min per day 3 times a week for 12 weeks. The hVCT program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, cycling for 20 min, and a cool-down exercise for 5 min.~Experimental: low level training group. The experimental group received training for 40 min per day 1-2 times a week for 12 weeks. The program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, fitness training for 20 min, and a cool-down exercise for 5 min.~Control:The control group will not receive fitness training program but maintain the usual life style."
45470969|NCT01378364|Drug|AbGn-168H|single very low dose of AbGn-168H i.v.
45470970|NCT01378364|Drug|AbGn-168H|single low dose of AbGn-168H i.v.
45470971|NCT01378364|Drug|Placebo|single dose of Placebo i.v.
45470972|NCT01378364|Drug|Placebo|single dose of Placebo i.v.
46117426|NCT04078464|Other|Acute Physical Activity and Mindfulness Training Together|Participants will listen to a pre-recorded mindfulness meditation which will guide them through a 6 minute stretching session, 1 minute transition to treadmill, 3 minute warm up at a participant chosen pace on the treadmill, 20 minutes of walking at a moderate pace at target heart rate, 3 minute cool down at 2.0-2.5 mph, 1 minute transition off treadmill and 2 minutes of stretching.
46117427|NCT00735033|Other|Physiotherapy with Swiss Ball|
45470973|NCT01378364|Drug|Placebo|single dose of Placebo i.v.
45470974|NCT01378364|Drug|Placebo|single dose of Placebo i.v.
45470975|NCT01378364|Drug|AbGn-168H|single medium dose of AbGn-168H i.v.
45470976|NCT01378364|Drug|AbGn-168H|single high dose of AbGn-168H i.v.
45470977|NCT01378364|Drug|AbGn-168H|single low dose of AbGn-168H s.c.
45470978|NCT01378364|Drug|Placebo|single dose of Placebo s.c.
45470979|NCT01378364|Drug|Placebo|single dose of Placebo s.c.
46117428|NCT00735111|Other|Karnofsky Performance Status Score|Karnofsky Performance Status scores will be independently completed by both the patient and their health-care provider at each routine clinic visit.
46028096|NCT02701075|Device|MC5-A Scrambler Therapy Sham Device|up to 10 sessions, each session lasting 30 minutes
46117429|NCT00735189|Other|anticoagulation clinic care|Patient receives care from the outpatient anticoagulation management service
46117430|NCT00735189|Other|usual care|patient receives usual anticoagulation care from their regular primary care physician
46028097|NCT00615745|Drug|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
46117431|NCT00735345|Drug|5-FU|750 mg/m2/d C.I. i.v.d1-5, d29-33 and 300 mg/m2/d C.I. i.v. on the days of radiotherapy
46117432|NCT00735345|Drug|Cisplatin|15 mg/m2/d i.v. d1-5, d29-33
46117433|NCT00735345|Drug|Taxotere|75 mg/m2/d i.v. d1 and d29, 15 mg/m2/d i.v. on d57, d64, d71 and d78
46117434|NCT00735345|Biological|Cetuximab|Cetuximab: 400 mg/m2 i.v. d1; 250mg/m2 weekly d8 through d85
46117435|NCT00735345|Radiation|Radiation during chemoradio-immunotherapy|39.6 Gy total dose
46117436|NCT00735501|Drug|insulin detemir|Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
46117437|NCT00727935|Drug|Lidocaïne|
46117438|NCT00727935|Drug|Ropivacaïne|
46117439|NCT00727935|Drug|Placebo|
46117440|NCT00728013|Drug|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins)
45470980|NCT01378364|Drug|AbGn-168H|single medium dose of AbGn-168H s.c.
45682147|NCT01817582|Drug|Restasis|Restasis emulsion will be administered as per the dose and schedule specified in the arms.
46117441|NCT00728013|Drug|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to moderate therapy (atorvastatin, 10 mg/d, or equivalent dose of other statins).
46117442|NCT02569749|Other|Berlin and Epworth questionaries|
45470981|NCT02731352|Drug|Apatinib|Apatinib Mesylate Tablets 750 mg q.d p.o. in 1-10 cases of differentiated thyroid cancer subjects.
45470982|NCT02731352|Drug|Apatinib|Apatinib Mesylate Tablets 500 mg q.d. p.o. in 11-20 cases of differentiated thyroid cancer subjects.
45470983|NCT05132660|Drug|Sinemet CR|25 mg carbidopa/100 mg levodopa
45682148|NCT01817582|Drug|Soothe® Lubricant Eye Drops|
45682149|NCT01594125|Drug|Nintedanib high dose|twice daily oral dosing
45682150|NCT01594125|Drug|Nintedanib low dose|twice daily oral dosing
45682151|NCT01594125|Drug|Nintedanib medium dose|twice daily oral dosing
45682152|NCT01594125|Drug|Nintedanib medium dose|twice daily oral dosing
45682153|NCT01594125|Drug|Nintedanib high dose|twice daily oral dosing
46117443|NCT02569749|Other|Sleep apnea monitoring in those patients in whom a pacemaker with monitoring apnea system has been implanted.|
46117444|NCT02569749|Other|Night polygraph / Polysomnography|
46117445|NCT00728247|Procedure|Manual Therapy Techniques|One of the following will be selected(1) soft-tissue stretch, (2) myofascial release, (3) muscle energy, or (4) functional (indirect) method
46117446|NCT00577707|Drug|erlotinib|One tablet daily of erlotinib pills (150 mg daily) for the first 21 days. After surgery, you will be asked to take adjuvant erlotinib 150 mg po daily x 2 years.
46117447|NCT00577707|Drug|Pemetrexed|pemetrexed 500 mg/m^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.
46117448|NCT00577707|Drug|Cisplatin|cisplatin 75 mg/m^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.
46117449|NCT00577707|Procedure|Resection|
46117450|NCT00728325|Behavioral|Supported Employment (SE)|SE(IPS)involves: a vocational rehabilitation employment specialist who is integrated into the clinical treatment team, carries out all phases of the vocational services, provides predominantly community-based services, provides assertive engagement and outreach, has a case load of ≤ 25 clients; engages in rapid job search, individualized placement in diverse and potentially permanent competitive job(s), ongoing work-based vocational assessment, and assistance in finding subsequent jobs if needed with the view that all jobs are positive learning experiences; continuous time-unlimited follow-along supports to provide vocational services; and weekly group supervision with IPS/VRP team and with IPS supervisor/trainer monthly.
45470984|NCT05132660|Drug|placebo|Placebo pill of similar size/shape
46117451|NCT00728325|Behavioral|Standard Vocational Rehabilitation (VRP)|Standard Vocational Rehabilitation (VRP) includes 1) the Vocational Assistance Program (includes routine prevocational testing and evaluation for all patients upon referral to VRP), 2) Vocational Rehabilitation Therapy that operates under the Compensated Work Therapy/Veterans Industries (CWT) and provides a work regimen with monetary incentives derived from contracts whereby participants are paid on a piece rate basis related to their production, and 3) Transitional Work Program (TWP) that includes a temporary work experience either within the VAMC or in community settings (called the Transitional Work External or TWE).
46028098|NCT04216069|Other|Total 12 regimen|"The volunteers will be invited with their caregivers to a lecture administered with the aim of clarifying the importance of oral hygiene and motivating brushing among the volunteers. Written clarifications will also be given in the form of an illustrative pamphlet. The volunteers will be trained in the technique through supervised brushing in front of a mirror. Subjects from the Group 1 will use a regimen with Colgate Total 12 toothpaste + Plax mouthwash + Colgate Ultrasoft toothbrush. Subjects will be instructed to use only their assigned group during the study period. The treatment products will be re-supplied at regular intervals. Subjects will return with their assigned products to the study site before receiving new products.~There will be no restrictions regarding diet habits during the course of the study. Upon completion of the study, subjects will be instructed to return all used and used products."
46028099|NCT04216069|Other|Toothbrushing alone|"The volunteers will be invited with their caregivers to a lecture administered with the aim of clarifying the importance of oral hygiene and motivating brushing among the volunteers. Written clarifications will also be given in the form of an illustrative pamphlet. The volunteers will be trained in the technique through supervised brushing in front of a mirror. Group 2 will use Colgate Cavity Protection Toothpaste + Colgate Ultrasoft toothbrush. Subjects will be instructed to use only their assigned group during the study period. The treatment products will be re-supplied at regular intervals. Subjects will return with their assigned products to the study site before receiving new products.~There will be no restrictions regarding diet habits during the course of the study. Upon completion of the study, subjects will be instructed to return all used and used products."
46028100|NCT02697721|Behavioral|Powerful Tools for Caregivers|Powerful Tools for Caregivers is a 6-week psychoeducational program. Each week the caregivers will attend a 90-minute workshop in a group setting. These sessions will be co-led by two trained and certified leaders who follow the scripted program. In addition to providing education about caregiving and the importance of self-care, the classes will help caregivers develop self-care tools to manage personal stress and improve communication skills.
46028101|NCT02697721|Other|Control with delayed intervention|Control with delayed intervention
46028102|NCT04215367|Dietary Supplement|High phenolic EVOO intake|During the pilot dietary intervention patients with CLL consumed before their meals, 40 ml/day high phenolic EVOO for 6 months
46028103|NCT04215367|Dietary Supplement|No High phenolic EVOO intake|Medical record of each patient's was followed during 6 month before dietary the intervention
46028104|NCT02697799|Behavioral|High-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a high-level recruitment strategy
46028105|NCT02697799|Behavioral|Mid-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a mid-level recruitment strategy
46028106|NCT02700607|Drug|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
46028107|NCT02700607|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
46028108|NCT04782739|Other|None - Descriptive study|Descriptive study
46028109|NCT04215913|Other|The investigators will extract total protein, DNA and RNA from PSC patients.|The investigators will extract total protein, DNA and RNA from PSC patients.
46028110|NCT02697643|Behavioral|BHCDS-based recommendations|
46028111|NCT02697643|Behavioral|Non-tailored recommendations|
46028112|NCT05324839|Drug|Botulinum toxin type A|injecting different dosage to different group
46117452|NCT00730743|Procedure|Intermittent Pringle maneuver|Pringle maneuver is performed by isolation of the hepatoduodenal ligament which is then encircled and occluded with atraumatic vascular clamp. The clamp is applied for 15 minutes followed by unclamping for 5 minutes and repeated till end of liver transection. Limits of clamp cycle: 3 cycles for cirrhotic liver; 4 cycles for non-cirrhotic liver.
46117453|NCT00728403|Dietary Supplement|American Ginseng (Panax quinquefolius L.) and Korean Red Ginseng (steamed Panax C.A. Meyer)|1.5 grams American Ginseng and 1.5 grams Korean Red Ginseng are to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
45470985|NCT02464436|Drug|hRPC|Participants will undergo vitrectomy surgery and subretinal implantation of hRPC in the study eye.
45682154|NCT04792684|Diagnostic Test|Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel|Evaluate the performance of a preliminary panel of biomarkers
46028113|NCT02700685|Dietary Supplement|Pycnogenol|Dietary supplement, standardised extract of French maritime Pine bark. This group receives a nutritional supplement for a period of 10 weeks.
46028114|NCT02700685|Drug|Methylphenidate|Standard pharmaceutical treatment for ADHD, slow release.
46028115|NCT02700685|Other|Placebo|Placebo treatment (identical capsules containing excipients only)
46028116|NCT02700763|Other|[18F]dabrafenib molecular imaging|A [18F]dabrafenib dynamic PET scan of the brain (60 minutes) and static total body PET scan will be performed at baseline.
46028117|NCT04188613|Device|Percutaneous tracheostomy|Age, gender, height, BMI, ASA scores, presence and type of additional diseases, tracheostomy day, pre- and post-procedure blood gas analysis, duration of procedure, duration of anesthesia, complications during the procedure (bleeding , desaturation, accidental extubation, malposition, bradycardia, hypotension, etc.) will be recorded from intensive care follow-up. Patients will be observed for mortality in the first 30 days after the procedure. Mortality results will be recorded.
46028118|NCT04215523|Drug|Dapagliflozin|Dapagliflozin dispensing claim is exposure
46028119|NCT04215523|Drug|DPP-4 inhibitor|DPP4 inhibitor dispensing claim is reference
46028120|NCT00616291|Biological|NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine|
46028121|NCT03151681|Drug|Propranolol Pill|1mg/kg of propranolol 60 minutes prior to memory reactivation
46117454|NCT00728403|Dietary Supplement|American Ginseng (Panax quinquefolius L.)|3 grams of American Ginseng is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
46117455|NCT00728403|Dietary Supplement|Wheat Bran|3 grams of Wheat Bran is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
45470986|NCT05762744|Drug|Exenatide Injection|Nurses administered exenatide (5 mcg) subcutaneously 15 minutes prior to conducting a frequently sampled intravenous glucose tolerance test.
45470987|NCT05762744|Drug|Saline injection|Nurses administered saline (0.2 mL) subcutaneously 15 minutes prior to conducting a frequently sampled intravenous glucose tolerance test.
45682155|NCT01673932|Biological|UCBMC|Transplant 10-40 million viable UCBMC suspension into brain adjacent to the infracted site
45470988|NCT02257424|Drug|Trametinib 2 mg daily|
45470989|NCT02257424|Drug|hydroxychloroquine (HCQ)|hydroxychloroquine (HCQ) is 600 mg orally every 12 hours
45682156|NCT01673932|Procedure|surgery|
45682157|NCT02986113|Behavioral|MAPS tailored multimedia patient activation program|
45682158|NCT02986113|Behavioral|Sleep hygiene video|3 minute video on sleep hygiene produced by HealthiNation
45682159|NCT02986113|Behavioral|Telephone evidence-based follow-up care|3 months of suicide-focused collaborative mental health care, directed by a supervising psychiatrist and implemented by a care manager working with the patient and their primary care provider
45682160|NCT02986113|Behavioral|Commitment to Living for Primary Care|Brief (30 minutes total time) video modules presenting participating patients' primary care providers with a patient-centered framework for suicide risk assessment and intervention
45682161|NCT04404868|Other|Normal clinical practice|There are no experimental interventions. The procedures are in line with normal clinical practice.
45682162|NCT04604288|Biological|HB-adMSC|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
45754565|NCT03620123|Drug|Docetaxel|docetaxel 75 mg/m² intravenous infusion every three weeks
46028122|NCT05324605|Procedure|Questionnaire and use of 3 D tools|Resulting computer tomography(CT) results are transferred to a 3 D projection. Patients will be asked to wear 3 D glasses to be able visualizing the diagnosed vascular pathology. The physician will explain the disaese and treatment. The patient is ask to fill out a questionnaire post 3D consulting
46028123|NCT02700373|Drug|PDC-APB|
46028124|NCT02700373|Drug|Placebo|
46028125|NCT04215445|Drug|Empagliflozin 25 MG|Tab.empagliflozin 25mg once daily for 28 days
46117456|NCT00735735|Other|The taking of a saliva sample from each subject.|After taking the sample, the saliva will be transferred via a pipette to a clean tube which will be labeled with the subject's name, the date and the hour. Once a month the tubes will be sent to the collaborating laboratory for analysis.
46117457|NCT04065867|Behavioral|ICT activities|Family interventions using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
46117458|NCT00730821|Drug|BIBW 2992|
46117459|NCT00730821|Drug|BIBF 1120|
46117460|NCT00728559|Drug|bupivacain 0.5%|trocar site injection
46117461|NCT00735813|Device|Taurolock|When not in use the childrens tunneled central venous catheters are locked with the liquid Taurolock instead of heparin.
46117462|NCT00735813|Device|Heparin|When not in use the childrens tunneled central venous catheters are locked with heparin
45470990|NCT02257424|Drug|dabrafenib 150 mg orally twice a day|
45470991|NCT02121158|Device|Implantable Cardioverter Defibrillator|The ICD and lead(s) will be FDA-approved.
46117463|NCT00736047|Biological|NIC002|
46028126|NCT04215445|Device|OCT-A|Optical coherence tomography angiography (OCT-A) is a non-invasive method to study the microvasculature of the retina and choroid.
46028127|NCT01032265|Behavioral|Web-based treatment with PFMT and elements of CBT|125 women with stress urinary incontinence(SUI) participate in web-based treatment for 3 months. Treatment consists of information, PFMT and uses elements of CBT. It includes regular email contact with urotherapist.
46028128|NCT01032265|Behavioral|Pamphlet treatment|125 women with SUI receive a pamphlet with information and a programme for PFMT.
46028129|NCT00951457|Drug|Bendamustine|
46117464|NCT00736047|Biological|Placebo|
46117465|NCT04064775|Behavioral|Smart snacking intervention|The smart snacking intervention aimed to examine whether peer-led nudging on social media influenced adolescents to reduce their self-reported ideal portion sizes for a variety of HED snacks and SSBs. In intervention 2, participants were randomly allocated to the intervention or control condition, and their ideal portion sizes were assessed through a survey at baseline and intervention end.
46117466|NCT04064619|Drug|Solifenacin Succinate 5 MG|gradual weaning of drug vs. stopping
45682163|NCT04115241|Device|Actigraph|Actigraphs are non-invasive, wearable devices that measure activity levels using an accelerometer
46028130|NCT00951457|Drug|Alemtuzumab|
46028131|NCT00918775|Other|Follow-Up Care|Undergo follow-up
46028132|NCT00918775|Other|Laboratory Biomarker Analysis|Correlative studies
46028133|NCT05324527|Other|Hand Massage|Hand massage procedure, 8 minutes to both hands and a total of 16 minutes hand massage was applied with liquid petrolatum.
46028134|NCT02691871|Drug|Apatinib (250 mg/d) + Docetaxel (60 mg/m2)|
46117467|NCT00728637|Behavioral|Family Passport to Heart Health Program|Participants in this group received personalized heart disease risk factor screening at the baseline study visit. They were taught lifestyle approaches to risk reduction based upon national heart disease prevention guidelines, including the Adult Treatment Panel (ATP) III recommendations for improving blood cholesterol levels with a TLC diet. Participants had regular contact with study staff and will receive individualized feedback throughout the study.
46117468|NCT00728637|Behavioral|General Educational Materials|Participants in the control group received an educational brochure about heart health at the baseline study visit.
46028135|NCT02691871|Drug|Apatinib (500 mg/d) + Docetaxel (60 mg/m2)|
46028136|NCT02691871|Drug|Apatinib (750 mg/d) + Docetaxel (60 mg/m2)|
46028137|NCT02700217|Procedure|Bupivacaine and Diamorphine|
46028138|NCT02700217|Procedure|Remifentanil, Propofol and Cistracurium|
46028139|NCT02700217|Procedure|Bupivacaine and Rectus Sheath injection|
46117469|NCT00730977|Drug|dry powder inhaled mannitol|single doses of 40 mg, 70 mg and 100 mg
46117470|NCT00728715|Drug|budesonide-formoterol single inhaler|High dose budesonide:Budesonide (Pulmocort turbuhaler) 400 mcg (2 inhalations bid) Medium dose budesonide plus formoterol (Rilast turbuhaler) 4,5 mcg of formoterol plus 400 mcg of budesonide: 2 inhalations bid
46117471|NCT00728715|Drug|High dose of budesonide|1600 mcg/d of budesonide
46117472|NCT00728715|Drug|A|medium dose of budesonide-formoterol
46117473|NCT00728715|Drug|B|High Dose Inhaled Budesonide
46117474|NCT00731289|Drug|hyaluronic acid|one intraarticular injection of hyaluronan (HA) 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
46117475|NCT00731289|Drug|triamcinolone|"one intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)~antiinflammatory intervention"
46117476|NCT00728793|Drug|CUDC-101|Doses will be given by intravenous infusion over 1 hour on days 1-5 of each treatment cycle. Total treatment cycle duration will be 14 days. Additional treatment cycles will be administered until the subjects withdraws consent, experiences unacceptable toxicity, or if there is documented tumor progression.
46028140|NCT02690467|Device|Insupen G34x3,5mm|
46028141|NCT02690467|Device|Insupen G32x4mm|
46028142|NCT02700139|Device|Aspheric lens|By using a special asphericity, MyLens is customized for various prescriptions and vision directions based on specific measurements, intended for myopia correction and control
46028143|NCT05323981|Drug|HS627(210mg/7ml)|Intravenous drip of 420mg HS627
46028144|NCT05323981|Drug|HS627(420mg/14ml)|Intravenous drip of 420mg HS627
46028145|NCT05323981|Drug|Perjeta|Intravenous drip of 420mg PERJETA
46028146|NCT02699827|Drug|Levobupivacaine hydrochloride|Patients will receive epidural 20 ml levobupivacaine hydrochloride 0.5%
46028147|NCT02699827|Drug|Magnesium sulphate|Patients will receive epidural 5 ml magnesium sulphate 10%
46028148|NCT02699827|Drug|Saline 0.9%|Patients will receive epidural 5 ml saline 0.9%
46028149|NCT02700061|Procedure|Robotic occupational therapy|Robotic Occupational Therapy three times a week for twelve weeks.
46028150|NCT02700061|Procedure|Induced Constraint Therapy - ICT|Standard Occupational Therapy two times a week for ten weeks, followed by two whole weeks of Induced Constraint Therapy.
46117477|NCT00728871|Procedure|peripheral blood isolation|To isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
46117478|NCT00736281|Other|Food Drops: Food Allergens (peptides)|The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
46117479|NCT00736437|Drug|ME-609|Cream applied topically 6 times daily over the UVR exposed area
46028151|NCT02705989|Drug|BMS-986195|Specified dose on specified day
46028152|NCT02705989|Other|Placebo|Specified dose on specified day
46028153|NCT00616447|Device|Repetitive transcranial magnetic stimulation|6 weeks of repetitive transcranial magnetic stimulation . Treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of MT, 20 trains, 9 sec/train, 51 sec ITI applied over right dorsolateral prefrontal cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
46028154|NCT00616447|Device|placebo sham|Sham treatment will mimic active treatment mentioned above.
45470992|NCT02121158|Other|Optimal Medical Therapy|Guidance on lifestyle modification, exercise training, and disease management including review of American Heart Association (AHA) Guidelines for Primary Prevention of Cardiovascular Disease and Stroke.
45470993|NCT02111642|Other|Online risk calculator|A new online risk calculator tool has been developed to predict a woman's individual risk of developing de novo stress urinary incontinence after prolapse surgery. This validated tool has been shown to outperform preoperative prolapse reduction stress testing results and expert predictions when providing risk assessment of de novo stress urinary incontinence after vaginal prolapse surgery. After inputting individual patient characteristics, including patient age, body mass index, number of vaginal deliveries, presence or absence of urgency urinary incontinence and diabetes, and prolapse reduction stress testing results if available, this tool calculates the theoretical risk of postoperative de novo stress urinary incontinence both with and without an anti-incontinence procedure.
45470994|NCT01569776|Other|Amino Acid formula|Amino Acid baby formula
46028155|NCT05323747|Other|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with a hydrogel spacer.
46028156|NCT02706067|Drug|Orlistat|Participants will receive orlistat on an intermittent basis as 120 milligrams (mg) three times a day: once with breakfast, once with lunch, and once with dinner. In case of weight relapse (increase 2.5 percent [%] or more from Baseline) orlistat will be administered for up to 2 months or until weight regain reaches 0% from Baseline. For special occasions (feasts, birthdays, anniversaries) orlistat will be given for up to 3 days.
46028157|NCT05323669|Diagnostic Test|Molecular testing|Molecular testing of thyroid nodules
46028158|NCT04215757|Procedure|peripheral nerve block|peripheral nerve blocks with low dose lignocaine in acute radiculopathy
46028159|NCT02699905|Other|phlebotomy|phlebotomy
46028160|NCT02699671|Device|Bioresorbable Vascular Scaffold|
46028161|NCT02941705|Biological|Allogeneic Derived Cells|patients will have the CAP-1002 solution delivered through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
46028162|NCT02941705|Biological|Placebo/Control Arm|patients will receive the placebo through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
46028163|NCT02939287|Drug|Aprepitant|Add aprepitant to anti-emetic regimen
46028164|NCT02939287|Drug|Olanzapine|add olanzapine to anti-emetic regimen
46028165|NCT02939287|Drug|Aprepitant plus Olanzapine|add aprepitant and olanzapine to anti-emetic regimen
46028166|NCT03366649|Procedure|Undersizing Mitral Annuloplasty|Participants will receive a commercially available annuloplasty ring of the surgeon's choice. Sutures are placed around the mitral annulus, and the metallic ring is then implanted onto the mitral annulus to reduce it in size.
46028167|NCT03366649|Procedure|Papillary Muscle Approximation|One or two 4-0 pledgeted sutures are used to draw the two papillary muscle tips together to reduce the inter papillary muscle separation (IPMS) before undergoing undersizing mitral annuloplasty.
46028168|NCT00615277|Dietary Supplement|Omega-3 fatty acids|600 mg EPA 120mg DHA daily, 16 weeks
46117480|NCT00736437|Drug|Vehicle|Treatment applied 6 times daily over the UVR exposed area
46117481|NCT00736515|Drug|Gliclazide MR and Insulin Glargine Injection|Combination therapy of oral administration of 60-120mg Gliclazide Modified Release Tablet once daily before breakfast and subcutaneous injection of Insulin Glargine Injection once daily before dinner (initial dosage 0.2U/KG/D) for 3 months
46028169|NCT05323201|Biological|fhB7H3.CAR-Ts|fhB7H3.CAR-Ts will be transhepatic arterial infused after lymphodepletion. Three dose levels will be evaluated: Dose Level 1 (1×10^6/kg), dose Level 2 (3×10^6/kg) and dose Level 3 (5×10^6/kg). If dose limiting toxicities (DLTs) are observed in each doses, Dose Level -1 (0.5×10^6/kg /infusion) will be evaluated.
46117482|NCT00736515|Drug|Biosynthetic Human Insulin Injection|Monotherapy of subcutaneous injection of Biosynthetic Human Insulin Injection twice daily (before breakfast and before dinner) (initial dosage 0.4-0.6U/KG/D) for 3 months
46117483|NCT00045201|Drug|Erlotinib Hydrochloride|Given orally
46117484|NCT00045201|Drug|Irinotecan Hydrochloride|Given IV
46028170|NCT05323201|Drug|Fludarabine|30 mg/m2 i.v. for 3 consecutive days (Day -5~Day -3)
46028171|NCT05323201|Drug|Cyclophosphamide|750 mg/m2 i.v. for once (Day -5)
46028172|NCT02905825|Device|BreathID® Hp System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
46028173|NCT02905825|Drug|BreathID® Hp Lab System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
46028174|NCT02905825|Diagnostic Test|Stool Test|Each subject was asked to perform a stool test in parallel to the breath test.
46028175|NCT01208051|Drug|Cediranib|Given PO
46028176|NCT01208051|Drug|Cediranib Maleate|Given PO
46028177|NCT01208051|Other|Laboratory Biomarker Analysis|Correlative studies
46028178|NCT01208051|Drug|Lenalidomide|Given PO
46028179|NCT00616837|Other|Telemedicine consultation|Outpatient consultation by help of telemedicine (video conference)
46028180|NCT00616837|Other|Standard care in orthopaedic outpatient clinic|Standard care in orthopedic outpatient clinic (usual care)
46028181|NCT04214041|Other|Autologous fat grafting|A fat graft will be aspirated from the abdomen under local anaesthesia and processed using the Microfat grafting technique. Afterwards the fat graft will be injected in the previously created pouch at the recipient site. Then the pouch will be closed using interrupted sutures 5-0 vicryl.
46117485|NCT00731367|Device|Aquacel Ag Gelled|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
46117486|NCT00731367|Device|Aquacel Ag Adherent|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
46117487|NCT00731445|Drug|Z-208|Oral pills taken daily; 8mg, 12mg, 16mg, 4mg
46117488|NCT00736593|Drug|Nexagon™ or Nexagon™ vehicle|
46117489|NCT02569359|Dietary Supplement|shea nut oil extract|
46117490|NCT02569359|Other|Placebo|
46117491|NCT00731523|Drug|fingolimod (FTY720)|
46028182|NCT04214041|Other|Sub-epithelial connective tissue graft|A subepithelial connective tissue graft of a size that corresponds to that of the defect will be harvested from the palate using the trap door technique. The donor site will be closed using cross horizontal sling sutures and interrupted sutures 4-0 vicryl. Subsequently, the graft will be inserted in the previously created pouch at the recipient site and secured to the flap using vicryl sutures 5-0. Then the pouch will be closed using interrupted sutures.
46028183|NCT04214197|Drug|Crisaborole 2% Top Oint|Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
46028184|NCT04214275|Other|pulmonary rehabilitation|Simple breathing techniques, secretion-removal techniques, airway-cleaning techniques, mobilization techniques and use of an incentive spirometer
46028185|NCT05322889|Drug|Telmisartan tablets|12 weeks treatment
46028186|NCT04214431|Behavioral|Mindfulness-Based Childbirth Education|8-week mindfulness-based childbirth education
46117492|NCT05601531|Procedure|Autologous Tooth Root|An autologous Tooth Root is made from one's own tooth root and covered in an extraction socket where bone graft is placed.
46117493|NCT05601531|Drug|Vit.D3|Local administration of Vit.D3, through the effect of Vit.D3 to explore whether it can help to accelerate the healing of tooth extraction cavity and the clinical effectiveness of bone regeneration.
46117494|NCT05601531|Other|bone graft|Selecting bone materials for alveolar ridge preservation according to treatment needs
46028187|NCT02705521|Device|Exergames- Laptop and MIcrosoft Kinect|Following surgery each patient will have a set of games for them to play using their affecting shoulder. These games have been designed by physiotherapists and shoulder surgeons to improve the functional range of movement in their shoulder
46117495|NCT02569125|Drug|Everolimus|4.5 mg/m² daily
46117496|NCT00731601|Drug|pantoprazole|pantoprazole 40 mg/q6h IV infusion for three days
46028188|NCT00616915|Drug|Wellbutrin XL|Wellbutrin XL 300mg daily
46028189|NCT01207583|Other|Non-interventional observational study|Non-interventional observational study
46117497|NCT00731601|Drug|pantoprazole|pantoprazole 8 mg/h IV infusion for three days
46117498|NCT02568969|Device|Eirus continuous lactate monitor|a triple-lumen central venous catheter (Eirus TLC) functioning as a regular central venous catheter (CVC) with an integrated microdialysis function will be inserted via the left jugular vein for continuous monitoring of lactate and glucose using Eirus intravascular microdialysis system (Maquet Critical Care, Solna, Sweden) after calibration with arterial sample. Eirus TLC will be used for both drug administration and blood sampling and will be removed postoperatively when a central line will no longer be necessary.
46028190|NCT01207427|Drug|Placebo|
46028191|NCT01207427|Drug|ADL5945 0.1 mg|
46117499|NCT02569593|Dietary Supplement|Iron supplements, more specific Ferrodyn and Vista Ferrum|Ferrodyn is an Fe-chelate supplement. One tablet contains 28 mg elemental iron. Vista Ferrum is an iron(II)sulfate supplement. One tablet also contains 28 mg elemental iron. The volunteers will be asked to take the provided supplement orally with 150 mL of water.
46117500|NCT02569281|Other|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon.
46117501|NCT02569281|Other|Eccentric exercise|An eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles will be learned by the patients allocated to this group
46117502|NCT02202681|Device|OFDI Capsule|Imaging of the duodenum with the OFDI capsule and system
46117503|NCT02568813|Behavioral|Multiscore Depression Inventory for Children scale|
46117504|NCT04065633|Drug|P3-Fast|200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions
46117505|NCT04065633|Drug|Comm-Fast|200 mg PF-04965842 commercial tablet formulation under fasted conditions
45470995|NCT01569776|Other|Commercially available Amino Acid Formula|Hypoallergenic Baby formula
45682164|NCT04115241|Other|Grip strength test|The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles
46028192|NCT01207427|Drug|ADL5945 0.25 mg|
46028193|NCT05410223|Drug|Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Yolk antibody: 7g*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
46117506|NCT04065633|Drug|Vari-Fast|200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions
46117507|NCT04065633|Drug|Comm-Fed|200 mg PF-04965842 commercial tablet formulation under fed conditions
46117508|NCT00731835|Procedure|Endovascular Revascularization|"angioplasty, also called percutaneous transluminal angioplasty (PTA) and/or~stent placement~atherectomy"
46117509|NCT03903237|Other|retrospective chart review|retrospective report review of HZ patients treated between 2005 and 2018 in the Department of Dermatology at the University Hospital Basel
46117510|NCT00736905|Drug|TMC278|
46117511|NCT00736983|Drug|adalimumab|24 weeks: 160 mg, 80 mg, and than 40mg every 2 weeks
46117512|NCT00736983|Drug|ciprofloxacin|12 weeks; daily 2 x 500mg
46117513|NCT00713349|Drug|Xenaderm Vehicle|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
46117514|NCT00713349|Other|Placebo comparator|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
46117515|NCT00729261|Procedure|extubation|Brian injured patients that remained intubation solely because of a depressed level of consciousness were randomized into immediate extubation or delayed extubation until their level of consciousness improved.All patients met standard ventilatory, and airway criteria for extubation.
46117516|NCT00729261|Procedure|continued intubation|patients remain intubated until their Glasgow coma scores improve to greater than 8.
46117517|NCT00731913|Other|Absorable, monofilament sutures: Monosyn and Monocryl|Subjects were randomized to Monosyn vs. Monocryl suture arms. The designated skin lesion was removed surgically. The surgical repair of the defect was performed by dividing the wound in half by a single Prolene suture. The appropriate suture was opened by the Study Coordinator and passed sterilely to the surgical technician. The surgical technician loaded the suture, and passed it in a blinded fashion to the physician who closed the appropriate half of the surgical defect. One half of the wound was closed with one suture and the other half was closed with the other suture. Each patient served as their own control, as both sutures were used in each study patient.
46117518|NCT00731991|Other|ART|ART to the levator scapulae.
46117519|NCT00731991|Other|PNF|PNF to the levator scapulae.
46117520|NCT00731991|Other|No Treatment|No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
46117521|NCT00729339|Drug|mosapride for the first month and placebo for the 2nd month|lansoprazole 30 mg once per day for 2 months mosapride 5 mg thrice per day, for the first month placebo thrice per day, for the second month
46117522|NCT00729339|Drug|placebo for the first and mosapride for the second month|lansoprazole 30 mg once per day for 2 months placebo thrice per day, for the first month mosapride 5 mg thrice per day, for the second month
46117523|NCT00737139|Procedure|Peri-articular injection of marcaine/epinephrine|60ml of 0.5% Bupivacaine and Epinephrine 1:200,000 Inj
46117524|NCT00737139|Procedure|Peri-articular injection of marcaine alone|60ml of 0.5% Bupivacaine
46117525|NCT00732147|Drug|Pramlintide acetate|120 micrograms given subcutaneously before each meal X 3.
46117526|NCT00732147|Drug|Placebo|120 micrograms given subcutaneously before each meal x 3.
46117527|NCT00737217|Behavioral|Behavioral assessment/questionnaire|Complete behavioral assessment/questionnaire
46028194|NCT05410223|Drug|IIaprazole, Amoxicillin/Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Ilaprazole: 5mg*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
46028195|NCT05410223|Drug|Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline|"Yolk antibody: 7g*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd."
46117528|NCT00737295|Procedure|CCK Injection and Ultrasound|"All subjects, whether they participate in this study or not, will undergo the HIDA scan as this is the accepted standard of care for diagnosing biliary dyskinesia. If a given subject agrees to participate in this study, he/she will be asked to undergo the following study procedures:~If a pregnancy test has not already been done, a urine pregnancy test will be done for women of childbearing potential.~An intravenous line (IV) will be inserted (if not already in place), and a standard dose of CCK (Kinevac®- 0.02 µg/kg) will then be injected according to the package insert. Ultrasound will be used to measure dimensions of the gallbladder (length, width and height) every minute for 35 minutes following injection of the CCK. This will be done by applying ultrasound jelly to the upper part of the abdomen and ultrasound probe will be used to obtain optimal images for three dimensional analysis of the subject's gallbladder."
46117529|NCT02569671|Device|Straumann Bone Level Tapered Implant - Immediate Placement|Immediate placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
46117530|NCT02569671|Device|Straumann Bone Level Tapered Implant - Delayed Placement|Delayed placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
46117531|NCT02569515|Drug|Epoetin Beta|Initial dose: 3X30 IU/Kg body weight administered subcutaneously using RecoPen. Dosage could be increased by 3X20 IU/Kg every 4 weeks up to a maximum of 720 IU/Kg per week.
46117532|NCT00737373|Drug|Docetaxel|50mg/m2 qd15
46117533|NCT00737373|Drug|5-Fluorouracil|2600mg/m2 qd15
46117534|NCT00737373|Drug|Oxaliplatin|85mg/m2 qd15
46117535|NCT00737373|Drug|folinic acid|200mg/m2 qd15
46117536|NCT02569047|Procedure|Atraumatic Restorative Treatment|No local anaesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Glass Ionomer Cement (GIC).The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed.
45470996|NCT01858922|Drug|ABVE-PC|"Doxorubicin (A) 25mg/m2/day IV over 10min on Day 1 & Day 2~Bleomycin (B) 5units/m2/day IV over 10min on Day 1 10units/m2/day IV over 10min on Day 8~Vincristine (V) 1.4mg/m2/day IV push with extravasation precautions on Day 1 & 8 (Max dose 2.8mg)~Etoposide (E) 125mg/m2/day IV over 1hr at a concentration of </=0.4mg/ml in NS on Day 1, 2 & 3~Prednisone (P) 40mg/m2/day PO divided in 2 doses every day on Day 1-7 IV equivalent of methylprednisolone is acceptable~Cyclophosphamide (C) 800 mg/m2 IV over 1 hr in 200 ml/m2 NS on Day 1"
46117537|NCT02569047|Procedure|Hall Technique|It employs the cementation of preformed metal crowns (PMC) without the need of any prior teeth preparation or caries removal. No local anesthesia is used neither tooth preparation.Different sizes of PMCs will be tested until the smallest size that perfectly fit the tooth is achieved. The PMC will be loaded with the dental material glass ionomer cement (GIC) and placed. Child will asked to bite firmly on it, until it is fitted. The excess of GIC will be removed with hand instruments and dental floss.
46117538|NCT00729495|Drug|celecoxib|dose form
46117539|NCT00737451|Behavioral|blood sampling|blood sampling 10ml from the study subjects
46117540|NCT00737685|Drug|cyclophosphamide, fludarabine , thymoglobulin|cyclophosphamide (50 mg/kg once daily i.v. on days -9, -8, -7 & -6) fludarabine (30 mg/m2 once daily i.v. on days -5, -4, -3 & -2) thymoglobulin (2.5 mg/kg once daily i.v. on days -3, -2 & -1)
46117541|NCT00732459|Device|Electro-acupuncture preconditioning|electro-acupuncture
46117542|NCT00712959|Biological|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 ml, IM
46117543|NCT00712959|Biological|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 mL, IM
46117544|NCT00729729|Drug|PCA|Placebo tablet, once
46117545|NCT00729729|Drug|PCA|PO, 700mg, once
46117546|NCT00729729|Drug|PCA|PO, 1000mg, once
46117547|NCT00732537|Drug|inhaled Nitric Oxide|"iNO started at 20 ppm for 1 hour, then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off). If >5% drop in oxygen saturation was observed during weaning, study gas was increased to the previous concentration and weaning done 2 hourly. If > 5% drop in oxygen saturation or >5% Methemoglobin was observed during initial administration, the study gas would be weaned over 30 minutes and the infant would exit. The iNO was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. Monitoring of O2, NO2, NO was done by placing the end of the sample line inside the oxyhood. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment."
46117548|NCT00732537|Drug|Oxygen (>90% by hood) - standard therapy|"Oxygen (>90% by hood, standard therapy for PPHN prior to intubation) was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. If the baby was randomized to the control group and did not receive NO, the INOmax® cylinder was opened and used only to pressurize the system, which prevented the Low NO Pressure alarm. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment."
46117549|NCT00712725|Drug|MK3207- 2.5 mg|Arm 1: MK3207 2.5 mg taken after migraine onset.
46117550|NCT00712725|Drug|MK3207- 5 mg|Arm 2: MK3207 5 mg taken after migraine onset.
46117551|NCT00712725|Drug|MK3207- 10 mg|Arm 3: MK3207 10 mg taken after migraine onset.
46117552|NCT00712725|Drug|MK3207- 20 mg|Arm 4: MK3207 20 mg taken after migraine onset.
46117553|NCT00712725|Drug|MK3207- 50 mg|Arm 5: MK3207 50 mg taken after migraine onset.
46117554|NCT00712725|Drug|MK3207- 100 mg|Arm 6: MK3207 100 mg taken after migraine onset.
46117555|NCT00712725|Drug|Comparator: placebo (unspecified)|Placebo taken after migraine onset.
46117556|NCT00737763|Drug|efalizumab|Enrollees randomized to efalizumab will receive the first dose of 0.7mg/kg subcutaneously given at enrollment, and 1.0 mg/kg subcutaneously weekly for 26 weeks self or family-administered after injection training. This is the FDA-approved initial and subsequent doses of efalizumab used for psoriasis treatment
46117557|NCT00737763|Drug|placebo|Enrollees receiving placebo will be given a subcutaneous injection of equal volume and appearance to treatment on the same schedule.
46117558|NCT00732693|Drug|Ethinylestradiol / Norethisterone|"Oral ethinylestradiol 30mcg and norethisterone 1.5mg daily for weeks 1-3, followed by 7 pill free days"
46117559|NCT00732693|Drug|Estradiol / Progesterone|Transdermal estradiol 100mcg daily for week 1, then 150mcg daily for weeks 2-4; and vaginal progesterone pessaries 200mg twice daily for weeks 3-4
46117560|NCT00737841|Drug|Bifidobacterium breve|1.0 g of Bifidobacterium breve, taking orally, 3 times a day for 8 weeks.
46117561|NCT00737841|Drug|Placebo|1.0 g of placebo, taking orally, 3 times a day for 8 weeks.
46117562|NCT00732771|Drug|LCI699|
46117563|NCT02568657|Device|Celox group|
46117564|NCT02568657|Device|Bakri Balloon|
46117565|NCT00737919|Dietary Supplement|Plant Stanol|Plant stanols in margarines daily 2 grams
46117566|NCT00737919|Dietary Supplement|Plant Sterol|Plant sterols in margarines daily 2 grams
46117567|NCT00729885|Device|Goggle with 20 degree error|The Vertigone Goggle is modified such that the head positions and visual feedback indicators are offset 20° from the classic Epley positions.
46117568|NCT00729885|Device|Optimized Goggle|The classic Epley maneuver involves 3 head positions: 1) the patient supine, the neck is extended 20°and the head turned 45° towards the affected ear, 2) the patient rotates his head 90° to the contralateral side, with the final head position 45° from vertical, 3) the patient turns his head 135° towards the floor on the contralateral side. For the classic Epley maneuver, the goggle coach ball markings will be set for correct positioning.
46028196|NCT05410223|Drug|IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Ilaprazole: 5mg*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
46028197|NCT04713553|Biological|BNT162b2|Intramuscular injection
46028198|NCT04713553|Biological|BNT162b2.B.1.351|Intramuscular injection
46028199|NCT01206101|Drug|liraglutide|Dose escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide dose for 52 weeks. Injected subcutaneously(under the skin) once daily.
45470997|NCT01858922|Drug|DECA|"Dexamethasone (D):~10 mg/m2 IV over 15 minutes on Day 1 and Day 2, prior to Etoposide/Cytarabine.~Etoposide (E):~100 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with cytarabine*~Cytarabine (A):~3000 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with etoposide*~*Mix together in NS at an etoposide concentration of </=0.4 mg/ml~Dexamethasone eyedrops:~2 drops in each eye 4 times a day on Day 1, Day 2, and Day 3.~Cisplatin (C):~90 mg/m2 over 6 hours in 1000 ml/m2 NS + 10 gram/m2 mannitol on Day 1 as continuous infusion."
46117569|NCT00732849|Drug|Reconvan, Dipeptiven, Omegaven|Reconvan (1ml=1 kcal), 30 kcal/kg b.w. Omegaven 1 ml/ kg b.w. Dipeptiven 1 ml/ kg b.w.
46117570|NCT00729963|Drug|Sibutramine|The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (< 1.8 kg) over the first month of treatment.
46117571|NCT00729963|Device|CPAP|
46117572|NCT00737997|Drug|Morphine|150 mcg/kg diluted in normal saline to a volume of 10 ml at time of induction of anesthesia
46117573|NCT00737997|Other|Saline|10 ml saline alone
46117574|NCT00732927|Drug|parnaparin|vials, 6.400 IU sc twice daily for 7 days, then once daily for a total of 3 months
46117575|NCT00732927|Drug|aspirin|tablets, 100 mg for 3 months
46117576|NCT00733083|Drug|0,1 mg/kg of oxycodone|solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
46117577|NCT00733083|Drug|Morphine 0,1 mg/kg|solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
45470998|NCT01378286|Drug|ARTESUNATE + AMODIAQUINE|"Pharmaceutical form:~Route of administration:"
46117578|NCT00733083|Drug|Dexamethasone 0,5 mg/kg|solution for injection, 0,5 mg/kg, one injection in the beginning of anesthesia
46117579|NCT00733083|Drug|NaCl 0,9%|solution for injection one injection in the beginning of anesthesia
46117580|NCT00738075|Device|Auditory cue|When device recognizes automatically freezing episode it will generate auditory cue
46117581|NCT00712335|Drug|Fluticasone Propionate|DPI 250 mcg BID for 3 weeks
46117582|NCT00712335|Drug|Montelukast|PO 10 mg QHS for 3 weeks
46117583|NCT00712335|Drug|Salmeterol|DPI 50mg BID for 3 weeks
46117584|NCT04065711|Device|Soliton's Rapid Acoustic Pulse (RAP)|Treatment for the temporary improvement in the appearance of cellulite.
46117585|NCT00733161|Other|Passive leg cycle exercise with stretching and resistance training|Passive leg cycle exercise for 15 minutes everyday as well as stretching and resistance training
46117586|NCT00733161|Other|Stretching and resistance training|Stretching and resistance training everyday but no Passive leg cycle exercise
45470999|NCT01378286|Drug|Chloroquine|Pharmaceutical form:tablet Route of administration: oral
46117587|NCT00738621|Drug|Aprepitant, Dexamethasone, Ondansetron|Aprepitant oral 40mg one dose, dexamethasone IV 4mg one dose, ondansetron 4 mg one dose
46117588|NCT00738621|Drug|Aprepitant, Dexamethasone, Placebo|Aprepitant 40mg oral one time, dexamethasone IV 4mg one time placebo one time
46117589|NCT00733239|Drug|2-4 of the drugs listed below|Cycloserine: 500, 675, 750 mg oral capsule may possibly be given Diltiazem: 30, 60, 120 mg oral capsule may possibly be given Gabapentin: 100, 200, 400 mg oral capsule may possibly be given Isradipine: 5, 10 mg oral capsule may possibly be given Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given Nifedipine: 5, 10, 20 mg oral capsule may possibly be given Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given Saline: I.M. injection may possibly be given Verapamil: 30, 60, 120 mg oral capsule may possibly be given
46117590|NCT00738153|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46117591|NCT04065165|Drug|Telotristat Ethyl|250 mg TID orally
46028200|NCT01206101|Drug|placebo|Dose escalation escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide placebo dose for 52 weeks. Injected subcutaneously (under the skin) once daily.
46117592|NCT04065165|Drug|Lanreotide|120 mg Q4W deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh
46117593|NCT00577629|Drug|cyclophosphamide|1.5g/m2 IV over 1 hour on days 1-4 of induction for a total dose of 6.0g/m2
46117594|NCT00577629|Drug|etoposide|300mg/m2 IV over 1 hour every 12 on days 1-3 of induction for a total dose of 1.8 g/m2.
46117595|NCT00577629|Drug|rituximab|375mg/m2 each week x 4 weeks of induction, beginning on day 1
46117596|NCT00577629|Drug|cytarabine|3g/m2 IV over 1 hour every 12 during consolidation for a total of 8 doses
46117597|NCT00577629|Drug|doxorubicin|45mg/m2/day IV over 30 minutes on days 1, 2, 3 during consolidation
45471000|NCT04151420|Other|Remote monitoring tool (infections questionnaire) validation|"There will be no treatment intervention in the current study (no drugs will be used). Instead, patients are enrolled in a routine care eHealth care-pathway with myIBDcoach. MyIBDcoach (MijnIBDcoach, Dutch, Sananet Care B.V., Sittard, The Netherlands, https://www.mijnibdcoach.nl) is a web-based platform for home-monitoring and patient- provider communication in patients with IBD.~Patients already using the myIBDcoach will be informed on this study. Patients will be asked to continue routine care including monitoring of PROs through the myIBDcoach. When a patient completes the infections disease questionnaire for the first time, this will be regarded as the starting point (T=0) for this patient. Patients will complete the questionnaire every three months after the starting point as part of their routine follow-up. Results from these questionnaires will be stored electronically and will be analyzed alongside medical records of GP's and drug delivery data from pharmacies."
46028201|NCT01205165|Drug|Adefor dipivoxil|All enrolled subjects were enrolled to adefovir dipivoxil arm.
46117598|NCT00577629|Drug|tositumomab|450mg unlabeled tositumomab over 1 hour, followed by 5 millicurie (mCi) Iodine I-131 labeled tositumomab over 20 minutes on day 0. Therapeutic dose of labeled tositumomab will be administered on day 15.
46117599|NCT00733317|Drug|0.5 mg/ml budesonide nebules|Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times
46117600|NCT00733317|Drug|Saline|Children will receive 2 ml of saline every 20 minutes for 3 times
46117601|NCT00738231|Behavioral|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
46028202|NCT00997503|Device|TAXUS Liberté Paclitaxel-Eluting Coronary Stent|The TAXUS Liberté Paclitaxel-Eluting Coronary Stent System is a device/drug combination product comprised of two regulated components: a device (Liberté Coronary Stent System) and a drug product (a formulation of paclitaxel contained in a polymer coating).The polymer coating serves as a carrier system to provide uniform and controlled biphasic release of the drug into the vessel wall once the stent is deployed.
46028203|NCT00997503|Drug|prasugrel|10mg or 5mg, oral, once daily as maintenance dose through 30-months following index procedure
46028204|NCT00997503|Drug|placebo|Oral placebo to match both 10mg and 5mg prasugrel tablets.
46117602|NCT00738231|Behavioral|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
46117603|NCT00733395|Dietary Supplement|Tart Cherry Juice|Participants will ingest 10.5 fl oz of cherry juice twice a day for 7 days prior to the race, and the day of the race (8 days total).
46028205|NCT00997503|Drug|aspirin|"Oral, as prescribed by physician through end of study.~."
46117604|NCT00733395|Dietary Supplement|Fruit juice|Participants will ingest 10.5 fl oz of fruit juice twice a day for 7 days prior to the race, and the day of the race (8 days total), which will serve as a 'placebo' juice.
46117605|NCT02568735|Drug|Dexketoprofen|After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
46117606|NCT02568735|Drug|Etoricoxib|After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
46117607|NCT00733473|Drug|Budesonide 0.5 mg/ml nebules|Children will receive 1 mg nebulized budesonide 2 times a day up to 5 days
46117608|NCT00733473|Drug|% 0.9 Saline solution|Children will receive 2 ml of nebulized saline 2 times a day up to 5 days
46117609|NCT00733551|Drug|GSK962040|GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.
46117610|NCT00733551|Drug|Placebo|Placebo tablets will be given orally, once daily, in the morning, in a fasted state.
46117611|NCT00710385|Drug|Heroin|Heroin (25 mg)
46117612|NCT00710385|Drug|Naloxone|.4 mg
46028206|NCT02705443|Other|No Intervention|Standard of Care Only
46028207|NCT02705053|Device|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump.
45471001|NCT01378208|Behavioral|Intermittent fasting - the effect on glucose metabolism, body composition and cognitive function|"Each of the 10 subjects must through a period of monitoring (four weeks) before the study period (four weeks). Before, during, and after both the monitoring period and the study period, the subjects will undergo tests at Rigshospitalet.~DAY 1: Inclusion and exclusion of subjects DAY 1 to DAY 28: Monitoring period (usual lifestyle)~28 days of dietary monitoring~28 days measurement by pedometer DAY 1, DAY 28 & DAY 56: Test 1~Oral glucose tolerance test with stable isotopes~Fat and muscle biopsies DAY 2, DAY 29 & DAY 57: Test 2~DXA scanning~Resting Metabolic Rate Measurement~VO2max test on bicycle~Cognitive testing~MRI of the brain and abdomen DAY 9, DAY 19, DAY 38 & DAY 48: Test 3~Actiheart for 3 days~72-hour blood glucose monitoring with CGMS System DAY 29 to DAY 57: INTERVENTION~Fasting from 7am - 9pm~28 days of dietary monitoring~28 days measurement by pedometer"
46117613|NCT00710385|Drug|Low Bup Dose|4 and 8 mg
46117614|NCT00710385|Drug|High Bup Dose|8mg and 16 mg
46117615|NCT00710385|Drug|Low Bup/Nal Dose|Buprenorphine/Naloxone 4/1 mg, 8/2 mg
46117616|NCT00710385|Drug|High Bup/Nal Dose|Buprenorphine/Naloxone 8/2 mg, 16/4 mg
46117617|NCT00710385|Drug|Placebo (PCB)|Placebo control administration
46117618|NCT04063605|Other|Clinical Pilates|This exercise model focus on the awareness of the neutral position of the spine and strengthen the deep postural muscles of the spine. Training of trunk muscles is emphasized and trunk stabilization is achieved and more difficult activities are initiated and thus, body awareness is improved. There are general principles to be followed during exercises. These; The principle of concentration is respiration, central focus, control, stability and isolation. These principles are achieved by simultaneous muscle activation of muscles responsible for trunk stabilization (multifidus, diaphragm, transversus abdominis and pelvic floor muscles). In order for an exercise to become a clinical pilates exercise, trunk stabilization must be ensured and breath control should be established in each exercise.
46117619|NCT04063605|Other|Classic Physiotherapy|This exercise program will include strengthening, stretching, posture exercises, balance and gait exercises. Aim is to improve muscle strength and prevent shortness of muscles. Also, balance and gait exercise aim to improve walking capacity.
45471002|NCT05762666|Device|nociception level index monitor|The nociception level index (NOL) is one of the new electrophysiological devices to asses pain-related nociception and differs with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives)
46117620|NCT04063527|Drug|adjuvant chemotherapy|combination of paclitaxel and carboplatin
46117621|NCT00738777|Drug|Anastrozole|1 mg,QD,PO
46117622|NCT00738777|Drug|Anastrozole+Fulvestrant|Anastrozole; 1 mg, QD, PO Fulvestrant; 500 mg, IM, day 1, 15, 29 and monthly thereafter
46117623|NCT00738777|Drug|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
46117624|NCT00738777|Drug|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
46117625|NCT03901443|Other|Survey on itch|self-administered patient questionnaire regarding the different aspects of itch
46028208|NCT02705053|Device|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:~DiAs - a smart-phone medical platform; Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)"
46028209|NCT01204775|Drug|Saxagliptin|Tablets, Oral, 2.5 mg or 5.0 mg (according to body weight category), Once Daily, 1-52 weeks
46028210|NCT01204775|Drug|Placebo (Saxagliptin)|Tablets, Oral, Once daily, 1-16 weeks
46028211|NCT01204775|Drug|Metformin IR|Tablets, Oral, 500 mg, Once Daily, 17-52 weeks
46117626|NCT00733707|Behavioral|Text messaging reminders|Subjects in this arm will receive daily text message reminders once per day at the same time each day. Messages will remind the subject to take their oral contraceptive pill.
46117627|NCT00733785|Drug|Rosiglitazone XR|Rosiglitazone extended release formulation
46117628|NCT00738855|Other|Oral Gastrografin|100 ml of the dye administered through a nasogastric tube
46117629|NCT00738855|Other|Nothing per os|A nasogastric tube
46117630|NCT00738933|Dietary Supplement|Dietary plant stanols|Daily 2 grams of plant stanols in a margarine preparation for 4-8 weeks before the operation
46117631|NCT00738933|Dietary Supplement|Dietary plant sterols|Daily 2 grams of plant sterols in a margarine preparation for 4-8 weeks before the operation
46117632|NCT00738933|Dietary Supplement|placebo|Margarine product without plant stanol or sterol esters
46117633|NCT05740917|Drug|XZB-0004|XZB-0004 orally Twice daily of every 28-day cycle
46117634|NCT05529459|Procedure|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
46117635|NCT03898713|Diagnostic Test|Intelligence quotient|intelligence quotient (IQ) is a total score derived from several standardized tests designed to assess human intelligence
46117636|NCT00739011|Device|SleepStyle 254/244 CPAP series CPAP humidifier|Therapeutic CPAP pressure will be determined for individual subjects during the titration portion of an overnight sleep study. This pressure will range from 4 to 20 cmH20
46117637|NCT05740761|Other|Gene editing in vitro|Testing of gene editing efficiency in vitro in human cellular models derived from patients
46117638|NCT00701415|Biological|Agalsidase beta|Powder for concentrate for solution for infusion 1.0 mg/kg/4 weeks
46117639|NCT00701415|Biological|Agalsidase beta|Powder for concentrate for solution for infusion 0.5 mg/kg/2 weeks
46028212|NCT01204775|Drug|Placebo (Metformin)|Tablets, Oral, Once daily, 1-16 weeks
46028213|NCT01204775|Drug|Metformin (Active Rescue)|Tablets, Oral, 500 mg, Titrated as needed, 2-52 weeks
46117640|NCT04063449|Drug|endostar/PD-1 inhibitor|Antiangiogenic therapy plus immunotherapy and chemotherapy
46117641|NCT04063449|Drug|endostar|Antiangiogenic therapy plus chemotherapy
46117642|NCT04062747|Device|I-gel|After standard anesthesia i-Gel was placed into the patient
46117643|NCT04062747|Device|Ambu aura i|After standard anesthesia ambu aura was placed into the patient
46117644|NCT00700011|Drug|Clofarabine|10 mg/m2 x 5 days per 4 to 6 week cycles
46117645|NCT00700011|Drug|Clofarabine|5 mg/m2 x 5 days per 4 to 6 week cycles
46117646|NCT05740683|Diagnostic Test|RT-QuiC|RT-QuIC measures the ability of aSyn to misfold other aSyn proteins and is an amplification technique.
46117647|NCT04064541|Other|Virtual Visit|Virtual Visit
46117648|NCT05512767|Other|Best Practice|Undergo self-manual lymphatic drainage
46117649|NCT05512767|Other|Consensus Auditory-Perceptual Evaluation of Voice|Ancillary studies
46117650|NCT05512767|Procedure|Diagnostic Imaging|Undergo photographs of face and neck
46117651|NCT05512767|Other|Lymphedema Management|Undergo skilled lymphedema treatment by a therapist
45682165|NCT04775134|Diagnostic Test|Lung biopsy|Biopsy of residuary material from a medically indicated pulmonary resection
46117652|NCT05512767|Procedure|Modified Barium Swallow|Undergo swallow study
46117653|NCT05512767|Procedure|Nasopharyngeal Laryngoscopy|Undergo Nasolaryngoscopy
45682166|NCT01870076|Behavioral|Healing Touch|
46028214|NCT02705131|Device|Balance Chiropractic Therapy|patients are in the sitting position and receive the following treatments.1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.
46028215|NCT02705131|Device|Traction Therapy|patients will received the traction therapy.The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
46117654|NCT05512767|Device|Pneumatic Compression Therapy|Undergo compression therapy - Flexitouch Plus System is an advanced pneumatic compression device (APCD) that consists of a 2-piece garment that provides systematic and sequential pressure changes to move fluid to intact lymphatic chains.
46117655|NCT05512767|Other|Quality-of-Life Assessment|Ancillary studies
46117656|NCT05512767|Other|Questionnaire Administration|Ancillary studies
46117657|NCT05512767|Other|Voice Handicap Index-10|Ancillary studies
46117658|NCT05740527|Device|Noninvasive electrical stimulation of genital nerves|A closed-loop system (in-bladder sensor, radio, algorithm, and stimulator) is being tested for the feasibility of inhibiting neurogenic bladder overactivity in an ambulatory setting.
46117659|NCT04063293|Biological|Platelet Rich Plasma|PRP injection into tha anal canal in patients underwent low anterior resection for rectal cancer
46117660|NCT04064385|Device|FES Cycling|Stimulation parameters will be 450μs, 40Hz, and up to 140mA, these values will be changed if needed based on individual response. For example, stimulation to the gluteal muscles often may to be decreased to prevent autonomic dysreflexia. To receive correct stimulation parameters, stimulation intensity will be chosen to ensure a palpable muscle contraction and sensor tolerance. Each session will include a 2-minute warm-up and 2-minute cool-down of passive cycling. The unit automatically delivers enough stimulation to maintain a speed of 30 rotations per minute (rpm). Where this is not achieved, the leg cycle will assist the stimulated movement to maintain a speed of 30 rpm.
46117661|NCT04063059|Behavioral|PRIDE counseling intervention|Step-by-Step program to create positive lifestyle change geared toward wellness and long term healthy living through group sessions and telephone counseling.
46028216|NCT04295733|Biological|4CMenB (Bexsero®) vaccine|Participants will receive 2 doses of 4CMenB (Bexsero®) vaccine administered intramuscularly 1-2 months apart
46117662|NCT02567955|Biological|Immunogenicity two doses of Gardasil-9|Subjects will receive two standard doses of Gardasil-9 (0.5 ml)
46117663|NCT02567955|Biological|Immunogenicity Cervarix and Gardasil-9|Subjects will receive a standard dose of Cervarix (0.5 ml) and a standard dose of Gardasil-9 (0.5 ml)
45471003|NCT05762588|Device|Juggerknot with Broadband tape|The JuggerKnot system is comprised of a coreless sleeve structure and suture. The anchors are intended for use in soft tissue to bone fixation by bunching against the bone when deployed. The anchor sleeve material is polyester. Suture materials are ultra-high molecular weight polyethylene. The device has 510K FDA clearance.
46117664|NCT00739479|Dietary Supplement|Weight Loss|Participants will reduce their total dietary intake by ~800 kcal/day. ~100 kcal will be replaced by either the PHWP of PHG protein supplement, resulting in a total energy restriction of ~700 kcal/day.
46117665|NCT04062903|Behavioral|Immediate Appointment|The participant will meet with the MIND Cymru link worker and decide upon a course of action requiring the use of local services appropriate for the participant.
45471004|NCT01377974|Drug|Miltefosine|1 Capsule of 50mg, taken orally 2 times a day for 28 days
46117666|NCT04062903|Behavioral|Delayed appointment|After a period of delay (Control) The participant will meet with the MIND Cymru link worker and decide upon a course of action requiring the use of local services appropriate for the participant.
46117667|NCT05740293|Procedure|VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism|Bilateral treatment with the approved VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism.
46117668|NCT02568423|Drug|Mirikizumab - IV|Administered IV
45471005|NCT01377974|Drug|Standard Treatment Meglumine antimoniate|20mgKg daily intravenous Meglumine antimoniate as oriented by the Brazilian Ministry of Health
45471006|NCT04929080|Biological|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|200mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
45471007|NCT04929080|Biological|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|600mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
45471008|NCT04929080|Biological|JS001 and JS004|Part B: 100mg JS004 + 240mg JS001 or 200mg JS004+ 240mg JS001
45471009|NCT04838990|Other|EDSS|Neurological Exam - EDSS (Expanded Disability Status Scale)
45471010|NCT04838990|Other|Discussion of symptoms, Patient reported outcome (MSIS)|Patients will be asked about their wellbeing
45471011|NCT05202548|Other|Immuno-histochemical staining|blocked paraffin that suit with inclusion and exclusion criteria proceed with immuno-histochemical staining to define immune dysregulation in lymphadenitis TB
46028217|NCT02844907|Drug|Exendin (9-39)|Upon establishing a hyperglycemic clamp (target blood glucose at basal +3 mM) Exendin (9-39) will be infused.
46117669|NCT02568423|Drug|Mirikizumab - SC|Administered SC
46117670|NCT02568423|Drug|Placebo - IV|Administered IV
46117671|NCT02568423|Drug|Placebo - SC|Administered SC
46117672|NCT00921063|Drug|PD 0332334|250 mg capsule, BID for 4 weeks
46117673|NCT00921063|Drug|PD 0332334|100 mg capsule, BID for 4 weeks
46117674|NCT00921063|Drug|placebo|0 mg capsule, BID for 4 weeks
46117675|NCT00921063|Drug|Alprazolam extended release|1 mg capsule, BID for 4 weeks
46117676|NCT05738811|Other|TENS treatment protocol|The 2 sets of electrodes of TENS would be placed over the common peroneal nerve as it passes over the head of fibula and the motor point of tibialis anterior to elicit dorsiflexion and eversion of foot.
46117677|NCT05738811|Other|EMS treatment protocol|The electrodes would be placed over the common peroneal nerve as it passes over the head of fibula and the motor point of tibialis anterior to elicit dorsiflexion and eversion of foot. A portable comfy EMS channel would be used to apply EMS protocol to set at threshold of muscle contraction level.
46117678|NCT05738811|Other|Exercises|Patient would be given 30 minutes treatment session, 10 minutes of supported walking 10 minutes of BWS treadmill training 10 minutes of Task-specific over ground locomotor training (LT) There would be rest of 2 minutes The frequency of the sessions would be five times a week for 12 weeks.
46117679|NCT00707031|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
46117680|NCT00707031|Device|Pen auto-injector|
46117681|NCT00707031|Drug|Exenatide|Self administered by subcutaneous injections twice daily within the hour preceding breakfast and within the hour preceding dinner.
46117682|NCT00707031|Device|Prefilled pen injector|
45471012|NCT05762510|Genetic|GMCN-508B (LentiRed)|LentiRed Drug Product is administered by intravenous infusion following myeloablative conditioning with busulfan.
45682167|NCT01870076|Behavioral|Healing Touch, Sham|
45682168|NCT01870076|Behavioral|Control, Presence|
46028218|NCT02844907|Drug|Dexamethasone|Between Visit-2 and Visit-3, Dexamethasone (4 mg tablet) once daily for 5-7 days.
46028219|NCT02844907|Other|Hyperglycemic Clamp|A variable infusion of 20% dextrose will begin to clamp the blood glucose at basal +3 mM.
46028220|NCT00628719|Drug|Liposomal Amphotericin B|a single dose of 10 mg/kg of liposomal amphotericin B
46028221|NCT00628719|Drug|amphotericin B deoxycholate|amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
46028222|NCT00616993|Drug|Difluprednate|Difluprednate
46028223|NCT00616993|Other|Placebo|Vehicle
46117683|NCT00707031|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
46117684|NCT00739635|Drug|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
46117685|NCT00739635|Drug|Placebo|Double-blind treatment period of 17 weeks placebo
45682169|NCT01592721|Biological|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
46117686|NCT00739713|Dietary Supplement|Sea buckthorn (Hippophaë rhamnoides) oil|Dosage 2 g/d, frequency twice/d, duration 3 months
46117687|NCT00739713|Dietary Supplement|Placebo comparison|Placebo comparison, dosage 2 g/d, frequency twice/d, duration 3 months
46117688|NCT00739791|Behavioral|exercise intervention|
46117689|NCT00739791|Genetic|gene expression analysis|
46117690|NCT00739791|Genetic|polymerase chain reaction|
46117691|NCT00739791|Genetic|proteomic profiling|
46117692|NCT00739791|Genetic|reverse transcriptase-polymerase chain reaction|
46117693|NCT00739791|Other|laboratory biomarker analysis|
46117694|NCT00739791|Other|medical chart review|
45682170|NCT02125396|Other|Transarterial chemoembolization|Adjuvant transarterial chemoembolization [5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)]
46117695|NCT00739791|Other|questionnaire administration|
46117696|NCT00739791|Procedure|psychosocial assessment and care|
46117697|NCT00739791|Procedure|quality-of-life assessment|
46117698|NCT00739791|Procedure|support group therapy|
46117699|NCT00739791|Procedure|therapeutic dietary intervention|
46117700|NCT02568579|Procedure|blood sample/ stool sample|blood sample to be done when possible with standard of care lab draw. Stool sample to be collected monthly at home.
46117701|NCT05388825|Drug|TPN171H 2.5mg|TPN171H 2.5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
46117702|NCT05388825|Drug|TPN171H 5mg|TPN171H 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
46117703|NCT05388825|Drug|TPN171H 10mg|TPN171H 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
46117704|NCT05388825|Drug|Placebo 5mg|Placebo 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
46117705|NCT05388825|Drug|Placebo 10mg|Placebo 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
46117706|NCT00711477|Drug|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
45682171|NCT02125396|Other|Radiotherapy|Adjuvant radiotherapy is used for postoperative curative HCC
45682172|NCT01613378|Other|No intervention|No intervention administered in this study
46028224|NCT02870361|Drug|intranasal insulin|
46028225|NCT02870361|Drug|Placebo|
46028226|NCT00617071|Other|medical chart review|
46028227|NCT00617071|Other|survey administration|
46028228|NCT00617071|Procedure|fecal occult blood test|
46028229|NCT00617071|Procedure|screening colonoscopy|
46028230|NCT00616681|Drug|Oxcarbazepine|
46117707|NCT00711477|Drug|Placebo|
46117708|NCT00711477|Other|fMRI scan|fMRI to assess the effects of the drug/placebo on areas of the brain
46117709|NCT05372913|Device|W-GenZD Mobile Application|"W-GenZD is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need."
46028231|NCT00997035|Drug|Voriconazole|"1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing <40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment."
46117710|NCT05372913|Behavioral|CBT-Light Teletherapy|The CBT-Light teletherapy group is a brief, 4-week intervention held once weekly for an hour, and limited to those triaged into the Children's Hospital of the King's Daughters low-intensity track and participating in this protocol. An assigned study clinician will facilitate each teletherapy group with approximately 10 adolescents in each session. Each group begins with orientation and reviewing group rules, individual check-ins with each participant (rating stress level and hopefulness), followed by a guided mindfulness moment. Sessions are designed to draw from elements of cognitive behavioral therapy (CBT) and the 4 topics include: building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.
46117711|NCT00739947|Other|Observational study of the surgical outcome|Subjects return for 7 follow-up visits following arthroscopic repair of their rotator cuff. During the follow-up visits subjects undergo imaging with MRI and ultrasound.
46117712|NCT00734474|Drug|LY2189265|
46117713|NCT00734474|Drug|Sitagliptin|
45471013|NCT05202236|Drug|pemigatinib|The patients will receive 13.5 mg (1 pill/time) of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen, with 21 days as a cycle. They should take pemigatinib at regular times of the day to avoid the effects of inconsistent timing on plasma concentrations.
46117714|NCT00734474|Drug|Placebo solution|
46117715|NCT00734474|Drug|Placebo tablet|
46117716|NCT00734474|Drug|Metformin|
45471014|NCT03071276|Drug|Selinexor|Given orally on days 1,3,8,10,22 and 24 of each cycle
45471015|NCT03071276|Drug|Fludarabine|Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
45471016|NCT03071276|Drug|Cytarabine|Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
45754566|NCT03581162|Diagnostic Test|Carotid Ultrasound and venous blood sampling|Carotid ultrasound and blood sampling
46028232|NCT00997035|Drug|Placebo|"1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment."
46028233|NCT00617149|Behavioral|Supervised exercise for the prevention high weight gain|Each session starts with ca 5 minutes warm up, followed by 30 minutes of aerobic activity, including cool down. This is followed by 15 minutes of strength training of the upper and lower limbs, and special focus on the deep abdominal stabilization muscles. The last 5 minutes contains stretching, relaxation and body awareness exercises. The exercise-program follows the ACOG exercise prescription, and all aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate), measured by ratings of perceived exertion at 11-14 (somewhat hard) on the 6-20 Borg's rating scale. Control-participants are neither encouraged nor discouraged from exercising.
46028234|NCT01204697|Drug|docetaxel|75 mg/m2 intravenously every 3 weeks for 4 cycles
46028235|NCT01204697|Drug|erlotinib [Tarceva]|150 mg/day orally, days 2-16 each 3-week cycle for 4 cycles; 150 mg/day orally thereafter
46028236|NCT01204697|Drug|erlotinib [Tarceva]|150 mg/day orally as monotherapy
46028237|NCT02705209|Other|Cayenne Pepper Cataplasm|Poultice of Kaolin, Cayenne Peppfer (5%) and Water
46117717|NCT00583362|Biological|Belimumab|Belimumab 10mg/kg IV over one hour every 28 days
46117718|NCT00577473|Drug|mesalamine|mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
46117719|NCT00577473|Drug|mesalamine|mesalamine 4.8 g/day (800 mg tablet) for 6 weeks
46117720|NCT00740103|Drug|Semapimod|60 mg IV x 3 days q 6 - 8 weeks
46117721|NCT05722665|Other|Categorization of chest xrays images|Use of Convolutional Neural Network Model to categorize chest xrays images in each group.
46117722|NCT02583828|Drug|Cyclophosphamide 50mg|
46117723|NCT02583828|Drug|Letrozole 2.5 mg|
46117724|NCT02568111|Drug|peginterferon beta-1a|SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29
45471017|NCT03071276|Drug|methotrexate/hydrocortisone/cytarabine|Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
46028238|NCT02705209|Other|Placebo Cataplasm|Poultice of Kaolin and Water
46028239|NCT01001325|Biological|Fluviral influenza vaccine, 2009-2010|0.5 mL intramuscular
46028240|NCT01001325|Biological|Normal saline|0.5 mL intramuscular
46117725|NCT02568111|Drug|brimonidine tartrate|Applied to injection site as specified in the treatment arm. Commercially available Mirvaso (Brimonidine tartrate) gel will be provided by Galderma.
46117726|NCT02568111|Drug|Vehicle Gel|Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma.
46117727|NCT05711667|Procedure|Biospecimen Collection|Undergo collection of blood samples
46028241|NCT02968459|Other|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1*10^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
46028242|NCT02968459|Other|0.9% Saline|Participants will receive direct local intramuscular injection 1ml of 0.9% saline in the uterine incision.
46117728|NCT05711667|Drug|Letermovir|Given PO or IV
46117729|NCT04384692|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
46117730|NCT04384692|Drug|Busulfan|Given IV
46117731|NCT04384692|Drug|Cyclophosphamide|Given IV
46117732|NCT04384692|Drug|Fludarabine|Given IV
46117733|NCT04384692|Drug|Melphalan|Given IV
46117734|NCT04384692|Drug|Methotrexate|Given IV
46117735|NCT04384692|Drug|Mycophenolate Mofetil|Given IV or PO
46117736|NCT04384692|Drug|Ruxolitinib|Given PO
46117737|NCT04384692|Drug|Tacrolimus|Given IV and PO
46117738|NCT04384692|Radiation|Total-Body Irradiation|Undergo TBI
46117739|NCT00785291|Biological|Bevacizumab|Given IV
46117740|NCT00785291|Drug|Ixabepilone|Given IV
46117741|NCT00785291|Other|Laboratory Biomarker Analysis|Correlative studies
45471018|NCT03629600|Drug|Lactated Ringer|High-volume Lactated Ringer Solution
46028243|NCT02870595|Device|Microvibratory Stimulator|Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.
46028244|NCT02870595|Device|Microvibratory Stimulator'|As above, Microvibratory Stimulator will be used as a sham device in parallel group.
46028245|NCT02704975|Device|Rehabilitation and Dry Needling|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months. Subjects in this group will also receive dry needling as an adjunct intervention. Dry needling treatment will be performed one time a week for four weeks and will begin four weeks post-operative.
46028246|NCT02704975|Device|Rehabilitation|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months.
46117742|NCT00785291|Drug|Nab-paclitaxel|Given IV
46117743|NCT00785291|Drug|Paclitaxel|Given IV
46117744|NCT00785291|Other|Questionnaire Administration|Ancillary studies
46117745|NCT04063137|Dietary Supplement|Anthocyanin fortified bread with beef patty (35% fat)|Bread is fortified at a 4% level using 25% (w/w) anthocyanin black rice extract. It is served with a beef patty (35% fat) to simulate a high-fat diet.
46117746|NCT00705939|Drug|Taliglucerase alfa|Intravenous infusion every 2 weeks
46117747|NCT02568891|Dietary Supplement|Probiotic|multispecies probiotic
46117748|NCT02568891|Dietary Supplement|Placebo|matrix
46117749|NCT00740259|Drug|Flunarizine|For 1 week, 40 mg/day. From week 2 to 3, 20 mg/day. Form week 4 onwards, dosage increment or reduction of 10mg/day was allowed according to efficacy and tolerability.
46117750|NCT04079010|Procedure|BFR|Blood flow restriction (BFR) training is a non-invasive technique that uses wraps, bands, or inflated blood pressure cuffs to change blood flow within targeted muscles. Occlusion pressure of the femoral artery will be determine before each training session using the Delfi Personalize Tourniquet System for Blood Flow Restriction (2.0) which has embedded ultrasound technology to continually measure the blood flow and with auto-adjust the pressure. The target percent of occlusion is 50% of total blood flow while completed a prescribed resistance training regimen 4 times per week.
45471019|NCT03629600|Drug|Rectal Form Indometacin|Post-ERCP rectal administration of 100 MG Indomethacin
45471020|NCT04804904|Drug|TQ-B3101|TQ-B3101 oral capsule
46117751|NCT04079010|Dietary Supplement|Arginine|"The BFR+Arg group will consume Arginine supplement daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg L-Arginine (ARG; Kyowa). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide."
46117752|NCT04079010|Dietary Supplement|Placebo Pill|"The CON and BFR groups will consume placebo pill daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg Maltodextrin placebo (PLA; MALTRIN-M100; Grain Processing Corporation; Muscantine, IA). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide."
46117753|NCT04555161|Device|Aria CV Pulmonary Hypertension System|The Aria CV PH System is indicated for the treatment of adult patients with World Health Organization (WHO) Group I Pulmonary Arterial Hypertension who remain symptomatic despite treatment with optimal medical therapy.
46117754|NCT05541029|Behavioral|Live music|Live Music. A board-certified music therapist will provide live music (singing with instrument accompaniment) of child preferred songs, per caregiver report, with the tempo entrained to the child's respiratory rate at intervention start and decreased as needed to facilitate relaxation, with a target tempo of 60-80 beats per minute (BPM). Song choices will be based on patient preferences, per caregiver report, and performed with relaxing characteristics (steady rhythm and volume)
46117755|NCT05541029|Behavioral|Recorded music|Recorded Music. MP3 players will be loaded with a recorded music playlist of the child's preferred songs, per caregiver report, and connected to two small speakers that are to be placed at either side of the head of the bed. Speakers will be tested with sound level meter and volume control set at 50-60 decibels. A member of the study team will stay at bedside throughout the recorded music condition. Study team member will log time of session and complete a checklist with open-response option to note relevant information (e.g., Session interruptions from other staff).
46117756|NCT05541029|Other|Usual care|Usual Care. A pharmacologic approach to ameliorating stress and pain in MV children is standard of care in CHP's PICU. CHP provides weight-based guidelines to aid clinical decisions on medications for sedation and analgesia. Bedside nurses assess the child's sedation and pain scores once an hour and administered PRN medications as needed, based on clinical judgement, using CHP's PICU weight-based guidelines. For example, if a child has a pain score of >1-2 above goal, guidelines suggest providing a fentanyl dose of 0.5 mcg/kg and assessing again in 1 hour. We will include usual care as a third condition to explore how our selected biomarkers vary over 20 min. without the addition of any musical stimuli. A member of the study team will stay at bedside throughout the usual care condition. Study team member will log time of session and complete a checklist with open-response option to note relevant information (e.g., Session interruptions from other staff).
46028247|NCT01203917|Drug|Gefitinib|250mg tablet oral, once daily until objective disease progression is documented or until other discontinuation criterion is met
45471021|NCT04801550|Device|Millimeter waves local exposure|several blocks of somatosensory evoked potentials with or without Millimeter waves local exposure
46028248|NCT02704741|Device|CO2RE|The CO2RE system device is intended for dermatological procedures requiring ablation, coagulation and resurfacing of soft tissue, including skin
46028249|NCT02704819|Other|Decision Support System (DSS)|"The EMBalance DSS is a program which summarises and structures clinical information. The structuring of medical information is based on algorithms that have been developed and are employed via the DSS platform. The non-specialist doctors who use the DSS will be asked to exercise their clinical judgement in order to come up with a diagnosis or management plan. The DSS use has the following characteristics:~Doctors can pace the process anyway they see fit (e.g. by switching from history taking to examination, stopping at any point, or going back to medical history) or by stopping the process entirely.~Although the EMBalance platform will propose 2-3 diagnosis (with probability estimation for each), doctors will be asked to either choose one of these or discard and choose their own."
46028250|NCT02704819|Other|Specialist Audiovestibular Consultation|"After the initial appointment with the non-specialist doctor, all patients will be invited to attend a specialist neuro-otology clinic where they will be seen by an overseeing expert in order to undergo a Gold Standard diagnostic process, and determine the management plan appropriate to the diagnosis, which will be compared to the management plan previously advised by the non-specialist doctor. The overseeing expert will review investigations carried out, results assessed by the non-specialist doctor."
46028251|NCT02704819|Other|DSS Customised Vestibular Physiotherapy|"Customised vestibular exercise programme suggested by the DSS. Such exercises are based on the eye, head, and postural exercises that provoke a patient's symptoms.~Adaptation exercises incorporating gaze fixation and head movements and postural exercises are prescribed to promote recovery of the vestibule-ocular reflex (VOR) and vestibulo-spinal reflex function. Up to 5 exercises will be practised by the patient at home for approximately 1-2 minutes each, twice daily initially at a slow speed which gradually increases as symptoms improve.~Patients presenting vestibular migraine will perform a maximum of three exercises. These exercises will be chosen by the DSS from a range of established exercises and chosen according to the patient's symptoms when performing the exercise/type of movement."
46028252|NCT02704819|Other|Standard Physiotherapy Practice|Patient will be referred to a local physiotherapy service by his/her non-specialist doctor within 18 weeks from referral. Standard vestibular rehabilitation practice consists of a customised exercise programme, this is service dependent and tailored for patient's symptoms. The rehabilitation programme might include lifestyle advice and education, sometimes accompanied by a leaflet.
46028253|NCT02704819|Other|Follow-up|All patients will be reviewed after three months follow-up by the overseeing expert.
46028254|NCT04318379|Biological|HCVax|HCVax is a lentiviral vector encoding several HCV antigens
46028255|NCT04213651|Other|No intervention|There is no intervention for this study
46028256|NCT04213495|Other|Anesthesia|Patients undergoing anesthesia from the cooperating Anesthesia center
46028257|NCT02688517|Other|Cytology Specimen Collection Procedure|Undergo collection of blood samples
46028258|NCT02688517|Other|Laboratory Biomarker Analysis|Correlative studies
46028259|NCT04318223|Drug|Palbociclib|Patients will be enrolled into the study and assign to receive Palbociclib 125 mg/day orally for 3 weeks followed by 1 week off plus fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, every 28 days (+/- 7 days) thereafter starting from Day 1 of Cycle 1
46028260|NCT02676349|Drug|mFolfirinox|oxaliplatin folinic acid irinotecan 5FU oxaliplatin
46028261|NCT02676349|Radiation|Chemoradiotherapy|conformational external irradiation (50.4 Gy) + capecitabine
46028262|NCT02676349|Procedure|surgery|1 to 4 weeks after neoadjuvant treatment according to tumour response
46028263|NCT02676349|Drug|Adjuvant chemotherapy|Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)
46028264|NCT02704897|Other|Wound Assessment Tool|A set of questions relating to the symptoms of wound infection
45471022|NCT04800068|Diagnostic Test|[Ga-68] PSMA-11 PET/CT|Imaging scan
46117757|NCT02581878|Drug|BAY1862864|Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg.
46117758|NCT04109651|Other|Nursing intervention|"Nursing Intervention: This intervention was planned based on Meleis' Transition Theory. So it includes individual counseling and training.~In the Health Promotion Monitoring Program; three training modules and one reminder module were implemented and telephone counseling was provided. Various training tools were used in these trainings. Three different power point presentations were made during the training sessions. Illustrated printed training material was used. At the end of the training, training booklet was given to the participants."
46117759|NCT04936308|Drug|Guselkumab|Participants will receive guselkumab as SC injection.
46117760|NCT04936308|Drug|Placebo|Participants will receive matching placebo as SC injection.
46028265|NCT01202903|Drug|Omalizumab|The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.
46028266|NCT01202903|Drug|Placebo|The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection.
46028267|NCT01001169|Biological|GSK Biologicals' Pandemic influenza (H1N1) candidate vaccine (GSK2340274A)|Two intramuscular injections
46028268|NCT00618631|Drug|Nicotine|
46028269|NCT00618631|Drug|Carfentanil|
46028270|NCT01202747|Device|LipiFlow System|In-office treatment for meibomian gland dysfunction
46028271|NCT04213339|Behavioral|Kegel Exercises|"Kegel exercise group will get exercise within duration of 3 to 6 weeks based on age factor. Kegel exercise can be performed at any time and at any place without any restrictions.~following steps will be followed by kegel exercises group members:~Tighten and hold pelvic floor muscles for five seconds (count 1 one thousand, 2 one thousand, 3 one thousand, 4 one thousand, 5 one thousand).~Relax pelvic muscles and perform 10 to 20 Kegel exercises three to four times each day.~Squeeze the muscles in anus like holding a bowel movement focus penile area~Relax the pelvic floor muscles after each attempt.~Repeat this exercise 10 to 20 times.~While performing Kegel exercises:~Do not hold the breath. Do not push down. Squeeze the muscles together tightly and imagine, trying to lift this muscle up. Do not tighten the muscles in the stomach, buttocks, or thighs.~While the control group did not participate in any kegel exercises"
46028272|NCT04213573|Drug|silver diamine fluoride|38% silver diamine fluoride liquid will be applied with a brush
46028273|NCT04213573|Drug|MI Varnish|topical fluoride varnish with calcium and phosphate
46028274|NCT05154175|Device|Ottobock helmet|Patients treated in current practice
46028275|NCT04293783|Dietary Supplement|L.Reuteri|daily supplementation with two tablet for six months
46028276|NCT04293783|Dietary Supplement|Placebo|daily supplementation with two tablet for six months
45471023|NCT04800068|Diagnostic Test|[Ga-68] PSMA-11 PET/MR|Imaging scan
46028277|NCT04395027|Device|atrial septal defect closure|The iatrogenic septal defect will be closed in the usual manner
46028278|NCT04294173|Behavioral|video education|tracheostomy care will be given to student nurses with video training
46028279|NCT04318977|Device|high-frequency rTMS|repetitive transcranial magnetic stimulation
46028280|NCT04318977|Device|TBS|theta burst stimulation
46028281|NCT04318977|Device|placebo|placebo transcranial magnetic stimulation
46028282|NCT02869659|Behavioral|Weight Loss Group|All participants will follow the Medifast Achieve TM 4 & 2 & 1 Plan® which includes the 4 MR products per day, with the addition of 2 Lean and Green™ Meals and 1 Healthy Snack
45471024|NCT04606628|Other|Eggshell membrane (ESM)|The intervention group will consume two capsules containing (in total) 500mg ESM with breakfast every day in 4 weeks.
46028283|NCT02869659|Behavioral|Delayed Weight Loss|18 weekly, group dietary and exercise sessions led by the study staff in which participants will follow a modified Diabetes Prevention Program
45471025|NCT04606628|Other|Placebo|The placebo group will consume two placebo capsules (Cellulose) with breakfast every day in 4 weeks
45471026|NCT03074162|Drug|Diclofenac Sodium|twice daily
45471027|NCT03074162|Drug|Diclofenac & Capsaicin|twice daily
46028284|NCT04210063|Other|Inspiratory Muscle Training (IMT)|IMT is a breathing training technique customized to participant's breathing capacity. Using a handheld electronic manometer (Pro2Fit from Smithfield), a study personnel will initiate training at 40-60% maximal inspiratory pressure. Adjustments will be customized to where the participant reports a difficulty of training between 4-6 out of 10. Training sessions will be performed about 30 minutes a day for 28 consecutive days.
46028285|NCT02870439|Other|Blood drawn|
45471028|NCT03074162|Drug|Diclofenac Sodium Topical Gel|twice daily
45471029|NCT04045496|Drug|JAB-3312|JAB-3312 will be supplied as 0.25 mg and 1.0 mg capsules.
45471030|NCT03070964|Drug|plitidepsin|
45471031|NCT05763992|Dietary Supplement|Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)|Each FLA cycle will consist of 5 consecutive days of a specific FLA scheme, which will be repeated with a three-week interval. The FLA will consist of a plant-based, low-calorie (about 600 Kcal on day 1; about 300 Kcal on day 2 to 5), low-protein, low-carbohydrate diet. The first FLA cycle will start two days prior to the day of first chemo-immunotherapy cycle administration and will continue for two more days after chemotherapy. In the absence of significant contraindications or severe adverse events, subsequent FLA cycles will recur with three-week intervals and will maintain the same timing with respect to chemo-immunotherapy administration.
46028286|NCT04209751|Diagnostic Test|Stool removal|Stool removal; freezing an aliquot at -20 ° C and performing a direct examination. DNA extraction and serial PCR (Polymerase chain reaction).
46028287|NCT00618709|Drug|ATX-101|ATX-101 single dose
46028288|NCT00620269|Drug|Erlotinib|Erlotinib 150 mg p.o. daily x21 days every 3 weeks
46028289|NCT00620269|Drug|Induction or consolidation IP chemotherapy|Irinotecan 65mg/m2 + Cisplatin 30mg/m2 IV on D1,D8 every 3 weeks X 3 cycles
46028290|NCT00620269|Drug|CCRT with IP chemotherapy (Irinotecan + Cisplatin)|Irinotecan (60mg/m2) + cisplatin (30mg/m2) IV on D1 & 8 every 3 weeks X 2 cycles
46028291|NCT00620269|Radiation|CCRT|CCRT :Concurrent Thoracic Radiotherapy (2.4 Gy/fr, Total 60 Gy, 25fr over 5 weeks)
46028292|NCT04213417|Other|Bobath therapy and Matrix Rhythm Therapy|MRT application that was applied to the study group in addition to the BC was applied to the affected side of the body and lower extremity for 60 minutes in each session.The treatment was started from the thoracic region and a treatment direction was toward the lower extremity in the affected side.During the MRT procedure, the patient's active participation was ensured and the treatment was combined with the exercises.The patients were informed about MRT verbally and in writing before the application. Participants were treated 3 days a week for 4 weeks for a total of 12 sessions.
46028293|NCT04213417|Other|Bobath therapy|Both groups were treated with the BC as a neurodevelopmental therapy. Considering individual requirements and wishes of the patient, an exercise program that supports active participation of the person was established.Each treatment session was performed for 60 minutes.The treatment program that was established appropriately according to the patient contained weight transfer to the affected side in different positions,approximation to increase proprioceptive input, providing sensorial input to the sole of the foot using materials such as sensory ball,foot-ankle mobilization,functional reach activities, forward-side step, gait, and balance activities. Participants in both groups were treated 3 days a week for 4 weeks for a total of 12 sessions.
46028294|NCT00618865|Dietary Supplement|Omega-3 fatty acids|
46028295|NCT04213183|Diagnostic Test|Hepatobiliary Disorders|The training dataset was used to train the deep learning model, which was validated and tested by the other two datasets.
46028296|NCT05111977|Device|Vibrant capsule|A capsule delivering mechanical vibrations
46028297|NCT00617617|Dietary Supplement|Prevastein HC®|Experimental Group - Participants in the experimental group will consume an isoflavones supplement in the form of Prevastein HC®, which will deliver 80 mgs (40 mg/dose) biologically active isoflavones.
46028298|NCT00617617|Other|Placebo|Control Group - Control Group participants will receive an identical placebo.
46028299|NCT02466217|Other|1: AID groups|Clinical and Biological investigations
46028300|NCT02466217|Other|2: Control groups|Clinical and Biological investigations
46028301|NCT05104957|Other|Dynamic tape|The experimental group will use a special dynamic patch made of cotton, coated with a hypoallergenic acrylic heat-activated adhesive arranged in sinusoidal-shaped layers. The tape will be applied using the muscle technique with a Y-shaped cut patch directly to the dried and non-greased skin. The application will be performed in a standing position, with the participant's lower extremities straight. The therapist will place the beginning of the tape (the base) on the participant's sacrum and then, asking them to bend 45 degrees forward, tape the tails of the tape along the spine on the extensor muscles of the lumbar region, without changing the tension of the tape, keeping the base in the initial position.
45839011|NCT04339842|Other|Assessment of Dietary Changes in Adults in the Quarantine|The online survey will help to collect demographic data from the volunteers. Personal information and contact details, such as email, will not be asked. The survey will include questions about any increase or decrease in the consumption of main meals, snacks and fluid intake. If the participants of the study have observed changes in their dietary pattern since the beginning of the quarantine, details of these changes, such as an increase in the amount of main meal consumption, will be questioned.
46028302|NCT05104957|Other|Sham tape|In the control group, a plain paper patch will be used to conduct the study, which, like the dynamic patch, will be applied using the same form of tape cutting and the same application technique. The entire method of applying the patch will also take place in the participant's standing position with forward bending. The paper patch will be placed at the levels from the L3 segment to the sacrum, along the spine on the lumbar extensor muscles.
46028303|NCT04212637|Other|MRI|Examine BOLD activity in relation to eye movements measures
46028304|NCT04212403|Drug|Levofloxacin|The control group receives AMP.
46028305|NCT00618943|Behavioral|Tobacco Use Cessation|The proposed intervention will proceed in three steps. Step 1, provided to all intervention participants, includes multimedia, stage-based, expert-system contacts at intake, 3- and 6-months follow-up supported with brief (15-min) motivational counseling sessions. Step 2, reserved for intervention participants interested in quitting, consists of 12-weeks of individual CBT sessions for smoking cessation. Step 3, a 12-week course of nicotine patch, will be offered to adolescents who enter the CBT Cessation Treatment, who do not have any medical contraindications, and who smoke an average of 5 cigarettes or more per day in the past month.
46028306|NCT00637117|Biological|Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS|Day 1 and Day 2: 2 Gy Radiation on Day 1 and Day 2 to tumor site. Day 4, 8, 11, 18: 0.5mL injection of Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS.
46028307|NCT02052193|Drug|Dabrafenib|Measurement of toxicity related to UV exposure
46028308|NCT02052193|Drug|Vemurafenib|Measurement of toxicity related to UV exposure
46028309|NCT00617695|Drug|Zolmitriptan|5mg nasal spray
45682173|NCT01592409|Drug|delta-9-tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
45682174|NCT01592409|Drug|Placebo|A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
46028310|NCT00617695|Drug|Placebo|
46028311|NCT02704585|Device|Nellcor|Measurement of pulse oximetry in the delivery room with Nellcor pulse oximeter
46028312|NCT02704585|Device|Masimo|Measurement of pulse oximetry in the delivery room with Masimo pulse oximeter
45682175|NCT02081638|Drug|Aspirin|Daily Asprin daily
45682176|NCT02081638|Drug|Atorvastatin|Daily Atorvastatin Daily
45682177|NCT04603508|Drug|BERLIM 25/10 association|Berlim 25/10 association coated tablet.
45682178|NCT04603508|Drug|EMPAGLIFLOZIN|Empagliflozin 25 mg coated tablet.
45682179|NCT04603508|Drug|ROSUVASTATIN CALCIUM|Rosuvastatin 10 mg coated tablet.
45682180|NCT04603508|Other|BERLIM 25/10 ASSOCIATION PLACEBO|Berlim 25/10 association placebo coated tablet.
45682181|NCT04603508|Other|EMPAGLIFLOZIN PLACEBO|Empagliflozin placebo coated tablet.
46028313|NCT00619021|Drug|gemcitabine hydrochloride|4 dose levels designated by cohort; 600 mg/m^2, 800 mg/m^2, 1000 mg/m^2, 1200 mg/m^2
46028314|NCT00620347|Drug|sunitinib|sunitinib (50mg/day, 4weeks on, 2 weeks off) Repeat every 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, or patients' refusal.
46028315|NCT01918735|Drug|Placebo|Placebo control matched to the oral or intravenous experimental comparator drug
46028316|NCT01918735|Drug|GWP42006|"Oral administration of 25 (Group/dose level 1a and 1b), 75 (Group/dose level 2a and 2b), 200 (Group/dose level 3a and 3b) and 400 mg GWP42006 (Group/dose level 4a and 4b), provided as 50 mg/mL GWP42006 solution in sesame oil containing flavourings and sweetener, for dilution on the day of dosing, as required.~Additional intravenous administration of 5 mg GWP42006 and 10 mL Solutol HS 15 solution to Group/dose level 3a and 3b subjects."
46028317|NCT04213105|Drug|QL1206|subcutaneous injection of 60 mg (1ml) only once,on the first day.
46028318|NCT04213105|Drug|Prolia®|subcutaneous injection of 60 mg (1ml)only once,on the first day
46028319|NCT01887301|Drug|Sativex|Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.
46028320|NCT00618085|Behavioral|Motor imagery practice|During motor imagery practice a person imagines performing a skill or movement with all its sensory consequences without actually moving. In this study the therapists follow a motor imagery guideline designed for rehabilitation of skills and movement performance in subjects with neurological disease or damage. The guideline offers therapists structure and a strategy to deliver subject-specific imagery. The guideline is based on three major frameworks, namely; principles of motor learning, phased process of human movement and a training guide for sports coaches and performers from the National Coaching Foundation.
46028321|NCT00618085|Other|Standard physiotherapy and occupational therapy|Patients with neurological disease or damage will receive standard physiotherapy and occupational therapy.
46028322|NCT00996801|Drug|MK-5442|MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months
45471032|NCT04352036|Other|no interventional study|no interventional study
46028323|NCT00996801|Drug|Placebo to MK-5442|Matching placebo to MK-5442 taken orally, once-daily, for 12 months
45471033|NCT04668872|Radiation|Y90 TARE|Y90 TARE will be performed as standard of care (SOC)/clinically indicated: 1) in a lobar or sub-lobar fashion (depending on tumor involvement and location; also targeting the tumor as selective as possible and sparing as much as possible of non-involved liver parenchyma), for participants with extensive bilobar disease or 2) in a radiation segmentectomy approach, intending to deliver 190 Gy radiation dose to target tumor: for patients with limited liver metastatic disease, not amenable for surgery or ablation.
45471034|NCT04668872|Diagnostic Test|PET/CT|Following 90Y TARE, participants will receive a PET/CT or PET/MRI scan to measure the dose administered to the target tumor(s) and uninvolved hepatic parenchyma.
45682182|NCT04603508|Other|ROSUVASTATIN CALCIUM PLACEBO|Rosuvastatin placebo coated tablet.
46028324|NCT00996801|Drug|Alendronate Sodium|Alendronate tablets 70 mg, taken orally, once-weekly, for 12 months
46028325|NCT00996801|Drug|Vitamin D3|Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months
46028326|NCT00996801|Drug|Calcium carbonate|Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months
46028327|NCT00996801|Drug|Placebo to Alendronate|Placebo to alendronate once-weekly for 12 months
46028328|NCT00619333|Drug|follitropin and lutropin|follitropin and lutropin
46028329|NCT02692027|Other|Same-day ART initiation|"Participants tested HIV-positive during community-based HIV testing and randomized to the intervention group receive post-test counseling and on-the-spot clinical and laboratory assessment. Directly after the positive HIV-test result the study nurse assesses the participant clinically and performs point-of-care laboratory baseline testing. Thereafter, the participant receives a standardized short adherence counselling. After adherence counseling the participant is offered to start ART immediately. Those who decide to start ART during the visit or intend to start within seven days will receive a 30 day ART-supply and an follow-up appointment at the clinic within 12 to 16 days.~In order to reduce travel time and transport cost, participants who are clinically stable, will have their follow-up visits and ART refills more widely spaced with appointments at 6 weeks, 3, 6, (9) and 12 months after ART initiation."
46028330|NCT02692027|Other|Standard of care|"Individuals found HIV-positive during the community-based HIV testing campaigns and randomized to the control arm receive post-test counselling and a referral letter with an appointment at their chosen health facility. On the first visit to the clinic, the participant receives laboratory assessment and a first adherence counselling session. The participant must then return to the clinic to receive his/her laboratory results and to undergo a second adherence counselling session.~Once the participant has started ART, the first and second follow-up visits are scheduled for 14 and 28 days after ART initiation, respectively. Thereafter, follow-up visits are scheduled monthly until 6 months after ART initiation. If the participant is clinically stable, clinical follow-up visits may then be spaced to 3-monthly intervals, but refills of ART must still be collected on a monthly basis."
46028331|NCT04212871|Other|watch food video 1|A 2 minutes video, with food content. The first study used a ramen mukbang here, the second study used a hotpot mukbang.
46028332|NCT04212871|Other|watch food video 2|A 2 minutes video, with food content (different content from video 1). The first study used a donut mukbang here, the second study used a hotpot cooking show here.
46028333|NCT04212871|Other|watch a non-food content video|a 2 minutes video without food content. The first study used a documentary introducing the forbidden city, the second study used a documentary introducing Cornell University.
45471035|NCT04668872|Diagnostic Test|PET/MRI|Following 90Y TARE, participants will receive a PET/CT or PET/MRI scan to measure the dose administered to the target tumor(s) and uninvolved hepatic parenchyma.
45471036|NCT01569620|Behavioral|Best clinical practices plus culturally targeted print materials|This intervention arm includes best clinical practices (or usual care at MSSM) and the culturally relevant print materials developed for this study.
45471037|NCT01569620|Behavioral|Best clinical practices plus standard print materials|This intervention arm includes best clinical practices (or usual care at MSSM) and the standard CRC screening print materials developed by the Centers for Disease Control (CDC).
46028334|NCT04924621|Device|Respiratory Humidification Treatment Device, AIRVO 2 PT101AZ, Fisher & Paykel Healthcare, Inc.|"The nasal cavity was disinfected with Iodophor cotton swab, and the appropriate nasal cavity was selected for endotracheal intubation assisted by fiberoptic bronchoscope according to the experience of anesthesiologists.~After the endotracheal intubation was fixed, the anesthesia machine was connected for mechanical ventilation. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg."
46028335|NCT04924621|Device|Mask ventilation|The Control Group will receive sequential intravenous infusion of Sufentanil 5ug, midazolam 0.05mg/kg, and propofol 1-2ug/ml, to make the BIS between 70 and 80. 2ml tetracaine was injected with cyclothyroid membrane puncture, and the nasal cavity was disinfected with iodophor cotton swab. According to the experience of anesthesiologists, the appropriate nasal cavity was selected for intranasal endotracheal intubation assisted by fiberbronchoscope. After the endotracheal intubation was successful, the anesthesia machine was connected for mechanical ventilation, full narcotic inducer will be injected. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg.
46028336|NCT04924621|Drug|Midazolam(T group)|Midazolam 0.05mg/kg, intravenous injection
46028337|NCT04924621|Drug|Sufentani(T group)|Sufentanil 0.02-0.05ug/kg, intravenous injection
45471038|NCT01569620|Behavioral|Best clinical practices alone|This intervention arm includes best clinical practices (or standard/usual care at MSSM) and no additional print materials.
46028338|NCT04924621|Drug|Propofol(T group)|Propofol 2-3ug/ml, intravenous injection
46028339|NCT04924621|Drug|Rocuronium(T group)|Rocuronium 0.06mg/kg, intravenous injection
46028340|NCT04924621|Drug|Drug use target(T group)|Make BIS < 60 .
46028341|NCT04924621|Drug|Sufentanil(C group)|Sufentanil 5ug, intravenous injection
45598665|NCT02295709|Procedure|CTF steroid (dexamethasone) injection|"deliver steroids (dexamethasone) into spinal epidural space with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)"
46028342|NCT04924621|Drug|Midazolam(C group)|Midazolam 0.05mg/kg, intravenous injection
46028343|NCT04924621|Drug|Propofol|Propofol 1-2ug/ml, intravenous injection
46028344|NCT04924621|Drug|Tetracaine(C group)|2ml tetracaine was injected with cyclothyroid membrane puncture.
46028345|NCT04924621|Drug|Drug use target|Make the BIS between 70 and 80.
46028346|NCT00516373|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
46028347|NCT02869737|Device|Coagucheck, Roche, France|Capillary puncture for POC INR measurement
46028348|NCT00619411|Behavioral|Interpersonal Therapy for Depressed Adolescents & Parents|15 weekly psychotherapy sessions
46028349|NCT04293705|Device|Teen On-line Problem Solving|The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.
45682183|NCT01674166|Drug|prucalopride|single dose 0.03 mg/kg prucalopride open label
46028350|NCT02213497|Radiation|18F-FDG (Fluorodeoxyglucose) PET|
45598666|NCT02295709|Drug|Dexamethasone|One of the most efficient steroids
45598667|NCT02295709|Device|Ultrasound|Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)
45682184|NCT05356546|Other|Study-required procedures include: tissue collection from device capsule, questionnaire collection, and photo collection|Enrolled participants will have already received the TYRX™ Absorbable Antibacterial Envelope and will be clinically indicated to have a replacement with any market-released, commercially available (in the geographies they are used) CIED and lead(s) with or without the use TYRX™ Absorbable Antibacterial Envelope, as prescribed by and used on-label by their physician.
45839012|NCT04339686|Diagnostic Test|Thoracic CT Scan|Retrospective analysis of the thoracic CT scan results compared to final discharge summary
46028351|NCT02213497|Drug|Carboplatin|
46028352|NCT02213497|Drug|Paclitaxel|
46028353|NCT04211467|Other|No Intervention|There is no intervention for this study
46028354|NCT02193841|Procedure|Curettage with puncture (C & P)|A curette will be inserted to scrape the contents of the cyst (curettage) and a hole in the cyst wall will be made (puncture) near the bone marrow cavity
46028355|NCT02193841|Device|Curette|A small surgical instrument with a rounded edge designed for scraping
45839013|NCT04338672|Other|COVID-19 Pandemic|Exposure: the novel coronavirus disease (Covid-19) outbreak
45839014|NCT04338906|Drug|Camostat Mesilate|400 mg tid, d1-d7
45839015|NCT04338906|Drug|Placebo|Instead of Camostat Mesilate, tid, d1-d7
46028356|NCT02193841|Device|Vitoss morsels|A bone substitute intended for use as a filler for voids or gaps in bones
46028357|NCT00996489|Device|Coaptite®|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier
46028358|NCT00618163|Drug|Meloxicam|
46028359|NCT04295343|Diagnostic Test|Three-dimensional (3D) rectal water contrast transvaginal ultrasonography|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
46028360|NCT04295343|Diagnostic Test|Computed colonography|Computed colonography or virtual colonoscopy uses special x-ray equipment to examine the large intestine. During the exam, a small tube is inserted a short distance into the rectum to allow for inflation with gas while computed tomographic images of the colon and the rectum are taken.
46028361|NCT04212949|Device|Repetitive transcranial magnetic stimulation (rTMS)|Stimulation will be performed from the contralateral M1 cortex of the painful side. Each stimulation session will consist of 1500 pulses (30 trains of 5 seconds each, with an inter-train interval of 25 seconds) delivered at a frequency of 10 Hz. The stimulation intensity will be set at 80% of the resting motor threshold.
45471039|NCT04268654|Procedure|Preoperative Arterial Embolization|"PAE will be performed by arteriographic procedure before esophageal resection surgery minimum 14 days before surgery.~An angiogram of the celiac trunk is performed through a femoral access before and after the embolization. Embolization by coils of the left gastric artery, splenic artery and the right gastric artery is realized."
45598668|NCT02295709|Radiation|C arm|the needle position will be re-confirmed by C arm C arm (Philips Healthcare, Best, the Netherlands）
45598669|NCT02228213|Biological|MIS416|Intravenous administration weekly for 52 weeks
45598670|NCT02228213|Drug|Saline|Intravenous administration weekly for 52 weeks
45598671|NCT02354937|Drug|GSK1265744 30 mg|White to almost white coated oval tablets with unit dose strength of 30 mg for oral administrations.
45839016|NCT04338906|Drug|Hydroxychloroquine|400 mg bid on day 1, 200 mg bid d2-d7
45839017|NCT04338282|Drug|toripalimab|240mg/d, every 3 weeks, for up to one year or until disease progression, whichever comes first
46028362|NCT04212949|Drug|Transforaminal epidural steroid injection|"An epidural steroid injection under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).~The following drugs will be used for this procedure: 80mg/2ml triamcinolone acetonide (sinakort-A) and 1 mL 0.5% bupivacaine (marcaine)"
46028363|NCT04295421|Procedure|adductor canal block|ACB was done in the immediate postoperative period under a high-frequency ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.2% ropivacaine was injected in the canal using a 22-gauge 100-mm short-beveled regional block needle and a catheter was kept for 48H with 4 ml/h ropivacaine 0.2%.
46028364|NCT04295421|Procedure|IPACK block|IPACK block was realized after spinal anesthesia with 40 ml 0.2% ropivacaine and at the end of surgery , patients were given ACB with 20 ml 0.2% ropivacaine and continued with 4 ml/H saline for 48H
46028365|NCT02187601|Device|MPBA System|MPBA is the new generation Multi Purpose Breath Analyzer
46028366|NCT02187601|Device|BreathID|BreathID is the name of the original Exalenz breath analyzer system
46028367|NCT00628797|Radiation|UVA1|intraindividual half body irradiation
45598672|NCT02289001|Behavioral|Education on SBAR worksheet|The intervention group will receive one hour of training in teamwork skills, distribution of roles and use of the SBAR worksheet before participating in the simulated scenario using a human patient simulator (HPS).
45839018|NCT04338438|Drug|Apatinib Mesylate tablets combined with S-1 capsules|Apatinib Mesylate tablets combined with S-1 capsules, p.o.
46028368|NCT00628797|Other|UVA1|60 J/cm2 at least 36 tx
46028369|NCT00618241|Drug|lamotrigine|100 mg
46028370|NCT00618241|Drug|Raltegravir|400 mg BD
46028371|NCT04213027|Procedure|native tissue repair procedures with conventional surgical instruments|Sacrospinous ligament fixation (SSLF): treatment for apical prolapse with vaginal fornix suspended to sacrospinous ligament; Ischial spinous fascia fixation (ISFF): treatment for apical prolapse with vaginal fornix suspended to ischial spinous fascia (ISFF).
46028372|NCT00619567|Behavioral|Smartbrain|The initial session will be set for 10 minutes, with weekly increases (of 10 minutes) to a maximum of 30 minutes per day, 7 days a week. Each subject will be trained using the same modules of the Smartbrain protocol, with an emphasis on speed of information processing.
46028373|NCT04212715|Radiation|Pelvic SABR with intra-prostatic SABR|SABR 25Gy / 5 fractions to pelvis; 35Gy / 5 fractions to prostate; up to 50Gy / 5 fractions to MR nodule
46028374|NCT04211623|Other|Constraint induced movement therapy|"Constrained on more affected side for three hours. To minimize the learned non use in hemiplegic CIMT is applied and criteria of applying CIMT is;~10 degrees active wrist extension on the affected hand,~10 degrees active thumb abduction,~10 º active extension of any two digits on the side or hand which is limited due to damage.~In order to gain the maximum good results from CIMT technique following points should also be considered attentively. Affected arm should move to 45 degrees shoulder flexion and abduction, and 90 degrees of elbow flexion and extension.~Constrained with cotton sling. 3 to 5 upper limb functional activities like~using fork or a spoon,~combing hair~brushing teeth~writing~dressing all activities are performed for 10 t0 15 minutes in period of three hours on alternate days in a week"
46028375|NCT04211623|Other|Bimanual activities|"Bimanual activities of both hands are performed like~Set of bimanual activities is used to assess the bimanual hand function. Five bimanual activities are performed such as~carrying a tray,~cutting a fruit with a knife,~holding and cutting the paper with scissor,~buttoning and~Carrying heavy objects with both hands.~Every activity was performed for 10 t0 15 minutes on alternate days for a period of 6 weeks session."
45839019|NCT04338126|Drug|Tranexamic acid|previously described
46028376|NCT00618397|Drug|Ketamine|Ketamine administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to PICU patients.
46028377|NCT04857151|Behavioral|App based mindfulness program (ABMP)|App based mindfulness program (ABMP)
46028378|NCT04211779|Device|Real tDCS|Real tDCS (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The active session of tDCS will consist in applying anodal stimulation over left M1 (C3 according to the 10-20 international EEG placement) and the cathodal stimulation over right supraorbital area (Fp2 according to the 10-20 international EEG placement), and to inject 2 mA for 20 minutes through sponge electrodes (35 cm²) placed on the scalp.
45839020|NCT04338126|Drug|Placebo oral tablet|previously described
45839021|NCT04337736|Other|Physical exercise|
46028379|NCT04211779|Device|Sham tDCS|Sham current (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The sham tDCS will use the same montage and device but direct current will only be injected for 30 seconds, with a ramp-up and ramp-down 15 seconds period, to mimic the somatosensory effects of active tDCS.
46028380|NCT04211779|Other|Exercise|The Exercise intervention will include only aerobic exercise 3 times a week on alternate days for consecutive 6 weeks. The program will last 20 minutes.
46028381|NCT00618475|Behavioral|Cognitive behavioral therapy|"10 sessions~1 hour per week"
46028382|NCT04211545|Drug|Rabeprazole|Rabeprazole
46028383|NCT04211545|Drug|CC-92480|CC-92480
46028384|NCT00620581|Drug|Paroxetine|Paroxetine 10mg and 20mg during the luteal phase of the menstrual cycle
46028385|NCT04656535|Drug|AB122|AB122 is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets PD-1 immune checkpoint.
46028386|NCT04656535|Drug|AB154|AB154 is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets TIGIT immune checkpoint.
46028387|NCT04656535|Drug|Placebo|Saline placebo comparator for pre-surgery treatment in cohort B4
46028388|NCT01739569|Other|Dietary treatment|Dietary treatment with healthy lunch and snack meal during working hours
46028389|NCT04211311|Other|hybrid high-intensity training|FES-legcycling combined with either arm skiergometer or arm-cycling in 4 x 4 min. intervals at 90% peak power output, 3 times a week for 8 weeks
46028390|NCT01000311|Biological|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2, 4, 6 and 12 months of age as IM injections in the anterolateral area of the thigh.
46028391|NCT01000311|Biological|DTaP-IPV/Hib|IM injections of 3 doses of 0.5 mL each of DTaP-IPV/Hib supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
46028392|NCT01000311|Biological|HBV|IM injections of 3 doses of 0.5 mL each of HBV supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
45471040|NCT04684862|Device|Medtronic SynchroMed II programmable pump connected to an Intera tapered catheter (Combined Infusion System)|This infusion system is composed of a Medtronic SynchroMed II programmable pump connected to a Intera tapered catheter. Specifically, the Medtronic pump comes with a small connector that ends in a metal flange. During the operation, under sterile conditions, the distal 1 cm of the flange is severed using a scissor. Then, using a Intera connector pin, the end of the Medtronic catheter is connected to the Intera catheter . Two 2-0 silk ties secure the catheters to the pin. The pump and catheter are then inserted into the patient into the abdominal wall or into the chest wall. The catheter is inserted into an artery within the abdomen (usually the gastroduodenal artery but it depends on the exact arterial branching in the individual patient) that feeds the liver.
45471041|NCT04210154|Device|Haemodiafiltration|pre-dilution and post-dilution Haemodiafiltration
45471042|NCT05069012|Drug|Morphine Sulfate|Morphine is administered to provide pain relief after cesarean delivery; this is an assessment of the dose-response as measured by the duration of pain relief
45471043|NCT04677374|Other|Standard of care|Standard of care referral approach which is a brief health talk conducted once every morning by a VMMC mobilizer.
46028393|NCT01000311|Biological|PCV|IM injections of 4 doses of 0.5 mL each of PCV supplied in prefilled vial were administered at 2, 4, 6 and 12 months of age in the anterolateral area of the thigh.
46028394|NCT01000311|Biological|MMR|Subcutaneous (SC) injection of 1 dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 12 months of age in the anterolateral area of the thigh.
46028395|NCT04211701|Procedure|Connective Tissue Massage|Connective tissue massage (CTM) will be applied to the lumbo-sacral region, lower thoracic, scapular and interscapular regions. Three to five pulling will be applied during massage. The treatment will be administered for four weeks, five days a week.
45471044|NCT04677374|Behavioral|Intensified Health Education|More detailed health talk conducted during each group health talk session by the VMMC mobilizer and champions describing VMMC, its benefits and how to access the service and testimonies from men who have successfully undergone VMMC
45471045|NCT04677374|Behavioral|SMS/telephonic Tracing|SMS tracing to remind participants of VMMC appointments
46028396|NCT04211701|Procedure|Classical Massage|Classic massage (CM) will be applied to the lower back and upper back while the patient is lying in the prone position. Three stroking will be applied during massage.The treatment will be administered for four weeks, five days a week.
46028397|NCT04209439|Drug|30 ml %0.25 bupivacaine|Ultrasound-guided erector spinae plane block
46028398|NCT04209439|Drug|Dexketoprofen-trometamol|50 mg Dexketoprofen-trometamol intravenous
45471046|NCT04677374|Behavioral|Transportation Reimbursement|Transportation reimbursement to offset the cost of transportation for VMMC appointments
45471047|NCT04670588|Diagnostic Test|Circulating tumor DNA(ctDNA) level measurement|The ctDNA level will be measured using the Signatera platform developed by Natera, Inc. Signatera is a patient-specific, tumor informed custom-built ctDNA monitoring assay.
45471048|NCT04660682|Other|Modified static cross-body posterior shoulder stretching|For the modified cross-body position patient will be positioned in the side-lying position to limit the scapular abduction, and the patient aligned his/her forearms to limit the ER of the humerus while moving into horizontal adduction (HAdd). First, we will ask the patient to pull his/her arm into HAdd to the physiological barrier of the ROM, and then the patient will perform active-assistive static stretching with the help of the other hand for 30 seconds. The stretching will perform five repetitions with 10-sec rest between stretches. Each stretching will begin from a new physiological barrier of the HAdd ROM. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
46028399|NCT00619879|Drug|Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients|"Total Body Irradiation (TBI) 1200 cGy will be given on days -8,-7,-6 and -5 in eight sessions, delivering 150cGy in each session.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3, -2."
46028400|NCT00619879|Drug|Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies|"Busulfan administration:~For children >/= 4 years of age, Busulfan 0.8 mg/kg/dose will be given every 6 hours over days -8,-7, -6, and -5 for a total of 16 doses.~For children < 4 years of age, Busulfan 1 mg/kg/dose will be given every 6 hours over days -8, -7, -6, -5 for a total of 16 doses.~Pharmacokinetic analysis will guide dose modifications targeted to receive an average AUC of 800-1200 microMols*min for the 16 doses.~Lorazepam (0.05 mg/kg) IV will be administered one half hour before the initial dose of Busulfan is given and every 6 hours through day -4.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3 and -2."
45471049|NCT04660682|Other|Traditional static cross-body posterior shoulder stretching|For the traditional static cross-body posterior shoulder stretching, in the standing position, the patient will perform cross-body stretch alone by active-assistive pulling the humerus across the body into HAdd with the opposite arm, without concern for scapular stabilization for 30 sec. The stretching will perform five repetitions with 10-sec rest between stretches. Each stretching will begin from a new physiological barrier of the HAdd ROM. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
45471050|NCT04660682|Other|Control Group|In sham stretching, the patient will be positioned in the traditional static cross body posterior shoulder stretching position, and then the patient will perform active-assistive HAdd ROM without enough stretching of the relevant tissue. Active assistive ROM will be stopped before reaching the individual PST measurement result (in this way, sham stretching will be performed without proper stretching of the relevant tissue). The HAdd ROM exercise will be performed 5 times. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
45471051|NCT04973852|Device|Ekso|Exoskeleton walking
45471052|NCT04065074|Drug|FX006 32 mg|Extended-release 32 mg FX006 IA injection
46028401|NCT00619879|Other|Hematopoietic Progenitor Cell Transplantation (HPCT)|Hematopoietic progenitor cells (HPCs) will be infused on day 0. Source of cells may be bone marrow, peripheral blood cells, or cord blood units, from matched related or unrelated donors.
45471053|NCT05762042|Other|dietary supplement|"Femal, a food supplement based on pollen extracts introduced in Europe in 1999, is a non-estrogenic alternative to hormone replacement therapy in women with vasomotor symptoms.~The mechanism of action of Femal has not yet been fully clarified: Femal inhibits the absorption of serotonin in a dose-dependent manner and has strong antioxidant properties.~The lack of estrogenic effects would make this preparation of particular interest for women with a previous hormone-dependent neoplasia who undergo an early iatrogenic menopause.~Femal tablets contain a standardized formulation containing: GC Fem pollen extract 40 mg, PI82 pollen / pistil extract 120 mg, vitamin E 5 mg, amino acids 14 mg per tablet.~The dosage is 2 tablets a day orally."
45471054|NCT03629834|Diagnostic Test|Epworth Sleepiness Scale|Maintenance Wakefulness Test
45471055|NCT03920306|Drug|oral anti-acid treatment|This study investigates a bundle of three commonly used treatments
45471056|NCT02888106|Drug|Myrcludex B|Lyophilised powder for solution for subcutaneous injection
45471057|NCT02888106|Drug|PEG IFN alfa-2a|solution for subcutaneous injection, once per week
45471058|NCT02888106|Drug|Tenofovir|Film-coated tablets, 300 mg, per os, once daily
46028402|NCT00619879|Radiation|CNS radiation treatment for ALL with prior CNS disease patients|"Patients with prior CNS disease over the age of 1 year will be treated with 600 cGy of cranial irradiation in addition to 1200 cGy of TBI.~Patients diagnosed with ALL with CNS disease (at the time of diagnosis or relapse) < 1 year of age will receive CNS treatment as Intrathecal Methotrexate as follows:~Infants ≤ 1 year of age at the time of Intrathecal Therapy will receive a dosing of 7.5 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count~Children 1-2 years of age at the time of Intrathecal Therapy will receive 8 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count"
46028403|NCT04212559|Other|Received negative pressure ventilation|Patients who received a negative pressure during inspiratory phase.
46028404|NCT05228041|Drug|Biologic treatments available in CRSwNP (dupilumab, mepolizumab and benralizumab according to their marketing approval)|Drug prescription according to their marketing approval (subcutaneously, every month or every two weeks)
46028405|NCT01003899|Drug|afatinib (BIBW 2992)|afatinib (BIBW 2992) po QD
46028406|NCT04160377|Drug|Fluvoxamine|Fluvoxamine was assigned to be the treatment for the depression patients with melancholic features or not .
46028407|NCT04150393|Drug|MaaT033 capsule|Oral capsule
45471059|NCT03793010|Drug|FX006|Single Intra-articular injection
45471060|NCT03793010|Drug|Normal saline|Single Intra-articular injection
46028408|NCT04142203|Other|23 h surgery|Patients were treated in 23 surgical unit
46028409|NCT01000155|Drug|vorinostat|
46028410|NCT00621595|Dietary Supplement|USDA School Breakfast|Breakfast containing 340 calories, 57 g carbohydrate, 14 g protein, 6 g fat.
46028411|NCT00318487|Procedure|Bilateral sinus augmentation with immediately loaded dental implants|Bilateral sinus augmentation with immediately loaded dental implants will be used.
46028412|NCT00999921|Drug|Tamoxifen|Tamoxifen is given at 10 mg once daily between Day 5 and Day 25 of menstrual cycle for 3 cycles.
46028413|NCT00999921|Drug|Evening Primrose Oil|Evening Primrose Oil is given at 1000 mg two times daily for 3 months.
45471061|NCT04018196|Other|motor imagery as training manual task|They will have a motor imagery as training manual task for 30 minutes. They will have 3 tests for performing manual task before training (pretest) and after training (post-test).
45471062|NCT04018196|Other|motor imagery as training motor task|"They will have a motor imagery as training motor task for 30 minutes before performing this task.~They will have 3 tests for performing motor task before training (pretest) and after training (post-test)."
45471063|NCT04018196|Other|emotionally neutral film as training of manual task|"They will have to watch an emotionally neutral as training manual task for 30 minutes before performing this task.~They will have 3 tests for performing manual task before training (pretest) and after training (post-test)."
45471064|NCT04018196|Other|emotionally neutral film as training of motor task|"They will have to watch an emotionally neutral as training motor task for 30 minutes before performing this task.~They will have 3 tests for performing motor task before training (pretest) and after training (post-test)."
45598673|NCT03152331|Behavioral|Receptive Awareness Training|Two 12-minute learning sessions will be conducted for each learning day. Separate instructions will be provided before session 1 and before session 2 to facilitate receptive awareness. The participant is seated in front of a BIS monitor and learns that the BIS number will decrease when in a state of receptive awareness. The trainee will learn to use attentional flexibility in daily activities and adopt willful attention (focal concentration) alternatively with receptive awareness (relaxed attention), as a situation dictates.
45598674|NCT02295787|Drug|Ketamine|Intranasal ketamine for late-life depression and suicidal ideation.
46028414|NCT02869581|Other|Data collection|
46028415|NCT00620737|Biological|Autologous Human Fibroblasts (Isolagen TherapyTM)|"Collection of skin biopsy.~Administration of 2 study injections~Performance of various study assessments during clinic visits"
45598675|NCT02295787|Drug|Placebo|
46028416|NCT00620737|Biological|Placebo|"Collection of skin biopsy.~Administration of 2 study injections~Performance of various study assessments during clinic visits"
46028417|NCT02869347|Drug|Conestat alfa|Two intravenous injections (over 5 minutes) of Conestat alfa immediately pre-procedure (elective coronary angiography) and 4 hours later; for patients less than 84kg at a dose of 50 U/kg, and for patients of 84kg body weight or greater at a dose of 4200 U.
46028418|NCT02869347|Drug|Sodium chloride 0.9%|Two intravenous injections of sodium chloride 0.9% (maximum 28 ml, matching the respective amount of the Conestat alfa arm) immediately pre-procedure (elective coronary angiography) and 4 hours later.
46028419|NCT00621673|Drug|Kogenate (BAY 14-2222)|Antihemophilic factor (recombinant) 20-40 IU/ kg based on body weight of rFVIII, IV, 3 times a week
45598676|NCT02228291|Dietary Supplement|Capsule containing citrus flavonoid|
45598677|NCT02228291|Dietary Supplement|Placebo|
46028420|NCT04293939|Diagnostic Test|Functional Magnetic Risonance Imaging (fMRI) acquisition|Infants will undergo an MRI exam with a 3 Tesla Philips Achieva scanner and a 32-channel head coil. MRI Protocol: T1 weighted image structural, T2 weighted image structural, fMRI task. Task fMRI: experiment will be implemented using the block design is as follow: 1.Rest (control condition): no touch; 2.Soft touch (stimulus condition): gentle strokes on infant's right leg (~15 cm area) with a soft brush at a velocity of ~5 cm/s Stimulus blocks will last for ~15s, allowing the blood-oxygen-level-dependen (BOLD) signal to reach the steady state. Control blocks duration will be randomized (10-18s) to avoid foresee activation phenomena. Condition will be administered multiple times (~10 times). Two run will be administered. The stimulus will be administered using a soft brush. A regular audio signal will help the operator to keep a constant stroke velocity. Audio commands will also be used to direct the operator. Infant must be asleep (natural sleep) during the fMRI acquisition.
45598678|NCT02292511|Behavioral|Square-stepping exercise|In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged.
46028421|NCT05008393|Drug|PJS-539 Dose 1|Patients will receive PJS-539 dose 1 daily for 10 days.
46028422|NCT05008393|Drug|PJS-539 Dose 2|Patients will receive PJS-539 Dose 2 daily for 10 days.
46028423|NCT05008393|Drug|Placebo|Patients will receive placebo daily for 10 days.
46028424|NCT02869503|Other|Data collection|
46028425|NCT04243005|Procedure|Supramarginal resection|Aim of supramarginal resection, where a margin of at least 10 mm is considered feasible prior to surgery. The resection is guided by the T2 volume (i.e. zone of edema) where removal of as much as possible of this zone (or beyond) is attempted as long as considered safe
46028426|NCT04243005|Procedure|Conventional surgery|Aim of gross total resection (i.e. removal of contrast enhancing tumor) according to institutional practice. No limit in use of technical adjuncts in this arm.
46028427|NCT04210921|Device|Acupuncture|"The acupuncture will be penetrated in an appropriate angle into a depth of 10-15 mm. Acupuncture manually manipulated by lifting, thrusting, and twirling methods to produce a characteristic sensation known as De Qi ."
46028428|NCT04210921|Device|The park sham needle|When the blunt needle goes through the adhesive and contact with skin, it will move back into the hollow centre of the handle rather than penetrate into skin.
46028429|NCT05662657|Diagnostic Test|Diagnostic Test: PCL-S Questionnaire|PCL-S and HADS questionnaires
46028430|NCT04052191|Biological|MCRcI® stem cells|Intra-Coronary Administration of MCRcI® stem cells
46028431|NCT01002573|Drug|ibuprofen|Ibuprofen, 10 mg/kg
46028432|NCT01002573|Drug|acetaminophen|Acetaminophen, 10mg/kg
46028433|NCT00620893|Drug|PEG- 400 based artificial tear|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
46028434|NCT00620893|Drug|Systane|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
46028435|NCT04211233|Device|invasive subdural grid electrode|A subdural EEG-electrode (PLATIN 1x4 or 1x6; Ad-Tech Medical Instrument Corporation, Oak Creek, WI, USA, Figure 1) will be implanted in the subdural space frontotemporal intraoperatively and diverted separately from the wound area. Afterwards, invasive Monitoring will be performed for 7 days and the grid will be removed simply by pulling out.
46028436|NCT04211233|Other|Control arm|Standard Treatment based on Brain Trauma Foundation
46028437|NCT00999687|Drug|Indigo Naturalis Extract in Oil|Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks
46028438|NCT00999687|Other|Olive Oil|Olive oil was applied to the fingernails of the contra-lateral hand (control group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
46028439|NCT04211077|Other|Date collection|Data collection from national SNIIRAM and PMSI database
46028440|NCT04293315|Behavioral|Improvement Cycles|"This is a multi-component intervention following the Institute for Healthcare Improvement (IHI)'s Collaborative Model for Achieving Breakthrough Improvement by implementing plan-do-study-act (PDSA) improvement cycles. The investigators will conduct 8 participative learning sessions for the primary care team. These sessions will be aimed at identifying opportunities for improvement oriented to the design and application of innovative approaches based on best practices."
46028441|NCT03970057|Behavioral|Internet-based Cognitive Behavioural Therapy|"MoodUP is an iCBT intervention that is tailored to perinatal women. The core content is presented via different types of devices, such as smartphones, tablets, laptops, or desktops, connected to the internet. The program is designed as an integration of online sessions, self-monitoring, homework, peer support, and therapist support.~MoodUP consists of six online sessions focused on CBT skills for improving stress, anxiety, and depressive symptoms among at-risk antenatal women; each session takes between 30 and 40 minutes to complete. The content of the sessions will be as follows: Session 1: Managing mood, Session 2: Psychoeducation, Session 3: Cognitive restructuring, Session 4: Behavioural activation, Session5: Lifestyle modification, Session 6: Problem-solving."
46028442|NCT03970057|Other|Usual Care|Participants will receive a series of six, weekly online sessions comprising general antenatal education. The content of the sessions will be as follows: Session 1: Parenthood; Session 2: Diet; Session 3: Exercise; Session 4: Breastfeeding; Session 5: Rest and sleep and Session 6: Common pregnancy problems.
46028443|NCT04293549|Drug|Cenegermin, recombinant human Nerve Growth Factor (rhNGF) eyedrops|"rhNGF 20µg/ml (Cenegermin) eyedrops, 1 drop every 2 hours (6 times a day) for 8 weeks.~Patients underwent clinical examination with corneal fluorescein staining, Schirmer I tear test, assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline and after 4 and 8 weeks of treatment"
46028444|NCT02691715|Procedure|Endometrial saline plus curettage|
46028445|NCT02691715|Procedure|Endometrial curettage|
46028446|NCT00996333|Drug|Gemcitabine, Docetaxel, Capecitabine|"1500mg/m2/day of Capecitabine for 14 days 750mg/m2 of Gemcitabine on Day 4 and 11 30mg/m2 of Docetaxel on Day 4 and 11~This 2-week regimen is followed by 1 week off for a total of a 21-day cycle. This is repeated for a total of 3 cycles."
45598679|NCT03152487|Other|Celiac Plexus Neurolysis|This intervention involves accessing the Celiac Plexus Nerve via endoscopic guided ultrasound and then injecting the nerve bundle with bupivacaine.
46028447|NCT00621829|Dietary Supplement|EPA enriched fish oils|Subjects will take the (EPA)-enriched omega-3 polyunsaturated fatty acids (n3-PUFA) supplements as a capsule (3-4 g of EPA/day) for 90 days, followed by an 8 week washout period, and then will take a Placebo capsule for 90 days.
46028448|NCT00621829|Dietary Supplement|EPA enriched fish oils|Subjects will take a Placebo capsule for 90 days, followed by an 8 week washout period, and then will take the (EPA)-enriched omega-3 polyunsaturated fatty acids supplements as a capsule (3-4 g of EPA/day) for 90 days.
46028449|NCT00621907|Drug|chirocaine (Levobupivacaine)|levobupivacaine 0,5 % 30 ml infiltration (150 mg)
46028450|NCT00621907|Drug|sodium chloride|sodium chloride : 0,9% 30 ml
46028451|NCT04140799|Device|vocal cord ultrasonography|assess vocal cord motion and recurrent nerve function by Transcutaneous laryngeal Ultrasonography in patients scheduled for anterior cervical spine surgeries
46028452|NCT04726423|Other|transcranial direct current stimulation|5 daily sessions of tDCS (2mA, 20 min) were recommended to all patients. Physical exercises were also done at the physiotherapy clinic. Physical exercises program was recommended to be continued at home after the week of physiotherapy visits.
46028453|NCT04717219|Other|Blood drawing|Blood will be drawn after inclusion of the participants.
46028454|NCT02870985|Device|Coronary Stent|
46028455|NCT01349101|Radiation|Total Body Irradiation|"Myeloablative HSCT Arm: Total body irradiation (TBI) is given in 8 fractions over 4 days (total dose of 12 Gy)~Reduced Intensity HSCT Arm: TBI is given in one fraction (total dose of 2 Gy)"
46028456|NCT01349101|Drug|Cyclophosphamide|Cyclophosphamide is administered on the third day after the hematopoietic stem cell transplantation (HSCT) to help reduce graft-versus-host disease (GVHD). It is given at a dose of 60 mg/kg/d for 2 days on days +3 and +4.
46028457|NCT01349101|Drug|Tacrolimus|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
46028458|NCT01349101|Drug|Mycophenolate mofetil|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
46028459|NCT01349101|Drug|Fludarabine|Started the fifth day before the transplant. Given for four days at 30 mg/m2/d.
46028460|NCT01349101|Drug|Busulfan|Started the fourth day before the transplant. Given for two days at 3.2 mg/kg.
46028461|NCT01349101|Genetic|Hematopoietic stem cell transplantation|Allogeneic marrow transplantation given after the last dose of total body irradiation (TBI)
46028462|NCT02870049|Behavioral|Inreach strategy|Inreach strategy: In clinic education and delivery of fecal immunochemical test (FIT) kit
46028463|NCT02870049|Behavioral|Outreach strategy|Outreach strategy: Mailed fecal immunochemical test (FIT) kit and telephone reminders
46028464|NCT02870049|Behavioral|Both Inreach and Outreach strategies|Both Inreach and Outreach strategies: Both In clinic education and delivery of fecal immunochemical test (FIT) kit and Mailed fecal immunochemical test (FIT) kit and telephone reminders
46028465|NCT02870049|Behavioral|Usual care|Usual care: FIT kit delivery as part of usual care
45598680|NCT03152487|Other|Radiofrequency Ablation|Radiofrequency ablation is performed via the probe for 90 seconds, followed by a 90 second rest. This is repeated until the entire ganglion becomes hyperechoic on EUS.
46028466|NCT04295109|Drug|the drug of intravenous patient-controlled analgesia|At present, opioids are most widely used in postoperative analgesia. This study aims to use different opioid receptor agonists---fentanyl, oxycodone and butorphanol for analgesia after laparoscopic hysterectomy.Compare the recovery of gastrointestinal function after operation.
46028467|NCT00620971|Drug|Vinorelbine|Vinorelbine (oral) 60 mg/m2, on days 1 and 8 every 3 weeks for 3 cycles
46028468|NCT00620971|Drug|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 3 cycles
45598681|NCT04464967|Biological|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
45598682|NCT04464967|Drug|Trastuzumab|HER2 receptor antagonistic, humanized immunoglobulin G subclass 1 (IgG1) monoclonal antibody
45598683|NCT04464967|Drug|Cetuximab|EGFR antagonist, chimeric immunoglobulin G subclass 1 (IgG1) monoclonal antibody
45598684|NCT02228369|Drug|AZD3759|Starting dose 50 mg, administered twice daily. If tolerated subsequent cohorts will test increasing doses of AZD3759, until a maximum tolerated dose or an effective dose is defined
45598685|NCT02228369|Drug|AZD9291|AZD9291 160mg once daily
45598686|NCT03146871|Drug|Azacitidine|Given IV or SC
45598687|NCT03146871|Drug|Decitabine|Given IV
45598688|NCT03146871|Other|Laboratory Biomarker Analysis|Correlative studies
45598689|NCT03146871|Other|Pharmacological Study|Correlative studies
45598690|NCT03146871|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
45598691|NCT02289235|Drug|Ginger|Ginger powder capsule 1000 mg twice daily for 3 months
46028469|NCT00620971|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 3 cycles
46028470|NCT00620971|Drug|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
46028471|NCT00620971|Drug|Gemcitabine|Gemcitabine(IV) 1,100 mg/m2 on day 1 and d8 every 3 weeks for 6 cycles
45471065|NCT05761340|Procedure|Helfer skin tap injection technique|"Place the patient in a seated position and open his right arm to inject into the deltoid muscle.~After determining the injection site, use the tips of the dominant hand fingers to hit the skin (about 15 strokes) for about five seconds to soften the muscles.~After cleaning the skin with alcohol, remove the syringe cover from the dominant hand. Make a V with the non-dominant hand and hit the skin three times.~During the third stroke, prick the syringe into the muscle at 90 degrees angle at the same time.~After aspiration, continue to hit the skin with the tips of the non-dominant hand fingers while injecting the drug with the dominant hand at a rate of 1 ml / 10 seconds.~After injecting the drug, make the non-dominant hand V-shaped and hit the skin three times, pulling the syringe needle out at the same time during the third stroke"
45682185|NCT04748380|Other|CRC decision aid pamphlet|A newly developed 8-10 page decision aid pamphlet that discusses:1. Information on CRC; 2. Information about risk and benefits including the 10-year lag-time to benefitting from CRC screening; 3. Information to help patients evaluate CRC screening options (colonoscopy or stool testing); 4. Possible outcomes relevant to LE and health status. In addition, there will be a values clarification exercise
46028472|NCT00620971|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
46028473|NCT00620971|Drug|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
46028474|NCT00620971|Drug|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 6 cycles
46028475|NCT00620971|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
46028476|NCT04673773|Behavioral|A Massive Open Online Course|Same as intervention
46028477|NCT00995865|Biological|XRX-001 Inactivated yellow fever vaccine|Inactivated yellow fever vaccine, alum adsorbed, High dose = 2.3 x 10^8 VE/0.5mL and Mid dose = 2.2 x 10^7 VE/0.5mL
46028478|NCT00995865|Biological|Placebo|NaCl Injectable 0.9%
46028479|NCT04210531|Dietary Supplement|Beetroot juice (BJ) acute supplementation|One serving 140 mL of BJ (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 3 h before initiating the testing session.
45471066|NCT05761340|Procedure|Standard Injection technique|"Place the patient in a seated position and open his right arm to inject into the deltoid muscle area.~After determining the injection site, prepare the skin with alcohol.~Grasp the skin with the thumb and index finger of the non-dominant hand and prick the syringe into the muscle at a 90-degree angle.~After aspiration, inject the drug with the dominant hand at a rate of 1 ml /10 seconds.~Remove the syringe needle 10 seconds after the drug is consumed"
46028480|NCT04210531|Dietary Supplement|Placebo acute supplementation|One serving placebo drink (0.08 mmol of NO3-; Salud Viva, Nano Salud 32 S.L) after an overnight fast and 3 h before initiating the testing session.
45471067|NCT04798716|Drug|MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)|Escalating dose 2 X 10^9, 4 X 10^9, 8 X 10^9/mL
45471068|NCT04798716|Drug|MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)|Escalating dose 8 X 10^9, 4 X 10^9, 8 X 10^9 mL
45471069|NCT04798716|Drug|MSC-exosomes delivered intravenously every other day (8:8:8)|Dosed 8 X 10^9, 8 X 10^9, 8 X 10^9 mL
45471070|NCT04767906|Drug|Cabozantinib|The medication is taken once a day for 336 days (max.). The start dose is 60mg and can be reduced according to the physicians decision. 40mg and 20mg are also available.
45471071|NCT05203016|Other|Hipotermia/Normotermia|The temperature will be measured at the beginning and at the end of the surgery, as well as during admission to the Post-Anesthesia Care Unit, where the temperature normalization time will be noted in the event of hypothermia. In retrospect, those variables corresponding to the late postoperative period will be evaluated and the telephone interview will be conducted to assess the quality of care received. All the data will be reflected in the collection booklet that we present in the annex.
46028481|NCT04223661|Drug|Lenalidomide Pill|Lenalidomide will be administered PO on Days 1 through 21 of each 28 day cycle at the dose according to the frailty score and creatinine clearance.
46028482|NCT04223661|Drug|Dexamethasone|Dexamethasone will be administered at 20 mg per week. During weeks when the subject receives an infusion of daratumumab, dexamethasone will be administered on infusion days at a dose of 20 mg IV before the infusion.
46028483|NCT04223661|Drug|Daratumumab|Daratumumab (1800 mg) will be administered by SC injection by manual push over approximately 3 - 5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses. The volume of the SC solution will be 15 mL for the 1800 mg dose
45471072|NCT03135990|Behavioral|Cognitive Behavioral Therapy with Virtual Reality Technology|Cognitive Behavioral Therapy Intervention: This manualized intervention is a modified version of the Unified Protocol for Emotional Disorders in Youth, a modular Cognitive Behavioral Therapy protocol for anxiety disorders and depression with demonstrated efficacy in youth. The 10-session intervention includes psychoeducation about anxiety disorders and their treatment (1 session), emotion awareness and regulation (2 sessions), exposure therapy using virtual reality environments (6 sessions), and review and relapse prevention (1 session). All treatment sessions will be videotaped to ensure fidelity to treatment manual and modules.
45471073|NCT03055026|Drug|Rivaroxaban|Tablets
45471074|NCT03055026|Drug|Placebo|Tablets
45839022|NCT04337658|Drug|Pertuzumab|Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
46028484|NCT04208503|Diagnostic Test|thyroid ultrasound|After meeting enrolment criteria the thyroid ultrasound will be performed at 32 and 36 weeks of gestation, blood test for TSH and FT4 will be obtained at 14-21 day of life, at 32 and 36 weeks of gestation
46028485|NCT04220853|Diagnostic Test|Rhinomanometry in patients after septoplasty and/or turbinoplasty|Rhinomanometry is an examination used to assess changes in resistance and airflow in patients after septoplasty and/or turbinoplasty.
45471075|NCT01313754|Procedure|Vicryl Suture|Vicryl suture material will be placed on the patients left sided incision.
45471076|NCT01313754|Procedure|Dermabond|Dermabond skin glue will be placed on the patients left sided incision.
45471077|NCT04561284|Dietary Supplement|Indigestible fiber (classified)|Participants will be asked to ingest 12 grams of indigestible fiber powder per day for a period of 8 weeks. Three times daily, they will take 4 grams of powder with their meal.
45598692|NCT02289235|Drug|Placebo|Placebo powder 2 capsules twice daily for 3 months
46028486|NCT04220853|Diagnostic Test|Acoustic rhinometry in patients after septoplasty and/or turbinoplasty|Acoustic rhinometry is an examination used to assess changes in the cross-sectional area of the nasal passage in patients after septoplasty and/or turbinoplasty.
46028487|NCT05662501|Device|Pleioflow-RF|Subjects who are going to undergo scheduled cardiac surgery and are prone to developing renal insufficiency, will receive the Pleioflow-RF device in conjunction with IABP during CPB. Subjects will be followed until 30-days post-intervention.
46028488|NCT04268277|Drug|Rituximab|100 mg concentrate for solution for infusion
46028489|NCT04268277|Drug|Pembrolizumab|100 mg/ 4mL concentrate for solution for infusion
46028490|NCT04210453|Drug|Vitamin C|"Participants in Vitamin C group are administered IV vitamin C diluted in 100 cc normal saline 1 day before surgery, at rewarming during surgery, 3 hours after surgery, and every 6 hours thereafter until postoperative 24 hours."
45598693|NCT03519841|Device|P0.1|Investigational Medical Device collecting spectral Raman data from tissue.
46028491|NCT04210453|Drug|Control (Normal saline)|"Participants in Control group are administered IV 100cc normal saline at the same timepoint as above."
46028492|NCT00622141|Drug|generic GPO saquinavir and novir vs invirase and norvir|Norvir® 100mg capsules, Invirase® 1,000 mg capsules Generic GPO Saquinavir 1,000 mg capsules For phase 1 and 2 - At day 1 subjects of group A will receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg, while group B will receive generic GPO saquinavir / Norvir® 1,000 mg / 100mg as single dose. The same day the first 24 hr PK curve will be done. After this, a 7-day washout period will follow. At day 8 group A will take generic GPO saquinavir / Norvir® and Group B will take Invirase®/Norvir®. At this day, the second 24 hr PK curve will be done
46028493|NCT04210765|Drug|Clomiphene Citrate|Clomiphene citrate used in incremental doses in nonresponsive cases.
45471078|NCT04561284|Dietary Supplement|Placebo|Participants will be asked to ingest 6 grams of placebo powder per day for a period of 8 weeks. Three times daily, they will take 2 grams of powder with their meal.
45471079|NCT04948398|Drug|Guselkumab|Guselkumab 100 milligrams (mg) will be administered subcutaneously once every 8 weeks.
45471080|NCT03304626|Drug|Budesonide 3Mg Capsule|Budesonide capsule in place of prednisone (standard of care)
45471081|NCT03304626|Drug|Standard of Care Prednisone|Prednisone taper (Standard of Care)
46028494|NCT00622219|Other|Randomized Drug Testing Trial|Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
46028495|NCT03735901|Drug|IMP Levodopa 100mg/Carbidopa 25mg|"Study treatment will comprise 3 phases:~Dose escalation phase: On day 1-3, patients will receive IMP solely in the morning; on day 4-6 in the morning and at lunch time;~full study treatment phase: from day 7 to day 34, 3 times per day (tid).~Treatment will stop with a tapering phase: On day 35-37, patients will receive IMP in the morning and at lunch time; on day 38 and 39 solely in the morning."
45471082|NCT03620682|Behavioral|Coaching sessions|Participants receive three 30-minute phone sessions with a doctorate-level therapist over the course of one month. These sessions are skills-based and focus on improving participants' problem solving through cognitive-behavioral techniques. Participants are allowed to text the therapist between sessions for information and support.
45598694|NCT02354625|Biological|Autologous human Schwann cells|Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
45839023|NCT04337658|Drug|Trastuzumab|Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
45839024|NCT04337658|Drug|Fulvestrant|500mg intramuscular injections at day 1, 15, 28 and 4 weeks thereafter
45471083|NCT03620682|Behavioral|Mobile applications|Participants will have access to 3 mobile apps for the duration of the study, and after it ends. One app will push participants a daily, self-reflective survey to complete, and a daily motivational or instructional tip to rate. Other apps will provide education and exercises on various aspects of mental health and wellness, such as sleep and relaxation.
46028496|NCT03735901|Drug|Matching placebo|"Study treatment will comprise 3 phases:~Dose escalation phase: On day 1-3, patients will receive Placebo solely in the morning; on day 4-6 in the morning and at lunch time;~full study treatment phase: from day 7 to day 34, Placebo capsules 3 times per day (tid).~Treatment will stop with a tapering phase: On day 35-37, patients will receive Placebo in the morning and at lunch time; on day 38 and 39 solely in the morning."
46028497|NCT05662267|Other|Pancreatic islet transplantation after kidney transplantation|Pancreatic islet transplantation consists in the intrahepatic transplantation of pancreatic islets, as a result of enzymatic digestion of a deceased-donor pancreas.
45471084|NCT05121714|Drug|Caffeine|This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 substrate (caffeine)
45471085|NCT05121714|Drug|ABX464|This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine) and a known CYP1A2 substrate (caffeine).
45471086|NCT05121714|Drug|Fluvoxamine|his is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine).
45471087|NCT02958150|Drug|Dexmedetomidine|
45471088|NCT02958150|Procedure|Standard Clinical Practice|
45471089|NCT03274986|Device|ACRYSOF® IQ Extended Depth of Focus IOL|Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL.
45471090|NCT03274986|Device|ACRYSOF® IQ Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject
45839025|NCT04337658|Drug|Capecitabine|1000mg/m2 orally Bid on day 1 to day 14 every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
46028498|NCT00621205|Behavioral|Weight reduction, Resistance training, Aerobic exercise training, Control|Weight reduction: 12 weeks intensive weight loss, 20 weeks maintenance Resistance and aerobic exercise training: individualized and progressive training programs
46028499|NCT04210609|Device|Vaporous Hyperoxia Therapy|55 minutes of treatment, 2 times per week
46028500|NCT00621283|Drug|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
46028501|NCT04575727|Drug|[11C]MPC6827|Subjects will receive a microdose ( 10 µg) of [11C]MPC6827 (dose of 20 mCi)
46028502|NCT00138853|Device|Tibial component|Tibial component inserted at the time of surgery
46028503|NCT00995709|Drug|AIN457|
46028504|NCT00995709|Drug|AIN457|
45471091|NCT03274986|Procedure|Cataract surgery|IOL bilateral implantation
45682186|NCT04748380|Other|Home Safety Pamphlet|The home safety information pamphlet is a 2-page fact sheet on home safety tips for older adults, and was designed by the AGS Health in Aging Foundation. It includes information in seven areas to help older adults stay safe in their homes. Areas include but are not limited to fall prevention and safety proofing homes. It has been used successfully in prior studies of DAs as a control intervention
45682187|NCT02235688|Drug|aldoxorubicin|administered at 170 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
46028505|NCT00995709|Drug|Placebo|
46028506|NCT05662189|Drug|68Ga-exendin-4|68Ga-exendin4 PET-CT scan
45682188|NCT02235688|Drug|aldoxorubicin|administered at 250 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
46028507|NCT05662189|Other|mixed meal test|before and after a standardized mixed meal venous blood samples will be collected at time intervals to measure plasma glucose, C-peptide,insulin, glucagon, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) curves
46028508|NCT04208113|Behavioral|School teacher training /.b|"The intervention is a multi-level, multi-component complex intervention. It consists of a school teacher training programme and the .b-programme to be delivered to pupils 11-15 years in the schools.~The school teacher training programme consists of three parts: 1) the establishment of own mindfulness practice by participation in the MBSR programme and sustaining mindfulness with a regular formal daily practice; 2) completion of the four days .b residential course, and 3) completion of the 3x2-days seminars on relational competences and implementation issues regarding teaching .b .~The .b programme consists of well-described, weekly 40-60 minutes classroom sessions over 10 weeks. All the sessions have a specific theme, associated teachers' notes, power points and animations. The .b programme can only be delivered with fidelity by a trained .b teacher."
46028509|NCT00629031|Drug|Paromomycin|11 mg/kg for 14 days
46028510|NCT00629031|Drug|Paromomycin|Paromomycin for 21 days @ 11mg/kg by intramuscular injections
46028511|NCT04295265|Device|smartphone message|Receive daily whatsapp/ SMS message to remind the drug intake
46028512|NCT00621361|Drug|AZD2171|Oral
46028513|NCT00621361|Drug|Etoposide|Intravenous
46028514|NCT00621361|Drug|Cisplatin|Intravenous
45682189|NCT02235688|Drug|aldoxorubicin|administered at 350 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
45682190|NCT02235688|Drug|gemcitabine|
45682191|NCT01676584|Drug|RO6811135|single ascending doses sc
46028515|NCT05661565|Other|No intervention|We try to find an association between insulin resistance with ovarian hormonal and morphological characteristics in patients with polycystic ovarian syndrome
46028516|NCT04208581|Drug|Yiqi Huoxue Huatan granule|Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
46028517|NCT04208581|Drug|Placebo Yiqi Huoxue Huatan granule|Placebo Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
46028518|NCT03551899|Other|Different ventilation parameters|mode of ventilation, tidal volume per body weight and PEEP settings
46028519|NCT02696863|Behavioral|questionnaire|
45682192|NCT01676584|Drug|placebo|single doses sc
45682193|NCT03152578|Other|BetaC + Capsaicin Topical Cream|BetaC + Capsacin Topical Cream applied to painful knee area 3 times per day.
46028520|NCT05368831|Drug|1024|Drug Drug interactions between 1024 and caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam
46028521|NCT05368675|Drug|medication for opioid use disorder|This is an open-label study. The project proposes to enroll up to 500 opiate dependent individuals entering Medication Assisted Treatment (Methadone or buprenorphine/naloxone) at Go Vap Clinic, HCMC, Vietnam. All participants who appear to meet inclusion criteria and who express interest in drug treatment will be invited to be screened for participation in the research. All participants will receive BDRC sessions (weekly for 12 weeks, monthly thereafter until week 52).
45471092|NCT02919306|Biological|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
45471093|NCT02919306|Biological|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
45471094|NCT02919306|Drug|Placebo|Participants will receive placebo intramuscularly Weeks 0, 12, 24 and 48.
45471095|NCT03274440|Drug|Cannabis|"THC and CBD are cannabinoids which are found naturally in the marijuana plant. Both act on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."
45471096|NCT03274440|Other|Placebo|Placebo control group, not receiving THC or CBD.
46028522|NCT04208425|Behavioral|Project Personality|"The intervention includes five components: 1. An introduction to the brain, including a lesson on the concept of neuroplasticity, describing how and why our behaviors are controlled by thoughts and feelings in their brains, which have potential for change; 2. Written testimonials from older youths who describe their beliefs that people's personal traits (e.g., sadness, anxiety) are malleable, given the brain's plasticity; 3. Additional vignettes written by older youths, describing times when they used growth mindsets to persevere through social and emotional setbacks; 4. A summary of selected scientific studies suggesting that personality can, and often does, change in positive ways over time; and 5. An exercise in which the participants write notes to younger students, drawing on scientific information to describe the malleability of people's personal traits (i.e., a self-persuasion exercise)."
46028523|NCT04208425|Behavioral|Sharing Feelings Intervention|The ST SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the web-based growth mindset intervention; it also mirrors the web-based growth mindset intervention as closely as possible, including vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family.
46028524|NCT05368207|Drug|Pembrolizumab|Pembrolizumab is an antineoplastic agent, monoclonal antibody against PD-L1.
46028525|NCT04208269|Other|postcard campaign|Post card sent to parent only
46028526|NCT04208269|Other|Health Information Technology system|Accessed by adolescent and provider only
46028527|NCT05368051|Combination Product|long course radiotherapy + capecitabine + PD-1 monoclonal antibody|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
46028528|NCT02648113|Procedure|Restrictive transfusion|Transfusions are withheld unless Hb is <= 8 g/dL, with a target Hb of 8 to 10 g /dL
46028529|NCT02648113|Procedure|Liberal transfusion|transfusions are allowed as soon as Hb <= 10 g/dL with a target of 11 g /dL
45471097|NCT04522908|Drug|Cabozantinib Oral Tablet|Cabozantinib starting dose of 40 mg, oral, once daily for 4 weeks followed by Cabozantinib escalated dose of 60 mg, oral, once daily from week 5 onwards
45471098|NCT04307004|Other|Unattended blood pressure measurement|Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician not present in the room.
45471099|NCT04307004|Other|Attended blood pressure measurement|Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician present in the room.
45471100|NCT04307004|Other|Ambulatory blood pressure monitoring|Participants will have their blood pressure measured every 30 minutes over 24-hours using an ambulatory blood pressure monitor.
45471101|NCT04307004|Other|Home blood pressure monitoring|Participants will have their blood pressure measured three times overnight while they are asleep using a home blood pressure monitor.
45598695|NCT02228447|Behavioral|Healthy Habits, Healthy Girls Group|The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
45598696|NCT03516565|Other|Saliva collection|
45598697|NCT03516565|Other|GCF collection|
46028530|NCT02648113|Biological|red blood transfusion|
45598698|NCT02351661|Other|There was no intervention|observational study, no intervention
46028531|NCT02641873|Drug|BBI608|240 mg twice daily (480 mg total daily dose)
46028532|NCT02641873|Drug|5-FU|400 mg/m2 bolus will be administered intravenously immediately following irinotecan/levofolinate infusion, followed by 1200 mg/m2/day (total 2400 mg/m2) continuous infusion per cycle(14 days).
46028533|NCT02641873|Drug|Irinotecan|180 mg/m2 together with levofolinate will be administered intravenously per cycle(14 days).
46028534|NCT02641873|Drug|Levofolinate|200 mg/m2 together with Irinotecan will be administered intravenously per cycle(14 days).
46028535|NCT02641873|Drug|Bevacizumab|5 mg/kg will be administered intravenously following irinotecan/levofolinate infusion per cycle(14 days).
46028536|NCT00998985|Drug|Grazoprevir|10, 30, 50, 100, 200, 400, 600 or 800 mg Grazoprevir tablets, orally, once a day for 7 days
46028537|NCT00998985|Drug|Placebo|Placebo tablet, orally, once a day for 7 days
46028538|NCT05240391|Drug|Midodrine Hydrochloride|Midodrine hydrochloride for PICD prevention
46028539|NCT05240391|Drug|Human Albumin 20%|Human ALbumin 20% for prevention of paracentesis induced circulatory disturbance
46028540|NCT00628953|Drug|Esomeprazole|40mg twice a day
46028541|NCT00628953|Drug|Placebo|40mg twice a day
46028542|NCT04294875|Drug|MPT0B640|PO, every 3 days. dose escalation per MTD
45598699|NCT02258555|Drug|GS-9901|GS-9901 tablets administered orally
46028543|NCT02870127|Other|blood sample|
46028544|NCT04294953|Drug|Duloxetine|Each Patient will receive oral Duloxetine capsule 60mg at the night before operation(12hrs before surgery), the 2nd dose 60 mg Duloxetine capsule 1hr before operation and 3rd dose 60mg capsule after 24hrs postoperative
46028545|NCT04294953|Drug|Placebo oral tablet|Each patient will receive a similar looking placebo capsule in the same time schedule. The placebo capsule will be prepared by hospital pharmacy to insure that active Duloxetine capsules will be indistinguishable from the placebo capsules contained starch
46028546|NCT04293861|Device|HYMOVIS|HYMOVIS is a clear hydrogel obtained by hydration of the HA-based derivative named HYADD4p5. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process.
46028547|NCT02869815|Procedure|ICG+Methylene Blue|"ICG+Methylene Blue Arm:~One ml of methylene blue (1%) would be in injected sub-areolarly 5 minutes before surgery, and 1ml of ICG (0.125%) in the same site 3 minutes later. Massage of the breast would be applied to facilitate the movement of the tracers. A small incision would be made in the axilla, and a special device would be used to search the light nodes. During the sampling, blue nodes would also be resected . After the completion of SLNB, complete axillary dissection would be carried out."
45598700|NCT02295943|Other|Positioning measuring device|Vitrectomy, intraocular gas fill. The supine time during the first postoperative day is measured
45598701|NCT02354391|Drug|Ingenol mebutate Picato® and MAL PDT day 1, day 5|Treatment of ingenol mebutate, Picato® 0.015% topical gel applied on day 1 followed by MAL PDT on day 5
45598702|NCT02354391|Drug|Ingenol mebutate Picato® day 2, 3, 4|Full treatment course with Ingenol mebutate (Picato®) 0.015% topical gel, apply day 2,3 and 4
45598703|NCT02354391|Procedure|MAL PDT day 5|Methyl aminolevulate combined with Photodynamic therapy at day 5
46028548|NCT04293081|Drug|Preemptive chlorepheniramine maleate intravenous injection|Participants of group A will receive only one ampoule of 45.5 mg/ 2mL chlorepheniramine maleate diluted in 8 ml isotonic saline intravenous (I.V) prior to induction of general anesthesia by 30 minutes
46028549|NCT04293081|Drug|normal saline|participants in group (B) will receive 10 ml isotonic saline (placebo) by the same route as control.
46028550|NCT00995553|Behavioral|Cognitive Remediation|This is an adaptive, computer-based cognitive training intervention. Participants will complete 3 1-hour cognitive training sessions focused on attention and working memory processes weekly for 4 months.
46028551|NCT00995553|Behavioral|Computer Skills|This is a computer-based course in which participants will be taught how to use Microsoft Office applications and typing skills. Participants will attend a 1-hour course three times a week four 4-months.
46028552|NCT04204473|Drug|TY-9591(10mg,40mg) qd. po|Increased dose cohorts from low dose to MTD(20mg Cohort1, 40mg Cohort2, 80mg Cohort3,120mg Cohort4, 160mg Cohort5, 200mg Cohort6)
46028553|NCT04293003|Other|fasting|6-hour fasting
46028554|NCT04293003|Other|Low carbohydrate|Consumption of a zero-carbohydrate breakfast
46028555|NCT04293003|Other|Mediterranean|Consumption of a Mediterranean-type breakfast
46028556|NCT04205643|Biological|CT-P13 SC (Infliximab)|Subcutaneous injection of CT-P13 SC
46028557|NCT04205643|Other|Placebo SC|Subcutaneous injection of Placebo SC
46028558|NCT04295187|Other|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages & Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
46028559|NCT04295187|Other|Physical development and General Health|Physical development and General health examination
46028560|NCT04295187|Other|Developmental Red flags|Developmental Red flags Questionnaires
46028561|NCT04292925|Other|New treatment protocol|The new treatment protocol focuses on training of executive processes using remedial strategies and on promoting the use of meta-cognitive strategies. Goal directed activities are used to improve the underlying cognitive process and transfer of the learned skill to everyday function will be encouraged.
45598704|NCT02231957|Other|educational text message reminders|
46028562|NCT04292925|Other|Conventional therapy|conventional therapy
46028563|NCT02868723|Other|Aggressive Management|With the aid of the nurse and pharmacist, the individuals in the interventional group will receive additional management of stroke by change is diet plan, increased exercise
46028564|NCT02869269|Device|Early stage|patients who classed as clinical stage 1 and 2
45682194|NCT03152578|Other|BetaC Topical Cream|BetaC Topical Cream Cream applied to painful knee area 3 times per day.
46028565|NCT02869269|Device|Late stage|patients who classed as clinical stage 3 and 4
45682195|NCT03152578|Other|Placebo Topical Cream|Placebo Cream applied to painful knee area 3 times per day.
46028566|NCT04181463|Drug|Isopropyl Alcohol|Given via nasal inhalation
46028567|NCT04181463|Other|Placebo|Given via nasal inhalation
46028568|NCT04181463|Other|Questionnaire Administration|Ancillary studies
45598705|NCT02231957|Other|conventional text message reminders|
45598706|NCT03519763|Diagnostic Test|ultrasound|All the patients will have a transvaginal ultrasound evaluation during the first visit to the clinic to evaluate the presence or not of isthmocele.
46028569|NCT04291833|Behavioral|Intervention group 1|Protein supplementation BID, Vitamin D and calcium supplementation Vitamin D 2000 IU / d, calcium 1000mg/d, exercise 6 months
46028570|NCT04291833|Behavioral|Intervention group 2|Protein supplementation QD, Vitamin D and calcium supplementation Vitamin D 1000 IU / d, calcium 500mg/d, exercise 3 months
45598707|NCT04478253|Device|HypnoVR|Insertion of the drain according to the usual management protocol supplemented by the use of a hypnosis software application (HYPNO-VR).
45598708|NCT02228603|Behavioral|high-intensity exercise training|
45598709|NCT02228603|Behavioral|web-based follow-up program|
45598710|NCT02228603|Behavioral|usual care|
45598711|NCT02292589|Device|Frontal Stimulation|The patient will receive anodal tDCS on left dorsolateral prefrontal cortex with an intensity of 1.5 mA for 20 minutes.
45598712|NCT02292589|Device|Temporal Stimulation|The patient will receive anodal tDCS on left temporal cortex with an intensity of 1.5 mA for 20 minutes.
46028571|NCT04291833|Behavioral|Control group 0|no protein supplementation , no Vitamin D and calcium supplementation , no exercise
46028572|NCT02868801|Drug|Placebo|same intervention as the experimental group
46028573|NCT02868801|Drug|Pregabalin SR tablet 165mg/day|According to the efficacy and safety in titration
46028574|NCT02868801|Drug|Pregabalin SR tablet 330mg/day|According to the efficacy and safety in titration
46028575|NCT02868801|Drug|Pregabalin SR tablet 660mg/day|According to the efficacy and safety in titration.
46028576|NCT00991887|Radiation|Radiation Therapy (XRT)|The dose will be 700 gray (derived unit of ionizing radiation dose in the International System of Units) in a single fraction, using AP-PA fields calculated to midplane. No Less than 6 MV energy photons will be used, and no bolus is placed on the skin. The field covers the entire joint, the antecubital fossa and the olecranon process. A strip of skin at the antecubital area is generally shielded, but is not an absolute requirement for this study.
45682196|NCT01065532|Device|Sequent Please Paclitaxel eluting balloon|Sequent Please Paclitaxel eluting balloon
46028577|NCT01002339|Drug|Tacrolimus with rapid steroid withdrawal|"Basiliximab induction (4 mg i.v., days 0 and 4).~Corticosteroids: 0.5 gr of i.v. Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7.~Tacrolimus: 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d."
46028578|NCT01002339|Drug|Tacrolimus with steroids minimization|"Basiliximab induction (4 mg i.v., days 0 an 4)~Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d."
45682197|NCT01065532|Device|Xience V everolimus eluting stent|Xience V everolimus eluting stent
45682198|NCT01674244|Behavioral|Integrative Exercise|
45682199|NCT01674244|Behavioral|Monitor Only Waitlist|
45682200|NCT03152734|Procedure|Surgical or non-surgical intervention|Each kind of surgical or non-surgical intervention with anesthesia applied by an anesthetist
46028579|NCT01002339|Drug|CsA with steroid minimization|"Basiliximab induction (4 mg i.v., days 0 an 4)~Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month and then 100-150 ng/ml.~Mycophenolate mofetil 1 gr b.i.d"
45471102|NCT03637998|Behavioral|Problem-solving Pain to Enhance Living Well (PROPEL)|PROPEL incorporates evidence-based, standard of care methods to promote physical activity among individuals with pain, and tools to improve knowledge, skills and confidence to cope with cLBP. The focus is self-management of cLBP. All eligible participants will then undergo baseline data collection, which entails completion of study questionnaires, quantitative sensory testing (QST) and venipuncture for collection of a blood specimen. Participants will be provided with the information to access the PROPEL intervention. All participants will be asked to complete questionnaires at 2, 4, 6, 8, and 10 weeks following baseline testing. At 12 weeks, participants will be scheduled for a final data collection visit, which will follow the same procedures as the baseline visit.
46028580|NCT01002105|Drug|Baclofen|Baclofen 50mg per day for 12 weeks and psychosocial intervention
46028581|NCT01002105|Other|Control group|psychosocial intervention and placebo for 12 weeks
46028582|NCT02605993|Biological|Ravulizumab|All treatments were given as IV infusions.
46028583|NCT00995085|Drug|Extended Release Metadoxine|one oral 1400mg dose (2 tablets)
46028584|NCT02867787|Drug|Botox arm|
46028585|NCT02868489|Dietary Supplement|LactoWise®|blend of bacillus coagulans and galactomannans
46028586|NCT02868489|Other|Placebo|Placebo to be selected is calcium carbonate (since participant routine standard of care already includes intake of calcium citrate)
46028587|NCT04209049|Drug|NNC0174-0833|A single subcutaneous (s.c., under the skin) dose of 0.6 mg NNC0174-0833.
45471103|NCT04498650|Drug|PQ912|PQ912 50 mg tablets and 150 mg tablets
45471104|NCT04498650|Drug|Placebo|Placebo tablets to mimic PQ912 50 mg and 150 mg tablets
46028588|NCT02868645|Biological|Blood sampling|Patients with bone fibrous dysplasia will have blood sampling to assess periostin rate in serum
46028589|NCT00136123|Procedure|Placement of functional loaded synthetic teeth after placement implants|Placement of functional loaded synthetic teeth after placement implants
46028590|NCT04208893|Behavioral|Exercise training|See description of Arms
46028591|NCT00603733|Drug|5-ASA (5-Aminosalicylate)|500 mg tablet (modified extended release)
46028592|NCT00603733|Drug|5-ASA (5-Aminosalicylate)|500 mg tablet
46028593|NCT02478151|Device|OrganOx Metra|Normothermic machine perfusion (NMP) Metra device
46028594|NCT02471911|Drug|KPT-330|KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy. Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle. Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.
46028595|NCT02471911|Drug|Rituximab|IV Rituximab 375 mg/m2 on D1
46028596|NCT02471911|Drug|Etoposide|IV Etoposide 100 mg/m2 on D1-3
46028597|NCT02471911|Drug|Carboplatin|IV Carboplatin AUC 5 on D2
45839026|NCT04337502|Diagnostic Test|Machine learning model|Machine learning, such as logistic regression, random forest, and deep learning
46028598|NCT02471911|Drug|Ifosfamide|IV Ifosfamide 5 g/m2 on D2
46028599|NCT02471911|Drug|Dexamethasone|20 mg qd on Days -5 and -3. 20 mg qd on Days 1-5
46028600|NCT02323321|Device|Preservation of Hearts for Transplantation|Preserving and Assessing Expanded Criteria Donor Hearts for Transplantation
46028601|NCT00622375|Drug|mesalamine|encapsulated mesalamine granules
46028602|NCT02239861|Biological|TAA-Specific CTLs|"Patients may be pre-medicated with Benadryl up to 1 mg/kg IV (max 50 mg) and Tylenol 10 mg/kg po (max 650 mg).~Cell Administration: Tumor-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients with stable disease or better will receive up to 6 further doses of CTLs, as long as they continue to show disease stabilization or improvement by RECIST criteria at their 8 week or subsequent evaluations. Each dose will consist of the same number as their second injection or less (if there is not enough product available for the subject's original dose).~Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
45839027|NCT04337424|Diagnostic Test|Sampling salivary|Collection of 1 to 2 ml of saliva
46028603|NCT02691559|Device|Amniotic fluid analysis by blood gas device|Amniotic fluid analysis by blood gas device in maternal inflammation group vs normal pregnancy group
46028604|NCT02691325|Drug|GSK2269557 ELLIPTA DPI|GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister.
46028605|NCT02691325|Drug|Placebo ELLIPTA DPI|Placebo ELLIPTA DPI contains lactose.
46028606|NCT02691325|Drug|Activated charcoal|The activated charcoal will be supplied by the clinical site. Charcoal will be administered as a suspension of 5 gram activated charcoal in 40 mL of water. The suspension will be made to drunk, in its entirety.
45471105|NCT03637530|Other|inverse ratio ventilation|during general anaesthesia in laparoscopic surgeries, this group of patients will receive inverse ratio ventilation with proper observation of hemodynamics
46028607|NCT02689687|Behavioral|Support partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
46028608|NCT02689687|Behavioral|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
45839028|NCT04337190|Biological|blood sampling|blood sampling at the day of admission, day 3 and day 7
46028609|NCT02689687|Behavioral|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherent to this medication.
46028610|NCT02689687|Behavioral|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
46028611|NCT00621439|Drug|Pegylated Interfon Alpha 2B|Patients will receive PEG-IFN 6 mcg/kg subcutaneously 4 days prior to surgery. Patients will be premedicated with acetaminophen 700 mb orally prior to the injection. Only one dose of drug will be given. Enucleation will follow in 4 days.
45471106|NCT04250142|Device|Self-etching Adhesive|A Self-etching adhesive will be used to cover deep carious dentin after a selective removal of caries lesion to soft dentin procedure.
45471107|NCT04250142|Device|Glass Ionomer|A conventional glass ionomer will be used to cover deep carious dentin after a selective removal of caries lesion to soft dentin procedure.
45471108|NCT02740608|Device|OrganOx metra|Normothermic Machine Liver Perfusion
46028612|NCT00621439|Drug|Placebo|Patients will receive placebo.
46028613|NCT00622453|Other|Screening|Electrocardiography Blood Test
46028614|NCT02689765|Dietary Supplement|Anthocyanins|Anthocyanins capsules, which comprises different natural Anthocyanins purified from bilberries and blackcurrants
46028615|NCT02689765|Dietary Supplement|Placebo|Placebo capsules is identically packaged.
46028616|NCT04643587|Biological|CSL787|Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer
46028617|NCT04643587|Drug|Placebo|Normal saline (0.9% NaCl)
46028618|NCT00622531|Device|BNP assay (Siemens ADVIA Centaur BNP)|Diagnostic test
45471109|NCT02714322|Biological|MYL-1401A (Adalimumab)|MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
45471110|NCT02714322|Biological|Humira® (Adalimumab)|Humira® initial dose of 80 mg administered sc, followed by 40 mg sc given every other week starting 1 week after the initial dose
45471111|NCT04728048|Procedure|Dural puncture epidural|already described
46028619|NCT00622531|Other|hidden BNP value|no intervention
45471112|NCT04728048|Procedure|Standard epidural|already described
45471113|NCT03268746|Device|AcrySof IQ PanOptix Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision intended for long-term use over the lifetime of the cataract subject
45471114|NCT03268590|Drug|Oxygen|Persons will undergo MRI, EEG, and complete computerized cognitive testing in baseline room air. Persons will then breathe 100% pure oxygen and undergo MRI, EEG, and complete computerized cognitive testing. Persons will serve as their own controls.
45471115|NCT03267576|Drug|Canagliflozin 300 mg|Participants will receive canagliflozin 300 mg oral tablet once-daily for 28 days.
45471116|NCT03267576|Drug|Sitagliptin 100 mg|Participants will receive sitagliptin 100 mg oral tablet once-daily for 28 days.
45471117|NCT03267576|Drug|Metformin|Participants will receive metformin at a stable dose of >= 1500 mg/day throughout the study including the washout period between each intervention.
45471118|NCT04236726|Other|Questionnaire|HRQoL questionnaires
45471119|NCT02472912|Biological|BMO-2|Volunteers randomized in Treatment A will receive a single subcutaneous injection of BMO-2 (40mg / 0.8mL).
45471120|NCT02472912|Biological|EU-Humira|Volunteers randomized in Treatment B will receive a single subcutaneous injection of EU-Sourced Humira (40 mg / 0/8 mL)
45471121|NCT02472912|Biological|US-Humira|Volunteers randomized in Treatment C, will receive a single subcutaneous injection of US-sourced Humira (40 mg / 0.8 mL).
46028620|NCT05661877|Other|DengueAid mobile application|•Education materials regarding dengue fever and self-care. The education section (My Dengue Knowledge) consists of seven modules (dengue essentials, risk, symptoms, aedes mosquito, self-care, prevention and interesting facts) with gamification properties. Each module contains a series of multiple-choice questions. After answering each question, the user would be instantly notified if they had answered the question correctly and be provided with some facts related to the question. A progress meter would allow users to keep track of each module answered. A medal would be awarded to users who have completed 100% of each module. The self-care section consists of basic information about dengue fever and points to look out for self-care. It contains information on dengue fever phases, signs of dengue, importance of keeping hydrated, complementary therapy, medicine to avoid and prevention practices.
45471122|NCT04489368|Radiation|Neo-Adjuvant Radiotherapy|Neo-Adjuvant Radiotherapy via any technique, delivered concurrently with Neo-Adjuvant Chemotherapy.
45471123|NCT04489368|Drug|Neo-Adjuvant Chemotherapy|Neo-Adjuvant Chemotherapy, delivered concurrently with Neo-Adjuvant Radiotherapy.
45471124|NCT04489368|Procedure|Esophagectomy|Esophagectomy, performed 4-6 weeks after completion of Neo-Adjuvant Concurrent ChemoRadiation
46028621|NCT05661877|Other|MyHealth website|MyHealth is developed by Ministry of Health, Malaysia (http://www.myhealth.gov.my/en/dengue-fever/) to provide information on dengue.
46028622|NCT04637815|Behavioral|Motivational Network Intervention|See earlier description
46028623|NCT04637815|Other|Usual Care|See earlier description
46028624|NCT04631107|Drug|AD109 dose1- A|Oral administration at bedtime
45682201|NCT01697319|Drug|BMN 110|Drug will be delivered through a 4 hour (approximate) IV infusion at a dosage amount of 2.0 mg/kg/week for up to 144 weeks of treatment.
45682202|NCT03152812|Procedure|plantar surface reconstruction by free flaps|use of free skin or free muscle flaps for reconstruction of plantar surface
45682203|NCT01674322|Drug|Ibrutinib|Type=exact number, unit=mg, number=50-140, form=solution, route=oral. Participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
45682204|NCT04746898|Other|Virtual Reality Training|Students received their basic life support application training through virtual reality glasses with special software.
45682205|NCT04746898|Other|High Fidelity Simulation Training|Students received their basic life support application training through high fidelity simulator mannequins.
45682206|NCT04746898|Other|Low Fidelity Simulation Training|Students received their basic life support application training through low fidelity simulator mannequins.
45682207|NCT03152344|Procedure|Timed Up and Go|It's a functional test evaluating the time to rise from a chair, walk 3 meters, turn around, walk back to the chair and sit down (abnormal cut-off value >12 seconds).
45682208|NCT03152500|Device|FEMTIS 313G IOL|Haptic design that enclaves the capsulorrhexis
45682209|NCT03152500|Device|Acrysof SN60WF IOL|IOL in the bag
46028625|NCT04631107|Drug|AD109 dose2- B|Oral administration at bedtime
46028626|NCT04631107|Drug|Placebo- C|Oral administration at bedtime
46028627|NCT02691481|Dietary Supplement|Oatmeal breakfast|
46028628|NCT02691481|Dietary Supplement|Glucerna formula|
46028629|NCT02691481|Dietary Supplement|Ultra Glucose Control formula|
46028630|NCT01678027|Drug|Placebo|Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.
46028631|NCT01678027|Drug|LAC triple therapy|Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.
46028632|NCT01449409|Other|Real-time asthma care outreach|Real-time asthma care identification of uncontrolled asthma and real-time notification of patients and their physicians of uncontrolled asthma and directions to improve care. Patients without an asthma specialist visit in the prior 3 years are offered an expedited allergy department referral.
46028633|NCT00622609|Drug|GSK249320A|GSK249320A intravenous infusion will be formulated as 100 milligrams/milliliters in 2 milliliters vials (filled to 1 milliliter), in phosphate buffer and delivered by a syringe and programmable pump.
46028634|NCT00622609|Drug|Placebo|Sodium chloride intravenous infusion will be given as matching placebo.
46028635|NCT04187287|Other|Radial Extracorporeal Shock Wave Therapy|Radial Extracorporeal Shock Wave Therapy will given for 3 weeks, 1 days in a week. moreover 10-12 minutes cold pack will apply for every session
46028636|NCT04187287|Other|Deep Friction Massage|Deep Friction Massage will given for 3 weeks, 3 days in a week. Massage duration will be 10-15 min. for each session. Moreover 10-12 minutes cold pack will apply for every session. Also Mill's manipulation technique will applied once a week during 3 weeks.
45471125|NCT02356458|Drug|Ibrutinib|"Combination therapy:~Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Ibrutinib: p.o daily; Phase I: according to DL; Phase II: RP2D established in phase I~Maintenance therapy:~p.o daily: 560 mg"
45471126|NCT02356458|Drug|bortezomib|"Combination therapy:~Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Injection of Bortezomib (s.c.), dose of 1.3 mg/m2 on day 1, 4, 8, 11"
46028637|NCT04596319|Biological|AP-PA02|Bacteriophage administered via inhalation
46028638|NCT04596319|Other|Placebo|Inactive Placebo administered via inhalation
46028639|NCT04208737|Procedure|recruitment maneuver|30 cmH2O pressure 15 seconds
46028640|NCT05661799|Behavioral|Intervention Group|The programme is a PA programme consisting of one weekly session for 12 weeks. The one hour of PA is supplemented by two 15-minute periods. At the end of each session, a PA challenge and a positive reinforcement exercise are proposed for the coming week. At the beginning of the next session, the facilitator has a dedicated time to give feedback on these challenges (successes and difficulties encountered). At the end of each session, the facilitator explains the theme of the next challenge and exercise. For the challenge, three options are proposed. Each participant chooses the option he/she prefers. Positive reinforcement exercises are also offered in the same way. They aim to strengthen motivation, hope and the sense of self-efficacy (SEP). In addition to these two 15-minute sessions, participants are offered a one-and-a-half hour group session for information and experience sharing. The aim of this session is to discuss different themes.
45471127|NCT03267264|Device|BD Nano™ vs Nucleus|"Subjects will be randomized to~Nucleus pen needle for the first 15-day period, or current pen needle (BD Nano™) for the second 15-day period or~subject's current pen needle (BD Nano™) for the first 15-day period, Nucleus pen needle for the second 15-day period"
45471128|NCT03267264|Device|NovoFine® vs Nucleus|"Subjects will be randomized to~Nucleus pen needle for the first 15-day period, or current pen needle (NovoFine®) for the second 15-day period or~subject's current pen needle (NovoFine®) for the first 15-day period, Nucleus pen needle for the second 15-day period"
45471129|NCT03267264|Device|NovoTwist®/NovoFine® Plus vs Nucleus|"Subjects will be randomized to~Nucleus pen needle for the first 15-day period, or current pen needle (NovoTwist®/NovoFine Plus®) for the second 15-day period or~subject's current pen needle (NovoTwis®t/NovoFine® Plus) for the first 15-day period, Nucleus pen needle for the second 15-day period"
45471130|NCT03267264|Device|Other Commercially Available Pen Needles (Unifine® Pentips®/Mylife Clickfine®) vs Nucleus|"Subjects will be randomized to~Nucleus pen needle for the first 15-day period, or current pen needle (Other Commercially Available Pen Needles) for the second 15-day period or~subject's current pen needle (Other Commercially Available Pen Needles) for the first 15-day period, Nucleus pen needle for the second 15-day period"
45471131|NCT02134392|Biological|Fecal Microbiota Transplantation|250 ml of a fecal suspension diluted in saline will be administered via colonoscopy or enema in patients with recurrent c-diff.
45471132|NCT03244800|Drug|MEDI0382|MEDI0382 will be administered subcutaneously once daily for 49 days.
45471133|NCT03244800|Drug|Placebo|Placebo will be administered subcutaneously once daily for 49 days.
45471134|NCT04516291|Drug|Vupanorsen|Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
45471135|NCT04516291|Drug|Placebo|Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
45471136|NCT03243630|Drug|IV nicotine|Subjects in each arm will receive three infusions in a random order one hour apart. The infusions will be saline, 0.25mg/70kg and 0.5mg/70kg
45471137|NCT03243630|Drug|Menthol flavor|American e-liquids' menthol flavor used in e-cigarettes will be used as the placebo comparator
45471138|NCT03243630|Drug|green apple|green apple will be added to the menthol flavor
45471139|NCT03243630|Drug|green apple and menthol|menthol and green apple will be the active intervention
46028641|NCT05661799|Behavioral|Control Group|The programme is a PA programme consisting of one weekly session for 12 weeks.
46028642|NCT04548037|Other|PET-CT examination|The subject is placed in supine position, the head immobilized in a headrest. The imaging sequence begins with a scout view (viewing angle 90 °, 120 kV, 20 mA), then an X-ray scan is performed for the attenuation correction (120 kV, 5 mAs per slice, pitch 0.531, collimation 40 mm , FOV 70) and diagnostic CT scan (120 kV, 100-250 mA: auto mA, pitch 0.531, 40 MM, DFOV 25, ASIR 60%, thickness 1.25 mm). Finally, the positron emission tomography is acquired: static in 3D mode for 15 minutes, 30 minutes after the injection of 18 FDG, the axial field of view is 25, the matrix in 256 x 256, OSEM reconstruction 6 iterations 24 subsets, attenuation correction, diffused, and PSF. Gaussian filter, cutoff frequency of 4. Obtaining forty-seven contiguous sections of 3.26 mm thick.
45471140|NCT03753841|Other|Adjustment of oral diet|Adjustment of oral diet based on findings in fiberendoscopic evaluation of swallowing (FEES)
46028643|NCT04325737|Drug|SEP-363856|Dosing of the SEP-363856 group in Cohort 1 will be initiated at 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days. The SEP-363856 group in Cohort 2 will be dosed at 25 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days.
45471141|NCT03750019|Behavioral|Satisfying rehearsal task|Participants rehearsed satisfying aspects of the lunchtime meal they just ate.
45471142|NCT03750019|Behavioral|Dissatisfying rehearsal task|Participants rehearsed dissatisfying aspects of the lunchtime meal they just ate.
45471143|NCT03750019|Behavioral|Neutral rehearsal|Participants rehearsed their journey to campus that day.
46028644|NCT04325737|Drug|Placebo|Placebo will be orally administered according to the same administration schedule as the SEP-363856 group in each cohort.
46028645|NCT00457873|Drug|0.9% saline in 5% dextrose (intravenous)|
46028646|NCT00457873|Drug|0.45% saline in 5% dextrose (intravenous)|
46028647|NCT02689375|Device|Senza Spinal Cord Stimulation system|Suitable participants will be booked to have spinal cord stimulator trial leads implanted and an external programmable High Frequency battery trial box as a day case
45471144|NCT03751345|Behavioral|Parenting Wisely|PW is a self-administered, interactive, multimedia online program. Parents will complete computer-administered sessions during in-person appointments.The program comes with a parent workbook so that parents can gain additional exposure to and practice with the skills. The complete PW program takes from 3 to 5 hours to complete depending on the users' speed and depth of use. Parents will be given a login at enrollment so that they have the option to practice sessions or view any additional sessions at home. Individual coaching sessions will take place in-person with parents. Coaching sessions are designed to tailor the PW skills to each parent's presenting concerns.
45839029|NCT04337268|Drug|Glucagon-Like Peptide 1|Intravenous infusion (1.5 pmol/kg/min) for 60 min.
46028648|NCT04504357|Behavioral|Tablet based U=U app|"Tablet based app focusing on TasP/U=U videos on: a) the science of TasP/U=U including risks, (b) benefits to self (e.g. psychological benefits, ability to have children), (c) benefits to partners (e.g. secondary prevention), (d) benefits to society (e.g. AIDS-free generation), and (e) TasP self-efficacy, including viral load (VL) literacy, disclosure, and couples testing."
45682210|NCT03885310|Device|GIE Drug Coated Balloon|The GIE DCB is a balloon catheter with a 3 stage inflatable balloon coated with a proprietary coating containing the drug and carriers.
45839030|NCT04337268|Drug|saline 0.9%|Intravenous infusion for 60 min.
45471145|NCT04761289|Other|Multimodal Exercise and Functional Rehabilitation Program|"Prescription of multimodal physical exercise.~Reeducation of Activities of Daily Living (ADL).~Prescription of support products and adaptations of the environment."
45682211|NCT03885232|Behavioral|Experimental: PIVOT with MI|Providers in participating intervention clinics will be trained in the PIVOT-MI strategy in which a presumptive format is used to initiate the childhood vaccine recommendation with all parents followed by use of motivational interviewing (MI) with parents who voice resistance to that recommendation. Parent participants will receive PIVOT-MI.
45682212|NCT03885232|Other|Active Comparator: Control|Providers at participating control clinics will deliver care as usual. Parent participants will receive standard care.
45682213|NCT04764916|Drug|Liposomal bupivacaine|Liposomal bupivacaine will be used as adductor canal block
45682214|NCT04764916|Drug|Bupivacaine Hydrochloride|This is the facility's standard of care medication for this procedure
46028649|NCT04504357|Behavioral|U=U videos played in clinic waiting rooms and integrated into HIV counseling session|TasP/U=U videos on: a) the science of TasP/U=U including risks, (b) benefits to self (e.g. psychological benefits, ability to have children), (c) benefits to partners (e.g. secondary prevention), (d) benefits to society (e.g. AIDS-free generation), and (e) TasP self-efficacy, including viral load (VL) literacy, disclosure, and couples testing.
46028650|NCT04504357|Other|Text messages|Monthly text messages reinforcing intervention content
46028651|NCT02697565|Behavioral|Healthy Caregivers- Healthy Children Toolkit|The treatment arm will receive the train-the-trainer model (utilizing Quality Counts coaches) to deliver the evidence- based HC2 toolkit.
46028652|NCT02697565|Behavioral|Safety Curriculum|Centers randomized to the control arm will receive an attention control consisting of three visits from 'Safety Sam,' a character and safety curriculum that was fully developed and implemented in phase I of HC2. The same delivery model (train-the-trainers utilizing Quality Counts coaches) will be implemented.
46028653|NCT04208191|Behavioral|Quality Improvement Collaborative|Facilities that participated in a QI collaborative to improve PCC for MH and FP services
46028654|NCT02697409|Behavioral|Education Against Tobacco intervention|
46028655|NCT02697331|Drug|Progesterone|"women will receive progesterone vaginal pesarries containing 200mg of progesterone twice daily . it will be used by the patient as one vaginal pessary per vagina twice per day .~women will be showed how to use tablets . medication will be started at 20 -24 weeks and stopped at 36+6 weeks"
46028656|NCT02697331|Other|Placebo|women will receive placebo pessary twice a day. women will be showed how to use tablets . medication will be started at 20-24 weeks and stopped at 36+6 weeks
46028657|NCT02697175|Device|Live Video-Colposcopy|The colposcopy will be shown in real time on a flat screen
46028658|NCT02697175|Other|No Live Video-Colposcopy|The TV will be shut off during colposcopy
45839031|NCT04337112|Drug|viltolarsen|Intravenous (IV) infusions, weekly, at 80mg/kg, once weekly (approximately every 7 days).
45839032|NCT04336566|Dietary Supplement|Melatonin|Melatonin 5mg
45839033|NCT04336566|Dietary Supplement|Placebo|Comparable Good Neighbor Pharmacy placebo tablet
45839034|NCT04336254|Biological|allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Intravenous injection of 3.0x10e7 human dental pulp stem cells solution (30ml) on day 1, day 4 and day 7, based on routine treatment of COVID-19
45839035|NCT04336254|Other|Intravenous saline injection (Placebo)|Intravenous injection of 3ml of 0.9% saline on day 1, day 4 and day 7, based on routine treatment of COVID-19
45682215|NCT04676386|Diagnostic Test|Primary Immune Response (PIR) test by Biodesix, Inc.|Blood draw for biomarker assessment will be performed at these time-points: pretreatment, start of 3rd cycle and investigator assessed progression. The biomarker analysis will be performed retrospectively.
45598713|NCT02292589|Device|Sham Stimulation|The patient will receive anodal tDCS over the occipital area for 30 seconds only and then it will be turned off without the patient's knowledge.
45682216|NCT01674790|Behavioral|Aerobic training|One 20-min session of body weight support treadmill training at moderate to high intensity (60-70% heart rate reserve) 5 days/week for 6-weeks.
45682217|NCT01674790|Behavioral|Cognitive training|One 20-min session of cognitive training (computerized dual n-back training program) 5 days/week for 6 weeks.
45682218|NCT01674790|Behavioral|Range of motion exercise|One 20-min session of range of motion exercise (non-aerobic passive and active movement of upper and lower extremity) 5 days/week for 6-weeks.
45682219|NCT01674790|Behavioral|Unstructured mental activity|One 20-min session of unstructured mental activity (e.g., listening to light novels on tape) 5 days/week for 6-weeks.
45682220|NCT01674868|Drug|fluoxetine|20 mg daily for 90 days starting day 5-10 after stroke.
46028659|NCT04187911|Behavioral|Dyadic Developmental Psychotherapy (DDP)|DDP involves approximately twenty 1 hour sessions (usually over 6-9 months) with the adoptive parent/foster carer and child, facilitated by a specifically trained therapist. The role of the therapist during sessions is to maintain an attuned relationship with both child and parent - modelling and encouraging development of a similarly attuned relationship between the child and parent. Therapists are trained to use Playfulness, Acceptance, Curiosity and Empathy (PACE). Our research suggests that key mechanisms of action in DDP might include the active participation of the parents and increased carer empathy and emotional warmth for the child. DDP experts believe this helps build parental capacity for attuned dialogue with the child, co-creation of the meanings underlying child behaviour, and co-regulation of experienced emotions aiming to address four main problem areas: 1. child emotional regulation 2. parental stress 3. the parent-child relationship 4. child mental health.
45471146|NCT04725331|Biological|BT-001|Oncolytic Vaccinia virus containing genes encoding the 4-E03 human recombinant anti-hCTLA4 antibody and human GM-CSF administered at different dose [Phase I, Part A] and at Recommended Dose for Part B [Phase I, Part B and Phase IIa] by intra-tumoral (IT) route.
45682221|NCT01674868|Drug|placebo|subjects will take one pill po daily for 90 days.
45682222|NCT01674946|Other|saline|intraduodenal perfusion
45471147|NCT04725331|Biological|Pembrolizumab [Keytruda]|Programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
45682223|NCT01674946|Other|bile acid (CDCA, chenodeoxycholic acid)|intraduodenal perfusion
45682224|NCT01674946|Other|oleanolic acid|intraduodenal perfusion
45682225|NCT01674946|Dietary Supplement|oleic acid|intraduodenal perfusion
46028660|NCT04187911|Behavioral|Services as Usual (SAU)|"SAU tends to be case-dependent with therapists and social workers attempting to respond to the sometimes changeable needs of the family as needs arise. At the time of our UK mapping and modelling work, these services were usually CAMHS based. This may have changed, at least for adoptive families, with the advent of the Adoption Support Fund, which, since May 2015, has allowed local authorities / adoption agencies to apply for funding for essential therapeutic services. A wide range of interventions, many with a scant evidence base, have been purchased - sometimes from private practitioners - since 2015. In addition, relevant NICE guidelines, particularly those on Looked After and Accommodated Children, Attachment and Child Abuse and Neglect, have been published or updated.Our detailed qualitative and quantitative process evaluation throughout all study Phases will be crucial to carefully characterise SAU in all study sites."
46028661|NCT04308109|Behavioral|Simulation|Simulation involves the use of a highly realistic tracheostomy mannequin and audiovisual devices which will be used to replicate emergent clinical situations. If home invasive ventilation is anticipated, a home ventilator will be used. The simulation will last approximately 2 hours and will end with reviewing the taped session as part of debriefing. Both active arms will occur in the simulation center or sleep lab and replicate the same clinical situations by the same simulation instructor.
46028662|NCT04284943|Procedure|Long limb Roux-en-Y reconstruction after subtotal gastrectomy|The jejunum will be divided approximately 150 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 50 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).
46028663|NCT04284943|Procedure|Conventional Roux-en-Y reconstruction after subtotal gastrectomy|The jejunum will be divided approximately 20 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 30-45 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).
46028664|NCT04284943|Procedure|Billroth II reconstruction after subtotal gastrectomy|The duodenum will be transected approximately 2 cm distal to the pylorus and anastomosis will be performed between the gastric remnant and a loop of jejunum chosen approximately 20 cm distal to the ligament of Treitz (Length of afferent loop)
46028665|NCT04278625|Drug|Acetaminophen|IV acetaminophen given as part of standard of care.
46028666|NCT02689141|Drug|Bendamustine|Debulking: Cycles 1 - 2, d1 & 2: 70 mg/m2 i.v.
46028667|NCT02689141|Drug|Ofatumumab|"Induction:~Cycle 1: Day 1 300 mg i.v.; Day 8 1000 mg i.v.; Day 15 1000 mg i.v. Cycle 2-6: Day 1 1000 mg i.v.~Maintenance: After the induction ofatumumab iv 1000 mg every three months will be continued.~Cycle 1-8: Day 1 1000 mg i.v."
45682226|NCT01675024|Drug|Rotigotine, Period 1|"Formulation: transdermal~Dosage: 2 mg / 24 hours once at Day 2~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"
46028668|NCT02689141|Drug|Ibrutinib|Induction: Cycle 2-6: d1-28: 420 mg p.o. Maintenance: After the induction ibrutinib p.o. 420 mg daily will be continued. Cycle 1-8: d1-84: 420 mg p.o.
46028669|NCT00622687|Drug|iloprost|0.5-2 ng/kg x min for 6hours a day for 21 consecutive days
46028670|NCT00622687|Drug|iloprost low dose|0.5 ng/kg x min over 6 h per day for 21 consecutive days
46028671|NCT00622687|Drug|iloprost therapy up to 2 ng/kg x min|starting therapy at doses of 0.5 ng/kg x min, increase the dose every two days for 0.5 ng/kg x min up to the maximally tolerated dose or to 2 ng/kg x min
45682227|NCT01675024|Drug|Rotigotine, Period 2|"Formulation: transdermal~Dosage: 2 mg / 24 hours for 3 days from Day 7 to Day 9, 4 mg / 24 hours for 3 days from Day 10 to Day 12~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"
46028672|NCT04432051|Behavioral|mechanical ventilator settings and position|Mechanical ventilation settings and patient position will be re-evaluated
45471148|NCT05457595|Radiation|carbon ion radiation therapy|"CIRT: Planning Target Volume (PTV) will be delivered a total dose of 48-52.8 GyRBE in 12 fractions, 4 fractions per week. Treatment duration 3 weeks.~Treatment lasting more than 5 weeks or cases of treatment with less than 6 fractions in 14 consecutive days will not be accepted."
45471149|NCT03753685|Drug|X-396(Ensartinib) Capsule|All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.
45682228|NCT03884374|Behavioral|Focused Breathing and Attention Training (BAT)|Participants will receive mindfulness-based mental training regimen to independently practice mindfulness meditation.
45682229|NCT03884374|Behavioral|Standard Breathing and Attention Training (BAT)|Standard BAT intervention will incorporate most of the general aspects of the Focused BAT intervention but without the specific instructions related to mindfully attending to the breath in a non-evaluative manner.
46028673|NCT02687659|Device|TEMIS system|Wearing TEMIS system over the day during one week
46028674|NCT04220983|Radiation|MR-Guided Prostate SBRT|Prostate SBRT has become a standard of care for the treatment of localized prostate cancer. Radiation is delivered to the prostate and seminal vesicles in 5 treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated good outcomes with acceptable toxicity when planning is delivered appropriately.
45471150|NCT03751267|Procedure|Tuina (massage)|Tuina is massage based on Traditional Chinese Medicine (TCM) principles.
46028675|NCT05662735|Device|Mesh repair|Augmentation of hiatal hernia repair with TiMESH® reinforcement
46028676|NCT05662735|Procedure|Suture repair|Primary laparoscopic repair of the hiatal hernia using non-absorbable sutures
46028677|NCT04215679|Other|Three-dimensional immersive virtual reality application|In this group, individuals will be included in a game program that will last for 3 days a week for a total of 6 weeks and 45 minutes a day. Individuals will use the IVR to rehabilitate functions that are frequently used in daily life through task-oriented games. The IVR device will be placed on the head of the individual by closing the eyes of the individual and the Leap Motion device will be used to enable individuals to see their own hands in a virtual reality environment. In order to ensure the safety of individuals, practices shall be carried out with the individual sitting in the chair and leaning against the back. A total of 3 different games will be used for upper extremity function, each game will be 15 minutes and the total session time will be 45 minutes.
45471151|NCT04450381|Device|Rad-67 Pulse oximeter & DCI Mini sensor|Noninvasive pulse oximeter that measures hemoglobin
45471152|NCT03068468|Drug|BIIB092|BIIB092 intravenous infusion on specified days
45471153|NCT03068468|Drug|Placebo|Placebo intravenous infusion on specified days
45471154|NCT04512001|Drug|MSB11456|Participants will receive MSB11456 subcutaneously, once a week.
45471155|NCT04512001|Drug|EU-approved RoActemra|Participants will receive EU-approved RoActemra® subcutaneously, once a week.
45471156|NCT01569698|Procedure|acute extra renal replacement therapy|usual modalities of pediatric acute extra renal replacement therapy : Intermittent Hemodialysis, Continuous Renal Replacement Therapies, and Peritoneal Dialysis
45471157|NCT05181176|Dietary Supplement|Coffee|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
45471158|NCT05181176|Dietary Supplement|Green tea|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
46028678|NCT04215679|Other|Motor imagery|Motor imagery will be performed with the eyes closed. In addition, for the safety of the individual, the individual will sit comfortably in a chair in a quiet environment and sit back. In the motor imagery group, individuals will be shown videos of the 3 games for 2 times in the IVR group and will be asked to imagine that they perform the same functions in the IVR games. The motor imagery will be 3 days a week for a total of 6 weeks and 45 minutes per day (including rest periods).
46028679|NCT04215679|Other|Conventional physiotherapy|Individuals in this group will be randomly recruited from hospitalized stroke volunteers. Since these individuals receive routine rehabilitation 5 days a week, they will be evaluated at the beginning and end of 18 sessions over a total period of 6 weeks. Conventional physiotherapy will include normal joint movements, muscle strengthening exercises, balance and mobility exercises, and exercises to improve daily life activity.
45839036|NCT04336488|Drug|Matrix Metalloproteinase Inhibitors (Orochem)|topical application of MMP inhibitors for 3 weeks to evaluate its effectiveness in treating oral lichen planus
46028680|NCT02691403|Drug|levo-bupivacaine|
46028681|NCT02691403|Drug|normal saline|
45839037|NCT04336488|Drug|Kenacort A,|topical application of both drugs 3 times daily for 3 weeks as an active control
46028682|NCT02685319|Procedure|muscle biopsy|a muscle sample will be taken from the mid-thigh (Vastus Lateralis) and analyzed
46028683|NCT04184713|Dietary Supplement|Experimental Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber and omega-3 enriched, with L-leucine, betaglucans and medium chain triglycerides) for 8 weeks.
46028684|NCT04184713|Dietary Supplement|Control Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber) for 8 weeks.
46028685|NCT03424915|Behavioral|Harvard Health Professionals survey|Participants will be asked a series of questions (using a validated questionnaire) to assess self-reported exercise exposure over the past 12 months.
46028686|NCT03424915|Other|Blood draw|Participant will provide a blood sample
45839038|NCT04336176|Device|PulseFlow DF boot|Offloading boot
45839039|NCT04336176|Device|Usual standard of care|Usual standard of care (offloading device)
45839040|NCT04336176|Device|Sham|Sham shoe (closest to barefoot or baseline pressures)
46028687|NCT03424915|Other|CPET Procedures|CPET with 12-lead ECG
46028688|NCT03424915|Other|stool sample|Research stool sample (within ±1 week of surgery), if possible
46028689|NCT03424915|Procedure|Research Tissue sampling|Sample of the tumor and normal breast tissue may be taken from the tissue removed during breast cancer surgery if there is enough tissue left over for research testing.
45471159|NCT05181176|Dietary Supplement|Herbal tea (placebo)|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
45839041|NCT04335864|Procedure|Laparoscopic salpingectomy|39 patients with hydrosalpinx will have laparoscopic salpingectomy
45839042|NCT04335864|Procedure|Hystroscopic proximal tubal occlusion|39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion
45839043|NCT04335786|Drug|Valsartan (Diovan)|"At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.~Study drug dosages will be titrated to blood pressure with a maximum of 160mg b.i.d."
45839044|NCT04335786|Drug|Placebo oral tablet|At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.
45839045|NCT04335630|Diagnostic Test|Electrocardiogram, telemetry, echocardiogram, laboratory values|Serial electrocardiograms, telemetry monitoring, echocardiographic assessment and serial laboratory testing will be used to identify differences among the two study groups.
45839046|NCT04335708|Dietary Supplement|Postibiotic formulation|5 mL daily of edible gel with intracellular content of Lactobacillus casei CRL-431
46028690|NCT00995007|Drug|ZD6474 (Vandetanib)|Vandetanib is an oral medication known to block angiogenesis and has shown significant antitumor activity in laboratory and animal studies. Vandetanib appears to be well tolerated by patients at specific daily doses.
46028691|NCT00995007|Drug|Carboplatin|Carboplatin is a drug that interrupts division of cancer cells and has been shown to be a useful drug in treatment of tumors known as gliomas. It is a useful drug for treating brain tumors, but researchers are interested in gathering more information about how it works as a treatment for patients who have not responded to initial surgery, radiation, or chemotherapy.
46028692|NCT00639847|Behavioral|In-home asthma management program (AMP) provided by nurses|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
46028693|NCT00639847|Behavioral|In-home asthma management program (AMP) provided by respiratory therapists|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
45471160|NCT04528160|Other|Pain neuroscience education and exercise|PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. Exercise will included genera exercise delivered at moderate intensity.
45839047|NCT04335708|Dietary Supplement|Placebo formulation|5 mL daily of edible gel without intracellular content of Lactobacillus casei CRL-431
46028694|NCT02685475|Drug|Axillary Brachial Plexus Blocks|All patients received ultrasound-guided axillary brachial plexus block (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
45471161|NCT04528160|Other|Usual Care|Usual care delivered at primary care for older adults with pain.
46028695|NCT00909883|Drug|Botulinum Toxin: Xeomin|45 patients with an Idiopathic Parkinson's disease and a foot dystonia. Double blind, randomized study
45471162|NCT05172050|Drug|Raloxifene|Raloxifene was administered as 60 mg hard gelatine capsule(s) once a day. Starting from day 2 of treatment: one single capsule (plus one of placebo to guarantee the blinding) containing 60 mg raloxifene was administered in Group 1, and 2 capsules 60 mg each for a total of 120 mg in Group 2.
45682230|NCT03884374|Device|Transcranial Direct Current Stimulation (tDCS)|A Soterix 1x1 Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two bicarbon rubber electrodes encased in saline-soaked sponges
45682231|NCT03884374|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Sham stimulation procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA (30s ramp up/down) of stimulation at the beginning of the session.
45682232|NCT03883828|Drug|Chlorhexidine gluconate solution|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
46028696|NCT00909883|Drug|Placebo|Placebo injection
46028697|NCT00639925|Biological|VEGFR1-1084, VEGFR2-169, and gemcitabine|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 of each 28-day treatment cycles. Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8 and 15.
46028698|NCT00994461|Drug|Celecoxib|Celecoxib 100mg tablet twice a day with meal for 2 weeks
46028699|NCT00994461|Drug|Loxoprofen|Loxoprofen 60mg tablet three times a day with meal for 2 weeks
46028700|NCT00994461|Drug|Placebo|Placebo tablet three times a day with meal for 2 weeks
46028701|NCT02685553|Device|NIR|Laparoscopic use of NIR
46028702|NCT04185961|Device|EVERA-RAPHA with 60mmHG|Apply EVERA-RAPHA with 60mmHG for 4weeks
46028703|NCT04185961|Device|EVERA-RAPHA with 100mmHG|Apply EVERA-RAPHA with 100mmHG for 4weeks
46028704|NCT00993915|Drug|Atorvastatin|Atorvastatin, 10- 80 mg, once daily, 6 month treatment
46028705|NCT03963739|Other|Interview|Undergo interview
46028706|NCT03963739|Other|Questionnaire Administration|Ancillary studies
46028707|NCT04174911|Drug|BOL-DP-o-08|BOL-DP-o-08 sublingual drops
46028708|NCT04174911|Drug|Placebo|sublingual drops
46028709|NCT01202591|Drug|AZD4547|Tablet oral twice daily
46028710|NCT01202591|Drug|Exemestane|Tablet oral once daily
46028711|NCT01202591|Drug|Placebo|Tablet oral twice daily
46028712|NCT01202591|Drug|Fulvestrant|A monthly intramuscular injection of a depot formulation with a loading dose 14 days after initial administration
46028713|NCT00639067|Device|Breath Collection Apparatus|Breath collected and analyzed for markers of lung cancer.
46028714|NCT02687503|Dietary Supplement|Probiotic|All children will receive a daily dose of probiotic (10⁹ cfu of L.acidophilus NCFM and B. lactis, Bi-07), a commercially available probiotic. Parents will give probiotic in 1 ounce of milk or water once a day for 30 days in an open label fashion.
46028715|NCT01202279|Drug|Guaifenesin|1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days
46028716|NCT01202279|Device|Placebo|Placebo bid for 7 days
45471163|NCT05172050|Other|Placebo|Placebo was administered orally once a day as 2 capsules (for maintaining the blinding design)
45471164|NCT04447417|Drug|Dupilumab SAR231893|Pharmaceutical form:solution for injection Route of administration: subcutaneous
45471165|NCT02787044|Biological|High Dose Trivalent Influenza Vaccine|High Dose Trivalent Influenza Vaccine
45471166|NCT02787044|Biological|Standard Dose Quadrivalent Influenza Vaccine|Standard Dose Quadrivalent Influenza Vaccine
45471167|NCT01345019|Drug|Denosumab|Administered by subcutaneous injection once every 4 weeks.
45471168|NCT01345019|Drug|Zoledronic acid|Administered by intravenous infusion over 15 minutes once every 4 weeks
45471169|NCT01345019|Drug|Placebo to Denosumab|Administered by subcutaneous injection once every 4 weeks.
45471170|NCT01345019|Drug|Placebo to zoledronic acid|Administered by intravenous infusion over 15 minutes once every 4 weeks
45471171|NCT01345019|Drug|Denosumab (for the open-label treatment phase)|Administered by subcutaneous injection once every 4 weeks.
45839048|NCT04335474|Procedure|Surgical drainage strategy|A laparotomy is performed and the operative approach to pancreatic trauma can consist of laparotomy with drainage of the peripancreatic area, distal pancreatectomy with or without preservation of the spleen, Rouxen-Y pancreaticojejunostomy, and, more seldom, pancreaticoduodenectomy. The type of operation depends on the grade of the pancreatic lesion. Spleen-preserving surgery will be attempted to avoid the lifelong increased risk of infections after splenectomy. In case of trauma where multiple organs are involved and an acute laparotomy is performed, the damage control surgery must be applied and the pancreatic resection will be done as part of a staged surgery.
46028717|NCT03877315|Device|Stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
46028718|NCT03877315|Device|Stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
46028719|NCT02687347|Drug|oral methadone|Oral methadone is the study drug
46028720|NCT02687347|Drug|oral morphine|Oral morphine is the active comparator. It is not a placebo intervention
46028721|NCT01201967|Other|Collaborative care|Study care manager provides psychoeducation, therapy, and care coordination between patient, psychiatrist, and primary medical physicians.
46028722|NCT01201967|Other|Usual care|Patient's primary medical physician informed of mental health symptoms/diagnosis
46028723|NCT02687425|Drug|Pioglitazone|15mg/day,po
46028724|NCT02687425|Drug|imatinib mesylate|400mg/day,po
46028725|NCT02537665|Other|heating precondition|
46028726|NCT02687269|Drug|Ranolazine|Patients in this arm receive Ranolazine at a dose of 375 mg twice daily in the three days before surgery
46028727|NCT02687269|Drug|Placebo|Patients receive Placebo twice daily in the three days before surgery
46028728|NCT03826927|Other|treatment with NOACs or VKAs|treatment with NOACs or VKAs initiated or continued for prevention of ischemic events
46028729|NCT02689297|Other|chlorine dioxide|First week, subjects were instructed to do regular tooth brushing. After that group A was requested to use chlorine dioxide mouthwash two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
46028730|NCT02689297|Other|small toothbrush for tongue cleaning|First week, subjects were instructed to do regular tooth brushing. After that group B was requested to brush their tongue with small toothbrush two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
46028731|NCT04186741|Drug|Hyperbaric oxygen|Patients already on treatment by hyperbaric oxygen therapy for medical conditions requiring treatment by it
46028732|NCT04185805|Drug|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
45682233|NCT03883828|Drug|Mupirocin Ointment|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
45682234|NCT02081950|Biological|Enoxaparin sodium|comparison of 2 different administration of drug
45682235|NCT03878212|Other|mHealth application with interactivity|a mHealth device with interactivity with nurse case manager
45682236|NCT03878212|Other|mHealth application|a mHealth device
46028733|NCT04185805|Drug|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
46028734|NCT03758755|Device|Blood Flow Restriction Therapy|A wide pressure cuff will be applied to the upper thigh prior to starting strengthening exercises. The cuff is inflated to 80% of resting systolic blood pressure. The cuff remains inflated for the entirety of the exercise (4 sets of a specific movement). Once the exercises are completed, it is deflated for a minimum of one minute before the next type of exercises are started.
46028735|NCT03758755|Other|ACL Reconstruction rehabilitation|post-operative rehabilitation according to current standards of care
46028736|NCT01201811|Drug|Azacitidine|Subjects will receive azacitidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment. In addition, subjects may receive best supportive care as needed, including antibiotics and transfusions, per Investigator discretion.
46028737|NCT04186897|Procedure|Occlusal reduction|Occlusal contacts on the functional and non-functional cusps were reduced.
46028738|NCT04186897|Procedure|Sham occlusal reduction|The occlusal surface left intact. No actual occlusal reduction.
45471172|NCT04507867|Dietary Supplement|Nutritional support system (NSS)|"Combination of three B vitamins (B1, B6 and B12) Neurobion 10 mg solution for IM injection, One every 24 hours for the first 5 days.~Probiotics Saccharomyces boulardii CNCM I-745 Floratil. One morning and one evening 250 mg capsule during the first 6 days~One envelope of NSS-1 in the morning and one envelope in the afternoon mixed with 400 ml of water each, contain nutritional support system."
45471173|NCT04507867|Other|Conventional nutritional support designed by hospital nutritionists|Diet designed by the nutrition department according to comorbidities and intubation probability. Food will be established according to the provisions of the ISSEMYM Toluca Arturo Montiel Rojas Medical Center.
45471174|NCT04487522|Procedure|Open retromuscular ventral hernia repair|With the subject under general anesthesia, a single incision is made in the abdomen. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
45471175|NCT04487522|Procedure|Laparoscopic retromuscular ventral hernia repair|With the subject under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the repair. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
45471176|NCT04487522|Device|Robotic-assisted retromuscular ventral hernia repair|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the subject and used to complete the procedure. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
45471177|NCT02610374|Other|Agrarian Diet|A diet higher in carbohydrates and lower in fats and sugars
45471178|NCT02610374|Other|Western-type Diet|A diet higher in fats and lower in carbohydrates
45471179|NCT03069716|Device|Smartphone Text Messaging|A HIPPA compliant text messaging platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network. Subjects will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule (defined at enrollment). These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
45471180|NCT03069716|Device|Fitbit Charge HR|The Fitbit Charge HR tri-axial accelerometer will be used to continuously gather data on physical activity, heart rate, and sleep. This device provides feedback in units of activity (steps, stairs climbed, activity time, and exercise time) and heart rate (per second when active, per 5 seconds when inactive). It has been validated against research devices in free-living conditions and is relatively inexpensive.
46028739|NCT05400785|Other|Circadian Rhythms for Mood (CRM) application - Active|The study subjects participating in this clinical trial wear wearable activity tracker 24 hours a day for a continuous period of time and run the CRM app once a day to check their conditions (feelings, vitality, sleep, etc.) in the Daily Symptom Assessment (eMoodChart). The active intervention group are provided with mood prediction results and instructions as feedback through the 'life report' and push notification in the application.
46028740|NCT05400785|Other|Circadian Rhythms for Mood (CRM) application - Sham|The study subjects assigned to the sham intervention group are provided with feedbacks operated by dummy algorithm. The application is visually indistinguishable from active CRM, and it is designed to minimize behavioral change.
46028741|NCT05392127|Drug|SHR0302 Tablets|SHR0302 Tablets once daily
46028742|NCT05392127|Drug|Midazolam Maleate Tablets|Midazolam Maleate Tablets single dose
46028743|NCT05392127|Drug|Warfarin Sodium Tablets|Warfarin Sodium Tablets single dose
46028744|NCT05392127|Drug|Omeprazole Enteric Capsules|Omeprazole Enteric Capsules single dose
46028745|NCT05392127|Drug|Vitamin K1 Tablets|Vitamin K1 Tablets once daily
46028746|NCT05392127|Drug|Repaglinide Tablets|Repaglinide Tablets single dose
46028747|NCT05378399|Drug|Descovy or Truvada|Descovy or Truvada prescribed with digital pills for PrEP
46028748|NCT05378399|Device|ID-Cap System|Digital pills overencapsulating Descovy or Truvada for PrEP
46028749|NCT05378399|Device|Beiwe|Digital phenotyping app
46028750|NCT03676465|Other|CloudConnect Report|Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. The participants will receive a weekly CloudConnect Report that is based on analysis of the data gathered from the downloads provided by the subject during that week. Participants will both receive weekly contact from the study team to discuss the communication that the subject & their parent had during the week about the participant's diabetes management.
46028751|NCT03676465|Other|Will not receive a CloudConnect Report|Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. Participants will receive weekly contact from the study team to discuss the communication that the subject & their parent had during the week about the participant's diabetes management.
46028752|NCT04379011|Drug|Brivaracetam|Escalating brivaracetam dose to 150 mg twice daily for 3 months
46028753|NCT04379011|Other|Placebo|Placebo twice daily for 3 months
46028754|NCT02687113|Device|CT/US fusion|Fusion of pre-RFA cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
46028755|NCT02685163|Other|Antioxidant ice-cream|Narutal Antioxidant ice-cream
45471181|NCT03749785|Other|Regular carbohydrate feeding|60 ml of water with 5 g sucrose given every 5 minutes 14 times up until 70 minutes followed by 5 g sucrose after 75 minutes in a 250 ml solution
45471182|NCT03749785|Other|Single carbohydrate bolus|60 ml of water given every 5 minutes 14 times up until 70 minutes followed by 75 g sucrose after 75 minutes in a 250 ml solution
45471183|NCT03749707|Diagnostic Test|HPV analysis|HPV analysis of SLNs
45471184|NCT02535884|Device|ACTIVA® PC neurostimulator (Model 37601)|the stimulator in the stimulation group will be turned on after implantation of the device
45471185|NCT04967989|Procedure|Low Energy SLT|SLT performed at low energy
45471186|NCT04967989|Procedure|Standard Energy SLT|SLT performed at standard energy
46028756|NCT02685163|Other|Control Ice-cream|Natural Control Ice-cream
46028757|NCT00638599|Device|LMA®|LMA® is placed after anesthesia induction and removed after the operation
46028758|NCT00638599|Device|Endotracheal tube|Standard endotracheal tube is inserted after anesthesia induction and extubated after the operation
46028759|NCT00640003|Drug|Baclofen|Drug given by orally via capsules. Escalation steps in 4-day intervals. Step 1: 5mg QAM. Step 2: 5mg BID. Step 3: 5mg TID. Step 4: 10mg QAM, 5mg BID. Step 5: 10mg BID, 5mg QMid-day. Step 6: 10mg TID. Step 6 will last up to 2 weeks. De-escalation will start from highest dose step and work backwards in 2-day intervals. Complete drug administration of escalating, staying constant at 10mg TID and de-escalating will be done with both drug and placebo.
46028760|NCT00640003|Drug|Placebo|placebo drug
46028761|NCT01201343|Drug|Interferon beta-1a|
45471187|NCT03629522|Drug|Ondansetron 8Mg/4mL Injection|investigators administrated intravenously Ondansetron 8 mg 5 minutes before spinal anesthesia.
45471188|NCT04742543|Device|SootheVR: AppliedVR, Los Angeles, California a head-mounted display|"For the study group, virtual reality content will be shown to the participant for the duration of the conization procedure through a head-mounted display, RelieVRTM. The default VR content for the trial will be swimming with dolphins or any other content chosen by the participant"
45471189|NCT03751111|Drug|Naloxone|Naloxone at an sublingual dose of 40 mg daily for one week will be given to each subject. Subjects will self-administer the drug at supervision in the primary care center.
45471190|NCT03751111|Drug|Placebo|Placebo will be given to each subject for one week. Subjects will self-administer the drug at supervision in the primary care center.
46028762|NCT04185727|Other|Supervised strength training|12 weeks supervised strength training exposure. The study will allocate patients to groups consisting of 4 members who receive strength training for 12 weeks. The strength training program will consist of three weekly supervised strength exercise sessions, each 40-60 min of duration, which starts with a 10 min warm-up and are completed with a meditation/relax session.
46028763|NCT04185649|Biological|BAT8001 for injection|3.6 mg/kg, q3w, administered intravenously on day 1 of each treatment cycle, 21 days/treatment cycle.
46028764|NCT04185649|Drug|Lapatinib|Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
46028765|NCT04185649|Drug|Capecitabine|Capecitabine 1000 milligrams per square meter (mg/m^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
46028766|NCT01201265|Drug|Bevacizumab|15 mg/kg iv every 3 weeks
46028767|NCT01201265|Drug|Carboplatin|to an AUC = 2, on days 1 and 8 of each 3-week cycle
46028768|NCT01201265|Drug|Gemcitabine|1000 mg/m2 iv on days 1 and 8 of each 3-week cycle
46028769|NCT02688673|Biological|adenovirus-transfected autologous DC vaccine plus CIK cells|
46028770|NCT00624533|Behavioral|GDS Method (muscular chains physical therapy method)|Experimental group received 15 GDS method sessions based on the equilibration of articular and muscular tensions that reduced trunk and lumbopelvic stability. GDS method combine specific technics of manual therapy, spinal stabilisation and stretching exercises (4 sessions),supervised group exercise therapy (10 sessions) and home exercise programme with individualised exercises (1 session) Experimental group received 2 sessions of 50 minutes per week during 8 weeks.
46028771|NCT00624533|Behavioral|Conventional Physical Therapy in Primary Health Care|"Conventional Physical Therapy in Spanish Primary Care Units are based on Electrotherapy (TENS and microwave thermotherapy) and a standard written advices. Patients received 14 sessions of 40 minutes of conventional TENS, 10 minutes of microwave thermotherapy and 1 last session of standard written advices.~Conventional Physical Therapy group received 2 sessions of 50 minutes per week during 8 weeks."
46028772|NCT04246801|Drug|Clobetasol propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05%, is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)
46028773|NCT04246801|Drug|Vehicle|Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
46028774|NCT04232917|Drug|2LPAPI®|Treatment
46028775|NCT04232917|Drug|Placebo|Placebo
46028776|NCT02686567|Procedure|with TDT|After completion of the anastomosis and further DS construction if necessary, the surgeon would be notified to implement the intervention based on the randomizing results. In this group, a silicone tube (28Fr, Sumitomo Bakelite Co, Japan) was inserted through the anus and the tip of the tube was placed approximately 5 cm above the anastomosis at the end of the surgery in patients from the TDT group. The tube was fixed with a skin suture and connected to a drainage bag. TDT was planed to remove 3-7 days after surgery and early removal was allowed if the patient experienced intolerable pain.
46028777|NCT02686567|Procedure|without TDT|After laparoscopic anterior resection and double-stapling technique anastomosis were finished, none additional proceduce was done.
46028778|NCT01200797|Drug|SJG-136|Given IV
46028779|NCT01200797|Other|laboratory biomarker analysis|Correlative studies
46028780|NCT00638677|Dietary Supplement|Sorbitol|Sorbitol tablet delivered with a slow-release pacifier starting 1 mo after delivery and lasting max 2 years
46028781|NCT00638677|Dietary Supplement|Xylitol + BB12|Xylitol + BB12 tablet delivered with a slow-release pacifier starting 1 mo after delivery and continuing max 2 years
46028782|NCT00638677|Dietary Supplement|Xylitol|Xylitol+BB 12 delivery with a pacifier max until 2 years
46028783|NCT02686723|Other|Clinical and biomechanical evaluations|Clinical evaluation : demographics, clinic and functional testing. Biomechanical evaluation : isokinetic, motion analysis of 2 specific motion (drop vertical jump and cutting task) and anterior tibial translation with GnRB
46028784|NCT01200485|Drug|Rasburicase|"Cycle 1: 3 mg/kg by vein on Day 1, plus as needed dosing (until day 5), during Cycle 1.~Cycle 2 Arm A: 0.15 mg/kg by vein on Day 1 of Cycle 2, plus as needed dosing (until day 5), during Cycle 2."
46028785|NCT01200485|Drug|Allopurinol|Arm B: 300 mg/day by vein, as standard of care, over 30 minutes each day on days 1-5 of cycle 2 in 21 day cycle.
46028786|NCT02688907|Drug|AZD1775|Dosage and Schedule : AZD1775 175 mg BID per os every 12 hours (x 6 doses, 3 days) administered days 1-3 the first & second weeks every 21 days Patients will continue to receive study treatment as described above, until they demonstrate objective disease progression (determined by RECIST 1.1) or they meet any other discontinuation criteria.
46028787|NCT02686645|Biological|Fecal Microbiota|The fecal microbiota will be by retention enema administered through a rectal tube.
46028788|NCT02686645|Drug|vancomycin|All subjects will be pre-treated with vancomycin 125 mg po qid X 7 days prior to the fecal microbiota.
46028789|NCT02686645|Drug|Loperamide|The subject will take 4 mg of loperamide after the morning bowel prep (approximately 1 hour prior to the procedure) and 2 mg again after the procedure.
46028790|NCT02686645|Drug|metronidazole|If unable to tolerate vancomycin, then it will be substituted with metronidazole 500 mg po tid X 7 days prior to the fecal microbiota.
46028791|NCT04318067|Drug|Melatonin 3 mg|Melatonin 3 mg is given ones a day - at bedtimes for 6 month
46028792|NCT04185181|Other|virtual reality|wii video game based exercise
46028793|NCT04185181|Other|proprioceptive neuromuscular facilitation|PNF with breathing
46028794|NCT04185181|Other|complete decogestive therapy|pneumatic compression, manual lymph drainage, skin care and home exercise program
46028795|NCT01200407|Drug|Amlodipine + Olmesartan medoxomil|start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up
46028796|NCT04186975|Device|Non-Invasive fetal ECG|Non-Invasive fetal ECG
46028797|NCT04186975|Device|Fetal heart rate monitor|Fetal heart rate monitor
46028798|NCT02685085|Drug|Misoprostol ( Prostaglandin E2)|
46028799|NCT02685085|Device|Foley's catheter|
46028800|NCT02688595|Device|Ultrasound|Ultrasound-guided central venous catheterization in internal jugular vein
46028801|NCT02688595|Other|General anesthesia|Scheduled operation under general anesthesia
46028802|NCT01200329|Drug|Gemcitabine|2775 mg/m2 by vein over about 3 hours on days -8 and -3.
46028803|NCT01200329|Drug|Busulfan|"32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient~AUC 4,000 by vein over about 3 hours on days -8 to -5."
46028804|NCT01200329|Drug|Melphalan|60 mg/m2 by vein over about 30 minutes on days -3 and -2.
46028805|NCT01200329|Procedure|Stem Cell Transplantation|Infusion of stem cells on Day 0.
45754567|NCT03574493|Procedure|TME with LAR|Several surgical techniques are used to perform TME. Dissection using open laparotomy and minimally-invasive laparoscopic or robot-assisted abdominal approaches is performed in a 'top-down' manner, where the instruments are inserted transabdominally and the procedure progresses from splenic flexure/sigmoid colon mobilization to rectal resection. A transanal approach may also be used, a 'bottom-up' procedure where instruments are inserted through the anus to perform rectal resection and TME
45754568|NCT00578071|Drug|Panitumumab|Dose per cohort level (3.6, 4.8 or 6.0 mg/kg ), given intravenously (IV) days 1, 15 and 29 of radiation.
45754569|NCT00578071|Drug|Capecitabine|Dose per cohort level (500, 625 or 825 mg/m2) taken by mouth twice each day of radiation
46028806|NCT01200329|Drug|Palifermin|60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2.
46028807|NCT04185493|Diagnostic Test|CCTA|128-multislice CT coronary angiography and complex atherosclerotic plaque analysis with the use of CT imaging post-processing techniques.
46028808|NCT04186273|Drug|Fibrosis-Inhibiting-Compound-FS2|There are three (3) experimental interventions: vehicle moisture balancing base, FS2-0.25 moisturizer, and 0.5 moisturizing base.
46028809|NCT04186273|Other|Vehicle moisture balancing base|Vehicle base without FS2.
46028810|NCT01199939|Drug|Etravirine|400mg once daily orally for 48 weeks
46028811|NCT01199939|Drug|Ritonavir|100mg once daily orally for 48 weeks
46028812|NCT01199939|Drug|Darunavir|800mg once daily orally for 48 weeks
46028813|NCT02688439|Other|Sciatic Nerve block|
46028814|NCT02688439|Other|Leg raised 30°|
46028815|NCT02688439|Other|Distal tourniquet placed on the lower part of the leg|
46028816|NCT02688439|Other|Leg in a neutral position|
46028817|NCT02688361|Drug|Fluimucil® 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference).
46028818|NCT02688361|Drug|Acetylcysteine 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Acetylcysteine (test)
46028819|NCT02686489|Other|Heated humidification|Water vapor (molecular water) will be added to the inspired gas of the spontaneously breathing tracheostomy patient by using the Fisher & Paykel Healthcare, (Auckland, New Zealand) AIRVO 2 Humidification System. The AIRVO 2 will provide respiratory gas flow at 2-60 L/min) that is conditioned to 37° C, 34° C, or 31° C (based on patient comfort) and 100% relative humidity via a heated breathing circuit.
46028820|NCT02686489|Other|Cool bland aerosol|Aerosol (particles of water suspended in gas) generated by a flow of gas through a pneumatically powered large volume jet nebulizer filled with sterile water (for inhalation) attached to a gas source via a flowmeter set between 10-15 L/min will add moisture to the inspired gas of the spontaneously breathing tracheostomy patient. The cold bland aerosol set-up will consist of corrugated aerosol tubing with one end connected to the nebulizer output port and the other end connected to a tracheostomy mask.
46028821|NCT01199861|Drug|Fingolimod|Fingolimod 0.5 mg capsules for oral administration.
45471191|NCT05167370|Drug|Amifostine|Amifostine (Ethyol) 1125 mg/m2 will be given intravenously daily over 5 minutes starting 30 minutes prior to chemotherapy (melphalan or thiotepa) on days -5, -4, -3, -2, and on day -1 twenty four hours after prior dose of amifostine.
45754570|NCT00578071|Drug|Oxaliplatin|Dose per cohort level (30, 40, or 50 mg/m2). Given IV one day each week during radiation
46028822|NCT01199861|Drug|Placebo|Matching placebo capsules for oral administration.
46028823|NCT01199861|Biological|Seasonal influenza vaccine|Commercially available injectable influenza vaccine for the 2010/11 influenza season.
46028824|NCT01199861|Biological|Tetanus toxoid vaccine|Commercially available tetanus toxoid vaccine booster injection.
46028825|NCT03196219|Drug|C16G2|C16G2
45471192|NCT03693625|Drug|GDC-0853|Participants were administered GDC-0853 200mg orally, as per the dosing schedules described above.
45471193|NCT03629366|Behavioral|Supported Employment (SE)|Supported Employment
45471194|NCT03629366|Behavioral|Treatment as usual (TAU)|Treatment as usual
45754571|NCT00578071|Radiation|Radiation Therapy (RT)|Daily for 6 weeks
46028826|NCT03196219|Drug|Placebo|Varnish Placebo
46028827|NCT02684929|Dietary Supplement|branched chain amino acids|15 (women) or 20 (men) grams of BCAA daily for 3 months
46028828|NCT05398211|Behavioral|Preferred Recorded Music (PRM)|Preferred Recorded Music (PRM) involves a credentialed music therapist in planning and administering, which qualifies it as music therapy, which is defined as a professional use of music and its elements to improve physical, social, communicative, emotional, intellectual, and spiritual health, optimize quality of life and wellbeing(Aigen, 2013; Bruscia, 2014). PRM intervention will be delivered for 30 minutes, once per day at the same time of the day, for three consecutive days. The intervention will consist of the previously assessed preferred songs/musical pieces. During the PRM intervention the MT will start/stop the music and otherwise not engage with the participants during the listening session.
45471195|NCT01265537|Drug|Tacrolimus|"Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx:~0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4"
45471196|NCT01265537|Drug|Tacrolimus|"Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx~0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8."
45471197|NCT05143736|Diagnostic Test|gut and nasal microbiota detection|The nasal and fecal specimens will be collected by swabs from subjects with sepsis. After that, total DNA of nasal and gut microbiota will be extracted , amplified, and sequenced to determine the gut and nasal microbiota.
45471198|NCT05330767|Device|DermaClose Continuous External Tissue Expander Device|Constant tension and self-tensioning device. Supplied sterile and for single use only.
45471199|NCT05330767|Device|DermaClose XL Continuous External Tissue Expander Device|Intended for large wounds that are greater than 8 cm in width. Constant tension and self-tensioning device. Supplied sterile and for single use only
45471200|NCT05330767|Device|Conventional wound dressings|Wet-to-dry, gauze, and negative pressure wound therapy.
45471201|NCT01250093|Device|acupuncture|
46028829|NCT05398211|Behavioral|Preferred Live Music (PLM)|Preferred Live Music (PLM) involves a credentialed music therapist in planning and administering which qualifies it as music therapy, which is defined as professional use of music and its elements to improve physical, social, communicative, emotional, intellectual and spiritual health, optimize quality of life and wellbeing (Aigen, 2013; Bruscia, 2014).PRM intervention will be delivered for 30 minutes, once per day at the same time of the day, for three consecutive days. The intervention will consist of the previously assessed preferred songs/musical pieces. The MT will be more actively engaged in a musical interaction with the participants in the PLM interventions.
45471202|NCT05763836|Drug|Ibuprofen 800 Mg in 8 mL INTRAVENOUS INJECTION [Caldolor]|Intravenous ibuprofen infusion
45471203|NCT05763836|Procedure|Scalp nerve block|Scalp nerves blocked by using local anesthetics
45471204|NCT04435249|Other|BPF-001|Expanded somatic mesenchymal stromal cells (MSCs) seeded onto a decellularised human tracheal-scaffold
45471205|NCT01237535|Drug|Luteal support with progesterone only|Luteal support with progesterone only (they will received vaginal P gel (Crinone 8% vaginal gel; Serono, Israel).Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
46028830|NCT02684773|Procedure|Conventional Hemodialysis|The intervention involves 3 hemodialysis sessions/week that consists of 4 hours/session
45471206|NCT01237535|Drug|Luteal support with estrogen + progesterone|Luteal support with estrogen + progesterone [(Crinone 8% vaginal gel; Serono, Israel) and Estrofem 4mg].Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
45471207|NCT01237535|Procedure|Insemination without luteal support|Routine insemination procedure without luteal support
46028831|NCT02684773|Procedure|In-centre Nocturnal Hemodialysis|The intervention involves 3 hemodialysis sessions/week administered overnight (8 hours/session) in-hospital
46028832|NCT00640081|Biological|cetuximab|
46028833|NCT00640081|Drug|capecitabine|
46028834|NCT00640081|Drug|fluorouracil|
46028835|NCT00640081|Drug|leucovorin calcium|
46028836|NCT00640081|Drug|oxaliplatin|
46028837|NCT00640081|Other|immunohistochemistry staining method|
46028838|NCT00640081|Other|laboratory biomarker analysis|
46028839|NCT01199705|Biological|Immune Globulin Subcutaneous (Human) (SCIG)|IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human SCIG. Subjects will receive weekly infusions of IgPro20 at a weekly dosage calculated based on previous IVIG treatment.
46028840|NCT02688127|Drug|Tranexamic Acid|tranexamic acid or placebo are given before cesarean section in patient with placenta previa
46028841|NCT02686333|Other|Meditation|10-15 minutes of individually conducted medication practices (silent meditations, guided meditations, body scans, gentle arm movement exercises).
46028842|NCT02688283|Other|Nutrient cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
46028843|NCT05396885|Biological|CART-ddBCMA|BCMA-directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-domain
46028844|NCT04185571|Device|PEPA|
46028845|NCT02686255|Other|complete blood count|complete blood count during follow up in the heart institute
46028846|NCT04185025|Drug|Ceramides|"On the 0th day, it is determined that one of the leg extensions of the participant is the test side using CeraVe Moisturising Lotion and the opposite side is the control side using Half Mu ceramide body milk by the random table. Participants are required to use the product in the morning and evening according to the Product Use Procedures, during which other moisturizing products or emollients are prohibited. And the follow-up tests are conducted at the prescribed time. At each visit, empty packaging of products used during this period must be collected; if they are not used up as required, the remaining products must be collected."
46028847|NCT04295239|Procedure|MRI|Pre and Post operative MRI
45471208|NCT03747913|Dietary Supplement|Antioxidative supplementation|Each participant conducts two identical cycling tests, first without and a week later with antioxidative supplementation
46028848|NCT02688205|Other|Cyriax's functional examination|included active range of motion, passive range of motion, resisted test and accessory test for shoulder pain evaluation
46028849|NCT02688205|Device|Ultrasound examination|to evaluate rotator cuff, acromio-clavicular joint, and subdeltoid-subacromial bursa
46028850|NCT04136665|Other|Physical Activity Adapted program|6-month APA home program, supervised by videoconferencing in post-cancer for children / AYA treated for leukemia
45471209|NCT03749551|Diagnostic Test|cardiac magnetic resonance (CMR) post haemodialysis|patients will undergo a second CMR scan immediately after receiving haemodialysis (native CMR study)
45471210|NCT05761028|Drug|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
46028851|NCT02684695|Other|MRI scan (adolescent spine protocol)|MRI scan of the lumbar spine and sacroiliac joints
46028852|NCT02684695|Other|MRI scan (whole body protocol)|MRI scan of multiple joints ('whole body')
46028853|NCT04184947|Drug|SGLT2 inhibitor|New prescription of a SGLT-2 inhibitor (dapagliflozin, empagliflozin or canagliflozin) at any dosage during routine clinical practice
46028854|NCT04184947|Drug|GLP-1 receptor agonist|New prescription of a GLP-1 receptor agonisty (exenatide, liraglutide, lixisenatide, dulaglutide) at any dosage during routine clinical practice
45471211|NCT05761028|Other|Placebo|Placebo
46028855|NCT04186507|Combination Product|Smartwatch with integrated Li+ sensor (provided by Spectrophon LTD)|"To confirm that Li+ is detectable in sweat using Macroduct Sweat Collection System for sweat collection.~Current studies demonstrate that Li+ can be detected in saliva and in sweat. To confirm it, patients that are on treatment with Li+ will be recruited for this aim; sweat will be collected and checked for Li+ levels.~To develop the algorithm for Spectrophon LTD biosensors for Li+ levels measurement in sweat that will allow assessing the level of Li+ in blood.~To evaluate the accuracy and the efficacy of biosensors developed by Spectrophon LTD for Li+ detection in sweat.~Following positive results in previous objectives, clinical trial will be conducted to estimate the suitability, efficacy and accuracy of developed biosensors for non-invasive detection of Li+ in sweat."
46028856|NCT02684383|Biological|rDEN3∆30|10^3 plaque-forming units (PFUs); administered by subcutaneous injection in the deltoid region of the upper arm
46028857|NCT02684383|Biological|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
45471212|NCT04396639|Biological|Moroctocog-alfa (AF-CC)|Moroctocog-alfa (AF-CC) is indicated for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).
45471213|NCT01146431|Drug|Inhaled anesthetics|Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of hemodynamic parameters (mean arterial pressure and heart rate greater or less than 20% compared to preoperative values).
45471214|NCT01146431|Drug|Inhaled anesthetics|Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of Bispectral Index (BIS) value which will be maintained between 40 and 50.
45471215|NCT02226458|Drug|EPI-743|
45471216|NCT01250249|Biological|BCG Vaccine IP - Serum Institute of India|0.1 ml for adults and children aged 1 month and over 0.05 ml for infants under 1 month of age
45471217|NCT03747679|Drug|200 Mg capsules of bosutinib in Water solution|200 mg (4X50) Capsules in water
45471218|NCT03747679|Drug|bosunitib sorbitol|200 Mg of bosutinib sorbitol solution
45471219|NCT03747679|Drug|Bosutinib Mannitol|Bosutinib mannitol solution
45471220|NCT03747679|Drug|bosutinib in mannitol low sweet|bosutinib in mannitol solution low sweet
45471221|NCT03747679|Drug|bosutinib in mannitol high sweet|bosutinib in mannitol high sweet
45471222|NCT03747679|Drug|bosutinib taste low flavour|bosutinib solution low flavour
45471223|NCT03747679|Drug|bosutinib high flavour|bosutinib solution high flavour
45471224|NCT03747679|Drug|bosutinib capsules in applesauce|Bosutinib capsules in applesauce
45471225|NCT03747679|Drug|Bosutinib capsules in yogurt|bosutinib capsules in yogurt
45471226|NCT03747679|Drug|bosutinib capsules in water|sham comparator, bosutinb in water retest
45471227|NCT03747679|Drug|Bosutinib capsules in low sweet|bosutinib capsules in low sweet
45471228|NCT03747679|Drug|bosutinib capsules high sweet|Bosutinib capsules high sweet
45471229|NCT03747679|Drug|bosutinib capsules low flavour|Bosutinib capsules low flavour
45471230|NCT03747679|Drug|bosutinib capsules high flavour|bosutinib capsules in high flavour
45471231|NCT04433065|Device|Intrepid™ TTVR System|Device: Intrepid™ TTVR System
45471232|NCT01243385|Drug|Metformin|Metformin Lifelong follow-up at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
45471233|NCT03751033|Device|BSS|Intraoperative aberrometry measurements for BSS will be performed.
45471234|NCT03751033|Device|DiscoVisc|Intraoperative aberrometry measurements for DiscoVisc will be performed.
45471235|NCT01147133|Drug|Plavix|1x75 mg
45471236|NCT01147133|Drug|Kardogrel|1x75 mg
45471237|NCT04633499|Behavioral|Social Cognition Task|Two paradigms will be tested: visual perspective taking and reading the mind in the eyes.
45471238|NCT04633499|Device|tDCS|tDCS either over the dmPFC or the rTPJ.
45471239|NCT04432298|Drug|Pamrevlumab|Sterile liquid for injection
45471240|NCT04432298|Drug|Placebo|Sterile liquid for injection
45471241|NCT01250795|Biological|HAI-05 Influenza Vaccine|injection, vaccine, twice every 3 weeks
45471242|NCT01250795|Other|Saline|
45754572|NCT03584438|Device|Real iTBS|This will be delivered with the Magventure Magpro system; pulses are delivered with the active coil (double blinded using the Universal Serial Bus key)
46028858|NCT04186351|Behavioral|Encounter notification service|The caring support and services provided by SCHSA will consist of multiple components, including standard call & care center support, medical appointment reminder, assistance to reschedule appointment, follow-up calls with either nurse or health workers to monitor health situation of service recipients, assessing needs of service recipient for elderly home care and/or rehabilitation services, providing elderly home care and/or rehabilitation services based on assessment, assessing needs of service recipient for emotional and community support, providing additional emotional support via either social calls by volunteers or counseling by social workers, and making referrals for community support services.
46028859|NCT04111549|Other|Home-based telehealth GOALS|Goal Oriented Attentional Self-Regulation (GOALS) is a manualized cognitive training intervention for problems with attention and executive control that has been shown to improve cognitive, emotional, and functional outcomes in civilians and Veterans with history of TBI, including Veterans 65 and older, and healthy older adults. It will be delivered to aging Veterans with history of TBI via in-home video telehealth.
46028860|NCT04111549|Other|In-person GOALS|Goal Oriented Attentional Self-Regulation (GOALS) is a manualized cognitive training intervention for problems with attention and executive control that has been shown to improve cognitive, emotional, and functional outcomes in civilians and Veterans with history of TBI, including Veterans 65 and older, and healthy older adults. It will be delivered to aging Veterans with history of TBI in person.
45754573|NCT03584438|Device|Sham iTBS|This will be delivered with the Magventure Magpro system; pulses are delivered with the sham coil (double blinded using the Universal Serial Bus key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
46028861|NCT00638833|Drug|Memantine|Memantine 30 mg/day (20-10-0)
46028862|NCT00638833|Drug|Placebo|Placebo pills
46028863|NCT01198145|Drug|sulfasalazine|Given orally
46028864|NCT01198145|Other|placebo|Given orally
46028865|NCT02684539|Device|tilt table Erigo®|tilting table with onset of syncope
46028866|NCT02687737|Procedure|Electromyography|During the fine wire electromyography (EMG), the participant will be asked to complete breathing exercises at 50% and 75% of their maximum capacity (determined prior to fine wire EMG using manometry) to determine activation and recruitment of genioglossus muscle.
46028867|NCT02687737|Procedure|Maximum expiratory pressure|The participants' maximum expiratory pressure (MEP) will be assessed using a hand-held digital manometer (MP01, Micro Direct Inc.). The subject will be standing and while wearing a nose clip be asked to blow out as hard and fast as they can to determine their MEP. This will be completed a maximum of three times to obtain values within close range of one another.
46028868|NCT02687737|Procedure|Videofluoroscopy|Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks.
45754574|NCT05703152|Other|Combined Exercise|Therapeutic exercise program will be applied that will include two modalities: aerobic and resistance exercise. The duration will be 8 weeks with a frequency of 3 sessions per week, with a duration per session of 60 minutes.
46028869|NCT02687737|Behavioral|Swallowing Tasks|"These include: an anterior tongue press to the alveolar ridge (behind the front molars), a saliva swallow, a 10 mL barium swallow, a 10 mL barium hard swallow (i.e. swallowing with extra effort), and two breathing exercise trials at 50% MEP and 75% MEP."
46028870|NCT02686099|Device|SternaLock 360|Sternal closure with SternaLock 360
46028871|NCT02686099|Device|Wire Cerclage|Sternal closure with standard wire cerclage
46028872|NCT02688049|Biological|NeuroRegen scaffold/mesenchymal stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million mesenchymal stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
46028873|NCT02688049|Biological|NeuroRegen scaffold/neural stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million neural stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
46028874|NCT02687893|Behavioral|Aerobic Exercise|Subjects will exercise on a treadmill for 45 minutes twice during the intervention week. Subjects will exercise at a fixed intensity level to a target heart rate (±10%) based on the heart rate achieved at 60% of their VO2max determined at screening. The speed and grade of the treadmill will be adjusted by trained research personnel with a goal of keeping participants within their target heart rate range for the entire 45 minutes.
46028875|NCT02687893|Behavioral|Resistance Exercise|Subjects will participate in resistance exercises for 45 minutes twice during the intervention week. Subjects will perform multiple-joint exercises with slow to moderate lifting velocity, for 1-3 sets per exercise at a weight that can be lifted for 8-12 repetitions (~60-80% of 1-repetition max). The exercises may include leg press, bench press, leg extension, leg flexion and seated row. Subjects will perform the exercises through the full range of motion. Between each set of repetitions, there would be a 2 minute rest period. The duration of the exercise testing would be approximately 45 minutes.
45471243|NCT03913793|Other|Exercise based-cardiac rehabilitation (EB-CR) program|The exercise group underwent an outpatient EB-CR program (phase II) according to the American College of Sports Medicine guidelines for exercise prescription for cardiac patients.[19] Sessions were 3 days/week for 8 weeks. The program included: (1) Warm up (10 minutes): stretching exercises. (2) Aerobic exercise training using treadmill (30 - 60 minutes/session): with target heart rate (HR) at 45 - 75% of HR reserve. The maximal HR (HR max) was derived from that obtained during exercise stress test (EST). Patients who had ischemic/arrhythmic manifestations during EST, exercise intensity was prescribed at a HR below the ischemic threshold (10 beats below). (3) Cool down (10 minutes): light intensity treadmill walking. Supervision was provided according to the risk status of each patient that was determined according to the American Association of cardiovascular and Pulmonary Rehabilitation criteria for risk stratification.
45471244|NCT02162420|Drug|Alemtuzumab|Alemtuzumab 0.2 mg/kg IV over 2 hours on days -10 to -6 from transplant.
45471245|NCT02162420|Drug|Fludarabine|Fludarabine 40 mg/m2 IV over 1 hour on days -6 to -2 from transplant.
45471246|NCT02162420|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -7 from transplant.
45471247|NCT02162420|Radiation|Total Body Irradiation|TBI 200 cGy as a single fraction on day -1 from transplant.
45471248|NCT02162420|Biological|Stem Cell Transplant|Stem cell transplant on day 0.
45471249|NCT02162420|Drug|Anti-thymocyte globulin|ATG (Thymoglobulin - Rabbit ) 3 mg/kg IV on days -5 to -3 from stem cell transplant.
45471250|NCT01237691|Behavioral|HOPE supervision|HOPE entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). HOPE includes regular random drug testing.
45471251|NCT01237691|Behavioral|Parole-as-usual|Parolees are supervised under standard parole supervision practice in California.
45471252|NCT04167085|Drug|Doxycycline|Doxycycline, 100 mg twice a day for 2 months
45471253|NCT04167085|Other|Placebo|Matching placebo, twice a day for 2 months
45471254|NCT00611585|Device|Birmingham Hip Resurfacing|Hip resurfacing system: single use device for hybrid fixation in patients requiring primary hip resurfacing arthroplasty
45471255|NCT03913403|Procedure|ECHO|Echocardiogram at baseline and 24 hours later
45471256|NCT03913403|Procedure|Blood Draw|Blood Draw for Troponin Levels - 5ml at baseline and 24 hours later
46028876|NCT04317677|Other|Study of the effect of bladder voiding on sleep fragmentation during day and night sleep|Vigilance state of babies will be continuously recorded during the first 24 hours of hospitalization by polysomnography and actigraphy. In parallel, bladder voiding episodes will be detected with an innovative device placed on babies diapers.
46028877|NCT01197911|Drug|aleglitazar|single oral dose
46028878|NCT01197755|Drug|fostamatinib|fostamatinib 100 mg twice daily
46028879|NCT01197755|Drug|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
46028880|NCT01197755|Drug|placebo|Placebo twice daily
46028881|NCT01179048|Drug|liraglutide|Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
46028882|NCT01179048|Drug|placebo|Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
45754575|NCT00555581|Drug|Imatinib Mesylate|In initial phase, patients will be treated with Gleevec 400 mg daily for 12 months. In the extension phase, patients will be treated with Gleevec 400 mg daily for 27 months.
46028883|NCT00603265|Drug|ADL5859|
46028884|NCT00603265|Drug|Duloxetine|
46028885|NCT00603265|Drug|Placebo|
46028886|NCT02686177|Drug|Liraglutide|
46028887|NCT02686177|Drug|Metformin or sulfonylurea|
45471257|NCT01562509|Other|Implementation tools|"Professionals receive audit & feedback~Patients (and clinicians) have access to a website with information tailored to patients with an NHL. This website gives insight into the logistic processes of each diagnostic tool and into the patients' personal care pathway.~Standardization of diagnostic and evaluative request forms and reports for clinicians.~Supporting material for standardizing the procedure for multidisciplinary meetings."
45471258|NCT01562509|Other|Standard intervention|Standard intervention consists of audit&feedback
45471259|NCT01250327|Device|Melody|insertion of a pulmonic valved stent
45471260|NCT01250327|Device|bare stent|insertion of a bare metal stent
45471261|NCT01250327|Procedure|Surgery|conventional surgery methode
45471262|NCT01147289|Drug|Dextralgen|Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
45471263|NCT01147289|Drug|Meloxicam|Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
45471264|NCT03749473|Behavioral|Choice + Immediate|Participants in the choice + immediate goal arm will choose a step goal and must attempt to achieve this new step goal immediately at the start of the study.
45471265|NCT03749473|Behavioral|Choice + Gradual|Participants in the choice + gradual goal arm will choose a step goal and will gradually work towards the chosen step goal over the first 8-weeks of the study.
45471266|NCT03749473|Behavioral|Assigned + Immediate|Participants in the assigned + immediate goal arm will be assigned a step goal and must attempt to achieve this new step goal immediately at the start of the study.
45471267|NCT03749473|Behavioral|Assigned + Gradual|Participants in the assigned + gradual goal arm will be assigned a step goal and will gradually work towards the chosen step goal over the first 8-weeks of the study.
45471268|NCT03749473|Behavioral|Daily performance feedback|Participants will receive daily performance feedback on their daily step count.
45471269|NCT03749473|Behavioral|Gamification|All participants in the intervention arms will be entered into a gamification platform that has points and levels designed to incorporate insights from behavioral economics.
46028888|NCT04010227|Behavioral|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers practice various mindfulness exercises, clarify their values, and set specific goals in alignment with their values. Through in-session and home practice of skills, participants learn new and more adaptive ways to respond to unwanted internal experiences (e.g., fatigue, distress). Participants receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.
46028889|NCT04010227|Behavioral|Education/Support|Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers are directed to resources for practical and health information and contact information for psychosocial services. Sessions include an orientation to the patient's medical center and treatment team, education regarding common quality-of-life concerns experienced by cancer patients and caregivers, and an overview of medical center and community resources for addressing these concerns. The therapist also describes resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants receive handouts summarizing session topics and are asked to review them as homework.
46028890|NCT02885298|Procedure|Upright intubation|Upright Intubation procedure performed with patient elevated above the supine position. Defined as upright greater to or equal to 45 degrees or inclined 10-44 degrees
45471270|NCT01237769|Drug|Vitamin D3|2200 IU/day
45471271|NCT01237769|Behavioral|Lifestyle advice|Diet and exercise
45471272|NCT03914963|Biological|Fibrin sealant hemipelvis|Following the manufacturer´s instructions, 5 ml of sealant was sprayed evenly across the entire surgical bed in only one hemipelvis (the treated hemipelvis) after pelvis bilateral lymphadenectomy.
45754576|NCT03589820|Other|artificial liver support system|Patients will receive the treatment of artificial liver support system using combination of plasma exchange and continuous hemodiafiltration and internal medicine. The volume of fresh frozen plasma used in plasma exchange is 2000 millilitre. The time for continuous hemodiafiltration is about 8 hours.
45471273|NCT03914963|Biological|Control hemipelvis|Contralateral hemipelvis not treated with fibrin sealant
45471274|NCT03915119|Other|GFT AI training|navigates a cluttered environment of stationary and moving/pursuing virtual obstacles to reach a way-point as quickly and efficiently as possible. Block order and difficulty, as well as the behavior of the obstacles in each block, will be driven by the AI and statistically weighted to specifically target the perceptual-motor and neuromechanical mechanisms based on each athlete's visit 1 performance
45471275|NCT04162795|Drug|Loratadine (Claritin, BAY76-2211)|Chewable tablet, oral, single dose
45471276|NCT03914807|Other|Whole (3.25%) cow's milk recommendation|Children randomized to the whole milk recommendation will receive a recommendation a primary care recommendation to consume 500 mL of whole fat (3.25%) milk instead of transitioning to reduced fat (1%) milk at 2 years of age. The primary care physician will verbally make this recommendation during the recruitment well-child visit. Parents will also be reminded bi-monthly by phone calls made by a research assistant. Children in the whole milk recommendation group will be provided with the same age-appropriate nutritional recommendations as children in the reduced fat recommendation group as part of routine healthcare according to the Rourke Baby Record.
45471277|NCT03914807|Other|Reduced (1%) fat milk|Children randomized to the reduced fat group will receive a primary care recommendation to transition from whole milk to 500 mL reduced fat (1%) milk daily once the child is two years of age (consistent with current guidelines). The physician will verbally make this recommendation during the recruitment well-child visit. Parents will also be reminded bi-monthly by phone calls made by a research assistant. Children who receive the reduced fat recommendation will be provided with the same age-appropriate nutritional recommendations as children who receive the whole fat recommendation as part of routine healthcare according to the Rourke Baby Record.
45471278|NCT01237847|Behavioral|2 Family-based problem solving phone sessions|2 family-based problem solving phone sessions to address and ameliorate barriers to adherence.
45471279|NCT01237847|Behavioral|4 Family-based problem solving phone intervention sessions|4 family-based problem solving phone sessions to address and ameliorate barriers to adherence.
45471280|NCT01237847|Behavioral|Wait list comparison group|Wait list comparison group to receive intervention at later point.
46028891|NCT00639613|Procedure|Double-balloon enteroscopy|Double-balloon enteroscopy allows for the entire gastrointestinal tract to be visualized in real time. The technique involves the use of a balloon at the end of a special enteroscope camera and an overtube, which is also fitted with a balloon. The procedure is usually done with the use of conscious sedation. The enteroscope and overtube are inserted through the mouth and passed in conventional fashion (that is, as with gastroscopy) into the small bowel. Following this, the endoscope is advanced a small distance in front of the overtube and the balloon at the end is inflated. Using the assistance of friction at the interface of the enteroscope and intestinal wall, the small bowel is accordioned back to the overtube. The overtube balloon is then deployed, and the enteroscope balloon is deflated. The process is then continued until the entire small bowel is visualized. Double-balloon enteroscopy allows for the sampling or biopsying of small bowel mucosa.
46028892|NCT00639613|Other|Standard meal test|"Liquid meal consisting of 100 g Ny NAN dissolved in 300 ml water (ca. 5000 kJ) to be ingested over 5 minutes. Blood will be sampled for 4 hours following ingestion. Samples are centrifuges and plasma will be analysed for glucagon, GLP-1, GIP, insulin and C-peptide concentrations."
46028893|NCT02686021|Drug|Metamizole and Ibuprofen|Metamizole (1000mg) plus Ibuprofen (400mg) 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
45471281|NCT04541953|Other|Telerehabilitation Therapy|Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - range of motion exercises and stretching.
45471282|NCT04541953|Other|In-person Rehabilitation Therapy|Range of motion exercises and stretching
45471283|NCT01250951|Drug|Deferasirox|
45471284|NCT03069482|Device|Learn to Quit App|A smartphone app designed for individuals with serious mental illness. The main intervention components of the app are skills based on an intervention called Acceptance and Commitment Therapy that will (a) teach smoking cessation skills and (b) help cope with mental health symptoms. The app incorporates gaming features to keep users engaged, and a tracking component to record smoking habits and moods.
45471285|NCT03069482|Drug|Nicotine patch|Participants enrolled in the study will be given an 8-week course of Nicotine patches. The 8-week course of trans-dermal nicotine patches starting at 21mg/24h for 4 weeks, then transitioning to 14mg/24h for 2 weeks, and finally to 7mg/24h for the last 2 weeks. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
45471286|NCT03069482|Drug|Nicotine lozenge|Each participant will be given a 1-week course of 4mg Nicotine lozenges to be taken orally as nicotine cravings arise (about 10 lozenges per day). They will be directed to use them for the week following their quit date, using no more than once every 1-2 hours. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
46028894|NCT02686021|Drug|Metamizole and Placebo|Metamizole (1000mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
46028895|NCT02686021|Drug|Ibuprofen and Placebo|Ibuprofen (400mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
45471287|NCT03069482|Behavioral|Technical Coaching|Coaching to assist the user on the use of each assigned smartphone app. This coaching will be delivered by research staff following a coaching procedure. These in-person coaching meetings will be brief (~15 minutes), done on a weekly basis for 4 weeks, and will have a focus on providing technical assistance.
45754577|NCT00504023|Drug|imiquimod|The patient will be seen in clinic every six weeks during treatment for examination. Imiquimod cream is to be applied 3 times per week for 12 weeks.
45754578|NCT00504023|Procedure|biopsy|Punch biopsy and photography will be performed at the baseline and 12 week time points.
45754579|NCT00504023|Procedure|therapeutic conventional surgery|If the lesion is still present after 12 weeks of therapy, the treating physician will recommend excision of the lesion four weeks after completion of therapy (week 16).
45754580|NCT03020108|Other|Blood sample|2 cc blood samples will be drawn from antecubital vein
46028896|NCT02886390|Device|ischemic conditioning|In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
46028897|NCT02685787|Behavioral|Psychosocial Intervention|The caregiver in the intervention arm will meet the counselors six times. The first and the last sessions will be attended by the caregiver only whereas the remaining four sessions will be attended by the caregiver and other family members. Interventions will be tailored for the caregivers based upon: 1) depression and anxiety; 2) burden; 3) self care and health-related behavior; 4) social support; and 5) behavioral symptoms. The design and management of the structured intervention will follow a published counseling caregiver manual, based on the experiences matured at New York University. Every session will be documented.
46028898|NCT02685787|Behavioral|Educational Intervention on AD|"The caregiver enrolled in this arm:1) will not receive counseling or support; 2) will participate to group sessions; 3) the six hours sessions will divulge information on AD using a slide-show. Each session will focus on the following topic: (a) diagnosis and treatment b) cognitive deficit management, c) behavioral disturbance management, d) daily living management, e) non-pharmacological treatment, f) legal issues and available health and social services.~Additionally, contrary to other arm, caregivers will not receive any telephone calls after the end of the educational sessions."
46028899|NCT04186039|Diagnostic Test|Functional magnetic resonance imaging - Blood Oxygenation Level Dependent|"First Functional magnetic resonance imaging - Blood Oxygenation Level Dependent sequence under ambient air.~Oxygenation of 5 minutes at a rate of 12 l / min. Second Functional magnetic resonance imaging - Blood Oxygenation Level Dependent sequence."
46028900|NCT01158534|Drug|celecoxib|Given orally
46028901|NCT01158534|Biological|recombinant interferon alfa-2b|Given subcutaneously
46028902|NCT01158534|Other|polymerase chain reaction|Correlative studies
46028903|NCT01158534|Other|laboratory biomarker analysis|Correlative studies
46028904|NCT01158534|Other|reverse transcriptase-polymerase chain reaction|Correlative studies
46028905|NCT01158534|Other|immunologic technique|Correlative studies
46028906|NCT01158534|Other|immunohistochemistry staining method|Correlative studies
46028907|NCT01158534|Other|flow cytometry|Correlative studies
46028908|NCT02687971|Drug|Miltefosine|Miltefosine (hexadecylphosphocholine) is an oral drug which has proven to be effective for the treatment of Visceral leishmaniasis (VL) in the Indian sub-continent. It has also been tested for CL, yielding varying results. Miltefosine was approved by FDA in 2014 for the treatment of CL in the New World for lesions due to L. braziliensis, L. panamensis and L. guyanensis only.
46028909|NCT02685631|Other|Yttrium-90 Resin Microspheres|Data collection into the RESIN registry
45471288|NCT03069482|Device|NCI QuitGuide App|A smartphone app developed by the National Cancer Institute which uses recommendations contained in the US DHHS Clinical Practice Guidelines and smokefree.gov. NCI QuitGuide has the following intervention components: (a) psycho-education about the impact of smoking in health, (b) tracking of smoking habits, and (c) Tips for quitting (e.g., distraction strategies).
45754581|NCT03580850|Other|No intervention in this restrospective study|This study is an obervational study
45754582|NCT03580772|Device|Persona TKR|Persona® TKR (Zimmer Biomet)
45754583|NCT03580772|Device|Attune TKR|Attune® TKR (Depuy synthes)
46028910|NCT05272878|Drug|IRBESARTAN, tablet, 150 mg|IRBESARTAN will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.
45471289|NCT01250405|Drug|Cinacalcet|One sequence receives Cinacalcet 30mg /d for 7 days followed by placebo for 7 days
45471290|NCT01250405|Drug|Placebo|One sequence receives placebo for 7 days followed by Cinacalcet 30mg/d for 7 days
45754584|NCT03589586|Other|DermACELL AWM|DermACELL AWM is a sterile, ready to use acellular dermal matrix
45754585|NCT03589508|Behavioral|In-person sessions: ABCP_P|6 weekly sessions of alcohol prevention conducted in person.
45754586|NCT03589508|Behavioral|Video conference sessions: ABCP_T|6 weekly sessions of alcohol prevention conducted by video conference.
45754587|NCT03028688|Device|High flow nasal cannula oxygen|Participants will receive high flow nasal cannula oxygen delivery during anesthesia. Participants will also have transcutaneous PCO2 measurements performed using a cutaneous electrode.
46028911|NCT05272878|Drug|Placebo, tablet, 150 mg|Placebo will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.
46028912|NCT02683213|Drug|Fluoxetine|Fluoxetine 20mg once daily for 6 months.
46028913|NCT02683213|Drug|Placebo|Matching placebo.
45471291|NCT01147367|Behavioral|3 month physical activity intervention|3 month physical activity intervention involving moderate intensity walking and strength training with resistance bands
45754588|NCT03589430|Other|Laboratory investigations ( protein C, protein S , antithrombin III)|laboratory investigations ( protein C , protein S , antithrombin)
45754589|NCT05702762|Drug|Gentamicin|5 mg/kg intramuscular injection
45754590|NCT05702762|Drug|Standard of Care|Usual oral antibiotic multi-day dosing based on local antibiogram
46028914|NCT04185103|Drug|Sacubitril-Valsartan|After signing the Informed Consent, in the shortest possible time, the study investigator will carry out an ergometric test for the T-wave alternans (TWA) while still taking the basal medication. The patient will also sign the prototype Informed Consent for carrying out a stress test on a treadmill. It will also be carried out a basal life quality questionnaire, an analytical determination and a colour doppler echocardiography.
46028915|NCT04033939|Drug|HSK3486|
46028916|NCT04033939|Drug|Propofol|
46028917|NCT04033939|Drug|Placebo|
46028918|NCT02685943|Behavioral|Psychotherapy|
46028919|NCT00639691|Biological|omalizumab|sc
46028920|NCT02684149|Procedure|relational touch|
46028921|NCT02684071|Drug|Intra thecal methotrexate|IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
46028922|NCT02684071|Drug|topotecan|To be administered in conjunction with methotrexate
46028923|NCT02684071|Drug|cyclophosphamide|To be administered in conjunction with methotrexate and topotecan
46028924|NCT01158378|Device|Adherus Dural Sealant|In situ polymerizing sealant
46028925|NCT00640159|Drug|Zelapar|Switch from oral selegiline to Zelapar 1.25 mg QD titrated to 2.5 mg QD
45471292|NCT03915197|Diagnostic Test|Pneumological evaluation|Consultation with a pneumopediatrician: collection of respiratory symptoms, respiratory treatments, evaluation of the atopic site and environmental risk factors for bronchial aggression, especially passive smoking
45471293|NCT05083910|Drug|I.V Oxytocin administration|Group I: Oxytocin( the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord). Group II:oxytocin plus intrauterine misoprostol (the oxytocin infusion was administered immediately after clamping the umbilical cord and misoprostol tablet (400 mg) was placed into uterine cavity at the fundus after delivery of the placenta and swabbing the cavity. Group III:100-mg carbetocin was intravenously administered immediately after birth of the baby.
45471294|NCT01250483|Other|PSA measurement, uroflowmetry, IPSS, transrectal ultrasonography|
46028926|NCT00640861|Biological|CpG oligodeoxynucleotide|
46028927|NCT00640861|Biological|HER-2/neu peptide vaccine|
46028928|NCT00640861|Biological|MUC-1 peptide vaccine|
46028929|NCT00640861|Biological|incomplete Freund's adjuvant|
46028930|NCT00640861|Biological|sargramostim|
46028931|NCT00640861|Other|immunoenzyme technique|
45754591|NCT03584126|Diagnostic Test|Electrocardiography, ecocardiography and MRI.|AF patients and healthy adult volunteers will be examined by the study physicians and included in the study according to the inclusion criteria. After a general examination, an electrocardiography, an ecocardiography and an MRI will be performed on the AF-affected and healthy hearts, respectively.
46028932|NCT00640861|Other|immunologic technique|
46028933|NCT04184011|Device|SRT-100™|SRT delivers a precise, calibrated dose of radiotherapy following surgical excision for large and more difficult-to-treat keloids that cannot otherwise be treated by or have failed more conservative measures.
46028934|NCT00602797|Drug|Paclitaxel|Given IV
46028935|NCT00602797|Other|Quality-of-Life Assessment|Ancillary studies
46028936|NCT00602797|Other|Questionnaire Administration|Ancillary studies
46028937|NCT00602797|Drug|Vinorelbine Tartrate|Given IV
46028938|NCT04183855|Dietary Supplement|Generation UCAN supplementation|carbohydrates - protein (Generation UCAN supplement, 250ml, 10% solution)
46028939|NCT04183855|Dietary Supplement|Mirexus PhytoSpherix supplementation|carbohydrates alone (Mirexus PhytoSpherix, 250ml, 10% solution)
46028940|NCT04183855|Behavioral|satiety ratings|questionnaire on satiety ratings will be provided to participants 15, 30, 45 and 60 min after the drink (or no drink)
46028941|NCT04184089|Device|High flow nasal cannula (15 L/m)|nasal cannula at a flow rate of 15 l/min and FiO2 of 40%
46028942|NCT04184089|Device|High flow nasal cannula (30 L/m)|nasal cannula at a flow rate of 30l/min and FiO2 of 40%
46028943|NCT04184089|Device|High flow nasal cannula (60 L/m)|nasal cannula at flow rate of 60L/min. Oxygen supplementation will be at an FiO2 of 40%.
46028944|NCT01158222|Drug|sunitinib malate|Given orally
46028945|NCT02682979|Other|Medical files analysis|Retrospective analysis of the medical files according to medical, social and geriatric criteria.
46028946|NCT02886780|Behavioral|Concentrated exposure treatment (cET)|Psychological cognitive behavioral treatment
46028947|NCT02886780|Behavioral|Self-help|
46028948|NCT02684305|Drug|Administration of Propess|"History taking and physical examination including cervical length~Eligibility assessment~Explanation regarding the study protocol~Signed informed consent (at VAS<3)~Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
45754592|NCT05702684|Other|electronic Holistic Needs Assessment (eHNA)|eHNA to be completed within 31 days of diagnosis (standard care). ARC clinic previously offered 6-24 months post-diagnosis.
45754593|NCT03589274|Behavioral|I-FS-CBT|12 manual-guided sessions of I-FS-CBT
45754594|NCT03589274|Behavioral|G-FS-CBT|12 manual-guided sessions of G-FS-CBT
46028949|NCT02684305|Device|balloon|"History taking and physical examination including cervical length~Eligibility assessment~Explanation regarding the study protocol~Signed informed consent (at VAS<3)~Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
46028950|NCT02684305|Drug|Intravenous oxytocin infusion|"History taking and physical examination including cervical length~Eligibility assessment~Explanation regarding the study protocol~Signed informed consent (at VAS<3)~Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
46028951|NCT02885376|Device|Dentoxol|Mouthrinse
46028952|NCT02885376|Device|Placebo|Mouthrinse
46028953|NCT02940769|Device|light glasses|light glasses
46028954|NCT02940769|Device|sham glasses (placebo)|sham light glasses
46028955|NCT04315584|Procedure|Positron Emission Tomography|Undergo PET/CT Scans
46028956|NCT04315584|Procedure|Computed Tomography|Undergo PET/CT Scans
45754595|NCT03583970|Device|Left Ventricular Assist Device Implantation|Veno-arterial extracorporeal membrane oxygenation prior to left ventricular assist device implantation : initial patients characteristics and 6 Month Follow-up
45754596|NCT03020810|Drug|Dupilumab|The patient will receive a 600 mg subcutaneous dupilumab loading dose on Day 1, and then 300 mg subcutaneous dupilumab every 2 weeks
46028957|NCT04315584|Procedure|Multiparametric Magnetic Resonance Imaging Scan|Undergo a multiparametric MRI scan
46028958|NCT04315584|Radiation|Fludeoxyglucose F-18|IV (intravenous) administration of radiotracer
46028959|NCT04315584|Radiation|fluorine F 18 fluorodopa|IV (intravenous) administration of radiotracer
46028960|NCT02683993|Device|Lumenis Pulse 120H holmium laser system and 200 DFL ball tip fiber|The Lumenis Pulse P120H will be utilized in high and low frequencies according to subjects group allocation.
46028961|NCT02683291|Drug|sirolimus|
46028962|NCT02683291|Drug|tacrolimus|
46028963|NCT02683291|Drug|mycophenolate|
46028964|NCT02683291|Drug|Prednisone|Prednisone 30mg/day
46028965|NCT02683291|Drug|Basiliximab|Basiliximab 20mg (first and fourth day) if panel reactivity class I less than 50 %
46028966|NCT02683291|Drug|Thymoglobulin|Thymoglobulin at a dose of 1mg/kg for 5 days if panel reactivity class I greater than 50 %
46028967|NCT02685865|Device|FCSEM Stent|Hot Axios Fully covered self-expandable metal stent - Boston Scientific
46028968|NCT02685865|Device|Plastic Stent|7 French 4 cm double pigtail plastic stent - Cook 7 French 4 cm double pigtail plastic stent - Boston Scientific
46028969|NCT02685397|Drug|Leuprolide Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
46028970|NCT02685397|Drug|Goserelin Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
46028971|NCT02685397|Drug|Triptorelin|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
45754597|NCT05702606|Other|Radial extracorporeal shock wave therapy (rESWT)|Radial shock waves are ballistic waves generated by injection of compressed air inside an applicator that fires a projectile into the itself and impacts against the application head
46028972|NCT02685397|Drug|Enzalutamide|Anti-androgen medication for the treatment of metastatic castration-resistant prostate cancer. 160 mg (four 40 mg capsules) taken as a single oral daily dose, with or without food, until disease progression.
46028973|NCT02685397|Radiation|Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) is a treatment modality in radiation oncology that delivers a very high dose of radiation to the tumour target with high precision using a single or a small number of fractions.
46028974|NCT02682745|Drug|HL151|Test drug l : HL151, 1T, single oral administration on an empty stomach, Test drug ll : HL151, 1T, single oral administration after meal
46028975|NCT02682745|Drug|TALION tab.|Reference drug: TALION tab, 1T, every 12 hours, oral administration
46028976|NCT01197521|Drug|fostamatinib|fostamatinib 100 mg twice daily
46028977|NCT01197521|Drug|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
45471295|NCT01147445|Biological|Double Mutant Heat- Labile Toxin (dmLT)|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat labile enterotoxin. LT(R192G/L211A) is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700 micrograms of vaccine protein in a 3 mL, multi-dose, Wheaton Serum Vial. Vaccine dosage levels: 5, 25, 50, 100 micrograms as a single, oral dose.
46028978|NCT01197521|Drug|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily
46028979|NCT02683915|Procedure|Therapeutic hypothermia|Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
46028980|NCT02683837|Drug|Remifentanil|
46028981|NCT02683837|Device|Pupillometry|Pupillary diameter measured every 5 minutes
46028982|NCT02683837|Drug|Sevoflurane|Administered to maintain a Bispectral Index between 40 and 60
46028983|NCT02002507|Other|comparison of different neurosurgical position|in 2 of 3 positions (supine, plus either prone or park bench) with both left and right internal jugular vein cross-sectional area of vein, doppler velocity, internal jugular venous flow, position of internal jugular vein in relation to carotid artery (All measured with the use of ultrasound)
46028984|NCT01157676|Procedure|Open radical cystectomy|Standard of care removal of urinary bladder.
46028985|NCT01157676|Procedure|Robotic assisted radical cystectomy|Standard of care removal of urinary bladder using DaVinci robot.
46028986|NCT01157676|Device|DaVinci robot|DaVinci robotic surgical system.
46028987|NCT02680873|Other|SASI bypass|he operation was done under general anesthesia. The technique commences with the devascularization of the greater curvature of the stomach with the harmonic scalpel.junction. The stomach is then tubularized over a 36 French calibration tube, with a linear stapler charged with a green cartridge, commencing 6 cm proximal to the pylorus. The ileocecal junction is identified and 250 cm is measured upwards. The selected loop is ascended antecolic without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just cranial 3 cm away from the pylorus with a linear stapler charged with a green cartridge.
45471296|NCT04426214|Device|tDCS|We will apply tDCS in combination with cognitive training. All participants receive cognitive training, and will be randomized to receive either active or sham tDCS
45471297|NCT04426214|Behavioral|Cognitive Training|cognitive training on computer
46028988|NCT04183543|Device|Pulsed Electromagnetic Fields|The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak.
45471298|NCT03266172|Drug|GSK2982772 Modified Release|GSK2982772 MR will be available as prototype MR minitablet in capsules with unit dose strength of 60 mg in Part A. In Part B, GSK2982772 MR minitablet in capsules with unit dose strength of 15, 30 or 60 mg will be administered by subjects for Days 1 to 3. In Part C, GSK2982772 MR tablet with unit dose strength of 240, 360 or 480 mg will be administered by subjects. GSK2982772 MR will be administered orally with 240 mL of water.
45471299|NCT03266172|Drug|GSK2982772 Immediate Release|In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 120 mg (4 tablets of dose strength 30 mg) orally with 240 mL of water. In part C, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water.
45471300|NCT04356937|Drug|Tocilizumab|"Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:~Tocilizumab 8mg x 1 (n=185)~Standard of care/Placebo (n=93)"
46028989|NCT04183543|Device|Sham Therapy|Inactive Pulsed Electromagnetic Field therapy
45471301|NCT04356937|Drug|Placebos|"Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:~Tocilizumab 8mg x 1 (n=185)~Standard of care/Placebo (n=93)"
46028990|NCT02680951|Drug|Dasatinib|Administered orally on a once daily schedule based on the dose level assigned to the patient at enrollment (60, 80, or 100mg/m2/day). Patients may adjust the time they take dasatinib as long as they take the drug approximately every 24 hours
46028991|NCT02680951|Drug|Fludarabine|"30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the fludarabine dose will be corrected as follows: [weight (Kg) x dose (per m2)] divided by 30"
46028992|NCT02680951|Drug|Cytarabine|"2000 mg/m2/dose intravenous infusion over 1 to 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the cytarabine dose will be corrected as follows: [weight (Kg) x dose (per m2)] divided by 30"
45471302|NCT01250561|Drug|Gabapentin|gabapentin 300mg/day, titrated up weekly to max tolerated dose or 3600mg/day (whichever is lower), for 4-9 weeks
45471303|NCT01250561|Drug|Valacyclovir|valacyclovir 1000mg three-times daily x 7 days
45471304|NCT05055908|Drug|First line EC/EP+Atezolizumab|Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 days
45471305|NCT01147523|Drug|Spironolactone/Vitamin E|Spironolactone, tablets, 25 mg daily plus Vitamin E, capsules, 400 mg daily, for 52 weeks
45471306|NCT05760950|Other|Routine clinical treatment|Routine clinical treatment is based on the latest international guidelines for intracerebral hemorrhage.
45471307|NCT05761808|Other|exercises|Before being included in the study, the multifudus muscle thickness at the L4-L5 level of each patient will be measured ultrasonographically. First of all, exercises to learn transversus abdominis activation will be performed in patients. They will then be included in the stretching and strengthening exercise program. Stretching and strengthening exercises were planned as dynamic abdominal bracing, finding and maintaining neutral position, and exercises on all fours. Exercise therapy will be applied by the same physiotherapist 3 days a week for 5 weeks. Patients will continue to exercise for 7 more weeks as a home program. During this period, they will be called once a week by phone.
45471308|NCT05761808|Other|neuromuscular electrical stimulation|NMES intensity will be planned individually according to the patients. Before being included in the study, the multifudus muscle thickness at the L4-L5 level of each patient will be measured ultrasonographically. NMES application will be applied by a specialist physiotherapist 3 days a week for 5 weeks, for a total of 15 sessions. Exercises will be applied 3 days a week for 5 weeks, accompanied by a physiotherapist. Patients will continue to exercise for 7 more weeks as a home program. In this process, patients will be called once a week by phone.
46028993|NCT02680951|Drug|Idarubicin|"8mg/m2/dose intravenous infusion over 15 minutes, once daily, on days 3 to 5, total 3 doses~Participants with body weight less than 12Kg, the idarubicin dose will be corrected as follows: [weight (Kg) x dose (per m2)] divided by 30"
46028994|NCT02680951|Drug|Intrathecal (IT) cytarabine|"Given intrathecally to all participants on day 1 of course 1 and 2. Omit on day 1 of course 1 if participant received IT therapy within 7 days prior to study enrollment. Intrathecal chemotherapy may be given during the end of course 1 disease evaluation (spinal fluid and bone marrow aspiration) and may be repeated every 7 days with bone marrow evaluations per institutional preference.~Cytarabine dose defined by age:~30 mg for patients age 1 - 1.99~50 mg for patients age 2 - 2.99~70 mg for patients ≥3 years of age~The participant may receive intrathecal triple therapy (ITT) if persistent blasts are present in the cerebral spinal fluid (CSF) based on the treating physician's clinical judgment."
45471309|NCT01251029|Drug|N-acetylcysteine|1200 mg orally; 600mg i.v.
45471310|NCT01251029|Drug|Siran (N-acetylcysteine)|
45471311|NCT03915041|Device|VR + active brain stimulation|Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
45471312|NCT03915041|Device|VR +sham brain stimulation|Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
45471313|NCT03914729|Procedure|Primary Closure|A symmetrical elliptical incision of skin and subcutaneous fat around primary and secondary orifices is performed. The cyst is excised en bloc down to the sacral fascia and removed. The lateral edges of the wound are approximated and sutured in the midline: subcutaneous fat - with a running suture, skin - with a separate running suture.
45754598|NCT03580694|Drug|REGN4659|REGN4659 will be administered by intravenous (IV) infusion.
46028995|NCT02680717|Drug|Clobetasol|ointment, twice daily (alternating weeks)
46028996|NCT02680717|Drug|Calcipotriene|ointment, twice daily
46028997|NCT02680717|Drug|Tacrolimus|ointment, 0.1%, twice daily
46028998|NCT05663983|Behavioral|Description of therapeutical results|Comparison between two groups of patients treated in different realities (Pediatric Hospital or Adult General Hospital)
46028999|NCT04182529|Device|Photoneuromodulation therapy|low-level LED near-infrared (670-810nm) including MedX Health Model 1100 or WiseFori5-3800
46029000|NCT04182529|Other|Sham|Sham, no active stimulation will be given to subjects
46029001|NCT02680795|Drug|Belinostat IV|"Cohort A:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort B:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort C:~Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion."
46029002|NCT00640237|Dietary Supplement|Alpha-D3|We will use the vitamin alpha-D3 drops of CTS pharmaceutical firm , that contains 5000 IU in ml. Every patient in the interventional group will receive two dose of 100000 IU (20 ml)vitamin alpha-D3 within a month period.
46029003|NCT02683759|Dietary Supplement|Bio-enhanced Curcumin Soft Gelatin Capsule|"Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)~Starting dose: 50 mg BID of Bioenhanced Curcumin Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug"
46029004|NCT02683759|Drug|5-Aminosalicyclic acid|Dosage is as instructed by patient's physician
46029005|NCT02682589|Procedure|Open surgery|A traditional midline incision is made through the abdominal wall and a colectomy with CME is performed.
45471314|NCT03914729|Procedure|Gluteus Maximus Fascia Plasty Flap|A symmetrical elliptical incision of skin and subcutaneous fat around primary and secondary orifices is performed. The cyst is excised en bloc down to the sacral fascia and removed. The lateral edges of the gluteus maximus muscles fascia bilaterally are mobilised in the direction from the fixation point to the sacrum and for 3-4 cm in lateral direction. The fascia flaps edges are approximated and fixed in the midline with a running suture. The subcutaneous fat is closed with a running suture, skin is closed with a separate running suture.
45471315|NCT01251107|Drug|Bleomycin|10 mg/m2 IV day 8 during cycles 1 to 8
45471316|NCT01251107|Drug|Etoposide|200 mg/m2 iv on days 1 to 3 during cycles 1 to 4; 100 mg/m2 iv on days 1 to 3 during cycles 5 to 8
45471317|NCT01251107|Drug|Doxorubicin|35 mg/2 iv on day 1 during cycles 1 to 4; 25 mg/m2 iv on day 1 during cycles 5 to 8
45471318|NCT01251107|Drug|Cyclophosphamide|1250 mg/m2 iv on day 1 during cycles 1 to 4; 650 mg/m2 iv on day 1 during cycles 5 to 8
45471319|NCT01251107|Drug|Vincristine|1.4 mg/m2 iv (max 2 mg) on day 8 during cycles 1 to 8
45471320|NCT01251107|Drug|Procarbazine|100 mg/m2 po from day 1 to 7 during cycles 1 to 8
46029006|NCT02682589|Procedure|Laparoscopic surgery|3-5 small incisions are made through the abdominal wall for the placement of trocars and the abdominal cavity is insufflated with carbon dioxide to allow access, visualization and operation. A 6-8cm auxiliary incision is made for specimen extraction and anastomosis. Conversion may occur due to technical difficulties or intraoperative complications, which is defined when completion of the dissection of the mesocolon is performed through a traditional open abdominal approach. Patients undergo conversion to laparotomy will be excluded from this study.
45471321|NCT01251107|Drug|Prednisone|40 mg/m2 po from day 1 to 14 during cycles 1 to 8
45471322|NCT01251107|Drug|Doxorubicin|25 mg/m2 iv on days 1 and 15 in each cycle
45471323|NCT01251107|Drug|Bleomycin|10 mg/m2 iv on days 1 and 15 in each cycle
46029007|NCT03072433|Behavioral|Counseling Intervention Package|Daily 45 minutes of group teaching for primary caregivers, followed by 45 minutes of supervised play and stimulation with their children for a total of four days. Teaching modules consist of psychosocial stimulation, nutrition and feeding, and water, sanitation and hygiene practices.
45471324|NCT01251107|Drug|Vinblastine|6 mg/m2 iv on days 1 and 15 in each cycle
45471325|NCT01251107|Drug|Dacarbazine|375 mg/m2 iv on days 1 and 15 in each cycle
45471326|NCT01125176|Drug|thalidomide|50 mg oral dosing every other day
45471327|NCT01125176|Drug|lenalidomide|varying oral doses every other day (max 25 mg/day)
46029008|NCT03072433|Behavioral|Standard of Care|Nutrition and water sanitation and hygiene counseling at any point prior to discharge from hospital as per the local nutrition rehabilitation unit standard of care. In addition, primary caregivers will be stimulated to play with their children in a play area.
46029009|NCT00991341|Biological|Red blood cell units stored <= 10 days|Pre-storage leukoreduced red blood cell units stored <=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
46029010|NCT00991341|Biological|Red blood cell units stored >= 21 days|Pre-storage leukoreduced red blood cell units stored >=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
45682237|NCT04404322|Other|IPT A Suicide Crisis Intervention|The intervention is comprised of five weekly sessions followed by monthly emails to the patients and their parents over a period of three months. The first session is aimed at introducing the intervention, assessing depression and suicidal risk and building a safety plan. The safety plan consists of a prioritized list of coping strategies that the patient can use when suicidal risk is increased. The second session is focused on reviewing the patient's interpersonal relationships (using the closeness circle and interpersonal inventory) and conceptualizing the interpersonal problem area. Sessions 3-4 focus on developing and practicing interpersonal, emotional and behavioral coping strategies relevant for suicidal risk. Lastly, in session 5, patient and therapist go over the process and main issues which were worked on, emphasizing relapse prevention by going back to the safety plan. First and fifth sessions always involve the parents.
46029011|NCT04291989|Device|Optimal Blood Sampling Site for Point of Care Lactate Assessment using the handled Lactate-Pro 2 device|This study aims to compare lactate levels using the Lactate Pro 2 device from the same patient at the same time with blood samples taken from three locations - fingertip, earlobe and forearm venepuncture
45682238|NCT04404322|Other|Treatment As Usual|patients receive an integrative combination of psychodynamic, supportive and cognitive behavioral therapy, usually lasting between 10-30 weeks
45682239|NCT01675180|Other|Information|Women in the intervention group will recieve information and counseling on oral health care during pregnancy
45682240|NCT01675180|Other|Control|No intervention
46029012|NCT04291677|Other|intervention musical|Intervention group in which musical intervention will be applied the first or third day of mechanical ventilation.
45682241|NCT03152422|Diagnostic Test|Urinary proteomics|Urinary proteomics for risk stratification and graft monitoring in recipients of a heart transplant
46029013|NCT04291677|Other|Without intervention musical|Control group with standard treatment without musical intervention.
46029014|NCT04292691|Drug|40ml of Ropivacaine 0.5% Injectable Solution|already outlined in the arm/group description
46029015|NCT04292691|Drug|40ml of Ringer's Lactate|already outlined in the arm/group description
46029016|NCT00990249|Drug|Busulfan|Test Dose 32 mg/m^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.
46029017|NCT00990249|Drug|Clofarabine|40 mg/m^2 by vein over 1 hour daily Day -6 through Day -3
46029018|NCT00990249|Drug|Thymoglobulin|0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors
46029019|NCT00990249|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
46029020|NCT02846545|Biological|Golimumab|Participants will receive subcutaneous golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area) in an OL extension period.
46029021|NCT02846545|Biological|Placebo|Matching Placebo to golimumab.
45471328|NCT01125176|Biological|rituximab|375 mg/m2 intravenously on days 1, 8, 15, and 22 of cycle 1. Then, repeated on days 1, 8, 15, and 22 of every 6th cycle thereafter (Cycle 7, 13, 19, etc.)
45471329|NCT03914339|Procedure|Periodontal and orthodontic treatment|Eighteen periodontally compromised patients who give be given both periodontal and orthodontic treatment
45471330|NCT03914339|Procedure|periodontal treatment|Eighteen periodontally compromised patients who give be given periodontal treatment alone.
46029022|NCT04291755|Drug|Pembrolizumab Injection|Any checkpoint inhibitor is acceptable
45682242|NCT03155932|Drug|APD334|APD334 active treatment for 24 weeks.
45682243|NCT01675258|Other|Salivary samples|Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.
45682244|NCT01675414|Other|evaluation visit by a pediatric gastroenterologist|medical history, physical exam completed by pediatric gastroenterologist
45754599|NCT03580694|Drug|Cemiplimab|Cemiplimab will be administered by intravenous (IV) infusion.
46029023|NCT05663827|Drug|Ruxolitinib|A dosage of 5mg once daily will be applied as initiation. After one week use, dose escalation or de-escalation would depend on clinical response.
46029024|NCT04292769|Drug|Decitabine|Decitabine 10mg / d, intravenous administration d-5 ～ d-1
46029025|NCT04292769|Biological|DC-CIK|Autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109;
46029026|NCT00640939|Drug|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
46029027|NCT00640939|Drug|Matching Placebo|Matching placebo patch, containing identical constituents to active patch except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
46029028|NCT04291443|Procedure|Heavy Force (225g)|Orthodontic Force
46029029|NCT04291443|Procedure|Light Force (25g)|Orthodontic Force
46029030|NCT05663749|Drug|Metformin|1000mg for 8 weeks
46029031|NCT05663749|Drug|Topiramate|50mg for 8 weeks
46029032|NCT02682433|Device|diagnostic hysteroscopy|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
46029033|NCT02682433|Device|diagnostic sonar test|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
46029034|NCT00990093|Device|test intermittent catheter|CH 12 hydrophilic coated catheter
46029035|NCT00990093|Device|Intermittent catheterization|CH 12 hydrophilic catheter
46029036|NCT04184167|Other|intermittent fasting 4 months before ICSI|women will start intermittent fasting before starting ICSI by 4 months
46029037|NCT02867553|Drug|rituximab|
46029038|NCT02867553|Radiation|Multi-fields radiotherapy|
45471331|NCT03301740|Other|UF profiling during HD|"Experimental arm: Linear UF profiling (linearly decreasing UF rate with a UF rate starting at 1.33 times the rate that would be needed at a constant UF rate to achieve the desired post-weight; pre-programmed profile 2 on a Fresenius 2008K machine, the machine used in all participating clinics). Ultrafiltration profiling will be performed using Fresenius 2008K dialysis machines in accordance with manufacturer instructions."
45682245|NCT01675570|Drug|RX-10045|One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
45471332|NCT03301740|Other|Conventional HD|Control arm: Conventional HD (routine care) is the participant's standard HD prescription without UF profiling.
45471333|NCT04337684|Drug|Long Term Follow-Up|"Menkes disease is a form of inherited copper deficiency associated with neurodevelopmental delays and neurological problems. Copper Histidinate is being evaluated for efficacy and safety in patients with Menkes disease. The purpose of this protocol is to collect long term follow-up data.~During the study, patients and/or parent/legal guardian will be contacted by the investigator by either telephone or an in-person visit to assess long term follow-up."
45682246|NCT01675570|Drug|Vehicle for RX-10045|One drop of RX-10045 placebo solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
45682247|NCT01675648|Drug|Lofexidine|
45682248|NCT01675648|Drug|Diazepam|
45682249|NCT01675648|Drug|Placebo for Lofexidine|
45682250|NCT01675648|Drug|Placebo for Diazepam|
46029039|NCT05663671|Diagnostic Test|Diagnostic Test|30% of IBD patients are misdiagnosed. This affects surgical care of patients. Investigators have unveiled a signature discriminator between UC&CC that also predicts the outcome of IC patients into authentic UC/CC. This is a bioassay that is specific, sensitive, linear, affordable, minimal risk, non-invasive and constitutes an inexpensive, simple to use, point-of-care test format. Investigators published data which have shown robust presence of DEFA5 in the colon crypt mucosa with aberrant expression of apparent crypt-cell-like cells (CCLCs) in areas identified with ectopic colon ileal metaplasia consistent with CC. Investigators propose to validate that UC/CC, the two unsolved medical sub-types of pathology can accurately be distinguished among IC patients by examining CCLCs secreted DEFA5 levels in endoscopy biopsies instantly. Diagnostics relies on the expression/localization/activation of DEFA5 and the ectopic CCLCs in the mucosal crypt of CC patients.
46029040|NCT02682277|Device|polygucosamine|2 times daily 2 polyglucosamine tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
46029041|NCT02682277|Other|placebo|2 times daily 2 placebo tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
46029042|NCT00909961|Drug|Zoledronic acid|
45839049|NCT04335474|Procedure|Percutaneous drainage strategy|The nonoperative management consists of close monitoring of the patient's clinical condition; repeated radiological investigations such as CT, ultrasound, and MRCP; monitoring of the amylase and lipase levels, initiation of post-pyloric enteral nutrition and parenteral nutrition. In addition, ERCP with the placement of a stent in the damaged pancreatic duct is used as part of the non-operative approach. Besides, percutaneous catheter drainage (PCD) management including ultrasound or CT-guided drainage of abdominal and peripancreatic fluid collections and pancreatic pseudocysts is applied to the HGPT patient.
45839050|NCT04335318|Device|AI-assisted colonoscopy|Colonoscopies performed with assistance of an AI tool that highlights the areas that are susceptible to be a polyp.
45839051|NCT04334694|Device|Atrial flow regulator (Occlutech® AFR device)|Atrial septostomy followed by implantation of AFR.
46029043|NCT05663593|Drug|HSK31858, tablet|Starting dose in single ascending dose: 5 mg
46029044|NCT05663593|Drug|Placebo, tablet|Matching placebo
46029045|NCT02680249|Drug|CTP-656|
46029046|NCT04184557|Behavioral|Staying Calm in the OR|"Staying Calm in the OR is a mindfulness-based stress-reduction smartphone tailored for people who are waiting for surgery. It consists of a free, accessible, on-demand, short training through a series of guided meditation practices. They are based on widely studied mindfulness-based programs, such as Mindfulness-Based Stress Reduction (MBSR) ir Mindfulness Self Compassion (MSC)."
46029047|NCT00641017|Biological|rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine|Live attenuated Human Parainfluenza Type 1 Virus Vaccine
46029048|NCT00641017|Biological|Placebo|Placebo for rHPIVI1 84/del170/942A, Lot PIV1 #104A vaccine
46029049|NCT00642577|Drug|bevacizumab [Avastin]|5mg/kg iv every 2 weeks
46029050|NCT00642577|Drug|irinotecan|125mg/m2 iv weekly for 4 weeks of each 6 week cycle
46029051|NCT00642577|Drug|leucovorin|20mg/m2 iv weekly for 4 weeks of each 6 week cycle
46029052|NCT00642577|Drug|fluorouracil|500mg/m2 iv weekly for 4 weeks of each 6 week cycle
46029053|NCT04184401|Drug|Ascites replacement with albumin and hartmann's solution|"Combined strategy for ascites replacement~30% of ascites: replacement with 5% albumin~40% of ascites: replacement with Hartmann's solution"
46029054|NCT04184401|Drug|Ascites replacement with hartmann's solution|"Hartmann's solution only strategy for ascites replacement~- 70% of ascites: replacement with Hartmann's solution"
46029055|NCT02679937|Behavioral|Fit4Duty|Small (<9) participant-driven groups meet weekly for 6, 1 hour sessions. Participants design small, gradual healthy lifestyle change plans with added verbal, written, and behavioral exercises designed to elicit dissonance regarding engaging in unhealthy eating and sedentary practices. Participants are asked to voluntarily discuss the health, interpersonal and societal costs of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of leanness, a healthy diet, and regular physical activity.
46029056|NCT02679937|Other|Nutrition Education|Two, 50 minute educational videos address basic concepts of healthy nutrition and weight management reviewing topics such as macro and micronutrients, the virtue of whole grains, fruit, vegetables and superfoods, the dangers of dehydration and vitamin deficiency. The role of poor eating habits, lack of exercise and cultural and technological issues in America's obesity epidemic is examined. A basic understanding of energy balance is conveyed. The role of nutritional supplements is addressed.
46029057|NCT02682121|Drug|Metformin|Metformin 850 mg twice daily
46029058|NCT02682121|Drug|Placebo|Placebo twice daily
46029059|NCT02680405|Procedure|Skin Biopsy|Full thickness skin biopsies will be collected from each subject used for proteomic and genomic analysis of associated biomarker levels.
46029060|NCT02680405|Procedure|Skin tape stripping|Skin tape stripping used for proteomic and genomic analysis of associated biomarker levels.
45471334|NCT03914183|Device|mCPN Intervention|"Each box of montméd Coloured Pen Needles (mCPN) has the following five features:~i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message Change color, change site siteTM iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened"
46029061|NCT02680405|Procedure|Blood draw|Whole blood and serum testing used for proteomic and genomic analysis of associated biomarker levels.
46029062|NCT02537587|Other|Control 1|67g of control bar
45471335|NCT03914183|Device|Control|Use of standard of care insulin pen needle
45471336|NCT04355767|Biological|Convalescent Plasma|SARS-CoV-2 convalescent plasma with neutralizing SARS-CoV2 antibodies titers of ≥1:160 administered via intravenous (IV) infusion.
46029063|NCT02537587|Other|Control 2|86g of control bar
46029064|NCT02537587|Other|15/0|66g of experimental bar 15/0
46029065|NCT02537587|Other|15/0LS|84g of experimental bar 15/0LS
45471337|NCT04355767|Biological|Saline|Saline with multivitamin administered via intravenous (IV) infusion..
45682251|NCT03872518|Device|Urovac|The Urovac is simply a regular plastic handheld urinal attached by tubing to a pump that evacuates urine to a reservoir. The Urovac is simply a regular plastic handheld urinal attached by tubing to a pump that evacuates urine to a reservoir. There is also a removable cloth-covered platform to reduce spills.
46029066|NCT02537587|Other|15/5|75g of experimental bar 15/5
46029067|NCT02537587|Other|10/5|72g of experimental bar 10/5
46029068|NCT02537587|Other|10/10|80g of experimental bar 10/10
46029069|NCT02683603|Drug|"AS colistin and imipenem"|colimycin (colistin) powder (1 million units (MU) by flakon) by AS route in addition to imipenem
45471338|NCT00882050|Drug|Exenatide 0.27 ng/kg/min|"Exenatide to be infused intravenously at 0.27 ng/kg/min (0.066 pmol/kg/min) for a duration of 3 to 6 hours.~Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
45682252|NCT03870802|Other|Characterization of breast stem & immune system cells infiltrated in the mammary gland|Isolation, quantification and characterization of breast stem and immune cells of samples obtained during the prophylactic mastectomy in women presenting different tumor progression risks.
46029070|NCT02683603|Drug|"IV colistin  and imipenem ."|colimycin (colistin) powder (1 MU by flakon) by intravenous route in addition to imipenem
46029071|NCT02683603|Drug|AS colimycin (colistin)|nebulisation of colimycin (colistin) for 30 minutes 3 times per day during at least 14 days. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland).
46029072|NCT02683603|Drug|IV colimycin (colistin)|intravenous colimycin (colistin) : 9 MU during 60 minutes followed by 4.5 million units 2 times per day
46029073|NCT02683603|Drug|AS colistin and imipenem|IV imipenem 1 g three times per day.
46029074|NCT02683603|Drug|IV colistin and imipenem|IV imipenem 1 g three times per day
46029075|NCT00641095|Biological|rituximab|concentrate for solution for infusion
46029076|NCT00641095|Drug|Cyclophosphamide|Tablets
46029077|NCT00641095|Drug|Fludarabine|Film coated tablet
46029078|NCT00984165|Procedure|Single fraction radiation|8-Gy fraction of radiation
46029079|NCT00984165|Biological|Donor Lymphocyte Infusion (DLI)|Unmanipulated Donor Lymphocyte Infusion
45839052|NCT04334928|Drug|Emtricitabine/tenofovir disoproxil|Emtricitabine/tenofovir disoproxil, 200 mg/245 mg tablets. A dose of one tablet once a day will be administered.
46029080|NCT00984165|Procedure|Apheresis|Donors will undergo a 5-liter apheresis procedure on a CS-3000 or equivalent machine.
46029081|NCT02869113|Drug|BAY98751 (Y65-110)|10 µL in one eye
45839053|NCT04334928|Drug|Hydroxychloroquine|Hydroxychloroquine, 200 mg tablets. A dose of one tablet once a day will be administered.
45839054|NCT04334928|Drug|Placebo: Emtricitabine/tenofovir disoproxil Placebo|Placebo: Tablets similar in appearance to Emtricitabine/tenofovir disoproxil
45839055|NCT04334928|Drug|Placebo: Hydroxychloroquine|Placebo: Tablets similar in appearance to Hydroxychloroquine
46029082|NCT02869113|Drug|BAY 98751 (Y65-102)|10 µL in one eye
46029083|NCT02869113|Drug|BAY 98751 (Y65-106)|10 µL in one eye
46029084|NCT02869113|Drug|Standard shampoo mixture (Control)|10 µL in other eye
46029085|NCT00993291|Procedure|Frequency change to 60 Hz|60 Hz stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
46029086|NCT00993291|Procedure|Frequency change to 130 Hz|130 Hz Stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
46029087|NCT02867631|Behavioral|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
46029088|NCT01196975|Biological|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose
46029089|NCT01196975|Biological|FluLavalTM-VB|Single intramuscular dose
45839056|NCT04334850|Procedure|Combined use of a respiratory broad panel multiplex PCR and procalcitonin|The actions or procedures added by the research are the application of the algorithm of early antibiotics de-escalation and discontinuation.
45839057|NCT04334850|Other|Usual antibiotic treatment|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
46029090|NCT01196975|Biological|FluLavalTM-YB|Single intramuscular dose
46029091|NCT00992589|Drug|Rabeprazole sodium 5 mg|Rabeprazole Sodium 5 mg capsules once daily in the morning.
46029092|NCT00992589|Drug|Rabeprazole sodium 10 mg|Rabeprazole Sodium 10 mg capsules once daily in the morning.
46029093|NCT00992589|Drug|Placebo|Matching placebo capsules once daily in the morning.
46029094|NCT01196741|Drug|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 6 weeks followed by a 2 week break (1 cycle), for 4 cycles initially (32 weeks). If there is evidence of on-going response after 4 cycles, 3 further cycles will be given, unless there is dose-limiting toxicity or the patient requests to discontinue treatment. If best response is stable disease after 4 cycles, treatment should be discontinued but may continue at the discretion of the Investigator.
45682253|NCT01566435|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
46029095|NCT01196741|Drug|Saracatinib|Saracatinib 175 mg PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
45682254|NCT01566435|Drug|Cisplatin|
45839058|NCT04334616|Device|Video Laryngocope|VDL used for VDL arm
45839059|NCT04334616|Device|Macintosh Conventional Laryngocope|Used for Conventional laryngocope arm
45682255|NCT01566435|Drug|Fluorouracil|
45682256|NCT01566435|Radiation|Intensity modulated radiation therapy|
45682257|NCT01566435|Drug|Cetuximab|
45682258|NCT01566435|Procedure|Quality-of-life assessment|ACF baseline, IMRT baseline, Day 7, Week 12, months 6 and 12
46029096|NCT01196741|Drug|Matched placebo|Matched placebo PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
46029097|NCT02868255|Procedure|Collection of human samples|Several types of samples will be used to test the effect of the drug candidate
46029098|NCT00629187|Drug|Temozolomide|Before taking part in this study, subjects will have stem cells collected in a procedure called apheresis. Once on this study, subjects will be admitted to the hospital and receive daily doses of temozolomide by mouth for 5 days. Stem cells will be given back to subjects who will remain in the hospital until blood counts have recovered. Doses of temozolomide will range from 350 mg to 1500 mg/m(squared) daily for 5 days (total dose 1750 to 7500 mg/m(squared).
46029099|NCT04291287|Drug|Antithrombotic Agent|"Adenosine diphosphate (ADP) receptor antagonists (or P2Y12 inhibitors) therapy include:~Clopidogrel (Plavix®)~Prasugrel (Efient®)~Ticagrelor (Brilique®)~DOACs therapy include:~Apixaban (Eliquis®)~Dabigatran (Pradaxa®)~Edoxaban (Lixiana®)~Rivaroxaban (Xarelto®).~Oral anticoagulant therapy (OAT) include:~Warfarin (Counmadin®)~Acenocumarol (Sintrom®)"
46029100|NCT04291365|Diagnostic Test|Blood pressure measurement|Study subjects will have a total of 9 blood pressure measurements taken (3 on upper arm, 3 on lower arm, and 3 on wrist)
45839060|NCT04334226|Other|Interview|Interviews will explore the patient's and caregiver's experiences and perceptions of ostomy surgery prior to the Bootcamp and after the Bootcamp from a physical, psychological, social, and spiritual perspective
46029101|NCT00983385|Drug|Tapentadol PR|Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusted with 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed a dose of 500 mg of Tapentadol per day.
46029102|NCT00983385|Other|Observation period|Eligibility assessment period to characterize the baseline over a one week period (week -1). Participants continued their previous treatment prior to allocation to tapentadol, if eligible.
46029103|NCT00983385|Drug|Tapentadol PR|Maintenance Period: In this period participants continued Tapentadol Prolonged Release (PR) on the dose established in the Titration and Optimal Dose Period. Tapentadol IR participants were not permitted to exceed a total daily tapentadol dose of 500 mg.
46029104|NCT02867475|Other|Physical activity motivation|Physical activity motivation
46029105|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|One intramuscular injection of initial process-manufactured GSK2340272A vaccine
46029106|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections of initial process-manufactured GSK2340272A vaccine
45471339|NCT00882050|Drug|Exenatide 0.41 ng/kg/min|"Exenatide to be infused intravenously 0.41 ng/kg/min (0.099 pmol/kg/min) for a duration of 3 to 6 hours Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
46029107|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|One intramuscular injection of new process-manufactured GSK2340272A vaccine
45839061|NCT04334382|Drug|Hydroxychloroquine|Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400mg po BID x 1 day, then 200mg po BID x 4 days (dose reductions for weight < 45kg). The drug dose (2.4 gm over 5 days) chosen falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of >20.
45471340|NCT00882050|Drug|Placebo|"Intravenous Placebo of NSS infused at same rate as drug comparator. Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
45839062|NCT04334382|Drug|Azithromycin|Patients in the azithromycin arm will receive azithromycin 500mg PO on day 1 plus 250mg PO daily on days 2-5.
46029108|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections of new process-manufactured GSK2340272A vaccine
46029109|NCT02868177|Dietary Supplement|Totum-63|Each randomized subject will consume 8 capsules daily of either active (5200 mg of Totum-63) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
46029110|NCT02868177|Dietary Supplement|Placebo|Each randomized subject will consume 8 capsules daily of placebo (5064 mg of maltodextrine) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
46029111|NCT02868099|Drug|Romiplostim|
46029112|NCT02868099|Drug|Placebo|
46029113|NCT02868021|Device|Strength testing|Test the strength of subject's lower extremity muscles on the dynamometer system
46029114|NCT02868021|Behavioral|Short Physical Performance Battery (SPPB)|The SPPB is a timed short distance walk, repeated chair stands, and balance test that measures lower extremity function.
46029115|NCT02868021|Behavioral|Six-minute walk (SMW)|Subjects walk back and forth along a 100-ft hallway for six minutes after instructions to complete as many laps as possible.
46029116|NCT02868021|Behavioral|Numerical pain scale|Measure pain using an 11-point numerical pain scale.
45471341|NCT01251185|Device|Cardiospec|Non-invasive, low-intensity extracoporeal shockwaves at energy density of 0.99 mJ/mm2. 9 treatment sessions, 20 minutes each, over a period of 9 weeks (3 sessions on weeks 1, 5 and 9).
45471342|NCT04455048|Other|Cervicothoracic thrust manipulation|The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. Thrust manipulation will be applied at the end of exhale.
45471343|NCT04455048|Other|Cervicothoracic thrust manipulation sham|The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. A soft compression will be applied at the end of exhale without a thrust.
45471344|NCT03912857|Drug|Camrelizumab|"Experimental: test group Drug:Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.~Apatinib :250 mg or 375 mg, qd"
45682259|NCT03868228|Procedure|Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC)|Use of CapnoPen device to aerosolise Oxaliplatin 92mg/m2 chemotherapy 6-8 weekly intervals for intraperitoneal distribution via laparoscopy.
45682260|NCT01675726|Other|questionary on quality of life|
45682261|NCT01675804|Other|Computerized cognitive rehabilitation|- Computerized cognitive rehabilitation: 20 ninety-minute sessions of computerized cognitive rehabilitation.
45682262|NCT01675804|Drug|Ritalin|-drug therapy: 2 or 3 doses of 10 mg tablets of Immediate-release Methylphenidate (Ritalin) per day for 2 months.
46029117|NCT02868021|Behavioral|Self-assessed function|Using the Late Life Function and Disability Instrument.
46029118|NCT02868021|Procedure|Muscle biopsies|During the course of the surgery two small muscle biopsies from the quadriceps muscle of the operative leg will be collected.
46029119|NCT02868021|Device|Determination of 1 Repetition Maximum (1-RM)|Following the warm-up, subjects will attempt to complete one repetition of the leg press exercise at progressively greater resistance until a full repetition can no longer be performed. The weight of the last complete unassisted repetition will be recorded as the 1-RM.
45682263|NCT01675804|Other|Placebo CACR [PCACR]|PCACR: 20 ninety-minute sessions of Placebo computerized cognitive training.
46029120|NCT02868021|Device|Blood flow restriction exercise|Perform lower-extremity exercises (leg press, leg extension, leg curl, and calf extension) at an intensity of 30% of 1-RM with external compression applied to the proximal thigh of each leg.
46029121|NCT02868021|Behavioral|Borg CR10 scale|Following each exercise session, participants will provide a rating of perceived exertion (RPE) for the session according to the Borg CR10 scale.
46029122|NCT02868879|Other|Quantitative multiparametric and functional MRI|"Structural connectivity assessed in the cortex and the white matter using multimodal quantitative parametric imaging (R1, R2, R2*, DTI, susceptibility, macromolecular proton fraction, cortical thickness, VBM).~Functional connectivity assessed using simple BOLD and combined ASL-BOLD sequences during multiple tasks including motor, language and working memory tasks."
46029123|NCT02867319|Biological|A dose of ACYW135 meningococcal polysaccharide vaccine|A dose of ACYW135 meningococcal polysaccharide vaccine will be given in certain arm.
46029124|NCT02869035|Drug|Escitalopram|Patients will be treated with an antidepressant drug (escitalopram) at flexible standard doses for 12 weeks. If no response after 4 weeks; shift to duloxetine arm.
46029125|NCT02869035|Drug|Duloxetine|Patients who at 4 weeks of escitalopram have not responded will be shifted to duloxetine at flexible standard dosages.
45682264|NCT01696929|Drug|Tocilizumab|"Therapeutic/Pharmacologic Class of Drug:~Tocilizumab is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody of the immunoglobulin (Ig) gamma-1 subclass.~Type of Dosage Form:~Concentrate for solution for infusion.~Route of Administration:~Intravenous (i.v.) infusion."
46029126|NCT04121871|Other|No intervention|Not required
45682265|NCT04649008|Diagnostic Test|3T Magnetic Resonance Imaging|Magnetic resonance imaging acquired at a field strength of 3 Tesla.
45682266|NCT04649008|Diagnostic Test|Intracranial electroencephalography recordings|Epilepsy patients may undergo implantation of intracranial electroencephalography (iEEG) electrodes for localization of epileptogenic foci, which also provide a means to record localized brain activity during memory or other tasks for research purposes.
45682267|NCT04649008|Diagnostic Test|7T Magnetic Resonance Imaging|Magnetic resonance imaging acquired at a field strength of 7 Tesla.
45682268|NCT04409847|Diagnostic Test|ABPM|24 hour ambulatory blood pressure monitoring
46029127|NCT02868957|Other|impression data from reference scanner|To create a reference images for the assessment of the trueness, the impressions of the upper and lower arch of the oral cavities of four patients were taken using a polyether impression material (3M ESPE Soft Monophase; Minnesota Mining and Manufacturing Co.), and the intaglio scanning was performed on the impression body using a desktop scanner. Scanned images were transformed to the Standard Tessellation Language (STL) file format, and used as reference images.
46029128|NCT02868957|Device|iTero|The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of iTero intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner.
46029129|NCT02868957|Device|Trios|The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of Trios intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner. .
46029130|NCT04290819|Dietary Supplement|Creatine Monohydrate|0.1g/kg of body weight (pre measured creatine) and 3mg/kg of body weight (pre measured micronized cellulose powder-caffeine placebo) self administered 1 hr prior to working out mixed in water.
46029131|NCT04290819|Dietary Supplement|Creatine Monohydrate and Caffeine|0.1g/kg body weight (pre measured creatine) and 3mg/kg body weight (pre measured caffeine) self administered 1hr prior to working out mixed in water.
46029132|NCT04290819|Dietary Supplement|Caffeine|3mg/kg of body weight (pre measured caffeine) and 0.1g/kg of bodyweight (pre measured maltodextrin- creatine placebo) self administered 1 hr prior to working out mixed in water.
46029133|NCT04290819|Dietary Supplement|Placebo|0.1g/kg of body weight (pre measured maltodextrin) and 3mg/kg of body weight (pre measured micronized cellulose powder) self administered 1 hr prior to working out mixed in water.
46029134|NCT04157517|Drug|Modakafusp Alfa|Modakafusp alfa intravenous infusion.
46029135|NCT04157517|Drug|Pembrolizumab|Pembrolizumab intravenous infusion.
45471345|NCT04932590|Other|End-expiratory occlusion test|The test consists in interrupting the ventilator at end-expiration for 15 seconds and assessing the resulting changes in cardiac output. Delays necessary to allow sufficient pulmonary transit time to allow good pulmonary venous return and therefore an increase in cardiac preload.
46029136|NCT02867943|Other|Effects of respiratory rate on gapCO2|respiratory rate was started at 10 breaths/min and added by 2 breaths/min every 60 min up to 16 breaths/min
45471346|NCT04917614|Device|Transcutaneous Electrical Acupoint Stimulation|Transcutaneous Electrical Acupoint Stimulation
45471347|NCT03912935|Other|comparison between two different intubating position|Comparing to different position (sniffing and BUHE) in endotracheal intubation for rapid sequence induction in simulated emergency cases
45471348|NCT03266094|Device|BiZact™: A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
45471349|NCT05206916|Procedure|cryotherapy|Cryotherapy at sites of vibration as origin of snoring and site of collapse for patients with obstructive sleep apnea syndrome
45471350|NCT04441879|Behavioral|Be a Mom Coping with Depression|Be a Mom Coping with Depression is a blended cognitive-behavioral intervention for the treatment of postpartum depression. It consists of 13 weeks of face-to-face and online sessions, each session targeting a specific thematic content, and providing participants with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content.
45682269|NCT04409847|Diagnostic Test|ECG|Electrocardiogram
45682270|NCT04409847|Diagnostic Test|FMD|Flow mediated dilatation
46029137|NCT01196429|Drug|Carboplatin|Given IV
46029138|NCT01196429|Drug|Docetaxel|Given IV
46029139|NCT01196429|Other|Laboratory Biomarker Analysis|Correlative studies
46029140|NCT01196429|Drug|Paclitaxel|Given IV
46029141|NCT01196429|Drug|Temsirolimus|Given IV
46029142|NCT02887703|Behavioral|Sensory Augmentation|Sensory augmentation is a technique of augmenting or replacing compromised sensory information. In the context of sensory-based balance impairments, a sensory augmentation device provides cues of body motion that supplement an individual's remaining intact sensory systems.
46029143|NCT01157364|Drug|bimatoprost 20 µg generation 2|Single dose of bimatoprost ophthalmic administered in the study eye on Day 1.
46029144|NCT01157364|Drug|bimatoprost 15 µg generation 2|Single dose of bimatoprost ophthalmic administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
46029145|NCT01157364|Drug|bimatoprost 10 µg generation 2|Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
46029146|NCT01157364|Drug|bimatoprost 6 µg generation 2|Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
46029147|NCT01157364|Drug|bimatoprost 15 µg generation 1|Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1.
46029148|NCT01157364|Drug|bimatoprost 10 µg generation 1|Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1.
45682271|NCT04409847|Diagnostic Test|PWV|Pulse wave velocity
46029149|NCT01157364|Drug|bimatoprost 0.03%|One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
46029150|NCT01195415|Drug|Gemcitabine Hydrochloride|Given IV
46029151|NCT01195415|Other|Laboratory Biomarker Analysis|Correlative studies
46029152|NCT01195415|Drug|Vismodegib|Given PO
46029153|NCT01195103|Drug|Fospropofol disodium|10 mg/kg bolus
45682272|NCT04409847|Diagnostic Test|Rarefaction|nailbed capillaroscopy
45682273|NCT03865654|Other|Communication Tool|Summarizes recommendations for clinicians and patients for surveillance mammography and follow-up care for breast cancer survivors
45682274|NCT01696773|Other|Tangerine tomato juice|Post-prandial feeding study
45682275|NCT01696773|Other|Red tomato juice|Post-prandial feeding study
45754600|NCT03583892|Drug|Gabapentin|One of the groups of patients was exposed to preoperative gabapentin. As the pain has a complex involvement of multiple mechanisms, multimodal analgesic techniques utilizing a number of drugs acting on different analgesic mechanisms are being used. In this case, some patients received gabapentin as a part of a multimodal analgesic technique.
46029154|NCT01195103|Drug|Fospropofol disodium|6.5 mg/kg bolus
46029155|NCT01195103|Drug|Placebo + Midazolam|Placebo bolus plus midazolam. The dose of midazolam will be based on the patient's weight: 1 mg for patients <60 kg; 1.5 mg for patients ≥60 kg to <90 kg; or 2 mg for patients ≥90 kg
45682276|NCT03158740|Behavioral|DII-Based Counseling System|DII-Based Counseling System, including 12 weekly classes in reducing inflammation by adopting dietary patterns low in inflammation and also through physical activity and stress reduction. Participants will also have access to our Imagine Healthy Online Portal. Group-based behavior change programs provide a way for members to share successes and obtain and provide support to one another.
46029156|NCT01195103|Drug|Fentanyl|All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients <60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.
46029157|NCT01194869|Drug|Sorafenib|Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
45754601|NCT03583736|Behavioral|Virtual visit|Virtual visit with oncologist following uterine cancer diagnosis prior to scheduled office visit.
46029158|NCT01194869|Drug|Cisplatin|75 mg/m² given IV
46029159|NCT01194869|Drug|Paclitaxel|175 mg/m² given IV
46029160|NCT04317833|Drug|SSS17|SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxia-inducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.
46029161|NCT04317833|Drug|Placebo|matched placebo
46029162|NCT01177800|Drug|Placebo|Placebo matched to infliximab given at Weeks 10, 12 and 16 in Infliximab arm and at Weeks 0, 2 and 6 in Placebo arm
46029163|NCT01177800|Drug|Infliximab|5 mg/kg infusion given intravenously at Week 0,2,6 (induction treatment phase) and at Week 14 and 22 in maintenance phase in infliximab arm and at Week 12 and 16 in Placebo arm.
46029164|NCT01177722|Biological|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
46029165|NCT01177722|Biological|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
46029166|NCT01177722|Biological|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
46029167|NCT01177722|Biological|DTaP-Hep B-IPV vaccine|0.5 mL, Intramuscular
46029168|NCT02884986|Drug|Etoricoxib|120mg of oral etoricoxib under the brand name Arcoxia® (Merck Sharp & Dohme) one hour prior to spinal anaesthesia induction
46029169|NCT02884986|Drug|Placebo|120mg of placebo
46029170|NCT04124562|Other|Nitrous Oxide|Nitrous Oxide use ratio in Turkey's hospitals
46029171|NCT01177410|Drug|Placebo|placebo capsules once daily for 12 weeks
46029172|NCT01177410|Drug|Mesalamine Granules 750 mg|750 mg mesalamine granules once daily for 12 weeks
46029173|NCT01177410|Drug|Mesalamine Granules 1500 mg|1500 mg mesalamine granules once daily for 12 weeks
46029174|NCT02884596|Drug|selective serotonin reuptake inhibitor|Taking any type of SSRI medicaments
45471351|NCT04441879|Behavioral|Be a Mom|Be a Mom is an online intervention consisting of 6 modules, each one targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Women will receive biweekly phone calls from a psychologist between completion of each module to provide support.
45471352|NCT04316390|Dietary Supplement|Control|study drink (two weeks)
46029175|NCT05264220|Behavioral|ACT Matrix|Participants will receive a 4 session psychological intervention based on the ACT Matrix
46029176|NCT01156116|Device|CPAP mask|"The subjects who are randomized to CPAP treatment will undergo an overnight CPAP titration in the laboratory, which will be performed manually by a registered technician according to American Academy of Sleep Medicine (AASM) guidelines .Subjects will be admitted in the early evening and will receive positive airway pressure education, hands on demonstration, careful mask fitting and acclimatization prior to titration. The goal during the titration will be to determine the optimal CPAP pressure setting that eliminates obstructive respiratory events, restore oxygen saturations and sleep continuity.~________________________________________"
46029177|NCT01156116|Drug|Placebo|oral placebo tablet
46029178|NCT01155726|Device|Nelfilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
46029179|NCT01155726|Device|Nelfilcon A contact lens with comfort additive (DACP), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses and removed inserted by participant.
46029180|NCT01155726|Device|Nelfilcon A contact lens with comfort additive (DACP), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
46029181|NCT01155726|Device|Nelfilcon A contact lens with comfort additive (DACP), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
46029182|NCT01155726|Device|Etafilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
46029183|NCT01155726|Device|Etafilcon A contact lens with comfort additive (1DAVM), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
46029184|NCT01155726|Device|Etafilcon A contact lens with comfort additive (1DAVM), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
46029185|NCT01155726|Device|Etafilcon A contact lens with comfort additive (1DAVM), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
46029186|NCT04205916|Drug|Dexamethasone|Drugs to be administer during cataract surgery to experimental group
46029187|NCT04205916|Other|Standard of care surgery|Standard method used for surgery and the use of post operative drops
46029188|NCT02886546|Procedure|pneumoperitoneum|
46029189|NCT02886546|Device|oesophageal Doppler monitor|
46029190|NCT04315428|Behavioral|swaddling|The two experimenters together evaluate the child's state of awakening throughout the experiment. If the child is considered by both experimenters to be too restless or too sleepy, the experiment is immediately stopped and postponed
46029191|NCT04315428|Behavioral|no swaddling|The two experimenters together evaluate the child's state of awakening throughout the experiment. If the child is considered by both experimenters to be too restless or too sleepy, the experiment is immediately stopped and postponed
45471353|NCT04316390|Dietary Supplement|Hesperidin|study drink + Hesperidin 600 mg (two weeks)
45471354|NCT04316390|Dietary Supplement|Vitamin C|study drink + Vitamin C 250 mg (two weeks)
46029192|NCT04315662|Other|Muscle power training with velocity loss (VL) of 10%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 10% (VL10) in each set.
46029193|NCT04315662|Other|Muscle power training with velocity loss (VL) of 30%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 30% (VL30) in each set.
46029194|NCT01155024|Device|Traditional fabricated prosthetic socket|A prosthetic socket constructed utilizing traditional techniques. This intervention is a control and the basis for comparison.
46029195|NCT01155024|Device|Direct manufactured (DM) prosthetic socket|A prosthetic socket constructed from direct manufacturing technique. The socket will be tested under both diagnostic and definitive environments. Diagnostic testing will span several hours (4-6 hours) and definitive testing will span several months (3-6 months)
46029196|NCT01176240|Drug|Droxidopa|100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment
46029197|NCT01176240|Other|Placebo|Placebo
45471355|NCT04316390|Dietary Supplement|Hesperidin + Vitamin C|study drink + Hesperidin 600 mg + Vitamin C 250 mg (two weeks)
45682277|NCT03158740|Behavioral|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC. Any participants in the standard of care arm who does not use email regularly may request for items to be mailed to their mailing address.
46029198|NCT00988221|Drug|Tocilizumab|Tocilizumab was supplied as a sterile solution in vials.
46029199|NCT00988221|Drug|Placebo|Placebo to tocilizumab was supplied as a sterile solution in vials.
46029200|NCT02884830|Device|continuous positive airway pressure|positive airway pressure given by a medical device through a nasal mask
45471356|NCT01147211|Drug|MK2206|MK-2206 will be administered orally in a starting dose level of 135 mg on a schedule of Qwk in repeating 3-week treatment cycles in combination with gefitinib in continuous 21-day cycles for the duration of the study
45471357|NCT04161079|Device|Medtentia Annuloplasty Ring (MAR)|Mitral valve repair using the MAR performed in clinical investigation 2010-040
45471358|NCT04206852|Procedure|Balloon pulmonary angioplasty|Balloon pulmonary angioplasty is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.
45471359|NCT04892420|Drug|Dexamethasone|The patients receive 20ml plain bupivacaine (0.5%) + 8 mg dexamethasone (2ml) in adductor canal block after spinal anesthesia.
45471360|NCT04892420|Drug|Dexmedetomidine|The patients receive 20 ml plain bupivacaine(0.5)+25 microgram dexmedetomidine( diluted in 2 ml normal saline) in adductor canal block after spinal anesthesia .
45471361|NCT04892420|Drug|Magnesium sulfate|The patients receive 20 ml plain bupivacaine(0.5)+200 milligram magnesium sulphate (2 ml of magnesium 10%) in adductor canal block after spinal anesthesia.
46029201|NCT02886312|Device|Supplemental Oxygen Delivery System|
46029202|NCT01149096|Procedure|Bone Marrow Donation|Undergo bone marrow harvest
46029203|NCT01149096|Biological|Filgrastim|Given subcutaneously
46029204|NCT01149096|Other|Laboratory Biomarker Analysis|Optional correlative studies
46029205|NCT02867397|Drug|Teysuno (S1) in combination with epirubicin and oxaliplatin|
45682278|NCT03865498|Behavioral|Twitter for Hispanic caregivers|This group will be asked to follow and use (i.e., retweet, reply, like) our Hispanic Twitter network for social support
45682279|NCT03865498|Behavioral|Twitter for African American caregivers|This group will be asked to follow and use (i.e., retweet, reply, like) our African American Twitter network for social support.
45471362|NCT04892420|Drug|Bupivacain|The patients receive 20ml plain bupivacaine (0.5%) + 2 ml of Normal saline in adductor canal block after spinal anesthesia.
45471363|NCT01251263|Drug|Estradiol or Placebo|Estradiol 1mg twice daily or placebo starting on the last day of OC and continuing during the HFI (total of 9 doses).
45682280|NCT01696695|Drug|Capecitabine|First line capecitabine based oral tablet treatment in line with the effective Summary of Product Characteristics
46029206|NCT04291053|Drug|Huaier Granule|standard treatment + Huaier Granule 20g po tid for 2weeks
46029207|NCT02884518|Device|PET|Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they and healthy controls will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity of presynaptic dopamine and relapse in the patients discontinuing treatment.
46029208|NCT02884518|Behavioral|clinical scale|Healthy controls should complete clinical scales at baseline. Patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
46029209|NCT02866851|Other|Monitoring by Web-application|Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.
45682281|NCT01696695|Drug|Chemotherapy|First line chemotherapy according to effective official Summary of Product Characteristics. The study protocol does not specify any particular therapy.
46029210|NCT01175382|Behavioral|Behavioral training|Behavioral treatment consists of skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, urge suppression techniques, delayed voiding, and daily bladder diaries to track increasing voiding intervals and enhance awareness of bladder habits. Training is supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
46029211|NCT01175382|Drug|Tolterodine + tamsulosin|Patients in drug therapy receive an anti-muscarinic (long acting tolterodine 4 mg daily) and an alpha blocker (tamsulosin 0.4 mg daily).
45471364|NCT01251263|Drug|Estradiol or Placebo|Estradiol 1mg will be taken twice daily starting with the last day of pills and the 4 days of the HFI(total of 9 doses)
45471365|NCT04707534|Drug|Dexamethasone|Dexamethasone
45471366|NCT04887896|Device|GS500|Device: GS500
45471367|NCT04887896|Device|Placebo|Device: Placebo
45682282|NCT01676038|Procedure|Pinless-Navigated Total Knee Arthroplasty|Brainlab VectorVision Knee 2.5 Navigation System
46029212|NCT01175382|Other|Combined Behavioral + Drug Therapy|Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
46029213|NCT01194245|Drug|Insulin lispro|
46029214|NCT01194245|Drug|recombinant human hyaluronidase PH20|
46029215|NCT01194245|Drug|Insulin aspart|
46029216|NCT01194245|Drug|Insulin glulisine|
45682283|NCT01676038|Procedure|Conventional Total Knee Arthroplasty|Conventional technique.
45682284|NCT05261386|Drug|CBT-008|Cyclodextrin
46029217|NCT01194245|Drug|Insulin glargine|
46029218|NCT02887547|Procedure|micro-osteoperforation|
46029219|NCT04311528|Biological|9-valent HPV vaccine|9-valent HPV vaccine
46029220|NCT00979407|Biological|Influenza vaccine GSK2340272A|Two intramuscular injections at Day 0 and Day 21
46029221|NCT00979407|Biological|Influenza vaccine GSK2340274A|Two intramuscular injections at Day 0 and Day 21
46029222|NCT01148862|Device|The MiniMed Paradigm® X54 System|"The MiniMed Paradigm® X54 System: A insulin pump equipped with a number of features to actively manage the user's glucose levels. One example is the Low Glucose Suspend (LGS) feature. The LGS feature is only available when the pump is used with the subcutaneous glucose sensor for continuous glucose monitoring. To use this feature, the user will be required to select a sensor low suspend limit, or threshold, at which the LGS feature will be triggered. When this feature is selected, if the sensor glucose reading reaches the level that is equal to or less than the programmed threshold, the user receives an alert and the pump suspends."
46029223|NCT02884674|Device|Active Repetitive Transcranial Magnetic Stimulation|modulation of the electrical activity of the right inferior frontal gyrus cortex in order to reduce Obsessive Compulsive Disorders symptoms by Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using a TMS neuronavigated robot
45471368|NCT05667467|Procedure|Care Bundle Implementation|"In this study, the control group received standard care. The nurse group was given training on the implementation of the care bundle. A cardiac surgery care bundle was applied to the study group by clinical nurses."
46029224|NCT02884674|Device|Placebo Repetitive Transcranial Magnetic Stimulation|Sham rTMS will be delivered using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using TMS neuronavigated robot. A subjective sensation will be obtained via frontal dermic electrical stimulation.
45471369|NCT05761730|Drug|Dexamethasone Oral|For a patient suffering from an irreversible pulpitis on a lower mandibular molar , 4mg of dexamethasone are administered at baseline , after inferior alveolar nerve block injection and 4mg are administered 8 hours after the first dose at office
45471370|NCT04904718|Device|DreaMed Advisor Pro|Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data consisting of glucose levels, insulin delivery history and meal consumption reported
45754602|NCT03583736|Behavioral|Office visit|Scheduled office visit with oncologist following uterine cancer diagnosis.
46029225|NCT02866773|Behavioral|PA1: Education sessions, Reminders, Whataps group|"The intervention includes three components:~Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise~Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
46029226|NCT02866773|Behavioral|PA2: Education sessions, Reminders|"The intervention includes two components:~Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise"
46029227|NCT02866773|Behavioral|PA3: Education sessions, Whataps group|"The intervention includes two components:~Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior.~Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
46029228|NCT02866773|Behavioral|PA4: Education sessions|"The intervention includes one component only:~- Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior"
45754603|NCT05702528|Device|Apollo Neuro|The group will complete daily use of the Apollo Neuro, a wrist-worn consumer wellness device
46029229|NCT02866773|Behavioral|HD1: Education sessions, Reminders, Whataps group|"The intervention includes two components:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake.~- Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
46029230|NCT02866773|Behavioral|HD2: Education sessions, Reminders|"The intervention includes two components:~Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake."
46029231|NCT02866773|Behavioral|HD3:Education sessions, Whataps group|"The intervention includes two components:~Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
46029232|NCT02866773|Behavioral|HD4: Education sessions|"The intervention includes one component only:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake."
45754604|NCT03589196|Procedure|Ejaculation Preserving Photoselective Vaporization|Ejaculation Preserving Photoselective Vaporization
46029233|NCT04290429|Drug|Teduglutide|Treatment of patients with SR-GI-GVHD with teduglutide
46029234|NCT00975975|Drug|Basiliximab|Basiliximab given 1 time on Day +7 or Day +9.
45471371|NCT03913871|Behavioral|Texts to support healthy eating|The intervention arm will receive tailored text messages to encourage healthy eating (increase consumption, fruits, vegetables and water; and a reduce intake of sugar sweetened beverages). Participants will receive an average of 1-2 messages per day for 4 weeks.
46029235|NCT04021485|Other|neurodevelopmental assessment|"As part of the usual follow-up of premature children, a follow-up consultation is planned around the age of 5 years. During this visit, a neurodevelopmental assessment will be carried out for the Betanino study. The duration of this evaluation is evaluated around 3h in total.~Interventions will include:~Standardized neurological exam~Morphometric measurements including height, weight, head circumference~Blood pressure measurement~Multiple aspects of cognition using ancillary indexes of WPPSI-IV subtests, NEPSY-II subtests,~Social Relativeness, using Social Relativeness Scale parental questionnaire,~Parental stress using PSI questionnaire"
45682285|NCT03899805|Drug|Eribulin|The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).
45682286|NCT03899805|Drug|Pembrolizumab|The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.
45754605|NCT03589196|Procedure|Ejaculation Preserving Plasma Kinetic Vaporization|Ejaculation Preserving Plasma Kinetic Vaporization
45754606|NCT03589196|Procedure|Ejaculation Preserving Transurethral Resection Of The Prostate|Ejaculation Preserving Transurethral Resection Of The Prostate
45754607|NCT03503474|Other|No intervention|There is no intervention, this is observational only
46029236|NCT01193153|Drug|Placebo|monthly by i.m. injection for 15 months
46029237|NCT01193153|Drug|paliperidone palmitate|78, 117, 156, 234 mg (50, 75, 100, or 150 mg eq.) monthly by i.m. injection for 15 months
46029238|NCT02867007|Drug|KHK2455|oral dosing
46029239|NCT02867007|Drug|Mogamulizumab|i.v. administration
45471372|NCT03913871|Behavioral|Texts to support physical activity|The intervention arm will receive tailored text messages to support increased minutes of physical activity per day. Participants will receive an average of 1-2 messages per day for 4 weeks.
45754608|NCT03589118|Other|Qi Gong sessions|13 sessions of Qi Gong in a 9 weeks period
45471373|NCT04257500|Drug|Etonogestrel/ethinyl estradiol vaginal ring|16 weeks of continuous use of contraceptive vaginal ring
46029240|NCT04121949|Device|CADScor®System|The CADScor®System is a low cost, low resource-demanding, non-invasive, radiation-free device using highly advanced analysis of sounds originating from blood flow turbulence in the coronary circulation and myocardial motion. Heart sound recordings are obtained transcutaneously during a 3 minutes recording period with a microphone mounted at the IC4. A CAD-score on a scale from 0 to 99 is estimated immediately after the recording with a fully automated algorithm. The algorithm measures eight acoustic properties and the resulting acoustic score is combined with the clinical risk factors gender, age, and hypertension. The entire procedure lasts approximately 10 minutes.
46029241|NCT04289883|Combination Product|Nano-particulated whey protein vs non-particulated whey protein (control)|Different particularisations of whey protein were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite and body weight based on animal studies compared to non-particulated whey protein, with nano-particulated whey protein suggested to be more efficient than micro-particulated.
46029242|NCT04289883|Combination Product|High molecular weight whey protein-alginate coacervates vs calcium alginate (control)|Different whey protein-alginate coacervates were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite based on animal studies compared to calcium alginate, with high molecular weight alginate suggested to be more efficient than low molecular weight alginate.
45839063|NCT04333758|Device|Jintronix Virtual Reality Telerehabilitation System|"System consists of an internet-based rehabilitation software linked to a Microsoft Kinect camera for motion detection.~Study team therapist prescribed a list of guided exercises and therapeutic activities (games) for training of whole body, lower and upper extremities. These can be done in sitting or standing, depending on individual participant's capacity.~Telemonitoring is done by study team therapist during each of the training day (Mondays-Fridays) of the home-based training phase. Training performance results are reviewed and training games are adjusted or changed to optimise home training."
45839064|NCT04333992|Drug|propofol and remifentanil|intravenous propofol and remifentanil using target-controlled infusion (TCI) devices
45471374|NCT03914027|Behavioral|Telerehabilitation|"Each patient will have the opportunity to have minimum one VC per week the first month, one Video Consultation each second week the second month one VC a month the rest of the trial. Here the physiotherapist, via history will extract the information needed to calibrate the daily TR program according to the patient's physical status and needs.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Instead of ergometer bike training, the patient will receive some easy training tools such as elastics, weights and a fitness-step that can be used in the different exercises showed by the VPA to reach the same intensity of workout. The VPA will then be animated to motivate and encourage the patient to exercises at home."
45839065|NCT04333992|Drug|sevoflurane and remifentanil|inhalator sevoflurane and remifentanil using target-controlled infusion (TCI) devices
45471375|NCT03243084|Device|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session
45471376|NCT03243084|Device|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied
45471377|NCT04353817|Drug|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration qd in the morning.
45471378|NCT04353817|Drug|IVA|Tablet for oral administration qd in the evening.
45754609|NCT03583502|Dietary Supplement|krill oil and fish oil supplement|Administration of 2 gelatin soft capsules per day of a combined krill and fish oil supplement, providing 250 mg/day of DHA and 70 mg/day of EPA, for overall 30 days.
45754610|NCT03589040|Drug|Etonogestrel 68Mg Implant|Etonogestrel single-rod subdermal implant (68mg/rod) will be administered to all study participants
45754611|NCT03589040|Drug|rilpivirine|Oral rilpvirine 25mg
45754612|NCT03589040|Drug|darunavir|Oral darunavir+ritonavir 600/100mg
45754613|NCT03580538|Other|resistive exercise with elastic tube|performed training with elastic tubing for six weeks, twice a week and the load was progressively increased every 15 days.
46029243|NCT05387057|Behavioral|Exergame training according to the 'Brain-IT' exergame-based training concept|For an overview, our 'Brain-IT' exergame-based training concept consists of an individually adapted multi-domain exergame-based simultaneous cognitive-motor training with incorporated cognitive tasks that will be adopted with a deficit-oriented focus on the neurocognitive domains of (1) learning and memory, (2) executive function, (3) complex attention, and (4) visuospatial skills. According to the training concept, each participant is instructed to train 5x/week for 24 min per session resulting in a weekly exercise volume of 120 min. All training sessions are planned to take place at participant's homes using the exergame training system 'Senso Flex' (Dividat AG, Schindellegi, Switzerland). For a detailed description of the complete 'Brain-IT' exergame-based training concept with sufficient details to allow full replication, consider our methodological paper (doi: 10.3389/fnagi.2021.734012).
46029244|NCT05387057|Behavioral|Usual Care|The control group will proceed with usual care as provided by the (memory) clinics where the patients are recruited.
46029245|NCT04000659|Device|Episealer Knee System|The Episealer Knee System is comprised of individualized endoprosthetic resurfacing implants and implantation tools (Episealer Toolkit). The implants are designed to replace the articulating surface which has been damaged due to femoral knee chondral and osteochondral defects.
45471379|NCT04353817|Other|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration once daily (qd) in the morning.
46029246|NCT04000659|Procedure|Microfracture|Microfracture is a minimally invasive surgical technique developed to repair defects in articular cartilage and reduce pain in the knee joint. Microfracture techniques are described in the orthopedic literature and are performed arthroscopically.
45471380|NCT04353817|Other|Placebo (matched to IVA)|Placebo matched to IVA for oral administration qd in the evening.
46029247|NCT04289649|Drug|K-924 LD|Pitavastatin 2 mg / Ezetimibe 10 mg tables
45471381|NCT05206760|Procedure|Brain biopsy|Biopsy of brain tissue
46029248|NCT04289649|Drug|K-924 HD|Pitavastatin 4 mg / Ezetimibe 10 mg tables
46029249|NCT04289649|Drug|K-924 LD Placebo|Pitavastain 2 mg
46029250|NCT04289649|Drug|K-924 HD Placebo|Pitavastain 4 mg
46029251|NCT04289337|Dietary Supplement|Combined probiotics (1)|Subjects used one oral combined probiotics (1) tablet each morning, noon, and evening for 4 weeks.
46029252|NCT04289337|Dietary Supplement|Combined probiotics (2)|Subjects used one oral combined probiotics (2) tablet each morning, noon, and evening for 4 weeks.
46029253|NCT04289337|Dietary Supplement|Combined heat-killed probiotics (1)|Subjects used one oral combined heat-killed probiotics (1) tablet each morning, noon, and evening for 4 weeks.
45754614|NCT05702450|Biological|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
46029254|NCT04289337|Dietary Supplement|Combined heat-killed probiotics (2)|Subjects used one oral combined heat-killed probiotics (2) tablet each morning, noon, and evening for 4 weeks.
46029255|NCT04289337|Dietary Supplement|Probiotic metabolites|Subjects used one oral probiotic metabolites tablet each morning, noon, and evening for 4 weeks.
46029256|NCT04289337|Dietary Supplement|Placebo|Subjects used one oral placebo tablet each morning, noon, and evening for 4 weeks.
46029257|NCT02865369|Drug|Daclatasvir and Asunaprevir|Daclatasvir and Asunaprevir combined treatment will not be assigned to the enrolled patients, but the patients who are treated with Daclatasvir and Asunaprevir will be included in this observational study.
46029258|NCT04290585|Other|Questionnaire Administration|Ancillary studies
46029259|NCT04290585|Behavioral|Telephone-Based Intervention|Receive text message reminders
46029260|NCT03978897|Device|Blood flow restriction tourniquet|A blood flow restriction tourniquet, which impedes arterial flow to extremity at 50% of usual flow.
46029261|NCT03978897|Other|Evidence based physical/occupational therapy|Up to date physical/occupational therapy for lateral epicondylitis
46029262|NCT01192295|Drug|Oxycodone HCl controlled-release tablets|Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.
46029263|NCT02866929|Procedure|Decortication|Under local anesthesia, vertical and inter-radicular gingival incisions will be performed on the vestibular of the maxillary and mandibular arch, starting 2-3 mm below the interdental papilla and with sufficient depth to the periosteum to allow the scalpel to reach the alveolar bone. These incisions will be kept as small as possible; then, through them, using a piezoelectric scalpel (piezotome), several bone cuts will be performed. These cuts will have sufficient depth for drilling the cortical alveoli.
46029264|NCT02866929|Device|Orthodontics|Self-ligation brackets in upper and lower teeth
46029265|NCT02866929|Drug|Mucograft|Porcine naturally cross-linked collagen matrix
46029266|NCT04289181|Other|Medically Tailored Meals|4 weeks of medically tailored meals
46029267|NCT02865291|Device|ForConti device|
46029268|NCT04317365|Other|Women receiving extra remembering by healthcare|Women receiving extra remembering by healthcare in covid infection
46029269|NCT04289103|Biological|Inolimomab (Leukotac)|"Patient screening phase - Patients diagnosed with aGvHD will be identified. Only patients with SR-aGvHD will be finally included in the study.~Treatment phase - Leukotac will be given up to D28~Primary Follow-up phase - Patient's response (CR and PR) will be evaluated at D29 post inclusion. Patients will then be followed for survival, long-term safety and chronic GvHD occurrence during 6 months after inclusion."
46029270|NCT04316897|Device|Echocardiography|It is a an observational cross-sectional echocardiographic screening study in Assiut Governate conducted after seeking approval from the local institutional review board and human subjects' protection.
46029271|NCT04272879|Other|Observational Group|Those requiring NIV following an acute exacerbation of COPD
46029272|NCT01154166|Drug|ReQuip PR|If subjects are still eligible at the end of the placebo run-in period they will be randomized (1:1) to receive once daily doses of ropinirole PR or identical appearing placebo tablets. Dosing will start at 2 mg ropinirole PR, or placebo equivalent. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control. All subjects must be titrated to a minimum dose of 6 mg/day.
46029273|NCT01154166|Drug|Placebo|Placebo
46029274|NCT04290195|Drug|Ziv-Aflibercept 25 MG/ML [Zaltrap]|Intravitreal injection of 1.25 mg of ziv aflibercept in patients
46029275|NCT05656937|Procedure|internal jugular venous cannulation|internal jugular venous cannulation
46029276|NCT04317131|Diagnostic Test|Research Diagnostic Criteria of Functional Disorders of the Masticatory System BKD / ZCURNŻ - Polish version|Interview and clinical examination of stomatognathic system based on standardized tool BDK/ZCURNŻ.
46029277|NCT04317131|Device|Clinical examination of the stomatognathic system (structural and functional)|Examination with the use of JMA+Analyser (Jaw Motion Analyser) to analyse movement and function of the temporomandibular joints, mandibular position, condyle position (EPA), and access the muscle action potentials through bipolar skin surface electrodes EMG, assessment of occlusion by visual method according to Angle Classification.
46029278|NCT04317131|Device|3D examination of the body posture|Comprehensive, three- dimensional examination of the body posture (static and dynamic) in the area of the spine, lower limbs and feet, performed by photogrammetric method (4th Generation MORA) and non- invasive image acquisition technology with the aid of infrared (Kineod) and The CQElektronik system.
46029279|NCT04317131|Device|Functional assessment of the spine and lower limbs|Functional assessment of the spine and lower limbs mobility trough a wireless motion sensor Moover.
46029280|NCT04317131|Device|Complementary tests|Anthropometric measurements (height, weight, waist and hip circumference, skin folds), foot pressure on the ground and body balance accessed by pedobarograph FreeMed, body mass components measured by the Tanita MC 980 MA (BIA method), evaluation of 7-days of physical activity by accelerometer ActiGraph GT3X-BT, blood pressure measurement by Medel Connect Cardio MB 10 monitor.
46029281|NCT02865603|Behavioral|PAX Good Behavior Game|PAX GBG includes evidence-based kernels and a classroom game where students are reinforced for their mutual success in withholding inappropriate behavior.
46029282|NCT05656859|Behavioral|Single group|Survey
46029283|NCT04289259|Other|TMB assessment|Tumor mutational burden could be calculated by cancer gene panel (CGP), whole-exome sequencing (WES), RNA-sequencing (RNA-seq), FoundationOne CDx assay panel (FMI).
46029284|NCT04313556|Procedure|Lateral patellar release|Arthroscopic lateral patellar reticular release
45471382|NCT01254695|Device|Medtronic InterStim / InterStim II|Standard stimulation (Amplitude: sensory threshold, frequency 14 Hz, Pulsewidth 210 microsec.) will be compared wiht experimental setting 1,2,3,4
46029285|NCT05656781|Other|Brief Intervention and Contact (BIC) based on Word Health Organization (WHO)|Intervention based on: Clinical WHO - SUICIDE PREVENTION DOCUMENT MULTISITE INTERVENTION STUDY ON SUICIDAL BEHAVIOURS - SUPRE-MISS: PROTOCOL OF SUPRE-MISS. Brief Intervention and Contact with participants using follow up questions about mood or any suicide attempts.
46029286|NCT05656703|Device|BIS guidance of anesthesia|Anesthesia is to be directed to a specific (light) level by the dosage of administered hypnotics and analgesics
46029287|NCT05656703|Other|Standard of Care|Anesthesia is administered as usual
46029288|NCT02866617|Device|Vacuum Formed Thermoplastic Retainers Constructed On 3D Reconstructed Orthodontic Study Model|
45471383|NCT03903575|Procedure|En masse anterior teeth retraction|After extraction of the four premolars the posterior teeth will be tied-together and the six anterior teeth will be retracted by sliding mechanics.
46029289|NCT00624611|Procedure|Residual pump blood management post aortic cannula removal|Residual pump blood will be maximally hemoconcentrated by further ultrafiltation within the CPB machine. Resulting hematocrit will be approximately 0.4. The total residual pump blood volume, approximately 300ml, will be reinfused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Additional protamine sulfate will be given every 30 minutes during the infusion, .03 mg/ml of residual pump blood. Procedures in this group do not deviate from current standard practice.
46029290|NCT00624611|Procedure|Residual pump blood management post aortic cannula removal|All residual pump blood will be processed with a bedside red cell washing device (Cell Saver). The resulting total volume of concentrated red cells will be infused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Administration of additional protamine is not required due to the low concentrations of heparin in the resulting product.
46029291|NCT02865213|Device|OBA|"The intrusion of posterior teeth using removable appliance OBA."
46029292|NCT02865213|Device|Miniplates|"The intrusion of posterior teeth using temporary anchorage Miniplates."
46029293|NCT02865213|Device|Miniscrews|"The intrusion of posterior teeth using temporary anchorage Miniscrews."
46029294|NCT05656079|Drug|Pegylated liposomal doxorubicin|Drug: Pegylated liposomal doxorubicin (35 mg/m2) will be administered by an intravenous infusion on day 1 of each21-day cycle.
46029295|NCT05656079|Drug|Epirubicin|Drug: Epirubicin (90 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
46029296|NCT05656079|Drug|Cyclophosphamid|Drug: Cyclophosphamide (600 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
45754615|NCT03580460|Behavioral|Computer delivered smoking cessation counseling|15 to 20 minute computer-delivered interactive smoking cessation counseling
46029297|NCT05656079|Drug|Trastuzumab|Drug: Trastuzumab (8 mg/kg loading dose at first day only, then 6 mg/kg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
45754616|NCT03583424|Drug|Carmustine|Given IV
45754617|NCT03583424|Drug|Cytarabine|Given IV
46029298|NCT05656079|Drug|Pertuzumab|Drug: Pertuzumab (840 mg loading dose at first day only, then 420 mg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
46029299|NCT05656079|Drug|Docetaxel|Drug: Docetaxel (75mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
45471384|NCT03903575|Procedure|Two-Step Retraction|After extraction of the four premolars the posterior teeth will be tied-together and the canines will be retracted by sliding mechanics. After the distalization of the canines they will be tied to the posterior teeth and the incisors will be retracted by sliding mechanics.
45754618|NCT03583424|Drug|Etoposide|Given IV
45754619|NCT03583424|Procedure|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
46029300|NCT05656001|Other|Real-time functional magnetic resonance imaging Neurofeedback and Real-time Biofeedback|Participants will take part in three runs of real-time functional magnetic resonance imaging feedback (rt-fMRI-NF) training with 4-8 days apart, which will be conducted at the Center for Medical Image Science and Visualization (CMIV) at the university hospital in Linköping. Participants who receive biofeedback will take part in three runs of biofeedback with 4-8 days apart conducted in the lab at the Center for Social and Affective Neuroscience (CSAN) at Linköping university. Participants will be given instructions and basic psychoeducation of brain function and the rational for down-regulating the area of the brain that drives emotion, as well as the physiological reaction that is triggered in response to emotional stimuli. The emotional stimuli are emotional pictures from the International Affective Picture System (IAPS) and the Open Affective Standardized Image Set (OASIS).
46029301|NCT05656001|Other|Sham functional magnetic resonance imaging neurofeedback and sham biofeedback|Participants will take part in three runs of sham neurofeedback with 4-8 days apart, which will be conducted at the Center for Medical Image Science and Visualization (CMIV) at the university hospital in Linköping. Participants who receive sham biofeedback will take part in three runs of sham biofeedback with 4-8 days apart conducted in the lab at the Center for Social and Affective Neuroscience (CSAN) at Linköping university. Participants will be given instructions and basic psychoeducation of brain function and the rational for down-regulating the area of the brain that drives emotion, as well as the physiological reaction that is triggered in response to emotional stimuli. The emotional stimuli are emotional pictures from the International Affective Picture System (IAPS) and the Open Affective Standardized Image Set (OASIS).
46029302|NCT00975585|Device|senofilcon A|soft contact lens, 2-week replacement indicated
46029303|NCT00975585|Device|lotrafilcon B|soft contact lens with a 4-week replacement indicated.
46029304|NCT01181921|Drug|Galantamine|Type= range, unit= mg, number= 8-24, form= capsule, route= oral use. The starting dose will be 8 mg/day for 4 weeks. Subsequently, the initial maintenance dose will be 16 mg/day for 4 weeks. Then, an increase to the maintenance dose of 24 mg/day should be considered on an individual basis after appropriate assessment.
46029305|NCT02883894|Other|Blood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9|
46029306|NCT05655923|Biological|ozonized olive oil|ozonized oil will be mixed with xenograft in group II and Group III
45471385|NCT00159588|Drug|Betablockers or other preventive drugs based on primary headache type|Several preventive drugs based on each individual regarding type of original headache type (i.e angiotensin II blockers, betablockers, valproate, tricyclic antidepressants or gabapentin)
45754620|NCT03583424|Drug|Melphalan|Given IV
45754621|NCT03583424|Drug|Venetoclax|Given PO
45754622|NCT03583346|Drug|M6495|Participants will receive escalated dose of M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
45754623|NCT03583346|Drug|Placebo|Participants will receive placebo matched to M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
45471386|NCT05760482|Diagnostic Test|Metobolites serum level measurement|Blood samples will be taken from all volunteer participants in 1 yellow cap tube of 10 cc. After the blood has cooled and the clot development process (approximately 15 minutes), the serum will be separated by centrifugation at 2000 g for 5 minutes. Separated sera will be aliquoted and stored at -40°C until analysis. The tryptophan and tryptophane metabolite levels of the participants will be measured by Liquid Chromatography-Tandem Mass Spectrometer API 3200 device. The kynurenine, kynurenic acid, 3-HK, 3-HAA, 3-HOA, and QA values obtained as a result of this test will be recorded.
45471387|NCT05760482|Behavioral|Anxiety and stress level measurement|Anxiety and stress levels will be evaluated by applying State-Trait Anxiety Inventory and Perceived Stress Scale Tests by all volunteer participants. Scores from these tests will be recorded.
46029307|NCT05655923|Biological|xenograft bone substitute|Xenograft bone substitutes in all Groups
45471388|NCT04166942|Drug|KD025|Single dose of 200 mg KD025 orally
46029308|NCT02867241|Behavioral|Behavioral Early|Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
46029309|NCT02867241|Behavioral|Behavioral Late|After the close of the study, Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
45471389|NCT03265938|Device|Indirect Laryngoscopy|The attending anesthesiologist will perform video laryngoscopy with the C-MAC D video laryngoscope and with the GlideScope AVL video laryngoscope and grade the view of the larynx obtained with each laryngoscope.
45471390|NCT04353037|Drug|Group 1 HCQ|Enrolled participants randomized in Group 1 receive the HCQ drug
45471391|NCT04353037|Drug|Group 2 Placebo|Enrolled participants randomized in Group 2 will receive a placebo drug
46029310|NCT02867085|Other|Observational|The BoHemE study does not provide any recommendations for treatment. Guidelines for osteoporosis treatment and standardized instructions for MDS patients are available, however the choice of treatment is up to the treating physician and should be reported as such.
45471392|NCT05206214|Procedure|Manual glide path|manual glide path will be established using manual thermal treated stainless-steel files in a watch winding maneuver. . Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone.
45471393|NCT05206214|Procedure|Mechanical glide path|glide path will be established using rotary Ni-Ti files in a reciprocating maneuver. Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone.
45471394|NCT01149161|Procedure|Routine central neck dissection|Level VI neck node dissection during thyroid operation
45471395|NCT05763680|Diagnostic Test|Molecular Culture|PCR based technique that amplifies the interspace region in bacterial DNA, that is located between the genes coding for 16S and 23S ribosomal subunits. Primers are used for the majority of known pathogenic phyla, i.e. FAFV, Bacteroidetes, Firmicutes and Proteobacteria. The nucleotide length of the Interspace region is species specific for bacterial single species. Bacteria all have one or multiple alleles for this interspace region. The combination of the amount of alleles, as well as the nucleotide strand length, makes for a specific profile that is distinctive for the species. Available software is able to match this profile to a particular pathogen, enabling confirmation and identification of bacteria in samples within 5 hours in our experimental workflow.
45471396|NCT03903653|Drug|Botulinum toxin type A|"Use of chemodenervation (botulinum toxin A) for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)"
45754624|NCT00578305|Biological|Rituximab|Rituximab was supplied as a sterile liquid for iv administration.
45754625|NCT00578305|Drug|Placebo|Placebo was supplied as a sterile liquid in single-use vials for iv administration.
45754626|NCT00578305|Drug|Methylprednisolone|
46029311|NCT05655845|Other|bowel function score(BFS) questionnaire survey|A cross-sectional bowel function score(BFS) questionnaire survey was conducted in patients with HD who underwent PTs between January 2014 and December 2019 at Children's Hospital of Nanjing Medical University.Patients consented to the survey were asked to complete the questionnaire,and were divided into two groups: dysfunction group(BFS<17 ); and normal group (BFS>=17 ). The operative age, birth weight, premature delivery status, operative weight, aganglionic segment, single or stage PT, surgical approach(laparotomy or laparoscopy), post-operative Hirschsprung-associated enterocolitis (HAEC),and immediate complications were recorded and compared between two groups。Both univariate and multivariate regression analysis were used to seek the risk factors of bowel dysfunction after PTs in HD. .
46029312|NCT05655767|Other|4D-flow MR & CT-scan|4D-flow MR and CT-scan after cardiac surgery (until 12 months afterwards), for the purpose of obtaining more precise data on (hemo)dynamic processes within the cardiovascular system, in combination with data extraction from the established biobank and databank (FIBAA-bank).
46029313|NCT04317443|Procedure|Super-mini percutaneous nephrolithotomy (SMP)|SMP will be performed under general anesthesia in prone/supine position. Renal puncture will be performed under ultrasound/fluoroscopy guidance based on the preference of the participating surgeon. Tracts will be dilated to 14 Fr. Stone fragmentation will be performed with holmium laser and fragments will be extracted with the active suction system. For the exit strategy, placement of a nephrostomy tube or JJ stent will be decided by the participating surgeon.
46029314|NCT04317443|Procedure|Extracorporeal Shock Wave Lithotripsy (ESWL)|ESWL will be performed under sedation/analgesia, shock wave lithotripsy parameters will be determined based on the device and the settings of local center. For patients requiring multiple sessions, maximum 3 (or more) sessions will be allowed. Ureteral stenting prior to ESWL will be performed based on the decision of the participating center.
46029315|NCT01174446|Biological|BAX 326|"Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX~Study Part 2: Open-label evaluation of prophylaxis and on-demand BAX326 only~Study Part 3: Open-label repeat of PK evaluation (repeat Study Part 1) with BAX326 only and same study participants as Study Part 1"
45471397|NCT03903653|Device|Serial Casting|"Using Serial Casting in conjunction with Botox injection for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)"
45471398|NCT04704804|Diagnostic Test|Synthetic CT Scan|method of generating CT-synthetic image from MRI
45471399|NCT05205902|Other|Low-dose total-skin electron-beam therapy|Low-dose total skin electron beam therapy (12 Gy) will be delivered to the patient in 4 Gy/week, 1 Gy/day over 3 weeks by symmetrical electron beams of 6 MeV energy via a linac accelerator.
45471400|NCT05205902|Other|Phototherapy|"Phototherapy will be given 3 times a week during 2 months, then twice a week during one month, then once a week during one month, or until disease progression or unacceptable side effect, whatever comes first.~Patients with plaques will receive PUVA therapy and patients with patches only will receive narrow-band UVB therapy."
45754627|NCT00578305|Drug|Methotrexate|
46029316|NCT01174446|Biological|BeneFIX|"Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX.~BeneFIX only used in Part 1 of this study.~Study Part 2 and 3 only utilized BAX326"
46029317|NCT04316273|Other|colonic surgery|resection of duplicated colon
46029318|NCT00932698|Drug|Ixazomib|Ixazomib capsules
46029319|NCT00978627|Drug|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily with a meal. Dose was individually adjusted.
46029320|NCT00978627|Drug|insulin detemir|Injected subcutaneously (under the skin) once daily or twice daily. Dose was individually adjusted.
45471401|NCT05558423|Behavioral|Time Restricted Eating|Participants are asked to follow a Time Restricted Eating regimen with eating window of ≤10 hours.
45471402|NCT04893954|Diagnostic Test|Full Spine Radiography|Full Spine Radiography
45471403|NCT04893954|Diagnostic Test|Lumbar spine MRI|Lumbar spine MRI
45754628|NCT00578305|Drug|Folic acid or folate|
46029321|NCT00978627|Drug|insulin aspart|Injected subcutaneously (under the skin) at the remaining meals. Dose was individually adjusted.
46029322|NCT00978627|Drug|insulin aspart|Injected subcutaneously (under the skin) as meal time insulin. Dose was individually adjusted.
46029323|NCT01181609|Drug|bevacizumab [Avastin]|5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks according to the chemotherapy regimen
46029324|NCT04261504|Behavioral|IBMT|mindful presence in a non-judgmental way
45471404|NCT04349917|Drug|Methylphenidate|A single, low dose of methylphenidate (0.3 mg/kg) will be administered on the drug day.
45471405|NCT04349917|Other|Placebo|A matching placebo pill will be administered on the placebo day.
45471406|NCT03903029|Drug|Low-dose (10mg) rosuvastatin|Low-dose (10mg) rosuvastatin in 4 statin benefit groups per 2013 ACC/AHA guideline
45471407|NCT02986620|Genetic|IDH mutation test performed at diagnosis or relapse until January 31st, 2019.|Observation of the test result.
45471408|NCT04775654|Dietary Supplement|Blackcurrant|Two capsules containing 455mg of CurrantCraft 11% black currant extract.
45471409|NCT04775654|Other|Placebo|Two capsules containing an inert material.
46029325|NCT04261504|Behavioral|RT|progressive muscle relaxation
46029326|NCT01154010|Device|PEMF|ActiPatch will be worn by patients over the eye with anterior uveitis for 8 hours/day for 7 days. Patients will also be treated with topical steroids.
46029327|NCT01154010|Device|PEMF Placebo|Patients wear the placebo device for 8 hours/day for 7 days over the eye being treated for anterior uveitis. Patients will also be treated with topical steroids.
46029328|NCT02866305|Procedure|VATS bullectomy and mechanical pleuradesis.|Thoracoscopic bullectomy is performed on all visible bullae, alternatively is no visible bullae, the apex is resected. Then mechanical pleuradesis is performed.
46029329|NCT02866305|Procedure|Chest tube insertion|Conventional chest tube insertion.
46029330|NCT02866305|Drug|Epidural|All surgical participants received an epidural prior to the procedure.The epidural was removed simultaneous with the the chest tube.
46029331|NCT02866305|Radiation|High-resolution Computer Tomography|All participants included in this study had a HRCT performed.
46029332|NCT04261426|Drug|Intravenous Immunoglobulin|IVIG 0.5g/kg/d for 5 days
46029333|NCT04261426|Other|Standard care|Standard care
46029334|NCT04264078|Biological|CD7 UCAR-T cells|Dose range:1 to 5 ×10^7 cells/Kg, Dose level one: 1×10^7 cells/Kg, Dose level two: 3×10^7 cells/Kg, Dose level three:5 ×10^7 cells/Kg
46029335|NCT04264078|Drug|Fludarabine|30mg/m^2 per day for 6 days
45471410|NCT02527889|Other|Exercise training|8-week resistive exercise training
45682287|NCT04617340|Other|Multifaceted clinical pharmacy intervention|"Assessing patient and caregiver preferences~Medication reconciliation on admission~Performing a comprehensive medication review before discharge~Promoting safe transition~4.a. Compiling a patient friendly medication list~4.b.Optimizing communication with healthcare providers in primary care:~4.b.i.Providing a copy of the medication list for the community pharmacist~4.b.ii. Contacting the general practitioner by phone~4.b.iii. Contacting, if applicable the home care nurse or the nurse from the nursing home by phone.~5.A motivation interview will take place before discharge with patients and caregivers~6.Post-discharge follow-up: 6.a.Follow-up call to discuss potential drug therapy issues, therapy adherence and to resolve any pending issues 6.b.A telepharmacology service will be provided to primary healthcare professionals as a means to consult the ward-based clinical pharmacists and/or research team after discharge."
46029336|NCT04264078|Drug|Cytoxan|600mg/m^2 per day for 2 to 6 days determined by tumor burden at baseline
46029337|NCT04264078|Drug|Melphalan|50 to 70 mg/m^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
46029338|NCT04290273|Diagnostic Test|MED Test|Participant is irradiated with several doses of UV light on small areas of the outer thigh. 24 hours later this area is visually inspected for erythema, and the minimal erythemal dose (MED) is determined.
45682288|NCT03862066|Other|Blood collection|5 milliliters (mL) of blood will be collected at the time of surgery
45682289|NCT03862066|Other|Tissue collection|Left over tissue will be collected at the time of surgery
46029339|NCT04290273|Device|Wearing device|Participants wear a portable erythema measurement device for 48 hours. The device shines light on the skin at frequent intervals and measures skin 'redness'. The device is removed by a technician after the 48 hours.
46029340|NCT01153698|Drug|dabigatran|anticoagulation
46029341|NCT00608218|Drug|Ciclesonide|This is an observational study. Therefore, the physician decides about dosage according to individual needs.
46029342|NCT01174368|Biological|Cancer Macrobead placement in abdominal cavity|8 macrobeads per kilogram
46029343|NCT02884050|Drug|Topiramate|antiepilepsy drug
46029344|NCT02884050|Drug|Placebo|non-active placebo
46029345|NCT00609934|Drug|Sorafenib|Dose level 1: sorafenib 200mg PO OD on Days 1-84 Dose level 2: sorafenib 400mg PO OD on Days 1-84
46029346|NCT00609934|Radiation|external beam radiotherapy|3000cGy in 10 fractions
45682290|NCT04768023|Drug|Juvit D3|Dosage based on the BMI as followed: for BMI under 25 - 4000 IU/day, for BMI between 25 and 30 - 5000 IU/day, and for BMI over 30 - 6000 IU/day.
46029347|NCT01147926|Drug|Placebo|Placebo matched to Prucalopride tablet orally once daily.
45471411|NCT04747730|Other|Transcendental Meditation training|The programme targets inmates in HMP Warren Hill who are eligible to learn the meditation technique, who are staying in prison for at least six months since the beginning of the programme and who provide the signed informed consent. The sample of eligible inmates is approximately 190 inmates out of 250 currently in the prison. Inmates will be contacted by the research team in prison during introductory sessions of the research intervention.
46029348|NCT01147926|Drug|Prucalopride|Prucalopride 2 mg tablet orally once daily for subjects greater than or equal to (≥) 18 to less than (<) 65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.
46029349|NCT05115136|Drug|Doxepin|25mg dose of Doxepin will be administered one time, by mouth
46029350|NCT05115136|Drug|Diphenhydramine|50 mg dose of Diphenhydramine will be administered one time, by mouth
46029351|NCT00608374|Drug|chlorambucil|
45471412|NCT04691856|Drug|Morphine Sulfate|Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
46029352|NCT00608374|Drug|fludarabine phosphate|
46029353|NCT00608374|Procedure|quality-of-life assessment|
45682291|NCT04768023|Behavioral|steps per day|The participants will be prompt to do 3500-8000 steps per day.
45682292|NCT04768023|Drug|Placebo|Matching amount of vegetable oil to the vitamin D3.
45682293|NCT03861988|Drug|Ketamine|0.5 mg/kg over 40 minutes, intravenous.
45682294|NCT03861988|Drug|Normal saline (placebo)|Normal saline infusion over 40 minutes, equivalent volume to ketamine infusion.
45682295|NCT01670266|Drug|ONO-9054|
45682296|NCT01670266|Drug|Placebo|
46029354|NCT00975507|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of V221 at Day 0 and Day 90
46029355|NCT00975507|Biological|Comparator: Placebo|a single 0.5 mL subcutaneous placebo injection at Day 0
46029356|NCT00975507|Biological|Comparator: Varivax|a single 0.5 mL subcutaneous injection of Varivax at Day 0
46029357|NCT00975507|Biological|Comparator: M-M-R II|a single 0.5 mL subcutaneous injection of M-M-R II at Day 0
46029358|NCT00625014|Drug|Haloperidol|Haloperidol 3 mg/day for 8 days
46029359|NCT04261348|Other|No intervention|There is no intervention
45682297|NCT03755440|Drug|PD-1 antibody (SHR-1210)|PD-1 antibody (SHR-1210), 200mg, ivdrip, every 2 weeks.
45682298|NCT01676194|Other|Intra-arterial administration of DC BeadsR|
45754629|NCT03583268|Other|Exercise|The intervention will be the different high intensity sessions. Time spent in hypoglycemia and glucose variability will be compared as follows: 70% vs. moderate, 80% vs. moderate, and 90% vs. moderate to see if high intensity is protective against hypoglycemia and provides lower glucose variability levels.
45754630|NCT03156374|Device|Test use|Use of home ovulation test to predict ovulation
46029360|NCT04271163|Device|MemorEM|The MemorEM device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range to the entire forebrain, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. Everyday for the 12M treatment period, the subject's caregiver will administer one or two 1-hour treatments (two daily treatments during the first 2M period).
46029361|NCT04083339|Drug|AT-001|"AT-001 will be administered as 3 capsules twice daily, before breakfast and before dinner.~At present AT001 is the sole name for the active substance. No INN/genetic name is available to date"
46029362|NCT04083339|Drug|Placebo|Matching placebo will be administered as 3 capsules twice daily, before breakfast and before dinner
46029363|NCT01147848|Drug|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 24 weeks
46029364|NCT01147848|Drug|Fluticasone propionate/salmeterol Inhalation Powder|Fluticasone propionate/salmeterol Inhalation Powder inhaled orally twice daily for 24 weeks
46029365|NCT01147848|Drug|Placebo (1)|Inhalation powder inhaled orally once daily for 24 weeks
46029366|NCT01147848|Drug|Placebo (2)|Inhalation powder inhaled orally twice daily for 24 weeks
46029367|NCT00610090|Device|UniFit AAA Stent Graft|Endovascular repair of Abdominal Aortic Aneurysms
46029368|NCT00606658|Procedure|Shirodhara Oil Treatment|Oil dripping on the forehead in a constant stream for about 40 minutes for five consecutive days.
45471413|NCT04691856|Drug|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
46029369|NCT02864823|Procedure|Perichondrium Autografts|Perichondrium tissue was harvested from the patient's ear cartilage and transplanted to reconstruct the scleral defect.
46029370|NCT00929656|Procedure|Real rTMS|rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
46029371|NCT00929656|Procedure|Sham rTMS|sham rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
46029372|NCT00929656|Procedure|Unimanual paretic UE Training|UE exercise for 4 hours (two hours 1:1 with therapist and two hours independent at home) for 16 sessions (4 sessions/week for 4 weeks)
46029373|NCT00629577|Genetic|microarray analysis|
46029374|NCT00629577|Other|flow cytometry|
46029375|NCT00629577|Procedure|biopsy|
45839066|NCT04333836|Device|Removable Clear Aligners|"Plaster dental models will be poured from the rubber base impression.~Digital dental models will be created through scanning of plaster dental models.~Planning of the aligners will be done on 3 shape clear aligner studio®.~Aligners will be fabricated on 3d printed models using vacuum formers.~Anchorage reinforcement for posterior segments by using buccal miniscrews.~Patient will receive the first aligner and will be instructed to wear it full time (except during eating and brushing) for 2 weeks.~Patient will receive the following aligner after 2 weeks.~Follow up visits every 2 weeks until complete canine retraction."
46029376|NCT00629577|Procedure|colposcopy|
46029377|NCT02866539|Drug|Polyherbal capsule coccinia, bougainvillea, catharanthus|A unique combination of 3 herbs that lower blood sugars
46029378|NCT02866539|Drug|Placebo|Similar looking inactive powder
46029379|NCT04261270|Drug|ASC09F+Oseltamivir|ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
46029380|NCT04261270|Drug|Ritonavir+Oseltamivir|Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
45682299|NCT03749902|Drug|Oral misoprostol|"An initial dose of misoprostol 25mcg will be given orally after randomisation (this must be a minimum of 2 hours after the previous misoprostol dose).~The next dose of oral misoprostol will be omitted if moderate or strong contractions are occurring at 3 in 10 minutes or more (i.e. 9 or more in the preceding 30 minutes)~If contractions subsequently reduce to less than 3 in 10 (under 9 in 30 minutes), or become irregular or mild, then the oral misoprostol 25mcg can be restarted~In the event of inadequate progress, clinicians will be advised to give further misoprostol if there are any concerns about contractions strength or frequency."
45682300|NCT03749902|Drug|Oxytocin|"Oxytocin infusion will be given through an electronic infusion pump. One unit of oxytocin will be injected in 500 mL of Ringer's lactate, started at a rate of 2 mU/min, and increased every 30 min by 2 mU/min until there are three to four contractions every 10 min. The rate will be titrated to maintain that contraction frequency. The maximum dose will be 20mU/min as oxytocin summary product characteristics.~The oxytocin group will not receive misoprostol after the membranes have ruptured."
45682301|NCT03860974|Drug|Serratus Plane block (single injection)|A single-injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL of local anesthetic for unilateral surgery; 16 mL of local anesthetic each side for bilateral surgery).
45839067|NCT04332978|Drug|Fluticasone Propionate|
46029381|NCT04261270|Drug|Oseltamivir|75mg ,once a day
46029382|NCT00977613|Behavioral|exercise counseling|motivational counseling to exercise a minimum 18 metabolic hours per week
46029383|NCT01152996|Drug|Vortioxetine|Vortioxetine tablets
46029384|NCT04265716|Other|Topical L. reeuteri|Tubes with ointment containing L. reuteri DSM17938
46029385|NCT05279976|Other|Visualized Education|The child assigned to intervention group 1 will be told the operation preparation room and the pre-anesthesia process through the picture booklet prepared immediately after the pre-test (first measurement). Children included in this group will be provided to touch the bonnet, mask, gloves and self-inflated balloon (representing the ambu device), and the questions of the child and the parent will be answered.
46029386|NCT05279976|Other|Distraction|Children included in intervention group 2 will be given a kaleidoscope. Each child will be given a separate kaleidoscope. It will be ensured that the child is with the parent while the child is looking at the kaleidoscope for an average of 15-20 minutes. After the attempt is over, the kaleidoscope will be presented to the child.
46029387|NCT00608452|Other|Symptom Assessment Scale|"Memorial Symptom Assessment Scale~History and neurologic examination"
46029388|NCT00624936|Drug|Vidaza|Vidaza 75mg/m2 IV over 30min daily on days 1-7. This dose is the same for all dose levels.
46029389|NCT00624936|Drug|Velcade|Dose level 1 Velcade 0.7mg/m2 IVP on days 2 and 5 Dose level 2 Velcade 0.7mg/m2 IVP on days 2, 5, 9, 12 Dose level 3 Velcade 1.0 mg/m2 IVP on days 2, 5, 9, 12 Dose level 4 Velcade 1.3 mg/m2 IVP on days 2, 5, 9, 12
46029390|NCT00979953|Drug|ADL5859|
46029391|NCT00979953|Drug|ADL5747|
46029392|NCT00979953|Drug|Oxycodone CR|
46029393|NCT00979953|Drug|Placebo|
46029394|NCT05086198|Behavioral|Mindfulness-based intervention|An instructor trained in Mindfulness-based Stress Reduction (MBSR; Kabat-Zinn, 1990) will conduct meditations lasting 15 to 30 minutes. The participants will have a mobile application designed ad hoc with the practice of the week so they can do it individually at home.
46029395|NCT05086198|Behavioral|Physical exercise|An aerobic and fitness trainer will conduct aerobic exercise lasting 15 to 30 minutes. The participants will watch it in a video platform. They will not be able to do anaerobic exercise like weight lifting. The intensity of the chosen exercise will be moderate, maintaining between 120-140 beats per minute.
46029396|NCT01181531|Drug|Traditional Vitamin D Therapy|Traditional vitamin D therapy (eg, calcitriol, paricalcitol, alfacalcidol, doxercalciferol), to manage secondary hyperparathyroidism (SHPT) in this study will be administered according to strategies that have been used in clinical practice and that conform to current therapeutic recommendations and available clinical practice guidelines and product labeling.
46029397|NCT01181531|Drug|Cinacalcet|Subjects randomized to treatment with cinacalcet will receive an initial oral dose of 30 mg once daily. Doses will be titrated incrementally to 60, 90,120, and 180 mg per day based upon periodic measurements of serum calcium and plasma PTH levels. Cinacalcet is formulated as light green tablets in 30, 60, and 90 mg free-based equivalents. Tablets will be 30, 60, and 90 mg, graduated in size, smallest to largest. Combinations of these 3 fixed dosage formulations will be used to achieve the 120 and 180 mg daily doses.
46029398|NCT01152450|Drug|Tiotropium 2.5 µg b.i.d|2.5 µg (two actuations of 1.25 µg) delivered via Respimat® inhaler
46029399|NCT01152450|Drug|Placebo|N/A (two actuations of placebo) delivered via Respimat® inhaler
45471414|NCT04691856|Drug|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
46029400|NCT01152450|Drug|Tiotropium 5 µg q.d.|5 µg (two actuations of 2.5 µg) delivered via Respimat® inhaler
45471415|NCT04691856|Drug|Morphine|All patients were instructed to use intravenous patient-controlled analgesia (IV PCA). All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
45471416|NCT03902873|Other|Real-time audiovisual feedback|During the chest compressions, doctors receive audiovisual feedback on the depth and speed of the appropriate chest compressions.
46029401|NCT05085262|Diagnostic Test|Bloodwork, Echocardiogram, PET/MRI|The study will use blood samples from COVID biobank at University Health Network. Samples will be collected at time of admission to ER in patients discharged after assessment and at three time points during admission in patients who are admitted for measurement of blood biomarkers. Echocardiography studies will be assessed for structural and functional abnormalities. All included patients will have prospective short-term follow-up (3-6 months) for assessment of clinical events and subclinical cardiovascular disease. 50 patients who had clinical cardiac MRI at our center within 5 years prior to COVID-19 (January 2015-January 2020) and have since tested positive for COVID-19 will be recruited for research cardiac MRI to compare changes between baseline (pre-COVID) and follow-up (post-COVID imaging). A subgroup of 50 patients will undergo cardiac PET/MRI at 1-3 months post COVID-19 diagnosis to evaluate for myocardial inflammation and other imaging markers of cardiac injury.
45682302|NCT03860974|Drug|Paravertebral block (single injection)|Single injection paravertebral blocks will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL each side for bilateral surgery). For paravertebral blocks without axillary involvement, this will be at the T3 and T5 levels. For paravertebral blocks with axillary involvement, this will be at the T2 and T4 levels. For unilateral PVBs, 10 mL of local anesthetic will be injected per level. For bilateral paravertebral blocks, 8 mL of local anesthetic will be injected per level.
45682303|NCT01565889|Drug|SOF|Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily
45471417|NCT03924986|Drug|Tislelizumab|200 mg administered intravenously (IV)
45682304|NCT01565889|Drug|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination (FDC) tablet administered orally once daily
45682305|NCT01565889|Drug|EFV|Efavirenz (EFV) 600 mg tablet administered orally once daily
46029402|NCT05085262|Diagnostic Test|Bloodwork, Echocardiogram, MRI|The study will involve use of blood samples from the COVID biobank at UHN (University Health Network) for measurement of blood biomarkers. Echocardiography Studies will be systematically assessed for structural and functional abnormalities. All included patients assessment of clinical events and subclinical cardiovascular disease.
46029403|NCT00610246|Drug|Sorafenib|Sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. Dose level 1 is 200mg of sorafenib. If full oral dose (400mg orally, twice a day) is reached in a given cohort then an additional dose level will open where sorafenib treatment is extended following radiation for a total of eight weeks.
46029404|NCT04265560|Other|Progressive Resistance Training|Progressive resistance training programme for individuals following spinal cord injury.
46029405|NCT05244382|Other|Overcome|Multimodal program individualized and supervised 12 weeks duration (three months), with two sessions weekly face-to-face. This program will combine aerobic exercise in unloading through the use of the TRAG (AlterG® Anti-Gravity Treadmill®), functional recovery of motor control with feedback ultrasound and occupational therapy. Physical activity will be measured in parallel with the test. Likewise, the patients will be monitored by means of a heart rate sensor.
46029406|NCT01181141|Drug|DU-176b (edoxaban)|
46029407|NCT01181141|Drug|Enoxaparin sodium 20mg|
46029408|NCT00606814|Drug|IPI-504, docetaxel|"IPI-504 administered IV at a dose of 300mg/m2~Docetaxel at a fixed dose of 75 mg/m2 for every 3 weeks dose administration or 36 mg/m2 for weekly administration"
46029409|NCT01173120|Device|Abatacept combination product (ACP)|Abatacept Solution, Subcutaneous, 125 mg/device, Weekly, 3 months
46029410|NCT05241730|Other|Training intervention|The training intervention will be a 10 week training plan for endurance runners. The plan consists of five sessions per week (three basic endurance sessions and two interval sessions)
45471418|NCT03924986|Drug|Placebo|Placebo to match Tislelizumab
45471419|NCT03924986|Drug|Gemcitabin|1 g/m2, administered as an IV infusion within 30 minutes
45471420|NCT03924986|Drug|Cisplatin|80 mg/m2, administered as an IV infusion over 4 hours
45682306|NCT01565889|Drug|ZDV/3TC|Zidovudine (ZDV) 300 mg/lamivudine (3TC) 150 mg FDC tablet administered orally twice daily
46029411|NCT05241730|Other|High Glycaemic Index|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from high glycaemic index carbohydrates per day, the other E-% are fats and proteins.
45471421|NCT04156399|Other|Acupuncture|All subjects will receive a standardized 18 needle acupuncture protocol.
45682307|NCT01565889|Drug|ATV|Atazanavir (ATV) 400 mg tablet administered orally once daily
46029412|NCT05241730|Other|LCHF|The subjects eat ≥ 65 E-% fats and a maximum of 50 g carbohydrates per day.
46029413|NCT05241730|Other|Low Glycaemic Index|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from low glycaemic index carbohydrates per day, the other E-% are fats and proteins.
45471422|NCT01254929|Device|F-18 PET bone scan|Following the intravenous administration of approximately 10 mCi F-18, subjects will undergo an F-18 PET bone scan.
45471423|NCT01254929|Device|Tc-99m bone scan|Following the intravenous administration of approximately 30mCi Tc-99m MDP, subjects will undergo a traditional bone scan on a gamma camera.
45471424|NCT03749395|Procedure|Erector Spinae Plane Block|The patient will be placed in a sitting position and the ultrasound probe will be placed in a longitudinal orientation 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae . the needle will be inserted in a cephalad-to-caudad direction until the tip lay deep to erector spinae muscles, as evidenced by visible linear spread of fluid beneath muscle upon injection . A total of 20 mL of 0.25% bupivacaine will be injected here.
46029414|NCT05332691|Procedure|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricle outlet tract gradient and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient relief of left ventricle outlet tract obstruction and mitral regurgitation, while preventing iatrogenic injuries.
46029415|NCT00977379|Radiation|WBRT|3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction).
45471425|NCT03902795|Diagnostic Test|Microperimetry|Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality.
45471426|NCT03902795|Diagnostic Test|M-charts|The M-chart (Inami Co., Tokyo, Japan) is a diagnostic tool developed by Matsumoto to quantify the degree of metamorphopsia in patients with macular diseases.
46029416|NCT00977379|Drug|Capecitabine|825 mg/m^2 orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by 1000 mg/m^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2.
46029417|NCT00977379|Drug|Standard of Care|The choice of standard of care will be at the discretion of the treating oncologist. The protocol does not specify any particular standard of care treatment.
46029418|NCT04263844|Drug|Intranasal dexmedetomidine|subject will receive premedication with intranasal dexmedetomidine thirty minutes before induction
46029419|NCT04263844|Drug|Intranasal Midazolam|subject will receive premedication with intranasal midazolam thirty minutes before induction
46029420|NCT01180985|Device|galyfilcon A prototype lens|silicone hydrogel contact lens
46029421|NCT01180985|Device|comfilcon A|silicone hydrogel contact lens
46029422|NCT00610324|Drug|Chlorhexidine gluconate|Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
46029423|NCT00610324|Drug|Potassium permanganate|Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
46029424|NCT04288635|Biological|Whole blood samples|Whole blood samples at admission, from day one to three after admission
46029425|NCT01147536|Biological|HSPPC-96|
46029426|NCT01154088|Biological|Mencevax ACWY|One dose, Subcutaneous injection
46029427|NCT01154088|Biological|GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612]|One dose, Intramuscular injection
46029428|NCT02864901|Drug|KSL-W|Plaque reducing gum
46029429|NCT02864901|Drug|Chewing Gum Placebo|
45471427|NCT04737122|Drug|LM-061|Oral dose with approximately 240 mL water in the fasting condition, and food will be forbidden 1 h prior to administration and 2h after dose. QD for continuous 28 days, and 4 weeks as one treatment cycle.
45839068|NCT04332900|Device|Elastic hip strap|The SERF Strap consist of a thin, elastic material that is secured to the proximal aspect of the leg, wraps in a spiral fashion around the thigh, and is anchored around the pelvis. The line of action of the SERF Strap pulls the hip into abdcution and external rotation.
46029430|NCT04288791|Other|Equia Forte Fil|Glass hybrid innovation achieved through the introduction of ultrafine, highly reactive glass particles dispersed with conventional GI. The restoration is coated with Equia Forte coat which incorporates multi-functional monomer producing a tougher resin matrix. This system is designed as alternative of amalgam in posterior teeth.
46029431|NCT04288791|Other|Zirconomer Improved|Zirconia reinforced GI, Glass Polyalkenoate restoration; it is designed to exhibit high strength where the glass component of this GI undergoes finely controlled micronization to achieve optimum particle size and characteristics .
45471428|NCT04737122|Drug|Toripalimab|For subjects in combination escalation levels, toripalimab will be administered 240mg, IV, every 3 weeks
46029432|NCT04260724|Device|TMS|"stimulation intensity : motor threshold 100%~stimulation frequency : 1600 pulses for 20 minutes~stimulation duration :for four weaks, 20 minutes/day, 5 days per week (Monday - Friday )"
45682308|NCT01565889|Drug|Ritonavir|Ritonavir (RTV) 100 mg tablet administered orally once daily
45682309|NCT01565889|Drug|FTC/TDF|FTC/TDF (200/300 mg) FDC tablet administered orally once daily
45682310|NCT01565889|Drug|DRV|Darunavir (DRV) 800 mg (2 × 400 mg tablets) administered orally once daily
45682311|NCT01565889|Drug|RAL|Raltegravir (RAL) 400 mg administered administered orally twice daily
45839069|NCT04332900|Device|Insole|Foot orthoses with semi-rigid arch support and medial elevation at the forefoot and at the rearfoot by 7° each that is made from a block of ethyl vinyl acetate with a thermo-moldable polymer (shore hardness of 45 A) and is manufactured through an automated computer numeric control machine (CNC routers).
45839070|NCT04333212|Device|DR. Chip HPV genotyping IVD kit|HPV typing by gene chip
45839071|NCT04332666|Drug|Angiotensin 1-7|endogenous peptide dilution: angiotensin-(1-7) 0.5 mg / L NaCl 0.9%
45839072|NCT04332666|Drug|Placebos|infusion of NaCl 0.9% without diluted peptide in it
45682312|NCT01565889|Drug|PEG|Pegylated interferon alfa (PEG) 180 μg administered once weekly by subcutaneous injection
46029433|NCT04260724|Device|sham coil stimulation|no stimulation Although the sound from device during stimulation is similar, no stimulation is applied.
46029434|NCT04313322|Biological|WJ-MSCs|"WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.~WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously."
45471429|NCT03300570|Drug|Dolcanatide|Given PO
46029435|NCT04067115|Drug|Trabectedin 1 MG [Yondelis]|Patients with Ewing sarcoma will be administered trabectedin intravenously. Cycles are 21 days.
46029436|NCT04067115|Drug|Irinotecan|Patients with Ewing sarcoma will be administered inirotecan intravenously. Cycles are 21 days.
46029437|NCT04067115|Diagnostic Test|tumor biopsy|Tumor tissue samples will be collected collected at two timepoints. The first biopsy will be prior to treatment. If a biopsy is not possible archival tissue may be submitted. A second tumor biopsy will be taken fro consenting patients when possible after the first administration of Trabectedin to evaluate the effect on the tumor cells.
46029438|NCT04067115|Other|3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging|Some patients will receive PET scans with the use of 18F-FLT, a radioactive tracer, performed at the National Institute of Health.
46029439|NCT02884284|Other|clinical biological database collection|
45471430|NCT03300570|Other|Laboratory Biomarker Analysis|Correlative studies
45471431|NCT03300570|Other|Placebo Administration|Given PO
45471432|NCT03300570|Other|Questionnaire Administration|Ancillary studies
45471433|NCT04154605|Device|ClariFix cryotherapy|Bilateral freeze ablation of nasal tissue using the ClariFix device.
45471434|NCT04154605|Device|Sham ClariFix cryotherapy|Bilateral sham ablation procedure using the ClariFix device.
45682313|NCT01565889|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
45682314|NCT01696071|Drug|Tiotropium 5 mcg qd|2 puffs (2.5 mcg each) in the evening 5 mcg in total and 2 puffs of matching placebo in the morning
45682315|NCT01696071|Drug|Tiotropium 2.5 mcg bid|2 puffs (1.25 mcg each) twice daily, in the evening and in the morning, 5 mcg in total
46029440|NCT02884128|Drug|PEP02|PEP02 was administered on Day 1. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
45682316|NCT03855280|Drug|APVO101|APVO101: 35 - 75 IU/kg; twice weekly
46029441|NCT02884128|Drug|5-FU|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
45471435|NCT03902561|Device|one time colonoscopy in inpatients|All the inpatients with indication of colonoscopy will be prepared with 4 liters polyethylene glycol bowel cleansing prior to colonoscopy. Colonoscopy will be performed as regular practice under conscious sedation.
45471436|NCT03264456|Diagnostic Test|[18F] Fluciclovine PET/MRI|[18F] fluciclovine PET/MRI
46029442|NCT02884128|Drug|LV|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
45471437|NCT03264456|Drug|[18F] fluciclovine|[18F] fluciclovine
45682317|NCT01591863|Drug|fidaxomicin|"6 months-5 years 11 months: oral suspension, 32 mg/kg/day with a maximum dose of 400 mg/day, divided into two doses, every 12 hours for 10 days.~6 years-17 years 11 months: tablets, 200 mg every 12 hours for 10 days."
46029443|NCT00629343|Drug|Azacitidine In Combination With Temozolomide|mg, oral
45471438|NCT03902327|Dietary Supplement|NAC group|Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + N - acetylocysteine supplementation (1600 mg /d, 400 mg x 4 times a day)(30 people).
46029444|NCT02864745|Device|functional electrical stimulation-assisted cycle ergometry|Early intensive rehabilitation protocol, which includes the use of functional electrical stimulation-assisted cycle ergometry
45471439|NCT03902327|Dietary Supplement|Control group|Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + placebo (4 times a day) (30 people).
45471440|NCT03853694|Drug|50 mcg Duramorph+ EXPAREL + multi-modal pain regimen|Intrathecal injection of 50 mcg Duramorph + EXPAREL administered via TAP infiltration + multi-modal pain regimen.
45471441|NCT03853694|Drug|150 mcg Duramorph + multi-modal pain regimen|Intrathecal injection of 150 mcg Duramorph + multi-modal pain regimen.
45471442|NCT03853694|Drug|Exparel TAP + multi-modal pain regimen|EXPAREL administered via TAP infiltration + multi-modal pain regimen.
45471443|NCT01255007|Other|MR imaging|Primovist enhanced MRI, Diffusion weighted MRI
45471444|NCT03902405|Behavioral|Active CEASAR Intervention|Healthy and stimulant-use related pictures will be presented on a computer screen. Using a joystick, participants will be trained to pull in pictures that are presented in portrait orientation, and push those presented horizontally. In the active experimental condition, pushed pictures will exclusively be stimulant-related pictures.
46029445|NCT02864745|Other|standard rehabilitation|This group will receive standard rehabilitation, which will be monitored, but not protocolised.
46029446|NCT01180049|Drug|temsirolimus|175mg IV once a week for first 3 weeks, followed by 75mg IV once a week until disease progression, provided that patient is tolerating treatment and getting clinical benefit
45471445|NCT03902405|Behavioral|Placebo CEASAR|In the control condition, stimulant cues and healthy cues will be randomized and stimulant use-related pictures will be equally divided into push and pull conditions.
45471446|NCT04154293|Drug|Isotretinoin|Topical Isotretinoin ointment
45839073|NCT04332822|Drug|R-pola-mini-CHP|"Rituximab 375 mg/m2 iv, day 1, cycle 1. 1400 mg s c OR 375 mg/m2 iv cycles 2-6~Cyclophosphamide 400 mg/m2 iv, day 1, cycles 1-6~Doxorubicin 25 mg/m2 iv , day 1, cycles 1-6~Prednisone, 40 mg/m2 po, days 1-5, cycles 1-6 - round up to nearest 25 mg~Polatuzumab vedotin 1.8 mg/kg iv day 1 cycles 1-6"
46029447|NCT01180049|Drug|temsirolimus|75mg IV once a week until until disease progression, provided that patient is tolerating treatment and getting clinical benefit
46029448|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
46029449|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
45471447|NCT04154293|Other|Vehicle|Topical Vehicle Ointment
45471448|NCT01148147|Drug|Adenosine|Intracoronary adenosine administration (180 ug for LCA and 120 ug for RCA)
45471449|NCT01148147|Drug|Placebo|Intracoronary Placebo administration
45471450|NCT05205824|Other|algorithm validation|stroke subjects are measured to validate algorithms previously developed after including healthy subjects
45471451|NCT03902249|Drug|Dexamethasone|
45471452|NCT05761652|Other|Observe and record|The general information, environmental indicators, and auxiliary examination indicators of the subjects were observed and recorded, as well as the TCM physical assessment was performed.
45471453|NCT05205668|Biological|F-652|IL-22 fusion protein administered intravenously
45839074|NCT04332822|Drug|R-mini-CHOP|"Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6~Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6~Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6~Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6~Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6"
45839075|NCT04332510|Other|Intact formula|600 ml of infant formula with intact protein
45839076|NCT04332510|Other|Partially hydrolyzed formula|600 ml of infant formula with partially hydrolyzed protein
45839077|NCT04332510|Other|High protein formula|600 ml of infant formula with high protein level
45839078|NCT04332510|Other|Human breast milk|600 ml of breast milk, safe for human consumption
46029450|NCT01147458|Drug|Naproxen placebo|Matching naproxen placebo tablets to be administered BID for 4 weeks
46029451|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
46029452|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
46029453|NCT01147458|Drug|Naproxen placebo|Matching naproxen placebo tablets to be administered BID for 4 weeks
46029454|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
46029455|NCT01147458|Drug|Naproxen|Naproxen 500 mg tablet administered BID for a total of four weeks
45471454|NCT05205668|Biological|Placebo|Placebo administered intravenously
45471455|NCT03908489|Procedure|vital pulpotomy primary molars using garlic oil|vital pulpotomy using garlic oil
45471456|NCT03908489|Procedure|vital pulpotomy using mta|mta vital pulpotomy
45471457|NCT01149317|Procedure|Acupuncture|Weekly acupuncture treatment for up to 14 weeks to augment usual care
45471458|NCT03901937|Drug|ω-3 polyunsaturated fatty acid|CD patients are divided into two groups, which include with and without ω-3 polyunsaturated fatty acid-based PN (0.1-0.2g/kg/d).
45471459|NCT03901937|Procedure|Intestinal surgery for Crohn's Disease|Patients receive bowel resection due to complications of Crohn's Disease
45471460|NCT04342897|Drug|LY3127804|Administered IV
45471461|NCT04342897|Drug|Placebo|Administered IV
46029456|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
46029457|NCT01147458|Drug|Naproxen|Naproxen 500 mg tablet administered BID for a total of four weeks
46029458|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
46029459|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
46029460|NCT01172808|Drug|Placebo|Placebo that represents comparator
46029461|NCT01172808|Drug|tiotropium Respimat® low dose|IMP
46029462|NCT01172808|Drug|Placebo|Placebo that represents comparator
46029463|NCT01172808|Drug|Placebo|Placebo that represents comparator
46029464|NCT01172808|Drug|tiotropium Respimat® high dose|IMP
46029465|NCT01172808|Drug|50 mcg salmeterol HFA MDI|Active comparator
46029466|NCT01172808|Drug|Placebo|Placebo that represents BI drug
46029467|NCT01172808|Drug|Placebo|Placebo that represents BI drug
46029468|NCT04315194|Drug|clarithromycin-naproxen-oseltamivir|to compare the safety and efficacy of clarithromycin-naproxen-oseltamivir combination therapy to that of oseltamivir treatment alone for hospitalised paediatric influenza patients.
46029469|NCT04066491|Drug|M7824|Participants received intravenous infusion of M7824 at a dose of 2400 milligrams (mg), once every 3 weeks (Q3W) 2 years (in case of Complete Response), otherwise until criterion pre-sepcified in protocol for discontinuation is met, in combination with intravenous infusion of Gemcitabine and Cisplatin at a dose of 1000 milligram per meter square (mg/m^2) and 25 mg/m^2 respectively on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks.
46029470|NCT04066491|Drug|Placebo|Participants received intravenous infusion of M7824 matched placebo, once every 3 weeks (Q3W) until 2 years (in case of CR), otherwise until crtiterion pre-sepcified in protocol for discontinuation is met.
46029471|NCT04066491|Drug|Gemcitabine|Gemcitabine was received intravenously at a dose of 1000 milligram per meter square (mg/m^2) on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks (Q3W).
46029472|NCT04066491|Drug|Cisplatin|Cisplatin was received intravenously at a dose of 25 mg/m^2 on Day 1 and Day 8 of 21-day cycle, for 8 cycles every 3 weeks (Q3W).
46029473|NCT01151280|Device|WallFlex Biliary Fully Covered Stent|Investigational device evaluated for the treatment for benign biliary strictures
46029474|NCT02884362|Other|clinical biological data collection on melanoma|collection and centralization of clinical and biological data of patients with melanoma
46029475|NCT01149486|Drug|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
45471462|NCT03902171|Device|Soberlink|Soberlink delivers real-time blood alcohol results to people who support individuals in recovery from alcohol use disorder. In-Home Addiction Treatment program Care Team monitors and responds to results as part of care to improve treatment outcomes.
46029476|NCT01149486|Drug|Hyzaar®|100/25 mg Tablets
46029477|NCT00640471|Biological|cetuximab|cetuximab (Erbitux®) - Initial dose - Day 1 (Week 1): 400 mg/m2 IV over 120 minutes Maintenance Infusions (subsequent weeks): 250 mg/m2 IV over 60 minutes
45471463|NCT05205590|Other|Non|Non
45471464|NCT03629444|Radiation|ct scan|all patients will be subjected to CT scan and anthroprometric measurments
46029478|NCT00640471|Drug|brivanib alaninate|brivanib (BMS-582664) 800 mg po, QD
46029479|NCT00601705|Drug|cisplatin|20 mg/m2/day IV continuous infusion over 24 hours for 96 total hours.
46029480|NCT00601705|Drug|epirubicin hydrochloride|50 mg/m2 IV bolus
46029481|NCT00601705|Drug|fluorouracil|200 mg/m2/day will be given as a continuous intravenous infusion for all 9 weeks, beginning on day 1.
46029482|NCT00601705|Drug|oxaliplatin|130 mg/m2 IV infusion over 2 hours
46029483|NCT00601705|Procedure|adjuvant therapy|Between 6-10 weeks after surgery patients will begin postoperative chemoradiotherapy. Daily radiation therapy fractions of 180-200 cGy will be given to the esophago-gastric bed and draining lymphatic regions to a total dose of 50-55 Gy (60 Gy in the event of an R1 or R2 resection). Concurrent with this radiation, two cycles of chemotherapy will be given, during the first and fourth weeks of the radiation
46029484|NCT00601705|Procedure|neoadjuvant therapy|"Three weeks after discontinuing the fluorouracil (12 weeks after study entry) patients will be fully restaged to assess for a clinical response, and to ensure that there is no contraindication to surgical resection, which will be scheduled for approximately one week later (13 weeks after study entry).~Surgery will consist of a transthoracic esophagogastrectomy or a total gastrectomy with Roux-en-Y esophagojejunostomy depending on the location and extent of the tumor at surgery. An appropriate lymphadenectomy will be performed. Immediate reconstruction is anticipated if possible."
46029485|NCT02680093|Other|Cervical length in pregnant women.|"Pregnant Women beyond the date of birth. will be followed while coming to routine monitoring. physiological parameter of cervical length will be measured as the differential predictor to determine their due date. the cervical length will be measured as part of routine gynecologic examination to women who come for routine over due date follow up.~additional medical data will be collected from the patient medical record.- demographic data, and all the routine prenatal medical care the women will receive up to the delivery.and delivery out comes."
45471465|NCT03908723|Other|Panretinal photocoagulation|Intravitreal Aflibercept with PRP to the peripheral vascular lesions
46029486|NCT01179737|Drug|Nilotinib|Nilotinib capsules for oral administration at 50 mg, 150 mg twice a day and 300 mg (2 capsules of 150 mg) twice a day.
46029487|NCT01179737|Drug|Placebo to nilotinib|Placebo to nilotinib capsules for oral administration to match 50 mg, 150 mg and 300 mg capsules twice a day
46029488|NCT04033705|Device|Freestyle Libre Pro glucose sensor|Participants will wear a Freestyle Libre Pro glucose sensor for approximately 2 weeks prior to elective surgery and then for 2 weeks following surgery.
46029489|NCT02679859|Other|BNP guided medical therapy optimisation|
46029490|NCT05664529|Diagnostic Test|Chatoor Feeding Scale|Chatoor Feeding Scale will be used to evaluate mother infant relationship during feeding. Mothers will be asked to record a natural feeding session at home by video. The videos will be sent to the investigators by the parents. The first 20 minutes of the video will be evaluated for scoring.
46029491|NCT03125083|Biological|Biological dosage from plasma|The purpose of this study is to determine the role of inflammation in the high prevalence of psychiatric disorders in skin-restricted lupus (SRL) patients. SRL is an inflammatory disease. Inflammation can lead to a decrease in the synthesis of neurotransmitters via the activation of the IDO enzyme and to induce the synthesis of neurotoxic molecules (kynurenin pathway). This leads to the development of psychiatric disorders.
46029492|NCT00641173|Drug|paroxetine|treatment with SSRI paroxetine
46029493|NCT00641173|Drug|placebo|treatment with placebo
45471466|NCT03263767|Drug|Fludarabine|30 mg/m² Intravenous 5 days from Day-6 to Day-2
45471467|NCT03263767|Drug|Clofarabine|30 mg/m² Intravenous 5 days from Day-6 to Day-2
45471468|NCT03263767|Radiation|Full body irradiation|2 grays at Day-1
45471469|NCT03263767|Drug|Cyclophosphamide|14 mg/kg intravenous 2 days at Day - 6 and day -5
46029494|NCT02399995|Behavioral|HRQoL questionnaires.|"Questionnaires/Forms to be completed preoperatively in clinic with assistance from research study administrator:~Baseline sociodemographic and clinical variable data sheet (RSA)~EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Baseline disease status and treatment assessment questionnaire Questionnaires/Forms to be completed at first postoperative clinic visit:~EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Questionnaires/Forms to be mailed to patients at ± 2 month window at the following time points 6,12,18,24, and 36 months following hepatectomy:~EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Post surgical follow up disease status and treatment assessment questionnaire~At 8 weeks following the mailing of the initial questionnaire package if no response has been received, research personnel will attempt to contact participants by phone."
45839079|NCT04332276|Drug|A-dopamine|"During the phase 1 (titration), it is planned to increase dopamine by maximum 0.25 mg per hour over the daytime period, which corresponds to a maximum increase of 4.5 mg per day (based on the 18 hours of the daytime period, since nocturnal needs are much less important).~Then, depending on tolerance and efficacy, conservative titration will be continued for a target dose of 30-87 mg per day.~During the phase 2 (efficacy), the treatment will be maintained at the minimum effective dose, planned between 30 and 87 mg per day, for 30 days."
46029495|NCT05664373|Procedure|Coronally advanced flap and deepithelized free gingival graft|Free gingival grafts, de-epithelialized intraoraly or extraoraly in combination with coronally advanced flap will be used in the treatment of multiple gingival recessions.
46029496|NCT02679625|Device|Ultrasound and NICOM|All patients enrolled will have all three ultrasound-based modalities for fluid responsiveness performed, as well as have NICOM data to serve as the comparison standard.
46029497|NCT02679703|Device|High voltage|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns
46029498|NCT02679703|Device|Neuromuscular transcutaneous electrical stimulation (TENS)|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns.
46029499|NCT02679703|Other|Control Group|The control group will not have electrical stimulation however, will be evaluated with digital digital imaging, thermography imaging, skin hardness and subjective pain and healing scales
46029500|NCT02681965|Behavioral|LEAN book/videos|The intervention focuses on achieving long lasting lifestyle changes to achieve weight loss and maintenance. Women randomized to the weight loss program will receive the LEAN book, as well as a CD and flash drive with the LEAN videos (and internet link), a pedometer and the Log Book for recording their food intake and physical activity.
45839080|NCT04332276|Drug|optimized oral treatment|The patient will received his usual dopaminergic treatment.
45839081|NCT04332354|Other|routine care. No intervention|no intervention
45839082|NCT04332042|Drug|Tofacitinib|Tofacitinib 10mg twice a day will be administered within 24h from hospital admission for 14 days
46029501|NCT00641875|Procedure|Nocturnal Hemodialysis|
46029502|NCT00929110|Drug|Glycopyrronium bromide|Glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
46029503|NCT00929110|Drug|Placebo to glycopyrronium bromide|Placebo to glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
45471470|NCT03263767|Drug|Cyclophosphamide|50 mg/kg intravenous 2 days at day +3 and day +4
45839083|NCT04332120|Procedure|tubal sterilization|
46029504|NCT00929110|Drug|Tiotropium|Tiotropium was supplied in powder-filled capsules together with the Handihaler® device.
46029505|NCT00922519|Other|18F-Sodium Fluoride (Na18F)|200-400 MBq/injection, up to 4 doses of Na18F will be permitted per patient as part of acceptable disease assessment.
46029506|NCT00640549|Drug|Atorvastatin|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the atorvastatin group were treated with atorvastatin 20 mg tablets administered once daily orally for 8 weeks.
46029507|NCT00640549|Drug|Placebo|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the placebo group were treated with placebo 20 mg tablets administered once daily orally for 8 weeks.
46029508|NCT02683369|Dietary Supplement|Blood Builder®/Iron Response®|"The low-dose iron dietary supplement is a tablet that contains vitamins and minerals selected to help maintain healthy red blood cells and iron levels in the blood. The supplement ingredients aim to generate a supplement by taking a food which contains the naturally occurring, complex matrix of proteins, lipids, carbohydrates and all other elements associated with the vitamin or mineral of interest. These natural food sources are used to generate tablets that maintain the vitamin and mineral potency found in the original food source as well as the associated elements that naturally accompany it.~One tablet will be taken once a day offering a total daily serving of:~15 mg of Vitamin C~400 mcg of Folate~30 mcg Vitamin of B-12~26 mg of Iron~125 mg of Beet Root"
46029509|NCT01147068|Biological|0.5mL Intramuscular Injection|0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle
46029510|NCT02683135|Behavioral|High-carbohydrate diet|Participants will engage in 4 days of high-carbohydrate low fat diet as recommended by the Canadian Diabetes Association. The macronutrients content will go as follow: 55% carbohydrate, 25% protein and 20% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
46029511|NCT02683135|Behavioral|Low-carbohydrate diet|Participants will engage in 4 days of low-carbohydrate high-fat diet. The macronutrients content will go as follow: 10% carbohydrate, 25% protein and 65% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
46029512|NCT02683135|Behavioral|Low-carbohydrate diet with post-meal walking|Participants will follow the same diet as in the low-carbohydrate diet arm but also perform 15 minutes of walking beginning ~15 minutes after breakfast, lunch and dinner. Approximately 70 kcal (individualized) will be added to main meals to account for exercise energy expenditure. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
46029513|NCT00640627|Drug|Celecoxib|200 mg oral capsule once daily for 6 weeks
46029514|NCT00640627|Drug|Placebo|Matched oral placebo for 6 weeks
46029515|NCT01146912|Other|Text Message|Text message vaccine reminders
46029516|NCT01146912|Other|automated call|Automated call
45839084|NCT04341870|Drug|Sarilumab|Sarilumab: 400 mg in a 1 hour - I.V. infusion on D1
46029517|NCT00641251|Other|intensive medical management|IMM will include rigorous lifestyle modification for weight loss and stepped pharmacologic treatment consistent with standard of care for diabetes and other CVD risk factors.
46029518|NCT00641251|Other|RYGB & IMM|Roux-en-Y gastric bypass Surgery combined with intensive medical management
46029519|NCT02682043|Device|Toy car|"The intervention is the provision of an electric toy car. This toy car will be modified to meet the postural and hand control preference of each child participant.~The child will have the toy car for an 8 week trial period. Parents and child will be instructed in the safe use of the toy car, given written guidelines, and encouraged to use frequently.~Parents will keep a log of what days they use the toy car, where and for how long."
46029520|NCT02679547|Other|Breastfeeding|All of the participants and patients will have a questionnaire about their breastfeeding
46029521|NCT00641953|Drug|IMX-150|(0.3%) 0.5g topically BID to each foot for 4 weeks
45471471|NCT03263767|Other|stem cell transplantation|at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)
46029522|NCT00641953|Drug|IMX-150|(0.6%) 0.5g topically BID to each foot for 4 weeks
46029523|NCT00641953|Drug|Placebo|0.5 g topically BID to each foot for 4 weeks
46029524|NCT02681887|Drug|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
46029525|NCT02681887|Drug|Placebo|placebo tablet identical to circadian
46029526|NCT01134042|Drug|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 24 weeks
45471472|NCT03263767|Other|nuclear cells|CD3+ cells if needed after transplantation
45471473|NCT03263767|Drug|Thymoglobulin Injectable Product|At day -2 2.5 mg/kg for patients inclued after 14 dec 2020
45471474|NCT03908411|Procedure|Paratracheal pressure|Paratracheal pressure is applied by 30N force with the ultrasound transducer.
46029527|NCT01134042|Drug|Fluticasone Furoate Inhalation Powder|Fluticasone furoate inhalation powder inhaled orally once daily for 24 weeks
46029528|NCT01134042|Drug|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 24 weeks
46029529|NCT01134042|Other|Placebo Inhalation Powder 1|Placebo in novel dry powder inhaler once daily
46029530|NCT01134042|Other|Placebo Inhalation Powder 2|Placebo in Diskus inhaler twice daily
46029531|NCT02681419|Procedure|Needle fenestration|This technique creates fenestrations along a nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
46029532|NCT02681419|Procedure|Suture wick|This technique places a single 10-vicryl suture wick through the nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
46029533|NCT00642031|Drug|Triciribine|15 mg/m^2 IV Weekly Over 1 Hour On Days 1, 8, and 15.
46029534|NCT01179347|Drug|tiotropium Respimat® inhaler|to evaluate safety and efficacy tiotropium delivered with Respimat® inhaler compared to placebo.
46029535|NCT01179347|Drug|Placebo Respimat® inhaler|patient to receive placebo matching active drug once daily
45471475|NCT03908411|Procedure|Sellick's maneuver|Conventional Sellick's maneuver is applied by 30N force
45471476|NCT04603742|Drug|Anakinra|100 mg of Anakinra will be mixed with 100 mL of 0.9% saline solution for IV administration.
46029536|NCT04182295|Device|acupuncture|A sterilised stainless steel needle (diameter 0.25mm X length 40mm, Dongbang Acupuncture Inc., Boryeong, Chungchenongnam-do, Korea) will be given at PC3, LI4, LI11, and LU5 of non-dominant arm for 15 minutes once a day for 3 days (immediately after inducing delayed onset muscle soreness (DOMS), and 2 consecutive days after inducing DOMS).
46029537|NCT04182295|Device|Park Sham Needle|A Park Sham Needle (Meridius Medical Ltd. & DongBang Acuprime Ltd., Exeter, UK), non-penetrating sham acupuncture, will be given at two points on the belly of biceps brachii, 1 cun proximedially from LI11, and 1 cun laterally from PC3 of non-dominant arm for 15 minutes once a day for 3 days (immediately after inducing delayed onset muscle soreness (DOMS), and 2 consecutive days after inducing DOMS).
46029538|NCT04182139|Other|Static Stretching Exercise|Each intervention group received a different duration and intensity of static stretching exercise protocol.
46029539|NCT04104373|Other|Observational Cohort|
45471477|NCT04603742|Drug|0.9% Saline|The placebo preparation will consist of a 100 mL of 0.9% saline solution without the addition of anakinra.
46029540|NCT01146288|Drug|Furosemide first, then Acetazolamide|Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests. A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
46029541|NCT01146288|Drug|Acetazolamide first, then Furosemide|Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
46029542|NCT02683057|Other|International Physical Activity Questionnaire (IPAQ)|all candidates for sperm donors clinic IVI IVI Bilbao and Valencia were will provide the international physical activity questionnaire (IPAQ) attached to analyze the total physical activity. This will be self-completed questionnaire beforeSperm donation. (Appendix 1) Age, snuff, weight, BMI, alcohol, drug use and the type of sport that practices will be analyzed: Additionally a tab for each donor collecting the existence of associated factors be drawn. (Appendix 2)
46029543|NCT01146054|Device|CyberKnife based stereotactic radiotherapy|"Initial orthogonal images will be obtained to confirm location of fiducial seeds.~Synchrony respiratory tracking system must be used to correct for respiratory associated tumor motion. This system utilizes a series of optical diodes placed upon the patient's chest wall. While the orthogonal images are obtained, the computer generates a model correlating the position of the chest wall with the position of the internal fiducials. This model is continuously updated during treatment to correct for subtle changes in tumor location.~Quality assurance will be performed as per standard practice at each participating institution."
46029544|NCT01146054|Drug|Gemcitabine|Treatment calculated per the needs of each patient and given at the instruction of the investigator; iv (intravenous).
46029545|NCT01146054|Drug|Fludeoxyglucose (18F) (FDG)|FDG-PET/CT scan is used in treatment planning. Treatment with 18F-FDG is calculated per the needs of each patient and given at the instruction of the investigator; iv
46029546|NCT00640705|Drug|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
46029547|NCT00640705|Drug|Matching placebo patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
46029548|NCT01145898|Drug|(Cosopt®, prostaglandin)|We did NOT provide any intervention, we observed groups of patients already on these drugs as observers only.
45839085|NCT04341870|Drug|Azithromycin|Azithromycin: oral administration, 500mg on D1 then 250mg QD on D2 to D5 (total duration 5 days)
45839086|NCT04341870|Drug|Hydroxychloroquine|Hydroxychloroquine: oral administration, 600mg QD (200mg TID) from D1 to D10 (total duration 10 days)
45839087|NCT04331808|Drug|Tocilizumab|Tocilizumab 8mg/kg D1 and if no response (no decrease of oxygen requirement) a second injection at D3.
45839088|NCT04331418|Drug|Dexmedetomidine|1 mcg/kg IV over 10 minutes followed by 0.5 mcg/kg/hr
46029549|NCT04181905|Other|Questionnaire|Firstly, demographic information (name-surname, date of birth, gender, age, height, body weight, dominant hand, family structure, social security, educational status, occupation, smoking, alcohol use, assistive device drug use, resume, surname, complaints). Data collection tools will then be applied to patients by face to face interview technique. Evaluation of kinesiophobia Assessment of quality of life in asthma patients with TAMPA questionnaire Assessment of physical activity level with Asthma Quality of Life Questionnaire (AQLQ) Assessment of physical activity level with International Physical Activity Questionnaire-Short Form (IPAQ) is planned.
46029550|NCT02681653|Drug|Atorvastatin|Atorvastatin or placebo given for 7 days to patients of septic shock admitted to ICU
46029551|NCT02681653|Drug|Placebo|Equally matched placebo for 7 days to patients of septic shock admitted to ICU
46029552|NCT04181983|Other|Personalized exercise program|Home-based personalized exercise program using a smart phone app
46029553|NCT04181983|Other|WHO exercise guidelines|Standard exercise counselling according to WHO guidelines
46029554|NCT04315116|Drug|pyrotinib maleate|a single oral dose of pyrotinib maleate on day 1 & day10 .
45471478|NCT03902015|Device|Nuance Phone case|"participants will receive a phone (iPhone) with the Nuance Phone case and a designated app required for the use of the device. Participants will first undergo hearing test via the app, and afterwards (in case they are not excluded based on hearing status), will receive a introduction on how to use the app and the device. Before starting the clinical trial, children will undergo three adjustments days in which they will practice using the device in school. During this period the researchers will make sure that the participants are adapting to the use of the device, and in any case there is a problem, will be able to contact a representative of Nuance Hearing who will be available to support technical issues."
46029555|NCT04315116|Drug|Loperamide|Loperamide 4 mg bid from day 7 to day 13
46029556|NCT02886078|Procedure|Dorsal approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the dorsal approach.
46029557|NCT02886078|Procedure|Volar approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the volar approach.
45471479|NCT03908333|Drug|Ascorbic Acid|25, 37.5, 56.25 or 75 grams/m2
45471480|NCT03908333|Drug|Paclitaxel protein-bound|125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
46029558|NCT04183933|Other|Pilates Exercise|Pilates exercises will be given for 6 weeks, 3 days in a week.
46029559|NCT04183933|Other|Combined Exercise|Combined exercise will be given for 6 weeks, 3 days in a week.
46029560|NCT02883114|Drug|PF-06648671|Subjects will receive a single dose of PF-06648671 25 mg oral suspension on day 1 in period 1 and a single dose on Day 4 in period 2.
46029561|NCT02883114|Drug|Itraconazole|Subjects will receive itraconazole 200 mg oral solution once a day for 14 days in period 2
46029562|NCT00640783|Behavioral|Mediterranean diet|The dietary advice was tailored to each patient on the basis of 3-day food records. The recommended composition of the dietary regimen was as follows: carbohydrates, 50% to 60%; proteins, 15% to 20%; total fat, less than 30%; saturated fat, less than 10%; and cholesterol consumption, less than 300 mg per day. Moreover, patients were advised to consume at least 250 to 300 g of fruits, 125 to 150 g of vegetables, and 25 to 50 g of walnuts per day; in addition, they were also encouraged to consume 400 g of whole grains (legumes, rice, maize, and wheat) daily and to increase their consumption of olive oil.
46029563|NCT00640783|Behavioral|Control|Patients consuming the control diet were given general oral and written information about healthy food choices at baseline and at subsequent visits but were offered no specific individualized program. However, the general recommendation for macronutrient composition of the diet was similar to that for the intervention group (carbohydrates, 50%-60%; proteins, 15%-20%; and total fat, <30%).
46029564|NCT04183387|Drug|Simvastatin 40mg|
46029565|NCT01133418|Other|Computerized Progressive Attention Training|Four comprehensive training tasks were developed and programmed based on expansions and modifications of various tasks that have been extensively investigated in the attention literature and are known to reflect primary attentional functions. Each task is discussed in detail in the Research Methods (section D.6.b). Briefly, they included a Continuous Performance Task, a Conjunctive Search Task, an Orienting and Flanker Task, and a Global-Local Task. All of the tasks were modified extensively from their original neuropsychological design to make them entertaining and stimulating enough for children to enjoy. Each task began at a relatively simple level of difficulty and gradually increased in difficulty across the training as children demonstrated proficiency according to reductions in RT variability
46029566|NCT01133418|Other|Sham Comparator Cognitive Training|Same tasks at Computerized Progressive Attention Training but the tasks do not progress in difficulty
46029567|NCT02677909|Device|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Will place device on admission to SICU. Measure bowel sounds and await bowel function
46029568|NCT02679313|Device|Phoropter|Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit). Oculomotor measurements, i.e., heterophoria, vergence ranges, AC/A and accommodative findings will be measured at each session using the different devices. Each session will be separated by a minimum of 24 hours and a maximum of 14 days.
46029569|NCT04314804|Combination Product|PPP001|1 pellet smoked up to 3 times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)
46029570|NCT04314804|Combination Product|Placebo|1 pellet smoked up to 3 times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
46029571|NCT02678065|Device|InPact Admiral DEB|
46029572|NCT04183153|Device|Repetitive Transcranial Magnetic Stimulation|Participants will receive repetitive transcranial magnetic stimulation (rTMS) to determine if stimulating areas with activating functional connectivity will activate the hypothalamus and in turn, have a measurable effect on hormone levels.
46029573|NCT00625092|Drug|fluorouracil|Post-operative day 1 and day 2, 600mg/m^2 intraperitoneal (IP) held for 23 hours
45471481|NCT03908333|Drug|Cisplatin|25mg/m2 in 500 mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
46029574|NCT00625092|Drug|leucovorin calcium|Day 0 200 mg/m^2 intraperitoneal held for 2 hours
45471482|NCT03908333|Drug|Gemcitabine|1000mg/m2 in 500 mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
45471483|NCT04340557|Drug|Losartan|Standard of care plus the starting dose of losartan 12.5mg (investigator has option to increase dose on days 2-10 based on tolerance of SBP) of losartan taken twice daily for up to 10 days. Upon the treating clinician's discretion, losartan may be continued beyond 10 days for non-COVID-19 indications.
46029575|NCT00625092|Drug|oxaliplatin|Day 0 hyperthermic intraperitoneal oxaliplatin held for 30 minutes - assigned dose level: Levels 1 through 7 - 300 to 600 mg/m^2
46029576|NCT00625092|Procedure|cytoreductive surgery|Day 0 Cytoreductive surgery is a systematic attempt to remove all or nearly all peritoneal nodules.
46029577|NCT00931918|Drug|Bortezomib|Bortezomib IV
46029578|NCT00931918|Drug|Rituximab|Rituximab IV
46029579|NCT00931918|Drug|Cyclophosphamide|Cyclophosphamide IV
46029580|NCT00931918|Drug|Doxorubicin|Doxorubicin IV solution
46029581|NCT00931918|Drug|Vincristine|Vincristine IV
46029582|NCT00931918|Drug|Prednisone|Prednisone tablet
46029583|NCT04183075|Dietary Supplement|FontActiv Superprotein/Hypercaloric Fiber|The product under study has a liquid presentation, in 200 ml bottles, ready to take
46029584|NCT04183075|Dietary Supplement|Carbohydrates and C Vitamin|The control product will be prepared with equal presentation and taste as similar as possible tan study product
46029585|NCT00642109|Procedure|midurethral sling procedure|quality of life, voiding dysfunction
46029586|NCT02681575|Behavioral|Cog-Fun - A|Meta-cognitive functional intervention for improved self management in adults with ADHD
46029587|NCT02679001|Drug|TNF inhibitor/TCZ|Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current SPC/local labeling will be observed.
46029588|NCT02678221|Drug|Sildenafil citrate|
46029589|NCT02678221|Drug|Aspirin|
46029590|NCT04033783|Other|6MWT - accompanied|Assessor walks behind the patient
46029591|NCT04033783|Other|6MWT - not accompanied|Assessor does not walk behind the patient
46029592|NCT00641329|Drug|CLONICEL (clonidine HCl sustained release)|Flexible Dose (0.1 - 0.4 mg)
46029593|NCT00641329|Drug|Placebo|Matching placebo tablets
46029594|NCT02681107|Radiation|APBI 27Gy in 5 fractions|Patients will be treated with 3-D conformal, external beam, partial breast RT to deliver 27 Gy in 5 daily fractions using 3-5 beams on a linear accelerator. The target PTV will be the CT-visible seroma plus a 1cm margin to form the CTV (minus 5mm from skin and excluding chest wall) and a further 7mm to form the PTV. Real time review will ensure compliance with target and normal tissues dose constraints in this multi-institutional study. Any (or no) systemic therapy is permitted.
46029595|NCT01179191|Drug|morphine sulfate and naltrexone hydrochloride (EMBEDA)|Capsules in dose strengths ranging from 20 to 100 mg morphine sulfate with 0.8 to 4 mg of naltrexone hydrochloride taken either once or twice daily with a starting dose calculated using the total daily dose of the current opioid being converted from until a stable dose is achieved or six weeks which ever comes first.
46029596|NCT01169844|Biological|AIN457A|
46029597|NCT01169844|Other|Other|
46029598|NCT00642421|Drug|C2L-OCT-01 PR, 10 or 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (35 days) and V3 (70 days). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
46029599|NCT00642421|Drug|C2L-OCT-01 PR, 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (Day 35) and V3 (Day 70). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
46029600|NCT00642187|Drug|budesonide|
46029601|NCT00642187|Drug|Placebo|
46029602|NCT05663125|Procedure|Laser interstitial thermal therapy|Ablation of the tumor will be done by MRI-guided laser interstitial thermal therapy with the assistance of neuro-navigation.
46029603|NCT05663125|Drug|Temozolomide|Temozolomide will be administered continuously from the 1st to the 21st day after LITT surgery. The oral dose of temozolomide is 75 mg/m2. And then, it will be given at a routine dose from the second month after surgery.
46029604|NCT05655533|Diagnostic Test|Magnetic resonance Imaging scanners of sacroiliac joints.|"Patients will undergo MR imaging examinations with a closed 1.5-Tesla Magnetic resonance Imaging scanners of sacroiliac joints.~The patients will be imaged in the supine position using a body phased-array coil.~Evaluate the added value of DWI in detection of acute sacroiliitis and whether ADC values can be helpful in detection and differentiation of active stage, so determine whether supplementation of DWI with quantitative ADC mapping to the routine MR examination is of great value as non-invasive tool or not"
46029605|NCT01132482|Drug|Sildenafil|During the course of the study, patients will receive 4 weeks of therapy: 28 days of placebo orally t.i.d. or 28 days of days of sildenafil orally t.i.d. Dosing of sildenafil will be escalated after the first week (20 mg orally t.i.d for the first week, then subjects will take 40 mg orally t.i.d. for 3 weeks). Patients not tolerating dose escalation will be discontinued from the study.
46029606|NCT01132482|Drug|Placebo|Patients receiving placebo will have sham dose escalation to maintain blinding.
46029607|NCT02678767|Drug|Ferumoxytol|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
46029608|NCT02886533|Other|Antithrombotic|Collection of clinical, biological data
46029609|NCT02678455|Biological|TV005 vaccine|Delivered by subcutaneous injection; contains 10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31, and 10^3 PFU of rDEN4Δ30.
45471484|NCT04599218|Other|Prostate Biopsy|Standard of care
45471485|NCT04599218|Other|MR US Fusion Guided Prostate Biopsy|Trans-rectal ultrasound (TRUS) guided fusion prostate biopsy (Arm 1) or a Transperineal Ultrasound guided fusion prostate biopsy (Arm 2). All patients will under go a standard ultrasound guided biopsy at the time of their targeted (fusion) biopsy.
45471486|NCT04599218|Device|MR/TRUS Fusion Guided Prostate Biopsy|TRUS images are overlaid on a previously obtained prostate MRI, combined with an electromagnetic tracking system. The urologist then performs directed prostate biopsies at MR-identified targets in addition to the standard prostate biopsies.
46029610|NCT02678455|Biological|Placebo|Delivered by subcutaneous injection
45471487|NCT01255085|Dietary Supplement|yellow pea protein|Served in a tomato soup
45471488|NCT01255085|Dietary Supplement|yellow pea fiber|Served in a tomato soup
45471489|NCT01255085|Dietary Supplement|Control Tomato Soup|Served in a tomato soup
45471490|NCT04566692|Biological|IGSC 20%|Subcutaneous (SC) infusion pump.
45471491|NCT04549376|Drug|Povidone-Iodine 0.4% NI|Povidone iodine (PVP-I) nasal irrigation at concentration of 0.4%
45471492|NCT04549376|Drug|Povidone-Iodine 0.5% NI|Povidone iodine (PVP-I) nasal irrigation at concentration of 0.5%
45471493|NCT04549376|Drug|Povidone-Iodine 0.6% NI|Povidone iodine (PVP-I) nasal irrigation at concentration of 0.6%
46029611|NCT02678845|Other|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
46029612|NCT00931762|Drug|Panobinostat|Panobinostat oral capsules
46029613|NCT02886455|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
46029614|NCT02886455|Other|New adhesive strip|This a newly developed adhesive strip.
46029615|NCT00641407|Drug|NPL insulin|Starting dose 10 IU bedtime and then titration
45839089|NCT04331418|Procedure|caudal block|After negative aspiration of blood or cerebrospinal fluid, 2 mg/ kg of bupivacaine at concentration of 0.5% (volume 0.5ml/kg) was given as per the group assigned, then the site of injection was dressed, and the patient was turned supine.
46029616|NCT00641407|Drug|Insulin glargine|10 IU bedtime and then titration
46029617|NCT00624689|Dietary Supplement|Modified formula (MFGM-enriched formula with reduced energy and protein content)|MFGM-enriched formula with reduced energy and protein content
46029618|NCT02677597|Drug|Cisplatin Combined With S-1|
46029619|NCT02677597|Drug|Cisplatin Combined With Paclitaxel|
45471494|NCT04549376|Drug|Povidone-Iodine 0.5% NS|Povidone iodine (PVP-I) nasal spray at concentration of 0.5%
45471495|NCT04549376|Drug|Povidone-Iodine 0.6% NS|Povidone iodine (PVP-I) nasal spray at concentration of 0.6%
45471496|NCT04549376|Other|Placebo comparator: DW-NI|Nasal irrigation will be provided by Distilled water
46029620|NCT00606970|Dietary Supplement|Seigen Alpha EV|Orally administered Seigen Alpha EV, 1 packet (6 grams)3 times daily, for maximum of 3 months. Each packet is clearly marked for breakfast, lunch, or supper. The contents are to be dissolved in water or liquid and taken orally with meal. Subjects will be required to return any unused packets to study doctor at end of each month.
46029621|NCT00606970|Dietary Supplement|Placebo Comparator|Identically packaged placebo packets (each 6 grams) taken 3x daily with meals for 3 months maximum.
45471497|NCT04549376|Other|Placebo comparator: DW-NS|Nasal spray will be provided by Distilled water
46029622|NCT02681029|Procedure|Blastocyte Transferring|Intra-uterine transferring of blastocyst from thawed cleavage embryo in infertile women.
46029623|NCT02681029|Procedure|Embryo Transferring|Inta-uterine transferring of thawed cleavage embryo transfer in infertile women.
45471498|NCT03746197|Device|Project EVO Multi- Treatment|The EVO platform assesses perceptual discrimination while single-and multi-tasking. Visuomotor tracking involves navigating a character through a dynamically moving environment while avoiding obstacles. EVO uses adaptive algorithms to change game difficulty on a trial by trial and patient by patient basis for the tracking task and discrimination task with real-time feedback.
45682318|NCT03851302|Other|Active Remote Ischemic Conditioning|The active RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The active RIC will be achieved via blood pressure cuff inflation to 200 mmHg.
46029624|NCT01132326|Drug|Droxidopa|Oral, 100, 200, 300, 400, 500, 600 mg TID, 12 months
46029625|NCT05662969|Device|MACHINE PERFUSION|Different outcomes of MP use in low/mid-volume and high-volume LT centres
46029626|NCT05372146|Procedure|GSV radiofrequency ablation with concomitant phlebectomy|Radiofrequency ablation with concomitant phlebectomy
46029627|NCT02882880|Device|The Luco Hybrid OSA Appliance|Group 1, initial treatment with the device, reassessed at 14 and 60 days, Group 2, removal of the treatment for 48 hours, to determine if relapse occurs, retested at 60 days with the device (recovery from intervention).
45471499|NCT03901703|Other|Physiotherapy and Rehabilitation|The children in each group will receive 6 weeks of functional strengthening exercises targeting each muscle group according to the arm they are included in.
45471500|NCT03713060|Diagnostic Test|Mixed meal test|All women will have mixed meal test, continous glucose monitoring and antenatal ultrasounds performed. The children born of these women will have DXA-scans performed after birth.
45682319|NCT03851302|Other|Sham Remote Ischemic Conditioning|The sham RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The sham RIC will be achieved via blood pressure cuff inflation to 10 mmHg below the subjects' diastolic blood pressure which would not cause the blood occlusion.
46029628|NCT02677675|Behavioral|Intervention (reminder module)|Reminder module (delivered via SMS and telephone call reminders)
46029629|NCT04260568|Other|Semi-structured interviews|Patients with a diagnosis of 3PD will be sought from a multidisciplinary balance clinic. Consenting participants will take part in a face-to-face interview about their diagnosis. Data collection will consist of recorded semi-structured interviews, which will be transcribed.
46029630|NCT00642343|Behavioral|Evaluation of motor proficiency skills.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
46029631|NCT00642343|Behavioral|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
46029632|NCT00642343|Behavioral|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
46029633|NCT00642343|Behavioral|Evaluation of motor proficiency.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
46029634|NCT01178411|Drug|Tivantinib|Tivantinib 360 mg (3 x 120 mg tablets or capsules) twice daily by mouth.
45682320|NCT03851302|Other|Isometric hand exercise|Participants will be instructed to pinch a dynamometer with thumb and index finger at different intensities and durations. The intensities of pinch force will be 10%, 25%, and 50% of the maximal voluntary contraction (MVC). For each intensity, durations of 2, 4, and 6 s will be employed, which resulted in nine different combinations delivered in pseudorandom order. Participants will perform 2 sets of the isometric hand exercise (18 pinches in total). The interval between each pinch will be 2 seconds, with 30 second intervals between each set.
45682321|NCT03850756|Diagnostic Test|Early kidney damage biomarkers|In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.
46029635|NCT01178411|Drug|Anti-Cancer Combination Therapy|Tivantinib 360 mg twice daily in combination with other anti-cancer therapy (eg, erlotinib,sorafenib, pemetrexed, docataxel, gemcitabine, irinotecan, and/or cetuximab) at the same dose and schedule in which they were administered in the original (previous) study.
46029636|NCT04263688|Other|Non-Intervention|Non-Intervention
46029637|NCT02681263|Drug|Temocillin|Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.
46029638|NCT00608686|Dietary Supplement|Pregnenolone|30mg of pregnenolone administered orally, once, at 2 of 5 study visits.
46029639|NCT02675803|Biological|VAY736|VAY736 treatment
46029640|NCT02675803|Biological|VAY736 placebo|VAY736 placebo
46029641|NCT02678611|Dietary Supplement|Basis 250|
46029642|NCT02678611|Dietary Supplement|Basis 500|
46029643|NCT02678611|Dietary Supplement|Placebo|
46029644|NCT02677519|Drug|Aptensio XR|Orally-administered extended release formulation of methylphenidate; once daily dosing
46029645|NCT01145508|Drug|Docetaxel|Given IV
45682322|NCT03850756|Diagnostic Test|Predisposition to kidney injury biomarkers|In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured.
46029646|NCT01145508|Other|Laboratory Biomarker Analysis|Correlative studies
46029647|NCT01145508|Drug|Prednisone|Given PO
46029648|NCT01145508|Biological|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
46029649|NCT01145508|Biological|Rilimogene Galvacirepvec|Given SC
46029650|NCT02675881|Device|DSM|Monopolar RFA using dual switching mode (DSM)
46029651|NCT02675881|Device|separable clustered electrode|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
46029652|NCT00931528|Drug|Tadalafil|Beginning ≤ 7 days after the start of radiotherapy, patients receive oral tadalafil 5mg once daily for 24 weeks.
46029653|NCT00931528|Other|Placebo|Beginning ≤ 7 days after the start of radiotherapy, patients receive oral placebo once daily for 24 weeks.
46029654|NCT04181749|Drug|aspirin and atorvastatin|Patients will be randomized and prescribed either no treatment or aspirin 75mg and Atorvastatin 40mg
46029655|NCT05528263|Device|Acupuncture|Standardized acupuncture protocol 1-2 times a week for 12 weeks (a total of 14 sessions).
46029656|NCT05528263|Other|Nature scenery with a relaxation exercise|Watch nature scenery videos with a relaxation exercise guide 1-2 times a week for 12 weeks (a total of 14 sessions)
46029657|NCT04312152|Dietary Supplement|Q10 Ubiquinol|Q10 Ubiquinol (50 or 100 mg b.i.d. depending on body weight) in capsules containing also Vit. E and Vit. B complex, as described above. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
46029658|NCT04312152|Dietary Supplement|Vitamin E|Vitamin E (30 mg b.i.d. regardless of body weight) in capsules containing also Vit. B complex, and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
46029659|NCT04312152|Dietary Supplement|Multi-Vitamin B complex|Multi-Vitamin B complex including Vit. B1, B2, B3, B5, B6, B8, B9, and B12, in capsules containing also Vit. E and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
46029660|NCT00975195|Drug|tiotropium inhalation|
46029661|NCT00975195|Drug|salmeterol xinafoate|
46029662|NCT00975195|Drug|fluticasone propionate|
46029663|NCT00975195|Drug|placebo matched for fluticasone propionate|
46029664|NCT00642499|Drug|Dronabinol|2.5 mg to 40 mg
46029665|NCT00642499|Drug|Placebo|placebo
46029666|NCT00644215|Drug|5-FU and Mitomycin|"5-FU injection 5mg~Mitomycin drop 0.02%"
46029667|NCT01145352|Drug|Etanercept (genetical recombination)|All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year).
46029668|NCT01178099|Drug|Prasugrel|Oral, daily for 12 days
46029669|NCT04016545|Device|Low profile endoprothesis (Navion Medtronic, NBS Low Profile Bolton Terumo)|Aortic aneurysm exclusion through endovascular procedure
45682323|NCT03850756|Diagnostic Test|Tobacco consumption|In order to know the degree of tobacco consumption, the biomarker cotinine will be measured in the urine samples of these patients.
46029670|NCT05323188|Other|Tryptase dosage|Collection of biological waste from a blood test for complete blood count (CBC) of care. Centrifugation to recover the plasma, then dosage of the tryptase.
46029671|NCT02673463|Drug|Spironolactone|25 mg once daily
45682324|NCT01591785|Drug|Retapamulin 1% ointment|Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
46029672|NCT02673463|Drug|Placebo|Visually identical to spironolactone, once daily
46029673|NCT00610636|Procedure|Hepatic resection|Hepatic resection
46029674|NCT01169532|Drug|ridaforolimus|Given PO
46029675|NCT01169532|Drug|vorinostat|Given PO
45682325|NCT01591785|Drug|Placebo|Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
45682326|NCT03850678|Device|Hearing Aid|Hearing Aid
46029676|NCT01169532|Procedure|biopsy|Optional correlative studies
46029677|NCT01169532|Other|pharmacological study|Correlative studies
46029678|NCT01169532|Other|laboratory biomarker analysis|Correlative studies
46029679|NCT02537353|Device|Metal clips|The group will be shot of adrenaline 1: 10,000 in four quadrants, associated with application of metal clips.
46029680|NCT02537353|Drug|Hemospray|The group will be shot of adrenaline 1: 10,000 in the four quadrants associated with application adsorption powder, marketed under the name Hemospray.
46029681|NCT02537353|Procedure|Endoscopy Exam|All patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
46029682|NCT02537353|Drug|Adrenaline|The injection of adrenaline solution with 50% glucose at a proportion of 1: 10000 in four quadrants.
46029683|NCT04181671|Other|Low Resistance training with venous blood flow restriction|"Total 20 males will participate in this group after warmup , Blood flow restriction will be provided through sphygmomanometer optimum pressure will be measured through following formula occlusion pressure (mmHg) = 0.514 (SBP) + 0.339 (DBP) + 1.461 (Arm circumference) + 17.236 then 30% of 1RM will be used for training . The standard protocol will be used which is four sets (1st set-30 repetitions, 2nd set-15 repetitions, 3rd set-15 repetitions, and 4th set-15 repetitions) with 30-60 s of interval between sets. ( the cuff must be deflated between sets of exercise) for 8 weeks (24) sessions on non-consecutive days. participants will be re-assessed for all baseline variables after 8 weeks of training biceps curls will be used for training.~Heart Rate and oxygen saturation will be measured during the session through Pulse oximeter"
46029684|NCT04181671|Other|High Resistance training|Total 20 males will participate in this group after warm up. 80% of 1RM will be used for training, 3 sets of 8 repetitions will be used with 30-60 s of interval between sets. for 8 weeks (24) sessions on non-consecutive days.No blood flow restriction will be applied to this group Participants will be re-assessed for all baseline variables after 8 weeks of training. Bicep curls will be used for training.
46029685|NCT00928564|Drug|Pudendal block|8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
46029686|NCT00928564|Drug|Placebo|5ml of saline at each block site.
46029687|NCT02883036|Other|blood sampling|sampling after diagnosis and the mononuclear cells will be given tigecycline stimulation in vitro
45682327|NCT04773639|Behavioral|Multi-Modal Palliative Care Intervention|An innovative muli-modal palliative care intervention that addresses the lack of advance care planning and unmet psychosocial needs commonly experienced by patients with metastatic cancer.
45682328|NCT04773639|Behavioral|Usual Care Control Condition|The control condition includes usual care (UC) at the collaborating clinics, consisting of access to a clinical social worker and nurse practitioners for advance care planning and supportive visits at patient request.
45682329|NCT03848728|Other|SEARCH Youth combination intervention|"Administration of life-stage assessment tool~Structured choice clinic access~Rapid feedback of VL results~Provider e-collaboratives with chat groups for discussions of challenging cases using de-identified information"
46029688|NCT02883036|Other|blood sampling|sampling after register and the mononuclear cells will be given tigecycline stimulation in vitro
46029689|NCT00643357|Drug|50% Oxygen/50% Nitrous oxide premix (KALINOX 170 bar)|gaz flow between 4 to 15 L/min inhalation between 15 to 60 minutes
46029690|NCT00643357|Drug|50%Oxygen/50% Nitrogen premix|inhalation between 15 to 60 minutes gaz flow between 4 to 15 l/min
46029691|NCT01177943|Drug|Atomoxetine|Administered orally, once.
45471501|NCT03901625|Device|Manual Toothbrush|A manual toothbrush is used to clean teeth surfaces.
46029692|NCT00608920|Other|Single Photon Emission Computed Tomography (SPECT)|
46029693|NCT01131312|Device|Thinprep|Pap test
46029694|NCT01131312|Device|Hybrid capture 2|Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) Test
45471502|NCT03901625|Device|Dental floss|A dental floss is used to clean inter-proximal areas.
46029695|NCT01131312|Procedure|Colposcopy|Procedure performed by a healthcare practitioner to examine the cervix, vagina, and vulva.
45471503|NCT03901625|Device|Waterjet|A waterjet is used to clean inter-proximal areas.
45471504|NCT03901625|Device|Electric Toothbrush|An electric toothbrush is used to clean teeth surfaces.
45471505|NCT01149395|Drug|Dexlansoprazole|Dosage: 30 mg once per day for 4 weeks by mouth
45471506|NCT04001192|Behavioral|aerobic exercise program|The intervention is exercise at home, 5-6 days per week during 12 weeks, guided by a schedule that the physiotherapist will design after initial treadmill testing. Exercise intensity is 80-90 % of the heart rate threshold that was identified by the treadmill test. During the 12 weeks program, intensity will be increased according to feedback from the participant.
46029696|NCT04181281|Diagnostic Test|Contrast enhanced ultrasound|This is a regular ultrasound scanner used with an ultrasound contrast agent injected through veins to allow for kidney perfusion acquisition.
46029697|NCT04181281|Diagnostic Test|Arterial Spin Labelling -Magnetic Resonance Imaging|Arterial spin labelling is an MRI technique allow for measuring tissue perfusion. It uses magnetically labelled arterial blood water protons as a tracer.
46029698|NCT02865057|Procedure|Vaginal assessment|Vaginal assessment of position prior to delivery
46029699|NCT04314960|Device|Functional electrical stimulation device (NESS L300Plus, Bioness, Valencia, CA)|Functional electrical stimulation (FES) is the application of high-intensity intermittent electrical stimuli to generate muscle contractions that may bypass spinal and supraspinal inhibition, and which is coupled with a functional task such as gait. Gait training will be conducted on a treadmill.
46029700|NCT04178785|Drug|Remifentanil|Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio.
46029701|NCT01177787|Device|zeltiq|Cryolipolysis had been conducted for targeted fat area on thigh for 1 hour through Zeltiq machine made in Zeltiq Aesthetics.
46029702|NCT01177787|Device|electrical stimulation|Lipolysis would be done on controlateral thigh for 30 minutes through 3000 Hz- amplitude modulated frequency.
45682330|NCT03660046|Drug|Depot medroxyprogesterone acetate (DMPA)|Depot medroxyprogesterone acetate (DMPA) will be dispensed from the Grady Pharmacy Service and will be administered every 12 weeks at the standard dose of 150 mg Intramuscular injection, beginning from week 3 of study enrollment and repeated every 13 weeks
46029703|NCT02864589|Behavioral|Internet-delivered habit reversal training|The I-HRT group will receive a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on habit reversal training (i.e. Woods, D.W. (2008). Managing Tourette syndrome: A behavioral intervention for children and adults therapist guide. OUP, USA.) with added interactive features as videos and illustrations. In short, the participants practice to become more aware of their tics and inhibit them by performing competing responses (movements). The treatment is therapist guided: the participants have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
46029704|NCT02864589|Behavioral|Internet-delivered exposure and response prevention|The I-ERP group receives a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on exposure and response prevention (i.e. Verdellen, C. et al. (2011). Tics: Therapist manual & workbook for children. Boom, Amsterd.) with added interactive features as videos and illustrations. In short, the participants practice to suppress their tics for longer and longer times, at the same time as premonitory urges are intentionally provoked. The treatment is therapist-guided: the children and parents have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
46029705|NCT02676037|Device|foot pressure plate form|
46029706|NCT00928486|Drug|Lenalidomide|Lenalidomide 25mg PO for (days 1 - 21) of a 28-day cycle
46029707|NCT00928486|Drug|Dexamethasone|Dexamethasone 40 mg by mouth (PO) daily (QD) on days 1-4, 9-12 and 17-20 of each 28 day cycle
46029708|NCT03867357|Drug|GnRH agonist|Zoladex is a gonadotropin-releasing hormone agonist, or GnRH-A. It is an implant that is injected under the skin (subcutaneously). The implant gradually dissolves and releases the drug over the time between injections. There are two dosages of Zoladex: Zoladex 10.8 mg, which is injected once every 3 months, and Zoladex 3.6 mg, which is injected once a month.
46029709|NCT05528029|Device|Leadless Pacemaker (Micra)|Micra leadless pacemaker is implanted in the right ventricle via femoral vein. The Micra introducer/dilator assembled system is inserted over a stiff guidewire in the right atrium. After the removal of the guidewire and the dilator, the delivery system is advanced into the introducer and the Micra is placed under fluoroscopy guidance, preferably in the septal region of the right ventricle.
46029710|NCT02887391|Other|No intervention - observational study|No intervention - observational study
46029711|NCT04056117|Biological|Shigella 4V|Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.
46029712|NCT04056117|Biological|MenACWY|Control vaccine administrated to adults and infants
46029713|NCT04056117|Biological|Rabies|Control vaccine administrated to children
45471507|NCT03901547|Behavioral|Communication Skills Training|Education training in the serious illness communication guide (SICG) by Ariadne labs.
45471508|NCT03901547|Behavioral|Profile feedback|Providing participants their personal documentation rate of SICG in the electronic medical record
46029714|NCT04056117|Biological|Diphtheria, Tetanus and Pertussis (DTaP)|Control vaccine administrated to infants
46029715|NCT04056117|Biological|Placebo|Control administrated to adults
46029716|NCT05655221|Drug|B1344|multi-site abdominal s.c. injections (maximum 2 mL at each site)
45471509|NCT03901547|Other|Maslach burnout inventory|Maslach burnout inventory
46029717|NCT05655221|Other|Placebo|multi-site abdominal s.c. injections (maximum 2 mL at each site)
46029718|NCT00610792|Drug|bortezomib|1.3 mg/m2 on Days 1, 4, 8 & 11 every 3 weeks (1 cycle = 21 days) for up to six cycles
46029719|NCT00610792|Drug|pegylated liposomal doxorubicin|30 mg/m2 on Day 1 every 3 weeks (1 cycle = 21 days) for up to six cycles
46029720|NCT02677441|Procedure|Conservative management|Specific standardized rehabilitation protocol under Cote et al (2010)
45682331|NCT03660046|Drug|Etonogestrel implant (Eng-Implant)|A standard Nexplanon rod Implant that is a subdermal implant in the arm. This will be placed at study week 3 by Dr. Haddad or a trained clinician. It contains Etonogestrel 68mg.
46029721|NCT02677441|Procedure|Surgery|Coracoclavicular and acromioclavicular fixation as described ly Lädermann et al (2011), followed by specific standardized rehabilitation protocol under Cote et al (2010).
46029722|NCT00610870|Drug|atorvastatin|atorvastatin 80mg/day before primary coronary intervention
46029723|NCT05655143|Behavioral|Balance training|Participants will undergo a 4-week balance training protocol modified from that described by McKeon et al.15 Participants will undergo supervised exercise three times per week for approximately 30 minutes per session, The exercise consists of single-leg balance training, hop to stabilization, and hop to stabilization plus reaching activities as presented in Figure 1. Particularly, the levels of difficulty will be progressed with visual conditions (eyes open and eyes closed), time (sec), and base of support (floor and foam pad) while hopping distance (inches) for single-leg and hopping activities, respectively. These activities will be progressed in difficulty as participants become proficient at the task.
46029724|NCT04181593|Drug|Omega 3 fatty acid|Omega 3 fatty acid Softgels
46029725|NCT04181593|Drug|Placebos|Mineral oil Softgels
46029726|NCT04265326|Other|Measurement of Quality of Life|Quality of life will be measured using Head and Neck Cancer Inventory and The Functional Assessment of Cancer Therapy - Head and Neck Cancer Version 4
46029727|NCT01168596|Drug|Rasagiline|"Comparison of Rasagiline versus placebo.~Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks."
46029728|NCT01168596|Drug|Placebo|Comparison of Rasagiline versus placebo. Placebo tablet, 1 per day, duration is approximately 12 weeks.
46029729|NCT02537275|Device|EyeLIKe Callamatch II, Koryo Eyetech Co, Seoul, Korea|tinted contact lens, daily-wear tinted lens
45471510|NCT03901547|Other|Emotion Regulation Skills Question (ERSQ)|This validated instrument consists of 27 items, and includes subscales related to nine competencies of coping with negative emotion (awareness, sensations, clarity, understanding, acceptance, tolerance, readiness to confront, compassionate self-support and modification) which can be summed to a total score (TOTAL). This validated instrument consists of 27 items, and includes subscales related to nine competencies of coping with negative emotion (awareness, sensations, clarity, understanding, acceptance, tolerance, readiness to confront, compassionate self-support and modification) which can be summed to a total score (TOTAL).
46029730|NCT02537275|Device|EyeLIKe Shine, Koryo Eyetech Co|clear lens
46029731|NCT05658419|Procedure|socket sheild|the socket shield technique, in which a partial root fragment was retained around an immediately placed implant with the aim of avoiding tissue alterations after tooth extraction. Histologic evaluation in a beagle dog showed no resorption of the root fragment and new cementum formed on the implant surface.
46029732|NCT02675647|Drug|Heparin, IV route, based on patients body weights (UI/kg)|
46029733|NCT02675647|Procedure|Cardiopulmonary bypass|
46029734|NCT02675647|Drug|Protamin administration|
46029735|NCT05370898|Drug|Caltrate D|Caltrate D is allowed for basic treatment when the patient is diagnosed with primary osteoporosis (Kidney Yang Deficiency Syndrome).Take it continuously for 3 months.
46029736|NCT05370898|Drug|Chinese medicine prescription|The Chinese medicine application prescription is composed of Rhizoma Drynariae 12g, psoralen 10g, dog ridge 10g, medlar 10g, raw oyster 10g, ginseng 6g, Panax notoginseng 3g, Amomum villosum 6g.Patients take 200ml each time, twice a day. Treatment duration are 3 months.
46029737|NCT05370898|Drug|Placebo|The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 3 months.
46029738|NCT04315805|Other|Integrative Yoga Therapy|Yoga therapy will be based on personalised care consisting of Yoga relaxing posture, strengthening exercise, Yoga breathing, meditative psychotherapy, sound and imagery yoga practices, relaxation, yoga diet and life style management.
46029739|NCT02677363|Other|Resistance Exercise|Participants 60 and above aged (both females and males) will perform one hour of resistance exercise twice weekly for 8 weeks.
46029740|NCT00610948|Biological|panitumumab|Given IV
46029741|NCT00610948|Drug|everolimus|Given orally
46029742|NCT00610948|Drug|fluorouracil|Given IV
46029743|NCT00610948|Drug|leucovorin calcium|Given IV
46029744|NCT00610948|Drug|oxaliplatin|Given IV
46029745|NCT04206137|Other|Group A (PNF rhythmic initiation group )|Lifting of arms and push the head back through the pattern of flexion -abduction-external rotation and neck in extension to the left in opposition of therapist hand resistance will be asked to do. At the end range of motion extensor muscles of back will start to contract.Then, reversing of that movement pattern to extension-adduction-internal rotation and neck flexion to right against the therapist resisting hands will be asked. this will be repeated on both sides
46029746|NCT04206137|Other|Group B (Swiss ball exercises)|"Supine position: A ball will be placed under patient neck, and will be asked to bend hip and knee up to 90°. 5 times, 10 seconds hold Supine position: With a ball below the pelvis, knees bent, the ball press will be done with pelvis. 5 times, for 10 seconds hold.~Crawling position: With a ball below one knee while keeping toes away from contact with the floor, the patient will balance first to stabilize the posture and slowly raise the other lower limb. This exercise will be performed in turn for the two lower limbs 10 times, with 10 seconds hold.~Prone position: the patient will place a ball in front of pelvis and will repeatedly raise and lowered the two lower limbs alternately. There will be 10 repetitions, with 5 sets, taking 15 seconds rest between each set."
45471511|NCT03901547|Other|Semi-structured interview|Interviewer asked subjects are a series of questions based on interview guide. Current guide designed to assess subject perception of implementation of training in clinical encounters, most recent encounter with patient with serious illness, barriers to documentation and coaching by faculty on communication. Interviews will be recorded and expected duration is 20-40 minutes.
45682332|NCT03660046|Drug|Levonorgestrel IUD (Lng-IUD)|The Levonorgestrel Intrauterine Device (Lng-IUD) (Mirena or copper) will be placed at study week 3 by Dr. Haddad or a trained clinician.
45682333|NCT03658798|Procedure|Functional Electrical Stimulation|Study participants will receive 40 sessions of intervention, 3 to 5 times a week over 2 to 3 months. Each session will be one hour in duration and participant will receive functional electrical stimulation therapy with their customized shirt. During therapy participants will be expected to carry out functional movements with assistance from the FES Garment.Participants will be expected to don, activate, and doff the garment as independently as possible. The exercises conducted will be defined by the investigator based on the functional status of the participant and eventual progress.
46029747|NCT04314726|Drug|Amelogenin|amelogenins applied on the distal surface of the lower second molar after adjacent third molar extraction
46029748|NCT04314726|Drug|Placebos|placebo applied on the distal surface of the lower second molar after adjacent third molar extraction
45682334|NCT03654742|Procedure|tonsillectomy|removal of tonsil tissue as described in the study arms
46029749|NCT04178395|Device|bihemispheric transcranial direct stimulation|"tDCS was applied with the anode placed over the M1 hand area of the ipsilesional motor cortex and the cathode over the same area of the contralesional motor cortex (C3/C4). For the active condition, patients received 5 consecutive daily sessions of 2 mA anodal tDCS over the AH and cathodal tDCS over the UH of 20 minutes each, with fade-in and fade-out periods of 1s. For the sham condition, the stimulation applied in the same sites and with the same parameters, was turned off after a fade-in period, 30 seconds of direct current stimulation and a fade-out period.~Repetitive peripheral nerve stimulation was performed by a peripheral nerve stimulator to the radial nerve and applied at the same time as tDCS. Radial nerve was chosen to improve wrist extension. Trains of 40 stimuli (ISI: 10 ms, duration: 1ms) were delivered every 6 seconds to the radial nerve through bipolar electrodes (5 cm diameter) at an intensity that could elicit a visible wrist extension (20-30 mA)."
46029750|NCT01177553|Procedure|selective laser photocoagulation of communicating vessels|Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. The use of these medications is safe in pregnancy in the doses and schedules outlined. Surgery will be performed under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. The patient will undergo either SLPCV or UCO depending on her choice. Patients will remain hospitalized for 24-48 hours. All subjects will be monitored during their hospital stay. Any unanticipated adverse events or serious adverse events will be reported to the IRB according to IRB reporting requirements. Prior to discharge from the hospital an investigator will perform a post-procedure ultrasound to assess fetal status
46029751|NCT01177553|Device|Expected Management|Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
46029752|NCT04178239|Diagnostic Test|fMRI, questionnaires, pneumologic diagnostics|fMRI neuropsychological questionnaires pneumologic diagnostics: blood samples, whole body plethysmography, walking test
46029753|NCT04260178|Other|An Education-Based Intervention Program and handbook (EBIP, hospital and home)|A handbook was developed in line with the literature and input from two specialist physicians. The handbook consisted of 4 sections that concerned improving breathing exercises, drug compliance, nutrition and illness self-care behavior.
45682335|NCT03654040|Biological|arTreg|"Eligible participants will receive a single dose of Treg product (arTreg). The target dose is at least 90 x 10^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 20 to 30 minutes."
45682336|NCT03654040|Procedure|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure on Day -3 (-1 day) prior to Treg product (arTreg) IV infusion."
45682337|NCT03654040|Drug|cyclophosphamide|40 mg/kg administered intravenously (IV) following leukapheresis and between 1 to 3 days prior to Treg product (arTreg) infusion, per institutional standard of care.
45839090|NCT04331184|Procedure|RFA using combined bipolar and monopolar energy deliver|RFA technique combining bipolar mode and switching monopolar mode using dual / Twin Cooled-wet electrodes is performed on residual tumors after transarterial chemo-embolization.
46029754|NCT04260178|Other|PFT, BMI, BDI, SCMP-G|pulmonary function test(PFT), the Baseline Dyspnea Index(BDI), body mass index(BMI) and the Self Care Management Process in Chronic Illness(SCMP-G) scale
46029755|NCT02675413|Drug|Dimethyl Fumarate|Open-label
45682338|NCT03654040|Drug|mesna|"Mesna is administered:~Intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide, and~In conjunction with the cyclophosphamide, per institutional practice with CTX."
45682339|NCT03654040|Drug|everolimus|EVR is approved for prophylaxis of allograft rejection in adults receiving a liver transplant. Per protocol: Post transplantation, subject will initially receive standard IS with tacrolimus (TAC),plus a mycophenolate product and/or steroids.Subsequently, evaluation for eligibility to be converted to EVR-based IS regimen will occur and, when applicable, proceed. Once the optimal EVR trough level is achieved,TAC dose will be reduced. When target EVR and TAC levels are maintained over two consecutive measurements, ALT liver function test (LFT) is ≤50 U/L, GGT LFT is ≤ the upper limit of normal or ≤ 1.5 times the baseline GGT, subject will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered/monitored/adjusted over time.
45682340|NCT01695993|Device|Acupressure bands|Bilateral acupressure wrist bands
45682341|NCT01695993|Other|Expectancy-neutral handout|The expectancy neutral handout has neutral information regarding the acupressure bands
45682342|NCT01695993|Behavioral|Expectancy-neutral MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery.
45682343|NCT01695993|Other|Expectancy-enhancing handout|The expectancy enhancing handout has expectancy-enhancing information regarding the acupressure bands
46029756|NCT02675725|Device|Measurement of sublingual microcirculation with Cytocam-IDF camera|"The normal treatment of a post-cardiac surgery patient is fluid bolus by indication. This indications are hypotension, hyperlactataemia, tachycardia or decreased urine production. This fluid bolus is 250 ml crystalloids in 15 minutes.~When this fluid bolus will be given, the investigators will observe the sublingual microcirculation and measure the red blood cell velocity and total vessel density on one spot for 20 minutes."
45471512|NCT03901547|Behavioral|Priming|"Participants will be provided a list of 30 patients they have encountered before that 1) have at least one documented note and 2) have a high probability for having serious illness as determined by electronic medical record screening. Participants will be asked 4 yes or no questions on each patient. Questions: 1) do you believe this patient has serious illness?; 2) would you be surprised if this patient died in the next year?; 3) would the patient benefit from the serious illness conversation guide? and 4) If you saw this patient again, would you use the serious illness conversation guide with him/ her?"
46029757|NCT00928408|Drug|Cinacalcet|
45471513|NCT02527733|Drug|Ranibizumab|
45839091|NCT04330872|Drug|Enteric Coated Aspirin Tablet|Study participants will be assigned to receive either EC Aspirin and will be required to continue taking them throughout the study (three days).
46029758|NCT04179877|Behavioral|IPS|Occupational rehabilitation and support Integrated with clinical treatment
46029759|NCT02675257|Behavioral|Diabetes-related affective problems analysis|Analysis of diabetes-related affective problems with regard to suboptimal glycaemic control
46029760|NCT02675257|Behavioral|Goal setting towards improvement of glycaemic control|Discussing and setting goals regarding improvements of suboptimal glycaemic control, depressive symptoms and diabetes distress
45471514|NCT02527733|Drug|Ranibizumab and laser|
45471515|NCT04382053|Drug|DFV890|DFV890 25 mg tablets orally/nasogastrically administered 50 mg b.i.d for 14 days in addition to SoC.
45471516|NCT04382053|Drug|Standard of Care (SoC)|SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
45471517|NCT03907865|Drug|Softacort|Group 1: 4 times daily for the first 12 days of the treatment period and then 2 times daily for 2 additional days Group 2: 3 times daily for the first 8 days of the treatment period and then 2 times daily for 3 additional days
46029761|NCT02675257|Behavioral|Diabetes-specific problem-solving therapy|Diabetes-specific problem-solving therapy with main focus on suboptimal glycaemic control, depressive symptoms and diabetes distress
46029762|NCT02675257|Behavioral|Interventions to increase diabetes treatment motivation|Interventions to increase diabetes treatment motivation in order to achieve improvements of glycaemic control as well as recovery from affective problems
46029763|NCT02675257|Behavioral|Activation of personal and social resources|Activation of personal and social resources with a view to diabetes control and affective problems
46029764|NCT02675257|Behavioral|Reduction of barriers to self-care/glycaemic control|Definition and reduction of barriers to adequate diabetes self-care behaviour as well as good glycaemic control
45471518|NCT03901079|Other|single-arm study|single-arm study
45471519|NCT04135495|Drug|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaroyotic ribosomal selective glycoside (ERSG)
45682344|NCT01695993|Behavioral|Expectancy-enhancing MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery. It also has expectancy-enhancing information regarding the acupressure bands.
46029765|NCT02675257|Behavioral|Cognitive restructuring of diabetes-related problems|Cognitive restructuring of diabetes-related problems such as suboptimal glycaemic control and diabetes-related affective problems
46029766|NCT02675257|Behavioral|Goal definition regarding self-care/glycaemia/well-being|Goal definition and agreement regarding diabetes self-care behaviour, optimal glycaemic control and activities supporting well-being and recovery from affective symptoms
46029767|NCT02675257|Behavioral|Health care and specific topics (e. g. blood pressure)|Education on health care and specific topics (e. g. blood pressure)
46029768|NCT02675257|Behavioral|Healthy foods, cooking recommendations, recipes|Education on healthy and unhealthy foods, cooking and recipes
46029769|NCT02675257|Behavioral|Sports, activities and exercise|Education on sports, activities and exercise
46029770|NCT02675257|Behavioral|Foot care: exercises, care & control, injuries, neuropathy|Education on foot care: exercises, care and control, injuries, and diabetic neuropathy
45471520|NCT04135495|Drug|Ivacaftor|CFTR potentiator
45471521|NCT01148303|Drug|Etoricoxib|Subjects will take etoricoxib 90mg by mouth just before the start of the daily fast. This will be for six days. After this they will receive placebo for eight days.
45471522|NCT01148303|Drug|Etoricoxib|This arm will receive placebo just before their fast for eight days. After this they will receive etoricoxib 90mg just before their daily fast for the next six days.
45471523|NCT01148303|Drug|Placebo|Placebo
45471524|NCT03901157|Dietary Supplement|Yogurt A: Active|Free fat yogurt containing oil-filled alginate gels
45471525|NCT03901157|Dietary Supplement|Yogurt B: Control|Free fat yogurt containing the same amount of fat as the active one, and empty alginate gels
45471526|NCT03907709|Behavioral|In-Home Addiction Treatment Program|"Treatment was delivered per treatment protocol~Primary IHAT Care Team consisted of a licensed Care Coordinator (LPN, RN, MSW, LPC, or LMFT) and two Recovery Advisors~Urine drug screens administered randomly~Appointments were scheduled per protocol for 52 weeks~Within first two weeks of care, all clients are provided an evaluation by a psychiatrist to ensure fitness for program"
45682345|NCT03743194|Drug|Exparel 266 MG Per 20 ML Injection|The local anesthetic (LA) used for the PECS II or serratus plane blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with bupivacaine HCL at a ratio not exceeding 2:1, but cannot be combined with other local anesthetics due to the concern of rapid release of encapsulated bupivacaine and subsequent local anesthetic toxicity.
45682346|NCT03743194|Drug|Placebo|Patients randomized to standard analgesia technique will be given pain medications.
46029771|NCT02675257|Behavioral|Diabetes complications|Education on diabetes complications
46029772|NCT02675257|Behavioral|Social aspects of living with diabetes|Education on social aspects of living with diabetes
46029773|NCT00928252|Drug|IV fluorine-18 labeled methylcholine before PET/CT|Intervention at pre-treatment, and at two timepoints post treatment intiation.
45471527|NCT03907787|Dietary Supplement|Zingiber officinale and Acmella oleracea|Subjects were supplied for four weeks with two tablets/day and there was the evaluation of pain intensity, by a 30-days Visual Analogue Scale (VAS) and b) the assessment of knee function by Western Ontario and McMaster Universities Arthritis Index and by Tegner Lysholm Knee Scoring collected at baseline, at 15 and 30 days after treatment, Health-related quality of life, by the ShortForm36, inflammation by C-reactive protein and Erythrocyte Sedimentation Rate, body composition by dual-energy X-ray absorptiometry measured at baseline and 30 days after treatment.
45471528|NCT03900611|Device|peripheral electrical stimulation|The subjects will undergo 8-week home-based peripheral electrical simulation on the median nerve. The peripheral electrical simulation will be performed once a day for 30 minutes. The stimulation will be active or sham depend on the group assignment.
46029774|NCT02673073|Other|Patient's diary|"Patients in the intervention arm will be educated to measure body weight, blood pressure, and heart rate every morning after using toilet. Number of remaining pills of the previous day is for the assessment of drug compliance. Degree of pitting edema is graded from 0 (no edema), 1 (mild), 2 (moderate), 3 (severe) and, degree of dyspnea is graded from 0, 1, 2, 3, corresponding to NYHA class I, II, III, and IV, respectively.~Patients are instructed to visit or call the HF-outpatient clinic, when they have (i) body weight gain more than 1 kg/day or 2kg in 7 days;(ii) aggravation of pitting edema by one degree; (iii) aggravation of dyspnea by one grade."
46029775|NCT02673073|Other|Patient's education|All patients will receive patient's information/education booklet on the heart failure including life style modification.
46029776|NCT02673229|Drug|Collagenase Santyl|A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP).
46029777|NCT02673229|Drug|Bacitracin|One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams.
46029778|NCT00644293|Drug|azithromycin (Zithromax)|azithromycin 500 mg tablet by mouth once daily for 3 days
45471529|NCT03066830|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
45471530|NCT03066830|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
45471531|NCT03066830|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
45471532|NCT03066830|Drug|Sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
45471533|NCT03907553|Diagnostic Test|targeted genome sequencing|
46029779|NCT00644293|Drug|placebo|placebo
46029780|NCT00644293|Drug|azithromycin SR|azithromycin SR 2.0 g by mouth as an oral slurry for 1 dose
46029781|NCT00644293|Drug|placebo|placebo
45682347|NCT03652636|Drug|Sulfur Hexafluoride Microspheres|2.5 mL intravenous injection given at the time of ultrasound, with second 2.5 mL intravenous injection given during ultrasound as needed to improve visualization
45471535|NCT03900455|Device|Hydrocellular polyurethane foam multilayer dressing|Application of a multilayer foam with 4 flaps that can be adapted to several areas of the body (including the sacrum) and consists of: an external polyurethane film, which is impermeable to liquids and bacteria using dynamic transpiration, which can form an impenetrable barrier to protect the skin; a protective layer that shields the skin against accidental knocks and helps to spread the pressure; a highly absorbent and leak-proof layer that traps the exudate inside; a layer of hydrocellular polyurethane foam; and, finally, in contact with the skin, a perforated evenly covered layer of silicone gel adhesive. in addition to Standard preventive care
45471536|NCT03900455|Procedure|Standard preventive care|Pressure Ulcer risk assessment using the Braden scale within 8 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score <17, daily inspection of the skin in the various pressure points and moving the patient at list every 4 hours. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure
45682348|NCT01565343|Drug|florbetapir F 18|IV injection, 370MBq (10mCi)
45754631|NCT05143567|Other|standard of care anticoagulation in absence of thrombotic complications|Subgroup IA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IB - patients receive LMWH (enoxaparin) for the prevention or treatment of VTE Subgroup IC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE
45471537|NCT05205278|Other|exercise training|The core stability training programme was performed 3 days per week over an 8-week period, and each training session lasted approximately 50 minutes.We created a special programme for our study based on the literature; the core stability training programme was divided into 3 phases: easy(1-2 weeks), moderate(3-5 weeks) and difficult(6-8 weeks In the easy phase(phase1), the athlete was intended to gain sensorimotor control that would ensure the smoothness of the neutral spine during slow movements. The participants learned the hallowing technique and how to use this technique while doing core exercises. In the moderate phase(phase2), muscular neural adaptation and neuromuscular facilitation were targeted with the transition to high threshold strength training.In the last, difficult, phase(phase3), subconscious control of movement was taught using combined movement patterns with the aim of transitioning to functional positions and activities.
45471538|NCT05205200|Drug|SHR-1316|PD-L1 antibody
45471539|NCT05205200|Drug|SHR6390|CDK4/6 inhibitor
45839092|NCT04330872|Drug|Plain Aspirin|Study participants will be assigned to receive either Plain Aspirin and will be required to continue taking them throughout the study (three days).
45471540|NCT05205200|Drug|Nab paclitaxel|Albumin bound paclitaxel
45471541|NCT05205200|Drug|SERD|Fulvestrant
45471542|NCT05205200|Drug|AI|aromatase inhibitor
45471543|NCT01149629|Drug|Droxidopa|One capsule containing 300 mg droxidopa, given once
45471544|NCT01149629|Drug|Droxidopa|3 capsules each containing 100 mg droxidopa, give 3 times at 4 hour intervals
46029782|NCT01177007|Device|TheraSphere, Yttrium-90 glass Microspheres|Patients with unilobar disease will receive 120 ± 10% Gy (dose may be lower if clinically indicated) of TheraSphere to the affected lobe. Patients presenting with bilobar disease will have their liver assessed and the lobe presenting the highest treatment priority will receive the first treatment of TheraSphere. Assigning priority of lobes to receive treatment is based on tumor bulk, associated clinical symptoms attributed to the tumor and technical/angiographic considerations. In patients with bilobar disease where the second lobe does not require immediate treatment, or in unilobar disease where tumors develop in the untreated lobe, additional TheraSphere treatment may be administered at any subsequent time. A treatment may consist of a single 120 ± 10% Gy infusion to a lobe, or, if angiography indicates the need, the 120 ± 10% Gy dose may be split into multiple infusions per lobe to ensure delivery of a total of 120 ± 10% Gy to each treated lobe.
46029783|NCT00930982|Drug|Ciprofloxacin (Cipro, BAYQ3939)|Inhalation of 32,5mg Ciprofloxacin inhaled twice a day
45471545|NCT01149629|Drug|Droxidopa|3 capsules each containing 100 mg droxidopa, given once
45471546|NCT03900143|Device|Tightra vaginal device|Vaginal device for improvement of vaginal symptoms, reduce vaginal laxity, improve sexual functioning, and treat stress urinary incontinence.
45471547|NCT05667311|Device|ECG|Finapres electrocardiography machine
46029784|NCT00930982|Drug|Placebo|Inhalation of matching placebo twice a day
46029785|NCT02673307|Behavioral|1 chewing gum over 45 minutes|
46029786|NCT05658341|Behavioral|ADA|"The 12-weeks program will include one-hour in adapted physical activity (APA), and a discussion on relaxation techniques and the undertaking of deep breathing exercises (making them APA+ sessions). A series of minute for nutrition short information sheets will be distributed at the end of each session.~Two workshops on living better after breast cancer will also be offered: one on general mobility and the other on daily nutrition.~Moreover, women will be asked to set personal challenges as a method of motivational reinforcement, and will also be called for motivational check-ins at least 3 times. Follow-up calls will allow for further individualization, motivation, and the reception of participants' concerns or remarks.~Further, participants in the intervention group will have access to a dedicated internet space containing several documents and videos on topics of concern to patients during the post-treatment phase."
46029787|NCT05658341|Behavioral|Usual Care|"Participants in the control group will be offered weekly APA sessions for 12 weeks, these sessions are based on current practices within the Siel Bleu organization. Sessions' content is adapted to people who have been treated for (all types) cancer and are based on current recommendations.~These sessions are commonly organized by Siel Bleu in hospitals, community groups or local committees of the national league against cancer organization."
46029788|NCT02677285|Other|Different type of wound|
45471548|NCT05205122|Procedure|Combined trabeculotomy-trabeculectomy with mitomycin C|Combined trabeculotomy-trabeculectomy with mitomycin C Will be done in all cases
45599296|NCT03513367|Other|Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale|"Scaling in multidisciplinary consultations in the form of a self-administered questionnaire with the help of a third party (psychologist). The child and his / her parent complete the questionnaire independently. The result of the questionnaire will then be scored.~To validate the French translation of the pediatric module of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale. The validation process is confirmatory, the scale being widely used in English. The scale will measure the quality of life of the child using two independent assessments : children and their parents."
46029789|NCT05662891|Other|Blood Flow Restriction|After randomization, a cuff was placed proximal to one lower extremity. Blood flow was restricted from 60% of the arterial occlusion pressure. The other extremity was determined as the control group. 3x5 nordic hamstring exercises were performed. Surface emg was measured for hamstring muscles during exercise.
46029790|NCT01176773|Device|hyaluronic acid gel|Dosage per Investigator's discretion to obtain lip treatment goal; 1 touch-up treatment is allowed 14 days after initial treatment. Maximum total volume per subject is 2.0 mL
46029791|NCT04102033|Drug|Eltrombopag|Thrombopietic agent approved for its efficacy in chronic immune thrombocytopenia in pediatric patients
46029792|NCT05029180|Other|Termination of resuscitation|Do estimate the approaches used worldwide when terminating resuscitative efforts
46029793|NCT04180111|Device|CATS Tonometer|CATS Tonometer Prism
46029794|NCT02887625|Drug|Pioglitazone plus exenatide|pioglitazone will be started at 30 mg/day and bydureon at 2 mg/week
46029795|NCT02887625|Drug|insulin glargine and insulin aspart|the dose will be escalated to maintain HbA1c <7.0%
46029796|NCT04180033|Diagnostic Test|Colonoscopy surveillance|Participants will be asked to undergo a first colonoscopy surveillance.
46029797|NCT02886377|Biological|blood test of anti-AQP4 antibody|Patients were sub-divided into an AQP4 seropositive group and an AQP4 seronegative group, according to blood test of the AQP4-Ab.
46029798|NCT05662813|Drug|Almonertinib|Almonertinib 110mg p.o qd. Patients receive Almonertinib treatment until disease progression, unacceptable toxicity or other discontinuation criteria.
46029799|NCT02675335|Drug|Sitagliptin|
46029800|NCT02675335|Drug|Placebo|
46029801|NCT02675101|Other|Whole Nuts|Participants will be advised on maintaining an iso-caloric diet. Aside consuming nuts, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Both walnuts and almonds will be provided to participants in the whole nut study arm.
45839093|NCT04331028|Device|Shockwave therapy|A shockwave therapy device will be applied in the alveolar socket area of a maxillary tooth, 2 weeks after tooth extraction was performed.
45839094|NCT04330794|Other|NMFACT|caries index
45839095|NCT04330794|Other|DMF index|caries index chart to collect data about decayed missed filled teeth
45839096|NCT04331106|Diagnostic Test|Online Questionnaire|Online Questionnaire via SoSci Survey
46029802|NCT02675101|Other|Olestra: Fat Free Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming fat free potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Fat Free Pringles will be provided to participants in the olestra study arm.
46029803|NCT02675101|Other|Vegetable Oil: Original Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Original Pringles will be provided to participants in the vegetable oil study arm.
46029804|NCT00928018|Drug|Sirolimus|Taken orally for at least 12 months
45599297|NCT03513367|Other|The following data of motor function|In parallel, the following data are collected on the day of the consultation: assessment of motor function (MFM, use of a wheelchair, age of loss of walking); assessment of respiratory function (EFR, FVC, respiratory assistance, type of respiratory aid); evaluation of cardiac function (FE); assessment of nutritional status (weight, height, BMI, nutritional support by gastrostomy), school status; ongoing drug treatments (corticosteroids, IEC).
45839097|NCT04330404|Behavioral|Cognitive strategy training|The Cognitive strategy training, including awareness enhancement, cognitive-related education, discussion of everyday cognitive difficulties, generation of cognitive strategies, cognitive strategy practice, and homework assignments
46029805|NCT00928018|Drug|Methotrexate|Given intravenously on the first, third and sixth day after transplant
46029806|NCT00928018|Drug|Tacrolimus|Taken orally or given intravenously for at least 6 months
46029807|NCT00928018|Drug|Cyclosporine|Taken orally or given intravenously for at least 6 months
46029808|NCT00928018|Drug|MMF|Taken orally for about 2 months
46029809|NCT04099225|Diagnostic Test|Multiple breath washout (MBW) testing|Lung clearance index (LCI), acinar (Sacin) and conductive (Scond) ventilation heterogeneity were derived from triplicate SF6-MBW measurements. Global ventilation heterogeneity was calculated for the 2.5% (LCI2.5) and 5% (LCI5) stopping points.
46029810|NCT02672839|Drug|LGD-6972 Solution|15 mg of LGD-6972
45839098|NCT04330404|Behavioral|group interactive game|The active control group will receive group interactive game, including table games and games using songs, balloons, newspapers and so on.
46029811|NCT02672839|Drug|LGD-6972 Capsules|15 mg LGD-6972
46029812|NCT00643435|Behavioral|Self-efficacy enhancing interviewing techniques training|Teaching by standardized patient instructors regarding use of self-efficacy enhancing interviewing techniques to be applied in patient encounters
46029813|NCT00643435|Behavioral|Control intervention|These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
46029814|NCT00927940|Device|MDT-4107 Drug Eluting Stent|Implantation of a MDT-4107 Zotarolimus-Eluting Coronary Stent
46029815|NCT02677129|Other|home-based exercise intervention|Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems.
46029816|NCT00609154|Drug|glucagon like peptide-1|GLP-1 1 pmole/kg/min
46029817|NCT00609154|Dietary Supplement|glucose control|glucose without GLP-1
46029818|NCT00910117|Drug|nimotuzumab|nimotuzumab 400 mg d1
46029819|NCT00910117|Drug|PF regimen (cisplatin and 5-FU)|cisplatin 75 mg/m2 d1 and 5-FU 750 mg/m2/d CIV d1-5
46029820|NCT04264936|Drug|RC48-ADC and JS001|Recombinant Humanized anti-HER2(Human epidermal growth factor receptor-2) Monoclonal Antibody-MMAE(Monomethyl Auristatin E) Conjugate For Injection and JS001 Injection
46029821|NCT04181437|Drug|NVP-1203-R1|1 tablet, Single oral dosing
46029822|NCT04181437|Drug|NVP-1203-R2|1 tablet, Single oral dosing
46029823|NCT04181437|Drug|NVP-1203-R1 and NVP-1203-R2|NVP-1203-R1,1 tablet and NVP-1203-R2, 1 tablet, co-administration, single oral dosing
46029824|NCT04181125|Other|Biodex Balance System|For the computerized evaluation of postural control, Biodex Balance System will be used.
46029825|NCT04181125|Other|Balance Error Scoring System (BESS)|For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
46029826|NCT00927862|Genetic|IWPC adapted genotype-guided dosing algorithm for warfarin|"Within the first or second dose, apply an International Warfarin Pharmacogenetics Consortium (IWPC) adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, weight, height, etc.), and VKORC1 and CYP2C9 genotypes, to individualize the initial dosing of warfarin. (IWPC algorithm submitted for publication, 5-08)~Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group."
46029827|NCT00927862|Genetic|Modified IWPC genetic-guided warfarin dosing algorithm|"Within the first or second warfarin dose, apply a modified International Warfarin Pharmacogenetics Consortium (IWPC)-adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin. The active comparator algorithm (see above) will be further modified to account for the temporal pharmacodynamics of warfarin metabolism, e.g., by ignoring the CYP2C9 variants for the first 2 days.~Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group."
46029828|NCT00927862|Other|Standard of care treatment|The parallel, standard-dosing patient control cohort was identified by a query of the electronic medical records databases of the 3 participating hospitals for the time interval spanning enrollment of the randomized pharmacogenetic cohorts (July 2008-December 2010). Patients >=18 years of age initiating warfarin therapy with a baseline and at least 1 follow-up INR level between days 3 and 14 were selected. Initial dose selection and therapy modification was at individual Intermountain-credentialed physician/healthcare provider discretion. Standard management is non-PG-based. A standard (fixed) initial maintenance dose of 5 mg/d is generally assumed.
46029829|NCT02672527|Drug|Trabectedin|
46029830|NCT02672527|Drug|Dexamethasone|
46029831|NCT04263220|Device|Industrial passive exoskeleton with a specific value of the torque of the spring for supporting the back|Both exoskeleton types are passive exoskeletons for supporting the back. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions
46029832|NCT04263220|Other|protocol will be performed without exoskeleton|protocol will be performed without exoskeleton
46029833|NCT00976989|Drug|Pertuzumab|840 mg loading dose intravenously (IV), then 420 mg IV 3-weekly.
46029834|NCT00976989|Drug|Trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg every 3 weeks.
46029835|NCT00976989|Drug|FEC|5-fluorouracil 500 mg/m^2, epirubicin 100 mg/m^2 and cyclophosphamide 600 mg/m^2.
46029836|NCT00976989|Drug|Docetaxel|75 mg/m^2 for the first dose; 100 mg/m^2 if no dose limiting toxicity occurs.
46029837|NCT00976989|Drug|TCH|Trastuzumab followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m^2. All treatments were given every three weeks by the IV route.
46029838|NCT05449171|Other|high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D|Patients will take an association of high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D, from the first visit at the experimental center (within the 12th week of gestation) for 3 months.
46029839|NCT00927784|Biological|Mesenchymal Precursor cells (RevascorTM)|Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs (in sequential cohorts).
46029840|NCT00927784|Drug|Cryoprotective media alone|Participants will receive intramyocardial injections of cryoprotective media (placebo).
46029841|NCT02675023|Biological|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
46029842|NCT04290117|Behavioral|Acceptance and Commitment Training|During the ACT-based intervention, participants will get 4 training sessions in groups, once a week for an hour. Additionally, participants will be asked to implement behavioural exercises such as mindfulness and value-based exercises into their daily schedule.
46029843|NCT04290117|Behavioral|Sleep Hygiene and bright light in the morning|During the chronobiological intervention, participants will get 4 training sessions in groups, one hour per week. Additionally, they will use a daylight lamp at home, for 30 minutes per day after waking up.
46029844|NCT02672605|Other|Pennsylvania State Abortion Consent|Measuring the level of stigma felt pre- or post-exposure to the abortion consent language.
45471549|NCT03907085|Other|HILT + exercise|High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
46029845|NCT04260100|Behavioral|Diabetes Care Self-Management Mobile Health Application|In day 1, the participant will receive a Foot Care Kit consist of a mirror, a tube of lotion, a small towel, and a nail clipper. The participant will enrol in 3-hour workshop for general management of diabetes mellitus, diabetic foot care and dietary management. The participant will be invited to install Diabetes Care Self-Management Mobile Health Application. The mobile application is meant for sources of referral for diabetic foot care and dietary care, and for record purpose (diary) of any foot care activities carried out that participant needs to enter in the application during his/her home. The participant will be trained for the use of Diabetes Care Mobile Health Application. In addition, the participant will be invited to join a WhatsApp group for the medium of communication. The program will be lasting for 5 weeks.
45471550|NCT03907085|Other|Placebo HILT + exercise|Placebo HILT group; Placebo therapy was applied in five sessions a week for three weeks, with a total of 15 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
45471551|NCT04379336|Biological|Bacille Calmette-Guérin (BCG)|BCG vaccine will be given intradermally in the upper arm after randomization.
45471552|NCT04379336|Other|Placebo Comparator|Placebo injection will be given intradermally in the upper arm after randomization.
45471553|NCT03900065|Procedure|Preconditioning|Foam-mediated intermittent negative pressure will be applied to the skin of the planned flap for 5 days before surgery.
45599298|NCT01337297|Device|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation (tDCS) will be applied by electrodes (5 x 7 cm2), with intensity of 2 mA, during 20 min, with cathode over the left dorsolateral prefrontal cortex (F3 site) and anode placed in the contralateral dorsolateral prefrontal cortex (F4 site).
46029846|NCT04179487|Diagnostic Test|OPTICA CTPA Protocol|Low dose CT pulmonary angiogram protocol
46029847|NCT04270227|Other|Survey study|The questionnaire including Exercise Benefits / Barriers Scale, IPAQ (International Physical Activity Survey), The Bady Awareness questionnaire and demographic information will be filled in one time by face-to-face interview method.
46029848|NCT05331352|Behavioral|Semi-structured interviews|Interview
46029849|NCT05331352|Behavioral|Projective methode|Rorschach + thematic aperception test
46029850|NCT05331352|Behavioral|Selfreported|RSQ - PBI - RFQ - QSCPGS - SSQ6 - ÉCHELLES DE CUNGI - STAI - PCL-S - IES-R
46029851|NCT00644371|Drug|Ibritumomab Tiuxetan (Zevalin)|"Conditioning Regimen~Rituximab, 250 mg/m2 on days -21 and -14.~Ibritumomab tiuxetan (Zevalin): 0.4 mCi/kg (14.8 MBq/kg). Maximum: 32 mCi on day -14.~Chemotherapy:~Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~Melphalan 70 mg/m2/day on days -3 and -2 as a 15-min infusion.~Chemotherapy for relapsing patients after autologous transplantation including melphalan over the last 6 months:~Thiotepa 5 mg/kg over 4 hours every 12 hours on day -8.~Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~Melphalan 70 mg/m2/day on day -2 as a 15-min infusion."
45599299|NCT03510793|Drug|balanced anesthesia|patients undergoing open elective abdominal aortic aneurysm repair will receive balanced (desflurane + remifentanil) anaesthesia
46029852|NCT04963972|Behavioral|Behavioral Intervention|Participate in Lucid Lane therapy program
46029853|NCT04963972|Other|Best Practice|Receive standard of care opioid education
46029854|NCT04963972|Other|Questionnaire Administration|Ancillary studies
46029855|NCT02677207|Drug|JNJ-39393406|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
46029856|NCT02677207|Drug|Placebo|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
46029857|NCT02864199|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered for 12 to 48 weeks. The dose will range from 135 mcg (Group C) to 180 mcg (Groups A, B, and D) once weekly via SC route.
45471554|NCT05208632|Other|INTERSCALEN BLOCK APPLICATION WITH USG|40 patients, including ASA1-2, 20 patients over the age of 18, who were planned for upper extremity surgery, in the interscalen group, and 20 in the supraclavicular group, were included in the study. Demographic data of the patients were recorded by measuring PI and PVI values at baseline before the block and at the 1st, 5th, 10th, 15th, and 20th minutes after the block, both simultaneously.
45471555|NCT03907007|Device|Percutaneous electrical nerve stimulation|Stimulation and medication at the same instant
45471556|NCT03907007|Device|Percutaneous electrical nerve stimulation|Stimulation is given without administering medication
45471557|NCT04360616|Diagnostic Test|imaging|perform US and mammography examination
45471558|NCT03907163|Drug|Dronabinol|Capsules containing 5 mg Dronabinol
46029858|NCT02864199|Drug|Ribavirin|Ribavirin will be administered for 12 to 48 weeks. The total daily dosage will range from 200 mg (Group C) to 1200 mg (Group D), depending upon CrCl and participant-specific factors.
45471559|NCT03907163|Other|Placebo|capsules identical in appearance to dronabinol
45471560|NCT04330274|Other|Bipedal with open eyes|Standing bipedal with open eyes on force platform
45471561|NCT04330274|Other|Bipedal with closed eyes|Standing bipedal with closed eyes on force platform
45471562|NCT04330274|Other|Bipedal with open eyes and with platform|Standing bipedal with open eyes and with platform under heel of prosthetic foot on force platform
45471563|NCT04330274|Other|Bipedal with closed eyes and with platform|Standing bipedal with closed eyes and with platform under heel of prosthetic foot on force platform
45471564|NCT01149707|Drug|PUR 0110 Rectal Enema 250 mg|PUR 0110 Rectal Enema 250 mg, once-daily, intrarectally
45471565|NCT01149707|Drug|PUR 0110 Rectal Enema 500 mg|PUR 0110 Rectal Enema 500 mg, once-daily, intrarectally
45471566|NCT01149707|Drug|PUR 0110 Rectal Enema 1000 mg|PUR 0110 Rectal Enema 1000 mg, once-daily, intrarectally
45471567|NCT01149707|Drug|Placebo Enema|Placebo Enema, once-daily, intrarectally
46029859|NCT05911269|Other|TiMBRe|"1 & 2 Music Listening~Live music played by the music therapist (e.g., guitar, voice) and AYA selected music will be used to facilitate attention to the present moment and provide cues for breathing/relaxation.~3 & 4 Music Facilitated Breathing~The therapist will lead participants in music facilitated breathing exercises using rhythmic features of the music to cue structured breathing for relaxation and self-awareness~5 & 6 Music Facilitated Progressive Muscle Relaxation for Stress Reduction~Using music as a structured auditory cue for tensing and releasing of muscles.~7 & 8 Body Percussion~The therapist will lead participants in a hands-on body percussion activity to bring attention to the sound of rhythm, sensation in their hands and body."
46029860|NCT05911269|Other|Control|Standard of care study staff calls and cancer survivorship resources
46029861|NCT05911256|Behavioral|Pharmacist Only|Clinical pharmacists conduct encounters with patients by videoconferencing or phone. Pharmacists conduct a broad range of activities including ongoing evaluation of medication and lifestyle adherence, setting therapeutic goals, formulating a provider-approved plan of care, and documenting the plan in the electronic health record. Pharmacists propose medication changes based on algorithms and protocols derived from national guidelines under physician guidance.
46029862|NCT05911256|Device|Continuous Glucose Monitor (CGM)|Patients will receive the Continuous Glucose Monitoring (CGM) system. The instruction on use of device is the intervention being tested, not the effectiveness of the device itself. Participants will receive instruction and training on how to use the device and will wear the device for 14 days.
45471568|NCT04320680|Other|description of a lupus patient cohort|description of a lupus patient cohort
45471569|NCT05761496|Device|Biliary stents insertion|Endoscopic placement of plastic and metal biliary stents
45471570|NCT01253681|Drug|AMG 386, paclitaxel and carboplatin|15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
46029863|NCT05911256|Behavioral|Community Health Worker (CHW)|Patients are connected to a community health worker(CHW). CHWs conduct home visits and facilitate 3-way Telehealth visits (Patients, pharmacists, and CHWs) via an iPad with cellular plan. Additional CHW activities include social determinants of health screening, health behavior education, problem solving, goal setting, and medication adherence support.
45682349|NCT03740932|Diagnostic Test|Study group (group A)|"Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
46029864|NCT05911217|Drug|CT041 autologous CAR T-cell injection|Treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion. Up to 3 times CT041 autologous CAR T-cell injection infusion
46029865|NCT05911204|Other|Questionnaire about intense noises exposure during pregnancy|Response to questionnaire given within 3 days after delivery about noise exposure
46029866|NCT05911191|Other|Exercise based prehabilitation|A peripheral muscle strengthening program
46029867|NCT05911178|Radiation|[11C]-UCB-J|"PET tracer binding to SV2A protein, used to study synaptic vesiscle density."
45682350|NCT03651700|Device|Active TMS|Active TMS will be at 90% motor threshold
45682351|NCT03651700|Device|Sham TMS|Sham TMS will be administered
45682352|NCT03651700|Behavioral|CILT|60-90 minutes of CILT will be administered during each treatment session
46029868|NCT05911178|Radiation|[18F]-DPA-714|"PET tracer binding to TSPO protein, used to study microglial activation."
46029869|NCT05911178|Radiation|[18F]-RO-948|"PET tracer binding to tau protein, used to study the topograhpy of tau deposition."
46029870|NCT05911178|Radiation|[11C]-PiB|PET tracer binding to Aβ40 and Aβ42 fibrils and insoluble plaques containing the aforementioned Aß peptides, used to study the topography of amyloid deposition.
46029871|NCT05911126|Drug|Celecoxib 200 mg, Hyoscine-N-butyl bromide (HBB), placebo tablet|Tablet form received prior to the procedure
46029872|NCT05911113|Other|sensory re-education training|the patients will receive sensory re-education training in the form of texture discrimination training, limb position sense and tactile object recognition
46029873|NCT05911113|Other|traditional treatment|the Patients in this group will receive traditional treatment in the form of proprioception neuromuscular facilitation (PNF) and graduated active and resisted wrist and hand muscle strengthening exercises.
46029874|NCT05911087|Biological|Phase II:SWIM816;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are 2 groups in phase 2 stage, total number 200 subjects who are ≥18 years old. Details as below:~Group 1: (N=100) - SWIM816 25 μg; Group 2: (N=100) - SW-BIC-213 25 μg;"
46029875|NCT05911087|Biological|Phase II:SW-BIC-213;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are 2 groups in phase 2 stage, total number 200 subjects who are ≥18 years old. Details as below:~Group 1: (N=100) - SWIM816 25 μg; Group 2: (N=100) - SW-BIC-213 25 μg;"
46029876|NCT05911087|Biological|PhaseIII:SWIM816;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are two groups in phase 3 stage., total number 600 subjects who are ≥18 years old. Details as below:~Group 1: (N=300) - SWIM816 (≥18 years old ) Group 2: (N=300) -Pfizer Bivalent vaccine (≥18 years old)"
45599300|NCT03510793|Drug|Total intravenous anesthesia|patients undergoing open elective abdominal aortic aneurysm repair will receive total intravenous (propofol + remifentanil with target-controlled infusion) anesthesia
45599301|NCT02336997|Procedure|FAT-GRAFT|Liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin at the density of 0.1 ml/cm2.
45599302|NCT02336997|Procedure|SVF-TRANSPLANTATION|Liposuction will be performed. SVF will be separated from autologous fat graft by collagenase digestion. Patients will receive resuspended SVF transplantation subdermally to expanded skin at the density of 1*10e6 cells/cm2.
45599303|NCT02336997|Procedure|PLACEBO|Saline will be injected into expanded skin.
45599304|NCT02299453|Behavioral|IPT|Nine sessions of telephone-administered interpersonal psychotherapy (IPT)
46029877|NCT05911087|Biological|PhaseIII:Pfizer(Pfizer Bivalent vaccine);SARS-Cov-2；|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are two groups in phase 3 stage., total number 600 subjects who are ≥18 years old. Details as below:~Group 1: (N=300) - SWIM816 (≥18 years old ) Group 2: (N=300) -Pfizer Bivalent vaccine (≥18 years old)"
46029878|NCT05911074|Diagnostic Test|The Abbott Panbio™ COVID-19 Ag Rapid Test|This is the intervention or medical device(s) intended to be used with a study participant according to the study protocol.
45682353|NCT00003460|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a primitive neuroectodermal tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
46029879|NCT05911061|Biological|High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)|boost with high dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
46029880|NCT05911061|Biological|Low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)|boost with low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
45839099|NCT04330326|Drug|Metabolic Cofactor Supplementation|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
46029881|NCT05911061|Biological|control group|boost with Recombinant Variant COVID-19 Vaccine(sf9 cell)
46029882|NCT05911061|Biological|Placebo group|saline
46029883|NCT05911048|Biological|Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)|boost with Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)
46029884|NCT05911048|Biological|Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)|boost with Recombinant COVID-19 vaccine (Sf9 Cell) (WSK-V101)
46029885|NCT05911009|Drug|BC 007 or matching placebo|Participants will be treated with two infusions of BC 007 or placebo two weeks apart, according to a double-blind design
45471571|NCT05204966|Diagnostic Test|AI analysis|"Bottle feeding filming~- With a camera that can measure depth, take a video of feeding milk from a bottle for 5-10 minutes.~NOMAS (Neonatal Oral-Motor Assessment Scale) evaluation~Evaluate NOMAS with bottle feeding video by certified evaluators.~NOMAS, developed by Marjorie Meyer Palmer in 1983, is an evaluation method for dysphagia applicable to infants under 48 weeks of PMA.~Implementation of video analysis using deep learning (A) Analysis method - Implement a deep learning network that sets keypoints of faces and environments related to swallowing and detects specified keypoints in units of frames.~(B) Analyze the movement of key points, and figure out the correlation between swallowing states.~(C) Create an input/output process that can automatically classify swallowing states with video as input."
45471572|NCT01149941|Drug|Ibuprofen|Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
46029886|NCT05908565|Behavioral|Demographic Matching|At randomization, students will be randomized to a Latinx or non-Latinx coach and will be informed whether or not their coach identifies as Latinx. Although we are not recruiting coaches or matching coaches with participants based on gender, gender identity or lived experience with mental health problems, we will collect these data from coaches in order to do conduct secondary exploratory analyses examining these variables as predictors or moderators of outcome.
46029887|NCT05908565|Behavioral|Supervision Intensity|Coaches will be assigned to either standard supervision or reduced supervision, with equal distribution across Latinx vs non-Latinx. Coaches assigned to standard supervision will receive weekly supervision by a licensed provider consistent with the procedures outlined in the Data and Safety Monitoring Plan for the Signature Project. Coaches assigned to reduced supervision will attend weekly group supervision, but their session recordings or live sessions will not be reviewed by licensed supervisors or advanced peers and they will not receive personalized feedback about how they are performing in their sessions. Students will not be informed which supervision condition they have been assigned to in order to maintain high treatment expectancies. Of note, this design prohibits the coach and supervisors from being blind to participant condition.
46029888|NCT05908539|Behavioral|Equipment box|Participants receive a box of exercise equipment containing dumbbell, elastic band, hand cycle machine, and booklet of exercise instruction only.
46029889|NCT05908539|Behavioral|Equipment box with briefing|Participants receive a box of exercise equipment containing dumbbell, elastic band, hand cycle machine, and booklet of exercise instruction, and they are given verbal briefing on how to use the equipment.
46029890|NCT05908539|Behavioral|Exercise training|Participants receive al box of exercise equipment. They attend an 8-week group exercise training program for 1 hour /session and 1 session/ week, and are supervised by a physical fitness training. The exercise program includes a combination of aerobic, resistance, balance and flexibility exercises.
45471573|NCT01253759|Procedure|TTT + ICG-based PDT|
45471574|NCT01589549|Biological|Mesenchymal stromal cell therapy|One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy
45839100|NCT04330326|Drug|Sorbitol|As placebo, sorbitol (5 g) flavored with strawberry aroma and coloring agent will be given. Sorbitol is widely used due to its solubility in water. It's approved by the U.S. Food and Drug Administration (FDA).
46029891|NCT05908539|Behavioral|Exercise training with behavioral modification|Participants receive al box of exercise equipment. They attend an 8-week group exercise training program for 1 hour /session and 1 session/ week, and are supervised by a physical fitness training. The exercise program includes a combination of aerobic, resistance, balance and flexibility exercises. After finishing the exercise training program, a 6-week behavioral modification is provided. Two home visits and four telephone visits are conducted to empower the participants for exercise at home.
46029892|NCT05908526|Behavioral|Baseline surveys, Cognitive testing and EMAs|Outcome assessments are conducted at two weeks while participants are on study treatment or placebo and include self-report questionnaires and cognitive testing administered by computer.
46029893|NCT05908526|Device|Actiwatch|Participants will wear an actiwatch for 16 days while completing EMA surveys. It has a small sensor that tracks motion.
46029894|NCT05908526|Drug|suvorexant (or placebo)|FDA approved which is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
46029895|NCT05908526|Other|Placebo|An inactive substance that looks like the drug or treatment being tested.
45471575|NCT03906773|Other|Patient Centered Medical Home Based Electronic Framework for Advance Care Planning|The intervention tested a pre-visit ACP workflow centered around a framework sent via secure Electronic Health Record (EHR)-linked patient portal in a real world clinical setting. The primary objectives were to determine its impact on frequency and quality of ACP documentation.
45471576|NCT03899675|Dietary Supplement|Placebo|On the first day of collection, the volunteers will not take placebo intake, the data will be collected in a standardized way, respecting the times defined for the analysis of the cardiac activity. Then the collection will be continued. On the next day of evaluation, volunteers will receive a capsule containing 300 mg of placebo and will be advised to consume 1 hour before the procedure.
45471577|NCT03899675|Other|Caffeine|On the first day of collection, the volunteers will not take caffeine intake, the data will be collected in a standardized way, respecting the times defined for the analysis of the cardiac activity. Then the collection will be continued. On the next day of evaluation, volunteers will receive a capsule containing 300 mg of caffeine and will be advised to consume 1 hour before the procedure.
46029896|NCT05908513|Drug|N-acetylcysteine|Will be used as capsule form, 600mg per day if the patient can tolerate it. If not, we may decrease the dosage.
45471578|NCT03899909|Drug|GLPG3121 SAD|GLPG3121 oral suspension, single ascending doses
45471579|NCT03899909|Drug|Placebo SAD|Placebo oral suspension
45471580|NCT03899909|Drug|GLPG3121 MAD|GLPG3121 oral suspension, multiple ascending doses, daily for 13 days
45471581|NCT03899909|Drug|Placebo MAD|Placebo oral suspension, daily for 13 days
45471582|NCT03906383|Other|Remote Ischemic Conditioning|Brief reversible restriction of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
46029897|NCT05908513|Drug|Placebo|Similar chemical structure of NAC but without function
46029898|NCT05908500|Other|CPR Training|Various methods of CPR training are implemented and compared
45471583|NCT01150019|Other|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
45471584|NCT04380961|Drug|Sirukumab|Participants will receive single dose infusion of sirukumab on Day 1.
45471585|NCT04380961|Drug|Placebo|Participants will receive placebo IV single dose infusion on Day 1.
45471586|NCT04380961|Other|Standard of Care (SOC)|SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
45839101|NCT04329936|Behavioral|Retention center Geispolsheim population|All recently held individuals in the retention center can be included in the study after signing the information and consent protocol.
45839102|NCT04329858|Procedure|silver modified glass ionomer|occlusal cavity filled with silver modified
45839103|NCT04329858|Procedure|zinc modified|occlusal cavity filled with zinc modified
45839104|NCT04329858|Procedure|conventional glass ionomer|occlusal cavity filled with conventional glass ionomer
45839105|NCT04329468|Device|DS-MCE|"The subjects swallowed the MCE to investigate the esophagus repeatedly by pulling up or down the string. After completion of the esophageal examination, MCE reached the stomach and was lifted away from the posterior wall, rotated if necessary and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After finishing the stomach examination, the capsule would enter the duodenum due to peristalsis when the pylorus opened. Then DS-MCE tried to inspect the duodenum repeatedly under the string and magnetic field control, including view of major papilla in the descending part of duodenum and retrograde view of pylorus in duodenal bulb with a 360-degree automatic scanning mode. After completion of the duodenum examination, the capsule started to view the small bowel."
45839106|NCT01628250|Procedure|laparoscopic complete mesocolic excision|laparoscopic complete mesocolic excision would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications. Lap.CME facilitaes medial approach to complete the procedure. CME and HMA are the two arms of the medial approach utilized.
45839107|NCT01628250|Procedure|D3-laparoscopic colectomy|D3-laparoscopic colectomy would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications.
45471587|NCT01253837|Drug|L19TNFa|"Phase I: Sequential assignment of Patient cohorts to one of six dose levels of L19TNFa: 1.3, 2.6, 5.2, 7.8, 10.4, 13.0 µg/kg.~Phase II: The Recommended Dose (RD) of 13.0 µg/kg of L19TNFα determined in Phase I.~Schedule: Infusions of L19TNFα on days 1, 3 and 5 of each 21-day cycle. Patients may remain on treatment for a maximum of six 21-day cycles."
46029899|NCT05908487|Behavioral|AA Communities Speak to Healthcare Professionals|The training program is designed to empower clinicians to improve goal-concordant EoL care delivery by using community-developed storytelling videos to create empathy with experiences of racism in EoL care, guidelines for culturally concordant EoL care delivery, and implicit bias recognition and management training to mitigate bias in goals of care communication.
46029900|NCT05908474|Dietary Supplement|Enriched fibre water|Blend of scientifically substantiated ingredients has been demonstrated to contribute to the reduction of body weight and aid the sustainability of weight loss by providing a healthy, hunger-free weight management system. iofibrewater, makes fibre and gut health simple and refreshing. Each 500 ml bottle of ió fibrewater provides 20%* of your recommended daily fibre intake and 100%* of your daily prebiotic fibre intake with minimal calories and carbohydrates, making us suitable for people on a variety of diets. ió fibrewater is a functional water infused with prebiotic fibre (aka prebiotics), which leads to sub-optimal gut health and often the onset of digestive disorders. By adding more prebiotic fibre to our diet, we can quickly change the environment in our gut for the better healthy living.
45599305|NCT02341443|Procedure|Implants|"Experimental arm: Rigid~Surgical treatment using arch bars and according to the following fixation:~Rigid fixation on one side (most anterior fracture) and non-rigid fixation on the other (most posterior fracture).~Active comparator: Non-rigid~Surgical treatment using arch bars and according to the following fixation:~Non-rigid fixation on both fracture sides.~Whereas non-rigid fixation is defined as a single miniplate of ≤1.00 mm thickness, and rigid fixation is defined as a single plate of ≥1.25 mm thickness, a combination of 2 plates or a 3D geometric plate."
45682354|NCT03646786|Device|Virtual reality tests|"The patient will complete 3 self-questionnaires and pass 3 exploratory tests of virtual reality:~10 minutes sitting test: detection of 5 targets in a 360 ° field of vision~10-minute stand-up motionless test: detection of 5 targets in a 360 ° field of view and placing ingredients of a recipe~Standing 10-minute test: the patient moves to the site of his mission, detection of 5 targets in a 360 ° field of vision and preparing a recipe"
45682355|NCT03646630|Procedure|Quadratus Lumborum Block|Posterior or QL block type 2 , a bolus of 0.5 ml/Kg bupivacaine 0.25%
46029901|NCT05908461|Behavioral|Early Childhood Friendship Project|Classroom-based intervention where teachers will implement 8 10-minute puppet shows, 7 5-minute active gross motor activities to reinforce the social skill of the week, and 7 5-minute passive rehearsal activities such as making their own puppet and practicing the steps of the week. Up to three 1 hour in vivo behavioral reinforcement periods will occur per week and during these free play sessions teachers and the main puppet will use developmentally appropriate praise to reinforce the use of the social skills of the week.
45682356|NCT03646630|Procedure|Caudal Block|caudal block with 1 ml/kg of bupivacaine 0.25%.
45682357|NCT03844048|Drug|Venetoclax|oral; film-coated tablets or tablets for oral suspension
46029902|NCT05908448|Device|13 CGM (continuous glucose monitor)|The I3 CGM consists of three main components: a Sensor Pack (Applicator-Sensor assembly), a Transmitter Pack (with Bluetooth Low Energy (BLE)) and a mobile application (I3 CGM App). The user can view their glucose data on the I3 CGM App running on a compatible mobile device.
45599306|NCT02299531|Other|Varying meal energy density and portion size|
45599307|NCT02234375|Drug|Gadolinium|agents will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agents to assess their feasibility as an alternative to Iodine based contrast agents
45599308|NCT02341521|Drug|OC000459|Taken orally for 8 days
45682358|NCT03842956|Procedure|Primary wound closure in Allgower Technique vs. secondary open wound healing of pin-sides after removal of the fixated-externe|We compare the outcome of primary wound closure (Allgower) and secondary open wound healing by comparing infection-rates, use of antibiotics, reoperation-rates, satisfaction of the patients and optical results using the Vancouver scar scale
45682359|NCT04763122|Other|not applicable as it is a retrospective study|It is a retrospective study
46029903|NCT05908435|Behavioral|Dispensers, Flyers, Enhanced Signage + a social media component delivered by teen ambassadors|The study intervention is designed to increase utilization of free sunscreen dispensers, applying and reapplying sunscreen, and motivating use of other forms of sun protection by teens. IMPACT Melanoma will install and maintain free sunscreen dispensers at the study sites. Flyers will be posted at locations at the park/beach to inform people of the availability of free sunscreen and the location of the dispenser. 'Teen enhanced' signage will be present on the dispenser in the intervention parks/beaches. Teen ambassadors will share 3-5 posts to their social media platform over the course of 1 week encouraging sun protection practices and use of the free sunscreen dispenser (when the intervention is occurring at the study site).
46029904|NCT05908422|Device|Alvision™ Interventional Cardiology Diagnostic Catheter|The Alvision™ Interventional Cardiology Diagnostic Catheter is a single use only, thin, flexible single lumen tube, with a proximal hub, sterilized with ethylene oxide (EO) gas, non-pyrogenic. The product is defined as a catheter to inject a contrast medium into selected blood vessels.
46029905|NCT05908396|Drug|IGM-2644|IGM-2644 is an engineered, bispecific IgM antibody directed against CD3 and CD38. IGM-2644 is designed to bind to CD38 to selectively target and kill myeloma cancer cells through both T-cell dependent cellular toxicity (TDCC) and complement dependent cytotoxicity (CDC) activities.
45682360|NCT03836872|Device|Acupuncture|Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints although there will be flexibility in case some points cannot be punctured (e. g. in case of lymphoedema), and alternative points (as in routine practice) may be selected by the acupuncture practitioner using their discretion to maintain an equal dose of treatment to all patients. Bilateral acupoints will be stimulated. These points will include Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
45682361|NCT03836326|Other|Sensorimotor intervention|Sensorimotor intervention involves, stroking of the whole body including the oral structures, trunk and limbs. This intervention does not involve any drugs or medical procedure.
46029906|NCT05908383|Drug|GMDTC for injection|GMDTC for injection with a specification of 0.5g/vial, 250mg,500mg,850mg,1200mg,1600mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
46029907|NCT05908383|Other|Normal saline|0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
46029908|NCT05908370|Procedure|Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)|Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)
45599309|NCT02234453|Device|Minicare H-2000|Patients will use the Minicare H-2000 at home to measure their capillary blood count, temperature, record questionnaire results and transfer the results via the 3G network to the hospital team.
45682362|NCT03836326|Other|Control|Routine care provided by health professionals in the NICU
45682363|NCT03836248|Other|Osteopathic treatment|"5 osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and treatment of necessary elements and a control of osteopathic treatment at the end of the session."
45682364|NCT03836248|Other|Sham osteopathic treatment|"5 sham osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and only contacts for no intent to treat. At the end of the session a control of the sham osteopathic treatment is performed."
45682365|NCT03836248|Other|Current practice Medication treatment|Analgesic medication of level 1 or a combination of level 1 and 2. Acetaminophen 1 g x 3 / day Ibuprofen 400mg x 3 / day
46029909|NCT05908357|Other|Exergaming|Use of the exergame XboX 360 series with kinect sensor
46029910|NCT05908357|Other|Booklet|Use of the booklet with instructions of exercises to be done at home with tele-health through whatsapp app.
46029911|NCT05908344|Device|Activated Sleep Pad system (Frequen-ZZZ)|The investigational device is a sleep pad and bedside controller system capable of producing a low-level magnetic field potential via radiofrequency. An individual laying in the correct orientation and with correct contact distance from the pad portion of a powered device experiences its specific area of effect. The field potentials generated by the pad are hypothesized to have benefit for sleep.
45599310|NCT05230797|Drug|Zinc oxide Propolis|antibacterial and anti-inflammatory
45599311|NCT05230797|Drug|Zinc Oxide-Eugenol Cement|Antimicrobial and antiseptic
45599312|NCT02039349|Drug|PF-05190457|
46029912|NCT05908344|Device|Deactivated Sleep Pad system (Frequen-ZZZ)|The investigational device is a sleep pad and bedside controller system that produces a low-level magnetic field potential via radiofrequency. An individual laying in the correct orientation and with correct contact distance from the pad portion of a non-powered device experiences all functional aspects of the device except the intended magnetic field potential that is hypothesized to have benefit for sleep.
46029913|NCT05908318|Behavioral|olfactory training|In this group, patients were performed 24-48h before surgery used phenylethyl alcohol (rose), phytol (press tree), citronella (lemon), eugenol (clove) 4 kinds of smell，twice a day for three days.
46029914|NCT05908305|Drug|articaine@ (4% 1:100000 epinephrine) dental anesthesia|Administration, calculation and adjustment of dental local anesthesia doses.
46029915|NCT05908292|Procedure|Episiotomy Scar Tissue Self-Scar Massage|Self scar-massage intervention of healed episiotomy scar for 5 minutes, 3x/week for 6 weeks.
46029916|NCT02672995|Radiation|Fractionated stereotactic radiosurgery|"Fractionated stereotactic radiosurgery:~Group 1: tumors 1.5~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break."
46029917|NCT02672995|Drug|bevacizumab|"Concurrent bevacizumab:~Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab."
46029918|NCT05908279|Other|Walking test|Walk with and without a metronome
46029919|NCT05908279|Other|Disease assessement|Disease stage assessed by a doctor
46029920|NCT05908266|Other|Reaching movements|Participants will be instructed to perform reaching movements by moving the handle of a robotic arm mounted with a virtual reality display.
46029921|NCT05908266|Other|Disease Assessment|Disease stage assessed by trained professionals
46029922|NCT05908253|Behavioral|sham neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop sham neurofeedback protocol.
46029923|NCT05908253|Behavioral|nonadaptive neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop nonadaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an open-loop attention model of the corresponding human subject.
46029924|NCT05908253|Behavioral|adaptive neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop adaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an adaptive algorithm.
45682366|NCT03835312|Procedure|Sequential transplantation|After successful matching of umbilical cord blood stem cells, patients will receive pretreatment and chemotherapy under protective isolation, followed by thawing and reinfusion of umbilical cord blood stem cells. Immunosuppressive agents will be used for GVHD prevention and anti-infection support will be provided after reinfusion. The status of umbilical cord blood stem cell implantation, immune reconstruction and therapeutic effect will be evaluated. Islet transplantation will be performed in those who meet the conditions. The long-term prognosis will be observed by long-term follow-up.
46029925|NCT05908240|Other|Care Coordinator Model|A centralized care coordinator at the National Psoriasis Foundation will provide evidence-based education regarding a heart healthy lifestyle (i.e., diet, exercise, smoking cessation) and guidance from the American Heart Association/American College of Cardiology regarding management of dyslipidemia and hypertension. This information will be conveyed to a primary care provider of the patient's preference.
46029926|NCT05908227|Other|NHF high|Nasal high flow therapy 8L/min.
46029927|NCT05908227|Other|NHF low|Nasal high flow therapy 6L/min.
46029928|NCT05908227|Other|NCPAP|Nasal continuous positive airway pressure 6 cm H20
46029929|NCT05908214|Other|wide pulse high frequency neuromuscular electrical stimulation training|Plantar flexors will be stimulated with wide pulse high frequency neuromuscular electrical stimulation 3 times a week for 6 weeks
45682367|NCT04762420|Other|Dose of sugammadex according to SSD and QSD|At the time of pharmacologic reversal of the NMB, both the SSD and QSD, according to portuguese guidelines on the management of the NMB, were recorded. The QSD was then administered to the patient. The SSD was considered appropriate if it was within 10% of the recommended dose for the given depth of NMB, as measured by TOFscan® monitor. The results were analyzed descriptively.
45682368|NCT04747132|Other|Telegeriatric intervention|Individualized, comprehensive and specialized counseling for older adults through the Internet
46029930|NCT05908201|Behavioral|early time restricted eating|The intervention group will eat in a prescribed daily feeding window (9am-5pm) and follow their normal exercise and resistance training routines. We will allow up till +/-1 hour for the eating window start and end times while aiming for an 8 hour eating window.
46029931|NCT05908175|Other|FES-assisted gait training|The participants will walk with functional electrical stimulation (and possible body weight support) on a treadmill for 10 weeks, twice a week for 30 minutes.
46029932|NCT05908162|Diagnostic Test|Bood leukocyte subsets|Determination of blood leukocyte subpopulations, subpopulation of monocytes and expression CD64 on neutrophils
46029933|NCT05908149|Device|Insole Splint|Insole splint used in 'Pes equinus' in patients with hemiplegia
46029934|NCT05908110|Behavioral|Health Communication Message|The health communication message is a single infographic developed iteratively with input from stakeholders (parents and providers). This image informs the parent that their child may have OSA, lists common nighttime symptoms parents may observe (e.g., snoring, apnea) and common daytime symptoms (e.g., hyperactivity, sleepiness) that can result from OSA. Parents are then encouraged to speak to their child's primary care provider if they observe these symptoms in their child.
46029935|NCT05908097|Device|Virtual Reality Avatar Intervention|In the Virtual Reality Avatar Intervention experience, participants will see an avatar resembling themselves in a park setting. The Virtual Reality Empty Park experience is a habituation experience that does not contain avatars.
46029936|NCT05908097|Device|Virtual Reality Empty Park|The Virtual Reality Empty Park experience is a habituation experience that does not contain avatars.
46029937|NCT05908084|Biological|HAV|HAV implantation
46029938|NCT05908084|Other|AVF|AVF creation procedure
45682369|NCT03642106|Behavioral|Unidos Se Puede|The intervention consists of: (1) encouraging parental involvement in child schooling, general parenting skills, and coping strategies ; (2) fostering child social emotional learning (SEL) through assigning a near-peer success coach to help develop critical thinking, problem solving, and goal setting skills; and (3) promoting positive peer affiliations through participation in regular activities that facilitate bonding to prosocial institutions.
45754632|NCT05143567|Other|standard of care anticoagulation in presence of thrombotic complications|Subgroup IIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) for the prevention or treatment of VTE Subgroup IIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE
46029939|NCT05908045|Other|KAP Survey|This is a cross-sectional study that utilizes a KAP (knowledge, attitude, and practice) survey. This type of survey can be conducted on a representative sample of physical therapists who are currently involved in clinical practice. These types of surveys are useful for identifying gaps between what people know and how they act on that knowledge. There have been previous studies that have utilized KAP surveys when identifying knowledge, attitude, and practice behaviors of physical therapists.
46029940|NCT05908032|Biological|CM310|IL-4Rα monoclonal antibody
46029941|NCT05908032|Biological|Placebo|Placebo
46029942|NCT05908019|Other|Web-based health care program|"According to the participants' feedback and recommends, we will modify this program to make it more suitable.~In the second and third years, we will conduct a parallel-group, double blind, and block randomization, experimental design study to examine the effectiveness of the Pulmonary Hypertension Web-Based Care Program on the improvements of patients' social support, self-care ability, active tolerance, symptom distress, depression, anxiety and quality of life in patients with PAH."
46029943|NCT05908006|Device|Velacur|Imaging Procedures Comparison
45471588|NCT03906305|Other|Dry needling in a myofascial trigger points area plus physical therapy based on Bobath concept|"Other: Dry Needling Participants will receive dry needling application over a myofascial trigger point by an experienced physical therapist with clinical experience in neurological patients, that will be inserted into taut bands of the following shoulder spastic muscles (when a trigger point was present): upper trapezius, supraspinatus, infraspinatus and deltoid anterior.~Other: Physical Therapy~Participants will receive physical therapy treatment based on the modulating Bobath technique. This technique will be applied using the general parameters, carrying out similar action protocols with every patient, based on the aim of normalizing upper limb muscle tone.~Device: stainless steel needles (0.3mm x 50mm)"
46029944|NCT05907980|Drug|ROSE12|ROSE12 as a IV infusion
46029945|NCT05907980|Drug|Atezolizumab|Atezolizumab as a IV infusion
46029946|NCT05907967|Device|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
46029947|NCT05907954|Drug|Darovasertib|Oral, potent, selective inhibitor of Protein Kinase C
46029948|NCT05907941|Device|ciNPT|Following closure of the abdominal donor site, the closed incision will be dressed with the ciNPT system [V.A.C.ULTA™ Negative Pressure Wound Therapy System (KCI, USA)] applied by the operating surgeon in a sterile fashion (Figure 2). The ciNPT device will be set at -125mmHg of continuous negative pressure for a period of 7 days or until patient discharge from hospital. Removal of the ciNPT dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied to the abdominal incision unless clinically indicated secondary to dehiscence.
45682370|NCT03834142|Device|NSS-2 Bridge|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
45682371|NCT03833674|Other|Daily AIH Block|Daily sessions of AIH (dAIH) with use of short episodes of low oxygen (9% O2)
46029949|NCT05907941|Other|Conventional Tape Dressings|Following closure of the abdominal donor site, the closed abdominal incision will be dressed with 1-inch Micropore™ Surgical Tape (3M, USA) with an alcohol swab applied to the tape for additional adhesion, by the operating surgeon in a sterile fashion. This dressing will remain in-situ for up to 7 days or until patient discharge from hospital. Removal of the traditional tape dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied unless clinically indicated secondary to dehiscence.
46029950|NCT05907941|Procedure|DIEP Breast Reconstruction|All patients enrolled in the study will undergo DIEP breast reconstruction and have their abdominal incision sutured according to routine clinical practice. At the Hamilton sites, we will use 3-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 4-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 5-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure. At the London sites, we will use 2-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 3-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 4-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure.
46029951|NCT05907928|Other|Scotchbond universal adhesive plus|New generation BPA free universal adhesive
46029952|NCT05907928|Other|Single bond Universal|Radiolucent universal adhesive
45471589|NCT03906305|Other|Dry needling in a non myofascial trigger points area plus physical therapy based on Bobath concept|"Other: Dry Needling Participants will receive dry needling application carried out over a non trigger point area by an experienced physical therapist with clinical experience in neurological patients, that will be inserted into a non trigger point spastic muscle of the shoulder area: upper trapezius, supraspinatus, infraspinatus and deltoid anterior.~Other: Physical Therapy Participants will receive physical therapy treatment based on the modulating Bobath technique. This technique will be applied using the general parameters, carrying out similar action protocols with every patient, based on the aim of normalizing upper limb muscle tone.~Device: stainless steel needles (0.3mm x 50mm)"
45682372|NCT03833674|Other|Sham dAIH Block|Daily sessions of sham dAIH which includes breathing room air (21% O2)
46029953|NCT05907915|Device|low level laser therapy|They recieved LLLT 1 session daily, 3 session per week for 3 weeks,with the following parameters( 650 nm wavelength, 150 mw power output, 0.25 cm2 radiation area, 0.6 W/cm2 power density, continuous mode, 2 j/ cm2, 90 seconds / cm2) in addition to the conventional medical treatment and traditional wound care (dressing)
46029954|NCT05907915|Behavioral|placebo|They received placebo laser 1 session daily, 3 session per week for 3 weeks in addition to the conventional medical treatment and traditional wound care (dressing)
45682373|NCT03833674|Other|Respiratory Strength Training Block|Respiratory strength training using a hand-held device that resists inspiration or expiration.
45682374|NCT03833674|Other|AIH + Strength Training Block|AIH followed by respiratory strength training.
46029955|NCT05907902|Drug|Aspirin Enteric-coated Tablets|low-dose aspirin 100 mg once daily (one 100mg tablet).
46029956|NCT05907863|Other|Use of intracardiac echocardiography|intracardiac echocardiography guided slow pathway ablation in patients with AVNRT
45471590|NCT03899441|Other|Video|Two short animated videos - one that reviews minimally-invasive surgery and sentinel lymph node mapping and biopsy for endometrial cancer treatment. This video as reviews possible complications. The second video reviews peri-operative instructions.
45682375|NCT03737032|Device|Intermittent Theta Burst Stimulation|Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered without interruption for a total duration of 40 seconds.
46029957|NCT05907850|Drug|Riboflavin|Commercially available source of riboflavin capsules
46029958|NCT05907850|Drug|Placebo|Placebo capsule compounded to be similar in appearance to the active intervention
46029959|NCT05907824|Other|Histopathological review, long-term prognosis and quality of life follow-up|Histopathological review, long-term prognosis and quality of life follow-up
46029960|NCT05907811|Procedure|Neuromuscular block|The patients were followed up, the total amount of muscle relaxant used was determined.
46029961|NCT05907798|Procedure|LIMA Blood flow|30 minutes after induction
46029962|NCT05907772|Other|No intervention|No intervention
46029963|NCT05907733|Diagnostic Test|Genotyping.|5 ml biood withdrawen by venipuncture in EDTA tube DNA extraction will be done after centrifucation and used for quantatitive Real-time polymerase chain reaction.
46029964|NCT05907720|Behavioral|Human-centered design prototype solutions for vulnerable pregnant women|The intervention package will include various social and behavior change programs derived from a human-centered design approach. The intervention will be tailored to vulnerable pregnant women's needs and contexts. It may include but is not limited to health communication campaigns, including radio and print media.
46029965|NCT05907707|Device|Gamma transcranial alternating current stimulation|tACS (gamma frequency, 40Hz) during cognitive testing (about 40 minutes duration).
46029966|NCT05907707|Device|Control transcranial alternating current stimulation|tACS (control frequency, 21Hz) during cognitive testing (about 40 minutes duration).
46029967|NCT05907707|Device|EEG headband|At-home, ambulatory, single-channel EEG headband which records brain activity during sleep
46029968|NCT05907707|Device|Actigraphy wristband|At-home, ambulatory, wrist-worn accelerometer which records levels of motor activity during the whole day
46029969|NCT05907694|Procedure|Transcatheter PFO closure|"Transcatheter PFO closure procedure will be performed according to the standards and experience of each participating center. Any approved PFO occluder device will be allowed in the study.~Patients will also receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient."
46029970|NCT05907694|Drug|Optimal medical treatment|Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
46029971|NCT05907668|Drug|IMVT-1401 (batoclimab)|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody.
46029972|NCT05907642|Other|Prune (dried plum)|Subjects who are assigned to the treatment group consume a total of 100 g of prune per day for 18 days and the subjects who are assigned to the control group are allowed to have a normal meal without prune for 18 days.
46029973|NCT05907629|Other|MRI|Additional MRI to the CAPTIVA study at baseline and 12 months follow-up
45471591|NCT01562197|Drug|axitinib|The starting dose of axitinib (AG-013736) is 5 mg BID administered orally with food.
45471592|NCT01562197|Drug|Axitinib plus Lomustine|Lomustine 90mg/m²
46029974|NCT05907616|Behavioral|Produce purchase incentive|Participants will be provided with a specific incentive amount per month for 10 months to purchase produce, nutrition education sessions and will be sent text message reminders to redeem their incentives every month and to provide them with nutrition tips.
46029975|NCT05907603|Drug|RD13-02 cell infusion|CAR-T cells
46029976|NCT05907590|Other|Interoceptive accuracy measurement|Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).
46029977|NCT05907590|Other|Interoceptive sensibility measurement|Interoceptive sensibility will be measured using two self-report questionnaires, the Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)
45471593|NCT01253915|Drug|Nasal Carbon Dioxide|10 sec/nostril up to 4 times to treat one migraine
45471594|NCT01253915|Drug|Placebo|10 sec/nostril up to 4 times to treat a migraine
46029978|NCT05907590|Other|Interoceptive awareness measurement|Interoceptive awareness will be measures using a visual analogue scale (VAS)
46029979|NCT05907590|Other|Proprioceptive accuracy measurement during postural control|"The effect of muscle vibration on center of gravity displacement (center of pressure or COP) will be examined. Muscle vibration of the m. triceps surae (ankle muscles) and the lumbar multifidus (back muscles) (Johanson et al., 2011; Brumagne et al., 2008; Claeys et al., 2011; Cleays et al., 2015) will be used to examine the role of proprioception during postural control."
46029980|NCT05907590|Other|Proprioceptive accuracy measurement of the neck|The head reposition accuracy task will be carried out to assess proprioceptive accuracy of the neck. The most commonly used procedure is the head repositioning accuracy to neutral head position (HRA-to-NHP), first described by Revel and colleagues (1991).
46029981|NCT05907577|Other|Observational|No interventions.
45471595|NCT03749239|Dietary Supplement|Collagen protein|Collagen protein
46029982|NCT05907538|Other|Interoceptive accuracy measurement|Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).
46029983|NCT05907538|Other|Interoceptive sensibility measurement|Interoceptive sensibility will be measured using two self-report questionnaires, the The Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)
46029984|NCT05907538|Other|Interoceptive awareness measurement|Interoceptive awareness will be measures using a visual analogue scale (VAS)
46029985|NCT05907499|Drug|Decitabine|Decitabine 6 mg/m2 daily subcutaneously for consecutive 3 days (day 1 to day 3)
46029986|NCT05907499|Drug|Granulocyte Colony-Stimulating Factor|5ug/kg/d when absolute neutrophil count ≤ 1.5 × 109/L
46029987|NCT05907499|Drug|Thrombopoietin Receptor Agonist|Eltrombopag initial dose: 25 mg orally once a day, may increase to up to 75 mg/day, when platelet count ≤ 30 × 109/L; Avatrombopag initial dose: 20 mg orally once a day, may increase to up to 60 mg/day, when platelet count ≤ 30 × 109/L.
46029988|NCT05907499|Drug|Recombinant human erythropoietin|10000 U/day when hemoglobin ≤ 85 g/L
45682376|NCT03737032|Device|Continuous Theta Burst Stimulation|Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered during 2 second periods (10 bursts/period) interleaved with 8-second stimulation-free intervals, for a total duration of 190 seconds.
45682377|NCT03737032|Device|Sham Theta Burst Stimulation|For the sham of theta burst stimulation, the device providing Theta Burst Stimulation can be placed in the same position and turned on, creating a similar experience for the participant, without providing any neural stimulation. Sham TBS will be delivered with a Cool-B65 Active/Placebo Coil, which includes a sham setting, and MagLink research software.
45682378|NCT03833440|Drug|Durvalumab (MEDI4736)|"1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days~c=cycle D= day"
46029989|NCT05907486|Drug|N-acetyl-cysteine|8g/d (>=45kg); 200mg/kg.d (<45kg), intravenously for at least 4 hours, day -9 to day +45
46029990|NCT05907486|Drug|Busulfan|3.2mg/kg, day-7 to day -5, intravenously
46029991|NCT05907486|Drug|Cytarabine|2g/m2, day -8, intravenously
46029992|NCT05907486|Drug|Cyclophosphamide|1.8g/m2, day -4 to day -3, intravenously
46029993|NCT05907473|Other|Virtual Reality Therapy|Patients in this group will play balance-based games with the Virtual Reality System.
45682379|NCT03833440|Drug|Monalizumab (IPH2201)|"1500 mg, every 4 weeks. CXD1 for each cycle, 1 cycle = 28 days~c=cycle D= day"
45682380|NCT03833440|Drug|Oleclumab (MEDI9447)|"3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days.~c=cycle D= day"
45682381|NCT03833440|Drug|Ceralasertib (AZD6738)|"240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28.~CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days~c=cycle D= day"
45682382|NCT03833440|Drug|DOCETAXEL|"75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days~c=cycle D= day"
45682383|NCT03833440|Drug|Savolitinib|"600 mg QD~1 cycle = 28 days"
45682384|NCT01677442|Procedure|no-intubated thoracic epidural anesthesia|VATS under no-intubated thoracic epidural anesthesia
46029994|NCT05907473|Other|Conventional Rehabilitation|In the conventional rehabilitation program, bed exercises, mat activities, balance exercises inside or outside the parallel bar and walking training will be given to the patients every weekday.
46029995|NCT05907447|Other|No interventions need to be specified for this study|No interventions need to be specified for this study
46029996|NCT05907395|Drug|PF-07293893|PF-07293893 will be prepared as an oral suspension given in escalating single doses to be determined.
46029997|NCT05907395|Drug|Placebo|Matching placebo will be prepared as an oral suspension given in each cohort.
46029998|NCT05907382|Drug|JMKX003002 will be administered orally|oral once
46029999|NCT05907382|Drug|JMKX003002 will be administered orally|oral once
46030000|NCT05907382|Drug|JMKX003002 will be administered orally|oral once
46030001|NCT05907382|Drug|Placebo in Cohorts 1 to 5|oral once
46030002|NCT05907382|Drug|Placebo in 2 Cohorts|oral once
46030003|NCT05907369|Other|Active EC training|The active EC includes pairing contamination-related pictures (CSs) with pleasant pictures (USs). The EC training takes about 15 minutes and is administered for ten sessions (5 days a week) in 4 difficulty levels.
46030004|NCT05907369|Other|Sham EC training|The active EC includes pairing contamination-related pictures (CSs) with neutral pictures (USs). The EC training takes about 15 minutes and is administered for ten sessions (5 days a week) in 4 difficulty levels, the same as active EC training.
46030005|NCT05907369|Other|Active tDCS|For the active tDCS, the cathode is placed over the left OFC and the anode over the right cerebellum. The brain stimulation is delivered with a 2mA current intensity for 20 minutes in 10 sessions (5 days a week).
45599314|NCT02234609|Device|modified ART class IV|Carious tissue was removed with an excavator until a sound probing was obtained. Restorations were performed using a mechanically improved glass-ionomer cement for ART. The modified class IV ART restoration was inserted into the cavity using a spatula. By these restoration technique, the cavity was (i) sealed to stop further caries progression. The cavity was (ii) capped to protect the vital dentin-pulp-complex from external stimuli. The modified class IV ART was aimed at conserving the carious incisor for prospective functional use and for prolonging tooth preservation rather than at anatomical reconstruction of the tooth form for cosmetic reasons.
46030006|NCT05907369|Other|Sham tDCS|For the sham tDCS, the cathode is placed over the left OFC and the anode over the right cerebellum, the same as active tDCS. The device is on for 20 minutes, but the current intensity is under the threshold of affecting cortical activity modulation. The participants receive the sham tDCS in 10 sessions (5 days a week).
46030007|NCT05907343|Device|Sham TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a sham coil when its output indicates that the participant is not properly engaged in the video game.
46030008|NCT05907343|Device|Closed-loop TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a real coil when its output indicates that the participant is not properly engaged in the video game.
45839108|NCT01620996|Behavioral|Minimal Intervention|There is no clear definition of this term and it has been used by many different groups to refer to attempts to alter behavior by providing very brief, focused interventions. A slightly more developed model guiding intervention is called the 5-A model. This refers to the acronym Ask, Advise, Assess, Assist and Arrange. This model has been endorsed by the US Public Health Department, who has incorporated the 5-A approach into their clinical practice guidelines (A Clinical Practice Guideline for Treating Tobacco Use and Dependence; A US Public Health Service Report. JAMA, June 20, 2000 - Vol 283 No. 24; see also http://www.surgeongeneral.gov/tobacco/tobaqrg.htm).
46030009|NCT05907343|Device|Open-loop TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. TBS with the real coil is delivered irrelevant of the BCI decoder output.
46030010|NCT05907330|Drug|CU104|CU104 will administer the study drug once a day after a meal
46030011|NCT05907330|Drug|Placebo|Placebo will administer the study drug once a day after a meal
46030012|NCT05907291|Drug|CRN04894|CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
46030013|NCT05907265|Behavioral|Behavioral: ONCOBrain_ImmersiveVR|A multimodal and digitally-based cognitive training, physical exercise and mindfulness intervention delivered face to face and through 360MK Virtual Reality technology
45682385|NCT01677442|Procedure|double-lumen endotracheal intubated anesthesia|VATS under double-lumen endotracheal intubated anesthesia
46030014|NCT05907265|Behavioral|Behavioral: Control_Condition|Traditional paper or pdf format multimodal intervention that will combine cognitive, mediation and physical activities.
45682386|NCT01695135|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
45682387|NCT01695135|Drug|Placebo|Placebo (4 tablets) taken orally once daily
46030015|NCT05907252|Behavioral|Supervised Group-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
45682388|NCT01695135|Drug|Prednisone|Prednisone 5 mg tablet taken orally twice daily
45682389|NCT01610414|Biological|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm
46030016|NCT05907252|Behavioral|Non-supervised Group-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and without being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
46030017|NCT05907252|Behavioral|Non-supervised Individual-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and without being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
45599315|NCT02341365|Other|vitamin D,AMH, AFC, reproductive outcome egg recipients|observational study of 269 donnors
45599316|NCT04837001|Drug|FDY-5301|FDY-5301 will be administered as a single IV bolus injection.
45599317|NCT04837001|Other|Placebo|Placebo will be administered as a single bolus injection.
45599318|NCT02299609|Other|Ultrasound beams Philips HD11 XE®|Ultrasound beams used during standard echocardiography
45682390|NCT01610414|Biological|Placebo|2 doses administered IM in deltoid region of non-dominant arm
45471596|NCT01255397|Procedure|Male Infertility Protocol|"Healthy women with a regular cycle between 28 and 35 days. For the man, an abnormal sperm exam.~Daily US examinations from day 8 of the menstrual cycle. Excluding weekends.~When the leading follicle is 14 mm she will be given 100 units puregon and orgalutran,once daily until the leading follicle is at least 16 mm at which point she will be given ovitrelle at 21:00.~35 hours after Ovitrelle at 8:00 the husband will present a sperm sample for analysis. A pelvic US will be done to the wife.~If the follicle has collapsed than IUI will be performed~It the total motile sperm count is above 5 million sperm/ml then IUI will be done~If the total motile sperm count is below 5 million and the follicle has not collapsed, proceed to oocyte aspiration and ICSI~6) ICSI and embryo transfer performed on the same day. 7) Luteal support: Endometrin 100 mg twice a day following IUI\ET until 6 weeks gestation Protocol can be repeated for up to 3 cycles per couple."
46030018|NCT05907239|Device|Focused Extracorporeal Shockwave Therapy|We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 1.5cm in depth, frequency of 8Hz and intensity of 0.048mJ/mm² as long as it is tolerable to the patient (it can be reduced to a tolerable intensity of at least 0.018mJ/mm²) starting with a density of energy flow between 0.12 to 0.15 mJ/mm2, starting from an adaptation dose of 0.10 mJ/mm2 in the first 500 impulses. The non-stationary technique will be used, slowly moving the applicator. Shockwave therapy will be weekly, totaling five consecutive weeks.
45682391|NCT03832114|Drug|LNP023|Increasing doses of LNP023 up to 200 mg.
46030019|NCT05907239|Device|Placebo Focused Extracorporeal Shockwave Therapy|We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 0cm depth, frequency of 8Hz and intensity of 0.048mJ/mm² with a fake gel pad applicator.
45471597|NCT03899363|Procedure|custom thermoplastic orthosis|extended the DIP by a custom thermoplastic orthosis or the Kirschner wire through the joint
46030020|NCT05907213|Drug|Dose Level 1|Loading Dose: 0.05 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
46030021|NCT05907213|Drug|Dose Level 2|Loading Dose: 0.08 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
46030022|NCT05907213|Drug|Dose Level 3|Loading Dose: 0.12 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
46030023|NCT05907213|Drug|Dose Level 4|Loading Dose: 0.18 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
45471598|NCT04331899|Drug|Peginterferon Lambda-1a|Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose along with Standard of Care
45471599|NCT04331899|Other|Placebo|Placebo subcutaneous injection along with Standard of Care Treatment for COVID-19 Infection
45471600|NCT03905915|Device|Virtual reality (VR) session with AQUA module|A device with virtual reality is given to the patients with a film of 15 minutes
46030024|NCT05907187|Behavioral|Cervical Cancer Prevention Education|Participants will receive in-person, one-time health education on the importance of cervical cancer screening using a short intervention/educational script; and motivation to encourage women to have human papillomavirus (HPV) screening. Participants will also be informed of the nature and risks of HPV infection, and the importance of seeing a doctor including having a gynecologic exam.
45682392|NCT01564407|Drug|ICX-RHY-013|"Drug Dosing for Cohorts as follows:~Cohorts (N=4)~Safety Cohort 1:~Empty control no injection~Vehicle only (0.5 ml of HypoThermosol solution)~5 million cells / cm² , single administration at Day 0~5 million cells/ cm² , single administration at week 4~5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4~At day 0, the subject will receive a total of 3 different injections and at week 4 the subject will receive a total of 2 different injections.~Cohort 2: 2.5 million cells/ cm2, single administration Cohort 3: 5 million cells /cm2, single administration Cohort 4: 2.5 million cells/ cm2, repeat dose administration @ 4 weeks Cohort 5: 5million cells / cm2 repeat dose administration @ 4 weeks"
46030025|NCT05907174|Behavioral|Siyakhana - P|A trained peer recovery coach (PRC) will be integrated onto the healthcare worker team randomized to Siyakhana - P. The PRC on this team will work with eligible and consenting patients who are seen by members of this healthcare team.
46030026|NCT05907161|Device|SRP+LASER (Dentsply Sirona - SIROLaser Blue)|adjunct irradiation with a diode laser (Dentsply Sirona - SIROLaser Blue) intrasulcularly to all sites with PD ≥ 4mm
46030027|NCT05907161|Device|SRP+HA|adjunct hyaluronic acid (Regedent, HyaDENT Cross linked hyaluronic intrasulcularly to all sites with PD ≥ 4mm
46030028|NCT05907161|Device|SRP|non-surgical periodontal therapy (SRP) with utrasonic device and curretes
46030029|NCT05907148|Other|Sensory integration training|"Sitting position:~Sit in a chair without a backrest while the feet on firm surface. without backrest while the feet on soft surface.~Sit on a ball while the feet on firm surface. while feet on soft surface.~Sit in a chair without a backrest with the feet on firm surface and perform sit-to-stand motion.~without a backrest with the feet on soft surface and perform sit-to-stand motion.~Sit on a ball with the feet on the firm surface and perform sit-to-stand motion. with the feet on the soft surface and perform sit-to-stand motion.~Perform bipedal standing on a firm surface. on a soft surface.~Perform a semi-tandem stance on firm surface. on soft surface.~Walk forward on firm surface. on soft surface.~Walk forward on firm surface, cross obstacle, and continue to walk.~Walk forward on the soft surface, cross obstacle, and continue to walk."
46030030|NCT05907148|Other|Routine physical therapy|It consist of active joint mobilization, muscle stretching, motor coordination exercises and general balance training
46030031|NCT05907148|Other|General coordination exercise|"In supine lying:~Patients are told to place heel of one leg on shin or knee of the other leg,~Patient bends one leg and extends the other leg like bicycling motion.~Flexing one leg while extending other leg~Flexing and extending of one leg while abduction and adduction of other leg.~In sitting:~Patient performs marching without backrest or back support,~Patient reaches forward and sideways with arms~Rotation of trunk with physioball in hand without back support.~Patient reaches with legs to marked point in sitting.~In standing:~Patient performs 10 repetitions of~Clock Reach~Side Leg Raises~Leg Swings and~Ball catch and throw"
46030032|NCT05907135|Dietary Supplement|Beet|Beet-based powder with other ingredients
46030033|NCT05907135|Dietary Supplement|Placebo|Placebo powder.
46030034|NCT05907122|Drug|ABP 206|ABP 206 will be given intravenously over a period of 30 minutes, every 4 weeks (Q4W) for a total of 12 months.
46030035|NCT05907122|Drug|FDA-licensed Nivolumab|FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.
46030036|NCT05907122|Drug|EU-authorized Nivolumab|FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.
46030037|NCT05907109|Behavioral|Remotely monitored parent-mediated hybrid home and clinic based multidisciplinary Early Intervention protocols.|"Parents receive manualized protocols, instructional videos, and toy and material kits to administer EIs at home.~New modules are provided according to infant age or stage of intervention during the length of brief interventions or 12-months.~The families will be monitored by clinical researchers weekly. -High risk infants will receive supplemental EI services at the clinic according to developmental needs.~Infants will receive outcome evaluations within a 42-month follow-up clinic."
46030038|NCT05907096|Biological|ARGX-117|Intravenous administration of ARGX-117
46030039|NCT05907096|Other|Placebo|Intravenous administration of placebo
46030040|NCT05907083|Radiation|cone beam computer tomography|Cone Beam CT Radiation
46030041|NCT05907057|Drug|Ivosidenib Oral Tablet|Provided as tablets, taken orally once daily.
46030042|NCT05907057|Drug|Azacitidine|Administered subcutaneously (SC) or intravenously (IV) for 7 days, either consecutively on Days 1-7 or discontinuously for Days 1-5 and 8-9 of each cycle. The 7 days of administration will occur at the beginning of every 4 week-long cycle.
46030043|NCT05907031|Device|active continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive days each week.
46030044|NCT05907031|Device|sham continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive days each week.
46030045|NCT05907005|Behavioral|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
46030046|NCT05906992|Biological|CT-P53|Intravenous(IV) infusion
46030047|NCT05906992|Biological|US-Ocrevus|Intravenous(IV) infusion
46030048|NCT05906992|Biological|EU-Ocrevus|Intravenous(IV) infusion
46030049|NCT05906979|Other|PAHOLA (digital health assistant)|Pahola is the Pan American Health Organization's new digital health specialist on alcohol use. Programmed with the latest information and research, she can help you make healthier decisions related to your alcohol consumption. Pahola is free to use and can easily be accessed from the privacy of your own home by making use of the online app.
46030050|NCT05906979|Other|Standard information on alcohol use and health|A brochure on alcohol use and health as produced by the Pan American Health Organization will be provided to participants.
46030051|NCT05906966|Other|Phone contact|. All mothers of children of born from cryopreserved oocytes will be contacted by phone and administered a questionnaire, to gather additional information about further psychomotor development of children.
46030052|NCT05906953|Drug|HG004|Low dose Medium dose High dose
46030053|NCT05906940|Device|Transcutaneous Vagus Nerve Stimulation|As a vagus stimulation protocol, bilateral auricular stimulation and stimulation frequency of 10 Hz, pulse width of 300 µs, biphasic application for 20 minutes, each participant will be stimulated twice, with at least 48 hours between them.
46030054|NCT05906914|Drug|cladribine + homoharringtonine + cytarabine|CHA Protocol: cladribine (5mg/m2, d1-3) + homoharringtonine (2mg/m2, d1-5) + cytarabine (100mg/m2 d1-7).
46030055|NCT05906901|Other|Cranial listening technique|5 minutes
46030056|NCT05906901|Other|Suboccipital muscles inhibition technique|6 minutes
46030057|NCT05906862|Drug|AMT-253|Administered intravenously
46030058|NCT05906849|Behavioral|ACT for anxiety disorders|A twelve session Acceptance and Commitment Therapy (ACT) for anxiety disorders, applied individually and remotely (through videoconference) to participants fulfilling inclusion criteria (i.e., participants included in the SAD and GAD Experimental Groups).
46030059|NCT05906836|Drug|Rosuvastatin|Administered orally.
46030060|NCT05906836|Drug|Selpercatinib|Administered orally.
46030061|NCT05906823|Other|Detection of pleural effusion|Detection of pleural effusion
46030062|NCT05906810|Procedure|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
46030063|NCT05906797|Procedure|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
46030064|NCT05906784|Other|group acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. Acupuncture treatments will include a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Acupuncture points will be selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
46030065|NCT05906784|Other|Integrative Group Medical Visits|"IGMV sessions will be weekly for 90 minutes in a group meeting space. Sessions will start with a check-in where participants can share their emotions, thoughts, hopes, and fears related to their health and pain and provide updates since the last session. Group sessions will be led by a primary care provider and a health educator and will include psychosocial support, tools for pain self-management, and psychoeducation for pain management. Invited experts will provide information on educational topics, including neurobiology of pain, medication safety, and connections between mood and pain, as well as participatory activities such as therapeutic movement or mindfulness practice."
45471601|NCT03905837|Drug|Lidocaine|Intravenous or paravertebral lidocaine
46030066|NCT05906758|Procedure|Angiography|Coronary angiography with less than 20cc of contrast materials
46030067|NCT05906719|Other|video recording|Patients' performance of MDS-UPDRS III will be recorded.
46030068|NCT05906706|Drug|dupilumab|Subcutaneous (SC) administration
45839109|NCT01620996|Behavioral|Motivational Interviewing|"Motivational Interviewing has its roots in alcohol abuse counseling and was pioneered by Miller and Rollnick. It is an approach to counseling that is geared toward increasing an individual's motivation, or buy-in, to the work that needs to be done to reduce substance dependence. Miller and Rollnick offer the approach as a brief intervention (hence some confusion with the term minimal intervention) guided by the following mediators of change, which they call ingredients of change, summarized by the Acronym FRAMES:~FEEDBACK of personal risk or impairment Emphasis on personal RESPONSIBILITY for change Clear ADVICE to change A MENU of alternative change options Therapist EMPATHY Facilitation of client SELF-EFFICACY or optimism~These mediators/ingredients are delivered by the clinician using the following principles:~Express Empathy Develop Discrepancy Avoid Argumentation Roll with Resistance Support Self-Efficacy"
46030069|NCT05906680|Procedure|Additional biopsies collection|We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
46030070|NCT05906667|Behavioral|Sharing History through Active Reminiscence and Photo-imagery (SHARP)|Participants engage in neighborhood walks and conversational reminisce three times per week over 24 weeks
46030071|NCT05906654|Behavioral|Sharing History through Active Reminiscence and Photo-imagery (SHARP)|Behavioral intervention to increase physical and social activity. In triads, participants walk 1-mile neighborhood routes three times per week and engage in image-based conversational reminiscence.
46030072|NCT05906641|Dietary Supplement|High-protein diet|Protein intake will be increased to be 30% calories from protein with calcium caseinate.
46030073|NCT05906628|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
45682393|NCT03830944|Diagnostic Test|Blood sampling|Assessment of complete blood count, biochemistry, inflammatory biomarkers, adhesion molecules
46030074|NCT05906628|Drug|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
46030075|NCT05906615|Drug|Lidocaine IV|Administration of IV lidocaine will take place according to the standard protocol as is currently already used in daily clinical practice. First, a lidocaine bolus of 1.5mg/kg is administered, followed by a continuous infusion of 1.5mg/kg/hour. When no pain relief is noticed, each 15 minutes the dose is raised with 1ml up to a maximum of 2mg/kg/hour. If again no pain relief is noticed, the anesthesiologist is consulted. When the anesthesiologist agrees, and no side effects occur, lidocaine infusion can be increased up to a maximum of 2.5mg/kg/hour, with a maximum of 250mg/hour. When there is a pain response - pain is reduced with at least two NRS points or 30% from baseline - that dose is administered for two hours continuously. Following treatment the patient will be observed for an hour before leaving the hospital or recovery unit, again, all according to current daily clinical practice.
46030076|NCT05906589|Dietary Supplement|Inulin|The participant will take inulin twice daily over a 14 day period.
45682394|NCT03830944|Diagnostic Test|transthoracic echocardiography|Assessment of the ventricular anatomy, size, function, speckle tracking, myocardial strain, valvular function.
45682395|NCT03830944|Diagnostic Test|Late Gadolinium-Enhancement Cardiac Magnetic Resonance|Assessment of the ventricular anatomy, function, viability, degree of fibrosis, quantification of infarct size, mass.
45682396|NCT03830944|Diagnostic Test|Coronary Angio Computed Tomography|Assessment of coronary plaque anatomy, morphology, vulnerability features, quantification of epicardial adipose tissue
45682397|NCT01590771|Drug|Sitagliptin|Sitagliptin 100 mg oral tablet once daily for 24 weeks
45682398|NCT01590771|Drug|Placebo|Matching placebo to sitagliptin oral tablet once daily for 24 weeks
45682399|NCT01590771|Drug|Gliclazide|Participants will continue ongoing open-label therapy with gliclazide (dosed according to the China drug label) throughout the study.
46030077|NCT05906589|Dietary Supplement|Psyllium|The participant will take psyllium twice daily over a 14 day period.
45471602|NCT03905837|Drug|Remifentanil|intravenous remifentanil
45471603|NCT03063632|Biological|Interferon Gamma-1b|Given SC
45682400|NCT01590771|Drug|Glimepiride|Participants will continue ongoing open-label therapy with glimepiride (dosed according to the China drug label) throughout the study.
46030078|NCT05906589|Dietary Supplement|Maltodextrin|The participant will take maltodextrin twice daily over a 14 day period.
46030079|NCT05906576|Drug|Infliximab|Infliximab in the treatment of Crohn's disease in children
46030080|NCT05906563|Drug|Melatonin gel|local application of Melatonin gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack
45839110|NCT01620996|Behavioral|Motivational Enhancement|"Motivational enhancement is the most comprehensive term and reflects the integration of two major theorists; Millner and Rollnick on the one hand, and Prochaska and his colleagues on the other. The work of Miller and Rollnick occurred within substance abuse, primarily alcohol abuse and is best summarized in the section above on motivational interviewing. As Prochaska's work, which initially began in the area of smoking cessation but quickly expanded to include wide-ranging health behaviours, developed Miller and Rollnick incorporated his work with theirs.Prochaska's model derives from his long term study of the process of behaviour change regardless of the model of intervention implemented.The model is often referred to as the stages of change model, or readiness to change model.~The stages of change model identifies five separate stages; precontemplation,contemplation, preparation, action, and maintenance~These stages are specific to different behaviours."
46030081|NCT05906563|Drug|Metformin and melatonin gel|local application of Metformin and melatonin gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack
45839111|NCT01138020|Behavioral|Cognitive Intervention|Cognitive rehabilitation treatment designed specifically to address the most common cognitive complaints in executive and memory function
45839112|NCT01138020|Behavioral|Educational intervention|Educational intervention is geared at personal management of TBI-related symptoms.
45682401|NCT01590771|Drug|Metformin|Participants will continue ongoing open-label therapy with metformin (at least 1500 mg daily) throughout the study.
45682402|NCT03735940|Other|Spot monitoring device, excl. Sham|o During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. o During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
45839113|NCT00704106|Drug|Entecavir|0.5 or 1 mg dose qd
46030082|NCT05906563|Drug|placebo gel|Local application of empty nanoparticles gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack.
45839114|NCT05620992|Device|Echocardiography|Echocardiography 3 and 6 months post operative
45839115|NCT05620680|Biological|CD7 CAR-T cells|patient was subjected to 0.5-2×10^6 cells/kg of CD7 CAR- T
46030083|NCT05906563|Procedure|scaling and root planning|full mouth supra- and subgingival scaling and root planning will be performed, and all periodontitis patients will be treated with ultrasonic tips and Gracey curettes for meticulous removal of subgingival and supragingival plaque and calculus.
46030084|NCT05906550|Diagnostic Test|Vascular access monitoring|Patients are referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present. These include physical signs, problems during dialysis, or an unexplained, sustained fall in dialysis adequacy. Patients will be referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present.
45682403|NCT03830242|Diagnostic Test|<Sup>18<Sup>F-FDG PET/CT dynamic scan|The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
46030085|NCT05906550|Diagnostic Test|Vascular access blood flow measurement|Monthly surveillance of vascular access blood flow volume by ultrasound dilution measurements during hemodialysis sessions. Patients will be referred for correction of the underlying stenosis at an access flow volume <500mL/min.
46030086|NCT05906537|Drug|SKB410 for injection|SKB410 for injection is administered every 2 weeks (q2w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
46030087|NCT05906524|Drug|KD6001|KD6001 will be administered intravenously.
46030088|NCT05906524|Drug|Tislelizumab|Tislelizumab will be administered intravenously.
46030089|NCT05906524|Drug|Bevacizumab|Bevacizumab will be administered intravenously.
46030090|NCT05906511|Drug|Dronabinol 5 MG|Dronabinol 5 mg
46030091|NCT05906511|Drug|Dronabinol 10 MG|Dronabinol 10mg
46030092|NCT05906511|Drug|2mg Purified THC in an ethanolic solution|2mg Purified THC in an ethanolic solution
46030093|NCT05906511|Drug|4mg Purified THC in an ethanolic solution|4mg Purified THC in an ethanolic solution
46030094|NCT05906511|Drug|Placebo|Oral placebo and/or vaporized saline
46030095|NCT05906498|Drug|Acetyl cysteine|N-acetyl cysteine (NAC) is synthetic cysteine amino acid, which in turn elevate the glutathione level in the body, which have important direct antioxidant activity.
46030096|NCT05906498|Drug|Vitamin E|vitamin E possessing an anti-inflammatory action
46030097|NCT05906485|Behavioral|fNIRS Neurofeedback-VR Training|In the fNIRS Neurofeedback-VR Training, we have designed a classroom scenario modeled and children are expected to learn how to regulate their attention based on the feedback provided by the fNIRS on the oxygenated haemoglobin level in their prefrontal cortex.
46030098|NCT05906485|Behavioral|Computerized Cognitive Training|In the Computerized Cognitive Training, children will complete a range of tasks covering attention control and working memory using a conventional training programme, namely Cogmed.
46030099|NCT05906472|Other|Feeds continued|Enteral feeds are continued up until time of surgery
46030100|NCT05906472|Other|Feeds held|Enteral feeds are stopped 6 or more hours before surgery
46030101|NCT05906173|Other|Augmented Reality (AR)|AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
46030102|NCT05905796|Other|Brain Health Assessment|Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. Research interventionalists will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.
46030103|NCT05905575|Behavioral|Family dyad diabetes intervention|The goals of the intervention are to encourage participants to (1) daily self-manage diabetes and stress; (2) establish a healthy eating pattern; (3) engage in brisk walking of 150 or more minutes a week; and (4) use solution-focused problem-solving strategy and supportive family communication skills.
46030104|NCT05905224|Device|Invisalign 7-day wear protocol|Clear Aligners' (Invisalign, Align technology, San Jose, Calif) 7-day wear protocol
46030105|NCT05905224|Device|Invisalign 3-day wear protocol|Clear Aligners' (Invisalign, Align technology, San Jose, Calif) 3-day wear protocol
46030106|NCT05904665|Diagnostic Test|ctDNA methylation dynamic monitoring|ctDNA methylation detection is performed within one month before surgery, within one month after surgery, and every three months after surgery, for a period of 2 years, a total of 10 times.
46030107|NCT05904639|Genetic|Decoding Your Diet|We will collect information from cardiac patients on their genes at baseline and then expose them to a diet intervention and collect genetic information after the intervention.
46030108|NCT05903911|Other|Trans Care Web App|an educational and interactive website designed to improve coping strategies of TNB individuals
46030109|NCT05903391|Device|Finger Splints|The invervention is wearing a finger splint produced by assigned finger splint typically used in a clinical setting
45682404|NCT03830242|Diagnostic Test|B-ultrasonography|The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
46030110|NCT05902156|Behavioral|DiaPaDeSS|Web-based mobile health application for patients with type 2 diabetes (the patient education information about type 2 diabetes, self-management practice tasks (daily, weekly, quarterly), type 2 diabetes patient education program according to DiaPaDeSS algorithms, and measurement questionnaires)
45471604|NCT03063632|Other|Laboratory Biomarker Analysis|Ancillary studies
45471605|NCT03063632|Biological|Pembrolizumab|Given IV
45682405|NCT04764058|Drug|Tienam 500|Imipenem and cilastatin sodium
45682406|NCT04764058|Device|Infusion|Health caregivers give the drug to the patients and monitoring the infusion rate
45682407|NCT04763824|Behavioral|Telementoring with Practice Facilitation|We are attempting to provide education and encourage practice change
46030111|NCT05902156|Behavioral|DiaPaDeSS|Web-based mobile health application for patients with type 2 diabetes (only self-management practice tasks (daily, weekly, quarterly), and measurements questionnaires. The diabetes patient education brochure of the Ministry of Health will be sent to the phones of the active control group in pdf format.)
46030112|NCT05901987|Genetic|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
46030113|NCT05901974|Drug|Venetoclax|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28);
46030114|NCT05901974|Drug|azactidine|azacitidine 75 mg/m2 subcutaneously once daily on days 1-7
46030115|NCT05901961|Drug|Whitfield solution|The patient will receive 60 mL of Whitfield solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
45682408|NCT03638674|Other|DXA + CT|Two dual-energy X-ray scans + CT scan
45682409|NCT03636724|Behavioral|E-intervention|The 10-week e-health intervention will target HAPA-based social-cognitive variables of PA and FVI. Particularly, Week 1: risk perception and outcome expectancies; Week 2: goal setting; Week 3: development of action plans; Week 4: revision and adjustment of previous action plans; Week 5: development of coping plans; Week 6: revision and adjustment of previous coping plans; Week 7: development of perceived social support; Week 8: revision and adjustment of previous social support. Week 9-10: self-monitoring. Self-efficacy will be a fixed intervention variable involved from week 2 to week 10. Additionally, some behaviour change techniques will be employed in the intervention in order to facilitate the implementation and maintenance of behaviour.
46030116|NCT05901961|Drug|Zinc oxide nanoparticles solution|The patient will receive 60 mL of 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
46030117|NCT05901961|Drug|Combined Whitfield and Zinc oxide nanoparticles solution|The patient will receive 60 mL of combined Whitfield and Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
46030118|NCT05901909|Behavioral|Educational intervention based on the Precede-Proceed Model for individuals caring for stroke home care patients|Home visits will be made to 50 stroke patients identified during the implementation phase of the research, and training based on the Precede-Proceed model will be given to 50 individuals who care for these patients in the meeting room of the hospital where the research will be conducted. In the research, pre-education evaluation will be collected at the hospital before the training for the caregivers and home visits for the patients. In the second stage, the training program planned for the caregivers will be implemented in the meeting room of the hospital. After the training program reaches all of the caregivers in the determined number, the first evaluation will be made for the caregivers and the patient in the 8th week after the training is over. The third stage is the 16th week after the completion of the training, and the final evaluation will be made for the patients and caregivers.
46030119|NCT05901675|Other|Lifestyle Management Program|The program utilizes registered dietitians, exercise physiologists and psychologists and is designed to induce larger initial weight losses than traditional lifestyle change programs. The early part of the program provides a highly structured dietary intervention, which consists primarily of meal replacements provided to the participant as part of the program (shakes and nutrition bars). Gradually, as the program progresses, there is a shift towards a primarily food-based meal plan that leads to more moderate and sustainable weight loss. Throughout the program, participants attend weekly individual appointments that rotate among the clinical specialties (dietary and behavioral). The emphasis on lifestyle change means the goal is to help the participant learn to make healthy behavior changes that can be sustained long after completion of the program, thus enabling maintenance of a healthier weight.
45682410|NCT01563237|Device|MIDI Arrow|Implantation of MIDI Arrow
45682411|NCT03636022|Other|VR System|Use of virtual reality to deliver exposure therapy
45682412|NCT03636022|Other|Control|Use of conventional delivery of exposure therapy
45682413|NCT03735316|Drug|Hydroxocobalamin|5g, IV, Infused once over 15 minutes. The drug comes in a 250ml glass vial with 5g of lyophilized hydroxocobalamin to be reconstituted in 200ml of Normal Saline, Dextrose or Lactated Ringers.
45682414|NCT03735316|Procedure|Cardiopulmonary Bypass|Technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the patient's body.
45682415|NCT03735316|Drug|Placebos|Placebo is a Normal Saline, 5g, IV, Infused once over 15 minutes. The placebo comes in a 250ml glass vial.
45682416|NCT01694433|Drug|Calcipotriene|1g daily BID
45682417|NCT01694433|Drug|Placebo|1g daily BID
45682418|NCT01694121|Behavioral|MEN Count|The MEN Count model integrates HIV risk reduction and gender-equity counseling with housing and employment case management via multiple one-on-one sessions delivered by a peer case manager over 60-90 day period.
45682419|NCT01694121|Behavioral|Comparison|general health intervention for men, not inclusive of HIV or relationship health
45682420|NCT03729388|Other|Prognosis factor associated with good outcome.|Implementation of a systematic assessment of patient with OMT initiation. Patients included in the TOPAZE study will receive standardized clinical interviews, electrocardiograms, urinary and blood tests during a 12 months follow-up.
45682421|NCT03634930|Behavioral|observation|Observation of growth, infant bodycomposition, 24h-drinkingvolume
45682422|NCT01676662|Device|Solace Bladder Control System|Subjects may undergo treatment every 12 months until study completion.
45839116|NCT05620602|Other|Remedial treatment within 3 months|"The interval between the time of this treatment and the last day of the last therapy is within 3 months.Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
46030120|NCT05901675|Other|Post-stroke Optimization of Walking using Explosive Resistance|POWER training will take place over a 12-week period (3 sessions/week) with exercises including leg press, calf raises, and jump training, all performed at high concentric velocity, as well as trials of fast walking and functional movements.
46030121|NCT05901584|Drug|Cadonilimab|Cadonilimab (10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy or Cadonilimab (10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit), Q3W, 4cycles), every 3 weeks (21 days) is a treatment cycle.
46030122|NCT05900765|Drug|Zimberelimab 240mg|"AVD regimen:~Doxorubicin 25mg/m2, d1, d15, IV; Vincristine 3mg/m2, d1, d15 IV; Dacarbazine 0.375mg/m2, d1, d15 IV"
45682423|NCT01676662|Device|Solace Sham Treatment|Sham procedure that resembles treatment with the Solace Bladder Control System
46030123|NCT05900076|Diagnostic Test|Curettage for the evacuation of the product of conception|The product of conception taken during the intervention will be recovered at Day 1
45682424|NCT01693185|Drug|Remifentanil|continuous infusion 0.4 mcg/kg/min
45682425|NCT01693185|Drug|Midazolam|bolus injection
45682426|NCT01693185|Drug|Meperidine|bolus injection for 30 sec 1.0 mg/kg
45682427|NCT01693185|Drug|placebo (for remifentanil)|normal saline mimic diluted remifentanil
45682428|NCT01693185|Drug|placebo (for midazolam)|normal saline mimic to midazolam injection
46030124|NCT05899634|Behavioral|Defaults|Participants will receive healthy recipes (3 main meal + 1 snack/breakfast/lunch recipe per week of the two-week intervention). In addition, in this group, participants' online grocery shopping carts will be pre-filled with ingredients corresponding to the provided recipes. They will be told that their cart has been filled with items that can be used to make recipes from the provided recipe cards, and that they can modify it as they like.
46030125|NCT05898581|Procedure|PENG Block|Participants will receive a PENG block with local anesthetics (which is a freezing medication, in this case, 0.5% ropivacaine) before receiving spinal anesthesia.
46030126|NCT05898581|Procedure|Control Group|Participants will receive a sham PENG block performed with 20ml of normal saline solution before spinal anesthesia. After, patients will receive ILAI (performed by the operating surgeon) with a plain solution of ropivacaine 0.25% 60ml.
46030127|NCT05898243|Procedure|Reduction|An Rx will be performed before and after the reduction of the dislocation. After that, the neurovascular state will be checked and also if there is some associated injury.
45682429|NCT01693185|Drug|placebo (for meperidine)|normal saline mimic meperidine injection
46030128|NCT05897619|Behavioral|Experimental: Maya Perinatal Cognitive Behavioral Skills App|The intervention includes the completion of a mobile skills app teaching evidence-based strategies tailored for perinatal mood and anxiety. Modules include psychoeducation, skill information, practice exercises, and homework.
46030129|NCT05897125|Other|Virtual at Home Medication Reconciliation Visit(s)|Patients will have their medications reviewed by the TELE-TOC interventionalist, a member of the pharmacy team (anticipated)
46030130|NCT05897125|Behavioral|Virtual At Home Medication Education Visit(s)|Patients will be provided with inhaler education by the TELE-TOC interventionalist, a member of the pharmacy team (anticipated)
46030131|NCT05897125|Other|COPD advanced practice nurse Inpatient Consult|Patients will receive a COPD consult by an advanced practice nurse as part of standard of care
46030132|NCT05897125|Other|Inpatient Medication Reconciliation|Patients will have their medications reviewed by member(s) of the clinical care team as part of standard of care
45682430|NCT03824938|Drug|Aspirin 650mg Oral Capsule|A 650mg dose of aspirin is administered in the laboratory one hour before participant completes a maximal exercise test.
45471606|NCT03899129|Procedure|simultaneous working length control using E-CONNECT S|E-CONNECT S (Eighteeth medical technology Co., Ltd, china) is an endomotor with integrated apex locator newly introduced in the market with continuous WL measuring function. It contains an optional module for rotary instrumentation, allowing the device to function as a low-speed handpiece, apex locator, or a combination of both. This motor has an attention-grabbing property that when an instrument reaches the predetermined working length, the motor automatically stops the instrumentation. Thus, it can be concluded that automatically stopping instrumentation when the instrument reaches the working length would decrease postoperative pain compared with manually controlling the working length by using stoppers during instrumentation (separate length determination and root canal preparation).
45471607|NCT03899129|Procedure|separate length determination and root canal preparation using Root ZX apex locator.|Using manual control of the working length by using stoppers during instrumentation (separate length determination and root canal preparation) using Root ZX apex locator.
46030133|NCT05897125|Other|Post-discharge nurse 48 hour phone follow-up call|Patients will receive a post-discharge nurse 48 hour phone follow-up call as part of standard of care
46030134|NCT05897125|Other|Post-discharge follow-up advanced practice nurse outpatient visit|Patients will be scheduled for a 1-2 week post-discharge visit with the COPD advanced practice nurse as part of standard of care
46030135|NCT05896358|Behavioral|ketogenic diet|a low calorie ketogenic diet
46030136|NCT05895955|Biological|TetraFluvac TF vaccine|"The vaccine is a seasonal quadrivalent inactivated split virion influenza vaccine [A/Sydney/5/2021(H1N1)pdm09-like virus and A/Darwin/9/2021 (H3N2)-like virus and B/Austria/1359417/2021 (B/Victoria Lineage)-like virus and B/Phuket/3073/2013 (B/Yamagata lineage)-like virus] produced by The Government Pharmaceutical Organization (GPO), Thailand.~Each dose of TetraFluvac TF contains a total of 60 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection."
45471608|NCT04328467|Drug|Hydroxychloroquine|Hydroxychloroquine; 200mg tablet; oral
45471609|NCT04328467|Other|Placebo|Placebo; tablet; oral
45471610|NCT04254770|Device|ADA approved Manual Toothbrush|ADA approved Manual Toothbrush
45471611|NCT04254770|Device|Marketed Power Toothbrush|Marketed Power Toothbrush
46030137|NCT05895955|Biological|seasonal quadrivalent split vaccine for Southern Hemisphere in 2023|"The vaccine is a Commercially available seasonal quadrivalent split vaccine for Southern Hemisphere in 2023 [A/Sydney/5/2021(H1N1)pdm09-like virus and A/Darwin/9/2021 (H3N2)-like virus and B/Austria/1359417/2021-like virus and B/Phuket/3073/2013-like virus]~Each dose of Commercially available seasonal quadrivalent split vaccine for Southern Hemisphere in 2023 contains a total of 60 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection."
46030138|NCT05894005|Other|Immersive 360 (3D) video|"Group A VR - Route 1: Students will be first taken to the anesthesia lounge. Here the students will receive VR instructions on how to navigate Route 1 (i.e. they will watch a 360-degree immersive video using Oculus VR headset). Then the students will be assessed with an observed walkthrough of Route 1.~Traditional - Route 2: After completing the Route 1 walkthrough, the same group will be given traditional instructions (2D video) on navigating Route 2, followed by an observed walkthrough of Route 2.~Group B Traditional - Route 1: Students will be first taken to the anesthesia lounge. Here the students will receive traditional instructions (2D video) on how to navigate Route 1. Then the students will be assessed with an observed walkthrough of Route 1.~VR - Route 2: After completing the Route 1 walkthrough, the same group will be given VR instructions on how to navigate Route 2, followed by an observed walkthrough of Route 2."
46030139|NCT05893797|Drug|Insulin Lispro|As prescribed.
46030140|NCT05893797|Device|Tempo Smart Button|Attached to the Tempo Pen
46030141|NCT05893797|Device|Dexcom G6 CGM|Continuous glucose monitor
46030142|NCT05893797|Device|Glooko Research Medical App (RMA)|Installed on a study provided android phone.
46030143|NCT05892510|Drug|Intra-arterial tenecteplase injection at the completion of thrombectomy|Intra-arterial tenecteplase (0.062mg/kg, maximum 6.25mg) administered as a bolus at the completion of thrombectomy through a microcatheter at the site of the initial-but-now-retrieved intracranial occlusion, or in direct contact with the residual thrombus
46030144|NCT05892510|Drug|Placebo|intra-arterial bolus of 0.9% Sodium Chloride solution
46030145|NCT05891587|Drug|Semaglutide|Semaglutide pen injector
46030146|NCT05891587|Drug|Placebo|Saline solution
45599319|NCT04899999|Behavioral|Financial reward graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping leads to nothing. Don't let your money vaporize away.
45599320|NCT04899999|Behavioral|Health reward graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Dying for a vape? It hurts more than you know.
46030147|NCT05887414|Other|Baseline|Measure Ottawa Decisional Regret at baseline when patients receive a diagnosis of appendicitis.
46030148|NCT05887414|Other|30 Day Follow Up|Measure Ottawa Decisional Regret after 30 days.
46030149|NCT05886972|Behavioral|Awareness about propofol injection induced pain|The aim of the study is to observe the effect of patient awareness about the possibility of occurrence of pain during propofol injection on the rate of incidence and severity of pain during injection as a primary goal as the pain score of propofol injection pain is the main end point of the study .
46030150|NCT05886270|Other|Housing Assessment/Safety Modifications|A GHHI Assessor will complete three home visits to assess home injury hazards and provide a scope of work that includes home modifications that directly address each of the identified home injury hazards. The Assessor will also provide do-it-yourself education materials and injury prevention supplies to assist them in completing the modifications.
46030151|NCT05883631|Device|Ablacath™ Mapping Catheter, Ablacath™ Mapping Catheter Accessory Cables, Ablamap® System inclusive of Amplifier, Monitor/Workstation with installed Ablamap® Software|EGF-Mapping and EGF-Guided Ablation of AF Sources
45599321|NCT04899999|Behavioral|Self-efficacy graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping companies are targeting Black and Latino teens. Your life matters. Don't let them take it away.
45599322|NCT04899999|Behavioral|Social norms graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Just because vaping is common, doesn't mean it's cool. Stay woke. Don't smoke.
45599323|NCT02299687|Drug|Omeprazole|
45599324|NCT02349243|Drug|Entacapone|200 mg entacapone, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
46030152|NCT05881551|Device|eEgg|In the eEgg-Arm, patients are given the eEgg immediately before the intervention to familiarize themselves with this method. Here, the patient is asked to press the device with maximum force for five seconds, which would correspond to an NRS value of 10, and to press the eEgg only with half force, which corresponds to an NRS value of 5. Following the instruction, the current pain score present is recorded and documented using the NRS and the eEgg. The same procedure takes place at the end of the 24h observation interval when the eEgg is returned. Within the 24h interval, pain assessment is performed hourly using the NRS (during the day) and the eEgg (preferably at hourly intervals throughout the day). If necessary, additional measurements can be taken with the eEgg.
45471612|NCT03899207|Other|training +acupressure|".Training+acupressure group; received training for coping with PMS prepared under the guidance of HBM and The Booklet of Training for Coping with Premenstrual Symptoms including information about the training given. In addition to the training, acupressure was applied by the researcher twice a week and 24 times in total. Acupressure application was continued with the same frequency until the end of the study (24 times in total for 3 months). One month after the first home visit, reminder training for coping with premenstrual symptoms was given to the women"
46030153|NCT05881551|Other|NRS|Patients record their pain on the numeric rating scale (NRS) within the 24-hour interval. An interval from 0 to 10 is given (0 = no pain, 10 = most pain imaginable).
45471613|NCT03899207|Other|training|"Training Group; received the training for coping with PMS prepared under the guidance of HBM and The Booklet of Training for Coping with Premenstrual Symptoms including information about the training given. One month after the first home visit, reminder training was given to the women."
45471614|NCT05614583|Device|MORT-PFPS app|The MORT-PFPS, developed by EverEx, Inc., is designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioural therapy for patients with patellofemoral pain syndrome.
45471615|NCT05614583|Other|treatment as usual (TAU)|In the control group, psychoeducation is delivered and self-exercise is recommended.
45471616|NCT04232618|Diagnostic Test|Multi-biomarker point-of-care test|Lateral flow device containing a combination of markers which have been shown to be associated with active tuberculosis.
45471617|NCT01148615|Drug|Aflibercept (AVE0005)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45471618|NCT01148615|Drug|Docetaxel (XRP6976)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45599325|NCT02349243|Drug|Placebo|200 mg placebo, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
45599326|NCT03513289|Other|Patient, Carer, and Clinician Interviews|Post-ICU follow-up interviews conducted over the phone, lasting between 30-60 minutes.
46030154|NCT05879835|Device|KiteLock 4% Sterile Catheter Lock Solution|KiteLock™ is a clear, colorless, and sterile 4% (40 mg/ml) tetrasodium EDTA solution that contains no preservatives, latex, antibiotics, or ethanol and is nonpyrogenic. Tetrasodium salt of EDTA has been shown to disrupt in vivo and ex vivo-generated biofilms by destabilizing the structural integrity of micro-organisms at the cellular level.
46030155|NCT05879835|Device|Heparin Lock Solution|Nonpyrogenic, hypertonic preparation of heparin sodium injection, USP with sodium chloride in water for injection.
46030156|NCT05879198|Behavioral|Computer-based Intervention|The current project proposes to pilot a computer-based working memory training program to improve delay discounting and prevent substance use among at-risk adolescents in a traditionally underserved area.
46030157|NCT05878769|Drug|Astegolimab|Participants will receive SC astegolimab Q2W
45471619|NCT04227470|Drug|HBM9161 Injection|Subcutaneous injection; Weekly administered for a period of 4 weeks. All subjects are treated with the testing drug, add on intravenous methylprednisolone (ivMP) with gradually reduce the dose then to oral prednisone. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.
46030158|NCT05878184|Drug|SC291|SC291 is an allogeneic CAR-T cell therapy
46030159|NCT05877612|Device|Implantable spinal cord stimulator|Spinal cord stimulation is possible thanks to implantable spinal cord neurostimulators. These are medical devices, which include a stimulation electrode and an implantable box, designed to deliver electrical stimulation for pain relief. The electrode is implanted in the epidural space in order to stimulate the posterior cords of the spinal cord through the dura mater, at the dorsal or cervical level.
46030160|NCT05876156|Behavioral|Virtual Reality Physical Therapy|Participants are allowed to freely choose one game from the game list. Participant will be asked to wear a validated activity tracker - ActiGraph. Baseline heart rate will be collected for 1 minute. Participants will be wearing the ActiGraph during Physical Therapy session. Participants receiving VR intervention will be instructed to wear an Oculus Quest 2 headset (Meta, Inc., Menlo Park, CA) and participate in VR applications under the supervision of the physical therapist.
46030161|NCT05876156|Behavioral|Traditional Physical Therapy|Participants will receive traditional Physical Therapy sessions (standard care) under the supervision of the accredited physical therapist. Participants will be wearing the Actigraph during Physical Therapy session. Participants will perform regular physical exercise, such as 20 minutes walking or biking on a stationary bike, under the supervision of a physical therapist.
46030162|NCT05874401|Drug|Trilaciclib|Participants will receive intravenous trilaciclib infusion
46030163|NCT05874401|Drug|Placebo|Participants will receive intravenous placebo infusion
46030164|NCT05874401|Drug|Topotecan|Participants will receive intravenous topotecan infusion
46030165|NCT05871853|Behavioral|Improved breastfeeding support|Cross-sectoral intervention to improve breastfeeding support among women giving birth at Slagelse Hospital, Region Zealand, Denmark
46030166|NCT05871164|Procedure|Pancreatic radiofrequency|Pancreatic radiofrequency is similar to a puncture under echoendoscopy. The lesion is located then punctured by transgastric or transduodenal route either using a 19 gauge needle with exchange of the stylet for a probe, or using a 19 gauge needle whose distal end of 5-10 mm corresponds to the active part, connected to a generator with an integrated cooling system.
46030167|NCT05869552|Other|STAT-PC|STAT-PC is an adapted version of Suicidal Teens Accessing Treatment after an ED Visit (STAT-ED). It is a brief intervention based on motivational interviewing (MI) that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management. The intervention will consist of an initial session with the youth focusing on accessing mental health care plus case management calls. The interventionist will also be available to assist with referrals for connection to other services later during the study period as needed for up to three months. The intervention may include contact with the youth's mental health provider to make sure linkages are made.
45471620|NCT01150175|Procedure|Endomyocardial Injection of Autologous Bone Marrow Cells|Endomyocardial Injection of Autologous Bone Marrow Cells
45471621|NCT01150175|Procedure|Endomyocardial Injection of Plasma|Endomyocardial Injection of Plasma
45471622|NCT03905447|Drug|PC945|Nebulized PC945 5mg OD for 28 days with an optional extended treatment period of a further 56 days.
45471623|NCT03905447|Drug|Standard of Care|Standard of Care antifungal medication
45471624|NCT03905681|Device|Transcutaneous Electrical Nerve Stimulation|Application of TENS pads and wearing of the TENS device.
45682431|NCT03824938|Drug|Acetaminophen Tablet 650mg|A 650mg dose of acetaminophen is administered in the laboratory one hour before participant completes a maximal exercise test.
45682432|NCT03824938|Other|Placebo|A placebo pill is administered in the laboratory one hour before participant completes a maximal exercise test.
46030168|NCT05869552|Other|YST-III|YST-III is an adapted version of Youth-Nominated Support Team for Suicidal Adolescents (YST-II). The intervention is a brief intervention originally developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation (SI). Participants will nominate supportive adults (age 18 and older) from their lives who agree to provide ongoing contact and support for up to 3 months. YST-III will include an introductory session with the youth who will nominate their support persons plus referrals for mental health services. The support persons will receive training and support on how to best support their youth partner and then ongoing calls to support them in working with their youth partner for up to 3 months.
45682433|NCT03630640|Drug|Nivolumab Injection [Opdivo]|Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant up to 12 months after EP
45471625|NCT04161248|Drug|Venetoclax|"Dose Level -1: Venetoclax 200 mg/day days 4-8 cycle 1, days 1-5 cycle 2 and 3, + R-GDP~Dose Level 1: Venetoclax 200 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 2: Venetoclax 400 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 3: Venetoclax 800 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP"
46030169|NCT05868850|Behavioral|auricular point sticking|"Acupoint selection: Select Shenmen, spleen, stomach, liver, sympathetic, tongue, digestive system under the cortex, three focal, ear-back spleen.~Operation: Use 75% ethanol to disinfect auricular broad skin; To be dry, use tweezers to pick up the middle of the small square tape stuck with Wang do not line seeds, align the indentation and stick well, press gently with the finger abdomen, the strength to the patient feel acid swelling, pain and heat sense and can tolerate it.~Press frequency and course of treatment: it is asked to press 4 times a day, once in the morning, middle and evening before going to bed, 3-5 minutes each time, the duration of hospitalization for patients with chemotherapy is generally 3-5 days, intervention begins on the first day of chemotherapy medication, the day of discharge for patients to replace the other side of the ear acupoint, removed after 4 days of discharge. A total of 2 chemotherapy courses were treated."
46030170|NCT05867875|Other|Unblinded ORI values|ORI and SpO2 monitoring will be performed using Masimo Rad 7 and both values will be provided to investigator
46030171|NCT05867875|Other|Blinded ORI values|ORI and SpO2 monitoring will be performed using Masimo Rad 7 and only SpO2 values will be provided to investigator
45471626|NCT04161248|Drug|RiTUXimab Injection|375 mg/m2 - Day 1, cycle 1.
45471627|NCT04161248|Drug|Rituximab SC|1400 mg fixed dose - Day 1, cycle 2 and 3
45471628|NCT04161248|Drug|Gemcitabine|1000 mg/m2 - Day 1 to day 8
46030172|NCT05866718|Behavioral|Self-Compassionate Touch Intervention|Participants will be taught the micropractice (<20-second/day personal practice) via video recording.
46030173|NCT05866718|Behavioral|Habit Formation Tools|Participants will receive evidence-based tools for promoting habit-formation.
46030174|NCT05866367|Drug|Low dose Regular Insulin|Regular insulin administered intranasally at either 40 IU
45471629|NCT04161248|Drug|Dexamethasone|40 mg daily - Day 1 to day 4
45471630|NCT04161248|Drug|Cisplatin|75mg/m2 - Day 1
45471631|NCT03905759|Drug|Dronedarone|Dronedarone (200 mg twice daily starting from day before operation till 5 days after)
46030175|NCT05866367|Drug|High dose Regular insulin|Regular insulin administered intranasally at either 80 IU
45471632|NCT03905759|Drug|Amiodarone|Group A:-amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery
45471633|NCT03905759|Drug|Colchicine|Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge
45599327|NCT02341131|Behavioral|Cognitive Remediation Therapy|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.
45599328|NCT02341131|Behavioral|Psychoeducation|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
45599329|NCT02341209|Drug|Doxycycline monohydrate|Doxycycline will be administered in either tablets or capsules for either five months or a year depending on response.
45599330|NCT02349165|Procedure|Transepithelial versus epithelium-off CXL|A comparison of the CXL procedure with and without epithelium removal
46030176|NCT05861895|Drug|HF158K1 /Arm 2 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
45471634|NCT05204498|Behavioral|Education plan and adherence to exercise|"Through phone calls with a motivating sense at any time of the day, twice a week.~It will be recorded in an Excel table each time the patient is called.~A monthly survey will be applied where the adherence to the exercise during the previous month is measured.~These activities will be carried out for 8 weeks. At the end of week 8, patients will be referred to the pulmonary rehabilitation unit to evaluate the anthropometric parameters, assess dyspnea with the modified scale of the Medical Research Council, the hospital anxiety and depression scale, the Saint George respiratory questionnaire , the pulmonary information You need the questionnaire and the 6-minute walk test again."
46030177|NCT05861895|Drug|HF158K1 /Arm 6 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
46030178|NCT05861895|Drug|HF158K1 /Arm 15 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
45471635|NCT01255475|Drug|Hydralazine/amlodipine|Patients will receive drug therapy aimed to reducing blood pressure - first line drug will be hydralazine up to 100mg/day; if systolic blood pressure reduces less than 20% from baseline and remains over 100mmHg patients will further receive amlodipine up to 10mg/day
45471636|NCT01255475|Drug|Placebo|Patients will receive placebo
45471637|NCT05204420|Procedure|Gastric wide local excision for bleeding mass|Laparoscopic partial gastrectomy for gastric submucosal mass
45471638|NCT01255553|Radiation|Partial Breast Irradiation|Partial breast irradiation will be administered using a 3D conformal external beam RT technique. Two fractions of 38.5 Gy separated by at least 6 hours will be given on 5 treatment days over a period of 5 to 10 days.
45471639|NCT05208398|Drug|Apixaban|5 mg twice daily, on top of standards of care.
45471640|NCT05208398|Drug|Warfarin|Warfarin, oral tablets, to achieve international normalized ratio (INR) of 2-3, on top of standards of care, as per updated guidelines of acue coronary syndrome management recommendations
46030179|NCT05861895|Drug|HF158K1 /Arm 30 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
46030180|NCT05861895|Drug|HF158K1 /Arm 45 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
45599331|NCT02349165|Drug|Ricrolin TE|Ricrolin TE was instilled during 30 minutes before ultraviolet-A irradiation
45471641|NCT05593991|Other|Elevated heels|"Each subject will undergo the following evaluations:~neutral barefoot position;~neutral barefoot position (re-test);~3 cm rise of both heels, made with plastic spacer;~7 cm rise of both heels, made with plastic spacer."
45471642|NCT04117802|Other|Maple syrup|Substitution of refined sugar by an equivalent quantity of maple syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with maple syrup.
45471643|NCT04117802|Other|Placebo|Substitution of refined sugar by an equivalent quantity of maple-flavored sucrose syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with the placebo (sucrose syrup).
45471644|NCT05593601|Drug|Neomycin|Neomycin (350 mg/tablet) 1.4 g three times a day (4.2 g per day) for 5 days
45599332|NCT02349165|Drug|Isotonic riboflavin|After epithelium removal, isotonic riboflavin was instilled during 30 minutes before ultraviolet-A irradiation
45599333|NCT02302963|Device|AP System (DiAs or inControl) with USS Virginia|Subject will participate in two 24-hour study insulin pump and AP System training sessions. At the conclusion of each training session, subject will wear the equipment at home for a total of 5 weeks.
45599334|NCT02302963|Device|Sensor-Augmented Pump Therapy (placebo)|Subject will participate in 5 weeks use of CGM and personal insulin pump at home.
45599335|NCT03112005|Procedure|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
46030181|NCT05861895|Drug|HF158K1 /Arm 60 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
46030182|NCT05858957|Drug|Magnesium sulfate|magnesium sulphate IV 30 mg/kg (10 min) infusion apply to the Group M
46030183|NCT05858957|Drug|Saline|100 ml saline infusion apply to the Group S
45599336|NCT03112005|Drug|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
45599337|NCT02341053|Other|Assisted Standing Treatment Program|Assisted Standing Treatment Program - Assisted standing treatment program will be gradually increase duration of standing by up to 75% after baseline.
45599338|NCT02303197|Drug|ChiNing decoction|ChiNing decotion was reformed by Liangge San that was stemed from Prescriptions of the Bureau of Taiping People.
45599339|NCT03111849|Other|sarcopenia|Prevalence of sarcopenia in hospitalized chronic obstructive patients
45682434|NCT03629470|Other|Standard Conservative Treatment|Range of motion exercises, medication and activity modification.
45682435|NCT03629470|Other|Nerve Gliding Exercises|Taught by occupational therapist. These exercises involve motions of the wrist, arm and neck. Subjects will be instructed to perform exercises regularly following the occupational therapists' protocol
45682436|NCT03723226|Behavioral|Low Load Resistance Exercise|Subjects allocated to Low Load Resistance Exercise will undergo 6 weeks of single-legged low load (25%) resistance exercise. Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
45682437|NCT03723226|Behavioral|Low Load Resistance Exercise + BFR|Subjects allocated to Low Load Resistance Exercise + BFR will undergo 6 weeks of single-legged low load (25%) resistance exercise with blood flow restriction (60% occlusion pressure). Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
46030184|NCT05847712|Other|Simulated work in the heat|Participants perform a continuous moderate-intensity work bout (metabolic rate of ~200 W/m2) until core temperature reaches 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels), which is immediately followed by intermittent work using a 3:1 work-rest allocation, starting with a 15 min rest break followed by a 45 min work bout for a total work duration of ~240 min. The work protocol is performed in the morning of day 1, and repeated in a post-lunch work period (i.e., afternoon of day 1) and on the morning of the next day (i.e., morning of day 2).
46030185|NCT05847530|Device|Potenza|Subjects will receive 1-4 treatments at approximately 1 month intervals, but other intervals from 2 to 12 weeks may take place at the PI's discretion. At the discretion of the PI, additional follow-up visits may take place to observe the time course of skin reactions after treatment and/or to assess if the skin condition continues to improve beyond 3 months after treatment.
46030186|NCT05847530|Device|Icon|Subjects will receive 1-4 treatments at approximately 1 month intervals, but other intervals from 2 to 12 weeks may take place at the PI's discretion. At the discretion of the PI, additional follow-up visits may take place to observe the time course of skin reactions after treatment and/or to assess if the skin condition continues to improve beyond 3 months after treatment.
46030187|NCT05844137|Behavioral|NAFLD Education|NAFLD Education
46030188|NCT05844137|Behavioral|diet/lifestyle support|diet/lifestyle support
46030189|NCT05844137|Drug|T2D medication management|T2D medication management
46030190|NCT05844137|Diagnostic Test|clinically-indicated liver testing and care|clinically-indicated liver testing and care
45839117|NCT05620602|Other|Remedial treatment within 3 to 6 months|"The interval between the time of this treatment and the last day of the last therapy is 3-6 months.~Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
46030191|NCT05840354|Device|repetitive transcranial magnetic stimulation|"60 minutes after administration of the lumbar FJI, participants will attend their first rTMS session. rTMS will be delivered using a biphasic stimulator (DuoMag) and a figure-of-eight coil to the corticomotor representation of the first dorsal interosseous muscle contralateral to the side of worst LBP. Recording electrodes will be positioned in a belly-tendon montage over the FDI for electromyography recording. The hotspot and resting motor threshold (rMT) of the FDI will be determined and saved using a Brainsight Neuronavigation system to ensure accurate coil repositioning within and between sessions.~The hotspot and rMT will be confirmed and adjusted if needed at each intervention session. Each rTMS session will consist of 40 trains of 5s delivered at 10Hz, at an intensity of 95% of the resting motor threshold for the FDI muscle and an intertrain interval of 25s (total of 2000 stimulations in a 20-minute session)."
46030192|NCT05840354|Device|sham repetitive transcranial magnetic stimulation|Sham intervention will follow same protocol as active rTMS using a sham coil that does not deliver actual magnetic stimulation.
46030193|NCT05840354|Drug|Facet Joint Injection|The facet joint injection will be given 1 week ahead of active rTMS and sham rTMS commencement. A dose of 0.5mL of 40mg/mL triamcinolone and 0.5mL of 2% lidocaine will be given per joint via spinal needle. The treatment team will determine how many joints will be injected based on their standard clinical assessment. Usually, about 2-4 joints are injected depending on a person's pain presentation. Standard practice is to place the needle in the region of the facet joint opening, resulting in a peri- +/- intra-articular infusion of the injectate. This project will utilize this standard clinical practice without modification.
46030194|NCT05836987|Device|AFSW Guided DOAC|The AFSW will intermittently and passively assess for rhythm irregularities consistent with AF and notify the wearer and coordinating center if a threshold AF event has occurred.
46030195|NCT05836987|Drug|Continuous DOAC therapy|DOACs will be prescribed to patients according to the treating healthcare provider(s) according to labeling instructions.
46030196|NCT05834114|Other|Mckenzie protocol|"In this group 20 participants will receive McKenzie protocol with conventional physical therapy. Participants will be asked to sit to treat extension deficit. The participant will be in a comfortable sitting position with a proper back support. Head is kept in forward facing without any up and done movement (10 to 15 times). Then, he restored the neutral sitting posture, and at the end of the range of motion (ROM), he' tuck in chin by pushing the chin with his fingers (10 to 15 times). Subsequently, the participant will be requested to return to the original position while the therapist one hand's forefinger placed alongside the participant's mandible (to stabilize the head at full retraction position), and the heel of the other hand placed on the first or second dorsal vertebra (to provide posterior-anterior force). The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week."
45682438|NCT03629080|Biological|HB-101 vaccine|HB-101 is a bivalent vaccine that contains two replication deficient recombinant lymphocytic choriomeningitis virus (rLCMV) vectors expressing pp65 and a truncated isoform of gB of human CMV.
46030197|NCT05834114|Other|Rhythmic Stabilization technique|In this group participants will receive Rhythmic stabilization, with Conventional physiotherapy treatment the flexion , extension exercises performed. During flexion pattern the experimenter stood at the right side of patient and used his tip of fingers at chin. The experimenter then put his left hand at anterior side of head to apply resistance. then extension pattern is resisted and asked patient to match my resistance. The experimenter provided resistance against right rotation and lateral flexion provided during the exercise in order to induce strong muscle contractions. 3 sessions of 45 minutes a week, over a period of 10 weeks.
46030198|NCT05833490|Other|Repetitive Peripheral Magnetic Stimulation (rPMS)|Repetitive Peripheral Magnetic Stimulation (rPMS) is an external device that delivers repetitive pulsed magnetic fields of sufficient magnitude, will be applied on the tibialis anterior muscle belly at ~ 10% of motor threshold, in order to induce neural action potentials in the lower extremities.
45682439|NCT03629080|Biological|placebo|Saline will be used for placebo.
46030199|NCT05833490|Other|Sham Priming|Sham Priming using the Repetitive Peripheral Magnetic Stimulation (rPMS), it will be applied on the dorsal part of the foot with a minimal intensity at 5% of maximum stimulator output, that is of insufficient magnitude to induce changes in the muscle or nerves of lower extremities.
46030200|NCT05831800|Device|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid balance. It is designed as an adhesive patch with four integrated electrodes. The outer electrodes are used to supply a low current, while the inner electrodes are used for voltage measurements.
46030201|NCT05827341|Other|No intervention|No intervention needed
45471645|NCT05207930|Device|GAmified HOme-based COgnitive-Nutrition training (GAHOCON)|"A home-based tablet game training, in which participants are expected to apply the nutrition knowledge they learn from the centre-based nutritional education and their cognitive functions.~Participants in the intervention group are expected to engage in the home-based training regularly during those 8 weeks. A team of registered social workers working in the elderly community centre will monitor the progress, remind, set goals, and provide supports to the participant remotely on WhatsApp."
46030202|NCT05826964|Drug|AI+CDK4/6i|"Participants will receive standard of care one of three available AI therapies in combination with one of three available CDK4/6i therapies:~AI: Anastrozole, Letrozole or Exemestane~CDK4/6i: Palbociclib, Ribociclib or Abemaciclib"
46030203|NCT05826964|Drug|SERD+CDK4/6i|"Participants will receive standard of care SERD therapy in the form of Fulvestrant, in combination with one of three one of three available CDK4/6i therapies:~SERD: Fulvestrant~CDK4/6i: Palbociclib, Ribociclib or Abemaciclib"
46030204|NCT05826964|Drug|mTOR inhibitor + AI|Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with AI therapy (Exemestane) in Step 2 Arm 2 and Step 3. mTOR inhibitor + AI therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
45471646|NCT05207930|Device|Centre-based online open-source cognitive games|During the 8 weeks in which the intervention group receives GAHOCON treatment, the control group will be introduced to some online open-source cognitive games (e.g. CogniFit) and are encouraged to play those games at the elderly community centre. However, the content of these games are unrelated to nutrition and the training is gamified to a less extent compared to GAHOCON. They will have free access to these online open-source cognitive games at the elderly community centre.
45471647|NCT04109690|Drug|CPX-351|Patients in both Phase I and II can receive a maximum of two induction and six consolidation cycles on an inpatient or outpatient basis per local hospital standard of care.
45471648|NCT03899051|Procedure|interdental papilla reconstructive surgery with PRF|Papilla reconstruction would be done with platelet rich fibrin
46030205|NCT05826964|Drug|mTOR inhibitor + SERD|Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with SERD therapy (Fulvestrant), in Step 2 Arm 2 and Step 3. mTOR inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
46030206|NCT05826964|Drug|mTOR inhibitor + Selective estrogen receptor modulator|Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with selective estrogen receptor modulator therapy (Tamoxifen) in Step 2 Arm 2 and Step 3. mTOR inhibitor + Selective estrogen receptor modulator therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
46030207|NCT05826964|Drug|PI3K inhibitor + SERD|Participants will receive standard of care one PI3K inhibitor therapy (Alpelisib), in combination with SERD therapy (Fulvestrant) in Step 2 Arm 2 and Step 3. PI3K inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
46030208|NCT05826964|Drug|PI3K inhibitor + AI|Participants will receive standard of care a PI3K inhibitor therapy (Alpelisib), in combination with an AI therapy (Letrozole) in Step 2 Arm 2 and Step 3. PI3K inhibitor + AI therapy administered as one of the available options for early switch from SERD+CDk4/6i therapy in administered in Step 1.
46030209|NCT05826964|Drug|Chemotherapy|Chemotherapy administered standard of care as an alternative therapy in Step 2 Arm 2 and Step 3.
45682440|NCT03628534|Device|Saline Enhanced Radiofrequency (SERF) ablation|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
46030210|NCT05820698|Other|The Mediterranean style diet|"Participants in the Mediterranean style diet group will be provided with recommendations to include a minimum of 5 servings of fruits and vegetables (combined) per day, 2 servings of whole grains per meal per day, at least two servings of extra virgin olive oil per day, a maximum two servings of dairy products per day (excluding milk in coffee/tea), a minimum of 3 servings of fish per week (of which two should be oily fish), less than 2 servings of red meat or processed meat per week. Confectionary and sugar sweetened beverages should be limited to less than 2 servings per week.~Participants randomised to the Mediterranean style intervention will be provided with support documents including a dietary guideline booklet, recipes, meal plans, shopping and product swap lists, as well as eating-out and budget-eating advice sheets. Food deliveries containing key food items of the diet intervention will be scheduled for week 1, week 4, and week 8 of the study."
46030211|NCT05820698|Other|The UK diet|"Participants in the UK diet with time-restricted eating group will be provided with recommendations of a nutritionally balanced diet, corresponding to the average intakes of the UK population. Participants will be advised to consume no more than 4 portions of fruits and vegetables combined per day, to have at least two servings of dairy per day, to limit the consumption of white fish to less than 1 serving per week, with ≤1 serving of oily fish per month. Nuts and seeds consumption should also be limited to ≤1 serving per week and at least 3 servings of white and red meat should be consumed per week.~Participants randomised to the UK diet will be provided with support documents including a dietary guideline booklet, recipes, and meal plans. A £30 reimbursement will be provided to participants for their grocery shopping on week 1, week 4, and week 8 of the study."
46030212|NCT05820698|Other|Time-restricted eating|Participants randomised to the time-restricted eating interventions will be advised to limit food intake to a 10-hour eating window and to abstain from food intake for a 14-hour fasting window. Hydration is to be maintained during the fasting window with water and/or plain teas/coffees
46030213|NCT05816447|Behavioral|interview|Interview patient's perception
46030214|NCT05813925|Drug|Cagrilintide|Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
46030215|NCT05813925|Drug|Semaglutide|Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
45682441|NCT03820882|Device|Catfish|Patients will be treated for mechanical recanalization with Catfish within 8 hours after stroke onset plus standard medical management.
46030216|NCT05813925|Drug|Placebo Semaglutide|Participants will receive placebo matched to semaglutide
46030217|NCT05806593|Behavioral|Get Back pilot|A health-promoting program, targeting physical activity behavior, with a person-centred approach led by a physiotherapist digitally during 12 weeks.
46030218|NCT05806580|Drug|Relmacabtagene Autoleucel Injection|For patients who had undergone at least one disease assessment after the first treatment of Relmacabtagene Autoleucel injection and whose disease status was not complete remission, the investigators decided to give the patients a second treatment of Relmacabtagene Autoleucel injection based on clinical practice, and the specific dosage was determined by the investigators according to the patient's condition and dose reserve.
46030219|NCT05806164|Drug|Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]|The beta-agonist oral medication will be prescribed and dose adjusted per usual care.
46030220|NCT05806164|Drug|OnabotulinumtoxinA 100 UNT [Botox]|OnabotulinumtoxinA will be prepared by dissolving 100 units into 10 ml of injectable saline. The injection will be an office based procedure, performed per usual care.
46030221|NCT05805501|Drug|RO7247669|Participants will receive IV RO7247669 Q3W.
46030222|NCT05805501|Drug|Tiragolumab|Participants will receive IV tiragolumab Q3W.
46030223|NCT05805501|Drug|Pembrolizumab|Participants will receive IV pembrolizumab Q3W.
45682442|NCT03820882|Device|Solitaire FR|Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
45682443|NCT03820726|Drug|Nintedanib|Bid
46030224|NCT05805501|Drug|Axitinib|Participants will receive axitinib PO BID.
46030225|NCT05802589|Procedure|Lumbar Erector Spinae Plane Block|Erector spinae plane block was applied with a 22G/80 mm block needle (Stimuplex A, Braun, Melsungen, Germany) using in-plane technique using a convex USG transducer from the 4th lumbar vertebral level.
46030226|NCT05802589|Procedure|Pericapsular Nerve Group Block|Pericapsular nerve group block was performed using a 22G/80 mm block needle (Stimuplex A, Braun, Melsungen, Germany) and a convex USG transducer using an in-plane technique under the iliopsoas muscle in the plane between the iliopsoas tendon and the periosteum and between the anterior inferior iliac spine and the iliopubic eminence.
46030227|NCT05802589|Procedure|no peripheral block|No peripheral block was applied. Standard multimodal analgesia method was applied.
46030228|NCT05788536|Biological|DB-OTO|"DB-OTO will be administered as a single intracochlear injection into one ear (Part A).~LD Cohort (starting dose)~HD Cohort (high dose)"
45471649|NCT03899051|Procedure|interdental papilla reconstructive surgery with subepithelial connective tissue graft|Papilla reconstruction would be done with subepithelial connective tissue graft
45682444|NCT03721120|Diagnostic Test|InvisionFirst® molecular panel|"During the first visit, liquid biopsy will be performed using the InVisionFirst® panel. Cytological or histological sampling will be planned. According to InVisionFirst® results, treatment will be initiated:~regardless of cytological/histological and tissue molecular analysis in case of EGFR, BRAF V600E-mutation, ALK- or ROS1-rearrangement identified on InvisionFirst® panel.~regardless of molecular characterization performed on tissue sample in case of ERBB2-, BRAF non V600E-, c-MET-, KRAS-,LKB1-, NTRK and/or RET mutation on InVisionFirst® panel. Treatment will be based on pathology results and if appropriate on PD-L1 level of expression.~for patients with none of the previous alterations, treatment will be initiated after obtaining pathology results and genomic characterization from the tumor tissue analysis."
46030229|NCT05788536|Biological|DB-OTO|DB-OTO will be administered as a single intracochlear injection into both ears (Part B). For bilateral injections (Part B), patients will receive DB-OTO in 1 surgical session.
46030230|NCT05787834|Other|Best Practice|Receive usual care
46030231|NCT05787834|Other|Medical Device Usage and Evaluation|Wear accelerometer
46030232|NCT05787834|Procedure|Respiratory Muscle Training|Undergo RMT
46030233|NCT05787834|Other|Survey Administration|Ancillary studies
46030234|NCT05777187|Other|Clinical Decision Support|The intervention will consist of clinical decision support alerts in the electronic health record directed towards anesthesiologists caring for patients with preexisting cognitive impairment. This intervention will alert towards delirium risk informed by history of cognitive impairment and promote 12 evidence based best practices during care for perioperative patients.
46030235|NCT05774184|Biological|barzolvolimab|subcutaneous administration
46030236|NCT05774184|Drug|Matching Placebo|subcutaneous administration
46030237|NCT05772429|Drug|Epidiolex|Administered as an oral solution
45839118|NCT05620602|Other|Remedial treatment within 6 to 12 months|"The interval between the time of this treatment and the last day of the last therapy is 6-12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
46030238|NCT05767619|Diagnostic Test|Troponin hs-cTnI|One sample of Troponin (hs-cTnI) is obtained and analyzed at the scene. Capillary blood sample or venous (lithium heparin) if peripheral venous catheter is inserted for standard care reasons. The sample is disposed after the result has been recorded in the clinical report form. The clinicians participating in the study are instructed and have been educated about the study to only collect the data (report form with measurements) and provide care as constituted by the guidelines. Patients will be monitored by board members that standard clinical care is provided.
46030239|NCT05767619|Diagnostic Test|Plasma glucose|One sample of plasma glucose is obtained and analyzed at the scene. The sample is then disposed and the measured value is recorded in the clinical report form. P-glucose measurement is clinical practice in standard care and is measured on all patients with diabetes and patients with altered mental status or at the ambulance nurse discretion.
46030240|NCT05763355|Procedure|Biopsy|Biopsies will be performed under local anaesthesia. In all patients with a suspicious lesion (PIRADSv2.1 3-5) noted on the mp-MRI, the software-based image fusion biopsies will be obtained collecting 3 to 5 cores per target area according to its volume, 10-12 systematic cores of the remaining areas of the prostate will be collected from sectors specified in the PIRADSv2.1 prostate map.
45471650|NCT03629210|Drug|OZURDEX|OZURDEX® (DEX implant, 0.7 mg) is a micro-ionized and non-preserved dexamethasone within a cylindrically-shaped 0.45 mm diameter x 6.5 mm length biodegradable Poly D, L-lactate-co-glycolic acid pellet allowing for sustained delivery dexamethasone into the vitreous cavity and retina following intravitreal injection. Health Canada has granted approval for use of DEX implant in the treatment of ME following central retinal vein occlusion, non-infectious uveitis affecting the posterior segment and pseudophakic DME in adult patients. (OZURDEX® Canadian Product Monograph, April 14, 2015). DEX implant will be provided as investigational treatment by Allergan Inc., Markham, ON, Canada.
45682445|NCT03815500|Behavioral|Enhanced Education|Enhanced educational curriculum will involve learning modalities including 3D modeling, video, and visual-aid enhanced text for references to improve caregiver and patient understanding of wound packing techniques.
46030241|NCT05762796|Device|tDCS in Youth with mild traumatic brain injury|The safety and tolerability of tDCS have been established in children with mTBI (1). A recent study of 13-18 year youths post-mTBI showed that three sessions of 1.5 mA anodal tDCS over the left DLPFC, positively influenced prolonged working memory deficits. (2) Additionally, rodent studies show the effectiveness of tDCS in improving cognitive-motor (motor planning and balance/gait) function in rats with mTBI. (3)
46030242|NCT05762471|Drug|GSBR-1290|Patients will receive GSBR-1290 or matching Placebo
46030243|NCT05762471|Drug|Placebo|Patients will receive GSBR-1290 or matching Placebo
46030244|NCT05876442|Device|Extracorporeal Shock Wave Therapy.|Patients will receive EPSW therapy at the area of the wrist for 5 minutes 3 times a week for 3 months.
46030245|NCT05876442|Device|High Intensity Laser Therapy|High intensity laser therapy at the area of the carpal bones for 5 minutes 2 times a week.
46030246|NCT05876442|Other|Traditional Physical Therapy Exercise Program|30 minutes of stretching exercise for the wrist and carpal region with the fingers flexed and extended. Followed by strengthening exercises for the wrist flexors, extensors, and radial and ulnar deviation muscles. Mobilizing exercise, tendon gliding exercise, and instructed to wear a wrist splint at night
45839119|NCT05620602|Other|Remedial treatment after 12 months|"The interval between the time of this treatment and the last day of the last therapy is more than 12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
46030247|NCT05761301|Drug|ALN-KHK|ALN-KHK will be administered by subcutaneous (SC) injection.
45682446|NCT03625726|Biological|Thrombin generation assay (in vitro)|One blood sample.
45682447|NCT03625024|Behavioral|Cognitive-behavioral therapy|Individual cognitive-behavioral therapy, including homework and behavioral change methods.
46030248|NCT05761301|Drug|Placebo|Placebo will be administered by subcutaneous (SC) injection.
46030249|NCT05760807|Drug|Oxytocin nasal spray|Intranasal oxytocin, administered dose 24 international units (IU) twice daily, delivered over 7 days of a residential inpatient withdrawal admission.
45471651|NCT03629210|Biological|Eylea|EYLEA® (AFL 2.0 mg intravitreal injections) is an anti-VEGF treatment. AFL (2.0 mg) has received approval from Health Canada for the treatment of DME. Health Canada has also granted approval for AFL (2.0 mg) in the treatment of age-related macular degeneration, and ME secondary to retinal vein occlusion.
45471652|NCT05569811|Drug|Patritumab deruxtecan|HER3-DXd will be administered as Lyo-DP, a sterile lyophilized powder in a dose of 5.6 mg/kg
45471653|NCT05569811|Drug|Chemotherapy|Anthracycline/taxane-based neoadjuvant regimen recommended by the NCCN or local guidelines. i.e. EC or AC (epirubicin 90 mg/m2 or doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 14 or 21 days) followed by weekly paclitaxel 80mg/m2 during 12 weeks
45471654|NCT05569811|Drug|Letrozole|Letrozole and LHRH will be used following SmPC specifications, according to standard therapy and clinical studies
45471655|NCT05560061|Other|Gait practice on an uneven terrain surface|Participants will walk back and forth on an uneven terrain surface wearing an overhead harness (with zero bodyweight support), at their self-selected comfortable speed.
45471656|NCT05560061|Other|Gait practice on a flat terrain surface|Participants will walk back and forth on a level surface wearing an overhead harness (with zero bodyweight support), at their self-selected comfortable speed.
45471657|NCT04007198|Drug|EQ001|Itolizumab [Bmab 600]
45839120|NCT05620446|Procedure|endoscopy|the technique was done by two doctor the patients were sedated then colonoscopy was done for the patients while the patients were put in lithotomy position , we identified the site of sigmoid colon fixation by radiological colongraphy then tip of artery forceps was moved at outer skin at anterior abdominal wall at left lower quadrant to meet tip of colonscopy at multiple point where fixation was done . fixation was done by exploratory puncture of skin by scalpel about (2-3 mm puncture) at site of these points then widening the puncture by artery forceps at level of subcutaneous tissue. A 2- shot anchor device was used to fix the sigmoid colon against anterior abdominal wall. The 2-shot anchor device was passed through the puncture to be entered inside the sigmoid colon and the thread with a metal T-bar was detachd and pulled towards the anterior abdominal wall. This was repeated at multiple point of fixation .
45839121|NCT05620290|Drug|Definity|Stimulation of Definity microbubbles using Sonalleve device within tumour vasculature
45839122|NCT05620290|Device|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
45471658|NCT04007198|Drug|EQ001 Placebo|EQ001 Placebo
45839123|NCT05620212|Behavioral|Recovery College participation|Recovery College participation in any way (visitors, course/retreat participants, volunteers, employees).
45839124|NCT05620056|Drug|chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs|medication (i.e., chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs ) exposure through the pregnancy life course
45839125|NCT05619978|Other|3L Therapy|Treatments received in 3L were dasatinib, nilotinib, imatinib, ponatinib, bosutinib, and allo-SCT
45471659|NCT03899285|Drug|Citalopram 20mg or 40 mg (phase 2)|For non-responders, a randomisation 1:1 was chosen. The group A will receive 40 mg and the group B will receive 20 mg once daily of citalopram for 14 days.
45471660|NCT04328077|Drug|TERN-101|Investigational drug
45471661|NCT04328077|Other|Placebo|Matching placebo
45682448|NCT03624400|Behavioral|Internet-based CBT-I|The adapted Internet-based CBT-I for adolescents with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 8 weekly modules and each module consists of several website pages that will be presented in a fixed order, with preprogrammed modules containing information, interactive questionnaires, descriptions of exercises and movies.
46030250|NCT05756361|Behavioral|Family-Based Treatment for T1D|"Our FBT curriculum, which has been delivered successfully in the specialty and primary care settings, has 3 components: 1. Meal planning including quality of carbohydrates and glycemic index for both parents and children while ensuring that youth have a balanced meal plan with adequate amounts of carbohydrates for optimal growth. Our FBT has a focus on Food Literacy including healthy food selection and sourcing of affordable healthy food, food preparation and preplanning, social engagement tailoring the meal plan to the needs to the family in socio cultural appropriate way and also feasibility based on logistics and economic aspects; 2. Physical activity (PA) component with shaping strategy to allow for a progressive shaping of easy PA starting, if needed, with as little as with 10 minutes of walking/day and strategies to incorporate PA in daily routines, family, and social activities; 3. Extensive behavioral component which has been shown to be very powerful in obesity treatment"
46030251|NCT05754996|Drug|Nifuroxazide|Nifuroxazide dosing : 200 mg capsule four times daily
45682449|NCT03624400|Behavioral|Internet-based psychoeducation|Internet-based psychoeducation contains information about ASD, sleep difficulties and aspects of sleep hygiene. The intervention takes place in 8 weeks modules.
45682450|NCT04403854|Diagnostic Test|MRI|If possible with spectroscopy
45682451|NCT04403854|Procedure|Spinal Tap|together with CSF pressure estimate
45682452|NCT03814954|Drug|Salbutamol|At first day of admission, patients will receive 3 doses of nebulized salbutamol every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
45682453|NCT03814954|Drug|Epinephrine|At first day of admission, patients will receive 3 doses of nebulized epinephrine every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
45682454|NCT03813160|Drug|Lenabasum 20 mg|oral capsule
46030252|NCT05754996|Drug|Lactulose|Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools
45682455|NCT03813160|Drug|Lenabasum 5 mg|oral capsule
45839126|NCT05619978|Other|T315I|Patients with chronic myeloid leukemia with T315I mutation
45839127|NCT05619900|Other|There is no intervention|This is an observational study. There is no intervention. The purpose of the project is to create a database of patients diagnosed either prenatally or after birth with a lysosomal storage disease. The database will be utilized to assess patient outcomes, build on existing clinical management, improve medical decision making, and improve quality of care.
46030253|NCT05748171|Drug|Inotuzumab ozogamicin|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved in several countries for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle.
46030254|NCT05748171|Drug|ALLR3|The ALLR3 chemotherapy regimen (vincristine, mitoxantrone, dexamethasone, and asparaginase) has been adopted by pediatric oncology groups as treatment for pediatric relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)
46030255|NCT05746442|Behavioral|Smartphone-delivered Automated Messaging|An interactive smartphone based intervention will provide weekly smoking-related assessments and personalized automated messages designed to increase motivation, self-efficacy, use of coping skills, social support and to reduce nicotine withdrawal symptoms and stress for a 26 week period.
46030256|NCT05746442|Drug|Nicotine patch|Participants will be provided with a 8 week supply of nicotine patches
46030257|NCT05746442|Behavioral|Brief Advice to Quit and Smoking Cessation Self Help Materials|Participants will receive self-help materials from Khmer Quit Now, a national smoking cessation campaign in Cambodia
46030258|NCT05746442|Behavioral|Diet Assessment|Participants will be asked to complete brief weekly smartphone assessments about their diet for a 26-week period
46030259|NCT05742802|Combination Product|Tozorakimab|Participants previously randomised to Tozorakimab in one of the predecessor studies will be assigned to the same Tozorakimab dose and regimen in the PROSPERO study.
46030260|NCT05742802|Combination Product|Tozorakimab|Participants previously randomised to Tozorakimab in one of the predecessor studies will be assigned to the same Tozorakimab dose and regimen in the PROSPERO study.
46030261|NCT05742802|Combination Product|Placebo|Participants previously randomised to placebo in one of the predecessor studies will be reassigned to one of the active doses of Tozorakimab or placebo in a 1:1:2 ratio.
45682456|NCT03813160|Drug|Placebo|oral capsule
46030262|NCT05736874|Drug|Fluticasone|Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.
46030263|NCT05736874|Other|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
46030264|NCT05734313|Behavioral|Unified protocol for cognitive behavioral therapy (UP-CBT)|UP-CBT consists of approximately 16 individual sessions of CBT, conducted over the course of approximately 20 weeks. The UP-CBT consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. UP-CBT sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.
45682457|NCT03812848|Other|Anticoagulation Stewardship Program|"A clinical-pharmacist led anticoagulation stewardship program that includes:~Warfarin monitoring and dosing protocol. 1a.Warfarin initial dosing algorithm. 1b.Recommended International normalized ration (INR) target and duration of Warfarin therapy by indication.~1c.Warfarin dosage adjustment algorithms.~1d.Management of high INR values. 2-Heparin weight-based protocol. 3-Perioperative anticoagulation use protocol. 4-Policies that address baseline and ongoing laboratory monitoring for anticoagulants.~5-Protocol for Heparin Induced Thrombocytopenia(HIT) management. 6-Anticoagulation reversal protocol. 7-Booklet for anticoagulant drugs and all of previously prepared protocols. 8-Education programs regarding anticoagulation's therapy for health care team dealing with anticoagulation and patients."
46030265|NCT05734313|Device|Continuous Glucose Monitoring (CGM)|Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing anxiety and depressive disorders, along with self-management information and treatment options to discuss with providers will also be provided.
45839128|NCT05619822|Behavioral|TAU + A comprehensive third-generation intervention|This is a individual intervention with with a total of 12 sessions: Session 1. Constructing the Therapy Experience. Session 2. Life history and immediate reactions to trauma. Session 3. Preparing to deal with trauma. Session 4. Regulating emotions. Session 5-9. Focusing on retelling and processing the traumatic event (EMDR PHASES_PHASE 3: Evaluation of the traumatic memory. EMDR PHASE 4: Desensitization. EMDR PHASE 5: Positive Belief Installation. PHASE 6: Body Scan). Session 9. Re-evaluating traumatic memory and self-care through positive emotions. Session 10. Cultivating self-kindness. Session 11. Developing a healthy identity. Session 12. Building a better future
45839129|NCT05619822|Behavioral|TAU|Treatment as usual
46030266|NCT05730036|Drug|Linvoseltamab|REGN5458 will be administered by intravenous (IV) infusion
46030267|NCT05730036|Drug|Elotuzumab|Elotuzumab will be administered by IV infusion
46030268|NCT05730036|Drug|Pomalidomide|Pomalidomide capsules will administered by mouth (PO)
45682458|NCT03619252|Biological|Vaccination with pneumococcal conjugate vaccine (PCV13)|Vaccination with pneumococcal conjugate vaccine - PCV13 (Prevnar 13/Prevenar 13, Pfizer Inc) containing saccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F individually conjugated to nontoxic diphtheria cross-reactive material. Vaccination regimen: 3 doses monthly, with a booster dose 6 months later.
45682459|NCT03619252|Drug|Standard Antibacterial Prophylaxis|Levofloxacin 500 mg once daily during the median four cycles of treatment by novel agents.
46030269|NCT05730036|Drug|Dexamethasone|Dexamethasone tablets/capsules will be administered PO and/or by IV infusion
46030270|NCT05727891|Drug|Tonabersat|Two pills of Study Drug (80 mg tonabersat) is taken orally once daily. It is recommended the Study Drug be taken in the evening without food, but it may be taken at an alternate time with or without food. The first dose (two pills) will be taken in the office, regardless of the time of day.
46030271|NCT05727891|Other|Placebo|Two pills of Study Drug (placebo) is taken orally once daily. It is recommended the Study Drug be taken in the evening without food, but it may be taken at an alternate time with or without food. The first dose (two pills) will be taken in the office, regardless of the time of day.
46030272|NCT05725564|Behavioral|FAST (Functional Activity Strength Training)|Daily exercise intervention including functional resistance exercises and personalized coaching.
46030273|NCT05725564|Behavioral|Band Together|3 times weekly group exercise over Zoom featuring strength and balance exercises for 45 minutes
46030274|NCT05725564|Behavioral|Behavioral Change Technique|Reminders, education, goal-setting, self-monitoring, and feedback used to encourage participants to increase effort and adherence
45682460|NCT03717142|Combination Product|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and tissue will be imaged in vivo and ex vivo with the LUM imaging device.
45682461|NCT03807856|Drug|Dabigatran Etexilate Mesylate|Dabigatran 150mg BID for 3 days
45682462|NCT03807856|Other|Standard of Care|Daily vital signs, lab work and one outpatient clinic visit
46030275|NCT05722834|Behavioral|SOAR intervention|"This program intervention will be over 6 weeks and participants will have two group sessions and individual sessions, all conducted by an asthma health coach over Zoom (or phone). The two Zoom group sessions will be recorded so that all the information from the conversations will be maintained and used for research purposes. Additionally, participants will keep track of asthma symptoms and complete surveys at specified time-points (the last one at 6 months after participation).~Primary care physicians will be sent emails regarding the self-management goals of their patients."
45682463|NCT03807154|Behavioral|ICBT|A nine week long ICBT-programme with therapist guidance. Based on cognitive and behavioral techniques that have been tailored to address loneliness.
46030276|NCT05712460|Drug|sisunatovir|Sisunatovir is an orally administered RSV F-protein inhibitor being developed to target viral-host cell fusion for the treatment of adult and pediatric patients with RSV
46030277|NCT05712460|Drug|Placebo|Placebo for sisunatovir
45682464|NCT03807154|Behavioral|IPT|A nine week long internet-based IPT-programme with therapist guidance. Contains three distinct phases: assessment phase (three weeks), focus phase (five weeks, during which the participants will choose from one of four primary problem areas during the three latter weeks), and end phase (one week).
45682465|NCT03716284|Procedure|Electromagnetic navigation bronchoscopy (ENB)|ENB is carried out by a ENB system（LungCare, China) with/without other guided bronchoscopy techniques and/or ROSE, which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.
45682466|NCT03806530|Drug|Gabapentin|100 mg capsule
45682467|NCT03806530|Drug|Ropinirole|0.50 mg capsule
46030278|NCT05710380|Other|Risk Map Decision Support System (DSS).|The Risk Map DSS tool is an image analysis software that automatically interprets images of the prostate that were captured using an MR (magnetic resonance) scanner (an imaging technique that uses scanners to take pictures of the body). This tool can potentially identify additional areas of cancer in your prostate that may have otherwise been missed.
45471662|NCT01254071|Drug|Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)|In the first dosing session, twenty-two subjects of each cohort will receive the FDC capsule (dutasteride and tamsulosin hydrochloride (0.5mg/0.2mg) and the other 22 will receive commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg co-administered. Following a wash-out period of at least 28 days, those subjects who received the FDC capsule in session 1, will be co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg while those who were co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg in session 1 will receive the FDC capsule in the second dosing session.
45682468|NCT03806530|Drug|Placebo Gabapentin|Placebo capsule
46030279|NCT05710380|Radiation|Magnetic Resonance Imaging (MRI)|A medical imaging test that uses a large machine/scanner to take images of the body and internal organs and structures.
45682469|NCT03806530|Drug|Placebo Ropinirole|Placebo capsule
45682470|NCT03804424|Drug|64Cu-LLP2A|-64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)
46030280|NCT05710380|Procedure|Magnetic Resonance Imaging (MRI) Guided Biopsy|A removal of tumor tissue from the body based on images of the prostate provided by a previous magnetic resonance imaging (MRI) test. Up to 2 biopsies on trial.
46030281|NCT05707806|Device|MRI|Enables the use of custom pulse sequence
46030282|NCT05704556|Drug|VX-548|Tablets for oral administration.
46030283|NCT05702229|Drug|AZD2936|a PD-1 and TIGIT bispecific antibody; IV infusion
45682471|NCT03804424|Device|PET/MR|-All PET imaging will be performed as PET/MR or PET/CT
46030284|NCT05702229|Drug|MEDI5752|a PD-1 and CTLA-4 bispecific antibody; IV infusion
46030285|NCT05702229|Drug|FOLFOX|5-fluorouracil 400 mg/m^2 IV, oxaliplatin 85 mg/m^2, leucovorin 400 mg/m^2 (or levoleucovorin 200 mg/m^2 when locally preferred and available), day 1, 5-fluorouracil 1200 mg/m^2 IV 24 h day 1-2
45839130|NCT05619666|Procedure|Acute rehabilitation program|Patients included in the study started the rehabilitation program when they were hemodynamic stable, when it was determined that it was safe for patients. Until discharge from the hospital, a re-evaluation of neuromuscular and respiratory function was performed.
46030286|NCT05702229|Drug|XELOX|capecitabine 1000 mg/m^2 BID, days 1 to 14, oxaliplatin 130 mg/m^2, day 1
46030287|NCT05699655|Drug|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 4 cycles. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
46030288|NCT05699655|Drug|apatinib|Participants will receive apatinib, 250mg, qd，every 3 weeks for 3 weeks
46030289|NCT05699655|Drug|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 4 weeks.
45839131|NCT05616702|Other|Pressure Biofeedback Therapy + Progressive Muscles Relaxation + thermotherapy|"Pressure Biofeedback Therapy~prone position, abdominal drawing in for 10 sec. (PBU inflated to 70 mmHg)~Supine position with flexed knees, abdominal drawing in for 10 sec. (PBU inflated to 40 mmHg)~Progress to leg loading in supine abdominal drawing in for 10 sec. (PBU inflated to 40 mmHg)~Exercising dosage:~Duration: 15 mins~Frequency: 3 sessions/ week~Repetitions: 3 sets of 15 reps~Progressive Muscles Relaxation Technique~Tense => five seconds and,~release => ten seconds (Each group of muscle)~2 circuits daily~Exercising dosage:~Duration: 15 mins~Frequency: weekly 3 sessions; for 6 weeks~Repetitions: 2 reps (cycles)~Thermotherapy at lumbar region via electrical heating pad Duration: 15 mins"
46030290|NCT05699655|Drug|S-1|Participants will receive S-1, day 1-14 of every 3 weeks for 4 weeks.
46030291|NCT05697042|Behavioral|MY-Skills for Long COVID|8 week online intervention with therapeutic yoga and self-management education
46030292|NCT05695079|Other|No cooling (control)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling intervention (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7.
46030293|NCT05695079|Other|Electric fan (low airflow)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling interventions (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7. While participants are seated, an electric pedestal fan positioned 1 m away will deliver a continuous airflow of 2 m/s to the front of the body.
46030294|NCT05695079|Other|Electric fan (high airflow)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling interventions (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7. While participants are seated, an electric pedestal fan positioned 1 m away will deliver a continuous airflow of 4 m/s to the front of the body.
46030295|NCT05692180|Drug|Benralizumab|Benralizumab active solution will be administered SC to the patients.
46030296|NCT05692180|Drug|Placebo|Placebo solution will be administered SC to the patients.
46030297|NCT05689593|Other|Low-intensity ESWT Group|ESWT; With the MODUS ESWT system, the patient's shoulder will be in 80° passive abduction, the elbow will be in 90° flexion, and the forearm will be applied to 2 separate parts of the shoulder. The first application will be applied from front to back in the anterior shoulder joint and the upper limit of the treatment will be approximately 1 finger lateral to the coracoid process, the second application will be applied from the lateral scapula to the posterior shoulder joint (0.06 mJ/mm2, 1500 impulses, 1.5 bar).( Modus ESWT® RadialShockwaveTherapy)
45471663|NCT03898739|Other|Cervical Traction from different angles|Intermittent traction will be applied, maximum force will be 16 kg, minimum force will be 12 kg, traction cycle of each minute consists of 20 seconds static traction at the maximum force then released down to the minimum force for 20 seconds then repeated for 20 seconds static traction. Traction session time will be 15 minutes, and the traction force will be increased progressively with speed (50%) of increment of force
45471664|NCT05761418|Drug|Dinoprostone|prostaglandin (PG) E2 analog
45471665|NCT05761418|Drug|Misoprostol|prostaglandin (PG) E1 analog
45471666|NCT03898661|Drug|Collagenase histiolyticum|local injection of collagenase histiolyticum into the esophageal stricture, 1 day before balloon dilation
45471667|NCT05207774|Drug|Oxytocin|8 weeks intranasal oxytocin 24 units per day. 8 units prior each meal. 4units/0.1 ml per puff
45471668|NCT05207774|Drug|placebo|8 weeks intranasal placebo 0.6 ml per day. . 0.1 ml per puff
45471669|NCT03905291|Drug|MT921|Formulated as an injectable solution
45471670|NCT03905291|Drug|Placebo|normal saline
45471671|NCT05214482|Drug|AK112|IV infusion,Specified dose on specified days
45471672|NCT05214482|Drug|AK117|IV infusion,Specified dose on specified days
45471673|NCT05214482|Drug|Chemotherapy|IV infusion,Specified dose on specified days
45471674|NCT03919370|Other|No intervention|there will be NO intervention
45471675|NCT03905213|Device|dressing MEPORE|assignation to three different authorised and on label dressing: conventional dressing (MEPORE)
46030298|NCT05689593|Other|Low-intensity laser Group|The laser will be made parallel to the joint line with the patient's arm, the arm will be in internal rotation at the posterior of the shoulder and the arm will be in external rotation at the anterior of the shoulder. The wavelength of 850 nm will be applied for 5 minutes in total 30 Joules.
46030299|NCT05689593|Other|Conventional Control Group|Exercises will be started with passive ROM exercises and passive stretching exercises for the flexor, abductor, internal and external rotator muscle groups until the level of pain tolerance in the supine position. In the second week, the program will be continued with active ROM and stretching exercises. In the third week, isometric strengthening exercises for flexor, abductor, internal and external rotator muscle groups will be given along with stretching exercises. Exercises will be performed 5 days a week, 60 minutes a day, accompanied by a physiotherapist.
46030300|NCT05687500|Drug|Glibenclamide|Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk
45471676|NCT03905213|Device|dressing MEPILEX|assignation to three different authorised and on label dressing: absorbent(MEPILEX)
45471677|NCT03905213|Device|dressing PICCO|assignation to three different authorised and on label dressing:vacuum Therapy dressing(PICCO)
45471678|NCT05742932|Device|Trauma surgery using Global D's implants.|Major or minor participants who will be treated by an trauma surgery with ORTRAUTEK® or MINITEK/MICROTEK® implant(s).
45471679|NCT03905057|Device|Dornier Aries 2 (with active applicator)|Active ESWT: 5000 shockwaves per session. 2 ESWT sessions per week, 12 sessions in total.
45471680|NCT03905057|Device|Dornier Aries 2 (with sham applicator)|Sham ESWT - No shockwave administered
45471681|NCT03629132|Procedure|Platelet-rich plasma|Platelet-rich plasma intrauterine injection
45471682|NCT03629132|Procedure|gel|Self-crosslinking sodium hyaluronate gel intrauterine injection
45471683|NCT03904901|Dietary Supplement|Probiotics|Individuals will receive individual capsules containing the daily dose of lyophilized probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium lactis and Bifidobacterium bifidum) and will be advised to remain at room temperature, ingest with water and drink before bed.
45471684|NCT03904901|Dietary Supplement|Placebo|The placebo product had only the excipient, microcrystalline cellulose, and was identical to the active product in relation to color, shape, size and packaging.
45682472|NCT03804424|Procedure|Blood samples for serum stability|-3 venous samples obtained from an IV site separate from the site of 64Cu-LLP2A injection (2 mL each) will be obtained at the following time points: Cohort 1: prior to injection, at completion of dynamic scanning in those who undergo dynamic imaging and at completion of one of the body imaging time points. In those who do not undergo dynamic imaging, prior to injection, and after completing body imaging at 2 of the 3 time points. Cohort 2: subjects will have samples drawn prior to injection, at completion of dynamic scanning, and at completion of body imaging.
45682473|NCT03804424|Procedure|Blood samples for metabolite analysis|-Typically, 2 blood samples obtained from an IV site separate from the site of 64Cu-LLP2A injection (preferably 1 within the first 5 min and 1 at the completion of the first hour of imaging) will be obtained.
45682474|NCT03804424|Procedure|Urine sample|-Cohort 1 only
45471685|NCT02528123|Procedure|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
45471686|NCT02528123|Drug|Tobramycin and dexamethasone|Tobramycin and dexamethasone (Tobradex) eye drops will be used four times a day for 1 week after the procedure
45471687|NCT02528123|Drug|Ofloxacin|Ofloxacin (Exocin) eye drops will be used four times a day for 1 week after the procedure
45471688|NCT02528123|Drug|Proxymetacaine 0.5%|Proxymetacaine 0.5% eye drops will be used as an anaesthetic during the procedure
46030301|NCT05687500|Biological|Pharmacokinetics study|"0.2 ml blood sampling at 3 hours, 6 hours, 10 hours and 24 hours after the first administration and after 24 hours of blood glucose stabilization.~PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant ,apparent clearance and volume of distribution"
45471689|NCT02528123|Drug|Oxybuprocaine 0.4%|Oxybuprocaine 0.4% eye drops will be used as an anaesthetic during the procedure
45471690|NCT05214248|Other|a multimedia admission orientation|A short video based on self-drawing characters and figures with Chinese dubbing and background light music, explaining the NICU environment, health care workers, and tests and examination that are essential for an infant admitted to this NICU of Cathay Hospital in Taipei, R.O.C.
45471691|NCT03992612|Other|control group: usual medical care|The patients received usual medical care.
45471692|NCT03992612|Behavioral|MBPM- Mindfulness-Based Pain Management|8 group session of maindfulness-based treatment to management pain
45839132|NCT05616702|Other|Progressive Muscles Relaxation + thermotherapy|"Progressive Muscles Relaxation Technique~Tense => five seconds and,~release => ten seconds (Each group of muscle)~2 circuits daily~Exercising dosage:~Duration: 15 mins~Frequency: weekly 3 sessions; for 6 weeks~Repetitions: 2 reps (cycles)~Thermotherapy at lumbar region via electrical heating pad Duration: 15 mins"
46030302|NCT05687500|Biological|C-peptide proinsulin ratio|blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio
46030303|NCT05687500|Biological|Blood glucose on fluorinated tube|0.3 ml blood sampling at 3 hours, 6 hours, 10 hours and 24 hours after the first administration and after 24 hours of blood glucose stabilization.
46030304|NCT05687500|Biological|Routine biological monitoring|If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment.
45471693|NCT02527811|Drug|Ulinastatin|Ulinastatin will be diluted into saline solution and administered intravenously in the intraoperative and postoperative
45471694|NCT03691831|Drug|Active|A-101 45% (hydrogen peroxide 45% topical solution)
45471695|NCT03691831|Other|Vehicle|Vehicle solution containing isopropyl alcohol and water
45471696|NCT01254383|Drug|Sildenafil Tablet|Tablet, 50 mg, Single Dose
45839133|NCT05614752|Drug|Fexuprazan|Fexuclue Tablet 40mg
46030305|NCT05687500|Biological|glycose holter monitor|glucose levels will be collected with a smarter continuous glucose monitoring system, placed on inclusion and until the end of treatment
46030306|NCT05683184|Drug|[11C]OMAR|For each [11C]OMAR PET scan, up to 20 mCi of [11C]OMAR will be administered.
46030307|NCT05681611|Drug|Rocuronium|Rocuronium bolus was administered, according to our protocol, to facilitate surgery and ventilation.
46030308|NCT05681351|Drug|Olezarsen|Administered as SC injection.
45471697|NCT01254383|Drug|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
45682475|NCT03804424|Procedure|Tumor biopsy|-Cohort 2 only and only if there hasn't been a recent biopsy of disease
46030309|NCT05680064|Behavioral|Tongue, lip, chin exercise group|In order to evaluate the effect of chewing gum and tongue, lip and chin exercises on salivary flow rate, xerostomia and dysphagia, both intervention groups will work in a determined time frame daily.
45682476|NCT03804424|Procedure|Electrocardiogram|-A standard 12-lead ECG will be obtained on all subjects at baseline (within 30 mins prior to injection of 64Cu-LLP2A), and at least 60 minutes post injection or prior to study discharge
45682477|NCT03804424|Device|PET/CT|-All PET imaging will be performed as PET/MR or PET/CT
46030310|NCT05677971|Drug|Fazirsiran Injection|Participants will receive fazirsiran 200 mg/ml SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
46030311|NCT05677971|Other|Placebo|Participants will receive placebo (sterile normal saline [0.9% NaCl]) SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
46030312|NCT05677256|Biological|nOPV2|Vaccination
45471698|NCT01254383|Drug|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
45471699|NCT03700970|Drug|Liposomal bupivacaine|20mL of Exparel® 1.3% mixed with 20mL of 0.25% bupivacaine, for a total of 40mL of local anesthestic mixture, 20mL to be injected on each side.
45682478|NCT03608020|Drug|BMX-001|Manganese butoxyethyl pyridyl porphyrin
45682479|NCT03608020|Radiation|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy per standard of care.
45471700|NCT03700970|Drug|Regular bupivacaine|20mL of 0.25% bupivacaine injected on each side.
45471701|NCT01256021|Drug|Botulinum Toxin Type A|1 time, gastrocnemius muscles injection, dose of 4U/kg body weight in patients with hemiplegia, dose of 6U/kg body weight in patients with diplegia, Maximum dosage 200U
45471702|NCT01256099|Behavioral|Therapist guided Internet-CBT for insomnia|An 8 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia
45471703|NCT01256099|Behavioral|Brief Internet-CBT for insomnia, without support|No support and less text, not including the CBT-methods that are presumed to be most effective to reduce Insomnia symptoms
45682480|NCT00003820|Drug|Rituximab|Rituximab (biosimilar is Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B-cells. Rituximab destroys B-cells and is therefore used to treat diseases which are characterized by excessive numbers of B-cells, overactive B-cells, or dysfunctional B-cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
46030313|NCT05676073|Drug|SHEN26 dose 1|Specification: 200mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
46030314|NCT05676073|Drug|SHEN26 dose 2|Specification: 400mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
46030315|NCT05676073|Drug|SHEN26 placebo|Placebo matching the SHEN26 capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
45471704|NCT01256099|Behavioral|Therapist Guided Internet-CBT for depression|An 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. Information and methods regarding sleep difficulties removed
45682481|NCT01693029|Drug|HX575 epoetin alfa|Solution for subcutaneous injection. The drug is administered subcutaneously at least once per week over 52 weeks. The dose will be individually titrated to maintain hemoglobin levels between 10 to 11 g/dL.
45471705|NCT04320745|Drug|Androderm®|Androderm® transdermal dose.
45471706|NCT01254461|Drug|AZD1981|100 mg per oral, twice daily for 8 days
45471707|NCT01254461|Drug|AZD1981|4x100 mg per oral, twice daily for 8 days
45471708|NCT01254461|Drug|pravastatin|40 mg, once daily at Day 1, period A and Day 8, period B
45682482|NCT01693029|Drug|US-licensed epoetin alfa|Solution for subcutaneous injection.
45682483|NCT01589445|Drug|Pioglitazone hydrochloride|77 patients were treated with pioglitazone hydrochloride (B001) for 3 months.Biomedical parameters were measured each month.
46030316|NCT05675163|Dietary Supplement|Vitamin K2|(K2VITAL® 1% MCT Oil)
46030317|NCT05675163|Dietary Supplement|Placebo|Sunflower oil
46030318|NCT05672589|Diagnostic Test|Relaxed Rotational Thromboelastometry|Relaxed rotational thromboelastometry will be done 12 hr,24 hr,48 hr, 72 hr and if patients. bleed.
46030319|NCT05672589|Diagnostic Test|Standard Coagulation Tests|Standard coagulation tests will be done baseline,12 hr,24 hr,48 hr, 72 hr and if patients bleed.
46030320|NCT05671835|Drug|TTI-101|Orally via a tablet.
46030321|NCT05671835|Drug|Placebo|Orally via a tablet.
46030322|NCT05669482|Drug|avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel|The RP2D of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel determined in Part A will be used in Part B dose expansion.
46030323|NCT05666687|Drug|MIJ821|MIJ821 will be administered as an i.v. infusion
46030324|NCT05664334|Biological|IVX-121|75 mcg of IVX-121 without MF59®
46030325|NCT05664334|Biological|IVX-241|75 mcg of IVX-241 without MF59®
46030326|NCT05664334|Biological|Placebo|Diluent
46030327|NCT05664334|Biological|IVX-121|75 mcg of IVX-121, without MF59®
45682484|NCT01589445|Drug|Metformin hydrochloride|After the treatment with pioglitazone(001) for 3 months first and then patients were on one month washout period;in the washout period they were given metformin tablet 850mg once daily,then treated with 002 (metformin) for further 3 months. The same biomedical measurements were assayed.
45682485|NCT00003910|Drug|Cyclophosphamide|Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule. In patients showing a partial response, but not a CR, the maximum period of therapy was 1 year.
45682486|NCT00003910|Drug|Methotrexate|Initial treatment consisted of MTX given orally at 10 mg/m2 in divided doses once weekly.
45682487|NCT00003910|Drug|Prednisone|Prednisone was given orally at 1 mg/kg per day for 30 days and then tapered off in the subsequent 24 days.
45682488|NCT01588509|Drug|Romosozumab|Administered by subcutaneous injection
45682489|NCT01588353|Drug|Collagenase Clostridium Histolyticum|AK160 (Collagenase Clostridium Histolyticum) 0.58 mg
45682490|NCT01588197|Behavioral|Attention/Distraction Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attend away from the thermal stimulus (for example, to the other side of the body). Vividly imagine they are somewhere else, or engage in a high-demanding mental task such as counting backward by 7's or completing math problems to distract from the experience
45682491|NCT01588197|Behavioral|Stimulus Quality/Severity Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to perceive the stimulus as a neutral sensory experience rather than pain. Attempt to perceive the stimulus as low intensity rather than high intensity.
45682492|NCT01588197|Behavioral|Control Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to take control of their perception of the painful experience.
45682493|NCT01561989|Dietary Supplement|cholecalciferol|Given PO
45682494|NCT01561989|Other|questionnaire administration|Ancillary studies
45471709|NCT03904511|Other|Souroubea-Platanus Preparation|Extracts of S. Sympetala and P. occidentalis.
45682495|NCT01561989|Biological|trivalent influenza vaccine|Given IM
45682496|NCT00004054|Drug|bicalutamide|Administered orally at a dose of one 50mg tablet per day. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
45682497|NCT00004054|Drug|estramustine phosphate sodium|280 mg three times a day for 14 days and repeated every 3 weeks for 4 cycles
45471710|NCT03904511|Other|Placebo|Placebo
45471711|NCT05712746|Drug|Samtasu for I.V. infusion|"Drug: 8 mg/vial or 16mg/vial~Dosage and Administration:~The usual adult dosage of tolvaptan sodium phosphate is 16 mg once daily and intravenously infused over 1 hour."
45471712|NCT03747523|Drug|Ergocalciferol|Investigational drug will be administered to eligible participants in a single dose of 200,000 USP units vitamin D
45682498|NCT00004054|Drug|etoposide|50 mg/m^2 in divided doses b.i.d. for 14 days and repeated every 3 weeks for 4 cycles
45471713|NCT03898505|Dietary Supplement|AvoMax (Low Dose)|AvoMax (Low Dose) is a natural spray-dried avocado powder, which contains 50 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.
45471714|NCT03898505|Dietary Supplement|AvoMax (High Dose)|AvoMax (High Dose) is a natural spray-dried avocado powder, which contains a total of 200 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.
45471715|NCT03898505|Other|Placebo|Placebo product is powder containing only non-medicinal ingredients used in the test product: Oryza sativa (rice) bran extract (65-70% w/w of total placebo formulation), sodium bicarbonate, rosemary extract, xylitol, silicon dioxide, microcrystalline cellulose, rice hull powder, strawberry flavour.
45471716|NCT03904667|Other|Watson on oncology surgery decision evaluation|Watson on oncology surgery decision evaluation. The system acquires and evaluates a large amount of structured and unstructured data from previous medical records through machine learning and natural language processing, and USES algorithms to select treatment options as the best choice for a particular patient.
45471717|NCT03747445|Procedure|Roux-en-Y gastric bypass|laparoscopic surgical procedure
45471718|NCT01150253|Dietary Supplement|L. paracasei fermented milk|
45682499|NCT00004054|Drug|flutamide|Administered orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
45682500|NCT00004054|Drug|paclitaxel|135 mg/m^2 given as a 1-hour infusion (on day 2 of each cycle) and repeated every 3 weeks for 4 cycles
45682501|NCT00004054|Drug|Luteinizing hormone releasing hormone [LHRH] agonist|Releasing hormone agonists (such as leuprolide, goserelin, buserelin, triptorelin) will be given for 4 months
45682502|NCT00004054|Radiation|Radiation therapy|Radiation will begin 8 weeks following the initiation of hormone administration: 46.8 Gy to the regional lymphatics followed by a 23.4 Gy boost to the prostate to bring the total dose to the prostate to 70.2 Gy. Daily tumor doses will be 1.8 Gy per day, 5 days per week x 7-8 weeks.
45682503|NCT00004054|Drug|warfarin|To keep international normalized ratio (INR) > 1.5 and < 2.5; begins with the start of chemotherapy and will be given continuously until 4 weeks after the end of the fourth cycle of chemotherapy
45682504|NCT01587885|Drug|Omeprazole 20 mg + Sodium Bicarbonate 1100 mg|Capsules, orally
45682505|NCT01587885|Drug|Omeprazole 20 mg|Tablets, orally
45471719|NCT05293171|Drug|1.25 mg/kg BL-8040 + BL-8040-matching placebo|Administered via subcutaneous (SC) injection
45471720|NCT05293171|Drug|2 mg/kg BL-8040|Administered via subcutaneous (SC) injection
45471721|NCT05293171|Drug|BL-8040-matching placebo|Administered subcutaneous (SC) injection
45471722|NCT05293171|Drug|400 mg Moxifloxacin (1x400 mg tablet)|Administered orally
45471723|NCT03904433|Other|Coconut oil|Coconut oil given in coffee with cream
45471724|NCT03904433|Dietary Supplement|Caprylic acid|Caprylic acid given in coffee with cream
45471725|NCT03904433|Other|Sunflower oil|Sunflower oil given in coffee with cream
45682506|NCT03802240|Drug|Sintilimab|200mg IV Q3W
45682507|NCT03802240|Drug|IBI305|15mg/kg IV Q3W
45682508|NCT03802240|Drug|Pemetrexed|500mg/m2 IV Q3W
45682509|NCT03802240|Drug|Cisplatin|75mg/m2 IV Q3W
45682510|NCT03802240|Drug|Placebo1|Placebo1 IV Q3W
45682511|NCT03802240|Drug|Placebo2|Placebo2 IV Q3W
45471726|NCT03904433|Other|Glucose|Glucose dissolved in water
45471727|NCT03063086|Drug|QVM149 150/50/80 μg o.d.|A
45471728|NCT03063086|Drug|QVM149 150/50/160 μg o.d.|B
45471729|NCT03063086|Drug|salmeterol/fluticasone FDC 50/500 μg b.i.d.|C
45471730|NCT03749161|Device|Low-add multifocal IOL|Lentis comfort, low-add multifocal, IOL
45471731|NCT03749161|Device|Monofocal IOL|Lentis L-313, monofocal IOL
45471732|NCT03904745|Drug|Atosiban|6,75mg of atosiban will be administered intravenously 30 minutes before embryo transfer
45471733|NCT03749083|Other|The Functional Assessment of Cancer Therapy- Colorectal|The Functional Assessment of Cancer Therapy- Colorectal (FACT-C) questionnaire measures health-related quality of life for people with chronic illnesses.
45471734|NCT05191160|Other|Soy Milk|250 mL, single-serve shelf-stable pack (Alpro Soya) 100 Kcal, 8g of soy protein
45471735|NCT05191160|Other|Cow's Milk|250 mL, single-serve shelf-stable pack (Organic Meadows) 130 Kcal, 8g of casein/whey protein
45471736|NCT05191160|Other|Sugar Sweetened Beverages|355 mL, single-serve cans 130-140 Kcal, 0g of protein
45682512|NCT03710746|Behavioral|Project Health|A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.
45682513|NCT03710746|Behavioral|Response and Attention Training|Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.
45682514|NCT03710122|Drug|Vancomycin|Firvanq by Azurity Pharmaceuticals, Inc.
45682515|NCT03710122|Other|Placebo|Placebo for Vancomycin
45682516|NCT01587651|Drug|Prasugrel Loading Dose|60mg given as six 10mg film coated tablets
45682517|NCT01587651|Drug|Prasugrel Maintenance Dose|10mg maintenance dose, given as one 10mg film coated tablet
45682518|NCT01587651|Drug|Ticagrelor Maintenance Dose|one 90mg film coated tablet
45682519|NCT03800992|Other|assessment of perception and evaluation of physicians advisory skills per questionnaire|questionnaire according to SPIKES - a Six-Step Protocol for Delivering Bad News to be completed by parents and children (older than eleven)
46030328|NCT05664334|Biological|IVX-241|150 mcg IVX-241, without MF59®
46030329|NCT05664334|Biological|IVX-241|225 mcg of IVX-241, without MF59®
46030330|NCT05664334|Biological|IVX-121|75 mcg of IVX-121, with MF59®
46030331|NCT05664334|Biological|IVX-241|75 mcg of IVX-241, with MF59®
46030332|NCT05664334|Biological|IVX-241|150 mcg IVX-241, with MF59®
46030333|NCT05664334|Other|MF59®|MF59® as an adjuvant
46030334|NCT05660538|Drug|VX-548|Tablets for oral administration.
46030335|NCT05660538|Drug|Pregabalin|Capsules for oral administration.
46030336|NCT05660538|Drug|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
46030337|NCT05659381|Drug|Cisplatin|Cisplatin 100mg/m2 IP over 90 minutes at 42 degrees Celcius
45598714|NCT02354547|Genetic|SGT-53|The starting dose of SGT-53 will be 1.4 mg DNA/m² (dose level 1). If MTD is reached at dose level 1, subsequent cohort will be treated at 0.7 mg DNA/m² (dose level -1). If MTD is not reached at 2.1 mg DNA/m² (dose level 2), additional dose level(s) may be added. Intra-patient escalation is not allowed. Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, SGT-53 will be administered in combination with 0.6 mg/m² topotecan and 200 mg/m² cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan and cyclophosphamide will be escalated to 0.75 mg/m² and 250 mg/m², respectively. No further dose escalation is permitted. If DLT develops at the higher doses, the doses should be decreased back to those in cycle 2.
45682520|NCT03799354|Other|Maximal strenght training (MST) plus endurance training (ET)|"Patients will perform an addictive out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions) consisting of:~MST- It will consist of four sets of five repetitions on a leg-press with a focus on the rate of force development during the concentric contraction of the quadriceps from a 90° to legs complete extension. The load will be 85-90% of 1RM. When a patient will be able to perform more than five repetitions in a set, the load will be increased. All strength training will be performed on a seated horizontal leg press.~ET - A cycling session will follow the MST and last 40 minutes at constant-load, starting from a load intensity corresponding to patient specific AT. The intensity will be gradually increased with a symptom-based progression."
46030338|NCT05659381|Other|No treatment|No treatment with Cisplatin
46030339|NCT05656170|Procedure|Stellate ganglion block|"Ultrasound will be utilized to identify anatomic landmarks and prepare for the stellate ganglion block. Skin will be prepped with chloraprep. The C6 level is identified. The Chassaignac tubercle (the anterior tubercle of the C6 vertebral body) is then identified. Placement of the ultrasound transducer helps retract the carotid sheath and sternocleidomastoid muscle laterally. Pressure is applied with the ultrasound transducer to reduce the distance between the skin and tubercle.~The needle is inserted towards to the Chassaignac tubercle after contact it is redirected towards the body of C6. The needle is then withdrawn 1-2 mm to bring it out of the longus colli muscle while still staying within the prevertebral fascia. After negative aspiration, 1-2 mL of local anesthetic (or normal saline in the placebo group) is injected, and spread can be visualized with ultrasound. Once confirming that the injection was subfascial, the remaining local anesthetic can be given (10 mL in total)."
46030340|NCT05656170|Drug|Bupivacain|The intervention group will receive bupivacaine injection guided by ultrasound at the location of the stellate ganglion.
46030341|NCT05656170|Drug|Saline|The control group will receive a normal saline injection guided by ultrasound at the location of the stellate ganglion.
46030342|NCT05655156|Device|OrthoPure XT|"Indication: reconstruction of knee ligaments to restore knee function and stability~The following device sizes are available for use in this indication:~Size 5~- Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~Size 6~- Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~Size 8~Primary ACL reconstruction where autograft tissue is not suitable~Revision ACL reconstruction~Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~Size 10~Multi-ligament reconstruction (recommended for posterior cruciate ligament (PCL) reconstruction)"
46030343|NCT05652686|Drug|PT217|A bispecific antibody (bsAb) against human DLL3 (huDLL3) and human CD47 (huCD47).
46030344|NCT05650879|Drug|ELVN-002|capsule
46030345|NCT05650879|Drug|Fam-Trastuzumab Deruxtecan-Nxki|intravenous
46030346|NCT05650879|Drug|Trastuzumab emtansine|intravenous
46030347|NCT05643027|Behavioral|Acceptance and Commitment Therapy|Six-session, skills-based behavioral intervention targeting risk factors for opioid use disorder in the context of cancer
46030348|NCT05639751|Drug|PRT3789|PRT3789 will be administered by intravenous infusion
45598715|NCT02354547|Drug|Topotecan|Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 0.6 mg/m² topotecan will be administered in combination with SGT-53 and cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan will be escalated to 0.75 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
45682521|NCT03799354|Other|Endurance training (ET)|"Patients will perform a usual out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions). They will perform ET by cycling sessions that will last 40 minutes/each at constant-load, starting from a load intensity corresponding to patient specific AT, assessed during the baseline incremental test. The intensity will be gradually increased during the sessions with a symptom-based progression, according to the protocol by Maltais and coworkers. A 3-min warm-up and cool-down will be provided. Heart rate (HR), blood pressure, oxygen pulsoxymetry, and symptoms by Borg CR10 scale will be monitored at the beginning and end of each session.~Out of the training-days, both groups will continue their normal daily living with modest regular activity, as recommended by their physician."
46030349|NCT05636449|Other|Group Suprainguinal fascia iliaca block|After the operation is completed, the fascia iliaca will be separated from the iliacus muscle. With ultrasound guidance, the local anesthetic injection will be made between the fascia and the muscle.
46030350|NCT05636449|Other|Group Periarticular Infiltration|A total volume of 80 ml local anesthetic will be applied to the medial and lateral capsule, the medial and lateral meniscus margins, the deep part of the medial ligament, the medial and lateral synovial space, and the patellar ligament and quadriceps tendon.
46030351|NCT05633160|Drug|64Cu-SAR-BBN|64Cu-SAR-BBN
46030352|NCT05633160|Drug|67Cu-SAR-BBN|67Cu-SAR-BBN
46030353|NCT05627557|Drug|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
46030354|NCT05627557|Drug|MMF|MMF will be administered as per schedule specified in the respective arm.
46030355|NCT05627557|Drug|Prednisone|Participants taking prednisone or equivalent at randomization will follow a guided tapering schedule to reach the goal of 0mg/day by Weeks 4-6 (and no later than Week 8 following randomization and continue without prednisone through Week 52.
45682522|NCT04763434|Drug|dexamethasone; dexmedetomidine; ropivacaine|Ultrasound-guided multilevelTPVB is performed at the end of lobectomy
45682523|NCT04763668|Other|Pregnant HIV positive women on ARTs|Cardiovascular disease risk in pregnant HIV positive women on ARTs
46030356|NCT05627557|Drug|Methylprednisolone|Methylprednisolone 80 mg (or 1.5 mg/kg if </=45 kg) IV will be administered as premedication prior to infusions.
46030357|NCT05627557|Drug|Acetaminophen/ Paracetamol|Acetaminophen 15 mg/kg (maximum dose 1000 mg) will be administered PO as premedication prior to infusions.
46030358|NCT05627557|Drug|Diphenhydramine Hydrochloride|Diphenhydramine HCl 0.5-1 mg/kg (maximum dose 50 mg) will be administered PO or IV as premedication prior to infusions.
46030359|NCT05618509|Device|STENDO session|"It is a combination enveloping the lower limbs up to the abdomen. The massage system induces pressure from the ankles to the abdomen between each heartbeat. The capacity for physical exercise is potentially improved.~STENDO : 45 minutes, 2 legs and the pelvis, pression of 65mm Hg"
46030360|NCT05618509|Other|A six-minute walking distance test|Before and after STENDO session, the patient has to walk 6 minutes in a flat corridor (30m long)
46030361|NCT05618509|Other|Near Infrared Spectroscopy|The goal is to measure the evolution of the oxygen consumption of the right leg during an effort on a bicycle at constant power for 5 minutes.
45471737|NCT05213702|Device|Renal Calyx punture with traditional free hand or ANT-X device|ANT-X device is a software-controlled automated electromechanical arm. It is developed to provide needle guidance for surgeon in MIS. This aims to reduce the surgery time taken and also minimize the radiation withstand by both surgeon and patient. ANT-X device is actually a Delta parallel robot implementing inverse kinematics to achieve effector's movement. Parallel structures excel in their great stiffness and high positioning accuracy. Most of the main components of ANT-X robot are made up of medical grade Polyether ether ketone (PEEK) material. PEEK is preferred to build the robot because it is radiolucent and lightweight while being able to provide relatively high material strength. The device is intended for use together with C-arm fluoroscope (fluoroscopy/CT technology). The fluoroscopy technology is used to provide image guidance for the needle
46030362|NCT05618509|Device|STENDO placebo|STENDO placebo : 45 minutes, on 2 legs and the pelvis, pression of 10 mmHg
46030363|NCT05616793|Biological|AAV8.hLCA5|Adeno-associated virus vector expressing human LCA5 gene
46030364|NCT05614102|Drug|BAY2965501|Daily oral application
46030365|NCT05605964|Drug|Relugolix|Relugolix tablet
46030366|NCT05605964|Drug|Leuprolide Acetate|Leuprolide acetate injection
45471738|NCT02528045|Procedure|Vitrectomy with scleral shortening|
45471739|NCT04128007|Drug|Roflumilast foam 0.3%|experimental
45471740|NCT04128007|Drug|Vehicle foam|experimental
45471741|NCT05187338|Drug|ipilimumab +pembrolizumab +durvalumab|"This study has 3 subgroups:~Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via vein, every 3 weeks.~Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, every 3 weeks.~Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 50-150mg via intra-tumor fine needle injection in 5 min, every 3 weeks."
45471742|NCT03898583|Drug|Microarray patch A|Microarray patch
45682524|NCT04763668|Other|Babies born to HIV positive mothers on ARTs|cardiovascular disease risk in the offspring of HIV positive mothers on ARTs
45471743|NCT03898583|Drug|Microarray patch B|Microarray patch
45471744|NCT03898583|Drug|Placebo|Microarray patch vehicle
45471745|NCT03898583|Drug|Daivobet|Daivobet Gel
45471746|NCT05213546|Other|Aerobic exercise training|bicycle ergometer exercise training
45471747|NCT03898193|Drug|Montelukast|Montelukast, 5 mg Chewable Tablets, manufactured by Pharmtechnology LLC, Republic of Belarus
45471748|NCT03898193|Drug|Singulair|Singulair, 5 mg Chewable Tablets, marketed by Merck Sharp & Dohme B.V., the Netherlands
45471749|NCT03321188|Procedure|HIPEC|HIPEC with cisplatin
45471750|NCT03321188|Drug|Carboplatin|Adjuvant IV chemotherapy
45471751|NCT03321188|Drug|Paclitaxel|Adjuvant IV chemotherapy
45471752|NCT03904355|Drug|Gonadotropins|Gonadotropin stimulation of follicular growth
46030367|NCT05601843|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS pads will be applied in a frame pattern around the area of maximal pain, as pointed out by the patient. The pads will be no more than 6 cm and no less than 3 cm away from the subjective area of maximal pain. The frequency of the TENS machine will be set to 100 Hz and the patient will be instructed on how to increase and decrease the amplitude based on their comfort. The patient will also be instructed on how to turn off the machine if they wish for any reason. Research assistants will be standing by during the intervention period to intervene if the patient requires assistance with the device.
46030368|NCT05601323|Device|Suizenji|HIFU treatment
46030369|NCT05601323|Drug|Nal-IRI/FL|Nanoliposomal irinotecan, Fluorouracil, Levofolinate
46030370|NCT05601323|Drug|mFOLFIRINOX|Fluorouracil, Levofolinate, Irinotecan, Oxaliplatin
46030371|NCT05601323|Drug|Gem/nab-PTX|Gemcitabine, nab-Paclitaxel
46030372|NCT05596786|Drug|Rituximab|One course of IV rituximab consisting of a first infusion of 1000 mg (500 mL solution) rituximab (day 1), and a second infusion of 1000 mg (500 mL solution) rituximab two weeks later (day 15)
46030373|NCT05596786|Other|Placebo|One course of IV placebo of rituximab consisting of a first infusion of 500 mL of saline (0.9% sodium chloride) infusion (day 1), and a second infusion of 500 mL of saline infusion two weeks later (day 15)
46030374|NCT05590728|Drug|Apramycin (EBL-1003)|A mono-substituted 2-deoxystreptamine comprising a unique bicyclic octadiose moiety. It is a crystalline free base of the amoniglycoside apramycin.
46030375|NCT05590039|Device|MyEllevate Procedure|"The defined study area will be identified and may be marked with a surgical marker.~A local tumescent anesthetic, such as lidocaine, will be injected to the area prior to the procedure. The MyEllevate® device will be used in accordance with the Instructions for Use (IFU) manual for soft tissue approximation and elevation of sub dermis and underlying muscle of the submentum and jawline."
45471753|NCT03904355|Drug|human chorionic gonadotropin|HCG triggering of ovulation
46030376|NCT05584657|Drug|Sulopenem etzadroxil/probenecid|Oral sulopenem twice daily for 5 days
46030377|NCT05584657|Drug|Amoxicillin/clavulanate|Oral Augmentin twice daily for 5 days
45471754|NCT03904355|Procedure|Ovum pick up|34 to 36 hours after oocyte retrieval
45471755|NCT03904355|Procedure|Embryo transfer|Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval
45471756|NCT03748849|Procedure|Physiotherapy|
45471757|NCT03747367|Behavioral|Insufficient Sleep|
45471758|NCT03898427|Device|Wrist Actigraphy Devices|A watch-like wearable sensor
45471759|NCT03898427|Device|Polysomnography|Sleep Monitor
45471760|NCT03898427|Device|Videography|Thermal Camera
45471761|NCT05187260|Drug|Nusinersen|SPINRAZA® (nusinersen) prescribed as part of standard of care
45471762|NCT03640325|Behavioral|PRISM (Promoting Resilience in Stress Management)|Manualized Skills-Training Program targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
45471763|NCT03261674|Behavioral|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I)
45471764|NCT03261674|Behavioral|ABT-I|Arousal-Based Therapy for Insomnia (ABT-I)
45682525|NCT03606538|Drug|MDMA|80 mg MDMA
45471765|NCT01254539|Procedure|Laminectomy and bone marrow stem cells transplantation|"Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation"
45471766|NCT01254539|Procedure|Intrathecal infusion of autologous bone marrow stem cells|"Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells."
45471767|NCT01254539|Procedure|Intrathecal infusion of placebo (saline solution).|Patients were infused 2 ml of saline solution
45471768|NCT03628664|Radiation|CT scan|Assessment of the actual posterior condylar angle using the CT scan
45471769|NCT04318093|Drug|BMS-986259|Specified dose on specified days
45471770|NCT04318093|Other|Placebo|Specified dose on specified days
45471771|NCT01254617|Biological|Cetuximab|Given IV
45471772|NCT01254617|Other|Laboratory Biomarker Analysis|Correlative studies
45471773|NCT01254617|Drug|Lenalidomide|Given PO
45682526|NCT04747210|Behavioral|contextual one-on-one coaching|Training workshop and coaching one-on-one
45471774|NCT05187026|Other|electronic PROMs questionnaire|Patients are asked to complete EPIC-26 questionnaire in paper and electronically
45471775|NCT01150331|Drug|Levetiracetam/Clonazepam|Association of two anti-epileptic drugs in first line
45471776|NCT01150331|Drug|Clonazepam/Placebo levetiracetam IV|Association of placebo to an active comparator (clonazepam)
45471777|NCT03191084|Drug|Low Dose THC Marijuana|Dosing via vaporized marijuana using a lower concentration of THC, participants receive this dose on two of the five study visits.
45471778|NCT03191084|Drug|High Dose THC Marijuana|Dosing via vaporized marijuana using a higher concentration of THC, participants receive this dose on two of the five study visits.
45471779|NCT03191084|Drug|Placebo Marijuana|Dosing via vaporized marijuana with no THC, participants receive this dose on one of the five study visits.
45471780|NCT03747289|Other|performing exercises in a weight bearing posture|20 participants will perform exercises in a weight bearing posture
45471781|NCT03747289|Other|performing exercises in a non weight bearing posture|20 participants will perform exercises in a non weight bearing posture
45682527|NCT04747210|Behavioral|Trainig workshop|Ten-hour training workshop.
45682528|NCT04762966|Drug|Metformin|Level of Metformin blood concentration
45682529|NCT03602560|Drug|seladelpar 5-10 mg|Seladelpar 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects will continue the seladelpar dose (5 or 10 mg) received during the double-blinded study
45682530|NCT03602560|Drug|seladelpar 10 mg|Seladelpar 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label safety study. Subjects will continue the seladelpar dose (10 mg) received during the double-blinded study
45682531|NCT03602560|Drug|Placebo|One capsule daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects on placebo will be re-randomized to initiate seladelpar at 5 or 10 mg once daily
46030378|NCT05584345|Other|Conventional Treatment|Cold pack, ultrasound, TENS, finger ladder, Codman, shoulder wheel, and Wand exercises, as well as stretching and capsule exercises, will be used in addition to conventional physiotherapy. Exercises with a wand will be performed 10 times in each direction. There will be 30 repetitions in each direction of the Codman exercises. 5 days a week, for a total of 30 sessions, the afflicted shoulder will get 6 minutes of daily US treatment, with complete contact to the shoulder area and at a right angle. All patients will receive manual stretching in the shoulder flexion, abduction, extension, external rotation, and internal rotation directions. The physiotherapist will perform these stretches 5 times in each direction, pausing for 20 seconds at the conclusion of each repeat. TENS will be applied for 20 minutes. In addition, a 15-minute cold pack application will be made to the shoulder region. The application of theraband strengthening exercises will depend on the patients' state.
46030379|NCT05584345|Other|Respiratory Exercises|Diaphragmatic breathing and thoracic expansion breathing exercises will be applied 5 days a week.
46030380|NCT05584098|Other|qSOFA and MEWS|qSOFA and MEWS used in emergency medicine department could be helpful in the identification of the occurrence of sepsis
46030381|NCT05582707|Drug|Pioglitazone 15mg|Study participants will be administered pioglitazone (15 mg tablet) either p.o. or enteral (via nasogastric tube). The first dose may be administered prior to surgery or within 3 hours of the end of surgery but must be administered within 24 hours of the index event or time last known normal (TLKN). Pioglitazone (15 mg tablet) administration will continue 3 times daily for 3 weeks, including after hospital discharge, if applicable.
45839134|NCT05578638|Combination Product|Aloe Vera rosemary tropical application|10 ml of the Aloe Vera rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
46030382|NCT05575492|Biological|mRNA-1647|Sterile liquid for injection
45471782|NCT01256489|Drug|Infliximab|The drug will be administered intravenously every month for 110 weeks (duration of the study). The initial dose of infliximab will be 5mg/kg of body weight. The dose may be adjusted up to a maximal dosing of 10mg/kg depending upon disease activity, as judged by the investigators.
46030383|NCT05575492|Other|Placebo|0.9% sodium chloride injection (normal saline)
45682532|NCT03702244|Diagnostic Test|cCTA with selective FFRct|PRECISE will evaluate whether a precision evaluation strategy that combines contemporary risk stratification using the PROMISE Risk Tool with functional and anatomic non-invasive evaluation with cCTA with selective FFRct can improve outcomes over usual care in stable chest pain patients while safely deferring further testing in low-risk patients and reducing cost overall
46030384|NCT05571306|Other|four core components care|"The intervention progresses throughout the first three months for the recently diagnosed T2DM patients and is divided into four core components: 1) Improve of cross-sectoral communication and information sharing, 2) ensure systematism in care, 3) guarantee participation at a one-stop-shop and a start-up conversation at the municipality, and 4) improve patients coping skills."
46030385|NCT05569746|Drug|INM004|Two 4 mg/kg doses of INM004, 24 h (±2 h) apart, will be assessed. Each dose will be administered as an intravenous infusion during 50 min.
46030386|NCT05569746|Other|SoC|Standard of care
46030387|NCT05566769|Device|NMOSDCopilot smartphone application|NMOSDCopilot includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to pain, fatigue, quality of life, bladder and bowel dysfunction, depression
46030388|NCT05566392|Diagnostic Test|Brain MRI|Brain MRI including diffusion spectrum image, and functional MRI Interview with questionnaires for neuropsychiatric evaluation Near infrared spectroscopy and resting-state connectivity evaluation
46030389|NCT05564936|Device|ME&MG mobile application|ME&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG.
46030390|NCT05564611|Drug|Omalizumab 150mg|A single dose of 150 mg lyophilized vial will be administered in the upper arm as the site of injection
45682533|NCT03597256|Device|Restylane Defyne|Intradermal injection
46030391|NCT05560789|Behavioral|Physical activity (cycling on a stationary bicycle ergometer or walking on a treadmill)|At time 0, exercise will be initiated and intensity will be increased at 2 minute intervals to achieve low intensity for 30 minutes (as defined by heart rate target 50-55% of maximum heart rate determined as 220-age). Next, intensity will be increased at 2 minute intervals until the heart rate target for moderate intensity exercise is achieved (55-65% of max heart rate), or the total duration of exercise of up to 60 minutes is achieved.
46030392|NCT05559164|Drug|Lipitor 40mg Tablet|LIPITOR® (atorvastatin calcium) tablets will be administered orally as a single dose of 40 mg once daily, with or without food
46030393|NCT05558098|Drug|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg once per day for 14 days or until intensive care unit discharge or death
46030394|NCT05558098|Other|Standard of Care|Current standard of care for management of critically ill patients
46030395|NCT05558007|Drug|Tadalafil 5mg|Daily oral administration of tadalafil 5mg
45682534|NCT03596788|Dietary Supplement|Carbohydrate Beverage|The carbohydrate beverage will supply approximately 100 grams of carbohydrate per day (in the form of glucose and fructose)
46030396|NCT05558007|Drug|BZ371A|Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL
45682535|NCT03596788|Dietary Supplement|Placebo Beverage|The placebo beverage will contain aspartame.
46030397|NCT05558007|Drug|Oral Placebo|Oral administration of a placebo pill
46030398|NCT05558007|Drug|Topical Placebo|Topical application of 1.5 mL of placebo
46030399|NCT05557162|Other|AI ECG Amyloid algorithm|Artificial intelligence enabled electrocardiogram screening tool used to identify the predictive model that best differentiates those at greatest risk for an amyloidosis diagnosis
46030400|NCT05554328|Procedure|Biopsy|Undergo tumor biopsy
46030401|NCT05554328|Procedure|Biospecimen Collection|Undergo blood collection
45682536|NCT03797326|Biological|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W.
45682537|NCT03797326|Drug|Lenvatinib|Administered orally once a day during each 21-day cycle.
45682538|NCT01691859|Drug|Mepolizumab|100 mg of mepolizumab will be injected subcutaneously (SC) once every 4 weeks
45682539|NCT00779116|Drug|Desloratadine|SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day
46030402|NCT05554328|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration or biopsy
46030403|NCT05554328|Procedure|Computed Tomography|Undergo CT scan
46030404|NCT05554328|Procedure|Echocardiography|Undergo ECHO
45471783|NCT03746119|Other|E-cigarette vapor containing nicotine|A fourth generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings, and pre-mixed e-solution containing nicotine.
46030405|NCT05554328|Procedure|Multigated Acquisition Scan|Undergo MUGA
46030406|NCT05554328|Drug|Olaparib|Given PO
46030407|NCT05554328|Drug|Selumetinib Sulfate|Given PO
46030408|NCT05553704|Drug|Metformin|metformin group will take mesalamine 1 gm three times daily plus metformin 500 mg two times daily
46030409|NCT05553405|Drug|Intralipid Infusion|Intralipid 20% (a 20% IV fat emulsion) is a sterile, non-pyrogenic fat emulsion prepared for IV administration as a source of calories and essential fatty acids. It is made up of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin and water for injection. In addition, sodium hydroxide has been added to adjust the pH so that the final product pH is 8.
45471784|NCT03746119|Other|E-cigarette vapor, nicotine free|A fourth generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings, and pre-mixed nicotine free e-solution.
45471785|NCT03160118|Drug|Seasonal,quadrivalent,influenza vaccine|1 dose to be administered on Day 0, the first visit
45471786|NCT01150565|Drug|LiRIS low dose and LiRIS high dose|Drug delivery system containing lidocaine; LiRIS (low or high dose) is inserted into bladder via cystoscopy on Day 1 and removed via cystoscopy on Day 14. Designed to release lidocaine over a 14 day period.
46030410|NCT05552326|Drug|Olezarsen|Olezarsen will be administered by SC injection.
46030411|NCT05552326|Drug|Placebo|Olezarsen-matching placebo will be administered by SC injection.
46030412|NCT05545280|Drug|Neostigmine with glycopyrrolate|Administration by intravenous infusion
46030413|NCT05545280|Drug|Sugammadex|Administration by intravenous infusion
46030414|NCT05544760|Other|CatchU Intervention|The CatchU Intervention arm will receive individualized recommendations (adapted from the CDC STEADI program) as outlined on the CatchU physician report sent to the participants physicians. These recommendations in combination with falls intervention referrals and falls counseling tips will be monitored and statistical investigation of the impact of CatchU intervention in preventing future falls will be determined.
46030415|NCT05543083|Behavioral|Cognitive-Behavioral Therapy followed by Exercise Training|6-week group CBT (cognitive-behavioral therapy; 1 hour/week for 6 weeks) followed by 6-week group exercise training (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
46030416|NCT05543083|Behavioral|Exercise Training followed by Cognitive-Behavioral Therapy|6-week group exercise training (1 hour/week for 6 weeks) followed by 6-week group CBT (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
45471787|NCT01149005|Drug|novorapid / humalog short acting insulin|1-4 units will be injected Subcutaneously (SC), before every main meal.
45471788|NCT01149005|Drug|Novo Rapid Insulin (Novonordisk)|Novo Rapid Insulin (Novonordisk) will be administered before each main meal 1-4 units depends on the patients weight
45471789|NCT03042104|Device|Edwards SAPIEN 3 / SAPIEN 3 Ultra THV|Patients will receive the SAPIEN 3 / SAPIEN 3 Ultra THV.
46030417|NCT05543083|Behavioral|Cognitive-Behavioral Therapy Only|6-week group CBT (1 hour/week for 6 weeks), with continuation of group CBT for a second 6-week period (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
46030418|NCT05543083|Behavioral|Exercise Training Only|6-week group exercise training (1 hour/week for 6 weeks), with continuation of group exercise for a second 6-week period (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
46030419|NCT05541848|Other|Cervical supervised exercises with laser-guided feedback (ELGF)|"Cervical supervised exercises with laser-guided feedback (ELGF) is defined as a procedure of proprioceptive training based on a type of therapeutic exercise that provides external feedback to exercise, achieving an improvement in range of motion and postural control in subjects with spinal pain. For the performance of the exercise program, Motion Guidance Clinician Kit (Motion Guidance LLC, Denver, CO, USA.) was used. The program consisted of 4 exercises, which progressed in difficulty according to the tolerance achieved over the course of the sessions: a) Maintaining the head position (cervical stabilisation); b) Cervical flexion-extension; c) Right-left rotations; d) Right-left lateral-flexions. Each exercise consisted of 4 series of 8 repetitions, except the first one, in which the head position is maintained by pointing the laser at the centre of the panel for 30 seconds (4 series). The average time to complete the entire program did not exceed 14 minutes."
45839135|NCT05578638|Combination Product|aloevera tropical application|10 ml of the Aloe Vera spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
45682540|NCT00779116|Drug|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day
45682541|NCT04112355|Other|Blood Collection|Blood draw
45682542|NCT03794284|Diagnostic Test|VereMTB|At least 2 mL of patient's expectorated or induced sputum would be collected for VereMTB assay and their clinical data would be retrieved for analysis use.
45754633|NCT05143567|Other|standard of care anticoagulation in combination with elastic compression|Subgroup IIIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE
45839136|NCT05578638|Combination Product|rosemary tropicalapplication|10 ml of the rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
45839137|NCT05508594|Drug|CT001|Intranasal
45839138|NCT05508594|Drug|Placebo|Intranasal
45839139|NCT05508594|Drug|Sufentanil|Intranasal
45839140|NCT05508594|Drug|Ketamine|Intranasal
45471790|NCT01256645|Other|blood transfusion|application of single units of red blood cell transfusions
45471791|NCT03903887|Biological|anti-PD1 antibody-activated TILs|Participants would receive one dose of anti-PD1 antibody-activated TILs at the final cycle of docetaxel and cisplatin (DP) regimen chemotherapy.
45471792|NCT05185310|Procedure|Ablation|Ablation strategy during repeat AF ablation
45471793|NCT01150643|Genetic|gene expression analysis|
45471794|NCT01150643|Genetic|microarray analysis|
45471795|NCT01150643|Genetic|polymerase chain reaction|
45471796|NCT01150643|Genetic|polymorphism analysis|
45471797|NCT01150643|Other|immunohistochemistry staining method|
45471798|NCT01150643|Other|laboratory biomarker analysis|
45471799|NCT05212844|Procedure|Musculoskeletal Physical Therapy|Therapeutic exercise and manual physical therapy based on the individual response to end range repeated movements.
45754634|NCT03583112|Drug|Dapoxetine Hydrochloride Tablet|oral one dapoxetine hydrochloride tablet before MRI scan
45754635|NCT03583112|Drug|Placebo Tablet|oral one placebo tablet before MRI scan.
45754636|NCT03156530|Device|Auricular acupunture|Evaluation of balance before, during and after applying of auricular acupuncture.
45754637|NCT03156530|Other|Control|Not receive stimulation.
45754638|NCT00578383|Device|Low Field Magnetic Stimulation Device|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1 kHz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. Subjects will receive one 20 minute treatment.
45839141|NCT05428020|Device|Indwelling foley catheter|short-term indwelling catheter inserted in the operating room prior to surgery, removed upon arrival to the floor from post-anesthesia care unit (approx 2-3 hours after surgery).
45839142|NCT05428020|Other|No foley catheter|No foley catheter is placed for surgery
45839143|NCT05417100|Drug|Methadone|methadone 0.2 mg/kg IV.
45839144|NCT05417100|Other|Saline placebo|Saline placebo
45839145|NCT05391438|Other|Meal-timing|We propose a cross-over, proof-of-concept study to measure glycemic and metabolic responses to a test meal (controlled for macronutrient profile and caloric amount) administered at various times of the day (early vs. afternoon vs. late) in thirty Latino adolescents (ages 13-19 years), with obesity, without diabetes, to determine how timing of eating impacts glycemic response to the test meal after a 16-h fasting period. All participants will consume three standard test meals administered in random order at different times of day over two-weeks: (1) Early: test meal consumed at 8 AM; (2) Afternoon: test meal consumed at 12 PM; (3) Late: test meal consumed at 4 PM. A continuous glucose monitor (CGM) will be placed on the participant for the duration of the 2-week period. Baseline and post-meal samples will be assayed for glucose, insulin, c-peptide, GLP-1, GIP, PP at times -10, -5, 0, 10, 20, 30, 45, 60, 90, 120, 150 and 180 minutes after glucose.
45839146|NCT05345106|Procedure|Bariatric Surgery|Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery
45839147|NCT05285826|Biological|9vHPV Vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) L1 virus-like particle vaccine administered as a 0.5-mL IM injection
45839148|NCT05285826|Other|Placebo|Sterile saline solution administered as a 0.5 mL IM injection
45598716|NCT02354547|Drug|Cyclophosphamide|Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 200 mg/m² cyclophosphamide will be administered in combination with topotecan and SGT-53 IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, cyclophosphamide will be escalated to 250 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
45839149|NCT05281536|Other|Ppostural change from 45° to 10° in supine position|The intervention will be a postural change from 45° to 10° in a semi-recumbent position of ARDS patients connected to mechanical ventilation.
45839150|NCT05278884|Behavioral|Advanced Cardiac Life Support Training|Advanced Cardiovascular Life Support (ACLS) is a resuscitation course to teach recognition and treatment of cardiopulmonary arrest in patients.
46030420|NCT05541848|Other|Interferential current electro massage (ICE)|Interferential current electro-massage (ICE) is defined as a technique which combines simultaneously manual therapy (massage) and ICT. We used a current bipolar mode, using a carrier frequency of 4000 Hz at constant voltage and an amplitude-modulated frequency of 100 Hz (Sonopuls 692®; Enraf-Nonius BV, Rotterdam, The Netherlands), was administered. The intensity was set to provide a strong and comfortable tingling, without evoking muscle twitches even though a slight vibration (fasciculation) was allowed. The sequence combined (A) superficial stroke over the neck-shoulder for 30-45 seconds; (B) deep sliding movements, alone or (C) combined with shoulder drop, for 4-5 minutes; (D) bilateral kneading of the upper trapezius (4-5 minutes); (E) slight stretching of cervical muscles (upper trapezius, sternocleidomastoid, and levator scapulae); and repetition of step (A). The electro-massage protocol lasted 15 minutes.
46030421|NCT05540665|Drug|Daxdilimab|"Daxdilimab will be administered subcutaneously as two injections for each dose.~Other Names: HZN-7734"
46030422|NCT05540665|Drug|Daxdilimab|"Daxdilimab will be administered subcutaneously as two injections for each dose.~Other Names: HZN-7734"
46030423|NCT05540665|Drug|Placebo (Normal Saline)|Placebo will be administered subcutaneously as two injections for each dose.
46030424|NCT05539937|Other|Quality of life questionnaire|Before TAVI, 30 days, 6 months and twelve months after TAVI, patients will answer TASQ questionnaire,
45754639|NCT05702294|Device|Diary pod ( measuring vessel that automatically calculates voided volume)|Women in the control arm of the study will be required to void in the measuring cup and write down their estimates on the paper diary and then transfer the voided volume to the diary pod provided (or vice versa).
46030425|NCT05536349|Drug|Pirtobrutinib|Given by PO
46030426|NCT05536349|Drug|Obinutuzumab|Given by (IV) vein
45754640|NCT05702294|Device|Diary pod ( measuring vessel that automatically calculates voided volume)|Women in the Lower Urinary Tract Symptoms ( LUTS) arm of the study will be required to void in the measuring cup and write down their estimates on the paper diary and then transfer the voided volume to the diary pod provided (or vice versa).
45839151|NCT05278884|Behavioral|Vital Anesthesia Simulation Training|The Vital Anesthesia Simulation Training (VAST) Course focuses on core clinical practices and non-technical skills needed to respond to the most common urgent and emergent clinical challenges found in hospitals in resource-limited settings like Rwanda.
45839152|NCT05136690|Drug|Nicotine patch|Nicotine 21 mg transdermal nicotine patch.
46030427|NCT05536349|Drug|Venetoclax|Given by PO
46030428|NCT05536349|Drug|Valacyclovir|Given by PO
46030429|NCT05536349|Drug|Allopurinol|Given by PO
45754641|NCT03583034|Procedure|Holmium laser enucleation of the prostate (HoLEP)|Surgery for benign prostatic hyperplasia
46030430|NCT05526768|Device|VITLS Device|VITLS remote vital sign monitoring device will be applied to consented patients so data obtained by the device can be compared to data obtained by traditional inpatient hospital monitoring devices.
46030431|NCT05521854|Behavioral|DynamiCare app (app-based contingency management)|Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.
46030432|NCT05521854|Behavioral|Sham control|Participants get access to the DynamiCare app but will not be provided with financial incentives.
46030433|NCT05518903|Procedure|Computed Tomography|Undergo CT
46030434|NCT05518903|Drug|Gallium Ga 68 FAPi-46|Given IV
46030435|NCT05518903|Procedure|Positron Emission Tomography|Undergo PET
46030436|NCT05518461|Device|iThrive WI Intervention|Participants will receive COVID-19 and overdose-related educational and motivational content over the course of 12 weeks through the Thrive4Life Connect, a mobile health application. They will be invited to set goals for lowering overdose and COVID-19 risk.
46030437|NCT05517642|Biological|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Subjects will be randomized to receive a second booster dose of IH Convidecia vaccine (treatment arm)
46030438|NCT05517642|Biological|mRNA vaccine BNT162b2 (Pfizer)|Subjects will be randomized to receive a second booster dose of BNT162b2.
46030439|NCT05514132|Drug|Ceralasertib|Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ATR, with good selectivity against other phosphatidylinositol 3-kinase-related kinase family members.
46030440|NCT05514132|Drug|Durvalumab|Durvalumab is a human mAb of the immunoglobulin G 1 kappa subclass that blocks the interaction of PD-L1 (but not PD-L2) with PD-1 on T cells and CD80 (B7.1) on immune cells.
46030441|NCT05511701|Behavioral|CHW Care Model|The CHW will measure the participant's blood pressure (BP) and along with other demographic variables, calculate the participant's absolute CVD risk score, using the mHealth (mobile health) app. If the participant's risk is > 10%, they are asked to sign the informed consent. The CHW will electronically schedule an appointment at the PCC. The participant will receive a SMS appointment confirmation. S/he will have their cholesterol tested by nurses using a home POCT. Nurses will repeat POCT lipids and BP measurements at all PCC visits and other clinical information will be entered into the electronic decision support tool that will generate a guideline based treatment recommendation for the physician. CHWs will make up to four home visits or telephone calls to intervention participants over the 12 month study period to check on medication adherence, as well as to determine if the patient is in possession of the medication
46030442|NCT05511701|Behavioral|Usual Care Model|All study participants will be visited in their home by a CHW and a nurse for eligibility assessment, screening, and enrollment. The CHW will then measure the participant's blood pressure and the readings along with other demographic variables already collected, to calculate the participant's absolute CVD risk score. In the usual care arm the CHW will use the WHO paper-based non-lab CVD risk calculator and, if the participant's risk is > 10%, they are asked to sign the informed consent and s/he will have their cholesterol tested by nurses using POCT during a home enrollment visit. The CHW will further verbally encourage her/him to schedule an appointment with a primary care physician at the PCC for evaluation. This is the usual care practice.
45598717|NCT02232035|Drug|normal saline/diazepam at the active phase of labor|A single dose intravenous injection of normal saline (2ml)/diazepam (10mg, 2ml) at the beginning of active phase of labor.
45754642|NCT03582644|Other|Cryotherapy|Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
46030443|NCT05510726|Device|shearwave elastography|shearwave elastography on upper or lower limb
46030444|NCT05494736|Drug|MK-8527|MK-8527 capsule taken by mouth.
46030445|NCT05494177|Diagnostic Test|bUDVA, bUIRA, bUNRA, bUICPS, bUNCPS|"All participants will be assessed on the following clinical indexes:~Binocular uncorrected distant visual acuity (bUDVA) at four meters distance~Binocular uncorrected intermediate reading acuity (bUIRA) at 60 cm~Binocular uncorrected near reading acuity (bUNVA) at 40 cm~Binocular uncorrected intermediate Critical Print Size (bUICPS) at 60 cm~Binocular uncorrected near Critical Print Size (bUNCPS) at 40 cm~All the above parameters are obtained using the Democritus Digital Acuity & Reading Test (DDART)."
45598718|NCT02296021|Drug|Berberine|Berberine-containing quadruple therapy group: given for 14 days at a dose of berberine 100 mg 5 tablets BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
45598719|NCT02296021|Drug|Bismuth|Bismuth-containing quadruple therapy group: given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
45839153|NCT05136690|Drug|MK-4334|MK-4334 250 mg capsule taken by mouth.
45839154|NCT05136690|Drug|Placebo patch|Placebo patch.
45839155|NCT05136690|Drug|Placebo capsule|Placebo capsule taken by mouth.
45839156|NCT05135754|Device|Heylo|Test of the supporting product (test product) for a 12 weeks period. No measurement will be conducted. All endpoints are captured via surveys send to the subjects every 14 days.
46030446|NCT05494177|Diagnostic Test|Contrast sensitivity|Contrast sensitivity is assessed with the Pelli-Robson test.
46030447|NCT05487261|Drug|Sacubitril-valsartan|level 1-24 / 26mg 2 times a day, level 2-49 / 51mg 2 times a day, level 3-97 / 103mg 2 times aday
46030448|NCT05487261|Drug|Enalapril|level 1-2.5 mg twice a day, level 2-5 mg twice a day, level 3-10 mg twice a day
46030449|NCT05487261|Drug|placebo|placebo matching for 24 / 26mg, 49 / 51mg, 97 / 103mg 2 of sacubitril/valsartan
46030450|NCT05487261|Drug|Placebo|placebo matching for 2.5 mg, 5 mg, 10 mg of enalapril
46030451|NCT05486156|Other|A Time with e-Nature|"Integrated multisensory experience (aesthetic, emotional and knowledge) in two stages:~Observation of nature through the senses (smell, hearing, sight, touch, taste) and the appreciative look.~Observation focused on the local avifauna and flora during the trail accompanied by a research biologist from the group."
45598720|NCT02296021|Drug|esomeprazole|Esmeprazole 20mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
45682543|NCT02073435|Behavioral|Donor pain management|"The evidence-based donor pain management solution entails the following elements:~Preoperative Assessment and Management:~Assessment of Patient Risk factors for Respiratory Depression (e.g. OSA Assessment: STOP BANG Questionnaire)~Bowel preparation (e.g. Colace or Golytely)~Patient Postoperative Pain Education - Educational handout on postoperative pain~At the end of the case in OR:~Local Anesthetic (TAP block, OnQ device, intrathecal, local infiltration)~I.V. Ketorolac (when adequate hemostasis is determined by surgeon and urine output is > 500cc)~I.V. Steroids (Dexamethasone or Solumedrol)~Postoperative Management:~NSAIDS x 72 hours followed by po cox-inhibitor until discharge (e.g. Celecoxib)~Opioids (Dilaudid PCA followed by oral opioids (e.g., Tylenol #3))~Postoperative Assessment:~o CO2 monitoring in PACU/ICU for early monitoring of respiratory depression"
45682544|NCT01676740|Drug|Iron Supplement,|Pills to be swallowed
45839157|NCT05106426|Behavioral|Healthy Caregivers- Healthy children|The HC2 intervention is an obesity prevention program that provides nutrition and healthy activities programs administered weekly via Zoom or in-person.
46030452|NCT05479240|Drug|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 6 cycles.
46030453|NCT05479240|Drug|Capecitabine|Participants will receive Capecitabine, 1000mg/m2, day 1-14 of every 3 weeks for 6 cycles
46030454|NCT05479240|Drug|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 6 cycles.
46030455|NCT05479240|Radiation|short-range radiotherapy|5*5Gy，d1-d5
46030456|NCT05471830|Drug|Apixaban|No drug will be provided to participants. Patients follow routine clinical practice/administration.
46030457|NCT05468619|Drug|Valacyclovir|Valacyclovir is a L-valyl ester of acyclovir.
46030458|NCT05467176|Drug|Relugolix|Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1
46030459|NCT05465954|Procedure|Biospecimen Collection|Correlative studies
46030460|NCT05465954|Biological|Efineptakin alfa|Given IM
46030461|NCT05465954|Biological|Pembrolizumab|Given IV
46030462|NCT05465941|Procedure|Biopsy|Undergo biopsy
46030463|NCT05465941|Drug|Pegylated SN-38 Conjugate PLX038|Given IV
45682545|NCT01676740|Drug|Placebo|Daily administration of active drug or placebo
45839158|NCT05106426|Behavioral|Jump Start|The Jump Start intervention is a behavioral health and safety program that provides behavior management and safety programs administered weekly via Zoom or in-person.
45682546|NCT01691781|Drug|Lisinopril|Each subject will receive one week of lisinopril and return for repeat for blood measurements.
45598721|NCT02296021|Drug|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus esmeprazole 20mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
45682547|NCT04112043|Behavioral|Walking Exercise|Participants randomized to this intervention 3 days/week of supervised, center-based walking exercise.
45682548|NCT04112043|Drug|Nicotinamide Riboside (NR)|Participants randomized to this intervention will receive 1,000 mg/day of NR.
45754643|NCT03580226|Other|No intervention|No intervention
45754644|NCT00578461|Drug|Ara C|3000 mg/m^2 - pts will recieve via IV every 12 hours for 6 doses starting at 20:00 hours on day -8
45754645|NCT00578461|Drug|Mesna|45 mg/kg; divided into 5 doses-will be administered 15 minutes prior to Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide
45754646|NCT00578461|Drug|Cyclophosphamide|45 mg/kg; IV once daily on day -7 and day -6 starting at 1400 hours
45839159|NCT05064462|Other|Collection of EDTA blood sample (5 to 7 ml)|"For all the patients included in the study, the samples to measure the viral load will be taken during the transplantation, then at each of the consultations planned as part of the usual care during the first year post-transplant (at minimum once and maximum twice a month).~These samples will be taken at the same time as those taken as part of standard care."
46030464|NCT05461573|Drug|Drospirenone|LPRI-CF113 consists of 24 active white tablets containing drospirenone (DRSP) 4 mg followed by 4 active pink tablets containing DRSP 2.8 mg, taken orally once daily for 28 consecutive days, in consecutive cycles for 12 months (13 medication cycles) without a break in daily tablet intake.
45598722|NCT02296021|Drug|clarithromycin|Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 20mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
45598723|NCT04777175|Drug|immunity therapy|The patient receives immunotherapy
46030465|NCT05458960|Behavioral|Social needs navigator program|4 months of assistance tailored to the needs of the participant
46030466|NCT05458960|Behavioral|Enhanced usual care|Referral to United Way 2-1-1
46030467|NCT05457972|Drug|Estradiol|Imvexxy is an FDA-approved drug produced by TherapeuticsMD.
46030468|NCT05457972|Device|Vaginal Moisturizer|Ingredients include hydrogenated coconut and palm oils and natural-source vitamin E (d-alpha tocopheryl acetate and tocopherols).
45839160|NCT05035680|Biological|Unadjuvanted seasonal influenza vaccine|Single 0.5 mL IM injection
45754647|NCT00578461|Radiation|TBI-Total Body Irradiation|Total dose 12 Gy, will be delivered in 8 fractions of 150 cGy, each, two fractions per day beginning day -4
45754648|NCT03580070|Biological|Immunotherapy|Patients with primitive head and neck squamous cells carcinoma diagnosed on surgical resection or biopsic sample, between 2008 and 2015. They were included when expressing p16 as assessed by immunochemistry and positive HPV DNA by in situ hybridation or positive HPV PCR
45754649|NCT03156296|Drug|Dexmedetomidine|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)
45754650|NCT03156296|Drug|Bupivacaine|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
45754651|NCT00578539|Drug|ARA C|Ara C (3000 mg/m2) IV every 12 hours for 6 doses (days -8 to -5)
46030469|NCT05454462|Drug|IMP Application KM-001|KM-001 will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. the patient will use IMP twice a day for 28 days.
45471800|NCT03903419|Diagnostic Test|Feasibility study for the realization of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT for identification of early recurrence in patients treated with radiotherapy for glioblastoma.|"This study is a non-randomized, prospective, feasibility study assessing 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT to differentiate early recurrence from post-radiation modifications in patients treated with radiotherapy for glioblastoma.~Patients with a MRI performed since the end of the radiotherapy until 12 months of follow up after the end of radiotherapy, will be referred for both 68Ga-PSMA and 18F-FDOPA PET-CT, whatever the conclusion of the MRI (post radiation modifications, relapse or doubtful MRI)."
45471801|NCT05122130|Drug|Melatonin|The donor site will be dressed with melatonin loaded gelatin sponge
45471802|NCT05122130|Drug|Carbopol|The donor site will be dressed with carbopol loaded gelatin sponge (placebo).
45471803|NCT03898271|Other|Virtual World|Participants will complete a synchronous PTSD training in an immersive virtual world environment.
45471804|NCT03897803|Diagnostic Test|strain elastography|strain elastography as apart of muscle ultrasound examination of the biceps brachii and rectus femoris muscles will be performed to the patients and control groups at baseline evaluation and after 4 months follow up in the patients groups only.
45471805|NCT05212766|Biological|COVID infection|Infections with COVID 19
45471806|NCT05212766|Biological|COVID vaccination|Vaccination against COVID 19
45471807|NCT05212766|Diagnostic Test|Oral examination|Assessment of oral and periodontal health status
45471808|NCT05212532|Drug|EOM613|peptide nucleic acid (PNA)
45471809|NCT01258205|Drug|AMG 139|Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).
45471810|NCT03893981|Other|Proprioception and Balance Program|Balance Trainer device and playing ball in tandem position for using to improve balance, vibration and reposition exercises for using to improve proprioception. Progressive of training will increase after each 2 weeks.Patients will be taken to the treatment program 3 days in a week for 8 weeks.
45471811|NCT03893981|Other|Strengthening Program|Exercises which include open and closed kinetic chain exercise will be applied to strength knee and hip muscle. Progressive of training will increase after each 2 weeks. Patients will be taken to the treatment program 3 days in a week for 8 weeks.
46030470|NCT05454462|Diagnostic Test|Chemistry|patients will provide a blood sample for a chemistry blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
46030471|NCT05454462|Diagnostic Test|Hematology|patients will provide a blood sample for a hematology blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
46030472|NCT05454462|Diagnostic Test|Urinalysis|Patients will provide a blood sample for a urine test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
46030473|NCT05454462|Diagnostic Test|Serelogy|Patients will provide a blood sample for serelogy test at day -14 (screening visit)
46030474|NCT05454462|Diagnostic Test|12-Lead ECG|patients will undergo an ECG examination on days -14 (screening visit), and day 28 (end of treatment visit).
45471812|NCT02898506|Drug|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
45471813|NCT02898506|Drug|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
45471814|NCT03897959|Device|Kohli vs Foley catheter|Alternative suprapubic catheter used for bladder drainage.
45471815|NCT03897647|Device|General Electric (GE) VScan|This is a small, point-of-care, hand-held device used for ultrasound (POCUS). It uses sound waves to generate images without using any radiation.
45471816|NCT04123405|Drug|acetylcysteine|600 mg tablet
45471817|NCT04123405|Drug|Placebo|Placebo to acetylcysteine
45839161|NCT05035680|Biological|SWE adjuvant mixed with unadjuvanted seasonal influenza vaccine shortly before dosing (SWE + QIV)|Single 0.8 mL IM injection
45839162|NCT05035680|Biological|MF59 adjuvanted seasonal influenza vaccine|Single 0.5 mL IM injection of MF59 adjuvanted seasonal influenza vaccine
45471818|NCT02611232|Drug|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
45471819|NCT02611232|Drug|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
45471820|NCT01258283|Other|Addional imaging|All patients will systematically have an 18F-FDG PET-CT (18F-fluorodeoxyglucose positron emission tomography/computed tomography) and a 123MIBG (Iodine 123 metaiodobenzylguanidine) scintigraphy
45471821|NCT05076734|Diagnostic Test|Redraw for analysis of blood samples from healthy pregnant women|If less than two fetal cells are recovered from maternal blood, a redraw is indicated
45598724|NCT04478643|Dietary Supplement|Probiotic: Lactobacillus Reuteri|Lactobacillus reuteri ATCC PTA 5289 (a minimum of 2 × 108 colony-forming units L. reuteri Prodentis/lozenge, BioGaia AB)
46030475|NCT05454462|Diagnostic Test|Pregnancy test|Women of child-bearing potential only will provide at all the on-site visits b-hCG concentration will be tested
46030476|NCT05454462|Diagnostic Test|Blood PK sampling|PK test will be performed on day 1, 7, 28, 35 and on ET visit
46030477|NCT05454462|Procedure|Physical Examination|patients will undergo a physical examination on all the clinical visits
46030478|NCT05454462|Procedure|Vital signa|patient's vital signs will be measured on all the clinical visits
45471822|NCT01150877|Drug|Vitamin D|We propose to study high-dose, oral vitamin D supplementation, raising serum 25-hydroxy-vitamin D (25(OH)D) concentrations to 200 -250 nmol/L, in metastatic colorectal cancer patients with safety, tolerability and survival as the main outcome measurements. The dose is not pre-set and will depend on the individual subjects' serum 25(OH)D concentration. Subjects will be supplemented for 16 months with a daily oral dose, followed by a 12 months follow-up period.
46030479|NCT05454462|Diagnostic Test|Investigator's Global Assessment|patient's disease evaluations will be evaluated on all the clinical visits
46030480|NCT05454462|Diagnostic Test|Itch Assessment via PP-NRSj|patient's disease evaluations will be evaluated on all the clinical visits
45471823|NCT03893591|Diagnostic Test|Anti Xa levels|one Blood sample
45471824|NCT01256801|Biological|cytokine|interleukin 2 2 million unit every week
45471825|NCT02519738|Drug|Silver Nitrate|Silver nitrate to be applied 3 times weekly for a period of 3 weeks.
45471826|NCT02519738|Drug|Kenalog (Triamcinolone)|Triamcinolone will be applied as an ointment to the granulation tissue site three times daily for a total of three weeks.
45471827|NCT02519738|Other|Washcloth Abrasion|Gentle wash and abrasion with washcloth done once daily for a total of 3 weeks.
45471828|NCT03747211|Behavioral|Aerobic exercise|High Intensity Interval Training (HIIT)
45471829|NCT01256957|Device|HEPA filter|
45471830|NCT03893669|Biological|NBP607|1 dose, 0.5ml, Intramuscular (IM) injection
45471831|NCT03893669|Biological|Agrippal|1 dose, 0.5ml, Intramuscular (IM) injection
45471832|NCT03893747|Biological|The first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
45682549|NCT04111731|Procedure|Cryoballoon pulmonary vein isolation|Catheter ablation using cryoballoon pulmonary vein isolation. Utilisation of a 'cold balloon' (Cryoenergy or cryoballoon ablation) to freeze the bases of the 4 pulmonary veins to achieve electrical isolation.
45682550|NCT04111731|Procedure|Radiofrequency pulmonary vein isolation|Catheter ablation using radiofrequency energy to achieve pulmonary vein isolation. Radiofrequency energy is delivered through the tip of a catheter to make tiny burns (ablation lesions) around the outlines of the 4 pulmonary veins at their bases
45754652|NCT00578539|Drug|Cyclophosphamide|Cyclophosphamide (45mg/kg) IV once daily on day -7 and day -6
45839163|NCT04902066|Other|Cognitive Behavioural Virtual Reality Therapy.|Cognitive Behavioural Therapy augmented with Virtual Reality.
46030481|NCT05454462|Other|E-diary data|The patient will record IMP adminidsration and AE events in a diary every day throughout the all study period
46030482|NCT05452772|Drug|Psilocybin|Participants will received two psilocybin sessions, 1 week apart
46030483|NCT05452772|Drug|Niacin|Participants will received two niacin sessions, 1 week apart
46030484|NCT05449457|Other|2-Octyl cyanoacrylate|Involves closure supplemented by 2-octyl cyanoacrylate (3 layers)
46030485|NCT05447247|Other|Acupuncturing Ba Liao point under ultrasound guidance|Acupuncturing Ba Liao point under ultrasound guidance
46030486|NCT05442684|Biological|Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O
46030487|NCT05442684|Biological|Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O-IH
46030488|NCT05442684|Biological|mRNA-based COVID-19 vaccine|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of mRNA-based COVID-19 vaccine
45471833|NCT03893747|Biological|The second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
45471834|NCT03893747|Biological|The third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
45471835|NCT03893747|Biological|The first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor|500 subjects will be randomized to receive the first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor
45471836|NCT03893747|Biological|The second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor|500 subjects will be randomized to receive the second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor
46030489|NCT05442047|Drug|NNC6019-0001|Participants will receive i.v infusionof NNC6019-0001.
46030490|NCT05442047|Drug|Placebo (NNC6019-0001)|Participants will receive i.v. infusion of placebo (NNC6019-0001).
46030491|NCT05441982|Other|Non-Nutritive Sweetener Intake and impact on glucose homeostasis|Provision of either saccharin, acesulfame potassium, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.
45471837|NCT03893747|Biological|The third batch of inactivated EV-A71 vaccine (vero cell) proudected by 150 L reactor|500 subjects will be randomized to receive the third batch of inactivated EV-A71 vaccine (vero cell) proudected by 150 L reactor
45471838|NCT02343224|Drug|Pegylated interferon alpha-2b|PEG-Intron 1mcg/kg/dose weekly through an injection under the skin on the same day each week
45471839|NCT01257035|Other|18F-FAZA-PET/CT|Contrast fluid injected prior to scan
45471840|NCT05212064|Device|high-flow oxygen nasal cannula therapy|Heated and humidified oxygen of 40L/minute through high-flow nasal cannula (HFNC) therapy machine.
45598725|NCT04478643|Dietary Supplement|Placebo|Placebo lozenge. Will be identical in taste, texture and appearance to the Probiotic one.
46030492|NCT05441540|Device|Internal Jugular Vein Compression Collar|The current FDA approved internal jugular vein compression collar, marketed as the Q collar, is manufactured by Q30 Innovations Home. It is designed to be worn around the neck of individuals aged 13 and older. It functions by lightly compressing the internal jugular vein's bilaterally, safely increasing intracranial volume and intracranial pressure. The FDA approved neck collar device is made of a thermoplastic elastomer that is specifically fitted to an individual to provide mild internal jugular vein compression. The product was developed and confirmed with ultrasonography to confirm appropriate fit and compression of the vein based on an athlete's neck circumference.
46030493|NCT05435859|Behavioral|Speech Tasks|Listen to 25-minutes of speech sounds in English.
45682551|NCT04111731|Procedure|Repeat electrophysiological study|All participants will receive a repeat electrophysiological study 2 months after the index procedure during which radiofrequency catheter ablation guided by ultra-high density mapping will be used to identify regions of reconnection that need re-isolation; other tests will be carried out including testing for arrhythmia inducibility
46030494|NCT05434936|Procedure|Oophorectomy|Patients undergoing surgery for any indicated procedure for fertility-threatening treatment will have attempt at collecting ovarian tissue at time of surgery.
46030495|NCT05431114|Diagnostic Test|MRI|Images of the injured shoulder will then be taken with magnetic resonance (MR) scanner. MRIs of each participant's shoulder will be acquired before and after completion of an exercise protocol.
46030496|NCT05419388|Drug|RO7247669|Participants will receive intravenous (IV) RO7247669 Q3W
46030497|NCT05566496|Diagnostic Test|Brain MRI|All participants receive brain MRI evaluation and clinical evaluation of tic severity.
45839164|NCT04902066|Other|Traditional Cognitive Behavioural Therapy|Traditional Cognitive Behavioural Therapy for psychosis.
45839165|NCT04831320|Drug|nab-paclitaxel|Supplied by Celgene Corporation
45839166|NCT04831320|Drug|Nivolumab|Supplied by Bristol-Myers Squibb
45839167|NCT04578678|Other|Steering|Fine tuning of the STN-DBS settings
45839168|NCT04506762|Procedure|Regional analgesia|Insertion of bilateral ESP catheters
45839169|NCT04505358|Drug|PU-AD|active vs placebo
46030498|NCT05419375|Other|Screening platform|The screening platform will be used to determine biomarker eligibility for a linked Roche study based on tissue-based testing.
46030499|NCT05415735|Behavioral|Stress Management and Resiliency Training Program|This is a multimodal mind-body program designed to teach participants a variety of different strategies to reduce their physiologic stress response.
46030500|NCT05413239|Behavioral|Psychoeducation to reduce diabetes distress and improve glycemic outcomes|The intervention includes two types of sessions - those targeting an improvement in glycemic outcomes and those targeting a reduction in diabetes distress. Evidence indicates that psychoeducation and support are needed to improve self-care behaviors and optimize use of advanced diabetes technologies, which, in turn, can help improve diabetes control while also reducing diabetes distress. Participants will receive 4 one-on-one glycemic sessions and 8 one-on-one distress sessions, each lasting ~30 minutes. Sessions will be conducted in-person or remotely. The virtual sessions are intended to provide the extra psychoeducation and support needed for this high risk group without increasing the burden associated with frequent face-to-face sessions.
46030501|NCT05413161|Biological|ADL-018|150 mg/mL, Solution for injection in PFS
46030502|NCT05413161|Biological|US-licensed XOLAIR|150 mg/mL, Solution for injection in PFS
46030503|NCT05413161|Biological|EU-Approved XOLAIR|150 mg/mL, Solution for injection in PFS
46030504|NCT05401565|Drug|Balovaptan|Intervention of oral administration of 10mg balovaptan QD for 12 weeks followed by two weeks of follow-up period
46030505|NCT05401565|Drug|Placebo|Matching placebo
45471841|NCT05212064|Other|nasal cannula oxygen therapy|Heated and humidified oxygen of 6L/minute through high-flow nasal cannula (HFNC) therapy machine.
46030506|NCT05400161|Behavioral|MoodGym|Participants in the control group will be enrolled in MoodGym, an evidence-based online Cognitive Behavioral Therapy (CBT) program for depression. Through the MoodGym program, participants will have access to interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files. Investigators will supplement Moodgym with a facilitator contact by texting or email to check-in and encourage completion of intervention. MoodGym will provide information on the number of sessions completed by participants (engagement and dosage).
46030507|NCT05400161|Behavioral|Social Media-Based Parenting Program|Participants in the intervention group will be enrolled in Facebook secret user groups, administered by a trained facilitator, to permit participants to view and comment on posted materials. Content and user identity are restricted to invited participants to maintain privacy. Investigators will organize educational materials into video vignettes, narrated PowerPoint presentations, and written materials. The facilitator reviews and comments on postings daily and provides feedback to participants. Facebook analytics for the secret groups are available to group administrators and will provide information on any sessions viewed and counts of sessions viewed and comments posted. Participants randomized to the intervention will also have the option to take part in a preliminary virtual session through a secure video platform (e.g. BlueJeans) and will receive weekly engagement text messages. Women in the intervention group will be enrolled in the online depression treatment program, MoodGym.
46030508|NCT05396469|Diagnostic Test|National guideline treatment|All discovered diseases will recieve national guideline treatment and follow up
45471842|NCT04314037|Drug|Cesol (Test)|Participant will receive coated cesol tablet in sequence 1 (Day 1 and Day 15) and in sequence 2 (Day 8 and Day 22). A washout period of 7 days will be maintained between 4 treatment periods.
45471843|NCT04314037|Drug|Biltricide (Reference)|Participant will receive biltricide tablet in Sequence 1 (Day 8 and Day 22) and in sequence 2 (Day 1 and Day 15). A washout period of 7 days will be maintained between 4 treatment periods.
46030509|NCT05394519|Drug|Cagrilintide|Cagrilintide administered subcutaneously (s.c., under the skin) once-weekly
45839170|NCT04505358|Drug|Placebo|active vs placebo
45839171|NCT04133142|Procedure|peripheral nerve block, inter fascial nerve block|regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. local anesthetic will be ropivacaine 0.5% posology according to the type of block
45839172|NCT03956082|Device|Ultravision™ Visual Field Clearing System|Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation
46030510|NCT05394519|Drug|Semaglutide|Semaglutide administered subcutaneously (s.c., under the skin) once-weekly
46030511|NCT05394519|Drug|Placebo cagrilintide|Placebo cagrilintide administered subcutaneously (s.c., under the skin) once-weekly
46030512|NCT05394519|Drug|Placebo semaglutide|Placebo semaglutide administered subcutaneously (s.c., under the skin) once-weekly
46030513|NCT05391503|Behavioral|Light therapy|Morning bright light for 60 minutes after awakening
46030514|NCT05391503|Behavioral|Placebo light therapy|Placebo morning bright light for 60 minutes after awakening
45682552|NCT04111731|Procedure|Left atrial posterior wall isolation|The left atrial posterior wall will be isolated in Group 2 participants (those who received radiofrequency ablation at the index procedure) during the repeat electrophysiological study in 2 months
45682553|NCT01561755|Drug|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
46030515|NCT05380388|Biological|Malaria Vaccine|blood stage Plasmodium vivax malaria vaccine
46030516|NCT05380388|Biological|HBV vaccine|HBV Vaccine
46030517|NCT05376449|Behavioral|HealthPartners NeuroWell Exercise Program|A 12-week exercise program geared towards individuals with neurological disorders or injuries run by the Regions Hospital Rehabilitation department at the HealthPartners Neuroscience Center. The exercise programming will be designed by the exercise physiologists and adapted to individuals' abilities. Exercise prescriptions will be designed based on established guidelines, level and completeness of injury, individual functional ability, individual goals, and baseline exercise assessments. Program will consist of strength and endurance adaptive exercise.
46030518|NCT05374616|Genetic|Observation|Retrospective and prospective Natural History Study
46030519|NCT05372185|Behavioral|VA Coordinated Anxiety Learning and Management- Substance Use Version|VA Coordinated Anxiety Learning and Management- Substance Use Version (VA CALM-S) is a cognitive behavior therapy (CBT) program that employs computer assistance to empower providers to deliver CBT with high fidelity. The computer program guides both providers and patients in a course of CBT, and in this study the content will focus on using transdiagnostic treatment elements to address co-occurring anxiety and substance use disorders.
46030520|NCT05372185|Behavioral|Usual care|Veterans will engage in VA care using the standard procedures of their facility.
45471844|NCT03893357|Other|Data extraction from medical files|Retrospective data extraction from the medical files
45839173|NCT03956082|Device|Ultravision Ionwand™|The Ionwand™ is introduced into the abdomen through either the Ultravision™ 5mm Trocar or a 2.5 mm percutaneous catheter. The Ionwand™ provides the source of electrons that create the negative ions that transiently charge the surgical smoke particles and accelerate their sedimentation.
46030521|NCT05370157|Behavioral|TeamTRACS|TeamTRACS is a team training intervention adapted from TeamSTEPPS (Team Strategies and Tools to Enhance Performance and Patient Safety), a widely used evidence-based team training developed by the Agency for Healthcare Research and Quality. TeamTRACS targets knowledge, skills, and attitudes related to team member roles, shared awareness, communication, mutual support, and goal-setting. TeamTRACS is structured, easy to use, flexible in length and intensity, and requires few resources. It incorporates didactic instruction, discussion, and interactive activities and can be delivered virtually or in-person.
46030522|NCT05369819|Drug|Midazolam|. Patients of the midazolam group will be treated with midazolam premedication (3 cc mixture of 0.035 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously a waiting area 3 minutes before transportation to an operating room
45682554|NCT01561755|Drug|Placebo|Placebo - 2gr/kg over 2 days of saline
45682555|NCT03789214|Drug|Placebo oral capsule|Placebo Sleep Medication
45471845|NCT02248688|Device|BeadBlock 300 - 500 Micron|Beadblock will be used intraarterially to occlude the left gastric artery and its branches. The left gastric artery supplies the fundus of the stomach, where it is known that the hormone Ghrelin (one of the hormones responsible for appetite) is produced.
46030523|NCT05369819|Drug|Saline|Control group patients are treated with 3 cc normal saline in a waiting area 3 minutes before transportation to an operating room
46030524|NCT05365334|Behavioral|Low intensity exercise session|subjects will exercise at 30% maximal oxygen consumption (VO2max) for 45-60 minutes
46030525|NCT05365334|Behavioral|Moderate intensity exercise session|subjects will exercise at 65% maximal oxygen consumption (VO2max) for 30-45 minutes
46030526|NCT05365334|Behavioral|High intensity exercise session|subjects will completed 10x1minute exercise intervals at maximal oxygen consumption (VO2max) with 1 minute active recovery between
46030527|NCT05365113|Procedure|alveolar recruitment maneuver|"When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order."
46030528|NCT05364957|Device|Intragastric balloon device|Patients in the experimental arm will benefit from the placement of an Intra Gastric Balloon endoscopically
45471846|NCT02248688|Procedure|Left Gastric Artery Embolization|
45682556|NCT03789214|Drug|Low Dose Suvorexant|Low Dose Suvorexant
45682557|NCT03789214|Drug|High Dose Suvorexant|High Dose Suvorexant
45682558|NCT01585155|Drug|TA-650|TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Weeks 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 22.
45682559|NCT03594994|Behavioral|Sleep extension|Extend time-in-bed to 8 hours
45682560|NCT04124367|Drug|Cerebrolysin|30 ml once daily (+70 ml 0.9% saline)
45682561|NCT04124367|Device|non-invasive brain stimulation|2 mA/35 cm² for 2x20 minutes, once daily
45682562|NCT04124367|Drug|Placebo|100 ml once daily 0.9% saline
45682563|NCT04124367|Device|sham intervention|0 mA/35 cm² for 2x20 minutes, once daily Run-in phase consisting of ramp-up (10 seconds), stimulation (10 seconds), and ramp-down (10 seconds).
45682564|NCT03594448|Procedure|Specimen Collection|Undergo collection of blood samples
46030529|NCT05364957|Procedure|Dietary|The patient will benefit from dietary intervention that follows a standard medical recommendation; In consultation with a dietician (at M1, M4, M7, M13, M19, M25), patients will be asked to follow an appropriate diet with a balanced intake of macronutrients (55% carbohydrates, 30% lipids and 15% proteins).
46030530|NCT05364957|Procedure|Exercise intervention|Patient will benefit from exercise intervention; Resistance and aerobic exercises will be performed twice a week for 3 months (between M4 and M7) under the supervision of a physiotherapist.
45471847|NCT03897569|Other|frontal projection angle, ankle dorsiflexion|Dorsiflexion measurements will be taken in 4 different positions and repeated and recorded 3 times in each position, Prone bent, straight knee and Standing bent, straight knee. Prior to the measurement, the participants completed two 30-second calf stretches The FPPA was determined as the angle at the knee formed by lines connecting the anterior superior iliac spine, the midpoint of the femoral condyles and the midpoint of the malleoli at the deepest part of the squat
46030531|NCT05358418|Other|AIS,START with films transferring|Excluding patients with incomplete clinical data of treatment
46030532|NCT05358106|Biological|AntiBKV|AntiBKV neutralising antibody
46030533|NCT05358106|Biological|Placebo|Solution with no active ingredients
46030534|NCT05356949|Behavioral|Intervention|The participants receive a psychological intervention including six weekly sessions. The intervention is based on methods of cognitive-behavioral therapy and delivered by a psychiatric nurse working in the participant's school.
46030535|NCT05355870|Behavioral|Cognitive Training Intervention|Participants in the intervention group will complete a series of cognitive training exercises adapted from the BrainHQ. Results from the intervention development activities will be used to finalize the dose, frequency, and duration of the training. Each session will include 2 training exercises that target different cognitive domains. As participants progress, the difficulty level will be automatically adapted based on participants' performance.
46030536|NCT05338970|Drug|Patritumab Deruxtecan|Intravenous administration, 5.6 mg/kg every 3 weeks (q3W)
45682565|NCT03594448|Procedure|Serial Liquid Biopsy|Undergo serial liquid biopsy
45471848|NCT03745963|Behavioral|Skin-to-skin contact|Infants allocated to the SSC arm will be placed in upright, ventral SSC position (holding of a diaper clad baby on the bare chest of a mother) for a minimum of 15 minutes prior to data collection.
46030537|NCT05338970|Drug|Platinum-based chemotherapy|Intravenous, pemetrexed 500 mg/m^2 plus either cisplatin (75 mg/m^2) or carboplatin (target area under the plasma concentration time curve of 5 [AUC5] by using the Calvert formula) q3W
45682566|NCT01560507|Drug|varenicline (Chantix)|For the first 3 days after being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
46030538|NCT05332561|Drug|Atezolizumab 1200 mg in 20 ML Injection|Arm 1
46030539|NCT05332561|Drug|Inavolisib|Arm 2
46030540|NCT05332561|Drug|Ipatasertib|Arm 3
46030541|NCT05332561|Drug|Olaparib|Arm 4
46030542|NCT05332561|Drug|Sacituzumab govitecan|Arm 5
46030543|NCT05332561|Drug|Trastuzumab/pertuzumab|Arm 6
46030544|NCT05332444|Drug|susceptibility-guided tailored therapy (Group A)|"Includes 5 treatment options. The priority order of treatment regimens is based on the selection principal through AST with MIC profile.~1. clarithromycin triple therapy: include rabeprazole 20mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid, for 14 days; or 2. levofloxacin triple therapy: include rapeprazole 20 mg bid, amoxicillin 1 g bid, and levofloxacin 500 mg bid, for 14 days; or 3. metronidazole triple therapy: include rabeprazole 20 mg bid, amoxicillin 500 mg qid, and metronidazole 250 mg qid, for 14 days; or 4. high-dose dual therapy: include rabeprazole 20 mg qid, amoxicillin 750 mg qid, for 14 days; or 5. bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days."
46030545|NCT05332444|Drug|guidelines-recommended empiric therapy (Group B)|bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.
46030546|NCT05331183|Drug|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablets for oral administration.
46030547|NCT05331183|Drug|IVA|Tablets for oral administration.
45471849|NCT03745963|Drug|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance.
45682567|NCT01560507|Drug|bupropion (Zyban)|After being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive 150mg of bupropion once daily and 21mg nicotine patch for first 3 days; 150mg of bupropion twice daily and 21mg nicotine patch for 7 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
45682568|NCT01560507|Drug|nicotine patches|21mg nicotine patch for first 11 weeks; 14mg nicotine patch for next 2 weeks; 7mg nicotine patch for final 2 weeks.
45682569|NCT03695146|Behavioral|Paced breathing|Individuals will be fitted with a respiratory transducer and receive auditory tones with which to pace their rate of inspiration and expiration in the experimental group.
46030548|NCT05328570|Diagnostic Test|Oral Glucose Tolerance Test|Subjects will complete an Oral Glucose Tolerance Test in which glucose is given and blood samples are taken every 15 minutes over a 2 hour period to determine how quickly the glucose is cleared from the blood.
46030549|NCT05327023|Procedure|donor lymphocyte infusion|The DLI will be given on Day +7 (Day +21 for dose level -1). If a recipient participant is deemed too critically ill/unstable to receive DLI on the protocol specified day, the DLI will be delayed up to 4 days at the discretion of the PI and given within this time frame once the recipient participant s clinical status has stabilized or improved. If the DLI cannot be given during this time frame, the recipient participant will be taken off study and not considered evaluable for DLT, outcomes, or adverse events since the experimental intervention will not have been given.
45682570|NCT03695146|Behavioral|Active relaxation|Individuals will be provided with headphones while resting quietly listening to relaxing tones/music.
46030550|NCT05327023|Drug|Cyclophosphamide|HLA-matched: 50 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight. HLA haploidentical: 25 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight.
46030551|NCT05327023|Drug|Busulfan|AUC targeted dose based on busulfan test dose, with a default dose of 130 mg/m2/day, given as IV infusion over 3 hours each day for 4 days Transplant days -6 through day -3
45839174|NCT03874884|Drug|Olaparib|During dose escalation doses of olaparib that can be administered are 50mg BD, 100mg BD, 150mg BD,200mg BD,250mg BD or 300mg BD. The recommended phase 2 dose of olaparib will be used during dose expansion. Olaparib will be given on days 2-15 of each 42 day cycle for upto 4 cycles.
45471850|NCT01257113|Other|supervised exercise|This group will receive 10 classes of supervised exercise in the 6 weeks intervention. In this classes the patients will be with a physiotherapist that will adjust their home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
45471851|NCT01257113|Other|homebased exercises|This group will receive 1 class of supervised exercise at the beginning of the 6 weeks intervention. In this class the patients will be with a physiotherapist that will put together a home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
45839175|NCT03874884|Combination Product|177Lu-PSMA|A fixed 7.4Gbq administered activity of 177Lu-PSMA will be given 6 weekly.
46030552|NCT05327023|Drug|Mycophenolate mofetil|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. Dosing will be according to actual body weight.
46030553|NCT05327023|Drug|Fludarabine|40 mg/m2 IV infusion over 30-60 minutes once daily for 4 days Transplant days -6 through -3
45471852|NCT05737862|Dietary Supplement|Moringa oleifera capsules|In this arm, pregnant mothers receive capsules containing 500 mg of powdered Moringa oleifera leaves which contain 13.09 mg of iron per100 gram. Dose: 2 × 2 capsules per day for 30 days
46030554|NCT05327023|Drug|Sirolimus|Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, maximum initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +70 with no taper. Doses should be modified as appropriate for drug interactions.
46030555|NCT05323825|Dietary Supplement|Probiotic|Fermented milk product containing a probiotic
46030556|NCT05323825|Dietary Supplement|Placebo|Product with identical characteristics to the experimental product.
46030557|NCT05323734|Drug|Ganaxalone|GNX will be administered
46030558|NCT05323734|Drug|Placebo|Placebo will be administered
45471853|NCT05737862|Dietary Supplement|iron and folic acid supplements|In this arm, pregnant mothers receive IFA tablets 2 × 1 tablet a day for 30 days. Each IFA tablet contains 400 mcg folic acid and 180 mg Ferrous Fumarate.
45471854|NCT03745885|Drug|Supaglutide injection|Administered SC in the Supaglutide arms.
45682571|NCT03785470|Other|Fructose and physical inactivity|Subjects will drink 6 cans of regular sodas daily (divided throughout the day) and will decreased physical activity to less than 5000 steps daily for 10 days.
45754653|NCT00578539|Drug|MESNA|MESNA (45mg/kg; divided into 5 doses) will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide.
45754654|NCT00578539|Radiation|Total Body Irradiation (TBI)|TBI: total dose 14.0 Gy, will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1
46030559|NCT05320666|Behavioral|Yes You Can…Make Smart Choices! (YYC…MSC!) program|The YYC…MSC! is an 11-lesson curriculum that will be delivered to 9th graders in Newark, New Jersey public schools during 40-minute health classes. The curriculum will be delivered in-person over approximately 2 weeks by NJPAG educators. The goal of the program is to prevent teen pregnancy and enhance character development in youth. Each time an NJPAG educator is in the classroom, they will deliver a single lesson of the curriculum. All NJPAG educators have received internal training for the program. The intervention addresses the following adult preparation subjects: parent-child communication, healthy relationships, healthy life skills, adolescent development, and financial literacy.
46030560|NCT05317728|Device|BAL-FAIOL IOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
46030561|NCT05317728|Device|Monofocal IOL|Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject
46030562|NCT05317728|Procedure|Cataract surgery|Phacoemulsification with a clear cornea incision
46030563|NCT05314491|Device|Multigen Plus CCK|Total Knee Arthroplasty
46030564|NCT05314491|Device|AMF TT cones|To fill a proximal tibia or distal femur defect
46030565|NCT05309733|Genetic|VOR33|VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell therapy product that lacks the CD33 myeloid protein.
45471855|NCT03745885|Drug|Placebo|Administered SC in the placebo arms and to maintain the blind in the Supaglutide injection arms.
46030566|NCT05309200|Drug|OCE-205|The drug product, OCE-205, is a sterile solution to be used for intravenous infusion.
46030567|NCT05309200|Drug|Placebo|Placebo to match OCE-205 is a sterile solution to be used for intravenous infusion.
46030568|NCT05307705|Drug|LOXO-783|Oral
46030569|NCT05307705|Drug|Fulvestrant|Intramuscular
46030570|NCT05307705|Drug|Imlunestrant|Oral
46030571|NCT05307705|Drug|Abemaciclib|Oral
46030572|NCT05307705|Drug|Anastrozole, Exemestane, or Letrozole|Oral
46030573|NCT05307705|Drug|Paclitaxel|Intravenous
46030574|NCT05303194|Behavioral|Patient Priorities Care (PPC) Approach|First, identify patient priorities, and second align care received with those priorities.
46030575|NCT05303194|Behavioral|Adapted PPC|First, identify patient priorities, and second align care received with those priorities.
45471856|NCT03893279|Behavioral|Smell and Taste and questionnaire|The questionnaire must be completed before the antibiotic is taken, if a change of antibiotic is planned (stop of a treatment or addition of another treatment) and at the end of the antibiotic treatment.
46030576|NCT05301114|Behavioral|Community Health Worker support|Participant will receive weekly or monthly support (via phone or in person) from a community health worker. The community health worker will be responsible for continuously assessing the patient's social needs, providing referrals to community based organizations, and assisting with the patient's non-medical needs as they progress through survivorship (e.g. social support, referrals, etc). Individuals who identify no risk factor will receive monthly phone calls, while individuals who identify 1-3 risk factors will receive monthly home visits with interim phone calls for 6 months. Those who identify 4 or more risk factors or have intensive needs such as behavioral health will receive the same services as the medium risk group and will also be connected with the social work teams within each institution.
46030577|NCT05291481|Behavioral|CAPAS-yOUTH|11-week parent training intervention exclusively delivered to parents
46030578|NCT05290740|Drug|Norepinephrine 5 mcg|norepinephrine bolus of 5 mcg for treatment of sever postspinal hypotension
46030579|NCT05290740|Drug|Norepinephrine 10 mcg|norepinephrine bolus of 10 mcg for treatment of sever postspinal hypotension
46030580|NCT05276570|Drug|ARO-RAGE|single or multiple doses of ARO-RAGE by inhalation of nebulized solution
46030581|NCT05276570|Drug|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
46030582|NCT05269186|Device|Virtual reality software|The patient will undergo a 20-minute virtual reality session before the planning CT scan
46030583|NCT05269004|Drug|Ocrelizumab|Ocrelizumab will be administered based on the dosage and administration received at the time of rollover from the Parent study.
46030584|NCT05260684|Drug|Encorafenib|450 mg QD
45754655|NCT00578539|Biological|Campath-1h|CAMPATH (3 mg IV for patients between 5 and 15 kg; 5 mg for patients between 16 and 30 kg; and 10 mg for patients greater than 30 kg) will be given on day -4, day -3, day -2 and day-1.
45754656|NCT00578539|Procedure|Stem Cell Infusion|Stem cells are infused on day 0
45754657|NCT03517085|Genetic|DTX401|DTX401 administered as a single peripheral intravenous (IV) infusion
45754658|NCT03517085|Drug|steroid regimen|prednisone or prednisolone to manage alanine aminotransferase (ALT) elevation
46030585|NCT05260684|Drug|Binimetinib|45 mg BID
46030586|NCT05260684|Drug|Vemurafenib|960 mg BID for 28 days/cycle
46030587|NCT05260684|Drug|Cobimetinib|60 mg QD for 21 days/cycle
46030588|NCT05260684|Drug|Dabrafenib|150 mg BID
46030589|NCT05260684|Drug|Trametinib|2 mg QD
46030590|NCT05255393|Other|Questionnaires|"A 13-item questionnaire specific to LEL, developed and validated by investigators at the Mayo Clinic.~The EORTC QLQ-C30 is a 30-item questionnaire designed to assess the quality of life of cancer patients.~The EORTC Quality of Life - Cervical Cancer Module."
46030591|NCT05252845|Biological|R21/Matrix-M vaccination|R21/Matrix-M is the standard formulation of the vaccine (Once prepared, a standard dose of R21/Matrix-M contains approximately 5 µg of R21 antigen, in 0.5 mL of liquid adjuvant containing 50 µg MatrixM). The reconstituted vaccine will be administered by slow IM injection on Day 0 at Study Months 0, 1 and 2.
46030592|NCT05252845|Drug|DHA-PIP|Dihydroartemisinin/piperaquine tablets for adult patients each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. Participants will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1 and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2.
46030593|NCT05252845|Drug|PQ|Each participant will receive a single low dose primaquine on the day of vaccination (Day 0) at Month 0, Month 1, and Month 2. One single low dose primaquine of approximately 0.25 mg/kg will be administered.
46030594|NCT05252390|Drug|NUV-868|NUV-868 is an investigational drug for oral dosing.
46030595|NCT05252390|Drug|Olaparib|Olaparib
46030596|NCT05252390|Drug|Enzalutamide|Enzalutamide
46030597|NCT05246280|Drug|TC99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
46030598|NCT05243966|Device|Myriad Matrix™ and Myriad Morcells™|Ovine forestomach matrix sheet graft and morselized extracellular matrix
46030599|NCT05241665|Device|SpectraWAVE Imaging System|Coronary imaging
46030600|NCT05234554|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed twice.
46030601|NCT05234554|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed twice.
46030602|NCT05233930|Procedure|TKR with augmented reality-based navigation system|Surgery
46030603|NCT05233930|Procedure|TKR with traditional mechanically aligned technique|As per local practice and standard guidelines.
46030604|NCT05233800|Behavioral|Faster Asleep Smart Speaker Program|Participants will receive a smart speaker device with a pre-loaded Faster Asleep program. Participants will be asked to engage with the program daily, either using the voice-activated speakers or an accompanying smart-phone app. The study duration is six-weeks and is completed individually using fully automated interaction to deliver components of cognitive behavioral therapy for insomnia.
46030605|NCT05233800|Behavioral|Faster Asleep Website|Controls will have access to a website with information about CBT-I and breast cancer survivorship and will be told to engage with the website as desired. The content will be drawn from the education script that is programmed into the phone app accompanying the smart speaker program.
46030606|NCT05231655|Diagnostic Test|Functional drug screen|High-throughput ex-vivo drug screen of cells processed directly from solid tumours to determine sensitivity / resistance profiles
46030607|NCT05229900|Drug|SGN-ALPV|Given into the vein (IV; intravenously)
46030608|NCT05224973|Behavioral|speech therapy|speech therapy during 2 months
46030609|NCT05224258|Device|MiniMed 780G System|780G System used with Insulin Fiasp® (Insulin Aspart Injection)
46030610|NCT05217888|Device|Sentinel|cerebral protection devices during transfemoral transcatheter aortic valve replacement
46030611|NCT05214378|Device|Finetech-Brindley Sacral Anterior Roots Stimulation System|Electrodes implanted on sacral roots connected to implanted induction coil. External controller box administers stimulation via induction through skin to electrodes. Stimulation activates nerves to modulate bladder, bowel, and sexual functions.
46030612|NCT05212311|Device|Chitosan Phonophoresis|Therapeutic pulsed ultrasound using EMS physio Ltd ultrasound device in presence of chitosan gel will be applied over the elbow. The following parameters will be used: US treatment was applied for 5 min per session at a frequency of 3 MHz and an intensity of 0.5 W/cm2 in pulsed mode with a transducer area of 5 cm2.
46030613|NCT05212311|Device|Therapeutic Ultrasound|US treatment will be applied for 5 min per session at a frequency of 3 MHz and an intensity of 0.5 W/cm2 in pulsed mode with a transducer area of 5 cm2 using aquasonic gel.
46030614|NCT05212311|Device|Splinting|"Splinting the elbow in comfortable flexion (40-70), forearm and wrist in neutral (slight forearm pronation and wrist flexion if symptoms are severe), can allow the nerve and surrounding supporting structures the rest and relief from compression and traction.~The elbow portion of the splint should be well padded or ''bubbled out'' to provide pressure relief for the area of the cubital tunnel. It may be necessary to splint the ulnar digits of the hand to prevent contracture, maintain passive and active range of motion, and improve hand function. If the motor branch of the nerve is sufficiently involved to cause muscle denervation, a hand-based intrinsic plus splint or the use of finger-based splints to prevent clawing of the ring and small fingers will provide balanced positioning of the affected structures."
45471857|NCT02101970|Dietary Supplement|Omega-3 Fatty Acids|Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
46030615|NCT05212311|Other|Neural mobilization exercises of the ulnar nerve|Nerve mobilization exercises Inflammation or adhesions anywhere along the ulnar nerve path can cause the nerve to have limited mobility and essentially get stuck in one place. These exercises help stretch the ulnar nerve and encourage movement through the cubital tunnel
46030616|NCT05208242|Drug|hyperoncotic human albumin solution|20% human albumin solution (presented in 100ml glass bottles)
46030617|NCT05208242|Drug|Buffered crystalloid solutions|Buffered crystalloids solutions for all intravenous fluid therapy
46030618|NCT05201404|Drug|Namodenoson|Adenosine A3 Receptor (A3AR) agonist
46030619|NCT05201404|Drug|Placebo|Control arm
45471858|NCT02101970|Other|Placebo Capsule|
46030620|NCT05194293|Biological|Durvalumab|Given IV
45471859|NCT02101970|Other|Diet and Exercise|Increasing physical activity required over 6 month period to be tracked by a Fitbit. Diet based on caloric intake and eating approved foods.
46030621|NCT05194293|Drug|Regorafenib|Given PO
46030622|NCT05182840|Drug|BI 690517|BI 690517
46030623|NCT05182840|Drug|Placebo to BI 690517|Placebo to BI 690517
46030624|NCT05182840|Drug|Empagliflozin|Empagliflozin
46030625|NCT05182840|Drug|Placebo to empagliflozin|Placebo to empagliflozin
46030626|NCT05179837|Device|Optical coherence tomography probe|The OCT probe is attached to an approximately 3-meter wire that is attached to the OCT fiber probe system setup. This setup consists of a power supply unit, and a control platform that controls fiber probe rotation and retraction. The OCT probe will be advanced through the colonoscope instrument channel
45471860|NCT01258361|Procedure|echocardiography|Echocardiography is performed for all patients
46030627|NCT05176353|Other|VAP diagnostic stewardship bundle|Multifaceted VAP diagnostic stewardship bundle targeting the respiratory culture testing workflow through a custom order set within the institutional electronic medical record. Interventions will be made at the three levels of the diagnostic testing pathway (ordering, collection and reporting of test results). Full details available in detailed study description.
46030628|NCT05174416|Drug|Mavacamten|Mavacamten Capsules
46030629|NCT05174416|Drug|Placebo|Matching PBO capsules during placebo controlled period，and mavacamten capsules during long term extension period
46030630|NCT05172986|Behavioral|Follow-up patient program|An additional paramedical visit will be carried out before the surgery. The interview is carried out by the healthcare team. An organization within the service has been set up so that a nurse can be totally seconded for the RAAC mission. The consultation lasts 30 to 45 minutes.
46030631|NCT05165238|Behavioral|Impact of four week coaching program on dietary habits|A registered dietitian will provide dietary coaching via online groups to participants.
45471861|NCT05211830|Drug|SXR1096 cream|Skin cream to be applied twice a day to a predefined area of the skin
45471862|NCT05211830|Drug|Placebo cream|Skin cream to be applied twice a day to a predefined area of the skin
45471863|NCT03893201|Other|Questionnaires|Questionnaires to assess quality of life
45471864|NCT02097680|Drug|Letrozole|One Letrozole 2.5 mg capsule every two days during four months
46030632|NCT05160480|Diagnostic Test|Total-body PET imaging|Total-body PET imaging at different timepoints
46030633|NCT05159752|Drug|Afamelanotide|Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
46030634|NCT05157724|Procedure|PLASMA|"The aim is to remove the prostatic adenoma by enucleation, i.e. to pass through the plane between the adenoma and the prostatic capsule, as opposed to resection, which also consists of removing the adenoma, but by making small cuts in the prostatic tissue, without necessarily reaching this anatomical plane between the adenoma and the capsule. This means removing less adenoma and therefore increasing the risk of adenomatous regrowth in the long term or obtaining worse results than enucleation in the short to medium term.~The other advantage of using this approach is that it reduces intra- and post-operative bleeding and does not require the systematic discontinuation of anti-aggregating or anticoagulant treatments prior to the operation. The field of indications is thus potentially enlarged."
46030635|NCT05155267|Other|Biomonitoring study to detect MNPLs in biological samples and study of their health effects|Determination of MNPLs levels, genotoxic damage and immunological effects
45471865|NCT02097680|Drug|Placebo|One placebo capsule every two days during four months
45471866|NCT01150955|Dietary Supplement|Resveratrol|500 mg three times a day for five weeks.
45471867|NCT01150955|Other|Placebo|Placebo (starch capsules) 500 mg three times a day for five weeks.
45471868|NCT03897413|Drug|S-888711|Administered orally as three 0.25 mg tablets
45471869|NCT03897413|Dietary Supplement|Calcium Antacid|Calcium carbonate 4000 mg chewable tablets
45471870|NCT03986372|Biological|Platlet-rich plasma|Multiple Platlet-rich plasma injection.
46030636|NCT05145582|Behavioral|The Self-Guided PSP Wellbeing Course|An unguided version of a transdiagnostic ICBT program that has shown promising initial outcomes in prior research (https://doi.org/10.2196/27610).
46030637|NCT05145582|Behavioral|Online Discussion Forum|An online discussion forum designed to provide an opportunity for participants to support one another in their use of the ICBT program.
46030638|NCT05145491|Procedure|Immediate Vitrectomy|Surgery to remove epiretinal membrane (ERM). Vitrectomy will be performed on eyes within 1 month of randomization
45471871|NCT01258439|Drug|raltegravir plus truvada|raltegravir 400 mg tablet with truvada 300/200 mg tablet for 24 weeks
45471872|NCT01258439|Drug|Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)|Darunavir two 400mg tablets with one ritonavir 100mg capsule once daily plus Tenofovir/emtricitabine (Truvada) one 300mg/200mg tablet once daily with food for 24 weeks
46030639|NCT05145491|Procedure|Deferred Vitrectomy|"Vitrectomy may be performed only if at least one of the following criteria is met:~Decrease in visual acuity ≥10 letters from baseline at a single visit presumed to be from ERM~Decrease in visual acuity ≥5 letters from baseline at two consecutive visits presumed to be from ERM~a. Visits must be at least one month apart~Participant actively requests surgery due to worsening symptoms~Complication requires prompt surgical intervention (e.g., macular hole, retinal detachment, non-clearing vitreous hemorrhage)"
46030640|NCT05141721|Drug|GRT-C901|A patient-specific neoantigen cancer vaccine administered via intramuscular (IM) injection as prime and single boost at a dose of 1x10^12 viral particles 2 times over the course of the first year.
46030641|NCT05141721|Drug|GRT-R902|A patient-specific neoantigen cancer vaccine boost, administered via IM injection at a dose of 30ug 4 times over the course of the first year.
46030642|NCT05141721|Drug|Atezolizumab|Atezolizumab will be administered via intravenous (IV) infusion at a dose of 1680 mg once every 4 weeks.
45598726|NCT03516409|Dietary Supplement|Biokult|"Bio-Kult Infantis® is a multi-strain formula containing a probiotic formulation comprising 7 strains of probiotics, high content of Omega-3, Vitamin D3 and Preplex® (50% FOS and 50% gum acacia).~Each sachet contains:~Minimum 1 billion microorganisms per sachet (1 x 109CFU/g), guaranteed throughout the shelf life~DHA + EPA: >1mg per sachet~Vitamin D3: 2.5mcg per sachet (50% of Nutrient Reference Value). Bio-Kult Infantis® presents itself in the form of a white powder, packaged in sachets of 1 g each"
46030643|NCT05141721|Drug|Ipilimumab|Ipilimumab will be administered via subcutaneous (SC) injection at a dose of 30 mg with the first dose of GRT-C901 and GRT-R902.
46030644|NCT05141721|Drug|Fluoropyrimidine plus leucovorin|Fluoropyrimidine (infusional 5-FU or capecitabine) and leucovorin administered as maintenance therapy per standard of care.
46030645|NCT05141721|Drug|Bevacizumab|Bevacizumab administered as maintenance therapy per standard of care.
45839176|NCT03552978|Behavioral|Tech-Facilitated IC Intervention|The Integrated Care (IC) treatment protocol for smoking cessation is a PTSD-informed intervention that has been adapted to be delivered over video or telephone and to incorporate technological components, including the Stay Quit Coach (SQC) smart phone application (app) which is a public domain, no-cost mobile app designed to complement the IC protocol with evidence-based tools to support smoking cessation. and the coVita Bedfont® Scientific Ltd iCO® Smokerlyzer® device and app which is a mobile carbon monoxide (CO) monitor that provides CO readings in order to self-monitor progress in quitting. The coVita mobile app is compatible with iOS &Android and used with the iCO® Smokerlyzer® to display CO readings. Content of sessions is consistent with that delivered in the IC treatment protocol for veteran smokers with post-traumatic stress disorder (PTSD).
45839177|NCT03552978|Behavioral|VA Quitline|The SFVAMC's standard of care referral service, known as the VA Quitline which involves weekly telephone sessions through the VA's proactive telephone Quitline, available to all veterans for up to 8 weeks.
46030646|NCT05139173|Device|Smart Physiotherapy Activity Recognition System (SPARS)|Wearable smart watch that records inertial data such as (accelerometer, gyroscope magnetometer) and the exercise is started on the tablet, while patients are performing physiotherapy exercises.
46030647|NCT05130762|Device|BD PureHub™ Disinfecting Cap Placements: Attachments/removals|Attachment/Removals of BD PureHub™ Disinfecting Cap
46030648|NCT05126433|Drug|Lurbinectedin|Lurbinectedin 3.2 mg/m^2 intravenous (IV) every 3 weeks (Q3W)
46030649|NCT05126381|Behavioral|Smoking|The Study contains patients who are allowed to smoke
46030650|NCT05126381|Behavioral|non-somking|The Study contains patients who are not allowed to smoke
45839178|NCT03538314|Drug|UV1|UV1 (300 microgram)
46030651|NCT05124561|Biological|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Nebulized inhalation through the mouth
45839179|NCT03538314|Drug|GM-CSF|GM-CSF (37,5 or 75 microgram)
45839180|NCT03233802|Behavioral|Individualized Assess & Treatment (IATP)|See previous description
46030652|NCT05124561|Biological|Placebo|Nebulized inhalation through the mouth
46030653|NCT05120830|Biological|Biological NTLA-2002|CRISPR/Cas9 gene editing system delivered by LNP for IV administration
46030654|NCT05120830|Other|Normal Saline IV Administration|The administration of IV normal saline
46030655|NCT05115890|Other|Exercise training|Patients with HFpEF will undergo 8 weeks of exercise training.
46030656|NCT05104723|Drug|XELJANZ (tofacitinib)|The XELJANZ 5-mg tablets will taken orally twice daily in this study.
46030657|NCT05102019|Device|Arm 1: treatment with Neovasc Reducer|Neovasc reducer is an implantable device being evaluated for the alleviation of refractory angina symptoms
46030658|NCT05102019|Other|Arm 2 (control): Implantation procedure with no device implanted|No device is implanted
46030659|NCT05102019|Device|Arm 3 (unblinded, non-randomized): Single arm registry|Neovasc reducer is an implantable device being evaluated for the alleviation of refractory angina symptoms
45839181|NCT03233802|Behavioral|Packaged Cognitive-Behavioral (PCBT)|See previous description
45839182|NCT03233802|Behavioral|Case Management (CaseM)|See previous description
45839183|NCT03063450|Drug|Nivolumab|Nivolumab at a dose of 240mg as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
46030660|NCT05095116|Drug|APT-1011 3 mg HS|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
46030661|NCT05093322|Drug|Surufatinib in combination with Gemcitabine|Surufatinib in combination with Gemcitabine
46030662|NCT05092451|Drug|Cyclophosphamide|Given by IV
46030663|NCT05092451|Drug|CAR.70/IL15-transduced CB-NK cells|Given by IV
46030664|NCT05092451|Drug|Fludarabine phosphate|Given by IV
46030665|NCT05087628|Biological|PRV-3279|Bi-specific antibody-based molecule
46030666|NCT05087628|Other|Placebo|Placebo
46030667|NCT05085561|Drug|REC-994|REC-994 200 mg tablets
46030668|NCT05085561|Drug|Placebo|Placebo Tablets
46030669|NCT05074355|Drug|Azacitidine|Azacitidine is a hypomethylating agent that works by activating certain genes in the body to help cells mature and to kill abnormal bone marrow cells.
46030670|NCT05074355|Drug|Venetoclax|Venetoclax is a drug that blocks a protein called B-cell lymphoma (BCL2) protein from working. BCL2 is a protein that helps control whether a cell lives or dies and is thought to help cancer cells to live. Blocking BCL2 is believed to help kill cancer cells.
45682572|NCT03591328|Diagnostic Test|Coronary CT angiography|"Comprehensive CCTA analysis of all culprit and non-culprit lesions to obtain their per-lesion and per-vessel quantitative, qualitative plaque, and hemodynamic features is performed by the independent core laboratory (HeartFlow, Mountain View, CA, USA) blinded to patient characteristics and ICA findings.~The current CCTA reporting variables, including % diameter stenosis, segment involvement score (SIS), and HRP features, are obtained for all lesions by another independent core laboratory (University of British Columbia, Vancouver, Canada) to construct a reference model. ICA and invasive imaging studies performed at the event of ACS are analyzed by the independent core laboratory (Samsung Medical Center, Seoul, Korea) to define the culprit lesion blinded to CCTA findings. Other independent experts match culprit and non-culprit lesion data between ICA and CCTA findings."
46030671|NCT05071586|Device|Soterix 1x1 tDCS LTE Stimulator Device Model 1401|Participants will receive 20 minutes of 1.5 mA (Milliampere) transcranial direct current stimulation (tDCS) via Soterix 1x1 tDCS LTE Stimulator Device Model 1401 with a bilateral M1 montage.
46030672|NCT05065047|Drug|Belantamab mafodotin|Given by IV
46030673|NCT05056987|Device|Lehfilcon A contact lenses|CE-marked spherical soft contact lenses worn according to to the product package insert/Instructions for Use
46030674|NCT05056987|Device|Senofilcon A contact lenses|CE-marked spherical soft contact lenses worn according to to the product package insert/Instructions for Use
46030675|NCT05056987|Device|AOSEPT PLUS with HydraGlyde|Hydrogen peroxide-based cleaning and disinfecting solution
46030676|NCT05055206|Diagnostic Test|SPECT-CT|99m-Technetium Sulfur Colloid will be injected prior to the scan.
45682573|NCT03694834|Drug|Pembrolizumab|"A single dose of Pembrolizumab (200 mg) will be administered IV over 30 min (-5 /+10 min) approximately 3 weeks prior to the scheduled hysterectomy.~Pembrolizumab (200 mg) will be administered IV over 30 min (-5/+10 min) every three weeks in combination with paclitaxel and carboplatin as adjuvant therapy over 6 cycles. Pembrolizumab should be given on D1 of each cycle after the infusion of cytotoxics."
45682574|NCT03694834|Procedure|Hysterectomy|Hysterectomy/Surgical Staging per institutional standard of care.
45682575|NCT03694600|Diagnostic Test|Multi-analyte blood Test|intended for the qualitative detection of DNA methylation profiles associated with hepatocellular carcinoma in cell-free DNA derived from patient whole blood specimens.
46030677|NCT05053035|Drug|AL001|Administered via intravenous (IV) infusion
46030678|NCT05053035|Drug|Placebo|Administered via intravenous (IV) infusion
46030679|NCT05051046|Procedure|Colonoscopy under hypnosis|The hypnosis used will be of the Ericksonian type. Before the colonoscopy begins, the IDE puts the patient in a hypnotic situation.
46030680|NCT05047926|Behavioral|Behavioral Counseling|Undergo behavioral counseling
46030681|NCT05047926|Dietary Supplement|Nutritional Supplement Drink|Given Boost or Ensure
46030682|NCT05047926|Other|Physical Activity|Complete physical activity assignments
46030683|NCT05045157|Procedure|Percutaneous A1 Pulley Release Under Ultrasound Guidance|the A1 pulley is cut off with Ultrasound guidance by a percutaneous insertion of the small needle under local anaesthesia.
46030684|NCT05045157|Drug|Corticosteroid injection|corticosteroid injection is performed
46030685|NCT05043441|Behavioral|Acceptance and commitment therapy (ACT)|Caregivers assigned to this intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 10 weeks through Zoom videoconferencing with psychoeducation materials provided.
46030686|NCT05043441|Behavioral|Psychoeducation|The psychoeducation control group will receive care as usual with psychoeducation materials provided.
46030687|NCT05039801|Biological|Bevacizumab|Given IV
46030688|NCT05039801|Drug|Glutaminase-1 Inhibitor IACS-6274|Given PO
46030689|NCT05039801|Drug|Paclitaxel|Given IV
46030690|NCT05032976|Biological|Tozinameran 12 Years of age and older|BNT162b2 (purple cap) is administered with dilution, while BNT162b2 (grey cap) is administered without dilution. Both formulations are administered by intramuscular injection (IM) of 0.3 mL. According to the approved and authorized label, the recommended dose of BNT162b2 is a series of two doses (1 day 1 dose, 0.3mL each) 21 days apart and administered IM.
46030691|NCT05032976|Biological|Tozinameran 5 to 11 Years of age|"BNT162b2 (orange cap) is administered with dilution by intramuscular injection (IM) of 0.2mL. According to the approved and authorized label, the recommended dose of BNT126b2 is a series of two dose (1day 1dose, 0.2mL) 21days apart and administered IM.~But, a third dose may be given at least 28 days after the second dose to individuals who are severely immunocompromised aged 5 to 11 years of age."
46030692|NCT05032976|Biological|Tozinameran 6 months to 4 years of age|"BNT162b2 (maroon cap) is administered with dilution by intramuscular injection (IM) of 0.2mL. According to the approved and authorized label, it is recommended that the recommended dose of BNT162b2 is administered by intramuscular injection (IM) twice (once a day, each 0.2mL) at least of 21 days apart, and Dose 3 at least 8 weeks later.~Children who will turn from 4 years to 5 years of age between their doses in the vaccination course should receive their age-appropriate dose at the time of the vaccination and the interval between doses is determined by the child's age at the start of the vaccination course.~The interchangeability of BNT162b2 with COVID-19 vaccines from other manufacturers to complete the vaccination course has not been established.~BNT162b2 (6 months to 4 years of age) should be used only for infants and children 6 months to 4 years of age."
46030693|NCT05032976|Biological|Riltozinameran 12 Years of age and older|"The bivalent COVID-19 Vaccine for omicron (BA. 1) (grey cap) is administered by intramuscular injection (IM) of 0.3mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 1) and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 1) is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
46030694|NCT05032976|Biological|Famtozinameran 12 Years of age and older|"The bivalent COVID-19 Vaccine for omicron (BA. 4-5) (grey cap) is administered by intramuscular injection (IM) of 0.3mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 4-5) and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 4-5) is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
46030695|NCT05032976|Biological|Famtozinameran 5 to 11 Years of age|"The bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age (orange cap) is administered after dilution by intramuscular injection (IM) of 0.2mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
46030696|NCT05023096|Other|Tobacco product administration and assessment|Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 3 ENDS flavor conditions, all contain 5% nicotine (Mentol+Tobacco, Tobacco, Unflavored) with equal probability and provided with a supply of their condition specific ENDS and asked to use it in place of their usual menthol cigarettes for the next 6 weeks.
46030697|NCT05020860|Drug|Paclitaxel|80 mg/m2 IV administered on Days 1, 8, 15 of each 21-day cycle
46030698|NCT05020860|Drug|Carboplatin|Carboplatin AUC 1.5 IV administered on Days 1, 8, 15 of each 21-day cycle
45682576|NCT03691870|Procedure|Standard Trans-Arterial Embolization (TAE)|"The standard TAE, without TVE, is used in patient allocated standard treatment. The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic.~If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means."
45839184|NCT03063450|Other|Placebo|Placebo consisting of sterile 0.9% sodium chloride as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
45839185|NCT02882646|Device|Bi-ADLER|Subjects will be asked to use the Bi-ADLER for 60 minutes. All subjects will be seated on the Bi-ADLER and asked to perform a battery of bimanual evaluation tasks (creating ovals, standard ADL tasks like pouring, reaching, drinking etc).
46030699|NCT05020860|Drug|Trastuzumab|Trastuzumab 8 mg/kg loading dose, followed by 6 mg/kg maintenance dose, administered on Day 1 of each 21-day cycle
45471873|NCT05011448|Other|Music Therapeutic Interaction and Verbal Interaction|"In both sessions (the Verbal Interaction and the Music Therapeutic Interaction) participants will be asked to perform three piano playing exercises in a fixed order: (1) playing a musical scale, (2) playing a short excerpt from a familiar song, and (3) free improvisation. Both sessions will also include a protocol of verbal instructions given by the therapist before each exercise. In session A ('Verbal Interaction') participants will perform these exercises alone while the therapist is only interacting with them verbally (asking them questions, commenting regarding their performance etc.). In session B ('Music Therapeutic Interaction') participants will perform these exercises while the therapist is interacting with them musically, using various music therapy techniques that are matched and attuned to each patient's playing dynamics and style. This is to reflect the dynamics of the music therapeutic interaction as it occurs in the real world of music therapy practice."
45471874|NCT01258517|Device|near infrared spectroscopy (INVOS 5100)|monitorization of cerebral oxygenation by INVOS 5100 during surfactant administration
45471875|NCT03628820|Behavioral|Dog Therapy|5 minutes spent with therapy dog during shift
45839186|NCT02788344|Other|Daily practice care for patients with suspected of STEMI|N/A: Practice care evaluation in real-life setting
46030700|NCT05020860|Drug|Pertuzumab|Pertuzumab 840 mg loading dose, followed by 420 mg maintenance dose, administered on Day 1 of each 21-day cycle
46030701|NCT05020860|Drug|Doxorubicin|60 mg/m2 IV administered on Day 1 of each 14-day cycle
46030702|NCT05020860|Drug|Cyclophosphamide|600 mg/m2 IV administered on Day 1 of each 14-day cycle
45839187|NCT02748018|Device|670G and 770G Insulin Pump|Medtronic 670G and 770G Hybrid Closed Loop Systems
46030703|NCT05020860|Drug|Pembrolizumab|"Either 200 mg IV administered on Day 1 of Cycles 1-4, or 400 mg IV administered on Day 1 of Cycles 1 and 3 of the paclitaxel/carboplatin regimen.~400 mg on Day 1 of Cycles 1 and 4 of the dose-dense AC regimen."
45471876|NCT03628820|Behavioral|Coloring|5 minutes spend coloring mandalas during shift
45839188|NCT02748018|Device|Subject's Current Diabetes Therapy|Subject will use current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump).
45839189|NCT02186418|Genetic|ARU-1801|"Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector~Subjects with sickle cell anemia will undergo hematopoietic stem cell procurement by bone marrow harvest or apheresis after mobilization with plerixafor~Reduced intensity chemotherapy conditioning with single dose melphalan will be used to facilitate engraftment of ex-vivo transduced cells."
46030704|NCT05020860|Drug|Pertuzumab/Trastuzumab/Hyaluronidase-zzxf|Can be used in place of separate IV formulations of pertuzumab and trastuzumab. 1200 mg pertuzumab/600 mg trastuzumab/30,000 U hyaluronidase administered subcutaneously on Day 1 of the first cycle, followed by a maintenance dose of 600 mg pertuzumab/600 mg trastuzumab/20,000 U hyaluronidase administered subcutaneously every 3 weeks.
45471877|NCT01257191|Drug|Carbon Black|source: commercial
45471878|NCT01257191|Drug|Diesel Exhaust Particles|source: diesel engine
45471879|NCT01257191|Drug|Fine Concentrated Ambient Particles|source: concentrated ambient air
45471880|NCT01257191|Drug|Ultrafine Concentrated Ambient Particles|source: concentrated ambient air
45471881|NCT01257191|Drug|Saline|Saline solution
46030705|NCT05018286|Drug|Apraglutide|Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2
45839190|NCT02173080|Other|PLD-Q|polycystic liver disease questionnaire
46030706|NCT05016622|Biological|BNT162b2 vaccine|administer an additional dose of the BNT162b2 mRNA vaccine to patients with cancer who have a negative SARS-CoV-2 Spike IgG at least 14 days after 2 doses of the mRNA vaccines (BNT162b2/mRNA-1273) or 28 days after the adenoviral based Ad26CoV2.S vaccine.
46030707|NCT05014555|Biological|COVID-19 Vaccine|Three-dose mRNA COVID-19 vaccine per standard of care
46030708|NCT05014009|Behavioral|FIFA11+ and multidirectional training (MD)|"This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by COD technique modification training, which contains exercises aimed at improving COD technique (safer and more effective body re-direction, use of penultimate step, avoiding knee valgus) and COD braking and re-acceleration impulse.~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their COD technique. Participants are encouraged to complete a third training session in their own time."
46030709|NCT05014009|Behavioral|FIFA11+ and linear sprint training (MD)|"This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by a linear sprint training, which contains exercises aimed at improving sprint technique (e.g. sagittal arm and leg movement, trunk lean), use of the stretch-shortening cycle, leg stiffness and propulsive impulse .~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their sprinting technique. Participants are encouraged to complete a third training session in their own time."
45839191|NCT01436292|Drug|5% human albumin solution (HAS)|"Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level:~≥ 30 gr/L: albumin will not be administered; 25 - 29.9 gr/L: 25 g of 5% HAS; 20 - 24.9 gr/L: 50 g 5% HAS; 15 - 19.9 gr/L: 75 g of 5% HAS; 10 - 14.9 gr/L: 100 g of 5% HAS; < 10 gr/L: 150 g of 5% HAS."
45839192|NCT01326000|Drug|FOLFIRI|standard iv chemotherapy
45839193|NCT01326000|Drug|RO5083945|1400 mg iv on Day 1 and Day 8, and every 2 weeks thereafter
45839194|NCT01326000|Drug|cetuximab|400 mg/m2 iv on Day 1, followed by 250 mg/m2 iv every week
46030710|NCT05006417|Drug|Botox|reconstituted at 100 units/mL, dosage will be based upon the affected muscles
46030711|NCT05001152|Drug|Ozanimod|Taste assessment
46030712|NCT05000632|Behavioral|Smoke Free SafeCare|SFSC is the systematically braided curriculum which combines both SafeCare and STBO programs, but in a new delivery format. To take full advantage of the home delivery mechanism of SafeCare, the content delivery of STBO has been adapted so that original mailings will be delivered in the SafeCare sessions. STBO has been fully braided into the Health and Safety modules. One of these interventions will be delivered first throughout the course of the study. The Smoke Free SafeCare intervention will involve 25 providers receiving training for the SFSC program. They will each recruit 10 mothers and conduct the SFSC program for each family. Overall, 250 families will receive the SFSC intervention.
46030713|NCT05000632|Behavioral|Standard SafeCare|SafeCare is a brief parenting intervention that is highly effective in reducing child maltreatment perpetration and improving behavioral outcomes for CPS-involved parents of young children (0 to 5 years) as the result of child physical abuse or neglect (the two most common forms of substantiated maltreatment). The Standard SafeCare intervention will involve 25 SafeCare providers delivering the SafeCare program as usual. They will each recruit 10 mothers and conduct SafeCare for each family. Overall, 250 families will receive the standard SafeCare.
46030714|NCT04999956|Procedure|dynamic navigation surgery|immediate implant placement using dynamic navigation
46030715|NCT04999956|Procedure|freehand surgery|immediate implant placement using freehand surgery
46030716|NCT04999306|Behavioral|Hypnosis|one weekly session during 6 weeks (6 sessions of 30min/1 hour).
46030717|NCT04999306|Behavioral|CBT|one weekly session during 6 weeks (6 sessions of 1 hour).
46030718|NCT04994665|Procedure|sleeve gastrectomy|The sleeve gastrectomy is a surgical weight-loss procedure, about 80% of the stomach is removed
46030719|NCT04994665|Procedure|sleeve gastrectomy with omentopexy|After sleeve gastrectomy procedure, the omentopexy involves suturing the omentum back to the greater curvature of the stomach in several locations, depending on the length of the greater curvature
46030720|NCT04979078|Device|Photobiomodulation therapy (PBMT)|Patients will receive PBM on the sole of their feet and palms of their hands
46030721|NCT04978636|Other|Continuous low-tidal volume ventilation with using FiO2 of 0.21|The continuous low-tidal volume ventilation with using FiO2 of 0.21 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 0.21 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients. During the sub-study extra blood samples will be drawn before and after CPB.
46030722|NCT04978636|Other|Continuous low tidal volume ventilation with using FiO2 of 1.0|The continuous low-tidal volume ventilation with using FiO2 of 1.0 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 1.0 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients. During the sub-study extra blood samples will be drawn before and after CPB.
46030723|NCT04978636|Other|Apnea During CPB|There will be no ventilation used. But, during the sub-study part of the Apnea CPB extra blood samples will be drawn before and after CPB.
46030724|NCT04976322|Drug|Dapirolizumab pegol|Subjects will receive dapirolizumab pegol at prespecified time-points.
46030725|NCT04967391|Procedure|Tumescence During STSG Harvest|Tumescence injections performed prior to STSG harvest
46030726|NCT04963296|Drug|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1 and at Weeks 2, 24 and 26.
46030727|NCT04963296|Drug|Placebo|Placebo matching obinutuzumab will be administered by IV on Day 1 and at Weeks 2, 24 and 26.
46030728|NCT04963296|Drug|Acetaminophen/Paracetamol|Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
45471882|NCT01850888|Drug|131 I-Metaiodobenzylguanidine (131I-MIBG)|Minimum dose of 10 mCi/kg and up to 18 mCi/kg maximum will be diluted in 25 ml of normal saline, and will be infused intravenously over 90-120 minutes.
45682577|NCT03691870|Procedure|Trans-Venous Embolization (TVE)|"The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session.~The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion."
45839195|NCT00807456|Device|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ Profile implants: Ø4.5, 5.0, 5.0S mm in lengths of 9, 11, 13, 15mm.
46030729|NCT04963296|Drug|Diphenhydramine hydrochloride|Diphenhydramine 50 mg will be administered as premedication prior to infusions.
46030730|NCT04963296|Drug|Methylprednisolone|Methylprednisolone 80 mg IV will be administered as premedication prior to infusions.
46030731|NCT04936035|Drug|Placebo|Placebo administered by SC injection
46030732|NCT04936035|Drug|ALN-AGT01|ALN-AGT01 administered by SC injection
46030733|NCT04930653|Procedure|Extracorporeal Photopheresis|Undergo ECP
46030734|NCT04930653|Biological|Mogamulizumab|Given IV
46030735|NCT04930653|Other|Quality-of-Life Assessment|Ancillary studies
46030736|NCT04930653|Other|Questionnaire Administration|Ancillary studies
46030737|NCT04929808|Other|Hydrating emollient for acute radiodermatitis|"The emollient has a calming effect, and hydrating and anti-oxidative properties.~An absorbable wound dressing will be applied on painful and moist wounds. In case of severe itch, a systemic antihistaminic agent can be prescribed by the radiotherapist."
46030738|NCT04929808|Other|Standard institutional skin care|The control patients will receive the institutional standard skin care, which includes the application of Flamigel® (Flen Pharma, Kontich, BELGIUM). In addition, Mepilex® (Mölnlycke Health Care, Berchem, Belgium), an absorbable wound dressing will be applied on painful and moist wounds. In case of severe itch, a systemic antihistaminic agent can be prescribed by the radiotherapist.
46030739|NCT04929392|Drug|Carboplatin|Given IV
46030740|NCT04929392|Procedure|Endoscopic Biopsy|Undergo endoscopic biopsy
46030741|NCT04929392|Radiation|External Beam Radiation Therapy|Undergo EBRT
46030742|NCT04929392|Drug|Lenvatinib Mesylate|Given PO
46030743|NCT04929392|Drug|Paclitaxel|Given IV
46030744|NCT04929392|Biological|Pembrolizumab|Given IV
46030745|NCT04929392|Procedure|Resection|Undergo surgical resection
46030746|NCT04923568|Device|EaseVRx|Participants will experience 2 sessions of the EaseVRx device for chronic pain
46030747|NCT04922268|Other|Internal focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving mirror feedback. Participants will be instructed to perform each functional task in a manner that keeps their knee in line with their toes.
46030748|NCT04922268|Other|External focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving visual feedback via laser. Participants will be instructed to perform each functional task in a manner that does causes the laser to move up and down but not side-to-side.
46030749|NCT04919824|Procedure|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection (ESD) is a novel technique for the removal of advanced colonic polyps with high-risk features. ESD is minimally invasive and allows the removal of colonic adenomatous polyp without resorting to surgery. The process of ESD includes marking the lesions selected for removal, followed by submucosal injection of a lifting agent, then circumferential incisions using a specialized knife followed by submucosal dissection of the entire lesion.
46030750|NCT04919824|Procedure|Endoscopic Mucosal Resection|Endoscopic mucosal resection (EMR) is a conventional endoscopic technique commonly used for the resection of superficial neoplastic lesions in the GI tract. EMR carries lower morbidity and mortality compared to surgery.
46030751|NCT04919629|Biological|Bevacizumab|Given IV
46030752|NCT04919629|Biological|Pegcetacoplan|Given IV (only for loading dose) and SC
46030753|NCT04919629|Biological|Pembrolizumab|Given IV
46030754|NCT04919629|Other|Quality-of-Life Assessment|Ancillary studies
46030755|NCT04919629|Other|Questionnaire Administration|Ancillary studies
46030756|NCT04918173|Drug|Atenativ|Antithrombin concentrate
46030757|NCT04902170|Procedure|25 gauge pars plana vitrectomy|25 gauge pars plana vitrectomy
46030758|NCT04889079|Behavioral|Contraceptive use (continuation/switching/discontinuation)|Assessing contraceptive continuation/switching/discontinuation over 12-months
46030759|NCT04881487|Radiation|Additional stereotactic body radiation therapy|5 fractions of 8 Gray stereotactic body radiation therapy in addition to standard of care.
46030760|NCT04880733|Procedure|Acupuncture for pain management|A manualized acupuncture protocol will be performed by a licensed acupuncturist in the patient's emergency department room.
46030761|NCT04880733|Other|Usual care for pain management|Patient will receive usual care for pain management.
46030762|NCT04880434|Drug|Fludarabine|Administered intravenously
46030763|NCT04880434|Drug|Cyclophosphamide|Administered intravenously
45682578|NCT03587740|Drug|T-DM1|T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy.
45682579|NCT03586414|Dietary Supplement|MITOQUINOL MESYLATE then placebo|MITOQUINOL MESYLATE then placebo: 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
46030764|NCT04880434|Biological|Brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells
46030765|NCT04874402|Procedure|Prepectoral approach|Two sheets of contour, fenestrated ADM sutured together are trimmed in accordance with the measurement of the expander/implant and fixed to the pectoralis major muscle (superiorly, medially, and inferiorly) and serratus fascia (laterally), covering the entire anterior surface of the device
45682580|NCT03586414|Dietary Supplement|Placebo, then MITOQUINOL MESYLATE|'Placebo, then MITOQUINOL MESYLATE' : Placebo administered twice daily for 4 weeks followed by a washout, then 'MITOQUINOL MESYLATE' capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
46030766|NCT04874402|Procedure|Partial Subpectoral approach|The leading edge of the pectoral muscle is elevated and a subpectoral pocket is fashioned. The lower medial origin muscle fibers are released for anatomical expander seating. An ADM sling is sutured from the leading edge of the pectoralis muscle to the inframammary fold (over the expander) and laterally to close the expander pocket. In both groups, the size of the expander and the intraoperative filling volume will be decided by the attending surgeon based on the pocket dimension and volume capabilities.
45682581|NCT03782194|Device|Low Intensity Focused Ultrasound Pulsation|A low intensity, focused ultrasound pulsation causes mechanical changed without causing heating or cavitation.
46030767|NCT04869202|Diagnostic Test|COVID-19 test|Naso-pharyngeal swab test
45682582|NCT03782194|Device|Sham Ultrasound|Low Intensity Focused Ultrasound Pulsation Transducer is left in place on the participant's head but is not turned on during the sham procedure.
45682583|NCT03690700|Other|BFRE|BFR will be performed in the aBFRE group by use of pneumatic occlusion cuffs placed proximally on the thigh close to the inguinal fold, using an occlusion pressure corresponding to 40 % of seated arterial occlusion pressure (AOP). The individual AOP will be documented at baseline using doppler ultrasound (Siemens ACUSON S2000TM). Previous studies have shown that this pressure level can promote significant muscle adaptations to a similar degree and are associated with significantly less discomfort than higher occlusion pressures. The occlusion pressure of the participants in sham BFRE group will be 10mmHg.
46030768|NCT04856462|Behavioral|Education Support|Structured education is provided every other week (biweekly) to family caregivers over the course of 12 weeks, along with facilitated video-teleconferencing group meetings.
45682584|NCT03686566|Drug|13C-glucose|Includes standard pre-operation nursing care, 13C-glucose infusion and finger stick/IV glucose checks and storage of blood sample approximately every 30 minutes
46030769|NCT04856462|Behavioral|Phone Call|Participants will participate in an unstructored support group phone call
46030770|NCT04849910|Biological|VOR33|Allogeneic, human leukocyte antigen (HLA) matched, genome edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 myeloid protein
46030771|NCT04849910|Drug|Mylotarg|Infusion of Mylotarg
46030772|NCT04841057|Procedure|50 cm BP limb length|50 cm biliopancreatic limb length
46030773|NCT04841057|Procedure|100 cm BP limb length|100 cm biliopancreatic limb length
45682585|NCT03686566|Other|No glucose infusion|Only includes standard pre-operation nursing care
45682586|NCT03685942|Device|active light therapy (LUMINETTE®)|light therapy on a portable light visor device
45682587|NCT03685942|Device|placebo light therapy|placebo portable light visor device
45682588|NCT03582748|Procedure|sleeve gastrectomy|removal of most of stomach as a bariatric surgical procedure
45682589|NCT03582748|Procedure|No sleeve gastrectomy|Non-receipt of sleeve gastrectomy procedure
46030774|NCT04841057|Procedure|150 cm BP limb length|150 cm BP limb length
46030775|NCT04840394|Drug|BDB018|BDB018 is an immunotherapy agent.
46030776|NCT04840394|Drug|Pembrolizumab|Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
46030777|NCT04839679|Behavioral|Culturally Oriented Educational Brochure|Culturally appropriate educational brochure summarizing pertinent treatment information in a visual manner
46030778|NCT04839679|Behavioral|Mayo Clinic Educational Booklet|"An Introduction to Radiation Simulation and Treatment- Barbara Woodward Lips, Patient Education Center"
45682590|NCT03684538|Other|Probiotics|Patients will receive probiotics (Saccharomyces boulardii) one dose per day (250 mg)
46030779|NCT04839549|Drug|Dextenza 0.4Mg Ophthalmic Insert|Dextenza 0.4Mg Ophthalmic Insert
46030780|NCT04839549|Drug|Fluoromethalone .01%|Fluoromethalone .01%
46030781|NCT04837404|Procedure|Ultrasound guided femoral access for complex PCI|Ultrasound guided femoral access for complex PCI
46030782|NCT04837404|Procedure|Fluoroscopy guided femoral access for complex PCI|Fluoroscopy guided femoral access for complex PCI
46030783|NCT04836221|Behavioral|Support|"Community Health Workers will conduct weekly phone calls to monitor blood pressure or blood glucose, to check in on patient need for social, practical or emotional supports, and to encourage healthy lifestyle modification.~Participants will also have access to a mobile app to support chronic disease management (Either diabetes or hypertension)."
46030784|NCT04833699|Other|rubber water bag|bboiled tap water (80 °C) was put in a rubber water bag with a fluffy cover (Fig. 1), and placed on the patient's abdomen at 3, 6, 9, and 12 h after the surgical procedure for 30 minutes in addition to clinical standard postoperative care (ERAS protocol)
46030785|NCT04829292|Behavioral|Supportive therapy and CBT|In this open trial participants are first offered supportive therapy followed by CBT
46030786|NCT04826185|Drug|IMB-1018972|Modified release (MR) oral tablet
45682591|NCT03684538|Other|Zinc|Patients will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
45682592|NCT03684538|Other|Probiotics & Zinc|Patients will receive a combination of probiotics (Saccharomyces boulardii 250 mg) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
45682593|NCT03684538|Other|Standard care|initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified
46030787|NCT04826185|Drug|Placebo|Matching oral tablet
46030788|NCT04821271|Other|Placebo|Arm 1 and 2 Control Intervention
46030789|NCT04821271|Drug|TS-161 (50 - 100 mg)|Arm 1 and 2 Experimental Intervention
45682594|NCT03582514|Radiation|Preoperative brain irradiation (single fraction)|Dose and volume escalation of preoperative single-fraction radiotherapy.
46030790|NCT04821089|Biological|IPN10200|Several different doses will be administrated in a dose-escalation manner. One single injection will be injected locally into several sites across the glabellar region.
46030791|NCT04821089|Biological|IPN10200 Placebo|One single injection of study intervention will be injected locally into several sites across the glabellar region.
46030792|NCT04821089|Biological|Dysport|Single administration of study intervention in stage 1 / step 2 only
45682595|NCT03682978|Drug|Arbaclofen|Arbaclofen tablet.
45839196|NCT03035214|Drug|Dexamethasone (Steroids)|Is to describe the use of integrated assessment of respiratory physiology using Targeted Neonatal Echocardiography, assessment of optimal Functional Residual Capacity and the tolerance of lung oxygen uptake at different oxygen levels, and hence early prediction of Bronchopulmonary Dysplasia and the underlying pathophysiology by periodic application of the oxygen tolerance test; which may help early targeted treatment of this common disease.
46030793|NCT04812314|Behavioral|Exercise|Participants will complete a moderate intensity continuous exercise 4 days/week.
45682596|NCT03682978|Drug|Placebo|Placebo tablet.
46030794|NCT04812314|Behavioral|No exercise|Participants will remain sedentary throughout the duration of the study.
46030795|NCT04807179|Device|Experimental: RF Device Arm|Non-invasive radiofrequency Alexandrite laser
46030796|NCT04802161|Procedure|Biospecimen Collection|Undergo collection of blood samples
45471883|NCT01850888|Drug|Potassium iodide solution|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection. The minimum dose of potassium iodide to be given is one drop, which equals 50 mg.
46030797|NCT04802161|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspirate and biopsy
46030798|NCT04802161|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
46030799|NCT04802161|Drug|Pomalidomide|Given PO
45471884|NCT01850888|Drug|G-CSF|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally >5000).
45471885|NCT01850888|Procedure|hematopoietic stem cell infusion|The majority of patients on this protocol will have autologous PBSCs available. Allogeneic stem cells may be utilized in patients who has received a prior allogeneic transplant. The minimum quantity for peripheral blood stem cells is 1.5 x 106 CD34+ cells/kg (optimum > 2 x 106 CD34+ cells/kg). The minimum dose for bone marrow is 1.0 x 108 mononuclear cells/kg (optimum >2.0 x 108 mononuclear cells/kg). Infusion will be performed according to institutional guidelines.
45839197|NCT03035370|Biological|Viaskin PT 25 mcg|Two applications of Viaskin 25 mcg PT at a 2-week interval (D0 and D14).
45839198|NCT03035370|Biological|Viaskin PT 50 mcg|Two applications of Viaskin 50 mcg PT at a 2-week interval (D0 and D14).
46030800|NCT04794569|Drug|tinzaparin|low molecular weight heparin
46030801|NCT04794569|Drug|Rivaroxaban|direct oral anticoagulant
46030802|NCT04790370|Drug|Anticoagulation with heparin|Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)
46030803|NCT04790370|Device|EkoSonicTM Endovascular System|EkoSonicTM Endovascular System [ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg]
46030804|NCT04787042|Biological|ST-067|ST-067 is an engineered variant of human interleukin-18. Pembrolizumab is a potent humanized immunoglobulin G4 monoclonal antibody.
46030805|NCT04786262|Biological|VX-880|Infused into the hepatic portal vein.
46030806|NCT04781322|Drug|Alirocumab|Alirocumab is a human monoclonal antibody (IgG1) that binds to and inhibits PCSK9 and was approved by the FDA in July of 2015. PCSK9 binds to and promotes degradation of low-density lipoprotein receptors (LDLR) on hepatocyte membranes.
46030807|NCT04781322|Other|Placebo|Heavy drinking healthy volunteers
46030808|NCT04780971|Diagnostic Test|post-PCI Pd/Pa|After angiographically successful CTO PCI, intra-coronary physiologic assessment (RFR, FFR, CFR and IMR) of the CTO vessel will be performed directly. A staged procedure including several measurements is planned at 4 ± 2 weeks after the index procedure. These measurements consists of the same intra-coronary physiologic assessments at index procedure and OCT imaging of the stented segment in the CTO target vessel.
46030809|NCT04779931|Behavioral|Convoy-Pal|12 week mobile self-management intervention with palliative care resources.
46030810|NCT04777409|Drug|Semaglutide|Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
46030811|NCT04777409|Drug|Placebo (semaglutide)|Oral placebo (semaglutide) once-daily. The study will last for up to 173 weeks
45471886|NCT05507021|Dietary Supplement|Lactobacillus plantarum DSM 33464, MegaMetalliQ|Pour Lactobacillus Plantarum DSM 33464 sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
46030812|NCT04737577|Procedure|Supramarginal resection|Tissue removal beyond the GAD-enhancing region extending to either at least 1 cm into non-enhancing tissue, or the nearest non-enhancing sulcal boundary/ventricle wall if these structures are closer than 1 cm.
46030813|NCT04737577|Procedure|Conventional (i.e. GTR) resection|Planned resection of ≥95% of the GAD-enhancing regions of tumor without expanding the resection beyond this margin.
45471887|NCT05507021|Dietary Supplement|Placebo|Pour placebo sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
45839199|NCT03035370|Biological|Viaskin PT Placebo|Two applications of Viaskin PT Placebo at a 2-week interval (D0 and D14).
46030814|NCT04725903|Radiation|High-Dose Rate Brachytherapy|Receive high-dose rate brachytherapy boost
46030815|NCT04725903|Radiation|Proton Beam Radiation Therapy|Undergo proton beam therapy
46030816|NCT04725903|Other|Quality-of-Life Assessment|Ancillary studies
46030817|NCT04725903|Other|Survey Administration|Ancillary studies
46030818|NCT04712097|Drug|Mosunetuzumab|Participants will receive intravenous (IV) mosunetuzumab in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12
46030819|NCT04712097|Drug|Lenalidomide|Participants will receive oral lenalidomide once daily on Days 1-21 of Cycles 2-12 (M + Len) or Cycles 1-12 (R + Len)
46030820|NCT04712097|Drug|Rituximab|Participants will receive IV rituximab on Days 1, 8, 15, and 22 of Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11
46030821|NCT04712097|Drug|Tociluzumab|Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events
46030822|NCT04710576|Drug|Axatilimab|Axatilimab is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor-derived macrophages that mediate the disease processes involved in cGVHD.
46030823|NCT04697810|Drug|Namodenoson|25 mg q12hours x 36 weeks
46030824|NCT04697810|Drug|Placebo|Matching capsules q12hours x 36 weeks
46030825|NCT04697004|Device|Investigational Arm: SMR Stemless Reverse|The SMR Stemless Reverse is intended for total, primary shoulder joint replacement by reducing pain and restoring shoulder articular mobility function.
45471888|NCT05211674|Other|quantified analysis of postural control during activities of daily living|functional tests that reproduce tasks of daily living (timed up and go test with and without dual cognitive task, modified Glittre ADL test)
46030826|NCT04697004|Device|Control Arm: SMR Reverse Shoulder System|Conventional stemmed shoulder prostheses are commonly used in the clinical practice.
46030827|NCT04682301|Behavioral|Behavioral Intervention|Receive SDM intervention
46030828|NCT04682301|Other|Discussion (focus group)|Attend focus group
46030829|NCT04682301|Other|Discussion (feedback on SDM)|Provide feedback on SDM
45682597|NCT03676192|Drug|CT-16|15mg/kg IV of CT-P16 every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
45682598|NCT03676192|Drug|Avastin|15mg/kg IV of Avastin every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
45682599|NCT05347888|Other|Nutritional therapy|Either enteral or parenteral nutrition is used for the patient admitted in the ICU
46030830|NCT04682301|Other|Interview|Attend a telephone interview
46030831|NCT04682301|Other|Survey Administration|Ancillary studies
45682600|NCT01584843|Drug|GSK1358820|IM injection of Botulinum Toxin Type A
45682601|NCT03580408|Drug|Nivolumab|240 mg
45682602|NCT03580408|Drug|Vinblastin|6mg/m²
45839200|NCT03035370|Biological|Boostrix™|Four weeks after the second Viaskin application (at Day 42 of the study), all subjects will receive a dose of diphtheria-tetanus-pertussis vaccine (Boostrix® dTpa) to ensure the optimal recall of their immunity against pertussis.
45839201|NCT03035058|Drug|Vedolizumab|Vedolizumab intravenous infusion
46030832|NCT04679194|Biological|Mana 312|"Mana 312 is a cellular product comprised of expanded T cells derived from allogeneic donor leukocytes that have been stimulated with monocyte derived dendritic cells pulsed with tumor-associated antigen (TAA) peptide mixes for 3 antigens: Wilms Tumor gene 1 (WT 1), the preferentially expressed antigen of melanoma (PRAME), and Survivin.~Each Mana 312 product is specifically matched for an individual subject and will be manufactured from leukocytes from the same donor who provided stem cells to that subject for their current allogeneic hematopoietic stem cell transplantation (HSCT)."
46030833|NCT04676022|Device|WaveWriter|To receive Spinal Cord Stimulation programming
46030834|NCT04676022|Other|Conventional Medical Managament|To receive conventional medical management
46030835|NCT04674969|Device|Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.|Ranger™ Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter; ELUVIA™ Drug-Eluting Vascular Stent System
46030836|NCT04672720|Drug|L-carnitine 1000 Mg|Prescription 3mg l-carnitine (L-carnitine® tablet 1000 mg, Karen Pharmaceutical Company, Iran) daily from day 2 of the previous menstrual cycle until pregnancy test day (approximately 8 weeks).
46030837|NCT04672655|Behavioral|ONBOARD|Session 1: Overview; Wearing diabetes devices; Session 2: Managing CGM data; Session 3: CGM & social situations; Session 4: Building trust with your CGM
46030838|NCT04665921|Drug|SGN-STNV|Given into the vein (IV; intravenously)
46030839|NCT04663646|Other|Optokinetic stimulation|"Participants are placed in a standing position, with support products, if necessary, and virtual reality glasses will be placed where the visual stimuli will be projected.~The study will be carried out for 10 weeks with a frequency of two weekly sessions. During them, the participants will receive stimulation with OKS.~Stimulation will be performed at 1 cm/second, the vertical black bars will move to the left. The bars change color and the participants will be asked to detect the changes that will occur in the stimulus."
46030840|NCT04663646|Other|Placebo|Participants are placed in a standing position, with support products, if necessary, and virtual reality glasses will be placed where the visual stimuli will be projected. In this group, stimulation consists of a video with static vertical bars that change their colour at a randon intervals, in the same way that in the intervention group. The difference between groups is that in control group, bars are not in movement, preventing from generating optokinetic stimulation.
45471889|NCT03893513|Device|Transthoracic Electrical Bioimpedance|Non-invasive hemodynamic monitor
45471890|NCT03893513|Device|Pulse Contour Analysis|Invasive hemodynamic monitor
45682603|NCT03775096|Drug|Carvedilol|At the end of Baseline visit, carvedilol 3.125 twice daily will be initiated and maintained for 1 week, increased to 6.25twice daily (dispensed at week 1visit), to 12.5mg twice daily (dispensed at week 2) and a max dose of 25mg twice daily (dispensed at week 4 visit), as tolerated. A subject that cannot tolerate at least a 25 mg daily dose will be excluded from the study. Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose. The project will include a washout period at study end.
45839202|NCT03035058|Drug|Placebo|Placebo
45839203|NCT03034824|Procedure|SRP+940±15 nm diode laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the 940±15 nm diode laser.
46030841|NCT04661358|Drug|Fenofibrate|Participants begin with a dose of either 160mg or 54mg fenofibrate, based on eGFR value at screening, taken once daily with food. The dose may be adjusted during follow-up based on protocol guidelines.
46030842|NCT04661358|Other|Placebo|Participants begin with a dose of either 160mg or 54mg placebo, based on eGFR value at screening, taken once daily with food. The dose may be adjusted during follow-up based on protocol guidelines.
46030843|NCT04654468|Drug|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight >=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight >=100kg). Dosing schedule will be as described above.
45839204|NCT03034824|Procedure|SRP+Er,Cr:YSGG laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the Er,Cr:YSGG laser.
45839205|NCT03034824|Procedure|Scaling and root planing (SRP)-Control|Only Non-surgical periodontal treatment
46030844|NCT04652700|Drug|ISL|ISL 60 mg tablet, QM, orally for up to 24 months
45839206|NCT03034746|Other|Physical activity (PA)|It will perform a program consist of 15 min of warm-up, 60 min of aerobic and resistance training, and 15 min of cool-down.
45839207|NCT03034746|Other|cognitive treatment (CT)|The cognitive stimulation group will received a rehabilitation program with multimodal repetitive stimulation in order to exercise and reinforce the cognitive skills of the participant to slow/prevent the decline. In particular the treatment will be focused on reorient the patient about his/her-self, his/her history and his/her environment, to improve the memory skill by teaching compensatory and restitutive strategies, to help the patient to the discussion about everyday life and in particular to the everyday problems
46030845|NCT04652700|Drug|FTC/TDF|Participants receive 200/245 mg of FTC/TDF combination tablet, QD, orally for up to 24 months
46030846|NCT04652700|Drug|FTC/TAF|Participants receive 200/25 mg of FTC/TAF combination tablet, QD, orally for up to 24 months
46030847|NCT04652700|Drug|Placebo to ISL|Placebo ISL 0 mg tablets QM, orally for up to 24 months.
46030848|NCT04652700|Drug|Placebo to FTC/TDF|Placebo FTC/TDF 0 mg tablets QD, orally for up to 24 months
46030849|NCT04652700|Drug|Placebo to FTC/TAF|Placebo FTC/TAF 0 mg tablets QD, orally for up to 24 months
46030850|NCT04647448|Diagnostic Test|Application of sensor patch|Application of sensor patch to chest to record acoustic signals due to disturbed blood flow.
46030851|NCT04644224|Other|Educational Activity|Attend health coaching session
46030852|NCT04644224|Other|Educational Intervention|Attend resource navigation session
46030853|NCT04644224|Other|Informational Intervention|Receive handbook
45471891|NCT05751824|Other|AI based automatic surveillance (AS) system (ENDOANGEL-AS)|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.
46030854|NCT04644224|Other|Questionnaire Administration|Ancillary studies
46030855|NCT04644224|Procedure|Support Group Therapy|Attend support group
46030856|NCT04630808|Drug|NCX 470 0.1%|NCX 470 Ophthalmic Solution, 0.1%
46030857|NCT04630808|Drug|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005%
46030858|NCT04629417|Device|Smart Physiotherapy Activity Recognition System (SPARS)|Wearable smart watch that records inertial data such as (accelerometer, gyroscope magnetometer) while patients are performing physiotherapy exercises.
46030859|NCT04627025|Drug|apraglutide|Apraglutide is a peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
46030860|NCT04624230|Drug|tofacitinib|Open label tofacitinib 5 mg BID weight based adult equivalent with the option for individual dose increase to 10 mg BID weight based adult equivalent for a limited time if dose escalation criteria are met, prior to returning to 5 mg BID.
46030861|NCT04624178|Drug|Rucaparib|Rucaparib at 600 mg, orally, twice daily, continuously for 28 days.
46030862|NCT04624178|Drug|Nivolumab|Nivolumab 480mg intravenously on day 1 of every four-week cycle.
46030863|NCT04619004|Drug|Patritumab Deruxtecan (Fixed dose)|Patritumab deruxtecan will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.
46030864|NCT04619004|Drug|Patritumab Deruxtecan (Up-Titration)|Patritumab deruxtecan will be dosed as an intravenous (IV) infusion administered at Cycle 1, 3.2 mg/kg; Cycle 2, 4.8 mg/kg; Cycle 3 and subsequent cycles, 6.4 mg/kg administered on Day 1 of each 21-day cycle.
46030865|NCT04608149|Device|Carpediem System|Continuous renal replacement therapy
45471892|NCT05751824|Other|Manually remind the patients to review.|Medical staff remind patients to review by telephone.
45471893|NCT01151033|Device|Drug Eluting Stent implantation|ProNOVA XR Drug Eluting Stent implantation
45471894|NCT05749562|Device|Cheneau-Toulouse-Munster brace|Full length, orthogonal anteroposterior and lateral X-rays will be taken with the Cheneau-Toulouse-Munster brace.
45839208|NCT03034980|Other|Training intensity (workload) during ergospirometry|The reached workload (W) during each training is noted during 12 weeks of rehabilitation. The relative intensity is expressed as a percentage of VT1 and VT2.
46030866|NCT04583735|Biological|TEPEZZA|TEPEZZA is a fully human anti-IGF-1R mAb.TEPEZZA will be provided in single-dose 20mL glass vials as a freeze-dried powder.Each vial of TEPEZZA must be reconstituted with 10 mL of sterile water for injection. Reconstituted TEPEZZA solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration.TEPEZZA will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses > 1800 mg).
46030867|NCT04583735|Drug|Placebo|Placebo (normal saline, 0.9% NaCl) solution will be administered in 100 mL or 250 mL infusion bags per weight based dosing volumes once every 3 weeks
45839209|NCT03034590|Other|questionnaire|
45839210|NCT03034434|Device|Trans-vaginal ultrasound|Three trans-vaginal ultrasounds, the 1st to be performed 8 hours post delivery, the 2nd 24 hours after delivery and the 3rd 48 hours after delivery.
45839211|NCT03034668|Dietary Supplement|CS16-003 Full dose|350 mg 'Rhodiola rosea L. & Rhaptonticum carthamoides extracts
45839212|NCT03034668|Dietary Supplement|CS16-003 Half dose|175 mg 'Rhodiola rosea L. & Rhaptonticum carthamoides extracts + maltodextrin 175 mg
46030868|NCT04578834|Drug|Placebo|Placebo to LNP023 200mg b.i.d
46030869|NCT04578834|Drug|LNP023|LNP023 200mg b.i.d
46030870|NCT04563338|Drug|Atezolizumab|Atezolizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Atezolizumab binds to PD-L1 which is a protein involved preventing the body's immune system (defense system against infection and disease) from fighting cancer cells. Blocking PD-L1 is expected to help the immune cells to destroy the cancer cells.
46030871|NCT04563338|Drug|Bevacizumab|Bevacizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Bevacizumab binds to vascular endothelial growth factor (VEGF) which is a protein involved with the growth of new blood vessels. Blocking VEGF will prevent blood vessels from forming and therefore stopping oxygen and nutrients to be supplied to cancer cells. Without oxygen and nutrients, the cancer cells will die.
46030872|NCT04562610|Drug|Intravenous Infusion group|The intravenous infusion group will receive two medications via the intravenous infusion route. These medications are Ofirmev ( acetaminophen ) 1,000mg and tranexamic acid 2,000 mg , an antifibrinolytic drug. In addition to these drugs, study subjects will receive Celecoxib 200mg by mouth and Gabapentin 600 mg by mouth prior to operation.
46030873|NCT04562610|Drug|All oral administration group|Subjects in the oral administration group will receive the following pre-emptive analgesic drugs, acetaminophen 1,000mg, Celecoxib 200mg and gabapentin 600mg via the oral route prior to operation. In addition they will receive the antifibrinolytic drug, tranexamic acid 2,000mg via an oral route as well prior to operation.
45839213|NCT03034668|Dietary Supplement|Placebo|Maltodextrin: 350 mg
45839214|NCT03034278|Other|Not applicable - no intervention|Not applicable - no intervention, observational survey study.
46030874|NCT04558957|Device|FLEBOGRIF|The catheter is a device dedicated to mechano-chemical ablation of insufficient veins of the superficial system.
46030875|NCT04557462|Drug|LNP023|Capsule 200 mg (b.i.d.) taken orally twice a day
45839215|NCT03033966|Device|NIRS based Cerebral Oximetry|Cerebral Oximetric measurement before and after decompressive craniectomy
46030876|NCT04531982|Drug|Pimavanserin|Pimavanserin 34 mg, taken as two blinded 17 mg tablets once daily by mouth
45839216|NCT03033810|Device|Fractional flow reserve and instantaneous wave-free ratio|"To explain discrepancies between FFR and iFR using demographic, morphological, genetic and functional indices.~The development of software for the automatic detection of the lowest point of microvascular resistance."
45839217|NCT03033654|Other|Sunscreen, Actinica|Two Consecutive Sunscreen Applications
46030877|NCT04531982|Drug|Placebo|Placebo, taken as two blinded tablets once daily by mouth
46030878|NCT04524910|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|As prescribed by the treating physician
46030879|NCT04518917|Behavioral|Mentally Singing|Participants sing their song in their head and match their footfalls to the beat.
46030880|NCT04518917|Behavioral|Listening to music|Participants listen to their song and match their footfalls to the beat.
46030881|NCT04518917|Behavioral|Singing|Participants will sing their song out loud and match their footfalls to the beat.
46030882|NCT04513522|Biological|Nivolumab|Specified dose on specified days
46030883|NCT04513522|Biological|Ipilimumab|Specified dose on specified days
46030884|NCT04506424|Other|CT Guided Cochlear Implant Programming|Flat Panel (high resolution) CT scans of the temporal bones, including the inner ears, will be obtained. The research team will use the scans to generate custom cochlear implant (CI) programs for use by the participants.
46030885|NCT04505501|Drug|N-803|N-803 is a novel IL-15 superagonist complex that enhances NK cell and CD8+ T-cell proliferation and activation.
46030886|NCT04486586|Device|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2 mA (estimated current density 0.04 mA/cm^2; estimated total charge 0.048 C/cm^2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will target apraxia of speech (AOS).
46030887|NCT04486586|Device|Sham plus Speech-Language Therapy|Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will target apraxia of speech (AOS).
46030888|NCT04465955|Biological|NGM621|NGM621 Dose 1
45471895|NCT01151969|Behavioral|"New multicomponent 7H intervention"|The GPs in the intervention group will undertake an interactive workshop training session (15 hours) on the '7 hypotheses' (7H) intervention. In short, this intervention encourages GPs to select from a list of seven possible hypotheses for why the patient is a frequent attender: biological, psychological, social, family, cultural, administrative-organisational, or related to the doctor-patient relationship.
45471896|NCT01151111|Behavioral|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the RGI and asked to listen to it at home.
45471897|NCT00647036|Dietary Supplement|Isonitrogenous Vaminolact|Isonitrogenous Vaminolact
46030889|NCT04465955|Biological|NGM621|NGM621 Dose 2
46030890|NCT04465955|Other|Sham Comparator|Sham Comparator
46030891|NCT04457193|Device|TIF|Transoral Incisionless Fundoplication (TIF) is an endoscopic procedure that mechanically creates fundoplication similar to traditional operative Nissen fundoplication. The role of TIF in patients with BE whom underwent successful endoscopic ablation has not been fully investigated.
45471898|NCT00647036|Drug|Dipeptiven (L-glutamine- Lalanine)|0.6g/kg/day
45471899|NCT03893123|Other|Observational study, prostate cancer is outcome of interest|Observational study
46030892|NCT04450368|Device|Sylvee|The investigators have developed a small sensor that has the same characteristics as a combined hearing aid used for Tinnitus. It has a noise generator intended to transmit white noise (2 - 20 KHz) and a microphone similar to those used in hearing aids to provide sound amplification. Our sensor is substantially equivalent to legally FDA approved marketed devices that can be used for several hours per day. Although it will introduce new indications for use (lung resonance capture), it has the same technological characteristics and will not introduce new hazards or safety risks. Several sound-based devices are already in use for clearing mucus from the lungs by generating and delivering low frequency sound that vibrates the airways and lung secretions, causing them to thin and become expelled. The devices are placed on the patient's chest for up to 3-4 hours in COPD, cystic fibrosis (CF) and other lung diseases.
46030893|NCT04444895|Drug|Lanadelumab|Rollover participants will receive 300 mg of lanadelumab solution in a PFS SC injection once Q2W or Q4W for 26 consecutive weeks.
45471900|NCT03893045|Drug|ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution
45471901|NCT03893045|Drug|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
45682604|NCT01560429|Procedure|Patient controlled epidural analgesia|Continuous epidural infusion rates were set to maintain pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in the post anesthesia care unit (PACU) following thoracotomy. Once stabilized patients were switched to Patient controlled epidural analgesia (PCEA) which meant they continued to receive 2/3rds of the dose as continuous background epidural infusions but they had the option to receive the remaining 1/3rd dosage via PCEA.
46030894|NCT04419649|Drug|KER-050|KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.
46030895|NCT04411823|Device|EndoFLIP measurement|EndoFLIP device can measure gastroesophageal junction distensibility index and esophageal contractile pattern under FDA cleared indication. It is performed during endoscopy.
46030896|NCT04410653|Drug|Afatinib 40 MG|single oral dose of afatinib each day starting at a dose of 40 mg on day 1, continuously, until the development of progressive disease or unacceptable adverse events
45839218|NCT03033732|Drug|Methadone|Methadone is a synthetic analgesic drug used as a substitute drug in the treatment of opioid use disorder. Methadone is administered via strict daily witnessed ingestion.
46030897|NCT04386005|Device|Continuous Glucose Monitoring Device|The Dexcom G7 Glucose Monitoring System (San Diego, CA) reports continuous interstitial blood glucose concentrations every 5 minutes, does not require calibration, and involves only 1 needle stick to place the sensor. The manufacturer recommends that a single sensor may be used for up to 10 days. The Dexcom G7 system is the only FDA approved CGM system for children (age >2 years).
46030898|NCT04384484|Drug|Loncastuximab Tesirine|Intravenous Infusion
46030899|NCT04384484|Drug|Rituximab|Intravenous Infusion
45471902|NCT00394550|Procedure|supraglottoplasty with laser|"Polysomnogram, fiberoptic flexible laryngoscopy, adenotonsillectomy, direct laryngoscopy, bronchoscopy, laser supraglottoplasty, general anesthesia, a proton-pump inhibitor ibuprofen, acetaminophen with codeine without alcohol, or other narcotic containing medication, antibiotic, possible use of other analgesics per anesthesia None of these procedures are new or experimental. Our investigation pertains to a broader use of the laser supraglottoplasty to include children with obstructive sleep apnea and laryngomalacia, as opposed to the more traditional use of laser supraglottoplasty for only severe laryngomalacia in young children"
45471903|NCT00394550|Procedure|supraglottoplasty with laser|laser excision of laryngomalacia (floppy tissue) on one side of the supraglottis
46030900|NCT04384484|Drug|Gemcitabine|Intravenous Infusion
46030901|NCT04384484|Drug|Oxaliplatin|Intravenous Infusion
46030902|NCT04377087|Drug|Olaparib|Olaparib is a potent oral poly (ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in BRCA1/2 deficient tumor cells through the formation of double-stranded DNA breaks which cannot be accurately repaired, which leads to disruption of cellular homeostasis and cell death.
46030903|NCT04374136|Drug|AL001|Administered via intravenous (IV) infusion
46030904|NCT04374136|Drug|Placebo|Administered via intravenous (IV) infusion
46030905|NCT04374136|Drug|Open label - AL001|Administered via intravenous (IV) infusion
45839219|NCT03033732|Drug|Buprenorphine-Naloxone|Buprenorphine/Naloxone is an opioid agonist treatment used to treat opioid use disorder. Buprenorphine/Naloxone is administered via flexible take home dosing once the patient has reached stabilization as per physician discretion.
46030906|NCT04360018|Other|Alcohol beverage|High-proof alcohol (e.g., Everclear) will be mixed with orange juice in an approximately 1:3 ratio and split evenly into two drinks. After splitting the orange juice into two cups, a small amount (approx. 6 ml) of high-proof alcohol will be floated on top of the beverage.
45471904|NCT01560572|Drug|tacrolimus OD, mycophenolic acid, prednisolone|tacrolimus maintenance 6-10 ng/ml, in the low dose tacrolimus group after 6 months fixed dose reduction of 50% tacrolimus through levels will be 3-5 ng/ml mycophenolic acid 2 dd 720mg, after 2 weeks reduced to 2 dd 540 mg in all groups methylprednisolone 500, 250, 125 mg on day 0, 1, and 2 in all groups prednisolone 1 dd 10 mg, and from week 6 prednisolone 7.5 mg in the standard immunosuppression and low dose tacrolimus group No prednisolone will be given the steroid free group
46030907|NCT04360018|Other|Placebo beverage|The final drink will have the same volume of liquid as the alcohol beverage.
45471905|NCT03897023|Biological|Gut Microbiota|Status of microbiota
45471906|NCT01258673|Drug|Fimasartan/HCTZ combination|Fimasartan/HCTZ combination 60/12.5mg 120/12.5mg
45471907|NCT01258673|Drug|Fimasartan|Fimasartan 60mg, 120mg
45471908|NCT05209256|Drug|Chemotherapy|Patients in the alflutinib group received alflutinib (80 mg daily) until disease progression, unacceptable toxicity, or death.
45839220|NCT03033498|Drug|ABBV-951|ABBV-951 administered by subcutaneous infusion.
45839221|NCT03033888|Behavioral|Health-Literacy Focused Education Session|
45839222|NCT03033264|Drug|Dinoprostone|10 mg of a Dinoprostone vaginal insert.
46030908|NCT04341779|Combination Product|Point-of-care viral load testing and tenofovir adherence testing|Point-of-care testing of HIV viral load and tenofovir, and providing same day results to participants
46030909|NCT04322994|Device|Transnasal Humidified Rapid-Insufflation Ventilatory Echange|The use of high-flow nasal cannula to augment the ability to oxygenate and ventilate a patient under general anesthesia.
46030910|NCT04319367|Drug|Investigational Medicinal Product|Recombinant human monoclonal antibody (mAb) or placebo
46030911|NCT04308512|Device|Care4AD system|Eligible subjects will be randomized to intervention, IG, and control groups, CG, with ratio of 1:1 and will be assessed at baseline and six months. All reminders will be activated in the intervention group and de-activated in the control group. Essential ADL tasks will be preprogrammed by our care coordination expert for the IG. Patients and their caregivers in the IG will be also able to schedule additional tasks.
46030912|NCT04297761|Other|Filtered Air|Ambient air will be filtered and used for control exposure.
46030913|NCT04297761|Other|Wood Smoke|Wood smoke is generated by smoldering dry white oak logs and the exposure level will be maintained at an average of 500 µg/m^3 for 2 hours.
46030914|NCT04294667|Drug|DZP|Subjects will receive dapirolizumab pegol at prespecified time-points.
45682605|NCT01560429|Procedure|Continuous epidural analgesia|The continuous epidural analgesia (CEA) infusion rates were titrated to achieve pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in post-anesthesia care unit (PACU) (as described for the PCEA group above). Those allocated to the CEA group remained on the same continuous epidural analgesia infusion which maintained the pain scores at ≤ 3.
45839223|NCT03033264|Device|Double lumen cervical ripening balloon.|Double lumen cervical ripening balloon.
45839224|NCT03033030|Diagnostic Test|Ultrasound|Ultrasound examination
46030915|NCT04294667|Other|Placebo|Subjects will receive placebo at prespecified time-points.
46030916|NCT04287868|Biological|PDS0101|PDS0101 will be administered on D1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. Subcutaneous 1.0mL (2.4mg of total peptide and 3 mg of R-DOTAP) injection.
45839225|NCT03033342|Drug|Oral single doses of MRX-4|Oral single escalating doses of MRX-4
46030917|NCT04287868|Biological|M7824|M7824 will be administered at a flat dose of 1,200 mg IV (over 1 hour) once every 2 weeks.
46030918|NCT04287868|Biological|NHS-IL12|NHS-IL12 will be administered at as dose of potentially de-escalating doses by SC injection every 4 weeks.
46030919|NCT04286776|Other|Direct electrical stimulation|Stimulation lasting from 500 to 2000 milliseconds on bipolar target electrode pairs at one of two target frequencies (e.g. 10 Hz and 200 Hz), up to 1.5 milliamperes in amplitude on depth contacts and 3.5 milliamperes in amplitude on surface contacts. (Pulse shape - Charge-balanced biphasic rectangular pulses with pulse width of 300 microseconds in duration per phase).
45471909|NCT05209256|Drug|Alflutinib plus chemotherapy|Those in the combination group received concurrent alflutinib (80 mg daily), as well as carboplatin (area under the curve [AUC] of 5 on day 1) and pemetrexed (500 mg/m2 on day 1) in a 3-week cycle for up to four cycles, followed by maintenance on alflutinib and pemetrexed until disease progression, unacceptable toxicity, or death.
45471910|NCT01258751|Drug|PF-05212377|Single dose of up to 70 mg PF-05212377, delivered as .25 mg, 5 mg and/or 15 mg on study day 1
46030920|NCT04276142|Behavioral|ceprica (additional to treatment as usual)|ceprica is a dialogue-based online psychological intervention for patients with migraine. This intervention includes elements that address pain management, pain reduction etc. Content is adapted to users needs using interactive dialogues, illustrations and audio files. Participants may also continue with their usual treatment.
46030921|NCT04276142|Behavioral|active control intervention (additional to treatment as usual)|the active control intervention contains psychoeducational content regarding migraine
46030922|NCT04272996|Procedure|Craniotomy only|evacuation of SDH
46030923|NCT04272996|Procedure|Craniotomy + Endovascular embolization of the middle meningeal vessels|evacuation of SDH + Embolization of middle meningeal vessels using standard techniques.
46030924|NCT04269005|Other|Implementation of the SCCM|Implementation of the SCCM includes a baseline survey, assessment of screening questions stage 1 (with consequence), screening questions stage 2 (with consequence) and if necessary psychosomatic-psychiatric consultation and liaison service including if applicable post hospital intervention and a follow-up survey in a distressed focus sample.
45471911|NCT05211206|Other|IV fluids|Amount of intravenous fluids delivered
45471912|NCT01258829|Other|Non-invasive haemodynamic optimisation|Comparing the method of non-invasive haemodynamic
45471913|NCT01258829|Other|ECHO optimisation|Standard ECHO optimisation method
45471914|NCT05211128|Procedure|Robotic Surgery|Surgical procedure using robotic technologies.
46030925|NCT04267393|Drug|BMS-986263|Specified dose on specified days
46030926|NCT04267393|Other|Placebo|Specified dose on specified days
46030927|NCT04259281|Drug|GTX-102|antisense oligonucleotide
45471915|NCT05211128|Procedure|Open Surgery|Surgical procedure using a large, open cut in the skin.
45471916|NCT05211128|Procedure|Laparoscopic Surgery|Surgical procedure using small incisions and trochars.
45471917|NCT03896321|Drug|Antiplatelet Agents|effect of dual antiplatelet in management of coronary artery ectasia
45471918|NCT03896321|Drug|Anticoagulants|effect of oral anticoagulants in management of coronary artery ectasia
45471919|NCT05211050|Drug|Levcromakalim|20 min infusion of 1 mg Levcromakalim followed by either sumatriptan or placebo.
45471920|NCT05211050|Drug|Sumatriptan|10 min infusion of 4 mg sumatriptan.
45471921|NCT05211050|Drug|Saline|10 min infusion of isotonic saline (placebo).
46030928|NCT04258436|Procedure|Serratus anterior block|Serratus anterior block will be performed using an ultrasound guided transducer to inject 2mg/kg of 0.2% ropivacaine
46030929|NCT04257214|Behavioral|Psychosocial treatment|Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.
46030930|NCT04814732|Drug|Surufatinib|HMP-012
45471922|NCT03892733|Behavioral|calorie health education knowledge and skills|45 minute intervention done by health educator to give participants skills to use calorie information posted in fast-food restaurants
45471923|NCT05210894|Biological|Anti-IL8|
45471924|NCT04883138|Drug|GIGA-2050|Recombinant Hyperimmune Polyclonal Antibody
45471925|NCT03892811|Other|Three study conditions|Continuous fluoroscopy (at 30 frames/second) will be used for intermittent periods to capture 10 swallows in the initial sucking sequence of each of three study conditions: 1) Dr. Brown's Ultra-Preemie bottle nipple, 2) Dr. Brown's Preemie bottle nipple, and 3) Dr. Brown's Level 1 bottle nipple.
46030931|NCT04252859|Drug|[18F]Fluoroestradiol (FES) PET/CT|[18F]Fluoroestradiol (FES) PET/CT for invasive lobular carcinoma (ILC)
45471926|NCT05210738|Device|Single incision sling|Single incision sling is used to treat occult SUI
46030932|NCT04247711|Behavioral|OTCH|OTCH is structured in three phrases (i. engagement and initial needs assessment, ii. ongoing intervention and monitoring, and iii. transition to long-term services) and lasts an average of two years. OTCH will maintain the central characteristics of the OnTrack model, as well as its core principles, which include (1) Person-centered care, (2) Shared decision-making, (3) Recovery orientation, and (4) Culturally-competent care.
46030933|NCT04247711|Behavioral|Usual FEP Services|These include services such as psychiatric medication, psychotherapy, and psychoeducation for people with FEP and are usually provided at outpatient mental health clinics.
45471927|NCT05210738|Drug|Bulkamid bulking agent|Urethral bulking by Bulkamid is used to treat occult SUI
45471928|NCT02527655|Behavioral|Choice-Based Physical Activity and Active Transportation|
46030934|NCT04246476|Behavioral|Mentally singing|All participants (people with PD and age-matched controls) sing their song in their head and match their footfalls or finger tapping to the beat.
45471929|NCT05209022|Dietary Supplement|Beetroot juice|140 mL of beetroot juice or beetroot juice placebo
45471930|NCT03892499|Drug|Olinciguat|Oral Tablet
45471931|NCT03892499|Drug|Itraconazole|Oral Capsule
45839226|NCT03033342|Drug|Oral multiple doses of MRX-4|Multiple ascending doses of MRX-4 given twice daily for 10 days
45471932|NCT05732558|Procedure|8 Patients who were prescribed a CT-guided percutaneous bone biopsy, performed with the aid of endosight navigation system|The study is based on a comparison of the number of CT scans required for needle placement in bone biopsies (trunk area) performed with augmented reality navigation system (endosight) and without.
45471933|NCT03896243|Diagnostic Test|Uterine artery ligation (UAL)|"Uterine artery ligation (UAL) We will invite the patients to the hospital at least 6 months after surgery who underwent only uterine artery ligation performed due to uterine atony during C-section.~They will evaluated for their ovarian reserve via hormones and antral follicle count (AFC)"
45471934|NCT01152047|Drug|oxytocin|40mU/min as infusion of oxytocin
45471935|NCT01257659|Procedure|STARR rectocele repair|The STARR transanal stapling system is used to repair a rectocele.
45839227|NCT03033342|Drug|MRX-4 co-administered with omeprazole|MRX-4 given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
45839228|NCT03033342|Drug|Oral single doses of placebo|Single doses of placebo to match MRX-4
45839229|NCT03033342|Drug|Oral multiple doses of placebo|Oral placebo given twice daily for 10 days to match the oral MRX-4
46030935|NCT04246476|Behavioral|Listening to music|All participants (people with PD and age-matched controls) listen to their song and match their footfalls or finger tapping to the beat.
46030936|NCT04246086|Drug|Mosunetuzumab (IV)|Participants will receive IV mosunetuzumab as defined by the study protocol
46030937|NCT04246086|Drug|Tocilizumab|Participants will receive IV tocilizumab as needed for adverse reactions as defined by the study protocol
46030938|NCT04246086|Drug|Lenalidomide|Participants will receive oral lenalidomide as defined by the study protocol
45471936|NCT01257659|Procedure|Elevate mesh rectocele repair|A posterior Elevate mesh is placed transvaginally to repair a rectocele.
45471937|NCT01151267|Other|Standard Anesthesia management for post surgical patients|The O2 flow on the anesthetic machine will be set at 15 L/min. Ventilatory assistance will be performed to maintain O2 saturation >97% and end tidal CO2 at 35-45mmHg.
45682606|NCT03895593|Other|rescue fecal microbiota transplantation|Fecal microbiota transplantation refers to the infusion of fecal microbiota from healthy donor into patients' gastrointestinal tract. The delivering ways for FMT include but are not limited to gastroscopy, colonoscopy, edema, nasogastric tube, transendoscopic enteral tube, and etc.
46030939|NCT04246086|Drug|Mosunetuzumab (SC)|Participants will receive SC mosunetuzumab as defined by the study protocol
46030940|NCT04245150|Other|Stool sample|Stool sample
46030941|NCT04245150|Other|Skin Swab Sample|Skin Swab Sample
46030942|NCT04221178|Other|Cessation of continuous matinenace therapy|Cessation of maintenance therapy for participants in sustained MRD-negative remission while under careful observation
46030943|NCT04216290|Drug|Cisplatin|Given IV
46030944|NCT04216290|Biological|Durvalumab|Given IV
46030945|NCT04216290|Drug|Fluorouracil|Given IV
46030946|NCT04216290|Drug|Gemcitabine Hydrochloride|Given IV
46030947|NCT04216290|Drug|Mitomycin|Given IV
46030948|NCT04216290|Other|Patient Observation|Undergo observation
46030949|NCT04216290|Radiation|Radiation Therapy|Undergo radiation therapy
46030950|NCT04205838|Biological|Anakinra|Given SC
46030951|NCT04205838|Biological|Axicabtagene Ciloleucel|Given via infusion
46030952|NCT04205838|Drug|Cyclophosphamide|Given via infusion
46030953|NCT04205838|Drug|Fludarabine|Given via infusion
46030954|NCT04205838|Drug|Fludarabine Phosphate|Given via infusion
46030955|NCT04196530|Drug|BDB001|BDB001 is an immunotherapy agent.
45471938|NCT01151267|Device|Hypercarbic Spontaneous Hyperpnoea|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. With O2 flow of 2 L/min patient will be gently ventilated until recovery of the spontaneous ventilation. After starting spontaneous ventilation basal O2 flow will be adjusted to keep ETCO2 in range of 50-60 mm Hg or minute ventilation of 15-17 L/min, whichever occurs first.
46030956|NCT04196530|Drug|Atezolizumab|Atezolizumab is a is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
46030957|NCT04190056|Biological|Pembrolizumab|Given IV
46030958|NCT04190056|Drug|Tamoxifen|Given PO
45471939|NCT03056300|Device|Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler|Powered Vascular Stapler used on vessels
45839230|NCT03033342|Drug|Placebo co-administered with omeprazole|Placebo given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
46030959|NCT04190056|Drug|Vorinostat|Given PO
46030960|NCT04170543|Drug|MEDI3506|Dose 1, Dose 2, Dose 3, Dose 4
46030961|NCT04170543|Drug|Placebo|Placebo
46030962|NCT04170543|Drug|Dapagliflozin|Dapagliflozin 10 mg
46030963|NCT04163016|Drug|Pharmacokinetics of certolizumab pegol|"The collection of blood samples for pharmacokinetics (PK) is considered interventional. Blood samples will be drawn at enrollment, predose every 4 weeks (Q4W), postdose every 8 weeks (Q8W) and postpartum predose and postdose.~Study participants will be responsible for obtaining and administering commercially available approved dosing regimens of certolizumab pegol (CZP) as prescribed by each study participant's own physician."
45839231|NCT03032874|Procedure|Colonoscopy|They all had screening colonoscopy
46030964|NCT04161391|Drug|TPX-0046|Oral TPX-0046 capsules
46030965|NCT04147013|Drug|Celecoxib|Patients will receive celecoxib 200 mg PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
46030966|NCT04147013|Drug|Placebo|Patients will receive placebo PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
46030967|NCT04122001|Device|Active HD-tDCS|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (angular gyrus). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.
46030968|NCT04122001|Device|Sham|Current will be administered in a ramp-like fashion but after the ramping the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.
46030969|NCT04122001|Other|Word List Learning Intervention (WordLLI)|Participants will receive a word list learning intervention (WordLLI) of semantically related and unrelated word lists. Word lists are presented across 10 trials, with an additional trial after a 10-minute delay to assess delayed recall. Immediately following verbal presentation of word lists during each trial, participants will be instructed to recall as many of the words from the list as possible. Participants may use the written modality as a strategy during recall. Word lists include 12 words matched based on psycholinguistics attributes (e.g., imageability, frequency). This task is designed to help participants improve memory via enhancing list learning capabilities.
46030970|NCT04121182|Other|On-line training|"Nursing teams randomized in the intervention group will benefit from an intervention in the form of a specific training online on the prevention of pneumonia and their management in the nursing home This training focuses on prevention, and management during the infectious period (the false food route and the management of pneumonia)."
45471940|NCT01152125|Other|Autologous bone marrow stem cells|Stem cells isolated from the patient's own bone marrow.
45471941|NCT05210426|Other|Pilates exercises|The Pilates Group completed a 10-week Pilates program. The intervention was performed in 20 sessions. In the first session, introduction and explanations regarding the principles and benefits of Pilates was made in a language that preschool children can understand. Exercises were supervised, and they were taught via gamification. In addition, the participation of the children was encouraged and stickers were given to increase their motivation at the end of the sessions. No adverse events occurred during intervention. The exercise program was created based on books and from the booklet acquired in the APPI Pilates Method training courses. Since the study was in preschool children, the basic level of Pilates was performed. Each exercise was performed 5 times for 30 minutes each twice a week.
45471942|NCT01259141|Drug|Moxifloxacin|0.4 Qd for 7days
46030971|NCT04121182|Other|Usual practice|Nursing home with usual practice : The act of comparison is defined by the usual care, as they are performed in the nursing home at the time of the study. No restrictions are placed on residents or caregivers of any kind in the care of the resident.
46030972|NCT04114357|Drug|Acetylated and Butyrylated High Amylose Maize Starch|Participants will be instructed to consume HAMS-AB in two divided doses at breakfast and dinner
45471943|NCT01259141|Drug|Cephalosporins and azithromycin|cefuroxime 1.5 bid for 7 days plus azithromycin 0.5 qd for 7 days
46030973|NCT04111900|Behavioral|Sleep/Circadian Friendly|This intervention attempts to improve sleep and prevent circadian rhythm dysregulation among patients admitted to the medical intensive care unit (MICU). Patients within his arm will be asked to try to keep their TV off and limit their telephone use from 10pm-7am, as well as limit the amount of visitors in their room as much as possible between those hours. Patients will also be offered ear plugs and eye masks if they wish to use at night to aid in helping them sleep, if deemed medically safe to do so. Additionally nurses will be asked to bathe patients either before 10pm or after 7am, to limit their conversations in the patient's room at night, and try as much as possible to limit blood draws and waking patients during those hours as is medically safe. Nurses will also be instructed to lower the blinds in the room at 10 pm and raise them up at 7am to help with patients sleep/wake cycle.
45471944|NCT03896087|Diagnostic Test|Abbott RealTime HCV assay from DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
45471945|NCT03896087|Diagnostic Test|HCV for use on the cobas® 6800/8800 Systems from PSC and DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays cobas® 6800/8800 Systems for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
46030974|NCT04086485|Drug|Lu-177-DOTATATE|Lu-177-DOTATATE will be given by IV every 8 (+/-2) weeks for a total of 4 administrations
46030975|NCT04086485|Drug|Olaparib|Olaparib is given as a pill taken orally and is to be taken twice a day, starting from 2 days before the first administration of Lu-177-DOTATATE until 4 weeks after the last administration
45839232|NCT03032952|Other|"Feel Stress Free mobile application"|This online and mobile application uses relaxation techniques, thought challenging, mini-games and mood tracking to help reduce feelings of stress, anxiety and depression.
46030976|NCT04086485|Diagnostic Test|Ga dotatate scanning|Ga68-DOTATATE PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.
46030977|NCT04086485|Diagnostic Test|FDG-PET scanning|F18-FDG PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.
46030978|NCT04086485|Drug|Amino Acid infusion|Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection. The AA infusion will begin at least 30-60 minutes prior to injection of Lu-177-DOTATATE and will continue during and after the Lutathera infusion until the entire prescribed amount is infused.
46030979|NCT04084717|Drug|Crizotinib|"Crizotinib is an orally administered, chemotherapy drug that works by blocking ALK, MET and ROS1 receptor tyrosine kinases from working.~Participants will receive crizotinib, orally (by mouth), at a dose of 250 mg, twice per day, every day of each 28 day cycle."
45682607|NCT03774394|Drug|Clopidogrel|Both CKD and Non-CKD patients will be administered a 600-mg LD of clopidogrel followed by a single 75-mg MD administered after 24 hours.
46030980|NCT04081038|Diagnostic Test|Brush biopsy|Brush biopsy will be performed by dentists and dental hygienists
45682608|NCT03774394|Drug|Clopidogrel active metabolite|In both CKD and Non-CKD patients, blood samples collected at baseline only (before clopidogrel LD administration) will be incubated with escalating concentrations of clopidogrel active metabolite (1, 3 and 10 μM)
45682609|NCT01582971|Other|Reflexology|Friend/family member trained in foot reflexology protocol by certified reflexologist; friend/family member provides 4 weekly sessions to patient
45682610|NCT03772834|Behavioral|Exercise Intervention|Undergo resistance training and walking
45682611|NCT03772834|Drug|Methylphenidate|Given PO
46030981|NCT04079868|Behavioral|Bone Health Service Model|Patients in PACTs randomized to the BHS model will have osteoporosis screening, education, and follow-up handled centrally by the bone health team.
46030982|NCT04079296|Biological|ASP7517|Intravenous (IV)
45682612|NCT03772834|Other|Placebo|Given PO
45682613|NCT03772834|Other|Quality-of-Life Assessment|Ancillary studies
45682614|NCT03772834|Other|Questionnaire Administration|Ancillary studies
46030983|NCT04061070|Other|Supplementation with mix of threalose plus polyphenols|The patients will be treated with a mix of trehalose plus polyphenols for 60 days
46030984|NCT04061070|Other|No Supplementation with mix of threalose plus polyphenols|The patients will not be treated with a mix trehalose plus polyphenols for 60 days
46030985|NCT04057352|Device|Citadel Embolization Device|The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.
45682615|NCT03772834|Other|Stretching|Undergo stretching
45682616|NCT03770182|Device|NEUROLITH|transcranial pulse stimulation (TPS)
46030986|NCT04042701|Drug|Trastuzumab deruxtecan (DS-8201a)|"Part 1: Two dose levels of DS-8201a (3.2 mg/kg Q3W and 5.4 mg/kg Q3W via intravenous (IV) infusion will be administered for the dose escalation part of the study in combination with pembrolizumab.~Part 2: Once Part 1 of the study is complete and a RDE for DS-8201a has been established, Part 2 will begin. All participants will receive DS-8201a at the RDE in combination with pembrolizumab."
46030987|NCT04042701|Drug|Trastuzumab deruxtecan (DS-8201a)|"Part 1: Two dose levels of DS-8201a (3.2 mg/kg Q3W and 5.4 mg/kg Q3W via intravenous (IV) infusion will be administered for the dose escalation part of the study in combination with pembrolizumab.~Part 2: Once Part 1 of the study is complete and a RDE for DS-8201a has been established, Part 2 will begin."
46030988|NCT04042701|Drug|Pembrolizumab|All participants will receive pembrolizumab (200 mg Q3W) via intravenous (IV) infusion prior to DS-8201a in Parts 1 and 2 of the study.
46030989|NCT04039841|Diagnostic Test|Motor Imagery Test|"Imagined Timed Up and Go (iTUG) is the imagined version of the actual Timed Up and Go (rTUG) described above). It is possible to calculate the absolute value of the difference between the time of execution of the TUG imagined and actually executed. This difference is called isochrony index. The alteration of this isochrony index is correlated with the decrease in walking speed during the double task. This test is performed during the osteoporosis screening consultation.~For patients who agree to participate in the FallMI study, the name and contact information of the attending physician will be collected during the same consultation.~Standardised email will be sent to the attending physicians to collect the presence of falls and its consequences. They will be classified as fatal, severe, moderate and inconsequential."
46030990|NCT04029922|Drug|MT-5111 (experimental study drug)|Experimental treatment with MT-5111
46030991|NCT04020575|Biological|huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells|huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head).
46030992|NCT04020575|Biological|huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D|huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head) @ RP2D
46030993|NCT04016389|Drug|Cisplatin|Cisplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.
46030994|NCT04016389|Drug|Carboplatin|Carboplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.
46030995|NCT04016389|Drug|Paclitaxel|Paclitaxel is an antineoplastic agent that is commonly used in combination with cisplatin or carboplatin for the treatment of cervical cancer.
46030996|NCT04016389|Procedure|Trachelectomy|Surgery to remove the cervix but keep the uterus intact.
46030997|NCT04007510|Combination Product|EPI-CAL data network|This mobile, app-based platform was designed to: 1) enable outcomes data collection from clients and family members/support person who are receiving care at an early psychosis program, 2) summarize the data visually for clients and providers on a secure web-based dashboard, and 3) allow download of de-identified data for program or research analysis.
45471946|NCT03896087|Diagnostic Test|Aptima® HCV Quant Dx Assay from DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays Aptima® HCV Quant Dx Assay from DBS for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
45471947|NCT03896087|Diagnostic Test|HCV for use on the cobas® 4800Systems from PSC and DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays cobas® 4800 for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
46030998|NCT04007510|Diagnostic Test|Community DUP Assessment Tool|A tool will be developed to enable measurement of the duration of untreated psychosis (DUP) for FEP individuals based on 1) data other assessments that are typically completed during the intake process (e.g. SIPS, SCID) or 2) specific questions, prompts, a rating scale, and anchor points to enable rating of the DUP. Participants would have their DUP rated on the new tool and also complete a second assessment of DUP by research evaluators using the Symptom Onset in Schizophrenia Inventory (SOS) to determine reliability and validity of the new tool.
46030999|NCT03991923|Device|XVIVO heart preservation devices|The intervention is to preserve hearts during transportation cold, cardioplegic and non-ischemic, with a high oncotic and hormone supplemented perfusate.
46031000|NCT03991923|Device|Standard ICSS|Cold static preservation using standard preservation solution
45839233|NCT03032796|Behavioral|Body-Brain Trainer|A novel video game-based intervention that incorporates i) adaptive algorithms critical for cognitive training, ii) physiological measures such as heart rate into the core game mechanics, and iii) motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks.
45471948|NCT05210192|Drug|Lidocaine Hydrochloride 1% Solution for Injection_#2|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The first group will be injected with 4ml of 1% lidocaine. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
45598727|NCT03516409|Dietary Supplement|Placebo|"IP placebo is manufactured so to contain maltodextrin DE19 and have the same organoleptic properties of the active product (similar to the study product in appearance and taste) but without active ingredient. It contains 100% maltodextrin DE19.~Moreover, placebo sachets are equal in color, shape and weight (1 g) to IP sachets."
45598728|NCT02232113|Drug|CERA|changing frequency of administration from once to twice monthly under a fixed total monthly dose of CERA
46031001|NCT03991819|Drug|Binimetinib|Binimetinib is a drug that, inside the cell, blocks an important series of chemical reactions called a molecular pathway. Binimetinib blocks the MEK1/2 pathway from working. In some types of cancers, this pathway becomes too active, which can cause tumor cell growth. Blocking the MEK1/2 pathway from working is thought to slow or stop tumor cell growth.
46031002|NCT03991819|Drug|Pembrolizumab|Pembrolizumab is an immunotherapy drug that is approved by Health Canada for the treatment of patients with PD-L1 positive non-small cell lung cancer as a first treatment. PD-1 is a type of protein that binds to another type of protein known as PD-L1. When these proteins bind together, it helps prevent cells from killing each other, including cancer cells. Some drugs, like pembrolizumab, are used to block PD-1 from binding to PD-L1. When the protein is blocked, the body's immune system can kill more cells.
46031003|NCT03983837|Other|Neocate Splash|Neocate Splash is a hypoallergenic, amino acid based elemental liquid diet that is taken orally.
46031004|NCT03973281|Device|Materna Prep Device|Materna Prep Device
46031005|NCT03973281|Other|Standard of Care (SOC)|Standard of Care (SOC)
46031006|NCT03970343|Device|OPTIMIZER Smart System|"Eligible subjects will receive the OPTIMIZER Smart, which is comprised of three major components:~Optimizer Smart or Optimizer Smart Mini~Vesta Charger or Guardio Charger~Two commercially available intravascular leads"
46031007|NCT03954041|Drug|BIIB093|Administered as specified in the treatment arm.
46031008|NCT03954041|Drug|Placebo|Administered as specified in the treatment arm.
46031009|NCT03951480|Other|Manual medicine|At a rate of 3 sessions of a maximum of 30 minutes each at one week interval. Depending on the clinical evolution, it is possible to stop manual medicine sessions according to the therapist's assessment as in current practice. If the patient has an EVA pain of activity < 2, manipulations will not be continued. The patient being considered as not very symptomatic.
46031010|NCT03951480|Drug|Corticosteroids infiltration|A unique echo-guided infiltration of one syringe of 1 mL of cortisone product
46031011|NCT03946228|Behavioral|Behavioral Intervention|The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
46031012|NCT03945513|Drug|LPRI424 (dienogest/ethinylestradiol)|One LPRI424 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
46031013|NCT03945292|Drug|Fazisiran Injection|solution for subcutaneous (sc) injection
46031014|NCT03945292|Other|Placebo|sterile normal saline (0.9% NaCl), calculated to match active comparator, for sc injection
46031015|NCT03944772|Drug|Osimertinib|Osimertinib given orally at 80 mg once daily
46031016|NCT03944772|Drug|Savolitinib|Savolitinib will be given orally at 300 mg or 600mg once daily
46031017|NCT03944772|Drug|Gefitinib|Gefitinib given orally at 250 mg once daily
46031018|NCT03944772|Drug|Necitumumab|Necitumumab given IV at 800 mg on Day 1 and Day 8 of every 3-week cycle
46031019|NCT03944772|Drug|Durvalumab|Durvalumab given IV at 1500 mg on Day 1 of every cycle
45598729|NCT02289391|Drug|Anesthesia induction|-Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.
46031020|NCT03944772|Drug|Carboplatin|Carboplatin given IV on Day 1 of every 21-day cycle for up to 6 cycles
46031021|NCT03944772|Drug|Pemetrexed|Pemetrexed given IV at 500 mg/m2 body BSA on Day 1 of every cycle
46031022|NCT03944772|Drug|Alectinib|Alectinib given orally at 600mg twice daily and for Japanese patients at 300mg twice daily.
46031023|NCT03944772|Drug|Selpercatinib|Selpercatinib given orally at 160mg twice daily
46031024|NCT03944772|Drug|Selumetinib|Selumetinib given orally at 75 mg twice daily for 4 days, followed by 3 days off treatment
46031025|NCT03944772|Drug|Etoposide|Etoposide 80-100 mg/m2 given IV on day 1, 2 and 3 of every 21-day cycle for up to 4 cycles.
46031026|NCT03944772|Drug|Cisplatin|Cisplatin 75-80 mg/m2 given IV on days 1 of each cycle
46031027|NCT03944772|Drug|Datopotamab deruxtecan|Datopotamab deruxtecan given IV at 4 or 6 mg/kg on Day 1 of every 3-week cycle.
46031028|NCT03919552|Drug|Docetaxel,Carboplatin|Patients receive docetaxel (75mg/m2 on day 1), carboplatin (AUC 4 on day 1) every three weeks for two cycles before the radiotherapy.
45598730|NCT02289391|Drug|Anesthesia maintenance|"Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3~8mg/(kg•h).~Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30~40 mmHg and bispectral index (BIS) to 45~60."
46031029|NCT03919552|Drug|Docetaxel,Cisplatin|Patients receive docetaxel (75mg/m2 on day 1), cisplatin (75mg/m2 on day 1) every three weeks for two cycles before the radiotherapy.
46031030|NCT03919552|Radiation|Carboplatin-based concurrent chemoradiotherapy|Patients receive radical radiotherapy and carboplatin (AUC 5) every three weeks for three cycles during radiotherapy.
46031031|NCT03919552|Radiation|Cisplatin-based concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
46031032|NCT03901469|Drug|ZEN003694|PO QD
46031033|NCT03901469|Drug|Talazoparib|PO QD
46031034|NCT03901339|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
45471949|NCT05210192|Drug|Placebo|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The second group will be injected with 4ml of 0.9% saline. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
45471950|NCT01152203|Drug|Bendamustine|Starting dose of 70 mg/m^2 by vein on Days 1 and 2 of a 28 day cycle
45471951|NCT01152203|Drug|Bevacizumab|10 mg/kg by vein on Days 1 & 15 of every 28 day cycle
45682617|NCT03769168|Drug|AIN457|Secukinumab (AIN457) is a high-affinity fully human monoclonal anti- human antibody that target IL-17A and neutralizes activity.
45598731|NCT02289391|Drug|Assisted anesthesia|Intervention 'Assisted anesthesia' has been included in Arm Descriptions.
45598732|NCT02354313|Drug|Lenalidomide|"Treatment Phase: consisting in an induction phase (3 cycles of RCHOP, given every 21 days); consolidation phase: (high-dose cyclophosphamide (CTX), 2 cycles of high dose Ara-C, BEAM and ASCT).~Randomization and maintenance phase: Patients who have achieved complete or partial response will be randomized between maintenance with lenalidomide or observation."
45682618|NCT03675256|Biological|immediate Gardasil 9, delayed MenVeo vaccine|Intervention is immediate administration of 9-valent HPV vaccine and delayed MenVeo vaccine
45682619|NCT03675256|Biological|immediate MenVeo vaccine, delayed Gardasil 9|Intervention is immediate administration of MenVeo vaccine and delayed administration of Gardasil 9
45682620|NCT03675256|Biological|immediate Cervarix, delayed MenVeo vaccine|Intervention is immediate administration of bivalent HPV vaccine and delayed MenVeo vaccine
46031035|NCT03901339|Drug|Eribulin|Administered intravenously per NCCN guidelines
46031036|NCT03901339|Drug|Capecitabine|Administered orally per NCCN guidelines
46031037|NCT03901339|Drug|Gemcitabine|Administered intravenously per NCCN guidelines
46031038|NCT03901339|Drug|Vinorelbine|Administered intravenously per NCCN guidelines
46031039|NCT03900845|Device|Dynamic Air Exchange - Rising Edge Design (DAE-RED)|The DAE-RED suspension system expels perspiration to the prosthesis exterior using a hybrid battery-powered pump and a body-weight activated pump. To use the DAE-RED, subjects will be fit with a modified patellar tendon-bearing socket that fits over a custom liner and sock. Up to four air intake ports are located proximally on the liner, approximately 25 mm superior to the socket brim. These ports incorporate a microvalve that allows air to flow into the liner-skin interstitial space while still maintaining a vacuum suspension. Distally, the pin lock has a 3-mm hole along its longitudinal axis that allows perspiration to be expelled into a distal reservoir. The prosthesis will also include: a standard aluminum pylon, pyramid adapters, and an Ossur Proflex XC prosthetic foot with Unity pump and foot cover.
45471952|NCT05210036|Device|Ultrasound Therapy (US)|"All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~Hot Pack at 60 degrees Celsius for 20 minutes~TENS at 80 Hz for 20 minutes~Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
45682621|NCT04762732|Device|NPWT|Wound of ALT donor site will be cared under PREVENA™ Incision Management System for 5 days post-operatively.
46031040|NCT03900845|Device|Perforated elastomeric liner|The unique element of this perforated elastomeric liner are small perforations (~0.3 mm diameter), uniformly distributed on a 4 x 5 mm grid, but with no perforations on the distal umbrella, that allow perspiration to be exuded into the liner-socket interstitial space. To use the perforated elastomeric liner, subjects will be fit with a modified patellar tendon-bearing socket that fits over a sock and the perforated elastomeric liner with a pin lock. The sock, worn between the socket and the liner, is used to absorb perspiration that is transported through the perforations in the liner. When needed for residual limb volume control, additional socks will be donned and included in tare weighing. The prosthesis will also include: a standard aluminum pylon, pyramid adapters, and an Ossur Proflex XC prosthetic foot and cosmesis.
46031041|NCT03900845|Device|As-prescribed prosthesis|The individual's as-prescribed suspension system is the prosthesis prescription that the patient and their clinical care team believes is the best prosthesis for their needs.
45682622|NCT04762732|Device|Traditional wound care|Wound of ALT donor site will be covered by vaseline gauze coated with tetracycline ointment (Genuine Chemical Pharmaceutical, Tao-Yuan, Taiwan), and layers of gauze.
45682623|NCT03766750|Drug|LIMA association|1 coated tablet, oral, once a day.
46031042|NCT03900468|Device|Activa™ PC and Percept™ PC Neurostimulation Systems|Implanted DBS system consisting of a Neurostimulator, Leads, Extensions, and potential accessories including Burr Hole Devices, Clinician Tablet, Clinician Programmer Therapy Application Software, Clinician Programmer Communicator, Patient Programmer
46031043|NCT03897998|Drug|Naloxone|"4mg of Naloxone will be administered (0.1 mL of 40 mg/ml naloxone solution given intranasally).~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
46031044|NCT03897998|Other|Saline|"Intranasal Normal Saline (0.1 mL 0.9% sodium chloride) will be administered shortly before beginning the fMRI experiment.~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
46031045|NCT03897595|Device|MPact Cup|Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
46031046|NCT03897530|Behavioral|Smoking Cessation Intervention|View and purchase hypothetical tobacco products during four distinctly different ETM
46031047|NCT03897530|Other|Functional Assessment|Visual attention is evaluated via eye-tracking equipment
46031048|NCT03897530|Other|Questionnaire Administration|Ancillary studies
45682624|NCT03766750|Drug|Tradjenta|1 coated tablet, oral, once a day.
45682625|NCT03766750|Drug|Forxiga|1 coated tablet, oral, once a day.
45682626|NCT03766672|Diagnostic Test|Intervention Arm|The intervention consists to the characterization of molecular mechanisms using to Next Generation Sequencing (NGS) technique.
45682627|NCT03577522|Device|Avenir cementless hip stem|Avenir cementless hip stem vs Corail HA-coated hip stem
45682628|NCT03577522|Device|Corail HA-coated hip stem|Avenir cementless hip stem vs Corail HA-coated hip stem
45682629|NCT03576742|Diagnostic Test|potential biomarkers|facs analysis, microbiome analysis
45682630|NCT03576586|Behavioral|Brief computerized intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department"
45682631|NCT03576586|Behavioral|Attention placebo control|Brief cognitive task plus usual care in the maternity department
45471953|NCT05210036|Device|High-Intensity Laser Therapy (HILT)|"All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~Hot Pack at 60 degrees Celsius for 20 minutes~TENS at 80 Hz for 20 minutes~Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
45471954|NCT01257815|Drug|Ranibizumab|
45471955|NCT04638920|Other|No intervention|No intervention
45471956|NCT03892421|Drug|Rituximab|Rituximab 375 mg/m²
46031049|NCT03896516|Other|Placebo|Participants will take GL WL-01 450 mg b.i.d or matched placebo for 16 days.
45471957|NCT03892421|Drug|Carboplatin|Carboplatin AUC5
45471958|NCT03892421|Drug|Cytarabine Injection|Cytarabine 2000 mg/m² qd 2 days
45471959|NCT03892421|Drug|Dexamethasone|Dexamethasone 40 mg
45471960|NCT03892421|Drug|Filgrastim 0.3 MG/ML|One subcutaneous injection daily for 5 days
45471961|NCT03892109|Other|No Cord impression material|the no cord self- retracting impression material placed directly in the tray
45471962|NCT03892109|Device|cord|Cords were placed in the gingival sulcus with use of a cord packer, and left in situ for 10 min before making the impression. None of the retraction cords were immersed in any solution or medicaments prior to insertion.
45471963|NCT03892109|Other|Gingitrac|packed into the sulcus
45471964|NCT01152281|Behavioral|Maximal Control|30 min video with stories of people with HIV. Content describes general health and emotional benefits of counseling.
45471965|NCT01152281|Behavioral|Instrumental and Empowering|Mix of Instrumental and empowering messages with stories of people living with HIV
45471966|NCT01152281|Behavioral|Minimal Control|Control messages to increase awareness of HIV risk
45471967|NCT01152281|Behavioral|Instrumental|Instrumental messages with stories of people living with HIV
45471968|NCT01152281|Behavioral|Empowering|Empowering messages with stories of people living with HIV
45682632|NCT04762810|Drug|Cyclophosphamide and glucocorticoids|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.
46031050|NCT03896516|Drug|GLWL-01|A within-subject, counterbalanced, double-blind, placebo-controlled study. Participants will take GLWL-01 450 mg b.i.d. or matched placebo for a minimum of 4 days (Stage I). After a wash-out window, Stage II will take place during which the counterbalanced study drug will be administered for a minimum of 4 days.
46031051|NCT03853707|Drug|Atezolizumab|Given IV
46031052|NCT03853707|Drug|Capecitabine|Given PO
46031053|NCT03853707|Drug|Carboplatin|Given IV
46031054|NCT03853707|Drug|Ipatasertib|Given PO
46031055|NCT03853707|Drug|Paclitaxel|Given IV
46031056|NCT03853707|Other|Quality-of-Life Assessment|Ancillary studies
46031057|NCT03853707|Other|Questionnaire Administration|Ancillary studies
46031058|NCT03836209|Drug|Gilteritinib|"Induction: 120 mg orally daily x 14 days starting on day 8~Consolidation: 120 mg orally daily x 14 days starting on day 8 of each cycle (up to 4 cycles)"
46031059|NCT03836209|Drug|Midostaurin|"Induction: 50 mg orally twice daily x 14 days beginning on day 8~Consolidation: 50 mg orally twice daily x 14 days beginning on day 8 of each cycle (up to 4 cycles)"
46031060|NCT03836209|Drug|Daunorubicin|"First Induction: Daunorubicin 90 mg/m²/day IV Days 1,2,3~Second Induction, if needed: Daunorubicin 45 mg/m²/day IV Days 1,2,3"
46031061|NCT03836209|Drug|Cytarabine|"Induction: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Second Induction, if needed: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Consolidation: Cytarabine 3 g/m² (recommend 1.5 g/m² for age ≥ 55 or patients with decreased creatinine clearance) every 12 hours IV Days 1,3,5 or Days 1-3 for 6 doses for up to 4 cycles"
46031062|NCT03834506|Biological|Pembrolizumab|IV infusion
46031063|NCT03834506|Drug|Docetaxel|IV infusion
46031064|NCT03834506|Drug|Prednisone|Oral tablets
46031065|NCT03834506|Drug|Placebo|IV infusion
46031066|NCT03834506|Drug|Dexamethasone|Oral tablets
46031067|NCT03824808|Drug|Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution|Lidocaine Hydrochloride and 5% Dextrose Injection, USP is a sterile, nonpyrogenic solution prepared from lidocaine hydrochloride and dextrose in water for injection.
46031068|NCT03824808|Drug|0.9% Sodium Chloride Injection|Sodium Chloride Injection USP is sterile, nonpyrogenic, isotonic and contains no bacteriostatic or antimicrobial agents.
45471969|NCT03895619|Other|Safer conception strategies|Individuals and couples adopt safer conception strategies including HIV-serostatus disclosure to partner, ART uptake and adherence and HIV-RNA suppression, STI testing and treatment, timing condomless sex to peak fertility, partner ARV use (ART if living with HIV, PrEP if HIV negative), and contraception until ready to conceive.
45471970|NCT05546567|Dietary Supplement|Nicotinamide Riboside|1200mg x1 Nicotinamide Riboside
46031069|NCT03822962|Drug|Ibuprofen 600Mg Tablet|ibuprofen 600 mg by mouth every 8 hours scheduled in addition to standard tylenol regimen.
46031070|NCT03822962|Other|"Standard Regimen | Tylenol"|Tylenol 1000 mg by mouth every 6 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed.
46031071|NCT03785405|Drug|sacubitril/valsartan|"Target dose 3.1 mg/kg bid~Formulations:~Tablets (50, 100, 200 mg) Granules [12.5 mg (4 granules), 31.25 mg (10 granules), in capsules] Liquid (1 mg/ml, 4 mg/ml, prepared from tablets)"
46031072|NCT03758950|Drug|Placebo|Once daily inhaled placebo for 48 weeks
45682633|NCT04762810|Drug|Glucocorticoids|Steroids have fast onset of action and multiple anti-inflammatory effects. Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.
46031073|NCT03758950|Drug|Mometasone|Inhaled Mometasone for 48 weeks (with 4-week washout at study completion)
45471971|NCT03895229|Drug|Empagliflozin 10 MG Oral Tablet [Jardiance]|Empagliflozin is a sodium-glucose co-transporter 2 inhibitor approved for treatment of type 2 diabetes mellitus
45682634|NCT03674242|Drug|eryaspase (L-asparaginase encapsulated in red blood cells)|IV infusion 100 U/kg
45682635|NCT03674242|Drug|Gemcitabine|IV infusion 1000 mg/m2
45682636|NCT03674242|Drug|Carboplatin|IV infusion AUC2
45682637|NCT04762654|Other|Modified Child Dental Anxiety Scale (MCDASf)|The MCDASf is self-reported dental anxiety measure effective among children aged 5-12 years.11 The scale has eight questions about 'going to the dentist generally,' 'having teeth examined,' 'teeth being scraped and polished,' 'injections in the gum,' 'fillings,' 'having a tooth taken out,' 'being put to sleep for treatment,' and 'having a mixture of gas and air that will help you feel comfortable for treatment but will not make you sleep.' The scores of each question ranged from 1 'relaxed' to 5 'very worried.' The scores are also represented by cartoon faces varied according to emotions and anxiety levels. The total scores can range from 8 to 40.
45682638|NCT04762108|Other|Standard of care|Patients will be given standard of care as per their clinical needs
45471972|NCT03892343|Diagnostic Test|Cardiac MRI|Cardiac Magnetic Resonance Imaging (Siemens Skyra 3T): will be performed using protocols and techniques already in use in our group. All CMR scan derived parameters will be analysed with the investigator blinded to treatment allocation as in previous studies.
45471973|NCT03895073|Other|healthy volunteers|the questionnaire has been assessed by both groups, healthy and heart failure
45471974|NCT01257893|Drug|Aspirin (acetylsalicylic acid)|Aspirin one 81 mg capsule per day for 10-14 consecutive days
45682639|NCT04761952|Drug|azathioprine|daily orally
45682640|NCT04761952|Drug|infliximab|intravenously, at 0, 2,6 weeks with every 8-week-interval later
45682641|NCT04761952|Drug|N-3 Polyunsaturated Fatty Acids|Ethyl polyenoate capsule is given as drug intervention. The main components are ethyl eicosapentaenoate (EPA-E) and ethyl docosahexaenoate (DHA-E), both of which will transform into ethyl eicosapentaenoate (EPA) and ethyl docosahexaenoate (DHA). Drug dose is 0.25 g EPA-E&DHA-E; per capsule one at a time, Three times a day.
46031074|NCT03751371|Device|Training with HWA device|Gait assessments will be conducted on participants randomized to the Trained group first during unassisted walking followed by HWA-assisted walking. Participants randomized to the Trained group will receive physical therapist supervised home and community-based walking training wearing the HWA device 2 times per week for 45-60 minutes for 8 weeks. Training will consist of walking in and outside of the home while encouraging larger and more symmetrical steps with practice of activities that challenge the person's balance and motor control. Rest breaks will be allowed as needed. If the therapist is unable to adjust the HWA to provide a safe gait pattern, the session will be ended and the device removed.
46031075|NCT03751371|Other|Usual Care|The Untrained group will continue their usual daily activities including any exercise regimen that they typically perform. However, they will be asked not to start any new exercise program during the study period.
46031076|NCT03749460|Biological|Nivolumab|Given IV
46031077|NCT03749460|Biological|Ipilimumab|Given IV
46031078|NCT03749460|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
46031079|NCT03738410|Behavioral|Mobile Health Messaging application|Mobile messaging sent to participants over a 12-month period.
45471975|NCT01257893|Drug|Placebo|1 placebo capsule identical in appearance and excipient to aspirin capsule per day for 10-14 consecutive days
46031080|NCT03738410|Other|Standard of Care Treatment|Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat HIV/AIDS. SOC associated procedures and policies may vary across clinical settings.
46031081|NCT03725007|Drug|Upadacitinib|Upadacitinib is administered as an oral solution or tablet as described in protocol.
46031082|NCT03712098|Drug|Liraglutide|Liraglutide 3.0 mg is an injectable medicine that may help some adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30) lose weight and keep the weight off. Liraglutide is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management when combined with a reduced-calorie meal plan and physical activity.
45754659|NCT00619255|Behavioral|Adolescent Trauma Support Program|The study team will be organized into an adolescent trauma support service. The adolescent trauma support service will fundamentally restructure psychosocial care by integrating post-injury medical treatment with alcohol and PTSD detection and treatment. The adolescent trauma support specialists will deliver a stepped collaborative care intervention to adolescents and their families over the 6-12 months post-injury.
46031083|NCT03712098|Drug|Placebo|The placebo is an inactive substance that is designed to look like liraglutide but contains no medication.
45471976|NCT03891797|Other|Cognitive Processing Therapy|Group-based psychotherapy.
45471977|NCT01152593|Drug|Mupirocin|Intranasal cream given to patient after confirmation of colonization
46031084|NCT03712098|Behavioral|Smoking Cessation Counseling|All participants receive manual-based counseling from a trained smoking cessation counselor. The counseling sessions are designed to enhance awareness of the harmful effects of smoking, assist the participant in developing skills to quit, and avoid relapse.
45839234|NCT03032796|Behavioral|Body Trainer|"A novel video game-based intervention that incorporates physiological measures such as heart rate into the core game mechanics, with motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks. The Body Trainer group will train using closed-loop adaptive algorithms to challenge physical performance as guided by heart rate, such that the amount of movement needed to respond on each task will dynamically change depending upon the participant being below/above a predetermined derived level of exertion. During Body Training, participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present"
46031085|NCT03711279|Drug|SHR-1210 plus Apatinib|SHR-1210 (200mg lyophilized powder in a single-dose vial for reconstitution) q3w+ Apatinib (250mg/375mg tablets) qd
46031086|NCT03711279|Drug|ADM plus IFO or IFO alone|ADM 60mg/m2 D1 + IFO 2mg/m2 D1-D4 q3w；if the cumulative doses of ADM is beyond 450mg/m2, the monotherapy of IFO (2mg/m2 D1-D5 q3w) will be used.
46031087|NCT03703297|Drug|Durvalumab|Durvalumab IV (intravenous infusion)
46031088|NCT03703297|Drug|Tremelimumab|Tremelimumab IV (intravenous infusion)
45471978|NCT01259219|Drug|Mycobutin|"Indication and Usage:~Mycobutin capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV Infection.~Dosage and Directions for use:~Mycobutin cab be administred as a single daily dose, independent of meals. In all cases Mycobutin is to be administred in combination regimens.~Identification:~Red-brown, self locking, hard gelatin capsule, size 0, containing a violet powder."
46031089|NCT03703297|Other|Placebo|Placebo IV (intravenous infusion)
46031090|NCT03684460|Device|Daytime Bright Light|Daytime Bright Light (DBL) will be delivered by a free-standing apparatus set to deliver 10,000 lux. The device will be placed at the bedside within 36 inches of the patient's head and is expected to provide at least 1,250 lux at the angle of gaze. To remain in the study, the patient must be in the Intensive Care Unit (ICU) through 13:00 on day 2 (e.g., the first day of potential intervention). After day 2, DBL and other study activities will continue if the patient is transferred out of the ICU to the general medical floor.
46031091|NCT03684460|Device|Usual Light|"Usual care lighting in ICU.~To remain in the study usual care patients must also remain in the MICU through 13:00 on day 2."
46031092|NCT03658538|Device|Active HEPA Air Cleaner|The active treatment arm will receive two active air cleaners with HEPA and carbon filters to support a home smoking ban and SHS reduction.
46031093|NCT03658538|Behavioral|Motivational interviewing|"The active treatment arm will receive 4 sessions of phone based motivational interviewing to support a home smoking ban and SHS reduction (in addition to the smoking cessation counseling received by all study participants).~The Control arm will receive only continued counseling for smoking cessation."
45682642|NCT03760432|Procedure|Laser Custom Corneal Collagen Cross-Linking|Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for smoothing the anterior corneal surface and removing any present opacities. The surgeon uses the OCT data to plan treatment parameters while preserving at least 360 microns of residual corneal stroma using a phototherapeutic keratectomy procedure. After the laser procedure, adjunctive MMC or saline solution will be applied to the cornea in accordance with the group to which the treated eye is randomized. The CXL procedure is then performed following the FDA-approved CXL regimen by Avedro, Inc.
45682643|NCT03673072|Drug|Gemcitabine|Gemcitabine (1000 mg/m2) in 250-500 ml 0.9% saline every three weeks on days 1 and 8 intravenously
45839235|NCT03032796|Behavioral|Brain Trainer|"The Brain Trainer group will train using the aforementioned closed-loop adaptive algorithms to challenge cognitive performance, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects). This group will train for 36 minutes per day, 3 days a week for 8 weeks."
46031094|NCT03658538|Device|Sham Air Cleaner|The Control arm will receive sham air cleaners
45754660|NCT03582410|Procedure|laparoscopic sacral colpopexy with absorbable suture|laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with absorbable suture
46031095|NCT03657368|Procedure|Low tidal Volume|Tidal volume = 6 ml/kg predicted body weight
46031096|NCT03657368|Procedure|High tidal Volume|Tidal volume = 10 ml/kg predicted body weight
46031097|NCT03657368|Procedure|Low PEEP|PEEP = 5 cm H2O
46031098|NCT03657368|Procedure|High PEEP|PEEP = 8 cm H2O
46031099|NCT03645590|Behavioral|Stroke Ready|Stroke Ready community intervention consists of peer facilitated educational workshops, stroke music video, and mass media campaign including print materials (e.g. posters, brochure), health promotion mailers, radio/Television public health service announcements, and the Stroke Ready website and Facebook page.
46031100|NCT03641456|Drug|bortezomib|The investigators gave patients subcutaneous bortezomib 1.3mg/m2 on days 1, 8,15, and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of bortezomib on days 1 and 15 at the dose level of 1.3mg/m2. Patients discontinued treatment if they had progressive disease or or unacceptable toxic effects not controlled with dose modifications.
46031101|NCT03641456|Drug|Lenalidomide|The investigators gave patients oral lenalidomide 25mg on days 1 to 21 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of lenalidomide on days 1 to 21 at the dose level of 10mg. Patients discontinued treatment if they had progressive disease or unacceptable toxic effects not controlled with dose modifications.
46031102|NCT03641456|Drug|Dexamethasone|The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.
46031103|NCT03639688|Procedure|Threading on the left lip commissure|Threading of the endotracheal tube over the fiberoptic bronchscope from the left lip commissure
46031104|NCT03639688|Procedure|Threading on the right lip commmissure|Threading of the endotracheal tube over the fiberoptic bronchoscope from the right lip commissure
45682644|NCT03673072|Drug|Cisplatin|Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously, in 1000 ml 0.9% saline with KCl 20 mmol and MgSO4 8 mmol during the one hour cisplatin infusion followed by 500 ml 0.9% saline over 30 minutes prior to gemcitabine; with adequate pre- and posthydration
46031105|NCT03636074|Procedure|Hypothermia during Extracorporeal Circulation|Normothermia during Extracorporeal Circulation
45682645|NCT03673072|Procedure|Oncologically radical margin-free (R0) resection|Oncologically radical margin-free (R0) resection
45682646|NCT03673072|Drug|Adjuvant chemotherapy|Can be selected by Investigator's Choice
46031106|NCT03582176|Drug|Lactose Placebo|One capsule by mouth twice per day
46031107|NCT03582176|Drug|Ketotifen Fumarate 2mg|2 mg tablets (over-encapsulated into one capsule) by mouth twice per day
46031108|NCT03582176|Drug|Ketotifen Fumarate 5mg|5 mg tablets (over-encapsulated into one capsule) by mouth twice per day
46031109|NCT03572660|Biological|Bone marrow derived mononuclear cells and G-CSF|Intra-coronary infusion
46031110|NCT03564626|Other|Health-IT +/- Scheduled Follow Up|"Training patient and caregiver on Patient Buddy and EncephalApp~Counseling regarding readmission~Daily contact through app~Standard of care counseling regarding readmission and discharge instructions~Follow up phone calls at Week 1 and Week 3~In-person follow up visits at Week 2 and Week 4"
45471979|NCT03891485|Biological|Immunological and tumour characterization|FFPE, blood samples (liquid biopsy, heparin and EDTA blood) performed in patients presenting a renal metastatic cancer receiving treatment as standard practice according to physician's choice (2nd or 3rd line of treatment with nivolumab, or other second line according to physician's choice)
45682647|NCT01677208|Drug|Danhong injection|A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
46031111|NCT03512197|Drug|Midostaurin|Midostaurin was provided as 25 mg capsules 8PC, was supplied as double-blind in blister packs and taken orally.
46031112|NCT03512197|Drug|Placebo|Placebo was provided as 25 mg soft gelatin capsules 8PC, was supplied as double-blind in blister packs and taken orally.
46031113|NCT03512197|Drug|Chemotherapy|Along with the study drug/placebo, chemotherapy was given as well: either Daunorubicin or Idarubicin and Cytarabine - all taken by i.v.
46031114|NCT03503097|Procedure|Biospecimen Collection|Provide saliva samples
46031115|NCT03503097|Other|Genetic Counseling|Undergo counseling
46031116|NCT03503097|Other|Genetic Testing|Undergo genetic testing
46031117|NCT03503097|Other|Laboratory Biomarker Analysis|Correlative studies
46031118|NCT03503097|Behavioral|Questionnaire|Complete questionnaire
46031119|NCT03493152|Drug|Everolimus|mTOR inhibitor
46031120|NCT03492671|Drug|Gemcitabine 1000 mg|Pre-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)
46031121|NCT03492671|Drug|nab-paclitaxel|Pre-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)
46031122|NCT03492671|Radiation|Stereotactic Body Radiation Therapy|Standard Stereotactic Body Radiation Therapy (SBRT) fractionation of 6 Gy per day will be used for all patients to a total dose of 30 Gy.
45839236|NCT03032796|Behavioral|Expectancy Matched Control|The placebo-matched control group will engage in a battery of three apps (playing each app 10 minutes per day, 5 days a week for 8 weeks completed in the laboratory that we believe will have no significant impact on the cognitive or physical fitness measures we are assessing: i) an app with 100 different logic games of varying difficulty and length, ii) a language-learning app with 10 language options, and iii) an app that offers a guided Tai Chi program. We have pre-determined that this approach generates matched expectancy compared to our training groups: we asked 100 naïve individuals to predict how they would expect to improve performance on our outcome measures after training on one of these platforms, revealing that placebo training generates equivalent expectations of improvement across each outcome measure as the BBT group.
46031123|NCT03489057|Behavioral|Prostate Cancer Education and Resources for Couples (PERC)|PERC uses mHealth technologies to dramatically increase couples' accessibility to posttreatment supportive care whenever and wherever they feel comfortable accessing it. PERC aims to improve QOL for both patients and partners by enhancing positive appraisals of illness and boosting self-efficacy, social support from multiple sources, and healthy behaviors for symptom self-management at home.
46031124|NCT03489057|Behavioral|usual care plus NCI website|The usual care plus NCI website provides generic information about prostate cancer treatment options, research, causes, and statistics; coping resources that are not prostate cancer-specific; support from non-providers via a toll free phone and LiveHelp Online Chat about cancer-related questions, clinical trials, and quitting smoking.
46031125|NCT03486301|Drug|BDB001|BDB001 is an immunotherapy agent.
46031126|NCT03486301|Drug|Pembrolizumab|Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
46031127|NCT03482245|Other|Blue Light|"Subjects that are to be exposed to blue light will be provided by the research personnel with a Day-Light Classic 10,000 lumen SAD light, a device that has been used in many of the previously listed published studies (Epilepsy Behav. 2012 Jul;24(3):359-64. doi: 10.1016/j.yebeh.2012.04.123. Epub 2012 May 30.) The light is small (4 X 16 X 21 inches) and weights less than a pound. It is UV filtered and glare free. There is a single On/Off switch. It will be attached to a rolling stand.~This light is fitted with a blue spectrum filter (peak 441 nm) such that it produces 1000 Lux of blue spectrum lighting when positioned at a distance of 12 inches from the subject."
46031128|NCT03446651|Drug|Lysine Chloride|Patients will receive 7 days of therapy using 115 mmol/day of lysine chloride. Patients will be given the option of a taste test of both lysine chloride & the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
46031129|NCT03446651|Other|Placebo|Patients will receive 7 days of therapy using placebo. Patients will be given the option of a taste test of both lysine chloride & the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
46031130|NCT03442322|Other|transdisciplinary approach|This approach is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability;
46031131|NCT03442322|Other|multidisciplinary approach|This is a problem-based approach that draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
46031132|NCT03439852|Behavioral|Light-to-Moderate Physical Activity / Sedentary Time|12 weeks of telephone counseling -motivational interviewing designed to increase leisure-time physical activity and decrease amount of sitting each day
46031133|NCT03401385|Drug|Datopotamab Deruxtecan (Dato-DXd)|A total anti-TROP2 antibody and MAAA-1181a
45471980|NCT03895151|Dietary Supplement|Milk supplementation|Fresh milk from local farmer. No artificial sweetener and preservatives. Brandless.
45682648|NCT01677208|Procedure|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
46031134|NCT03401385|Drug|Steroid Containing Mouthwash|A mouthwash containing a steroid ingredient administered in sub-study
46031135|NCT03401385|Other|Non-Steroid Containing Mouthwash|A mouthwash containing a non-steroid ingredient administered in sub-study
46031136|NCT03391479|Drug|Avelumab|Avelumab is a fully human monoclonal antibody (mAb) of the immunoglobulin (Ig) G1 isotype. Avelumab selectively binds to programmed death-ligand 1 (PD-L1) and competitively blocks its interaction with programmed death protein 1 (PD-1).
46031137|NCT03391479|Other|Best Supportive Care|As required.
46031138|NCT04218851|Drug|Posaconazole IV|Posaconazole (POS) 6 mg/kg body weight by IV infusion
46031139|NCT04218851|Drug|Posaconazole PFS|POS PFS 6 mg/kg body weight taken orally
46031140|NCT04218851|Drug|Posaconazole tablet|POS tablet 300 mg taken orally
46031141|NCT03387423|Drug|Tofacitinib|Patients who are started on Tofacitinib treatment according to the drug label
46031142|NCT03355300|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
46031143|NCT03350529|Device|MRI guided transurethral HIFU ablation of prostatic tissue|The technology is developed to ablate targeted benign and malignant prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.
46031144|NCT03345420|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
46031145|NCT03333031|Drug|HS-196|HS-196 will be administered intravenously as a single dose
45471981|NCT03895151|Other|Food Based Recommendation (FBR) nutrition education|Food Based Recommendation is result of OPTIFOOD WHO that analysed local food to optimize nutritional status according to problem nutrient.
45471982|NCT03891407|Diagnostic Test|Self-Testing Education and Promotion|Camp members will receive the Self-Testing Education and Promotion (STEP locally referred to as Mate Yako Afya Yako) intervention and will receive HIV-counseling and oral HIV self-testing kits.
45471983|NCT03895385|Drug|Bimekizumab|Subjects will receive a single dose bimekizumab at a predefined time point during the Treatment Period.
45471984|NCT03891719|Procedure|Unilateral cleft lip rhinoplasty|"Perform marking with methylene blue tattoo marks~Inject Local anesthetic solution with epinephrine~Harvest auricular cartilage~Make the incisions parallel the lip scar, extende into the marginal incision and encompass any alar webbing. The incisions outline the entirety of the lower lateral cartilage and create sliding chondrocutaneous flap. This flap combines with reverse U incision.~Harvest septal bony cartilaginous unit for grafting the caudal septum and suspend the medial crural cartilages~Create dome symmetry at the cartilage level and reconstruct nasal tip with other grafts (shield-type tip graft, cap graft, alar batten graft)~Dorsal augmentation~Lip reconstruction and alar base repositioning.~Closure and repair vestibular deficiency with the reverse-U component of the chondrocutaneous flap at the alar rim."
45471985|NCT01151501|Device|noninvasive positive pressure ventilation|Patients in whom the spontaneous breathing trial fail and in whom exclusion criteria are not present during this period were randomly allocated. Patients who are randomized to NPPV goup will be extubated and non-invasive ventilation (BiPAP Vision, Respironics Inc., Murrysville，Pennsylvania) will be delivered immediately after extubation using spontaneous/timed (S/T) mode. Expiratory positive airways pressure (PEEP) was initially set at 4 cmH2O and gradually increased to 6-8 cmH2O or more；and fraction of inspired oxygen (FiO2) was set to achieve pulse oximeter oxygen saturation (SpO2) >92% in cooperation with PEEP. On condition that tidal volume is no less than 6ml/kg，continuous positive airway pressure (CPAP) is permitted to apply，in which the adjusting procedures of CPAP and FiO2 is similar with PEEP and FiO2 in S/T mode. NPPV is terminated When patients can spontaneously breath oxygen provided by a Venturi device at FiO2≤0.35 for more than 24 hours with SpO2>92%.
45471986|NCT03891095|Drug|Oxytocin|intranasally administrated
45471987|NCT03891095|Drug|L-DOPA|orally administered
45471988|NCT03891095|Drug|Placebos|intranasally administrated and orally administered
45471989|NCT05667077|Drug|Amantadine|The amantadine group is treated with amantadine capsules 100mg twice a day for two weeks
46031146|NCT03332056|Drug|Belladonna and Opium|
45471990|NCT03891017|Other|vacuum casting|Participants will be cast using vacuum casting (Ottobock Harmony) method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
45682649|NCT01677208|Drug|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
45682650|NCT01690299|Drug|Apremilast|Apremilast 30 mg tablet orally BID
45682651|NCT01690299|Drug|Etanercept|Etanercept 50 mg evaluator/subject-blinded SC QW injection
45682652|NCT01690299|Drug|Placebo tablet|Placebo tablets BID
45682653|NCT01690299|Drug|Placebo injection|Once weekly evaluator/subject-blinded SC placebo (1 mL x 2 injections SC)
45682654|NCT03570814|Drug|Administration of Albendazole on Day 1|Participants will receive Albendazole 400mg on study day 1.
46031147|NCT03332056|Other|Placebo suppository|
46031148|NCT03331380|Device|MRI scan - obj 1|For objective 1 (protocol optimization), healthy volunteers undergo imaging using an investigational low SAR CMR scanner for up to two hours, some without and some with administration of intravenous gadolinium based contrast agents (GBCAs).
46031149|NCT03331380|Device|MRI scans - obj 2|For objective 2 (comparative scanning of normals), healthy volunteers undergo two CMR examinations on two different MRI scanners (investigational low SAR CMR and conventional 1.5T CMR), some without and some with administration of intravenous GBCA.
46031150|NCT03331380|Device|MRI scans - obj 3|For objective 3 (comparative scanning of patients), subjects with known stable cardiovascular disease undergo two CMR examinations on two different MRI scanners (investigational low SAR CMR and conventional 1.5T CMR), some without and some with administration of intravenous GBCA.
46031151|NCT03331380|Device|MRI scans - obj 4|For objective 4 (comparative scanning of patients), subjects with known or suspected disease, including neurological, musculoskeletal disease, abdominal or lung disease, will undergo two MR examinations on two different MRI scanners (investigational low SAR CMR and conventional MR).
45471991|NCT03891017|Other|hydrostatic casting|Participants will be cast using aqua casting method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
45471992|NCT03890939|Device|BiPAP AutoSV Advanced System One|A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
45471993|NCT03890939|Device|Dreamstation BiPaP AutoSV|A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
45471994|NCT03890939|Device|ResMed S7 VPAP Adapt Device|A mode of positive airway pressure used to treat sleep apnea. This device is widely used by physicians to treat sleep apnea and will be the active comparator to the two experimental devices.
46031152|NCT03255434|Drug|Oxaliplatin|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (85 mg/m² ) + simplified LV5FU2 Length of a cycle : 2 days Interval between 2 cycles : 2 weeks (D1=D15) Expected number of cycles: 12
46031153|NCT03255434|Drug|Oxaliplatin LBM|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (LBM) + simplified LV5FU2
46031154|NCT03243422|Other|Successful aging health education intervention|"The Successful Aging intervention will follow the protocol and materials developed for the 10 Keys™ to Healthy Aging program by the Center for Aging and Population Health Prevention Research Center at the University of Pittsburgh. This interactive, dynamic program informs older adults about risk factors for diseases. Participants will meet individually with a health educator certified to administer the program every 2-3 weeks for a total of 4 visits over approximately 8-10 weeks, and the session content will focus on a Key. Each session will also include a 5-10 minute active upper body extremity stretching program as used in the Lifestyle Interventions and Independence for Elders (LIFE) study. Participants will return for booster sessions semi-annually beginning at 6 months post-randomization."
46031155|NCT03243422|Other|Hearing intervention|The hearing intervention consists of fitting with hearing aids and other hearing assistive technologies plus four 1-hour comprehensive, individualized hearing rehabilitation sessions spaced over the 2-3 months post-randomization designed to provide all of the active components of the intervention. Hearing aids are instructed to be worn on a daily basis for study duration. Audiologic outcomes (e.g., hearing aid data logging, real ear measures, speech in noise, etc.) to verify the best-practices hearing intervention are gathered during study intervention visits and semi-annually beginning at 6 months post-randomization.
46031156|NCT03199040|Drug|Durvalumab|-Human monoclonal antibody
46031157|NCT03199040|Biological|Neoantigen DNA vaccine|-The vaccine will be given by the TDS-IM system
46031158|NCT03199040|Device|TDS-IM system (Inchor Medical Systems)|-At each vaccination time point, patients will receive two injections at separate sites.
45471995|NCT01589627|Device|Wrist Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
45471996|NCT01152671|Drug|Placebo|single oral dose
45471997|NCT01152671|Drug|RO5024048|single oral dose
46031159|NCT03199040|Procedure|Peripheral blood draw|-Baseline, following completion of standard of care therapy, Day 1, Day 57, Day 113, Day 159, and 1 year after initiation of neoantigen DNA vaccine therapy
45471998|NCT03894839|Other|glutaraldehyde disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
45471999|NCT03894839|Other|Chlorhexidine gluconate disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
45682655|NCT03570814|Drug|Administration of Ivermectin on Day 1|Participants will receive Ivermectin 150mcg/kg (max 12mg) on study day 1. Doses of Ivermectin will be determined using a standard dosing pole.
45472000|NCT03894839|Other|Sodium hypochlorite disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
45472001|NCT03894839|Other|glutaraldehyde disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
45472002|NCT03894839|Other|Chlorhexidine gluconate disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
45472003|NCT03894839|Other|Sodium hypochlorite disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
45682656|NCT03570814|Drug|Administration of Azithromycin on Day 1|Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 1. Doses of Azithromycin will be determined using a standard dosing pole.
45682657|NCT03570814|Drug|Administration of Azithromycin on Day 15|Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 15. Doses of Azithromycin will be determined using a standard dosing pole.
45682658|NCT00723736|Drug|Desloratadine|2.5 ml (1.25 mg) once daily
46031160|NCT03190954|Drug|[11C]raclopride plus placebo|Placebo (po) will be given 60 minutes prior to [11C]raclopride scan to measure baseline dopamine D2 receptors. MRI scan to follow end of PET scan. Subject blind as to drug administration.
46031161|NCT03190954|Drug|[11C]raclopride plus drug|Methylphenidate 60 mg. po will be given 60 minutes prior to [11C]raclopride scan to measure striatal dopamine release. MRI scan to follow end of PET scan. Subject blind as to drug administration.
46031162|NCT03190954|Drug|[11C]NNC-112|[11C]NNC-112 PET scan obtained without any drug intervention to measure dopamine D1 receptors. Blind N/A
46031163|NCT03178552|Drug|Alectinib|Participants will receive 600 mg BID (Cohort A); 900, 1200, or 750 mg BID (Cohort B) or RP2D BID; orally until disease progression, unacceptable toxicity, withdrawal of consent or death.
46031164|NCT03178552|Drug|Atezolizumab|Participants will receive atezolizumab 1200 mg IV infusion Q21D (Cohorts C and F) or 1680 mg IV infusion Q4W starting on Day 29 (Cohort E).
46031165|NCT03178552|Drug|Pemetrexed|Participants will receive pemetrexed 500 mg/m^2 IV infusion on Day 1 Q21D.
46031166|NCT03178552|Drug|Cisplatin|Participants will receive cisplatin 75 mg/m^2 IV on Day 1 Q21D.
46031167|NCT03178552|Drug|Carboplatin|Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D.
46031168|NCT03178552|Drug|Gemcitabine|Participants will receive gemcitabine 1000 or 1250 mg/m^2 on Days 1 and 8 of every cycle (1 Cycle=21 days).
45472004|NCT03894761|Other|Night Pain in Patients with Rotator Cuff Syndrome|The pain severity was evaluated using a 10 cm visual analogue scale , where 0 represented no pain, while 10 represented unbearable pain.At evaluation, the average of the pain during night for the last one week were inquired.
45472005|NCT01152749|Drug|Nicotine|Single-dose of new NRT product
45472006|NCT01152749|Drug|Nicotine Gum|Single-dose of marketed nicotine gum
46031169|NCT03178552|Drug|Entrectinib|Participants will receive entrectinib 600 mg orally QD.
46031170|NCT03178552|Drug|Cobimetinib|Participants will receive 60 mg PO QD on Days 1-21 of the initial run-in and triple-combination periods.
46031171|NCT03178552|Drug|Vemurafenib|Participants will receive 960 mg PO BID on Days 1-21 of the initial run-in period, and 720 mg PO BID on Days 22-28 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.
45472007|NCT03894683|Drug|Melatonin 10 mg|Melatonin tablets (10 mg)
45472008|NCT03894683|Drug|Placebo Oral Tablet|Placebo tablets manufactured the same as melatonin tablets
45472009|NCT01259453|Biological|Vaccination to prevent hepatitis B virus infection|Standard dosing with Twinrix; comparison of standard and acceleration dosing schedule
45472010|NCT01151657|Dietary Supplement|Probiotics|Capsules with probiotics containing the strains : Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12. Dose/capsule : 2 x 109 - 10 x 109 CFU.
45472011|NCT01151657|Dietary Supplement|Placebo|Placebo capsules containing maltodextrin
46031172|NCT03178552|Drug|Bevacizumab|Participants will receive 15 mg/kg of IV bevacizumab on Day 1 of each 21-day cycle during the induction and maintenance periods.
46031173|NCT03178552|Drug|GDC-6036|Participants will receive GDC-6036 PO QD until disease progression or unacceptable toxicity.
46031174|NCT03178552|Drug|Docetaxel|Participants will receive IV docetaxel Q3W (75 mg/m^2) until disease progression or unacceptable toxicity
46031175|NCT03173924|Drug|18F-NaF|Baseline IV followed by PET/CT IMAGING
46031176|NCT03173924|Drug|18F-DCFPyL|Baseline IV followed by PET/CT IMAGING. Additional 18F-DCFPyL PET/CTs might be performed during the subject s follow up period if, in the opinion of the referring clinician, there has been a considerable change in patient status (progression or response) based on clinical grounds/PSA value or to help assess changes of standard of care therapy.
46031177|NCT03173924|Drug|18F-FDG|Baseline IV followed by PET/CT IMAGING. Additional 18F-FDG PET/CTs may be obtained per PI discretion within a 21-day window relative to each 18F-DCFPyL PET/CTs.
45682659|NCT00305344|Procedure|Autologous Umbilical Cord Blood Transfusion|Cord Blood infusion
46031178|NCT03136393|Behavioral|Community based dietary counselling|The dietary counseling will be delivered to mothers through group sessions (will include cooking demonstration) and home visits by lay health workers. The counseling will promote foods that are nutritious and locally available and general better food preparation practices. The choices of the foods to be promoted will be based on linear programming results from a preceding survey on dietary intake of pregnant women in the area as well as results of analysis of foods associated with infant birth size (same data). The goal in the linear programming was to find a model of food combinations among the most frequently consumed foods which better meets required intakes during pregnancy. Additionally, adherence to pregnancy iron supplements will also be promoted.
46031179|NCT03136393|Behavioral|Community based antenatal counselling|The antenatal counselling will focus on preparations for neonatal care and encouragement for facility based delivery.
46031180|NCT03135275|Procedure|Staged complete PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 19-45 days to undergo PCI of all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
46031181|NCT03135275|Procedure|Immediate complete PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion, as well as all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
46031182|NCT03135275|Device|Synergy™ stent|Bioabsorbable Polymer Drug-Eluting Stent
46031183|NCT03121586|Drug|Pimavanserin|Pimavanserin 10 mg, tablet, taken as one 10 mg tablets, once daily by mouth, OR Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
46031184|NCT03115359|Behavioral|Mindfulness Meditation|"The Mindfulness Meditation intervention will teach participants the mindfulness meditation-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
45682660|NCT00305344|Biological|Cord blood|Develop Cord blood vaccine
46031185|NCT03115359|Behavioral|Cognitive Behavioral Therapy|"The Cognitive Behavioral Therapy (CBT) intervention will teach participants the CBT-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
45682661|NCT03569566|Other|Age, Genes, Training, Tickbourne Disease and Endurance|Testing of genes, exosomes, physiological variables, tick-bourne disease markers, observation of training modality and performance
46031186|NCT03093350|Biological|TAA-specific CTLs|"Each patient will receive 2 injections at a fixed dose, 28 days apart, according to the following dose schedule: The expected volume of infusion will be 1 to 10 cc.~Dose schedule:~Day 0: 2 x 10^7 cells/m2~Day 28: 2 x 10^7 cells/m2~If patients have stable disease or a partial response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at their 6 week evaluation after the 2nd cell dose, they will be eligible to receive up to 6 additional doses of CTLs, At least one month should have passed before each additional dose.. Each additional infusion will consist of the same cell number or less (if there is not enough product available for the subject's original dose) than their second infusion. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
45472012|NCT03894527|Behavioral|Single Bout of Exercise|An exercise condition, which will be walking at a moderate intensity (~70% VO2peak). Time will vary based upon individual fitness levels to burn ~400kcals (estimated 0.5 - 1hr). Oxygen consumption will be measured during exercise via a metabolic cart to confirm energy expenditure. Participants will then rest following the exercise procedure for 20 minutes. Between 20 and 45 minutes following exercise, oxygen consumption will be measured to understand and capture excess post-exercise oxygen consumption (EPOC). Following this, participants will be provided with a standardize dinner and snack to consume in the AMP lab.
45472013|NCT03894527|Behavioral|Control Condition|A control (no-exercise) condition. Participants will report to the AMP lab to rest for the same duration as the exercise bout and consume the standardized dinner and snack.
45472014|NCT03890783|Other|Evaluation of phonation quality|"Evaluation of phonation quality by :~Self-evaluation: completion of the Voice Handicap Index questionnaire, in its 30 items version~Hetero-evaluation: reading and recording of 2 texts, and notation by 3 practitioners using the grade, rough, breathy, asthenic, strained (GRBAS) scale, to evaluate the occurrence and the gravity of rhinolalia"
45472015|NCT03890783|Other|Evaluation of swallowing quality|"Evaluation of swallowing quality by:~Self-evaluation: completion of the Deglutition Handicap Index questionnaire~Hetero-evaluation: nasofibroscopy to evaluate the occurrence of aspiration and nasal regurgitation"
46031187|NCT03087903|Dietary Supplement|Grape Seed Extract|Patients will take 150 mg of Grape Seed Extract (GSE) product by mouth twice daily (in the form of 75 mg capsule of Leucoselect Phytosome preparation). Total oral dosage is 300 mg of GSE per day for one year. Patients will be evaluated every 6 weeks for 3 months, then every 3 months thereafter for up to one year. PSA measurements will be obtained at these scheduled visits.
46031188|NCT03074045|Drug|Levonorgestrel (Kyleena, BAY86-5028)|Low-dose LNG IUS with an initial in vitro release rate of 16 μg LNG/day, used continuously. The total LNG content in LCS16 is 19.5 mg. Administered intrauterine, for 12 months with an option for extended use for up to 5 years
46031189|NCT03074045|Drug|Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)|COC tablet containing 30 μg ethinyl estradiol and 3 mg drospirenone (taken on cycle days 1-21, inclusive, followed by a 7-day tablet-free week) for 12 months
45839237|NCT03032562|Diagnostic Test|Multimodal measurement of respiratory muscle function and strength|Sleep-studies, capnography, spiromanometry, phrenic nerve conduction studies, magnetic phrenic nerve stimulation, diaphragmatic ultrasound
45472016|NCT03890783|Other|global quality of life questionnaire|Completion of the European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ - C30) and the EORTC QLQ - H&N35 questionnaires
45839238|NCT03032718|Behavioral|Whole-body vibration training|Whole-body vibration exercise
45839239|NCT03032094|Procedure|connective tissue graft|palatal connective tissue graft to attain root coverage
45839240|NCT03031860|Other|Semiquantitative Cough Strength Score|Evaluate extubation outcome according to degree of evaluated Semiquantitative Cough Strength Score
46031190|NCT03035877|Behavioral|Multisystemic Therapy-Emerging Adults|MST-EA is a home- and community-based treatment for emerging adults (ages 17-21) that aims to address antisocial behavior and problems caused by substance use disorders. The model also addresses co-occurring mental health problems when present. Therapists work directly with the young adult and his/her social network. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
46031191|NCT03035877|Behavioral|Enhanced Treatment as Usual|With Enhanced Treatment as Usual (E-TAU), emerging adults will get the treatments that they usually receive when they have a substance use disorder and have been in trouble with the law. In addition, they will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
46031192|NCT03035604|Other|Comprehensive Geriatric Assessment|Undergo nutritional geriatric assessment
46031193|NCT03003052|Procedure|Dental implants|Data collection from pre-implant assessment, implant surgery, and hygiene recall appointments, to assess implant survival and success.
46031194|NCT03000439|Drug|In open-label phase: treatment with tofacitinib|Treatment with investigational drug
46031195|NCT03000439|Drug|In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio|Treatment with investigational drug or placebo
46031196|NCT02982564|Behavioral|Exercise Program Low Intensity|This arm includes a low-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
46031197|NCT02982564|Behavioral|Exercise Program Moderate Intensity|This arm includes a moderate-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
46031198|NCT02960022|Drug|enzalutamide|Subjects will receive enzalutamide orally once daily at the same time each day.
45682662|NCT01690143|Drug|Carfilzomib|Subjects will receive the appropriate dose of carfilzomib (according to assigned cohort in phase 1 and at the determined MTD in phase 2) on days -3 and -2. Carfilzomib will be infused over 30 minutes. Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
45472017|NCT01259531|Drug|Silodosin|Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
45682663|NCT01690143|Drug|Melphalan|Subjects will receive 200 mg/m2 of intravenous melphalan on Day -2. Administered as an intravenous push or a fast infusion according to institutional standard operating procedure (SOP). Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
45839241|NCT03031704|Procedure|Endoscopic mucosectomy|Performing adenoma resection through standardized endoscopic mucosectomy of duodenal adenoma.
45472018|NCT03894137|Dietary Supplement|Grains of Paradise (Aframomum Melegueta)|This is a randomized, double blind, crossover design testing the effect of grains of paradise on resting energy metabolism
45472019|NCT01586351|Device|Patch Augmentation and ACP injection|Patch augmentation and 4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
45472020|NCT03894371|Device|Thermage FLX|Thermage FLX system for the correction of mild to moderate laxity of the skin of the face, neck, and eyelids.
45472021|NCT01151735|Drug|C-1-esterase|1000 units of C-1-esterase inhibitor
45472022|NCT01151735|Drug|C-1-esterase|1500 units of C-1-esterase inhibitor
45472023|NCT01151735|Drug|placebo|placebo
45682664|NCT05347498|Drug|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd in Week 1 and 2, HR091506 tablets 80mg qd + placebo of febuxostat tablets 80mg qd in Week 3 and 4
45472024|NCT03890393|Device|Electromyography|Muscle activity was bilaterally tested with needle electromyography at rest status, targeting at myofascial trigger points (MTrPs) in the frontal, temporal, sternocleidomastoid (SCM), splenius capitis, splenius cervicis and trapezius of each subject.
45472025|NCT03061214|Drug|Semaglutide 0.5 mg|Up to 0.5 mg semaglutide injected subcutaneously (s.c., under the skin) once-weekly (OW) for 30 weeks
45472026|NCT03061214|Drug|Semaglutide 1.0 mg|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 30 weeks
45682665|NCT05347498|Drug|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd in Week 1 and 2, febuxostat tablets 80mg qd + placebo of HR091506 tablets 80mg qd in Week 3 and 4
45472027|NCT03061214|Drug|Sitagliptin placebo|Sitagliptin placebo tablets taken once-daily for 30 weeks
45472028|NCT03061214|Drug|Sitagliptin|100 mg sitagliptin tablets taken once-daily for 30 weeks
45472029|NCT03061214|Drug|Semaglutide placebo 0.5 mg|Semaglutide placebo (0.5 mg) injected subcutaneously once-weekly for 30 weeks
45472030|NCT03061214|Drug|Semaglutide placebo 1.0 mg|Semaglutide placebo (1.0 mg) injected subcutaneously once-weekly for 30 weeks
45472031|NCT01152827|Drug|RAD001|"RAD001 10 mg daily po medication.~Treatments will be continued until any of the following events occur~progression of disease~the subject develops unacceptable toxicity~consent to participate in the study is withdrawn"
45472032|NCT03890471|Behavioral|Preoperative telephone call three days before surgery|Patients will receive a provider-initiated telephone call three days before surgery. In order to standardize counseling across providers, each provider will use a telephone script addressing the following components: Purpose of the surgery, alternatives to the surgery, surgical benefits, surgical risk (such as infection, bleeding, injury to other organ systems), potential surgical complications (such as mesh erosion, voiding dysfunction, urinary retention requiring indwelling catheter), bowel complaints (such as nausea, vomiting, constipation, diarrhea), and postoperative expectations (such as Foley management, pain management, activity restrictions, and diet. The following ERAS-specific components will be incorporated into the counseling: management of chronic medical conditions, cessation of alcohol and tobacco, and daily exercise until surgery. Questions from patients and total counseling time will be recorded.
46031199|NCT02960022|Drug|abiraterone acetate|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
45472033|NCT03890549|Diagnostic Test|SnoreLab (smart phone application for snoring recording)|The investigators selected 3 appropriate downloadable smart phone applications for snoring recording and make validation with the golden standard of polysomnography.
45472034|NCT01259921|Behavioral|neurofeedback|Operant conditioning of the EEG provided by computer reinforcement.
45472035|NCT01153373|Behavioral|Self-administered computerized assessment for tobacco, substance abuse, and alcohol use.|"All patients that give consent to participate in the study (participants) who are randomly assigned to the control condition will complete the computerized DARSSA for assessment purposes only."
45472036|NCT01153373|Behavioral|Self-Administered Computerized Assessment and Counseling for Tobacco, Alcohol, and Substance Abuse|All participants randomized to the DARSSA Intervention will be given instructions for how to complete the assessment. Once completed, the treating emergency physician will be expected to (1) give substance using patients the Patient Feedback Report, (2) recommend they review it carefully, and (3) encourage them to consider following up with the referrals.
45682666|NCT05347420|Diagnostic Test|The visual Neuropad test and the quantitative Neuropad test|The visual screening test includes whether the Neuropad test paper changes completely from blue to pink within 10 minutes (visual screening test a) and the time to complete color change (visual screening test b). the quantitative screening test using a handheld color scanner to scan the rate of color change, which estimated by the slope of the Neuropad color change per minute.
46031200|NCT02960022|Drug|prednisone|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
45682667|NCT03669250|Drug|CVN058|3-way crossover
45682668|NCT03669250|Drug|Placebos|Placebo
45839242|NCT03031548|Device|Point-of-care ultrasound exam|No intervention
46031201|NCT02948543|Biological|Bacillus of Calmette-Guerin (BCG)|A strain of tubercle bacillus which modifies biologic response.
46031202|NCT02948543|Drug|Mitomycin (MM)|An antibiotic produced by a soil actinomycete which inhibits DNA synthesis.
46031203|NCT02925780|Device|Resin infiltration|"Teeth selected for this group will be treated with the resin infiltrant Icon according to the manufacturer's instructions. In short, teeth will be isolated with a rubber dam and the labial tooth surface cleaned with non-fluoride prophylactic paste and pumice. After an etching and drying step (to open the lesion surface), Icon will be applied following the manufacturer's instructions and subsequently light cured, followed by polishing.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
46031204|NCT02925780|Device|Microabrasion|"The labial surfaces of teeth selected for this group will be isolated and precleaned. Subsequently, the microabrasive material, Opalustre, will be applied according to the manufacturer's instructions, using a rubber cup at low speed (5 times each for 5 seconds). Between each of the applications the surface is washed by flushing water using a syringe.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
46031205|NCT02916472|Behavioral|CyberCycling|All exercise training will be performed under the supervision of a qualified exercise trainer certified in Advanced Cardiac Life Support. Participants in the exercise groups will be asked to perform aerobic exercise on a stationary bike ('cybercycle') 3 days per week for 12 weeks. Exercise intensity and duration will be based on a progressive program and adapted, as needed, based on the participants' tolerability. Heart rate will be monitored throughout the exercise session and Rating of Perceived Exertion (RPE) monitored at least every 10 minutes. The target heart rate (THR) zone will be determined using the Karvonen formula.
46031206|NCT02916472|Behavioral|Stretching|Participants randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks. The resistance band program will include upper body and lower body exercises. Participants will be provided with two different colored resistance bands (lighter colored - easier resistance; darker colored - harder resistance). Participants will start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all participants in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the participant by the exercise physiologist before the 12 week program begins.
45839243|NCT03031548|Radiation|Reposition ETT|ETT will be repositioned based on CXR by fluoroscopy
45839244|NCT03031314|Device|barbed suture|
45839245|NCT03031314|Device|standard suture|
46031207|NCT02916472|Behavioral|Resistance Bands|"Participants randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks.~The resistance band program will include upper body and lower body exercises and will be provided with two different colored resistance bands (one lighter colored for easier resistance; one darker colored for a harder resistance). Participants will start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all participants in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the participants by the exercise physiologist before the 12 week program begins."
46031208|NCT02901184|Drug|Spironolactone|Treatment with Spironolactone tablets on top of standard care
46031209|NCT02901184|Other|Standard care|Standard care does not involve Spironolactone
45839246|NCT03031158|Behavioral|SFEX+H|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
45839247|NCT03031158|Behavioral|SFEX|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
45682669|NCT03553732|Other|Registry|Patients who are diagnosed with prostate cancer and elect to be monitored by an Active Surveillance protocol by the Urology Clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group. The intervention is the implementation of a registry, designed to replace existing but suboptimal systems for tracking patients. All Active Surveillance patients monitored by the clinic will be included.
45839248|NCT03031470|Drug|Reparixin|Reparixin 168 hrs continuous infusion
46031210|NCT02901041|Drug|Zonisamide|ZONEGRAN® (zonisamide) is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. A dose of 400 mg daily will be used as the target maintenance dose in this study but dosing will be modified if needed to adjust for subject tolerance of drug dosing.
46031211|NCT02901041|Behavioral|Take Control|"Take Control is a seven module computer-based intervention which presents evidence-based alcohol education that includes motivational interviewing and cognitive-behavioral skills building. This program is derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA's) self-help approach, Rethinking Drinking.~Starting on March 23, 2020, participants will participate in a simplified Take Control treatment at home due to the COVID-19 pandemic"
46031212|NCT02901041|Drug|Placebo (for Zonisamide)|Sugar pills manufactured to mimic Zonisamide capsules.
46031213|NCT02840227|Procedure|General anesthesia with opioid analgesia|General anesthesia with routine drugs and intravenous patient controlled opioid analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs.
46031214|NCT02840227|Procedure|Combined general/epidural anesthesia|Combined general/epidural anesthesia and analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs. Epidural anesthesia will include bupivacaine and other local anesthetics.
45472037|NCT03889301|Behavioral|E-E Video|The E-E video was developed by the research team and chronicles the story of Ana who while enjoying coffee with two family members, shares her challenges with depression and her successful outcome with therapy. The video utilizes the genre of the telenovela which creates an entertaining environment where the audience is captivated by the content and absorbs the messages portrayed.
46031215|NCT02830594|Radiation|External Beam Radiation Therapy|Undergo palliative external beam radiation therapy
46031216|NCT02830594|Other|Laboratory Biomarker Analysis|Correlative studies
45472038|NCT03889301|Behavioral|Discussion|Structured psychoeducation and pamphlet about anxiety and depression.
45472039|NCT01259999|Dietary Supplement|Calogen extra strawberry|A daily dose of 3 x 30 ml Calogen extra strawberry flavour will be distributed at the same time as the medicines i.e. at 8.00, 12.00 and 20.00.
45472040|NCT05209958|Diagnostic Test|Neutrophil Lynphosite ratio|The patients were divided into 2 groups as NLR level above 2 (Group A) (n:32) and NLR level below 2 (Group B) (n:28).
45472041|NCT05209802|Other|Group A: High intensity exercise training|Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
45472042|NCT05209802|Other|Group B: moderate intensity exercise training|Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
46031217|NCT02830594|Biological|Pembrolizumab|Given IV
46031218|NCT02797964|Drug|SRA737|SRA737 will be administered orally on each day of a 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Subjects can continue taking SRA737 if they are receiving clinical benefit and able to safely take the drug and follow the requirements of the study.
46031219|NCT02717403|Behavioral|Questionnaires|Participants complete a self response electronic questionnaire at baseline, and at three and six months.
46031220|NCT02717403|Behavioral|Facebook|Participant accesses Facebook page regarding rheumatoid arthritis.
46031221|NCT02717403|Behavioral|Educational Website|Participant accesses Educational Website on the internet about rheumatoid arthritis.
45472043|NCT03889145|Drug|Telmisartan 80mg|Telmisartan 80mg
45472044|NCT03889145|Drug|Amlodipine10mg|Amlodipine 10mg
46031222|NCT02717403|Behavioral|Phone Interview|Research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
46031223|NCT02705508|Drug|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle.
46031224|NCT02705508|Drug|etoposide|100mg/m2，4h-intravenous infusion on day1-3 of each 21 day cycle.
46031225|NCT02705508|Drug|Pegaspargase|2500U/m2 im on day 1 of each 21 day cycle.
45682670|NCT03553186|Drug|Tranexamic Acid 100 MG/ML|TXA lavage solution (200 cc sterile normal saline + 5 g tranexamic acid 100mg/ml (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after instrumentation. Excess solution will be suctioned away using a non-cell saver suction.
46031226|NCT02705508|Radiation|involved-field radiotherapy|Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 50-56 Gy.
45682671|NCT03553186|Drug|Placebo|Placebo solution (200 cc sterile normal saline + placebo TXA ampule (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after pedicle screw instrumentation. Excess solution will be suctioned away using a non-cell saver suction.
45682672|NCT03551392|Device|Medx Console System|This intervention delivers near infrared (NIR) light using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
45754661|NCT03582410|Procedure|laparoscopic sacral colpopexy with non absorbable suture|laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with non absorbable suture
46031227|NCT02700841|Drug|Melphalan|Given IV
46031228|NCT02700841|Procedure|Peripheral Blood Stem Cell Transplantation--CD34 HSCT|Undergo autologous CD34 HSCT
46031229|NCT02700841|Procedure|Peripheral Blood Stem Cell Transplantation--AHSCT|Undergo AHSCT
46031230|NCT02700841|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo autologous CD34 HSCT
46031231|NCT02700841|Biological|Tetanus Toxoid Vaccine|Given IM
46031232|NCT02673398|Other|Comprehensive Geriatric Assessment|Ancillary studies
46031233|NCT02673398|Other|Laboratory Biomarker Analysis|Correlative studies
46031234|NCT02673398|Drug|Neratinib|Given PO
46031235|NCT02673398|Other|Pharmacological Study|Correlative studies
46031236|NCT02672917|Drug|MVT-5873|intravenous infusion (IV)
46031237|NCT02672917|Drug|modified FOLFIRINOX (mFOLFIRINOX)|IV
46031238|NCT02672917|Drug|gemcitabine + nab-paclitaxel|IV
46031239|NCT02636322|Drug|Cyclophosphamide|Given IV
45472045|NCT03889145|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg
45472046|NCT05209724|Behavioral|Provider supervision/ feedback|Provider supervision/ feedback provided before and after walking sessions
45682673|NCT03551392|Device|Sham Medx Console System|This intervention uses sham application of near infrared light (NIR) using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
45682674|NCT03551392|Device|Vielight 810 intranasal stand alone unit|Daily at home intranasal NIR stimulation sessions, 25 minutes in duration, 4 days each week.
45682675|NCT03551392|Device|Sham Vielight 810 intranasal stand alone unit|"Daily at home intranasal sham NIR stimulation sessions, 25 minutes in duration, 4 days each week."
45839249|NCT03031470|Other|Standard care procedures|Standard procedures for administration of Immunosuppressive and support post transplant therapies
45839250|NCT03031080|Device|Thermoplastic Hand Splint|Thermoplastic Night splint created and moulded to the individual patients hand in-house using generic thermoplastic.
46031240|NCT02636322|Drug|Doxorubicin Hydrochloride|Given IV
46031241|NCT02636322|Drug|Etoposide|Given IV
46031242|NCT02636322|Drug|Ibrutinib|Given PO
46031243|NCT02636322|Drug|Lenalidomide|Given PO
46031244|NCT02636322|Drug|Prednisone|Given PO
46031245|NCT02636322|Biological|Rituximab|Given IV
46031246|NCT02636322|Drug|Vincristine Sulfate|Given IV
46031247|NCT02547987|Drug|Docetaxel|Docetaxel 75 mg/m2 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
46031248|NCT02547987|Drug|Carboplatin|Carboplatin AUC 6 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
46031249|NCT02530489|Drug|Atezolizumab|Given IV
46031250|NCT02530489|Drug|Nab-paclitaxel|Given IV
46031251|NCT02523040|Drug|Lenalidomide|
46031252|NCT02513199|Radiation|SBRT|Radiation is to be delivered to 30-45 Gy in 5 fractions. 40 Gy in 5 fractions will be utilized, unless dose constraints preclude it. Treatment will optimally be delivered every other day with no more than 3 fractions per week. The ideal treatment team will be less than 15 total days.
46031253|NCT02513199|Drug|TACE|two sessions of standard TACE with ethiodol separated by a 4-week interval.
46031254|NCT02440672|Device|JOURNEY™ II CR Total Knee System (J II CR TKS)|TKA with Journey II CR Total Knee System
46031255|NCT02419495|Drug|Capecitabine|Given PO
45472047|NCT04299776|Device|CirQPOD|CirQPOD is connected between the wye piece on ventilator/anesthesia machine tubing and the patient's airway and generates negative intrathoracic pressure during the expiratory phase of ventilation which has been shown to improve blood flow.
45472048|NCT04299776|Device|Standard airway management|Standard airway management during surgery (PEEP of +5 cmH2O)
46031256|NCT02419495|Drug|Carboplatin|Given IV
46031257|NCT02419495|Drug|Cyclophosphamide|Given IV
46031258|NCT02419495|Drug|Doxorubicin|Given IV
46031259|NCT02419495|Drug|Eribulin|Given IV
46031260|NCT02419495|Drug|Fluorouracil|Given IV
46031261|NCT02419495|Biological|Ipilimumab|Given IV
46031262|NCT02419495|Drug|Irinotecan Hydrochloride|Given IV
46031263|NCT02419495|Drug|Leucovorin Calcium|Given IV
46031264|NCT02419495|Biological|Nivolumab|Given IV
46031265|NCT02419495|Drug|Olaparib|Given PO
46031266|NCT02419495|Drug|Oxaliplatin|Given IV
46031267|NCT02419495|Drug|Paclitaxel|Given IV
46031268|NCT02419495|Biological|Pembrolizumab|Given IV
46031269|NCT02419495|Drug|Pemetrexed|Given IV
46031270|NCT02419495|Drug|Selinexor|Given PO
46031271|NCT02419495|Drug|Topotecan|Given IV
46031272|NCT02396043|Drug|induction phase1|"Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8,22"
46031273|NCT02396043|Drug|induction phase2|Cyclophosphamide: 1000 mg/m2 iv on days 35, 59,Cytarabine: 75 mg/m2 iv on days 35-38, 42-45, 49-52, 56-59,Mercaptopurine: 60 mg/m2 po on days 35-59
46031274|NCT02396043|Drug|protocol M|Methotrexate: 5 g/m2 d 8, 22, 36, 50;Mercaptopurine:25 mg/m2 1-56
45839251|NCT03031002|Behavioral|Exposure treatment for spider fear|Two sessions (each session = 60 minutes) of in-vivo exposure treatment (including psychoeducation) with two different spiders. Exposures comprise a hierarchy of 7 steps, to be completed with both spiders.
46031275|NCT02396043|Drug|maintenance therapy|6-mercaptopurine , 50 mg/m 2 daily, and Methotrexate, 20 mg/m 2 once a week.The treatment lasted 2.0 years.Note that there were four additional doses of HD-MTX(5 g/m2 ) every 3 months during the maintenance phase
46031276|NCT02396043|Drug|reinduction phase1|"Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8"
46031277|NCT02396043|Drug|reinduction phase2|Cyclophosphamide: 1000 mg/m2 iv on days 29,Cytarabine: 75 mg/m2 iv on days 31-34, 38-41,Mercaptopurine: 60 mg/m2 po on days 29-42
46031278|NCT02396043|Drug|Intrathecal (IT)|methotrexate (15 mg/m 2 ), cytarabine (40 mg/m 2 ) and dexamethasone (4 mg).induction :d1, 15, 29, 45 ;Protocol M:d1, 15, 29, 43;Reinduction:d31,38
46031279|NCT02258919|Procedure|Decompressive craniectomy (DC) and best medical treatment|"Decompressive craniectomy:~All patients in the treatment group will receive DC of at least 12 cm according to institutional guidelines and a published surgical protocol.~Best medical treatment:~Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively."
46031280|NCT02258919|Procedure|Best medical treatment|Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively.
46031281|NCT02232191|Biological|Pneumovax-23|
46031282|NCT02203604|Biological|aldesleukin|Given IV
46031283|NCT02203604|Biological|ipilimumab|Given IV
46031284|NCT02203604|Other|laboratory biomarker analysis|Correlative studies
46031285|NCT02181413|Drug|Ixazomib Citrate|Ixazomib citrate capsules
46031286|NCT02181413|Drug|Placebo|Ixazomib citrate placebo-matching capsules
46031287|NCT02151981|Drug|Chemotherapy|Randomization to either Osimertinib or platinum-based doublet-chemotherapy on Day 1 of every 21d cycle in a 2:1 (Osimertinib:platinum-based doublet-chemotherapy) ratio
46031288|NCT02151981|Drug|Cross-over to Osimertinib|"Once subjects on the platinum-based doublet chemotherapy arm are determined to have objective radiological progression according to RECIST 1.1 by the investigator and confirmed by independent central imaging review, they will be given the opportunity to begin treatment with Osimertinib 80mg, once daily. These subjects may continue treatment with Osimertinib even after disease progression, as long as they are continuing to show clinical benefit, as judged by the investigator.~Subjects who stop platinum-based doublet chemotherapy for reasons other than objective disease progression according to RECIST 1.1 will not be eligible to cross-over to Osimertinib."
46031289|NCT02143752|Behavioral|Mindfulness|Group behavioral intervention using mindfulness to help smokers quit smoking
46031290|NCT02143752|Behavioral|Quit Line|see arm
46031291|NCT02141828|Drug|EPZ-5676|28-day continuous IV infusion of each 28-day cycle, given until disease progression or unacceptable toxicity develops.
45472049|NCT01153451|Other|Email Notification|BWH inpatient clinical information systems will automatically file all non-finalized chemistry, hematology, pathology, and radiology tests, as well as inpatient and ambulatory provider email addresses for all study patients discharged. This process will be initiated using a time stamp most proximate to actual discharge time. At midnight on every day, all tests filed at time of discharge will be updated if final results have become available. An email with all finalized and pending test results for each patient discharged will be sent to the inpatient and primary care provider at this time. For patients discharged with more than one pending test, subsequent email notification(s) will be sent out until all pending tests are finalized (no more than one email per day).
46031292|NCT02097134|Drug|Melphalan|Given IA
46031293|NCT02015871|Drug|Degarelix|
46031294|NCT02000050|Drug|FOLFOX4|FOLFOX4
46031295|NCT02000050|Radiation|Tomotherapy|Tomotherapy
46031296|NCT02000050|Procedure|TME (Total Mesorectal Excision)|TME (Total Mesorectal Excision)
46031297|NCT01812694|Behavioral|Enhanced standard care|Standard prenatal care plus education
46031298|NCT01812694|Behavioral|Intensive lifestyle intervention|Intervention to limit excess gestational weight gain
46031299|NCT01765491|Other|Split-dose polyethylene glycol|Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy
46031300|NCT01765491|Other|Morning-only polyethylene glycol|One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy
46031301|NCT01684150|Drug|EPZ-5676|MLL-r and MLL-PTD 28-day continuous IV infusion of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity develops.
46031302|NCT01525966|Drug|carboplatin|Given IV
46031303|NCT01525966|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
46031304|NCT01525966|Other|laboratory biomarker analysis|Correlative studies
46031305|NCT01273610|Drug|Lapatinib|250 mg tablets
46031306|NCT01273610|Drug|Trastuzumab|Intravenous injection
46031307|NCT01273610|Other|laboratory biomarker analysis|
46031308|NCT01273610|Other|pharmacological study|
46031309|NCT01231906|Drug|Cyclophosphamide|Given IV
45472050|NCT03889223|Procedure|Anatomical intervention with USG and comfort evaluation with NRS|The anatomical evaluation of the two neuraxial positioning techniques sonographically and comparison of comfort with the 7-point NRS
46031310|NCT01231906|Drug|Dexrazoxane|
46031311|NCT01231906|Drug|Doxorubicin Hydrochloride|Given IV
46031312|NCT01231906|Drug|Etoposide|Given IV
46031313|NCT01231906|Drug|Ifosfamide|Given IV
46031314|NCT01231906|Other|Laboratory Biomarker Analysis|Correlative studies
46031315|NCT01231906|Drug|Topotecan Hydrochloride|Given IV
46031316|NCT01231906|Drug|Vincristine Sulfate|Given IV
46031317|NCT01165762|Drug|Immune Tolerance|"Immune tolerance Kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and antithymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no rejection of the transplant kidney.~The IDE used in this study is the column used for hematopoietic cell sorting."
45472051|NCT03888677|Drug|5-FU, epirubicin and cyclophosphamide|Tailored dose escalation of epirubicin and cyclophosphamide.
45472052|NCT01153607|Drug|BAY1006578|Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
45472053|NCT01153607|Drug|BAY1006578|Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
46031318|NCT00999804|Drug|Lapatinib|1000 mg of Lapatinib by mouth daily
46031319|NCT00999804|Drug|Letrozole|Letrozole, 2.5 mg by mouth daily (for hormone receptor positive participants only)
46031320|NCT00999804|Drug|Trastuzumab|6 mg/kg intravenously, every 3 weeks
46031321|NCT00930111|Other|2-week rotation|Attending physician is assigned to a 2-week rotation.
45472054|NCT01153607|Drug|BAY1006578|Healthy volunteers for whole body imaging: Single intravenous bolus injection of 190 MBq BAY1006578, whole body PET for evaluation of effective dose, kinetics of BAY1006578 in blood
45472055|NCT04208126|Device|ECMO|ECMO implantation immediately after ICU admission
46031322|NCT00930111|Other|4-week rotation|Attending physician is assigned to a 4-week rotation.
46031323|NCT00911118|Radiation|Hypofractionated, image-guided, intensity-modulated external beam radiation|A standard dose escalation design is utilized, with the initial treatment assigned as 6.5 Gy/fraction for five fractions to a total dose of 32.5 Gy. For any given dose tier, an initial cohort of 30 patients will be treated. However to adjust for potentially inevaluable patients who dropout prior to a full toxicity collection to assess potential DLTs enrollment of up to five additional patients per cohort can occur, per PI's discretion. Dose escalation will proceed if < 10% of the 30 patients treated per tier exhibit any dose limiting toxicity (DLT) once the entire tier cohort has a minimum follow-up of 3 months and half the tier cohort has a minimum follow-up of 6 months. Dose escalation to the next tier will occur by increasing the dose per fraction by 0.5 Gy while keeping the fraction number constant at 5, leading to a total dose increase of 2.5 Gy per dose tier.
46031324|NCT00797888|Behavioral|telephonic|Between 4-8 phone calls each year for health behavior counseling to improve HbA1c
46031325|NCT00544830|Drug|Bicalutamide|Given PO
46031326|NCT00544830|Drug|Goserelin Acetate|Given SC
46031327|NCT00544830|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
46031328|NCT00544830|Other|Laboratory Biomarker Analysis|Correlative studies
46031329|NCT00544830|Drug|Leuprolide Acetate|Given via injection
46031330|NCT00487305|Biological|Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells|Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.
46031331|NCT00349869|Behavioral|yoga|8-week yoga program.
46031332|NCT00309933|Procedure|cognitive assessment|
46031333|NCT00309933|Procedure|psychosocial assessment and care|
46031334|NCT00309933|Procedure|quality-of-life assessment|
46031335|NCT00303914|Procedure|assessment of therapy complications|
46031336|NCT00303914|Procedure|cognitive assessment|
46031337|NCT00303914|Procedure|psychosocial assessment and care|
45682676|NCT03668938|Other|Occupational Therapy|The intervention in the hospitalization phase is mainly aimed at achieving the objectives related to the self-care area and, secondly, to the objectives in the areas of productivity and leisure time, identified in T0 and to the environmental assessment of the places of life of the patient; more an intervention in the patient's post-discharge home, mainly aimed at achieving the objectives related to social reintegration, the area of productivity and leisure time and, secondly, to possible objectives in the areas of self-care identified in T1.
45682677|NCT03668938|Other|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
45472056|NCT01260155|Drug|E5501|Treatment A: 40 mg new tablet formulation (1 tablet) under fasted conditions
45472057|NCT01260155|Drug|E5501|Treatment B: 20 mg old tablet formulation (2 tablets) under fasted conditions
46031338|NCT00130221|Drug|2% chlorhexidine gluconate impregnated cloth|
45472058|NCT01260155|Drug|E5501|Treatment C: 40 mg new tablet formulation administered with food
45754662|NCT05660408|Biological|RNA-LP vaccine|All subjects will receive two doses of RNA-LP vaccine every two weeks and then once monthly for 12 months afterward. Subjects on the phase 1 portion of the study will be assigned to receive either 0.01 mg/kg mRNA encapsulated in 0.15 mg/kg LPs (dose level -1), 0.02 mg/kg mRNA encapsulated in 0.3 mg/kg LPs (dose level 0), 0.04 mg mRNA encapsulated in 0.6 mg/kg LPs (dose level +1), 0.08 mg mRNA encapsulated in 1.2 mg/kg LPs (dose level +2) following a 3 + 3 design. All subjects on the Phase II portion will receive the maximum tolerated dose determined in the phase I portion of the study.
46031339|NCT00130221|Other|Daily bathing with Bar soap|bathed daily with bar soap (Dial Corp., Scottsdale, AZ), warm water, and cotton washcloths.
46031340|NCT00077129|Drug|carboplatin|
46031341|NCT00077129|Drug|paclitaxel|
46031342|NCT00052884|Biological|filgrastim|
46031343|NCT00052884|Drug|amifostine trihydrate|
46031344|NCT00052884|Drug|melphalan|
46031345|NCT00052884|Procedure|bone marrow ablation with stem cell support|
46031346|NCT00052884|Procedure|peripheral blood stem cell transplantation|
46031347|NCT00040807|Drug|docetaxel|
46031348|NCT00040807|Drug|irinotecan hydrochloride|
46031349|NCT00028678|Drug|dalteparin|
46031350|NCT00028678|Radiation|radiation therapy|
46031351|NCT00005095|Other|Ca-125|Subject's blood collected at their follow-up blood draw will be assessed for biomarkers that could lead to a panel for detecting early stage ovarian cancer.
46031352|NCT00005095|Other|screening questionnaire administration|Questionnaires designed to assess quality of life for women at increased risk of ovarian cancer will be administered to the subjects. Clinical data will also be collected.
46031353|NCT00005095|Procedure|Surgery|Subjects will be assessed for high risk factors.
46031354|NCT00004223|Drug|docetaxel|
46031355|NCT00004223|Drug|gemcitabine hydrochloride|
46031356|NCT00003764|Drug|cyclophosphamide|
46031357|NCT00003764|Drug|fludarabine phosphate|
46031358|NCT00003601|Drug|fenretinide|
46031359|NCT00003601|Drug|tretinoin|
45472059|NCT04655690|Drug|NNC0471-0119|Participants will be randomised to either of five dose levels 0.3, 0.6, 1.2, 2.4 or 3.6 of NNC0471-0119 nanomol per kilogram body weight, which will be administered as a single dose. NNC0471-0119 will be administered subcutaneously (s.c., under the skin) in fasting state.
45472060|NCT04655690|Drug|Fast-acting insulin aspart|Participants will get a fixed dose of 0.2 units of fast-acting insulin aspart (Fiasp®) per kilogram body weight, administered subcutaneously (s.c., under the skin) in fasting state.
46031360|NCT00003266|Drug|methylphenidate hydrochloride|
46031361|NCT00003266|Procedure|quality-of-life assessment|
46031362|NCT00003236|Biological|ISIS 3521|
46031363|NCT00003236|Drug|ISIS 5132|
46031364|NCT00003057|Drug|loperamide hydrochloride|
46031365|NCT00003057|Drug|octreotide acetate|
46031366|NCT00002922|Drug|paclitaxel|
46031367|NCT00002514|Biological|sargramostim|
46031368|NCT00002514|Drug|asparaginase|
46031369|NCT00002514|Drug|cyclophosphamide|
46031370|NCT00002514|Drug|cytarabine|
46031371|NCT00002514|Drug|daunorubicin hydrochloride|
46031372|NCT00002514|Drug|dexamethasone|
46031373|NCT00002514|Drug|etoposide|
46031374|NCT00002514|Drug|imatinib mesylate|
46031375|NCT00002514|Drug|leucovorin calcium|
46031376|NCT00002514|Drug|mercaptopurine|
46031377|NCT00002514|Drug|methotrexate|
46031378|NCT00002514|Drug|prednisone|
46031379|NCT00002514|Drug|thioguanine|
46031380|NCT00002514|Drug|vincristine sulfate|
46031381|NCT00002514|Procedure|allogeneic bone marrow transplantation|
46031382|NCT00002514|Procedure|autologous bone marrow transplantation|
46031383|NCT00002514|Procedure|peripheral blood stem cell transplantation|
46031384|NCT00002514|Radiation|radiation therapy|
46031385|NCT05448469|Procedure|ultrasound guided erector spinae plane block|patients will receive combined general anesthesia and ultrasound guided erector spinae plane block with 20 ml of bupivacaine 0.2 % at T9 level bilaterally.
46031386|NCT05448469|Procedure|ultrasound guided paravertebral block|patients will receive combined general anesthesia and ultrasound guided paravertebral block with 7 ml of bupivacaine 0.2 % at T8 and T10 bilaterally.
46031387|NCT05448469|Drug|conventional analgesia|patients will receive combined general anesthesia and conventional analgesia
46031388|NCT00607282|Drug|Udenafil|oral administration of Udenafil, prn(2hours before anticipated intercourse, 8 times/months)
46031389|NCT04288869|Other|Continuous monitoring of arterial blood pressure|For all patients, mean arterial pressure (unit mmHg) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation.
46031390|NCT04288869|Other|Transcranial Doppler|"Measurement of cerebral blood flow velocity (CFV) with use of Transcranial Doppler ultrasonography.~For all patients, CFV (unit cm/s) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation."
46031391|NCT04288869|Other|Bispectral Index (BIS)|"Continuous measurement of burst suppression (BS; %) with use of Bispectral Index (BIS).~For all patients, BS will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation"
46031392|NCT04288869|Other|Near-infrared spectroscopy|"Continuous measurement of cerebral oxygen saturation (SO2) with Near-infrared spectroscopy (NIRS).~For all patients, SO2 (%) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation."
46031393|NCT02674789|Behavioral|Exercise protocol|70% VO2max bike ergometer test for 90 minutes
46031394|NCT00609310|Dietary Supplement|Flavonoids|Nutritional Supplement: flavonoid mixture with 20 mg apigenin and 20 mg epigallocathechin gallate as tablets per day
46031395|NCT02674867|Other|Blood draw|
46031396|NCT04265248|Device|Virtual Reality Headset|The subjects will wear the Virtual Reality Headset with a mobile phone inserted into it with the applications Full Dive VR and VR Ocean Aquarium 3D.
46031397|NCT04265248|Behavioral|Exercise|The subjects will perform evidence-based exercises for the neck.
45472061|NCT03912545|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
46031398|NCT00643591|Other|imaging (dynamic PET-CT scan)|dynamic PET-CT scan
46031399|NCT05437705|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. The MagPro X100* magnetic stimulator and Cool-B65 Butterfly Coil are FDA-approved for rTMS treatments of depression.
46031400|NCT00927472|Drug|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
46031401|NCT00927472|Drug|Permethrin 1% rinse|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head lice are still present.
46031402|NCT00642655|Drug|IVIG and Rituximab|IVIG 2gm/kg given intravenously on day#0 and day#30 Rituximab 1gm given intravenously on day#7 and day#22
46031403|NCT00643747|Biological|tgAAG76 (rAAV 2/2.hRPE65p.hRPE65)|Single subretinal injection of vector suspension; up to 3x10e12 vector particles
46031404|NCT00642733|Drug|erlotinib [Tarceva]|100mg po daily
45472062|NCT04107662|Device|Tbit system|Suspected traumatic brain injury with head CT
45472063|NCT01251341|Behavioral|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
46031405|NCT00642733|Drug|gemcitabine|1000mg/m2 iv weekly for 8 weeks, then weekly for 3 weeks of each 4 week cycle
46031406|NCT02672371|Device|Active eMNS|Each session will consist of right eMNS stimulation that will last 20-minutes. The frequency of stimulation will be random assigned using random frequency interval. The electrodes that will be used will be standard transcutaneous electrodes. The electrodes will be placed on the wrist.
46031407|NCT02672371|Device|Sham eMNS|Each session of sham eMNS will be the same as active, except the device will be turned off. Similar parameters will be used (for 20 minutes and same electrode placement), except no stimulation will be delivered.
46031408|NCT00927394|Drug|Aliskiren|Aliskiren 150 mg tablet
46031409|NCT00927394|Drug|Valsartan|Valsartan 160 mg capsules
46031410|NCT00927394|Drug|Placebo for Aliskiren|Placebo for Aliskiren 150 mg tablets
46031411|NCT00927394|Drug|Placebo for Valsartan|Placebo for Valsartan 160 mg capsules
46031412|NCT04179253|Diagnostic Test|office micro hysteroscopy|One hundred women with unexplained infertility recruited for office micro hysteroscopic sessions. A rigid fiberoptic 2-mm, 0 and 30 degrees angled hysteroscopy along with an operative channel for grasping forceps or scissors were used for both diagnostic and operative indications. The findings, complications, and patient tolerance were recorded.
46031413|NCT05014126|Behavioral|Pain, Stress and Emotions|2-hour, zoom-delivered, group intervention focused on teaching patients how pain is processed in their brain and learning about the role of psychosocial factors in their pain conditions.
46031414|NCT00643825|Drug|Temozolomide|Capsules 5,10,20,100,250 mg 200mg/m2/day , 5days per 28 till PD
46031415|NCT00643825|Drug|Temozolomide|Observation till Progression then rechallenging with TMZ
46031416|NCT05345158|Procedure|Robotic Retroperitoneal Lymph Node Dissection (RPLND)|Robotic RPLND performed using the DaVinci robotic surgical system.
46031417|NCT04178863|Device|CATS Tonometer|latanoprost vs. timolol
46031418|NCT04178863|Drug|Latanoprost|latanoprost IOP reduction
45472064|NCT01251341|Behavioral|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
46031419|NCT05329636|Other|FMT|FMT through capsules- patients will evacuate the bowel with 1 liter of Meroken solution 12 hours prior to the procedure and will fast from food for 12 hours prior to the procedure. Patients will swallow 30 frozen capsules on two consecutive days.
46031420|NCT05329636|Other|Placebo capsules|Patients will evacuate the bowel with 1 liter of Meroken solution 12 hours prior to the procedure and will fast from food for 12 hours prior to the procedure. Patients will swallow 30 frozen placebo-capsules on two consecutive days.
46031421|NCT05329636|Other|FMT- enema|3.FMT through enema- patients will evacuate the bowel prior to the procedure and will fast for 3 hours prior to the procedure . Patients will receive 80 ml of enema. Enemas will be administered with the assistance of the study nurse. Patients will be asked to hold the enema content for at least 15 minutes.
46031422|NCT05635435|Other|Detection of Immune and Inflammatory Indices in Peripheral Blood|We detected immune and inflammatory indices in peripheral blood at each patient's at first hospitalizatin from October 13th, 2006, to April 6th, 2022.
46031423|NCT04264858|Drug|Immunoglobulin of cured patients|0.2g/kg, ivdrip, once a day, for 3 days
46031424|NCT04264858|Drug|γ-Globulin|0.2g/kg, ivdrip, once a day, for 3 days
46031425|NCT04178473|Procedure|total abdominal hysterectomy|total abdominal hysterectomy at time of sacrocolpopexy
46031426|NCT04178473|Procedure|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy at time of sacrocolpopexy
46031427|NCT05342350|Other|GALAD Score|GALAD score, a blood-based biomarker panel (gender, age, AFP, AFP-L3%, DCP)
46031428|NCT00976911|Drug|Bevacizumab|10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
46031429|NCT00976911|Drug|liposomal doxorubicin|40mg/m2 iv every 4 weeks
46031430|NCT00976911|Drug|paclitaxel|80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
46031431|NCT00976911|Drug|topotecan|4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
46031432|NCT04177927|Device|Capnostream 20p / Coviden|The special nasal canule is used for detection carbondioxide from breathe of patients
46031433|NCT04177927|Device|Rutine monitoring|peripheric Oxygen saturation is monitored.
46031434|NCT05336968|Drug|Triamcinolone acetonide-Ketorolac-Ropivacaine|Experimental for Osteoarthrosis of the Knee. One randomized injection to intraarticularly into affected knee at time of randomization
46031435|NCT04178161|Device|Laser treatment|Iontophoresis of methylene blue is used to identify the sweat glands. An image guided fractional erbium laser is used to specifically target these glands for ablation.
46031436|NCT02674555|Drug|radio-labeled naquotinib|Oral administration
46031437|NCT02674555|Drug|naquotinib|Oral administration
45682678|NCT03567850|Behavioral|Problem solving Skills Training|"Participants will be encouraged to identify specific problems particularly relevant to them and to their family's situation (instead of providing them with standardized examples) to be discussed and solved during the PSST sessions. The eight sessions of PSST will be organized in a systematized, therapeutic manner. Session 1 will be face-to-face and devoted to rapport building and understanding relevant social and medical information. The therapist (RA) will introduce PSST and the Bright IDEAS paradigm, present worksheets to guide PSST homework assignments, and give an overview of subsequent sessions. Starting at session 2, participants will continue training over the phone, with the same general structure and format. In sessions 2-7, the therapist and patient, with a supportive other (SO) if available, will review the patient's identified problems and work on application of problem-solving strategies and skills learned earlier."
45682679|NCT03668626|Other|Family-centered intervention program (FCIP)|This program included in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention emphasized modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention consisted of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education.
45682680|NCT01677364|Drug|Oxytocin|Arm - Induction of labour
46031438|NCT00934648|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
46031439|NCT00934648|Drug|methotrexate|10-25mg weekly
46031440|NCT00643903|Behavioral|Cognitive behavioral coping effectiveness training|Coping effectiveness training will include five individual 90-minute counseling sessions. The sessions will focus on coping with stress, dealing with medication side effects, and staying on track with medications.
46031441|NCT00643903|Behavioral|Standard care|Participants will receive standard of care for HIV infections.
46031442|NCT00643903|Behavioral|Single group workshop on coping effectiveness training|Participants will attend one group workshop covering the same material as in the individual sessions. The workshop will be delivered after completion of the Month 18 final assessment.
45472065|NCT01251341|Behavioral|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
46031443|NCT04178083|Diagnostic Test|medical examination|medical examination
45682681|NCT03567538|Procedure|Thoracic surgery|Thoracic surgery, pulmonary resection, minimally invasive thoracic surgery, video assisted thoracic surgery (VATS)
45682682|NCT03668002|Procedure|Arteriovenous Fistula (AVF)|If the participant is randomized to the AVF arm of the trial, the surgeon will connect an artery to a vein in the upper extremity, without using artificial material as conduit.
45682683|NCT03668002|Procedure|Arteriovenous Graft (AVG)|If the participant is randomized to the AVG arm of the trial, the surgeon will place a synthetic graft connecting an artery and vein under the skin in an upper extremity.
46031444|NCT01175213|Biological|SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)|"Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the SC route. Treatment occurred once every week. The dose was the weekly equivalent of the most recent IV dose (adjusted per body weight) and multiplied by 1.37."
46031445|NCT01175213|Biological|SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)|"Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route. Treatment occurred once every 3-4 weeks. The weekly dose equivalent was 100% of the most recent IV dose."
46031446|NCT01175213|Biological|IV treatment with IGSC, 10%|During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route.
45682684|NCT03667378|Behavioral|Expectations Survey (CanCORS)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
46031447|NCT02865837|Other|brachytherapy|"The brachytherapy applicator and a urinary catheter are set up in the operating room under general anesthesia.~Then, an MRI (or a scanner if contra-indication) is performed after a bladder filling with 120cc of normal saline solution and urinary catheter clamping.~Right after, a scanner is performed with urinary catheter declamping and emptied bladder.~Delineation of CTVs and organs at risk (bladder, rectum, sigmoid, small bowel), and dosimetric optimisation are made on study with filled bladder.~Then, organs at risk are delineated on the study with emptied bladder. The prior dosimetry is reset on this study and organs at risk doses are compared."
46031448|NCT00643981|Biological|MESENDO|"2 ml of the final cell mixture will be injected through the lumen of an intracoronary percutaneous balloon designed for angioplasty into the ishcemic vessel."
46031449|NCT04287699|Other|labor dance|The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing.
46031450|NCT00644449|Other|placebo|placebo
46031451|NCT00644449|Drug|azithromycin SR (Zithromax; compound: CP-62,993)|azithromycin 2.0 g by mouth in the form of a slurry for 1 dose
45754663|NCT03156140|Other|Motion|Volunteer has motion on right hand while with continuous pulse oximetry during three oxygenation plateaus
45754664|NCT00578617|Drug|Rate Control|Metoprolol 50-100mg
46031452|NCT00644449|Other|placebo|placebo
45754665|NCT00578617|Device|Ablation Therapy|
46031453|NCT00644449|Drug|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
46031454|NCT04287777|Drug|Mupirocin gel|Topical administration of Mupirocin gel 20 mg/g BID for 7 days
45754666|NCT00578617|Drug|Rate Control|Atenolol 50-100mg,
46031455|NCT04287777|Drug|Mupirocin ointment|Topical treatment of Mupirocin ointment 20 mg/g TID for 7 days
46031456|NCT04287777|Drug|Placebo|Topical administration of Placebo (ointment) TID during 7 days
46031457|NCT04180657|Genetic|Protein C deficiency|The effect of protein C deficiency on ghrelin levels are investigated.
45472066|NCT01260233|Other|Smoking cessation program|"Smoking cessation program includes:~brief smoking cessation counselling by preadmission nurse (less than 5 minutes)~smoking cessation brochures~referral to the Smokers' Helpline telephone advice line, run by the Canadian Cancer Society~free transdermal nicotine replacement therapy for 6 weeks Smokers of 10 cigarettes per day or more receive 4 weeks of nicoderm 21mg/day, 1 week of 14mg/day and 1 week of 7mg/day Smokers of less than 10 cigarettes per day receive 4 weeks of nicoderm 14mg/day and 2 weeks of 7mg/day"
45472067|NCT03888521|Behavioral|Resound Relief smartphone app|The intervention is a smartphone app which has been developed to include a wide range of sounds and techniques aimed at reducing the impact of tinnitus.
45682685|NCT03667378|Behavioral|Values Survey (Serious Illness Care Program)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
45472068|NCT05206058|Procedure|venipuncture|Plan to enroll 240 health people who are 20-35 years of age. People with received veinpuncture. Blood will be collected at time and drawn into Heparin-coated tube.
46031458|NCT05233371|Other|Parenting Stress Index (PSI)|"collected by self-questionnaire during the follow-up carried out within the framework of the usual care (at 4, 9, 24 months of corrected age, +/- 18 months according to the neurodevelopmental evolution).~Parental stress will be measured at each visit with the same parent (father or mother)."
46031459|NCT05233371|Other|Collection of health care consumption|"Type and number of health professionals consulted between the different visits scheduled as part of the usual follow-up of the Dijon Bourgogne University Hospital,~Frequency and duration of rehabilitation sessions by type of health professionals,~Follow-up methods (institutional or private),~Consumption of care will be evaluated by means of self-questionnaires given to parents during follow-up consultations as part of the usual care."
46031460|NCT05233371|Other|Assessment of parent satisfaction|"their level of information, their child's follow-up, and the support provided by the professionals.~Satisfaction will be evaluated by means of a self-questionnaire (Likert scale) given to parents during follow-up consultations as part of their usual care."
46031461|NCT02676583|Procedure|Tonsillectomy|Closure or not closure of tonsil fossa
46031462|NCT00642889|Drug|Safinamide|
46031463|NCT00642889|Drug|Safinamide|
46031464|NCT00642889|Drug|Placebo|
46031465|NCT00629655|Other|motor task, sensory stimulation|"motor task: finger tapping, simple type and complex type~sensory stimulation: electric or tactile stimulation"
45472069|NCT03888833|Device|ECMO|ECMO installation
45472070|NCT01251419|Other|Social Proximity and Conversion to Generic Medications|At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.
45472071|NCT03912623|Other|SPA Treatment with therapeutic education and physical activity|3 weeks SPA Treatment plus therapeutic education plus physical activity
45472072|NCT03912623|Other|Week end|access to the station for a week end after maintenance of usual treatment during 6 months
45682686|NCT03667378|Behavioral|Functional Assessment of Cancer Therapy-General (FACT-G)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
46031466|NCT03920163|Other|Enhanced Recovery Measures|Perioperative measures
45682687|NCT03667378|Behavioral|NCCN Distress Thermometer|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
45754667|NCT00578617|Drug|Rate control|Propranolol 40-80mg
45754668|NCT00578617|Drug|Rate control|Acebutolol 200mg
46031467|NCT00974259|Device|Management protocol based on pBrO2 and ICP values.|For patients who experience falls in pBrO2 below 20 mm Hg, a hierarchical treatment algorithm will be instituted, adapted from published recommendations49. In principle, episodes requiring therapy will fall into one of 4 scenarios (scenario A, B, C, and D, defined in figure 7), which will require different management strategies. The treatment protocol depends on which type of episode is being treated. Treatment is triggered by abnormalities in either ICP (> 20 mm Hg) or pBrO2 (< 20 mm Hg) are noted. Elevations in ICP above 20 mm Hg or decline in pBrO2 below 20 mm Hg for more than 5 minutes will trigger a treatment intervention. Treatment is directed to an episode. Patients may start in one type of episode and move to another. Therapy will depend on which type of episode they are in at any given time.
46031468|NCT00974259|Device|Management protocol based on ICP values only.|For the patients randomized to ICP treatment alone, only Scenario A and Scenario B episodes are relevant.
45754669|NCT00578617|Drug|Rate control|Carvedilol 6.25mg
46031469|NCT04177615|Procedure|Thromboectomy|Thromboectomy in Basilar Artery Occlusion patients
46031470|NCT00927082|Drug|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms/week sc for 24 or 48 weeks in original study (WV19432). No study treatment in long-term post-treatment follow-up study (MV22430)
46031471|NCT02672137|Behavioral|knowledge translation|knowledge translation that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
46031472|NCT02864511|Procedure|Nefertiti lift|
46031473|NCT04287933|Device|Drain insertion|insertion of a drain
46031474|NCT02674243|Drug|Iodopovidone solution|In this group, iodopovidone solution will be used as pleurodesis substance
46031475|NCT02674243|Drug|Talc|In this group, Talc will be used as pleurodesis substance
46031476|NCT04256200|Drug|Dienogest 2 MG Oral Tablet|Deinogest (Visanne) 2mg/day, orally for 24 weeks versus combined OCP (Yasmin, 0.03mg
46031477|NCT04256200|Drug|Yasmin|0.03mg Ethinyl Estradiol and 3mg Drospirenone daily for 24 weeks
46031478|NCT05294029|Other|standard of care for patients with neuromotor disability|clinical examination, radiological, biological and physiological examinations.
46031479|NCT04265014|Other|Goal-directed fluid treatment|Goal-directed fluid treatment for major abdominal surgery
45472073|NCT04435964|Drug|Immunotherapy|Patients treated as per clinical prescription with immunocheckpoint inhibitors (ICI) irrespective of treatment schedule, either as single agent or in combination with chemotherapy and/or radiotherapy
45472074|NCT03912779|Behavioral|C2Hear RLOs|Freely available online RLOs
46031480|NCT04265014|Other|Liberal Fluid Therapy|Liberal Fluid Therapy for major abdominal surgery
45472075|NCT03912779|Behavioral|Printed hearing aid booklet|Departmental printed hearing aid booklet (standard care)
45472076|NCT04040426|Other|Human split thickness skin allograft|Application of a fenestrated human skin graft
45472077|NCT04040426|Other|Additional Outer Dressing Applicaiton|Application of Moisture retentive dressing, and a multi-layer compression dressing
46031481|NCT02674009|Drug|Vismodegib|Participants with laBCC will receive a dosing of Vismodegib in accordance with local clinical practice and local labeling.
45472078|NCT04040426|Other|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
45472079|NCT04040426|Other|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
45472080|NCT01153919|Biological|romiplostim|Given subcutaneously
45472081|NCT01153919|Drug|ribavirin|Given orally
45472082|NCT01153919|Other|placebo|Given subcutaneously
45472083|NCT01153919|Biological|PEG-interferon alfa-2a|Given subcutaneously
45472084|NCT01153919|Other|laboratory biomarker analysis|Correlative studies
45472085|NCT03912701|Diagnostic Test|Vitalpac early warning score (VIEWS)|The Vitalpac early warning score (ViEWS) is an early warning system aimed primarily at prediction of the first 24-hour mortality in emergency patients and has not been used to assess intensive care unit discharge.
45472086|NCT04005638|Biological|blood sample|45 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
45472087|NCT04005638|Biological|urine sample|12 ml
46031482|NCT02676739|Drug|Adderall XR|
46031483|NCT00976677|Drug|erlotinib hydrochloride|Given PO
46031484|NCT00976677|Drug|paclitaxel|Given IV
46031485|NCT00976677|Drug|carboplatin|Given IV
46031486|NCT00976677|Biological|bevacizumab|Given IV
46031487|NCT05335408|Device|Acunex Vario intraocular lens|This is an extended depth of focus IOL, made by Teleon Surgical B.V.
46031488|NCT05335408|Device|Alcon AcrySof IQ Vivity intraocular lens|This is an extended depth of focus IOL, made by Alcon.
46031489|NCT04178941|Behavioral|Audit and Feedback|The audit and feedback intervention includes providing each hospital's own continuous pulse oximetry use data back to them on a weekly basis for review and action.
46031490|NCT04178941|Behavioral|Educational outreach|Educational outreach includes staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for continuous pulse oximetry use in bronchiolitis.
46031491|NCT05329480|Dietary Supplement|Creatine Monohydrate|Creatine Monohydrate powder, 4 separate 5g doses per day for 7 days.
46031492|NCT05329480|Dietary Supplement|Maltodextrin|Maltodextrin powder, 4 separate 5g doses per day for 7 days.
45472088|NCT01260389|Behavioral|pharmaceutical care intervention|Pharmaceutical care intervention, focused at improving inhalation technique and drug adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
46031493|NCT05332600|Other|drop-jump test|The participants will be submitted to a kinematic evaluation protocol before and after fatigue protocol and after two weeks they will be submitted again to the same protocol, however, they will be guided and trained on the correct execution of the tested movement.
45472089|NCT03888443|Device|"Bimanual 3D Motion Analysis  Be-API "|"Movements will be measured using an optoelectronic system (12 cameras) which captures the displacement of 26 markers placed on the upper limbs and trunk of the child, according to the standards of the International Society of Biomechanics.~The child is installed on a chair and table height (equipment adapted and approved for pediatrics). A game board is installed in front of the child, with objects to handle, set and placed according to its anthropometry (joystick, steering wheel, buzzer, board, chip)."
45472090|NCT03941444|Drug|ANAVEX2-73|Liquid oral solution
46031494|NCT04179331|Other|Neurotensin|Neurotensin is an endogenous peptide released from the distal small intestine. It will be administered at three doses (2.5, 5.0 and 7.5pmol/kg/min), each for 1h, in sequence.
45682688|NCT03667378|Behavioral|Hospital Anxiety and Depression Scale (HADS)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
45472091|NCT03941444|Drug|Placebo|Liquid oral solution
45472092|NCT03912389|Biological|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
45472093|NCT03912389|Drug|Pemetrexed|IV infusion
45472094|NCT03912389|Drug|Cisplatin (or carboplatin)|IV infusion
45472095|NCT03912389|Other|Placebo|IV infusion
45472096|NCT05703464|Drug|Elobixibat 10mg|Patients of chronic constipation with loss of defecation desire are administered Elobixibat 10mg for 4 weeks
45472097|NCT03934658|Device|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
45754670|NCT00578617|Drug|Rate Control|Diltiazem 180-240mg
45754671|NCT00578617|Drug|Rate Control|Verapamil 180-240mg
46031495|NCT04179331|Other|Saline|Isotonic saline will serve as a placebo.
46031496|NCT02676271|Procedure|Proximal varus derotational osteotomy|The purpose of surgery was to relocate the protruded, deformed femoral head from its lateral position back to the acetabulum to achieve containment. Surgery was preceded by a hip arthrography with dynamic examination to find the suitable containment position and plan the correct osteotomy angles accordingly. A sub trochanteric osteotomy was performed then after in an open or closed wedge form, with fixation in an angle that gave best coverage.
46031497|NCT02864277|Procedure|No Intervention Conventional Strategy|"The Conventional Strategy Group description encompasses over 4 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters.~Preoperative Management Interoperative Management Postoperative Management Post discharge"
46031498|NCT02864277|Procedure|ERAS|"The ERAS Group description encompasses over 3 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters.~Preoperative Management Interoperative Management Postoperative Management Post discharge"
45472098|NCT03934658|Device|NightWare Therapeutic System in Sham Mode|A wearable digital therapeutic system that will measure physiologic data when worn during sleep that does not deliver interventions.
46031499|NCT02674165|Behavioral|HART|Skills based sexual education intervention plus PTSD awareness
46031500|NCT04288167|Diagnostic Test|Sample collection|Samples of urine and saliva will be collected from participants using customary sample collection means.
45472099|NCT01147757|Drug|remifentanil|During surgery, 3 different dose of remifentanil or placebo was infused.
45472100|NCT01251497|Behavioral|diabetes self-management education|
45472101|NCT01153997|Drug|catridecacog|Single rFXIII dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
45472102|NCT01153997|Drug|placebo|Single rFXIII placebo dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
46031501|NCT00642967|Drug|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 mcg will be determined based on the previous dose of epoetin or darbepoetin received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
46031502|NCT00926536|Device|C-arm CT + DSA as needed|C-arm CT images obtained and supplemented with DSA if needed
45682689|NCT03667378|Behavioral|Quality of Communication (QOC)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
45682690|NCT03667378|Behavioral|visits with a supportive care clinician|Monthly visits with a supportive care clinician
45682691|NCT03549520|Drug|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg.
45682692|NCT03566524|Dietary Supplement|Citrulline|Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
45682693|NCT03566524|Dietary Supplement|Alanine|Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
45754672|NCT00578617|Drug|Rate Control|Digoxin 0.125mg
45754673|NCT00578617|Drug|Rhythm Control|Propafenone 450mg
45754674|NCT00578617|Drug|Rhythm control|Flecainide 200mg
45754675|NCT00578617|Drug|Rhythm control|Sotalol 240mg
45754676|NCT00578617|Drug|Rhythm control|Dofetilide 500mcg
46031503|NCT00926536|Device|DSA only|DSA imaging only
46031504|NCT02864043|Device|NvisionVLE with Real Time Targeting|Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe
46031505|NCT02864043|Procedure|esophagogastroduodenoscopy (EGD)|Standard of care EGD
46031506|NCT04287231|Device|Transcranial direct current stimulation|This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
45682694|NCT03563248|Drug|FOLFIRINOX|"FOLFIRINOX is a combination of 4 chemotherapy agents that may help shrink your tumor before surgery~5-Fluorouracil (5-FU) - 400 mg/m2 on day one, followed by 1200 mg/m2 by continuous infusion for the subsequent 46-48 hours~Oxaliplatin - 85 mg/m2 by intravenous infusion over 120 minutes on day 1 of each 14 day cycle~Irinotecan - administered at a starting dose of 180 mg/m2 by intravenous infusion over 90 minutes on day 1 of each 14 day cycle~Leucovorin - Administered at a starting dose of 400 mg/m2 over 2 hours on day 1 of each 14 day cycle"
45682695|NCT03563248|Drug|Losartan|Losartan is a drug that is used to lower blood pressure
46031507|NCT00607360|Behavioral|Therapeutic Workplace Intervention|Therapeutic workplace intervention is intended for individuals with drug addiction and chronic unemployment. Participants are invited to participate in work and receive salary for participation and productivity contingent upon drug abstinence.
45682696|NCT03563248|Drug|Nivolumab|Nivolumab is an antibody that may cause programmed cell death of cancer cells
45754677|NCT00578617|Drug|Rhythm control|Amiodarone 200mg
46031508|NCT02865993|Other|betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
46031509|NCT02865993|Other|no betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
46031510|NCT02865759|Behavioral|Mindfetalness|The pregnant woman is motivated to practice Mindfetalness verbally, by a brochure and at a website.
45682697|NCT03563248|Radiation|SBRT|Radiation therapy is believed to increase the likelihood of response of immunotherapy
45682698|NCT03563248|Procedure|Surgery|definitive surgical resection
45682699|NCT03663400|Diagnostic Test|GWAS analysis by Illumina BeadChip|will generate comprehensive genotype data for patients. Samples will be used for transcriptional profiling, microbiota profiling by 16S analysis and immunological profiling by flow cytometry
46031511|NCT00923260|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass was performed according to the following standards: Gastric pouch was constructed using the lesser curvature of the stomach. A 45mm stapler was initially fired horizontally 2 to 3 cm below the gastroesophageal junction and then 2 o 3 additional fires towards the angle of His and against a 32 French intragastric tube completed the vertical transection. Lengths of the biliopancreatic and alimentary limbs were approximately 50, and 150 cm respectively. An antecolic and antegastric gastrojejunostomy, 1.0 to 1.5 cm in size was hand sewn and the jejuno-jejunostomy was completed in a latero-lateral fashion using one fire of 45 mm lineal stapler with hand sewn closure of the common enterotomy.
46031512|NCT00923260|Procedure|Omentectomy|After laparoscopic gastric bypass, the greater omentum was divided in the middle from the free edge to the colonic margin using ultrasonic energy. Attachments between the omentum and the transverse colon were dissected. The omentum was detached from the stomach transecting the vessels between the right gastroepiploic vessels and the greater curvature of the stomach. Once the omentum was freed from the stomach, the duodenum and the lower pole of the spleen, it was extracted from the abdominal cavity in a sterile plastic bag.
45754678|NCT00578617|Drug|Rhythm control|Quinidine 600-900mg
46031513|NCT04180735|Procedure|Liver transplantation|Liver transplantation
46031514|NCT04256278|Other|Spermotrend|oral administration of antioxidants for three months
46031515|NCT04287543|Drug|Melatonin|25 mg of melatonin gel at noon and 25 mg of melatonin gel 30 minutes before sleeping for 12 months
46031516|NCT04287543|Drug|Placebos|25 mg of placebo gel at noon and 25 mg of placebo gel 30 minutes before sleeping for 12 months
45472103|NCT01153997|Drug|catridecacog|Single rFXIII dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
45754679|NCT00505895|Drug|Melphalan|Arm 1 = 140 mg/m^2 intravenous over 20 Minutes on Day -1; Arm 2 = 100 mg/m^2 intravenous over 20 Minutes on Day -1.
45472104|NCT01153997|Drug|placebo|Single rFXIII placebo dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
45754680|NCT00505895|Drug|Fludarabine|30 mg/m^2 intravenous daily over 30 Minutes for 4 Days (Beginning Day -4).
46031517|NCT04100395|Device|sonoclot|Sonoclot Analyzer is best described as a microviscometer. The electronics are sensitive to any resistance to motion that the oscillating probe encounters as it moves within the test sample.
46031518|NCT02676505|Behavioral|Coached pushing group|It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds.
46031519|NCT02676505|Behavioral|uncoached pushing group|It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth. .
46031520|NCT04287387|Drug|Glucophage 500Mg Tablet|0.5g three times daily
46031521|NCT04287387|Drug|Acarbose Tablets|50mg three times daily
46031522|NCT04287387|Drug|Sitagliptin tablet|100mg once daily
46031523|NCT04287387|Drug|Dapagliflozin Tablet|10mg once daily
46031524|NCT04287387|Drug|Pioglitazone Tablets|30mg once daily
46031525|NCT04287387|Drug|Glimepiride Tablets|2mg once daily
46031526|NCT00644527|Other|Purpose designed music and sound listening program|Listening to one of two different specific music programs (Group A and B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
46031527|NCT00644527|Other|Sham music for depression|Listening 30 min in the morning and 30 min in the evening to selection of Mozart compositions over 5 weeks.
46031528|NCT04287153|Device|Cryotherapy on abdomen and saddlebags|Application of variable temperature (-10°c to -7°c) on the treated areas using the cryotherapy device FG660L-006 (Beijing ADSS Development CO., Ltd)
46031529|NCT00644605|Drug|sildenafil|sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
45472105|NCT03619928|Device|Dry needling|20 minutes through a sterile, disposable Dong Bang® needle size of 0.25X30 mm. At the moment of insertion of the needle, the therapist will perform a muscular shortening around the application site, in a pincer movement performed by the index and thumb fingers, in order to isolate the muscle fibers of the biceps brachii. Five needles will be applied to the short head brachii biceps in five points: origin, insertion, center of the muscular womb (60% of the distance from the medial acromion to the cubital fossa in the elbow line) and two points equidistant from the center 2 cm.
45682700|NCT03662776|Behavioral|BASC-3 survey|A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.
46031530|NCT00644605|Drug|sildenafil|sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
46031531|NCT00644605|Drug|placebo|placebo by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
46031532|NCT00644605|Drug|sildenafil|sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
45682701|NCT03662776|Behavioral|PROMIS survey|A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.
45682702|NCT04403776|Drug|tofacitinib MR 11 mg|Single oral dose of tofacitinib MR 11 mg, administered as 1 x MR 11 mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.
45682703|NCT04403776|Drug|tofacitinib IR 5 mg|Two separate oral doses (12 hours apart) of tofacitinib IR 5 mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7.
45682704|NCT03662074|Drug|Gemcitabine|Given IV
45682705|NCT03662074|Biological|Nivolumab|Given IV
46031533|NCT02865681|Drug|Menopur|Nasal versus injectable
46031534|NCT02865681|Drug|Synarel|nasal
46031535|NCT02865681|Drug|HCG trigger|injectable
46031536|NCT02865681|Drug|Clomiphene citrate|oral
46031537|NCT02865681|Drug|Letrozole|Oral
46031538|NCT04287309|Other|CAR-T cells|CD19 targeted CAR-T treatment
46031539|NCT00644137|Drug|pregabalin|Help stop smoking
46031540|NCT00644137|Other|cigarettes|help stop smoking with study medication
46031541|NCT04286997|Device|GRAIL population|each subjects included in the intervention group will receive 20 GRAIL sessions, aimed to the walking pattern improvement, associated with 20 traditional physiotherapy sessions, aimed to the stabilization of the trained competences
46031542|NCT02672059|Other|Observation|No intervention
46031543|NCT04256356|Dietary Supplement|Feeding infants with formula milk with fermented matrix at dosage of 4.6 g per 100g of powder|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
46031544|NCT04256356|Dietary Supplement|Feeding infants with formula milk with fermented matrix at dosage of 6.9 g per 100g of powder|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
46031545|NCT04256356|Other|Feeding infants with standard formula milk|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
46031546|NCT04256356|Other|Breastfeeding infants|reference group
45472106|NCT03619928|Device|Massotherapy|A 20-minute massage will be applied to the non-dominant upper limb exercised by a therapist for the massage condition. The massage will consist of: 1) surface slip; 2) deep slip; 3) kneading; 4) friction with the thumbs; 5) friction with four fingers; 6) percussions with open and alternating hands; 7) percussions with open and simultaneous hands; 8) tapping; and 9) surface slip.
45472107|NCT01147835|Dietary Supplement|Chinese Licorice Root|Chinese Licorice Root lollipops are given to the subjects in the study group to ingest twice daily for 10 days. Then the subjects must wait 3 months, and then again ingest the lollipops twice daily for 10 days.
45754681|NCT00505895|Procedure|Stem Cell Infusion|Stem Cell Infusion on Day 0.
45839252|NCT03030768|Drug|PrEP|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
46031547|NCT02864121|Other|all patients included in IDAHO study|
45754682|NCT00505895|Drug|Rituximab|375 mg/m^2 intravenous on Day -5, +2 +9 and +16.
45754683|NCT03582332|Drug|Indomethacin SR, 75 Mg Oral Capsule, Extended Release|Indomethacin SR, 75 Mg Oral Capsule, Extended Release orally twice daily
45754684|NCT03582332|Drug|Indomethacin 25 Mg Oral Capsule|Indomethacin 25 Mg Oral Capsule, 2 capsule orally twice daily
45754685|NCT03582332|Drug|Etoricoxib 90 mg|Etoricoxib 90 mg once daily orally
45754686|NCT03582332|Drug|Etoricoxib 60 mg|Etoricoxib 60 mg once daily orally
45839253|NCT03030768|Behavioral|Counseling on timed condomless sex, ART and PrEP adherence|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex
46031548|NCT04177537|Device|Low Intensity Continuous Ultrasound|3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device provided by Zetroz Systems LLC
45839254|NCT03030846|Other|Stabilization exercise|18 sessions during 6 consecutive weeks, three times per week, 30 or 40 minutes per session including: Twenty minutes for receiving hot pack and TENS and 10 or 20 minutes for training the exercises in 7 level : 1.Train the specific contraction of the deep abdominal muscles, multifidus and pelvic floor muscles(PFM). 2.Train the specific contraction of deep abdominal muscles with coactivation of multifidus and PFM in supine, prone, sitting, standing and quadruped position. 3. Segmental control exercises in close kinematic chain. 4. Segmental control exercises in open kinematic chain with limb loading, emphasis on abdominal muscles. 5. Segmental control exercises in open kinematic chain with limb loading, emphasis on back extensor muscles. 6. Progress exercises to functional task. 7. Coactivation of abdominal and multifidus muscles with limb loading in aerobic tasks.
46031549|NCT00934102|Device|Narafilcon A contact lens|Investigational, silicone hydrogel, spherical soft contact lens
46031550|NCT00934102|Device|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
46031551|NCT00934102|Device|Galyfilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
45472108|NCT04184726|Behavioral|Mindfulness Based Cognitive Therapy|mindfulness and cognitive behavioural therapy techniques taught in group sessions meeting once weekly for 8 weeks, and home practice between sessions.
45682706|NCT03559348|Drug|chemotherapy: TS-1, Leucovorin and Gemcitabine|Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 - 7; Leucovorin 60 mg/d, orally twice daily on day 1 - 7; Every 14 days as one cycle.
45472109|NCT01154309|Behavioral|Group CBT for Depression and AOD Disorders|18 sessions of 2-hour group CBT
45682707|NCT01679938|Behavioral|primary obesity prevention|"Training of child care providers.~Curriculum sessions for children. Child care providers will facilitate 12 interactive education sessions that focus on key obesity-related behaviors.~Family outreach activities. Child care providers and research staff will communicate behavior change messages to families through ten take-home activities focused on key obesity-related behaviors and through monthly family workshops at the child care center.~Maintenance activities. Over the six months following the main intervention, research staff will conduct eight booster sessions for the children and one booster session for the family that will build upon activities and behavior change messages of the main intervention."
45682708|NCT03541018|Procedure|Type of repositional maneuvre|Patients randomized to 2 different repositional maneuvres related to the subtypes of BPPV
45472110|NCT01586429|Other|Ultrasound guided femoral nerve block catheter analgesia compared with epidural analgesia for patients with knee OA (osteoarthritis)|
45682709|NCT04762030|Drug|Durvalumab Anlotinib Carboplatin Nab-paclitaxel|"Neoadjuvant treatment (durvalumab+carboplatin+nab-paclitaxel + anlotinib) will start within 1-3 days from enrollment. 2 cycles will be administered at 21-day (+/- 3 days) intervals (QW3). Then, two cycles of combined durvalumab and anlotinib (QW3) will be administered prior to surgery. Before surgery, a tumor assessment will be done. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 5rd-7th week from day 1 cycle 4 of neoadjuvant treatment (day 35-49 after day 1 of cycle 4). Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Twelve cycles of durvalumab adjuvant treatment (Q4W) will be administered."
45472111|NCT01251731|Drug|E5501|Treatment Group 1: 10mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 40mg E5501 in Treatment Period 2, followed by a single dose of 80mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose reatment Period.
45472112|NCT01251731|Drug|E5501|Treatment Group 2: 40 mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 80mg E5501 in Treatment Period 2, followed by a single dose of 10mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
45682710|NCT04761874|Other|Telestroke|In the telestroke cohort, acute ischemic stroke patients at a single comprehensive stroke center received their stroke care and management exclusively via telestroke.
45682711|NCT01559259|Drug|Ibuprofen/acetaminophen|Two caplets of ibuprofen 100 mg plus acetaminophen 250 mg
45682712|NCT01559259|Drug|Ibuprofen/acetaminophen|Two caplets of ibuprofen 125 mg plus acetaminophen 250 mg
45839255|NCT03030846|Other|Control group|8 sessions during 6 consecutive weeks, three times per week, per session including: Twenty minutes for receiving hot pack and TENS
45472113|NCT01251731|Drug|E5501|Treatment Group 3: 80mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 10mg E5501 in Treatment Period 2, followed by a single dose of 40mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
45472114|NCT01251731|Drug|E5501|Treatment Group 4: A single dose of matching placebo in each of the three Single Dose Treatment Periods and in the Multiple Dose Treatment Period
45472115|NCT01260545|Drug|CA-18C3|2.5 mg/kg, 3.75 mg/kg IV (in the vein) on Day 1 of each 14 day cycle until the subject is no longer benefiting clinically or unacceptable toxicity occurs.
45682713|NCT01559259|Drug|Ibuprofen/acetaminophen|Two caplets of ibuprofen 150 mg plus acetaminophen 250 mg
45682714|NCT01559259|Drug|Ibuprofen|Two caplets of ibuprofen 200 mg
45682715|NCT01559259|Drug|Placebo|Two caplets of placebo
45682716|NCT01679548|Procedure|Single-port LAVH|LESS LAVH was performed using a commercially available four-channel, single-port system. A rigid, 0-degree, 5 mm laparoscope was used.
45839256|NCT03030690|Other|Glass Carbomer Cement|Restoration of proximal lesions in primary molars using glass carbomer cement
45839257|NCT03030690|Other|Composite Resin|Restoration of proximal lesions in primary molars using composite resin.
45472116|NCT01147913|Behavioral|Computerized Information-Processing Bias Retraining|The intervention consists of the presentation of three-line ambiguous scenarios via a computer program, one line at a time. A disambiguating word fragment completes the scenario (in either a positive or neutral valence, depending on the scenario), after which participants will type the first letter of the word on the keyboard to ensure they are encoding the interpretation valence. The computer will indicate if they have correctly identified the word. This is followed by a Y/N comprehension question. Each session presents 100 training scenarios.
45682717|NCT01679548|Procedure|Three-port LAVH|Conventional LAVH was performed using three ports; a 12, 10, and 5-mm port was placed in the umbilicus, left lower quadrant, and suprapubic area, respectively. A rigid, 0-degree, 12 mm laparoscope was introduced through 12mm port of umbilicus.
46031552|NCT05587153|Other|perfusion index in all parturient recruited for the study|Using perfusion index and positional hemodynamic changes for the prediction of postspinal hypotension in all parturient recruited for the study
45682718|NCT03538912|Other|Biomarker strategy|EAT duration is determined by β-D-1,3-glucan and mannan serum assays, performed at day 0 (day of EAT initiation) and day 3.
45682719|NCT03538912|Other|Routine strategy|EAT duration is based on IDSA guidelines, which recommend 14 days of treatment for patients without subsequent proven ICI, and who improve under antifungal treatment, or less in other situations.
45682720|NCT03537118|Procedure|Fluoroscopic + Ultrasound Guidance|Fluoroscopic Guidance Alone
46031553|NCT03760419|Behavioral|Clinical Decision Support|For enrolled subjects assigned to the decision support arm, providers will receive antibiotic recommendations in accordance with the 2011 PIDS/IDSA guideline, tailored to site of care and illness severity. The tool will offer treatment recommendations only and will not proscribe a specific treatment plan.
45472117|NCT01147913|Behavioral|Attention Control Training|"Four sessions of interpretation training for filler or neutral scenarios, unrelated to themes associated with depression."
45472118|NCT03888209|Device|tDCS|20 minutes of anodal tDCS (C3/FP2 or C4/FP1 depending on side of lesion) 2mA or sham
46031554|NCT00910195|Device|CPAP treatment with subsequent Bi-Level-APAP treatment|CPAP treatment during the first night and then Bi-level-APAP treatment during second night
46031555|NCT00910195|Device|Bi-Level-APAP treatment with subsequent CPAP treatment|Bi-level-APAP treatment during the first night and then CPAP treatment during the second night
46031556|NCT04285905|Other|Access to Fast Track TB clinic|Male partner can attend clinic with dedicated services for men
46031557|NCT04285905|Other|Information leaflet for male partner|Female participants will be provided with a letter asking their male partner to attend the clinic for tuberculosis screening
46031558|NCT04285905|Other|Home sputum collection|Female participants will be provided with sputum cups to take home and collect a sample of sputum from their male partner
45472119|NCT01251809|Drug|Oncaspar|2000 U/m2 BSA, single infusion
45472120|NCT01251809|Drug|PEG-rASNase|500, 1000 or 1500 U/m2 BSA single infusion
46031559|NCT04285905|Other|Home HIV testing|Female participants will be provided with an oral HIV self-test kit to be given to their male partner with instructions for use
46031560|NCT04285905|Other|Financial incentive|Female participants will be provided with a voucher for MKW5000 which can be redeemed when the male partner attends the clinic for TB testing
46031561|NCT04203784|Other|Plasma concentration measurements|Plasma concentration measurements
46031562|NCT02671825|Drug|PUR0200|PUR0200 dry powder inhalation
46031563|NCT02671825|Drug|Reference Product|Dry Powder Inhalation Reference Product
46031564|NCT04256122|Other|No intervantion on patients. retrospective study is performed on paraffin embedded tumor tissue specimens routinely collected during TURBT.|evaluate an immunophenotypical profile related to mitochondrial functions in tumors responders vs non-responder to intravescical chemotherapy or immunotherapy. Verify the possible prognostic differences in clinical behavior between the two populations.
45472121|NCT03912077|Behavioral|Culturally Adapted Cognitive Behavioural Therapy|7-session psychosocial intervention
45472122|NCT01154387|Drug|Anti-Thymocyte Globulin|1.5mg/kg IV on Day of Transplant and 1.0-1.5 mg/kg IV once daily for a minimum of 4.5mg/kg and a maximum of 7.5mg/kg total cumulative dose
45472123|NCT01154387|Drug|TOL101|Potential Therapeutic Dose (PTD)-A (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
45472124|NCT01154387|Drug|TOL101|Potential Therapeutic Dose (PTD)-B (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
45472125|NCT01154387|Drug|Steroids|IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months
45472126|NCT01154387|Drug|Tacrolimus|Oral administration started by 6 days post-transplantation and continued for 6 months
45839258|NCT03030690|Other|Resin Modified Glass Ionomer Cement|Restoration of proximal lesions in primary molars using resin modified glass ionomer cement
45839259|NCT03030456|Device|Power Plate®|Training of elderly women with Whole Body Vibrations through the use of a vibratory platform.
46031565|NCT04176367|Drug|Nicergoline from China|This is the test arm of China local manufactured Nicergoline
46031566|NCT04176367|Drug|Nicergoline from Italy|This is the reference arm of Italy originator Nicergoline.
46031567|NCT04259476|Drug|Ketamine Hydrochloride|low dose perioperative ketamine infusion. and its effects on post-operative pain.
46031568|NCT05276011|Biological|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.
46031569|NCT05276011|Biological|Placebo Control|2 mL normal saline injection
46031570|NCT05319574|Radiation|SBRT|Stereotactic body radiation therapy delivered with a fixed dose (8Gy) in 3 daily fractions 1-7 days before the first cycle of immunochemotherapy
46031571|NCT05319574|Drug|Tislelizumab|200mg q3w for two cycles administrated concurrently with chemotherapy
46031572|NCT04177147|Other|Clinical decision support via alert tool|The alert tool displays the risk of hypoglycemia for outpatients with diabetes mellitus.
46031573|NCT04255732|Device|extent of retinal area viewing Optos, Daytona, Optos PLC, Dunfermline, UK|Comparison of the extent of retinal periphery view between two wide field imaging devices.
45472127|NCT01154387|Drug|Mycophenolate mofetil (MMF)|Oral administration started by Day 1 post-transplantation and continued for 6 months
45472128|NCT03911765|Behavioral|digital cognitive training|Digital cognitive exercises, used in the intervention group, have the primary objective of stimulating executive functions, and will be made available through the Internet using the BrainHQ platform.
45598733|NCT02224547|Radiation|Radiotherapy (Fractionated stereotactic body radiation)|Radiation: Fractionated stereotactic body radiation therapy For centrally located T1 and T2 lesions 4 x 12 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 17Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
45839260|NCT03031392|Diagnostic Test|Sensitivity test|Routine clinical and radiographic examination
46031574|NCT04255732|Device|extent of retinal area viewing Clarus, 500 Carl Zeiss, Meditec AG, Jena, Germany|Comparison of the extent of retinal periphery view between two wide field imaging devices.
46031575|NCT04177459|Behavioral|Health promoting dialogue|Health promoting dialogues based on the salutogenic theory, focusing on resources within and around the individual, and on coping strategies. Seven individual dialogues for each participant, individually adapted due to the fatigue. The intervention is offered in the participants home or at the local hospital, dependent on the participants fatigue and what is preferred.
46031576|NCT04177459|Other|standard treatment / treatment as usual|Follow-up from primary and secondary health care, and from schools.
46031577|NCT00970281|Drug|Rapid-Acting Intramuscular Olanzapine|Administered by means of intramuscular injection (IM) with the possibility of second 10 milligram (mg) injection 2 to 4 hours after first injection, for a maximum of 2 injections
46031578|NCT00970281|Drug|Placebo|Administered by means of IM with the possibility of second injection 2 to 4 hours after first injection, for a maximum of 2 injections
46031579|NCT00607438|Drug|Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)|125 mg/m2 Paclitaxel by 30-minute IV infusion weekly for 3 weeks.
46031580|NCT00607438|Drug|Sorafenib (Nexavar)|400 mg orally twice a day continuously (even during rest week) starting on Day 1.
45682721|NCT03088306|Drug|Standard analgesia use [Oxygen]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
45682722|NCT03088306|Drug|Standard analgesia use [Hydromorphone]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
45682723|NCT03088306|Drug|Standard analgesia use [Volatile Anesthesia]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
46031581|NCT00643045|Drug|Safinamide|
46031582|NCT00643045|Drug|Safinamide|
46031583|NCT00643045|Drug|Placebo|
46031584|NCT04203706|Other|Neurofunctional imaging|Subjects will be submitted to a functional neuroimaging scanning procedure
46031585|NCT02670733|Procedure|Positive end-expiratory pressure|Positive end-expiratory pressure will be applied at 5 cmH2O and 15 cmH2O
46031586|NCT00976209|Drug|Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg|Phenylephrine HCl ER tablets 30 mg taken every 12 hours, twice daily, for 3 days.
46031587|NCT00976209|Drug|Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg|Phenylephrine HCl IR tablets 10 mg taken every four hours (no more than 6 times daily) for 3 days.
46031588|NCT04180423|Device|Off-the-Shelf Implant Total Knee Replacement|Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Off-the-Shelf implants use standard sizing.
46031589|NCT04180423|Device|Customized Implant Total Knee Replacement|Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Customized implants are customized individually made knee implants which are designed specific to each patient's unique anatomy.
46031590|NCT02676427|Procedure|passive leg raising|passive leg raising under echocardiographic monitoring with intravascular doppler in place
46031591|NCT03747627|Diagnostic Test|Genetic profiling|All participating subjects will undergo detailed genetic analysis, with the aim of detecting novel genetic drivers for the development of interstitial lung disease in the context of known sensitising agent (pigeon antigen)
46031592|NCT05275465|Drug|HH-006|Different dose levels of HH-006
46031593|NCT05275465|Drug|Placebo|Different dose levels of placebo
46031594|NCT02862639|Device|Experimental group|patient receive intra articular injection (hip joint) of viscosupplementation in combination with corticosteroid
46031595|NCT02862639|Device|control group|patient receive intra articular injection (hip joint) of corticosteroid alone
46031596|NCT04177069|Dietary Supplement|Visucomplex Plus|capsule contains: Lutein, Zeaxanthin, alphalipoic acid MATRIX, Vitamine E, Zinc, Maquibright® (Aristotelian chilensis berry standardized, containing Anthocyanin and delphinidin extracts), Vitamin D and cupper.
46031597|NCT03746301|Drug|Rivaroxaban(Xarelto,BAY 59-7939)|10mg, 15mg and 20 mg film-coated tablets
46031598|NCT00925990|Drug|ribavirin|200 mg capsules, either 1000 or 1200 mg taken twice daily for up to 24 weeks
46031599|NCT00925990|Drug|CTS-1027|5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks
46031600|NCT00925990|Drug|Placebo for ribavirin|Capsules identical to ribavirin in appearance containing inactive ingredients
46031601|NCT02670655|Drug|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
46031602|NCT02670655|Device|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
45682724|NCT03088306|Drug|Standard analgesia use [Fentanyl]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
46031603|NCT02670655|Drug|MAL application|Immediately after AFL treatment, an approximately 1-mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue.
46031604|NCT02670655|Device|Iontophoresis application|In Group A, ionotophoresis was performed on MAL-applied sites. We used iontophoresis (vitaliont II®, ITC Inc, Korea) with a patch. The active electrode was the anode, and 0.50-mA/cm2 current was applied to each AK lesion for 10 min.
46031605|NCT02670655|Device|irradiation with red light-emitting diode lamp|After incubation for 2 (Group A and B) or 3 hours (Group C), the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
46031606|NCT03472599|Other|Genital Nerve Stimulation|Genital nerve stimulation activates sensory afferents that travel through the pudendal nerves and enters the spinal cord through the sacral dorsal root ganglia. Inhibitory spinal reflex pathways are activated, causing increased sympathetic outflow through the inferior mesenteric ganglion and hypogastric nerve and also decreased parasympathetic efferent drive through the pelvic nerve, resulting in inhibited bladder contractions.
46031607|NCT04176991|Biological|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
46031608|NCT04176991|Biological|Placebo|Placebo Comparator
46031609|NCT03744351|Other|Biological Samples|Venous sampling that is performed solely for the purpose of research. The total blood volume taken is 80 ml maximum (8 tubes of 10 ml).
45682725|NCT03088306|Drug|Multi-modal pain management [Acetaminophen + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
46031610|NCT03744351|Other|Biological Samples|"Eight additional 10 ml tubes of blood and an additional 5 ml CSF tube will be taken from the patient during a sample taken for the patient's usual check-up /follow-up.~Inpatients will also be offered stool removal."
45682726|NCT03088306|Drug|Multi-modal pain management [Fentanyl]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
46031611|NCT03744351|Other|Biological Samples|The patient will be taken 8 additional tubes of 10 ml of blood (during a blood test performed for the usual assessment of the patient) and an additional 5 ml of CSF in a sample taken for the assessment of the patient.
46031612|NCT03744351|Other|Biological Samples|"Eight additional 10 ml tubes of blood will be taken from the patient during a sample taken for the patient's usual check-up / follow-up.~Inpatients will also be offered stool removal"
46031613|NCT01131078|Drug|Bevacizumab [Avastin]|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle.
46031614|NCT01131078|Drug|Capecitabine|Capecitabine was administered orally at a doses of 1000 or 1250, mg/m^2 twice daily (Day 2 to 15) or as 650 mg/m^2 twice daily on Days 1 to 21.
45682727|NCT03088306|Drug|Multi-modal pain management [Intravenous Ketamine]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
46031615|NCT01131078|Drug|Irinotecan|Irinotecan was administered as a 240 mg/m^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks.
46031616|NCT03738501|Other|Chest physiotherapy with SET|Chest physiotherapy with SET, and standard treatment (medical treatment, health education, nasopharyngeal clearance, advice)
45839261|NCT03031236|Behavioral|Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice|The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
45839262|NCT03030144|Other|Evidence based nursing recommendations|The intervention group gets the evidence based nursing interventions for the conservative management of urinary incontinence in female nursing homes.
45839263|NCT03030300|Drug|Novolin 30R;Pioglitazone;Metformin|"Insulin (Novolin 30R) was titrated according to the level of blood glucose until reached euglycemia (FPG≤6.1mmol/L and/or P2hBG≤8.0mmol/L and/or HbA1c ≤6.5%). After glucose was well controlled within these targets for 4 weeks, insulin dosage was gradually decreased until discontinued;~Pioglitazone hydrochloride was discontinued if the glucose was well controlled at the 6th week after the cessation of insulin;~Metformin was the last drug that to be discontinued if the glucose was still well controlled at the 4th week after the cessation of pioglitazone."
46031617|NCT03738501|Other|Standard Treatment|Standard pharmacological and non-pharmacological treatments (medical treatment, health education, rhinopharyngeal clearance, advices)
45839264|NCT03029442|Drug|Denosumab (Prolia)|In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates. The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
45839265|NCT03029442|Other|Placebo (normal saline)|Identical Denosumab volume of normal saline
45598734|NCT02292667|Procedure|TAP block|The aim of the Transversus Abdominis Plane (TAP) Block is to deposit local anesthetic in the plane between the internal oblique and the transversus abdominis muscles targeting the spinal nerves in this plane. The local anesthetic used in the ETAP study is Ropivacaine 0.375%. 2 ultrasound-guided injections of 10 ml will be performed on each side of the abdominal wall: 1 subcostal injection and 1 supra-iliac injection.
45839266|NCT03029286|Behavioral|Usual Care Arm|Health information provided by the American Cancer Society Website
45839267|NCT03029286|Behavioral|Personalized Web Intervention Arm|Women will be assigned to view a tailored website featuring their personalized risk information for breast cancer related to breast density and other factors.
45839268|NCT03027492|Other|Gluten free diet|The investigators will evaluate the modification of gynaecological disorder after a gluten (wheat)-free diet.
45839269|NCT03025620|Dietary Supplement|Rapeseed oil|Active comparator arm : Dietary Supplement: rapeseed oil supplementation (10g per day) and margarine with a high level of alpha-linolenic acid (12.5g per day) during 42 days.
45598735|NCT02292667|Drug|PCA with Chlorhydrate of Morphine|Doses of 1 mg of Chlorhydrate of Morphine will be delivered intravenously by the Patient Controlled Analgesia (PCA) pump. The PCA pump is a computerized pump which contains a syringe of 1 mg/ml of Chlorhydrate of Morphine as prescribed by the physician in charge of the patient, and connected directly to a patient's intravenous line. Doses of Chlorhydrate of Morphine can be self-administered by the patient as needed by the having the patient press a button.
45598736|NCT02292667|Drug|Acetaminophen|1 g of Acetaminophen will be given intravenously each 6 h during 48 hours after the surgical procedure.
45839270|NCT03025620|Dietary Supplement|Sunflower oil|Placebo comparator arm : Dietary Supplement: sunflower oil supplementation (10g per day) and margarine with a high level of inoleic acid (12.5g per day) during 42 days.
45839271|NCT03024372|Device|AV Fistula creation with sutures|End-to-side anastomosis (of AV fistula) is to be constructed using sutures. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
46031618|NCT04180501|Combination Product|SRS sequential sintilimab|The subjects first received a targeted radiotherapy of SRS, and started the treatment of sintilimab per 3 weeks within 35 days after SRS.
46031619|NCT04286061|Other|Assisted soft tissue mobilization|It will be done for 60 seconds, making a total of 30 strokes with the tool in the longitudinal direction to the muscle fibers. The physiotherapist will previously apply some massage cream to the area to be treated (adductor musculature) so that the tool slides at a 45º angle. Landslides will be made from the femoral condyle to the groin, and vice versa, exerting a pressure with the instrument of 3 over 10 on the analog visual scale that the subject feels
45839272|NCT03024372|Device|AV Fistula creation with clips|End-to-side anastomosis (of AV fistula) is to be constructed using clips. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
46031620|NCT02670499|Device|CPM|Used to aid in recovery from TKR
45839273|NCT03023514|Dietary Supplement|Oral Lipoic acid|300 mg ALA x2 (1pill orally/12h) to the recipient from the day of the donors pick up until 8 week of pregnancy
45839274|NCT03023514|Drug|Vaginal Progesterone|200 mg Vaginal Progesterone (1 vaginal capsule/24h) from the day of the donors pick up until 8 week of pregnancy
45839275|NCT03022812|Other|Neck-specific exercise|Neck-specific exercise
46031621|NCT02670499|Device|GAPFLEX|Used to aid in the recovery of TKR
45682728|NCT03088306|Drug|Multi-modal pain management [Valium + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
46031622|NCT04180345|Other|Psychometric validation of the questionnaire|"Delph Process : expert panel will include HCPs and patients. They will evaluate the relevance of items on a Likert scale (HCPs N = 25 ; Patients N = 25 ) Think aloud interviews (N = 10 patients) Psychometric validation ( N = 200 patients)"
46031623|NCT03709017|Drug|Ponatinib|Iclusig 45mg, 15mg
46031624|NCT02671903|Device|Pacemaker: AV optimised, His pacing.|Direct His bundle pacing: a Medtronic Select Secure 3830 pacing lead will be positioned at the His bundle. If selective direct His bundle pacing cannot be achieved then non-selective His bundle pacing will be accepted. AV delay optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems, Netherlands).
45682729|NCT01672762|Drug|ipragliflozin|oral
46031625|NCT01167582|Biological|Red blood cell transfusion|Liberal versus restrictive transfusion
46031626|NCT03695445|Drug|Peripheral administration of Norepinephrine|Systematic follow-up of complications from peripheral administration of Norepinephrine
45472129|NCT01154465|Procedure|Central Venous Catheter Insertion|"The preparation of the CVC installation will follow the procedures for skin preparation of the operator, installation of sterile fields and local anaesthesia.~The patients' skin disinfection before catheter insertion and care will follow the protocol:~Clean the area of insertion of the catheter with a solution of 4% aqueous povidone foaming (Betadine Scrub).~Rinse with sterile water and then drying.~First application of 5% alcohol povidone-iodine (alcoholic Betadine) far beyond the area of insertion.~Second application of 5% alcoholic povidone-iodine (alcoholic Betadine) by the operator after sterile draping.~After sterilisation and puncture, the Seldinger technique is employed to insert the line: a blunt guidewire is passed through the needle, and the needle is then removed."
45472130|NCT01154465|Device|Ultrasound guidance|"The ultrasound probe will be isolated by a sterile protective plastic and the operator will mount a ramp on which the puncture syringe needle is placed.~A sterile gel will be used in order to visualize the vein and directly puncture under ultrasound guidance following:~- The anterior Boulanger's incision for the internal jugular vein When venous aspiration is obtained, the needle can easily be removed from the ramp and the syringe to mount the catheter following Seldinger's method."
45682730|NCT03088384|Drug|Ketamine|Psychological survey instruments administered before and after a series of six low-dose infusions of ketamine.
45682731|NCT03534934|Diagnostic Test|Vital signs|"Heart rate, respirations, blood pressure, temperature, oxygen saturation~arterial oxygen saturation (SaO2), height and weight"
45682732|NCT03534934|Diagnostic Test|Urine Pregnancy Test|Urine pregnancy test done on woman of childbearing potential.
45472131|NCT03887975|Procedure|Monoplane Occlusion|Monoplane and lingualized occlusion effect on force distribution
46031627|NCT04204551|Behavioral|high-intensity interval training (HIIT)|Two 12-week HIIT cycles will be divided with 3 months of break. Each HIIT cycle will consist of three 1-hour training sessions weekly. Each 1-hour training session will consist of 10-minutes warm-up (at slow voluntary speed), 40-minutes of interval exercise and 10-minutes cool-down phase. The interval exercise part will consist of 10 sets of 4 minutes interval including 2-minutes cycling at ≥ 60 [rpm], but preferably at 80-90 [rpm] (fast phase of interval) and 2-minutes cycling at ≤ 60 [rpm] (slow phase of interval). The training will be performed on a stationary cycle ergometer (MONARK, Ergomedic 874E, Sweden). The heart rate (HR, [bpm]) will be measured by Polar system (Polar, Finland). The patients will pedal on the cycloergometer at 60%-80% of their individualized HRmax.
46031628|NCT04204551|Behavioral|conventional physical therapy|Conventional physical therapy as prescribed and provided by the National Health Fund of Poland, which includes activities for improving motor control, but without any kind of moderate or high intensity aerobic interval or continuous physical training (example: cycle ergometer, treadmill, or Nordic walking training)
46031629|NCT04177303|Drug|Metformin|Participants will be randomized to metformin 2000 mg
46031630|NCT04177303|Drug|Placebo|Participants will be randomized to placebo
46031631|NCT04177225|Procedure|Trans thoracic Ultrasound Examination|Ultrasound examination of cardiac function before and after induction of general anesthesia.
46031632|NCT04177225|Other|Intravenous fluid administration|Intravenous fluids will be administered as a bolus in response to standard clinical indications
46031633|NCT01167426|Drug|Glatiramer Acetate 20 mg/0.5 mL|20 mg/1.0 mL formulation of glatiramer acetate utilizing the autoject 2 for glass syringe.
46031634|NCT01167426|Drug|Glatiramer acetate 20 mg/0.5 mL|20 mg/0.5 mL formulation of glatiramer acetate utilizing the autoject 2 20 mg/0.5 mL device.
46031635|NCT04091035|Other|To describe the incidence of disease and evaluate risk factors|Se above
46031636|NCT04204785|Behavioral|Noise Reduction Education|OR staff will be offered education regarding the importance of minimizing noise in the OR. There will also be reminder signs and posters for the duration of the post-education period.
46031637|NCT04286919|Behavioral|A Randomized Controlled Trial Comparing the Physical Activity Guidelines for Americans to a New Method of Exercise Prescription Among College Students|A randomized controlled trial comparing the 2018 Physical Activity Guidelines for Americans weekly recommendations of 150-minutes of moderate intensity physical activity plus 2 days of muscle-strengthening physical activity to the Move Your Way Campaign message of increasing any and all physical activity to accumulate more movement throughout the week across all types and intensities.
46031638|NCT04090333|Other|Standard withdrawal therapy|All painkillers are abruptly stopped for a 2 months period.
45472132|NCT03887975|Procedure|Lingualized occlusion|Monoplane and lingualized occlusion effect on force distribution
45472133|NCT03911921|Drug|RSYRT decoction|Compound granules of traditional Chinese medicine
45682733|NCT03534934|Other|Questionnaires|Subject Questionnaire Calcium Intake Questionnaire Home and Work Activities Survey
45682734|NCT03534934|Diagnostic Test|Blood Test|Blood test for vitamin D level, Hemoglobin A1c, and creatinine level
45682735|NCT03534934|Diagnostic Test|Duel-energy X-ray absorptiometry scan|Bone density measurement
45682736|NCT03534934|Diagnostic Test|Multi-detector computed tomography|Hip and ankle CT scan
45682737|NCT03534934|Diagnostic Test|Dual-energy X-ray absorptiometry scan|Vertebral fracture assessment
46031639|NCT04089475|Device|Dermoscope|Dermoscopy is a noninvasive diagnostic tool that permits the visualization of morphological features that are not visible to the naked eye thus representing a link between macroscopic clinical dermatology and microscopic dermatopathology.
46031640|NCT02862873|Procedure|Spinal anaesthesia|
45472134|NCT03911921|Drug|Astragalus membranaceus|One herb
45472135|NCT01260623|Drug|Prednisolone and prednisone|oral, or intravenous prednisone, prednisolone, given the first time for asthma exacerbation
45472136|NCT03887897|Procedure|Tracheal Intubation|Tracheal intubation performed by attending anesthesiologists using either Airtraq laryngoscope or Macintosh laryngoscope
46031641|NCT02862873|Drug|Ondansetron|
46031642|NCT02862873|Other|saline solution|
46031643|NCT02671513|Drug|SHR6390|SHR6390 either 50mg,75mg,100mg,125mg,150mg,175mg given orally, QD
46031644|NCT04266951|Behavioral|Singstrong:|Group singing and breathing control training
46031645|NCT02671669|Behavioral|Usual Care|Discharge packet of Heart Healthy instructions, with self-report health status, quality of life and psychosocial questionnaires, as well as other educational handouts, exit interview to review exercise progress, receive referrals to additional medical services they might need after discharge from the program, with physician.
46031646|NCT02671669|Behavioral|Movn application (MVN)|"Intervention participants will receive the same discharge packet as the UC group along with their exit interview and will receive the following:~Participant individualized Heart Healthy instructions for post-cardiac rehabilitation will be integrated into the MVN application including daily medication reminders, physical activity prompts, educational materials, and patient-reported outcome assessment of behavior and psychosocial status.~Text messages will be used on an ad hoc basis to provide positive feedback to the participant; two-way messaging between the participant and the research coordinator will be available to provide opportunities to answer specific questions."
46031647|NCT03814005|Drug|Azacitidine|Azacitidine subcutaneous or intravenous injection.
45472137|NCT03890315|Diagnostic Test|Functional MRI|"In fMRI, patients will first be taking a resting state phase in case of activations. In the block design phase, they will be given tactile stimuli in affected extremity, and then healthy extremity in 3 blocks, followed by pauses.~Primary and secondary sensorial cortex, insular cortex, anterior cingulate cortex, preforntal cortex and amygdala activation will be chosen as regions of interest, and their activation will be recorded for analyses."
45472138|NCT01259609|Procedure|Pars Plana Vitrectomy|25-gauge three-port pars plana vitrectomy
45472139|NCT01147991|Biological|EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine|
45472140|NCT01147991|Other|laboratory biomarker analysis|
46031648|NCT03814005|Drug|Pevonedistat|Pevonedistat intravenous infusion.
46031649|NCT03814005|Drug|Docetaxel|Docetaxel intravenous infusion.
45472141|NCT01147991|Other|pharmacological study|
45472142|NCT03887585|Procedure|Achilles tendon lengthening|Achilles tendon lengthening by triple hemisection for Achilles tendon contracture
45472143|NCT04115839|Drug|Filgotinib|Tablets will be administered orally once daily with or without food.
45472144|NCT04115839|Drug|Placebo to match filgotinib|Tablets administered orally once daily with or without food.
45598737|NCT02228759|Procedure|Adductor canal block|All patients will recieve fast tracking with reduced fasting times, multimodal analgesia and adductor canal block
45598738|NCT02354157|Other|no intervention|no intervention
46031650|NCT03814005|Drug|Paclitaxel|Paclitaxel intravenous infusion.
45472145|NCT01152983|Device|Rapid Ring|Rapid Ring is a ring-shaped device that encircles the distal phalanx of the middle finger and blocks the arterial blood to quickly and passively withdraw blood following a finger stick, and to reduce the pain of the lancet.
45472146|NCT01252121|Other|Systane Ultra Lubricant Eye Drops|One drop in study eye, one time, during office visit.
45472147|NCT01252121|Other|Hialid 0.1 Artificial Tears Eye Drops|One drop in study eye, one time, during office visit.
45472148|NCT01252121|Other|Unisol 4 Saline Solution|One drop in study eye, one time, during office visit.
45472149|NCT01260779|Drug|PV-10 (10% rose bengal disodium)|Intralesional injection for chemoablation of cutaneous or subcutaneous lesions
46031651|NCT03814005|Drug|Carboplatin|Carboplatin intravenous infusion.
46031652|NCT02676115|Other|Standard Post Operative Skin Care|Control group subjects will receive the standard post-operative skin care which are steri-strips covered with gauze, and this will be removed at the first visit. No additional skin dressings will be used in the control group.
45472150|NCT03911609|Other|Exercise|Subjects will perform isometric (static) handgrip exercise at submaximal intensity for four minutes. The exercise will be performed while the subject is seated, and the elbow bent at around 90° and unsupported. Subjects will be asked to rate their pain using numerical pain rating scale that ranges from 0 (no pain) to 10 (worst pain), perceived exertion (RPE) from 0 (Nothing at all) to 10 (extremely strong), and perceived stress from 0 (not stressed at all) to 10 (extremely stressed). The ratings of pain intensity, RPE and perceived stress will be provided before, at the middle and at the end of the exercise.
45472151|NCT03911609|Other|Cognitive Task|The mental math task, which is also known as serial subtraction test, will be performed for four minutes. Subjects will be asked to rate their pain intensity and perceived stress before, at the middle and at the end of the mental math task.
45472152|NCT01148069|Procedure|Surgery combined with IMRT-IGRT|Patients will have surgery consisting in extensive pelvic dissection and ablation of seminal vesicles. Surgery will be followed by prolonged hormonotherapy (3 years) associated, after 2 months, with prostatic only irradiation.
45472153|NCT01153061|Device|Fistula closure with Gore Helex Septal Occluder|The occluder will be released at the tracheoesophageal fistoulous traject through endoscopic procedures
45472154|NCT01153061|Device|Gore Helex Septal Occluder|Fistula closure with endoscopic release of occluder in the fistula traject.
45682738|NCT03534700|Procedure|parasacral flap reconstruction|parasacral flap reconstruction
46031653|NCT02676115|Other|Medipore Tape|"One layer of Medipore tape will be placed across the incision.~Patients will be instructed on how to change the tape, and will be encouraged to change the tape as often as once per week for hygiene.~When patients return to the office for their regularly scheduled visit, the Medipore tape will be changed and a picture of the scar will be taken."
45839276|NCT03022266|Behavioral|Financial Incentive and Mobile Phone App|Subjects receiving the Financial Incentive and Mobile Phone App will each participate in a 90-day adherence promotion program. When users first log in to the app, the screen will display an incentive of $150 that participants have earned by enrolling in the program. Participants will be told that each missed medication check-in will result in a $2 deduction from the account before it is paid out. Each $50 portion (minus any penalties) of the $150 incentive will be paid out in 30-day installments by remotely crediting a previously distributed debit card. Adherence will be measured simultaneously by app photos and CleverCap(R) electronic monitoring (EM) devices filled with a 90-day supply of aspirin. Claims data will be analyzed for a 90 day period to account for any hospital admissions.
45472155|NCT03890159|Behavioral|Computer Assited Cognitive rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The computer-aided cognitive rehabilitation group will perform simulation-based exercises, including exercises related to attention, in a special computer program (Cogniplus TR version) during therapy hours. The total duration of intervention will be 1 month.
45682739|NCT03534700|Procedure|open excision|open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.
45682740|NCT01677598|Drug|No intervention|No intervention will be administered during study. This will be an observational study in patients using ustekinumab as label-recommended or other/missed dose interval in Asia-Pacific countries
45472156|NCT03890159|Behavioral|Conventional Cognitive Rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The home (paper pen) exercise group will take the necessary exercises on paper suitable for their respective levels and the daily tasks suitable for their functional needs and interests. The total duration of intervention will be 1 month.
45682741|NCT01676350|Procedure|IO access using EZ-IO®|IO line placed using an FDA-approved device called an EZ-IO®.
45682742|NCT03422770|Diagnostic Test|Echocardiography|Conventional transthoracic echocardiography will be performed, in addition 3D-imaging and acquisitions with high frame rate. The data from these patients will be anonymized and transferred for post-hoc analysis in dedicated computer software (GE Vingmed, EchoPac 2.0) and in validated machine learning algorithms.
45682743|NCT03422770|Diagnostic Test|MRI|Cardiac MRI will be performed. In all patients without contraindications a gadolinium-based contrast agent will be given.
45682744|NCT03422770|Diagnostic Test|Blood test|Conventional brachial venous blood samples will be drawn. Blood samples will be analyzed for markers of myocardial fibrosis at Oslo University Hospital.The findings will be related to imaging findings.
45472157|NCT01260857|Drug|Aldazide|Aldazide 25 mg OD
45472158|NCT03889847|Device|Fibreoptic intubation with silicone double lumen tube|Fibreoptic intubation with silicone double lumen tube
45472159|NCT03889847|Device|Fibreoptic intubation with PVC double lumen tube|Fibreoptic intubation with PVC double lumen tube
45472160|NCT03890003|Device|AID System|AID system
45682745|NCT03422770|Diagnostic Test|ECG and Holter-ECG|ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.
46031654|NCT02863887|Behavioral|Weight loss intervention|The intervention will involve utilizing trained community health coaches to deliver the weight loss intervention. There will be 10 group based sessions conducted at each church over 6 months. Session frequency will be 4 weekly sessions (4) for the first month, bimonthly sessions for 2 months (4) and monthly sessions for 2 months (2). The study is based upon weight loss strategies that have been utilized in the Diabetes Prevention Program. The group sessions will be augmented by utilizing text messages. The text messages will be delivered weekly and three types of messages will be delivered: 1) lesson content, 2) motivational, 3) behavioral prompts.
46031655|NCT05552131|Device|T-wave coronary lithotripsy catheter system|Subjects who plan to receive possible interventional therapy meet all admission criteria and do not meet any exclusion criteria, and enter the screening stage of this clinical trial after signing informed consent. All subjects who sign the informed consent will be provided with a unique subject screening number. All subjects who met the inclusion criteria and did not meet the exclusion criteria were enrolled and lumen pretreated with a coronary shock catheter system followed by the implantation of drug-eluting stents.
45682746|NCT03422770|Diagnostic Test|6 min walking test|6 MWT will be performed, and the findings will be related to findings from MRI/echocardiography.
46031656|NCT03683433|Drug|Azacitidine|Given SC or IV
46031657|NCT03683433|Drug|Enasidenib Mesylate|Given PO
46031658|NCT02668471|Procedure|Ultrasound|ultrasound at radial site and measure the size and depth of radial artery and perform radial artery cannulation
46031659|NCT02668471|Procedure|traditional method|Radial artery catheters will be placed by the palpation technique only.
46031660|NCT02668549|Other|DB review for Doctor/Pharmacy Shopping Behavior|Database review to evaluate of doctor/pharmacy shopping behaviors
46031661|NCT03449901|Drug|pegylated arginine deiminase|-Arginine deiminase (ADI) is a recombinant protein cloned from M. hominis, produced in E. coli, and conjugated with PEG of 20,000 mw using a succinimidyl succinate linker. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
46031662|NCT03449901|Drug|Gemcitabine|-Gemcitabine is a nucleoside metabolic inhibitor that exhibits antitumor activity.
46031663|NCT03449901|Drug|Docetaxel|-Docetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared by semisynthesis beginning with a precursor extracted from the renewable needle biomass of yew plants.
46031664|NCT03449901|Procedure|Tumor biopsy|"Up to 21 days prior to initiation of ADI-PEG 20 Day -1 (+/- 1 day as long as performed prior to initiation of gemcitabine.~Tumor biopsies are mandatory for the first 20 patients amendable to biopsy enrolled at Washington University only (completed as of 05/14/2019) and for all patients enrolled to the SCLC cohort"
46031665|NCT03449901|Procedure|Research blood draw|-Day -7 (pre-treatment), Day -1, and Days 1 and 8 of each cycle
46031666|NCT00968799|Procedure|Hyperthermic intraoperative intraperitoneal chemotherapy|Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution.
46031667|NCT00968799|Procedure|Cytoreduction|"Surgical removal of tumor nodules~including resection of organs infested with tumor"
46031668|NCT00968799|Drug|Cisplatin|Cisplatin is applied as chemotherapy during surgery
46031669|NCT04175353|Dietary Supplement|Dairy snack|The effects of dairy snack are compared with orange juice.
46031670|NCT04175353|Dietary Supplement|Berry snack|The effects of two berry snacks are compared with berry soup.
46031671|NCT04175743|Drug|CT-044 HCl|CT-044 HCl is a reactive species decomposition accelerant
45472161|NCT03890003|Drug|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
45472162|NCT01252199|Drug|cαStx1/cαStx2|cαStx1/cαStx2 administered concomitantly at a dose of 1 mg/kg (low dose cohort) or 3 mg/kg (high dose cohort)per antibody over 1 hour + standard of care
45472163|NCT01252199|Drug|Placebo|Placebo administered over 1 hour + standard of care
45598739|NCT02296177|Behavioral|Peace of Mind Program|The Peace of Mind Program (PMP) is a telephone counseling program based on the Transtheoretical Model of Change, with messages matched to readiness (assessed with a stage of change question)and barriers identified by women who are non-adherent to mammography. The program telephone protocol guides counselors to assess a woman's readiness to be screened and counsel her through barriers to increase appointment keeping.
45598740|NCT02232269|Other|Black Coffee|
46031672|NCT04016233|Drug|Tenofovir douche|660 mg TFV in 125 mL hypo-osmolar solution
46031673|NCT04175899|Other|Pharmacist-led Oral Chemo Care Program (POCCP)|"Structured intensified pharmaceutical care program for patients ongoing oral chemotherapy treatment.~Led by oncology experienced clinical pharmacist and run alongside oncologist patient review at the clinic or daycare.~It utilizes structured educational material (for patients) and monitoring guideline or checklists (for pharmacists) during provision of service at each clinic visit such as patient education, pre-treatment review, medication reconciliation, prescription screening (dose, regime, supportive meds), adherence, adverse drug event monitoring and treatment recommendations on basis of agreed protocols.~Pharmacist scheduled additional review within 1-week interval of start of oral chemotherapy at clinic or via phone call (according to patient's preference) will also be conducted to review patients taking their oral medications at home, assess adherence and symptom experienced to provide individualized recommendations or support to patients."
46031674|NCT02671591|Behavioral|MI-PrEP|This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP and it will help YBMSM think more about using condoms consistently and correctly with every sex partner.
46031675|NCT02671591|Behavioral|control condition|This is a behavioral program designed to provide men with condoms and lubricants that make sex feel good even though it is fully protected by latex condoms
46031676|NCT02671747|Behavioral|Mind Over Matter; Healthy Bowels, Healthy Bladder|3 workshop sessions over a one-month period using self-efficacy and health behavior change to improve incontinence symptoms and promote care-seeking if symptoms do not improve sufficiently
46031677|NCT04033471|Drug|midazolam|epidural needle in the L1-2 or L2-3 space , and using loss of resistance technique udder strict aseptic condition 10 ml of the prepared drug will be given
46031678|NCT02670421|Behavioral|Face to Face Heart SMART Program|The Heart SMART stress management program survey consists of Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), Patient Health Questionnaire (PHQ - 9) and Generalized Anxiety Disorder (GAD - 7), followed by email communication every three weeks.
46031679|NCT02670421|Behavioral|On-line Heart SMART Program|The Heart SMART stress management program survey consists of PSS (Perceived Stress Scale), BRS (Brief Resilience Scale), PHQ-9 (Patient Health Questionnaire) and GAD-7 (Generalized Anxiety Disorder) taken on-line in twelve, 10 minutes sessions.
46031680|NCT02670421|Behavioral|Mayo Clinic Guide to Stress Free Living|All subjects will be provided with a copy of the book entitled Mayo Clinic Guide to Stress Free Living and encouraged to read it over the twelve week study period.
46031681|NCT02671279|Dietary Supplement|Low calorie diet|6 days of low calorie diet, estimated kcal 400-600/day.
45598741|NCT02232269|Other|Grapefruit Juice|
46031682|NCT02671201|Other|Education|Different methods in education of emergency ultrasound
46031683|NCT02668081|Procedure|Endoscopic papillary balloon dilation|treatment of endoscopic papillary balloon dilation
46031684|NCT02668081|Procedure|Endoscopic sphincterotomy|treatment of endoscopic sphincterotomy
46031685|NCT00910351|Drug|Ciprofloxacin (Cipro, BAYQ3939)|25 mg inhaled Ciprofloxacin
46031686|NCT02671357|Procedure|ERAMIP|3D-LPD with stented umbrella-pancreaticogastrostomy & Roux-en-Y reconstruction of the biliary limb of the hepatico-jejunostomy onto the efferent limb of the gastro-enterostomy (RY-GES)
46031687|NCT04175665|Drug|Semaglutide|Prescription for semaglutide as part of usual clinical practice
46031688|NCT02671123|Procedure|Coronary PCI with OCT with Co Registration|Co-Registration is an online tool used to take measurements during a stent procedure ( PCI-percutaneous coronary intervention) as part of the OCT ( Optical Coherence Tomography intravascular system. Co Registration software may provide additional imaging details during stent implantation when using OCT.
46031689|NCT02671123|Procedure|Coronary PCI with OCT without Co Registration|Coronary PCI will be performed using OCT ( Optical Coherence Tomography intravascular system) guidance without the Co Registration software tool enabled.
45682753|NCT01677754|Drug|RO4602522|Participants will receive RO4602522 orally once daily for 12 months.
45682754|NCT01677754|Drug|Placebo|Participants will receive placebo for RO4602522 orally once daily for 12 months.
45682755|NCT01677754|Drug|Donepezil|Stable dose as background medication
46031690|NCT04174729|Device|handgrip strength|First, the hand measurements of each volunteer were evaluated, followed by the measurement of handgrip strength using the Jamar® dynamometer. And later the tests were performed using the system that contains the 5 devices to quantify the hand strength.
45598742|NCT02232269|Other|Water|
45682756|NCT01677754|Drug|Memantine|Stable dose as background medication in combination with AChEIs
46031691|NCT04174729|Device|Door handle device|To evaluate the cylindrical grip movement, a door handle was used, which evaluated the full force in the range of motion.
46031692|NCT04174729|Device|Tap device|To evaluate the spherical grip movement, a tap was used, which evaluated the full force in the range of motion.
46031693|NCT04174729|Device|Door pull handle|To assess the hook grip movement, a door pull handle was used, which assessed the full force in the range of motion
46031694|NCT04174729|Device|Linear Switch device|To evaluate the pulp-pulp pinch movement, a switch was used, which evaluated the full force in the movement of the movement.
45598743|NCT02232269|Drug|Felodipine|
45598744|NCT04478331|Behavioral|Technology-based physical activity interventions|The technology groups will receive a PA program for 12 weeks. These PA programs will be given twice a week and include: 5-10 minutes of warm-up, 20-40 minutes of aerobic exercise and muscle strengthening via circuit training composed of 8-10 exercises with 8-12 repetitions per exercise for 2-3 series, and 5-10 minutes of stretching. In addition, advice and counseling will be given about walking activities to achieve the recommendations.
45598745|NCT02292745|Radiation|stereotactic radiotherapy|
45682757|NCT01677754|Drug|Rivastigmine|Stable dose as background medication
45682758|NCT01677754|Drug|Galantamine|Stable dose as background medication
45682759|NCT03419572|Other|Data collection|Only available evaluations as decided by the investigator based on local clinical practice will be collected.
45682760|NCT01670032|Drug|Experimental: CD07223 1.5 % Topical Gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
46031695|NCT04174729|Device|Door Key device|To assess the pulp-side pinch movement, a door key was used, which evaluated the full force in the range of motion.
46031696|NCT02670265|Dietary Supplement|Olimel Peri 2.5% ®|During hospital stay patients received 1 l Olimel peri 2.5 %® containing 700 kcal (25.3 g protein, 30.0 g fat and 75.0 g glucose) daily by intravenous route.
46031697|NCT02670265|Dietary Supplement|Isotonic fluid (E153)|Controls received 1l of isotonic fluid daily by intravenous route.
46031698|NCT00645463|Drug|CP-945,598|20 mg CP-945,598 + 240 mg MR Diltiazem
46031699|NCT00645463|Drug|CP-945,598|20 mg CP-945,598 alone
46031700|NCT04175587|Drug|Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid|Randomization is done centrally according to trial centers Eligible patients are randomly assigned (2:1) to the Treatment Group or the Control Group, with a 24-month follow-up.
46031701|NCT02668159|Dietary Supplement|Fish peptide supplement|6 capsules of fish peptide supplement (3g/each) administered prior to one of the OGTT
46031702|NCT02668159|Dietary Supplement|Vitamin D supplement|1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
46031703|NCT02668159|Dietary Supplement|Fish peptide + Vitamin D3 supplements|6 capsules of fish peptide (3g/each) + 1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
46031704|NCT02668159|Dietary Supplement|Placebo|7 tablets of placebos administered prior to one the OGTT
46031705|NCT02670109|Drug|Carmustine|300mg/m2, IV, in 3 hours, during day -4
46031706|NCT02670109|Drug|Cyclophosphamide|80mg/kg, IV, in 2 hours, during two days -2, -3
45598746|NCT02031575|Behavioral|Interactive Treatment|Mobile phone text messaging service about reproductive health
45598747|NCT02031575|Behavioral|Basic Treatment|Mobile phone text messaging service about reproductive health
45598748|NCT02031575|Other|Control, comparator arm|
46031707|NCT02670109|Drug|Carboplatin|1400/m2, IV, in 1 hour, during day -3
46031708|NCT02670109|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Transfusion, in 3 hours, during day 0
46031709|NCT02670109|Drug|Busulfan|16mg/kg, Oral, during day -4
46031710|NCT02670187|Biological|GLS-5300|
46031711|NCT00922636|Drug|LY2216684|Taken in tablet form QD po.
46031712|NCT00922636|Drug|Methylphenidate|Extended-release methylphenidate 18 mg/day to 54 mg/day, based on weight, QD po as a capsule for the 8-week double-blind treatment phase.
46031713|NCT00922636|Drug|Placebo (tablet)|Placebo given as a tablet for LY2216684 blind QD po for the 8-week double-blind treatment phase, followed by 2 weeks in the taper phase.
46031714|NCT00922636|Drug|Placebo (capsule)|Placebo given as a capsule for methylphenidate blind QD po for the 8-week double-blind treatment phase followed by 2 weeks in the taper phase.
46031715|NCT02667925|Drug|Intraperitoneal cisplatin with nanocis|Patients will receive an intraperitoneal chemotherapy combined to a radiotracer in order to assess the intraperitoneal distribution of the chemotherapy
46031716|NCT02669719|Biological|chemotherapy followed dendritic cells|Pemetrexed and carboplatin would be administered on day 1 of each 3-week cycle.Patients will start with dendritic cells treatment on Day 15 of pemetrexed and carboplatin chemotherapy from Cycle 3 provided that both leukapheresis and the production of dendritic cells are successful.
45682761|NCT01670032|Drug|Experimental: CD07223 1.5% Topical Gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
46031717|NCT02669719|Drug|pemetrexed and carboplatin|Chemotherapy with 4-6 cycles of pemetrexed and carboplatin as first-line induction chemotherapy followed by pemetrexed as maintenance therapy.
46031718|NCT00644761|Drug|Adefovir Dipivoxil|Adefovir dipivoxil 10 mg once daily for 14 days co-administered with tacrolimus or cyclosporine
46031719|NCT05330728|Other|Suggestions for lifestyle changes+ Abdominal massage|Suggestions for lifestyle changes+ abdominal massage will be applied. Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once. Abdominal massage will be applied 3 times a week for 4 weeks.
46031720|NCT05330728|Other|Suggestions for lifestyle changes+ Kinesio taping|Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once. Kinesio taping will be applied 3 times a week for 4 weeks.
46031721|NCT05330728|Other|Suggestions for lifestyle changes|Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once.
46031722|NCT00645073|Drug|cefdinir (Omnicef)|Two 300 mg cefdinir capsules on Study Days 1-10.
46031723|NCT00645073|Drug|levofloxacin|Two 250 mg levofloxacin capsules on Study Days 1-10
46031724|NCT04259008|Other|Manganese omission|Participants randomized to the experimental intervention arm will not receive added manganese in their parenteral nutrition.
46031725|NCT04259008|Other|"5 mCg/kg/day manganese from Multitrace-4 Neonatal."|"5 mCg/kg/day manganese from Multitrace-4 Neonatal."
46031726|NCT04258930|Other|Aluminum sulphate and calcium acetate drying soaks|Dilute one envelope of the powder in 500 ml of clean cold water and apply for 10 minutes every 8 hours until completely healed.
46031727|NCT04258930|Device|Topical sterile silicone gel for wounds|Apply a thick layer of silicone gel to all open areas every 8 hours until completely healed.
46031728|NCT04258930|Device|Hydrocolloid dressing|Apply enough hydrocolloid dressings to cover all open areas and change every 2 to 3 days once the dressing becomes saturated (starts to drain around the borders).
46031729|NCT02669875|Drug|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
45682762|NCT01670032|Drug|Placebo Comparator: CD07223 vehicle gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
46031730|NCT02669875|Drug|Placebo|Placebo solution (20mM sodium acetate pH5) diluted in 5% v/v glucose solution
46031731|NCT04176289|Diagnostic Test|PPI measurement|The pupillary dilatation reflex (PDR), induced by a standardized noxious stimulus will be measured as Pupillary Pain Index(PPI,11-point numeric scale, 0= no pain, 10= worst pain) determined with a portable pupillometer. Patients experiencing mild or more severe pain (PPI> 3) will receive intravenous opioid titration (piritramid, 3 mg bolus steps) and PPI measurement performed before and after intravenous opioid titration.
46031732|NCT02671045|Genetic|Genomic profile by FoundationOne|Proprietary comprehensive genomic profile.
46031733|NCT02671045|Genetic|Genomic profile by other methods|Genomic profiling by other testing methods.
46031734|NCT04084327|Other|stastical analysis|1-Clinical examination data-Complete Blood Count (CBC).Bone Marrow Aspiration (BMA)-Bone Marrow Biopsy (BMB). (if available)-Immunophenotyping results (IPT).Cytogenetic results
45682763|NCT01670032|Drug|Placebo Comparator: CD07223 vehicle gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
45682764|NCT03088228|Diagnostic Test|gingival crevicular fluid collection|
45682765|NCT01670500|Drug|Cisplatin|administered intravenously every 3 weeks for 4 doses
46031735|NCT01175135|Drug|PF-02545920|5 mg tablet every 12 hours for 28 days
46031736|NCT01175135|Drug|PF-02545920|15 mg tablet every 12 hours for 28 days
46031737|NCT01175135|Drug|Placebo|One tablet/capsule every 12 hours for 28 days
46031738|NCT01175135|Drug|Risperidone|3 mg capsule every 12 hours for 28 days
46031739|NCT02667613|Other|HABIT-ILE|Hand and arm bimanual intensive therapy including lower extremities
46031740|NCT02667613|Other|Control|Usual customary care
46031741|NCT00645541|Procedure|Axillary Reverse Mapping|Lymphazurin, isosulfan blue dye, injected into arm then a standard axillary lymph node surgery to remove any blue dyed lymph nodes found (lymph nodes that have traveled down the drainage pathways).
46031742|NCT02667769|Other|Fasting day|A day of fasting started at 18.00 clock with a blood glucose test and is only started when on the same day no significant hypoglycemia (blood glucose <55 mg / dl) occurred, and when at 18.00 clock the blood sugar in the defined target range (70-180 mg / dl) is. Carried out during the fasting day standardized blood samples for measurement of plasma glucose with an appropriate laboratory method at 18.00, 20:00, 22:00, 12:00, 2:00, 4:00, 6:45, 9:00, 12:00, 14:00 and again at 18.00 clock. Because the determination of plasma glucose in the laboratory will take some time, is always for guidance and also measured with a fast measurement method, in order to treat at high levels of blood sugar with additional insulin correction, and to treat hypoglycaemia low blood sugar or to prevent hypoglycaemia.
45682766|NCT01670500|Drug|Cyclophosphamide|administered with doxorubicin intravenously every 2 or 3 weeks for 4 doses
45472164|NCT05499377|Device|Tobacco product administration and assessment|Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 2 HTP flavor conditions (tobacco-flavored HeatSticks or Fresh Menthol-flavored HeatSticks), with equal probability and provided with a supply of their condition specific HTP and asked to use it in place of their usual menthol cigarettes for the next week. Participants use their own brand menthol cigarettes and assigned HTP both at home (naturalistic use) and in the clinical laboratory (two visits/week).
45472165|NCT05484245|Device|Sonography|Surgeon detects brain mass lesion and assesses extent of it's resection with sonography
45472166|NCT01259687|Device|Non-invasive cardiac output monitoring|During the surgery the continuous monitoring of blood pressure by peripheral artery catheter and cardiac output by NICOM (non-invasive cardiac output monitoring) will be applied. In case of intraoperative hemodynamic changes (hypertension, hypotension) the patient will be treated according to the standard care by Phenylephrine, Nitroglycerine or Colloid fluid boluses. Cardiac output will be measured by NICOM just before and after each treatment of hemodynamic events that described above. Simultaneous records of ECG, arterial and plethysmographic waveforms will be made just before and after each event. Systolic blood pressure and PuTT will be measured OFFLINE from the recorded waveforms
45472167|NCT03889769|Diagnostic Test|OSNA test|Analysis of lymph node with OSNA
45472168|NCT01154621|Drug|AZD9742|Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL
46031743|NCT02667691|Dietary Supplement|SODB Dimpless|Subjects are supplemented with SODB, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
46031744|NCT02667691|Dietary Supplement|Placebo|Subjects are supplemented with placebo, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
45472169|NCT01154621|Drug|Placebo|Sterile 5% dextrose solution
45472170|NCT03889691|Procedure|Third molar surgery|Surgical extraction of impacted lower third molar tooth under local anesthesia
45472171|NCT01260935|Procedure|Laparoscopic Hill Repair|With the Hill repair, stitches are placed right where the esophagus and stomach meet and attached to muscle tissue that is fixed to the spine.
45472172|NCT01260935|Procedure|Laparoscopic Nissen Repair|With the Nissen repair, the upper part of the stomach is wrapped around the esophagus, with some anchoring of the wrap at several locations.
45682767|NCT01670500|Drug|Doxorubicin|administered with Cyclophosphamide intravenously every 2 or 3 weeks for 4 doses
45682768|NCT03527992|Device|O2 automated|"In the O2 automated group, patients benefit from oxygen therapy via the FreeO2 device. The O2 saturation target is set by the clinician on the device. Saturation is continuously sensed by an oximeter and the oxygen flow is automatically adjusted. The clinician has access to instantaneous values and trends of O2 and SpO2 flow rates."
45682769|NCT03527992|Device|O2 standard|"In the O2 standard group, patients benefit from oxygen therapy with nasal goggles or a high concentration mask. Saturation is continuously captured by an oximeter. The flow rate of oxygen, evaluated in L/min, is adapted according to local protocols (every 8 hours in conventional hospital services, continuous in intensive care"
45682770|NCT01678612|Other|Copper-alloy surfaced objects|Room assigned to the Experimental arm will be furnished with copper-alloy surfaced objects,i.e. bed-rails, bed-rail levers, IV poles, nurse workstation, HCW clipboards, sink handles.
45682771|NCT03525574|Drug|VX-445|Fixed-dose combination (FDC) tablets (VX-445/TEZ/IVA)
45682772|NCT03525574|Drug|TEZ|FDC tablets (VX-445/TEZ/IVA)
45682773|NCT03525574|Drug|IVA|FDC tablets (VX-445/TEZ/IVA)
45682774|NCT03525574|Drug|IVA|IVA tablet
45682775|NCT03418402|Device|Airseal®|Total laparoscopic hysterectomy: Approach according to the Open-Laparoscopy technique and use of the insufflation system.
45682776|NCT03418402|Device|Standard insufflator|Standard insufflator
45682777|NCT02402920|Drug|Carboplatin|Given IV
45682778|NCT02402920|Drug|Cisplatin|Given IV
46031745|NCT02667691|Other|caloric restriction|Caloric recommendation reduced by 20%
46031746|NCT05098561|Other|Music Treatment|The nurse will set up the appropriate music genre for the each music treatment patient, based on patient's preference obtained from the pre-operative questionnaire, by using the bedside computer and using Pandora, the internet music streaming service.
45682779|NCT02402920|Drug|Etoposide|Given IV
45682780|NCT02402920|Other|Laboratory Biomarker Analysis|Correlative studies
46031747|NCT02669641|Dietary Supplement|Combination Silimarin, Phyllanthus niruri and Choline|Combination of one capsule: Phyllanthus niruri (225 mg), Silybum marianum (150 mg), Choline (60 mg) The dose: 3 capsules per day.
46031748|NCT02886221|Procedure|Reverdin-Isham Osteotomy|Incision on the medial part of the foot, a Shannon Isham burr was introduced at the junction of metaphysis and epiphysis. It was applied to the flat bone surface achieved previously at approximately 45°, keeping the articular cartilage surface of the first metatarsal head as reference point on the superior cortex. In this position, under fluoroscopic control, the osteotomy was started following a distal-dorsal and proximal-plantar direction. At this point, the burr was slightly withdrawn in order to preserve a few millimetres of the lateral cortex, and the osteotomy of the plantar cortex was performed completely. Then, a Wedge burr was used to create a wedge with a medially oriented base. At the point of closing the wedge, osteoclasis of the preserved lateral cortex was achieved, modifying the orientation of the articular surface, normalizing the DMAA value, and adding an intrinsic stability to the osteotomy by producing contact of the trabecular bone.
46031749|NCT02669485|Drug|indocyanine green|Injection of indocyanine green and using fluorescence imaging to assess perfusion of bowel before bowel transection and anastomosis
46031750|NCT02669485|Device|Fluorescence imaging|
45682781|NCT02402920|Biological|Pembrolizumab|Given IV
45682782|NCT02402920|Procedure|Radiation Therapy|Undergo radiation therapy
45682783|NCT03087682|Diagnostic Test|Optical Coherence Tomography (OCT)|OCT is used to measure thickness (numbers) of retinal nerve fibres in different areas of the retina
45682784|NCT03087526|Genetic|Non invasive prenatal diagnosis|Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
46031751|NCT05658185|Behavioral|MIDITRA|"The psychological treatment protocol will be implemented over 10 group sessions of face-to-face psychological treatment with patients. The treatment sessions will have the following objectives and themes:~Adjustment to the disease:~Self-esteem/self-concept:~Coping with fear:~Emotional self-regulation:~Social area and enjoyment:~Decision making and problem solving:~Communication and listening skills:"
45839277|NCT03021252|Device|High intensity IEMT|Training load will be the maximum inspiratory / expiratory load defined according to patient tolerance equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations / expirations (x 5 set), three times per day, during 8 weeks. External loads will be increased weekly at intervals of 10 cm H2O as tolerated. Patients will receive standard swallow therapy consisting of swallowing manoeuvres, oral exercises, and compensatory techniques aimed to improve self-management of dysphagia and protect the airway.
45472173|NCT01153139|Device|Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation, TBS)|intermittent TBS (iTBS) to the left DLPFC (600 stimuli, 80% resting motor threshold) continuous TBS (cTBS) to the right DLPFC (600 stimuli, 80% resting motor threshold)
45839278|NCT03021252|Device|Sham IEMT|5 sets of 10 inspirations and expirations in a sham IEMT trainer, three times a day, during 8 weeks.
45839279|NCT03020784|Drug|Placebo|Placebo
45839280|NCT03020784|Drug|PF-06818883|Treatment
45839281|NCT03019926|Biological|Hydroxychloroquine dosage|Blood sample from a 6 ml tube, performed in the common practice.
45839282|NCT03019848|Dietary Supplement|Curcumin|
45839283|NCT03019848|Other|Placebo|
45839284|NCT03019770|Behavioral|PrEP Decision Aid|All participants will participate in a simulated or actual clinical visit with a healthcare provider. During this visit, they will review the Decision Aid which will give them an HIV risk score and ask questions about their values. The goal of these visits will be to make an informed decision about whether or not to begin using PrEP.
46031752|NCT00922480|Drug|Fimasartan|Fimasartan 60 ~ 120mg/po take one tablets once a day
45472174|NCT01261091|Procedure|Early Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
45472175|NCT01261091|Procedure|Late Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
45839285|NCT03019614|Drug|Hydrocortisone|Generic hydrocortisone
45839286|NCT03019614|Drug|Chronocort|Modified formulation of hydrocortisone
46031753|NCT00922480|Drug|Losartan (Control)|Losartan 50 mg ~ 100 mg/po, take one tablets once a day
45839287|NCT03019380|Device|removing cerumen from external ear (Wondertip)|The wondertip will be coiled into the external ear canal with the purpose of grasping and evacuating the cerumen. Following the evacuation, the depth of the external ear canal will be messured.
45839288|NCT03019536|Drug|LY3303560 - IV|Administered IV
45839289|NCT03019536|Drug|Placebo - IV|Administered IV
45839290|NCT03019536|Drug|Florbetapir F 18|Administered IV during the Positron Emission Tomography (PET) scan performed during screening.
45839291|NCT03019536|Drug|Flortaucipir F18|Administered IV during the PET scan performed during the study.
45472176|NCT03889457|Other|anticoagulation choice|Type of anticoagulant chosen by the patient (oral or injectable).
45472177|NCT01153217|Drug|Switch from tenofovir to abacavir|Switch from tenofovir to abacavir
45472178|NCT03887273|Biological|Q-Cells|cellular therapeutic comprised of human cells of the glial lineage
45472179|NCT01561430|Drug|LY2886721|
45472180|NCT01561430|Drug|Placebo|
46031754|NCT04174885|Procedure|epicardial ablation|"In general anesthesia and left lung ventilation, authors will access the right thorax by three working ports. However, a rigid video thoracoscopic camera with a direct optics will be used. Pericardium will be widely opened anterior to a phrenic nerve and transverse and oblique sinuses were dissected. An insertion of the ablation catheter will be a tricky part of the surgery with the first MW catheter, while no special introducer will be provided. Later RF devices will be equipped with a special flexible introducers, lately also with a magnetic tip and the positioning of the catheter around PVs became much safer and easier.~The correct position of catheter will be visualized by trans esophageal echocardiography before the ablation."
46031755|NCT02886143|Procedure|Active Voiding Trial|"Nursing protocol:~Instill 250-400 cc of STERILE SALINE via the lumen of the Foley catheter into the bladder via gravity drainage or slow push~Clamp the Foley~Deflate the catheter balloon and remove the catheter from the bladder.~Record the amount of saline that was instilled into the bladder.~Immediately assist the patient to void. Report the amount instilled and the amount voided to the physician within one hour a. Unless the patient reports extreme bladder fullness or pain, give the patient one hour to urinate~7. If the patient fails the voiding trial, the physician will decide to do in and out catheterization or place a new Foley catheter"
46031756|NCT02886143|Procedure|Passive Voiding Trial|"Nursing protocol:~Deflate the catheter balloon and remove the catheter from the bladder.~Record the time that the catheter was removed and the time the patient is due to void (approximately 6 hours).~5. If the patient has not voided within 5 hours, assist the patient to try to void.~6. If the patient is unable to void, is only voiding in small amounts, or reports fullness or abdominal pain, perform a bladder scan.~7. If the patient has not voided after 6 hours, report this to the physician along with the results of the bladder scan 8. The physician will decide to do in and out catheterization or place a new Foley catheter"
46031757|NCT02670967|Dietary Supplement|Soluble Fibre|
46031758|NCT04258618|Behavioral|CBT-I (Cognitive Behavioral Therapy for Insomnia) with rTMS|Cognitive Behavioral Therapy for insomnia (CBT-I) with rTMS (repetitive Transcranial Magnetic Stimulation) will be performed as part of this study by the PI. This includes weekly, one hour sessions addressing sleep for 6 weeks.
45472181|NCT03887507|Other|Vojta Therapy|Each session will consist of a 45-minute Vojta thera between py protocol based on three exercises, 15 minutes per exercise: Crawling reflex, and 1st phase and 2nd phase Rolling reflex.
45472182|NCT03887507|Other|Standard Program|The program consist in balance exercises targeting core stability, exercises of coordination and Pilates as well as individual sessions using the Bobath concept.
45598749|NCT04478565|Other|Indirect Calorimetry|"RMR was calculated by breath oxygen consumption (O2 in mL·min-1), minute by minute, using a portable device (Breezing®, Arizona, USA), and the Weir equation (1949), while participants remained in a sitting position for ≈15 to 20 minutes.~The anthropometric measurements were performed by certified level 3 anthropometrists following the guidelines of the International Society for the Advancement of Kinanthropometry, ISAK"
45598750|NCT03516331|Drug|FDL176 & FDL169 coadministration|CFTR corrector and potentiator
46031759|NCT04258618|Device|Repetitive Transcranial Magnetic Stimulation|Participants in this study will be undergoing repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder as part of their clinical treatment. This involves magnetic stimulation with specific settings to a specific region of the brain to help treat depression. Treatment time ranges, but is around 30 minutes per session and occurs 5 days a week for 6 weeks.
46031760|NCT02669563|Drug|[18F]4F-MHPG|IV injection of [18F]4F-MHPG
46031761|NCT02669563|Drug|[18F]3F-PHPG|IV injection of [18F]3F-PHPG
46031762|NCT02669563|Drug|[13N]ammonia|IV injection of [13N]ammonia
46031763|NCT02669563|Drug|[11C]HED|IV injection of [11C]HED
46031764|NCT04963036|Other|Entropy and NOL-Guided Goal Directed Anesthesia|Entropy-guided Anesthesia (Propofol infusion in order to maintain Entropy between 45 and 55) and NOL-guided Analgesia (Remifentanil infusion in order to maintain NOL-Index between 10 and 25).
46031765|NCT04963036|Other|Standard of Care Group (Entropy and blinded NOL)|"Entropy-guided Anesthesia (Propofol infusion in order to obtain Entropy between 45 and 55) and Remifentanil infusion at the discretion of the anesthetist in charge, based on current practice: patient vitals (Heart Rate, Blood Pressure, Respiratory Rate…), movements, spontaneous breathing, experience....~In this group, nociception monitor screen will be concealed and the NOL index will not be available for guidance of remifentanil dosing)."
46031766|NCT02537119|Procedure|Dynamic massage therapy|Dynamic massage therapy on hamstring combined with knee extension
46031767|NCT02537119|Procedure|Massage therapy|Rubbing on hamstrings
46031768|NCT04255420|Procedure|SPG Block|A cotton-tipped applicator soaked in 1% lidocaine will be inserted into the nostril on the side of the headache. If the headache is bilateral, two cotton-tipped applicators will be inserted. The cotton-tipped applicators will be left in place for 15 minutes.
46031769|NCT04255420|Drug|Standard IV Treatment|Intravenous prochlorperazine 10 mg plus diphenhydramine 50 mg will be administered.
46031770|NCT00973479|Drug|Golimumab|Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes. Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100). Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).
46031771|NCT00973479|Other|Placebo|Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.
46031772|NCT00973479|Drug|methotrexate (MTX)|Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
46031773|NCT04082221|Other|no intervention|no intervention
46031774|NCT01174043|Drug|Erlotinib|Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles.
46031775|NCT04174183|Device|Closed-incision Negative-pressure Therapy - Dry dressing|A Closed-incision Negative-pressure Therapy is applied on one groin incision - A dry dressing is applied on one groin incision .
46031776|NCT04174495|Diagnostic Test|DXA and CT-scan|DXA and CT-scan are usually performed during the following of these patients before bariatric surgery
46031777|NCT04315493|Drug|pyrotinib maleate fasted in P1, low-fat diet in P2|pyrotinib maleate administration in fasted condition in period 1, pyrotinib maleate administration after low-fat diet in period 2
46031778|NCT04315493|Drug|pyrotinib maleate low-fat diet in P1, fasted in P2|pyrotinib maleate administration after low-fat diet in period 1, pyrotinib maleate administration in fasted condition in period 2
46031779|NCT04173871|Device|Protac Myfit®|A systematic proprioceptive-tactile stimulation by the Protac MyFit® vest. The children are asked to wear the Protac Myfit® vest from the beginning of every school day and for at least two sessions for three weeks.
45682785|NCT02404402|Other|LED|Low Level Light Therapy
45682786|NCT02404402|Other|sham LED|Inactive (sham) LED treatment
46031780|NCT02862483|Drug|Tamsulosin 0.2mg|
46031781|NCT02862483|Drug|Tadalafil 5mg|
46031782|NCT02862483|Drug|Placebo for Tamsulosin|
46031783|NCT01173653|Other|Smoking Cessation|Randomly introducing patients to a Department of Health program to help them quit smoking.
46031784|NCT01173653|Other|Smoking Cessation|A simple intervention where ED patients who were motivated to quit smoking were put in direct phone contact with a trained smoking cessation counselor during their ED stay.
45598751|NCT04486313|Drug|Nitazoxanide|Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days
45598752|NCT04486313|Drug|Placebo|Two placebo tablets administered orally twice daily with food for 5 days
45839292|NCT03019302|Device|Arrow PICC with Chloragard Technology|chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body
45839293|NCT03019224|Procedure|Selection and preparation of the volunteers|Patients who sought the postgraduate dental clinic for whitening were invited to participate in the study. They were informed by the researcher (dentist) about all the aspects of the study and who might participate or discontinue the participation at any moment during the treatment. In addition, it was clarified that their participation was voluntary and refusal to participate would not result in any penalty or loss of benefits.
46031785|NCT02667535|Drug|Isosorbide Mononitrate|"Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days.~Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days."
45472183|NCT03887195|Other|Training mandatory module about the therapeutic relationship|"The training programme is composed by:~2 lectures (optional)~6 supervision sessions by Balint type groups (5 of which are mandatory);~5 role-plays (all required);~2 OSCE with patient actors (all required). This teaching is initiated by two lectures on the relationship, the awareness, the listening, the empathy, the therapeutic distance, and the personal impacts that affect the relationship.~It included six sessions of Therapeutic Relation Training Groups inspired by the Balint groups. Five role-play sessions are also organized from January to May, the students could play the doctor or the patient. The scenarios are about the following themes: announcement of bad news; accompaniment of chronic disease; management of aggressiveness and hostility; etc. After the role-play, a feedback done by the teacher and the group helps to elaborate what has happened. Finally, a formative assessment will be made during the Clinical Objective Structured Examination."
45472184|NCT03931070|Drug|Ramelteon|Nightly administration of Ramelteon 8 mg
45472185|NCT03931070|Drug|Placebo - Cap|Nightly administration of Placebo capsule, which is indistinguishable from Ramelteon
45472186|NCT01153295|Procedure|Clinical diagnosis based on symptom criteria|The diagnosis is based on ROME III criteria, abscence of danger signals and FBC, CRP
45598753|NCT04486313|Dietary Supplement|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
45839294|NCT03019224|Procedure|Evaluation of the tooth color|"The evaluation of the tooth color was performed by using a spectrophotometer (Easyshade, Vident, Brea, CA, USA). The color was analysed with the tooth hydrated before of the start the first whitening session and one week after.~The spectrophotometer was always used in the same position by a silicon guide, which was prepared with dental arch molds by adding high viscosity vinyl polysiloxane material (Express XT, 3M ESPE, Sumaré, SP, Brazil). After polymerization, an opening was made in the mold corresponding to the buccal surface of the upper central incisors, allowing the color of the tooth to be evaluated with the tip of the spectrophotometer at the height of the middle third."
45839295|NCT03019224|Procedure|Relative isolation|The clinical procedures were performed under relative isolation using lip retractor (Arcflex, FGM, Joinville, SC, Brazil) and dental cotton rollers to apply a gingival protection barrier (Top Dam, FGM, Joinville, SC, Brazil) extending from right first molar to left first molar in both arches.
45839296|NCT03019224|Procedure|Gingival protection barrier|The gingival protection barrier was placed over the margins and gingival papilla corresponding to the areas receiving the whitening gel with approximately 3 mm in height and photopolymerized for 20 seconds in each group of three tooth. Photo-activation was performed with high power LEDs (light intensity = 600mw / cm²) (RadiiCal, São Paulo, SP, Brazil).
45839297|NCT03019224|Procedure|Application of desensitizing gel|The desensitizing gel containing 5% potassium nitrate associated with 2% sodium fluoride (Desensibilize KF 2%, FGM, Joinville, SC, Brazil) was applied with a microbrush (Brush KG, KG Sorensen, Cotia, SP) on the buccal surface from right first molar to left first molar in both arches and remaining for 10 minutes. Then, the desensitizer was then removed with water jet and disposable plastic suction cannula.
45472187|NCT01153295|Procedure|Diagnosis of exclusion|The diagnosis is based on normal investigations involving endoscopy with biopsy, stool for ova and parasites, FBC, CRP, TSH, Ca, ALT, alanine aminotransferase; alkaline phosphatase, serum bilirubin, Screening for lactose and celiac sprue
45472188|NCT03773120|Device|Using Neuromonitoring to find EBSLN|intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
46031786|NCT04284735|Other|Quantitative ATX and LPA determination in plasma and sputum|"Determination of ATX and LPA levels in plasma and sputum from RA-ILD patients (cases) and in plasma and sputum from RA patients without ILD (controls) after sputum induction using hypertonic saline inhalation"
46031787|NCT05657951|Device|ArcScan Insight 100 very high-frequency digital ultrasound|The Insight-100 (ArcScan Inc., Golden, CO, USA) employs the high-frequency B-scan in the assessment of anterior segment parameters. Anormal saline coupling medium is formed with a disposable eyepiece between the 50 MHz transducer and the eye. The instrument moves the transducer in an arc so that the beam axis maintains approximate normality to the surface of the eye. The frequencies of cornea, anterior chamber, and lens are 60 MHz, 50 MHz and 50 MHz, respectively. The maximum arc scanning range is 70 degrees, and there is a linear scanning range of 29mm. The axial and lateral resolutions are 35 μm and 65 μm, respectively. It can measure structures behind the iris, including lens zonule.
45472189|NCT01259765|Drug|VHH batch 203027|The active product is 165 mg of VHH batch 203027 and 835 mg maltodextrin with 0.5% (w/w) caramel colour in 10 mL ORS. The osmolality (concentration of the osmotically active substances in the solution such as sugar molecules, salts etc. ) of this solution will be around 60 mOsmol/kg. The mixture of the 165 mg of VHH batch 203027 and 835 mg maltodextrin (0.5% (w/w) caramel colour will be provided per sachet.
45472190|NCT01259765|Drug|Placebo product|The Placebo treatment consisted of 1000 mg of maltodextrine with 5% (w/w) caramel colour in 10 mL ORS.
45472191|NCT05683886|Drug|KC1036|Patients take 60mg QD of KC1036 for the efficacy and safety study. KC1036 are given orally once daily, 21 days as a cycle.
45472192|NCT01261169|Drug|Myfortic|Myfortic in uveitis
45598754|NCT02354001|Drug|Raloxifene hydrochloride|120mg daily- 1 capsule for 12 week trial
45472193|NCT03747848|Behavioral|CBT group|Each interested individual will complete eligibility screening, consent form, and pre-intervention assessment. Demographic information such as gender, age, and number of years since diagnosis of PD will be collected. This investigator will implement the treatment program by meeting with the participants in groups, once a week, for six weeks. Group meetings will encourage interaction and support among group participants. Program content includes encouraging physical exercise with higher intensity, changing poor sleeping hygiene habits, stress management, and encouraging utilization of social support.
45472194|NCT03911063|Behavioral|CBT sessions|weekly 20-40 min CBT sessions during 8 weeks; Both the talking sessions (i.e., placebo) and CBT sessions will be performed via telemedicine either via a HIPAA secure telemedicine platform or the telephone based on the preference of the individual patient.
45598755|NCT02354001|Drug|Placebo|1 capsule daily for 12 week trial - lactose
46031788|NCT02667145|Other|Self care program focusing on the assistive device|self-heed program focusing on the assistive device will consist of four weekly meetings lasting approximately 90 minutes. it will be stimulated the self-heed through knowledge of pathology and guidelines of protection articulate, and will be supplied, and trained the use of assistive devices to improve the performance of volunteers in their daily activities. Assistive devices are devices, not attached to the body, which help people with limited movements and restrictions on participation in the activities of everyday life. Example: thickening of tableware, tin openers. These volunteers will be evaluated in three stages: 1-initial assessment 2-after completion of the program and 90 days after the initial assessment. The questionnaires that will be used are: EVA; SACRAH; COPM; WHOQOL-Bref.
46031789|NCT04316819|Other|Packed Promise Demonstration Benefits|Monthly: Home-delivered food box, nutrition education handout, and $15 monthly voucher for fruits and vegetables
45598756|NCT03516253|Dietary Supplement|Fish oil + EPO|Supplementation with both fish oil and EPO
46031790|NCT04286841|Drug|Immunotherapy|Patients in this group should be histologically confirmed potentially resectable NSCLC with stage II-IIIA. Furthermore patients would receive either single agent immunotherapy or immunotherapy combined with chemotherapy.
46031791|NCT00645151|Drug|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
46031792|NCT00645151|Drug|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
46031793|NCT00645151|Drug|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
46031794|NCT03679299|Other|Observational - No intervention|See outcomes
45598757|NCT02228837|Dietary Supplement|Pear|
46031795|NCT00645229|Drug|Ziprasidone|Ziprasidone 20 mg capsules twice daily on Days 1-3; dose could be increased if clinically indicated up to 80 mg twice daily; total treatment duration was to be 24 weeks
45682787|NCT03521518|Diagnostic Test|Conner's Continuous Performance Test-3|CPT-3 allows quantitative assessment of visuospatial, attention and reaction time in patients being evaluated for Normal Pressure Hydrocephalus undergoing a CSF tap test.
45682788|NCT02405260|Drug|TTP399 400 mg|once daily
45682789|NCT02405260|Drug|TTP399 800 mg|once daily
45682790|NCT02405260|Drug|Sitagliptin 100 mg|once daily
45682791|NCT02405260|Drug|Placebo|once daily
45682792|NCT03519646|Drug|Eliglustat|"This is a 3-year study and the enrollment time of this study is 24 months.~The participants have to receive the investigational agent, Cerdelga~The participants have to go back to the hospital and receive the investigational agent and take the test before receving Cerdelga, and 2 weeks, 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga.~IMP Administration Method: Cerdelga have 21 mg、42 mg and 84 mg capsule.~No need for fasting before use, but can't take with grapefruit juice.~Five ml Blood and 10 ml urine shoud be taken before receiving Cerdelga, and 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga for Gaucher related biomarkers test."
45682793|NCT02984722|Drug|Metformin|
45682794|NCT02402530|Drug|Placebo|Matching placebo administered as intravenous infusion.
45682795|NCT02402530|Drug|Neridronic acid 62.5 mg|Neridronic acid administered as intravenous infusion.
45682796|NCT03087370|Other|No intervention|No intervention
45682797|NCT03515512|Drug|Enasidenib|Enasidenib may help block the over production of IDH2, which when mutated, can overproduce metabolites and compounds that contribute to the growth of tumors and cancerous cells
46031796|NCT01172873|Drug|D-cycloserine|50 mg dose of D-cycloserine administered at the end of each session of Cognitive Behavioral Therapy With Exposure and Response Prevention: twice weekly CBT/ERP of 60 minutes
46031797|NCT01172873|Behavioral|Exposure and Response Prevention (EX/RP)|Exposure and response prevention treatment. Participants complete graded exposure during twice weekly treatment sessions with therapist
46031798|NCT02886299|Drug|Fenofibrate|
46031799|NCT02886299|Drug|Simvastatin|
46031800|NCT02667379|Other|Diagnostic skin testing|14 Skin prick tests on each volar forearm with cat dander samples.
46031801|NCT04942717|Behavioral|CONVO intervention|The CONVO intervention consists of oncology nurse-led discussions exploring patients' health-related values as part of routine oncology care for all patients, from the beginning of oncologic care. Nurses will use the Nurse's Values Discussion Guide. At these sites, chemotherapy nurses will deliver the CONVO discussion, as patients at these sites do not have primary nurses assigned and because oncology doctors, BPs and PAs do not work one-on-one as a pair with a unique nurse.
45682798|NCT03514888|Procedure|HIPEC|40mg of Mitomycin-C dissolved in 100ml normal saline will be added into the perfusate and instilled into the patient for a total of 60 minutes. After 60 minutes, the abdomen will be irrigated with 3 liters of normal saline.
46031802|NCT05261659|Behavioral|Exposure Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound is associated with a waking experience (i.e., positive feedback in this study) and strengthening it during REM sleep, the investigators aim to accelerate the remission of social anxiety disorder.
45682799|NCT03087292|Other|Resistance training with vascular occlusion|Patients will perform unilateral leg extension resistance training with vascular occlusion 2 times per week for a period of 8 weeks. Each training session will consist of 3 sets of 15 repetitions at the intensity of 30% 1 RM with 30 s of rest period between sets.
46031803|NCT05261659|Behavioral|Exposure Therapy|These patients will receive the classic treatment of Exposure Therapy (ET) for social anxiety disorder without any association with a sound.
46031804|NCT00925600|Biological|Denosumab|Prefilled syringe for subcutaneous (SC) injection administered at a dose of 60 mg
46031805|NCT00925600|Biological|Placebo|Prefilled syringe for subcutaneous (SC) injection
46031806|NCT00645307|Drug|Extended Release OROS® Paliperidone|
45472195|NCT03911063|Behavioral|Talking Sessions|20-40 min talking sessions (i.e., placebo) for 8 weeks; The placebo talking sessions will be performed by an acute care and palliative care board certified, New York State licensed nurse practitioner at the NYU Dysautonomia Center who is familiar with each FD subject enrolling in the study and an expert in familial dysautonomia. The NP will focus the 20-40 minute conversation on typical medical questions and concerns that the FD patient routinely calls the Center to discuss.
45598758|NCT02228837|Dietary Supplement|Placebo|
45598759|NCT02347839|Procedure|Gefitinib-surgery-gefitinib|neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib
45682800|NCT02401750|Drug|Oxycodone Naltrexone (a)|
45682801|NCT02401750|Drug|Oxycodone Naltrexone (b)|
45682802|NCT02401750|Drug|Placebo|Matches both experimental drugs
45598760|NCT02289547|Drug|Capecitabine|maintenance capecitabine therapy after six cycles of XELOX
46031807|NCT02666287|Drug|BAT/FF|BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.
46031808|NCT02666287|Drug|BAT|BAT is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose appear as dry white powder. Second strip contains lactose which appear as a dry white powder.
46031809|NCT02666287|Drug|FF|FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose which appear as dry white powder.
46031810|NCT02666287|Drug|FF (MgSt)|FF magnesium stearate is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose with magnesium stearate which appear as dry white powder.
46031811|NCT02666287|Drug|FF/Vilanterol|FF/Vilanterol is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 25 mcg per blister of vilanterol blended with lactose and magnesium stearate appear as dry white powder and second strip contains 100 mcg per blister of FF blended with lactose which appear as dry white powder.
45682803|NCT02400736|Behavioral|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is the evidenced based model of supported employment.
45682804|NCT02400736|Other|Treatment as Usual Vocational Rehabilitation/Transitional Work (TUA-VR)|Vocational Rehabilitation Treatment as Usual includes pre-vocational counseling, Community Based Supported Employment, or most commonly Transitional Work assignments (TW).
45682805|NCT03087136|Diagnostic Test|anti-aquaporin-4 antibody|Serum anti-aquaporin-4 antibody
45682806|NCT03087136|Diagnostic Test|anti-myelin oligodendrocyte glycoprotein|Serum anti-myelin oligodendrocyte glycoprotein
45682807|NCT03086980|Other|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
45682808|NCT03086980|Other|Treatment as Usual|Usual Care will be provided.
45682809|NCT03086668|Procedure|Conventional Jaw thrust Group|a video-stylet assisted nasotracheal intubation and facilitate by conventional jaw thrust technique
45682810|NCT03086668|Procedure|Fingers hook Group|a video-stylet assisted nasotracheal intubation and facilitate by fingers-hook technique
45682811|NCT01689519|Drug|Placebo|Placebo supplied as tablets
45682812|NCT01689519|Drug|Vemurafenib|Vemurafenib supplied as tablets
46031812|NCT02668861|Drug|Vitamin D|Vitamin D 4000IU/day for 8 weeks
46031813|NCT02668861|Drug|Budesonide Nasal Spray|Budesonide Nasal Spray 128ug/d for 8 week
46031814|NCT02668861|Other|placebo|placebo for 8 weeks
46031815|NCT05330650|Drug|Coated Vicryl+|We used coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
46031816|NCT05330650|Drug|Vicryl|We used non coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
46031817|NCT05330572|Other|No interventions were administered to the patients as a part of this study.|No interventions were administered to the patients as a part of this study. Patients who were under topical steroid regime as a part of their management plan for lichen planus will be enrolled on the study. Details of prescribed topical steroid regime for lichen planus: type of corticosteroid, formulation, frequency of application, duration of treatment will be recorded.
46031818|NCT02668705|Other|Embodied Conversational Agent|A computer generated character that can administer informed consent to a potential research subject.
46031819|NCT04879654|Procedure|endoscopic surgery|endoscopic surgery followed by multimodality treatment including radiotherapy,Toripalimab,and/or chemotherapy
46031820|NCT04997005|Device|AMIStem-P|Performance of Total Hip Arthroplasty (THA) with AMIStem-P femoral stem implant
45682813|NCT01689519|Drug|Cobimetinib|Cobimetinib supplied as tablets
45682814|NCT01689363|Drug|Hyaluronidase|Subjects received intradermal injections of 0.02 mL Amphadase® (hyaluronidase 150 USP units/mL) at two random sites on their forearms.
46031821|NCT04255888|Procedure|Laterally positioned flap in thick periodontal phenotype.|Laterally positioned flap will be performed in isolated gingival recession belonging thick periodontal phenotype .
46031822|NCT04255888|Procedure|Laterally positioned flap in thin periodontal phenotype.|Laterally positioned flap will be performed in isolated gingival recession belonging thin periodontal phenotype .
46031823|NCT02668627|Procedure|Endovascular treatment|Endovascular mechanical thrombectomy or endovascular delivery of thrombolytic agent
45682815|NCT01689363|Drug|Histamine|Subjects received one intradermal injection of 0.02 mL Histatrol® (histamine base 0.1 mg/mL) at one random sites on their forearms.
46031824|NCT00968253|Drug|Everolimus (RAD001)|Beginning dose of 5 mg tablets every other day by mouth followed by a big glass of water. First dose will occur 1 day before receiving chemotherapy.
46031825|NCT00968253|Drug|Cyclophosphamide|300 mg/m^2 intravenous (IV) over 3 hours every 12 hours x 6 doses on Days 1, 2, 3 (total dose 1800 mg/m2).
46031826|NCT00968253|Drug|Vincristine|2 mg IV on Day 4 and Day 11 ± 2 days.
46031827|NCT00968253|Drug|Doxorubicin|50 mg/m^2 IV over 24 hours via central venous catheter on day 4, after last dose of Cyclophosphamide given.
46031828|NCT00968253|Drug|Dexamethasone|40 mg IV or orally daily days 1-4 ± 2 days and days 11-14 ± 2 days.
45472196|NCT03939962|Drug|SHR1210 combined with FOLFOX|"SHR1210, iv, 200 mg d1, 30-minute intravenous infusion, repeated every 14 days.~FOLFOX: Oxaliplatin 85mg/m2 ivgtt 2h d1; 5-fluorouracil 400mg/m2 iv d1; leucovorin 400mg/m2 ivgtt 2h d1,5-fluorouracil 2400mg/m2 CIV 46h, repeated every 14 days Patients who have no disease progression and can tolerate surgery receive surgery. When the investigator believes that the patient is not suitable for continued medication or according to the RECIST 1.1 standard, the evaluation is PD and the medication is over. The PD-1 monoclonal antibody does not allow for reductions and can only delay or suspend medication."
46031829|NCT00968253|Drug|Mesna|600 mg/m^2 IV continuous infusion daily for 24 hours days 1-3.
45682816|NCT01689363|Drug|Saline|Subjects received one intradermal injection of 0.02 mL saline at one random site on their forearm.
46031830|NCT00968253|Drug|Methotrexate|200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 IV over 22 hours day 1.
46031831|NCT00968253|Drug|Ara-C (Cytarabine)|3 gm/m^2 IV over 2 hours every 12 hours for 4 doses on days 2, 3.
46031832|NCT00968253|Drug|Methylprednisone|50 mg IV over 2 hours approximately every 12 hours for 6 doses days 1-3.
46031833|NCT00968253|Drug|G-CSF|10 mcg/kg/day (rounded) within 72 ± 48 hours after completion of chemotherapy until neutrophil recovery 1 x 109/L or higher. Pegfilgrastim (given at 6 mg subcutaneous for one dose approximately 24 hours after completion of the chemotherapy) may be substituted for G-CSF.
46031834|NCT04258540|Behavioral|Yoga group|The intervention group received yoga 2 times a week for 12 weeks (á 1.25 hr).
46031835|NCT04258540|Behavioral|yoga course|yoga course
46031836|NCT00646009|Drug|budesonide/formoterol|
46031837|NCT00646009|Drug|fluticasone/salmeterol|
46031838|NCT00646009|Drug|albuterol|
45682817|NCT04410471|Diagnostic Test|CLIA of IgG and IgM against SARS-Cov-2|Report of clinical data
45682818|NCT02072421|Procedure|PCI|
45682819|NCT01558635|Device|Cardioblate CryoFlex Surgical Ablation|Longstanding persistent AF was treated with the Cox Cryo Maze III procedure During mitral valve surgery a surgical ablation was performed, using the Cardioblate CryoFlex Surgical Ablation System. In addition, the Medtronic Reveal XT Insertable Cardiac Monitor, was implanted.
45682820|NCT01558635|Procedure|Mitral Valve surgery|Classic mitral valve surgery was performed
45682821|NCT01558635|Device|Medtronic Reveal XT Insertable Cardiac Monitor|During the procedure, a Medtronic Reveal XT Insertable Cardiac Monitor was implanted to monitor episodes of AF during follow-up period
45682822|NCT01558635|Procedure|MAZE III|Longstanding persistent AF was treated with the Cox Cryo Maze III procedure
45682823|NCT00089986|Drug|Intravenous GR270773- Phospholipid Emulsion|
45682824|NCT00089986|Other|Placebo|
45682825|NCT03507946|Device|Dermawrap - combined 460nm, 633nm and 830nm LED therapy|Daily treatments of 15 minutes of combined LED phototherapy, 5 days per week for 12 weeks.
46031839|NCT04069663|Other|No interventional study|Retrospective data analysis
46031840|NCT04255654|Other|Brief Intervention for Food Insecurity|2 item screening tool (brief intervention)
46031841|NCT00646087|Drug|Ketamine|0.5 mg/kg of ketamine every other day for 12 days (days 1, 3, 5, 7, 9, 11)
46031842|NCT00646087|Drug|Ketamine/Saline|0.5 mg/kg of ketamine on days 1 and 7, placebo (saline) on days 3, 5, 9, 11
46031843|NCT04255576|Dietary Supplement|Dietary Supplement: Calcium/Vitamin D|All subjects should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
46031844|NCT02668315|Biological|Transplantation of cord blood expanded with UM171|Myeloablative or submyeloablative conditioning regimen followed by an expanded cord blood transplant
46031845|NCT05309434|Behavioral|Coach|The coach coordinates the initiation of CPR, communicates feedback device data to assist those performing compressions, communicates average targets for compressions and ventilations and coordinates operations to achieve those values, and communicates with the team to reduce pauses in compressions.
46031846|NCT04175197|Device|Drug Coated Balloon|Legflow Drug Coated Balloon
46031847|NCT02862405|Other|vision tests|
45682826|NCT03504124|Other|Multicomponent intervention|An 18-month multicomponent intervention, which includes protocol-based treatment using: a standard blood pressure (BP) management algorithm, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.
45682827|NCT03503344|Drug|Apalutamide|Given PO, 240 mg per day (4 x 60mg tablets)
45682828|NCT03503344|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45682829|NCT03455686|Other|Hyperpolarized 129Xe MRI|Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas is a research approach for the non-invasive visualization and measurement of lung structure and function.
45682830|NCT03086824|Device|magnetic resonance-guided focused ultrasound|
45682831|NCT03455140|Drug|PEG- BCT-100|PEGylated recombinant human arginase 1
46031848|NCT04258696|Device|diode laser|using Ultrapak Knitted retraction cord as a gingival retraction method . using Wiser Cordless Dental Diode Laser from Doctor Smile Dental Laser By LAMBDA SpA Italy as a gingival retraction method.• The tip of diode laser, will be angled toward the soft tissue and away from the prepared tooth, will be passed along the gingival sulcus to remove the sulcular epithelium. Constant and steady short brushing strokes gently removed the lining of the sulcus in order to achieve a full 360-degree trough. The tip will be constantly cleaned with a gauze sponge wetted with hydrogen peroxide to remove debris and to eliminate potential bacterial contamination. sufﬁcient epithelium will be removed to place the impression material and visualize the ﬁnishing line. The tissue will be kept moist with water during the procedure then impression will be taken
46031849|NCT04258696|Device|ultrapak Knitted retraction cord|using Ultrapak Knitted retraction cord as a gingival retraction method retraction cord will be applied for 8-10 mins then an impression will be taken , poured to obtain a cast and the die sectioned
46031850|NCT05180565|Device|Colovac|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
46031851|NCT04255498|Drug|Etanercept|"Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies."
46031852|NCT04255498|Drug|Mifepristone|"Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies."
46031853|NCT00645775|Dietary Supplement|IGOB131|Comparison of 250 mg per day of Irvingia gabonensis to placebo
46031854|NCT02862249|Biological|Faecal microbiota transplantation|The FMT (200mls) will be administered following preparation of the bowel with MoviPrep®, into the duodenum via a gastroscope derived from 50g of fresh donated stool from a healthy donor. The gastroscopy will be performed as per the King's College Hospital Gastroenterology Protocol.
46031855|NCT02862249|Biological|Placebo|An identical appearing placebo solution (200mls 0.9% normal saline and 12.5% glycerol) will be administered into the duodenum via a gastroscope in a single blinded fashion following preparation of the bowel with MoviPrep®.
45472197|NCT02527499|Behavioral|Ride-On Cars with Bimanual Training Program (ROCBT)|The car driving training includes 2 phases: I-car exploration and II-prompted driving. Participants can learn how to move and stop the car in the car exploration phase. Through prompted driving in phase II, they can use the car as a mean to explore environments (e.g., to the elevator, to different stores) and contact with people (e.g., drive to the caregiver and get the toy). Bimanual training involves activities which include perceptual motor tasks (e.g., smear both hands with color), holding and manipulative tasks (e.g., cutting toy vegetables or fruits), posture and balance (e.g., pull a cart), and self-care and activities of daily living (e.g., drinking water from a cup with two handles).
46031856|NCT04258384|Other|survey application|Data collection tools used in the study; Demographic Data Form, Mcgill and Melzack Pain Questionnaire, Short Form-36 (SF-36), Vanderbilt Multidimensional Pain Coping Inventory (VMPCI), Pain Coping Inventory (PCI), Pain Coping Scale were used.
46031857|NCT02666209|Drug|Ulocuplumab|CXCR4 inhibitor given weekly on a 28 day cycle intravenously
46031858|NCT02666209|Drug|Lenalidomide|immunomodulatory agent given days 1-21 of a 28 day cycle orally in subjects not receiving bortezomib
46031859|NCT02666209|Drug|Bortezomib|proteasome inhibitor given at physician discretion in subjects not receiving lenalidomide
46031860|NCT02666209|Drug|Dexamethasone|steroid given at physician discretion on a 28 day cycles
46031861|NCT00964743|Drug|DepoCyt|Patients were to receive DepoCyt through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses.
46031862|NCT00964743|Drug|Sorafenib|Patients received oral sorafenib at 400 mg twice a day
46031863|NCT04258774|Other|Carbon Dioxide|The study team will administer inhaled carbon dioxide to the participants during an MRI at a level
46031864|NCT02537041|Procedure|elastography function ShearWave Imaging|non-invasive assessment of myocardial stiffness by elastography
46031865|NCT02537041|Procedure|MRI|
46031866|NCT02862327|Drug|intravenous dexamethasone|intravenous injection of dexamethasone
45472198|NCT02527499|Behavioral|Early Mobility Training Program|Most of the guidelines are similar with ROCBT, except for the bimanual training. The therapist and family will merely focus on independent mobility training and improving socialization. The training time and period is the same as ROCBT.
45682832|NCT03086512|Device|Acutrak 2® - 7.5 Screw|"The Acumed Acutrak 2® - 7.5 is a fully-threaded headless screw fixation, composed of 17 unique screw size options. The Acutrak 2® - 7.5 is available in sizes from 40 mm to 120 mm and is inserted using a 4.0 mm hex driver over a .094 guide wire. The Acutrak 2 Part Number is 30-0XXX and 30-0XXX-S."
46031867|NCT02862327|Drug|intravenous placebo|intravenous injection of placebo
46031868|NCT02862327|Drug|perineural ropivacaine|brachial plexus block with perineural injection of Ropivacaine in the axillary fossa
46031869|NCT02862327|Other|ultrasound guidance|ultrasound guidance for brachial plexus block in the axillary fossa
46031870|NCT04945720|Procedure|Hepatic artery infusion chemotherapy（HAIC）|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
46031871|NCT04945720|Drug|Durvalumab|Patients received anti-PD-L1 agents will begin no earlier than 7 days following the first HAIC procedure. Anti-PD-L1 agents were used intravenously at the standard dose: Durvalumab was given every 3 weeks during HAIC treatment (Q3W) and every 4 weeks after HAIC treatment (Q4W).
46031872|NCT02666365|Procedure|Bolus infusion of Cefazolin|Subjects in the bolus infusion arm of the study will receive bolus infusions of cefazolin throughout the surgical procedure
46031873|NCT02666365|Procedure|Continuous infusion of Cefazolin|Subjects in the continuous infusion arm of the study will receive a continuous infusion of the cefazolin throughout the surgical procedure
46031874|NCT03423303|Diagnostic Test|Prostate cancer screening|Depending on each diagnostic test result the participants in the screening arm will undergo PSA-testing, 4Kscore determination, MRI, and MRI/US fusion biopsy only.
45472199|NCT02527499|Behavioral|Regular Therapy Program|The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance at the hospital for 1 hour/per session, 1 session/per week during the 9-week intervention phase.
46031875|NCT04939402|Diagnostic Test|Serological testing|Antibody testing for Sars-CoV-2 specific antibodies in blood + T cell immunity
46031876|NCT04268433|Other|N/A - Non-interventional study|"Stages:~Patient information and written informed consent (3 Copies. To be carried out >24 hours after receiving the patient information sheet)~Physiological recording set up (ECG, BP, sensor and respiratory band)~Control period - no music played~Series of pieces of music without tempo control~Repeat series of pieces of music with tempo control~Participant leaves the study"
45682833|NCT03086512|Device|Synthes® 7.3 Cannulated Screw|The Synthes® 7.3 mm Cannulated screws are available in three thread options: 16 mm, 32 mm or fully threaded. This study will use the partially threaded options. The screws can be placed by small diameter guide wires. They are composed of 316L stainless steel or titanium alloy (Ti-6Al-7Nb).
45682834|NCT03452878|Behavioral|Aggressive behavior|Aggressive Behavior Scale, Quality of Life (SF-36) and Agitated Behavior Scale, measurement of thyroid-stimulating hormone (TSH), T4, T3, Cortisol, Luteinizing Hormone (LH), Estradiol, Prolactin, Progesterone, testosterone, and sex hormone-binding globulin (SHBG) and Resonance Magnetic Imaging.
45472200|NCT03889379|Drug|Administration of albuterol|Participants will inhale nebulized albuterol at a concentration of 2.5mg diluted in 3mL of normal saline for 20 minutes.
45472201|NCT03911219|Other|eHealth system support for symptom management via CANKADO|Regular use of eHealth support system CANKADO by the patient: symptom self-reporting triggering alerts to the patient; in addition to standard of care symptom management.
45472202|NCT05168228|Procedure|Oil- versus waterbased contrast in hysterosalpingography (HSG)|The Neuro-H2Oil study looks at the offspring of the H2Oil study, a randomized controlled trial (RCT) comparing hysterosalpingography (HSG) with oil- versus water-based contrast during fertility work-up. For more information please see NTR 3270 (original H2Oil study), www.trialregister.nl. The control group is the Database for Controls in Neuroscience Studies (D-CNS), registered as NL9574 (https://www.trialregister.nl/trial/9574).
45472203|NCT05161676|Dietary Supplement|Ketone monoester|Commercially available ketone supplement
46031877|NCT00645385|Other|MRS Spectroscopy|"Magnetic Resonance Spectroscopy uses a continuous band of radio wave frequencies to excite hydrogen atoms in a variety of chemical compounds other than water. These compounds absorb and emit radio energy at characteristic frequencies, or spectra, that can be used to identify them. Generally, a color image is created by assigning a hue to each distinctive spectral emission. This comprises the spectroscopy part of MRS. MRS is still experimental, and is available in only a few research centers.~Physicians mainly use MRS to study the brain and disorders such as epilepsy, Alzheimer's disease, brain tumors, and the effects of drugs on brain growth and metabolism. The technique is also useful in evaluating metabolic disorders of the muscles and nervous system. MRS is a noninvasive scan similar to an MRI that may be done at the same time as an MRI."
46031878|NCT02862093|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation of the dorsolateral prefrontal cortex
45472204|NCT05161676|Dietary Supplement|Placebo drink|Isocaloric placebo
45472205|NCT03887039|Other|clinical examination|clinical examination for all the oral findings
45472206|NCT05159492|Device|PVI using PEF|PVI using PEF
45472207|NCT05159492|Device|PVI using CFRF|PVI using CFRF
45472208|NCT03910829|Behavioral|Action Observation|Action observation training
45472209|NCT03910829|Behavioral|Motor Imagery|Motor imagery protocol
45472210|NCT03910829|Behavioral|Placebo Action Observation|Placebo Action Observation
45472211|NCT05159102|Other|12-week FMS Intervention|4 sessions, no more than 3 hours per session covering 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) and Sports (during intervention)
46031879|NCT02666443|Drug|Control intervention (no dexamethasone)|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 50 mL normal saline.
46031880|NCT02666443|Drug|Peri-neural Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL dexamethasone 1% (1 mg dexamethasone), and an intravenous solution of 50 mL normal saline.
46031881|NCT02666443|Drug|Intravenous Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 49.9 mL normal saline with 0.1mL dexamethasone 1%
46031882|NCT00925522|Device|Therapy Cool Path Duo Cardiac Ablation System|"Cardiac Ablation Procedure for Ischemic VT using a flexible, insulated 7F all braided catheter that contains an internal lumen connected to 12 open conduits at the 4mm tip electrode for infusion of heparinized saline during radiofrequency ablation; records intracardiac electrograms and can be utilized for cardiac simulation during diagnostic electrophysiologic studies/evaluation.~1500T9-VT generator is a microprocessor-controlled device that produces a continuous unmodulated radiofrequency (RF) output of 485 kHz. The Generator will be used in Temperature Control mode only. The catheter delivers the RF power from the generator in a monopolar mode between its distal electrode (tip electrode) and a large indifferent electrode."
46031883|NCT03639753|Behavioral|Parent-Teen Intervention|Parent health coaching and resources + teen on-road driver experience + safe driving eLearning Modules
46031884|NCT03639753|Other|Usual Practice|Standard care for teens who get licensed in the state of PA
46031885|NCT01130532|Drug|Tadalafil|Administer orally
46031886|NCT01130532|Drug|Placebo|Administer orally
46031887|NCT04258306|Dietary Supplement|Revifast|Revifast® is based on natural resveratrol supported on Magnesium hydroxide. Revifast® particles confer an improved dissolution rate in tests that mimic the gastric environment compared to Polygonum cuspidatum resveratrol (98%).
46031888|NCT04258306|Dietary Supplement|pure resveratrol|resveratrol extracted from Polygonum cuspidatum resveratrol (98%).
46031889|NCT04068961|Other|Genetic analyzes|Analysis by CGH array, homozygotic cartography and candidate gene sequencing
46031890|NCT04284501|Behavioral|Non|questionnaire
46031891|NCT00646165|Drug|Forodesine|
46031892|NCT04253158|Behavioral|Educational standard|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs.
46031893|NCT04253158|Behavioral|Educational standard and Harm prevention|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs increasing intentions to use harm prevention strategies.
46031894|NCT04253158|Behavioral|Educational standard and Expectancies|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs and shifting alcohol-related expectancies.
46031895|NCT04253158|Behavioral|Expectancies and Harm prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use and shifting alcohol-related expectancies.
46031896|NCT04253158|Behavioral|Educational standard and Normative perceptions|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs and correcting erroneous norms about alcohol use.
46031897|NCT04253158|Behavioral|Normative perceptions and Harm prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use and increasing intentions to harm prevention strategies.
46031898|NCT04253158|Behavioral|Educational standard, Normative Perceptions, and Expectancies|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs, correcting erroneous norms about alcohol use, and shifting alcohol-related expectancies.
46031899|NCT04253158|Behavioral|Normative perceptions, Expectancies, and Harm Prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use, shifting alcohol-related expectancies, and increasing intentions to use harm prevention strategies.
46031900|NCT04068415|Other|Constipation risk assessment scale|questionnaires
46031901|NCT04912804|Other|Questionnaires|SF-12, GHQ-12 and HAQ
45472212|NCT05159102|Behavioral|Physical Activities & Activity Booklets (via FitFamilies app)|expected to engage in physical activity at least 3 hours per week, parent workshops provide them with resources to engage in Physical activity
45472213|NCT01252433|Other|Energy density feeding study|In a crossover study, children are served all foods 1 day a week for 3 weeks. Meal entrees will vary in energy density (100%, 85%, 75%).
45472214|NCT03361982|Other|Slow Freezing and Thawing|half of the surgically obtained testicular sperm will be frozen for 30 minutes and subsequently thawed prior to performing ICSI
46031902|NCT02668237|Other|OptiPAC|Molecular and urinary tests.
46031903|NCT02668237|Other|Usual care|Antibiotics for prevention.
46031904|NCT04856800|Dietary Supplement|Whey|20 g protein of whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients)
46031905|NCT04856800|Dietary Supplement|Placebo|The placebo contains <1 kcal and 0 g protein
45472215|NCT03886337|Device|Germicidal lighting|Germicidal ambient lighting
45472216|NCT03898388|Procedure|Bone Marrow Concentrate treatment|Correlate patient outcomes 6 months after receiving the Regenexx SD treatment with measurements of synovial fluid collected before treatment
45472217|NCT01586507|Drug|ULTRAM ER|One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
46031906|NCT00646711|Drug|Depakote Delayed-Release/Depakote Sprinkle|Administered according to the subject's usual regimen.
46031907|NCT00646711|Drug|Depakote ER|Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.
46031908|NCT04255186|Device|Thermal 448 kHz Capacitive Resistive Monopolar Radiofrequency|Thermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method
46031909|NCT04255186|Device|Subthermal 448 kHz Capacitive Resistive Monopolar Radiofrequency|Subthermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method
46031910|NCT04255186|Device|Sham stimulation|a simulated stimulation protocol so that the device does not emit current
46031911|NCT00972777|Drug|Besifloxacin|Besifloxacin 0.6% administered into the study eye two times a day for three days.
46031912|NCT00972777|Drug|Vehicle (Placebo)|Vehicle administered to the study eye two times a day for three days.
46031913|NCT04254874|Drug|Abidol hydrochloride|0.2g once, 3 times a day,two weeks
46031914|NCT04254874|Drug|Abidol Hydrochloride combined with Interferon atomization|Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks
46031915|NCT02667223|Biological|Cohort 1: bococizumab 150 mg + rHuPH20|bococizumab 150 mg + rHuPH20 administered SC to healthy volunteers
45472218|NCT01586507|Drug|ULTRAM ER|The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
45472219|NCT03574727|Procedure|Injection to or release of anterior cutaneous nerves|Patients who have undergone at least one injection to the nerves
45682835|NCT03502018|Drug|Bupivacaine liposome|A long-acting liposomal bupivacaine
45839298|NCT03019224|Drug|Hydrogen peroxide|The handling of 35% hydrogen peroxide (Whiteness HP, FGM, Joinville, SC, Brazil) followed the manufacturer's recommendations, which consisted of mixing 3 drops of 35%hydrogen peroxide for 1 drop of thickener, with this mixture being sufficient for application to at least three tooth. The gel remained in contact with the buccal surface of the tooth for 15 minutes and was removed with disposable plastic suction cannula and water wash. This procedure was performed three times per clinical session. The volunteers underwent three whitening clinical sessions with one week interval between them.
46031916|NCT02667223|Biological|Cohort 2: bococizumab 300 mg|bococizumab 300 mg administered SC to healthy volunteers
45682836|NCT03502018|Drug|Saline|Saline injection used as control
46031917|NCT02667223|Biological|Cohort 3: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to healthy volunteers
45472220|NCT05152394|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
45682837|NCT03501082|Other|L Reuteri PB-W1 Strain|L. Reuteri PB-W1 strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions
45682838|NCT03501082|Other|L. Reuteri DSM20016T Strain|L. Reuteri DSM20016T strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions
45682839|NCT03501082|Other|Placebo|2 g of maltodextrin will be dissolved in 50 ml water in food grade conditions
46031918|NCT02667223|Biological|Cohort 5: bococizumab 450 mg + rHuPH20|bococizumab 450 mg + rHuPH20 administered SC to healthy volunteers
46031919|NCT02667223|Biological|Cohort 4: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to subjects with hypercholesterolemia receiving a statin
46031920|NCT04240912|Device|CompuFlo Epidural Computer Controlled System|"The CompuFlo Epidural Instrument allows the objective identification of the epidural space by pressure measurement at the needle tip and consequently enables the physician to perform epidural anesthesia and epidural injections using standard methods. However, for the purpose of this study the instrument will be used only as a monitor to detect the occurrence of EPW.~The CompuFlo Epidural Computer Controlled Anesthesia System has received a CE mark in the European Union and it received 510(k) clearance from the FDA in June 2017."
46031921|NCT02883660|Genetic|Genocept Assay|battery of pharmacogenetic tests relevant to psychiatry
46031922|NCT03420651|Other|Peak Expiratory Flow Rate (PEFR)|PEFR values and the National Asthma Prevention and Education Program guidelines will be used by providers in the management of these patients.
46031923|NCT03420651|Other|Standard Clinical Judgement|Providers will use physical exam and standard clinical judgement to guide management.
46031924|NCT02882724|Behavioral|Exercise|8-week aquatic exercise training program
45682840|NCT03501082|Other|Non-Industrialized-Type Diet|Non-industrialized-type diet will be prepared in a metabolic kitchen, with all meals and snacks provided to participants for three weeks.
46031925|NCT02882724|Behavioral|Control|Control group did not do the exercise training.
46031926|NCT04173091|Diagnostic Test|No Intervention|No Intervention planed
46031927|NCT00918736|Drug|sodium hyaluronate|3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
46031928|NCT02666053|Drug|BMS-663068|BMS-663068
46031929|NCT04257838|Drug|Piperacillin/tazobactam or Meropenem|"The plasmatic levels determinations will always be made in state of equilibrium (after the fourth dose) and two samples will be collected:~Just before the antibiotic infusion (T0)~In the midpoint of time (T50). If the antibiotic is administered every 8 hours this determination will be made at 4 hours. If the antibiotic is administered every 6 hours, the determination will be made at 3 hours.~A second complete determination will be made (before the infusion, in the midpoint of time and before the next dose) after the administration of 4 doses as long as a posology modification is made as a consequence of the information received from the plasmatic levels."
46031930|NCT01172639|Drug|Methotrexate|Methotrexate tablet
45682841|NCT05346640|Device|Cionic Neural Sleeve|Adaptive, functional electrical stimulation
45682842|NCT03086278|Drug|AST-008|AST-008 is a toll-like receptor 9 agonist.
45682843|NCT03086434|Other|Culturally Tailored Intervention|School-based substance use prevention
45682844|NCT03086434|Other|Standard Substance Abuse Education|Class room program
45682845|NCT03497806|Biological|CP101|Study drug will be administered at Treatment (Day 1) as an oral dose after cessation of standard-of-care CDI antibiotic treatment of the current episode of recurrent CDI.
45682846|NCT01689207|Drug|Avibactam (AVI)|PART A: AVI IV infusion
45682847|NCT01689207|Drug|Aztreonam (ATM)|PART A: ATM IV infusion
46031931|NCT01172639|Drug|Sulfasalazine|Sulfasalazine tablet
46031932|NCT01172639|Drug|Leflunomide|Leflunomide tablet
46031933|NCT01172639|Drug|Prednisone|Prednisone tablet
46031934|NCT01144182|Behavioral|Comprehensive quality improvement program (QIP)|Comprehensive quality improvement program (QIP) that intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
46031935|NCT00646789|Drug|Comparator: MK0633|patients will receive single 50mg oral dose with follow-up observation for 5 weeks.
46031936|NCT01225562|Drug|Ticagrelor 90 mg|Oral dose twice a day
46031937|NCT01225562|Drug|Ticagrelor 60 mg|Oral dose twice a day
46031938|NCT01225562|Drug|Ticagrelor Placebo|Oral dose twice a day
46031939|NCT04203628|Diagnostic Test|Xpert MTB/Rif Ultra on stool samples|"The Xpert MTB/Rif Ultra will be performed on stool samples processed using four different processing methods:~Standard sucrose flotation method~Optimized sucrose flotation~Stool processing kit (SPK)~Simple One-step method (SOS)"
45682848|NCT01689207|Drug|combination of Aztreonam - Avibactam (ATM-AVI)|PART A: ATM-AVI IV infusion. PART B and C: ATM-AVI IV infusions.
45682849|NCT01689207|Drug|Placebo|PART A, PART B, PART C: matching placebo IV infusions
46031940|NCT04203628|Diagnostic Test|Xpert MTB/Rif Ultra on respiratory sample|The Xpert MTB/Rif Ultra will be performed on gastric aspirate or expectorated sputum
45472221|NCT03910595|Other|Mepitel Film|Mepitel film is a barrier film that may help in reducing radiation dermatitis by limiting friction.
45472222|NCT01154777|Behavioral|Neurofeedback training|60 sessions of Neurofeedback on 6-18 year olds with Autism
45472223|NCT01252511|Procedure|RYGB for surgical treatment of severe obesity|Twenty severely obese patients who have been scheduled to receive long limb RYGB will be enrolled in the study. By randomization, 10 patients will have a biliopancreatic limb that includes 40 cm of jejunum and a Roux limb that contains 150 cm of jejunum. The other 10 patients will receive a biliopancreatic limb that contains 75 cm of jejunum and a Roux limb of 115 cm.
46031941|NCT04067557|Diagnostic Test|molecuar test of BV|diagnosis of BV
46031942|NCT02665819|Other|Pediatric cancer women survivors|Women will incur a blood taking to obtain fertility indication.
45472224|NCT03910517|Other|No intervention|No intervention
45472225|NCT03910361|Drug|Evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to pioglitazone 15mg qd
46031943|NCT00925288|Biological|Gardasil|Dosage Form: 0.5 ml intramuscular injection Dosage: Gardasil 0.5ml suspension Frequency: 3 doses
46031944|NCT04174573|Other|GTO|"Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)"
46031945|NCT04174573|Other|GT-tDCS|"Group therapy~Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~tDCS Left anodal and right cathodal tDCS : Anode- F3, Cathode- Right Supra orbital area, Intensity- 2mA, Duration- 30 minutes, once in a week for 6 weeks"
46031946|NCT01143714|Drug|Santyl|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
45472226|NCT03910361|Drug|Pioglitazone|pioglitazone 15mg tablet qd + placebo tablet matching to evogliptin 5mg qd
46031947|NCT01143714|Other|White Petrolatum|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
46031948|NCT04800757|Behavioral|individual -Brief Motivational Intervention (BMI)|"A baseline survey will be administered prior to the session.Sessions will be initiated by exploring working conditions and psychosocial factors that may influence risk for work related injuries. If the LDL is motivated to change the target behavior, a 'change plan' will be developed which involves identifying reasons for change, goals in making change, specific actions and timelines, and others who may help the person change. The final step will be the development of a personal safety plan to reduce work place risks and a discussion of the following topics: (a) how they will know if their plan is successful, (b) potential obstacles, and (c) what the worker can do if the plan does not work. Finally,each worker will be asked to write and sign a personal pledge (Mi Promesa) to implement his own safety plan.Follow-up surveys will be conducted 4 weeks after the baseline survey."
46031949|NCT04800757|Behavioral|Group (Group Problem Solving)|Participants will be administered a baseline survey prior to session. The GPS intervention consists of a discussion between 2-5 LDLs and a trained group facilitator. The sessions will last 30-45 minutes and are intended to encourage and support Latino day laborers (LDL) to act to reduce work-related hazards and promote worksite safety. The intervention combines four participatory and group problem solving activities to engage in collaborative learning: an icebreaker, the risk identification, action planning, and Nuestra Promesa (Our Pledge). The last activity requires LDL to select a risk reduction behavior and then to fill out and sign a card detailing a pledge to implement a safety plan. Follow up surveys will be conducted four weeks post intervention, to assess participants' change in attitudes, beliefs, and risk reducing behavior and their implementation or their safety plan.
46031950|NCT04800757|Behavioral|Standard of Care (OSHA 10 Safety Cards)|Participant will be administered a baseline survey prior to the session.Participants in this standard of care control group will receive four wallet size cards with information about risk reduction strategies to deal with the four hazards responsible for most workplace fatalities in Texas: falls, struck by, heat exposure and cuts. The laminated cards are adapted from OSHA's website publicly available materials in Spanish for workers with limited literacy.
46031951|NCT04257916|Other|Experimental|Myofascial technique intervention of the subastragalar joint, kinesiotape and eccentric training with isoinercial machine. The intervention lasted 4 weeks. Each treatment session lasted 50 minutes, with 2 sessions a week. Between training sessions, the indicated break was 48 hours.
46031952|NCT04257916|Other|Manual therapy group|Myofascial technique of the subastragalar joint and eccentric training with isoinercial machine. The intervention lasted 4 weeks. Each treatment session lasted 50 minutes, with 2 sessions a week. Between training sessions, the indicated break was 48 hours.
46031953|NCT04920682|Drug|Reversal of moderate neuromuscular blockade|Neostigmine 60 mcg/kg when TOF (Train-of-Four) = 3 and saline when TOF (T4 / T1)> 0.4
46031954|NCT04920682|Drug|Reversal of superficial neuromuscular blockade|Neostigmine 30 mcg/kg when TOF (T4 / T1)> 0.4
45472227|NCT03910205|Diagnostic Test|ELISA|Enzim linked immunoabsorbant assay
46031955|NCT04920682|Drug|Two-step reversal|Neostigmine 30 mcg/kg when TOF = 3 and neostigmine 30 mcg/kg when TOF (T4 / T1)> 0.4
46031956|NCT04920682|Drug|Placebo|0.9% saline solution (SF) when TOF = 3 and when TOF (T4 / T1)> 0.4
46031957|NCT04174339|Drug|Camrelizumab|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial，d1
46031958|NCT04174339|Drug|Apatinib Mesylate|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet，TID
46031959|NCT04174339|Drug|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
46031960|NCT00972543|Biological|Efalizumab (Raptiva)|"Double-blind phase 0.7mg/kg subcutaneously (sc), followed by 1mg/kg/wk sc for 12 weeks.~Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks."
46031961|NCT00972543|Biological|Placebo|Double-blind phase sc Placebo for 12 weeks. Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.
45472228|NCT03700658|Drug|TV-46046|TV-46046 will be administered per dose and schedule specified in the arm.
46031962|NCT04173481|Other|Rood's Group|"ROOD'S sensory motor training~Brushing & strokings 3-5 strokings after 30sec, joint compressions and slow stretch 10 rep of 3 sets on alternative days for consecutive 6 weeks CIMT training~Writing, combing hairs and using spoon activity 1 hour training concentrated on affected limb along with restraint of non affected limb by cotton sling under supervision of therapist and 5 hours training in home plan 3 times a week on alternative days for consecutive 6 weeks along with conventional physical therapy."
46031963|NCT04173481|Other|Conventional Physical Therapy Group|Conventional training Proprioceptive neuromuscular facilitations (PNF) Combination of Isotonics technique 10 rep 3 sets 10 sec hold on alternative days for consecutive 6 weeks Stretching's 10 rep 3 sets on alternative days for consecutive 6 weeks Joint approximation 10 rep of 3 sets on alternative days for 6 weeks
45472229|NCT03700658|Drug|Depo-subQ 104|Depo-subQ 104 will be administered per dose and schedule specified in the arm.
45472230|NCT03700658|Drug|TV-46046 Placebo|TV-46046 Placebo will be administered per schedule specified in the arm.
45472231|NCT03910127|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
46031964|NCT04790305|Drug|Huaier Granule|The subjects in the experimental group will be treated with Huaier Granule continuously for 2 years or until the disease progressed, intolerable toxicity, withdrawal of informed consent form or died for any reason.
46031965|NCT00925132|Drug|Temozolomide, Decitabine, Panobinostat|"Temozolomide - given each cycle.~Decitabine - 6 cohorts with dose escalation.~Panobinostat - 6 cohorts with dose escalation."
46031966|NCT02862015|Other|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
46031967|NCT02862015|Drug|FOLFIRINOX or Gemcitabine based chemotherapy|As a standard palliative chemotherapy, FOLFIRINOX or Gemcitabine based chemotherapy will be treated to the patients.
45472232|NCT03910127|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
46031968|NCT00646867|Device|Tetrix|Twice daily topical application
45472233|NCT03910127|Drug|Anlotinib|matching placebo
45472234|NCT03886103|Drug|14C labeled PXL770|Single administration
46031969|NCT00646867|Device|Placebo|Twice daily topical application
46031970|NCT02863653|Other|observational study|application of several standard instruments in patients with rheumatoid arthritis
46031971|NCT04254718|Behavioral|Digital Storytelling|Creation of a digital story about the infant with video and music selected by parents
46031972|NCT02664805|Drug|LEO 124249 ointment|Ointment
46031973|NCT02664805|Drug|LEO 124249 ointment vehicle|Ointment vehicle
46031974|NCT04285593|Other|Bulgarian squats|The intervention using Bulgarian squat exercises will consist in the application of the protocol described by Aguilera-Castells et al. The technique will be done with the footballer standing. The athlete with one foot in front and the other behind the body, arms crossed over her chest, and her upper body, will remain upright with a natural swing in the lower back during the entire exercise. The players will lower the body (eccentric phase) until the front knee flexes to 90º. Subsequently, they will return to the initial position with a full extension of the knee of the front leg (concentric phase), maintaining an erect trunk position. The front foot will be placed in a fixed position contacting the ground, and the rear foot will rest on a horizontal press bench.
46031975|NCT01143402|Drug|Dacarbazine|Given IV
46031976|NCT01143402|Other|Laboratory Biomarker Analysis|Correlative studies
45472235|NCT03031964|Device|revision multihole acetabular cup|post market study of multi hole revision acetabular cup
46031977|NCT01143402|Other|Quality-of-Life Assessment|Ancillary studies
46031978|NCT01143402|Drug|Selumetinib|Given PO
46031979|NCT01143402|Drug|Temozolomide|Given PO
46031980|NCT00646945|Drug|50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)|gas flow between 4 to 15 L/min
46031981|NCT00646945|Drug|50% Oxygen/50% Nitrogen premix|gas flow between 4 to 15 L/min
46031982|NCT01171625|Device|Implantation of CEP Magna Ease Model 3300TFX|Heart Valve Surgery
46031983|NCT00629889|Drug|levetiracetam|"After inclusion, patients receive Levetiracetam 2x250mg per day. The medication may be increased, in intervals of 500mg of Levetiracetam of at least 24h up to maximally: Levetiracetam 2x1500mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
46031984|NCT00629889|Drug|pregabalin|"After inclusion, patients receive Pregabalin 2x75mg per day. The medication may be increased, in intervals of 150mg of Pregabalin of at least 24h up to maximally: Pregabalin 2x300mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
46031985|NCT04898686|Biological|Probiotic chewables|chewables containing Lacticaseibacillus rhamnosus GG
46031986|NCT04898686|Biological|Placebo chewables|chewables without probiotic strain. Ingredients: Xylitol, microcrystalline cellulose, stearic acid, natural orange flavor, silica, magnesium stearate, citric acid and malic acid.
46031987|NCT04257604|Drug|Perampanel|Perampanel tablets.
46031988|NCT03381261|Drug|Botulinum toxin type A|Injection of Botulinum toxin type A in back of head
46031989|NCT05224752|Other|Online Survey|Online survey void of individual traceable identifiers, and launched via the Survey Monkey® portal
46031990|NCT04315259|Device|Diode laser|irrigation activated by diode laser versus soft tissue laser application therapy
46031991|NCT04980391|Biological|RSV MAT|Single dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
46031992|NCT04980391|Drug|Placebo|Single dose of placebo, administered intramuscularly in the non-dominant arm, at Day 1.
45472236|NCT03885947|Biological|Cord blood stem cells|CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood .
45472237|NCT03885947|Drug|Valproic Acid|Valproic Acid (VPA) expanded cord blood stem cells
46031993|NCT04849936|Diagnostic Test|Testing Fecal Biomarkers In Comparison To Endoscopic Examination With Confocal Laser Endomicroscopy|Patients, who were examined during a routine diagnostics, should submit an extra morning stool sample up to two weeks before or after the gastroscopy and/or coloscopy to generate the data of the fecal biomarker mentioned above.
46031994|NCT00630045|Drug|neoadjuvant chemotherapy with oxaliplatin and capecitabine|oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)
46031995|NCT00630045|Procedure|resection of liver metastasis|surgery with the aim of R0 resection
45682850|NCT00089284|Drug|Rituxan|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
45682851|NCT00089284|Drug|motexafin gadolinium|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
45682852|NCT00089284|Drug|111Indium-Zevalin and 90Yttrium-Zevalin|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
45682853|NCT03497104|Other|Surplus blood tests|Surplus blood donation
46031996|NCT04315103|Combination Product|a single intraarticular injection of HYAJOINT Plus (3 ml) followed by 3 ml PRP|All the injections were done by the same experienced physician using aseptic procedures.
46031997|NCT02861859|Drug|Olanzapine|Olanzapine 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
46031998|NCT02861859|Drug|Olanzapine Placebo|Olanzapine Placebo 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
45472238|NCT03885947|Drug|Fludarabine|Fludarabine 150 mg/m2
45472239|NCT03885947|Drug|cytoxan|Cytoxan 50 mg/m2
45472240|NCT03885947|Drug|Thiotepa|Thiotepa 10 mg/m2
45472241|NCT03885947|Biological|TBI|TBI 400cGy
46031999|NCT00910507|Behavioral|Exercise counseling|Each participant in the experimental group receives 2 months of exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.
46032000|NCT00910507|Behavioral|Supervised exercise training|Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
45472242|NCT04653272|Other|Questionnaire|Patients will be evaluated identically to routine care with reference tests (Lysholm-Tegner, and Knee injury and Osteoarthritis Outcome Score (KOSS) and, IKDC (Evaluation of knee ligament injuries). This is filled in without any external help. The questionnaire includes the Lysholm-Tegner (young adult group), IKDC and KOOS scores (young and senior adult groups).
45472243|NCT01155557|Device|Specific Strength Training|10 weeks of progressive specific strength training for neck and shoulder muscles.
45472244|NCT01155557|Behavioral|Lifestyle Counseling|10 weeks of counseling by nurse and physiotherapist in lifestyle changes.
45472245|NCT03885869|Other|Ankle Joint Position Sensation Evaluation|In this test, individuals are placed in the supine position with their eyes closed for prevent visual cues; measurements are performed with the plex of the goniometer, 1.5 cm below the lateral malleol, the fixed arm parallel to the long axis of the fibula and the movable arm parallel to the long axis of the 5th metatarsal. Desired target angles were defined as 10 ° dorsi flexion, 10 ° plantar flexion and 20 ° plantar flexion. Individuals are instructed to focus on the position of the ankle joints in space for 5 s by bringing the feet in neutral position to the target position by the researcher. This procedure is repeated 3 times and the patient is expected to learn this position. The target angle is then asked to repeat in the testing phase. The measurement is repeated 3 times for each target angle. As a result criterion; By recording the absolute value of the deviation amounts from the target angles; The averages of the deviations during the 3 repetitions are averaged.
45598761|NCT03632993|Drug|collagenase clostridium histolyticum (CCH)|Endo Pharmaceuticals Inc. (Endo) is developing collagenase clostridium histolyticum (CCH) for the treatment of EFP. Because CCH is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions, CCH has the potential to be effective in lysing sub-dermal collagen, such as those observed in the dermal septa, which are the underlying cause of the skin dimpling in women with Edematous Fibrosclerotic Panniculopathy (EFP). CCH targets the collagenase structural matrix (e.g., dermal septa) at the site of injection and does not require systemic exposure to be effective.
45598762|NCT02292823|Device|MGuard™ Prime Embolic Protection Stent System|
45598763|NCT02353923|Dietary Supplement|OcuStem Supplementation|2800 mg daily dosage of OcuStem, 2 capsules BID.
46032001|NCT05657795|Device|Closed-loop automated oxygen control (Oxygenie, SLE6000)|The OxyGenie closed-loop oxygen saturation monitoring software (SLE) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
46032002|NCT00910585|Behavioral|Coaching, providing social support|Active telephone and in person coaching
45598764|NCT03516175|Device|High flow transnasal oxygen|High flow nasal oxygen that is Transnasal Humidified Rapid Insufflation Ventilatory Exchange
46032003|NCT04317209|Drug|SHR0410|administered intravenously
45598765|NCT03516175|Device|Pre oxygenation using tight fitting facemask|100% oxygen via a tight fitting facemask
45598766|NCT04461275|Other|ERAS 2.0|ERAS 2.0 accelerated protocol with adequate fluid management, pain control and truly minimally invasive surgery (intracorporeal anastomosis)
45598767|NCT02292901|Device|Macintosh laryngoscope|
45598768|NCT02292901|Device|McGrath Mac videolaryngoscope|
45682854|NCT01688973|Drug|Erlotinib Hydrochloride|150 mg (1 tablet) by mouth on days 1-28, once daily, until disease progression
45682855|NCT01688973|Other|Laboratory Biomarker Analysis|Correlative studies
45682856|NCT01688973|Drug|Tivantinib|360 mg (3 tablets) by mouth, Twice daily (720 mg total daily dose) on days 1-28, until disease progression
45682857|NCT00087646|Drug|Ribavirin|1000/1200mg po daily for 72 weeks
45682858|NCT00087646|Drug|Ribavirin|1000/1200mg po daily for 48 weeks
45839299|NCT03019224|Procedure|Used a dentifrice|Among the clinical whitening sessions, each volunteer used an unidentified dentifrice corresponding to their experimental group, which was previously defined by means of a draw made by a dentist who did not participate in the study. Thus, the researcher (dentist) who provided the dentifrice and the volunteer were not aware of which experimental group belonged (i.e. double blind).
46032004|NCT04317209|Drug|Placebo|administered intravenously
45839300|NCT03019146|Other|HIIT|
45839301|NCT03019146|Other|HOLD|
45839302|NCT03019146|Other|HUG|
45839303|NCT03018990|Other|Ethanol|1 milliliter per kilogram body weight adjusted for elevated body mass index
45839304|NCT03018600|Behavioral|diet and exercise intervention|consult nutrious doctors giving specific food and take regular exercise when under steroid therapy
46032005|NCT00647023|Drug|metformin|1000 mg metformin x 2 daily during 8 months
45598769|NCT02347449|Other|Questionnaires, Oncotype Dx Assay|"Physician pre-assay questionnaire~Patient pre-assay questionnaire~Oncotype DX® Assay~Physician post- assay questionnaire~Patient post-assay questionnaire"
45682859|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 60 weeks
45682860|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 36 weeks.
45682861|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 72 weeks
45682862|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
46032006|NCT05657717|Drug|Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey|After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
46032007|NCT00924898|Drug|efavirenz, emtricitabine, and tenofovir|Once daily ART with emtricitabine, tenofovir DF and efavirenz
46032008|NCT01167192|Drug|Cisplatin|
46032009|NCT01167192|Drug|Carboplatin|
46032010|NCT01167192|Radiation|Radiation therapy|
46032011|NCT01167192|Procedure|Mastectomy (recommended but not mandatory)|
46032012|NCT00646321|Drug|budesonide/formoterol (Symbicort)|
46032013|NCT00646321|Drug|budesonide|
46032014|NCT00647101|Drug|Latanoprost|Latanoprost 0.005% drops: 1 drop in the diseased eye(s) in the evening for 3 months
46032015|NCT01166958|Drug|Teriparatide|Teriparatide (TPD; Forteo) is supplied as a pre-filled syringe that dispenses 20 ug. The dose is one subcutaneous injection daily. Each pre-filled injection delivery device contains sufficient TPD for a 28-day supply of 20 mcg/day.
45598770|NCT02289625|Other|Exercise Training|six month of Exercise training will be conducted in individuals with moderate to severe sleep apnea. The training include aerobic exercise, resistance exercise, flexibility.
46032016|NCT01166958|Drug|Raloxifene|Raloxifene (RLX; Evista) is supplied as a 60 mg tablet. RLX is stored at room temperature.
46032017|NCT01170221|Drug|TR-701 FA|Oral TR-701 FA 200 mg once daily for six days followed by four days of placebo.
46032018|NCT01170221|Drug|Linezolid|Oral Linezolid 600 mg twice daily for 10 days
46032019|NCT04849624|Other|No Intervention|This is an observational study and involved no intervention
46032020|NCT04254640|Drug|Cladribine Injection|Cladribine 5 mg/m2, intravenous drip,d1-5,4 weeks per cycle.
46032021|NCT04254640|Drug|Aclarubicin|aclarubicin 10 mg, intravenous drip,d3-6,4 weeks per cycle.
46032022|NCT04254640|Drug|G-CSF|G-CSF 300 µg,subcutaneous injection, d0-9,4 weeks per cycle.
46032023|NCT04254640|Drug|cytarabine|cytarabine 10mg/ m2, subcutaneous injectionq,q12h, d3-9,4 weeks per cycle.
46032024|NCT01166646|Drug|Halobetasol Proprionate Lotion 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
46032025|NCT01166646|Drug|Halobetasol Proprionate Cream 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
45472246|NCT03885869|Other|Knee Joint Position Sensation Evaluation|Bilateral knee joint position sensation will be evaluated in the literature with an analogue inclinometer(BASELINE®),which is a valid and reliable method for measuring joint position sensations.Measurements were planned to made in the sitting position,with the eyes of the individual closed and the joint to be evaluated bare,without any socks or shoes worn,fixing the inclinometer with a strap to the lower leg perpendicular to the knee flexion axis.In this measurement,the knees of the participants are passively shifted from the initial (90°flexion)position to the 30°flexion position,at this point 5 sec is waited and after they are told to keep this angle in mind,the starting position is returned.This procedure is repeated 3 times and the patient is expected to learn this position.After the individuals are rested for 5 s,they are asked to actively perform the target angle again.The same procedure was planned to be repeated 3 times for each angle at 45° and 60° knee flexion target angles.
45598771|NCT02351427|Drug|Bortezomib|In one group, investigators administer bortezomib and steroid to manage acute cellular rejection in kidney transplantation, and compare the results with another group in which only steroid was administered.
45598772|NCT02351427|Drug|Steroid|Investigators administer steroid in both groups for conventional treatment of acute cellular rejection.
46032026|NCT04203394|Other|Schroth Exercise Group|12 week , Exercises 1 hour, 2 times for a week with physiotherapist 20 minutes home exercise
46032027|NCT04203394|Other|Home Exercise Group|Home exercise 20 min at home Once, one hour to determine the Schroth program + teaching home exercises 20 minutes home exercise
46032028|NCT00647179|Procedure|Transsphenoidal adenomectomy|Surgery
46032029|NCT04909840|Other|Instructions oral hygiene with toothbrush plus dental floss|Instructions of oral hygiene with toothbrush plus dental floss
46032030|NCT04909840|Other|Instructions oral hygiene with toothbrush only|Instructions only with toothbrush
46032031|NCT04065763|Other|Ultrasound assessment of dural sac dimension|Dural sac dimension is assessed using ultrasonography in the lateral decubitus position for spinal anesthesia.
46032032|NCT01129284|Drug|ACTHAR gel|Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
46032033|NCT04065607|Procedure|Reopen the abdomen to check missed pathology or abdominal washouts|Re opening of the abdomen once the patient is stabilized after 24-48 hours to check the missed injury after damaged control surgery in trauma and to control the sepsis in fecal peritonitis due to abdominal tuberculosis or typhoid perforation
46032034|NCT00647257|Drug|Losartan|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Losartan 100mg add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
46032035|NCT00647257|Drug|Placebo|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Placebo add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
46032036|NCT04033393|Other|Game based dual-task training|Participants in the experimental group will receive game based dual-task training with a treadmill
45598773|NCT04437563|Behavioral|HERMES|Via an app, the caregiver answers 14 questions about his/her need for (more) information. The caregiver presents his/her answers (i.e., need for information) to the health care professionals (HCPs), and the HCPs provide the caregiver with the lacking information.
46032037|NCT04033393|Other|Treadmill training|Participants in the control group will receive treadmill training
46032038|NCT01166568|Device|PresVIEW Scleral Implants|Subjects are implanted with the PresView Scleral Spacing Implants and followed for 24 months.
46032039|NCT04895761|Biological|DPX-Survivac|"DPX is a novel formulation that when combined with target antigens acts to activate T cells. It is a lipid-based formulation that creates a long lasting depot at the site of injection, forcing an active uptake by antigen presenting cells (APCs). APCs traffic to regional lymph nodes where naïve T cells are activated, inducing strong and sustained immune responses. All arms will receive DPX-Survivac on weeks 2 and 5."
46032040|NCT04895761|Drug|Letrozole 2.5mg|Aromatase inhibitor all arms will receive
46032041|NCT04895761|Drug|Cyclophosphamide 50mg|oral chemotherapy used in the neoadjuvant setting for Arm C only
46032042|NCT04895761|Radiation|XRT 10Gy x2|Directed radiation at week 4 for Arm B only
46032043|NCT02664727|Behavioral|The effects of acute exercise in heavy drinkers|A group of heavy drinkers and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 50-60% of HRR. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
46032044|NCT02664727|Behavioral|The effects of acute exercise in alcoholic patients|A group of alcoholic patients (10-14 days after detoxification) and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 55-60% of HRmax. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
45839305|NCT03018522|Other|Postoperative cognitive dysfunction|Neuropsychological tests of all patients will conduct on the one day prior to surgery, the 7th day after surgery, and the 3rd month after surgery
46032045|NCT02666989|Drug|placebo|2 placebo pills twice a day
46032046|NCT04742179|Other|Manteinance and care intervention on the green areas.|Manteinance and care intervention on the green areas.
46032047|NCT01166178|Drug|Zoledronic Acid|Zoledronic acid 5 mg once a year via intravenous infusion
46032048|NCT01166178|Drug|Placebo|Placebo to zoledronic acid once a year via intravenous infusion
46032049|NCT01166178|Dietary Supplement|Calcium and Vitamin D combination|Calcium 500 mg and Vitamin D 400 IU combined tablet, taken orally twice a day
45839306|NCT03018756|Drug|Fentanyl Citrate|100 mcg fentanyl citrate will be inhaled via nebulizer.
45839307|NCT03018756|Drug|Placebo|0.9% saline solution will be inhaled via nebulizer
45839308|NCT03018444|Drug|Atorvastatin|Atorvastatin tablet
45839309|NCT03018444|Other|Placebo|Placebo tablet
45839310|NCT03018210|Procedure|Surgical repair of the rotator cuff|
45682863|NCT03492658|Drug|Abatacept|Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
45682864|NCT03492658|Drug|Methotrexate|Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
46032050|NCT00646477|Device|titration night|"Each subject undergo 1 night of full polysomnography split into 2 consecutives and randomized sequences, using the Sandman device into two different modes:~in APAP mode - Data analysis of this sequence will be used to evaluate the therapeutic effectiveness of the CPAP/autoCPAP Sandman in APAP mode compared both to the polysomnography registration and the diagnosis night for each enrolled patient. The type of respiratory events and their index/hour of sleep and the total arousal index will be appraised as markers of the efficacy of OSAS treatment, constituting the primary outcomes.~in CPAP mode for manual titration sequence.During the manual titration, 5 constant pressure levels settings were studied for equal periods of 30 minutes gradually increasing the pressure. The aim of this sequence is to determine the sensitivity and the specificity of the CPAP/autoCPAP Sandman in detecting respiratory events."
46032051|NCT00924820|Drug|Bevacizumab|10 mg/kg by vein over about 1 hour, every 2 weeks.
45598774|NCT02293057|Behavioral|VOICES Group|VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 60 minutes long and include required and optional activities.
45839311|NCT03018132|Other|mental health screening, education and referral program|"I. Psychosocial assessments:~Mental health screening for: (1) depressive symptoms with the EPDS, (2) post-traumatic stress symptoms with the IES, (3) for perceived stress with the PSS (4) for anxiety with the OASIS.~Exercise, smoking & substance use, sleep and nutrition.~II. If women are above cutoff values the SCID will be conducted.~III. Education and referral information via Maternal Mental Health NOW:~All receive a brochure entitled, Speak Up When You Are Down~If above cutoffs, participants will also receive referral information; and will be scheduled for a SCID~Trained study staff will review the brochure and show the woman how to use the MMHN online referral system to input their zip code and find preferred maternal mental health practitioners.~IV. Follow up with a survey at 3 months postpartum: acceptability of screening, benefit of referral service, and outcome of this referral."
45839312|NCT03018054|Drug|E6007|once daily administration
45839313|NCT03018054|Drug|Placebo|once daily administration
45472247|NCT03885869|Other|The Evaluation of Plantar Sensation|"In the plantar sensory evaluation of the participants, Semmes-Wenstein Monofilament, which is frequently used in the literature and to be a reliable method in the diagnosis of neuropathy, was aimed to be tested by touching 7 regions on the foot base .~In this evaluation, the individual is in the supine position, the physiotherapist is at the foot end of the patient; monofilament should be applied 90⁰ to the surface.~The filament thickness which is the first feeling of the individual is recorded by being asked whether the individual is feeling. The 3 most commonly used monofilaments for patients with diabetic neuropathy are 4.17, 5.07 and 6.10 monofilaments. The highest monofilament value is the hardest and most difficult bending monofilament."
45472248|NCT03885869|Other|The Evaluation of Balance|In order to evaluate the static and dynamic balances of the participants, determination of open and closed postural oscillations and stability limits were planned with Prokin branded isokinetic balance system.
46032052|NCT01225172|Drug|BMS-754807|Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity
45839314|NCT03017664|Other|Peptide-based enteral formula|Peptide-based, higher protein and higher calorie enteral formula
46032053|NCT01225172|Drug|letrozole|Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity
45472249|NCT03885869|Other|Evaluation of Dual Task Performance|"In order to evaluate double task performances, it is planned to evaluate 1 dynamic and 1 static 2 different performances, including Time Up and Go Test (TUG) and single leg standing time. For each performance; the single task, the motor second task and cognitive seconder tasks separately, and again for each application to be performed in such a way that two trials, the average time was planned to record. Motor and cognitive tasks for each test are planned as described below.~Motor Task (TUG): Carrying cup full of water on tray. Cognitive Task (TUG): Counting the days of the week backwards from the current day Motor Task (Single Leg Standing Time): Hand-Over ball transfer Cognitive Task (Single Leg Standing Time): Counting backward month names from the current month"
45472250|NCT03885869|Other|General Evaluation Form|A form, which is prepared by us, including demographic information and physical characteristics of the individuals.
45839315|NCT03017664|Other|Retrospective review of enteral tube feeding formula|Enteral formula tube feeding will be retrospectively reviewed
45839316|NCT03017586|Device|Beijing Pins Medical Co., Ltd. Deep Brain Stimulator|Deep Brain Stimulation for primary dystonia subjects
45839317|NCT03017196|Other|My Life, My Healthcare Discussion Aid|The My Life, My Healthcare instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinical conversations of primary care.
46032054|NCT02665039|Drug|Vinflunine|"Vinflunine will be given intravenously once every 21 days, starting at a dose of:~280 mg/m2 in patients with GFR 40-60 ml/min~250 mg/m2 in patients aged >80 years and/or GFR 30-40 ml/min"
46032055|NCT02665039|Drug|Gemcitabine|Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2
46032056|NCT02665039|Drug|Carboplatin|Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5
46032057|NCT04203238|Other|Reduced Meat High Potato Diet|The main entrée in the PLM arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with potatoes.
46032058|NCT04203238|Other|Reduced Meat High Pulses Diet|The main entrée in the LMP arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with pulses.
45839318|NCT03017430|Drug|Pregabalin|Pregabalin 600 mg a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).
46032059|NCT02665663|Device|medical device|
45472251|NCT03886883|Other|Exercise induced hypoalgesia (EIH)|An EIH response was induced by a 3-minute isometric contraction of the hand flexor muscles at 25% of maximal voluntary contraction (MVC).
45472252|NCT03886883|Other|Static stretch (SS)|Two bouts of 30 seconds of static stretching (SS) of the knee flexors.
45472253|NCT03886883|Other|Rest|The participants rested in a seated position for 10 minutes
45472254|NCT03886883|Other|Conditioned pain modulation (CPM)|A CPM response was induced by way of the cold pressor test.
45472255|NCT03885791|Device|vaginal cryotherapy|"Both groups will be given the same instructions for use, which will include intravaginal placement of one tube for 10 minutes while resting in a supine position. A lubricant may be used for comfort with insertion.~Patients will perform their first intervention in the office with a repeat examination within 10 minutes of completing therapy. Patients participating in Specific Aims #2 will perform the intervention once daily at home. Patients will be asked to complete a short diary for each session, which will include the time of day, duration of application, pain score prior to and after application, and presence of any pelvic floor disorder symptoms prior to and after application."
45472256|NCT01252589|Other|HRQOL questionnaire|
45472257|NCT01261481|Drug|Tolvaptan|Tolvaptan 15 mg administered once orally as an intact tablet.
45472258|NCT01261481|Drug|Tolvaptan|Tolvaptan 15 mg administered once via nasogastric tube.
45472259|NCT01261637|Drug|Saline placebo|20ml saline
46032060|NCT04844086|Biological|RPM CD19-mbIL15-CAR-T cells|"Single dose of RPM CD19-mbIL15-CAR-T cells will be infused, and a standard 3+3 design will be applied.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion"
46032061|NCT05329870|Other|SNP array|SNP arrays for known bleeding SNPs to compare genetics of patients with normal colonoscopy and normal qFIT vs raised qFIT
46032062|NCT01143324|Device|MAST™ procedure|Single or double level instrumented fusion receiving the CD Horizon® Spinal System using PLIF or TLIF techniques via a MAST™ procedure.
46032063|NCT04172935|Device|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal picking distance, astigmatism is corrected.
45472260|NCT01261637|Drug|Ropivicaine|0.25% ropivicaine (maximum 1.5mg/kg)
45839319|NCT03017430|Drug|Clonidine|Clonidine 600 micrograms a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)
45839320|NCT03017430|Drug|Doxylamin|
45839321|NCT03017430|Drug|Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)|
45472261|NCT03910049|Drug|Indocyanine Green|Indocyanine green will be administered intravenously to patients enrolled in this study after the completion of total thyroidectomy in order to assess the visibility of parathyroid glands and to assess the possible correlation of ICG score with post-operative parathormone levels in order to predict post-thyroidectomy hypoparathyroidism.
46032064|NCT04254016|Dietary Supplement|HIBISTEVER1|During 8 weeks, administration of a Hibiscus-Stevia drink for 8 weeks at a dose of 4 mg / kg / day for Stevia and 4 g / day for Hibiscus. Evaluation will take place the 30th and 60th days.
45839322|NCT03017352|Drug|Exenatide|
45839323|NCT03017352|Drug|Placebos|
46032065|NCT02665585|Procedure|Carotid stenting procedure by carotid stent implantation|Carotid stenting procedure by carotid stent implantation
45839324|NCT03016884|Biological|Zostavax vaccine|After the screening, the eligible patients who provided the informed consent, will be administered the zoster vaccine.
45839325|NCT03016962|Device|cap-assisted colonoscopy|cap-assisted colonoscopy
45472262|NCT03885635|Procedure|Hemiarch repair|Current standard of surgical repair consisting of ascending aortic replacement with open distal anastomosis at level of proximal arch under a period of hypothermic circulatory arrest . No surgical or endovascular intervention is carried out in the mid arch or descending aorta. Intra-operative management, including cannulation, cardioplegia, cerebral perfusion technique, and neurologic monitoring will be done according to each institution's current standard of practice.
45839326|NCT03016962|Device|Standard colonoscopy|Standard colonoscopy
45839327|NCT03017274|Other|Abdominal ultrasound examination|All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
45839328|NCT03016572|Behavioral|Standard of Care|Follow-Up Calls, Questionnaires
45839329|NCT03016572|Behavioral|Crisis Intervention|Frontline Services will be administering follow up phone calls for participants of the study, recently discharged from the emergency room.
45839330|NCT03016572|Behavioral|Wraparound Services|Tapestry will be assigning case management services for participants randomized into the third arm of the study.
45839331|NCT03016728|Behavioral|Physical Activity|Participants will receive a 12-week home-based physical activity program that has been individualized using their baseline assessment results. The program will be comprised of aerobic training (2 days/week) and resistance training (2 days/week). The aerobic training will be performed unsupervised. The resistance training will be performed under the supervision of a study team member (who will visit participants homes) for the first 6 weeks to ensure proper form and safety.
45839332|NCT03016806|Radiation|Total Body Irradiation 1200 cGy|Total Body Irradiation 1200 cGy in 8 fractions
45839333|NCT03016806|Radiation|Total Body Irradiation 200 cGy|Total Body Irradiation 200 cGy in one fraction
46032066|NCT04252924|Other|lifestyle characteristics|Exposures of interest: Mediterranean diet, orthorexia nervosa, smoking, physical activity, sleep duration, stress level
46032067|NCT02883816|Other|assessment of lung function|measurement of lung volumes and flow rates of bronchial
45598775|NCT02293057|Behavioral|Girl Health Group|The Girl Health group comparison condition includes adolescent groups matched for time and attention to VOICES groups. Intervention take a psychoeducational/didactic approach and content focuses on a range of health behaviors, including substance use, exercise, nutrition and sleep.
46032068|NCT00647413|Behavioral|bio-chemical feedback and expert system intervention ETS|"Urinary cotinien will be measured using urine collected from the infants diaper. It will be analysed and the result will be explained to the participant in a written letter approximately 2 weeks after the intervention.~The intervention will also be a counselling session about the consequences of ETS to the infant. The counselling will be guided by the principles of motivational intervieweing and an expert system letter tailored to the data assessed will be send to the participants"
46032069|NCT00647491|Biological|adalimumab|20 mg sc eow
46032070|NCT00647491|Biological|adalimumab|40 mg sc eow
46032071|NCT00647491|Biological|adalimumab|80 mg sc eow
46032072|NCT00647491|Biological|placebo|placebo sc eow
46032073|NCT04253704|Combination Product|IDL lotion|IDL lotion is water-based (> 80%) with isosorbide di-(linoleate/oleate) (2.0%), caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
46032074|NCT04253704|Combination Product|Control lotion|Control lotion is water-based (> 80%) with caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
46032075|NCT04252456|Procedure|Aflibercept, 5fluorouracil, Folinic Acid andIrinotecan|All patients will receive aflibercept in combination with FOLFIRI according to the Italian label
45839334|NCT03016806|Drug|Cyclophosphamide|50 mg/kg or 60 mg/kg
45839335|NCT03016806|Drug|Mesna|50 mg/kg or 60 mg/kg plus 10% loading dose
46032076|NCT01224158|Device|Experimental Power Toothbrush|Following a placebo mouthwash phase, Subjects will be asked to brush their teeth (twice per day with the experimental toothbrush and toothpaste provided) moving to the next quadrant of the mouth at 30-second intervals.
45839336|NCT03016806|Procedure|Cord Blood Infusion|Intravenous infusion of cord blood stem cells
45472263|NCT03885635|Procedure|Extended arch repair|Surgical replacement of the ascending aorta along with intervention on the arch and descending aorta. Techniques for distal aspect of extended arch technique include but are not limited to total arch replacement along with TEVAR, Frozen Elephant Trunk procedure or surgical proximal arch replacement with bare metal stents in arch and descending aorta. Intra-operative management, including cannulation, cardioplegia, cerebral perfusion technique, and neurologic monitoring will be done according to each institution's current standard of practice.
45839337|NCT03016806|Drug|Busulfan|0.8 mg/kg x 16 doses
45839338|NCT03016806|Drug|Fludarabine|30 mg/m2/day x 5 or 40 mg/m2/day x 5
45839339|NCT03016806|Drug|Melphalan|140 mg/m2
46032077|NCT01224158|Device|Flat trimmed Manual Toothbrush|Following a placebo mouthwash phase, Subjects will be asked to brush their teeth (twice per day using the toothbrush and toothpaste provided) in their usual manner.
46032078|NCT02665351|Drug|Peramivir|The two regimens of Peramivir were compared
45839340|NCT03016650|Drug|Acetaminophen|Patients receive 100 mL of physiologic saline with 1 g IV paracetamol 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
46032079|NCT02666911|Procedure|4D Ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
45839341|NCT03016650|Drug|Ibuprofen|Patients receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
45839342|NCT03016494|Drug|Co-administration of DWC20155 and DWC20156|
46032080|NCT02666911|Procedure|2D ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
46032081|NCT04253860|Device|Transcutaneous electrical neurostimulation|Sessions of 30 minutes of TENS will be applied three times a week during 90 days
46032082|NCT01129128|Biological|Echinacea purpurea product|5 ml by mouth 3 times per day for 10 days
46032083|NCT01129128|Biological|Echinacea purpurea product|1 ml by mouth 3 times per day for 10 days
46032084|NCT01129128|Biological|Placebo|either 5 ml or 1 ml by mouth three times per day for 10 days
46032085|NCT04172389|Procedure|vesico-vaginal fistula robot assisted laparoscopic repair|realization of O'conor technique or extra-vesical technique for vaginal vesico fistula repair in robot assisted coelioscopy
46032086|NCT01222520|Drug|Telmisartan and amlodipine|Telmisartan 80 mg and amlodipine 5 mg once a daily
46032087|NCT01222520|Drug|Telmisartan|80 mg once a daily
46032088|NCT04252222|Device|Videolaryngoscopy with VL3|Tracheal Intubation aided by VL3 Videolaryngoscope
46032089|NCT05312424|Dietary Supplement|Placebo|300 mg olive oil
46032090|NCT05312424|Dietary Supplement|Low GG|150 mg GG
46032091|NCT05312424|Dietary Supplement|High GG|300 mg GG
46032092|NCT02888210|Device|MD-15 Intraocular Lens|
46032093|NCT04172233|Biological|AK101|AK101 is an anti-IL-12/23p40 monoclonal antibody.
46032094|NCT04172233|Biological|placebo|matching placebo
46032095|NCT01221350|Dietary Supplement|Lipoic acid|Lipoic acid 600 mg dose (two 300 mg capsules) once daily in the morning. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed.
45472264|NCT01262183|Drug|CRT + Panitumumab|Day -7, day +15 and day +36: panitumumab 9.0 mg/kg i.v. Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
45472265|NCT01262183|Drug|Concurrent chemoradiation therapy without panitumumab|Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
45472266|NCT03885479|Diagnostic Test|ELISA for the semi-quantitative analysis of serum food-specific IgGs against food-derived antigens|An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)
45472267|NCT03885557|Other|Group I Experimental DOS|After the application of hot pack treatment of 7-10 minutes, dynamic oscillatory stretch(DOS) technique (30 repetitions each of 2 seconds stretch duration in one session) was applied to DOS group. An experienced orthopedic manual physical therapist provided these techniques to patients .
45839343|NCT03016494|Drug|DWJ1386 Tab.|
45839344|NCT03016260|Biological|Infliximab|Anti-TNF alpha originator
46032096|NCT01221350|Dietary Supplement|Placebo|Placebo (two capsules filled with 300 mg vehicle) once daily in the morning during 60 days. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed
46032097|NCT02665429|Behavioral|Individual prescribing data profile and self-assessment|Prior to receiving his or her individual data profile, each provider in the intervention group will be asked to identify his or her self-assessment of his or her own opioid prescribing practices. Immediately after providing self-perception data, providers will be provided with their true profile data with a visual display of where they fall within the distribution of their peers. All peer data are de-identified.
46032098|NCT00646633|Procedure|Acupuncture and patient education|Acupuncture involves the insertion of extremely thin needles, much thinner than those used for drawing blood, into very specific acupuncture points. Patients will receive a total of 8 acupuncture treatments, each lasting 50 minutes. Patient education will be delivered to individuals over the course of approximately 50 minutes for each of the four sessions; topics will include acupressure, nutrition, exercise, stress management, and lifestyle advice.
46032099|NCT00647569|Procedure|Mesh repair|A Surgisis Gold Hernia repair graft (Cook Biotech Incorporated, West Lafayette, IN, U.S.A) is placed at the donor site of the rectus abdominis muscles used for the rotation flap before the abdominal fascia is sutured with continuous running suture.
46032100|NCT00647569|Procedure|Conventional facial closure|The abdominal facia is closed with with continuous running suture
46032101|NCT00647647|Drug|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fasting
46032102|NCT00647647|Drug|Lamisil® Tablets 250 mg|250mg, single dose fasting
46032103|NCT01221272|Drug|Ranolazine|"One 500 mg tablet in the evening on Day 1 of the period~One 500 mg tablet, twice daily on Days 2-3 of the period~Two 500 mg tablets (1000 mg total), twice daily from Day 4 to the end of the period (Day 15 ± 2 days)"
46032104|NCT01221272|Drug|Placebo to match ranolazine|Placebo to match ranolazine administered in the same form and frequency as the active drug.
46032105|NCT01221272|Procedure|SPECT MPI|Gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) to confirm the presence of reversible exercise-induced left ventricular perfusion defect size (PDS) performed within 12 weeks prior to baseline or at the baseline visit, and at the end-of-period 1 and end-of-period 2 visits.
46032106|NCT01221272|Behavioral|Exercise|Treadmill stress test
46032107|NCT00647725|Procedure|Active phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
45472268|NCT03885557|Other|group II SS group|After the application of hot pack treatment of 7-10 minutes , Static stretching (2 repetitions each of 30 seconds in one session) was applied to SS group. An experienced orthopedic manual physical therapist provided these techniques to patients .
46032108|NCT00647725|Procedure|Latent phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
45472269|NCT03886805|Other|Dual task with variable- and fixed-priority instructions|The participants were asked to perform dual-task activities focused, interchangeable or simultaneously, on balance (motor tasks) and on cognitive tasks performance, according to the instructional priority established by the physical therapist.
45472270|NCT03886805|Other|Dual-task with variable-priority instructions|The participants were asked to spend half the session focused on balance (motor tasks) and half the session focused on cognitive tasks performance, according to the instructional priority established by the physical therapist.
45472271|NCT01154855|Procedure|Prophylaxis ; Gross debridement for diseased patients|1 per patient at 2nd visit lasting approximately 1 hour.
46032109|NCT01220414|Drug|Naltrexone, then placebo|50 mg of naltrexone
46032110|NCT01220414|Drug|Placebo, then Naltrexone|sugar pill
46032111|NCT01128894|Biological|albiglutide|albiglutide weekly subcutaneous injection
46032112|NCT01128894|Drug|liraglutide|liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
46032113|NCT01128816|Device|Adaptive Servo Ventilation|BiPAP autoSV ADVANCED device worn nightly during sleep
46032114|NCT01220180|Drug|pregabalin (Lyrica)|Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after 1 week. The maximum dosage of 600 mg per day may be achieved after an additional week.
45839345|NCT03016260|Biological|Adalimumab|Anti-TNF alpha originator
46032115|NCT01220180|Drug|pregabalin (Lyrica)|"Peripheral neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.~Central neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 1 week, and if needed, to a maximum dose of 600 mg per day after an additional 1 week interval. In case that tolerability could not be shown in the targeted daily dose, dose reduction may be considered."
45472272|NCT03884933|Other|Mobile team community mental health services|The intervention focuses on changing mental health care systems to be able to provide community-based mental health care for people with severe mental illness. This will be done through the development and implementation of multidisciplinary community mental health teams (CMHTs) in each of the implementation sites, consisting of at least one nurse, psychiatrist, psychologist, social worker, and peer worker (person with lived experience of a severe mental illness). The structure and delivery method of the community mental health teams is part of an evidence-based service delivery model providing flexible, assertive community mental health teams providing integrated services to people with severe mental illness (SMI) in order to structurally attain their recovery goals, as well as timely and appropriate care in the event of a crisis.
45472273|NCT03885323|Device|RF utilizing powered toothbrush|RF utilizing Powered toothbrush
45472274|NCT03885323|Device|Control placebo with no RF|Placebo control, with no RF
45472275|NCT01154933|Drug|exenatide 5 mcg|exenatide 5 mcg
45472276|NCT01154933|Drug|exenatide 10 mcg|exenatide 10 mcg
45472277|NCT01154933|Drug|placebo|saline sq
46032116|NCT01220180|Drug|pregabalin (Lyrica)|The recommended dose of pregabalin for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Subjects who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). Treatment with doses above 450 mg/day is not recommended.
45472278|NCT01155635|Drug|Carvedilol|Use of Carvedilol with any dose
46032117|NCT01220024|Drug|Bupivacaine Collagen Sponge|Drug: Bupivacaine Collagen Sponge
46032118|NCT01220024|Drug|Placebo collagen Sponge|Drug: Placebo Collagen Sponge
46032119|NCT01128738|Drug|GSK1358820|Onabotulinum toxin type A
45472279|NCT01155635|Drug|No Carvedilol|No use of Carvedilol
46032120|NCT01128738|Drug|Placebo|Placebo
45472280|NCT01155089|Drug|Anastrozole|1 mg tablet
45472281|NCT03886727|Device|Rubber Dam Set|Rubber dam set is the generic name of an isolation device that consists of a rubber sheet that isolates the tooth from saliva, a clamp to hold the rubber sheet on the tooth to be isolated, and a metal frame to keep the rubber sheet in a stretched position during dental procedures.
45472282|NCT03886727|Device|Dental Cotton Roll|Cotton roll is the generic name of a disposable isolation device made of cotton in a cylindrical form. Cotton rolls are used to isolate the teeth from saliva, by being placed in the cheek and tongue during placement of sealants or filings.
45839346|NCT03016260|Biological|Etanercept|Anti-TNF alpha originator
45839347|NCT03016260|Biological|Golimumab|Anti-TNF alpha originator
46032121|NCT00625248|Drug|Antithrombotics|With or without or discontinuted use of Antithrombotics
46032122|NCT01143090|Drug|Lurasidone HCl|40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months
46032123|NCT05125146|Behavioral|e-CBTi|See arm/group description
46032124|NCT05125146|Drug|Trazodone|See arm/group edescription
46032125|NCT01165554|Drug|[18F] Flutemetamol|Flutemetamol (18F) Injection, 111 to 370 MBq (3 to 10 mCi), single intravenous injection.
46032126|NCT01218308|Biological|FluLaval® Quadrivalent|One intramuscular dose for primed subjects. Two intramuscular doses for unprimed subjects.
46032127|NCT01218308|Biological|Havrix™|Two intramuscular doses for primed subjects. Three intramuscular doses for unprimed subjects.
46032128|NCT02887976|Drug|SoluMatrix™ Abiraterone Acetate|SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) is an androgen synthesis inhibitor
46032129|NCT02887976|Drug|Methylprednisolone|Methylprednisolone (4mg bid) to maintain physiologic levels of corticosteroids which are reduced by SoluMatrix Abiraterone Acetate
46032130|NCT01165320|Drug|Caspofungin|
46032131|NCT01217606|Drug|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
45472283|NCT01261949|Device|Combined frontal and temporal rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 1000 stimuli of 1Hz rTMS over the right DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
45682865|NCT05347108|Procedure|laser-assisted neural decompression (LAND) procedure|"The LAND procedure is a minimally invasive spinal decompression procedure that uses a focused laser beam to reduce and remove disc herniations that are causing nerve compressions and impingements within the spinal canal. It is performed in an outpatient setting and the patient receives local anesthesia.~The LAND procedure has been performed extensively over the past 2-years on hundreds of patients, so including patients that have previously had the surgery allows for additional data points and improved reporting."
46032132|NCT01217606|Drug|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.
45472284|NCT01261949|Device|Temporal low frequency rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold)
45682866|NCT03086122|Device|Continuous positive airway pressure|Continuous positive airway pressure treatment for patients randomized to CPAP treatment group. Treatment duration: 3 months.
45472285|NCT01155245|Drug|Forteo|Forteo pen
45682867|NCT03085966|Biological|autologous immune cell therapy|Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)
45682868|NCT03085654|Drug|Oxytocin nasal spray|Intranasal administration of oxytocin 24 international units per dose.
45682869|NCT03085654|Drug|Placebo nasal spray|Intranasal administration of placebo 24 international units per dose.
45682870|NCT03085732|Drug|Irrigation with Saline Solution|During hysterectomy after vaginal cuff closure 500-1000 mL saline irrigation will be done.
46032133|NCT05463146|Other|Deep breathing excercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
46032134|NCT05463146|Other|Deep breathing exercises +and progressive muscle relaxation techniques|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
45472286|NCT03884699|Procedure|Accuracy of planned transverse Maxillary distance using Mimics software after fixation using Patient specific implant|"Virtual planning: based on clinical evaluation and 3D cephalometric analysis. Virtual osteotomies mimicking segmental Lefort I and a bilateral sagittal split osteotomy.~Designing the virtual cutting guide. Virtual movement into the desired positions of the segmented maxilla and mandible, based on: clinical evaluation, 3D cephalometric analysis and the desired occlusion.~Once the optimal position of the maxilla is achieved, a patient specific implant will be virtually designed to fix the segmented maxilla in its new position.~Fabrication of the cutting guide using additive manufacturing technique from polymer material.~Fabrication of PSI from titanium alloy using additive manufacturing technique."
45472287|NCT01155713|Drug|TKI258|
45472288|NCT01157039|Dietary Supplement|Glutamine|Glutamine- During the first cycle of oxaliplatin based combination therapy (mFOLFOX 6 or XELOX) no patient will receive glutamine. At cycle 2, patients will be randomized to receive for 6 days either : Glutamine 30g/day during cycle 2 and glutamine 40g/day during cycle 3 (ARM A) or glutamine 40g/day at cycle 2 and glutamine 30g/day at cycle 3 (Arm B).
45472289|NCT03881735|Drug|Enasidenib|Given PO
45472290|NCT03881735|Procedure|Hematopoietic Cell Transplantation|Undergo HCT
45472291|NCT01262417|Procedure|- use of resorbable membrane Seprafilm|use of resorbable membrane during the first surgery for the resection of hepatic metastases, 1 to 4 membranes should be used around the liver
45472292|NCT01262417|Procedure|without resorbable barrier (seprafilm)|non use of resorbable membrane during the first surgery for the resection of hepatic metastases
45472293|NCT01157195|Behavioral|Tele-AutoCITE|Automated, remotely-administered form of CI therapy
45472294|NCT01157195|Behavioral|CI therapy|CI therapy is a behavioral approach to physical rehabilitation that has three components: 1. intense training of the more affected arm for several hours daily for multiple consecutive days, 2. restraint of the less affected arm during training hours and afterwards during the treatment period, 3. A package of behavioral techniques designed to transfer gains from the treatment setting to daily life. In this trial, CI therapy will be administered for 3 1/2 hours per day for 10 consecutive weekdays.
45839348|NCT03016260|Biological|Certolizumab Pegol|Anti-TNF alpha originator
45472295|NCT03884621|Other|EHP Group|The Enhanced post-discharge home-based care program (EHP) plus usual care
45472296|NCT01155791|Drug|Docetaxel|IV 75 mg/m2
45472297|NCT01155791|Drug|Biosyn|IV dosage varies
45472298|NCT01155791|Drug|Prednisone|5mg, orally
45472299|NCT01263743|Behavioral|Relaxation Response|The Relaxation Response is a type of relaxation. The goal of the Relaxation Response is to consciously elicit a reaction opposite in direction to the stress response.
45472300|NCT01263743|Behavioral|Relaxation Response|Relaxation Response is a type of relaxation. This is a technique that elicits a state that is opposite to the stress response.
45472301|NCT03881657|Behavioral|Reverse Colocated Integrated Care|A reverse colocated integrated care model is one where primary care and preventive services are embedded within a behavioral health service setting.
45472302|NCT03881657|Behavioral|Usual Care|Behavioral health services without primary care or integrated care services
45839349|NCT03016260|Biological|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilars
45839350|NCT03016260|Biological|Etanercept biosimilar|Anti-TNF alpha Etanercept biosimilar
45839351|NCT03016260|Biological|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilar
46032135|NCT05463146|Other|Deep breathing exercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
45472303|NCT03881813|Device|Orthodontic retainers|Orthodontic retainers were bonded on the lower teeth of the subjects after fixed orthodontic treatment and were evaluated for their effectiveness for the followup of one year.
45472304|NCT01589783|Other|completion of a questionnaire|Completion of a questionnaire
45472305|NCT01589783|Other|Blood draw|A subset of 100 women will have a blood test to measure Vitamin D levels
45839352|NCT03016182|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
45839353|NCT03016182|Procedure|Control|Control group witnout remote ischemic preconditioning
45839354|NCT03016026|Procedure|ERAS|Undergo an ERAS program
45839355|NCT03015870|Behavioral|Vocal exercise with real-time feedback|The feedback intervention will use iPads pre-installed with a PDF of vocal exercises for the full duration of the study and with an app which will provide tailored feedback regarding pitch, loudness, and duration of phonation during practice sessions.
46032136|NCT05460962|Other|Deep breathing excercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
46032137|NCT05460962|Other|Deep breathing exercises +and progressive muscle relaxation techniques|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
45839356|NCT03015870|Behavioral|Vocal exercise with recording|The recording intervention will use an iPad pre-installed with the PDF of vocal exercises for the full duration of the study, but no feedback app.Participants audio record self while performing vocal exercises
46032138|NCT01128114|Drug|Quetiapine fumarate (Seroquel XR)|Extended Release(XR) 50 mg, 200 mg, 300 mg and/or 400 mg tablet, oral, once daily in the evening, from assignment to the end of the study.
45472306|NCT03881969|Behavioral|Financial Payment of £100|No financial payment
45682871|NCT00087568|Drug|Ribavirin|1000/1200mg po bid for 36 or 60 weeks
45682872|NCT00087568|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 36 weeks (non-responders) or 60 weeks (non-tolerators)
46032139|NCT05458544|Drug|[177Lu]Ludotadipep 3.7 GBq|"Phase 1:~Patients will receive a single dose of 3.7 GBq of [177Lu]Ludotadipep~Test article code/name: [177Lu]Ludotadipep~Administration route: intravenous injection~Total dose strength: 3.7 GBq~Dosage form: solution for injection~Phase 2a:~Patients will receive 3.7 GBq of [177Lu]Ludotadipep every 8 [±1] weeks (4 to 6 times)~Test article code/name: [177Lu]Ludotadipep~Administration route: intravenous injection~Total dose strength: 4 to 6 x 3.7 GBq~Dosage form: solution for injection"
46032140|NCT01217060|Drug|Docetaxel|20 mg/m2 given by vein (IV) over 1 hour once a week for up to 5 1/2 weeks.
45682873|NCT04402216|Behavioral|Child Life-led preparation|Support from a certified child life specialist in preparation for MRI
45682874|NCT04402216|Behavioral|MRI preparation video|A descriptive video about what to expect when undergoing MRI
45682875|NCT04402216|Behavioral|KindVR Virtual Reality MRI Preparation Experience|A VR experience to prepare pediatric patients for MRI, to be used in addition to support from a certified child life specialist
45682876|NCT04402762|Drug|Ovine Enoxaparin|The test drug is ovine enoxaparin sodium 60 mg (0.6 mL taken from 1.0 mL vial containing 100 mg = 10,000 IU anti-FXa), from Metiska Farma.
45682877|NCT04402762|Drug|Enoxaparin Prefilled Syringe [Lovenox]|The reference drug is enoxaparin sodium 60 mg (Lovenox® 0.6 mL prefilled syringe containing 60 mg = 6,000 IU anti-FXa) from Sanofi, France.
45839357|NCT03015714|Other|MIRT|MIRT consists of a 4-week rehabilitation program in a hospital setting, which entails four daily sessions of physical therapy for five days and one hour of physical exercise on the sixth day. On the seventh day the patient rests. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with a physical therapist. The second session includes aerobic exercises to improve balance and gait, using different devices: a stabilometric platform with visual cues, a treadmill plus and a cycloergometer. The third session consists of occupational therapy, the fourth one includes one hour of speech therapy.
46032141|NCT01217060|Drug|5-FU|300 mg/m2 given by vein, continuously for 96 hours a week for about 5 1/2 weeks.
46032142|NCT01217060|Radiation|Radiotherapy|50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks, Monday through Friday.
46032143|NCT01217060|Procedure|Esophagectomy|Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.
46032144|NCT01217060|Drug|Dexamethasone|10 mg IV 30 minutes prior to weekly Docetaxel.
46032145|NCT01216202|Radiation|Preoperative radiotherapy|"Preoperative radiotherapy (RT) was administered as either short course (5Gy x5) or long-course (2Gy x25 or 1.8 Gy x25 with or without 3 fractions of boost to the primary tumor and radiologically malignant lymph nodes) treatment with or without concomitant or sequential chemotherapy. Oncological treatment was decided at a multidisciplinary team conference.~Testicular doses (TDs) was calculated from planning CT-scans and reported as mean cumulative testicular dose. Relative TD was calculated based in the assumption that RT regimens for rectal cancer are bioequivalent and referred to as proportion of prescribed dose absorbed by the testes."
45472307|NCT01157507|Drug|Intravesical injection of Botulinum A Toxin|One treatment, 100 U vials diluted in 10 ml normal saline
45472308|NCT01157507|Procedure|Bladder overdistension|Bladder overdistension
46032146|NCT04816669|Biological|BNT162b2|Intramuscular injection
45472309|NCT01157507|Drug|Placebo|One single injection of placebo
45472310|NCT03881267|Other|Human Autologous Homologous Skin Construct|Application of a autologous human derived skin polar units
46032147|NCT01165242|Biological|Meningococcal vaccine GSK 134612|One intramuscular injection
45472311|NCT03881267|Other|Additional Outer Dressing Application|Application of Moisture retentive dressing, and a multi-layer compression dressing
45472312|NCT03881267|Other|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
46032148|NCT01165242|Biological|Menactra®|One intramuscular injection
45472313|NCT01263821|Procedure|Diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
45472314|NCT01263821|Procedure|Perfusion-weighted magnetic resonance imaging|Undergo perfusion-weighted magnetic resonance imaging
45472315|NCT01263821|Procedure|Functional magnetic resonance imaging|Undergo functional MRI
45472316|NCT01263821|Procedure|Magnetic resonance spectroscopic imaging|Undergo MR spectroscopic imaging
45472317|NCT01263821|Procedure|Therapeutic conventional surgery|Undergo maximal surgical resection
46032149|NCT01170065|Drug|BIBF 1120|Intermediate dose BIBF 1120 twice daily
46032150|NCT01170065|Drug|BIBF 1120|High dose BIBF 1120 twice daily
45472318|NCT01263821|Procedure|Quality-of-life assessment|Ancillary studies
45472319|NCT01263821|Procedure|Radiation therapy treatment planning/simulation|Undergo IMRT planning
45472320|NCT01263821|Procedure|Intensity-modulated radiation therapy|Undergo intensity-modulated radiation therapy
45472321|NCT01263821|Other|Questionnaire administration|Ancillary studies
45472322|NCT01262495|Other|cryopreservation|cryopreservation of testicular tissue
46032151|NCT01170065|Drug|BIBF 1120|Low dose BIBF 1120 twice daily
46032152|NCT01170065|Drug|BIBF 1120|Low dose BIBF 1120 once daily
45472323|NCT01263899|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28 day cycle.
45472324|NCT03881423|Drug|Rocuronium Bromide|DEEP block to PTC 1-3
45472325|NCT03884465|Drug|Inhaled dry powder treprostinil (LIQ861)|Inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg, or 100μg capsule strengths. Single dose in the acute setting. QID in the chronic setting.
45472326|NCT01263977|Device|Picco- thermodilution catheter|Transpulmonary thermodilution and pulse contour analysis with arterial catheter Arterial access via femoral
45472327|NCT01155947|Drug|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
46032153|NCT02885922|Drug|anti-diabetic drug|Add-on anti-diabetic drug in type 2 diabetic patients
45472328|NCT03881189|Device|SUNEKOS® 200|The intradermal injection procedure was performed bilaterally, on the area around the eyes including the eyelids, using periosteal and subepidermal injection techniques. This injective procedure consists of micro-wheals of 0.2 ml just above the periosteum and micro-wheals of 0.1 ml very superficially, just under epidermis.
45472329|NCT03884309|Other|Experimental Hydrolyzed Protein Infant Formula|fed ad libitum
46032154|NCT04174417|Procedure|systolic blood pressure (SBP)|"Systolic blood pressure (SBP) 80-90 mmHg remifentanil infusion was applied to Group 1 patients. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory"
45472330|NCT01157585|Drug|paliperidone ER|8 week prospective study
45472331|NCT01264133|Drug|Clevudine, Adefovir|Clevudine 30mg qd or Clevudine 30mg + Adefovir 10mg qd
45472332|NCT02527577|Drug|RopivacaIne chlorhydrate|3mg/kg injection Hour (H) 0, H12 ; H24, H36 ; H48
45472333|NCT02527577|Drug|Placebo|injection Hour (H) 0, H12 ; H24, H36 ; H48
45472334|NCT03883841|Drug|Iron Sucrose Solution for Injection|intravenous infusion of iron sucrose
45472335|NCT03881111|Biological|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
45472336|NCT03881111|Drug|Placebo|Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
45472337|NCT03881111|Drug|Cisplatin|80 mg/m^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
45472338|NCT03881111|Drug|5-FU|800 mg/m^2/day (4000 mg/m^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration.
45472339|NCT01157663|Other|Adapted balance training|during 8 weeks
45472340|NCT01157663|Other|Balance Training|Balance training with unipedal standing during 8 weeks
45472341|NCT03884387|Other|Patient Decision Aid|The Patient Decision aid used in this project is a tool designed to facilitate shared decision making in patients with lumbar herniated disk. It is intended to complement counseling with health professionals and help patients become involved in decision making by making explicit the decision that needs to be made, providing information about the advantages and disadvantages of having or not having surgery, knowledge of treatment outcomes, and by clarifying personal values.
45472342|NCT03883997|Other|No intervention|Cross-sectional
45472343|NCT01264211|Drug|Diacerein|Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
45472344|NCT01264211|Drug|Placebo|Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
45472345|NCT03881033|Other|Peep 5cmH2O|Face mask ventilation with peak inspiratory pressure according to the group P7+5 means face mask ventilation with peak inspiratory pressure 7cmH2O plus PEEP 5 cmH2O.
45472346|NCT03881033|Other|Peak inspiratory pressure|Face mask ventilation with peak inspiratory pressure according to the group P12 means face mask ventilation with peak inspiratory pressure 12cmH2O without PEEP.
45472347|NCT03880877|Drug|Regorafenib|Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle
45472348|NCT03880877|Genetic|UGT1A1 genotyping (TA6/TA6)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2
45338497|NCT05609825|Drug|LY3875383|Administered SC.
45472349|NCT03880877|Genetic|UGT1A1 genotyping (TA6/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2
46032155|NCT04174417|Procedure|mean blood pressure (MBP)|"For group 2, remifentanil infusion was performed with a mean blood pressure (OCD) of 50-65 mmHg. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory."
46032156|NCT02885844|Procedure|INVERTED VISION|The tasks will be performed either with normal or inverted vision (upside down) using commercial off-the-shelf inverting prism goggles
46032157|NCT02885844|Procedure|NORMAL VISON|subject's field of view will be restricted by goggles without lenses in order to be equivalent to the inverted vision one.
45338498|NCT05609825|Drug|Placebo|Administered SC.
45472350|NCT03880877|Genetic|UGT1A1 genotyping (TA7/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2
45682878|NCT03412630|Radiation|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
45682879|NCT03487900|Diagnostic Test|Colonoscopy|Colonoscopy for CD patients in clinical remission
45682880|NCT00085540|Drug|depsipeptide|Given IV
45682881|NCT01677676|Biological|FP-01.1|IM injection
45682882|NCT01677676|Biological|FP-01.1-Adjuvant|IM injection
45682883|NCT02984488|Procedure|single visits|Endodontic treatment is done and completed in a single visit using protaper next rotary system.
46032158|NCT00966693|Drug|Dexamethasone|Given PO
46032159|NCT00966693|Drug|Lenalidomide|Given PO
45472351|NCT03880877|Drug|Leucovorin and 5-FU|Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period)
45472352|NCT01157741|Behavioral|C-C|Mx as H-C plus positioning follow up in the community clinic
45472353|NCT01157741|Other|C-SF|As C-C but with additional supplementary food (SF) (C-SF)
45682884|NCT02984488|Procedure|two visits|Endodontic treatment is done and completed in two visits using protaper next rotary system.
46032160|NCT00966693|Drug|Thalidomide|Given PO
45682885|NCT01688739|Drug|Erenumab|Administered by subcutaneous injection or intravenous injection
45338499|NCT05393232|Behavioral|Dietitian-Assisted DASH groceries|"The DASH (Dietary Approaches to Stop Hypertension), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.~Intervention Phase:~This intervention is a weekly, 12-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size.~Observation Phase:~For months 4-12 of the study, participants will be asked to continue following a DASH grocery shopping pattern without the provision of weekly groceries."
45338500|NCT05393232|Behavioral|Self-directed shopping|"Intervention Phase:~Participants will receive some basic information on healthy eating and a monthly stipend at 4, 8, and 12-weeks of the intervention.~Observation Phase:~For months 4-12 of the study, participants will be asked to follow their typical shopping pattern without the provision of a monthly stipend."
45682886|NCT01688739|Drug|Placebo|Administered by subcutaneous injection or intravenous injection
46032161|NCT01215968|Biological|LY2189265|1.5 mg administered subcutaneously
45338501|NCT04063839|Drug|Elbasvir / Grazoprevir Oral Tablet|HCV treatment according to Norwegian guidelines
45338502|NCT04078074|Device|Maxillary OSS|Maxillary OSS will be a night guard for the top teeth. Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo cone beam computed tomography (CBCT) airway imaging with and without splint.
45682887|NCT03085264|Behavioral|Community Health Worker|Community Health Workers calls, texts and visits patient to support them in pre-established care plans as well as medication compliance/appointment attendance
45682888|NCT00084838|Biological|filgrastim|
45682889|NCT00084838|Drug|cisplatin|
45682890|NCT00084838|Drug|cyclophosphamide|
45682891|NCT00084838|Drug|cytarabine|
45682892|NCT00084838|Drug|dexrazoxane hydrochloride|
46032162|NCT01215968|Drug|Placebo|Administered subcutaneously
46032163|NCT02663713|Drug|Ticagrelor|Ticagrelor 60mg twice daily
46032164|NCT02663713|Drug|Clopidogrel|Clopidogrel 75 mg once daily
46032165|NCT02664649|Drug|Apixaban|"Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight <60 kg, serum creatinine ≥1.5 mg/dL [133 μMol/L].~- Also, subjects with severe renal insufficiency [calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min] will take apixaban 2.5 mg tablets orally twice daily"
46032166|NCT02664649|Drug|Standard of care|VKA or Antiplatelet therapy
46032167|NCT02664493|Drug|Methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
45472354|NCT01157741|Other|As C-C with additional psychosocial stimulation (PS) (C-PS)|Giving psychosocial stimulation
45472355|NCT01157741|Other|As C-C but with both SF & PS (C-SF+PS)|Giving both SF & PS
46032168|NCT00963807|Drug|Cisplatin|Given IV
46032169|NCT00963807|Procedure|CT|Undergo FDG PET/CT, FLT PET/CT and thoracic CT
46032170|NCT00963807|Drug|Docetaxel|Given IV
46032171|NCT00963807|Drug|FDG|Undergo FDG PET/CT
45338503|NCT04078074|Device|Mandibular OSS|Mandibular OSS will be a night guard for the bottom teeth.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
45338504|NCT04078074|Device|Modified farrar splint|Modified farrar splint will be a night guard for the top teeth that positions and maintains the lower jaw in a more forward position.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep. This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
45338505|NCT00785213|Drug|Rosiglitazone 4 mg Tablets|Rosiglitazone 4 mg tablet administered as a single oral dose on the morning of Day 1.
45338506|NCT00785213|Drug|Rosiglitazone 4 mg Tablets|Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
45472356|NCT01157741|Other|H-C|Follow-up at Hospital
45472357|NCT05666999|Device|FibDex®|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
45472358|NCT05666999|Device|Suprathel|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
45472359|NCT05666999|Device|Aquacel Foam|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
45472360|NCT03000530|Drug|SAGE-217|
45682893|NCT00084838|Drug|doxorubicin hydrochloride|
45682894|NCT00084838|Drug|etoposide|
45682895|NCT00084838|Drug|leucovorin calcium|
46032172|NCT00963807|Drug|FLT|Undergo FLT PET/CT
46032173|NCT00963807|Procedure|PET/CT|Undergo FDG PET/CT and FLT PET/CT
45472361|NCT03000530|Drug|Placebo|
45472362|NCT03880799|Behavioral|Mindfulness Session|one hour mindfulness session conducted by a certified mindfulness teacher with the breast cancer patient
45682896|NCT00084838|Drug|methotrexate|
45682897|NCT00084838|Drug|temozolomide|
45682898|NCT00084838|Drug|therapeutic hydrocortisone|
45682899|NCT00084838|Drug|vincristine sulfate|
45682900|NCT00084838|Radiation|radiation therapy|
45682901|NCT00084838|Drug|Dactinomycin|
45682902|NCT01558089|Drug|etanercept|according to SmPC and clinical practice
46032174|NCT00963807|Procedure|Surgery|Undergo surgery
46032175|NCT01142466|Drug|Interferon beta-1a (Rebif)|The dosage of IFN-beta-1a , following initial dose titration, was 44 mcg injected subcutaneously (s.c.) tiw. An auto-injector device, Rebiject, was available as an optional aid for the administration of IFN-beta-1a . IFN-beta-1a was administered, if possible, at the same time (preferably in the late afternoon or evening) on the same three days at least 48 hours apart each week.
46032176|NCT02663635|Device|Safe'N'Sound|
46032177|NCT00648505|Drug|Glipizide and Metformin HCl Tablets 5 mg/500 mg|5/500mg, single dose fed
46032178|NCT00648505|Drug|Metaglip® Tablets 5 mg/500 mg|5/500mg, single dose fed
46032179|NCT01215734|Biological|High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)|0.5 ml of HD-TIV on visit 1
46032180|NCT01215734|Biological|Standard Dose Trivalent Inactivated Flu Vaccine|Twenty adult hematopoetic stem cell transplant recipients will receive 0.5 ml standard dose trivalent influenza vaccine on visit 1.
45839358|NCT03015714|Other|MIRT-AT|Patients in the MIRT-AT group will undergo the land-based therapy described in MIRT plus three sessions per week (Monday, Wednesday, Friday) of aquatic therapy. On days of aquatic therapy the first session of MIRT was not provided. The aquatic therapy program included aerobic exercises and physical activities to improve balance, motor skills, coordination and joints mobility. The water sessions were divided into 3 phases: i) Warm Up Exercises, ii) Central session Training, iii) Cool-down.
46032181|NCT04172311|Other|Modified Atkins Diet|Modified Atkins diet is a type of ketogenic diet which is less restrictive
46032182|NCT04172311|Drug|Levetiracetam|Levetiracetam is a second generation anti-epileptic drug which is broad spectrum and commonly used as add-on in refractory epilepsy
46032183|NCT02863185|Drug|Pitavastatin|
46032184|NCT02863185|Drug|Atorvastatin|
45338507|NCT00785213|Drug|Quinine Sulfate 324 mg Capsules|Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
45472363|NCT01262729|Procedure|therapeutical hypothermia|Patients after successful cardiopulmonary resuscitation will be treated in accordance to international guidelines (Guidelines 2005 on cardiopulmonary resuscitation. Resuscitation 2005; 67: S7-S23)
45682903|NCT01558089|Drug|methotrexate|according to SmPC and clinical practice
45682904|NCT01581021|Device|Pedicle screws|Screws that are placed into the pedicle of vertebral body.
45682905|NCT01581021|Device|Laminar Hooks|Hooks are placed over the lamina of the vertebral body
45338508|NCT00577317|Procedure|Management of Therapy Complications|Receive standard home maintenance therapy and perform self-manual lymphatic drainage
45682906|NCT03085342|Diagnostic Test|Liver MRI|Multiparametric Liver MRI including following sequences: DCE, DWI, MRE, precontrast flow measurement, fat quantification.
45682907|NCT04410003|Biological|Fecal microbial transplant|Fecal microbial transplant
45682908|NCT03486340|Procedure|Cardiologic assessment|Aggressive ischemic risk factor management
45682909|NCT00084682|Drug|romidepsin|Given IV
45338509|NCT00577317|Procedure|Management of Therapy Complications|Receive Flexitouch home maintenance therapy
45338510|NCT00577317|Other|Quality-of-Life Assessment|Ancillary studies
45682910|NCT01556997|Drug|XOMA 985|PERa/AMLb capsule taken once daily by mouth for six weeks
45682911|NCT01556997|Drug|Amlodipine Besylate|AMLb capsule taken once daily by mouth for six weeks
45682912|NCT01556997|Drug|Perindopril Erbumine|PERe capsule taken once daily by mouth for six weeks
45682913|NCT00082888|Other|Laboratory Biomarker Analysis|Correlative studies
46032185|NCT02666833|Device|Polarization Enhanced Reflectance and Fluorescence System|Subjects will receive preoperative imaging of their skin cancer with the PERFIS optical imaging device.
45338511|NCT02583594|Drug|Acyclovir|Pharmaceutical form:tablet Route of administration: oral
45338512|NCT02583594|Drug|Methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
45338513|NCT02583594|Drug|alemtuzumab GZ402673|Pharmaceutical form:solution for infusion Route of administration: intravenous
45338514|NCT02583594|Drug|alemtuzumab GZ402673|Pharmaceutical form:injection Route of administration: subcutaneous
45338515|NCT02583594|Drug|Paracetamol|Pharmaceutical form:tablet Route of administration: oral
45472364|NCT01262729|Drug|Xenon Inhalation|Patients after successful cardiopulmonary resuscitation will be inhalated with 65-70% Xenon within 2 hours additional to therapeutical hypothermia
45472365|NCT01156025|Drug|GV550|Ganciclovir 1.5 mg/g, 1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
45472366|NCT01156025|Drug|placebo|1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
45682914|NCT00082888|Drug|Tipifarnib|Given PO
45839359|NCT03015948|Drug|SHR4640|a single dose of SHR4640 (n=8) for each dose cohort
45839360|NCT03015948|Drug|Placebo|a single dose of placebo (n=2) for each dose cohort .
46032186|NCT01215422|Procedure|timed intubation|timed intubation
46032187|NCT03633201|Device|Cruciate Retaining|Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The standard insert.
46032188|NCT03633201|Device|Medial Congruent|Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The new anatomical congruent shaped insert.
46032189|NCT04315025|Biological|Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar
46032190|NCT04315025|Biological|Conditioned Medium (CM)|Conditioned Medium (CM) injected by peribulbar
46032191|NCT02664571|Device|Pet scan with FBB|"Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care.~Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself."
46032192|NCT02664571|Device|MRI scan|Subjects will have an MRI scan at inclusion.
45338516|NCT02583594|Drug|Loratadine|Pharmaceutical form:tablet Route of administration: oral
45682915|NCT03482986|Behavioral|Dietary habits plan|Patients will be given a personalized plan regarding their diet.
45338517|NCT02583594|Drug|Ceterizine|Pharmaceutical form:tablet Route of administration: oral
45338518|NCT02583594|Drug|Dexchlorpheniramine|Pharmaceutical form:tablet Route of administration: oral
45338519|NCT05571761|Behavioral|Cognitive stimulation program|"The cognitive stimulation program consists of 12 sessions of approximately 45 minutes, distributed in a first stage of training and psychoeducation (1 session), a second stage to address emotional aspects of anxiety and depression (2 sessions), and neuropsychological training (8 sessions) and a final closing stage with one session. There will be two sessions per week for 6 weeks.~The neuropsychological training includes 20 activities whose level of difficulty will vary according to the number of stimuli and the time of stimuli presentation. It includes 5 attentional activities, 3 memory activities, 5 executive functioning activities, one visuospatial skills activity and 6 ecological activities. These activities will be developed on a digital computer platform where patients will be assigned an identification and password to ensure confidentiality."
45682916|NCT04403152|Other|Post-operative rehabilitation|Patients received the exercises programme for five days, 30 minutes, two times per day with supervision by a physical therapist.
46032193|NCT02664571|Biological|APO E genotyping|Subjects will have APO (apolipoprotein) E genotyping if not already known.
45338520|NCT00740415|Biological|rituximab|Rituximab, 375 mg/m2 Intraveinous
45338521|NCT00740415|Drug|bortezomib|-Velcade®, 1,3 mg/m2 Intraveinous on days 1, 4, 8 and 11
45338522|NCT00740415|Drug|dexamethasone|day - Dexamethasone, 40 mg Intraveinous
45338523|NCT00740415|Drug|Bendamustine|-Day 1 and day 2 Bendamustine/Levact ®,, 90 mg/m2 Intraveinous
45338524|NCT02581722|Device|PrePex Device|The PrePex device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures. For contraindicated subjects, a preparation procedure will take place.
45338525|NCT00734162|Drug|Tenofovir disoproxil fumarate (TDF)|TDF administered as a 300-mg tablet once daily
45338526|NCT00734162|Drug|Placebo|TDF placebo tablet once daily
45338527|NCT00740493|Drug|warfarin|18 months of warfarin therapy
46032194|NCT00972153|Device|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the surgery site.
46032195|NCT00972153|Device|Sham Air Barrier System device|Device is deployed to the surgery site, but the airflow is not activated. This intervention is used to determine any effects that the presence of the device alone may have.
46032196|NCT04736485|Drug|perioperative treatment|FLOT + Spartalizumab
45338528|NCT00740493|Drug|placebo of warfarin|18 months of placebo of warfarin therapy
45472367|NCT03880721|Procedure|Microwave abaltion|Use microwave ablation to treat hepatocellular carcinoma
45472368|NCT01264289|Drug|Finasteride|Finasteride Tablets 5 mg
45682917|NCT04403152|Other|Post-operative mobilization|Patients received usual mobilization programme for 2-5 minutes, two times per day the five days with supervision by a physical therapist.
46032197|NCT00647881|Drug|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fed
46032198|NCT00647881|Drug|Paxil CR™ Tablets 25 mg|25mg, single dose fed
46032199|NCT02861625|Behavioral|Letter of condolence and post-death medical consultation|Process of sending a letter of condolence with consultation proposition.
46032200|NCT04174261|Drug|Ticagrelor|Preprocedural ticagrelor loading and standard dose thereafter
46032201|NCT04174261|Procedure|Remote Ischemic Preconditioning|Preprocedural remote ischemic preconditioning on the non-dominant arm
46032202|NCT04174261|Drug|Clopidogrel|Preprocedural clopidogrel loading and standard dose thereafter
45682918|NCT03409588|Drug|Adempas|After obtaining baseline data, patients will be placed on oral riociguat at a dose of 0.5 mg TID which will be up titrated over two months to a maximum dose of 2.5 mg TID or maximum tolerated dose. After 3 months from onset of riociguat initiation, the University of California San Diego (UCSD) shortness of breath score, 6 Minute Walk Test (6MWD), and resting/exercise Right Heart Catheterization (RHC) will be repeated.
45682919|NCT03085186|Drug|Crizotinib|
45338529|NCT02582580|Other|Perineal massage|"Perineal massage should be practiced once a day, from the 34th week of gestation until the beginning of labor. It should obey the following sequence: the pregnant woman must be positioned comfortably and use intimate water based lubricant at her fingertips; start the massage in the outdoor area of the vulva with circular movements of the skin and connective tissue around the vagina and at the central tendon of the perineum, clockwise, clitoris to clitoris; introduce two thumb fingers or index and middle fingers into the vagina at a distance of approximately 4 centimeters; perform internal massaging with laterally semicircles towards the anus for 20 to 30 seconds; put pressure down towards the anus and to each side of the vagina until feeling a slight burning or stretching sensation and hold the position for 2 minutes; massage the lower half of the vaginal introitus in a movement simulating the letter U. All movements should be repeated four times."
45472369|NCT03883451|Other|Helmet Model|helmet model worn by football players
46032203|NCT00971997|Drug|Lispro Mix 50/50|Administered subcutaneously once daily for 16 weeks, twice daily for 16 weeks, and three times daily for 16 weeks dependent on glycemic control.
45472370|NCT01156103|Behavioral|America SCORES, Bay Area|After-school program promoting physical activity via soccer 3 days/week
46032204|NCT01142388|Biological|Cixutumumab|Given IV
45472371|NCT03880487|Drug|KP-1199|Single dose and Multiple ascending doses of KP-1199 oral capsules
45839361|NCT03015480|Behavioral|Remote counseling|For an 8 week period, patients will be asked to enter dietary information into the MyFitnessPal mobile application or website. Dietitians will access this information and provide personalized motivational interview phone calls on a weekly basis. After the initial 8 weeks, patients will receive a dietitian follow-up phone call around 5 and 11 months later.
46032205|NCT01142388|Other|Laboratory Biomarker Analysis|Correlative studies
46032206|NCT01142388|Drug|Paclitaxel|Given IV
46032207|NCT01142388|Other|Pharmacological Study|Correlative studies
46032208|NCT04171609|Behavioral|Expressive writing|During this daylong expressive writing workshop intervention, the writing instructor coached participants through a series of simple writing exercises. Participation required neither any prior writing experience, nor any desire to become a writer. The practices cultivate natural abilities to express the ideas that define who you are and how you experience your life.
46032209|NCT00910741|Drug|Nanoplatin (NC-6004) and Gemcitabine|
46032210|NCT02863731|Other|Alternating working postures, first day|On the first day of measurement participants execute five test battery trials in alternating postures (sit/stand/sit/stand/sit). On the second day of measurement participants execute the test battery in a sitting posture (sit/sit/sit/sit/sit).
46032211|NCT02863731|Other|Alternating working postures, second day|On the first day of measurement participants execute five test battery trials in a sitting posture (sit/sit/sit/sit/sit). On the second day of measurement participants execute the test battery in alternating postures (sit/stand/sit/stand/sit).
46032212|NCT04604665|Other|High frequency postural change|"Repositioning of patients hospitalized in bed in intensive care units will be carried out with a frequency interval that we call high-frequency to be performed on each patient between an interval between less than or equal to every 2 hours in a full day (24 hours) (minimum goal of 8-10 in 24 hours subtracting 2 or 4 at night and not alter the circadian cycle). The position must be modified in each postural change to right lateral, supine, left lateral, or prone to supine if the position changes every 2 hrs."
46032213|NCT04604665|Other|Conventional care|Repositioning of patients hospitalized will be performed in the current way it is commonly applied to patients.
46032214|NCT02863497|Behavioral|Mindfulness-based Sex Therapy|These group sessions will include education about sexuality, and the practice of mindfulness skills (including paying attention to the present moment, and to body sensations). Each group will include 7-8 women, plus the group facilitators. The group facilitators for the study will include Dr. Laurel Paterson (who has extensive experience in administering Mindfulness-based sex therapy in other populations of women), and occasionally one of the research team members.
46032215|NCT00647959|Drug|Doxycycline Tablets, 150mg|150mg, single dose fasting
46032216|NCT00647959|Drug|Adoxa Tablets 150 mg|150mg, single dose fasting
46032217|NCT03602235|Other|Ascorbate|Ascorbate is in the vitamin drug class
46032218|NCT03602235|Drug|Melphalan|Melphalan is an alkylating agent coupled to an amino acid
46032219|NCT00648583|Drug|Ondansetron Tablets 24 mg|24mg, single dose fed
46032220|NCT00648583|Drug|Zofran® Tablets 24 mg|24mg, single dose fed
46032221|NCT04284579|Device|IV cannula|We measure the time duration needed for IV cannulation
46032222|NCT02882334|Device|Finger Force Manipulandum|
45338530|NCT02582580|Device|Vaginal Dilator|Vaginal dilator Epi-No® should be used once a day for 15 minutes, from the 34th week of pregnancy until the beginning of labor. It should be coated with a condom and intimate water based lubricant and then be inserted into the vaginal canal in such way that the balloon stays two centimeters away from the vaginal introitus. The device will be inflated by manual pumping until the tolerable woman's limit. The pregnant woman will be encouraged to daily inflate a greater volume of compressed air into the balloon so that the amount of air is greater than the quantity in the previous day, achieving, day after day, a greater stretching of perivaginal structures, always respecting the individual tolerance limit. The amount of manual pumping imposed to inflate the balloon should be written in an Intervention Diary so that the next use, the pregnant woman will be sure that pumped the device more times than in the previous session.
45338531|NCT02582580|Other|Pelvic floor muscles training|Pregnant women allocated to this group will perform pelvic floor muscles training. The progression of the protocol of this study will occur gradually in view of the peculiarities that involve the pelvic floor in the gestational stage and the ultimate goal is the promotion of an intact perineum after vaginal delivery. The exercises will obey a sequence, according to the gestation week, considering the following factors/parameters: exercise position, number and sustaining period of slow and fast contractions, and relaxation time between contractions. All contractions should be during the expiratory phase of breathing associated with an isometric contraction of the abdominal muscles and at the end of each series of contractions, perform a one minute interval between sets and in that time perform the diaphragmatic breathing exercise to promote overall relaxation. This protocol should be practiced once a day, every day from the 34th week of gestation until the beginning of labor.
46032223|NCT02882334|Other|Conventional physiotherapy|
46032224|NCT02664259|Procedure|VBN|VBN is carried out by a VBN software（DirectPath;Olympus,Japan) which can automatically create virtual bronchoscopic images.
46032225|NCT02664259|Procedure|EBUS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm.
46032226|NCT02664259|Procedure|X-ray|The radiograph fluoroscopy is performed when the probe is confirmed to reach the lesion by EBUS image ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
46032227|NCT04285749|Drug|Fluvastatin|Fluvastatin PO 80mg QD for 2 weeks
46032228|NCT04285749|Other|RNA-sequencing|RNA-sequencing will be completed on the original diagnostic biopsy and the final melanoma excision
46032229|NCT04285749|Other|Gene expression profiling|Gene expression profiling will be completed on the original diagnostic biopsy and the final melanoma excision
46032230|NCT02660125|Procedure|Endometrial scratch injury|midluteal single endometrial strip will be taken using a Novak curett under general anasthesia to avoid discomfort and cramping and to proceed to cervical dilatation in case of forbidden cervix
46032231|NCT03809481|Drug|Danaparoid Sodium|inhibits thrombin generation by indirect anti-Xa inhibition and direct inhibition of factor IX activation
45472372|NCT03880487|Drug|Placebo oral capsule|Single dose and Multiple dose identical to active treatment but without KP-1199.
45472373|NCT03880487|Drug|Oxycodone oral capsule|10 mg Oxycodone Capsules
46032232|NCT03809481|Drug|Argatroban|Synthetic direct thrombin inhibitor
45338532|NCT03897231|Other|questionnaire|Participants will be invited to participate in the study during their dialysis treatment at the participating hemodialysis outpatient centres. Allocated nurses at Copenhagen University Hospital, Rigshospitalet (MS, AB, LFH, AH), Copenhagen University Hospital, Hillerød (MPL) and Copenhagen University Hospital Herlev (TM) will be responsible for recruitment. Eligible patients will be informed orally and in writing about the study. Participants who wish to participate will be asked to provide informed consent and, following this, complete a paper-based questionnaire during treatment. Patients who have difficulty reading Danish and patients with visual or physical impairments that impinge on their ability to complete the questionnaires will be interviewed using a structured interview approach based on the questionnaires.
45338533|NCT00790751|Drug|placebo|30 minutes orally prior to initiation of sexual activity
45338534|NCT00790751|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
45338535|NCT00790751|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
46032233|NCT00649129|Drug|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fasting
46032234|NCT00649129|Drug|Ditropan XL® Tablets 10 mg|2x10mg, single dose fasting
46032235|NCT01127646|Drug|Atomoxetine|25-80 milligrams (mg) administered orally, once daily.
45338536|NCT00790751|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
46032236|NCT01127646|Drug|Osmotic-release oral system methylphenidate|18-54 mg administered orally, once daily.
45338537|NCT00740571|Drug|amitriptyline|strategy in which the patient starts with amitriptyline, during 8 weeks
45338538|NCT00740571|Drug|pregabalin|Strategy in which patient starts with pregabalin
45338539|NCT02582502|Other|Hyperbaric Oxygen|The only intervention given will be 100% oxygen under hyperbaric pressure.
45338540|NCT00740649|Drug|HSD-016|
45472374|NCT03880409|Drug|2% lidocaine with 1:000,000 epinephrine|2% lidocaine with 1:000,000 epinephrine is dental local anesthesia
45472375|NCT03880409|Drug|4% articaine with 1:000,000 epinephrine|4% articaine with 1:000,000 epinephrine is dental local anesthesia
45472376|NCT01262807|Other|Exercises|A specific set of standardized exercises will be taught to patients who are randomized to the intervention group. They will be instructed to do these exercises daily while in-cast. They will have an exercise log to track adherence.
45472377|NCT01157819|Drug|0.3% Ciprofloxacin Ear Drops|4 gtt b.i.d. for 7 days.
45472378|NCT01157819|Drug|FoamOtic Cipro|0.3% Ciprofloxacin Otic Foam, 1 application, q.d. for 7 days
46032237|NCT01127646|Drug|Placebo|Administered orally, once daily for random nonconsecutive 6 days during 4-week treatment period.
46032238|NCT04284423|Diagnostic Test|joint fluid lactate|Analysis of lactate level in joint fluid to determine presence of septic joint
45338541|NCT00740649|Drug|placebo|
45338542|NCT04107155|Dietary Supplement|Weight Management Formulation|Saffron extract and Gynostemma extract with hesperidin
45338543|NCT04107155|Dietary Supplement|Placebo|Placebo
45338544|NCT04107155|Other|Handout with Suggestions for Healthy Eating and Overall Health|Suggestions for Healthy Eating and Overall Health
45338545|NCT04107155|Other|Handout with Suggestions for Healthy Eating and Overall Health|Suggestions for Healthy Eating and Overall Health
45472379|NCT03883373|Procedure|alveolar bone graft with cancellous bone and a cortical block|alveolar bone graft with cancellous bone only
45472380|NCT03883373|Procedure|alveolar bone graft with cancellous bone only|alveolar bone graft with cancellous bone only
45472381|NCT01264367|Drug|Clevudine|30mg,QD
45472382|NCT01264367|Drug|Clevudine + Peg-interferon|30mg, QD(for 24 weeks) + 180mcg,QW(for 24 weeks)
45472383|NCT01262885|Drug|GSK2251052|500 mg tablet, dose levels detailed in Arm description
45472384|NCT01262885|Drug|Placebo|matching placebo tablet
45338546|NCT02582424|Other|PD-L0101|92% EPA+6 mg ATX+50 mg TCT GG BID
45338547|NCT02582424|Other|placebo|placebo
46032239|NCT02660047|Drug|Liraglutide|"Drug: Liraglutide~Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
45472385|NCT05097716|Drug|Ritlecitinib|Ritlecitinib 200 mg provided as four 50 mg oral capsules
45472386|NCT05097716|Drug|Tolbutamide|Tolbutamide 500 mg provided as one 500 mg oral tablet
45472387|NCT05666921|Other|psychological assessment|The intervention consists in the assessment of some psychological aspects (emotional awareness, attachment style and the ability to abstract and symbolize (IQ)) of pediatric patients who present with somatic symptom disorders. , through specific tests. Each patient fills out the test battery during the psychological consult. At the same time, it is involved a parent to collect personal and clinical data through an ad hoc questionnaire.
45338548|NCT05248893|Drug|AGN-151586|Intramuscular Injection
45472388|NCT05466383|Behavioral|Exercise|Exercise rehabilitation with Schroth method
46032240|NCT02660047|Drug|Liraglutide - Placebo|"Drug: Liraglutide - Placebo~Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
45472389|NCT05466383|Device|Brace|Wear an orthopedic brace
45472390|NCT01262963|Drug|GSK2118436|A single oral dose of 95 mg of GSK2118436 containing approximately 80 µCi of radioactivity
45472391|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 1|Receive at Months 0 and 1
45338549|NCT00784979|Drug|CMVIG|400mg/kg IV (60mg/kg/IV/hr initially, titrated up) once a week up to four weeks
45338550|NCT02595242|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 will be infused intravenously once 1-2 minutes in 20-30 ml saline on the first day during a treatment phase of 3 weeks.
45338551|NCT02595242|Drug|Vincristine|Vincristine 0.3-0.5 mg/ml will be infused intravenously once about 5 minutes in saline on the first day during a treatment phase of 3 weeks.
45472392|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 0 and 1
45472393|NCT01264445|Biological|Ad35 investigational HIV vaccine|Receive at Month 0
45472394|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 3 and 4
45839362|NCT03015636|Behavioral|Adjusted CBT-i for ADHD|This is a version of CBT for insomnia (CBT-i) developed during the pilot phase of this Project. Traditional CBT-i is adjusted for use in the adult ADHD population. This behavioral intervention adresses not only traditional aspects of insomnia, but also sleep phase problems and other aspects of sleep specifically relevant to the ADHD-population. Treatment is given as 10 weekly group sessions with telephone calls from the therapist between sessions to increase adherence and adress individual patient needs.
45338552|NCT02595242|Drug|Prednisone|Prednisone 100 mg/d will be taken orally on the first 1-5 day during a treatment phase of 3 weeks.
45338553|NCT04487106|Drug|Azacitidine|Given IV or SC
45338554|NCT04487106|Drug|Trametinib|Given PO
45338555|NCT04487106|Drug|Venetoclax|Given PO
45338556|NCT00740883|Drug|warfarin|18 months of warfarin therapy, once daily
45338557|NCT00740883|Drug|placebo of warfarin|18 months of placebo of warfarin therapy, once daily
45472395|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 0, 1, and 4
45472396|NCT01264445|Biological|Ad35 investigational HIV vaccine|Receive at Month 4
45472397|NCT01264445|Biological|Ad35 investigational HIV vaccine|Receive at Months 0, 1, and 4
45472398|NCT01264445|Biological|Placebo (saline)|(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)
45472399|NCT01263041|Drug|Glutamine|enteral or via NG tube dose of 312mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
45338558|NCT00738920|Behavioral|Self Administered Cognitive Behavior Therapy|This 4 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
46032241|NCT04285437|Behavioral|infant massage|Mother will be trained how to massage their babies by International Association of Infant Massage (IAIM) Certified Infant Massage Instructor, and then their babies will be massaged by themselves during the first 2 months after birth.
46032242|NCT00648661|Drug|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fed
45338559|NCT00738920|Behavioral|Therapist Administered Cognitive Behavior Therapy|This 10 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
46032243|NCT00648661|Drug|Lexapro® Tablets 20 mg|20mg, single dose fed
46032244|NCT05367414|Other|aromatherapy massage (diluted tea tree oil)|massage with diluted tea tree oil was applied
46032245|NCT05367414|Other|aromatherapy massage (sweet almond oil)|massage with sweet almond oil was applied
46032246|NCT04284111|Device|Orthokeratology lenses|Orthokeratology lenses
45338560|NCT00738920|Behavioral|Behavioral Education and Supportive Therapy|This 4 session treatment aims at controlling symptoms through support and the provision of information about IBS symptoms, how it is diagnosed, its causes, and treatment options and a collaborative, relationship between the patient and doctor
46032247|NCT04171687|Drug|Clopidogrel 75mg|Clopidogrel 75 mg tablet
46032248|NCT04171687|Drug|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
46032249|NCT04171687|Drug|RAPA113|RAPA113 tablet
46032250|NCT03556215|Device|Eustachian tube dilatation device|Balloon Eustachian tuboplasty will be performed using a Eustachian tube dilatation device.
46032251|NCT03556215|Procedure|Myringotomy|Myringotomy will be performed using a standard procedure.
46032252|NCT00648817|Drug|Tenofovir Disoproxil Fumarate|Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil)
46032253|NCT00648817|Drug|Tenofovir DF placebo|Tenofovir DF placebo tablet QD
46032254|NCT02664025|Procedure|vaginal examination simulator|
46032255|NCT04284033|Device|Extended Wear Infusion Set|For two of the 4 weeks, the Extended Wear insulin infusion set will be used
46032256|NCT04284033|Device|Standard Infusion Set|For two of the 4 weeks, the standard insulin infusion set will be used
46032257|NCT02663479|Dietary Supplement|Cardiopressin|
45338561|NCT02568033|Drug|Pemetrexed|
45338562|NCT02568033|Drug|Carboplatin|
46032258|NCT02663479|Dietary Supplement|Placebo|
46032259|NCT03391869|Biological|Ipilimumab|Given IV
45338563|NCT02568033|Drug|Cisplatin|
45338564|NCT02568033|Drug|Docetaxel|
45338565|NCT02568033|Drug|Paclitaxel|
46032260|NCT03391869|Procedure|Local Consolidation Therapy|Undergo radiation and/or surgery
46032261|NCT03391869|Biological|Nivolumab|Given IV
46032262|NCT03391869|Other|Quality-of-Life Assessment|Ancillary studies
46032263|NCT03391869|Radiation|Radiation Therapy|Undergo radiation
45338566|NCT02568033|Radiation|stereotactic radiosurgery|
45338567|NCT00582972|Drug|Omeprazole|40 mg po qAM one-half hour before breakfast for 30 days
45338568|NCT02595086|Procedure|Laparoscopic PPG|Laparoscopy assisted pylorus-preserving gastrectomy with D1+ lymphadenectomy (exclude lymph node station No. 5) in Japanese classification.
45338569|NCT02595086|Procedure|Laparoscopic DG|Laparoscopic distal gastrectomy with D1+ lymphadenectomy in Japanese classification.
46032264|NCT03391869|Procedure|Therapeutic Conventional Surgery|Undergo surgery
46032265|NCT04513171|Drug|Y-shape pegylated somatropin|Y-shape pegylated somatropin 100μg/kg, subcutaneous injection, Once weekly.
46032266|NCT04513171|Drug|Y-shape pegylated somatropin|Y-shape pegylated somatropin 120μg/kg, subcutaneous injection, Once weekly.
46032267|NCT04513171|Drug|Y-shape pegylated somatropin|Y-shape pegylated somatropin 140μg/kg, subcutaneous injection, Once weekly.
46032268|NCT04513171|Drug|Norditropin®|Norditropin 245μg/kg/week, subcutaneous injection, Once daily.
46032269|NCT04513171|Drug|Y-shape pegylated somatropin|Y-shape pegylated somatropin 140μg/kg, subcutaneous injection, Once weekly.
46032270|NCT04513171|Drug|Norditropin|Norditropin 245μg/kg/week, subcutaneous injection, Once daily.
46032271|NCT02663401|Behavioral|Front-of-pack labelling 5-CNL|Introduction of the 5-CNL Front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
46032272|NCT02862561|Drug|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
45472400|NCT01263041|Drug|l-arginine|enteral or via NG tube dose of 260mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
46032273|NCT02862561|Biological|Precision Cells|DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
45472401|NCT03883685|Dietary Supplement|Probiotane|probiotics capsules of blended strains including Lactobacillus acidophilus, L. casei and L. rhamnosus
46032274|NCT02663323|Device|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the treatment of de-novo coronary artery lesions.
46032275|NCT01215188|Biological|V114 Aluminum-adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
46032276|NCT01215188|Biological|V114 Non-adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose.
45472402|NCT03883685|Dietary Supplement|Placebo|Placebo
45472403|NCT03883295|Procedure|Control|The specimens will be root canal treated conventionally
45472404|NCT03883295|Procedure|NeoMTA Plus|The specimens will be subjected to vital pulp amputation using NeoMTA Plus.
45472405|NCT03880331|Procedure|Debridement|Aggressive vs Minimal Debridement
45472406|NCT01261715|Procedure|Dermabond- liquid skin adhesive|Dermabond- liquid skin adhesive
45472407|NCT01156181|Procedure|Cervical discharge removal|Cervical discharge will be removed using a cotton swab before embryo transfer during ICSI cycles
46032277|NCT01215188|Biological|Prevnar 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
45472408|NCT01156181|Procedure|control|Embryo transfer without any intervention
46032278|NCT04285281|Drug|Gabapentin oral capsules|Oral capsule pharmaceutical treatment.
46032279|NCT02663245|Other|Intervention 1|"Diabetes specific consultation~Basic training in clinical guidelines~Platform of communication for professionals~Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hours training programme to update and review the training of month 0.~7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
46032280|NCT02663245|Other|Intervention 2|"7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hour training programme to update and review the training of month 0.~Basic training in clinical guidelines.~Platform of communication for professionals.~Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
45338570|NCT05236413|Behavioral|High Intensity Interval Exercise|"Patients will be required to report for three sessions of supervised stationary cycling exercise per week over a period of 4-weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR). All sessions will be supervised by trained personnel.~Patients will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2.~Each training session will begin with a 10-min warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Subjects will be weighed prior to every exercise session and weight tracked to ensure that their volume status hasn't changed significantly. Subjects will be instructed to maintain usual levels of physical activity and usual diet during the study and not to make any modifications to the same."
46032281|NCT00629733|Drug|RO-14|
46032282|NCT02659657|Drug|Interleukin-2|Interleukin-2 (IL-2), 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days)
46032283|NCT02861547|Other|death|
45338571|NCT05236413|Behavioral|Dietary Approaches to Stop Hypertension (DASH) Diet|Patients will be interviewed with regard to their food/religious preferences and food allergies and a 7-day rotating meal plan will be designed per their preferences along with a registered dietitian. This will ensure that patients receive food that is acceptable to them. Participants will then be provided pre-packaged meals for 4-weeks with macronutrient compositions as follows - (Carbohydrates -55-60%, Protein -15-20%, Fat -15-25%, Fiber -35-45g/day). All foods will be labeled, sealed, and packed for weekly delivery and will be designed such that they can be refrigerated or frozen and stored without significant alterations to nutritional content. All food will be prepared by the UVA Hospital Nutrition Services department in conjunction with a registered dietician. Deviations (if any) from the study meal plan will be recorded by the participants in a food record provided at the start of each diet intervention period.
45338572|NCT05236413|Behavioral|Exercise + DASH Diet|Patients will undergo both the exercise training intervention and DASH diet as explained above.
45338573|NCT02597972|Procedure|Fracture repair|
45338574|NCT02597972|Procedure|Fracture repair with joint replacement|
45338575|NCT05224401|Drug|Pivmecillinam and amoxicillin/clavulanic acid|1 tablet pivmecillinam 400 mg and 1 tablet Amoxicillin/clavulanic acid 875/125 mg, three times daily.
45338576|NCT05224401|Drug|Standard treatment, ciprofloxacin, trimethoprim/sulfamethoxazole or ertapenem depending on susceptibility|Ciprofloxacin 500 mg twice daily, trimethoprim/sulfamethoxazole 800 mg/160 mg twice daily or ertapenem 1 g once daily.
45338577|NCT02598206|Drug|PF-04136309|"Treatment A (n=18): a single dose of 1000 mg PF 04136309 will be administered in a fasted state as 8 × 125 mg Tablets.~Treatment B (n=18): a single dose of 1000 mg PF-04136309 will be administered with a high fat breakfast as 8 × 125 mg Tablets."
45338578|NCT00740961|Behavioral|compliance monitoring|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
45338579|NCT00740961|Drug|systemic chemotherapy|Learning about changes over time in older patients' ability to function after receiving chemotherapy for breast or colon cancer
45839363|NCT03015636|Other|Treatment as Usual|Usual care at the ADHD-clinic. This mostly entails managing pharmacological treatment for ADHD, comorbid psychiatric problems and/or sleep problems. The clinic also provides different group treatments, for instance mindfulness groups and groups for developing behavioral strategies for managing ADHD symptoms, and individual therapy.
45839364|NCT03015246|Drug|Extended release morphine|Dose (tailored to each participant based on his/her pre-experimental opioid use amount) is administered in 3 divided daily doses.
45839365|NCT03015246|Drug|Buprenorphine/Naloxone low dose|Buprenorphine/Naloxone dose of 1.4/0.36 mg/day
45839366|NCT03015246|Drug|Buprenorphine/Naloxone moderate dose|Buprenorphine/Naloxone dose of 4.2/1.08 mg/day
45839367|NCT03015246|Drug|Buprenorphine/Naloxone high dose|Buprenorphine/Naloxone dose of 12.8/3.16 mg/day
46032284|NCT02659891|Biological|IVIg|
46032285|NCT02659891|Other|Placebo|
46032286|NCT02863341|Other|Team-care deprescribing with deprescribing guide|Beers criteria 2015, STOPP criteria 2014, drug interaction
46032287|NCT02659735|Drug|JNJ-63623872 300 milligram (mg)|Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.
46032288|NCT02659735|Drug|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.
46032289|NCT02659735|Drug|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.
46032290|NCT02659735|Drug|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.
46032291|NCT05438498|Drug|Evusheld (tixagevimab+cilgavimab) IM or IV|Evusheld (tixagevimab 300 mg +cilgavimab 300 mg) IM or IV
45472409|NCT01264523|Other|Chronologically scheduled snacking with 40-30-30 products|Short-term analysis of the effects of the substitution of the habitual breakfast, mid-morning and afternoon snack of type-2 diabetes patients by 40-30-30 products. Longitudinal 2-period study
45472410|NCT03880253|Drug|CTP-692|Placebo or CTP-692
45839368|NCT03015246|Drug|Active stressor|Yohimbine hydrochloride 60mg + Hydrocortisone 20mg tablet
45839369|NCT03015246|Drug|Placebo stressor|Lactose
46032292|NCT04283799|Dietary Supplement|A new human milk fortifier|Contents of protein, protein/energy ratio, moderate hydrolysis of whey protein, medium-chain fatty acid are increased in the new HMF
45338580|NCT00740961|Other|medical chart review|A limited review of medical records for the sole purpose of evaluating patients for study eligibility will be undertaken by the research team.
46032293|NCT04286763|Diagnostic Test|Biliary RMI and CT scan.|"For a good appreciation of the anatomy of the biliary lesion, an MRI was systematically performed on all our patients.~For a good appreciation of the presence of an associated vascular lesion, a CT-scan was systematically performed on all our patients."
45338581|NCT00740961|Other|study of socioeconomic and demographic variables|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
45338582|NCT00740961|Other|survey administration|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
45338583|NCT00740961|Procedure|cognitive assessment|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
45338584|NCT00740961|Procedure|psychosocial assessment and care|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
45472411|NCT03880097|Procedure|Research Biopsy|"The Research Biopsy is a biopsy in addition to the standard of care biopsies that the patient will have to inform their diagnosis. The actual procedure is not any different to the standard per-cutaneous biopsy, this is just an additional procedure, solely for research purposes."
45472412|NCT01157975|Drug|Pioglitazone|Pioglitazone will be taken at a dose of 30 mg for up to 14 days
46032294|NCT00648193|Drug|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fasting
45338585|NCT04319718|Combination Product|MK-2048 High Eudragit Vaginal Film|"2 x 2 vaginal film containing 30 mg of MK-2048 and either 68.1 mg of ammonio methacrylate copolymer type B (Eudragit®)"
45338586|NCT04319718|Combination Product|MK-2048 Low Eudragit Vaginal Film|"2 x 2 vaginal film containing 30 mg of MK-2048 and 41.5 mg of ammonio methacrylate copolymer type B (Eudragit®)"
45338587|NCT00918086|Dietary Supplement|Vitamin D pill|Oral tablet taken for 16 weeks
45338588|NCT00918086|Dietary Supplement|Placebo|An inactive pill that looks and tastes like the Vitamin D pill
46032295|NCT00648193|Drug|Paxil® 40 mg Table|40mg, single dose fasting
45839370|NCT03014856|Other|Blood sampling|Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
45839371|NCT03015168|Radiation|capecitabine and concurrent intensity modulated radiotherapy|patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy
46032296|NCT04283721|Other|Educational video|Ten-minutes educational video on epidural/spinal analgesia benefits and side effects (sample video link: https://youtu.be/jAhoKhvcbP4). The informational video will be administered by co-investigators, who are anaesthesiologists. The video will be shown on an institutional iPad that will be thoroughly disinfected by the co-investigators before and after each use. Co-investigators will receive training on the disinfection process, and each disinfection will be documented on a logbook, dated and signed by the co-investigators.
45472413|NCT01157975|Drug|Prednisone|Prednisone will be taken at a dose of 40 mg for up to 4 days
46032297|NCT01215032|Drug|Metformin|Taken orally twice daily each 28-day cycle, for 12 cycles
46032298|NCT02659579|Behavioral|The Reader Organisation's Shared Reading Programme|In The Reader Organisation's Shared Reading Programme, parents and children will attend weekly shared book reading sessions for 8 weeks which focus predominately on how to read interactively with children.
45338589|NCT02567487|Drug|Levobupivacaine|Transversus abdominis plane block with levobupivacaine
45338590|NCT02598050|Other|No Interventions as this is a observational study|
45338591|NCT04062435|Drug|Drop application in the inferior fornix|See Arms
45338592|NCT04062435|Drug|Drop application on the cornea|See Arms
45338593|NCT02597894|Procedure|Biopsy of Prostate|Undergo biopsy
45338594|NCT02597894|Other|Laboratory Biomarker Analysis|Correlative studies
45598776|NCT03149835|Other|Non-invasive ventilation|NIV was provided by BiPAP-Vision™ ventilator (Philips Respironics Inc, Murrysville, PA, USA) set at the BIPAP mode and applied by a nasal mask, with room air, for 60 minutes. Volunteers were studied during the application of NIV (inspiratory pressure of 14cmH2O and expiratory pressure of 4cmH2O), with a pressure support of 10cmH2O and without oxygen support (FIO2 0.21). These pressure levels were chosen based on the current practice of NIV in the intensive care setting.
45598777|NCT02296255|Biological|Cervarix®, GlaxoSmithKline|3 doses (0,1,6 months) of Cervarix®, GlaxoSmithKline
45839372|NCT03015012|Genetic|Personalized Nutrigenomics Testing (PNT)|Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition and physical activity advice based on the results of their nutrigenomics test. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
45338595|NCT04317066|Drug|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
45338596|NCT04311996|Other|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
45338597|NCT04311996|Other|TSST|Participants will, via an online session, complete the TSST which is a standardized speech & math performance known to elicit a cortisol stress response.
46032299|NCT02659579|Behavioral|Shared Reading control|Parents and children will attend a weekly shared reading group at a library for 8 weeks
45598778|NCT02229071|Drug|Donafenib(200mg)|Donafenib 200mg,bid,po
45598779|NCT02229071|Drug|Donafenib(300mg)|Donafenib 300mg,bid,po
45598780|NCT03150147|Other|Non-ischemic preservation|The device is a portable heart-lung machine; an automatic pressure and flow-controlled perfusion system. The heart is submerged in a solution and the medium is circulated in the heart, at a temperature of 8°C.
46032300|NCT00962247|Device|Television reduction device|A TV allowance helps turn off the television when the time limits have been met.
46032301|NCT02659423|Behavioral|BIC 1|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
46032302|NCT02659423|Behavioral|BIC 2|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
46032303|NCT02659423|Behavioral|BIC 3|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
46032304|NCT02663089|Drug|[14C]-GSK961081 solution for IV infusion|Subjects will receive 10 mL of solution equivalent to 4 mcg of [14C]-GSK961081 (approximately 6.2 kilobecquerel [kBq]) intravenously as a single dose over 1 hour.
45338598|NCT04375800|Drug|Doravirine|DOR capsules (3.2 to 100 mg); sachets (3.2 to 100 mg); or tablets (100 mg) taken once or twice daily by mouth.
45338599|NCT04375800|Drug|2 NRTIs|Participants receive 2 NRTIs per local label by mouth for 96 weeks as background therapy.
45338600|NCT04372602|Drug|Duvelisib|-For patients unable to administer orally, a duvelisib suspension will be administered through a nasogastric/orogastric tube.
45598781|NCT03150147|Other|Ischemic cold static storage|Standard ischemic cold static storage; a crystalloid solution (cardioplegia) is used to stop and preserve the heart. Cardioplegia is given. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
45598782|NCT03516097|Behavioral|Structured school based intervention|Intervention includes behavioral, nutritional and physical activity counselling (online and face-to-face psycho-educative sessions).
45839373|NCT03015012|Other|Standard Nutrition Intervention (SNI)|Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the standard GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
45839374|NCT03014544|Device|Computer- administered test battery|Participants in this observational study will only undergo sequential cognitive performance evaluations by computer- administered cognitive test battery.
45839375|NCT03014544|Device|Examiner- administered test battery|Participants in this observational study will only undergo sequential cognitive performance evaluations by examiner- administered cognitive test battery.
46032305|NCT02663089|Drug|[14C]-GSK961081 oral solution|Subjects will receive 10 mL of solution equivalent to 200 mcg of [14C]-GSK961081 (approximately 311 kBq) orally as a single dose with up to 250 mL of water.
45338601|NCT04372602|Procedure|Peripheral blood draw|"First 10 patients enrolled~Screening, Day 2, Day 4, Day 8, Day 10, Day 15, and Day 29"
45338602|NCT04372602|Drug|Placebo|-Provided by Verastem
45338603|NCT04118088|Biological|Darvadstrocel|Darvadstrocel suspension of human expanded adipose stem cells.
45338604|NCT04366908|Drug|BAT + Calcifediol|"The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS) plus Calcifediol caps. 266 µg. According to the pharmacokinetics of Calcifediol evaluated in an inflammatory model, the posology will be~Start: 2 capsules Days 3, 7, 14, 21, 28: 1 capsule"
45598783|NCT03516097|Device|mobile app usage|The e-therapeutic platform and mobile app (TeenPower) includes educational resources, self-monitoring, social support, interactive training modules and motivational tools. In addition to the case manager, the program will also have the direct support of an interdisciplinary team (nurse, nutritionist, exercise physiologist, psychologist among others).
45839376|NCT03014778|Drug|The Chlorhexidine gluconate 0.05%|Washing vagina pre- operatively with Chlorhexidine gluconate 0.05%
46032306|NCT02663089|Drug|GSK961081 dry powder for inhalation|Subjects will receive single dose of 4 actuations of 300 mcg GSK961081 per actuation (1200 mcg GSK961081 total) as inhalation immediately after the start of infusion.
46032307|NCT02663167|Behavioral|Internet-delivered Cognitive Behavioral Therapy|The treatment consists of a standard cognitive behavioral therapy for obsessive-compulsive disorder. The treatment is delivered through an Internet platform. The child and his/her parent(s) work through the treatment with regular therapist contact several times per week.
45682920|NCT03084874|Behavioral|Physical activity and sedentary behavior coaching program|The intervention group will receive an individualized coaching program. During a motivational interview an experienced physiotherapist will asses participant's usual exercise habits, possible barriers and facilitators, self-efficacy and motivation to increase physical activity and reduce sedentary time. Based on these data (and baseline physical activity/sedentary information) an individualized, progressive program with specific goals setting and self-monitoring will be established (patients will be active participants and decision makers in this process).
46032308|NCT02664103|Drug|Fixed-dose combination of capecitabine and cyclophosphamide SAR439281|Pharmaceutical form:Tablet Route of administration: Oral
45338605|NCT04366908|Drug|BAT|The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS).
46032309|NCT02663011|Other|Language Evaluation-Preschool Language Scale Corrected edition(PLS-C), Lin|"To assess age and gender effect in the language error type (semantics, syntax and pragmatics)of developmental delay preschool aged children, a standardize tool Preschool Language Scale Corrected edition(PLS-C), Lin was adopted for evaluation."
46032310|NCT02659345|Behavioral|Emotions Thermometer|The Emotions Thermometer, was chosen to assess patients' mood, anxiety level, and pain scale for this study. For patient ease, the study team chose to utilize a scale of 1-10 for all subjective measurements to be obtained from patients (mood and anxiety level). The study team included the thermometer image to mirror the NCCN Guidelines Version Distress Management Screening tool, for measuring distress and mood level. This screening tool has been shown to be effective in assessing patient distress and mood in oncology patients with ease of use in patients and utility in providers.
45338606|NCT00733304|Drug|Pazopanib|5 mg/ml TID, 2 mg/ml TID or 5 mg/ml QD
45338607|NCT00711243|Drug|docetaxel|Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.
45682921|NCT03084952|Drug|18-Methoxycoronaridine|Drug under evaluation for leishmaniasis treatment
45682922|NCT03084952|Drug|Glucantime|Leishmaniasis standard drug in Brazil
45682923|NCT00082810|Drug|fulvestrant|Given intramuscularly
45839377|NCT03014778|Drug|10% Povidone iodine|Washing vagina pre- operatively with 10% Povidone iodine
46032311|NCT02659345|Behavioral|Art Therapy|Each participant will participate in a private art therapy session with the Art Therapist for 50 minutes. The participant will have a choice of materials to work with, including painting, drawing, clay, and collage materials. The session will conclude with processing of the art and supportive counseling.
46032312|NCT00918580|Biological|13-valent Pneumoccocal Conjugate Vaccine|2 doses of 13vPnC will be administered by intramuscular injection separated by approximately 6 months.
46032313|NCT02662855|Other|WHO-recommended therapies|symptomatic and supportive treatments according to the WHO manual
46032314|NCT02662855|Drug|Favipiravir|oral administration of Favipiravir tablets
46032315|NCT00648271|Drug|Metoprolol Tartrate Tablets 25 mg|2x50mg, single dose fed
45839378|NCT03014466|Behavioral|Use of Video Projector|Bed mounted video projector that is used to play videos of the patient's choosing prior to induction of anesthesia
45839379|NCT03014466|Behavioral|Use of Video Tablet|7 inch video tablet that is used for displaying videos of the patient's choosing prior to induction of anesthesia
45839380|NCT03014310|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
45839381|NCT03014310|Drug|MF59 adjuvant|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
46032316|NCT00648271|Drug|Lopressor® Tablets 50 mg|1x50mg, single dose fed
46032317|NCT04170127|Procedure|Irradiation of implants with 635nm laser|Irradiation of implants with 635nm laser
46032318|NCT05180812|Device|ExoNet Tuned to Gravity Support|This study's primary goal is to test the safety, feasibility, and efficacy of the ExoNET device developed in the Robotics Lab at the Shirley Ryan AbilityLab. We want to observe if individuals using the ExoNET tuned to gravity support will notice a reduction in bicep muscle activity, leading to an improvement in functional outcome measures in stroke patients.
46032319|NCT00648349|Drug|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fasting
46032320|NCT00648349|Drug|Aciphex® Delayed-Release Tablets 20 mg|20mg, single dose fasting
46032321|NCT04253938|Other|Education|Subjects will be provided education about AAP approved feeding practices for infants 1 to 12 months of age.
46032322|NCT00649207|Drug|ABT-888|Oral Capsules
46032323|NCT00649207|Radiation|Whole Brain Radiation Therapy|15 fractions of 2.5 Gy over 3 weeks to a total dose of 37.5 GY or 10 fractions of 3.0 Gy over 2 weeks to a total dose of 30 Gy
46032324|NCT02662621|Other|blood samples|
46032325|NCT02662621|Other|Urine samples|
46032326|NCT02663947|Device|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 7.5-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Three measurements are taken for each optic nerve in the transverse plane, with the probe being horizontal. The final ONSD is the mean of these measurements.
45338608|NCT00711243|Drug|fluorouracil|Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.
45338609|NCT00711243|Drug|oxaliplatin|Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel
46032327|NCT00920686|Drug|NXN-188|NXN-188 hard gelatin capsules, 600 mg administered as three 200 mg capsules
46032328|NCT00920686|Drug|placebo|administered as 3 placebo hard gelatin capsules
46032329|NCT00920686|Drug|sumatriptan succinate|administered in a hard gelatin capsule with 2 capsules of placebo
46032330|NCT00648427|Drug|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fasting
46032331|NCT00648427|Drug|Paxil CR™ Tablets 25 mg|25mg, single dose fasting
46032332|NCT02656225|Drug|Ejiao compound|20ml,twice daily, orally after breakfast Duration:4 weeks
45338610|NCT04366518|Drug|Rivastigmine Capsule|Consistent with safety and efficacy demonstrated in prior studies, a 6 mg capsule of Rivastigmine will be dosed. Participants will be randomized to two treatments with oral rivastigmine vs. placebo separated by a 15-hour washout period (>5 half-lives to eliminate any residual effects). This will require three separate visits: a baseline visit, a visit for the first oral treatment and a visit for the second oral treatment. All visits include fMRI scans. The first capsule will be administered during the 1-hour treatment. After the washout period, a second capsule will be administered. Blood levels will be used to verify absorption of Rivastigmine and used as a regressor in subsequent analyses. No study team member except for the unblinded team member will know which capsule the participant receives first. Because we are interested in rivastigmine as a probe for a pre-identified computational/physiological abnormality, we will median-split groups post-hoc for the purposes of analysis.
45338611|NCT04366518|Drug|Scopolamine|The authors have chosen to use scopolamine to determine the effects of cholinergic antagonism, as treatment with scopolamine demonstrates a dose-related increase in propensity toward conditioned hallucinations and in doses much higher than those proposed here, can cause spontaneous hallucinations. At the proposed dose, scopolamine has an excellent safety profile and has been used routinely for nearly 20 years for treatment of nausea due to surgery or motion sickness in adults and children. Scopolamine is available in the US only as a 1mg / 72 hours transdermal patch, and peak plasma levels are reached within 24 hours. This standard dosage level is very well tolerated in the general population.
46032333|NCT02656225|Drug|Niferex|one tablet,once daily, orally after breakfast Duration:4 weeks
46032334|NCT04253470|Other|embryo transfer|Step of the assisted reproduction in which embryos are placed into the uterus in order to obtain a pregnancy
46032335|NCT04170751|Drug|16 mcg / cc of norepinephrine(group N)|In group N, 16 mcg / cc of norepinephrine was infused through the central catheter. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
46032336|NCT04170751|Drug|0.4 unit / cc of vasopressin(group V)|In group V, 0.4 unit / cc of vasopressin was infused through the central catheter and the respective doses recorded. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
46032337|NCT04865536|Drug|1800 mg TBI-223|3 x 600 mg SR1 tablets
46032338|NCT04865536|Drug|2400mg TBI-223|3 x 600 mg SR1 tablets and 1 x 600 mg IR tablets
46032339|NCT04865536|Drug|3000mg TBI-223|4 x 600 mg SR1 tablets and 1 x 600 mg IR tablets
46032340|NCT04865536|Drug|TBI-223 Placebo|3 x Placebo tablets
46032341|NCT04865536|Drug|TBI-223 Placebo|4 x Placebo tablets
46032342|NCT04865536|Drug|TBI-223 Placebo|5 x Placebo tablets
46032343|NCT02662465|Procedure|Laser|Patients who develop oral mucositis even after the prevention, will be divided into three groups for laser sessions with the purpose of treatment of oral mucositis. The group assignment obeyed severity of oral mucositis.
46032344|NCT02659111|Other|High Intensive Functional Exercise (HIFE)|Patients invited to high-intensity physical exercise, HIFE by a physiotherapist with special competence in neurology at one of the two centers, or by a general physiotherapist where the patient lives. Goal Attainment Scaling is performed. The training will be given twice a week for one hour during 12 weeks . At least 18 of 24 training session in a four month period of time will be required. A training manual will be distributed to each training physiotherapist. The patients will also be encouraged to do additional training and they will receive standardized written physical training advice
45839382|NCT03014310|Biological|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
45338612|NCT04366518|Drug|Placebo Capsule|Participants in Aim 2 will receive a placebo capsule versus rivastigmine capsule.
45839383|NCT03014154|Other|Training|
46032345|NCT02659111|Other|Physical training advice|Patients randomized to written advice for physical training will be given a leaflet with instructions how to train by there own.The physiotherapist responsible for evaluating sets goals together with the patient according to Goal Attainment Scaling.
45338613|NCT04366518|Drug|Placebo Patch|Participants in Aim 1 will receive a placebo patch versus scopolamine patch.
45338614|NCT04088240|Dietary Supplement|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (~980 mg DPA, 380 mg EPA, 1720 mg DHA)
45338615|NCT04088240|Dietary Supplement|n-3 control|4 g/d n-3 control (~980 oleic acid, 380 mg EPA, 1720 mg DHA)
46032346|NCT02656147|Biological|Anti-CD19-CAR γδT|Cells extracted, followed by induction chemotherapy before Anti-CD19-CAR γδT infusion (dose escalation.)
45338616|NCT04088240|Dietary Supplement|Placebo|"4 g/d placebo control (light olive oil)"
45338617|NCT02568501|Behavioral|Daily feedback|Daily feedback on glucose levels from wireless glucometers
45682924|NCT00082810|Drug|tipifarnib|Given IV
45682925|NCT04402918|Diagnostic Test|biological samples day of delivery|mother samples: serology, viremia, nasopharyngeal swab, vaginal swab, placenta swab, piece of placenta newborn: serology, viremia, nasopharyngeal aspiration
45682926|NCT03085108|Other|No Intervention|No Intervention
45682927|NCT01678066|Device|Bilateral cardiac output|
45682928|NCT03445000|Drug|Alectinib|"Alectinib is administered orally 600mg (4x150mg capsules), twice per day (8 capsules, total 1200mg daily). The appropriate number of alectinib capsules will be provided to patients to be self-administered at home.~Alectinib capsules must be taken at the same time each day with food. If a planned dose of alectinib is missed, patients can take the missed dose up until 6 hours before the next dose."
45839384|NCT03014232|Procedure|SLED-f with HCO dialyzer|Online SLED-f with high cut-off dialyzers were performed using the Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). Super-flux, Sureflux 150FH (Nipro Corporation, Osaka, Japan; cellulose triacetate material, pore size 78 A◦, Kuf 66.9 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
45839385|NCT03014232|Procedure|SLED-f with HF dialyzer|Online SLED-f with standard high-flux dialyzers were performed using the same Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). High-flux ELISIO 150H (Nipro Corporation, Osaka, Japan; polynephron material, pore size 50-60 A◦, Kuf 67 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
46032347|NCT04170049|Behavioral|Sensory Stimulative Activitiy ( proprioceptive intervention, music intervention )|Music intervention: Listening to soft music was found to be an effective method of relaxation, as indicated by a shift of the autonomic balance toward parasympathetic activity. Participants listen to preferred soft music for 30 minutes before sleeping. Proprioceptive intervention: The proprioceptive intervention can activate the parasympathetic nervous system through pathways of the central nervous system, providing calming effects that significantly reduce anxiety, hyperactivity and agitation in various populations.Participants do 10-minute joint compression exercise three times per day by themselves.
45839386|NCT03014388|Other|autogenous bone|Autogenous bone graft (gold standard). sinus lift with autogenous bone.
45338618|NCT02568501|Behavioral|Financial incentive|Participant receive a $2 daily financial incentive framed as a loss with money allocated upfront and taken away each day of non-adherence to goal
45338619|NCT00733226|Drug|OM-85 BV (Broncho-Vaxom)|3.5 mg capsule, 1 capsule per day for first 10 day of the month, for 3 months
45338620|NCT00733226|Drug|OM-85 BV (placebo)|3.5 mg oral placebo capsule, 1 placebo capsule per day for first 10 days of the months for 3 months
45338621|NCT04076436|Other|Drug: Intravenous fosfomycin|"Patients will be visited on days 1 (Day of the urine and blood culture taking), 2, 5, 7, 14, on the test of cure and on day 30.~Visit on day 1: First day of treatment. Basal data collection.~Visit on day 2: Blood collection to fosfomycin levels calculation.~Visits on days 5, 7, 14, on the test of cure (day 21): Clinical evolution data, Urocultures and Adverse effects.~Visit on day 30: Assess mortality"
46032348|NCT02659267|Behavioral|Interventions Group|VAMOS is a lifestyle promotion strategy, designed to promote physical activity and healthy eating habits. The intervention is composed by a weekly meeting, 12-week, in group, lasting about 60 min. In each weekly meeting, were discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the VAMOS strategy are based in behavior changes theories. The participants of this group received educational material and, in the middle of the program, they received a pedometer to aid in motivation and in the self-monitoring physical activity.
46032349|NCT02659033|Drug|ceftriaxone|ceftriaxone (1 gram per day)
46032350|NCT02659033|Drug|Cefotaxime|cefotaxime (1 gram every 8 hours)
46032351|NCT04170595|Biological|GB221,2 mg/kg|Single dose, 2mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
46032352|NCT04170595|Biological|GB221,6 mg/kg|Single dose 6mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
45682929|NCT03480334|Other|Nivolumab plus radiotherapy|Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
45682930|NCT03085030|Drug|Antioxidant Formula|Antioxidant tablet will be taken by the patients
46032353|NCT04170595|Biological|Herceptin,6 mg/kg|Single dose group: lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
46032354|NCT04170595|Biological|GB221,8mg/kg|Single dose 8mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 8mg/kg for one dose, intravenous infusion, completed for over 90 minutes
45839387|NCT03014388|Other|Mineralized plasmatic matrix|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM.
46032355|NCT04170595|Biological|GB221:2mg/kg and Capecitabi:1000mg/kg|GB221:Lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose group; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.
45338622|NCT04076436|Other|Drug: Intravenous quinolone or beta-lactam|"Patients will be visited on days 1 (Day of the urine and blood culture taking), 5, 7, 14, on the test of cure and on day 30.~Visit on day 1: First day of treatment. Basal data collection.~Visits on days 5, 7, 14, on the test of cure (day 21): Clinical evolution data, Urocultures and Adverse effects.~Visit on day 30: Assess mortality"
45338623|NCT05526417|Procedure|Computed Tomography|Undergo CT
45338624|NCT05526417|Other|Educational Intervention|Receive educational materials
45338625|NCT05526417|Procedure|Magnetic Resonance Imaging|Undergo MRI
45682931|NCT03085030|Drug|Placebo|The placebo will be taken by the patients
45682932|NCT03444064|Biological|PolyTregs|Treatment group receive PolyTregs 6 weeks after islet transplantation as immunotherapy to improve islet survival and reduce the need for immunosuppression drugs.
46032356|NCT04170595|Biological|Herceptin:2mg/kg and Capecitabin:1000mg/kg|Herceptin:Lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose groups; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.
46032357|NCT04511533|Drug|Dacomitinib|Dacomitinib is a kinase inhibitor indicated for the first line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
46032358|NCT02662231|Procedure|Emergency, or elective gastrointestinal resection|Gastrointestinal resection is defined as complete transection and removal of a segment of the oesophagus, stomach, small bowel, colon or rectum, including cholecystectomy, and appendicectomy.
46032359|NCT00648973|Drug|Diphenhydramine 50 mg|"Three times daily: two diphenhydramine 25 mg capsules~Twice daily: one pseudoephedrine-matching placebo tablet"
46032360|NCT00648973|Drug|Diphenhydramine 25 mg|"Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule~Twice daily: one pseudoephedrine-matching placebo tablet"
45338626|NCT05526417|Procedure|Physical Therapy|Receive prehabilitation physical therapy
45338627|NCT05526417|Other|Questionnaire Administration|Ancillary studies
45338628|NCT05526417|Other|Telemedicine|Attend telemedicine visits
45338629|NCT04364178|Biological|Adenovirus Specific T- Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
45338630|NCT04364178|Biological|Cytomegalovirus Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Cytomegalovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
45839388|NCT03014076|Drug|GP2 peptide + GM-CSF vaccine plus trastuzumab|HLA-A2+/A3+ subjects are given the GP2 peptide vaccine plus trastuzumab
45839389|NCT03014076|Drug|Trastuzumab|HLA-A2-/A3- patients are followed as controls receiving trastuzumab only.
45839390|NCT03013842|Device|Raydiant Oximetry Sensor System|Administration of Fetal Oximetry Probe on 36 weeks or greater pregnant women
45839391|NCT03013686|Procedure|Interval appendectomy|Laparoscopic appendectomy
45839392|NCT03013686|Procedure|Follow-up with MRI|Abdominal MRI
46032361|NCT00648973|Drug|Pseudoephedrine 120 mg|"Three times daily: two diphenhydramine-matching placebo capsules~Twice daily: one pseudoephedrine 120 mg tablet"
45338631|NCT04364178|Biological|Epstein-Barr Virus Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Epstein-Barr viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
45338632|NCT04096170|Drug|IV lidocaine|Patients randomized to the IV lidocaine group will receive a 100 mg lidocaine bolus on induction then an infusion of 1.5 mg/kg/hr prior to incision. This infusion will continue throughout operation and into the PACU for 1 hour OR until the 2gm/250 mL D5W bag has been infused, whichever occurs first.
45338633|NCT04096170|Drug|Placebo|o Patients randomized to the placebo group will receive D5W solution (as this is the carrier for lidocaine) at the same volume and rate as the IV lidocaine.
45338634|NCT02567721|Other|Vaccine safety surveillance|Extraction of routinely collected primary care data from nine GP practices and an active surveillance approach in 3 of the 9 GP practices, by using an existing card-based ADR reporting system (MHRA Yellow Card), to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
45338635|NCT02581800|Other|App group|
45338636|NCT00741117|Procedure|Arterial Blood Gas|One blood gas sample will be obtained from an artery in the arm.
45338637|NCT00741117|Procedure|Pulse Oximetry Machine|A pulse oximetry machine will be used at one time point to obtain an oxygen saturation reading. This is done by placing a clip onto the finger. The pulse oximetry value displays on the pulse oximeter machine within seconds.
45338638|NCT00741117|Procedure|Direct and Indirect Serum Bilirubin Measurement|One tube of blood will be drawn from a vein in the arm at one timepoint to measure the direct and indirect serum bilirubin levels.
45338639|NCT03900819|Other|dexterity measurement|4 non-invasive tests will be performed
46032362|NCT02662309|Drug|MPDL3280A|Intravenous infusion
46032363|NCT02658955|Procedure|Short stitch|Surgeons will receive instructions to change the technique of abdominal wall closure
46032364|NCT02655835|Behavioral|Internet Mindfulness Meditation|
46032365|NCT02655835|Behavioral|Access|
46032366|NCT02662075|Device|E-cigarette/tobacco Smoking Exposure|Subjects will be asked to smoke an e-cigarette containing the equivalence of nicotine in one tobacco cigarette (15 puffs) in the presence of research staff. Each puff will be timed at 4 seconds and there should be a 20-30 seconds interpuff interval as previously recommended.
45839393|NCT03013764|Behavioral|normal protein diet|subjects will undergo 10 days of low physical activity while consuming a normal protein diet
46032367|NCT02661919|Device|Emfit mattress sensor|Patients who are being monitored in the Epilepsy Monitoring Unit will have an Emfit mattress sensor placed under their mattress and the effectiveness of the alarm system will be tested.
46032368|NCT04032691|Drug|Clonidine Pill|0.1 mg by mouth daily at bedtime for one week
46032369|NCT02658799|Drug|cataflam (diclofenac potassium)|Cataflam (diclofenac potassium, 50 mg) b.i.d. after a meal for 6 months in a cyclic regimen. Administration of diclofenac potassium was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly.
45839394|NCT03013764|Behavioral|high protein intake|subjects will undergo 10 days of low physical activity while consuming a high protein diet
45839395|NCT03013530|Procedure|Decision making for ICU patients' care|Study of factors involved in the decision-making for ICU patients' care. Effect of advance directives (AD).
45839396|NCT03013296|Other|GIP-A|GIP-A
46032370|NCT02658799|Drug|placebo|"Placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of placebo was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly."
46032371|NCT02536885|Procedure|Liberal group|If the pressure decreases below 75% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 125% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
46032372|NCT02536885|Procedure|Restrictive group|If the pressure decreases below 90% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 110% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
45839397|NCT03013296|Other|Placebo|Placebo
46032373|NCT02655757|Drug|Sitagliptin|5 mg, 1 tablet per day for 12 months
46032374|NCT02655757|Drug|Placebo|Placebo,1 tablet per day for 12 months
45839398|NCT03013296|Other|GLP-1 receptor antagonist Exendin[9-39]|Exendin[9-39]
46032375|NCT02661841|Other|LI-Guided Therapy|Preemptive treatment according to LI monitoring
45338640|NCT04283994|Behavioral|Survey-based Patient/Clinician Jumpstart|"The Jumpstart Guide is a communication-priming intervention for clinicians, patients and their families that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The Jumpstart takes two forms. One is EHR-based and provides information to the clinician about prior advance care planning documentation derived from the EHR. The other is bi-directional and patient-specific (Survey-based Patient/Clinician Jumpstart Guide). It provides the same information as the EHR-based Clinician Jumpstart Guide but also includes information about patients' self-reported preferences for communication and care as well as primary barriers and facilitators to this communication. The Jumpstart Guides include tips to improve this communication for clinicians, patients and families."
45839399|NCT03013296|Other|GIP-A + Exendin[9-39]|GIP-A + Exendin[9-39]
45839400|NCT03013452|Device|oPEP|Daily chest clearance (chest physiotherapy) using an oPEP (Aerobika) device.
45839401|NCT03013452|Behavioral|Autogenic drainage|Daily chest clearance (chest physiotherapy) by Autogenic Drainage method.
46032376|NCT02661841|Other|Heart Failure Guidelines|Treatment according to clinical signs
46032377|NCT01214720|Drug|bevacizumab [Avastin]|Intervenous repeating dose
46032378|NCT02655991|Behavioral|Telephone Case Monitoring|Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy) augmented by up to six fortnightly telephone monitoring and support calls from a case manager during the first three months of treatment.
46032379|NCT02655991|Behavioral|Treatment as Usual|Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy).
45839402|NCT03013608|Procedure|Simple relocation of the nail plate in nailbed injuries in paediatric population|Repositioning the nail bed without sutures
45839403|NCT03013140|Drug|Fluid therapy|"Goal directed Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until ΔSV<5%"
45839404|NCT03013140|Procedure|Spinal anaesthesia|Inject marcaine and fentanyl to CSF for anaesthesia
45839405|NCT03012906|Other|the prevalence of ischemic events|
45839406|NCT03012516|Behavioral|PAP-treatment by physiotherapist|
45839407|NCT03012516|Behavioral|Ordinary PAP-treatment at the health care center|
45839408|NCT03012750|Drug|Indocyanine Green|Perioperative application of 0.1 mg ICG per kg Body weight
46032380|NCT02655913|Drug|vitamin C|Vitamin C infusion, as an alternative anticancer therapy, has been used for many years. In the last 10 years, an increasing number of studies have indicated that VitC in pharmacological concentration can selectively kill cancer cells. Phase I clinical trial showed that VitC(1.5g/kg, 90-120mins, 3 times a week) infusion is safe without significant adverse reactions. A phase II clinical trial indicated that large dose of vitC infusion can reduce toxic side effects from chemo drugs when it was used synergy with chemotherapy.
46032381|NCT02655913|Device|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
46032382|NCT02655913|Other|Supportive care|Supportive care focuses on helping patients get relief from symptoms such as nausea, pain, fatigue, or shortness of breath,etc.
45839409|NCT03012204|Device|real LFrTMS at unaffected M1|"Compare the effect of LFrTMS at unaffected M1 to that of all sham stimulation on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
46032383|NCT00649285|Drug|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|100mg, single dose fed
46032384|NCT00649285|Drug|Macrobid® Capsules 100 mg|100mg, single dose fed
46032385|NCT04318574|Other|Balance, Agility, Strengthening Exercise (BASE) Class|The BASE class will be conducted twice weekly for 1.5 hours each session over a 6-week period and will include a 10-minute warm-up, 30 minutes of static and dynamic balance exercises, 20 minutes of lower extremity strengthening exercises, and a 10-minute cool-down. There will be weekly falls prevention and mobility enhancement education provided during the class.
46032386|NCT02661685|Biological|autologous IKDC-like cells|Subject received autologous IKDC-like cells every 14 days
46032387|NCT04169269|Drug|Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters|anticoagulant, subcutaneous injection
46032388|NCT04169269|Drug|Rivaroxaban 10 milligram Oral Tablet|anticoagulant, oral
45338641|NCT04283994|Behavioral|EHR-based Clinician Jumpstart|The Jumpstart Guide is a communication-priming intervention for clinicians that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The one-page EHR-based Clinician Jumpstart Guide provides information to the clinician about prior advance care planning documentation derived from the EHR. The EHR-based Clinician Jumpstart Guide includes tips to improve goals-of-care communication.
45338642|NCT05288556|Device|Placement of stoma site enteral feeding tube accessory|The study stoma site accessory will be attached at the stoma site during an enteral tube replacement procedure the patient is scheduled to have as a standard of care procedure. The study stoma site accessory is compatible with commercially available enteral nutrition feeding tubes ranging from size 16 to 20 French tubing that are adjustable to variable length.
45338643|NCT02567565|Other|LipiView|tear film lipid layer thickness measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
45338644|NCT00732992|Drug|Sunitinib, Pemetrexed|Sunitinib daily by oral capsule in a continuous daily dosing regimen with pemetrexed every 3 weeks until progression or unacceptable toxicity.
45338645|NCT00732992|Drug|Sunitinib, Pemetrexed|Sunitinib daily by oral capsule administered for 2 weeks out of every 3 weeks with pemetrexed every 3 weeks until progression or unacceptable toxicity.
45839410|NCT03012204|Device|real primed LFrTMS at unaffected M1|"Compare the effect of primed LFrTMS at unaffected M1 to that of LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
46032389|NCT02655367|Other|Flaked oats|Test meal consisting of 264g porridge made with flaked oats
46032390|NCT02655367|Other|Milled oats|Test meal consisting of 264g porridge made with milled oats
45754687|NCT03474731|Behavioral|Diabetes Self Management Program|"Diabetes Self Management Program (DSMP) in a group setting: The goal of this arm of the project is to try to get participants to engage in better diabetes self-care (blood glucose testing, medication taking, diet, exercise, stress reduction, etc.).~Groups randomized to one of two arms (DSMP only and CCN) will receive the DSMP. The DSMP has demonstrated significant improvements in communication with physicians, healthy eating, and hypoglycemia at six and twelve months. The DSMP and other self-management programs have been shown to increase self-efficacy, knowledge, and skill building; ensure accountability/monitoring; improve patient-provider interaction; leverage local assets; address sustainability, and be cost effective."
46032391|NCT02661529|Procedure|Transesophageal Echocardiogram (TEE)|Transesophageal echocardiography (TEE) is a test that produces pictures of the heart. TEE uses high-frequency sound waves (ultrasound) to make detailed pictures of the heart and the arteries that lead to and from it. Unlike a standard echocardiogram, the echo transducer that produces the sound waves for TEE is attached to a thin tube that passes through the mouth, down the throat and into the esophagus. Because the esophagus is so close to the upper chambers of the heart, very clear images of those heart structures and valves can be obtained.
45338646|NCT02582346|Procedure|MRI acquisition - no contrast agent|No surgery. Volunteers will have an MRI with a 3T clinical system. Installation will be performed according to standard protocols. Different neurography and tractography sequences will be acquired in order to get different contrasts.
45338647|NCT00741195|Drug|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV on days 1 every 3 weeks for 6 consecutive cycles.
46032392|NCT02661529|Procedure|Transthoracic Echocardiogram (TTE)|"An echocardiogram is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of the heart. These echoes are turned into moving pictures of the heart that can be seen on a video screen.~Transthoracic echocardiogram (TTE) is the most common type of echocardiogram. Views of the heart are obtained by moving the transducer to different locations on the chest or abdominal wall."
45338648|NCT00741195|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
45338649|NCT05338632|Drug|Narcan 40 MG/ML Nasal Spray|naloxone 4mg/0.1 mL intranasal spray, up to 4 doses intranasally, followed by 1ml 0.4 mg/ml naloxone hydrochloride intravenously
45338650|NCT05338632|Drug|Naloxone Hydrochloride|naloxone 0.4mg/ml, up to 4 doses 2mg intramuscularly, followed by 1ml 0.4 mg/ml naloxone hydrochloride intravenously
45338651|NCT02597816|Radiation|Three dimensional ultrasound|
45338652|NCT04078932|Behavioral|Violence Prevention Conversation Script to Discuss Safely Navigating Police Encounters|A conversation script to facilitate conversations on safely navigating police encounters as anticipatory guidance and violence prevention strategy. The conversation script will be created using expert recommendations from existing resources and using recommendations (determined from focus groups) from black male youth and their caregivers. The script will be patient-centered.
46032393|NCT02661529|Other|Saline/Air Mixture|The Saline/Air mixture consists of 10 milliliters of sterile saline and 0.5 milliliters of air agitated together in a syringe prior to injection.
46032394|NCT02661529|Other|Saline/Blood Mixture|The Saline/Blood mixture consists of 9 milliliters of sterile saline and 0.5 - 1.0 milliliters of blood agitated together in a syringe prior to injection.
45338653|NCT00732758|Dietary Supplement|Vitamin D3 1000 IU|Vitamin D3 1000 IU Tablet once daily for 6 months
45338654|NCT00732758|Dietary Supplement|Placebo Tablet|Placebo Tablet once daily for 6 months
45338655|NCT00741351|Drug|Sevoflurane + Fentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and fentanyl (2-3 microg/kg/hr or 0.7 microg/kg boluses). Just before incision of the scalp, fentanyl (1-2microg/kg/hr) can be supplemented, if necessary
45682933|NCT03443128|Drug|Vinorelbine|During each course, patients will be treated with vinorelbine (25mg/m2/week on weeks 1-3). After 1 course(4 weeks) of vinorelbine, response will be evaluated by simple assessment: clinical symptoms, signs, B ultrasound, chest X-ray, peripheral blood test and bone marrow smear(if needed). After 2 courses, response will be evaluatedy by simple assessment, CT and FDG-PET. The CR/CRu was defined by anatomic tumour shrinkage more than 75% after 2 courses based on CT with negative PET assessment, with negative bone marrow PCR(if needed) and without CNS involvement. Patients who achieved a CR/CRu after two courses either will proceed to stem cell transplantation (SCT) or will receive additional courses of therapy while awaiting SCT. Response was re-evaluated at the end of every 2 courses. Patients with progressive disease at any time during treatment will be removed from protocol therapy.
45682934|NCT03437746|Drug|injection of methylprednisolone at anesthetic induction|intravenous administration : 20 mg/kg, over 30 minutes at anesthetic induction
45682935|NCT03437746|Biological|Blood samples|Blood samples (D0, D1, D2, D3, D4)
46032395|NCT02661373|Drug|SJ733|SJ733 is an oral, novel inhibitor of Plasmodium Falciparum plasma membrane protein PFATP4. It will be administered as a single, multi, or boosted oral dose.
45682936|NCT03084562|Other|collect examination time, functional and clinical tolerability|Examination time : time from patient setup and launch of the pre-test to the end of the patient monitoring Functional tolerability : functional assessed by the patient Clinical tolerability : clinical score by the cardiologist
45682937|NCT03479710|Biological|FMT infusion|Fecal microbiota transplantation via OGD
46032396|NCT02661373|Drug|Cobicistat|Commercially available cobicistat 150 mg tablets will be used. It will be administered as a single oral dose together with SJ733.
46032397|NCT00649051|Drug|Metolazone Tablets 2.5 mg|4x2.5mg, single dose fasting
46032398|NCT00649051|Drug|Zaroloxyn® Tablets 2.5 mg|4x2.5mg, single dose fasting
45682938|NCT01577745|Biological|MEDI0639|MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. MEDI0639 selectively binds to DLL4 and blocks its ability to bind to and activate signaling through the Notch receptors.
45682939|NCT03479476|Drug|Placebo Medication|Placebo liquid or capsules given in parallel to active medication.
45682940|NCT03479476|Drug|Metformin|Active medication.
46032399|NCT02536573|Other|Radlink Surgical Positioning Software|
46032400|NCT02655289|Device|Modulated TENS|"Frequency: 100 Hz~Intensity: individual; TENS should be clearly perceptible but not painful; impulse width is coupled with intensity~Mode: intensity modulation (40% decrease every 0.5 seconds)~TENS device: ARTROSTIM® SELECT~Channels: 2~Electrodes: 4 (5x5cm), placed on site of pain (a little more proximal if allodynia is present)"
45682943|NCT01678378|Behavioral|SHARP Intervention|Providers and staff located in high school school health centers (i.e., nurse practitioners, nurses,physicians, health educators, medical assistants) will be trained to address adolescent relationship abuse with school health center clients using knowledge, skills, and resources gained through the SHARP Intervention training. The training includes strategies to help youth recognize adolescent relationship abuse among themselves and their peers, to learn strategies to increase safety (harm reduction), and to utilize adolescent relationship abuse-related resources.
45682944|NCT03084250|Drug|Peginterferon Alfa-2A|180μg/week, 48 weeks; 135μg/week,48weeks
45682945|NCT03084250|Drug|Adefovir, entecavir,tenofovir, either of them|Adefovir, entecavir,tenofovir, either of them is ok
45682946|NCT01688037|Drug|NBI-98854|25 mg capsule
45682947|NCT01688037|Drug|NBI-98854|50 mg capsule
45682948|NCT01688037|Drug|Placebo|
46032401|NCT02655289|Device|Placebo TENS|"Frequency: 100 Hz (conventional for High TENS; Placebo is achieved by reduction of intensity, see below)~Intensity: The device is on and will be up-regulated together until the first sensation is perceptible. Then the activated device will be down-regulated minimally (no sensation perceptible) and this configuration will be retained.~Mode: continuous~TENS device: ARTROSTIM® SELECT~Channels: 2~Electrodes: 4 (5x5cm), placed on site of pain (a little proximal if allodynia is present)"
46032402|NCT04169971|Other|Music|Played through headphones during the operation under spinal anaesthesia
46032403|NCT02661607|Procedure|Point of care echocardiography|Point of echocardiography is performed after routine placement of central venous catheterization and compared with routine chest radiography
46032404|NCT02661607|Device|Central venous catheter placement|Central venous catheter placement is performed as per local guidelines in critically ill patients
46032405|NCT02661607|Procedure|Chest radiography|Routine chest radiography is performed after central venous catheter placement in critically ill patients
46032406|NCT04170829|Biological|ChAdOx1 MERS|a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.
46032407|NCT02655211|Procedure|CO2 laser treatment|Surgical treatment using fractionated ablative carbon dioxide laser (CO2)
46032408|NCT02655211|Procedure|PDL laser treatment|Surgical treatment using flashlamp-excited pulsed dye laser (PDL)
46032409|NCT02655211|Other|Usual care|Usual care (i.e., non-surgical) therapy (compression garments, massage, physical therapy, silicone gel sheeting)
46032410|NCT04410367|Drug|18F fluciclovine|18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
46032411|NCT04168879|Drug|Bupivacaine 0.5% Preservative-Free Injectable Solution|1.5 ml of Bupivacaine 0.5% Preservative-Free Injectable Solution used transnasally to block the sphenopalatine ganglion
46032412|NCT04168879|Drug|normal saline|1.5 ml of normal saline is delivered transnasally to the sphenopalatine ganglion
46032413|NCT02655445|Procedure|Mini-craniotomy|chronic subdural hematoma evacuation through minicraniotomy
46032414|NCT02655445|Procedure|Twist Drill Craniostomy|chronic subdural hematoma evacuation through twist drill craniostomy
45338656|NCT00741351|Drug|Sevoflurane + Remifentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and remifentanil (0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening). Just before incision of the scalp, remifentanil can be supplemented, if necessary
46032415|NCT02655445|Procedure|Burr Hole Craniostomy|chronic subdural hematoma evacuation through burr holes
46032416|NCT00649987|Drug|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
45338657|NCT00741351|Drug|Propofol + Remifentanyl|Propofol is maintained with continuous infusion at 10 mg/kg/h for the first 10 minutes, then reduced to 8 mg/kg/h for the following 10 minutes and reduced to 6mg/kg/h thereafter and remifentanil 0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening. Just before incision of the scalp, remifentanil could be supplemented, if necessary
45682949|NCT03084484|Dietary Supplement|Kiwifruit addition to the diet|Subjects were instructed to eat two kiwifruit per day during the whole study period. No recommendation on the type of kiwifruit, brand or origin was delivered. Kiwifruit was suggested to be taken as a whole and not mixed with sugar or other ingredients. No changes to their routinely dietary habits were suggested.
46032417|NCT00649987|Drug|VoSpire® ER Tablets 8 mg|8mg, single dose fed
45682950|NCT03084484|Procedure|Non Surgical periodontal treatment|Non-surgical treatment of periodontal pockets with hand and ultrasonic instrumentation
45839411|NCT03012204|Device|combined rTMS at both M1|"Compare the effect of combined rTMS at both M1 to that of primed LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
45839412|NCT03012204|Device|all sham stimulation|used as controls to eliminate the placebo effect of all kinds of combinated rTMS
45839413|NCT03012438|Device|NIRF imaging in thyroid surgery|a fluorescence imaging system and 7.5 mg of ICG will be used to visualize the parathyroids glands.
46032418|NCT04169035|Device|The BD Odon DeviceTM is a new device for AVB that has been designed by a team of midwives, doctors and engineers.|The BD Odon DeviceTM works by placing a cuff of air attached to a plastic sleeve, around the baby's head. The doctor then gently pulls on this sleeve and air cuff to assist the birth of the baby.
45338658|NCT02582268|Device|intrauterine device TCu 380A|
45338659|NCT02582268|Radiation|Trans-abdominal sonography|
45338660|NCT02582190|Drug|Colchicine group|antiarrhythmic therapy plus colchicine & antiarrhythmic therapy alone.
45338661|NCT00699153|Drug|Loteprednol Etabonate|Loteprednol Etabonate in an ophthalmic base will be administered to study eye 4 times a day(QID) for 14 days.
46032419|NCT04169035|Procedure|forceps or ventouse|"The woman is unable to have an Odon assisted birth as no Odon trained practitioner is available to assist the birth.~Forceps is a metal instrument with two handles used to encircle a baby's head and assist in birth.~Ventouse is a device used to help a baby be born by putting it over the baby's head and using suction (= removing air) to pull the baby out of the mother's body."
46032420|NCT01142232|Drug|Lenalidomide plus Melphalan during autologous stem cell transplantation|Patients will receive a fixed dose of melphalan, while the dose of lenalidomide is escalated according to the protocol defined cohorts. Lenalidomide is given on day -7 to day +2, while intravenous melphalan is given on day -2 and -1. Lenalidomide dosing will be in the morning at approximately the same time each day.
45338662|NCT00699153|Drug|Vehicle of Ophthalmic Loteprednol Etabonate|Vehicle of ophthalmic loteprednol etabonate administered postoperatively to study eye 4 times a day(QID) for 14 days.
46032421|NCT01142232|Drug|Lenalidomide maintenance|Lenalidomide maintenance therapy will begin on Day +100 to Day +110 provided the protocol-defined criteria are met. The initial starting dose of lenalidomide during maintenance is 10 mg daily on Days 1-28 of each 28-day cycle.
45682951|NCT03084406|Other|Centervention-ATOD (CV-ATOD)|A customizable suite of online tools specifically designed to support quality implementation and sustainability of any ATOD-EBP within real-world service settings.
45682952|NCT03084328|Dietary Supplement|Vitamind D|Patients will be given an over the counter vitamin D supplement of 2000 units of D3 daily for 6 months
46032422|NCT04169659|Device|Kyphoplasty with insertion of Sctructured Titanium Microspheres|Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce structured titanium microspheres until the dome is full of material.
45338663|NCT02582112|Other|Active Comparator: Warming group|Placebo Comparator: Control group
45338664|NCT04277442|Drug|Decitabine|Given IV
45338665|NCT04277442|Biological|Nivolumab|Given IV
45338666|NCT04277442|Drug|Venetoclax|Given PO
45338667|NCT05742243|Drug|Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®)|Abatacept injected subcutaneously once per week and nasal insulin inhaled for 10 consecutive days initially and twice per week thereafter
45338668|NCT05742243|Drug|Abatacept (CTLA4-Ig) and nasal placebo (0.9% sodium chloride)|Abatacept injected subcutaneously once per week and nasal placebo inhaled for 10 consecutive days initially and twice per week thereafter
45682953|NCT03707314|Procedure|Angiography with follow-on revascularisation if indicated|Angiography with follow-on revascularisation (if indicated)
45682954|NCT03435718|Drug|Oxfendazole|oral suspension
45682955|NCT03435718|Drug|Albendazole|tablet
45682956|NCT01678534|Drug|Allogenic mesenchymal stem cells from adipose tissue|
45682957|NCT01678534|Drug|Placebo|
46032423|NCT04169659|Device|Kyphoplasty with Polimethylmetacrilate (convetional surgery)|Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce Polimethylmetacrilate until the dome is full of material.
46032424|NCT02655133|Drug|Pentaglobin®|Immunoglobulins that will be used are IgM enriched and will be infused at 5 ml/Kg/day for 3 days.
46032425|NCT02655133|Drug|Physiologic solution|Physiologic solution will be infused and will be infused at 5 ml/Kg/day for 3 days.
46032426|NCT02536807|Drug|Hyaluronan|HA gel injection
46032427|NCT02883738|Other|tremor|evaluation of the intensity of the tremor
46032428|NCT04395547|Dietary Supplement|JointAlive™|Combination herbal extract
46032429|NCT04395547|Dietary Supplement|Placebo|Combination placebo product
46032430|NCT02660671|Behavioral|Email outreach|Subjects will receive an email describing the importance of colorectal cancer screening and that s/he has been selected to participate in this VIP concierge service.
46032431|NCT02660671|Behavioral|Active choice|S/he will receive the ability to pre-commit and choose from 3 different appointment slots by clicking directly on the email.
46032432|NCT02660671|Behavioral|Financial incentive|The participant will receive the offering of $100 if s/he follows through with screening colonoscopy.
46032433|NCT02536495|Drug|Docetaxel|Given IV
46032434|NCT02536495|Other|Laboratory Biomarker Analysis|Correlative studies
46032435|NCT02536495|Other|Pharmacological Study|Correlative studies
46032436|NCT02536495|Drug|Selinexor|Given PO
45472414|NCT01158053|Device|FFR and VH-IVUS|"Stable Angina(SA), Unstable Angina(UA),Non ST-segment Elevation Myocardial Infarction(NSTEMI) or ST-segment Elevation Myocardial Infarction(STEMI) >48hrs scheduled for cardiac catheterization ± PCI. All patient level inclusion and no exclusion criteria are met Signed Informed Consent~No PCI or successful and uncomplicated PCI of all non study lesions. One or more study lesions identified.~All lesion level inclusion criteria and no exclusion criteria are met.~FFR followed by VH-IVUS of study lesion(s)~Any additional PCI based on routine clinical practice and FFR/IVUS data?~If Yes: Final IVUS with VH imaging, Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years~If No: Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years"
46032437|NCT02536417|Drug|Melatonin|To determine the effectiveness of melatonin in preventing the development of delirium compared with placebo
45338669|NCT04077918|Dietary Supplement|protein diet|100 CHD patients will be recruited and randomized into 2 groups with an additional animal or plant protein 18g per day
45338670|NCT04076748|Drug|Sufentanil|The intervention is intranasal Sufentanil adminstration, then IV morphine as soon as possible.
45338671|NCT04076748|Drug|EMONO|In the control group, patients will receive EMONO then IV morphine as soon as possible.
45338672|NCT00698997|Behavioral|Early Start Denver Model|"Phase 1 of ESDM intervention: 12 weekly, 1 to 1.5 hr. sessions focused on teaching & coaching parents to use the ESDM in all natural caretaking routines & play periods with their child. Parents are taught & coached on 1 aspect of the ESDM each week in the clinic session, & then practice it at home daily in natural family routines & play.~Phase 2: each child in the ESDM will receive 25 hrs. a week of ESDM intervention in their homes, 50 wks. a year, for 2 years. 20 hrs. weekly will be delivered by trained interventionists (ITs); 5 hrs. weekly will be delivered by parents. (ITs) will provide ten 2 hour teaching episodes involving play activities per week in the home. Parents will continue to deliver the ESDM in natural family routines & play activities. In addition, each child will receive additional services through public services, or other therapies that the parents may choose, for several more hrs. per week."
45338673|NCT00698997|Behavioral|Standard community care|Treatment and interventions, chosen by families, meeting current standards of community intervention for toddlers with autism and ASD
46032438|NCT02536417|Drug|Sugar pill|To determine if placebo effect plays a part in preventing the development of delirium
46032439|NCT01140906|Drug|Placebo|capsules, daily, orally
46032440|NCT01140906|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
45338674|NCT00711087|Drug|BOTOX-A|Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90
46032441|NCT01140906|Drug|Duloxetine|encapsulated capsules, daily, orally
46032442|NCT00650065|Drug|Cetirizine HCl Tablets 10 mg|10mg, single dose fasting
45338675|NCT00711087|Other|Saline injection|Group 2-sham saline injections on both Day 0 and Day 90.
45338676|NCT04078308|Biological|Intravenous Injection of autologous mesenchymal stem cells|Intravenous injection 1 millions of bone-marrow derived autologous Mesenchymal Stem Cells (MSCs) per kg of patient's body weight in each dose, weeks 0 & 3
45338677|NCT04078308|Other|Intravenous injection of placebo|Intravenous injection of normal saline (sodium chloride 0.9%)
46032443|NCT00650065|Drug|Zyrtec® Tablets 10 mg|10mg, single dose fasting
46032444|NCT02654821|Biological|TCR transduced T-cells|Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
46032445|NCT02654821|Procedure|Biopsy|During screening, after treatment and at time of regression/progression a biopsy will be taken for translational research.
46032446|NCT02654821|Procedure|Blood taking|During screening, after the infusion with T-cells, after treatment and at time of regression/progression blood will be taken for translational research.
46032447|NCT02882412|Other|observational|
45472415|NCT01158053|Device|IVUS and FFR|
45682958|NCT01678690|Drug|Gemcitabine HCl Oral Formulation|Gemcitabine HCl Oral Formulation 80 mg/vial Subjects will be treated on Day 1 of the 7-day study treatment period
46032448|NCT04170439|Drug|Clomiphene plus metformin plus N acetyle cysteine in arm number 1|oral adminstration of clomiphene citrate plus metformin plus N acetyl cysteine or chromium
45682959|NCT01679080|Drug|Zoledronic acid|antiresorptive and calcium and vitamin D
46032449|NCT04170439|Drug|Clomiphene citrate plus metformin with chromium|oral adminstration of clomiphene citrate plus metformin and chromium
46032450|NCT04170439|Drug|clomiphene citrate plus metformin|oral adminstration of clomiphene citrate plus metformin
45338678|NCT05137782|Other|Specialty Palliative Care|Specialty palliative care, as opposed to primary palliative care.
45338679|NCT02582034|Radiation|Optimized Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).~Optimized dosimetry arm: the activity to be administered is calculated so as to deliver predictive dosimetry:~An absorbed dose to the tumor of at least ≥ 205 Gy and if possible exceeding 250 Gy or even 300 Gy~A dose at the treated healthy liver < 120 Gy in case of lobar treatment~Dose to the treated healthy liver can exceed 120 Gy in case of segmental treatment and hepatic reserve > 30%~A pulmonary dose < 30 Gy for one treatment and < 50 Gy in cumulative dose in case of multiple treatments."
45472416|NCT03060512|Drug|Polyethylene Glycol 3350|"Polyethylene Glycol 3350, 17 grams of powder to be dissolved in 4 to 8 ounces of water, juice, soda, coffee or tea to be taken once a day.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
45472417|NCT03060512|Drug|Movantik|"Movantik 25 mg, 1 tablet taken once a day on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
45472418|NCT01263275|Device|tDCS (Eldith DC-Stimulator (CE certified))|Each tDCS session lasting continuously for 20 minutes at 2 mA
45682960|NCT01679080|Drug|Teriparatide|anabolic and calcium and vitamin D
45472419|NCT01263353|Drug|Pasireotide LAR followed by Pasireotide LAR + Everolimus|
45682961|NCT01679080|Other|No active treatment|Calcium and vitamin D
45682962|NCT03473782|Other|Voiding Diary|A log kept by each patient to record frequency and volume of urine output and fluid input.
46032451|NCT05188092|Other|Lung ultrasound guided deresuscitation|"With every new LUS examination, the following scenarios, with distinct recommendations, are possible:~LUS observations suggest massive pulmonary fluid overload, with the recommendation to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance of at least -1500 ml in the next 24 hours;~LUS suggests some pulmonary edema and/or significant pleural effusion. These LUS observations suggest little pulmonary fluid overload, with the suggestion to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance at least -500 ml in the next 24 hours;~LUS suggests absence of pulmonary edema and no pleural effusion. These LUS observations suggest no fluid overload, with the suggestion to target a neutral fluid balance in the next 24 hours."
46032452|NCT02660515|Procedure|Additional wrist arthroscopy|
46032453|NCT02660515|Procedure|ORIF|
46032454|NCT02883504|Procedure|Echo-Doppler examination and left heart catheterization|
45472420|NCT01263353|Drug|Everolimus followed by Pasireotide LAR + Everolimus|
46032455|NCT02660593|Dietary Supplement|SanGrow Decoction|SanGrow Decoction is perpared according to the principle of Chinese medicine to treat thirsty and maransis.
46032456|NCT00962091|Drug|Alisertib|Alisertib OS Alisertib PIC Alisertib PIC
46032457|NCT02660437|Other|Pulmonary Rehabilitation program|Patients will attend a comprehensive 3-week PR program (12sessions/ 60min·day) including high intensive interval exercise equivalent to 100% of peak work rate (WRpeak) with 30sec work periods interspersed with 30sec rest periods for 30min and light resistance training (3muscle groups/ 4sets each/10repetitions; ~30min).
46032458|NCT02536651|Procedure|Ankle surgery|Plastic or orthopedic surgery of the ankle
46032459|NCT00649363|Drug|Ondansetron Orally Disintegrating Tablets 8 mg|8mg, single dose fasting
46032460|NCT00649363|Drug|Zofran ODT® Tablets 8 mg|8mg, single dose fasting
46032461|NCT04285203|Other|Educational Video Intervention|Educational videos
46032462|NCT02654899|Drug|PF-06815345|PF-06815345 will be administered as a liquid dosage formulation
46032463|NCT02654899|Other|Placebo|Placebo
45472421|NCT01156259|Radiation|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 30Gy
45472422|NCT01156259|Radiation|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 40Gy
45682963|NCT03473782|Other|Urodynamics Correlation Study|Provides patho physiological data by assessing bladder sensation, bladder capacity, the presence of involuntary bladder contractions, bladder compliance and bladder outlet obstruction.
45682964|NCT01679158|Device|Using The IOP system from USGI to place suture anchors|"Sutures are placed in the distal body in one of three randomized techniques:~A = reduction in ring opening to antrum using plications B = continuous horizontal row, running from distal body into proximal antrum C = Control. Current V shape as Control"
45682965|NCT03083782|Drug|Apixaban alone|A single dose of 10 mg apixaban administered orally at 0H on Day 1.
45682966|NCT03083782|Drug|Cyclosporine|Once daily dose of 100 mg cyclosporine administered orally on Days 1 to 3.
45682967|NCT03083782|Drug|Tacrolimus|Once daily dose of 5 mg tacrolimus administered orally on Days 1 to 3.
46032464|NCT02654899|Drug|PF-06815345|PF-06815345 will be administered as either solid dosage formulation or liquid dosage formulation
46032465|NCT03531645|Drug|Fulvestrant|"Neoadjuvant Treatment (Cycles 1-4): Fulvestrant 500 mg injection in buttocks on Days 1 and 15 of Cycle 1 and Day 1 of Cycles 2-4.~Adjuvant Treatment (Cycles 5 and beyond): Fulvestrant 500 mg injection in buttocks on Day 1 of each cycle.~Study cycle is 28 days."
46032466|NCT03531645|Drug|Abemaciclib|"Neoadjuvant Treatment (Cycles 1-4): Abemaciclib 150 mg by mouth On Days 1-28 of each cycle.~Adjuvant Treatment (Cycles 5 and beyond): On Days 1-28 of each cycle, you will take Abemaciclib 150 mg by mouth on Days 1-28 of each cycle.~Study cycle is 28 days."
46032467|NCT02654743|Dietary Supplement|Sulforaphane|Children with ASD will receive Sulforaphane in this study
46032468|NCT04314258|Dietary Supplement|Moringa oleifera tea|4 grams of Moringa oleifera tea twice daily
45472423|NCT01158131|Behavioral|Balance after Baby Lifestyle Intervention Program|Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips. Weekly phone conversations with the lifestyle coach, as well as logging diet and physical activity will also be required of intervention participants.
46032469|NCT02862795|Procedure|HPV detection in anal canal samples|Additional anal taking during the colonoscopy with cytobrush
45682968|NCT03083782|Drug|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following cyclosporine
45682969|NCT03083782|Drug|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following tacrolimus
46032470|NCT04168723|Drug|MD1003|Group A: Daily dose of 1200 mg of MD1003 from Day 1 to Day 8
46032471|NCT04168723|Drug|Moxifloxacin 400mg|Group B1: Moxifloxacin 400 mg on Day 1 Group B2: Moxifloxacin 400 mg on Day 9
46032472|NCT04168723|Drug|Placebo for MD1003|Group A: Placebo for MD1003 on Day -1 Group B1: Placebo for MD1003 on Day -1 Group B2: Placebo for MD1003 on Day -1
46032473|NCT04168723|Drug|Placebo for moxifloxacin|Group A: Placebo for moxifloxacin on Day 1 and Day 9 Group B1: Placebo for moxifloxacin on Day 9 Group B2: Placebo for moxifloxacin on Day 1
46032474|NCT04168801|Dietary Supplement|early oral refeeding|Once the patient had a score of 1-3 of the analogue numerical scale (ENA), he was interrogated about symptoms such as nausea or vomiting, receives diet indicated between 16 and 24 hours after admission.
46032475|NCT00649441|Drug|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
45338680|NCT02582034|Radiation|Standard Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).Standard dosimetry arm: the activity to be administered is calculated so as predictive dosimetry:~An absorbed dose of 120 ± 20 Gy to the treated volume (whatever the tumor absorbed dose)~A pulmonary dose < 30 Gy for one treatment and < 50 Gy in cumulative dose in case of multiple treatments."
46032476|NCT00649441|Drug|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fasting
46032477|NCT01122576|Device|Crystalens AO|Crystalens AO surgically implanted bilaterally. Study observation up to 180 days.
46032478|NCT01122576|Device|ReSTOR|ReSTOR surgically implanted bilaterally. Study observation up to 180 days.
46032479|NCT01122576|Device|Tecnis Multifocal IOL|Tecnis surgically implanted bilaterally. Study observation up to 180 days.
46032480|NCT02660203|Procedure|Forced expiration|"Amongst chest physiotherapy technics, forced expiration is one of the passive procedures used in pediatrics.~The patient is positioned on ipsilateral decubitus and the physiotherapist is behind the patient, placing one hand on the patient abdomen and the other on the patient lateral chest. During expiration, the abdominal hand apply a pressure directed posteriorly and superiorly for the patient. Simultaneously, the thoracic hand apply a pressure posteriorly and inferiorly for the patient. The session's duration is 15 minutes after what the physiotherapist replace the patient in dorsal decubitus.Two sessions a day will be performed"
45338681|NCT02581956|Behavioral|Walking exercise|Walk normally with the duration and frequency at a 30- minute or more daily at least five days per week and gradually increased to a maximum of 60 minutes daily.
46032481|NCT02654665|Behavioral|Lifestyle modification|Diet and exercise designed for 5-7% weight loss over 6 months
46032482|NCT02654665|Drug|Liraglutide|GLP-1 agonist
46032483|NCT02654509|Biological|Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104|Eastern Equine Encephalitis Vaccine, Inactivated, Dried
46032484|NCT04168333|Biological|T101 Group|"Single Dose (SD) Cohort:~In each group, 3 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+9VP (Group1)/1.0E+10VP (Group2)/1.0E+11VP (Group 3) on D1.~Multiple Dose (MD) Cohort:~In each group, 9 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+10VP (Group1)/1.0E+11VP (Group2) on D1, D8, D15."
45338682|NCT02581956|Behavioral|No walking exercise|no exercise
45338683|NCT04262466|Drug|IMC-F106C|IMC-F106C weekly IV infusions or SC injections
45338684|NCT04262466|Drug|IMC-F106C and atezolizumab and pembrolizumab|IMC-F106C weekly IV infusions and atezolizumab Q3W IV infusion and pembrolizumab Q6W IV infusion
45472424|NCT02622542|Device|BMT+TEVAR|These FDA-approved devices will be used for performing TEVAR in the patients randomized to this arm, in addition to the medical therapy to control blood pressure (BMT)
45682970|NCT03406624|Procedure|Biopsy|Biopsies will be taken from disc and / or endplates during elective lumbar fusion surgery or disc herniation surgery (endplate biopsy is omitted in disc herniation surgery)
45338685|NCT04262466|Drug|IMC-F106C and chemotherapy|IMC-F106C weekly IV infusions and chemotherapy Q1-3W IV infusion
46032485|NCT04168333|Biological|Placebo Group|"Single Dose (SD) Cohort:~3 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1.~Multiple Dose (MD) Cohort:~6 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1, D8, D15."
46032486|NCT02654431|Procedure|Breast Cancer patient|Samples
46032487|NCT02654431|Procedure|Cancer patients|Samples
45338686|NCT04262466|Drug|IMC-F106C and tebentafusp|IMC-F106C weekly IV infusions and tebentafusp weekly IV infusions
45338687|NCT04255602|Drug|Ticagrelor 60mg|Ticagrelor 60mg plus Aspirin 100mg for experimental group
45338688|NCT04255602|Drug|Ticagrelor 90mg|Ticagrelor 90mg plus Aspirin 100mg for active comparator group
45338689|NCT05275920|Other|Best Practice Alert (BPA)|A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.
45472425|NCT02622542|Other|BMT|Optimal medical therapy will be administered to the patients randomized to this arm, involving but not limited to, beta-blockers, etc., to control the blood pressure and pain for stabilizing the patient upon presentation.
45338690|NCT05275920|Other|In-Basket Message|An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
45338691|NCT04250688|Device|Ekso Training with FES|
46032488|NCT04167865|Other|Exercise|Orthosis, mobilization, strengthening, posture and segmental breathing exercises
46032489|NCT02658643|Procedure|Continuous suture technique|The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
46032490|NCT02658643|Procedure|Interrupted suture technique|The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
45682971|NCT03083860|Device|BEI|BrainMARC Ltd. has demonstrated in recent years the ability to extract effective attention markers from averaged ERP waves sampled with a single EEG channel (two electrodes). In addition, BrainMARC has developed a template matching method to extract the attention-related markers at the single-trial level. An index (termed Brain Engagement Index - BEI) can then be generated from a 1-minute, single-channel sample.
45682972|NCT04274374|Dietary Supplement|Gluten-Free Diet|Dietary supplement without gluten
45682973|NCT04274374|Dietary Supplement|Gluten Diet|Dietary supplement with gluten
46032491|NCT02658721|Drug|Lidocaine|
46032492|NCT02658721|Drug|lidocaine+adjunct tramadol|IVRA was performed with 3 mg/kg lidocaine (10% Lidocaine) plus 50 mg tramadol, which were administered after diluting with saline to 40 mL. While performing IVRA, 30 mL saline was simultaneously administered to the systemic circulation
45472426|NCT01158209|Procedure|Endocervical samples|Endocervical samples collection during routine gynaecological examinations.
46032493|NCT02658721|Drug|lidocaine+systemic tramadol|IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL. While performing IVRA, 50 mg tramadol diluted with saline to 30 mL was simultaneously administered to the systemic circulation
46032494|NCT02658721|Drug|Fentanyl|If the patient had a VAS score of >4 and if required, 1 μg/kg fentanyl was administered for analgesia and the dosage and time were recorded.
46032495|NCT02658721|Drug|Atropine|"The patients received premedication 45 min before the surgery with intramuscular 0.01 mg/kg atropine.~In case of bradycardia (HR <50/min), 0.5 mg intravenous atropine was administered."
46032496|NCT02658721|Drug|Midazolam|The patients received premedication 45 min before the surgery with intramuscular 0.07 mg/kg midazolam
46032497|NCT02658721|Drug|Diclofenac sodium|The patients with a VAS score of >4 were administered with 75 mg diclofenac sodium via intramuscular route.
46032498|NCT02658721|Drug|Ephedrine|In the event of hypotension (systolic arterial pressure <90 mmHg or a decrease of more than 50 mmHg from the normal value) during the surgery, 5 mg intravenous ephedrine was administered.
46032499|NCT02658721|Drug|Ondansetron|Intravenous 4 mg ondansetron was administered for nausea and vomiting.
45472427|NCT03882983|Drug|Antria Cell Preparation Process|"Biological/Vaccine: Stromal Vascular Fraction The SVF obtained from adipose tissue will be added to the graft~Other Names:~Stromal Vascular Fraction~Adiployx Biological/Vaccine:"
45472428|NCT03883061|Other|regular medical treatment|regular medical treatment
45472429|NCT03882593|Procedure|Analysis of arterial filters after CPB|At the end of surgery, the arterial filter is withdrawn from cardiopulmonary bypass circuit to be prepared and analysed by SEM.
46032500|NCT00965523|Drug|Eribulin Mesylate|Eribulin mesylate 1.4 mg/m^2 intravenous infusion (IV) given over 2 to 5 minutes on Day 1 and 8 every 21 days.
46032501|NCT02652013|Other|cognitive evaluation|
46032502|NCT00629967|Drug|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and ribavirin 1000-1200 mg/day for 48 weeks
46032503|NCT00629967|Drug|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
45338694|NCT04024488|Behavioral|TI-CBT Intervention Arm|"TI-CBT teaches techniques and ways to manage distress through psychosocial health education, cognitive restructuring, and mastery of trauma, which refers to the process by which survivors of psychological trauma work through the traumatic experience in a meaningful way, and are able to move on with life. TI-CBT addresses both the trauma of learning one has HIV and the trauma associated with managing a chronic and stigmatized illness. The intervention highlights links between HIV and traditional gender roles, gender inequities, and gender based violence. Finally, the relaxation training teaches youth strategies to relax and these are integrated at the beginning and end of each session. TI-CBT Youth and Caregiver Intervention Manuals are distributed to sites for translation, backtranslation, and cultural adaptation in preparation for the Randomized Trial."
45472430|NCT01158287|Drug|sorafenib tosylate|
45472431|NCT01158287|Other|laboratory biomarker analysis|
45472432|NCT01158365|Drug|LACTIC ACID (Dermacid)|Route of administration: local
46032504|NCT02654587|Drug|OSE2101|
46032505|NCT02654587|Drug|Docetaxel|
46032506|NCT02654587|Drug|Pemetrexed|
46032507|NCT04283643|Other|Transcranial Focused Ultrasound|Non-invasive brain stimulation technique
46032508|NCT04283643|Other|Transcranial Magnetic Stimulation|Non-invasive brain stimulation technique
46032509|NCT02861703|Behavioral|Online lifestyle intervention|Online, computer-mediated interactive group-based lifestyle intervention addressing thoughts, feelings, behaviours related to eating, physical activity, and other psychosocial issues related to breast cancer survivorship (e.g., mood, body image, existential issues, social support).
46032510|NCT04167631|Radiation|Multi-parametric MRI|Vesical Imaging-Reporting And Data System (VI-RADS) for predicting non-muscle invasive bladder cancer (NMIBC) using multi-parametric MRI.
45472433|NCT01158365|Drug|Glycerine Vegetal Soap Granado Traditional|Route of administration: local
46032511|NCT02861313|Device|CM LOC attachment|CM LOC attachment
46032512|NCT02861313|Device|ball attachment|Ball attachment
46032513|NCT02654353|Procedure|Ablation|In both arms, patients will undergo an ablation procedure for persistent atrial fibrillation. The sequence of ablation steps are different between both arms.
45338695|NCT04024488|Behavioral|Discussion Control Arm|Each youth discussion control group session will be led by IYL and each caregiver discussion control group will be led by adult study staff. Discussion topics will be selected by youth and caregivers in the group as applicable. Discussion Control group session will take place at a separate time from TI-CBT youth group sessions in attempt to minimize contamination. To note, participant and caregiver group sessions are always held separately.
45338696|NCT00738530|Drug|Bevacizumab [Avastin]|10 mg/kg IV every 2 weeks
45338697|NCT00738530|Drug|Interferon alfa 2a [Roferon]|9 MIU SC 3 times/week
45338698|NCT00738530|Drug|Placebo|IV every 2 weeks
46032514|NCT01122264|Drug|Tadalafil|Administered orally for 24 weeks.
46032515|NCT01122264|Drug|Sildenafil Citrate|Administered orally for 24 weeks.
46032516|NCT03288675|Device|aiTBS|In the active aiTBS arm, the patients will receive 100 cycli of thetaburst trains of 2s, separated by an inter-train-interval of 6 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC; i.e. 3000 pulses per session). On each stimulation day, a given patient will receive 5 sessions with a between-session interval of 15 minutes. The treatment protocol of in total 20 aiTBS sessions will be spread over 4 days (i.e. 60.000 pulses in total). The sham coil has been specifically developed to mimic the real one.
45682974|NCT03083704|Biological|Andexanet alfa (Gen 1 Process 2)|factor Xa inhibitor antidote
46032517|NCT03288675|Behavioral|CCT|By training working memory processing, the CCT aims at modulating similar prefrontal cortex regions as being stimulated previously by aiTBS, namely the DLPFC. thereby possibly stabilizing clinical effects of aiTBS over time. In total 20 sessions of CCT vs. control training (of approximately 25 minutes per session), will be spread over a period of 4 weeks.
46032518|NCT03288675|Drug|SSRI|All patients will be prescribed antidepressant medication (SSRI) again when starting the CCT (vs. control training).
45338699|NCT04077684|Drug|Interleukin-2|IL2 (0.2 MIU, 0.5 MIU or 1 MIU) : placebo = 1:1:1:1
45338700|NCT00711009|Drug|lopinavir/ritonavir (LPV/r)|LPV/r 400/100 mg BID
45338701|NCT00711009|Drug|emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC/TDF 200/300 mg QD
45338702|NCT00711009|Drug|raltegravir (RAL)|RAL 400 mg BID
45338703|NCT02441322|Device|Novo-TTF|Procedures: MRI and advanced MRI sequence Advanced brain MRI's with special sequences will be obtained. First MRI prior to starting Novo-TTF therapy, second MRI up to 2-3 weeks after beginning therapy, third MRI up to 2 months from starting treatment and the last MRI up to 4 months after starting treatment.
45682975|NCT03083704|Drug|Apixaban 5 MG|factor Xa inhibitor
45682976|NCT03083704|Drug|Rivaroxaban 20 MG|factor Xa inhibitor
46032519|NCT04311294|Drug|ANS-6637 Low Dose|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
45338704|NCT02592824|Drug|glutamate infusion|Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
46032520|NCT04311294|Drug|ANS-6637 High Dose|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
46032521|NCT04311294|Drug|Matched Placebo|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
46032522|NCT04265131|Other|art therapy|Art therapy is a form of psychotherapy that uses creative methods of expression through art media, such as pencils, clay, paint etc.
45338705|NCT02592824|Drug|saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
45338706|NCT03838536|Dietary Supplement|Whole Egg Powder|Breastfeeding mothers will consume the equivalent of 5 whole eggs per week for 3 months.
45338707|NCT03838536|Dietary Supplement|Egg White Powder|Breastfeeding mothers will consume the equivalent of 5 egg whites per week for 3 months.
45682977|NCT03083704|Drug|Enoxaparin sodium|low molecular weight heparin
45338708|NCT04076124|Device|Active rTMS-DLPFC|Participants in the rTMS active stimulation group will receive 4-week 10 Hz 120% of RMT to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
45472434|NCT01158443|Behavioral|Behavioral Activation Therapy|8 session, manualized intervention. Homework, short-term activities and goals specified, problem solving skills.
45682978|NCT03083704|Drug|Edoxaban 60 MG|factor Xa inhibitor
45682979|NCT03083704|Biological|Andexanet alfa (Gen 2)|factor Xa inhibitor antidote
46032523|NCT00920218|Biological|Herpes Zoster Vaccine 1437173A|Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.
46032524|NCT00920218|Biological|Placebo vaccine (saline)|1 or 3 doses of Placebo (saline) injected intramuscularly.
46032525|NCT02861235|Other|Stress thallium-201 tomoscintigraphy, followed by a second rest tomoscintigraphy if necessary|with gamma-camera and D.SPECT camera
45338709|NCT04076124|Device|Active iTBS-DLPFC|Participants in the intermittent TBS(iTBS) active stimulation group will receive 4-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
45682980|NCT03083704|Biological|Andexanet alfa (Gen 1 Process 3)|factor Xa inhibitor antidote
45682981|NCT03083704|Drug|Apixaban 10 MG|factor Xa inhibitor
45682982|NCT03083704|Drug|Rivaroxaban 10 MG|factor Xa inhibitor
46032526|NCT02861235|Other|Rest technetium-99m tomoscintigraphy followed by stress technetium-99m tomoscintigraphy on the same day|with gamma-camera and D.SPECT camera, in Toulouse centre
46032527|NCT02861235|Other|Stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy on the same day|with gamma-camera and D.SPECT camera, in Nancy centre
46032528|NCT02861235|Other|stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy in two different days|with gamma-camera and D.SPECT camera, in Paris centre
46032529|NCT02861235|Other|Rest thallium-201 tomoscintigraphy with gamma-camera and D.SPECT camera|rest thallium-201 tomoscintigraphy for myocardial viability assessment
46032530|NCT02861235|Other|Rest technetium-99m tomoscintigraphy with gamma-camera and D.SPECT camera|rest technetium-99m tomoscintigraphy for myocardial viability assessment
46032531|NCT00649519|Drug|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/20mg, single dose fasting
46032532|NCT00649519|Drug|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fasting
46032533|NCT00629811|Drug|Avotermin (Juvista)|"Intradermal avotermin administered to four wound sites per subject, one wound site per anatomically matched pair, according to the subject's assigned dose group:~Group 1: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 1)~Group 2: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 0)~Each subject received four doses of active drug at concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site, one dose to one wound site per anatomically matched pair of wounds."
46032534|NCT00629811|Drug|Placebo|"Reference therapy was Placebo (vehicle). On Day 0, the four sites randomised to receive Placebo were administered with a 100μL intradermal injection of Placebo.~Subjects in Group 2 were dosed again on Day 0 at 10 to 30 minutes after wound closure.~Subjects in Group 1 were dosed again on Day 1 at 24 (+/-4) hours after initial administration of drug."
46032535|NCT02654275|Other|Proprioceptive Intervention|
46032536|NCT02882256|Other|Video discharge instructions|Discharge instructions provided in video form
45472435|NCT01158443|Behavioral|Supportive Counseling|8 sessions of manualized supportive counseling. Frequency and duration are designed to match the Behavioral Activation arm.
45682983|NCT03402334|Behavioral|Patient counseling for HCV associated CVD risk factors|Patients will be counseled for cardiovascular disease risk factors associated with Hepatitis C infection. Such risk factors include atherosclerosis, heart attack, and stroke. Cardiovascular risk factors can be managed through connection with primary care and reduced through curative HCV treatment.
46032537|NCT02652091|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Applied via the BETACONNECT device. Dose as prescribed by physician.
46032538|NCT02652091|Device|BETACONNECT device|Used to apply Betaseron.
46032539|NCT00625560|Drug|Entecavir|entecavir 1.0 mg QD
46032540|NCT00625560|Drug|Lamivudine|lamivudine 100 mg QD
46032541|NCT02651857|Device|Fuse® Colonoscope|Endoscopic diagnostic procedures for lower GI tract
46032542|NCT02651857|Device|Fuse® Gastroscope|Endoscopic diagnostic procedures for upper GI tract
46032543|NCT04167709|Other|Education in clinical competence in detecting signs of postpartum depression in immigrant mothers|Groupbased educational intervention aimed at nurses in the Child Health Services in strengthening clinical competence in detecting signs of postpartum depression in non-native-speaking immigrant mothers
46032544|NCT04310982|Device|The G-Walk sensor system (G-Walk)|The G-Walk is a wireless sensor device which is placed on an elastic belt and worn on the waist of the person being evaluated. The device is placed with the center of the device at the fifth lumbar vertebrae and the patient is completely free to walk, run and jump wearing this device. The gait and jump performance of the participants was assessed with the participants wearing this device two times to investigate the test-retest reliability. The second being 7 days after the first.
46032545|NCT02651935|Device|Intellivent ASV|Automated Invasive mechanical ventilation and weaning strategy
46032546|NCT04311138|Other|community-based reablement service|Experimental group receive a 10-wk diversified community-based reablement service including group exercise, cognitive training, health education for 1.5 hours, and individualized reablement for 1.0 hour.
46032547|NCT04311138|Other|multicomponent training|control group receive a 10-wk multicomponent training including 1.5-hr group intervention (group exercise, cognitive training, and health education) and 1.0-hr placebo intervention.
45338710|NCT04076124|Device|Sham TBS-DLPFC or Sham rTMS-DLPFC|Half of the patients in the sham group received 4-week the same iTBS parameter stimulation (sham-iTBS), and the other half received the same rTMS parameter stimulation using a sham coil (sham-rTMS), which also improved the blinding process.
45338711|NCT02592902|Procedure|Surgical collection of histology specimen|Collection of a histology specimen from the vocal cords and rear laryngeal commissure
45338712|NCT02592902|Procedure|Performance of immunohistochemical analysis|Immunohistochemical analysis - presence of pepsin, HPV 6 and 11, HSV 2 and chlamydia trachomasis
45338713|NCT04062513|Other|Olfactive stimulation intervention with familiarization|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick. For the familiarization stage, infants were familiarized with the odor of their mothers' milk for 9 hours before heel prick.
45338714|NCT04062513|Other|Olfactive stimulation intervention|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick.
45338715|NCT04062513|Other|Standard care|Preterm infants will receive sucrose during heel prick.
45682984|NCT03087994|Behavioral|Nutritional guidance intervention|participants in this group will attend 12 meeting of nutritional guidance
46032548|NCT00650455|Drug|valdecoxib|valdecoxib 10 mg tablet once daily for 12 weeks
46032549|NCT00650455|Drug|naproxen|naproxen 500 mg capsule twice daily for 12 weeks
46032550|NCT00650455|Drug|placebo|placebo tablet every morning and capsule every evening for 12 weeks
46032551|NCT02654041|Drug|Combined T3 and Methimazole treatment|Oral administration of T3 and Methimazole
46032552|NCT02651779|Procedure|Open reduction and internal plate fixation|
45338716|NCT04075890|Device|transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation method by which constant low direct current can be delivered to the sculpt for changing the excitability of neuronal structure adjunct to the stimulating electrode.
46032553|NCT02651779|Other|Closed reduction and plasterimmobilisation|
45338717|NCT04087850|Behavioral|Making Socially Accepting Inclusive Classrooms|Using a consultation model, study staff members met with teachers approximately twice per month and observed them an additional two times per month. The goal was to help teachers implement practices that create a socially accepting classroom climate for children.
45338718|NCT02567799|Drug|BIO 300 Oral Suspension|Cohort 1: BIO 300 500 mg Cohort 2: BIO 300 1,000 mg Cohort 3: BIO 300 1,500 mg Cohort 4: BIO 300 Optimal dose (TBD) BIO 300 dose will be given daily, 7 days/week (Week 1, day 1 through week 6) The 2nd and 3rd dosing cohort (1,000 and 1,500 mg/day) will begin following the accrual of a minimum of 6 subjects at the previous dose level, dose escalation to the next BIO 300 dose level will be allowed to occur when a cohort has completed concurrent chemoradiotherapy with fewer than 33% Dose Limiting Toxicities (DLTs) attributed to BIO 300 Oral Suspension.
45338719|NCT02567799|Drug|Paclitaxel|"During the Concurrent Therapy period, paclitaxel 45 mg/m2 will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, paclitaxel 200 mg/m2 will be administered by intravenous drip two times, 21 days apart."
46032554|NCT02658409|Biological|GC3106(quadrivalent cell-culture based influenza vaccine)|GC3106(quadrivalent),0.5ml, intramuscular, a single dosing at Day 1
46032555|NCT02658409|Biological|Fluarix™tetra Syringe Inj.(quadrivalent influenza vaccine)|Fluarix™tetra Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
45338720|NCT02567799|Drug|Carboplatin|"During the Concurrent Therapy period, area under the curve (AUC) = 2mg* min/mL will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, carboplatin AUC = 6mg*min/mL will be administered by intravenous drip two times, 21 days apart."
45598784|NCT03519607|Behavioral|FertiStrong App|The FertiStrong mobile app is similar to FertiCalm, which is designed for women with infertility. FertiCalm (www.FertiCalm.com) can be downloaded for free anywhere in the US, for both Apple and Android phones. Each app contains twelve main categories and each main category contains up to five tailored situations. For each situation, there are six options. Three of the options are the same for all situations (humor, self-nurture, relaxation) and three are unique (cognitive solutions, behavioral solutions, social solutions).
46032556|NCT02653885|Other|Red red cell distribution width|Results from hemogram
46032557|NCT02653807|Other|mobilization with movement|manual therapy intervention
46032558|NCT02653807|Other|osteopathic mobilization|manual therapy intervention
46032559|NCT01121562|Drug|Sunitinib|Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg in the morning (regardless fasting or non-fasting, One cycle will be 28days)
46032560|NCT04169425|Procedure|elective diverting ileostomy|
46032561|NCT02658253|Biological|PRIMVAC|3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
46032562|NCT02658253|Biological|GLA-SE|2.56 µg of GLA content
46032563|NCT02658253|Biological|Alhydrogel|0.85 mg og Aluminium content
46032564|NCT02658253|Biological|Placebo|0.9% Na cl
46032565|NCT04311060|Diagnostic Test|Molecular panel|"Detection of CBF rearrangements using PCR: CBFB-MYH11 [inv(16)(p13;q22), isoforms A, E and D; AML-ETO (RUNX1-RUNX1T1) (t8;21)(q22;q22).~NGS panel to detect classic mutations in: FLT3-ITD and TKD, NPM1, CEBPA, RUNX1, TP53, ASXL1, IDH1, IDH2 and KIT"
46032566|NCT02651623|Drug|Sertraline|Multiple doses of sertraline for 14 days
46032567|NCT02651623|Drug|Moxifloxacin|A single dose of 400 mg Moxifloxacin
46032568|NCT02651623|Drug|Drug - Placebo|Placebo administered for 14 days
46032569|NCT02651701|Procedure|MR-PET|whole body MR-PET with dedicated liver+rectal protocol
46032570|NCT04167475|Dietary Supplement|Probiotic capsule|Each probiotic capsule contains 1 x 10^9 CFU B. longum 1714™ with corn starch and magnesium stearate. The probiotic capsules will be supplied by PrecisionBiotics Ltd.
46032571|NCT04167475|Dietary Supplement|Placebo capsule|Each placebo capsule contains corn starch and magnesium stearate. The placebo capsules will be supplied by PrecisionBiotics Ltd.
46032572|NCT01121484|Drug|desvenlafaxine succinate sustained-release|50-mg DVS SR tablets taken orally once daily.
45839414|NCT03012048|Device|Silver-impregnated ceramic tablet|"A silver-impregnated ceramic disk used for drinking water treatment that was developed by engineers at the University of Virginia. When the ceramic disk is placed in a household water storage container, silver diffuses through the porous ceramic into the water at a release rate that is effective for continual disinfection of waterborne pathogens while remaining below the silver drinking water standard. The disk is effective for daily treatment of 10 to 15 liters for at least six months.~This intervention was removed from the study in July 2017 (approximately at 1 year of follow-up)."
45338721|NCT02567799|Radiation|Radiotherapy|Radiation treatment will be scheduled at the discretion of the investigator provided the subject has completed a minimum of 2 days of BIO 300 dosing. Subjects will receive radiation therapy 5 days per week, once daily fractions, 1.8-2.0 Gy per fraction, for 6-7 weeks.
45839415|NCT03012048|Device|Silver-impregnated ceramic water filter|"Silver-impregnated ceramic water filter are well-developed, tested, and widely-used devices. In addition to mechanically removing pathogens, the filter is treated with silver to reduce live pathogens that pass through the filter and to provide residual disinfectant to reduce risk of recontamination after treatment.~This intervention was replaced with ceramic filters without silver in Dec 2017 (approximately at 1.5 years of follow-up)."
45839416|NCT03012048|Device|Safe-storage water container|The safe-storage water containers used in this study are plastic buckets with a spigot, purchased locally.
45338722|NCT03825510|Radiation|Stereotactic Body Radiotherapy|"All patients in this trial will be treated with fractionated Stereotactic body radiation therapy.~SBRT will be delivered to <=3 sites in 3-5 fractions followed by administration of the specified immunotherapy agent (Nivolumab or Pembrolizumab). This approach will take advantage of the transient increase in antigen availability, increased antigen presentation and upregulation of PD-1 by tumor cells following ablative radiation therapy."
45338723|NCT00921219|Drug|ivermectin|Each subject will receive single doses of (i) 22.5 ml ivermectin oral solution (22.5 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
45338724|NCT04076514|Procedure|central neck dissection|dissection of central cervical lymph node grope in low grade papillary thyroid cancer
45338725|NCT02567097|Behavioral|Self-Incentive|Participants are asked to form plans to quit smoking using various descriptions specified dependent on the arm in which they are randomised.
46032573|NCT01121484|Drug|placebo|Placebo tablets taken orally once daily.
46032574|NCT00650221|Drug|Pravastatin|Single-dose 80 mg immediate-release oral tablet
46032575|NCT00650221|Drug|Pravastatin|Single-dose 80 mg immediate-release tablet
45338726|NCT02580552|Drug|Cobomarsen|
45338727|NCT02567331|Drug|Capecitabine|Participants will receive 1250 mg/m^2 capecitabine administered twice daily as oral tablets for 14 days followed by a 7 day rest period for up to 6 treatment cycles.
45598785|NCT02232971|Drug|Glucagon|Glucagon is given in three different doses according to three research days.
45598786|NCT02232971|Other|Isotonic saline solution|Placebo
45839417|NCT03012126|Behavioral|Healthy Weight Clinic|
45839418|NCT03012126|Behavioral|Healthy Weight and Your Child|
46032576|NCT01169675|Drug|BIBW 2992 low dose|patient receives low dose BIBW 2992 po daily on day 1 of 21 day cycle
46032577|NCT01169675|Drug|BIBW 2992 high dose|patient receives high dose BIBW 2992 po daily on day 1 of 21 day cycle
46032578|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
45839419|NCT03011970|Drug|Oxytocin|
45839420|NCT03011970|Drug|Placebo|
45839421|NCT03011736|Other|Laboratory Biomarker Analysis|Correlative studies
46032579|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
46032580|NCT01169675|Drug|BIBW 2992 high dose 6 day|patient receives high dose BIBW 2992 po daily on days 1-6 on 1 of 21 day cycle
46032581|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
46032582|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
46032583|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
45338728|NCT02580396|Device|CanADVICE+® (smart phone app)|The main objective of this project is to optimise pharmaceutical counselling services by providing drug related information, in a digital format, to patients with metastatic breast cancer receiving Capecitabine.
45839422|NCT03011736|Procedure|Parathyroidectomy|Undergo parathyroidectomy
46032584|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
46032585|NCT01169675|Drug|BIBW 2992 low dose 6 day|patient receives low dose BIBW 2992 po daily on days 1-6 on day 1 of 21 day cycle
46032586|NCT01169675|Drug|BIBW 2992 medium dose 6 day|patient receives medium dose BIBW 2992 po daily on day1 to 6 of a 21 day cycle
46032587|NCT01169675|Drug|BIBW 2992 medium dose|patient receives medium dose BIBW 2992 po daily on day 1 of 21 day cycle
46032588|NCT00650533|Drug|Glimepiride Tablets 1 mg|1mg, single dose fed
46032589|NCT00650533|Drug|Amaryl® Tablets 1 mg|1mg, single dose fed
45338729|NCT03793140|Drug|CPI-613|CPI-613 [2,500 mg/m2/day IV] over 2 hours (+/- 10 mins) Induction tx: Cycle 1 and 2: Treatment on Days 1-5 (Each cycle is 14 days). (Each Cycle is 14 days) Maintenance tx: All subsequent Cycles: Treatment with CPI-613 [2,500 mg/m2/day IV] over 2 hours (+/- 10 mins) on Days 1-5 (Each Cycle is 21 days)
45839423|NCT03011658|Procedure|venepuncture|for both the groups, HADS questionnaire will be administered to assess the levels of anxiety and depression. The placebo group ( group A) will not be having subjects suffering from oral lichen planus
45338730|NCT04077606|Other|ceramo-metallic crown prepartion|tooth will be prepared to receive ceramo-metallic crowns
46032590|NCT02653729|Behavioral|cognitive behaviour therapy|
46032591|NCT02653729|Drug|Espidone|
46032592|NCT02653729|Drug|Olepra|
45839424|NCT03011502|Other|Biological samples collection of blood and feces|
46032593|NCT02653729|Drug|Donu|
46032594|NCT02881866|Drug|Furosemide|
46032595|NCT02881866|Drug|Saline|
45338731|NCT04077606|Other|full anatomical monolithic zirconia crown|tooth will be prepared to receive monolithic zirconia crowns
45338732|NCT04077450|Behavioral|Online Heart-Focused Breathing Intervention|Participants will receive an online standardized HeartMath© heart-focused breathing intervention.
45338733|NCT00577005|Drug|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will be blind to the subject's medication administration. The medication will be discontinued over a two-week period.
45839425|NCT03011424|Device|Extracorporeal liver support therapy (ELS)|ELS by using the Molecular Adsorbent Recirculating System (MARS) is based on a modified haemodialysis that allows the removal of water-soluble and protein bound toxins over an albumin-coated high flux membrane against recycled exogenous albumin.
46032596|NCT00924664|Biological|Tanezumab 20 mg|Tanezumab 20 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
46032597|NCT00924664|Biological|Tanezumab 10 mg|Tanezumab 10 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
46032598|NCT04314869|Procedure|Uterus transplantation|Patient will undergo surgery in order to transplant the graft (uterus). After that, a follow-up in order to detect early rejection. After 6 months, embryo transfer will be perfomed. Labour route will be C-Section. Two pregnancies are agreed, and after the second one, a hysterectomy will be performed in order to remove the graft.
46032599|NCT05252611|Other|Turkish version of the Chronic Pain Acceptance Questionnaire-8 (CPAQ-8)|The aim of this study is to test the validity of the Turkish version of the Chronic Pain Acceptance Questionnaire-8 (CPAQ-8).
46032600|NCT02653651|Drug|Ketamine|Ketamine infused at 0.1 mg/kg/hour
46032601|NCT02653651|Drug|Lidocaine|Lidocaine infused at 1 mg/kg/hour
46032602|NCT02653651|Drug|Placebo|An equal volume of saline
46032603|NCT05657483|Diagnostic Test|Venous blood sample|Blood chemistry tests: neutrophil; lymphocyte; monocyte; platelet counts.
46032604|NCT05657483|Other|Surgical staging of endometrial cancer|Endometrial, adnexal, and lymphoid tissue samples.
46032605|NCT02653573|Behavioral|Coaching|Self-management education
46032606|NCT02887469|Drug|3% hypertonic saline|The same as above
46032607|NCT02651233|Other|ADRCs therapy|Patients are submitted to manual liposuction and extraction of ADRCS is done with closed system. All patients were candidates for subcutaneous transplantation of autologous cell enriched adipose tissue for different indications.
46032608|NCT05376839|Drug|Cedirogant|Capsule, Oral
46032609|NCT02651311|Other|intermediate cervical plexus block|ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg
46032610|NCT02651311|Drug|Fentanyl|fentanyl 0.5 µg/kg in postanesthetic care unit when more or equal to FLACC scale 4.
46032611|NCT02651311|Drug|Ibuprofen|ibuprofen in ward when more or equal to FLACC scale 4.
46032612|NCT04168177|Procedure|PCA|Patient controlled analgesia
45472436|NCT03882515|Other|Myofascial Release|With the right hand in hand exerts caudal pressure in the superior fibers of the muscle, both sides by a minute and a half each. In the ventral decubitus, apply pressure and slip from T12 to the base of the skull nine times. Thumb in the individual's acromion and with the other to hold the pressure and slide in the direction of the other acromion three times. Hand at the base of the skull and with the contralateral tenar region perform pressure and slip in caudal direction on both sides by three times. Hand at the base of the skull and with the contralateral thumb exerting pressure and slip of C3 the distal insertion of the upper fibers on both sides. Thumbs at the base of the skull, exerting lateral traction of the fascia in opposite directions. Dorsal decubitus, thumbs above clavicles, perform detachment of fibers for one and a half minutes. Patient sitting, support the head of the metacarpals beside the spinous process from T1 to T12 and exert pressure and slip three times each.
46032613|NCT04168177|Procedure|ESP|erector spinae plane block
46032614|NCT02653261|Drug|Tranexamic Acid|Tranexamic acid (TXA) is a synthetic analog of serin than reversibly inhibits fibrinolysis by blocking lysine union sites in the plasmin and plasminogen activator molecules. TXA: bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively
46032615|NCT02653261|Drug|Placebo|An equal volume of saline
46032616|NCT04252378|Procedure|Deep Serratus Anterior Plane Block|Deep Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
45338734|NCT00577005|Drug|Placebo|
45338735|NCT05162157|Device|NuvoAir platform|Nuvoair platform, consisting of a bluetooth spirometer, smartphone application and clinical portal
45598787|NCT02347293|Other|High levels of indigestible carbohydrates|
45598788|NCT02347293|Other|Low levels of indigestible carbohydrates|
45598789|NCT03146637|Biological|Activated CIK|Activated CIK armed with bispecific antibody were infused for 3 days，after 2 days，bispecific antibody was infused separately for 3 days
45598790|NCT03146637|Biological|CIK|Traditional CIK were infused for 3 days
46032617|NCT04252378|Procedure|Superficial Serratus Anterior Plane Block|Superficial Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
46032618|NCT02657941|Behavioral|Motivational group|"Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and the means of prevention, motivational balance on the practice of physical activity, developing a personal goal, information about the sports center Session 2: brainstorming and card game on Food Hygiene Session 3: Find situations at risk of snacking and consider alternative lines"
46032619|NCT02657941|Behavioral|educational group|"Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and means of prevention, video on physical activity, discussions with therapists, information about the sports center Session 2: Video on Food Hygiene, discussions with therapists Session 3: Return on basic concepts covered in the first 2 sessions"
46032620|NCT02653339|Drug|Qufeng Shengshi Fang and Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD"
45598791|NCT02296333|Drug|ondansetron|8 mg intravenous in the skin closure
45338736|NCT04077060|Diagnostic Test|NIPT|"Women randomized in the intervention group will be offered cfDNA screening, along with an early detailed anatomy scan, including nuchal measurement, at 11-13 weeks of gestation. cfDNA analysis will include a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. NIPT will be performed at the time of randomization or after if gestational age at randomization < 9 6/7 weeks of gestation.~Women in both groups will be given oral counseling by obstetricians and will be counseled about test procedures, reporting time, test sensitivity and specificity, and the necessity to confirm abnormal screening results with invasive testing."
45472437|NCT03882515|Other|Continuous Surface Slip Technique|"Individual in the ventral decubitus, position the entire palmar surface bilaterally in the spinous process of T1 in the caudal direction, performing superficial smoothing in a smooth and rhythmic movement up to T12.~Return of the hands from the caudal direction towards the cranial direction, bypassing the lateral borders of the trapezius muscle following the direction of the inferior, middle and superior fibers.~Continue surface smoothing with a smooth and rhythmic movement until the distal insertion of the trapezius upper fibers into the skull and resume step 1 slowly and continuously for 10 minutes."
45472438|NCT03882515|Other|Without intervention|Evaluation and re-evaluation without intervention
46032621|NCT02653339|Drug|Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The control group patients are treated with Loratadine by oral, 10mg QD"
45472439|NCT01156493|Other|Protein Hydrolyzed Premature Formula|Infants will be fed with a protein hydrolyzed premature formula until they reach full feeds
45472440|NCT01264757|Behavioral|Physical Activity Educational Materials|A brochure was provided to participants about the health benefits of physical activity and physical activity recommendations
45472441|NCT01264757|Behavioral|Pedometer|A pedometer was provided to participants in addition to educational materials about the health benefits of physical activity.
46032622|NCT04169503|Drug|Immune Checkpoint Modulator|identification of cases of immune-related adverse events due to immune checkpoint inhibitors. Among these cases, identification and description of those with immune checkpoint inhibitor rechallenge.
45472442|NCT01263431|Procedure|Hemorrhoidectomy|Each of the main haemorrhoid is dissected and the apex is ligated and then cut, near to the dentate line
45472443|NCT01263431|Procedure|Hemorrhoidal dearterialization|A special instrument (THD, G.F., Medical Division, Correggio, Italy )with an incorporated Doppler probe is used to detected the six terminal branches of the superior rectal artery which are ligated above the dentate line, then a running suture is performed in order to obtain a mucopexy
45598792|NCT02296333|Drug|isotonic|8 mg intravenous in the skin closure
45682985|NCT03087994|Behavioral|Nutritional guidance intervention|Participants in this group will only receive nutrition guidance once during the study
46032623|NCT00649597|Drug|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
46032624|NCT00649597|Drug|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fasting
46032625|NCT02653105|Biological|OLFM4|patient have an additional blood test every 6 months for dosing OLFM4
46032626|NCT02657785|Drug|R-IDARAM plus intrathecal chemotherapy|R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2 and 3); methotrexate 2 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
45682986|NCT03083392|Procedure|treatment of chronic maxillary sinusitis using DIVA system|chronic maxillary sinusitis treatment utilizing DIVA system for antral lavage
45338737|NCT04077060|Diagnostic Test|combined screening|Control group includes the standard of care. In our department, first-trimester risk assessment is performed routinely at 11-13 weeks of gestation by FTCS as per standard of care. FTCS includes crown-rump length, NT measurements, and a detailed ultrasound examination based on ISUOG guidelines. All operators who perform this examination are certified by the UK Fetal Medicine Foundation (FMF). A specific risk for aneuploidy is not calculated if NT measurement is >3.5 mm or if fetal anomaly is identified. These cases are deemed to be at a very high risk for chromosomal abnormalities and are offered invasive testing.
46032627|NCT02653027|Drug|Lumacaftor-ivacaftor|Subjects who are planning on starting the combination therapy (lumacaftor-ivacaftor) will participate in OGTTs before and after starting the medication.
45338738|NCT02581566|Drug|Intrathecal Dexmedetomidine|Addition of Intathecal Dexmedetomidine plus Intrathecal Bupivacaine
45338739|NCT02581566|Drug|Intraarticular Dexmedetomidine|Addition of Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine
45682987|NCT03083392|Device|"dynamic implant valve approach - DIVA system"|The DIVA system will be used to apply saline lavage to the maxillary sinus
45338740|NCT02581566|Drug|Bupivacaine|Intrathecal Bupivacaine
46032628|NCT02653027|Other|OGTT|A subject is given an oral glucose load and insulin and glucose measurements are taken at specified time periods.
45338741|NCT02567019|Other|blood samples|blood samples will be done for patients patients suffering of periodontal diseases and healthy volunteers
45338742|NCT05237076|Diagnostic Test|Hyperinsulemic-Euglycemic Clamp & Hypoxic Ventilatory Response (HVR)|Hyperinsulemic-Euglycemic Clamp as described by deFronzo et al.
45682988|NCT03471442|Procedure|Paravertebral block|Ultrasound-guided paravertebral block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
46032629|NCT04168255|Procedure|Double tamponade|Double tamponade procedure in retinal detachment with PVR and inferior breaks
46032630|NCT02650765|Other|Indications for head CT imaging after acute head injury|Indications for head CT imaging after acute head injury as per the Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults.
46032631|NCT02652793|Drug|Boosted atazanavir|Atanazir 300 mg once dailly boosted with 100 mg of ritonavir once dailly
46032632|NCT02652793|Drug|Lamivudine|Lamivudine 300 mg once dailly
46032633|NCT02650687|Procedure|Processed EEG|In the operating room. Processed EEG will be measured using the Bispectral Index (BIS) monitor which is standard of care.
46032634|NCT00650611|Drug|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 20 mg twice daily, which was titrated up in 20 mg twice daily increments to a maximum dose of 80 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
45682989|NCT03471442|Procedure|Erector spinae plane block|Ultrasound-guided erector spinae plane block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
45682990|NCT03471442|Drug|General anesthetic|General anesthesia administered as per preference of intra-operative attending anesthesiologist
46032635|NCT00650611|Drug|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 10 mg twice daily, which was titrated up in 10 mg twice daily increments to a maximum dose of 40 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
46032636|NCT00600067|Drug|Phentermine/Topiramate|phentermine 15mg/ topiramate controlled release (CR) 92mg, oral capsule, once daily, 28 weeks
45338743|NCT04077216|Dietary Supplement|Extra Virgin Olive Oil (EVOO)|This study used the FDA approved Doña Elena Extra virgin olive oil, which is readily available in local supermarkets. Its free acidity expressed as oleic acid was found to be 0.26%, comparable with the International food standards.15
46032637|NCT00600067|Drug|Placebo|Oral placebo capsules, once daily, 28 weeks
46032638|NCT02650609|Drug|Methylprednisolone|
46032639|NCT02650609|Drug|Placebo|
46032640|NCT02652871|Drug|LY2510924|"Dose Escalation Phase: Starting dose level of LY2510924 is 10 mg subcutaneously each day of a 28 day cycle. Dose escalated in successive cohorts of patients.~Dose Expansion Phase: LY2510924 given at the maximum tolerated dose (MTD) from Dose Escalation Phase."
46032641|NCT02652871|Drug|Idarubicin|"Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients > 60 years of age Idarubicin given for 2 days.~Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days."
46032642|NCT02652871|Drug|Cytarabine|"Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age < 60 years). In patients > 60 years of age Cytarabine given for 3 days only.~Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days."
46032643|NCT00650299|Drug|Alprazolam Extended-release Tablets 3 mg|3mg, single dose fed
46032644|NCT00650299|Drug|Xanax XR® Tablets 3 mg|3mg, single dose fed
46032645|NCT00970593|Drug|OAP-189|Group 1: OAP-189 BID (0.2 mg BID) x 7 days Group 2: OAP-189 (0.4 mg BID) x 7 days Group 3: OAP-189 QD (0.9 mg x 7 days followed by 1.2 mg x 7 days; MR formulation) Group 4: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; MR formulation) Group 5: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation) Group 6: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation)
46032646|NCT00970593|Drug|placebo comparator|Group 1 & 2: PBO x 7 days BID Group 3: PBO QD x 14 days Group 4: PBO QD x 14 days Group 5: PBO QD x 14 days Group 6: PBO QD x 14 days
46032647|NCT04167553|Drug|HM15136|In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.
45338744|NCT00576927|Drug|Ramelteon|Subjects demonstrating low sleep efficiencies and prolonged sleep latencies, will be randomly assigned to continue to receive SHI accompanied by either placebo or Ramelteon (8 mg). Matching placebo will be obtained and the medication pre-packaged and ordered based on the randomization results.
45472444|NCT05064683|Other|white noise|Newborns in the control group did not receive any treatment other than routine applications while receiving nasal CPAP support in the neonatal intensive care unit.The newborns in the faciliated tucking group were given supine, prone, and lateral positions for 24 hours, depending on their clinical status.The newborns in the white noise group were listened to white noise for 24 hours using an Mp3 player and a decibel measuring device to measure the sound level.
45472445|NCT03880175|Behavioral|FCC (Força à Comunidade e Crianças) program- direct beneficiary|Households are directly linked to the FCC implementing organization
45472446|NCT03880175|Behavioral|FCC (Força à Comunidade e Crianças) program- non-direct beneficiary|Households live in FCC implementing communities but are not directly linked to the FCC implementing organization
45472447|NCT03880175|Behavioral|Anti Stigma Information|Adults in the households are provided anti-stigma information
45338745|NCT00576927|Drug|Placebo|
45338746|NCT05742087|Other|Clinical examination|The examination performed by the clinician of the patient will be analyzed from the cohort as previously explained.
45338747|NCT05742087|Other|electroneuromyography (ENMG)|Data from the ENMGs will be extracted from the cohort and analyzed.
45338748|NCT04003506|Drug|Liposomal bupivacaine|LIA with ACB will be given using 10ml of 1.33% liposomal bupivacaine + 10ml 0.5% standard bupivacaine
45338749|NCT04003506|Drug|Bupivacaine Injection|LIA with ACB will be given using 20ml 0.5% standard bupivacaine
45338750|NCT05674578|Behavioral|Patient Navigation|Assigned a patient navigator and receive coaching
45338751|NCT05674578|Other|Quality-of-Life Assessment|Ancillary studies
45338752|NCT05674578|Other|Questionnaire Administration|Ancillary studies
45338753|NCT02580630|Behavioral|Reduction in running and jumping|Advocate to avoid running and jumping sports for the first 3 months, thereafter slowly progressing to normal sport activity.
45472448|NCT03880175|Behavioral|HIV/AIDS Information|The households receive information about HIV infection and AIDS
46032648|NCT04167553|Drug|Placebo|In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.
46032649|NCT02657395|Device|PriMatrix|Use of PriMatrix under a coronal positioned flap to obtain root coverage.
46032650|NCT04168411|Procedure|Symptomatic Treatment|Conservative treatment methods of tuberosity fractures of the proximal fifth metatarsal
46032651|NCT02861469|Other|Semi-structured interviews|individual semi-structured interviews with general practitioners and family members
46032652|NCT04168099|Drug|Cefotaxime|Cefotaxime IV
46032653|NCT04168099|Drug|Gemifloxacin|Gemifloxacin oral
46032654|NCT04283877|Drug|Methylphenidate|3 x 10 mg oral tablets. Single acute dose for all participants
46032655|NCT04283877|Drug|Placebo oral tablet|3 x 10 mg oral lactose tablet for all participants
46032656|NCT02650453|Procedure|Deep venous reconstruction|PTA & stenting with/without endophlebectomy and/or arteriovenous fistula creation
46032657|NCT00962013|Device|Restoration® Modular Revision Hip System|Restoration® Modular Revision System
45472449|NCT03880175|Behavioral|ART Information|The households receive information about antiretroviral therapy.
45472450|NCT03880175|Behavioral|HIV/AIDS and ART Information Combined|The households receive both information about HIV/AIDS and information about antiretroviral therapy.
46032658|NCT02650375|Drug|Metatinib Tromethamine|Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred.
46032659|NCT02652715|Other|Laboratory Biomarker Analysis|Correlative studies
46032660|NCT02652715|Other|Quality-of-Life Assessment|Ancillary studies
45682991|NCT03471442|Drug|Opioids|Intra-operatively, opioids will be titrated to heart rate and spontaneous respiration rate e.g. fentanyl, morphine, hydromorphone. Post-operatively in post anesthesia care unit, morphine and hydromorphone will be titrated to effect as necessary. After discharge from post anesthesia care unit, oral analgesia will be administered on an as required basis e.g. acetaminophen, non-steroid anti-inflammatory medications, acetaminophen / codeine and acetaminophen / oxycodone.
45338754|NCT02580630|Other|Training|Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then week 3, 6, 10. The patient will register all training on a diary and on an App.
45338755|NCT02580630|Drug|Ultrasound guided injection with Glucocorticosteroid|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml. Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
45682992|NCT03471442|Drug|Anesthetics, Local|Weight-based dosing of this local anesthetic mixture.
45682993|NCT01679392|Drug|Ropivacaine|Unilateral, single shot, ultrasound-guided, transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
45338756|NCT02580630|Drug|Ultrasound guided injection with local anaestethic|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml of intralipid (for blinding). Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
45472451|NCT03880175|Behavioral|High coupon value|The HIV testing coupons distributed to households in this group have higher values.
45682994|NCT01679470|Device|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions.
45682995|NCT04279912|Device|Focused Ultrasound (MRgFUS) for the Management of Tremor in Patients With Multiple Sclerosis|The intervention is MRIgFUS thermal ablation of the ventral intermedius (Vim) thalamus contralateral to the most affected side of the body.
45682996|NCT03083158|Drug|Hepatitis B vaccine|1.0 ml (20 micrograms) suspension of hepatitis B surface antigen for intramuscular injection
46032661|NCT02652715|Other|Questionnaire Administration|Ancillary studies
46032662|NCT02652715|Dietary Supplement|Salvia hispanica Seed|Given PO
46032663|NCT04283487|Dietary Supplement|Fructans|500ml 0.9% normal saline containing 40g fructans
46032664|NCT04283487|Dietary Supplement|Glucose|500ml 0.9% normal saline containing 40g glucose
46032665|NCT04283487|Dietary Supplement|Saline|500ml 0.9% normal saline
46032666|NCT02657317|Behavioral|FORT-A|FORT-A is based on a functional restoration paradigm of pain management in which treatment is interdisciplinary and designed to achieve a functional goal (often specified by the patient; e.g., doing more with family, returning to work). FORT-A includes intensive functional rehabilitation, group-based pain management intervention, and individual interventions tailored to the patient's specific needs (e.g., biofeedback for stress, individual psychotherapy for mood or trauma symptoms).
45338757|NCT00698841|Drug|Cetuximab|Cetuximab administered by intravenous (IV) infusion at an initial dose of 400 mg/m^2 over 120 minutes on Day 1 followed by a weekly maintenance IV dose of 250 mg/m^2 over 60 minutes.
45338758|NCT03787290|Drug|Tocilizumab|participants will receive a single subcutaneous injection of tocilizumab (162 mg)
45338759|NCT03787290|Drug|Placebo|participants will receive a single subcutaneous injection of saline
46032667|NCT02657317|Other|VA Treatment as Usual|VA TAU includes referrals for specialty intervention, rehabilitation, and behavioral health intervention within the VA medical system. Some participants may be referred for care outside of the VA system. The South Texas Veterans Health Care System offers a wide range of pain management services.
46032668|NCT04283331|Drug|Proparacaine Ophthalmic|Each subject will have one eye randomized to receive a bandage contact lens soaked in anesthetic solution (proparacaine hydrochloride 0.5%) and the following eye will serve as a control and receive a bandage soft contact lens soaked in balanced salt solution, which is the current standard of care for PRK.
46032669|NCT02657473|Drug|tobramycin inhalation solution|
45338760|NCT03787290|Device|Whole-Body Hyperthermia|subjects' core temperature will be increased to 38.5 degrees Celsius (typically 60-120 minutes) then they will begin a 60-minute cool-down phase
46032670|NCT02657473|Drug|Saline 0.9% inhalation solution|
45338761|NCT00577395|Drug|placebo|oral tablet once a month for 12 months
45338762|NCT00577395|Drug|risedronate|tablet, 150 mg once a month for 12 months
45338763|NCT05055843|Procedure|Magnetic Resonance Imaging|Undergo 3D MRI
45338764|NCT04062357|Drug|Lidocaine 5% spray|Group 1 (n₌75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (1-2 ml) of lidocaine 5% sprays; contain 5 -10 mg of lidocaine, in a metered dose aerosol-delivery system).
45338765|NCT04062357|Other|Placebo|Group 2 (n₌75); was given placebo in form on demand alcohol spray for 8 weeks.
45338766|NCT04482309|Drug|Trastuzumab deruxtecan|Trastuzumab deruxtecan by intravenous infusion
45338767|NCT05190120|Procedure|Femoral Nerve Block|Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
45338768|NCT05190120|Procedure|Adductor Canal Nerve Block|Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
45472452|NCT01264913|Behavioral|sleep extension & circadian alignment|Both groups of workers will undergo a 1-week period of fixed bedtimes, light-dark cycles and mealtimes in the laboratory to pay the sleep debt and align the circadian system
46032671|NCT04281459|Other|HIV Treatment Satisfaction Questionnaire status|Administration of pseudoanonymous HIV-TSQs (translated into Italian) to all included patients.
46032672|NCT02652637|Drug|neomycin, metronidazole, polyethylene glycol (PEG)|
46032673|NCT02861079|Device|Foley catheter|An 18-F Foley catheter will insert into the endocervical canal and the balloon will fill with 30 mL of saline solution.
45338769|NCT05190120|Drug|preoperative Femoral Nerve Block using 20ml of 0.5% ropivacaine|
45338770|NCT05190120|Drug|Preoperative Adductor canal block with 0.75%% ropivacaine 13.3ml.|
45682997|NCT04277416|Device|Total Hip Arthroplasty|To evaluate Implant survival based on removal or intended removal of any component of the Entrada™ Hip System at five years of follow-up.
46032674|NCT02861079|Drug|PGE2|10 mg PGE2 vaginal ovul (Propess,Ferring®) will place high into the posterior vaginal fornix.
45472453|NCT01264991|Procedure|Arthroscopic partial meniscectomy|The arthroscopic partial meniscectomy will be performed on an outpatient basis by experienced surgeons at a level of at least attending physicians or at the last year of residency. All arthroscopies will be performed in general anaesthesia combined with local anaesthesia. After general anaesthesia is induced, the knee will be examined for stability. Thereafter two standard portals on the lateral and medial side of the ligamentum patella will be created but no outflow cannula inserted. An arthroscope will be used with a pressure-controlled irrigation system. Tourniquet use will be according to surgeon preference. The strategy for the meniscectomy will be to preserve as much tissue as possible. A standard operation protocol will be used to document possible findings in cartilage, ligaments, synovium and the medial and lateral meniscus. Meniscus lesions and type of will be registered and changes in the articular cartilage will be classified according to the ICRS classification
45472454|NCT01264991|Procedure|Sham procedure|The placebo procedure will be performed under the same conditions as above. The patient will be fully sedated in general anaesthesia. As above, the stability of the knee will be examined. Local anaesthetic will be applied as above and 2 skin incisions will be made at the same location and the same size as above. Then the knee will be manipulated as if a real arthroscopy were being done, the spillage of water and all the other equipment needed for an arthroscopy will be used and manipulated. No instruments will enter the portals for arthroscopy to avoid the possibility of osteochondral lesions and unwanted interventions by the surgeon.
45472455|NCT01158599|Biological|IXIARO®|IXIARO®, 0.5 ml (6 µg), intramuscular (i.m.) injection, two vaccinations, Days 0 and 28
45682998|NCT03083236|Other|Standard PBI|Standard Parent Based Intervention (PBI)
45682999|NCT03083236|Other|Enhanced|Enhanced Parent Based Intervention (EPBI)
45683000|NCT03082924|Device|Control group|Neither cycle training nor inspiratory muscle training.
45683001|NCT03082924|Device|Calibrated cycle ergometer|The most common device to perform cycle training is calibrated cycle ergometer.
45683002|NCT03082924|Device|Threshold loading device|Threshold loading device is used to perform inspiratory muscle training.
46032675|NCT02652403|Device|Complete conventional dentures|"The typical operations of conventional technique will be carried out dentures fabrication and clinical appointments and laboratory steps will be necessary until denture insertion:~Preliminary impression using irreversible hydrocolloid in a stock trays; Individual acrylic resin trays fabrication; Functional impressions using Zinc oxide-eugenol paste and low fusion compound in a individual acrylic resin trays; Maxillary occlusion rims fabrication; Maxillary occlusion rims fabrication adjustments, Centric relation records and transference of the maxillary occlusion rims positions to semiadjustable articulators using a facebow; Setting of teeth in wax; Complete denture wax try-in; Insertion, instructions and postinsertion appointments."
46032676|NCT02652403|Device|Complete simplified dentures|For a complete simplified denture fabrication, individual acrylic resin trays fabrication and functional impressions steps will be deleted, and the facebow for transference of the maxillary occlusion rims positions to semiadjustable articulators will be replaced by the table Camper.
46032677|NCT02861157|Behavioral|Planet T1D|Planet T1D is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' type 1 diabetes disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
46032678|NCT00649675|Drug|Meloxicam Tablets 15 mg|15mg, single dose fed
46032679|NCT00649675|Drug|Mobic® Tablets 15 mg|15mg, single dose fed
46032680|NCT04283565|Other|Systematic screening of AOMI by BPI measurement.|The strategies will be associated according to a 2*2 factorial design in order to obtain 4 arms
46032681|NCT04283565|Other|Management of CVRF by a motivationnal interviewing.|The strategies will be associated according to a 2*2 factorial design in order to obtain 4 arms
46032682|NCT02652559|Device|Transcutaneous measurements of PCO2|PCO2 will be measured transcutaneously with an ear lobe sensor before initiation of NIV, and during the initiation period (SenTec DM®, Software V-STATS 4.0; SenTec AG; Therwil, Switzerland)
46032683|NCT02652559|Device|Telemonitoring|Telemonitoring will be used to send data from the transcutaneous measurements, data from the EMG measurements and data from the ventilator from home to the hospital.
46032684|NCT02652559|Device|EMG|Surface EMG of the respiratory muscles will be used to monit patients in both groups as a surrogate marker of respiratory muscle unloading and to detect PVA during NIV
45683003|NCT03082924|Device|Calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
46032685|NCT02652559|Other|Home initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
46032686|NCT02652559|Other|Inhospital initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
46032687|NCT02860923|Drug|Exenatide|
46032688|NCT02860923|Drug|Placebo|
46032689|NCT04166461|Other|Not application, observational study|Not application, observational study
46032690|NCT02861001|Device|conventional bronchoscopy|optical guidance of percutaneous tracheotomy is done by conventional bronchoscopy
45338771|NCT02581332|Behavioral|Mindfulness Meditation Training|Training will be held in groups of up to five participants. All of the participants within this group will receive up to 6 days (20m/d) of meditation training to be administered over 15 days. This is a paradigm similar to one employed in previous studies.
45338772|NCT03896061|Device|Laparoscopic sleeve procedures|Laparoscopic sleeve procedures with powered stapler
45472456|NCT01156649|Device|PAP therapy|Nightly use of automatic positive airway pressure delivered at therapeutic levels and to be delivered through a nasal interface device selected to maximize comfort for each child.
45683004|NCT01679704|Dietary Supplement|Food products|
46032691|NCT02861001|Device|VivaSight-SL tube|optical guidance of percutaneous tracheotomy is done by the VivaSight-SL tube
46032692|NCT04168021|Behavioral|Leg ischemia|potential neuroprotection of ischemia/reperfusion of a peripheral organ or tissue against cerebral I/R injury
45338773|NCT00738374|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv on day 1 of course 3; 500mg/m2 iv on day 1 of courses 4-8 (induction phase); 375mg/m2 iv every 8 weeks (maintenance phase).
45338774|NCT00738374|Drug|chlorambucil|8mg/m2 po on days 1-7 of courses 1-8
46032693|NCT04032769|Other|MODS (MOdified Diagnostic Strategy)|"Modified diagnostic strategy (MODS):~All included patients will be tested with quantitative D-dimer. The MODS work-up strategy will be based on YEARS rule, that included three criteria (hemoptysis, signs of DVT, PE is the most likely diagnosis)~- If all YEARS criteria are absent, the threshold of D-Dimer for ordering a CTPA will be raised at 1000 ng/ml.~If at least one criterion of YEARS is present, then the D-dimer threshold for ordering a CTPA will be as usual (500 ng/ml, or agex10 for patients aged 50 and over)"
45338775|NCT05325450|Procedure|Program A|Presentation of the sentence to the implant alone
45338776|NCT05325450|Procedure|Program B|Presentation of the sentence to the implanted ear, associated for the non-implanted ear
45338777|NCT05325450|Procedure|Control|Presentation of the sentences alternately to the most recently implanted ear and both implanted ears at the same time
45683005|NCT04273360|Other|Systematic use group|Patients in this group will be subjected to initial systematic PR, which will be re-evaluated every day every day between day 0 and day 14
46032694|NCT00970359|Biological|AZD6244|"Within 1 week of starting the study: Low iodine diet~The patient will receive three bottles of capsules containing the drug AZD6244. Each capsule contains 25 milligrams of AZD6244. They will take 3 capsules orally, by mouth twice a day for 4 weeks. AZD6244 should be taken on an empty stomach (either one hour before or 2 hours after meals). AZD6244 capsules should be taken with water only. Lesional dosimetry with iodine-124 PET will be done twice, at the beginning and at the end of the study. This is done the same way that a radioactive iodine scan is done and is spread out over 5 days. It requires injection with human recombinant TSH (Thyrogen) on day 1 and 2, as well as blood tests on day 1 and day 5. On day 3, you will receive the iodine-124 in form of an oral drink, and the PET scan will be obtained on day 5. You will need to follow a low iodine diet starting 5 days before and throughout the process."
46032695|NCT01121406|Drug|Paclitaxel|Patients receive paclitaxel in a 4 week schedule
46032696|NCT01121406|Drug|Gemcitabine|Patients receive gemcitabine in a 3 week schedule
46032697|NCT01121406|Drug|Topotecan|Patients receive topotecan in 3 or 4 week schedule
45683006|NCT04273360|Other|Restrictive use group|Patients in this group will be subjected to PR only in case of severe agitation, defined by a RASS ≥ +3 on any given day between day 0 and day 14
45683007|NCT03083080|Procedure|VATS|VATS is the abbreviation of video-assisted thoracic surgery, which aims to minimize the wound for thoracic surgery and to enhance patient recovery after surgery
45683008|NCT03083080|Drug|Ropivacaine|30 mL 0.5% ropivacaine is used to achieve VATS block
46032698|NCT01121406|Drug|Pegylated liposomal doxorubicin (PLD)|Patients receive PLD in a 4 week schedule
46032699|NCT01121406|Drug|BI 6727|Patients receive BI 6727 infusion every 3 weeks
46032700|NCT02650141|Drug|ziyinxiehuo Granules|"Ziyinxiehuo granules Herbs (1 bag ): shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g Therapeutic Principle: Nourishing Yin, removing Fire Usage: administered after dissolved, 3 times per day after breakfast and supper"
46032701|NCT02650141|Drug|zishenqinggan Granules|"Zishenqinggan granules Herbs (1 bag ): Shengdi 5g, baishao 3g, huangqin 3g, fuling 4g, danpi 3g, maiya 6g, shanzha 3g, zhebei 3g, zhigancao 2g Therapeutic Principle: replenishing Kidney, Clearing Liver Usage: administered after dissolved, 3 times per day after breakfast and supper"
46032702|NCT02657239|Behavioral|MOVE UP|Weight management behavioral program
46032703|NCT02652325|Drug|Saline|
45472457|NCT01156649|Device|Sham PAP therapy|During sleep, the sham PAP device will administer a constant pressure of subtherapeutic air (approximately 1 cm of water) through a custom fit nasal interface chosen for the child's maximum comfort.
45683009|NCT03083080|Drug|Epinephrine|1:400000 epinephrine is mixed with ropivacaine (local anesthetic) to reduce the risk of local anesthetic systemic toxicity
45683010|NCT03087760|Drug|Pembrolizumab|Concurrent Pembrolizumab after proton reirradiation
45751994|NCT04303650|Device|Ultrasound measurement of quadriceps muscle layer thickness|With patient in supine position ultrasound will be performed using a 12MHZ Transducer connected to Sonosite M Turbo machine. The probe will be placed perpendicular to the long axis of the thigh on its anterior surface at the two thirds of the length between the anterior superior iliac spine and the upper border of the patella. After identifying the muscle tissue, the thickness of the quadriceps muscle will be obtained by measuring the distance between the cortex of femur and the most superficial muscular fascia. Measurements will be performed by applying maximal compression on the probe without inflicting pain to prevent underestimation of muscle wasting linked to subcutaneous edema. measurements will be made on both sides repeatedly on ICU days 1, 3, 7, and 10. Every time three ultrasound measurements will be taken per site and the average of three measurements for each site will be used and combined to provide total muscle depth
46032704|NCT02652325|Drug|Povidone-Iodine|
46032705|NCT02652325|Drug|5% Povidone-Iodine USP swabs|
46032706|NCT00960687|Drug|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered 30 minutes after the initiation of a standard breakfast.
45839426|NCT03011580|Dietary Supplement|Fultium-D3|Fultium-D3 (oral cholecalciferol or vitamin D3) will be given to participants in the immediate supplementation arm at a dose of 9,600 IU/day for 8 weeks at V2. At V3, all participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day.
45839427|NCT03011580|Dietary Supplement|Placebo|3 capsules of placebo will be given daily to participants in the delayed supplementation arm for 8 weeks at V2.
45839428|NCT03011190|Behavioral|Emotional regulation|Educate people with difficulty in regulating their emotions and help them acquire skills to do so
45839429|NCT03010878|Other|Yoga|"The yoga intervention group addressed pain as a primary variable and balance as a secondary variable and how to best manage these symptoms in the clinic and community.~Yoga was delivered in sitting, standing, and floor postures"
45839430|NCT03010878|Other|Self-management|The self-management education group was provide once a month through University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic. The program consisted of lifestyle variations, accountability, modifications, and strategies to management pain in daily life.
45839431|NCT03011112|Procedure|Observational procedure|All the patients will undergo a standard observational procedure: i) diagnosed with KOA; ii) take a radiographic examination (x-ray); iii) assessed by WOMAC; iv) take an physical examination to avoid other disease; iv) take a gait examination on a treadmill in barefoot.
46032707|NCT00960687|Drug|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered 30 minutes after the start of a standard breakfast.
46032708|NCT00920140|Drug|GSK1120212|Starting dose based on GSK protocol MEK111054 and then dose escalation based on Dose Limiting Toxicities per protocol.
46032709|NCT00920140|Drug|GSK1120212|Dose will be maximum tolerated dose based on Phase I results.
46032710|NCT00649753|Procedure|Category II Pelvic Blocking|Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction.
46032711|NCT00649753|Procedure|Category II Pelvic Blocking and Cranial|Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction. During pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
45472458|NCT01158755|Drug|Moxifloxacin|Subjects on both arms will further be randomized into receiving moxifloxacin either in standard dose (400 mg p.o.), high dose (800 mg p.o.) of moxifloxacin, or not receiving moxifloxacin (ethambutol 750 mg p.o., instead) Intervention drug will be given for 14 days, and the drug will be switched to ethambutol 750 mg p.o. (in accordance with National TB Program)
45472459|NCT01158833|Other|classification of gait in diplegic children with CP|To determine the criterion validity of the classification of the pattern of diplegic gait proposed by Ferrari et al. we correlated gait patterns with the score of the FMS.
45839432|NCT03010722|Drug|Regorafenib|"Patients meeting all of the inclusion criteria and none of the exclusion criteria will receive regorafenib 160 mg orally (po) od for 3 weeks of every 4-week cycle. Each cycle will comprise 3 weeks of treatment followed by 1 week without treatment, hereafter described as 3 weeks on/1 week off. Each 160-mg dose will include four regorafenib 40-mg tablets."
45839433|NCT03010644|Other|n/a - observational study|n/a - observational study
45839434|NCT03010098|Device|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46
45839435|NCT03010098|Device|Open-Loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
46032712|NCT00649753|Procedure|Cranial Only|Without pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
45338778|NCT04076982|Dietary Supplement|mung bean protein|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
45338779|NCT04076982|Other|control biscuit|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
45839436|NCT03010332|Biological|Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)|ATA230 (third-party donor-derived CMV-CTLs) are cytotoxic T lymphocytes that specifically kill cells presenting CMV protein antigens.
45839437|NCT03010020|Behavioral|PCC|Personalized Cognitive Counseling (PCC) sessions will be delivered as described above.
45338780|NCT04088474|Dietary Supplement|Vigiis 101-LAB|examined the effects of the Vigiis 101-LAB capsules (5 billion CFU/day)
45338781|NCT04088474|Dietary Supplement|Placebo|Maltodextrin was used as a placebo
45338782|NCT05016999|Dietary Supplement|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion)
45751995|NCT04303416|Drug|Albumin solution|plasma exchange with albumin, one per week for one month, then one per month for 5 months
45839438|NCT03010020|Behavioral|Traditional Counseling|GC/CT-infected participants in the standard of care arm (and all GC/CT-negative participants screened for infection) will receive standard post-test counseling in accordance with Peruvian Ministry of Health guidelines.
45751996|NCT05330286|Drug|LMI070|oral solution
46032713|NCT01120782|Device|etafilcon A toric contact lens with new wetting agent|Investigational toric contact lens made of etafilcon A material with a new wetting agent.
45839439|NCT03009864|Drug|Tangshen Prescription|The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
45839440|NCT03009864|Drug|Placebos|Treatment with placebo corresponding to each dose of Tangshen Prescription , every bag weighs 4.87g, take it one bag each time, two times a day.
45839441|NCT03009708|Other|Blood samples|Two blood tubes will be collected each week during 8 weeks maximum for the present study. Samples will start at day 30 post-graft and finish at day 90 post-graft maximum.
45839442|NCT03009630|Procedure|RFA|Patients diagnosed with early-stage NSCLC and signing the informed consent will be performed RFA under the guidance of ENB.
46032714|NCT01120782|Device|etafilcon A toric contact lens|Marketed toric contact lens made of etafilcon A material.
46032715|NCT02650297|Other|combined decongestive therapy|Patients in the intervention group received treatment with combined decongestive therapy and pneumatic compression pump. Patients in the control group received no treatment for lymphedema but were placed on the waiting list for combined decongestive therapy and pneumatic compression pump as soon as possible after the 8 weeks follow-up period.
46032716|NCT02650297|Device|pneumatic compression pump|Intermittent pneumatic pump or pressure therapy is not as a part of CDT, but it can be used as an adjunct method. This device intermittently and according to a specific program is air filled and emptied. The device leads the lymphatic fluid from distal to the proximal part of extremities and then to the trunk
46032717|NCT04032847|Biological|ATL001|ATL001 infusion
46032718|NCT04032847|Drug|Pembrolizumab|Checkpoint inhibitor
45338783|NCT02594930|Procedure|synovial biopsy of total knee arthroplasty|synovial biopsies are taken via two different techniques in the same patient to allow direct comparison of results
45338784|NCT02581176|Drug|Apixaban|
45338785|NCT03746184|Other|Treatment course|Pursued treatment for knee OA, including type of health care provider, time period of treatment course, and types of treatments received, will be recorded via the patient-reported questionnaire.
45338786|NCT04075500|Device|24-h Holter monitoring|Patients will be randomized to either receive 24-h Holter monitoring or receive one of the two modes for prolonged ECG recording (interventional arms). There are two interventional arms. Patients will either undergo 28-day ECG recording using a commercially available Holter recorder that can function as a non-invasive ECG patch or receive an implantable cardiac device (REVEAL LINQ).
45338787|NCT03967626|Device|external cooling with the xxxxx device|external cooling with the xxxxx device
45751997|NCT05330286|Drug|LMI070|Oral solution
45751998|NCT05330286|Drug|LMI070|Oral solution given in fasted state
45751999|NCT05330286|Drug|LMI070|Oral solution given in fed state
45839443|NCT03009630|Device|ENB|ENB will be used to guide bronchoscope into the accurate location of the lesion during RFA.
45839444|NCT03009786|Other|Measurement of salivary flow|A compress of about 0.95 g which is weighed and then placed under the tongue of the subject for 5 minutes. Once the time has elapsed, the compress is weighed, a simple subtraction determines the weight of saliva produced in 5 minutes
46032719|NCT04203862|Drug|NPC-22|Single administration of low dose NPC-22
46032720|NCT04203862|Drug|NPC-22|Single administration of low/middle dose NPC-22
46032721|NCT04203862|Drug|NPC-22|Single administration of middle dose NPC-22
46032722|NCT04203862|Drug|NPC-22|Single administration of middle/high dose NPC-22
46032723|NCT04203862|Drug|NPC-22|Single administration of high dose NPC-22
46032724|NCT04203862|Drug|NPC-22 Placebo|Single administration of NPC-22 Placebo
46032725|NCT01120626|Drug|donepezil|donepezil (2.5 mg to 10.0 mg per day for 12 weeks)
46032726|NCT01120626|Drug|sugar pill|sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
45754688|NCT03474731|Behavioral|Tailored Patient Navigation (PN) only|Tailored Patient Navigation (PN) only: The goal of this arm of the project is to try to get participants to attend their recommended medical appointments. PN has been shown to improve health behavior and increase self-efficacy, all with low costs. We will have to add an additional eligibility criterion for this group-they have to be out of compliance with medical appointments. Most participants will need PN services, owing to missed, rescheduled, or infrequent appointments. This means not attending their office visits, as recommended, which typically is every 3 months. We will interact with them to verify attendance and, at times, to access patient medical records if needed.
46032727|NCT04252534|Combination Product|PRP combined Magnovision|The rEMS helmet is used to stimulate the retina and visual pathways. (MagnovisionTM) combined with subtenon platelet rich plasma injection
45338788|NCT05119608|Behavioral|CBT/ACT|10-session ACT-re-enforced CBT intervention.
46032728|NCT04252534|Biological|PRP|Fresh autologous platelet rich plasma, injected subtenon space.
46032729|NCT00650377|Drug|Finasteride Tablets 5 mg|5mg, single dose fed
46032730|NCT00650377|Drug|Proscar® Tablets 5 mg|5mg, single dose fed
46032731|NCT05115370|Other|Semi-structured qualitative interview|A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
46032732|NCT02649985|Drug|[F-18]PBR06|PET radiopharmaceutical
46032733|NCT02649985|Drug|[C-11]PBR28|PET radiopharmaceutical
46032734|NCT02650063|Drug|DE-117|
46032735|NCT02649751|Drug|Roscovitine|Roscovitine is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9. Seliciclib is a 2,6,9-substituted purine analog.
45472460|NCT03879785|Other|Screening|Screening and validation of assessment tool translated into Spanish
45338789|NCT00697593|Drug|Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)|Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1mg/kg/week for up to 12 weeks.
45752000|NCT05532462|Procedure|Trans-nasal complete nasalabial cyst excision|The surgery is carried out mainly using x5 magnification loupe and 0° degree sinoscope. Submucosal infiltration (lidocaine 2% and 1:100,000 adrenaline). An incision was made at the mucosal covering of the cyst wall and nasal floor in a transverse and anteroposterior direction. The mucosal flap is elevated and separated from the cyst wall and reflected toward the septum side. During dissection, cyst content is usually drained. The whole cyst wall was carefully dissected with sharp and blunt dissection from the mucous membrane, and laterally from the premaxillary area. Finally, endoscopic examination to check the operative bed and refashioning mucosal flap coverage. If mucosal flap is lacerated, then excised and operative bed left for healing by creeping from surrounding edges. Endoscopic trans-nasal complete excision has a shorter operative time, minimal intraoperative bleeding, and no postoperative pain or edema reported.
45338790|NCT04183452|Drug|17-Hydroxyprogesterone Caproate 250 mg IM Dose|17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
46032736|NCT02649751|Drug|Placebo|The placebo treatment is lactose capsule.
46032737|NCT04252300|Drug|Rosuvastatin|Single dose of 5 mg rosuvastatin is administered as tablet orally on Day 1 of Period 1 (total length = 5 days).
46032738|NCT04252300|Drug|Rosuvastatin + BAY1817080|A single dose of 5 mg rosuvastatin tablets is administered on Day 8 of Period 2 (total length = 15 days). BAY1817080 is administered as tablets twice daily on Days 1 to 14 of Period 2.
46032739|NCT02649595|Other|Red Cross Respite care|See detailed description.
46032740|NCT04256746|Other|Boiled Rice|
46032741|NCT04256746|Other|Boiled Rice+0.37 gr mulberry fruit powdered extract|
46032742|NCT04256746|Other|Boiled Rice+0.75 gr mulberry fruit powdered extract|
46032743|NCT04256746|Other|Boiled Rice+1.12 gr mulberry fruit powdered extract|
46032744|NCT04256746|Other|Boiled Rice+1.50 gr mulberry fruit powdered extract|
46032745|NCT04256746|Other|Rice Porridge|
46032746|NCT04256746|Other|Rice porridge+1.50 gr mulberry fruit powdered extract|
45338791|NCT04183452|Drug|17-Hydroxyprogesterone Caproate 275 mg SC Dose|17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth
45338792|NCT05012475|Behavioral|Modified Virtual Reality Gaming|Investigators customize each gaming session based on the motivators and interests of each participant. The intervention facilitates independent hand separations (minimizing stereotypies) and encourages independent arm/hand movement that serves to activate or control the computer-generated activities.
45472461|NCT03879707|Drug|Melatonin 5 mg|Melatonin is known to induce sleep
45472462|NCT03879707|Drug|Placebo Oral Tablet|Placebo
45338793|NCT05325021|Diagnostic Test|Axial length measurement in millimeter (mm) by optical biometry device|Axial length measurement of the anisometropic eye and the fellow one in millimeter (mm) by optical biometry device.
46032747|NCT04167319|Other|QST and PRO measurements during treatment|We will observe the natural course of CIPN using multiple measurements
45338794|NCT05325021|Diagnostic Test|Autorefractometer to measure the refractive error in both eyes.|Measurement of the refractive state of both eyes for each subject to asses the refractive error in diopter (D).
45472463|NCT03879707|Drug|Magnesium 500Mg Oral Tablet|Magnesium plays a role in supporting deep, restorative sleep by maintaining healthy levels of GABA, a neurotransmitter that promotes sleep. Research indicates supplemental magnesium can improve sleep quality, especially in people with poor sleep
45472464|NCT01265069|Drug|high dose dual therapy|rabeprazole 20mg qid,amoxicillin 750mg qid for 14days
46032748|NCT04256668|Diagnostic Test|Obtaining one or semen samples|Through staining of semen samples with sets of dyes to measure features of chromatin density, nuclear morphology and mitochondrial status in large numbers of single spermatozoa and to compare differences in the staining results with known fertility outcome. Through comprehensive comparative epigenetic studies we anticipate to explain different efficiencies of sperm from men with seemingly normal semen quality in driving embryonic development.
45752001|NCT00352001|Drug|azacitidine|Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
45839445|NCT03009474|Drug|CJ-30060|Fixed-dose combination drug containing Amlodipine 5 mg and Valsartan 160 mg and Rosuvastatin 10 mg
46032749|NCT02649517|Procedure|Endomyocardial biopsy|Endomyocardial biopsy will be performed through a puncture in the femoral vein. 3-6 samples taken under the control of myocardial echocardiography or flyuroskopii. Samples of biopsy material then transmitted Pathomorphology for immunohistochemistry, light microscope.
45338795|NCT04075578|Drug|OnabotulinumtoxinA / Botox®, Allergan Ltd, Irvine, CA, United-States|Botox® intradetrusor injections, with a rigid cystoscope, under local anaesthesia performed by Lidocaïne 2% diluted in 30ml of bicarbonate 14‰. 20 injections of 0,5ml each will be heterogeneously administrated into the bladder wall, sparing the trigone
45338796|NCT05741931|Device|mobile application REST (Risk identification, Evaluation counseling, Systematic monitoring, Troubleshooting)|The mobile application will be installed on the mobile phone. The application is used to monitor pregnant women. Users of the application are midwives and pregnant women. The application contains documentation of the health condition of pregnant women.
45338797|NCT04445025|Drug|Elagolix 200 MG|Elagolix 200mg twice daily orally for 60 days prior to beginning frozen embryo transfer preparation
45472465|NCT01265069|Drug|concomitant therapy|rabeprazole 20 mg,amoxicillin 1000 mg,metronidazole 500 mg,clarithromycin 500 mg, bid for 10 days
45598793|NCT04409561|Device|Blood collection|9 mL K3-EDTA anticoagulated venous whole blood and 9 mL lithium heparin anticoagulated venous whole blood will be collected, processed in plasma and stored until the shipment to the sponsor for PSP measurement on the abioSCOPE device with IVD CAPSULE PSP kits
45598794|NCT03149913|Device|SequentPlease OTW paclitaxel coated balloon catheter|PTA with SequentPlease OTW paclitaxel coated balloon catheter
46032750|NCT00924508|Device|hydrogel patch|occlusion of eczema with a hydrogel patch composed of an adhesive, thin, flexible, hydrogel layer on an impermeable urethane surface.
46032751|NCT00924508|Drug|Triamcinolone (TAC) 0.1% cream|Triamcinolone Acetonide (triamcinolone acetonide cream) is a topical corticosteroid used as anti-inflammatory and antipruritic agent. Each gram of TAC Cream USP, 0.1% contains 1 mg Triamcinolone Acetonide (triamcinolone acetonide cream) in a cream base consisting of cetyl alcohol, glyceryl monostearate, cetyl esters wax, isopropyl palmitate, polysorbate-60, polysorbate-80, propylene glycol and purified water.
46032752|NCT00650923|Drug|ziv-aflibercept|Given IV
45472466|NCT01158989|Device|PillCam|Within four days of hospital admission, qualifying critically ill patients were assigned to the study and received a gastro-jejunal tube and one PillCam video telemetry capsule (Given Imaging Ltd., Yoqneam, Israel). In each critical care patient, placement of the video capsule was coupled with the placement of the medically necessary feeding tube. A flexible endoscope was inserted into the patient's mouth, and then advanced into the esophagus, stomach, and upper small intestine. The capsule was placed into a capsule delivery device and released into the distal duodenum after it had passed beyond the sight of the scope; a wire was placed to facilitate passage of the feeding tube. An abdominal X-ray was obtained to confirm feeding tube tip placement.
45472467|NCT01265147|Drug|Cisplatin|40mg/m2/w
46032753|NCT00650923|Procedure|radiation therapy|Undergo RT
46032754|NCT00650923|Drug|temozolomide|Given PO
45472468|NCT01265147|Drug|Nedaplatin|40mg/m2/w
45752002|NCT00352001|Drug|lenalidomide|Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
45752003|NCT00401401|Drug|zalutumumab|Eight weekly infusions
45752004|NCT00401401|Drug|cisplatin|Infusions
46032755|NCT00650923|Procedure|pharmacological study|Correlative studies
45472469|NCT03882281|Drug|HQP1351|Orally, single dose of 30mg on day 1 and day 8.
45472470|NCT01159145|Drug|D961H|Oral, capsule
45472471|NCT01159145|Drug|Omeprazole|Oral, tablet
45472472|NCT01156883|Drug|asparaginase|
45472473|NCT01156883|Drug|cyclophosphamide|
45472474|NCT01156883|Drug|cytarabine|
45752005|NCT00401401|Procedure|Radiotherapy|Daily in the treatment period
45752006|NCT00352781|Drug|nicotine replacement therapy|nicotine transdermal patches as per product monograph
45752007|NCT00352781|Behavioral|behavioural intervention|Smoking cessation counselling and relapse prevention
46032756|NCT00650923|Procedure|laboratory biomarker analysis|Correlative studies
45338798|NCT04445025|Drug|Leuprolide Acetate 3.75 MG/ML|Leuprolide Acetate intramuscularly every 28 days (twice) prior to beginning frozen embryo transfer preparation
45338799|NCT04445025|Diagnostic Test|Lab work|Serum follicle stimulating hormone (FSH), estradiol, luteinizing hormone (LH), progesterone, human chorionic gonadotropin (hCG), serum for microarray analysis, complete blood count, and chemistry panel with liver functions levels will be drawn via blood draw
46032757|NCT04241926|Diagnostic Test|transpolmonary thermodilution|Thermodilution was attempted via PICC and via CICC in the same patient
46032758|NCT02649205|Other|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
45338800|NCT02580474|Drug|Daclatasvir plus Asunaprevir|
45338801|NCT04061811|Diagnostic Test|Diagnostic biomarker study|Comparing circulating concentrations of NT-proBNP, GDF15, and neprilysin (NEP) along with NEP activity in patients with and without HF, as diagnosed by clinical parameters and post-dialysis echocardiography.
45338802|NCT04166604|Drug|Trifluridine/Tipiracil|"after morning and evening meal,~Days 1 through 5: 35mg/m2 (twice daily)~Days 6 through 7: recovery~Days 8 through 12: 35mg/m2 (twice daily)~Day 13 through 28: recovery~In case of first event of grade 3-4 neutropenia : patients will not have a dose reduction and will receive a secondary prophylaxis with G-CSF (filgrastim or lenograstim) during subsequent cycle: a starting 5 mg/kg/day dose of filgrastim or lenograstim as a single daily injection, for 5 days, from day 14 to day 18~In case of secondary event of grade 3-4 neutropenia despite G-CSF secondary prophylaxis, dose adjustment of trifluridine/tipiracil will be done according to Summary of Product Characteristics (SmPC). G-CSF secondary prophylaxis will be continuing with the reduction.~dose"
45338803|NCT00697515|Drug|LDX|oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting
46032759|NCT04256590|Diagnostic Test|Ultrasonography imaging|This study aimed to measure the tongue surface areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue surface areas.
46032760|NCT00637858|Dietary Supplement|Lyc-O-Mato 5mg|Daily Lyc-O-Mato 5mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
46032761|NCT00637858|Dietary Supplement|Lyc-O-Mato 15mg|Daily Lyc-O-Mato 15mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
46032762|NCT00637858|Dietary Supplement|Lyc-O-Mato 30mg|Daily Lyc-O-Mato 30mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
46032763|NCT00637858|Dietary Supplement|Lycopene capsules (non Lyc-o-mato) 15 mg|Daily Lycopene capsules (non Lyc-o-mato) 15 mg with lunch for 8 weeks (After 4 weeks of placebo run in).
45338804|NCT00697515|Drug|Placebo|Placebo administered once-daily for one week during the adult workplace environment setting
45338805|NCT04163640|Other|intra-ovarian platelet rich plasma injection|patients will undergo a transvaginal intra-ovarian platelet rich plasma injection
45338806|NCT03951636|Procedure|Mechanical debridement with curettes|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments
45338807|NCT03951636|Procedure|Er:YAG laser|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments. Furthermore, an Er:YAG laser will be used for the implant surface decontamination.
45338808|NCT03951636|Procedure|Air Powder|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments. Furthermore, an Air-Powder treatment will be provided on the implant/abutment surface.
45338809|NCT00738062|Drug|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
45338810|NCT00738062|Drug|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
45338811|NCT04156074|Dietary Supplement|Vitamin D enriched (20 mcg/day) olive oil emulsion drink|Vitamin D enriched (20 mcg/day) olive oil emulsion drink. 30 mL drink daily
45752008|NCT03587519|Procedure|Early|Early ileostomy closure
45752009|NCT03587519|Procedure|Late|Late ileostomy closure
45338812|NCT04156074|Dietary Supplement|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink 30 mL drink daily
45338813|NCT04156074|Dietary Supplement|Placebo coconut oil emulsion drink|Placebo coconut oil emulsion drink 30 mL drink daily
45338814|NCT04156074|Dietary Supplement|Vitamin D supplement (20 mcg/day)|Vitamin D supplement (20 mcg/day) Pill consumed daily
45472475|NCT01156883|Drug|daunorubicin hydrochloride|
45754689|NCT03474731|Behavioral|DSMP AND Tailored Patient Navigation|DSMP AND Tailored Patient Navigation : Both group education classes and patient navigation
46032764|NCT00637858|Other|Placebo|Placebo capsules, identical looking to previous capsules for double-blind treatment period (8 weeks) and single blind run-in (4 weeks).
45338815|NCT04061889|Other|intervention name is not applicable|Another intervention is not applicable either, due to the observational study design
46032765|NCT04167241|Diagnostic Test|Echocardiography|Before and after right pneumonectomy or bi-lobectomy patients will receive echocardiography
45754690|NCT03156218|Drug|Modulation of FiO2|Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%.
45754691|NCT03447119|Behavioral|Living Well with a Disability|Implementation of an adapted health promotion program.
45338816|NCT04076670|Other|Psychological intervention for family caregivers of patients at the end of life|The intervention protocol is a structured programme within the framework of counselling, that aims to reduce anxiety and depression symptoms, as well as symptoms of burden (overburden).
45338817|NCT04062045|Drug|Ropivacaine Hcl 0.2% Inj Vil 10Ml|Group A will receive the medicine through the erector spinae catheter.
45338818|NCT04062045|Drug|Saline 0.9%|Group B will receive Saline 0,9% through the erector spinae catheter.
45338819|NCT03740256|Biological|CAdVEC|The intratumoral administration of CAdVEC will create a pro-inflammatory tumor microenvironment and will promote the recruitment and expansion of adoptively transferred HER2 specific CAR T cells via CAR (tumor antigen). We expect HER2 CAR T cells expanded at primary tumor sites will re-circulate and target metastasized tumors. The combination we propose to test has the potential to overcome each of the established individual limitations of oncolytic viruses and of CAR T-cells. Testing each element separately would not be beneficial or informative, since the combination therapy is anticipated to have unique profiles of both therapeutic benefit and potential toxicities.
45472476|NCT01156883|Drug|dexamethasone|
45472477|NCT01156883|Drug|doxorubicin hydrochloride|
45472478|NCT01156883|Drug|ifosfamide|
45472479|NCT01156883|Drug|mercaptopurine|
45472480|NCT01156883|Drug|methotrexate|
45472481|NCT01156883|Drug|methylprednisolone|
46032766|NCT02649127|Behavioral|imaginal therapy|imaginal exercise of Prolonged Exposure therapy
46032767|NCT02649127|Behavioral|exercise|aerobic training at a frequency of a minimum of 3 sessions per week, at vigorous intensity [i. e., >60% of oxygen uptake reserve (VO2R)], and a time of 20-25 minutes each bout of training
46032768|NCT02649127|Behavioral|self-care|meeting with a nurse to review and discuss publically available written materials that outline approaches for dealing with posttraumatic stress symptoms
46032769|NCT04251598|Behavioral|I Am Protecting My Child from the Sun|"The parents in the intervention group were administered the I Am Protecting My Child from the Sun program for a period of six weeks.~Intervention groups received Sun Protection Guide for Parents, Developmental, Characteristics of 3-6 Age Group Children Brochure, Melanoma Brochure, Video, Frame, Key chain, Magnet, Puzzle, Sunscreen product, T-shirt, hat and UV testing wristband."
46032770|NCT04251598|Behavioral|SMS for sun protection|While the education+SMS group, in addition to the program, also received a total of 25 short text messages twice a week.
45683011|NCT03080038|Other|Fluid Sparing Resuscitation Strategy|"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy [crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)] should be avoided; small volume isotonic fluid boluses [5-10 mL/kg (250-500 mL for participants ≥ 50 kg)] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy [crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)] should be avoided; small volume isotonic fluid boluses [5-10 mL/kg (250-500 mL for participants ≥ 50 kg)] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed."
45683012|NCT04761562|Drug|Platelet- and extracellular vesicle-rich plasma|PVRP will initially be applied to the gelatine sponge without prior exogenous activation, which will first be inserted into the middle ear cavity to support the reconstructed tympanic membrane. The remainder of the PVRP will then be exogenously activated with calcium chloride. Gel rich with platelets and extracellular vesicles will be created and applied on top of the reconstructed tympanic membrane. Finally, the external auditory canal will be filled with pieces of gelatine sponge soaked with PVRP.
45338820|NCT05007015|Procedure|Transanal Irrigation|Each participant will receive a mailed package of TAI materials, given access to the LARS website, and have two scheduled virtual visits with a trained research nurse to learn how to use TAI once assigned to the intervention arm. These sessions will include one on one session with the nurse for review of the material, discussion of the device and any questions. TAI involves introducing an applicator into the anus for irrigation. An initial volume of 1000 mL will be suggested but can be increased to 1500 mL or reduced to 500 mL as per patient preference and tolerance. Applicators are single-use instruments that can be disposed of into standard waster receptacle after each treatment. The irrigation system is multiple-use and can be used for the duration recommend by the manufacturer manual. Daily irrigation can take anywhere between 20 and 90 minutes depending on individual patient experience.
45338821|NCT03733314|Drug|E6011|E6011, infusion, intravenously.
45338822|NCT03733314|Drug|Placebo|Placebo, infusion, intravenously.
45338823|NCT04064073|Drug|DWP16001|Tablets, Oral, once daily single dose
45338824|NCT04064073|Drug|Metformin IR|Metformin IR 1000mg, Tablets, Oral, BID for 7 days
45338825|NCT04064073|Drug|DWP16001+Metformin IR|Tablets, Oral, once daily single dose DWP16001 Metformin IR 1000mg
45338826|NCT04075344|Other|Multimodal Infection control programme|12 weekse educational programme with 6 sessions, 45 minutes per session will be provided to experimental group RCHEs staff
45338827|NCT02580942|Device|Magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
45472482|NCT01156883|Drug|prednisone|
45472483|NCT01156883|Drug|thioguanine|
45472484|NCT01156883|Drug|vincristine sulfate|
45472485|NCT01156883|Drug|vindesine|
45839446|NCT03009474|Drug|Exforge tab 5/160mg, Crestor tab 10mg|Co-administration of Amlodipine 5 mg/ Valsartan 160 mg(combination drug) and Rosuvastatin 10 mg
46032771|NCT02657161|Biological|RABIPUR®|Biological rabies vaccine
45839447|NCT03009552|Procedure|speckle tracking echocardiography|Speckle tracking echocardiography is used for measuring parameters of cardiac mechanics: left ventricle strain and strain rate; left ventricle twist, untwist and torsion; left atrium strain and strain rate; right ventricle longitudinal strain and strain rate. Echocardiography will be performed within 24 hours of admission, 72 hours after admission and 1 month after discharge.
46032772|NCT02657161|Biological|PIKA rabies vaccine|Biological rabies vaccine
46032773|NCT02657161|Biological|PIKA rabies vaccine with an accelerated regimen|Biological rabies vaccine
46032774|NCT01139580|Drug|Calcipotriene Foam|Calcipotriene Foam 0.005%. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
46032775|NCT01139580|Drug|Vehicle Foam|Vehicle Foam. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
45839448|NCT03009318|Other|tumors are confirmed by surgery and pathology|Each patient undergoes both MRS and MET PET scan before surgery. The lesion will be considered as a glioma when either MRS or MET PET results indicated the diagnosis. Pathologic diagnosis will be performed to confirm the final diagnosis.
45472486|NCT03882125|Behavioral|Mindfulness-based relapse prevention|Psychosocial intervention integrating mindfulness practice and cognitive behavioral relapse prevention approaches
45839449|NCT03009084|Behavioral|Lifestyle counseling|Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
45472487|NCT01156961|Drug|bevacizumab [Avastin]|10 mg/kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
45472488|NCT01156961|Drug|paclitaxel|90 mg/m2 iv days 1, 8 and 15 of every 28-day cycle or 175 mg/m2 iv day 1 of each 21-day cycle
45472489|NCT01265303|Device|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
45472490|NCT03355781|Device|magnetic resonance imaging (MRI)|brain imaging : structural anatomy, emotional congruence, anatomic connectivity, functional connectivity
45472491|NCT03355781|Procedure|Blood sample|27,5 ml of blood sample : genetic analysis and biobank
45472492|NCT03355781|Other|Clinical psychiatric evaluation|Global Assessment Scale(GAS),Mini International Neuropsychiatric Interview(MINI),Positive and Negative Symptoms Scale(PANSS),Family Interview for Genetic Studies(FIGS),Calgary Depression Scale for Schizophrenia(CDSS),extrapyramidal side effects evaluation or Simpson-Angus scale evaluation(ESRS),Apathy Evaluation Scale(AES-C),State-Trait Anxiety Inventory(STAI),Beck Depression Inventory(BDI-13),Eysenck Personality Questionnaire-Revised(EPQ-R),Assessment of Schizotypal Personality(SPQ),Emotion Regulation Questionnaire(ERQ),Emotional Reactivity Scale(ERS),Toronto Alexithymia Scale(TAS-20),social anhedonia scale(SAS),Childhood Trauma Questionnaire(CTQ),Clinical-administered Post Traumatic Stress Disorder Scale(CAPS),Wechsler Adult Intelligence Scale(WAIS-III),Trail Making Test(TMT),Pen and paper visuospatial working memory(DOT-test),impulsivity test(GoStop),Stroop test,National Adult Reading Test(NART),Wechsler Adult Intelligence Scale(WAIS-III),Facial Emotion Recognition task(FER)
45472493|NCT01159457|Biological|Hepatitis B vaccination (Sci-B-Vac)|A dose of 5mcg (0.5 ml) (up to 10yr old) and 10mcg (1.0 ml)(above 10yr old) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
45472494|NCT01159457|Biological|Hepatitis B vaccination (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
45839450|NCT03008694|Device|PET/CT|pet/ct is used as radiotherapy simulation
45839451|NCT03008928|Behavioral|Alcooquizz|
45338828|NCT02580942|Device|Sham magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
45338829|NCT02580942|Drug|Chinese herbal medicine|72 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22).
45338830|NCT02565927|Device|Traditional airway stent|process airway stenting
45338831|NCT02565927|Drug|Iodine-125 seeds|process intraluminal brachytherapy
45338832|NCT04137354|Other|Intermittent placebo iron supplement|Placebo iron supplements are also three tablets containing the same ingredients as for iron tablets and will be given to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
45338833|NCT04137354|Other|Intermittent iron supplement|Three iron tablets containing 42 mg of elemental iron will be provided to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
45598795|NCT03149913|Device|conventional uncoated balloon for BTK endovascular therapy|PTA with uncoated balloon for BTK endovascular therapy
45338834|NCT04137354|Other|Placebo Vitamin A|Children will receive in a colorful Eppendorf tube 400 micro-liter of corn oil stabilized with vitamin A twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
46032776|NCT02657083|Device|DreaMed Substance Administration Device|"2 exercise days under DreaMed MD-AID control with afternoon exercise (in the time between 16:30 and 19:30).~New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.~The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.~The DreaMed MD-AID uses a vendor-supplied and self-developed (communication module) communication application programming interface (API) in order to retrieve glucose / insulin data from the Paradigm Veo and set insulin treatment according to the algorithm decision."
46032777|NCT02657083|Device|Sensor Augmented Pump (SAP)|"2 exercise days under Sensor Augmented Pump with afternoon exercise (in the time between 16:30 and 19:30).~New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.~The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.~During the exercise the group will turn off the insulin pump and lower their basal insulin for 20% for the next 4 hours after the exercise"
46032778|NCT04686760|Drug|Nitroglycerin|2 mg/ml solution of nitroglycerin used for nebulization four hourly
46032779|NCT04312698|Drug|D013, D326, D337|Experimental: Group 1 Patients assigned to this group are treated with D013, D326, D337
46032780|NCT04312698|Drug|placebo of D013, D326, D337|Placebo Comparator: Group 1 Patients assigned to this group are treated with D326, D337, placebo of D013
45338835|NCT04137354|Other|High-dose Vitamin A supplement|Children will receive in a colorful Eppendorf tube 400 micro-liter of oil-based preparation of retinyl palmitate that contains the equivalent of 100,000 IU (110μmol) of vitamin A and stabilized with 20IU of vitamin E twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
45338836|NCT05006859|Other|Cohorte|Assessment of postural wheelchair disorders, as well as PW pain, and pressure ulcers associated with sitting
45338837|NCT02566629|Other|collect faeces from participants|analyze the fecal microbiota community using 16S rDNA detection technique
45338838|NCT02566941|Device|Gymna Belgium, DUO 400 (Neuromuscular electrical stimulation)|
45338839|NCT05000073|Other|dialysis and socio-aesthetic care|dialysis and socio-aesthetic care
45338840|NCT05000073|Other|dialysis|dialysis
45338841|NCT04130958|Device|Intermittent Theta Burst Transcranial Magnetic Stimulation (Active)|iTBS-TMS is a noninvasive neuromodulation technique that uses a powerful magnet to induce focal electrical currents in target brain regions.
45338842|NCT04130958|Device|Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham)|The sham version of iTBS-TMS involves placing the magnet over the same target brain region but the device will not be turned on during the treatment. There will be two electrodes placed on the scalp that mimic the sensation of iTBS-TMS but does not induce focal electrical currents.
45598796|NCT02289703|Drug|Rivaroxaban 15 mg|Single oral dose of rivaroxaban 15-mg tablet on Day 1 of each of the treatment periods.
45598797|NCT02232347|Drug|Ketamine|
46032781|NCT04312698|Drug|D013, placebo of D326, placebo of D337|Placebo Comparator: Group 2 Patients assigned to this group are treated with D013, placebo of D326, placebo of D337
46032782|NCT04251832|Drug|Sodium Thiosulfate|Ultrasound guided percutaneous lavage with and without Sodium Thiosulfate
46032783|NCT04312464|Other|non|no intervention
45338843|NCT04063917|Device|ZENS|ZENS transcutaneous nerve stimulator (ZENS Device), a wearable and non-invasive device which stimulates nerves in the neck to reduce airway obstruction and maintain muscular tension while sleeping to reduce snoring severity.
46032784|NCT02656927|Behavioral|Yoga Condition|
46032785|NCT04251988|Device|Oculus Go VR|virtual reality headset
46032786|NCT04312776|Other|none intervention|
45338844|NCT04075032|Dietary Supplement|Pomegranate extract|Pomegranate extract consumption (900 mg/day) for 4 weeks
46032787|NCT02656849|Drug|BAY 1000394|
46032788|NCT04313010|Other|PRF|A sample of whole venous blood was drawn from the patient's forearm. The blood sample was transferred into a tube without anticoagulant and centrifuged immediately using a centrifuge.
45338845|NCT04075032|Other|Placebo|Placebo (microcrystalline cellulose) consumption (900 mg/day) for 4 weeks
46032789|NCT04313010|Other|BC|According to the procedures of regenerative endodontics therapy, BC was made by the way of provoking apical bleeding into root canal.
46032790|NCT05252260|Procedure|Diode Laser|Vestibuloplasty surgery was performed via diode laser. Laser irradiation was performed in continuous wave mode, using a 980 nm diode laser with a power of 1.5W, 600 μm optical fiber.
46032791|NCT05252260|Procedure|Conventional Surgery|A local anesthetic was administered bilaterally to the mental area and waited for 5 min for diffusion of the solution. Then, a horizontal incision was prepared at the mucogingival junction with a scalpel blade no. 15c. All the muscle fibers over the periosteum were resected carefully. Following, the mucosal flap was sutured to the depth of the vestibule sulcus with 4-0 polypropylene suture material, once every 4 mm, from a total of 5 regions.
45472495|NCT01159223|Drug|ATV/r|All participants will be randomized to take ATV/r 200 mg/100 mg OD or ATV/r 300/100 mg OD. NRTIs background regimens will remain unchanged if possible. NRTIs background may include zidovudine/lamivudine, zidovudine plus ddI, ddI plus lamivudine, tenofovir plus lamivudine, tenofovir/emtricitabine, zidovudine plus tenofovir. NRTI backbone could be switched or modified due to toxicity or intolerance
46032792|NCT05252260|Other|Low level laser therapy (LLLT)|Vestibuloplasty surgery was performed via diode laser. Following, LLLT was applied in continuous wave mode for 1 minute without contacting the tissue, using a phototherapy probe (power output, 0.5W; total energy of 6 J / cm²) at a distance of 1-2 mm from the tissue. LLLT was repeated immediately after the surgery, on the 1st, 3rd and 7th days
46032793|NCT02536729|Drug|Oral Sodium Phosphate - Normal preparation|
46032794|NCT02536729|Drug|Oral sodium phosphate - Modified Preparation|
46032795|NCT02536729|Drug|polyethylene glycol + Electrolytes|
46032796|NCT02656771|Device|Echo Bi-Metric|The insertion of the Echo® Bi-Metric® THA stem
45472496|NCT01159301|Drug|entinostat|Given orally (PO)
46032797|NCT02883582|Device|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
46032798|NCT02883582|Device|oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
46032799|NCT02656537|Device|EnSite™ HD Grid Catheter mapping system|
46032800|NCT00917644|Drug|Atorvastatin|A single 80 mg dose of marketed 80 mg atorvastatin tablets
46032801|NCT00917644|Genetic|Atorvastatin|A single dose of new formulation of 80 mg atorvastatin tablets
46032802|NCT02649283|Device|OrbiSymm device|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, with the OrbiSymm device, that requires reduction of at least 150grams.
46032803|NCT02649283|Procedure|Breast symmetrisation|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, without the OrbiSymm System, that requires reduction of at least 150grams.
46032804|NCT01137786|Drug|Non ionic contrast media comparator|One time administration for PCI
46032805|NCT01137786|Drug|Non ionic contrast media comparator|one time administration for PCI
46032806|NCT00631774|Dietary Supplement|Glucerna SR|Each randomized subject in the meal replacement group will receive Glucerna SR to replace one meal (breakfast) and one pre-sleep snack for 24 weeks. The subjects in the group with exchange-diet plan only will receive a meal plan like they have in the lead-in period.
45472497|NCT01159301|Drug|sorafenib tosylate|Given PO
45472498|NCT01159301|Other|pharmacological study|Correlative studies
46032807|NCT05367258|Other|Patients satisfaction after medical and surgical treatment for umbilical endometriosis|It is a retrospectively evaluation of cases of umbilical endometriosis in our clinic over the last 30 years, based on the review of medical records and on outpatient follow-up visits. The questionnaire are filled in routinely by patients attending the endometriosis center of this institute every 6 months. We will collect data relating to these questionnaires referring prospectively to the study period. If the questionnaires have not already been filled in by the patient, she will be contacted to fill them in, after signing the informed consent of the study.
45683013|NCT04761562|Procedure|Control group|Edges of the tympanic membrane perforation will be refreshed and the tympanomeatal flap raised. Under the tympanic membrane perforation, a guide (fascia of the temporalis muscle, perichondrium, cartilage or fat) will be placed. An absorbent gelatin sponge will be placed under the guide and on the outer surface of the reconstructed tympanic membrane.
46032808|NCT05252104|Diagnostic Test|CORE-TOS diagnostic tool|Collection of clinical findings from clinical examination, subdivided into 5 sub-categories. Positivity in 4 or 5 of these subcategories is considered diagnostic for thoracic outlet syndrome (TOS).
46032809|NCT00625170|Drug|olanzapine|olanzapine 10 mg/day for 8 days
46032810|NCT00625170|Drug|Haloperidol|haloperidol 3 mg/day for 8 days
46032811|NCT00599755|Radiation|Comparator: CT or MRI and FDG-PET|Participants have 4 computed tomography (CT) or magnetic resonance imaging (MRI) scans at screening, baseline, at the end of each treatment cycle (day 21 and day 42.) They also have FDG-PET scans, 2 at Baseline and one at the end of each treatment cycle.
45598798|NCT02232347|Drug|Sufentanil|
45683014|NCT05346328|Drug|Injection of A166|4.8 mg/kg for each 21 (±3) -day cycle
45683015|NCT03082690|Drug|DuoGel|1% IQP-0528 in gel formulation
45754692|NCT00619723|Drug|Citicoline|Citicoline is a psychostimulant/nootropic. It is an intermediate in the generation of phosphatidylcholine from choline.
45472499|NCT01159301|Other|laboratory biomarker analysis|Correlative studies
45472500|NCT03610334|Drug|IFB-088 (2.5-60.0mg) oral capsule|SAD phase: IFB-088 will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
45472501|NCT03610334|Drug|Placebo (2.5-60.mg) oral capsule|SAD phase: placebo (microcrystalline cellulosis) will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
45472502|NCT03610334|Drug|IFB-088 (15.0-50.0mg) oral capsule|MAD phase: multiple doses of IFB-088 (15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.
45472503|NCT03610334|Drug|Placebo oral (15.0-50.0mg) capsule|MAD phase: multiple doses of placebo (microcrystalline cellulosis, 15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.
45472504|NCT01265771|Device|Prolonged telemetric Full Disclosure ECG recording.|Thirty days Telemetric Full Disclosure ECG monitoring; subsequently analyzed in the Event Holter monitoring mode
45472505|NCT01265771|Device|Repeated 24 hours ECG Holter monitoring|Repeated 24 hours ECG Holter monitoring
45472506|NCT01159613|Other|Responders|Responders
45472507|NCT01159613|Other|Non Responders|Non Responders
45472508|NCT01159379|Drug|ertapenem|intravenous, 1 gram, once
45472509|NCT01159847|Drug|sitagliptin|sitagliptin tablet,100 mg p.o. qd,2 year
45472510|NCT01159847|Drug|Insulin|
45472511|NCT02539160|Drug|ticagrelor|Diabetic patients with or without chronic kidney disease will be randomized 1:1 to either (A) standard dose (90mg twice daily of ticagrelor) for 7-10 days and then cross-over to low dose (60mg twice daily of ticagrelor) for 7-10 days; (B) low dose (60mg twice daily of ticagrelor) for 7-10 days (phase 1) and then cross-over to standard dose (90mg twice daily of ticagrelor) for 7-10 days (phase 2).
45472512|NCT04988906|Device|Zoll Accuvent Ventilation Monitor|Provides real-time ventilation quality monitoring (rate and volume)
45472513|NCT01265927|Drug|GRN163L in combination with trastuzumab|GRN163L will be administered in escalating dose cohorts on Day 1 of each 21-day cycle prior to trastuzumab infusion. Trastuzumab will be a administered day 1 of each 21-day cycle after GRN163L. There will be a 30 minute observation period between the end of the GRN163L infusion and the beginning of the trastuzumab infusion.
45472514|NCT04975646|Behavioral|Prescribed exercise program|Active or passive exercises for the spastic upper limb, including functional electrical stimulation (FES), performed regularly for two weeks.
45472515|NCT01266005|Drug|Clevudine|30mg,QD
45472516|NCT01266005|Drug|Entecavir|0.5mg QD
45472517|NCT03879395|Procedure|Abdominal surgery with metastasectomy|Emergency or elective surgery on indications related to abdominally metastasized malignant melanoma
45472518|NCT04292899|Drug|Remdesivir|Administered as an intravenous infusion
45472519|NCT04292899|Drug|Standard of Care|Standard of Care Treatment for COVID-19 Infection
45472520|NCT02530112|Other|Survey|
45472521|NCT03876899|Dietary Supplement|Evening Primrose Oil|botanical oil derivative from the seeds of Evening Primrose (Oenothera biennis),1,300 milligrams t.i.d.
46032812|NCT00599755|Drug|Gemcitabine and Cisplatin or Gemcitabine and Carboplatin|Gemcitabine administered intravenously at a dose of 1000-1250 mg/m^2 on Day 1 and Day 8 of each cycle; Cisplatin administered intravenously at a dose of 60-85 mg/m^2 or Carboplatin at a dose of 4-6 Area Under the Curve (AUC) on Day 1 of each cycle. Two cycles are given 3 weeks apart.
45472522|NCT03876899|Dietary Supplement|Placebo|Pill
45472523|NCT03490604|Device|wrist-worn accelerometer|accelerometer worn on the patient's wrist, changed every 15 ± 7 days for 6 months when the patient comes for a chemotherapy session
46032813|NCT04251364|Drug|Acetazolamide|Daily acetazolamide pill intake
45472524|NCT03490604|Other|Auto-questionnaires|Questionnaire regarding physical activity over the previous 7 days, questionnaires EORTC QLQ-C30 and EORTC QLQ-PAN26
45472525|NCT03241173|Drug|INCAGN01949|In Phase 1, participants will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will receive INCAGN01949 administered IV at the recommended dose from Phase 1.
45472526|NCT03241173|Drug|Nivolumab|Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
45472527|NCT03241173|Drug|Ipilimumab|Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
45472528|NCT01159925|Procedure|Serum sample|Serum samples collected
46032814|NCT04251364|Drug|Atorvastatin|Daily atorvastatin pill intake
46032815|NCT04251364|Drug|Placebo oral tablet|Daily placebo pill intake
45472529|NCT01267877|Other|read unfavorable article prior to answering questions|"article title: Taking a hit on healthcare- why that's women's work"
45472530|NCT01267877|Other|read favorable article prior to answering questions|"read A Backlash of Mistrust"
45683016|NCT04403230|Procedure|Retreatment of teeth prepared without finish line|Retreatment of teeth treated using biologically oriented preparation technique (BOPT). The sample (149 teeth) was divided into two groups: Seventy four teeth restored with crowns, and 75 teeth supporting fixed partial dentures (FPD).
45472531|NCT01161719|Behavioral|parent training|Behavioral management skill training
45472532|NCT01266083|Biological|WT1 peptide vaccine|Six vaccinations of the WT1 peptide preparation (1.0 ml of emulsion) will be administered on weeks 0, 2, 4, 6, 8, and 10. All vaccinations will be administered subcutaneously with vaccination sites rotated among extremities. Patients who are clinically stable and have not had disease progression, may receive up to 6 more vaccinations administered appropriately every month.
45683017|NCT03466918|Device|SAPIEN 3 THV with the Commander delivery system|Edwards SAPIEN 3 Transcatheter Heart Valve is implanted using the Commander delivery system
45683018|NCT03466294|Drug|Azacitidine and Venetoclax|Azacitidine will be given at dose of 75mg/m2 in Cycle 1 days 1-7; repeat in cycle 2 and 3 if no response. Starting on day 2 of cycle 1, venetoclax will be administered orally with doses increased to a target dose of 600 mg (administer 100 mg on day 2, 200 mg on day 3, 400 mg on day 4 and 600 mg on day 5), then 600 mg daily.
45683019|NCT03082300|Drug|naquotinib|Oral
46032816|NCT00637260|Device|Motor cortex stimulation on.|The parameters of stimulation will be: contact 0 cathode, contact 3anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5Volts. The stimulator will be switched on, continuously.
45338846|NCT04245345|Device|Accelerometer Sensing for Micra AV Study|Characterize AV synchrony in subjects implanted with Micra AV device. The study will be conducted upon market approval of the Micra AV Transcatheter Pacing System.
46032817|NCT00637260|Device|motor cortex stimulation off|The parameters of stimulation will be: contact 0 cathode, contact 3 anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5 volts. The stimulator will be switched off.
46032818|NCT04811014|Drug|Buprenorphine, Naloxone Drug Combination|8mg of buprenorphine/2mg of naloxone to initiate MOUD treatment and bridge, if necessary, until referral to MOUD clinic can be made for ongoing treatment
46032819|NCT04811014|Behavioral|Individual Counseling|One-on-one counseling with a licensed chemical dependency counselor
45338847|NCT02580786|Behavioral|Breastfeeding peer support|
45338848|NCT03900507|Procedure|endometriosis surgery|"Medical treatment was initiated in patients with abdominal incision due to endometriotic focus in the incision line.~however, patients with surgical excision indications were the study group."
45338849|NCT05741775|Other|Aerobic training|The warm-up exercise will include light aerobic activity and some dynamic stretching movements. Similarly, the cool down exercises will include buttock stretch, hamstring stretch, inner thigh stretch, calf stretch and thigh stretch. Each stretch to be performed for 5 repetitions with a hold time of 15 seconds for each. An elastic band secured around the head will be used to apply local pressure over the area. Kettler Computeranleitung Advanced display will be used to train static cycling. ProAction BH Treadmill G6700 instrument will be used for aerobic training.
46032820|NCT04811014|Behavioral|Peer Recovery Support Services|24/7 support from our team of certified peer recovery support specialists to assist with emotional support and case management
46032821|NCT04811014|Behavioral|Support Group|Referrals to youth-focused support groups and eventual creation of in-house youth-focused support groups
45754693|NCT00619723|Drug|Placebo|Inactive ingredient matching the active medication in appearance.
46032822|NCT04811014|Behavioral|Referral to Medication Management|Study staff will refer patients to long-term MOUD providers in the community
46032823|NCT04811014|Behavioral|Assertive Outreach|The investigators will conduct weekly outreach to youths who experienced an opioid overdose and attempt to initiate treatment. Outreach is completed by a paramedic and peer coach.
45683020|NCT03082768|Drug|[18F]MNI-968|Healthy volunteers recruited for the study will undergo two [18F]MNI-968 injections and PET scans.
46032824|NCT02648425|Drug|ASLAN001|ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
45839452|NCT03009006|Drug|Chlorhexidine 2% gel - Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide Mixed With Chlorhexidin efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria
45839453|NCT03009006|Drug|Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
46032825|NCT02648425|Drug|cisplatin + capecitabine|Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks
46032826|NCT02648425|Drug|cisplatin + 5-fluorouracil (or+ Leucovorin)|"Cisplatin 80 mg/m2 IV infusion and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks;~Or~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks."
45338850|NCT05741775|Other|Biofeedback Training|Neurotrac myoplus 4 pro instrument will be used for EMG biofeedback training.
45338851|NCT05741619|Other|Long-term outcome|Autonomy, physical examination, behavioural disorders
45338852|NCT00921297|Procedure|Immediate Cataract Surgery|Cataract surgery, as part of standard of care, will be performed on 1/2 of the group under investigation.
45338853|NCT04902729|Drug|Carbetocin|Patient is given carbetocin (80mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
45338854|NCT04902729|Drug|Oxytocin|Patient is given oxytocin (1IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby, followed by infusion 80 mU/min (40 IU in 1L given at a rate of 120 mL/h).
45338855|NCT03498378|Drug|Avelumab|Avelumab (IV on days 1 and 15 of 28 day cycle)
46032827|NCT00637338|Biological|PF-04603629|Subjects will be given either PF-04603629 or Placebo in a blinded fashion. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
45683021|NCT03082456|Diagnostic Test|Molecular breast imaging|Molecular breast imaging will be performed at 5-10 minutes after intravenous injection of 15-20 millicurie (mCi) Tc-99m sestamibi. Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
46032828|NCT00637338|Biological|Placebo|Subjects will be given either PF-04603629 or Placebo in a blinded fashion during the study. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
45472533|NCT05571501|Device|Gait assessment using the GAITRIte walkway|10-20 walking assessment using the GAITRite walkway
46032829|NCT00625482|Biological|OPV|
46032830|NCT00625482|Biological|OPV plus BCG|
45472534|NCT01266239|Procedure|kissing balloon inflation|Kissing balloon inflation following the MV stenting
45472535|NCT01266239|Device|EES vs. SES|Rapid endothelialization after EES deployment has been reported compared to that after SES deployment.
46032831|NCT00625482|Biological|OPV|
46032832|NCT00625482|Biological|OPV plus BCG|
46032833|NCT02648503|Drug|Deep neuromuscular block|Using rocuronium and reversal with sugammadex
46032834|NCT02648503|Drug|Moderate neuromuscular block|Using rocuronium and reversal with neostigmine (1 to 2 mg) and atropine (0.5 to 1 mg)
46032835|NCT04787614|Other|No intervention|No intervention
46032836|NCT04250896|Other|Control group|Standard child care in health unit plus exposure to EsIAN
46032837|NCT04250896|Behavioral|SMS´s sending by cell phone for behavior change|SMS messages sent through a cell pone through the RapidPro platform on practices related to the prevention of infant malnutrition to primary caregivers and the strengthening of counseling for the prevention of infant malnutrition with health providers.
46032838|NCT05253508|Drug|Lidocaine 2% Injectable Solution|A digital nerve block by injections to the base of the finger
45472536|NCT01562431|Other|Feed-back|Counselors will receive the results of the completed Signal-checklist completed by participants in the intervention group
45683022|NCT03082456|Diagnostic Test|Mammography|During the procedure, the breast is compressed using a dedicated mammography unit. Parallel-plate compression evens out the thickness of breast tissue to increase image quality by reducing the thickness of tissue that x-rays must penetrate, decreasing the amount of scattered radiation, reducing the required radiation dose, and holding the breast still (preventing motion blur). Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
46032839|NCT04047979|Biological|Shingrix®|A zoster vaccine recombinant, adjuvanted, recently approved by the FDA for prevention of herpes zoster (shingles) in adults aged 50 years and older. It is given in two doses (0.5 mL each): at 0 and 2 to 6 months.
46032840|NCT04033003|Behavioral|Group ANC|Intervention groups of up to 14 women of similar gestation age (10 to 20 weeks) for nine meetings. The first meeting is an individual meeting with the midwife and the standard history and physical exam as well as lab tests are completed. Group meetings are held once a month until 28 weeks of pregnancy, then every 2 weeks until 34 weeks of pregnancy, and the remaining group meetings are once a week. Prior to the start of each group, blood pressure, weight, and a urinalysis are measured for each woman.
46032841|NCT04524130|Drug|Lidocaine Hydrochloride|lidocaine will be given 1.5 mg/kg bolus at induction then 2mg/kg/hr until the end of surgery.
46032842|NCT04524130|Drug|Ketamine|Ketamine will be given 0.35 mg/kg bolus at induction then 0.2 mg/kg/hr until the end of surgery.
46032843|NCT04524130|Drug|Placebo|Normal saline will be given with the same rate of lidocaine or ketamine.
45338856|NCT03498378|Drug|Palbociclib|"Palbociclib (PO daily, days 1-21 of 28 day cycle)~Palbociclib will be administered in capsules of 125 mg, 100 mg, and 75 mg, depending on dosage. Patients will be instructed to take their assigned dose once daily with food for 21 days followed by 7 days off therapy. Patients will be encouraged to take their dose at approximately the same time each day."
45338857|NCT03498378|Drug|Cetuximab|"Cetuximab (IV 400 mg/m2 x 1, then weekly)~Cetuximab is administered intravenously once weekly via infusion pump or syringe pump with infusion rate not to exceed 10 mg/min."
46032844|NCT00600613|Radiation|cone beam imaging|All study patients will undergo simulation, treatment planning and verification as currently practiced. The contrast injection and cone beam imaging will be added to the standard procedure just prior to treatment delivery on the first and last days of treatment only.
46032845|NCT00649831|Drug|Amoxicillin/clavulinic acid|amoxicillin/clavulinic acid 500 mg/62.5 mg tablet; take 2 tablets by mouth twice daily (BID) for 10 days
46032846|NCT00649831|Drug|Azithromycin|Azithromycin 250 mg tablet; take 2 tablets by mouth on the first day, then 1 tablet by mouth from Days 2 to 5
45683023|NCT03082456|Diagnostic Test|Breast ultrasound|Ultrasound investigation of breast is performed by members of breast cancer team. If abnormality is found by the procedure, biopsy will not be performed directly.
45683024|NCT04761172|Procedure|Intraoperative near-infrared fluorescence imaging using indocyaninegreen|ICG administration before/during surgery and using near-infrared fluorescence imaging for intra-operative detection and identification of GISTs
46032847|NCT05251870|Drug|autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70|Intranodal administration into an inguinal lymphnode. Two administrations at the same injection site with a four week interval.
45338858|NCT03674814|Drug|Enzalutamide|Enzalutamide will be taken by mouth at assigned dose. Enzalutamide will be obtained as standard of care prescription (not provided by study).
45338859|NCT03674814|Drug|Relacorilant|Relacorilant will be taken by mouth at assigned dose. Relacorilant will be provided by the study.
45338860|NCT03912558|Procedure|Butterfly device implantation|The Butterfly device will be positioned and deployed with cystoscopy guidance
46032848|NCT04764604|Device|Acapella Choice|3 minutes of exercise consisting of blowing through the device (on setting '5') and phonating at the same time.
46032849|NCT04764604|Device|Tube-in-water|3 minutes of exercise consisting of blowing through a silicone tube (10mm internal diameter) submerged in 5 cm of water whilst phonating at the same time.
45338861|NCT03493932|Drug|Nivolumab|OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
45338862|NCT03493932|Drug|BMS-986016|Anti-Lymphocyte Activation Gene-3 antibody undergoing clinical evaluation by Bristol-Myers Squibb
46032850|NCT05117944|Other|"drama-supported patient role experience"|The students participated in 3 hours of drama activities and played the role of a patient whose basic needs such as nutrition, dressing and oral care were met by the nurse, lying down for 4 hours in the skills laboratory.
45338863|NCT03911700|Device|Phasix™ Mesh|Phasix™ Mesh is a resorbable mesh prepared from Poly-4-hydroxybutyrate (P4HB).
45338864|NCT04211259|Drug|Loratadine|Given PO
45338865|NCT04211259|Other|Placebo|Given PO
46032851|NCT02648659|Drug|Ilaprazole|Ilaprazole 10mg 1tablet qid(4 times/day)
46032852|NCT02648659|Drug|Amoxicillin|Amoxicillin 500mg 1capsule qid(4times/day)
46032853|NCT02648659|Drug|Clarithromycin|Clarithromycin 500mg 1tablet bid(2times/day)
45338866|NCT04211259|Other|Questionnaire Administration|Ancillary studies
45338867|NCT05087394|Other|Comorbidities|Risk factors (comorbidities), requirements of respiratory suppot and chest imaging will are considered exposure for primary outcomes
45338868|NCT03490812|Diagnostic Test|PET scan|Investigational PET scan as add-on to standard-of-care scan
45338869|NCT03490812|Other|Retrospective data analysis|Review of pre-existing data from January 1, 2001 through December 5, 2017
46032854|NCT02648659|Drug|Metronidazole|Metronidazole 250mg 2tablets tid(3times/day)
46032855|NCT04567888|Behavioral|Happify Teens|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
46032856|NCT01125930|Drug|vehicle gel|Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
46032857|NCT01125930|Drug|Atralin gel|Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
46032858|NCT02656615|Drug|abiraterone acetate|Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
45338870|NCT03650712|Diagnostic Test|Oral glucose tolerance test|oral glucose solution is given by mouth, blood is drawn prior to the administration of the oral glucose beverage and then at timed intervals afterward. This is the standard test to diagnosis cystic fibrosis related diabetes mellitus. However, this study will have more time points than standard screening for cystic fibrosis related diabetes mellitus
46032859|NCT05253430|Procedure|Lymphadenectomy type|D1 vs D2 lymph node dissection
46032860|NCT03946579|Other|self questionnaires|FSFI, QLQ-C30, BR23, ELD15, HADS, GDS 15, FACIT, BIS
46032861|NCT05031988|Other|No intervention will be used.|Determinants of physical activity and mental health among the students during Covid-19 lockdown will be assessed.
46032862|NCT00651235|Drug|Losartan and Atenolol or Propranolol|"50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children.~Losartan is 100 mg/day for adult and 50 mg/day for children."
46032863|NCT00651235|Drug|Atenolol or Propranolol|The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.
46032864|NCT04663204|Drug|Sparsentan|Target dose of 400 mg daily
46032865|NCT02656459|Other|11-gene set|This trial is NOT interventional. The 11-gene set / Sepsis MetaScore will be tested post-hoc.
45338871|NCT03650712|Diagnostic Test|Continuous glucose monitoring|a device is placed on the subject's arm that continuously monitors subcutaneous glucose levels for up to 10 days
45338872|NCT03650712|Diagnostic Test|Dexa scan|low dose x-rays are used to measure the subject's bone density. This is the standard test to diagnose osteoporosis
45338873|NCT00698685|Drug|Pentostatin|Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)
45472537|NCT01161875|Device|Neurally Adjusted Ventilatory Assistance|"In ICU following abdominal aortic surgery, in extubated patient, non-invasive ventilation was performed as follows:~facial mask with non-invasive pressure support ventilation mode to define settings for helmet ventilation~helmet use with non-invasive pressure support ventilation mode to define adequate settings~helmet use with neurally adjusted ventilatory assist mode, based on previous settings"
45338874|NCT00698685|Biological|Alemtuzumab|Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)
45338875|NCT00698685|Procedure|Allogeneic hematopoietic stem cell transplantation|Infusion of related or unrelated donor peripheral blood progenitor cells on day 0.
46032866|NCT04806178|Biological|Bacillus Calmette Guerin|0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
46032867|NCT04806178|Other|PLACEBO|0.1 ml 0.9% saline in the same volume as the BCG vaccine in a single dose.
46032868|NCT04015219|Device|Self retained cryopreserved amniotic membrane|PROKERA SLIM
46032869|NCT04015219|Other|lifitegrast ophthalmic solution|Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA)
45338876|NCT00737672|Device|GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface|Deployment of investigational stent graft at the venous anastomosis
45338877|NCT00737672|Procedure|Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty at the venous anastomosis
45338878|NCT03649308|Device|Negative Pressure Wound Therapy|An immediate mobilization and negative pressure wound therapy (PICO) initiated after surgery.
45338879|NCT03649308|Procedure|Conventional treatment|Traditional treatment with conventional wound dressing and 5 days of immobilization after surgery.
45338880|NCT02580084|Procedure|Hybrid Intervention|"The puncture of the femoral artery general is executed and the introducer 7Fr is set. Further, the hydrophilic conductor executes a recanalization of the Vasa of iliac artery occlusion. if you cannot pass the occlusion retrograde is additional access to antegrade recanalization. Then using hydrophilic conductors, an iliac artery antegrade or retrograde recanalization of the Vasa is made.~Femoral artery arteriotomy. Further execute a direct endarterectomy femoral artery and from the mouth of a hip artery.~arteriotomy of the femoral artery is closed with a vascular patch use (synthetic or biological).~Balloon angioplasty and stenting, iliac artery is done, the controlling angiography Closing maims."
45338881|NCT02580084|Procedure|Aorta femoral Bypass|It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
45472538|NCT03264066|Drug|Cobimetinib|Participants will receive cobimetinib 60 mg (3 tablets of 20 mg each) orally once a day on Days 1-21 of each 28-day cycle.
45472539|NCT03264066|Drug|Atezolizumab|Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
45472540|NCT03264066|Drug|Atezolizumab Cohort 7|Only for participants in cohort 7, the first dose of atezolizumab of 840 mg will be given by IV infusion on Day 15 of Cycle 1; thereafter, they will receive atezolizumab 840 mg IV infusion Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles.
45472541|NCT03759041|Drug|Vancomycin Pre-Treatment|Four times per day dosing of vancomycin pre-treatment
45472542|NCT03759041|Drug|Placebo for Vancomycin Pre-Treatment|Four times per day dosing of placebo pre-treatment
45472543|NCT03759041|Drug|SER-287|Once-daily dosing of SER-287
45472544|NCT03759041|Drug|Placebo for SER-287|Once-daily dosing of Placebo for SER-287
45472545|NCT04110145|Drug|Linaclotide|Linaclotide, capsules, mixed with water and administered orally, once daily in fasted state.
45472546|NCT04110145|Drug|Placebo|Matching placebo, capsules, mixed with water and administered orally, once daily in fasted state
46032870|NCT02648269|Drug|SEL-110|
46032871|NCT02648269|Biological|SEL-212|
46032872|NCT02648269|Biological|SEL-037|
46032873|NCT00918346|Drug|Tafluprost 0.0015%|Eye drops, 0.015 mg/ml, once daily to affected eye(s)
46032874|NCT02649361|Drug|Anlotinib|Anlotinib p.o. qd
46032875|NCT02649361|Drug|Placebo|Placebo p.o. qd
46032876|NCT02648815|Procedure|Percutaneous catheter drainage|Depending on the operator experience, tandem trocar technique or Seldinger technique can be used. If the Seldinger technique is used, then the catheter tract should be sequentially dilated over a guidewire. Access routes that avoid crossing the bowel and other intervening organs, or major mesenteric, peripancreatic, or retroperitoneal blood vessels are selected to minimize the risk of bacterial contamination and hemorrhage. Successful percutaneous treatment of necrotic collections of the pancreas depends on several important factors. Catheters often need to remain in place for several weeks and sometimes months; hence, close follow-up is required.
46032877|NCT02648815|Procedure|Abdominal paracentesis evacuation|Evacuation of peritoneal ascitic fluid using percutaneous catheters
46032878|NCT00913978|Device|Group 1: VitaHeat|Patients will receive active warming via a heating mattress (VitaHEAT Medical) placed on the OR table with two thin sheets between the patient and the device; one covering the mattress and the other used as the draw sheet as usual practice. The device will be turned on 10 minutes prior to the patients' arrival to the operating room table. Patients' upper body will be covered with blankets. To increase skin surface contact with the mattress any blankets remaining under the patients' chest or head will be removed after intubation and replaced with a donut. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
46032879|NCT00913978|Device|Group 2: Bair Hugger|Patients will receive standard forced air warming applied to the upper body and turned on after the patient is prepped and draped. These warmers will be placed directly in contact with the skin without any intervening insulation. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
45683025|NCT01679860|Procedure|Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT|"Clin A:~CHOP-Campath (CHOP-C) for 2 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO on days +1 to +5; Campath-1H (alemtuzumab) dose escalation 3-10-20mg IV days - 2, - 1, 0 (first CHOP-C) or 30mg SC day 0 (second CHOP-C). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on days + 1 and 21 (first and second CHOP-C).~HYPER-C-HiDAM for 2 cycles: Methotrexate 1.5gr/m2 day +1; Cyclophosphamide 300mg/m2 every 12 hours days +2-3-4; ARA-C 2gr/m2 every 12 hours days +2-3-4; G-CSF 5μcg/kg/day starting from day +5 until peripheral blood stem cell harvest~Myeloablative regimen followed by autologous transplantation or Reduced intensity conditioning followed by allogeneic transplantation."
45338882|NCT05673954|Diagnostic Test|C-Read test|C-Read is a reliable and valid clinical tool for quantitatively testing the reading ability of readers of simplified Chinese characters.
45839454|NCT03008850|Drug|MgSo4|"Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally."
45472547|NCT02477618|Drug|SAGE-547|
45472548|NCT02477618|Drug|Placebo|Placebo
45472549|NCT04102501|Drug|RT001|RT001 is encapsulated 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester, which is a site specific (C11) di-deutero synthetic homologue of LA ethyl ester. Each capsule contains 960 mg of RT001.
45683026|NCT01679860|Drug|Clin B (CHOP- CAMPATH) Chemo-immunotherapy|"Clin B:~CHOP-Campath (CHOP-C) for 6 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO from day +1 to day +5¸ Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0 (for the following 5 C-CHOP courses). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on day +1 of each CHOP-C course."
45839455|NCT03008850|Drug|Placebo|"Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally."
45839456|NCT03008538|Other|MPM(Mineralized plasmatic matrix).|Preparation of sticky bone graft by addition of growth factors obtained from patient's vebous blood.
46032880|NCT02648893|Other|Multiple biofortified food crops (MBFC-Exp)|Meals from three biofortified food crops will be consumed by children (and potentially their lactating mothers) three times per day, six days per week, for 9 months.
46032881|NCT02648893|Other|Commercially available non-fortified food crops (MBFC-C)|This arm will consume meals based on three commercially available (non-biofortified) food crops three times per day, six days per week, for 9 months.
46032882|NCT02649049|Other|there is no intervention|
45472550|NCT04102501|Drug|Placebo|The placebo product is composed of encapsulated USP safflower oil. The placebo capsules are identical in appearance and size to RT001.
45839457|NCT03008538|Other|Autogenous Bone Graft|Socket preservation using autogenous bone graft for preservation of bone width and height for future implant insertion.
46032883|NCT04687540|Drug|Tocilizumab|Baseline: Tocilizumab (infusion of 8 mg/kg bodyweight or a maximum of 800 mg) will be infused over 60 minutes at the end for the study day, therefore study visit 1 (study day 1) measurements are baseline.
46032884|NCT04687540|Drug|Saline 0.9%|Participants are under influence of tocilizumab since the effect of the drug will last for 4 weeks. Participants will be infused with saline at study visit 2 (study day 21). Placebo to tocilizumab will be saline (NaCl 0.9%) as tocilizumab is a colorless solution and has to be diluted with NaCl 0.9% prior to administration
46032885|NCT01137474|Drug|Dapagliflozin|Oral tablets administered as 2.5, 5, or 10 mg, once daily for up to 12 weeks
46032886|NCT01137474|Drug|Placebo-matching dapagliflozin|Oral tablets administered as 0 mg once daily for up to 12 weeks
46032887|NCT02648191|Device|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are active."
46032888|NCT02648191|Device|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are inactive."
46032889|NCT04791436|Diagnostic Test|Gustatory and olfactory function test|The gustatory and olfactory function will be tested by using the combined Burghart Screening 12 test containing smelling sticks and taste strips (Fa. MediSense, Groningen, Netherlands). Evaluation of taste and smell is performed by offering the sticks/strips and demand a forced multiple choice.
45683027|NCT05346952|Drug|TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection|PD-L1(programmed cell death-Ligand 1) may be expressed on tumor cells and/or tumor-infiltrating immune cells, which can inhibit the anti-tumor immune response in the tumor microenvironment. On T cells and antigen-presenting cells, PD-L1 binding to PD-1 (programmed cell death-1) and B7.1 receptors inhibits cytotoxic T cell activation, T cell proliferation, and cytokine production.
46032890|NCT04791436|Diagnostic Test|Molecular assessment of saliva|Saliva samples will be taken for molecular biological determination of the oral microbiome. The microbiome is determined at the Institute for Medical Microbiology by 16s-rRNA gene analysis with Next Generation Sequencing and bioinformatics.
46032891|NCT04790188|Dietary Supplement|Nootropic|10g of Evo-Gamers® lemon flavor (HSN®). The nutritional composition per service is: L-Tyrosine (1000mg), Acetyl L-Carnitine HCL (500mg), Citicoline sodium (200mg), L-alpha-Glycerylphosphorylcholine (Alpha-GPC; 100mg), Vitamin C (150mg), Vitamin E (12.1mg), Vitamin B6 (3mg), Vitamin B2 (3mg), Vitamin A (810μg), Vitamin D (10μg), Vitamin B12 (5μg), Taurine (500mg), Caffeine (300mg), L-Theanine (150mg), Mango Leaves (2000mg), Huperzia Leaves (200mg). The dose to be administered is that recommended on the labeling and nutritional information of the nootropic which has been produced under GMP procedures and approved by the EFSA.
45683028|NCT03089788|Other|Home-based test|Home-based tests in which the participant pets his/her cat until he/she reaches a certain symptom strength.
45683029|NCT03089788|Other|Skin test|Skin Prick Tests will be performed with registered cat allergen extract.
45683030|NCT03089632|Other|Gluten-free diet|One-month gluten-free diet
45683031|NCT03081442|Drug|Misoprostol|600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion
45754694|NCT00619723|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants will receive manual-driven Cognitive Behavioral Therapy (CBT: two sessions each week for 4 weeks followed by weekly sessions, total 16 sessions) specifically designed for persons with bipolar 1 disorder and substance abuse, and provided by a therapist with experience in CBT.
46032892|NCT04790188|Dietary Supplement|Placebo|10g of maltodextrin lemon flavor (HSN®).
46032893|NCT02648737|Behavioral|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is considered the gold standard in psychotherapeutic treatments of anxiety. CBT is defined as: 'An amalgam of behavioural and cognitive problem-based interventions guided by principles of applied science. The behavioural interventions aim to decrease maladaptive behaviours and increase adaptive ones by modifying their antecedents and consequences and by behavioural practices that result in new learning. The cognitive interventions aim to modify maladaptive cognitions, self-statements, or beliefs.' (Arch & Craske, 2009; Craske, 2010).
45338883|NCT02594696|Other|Proactive Psychiatry Consultation (PPC)|"The psychiatrist conducts a tailored, cancer-specific assessment to optimize psychiatric symptoms and collaborates with the oncologist to develop and modify the cancer treatment plan.~The case manager, a social worker, engages with the patient to promote self-management, identify and address barriers to care, and bridge communication with oncology and mental health.~The psychiatrist and case manager proactively monitor symptoms and the process of cancer care, remain in regular contact with the patient and communicate with the oncology team at least every 4 weeks~The psychiatrist and case manager are available for consultation across care settings (outpatient, inpatient, home).~Recommendations are documented in the medical record and communicated directly to the oncology team"
45338884|NCT04972968|Drug|ABBV-154|Subcutaneous Injection
45338885|NCT04972968|Drug|Placebo|Subcutaneous Injection
45338886|NCT04972968|Drug|Glucocorticoid|Oral Tablet
45683032|NCT03081442|Device|Intrauterine contraceptive device IUCD|"bimanual examination. The cervix was exposed by introducing a vaginal speculum, the cervix and vaginal vault were cleaned with povidone- iodine solution.~The Next step was to sound The IUD was folded into the insertion tube immediately prior to insertion. The cervix was grasped with a tenaculum, and gently pulled downward The insertion tube was advanced into the uterus to the correct depth as marked on the tube by a sliding plastic flange.~The outer sheath of the insert was withdrawn ashort distance to release the arms of the T and was then gently pushed inward again to elevate the opened T against the fundus of uterus ."
45839458|NCT03008304|Drug|High-activity natural killer|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
46032894|NCT02648737|Other|Clinical monitoring|Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status.
46032895|NCT02645305|Biological|Adipose derived stem cells|Adipose derived stem cells that are isolated from adipose tissue are mesenchymal stem cells with high immune modulation capacity. Therefore, they can effectively modulate the immune system.
46032896|NCT04609696|Drug|Danicopan: Powder-In-Capsule 1|Danicopan (200 milligrams) will be administered orally on Day 1.
46032897|NCT04609696|Drug|Danicopan: Powder-In-Capsule 2|Danicopan (200 milligrams) will be administered orally on Day 1.
45472551|NCT03879083|Other|Addition of palatal rugae to the complete denture surface|The addition and reproduction of the patient's own palatal rugae to the complete maxillary denture palatal surface.
45472552|NCT03879083|Other|The removal of the palatal rugae from the complete denture surface|The removal of the palatal rugae from the complete maxillary denture palatal surface to become a smooth surface
45472553|NCT01266473|Other|Physiotherapy|Physiotherapy for Airway Clearance
46032898|NCT04609696|Drug|Danicopan: Tablet|Danicopan (200 milligrams) will be administered orally on Day 1.
46032899|NCT01168973|Biological|Ramucirumab|10 milligrams per kilogram (mg/kg) administered intravenously (IV) on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
45472554|NCT01268033|Drug|Rituximab|two infusions - at the dose of 375 mg/m²- will be administered at one week of interval
45472555|NCT01268033|Drug|Placebo|two infusions - at the dose of 375 mg/m² - will be administrered at one week of interval
45472556|NCT01162031|Drug|Velcade|IV
45472557|NCT02879162|Drug|Durvalumab|
45472558|NCT02879162|Drug|Tremelimumab|
45472559|NCT01266551|Device|car safety seat|The positions in the car safety seat and in supine 15 degrees anti-Trendelenburg are compared on the basis of a 20 hour pH monitoring.In one group the infants were first continuously positioned at 45 degrees elevation in a car safety seat (car safety seat type Maxi cosi Citi for infants from 0-13kg). During the next period the infants were kept in a supine 15 degrees anti-Trendelenburg position (hospital infant bed), and vice versa for the other group.
45683033|NCT04402450|Procedure|Ultrasound-guided suprainguinal fascia iliaca nerve block|After an ultrasound-guided insertion of a block needle below the inguinal ligament, the needle will be advance in the plane between fascia iliaca and iliopsoas muscle up to a point cranial to the ligament in order to inject a 40 mL of adrenalized 0.25% levobupivacaine.
45683034|NCT04402450|Procedure|Ultrasound-guided pericapsular nerves group of the hip block|After an ultrasound-guided insertion of a block needle at the level of the inguinal ligament, the needle will be advance into the plane between iliac bone periosteum and the tendon of the iliopsoas muscle in order to inject 20 mL of adrenalized 0.5% levobupivacaine.
46032900|NCT01168973|Drug|Placebo (for Ramucirumab)|Administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
46032901|NCT01168973|Drug|Docetaxel|75 milligrams per square meter (mg/m^2) (60 mg/m^2 for the countries of Korea and Taiwan only with protocol amendment dated 22 May 2012) administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
46032902|NCT00631462|Drug|TG101348|Orally administered, once a day, for 28 days, up to 6 cycles.
46032903|NCT04749862|Other|Online symptom reporting|Online symptom reporting questionnaire with linked self-management advice
46032904|NCT03918109|Drug|OTO-313|single intratympanic injection of gacyclidine
46032905|NCT03918109|Drug|Placebo|single intratympanic injection of placebo
46032906|NCT04747912|Drug|Inotuzumab ozogamicin|Inotuzumab ozogamicin, sold under the brand name Besponsa, is an anti-cancer drug used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
45472560|NCT03285477|Drug|Placebo|Vehicle Ointment was used in participants with Clinically typical AK on the face or scalp.
45839459|NCT03008226|Device|Implementation of 9 mm intrabronchial valves|
46032907|NCT04747912|Drug|Dasatinib|Dasatinib is a prescription treatment for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
45472561|NCT03285477|Drug|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% was used in participants with Clinically typical AK on the face or scalp.
45472562|NCT01160003|Drug|GW870086X|5mg and 8.75mg GW870086X once daily for 14 days in separate traetment periods.
45472563|NCT01160003|Drug|Placebo|placebo will be randomly inserted into one of the treatment periods following the treatment sequences outlined in the protocol.
45683035|NCT03089710|Other|Mini-fluid challenge|Mini-fluid challenge test with 100mL colloid infusion in 1 min
45683036|NCT03080818|Dietary Supplement|Probiotic - Lactobacillus Rhamnosus GG|2 capsules per day for 90 days
45683037|NCT03080818|Other|Placebo|2 placebo capsules per day for 90 days
45683038|NCT03080662|Device|ORYGEN DUAL Sham Valve|Training of the inspiratory muscles during 5 weeks
45683039|NCT03080662|Device|ORYGEN DUAL Valve|Training of the inspiratory muscles during 5 weeks
46032908|NCT04747912|Drug|Dexamethasone|Dexamethasone is a steroid that prevents the release of substances in the body that cause inflammation.
45683040|NCT03431194|Drug|midodrine|oral midodrine tablets 5 mg
45683041|NCT03431194|Drug|Placebo|
45683042|NCT03080740|Drug|Clindamycin palmitate hydrochloride dispersible tablet|300mg, oral after meal, twice daily, a total of 7days
45683043|NCT03080740|Drug|Metronidazole Tablet|400mg, oral after meal , twice daily, a total of 7days
45683044|NCT03084094|Device|Transcranial Direct Current Stimulation|Non invasive brain modulation at a 2mA current during 20minutes
45839460|NCT03008148|Radiation|CCRT|CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).
46032909|NCT04747912|Drug|Methotrexate|Methotrexate is a chemotherapy drug that is used to treat certain types of cancer and leukemia.
45839461|NCT03008148|Drug|Temozolomide|Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.
45839462|NCT03008148|Drug|Siroquine|"Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).~Maintenance Phase: JP001(2 tablets once a day) until disease progression confirmed."
45839463|NCT03007992|Drug|Vinorelbine|Oral vinorelbine will be administered at a daily dose of 30 mg (flat dose without any adaptation to body weight or body surface area) without breaks. Treatment will continue until disease progression, occurrence of unacceptable toxicity, patient's refusal or investigator's decision to stop the treatment.
45839464|NCT03007836|Biological|High-activity natural killer|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
45839465|NCT03007446|Drug|Apatinib|Apatinib :A starting dose of apatinib was administered 500 mg daily
46032910|NCT04747912|Drug|Vincristine|Vincristine, also known as leurocristine and marketed under the brand name Oncovin among others, is a chemotherapy medication used to treat various types of cancer such as acute lymphocytic leukemia, acute myeloid leukemia, Hodgkin's disease, neuroblastoma, and small cell lung cancer among others.
46032911|NCT04747912|Drug|Ponatinib|A drug used to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. It is used in patients whose cancer has the T315I mutation or whose cancer cannot be treated with other tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Ponatinib blocks BCR-ABL, which may help keep cancer cells from growing and may kill them.
46032912|NCT04747912|Drug|Methotrexate for Injection|Methotrexate is a chemotherapy drug that is used to treat certain types of cancer and leukemia. When given intrathecally, it prevents leukemia cells entering the cerebrospinal fluid (CSF) around the spine and brain. Intrathecal chemotherapy is administered during a procedure called a lumbar puncture or through an ommaya reservoir (shunt).
45839466|NCT03007446|Drug|Oxaliplatin|Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle
45839467|NCT03007446|Drug|S-1|S-1:40mg，bid，d1-14，po，in a 21 day cycle.
46032913|NCT04747912|Procedure|Allogenic Stem Cell Transplantation|A procedure in which a patient receives healthy blood-forming cells (stem cells) from a donor to replace their own stem cells that have been destroyed by treatment with radiation or high doses of chemotherapy. In an allogeneic stem cell transplant, the healthy stem cells may come from the blood or bone marrow of a related donor who is not an identical twin of the patient or from an unrelated donor who is genetically similar to the patient. An allogeneic stem cell transplant is most often used to treat blood cancers, such as leukemia and lymphoma, and certain types of blood or immune system disorders.
45683045|NCT03464500|Dietary Supplement|Mitopure 500mg|Mitopure containing softgels
45839468|NCT03007368|Other|Rice|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
45839469|NCT03007368|Other|Potato|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response .
45683046|NCT03464500|Dietary Supplement|Mitopure 1000mg|Mitopure containing softgels
45683047|NCT03464500|Dietary Supplement|Placebo|Placebo containing softgels
45839470|NCT03007368|Other|Pasta|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
46032914|NCT04187430|Behavioral|Retrospective|Those patients with a positive sample for ICD will be randomly selected from the microbiology database.
46032915|NCT04187430|Behavioral|Prospective|After the routine identification of a case of DCI by the microbiology laboratory, those new cases will be included in the study.
45839471|NCT03007368|Other|Sorghum thick porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
45839472|NCT03007368|Other|Millet thick porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
45839473|NCT03007368|Other|Millet couscous|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
46032916|NCT02648035|Biological|Tocilizumab|Subcutaneous Tocilizumab according to approved label.
46032917|NCT04311372|Behavioral|Educational Sesssion+Material+Videos|n =50 participants (Educational Session + Material from Educational Session (Handout form) + Access to Online Video Library)
45683048|NCT03399994|Device|device implantation during coronary angioplasty|device implantation during coronary angioplasty
45683049|NCT03081988|Other|chemoradiotherapy|concomitant chemoradiotherpay is routine treatment in locally advanced and advanced esophageal cancer and it is not for research.
45839474|NCT03007368|Other|Millet thin porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
46032918|NCT04311372|Behavioral|Educational Sesssion+Material ONLY|n =50 participants (Educational Session + Material from Educational Session (Handout form) ONLY)
45839475|NCT03007368|Other|Millet thin monikuru porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
45839476|NCT03007602|Other|Upper Extremity Aerobic Exercise|"Range of maximal heart rate is being followed by a polar band during supervised session each week.~Aerobic exercise is being trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department."
45839477|NCT03007680|Other|Core muscle activation|
45839478|NCT03007524|Drug|High dose Rosuvastatin|20mg/d qN, at least 6 months
45839479|NCT03007524|Drug|Low dose Rosuvastatin|10mg/d qN, at least 6 months
45839480|NCT03007290|Other|Therapeutic drug monitoring|Therapeutic drug monitoring for colistin
45839481|NCT03007134|Other|Retrospective Chart Review|No intervention.
45839482|NCT03007212|Procedure|transarterial chemoembolization versus the standard treatment with sorafinib|TACE procedures were performed by the interventional radiologist through femoral artery approach in all patients. Super-selective cannulation of the main feeders was performed using a microcatheter whenever possible. The c-TACE protocol consisted of intra-arterial infusion of cisplatin 50-100 mg mixed with lipiodol ,Just prior to injection, emulsion is prepared by intensive mixing of equal volumes of cytotoxic drug solution and iodized oil using the pumping method with two syringes and a three way stop cock. Injection is guided by fluoroscopy and results in dense accumulation of the emulsion within the tumor vascular bed. Injection of poor iodized oil up to a maximum volume of 10-20 cc is an option and is followed by embolization of feeding arteries by Gelfoam cubes .Endpoints of conventional TACE are complete filling of the tumor vascular bed with iodized oil and stop-flow in subsegmental and segmental feeding arteries..
45839483|NCT03006900|Other|Pilates|Pilates
46032919|NCT04744012|Procedure|Modified Periostal Pocket Flap Technique|"After local anesthesia, a full thickness flap was elevated from the lingual wall and a partial thickness flap was performed in the buccal one. After that, the buccal periosteum was detached and dental implants were placed following the biological drilling protocol, getting autologous bone particles from the implant site.~Patient's blood collection was performed and the plasm obtained was poured down on a sterile container and mixed with autologous bone particles collected previously during the drilling procedure. Finally the graft was placed in the pocket prepared previously and the surgical wound was sutured in two planes."
45472564|NCT03748693|Procedure|Hysterectomy|Surgery performed on women with a variety of gynecological indications
45839484|NCT03006900|Other|Massage|Massage
46032920|NCT02644993|Radiation|Proton therapy|
45754695|NCT03582254|Radiation|[18F]-FDG PET/MR|"[18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital:~prior to initiation of chemotherapy (rituximab, methotrexate, procarbazine, vincristine and cytarabine) (PET#1),~after two chemotherapy cycles (PET#2),~at the end of the first-line chemotherapy regimens (PET#3)."
45754696|NCT03410615|Radiation|Radiation|70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)
45839485|NCT03006978|Device|TearCare|
45839486|NCT03006978|Device|Warm Compress|
45839487|NCT03007056|Other|High flow nasal cannula|High flow nasal cannula added to the therapeutic arsenal in neonatal care
46032921|NCT04117438|Other|no intervention|There is no intervention. We are just asking breast cancer patients what their food story is.
46032922|NCT05173506|Other|Computer decision support for physician|The Child Health Improvement through Computer Automation - Child Neurology (CHICA-CN) system will screen patients for needed services and provide reminders to physicians to provide the needed services.
45472565|NCT03748693|Procedure|Colporrhaphy|Surgery performed on women with POP
45472566|NCT02285504|Drug|SAGE-547|Intravenous injection
45472567|NCT01160081|Other|Serum sample|Serum samples collected
45472568|NCT04289623|Behavioral|Email|Email
45472569|NCT04289623|Behavioral|Loss frame|Email
45472570|NCT04289623|Behavioral|Testimonial (medical expert)|Email
45472571|NCT04289623|Behavioral|Testimonial (rank-and-file)|Email
45754697|NCT03410615|Drug|Cisplatin|100 mg/m2 days 1, 22, 43 concurrently with RT
45754698|NCT03410615|Drug|Durvalumab|Given in concurrent and adjuvant phase
45754699|NCT03410615|Drug|Tremelimumab|ARM CLOSED TO ACCRUAL - 2019
46032923|NCT00652561|Drug|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the second stage only if the stage 2 criteria are met, where 3/30 (10%) or more patients must have achieved a confirmed response (CR or PR) in stage 1.The study may go to the third stage only if at least 8/50 patients (16%) must have achieved a confirmed response in stage 2
46032924|NCT01168427|Device|Reveal® DX or Reveal® XT Insertable Cardiac Monitor|Reveal® DX and Reveal® XT Insertable Cardiac Monitors are implantable patient-activated and automatically-activated monitoring systems that record subcutaneous ECG.
46032925|NCT00653497|Behavioral|Aquatic exercise|"Arthritis Foundation Aquatics Program~community-based aquatic exercise program~participants asked to attend 2 classes per week for 20 weeks~each class 45-60 minutes in duration"
46032926|NCT05251168|Procedure|PET Guided Bone Marrow Biopsy|"The results of PET/CT images were discussed with the referring physician. PET/CT targeted metabolic marrow biopsy was planned two hours after the whole body diagnostic imaging or on a subsequent day one hour after injecting 2-3 mCi of FDG to minimize the radiation exposure burden to the interventionist.~Society of Interventional Consensus guidelines was followed for image-guided biopsy.~The bone marrow biopsy was done under the PET/CT guidance using the same PET/CT scanner with the help of an automated robotic arm (ARA) workstation"
46032927|NCT05251168|Procedure|Trephine Bone Marrow Biopsy|All the participants underwent trephine bone marrow biopsies from the bilateral posterior superior iliac spine before treatment planning.
45472572|NCT04289623|Behavioral|Social norms (percentage)|Email
45683050|NCT04279990|Other|No intervention: assessment of GI function|"Gastrointestinal function is assessed by the intragastric pressure measurement by a high resolution manometry. This is an examination test considered standard of care for the diagnosis of functional dyspepsia in the university hospital of leuven.~The joint hypermobility syndrome is assess by means of the Brighton criteria."
45683051|NCT03080584|Other|acupuncture|12 weeks of acupuncture comprising basic acupuncture, ear acupuncture and Moving cups. On top of the basic acupuncture, additional locations can be added.
45683052|NCT03089242|Other|observation of microRNA expression|no intervention
45683053|NCT03089164|Diagnostic Test|Right heart catheterization|Each patient will have variables measured supine, sitting and standing positions
45839488|NCT03006822|Other|Pressure release 90|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
45839489|NCT03006822|Other|Pressure release 60|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
46032928|NCT03206437|Behavioral|Mindfulness-Based Stress Reduction|The MBSR course teaches mindfulness meditation skills. This 8-week course meets in person once a week for 2.5 hours. Participants are expected to complete practice assignments at home.
45472573|NCT04289623|Behavioral|Social norms (number)|Email
45472574|NCT03248037|Drug|Netarsudil|netarsudil opthalmic solution 0.02%
45472575|NCT03248037|Drug|Placebo|Placebo eye drops
45472576|NCT05009927|Drug|Imatinib tablets|Imatinib interruption
45472577|NCT02227394|Drug|Z7200|"Total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01).~At visit 2 or 3 (cross-over design)"
45472578|NCT02227394|Drug|Symbicort® Turbohaler®|Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)
45472579|NCT04287517|Device|Capacitive-Resistive Therapy|Capacitive-resistive diathermy therapy heats deep tissues by transferring energy through radiofrequency waves.
45754700|NCT01798693|Dietary Supplement|Placebo (maltodextrin)|
45754701|NCT01798693|Dietary Supplement|Multi-nutrient Blend|
46032929|NCT03206437|Behavioral|Waitlist|This group will wait 8-16 weeks after their first testing visit and after their second study visit is completed they will be able to participate in an 8-week MBSR course.
46032930|NCT01124916|Procedure|Robotic assisted laparoscopic abdominal sacrocolpopexy|Robotic assisted laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
46032931|NCT01124916|Procedure|Standard laparoscopic abdominal sacrocolpopexy|Standard laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
46032932|NCT00631618|Drug|Sutent (sunitinib)|The initial dose will be 50mg daily taken for 4 consecutive weeks followed by 2-weeks off to comprise a complete cycle of 6 weeks.
46032933|NCT02647801|Behavioral|Mindfulness intervention|"Mindfulness is practiced with a weekly computer based guided breathing meditation in which one's own breath has to be counted repetitively from 1 to 9. Participants have to press a specific button for breaths 1 to 8 and then press another button for breath 9 on a keyboard. During this practice they put on headphones and listen to a voice that guides them through breathing meditation. A click sound will occur if breath is miscounted (Levinson et al., 2014). After each computer based breathing meditation the experimenter and participants exchange meditation experiences and views. After the first mindfulness training participants in the experimental group are also able to practice mindfulness at home by listening to audio files on the mobile phone (bodyscan or breathing meditation)."
46032934|NCT04627090|Other|Data collection|Diagnostic and therapeutic data of adult patients with LCH, collected from clinical and laboratory evaluations, carried out during clinical practice.
46032935|NCT04777630|Diagnostic Test|None, neuroimaging|Observation only to observe differences in neuroimaging
46032936|NCT04714060|Biological|UB-621|mAb by SC administration
46032937|NCT04431778|Drug|Ethosuximide|"Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks)."
46032938|NCT04431778|Drug|Placebo|"Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks)."
46032939|NCT05252650|Behavioral|pain|postoperative pain
46032940|NCT05252572|Biological|CLL1 CAR T-cells|Drug: CLL1 CAR T-cells Each subject receive CLL1 CAR T-cells by intravenous infusion Other Name: CLL1 CAR T-cells injection
46032941|NCT00631384|Behavioral|Couples VCT|Offer women coming to antenatal clinics to have their husbands come with them for couples VCT
46032942|NCT00631384|Behavioral|Individual VCT|Women to receive individual VCT
46032943|NCT05252494|Other|animal assisted therapy|In the intervention group, the child will be given to the mother's lap just before the invasive procedure. During the process, the aquarium with the fish will be placed on a shelf at a distance of about 50-60 cm, at an angle that the child can see. The camera on which the blood collection will be recorded will be placed on a tripod and placed on another shelf in such a way that the child can be seen completely. A video recording will be started 1 minute before the procedure, a pulse oximeter device will be attached to the child immediately after the child is seated on his mother's lap, physiological parameters, pain scores and stress will be determined. During the procedure, children's physiological measurements pain score and stress will be re-evaluated after the needle is inserted into the site. After the procedure, children's physiological measurements pain score and stress will be re-evaluated 1 minute after the needle is removed from the injection site
46032944|NCT02691130|Biological|Multimeric 001 (M-001)|Multimeric 001 is a recombinant protein comprising 9 conserved peptides from influenza A and B
46032945|NCT02691130|Biological|H5N1 influenza vaccine|Alum adjuvanted whole virion inactivated H5N1 vaccine produced by FluArt (Hungary)
46032946|NCT02691130|Biological|Saline|0.9% NaCl in double distilled water
46032947|NCT00916006|Drug|PEP005 Gel|0.015%, three day treatment
46032948|NCT00916006|Drug|Vehicle gel|Vehicle gel, three day treatment
46032949|NCT04606186|Dietary Supplement|Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289)|Supplementary intake of Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) 2 times per day for 12 weeks
46032950|NCT04606186|Dietary Supplement|Placebo-lozenges (BioGaia)|Placebo-lozenges (BioGaia)
46032951|NCT04701814|Other|biomechanical scapular mobilization with movement and motor learning|the therapist applied posterior tilt and exteral rotation with upward rotation mobilization to scapula and therapist also warp bilt around GH joint to applied inferior and posterior glid then ask patient to elevate his arm. then we applied motor learning approach by asking patient to elevate his arm with maintaining of external rotation with posterior glid of scapula.
45683054|NCT04402372|Device|Novel bidirectional cannula (BiflowTM, LivaNova, Italy)|We are going to evaluate the safety and efficacy of the novel bidirectional cannula (BiflowTM, LivaNova, Italy) with specific design to ensure stable distal perfusion compared to conventional cannula with downstream line in patients undergoing femoral arterial cannulation for CPB during minimally invasive surgery
45683055|NCT03081832|Drug|Oxytocin|Infant included in the ancient study (repeated administrations of oxytocin in infants with Prader Willi Syndrome aged from 0 to 6 months)
45683056|NCT03081832|Other|Control|Not treated.
45839490|NCT03006822|Other|Pressure release 30|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
45839491|NCT03006744|Behavioral|Phonological awareness training|Training on specific ways to improve children's phonological awareness by making them more aware of the sound structure of words.
45839492|NCT03006744|Behavioral|Reading enjoyment training|Training on how to make reading enjoyable for children.
46032952|NCT04589572|Procedure|XLIF|the XLIF procedure, a minimally invasive procedure that approaches the spine from the lateral via the space between the 12th rib and the highest point of the iliac crest.
46032953|NCT04589572|Procedure|PLIF|open posterior lumbar interbody fusion (PLIF) or transforaminal lumbar interbody fusion (TLIF) are used to treat degenerative diseases of the spinal column.
46032954|NCT04669132|Drug|Olanzapine|- Olanzapine 5mg, administered once daily, during 5 days (day before chemotherapy, the D day of the chemotherapy and 3 day after chemotherapy)
46032955|NCT04669132|Drug|Netupitant|- Netupitanto 300 mg, once daily, on chemotherapy day;
45839493|NCT03006588|Procedure|EUS-FNA for RPLN in NPC patients|An EUS probe was introduced to nasopharynx and the retropharyngeal space (RPS) were scanned. The suspicious recurrent RPLN, which was characterized as (1) roughly round and homogeneously hypo-echoic lesion in RPS; (2) located anterior to the carotid sheath which contained the internal carotid artery (ICA) and the internal jugular vein (IJV). Subsequently, guiding by EUS, a dedicated 22G needle was used to puncture into the enlarged RPLN, then the aspiration was conducted The entire EUS-FNA procedure was repeated at least three times till the satisfied strip tissue was obtained. The obtained tissue samples were sent for pathologic detection and the supernatant fluid was for thinprep cytologic test (TCT).
45839494|NCT03006510|Other|Hypoglycemia prediction alert|"In real time, for a patient with a glucose <90 mg/d, using a hypoglycemia prediction model that takes into account patient weight, renal function, eating and insulin dosing a risk score is produced.~If the Risk score is >35, then the patient is determined to be at risk for hypoglycemia in the next 72 hours.~If a patient is determined to be at risk for hypoglycemia, the following will occur:~Alert will be generated and sent via careweb a pager alert system that sends the alert specifically to the current oncall provider The alert also points the provider to the EMR order section where a formal more detailed alert gives recommendationsd for changes in insulin dosing to potentially prevent hypoglycemia."
45839495|NCT03006354|Device|nHFOV|Ventilator (Leoni-Plus Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
45338887|NCT00737438|Drug|epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan|"Patients with FDG avid locally advanced but resectable gastric or GEJ adenocarcinoma will receive preoperative therapy with epirubicin, cisplatin, capecitabine (ECX), and bevacizumab. Each cycle of therapy is 21 days. Near the completion of cycle 1 of therapy (eg during week 3, target days 18-21), patients will undergo a second FDG-PET/CT scan. Note, patients will hold capecitabine for 48 hours prior to the FDG-PET/CT scan.~Patients with a good metabolic response (eg. > 35% reduction in FDG uptake at the primary tumor on the week 3 PET scan as compared with baseline FDG uptake) will continue ECX for 2 additional cycles (cycle 2 and 3).~Cycle 2 will be administered with bevacizumab and cycle 3 will be administered without bevacizumab. Patients will then proceed to surgery approximately 4-6 weeks following the completion of cycle 3. There is a 10-12 week time interval (eg. 70-84 days) between the last bevacizumab treatment and surgery."
45338888|NCT00737282|Drug|Proellex 25 mg|One capsule Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
45338889|NCT00737282|Drug|Proellex 50 mg|Two capsules Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
45338890|NCT03884478|Behavioral|Personalized Normative Feedback|Personalized Normative Feedback (PNF) is a popular social norms-based intervention strategy which presents individuals with a personalized, individual report designed to correct misperceived peer norms using a graphical display. Bar charts compare actual alcohol use statistics for the peer group to A) participants' estimates of peer drinking and, B) their own self-reported drinking.
45338891|NCT03448458|Procedure|CT (Computed Tomography)|Undergo PET/CT
45338892|NCT03448458|Drug|Gallium Ga 68-DOTATATE|Given IV
45338893|NCT03448458|Procedure|Positron Emission Tomography|Undergo PET/CT
45839496|NCT03006354|Device|nCPAP|Ventilator (Leoni-Plus or Leoni-2 Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
46032956|NCT04669132|Drug|Palonesetron|- Palonosetron 0.56 mg, once daily, on chemotherapy day;
46032957|NCT04701346|Other|Low SAA diet|Diet with low content of methionine and cysteine
46032958|NCT04701346|Other|High SAA diet|Diet with high content of methionine and cysteine
46032959|NCT01168349|Drug|epoetin beta [NeoRecormon]|As prescribed by physician
46032960|NCT00915772|Drug|Linagliptin + metformin|Linagliptin tablet low dose + metformin tablet 500 mg bid
46032961|NCT00915772|Drug|Linagliptin+metformin|Linagliptin low dose tablet + metformin 1000 mg tablet bid
46032962|NCT00915772|Drug|Metformin|Metformin 1000 mg tablet bid
46032963|NCT03571828|Drug|AMG 562|AMG 562 is a BiTE® antibody construct that targets CD19 and is intended for the treatment of patients with B-cell malignancies.
46032964|NCT04363606|Other|Questionnaires|Quality of life Depression Physical pain Social provisions Quality of sleep
46032965|NCT04363606|Biological|blood test|complete blood count and cytokine concentration, TNF-alpha, LDL oxidized, AOPP, SOD, GPX, catalase, albumin, transthyretin, RBP, transferin, α-1 glycoprotein acide, ferritine, selenium, zinc, magnesium
46032966|NCT04363606|Other|Maximal effort test|The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.
45338894|NCT04075422|Drug|Bezlotoxumab Injection [Zinplava]|Treatment with bezlotoxumad according to the routine clinical practices
46032967|NCT04363606|Device|actigraphy|assessment of sleep quality
46032968|NCT04363606|Device|Neuromuscular evaluation|"The maximum isometric force produced by the knee extensors will be measured on the ergometer~the intensity of muscular electrical activity recorded by surface electromyography~Peripheral nerve stimulation~Transcranial magnetic stimulation~Magnetic resonance imaging"
45338895|NCT04075968|Other|Cognitive exercise|Cognitive exercise will be applied
45338896|NCT04075968|Other|Home exercise|Home exercise will be applied
45338897|NCT04074954|Procedure|Cataract surgery|Patients will receive cataract surgery
46032969|NCT04363606|Other|stool analysis|analyze the composition of the intestinal microbiote. concerns only the patients of Saint Etienne
45598799|NCT03521557|Behavioral|Gaze and Postural Stability|The duration and content of the GPS intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.
46032970|NCT04363606|Other|food diary|3 days of information to determine nutrient intakes. concerns only the patients of Saint Etienne
46032971|NCT00632086|Drug|PA32540|
46032972|NCT00632086|Drug|aspirin component of PA32540|The 325 mg aspirin component of PA32540
46032973|NCT00632086|Drug|Ecotrin|325 mg Ecotrin
46032974|NCT00912964|Drug|Mirabegron|Mirabegron tablets
46032975|NCT00912964|Drug|Placebo|Matching mirabegron placebo tablets.
46032976|NCT02647957|Procedure|Code Stroke|Apply a protocol called Code Stroke that involves the entire care chain from emergency teams outpatient specialists of Neurology, Internal Medicine, Radiology or Intensitivos Care, among other hospital areas.
46032977|NCT02641639|Drug|Fosbretabulin tromethamine|CA4P is a synthetic phosphorylated prodrug of CA4, a naturally occurring derivative of the South African willow tree, combretum caffrum. CA4P targets pre-existing tumor vasculature, resulting in an acute, reversible reduction in TBF that leads to central necrosis within tumors.
45683057|NCT03081754|Radiation|Doppler velocimetry|Doppler studies were performed within the last week before delivery using a 3.5-Mhz transducer, all measurements were performed with the mothers in a semi recumbent position. Color-flow imaging was used to visualize the ascending branch of the uterine arteries. Pulsed Doppler velocimetry was performed with a sample volume of 5 mm.
45338898|NCT03414372|Behavioral|Tough Talks Online|Those randomized to the online condition will receive information about how to access Tough Talks online and be given their unique log-in and password information and information on how to contact study personnel for any technical issues. Arm 1 participants will have 24-hour access to all of the intervention features and will be able to access the program for additional sessions at any time. Study staff will provide reminders using text or email (participant preference) if they have not accessed the intervention at the specified time intervals.
45839497|NCT03005886|Procedure|Periodontal examination|"periodontal examination included the assessment of plaque index (PI), gingival index(GI), probing depth (PD), bleeding on probing (BOP) and clinical attachment level (CAL).~All subjects underwent a periodontal examination performed by the same periodontitis (ZTÇ) Prior to the study, the examiner was calibrated for reproducibility of PD and CAL measurements"
45683058|NCT03081520|Behavioral|Affective response MIT|Examine acute affective responses during and after five sessions of endurance training with moderate intensity continuous training
46032978|NCT02641639|Drug|Placebo|Saline for infusion
46032979|NCT02647723|Dietary Supplement|DHA|2 dietary supplement gel capsules providing 450 mg of DHA twice daily by oral intake for 24 weeks
46032980|NCT02647723|Dietary Supplement|Sugar pill|2 dietary supplement gel capsules providing 450 mg of soybean oil twice daily by oral intake for 24 weeks
45839498|NCT03005886|Procedure|GCF sampling|GCF samples were collected using commercially available periopaper . The sample site was gently air-dried and all supragingival plaque was removed. The area was carefully isolated with cotton rolls and a saliva ejector was used to prevent the samples from being contaminated by saliva. The paper strips were inserted into the pockets until slight resistance was felt and left in place for 30s.
46032981|NCT02647567|Other|Caffeine Intake|The experimental group ingest 500 mg of caffeine before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
45839499|NCT03005886|Procedure|phase I therapy|comprehensive proper plaque control program, scaling, subgingival curettage and root Phase I Periodontal Therapy planning
46032982|NCT02647567|Other|Placebo Intake|The control group ingest 500 mg of placebo before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
46032983|NCT00651469|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
45598800|NCT03521557|Behavioral|Standard Care Control|The Standard Care Control intervention is specifically designed to be focused on improving overall endurance and lower extremity muscular strength.
45683059|NCT03081520|Behavioral|Affective response HAIT|Examine acute affective responses during and after five sessions of endurance training with high-intensity aerobic interval training
45839500|NCT03006120|Procedure|Retroperitoneal hematoma due to cardiac catheterization|
45839501|NCT03006042|Drug|Bupivacaine|
46032984|NCT00651469|Drug|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
46032985|NCT02647489|Biological|PAMVAC|
46032986|NCT02647489|Biological|Alhydrogel|
45683060|NCT03081520|Behavioral|Affective response HIIT|Examine acute affective responses during and after five sessions of endurance training with high-intensity sprint interval training
45754702|NCT05701982|Behavioral|Every Step Counts-Tai Chi|The intervention is ESC-TC which is a web-based platform (Every Step Counts) to promote walking combined with pain management content, an online Tai Chi video library, and synchronous Tai Chi classes led by an instructor via teleconference. The intervention is delivered remotely.
45754703|NCT05701982|Other|Usual Care|Usual Care
45839502|NCT03005496|Drug|Zinc|included in intervention arm
46032987|NCT02647489|Biological|GLA-SE|
46032988|NCT02647489|Biological|GLA-LSQ|
45338899|NCT03414372|Behavioral|Tough Talks Clinic|Those randomized to the in-clinic condition (Arm 2) will immediately begin the Tough Talks intervention. Study staff will ensure participants are logged on and will also be available to answer technical issues should they arise. After completion, those in this arm will have an in-person follow-up visit scheduled for approximately two weeks. The in-person sessions were adapted to be delivered via Zoom or a similar HIPAA compliant platform due to the COVID-19 pandemic.
46032989|NCT02647489|Other|Placebo|
45338900|NCT03414372|Behavioral|Standard of Care|Those randomized to the control arm (SOC) will receive a paper-based disclosure informational packet based on available Centers of Disease Control (CDC) guidance. At one-month, all participants will complete an online survey to assess intervention acceptability as well as to assess Social Cognitive Theory (SCT model) constructs.
45338901|NCT00582816|Device|Clinimacs Cell Separation System|Depletion of T-cells
45338902|NCT00582816|Drug|conditioning chemotherapy|Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.
45338903|NCT00582816|Other|DLI|NK Cell selected DLI
45338904|NCT00737048|Drug|Tramadol Hydrochloride|Tramadol hydrochloride two oral capsules will be administered once as 75 milligram (mg).
45338905|NCT00737048|Drug|Acetaminophen|Acetaminophen two oral capsules will be administered once as 650 mg.
45338906|NCT00737048|Drug|Placebo|Two oral tablets or capsules of matching Placebo will be administered once along with Tramadol Hydrochloride and/or acetaminophen.
45338907|NCT00737048|Drug|Tramadol plus Acetaminophen|Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively.
45839503|NCT03005496|Drug|Nifedipine|included in intervention and control arm
46032990|NCT04577716|Diagnostic Test|18F Sodium Fluoride Positron Emission Tomography / Computed Tomography|PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan
46032991|NCT04577716|Diagnostic Test|CT Aortic Angiogram|CT scan to assess aortic morphology and contextualise PET scan
45754704|NCT03582098|Drug|Idelalisib|Tablets were administered in accordance with the marketing authorization.
45754705|NCT03582098|Drug|Rituximab|Tablets were administered in accordance with the marketing authorization.
45839504|NCT03005496|Drug|Beta Carotene|included in intervention arm
45839505|NCT03005496|Drug|Vitamin D3|included in intervention arm
45839506|NCT03005496|Drug|Dexamethasone|included in intervention and control arm
45839507|NCT03005808|Drug|Ropivacaine|Surgery for appendicitis
46032992|NCT04577716|Diagnostic Test|12-month CT Aortic Angiogram|CT scan to assess aortic morphology and the stent graft
46032993|NCT04577716|Other|24-month review|This will consist of a telephone consultation with the study participant and review of electronic clinical records
45839508|NCT03005730|Other|phototherapy|The portable PainAway® nine-diode cluster (Multi Radiance Medical®, Solon, OH, USA) will be employed. This system has one 905 nm laser diode, four 875 nm LED diodes and four 670 nm LED diodes. The aperture size of device is 4 cm2.
46032994|NCT00653575|Behavioral|Information-Motivation-Behavioral Skills model|The Information-Motivation-Behavioral Skills model is an influential and empirically supported theory of health behavior. The model suggests that HIV-related information, motivation, and behavioral skills are important determinants of sexual behavior; thus, childhood sexual abuse may lead to deficits in these areas. This model will be used to guide research interviews.
45683061|NCT03080506|Device|Elastic abdominal binder|Participants will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
45839509|NCT03005730|Other|phototherapy placebo|The placebo portable. The aperture size of device is 4 cm2 .
46032995|NCT00653575|Behavioral|Traumagenic Dynamics model|The Traumagenic Dynamics model is an influential and empirically supported model of the effects of childhood sexual abuse. The model suggests that childhood sexual abuse leads to traumatic sexualization, stigmatization, betrayal, and powerlessness and that these four traumagenic dynamics lead to adverse outcomes, including increased rates of sexual risk behavior. This model will be used to guide research interviews.
46032996|NCT02641171|Other|Specimen sampling|exhaled air samples blood samples fecal samples
46032997|NCT00910897|Drug|Velcade-Dexamethasone|
45683062|NCT03394456|Other|diabetes program|Comprehensive diabetes program (weekly to bimonthly CHW mHealth contact (phone, text) for 12-months and monthly diabetes group visits for 6-months)
46032998|NCT00910897|Drug|Velcade-Thalidomide-Dexamethasone|
46032999|NCT00913744|Drug|Ocriplasmin|ocriplasmin intravitreal injection (125 µg)
46033000|NCT00913744|Drug|Sham injection|Sham injection
46033001|NCT00651547|Drug|budesonide/formoterol|
46033002|NCT00651547|Drug|budesonide|
46033003|NCT00651547|Drug|formoterol|
45839510|NCT03005652|Behavioral|Mindfulness weekly courses for 8 weeks|The mindfulness intervention combines intensive training in mindfulness and compassion meditations, light movement and yoga activities, and psycho-educational components to promote nonjudgmental awareness of present moment experiences.
46033004|NCT04202848|Diagnostic Test|Flora analysis|diversity and abundance of bacteria in patients who received malignant tumors
46033005|NCT04589260|Drug|TD-1058|Study drug to be administered by oral inhalation
46033006|NCT04589260|Drug|Placebo|Placebo to be administered by oral inhalation
46033007|NCT02641327|Device|EarlySense (Passive monitoring)|Passive contact-free monitoring
46033008|NCT02644759|Biological|Stem Cell Transplantation|Interventional radiology-mediated transplantation of purified, autologous stem cells into pancreatic artery and capillaries, and intravenous injection of autologous, immunomodulated mononuclear cells.
46033009|NCT00912808|Drug|Donepezil|donepezil, 5 mg, capsule, once a day, 3 weeks
46033010|NCT00912808|Drug|Sugar Pill (placebo)|sugar pill, one capsule, once a day, 3 weeks
46033011|NCT02647333|Dietary Supplement|Omega-3 Fatty Acid|Experimental: Omega-3 fatty acid In the intervention period the participants will receive a daily supplement of omega-3 fatty acids for 8 weeks, where the dosage are 3 and 4 g/day for women and men, respectively. The omega-3 supplement is a hydrolyzed and reesterified TAG fish oil, containing 33 area percent eicosapentaenoic acid and 22 area percent docosahexaenoic acid.
45683063|NCT03394456|Other|telehealth training and support for Community Health Workers|weekly 1-hour diabetes training and patient support for CHWs via telehealth i.e., ZOOM technology for the study duration
45683064|NCT05345938|Drug|Mitoxantrone Hydrochloride Liposome|Intravenous injection (IV), on day 1 of each 28-day cycle (q4w)
45683065|NCT03080350|Drug|Fentanyl sublingual|Fentanyl sublingual
45683066|NCT03080350|Drug|Fentanyl ev|Fentanyl ev
45683067|NCT03080350|Drug|Placebo sublingual|Placebo sublingual
45683068|NCT03080350|Drug|Placebo ev|Placebo - NaCL 0,9% ev
45683069|NCT03080428|Diagnostic Test|Genomic test|genomic test realized on surgery block or formalin-fixed paraffin-embedded slides
46033012|NCT02647333|Dietary Supplement|Omega-6 Fatty Acid|Experimental: Omega-6 fatty acid In the intervention period the participants will receive a daily supplement of omega-6 fatty acid for 8 weeks, where the dosage are 20 and 27 g/day for women and men, respectively. The omega-6 supplement is a high-quality organic, cold pressed and filtered safflower oil, containing 68-83% linoleic acid, 5-15% saturated fatty acid, 8-21% oleic acid, 0,0-0,5% ALA and maximum 2% other fatty acids.
46033013|NCT04168684|Behavioral|Attachment and Biobehavioral Catch-up (ABC)|Manualized intervention implemented in home with parent and child present focused on parental responsiveness
45683070|NCT03392974|Biological|Valoctocogene Roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
46033014|NCT04168684|Behavioral|Developmental Education for Families (DEF)|Manualized intervention implemented in home with parent and child present focused on parental enhancement of child learning
46033015|NCT02641405|Device|Equistasi|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive three patches to be placed at C7 and at the gastrocnemial junction of both legs.
46033016|NCT02641405|Device|Inactive Equistasi|Inactive Equistasi will be given to every patient in the form of three patches to be placed at C7 and at the gastrocnemial junction of both legs.
46033017|NCT02647255|Procedure|Plasma Exchange (PE)|PE treatment>7 within 3weeks; Volume exchanged: 60ml/kg/course; Replacement fluid: 5% Albumin or fresh frozen plasma; PE was performed by dialysis machine (IQ-21, Asahi Japan) and plasma separator (OP- 08W, Asahi Japan)
46033018|NCT02647255|Drug|Methylprednisolone pulse|methylprednisolone 7-15mg/kg/d 3 times, Qd. or Qod
45683071|NCT03080194|Drug|paliperidone palmitate|Subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement. Previous oral antipsychotics could be continued or withdrawn in 2-4 weeks after first paliperidone palmitate administration according to doctors' clinical judgement.
45683072|NCT03080194|Drug|control group|Subject in control group will be applied with oral antipsychotics or other conventional medication.
45683073|NCT03080116|Drug|ARN-509|240mg/day (4x60mg tablets, Oral administration: OS)
45839511|NCT03005652|Behavioral|Health education weekly courses for 8 weeks|The health education intervention is group-based programme has been developed and validated in an SCD population. Each session of the course covers different subjects, which include self-management, problem-solving, sleep, stress, exercise, managing medicines and memory, communicating with healthcare professionals, eating, and planning for the future.
46033019|NCT04415086|Biological|convalescent plasma|The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.
45683074|NCT03080116|Drug|Degarelix|1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly
45683075|NCT03080116|Other|Placebo|4 tablets, per OS
45683076|NCT03081598|Drug|PBI-4050|Soft gelatine capsule containing 200 mg of the active ingredient per capsule
45683077|NCT03081598|Other|Placebo|Placebo soft gelatine capsule
45683078|NCT04401670|Other|HPV screening and triage tests|The participants underwent a pelvic exam to have a provider-collected sample placed in PreservCyt [Hologic, Inc., Bedford, MA, USA] and a visual inspection by acetic acid (VIA) by a nurse.
46033020|NCT04329442|Drug|Emtricitabine / Tenofovir Disoproxil Oral Tablet|30 day supply of 200mg tablets
45683079|NCT04401670|Behavioral|HPV self-sampling|"The participant was escorted by the nurse to a private room and given instructions on how to self-collect their sample using Just for Me sampler [Preventive Oncology International, Cleveland, OH, USA]."
45683080|NCT03088774|Other|Information material|Online web-application developed together with patients with low back pain
46033021|NCT04414228|Device|M-Entropy guidance of anesthesia depth|In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the response and state entropy values between 40 and 60 from the start of anesthesia to the end of surgery. In the control group, dosage of volatile anesthetics will be titrated according to clinical judgment.
46033022|NCT04414228|Device|ProAQT in guiding goal-directed hemodynamic therapy|If stroke volume variation is ≥ 10%, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is < 10%. If mean arterial pressure is < 70 mmHg and/or cardiac index < 2.5 l·min-1·m-2 despite the stroke volume variation of < 10% following fluid challenge, single or consecutive boluses of ephedrine 4 mg and/or continuous intravenous infusion of norepinephrine 2-10 μg·min-1 will be administered.
46033023|NCT00960531|Biological|ACC-001+ QS21 (3mcg)|ACC-001 3mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
45683081|NCT03396718|Radiation|De-escalation radio(chemo)therapy - Level 1|54/ 59,4 Gy
45683082|NCT03396718|Radiation|De-escalation radio(chemo)therapy - Level 2|48,8/ 55 Gy
45683083|NCT03396718|Radiation|Standard radio(chemotherapy)|60/ 66 Gy
45683084|NCT03396640|Procedure|Unicondylar Knee Arthroplasty|"Incision will be midline incision, as with a TKA, for maximum security of blinding.~Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not."
46033024|NCT00960531|Biological|ACC-001 (10 mcg) + QS-21|ACC-001 10mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
46033025|NCT00960531|Biological|ACC-001+QS-21 (30mcg)|ACC-001 30mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
46033026|NCT02647021|Behavioral|Therapeutic Exercise|A specialized therapeutic exercise program to address neck and shoulder dysfunction due to spinal accessory nerve damage.
46033027|NCT02647021|Behavioral|Therapeutic + Lower Body Exercise|A combined therapeutic exercise program (as per the comparison arm) plus the addition of lower body resistance exercise
46033028|NCT04280367|Diagnostic Test|Standardised semi-structured talk|Comprehensive assessment of at-risk mental states (CAARMS) will be used.
45839512|NCT03005574|Behavioral|TSW-HP|TSW-HP involves home practice of cognitive exercises along with the training sessions facilitated by the cognitive specialist at the agency.
45839513|NCT03005574|Behavioral|TSW-T|Participants assigned to traditional TSW will receive the usual TSW program which includes a one hour session per week at BCS for 6 months. This group will not receive home based cognitive practice exercises
46033029|NCT04280367|Diagnostic Test|Autistic spectre disorder screening|Autism-spectrum quotient (AQ) auto-questionnaire will be used.
46033030|NCT04280367|Diagnostic Test|Anxiety measuring|An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.
45839514|NCT03005262|Drug|MLN8237|
45839515|NCT03005340|Drug|Treatment B|Bazedoxifene 20 mg
46033031|NCT03017833|Other|Laboratory Biomarker Analysis|Correlative studies
46033032|NCT03017833|Drug|Metformin|Given PO
46033033|NCT03017833|Other|Pharmacological Study|Ancillary studies
46033034|NCT03017833|Drug|Sapanisertib|Given PO
46033035|NCT02859909|Biological|BT595|
46033036|NCT00652639|Drug|Clonazepam|Tablets, 1 mg, single-dose
46033037|NCT00652639|Drug|Klonopin|tablets, 1 mg, single-dose
46033038|NCT02858271|Drug|AKB-9778 subcutaneous injection|
46033039|NCT02644681|Procedure|Aortic Aneurysm, Thoracic surgery|
46033040|NCT02859987|Procedure|PICC Placement by Landmark Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
45338908|NCT03627624|Other|Pulmonary rehabilitation|Stable COPD inpatients undergoing 30-STST and 6-minute walk test (6MWT) before and after PR were included. Responsiveness to PR was determined by pre-to-post PR (Δ) evaluation of 30-STST.
45338909|NCT03603600|Device|enVista MX60E|enVista MX60E monofocal IOL
45338910|NCT03603600|Device|enVista MX60EF|enVista MX60EF (trifocal) multifocal IOL (MIOL)
45338911|NCT00731822|Drug|GW685698/GW642444|GW685698/GW642444
45338912|NCT04076358|Behavioral|Tab-CBI|Participants receive a tablet preloaded with Tab-CBI application and an accelerometer.
45839516|NCT03005340|Drug|Treatment C|Cholecalciferol granule 10 mg
45839517|NCT03005340|Drug|Treatment BC|Bazedoxifene 20 mg, Cholecalciferol granule 10 mg
45839518|NCT03005184|Drug|Valsartan 80 mg bid|oral medication during run-in and washout period
45839519|NCT03005184|Drug|Enalapril 10 mg bid|oral medication
45839520|NCT03005184|Drug|Sacubitril-Valsartan 200 mg bid|oral medication
45839521|NCT03005184|Drug|Icatibant|intravenous medication
45839522|NCT03005184|Drug|Placebo|intravenous medication
45839523|NCT03004794|Other|medical records review|
45839524|NCT03004560|Procedure|Standard Laparoscopic Approach|Minimally invasive laparoscopic surgery with 5-10 mm incisions.
45839525|NCT03004560|Procedure|Percutaneous Approach|Minimally invasive laparoscopic surgery with 2-3 mm incisions.
46033041|NCT02859987|Procedure|PICC Placement by Ultrasound-guided Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
46033042|NCT02859987|Device|Ultrasound Scan|Initially the nurses use ultrasound for explore venous anatomy and then they use real-time ultrasound imaging during needle placement
46033043|NCT02644915|Drug|Edaravone|Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.The number of dialysis and the serum creatinine level within the first week after the transplantation will be recorded.The participation of each patient is scheduled for 1 month.
46033044|NCT02644915|Drug|0.9%%NaCl solution|"100ml 0.9%%NaCl solution,but without edaravone ,will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)> 6 mmHg"
46033045|NCT00960375|Behavioral|BTSCS|BTSCS lasts 3 months, includes two 60-minute group meetings per week (24 group meetings total), and is delivered in small groups of 4-8 participants run by a trained interventionist. BTSCS includes: (1) An individual motivational enhancement meeting during the first week of treatment to help participants think about individual reasons for smoking cessation; (2) Breath carbon monoxide monitoring and goal-setting at the beginning of each meeting; (3) Skills for reducing smoking; (4) Social Skills Training; (5) Education about the biology of SPMI and smoking and the physiological harm caused by smoking; (5) Relapse prevention training; (6) Education about and assistance with nicotine replacement therapy for participants who are interested in learning about and trying it.
46033046|NCT00960375|Behavioral|StSST|The StSST program is adapted from a 9-session weekly smoking cessation group program developed at the Outpatient Research Program of the Maryland Psychiatric Research Center and designed for people with schizophrenia. In this study, the StSST program meet twice per week for 3 months (24 sessions total). Participants complete a breath carbon monoxide (CO) test at the start of each group. StSST groups provide education about smoking and support for quitting.
46033047|NCT00651703|Biological|CYT004-MelQbG10 + Montanide|
46033048|NCT00651703|Biological|CYT004-MelQbG10 + Montanide + Imiquimod|
45683085|NCT03396640|Procedure|Total Knee Arthroplasty|Incision will be midline incision, as standard. Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not.
46033049|NCT00651703|Biological|CYT004-MelQbG10 + Imiquimod|
45683086|NCT03089008|Other|Eccentric exercises|
46033050|NCT00651703|Biological|CYT004-MelQbG10 intra nodal injection|
46033051|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min.
46033052|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min.
45683087|NCT03089008|Other|Stretching exercises|
45683088|NCT03081286|Procedure|Liposuction|Liposuction is performed on the abdomen or thighs as determined before randomization by the surgeon.
45683089|NCT03081286|Procedure|Fat graft|The harvested lipoaspirate is injected at the site of pain.
45683090|NCT03081286|Procedure|Sham graft (saline injection)|Saline will be injected at the site of pain instead of fat
45683091|NCT04279678|Procedure|Mitral valve repair|surgical repair of moderate ischemic mitral regurgitation using pericardial patch or rigid semi-annular ring
46033053|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.46 mg/kg over 30 minutes and subsequent continuous infusion of an additional 2.88 mg/kg given over 24 hours at a rate of 0.002 mg/kg/min.
45683092|NCT03089320|Behavioral|Contingency Management Counseling|Contingency management (CM) is an efficacious treatment for individuals with substance use disorders. In line with operant conditioning, CM typically provides reinforcers (rewards) contingent upon attaining specified goals such as decreased substance use and/or abstinence.
45472580|NCT03284229|Device|Excimer Laser Coronary Atherectomy|Excimer Laser Coronary Atherectomy (ELCA ®) uses the high energy, monochromatic light beam to alter or dissolve (vaporize) the plaque without damaging the surrounding tissue. Fiber-optic catheters are used to deliver this light beam. For endovascular applications, Xenon Chloride excimer laser is used and its fiber-optic catheter has multiple small fibers, rather than just a few large fibers, in order to be flexible enough to navigate in the arterial tree.
46033054|NCT00632242|Drug|ARC1779|"Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min to produce a target plasma concentration of 6 mcg/mL.~Continuous infusion of ARC1779 Injection may continue for ≤ 14 days. After initial 24 hours dose may be titrated to achieve a target plasma concentration of 12 mcg/mL as needed, on the basis of clinical and laboratory data, according to the Investigator's judgment."
45472581|NCT03242928|Drug|AFQ056|50 mg and 100 mg tablets taken orally
45472582|NCT03242928|Drug|Placebo|Matching placebo tablets taken orally BID
45472583|NCT04283227|Genetic|OTL-200|All subjects will receive OTL-200 gene therapy and will be followed up for 8 years following treatment with OTL-200.
45472584|NCT05571423|Behavioral|Medical Play|Study subject will be engage in the medical play.
45472585|NCT05571423|Behavioral|Routine Play|Study subject will be engage in the routine play (coloring exercise).
45472586|NCT03876353|Other|Floss|All participants will have half of their mouth flossed. Each participant will act as their own control.
45472587|NCT03747055|Behavioral|Group problem management plus|Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support
45472588|NCT03747055|Behavioral|Enhanced treatment as usual|Referral to primary care workers trained in mental health Gap Action Program Implementation Guide
45472589|NCT05158491|Drug|JK-1201I|JK-1201I will be given every 3 weeks, maximum of 4 treatment cycle.
45472590|NCT03876665|Other|No intervention|No intervention
45472591|NCT03300024|Device|Expanded polytetrafluoroethylene Graft|Group will receive any standard ePTFE graft (control) based on the surgeons' discretion. The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
45472592|NCT03300024|Device|Bovine Carotid Artery Graft|Group will receive the BCA graft (experimental).The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
45839526|NCT03004716|Other|Aerobic training|"5 consecutive patients with chronicle obstructive pulmonary disease are offered to participate in the protocol when they have reached 45 min of aerobic training during their pulmonary rehabilitation program.~During 5 sessions of 45 min, they are monitored with an oximeter device (Nonin 3150) which records heart rate (HR) and oxygen transcutaneous saturation (SpO2). The device also communicates with a telemedicine medical gateway which sends these data to a remote telemedicine center. Data are then provided on a secured online platform and compared with data recorded on the device (Nonin 3150)."
46033055|NCT00632242|Drug|ARC1779|In one period of the sequence, ARC1779 will be administered to all subjects as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min in combination with a dummy 30-minute infusion of placebo. In another period, subjects will receive a single infusion of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes in combination with a dummy 30-minute stepwise infusion followed by 4-hour continuous infusion of placebo. In the one other period, subjects will receive the combination of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes and ARC1779 given as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min
46033056|NCT02644837|Device|Insertion of Ambu AuraGain laryngeal mask airway and Igel|Insertion of Ambu AuraGain and iGel laryngeal mask airways in accordance with manufacturer instruction
45472593|NCT01162577|Behavioral|Weight Concerns|Standard Quitline plus weight coaching
46033057|NCT02644837|Device|Fibreoptic assessment with Ambu A-scope|Passage of Ambu a-scope fibrescope down shaft of laryngeal mask airway and assessment of alignment with glottis in relation to amount of glottis that is easily visualised
45472594|NCT04276207|Drug|LY900014|Administered by CSII
45472595|NCT04276207|Drug|Insulin Lispro|Administered by CSII
45472596|NCT01162655|Behavioral|Cognitive-behavioral therapy for Insomnia (CBT)|6-week course of CBT delivered either using internet or telehealth
45472597|NCT03748615|Device|Computer Guided ridge splitting in posterior mandible|"The computer guided ridge splitting for patients with atrophic posterior mandible and with residual bone width at least 3 to 5mm of residual ridge.~The selected patients will be informed of the nature of the research work and informed consent will be signed.~Radiographic examination included preoperative digital panoramic radiograph with 1:1 magnification for each patient as a primary survey to obtain an approximation of the available bone height and detect the presence of remaining roots and localized pathosis.~Computer surgical guides are fabricated for partially edentulous patients using teeth and tissue as support for the guide.~The same surgeon performed all surgeries. All surgical procedures were performed under strict aseptic conditions, all patients received nerve block local anesthesia (Articaine 4% 1:100 000 epinephrine).~A crestal incision is made using No. 15 blade extending over the posterior mandible using computer guided surgical stent.~no flap elevation ."
45839527|NCT03004092|Procedure|blood sample|Twice weekly blood sample, and at every outpatient visit
46033058|NCT02644837|Device|Ability to insert nasogastric tube|Passage of nasogastric tube down the gastric drainage channel of the device in accordance with manufacturer guidance
46033059|NCT02644837|Device|Measurement of OLP|Measurement of OLP by closing the adjustable pressure limiting valve against a constant fresh gas flow rate of 3 litres/minute
46033060|NCT02644837|Device|Ability to perform positive pressure ventilation|The ability to deliver 6 mls/kg volumes breaths by means of positive pressure ventilation will be assessed
46033061|NCT02644837|Device|Assessment of ease of insertion|Ease of insertion will be subjectively assessed by operator in relation to presence and nature of resistance to insertion of the device
45338913|NCT02593448|Procedure|NIRS during VOT|"Near infrared spectroscopy with INVOS oximeter during vascular occlusion test (VOT) on following timepoints:~30 minutes after anaesthesia induction,~directly after the sternotomy,~during CPB - 20 minutes after aortic cross-clamping ,~40 minutes after aortic cross-clamping,~20 minutes after the release of the aortic cross-clamp,~45 minutes after weaning of CPB."
45472598|NCT03876587|Drug|Pyrotinib Maleate combine with Docetaxel|Pyrotinib Maleate combine with Docetaxel as the first-line treatment to HER2-positive Metastatic Breast Cancer
45472599|NCT01268345|Device|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being
45472600|NCT01268345|Device|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
45472601|NCT01162811|Behavioral|visualization together with structured behavioural attention.|visualization and relaxation exercises together with structured behavioural attention.
45472602|NCT04646343|Other|administration of F-CISS and F-PWES pre version|the CISS questionnaire is a 6 items questionnaire, the PWES is a 3 items questionnaire. Only 10 minutes are required to fulfilled the questionnaires.
45839528|NCT03004404|Drug|Placebo|
45839529|NCT03004404|Drug|BI 730357|
46033062|NCT02644837|Device|Record number of manipulations|The number of manipulations/adjustments will be recorded for the second device only for the remainder of the device use during surgery until the patient wakes.
46033063|NCT02644837|Device|Assessment of device related trauma|Observation and assessment of any trauma caused by the insertion of the first device used
46033064|NCT02964585|Drug|Canagliflozin|100 mg
46033065|NCT02964585|Drug|Placebo|1 tablet daily for 16 weeks
46033066|NCT00637936|Drug|Oxygen|Inspiratory fraction during anaesthesia
45338914|NCT02593448|Procedure|General anaesthesia with propofol use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Maintenance of anaesthesia in 'Propofol' group will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.~Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60."
45472603|NCT04646343|Other|administration of definitive version of F-CISS and F-PWES plus F-DASH, F-HFS and F-SF 36|The administration will required 25 minutes
46033067|NCT02644603|Procedure|Enhanced Recovery After Surgery|"Before operation:~Preoperative optimization of organ function, No preoperative bowel preparation, Prohibit eating 6h, drinking water 2h before operation, Oral rehydration before operation.~In operation:~Optimized combined anesthesia, Minimal invasive operations, Normothermia, Minimal use of tubes and drains.~After operation:~Postoperative analgesia and antiemetic, Early mobilization, Oral nutrition, Early and scheduled mobilization."
46033068|NCT02640703|Biological|Infanrix + Prevenar 13|Different time of application
46033069|NCT00630279|Drug|Placebo|Placebo
45472604|NCT01162889|Drug|Placebo SC Injection|Single injection
45472605|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single intravenous infusion, 60 minute duration
45472606|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
45472607|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
46033070|NCT00630279|Drug|Recombinant Microbial Lipase SLV339|oral, 150 mg/d, 7 days treatment
46033071|NCT00630279|Drug|Recombinant Microbial Lipase SLV339|oral, 300 mg/d, 7 days treatment
45472608|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
46033072|NCT00630279|Drug|Recombinant Microbial Lipase SLV339|oral, 600 mg/d, 7 days treatment
46033073|NCT03850522|Biological|PD-L1 peptide|PD-L1 peptide (100 micrograms) emulsified with the adjuvant Montanide ISA-51 given subcutaneously 10 times every second week over the course of 26 weeks including a five-week break.
46033074|NCT02640781|Procedure|self-expandable metal stent insertion(covered stent)|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal covered stent delivery catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
46033075|NCT02640781|Procedure|self-expandable metal stent insertion(uncovered stent)|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal stent delivery uncovered catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
46033076|NCT02963025|Procedure|PEEP level|
46033077|NCT02963025|Procedure|Use of recruitment maneuvers|
45472609|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
45472610|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single subcutaneous injection
45472611|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
45472612|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
46033078|NCT00651781|Drug|Bortezomib|2 times per week of Velcade administration.
46033079|NCT04166617|Other|Conventional therapy|conventional physcial therapy rehabilitation for the upper limb
45472613|NCT01162889|Drug|Placebo IV Infusion|Single intravenous infusion, 60 minute duration
45472614|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
45472615|NCT04635423|Biological|V503|9-valent vaccine, HPV 6/11/16/18/31/33/45/52/58, L1 virus-like particle (VLP) 30/40/60/40/20/20/20/20/20 mcg per dose.
45472616|NCT04635423|Other|Placebo|0.9% sodium chloride (NaCL)
45472617|NCT05666843|Behavioral|Personalized Dietary Advice|Personalized dietary guidance to increase the intake of fibre-rich foods on top of usual care.The dietary guidance is implemented by dieticians and is personalized based on current adherence to the dietary guidelines, usual dietary intake, gender and personal goals and preferences.
45472618|NCT03876431|Device|Easy-Flex|The Easy-Flex device will be used to increase knee flexion and extension ROM.
45472619|NCT03876431|Other|Exercise|After total knee replacement surgery, exercise program including strengthening, stretching and patient training will be applied.
46033080|NCT04166617|Other|Leap motion plus conventional therapya|leap motion plus conventional physcial therapy rehabilitation for the upper limb
46033081|NCT02646787|Behavioral|Active Virtual Reality|The subject is actively engaged in using virtual reality during a painful burn wound care session.
45338915|NCT02593448|Procedure|General anaesthesia with sevoflurane use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60."
45472620|NCT03282357|Device|Radiesse injectable implant (dermal filler)|Subdermal injection.
45472621|NCT03282357|Device|Restylane injectable implant (dermal filler)|Subdermal injection
45472622|NCT03876509|Diagnostic Test|Impedance Cardiography|"Impedance Cardiography will be conducted in patients with suspected Pulmonary Hypertension within an interval of 24 hours to right-heart catheterization. Usually, 8 electrodes will be attached on the neck and thorax of the patient. These electrodes will produce current (max 400µA) and measure the voltage which is produced by the current running through the body. The Signal will be analyzed for specific signs of Pulmonary Hypertension.~At the same time electrocardiography and non-invasive continuous blood pressure will be measured."
46033082|NCT02646787|Behavioral|Passive Virtual Reality|The subject is passively engaged in using virtual reality during a painful burn wound care session.
45338916|NCT03387618|Diagnostic Test|Digital PET/CT imaging|Next generation PET/CT imaging
45338917|NCT00731666|Device|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction. The implant provides the participant with voluntary control over the erect and flaccid states of the penis.
45338918|NCT05015166|Behavioral|Experimental: Internet delivered self-help program with therapist support|During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises which a therapist gives feedback on.
45472623|NCT01162967|Drug|Benznidazole|Standard dosage
45472624|NCT01162967|Drug|Posaconazole|
45472625|NCT01268423|Procedure|Percutaneous tracheostomy|Percutaneous tracheostomy within the first 4 days of mechanical ventilation.
45472626|NCT01268423|Procedure|Prolonged translaryngeal intubation|Prolonged endotracheal intubation, and reevaluation at day 10 to establish the requirement of percutaneous tracheostomy. If clinical condition determines that the patient needs a percutaneous tracheostomy, this will be performed between days 11 and 14.
45472627|NCT01163045|Procedure|thyroidectomy|total thyroidectomy and lobectomy
45472628|NCT01268657|Behavioral|Education|Learning about anxiety
45472629|NCT01268657|Behavioral|Relaxation Training|Learning skills to reduce tension
45472630|NCT01268657|Behavioral|Cognitive Restructuring|Learning skills needed to cope better with distressing thoughts
45472631|NCT01268657|Behavioral|Behavioral Activation|Learning to initiate healthy activity
45472632|NCT01268657|Behavioral|Exposure|Coaching in how to confront avoided thoughts, situations, and people)
45472633|NCT04635345|Other|External Vibrator - patient-administered.|Patient provided with external vibrator for self-use, as well as vaginal dilators.
46033083|NCT02646865|Behavioral|Self-Compassion Enhanced Cognitive-Behavioral Therapy|12 group sessions of CBT for social anxiety based on Heimberg & Becker's (2002) protocol with additional self-compassion exercises integrated into the treatment
45472634|NCT04635345|Other|Standard care|Dilators, lidocaine topical gel, referral to psychotherapy, group therapy or womens health physio if required, self-help resources.
45472635|NCT01268735|Drug|Lubricating eyedrops containing hydroxypropyl-guar|Eyedrops BID
45472636|NCT04272775|Drug|Ixazomib|Ixazomib capsules.
45472637|NCT04272775|Drug|Lenalidomide|Lenalidomide capsules.
45472638|NCT04272775|Drug|Dexamethasone|Dexamethasone tablets.
45472639|NCT03876197|Biological|Autologous adipose-derived mesenchymal stem/stromal cells|Autologous adipose-derived mesenchymal stem/stromal cells
46033084|NCT02646865|Behavioral|Cognitive-Behavioral Therapy|12 group sessions of CBT for social anxiety based on Heimberg & Becker's (2002) protocol
46033085|NCT00957801|Drug|Testosterone injection|100 mg single IM injection
46033086|NCT00957801|Drug|Testosterone gel|Testosterone gel 10 mg. administered topically daily for seven days
46033087|NCT00957801|Drug|Medrol|Medrol 6 day dose pack with an additional 4mg dose on day 7
46033088|NCT02640469|Other|Chlorhexidine with water rinse|"This procedure will be followed for both the right and left hands and arms:~scrub each side of finger, in between fingers and back and front of hands for 2 minutes, followed by scrubbing of arms, keeping hands higher than arms at all times, wash each side of the arms from wrist to elbow for 1 minute"
45338919|NCT05015166|Behavioral|Internet delivered self-help program without therapist support|During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises.
46033089|NCT02640469|Other|Chlorhexidine without water rinse|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm.
45338920|NCT02592746|Drug|Palbociclib|Palbociclib 125mg, orally once daily on D1 to D21 followed by 7days off
46033090|NCT02640469|Other|Chlorhexidine + sterillium hand rub|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm. Rinse hands and arms by passing through water in one direction, dry hands, and rub 5 mL of alcohol into the palm of the hands, forearms and elbows. Ensure that the whole skin area on both arms is covered.
45338921|NCT02592746|Drug|Exemestane|Exemestane 25mg, orally once daily
45472640|NCT03876197|Other|Placebo|Isotonic NaCl (0,9mg/ml) and human albumin (HA) 1%
45472641|NCT03232983|Drug|LY900014 (SC)|Administered SC
45472642|NCT03232983|Drug|LY900014 (IV)|Administered IV
45472643|NCT01163201|Biological|Treg cells|Given by infusion on Day 0 after transplantation - Five doses of Treg (3 x 10^6/kg, 10 x 10^6/kg, 30 x 10^6/kg, 100 x 10^6/kg and 300 x 10^6/kg)
46033091|NCT02640391|Other|colonoscopy|
45338922|NCT02592746|Drug|Leuprolide Acetate|Leuprolide Acetate 3.75mg SC q 4weeks
45338923|NCT02592746|Drug|Capecitabine|Capecitabine 1,250mg/m2 bid orally form day1 to day 14 q 3weeks
45472644|NCT01163201|Biological|CD3+ Teff cells|Given by infusion on Day 0 after transplantation - 5 doses of CD3+ Teff cells (3 x 10^6 cells/kg, 6 x 10^6 cells/kg, 9 x 10^6 cells/kg, 12 x 10^6 cells/kg, and 15 x 10^6 cells/kg with the latter dose representing the median number of CD3+ cells in two UCB unit grafts
45472645|NCT01163201|Drug|Fludarabine|Given intravenously on Days -8 through -6, 25 mg/m^2 over 1 hour
45472646|NCT01163201|Drug|Cyclophosphamide|Given intravenously on Day -7 and -6, 60 mg/kg
45472647|NCT01163201|Radiation|Total body irradiation|Given on Days -4 through -2, 165 cGY twice a day.
46033092|NCT02646709|Drug|Rocuronium|Low dose rocuronium (0.3 mg/kg) will be injected after induction of anesthesia with ketamine.
46033093|NCT02646709|Drug|ketamine 1|ketamine 1 mg/kg will be injected for induction of anesthesia
46033094|NCT02646709|Drug|ketamine 1.5|ketamine 1.5 mg/kg will be injected for induction of anesthesia
45472648|NCT01163201|Biological|Umbilical cord blood transplantation|Infusion given on day 0
45839530|NCT03004170|Behavioral|Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training|
45839531|NCT03004170|Behavioral|Telephone-Administered Coping Effectiveness Training|
45839532|NCT03004014|Other|Sleep endoscopy during propofol induced sleep|It will be performed a sleep endoscopy during drug induced sleep endoscopy
45839533|NCT03003858|Device|0.1% HA-based film-forming device (Gengigel Prof® Fluid)|0.1% HA-based film-forming device (Gengigel Prof® Fluid, Ricerfarma, Milano, Italy) administered (oral rinses for 3-5 min.) three to five times a day over a 4-week period as an adjunct to domiciliary care and oral hygiene instructions and motivation
45839534|NCT03003702|Device|Nonin|
46033095|NCT02646709|Drug|ketamine 2|ketamine 2 mg/kg will be injected for induction of anesthesia
46033096|NCT00651859|Drug|Bimatoprost 0.01% Ophthalmic Solution|Bimatoprost 0.01% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
45472649|NCT03876041|Drug|solumedrol|intravenous solution for injection
45472650|NCT03876041|Drug|Dexamethasone phosphate|intravenous solution for injection
45472651|NCT04102345|Other|Lavender Aromatherapy|Commercially available lavender essential oil and diffuser.
46033097|NCT00651859|Drug|Bimatoprost 0.03% Ophthalmic Solution|Bimatoprost 0.03% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
46033098|NCT00651859|Drug|Bimatoprost Vehicle Ophthalmic Solution|Bimatoprost vehicle ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
45683093|NCT03089320|Behavioral|Addiction Physician Management|Patients in the CM plus stepped care arm who have PEth > 8 ng/ml at 3 months will progress to Step 2 and receive onsite treatment from an Addiction Psychiatrist (APM) in the HIV clinic. APM will provide care that is typically provided by physicians in specialty referral programs.
46033099|NCT02962557|Device|NM3, Phillips Medical, Wallingford CT: verbal prompts to breathe with an optional shoulder shake|The device used is the NM3 by Phillips Medical, Wallingford CT. The prompting for breaths will include a recorded voice played at 100 decibels played by a speaker placed within 4 feet of the patient's head. If successful breath response is monitored by the patient monitors but no additional subsequent breaths occur within 20 seconds, the verbal prompt will be repeated for the patient to breathe. If the verbal prompting does not result in a breath detected by the patient monitors, the verbal prompt will be repeated within 20 seconds, optionally accompanied by a shoulder shake from the shoulder massager.
46033100|NCT02640313|Drug|18F-choline PET-MR imaging|Dynamic and static 18F-choline PET-MR imaging
46033101|NCT02955823|Drug|Rituximab-Dexamethasone-Lenalidomide|"st CYCLE: Rituximab 375 mg/m2 i.v. on days 1,8,15; Dexamethasone 5 mg p.o. on days 1,8,15,22; Lenalidomide 15 mg/day p.o. day 2-22~nd-4th CYCLE: Rituximab 375 mg/m2 i.v. on day 1; Lenalidomide 20 mg/day p.o. from day 2 to day 22 At the end of 4th CYCLE disease restaging: - if ≥ PR continues with the 5th and 6th cycle: Rituximab 375 mg/m2 i.v. on day 1, Lenalidomide 20 mg /day p.o. day 2-22~if <PR stops the treatment, only follow-up At the end of the 6th CYCLE disease restaging: - if ≥ PR continues with beyond the 6th cycle with Lenalidomide 10mg dd1-21q28 until cycle 12th~if <PR stops the treatment, only follow-up Then, accordingly response rate after the sixth cycle assessment(≥ PR) lenalidomide will be continued at 10 mg dd1-21q28 until 12th cycle or unacceptable toxicity."
46033102|NCT02644447|Biological|HUC-MSCs Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs.
46033103|NCT02644447|Biological|HUC-MSCs with Injectable Collagen Scaffold Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs with injectable collagen scaffold.
46033104|NCT02646631|Other|Usual Care|Participants assigned to this treatment will receive the usual care as determined by their physician
46033105|NCT02646631|Behavioral|Management of Risks in Epilepsy (MORE)|MORE is a smartphone application which participants use to record information on a daily basis about seizures (severity, type), medications, and mood and stress levels. It also includes a camera-based application which uses a pill scanner and photo to record the identity and quantity (dose) of medications just prior to them being taken. Also included in the app are medication reminders, educational video clips, and self-management tips.
46033106|NCT02646631|Behavioral|Telephone-based motivational interviewing (MORE+MI)|Participants will receive a total of 4 motivational interviewing sessions over the phone. These sessions last approximately 20 minutes each and build on the educational materials already provided within the MORE app.
46033107|NCT02646631|Other|Educational Materials|Printed educational materials on the management of epilepsy
46033108|NCT02535793|Other|blood test (four dry tubes 7ml) and prick tests|
46033109|NCT00957723|Device|Triathlon® CR Total Knee System|The purpose is to evaluate the Triathlon® CR Total Knee System.
46033110|NCT02646397|Drug|Fosinopril|Fosinopril is an angiotensin-converting enzyme inhibitor.
45472652|NCT04102345|Drug|Zolpidem|Physician directed, pre-prescribed. Study team does not prescribe zolpidem.
46033111|NCT02646397|Drug|Benidipine|Benidipine is a dihydropyridine-derived calcium channel blocker.
45472653|NCT01163435|Drug|high dose dual therapy|rabeprazole 20 mg qid,amoxicillin 750 mg qid for 14 days
45472654|NCT01163435|Drug|sequential therapy|rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days
45472655|NCT01163435|Drug|clarithromycin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days
45839535|NCT03003936|Behavioral|Dinner timing|Glucose tolerance after a late diner (1 hour before habitual bedtime) differs from early dinner (4 hours before habitual bedtime) due to the concurrence of meal timing with different levels of endogenous melatonin. This effect can be different among risk allele carriers (G) or non-rick allele carriers (C) of the MTNR1B.
46033112|NCT02646397|Drug|Hydrochlorothiazide|Hydrochlorothiazide is a diuretic medication.
46033113|NCT00653731|Behavioral|Snoezelen ©|Nursing individual intervention one time a week for 20 minutes
46033114|NCT00653731|Behavioral|structured reminiscence therapy|Individual nursing intervention: one time a week 20 minutes
46033115|NCT00653731|Behavioral|10-minutes activation|Individual nursing intervention: two times a week for 10 minutes
46033116|NCT00653731|Behavioral|Unstructured verbal communication|Individual nursing intervention: one time a week for 20 minutes
46033117|NCT02646553|Other|Children refered to the obesity clinic|Compere if urine cortisol is as good as saliva cortisol as a screening for hypercortisolism in children.
45839536|NCT03003624|Device|Colorado® microdissection needle|The primary feature of the Colorado® microdissection needle is the ultra-sharp tungsten tip that delivers the wave-form from the electrosurgery generator to a very small spot. This allows the use of extremely low wattages, resulting in less tissue necrosis, precision cutting and cautery, and less post-operative pain.
45839537|NCT03003624|Device|Cautery tip|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
46033118|NCT04204395|Device|Peanut Ball|The participants in the experimental group will use the peanut ball at least every 2 hours, 30-minute usage for each time. More frequency will be available. Then, the participants will stop using the peanut ball when cervical os is dilated and effaced, may be ready to push.
46033119|NCT02640079|Behavioral|Cognitive behavioral therapy|
46033120|NCT02859831|Other|water samples|
45472656|NCT01163435|Drug|levofloxacin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days
46033121|NCT04279353|Other|Mindfulness Based Intervention|this intervention is a 4 weeks program with logbook and follow up during intervention
45472657|NCT04271605|Behavioral|diet and exercise suggestion|diet and exercise suggestion according to blood biochemistry data and bone mineral density
45472658|NCT03299244|Drug|Etelcalcetide|Administered intravenously three times per week.
45472659|NCT03299244|Drug|Cinacalcet|Cinacalcet administered orally once a day.
46033122|NCT02859753|Other|Percutaneous Radiofrequency Ablation|
46033123|NCT02859753|Other|Percutaneous Microwave Ablation|
45839538|NCT03003624|Device|BP blade|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
45839539|NCT03003234|Procedure|Duodenogastroscopy|Catheter goes through the mouth in the duodenum to take duodenal biopsies.
45472660|NCT03875963|Other|Antibiotic loaded bone filler|Defect management by placement of antibiotic loaded Stimulan as a bone void filler [calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin].
45472661|NCT03757715|Drug|Bupivacaine|20 mL of 1.3% bupivacaine
45472662|NCT03757715|Drug|Dexamethasone|2 mg dexamethasone
45683094|NCT03089320|Behavioral|Motivational Enhancement Therapy|"Patients in the CM plus stepped care arm who have PEth > 8 ng/ml at 3 months will progress to Step 2 and receive onsite Motivational Enhancement Therapy (MET) from the Social Worker in the HIV clinic.~MET is grounded in research on processes of natural recovery during which patients move through stages of change - precontemplation, contemplation, determination, action, and maintenance. The Social Worker's role is to assist the patient in moving through the stages of change. MET uses motivational interviewing and reflective listening to help patients identify internal sources of motivation to support reductions in alcohol."
45754706|NCT00555893|Drug|Oseltamivir|"Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight:~for weight <=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)"
45839540|NCT03003234|Device|Duodenal aspiration catheter|Catheter goes through the nose in the duodenum to aspirate duodenal fluid in fasted and fed state.
46033124|NCT04282863|Procedure|RM|All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained. Trocar sites varied according to different procedures. Generally, umbilical site for the scope and 8-10 cm lateral to the scope at 15 degrees for the arms are the most commonly adopted sites for robotic myomectomy.
45839541|NCT03003234|Dietary Supplement|Nutri drink|Liquid meal of 200 ml.
45839542|NCT03003156|Procedure|25 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 25 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
45839543|NCT03003156|Procedure|50 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 50 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
45839544|NCT03002844|Drug|EGFR-TK Inhibitor|EGFR-TKI (gefitinib 250mg per day)
45839545|NCT03002844|Drug|EGFR-TKI|EGFR-TKI (gefitinib 250mg per day)
45839546|NCT03002844|Drug|EGFR-TKI and Chemotherapy|pemetrexed 500mg per kg q3w/gemcitabine 1000mg per kg q3w and carboplatin AUC=5 q3w
45839547|NCT03002922|Drug|BAY987517|Sunscreen formula Y65-158
46033125|NCT04282863|Procedure|LM|All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained: a 10 mm port is inserted through the umbilicus to introduce the video-laparoscopic system. Other three accessory 5 mm trocar are inserted into the abdomen to the left lower quadrant, right lower quadrant, suprapubic area, for operative instruments and the suction irrigator cannula.
45472663|NCT01163825|Drug|Nerve Growth Factor|Encapsulated cell biodelivery of Nerve Growth Factor (NGF) to the basal forebrain nuclei of the brain by multiple implantable devices housing NGF-secreting human cells
45472664|NCT01163903|Drug|pantoprazole sodium for injection|Single 3-weekly doses of pantoprazole using the following dose escalation scheme for successive groups of patients: 80, 160, 240 and 320mg i.v. of pantoprazole to be given every 3 weeks, 30-60 (±5) minutes prior to doxorubicin. Treatment will be repeated on Day 1 of a 21-day cycle until radiographic or symptomatic progression or unacceptable toxicity or a maximum of 4 cycles (for patients who have received prior anthracyclines), and up to 8 cycles (for those with no prior exposure to anthracyclines).
45839548|NCT03003078|Device|OncoSil™|The implantation of OncoSil™
45839549|NCT03002688|Other|Survey|Verbal survey will be given before and after the cataract surgery, and on the day following the second cataract surgery.
46033126|NCT00652795|Drug|Doxycycline Monohydrate|Tablets, 150 mg, single-dose
46033127|NCT00652795|Drug|Monodox|Capsules 50 mg (3 x 50 mg dose), single-dose
45839550|NCT03002766|Procedure|Breast conservative surgery|
45839551|NCT03002532|Radiation|whole brain radiotherapy|
45839552|NCT03002220|Drug|radium-223|Radium-223 at a dose of 55 kBq
45683095|NCT04402528|Behavioral|Behavioral tools integrated within mehealth for ADHD software|Integrated functionality within the mehealth for ADHD software allows parents and teachers/childcare providers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.
46033128|NCT03778021|Behavioral|Behavioral Gardening Exposure|Assistance provided with planting and maintaining the school garden
46033129|NCT03778021|Behavioral|Healthy Eating and Gardening Curriculum|14 to 17 lessons (about 45 minutes each) throughout the school year, during the normal school day, that are focused on healthy eating and gardening, coordinated with the growing season
46033130|NCT00911170|Drug|Pegfilgrastim|Administered as a single 6 mg subcutaneous injection using a pre-filled syringe. There will be no dosage adjustments for investigational product.
46033131|NCT00911170|Drug|Placebo|Administered as a single subcutaneous injection using a pre-filled syringe.
46033132|NCT00911170|Biological|Bevacizumab|5 mg/kg by intravenous (IV) infusion on day 1 of each 14-day cycle.
46033133|NCT00911170|Drug|Standard Chemotherapy|"Each participant received one of the following chemotherapy regimens at the discretion of treating physician:~FOLFOX: Oxaliplatin, leucovorin, and 5-fluorouracil; FOLFIRI: Irinotecan, leucovorin and 5-flurouracil."
45683096|NCT01610336|Drug|INC280|During Phase Ib, INC280 was taken at escalating doses. During Phase II part, INC280 was taken at recommended Phase II dose.
45683097|NCT01610336|Drug|Gefitinib|Gefitinib 250 mg taken once daily
45683098|NCT03086200|Behavioral|brief Motivational Interviewing|"All study participants will receive daily dosing text message reminders.~Participants randomized to the MI-b Intervention and who are persistently non-adherence based on negative or non-responses to iTAB will be sent automated high alert messages notifying the participant to take their study medication and respond to iTAB. Both the study coordinator and the MI counselor will also receive the high alert message. Participants will be contacted by the MI counselor for a phone MI-b session within 72 hours of a high alert message to discuss adherence. Participants who continue to be non-adherent despite receiving these messages will be switched to receive alert messages on a monthly schedule."
45683099|NCT05689138|Other|Oral and Fecal Sample Collection|No interventions
45683100|NCT05685550|Drug|Toposide capsules combined with anrotinib and Emvolizumab group|Elderly patients with extensive SCLC were given etoposide capsules 100mg PO qd*7d and Envollizumab 300mg/ time IH Q3W in combination with anrotinib 12mg PO qd*14d,every 21 days until disease progression or adverse reactions that were tolerated.
45839553|NCT03002298|Behavioral|DMD gesture task|Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task
45839554|NCT03002298|Behavioral|DMD button-press task|Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
45839555|NCT03002298|Behavioral|Control group gesture task|Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task
45839556|NCT03002298|Behavioral|Control group button-press task|Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
45839557|NCT03002376|Drug|REGN2810|REGN2810 treatment
45839558|NCT03002064|Drug|Docetaxel|60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
46033134|NCT02644213|Other|protocol of using CAREN and MOTEK systems|"The subjects will perform randomly 3 experimental days (at least weak between one to another):~simulated road march using a virtual reality environment without additional load~simulated road march using a virtual reality environment which combines cognitive load during the road march. Cognitive tasks for example: navigation, identification and remembering cars/aircraft.~without physical or cognitive load (without march, waiting between performance evaluations) as control."
46033135|NCT00910975|Drug|Peg-interferon-alfa2a (Pegasys)|Peg-interferon-alfa2a 180 µg per week
46033136|NCT00910975|Drug|Ribavirin (Copegus)|Ribavirin 1000 or 1200 mg per day depending on if body weight is below or above 75 kg
46033137|NCT04165057|Other|Optimal muscle tension management|including TOF monitor and reversal of neuromuscular blockade agent : sugammadex
46033138|NCT00653887|Other|Biofeedback|4 sessions of biofeedback one session each week
46033139|NCT00653887|Other|Placebo|4 sessions, one each week, of discussion about anorectal disease
46033140|NCT01167881|Drug|BI 10773|Medium dose once daily
45472665|NCT01163903|Drug|doxorubicin hydrochloride injection|60 mg/m2, IV, scheduled on day 1 of every 3-week interval, 30-60 (±5) minutes after pantoprazole administration.
46033141|NCT01167881|Drug|Glimepiride|1-4 mg once daily
46033142|NCT01167881|Drug|Placebo|Placebo matching BI 10773
46033143|NCT01167881|Drug|Placebo|Placebo matching Glimepiride
46033144|NCT02646085|Drug|C11 Methionine positron emission tomography|diagnostic positron emission tomography imaging after intravenous injection of C11 Methionine
46033145|NCT02639767|Drug|Pemetrexed/Cisplatin|Dose escalation of pemetrexed and cisplatin will follow the dose levels. The escalation will not exceed 500 mg/m^2 for pemetrexed in combination with 75 mg/m^2 of cisplatin even if the maximum tolerated dose is not identified. Each treatment cycle of chemotherapy will be 21 days. Patients will receive up to 2 cycles of chemotherapy during the radiation, and be followed for any DLT during the radiation therapy and for 12 weeks afterwards.
46033146|NCT02639767|Radiation|Pleural Intensity Modulated Radiation Therapy|Pleura intensity modulated radiation therapy (IMRT) will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions. The prescription radiation dose may anywhere between 45 and 50.4 Gy in 25 fractions if necessary to meet the normal tissue dose constraints.
46033147|NCT02639767|Device|MRI|A pre-treatment MRI before chemo-RT will be acquired and will be used for target delineation. A three month post-treatment MRI will be acquired with the same protocol to assess the response from concurrent chemo-RT.
46033148|NCT04296136|Other|Advance Care Planning Discussion|Goals of care discussion with patient, documentation with electronic health record note and advance care planning billing. This will also include: pharmacy review of medications, case management review, and coding specialist review.
46033149|NCT02646241|Procedure|unroofing biopsy|Unroofing biopsy menas that the mucosa is resected with endoscopic mucosal resection and biopsies are done repeatedly for the exposed tumor with a conventional forcep. It will be performed for the patients with a suspected upper gastrointestinal subepithelial tumor after EUS-FNB. After unroofing biopsy, the final histopathological result will be used to determine diagnostic accuracy.
46033150|NCT02646241|Procedure|EUS-FNB(endoscopic ultrasonography guided fine needle biopsy)|EUS-FNB will be performed for the same patients who have a gastrointestinal subepithelail tumor before unroofing biopsy. EUS-FNB is called when the tissue is obtained by puncutre of a tumor, the tissue whithin the lumen of the fine needle being detached by rotatin, and the needle withdrawn. The pathological result will be also used to compare diagnostic accuracy between EUS-FNB & unroofing biopsy.
46033151|NCT02639689|Device|WALKAIDE|"A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.~Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device."
46033152|NCT04829344|Drug|AG-920|AG-920 Sterile Topical Ophthalmic Solution
46033153|NCT04829344|Drug|Placebo|Placebo Topical Ophthalmic Solution
46033154|NCT04166305|Genetic|Genetic study for SCN1A c.3184 A/G and CCL2-2518G>A polymorphism:|"DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN).~Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism"
45338924|NCT02833428|Device|Biomedical equipment (Eclipse Nim, Medtronic®)|"It is the principal investigator (coordinator investigator moving on the website of the Pitié-Salpêtrière) that will install bedside biomedical equipment for the project (Eclipse Nim, Medtronic®) The term of monitoring will depend of length of stay in the PACU (the post anesthesia care unit) Gaston Cordier and will not exceed 72 hours.~• Patients will be reviewed at 6 and 12 months for conventional control with establishing a ASIA score (American Spinal Cord Injury Association). Of SEP (Somatosensory evoked potentials) and MEP(Motor Engine Potentials) will be performed in the laboratory at 6 and 12 months (electrophysiology laboratory Pitié-Salpêtrière). They are part of the traditional support in the context of spinal cord trauma."
45472666|NCT01163981|Other|Use of ultrasound guidance in cannulation|Use of guidance with duplex ultrasound to complete cannulation of dialysis access
45839559|NCT03002064|Drug|Fluorouracil|5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles
45472667|NCT03281577|Drug|TAK-954|TAK-954 IV infusion.
45839560|NCT03002064|Drug|Cisplatin|Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles
46033155|NCT04522960|Diagnostic Test|MEG+hdEEG+MRI|"We will perform several tests:~Neuropsychological testing to evaluate evolution of cognition during our study.~Lumbar puncture, blood sampling, saliva and urine collection to assess melatonin levels at several timepoints within these biological fluids.~MEG+hdEEG and MRI (to project MEG information) ; LTM-EEG to detect epileptiform activity in patients and healthy controls"
45839561|NCT03001908|Other|glenohumeral mobilization-oscillation|posterior glide mobilizations oscillated at 1hz, 4 x 30 seconds
46033156|NCT00960063|Drug|Temozolomide|
46033157|NCT00960063|Drug|Vincristine|
46033158|NCT00960063|Drug|Ifosfamide|
46033159|NCT00960063|Drug|Irinotecan|
46033160|NCT00960063|Biological|Robatumumab|
45472668|NCT03281577|Drug|Placebo|TAK-954 placebo-matching IV infusion.
45683101|NCT05689060|Other|mulling Straight leg raising technique|Subject was in supine lying, therapist stood at the side of limited, therapist placed subjects flexed knee over therapists shoulder and subject was asked to push therapist away with his leg and then relax. At this point therapist pushed subjects bent knee up as far as in the direction of shoulder.
45683102|NCT05689060|Other|post facilitation stretch|Muscle energy technique was applied using post facilitation stretch While the participant lying in supine position, the pelvis was strapped down to the table for stabilization and control on accessory movement and the contralateral limb was securely strapped down to the table to prevent excessive hip and pelvic rotations during procedures.The participant's hip was passively flexed and the leg extended until tension was sensed and the participant reported a moderate stretching sensation.
45839562|NCT03001908|Other|glenohumeral mobilization-sustained|posterior glide mobilization, sustained 4 x 30 seconds
46033161|NCT00960063|Drug|Doxorubicin|
45839563|NCT03002142|Device|Hearing aids|Phonak Audéo B-R (Target V 5.0)
45839564|NCT03002142|Device|Placebo|Phonak Audéo B-R (Target V 5.0) without amplification
46033162|NCT00960063|Drug|Cyclophosphamide|
46033163|NCT00960063|Drug|Etoposide|
45839565|NCT03001752|Device|Open flap immediate implant|Post-extraction implants will be inserted through open flap, without bone grafting
45839566|NCT03001752|Device|Open flap immediate implant and bone grafting|Post-extraction implants will be inserted through open flap, adding bone grafting
45839567|NCT03001752|Device|Flapless immediate implant|Post-extraction implants will be inserted without elevating flap or inserting bone grafting
46033164|NCT02646319|Other|Laboratory Biomarker Analysis|Correlative studies
46033165|NCT02646319|Drug|Nanoparticle Albumin-Bound Rapamycin|Given IV
46033166|NCT02646319|Other|Quality-of-Life Assessment|Ancillary studies
46033167|NCT00653965|Drug|Rosuvastatin|
46033168|NCT00653965|Drug|Atorvastatin|
46033169|NCT02646163|Drug|REP 2055|"(First two patients) REP 2055 is administered once weekly by slow IV infusion in dose escalation from 100 to 1200mg until a grade 3 adverse event is observed not to exceed 40 weeks of dosing.~(Subsequent patients) 400mg of REP 2055 is administered by slow IV infusion. First week of infusion to include daily dosing followed by twice weekly dosing for 40 weeks."
46033170|NCT00959907|Drug|BOTULINUM TOXIN TYPE-A|"On Visit 1 (Day 0):~Botulinum toxin A (Dysport® and Botox®) will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~Dysport®: 4 units will be injected in the left or right forehead side.~Botox® : 2 units will be injected in the left or right forehead side.(opposite side of dysport injection)"
45472669|NCT04098367|Device|VIVITY|Extended vision intraocular lens intended for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed by extracapsular cataract extraction
45683103|NCT03088696|Other|stimulation|activation of the acupuncture point
45683104|NCT03088696|Other|no stimulation|no activation of the acupuncture point
46033171|NCT00912340|Drug|Everolimus|
46033172|NCT00912340|Biological|Trastuzumab|
46033173|NCT01167257|Drug|Liposome encapsulated botulinum toxin A|Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day
46033174|NCT01167257|Drug|Normal saline instillation|Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation
46033175|NCT01119846|Drug|GSK1292263|GSK1292263 is an immediate-release round, white, film-coated tablet provided in 3 strengths, 25mg, 75mg and 200mg being developed for the treatment of type 2 diabetes.
46033176|NCT01119846|Drug|GSK1292263 matching placebo|Matching placebo to active drug GSK1292263
46033177|NCT01119846|Drug|Sitagliptin|"Sitagliptin (Januvia) 100mg tablets are beige, round, film-coated tablets with 277 on one side."
46033178|NCT03775525|Drug|GZ17-6.02|Super enhancer Inhibition
45839568|NCT03001986|Biological|inactivated EV71 vaccine (KMB-17 cells)|Receiving 2 doses of the EV71 inactivated vaccine at an interval of 1 month.
46033179|NCT03775525|Drug|Capecitabine|antimetabolite
46033180|NCT00654043|Drug|Torsemide|tablets, 20 Mg, single-dose
46033181|NCT00654043|Drug|Demadex|Tablets, 20 mg, single-dose
45338925|NCT03922464|Device|Poly-L-lactic acid (Sculptra® Aesthetic)|"Sculptra® Aesthetic is a commercially available product that is licensed for sale in Canada. It is an injectable implant that contains microparticles of poly-L-lactic acid (PLLA), a biocompatible, biodegradable, synthetic polymer from the alpha-hydroxy-acid family. Sculptra® Aesthetic is suitable for increasing the volume of depressed areas, particularly to correct skin depressions, such as in skin creases, wrinkles, folds, scars and for skin aging. Sculptra® Aesthetic is also suitable for large volume corrections of the signs of facial fat loss (lipoatrophy).~The safety and efficacy of Sculptra® Aesthetic has been investigated in the literature and is generally considered safe and effective. PLLA has been used successfully to reverse HIV-associated lipoatrophy as well as to rejuvenate the face, neck, décolletage, hands, abdomen and gluteal regions."
46033182|NCT02816632|Other|mRI|Neural bases of feedbacks' influence on decision making processes
46033183|NCT02816632|Other|Effect of Galvanic Vestibular Stimulation on decision making processes|Galvanic Vestibular Stimulation (GVS) stimulates the vestibular system through low intensity electric currents applied at the basis of the VIII cranial nerve, upon the mastoid processes. In the Right-Anodal condition the positive electric charge is applied through electrodes placed upon the right mastoid and it mainly activates structures within the left brain hemisphere. In the Left-Anodal condition the positive electric charge is applied through electrodes placed upon the left mastoid and it mainly activates structures within the right brain hemisphere. In the SHAM condition, low intensity electric currents are applied 5 cm below the mastoid processes. This condition does not activate the vestibular system and serves as a control condition to account for unspecific activating effects of all electric stimulations (e.g., arousal, discomfort). The three conditions will be applied in three different sessions (i.e. days) in randomized order.
46033184|NCT04167007|Drug|Gemcitabine|Gemcitabine at 1000 mg/m² as intravenous (IV) infusion over 30-40 minutes on days 1, 8, and 15, followed by 1 week of rest, every 28 days
46033185|NCT04167007|Drug|FOLFOX|Oxaliplatin at 85 mg/m² given as a 2 hours IV infusion on days 1 and 15; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) in 250 ml glucose 5% solution given as a 2 hours IV infusion on days 1 and 15; and 5-FU 2400 mg/m² administered as continuous 46-hour IV infusion on days 1-3 and 15-17, every 28 days.
46033186|NCT01167179|Behavioral|nurse-led consultation|Content of the intervention The intervention consists of structured and standardised nursing follow up consultations comprising a thorough needs assessment, supportive counseling, adequate referral to other care providers if necessary and improvement of the continuity of follow-up care. The goals of nursing follow-up care are summarised as helping patients (and often their partners too) to cope with the physical and psychosocial consequences of treatment and help them to gradually adjust to 'the life after', and into survivorship.
45338926|NCT03375216|Behavioral|sensory testing (Heat, cold, and pressure)|sensory threshold measurement is the point at which the participant feels pain due to either heat, cold, or pressure
46033187|NCT04345120|Drug|SY-008|The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.
46033188|NCT04345120|Drug|SY-008 matching placebo|SY-008 matching placebo
46033189|NCT02951455|Behavioral|Critical Dialogue|Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.
46033190|NCT02951455|Behavioral|Capacity Building Project|Designed to create collaborative efforts to overcome and dismantle marginalizing processes by building positive social and organizational relationships and community capacity through the development and implementation of community projects aiming to address social determinants of health.
46033191|NCT02951455|Behavioral|Quality of Life Wheel|Aims to increase self-efficacy and help participants develop a vision for their future, breaking this vision down into small, feasible, measureable goals they can implement on a weekly basis (e.g. quitting smoking, improving relationships with family members, paying down debt).
45338927|NCT03375216|Behavioral|Promis Survey|PROMIS computer adaptive survey in anxiety, depression, pain behavior, fatigue, pian interference, physical function, sleep disturbance, self efficacy
45338928|NCT03365622|Drug|acetaminophen|Active Intravenous doses will consist of a single 1,000mg/100 ml IV dose with contents of commercial vials transferred to an empty sterile IV bag.
45338929|NCT03365622|Drug|Acetaminophen|500mg acetaminophen tablet ,2 capsules oral every six hours for 24 hours
46033192|NCT02951455|Behavioral|PF|Whether the intervention is delivered by a peer facilitator.
46033193|NCT02951455|Behavioral|LC|Whether the intervention is delivered by a licensed clinician.
46033194|NCT02639611|Other|Immediate Post Operative Acupuncture Treatment|acupuncture treatment immediately after surgery (twice a week for 6 weeks)
46033195|NCT02639611|Other|No Acupuncture Treatment|no acupuncture treatment for 6 weeks, but offered acupuncture at the end of the 6 week study period.
46033196|NCT01167023|Drug|Prasugrel|Administered orally, once daily for 30 days.
46033197|NCT01167023|Drug|Placebo|Administered orally, once daily for 30 days.
46033198|NCT04273126|Behavioral|Adapted Family Resilience Intervention|The program consists of approximately 8-10 modules lasting approximately one hour. Sessions focus on psychoeducation and key resilience skills.
46033199|NCT00654121|Drug|Actrapid HM|56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
46033200|NCT04336852|Procedure|Flow mediated dilation (brachial and femoral arteries)|Assessment of vascular function of the brachial and femoral arteries.
46033201|NCT04336852|Procedure|Cerebral vascular reactivity to carbon dioxide (CO2)|Cerebral blood flow responses to increasing partial pressure of CO2
46033202|NCT04336852|Procedure|Cerebral vascular function test|Cerebral blood flow responses to a reactive hyperemia stimulus
46033203|NCT03484117|Behavioral|Community Health Worker|Participants will receive 5 one-on-one sessions with a CHW over 24 weeks.
45338930|NCT03365622|Drug|Placebos|Placebo Intravenous doses will consist of 100ml of normal saline transferred to an empty sterile IV bag.
45338931|NCT03365622|Drug|Placebo Oral Tablet|Placebo, opaque capsules that have been filled with inert powder (lactose USP), 2 capsules oral every six hours for 24 hours
45338932|NCT00731120|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
45338933|NCT00731120|Drug|Placebo|Vortioxetine placebo-matching capsules
45338934|NCT02795442|Other|Even protein|5 day intake of even protein 3 day rotating menu.
45338935|NCT02795442|Other|Skewed protein|5 day intake of skewed protein 3 day rotating menu.
45338936|NCT02580006|Drug|EPORON|single dose administration subcutaneously
46033204|NCT03421288|Drug|Atezolizumab|Day 1 q2w: 840 mg IV over 1 hour (4 cycles perioperative with FLOT) + Day 1 q3w: 1200 mg IV over 1 hour (8 additional cycles monotherapy)
46033205|NCT03421288|Drug|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
46033206|NCT03421288|Drug|Calciumfolinat|Day 1 q2w: 200 mg/m² IV over 1 hour
46033207|NCT03421288|Drug|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
46033208|NCT03421288|Drug|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
46033209|NCT01166945|Drug|Amoxicillin-Potassium Clavulanate Combination|All subjects will be started on treatment with 5 days of high dose amoxicillin (90mg/kg) with potassium clavulanate (6.4 mg/kg) twice daily in bottle A. The allocation to group B1 or B2 will be concealed until after the family and subject has signed the assent and consent, respectively. The maximum dose will be 2 gms twice daily. After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
46033210|NCT01166945|Drug|Placebo|After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
45338937|NCT02580006|Drug|EPREX|single dose administration subcutaneously
46033211|NCT02639533|Drug|Pregabalin|Pregabalin 150 mg PO, single dose.
46033212|NCT02639533|Other|Placebo|Pill of same physical characteristics as the one used for the intervention, containing starch only. Administered PO in single dose.
46033213|NCT03603730|Device|taVNS|Active or inactive taVNS delivered to the external ear at a moderate, non-painful level.
46033214|NCT02885987|Device|AmplifEYE|AmplifEYE will be attached to the tip of the colonoscope prior to start of procedure.
46033215|NCT02646007|Biological|BM-MSC transplantation|Transplantation of bone marrow derived mesenchymal stem/ stromal cells in combination with bone decompression surgery in Kienböck's disease.
46033216|NCT02885675|Other|blood sampling|sample no more than 3ml
45338938|NCT00731042|Drug|Avagard|Topical solution, 6 mL, 6 applications/day for 14 days.
45338939|NCT00731042|Drug|Purell Surgical Scrub|Topical solution, 4 mL, 6 applications/day for 14 days.
45338940|NCT02787642|Drug|Olaparib|Olaparib will be administered per os bidaily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression.
46033217|NCT02639377|Drug|Chlorhexidine gluconate|
45338941|NCT02787642|Radiation|Concomitant Radiotherapy|Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.
45683105|NCT05688982|Behavioral|General information provision|Patients will receive information with general oral health and aSDoH resources.
45683106|NCT05688982|Behavioral|Geographic information provision|Patients will receive information with geographically-proximate oral health and aSDoH resources based on a directory created by the study team.
46033218|NCT02639377|Drug|Placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
46033219|NCT02639455|Behavioral|Exercise|Participants will exercise 4 days per week, 20 minutes per session for 5 weeks (a total of 400 minutes). Exercise will be independent (with the goal of 85% of max effort for at least 2 minutes each session) and consist of running, jumping jacks, sit ups, push ups, or burpees depending on the participant's comfort and skill.
46033220|NCT00910000|Drug|Vorinostat|
46033221|NCT00910000|Drug|Carboplatin|
46033222|NCT00910000|Drug|Gemcitabine|
46033223|NCT02885909|Device|CONTINUE GLUCOSE MONITOR|Continue glucose monitor
46033224|NCT02885909|Procedure|Insulin protocal|Using insulin protocal based on glucose monitor
45683107|NCT05688982|Behavioral|Navigational assistance|Patients will receive phone-based navigational assistance from the study navigator.
46033225|NCT02700945|Device|Reveal LINQ™ Insertable Cardiac Monitor|The Medtronic Reveal LINQ™ ICM is a programmable device that continuously monitors a patient's ECG (electrocardiogram) and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient activation.
46033226|NCT05657171|Drug|cyproterone Acetate/Ethinyl Estradiol Combination|cyproterone acetate (CPA) 2 mg, combined with EE 35 µg.
45338942|NCT02740218|Other|Patient questionnaire|Patients will be asked to complete a questionnaire regarding their expectations, experience and satisfaction in taking OTEZLA (apremilast) treatment
46033227|NCT00652873|Drug|Cabergoline|Tablets 0.5 mg (2 x 0.5 mg dose), fed
46033228|NCT00652873|Drug|Dostinex|Tablets, 0.5 mg (2 X 0.5 mg dose), fed
46033229|NCT02887235|Other|Home Delivered, Medically Tailored Meals (HDTM)|
46033230|NCT03253978|Radiation|Stereotatic Radiotherapy|SABR to prostate / seminal nodes
46033231|NCT00652171|Drug|Lamotrigine|Lamotrigine was added to the ongoing antidepressant. The doses were titrated to 200mg/day.
45338943|NCT02594774|Other|Manipulative osteopathy|Osteopathic treatment (BMT) which works on the influence on the pressure distribution in the (especially abdominal) body cavities and consequently on the viscera contained therein, proper arterial supply and venous and limphatic drainage.
45338944|NCT02580162|Behavioral|FBT for Pediatric Weight Management by Professionals|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is delivered by PROFESSIONAL interventionists.
45472670|NCT04098367|Device|SYMFONY|Extended range of vision intraocular lens indicated for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of pre-existing corneal astigmatism in whom a cataractous lens has been removed
46033232|NCT00652171|Dietary Supplement|Amide|Capsule of amide were given to this group of patients. They continued the ongoing antidepressants.
45839569|NCT03001596|Procedure|Neoadjuvant Chemoradiotherapy|Before surgery, patients in this group receive neoadjuvant chemoradiotherapy. A total dose of 40 Gy is delivered in 20 fractions (5 fractions per week) for 4 weeks. Chemotherapy is delivered concomitantly and composed of four cycles of paclitaxel 50mg per square meter of body-surface area and cisplatin 25mg per square meter of body-surface area weekly at the intervals of radiotherapy. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
46033233|NCT01119768|Drug|Esomeprazole|20mg Esomeprazole once daily, 8 weeks and 24 weeks on-demand treatment
46033234|NCT01119768|Drug|Esomeprazole|20mg Esomeprazole once daily, 2 weeks and 24 weeks follow up
46033235|NCT04281303|Procedure|Endoscopic vertical gastroplasty|endoscopic vertical gastroplasty + lifestyle modification
46033236|NCT02885831|Device|Abduction splintage|Treatment by abduction splintage 24 hours a day and 7 days a week, for 2 months.
46033237|NCT02904577|Other|Any treatment, watch and wait policy included|"Patients registered in the study despite their planned treatment, watch and wait policy included. The planned treatment mentioned in the protocol is just the ideal approach proposed by investigators.The treatment can change depending on the evolution of the disease, without this affects the study's purposes."
46033238|NCT02859363|Genetic|26 common Fabry mutation types in Taiwan|Historical DNA samples from projects 103-3254C (98-3889A3) and 100-4008C (97-0470B) will perform specific genetic testing.
46033239|NCT02656953|Other|VDU lenses (Zeiss® Officelens Plus)|The treatment group (n=22) was given progressive VDU glasses (Zeiss® Officelens Plus), specially designed for VDU work. The participants were asked to wear their new glasses for six months during computer work.
46033240|NCT02656953|Other|Progressive lenses (Zeiss® Multifocal Precision Plus)|The comparison group (n=18) was given progressive glasses (Zeiss® Multifocal Precision Plus). The participants were asked to wear their new glasses for six months during computer work.
46033241|NCT02645929|Behavioral|Interpersonal Psychotherapy (IPT)|IPT is a 14 week psychotherapy for PTSD. SSRF is a brief interview to assess emotional understanding of one's symptoms.
46033242|NCT01165307|Drug|Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills|Each packet consists of a fixed dose of 30mcg estradiol and a 150mcg dose of levonorgestrel for the first 21 days of the cycle, followed by a 7 day pill free period. Subjects will be instructed to administer the pills orally, starting 5 days after the start of menstrual blood flow, continuing cyclically, thus allowing for withdrawal bleeding after the 21 day pill cycle.
46033243|NCT01165307|Drug|Naproxen sodium pills|As an alternative to oral contraceptive pills, subjects may take Naproxen 500 mg with onset of menses, then 250 mg three times daily for the duration of the menses (or maximum of five days)
46033244|NCT01165307|Device|NovaSure® Radiofrequency Endometrial Ablation|Radiofrequency endometrial ablation is performed in the outpatient surgery department. Subjects receive intravenous medication, determined by the attending anesthesiologist, sufficient to induce conscious sedation during the procedure.
45472671|NCT04098367|Device|AT LARA|Extended depth of focus intraocular lens indicated for implantation for the visual correction of aphakia in patients with and without presbyopia in whom a cataractous lens has been removed by extracapsular cataract extraction
46033245|NCT02639143|Drug|ticagrelor|
46033246|NCT02639143|Drug|Clopidogrel|
45472672|NCT04098367|Procedure|Cataract surgery|Cataract removal by routine small incision surgery
45472673|NCT03759587|Drug|Niraparib|Niraparib capsule
45472674|NCT03745807|Biological|NKTR-214|Specified dose on specified days
45472675|NCT03745807|Biological|Nivolumab|Specified dose on specified days
45472676|NCT01164059|Drug|Olanzapine|Olanzapine 10, 15, or 20 mg / day
45472677|NCT01164059|Drug|Flupentixol|Flupentixol 6, 9, or 12 mg / day
45472678|NCT01164059|Drug|Quetiapine|Quetiapine 400, 600, or 800 mg / day
46033247|NCT02536027|Procedure|continuous venovenous hemofiltration|Continuous renal replacement therapy (CRRT) has become routine for patients with AKI, chronic renal failure, ﬂuid overload as well as oliguria in ICU. In clinical practice, continuous venovenous hemofiltration (CVVH) is actually the method of choice for CRRT in critically ill and hemodynamic instable patients. CVVH has significant beneficial effects on removing inflammatory cytokines, improving oxygen index, decreasing vasopressor requirements, increasing cardiac index, and regulating immune dysfunction, specifically in patients with septic shock.
46033248|NCT02645773|Device|non-ablative laser|non-abaltive laser pre, immediate and post wounding
46033249|NCT02644057|Drug|Milrinone|Patients who meet the inclusion criteria for the study will receive milrinone and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
46033250|NCT02644057|Drug|Dobutamine|Patients who meet the inclusion criteria for the study will receive dobutamine and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
46033251|NCT00960999|Radiation|Single-fraction stereotactic body radiation therapy (SBRT)|34 Gy in 1 fraction to the prescription line at the edge of the planning target volume (PTV). The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and < 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least < 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be < 10%.
46033252|NCT00960999|Radiation|Multiple-fraction stereotactic body radiation therapy (SBRT)|48 Gy in four 12 Gy fractions to the prescription line at the edge of the planning target volume (PTV). Treatments are given on 4 consecutive calendar days, but at least 18 hours apart. The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and < 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least < 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be < 10%.
46033253|NCT00654277|Drug|Ondansetron|ODT, 8 mg, single-dose
46033254|NCT00654277|Drug|Zofran|ODT, 8 mg, fasting conditions
46033255|NCT01124838|Drug|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by 40 mg eow starting at Week 1.
46033256|NCT01124838|Drug|Prednisone|Administered orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all subjects continuing in the study were to discontinue prednisone no later than Week 19.
46033257|NCT01124838|Drug|Placebo|Administered by subcutaneous injection
46033258|NCT02639221|Drug|PXT002331|
46033259|NCT00959751|Drug|NXN-188|200 mg capsules, 600 mg, PRN
45472679|NCT01164059|Drug|Aripiprazole|Aripiprazole 10, 15, or 20 mg / day
45839570|NCT03001596|Procedure|Neoadjuvant Chemotherapy|Before surgery, patients in this group receive neoadjuvant chemotherapy. Chemotherapy is delivered and composed of two cycles of paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 4 weeks. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
45839571|NCT03001596|Procedure|Minimally Invasive Esophagectomy|After neoadjuvant therapy, patients in groups receive minimally invasive esophagectomy
45839572|NCT03001830|Biological|AAV2/8-HLP-FVIII-V3|Infusion of AAV2/8-HLP-FVIII-V3
45472680|NCT01164059|Drug|Haloperidol|Haloperidol 3, 4.5, or 6 mg / day
45598801|NCT03545321|Behavioral|MOON+|MOON+ is an intervention to support the pharmacy and pharmacist to improve opioid safety and naloxone provision. Materials include educational trainings, materials for use with pharmacists, information for patients, and materials for standardizing overdose safety at the pharmacy
45839573|NCT03001440|Other|KAB survey|The KAB survey will be conducted among study population to evaluate their understanding of the potential serious risk with the use of ZYBAN. The 20 minutes survey can be completed either online or through a telephone interview.
45839574|NCT03001284|Other|NO intervention|
46033260|NCT00959751|Drug|Placebo|200 mg capsules with no active ingredient designed to match the NXN-188 capsules
46033261|NCT00630435|Drug|Premarin®/MPA formulation A|
46033262|NCT00630435|Drug|Premarin®/MPA formulation B|
46033263|NCT00630435|Drug|Premarin®/MPA formulation C|
46033264|NCT00630435|Drug|Premarin®/MPA currently marketed product|
45839575|NCT03001050|Device|PINPOINT System|To use the camera probe and identify the tendon and footprint vascularity at the time of surgery
45839576|NCT03000972|Procedure|Cement augmentation|
45839577|NCT03000972|Procedure|PFN-A Nail|
46033265|NCT02858193|Drug|1.35 g SCMC- lys powder|1.35 g SCMC- lys powder for oral solution
46033266|NCT02858193|Drug|Fluifort® syrup|SCMC-lys Syrup 90 mg/ml
46033267|NCT02858115|Other|Fluid challenge|100 ml of crystalloid was infused over 1-min
46033268|NCT02858115|Other|Trans-oesophageal echography|an echocardiographic assessment at 1-min,
46033269|NCT00630591|Behavioral|Standardized Materials Group|7 sets of print materials will be mailed every 6-7 weeks. A short survey about the information received and how useful it was will be completed.
46033270|NCT00630591|Behavioral|Independent Tailored Intervention|Personalized notebooks and newsletters of diet and exercise information will be mailed. A short survey about the information received and how useful it was will be completed.
46033271|NCT00630591|Behavioral|Partner-Assisted Tailored Intervention|Daughters and Mothers, as a team, will each receive personalized notebooks and newsletters of diet and exercise information. A short survey about the information received and how useful it was will be completed.
45839578|NCT03001206|Device|Master Caution System|"The purpose of this study is to evaluate the effectiveness and usability of the Master Caution System for 12 leads continuous monitoring of ECG signal in the ICCU.~The purpose of the study is to evaluate the effectiveness and usability of using Master Caution 12 leads Garment for stress test.~The purpose of the study is to reassess the adequate size of the Master Caution Garment (MCG)."
46033272|NCT02859675|Other|triangular test|metabolic state, impedance measurement, potential flavours evoked by sucrose,
46033273|NCT02859675|Biological|blood sampling|sampling of 2 mL
46033274|NCT02859675|Other|Questionnaires|Stunkard, PrefQuest
45839579|NCT03001128|Drug|Antiretroviral treatment pause|Antiretroviral treatment pause
45839580|NCT03000894|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This CBT-I is a 4 sessions 60-90 minutes group-based therapy administered by a nurse therapist. Each session has 6-8 participants.
45839581|NCT03000660|Drug|Venetoclax|Venetoclax at one of four escalating doses
46033275|NCT02581215|Drug|mFOLFIRINOX|"mFOLFIRINOX:~Oxaliplatin 85 mg/m2 over 2-4 hours~Irinotecan 165 mg/m2 over 90 minutes~5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia."
46033276|NCT02581215|Drug|Ramucirumab|Ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks.
45338945|NCT02580162|Behavioral|FBT for Pediatric Weight Management by Peers|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is provided by PEER interventionists.
45338946|NCT02580162|Behavioral|Peer Interventionists|Parents who receive FBT complete 6 weeks of training and then serve as peer interventionists to a new group of families.
45839582|NCT03000660|Drug|Dexamethasone|Dexamethasone 20mg by mouth on days 1, 8, 15, and 22 of each cycle.
46033277|NCT02581215|Other|Placebo|Placebo infusion with volume calculated as if it were ramucirumab every 2 weeks.
46033278|NCT04282941|Drug|Ibuprofen in continuous (24 hours) iv infusion and EchoG|The first dose of ibuprofen will be 10 mg / kg to be administered as a continuous infusion for 24 hours. An echocardiogram will be performed before each of the following 2 doses of 5 mg / Kg and will only be administered if it meets echocardiographic criteria that indicate open DA (observation of ductus permeability with color Doppler regardless of its size). Each dose will be administered as a 24-hour continuous infusion.
46033279|NCT04282941|Drug|IV bolus Ibuprofen slow (15 minutes) and EchoG|The first dose of ibuprofen of 10 mg / Kg to be administered in slow iv bolus (15 minutes). Before each of the following 2 doses of 5 mg / Kg, echocardiography will be performed and will only be administered if it meets the echocardiographic criteria indicated by open DA (observation of ductus permeability in color Doppler regardless of its size). Each dose will be administered in iv boluses in 15 minutes
46033280|NCT04280913|Other|retrospective analysis|The investigators retrospectively analyzed the hospitalized patients with COVID-19.
46033281|NCT04282707|Procedure|Endoscopic closure of ESD defect|Closure of ESD defect would be performed with clip loop purse string technique
46033282|NCT04282707|Other|Gastric ESD without closure of ESD defect|Historical control with patients undergoing ESD without closure of ESD defect
45472681|NCT04091659|Other|Virtual Reality Education|Virtual Reality Education (Intervention): The experimental group of libraries will receive the virtual reality simulation, which is guided by the NLN Jeffries Simulation Theory, and lasts 9 minutes. The virtual reality education is based on scenes and dialogue conducted during the hybrid high-fidelity simulation, from a script developed using the existing hybrid simulation on opioid overdose intervention. This virtual reality education is an educational intervention.
45472682|NCT04091659|Other|Standard Education|Standard Educational (Control): The public health department's training includes printed handouts on how to administer naloxone and youtube videos on how to spot signs and symptoms of overdose and administer naloxone. Additionally, staff are on hand to provide one on one verbal educational trainings to local community members voluntarily seeking education.
45598802|NCT03158961|Procedure|Transoral endoscopic thyroidectomy vestibular approach|TOVETA is a new approach in surgery of thyroidectomy no longer open on the neck
45598803|NCT03542669|Drug|6B11-OCIK Injection|Two infusions of 6B11-OCIK will be performed at each chemotherapy cycle (Day 3 an Day 7) during the first three cycles, while PBMC will be collected before each cycle (Day -12) during the first three cycles.
45839583|NCT03000582|Dietary Supplement|Creatine monohydrate|Creatine monohydrate (5.0 g creatine monohydrate, 1.5 g dextrose)
45839584|NCT03000582|Dietary Supplement|Creatine nitrate-1|Creatine nitrate-1 (1.0 g creatine monohydrate, 0.5 g nitrate, 5.0 g dextrose)
45338947|NCT04075188|Drug|Aflibercept Injection|Patients will be treated with combined therapy to determine the synergy of this treatment, causing anti- Vascular Endothelial Growth Factor (anti-VEGF) to block neovascular exudation and photodynamic therapy to close aneurismal vessel and reduce choroidal vascular congestion.
45338948|NCT00726986|Drug|cisplatin|Cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
45839585|NCT03000582|Dietary Supplement|Creatine nitrate-2|Creatine nitrate-2 (2.0 g creatine monohydrate, 1.0 g nitrate, 3.5 g dextrose)
45338949|NCT00726986|Drug|etoposide|Etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
45338950|NCT00726986|Drug|sorafenib tosylate|Oral sorafenib tosylate twice daily beginning on day 1 of course 1 and continuing for up to 1 year in the absence of disease progression or unacceptable toxicity.
45338951|NCT02594852|Device|+ laser|Use of laser in the treatment
45338952|NCT02594540|Device|Mechanical Peripheral Stimulation (GONDOLA)|
45338953|NCT02594306|Device|Emotional pictures stimulation system|Emotional pictures stimulation system is component of neutral and drug-related images.
45338954|NCT02594306|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral NAc/ALIC
45338955|NCT02594306|Procedure|adjacent contact stimulation|The electrode of deep brain stimulation has four contacts.We stimulate one contact,and record the local field potential of other contacts.
45598804|NCT03542669|Drug|Doxorubicin|Subjects will be adminitered 4~6 cycles of chemotherapy (Doxorubicin, 30 mg/m^2 IV on Day 1 of every cycle)
45839586|NCT03000582|Dietary Supplement|Placebo|Placebo (6.5 g dextrose)
46033283|NCT04282395|Behavioral|Resilience-Based Diabetes Self-Management Education|"During the group sessions led by professional nurses, participants are provided information and group activities to enable them to more effectively manage their personal diabetes challenges. During the support group sessions, participants discuss personal challenges and solutions to diabetes self-management, using a more informal approach. Booster sessions are held to refresh participants' understanding of how resilience resources can sustain self-management behaviors and maintain improved T2DM health outcomes. The RB-DSME also incorporates cultural characteristics and preferences of African Americans (AAs), to include:~the location in community-based church settings,~recognition of cultural dietary preferences, and~emphasis on cultural/historical significance of resilience in AAs."
46033284|NCT04282395|Behavioral|Standard Diabetes Self-Management Education|"Control group sessions, led by professional nurses, cover topics such as:~causes and symptoms of type 2 diabetes,~glucose self-monitoring,~models for and principles of healthy eating, grocery shopping and dining out,~physical activity,~diabetes medications,~managing sick days and stress, and~community resources."
46033285|NCT00910858|Drug|Lenalidomide|Lenalidomide 5-mg capsules for oral administration
46033286|NCT00910858|Drug|Recombinant human erythropoietin|Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units.
46033287|NCT02567253|Procedure|Cytoreductive surgery|Complete or nearly complete (CC-0 or CC-1) macroscopic cytoreduction at the time of surgery of peritoneal carcinomatosis from ovarian cancer
45338956|NCT02594306|Procedure|microelectrode|We put the microelectrodes into bilateral nucleus accumbens and anterior limb of the internal capsule,to record the waveform of bilateral NAc/ALIC.
45338957|NCT03334266|Behavioral|Family Spirit Nurture (FSN)|The FSN home-visiting module consists of 36 60-minute lessons delivered by trained local FHCs, from 28 weeks gestation to 18 months postpartum. The lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.
46033288|NCT02567253|Drug|IPEC with Cisplatin (75mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (75mg/m²) , during 90min
46033289|NCT02567253|Drug|IPEC with Cisplatin (100mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (100mg/m²), during 90min
45338958|NCT03334266|Other|Injury Prevention Education (IPE)|The control group will receive Injury Prevention Education (IPE). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.
45338959|NCT03334266|Other|Optimized Standard Care (OSC)|OSC will be available to both in the FSN intervention and control groups. OSC consists of transportation assistance to prenatal and well-baby clinic visits as recommended by the Indian Health Service (IHS) and American Academy of Pediatrics (AAP) and rescue services through linkages to community agencies as needed.
45338960|NCT00696657|Drug|semaglutide|0.1 mg, once weekly, s.c. injection
45338961|NCT00696657|Drug|semaglutide|0.2 mg, once weekly, s.c. injection
46033290|NCT02567253|Drug|Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (75mg/m²), during 90min
45839587|NCT03000816|Radiation|SBRT|Patients with 1-4 metastases located in less than 2 organs/ lymphatic drainage regions that are 5 cm or less from each other and simultaneously treated with SBRT.
45839588|NCT03000504|Device|Ballooned intercostal drain|Patients will have a Rocket Medical 16F ballooned intercostal drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
45839589|NCT03000270|Device|Impella unloading prior to PPCI|Impella unloading prior to PPCI
45839590|NCT03000114|Procedure|Percutaneous Needle Aponeurotomy|
45472683|NCT02814708|Biological|rTSST-1v|Each subject of a total of seven groups will receive three injections (first injection day 0; second injection 3 months ± 4 weeks after the first, third injection 6 months ± 4 weeks after the second) of one of two different doses of Vaccine or Adjuvant, each group comprising 20 subjects. Subjects will be controlled 24 h post vaccination. Follow-up will last 18 months on the average, with visits every three months (± 2 weeks). Response to treatment is defined by seroconversion from a TSST-1 binding Ab titer of < 20 to > 40 or a 4-fold increase in TSST-1 binding Ab titer .
45839591|NCT03000114|Drug|XIAFLEX|
45839592|NCT03000036|Drug|Doxorubicin|Patients had prescribed endovenous doxorubicin as part of their chemotherapy regimen (mean cumulative dose 102,66 mg/m2, administered in 4 doses with 21 days interval).
46033291|NCT02567253|Drug|HIPEC with Cisplatin (100mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (100mg/m²), during 90min
46033292|NCT02859285|Other|Placebo vulvar cream|
46033293|NCT02859285|Other|Estradiol vulvar cream|
46033294|NCT04260412|Device|medium cut-off (MCO) dialysis membrane|Medium cut-off dialysis (MCO) membrane is a dialysis membrane with a higher molecular weight retention onset and similar cut-off as standard high-flux dialysis membranes. It is capable of providing increased clearance of medium sized uremic toxins and some plasma proteins (cytokines, inflammatory mediators).
45338962|NCT00696657|Drug|semaglutide|0.4 mg, once weekly, s.c. injection
45472684|NCT01268813|Other|Breath analysis and blood analysis|Exhaled breath and blood samples will be collected and further tested using Gas Chromatography-Mass Spectroscopy system.
46033295|NCT04260412|Dietary Supplement|Dietary fiber mixture (Plantago Psyllium 69% and Inulin 30%)|Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.
45338963|NCT00696657|Drug|semaglutide|0.8 mg, once weekly, s.c. injection
45472685|NCT03879005|Other|renal scintigraphy|"99mTc-DTPA Scintigraphy Five mci of 99mTc-DTPA will be injected by IV route together with diuretic. Dose will be adjusted according to the age and weight of the patients. A total of 20 min dynamic imaging followed by calculation of GFR and SRF according to the built-in processing protocol Gate's method.~99mTc-DMSA scintigraphy Five mci of 99mTc- DMSA will be injected by IV route with adjustment according to age and weight. Static images will be acquired in the posterior, anterior, andposterior oblique projections for 60 s each."
45472686|NCT04256785|Dietary Supplement|VSL#3|sachets containing probiotic
45472687|NCT04256785|Dietary Supplement|Placebo|sachets containing placebo
45472688|NCT03878771|Biological|Platelet rich fibrin gel in Orabase|applied on oral mucositis and /or ulcer 3 times per day
45472689|NCT03878771|Drug|Dermovate cream in Orabase|applied on oral mucositis and /or ulcer 3 times per day
45338964|NCT00696657|Drug|semaglutide|0.8 mg with titration, once weekly, s.c. injection
45338965|NCT00696657|Drug|semaglutide|1.6 mg with titration, once weekly, s.c. injection
45338966|NCT00696657|Drug|placebo|0.1 mg, once weekly, s.c. injection
45472690|NCT02959918|Drug|SEL-212|SEL-212, biologic
45472691|NCT02959918|Drug|SEL-037|SEL-037, biologic
46033296|NCT04260412|Dietary Supplement|Sodium propionate|Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.
46033297|NCT03223155|Drug|Nivolumab|"Patients in Sequential Arm will begin treatment with nivolumab (given with ipilimumab) between 1-7 days after completion of SBRT.~Patients in Concurrent arm will begin treatment with nivolumab (given with ipilimumab) first and will continue treatment within 2 weeks, after completion of SBRT to 2-4 sites.~In both arms, patients will receive treatment with nivolumab 3 mg/kg as a 30-minute infusion +/- 10 minutes every 2 weeks for a maximum of 24 months. Patients will receive treatment on days 1, 15, and 29 of each 6 week cycle."
45338967|NCT00696657|Drug|placebo|0.2 mg, once weekly, s.c. injection
45338968|NCT00696657|Drug|placebo|0.4 mg, once weekly, s.c. injection
45338969|NCT00696657|Drug|placebo|0.8 mg with titration, once weekly, s.c. injection
45338970|NCT00696657|Drug|placebo|1.6 mg, once weekly, s.c. injection
45338971|NCT00696657|Drug|liraglutide|1.2 mg with titration, once daily, s.c. injection
45472692|NCT02959918|Drug|SVP-rapamycin (SEL-110)|SVP-rapamycin, biologic
45472693|NCT01160159|Other|Tests|Arterial parameters
45472694|NCT01160159|Other|Healthy volunteers|Arterial parameters and blood test
45472695|NCT01266707|Biological|antiangiogenic paptide vaccine|for drugs include administration time frame
45472696|NCT03263442|Drug|Thiamine|200 mg IV three times daily for seven days
45472697|NCT03263442|Drug|Normal saline|Normal saline IV three times daily for seven days
46033298|NCT03223155|Drug|Ipilimumab|"Patients in Sequential Arm will begin treatment with ipilimumab (given with nivolumab) between 1-7 days after completion of SBRT.~Patients in Concurrent arm will begin treatment with ipilimumab (given with nivolumab) first and will continue treatment within 2 weeks, after completion of SBRT to 2-4 sites.~In both arms, patients will receive treatment with ipilimumab 1 mg/kg as a 30-minute +/- 10 minutes infusion every 6 weeks for a maximum of 24 months. Patients will receive treatment on day 1 of each 6 week cycle."
46033299|NCT03223155|Radiation|Stereotactic body radiation therapy|All patients will receive 3 or 5 fractions of radiation as determined by the location of the lesions to be irradiated. There should be a minimum of 40 hours between treatments for an individual lesion. However, a patient may receive radiation for different lesions on consecutive days. Starting dose depends on metastasis locations.
46033300|NCT02859051|Device|Humanoid Robot MEDi|Humanoid robot programmed with cognitive-behavioral interventions such as role modeling, teaching coping strategies, positive reinforcement, parent encouragement
46033301|NCT04476550|Drug|Filgrastim|5 days of daily sub-cutaneous administration of 10mcg/kg filgrastim
46033302|NCT00598975|Drug|NKTR-102 100 mg/m2|"NKTR-102 100 mg/m2 + Cetuximab Arm:~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
45338972|NCT00696657|Drug|liraglutide|1.8 mg with titration, once daily, s.c. injection
45472698|NCT01164215|Drug|fluorouracil|200-400 mg/m2 intravenously, 1 -5 minutes, once every 2 weeks 2400 mg/m2 intravenously over a period of 46 hours, once every 2 weeks
45338973|NCT00730886|Device|ExAblate 2000|Magnetic resonance image guided focused ultrasound (MRgFUS) for fibroid ablation
45472699|NCT01164215|Drug|leucovorin|200-400 mg/m2, intravenously over a period of 2 hours, once every 2 weeks
45338974|NCT00730886|Procedure|Myomectomy|Invasive surgical procedure for fibroid removal
45338975|NCT01877772|Procedure|Bone Trephination|For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
45472700|NCT01164215|Drug|oxaliplatin|85 mg/m2, intravenously for 2 hours, once every 2 weeks
45598805|NCT03146481|Drug|Aceclofenac|Aceclofenac 100 mg tablet given one hour before starting the root canal treatment
45598806|NCT03146481|Other|Placebo|Placebo tablet given one hour before starting the root canal treatment
46033303|NCT00598975|Drug|NKTR-102 125 mg/m2|"NKTR-102 125 mg/m2 + Cetuximab Arm:~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
46033304|NCT00598975|Drug|Cetuximab|Cetuximab was administered once weekly via a 2-hour IV infusion at a starting dose of 400 mg/m2 on Day 1 and subsequently administered weekly at 250 mg/m2 via a 1-hour infusion thereafter.
46033305|NCT00957021|Device|Triathlon® PS Total Knee System|Triathlon® PS Total Knee system
45338976|NCT01877772|Procedure|Control|The control group will undergo standard rotator cuff repair.
45338977|NCT02720874|Behavioral|Rheumatoid arthritis educational booklet|Participants will receive a low-literacy rheumatoid arthritis educational booklet that provides general disease state information.
46033306|NCT01124604|Drug|Tapentadol Hydrochloride|Tapentadol hydrochloride extended release (ER) tablets 25 to 250 milligram (mg) will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
45338978|NCT02720874|Behavioral|Multidisciplinary rheumatologic care|At each regularly scheduled clinic appointment, participants will receive treatment from their assigned rheumatologist, undergo an in-clinic physical therapy evaluation and, if indicated, a psychological evaluation. Physical therapy and psychology follow-up sessions will occur as directed by the individual services.
45338979|NCT02720874|Behavioral|Nurse education and monthly calls|Participants will meet one-on-one with a rheumatology nurse for a tailored educational session encompassing disease state education, an introduction of the treat to target concept, an overview of treatment options, and goal setting and planning. During monthly follow-up calls, participant educational needs will be addressed; goal setting, planning and review will also be conducted.
45338980|NCT02720874|Behavioral|Monthly healthcare coordinator calls|During monthly calls with the healthcare coordinator, specific questions and concerns raised by participants may be addressed. The primary purpose of these calls is to control for potential benefit derived from time on the phone with a health professional.
45338981|NCT02720874|Behavioral|Technology-based symptom monitoring and reporting|When at home patient self-monitoring reports indicate a significant increase in RA disease activity, participants will be promptly contacted and scheduled for an ad hoc evaluation with their treating rheumatologist.
45598807|NCT03521401|Behavioral|Exercise|Participants assigned to the exercise group will undergo structured, progressive resistance and aerobic exercise for 8 weeks. Resistance training and aerobic training will each be completed twice weekly for a total of 16 resistance and 16 aerobic exercise training sessions.
45598808|NCT02353767|Procedure|Noninvasive evaluation of liver fibrosis and steatosis|Transient elastography (using the Fibroscan, CAP Fibroscan) and biomarker panels (FibroTest, Fibromètre, Hepascore, Steatotest, Nashtest)
46033307|NCT01124604|Drug|Placebo|Placebo matched to tapentadol hydrochloride ER tablets 25 to 250 mg will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
46033308|NCT00909844|Drug|Triptorelin (I.N.N.)|Decapeptyl® SR 11.25mg
46033309|NCT02645695|Device|routine pulmonary rehabilitation|received routine pulmonary rehabilitation consisted of position giving technique (left lateral, supine, right lateral), chest wall percussion, postural drainage and airway aspiration at every 3 hours.
46033310|NCT02645695|Device|chest wall vibration technique|administered chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours. Chest vibration method was applied with 7-10 hz frequency given by a ped wrapped around the thorax and pulmonary rehabilitation with 3 mmHg pressure four times a day with 15-minute periods (TheVest® Model 205).
46033311|NCT02882568|Biological|blood analysis|Pilot study, single center, interventional including 15 obese subjects with acute sepsis. Inflammatory and immunological tests during acute phase and one month later after a presumed return parameters at baseline
46033312|NCT04232020|Diagnostic Test|Mismatch repair|MSI testing using Biocartis Idylla and MMR immunohistochemistry
46033313|NCT00654433|Biological|ALD-101|A subpopulation of cord blood cells composed of cells that express a high level of the intracellular enzyme aldehyde dehydrogenase (ALDH).
46033314|NCT01124448|Biological|Lactobacillus salivarius PS2|9.5 log10 (colony-forming units), freeze-dried powder, daily for 21 days
45598809|NCT03541655|Drug|Bupivacaine HCl|0.25% Bupivacaine HCl
45598810|NCT03541655|Drug|F14 (celecoxib)|Celecoxib in novel drug delivery system (BEPO™)
45598811|NCT02296411|Drug|CHF 5259 12.5 µg|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
45598812|NCT02296411|Drug|CHF 5259 placebo|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
46033315|NCT01124448|Biological|Lactobacillus salivarius PS2|9.5 log10 colony-forming units, oral route, freeze-dried powder, daily for 21 days
45598813|NCT02353689|Dietary Supplement|low FODMAP|consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention
45598814|NCT02353689|Dietary Supplement|moderate FODMAP|consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention
46033316|NCT02643745|Procedure|Nephrology Intervention|"pre-operative study:~Kidney function: creatinine, Glomerular filtration rate (GFR) and presence albuminuria or proteinuria. Assessment whether there is a functional component added.~Discard presence of renal disease: renovascular disease, glomerular disease, toxic, etc.~optimise the patient' s overall condition with a pre-operative strategy:~Obesity control~Control protein, caloric, salt intake~Stop smoking~Good glycemic control~Start ACEI/ARA II if there is proteinuria~Start additional antihypertensive drug if required~Start hypolipemic treatment if required~Start hyperuricemia treatment if required~Start AAS, clopidogrel if it is necessary (prophylaxis)~Phosphate control~Anemia control~Metabolic acidosis correction"
46033317|NCT02638909|Drug|ceritinib|Treatment with ceritinib will continue until patient experiences unacceptable toxicity that precludes further treatment, discontinues treatment at the discretion of the investigator or patient, starts a new anticancer therapy and/or dies.
46033318|NCT01124292|Procedure|Tongue Piercing|Subjects brush their teeth, and then swish and spit with chlorhexidine mouthwash for 30-60s. Subjects would be placed in a semirecumbent position in a procedure chair. After marking the piercing site using a sterilized surgical marking pen the protruded tongue would be pierced. Anesthesia may be used during the piercing at the discretion of the operator and the subject. A sterilized titanium or surgical grade stainless steel piercing tongue stud would be placed in an appropriate position on the tongue to minimize complications from the piercing but also facilitate good functionality of the TDS.
45338982|NCT02592590|Behavioral|Group A|"This condition receives three study components:~The base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, quiz questions), activity tracking, and graphical feedback.~The guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription.~The points-based feedback module. For each action in the app (e.g., setting goals, achieving goals, viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser)."
45598815|NCT02353689|Dietary Supplement|high FODMAP|consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
45338983|NCT02592590|Behavioral|Group B|"This condition receives two study components:~The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~The second is the guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription."
46033319|NCT01124292|Device|Usability assessment|"Computer access: Subjects wear the TDS and get trained. Then they sit 1.5 m from a 22 LCD monitor. Then they use TDS to conduct several tasks using their tongues, such as clicking on target objects and navigating through on-screen maze, while the computer registers their tongue commands and measures their performance.~Wheelchair control: Subjects wear the TDS and use it to drive an electrically powered wheelchair through an obstacle course using their tongues. The operator measured the time it takes for the subjects to drive through the course as well as the number of collisions."
45338984|NCT02592590|Behavioral|Group C|"This condition receives two study components:~The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~The second is the points-based feedback module. For each action in the app (e.g., viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser). As the intervention is goal drive, these participants will also receive printed goal setting worksheets."
45839593|NCT03000036|Device|Achieva, Philips Medical Systems (3T magnet)|Patients were imaged in supine position in a 3T magnet (Achieva, Philips Medical Systems, Best, The Netherlands). The protocol consisted of electrocardiographically gated cine imaging with steady state free-precession to assess left ventricular (LV) ejection fraction and LV mass. For imaging of late gadolinium-DTPA enhancement (LGE) we used an inversion-recovery-prepared, gradient-echo sequence with segmented acquisition, which was triggered every other heartbeat. LGE images were acquired during end-expiratory breath-holding, after administration of Dotarem. T1 was performed with a Look-Locker sequence with a non-slice-selective adiabatic inversion pulse, followed by segmented gradient-echo acquisition for 17 times after inversion, covering approximately two cardiac cycles. T1 imaging was repeated in the same LV short-axis slice, once before and five to seven times after the injection of gadolinium to cover an approximately 30-min period of slow contrast clearance.
46033320|NCT02645539|Device|intravascular ventricular assist system (iVAS)|A mechanical circulatory support device using the principles of counterpulsation.
46033321|NCT02638675|Behavioral|Wellness program|All participants have access to Change4Life, a web-based health education and behaviour change program. Individuals are rewarded with very modest incentives (uncertain chance; less than 1 in 100 chance of earning) when they complete learning modules or health tasks.
46033322|NCT02638675|Device|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, which tracks steps and bout minutes of MVPA per day, synchronize the device to the Change4Life program, and reach daily step count goals for 24 weeks.
46033323|NCT02638675|Behavioral|Incentive|During the first 12 weeks, participants will be eligible to earn $1 in vouchers (e.g., grocery, cinema) when daily goals are reached. The total amount available over the 3-month intervention period will be $90 (9,000 points). During weeks 13 to 24, participants will not receive daily reward points for completing step count goals.
45598816|NCT02229305|Behavioral|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
46033324|NCT02638753|Other|education|Patients will be educated about pain neurophysiology.
46033325|NCT02638753|Other|education combined with hypnosis|Patients will be educated about pain neurophysiology combined with hypnosis.
46033326|NCT05104476|Drug|Lu AF82422|Solution for infusion
46033327|NCT05104476|Drug|Placebo|Solution for infusion
46033328|NCT02643589|Drug|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
46033329|NCT02643901|Biological|GW003|single SC injection
46033330|NCT02645383|Device|PASCAL laser|A novel semi-automatic and multi-shot photocoagulator called as PASCAL (Pattern scan laser, Opti-Medica Corp., Santa Clara, California, USA) was introduced with a reduction in pulse duration of each laser spot from typical 100 ms down to 10-30 millisecond. Compared with the conventional laser, shorter pulses have been shown to significantly reduce the risk of damage to the adjacent retinal tissues. One eye was treated with PASCAL laser, the other was treated with conventional laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, PASCAL laser was performed in the first eyes in half of the patients (14 patients) randomly.
45338985|NCT02592590|Behavioral|Group D|This condition receives only the base-level smartphone app. This contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback. As the intervention is goal drive, these participants will also receive printed goal setting worksheets.
45338986|NCT02712762|Other|Cross-sectional study|
45683108|NCT01613222|Device|Pulse oximetry|Pulse oximetry measurement using SpO2 sensors, patient monitors, co-oximeters, and various modules.
46033331|NCT02645383|Device|Conventional laser|Maintaining of good glycemic regulation and performing panretinal laser photocoagulation (PRP) with conventional laser device (ELLEX Integre, Adailade, Australia) when it is indicated are evidence based effective methods for proliferative diabetic retinopathy.One eye was treated with conventional laser, the other was treated with PASCAL laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, conventional laser was performed in the first eyes in half of the patients (14 patients) randomly.
46033332|NCT02881944|Behavioral|Low FODMAP Diet|Diet low in foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
46033333|NCT02881944|Behavioral|High FODMAP Diet|Typical diet of foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
46033334|NCT00652405|Dietary Supplement|alcohol|250 ml of white wine (13% vol; ~25 gram of alcohol per day)
46033335|NCT00652405|Dietary Supplement|Placebo|250 ml of mineral water (Brand name: Vittel)
46033336|NCT02881710|Other|contrast product used to assess biomarkers variations|
46033337|NCT02643823|Biological|hUC-MSC + DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease. Combinated with a single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
46033338|NCT02643823|Drug|DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease.
46033339|NCT02638831|Drug|Ketorolac Tromethamine|Ketorolac tromethamine gel 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
46033340|NCT02638831|Drug|Ketoprofen|Ketoprofen gel 2.5% for external application Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
46033341|NCT01136772|Drug|haloperidol decanoate|haloperidol decanoate injections, 25-200 mg once a month
46033342|NCT01136772|Drug|paliperidone palmitate|Paliperidone palmitate injections, 39 mg - 234 mg once a month
46033343|NCT00909532|Drug|Ivacaftor|150-mg tablets given orally q12h for up to 48 weeks
46033344|NCT00909532|Drug|Placebo|Tablet given orally q12h for up to 48 weeks
46033345|NCT02756845|Drug|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection only into injectable cutaneous, subcutaneous, nodal tumors, and other non-visceral tumors with or without image ultrasound guidance. The first dose of talimogene laherparepvec will be up to 4.0 mL of 10^6 PFU/mL administered on day 1. The second injection, up to 4.0 mL of 10^8 PFU/mL (or up to 4.0 mL of 10^6 PFU/mL for a dose de-escalated cohort), will be administered 21 (+3) days after the initial injection. All subsequent injections, up to 4.0 mL of 10^8 PFU/mL (or up to 4.0 mL of 10^6 PFU/mL for a dose de-escalated cohort), will be administered every 14 (± 3) days. The treatment cycle interval may be increased due to toxicity.
45338987|NCT03301116|Behavioral|Healthy Moves for Aging Well (Healthy Moves)|A safe physical activity program which consists of a brief motivational enhancement and three movements to be performed in a seated position. The intervention will be delivered by home care aides for their clients.
46033346|NCT02882490|Behavioral|Parent Training|
46033347|NCT02882490|Other|Supportive Therapy|
46033348|NCT04312308|Other|Sample collection|".Analysis of immune marker using FACS before treatment and Cycle1, Cycle2, Cycle3 and the time of disease progression.~.Multiplexed biomarker analysis of tumor and immune cells in tumor microenvironment (TME) at pre-treatment and progression (Pre-treatment biopsy is mandatory but biopsy is optional for disease progression)~3. microbiome Pretreatment stool sample will be collected. (Stool sample is optional)~4.Genetic analysis For RNAseq or exome seq, biopsied tissue at baseline or progression are optional.~4.Single cell RNA sequencing (scRNA-seq) scRNA-seq will be performed by collecting selectively tissues from pre-treatment tumor biopsies and at relapse/acquired resistance tumor biopsies. Screening and treatment biopsies are optional."
45338988|NCT03301116|Behavioral|Active Mind for Aging Well (Active Mind)|A word puzzle program which consists of a brief motivational enhancement and word search activities. The intervention will be delivered by home care aides for their clients.
45338989|NCT00726752|Drug|Axitinib (AG-013736)|Three single dose level of AG-013736 (5 mg, 7 mg and 10 mg) will be given for all patient. After single dosing at each dose level, multiple doses of 5 mg twice a day (BID) will be started.
45839594|NCT03000036|Drug|Gadoterate Meglumine|LGE images were acquired starting within 10 min after bolus administration of a cumulative dose of 0.2 mmol/Kg of gadoterate meglumine (Dotarem, Guerbet, Aulnay-sous-Bois, France).
46033349|NCT05367024|Other|Broccoli soup|Participants will consume one broccoli soup three times a week for one 12-week intervention period as part of their normal diet.
46033350|NCT05367024|Other|Courgette soup|Participants will consume one courgette soup three times a week for one 12-week intervention period as part of their normal diet.
45839595|NCT02999802|Behavioral|Exercise|Progressive resistance exercise training
45338990|NCT00917930|Behavioral|physical training|intensive cardiac rehabilitation program
45338991|NCT02594462|Drug|etonogestrel-releasing implant contraceptive|The etonogestrel implant will be inserted until the fifth day of the menstrual cycle . Anthropometric measurements will be performed , blood pressure measurement , application of pain questionnaire for the last three months, and collection of fasting blood in our clinic . After these measures , the ENG implant will be applied per researcher trained for such a procedure , following the recommendations outlined by the manufacturer. Women are instructed to return after 3, 6, 9, 12 months, fasting 8h , when they will be measured anthropometric measurements , blood collection, and delivery of pain questionnaires and standard of menstrual bleeding.
46033351|NCT02377570|Device|THERANOVA 400 dialyzer prototype AA|Hemodialysis
45839596|NCT02999412|Procedure|Comprehensive medication review|"A thorough medication reconciliation, including a patient/carer interview, by a clinical pharmacist.~The clinical pharmacist performs a comprehensive medication review in collaboration with the ward physician and patient, similar to a level three clinical medication review as earlier described in the literature [4]. This includes a structured, critical examination of all of the patient's medications in relation to the patient's conditions, based on information from the patient and the medical record. The objective is to optimise the impact of medications and minimizing the number of medication-related problems. The effects of medication changes will be monitored during the hospital stay by the physician or pharmacist, depending on the specific situation.~Before discharge, the clinical pharmacist performs another medication reconciliation to check if the patient's prescriptions for medications to be used after hospital stay are consistent with the patient's medical record."
46033352|NCT02377570|Device|THERANOVA 400 dialyzer prototype BB|Hemodialysis
46033353|NCT02377570|Device|THERNOVA 400 dialyzer prototype CC|Hemodialysis
46033354|NCT02377570|Device|FX CorDiax 80 dialyzer|Hemodialysis
46033355|NCT01136382|Drug|budesonide|pMDI, inhalation, bid, 6 weeks
46033356|NCT01136382|Drug|placebo|pMDI, inhalation, bid, 6 weeks
46033357|NCT04772326|Other|Questionnaire|Questionnaire
46033358|NCT04467502|Other|cognitive-behavioral therapy for gambling disorder|6 sessions of cognitive-behavioral therapy for gambling disorder
46033359|NCT04467502|Other|imaginal exposure therapy focus on gambling cues|6 sessions of imaginal exposure therapy focus on gambling cues
46033360|NCT04467502|Other|virtual reality exposure therapy focus on gambling cues|6 sessions of virtual reality exposure therapy focus on gambling cues
46033361|NCT00912028|Device|senofilcon A|contact lens
46033362|NCT00912028|Device|lotrafilcon B|contact lens
45338992|NCT02664558|Drug|ubenimex|
45338993|NCT02664558|Other|placebo|
45338994|NCT02566707|Drug|Atazanavir|HIV therapy will be adapted: atazanavir 400mg QD
45338995|NCT02566707|Drug|Dolutegravir|HIV therapy will be adapted: dolutegravir 50mg QD
46033363|NCT00912028|Device|balafilcon A|contact lens
46033364|NCT00912028|Device|methafilcon A|contact lens
46033365|NCT00912028|Device|vifilcon A|contact lens
46033366|NCT00632008|Drug|Soluble beta-glucan (SBG)|Topical application of SBG to the wound, at least twice a week until complete healing or for 8 maximum weeks
46033367|NCT00632008|Drug|Placebo comparator|Topical application of placebo to wound, at least twice a week until compleate healing or for maximum 8 weeks.
46033368|NCT03513562|Drug|Ibrutinib|Given PO
46033369|NCT03513562|Other|Laboratory Biomarker Analysis|Correlative studies
46033370|NCT03513562|Drug|Venetoclax|Given PO
46033371|NCT05581186|Other|Pulse electromagnetic field therapy|"It was applied with an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italia) at 25 Hz frequency, Gauss (8.5 milliTesla) intensity and for 25 minutes. The treatment period was 5 days a week for 3 weeks, in total. It was applied as 15 sessions.~Therapeutic Exercise As a therapeutic exercise program; active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
46033372|NCT05581186|Other|Sham pulse electromagnetic field therapy|"Sham pulse electromagnetic field therapy was applied five sessions a week for four weeks, for a total of 15 sessions a day, using electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italy) without current flowing through the device.~Therapeutic Exercise As a therapeutic exercise program; active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
46033373|NCT05581186|Other|Therapeutic Exercise|Therapeutic Exercise As a therapeutic exercise program; active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.
46033374|NCT04071730|Dietary Supplement|Immulina Dietary Supplementation|Immulina Dietary Supplementation is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
46033375|NCT02731729|Drug|ipilimumab|
46033376|NCT02731729|Drug|nivolumab|
46033377|NCT02645461|Drug|endocannabinoid palmitoylethanolamide (PEA)|Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily
46033378|NCT02645461|Drug|Riluzole|Riluzole 50 mg twice daily
45338996|NCT02566707|Drug|Lamivudine|HIV therapy will be adapted: lamivudine 300mg QD
46033379|NCT00654589|Drug|Deferasirox|
46033380|NCT02645227|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by OFD for treating bone defect
46033381|NCT02645227|Procedure|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by OFD with PRF placement into the bone defect
46033382|NCT02645227|Procedure|OFD with PRF and 1.2% Rosuvastatin|Oral prophylaxis followed by OFD with PRF and 1.2% Rosuvastatin placement into the bone defect
46033383|NCT00652483|Drug|Brimonidine ophthalmic solution 0.1%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
46033384|NCT00652483|Drug|Brimonidine ophthalmic solution 0.2%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
45338997|NCT04063683|Drug|Anlotinib Hydrochloride, Paclitaxel, cisplatin|"anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~Paclitaxel: intravenously infused at 135mg/ m2, administered d1 per cycle, 3 weeks for a treatment cycle.~Cisplatin: administered after paclitaxel, intravenously infused at 60-75 mg/m2, divided into d1-d3 medications per cycle; 3 weeks for one treatment cycle."
46033385|NCT01119066|Radiation|total body irradiation|dose of 1375-1500 cGy
45338998|NCT02578290|Other|Clinical Decision Support (CDS)|"A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-3, and scans scored 4-6 for which an alternative scan scored 7-9 exists.~This screen will show the appropriateness score of the original scan order, and will display any alternative scans that are scored 7-9 for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication.~Any time the pop-up alert appears, a checkbox removing the selected scan from unsigned orders will be checked by default."
45839597|NCT02999412|Procedure|Comprehensive medication review with active follow-up|"The same as I1 but with the following additions:~In case of any monitoring needs or necessary subsequent actions to be taken after hospital discharge, the clinical pharmacist and the ward physician send an electronic medication review referral to the patient's primary care physician upon discharge.~A first phone call to the patient or carer is made by the clinical pharmacist 2-7 days after the patient is discharged depending on health condition and the pharmacist's availability. This phone call aims to ensure that all information has been understood correctly and to find out if any problems, concerns or questions have arisen after discharge.~A second phone call will be made by the clinical pharmacist approximately 30 days after hospital discharge. This phone call aims to find out how the patient is managing the medication and if any problems, concerns or questions have arisen, and to provide the patient with a motivational boost."
46033386|NCT01119066|Drug|Thiotepa|5 mg/kg/day x 2 or 10 mg/kg/day x 1
46033387|NCT01119066|Drug|Cyclophosphamide|60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).
46033388|NCT01119066|Drug|Busulfan|0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
46033389|NCT01119066|Drug|Melphalan|70mg/m2/day x 2
46033390|NCT01119066|Drug|Fludarabine|25mg/m2/ day x 5
46033391|NCT01119066|Drug|Clofarabine|20mg/m2/ day x 5 (or, for children <18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval)
45598817|NCT02229305|Behavioral|Modular Approach to Therapy for Children|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC; Chorpita & Weisz, 2010).
45598818|NCT02347137|Other|step-reduction|reduce daily physical activity to less than 1500 steps per day
45598819|NCT02347137|Other|step-reduction plus resistance exercise|reduce physical activity to less than 1500 steps per day with thrice weekly low-load, high effort resistance exercise
46033392|NCT01119066|Procedure|(CliniMACS) T-cell depleted PBSC Transplant|
46033393|NCT00910624|Drug|Boceprevir|Boceprevir, 200-mg capsules, 800 mg three times a day (TID) orally (PO)
46033394|NCT00910624|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b 1.5 µg/kg/week subcutaneously (SC)
46033395|NCT00910624|Drug|Ribavirin (SCH 18908)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day PO divided twice daily (BID).
46033396|NCT00654667|Drug|Placebo|Placebo, no active drug, take 5 capsules by mouth daily for one month
46033397|NCT00654667|Drug|Resveratrol|
46033398|NCT04164511|Dietary Supplement|2 daily standard doses of vanilla-chocolate ice cream (cryotherapy)|The patients will receive 2 daily standard doses of vanilla-chocolate ice cream (cryotherapy) for 2 weeks post-op, with amount of analgesic consumption and subjective pain levels recorded on a VAS scale.
46033399|NCT04066738|Diagnostic Test|Cardiac MRI with gadolinium contrast|Imaging of left ventricular scar and coronary sinus venous system
46033400|NCT04066738|Diagnostic Test|3D reconstruction and location of coronary sinus venous system relative to myocardial scar|Three dimensional mapping of coronary sinus venous system with Abbott Precision mapping system and Biotronik Vision wire Merge with MRI images of CS and myocardial scar
46033401|NCT04066738|Diagnostic Test|Acute haemodynamic measurements during CRT implant|Advancement of pressure wire to LV cavity via femoral/radial arterial access. Real time measurement of LV-dP/dTmax during conventional CRT and MPP after consecutive placement of LV lead in two different CS branches (peri-infarct region and remote myocardium)
46033402|NCT05095428|Behavioral|PARTS Program|The PARTS Program is a 16-week group intervention model of Internal Family Systems (IFS), with 8 individual IFS clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
46033403|NCT05095428|Behavioral|NBSR-T Program|The NBSR-T Program is a 16-week nature-based group intervention model, with 8 individual non-IFS clinical sessions on a biweekly basis, developed as an attention placebo control for individuals diagnosed with PTSD.
46033404|NCT04063150|Biological|fIPV (0.1 mL) ID|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal (ID) injection in lieu of the full 0.5 mL dose.
46033405|NCT04063150|Biological|fIPV (0.1mL) IM|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.
45839598|NCT02999412|Procedure|Usual Care|The control group will receive usual hospital care. According to Swedish legislation, usual care includes medication reconciliation upon admission. Next to that, the law requires a medication report addressing the patient's medication treatment to be given to the patient or carer upon hospital discharge and to be attached to the electronic discharge letter. This report contains a motivation and explanation to the changes in medication treatment that have been made during hospital stay, as well as the patient's updated medication list. These mandatory activities are currently carried out to various degree within the different hospitals and wards. Other activities as described in the interventions above may be carried out to a certain degree as well, but no clinical pharmacist will be involved.
45839599|NCT02998944|Other||not any intervention for this study
45839600|NCT02998008|Behavioral|high intensity interval training|
45839601|NCT02996292|Device|Traditional brackets|Treating of crowding using traditional brackets
45839602|NCT02996292|Device|Active self-ligating brackets|Treating of crowding using active self-ligating brackets
45839603|NCT02996292|Device|Passive self-ligating brackets|Treating of crowding using passive self-ligating brackets
46033406|NCT04063150|Biological|fIPV (0.2mL) IM|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.2 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.
46033407|NCT04063150|Biological|IPV|Full dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.5 milliliter (mL) dose by intramuscular (IM) injection.
46033408|NCT02645071|Behavioral|Physical Activity|A brief education program in reducing sedentary behavior and promoting physical exercise with family would be conducted. Assessments will be conducted in two different time points, before training session (T1), immediately following training (T2) and two weeks after training (T3) to evaluate the effectiveness of training program.
46033409|NCT04165681|Other|Limbix Spark|5-week, self-guided mobile + VR CBT-based program for adolescent depression
46033410|NCT01123980|Drug|biphasic insulin aspart 30|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
46033411|NCT01123980|Drug|metformin|"China: Tablets, 500 mg. Min. 1500 mg/day.~Japan: Tablets, 250 mg. Min 500 mg/day."
45338999|NCT03895281|Diagnostic Test|FilmArray Meningitis/Encephalitis (ME) Panel|The FilmArray ME pouch is a closed system disposable that houses all the chemistry required to isolate, amplify and detect nucleic acid from multiple meningitis and encephalitis pathogens within a single CSF specimen obtained from a lumbar puncture. The rigid plastic component (fitment) of the FilmArray ME pouch contains reagents in freeze-dried form. The flexible plastic portion of the pouch is divided into discrete segments (blisters) where the required chemical processes are carried out. The user of the FilmArray ME Panel loads the sample into the FilmArray ME pouch, places the pouch into the FilmArray instrument/Module, and starts the run. All other operations are automated.
46033412|NCT01123980|Drug|glimepiride|"China: Tablets, 2 mg. Min. 4 mg/day.~Japan: Tablets, 1 mg. Min. 4 mg/day."
46033413|NCT01123980|Drug|insulin glargine|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
46033414|NCT04037800|Procedure|SFUR-RARP|Robotic-assisted radical prostatectomy with sustainable functional urethral reconstruction (SFUR)
46033415|NCT04037800|Procedure|Standard RARP|Robotic-assisted radical prostatectomy with conventional RARP procedures.
45339000|NCT02578524|Other|Survey|
45339001|NCT02627508|Drug|Pregnenolone|orally administered Pregnenolone capsules
45339002|NCT02627508|Drug|Placebo|orally administered placebo capsules
46033416|NCT02676973|Procedure|Open, Robotic, or Laparoscopic|Sacral Colpopexy is a surgery performed either through an incision in the abdomen or through several small incisions with the help of a laparoscope (a slender tube) or robot. The surgery is done with a permanent synthetic (man-made) mesh. The mesh is sutured (stitched) to the vagina and sacrum (tail bone) and is used as reinforcement. It provides additional support to weakened tissues and/or muscles.
46033417|NCT02676973|Procedure|Transvaginal Native Tissue Repair|Transvaginal Native Tissue Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done using both permanent and absorbable sutures (stitches), to support weakened tissue and/or muscles, and attach the top of the vagina to ligaments in the pelvis (either to the sacrospinous ligament or uterosacral ligament).
46033418|NCT02676973|Procedure|Uphold™ LITE|Transvaginal Mesh Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done with a permanent synthetic (man-made) mesh. The mesh is attached to ligaments in the pelvis and is used to reinforce natural tissue and/or muscles, which are no longer able to provide support to the vagina.
46033419|NCT04015648|Biological|ChAdOx1 Zika|Single dose of ChAdOx1 Zika at different concentrations: 5 x 10^9 vp, 2.5 x 10^10 vp, 5 x 10^10 vp
46033420|NCT02638441|Other|hospital anxiety and depression scale|Detection of infertility effect on emotional status
45339003|NCT00921531|Drug|Thalidomide|"Thalidomide is used for adjuvant therapy for TACE~Thalidomide will be given at the dose of 200 mg/day in beginning, with dose escalation of 100 mg/day each week, until to the dosage of 400 mg/day."
45339004|NCT00921531|Drug|TACE|TACE (5-FU 1.0 g, OXP 150mg, MMC 10 mg, lipiodol 5-30 ml) will be performed every two months (defined as a course) until no radiological evidence of survival of tumor (based on contrast MRI) or 6 courses.
45339005|NCT04072692|Other|Hybrid rehabilitation training|Hybrid rehabilitation training is modified tendon gliding exercise with median nerve mobilization.
46033421|NCT02643511|Radiation|Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy|A re-staging transperineal template guided mapping prostate biopsy as currently performed at participating institutions. Hemiablative Focal brachytherapy will be performed . The affected half of the prostate will be targeted with the prescription dose and receive 145 Gy of Iodine-125 (I-125). A postimplant dosimetry will be performed 30 days after procedure. The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then 4 weeks, 6 months, 12 months, 20 months, 24 months, 32 months and 36 months after treatment. A second transperineal biopsy will be performed 36 months after the implant.
46033422|NCT02859207|Drug|E2609|Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).
46033423|NCT05090748|Device|Echocardiographic.|Echocardiographic test.
45683109|NCT03088462|Other|Psychiatric management|Routine treatment for bipolar disorder with a psychiatrist including prescription of medications and potentially other treatments such as individual, group or light therapy.
45683110|NCT03088462|Behavioral|Psychosocial treatment|Any psychosocial treatment participant is involved in such as individual therapy, group therapy, or support groups.
46033424|NCT02859129|Drug|rosuvastatin 40 mg tablet|Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).
46033425|NCT02859129|Drug|Epanova™ QD (2 x 1 g capsules)|Multiple oral doses of 2 g (2 x 1 g capsules) Epanova™ QD for 10 consecutive days (Days 4 to 13)
45683111|NCT03088462|Behavioral|LiveWell Program|Participants work with a health coach to facilitate use of a smartphone application designed for people with bipolar disorder.
45683112|NCT05481424|Other|Biodynamic|This will be a nine-hour lighting scheme that includes three modes: morning, noon, and afternoon. It mimics natural lighting by providing blue-enriched bright lighting in the morning and yellowish dimmed lighting in the afternoon. The lighting scheme is designed to satisfy the visual lighting needs of office workers while maintaining a robust circadian clock.
46033426|NCT02859129|Drug|Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose|Multiple oral doses of 4 g Epanova™ QD for 13 consecutive days with coadministration of single 40 mg oral dose of rosuvastatin (Crestor®) with the 11th dose of Epanova™ on Day 24
45339006|NCT04072692|Other|Traditional rehabilitation training|Traditional rehabilitation training uses traditional physiotherapy, such as splint, therapeutic ultrasound and electrotherapy.
45339007|NCT04072692|Other|Wearable anti-bowstringing orthosis (WABO)|WABO is a custom-designed orthosis to restrict the bowstringing effect of the flexor tendon in the carpal tunnel.
45339008|NCT04114851|Device|NoL|NoL active
45683113|NCT05481424|Other|Active Placebo|"We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness during working hours. This condition is designed to serve to requirements: (1) to simulate a conventional, well-lit office lighting in compliance with the WELL standard V1 recommendations for circadian lighting design, and (2) to provide an Equivalent Melanopic Lux (EML) equal to the geometric average of EML delivered by the Biodynamic condition. Participants will receive a similar dose of lighting under both the Placebo and Biodynamic conditions; however, the time factor is ignored in the Placebo, and hence the method of delivery is different (constant versus dynamic)."
46033427|NCT02859129|Drug|Multiple (20) oral doses of 2 g Vascepa® every 12 hours|Multiple oral doses of 2 g (2 x 1 g capsules) Vascepa® every 12 hours for 20 consecutive days (Days 1 to 20).
46033428|NCT04164823|Device|Medical taping|For the medical taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.
46033429|NCT04164823|Drug|Analgesic self-medication (OTC)|Participants will note the usual analgesic self-medication used to relief pain (ibuprofen, acetaminophen...).
46033430|NCT03976336|Dietary Supplement|Berberine|500 mg berberine (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
46033431|NCT03976336|Other|Identical Placebo|500 mg (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
46033432|NCT04164589|Device|SCENAR 1NT-02.2|The neuro-adaptative regulation will be carried out in vulvo-perineal and sacral area
46033433|NCT02857959|Drug|Benzathine Penicillin G|
46033434|NCT00632398|Behavioral|Attention control (reading)|Caregivers read to the patient from literature of the patient's choice for recommended 20 minutes at least 3 times per week for 4 weeks
46033435|NCT00632398|Behavioral|Touch, Caring and Cancer DVD program|DVD- and manual-based instruction for caregivers and patients in the use of touch and massage techniques as supportive care in cancer, including: preparation for a session, safety precautions related to cancer and its treatments, communication about touch, centering to calm the mind; manual techniques for the head, neck, shoulders, back, feet and hands to promote relaxation; and acupressure for pain, nausea and anxiety.
46033436|NCT00654979|Device|SafeFlo IVC Filter|SafeFlo IVC Filter
45339009|NCT04094415|Drug|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
45683114|NCT05345860|Other|The MRD strategy for high risk or MRD+ TNBC patients|"Standard adjuvant chemotherapy + additional chemotherapy:~BRCA positive patients: standard adjuvant chemotherapy + olaparib~BRCA negative patients: standard adjuvant chemotherapy + capecitabine~In the period of once 3 months follow-up, if MRD remains positive, the additional chemotherapy will be changed for at most once."
45754707|NCT00555893|Drug|Placebo|Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: <=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
46033437|NCT04280757|Procedure|Biopsied ICSI embryos (PGS)|Biopsied ICSI embryos (PGS)
46033438|NCT04231786|Procedure|Breast ultrasonography findings|Breast ultrasonography findings in patients over 30 years of age diagnosed with polycystic ovary syndrome.
46033439|NCT02643433|Biological|Measles-Rubella combined vaccine(MR)|0.5ml for each dose,be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
45339010|NCT00730028|Drug|Trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole (TMP-SMX) will be administered orally at a dose of 160 mg TMP and 800 mg SMX (as 2 single strength over encapsulated tablets) twice daily (adult or child > 40 kg dose) or 8-10 mg TMP, 40-50 mg SMX per kg daily, divided into 2 daily doses (child < 40 kg dose). Study drug will be administered for 10 days.
46033440|NCT02643433|Biological|Japanese Encephalitis alive vaccine(JE)|0.5ml for each dose be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
46033441|NCT00632476|Other|Placebo|Placebo capsule once a day
45339011|NCT00730028|Other|Placebo|Placebo capsules will be identical in appearance to the CLINDA and TMP-SMX. Administered 3 times daily for 10 days.
45683115|NCT05345860|Other|The MRD strategy for high risk or MRD+ HER2+ patients|"Standard adjuvant chemotherapy + intensive targeted therapy:~Neoadjuvant therapy non-pCR patients: standard adjuvant chemotherapy completed+ T-DM1/HP~Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy completed + HP~Adjuvant therapy patients: AC-T/TCb + HP~In the period of once 3 months follow-up, if MRD remains positive, the intensive targeted therapy will be changed for at most once."
45683116|NCT05345860|Other|The MRD strategy for high risk or MRD+ ER+ patients|"Standard adjuvant chemotherapy + intensive endocrine therapy:~Premenopausal patients: Standard adjuvant chemotherapy followed by OFS + TAM/TOR, OFS + ANA/LET/EXE, or OFS + ANA/LET/EXE + Abemaciclib.~Postmenopausal: Standard adjuvant chemotherapy followed by ANA/LET/EXE + Abemaciclib.~In the period of once 3 months follow-up, if MRD remains positive, the intensive endocrine therapy will be changed for at most once."
45683117|NCT05345860|Other|The MRD strategy for low risk and MRD- TNBC patients|"Standard adjuvant chemotherapy: AC-T/TC/TCb/AC.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant therapies listed in The MRD strategy for high risk or MRD+ TNBC patients will be added for at most twice."
45754708|NCT00578929|Drug|Olopatadine Hydrochloride Nasal Spray 0.6%|Olopatadine HCl 1 or 2 sprays per nostril twice daily
45754709|NCT00578929|Drug|Vehicle|Vehicle 1 or 2 sprays per nostril twice daily
45339012|NCT00730028|Drug|Clindamycin|CLINDA (adult dose of 300 mg three times daily; pediatric dose of 25-30 mg/kg/day divided three times daily up to a maximum dose of 900 mg/day). Study drug will be administered for 10 days.
46033442|NCT00632476|Dietary Supplement|Vitamin C|A 500-mg vitamin C capsule once a day
46033443|NCT04164745|Drug|Anlotinib, oral capsule|Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
46033444|NCT04164745|Biological|Pembrolizumab|Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
46033445|NCT05579782|Device|NIRAF Detection Technology|"Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio > 1.2 is interpreted by device as the suspect tissue being positive for parathyroid.~Other Name: PTeye Device"
46033446|NCT00655213|Device|Symphony D 2450|
45339013|NCT04074642|Procedure|Neurosurgery|adenoma removal
45339014|NCT05673642|Other|Myofascial Release Techniques|Myofascial Release Technique (MFR), which we will apply to the muscles we choose related to the facial system connection
45339015|NCT02594228|Behavioral|Whey Protein and exercise training|Six meals per day four of which were whole food and two of whey protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
45339016|NCT02594228|Behavioral|Food Protein and exercise training|Six meals per day all of which were whole food protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
45339017|NCT03356223|Drug|Abemaciclib|"400mg/day with 2 doses of 200mg 12-hour apart For each 28-day cycle, a total of 56 doses of study drug will be dispensed.~Route of administration : oral~Duration of treatment until the patient experiences an unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
45339018|NCT04087694|Procedure|Microdecompression|comparative surgical treatment
45598820|NCT03516019|Other|personalized notices|The personalized notices take into account if data were received over the previous week, and accordingly encourages the participant to use the device and send her data, or encourages the participant to continue using the device and sending data. A library of personalized notices with alternative motivational content was developed. Each time a notification is sent, it will be drawn at random from the library.
46033447|NCT00655213|Device|Symphony DR 2550|
46033448|NCT01198522|Drug|L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine|"Part A) Patient cohorts will sequentially be assigned to 800 or 1,000 mg/m2 of gemcitabine. gemcitabine will be given in combination with a fixed dose of L19IL2. Part B) Patient cohorts will sequentially be assigned to 10, 15,22.5,30 or 37,5 MioIU IL2 equivalents of L19IL2. L19IL2 will be given in combination with gemcitabine at the dose recommended from Part A. Should the MTD of L19IL2 not be reached within the planned cohorts listed above, the dose of L19IL2 will be further increased following 7.5 MioIU increasing steps.~Induction treatment: Intravenous (i.v.) infusions of L19IL2 on days 1,3,5,22,24, 26,43,45,47, followed by i.v. infusions of gemcitabine on days 1,8,15,22,29,36,43. Maintenance treatment: Patients with objective tumor responses or stable disease will receive up to 4 cycles of maintenance treatment, starting on day 57: i.v. infusions of L19IL2 on days 1 (day 57), 8,15, followed by an i.v. infusion of gemcitabine. Treatment cycles will be repeated on day 29."
45339019|NCT04060875|Device|Karuna Labs Virtual Reality Software|The subjects will engage in the three therapeutic modules: laterality, motor imagery, and 'mirroring.' The decision of which module to employ will be based on the subject's readiness and comfort on a case-by-case basis. A subject visit can be expected to last 40 minutes, with enough time to complete PHQ-9, and to accustom to the virtual reality setup by playing in a non-therapeutic virtual environment should they choose to do so. Time in the virtual reality is expected to last approximately 20 minutes per session.
45339020|NCT04088084|Dietary Supplement|palmitoylethanolamide (PEA) 600 mg|PEA 600 mg was added to topical therapy
45754710|NCT00556049|Drug|Gemcitabine|Intravenously on days 1 and 8 of each 21-day treatment cycle.
46033449|NCT02638285|Drug|LH|
46033450|NCT02638285|Drug|HCG|
46033451|NCT02638285|Drug|Clomiphene|
46033452|NCT04201210|Other|TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation|Haploidentical 5+/10 HSCT from a relative, α/β T-depleted
46033453|NCT04201210|Other|Matched sibling donor transplantation|10/10 HSCT - matched family donor
45339021|NCT02593370|Drug|Lidocaine-epinephrine added gadoterate meglumine|
45754711|NCT00556049|Drug|Sunitinib|Orally on days 1-14 of each 21-day treatment cycle
46033454|NCT01134250|Drug|F16IL2 in combination with paclitaxel|"Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 to 35 MioIU, the dose could be further increased until MTD is reached, following a pharmacokinetic-guided design) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 1 hour i.v. infusion of paclitaxel (Dose escalation: from 60 up to 90 mg/m2) on days 1, 8, 15, 29, 36 and 43.~Patients with objective tumor responses or stable disease will receive additional combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent."
46033455|NCT03751774|Behavioral|MAMAACT|Post graduate training and health education materials
46033456|NCT05574868|Device|Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis|Treatment: Erectile dysfunction
46033457|NCT03414268|Other|Micronized dHACM|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
46033458|NCT03414268|Drug|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
46033459|NCT01118520|Drug|perindopril arginine|10mgs orally daily for the duration of the trial
46033460|NCT01118520|Drug|amlodipine 5mgs|5 mgs taken orally daily for the duration of the trial
46033461|NCT01118520|Drug|placebo|one daily
46033462|NCT04226638|Diagnostic Test|Dynamic ultrasound|Diagnosis was based on clinic suspicion and positive ultrasonography dynamic maneuvers by reproducing pain and slipping rib exam
46033463|NCT03744832|Diagnostic Test|Alere i™ Strep A assay|Point of care (POC) molecular-based, nucleic acid amplification test (NAAT). This isothermal molecular assay is CLIA waived (Clinical Laboratory Improvement Amendments) and Health Canada licensed for POC use, and is anticipated to have approval for use without need for back up culture testing.
45339022|NCT04061109|Drug|Recombinant Human Coagulation FVIII|A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
45339023|NCT04087616|Behavioral|ICBIT|The intervention consists of 9 modules delivered over 9 weeks comprise of age-appropriate texts and descriptive diagrams, animations, films of clinicians demonstrating techniques such as competing response exercising.
45683118|NCT05345860|Other|The MRD strategy for low risk and MRD- HER2+ patients|"Standard adjuvant chemotherapy + standard targeted therapy:~Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy (AC-T/TC/TCb) completed + H.~Adjuvant therapy patients: AC-T/TC/TCb/wP + H.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant targeted therapies listed in The MRD strategy for high risk or MRD+ HER2+ patients will be added for at most twice."
45683119|NCT05345860|Other|The MRD strategy for low risk and MRD- ER+ patients|"Standard adjuvant chemotherapy + standard endocrine therapy:~Premenopausal patients: Standard adjuvant chemotherapy followed by TAM/TOR.~Postmenopausal patients: Standard adjuvant chemotherapy followed by ANA/LET/EXE.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant endocrine therapies listed in The MRD strategy for high risk or MRD+ ER+ patients will be added for at most twice."
45683120|NCT03323866|Drug|Budesonide 0.5 MG/ML|2 cc nebule of budesonide in 240 cc of saline water (Sinus Rinse) once daily
45683121|NCT03323866|Drug|Mometasone nasal spray|Mometasone 50 mcg/spray 2 sprays twice daily
45839604|NCT02995824|Other|Raltegravir-based antiretroviral therapy|To analyze retrospectively the efficacy and safety of raltegravir plus 2 nucleoside reverse transcriptase inhibitors (NRTI) [lamivudine (3TC) or emtricitabine.(FTC) plus abacavir (ABC) or tenofovir (TDF)] [Group 1] versus other ART regimens including boosted PI or NNRTIs [Group 2] in 271 HIV/HCV-coinfected patients who underwent liver transplantation between 2002 and 2012 and were followed until December 2016.
45839605|NCT02995356|Other|Collecting cervical liquid and sera samples|
45839606|NCT02989974|Behavioral|KY LEADS Survivorship Care|"Survivor: Survivor questionnaire 1 at enrollment; KY LEADS Survivorship Care Program; survivor questionnaire 2 one week after program completion; survivor questionnaire 3 six months after enrollment.~Caregiver: Caregiver questionnaire 1 at enrollment;KY LEADS Survivorship Care Program; caregiver questionnaire 2 one week after program completion; caregiver questionnaire 3 six months after enrollment"
46033464|NCT03744832|Diagnostic Test|Throat culture|Standard bacterial throat culture.
46033465|NCT03742960|Behavioral|Behavioral Sleep Restriction|Participants will be instructed to go to bed 30 minutes later than their usual bedtime. On the other hand, wake up time will be unchanged resulting a nightly sleep restriction of 30 minutes. This protocol will be followed for two weeks.
45339024|NCT04087616|Behavioral|waiting list|Participants initially assigned to the wait list received no psychosocial intervention for 9 weeks. Following post-WL assessment, all participants chose to receive ICBIT.
46033466|NCT01135992|Drug|insulin degludec|Individually adjusted insulin degludec administered three times weekly with continued unchanged pre-trial OAD (oral anti-diabetic drug) treatment for 12 weeks
46033467|NCT01135992|Drug|insulin glargine|Subjects continue their pre-trial insulin glargine once daily plus OAD (oral anti-diabetic drug) treatment for four weeks before switch to insulin degludec
46033468|NCT03734770|Drug|Subcutaneous Progesterone|Subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference).
45339025|NCT00918320|Drug|Temozolomide/Hycamtin (Topotecan)|"Temozolomide: bottles containing 5 capsules of 5, 20, 100 and 250 mg~Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg~Patients receive during 5 days (Day 1 to Day 5):~Temozolomide 150 mg/m2/day per os, dose will be adjusted to the closest 5 mg, followed one hour later by Hycamtin(Topotecan) 0.75 mg/m2/day as an intravenous infusion over 30 minutes"
45839607|NCT02989740|Procedure|Optical Coherence Tomography|Patients aged ≥ 18 years bearing target lesions that fulfil the inclusion criteria and have undergone FFR and OCT imaging as per clinical practice will be enrolled in the study.
45839608|NCT02989896|Device|perfusion index|
45839609|NCT02989350|Dietary Supplement|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 vs Placebo
46033469|NCT03734770|Drug|Vaginal progesterone|Micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours).
45472701|NCT04245709|Drug|Clenbuterol|The intervention is treatment with oral clenbuterol at 40-80 micrograms twice daily for 24 weeks. Dosage will initially be 40 mcg daily for one week, then 40 mcg BID per oral daily for the next 5 weeks. If the 40 mcg BID per oral is well tolerated in the opinion of Dr. Bedlack, the dose will be increased to 80 mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID per oral for the remainder of the study. The selected target dose (80 mcg BID) is based upon the experience with the long-term administration of clenbuterol, specifically the beneficial muscle effects in a Phase I/II clinical trial that enrolled patients with late-onset Pompe disease who were previously treated with enzyme replacement therapy (Koeberl et al. 2018).
45472702|NCT03878693|Drug|Fomepizole|IV 4-MP.
45472703|NCT03878693|Drug|APAP|Oral APAP
45839610|NCT02989350|Dietary Supplement|Placebo|Lactobacillus reuteri DSM 17938 vs Placebo
46033470|NCT03725956|Procedure|Endoscopic sinus surgery|"Surgical procedure under general anaesthesia:~Consists of the removal of bone boundaries between sinus cavities (ethmoidectomy) with nasal polyps resection in order to retrieve nasal patency and sinus drainage Polysomnographic assessment as routinely applied in clinical practice"
46033471|NCT00959049|Biological|CSL's Influenza Virus Vaccine (Afluria)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
46033472|NCT00959049|Biological|Influenza Virus Vaccine (Fluzone)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
45683122|NCT05688670|Procedure|Regional Anesthesia|Bilateral pecto-intercostal fascial plane block (PIFB) and unilateral rectus sheath block (RSB) with Ropivacaine 0.2%
46033473|NCT00956943|Drug|Nicoderm CQ transdermal nicotine|Transdermal nicotine patch (21mg vs. 42mg), 8 weeks
46033474|NCT00956943|Drug|placebo|placebo patch
46033475|NCT00958893|Drug|25 mg Proellex|one 25 mg capsules
45472704|NCT05305495|Drug|Empagliflozin 25 MG|Patients who fulfill the inclusion criteria will receive an intravenous dose of 1.0-1.5 mg/kg of furosemide (≤120 mg) and urine output will be monitored for three hours. Those with a urine output < 300 ml in the first two hours post furosemide administration will receive a single oral dose of 25 mg of empagliflozin. Two hours after taking empagliflozin, patients will receive a second intravenous dose of 1.0-1.5 mg/kg of furosemide with another timed urine collection at three hours. Empagliflozin will then be continued daily for five days or until hospital discharge, unless the treating physician considers this not to be clinically appropriate.
45472705|NCT01164293|Device|Atopy patch test with food allergen|Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate the reaction one day later (72 hr after applying atopy patch test)
45683123|NCT05688670|Procedure|Wound infiltration|Surgeon-delivered wound infiltration with Ropivacaine 0.2%
45683124|NCT05688670|Drug|Ropivacaine 0.2% Injectable Solution|Ropivacaine 1.5 mL/kg will be used for both interventions
45683125|NCT05684848|Device|Resveratrol + CMG|As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
45839611|NCT02989428|Procedure|Early parathyroidectomy group (EPTX-group)|Participants will undergo parathyroidectomy as soon as possible
45839612|NCT02989116|Behavioral|Inhibition training|Inhibition training on a tactile tablet for a month (20 sessions of 15 min)
45839613|NCT02989116|Behavioral|Working memory training|Working memory training on a tactile tablet for a month (20 sessions of 15 min)
45839614|NCT02989116|Behavioral|Mindfulness training|Mindfulness training on a tactile tablet for a month (20 sessions of 15 min)
46033476|NCT01135914|Drug|ranibizumab|Ranibizumab 0.5 mg fixed loading dose via intravitreal injection, given once per month for 3 consecutive months (Day 1, Month 1 and Month 2). This treatment could be reapllied, depending on symptoms.
46033477|NCT01135914|Procedure|Laser|Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.
46033478|NCT04281927|Device|Monitoring with wearable (the tested device) and Holter ECG (eMotion Faros 90)|Participants will use the wearable (the tested device) to record at least 2 minutes of photoplethysmography and 6-lead ECG. In addition, each subject will be monitored with synchronous ECG Holter monitoring (with eMotion Faros 90).
46033479|NCT02858973|Drug|Q203|
46033480|NCT02858973|Drug|Placebo|
46033481|NCT04282005|Procedure|Metabolic/Bariatric surgery|Patients will undergo surgery; 7 RYGB and 7 SG, as planned for their standard care.
46033482|NCT04282005|Other|Lifestyle and Diet|Patients will be provided with a lifestyle interventions including dietary counselling choosing between a Low-Calorie Diet or a Meal Replacement Diet.
46033483|NCT04280679|Device|Sonovein 2|Patient are treated with the HIFU device and the pysician is doing a compressive bandage
46033484|NCT00907738|Drug|vorinostat|All patients will receive vorinostat at the same dose and schedule as they received in the base protocol until disease progression or unacceptable toxicity.
46033485|NCT02829723|Drug|BLZ945|
46033486|NCT02829723|Drug|PDR001|
46033487|NCT04282161|Device|Axys EX device|Rotational atherectomy system for endovascular treatment of peripheral arterial disease prior to adjunctive therapy, if needed
46033488|NCT01123356|Drug|Ofatumumab|"Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1 for up to 6 cycles (28 day cycles)~Treatment to be administered for up to 6 cycles"
45472706|NCT03748537|Drug|Hydrocortisone|After resuscitation, hypoperfusion in the sepsis patients will be treated by fluid resuscitation and vasopressor. Some groups of patients may be not responsive to this treatment (MAP <65 mmHg), administration of steroids to this group will be blindly randomized (treatment and control group). During resuscitation of septic shock patients with fluid resuscitation and vasopressors, some may not respond to treatment (MAP < 65 mmHg). Patients who have shock refractory to fluid resuscitation and norepinephrine therapy for more than 0.5 mcg/kg/min will be blindly randomized to receive steroid (treatment group) or placebo (control group). Blood samples will be obtained to determine mitochondrial functioning before, at day 1 and day 7 after administration of study medications in both groups.
46033489|NCT01123356|Drug|Lenalidomide|-Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28 for up to 6 cycles (28 day cycles)
46033490|NCT00630357|Drug|Levetiracetam (Keppra)|
46033491|NCT02858817|Drug|atovaquone/proguanil 250mg/100mg (A/P)|Combination drug for chemo-prophylaxis or treatment of malaria
46033492|NCT02858817|Biological|PfSPZ Challenge (NF54)|cryo-preserved Plasmodium falciparum sporozoites injected by venous inoculation
46033493|NCT02858817|Other|NaCl 0,9%|0.9% NaCl solution for injection
46033494|NCT02883192|Drug|Ondansetron|Zofran 4 mg.
46033495|NCT02883192|Drug|Placebo|Placebo
46033496|NCT04280835|Behavioral|Group Psychoeducation that Focused on Social Skill Development|Psychoeducation Program consists of; Preparatory Session, Recognition of Schizophrenia, Evaluating the Treatment of Schizophrenia, Stress and Coping with Stress, Improving Communication Skills, Improving Problem-solving Skills, Improving Interpersonal relationships and social activities and Evaluating Session.The sessions were held in the form of PowerPoint presentations. In the psychoeducation program, lecture, question-answer, homework, sharing experiences, group discussion, repetition, video presentation, summarization, reinforcer, and role-playing techniques were used. The day before each session, patients were phoned and reminded of the time of the session. At the end of each session, the content of the subject is given as hard copy and cookies, tea and coffee were served.
46033497|NCT02883270|Device|Robot-assisted Gait Training|Robot-assisted Gait Training is an effective alternative to treadmill therapy with partial body weight in intense gait rehabilitation and provided to the feet and the patient actively controls the knee and hip joints.
46033498|NCT02883270|Other|conventional rehabilitation|The participants of controls receive 60 min conventional rehabilitation daily for 8 weeks. Interventions included physiotherapy for muscle strengthening, endurance and gait training; occupational therapy to improve activity of daily living (domestic, community tasks).
46033499|NCT02860455|Device|RAD57 measurement (SpCO)|"SpCO measurement (Experimental)~Non invasive pulse CO-oximetry will be carried out by prehospital emergency nursing staff trained in the use of the Rad-57 pulse CO-oximeter (Masimo, Inc., Irvine, CA, USA), using the adult sized sensor (Sensor, Rev. B) placed on the 3rd or 4th digit, according to manufacturer recommendations. Nail polish will be removed if necessary. SpCO was expressed in total percentage of hemoglobin."
46033500|NCT02860455|Device|CO-oximeter|"COHb measurement (Active Comparator)~Venous blood will be collected into EDTA treated tubes (Beckton Dickinson) prehospitally and sent to the toxicology laboratory for further carboxyhemoglobin testing. Blood carboxyhemoglobin will be analyzed by derivative spectrophotometry using an automated CO-oximeter (IL 682, Instrumentation Laboratory SpA V.le Monza 338-20128 Milan, Italy). Blood carboxyhemoglobin will be detected within a range of 0-100% and accuracy of 0.5% and reported as percentage of total haemoglobin."
46033501|NCT00908596|Drug|Gadoxetic acid disodium (Primovist, BAY86-4873)|Primovist/Eovist in approved indications at approved dosages
46033502|NCT03116529|Combination Product|Combination Radiation, Immunotherapy, Surgery|"Three doses of Durvalumab (1500 mg) and Tremelimumab (75 mg) given intravenously once every four weeks during radiotherapy prior to surgery.~Radiation therapy delivered with a minimum dose of 50 Gy and 1.8-2 Gy per fraction. Bulky sarcomas, defined as >10 cms in greatest dimension, receive a single 15 Gy fraction of high-dose spatially fractionated (GRID) radiation therapy within 1-3 days prior to radiation therapy~Surgical resection is performed at least 5-8 weeks after cessation of radiotherapy and 4 weeks after completion of neoadjuvant immunotherapy.~Patients with no evidence of disease following surgical resection receive four additional doses and patients with evidence of disease receive nine additional doses of Durvalumab (1500 mg IV) once every four weeks unless there is clear progression of disease."
46033503|NCT05143593|Diagnostic Test|SSBD(PCR-CRISPR/Cas12a)|Based on 1791 microorganism genomes of 232 species from the public database, we identified species-specific DNA-tags for 12 common pathogenic bacteria, which allowed us to design our Cas12a system for using the trans-cleavage activity and judging whether bacterium infects the patient or not by fluorescence value.
46033504|NCT02860689|Other|using questionnaires - International Index Erectile Function|using questionnaires
46033505|NCT02590120|Dietary Supplement|Enteral nutrition|
46033506|NCT02860533|Device|cuff device|Measurement of blood pressure during stress testing with cuff device
46033507|NCT02860533|Device|iphone|Measurement of blood pressure during stress testing with iPhone
45472707|NCT04091581|Drug|Systane Complete|Systane Complete will be instilled and rate of evaporation assessed before and after.
45472708|NCT02527109|Drug|Nifedipine|
45472709|NCT02940522|Drug|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
45472710|NCT02940522|Drug|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
45472711|NCT03878615|Procedure|elective surgery, according to deprtement routine|none, descriptive study
46033508|NCT01118052|Other|Laboratory Biomarker Analysis|Correlative studies
45472712|NCT01266785|Drug|Infliximab|Patient will receive Infliximab infusions during Weeks 0, 2 and 6. Therefore, the duration of the Infliximab treatment will last 6 weeks.
46033509|NCT01118052|Biological|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|Given intraperitoneally
46033510|NCT02860377|Procedure|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath. ~At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
45472713|NCT03875807|Procedure|ACLR done at 0 degrees KFA|Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 0 degrees knee angle flexion (KFA)
45472714|NCT03875807|Procedure|ACLR done at 30 degrees KFA|Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 30 degrees knee angle flexion (KFA)
45754712|NCT01797107|Drug|Azasite|Patients will be given 1 drop twice a day for 2 days followed by 1 drop nightly for 4 weeks.
45839615|NCT02989116|Behavioral|Active control training|Active control training on a tactile tablet for a month (20 sessions of 15 min)
45839616|NCT02989116|Genetic|Saliva collection|Collection of a saliva sample for genotyping
45839617|NCT02989116|Procedure|Brain Magnetic Resonance Imaging|Structural and functional MRI
45839618|NCT02989116|Behavioral|Cognitive testing|Battery of cognitive and academic tasks on executive functions
45754713|NCT03155984|Drug|Anti-CD20 antibody|All patients receiving anti-CD20 therapy (rituximab, ofanumumab, obinutuzumab) for hematological malignancies
45754714|NCT00620191|Drug|Metformin|Metformin 1000 mg twice a day titrated from 500 mg once a day
45754715|NCT00620191|Drug|Placebo|Placebo identical to metformin 2 tablets twice a day titrated from one table once a day
46033511|NCT02860377|Procedure|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath. "
46033512|NCT03394534|Other|CGA group|CGA Plus Individualised Care and Support Plan delivered by Advanced Clinical Practitioner (ACP)
46033513|NCT04277949|Device|Erbium:YAG|Treatment with Erbium:YAG laser
46033514|NCT04277949|Drug|UV endonuclease from Micrococcus luteus|Application of topical DNA repair enzymes
46033515|NCT00632554|Drug|prednisolone 0.5 mg/kg/day for three months|period of treatment
46033516|NCT00632554|Drug|prednisolone 0.5 mg/kg/day for six months|period of therapy
46033517|NCT01123200|Device|Brain Computer Interface for Wheelchair Tilt Control|Patients will be given the BCI for use in-home, as long as they use the BCI at least 10 hours per week and complete monthly performance assessment sessions.
45472715|NCT02526719|Procedure|Nipple Delay surgery|The nipple delay surgery will be performed by the plastic surgeon as an outpatient procedure in the minor procedure room under local anaesthetic 7 - 21 days prior definitive NSM with IBR. The skin flap will be elevated in the plane of the prophylactic mastectomy beneath the NAC. A nipple core biopsy and a 1cm thick biopsy of immediately subareolar ductal tissue will be submitted for permanent section pathology. This approach is consistent with the previous case series of nipple delay for NSM and has been approved by the multi-disciplinary breast cancer team at our institutions. Patients that have a positive nipple core or sub-areolar biopsy will have the NAC removed at time of definitive mastectomy.
45472716|NCT03746977|Dietary Supplement|Protein|Protein supplementation 1.2 or 1.5 g/kg body mass/d
45472717|NCT03746977|Behavioral|Walking|Walking with a volume corresponding to 250 kcal/d
46033518|NCT02857803|Procedure|Virtual Reality|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
46033519|NCT02857803|Procedure|Paper and Pencil|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
46033520|NCT02857803|Procedure|Conventional Therapy|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
46033521|NCT05054088|Device|T-Detect COVID test|• The T-DetectTM COVID test is an EUA granted investigational device that is indicated to assess a T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19.
45339026|NCT02593292|Behavioral|PROSPERO|"The intervention is carried out in 3 steps:~At the start of the pregnancy: a number of process steps are defined for a patient's pathway adapted to medical, obstetric and social risk factors.~During pregnancy: city based doctors and midwives work together with their hospital peers enabling patients to participate through the reporting via a medical information system~The entrance in the delivery room: patients are classified as low or high risk for greater vigilance from midwives."
46033522|NCT03335722|Behavioral|Metronome-timed speech|Reading, narrative, and conversational speech tasks will be completed on each of the five intervention days. Metronome- timed speech will be practiced during these tasks, at near-normal (comfortable) speech rate for each participant. Each intervention session will be 40 minutes in duration.
46033523|NCT03335722|Device|Active tDCS|1-mA tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes. The current is ramped up to 1 mA over the first 15 seconds of stimulation and maintained at this level for remainder of the 20-minute stimulation session.
46033524|NCT03335722|Device|Sham tDCS|Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes. Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session.
46033525|NCT04310670|Other|Psychotherapy|The patient will be treated according to Lacanian psychoanalytic ethics, which allows to adequately respond to the patient's request for healing but who at the same time does not ignore the progress of scientific research in the neurological field
46033526|NCT04310670|Behavioral|Physiotherapy|Physiotherapy treatment will be articulated through the use of techniques designed to qualify the functionality of the subject divided by symptom: weakness, dystonic attitudes of the limbs, walking disorders, tremor.
46033527|NCT04310670|Other|Non-Invasive Brain Stimulation (NIBS)|"Diversified transcranial electrical maneuver protocols with an on-line or off-line approach may be applied for therapeutic purposes. This will include: transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), random noise stimulation (tRNS)."
46033528|NCT00955617|Other|Contrast-enhanced MRA - Imaging examination|Administration of 0.1 mmol/kg of contrast product (Dotarem and Gadovist)
46033529|NCT03896854|Biological|CART-19|CART-19 Split intravenous infusion of CART-19 cells of (Dose escalating infusion of 1 - 20 x10^6 CART-19 cells/kg).
46033530|NCT05462860|Other|Suprathel®|Application of standard of care dressing.®
46033531|NCT05117775|Other|No intervention - Just description and predictive models|All the groups will be descriptive, there is not intervention, as it is an Observational study applying artificial Intelligence (RWE).
46033532|NCT04277871|Behavioral|Pelvic floor muscles training (PFMT) combined with yoga|All study participants were instructed to perform PFMT combined with yoga with an expectation of performing a 70-minute practice section 3 days in a week. All study participants received a booklet with menopause-related information, a booklet plus an instructional Digital Video Disc for PFMT and yoga practice.
46033533|NCT05331898|Behavioral|Education|the education given increased the rational drug use of the parents.
46033534|NCT03082209|Drug|ABBV-621|Intravenous (IV)
46033535|NCT03082209|Drug|Venetoclax|tablet, oral
46033536|NCT03082209|Drug|Bevacizumab|IV infusion
46033537|NCT03082209|Drug|FOLFIRI|IV infusion
45472718|NCT03746977|Behavioral|WB-EMS application|WB-EMS application 1.5x 20 min/week
45472719|NCT03262038|Drug|Ondansetron|This arm will receive (in a blinded fashion) 0.1 mg/kg of Ondansetron IV made up to 5 mLs intra-operatively and Ondansetron IV 0.1 mg/kg made up to 5 mLs every 6 hours for 24 hours postoperatively.
45472720|NCT03262038|Drug|Placebo Comparator|This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively as well as IV every 6 hrs for 24 hours postoperatively.
45598821|NCT03516019|Other|standard notices|The standard notices which are neutral and invite participants to wear the watch daily and to measure their blood pressure weekly.
46033538|NCT05423860|Other|no interventions will be performed (observational)|Not applicable. (no interventions will be performed with this observational study
46033539|NCT02224144|Drug|Vitamin D3|Vitamin D3 1000 IU per day for 12 months
46033540|NCT02224144|Drug|Calcitriol|Calcitriol (Rocaltrol) 0.5 mcg per day for 12 months
45598822|NCT03516019|Other|am notices|notifications sent at 7 am.
46033541|NCT02224144|Drug|Placebo|Placebo (sugar pill) 1 pill per day for 12 months
46033542|NCT00958347|Device|Omnifit HA Hip Stem|Total Hip Replacement with Omnifit HA Hip Stem
46033543|NCT05419180|Drug|Stiripentol|Since the treatment usually received by patients should not be modified, the sponsor will not intervene in any way in the therapeutic management of patients.
46033544|NCT04281615|Other|Generic Message|Exposed to four sets of promotional materials hypothesized to increase perceptions of self-efficacy to meet Guidelines.
46033545|NCT02857647|Behavioral|An information video|Participants who will assigned to the experimental group will be asked to watch a 30 minutes videotaped lecture 1-2 weeks prior to the surgery date. Topics includes: types of surgeries, preparation to the hospitalization process and to the surgery (e.g. what to expect, personal equipment needs, description of the surgery admission process, etc.), dietary guidelines pre- and post-surgery (e.g. low carb diet 2-3 week prior to the surgery, post-surgery diet progression, techniques of eating and drinking, recommended dietary supplements), recommendation and tips for long term surgery success (e.g. definition of weight loss expectations, physiological, nutritional and life-style strategies for long-term weight loss).
45339027|NCT02593292|Other|control|At the start of the pregnancy, medical, obstetric and social risk factors are checked in the same way than the PROSPERO group. An adapted patient pathway was defined by a Clinical Research Assistant but unreachable from patients, midwifes and physicians. The electronic patient care reporting information system will be disabled and midwifes cannot create the classification checklist for low or high risk delivery.
45339028|NCT03960632|Diagnostic Test|Abbott SD Bioline Malaria Pf Plus (05FK150) and Abbott SD Bioline Malaria Pf/Pv Plus (05FK160))|Qualitative in vitro tests for the detection of Plasmodium antigens
46033546|NCT02067052|Procedure|Surgery, radiotherapy and chemotherapy|Surgery: vulvectomy and lymphadenectomy Radiotherapy: 180 cGy / day per 5 days untill maximum dose 4500 - 5940 cGy Chemotherapy: vulvectomy, lymphadenectomy
46033547|NCT02067052|Procedure|Surgery|Vulvectomy & lymphadenectomy
45339029|NCT05478759|Behavioral|Multimodal affect recognition training|8 session, trains participants to recognize expression of emotion from a variety of stimuli, including dynamic stimuli (e.g., video instead of still pictures) and it employs both facial and vocal examples of emotion expression.
46033548|NCT05418712|Drug|Placebo|Placebo matched to VX-150 for oral administration.
45339030|NCT05478759|Behavioral|Attention Training|computerized attention drill training
45339031|NCT05478759|Behavioral|Brain Health Workshop|an education presentation on brain function and cognitive principles of learning with homework and quizzes on information covered.
45339032|NCT05478759|Behavioral|National Geographic Movies|participant will watch movies and answer questions after
45339033|NCT00729560|Drug|Flutamide|250 mg twice daily for 4 weeks
45339034|NCT00729560|Drug|Placebo|Placebo twice daily for 4 weeks
45339035|NCT03202017|Procedure|Expiratory Muscle Strength Training (EMST)|EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
45339036|NCT03202017|Procedure|EMST + Lung Volume Recruitment (LVR)|"EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.~LVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough. Half of the participants will perform the LVR technique in addition to the ESMT technique."
45339037|NCT00918008|Genetic|Blood draw|The research intervention is the blood sample only collected prior to surgery. Analyses of the data will be made by correlating the gene profile expression with the pathologic finding at surgery and the clinical status of the patients 2 years after surgery.
45339038|NCT03960320|Other|questionnaire|questionnaire to assess the quality of life of children using KINDL, SDQ and SF-36
45339039|NCT04088162|Device|Postoperative Negative Pressure Wound Therapy KCI NANOVA|
45339040|NCT00736190|Drug|Tenofovir disoproxil fumarate|300-mg tablet (marketed formulation) taken orally once daily
45598823|NCT03516019|Other|pm notices|notifications sent at 7 pm.
46033549|NCT05418712|Drug|VX-150|Solution or Suspension for oral administration.
46033550|NCT04280289|Drug|cannabidiol extract|"The test article CBD Cannabis Extract Oral Solution will be manufactured by the University of Mississippi National Center for Natural Products Research (NCNPR) at the Coy Waller Laboratory under FDA Current Good Manufacturing Practices. The drug product, derived from hemp and containing less than 0.3% of Δ9-tetrahydrocannabinol, is no longer a Drug Enforcement Agency (DEA) controlled substance. DEA registrations are not required for the manufacturing, handling or dispensing of these clinical test materials"
46033551|NCT03302728|Drug|Lenalidomide 15mg|At commencement of study : Lenalidomide will commence at 15 mg daily for days 1-14 of each cycle. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may vary from 5 mg -25 mg daily depending on dose escalation results and recommendation of safety committee
45598824|NCT03516019|Other|weekday notices|notifications sent on Wednesday
46033552|NCT03302728|Drug|Brentuximab Vedotin 1.8 mg/Kg|At commencement of study : Brentuximab vedotin 1.8mg/kg IV on day 1, repeated every 21 days. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may be either 1.2 mg/Kg q21 days or 1.8 mg/kg q21 days depending on dose escalation results and recommendation of safety committee
46033553|NCT05331742|Drug|Vaccine|patients who have received vaccine against coronavirus disease infection
46033554|NCT03863236|Dietary Supplement|regular diet|The control group (group 1) will continue their regular diet.
46033555|NCT03863236|Dietary Supplement|nutritional support Resource 2.5|The intervention group (group 2) will get preoperative nutritional support (Resource 2.5 Compact/fibre combact) two weeks before the operation and the nutritional support will continue 10 days after the operation.
46033556|NCT00958191|Device|Trident® X3 Polyethylene Insert|Trident® X3 Polyethylene Insert
46033557|NCT05322382|Procedure|A-line|Subjects breathe air mixtures containing reduced amounts of oxygen to produce the desired level of hypoxemia.
46033558|NCT04276935|Other|Interview|Participate in cognitive interview
46033559|NCT04276935|Other|Quality-of-Life Assessment|Ancillary studies
46033560|NCT04276935|Other|Questionnaire Administration|Ancillary studies
46033561|NCT03832972|Other|estrogen level|Women are tested at different times in their menstrual cycle, if there is a cohesion between performance and level of estrogen
46033562|NCT03051477|Drug|Helixor® M|3-hour IV infusion on Monday, Wednesday, and Friday of each week.
46033563|NCT03125356|Other|Diet Soda|Subjects will be asked to consume diet soda three times daily for eight weeks.
46033564|NCT05314114|Procedure|No axillary surgery|No axillary surgery
46033565|NCT02860299|Drug|citrate 4%|
46033566|NCT02860299|Drug|unfractionated heparin|
46033567|NCT02860299|Biological|blood sample|
46033568|NCT05374564|Drug|(18F)Flutemetamol|18F-Flutemetamol binds to β-amyloid plaques and the F-18 isotope produces a positron signal that is detected by a PET scanner. Multiple recent studies have shown that thioflavin-analogue tracers such as 18F-flutemetamol may be able to fulfill the unmet need of elucidating the presence of amyloid deposition in the heart. Because it binds to the beta-pleated motif of the amyloid fibril due to their similarity to the thioflavin structure, 18F-Flutemetamol could potentially be used to image cardiac amyloidosis (CA)
46033569|NCT02858739|Device|BIOFREEDOM STENT|
45339041|NCT04060797|Device|endovascular denervation|multi-electrode catheter-based endovascular denervation
45339042|NCT02565771|Other|Adapted physical activity|The adapted physical activity is done by Education Physique et Gymnastique Volontaire (EPGV) centres.
45339043|NCT04705779|Behavioral|HARMONY|The HARMONY intervention will be delivered over 8 every-other-week sessions and 6 monthly booster sessions. Each session will have three components; an exercise sampler, cool down and tailored education on cardiometabolic prevention and risk reductions.
45339044|NCT04705779|Behavioral|Nutrition and Exercise Education (NEEW)|The Nutrition and Exercise Workgroup (NEEW) group will be delivered over 8 every-other-week sessions and 6 monthly booster sessions. Each session will have three components; an exercise sampler, cool down and tailored education on cardiometabolic prevention and risk reductions.
45839619|NCT02989272|Drug|Sulfate, Magnesium|magnesium group (30 patients) who will receive pretreatment by intravenous infusion of magnesium sulfate 60 mg / kg
45839620|NCT02989272|Other|saline group|saline group (30 patients) who will receive pretreatment by saline solution
46033570|NCT02858505|Drug|27 mg elemental iron|
46033571|NCT02858505|Drug|54 mg elemental iron|
46033572|NCT05313100|Drug|sugammadex|At the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups
46033573|NCT00960843|Device|Intraband pressure recording system|Intraband pressure will be measured by a pressure recording system.
46033574|NCT00960843|Other|Conventional Adjustment|Band adjustments will be made via conventional standard of care (e.g., volume, hunger).
46033575|NCT01518556|Drug|Idarubicin|"In the phase I study, idarubicin dose is increased step by step as follows: 12 mg/m2/day for 3 days IV in the 1st step; 15 mg/m2/day for 3 days IV in the 2nd step; 18 mg/m2/day for 3 days IV in the 3rd step.~In the phase II study, idarubicin dose is the maximum tolerated dose that is determined from the phase I study or 18 mg/m2/day for 3 days ."
46033576|NCT04281693|Diagnostic Test|Standard screening strategy|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by individual testing.
46033577|NCT04281693|Diagnostic Test|New screening strategy|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing.
46033578|NCT02994069|Drug|Cisplatin|Cisplatin
46033579|NCT02994069|Radiation|XRT|Radiation Therapy
45339045|NCT04686279|Drug|Tenofovir Douche|660 mg TFV in 125 mL hypo-osmolar solution
46033580|NCT02860221|Drug|Tranexamic acid (TXA)|IV and topical administration
46033581|NCT02860221|Drug|Epinephrine|
46033582|NCT02860065|Drug|CPC-201|solifenacin and donepezil
46033583|NCT02860065|Other|Positron emission tomography (PET)|measure activity of cerebral acetylcholinesterase
46033584|NCT04274829|Procedure|Thyroidecomt and lymphectomy|Patients underwent total thyroidectomy or lobectomy associated to lymph node sampling or neck lymphectomy
46033585|NCT01874353|Drug|Olaparib 300mg tablets|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
46033586|NCT01874353|Drug|Placebo to match olaparib 300mg|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
46033587|NCT02396199|Device|Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
46033588|NCT02857881|Procedure|De-epithelization and therapeutic photokeratectomy|
45839621|NCT02989038|Other|Very Low Nicotine Content Cigarettes|cigarettes with 0.03 nicotine yield with 0.4 mg/g nicotine content and 9.0 mg tar yield
46033589|NCT02857569|Drug|Ipilimumab IT|
45839622|NCT02989038|Other|Intermediate Nicotine Content Cigarettes|cigarettes with 0.12 nicotine yield with 2.4 mg/g nicotine content and 9.0 mg tar yield
45839623|NCT02989038|Other|Normal Nicotine Content Cigarettes|cigarettes with 0.8 nicotine yield with 15.8 mg/g nicotine content and 10.5 mg tar yield
45839624|NCT02988804|Device|endotracheal tube|"In the Endotracheal group In the ETT group, the procedure will be exactly the same except that the ETT will not be exchanged and the patient will be directly extubated~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
46033590|NCT02857569|Drug|Ipilimumab IV|
46033591|NCT02857569|Drug|Nivolumab IV|
46033592|NCT02638363|Behavioral|Cognitive behavioral therapy|The participants will receive 12-16 sessions of manualized group-based CBT with a maximum of 8 participants in each group. The therapists are trained psychiatrists, psychologists, or nurses under supervision. The treatment manuals are developed by mental health professionals in the Capital Region of Denmark. The treatment program includes traditional CBT components (e.g., psychoeducation, identification of thoughts and feelings, exposure, cognitive restructuring, and relapse prevention).
46033593|NCT04164667|Behavioral|Directed instruction of the combined intervention of physical activity and mindfulness meditation|By using the VA's ANNIE text messaging systems, the participant's will receive detailed guidance on the exercise and mindfulness session.
46033594|NCT04164667|Behavioral|Self-guided practice of the combined intervention of physical activity and mindfulness meditation|The participants will receive the same goals about exercise and mindfulness practice, but without the added text messages where explicit instruction will be provided
46033595|NCT04164355|Drug|Tadalafil 20 MG|To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy
46033596|NCT01605253|Drug|Eszopiclone|Eszopiclone has been approved by the US Food and Drug Administration (FDA) for the treatment of insomnia (inability to sleep). Eszopiclone has not been specifically approved by the FDA for people who have PTSD-related sleep disturbance.
46033597|NCT01605253|Drug|Placebo|The placebo used in this study looks exactly like eszopiclone but contains no active ingredients.
46033598|NCT04164433|Device|Oral HIV Self-Test (OraQuick)|The oral HIV self-test is a device for taking a test which is painless. The user gently swipes the test swab along the upper gums once and the lower gums once. The swab is then inserted inside the test tube provided and results are ready in 20 minutes.
46033599|NCT00655135|Drug|LDP-02|Each patient in arms 2 & 3 received a single IV dose of study drug at 0.5 or 2.0 mg/kg LDP-02 on Days 1 and 29.
45339046|NCT00729326|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
45339047|NCT00729326|Drug|sitagliptin|oral administration (100mg), once a day in the morning
45339048|NCT00729326|Drug|placebo|subcutaneous injection (5mcg or 10mcg), twice a day
45339049|NCT00729326|Drug|placebo|oral administration (100mg), once a day in the morning
45339050|NCT02565303|Procedure|Intervertebral space|
45339051|NCT02565303|Drug|Ropivacaine|The initial dose of ropivacaine is chosen as 12 mg in L2-3 group and 15 mg in L3-4 group with the volume of 3 mL in both groups. The testing interval is 0.5 mg with subsequent doses being determined by the outcome of the previous injection in the same group.If the previous response is ineffective, the next patient will receive 0.5 mg more than the last patient. If the response of the previous patient is effective, the next patient decrease 0.5mg.
46033600|NCT00655135|Drug|Placebo|Each patients in arm 1 received a single IV dose of placebo on Days 1 and 29.
45598825|NCT03516019|Other|weekend notices|notifications sent on Saturday
45598826|NCT04581473|Drug|CT041 autologous CAR T-cell injection|Up to 3 times CT041 autologous CAR T-cell injection infusion
46033601|NCT02643121|Other|therapy sepsis|Treatment of sepsis varies depending on the site and cause of the initial infection, the organs affected and the extent of any damage
46033602|NCT04163965|Device|Capacitive ECG|Patients having a pacemaker will sit down on a seat bearing capacitive ECG electrodes during their routine heart checkup at the cardiology.
46033603|NCT02643277|Behavioral|Mobile phone text messaging|The intervention will be text messages delivered by an automated text messaging manager. The message content will be designed to induce lifestyle modification (diet and physical activity) and will be motivational, based on the content which has been proven to be effective in reducing progression to diabetes in people with pre-diabetes. Other text messages will aim to improve drug compliance and disease monitoring, based on our pilot studies in India. The control arm will receive conventional management, according to local guidelines in the Indian centers, which in all cases are compatible with those of the International Diabetes Federation.
45839625|NCT02988804|Device|Laryngeal mask|"In the LMA group, after aspirating pharyngeal secretions and with the patient still under general anesthesia, we will insert a Proseal LMA (Laryngeal Mask Co. Ltd., Le Rocher, Victoria, Mahe Seychelles) and extubate the trachea using a guided Bailey technique~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
46033604|NCT02643277|Other|Conventional care|Conventional care is comprised of a one-to-one interview by a trained research personnel on diet and exercise advice at baseline and during every visit. The goals were to reduce portion size (total calories) and, to avoid simple sugars and refined carbohydrates, reduce total fat intake, restrict use of saturated fat, include more fibre rich food-(e.g., whole grains, legumes, vegetables, and fruits).
46033605|NCT02635945|Drug|PBF-680|
46033606|NCT02635945|Drug|Placebo|
46033607|NCT04059991|Biological|Influenza Vaccination|Only subjects vaccinated against influenza will be enrolled. The study itself is observational
46033608|NCT02635867|Drug|Resin-modified calcium silicate - TheraCal LC|
46033609|NCT02635867|Drug|Calcium hydroxide - Dycal|
46033610|NCT02635867|Drug|Resin-based dentin bonding agent|
46033611|NCT04162249|Other|Conventional LSI/AI-guided pulmonary veins ablation.|Conventional (low-power and long-duration) radiofrequency application.
46033612|NCT04162249|Other|High-power pulmonary veins ablation.|Experimental (high-power and short-duration) radiofrequency application.
46033613|NCT04162249|Other|Esophageal temperature monitoring|Two probes were simultaneously used: a deflectable one and a non-deflectable one.
45472721|NCT01268969|Procedure|KARYDAKIS GROUP|The technique consisted of a vertical eccentric elliptical incision carried down to the post sacral fascia, complete removal of unhealthy tissue with the normal tissue around the cyst and sinus tracts, mobilization of the medial wound edge by undercutting the adipose tissue at a depth of 1 cm, the advancement of the flap across the midline to the post sacral fascia and suturing of its edge to the lateral one
45683126|NCT05684848|Device|Isotonic solution|As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
45683127|NCT03322618|Biological|blood samples|7 tubes of 6 ml (42 ml of blood )
45683128|NCT03390244|Device|Foldable Capsular Vitreous Body Implant|Vitrectomy augmented with the implantation of the FCVB implant
45839626|NCT02988726|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a recurrent/residual Neurofibroma or Schwannoma will receive Antineoplaston therapy (Atengenal + Astugenal).
45683129|NCT04761484|Procedure|Vascular access on admission|PIVC insertion
46033614|NCT04162249|Diagnostic Test|Esophageal endoscopy|Esophageal endoscopy for acute detection of esophageal thermal lesions <72 hours after ablation.
46033615|NCT04164043|Behavioral|Wellness Recovery Program|12-week community-based recreation therapy
46033616|NCT00955305|Biological|Bevacizumab|Given IV
46033617|NCT00955305|Drug|Carboplatin|Given IV
46033618|NCT00955305|Biological|Cixutumumab|Given IV
46033619|NCT00955305|Drug|Paclitaxel|Given IV
46033620|NCT02635789|Drug|NPC-12G gel|NPC-12G gel is administered topically twice a day for 12 weeks
46033621|NCT02635789|Drug|Placebo gel|NPC-12G gel placebo is administered topically twice a day for 12 weeks
46033622|NCT02635711|Behavioral|Adapted Taekwondo training|Adapted Taekwondo training for beginners
46033623|NCT02635711|Behavioral|Control|Daily jogging
46033624|NCT00655291|Drug|XP20B|
46033625|NCT00655291|Drug|Placebo|
46033626|NCT02857725|Drug|BAY 987517|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
46033627|NCT02857725|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
46033628|NCT00656695|Drug|Iminoral|Iminoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
46033629|NCT00656695|Drug|Neoral|Neoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
46033630|NCT02858427|Behavioral|eye tracking|"several oculomotor parameters will be recorded using vide-oculography techniques (eye tracking) trough different tasks: saccade, antisaccade, and picture scanning.~Saccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the red dot appearing on the periphery of the screen.~Prosaccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the opposite side relative to the red dot appearing on the periphery of the screen.~Picture Scanning: participant is instructed to freely watch pictures with different emotional valence."
45339052|NCT05476809|Behavioral|smart-cloth assisted home nursing|The upgraded smart-cloth assisted home nursing integrate smart-cloth monitoring system, home nursing, and family caregiver feedback app. The persons living with dementia will be asked to wear a smart cloth 24 hours a day and will be monitored on abnormal activity level, going out alone, abnormal number of getting-up at night, fall risks. In addition, monitoring for medication, abnormal life pattern, quality of hired help will also be included. The warning signals, along with weekly summary and related information will be sent to the family caregiver interactive App after the assessment of the home care nurses to provide guidance for family care.
45339053|NCT00696423|Biological|Infanrix™|Intramuscular injection, one dose
46033631|NCT02858427|Behavioral|neuropsychological assessement|the neuropsychological assessment aims to identify any impairment of executive functioning through several tasks: Mini mental state examination (mmse), isaac set test (STI) trail making test (TMT A and B), Grober test, Stroop test, verbal fluency, Go No Go task, memory impairment screen (MIS), picture naming test (DO30), copying figure test, digit span and categorical matching test.
46033632|NCT02858427|Behavioral|psychiatric assessment|this evaluation aims to characterize the mental status of the patient. Different scales will be used: Montgomery and ASberg depression rating scale (MADRS), Columbia-suicide severity rating scale (C-SSRS), Beck depression inventory (BDI), Barratt impulsiveness scale (BIS-10), Buss and Durkee Hostility Inventory (BDHI), Balloon, analogue risk task (BART), Iowa gambling task (IGT), and Childhood trauma questionnaire (CTQ).
46033633|NCT02858427|Behavioral|sociological interview|this interview aims to characterize social interactions of the patients, their duration, their evolution and the perception of each participant on this subject.
46033634|NCT02642887|Procedure|mTA + SCTG|These recession defects will be covered by modified tunnel approach; using a full thickness flap till the level of mucogingival junction then, partial thickness flap will be applied in the vestibular mucosa. SCTG will be harvested from the palate, put on the root surface then covered by the mTA and sutured.
46033635|NCT04204083|Device|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose in a 5-mL glass syringe.
46033636|NCT04271865|Other|Nutritional Education|Provision of weekly awareness and educational sessions for 6 months. Sessions were conducted at the community based associations within the cases respective villages. Cases were subjected to 24 sessions for improving the patients' own nutrition situation through nutritional education about food rich in iron and counselling. The sessions focused on basic knowledge on iron deficiency anaemia, the most common presenting symptoms, iron rich dietary sources, factors that enhance and inhibit iron absorption, effects of anaemia on health and how to prevent it, Role of dates fruit in preventing and treating anaemia. Th e sessions also focused on the provision of a diverse range of local iron rich food. Special focus was on increasing patients' awareness for self-management of their status
45339054|NCT00696423|Biological|Hiberix™|Intramuscular injection, one dose
45472722|NCT01268969|Procedure|Lamberg flap technique|The area to be excised was mapped on the skin in a rhomboid form . The skin incision was deepened to the presacral fascia centrally and to the gluteal fascia laterally. After removing the specimen, the Limberg fasciocutaneous flap was prepared by extending the incision down to and through the right gluteus maximus fascia
46033637|NCT04271865|Other|model nutrition kitchen|Implementing model nutrition kitchen; once every month for six months with six sessions for each village (6 sessions/village) with cooking sessions was done to promote eating healthy and provide innovative ideas for feeding anaemic cases. 117 patients were reached by the nutritional kitchen activities with 6 sessions until the end of the project. Special focus was done on skills like sharing cooking, meal planning, and label reading that help support healthy eating patterns. Suggesting ways that individuals can model healthy eating behaviors for friends and family members that is based on Dates fruit was encouraged.
46033638|NCT04271865|Other|recipe book|3) Development of recipe book that is based on the local food in the market to increase the number of nutritionally balanced meals and increase the frequency of iron-rich foods per day and improve current and risky nutritional habits
46033639|NCT04271865|Other|Provision of Dates|"Dates fruit intake for all the anaemic patients was provided for 16 weeks (four months):~• Diagnosed anemic patients were given five to seven pieces of Dates (dependent on its weight) on daily basis for 16 weeks (each date fruits is about 10 -20 gm). Dates was taken as breakfast on daily base.~The Dates fruit that was used during the proposed trial is Saudi's Dates extract know as Barni which is organic Dates. The fruit is mentioned more than 20 times in the Quran, This Barni is known for its very high nutritive value (vitamins, minerals and antioxidants) compared with other Dates types. The nutritive value of Barni is shown in the below table, calculated per every 100 gram (range 5- 10 pieces) of dry weight (DW) :~The nutritive value of Barni calculated per every 100 gram (average 7-10 pieces) of dry weight (DW) of which iron constitutes 6.78 mg that represent 67.8 % of the recommended dietary allowance (RDA) of the males and 45.20 % of the RDA of the females"
46033640|NCT00598585|Drug|Sildenafil (Viagra)|25 mg tid of either Sildenafil(Viagra) for first week. 50 mg tid of either Sildenafil (Viagra) for second week. 100 mg tid of either Sildenafil (Viagra) 3rd,4th, 5th and 6th week of study participation.
45339055|NCT05325944|Behavioral|Self-guided digital intervention for NSSI|"Psychoeducational content, skill-based practice, and daily ecological momentary assessments will be delivered over an 8-week period.~Psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies. Daily EMAs assess NSSI and use of cognitive, behavioral, and emotion regulatory strategies."
46033641|NCT00598585|Drug|Placebo|Placebo pills 3X/day for 6 weeks
46033642|NCT04271553|Other|Video|In addition to standard workflow, participants will also receive the PFO bundle which consists of: 1) A cartoon video of about 6 minutes duration illustrating the events occurring during admission, anaesthesia and surgery and 2) Sets of activity sheets which have been tailored for different age groups. Families would be encouraged to complete activity sheets together.
46033643|NCT00175201|Procedure|Proactive care and rehabilitation|
46033644|NCT03406351|Other|Observational|Observational deep phenotyping physiological readouts
46033645|NCT00653107|Procedure|Stent insertion|Self-expanding metal stents will be used. These will be of the type which the hospital at any given time uses, at present Ultraflex®.
45339056|NCT05325944|Behavioral|Digital intervention for NSSI with coaching|Psychoeducational content and psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies. Daily EMAs assess NSSI and use of cognitive, behavioral, and emotion regulatory strategies. Human coaching will be used to support intervention use and engagement twice per week via text, call or email.
45339057|NCT05325944|Behavioral|Active control|Psychoeducational content and psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies.
45339058|NCT02592668|Device|Epidural Stimulator|Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function.
45472723|NCT03745573|Behavioral|Empateach|Empateach is a behavioural intervention for teachers.
45472724|NCT01266863|Other|E test method|E test strips directly applied to BAL
45472725|NCT03746821|Dietary Supplement|Biotin|Biotin supplements (2) to be taken daily
46033646|NCT00653107|Radiation|Brachytherapy|a flexible applicator (with a diameter adapted to the stent's diameter) will be introduced into the oesophagus, so the applicator will be lying in the middle of the lumen of the stent. Thereafter, the flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (> 12 Gy/h).
46033647|NCT00653107|Radiation|Brachytherapy|a flexible applicator will be introduced into the oesophagus. The flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (> 12 Gy/h).
46033648|NCT02635243|Drug|SAR438544|"Pharmaceutical form:solution~Route of administration: subcutaneous"
45339059|NCT00736034|Dietary Supplement|Phosphatidylserine-Omega3 (SharpPS™-Gold)|Treatment will consist of capsules containing 100 mg phosphatidylserine-Omega3. Dosage: 1 capsule X 3 times daily, with meals. Duration: 15 weeks
45339060|NCT00918164|Drug|PF-04457845|Single dose, 8 mg as oral tablet and solution formulation
46033649|NCT02635243|Drug|r-glucagon|"Pharmaceutical form:solution~Route of administration: subcutaneous"
45339061|NCT00576693|Device|intracranial angioplasty and stenting|intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl).
46033650|NCT02635243|Drug|insulin|"Pharmaceutical form:solution~Route of administration: intravenous"
46033651|NCT00953667|Drug|Immediate Release Niacin, Extended Release Niacin, Endotoxin|Subjects receive a one-time 1000mg dose of immediate release Niacin (Niacor pills), a one-time 1000mg dose of extended release Niacin (Niaspan pill) and one-time 1ng/kg injection of endotoxin (LPS).
45339062|NCT00576693|Other|intensive medical management|intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl)
46033652|NCT04274439|Other|Internet-Based Pain Education and Exercise|Telerehabilitation is defined as providing techniques for therapeutic rehabilitation remotely or off-site using telecommunication technologies. Thus, our intervention will be based on the use of a website created and registered especially for the study that will have the shooting of 1 video of pain education and 1 video of exercises for the subjects of the study, totaling 8 videos of pain education and 8 exercise videos. We will provide complimentary materials along with the triggered videos and a booklet of chronic pain information. We will also make weekly calls for a health coaching service and the sending of smartphone messages for the motivation and accountability of the subjects.
46033653|NCT04274439|Other|Online Booklet|An online booklet containing information about chronic pain and suggestions for lifestyle modifications and behavior will be delivered, as well as an incentive to perform physical exercises.
45339065|NCT00698451|Drug|doxorubicin HCL liposome; bevacizumab; carboplatin|30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
46033654|NCT02812173|Device|suprapubic tube ex 2 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the second day after the surgery
45339066|NCT00921375|Drug|TULY|TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
45339067|NCT00697827|Device|Interspinous Spacer device|Device: In-Space
45339068|NCT00697827|Device|Interspinous Process Distraction Device|Device: X STOP
45339069|NCT02566551|Procedure|PAE|Embolization of the prostate with gelatin embolization spheres via microcatheterization of the prostatic arteries.
45598827|NCT04581473|Drug|Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）|Physician's choice of any BSC listed above
46033655|NCT02812173|Device|suprapubic tube ex 5 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the fifth day after the surgery
46033656|NCT02812173|Device|transurethral catheter ex 5 day|transurethral catheter withdrawal removal on the fifth day after the surgery
46033657|NCT00630669|Procedure|Rubber band ligation|placing rubber bands around the internal hemorrhoids
46033658|NCT00630669|Procedure|Bipolar coagulation|using electricity to cauterize
46033659|NCT02857335|Behavioral|neurocognitive tests|Subjects will undergoe a battery of neurocognitive testing which will test memory, flexible thought process, problem, attention span
46033660|NCT02857491|Drug|ranibizumab|intravitreal injection of 0.5 mg ranibizumab before vitrectomy
46033661|NCT02857491|Drug|sham|sham intravitreal injection before vitrectomy
46033662|NCT02857491|Procedure|pars plana vitrectomy|surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina.
45339070|NCT02566551|Device|Gelatin microspheres|Gelatin embolization microspheres (300-500 microns) will be used as embolic material for the prostatic artery embolization (PAE) protocol
46033663|NCT02857179|Procedure|bariatric surgery|gastric bypass Or gastric banding Or Biliopancreatic diversion with duodenal switch Or sleeve gastrectomy Or endoscopic procedure (Endobarrier,…)
46033664|NCT00883129|Drug|Mycophenolate mofetil|24 months of oral mycophenolate mofetil, up to a maximal dose of 1.5 grams twice daily as tolerated
46033665|NCT00883129|Drug|Cyclophosphamide|12 months of oral cyclophosphamide, up to a maximal dose of 2 mg/kg daily as tolerated
46033666|NCT00883129|Drug|Placebo|12 months of placebo will be delivered to participants in the Cyclophosphamide arm during the second year in order to maintain the blind with the Mycophenolate arm, which receives drug for the entire 2 years.
46033667|NCT02856867|Drug|Nintedanib|
46033668|NCT02856867|Drug|Fluorouracil|
46033669|NCT02856867|Drug|Leucovorin|
46033670|NCT02856867|Drug|Oxaliplatin|
45339071|NCT02566551|Procedure|TURP|Bipolar transurethral resection of the prostate
45339072|NCT02566551|Device|Bipolar electrosurgery generator|A bipolar electrosurgery generator will be used to perform transurethral resection of the prostate (TURP)
45339073|NCT00728936|Drug|IMO-2125|IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system
45339074|NCT00728936|Drug|Saline placebo|saline placebo given subcutaneously
46033671|NCT02856867|Drug|Placebo|
46033672|NCT00630513|Drug|Ertapenem|3 days regimen with Ertapenem (1 g/day i.v.)
45339075|NCT03980925|Drug|Nivolumab|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
45683130|NCT03320668|Other|Otago Exercise Program (OEP)|"A nurse/physiotherapist supported by an instructor-trained professional will give Otago Exercise Program (OEP) education to 10-people groups in 5 sessions (1st, 2nd, 4th and 8th week and one reinforcement session after 6 months). Telephone calls to participants will be made during non-training months (following a predefined telephonic interview protocol) to follow up. The OEP reduces the number of falls and fall-related injuries, improving balance and strength, confidence in performing everyday activities without falling. Whilst it has been shown to be effective in 4 controlled trials in New Zealand, it has not been tested in a primary care setting in Spain for feasibility, impact, acceptability and cost-effectiveness."
45839627|NCT02988648|Radiation|Radioiodide (131I-)|The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
46033673|NCT00630513|Drug|Ampicillin-Sulbactam|3 days treatment with Ampicillin-Sulbactam (AS 3g x 3/ day i.v.)
45472726|NCT01266941|Drug|Inhaled FF 200mcg/GW642444M 25mcg|All subjects are scheduled to receive FF 200mcg/GW642444M 25mcg once daily for 7 days. The dose for subjects with severe hepatic impairment may be adjusted to FF 100mcg/GW642444M 12.5mcg after review of the PK and safety data from the moderate and healthy matched control subjects.
45472727|NCT02472964|Biological|Trastuzumab|Trastuzumab 8mg/kg Iv over 90 minutes x 1 then Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
45683131|NCT03366298|Combination Product|Epipen 0.3mg|Epipen 0.3mg auto-injector
45683132|NCT03366298|Combination Product|Emerade 300mcg|Emerade 300mcg auto-injector
45683133|NCT03366298|Combination Product|Emerade 500mcg|Emerade 500mcg auto-injector
45839628|NCT02988570|Behavioral|computer-evaluation of the language|A computer-evaluation of the language will be done for children born very preterm preterm in 2011 in the region of Haute-Normandie in France
45839629|NCT02988492|Device|MRI perfusion imaging|Evaluate the sensitivity and specificity of whole---brain CTP in predicting 24 hour DWI---MRI infarct in patients with acute proximal anterior circulation occlusions successfully recanalized with endovascular treatment.
45839630|NCT02988024|Drug|LY03005|LY03005
45839631|NCT02988024|Drug|Pristiq|
46033674|NCT04059211|Diagnostic Test|Urinary dipstick|Sensitivity and specificity of urinary dipstick for proteinuria in emergency departments
45839632|NCT02988102|Other|Following S100B and NSE in head trauma|Following S100B and NSE in head trauma in correlation with Head CT and post concussion syndrome and Lisat11
45839633|NCT02988258|Genetic|CMV-TCR transduced donor-derived T cells|Dose escalation
46033675|NCT01278927|Behavioral|Exercise|Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief personalized introduction to the home-based exercise intervention.
46033676|NCT01278927|Behavioral|Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (10 minute) standardized introduction to the self-administered intervention.
46033677|NCT01278927|Behavioral|Exercise and Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions.
46033678|NCT01278927|Other|Standard Care|Patients randomized to standard care only will be informed of their assigned condition and receive the DVD.
46033679|NCT02635399|Procedure|PPPD (pylorus-preserving pancreaticoduodenectomy)|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
46033680|NCT02635399|Procedure|PPPD (pylorus-preserving pancreaticoduodenectomy) with DJ-pexy|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
46033681|NCT04162483|Device|Neuroform Atlas Stent System|Stenting Assisted coiling procedure
46033682|NCT02157051|Biological|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
46033683|NCT02157051|Other|Laboratory Biomarker Analysis|Correlative studies
46033684|NCT04270773|Biological|Human Papillomavirus 9-valent Vaccine, Recombinant|Vaccine administrated
46033685|NCT00905632|Drug|BI 207127 middle dose +SOC|BI 207127 middle dose tid + SOC
46033686|NCT00905632|Drug|BI 207127 high dose+SOC|BI 207127 high dose tid +SOC
46033687|NCT00905632|Drug|Placebo + SOC|Placebo tid +SOC
46033688|NCT00905632|Drug|BI 207127 low dose + SOC|BI 207127 low dose tid + SOC
46033689|NCT01213732|Other|Isolated inferior limb perfusion|Single Melphalan bolus perfused for 60 min after 30 min of L19TNFα bolus. Intra-arterial (IA) infusion via bolus at 39˚C to 40˚C (mild hyperthermia).
46033690|NCT05287360|Drug|Rivoceranib|Rivoceranib will be supplied as film-coated tablets for oral administration as 4 different formulations: Formulation 1, 3, and 4 = 250 milligrams; Formulation 2 = 200 milligrams.
46033691|NCT05333770|Device|High-frequency repetitive transcranial magnetic stimulation|TMS is an investigational device that provides a way to test the function of a specific part of the brain that is devoted to moving my affected upper limbs by directing a low electrical current to that part of the brain through the scalp.
46033692|NCT05333380|Device|ECG/PPG monitoring|"The enrolled patients will wear an ECG patch and watch at the same time to collect ECG and PPG data respectively. The data collection time is from the day of hospitalization to before the ablation operation, and from 2 hours after the removal of ECG monitoring equipment to before leaving the hospital. The monitoring duration of each patient shall not be less than 18 hours."
46033693|NCT00954447|Drug|Placebo|Placebo, identical to Linagliptin tablet
46033694|NCT00954447|Drug|Linagliptin|intended final marketed dose
46033695|NCT05195320|Behavioral|Reinvention with MS|A manualized group therapy to build self-efficacy among people living with multiple sclerosis.
46033696|NCT05186584|Other|MAITLAND'S ANTEROPOSTERIOR(AP) MOBILIZATION|"Group A will receive the 5 sets of 10 seconds Grade 1 mobilizations with a rate of 15 oscillations each set (total 75 oscillations) for AP mobilizations at most symptomatic segment, with 10 seconds rest between sets. Most symptomatic segment is that segment of cervical spine at which patient will feel greatest pain by palpation.~For AP mobilizations, patient will lye supine and therapist will stand by his head. Therapist will make broad contact with the thumb, at the costal process of the vertebrae to be mobilized and spread fingers around adjacent neck for stability. Shoulder will be positioned above the joint being treated. Gentle oscillatory Anteroposterior pressure will be performed by the therapist's arm and trunk."
46033697|NCT05186584|Other|MAITLAND'S LATERAL MOBILIZATION|Group B will receive the same sets (i.e. 5 sets of 10 seconds Grade 1 mobilizations with a rate of 15 oscillations each set) for lateral mobilizations at most symptomatic segment, with 10 sec rest between each set. For lateral mobilization, patient will lye supine and therapist will stand by his head. Therapist will place the anterolateral aspect 2nd metacarpophalangeal joint over the lateral aspect of transverse process of most symptomatic segment. Gentle lateral oscillations towards the asymptomatic side will be provided by the therapist.
46033698|NCT04735744|Other|Patients recovering from COVID19 receive usual care by allied health professionals|We will not develop specific interventions for this prospective observational cohort study. The care provided by allied health professionals in daily practice are based on recommendations published by the professional bodies of allied health professionals and on the interdisciplinary guidance developed by the LAN. All allied health professionals are working according to these recommendations. Dissemination of these recommendations is done by the professional bodies of the allied health professionals. Given the observational nature of our study, no additional implementation strategies will be employed to stimulate this care by the research group.
46033699|NCT00903760|Drug|Decitabine|Decitabine 20 mg/m^2 by vein daily over 1-2 hours for 5 days for both Group 1 and Group 2. Group 1 receives decitabine on Days 1-5 of Cycles 1-3, 7-9, 13-15, and 19-21; and Group 2 is on Days 1-5 of every cycle.
46033700|NCT00903760|Drug|Clofarabine|Clofarabine 10 mg/m^2 by vein daily over 1-2 hours for 5 days on Days 1-5 of Cycles 4-6, 10-12, 16-18, and 22-24.
46033701|NCT02969512|Other|HIPPER|Participants can complete the online educational modules at home or another location with internet access. The total time to complete all of the modules is about 2 hours and 30 minutes.
46033702|NCT02969512|Other|OASIS Online Educational Webinars|2-hour online educational large group sessions
46033703|NCT05273554|Drug|Pembrolizumab|Given by IV
46033704|NCT05273554|Drug|lenvatinib|Given by PO
46033705|NCT05177614|Dietary Supplement|Upper-level multiple micronutrient-fortified bouillon cube|80 µg/g Folic acid 1.2 µg/g Vitamin B12 3 mg/g Zinc (ZnO) 4 mg/g Iron (FePP/citric acid/trisodium citrate) 200 µg/g Vitamin A (retinyl palmitate) 30 µg/g Iodine (KIO3)
46033706|NCT05177614|Dietary Supplement|Lower-level multiple micronutrient-fortified bouillon cube|28.8 µg/g Folic acid 0.288 µg/g Vitamin B12 1.68 mg/g Zinc (ZnO) 1.3 mg/g Iron (FePP/citric acid/trisodium citrate) 96 µg/g Vitamin A (retinyl palmitate) 30 µg/g Iodine (KIO3)
46033707|NCT05177614|Dietary Supplement|Iodine-fortified bouillon cube|30 µg/g Iodine (KIO3)
46033708|NCT04165603|Procedure|Preoperative Infusion of Indocyanine Green|preoperatively infuse indocyanine green through peripheral vein
46033709|NCT02846272|Procedure|Observation|Observation of MRI changes in subjects
46033710|NCT04202536|Drug|Besifovir Dipivoxil Maleate|Besifovir 150 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d. Other Name: Besifovir®
46033711|NCT04202536|Drug|Tenofovir disoproxil fumarate(TDF)|300 mg tablet administered orally once daily Other Name: VIREAD®
46033712|NCT02817880|Device|rTMS|
46033713|NCT02817880|Device|tDCS|
46033714|NCT02817880|Device|tsDCS|
46033715|NCT02794402|Drug|Exenatide|Bydureon (Exenatide once weekly) injections s.c.
46033716|NCT02794402|Behavioral|Placebo|Placebo once weekly injections sc
46033717|NCT00883051|Drug|Lasmiditan|Oral application of one dose of either 50 mg lasmiditan,100 mg lasmiditan, 200 mg lasmiditan, 400 mg lasmiditan or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.
46033718|NCT00883051|Drug|Placebo|Placebo
46033719|NCT02637739|Device|hysteroscope|Women of PUL with β-hCG > 1000 IU/L or abnormal β-hCG trend (increase < 66% or decrease < 15%) were offered HSC.
46033720|NCT00655525|Dietary Supplement|fish oil|2.9 g of fish oil (2:1 EPA:DHA) administered orally every day for 3 months
46033721|NCT00655525|Dietary Supplement|placebo|placebo administered orally every day for 3 months
46033722|NCT03395587|Biological|Autologous, tumor lysate-loaded, mature dendritic cells (DC)|Advanced therapy medicinal product (ATMP) produced at the University Hospital Düsseldorf according to Good Manufacturing Practice (GMP) with production permission according §13 AMG (German Drug Law) of the local authorities (Bezirks¬regierung Düsseldorf)
46033723|NCT03395587|Drug|standard therapy|temozolomide, fractionated radiochemotherapy
46033724|NCT00903682|Drug|etravirine (ETR, TMC125)|400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
46033725|NCT00903682|Drug|efavirenz (EFV)|600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
46033726|NCT00655603|Other|Infusion of native hormones from the pancreas and gut (GLP-1)|Glucose-clamps at fasting levels during infusion of hormones in different combinations.
46033727|NCT04162327|Drug|IBI315|Patients will receive IBI315 until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue.
46033728|NCT04162327|Drug|IBI315|Patients will receive IBI315 RP2D until disease progression,intolerability, informed consent withdraw, or otherreasons leading to treatment discontinue.
45472728|NCT02472964|Biological|MYL- 1401O|MYL-1401O 8mg/kg Iv over 90 minutes x 1 then HERMyl 1401O Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
45472729|NCT02472964|Drug|Paclitaxel|Paclitaxel 80mg/m2 IV over 60 minutes weekly.
46033729|NCT01117428|Drug|Sym004|"In part A, patients in all dose cohorts will continue weekly treatment with the assigned dose of Sym004 until disease progression.~In Part B, patients will continue weekly treatment with the tolerated dose of Sym004 until disease progression.~In Part C, patients will receive weekly doses of Sym004 at the dose level below 12 mg/kg i.e. 9 mg/kg until disease progression.~In Part D and E, patients will receive doses of Sym004 administered every 2 weeks at dose level 12 mg/kg and 18 mg/kg, respectively until disease progression.~In Part F, patients will receive a single loading dose of 9 mg/kg followed by weekly doses of 6 mg/kg."
46033730|NCT05223322|Behavioral|Taking Charge during Treatment (TCT) Intervention|CT is a 16-20week intervention that promotes adoption of the ACSM exercise guidelines for cancer survivors during treatment, including regular moderate to vigorous physical activity (150 minutes per week of moderate activity or 75 minutes per week of vigorous activity) and a minimum of twice weekly resistance training (RT) minutes during CTx and after. Program components include (1) a binder of information, (2) weekly coaching, (3) 2-4x weekly text messaging and (4) exercise supplies. The TCT program is grounded in Social Cognitive Theory.
46033731|NCT04162405|Behavioral|Tinnitus Handicap Inventory Test|A prospective cohort nonrandomized study of non-masked parallel paired groups. The data will be collected from an electronic database that is filled in during diagnostic processing. During the diagnostic processing, TSI and THI questionnaires will be filled in, a tone audiogram (TA) and DPOAE will be performed.
45339076|NCT03980925|Drug|Carboplatin|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
46033732|NCT02637661|Other|earlobe crease positive|
46033733|NCT02637661|Other|earlobe crease negative|
46033734|NCT02715466|Drug|Balanced gelatine solution|Gelaspan combined with Sterofundin ISO
45339077|NCT03980925|Drug|Etoposide|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
45339078|NCT00693693|Drug|hydrocortisone 17-butyrate 0.1% Cream preparation|Apply medication twice a day to affected areas of atopic dermatitis
45754716|NCT05701904|Other|Local mechanical vibration|Before the injection, local mechanical vibration will be applied for 3 minutes with a vibration device to the deltoid muscle where the injection will be made, and then the vaccine will be given. The vibration device to be used is suitable for contact with the skin and provides 6000 rotations per minute with vibration.
45839634|NCT02988180|Other|basic services|The age-matched control children received the basic services such as family-home, food, clothing, health care, protection and education. However, they were not provided with the play-based developmental stimulation.
45339079|NCT00693693|Drug|hydrocortisone 17-butyrate 0.1% Ointment preparation|Apply medication twice a day to affected areas of atopic dermatitis
45339080|NCT00693693|Drug|hydrocortisone 17-butyrate 0.1% Lipocream preparation|Apply medication twice a day to affected areas of atopic dermatitis
45339081|NCT03966807|Behavioral|Digital-based support|Digital support will consist of referral for the participant to visit https://smokefree.gov, a website which offers a menu of internet- and text-based support options.
45472730|NCT02472964|Drug|Docetaxel|Docetaxel 75mg/m2 IV over 60 minutes on day 1 of a 3 week cycle
45472731|NCT01160315|Drug|Triptorelin|Triptorelin: intramusculAR injection every 3 months
45839635|NCT02988180|Other|the play-based developmental stimulation|Children in the intervention group received basic services such as family-home, food, clothing, health care, protection and education for older children. In addition, there received play-based developmental stimulation integrated into the services.
46033735|NCT02715466|Drug|Balanced electrolyte solution|Sterofundin ISO
46033736|NCT00655681|Drug|pamidronate|The pamidronate is mixed 1 to 10 (10 cc of saline for each 1 mg pamidronate), with a minimum volume of 50 cc saline. The medication is administered as an IV infusion to run at a rate beginning at 20 cc/hr, adjusting the rate so that the infusion will run over 4 hours. For children < 8 kg (80cc infusion), the rate would be 20 cc/hr and the duration would be determined by the volume.
46033737|NCT00655681|Other|saline|receives saline 10cc/kg over 4 hours post operatively in addition to routine post operative fluids
46033738|NCT04187586|Other|Extracorporeal shock wave therapy|ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 6 sessions.
45839636|NCT02987790|Other|C-reactive protein|PCR assays shall be performed daily on serum obtained from blood collected for routine intensive care examinations up to 2 days after antibiotic withdrawal. In the PCR group, antibiotic suspension will be encouraged when levels of this marker are <35mg / L (if peak PCR below 100mg / L); or reduce 50% of the highest value (if PCR peak> 100mg / L), with a limit of seven days, if there is clinical improvement.
45472732|NCT01160315|Drug|Norethisterone acetate|5 mg/day per os until during chemotherapy
45839637|NCT02987712|Other|Thromboelastography based protocol|patients will be treated according to a new thromboelastography based protocol
45839638|NCT02987556|Device|Continuous Glucose Monitoring|Collection of glucose data
45839639|NCT02987556|Device|External Insulin Pump|insulin delivery
45839640|NCT02987556|Other|telemdecine|Remote follow up by care health providers team
45839641|NCT02987556|Device|The Diabeloop Software (Model predictive control)|Diabeloop is a Closed-loop (CL) system with a Model Predictive Control (MPC) algorithm reinforced by a decisional matrix, uploaded on a dedicated android smartphone linked to Dexcom CGM and a Cellnovo or Kaleido insulin patch-pump. The Diabeloop software calculates the insulin dose according to the patient's needs.
45839642|NCT02987400|Drug|Venetoclax|3 cycles followed by 9 cycles consolidation if not transplant eligible
45839643|NCT02987400|Drug|Obinutuzumab|3 cycles followed by 9 cycles consolidation if not transplant eligible
46033739|NCT02345356|Genetic|Genotype-guided|Individual warfarin dose adjustments by using a pharmacogenetically driven algorithm
45472733|NCT03875417|Procedure|liver resection|resection of one or more HCC nodules within the liver
46033740|NCT02345356|Other|Standard-of-Care|Individual warfarin dose adjustments by using a clinically driven algorithm (standard care)
46033741|NCT02635477|Behavioral|Intervention|Behavioral: actigraphy device, adaptive step count algorithm
45339082|NCT03966807|Behavioral|Traditional-based support + Nicotine replacement therapy (NRT)|Traditional support will consist of participant referral to the Indiana Tobacco Quitline (1-800-QUIT-NOW) which is a telephone hotline that connects participants to Indiana smoking cessation resources.
45339083|NCT04620681|Biological|CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes|Infusion of mononuclear cells, apheresis products depleted of CD8+ T cells using the CliniMACS® system with CliniMACS® CD8 reagent
45339084|NCT04620681|Drug|Standard of Care Chemotherapy|Standard of care cytarabine-based chemotherapy
45339085|NCT02565693|Drug|Apixaban|
45339086|NCT02565693|Drug|Aspirin|
45339087|NCT02565693|Drug|Carbasalate calcium|
45339088|NCT02565693|Drug|Clopidogrel|
45339089|NCT02565693|Drug|Dipyridamole|
45339090|NCT02565693|Other|No antithrombotic treatment|
45339091|NCT04603989|Drug|HNC042 for Injection|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, doses: 300mg to 1200mg
45339092|NCT04603989|Drug|Placebo Comparator|Placebo , Intravenous route , multiple ascending doses
45339093|NCT00728468|Drug|PF-00299804|PF-00299804: Patients take oral 45 mg PF-00299804 once daily starting on Cycle 1 Day 1 until disease progression or unacceptable toxicities occur. One cycle equals 21 days. Dextromethorphan: Patient take a single 30 mg oral dose of dextromethorphan HBr three days prior to Cycle 1 Day 1, and then on Cycle 2 Day 7.
45339094|NCT04061655|Drug|Iron Isomaltoside 1000|Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.
45339095|NCT04061655|Other|placebo|Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.
45339096|NCT04061265|Drug|Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml|Local anesthetic agent
45339097|NCT04061265|Drug|lidocaine hydrochloride 2% and epinephrine 1:100000|Local anesthetic agent
45339098|NCT02592980|Genetic|Pharmacogenetic anticoagulation|The investigators use a algorithm pharmacogenetic for adjust only the first dose in the study.
45339099|NCT02592980|Drug|Traditional anticoagulation|The physician will adjust the dose according to current INR value based on guidelines.
45339100|NCT03963284|Procedure|cardiac surgery|pediatric cardiac surgery with cardiopulmonary bypass
46033742|NCT02635477|Behavioral|Control|Behavioral: actigraphy device, step count measurement only
45339101|NCT03963284|Device|NephroCheck test|Urine of the subjects undergoing cardiac surgery with CPB will be tested by NephroCheck test
45339102|NCT05464329|Drug|Mosunetuzumab|Provided by Genentech.
45339103|NCT05464329|Drug|DHAX|-Standard of care. Flexibility in administration is permitted at the discretion of the treating physician.
46033743|NCT05139550|Device|Smartphone Rehabilitation Application|"Upper Limb Exercise Protocol:~Passive Exercises~ROMs for shoulder, ROMs for elbow, ROMs for wrist,fingers and thumb~Active/Assisted Exercises~bilateral shoulder flexion with both hands interlocked, Elbow pronation and supination, Wrist flexion and extension with the help of unaffected hand, Forearm to box, Extend elbow (side), Hand to box (front)~Functional Activities~Lift can, Lift pencil, Lift paper clip, Stack checkers,Flip cards, Fold towel, drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, combing their hair, Eating with affected hand, opening and closing jars"
46033744|NCT04221568|Drug|Bupivacaine-fentanyl|local anathetic&analgesic drugs
46033745|NCT04221568|Drug|levobupivacaine-fentanyl|local anathetic&analgesic drugs
46033746|NCT02635087|Device|miRNA tool|patients to be assessed by the miRNA tool. MicroRNA tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miR-21-5p)+(0.086×status of miR-20a-5p)+(0.240×status of miR-103a-3p)+(0.095×status of miR-106b-5p)- (0.238×status of miR-143-5p)-(0.237×status of miR-215),low expression status equals 0 and high expression status equals 1.Then we determine the patients who with a score higher than 1 as exposed patient.
46033747|NCT02707198|Drug|kefir|4 ounces of kefir 3 times a day, with or without food.
46033748|NCT04163497|Device|ICU Diaries|To explore the effects of providing an ICU Diary in the symptoms of anxiety, depression and PTSD within patients who were hospitalized in the unit.
45339104|NCT05464329|Drug|ICE|-Standard of care. Flexibility in administration is permitted at the discretion of the treating physician.
45339105|NCT00727844|Drug|Immediate Start Linezolid|
45339106|NCT00727844|Drug|Delayed Start Linezolid|
45472734|NCT03875417|Procedure|Thermic ablation|ablation of HCC nodule through a percutaneous needle, by using radiofrequency or microwaves
45839644|NCT02987244|Drug|Chidamide|"Six cycles of therapy will be administered,and each cycle of treatment is 28 days.~Phase I: Patients were treated at the following dose levels: 15, 20, and 25 mg twice per week to determine the MDT Phase II: If MTD was not reached at 25mg dose level of Chidamide. The followed study will use 20mg twice per week as experimental dose."
45472735|NCT03875417|Procedure|Transcatheter arterial chemoembolization|embolization of HCC nodule via drug-eluted microbeads.
45472736|NCT01160393|Device|Miniaturized bypass system|Compare the conventional bypass system and miniaturized bypass system of the incidence of atrial fibrillation after cardiac surgery
45839645|NCT02987244|Drug|Cyclophosphamide|Cyclophosphamide(750mg/m2) was administered intravenously on d1
45839646|NCT02987244|Drug|Epirubicin|epirubicin (70mg/m2)was administered intravenously on d1;
45839647|NCT02987244|Drug|Vindesine|vindesine (4mg)was administered intravenously on d1;
46033749|NCT02635165|Device|Thoracic osteosyntheses with Stracos|
46033750|NCT01135524|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied transdermally for 7-day wear.
46033751|NCT01135524|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied transdermally for 7-day wear.
46033752|NCT01135524|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied transdermally for 7-day wear.
46033753|NCT04165447|Behavioral|Front-of-pack labeling strategy|We designed a simple 'Lower Calorie' directive logo. We labeled the 20% of products with the lowest calories per serving within or across categories. All serving sizes used in this study were the average of the serving sizes within each category. Prior to conducting the analysis, we standardized the serving size by using the mean serving size within each subcategory. This standardization ensures that similar products are compared equally as serving sizes can be arbitrarily set by the manufacturers. The labels were displayed below the product images.
46033754|NCT00948675|Drug|Pemetrexed|Induction therapy: 500 milligrams/square meter (mg/m²) given intravenously every 21 days for 4 cycles. Maintenance therapy: 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation.
46033755|NCT00948675|Drug|Carboplatin|Induction Therapy (every 21 days for 4 cycles): Area Under the Curve (AUC) 6 [maximum possible dose of 900 milligrams (mg)] intravenously infused over 30 minutes.
46033756|NCT00948675|Drug|Paclitaxel|Induction Therapy (every 21 days for 4 cycles): 200 mg/m² intravenously infused over 3 hours
46033757|NCT00948675|Biological|Bevacizumab|Induction therapy: 15 milligrams/kilogram (mg/kg) given intravenously every 21 days for 4 cycles. Maintenance therapy: 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation.
46033758|NCT02850172|Behavioral|Walk, Eat, & Breathe|"Walking exercise: 3 times per week, 20~30 mins per section~Eat: nutritional assessment and advice weekly~Inspiratory muscle training: twice every day, 7 days a week, 6~8 weeks before surgery"
46033759|NCT02642497|Drug|intra-wound instillation of ketamine|intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
46033760|NCT02642497|Drug|intra-wound instillation of normal saline|intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
46033761|NCT02642497|Drug|systemic administration of ketamine|intra-muscular administration of ketamine (1 mg/ kg), given before wound closure.
46033762|NCT00911131|Device|Capsule endoscopy (PillCam ESO)|The capsule endoscope is placed in the mouth and the patient is asked to swallow it with 100cc of water with simethicone in the supine position. Recording is done for 2 minute in this position and then the head is elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient sips 10cc of water and after 15 seconds, they sit upright and sip water again. They can then walk and resume normal activity for 15 minutes.
46033763|NCT00911131|Procedure|EGD|Patients will undergo conventional EGD under conscious sedation for routine screening of esophageal varices.
46033764|NCT00911131|Device|Capsule endoscopy (PillCam ESO) with abdominal binder|An abdominal binder with and inflatable girdle is wrapped around the stomach prior to swallowing the capsule endoscope. The girdle is inflated to 10mmHg for 10 minutes. The capsule is swallowed by the patient and the routine method for the procedure is performed.
46033765|NCT02857257|Biological|ACHIM|After an observation period of 4 weeks patients with IBS-D will be treated with ACHIM
46033766|NCT00903370|Procedure|MVS|All participants will have their left atrial appendage excised or excluded. For mitral regurgitation, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, and for most cases of mitral stenosis, a valve replacement will be performed.
46033767|NCT00903370|Device|Ablation|For participants treated by pulmonary vein isolation, two separate encircling lesions will be made around the left and right pulmonary veins. For participants treated with biatrial maze lesion set, the left atrial lesions will include, the two encircling lesions, as well as connecting lesions between to the pulmonary veins, from the pulmonary veins to the mitral valve annulus, and from the pulmonary veins to the left atrial appendage. The right pulmonary veins will be isolated first. Isolation will be confirmed by pacing the pulmonary veins at the previously identified threshold for capture. If no atrial capture is noted, it will be inferred that the right pulmonary veins were isolated. If atrial capture is noted, additional ablations on the atrial cuff will be performed until isolation is confirmed. This will be repeated on the left pulmonary veins.
45339107|NCT00735878|Drug|ABT-751 and Carboplatin|This primary objective of this Phase 1/2 study is to evaluate the DLT and MTD of escalating oral doses of ABT-751 given BID on Day 1 of each cycle for 7 days in combination with carboplatin given on a 21-day schedule. The carboplatin dose is fixed at AUC 6 and will be administered on Day 4 during the first cycle to facilitate the pharmacokinetic analysis. During the subsequent cycles both agents will be administered on Day 1. ABT-751 is administered at the following dose levels using the Simon rapid dose escalation model: 100, mg, 125 mg, 150 mg, 175 mg and 200 mg BID.
45339108|NCT02594150|Other|Financial Incentive|Financial incentives provide small immediate and tangible rewards that are aligned with the abstract long-term rewards of cancer prevention.
45339109|NCT02593838|Other|CT-MPI and SPECT-MPI|All patients undergo CT-MPI plus SPECT-MPI
45472737|NCT03385252|Other|Eggs|Eggs provided as complementary food for the infant
45472738|NCT03385252|Behavioral|Visits|Twice weekly household visits by study staff
45839648|NCT02987244|Drug|Etoposide|etoposide (100mg) was administered intravenously on d1,2,3.
45839649|NCT02987244|Drug|Prednisone|prednisone (60mg/m2)was administered intravenously by oral d1-5.
45839650|NCT02987166|Radiation|High-Dose Conformal Radiation Therapy|"24 Gy in 3 fractions of 8Gy each for bone and/or soft tissue lesions~30 Gy in 5 fractions of 6 Gy each for prostate gland"
45839651|NCT02987166|Drug|Pembrolizumab|200 mg
45839652|NCT02987088|Drug|Sodium Nitrite|
45839653|NCT02987322|Dietary Supplement|honey|Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months
45839654|NCT02986932|Device|BBB opening|Open BBB using ExAblate focused ultrasound and (Definity®) contrast agent
46033768|NCT04273581|Drug|placebo|100mg/d，qn，for 14 days.
46033769|NCT04273581|Drug|Thalidomide|100mg/d，qn，for 14 days.
46033770|NCT01110408|Drug|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg,Number=20mg/kg up to 500mg/dose, Form=solution for infusion,Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
46033771|NCT01110408|Drug|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
45339110|NCT00695955|Drug|Azilsartan medoxomil with or without add-on chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.
45839655|NCT02987010|Drug|IDH305|Isocitrate Dehydrogenase 1 inhibitor
46033772|NCT01110408|Drug|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
46033773|NCT01110408|Drug|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
46033774|NCT01110408|Drug|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
45339111|NCT00695955|Drug|Azilsartan medoxomil with or without add-on hydrochlorothiazide|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.
45339112|NCT04547205|Drug|AK109|AK109, 2#4#8#12#18mg/kg, IV, every 2 weeks (Q2W), or 15 mg/kg every 3 weeks(Q3W)
45339113|NCT00693225|Drug|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate powder for oral suspension 40 mg was supplied in individual packets that were emptied into a small cup containing 15-30 ml (1-2 tablespoons) of water, one per day, for 8 weeks.
45472739|NCT01164449|Device|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
45472740|NCT03878225|Dietary Supplement|H.V.M.N. Ketone Ester|The ketone mono ester will be ingested 5 times daily for 3 days (72 hours). Please see above for details.
45472741|NCT03878225|Other|Placebo|The placebo will be ingested 5 times daily for 3 days (72 hours). Please see above for details.
45839656|NCT02986776|Behavioral|Inpatient Care|21 days of inpatient substance misuse treatment
45839657|NCT02986776|Behavioral|Outpatient Care|21 days of outpatient substance misuse treatment
45839658|NCT02986542|Procedure|Femoral artery catheterization|The intervention will be performed by a single experienced individual.
46033775|NCT02850328|Other|examination of muscle function and MVC in weightlessness|"MVC tested during three different tasks: (1) leg press, (2) plantarflexion and (3) grip strength.~parameters of muscle function that can be easily implemented in parabolic flight:~Rate of force development~Electromyographic activity~Ultrasound measure: fascicle length and pennation angle of the gastrocnemius medialis muscle~Superimposed twitch torque (M-waves at rest and V-waves in MVC conditions)~Maximum voluntary activation capacity (%VA): %VA = (1-[torque superimposed twitch/torque resting twitch])*100%."
46033776|NCT00953043|Drug|lubiprostone|Lubiprostone 24 micrograms, one dose daily for three days in 30 subjects
46033777|NCT00953043|Drug|Placebo|Placebo medication given for three days
46033778|NCT00953043|Other|Bowel preparation|Polyethylene glycol-based bowel preparation
46033779|NCT02850484|Drug|Budesonide|Inhaled corticosteroid
46033780|NCT02850484|Drug|Formoterol|Long Acting Beta Agonist (LABA)
46033781|NCT01135134|Drug|Mometasone furoate|"The study drug is MFNS (50 μg spray device) and the dose will be:~5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks~12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks"
45339114|NCT03773757|Behavioral|IN-PEACE Dementia Care Coordination|Patient/Caregivers assigned to the intervention arm will have monthly phone calls with a Nurse or Social Worker, in the capacity of a Dementia care coordinator (DCC) to identify symptoms and behavior problems the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors. In addition, education and support materials will be provided to the caregiver in the role caring and management of a patient with dementia.
45339115|NCT00735644|Biological|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
46033782|NCT01135134|Drug|Placebo|"MF Placebo nasal spray and administration will be as follows:~5 to 11 years: one spray per nostril once daily in the morning for 2 weeks~12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks"
46033783|NCT02850094|Behavioral|Financial Bonuses|Each participant is eligible to receive $10 per week for increasing their minutes of moderate to vigorous physical activity by 10% from the previous week, or for meeting CDC guidelines of 150 minutes/week. Participants who meet their target minutes of PA every week for one month, three months, or six months receive $15, $25, or $50 bonuses respectively. If all members of a team meet their individual PA goals, each participant's reward is doubled. In total, participants can earn up to $860 if they meet all their goals.
46033784|NCT00948441|Drug|25% ethanol|Study Lock -25% Ethanol- The ethanol lock therapy consists of placing up to 2.3 ml of 25% ethanol into the central venous catheter and allowing it to dwell for 4 to 12 hours per day.
46033785|NCT00948441|Other|heparin lock|Placebo Lock - Heparin - These will be prepared in a sterile fashion in the Pharmacy of Children's Hospital of Pittsburgh in 10 day supplies as 1ml lock syringes utilizing 100 units/ml if the central venous catheter is accessed once daily and 10 units/ml if accessed more than once daily. The lock solution will be instilled and allowed to dwell for 4 to 12 hours.
46033786|NCT02849860|Drug|IDP-121 Lotion|Lotion
46033787|NCT02849782|Drug|Fampridine|Oral intake of 10 mg twice daily
46033788|NCT00630903|Drug|PUVA (8MOP + UVA) + IFN|Weeks 3-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated) IFN: week1: 3, 6 and 9 MU (Mon, Wed, Fry). Weeks 2-24: 9MU 3 times a week)
46033789|NCT00630903|Drug|PUVA (8-MOP + UVA)|Weeks 1-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated)
45683134|NCT03320512|Behavioral|P3|P3 is an interactive smartphone app that utilizes social networking and game-based mechanics to improve PrEP adherence and persistence in PrEP care. The participant will install P3 on their phone, receive a guided tour of the app and a reminder card with the research coordinator's phone number and email address and instructed to contact the research coordinator immediately to report difficulties with any app components or to report any problems with their phone or phone service. A help link is embedded within the app that directly links to study staff if assistance is needed. P3 arm participants will have 24-hour access to all features of P3.
46033790|NCT02883426|Biological|H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV)|Approximately 10^7.0 Fluorescent Focus Units (FFU) per 0.2 mL dose; administered intranasally
45472742|NCT01440244|Procedure|Cervical mediastinoscopy|minimally invasive technique to perform pleural evaluation, pleural biopsy and pleurodesis
45683135|NCT03320512|Behavioral|P3+|In P3+, participants receive all of P3 and the ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve PrEP adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. Participants will install P3+ on their phone. The adherence counselor feature will be unlocked for those in the P3+ arm. P3+ participants will have 24-hour access to all features of P3+.
46033791|NCT02883426|Biological|H3N2v inactivated subvirion influenza vaccine|15 μg; administered intramuscularly
46033792|NCT02883426|Biological|Placebo|Administered by nasal spray
46033793|NCT01238289|Behavioral|Peer Education|Conduct peer education classes for 8 weeks and support groups monthly for a total of 10 months and evaluate effects on metabolic and behavior outcomes
46033794|NCT01238289|Behavioral|Control|This group continues with standard care at the community health center
46033795|NCT02849314|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
46033796|NCT02849314|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
45472743|NCT03385174|Other|Carbon monoxide|Carbon monoxide inhalation
45472744|NCT03878303|Drug|AC0058TA|25 mg capsules
46033797|NCT05171478|Diagnostic Test|Full-field optical coherence tomography|Sample obtained during bronchoscopy will be imaged using full-field optical coherence tomography
45339116|NCT00735644|Biological|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
45339117|NCT00735644|Biological|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
45339118|NCT00735644|Biological|Japanese encephalitis vaccine (Acambis)|0.5 mL, Subcutaneous
45339119|NCT00735644|Biological|Hepatitis A vaccine|0.5 mL, Intramuscular
45339120|NCT03718299|Drug|Injections of tildrakizumab|given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52
46033798|NCT02857101|Other|dosage of calprotectin|
46033799|NCT02849392|Other|Pistachio added 20% of kcals to diet|Pistachio added 20% of kcals to diet
46033800|NCT02857023|Behavioral|Cogmed RM|Cogmed consists of 12 increasingly challenging exercises (completed over 25 sessions spanning 5-8 weeks) that target skills involving visuo-spatial and verbal working memory.
46033801|NCT01207479|Device|VitalaTM|A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
46033802|NCT02849236|Drug|Ropivacaine (PECS bloc)|"Ropivacaine 3.75mg/mL~Injection of a local anesthetic between pectoral major and pectoral minor muscles"
46033803|NCT02849236|Drug|Placebo|20 mL saline 0.9%
46033804|NCT02856789|Other|Routine hemostasis tests|Prothrombin Time (PT),Thrombin Time (TT), Activated Partial Thromboplastin Time (APTT), Fibrinogen, D-Dimers
46033805|NCT02856789|Other|Fibrin structure (FS)|FS will be determined on STA-R® prototype at Percy and at Stago
46033806|NCT02856789|Other|Thromboelastography (TEG)|Thromboelastography will be processed on TEG® at Percy
46033807|NCT02856789|Other|Specialized hemostasis tests|Coagulation factors
46033808|NCT02856711|Behavioral|Trauma-informed group|"The two interventions will be: 1) A viewing of All Babies Cry and a discussion of what it's like to be a new parent, 2) A Planning to Parent stress activity where parents discuss when they have felt overwhelmed, the coping mechanisms they used, and what can be done to manage those emotions in the future. The goal of this project is to gain insight from current participants in CenteringPregnancy group care around the ways that these interventions can better prepare parents to deal with the common stresses of parenthood."
46033809|NCT02849002|Device|BrainPulse|Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
45339121|NCT02591888|Drug|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of normal saline injected.
46033810|NCT02848924|Other|No intervention|
46033811|NCT04368676|Other|Sudarshan Kriya Yoga (SKY)|The SKY program is a standardized, easy to learn sequential breathing yoga consisting of regulated breathing techniques followed by a timed rhythmic breathing practice. Participants will learn various exercises including rhythmic breathing, gentle yoga, and guided meditation.
46033812|NCT04368676|Other|Health Enhancement Program|HEP is a structured group program designed to help participants with information and instruction how to lead a healthier life. Participants will be provided psychoeducation and support regarding healthy active living using techniques like music therapy, diet control, exercise, and monitoring these via journaling.
46033813|NCT01117350|Drug|Insulin glargine|100 Units/mL solution for injection in a pre-filled SoloStar pen
46033814|NCT01117350|Drug|Liraglutide|6 mg/mL solution for injection in a 3-mL pre-filled pen (18mg)
46033815|NCT01117350|Drug|Metformin|Metformin was a background treatment, mandatory for each patient randomized in the study (at the minimum dose of 1g/day). It was not supplied by the sponsor.
46033816|NCT00952731|Drug|oral placebo|Oral placebo taken daily for 4-10 weeks.
45339122|NCT02591888|Drug|Liposomal bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of dilutional liposomal bupivacaine injected.
45339123|NCT00724958|Biological|Infliximab|Not specified in the protocol.
45339124|NCT02565225|Behavioral|RheumaLive App use|
46033817|NCT00952731|Drug|afimoxifene|2mg/breast applied daily in the form of a gel for 4-10 weeks.
45339125|NCT04086836|Device|TAVR|Patient recieving a TAVR
45339126|NCT03717441|Diagnostic Test|chromosome numeration of embryos|Use genomic technologies to analyze the discarded media drop for chromosome counting
45683136|NCT03320512|Behavioral|Control|Control participants will receive the standard of care for receiving a prescription for PrEP.
46033818|NCT00952731|Drug|tamoxifen citrate|20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks.
46033819|NCT00952731|Drug|placebo gel|Placebo gel applied to breasts daily for 4-10 weeks.
46033820|NCT04202224|Drug|Ibuprofen 400 mg and Acetaminophen 500 mg|Analgesia.
46033821|NCT04202224|Drug|Glucose|Placebo.
46033822|NCT04202224|Other|No drug|Standard surgical procedure without any preoperative medication.
46033823|NCT02848690|Behavioral|Educational Intervention|The educational intervention sessions will be conducted face-to-face, one hour-long and with the aim to encourage and motivate the low-sodium diet adherence. The dietitian's approaches will provide individual skills to achieve the goals (sodium restriction), developing changes in behavior and monitoring the progress towards the skills needed to reduce patient's barriers and difficulties for sodium restricted diet adherence.
46033824|NCT02848690|Other|Usual Care Intervention Group|Participants assigned to the control group will have a dietitian consultation receiving general recommendations for hypertension, such as increasing the consumption of fruits and vegetables, reducing salt intake, avoiding processed and high-sodium foods, reducing body weight if BMI> 25Kg/m2 and limiting consumption of alcoholic beverages. They will be provided with an explanatory folder about hypertension. During six months, participants assigned to the control group will be monitored in monthly visits to the dietitian without modifying their usual care
46033825|NCT00947427|Drug|canakinumab (anti IL-1beta)|canakinumab subcutaneous injections given at 2.0mg/kg dose on monthly basis for 12 months
46033826|NCT00947427|Drug|Placebo|Placebo subcutaneous injections
46033827|NCT02848612|Drug|anticoagulation by unfractionated heparin|anticoagulation by unfractionated heparin
45339127|NCT04088006|Device|Injection of STYLAGE® HydroMax|"STYLAGE® HydroMax is a hyaluronic acid injectable gel intended to improve skin moisturization and elasticity of the face and neckline area in this study.~A total of 3 injection sessions will be performed one month apart for each subject.~At each injection session, 1 mL of product will be injected in the mid to deep dermis of one cheek and another 1 mL in one site of neckline area for each subject."
45339128|NCT03706677|Device|Cryoballoon (Arctic Front Advance Cryoballoon)|Ablation using a Cryoballoon catheter (Arctic Front Advance Cryoballoon Cardiac Ablation Catheter)
45683137|NCT05683756|Behavioral|Brief Parent Behavioral Intervention|PBI administered in pediatric primary care by an embedded therapist.
46033828|NCT04811404|Drug|Ethyl Eicosapentaenoic Acid|Treatment will be for six weeks
46033829|NCT01116882|Procedure|PCI|
45339129|NCT03706677|Device|Radiofrequency Catheter (ThermoCool Smarttouch)|Ablation using a Radiofrequency ablation catheter (ThermoCool Smarttouch catheter)
45339130|NCT02593136|Dietary Supplement|Home Fortification Product (HFP)|"The home fortification product (HFP) is a sachet containing multiple vitamins and nutrients as follows:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30 mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin (Base)"
45683138|NCT05683756|Behavioral|Sleep-Focused Parent Behavioral Intervention|SF-PBI administered in pediatric primary care by an embedded therapist.
45683139|NCT05683522|Other|Sub-omohyoidal Plane Block|The ultrasound guided sub-omohyoidal plane block will be performed. Patients in this group will be given 15 mL of local anesthetic into the interfascial plane under the omohyoid muscle. This block will be performed preoperatively.
46033830|NCT02054013|Procedure|Prostatic artery embolization|
46033831|NCT02054013|Procedure|monopolar transurethral prostatectomy|
46033832|NCT02848846|Device|Robotic Hand|"The patients will use the robotic hand for a period of one year that will be divided in 3 different phases. The first phase is the intensive phase where the patient will use the robotic hand from Monday to Friday all days. This phase will last 6 weeks. The second phase is the semi-intensive where the patient will use the robotic hand only two days per week. This phase will last 6 weeks. The third phase is the monitoring where the patient will use the robotic hand only one day per week until the end of the trial.~During this phases the patient will perform different task requiring the use of the robotic hand."
46033833|NCT02850562|Behavioral|Walking|The Walking Arm will walk 5 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point.
46033834|NCT02850562|Behavioral|Walking + Exercise|The Walking + Exercise Arm will walk 2 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point and in addition, complete exercises to improve strength and balance on 3 days each week.
46033835|NCT02856477|Biological|urine analysis|a sample of urine is collected during 8 hours.
46033836|NCT04235062|Drug|Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) Solution|A 2-hour of infusion of Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) solution will be given following completion of the first 3-hour urine collection period: 0.5 liter infused over 10 min followed by 0.5 liter infused over 1 hour 50 minutes.
46033837|NCT04235062|Drug|Intravenous Bolus Furosemide|Following completion of the second 3-hour urine collection period and after the second set of blood and urine samples are obtained, 40 mg of furosemide will be given as an IV bolus.
46033838|NCT02848534|Biological|neutrophil to lymphocyte ratio|value of the neutrophil to lymphocyte ratio in the diagnosis of bacterial infections
46033839|NCT02848768|Drug|Sunitinib|
45339131|NCT02593136|Other|Infant and Young Child Feeding (IYCF) Practices Counseling|Infant and Young Child Feeding (IYCF) Practices Counseling provides direction on breast milk and milk feeding, food variety, and frequency for caregivers of children aged 6 to 18 months. Participants will be visited at least monthly by a field line worker for IYCF counseling and educational materials distribution.
46033840|NCT02848456|Procedure|Spinal Manipulation|Manual, side-posture, high-velocity low-amplitude spinal manipulation targeting the lower lumbar spine and sacroiliac joints
46033841|NCT02848456|Procedure|Max Voluntary Isometric Contraction|A 10 second plantar flexion maximal voluntary isometric contraction
46033842|NCT02848456|Procedure|SM+MVIC|The spinal manipulation immediately preceding the maximal voluntary isometric contraction
46033843|NCT02283255|Other|Aerobic Exercise Training|Supervised aerobic and light muscle resistance exercise training
46033844|NCT02283255|Other|Inspiratory Muscle Training|Inspiratory muscle training with POWERbreathe device
46033845|NCT02283255|Other|No Exercise Training|Usual care
45683140|NCT05683522|Other|Cervical Plexus Block|A cervical plexus block will be applied by applying 10 mL of local anesthetic under ultrasound guidance. This block will be done before the surgery.
45683141|NCT05683522|Other|Costoclavicular Block|Costoclavicular brachial plexus block will be applied by administering 20 mL of local anesthetic under ultrasound guidance. This block will be performed preoperatively.
45339132|NCT04087928|Device|FMV_flex|Fisiocomputer EVM (Endomedica, Italy) for application of FMV to flexor muscles of the upper limb (brachial biceps and carpal flexors).
45339133|NCT04087928|Device|FMV_ext|Fisiocomputer EVM (Endomedica, Italy) for application of FMV to extensors muscles of the upper limb (triceps brachial and carpus extensors).
45339134|NCT00695565|Drug|Placebo Gel|TID x 12 weeks
45339135|NCT00695565|Drug|Clonidine Topical Gel (ARC-4558)|TID x 12 weeks
45339136|NCT00727532|Drug|Sorafenib|400mg by mouth twice daily for 28 consecutive days
45683142|NCT03364582|Other|Observed dietary pattern|No intervention will be used. This is an observational study with dietary patterns as main exposure
46033846|NCT02848144|Other|blood samples|
46033847|NCT02848144|Other|Collection of nosocomial infections|
45339137|NCT00742599|Drug|NPO-11|20 ml NPO-11
45339138|NCT00742599|Drug|Placebo|20 ml NPO-11(Placebo)
45339139|NCT00742677|Procedure|nutritional support|Given orally
45472745|NCT03878303|Drug|Placebo AC0058TA|equivalent dose of investigational product
45472746|NCT01164605|Drug|Raltegravir|60 tablets (30-day supply)
46033848|NCT02848300|Drug|Bimatoprost 1% Formulation A|Bimatoprost 1% Formulation A solution applied to the scalp and trunk once daily for 14 days.
46033849|NCT02848300|Drug|Bimatoprost 1% Formulation B|Bimatoprost 1% Formulation B solution applied to the scalp and trunk once daily for 14 days.
46033850|NCT00953745|Drug|Escitalopram|All subjects will begin on escitalopram and placebo for 8 weeks
46033851|NCT00953745|Drug|Aripiprazole|Subjects who fail to respond to Escitalopram will continue on Escitalopram and augment with active Aripiprazole.
46033852|NCT00953745|Drug|Placebo Capsule|All subjects will begin on escitalopram and placebo capsule for 8 weeks.
46033853|NCT00953745|Drug|Placebo Tablet|After 8 weeks, subjects will be given a 2 week supply of escitalopram and placebo tablet.
45472747|NCT03380806|Drug|LHRH agonist|Standard LHRH agonist for 3 years
45472748|NCT03380806|Radiation|Pelvic Radiation|Pelvic Radiation
45472749|NCT03380806|Radiation|Stereotactic Body Radiotherapy (SBRT)|SBRT: 19.5 - 21 Gy in three fractions (1 treatment per week - over 22days)
45472750|NCT03380806|Radiation|Conventional Radiotherapy (CRT) Prostate Boost|CRT: 33 - 35 Gy in 16 fractions (5 days per week - over 22 days)
46033854|NCT02847910|Procedure|the disposable tissue suction set|Induced abortion is a main backstop for terminating unwanted pregnancies, however, traditional hard metal instruments has lots of insufficiencies such as easily tissue damage, and repeatedly sterilization increases the incidence of cross infection in the hospital what leads to more complications of pelvic inflammation, infertility and so on. Therefore disposable non-metallic instruments are desperately needed as a way to decrease the complications and provide better medical services to patients. So, the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
46033855|NCT02847910|Procedure|traditional metal instruments of abortion|Induced abortion is a main backstop for terminating unwanted pregnancies. In Chinese hospital, traditional metal instruments are always used during the surgery. So the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
46033856|NCT02848066|Procedure|Blood sample(10cc) collection|In both groups, serum haptoglobins to be collected and analyzed
45339140|NCT02593058|Behavioral|Positive Emotions Program for Schizophrenia|Each session of PEPS includes relaxation-meditation exercise, review of homework task given during the previous session, exercises to challenge defeatist beliefs. According to the session's theme, participants learn skills to improve their anticipation or maintenance of pleasure such as savoring a pleasant experience, expressing emotions by increasing behavioral expression, capitalizing on positive moments, and anticipating pleasant moments. A simple homework task is assigned to be done between each session. The pedagogical concept underpinning the program was built according to Kolb and Kolb's model of experiential learning. The program uses a collaborative, egalitarian approach.
45339141|NCT02593058|Behavioral|Treatment As Usual|TAU consists of psychiatric management by a clinical team composed of at least one psychiatrist and a social worker and/or a psychiatric nurse with additional access to community treatment or hospital admission. Treatment involves antipsychotic medication, regular office-based or community contact with the clinical team for treatment monitoring, and socialization groups, therapy, and psychoeducational groups. No attempts have been made to standardize this treatment as TAU is tailored to the patient's specific needs.
45339142|NCT02565459|Biological|Mesenchymal Stromal Cells|
45339143|NCT03957824|Diagnostic Test|PREVENTION-ACHD risk score|The predicted risk of sudden cardiac death according to a risk score will be tested by the actual rate of sudden cardiac death
45472751|NCT03746743|Diagnostic Test|score for neonatal sepsis|score for neonatal sepsis to predict morbidity
45472752|NCT03875261|Drug|Cannabinoid treatment|Participants are treated with cannabinoid derivates with a dose between 1 to 12 puffs, each puffs contains 2,7 mg of delta-9-tetrahidrocannabinol and 2,5 mg of cannabidiol.
45472753|NCT03748459|Other|Closure with Permanent Suture|Skin closure with permanent suture (prolene) (6-0 polypropylene) in open rhinoplasty.
45472754|NCT03748459|Other|Closure with Resorbable Suture|Skin closure with Resorbable Suture (5-0 fast absorbing plain gut) in open rhinoplasty.
45472755|NCT03380728|Drug|Ibogaine Hydrochloride|The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design. If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly in 3 different groups.
45472756|NCT03874949|Device|SEALITE Regular|Patients are treated with SEALITE Regular sealer (zinc oxide eugenol sealer). The SEALITE Regular powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control.
45472757|NCT03874949|Device|SEALITE Ultra|"Patients are treated with SEALITE Ultra sealer (zinc oxide eugenol sealer containing 1% Enoxolone).~The SEALITE Ultra powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control."
45472758|NCT03877835|Procedure|Peripheral nerve blocks|LSIB + SSNB
46033857|NCT04202380|Drug|Azithromycin|Patients will receive Azithromycin orally 1000 mg
46033858|NCT04202380|Drug|Ampicillin|All patients will receive Ampicillin 2gm IV every 6 hours for 2 days
45339144|NCT03957512|Procedure|Heart surgery|All invasive procedures
45339145|NCT00742755|Behavioral|Prospective intervention|Prospective Intervention: Peer navigator who assists with appointment making, transportation, translations, completing forms, etc.
45339146|NCT03567213|Device|Surgical implantation of CortiCom system|Implantation of Cortical communication system, consisting of one or two Electrocorticography (ECoG) grids connected to a transcutaneous patient pedestal.
45339147|NCT00721214|Drug|5-azacytidine|The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology laboratory values, is 75 mg/m2 subcutaneously or intravenously, daily for 7 days.
46033859|NCT04202380|Drug|Azithromycin|Azithromycin 500 mg orally once
46033860|NCT04202380|Drug|Azithromycin|Azithromycin 250 mg orally daily for 4 days
46033861|NCT04067674|Biological|Blood sampling|Blood sampling for biomarker measurement
46033862|NCT02847988|Device|Neuromuscular electrical Stimulation (NMES)|Electrical stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo). The intensity of stimulation will be titrated based on maximal tolerable muscle contraction
46033863|NCT02847988|Device|Sham Stimulation|Sham stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo).
46033864|NCT02847832|Other|Standardized transvaginal ultrasound examination|
46033865|NCT02167048|Drug|Psychostimulants|"Participants will be tested twice 2 weeks apart. All will continue on their normal Psychostimulant dose up until 3 days before the testing day. 3 days before their 1st testing session, half the participants will start on either their current-dose of Psychostimulant or half their current dose depending on the arm they were randomized to (we provide those pills).~To control for different pharmacokinetics of the Psychostimulant medications, a given participant will be tested at roughly the peak time for his/her specific version of Psychostimulant and at the same time of day for his/her two testing sessions."
46033866|NCT02847754|Other|Isometric resistance training|"Exercises in the all-fours position Exercises in the swimming Position Exercises in the forearm support Position Exercises with elastic rubber band"
46033867|NCT02075710|Other|High sugar/meal feed|Weight-maintaining diet relatively high in sugar fed as two large meals daily
46033868|NCT02075710|Other|High sugar/nibble|Weight-maintaining diet relatively high in sugar fed as 8 meals daily
46033869|NCT02075710|Other|High fat/meal feed|Weight-maintaining diet relatively high in fat fed as two large meals daily
46033870|NCT02075710|Other|High fat/nibble|Weight-maintaining diet relatively high in fat fed as 8 small meals daily
46033871|NCT02075710|Other|High sugar/ 3 meals a day|Weight-maintaining diet relatively high in sugar fed as 3 meals daily
46033872|NCT02075710|Other|High fat/ 3 meals a day|Weight-maintaining diet relatively high in fat fed as 3 meals daily
46033873|NCT04761328|Behavioral|cognitive behavioral therapy|Cognitive-behavioral therapy involves changing these erroneous cognitions and beliefs through cognitive restructuring, modification of behavior, and development of alternative coping skills.
46033874|NCT02847442|Drug|BIA 9-1067|Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily at bedtime, at least one hour before or after the last daily dose of L-dopa/DDCI.
46033875|NCT02847442|Drug|levodopa/dopa decarboxylase inhibitor|OPC enhances the effects of L-dopa. Hence, it may be necessary to reduce the subject's L-dopa/DDCI dose within the first days or weeks of OPC treatment by extending the dosing intervals and/or reducing the amount of L-dopa/DDCI per dose
46033876|NCT04736602|Drug|Triptorelin pamoate 15mg|Intramuscular injection (IM)
46033877|NCT01858012|Behavioral|Moderate alcohol cessation|patients will have moderate alcohol use discontinued for 6 weeks and have before and after alcohol cessation clinical and metabolic assessment and also patients with hepatitis C who have undergo therapy for hepatitis C may have repeat clinical and metabolic assessement
46033878|NCT02847520|Behavioral|Canadian Index Excessive Game|self-administered questionnaire Canadian Index Excessive Game
46033879|NCT01739062|Genetic|Genetic risk assessment|
46033880|NCT01698658|Other|ultrasound tomography|Undergo ultrasound tomography using SoftVue
46033881|NCT01698658|Procedure|magnetic resonance imaging|Undergo MRI of the breast
46033882|NCT02847676|Procedure|Tissue sample donation|Patients undergo planned gynaecological surgery. Tissue samples, which are routinely taken, are donated.
45683143|NCT05688514|Device|Innovalve MR system|Innovalve MR system
46033883|NCT04218292|Device|Micro Plug Set|The Micro Plug Set is indicated for arterial embolization in the peripheral vasculature.
46033884|NCT04710706|Other|Colonoscopy insertion technique used during procedure|Each arm is using a different colonoscopy insertion technique: either water-alone colonoscopy or water-CO2 colonoscopy.
46033885|NCT02847208|Other|self-report written questionnaire|The questionnaire was filled-in by the patients in presence of a clinical nurse. The gynaecological healthcare options and contraceptive choices were recorded. All following questions were closed-ended (answer yes/no): use of contraception; use of contraceptive pill; use of contraceptive implant; use of intrauterine device; use of tubal sterilization; use of mechanical contraception; use of other type of contraception; previous delivery (term pregnancy); gynaecological follow-up; previous Pap smear. In case of a positive answer to one of these questions, more details were requested (depending on the situation: name of the contraception, date of delivery, frequency of the gynaecological follow-up, date of the last pap smear). An internal validation of the questionnaire was performed on a subgroup of patients.
46033886|NCT01551550|Procedure|GDD|The surgery includes conjunctival incision, placement and securing the GDD plate in one quadrant, paracentesis and tube insertion into the anterior chamber, tube fixation to the episclera.
46033887|NCT01551550|Procedure|Amniotic Membrane Graft|For subjects assigned to the treatment group, Amnioguard is used to cover the shunt tube. The conjunctiva is then closed.
45339148|NCT02564601|Behavioral|Piano Training|The intervention focuses upon progressively difficult piano performance exercises (repertoire), technique, and finger dexterity exercises.
46033888|NCT01551550|Procedure|Pericardial Graft|For subjects assigned to the control group Tutoplast is used to cover the tube. The conjunctiva is then closed.
46033889|NCT01478698|Drug|Tissue Plasminogen Activator (tPA)|tPA 10mg per dose intraperitoneal
46033890|NCT01478698|Drug|recombinant deoxyribonuclease (DNase)|DNase 5mg per dose given intraperitoneally.
46033891|NCT04968340|Procedure|conventional cs|opening the lower uterine segment with introduction of the surgeon hand below the fetal head during its extraction
46033892|NCT04968340|Procedure|external pop out teqnique|support of lower uterine segment without introduction of the surgeon hand below the fetal head during its extraction
46033893|NCT00902746|Drug|NPC-01|"This study consist of the following steps.~Step 1(Norethisterone 0.6mg, Ethinyl Estradiol 0.035mg):From first study medication to 3th menstrual cycles.~Step 2(Norethisterone 1mg, Ethinyl Estradiol 0.035mg):~After interim analysis of the results of step 1, in the case of the efficacy results meet prespecified criterion, same dose level will be continued to 13th menstrual cycles including step 1. If the results do not meet prespecified criterion, the dose will be increased to Norethisterone 1mg, Ethinyl Estradiol 0.035mg and be continued newly until 13th menstrual cycle from this point."
46033894|NCT00632710|Other|phototherapy|The laser used was low-level Aluminum Gallium Arsenide (AlGaAs)diodo laser, at a wavelength of 785 nm (infrared), dose of 3 J/cm2, mean power of 70 mW, 3 sec. per point, laser beam of 0,06cm2, BIOSET brand - Indústria de Tecnologia Eletrônica Ltda -Rio Claro, Brazil.
46033895|NCT00632710|Other|phototherapy placebo|disconnected laser (same device - experimental group)
45339149|NCT02564601|Behavioral|Computer Cognitive Training|The intervention focuses upon progressively difficult perceptual exercises using the Brain Fitness program plus working memory exercises.
45339150|NCT03543813|Drug|CX-2029|CX-2029 Monotherapy
45339151|NCT02592512|Other|NIV-NAVA|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
45339152|NCT02592512|Other|NIV-PS/PC|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
45339153|NCT02593214|Device|Wondaleaf®|Use of Wondaleaf® during sexual intercourse with husband for 5 times in a month period
45339154|NCT02592200|Dietary Supplement|Lactobacillus gasseri DSM 27123|109 CFU (divided in two doses) per day for 28 days
45339155|NCT02592200|Dietary Supplement|Placebo|Two doses per day for 28 days
45339156|NCT00720902|Procedure|Blood draws|Subjects will have serum cardiovascular markers assessed
45339157|NCT00720902|Drug|growth hormone releasing hormone (GHRH) & arginine|Subjects will receive GHRH and arginine intravenously and then have blood drawn at frequent intervals over a 90 minutes to assess growth hormone secretion.
45598828|NCT02293135|Device|Verum Stendo session on V1 and Phantom Stendo session on V2|On the firt V1 visit, the patient will receive the verum Stendo session ; then on V2 visit ((V1 + 13 days +/- 2), the patient will receive the verum Stendo session On the firt visit, V1 the patient will have a phantom Stendo session (no pressure will be applied)
46033896|NCT01224886|Behavioral|Physical activity|Supervised exercise intervention
46033897|NCT01199380|Behavioral|Standard Treatment|Participants will receive a standard, group smoking cessation treatment, based on the most recent clinical practice guideline for treating tobacco use from the U.S. Department of Health and Human Services. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Patients in ST will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events as a means to equate for time spent on daily activity monitoring in the BATS condition.
46033898|NCT01199380|Behavioral|Behavioral Activation Treatment for Smoking|BATS is focused on identifying life areas, values, and daily activities to help one live according to his or her values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period.
46033899|NCT01199380|Drug|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level.
46033900|NCT02847286|Drug|Dapivirine Ring-004|Treatment A: Dapivirine Ring-004 for 28 days
45339158|NCT00720902|Procedure|Carotid ultrasound|Subjects will have an ultrasound of their neck to assess their carotid arteries to look for intima-medial thickness.
45339159|NCT00720902|Procedure|MRI|Subjects will have MRI and MR spectroscopy of the abdomen and lower extremities to assess for fat in internal organs and muscle.
45339160|NCT00720902|Procedure|Endothelial cell biopsy|Subjects will undergo endothelial cell biopsies to harvest endothelial cells to study. It will occur once and takes approximately 20 minutes. Patients will have an iv placed and then a sterile wire is passed back and forth in the iv a couple of times. Three wires are passed.
45339161|NCT02592278|Drug|Fluoride Varnish|Application of fluoride varnish every 3 and 6 months.
46033901|NCT02847286|Drug|Dapivirine Ring-004 for 28 days along with clotrimazole|Treatment B: Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days
46033902|NCT02847286|Drug|Clotrimazole|Treatment C: Clotrimazole, 5 g per day for 7 days
46033903|NCT00959452|Behavioral|Cognitive behavioural therapy|16 sessions vs 5 sessions of cognitive behavioural therapy
45339162|NCT02592278|Drug|Control Group|Twice a day brush with fluoride toothpaste.
46033904|NCT00902668|Drug|lovastatin|
46033905|NCT00902668|Other|questionnaire administration|
46033906|NCT00902668|Procedure|adjuvant therapy|
45339163|NCT00695019|Drug|interferon-alpha lozenges|500 IU lozenges of natural human interferon-alpha for oral dissolution given once or three times per day for 24 weeks
45339164|NCT00695019|Drug|placebo lozenges|200 mg matching placebo lozenges
45339165|NCT00918398|Drug|AZD1981|100 mg iv infusion, single dose, 4 hours infusion
45339166|NCT00918398|Drug|AZD1981|514 mg oral solution, single dose
45339167|NCT00918398|Drug|AZD1981|500 mg oral tablet A (optimal dissolution) give as 2x250 mg tablets, single dose
45339168|NCT00918398|Drug|AZD1981|500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose
45339169|NCT04019600|Other|Echocardiography|Demographic data and health risk factors will be collected on day of screening, together with the above tests. Right heart catheterization will be separately arranged in patients with a high echocardiographic probability of PAH. For those with a low-intermediate echocardiographic probability, screening will be repeated within 1 year to ensure true negativity of the original scan.
45683144|NCT03315598|Procedure|Electroacupuncture|lectroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. According to some acupuncturists, this practice augments the use of regular acupuncture, can restore health and well-being, and is particularly good for treating pain.
46033907|NCT00902668|Radiation|accelerated partial breast irradiation|
46033908|NCT00902668|Radiation|external beam radiation therapy|
45339170|NCT04086602|Drug|IZD334|Active Drug
46033909|NCT02846662|Behavioral|CONEMO|The study intervention has two components: the smartphone application CONEMO and primary care nurses monitoring patients' adherence to the intervention. CONEMO is a 6-week low-intensity behavior activation program delivered in 18 sessions that include messages related to the treatment goals, motivating them to do certain activities, helping to select and plan activities and messages related to psychological skills that facilitate the incorporation of activities in everyday life and to tackle obstacles that hinder patients to be more active. Primary care nurses are responsible for training participants to use the CONEMO app, monitoring patients' adherence to CONEMO, calling patients when they are non-adherent, and giving technical support when necessary.
46033910|NCT00433420|Biological|pegfilgrastim|
45339171|NCT04086602|Drug|Placebos|Placebo to Match
46033911|NCT00433420|Drug|cyclophosphamide|
46033912|NCT00433420|Drug|epirubicin hydrochloride|
46033913|NCT00433420|Drug|fluorouracil|
46033914|NCT00433420|Drug|paclitaxel|
46033915|NCT00433420|Procedure|adjuvant therapy|
46033916|NCT02846818|Procedure|Microdialysis|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein.
46033917|NCT02846584|Biological|CD19 or CD20 CAR T cells briging HSCT|Patients will receive a one-week regimen of chemotherapy consisting of fluid arabise and cyclophosphamide aimed to deplete the lymphocytes. One week later, patients are intravenously infused autologous anti-CD19 or anti-CD20 CAR T cells.
46033918|NCT04835038|Drug|Sodium Bicarbonate Ringer's Injection|Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)
45339172|NCT00742833|Drug|KUC-7483|
45339173|NCT00742833|Drug|Placebo|
45339174|NCT04060953|Other|Health-Related Quality of Life Report|Subject report and interpretation guide based on SPADE cluster scores
45339175|NCT03472989|Device|Radial extracorporeal shock wave|"Patients will receive treatment once a week for 3 weeks. Treatment will be administered by using the rESWT device named Swiss DolorClast (EMS). 2000 impulses are implied via the power hand piece to the area of max tenderness at the insertion of the plantar fascia, with a pressure of 1.5-3 bars depending on what the patient tolerates. The treatments will be given by a trained physiotherapist at our Department.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
45683145|NCT05688436|Drug|Diroximel Fumarate|Administered as specified in the treatment arm.
45683146|NCT05688436|Biological|Alemtuzumab|Administered as specified in the treatment arm.
45683147|NCT05688436|Drug|Fingolimod|Administered as specified in the treatment arm.
46033919|NCT04835038|Drug|Sodium Lactated Ringer's Injection|Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)
45683148|NCT05688436|Drug|Glatiramer acetate|Administered as specified in the treatment arm.
45683149|NCT05688436|Biological|Interferon beta|Administered as specified in the treatment arm.
46033920|NCT03856918|Procedure|PEEP 3 cm of water|PEEP of 3 cm of water will be applied during one-lung ventilation.
46033921|NCT03856918|Procedure|PEEP 6 cm of water|PEEP of 6 cm of water will be applied during one-lung ventilation.
46033922|NCT03856918|Procedure|PEEP 9 cm of water|PEEP of 9 cm of water will be applied during one-lung ventilation.
46033923|NCT03825094|Device|DyeVert™ Contrast Reduction Systems|Osprey Medical DyeVert™ Contrast Reduction Systems (DyeVert Systems) provide fluid pathway resistance modulation such that excess contrast media (CM) (i.e. CM that is not needed for diagnostic or therapeutic purposes) is minimized in the patient's vasculature and total contrast media volume (CMV) reduction occurs, while maintaining adequate image quality.
46033924|NCT04201912|Diagnostic Test|saliva analysis for Toll like receptor activity|Stimulated whole saliva will be obtained from patients and tested for Toll like receptor activity
45683150|NCT05688436|Biological|Natalizumab|Administered as specified in the treatment arm.
45683151|NCT05688436|Biological|Ocrelizumab|Administered as specified in the treatment arm.
46033925|NCT02850952|Other|Rehab MATRIX|Rehab MATRIX is a patient assignment tool that objectively categorizes patients undergoing inpatient rehabilitation based on nurse identified acuity variables.
46033926|NCT03678766|Behavioral|Regulation of Cues (ROC)|Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger, satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.
46033927|NCT03678766|Behavioral|Cognitive Behavior Therapy (CBT)|"Participants are taught to identify problems in eating, thinking, and mood patterns that served to trigger binge episodes through self-monitoring and to gradually develop alternative patterns aimed at facilitating healthy, binge-free eating patterns. Participants are taught to eat a healthy variety of foods and reducing the avoidance of forbidden foods that are typically consumed during a binge."
46033928|NCT02850796|Behavioral|Kg-Free|Cognitive-behavioral intervention based on promoting acceptance, mindfulness and self-compassion abilities
45683152|NCT05688436|Biological|Peginterferon beta-1a|Administered as specified in the treatment arm.
46033929|NCT02850796|Other|Treatment as Usual|Standard nutritional treatment that involves dietary and physical activity support provided by the medical units Standard
46033930|NCT04802200|Other|Data collect|Data collect following a vascular closure by MANTA
46033931|NCT03630562|Procedure|Aqueous humor samples collection|In addition to the routine examinations performed as part of the usual care of AMD patients, an anterior chamber puncture will be performed to collect the aqueous humor samples.
46033932|NCT04801030|Behavioral|YourCoViDVaxFacts|The intervention will be delivered via multiple strategies- social media (YouTube, Facebook), radio, newspaper, tv ads, community partner networks. Participants receive culturally-tailored message on COVID-19 and the vaccine. The strategies will have a link that will open to a website that is optimized for viewing on a computer or mobile phone which has the look and feel of an app, but without requiring the user to download anything to the phone. On the website, participants will be prompted to select their top concerns from a list. Based on the responses, the top barriers or need will each be mapped to a corresponding educational message, which will be displayed to the user with appropriate images or graphics.
45339176|NCT03472989|Device|Sham-radial extracorporeal shock wave|"Patients will receive the same treatment as the patients in the group receiving real shock waves, but no real shock waves are conducted. The probe is similar in design, sound and shape.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
45683153|NCT05688436|Drug|Siponimod|Administered as specified in the treatment arm.
45683154|NCT05688358|Diagnostic Test|serum levels of interleukin-17A in JIA|IL17 A by Enzyme linked immunosorbent assay method
45683155|NCT03386734|Procedure|SLN biopsy only|In experimental arm, SLN dissection only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.
45683156|NCT03386734|Procedure|SLN biopsy + PLN dissection|In active comparator arm, SLN dissection + full lymphadenectomy will be performed.
45683157|NCT04401124|Other|no intervention|no intervention
45683158|NCT03364270|Drug|PET/CT Imaging with [F-18] RGD-K5|PET Imaging/scan with [F-18] RGD-K5, PET Imaging/scan with RGD-K5, PET Imaging/scan with K5
45683159|NCT05681962|Diagnostic Test|Bronchoscopy|Patients will undergo to the bronchial endoscopy procedure required for their clinical condition: toilet bronchoscopy (for secretions, blood, mucus plugs removal), broncho-aspirate (BAS), bronchoalveolar lavage (BAL), brushing for cytology, biopsy, endobronchial ultrasound (EBUS).
45683160|NCT03364114|Device|EndoRotor Mucosal Resection System|The EndoRotor® Endoscopic Mucosal Resection System is an automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract for benign neoplastic or pre-malignant tissue removal by interventional gastroenterologists and GI surgeons. The EndoRotor® System performs both tissue dissection and resection with a single device through an endoscope's instrument biopsy channel.
45683161|NCT03364114|Device|Continued Ablation|Continued ablation control shall include either cryotherapy or continued radial frequency ablation.
45683162|NCT04401514|Device|Rocking chair therapy|20 min long rocking therapy with music cure. The therapy can be extended if needed
45339177|NCT03472989|Behavioral|Standardized high-load exercise program|"Patients will be instructed to do 2 exercises: Unilateral heel raise and unilateral leg squat three times a week for 12 weeks. The patients will have a total of 8 sessions supervised by a physiotherapist at our Department.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
46033933|NCT04202068|Drug|Ceftriaxone sodium and Sulbactam Sodium for injection|Ceftriaxone sodium and Sulbactam Sodium for injection is available as sterile powder for reconstitution.It will be administered as one 3g IV dose for adult or one 75mg/kg IV dose for children under 12.
46033934|NCT02850250|Drug|Cefuroxime|Patients selected and treated as per normal pathway of care. Drugs will be prescribed as per standard Alder Hey Policy at the doses defined in the hospital policy Cefuroxime 50mg/kg 8 hourly (12 hourly if less than 7 days of age, or undergoing peritoneal dialysis - maximum 1.5grams per dose)
46033935|NCT05012644|Drug|Palbociclib + aromatase inhibitor|Palbociclib + aromatase inhibitor
45339178|NCT03472989|Behavioral|Usual care|Patients will get standardized information as in the other three intervention groups with information on pathogenesis, etiology and prognosis, and they will get custom made foot orthosis
45339179|NCT00742911|Drug|Disulfiram|"Patients will take a pill of disulfiram at a fixed dose of 250 mg with their evening meal. This dose of disulfiram used to treat alcoholism. We will start by administering 2 mg of copper as copper gluconate along with 250 mg disulfiram.~Patients must not consume beverages containing alcohol while taking disulfiram."
46033936|NCT05012644|Drug|Aromatase inhibitor|Aromatase inhibitor
46033937|NCT04202302|Procedure|IVF/ICSI|ovarian stimulation ，vaginal disinfection of flushing
46033938|NCT02846506|Drug|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
46033939|NCT02846506|Drug|Canagliflozin 50 mg|Participants will receive canagliflozin 50 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
46033940|NCT02846506|Drug|Canagliflozin 100 mg|Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
46033941|NCT02846506|Drug|Metformin Extended Release (XR)|Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
46033942|NCT02846428|Drug|5-Fluorouracil|5-FU will be administered at 500 mg/m^2 by short IV infusion on Day 1 of each 21-day cycle during neoadjuvant treatment period for 4 cycles.
46033943|NCT02846428|Drug|Capecitabine|Capecitabine will be administered at 900 mg/m^2 orally twice daily on Days 1-14 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
46033944|NCT02846428|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
46033945|NCT02846428|Drug|Docetaxel|Docetaxel will be administered at 100 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles during adjuvant treatment period.
46033946|NCT02846428|Drug|Epirubicin|Epirubicin will be administered at 100 mg/m^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
45339180|NCT00742911|Drug|Copper Gluconate|"Commercially available. Copper gluconate has long been manufactured and sold as a food supplement. Copper gluconate should be taken separately from disulfiram, and if possible with breakfast.~Copper gluconate should not be administered to individuals with Wilson's disease or a family history of Wilson's disease.~Patients will receive 2 mg, 4mg, 6mg or 8mg daily"
45339181|NCT00742989|Other|OLT maneuver|direct myofascial release for the thoracic inlet for 30 seconds, supine rib raising for 1 minute on each side of the body, thoracic pumping for one minute, thoracic vacuum for 30 seconds, doming of the abdominal diaphragm for 30 seconds, abdominal pumping for 1 minute, pedal pumping for 1 minute, a second thoracic pump for 1 minute, a second thoracic vacuum for 30 seconds, and a final direct myofascial release for the thoracic inlet lasting 30 seconds
46033947|NCT03568084|Other|MEFAP|multicomponent physical activity program (MEFAP) with 12 weekly sessions of an hour and a half which includes 1) briefing 2) exercises for improving aerobic resistance, muscle strength, proprioception-balance and flexibility and 3) delivery of exercise chart to do at home (two times per week).
46033948|NCT03568084|Other|control usual practice|Individuals allocated to this arm, will be look after as usual in their health Centers.
46033949|NCT04368130|Behavioral|SIGNAL|"SIGNAL is a smartphone-based mobile health intervention designed to improve important outcomes in cancer patient patients (e.g., symptom burden, physical functioning).~Patients will download the adapted Beiwe app for a 6-month period and investigators will collect passive smartphone sensor data and active PRO data bi-weekly."
46033950|NCT03561376|Drug|Topical zinc oxide vs. petrolatum post-surgical scars|"Following linear closure on non-scalp skin with scar length > 4.5 cm, incision site will be split and petrolatum applied to one half and zinc oxide ointment to the other half daily for one month following surgery."
45339182|NCT00742989|Other|Sham OLT|Therapeutic massage performed
45339183|NCT02678871|Device|Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)
46033951|NCT02844712|Other|Evaluation of reexposure to a negatively tested betalactam|
46033952|NCT00947349|Drug|ribavirin (RBV)|ribavirin (RBV)
46033953|NCT00947349|Drug|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
46033954|NCT00947349|Drug|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
46033955|NCT00947349|Drug|ribavirin (RBV)|ribavirin (RBV)
46033956|NCT00947349|Drug|BI 201335 NA low placebo|Placebo
45339184|NCT02678871|Device|WATCHMAN|LAA closure with the WATCHMAN device
46033957|NCT00947349|Drug|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
45339185|NCT02565069|Device|CartoFinder™ Device with CARTO® 3 System V5 Navigation|Ablation treatment
46033958|NCT00947349|Drug|ribavirin (RBV)|ribavirin (RBV)
46033959|NCT00947349|Drug|BI 201335 NA high|BI 201335 NA high
46033960|NCT00947349|Drug|BI 201335 NA low|BI 201335 NA
46033961|NCT00947349|Drug|BI 201335 NA high placebo|placebo
46033962|NCT00947349|Drug|BI 201335 NA high|BI 201335 NA high
46033963|NCT00947349|Drug|Placebo|
46033964|NCT02846194|Behavioral|brief guided imagery|
46033965|NCT02844556|Procedure|SMILE surgery|SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
46033966|NCT02844556|Other|FS-LASIK surgery|SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
46033967|NCT02846116|Other|Prosthetic crown|
46033968|NCT00947193|Drug|Ataluren|Oral powder
46033969|NCT03425812|Drug|To withdraw NSAIDs therapy|NSAIDs therapy will be withdrew after washout period.
46033970|NCT03425812|Drug|To continue NSAIDs therapy|NSAIDs therapy will be continued.
46033971|NCT04317586|Device|Trident II Tritanium Acetabular Shell for Revision|A hemispherical acetabular shell indicated for cementless application in a previously failed total hip arthroplasty (THA)
46033972|NCT04302844|Behavioral|Imago Relationship Therapy|Imago relationship therapy (IRT) involves learning the Imago dialogue process, which helps couples understand more clearly why they and their partners react as they do. Couples practice communicating in a manner that helps them move from reactivity and blame to understanding and empathy. The dialogue is used to transform conflicts into opportunities for healing and growth, and to connect more deeply and effectively with one another. Specific topics of therapy are determined by the couple's needs and goals. In general, the therapist helps them use the Imago dialogue to promote understanding, heal painful emotions, and make requests of one another to change behaviors. In effort to minimize risk of exposure to the virus that causes COVID-19, since the spring of 2020, therapy sessions will be conducted via telehealth, with a HIPAA-compliant audio/visual platform, and with couples at home or in another private place during the therapy sessions and the therapist in his or her office.
45339186|NCT00694707|Drug|Placebo|Placebo was supplied in capsules.
45339187|NCT00694707|Drug|Cariprazine|Cariprazine was supplied in capsules
45339188|NCT00694707|Drug|Risperidone|Risperidone was supplied in capsules
45339189|NCT00692913|Drug|FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)|FOSAVANCE 5600 international units (IU)(Alendronate Sodium 70 mg/Vitamin D 5600 IU) combination tablet once weekly for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
45339190|NCT00692913|Dietary Supplement|Calcium Supplement 500 mg|"Calcium supplied locally by the investigator (containing 500 mg~calcium supplement) daily for 52 weeks (unless the patient's dietary intake of~calcium exceeds 1000 mg per day)."
45339191|NCT00692913|Other|Referred-Care Model|Usual treatment for osteoporosis chosen and prescribed by patients' own physicians for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
45339192|NCT00743067|Drug|GSK1363089 (formerly XL880)|GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally
45683163|NCT03310918|Other|Palliative Care|Specialized medical care for people with serious illness. This type of care is focused on providing relief from the symptoms and stress of a serious illness. The goal is to improve quality of life for both the patient and the family
46033973|NCT04302844|Behavioral|Waitlist with Bibliotherapy followed by Workshop|"Participants assigned to this group will be asked to wait for 12 weeks before receiving any intervention, and will be given a relationship-focused self-help book to read, with exercises to practice, during that time. After 12 weeks and the 12-week assessment has been completed, couples will attend an educational workshop that provides the principles and communication skills of Imago Relationship Therapy, typically in a weekend format that is usually about 18-20 hours. The workshops, called Getting the Love You Want (GTLYW), are led by certified and experienced Imago workshop presenters, and are attended by a group of couples. The workshop includes presentations, discussions, and practice of communication exercises. Participation in the workshops will also be virtual or via telehealth, as described above."
46033974|NCT00947115|Procedure|Blood sampling|Blood samples were collected at Years 5, 6, 7, 8, 9 and 10.
46033975|NCT00947115|Procedure|Cervico-vaginal secretion (CVS) samples|CVS samples were collected at Years 5, 6, 7, 8, 9 and 10 in subjects who volunteered for this procedure.
46033976|NCT02845804|Device|Alpine|
46033977|NCT02845960|Behavioral|rapid recovery|rapid recovery
46033978|NCT02844634|Drug|Doxycycline 100mg PO daily x 12 months|Immediate use of daily doxycycline (12 months duration, to start immediately)
46033979|NCT02844634|Drug|Tenofovir/emtricitabine 200/300mg PO daily|Daily use of tenofovir/emtricitabine
45683164|NCT03310918|Other|Standard Leukemia care|Standard care per the hospital guideline
45683165|NCT03082066|Other|CT or MRI scan|CT or MRI performed for underlying disease. CT and MRI scans used to asses bone and soft tissue diameter
45683166|NCT04279288|Device|Hilotherm mask|a cooling mask used to treat localized swelling and bleeding
46033980|NCT02844634|Drug|Doxycycline 100mg PO daily x 6 months|Deferred use of doxycycline (6 months duration, to start 6 months post-randomization)
45683167|NCT03386578|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|200 mg/300 mg of FTC/TDF administered orally as a fixed-dose combination tablet once daily
46033981|NCT02844478|Behavioral|SBP English|The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks.
46033982|NCT02844478|Behavioral|SBP SPANISH|The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks. The Spanish translation and cultural adaptation of the SBP has been completed under the direction of the PI.
45683168|NCT03386578|Behavioral|Behavioral HIV risk reduction package|HIV risk reduction package, including cohort-appropriate SMS messages. Participants in the PrEP Comparison Component: Cohort 1 will also receive enhanced adherence support, including two-way SMS messaging and tailored counseling with near-real time drug level feedback.
45683169|NCT01612676|Drug|FE 202158|
45839659|NCT02986152|Behavioral|Cancer Distress Coach Mobile App|"Cancer Distress Coach is a stand-alone symptom management tool with three basic components. The Learn about Distress module provides psycho-education. The Insights module includes an inspiring Quote of the Day, daily activity planning tips, a graph displaying the user's distress level plotted over time, and assessment feedback. The main action of the application is in the Activities module that provides patients with skills to manage their stress in the moment they experience it. Depending on the severity, the patient is routed to any of a number of helpful skills based on cognitive-behavioral principles. The stress management tools include positive imageries, soothing songs and pictures, and the Relax-Identify-Decide tool. Also included is find support and get support now to connect the user to his/her support network and locate informal cancer and non-cancer related support or (immediate) professional care."
45839660|NCT02986464|Device|Virtual Reality Prototype|VR prototype installed around the tank in the hydrotherapy room to give the child a sense of immersion in the virtual world with a possibility of interaction depending on the child's age and condition.
45839661|NCT02986464|Other|Standard Pharmacological Treatment|According to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and the pain clinic nurse.
45839662|NCT02986230|Other|Cancer prevention wizard (CPW)|The cancer prevention wizard is a point of care clinical decision support system designed to identify patients that are due for preventative cancer services and provides evidenced-based recommendations to the patient and provider.
45839663|NCT02986308|Other|No intervention|
45839664|NCT02982642|Drug|1612 capsule|Subjects will be assigned 1612 capsule,3 capsules per time(0.38g per capsule), 3 times per day.1612 capsule is a Chinse herbal medicine,which can tonification of spleen and kidney, mainly contains shudihuang(Rehmannia glutinosa),shanyao(Dioscorea opposita),shichangpu(Uncaria rhynchophylla)and so on,
45839665|NCT02982642|Drug|Placebos|Subjects will be assigned placebo identified to 1612 capsule,3 capsules per time, 3 times per day
45839666|NCT02982486|Drug|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
45754717|NCT05701904|Other|Shotblocker group|It is a U-shaped device with skin contact points on the shotblocker and an opening in the middle for injection (Tugrul, Celik, and Khorshid 2017). The Shotblocker will be placed on the skin surface just before inserting the needle and gently pressed with the fingertips, and the vaccine will be administered immediately afterwards. After removing the needle, the shotblocker will be removed.
45754718|NCT00506597|Drug|Erwinase|If allergic to E.Coli Asparaginase = 1 Dose (20,000 Units/m^2) Daily; If allergic to Pegylated Asparaginase = 6 Doses (25,000 Units/m^2) Daily Every Other Day. Received as an injection through a needle in vein, under the skin, or in muscle.
45839667|NCT02982486|Drug|Nivolumab|Ninolumab 240 mg IV every 2 weeks
46033983|NCT02845648|Drug|anticholinergic|Initial anticholinergic therapy to all patients
46033984|NCT02844166|Other|viscoelastic surface support|Patients will be placed in an ICU bed with viscoelastic surface support
46033985|NCT02844166|Other|pyramidal foam surface support|Patients will be placed in an ICU bed with pyramidal foam surface support
46033986|NCT03337906|Other|Observation|
46033987|NCT00952419|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on Day 0 and Day 21 (6 months to 35 Months)
46033988|NCT00952419|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
46033989|NCT00952419|Biological|Normal saline solution (placebo)|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
45339193|NCT00743223|Other|The measure of the cervical posture|The investigation of the cervical position consisted of locating the individual in side view with the parallel feet in erect position and tracing an imprisoned plumb wire to the ceiling and tangent to the kyphosis curve of the thoracic column. With a ruler it was verified at a distance of this line until the point deepest of the cervical lordosis curve.
46033990|NCT02000037|Device|IR Reflexotherapy|"18 IR reflexotherapy sessions :~Once a week for 12 weeks at the beginning of the study~Once a week for 3 weeks, 9 months after the beginning of the study~Once a week for 3 weeks, 15 months after the beginning of the study"
46033991|NCT02000037|Behavioral|Dietary care|Dietary consultation 1, 2, 3, 6, 9, 12, 15 and 18 months after the beginning of the study
46033992|NCT04259541|Diagnostic Test|Psychodiagnostic|Intensity and frequency of specific symptoms, signs of problems in mental health
46033993|NCT00902278|Biological|Flulaval|one 0.5-mL dose via intramuscular injection
46033994|NCT00902278|Biological|Fluvirin|one 0.5-mL dose via intramuscular injection
45339194|NCT00743301|Other|Palm olein vs olive oil and lard|17E% from test fat is incorporated into three rolls and a piece of cake
45683170|NCT05688202|Procedure|Simultaneous combination of fractional CO2 laser and subcision|"Fractional CO2 laser is performed immediately following subcision. Subcision is operated in all participants using an 181/2G Nokor needle (BD Nokor™ Admix Needles, United States). The insertion depth is at the dermal-hypodermal junction. The subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue, then slid in a direction parallel to the skin's surface in order to detach the scar from its tethers.~All participants undergo FrCO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes: (1)Only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density. (2)The whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density, <10% overlap."
45754719|NCT01797419|Drug|GS-5806|Single dose, oral liquid, .5 mL/kg
45754720|NCT01797419|Drug|Placebo|Single dose, oral liquid, .5 mL/kg
46033995|NCT00902278|Biological|Fluzone|one 0.5-mL dose via intramuscular injection
46033996|NCT00902278|Biological|Fluarix|one 0.5-mL dose via intramuscular injection
46033997|NCT00902278|Biological|Afluria|one 0.5-mL dose via intramuscular injection
46033998|NCT02854293|Other|Booklet-Question List|"Booklet-Question List (BQL) proposed in palliative cares, divided into 8 chapters, given to the patient before the first palliative care consultation.~Providing a list of questions to patients and their families without any obligations allows individual adaptation of information; patients or families who are afraid of asking these questions can take advantage of this opportunity, while respecting the need to avoid these subjects for other patients"
46033999|NCT02845726|Other|Stent examination, urinary analysis, USSQ questionnaire|
46034000|NCT02844322|Drug|Bortezomib|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
46034001|NCT02844322|Drug|Rituximab|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
46034002|NCT01998633|Biological|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10~Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4~Melphalan 140mg/m2 on Day -3~The GVHD prophylaxis will consist of the following:~Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.~Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)"
45339195|NCT00694551|Biological|Peptide Vaccine|Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.
45339196|NCT00694551|Drug|Poly IC-LC|Administered subcutaneously, one 2 mg/ml vial,(divided into two equal portions for each injection site).
45339197|NCT03383133|Drug|SULT Allosteric Inhibition|A single, therapeutic dose of acetaminophen (APAP, 1.0 g)) or dehydroepiandrosterone (DHEA, 75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (MEF, 0.75 g). In total, 5 experiments will be performed. Each experiment is performed in duplicate. Compounds are taken prior to eating breakfast. One hour later, the patient has a light breakfast and eats normally thereafter. Urine samples are collected at 15', 30', 1 h, 2h, 3h, 4h, 5 h, 6h, 7h, 8h, 9h, 10h, 11h, and 12h intervals following dosing. The samples are weighed. A 10 ml aliquot is taken from each time point and the aliquots are stored at -20 °C. Samples (0.5 ml) are then transferred to NMR tubes spectra are taken to assess drug metabolites in urine.
46034003|NCT02845570|Other|68Ga-DOTANOC PET/MRI|
45339198|NCT00743379|Drug|TH-302|TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.
45339199|NCT00689871|Device|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
45754721|NCT03589976|Drug|Sirolimus 2 MG|Dose will be adjusted throughout this trial based on sirolimus plasma levels and the presence of drug-related adverse events. The maximum dose will be 6mg/day.
45754722|NCT03589976|Other|Placebo|Patients receiving placebo will undergo analog sham level measurements and the number of tablets will be also adjusted to maintain the blinding of the trial.
46034004|NCT02845570|Other|18F-FDG PET/MRI|
46034005|NCT02844400|Device|Biometric Devices|Patients will wear two devices: HealthPatch Sensor and Phillips Actiwatch. Health data (e.g. average steps per day, resting heart rate) will be collected and monitored over the course of a cycle of cytotoxic chemotherapy.
46034006|NCT02844400|Other|Physical Performance Testing|Patients will complete a CPET and 6 minute walk test within one week of starting an upcoming chemotherapy cycle and they will undergo a second CPET upon completion of said chemotherapy cycle.
46034007|NCT01996605|Drug|Oxytocin 15 mcg|Oxytocin 15 mcg will be administered spinally
46034008|NCT01996605|Drug|Oxytocin 150 mcg|Oxytocin 150 mcg will be administered spinally
46034009|NCT01996605|Drug|Placebo|placebo will be administered spinally
46034010|NCT03097276|Procedure|blood sample|blood sample will be collected
45339200|NCT00793793|Drug|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
45339201|NCT00793793|Drug|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
45839668|NCT02982408|Dietary Supplement|High carbohydrate overfeeding|"All participant's individual energy requirement will be determined in mega joules (MJ) per day. The energy requirement will be multiplied by a factor 1.5 for a low physical activity level (PAL). The MJ will be rounded up or down to the nearest whole number.~The participant will receive food corresponding to ~25% additional energy above their calculated energy requirement. The 25% extra energy will be supplied to the participants for 4 weeks in the form of food containing simple carbohydrates. The subjects will be given a daily snack package containing processed foods or refined foods such as sweets, cookies, soft drinks, juice etc. To ensure an adequate energy surplus (i.e. weight gain), physical activity has to be decreased to a low level during the 4 weeks overfeeding period."
45339202|NCT00793793|Drug|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
46034011|NCT03097276|Radiation|CT scan|CT scan
45339203|NCT00793793|Drug|BI201335|patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
45339204|NCT00793793|Drug|Placebo|
45339205|NCT00743457|Device|Ocular Ultrasound|B-mode ultrasound of the eye with 90 and 30 degree view of optic nerve sheath
45339206|NCT02483637|Device|RejuvenAir|Device: RejuvenAir
45339207|NCT02602613|Device|AMEND Mitral Valve Repair System|Annuloplasty ring applied in a transcatheter method
45339208|NCT02602379|Other|Tetanic stimulation|Standard Tetanic stimulation will be used as the stimulus to evaluate responses of the intraoperative pain indexes (ANI and NoL) at different concentration of i.v. remifentanil during anesthesia.
45339209|NCT03999593|Procedure|Resection of perihilar cholangiocarcinoma|Resection of perihilar cholangiocarcinoma
45339210|NCT02603705|Drug|Oxycodone extended-release|
46034012|NCT01987635|Device|MEMO 3D ring|The experimental MEMO 3D ring is placed.
46034013|NCT01987635|Device|Standard use of rigid ring.|The rigid ring is placed, which is standard procedure.
46034014|NCT01987635|Procedure|3D Echocardiography|
46034015|NCT05337904|Device|On-Stimulation|"The surgical electrode implanted in target 1 (ACC) or target 2 (NAcc) by a pulse generating device is on."
46034016|NCT05337904|Device|Off-Stimulation|"The surgical electrode implanted in target 1 (ACC) or target 2 (NAcc) by a pulse generating device is off."
46034017|NCT02854137|Drug|BAY987521|10 micro L of the appropriate test product is place into the lower conjunctival sac of the designated eye (Formulation code: Y49-103).
45839669|NCT02982408|Behavioral|Exercise|"Half of the participants will be randomized to a 3-month exercise-training program.~The training program consists of combined aerobic training and strength training. The training program is performed unsupervised 3 times per week 45 minutes per session for 3 months in the local fitness center. Before engaging in the training program a maximal oxygen consumption test (VO2 max) are conducted and the maximal heartrate (HR) are determined.Participants are wearing the Polar V800 HR monitor and are asked to note their HR in a training log at the end of the last interval at each training session. The strength training program consist of 6 exercises (2 exercises paired together) involving the large muscle groups. The first training session is completed supervised at Rigshospitalet . After 6 weeks the training program is adjusted. Compliance will be ensured by phone calls, text messages and e-mails from study personnel."
45839670|NCT02982408|Behavioral|Normal physical activity|"The other half of the participants will be randomized to a 3-month with normal physical activity level (control).~The participants will have to return to the physical activity level they had before entering the study (baseline level). Compliance will be ensured by phone calls and text messages from study personnel. The subjects will wear a simple pedometer on the hip showing the number of steps. Once a week a text message (SMS-track) is automatically sent asking the participants to enter the weekly number of steps. The test personnel receive the reply and contact the participant if the number of steps does not match the baseline level. During the first and the last 7 days of the exercise intervention participants are wearing 2 accelerometers measuring their physical activity behavior."
45839671|NCT02982252|Behavioral|CoPILOT|Participants in all groups will receive either six or twelve hours of training in a standard powered wheelchair; however, the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
45839672|NCT02982330|Behavioral|Low Carbohydrate Breakfast|A low carbohydrate breakfast containing <10% carbohydrate, ~75% fat, and 15% protein. Matched for calories to the active comparator arm.
45839673|NCT02982330|Behavioral|Guidelines Breakfast|A low fat breakfast containing ~55% carbohydrate, <30% fat, and 15% protein. Matched for calories to the experimental arm.
45839674|NCT02981784|Drug|Ponatinib (Iclusig®)|Novel tyrosine kinase inhibitor active in patients with an ABL T315I mutation compared to conventional or reduced intensity allogeneic stem cell transplantation.
46034018|NCT02854137|Drug|Control|10 micro L of the appropriate controlled product is place into the lower conjunctival sac of the designated eye.
46034019|NCT00630981|Behavioral|Psychotherapy|Specific psychotherapy for dissociative disorders
46034020|NCT00630981|Drug|Pharmacological treatment (Quetiapine and/or Escitalopram)|Quetiapine for psychotic symptoms/Escitalopram if depressive disorders
46034021|NCT05243134|Other|Collect the clinical data|We analyze the influence of the anatomic deformity on the clinical efficacy at the follow-up.
46034022|NCT02854371|Drug|gadoxetic acid enhanced liver MRI|"Gadoxetic acid enhanced liver MRI is performed and the standard dose of contrast media (0.025mmol/kg) is administered intravenously at a rate of 1mL/sec. Before and after contrast media injection, T1 map sequence is performed to calculate hepatocyte fraction.~Routine MR sequences (T2WI, T1WI, dual-echo sequence, DWI, MR elastography) are performed according to clinical protocol in the institution."
46034023|NCT02854371|Drug|ICG R15|ICG R15 (Indocyanine green retention test) is performed within 3 days after gadoxetic acid liver MRI, according to clinical standard protocol.
46034024|NCT02845180|Procedure|Adipose Allograft Extracellular Matrix (AAM) Injection|Injection followed by surgery
46034025|NCT02845414|Drug|CD133KDEL (dCD133KDEL)|Patients will receive dCD133KDEL at the assigned dose level via a 30-minute intravenous infusion on days 1, 3, 5, 8, 10 and 12 (total of 6 doses) of a 28-day cycle.
45339211|NCT00776789|Other|skin to skin contact|Infants randomized to SSC group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. breastfeeding at the time of discharge.
45339212|NCT00776789|Other|Control group|The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC.
45339213|NCT00776555|Drug|Lisdexamfetamine Dimesylate|Study is a two-period cross-over design where subjects will have 2 Screening visits, a Baseline visit, and then be enrolled into the study for 2 Periods. Each Period has 2-3 visits and lasts from 2-6 weeks. At each Period visit subjects will be given one of the two treatment arm drugs that have been solubilized and then have blood drawn for pharmacokinetic analysis and the Drug Rating Questionnaire administered. At the end of Period 1 subjects will be crossed-over to the alternative treatment drug for the Period 2. The Vyvanse™ capsule contents will emptied into water to make a solution and given to subjects to drink at the beginning of each Period visit.
45754723|NCT00620503|Drug|Proellex 25 mg formulation A|One Proellex 25 mg formulation A capsule
45754724|NCT00620503|Drug|Proellex 25 mg formulation B|One 25 mg Proellex capsule formulation B administered both fed and fasted
45754725|NCT01797497|Behavioral|Care plan and coaching|In the intervention group, primary care providers and parents complete their sections of the referral care plan. Parents and referred specialists receive a copy of the form. Parents receive a 5-10 minute brief intervention by phone consisting of education and coaching. The care plan is reviewed with parents to help them practice exchanging information with the specialist and encourage parents to contact their child's primary care provider with any further questions. At the specialist visit, specialists review and complete the care plan with the parent and return the plan to the referring primary care provider. Outcome data are collected from parents before and after the specialist visit.
45754726|NCT03581630|Drug|naltrexone/bupropion|Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week, followed by Naltrexone HCl 8 mg/Bupropion HCl 90 mg ER combination tablets, orally, one tablet in the morning and one in the evening, daily, for 7 weeks.
45754727|NCT03581630|Behavioral|Mediterranean Diet|Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.
45754728|NCT03349073|Drug|T-1101 (Tosylate)|T-1101 (Tosylate) powder in bottle
45754729|NCT03282656|Biological|single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a|single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a
45754730|NCT03155672|Behavioral|Art therapy|Art Therapy
45754731|NCT00506675|Device|Patching|42 hours per week of patching
45754732|NCT00506675|Drug|Atropine|daily atropine (1%)
45754733|NCT00506675|Device|Patching|two hours of daily patching for 4 weeks, then no treatment
45754734|NCT00506675|Drug|Atropine|once weekly atropine for 4 weeks, then no treatment
45754735|NCT03580304|Behavioral|Industrial work|Subjects perform simulated industrial work in lab setting. The industrial task exists of a physical component and a cognitive component. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Mental fatigue will be determined by questionnaires and a cognitive stroop task before and after the trial.
45754736|NCT03580304|Behavioral|Physical load|The physical load of an industrial task will be simulated during this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
45754737|NCT03580304|Behavioral|Cognitive load|The cognitive load of an industrial task will be simulated in this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
45754738|NCT00507767|Drug|dasatinib|Given PO or via PEG tube
45339214|NCT00776555|Drug|Racemic mixture of dextroamphetamine and lisdexamfetamine|Same visits as described for Vyvanse™. The ADDERALL XR® capsule contents will be crushed, solubilized with water, and given to subjects to drink prior to pharmacokinetic blood draws and DRQ-S administration over the course of two periods.
46034026|NCT02845492|Other|Qigong|Qigong is a mind-body exercise based around gentle exercise and the cultivation of a meditative focus on bodily sensations
45339215|NCT05538533|Radiation|46 Gy Radiation Therapy|Dose per fraction of 4.6.
46034027|NCT02845492|Other|Complete Health Improvement Program (CHIP)|The CHIP program is a validated weekly wellness and exercise program designed to promote health and wellbeing.
45339216|NCT05538533|Radiation|40 Gy Radiation Therapy|Dose per fraction 5.7.
45339217|NCT05538533|Radiation|35 Gy Radiation Therapy|Dose per fraction 7.0.
45339218|NCT00915785|Drug|5 azacytidine|Patients will receive azacytidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment.
45339219|NCT04104581|Other|Control Refined Grain Diet|Subjects will be fed the average American diet except it will be free of whole grains
46034028|NCT00952341|Drug|aprepitant|Day 1: Oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Oral aprepitant 80 mg
46034029|NCT00952341|Drug|Comparator: Placebo to aprepitant|Day 1: Placebo to oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Placebo to oral aprepitant 80 mg
46034030|NCT00952341|Drug|dexamethasone|Day 1: Oral dexamethasone 10.5 mg prior to administration of cisplatin; Days 2, 3, and 4: Oral dexamethasone 7.5 mg
45339220|NCT04104581|Other|Low Whole Grain Oat Diet|Subjects will be fed the average American diet with addition of a low level of whole grain oats
45339221|NCT04104581|Other|High Whole Grain Oat Diet|Subjects will be fed the average American diet with addition of a high level of whole grain oats
45339222|NCT04104581|Other|Low Whole Grain Wheat Diet|Subjects will be fed the average American diet with addition of a low level of whole grain wheat
45754739|NCT00507767|Procedure|pharmacological study|Correlative studies
45754740|NCT00507767|Procedure|laboratory biomarker analysis|Correlative studies
45754741|NCT03134027|Procedure|Bone marrow biopsy|Subjects will undergo a bone marrow biopsy to obtain aspirate for stem cell collection.
45754742|NCT03134027|Procedure|Tumor biopsy|Subjects will undergo a tumor biopsy to obtain tissue for generation of a PDX.
46034031|NCT00952341|Drug|granisetron|Day 1: IV granisetron 3 mg prior to administration of cisplatin
46034032|NCT00952341|Drug|dexamethasone|Day 1: oral dexamethasone 6 mg prior to the administration of cisplatin; Days 2 and 3: oral dexamethasone 3.75 mg
46034033|NCT02845024|Drug|Doxycycline Group|Oral doxycycline 100mg was taken within 15 days
45839675|NCT02981784|Procedure|allogeneic stem cell transplantation|
46034034|NCT02845024|Drug|placebo Group|Oral placebo was taken within 15 days
45839676|NCT02981862|Other|CaptHPV method|"20 ml of blood sample will be made before the beginning of all treatment. This blood sample will be sent to the CERBA Laboratory for analysis.~In parallel, a standard anatomopathological and virological analysis will be carried out from a biopsy or from a tumor sample by the Tumor Biology Unit at Lorraine Institute of Oncology~The results of both analyzes will be compared blindly."
46034035|NCT05242588|Biological|JS005|30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
46034036|NCT05242588|Biological|Placebo|10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
46034037|NCT02852733|Other|end-of-life emergencies' management|
46034038|NCT02853903|Biological|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfusion in 3 times, i.v.
46034039|NCT04269525|Biological|UC-MSCs|After enrollment, each subject will receive UC-MSCs infusion intravenously on day 1, day 3, day 5, and day 7.
45339223|NCT04104581|Other|High Whole Grain Wheat Diet|Subjects will be fed the average American diet with addition of a high level of whole grain wheat
45339224|NCT04104737|Device|Spire Medical Health Tag|"Collect data to validate the respiratory rate performance of the Medical Health Tag developed by Spire Health. The Medical Health Tag respiratory rate will be evaluated during non-motion conditions over the range a range of 5-50 breaths per minute via Reference EtCO2.~A FDA cleared, GE Healthcare S5 Multi-parameter monitoring system with End Tidal Carbon Dioxide (EtCO2) and 3- lead ECG will be used for the Respiratory and Pulse Rate References."
45339225|NCT00720434|Drug|PF-00868554|500 mg BID administered as 5x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks.
45339226|NCT00720434|Drug|PF-00868554|300 mg BID administered as 3x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
46034040|NCT05242120|Other|Survey to access the impact of COVID 19 on anesthesia residency|This is a cross-sectional study using an online survey will be conducted on 75 anesthesia residents in Cairo University hospitals. Invitations were sent to residents' groups on WhatsApp. Study objectives were clearly explained at the beginning of the survey, and the participants were encouraged to roll out the survey to as many physicians as possible. This survey contains 62-question, divided into four main sections
46034041|NCT00602277|Other|Laboratory Biomarker Analysis|Correlative studies
45339227|NCT00720434|Drug|PF-00868554|200 mg BID administered as 2x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
46034042|NCT00602277|Biological|Wild-type Reovirus|
46034043|NCT02916550|Behavioral|Breathing exercise|Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.
46034044|NCT05241964|Biological|PRP|4~6ml autologous platelet rich plasma injection every 14±2 days for a total of 5 injections.
46034045|NCT01909089|Drug|Spinal administration of chloroprocaine.|"In order to determine the minimum effective dose that is to be given spinally, an up-down sequential allocation will be used.~Efficacy of the analgesia will be evaluated by a 100mm visual analogue pain score (VAPS). There are two possible outcomes here:~effective: the VAPS is 10mm or lower after the 15 minutes of monitoring. An effective result will decrease the test dose of chloroprocaine with 2mg for the next patient in this study.~Ineffective: the VAPS is more than 10mm after 15 minutes of monitoring. An ineffective result will increase the test dose of chloroprocaine with 2mg for the next patient in this study. Patients who indicate an ineffective result will receive a rescue treatment by the administration of 12ml levobupivacaine epidurally."
45754743|NCT04405544|Diagnostic Test|CT-scan|chest CT-scan
46034046|NCT02844790|Drug|insulin degludec/insulin aspart|A single dose of IDegAsp will be administered subcutaneously (s.c., under the skin).
46034047|NCT05337358|Procedure|endocrown|endocrown
46034048|NCT02845102|Other|Pre-Post Feasibility|The feasibility testing phase will include 25 subjects. Total duration of pre-post feasibility testing will be 6 weeks upon retrieval of the RA-CBT tablet and follow up questionnaires, quantitative exit interview, and/or an optional extended qualitative exit interview. The extended exit interview is a qualitative semi-formal interview focusing on gathering participant experiences working with the intervention, the barriers and facilitators encountered, as well as overall feedback for the pre-post feasibility study and the relational agent.
45754744|NCT04405544|Diagnostic Test|EEG|Electroencephalography
45754745|NCT04405544|Diagnostic Test|EP|Evoked potential
45754746|NCT04405544|Diagnostic Test|Pulse oximetry|Pulse oximetry
45754747|NCT04405544|Diagnostic Test|Blood tests|Blood tests
46034049|NCT00946881|Drug|WST 11 -mediated -VTP|The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers for 20 minutes using 753 nm laser light at escalating fixed energy doses of 200 J/cm and 300 J/cm, by escalating power at each energy to 167 mW/cm and 250 mW/cm, respectively. A brachytherapy-like template is used for the placement of the optical fiber(s) that are positioned in the prostate areas of interest under trans-rectal ultrasound image guidance.
45339228|NCT00720434|Drug|Placebo|Placebo administered for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
45339229|NCT00776009|Drug|Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)|10 mg and/or 20 mg capsules
46034050|NCT01214642|Drug|pegfilgrastim|Administered subcutaneously
46034051|NCT01214642|Drug|LY2523355|Administered intravenously
46034052|NCT02856633|Device|Vitaliti|
46034053|NCT05241652|Other|Inspiratory Muscle Training with an intensity of 50% MIP|Patients received IMT exercise program at a 50% MIP intensity for 12 weeks
45339230|NCT00776009|Drug|Placebo|Placebo Comparator
45339231|NCT00694161|Drug|Fx-1006A|Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for 12 months
45339232|NCT00720356|Drug|bevacizumab|10mg/kg administered intravenously every 2 weeks
45339233|NCT00720356|Drug|erlotinib hydrochloride|150 mg/daily orally
45339234|NCT00743535|Procedure|Transobturatory correction of anterior defect plus TOT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of mono-use needle"
46034054|NCT05241652|Other|Inspiratory Muscle Training with an intensity of 10% MIP|Patients received IMT exercise program at a 10% MIP intensity for 12 weeks
46034055|NCT02856243|Drug|new antiviral therapy|
46034056|NCT02690740|Other|(diagnostic) conjunctival provocation test with solution: ALK 100, 1.000, 10.000, 20.000, 50.000 and 100.000 SQ-U/ml|"see information in arm/group descriptions"
45683171|NCT05688202|Procedure|Sequential combination of fractional CO2 laser and subcision|"Fractional CO2 laser conducted two weeks after subcision. Subcision is operated in all participants using an 181/2G Nokor needle (BD Nokor™ Admix Needles, United States). The insertion depth is at the dermal-hypodermal junction. The subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue, then slid in a direction parallel to the skin's surface in order to detach the scar from its tethers.~All participants undergo FrCO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes: (1)Only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density. (2)The whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density, <10% overlap."
45839677|NCT02981706|Procedure|Arteriovenous Fistula (AVF)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous fistula, or connection between a native artery and vein.
46034057|NCT02852499|Other|Urine sampling|
45839678|NCT02981706|Procedure|Arteriovenous Graft (AVG)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous graft, or synthetic connection between a native artery and vein.
46034058|NCT02852499|Other|Carry a GPS and BET|
46034059|NCT02852499|Other|Carry pollution sensor|
46034060|NCT02852499|Other|Sampling at the maternity|
46034061|NCT02852499|Other|Self-questionnaires|
46034062|NCT02852499|Other|Sampling in partum period|Meconium and a strand of hair.
46034063|NCT04410328|Drug|Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care|Participants in the experimental group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally (if they have a feeding tube), 2 times daily starting on the day of enrollment for a total of 2 weeks.
46034064|NCT04410328|Other|Standard of care|Participants will receive standard care starting on the day of enrollment for a total of 2 weeks.
46034065|NCT01214252|Device|Permacol Surgical Implant|Permacol Surgical Implant
46034066|NCT02852577|Drug|Clonazepam|Administration of clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 36 months. If no remission after 8 weeks augmentation with paroxetine once a day, flexible dose (10 - 40 mg/day), for 34 months.
46034067|NCT02852577|Drug|Paroxetine|Administration of paroxetine once a day, flexible dose (10 - 40 mg/day), for 36 months. If no remission after 8 weeks augmentation with clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 34 months.
46034068|NCT05337202|Device|HeartSDK|The photoplethysmography (PPG) application enables patients to perform a finger tip heartbeat measurement and automatic analysis
45339235|NCT00743535|Procedure|Transobturatory correction of anterior defect plus TVT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle."
45339236|NCT02564913|Other|clinical evaluation|
45339237|NCT00745953|Drug|Valsartan|Valsartan 320mg PO daily for 8 months
45754748|NCT00621049|Drug|Docetaxel/Carboplatin/Bevacizumab/Erlotinib|"Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1~Docetaxel should be administered before carboplatin.~After completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:~Maintenance Treatment for patients in Cohort A:~Bevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily~Treatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity."
45339238|NCT00745953|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg PO daily for 8 months
45339239|NCT00720278|Drug|0.15% azelastine hydrochloride 1644 mcg daily|0.15% azelastine hydrochloride 1644 mcg daily
45339240|NCT00720278|Drug|0.1% azelastine hydrochloride 1096 mcg daily|0.1% azelastine hydrochloride 1096 mcg daily
45339241|NCT00720278|Drug|Placebo|0 mcg Placebo daily
45339242|NCT00743613|Behavioral|Sexual Health Inventory for Men (SHIM)|Five question test with maximum score of 25 points administered on the initial visit. Erectile dysfunction is indirectly related to the score.
45339243|NCT00743613|Procedure|Ankle-Brachial Index (ABI)|Measure Ankle-Brachial Index with a hand held doppler and sphygmomanometer to determine the ABI.
45339244|NCT00743691|Other|Community Based|In Arm 2 health extension workers will make a diagnosis of Neonatal infection and treat with antibiotics
45339245|NCT00746031|Drug|GnRH analogue (Zoladex)|3.6mg subcutaneous implant. Monthly doses x 3.
45339246|NCT00746031|Drug|GnRH antagonist-Cetrorelix|Subcutaneous injection 3mg x3 over 7 days
46034069|NCT05234476|Behavioral|Behavioral Activation plus Savoring|Individuals in this intervention will complete two sessions of behavioral activation, where they will be provided psychoeducation on behavioral models of mood, schedule activities, and discuss barriers to completion. Additionally, they will practice savoring as a cognitive strategy to increase positive emotions with a study therapist.
46034070|NCT05234476|Behavioral|Empathic Listening|Individuals in the active control condition will complete two sessions of reflecting on tracking their mood and empathic listening with a study therapist.
46034071|NCT01214174|Drug|IBI-10090|
45339247|NCT00720122|Drug|Recombinant human insulin like growth factor-1 (rhIGF-1)|Twice daily
45839679|NCT02981394|Procedure|Bone Marrow Aspirate Concentrate Injection|BMAC will be collected in the outpatient setting with local anesthesia. The collection site will be the Posterior Superior Iliac Spine (PSIS). This will be visualized under ultrasound prior to collection. Local anesthesia with 1% lidocaine will be performed prior to the harvest. BMAC harvest will be performed using the Arthrex Angel BMAC System using the Arthrex collection protocol. The Arthrex Angel machine will be used to separate BMAC contents for injection based on Arthrex collection protocol. Machine settings, volume of collection and volume of output have not been standardized and will be based upon harvest and the condition treated. These will be variables recorded for consideration of optimal settings based on the patient-reported outcomes.
45339248|NCT00746109|Procedure|Wound packing|"1/4 non-iodoform packing loosely placed inside abscess cavity."
45339249|NCT00746109|Procedure|NoPacking|This is a routine incision and drainage procedure but without the use of packing. Sterile gauze dressing will be placed over the abscess cavity.
45339250|NCT03961490|Other|No interventional study|No interventional study
45339251|NCT02564133|Device|Transthoracic echocardiography|A transthoracic echocardiography is performed to discover a patent foramen ovale
45339252|NCT04087382|Device|thrombectomy|Transfemoral a microcatheter with its distal end was positioned a few millimeters beyond the distal aspect of the clot, the guide wire was exchanged by Solitaire stent device. The device was held in place when 3 mm was out of the microcatheter. The microcatheter was slowly pulled back to deploy the TR or ST device over the clot.
45339253|NCT04087382|Other|non intervention group|medical treatment (Asprin, statin, nootropic drug)
45839680|NCT02981316|Biological|RBX7455|Microbiota capsule(s) given twice daily in the morning, and in the evening.
45339254|NCT03880929|Other|no intervention|no intervention
45339255|NCT04085744|Drug|Lidocaine 10% Spray|lidocaine will be apply on the cuff
45339256|NCT04085744|Drug|Mometasone nasal spray|mometasone spray will be applied on the cuff
45339257|NCT02564835|Other|Yoga|The yoga curriculum in this study is based is based on the Integral Yoga approach that includes branches of yoga associated with cognitive and immune benefits (Hatha, Raja). Within the Integral Yoga approach, physical poses, breathing techniques and mediation practices were chosen to provide benefits to the nervous system, immune system, musculoskeletal system and gastrointestinal system. Poses will be adapted to individual needs. The number of repetitions and/or length of hold will be increased through standard progression.
45839681|NCT02981238|Dietary Supplement|Phytostandard® Eschscholtzia / Valerian|
45839682|NCT02981160|Other|Dietary|The REE testing will be done with the Breezing device, a breath analyzer developed at Arizona State University. The Breezing device is an indirect calorimetry analyzer that measures the rate of oxygen consumption and carbon dioxide production, and determines how much energy the body is burning (REE), and the type of nutrients the body uses to produce energy (energy source). The Breezing device is a cellphone-size, battery-operated, portable technology that syncs with smartphones and electronic pads. The patients will be asked to breathe into a mouthpiece connected to the Breezing device; the data will be then beamed wirelessly to the device. The breath analysis data will displayed on the screen in conjunction with an estimate of total calories burned each day (total energy expenditure, TEE).
45839683|NCT02980926|Drug|Mepivacaine|This is a shorter acting spinal anesthetic as compared to the current standard of care at this institution.
45839684|NCT02980926|Drug|Bupivacaine|This is the current standard of care at this institution and many centers. This is a longer acting spinal anesthetic compared to the study drug.
45339258|NCT02564835|Other|Physical Activity|The physical activity intervention is based on the Exercise for People Living with Cancer program. The intervention will include nine resistance exercises (e.g. squats) and 8 flexibility exercises (e.g. shoulder stretch) targeted for the whole body as well as a brief warm up and cool down (walking). Exercises will be adapted to individual needs. The number of repetitions and/or length of hold will increase through standard progression.
45339259|NCT04085666|Drug|CDX 6114|CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug.
45339260|NCT04085666|Other|Matching Placebo|The placebo oral dosing solution will also be supplied as an approximately 240 mL oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
45839685|NCT02980614|Device|4D flow imaging|To compare the quantification of pulmonary valve leakage by standard 2D flow MRI and 4D flow MRI by measuring the regurgitation fraction (ratio of retrograde blood flow to anterograde flow) in the pulmonary artery
45839686|NCT02980458|Drug|Deferiprone 500Mg Tablet|
45839687|NCT02980458|Drug|Deferiprone 500 MG Oral Tablet [Ferriprox]|
45839688|NCT02980380|Other|Non-invasive brain computer interface|"The hemodynamic change in the motor cortex of the CLIS patient will be recorded across many sessions spread over more than a year and will be used to train a classifier to predict the yes and no answering pattern of the CLIS patient. For patient who can still open their eyes but cannot use any other means of communication will control an EEG based BCI for communication."
45839689|NCT02980302|Procedure|Cutaneous biopsy|Under local anesthesia
45839690|NCT02980146|Other|Non interventional study|
45839691|NCT02979912|Biological|Platelet Lysate|Eye drops of Platelet Lysate
45839692|NCT02979990|Other|Instructional Video|The experimental group will be asked to view a set of videos that demonstrate proper usage of controlled ovarian stimulation medication. They will have the opportunity to review instructional videos as needed throughout the ovarian stimulation process.
45839693|NCT02979990|Other|Control Video|The control group will have access to a video about the IVF process
45339261|NCT00746265|Behavioral|Behavioral weight loss intervention|Participants in both conditions are provided nutritional education and behavioral strategies for weight loss (consistent with the LEARN program). Participants in SBT are taught the cognitive and motivational strategies used in LEARN while participants in ABT are taught acceptance-based strategies (e.g., acceptance, mindfulness).
45839694|NCT02979756|Procedure|Decentralized GDM screening and initial management|Screening for GDM and initialization of nutritional therapy at the first level of care
45839695|NCT02979288|Drug|Lactobacillus casei rhamnosus (Lcr 35 regenerans)|Probiotic vaginal tablets vith active probiotic strains
45839696|NCT02979288|Other|NO Intervention|NO Intervention
45839697|NCT02979210|Other|Artificial Fecal Insult|protease/bile acid cocktail 200 microliters (1500 µg/ml trypsin/chymotrypsin protease mixture, 6.5 mg/ml cholic acid sodium, 6.2 mg/ml deoxycholic acid sodium, and 3.1 mg/ml chenodeoxycholic acid sodium in phosphate buffered saline
45839698|NCT02979210|Other|Phosphate Buffered Saline|200 microliters of phosphate buffered saline
46034072|NCT00902044|Genetic|Autologous HER2-specific T cells|Each patient will receive one intravenous injection of autologous HER2-specific T cells at one of the dose levels. If the patient has stable disease or a reduction in the size of the tumor they can receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the same cell number as their HER2-specific T-cell injection. For the first two subsequent HER2-specific T-cell infusions, patients will be able to receive additional lymphodepleting chemotherapy according to their dose levels.
46034073|NCT00902044|Drug|Fludarabine|"Fludarabine will be administered for 5 days prior to the T cells~The dose:~>10 kg: 25 mg/m2/day;~<10 kg: 1 mg/kg/day IV over 30 minutes"
45339262|NCT00743769|Drug|thymosin beta 4|Single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD of thymosin beta 4
45339263|NCT00743769|Other|Placebo|Single bolus injections of ascending doses of 0.00 mg QD of thymosin beta 4
45339264|NCT02563977|Device|2 year postop CT scan of the abdomen|CT scan of the abdomen (from the xiphoid process to the symphysis) performed approximately two years after performed DIEP flap breast reconstruction. No contrast used. Low dose of radiation.
45339265|NCT00743847|Drug|placebo|Subjects randomized to placebo will receive matching placebo and follow the titration schedule and dosing schedule of those randomized to varenicline.
45339266|NCT00743847|Drug|varenicline|Subjects randomized to the 0.5 mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 7 days, then 0.5mg BID for the remainder of the 6 week trial.
45339267|NCT00743847|Drug|varenicline|Subjects randomized to the 1mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 3 days, 0.5mg BID x 4 days, then 1mg BID for the remainder of the 6 week trial.
45339268|NCT00746343|Behavioral|IRRI|Subjects will remain in their assigned treatment condition for 24 months. IRRI subjects will meet with the lifestyle coach 25-27 times throughout the duration of the study.
46034074|NCT00902044|Drug|Cyclophosphamide|"Cyclophosphamide will be administered for 2 days.~Fludarabine and cyclophosphamide will be given for 2 days, followed by fludarabine alone for the next 3 days, followed by 2 days of rest, before the T cells will be administered.~Cyclophosphamide Dose:~30 mg/kg/day IV over 1 hour (with Mesna and IV hydration)~Fludarabine Dose:~>10 kg: 25 mg/m2/day; <10 kg: 1 mg/kg/day IV over 30 minutes"
46034075|NCT00902044|Genetic|Autologous CAR Positive T cells|Patient will receive one intravenous injection of autologous CAR T cells at dose level 9C. Further CAR T-cell dose escalation at dose level 9C will be done using the lymphodepletion schema as in dose level 9B.
46034076|NCT04201990|Drug|Camrelizumab and Apatinib|Camrelizumab, iv, Q3W; Apatinib, po, QD
45339269|NCT00746343|Behavioral|PCCM|Subjects will remain in their assigned treatment condition for 24 months.
45339270|NCT00717860|Drug|caspofungin acetate|Caspofungin acetate (50 mg/day for participants with esophageal candidiasis and 50 mg/day for participants with invasive candidiasis or aspergillosis after a 70 mg loading dose on Day 1), once daily intravenously (IV) for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
45339271|NCT00717860|Drug|Comparator: Micafungin sodium|Micafungin sodium 150 mg/day, once daily IV, for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
46034077|NCT00901342|Biological|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
45839699|NCT02978976|Drug|Betamethasone|will receive two doses of 12mg betamethasone ( Dipropfos ® SCHERING-PLOUGH; Kenilworth, New Jersey, USA) intramuscularly (IM) 24 hours apart.
45839700|NCT02978976|Drug|saline|saline placebo injection in the same regimen.
45839701|NCT02979132|Drug|Eisensulfat LOMAPHARM 50 mg|oral intake of an 'Eisensulfat LOMAPHARM 50 mg' tablet every morning for 90 days
46034078|NCT00632866|Drug|Hydroxychloroquine|Hydroxychloroquine : 200mg / day since 24 weeks
46034079|NCT00632866|Drug|Placebo|Placebo : 2cp/ day since 24 weeks
45839702|NCT02979132|Drug|Ferinject(R)|Single-dose Ferinject(R) administration
45839703|NCT02979132|Dietary Supplement|iron fortified biscuits|consumption of an iron-fortfied biscuit every morning for 90 days
45839704|NCT02978664|Procedure|Air insufflation|Air insufflation during colonoscopy including insertion phase
45839705|NCT02978664|Procedure|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy.
45839706|NCT02978664|Procedure|Water exchange|Water will infused and removed during insertion phase of colonoscopy
46034080|NCT00901186|Drug|RFB002|0.5 mg
46034081|NCT00901186|Procedure|Laser photocoagulation|
46034082|NCT01213472|Biological|GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)|Up to 24 intramuscular administrations
46034083|NCT05040880|Drug|Telmione plus 80/12.5mg|Test drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
46034084|NCT05040880|Drug|Micardis plus 80/12.5mg|Reference drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
46034085|NCT05034250|Diagnostic Test|Blood sample|Blood samples were taken from a peripheral vein as part of clinical routine. Subsequently, the iron status is determined.
45683172|NCT05688202|Device|Fractional CO2 laser|Fractional CO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) on both sides of the face sequentially with a two-week interval between sessions for each face's side by a single physician, with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes. At the first pass, only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density in the static operating mode. At the second pass, the whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density in the static operating mode with less than 10% overlap.
46034086|NCT00900796|Other|Treatment switching|If the patients do not response to first AntiTNF treatment, Investigator can switch to another anti TNF.Spanish Guidelines will be provided to the investigators, which recommend stopping biologics if there is an inadequate response after 16w of therapy and switch to another biologic. Responsive patients to the first anti-TNF who continue with this first anti-TNF adjusting dose treatment according to the Spanish guidelines or investigator criteria. The doses for each Anti TNF will be done following specific SmPc and under Investiagtor criteria
46034087|NCT01213082|Drug|24GyE proton and Anti-VEGF|24GyE proton beam will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
46034088|NCT01213082|Drug|16GyE and anti-VEGF|16GyE of Proton Beam Irradiation will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
46034089|NCT01213082|Drug|Sham Irradiation and anti-VEGF|2 Sessions of Sham Proton Beam Irradiation 24 hrs apart administered 2 to 6 weeks after intravitreal anti-VEGF therapy
46034090|NCT04073290|Drug|Rifaximin 550 milligram Oral Tablet [XIFAXAN]|Rifaximin 550 milligram b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
46034091|NCT04073290|Drug|Placebo oral tablet|Placebo b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
46034092|NCT04073290|Drug|Lactulose 667 milligram/milliliter Oral Solution|Lactulose based on soft stool frequency, 72 hours before TIPS placement till 3 months post-TIPS
46034093|NCT05017558|Diagnostic Test|point of care|"HIV-1 infected women will benefit from a viral load measurement by POC (Cepheid GenXpert HIV-1 viral load) at the time of delivery.~Newborns will benefit :~Antiretroviral preventive treatment differentiated according to their risk of infection in accordance with national recommendations:~High risk (maternal VL ≥1000 cp/ml): AZT/NVP for 12 weeks.~Low risk (maternal VL <1000 cp/ml): NVP for 6 weeks.~virological screening for HIV by qualitative POC (Cepheid GenXpert HIV-1 qual) from birth (for high-risk newborns) at 6 weeks, at 9 months and at any time in the event of clinical manifestations suggestive of HIV infection.~In the event of a positive HIV test, the child will initiate immediately AZT/3TC/LPV/r~support from volunteers to improve retention in care, promotion of exclusive breastfeeding and family nutritional support"
46034094|NCT03763162|Drug|Bortezomib|Given SC
46034095|NCT03763162|Biological|Daratumumab|Given IV
46034096|NCT03763162|Drug|Dexamethasone|Given IV or PO
46034097|NCT03763162|Drug|Ixazomib|Given PO
46034098|NCT03763162|Other|Quality-of-Life Assessment|Ancillary studies
46034099|NCT00632788|Other|acute myocardial infarction checklist|For every patient fulfilling the criteria of enrollment, an acute myocardial infarction checklist was incorporated into the patient's medical records at emergency department immediately after a diagnosis of acute ST-elevation myocardial infarction was made. All the time sequences concerning different managements at different locations were recorded by nurses and/or physicians as instructions on the checklist.
45339272|NCT05341700|Behavioral|Impact Load Exercises|Participants will complete 50-65 min running protocol on treadmill and 5 sets of 10 jumping exercises for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
45339273|NCT05341700|Behavioral|No Impact Load Exercises|Participants will complete only a 50-65 min running protocol on treadmill for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
46034100|NCT04975828|Diagnostic Test|albumin creatinine ratio -EGFR-fundus examination- coronary angiography.|albumin creatinine ratio and EGFR to assess. diabetic nephropathy. fundus examination to assess. diabetic retinopathy. assess of coronary artery disease by coronary angiography. assess diabetic nephropathy by neurologic examination.
45598829|NCT02293135|Device|Phantom Stendo session on V1 and Verum Stendo session on V2|On the firt V1 visit, the patient will have a phantom Stendo session (no pressure will be applied) ; then on V2 visit ((V1 + 13 dayx +/- 2), the patient will receive the verum Stendo session
46034101|NCT03936790|Other|Ropivacaine|In case of successful spinal anaesthesia, the dose of spinally administered ropivacaine will decrease by 0.375 mg for the next participant.In case of unsuccessful spinal anaesthesia, the dose of spinally administered ropivacaine will increase by 0.375 mg for the next participant.
46034102|NCT03936790|Other|Fentanyl|A fix dose of fentanyl (15 mcg) will be co-administered spinally to all participants.
45598830|NCT02293213|Behavioral|EMR Referral|EMR referral to California Teratogen Information Services (CTIS) for use of category D or X medication.
46034103|NCT04782700|Other|Steroid Taper (Prednisone)|The patients randomized to the steroid group will be prescribed prednisone PO or an equivalent corticosteroid at a dose of 0.5 mg/kg/day for 4 weeks ((plus BACTRIM-DS (1PO qd. 160/800mg) as prophylaxis against infection - If patient have a sulfa allergy, their physician will prescribe atovaquone 1500mg qd instead of Bactrim) and followed by a gradual taper of 0.25 mg/kg/day for 4 weeks, followed by 0.125 mg/kg qd for 4 weeks.
46034104|NCT04745884|Device|Non-invasive bilateral monitoring of ICP waveform|Brain4care non-invasive bilateral monitoring of ICP waveform
45839707|NCT02978820|Other|SEAS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The SEAS group received SEAS exercises one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
45598831|NCT02293213|Behavioral|CTIS Counseling|Counseling from MotherToBaby teratogen information specialist.
45839708|NCT02978820|Other|CS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The CS group received core stabilization exercise training one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
45839709|NCT02978742|Behavioral|Adaptive Recovery Record App|Participants will use the Recovery Record smartphone app, which is a meal monitoring tool, that incorporates discrete reminders, motivational tools, social support, summative feedback, and coping skill suggestions. Participants will also receive tailored, algorithm-generated content in a structured manner that mimics the progression of psychotherapy (e.g., checking in with users, reminding them of their reasons for wanting to recover, and working towards goals) over the course of 8 weeks.
45839710|NCT02978742|Behavioral|Standardized Coaching|Coaches (dietitians or mental health clinicians) will review patients' logs daily and participants will receive one communication of standardized feedback each day through the app based on their food records. A standardized feedback manual to be used by coaches has been developed by co-investigators (two PhD psychologists and one psychiatrist), and all feedback will be monitored for consistency and quality by co-investigators.
46034105|NCT05336734|Behavioral|Psychotherapy|see group description
46034106|NCT03711448|Drug|prednisone treatment|tapering prednisone regimen
46034107|NCT03711448|Drug|prednisone and ustekinumab treatment|Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4, W16 and W28)
46034108|NCT03711448|Other|questionnaires|HAQ ; SF-36 ; FACIT-fatigue
46034109|NCT03711448|Biological|Blood samples|Additional blood samples for immunomonitoring
46034110|NCT00885703|Drug|Fluconazole|"Step 1: [For participants randomized to Fluconazole] Induction dose of daily treatment of fluconazole given orally (adjusted according to weight).~Step 2: [For participants randomized to Ampho B only] If participant is intolerant to Ampho B, participant transitions to fluconazole dosage of 400-800mg daily given orally.~Step 3: If participant has a negative culture before week 10, participant transitions to consolidation therapy at dosage of 400mg daily given orally.~Step 4: At week 10, participant transitions to maintenance therapy at dosage of 200mg daily given orally."
46034111|NCT00885703|Drug|Amphotericin B|Step 1: [For participants randomized to Ampho B] Ampho B given intravenously for approximately 2 weeks at a dosage of 0.7 to 1.0 mg/kg, dependent on a participant's weight
46034112|NCT04210258|Device|Etermis 3|Cross-linked hyaluronic dermal filler. Treatment and follow-up according to standard of care and instruction of use for filling facial moderate wrinkles (marionette lines) and/or to increase lip volume
46034113|NCT04210258|Device|Etermis 4|Cross-linked hyaluronic dermal filler. Treatment and follow-up according to standard of care and instruction of use for filling deep and severe volume loss (nasolabial folds and/or marionette lines) and/or to increase lip volume
45339274|NCT02564679|Procedure|Laparoscopic Sleeve gastrectomy (LSG)|"These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with laparoscopic sleeve gastrectomy associated to lifestyle intervention. Concomitantly to surgical intervention, liver biopsy is performed.~At 6 and 12 months after LSG the patients are evaluated with laboratory, clinical and echographic assessment. Moreover, one year after LSG liver biopsy is repeated."
45598832|NCT02293213|Behavioral|Baseline Questionnaire|Baseline Questionnaire capturing contraceptive use immediately after counseling with MotherToBaby
45839711|NCT02978586|Device|[Ga-68]PSMA PET/MR|All participants will undergo at least 1 baseline [Ga-68]PSMA PET/MR. If participants test positive for [Ga-68]PSMA tumor uptake, they will under up to 2 additional scans
45839712|NCT02978274|Drug|MMF|MMF withdrawal by engraftment post haplo-SCT
46034114|NCT04554784|Other|Conventional|Patients' condition will be continue managed by pain specialists with regular follow-ups and continue patients' active concurrent pain treatment such as taking analgesics, physiotherapy, massage, chiropractor.
45839713|NCT02978274|Drug|MMF|MMF withdrawal by 2 month post haplo-SCT
45598833|NCT02293213|Behavioral|Contraception Provision Appointment|Appointment with contraception provider to discuss contraception options.
45839714|NCT02978430|Device|Computer-assisted GDFT|Patients receive fluid therapy via a computer-assisted goal-directed fluid therapy (GDFT) prototype closed-loop (automated) system guided by a cardiac output monitor.
45339275|NCT02564679|Behavioral|Lifestyle Intervention|"These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with lifestyle intervention. At 6 and 12 months after enrollment the patients are evaluated with laboratory, clinical and echographic assessment."
45339276|NCT00746499|Drug|Raltegravir|400mg raltegravir BID x 7 days
45339277|NCT03888417|Device|Therapeutic plasma exchange (TPE)|All TPEs were performed by the centrifugation technique using the Fresenius Kabi COMTEC machine
45339278|NCT02592122|Drug|Salbutamol Aerosol|
45339279|NCT02592122|Drug|No drugs|
45339280|NCT01497015|Behavioral|memory training|10 1-hour sessions over 6-8 weeks
45339281|NCT01497015|Behavioral|speed of processing training|10 1-hour sessions delivered over 6-8 weeks
45339282|NCT01497015|Behavioral|waitlist control|Breast cancer survivors will receive the speed of processing training compact disc in the mail after study completion.
45339283|NCT02564445|Behavioral|Gamification|All participants will be entered with their teammate into a game that includes points and levels
45339284|NCT02564445|Behavioral|Share Data with PCP|Weight and step count data will be shared with the participant's primary care physician
45598834|NCT02293213|Behavioral|3 Month Follow Up Questionnaire|Questionnaire 3 months after CTIS counseling to assess contraception use and plans
45598835|NCT02293213|Behavioral|6 Month Follow Up Questionnaire|Questionnaire 6 months after CTIS counseling to assess contraception use and plans
45598836|NCT02229617|Drug|Subcutaneous testosterone|
45839715|NCT02978430|Other|Standard of care|Patients receive fluid management based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output). This control group (started retrospectively before the first included patient of the closed-loop goal directed fluid therapy group) consists of the same population undergoing the same surgery as the closed-loop GDFT group.
45598837|NCT02347059|Drug|L-dopa|Antiparkinsonian medication
45839716|NCT02978352|Other|learning|
45839717|NCT02977962|Behavioral|Cognitive-Behavior Therapy|This therapy has been designed for adolescents with high functioning ASD and involves 16 weekly session where the participant learns coping skills related to addressing anxiety (e.g., exposure therapy, cognitive therapy, social skills training).
45598838|NCT02347059|Drug|Dopamine Agonists (pramipexole, ropirinole)|Antiparkinsonian medication
45339285|NCT02564445|Behavioral|Feedback on weight|Participants will use a wireless weight scale to weigh-in at home and receive feedback on weight.
45339286|NCT02564445|Behavioral|Feedback on step counts|Participants will use a smartphone application that uses accelerometers within the phone to track step counts and receive feedback on step counts
45339287|NCT02564367|Drug|S-1|"18 cycles S-1, orally administered twice daily D1-14, q 3 wks~S-1 starting dose: 2 x 30 mg/m^2 body surface area (BSA), D1-14, q 3 wks First dose reduction: 2 x 25 mg/m^2 BSA, D1-14, q 3 wks Second dose reduction: 2 x 20 mg/m^2 BSA, D1-14, q 3 wks"
45598839|NCT02296489|Device|Capnostream20p|The device will be used to monitor respiratory co2 values during the methacholine challenge, a well known diagnostic procedure
45598840|NCT02353611|Other|6% hydrogen peroxide|
45598841|NCT02353611|Other|35% hydrogen peroxide|conventional peroxide whitening compound acted like control
45598842|NCT02258867|Drug|Placebo|Solution for subcutaneous injection
45754749|NCT00621049|Drug|Docetaxel/Carboplatin|"Adjuvant Treatment Cohort B:~Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1~Docetaxel should be administered before carboplatin.~Treatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment."
45339288|NCT00923637|Drug|Pemetrexed/Oxaliplatin|In the first cycle, patients received Pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) on day 1 of a 21-day cycle. From 2nd cycle, patients received pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) then oxaliplatin 120 mg/m2 (i.v. infusion over 120 minutes) on day 1 of a 21-day cycle. Study drug administration is to begin on d14 to d28 after R0 resection of the tumor. A total of three cycles is intended for patients with stage IB NSCLC, and four cycles for II-IIIA NSCLC, respectively.
46034115|NCT04554784|Procedure|Bowen|"Patients will be referred to Occupational therapist for Bowen Therapy. There will be a week washout period before the start of Bowen Therapy. During a week washout period and study period, patients can continue taking analgesia, but advised to stop the concurrent treatments which can affect the deep tissue such as massage, physiotherapy, and chiropractic to minimize the counteracting effect on the Bowen's action.~During a Bowen Therapy session, patients will lie relaxed on the examination couch wearing loosely fitting clothing or only the affected area being exposed. The therapist applies a series of gentle movements across the body. The gentle movements focus on a body of muscle, tendon or nerve and release tension through the nerve within the area. Each session will last for 30 minutes to an hour. After each session, the next appointment will be given to patients. The first four sessions will be scheduled on weekly basis, and the remaining four on biweekly session."
46034116|NCT04549480|Drug|Bosutinib capsule|100 mg dose of bosutinib pediatric capsule
45754750|NCT05701748|Other|Stimuli|placement of oral pacifier, electrical stimulation, and laryngoscopy
46034117|NCT04549480|Drug|Bosutinib tablet|100 mg dose of bosutinib tablet
46034118|NCT05336578|Other|Platelet rich fibrin application|PRFs were prepared by obtaining10 ml blood samples from each patinet and inserting them in a centrifuge device (Intra-Lock International Inc., Boca Raton, USA), under 2700 rpm for 12 min using high speed. The platelet-rich fibrin layer remaining between the acellular plasma and red blood cells in the tube was separated with the help of scissors or a scalpel. After the tooth extraction in the experimental group PRF located to the extraction socket.
45472759|NCT01104922|Drug|Cetuximab|Cetuximab will be administered for 3 weekly doses commencing one week prior to stereotactic radiosurgery treatment as follows: * Cetuximab 400 mg / m2 day -7 (1 week prior to initiation of radiosurgery) * Cetuximab 250 mg/m2 days 0 and +8 (i.e. during the first and second week of fractionated stereotactic radiosurgery) Cetuximab will be administered at 400 mg/m2 IV over 120 minutes on day -7 (loading dose) and 250 mg/m2 IV on days 0 and 8 during the course of stereotactic radiosurgery.
45339289|NCT00717314|Drug|Mycophenolate mofetil|1.5 to 2.0 g daily PO BID
45339290|NCT00717314|Drug|CNI (50%)|50% reduction from BL
45339291|NCT00717314|Drug|CNI (≥75%)|≥75% reduction from BL
45339292|NCT01090089|Drug|Lenalidomide, Dexamethasone|Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
45339293|NCT01090089|Drug|Lenalidomide, Dexamethasone, PBSCT|Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
45598843|NCT02258867|Drug|Gevokizumab|Solution for subcutaneous injection
45754751|NCT00508469|Drug|Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav)|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
46034119|NCT02642419|Drug|Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)|"Rivaroxaban will be orally administered after a meal at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min (regardless of time)~Antiplatelet will be selected from aspirin or thienopyridine derivatives (clopidogrel or prasugrel)~Aspirin will be orally administered once a day at a dose of 81 mg or 100 mg~Clopidogrel will be orally administered once a day after a meal at a dose of 75 mg. The dose will be reduced to 50mg once a day depending on age, body weight or clinical findings.~Prasugrel will be orally administered once a day at a dose of 3.75 mg. If the body weight is 50kg or less a reduced dose(2.5 mg once a day) will be considered depending on the age, renal function or other bleeding and thrombotic risk."
46034120|NCT02642419|Drug|Rivaroxaban|Rivaroxaban will be orally administered at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min.
46034121|NCT00901576|Drug|SPD503|SPD503 (guanfacine hydrochloride) extended-release 4 mg orally administered tablets
45339294|NCT00689793|Drug|Ferrous sulphate|"Volunteers will receive 80 mg/day oral ferrous sulphate (Tardyferon®) for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
45339295|NCT00689793|Drug|Placebo|"Volunteers will receive 1 pill/day oral placebo for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
45339296|NCT04086290|Procedure|RARP|Radical prostatectomy + extended pelvic lymph node dissection
45339297|NCT04086290|Radiation|SBRT|Stereotactic body radiotherapy to osseous lesions
45339298|NCT04086290|Drug|ADT|six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.
45339299|NCT05431491|Device|Ultrafiltration|Ultrafiltration through much smaller intravenous cannula than what has previously been used.
45339300|NCT00723944|Device|Osseotite Certain Prevail|Root form titanium dental implant
45339301|NCT00723944|Device|Osseotite Certain|Dental implant without the lateralized design
45339302|NCT04086134|Other|Fruit Products|Fruit Products with the potential to improve constipation-related outcomes
45339303|NCT04060329|Behavioral|coopeRATE Prompt|The coopeRATE Prompt intervention is a set of two questions delivered to patients immediately before the clinical encounter that elicit their concerns and goals.
45339304|NCT02591264|Other|Blood sample|Blood sample drawn from participants for analysis of neutrophil peptide level
45339305|NCT04060563|Device|INSPIRSTAR IS02 MICROCURRENT STIMULATOR|"Investigators will use the Inspirstar microcurrent stimulator TENS device. It is an FDA 510k approved portable hand-held device used for the symptomatic relief of chronic pain. It generates low current intensity pulses in the ranges of 20μA to 400μA.~For this study, investigators will use a treatment range of 100-300μA. Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8), times 2 treatments for a consistent total of 11 hours 32 minutes."
45472760|NCT01104922|Device|Stereotactic radiosurgery|Fractionated stereotactic radiosurgery, 8.0 Gy per fraction for 5 fractions (total: 40.0 Gy)
45754752|NCT00508469|Drug|Travoprost 0.004% eye drops|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
45339306|NCT00744315|Procedure|Mini-thoracotomy for intramyocardial injection of VEGF165|Patients with previous diagnosis of ischemic cardiopathy were included. The patient must accept and agree to be subject of clinical observation with current optimal treatment for at least 6 months. Following to that, subject undergoes intervention, in addition to consultation and assessments. Surgical technique -Ten injections VEGF165 will be made through a 25F butterfly needle in any ischemic territory where previously identified through scintigraphy. Dosis: 2.000 mg of VEGF165 in 5ml of saline solution. After the procedure, the patients will be kept in a recovery room for about 24hs and in the hospital until full clinical recovery.
45339307|NCT00689481|Drug|U0267 Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
45754755|NCT03155750|Other|Zero Time Exercise|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
45754756|NCT03155750|Other|Sleep hygiene education|We offer a 2-session education course to teach the subjects about sleep hygiene practice.
45339308|NCT00689481|Drug|Vehicle foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
46034122|NCT00901576|Drug|Concerta|CONCERTA (methylphenidate HCl) extended-release 36 mg orally administered tablets.
46034123|NCT00901576|Drug|SPD503 + Concerta|SPD503 4 mg + CONCERTA 36 mg orally administered tablets (taken together).
45339309|NCT00744393|Drug|sodium oxybate|The dose of sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and crossed over the next day
45339310|NCT00744393|Drug|placebo|The dose of placebo sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and then crossed over the next day
45754753|NCT00508469|Drug|Timolol 0.05% eye drops|One drop in the study eye twice daily at 9 a.m. and 9 p.m. for six months using the Travalert device.
46034124|NCT00655837|Drug|SGN-40|4-12mg/kg IV; Days 1, 4, 8, 15 and 22 of Cycle 1 and Days 1, 8 and 15 of Cycles 2-8.
45339311|NCT00746577|Other|Organizational change to improve the implementation of evidence-based practices.|Some sites will receive assistance with the creation and implementation of an organizational development plan.
46034125|NCT00655837|Drug|rituximab|375 mg/m2 IV injection; Days -2, 8, 15 and 22 of Cycle 1 and Day 1 of Cycles 2-8.
45339312|NCT02563353|Other|whole-body vibration|"Whole-body vibration on vibration platforms. 30-40 Hertz, from 2 mm (low) to 4 mm (high) amplitude,~1 minutes x 6 with 1 minute break between. 3 times a week."
45339313|NCT02563353|Drug|teriparatide|Teriparatide, 20 microgram/day. 24 months of treatment.
45598844|NCT02296567|Drug|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
45598845|NCT02296567|Drug|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care.
45598846|NCT02296567|Drug|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care.
45598847|NCT02296567|Drug|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
45754757|NCT05702996|Drug|Eculizumab administration|Patient with Thrombotic microangiopathies induced by gemcitabine will be treat with Eculizumab
45839718|NCT02977962|Other|Treatment as Usual|Those who choose to participate will be enrolled in the 16 week study. They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 16). Those in this group will not receive the Cognitive-Behavior Therapy, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
46034126|NCT00655837|Drug|gemcitabine|1000 mg/m2 IV Injection; Days 1 and 15 of all Cycles.
46034127|NCT02634931|Drug|NPC-12G gel|NPC-12G gel is administered topically twice a day for 52 weeks or longer
46034128|NCT05336422|Other|training on the risks associated with sun exposure|15-minute power point and presentation on the risks of sun exposure
46034129|NCT00655915|Other|Corticosteroid Injection- 1ml of Betamethasone and 1 ml of 1% Lidocaine|Patients will receive a carpal tunnel injection of 1 mg of betamethasone and 1 mL of 1% lidocaine will be infiltrated by small gauge (ie. 25- or 27-gauge) needle via attending surgeon preference. These are routinely performed by injecting 1cm proximal to distal wrist crease just ulnar to palmaris longus tendon although multiple techniques have been described. Elicitation of median nerve symptoms during needle placement requires redirecting needle prior to injection to avoid median nerve infiltration.
45598848|NCT02296567|Drug|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care
45754754|NCT00508469|Device|Travalert Dosing Aid|Approved device used with study medication to record time of instillation and quantify dosing
46034130|NCT02637271|Other|Low calorie total meal replacement|Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.
45839719|NCT02978040|Drug|Cangrelor|Cangrelor will be administered as bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight < 60 kg or age > 75 years old).
46034131|NCT02637271|Other|Low calorie typical diet|Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
45339314|NCT00688701|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
45339315|NCT00688701|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
45339316|NCT00688701|Device|Pen auto-injector|
45339317|NCT02563743|Behavioral|Problem-solving based intervention|The intervention comprises both the employee and the employer, and follows a clear structure comprising problem solving, stepwise activation and relapse prevention. It includes three meetings at the OHS with additional follow-ups.
45339318|NCT02563743|Behavioral|Treatment as usual|Study participants that are randomized into the control group will receive the usual care given at the OHS. This intervention will differ due to differences between the OHS units.
45339319|NCT00999609|Biological|AAV2-hRPE65v2,voretigene neparvovec-rzyl|Subretinal administration of gene therapy vector AAV2-hRPE65v2 (1.5E11 vector genomes per eye) to both eyes via surgical procedures on separate days.
45339320|NCT02563119|Procedure|Gastric Bypass or Sleeve gastrectomy|
45339321|NCT00744549|Dietary Supplement|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
45339322|NCT00744549|Drug|Placebo|Twice a day with meals.
45339323|NCT00746655|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The first four patients will receive 50 Gy in 5 fractions (10 Gy /fx) over a 2 week period. The next four patients will be treated to a total dose of 60 Gy in 5 fractions (15 Gy/fx) over two weeks. The final four patients will receive 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period,
45339324|NCT00746655|Procedure|Transcatheter Arterial Chemoembolization (TACE)|. Intra-arterial cisplatin treatment will be given at a dose of 125 mg/m2. After delivery of the drug(s) to the tumor, embolization will be accomplished with Embospheres (Biosphere Medical, Inc.,Rockland, MA, USA) until moderate to marked stasis of antegrade flow is seen in the artery.
45339325|NCT04060719|Drug|BI 894416|tablet
45339326|NCT04060719|Drug|Rifampicin|tablet
45339327|NCT00746811|Drug|P-OM3|4 grams/day - 4 one gram capsules
45339328|NCT00746811|Drug|Placebo|4 grams/day - 4 one gram capsules
45339329|NCT04060173|Drug|ABP-671|ABP-671 is an investigational drug
45339330|NCT04060173|Other|Placebo|Matching placebo
45339331|NCT00741429|Drug|Technosphere Insulin Inhalation Powder|Subjects previously treated with Technosphere Insulin Inhalation Powder
45339332|NCT00741429|Drug|Comparator|Subjects previously treated with other anti-diabetic medications
45339333|NCT02563197|Device|T-326 Inhaler|No drug dosing,three test inhalations through the inhaler device filled with an empty capsule.
45339334|NCT00741507|Behavioral|Alcohol drinking|Never drinking of alcohol
45339335|NCT00741507|Behavioral|Alcohol drinking|"Mild drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
45339336|NCT00741507|Behavioral|Alcohol drinking|"Moderate drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
45339337|NCT00741507|Behavioral|Alcohol drinking|"Severe over drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
46034132|NCT02637349|Behavioral|POST Intervention|POST Intervention group will receive a tailored survivorship care plan (SCP) at the end of their active treatment. The SCP will be discussed with them. Patient will be asked about satisfaction with the end of treatment session.
45598849|NCT02296567|Drug|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
46034133|NCT02637349|Behavioral|POST Treatment as Usual|The POST control group may receive a survivorship care plan (SCP) as part of treatment as usual though it is not a usual procedure. They will be asked about their satisfaction with the end of treatment session.
46034134|NCT04162093|Procedure|uretero ileal anastomosis in single trough|
46034135|NCT02637193|Drug|Venlafaxine|Multiple doses of Venlafaxine for 14 days plus 3 days of down titration
46034136|NCT02637193|Drug|Moxifloxacin|400 mg single dose moxifloxacin
46034137|NCT02637193|Drug|Drug - placebo|Placebo administered for 16 days
46034138|NCT04163575|Biological|:Anti-CD22-CAR|Cells extracted, followed by induction chemotherapy before CD22-CAR infusion (dose escalation.)
45339338|NCT00741507|Behavioral|Alcohol drinking|"Alcohol-dependent assessed by alcohol use disorders identification test (AUDIT)"
45339339|NCT00688623|Drug|Everolimus|Everolimus 5 mg tablets were supplied in blister packs
45339340|NCT02563821|Procedure|Patient Controlled Epidural Analgesia for third trimester termination of preganancy analgesia|
45339341|NCT02563821|Drug|Levobupivacaine|
45339342|NCT02563821|Drug|sufentanil|
45339343|NCT02563821|Drug|clonidine|
45339344|NCT02563821|Device|epidural catheter|
46034139|NCT00656773|Drug|Sufentanil|0.15 μg/kg, IV following by 0.075 μg/kg every 3 minutes during 15 minutes
45339345|NCT02563587|Other|Laughter therapy|Laughter therapy sessions will begin as soon as / after that the complete anesthesia recovery, then we could start with two interventions, each of them in morning and during the afternoon will be held until their discharge lasting 30 minutes per each one, these sessions will be held in the service pediatric hospital by trained personnel in laughter therapy, which will be implemented through hospital clowns.
45598850|NCT02296567|Drug|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care
45339346|NCT02563587|Other|Accompaniment without causing the laughter of children.|The interventions will be carried out by means of reading stories and own stories for the age. These sessions will begin subsequent to the full recovery of the anesthesia, and then two interventions per day, in the morning and evening, with duration of 30 minutes, until the time of his discharge, these sessions will take place in the service of Hospital pediatrics by the resident in charge.
45339347|NCT02563587|Drug|Conventional treatment|Conventional treatment involves handling analgesic with non-steroidal anti-inflammatory drugs (paracetaol, metamizol and ketorolac) as prescribed by the doctor surgeon treating, which starts immediately in the postoperative period.
45339348|NCT00717236|Drug|Certolizumab pegol (CZP)|400 mg CZP given as two 200 mg subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by 200 mg CZP given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
45598851|NCT02296567|Drug|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal bevacizumab as part of their routine medical care
45339349|NCT00717236|Other|Placebo|Placebo (0.9% saline) given as 2 subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by placebo given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
45598852|NCT02296567|Drug|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
45598853|NCT02296567|Other|Control Group|Control group Subjects will no previous anti-VEGF treatment
45598854|NCT02351193|Other|transvaginal Ultrasound|
46034140|NCT00656773|Drug|Morphine|0.15 mg/kg, IV following by 0.075 mg/kg every 3 minutes during 15 minutes
46034141|NCT04017559|Behavioral|Motivational Interviewing|A pharmacist trained in MI delivered three recorded MI sessions over 2 months, with follow up at 3, 4 and 6 months.
46034142|NCT04165525|Device|Ablation|comparison of using an argon gas and high frequency electrical current ablation device with a standard Bovie electrosugical device without argon gas.
46034143|NCT04163263|Drug|BOS-356|topical gel
46034144|NCT04163263|Drug|Vehicle|topical gel
46034145|NCT02634697|Behavioral|Relaxation Response Resiliency Program|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga
46034146|NCT00882583|Drug|Cetuximab|single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8
46034147|NCT00882583|Drug|Dasatinib|Oral Dasatinib Days 8 through 64.
45339350|NCT04085354|Drug|Multi-Vitamin Tablets|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse.
45598855|NCT03503669|Behavioral|Memory Training|Participants will attend a weekly memory training class for 12 weeks as well as receive daily memory homework (12 minute duration) for the 12 weeks.
45598856|NCT03503669|Behavioral|Kundalini yoga and meditation|Participants will participate in a 60 minute yoga and meditation session weekly for 12 weeks and will be assigned a daily Kirtan Kriya meditation (12 minute duration) for 12 weeks.
46034148|NCT00882583|Drug|Cisplatin|Q 3 weeks (Days 15, 36 and 57): +/- 3 Days
46034149|NCT00882583|Radiation|Radiation Therapy|Standard Radiation Therapy.
46034150|NCT00656149|Procedure|Telerehabilitation of hand function|6 weeks, 1 hr/day FES-assisted exercise therapy on a workstation, supervised over the Internet.
46034151|NCT00656149|Procedure|Conventional exercise therapy|For one hour per day subjects perform range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 min).
46034152|NCT00900562|Drug|Zalypsis ( PM00104)|Zalypsis (PM00104) (2.5 mg/vial) is provided as a powder for concentrate for solution for infusion
46034153|NCT02634775|Other|Change in treatment strategy|Start on dialysis, transplantation, change of PD prescription, change of HD prescription
46034154|NCT02636959|Other|saline irrigation|HVSI (NeilMed® Sinus Rinse™) versus LVSI (Salinex®) in the early post-operative management in patients with chronic rhinosinusitis. Both are a saline rinse spray.
45339351|NCT04085354|Drug|Dapoxetine|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 2 was given on-demand 30 mg dapoxetine 1-2 h before intercourse.
45339352|NCT04085354|Drug|Dapoxetine and folic acid.|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
45339353|NCT04085354|Drug|Dapoxetine and vitamin B12|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse. Group 4 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg vitamin B12
45339354|NCT00719810|Drug|delafloxacin|300 mg intravenous every 12 hours
45339355|NCT00719810|Drug|delafloxacin|450 mg intravenous every 12 hours
46034155|NCT04510480|Other|Observational study without specific intervention|Observational study with standard cardiac arrest approach
45339356|NCT00719810|Drug|tigecycline|100 mg then 50 mg intravenous tigecycline every 12 hours
45339357|NCT02591498|Behavioral|Computerized cognitive training|
45472761|NCT01164683|Behavioral|Peer-driven intervention|Trained peers with sleep apnea will be paired with the newly diagnosed patients over a 3-month period. During this time the trained peers will share experiences on coping strategies with CPAP device and equipment (promote self efficacy), share their positive experiences (motivational effects and outcome expectancies), share their knowledge of perceived vulnerabilities due to untreated sleep apnea (promote risk perception), share methods for improving efficacy of CPAP equipment and interface (patient education) and prepare their subjects for upcoming physician or respiratory therapist appointments (patient activation).
45598857|NCT02353533|Device|over- the- scope full- thickness resection device (FTRD)|Endoscopic resection of adenomatous lesions of the colon using the over- the- scope full- thickness resection device
45598858|NCT02353533|Device|EMR|Standard endoscopic mucosal resection using a resection snare
46034156|NCT04488094|Drug|[18F]FSPG|A radioactive dose of 200 MBq of the study drug with a total quantity of ≤ 100 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 60-75 min after the administration of [18F]FSPG.
46034157|NCT02634619|Procedure|Ventral buccal mucosa onlay urethroplasty|Ventral buccal graft onlay involves a midline perineal incision and retraction of the bulbospongiosum muscle downward to expose the ventral urethral surface. The corpus spongiosum is incised longitudinally to expose the urethral lumen and the incision is extended proximal and distal to the established stricture. The buccal mucosa graft is harvested and trimmed to the length and width of the urethrotomy and the graft is sutured at the proximal and distal apices and a running suture at the lateral margins to establish a tight anastomosis. Ventral placement allows for limited urethral mobilization and easy access, but there is concern about higher likelihood of diverticulum formation and development of other associated complications - such as post void dribbling and ejaculatory dysfunction.
45598859|NCT02296723|Drug|Valganciclovir Hydrochloride|Valganciclovir Hydrochloride Tablets 450 mg
45339358|NCT00719732|Device|ReSTOR|Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
45339359|NCT02590718|Procedure|optimized postoperative management|lying without the pillow for half an hour after lumbar puncture
45339360|NCT00723710|Biological|Intron A (interferon alfa-2b; SCH 30500)|The recommended regimen includes an induction treatment of 5 consecutive days per week for 4 weeks as a 20-minute intravenous (iv) infusion at a dose of 20 million international units per square meter (MIU/m^2). The induction treatment should be followed by a maintenance treatment of 3 times per week for 48 weeks as a subcutaneous (sc) injection at a dose of 10 MIU/m^2. Therapy should be administered for a total of one year unless the disease progresses or the treatment has lead to recurrent unmanageable serious adverse effects.
45339361|NCT04085198|Procedure|Light physics enhanced 'no-touch' hysteroscopy|The light source used in hysteroscopy provides an illumined environment during the imagination with these techniques. During hysteroscopy, the light reflecting from the adjacent tissue appears bright, however, this reflection is weaker in farther tissue and these structures appear dark. This information will be used in determining the route from the vaginal introitus to the uterine cavity during the hysteroscopy.
45839720|NCT02978040|Drug|Tirofiban|Tirofiban will be administrated as 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance < 60 ml/min); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight < 60 kg or age > 75 years old) .
46034158|NCT02634619|Procedure|Dorsal buccal mucosa onlay urethroplasty|Dorsal buccal onlay also involves a midline perineal incision. The bulbo-cavernosum and corpora cavernosum are dissected from the bulbar urethra allowing for complete mobilization of the urethra. The urethra is rotated 180 degrees to allow for dorsal access and an incision is made on the dorsal urethra proximal and distal to the stricture location. The buccal graft is harvested and trimmed to the appropriate size of the urethrotomy and spread on the overlying tunica albuginea of the corporal bodies. The urethra is rotated back to allow for suturing of the left mucosal margin to the left margin of the buccal graft and corporal bodies, essentially covering the entire urethral plate. Dorsal placement has potential for a more stable vascular bed for graft sustainability and less spongiosal bleeding, but requires a greater urethral mobilization and longer operative times.
45839721|NCT02978040|Drug|Prasugrel|In the prasugrel arm no intravenous anti-platelet drug will be administered. Patients will be randomized to oral integer prasugrel or chewed oral prasugrel at an identical loading dose of 60 mg, then 10 mg daily (5 mg daily if body weight < 60 kg or age > 75 years old).
45839722|NCT02977416|Other|anti-TNFα|
46034159|NCT04481308|Drug|propofol (2 mg/kg) and fentanyl (1ug/kg) and 4 liters O2 flow through nasal cannula|propofol (2 mg/kg) and fentanyl (1ug/kg) and 4 liters O2 flow through nasal cannula
45839723|NCT02977728|Other|Olfactory Evaluation|The investigators will evaluate the olfactory system of all participants by the use of the Sniffin'Sticks batterie
45839724|NCT02987634|Other|PeriActive|mouthwash
45839725|NCT02977650|Procedure|Endoscopic ultrasonography-guided fine needle aspiration|
45839726|NCT02977338|Other|Retrospective review|
45839727|NCT02977104|Other|Maestro ECG|Telemetry is obtained through the Maestro handheld ECG device.
46034160|NCT02634541|Drug|Adalimumab|Biologic drug
46034161|NCT02634541|Other|PET/CT imaging|PET/CT imaging
46034162|NCT04475848|Drug|RO6953958|"Part 1: RO6953958 will be administered in an adaptive manner. The starting dose is planned to be 5 milligrams (mg).~Part 2: The starting dose is planned to be 45 mg.~Part 3: RO6953958 will be administered QD following a standardized breakfast on Day 3 to Day 14 at the maximum dose QD that was tested in the ongoing Part 2 (MAD)."
46034163|NCT04475848|Drug|Placebo|"Part 1: A placebo will be administered in an adaptive manner. The starting dose is planned to be 5 mg.~Part 2: The starting dose is planned to be 45 mg."
46034164|NCT04475848|Drug|Midazolam|Midazolam will be administered as single intervenous (IV) bolus injection of 100 micrograms (ug) on Day 1 and Day 13, and as single oral dose of 300 ug on Day 2 and Day 14.
46034165|NCT04653142|Drug|BI 765063|BI 765063
45683173|NCT05688202|Procedure|Subcision|Subcision is operated in all participants using an 1812G Nokor needle (BD Nokor™ Admix Needles, Becton, Dickinson and Company, New Jersey, United States). The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine. After obtaining appropriate anesthesia, a Nokor needle is inserted into the skin close to the depressed scars and progressed until it lays precisely under the scar. The insertion depth is at the dermal-hypodermal junction. Initially, the subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue. Once the fibrous mass has been sufficiently fractured, the needle is slid in a direction parallel to the skin's surface in order to detach the scar from its tethers. For densely fibrous scars, several needle insertion sites are used to undermine the defect from various angles.
46034166|NCT04653142|Drug|BI 754091|BI 754091
45839728|NCT02977182|Other|Complete Decongestive Therapy (CDT)|CDT is a multimodal therapy consisting of four components: manual lymph drainage, compression wrapping, exercise, and skin care
46034167|NCT00599521|Drug|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
46034168|NCT00599521|Drug|Adapalene Lotion Vehicle|Vehicle will be applied topically to the face, once a day, for 12 weeks
46034169|NCT04651582|Behavioral|Cognitive Training|20 hours of computerized activities designed to improve processing speed and divided attention
46034170|NCT04651582|Behavioral|Cognitive Stimulating Activities|20 hours of traditional computer games
46034171|NCT04201678|Procedure|CLIA Group (conventional local anesthesia infiltration)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the CLIA group, the needle (50 mm 22 Gauge) was directed towards the laminar periosteum at the pedicular projection point at the 10-15 ° angle with the sagittal plane. A mixture of 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be applied bilaterally."
45839729|NCT02977260|Other|Thin/Low Energy|Thin textured rice meal (ground rice grains) with lower energy density (0.57 kcal/g)
45683174|NCT05688202|Drug|Lidocaine/Prilocaine 2.5%-2.5% Topical Application Cream|Preoperative, lidocaine 2.5% and prilocaine 2.5% cream (EMLA 5%, eutectic mixture of local anesthetic; AstraZeneca LP, Wilmington, DE, USA) is applied under occlusion for 60 minutes prior to the removal of local anesthetics
45683175|NCT05688202|Drug|Paracetamol|A 500 mg paracetamol-based oral analgesic (Efferalgan, Upsa SAS, France) is administered right before the procedure.
45839730|NCT02977260|Other|Thin/High Energy|Thin textured rice meal (ground rice grains) with higher energy density (1.01 kcal/g)
46034172|NCT04201678|Procedure|EPIAA Group (Extrapedicular infiltration anesthesia)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~The anesthesia process of the CLIA + EPIA group also includes the third step called EPIA. For this stage, the anesthetic needle (50 mm 22 Gauge) is first drawn into the subcutaneous tissue, then through the lateral superior articular process to the lateral half of the pedicle and the upper border of the transverse process (5-10 degrees with sagittal plane and 5-10 with coronal plane), and after negative aspiration 3 mL 2% Lidocaine Hydrochloride and 7 mL 0.5% bupivacaine mixture will be applied bilaterally"
45683176|NCT05688202|Drug|Lidocaine 2% Injectable Solution|The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine.
45683177|NCT05424172|Behavioral|Stage-I, Group 1: Self monitoring using Non-interactive App|Participants in Group 1 will have minimal features that affect compliance (notifications, rewards, EMA, etc.) and no modifications to their exercise program after initial prescription.
45839731|NCT02977260|Other|Thick/Low Energy|Thicker textured rice meal (whole rice grains) with lower energy density (0.57 kcal/g)
45839732|NCT02977260|Other|Thick/High Energy|Thicker textured rice meal (whole rice grains) and high energy density (1.01 kcal/g)
45839733|NCT02976870|Radiation|Ultrasound|Single ultrasound scan of kidney on side of body where ALIF was performed. If hydronephrosis of this kidney is detected, the second kidney will also be scanned.
45839734|NCT02977026|Behavioral|CYD|
45839735|NCT02977026|Behavioral|AHC|
45839736|NCT02976558|Behavioral|Clown theatrical Performance|
45839737|NCT02976558|Procedure|Acupuncture|Acupuncture according to Traditional Chinese Medicine
45839738|NCT02976558|Behavioral|Music Therapy TaKeTiNa|
45839739|NCT02976324|Device|external diaphragmatic pacemaker group|9 counts per minute, with stimulate frequency 40 Hz
45839740|NCT02976402|Radiation|SBRT|"Postoperative RT consisting in:~31 Gy in 5 sessions each of 6.2 Gy (adjuvant intent) delivered in one week~32.5 Gy in 5 sessions each of 6.5 Gy (salvage intent) delivered in one week"
45839741|NCT02976168|Other|12° head down tilt|supine head down tilt
45839742|NCT02976246|Dietary Supplement|Vitamin K2 (MK7)|One tablet of vitamin K2 (MK7) 360 micrograms given once daily.
45839743|NCT02976246|Other|Placebo|One tablet of placebo given once daily.
45839744|NCT02976480|Procedure|Irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair and perform the irrigation. Irrigation will be delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. The volume of normal saline used will be calculated as 60 millilitre per centimetre length of laceration for a maximum of 300 millilitre. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
45839745|NCT02976480|Procedure|No irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair. The laceration will not directly be irrigated. In order to ensure blinding of the subjects, the surrounding of the wound will be irrigated with a total of 60 millilitre of normal saline delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. Care will be taken not to enter a margin of 5cm from the laceration edges. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
46034173|NCT04201678|Procedure|ESP Group (Erector Spina Block)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the ESP group, a high-frequency-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally at the point of application. Once the erector spinae muscle and transverse process have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane was opened. Bilateral 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be administered."
46034174|NCT00653341|Drug|insulin glargine|
46034175|NCT00653341|Drug|NPH human insulin|
45339362|NCT04085198|Procedure|Standard hysteroscopy|Anatomical structures as illumined by the light source of the camera will be used to find the route from the vaginal introitus to the uterine cavity
45839746|NCT02975856|Dietary Supplement|Table Red Wine|
45839747|NCT02975856|Dietary Supplement|Young Port Red Wine|
45839748|NCT02976012|Drug|Aflibercept|. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) <21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.
45339363|NCT02590796|Other|No intervention given to participants|This is an observational study. Participants will receive no intervention.
45339364|NCT00688545|Drug|Celecoxib|Non-interventional: Treatment assignment as per treating physician's judgement
45339365|NCT00688545|Drug|nsNSAIDs|Non-interventional: Treatment assignment as per treating physician's judgement
45339366|NCT02563275|Other|motion analysis system|
45339367|NCT02563275|Other|parabolic flight|
45339368|NCT04060407|Drug|CD24Fc|CD24Fc will be administrated as IV infusion in a dose of 480 mg, q3w x 4, then q4w for up to 6 times.
45339369|NCT04060407|Drug|Ipilimumab|Ipilimumab will be administrated as IV infusion, q3w x 4. For metastatic melanoma, the dose will be 3mg/kg, q3w x4.
45339370|NCT04060407|Drug|Nivolumab|Nivolumab will be administrated as IV infusion. For metastatic melanoma, the dose will be 1mg/kg, q3w x 4, then 480 mg, q4w for up to 1 year.
45339371|NCT00741585|Drug|Any antihypertensive medication alone or in combination|All drugs on awakening
45839749|NCT02976012|Procedure|Endolaserless Vitrectomy|Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage
45839750|NCT02975778|Device|Pain Monitor™|Pain measured by Pain Monitor™
45839751|NCT02975388|Drug|RO7079901|Participants will receive a single dose of 1000 milligrams (mg) RO7079901 as a 30-minute intravenous (IV) infusion.
45339372|NCT00741585|Drug|Any antihypertensive medication alone or in combination|One or more drugs at bedtime
45339373|NCT00741585|Device|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours
45339374|NCT00746967|Drug|sildenafil|sildenafil 50 mg (starting dose) tablet by mouth taken as needed 1 hour before anticipated sexual activity; the dose could be increased to 100 mg or decreased to 25 mg; the duration of therapy in this open-label study was 52 weeks
45339375|NCT02563041|Drug|30% TSC|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
46034176|NCT03542812|Drug|L-Citrulline|The L-citrulline will be procured in powder form and will be solubilized in sterile water to achieve a concentration of 50 mg/ml. Therefore, 3 ml/kg of the solubilized L-citrulline (50 mg/ml) will be administered per dose for the single-dose groups and the dose administered to the steady-state group will be determined from results from the single-dose studies.
45339376|NCT02563041|Drug|Heparin|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
45339377|NCT00741663|Drug|Spironolactone and furosemide|Patients in arm A will receive potassium canrenoate at the initial dose of 200 mg/day, then increased up to 400 mg/day. Non responders will be treated with 400 mg/day of potassium canrenoate and furosemide at an initial dose of 50 mg/day, then increased up to 150 mg/day.
46034177|NCT02642263|Drug|Carbetocin|Postpartum uterotonic drug
46034178|NCT02637115|Dietary Supplement|Placebo|Consumption of one dose-sachet per day. This dose-sachet contains a placebo (PBS/Glycerol)
46034179|NCT02637115|Dietary Supplement|Live Akk 9|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (one billion per dose-sachet)
46034180|NCT02637115|Dietary Supplement|Live Akk 10|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (ten billion per dose-sachet)
46034181|NCT02637115|Dietary Supplement|Killed Akk|Consumption of one dose-sachet per day. This dose-sachet contains heat-killed Akkermansia muciniphila
45339378|NCT00741663|Drug|Spironolactone and furosemide|Patients in arm B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.
45339379|NCT00745017|Behavioral|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
45339380|NCT00745017|Behavioral|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
45839752|NCT02975466|Device|Insertion of AirQ Blocker and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
45839753|NCT02975466|Device|Insertion of AuraGain and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
45598860|NCT03496571|Drug|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
46034182|NCT00779740|Drug|mometasone furoate|The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
46034183|NCT00779740|Drug|mometasone furoate|The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
46034184|NCT00656227|Drug|Avotermin|Comparison of different dose levels (20ng, 50ng, 100ng or 200ng/100 ul) versus placebo
46034185|NCT02636803|Drug|oxfendazole|group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses
46034186|NCT02636803|Drug|albendazole|group receives one 400 mg dose of albendazole
46034187|NCT02535871|Drug|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
46034188|NCT02535871|Drug|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
46034189|NCT02634385|Procedure|Renal Artery Embolization|Patients will be receiving embolization prior to planned partial nephrectomy.
45839754|NCT02975466|Device|Insertion of I-Gel and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
46034190|NCT02634385|Procedure|Partial Nephrectomy (Surgical Resection)|Patients will be undergoing planned partial nephrectomy post embolization.
46034191|NCT02634463|Drug|Aripiprazole|No study agent will be administered as a part of this study. Participants must be on Aripiprazole 5 milligram (mg) (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (300-400 mg once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for development of antipsychotic immunoassays.
46034192|NCT02634463|Other|Olanzapine|No study agent will be administered as a part of this study. Participants must be on Olanzapine 5 mg (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (150-405 mg once every 2-4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
45839755|NCT02975622|Procedure|Central venous catheterization|Ultrasound guided central venous catheterization
45839756|NCT02975544|Behavioral|CRECES programme|The first unit of CRECES programme was implemented in 8 sessions. Each session was 40-50 minutes long and delivered during four weeks. Parents were provided with home-extension activities.
46034193|NCT02634463|Drug|Paliperidone|No study agent will be administered as a part of this study. Participants must be on Paliperidone 3 mg (minimum dose) to 12 mg (maximum dose), orally, daily or long-acting injectable versions (25-150 mg equivalent [eq.] once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
46034194|NCT02634463|Drug|Risperidone|No study agent will be administered as a part of this study. Participants must be on Risperidone 1 mg (minimum dose) to 8 mg (maximum dose), orally, daily or long-acting injectable versions (12.5-50 mg once every 2 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
46034195|NCT02535403|Behavioral|ICBT|
46034196|NCT00882115|Drug|Broccoli sprout extract (BSE)|BSE will be ingested by drinking a liquid formula containing 1.25 g BSE in a volume equaling 1 cup daily for 4 consecutive days in the BSE intervention phase.
46034197|NCT00881959|Device|Puros® Dermis versus Alloderm®|Puros Dermis and Alloderm (both Allograft Tissue Matrix)
45598861|NCT03496571|Other|Placebo|Placebo
46034198|NCT00653419|Drug|buspirone HCl|Tablets, 30 mg, single-dose
46034199|NCT00653419|Drug|Buspar|Tablets, 30 mg, single-dose
46034200|NCT00884377|Drug|Sodium stibogluconate (Pentostam)|intravenous 20 mg/kg/day for 10 days
46034201|NCT00884377|Device|ThermoMed|ThermoMed heat treatment device, one treatment
46034202|NCT00656929|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol) 50 mcg (2000 IU) daily x 3 months
46034203|NCT00656929|Other|Placebo|Placebo tablets
46034204|NCT00656383|Other|Clients randomized to nurse-led clinic|Clients receive leg ulcer care in a nurse-led clinic; both groups are treated by the same health care providers using the same protocol
45839757|NCT02975076|Drug|Sanchitongshu|The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.
46034205|NCT00656383|Other|Clients receive leg ulcer care in their homes|Clients receive leg ulcer care in at home; both groups are treated by the same health care providers using the same protocol
46034206|NCT04161937|Behavioral|Behavioural Intervention|Behavior intervention will comprise of combination of intensive education session, group counseling, goal setting and monitoring based on the Diabetes Prevention Program (DPP).The curriculum includes 24 sessions: 16 core sessions weekly during the first four months of the program followed by a monthly maintenance sessions.
46034207|NCT00884221|Drug|Highly purified menotrophin|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
45339381|NCT00745017|Drug|Antidepressant medication|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
46034208|NCT00884221|Drug|Recombinant FSH|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
45339382|NCT00688467|Drug|Navarixin|30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
46034209|NCT02634229|Genetic|blood sample|
46034210|NCT02153632|Drug|amantadine HCl ER|Subjects are given either 240 mg amantadine HCl ER tablet or 320 mg amantadine HCl ER tablet
46034211|NCT02153632|Drug|Placebo|subjects are given an identical placebo tablet
45339383|NCT00688467|Drug|Placebo|Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
45339384|NCT00741741|Drug|TMC278|
45339385|NCT02562807|Drug|TAS-303 18mg single-dose|
45339386|NCT02562807|Drug|Placebo 18mg single-dose|
45339387|NCT02562807|Drug|TAS-303 9mg single-dose|
45339388|NCT02562807|Drug|Placebo 9mg single-dose|
45339389|NCT00745173|Drug|Premarin|
45839758|NCT02975076|Drug|placebo of Sanchitongshu|The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).
45339390|NCT00747045|Other|Ventilation Strategy|Comparison of low vs standard tidal volumes in patients undergoing PTE
45839759|NCT02975076|Drug|Aspirin|
45839760|NCT02975076|Drug|Clopidogrel|
45839761|NCT02975076|Drug|placebo of clopidogrel|
45839762|NCT02974998|Behavioral|Young Women's Health CoOp (YWHC)|Participants received HTC and engaged in a two-session gender-focused intervention. The intervention included information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal. The intervention also encouraged positive goal-seeking to access linkages to health care within the larger social ecological framework of where the young women live.
45339391|NCT04060095|Procedure|standardized noxious stimulus under general anesthesia.|"50 adult patients undergoing general anesthesia for any types of surgery and who have been chronically treated with β1-adrenergic antagonists for at least three months. .Induction of anesthesia will be standardized.~At least 10 min after the post-intubation decrease of the remifentanil infusion rate, the OR team will stop any physical contact/stimulation of the patient allowing at least 3-minutes.~At this point, the standardized electrical (tetanic) stimulation will be applied on the area of the ulnar nerve at the wrist level, at a frequency of 100 Hz and a current of 70 mA for a duration of 30 seconds, followed by 3 minutes of observation period without any other stimulation of the patient by the anesthesia or the surgical team. At the end of the observation period, the study is discontinued and the anesthesia will be conducted at the discretion of the anesthesiologist in charge of the patient."
46034212|NCT01934452|Drug|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
45339392|NCT02562885|Device|Acoustic pulses|"Acoustic pulses applied during NREM sleep slow waves Up-phase or Down-phase. The acoustic stimulus will be delivered by speakers with a volume of about 50 dB."
45339393|NCT00745329|Other|sperm quality test|All participants will undergo sequential sperm quality tests and blood tests
45339394|NCT00741897|Drug|Fexofenadine|Fexofenadine: One 30 mg Tablet once daily for two weeks
45839763|NCT02974998|Behavioral|Standard HTC|Participants received the standard HTC available in South Africa for this population.
45839764|NCT02975232|Behavioral|F&V economic incentive|50% off eligible fresh, frozen and canned fruits and vegetables (up to $10/day)
46034213|NCT01934452|Drug|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
46034214|NCT03524326|Drug|Lenvatinib Pill|24 mg oral daily
46034215|NCT03524326|Drug|Lenvatinib Pill|20 mg oral daily
46034216|NCT03524326|Drug|Lenvatinib Pill|14 mg oral daily
46034217|NCT03524326|Drug|Cetuximab|400mg/m2 IV, then 500mg/m2 IV weekly
45839765|NCT02975232|Behavioral|Cooking Matters Store Tour|Participants will be asked to attend one Coking Matters store tour during January or February 2017
46034218|NCT03524326|Drug|Lenvatinib Pill|10 mg oral daily
46034219|NCT03524326|Drug|Lenvatinib Pill|4 mg oral daily
46034220|NCT01236430|Drug|Ezetimibe|Ezetimibe 10mg tablet given orally after an overnight fast (at least 10 hours).
46034221|NCT01236430|Drug|Ezetimibe/atorvastatin 10mg/10mg FDC|Ezetimibe/atorvastatin 10mg/10mg FDC tablet given orally after an overnight fast (at least 10 hours).
46034222|NCT01236430|Drug|Atorvastatin 10mg|Atorvastatin 10mg given orally after an overnight fast (at least 10 hours).
46034223|NCT01236430|Drug|Atorvastatin 80mg|Atorvastatin 80mg tablet given orally after an overnight fast (at least 10 hours).
46034224|NCT01236430|Drug|Ezetimibe/atorvastatin 10mg/80mg FDC|Ezetimibe/atorvastatin 10mg/80mg FDC tablet given orally after an overnight fast (at least 10 hours).
45339395|NCT00688155|Behavioral|Physical Activity Training|Two 1-hour center and two 15- to 45-minute home-based training sessions per week to include aerobic, strength, flexibility, and balance training for 6 months. The ultimate goal is to accumulate 150 minutes of walking per week between center and home-based sessions.
45339396|NCT00688155|Behavioral|Cognitive Training|Two 1-hour sessions per week for the first two months and then one 1-hour session per week for months 3-6.
45339397|NCT00688155|Behavioral|Healthy Aging Education|One 1-hour lecture each week for 3 months, then monthly.
46034225|NCT00726856|Drug|Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate|Ezetimibe 10 mg taken daily for 3 months
46034226|NCT00651274|Drug|Ezetimibe|oral tablets: ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
46034227|NCT00651274|Drug|Placebo|oral tablets: placebo to match ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
46034228|NCT05335330|Other|Evaluation of biomechanics and viscoelastic properties of Thoracolumbar fascia|The biomechanical and viscoelastic properties of the Thoracolumbar fascia will be measured in the prone position. Measurements will be taken from three different points.
46034229|NCT04608448|Drug|Rapamycin Topical Ointment|8% topical rapamycin ointment
46034230|NCT04608448|Other|Placebo|Petrolatum ointment containing no active ingredient
46034231|NCT05335798|Device|Bodyweight augment system|Motorized cables will be providing downward force on the participant's pelvis
46034232|NCT05335798|Device|Smart insole|Insole provided auditory feedback when heel strike or toe-off events happen
46034233|NCT00351988|Behavioral|Phenomenological Interviews|Part 1 will collect phenomenologic data to understand the meaning of caregiver burden, and the positive experiences faced when caring for a underserved patient with advanced lung cancer.
46034234|NCT00351988|Behavioral|Quantitative Interviews|Part 2 will collect quantitative data to determine the prevalence and severity of symptoms experienced by caregivers and their contribution to caregiver burden.
45339398|NCT00741975|Behavioral|Affect Management|12-session group intervention including affect management training as well as sexual health skills training
46034235|NCT00212836|Drug|asenapine|5-10 mg sublingually twice daily for 26 weeks
46034236|NCT00212836|Drug|olanzapine|5-20 mg by mouth once daily for 26 weeks
46034237|NCT00805324|Drug|Desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
46034238|NCT00157924|Drug|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg.
46034239|NCT00157924|Drug|atorvastatin|atorvastatin 10mg
46034240|NCT05335642|Procedure|EVAR|Endovascular repair of abdominal aortic aneurysms
46034241|NCT00794794|Drug|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
46034242|NCT00794794|Drug|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
46034243|NCT03612466|Drug|153Sm-DOTMP|For Levels 1- 3, the Day 1 dosages will be the same (0.5 millicurie (mCi)/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 0.5, 1.0 and 3.0 mCi/kg respectively. For Levels 4, 5 & 6, the Day 1 dosages will be the same (0.5 mCi/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 3, 6, then 10 mCi/kg 153Sm-DOTMP respectively.
45472762|NCT01164683|Other|Usual Care|All participants will receive usual care following initiation of CPAP therapy. Visits with respiratory therapist and sleep physician wherein patients are educated about the basics of the care and operation of the device, mask and related equipment. Subsequently, their CPAP adherence is monitored and appropriate interventions such as mask change and re-education undertaken as needed.
46034244|NCT03612466|Radiation|External beam radiotherapy.|The amount of radiation will be determined based on how much radiation was delivered to each tumor by the 153Sm-DOTMP, and will be targeted to 70 Gray (Gy)
46034245|NCT03612466|Drug|Calcium Carbonate|Calcium carbonate will be given to participants as prophylaxis against hypocalcemia..
46034246|NCT03612466|Drug|Mozobil|Participants who require stem cell collection will be given Mozobil to help mobilize hematopoietic stem cells into the circulation for collection.
45339399|NCT00741975|Behavioral|General Health Promotion|12-session group intervention including health information on a variety of developmentally relevant health topics
46034247|NCT03612466|Drug|Neupogen Injectable Product|Participants who require stem cell collection will be given Neupogen to help mobilize hematopoietic stem cells into the circulation for collection.
45339400|NCT00745407|Drug|fenofibrate|
45339401|NCT00745485|Drug|zoledronic acid|
45339402|NCT02562729|Procedure|Nerve-Sparing Radical Hysterectomy|Type C1 NSRH Removal indwelling catheter on day 4 after surgery
45339403|NCT00745563|Device|Fertiligent|Fertility treatment by using the EVIE - Slow Release Insemination method
45472763|NCT04079803|Drug|Placebo oral tablet|Oral placebo tablet
45472764|NCT04079803|Drug|Simufilam 100 mg tablet|Simufilam 100 mg oral tablet
45472765|NCT04079803|Drug|Simufilam 50 mg oral tablet|Simufilam 50 mg oral tablet
45472766|NCT00894244|Device|Radiofrequency device|One treatment pass on one arm. 2-5 treatment passes on the other
46034248|NCT00142558|Drug|MK0663; etoricoxib / Duration of Treatment: 5 Days|
46034249|NCT00142558|Drug|Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days|
46034250|NCT02842606|Other|Test meal|The two test meals are designed to have the same energy and macronutrient composition. They differ only in the carbohydrate source: fiber-enriched pasta or control pasta. Blood samples are taken at fasting and every 30 minutes over 4 hours. Fasting and postprandial intestinal fermentation is evaluated by breath test.
45839766|NCT02975154|Device|Microcurrent therapy|The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
45839767|NCT02974920|Drug|Rivaroxaban 10 MG|Rivaroxaban 10 mg once daily for 180 days
46034251|NCT02842684|Device|TraumaCad software|restitution of anatomical- radiological parameters after total hip arthroplasty with TraumaCad , conventional planning systems and without planning.
46034252|NCT00899548|Genetic|DNA methylation analysis|laboratory analysis
45839768|NCT02974920|Drug|Aspirin|Aspirin 100 mg once daily for 180 days
45839769|NCT02974764|Other|No intervention/exposures|
45839770|NCT02974530|Other|Neurological evaluation|
45839771|NCT02974530|Other|Laryngological evaluation|
46034253|NCT00899548|Genetic|microarray analysis|laboratory analysis
46034254|NCT00899548|Genetic|polymerase chain reaction|laboratory analysis
46034255|NCT00899548|Other|laboratory biomarker analysis|laboratory analysis
46034256|NCT04201366|Other|No intervention|No intervention
46034257|NCT02690818|Behavioral|Regularly scheduled LTBI medication reminder text messages|"Regularly scheduled medication reminder text messages Daily LTBI text messages without the option to text back. The messages will read, This is a reminder to take your medication."
45839772|NCT02974530|Other|MRI evaluation|
45839773|NCT02974530|Other|Breathing investigation|
45839774|NCT02974530|Other|MRI and articulatory investigation|
45839775|NCT02974530|Other|Postural investigation|
45839776|NCT02974530|Other|Voice and soundscape investigation|
45839777|NCT02974374|Drug|PF-06835919|Single or repeated, escalating dose
45839778|NCT02974374|Other|Placebo|Single or repeated, escalating dose
45839779|NCT02974062|Other|Lumbar stabilization exercise|Participants were trained using lumbar stabilization exercise based on their initial lumbar stability level. They were received a 30-minute exercise for 1 session in this study.
46034258|NCT02842528|Behavioral|Diagnostic Interview for Genetic Studies|
46034259|NCT02842528|Behavioral|Family Informant Schedule and Criteria|
46034260|NCT02842528|Behavioral|Temperament and Character Inventory|
46034261|NCT02842528|Behavioral|Barratt Impulsiveness Scale|
45839780|NCT02973906|Other|ADAPT Self Directed web|In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum
46034262|NCT02842528|Behavioral|Wisconsin Card Sorting Test|
46034263|NCT02842528|Genetic|blood sample withdrawn|
45472767|NCT03278613|Device|ES-130|"The ES-130 device will be used for the indication of Posterior Tibial Nerve Stimulation for the treatment of fecal incontinence using the FDA-approved protocol for treatment of urge urinary incontinence (UUI) in the PFDN NOTABLe study. There is no PTNS device cleared by the FDA for the indication of FI treatment; therefore, this is considered an investigational device."
46034264|NCT04201522|Other|Normocapnic hyperpnoea intervention|Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at 60% of the peak of minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).
46034265|NCT04201522|Other|Sham intervention|Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at rest's minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).
46034266|NCT02842450|Device|Photos + definitions|A broad group of experts (19 proctology and a dermatologist) will be contacted to choose two typical images of LAP (superficial ulceration, deep ulceration ...). 12 photos lesion initially selected by experts.
45339404|NCT00742131|Drug|GSK1363089|GSK1363089 will be administered orally as a cinnamon-flavored liquid (250 milligrams of GSK1363089 in 50 milliliters liquid [5 milligrams/milliliter] or 1000 milligrams of GSK1363089 in 50 milliliters liquid [20 milligrams/milliliter]) or as solid capsules of 20, 100, and/or 200 milligrams.
45839781|NCT02973906|Other|ADAPT individualized web-facilitated|This condition comprises access to the full ADAPT web program as described above, with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).
45839782|NCT02973906|Other|Group-based ADAPT|Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics:
46034267|NCT02842450|Other|definitions only|
45339405|NCT00747201|Behavioral|Replicating Effective Programs Framework for the Bipolar Care Model|Health care providers will receive adapted manuals, training, and technical assistance in the bipolar care model.
45339406|NCT00747201|Behavioral|Bipolar Care Model Package Only|Health care providers will receive only the adapted manuals.
45339407|NCT03884283|Device|FIBERGRAFT BG Matrix|Subjects who meet the criteria for entrance into the study will undergo posterolateral fusion using FIBERGRAFT® BG Matrix in combination with autograft and bone marrow aspirate (BMA)
45339408|NCT02563509|Biological|HIV-specific CD8 cells|Based on HAART, receive HIV-specific CD8 cells transfuion.
45339409|NCT00747279|Other|Carbohydrate restrictive strategy|Patients will receive intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16.7% proteins and 50% lipids. These patients will receive regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and in stable patients, ideally below 150 mg/dl.
45472768|NCT03761147|Other|Paula exercises|structured exercises aimed to stimulate ring muscles
45472769|NCT03389152|Device|Elastography|liver stiffness measurements by shear wave-based elastography
45472770|NCT00560716|Drug|CYC116|Dose escalation of CYC116
45472771|NCT03909659|Behavioral|Dietary sodium reduction|A supply of a reduced-sodium added-potassium salt substitute
45839783|NCT02973672|Drug|SGM-101|4 days before surgery, SGM-101 will be administered to the patient by intravenous injections.
46034268|NCT02844088|Other|Meningococcus C conjugate vaccine|
46034269|NCT00899392|Other|Emmi Pediatric Upper Endoscopy Patient Education Module|Emmi Pediatric Upper Endoscopy Patient Education Module as designed by EMMI SOLUTIONS, LLC
46034270|NCT02842294|Drug|Bevacizumab|
45472772|NCT03380650|Device|directional atherectomy and locol drug delivery|combined use of directional atherectomy and locol drug delivery for the treatment of femoralpopliteal disease
45472773|NCT03380650|Device|drug-coated balloon dilation|use of drug-coated balloon dilation for the treatment of femoralpopliteal disease
45472774|NCT01164761|Drug|Ramipril|Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
45472775|NCT01164761|Drug|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
46034271|NCT05334862|Procedure|8 plate hemiepiphysiodesis|surgical procedure by lateral incision in proximal tibia and fixation by usuing 8 plate and screws.
46034272|NCT01176604|Radiation|Yttrium Y 90 Glass Microspheres|Given via catheter
46034273|NCT03240406|Other|Multicultural Healthy Diet|An anti-inflammatory dietary pattern consists of a dietary pattern that has high anti-inflammatory potential
46034274|NCT03240406|Other|Usual Diet plus Self-Care|Usual diet plus sessions that focus on self-care such as dealing with aches and pains of aging.
46034275|NCT02843932|Other|functional brain MRI|functional imagery during motor-perception tasks
46034276|NCT02844010|Other|weighing|
46034277|NCT02842138|Biological|autologous anti-CD19 CAR T cells|Patients will receive a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes. Four days after lymphodepletion, patients are intravenously infused autologous anti-CD19 CAR T cells. A prescribed CAR T cell dose will be intravenously infused to patient in a three-day split-dose regimen (day0,30%; day1, 30%; day2, 40%).
46034278|NCT02844244|Behavioral|training group|The training workshop included two two-hour sessions. It focused on the enhancement of knowledge, attitude, and practice of peer health promoters on implementing community activities for the residents.
46034279|NCT02841982|Procedure|single-injection QLB(quadratus lumborum block)|Inject local anesthetics in between quadratus lumborum and psoas major without continuous local infusion
46034280|NCT02841982|Device|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
46034281|NCT02841982|Device|PAJUNK StimuLong|
46034282|NCT02841982|Drug|single dose ropivacaine|"0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline.~given immediately after the correct position of the tip of the needle has been verified."
46034283|NCT02841982|Drug|Morphine given as IPCA(intravenous patient controlled analgesia)|bolus: 1.5~2mg, lock time: 10min, 1h limitation: 6~8mg
46034284|NCT02841826|Other|IUD|
46034285|NCT02841826|Other|Uterine sounding|
45472776|NCT03748381|Procedure|Cataract surgery|During cataract surgery patients will be implanted with the AT Zeiss Lisa tri in one eye and the Rayner trifocal in the contralateral eye
45472777|NCT03385096|Drug|Busulfan (BU)|"Busulfan was administered at 3.2 mg/kg/day on days -8 to -6.~-7 to -4."
45839784|NCT02973360|Drug|Docosahexaenoic Acid|Oral Capsule
45839785|NCT02973360|Drug|Placebo|Oral Capsule
45839786|NCT02973282|Other|Recording of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease
45839787|NCT02973204|Drug|Sorafenib|
46034286|NCT02841826|Radiation|Transvaginal ultrasound|
46034287|NCT00633178|Behavioral|Group interpersonal therapy (IPT)|Group IPT will include weekly treatment sessions with a psychiatrist for 12 weeks. The sessions will focus on overcoming relationship problems associated with depression. The first two and last sessions will be alone with the psychiatrist and the remaining sessions will be with a group of five to eight other pregnant women.
46034288|NCT00633178|Behavioral|Treatment as usual (TAU)|TAU will include referrals to outpatient treatment, which may include cognitive behavioral psychotherapy, insight-oriented psychotherapy, and/or antidepressant medication. TAU participants receiving psychotherapy will attend 12 weekly treatment sessions comparable to the IPT group sessions; treatment for TAU participants receiving medication for their depression may last longer than 12 weeks.
45472778|NCT03385096|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -5 to -4. on days -3 to -2.
45839788|NCT02973204|Procedure|Radiofrequency ablation (RFA) or surgery|Intended curative surgery or RFA
45839789|NCT02973204|Drug|Everolimus|
45839790|NCT02973204|Drug|Lanreotide|Or other somatostatin analogues (SSTA), eg. Sandostatin
45839791|NCT02972970|Device|Aveera|Subjects will use the 3D crafted CPAP mask. All subjects will receive a mask to use
45839792|NCT02972736|Radiation|Radiation dose expressed as DAP|
45839793|NCT02972814|Device|Laboratory based troponin test|acquisition of blood troponin level by Roche Cobas E 603
45339410|NCT00747279|Drug|Intensive insulin therapy|Continuous intravenous regular insulin infusion will be adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 and 120 mg/dl. Patients will be submitted to capillary glycemic measurements every 2 hours. The insulin dose is adjusted according to an algorithm run by nurses and overseen by physicians. These patients will receive glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids.
45839794|NCT02972814|Device|Point of care based troponin test 1|acquisition of blood troponin level by Radiometer EQT 90 Flex
45839795|NCT02972814|Device|Point of care based troponin test 2|acquisition of blood troponin level by Philips Minicare I-20
46034289|NCT02841904|Device|Confocal LASER Endomicroscopy|Patients scheduled for bladder endoscopic surgery under general anesthesia are offered to be included in our study. The suspicious mucosal areas are marked then examined with CLE. Tissue samples are taken based on the usual standard criterias. The samples are evaluated microscopically and compared with the results of the CLE technique. A single surgeon performs all surgeries. Biopsies are anlysed by a pathologist from Herlev and Gentofte Hospital's Pathology Department, which is affiliated CLE- study.
46034290|NCT02841514|Device|The Y10 Tooth Whitening system including the Y10 toothpaste and the Y10 device|
45339411|NCT00747357|Device|Drug Eluting Balloon SeQuent Please|Drug Eluting Balloon is followed by Bare Metal Stent
45339412|NCT00747357|Device|Drug Eluting Balloon SeQuent Please|Bare Metal Stent followed by Drug Eluting Balloon
45339413|NCT00747513|Behavioral|lifestyle program|a comprehensive program designed to encourage healthier food choices and eating habits and increased physical activity among children, by use of school, family and community measures.
45839796|NCT02959476|Drug|Ropivacaine|Anesthetic
45839797|NCT02959476|Drug|Placebos|Inactive comparator
45839798|NCT02959398|Device|Standard mammography|Standard mammography
45839799|NCT02959398|Device|Standard mammography and tomosynthesis|Standard mammography and tomosynthesis
46034291|NCT02841514|Other|OTC toothpaste and an unoperated Y10 device|
46034292|NCT04533958|Device|HYPNO VR® device|"The HYPNO VR® device is a software application of medical hypnosis in the treatment of pain and anxiety. It is associated with equipment: a virtual reality headset and a headphone.~Before each Docetaxel infusion, the nursing staff offers patients the choices: visual universe, musical theme, male or female voice. The nursing staff selects the chemotherapy program, selects a duration of 20 minutes and presses start to start the medical hypnosis session in virtual reality.~After completing the hypnotic trance sequence, as in a classic session, the patient is brought back to the return and exit hypnosis phase under the supervision of the nursing staff."
46034293|NCT02841670|Device|InFo - Instant Focus (c) lens implantation|
46034294|NCT02841592|Other|Flush rate oxygen|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes.
46034295|NCT02841592|Other|Flush rate oxygen with assist|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes. Positive pressure breaths to match the subject's inspiration will be provided during the three minute period.
46034296|NCT02841436|Device|Irreversible Electroporation (IRE) System|
46034297|NCT02843776|Other|Questionnaires completion|
46034298|NCT02841358|Biological|Blood sampling|
46034299|NCT02841358|Biological|Biopsy|
46034300|NCT02843698|Drug|Dexmedetomidine|Dexmedetomidine infusion was previously reported to improve oxygenation and lung dynamics in patients with obstructive lung diseases. In our study we are going to investigate its effect on oxygenation and lung dynamics in restrictive lung disease
46034301|NCT02843698|Drug|Normal saline|Normal saline
46034302|NCT00690898|Drug|Lanreotide autogel 120 mg|12 months
45339414|NCT00745719|Procedure|parathyroidectomy|total parathyroidectomy with forearm autografting
45339415|NCT00745797|Radiation|Radiotherapy|blood transfusions, platelet transfusions, antibiotics, antipyretic analgesics and anesthetics
45839800|NCT02959008|Device|measure TOI and BP|Both groups measure TOI and BP.
46034303|NCT02841202|Drug|oral contraceptive pills|
46034304|NCT02841124|Other|interviews|face-to-face interviews with the referent oncologist (or hematologist) and his patient (conducted by a physician and a psychologist respectively) as well as interviews with other partners involved in the situation (care staff and relatives)
46034305|NCT00895414|Drug|doxorubicin hydrochloride|Given IV 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity.
46034306|NCT00895414|Drug|enalapril maleate|Given orally - Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2. OR Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
46034307|NCT02843464|Other|reported remote ischemic preconditioning (RIPC)|Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
46034308|NCT02840890|Procedure|osteopathic technique|Osteopathe will perform continuous pressure on the middle ribs in order to reduce the mechanical stress of the anatomical elements related to liver
46034309|NCT02840890|Procedure|Placebo|patients will have a relaxing osteopathic technique. A non therapeutic abdominal technique
46034310|NCT02843620|Dietary Supplement|b-2Cool|b-2Cool® is native type II collagen extracted from chicken sternums
46034311|NCT02843620|Other|Placebo|Excipients only
46034312|NCT05334394|Other|Mulligan Technique|Mulligan suggested that injuries or sprains can cause a minor positional error in a joint, thereby causing limitations in physiological movement. Unique to this concept is mobilization of the spine while weight bearing and directing the mobilization parallel to the spinal facet planes. Although it includes various mobilization techniques, one of the most important techniques, motion co-mobilization, is the SNAG's technique, which includes the application of accessory passive gliding to the lumbar vertebra while the patient performs active movement simultaneously.
46034313|NCT05334394|Other|Exercise Therapy|Exercise is recommended by physical therapists for most chronic low back pain patients.
46034314|NCT01822288|Drug|Tibolone|Tibolone 2.5 mg once a day for patients with menopausal syndrome (self-paid)
46034315|NCT01822288|Drug|Estradiol & medroxyprogesterone acetate|Estradiol & medroxyprogesterone acetate once a day for patients with menopausal syndromes, for patients without the need for self-paid drug
46034316|NCT02843542|Device|PET-MR|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo 18FCH PET/MRI for detecting adenomas and their location.
46034317|NCT02843542|Device|PET-CT|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo PET-CT for detecting adenomas and their location.
46034318|NCT02811952|Other|without intervention|without intervention
46034319|NCT02686606|Dietary Supplement|Vital 1.5|Oral nutritional supplement
46034320|NCT02686606|Dietary Supplement|Ensure Plus|Oral nutritional supplement
46034321|NCT01328626|Drug|ABT-199|Arm A (Cohorts 1-8) and Arm B (Cohort 1-6): Subjects in dose escalation phase will receive 1 dose of ABT-199, followed by 6 days off drug, followed by continuous once daily dosing with ABT-199. Arm B (Cohorts 7+): Subjects in dose escalation phase will receive continuous once daily dosing with ABT-199. Arm A and Arm B: Subjects in expanded safety cohort will receive continuous once daily dosing with ABT-199.
46034322|NCT02842918|Procedure|Spinal Manual Therapy|
46034323|NCT02842918|Procedure|Spinal Range of Motion|
46034324|NCT02840812|Drug|Nemonoxacin|Nemonoxacin Malate Capsules 500mg single dose oral
46034325|NCT01212770|Drug|Apremilast 20mg|Apremilast 20 mg twice daily, orally
45339416|NCT00742287|Dietary Supplement|oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs) per day over 8 weeks
46034326|NCT01212770|Drug|Apremilast 30mg|Apremilast 30 mg twice daily, orally
46034327|NCT01212770|Drug|Placebo|
46034328|NCT02840422|Device|ARTHRUM H 2%|ARTHRUM H 2%
46034329|NCT05334316|Drug|Dexamethasone|Administered intravenously or orally based on daily CRP values and CRP corticosteriod dosing algorithm
46034330|NCT00598273|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
46034331|NCT00598273|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
46034332|NCT00598273|Drug|Darbepoetin alfa|As prescribed, starting dose of 0.75 microgram per kilogram (mcg/kg) administered by subcutaneous injection once every 2 weeks. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
46034333|NCT05334238|Drug|Orelabrutinib|oral administration of Orelabrutinib 150mg daily for 1 year, beginning 8 weeks after autologous transplantation
45339417|NCT00742287|Dietary Supplement|Placebo|placebo
45339418|NCT00747669|Drug|lidocaine 70mg and tetracaine 70mg topical patch|One Synera Patch applied for 30 minutes.
45339419|NCT00742365|Device|Bright light|One hour of exposure to bright light daily upon awakening for 6 weeks.
45339420|NCT00742365|Device|Red light placebo|One hour of exposure to red light.
45339421|NCT00690573|Biological|Adalimumab|Adalimumab administered subcutaneously every other week, with dosage determined by body weight at study entry (20 mg for children weighing less than 30 kg, 40 mg for children weighing 30 kg or more).
46034334|NCT02842840|Behavioral|Patient-based intervention|
46034335|NCT02842840|Behavioral|Family based intervention|
46034336|NCT02842840|Other|Routine counseling|
46034337|NCT04161625|Behavioral|Digital exercise program with support|"The Safe Step application includes an instruction movie on how to create and progress an individual exercise program. The exercises, presented in video format, are organized into 10 groups with a main focus on balance (3 groups), lower-limb strength (4 groups), and gait/step (3 groups). The participants choose an exercise suitable for their needs from each group to compose a program of ten exercises.~Participants use the app to plan their exercises, set reminders, register their exercise, and view statistics. A virtual physiotherapist delivers motivational messages and feed-back. At the end of each month the participants receive an email asking them to report any falls during the past month in a short digital survey. These messages also contains a new video with general falls prevention information.~Technical support will be provided weekly at senior meeting sites. Try-out group exercises (step 1-3) will be provided by a local wellness association (Friskis&Svettis)"
46034338|NCT02641951|Other|Stellate ganglionic block|Ultrasound guided stellate ganglionic block
46034339|NCT02641951|Other|Pecs II block|Ultrasound guided Pecs II block
46034340|NCT04163029|Procedure|Preoperative oral care|tooth brushing and mouthwash with chlorhexidine 0,2% five day before surgery
46034341|NCT04161703|Procedure|focused ultrasound, diet and exercise|"Focused Ultra Sound using a device of Mabel6 DUO Ultra Cavitation Technology produced by DAEYANG MEDICAL CO., KOREA applied on the abdominal region which extending bilaterally from the line extending from mid-axilla to iliac crest, and above from center of diaphragm to the line extending between two iliac crests below.~an aerobic exercise 3 to5 times/week for 12 weeks in the form of walking on treadmill for 30 minutes with moderate intensity a weight maintenance diet, which ranged from 1700 kcal to 2200 kcal/day, which was calculated in an individual basis for each subject according to his BMR, throughout the study period (12 weeks) to ensure that the reduction in the circumference was due to the treatment intervention rather than due to their weight reduction"
46034342|NCT04161703|Procedure|diet and exercise|weight maintenance diet, which ranged from 1700 kcal to 2200 kcal/day, which was calculated in an individual basis for each subject according to his BMR, throughout the study period (12 weeks) to ensure that the reduction in the circumference was due to the treatment intervention rather than due to their weight reduction. All subjects in both groups (A & B) followed an aerobic exercise 3 to5 times/week for 12 weeks in the form of walking on treadmill for 30 minutes with moderate intensity (moderate intensity = 12-14 according to Borg Scale). The beginning period will be 15 mints and increased gradually until reaching 30 mints per time.
45472779|NCT03385096|Drug|Etoposide (VP-16)|"Etoposide was administered at 10 mg/kg/day on days -3 to -2.~-3 to -2."
46034343|NCT02636491|Device|MD-Logic-Automated Insulin Delivery System|"Subjects will undergo 60 hours at home under MD-Logic control and continuing with their regular routine life. At evening of the first intervention day patients will switch to MD-Logic control. Patients will be asked to connect study sensor and pump to the computer using the MD-Logic software. After the activation of the MD-Logic system, basal insulin dosing and correction boluses will be fully automated and controlled by the MD-Logic system except to meal boluses. Patients will be encouraged to measure capillary blood glucose at least 4 times a day, before each meal and before bed time. After the third night the patient will turn the closed-loop controller OFF, this will automatically save the log file. The patient will return to his regular insulin treatment."
46034344|NCT02636491|Device|MiniMed Paradigm® Veo™ System|Subjects use 60 hours at home their conventional insulin pump and continuing with their regular Routine life. During this therapy the Insulin pump operating separately and are not controlled by the MD-Logic System.
45472780|NCT03385096|Drug|Melphalan|Melphalan was administered at 200mg/m2 on day -2.
46034345|NCT00657007|Biological|belimumab|"1 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 1).~1 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 5)."
46034346|NCT00657007|Biological|belimumab|"4 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 2).~4 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 6)."
46034347|NCT00657007|Biological|belimumab|"10 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 3).~10 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 7)."
46034348|NCT00657007|Biological|belimumab|"20 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 4).~20 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 8)."
46034349|NCT00657007|Biological|Placebo|"IV (in the vein) on Day 0 (Cohorts 1-4).~IV (in the vein) on Days 0 and 21 (Cohorts 5-8)."
46034350|NCT04318652|Drug|Methylprednisolone eyedrops|instillation of methylprednisolone eye drops
46034351|NCT04161547|Drug|CSPCHA115 100 mg; Matching placebo 100 mg|CSPCHA115 100 mg once daily in the fasted state for 7 days; Matching placebo 100 mg once daily in the fasted state for 7 days.
46034352|NCT04161547|Drug|CSPCHA115 200 mg; Matching placebo 200 mg|CSPCHA115 200 mg once daily in the fasted state for 7 days; Matching placebo 200 mg once daily in the fasted state for 7 days.
46034353|NCT04161547|Drug|CSPCHA115 400 mg; Matching placebo 400 mg|CSPCHA115 400 mg once daily in the fasted state for 7 days; Matching placebo 400 mg once daily in the fasted state for 7 days.
46034354|NCT04161547|Drug|CSPCHA115 600 mg; Matching placebo 600 mg|CSPCHA115 600 mg once daily in the fasted state for 7 days; Matching placebo 600 mg once daily in the fasted state for 7 days.
46034355|NCT02887898|Device|Automated bolus calculator|
45472781|NCT01252823|Device|Implantation of ILR|Subcutaneous implantation of ILR under local anesthesia
46034356|NCT02887898|Other|Education|
46034357|NCT02633995|Procedure|spinal anaesthesia|regional anesthesia will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 25 µg fentanyl (total volume 2.5 ml) at the L3-4 interspace in the sitting position then the patient will be returned immediately to the supine position with left lateral tilt.
46034358|NCT02633917|Behavioral|Motor control exercises|exercises to strength the lumbar musculature and control the posture
46034359|NCT02633917|Behavioral|Standard exercises|general exercises
46034360|NCT02633683|Drug|HORIZANT 600 mg|HORIZANT 600 mg once daily
46034361|NCT01211522|Drug|Haloperidol|Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.
46034362|NCT01211522|Drug|Ziprasidone|Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.
46034363|NCT01211522|Drug|Placebo|Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.
45839801|NCT02958930|Device|MemorEM 1000|The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized antennas in the head cap worn by the subject. The device provides global RF treatment to the entire forebrain, including deep brain areas. For each of the 60 days of in-home treatment, two one-hour treatment will be given (early morning and late afternoon). Each treatment will be administered by the patient's caregiver, who will position the device on the patient's head and monitor treatment.
45839802|NCT02958852|Drug|Letrozole|
45839803|NCT02958852|Drug|Letrozole and atorvastatin|
45839804|NCT02958852|Drug|Fulvestrant|Fulvestrant will be used as second line treatment upon progression on first line treatment with letrozole +/- atorvastatin.
46034364|NCT04161235|Device|The Pulmonx Zephyr Endobronchial Valve (EBV) 5.5- LP|The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
46034365|NCT04161469|Procedure|Laser closure of the anal fistula tract (FiLaC)|The FiLaC procedure was performed using a ceramic diode laser platform (12 watts, 1470-nm wavelength). The laser fiber was introduced into the fistula tract via the external orifice using the seldinger maneuver until the internal orifice was found. The fiber delivered laser energy homogenously at 3600, causing shrinkage of the fistula tract around the fiber while it was withdrawn at the speed of 1 mm/s
45839805|NCT02958774|Radiation|Hypofractionated Radiation Therapy|Chest/Breast 4005 centigray (cGy)/15 fractions/267 cGy daily Regional nodes 4005 cGy/15 fractions/267 cGy daily 1000 cGy boost to lumpectomy/scar/undissected nodes 200 cGy daily
46034366|NCT04161469|Procedure|Internal orifice closure|Closure of internal orifice with a purse-string suture using 2-0 polyglactin suture material.
46034367|NCT01211288|Device|Astra implants|Root form OsseoSpeed TX Astra Tech Implant System
46034368|NCT02641795|Device|Minimally invasive robotic cochlear implantation|
46034369|NCT05404724|Drug|itraconazole、 SHR0302 tablets|Itraconazole 7 times and SHR0302 tablets twice. On the 8th day of this, itraconazole and SHR0302 tablets were taken simultaneously.
46034370|NCT03314935|Drug|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
46034371|NCT03314935|Drug|Oxaliplatin|Oxaliplatin administered intravenously at the protocol-defined dose and schedule.
46034372|NCT03314935|Drug|Leucovorin|Leucovorin at the protocol-defined dose and regimen.
46034373|NCT03314935|Drug|5-Fluorouracil|5-Fluorouracil at the protocol-defined dose and regimen.
46034374|NCT03314935|Drug|Gemcitabine|Gemcitabine at the protocol-defined dose and regimen.
46034375|NCT03314935|Drug|Cisplatin|Cisplatin at the protocol-defined dose and regimen.
46034376|NCT03314935|Drug|Paclitaxel|Paclitaxel at the protocol-defined dose and regimen.
45839806|NCT02676804|Other|High-intensity, aerobic exercise.|"Aerobic exercise will blend unsupervised moderate and supervised high intensity exercise. It will consist of walking/jogging modalities, dependent on the subject's level of bradykinesia, paced by the subject's level of perceived exertion. The exercise protocol will be designed to target an total of at least 150 minutes of cardio exercise per week.~Exercise training will be performed 5 times per week for 6 weeks, consisting of 3 supervised high intensity sessions and 2 at home moderate intensity sessions. High intensity sessions will be performed on a treadmill at an intensity rating of ~ 15 and 17 on a rating of perceived exertion (RPE) scale of 6 to 20. The moderate intensity exercise will target an RPE of ~10 - 12 and participants will be asked to complete this on their own."
45839807|NCT02641782|Drug|antibody ch14.18|17.5mg/m²d 10-20h i.v, d4-7 in cycles 1,3,5 and d8-11 in cycles 2,4.
45839808|NCT02641782|Drug|GM-CSF|250µg/m²xd, d1-14 s.c. or i.v (2h) in cycles 1,3,5
45839809|NCT02641782|Drug|IL-2 i.v.|3.0 mio U/m²xd d1-4 continuous infusion i.v. and 4.5 mio U/m²xd d8-11 continuous infusion i.v. in cycles 2,4
45839810|NCT02641782|Drug|IL-2 s.c.|0.06 mio U/m² i.v. test dosis for 30min. i.v. at least 2h before first subcutaneous (s.c.) application. 6 mio U/m²xd d1-5 and 8-12 s.c. in cycles 2,4
45839811|NCT02641782|Drug|Retinoic acid|160mg/m²xd b.i.d.oral d 11-24 in cycles 1,3,5,6 and d15-28 in cycles 2,4
46034377|NCT02636257|Procedure|Recessive Spherical Headed Silicone Intubation|Local anesthesia,regular disinfection, spread sterile towels, exposure operative side.2%lidocaine infiltration anesthesia to inferior orbital nerves, lacrimal punctum and lacrimal sac. Nasal cavity was packed with gauze soaked in 2%ephedrine with 1%tetracaine 15 minutes before procedure.A routine silicone tube of spherical intubation was performed. Dilatated lacrimal point to the end, then inserted the probe with line from lacrimal punctum to inferior meatus through nasolacrimal duct.Cut the line and flush the lacrimal duct physiological saline in 5 mL, flowing the line into the inferior meatus, then suctioned out the line with nasal endoscopy and extracted the probe and dilatated the lacrimal duct again. Insert the spherical silicone tube from lacrimal point to the lacrimal sac, reversing to vertical direction to ensure the tube is inserted into the nasolacrimal duct, then catch the above line but cut short the follow one and fix.Unobstructed lacrimal irrigation.
46034378|NCT02636257|Procedure|Dacryocystorhinostomy|Surgery was performed under local anesthesia.Incision was taken over anterior lacrimal crest.Medial palpebral ligament was identified.Orbicularis was separated.Reflection of periosteum and dissection of lacrimal sac from lacrimal fossa was done.Sac was excised to make'H'shaped anterior and posterior flaps. Bony osteum of sufficient size was made with bone punch.Nasal mucosa was cut to make anterior and posterior flaps.Subsequently anterior to anterior and posterior to posterior flaps were sutured.
46034379|NCT00656461|Drug|MKC-1|30 mg and 100 mg capsules, dosed BID daily on a continuous schedule
46034380|NCT02633761|Drug|Mifepristone|200mg mifepristone followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
46034381|NCT02633761|Drug|Placebo|placebo followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
46034382|NCT02633761|Drug|Misoprostol 200mcg|Buccal misoprostol 200mcg
46034383|NCT04161313|Other|Measurement of functional capacity|Functional capacity of participants will be measured with six-minute walk test.
45472782|NCT03746665|Biological|meningococcal serogroup A conjugate vaccine|Once final eligibility has been confirmed by a study clinician on the day, expectant mothers will be administered a single intramuscular dose of MenAfriVac™.
45839812|NCT02641314|Drug|metronomic therapy|"Propranolol 0.5 mg/kgxd p.o. day 1,~mg/kgxd p.o. day 2,~mg/kgxd p.o. day 3-365 (maximum total daily dose: 120 mg) divided in 2 doses per day~Celecoxib 400 mg/m2xd p.o.; day 1-365 (maximum total daily dose: 800 mg) divided in 2 doses per day~Cyclophosphamide cycle 1, day1: loading dose: 500 mg/m2 intravenous 1-h-infusion, single dose day 2-365 25 mg/m2xd p.o (maximum total daily dose: 50 mg) as single daily dose~Vinblastine 3 mg/m2xd i.v. (maximum total daily dose: 6 mg) administered day 1 and 15 (every two weeks) as single daily dose~Etoposide 25 mg/m2xd p.o.; day 1-21 weeks 1-3, 9-11, 17-19, 25-27 (maximum total daily dose: 50 mg) as single daily dose"
45839813|NCT01711710|Device|Cohesive Gel Breast Implant|"Cohesive Silicone Gel-Filled Breast Implant insert under the submuscular with axillary incision in breast augmentation mammoplasty.~Remove tissue expander and insert Cohesive Silicone Gel-Filled Breast Implant in breast reconstruction."
45839814|NCT04769622|Procedure|Non-surgical periodontal treatment|all included patients will be subjected to non-surgical periodontal therapy
45839815|NCT04769622|Other|Questionnaires|"All patients will be asked to complete a set of questionnaires regarding:~adherence to Mediterranean Diet;~sleep quality;~physical activity;~perceived stress."
45839816|NCT04769778|Drug|Valsartan 80Mg Oral Tablet|treatment with 80mg /day of valsartan
46034384|NCT04161313|Other|pulmonary function test|It will be measured using basic spirometry and presented lung volume parameters such as FEV1,FVC,FEV1/FVC,PEF, FEF25-75
46034385|NCT04161313|Other|Functional capacity|Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
46034386|NCT04161313|Other|Peripheral muscle strength|Isometric M. Quadriceps strength will be measured using electronic hand held dynamometer in sitting position.
46034387|NCT04161313|Other|Respiratory muscle strength|Inspiratory and expiratory muscle strength has been assessed by maximal inspiratory and expiratory mouth pressures.
45839817|NCT04769700|Behavioral|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale is a self-administered questionnaire made up of 10 items scored using a four-point Likert scale (0-3) designed to screen for symptoms of postpartum depression. Postpartum depression represents the end of a continuum of severity of symptoms. The present study used a cutoff point for depressive symptomatology risk of higher than 12.
46034388|NCT02633605|Device|First Sense Medical®|
46034389|NCT00883753|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg IV (maximum dose not exceeding 800 mg in a single infusion) every 4 weeks.
45839818|NCT04769700|Behavioral|Breast Feeding Adherence|This will be addressed according to the breastfeeding initiation practices according to the WHO.
46034390|NCT02641717|Other|vaginal swab|
46034391|NCT04162639|Biological|Skin allograft|Participants will receive skin allograft from either 1, 2 or 3 distinct cadavers. This skin allograft will be applied in a routine fashion, with no deviation from the typical clinical course of treatment.
46034392|NCT01210664|Biological|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|The researchers will multiply/expand the Tregs in the laboratory using anti-CD3/anti-CD28 coated beads plus IL-2. Then, the Tregs will be infused back into the patient in a single infusion. The first cohort will receive 0.05 x10^8 cells. The second cohort will receive 0.4 x10^8 cells. The third cohort will receive 3.2 x10^8 cells. The fourth cohort will receive 26 x10^8 cells.
46034393|NCT02633839|Drug|CVT-301|Levodopa inhalation powder, will be supplied in capsules containing levodopa (l-dopa), designed to deliver to the lung using the CVT-301 inhaler.
46034394|NCT02633839|Drug|Carbidopa|Administered orally according to the carbidopa dosing schedule.
46034395|NCT02636335|Device|Phillips Energy Light HF3319|Exposure to Light administered with Phillips Energy Light HF3319.
46034396|NCT02632903|Drug|Zoledronic acid|
46034397|NCT00657397|Drug|Methadone|Methadone sirup once daily
46034398|NCT04160611|Drug|Midazolam 7.5mg|The patient groups differ only in that respect that the intervention group will receive oral midazolam 7.5 g before oocyte aspiration.
46034399|NCT04160299|Behavioral|Dance-based exergaming|Dance sessions
46034400|NCT02535559|Behavioral|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
46034401|NCT04161001|Drug|Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Olmetec Tab. 40mg(Olmesartan 40mg)
46034402|NCT04161001|Drug|Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Sevikar tab. 10/40mg (Amlodipine/Olmesartan 10/40mg)
45339422|NCT00742443|Drug|Juvista (avotermin)|100ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
46034403|NCT04161001|Drug|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg, and placebo of Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg), Olmetec Tab. 40mg(Olmesartan 40mg)
46034404|NCT02636413|Drug|gaxilose|After gaxilose administration, urine collection, cuantification (firstly from 0 to 4 hours, and total urine from 0 to 5 hours), and xilose cuantification afterwards.
46034405|NCT02636413|Dietary Supplement|lactose|After lactose administration, expired hydrogen measurement at pre-specified intervals.
46034406|NCT04160767|Drug|Probiotic Vivomixx|VIVOMIXX once a day for 4 months. VIVOMIXX® is a probiotic containing 8 differenct strains of bacteria: Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) lactobacilli (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734). Every sachet contains 450 billions of bacteria, maltose and silicon dioxide. VIVOMIXX® will be freely given by the society MENDES S.A. - Lugano Switzerland.
46034407|NCT04160767|Behavioral|Gluten free diet|Gluten free diet will be encouraged in both arms
46034408|NCT04160767|Other|Placebo|Placebo with same taste than VIVOMIXX, containing maltose and silicon dioxide once a day for 4 months.
46034409|NCT02633449|Behavioral|cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy, six patients, two therapists, duration: 100 minutes, two sessions per week for a total of six weeks
45339423|NCT00742443|Drug|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
46034410|NCT02633449|Device|tDCS|transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, 1-2 mA, anode over electrode position F3, cathode over F4
46034411|NCT02633449|Device|sham-tDCS|sham transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, anode over electrode position F3, cathode over F4
46034412|NCT02535637|Other|Exclusively breastfeed|There is no intervention other than mothers must exclusively breastfeed.
46034413|NCT04162717|Behavioral|The Effect of Telephone Symptom Triage Protocols on Symptom Management, Quality of Life and Self-Care Maintenance in Patients with Cancer Who Applied Systemic Treatment|"Symptom management, quality of life and self-maintenance were assessed by scales at the first interview and 3 months later.~Intervention group received symptom triage application with telephone, which consisted of guiding in line with symptom triage protocols. The patients who were included in the intervention were followed up by telephone on the 3rd, 7th and 10th day of after chemotherapy total of nine times during three chemotherapy cycles."
46034414|NCT00911209|Behavioral|Dietitian counselling|Once a week for 14 weeks then 1 monthly visit. Visits last 40-50 minutes
46034415|NCT00881569|Drug|CS-7017|CS-7017 administered orally, twice daily continuously for 6 weeks
45839819|NCT04769700|Behavioral|Fear of Covid-19 Scale|The Fear of Covid-19 Scale is a questionnaire that evaluates fear of the global pandemic caused by the SARS-CoV-2. It consists of seven items, each with a five-point Likert scale of options. The participant is instructed to choose the option that best represents their perception about the statement presented. The maximum possible total is 35 points. The scale's authors indicate that the higher the score is, the higher is the level of the participants' fear of COVID-19.
45839820|NCT04769076|Combination Product|Paclitaxel（Albumin-bound）|Three courses of albumin-bound paclitaxel combined with cisplatin and PD-1 monoclonal antibody neoadjuvant treatment followed by cisplatin combined with IMRT (intensity modulated conformal radiotherapy) concurrent radiotherapy and chemotherapy
45839821|NCT04769232|Device|EG-760Z endoscope by Fujifilm|"Within a single endoscopic procedure under propofol sedation, images of the esophageal wall will be acquired and biopsies will be taken. All patients will be examined using the EG-760Z endoscope by Fujifilm.~In all patients as part of the clinical routine 4 biopsies of the proximal and 4 biopsies of the distal esophagus will be taken."
45839822|NCT04768998|Other|Observational of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings|Observatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care.
45839823|NCT04768842|Drug|LY3209590|Administered SC.
45839824|NCT04768764|Procedure|Ultrasound Guided Middle Adductor Canal Block|"Middle adductor canal block will be applied post-operatively with guidance of USG.~Drug:Bupivacaine 0.25% Injectable Solution"
46034416|NCT04017481|Other|Repetitive transcranial magnetic stimulation (rTMS)|The intervention intends to change the cortical plasticity in specific cortical areas. rTMS is a non-invasive exogenous neuromodulation technique that uses repetitive magnetic pulses administered in a specific area of the head in order to influence the connectivity of the underlying brain area.
46034417|NCT04017481|Other|EEG guided Neurofeedback (NFB)|The intervention intends to change the cortical plasticity in specific cortical areas. The NFB is a non-invasive endogenous technique that seeks the self-regulation of cortical activity through the information represented in a videogame which is used to interact with the subject.
46034418|NCT04160143|Procedure|Surgical resection and stereotactic body radiation therapy (SBRT)|Surgical resection and stereotactic body radiation therapy (SBRT) are generally regarded as mutually exclusive treatment options for the local management of pulmonary malignancies. This Phase 2 prospective trial is a collaborative effort between the divisions of Thoracic Surgery and Radiation Oncology to evaluate the effects of dual treatment of pulmonary metastasis amenable to curative resection with neoadjuvant SBRT followed by surgical resection.
45339424|NCT00742443|Drug|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of both wound segments by intradermal injection immediately after and then 24h after wound closure
45339425|NCT00719264|Drug|RAD001(everolimus)|10 mg qd
45339426|NCT00719264|Drug|interferon alfa-2a|dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3
45339427|NCT00719264|Drug|bevacizumab|10 mg/kg every 2 weeks
46034419|NCT02636179|Other|Comparative epidemiological survey|The method used to select the control group will be the random sampling of eligible schools. It will be defined according to the place of schooling of the historic cohort of children. The children will be matched as close as possible based on sex, age, school class and type of school (public/private).
46034420|NCT00657163|Drug|fluoxetine|fluoxetine per os 20 mg daily
46034421|NCT00657163|Drug|placebo|placebo per os daily
46034422|NCT02636101|Drug|Calcipotriol/betamethasone dipropionate gel|Topical treatment of psoriasis plaques located on the body
46034423|NCT04032457|Device|Phase A - olifilcon B with Tangible Coatings|Daily disposable silicone hydrogel contact lens
46034424|NCT04032457|Device|Phase B - etafilcon A with Tangible Coatings|Daily disposable hydrogel contact lens
45339428|NCT00749151|Behavioral|telephone counseling|First time callers to telephone help line agreed to one year follow-up on smoking cessation.
45339429|NCT00687609|Drug|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
46034425|NCT00657475|Drug|Heparin Low Dose|Loading heparin dose of 150 IU / kg to achieve an ACT (activating clotting time) target more than 240 seconds.
45839825|NCT04768764|Procedure|Ultrasound Guided Femoral Nerve Block.|Femoral nerve block will be applied post-operatively with guidance of USG. Drug:Bupivacaine 0.25% Injectable Solution
45839826|NCT04768764|Drug|Bupivacain|10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution. Bupivacaine 0.25% Injectable Solution
45839827|NCT04768764|Procedure|Spinal Anesthesia|Patients will be placed in the lateral decubitus position.Subarachnoid space will be entered through the most suitable intervertebral space.Bupivacaine 0.5% Heavy will be given in the appropriate dose.
45839828|NCT04768530|Procedure|Scaling and Root Planing|Supra- and sub-gingival calculus and debris were removed
46034426|NCT00657475|Drug|Heparin Full Dose|Loading heparin dose of 300 IU / kg to achieve an ACT (activating clotting time) target more than 400 seconds.
45839829|NCT04768530|Drug|Nitazoxanide hydrogel|Scaling and root planing was performed in combination with the subgingivally delivered thermosensitive Nitazoxanide hydrogel as adjunct antimicrobial therapy.
45839830|NCT04768140|Procedure|Bobath treatment approach|scapulothoracic mobilization exercise, reaching in different directions in the supine position and upper extremity weight transfer exercise.
45839831|NCT04768140|Procedure|Conventional physiotherapy|range of motion, stretching, strengthening exercises, electrotherapy, thermotherapy, balance and mobility exercises and exercises for daily living activities.
45839832|NCT04749654|Other|The Salivary pH measured|The saliva samples were obtained at 10-12 a.m. from all children. The saliva was collected into plastic cylinders and the salivary pH was measured with a pH meter (Compact pH meter B-212 twin pH, HORIBA, Osaka, Japan).
45839833|NCT04749654|Other|The saliva flow rate was measured|The saliva flow rate was estimated by during the first 30 s of paraffin chewing. The saliva was collected into plastic cylinders for a period of 5 minutes. Afterward, the saliva were weighed with a in a precision balance (Mettler PC 400, Zurich, Switzerland) and the flow rate was computed in gms/ml.
45839834|NCT04749654|Other|Streptococcus mutans and Lactobacillus counts in saliva were measured|The saliva samples were obtained according to described above. Numbers of colony-forming units (CFU) of S. mutans were counted on TSY20B agar and Lactobacilli were counted on Rogosa agar.
45839835|NCT04749498|Other|White Bread|Test breakfast with white bread was served after 12-hours of fasting and participants were asked to consume the meal in full, within 15 minutes.
46034427|NCT02636023|Device|SPhENo-Cardiograph|SPhENo-Cardiograph
46034428|NCT02632981|Other|nonsurgical periodontal treatment|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
46034429|NCT02632981|Other|Gingival crevicular fluid and saliva collection|GCF collection with filter paper (Periopaper) using the intracrevicular method. Patients' mouths were rinsed with distilled water, and unstimulated salivary samples were collected by patients expectorating into disposable tubes.
46034430|NCT04160689|Biological|implantology|placing of implant
46034431|NCT02631889|Device|Transcollation technology|The use transcollation technology for dissection during lung surgery
46034432|NCT02631889|Device|Traditional electrocautery|The use of traditional Electrocautery for dissection during Lung Surgery
46034433|NCT00657319|Drug|biphasic insulin aspart 30|The observation is performed under normal clinical practice conditions without any additionally required diagnostic/therapeutic features. Physicians are allowed to decide the treatment regimen according to the medical standards.
46034434|NCT00881335|Device|flutter mucus clearance device|five minutes every sessions, three sessions per day
45472783|NCT04445974|Behavioral|Expand your horizons: More than my skin|'Expand Your Horizon' is a self-help intervention which uses writing exercises to help individuals with poor body image practice focusing on their body-functionality rather than their physical appearance (Alleva et al., 2015). The materials for 'Expand Your Horizon' are freely available (Alleva et al., 2015), and permission has been granted to use and adapt the materials in this research. 'Expand Your Horizon' comprises of three 15 min writing exercises, typically completed over approximately six days. The intervention materials have been adapted for use with a population with skin diseases, and modified to use gender neutral language. Adaptions were made in consultation with experts by experience. The changes were reviewed and approved by the first author of the original intervention to ensure the materials were in keeping with the original intervention.
45339430|NCT00742521|Procedure|glucose clamp|Day 1 hyperinsulinemic euglycemic glucose clamp procedure x 2 and Day 2 hyperinsulinemic hypoglycemic glucose clamp procedure
45472784|NCT04445974|Behavioral|Creative writing activities|In line with previous studies examining 'Expand Your Horizon' the active control condition will involve creative writing tasks (Alleva et al., 2015). Participants in the intervention condition will complete three 15 minute creative writing exercises, completed over six days.
46034435|NCT02632825|Device|Nasal High Flow|Nasal High Flow Therapy
46034436|NCT00657631|Behavioral|Acceptance and Commitment Therapy|"Considered part of the third wave of CBT along with Dialectical Behavior Therapy (DBT; Linehan, 1993) and Mindfulness-based Cognitive Therapy (MBCT; Segal, Williams, & Teasdale, 2001), ACT is built upon the strong, research-based foundation of CBT. However, while CBT for psychosis focuses on reducing symptoms, ACT focuses on changing the way in which the person experiences his or her symptoms so that the person can still live his or her life in accordance with his or her life values. Specifically, CBT attempts to reduce delusions by disputing the evidence for the delusion and ACT attempts to increase the person's ability to live his or her life while still experiencing delusions (Hayes, Strosahl & Wilson, 1999)."
46034437|NCT04159597|Drug|Upadacitinib|Upadacitinib will be administered as oral tablet.
45339431|NCT00742521|Procedure|glucose clamp|Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
45339432|NCT00742521|Procedure|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 2 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
45339433|NCT00742521|Procedure|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
46034438|NCT00661219|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
46034439|NCT00661219|Drug|Placebo|Identical placebo will be matched for each vardenafil dosage form and will be indistinguishable from active treatment.
45339434|NCT00747825|Drug|131-I-MIP-1145|IV injection between 4.0 to 6.0 mCi (148-222 MBq) of 131-I-MIP-1145
45339435|NCT00751959|Drug|Curosurf|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
45339436|NCT00751959|Drug|Curosurf|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
45339437|NCT00723554|Drug|Iloprost PD-6|Period 1 (PD-6): study period defined as the 14 days prior to the first dose of study iloprost inhalation with PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-6 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day
46034440|NCT00665665|Drug|NNC 0070-0002-0182|4mg initial dose (12 subjects active; 3 subjects placebo); 2mg weekly maintenance dose; for s.c. injection 20mg/vial
46034441|NCT00665665|Drug|placebo|Placebo for s.c. injection
46034442|NCT00665665|Drug|NNC 0070-0002-0182|12mg initial dose (12 subjects active; 3 subjects placebo); 6mg weekly maintenance dose; for s.c. injection 20mg/vial
46034443|NCT00665665|Drug|NNC 0070-0002-0182|32mg initial dose (12 subjects active; 3 subjects placebo); 16mg weekly maintenance dose; for s.c. injection 20mg/vial
46034444|NCT00665665|Drug|NNC 0070-0002-0182|60mg initial dose (12 subjects active; 3 subjects placebo); 30mg weekly maintenance dose; for s.c. injection 20mg/vial
46034445|NCT00665743|Drug|PN400|naproxen 500 mg /esomeprazole 20 mg
46034446|NCT00665743|Drug|naproxen|naproxen 500 mg tablet
45339438|NCT00723554|Drug|Iloprost PD-15|"Period 2 (PD-15): study period between the administration of the first dose with PD-15 on Day 1 until Day 28 inclusive.~Period 3 (PD-15): study period from Day 29 until discontinuation of the PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-15 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day"
46034447|NCT00665743|Drug|naproxen|naproxen 500 mg
45339439|NCT00687219|Biological|Peginterferon alfa-2b|Administered at 1.0 µg/kg/week SC for 48 weeks
45339440|NCT00687219|Drug|Ribavirin|Administered based on body weight and hemoglobin value at Screening: 600-1000 mg/day for subjects with hemoglobin value at screening >=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening >=12g/dL and <14g/dL; treatment duration is 48 weeks
46034448|NCT04156711|Procedure|Remote Ischemic Preconditioning (RIPC)|Cycles of forearm ischemia and reperfusion by the inflation of a blood-pressure cuff over the systemic blood pressure for brief periods
46034449|NCT02357992|Radiation|Stereotactic Body Radiotherapy (SABR)|SABR once a day for 3-4 days in a row, 50Gy in 4 fractions for central tumor, or 54Gy in 3 fractions for peripheral tumor.
46034450|NCT00661297|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil to be taken 1 h prior to sexual attempt
46034451|NCT00661297|Drug|Placebo|Matching placebo
46034452|NCT00665821|Behavioral|Classic back pain prevention education, and cognitive behavioral management.|Classic education: postural hygiene, Back Guide. Cognitive behavioral management: active management, Back Book.
46034453|NCT00665821|Behavioral|General health education|General health education: a booklet describing general norms for maintaining good health
46034454|NCT02842762|Device|Right ventricular epicardial pacing|The patient's own heart rate at that moment will be the starting point for the study. Right ventricle pacing will be instituted by selecting a rate that is 5 beats above the patient's own heart rate. We will use a stepwise approach where we increase the pacermaker's rate with steps of 5 beats until we have 100% capture of the pacemaker beats. After waiting for at least one minute of pacing we will obtain a set of measurements.
46034455|NCT02842762|Procedure|cardiac surgery|Elective cardiac surgery, with use of cardiopulmonary bypass.
46034456|NCT02842762|Device|3D TEE|Intraoperatively, all patients will be monitored by means of TEE
45339441|NCT02562105|Procedure|Mechanical ventilation|requiring mechanical ventilation at admission to ICU for one day or more during the study period
46034457|NCT02842762|Device|Pacemaker lead|All patients will have a epicardial pacemaker lead in situ.
45339442|NCT00749229|Device|balloon kyphoplasty|During the same surgery or some days later on, percutaneous Balloon kyphoplasty of the fractured vertebral body (ies) using polymethylmetacrylate cement injection through a posterior transpedicular approach will be carried out in replacement of anterior spine surgery to restore vertebral body strength
45339443|NCT04085120|Procedure|0.75 % Ropivacaine/ 4mg/mL dexamethasone injection|Distal glossopharyngeal nerve in the neck will be blocked by using 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection
46034458|NCT02690896|Behavioral|UCF Caregiver Support Group|The intervention will be a 90 minute group session, once a week, for a period of 6 consecutive weeks. The intervention will teach caregivers specific behavioral techniques for managing care recipients' symptoms in the home environment and encourage caregiver self-care.
46034459|NCT02690896|Behavioral|Community Support Groups|Comparison group members will come from local community support groups, which typically include components of social support and limited psychoeducation, and are relatively unstructured.
46034460|NCT00879775|Drug|Caffeine|Intravenous injection of caffeine 200mg with 100ml of normal saline over 1 hour, once a day, for two days.
46034461|NCT00879775|Drug|Normal saline|Intravenous injections of 100ml of normal saline over 1 hour, once a day, for two days
46034462|NCT02840344|Behavioral|Couples MBSR|Both members of the couple will be asked to participate in the weekly video sessions and activities.
46034463|NCT02840344|Behavioral|Individual MBSR|Only the young breast cancer survivor will participate in the weekly video sessions and activities.
46034464|NCT00665899|Behavioral|Cancer-Focused Relationship Enhancement|Couples meet individually with a health educator for 6 sessions to learn about ways to support each other and communicate about breast cancer related issues.
46034465|NCT00665899|Behavioral|Couple's Cancer Education|Couples meet individually with a health educator for 6 sessions to discuss the medical aspects of breast cancer and treatment options.
46034466|NCT00894790|Drug|Celecoxib|celecoxib 200 mg BID (twice a day) with a loading dose of 400 mg
46034467|NCT00894790|Drug|oral Diclofenac|diclofenac 75 mg tablet BID (twice a day)
46034468|NCT04156867|Device|Dynesys|discectomy with Dynesys
46034469|NCT04156477|Dietary Supplement|Ketone ester|Intake of weight adjusted drink of a ketone ester
46034470|NCT04156477|Dietary Supplement|Glucose|Isocaloric and - volumetric taste adjusted drink
46034471|NCT04156477|Dietary Supplement|Tap water|Isovolumetric taste adjusted tap water (placebo)
46034472|NCT02840110|Other|ACTR T Cell Product|
46034473|NCT00665977|Drug|Thermosmart & placebo|a Fisher & Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
46034474|NCT00665977|Drug|Placebo Device & Nasacort|Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher & Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
46034475|NCT00665977|Device|Placebo Arm|"To enter into the single-blind placebo phase, subjects will be setup with a Fisher & Paykel 604 CPAP unit with a heated humidifier and deactivated Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still appear to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily."
46034476|NCT02840500|Other|No intervention|No intervention
45339444|NCT04085120|Procedure|10% lignocaine injection|Distal glossopharyngeal nerve in the neck will be blocked by using 10% lignocaine injection
45339445|NCT00747903|Drug|aminolevulinic acid hydrochloride|
45339446|NCT00749307|Dietary Supplement|Docosahexaenoic acid (DHA)|
46034477|NCT02631811|Other|Supportive /palliative care intervention|patients will be seen by palliative care team at least once a month until the 12th week, more if needed. The symptom and suffering will be assessed by a multidisciplinary palliative specialist team of physician, nurse and psychologist. Physical, psychological, social and existential suffering will be addressed.
46034478|NCT00666055|Drug|ARV regimen chosen by treating physician|"Women may also be naïve to either NNRTI or PIs and initiating their first, second or third HAART regimen (ARVs to be investigated: zidovudine, lamivudine, emtricitabine, abacavir, tenofovir, efavirenz, lopinavir/ritonavir, atazanavir with or without ritonavir).~Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI)."
46034479|NCT02840734|Other|Kinesio taping|This study was conducted in a randomized crossover double-blind design. Each subject was tested for muscular power, strength, endurance, and fatigue of the lower extremities under three conditions: 1) NT (no taping), 2) PT (placebo taping, 3M tape) and 3) KT (Kinesio taping). For allocation of treatment sequence, the participants drew straws for which treatment first (each treatment indicated different numbers).
46034480|NCT02839954|Biological|anti-MUC1 CAR-pNK cells|
46034481|NCT04159285|Behavioral|EffEKTiv 2.0 group CBT as continuation treatment after ECT in depressed patients|Group CBT with a maximum number of 8 participants. Group is half-open allowing a starting date right after completion of acute ECT treatment. Patients participate for 15 sessions, which are framed by 2 individual sessions before joining the group and one individual session at treatment end.
46034482|NCT04159285|Other|Treatment as usual|Can include continuation ECT, psychopharmacological treatment, individual psychotherapy
45339447|NCT00749307|Dietary Supplement|Placebo|
45339448|NCT02562573|Drug|PBI4050|
45339449|NCT02562183|Drug|kallikrein|Using kallikrein
45339450|NCT02562027|Behavioral|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30|"30 quality of life questions for the participant to answer~The first 28 questions have answers that range from 1 (Not at All) to 4 (Very Much)~The final 2 questions answers range from 1 (Very Poor) to 7 (Excellent)~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
45339451|NCT02562027|Behavioral|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13|"13 quality of life questions for the participant to answer~The answers range from 1 (Not at All) to 4 (Very Much)~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
45339452|NCT02562027|Behavioral|Modified Medical Research Council|"Participants is given 5 grades to choose from ranging from 0 to 4 and participant will choose grade~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
45339453|NCT02562027|Behavioral|EQ-5D|"5 headings with 5 statements and the participant will check the box that best describes how he or she feels that day~The second part shows a scale ranging from 0 (worst health) to 100 (best health) and the participant chooses the best number on the scale~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
46034483|NCT02690662|Behavioral|Hypocaloric diet|recommendation of daily ingestion of 2500 ml of water and low-calorie diet of 16 Kcal/kg bw/day
46034484|NCT02631655|Other|impact of device 18F-FDOPA PET on treatment decisions|Imagery device: impact of 18F-FDOPA PET imaging on treatment decisions for patients with high-grade gliomas with an uncertain diagnosis.
46034485|NCT02840188|Other|Radius tilt angle|Fracture classification in children. Tilt angle measurement of the distal radius growth plate.
46034486|NCT00661375|Drug|Nexavar (Sorafenib, BAY43-9006)|BAY 43-9006 400mg b.i.d. Treatment will continue until progression of underlying disease, unacceptable toxicity whose causal relationship to the study drug cannot be ruled out and which requires discontinuation of the drug, or consent withdrawal.
46034487|NCT04250974|Other|electroacupuncture|acupuncture with electricity
46034488|NCT00911287|Drug|Oxymorphone extended release|Study Medication: Oxymorphone ER 5 mg, 10 mg, and 20 mg tablets. Rescue Medication: Oxymorphone IR 5 mg tablets. Treatment will consist of up to 6 months of dosing with oxymorphone ER.
46034489|NCT04494880|Drug|Bupivacaine Injection|Treatment group receives Marcaine (Bupivacaine) injected into one breast following breast reduction surgery and a saline injection in the other group.
46034490|NCT04154527|Other|Pelvic Floor and Abdominal Exercises|two repetitions of each exercise, during exhalation phase
46034491|NCT02837848|Procedure|Coactivation Strengthening|Coactivation strengthening implies a recruitment of the pectoralis major and the latissimus dorsi while performing regular strengthening.
46034492|NCT02837848|Procedure|Regular Strengthening|Regular strengthening implies external rotation, internal rotation, flexion and abduction of the gleno-humeral joint and scapular protraction and retraction of the scapulothoracic joint strengthening.
46034493|NCT02631031|Drug|Valsartan|single oral dose of 160 mg valsartan under fasting conditions
46034494|NCT02839564|Procedure|Laparoscopic adhesiolysis|After diagnostic laparoscopy to confirm adhesions and exclude other pathology laparoscopic adhesiolysis was performed
46034495|NCT02839564|Procedure|Diagnostic laparoscopy|After diagnostic laparoscopy to confirm adhesions and exclude other pathology treatment was stopped.
46034496|NCT00911365|Biological|autologous mesenchymal stem cells|"4*107 stem cell (100ml) Intra arterial infusion/ one time, then 4*107 stem cell(100ml)Intravenous infusion 3 times/monthly~-> Total four times"
46034497|NCT00911365|Biological|normal saline|saline
46034498|NCT04250272|Procedure|Thoracoscopic lobectomy|Thoracoscopic lobectomy was performed for lung cancer
46034499|NCT02838160|Behavioral|Routine Care|After baseline measurement, Group 1 did not receive any intervention or education.
46034500|NCT02838160|Behavioral|Routine care Plus the designed booklet|Group 2 received only the designed booklet without any participation in the oral presentation.
46034501|NCT02838160|Behavioral|Routine care Plus the designed booklet Plus participation in oral presentations|Group 3 participated in oral presentations 14 days after completing self-study booklet. Interactive, standardized and mandatory oral presentations were held five times to ensure maximum attendance of the three nursing shifts.
45472785|NCT02526875|Drug|Telminuvo®Tab. 40/2.5mg|per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
45472786|NCT05570877|Device|ChitoCare medical Wound Healing Gel|ChitoCare medical Wound Healing Gel is a CE-marked medical device.
45472787|NCT03380494|Other|Overhead perturbation training|A specifically chosen weight is attached to a 1m resistance band held above the head, hanging against gravity. The participant is encouraged to sustain a static position, where the weight and band provide variable magnitude perturbations to arm position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
45598862|NCT03158649|Other|"Embarazo y Bienestar"|"The intervention programme is called Embarazo y Bienestar (Pregnancy and Well-being). Embarazo y Bienestar is a modular, self-placed program mainly designed to foster women's prenatal well-being by practicing some positive psychology-based exercises. The intervention programme consist of four modules of intervention, one welcome module, and a final resume page."
46034502|NCT02838160|Behavioral|Routine care Plus the designed booklet Plus participation in oral presentations Plus clinical teaching in bedside|The Group 4 received clinical teaching in bedside after completing self-study booklet and a series of interactive, standardized and mandatory 90-120-minute oral presentations.
46034503|NCT02839408|Dietary Supplement|Lactobacillus rhamnosus SP1|Sachet containing Lactobacillus rhamnosus SP1
46034504|NCT02839408|Drug|Azithromycin|Tablet containing 500mg Azithromicyn
46034505|NCT02839408|Other|Talc powder|Sachet containing talc powder and tablet containing talc powder
46034506|NCT02839408|Procedure|Periodontal treatment Scaling and root planning|
46034507|NCT02838082|Behavioral|Sleep Hygiene Protocol|Sleep Hygiene Protocol involving 1) Improved sleep environment 2) Enhanced Circadian Stimuli 3) Increased Daytime Activation (blue light therapy, daytime light exposure and daytime sleep restriction) 4) Adjusted morning ADL routines and 5) Restricted Caffeine intake
46034508|NCT02838082|Behavioral|Standard of Care|All standard of care procedures in a specialized traumatic brain injury inpatient rehabilitation unit
46034509|NCT02838004|Device|IOL MINI WELL READY|IOL MINI WELL READY
46034510|NCT05334082|Other|FIFA 11+|15 progressive exercise drills for training preparation (warm-up)
46034511|NCT02837614|Drug|dexamethasone acetate|1 milliliter of dexamethasone (4milligram) administered in the deltoid muscle before commencement of surgical procedure
45683178|NCT05424172|Behavioral|Stage-I, Group 2: Self monitoring using Interactive App|Participants in Group 2 will use the version of the exercise app that has been modified based on the findings from Phases 1 and 2 of this study. Group 2 will be able to use the full features of the interactive app including notifications, ability to submit videos, and non-synchronous messaging/communicating with the researcher. Additionally, participants in Group 2 will be asked to complete 2-5 EMA-based surveys daily to gain information about the participant's barriers and facilitators to exercise. The information from the EMA questionnaires will be used to progress and modify the exercise program at regular intervals for each participant in Group 2.
45683179|NCT05424172|Behavioral|Stage-II, Groups 1a/2a: E-Coaching 2x per month|In addition to the Stage-I assigned app, participants will be asked to complete at least daily EMA questionnaires and e-coaching sessions two times a month throughout Stage-II (weeks 13-24). Participants will only receive the augmented e-coaching intervention if they were not adherent to the exercise guidelines for at least 50% of the weeks during Stage-I (weeks 1-12).
46034512|NCT02837614|Drug|submucosal dexamethasone injection|Local anesthesia was achieved using 2% lignocaine hydrochloride and 1:100 000 adrenaline and a standard technique was followed to block Inferior alveolar, lingual and long buccal nerve in all patients. In Group B patients, 1 ml of dexamethasone was administered in submucosa. Investigators divided 1 ml Dexamethasone is into 0.4 milliliter, 0.3 milliliter and 0.3 milliliter parts. Following the local anesthesia, each part of dexamethasone was injected submucosally in the buccal, lingual and retromolar region around the tooth to be extracted. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation and tooth elevated. The flap was sutured using three simple interrupted 3-0 black braided silk suture. All patients were given amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively.
45339454|NCT02562027|Behavioral|Center for Epidemiological Studies Depression Scale|"20 quality of life questions for the participant to answer~Answers range from Rarely or none of the time to Most or all of the time~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
45339455|NCT02562027|Behavioral|Medical Outcomes Study Social Support Survey|"19 quality of life questions for the participant to answer~Answers from from 1 (None of the time) to 5 (All of the time)~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
45339456|NCT00723398|Dietary Supplement|Lovaza 4gm oral|Dietary supplement; Take 4 mg oral capsules daily
45339457|NCT00723398|Drug|Raloxifene 60 Mg Oral Tablet|60 mg orally every day for two years
45339458|NCT00723398|Drug|Raloxifene 30 Mg Oral Tablet|30 mg orally daily for two years
45339459|NCT00723398|Drug|Lovaza 4gm & Raloxifene 30mg|Lovaza 4gm and Raloxifene 30 Mg orally once per day for 2 years
45683180|NCT05424172|Behavioral|Stage-II, Groups 1b/2b: E-Coaching 4x per month|In addition to the Stage-I assigned app, participants will be asked to complete at least daily EMA questionnaires and e-coaching sessions four times a month throughout Stage-II (weeks 13-24). Participants will only receive the augmented e-coaching intervention if they were not adherent to the exercise guidelines for at least 50% of the weeks during Stage-I (weeks 1-12).
45839836|NCT04749498|Other|Whole Wheat Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
46034513|NCT02837614|Procedure|Third molar surgery|Surgical access was gained through standard Terrence Ward's incision to raise a full thickness mucoperiosteal flap. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation. The tooth sectioned at cemento-enamel junction whenever required and a Coupland elevator is used to elevate tooth or fragmented tooth out of socket. The socket examined for any debris and sharp bony margins smoothened. The empty socket was irrigated copiously and flap was sutured using three simple interrupted 3-0 black braided silk suture.
46034514|NCT02837614|Drug|Amoxicillin and paracetamol|Amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively (every 6 hours 1 tablet for 2 days).
45472788|NCT03380494|Other|Non-perturbed training|A weight is grasped by the participant and elevated above head to the same position as the OPT intervention. The participant is encouraged to sustain a static position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
45472789|NCT01267097|Behavioral|Cognitive Behavioural Therapy (CBT)|Clinical research supports the use of CBT-based interventions in weight management for adults and children. However, the current study will advance the existing knowledge-base by combining CBT with the parents as agents of change approach for pediatric weight management. CBT is a theoretically-based therapy that focuses on the role that cognitive processes play in the maintenance of problem behaviours, mood states, and habits. CBT highlights the relationship between thoughts, feelings and actions, and utilizes techniques involving motivation, goal-setting, problem-solving, and knowledge/skill acquisition that can facilitate sustainable behaviour changes.
46034515|NCT02839486|Other|vancomycin pharmacokinetics|vancomycin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
46034516|NCT02839486|Other|cefoxitin pharmacokinetics|cefoxitin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
45472790|NCT01267097|Behavioral|Psycho-Education Program (PEP)|PEP is a knowledge-based intervention that is modelled after traditional nutrition and health education programs. Research has demonstrated that knowledge based programs can improve health behaviours and outcomes in overweight and obese populations. In relation to CBT, PEP is a more passive intervention and there is limited focus on active skill building. While PEP does not represent a true control group, its content and delivery are consistent with what many clinicians provide for weight management.
46034517|NCT05333536|Other|Experimental: Experimental group exercises|Experimental performs Strengthening exercises of core.10 reps , 3 sets of each.Prone plank(10 sec hold)(18) ,Side plank (8 sec hold),Bridging (8 sec hold)(19),Bird dog (10 reps ,3 sets),Leg drop (10 reps, 3 sets)(15),Dying bug with their regular swimming practice. First 2 weeks simple strengthening exercises.Next 4 weeks stability ball exercises. Dying bug without stability ball. And strengthening exercises of Upper Limb and Lower Limb with theraband ,10 reps each.Upper Limb: Latissimus dorsi,Serratus anterior, Upper trapezius.Lower limb : Flexors of hip, Extensors of hip,Plantar flexors.
46034518|NCT05333536|Other|No Intervention: Control group|control only participates in their yearly swimming trainings.
46034519|NCT00879229|Drug|Ambrisentan|Ambrisentan (5 mg or 10 mg tablet) administered orally once daily.
45472791|NCT03389074|Procedure|Radiofrequency catheter ablation|minimally-invasive procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias.
45839837|NCT04749498|Other|Barley Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
46034520|NCT00879229|Drug|Placebo|Placebo to match ambrisentan administered orally once daily.
46034521|NCT02837692|Drug|JNJ-42847922 10 milligram (mg)|JNJ-42847922 will be administered as single tablet of 10 mg, orally, once on Day 1.
46034522|NCT02837692|Drug|JNJ-42847922 20 mg|JNJ-42847922 will be administered as 1 tablet of 20 mg, orally, once on Day 1.
46034523|NCT02837692|Drug|JNJ-42847922 40 mg|JNJ-42847922 will be administered as 2 tablets of 20 mg, orally, once on Day 1.
46034524|NCT02837692|Drug|JNJ-42847922 60 or 80 mg|JNJ-42847922 will be administered as 3 or 4 tablets of 20 mg, orally, once on Day 1. Dose to be determined from Cohort 3, Period 1.
46034525|NCT04249726|Procedure|Direct composite resin restoration|A direct composite resin restoration will be provided intracoronally without cuspal coverage.
46034526|NCT04249726|Procedure|Direct composite resin restoration followed by full coverage metal ceramic crown|A direct composite resin restoration will be provided intracoronally followed by a full cuspal coverage metal ceramic crown.
46034527|NCT04249960|Behavioral|Managed transition|Young people, their family and clinicians will receive transition guidelines and will be asked to follow them as much as possible.
46034528|NCT04249570|Other|Povidone iodine|
46034529|NCT02837770|Drug|Diclofenac Eye Drops|One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
46034530|NCT02837770|Drug|Pacebo pill|Pacebo pill will be administered 4 hours before the IVI.
45339460|NCT00716456|Drug|erlotinib with cetuximab|The phase I portion will accrue as many as 3 cohorts of 3-6 patients; receiving erlotinib 100 mg daily along with escalating doses of cetuximab administered every 2 weeks beginning at 250mg/m2 IV without a loading dose. Subsequent cetuximab dose levels will be 375 mg/m2, and 500 mg/m2, administered IV every 2 weeks. Patients will have baseline CT, labs and ECG done within 2 weeks of study entry. Three patients will be enrolled per dose level. Patients will be monitored for toxicity weekly for the first 5 weeks, and every 2 weeks thereafter. Patients will be monitored for response by CT in the fourth week of combined therapy and every 8 weeks. All patients in this portion of the trial will receive intravenous cetuximab every two weeks at the MTD (to be determined in phase I portion) and daily erlotinib on an outpatient basis and will obtain clinical re-evaluation and radiographic re-imaging on a schedule similar to that followed in the phase I portion
45339461|NCT03945890|Other||
46034531|NCT02837770|Drug|Oral Diclofenac|One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI.
46034532|NCT02837770|Drug|Diclofenac Eye Drops|One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
46034533|NCT02837770|Drug|Pacebo pill|Pacebo pill will be administered 4 hours before the IVI.
46034534|NCT02837770|Drug|Artificial Tears|One drop Artificial Tears will be instilled 45' prior to the IVI.
46034535|NCT02837458|Device|High-Frequency|high-Frequency electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
46034536|NCT02837458|Device|Sham Stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
46034537|NCT00878995|Drug|Placebo Testosterone|Placebo (Saline) Testosterone given IM once per week.
46034538|NCT00878995|Drug|Testosterone Enanthate 100 MG/ML|Testosterone Enanthate 100mg/ml given once per week IM.
46034539|NCT02837536|Other|Horizontal iCare|IOP of the right eye will be measured using the iCare tonometer held in the horizontal position first and then in the vertical position.
46034540|NCT02837536|Other|Vertical iCare|IOP of the right eye will be measured using the iCare tonometer held in the vertical position first and then in the horizontal position.
45472792|NCT04222699|Drug|Mupirocin calcium ointment, 2%|Mupirocin nasal ointment is used to treat or prevent infections in the nose due to certain strains of Staphylococcus aureus bacteria. This medicine works by killing bacteria or preventing their growth.
46034541|NCT04250584|Device|iSlpr™|mandibular advancement device
46034542|NCT04250584|Device|SomnoDent® Classic|mandibular advancement device
45339462|NCT00684645|Drug|SUTENT|SUTENT® hard gelatin capsules containing 12.5 mg, 25 mg or 50 mg equivalent of sunitinib malate; daily dosage of 50 mg for 4 consecutive weeks followed by a 2-week rest period. Sutent is administered until disease progression or occurrence of unacceptable toxicity.
45339463|NCT04054869|Other|Bio-mechanically correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments congruently to the direction of rotational loss.
46034543|NCT02837146|Biological|Tocilizumab (TCZ)|Induction phase: TCZ subcutaneously (162 mg weekly) from baseline to week 24
46034544|NCT02837146|Drug|Methotrexate (MTX)|Induction and maintenance phase: Methotrexate 15-20 mg/week from baseline to week 54
45472793|NCT04222699|Drug|Topical Chlorhexidine, 4%|"Chlorhexidine is an antiseptic that fights bacteria.~Topical chlorhexidine is used to clean the skin to prevent infection that may be caused by surgery, injection, or skin injury."
46034545|NCT02837068|Device|Wheelchair handrail compensator|Patients were treated by wheelchair handrail compensator for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks. The handrail compensator would help the paralysis upper limb kept the shoulder joint stretch forward, the elbow joint extend, the forearm in pronation, the wrist in flection and the fingers extend.
45472794|NCT03637179|Other|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
46034546|NCT02837068|Device|Ordinary wheelchair|Patients were treated by ordinary wheelchair for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks.The ordinary handrail could prevent the disable arm from sinking, but could not help the upper limp keep a normal position.
46034547|NCT02630875|Drug|A4250|A4250
46034548|NCT02837224|Device|The Situate Detection System|The Situate Detection System for locating surgical sponges
46034549|NCT00657865|Drug|ramipril|oral intake
46034550|NCT00657865|Drug|placebo|placebo
46034551|NCT00661765|Drug|varenicline tartrate|Single dose of 2.0 mg oral Chantix (varenicline) immediate release tablet formulation
46034552|NCT00661765|Drug|varenicline free base|A single 2.0 mg dose of varenicline transdermal delivery system applied to the skin for a 24 hour period.
46034553|NCT02839252|Behavioral|Iggy and the Inhalers Asthma Education for Kids|It is a comic book, trading cards, and stickers that teach kids about asthma. There is also a 12-minute cartoon video which teaches kids about asthma.
45339464|NCT04054869|Other|Bio-mechanically in-correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments in-congruently to the direction of rotational loss.
46034554|NCT00657943|Drug|metformin|metformin tablets 2 g x 2
46034555|NCT00657943|Drug|insulin detemir|insulin as requested
46034556|NCT00657943|Drug|insulin aspart + insulin aspart protamin|insulin as requested
46034557|NCT00657943|Drug|Insulin aspart|insulin as requested
46034558|NCT02837380|Drug|FF|FF is a dry white powder blended with lactose. It is the first strip of DPI. Per blister contains 100 mcg of dose
45339465|NCT00752037|Drug|lopinavir/ritonavir and raltegravir|lopinavir/ritonavir 400/100 mg po b.id. in combination with raltegravir 400 mg po b.i.d.
45339466|NCT00747981|Procedure|Thoracic CT Scan|Perform a CT Scan and an endoscopy
45339467|NCT05416983|Procedure|Discussion|Attend discussion
46034559|NCT02837380|Drug|VI/UMEC|VI and UMEC bromide combination is a dry white powder blended with lactose and magnesium stearate. It is the second strip of DPI. Per blister contains 25 mcg/62.5 mcg of VI/UMEC dose
46034560|NCT02837302|Drug|Livact|Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.
45339468|NCT05416983|Other|Questionnaire Administration|Complete questionnaire
45339469|NCT00716144|Drug|Talarozole|Oral Capsule Once Daily
45339470|NCT00752115|Drug|sildenafil|50mg, day1,8 and 15 in each cycle
45339471|NCT00752115|Drug|placebo|1 tab, day 1,8 and 15 in each cycle.
46034561|NCT04249804|Drug|Magnesium Sulfate 1000 MG|intrathecal versus IV infusion of Magnesium sulfate for prevention of postspinal shivering
46034562|NCT02630797|Dietary Supplement|Blueberry Baseline|Before the study beginning, eligible participants will receive a radioactive tracer, Ca-41, by iv infusion. A total of 150 days will be required for the equilibration of tracer in the body i.e. elimination from soft tissue and deposition in the bone. After equilibration, a baseline period of 42 days will occur, during which no blueberry products will be provided.
46034563|NCT02630797|Dietary Supplement|Blueberry Low|One food or beverage product containing freeze-dried blueberry powder equivalent to 0.75 cups of fresh blueberries will be provided daily for 42 days.
46034564|NCT02630797|Dietary Supplement|Blueberry Medium|Two food or beverage products containing freeze-dried blueberry powder equivalent to 1.5 cups of fresh blueberries will be provided daily for 42 days.
46034565|NCT02630797|Dietary Supplement|Blueberry High|Four food or beverage products containing freeze-dried blueberry powder equivalent to 3 cups of fresh blueberries will be provided daily for 42 days.
46034566|NCT02836834|Biological|JS001|Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS-001.Each of the 3 dose levels will use 2 dose schedules: single dose, and repeated doses every 2 weeks. Subjects will be assigned to a dose schedule in the order of study entry.
46034567|NCT02631109|Drug|Pegaspargase|2000U/m2 day5
46034568|NCT02631109|Drug|doxorubicin|25mg/m2 day1
46034569|NCT02631109|Drug|etoposide|100 mg/m2 was administered once on the first day of every week
46034570|NCT02631109|Drug|methylprednisolone|15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
46034571|NCT02839096|Drug|Placebo|Cellulose placebo that will be used in place of a second dose of ferrous sulfate in the subjects randomized to once daily dosing of ferrous sulfate
46034572|NCT02839096|Drug|Ferrous Sulfate|Subjects will receive once or twice daily dosing of ferrous sulfate. This will be provided by our hospital pharmacy and be identical in appearance to the placebo.
46034573|NCT04156321|Dietary Supplement|Moringa fry|"School Tiffin:~Each of the adolescent girls will receive fresh Moringa leaves (150 gram) cooked in a traditional manner as Sajna shak (stir-fried)/ bora with rice and concentrated dal once daily for 5 days during tiffin time. Sajna Stir fry and bora will be given on every alternative day. Standard questionnaire will be used to measure the compliance of food. As we are serving the food in school premises during tiffin period, it would be both unethical and socially unacceptable if few of the students from a section receive the meal. Therefore, all the students from selected section/sections will receive the daily meal. However, we will only collect information from the selected study participants who would give consent to participate in the study Each of the combination of tiffin meal will supply 411 calories in the both arm ."
45472795|NCT03637179|Other|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
45472796|NCT01269203|Drug|Curcumin|1000 mg per day
45472797|NCT01269203|Other|Placebo|Administered daily same as Curcumin.
46034574|NCT02838784|Other|Artacent Human Amniotic Membrane|Double layer dehydrated amnion product
45339472|NCT00752115|Drug|paclitaxel (taxol)|paclitaxel; 70mg/m2 div on day 1, 8 and 15, every 28 days
45339473|NCT00752115|Drug|carboplatin (palaplatin)|carboplatin; AUC=6 on day 1, every 28 days
46034575|NCT02838784|Procedure|Standard of Care|Off loading with a cast walker, non-adherent dressings, debridement and moisture retentive dressings
46034576|NCT02630485|Behavioral|Graceful Lifestyle Changes|Participants will be educated in small groups of 8-10. A wellness booklet designed by physicians and researchers at Grace Fertility Centre will be provided.The target diet for our study is 45% carbohydrates and 55 grams of glycemic load. Participants will keep a 3-day food diary at baseline, 4, 8 and 12 weeks. Secondly, participants will be provided a pedometer and a goal to reach 10,000 steps a day. The third aspect of the program will be to decrease overall stress through mindfulness. Educational sessions will be held to teach the relaxation response and meditation techniques such as breathing and grounding exercises. Participants will be required to meditate for at least 20 minutes each day and record this.
46034577|NCT02630485|Dietary Supplement|Myo-inositol|Myo-inositol will be consumed in juice or water every morning (6 grams) for 12 weeks.
46034578|NCT02630485|Drug|Letrozole|Letrozole will be administered to patients. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
46034579|NCT00666133|Device|SpringFusor Pump|Women in Group I (Springfusor® arm) will receive loading and maintenance doses of magnesium sulfate administered via an IV infusion administered with the Springfusor pump, a simple, inexpensive flow-controlled pump system.
46034580|NCT04159363|Other|An interactive Colorectal Cancer self-Management enhancement smartphone-based psychosocial intervention programme (iCanManage)|The iCanManage consists of two components: (1a) Existing functions from the BuddyCare mobile application that provide a comprehensive 29 day-by-day perioperative guide for patients who will be undergoing colorectal elective surgery; (1b) a dashboard for healthcare professionals to monitor patients and their caregivers' well-being as well as allow mutual communication; and (2) Newly developed digitalised psychosocial content (e.g., mindfulness-based activities with audio cover, video materials related to positive psychology, patient ambassadors' success stories and relevant psychoeducation) tailored for colorectal cancer patients and caregivers, with the aim of providing them emotional and psychosocial support.
46034581|NCT02632513|Device|Proultra PiezoFlow (Dentsply Tulsa Dental Specialties)|In continuous ultrasonic irrigation group, Proultra PiezoFlow (Dentsply Tulsa Dental Specialties, Tulsa,OK) was used for the activation of the irrigating solution according to manufacturer's recommendations.
46034582|NCT00661843|Other|Integrated Yoga style practice|Intervention constitutes of 2 supervised yoga style classes per week incorporating gentle postures,relaxation and meditation sequences. In addition daily home based sessions of yogic relaxation, and meditation a an audio CD
46034583|NCT00879697|Behavioral|Walking Training|The Walking Training program was performed using a treadmill. In each session, patients performed fifteen 2-min bouts of exercise followed by a 2-min rest interval, as previously described. Walking speed was set in order to induce perceived exertion of 11 to 13 and claudication pain in the last 30 seconds of each exercise bout.
46034584|NCT00879697|Behavioral|Strength Training|The strength training program consisted of 8 exercises (leg press, crunches, unilateral knee extension, seated row, unilateral knee flexion, seated bench press, calf raises on leg press, and seated back extension). In each exercise, subjects performed 3 sets of 10 repetitions with a 2-min interval between sets and exercises.
46034585|NCT00894556|Drug|rizatriptan|Single dose of 10 mg orally disintegrating tablet at onset of migraine attack
46034586|NCT00894556|Drug|Comparator: Placebo|Placebo to Rizatriptan
45472798|NCT05569083|Genetic|Genetic analysis of APOE and BDNF genes.|The three SNPs (rs429358, rs7412 and rs6265 on APOE and BDNF genes respectively) will be analyzed by the polymerase chain reaction (PCR) on genomic DNA and with the analysis of melting curves (HRMA) using the Rotor-Gene 6,000 (Rotor-Gene, Corbett Research, Mortlake, Australia).
45598863|NCT02289859|Procedure|Wound Closure with Undermining|The side assigned to undermining will have undermining performed prior to wound closure in the subcutaneous plane. The amount of undermining will range from 1 cm for wounds with low tension to 2 cm for those with moderate tension. Since wound diameter will be 3 cm or less and exclude the scalp, high tension wounds are not anticipated.
46034587|NCT00894556|Drug|Comparator: Sumatriptan|single dose of generic sumatriptan 100 mg at onset of migraine attack
46034588|NCT00666367|Drug|D-cure|4 ml of D-cure (SMB oral intake) in syringe Exacta-Med Oral Dispenser.
46034589|NCT00666367|Drug|Placebo|4 ml of Arachidis oleum raffinatum Ph. Eur. in syringe Med Oral Dispenser.
46034590|NCT01210352|Drug|oxymorphone HCl|Comparison of different dosages of drug, 0.05mg/kg, 0.10mg/kg, 0.15mg/kg or 0.20mg/kg oral liquid oxymorphone
46034591|NCT00661921|Biological|AMG 108|IL-1 inhibitor, subcutaneous injection given every 2 weeks for the duration of the trial. Doses include 150 mg, 75mg, and 40 mg.
46034592|NCT00661921|Biological|Placebo|AMG 108 volume matching placebo
46034593|NCT04250506|Drug|Daridorexant|Daridorexant (ACT-541468) administered as film-coated tablets for oral use.
46034594|NCT04250506|Drug|Placebo|Placebo administered as tablets for oral use.
46034595|NCT04250506|Drug|Moxifloxacin|Moxifloxacin administered as film-coated tablets for oral use.
46034596|NCT02836912|Other|Exercise|Besides the same information for the education group, exercise of upper extremity without loading, exercise of lower extremity, and training of respiratory muscles are used for the exercise group
45472799|NCT05569083|Diagnostic Test|EEG recording|The EEG activity will be recorded continuously from 19 sites by using electrodes set in an elastic cap and positioned according to the 10-20 international system. The recording will be referenced to the common average of all electrodes, excluding Fp1 and Fp2. Re-referencing will be done prior to the EEG artifact detection and analysis. Data will be recorded with a band-pass filter of 0.3-70 Hz and digitized at a sampling rate of 512 Hz and analogue-digital precision was 16 bits (Gal-Nt, EbNeuro®, Florence, Italy). Horizontal and vertical eye movements will be detected by electrooculogram (EOG). Subjects will be sat in a reclined chair for approximately 20 min. Data will be collected at a sampling rate of 256 Hz, with a common mode rejection ratio of 105 dB (decibel), and the following band pass characteristics: 0.1 Hz high-pass filter, 100 Hz fifth order low-pass filter.
46034597|NCT04158973|Other|Bleeding-risk based prophylaxis strategy during hospitalization and extended pharmacological treatment after discharge|At admission, patents undergo bleeding risk assessment and receive prophylaxis according to bleeding risk. After discharge, they will undergo an extended treatment of 5mg Rivaroxaban once daily for 15 consecutive days,
46034598|NCT04158973|Other|Routine VTE prophylaxis in hospital|Patients randomized to the standard treatment (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices, VTE risk assessment and prophylaxis if indicated during hospitalization according to current policies for hospitals in China but no further treatment prophylaxis after discharge
46034599|NCT02836678|Biological|Ridge splitting, immediate implant, Nanobone with PRF.|"Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~Alloplast bone graft material (Nanobone)~PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
46034600|NCT02836678|Biological|Ridge splitting, immediate implantand PRF.|"Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
46034601|NCT00662077|Drug|Ibandronate|Ibandronate endovenous 3 mg every 3 months
46034602|NCT00662077|Behavioral|Lifestyle modifications|Lifestyle modifications: counseling every 3 months
46034603|NCT04250428|Behavioral|Demand intervention|"Women in the demand intervention arm will receive a home visit by a study nurse who will highlight the importance of supplementation and prophyllaxis to women. During this session, women will also be informed regarding side effects and the ideal timing of supplementation (after meals)."
46034604|NCT04250428|Behavioral|Supply intervention|In order to directly test the importance of access barriers, we will deliver supplements as well as malaria chemo- prophyllaxis directly to women through home visits by study nurses.
46034605|NCT01210118|Behavioral|Low intensity intervention|Control group participants received a face to face low intensity intervention which lasted 5 minutes and included brief advice and the provision of a leaflet on smoking and pregnancy. This leaflet summarized the main effects of smoking during pregnancy and gave clear short messages for encouraging smoking cessation by setting up a quit date.
46034606|NCT01210118|Behavioral|Higher intensity intervention|"Experimental group participants received a higher intensity intervention, which include: 30 minutes of individualized cognitive-behavioural counselling delivered by a trained health care professional and a self-help manual especially tailored for smoking cessation during pregnancy. Counseling was based at the 5 Αs (Ask,Advise, Asses, Assist, Arrange). In addition to counselling, a self help manual especially tailored for smoking cessation during pregnancy for Greek women was provided."
46034607|NCT00658099|Drug|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
46034608|NCT00658099|Drug|insulin NPH|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
46034609|NCT00658177|Drug|Levitra (Vardenafil, BAY38-9456)|20mg to be taken 1 h prior to sexual intercourse
46034610|NCT00658177|Drug|Placebo|Matching placebo
46034611|NCT02691104|Device|SMART COPD app to promote physical activity in COPD. Used in conjunction with a Fitbit Charge|An app which allows users to set physical activity goals, monitors progress towards those goals, and provides feedback to users. Several options for types of physical activity (daily walk, daily step count, and aerobic / strengthening exercises) which can be tailored to the individual user. Designed to be used in consultation with a physiotherapist initially, and then used independently by the individual with COPD. The app will first be used alongside pulmonary rehabilitation (PR), with physiotherapist advice on exercises and setting goals. After PR the individual with COPD will receive weekly contact from a physiotherapist for the first 4 weeks, and then no contact for the second 4 weeks
46034612|NCT02691104|Device|Control|Participants will follow the (usual care) PR programme. They will be asked to wear a blinided (cannot see step count) Fitbit Charge during the time they are on PR and then for 8 weeks afterwards
46034613|NCT00658255|Drug|budesonide/formoterol|
45472800|NCT05569083|Diagnostic Test|CSF collection and AD biomarker measurement|The CSF samples will be collected by lumbar puncture, immediately centrifuged and stored at -80 °C until performing the analysis. Aβ42, Aβ42/Aβ40 ratio, t-tau, and p-tau will be measured using a chemiluminescent enzyme immunoassay (CLEIA) analyzer LUMIPULSE® G600 (Fujirebio, Tokyo, Japan).
45598864|NCT02289859|Procedure|Wound Closure without Undermining|One side of the wound will remain un-undermined.
46034614|NCT00658255|Drug|formoterol|
46034615|NCT04158661|Procedure|thymectomy (robotic-assisted thoracoscopic, minimally-invasive thymectomy)|preferring one unilateral access and placing three trocars between 3rd and 5th intercostal space in a triangular configuration, with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
46034616|NCT04158661|Procedure|thymectomy by means of median sternotomy (transsternal)|with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
46034617|NCT04158661|Procedure|no thymectomy (control)|routine medical care
46034618|NCT01208870|Behavioral|Variety Group|The intervention will consist of our traditional family based weight control intervention with elements of reducing variety of high energy dense foods for the variety group.
46034619|NCT01208870|Behavioral|Nutrition Education Control|The intervention will consist of our traditional family based weight control intervention.
45598865|NCT04330391|Behavioral|Remote dietitian supervised weight loss intervention and mobile app|Please see intervention arm description for more details.
46034620|NCT02836210|Device|27-gauge vitrectomy wound construction|Conventional, 3-port pars plana vitrectomy with membrane peeling is performed for epiretinal membrane indication. Angled and straight trocar entry will be directly compared.
46034621|NCT04249102|Device|Guardian Connect, Medtronic|Guardian Connect is real-time continuous glucose sensor systems which provide glucose information updated every 5 minutes
45598866|NCT03519139|Other|individual dietary counselling|individual dietary counsellings with the aim to ensure sufficient coverage of energy and protein needs of the test subjects
45683181|NCT05415358|Other|Blood and tissue samples|Blood and tissue will be collected to perform ctDNA and immune biomarkers assessment to predict progression within 6 months of pembrolizumab discontinuation.
45683182|NCT05688124|Drug|IBI351|IBI351 is administered orally
45683183|NCT05688124|Drug|Esomeprazole|Esomeprazole is administered orally
45683184|NCT01869764|Drug|omega-3 fatty acid|Given PO
45683185|NCT01869764|Other|placebo|Given PO
45683186|NCT01869764|Other|laboratory biomarker analysis|Correlative studies
45683187|NCT05670964|Device|Connecting valve system|UPLUG Port (changed every 29 days) and UPLUG Disposable (changed at every dialysis session) ensure the connection between a regular haemodialysis catheter and an extracorporeal circuit, and proceed to different steps of haemodialysis session without handling the Luer-Lock connectors of the haemodialysis catheter
45683188|NCT05670964|Device|Central haemodialysis Venous Catheter|Central haemodialysis venous catheter (CE marked) will be used within the scope of their intended purpose during the dialysis session
45839838|NCT04749498|Other|Oat Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
45839839|NCT04749342|Other|Physiotherapy Treatment|Physical Therapy sessions for treatment of advanced Lymphedema Cases
46034622|NCT04249102|Device|Abbott Diabetes Care|Abbott Diabetes Care is a Flash Glucose Monitoring system that provides up to 8 hours of retrospective continuous glucose monitoring data to users when the monitor is waved in proximity with the sensor.
46034623|NCT00658489|Behavioral|Education|One group of residents will receive extensive web-based training in the promotion of oral health. The second group of residents will complete a single training module in the prevention of iron deficiency. The third arm consists of parent-child dyads, who will participate in one well-child care visit.
46034624|NCT02836288|Drug|Ketamine|Ketamine 1.0 mg/kg mixed with syrup will be given by mouth once a day for 12 weeks.
46034625|NCT02836288|Other|Placebo|Placebo syrup will be given by mouth once a day for 12 weeks.
46034626|NCT02632435|Device|PICC|Participants will be randomized to a PICC for vascular access during chemotherapy.
46034627|NCT02632435|Device|PORT|Participants will be randomized to a PORT for vascular access during chemotherapy
46034628|NCT00658645|Drug|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
46034629|NCT00658645|Drug|Placebo|Encapsulated tablets, orally, 12 weeks
46034630|NCT00658645|Drug|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
46034631|NCT02836132|Behavioral|Weight Watchers Online|
45839840|NCT04749420|Other|Survey study|Cervical Radiculopathy Impact Scale (CRIS) will be applied
46034632|NCT02836132|Behavioral|Experience Success Virtual Reality Platform|
46034633|NCT01208402|Drug|Esmolol|Infusion will be started at 50 mcg/kg/min for 4 minutes and titrated in increments of 50 mcg/kg/min up to a maximum of 300mcg/kg/min (maintenance dose) to maintain a heart rate between 60 and 80 beats per minute (bpm) while maintaining a minimum systolic blood pressure (SBP) of 95 mmHg during the length of surgery and up to 12 hours post-operatively.
45839841|NCT04748562|Drug|Progesterone|Taking prontogest vaginally
45839842|NCT04745286|Drug|S-ketamine|Patients will receive the label-covered trial agent covered by the label after premedication 5 min before induction. Agent preparation method of S-ketamine group (Group S): Draw the dosage of S-ketamine 0.25mg ·kg -1 and dilute it with normal saline to 5ml in opaque 5-ml syringes.
46034634|NCT00633334|Other|Specimen bank|Patients will be asked to provide approximately 60-120 cc (4-8 tablespoons) of peripheral blood. Select patients who undergo surgical resection of their tumor will be asked to provide portions of the tumor and tumor draining lymph nodes for further analysis. In addition patients undergoing surgical resection may be asked to provide additional peripheral blood samples at time of routine follow-up (at least 4-6 weeks after initial blood draw and between subsequent draws).
46034635|NCT04248946|Other|Transcranial direct current stimulation|tDCS alters neural excitability in a polarity-specific manner via a weak direct electric current delivered through electrodes placed on the scalp. There are 3 types of stimulation: anodal, cathodal, and sham. In anodal tDCS, the positive electrode is placed over the target brain area to increase neuronal excitability. In cathodal tDCS, the negative electrode is placed over the target brain area to decrease neuronal excitability. Sham tDCS emulates the physical sensations of active (anodal/cathodal) tDCS but current is only delivered for a short period of time and is not enough to cause any neuromodulations
46034636|NCT01208324|Drug|estrogen patch|150 subjects will be enrolled in a double blind placebo controlled study where they will be randomized to receive either treatment with 17β-estradiol (Vivelle Dot® 0.10 - 0.15 mg/day) or a look-alike placebo patch for a total of approximately 8 weeks. There will be four fMRI test sequences: two test sequences one week apart prior to estrogen treatment (ET) or placebo treatment (PT), and two sequences one week apart following approximately 6-weeks of double-blind ET or PT. During each test day, all subjects will have their blood drawn at specific time intervals and undergo a battery of cognitive testing.While on the ET or PT treatment, all subjects will be instructed to change the patch every 3.5 days.
45839843|NCT04745286|Drug|normal saline group|"Patients will receive the label-covered trial agent covered by the label after premedication 5 min before induction. Normal saline group (Group N): 5ml of normal saline, labeled as study agents."
46034637|NCT01208324|Drug|Amino acids|31.5 mg of amino acids or 31.5 mg of lactose will be administered to subjects on each of their 4 test days. On 2 of the test days subjects will receive the active pills (amino acids) and on the other 2 test days subjects will receive the placebo pills (lactose).
46034638|NCT01208324|Drug|Placebo Patch|placebo
46034639|NCT01208324|Drug|Placebo pills|There are 4 test days in this study. Each test day will involve the ingestion of 70 capsules. During one of each pair of tests, the 70 capsules will contain 31.5 g of lactose (sham depletion), while during the other test they will contain a total of 31.5 g of amino acids.
46034640|NCT05333848|Behavioral|Internet-based storytelling programs with interactivity and stigma content|Participants viewed an interactive stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
46034641|NCT05333848|Behavioral|Internet-based storytelling programs with stigma content only|Participants viewed a non-interactive stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
46034642|NCT05333848|Behavioral|Internet-based storytelling programs with interactivity only|Participants viewed an interactive non-stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
46034643|NCT05333848|Behavioral|Internet-based storytelling programs with no interactivity and no stigma content|Participants viewed a non-interactive non-stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
46034644|NCT05422976|Device|EVI-01|High molecular weight Hyaluronic Acid
45839844|NCT04745364|Behavioral|A 4-week Bharatanatyam course from the organization Mindful Kala|The 4-week Mindful Kala program focuses on three components of Bharatanatyam: nritta (i.e. technical movements), natya (i.e. storytelling), and nritya (i.e. a combination of movements and narration; nritta + natya).
45839845|NCT04745442|Drug|Antithrombin + best available treatment|The subject will be treated with Antithrombin (50 IU/Kg/12h) for 72 hours and the best available treatment for COVID-19.
45839846|NCT04745442|Drug|Best available treatment|The subject will be treated with the best available treatment for COVID-19.
45839847|NCT04744740|Device|in-home sleep recording|in-home, nightly, zero-burden objective quantification of sleep scheduling and sleep heart rate via a mattress-top sensor (Sleepace RestOn) + ad lib quantification of blood SaO2 via a ring-based sensor (Bodimetrics Circul) + ad lib quantification of sleep and waking activity and heart rate via a wrist-worn sensor (Garmin Vivosmart 4)
45839848|NCT04744818|Dietary Supplement|Iron syrup|Daily supplementation with iron
45839849|NCT04744818|Dietary Supplement|Multivitamin syrup|Daily supplementation with multivitamins
46034645|NCT02838940|Procedure|Blood samples.|"At the beginning of the first incision in the skin, first blood sample will be taken for levels of antibiotics in serum test.~Second blood sample for drug levels in serum test, will be taken while closing the surgical incision in the skin at the end of the operation."
46034646|NCT02838940|Drug|Cefazolin|According to the ward protocol prior to the anesthesia by an anesthesiologist, the women will receive one dose of 1 g Cefazolin the usual loading dose. Women with a BMI over 30 will receive Cefazolin of about 2 grams.
46034647|NCT05422430|Behavioral|Rebreathing-induced hypoxia|Participants will rebreathe room air from a low-volume closed-circuit system for a period of 2 minutes.
46034648|NCT05422430|Behavioral|Spontaneous breathing|Participants will be spontaneously breathing during an oral glucose tolerance test.
46034649|NCT00880399|Drug|orvepitant|Neurokinin-1 (NK-1) antagonist
46034650|NCT00880399|Other|placebo|inactive placebo to match orvepitant 30 and 60 mg dosage forms
46034651|NCT05416658|Other|The Antipsychotic Medication Decision Aid (APM-DA)|The APM-DA intervention is the first and only International Patient Decision Aid Standards (IPDAS) approved shared decision making (SDM) decision aid intervention for Antipsychotic Medication decisions in psychiatric visits. The APM-DA intervention developed by the research team addresses a common issue among psychiatric care providers and patients that lies in the heart of pharmacotherapy - taking, tapering or stopping APM. The APM-DA has a print format and can be used online as a PDF. It includes a concise table describing what each option involves, its benefits, risks, and strategies to reduce risks. The intervention was developed in co-production with various stakeholders (patients, clinicians, service leadership, family members, researchers). Additional intervention materials are an evidence document to support the information and an APM side effects table.
46034652|NCT02835898|Other|Conventional periodontal treatment|Conventional routine periodontal treatment will be done for patients in test group
46034653|NCT02835976|Drug|Olesoxime|Olesoxime will be given orally on Day 1 as a 600-mg liquid suspension within 30 minutes after starting a standardized high-fat breakfast.
46034654|NCT02838706|Procedure|Surgery for hip fracture|
46034655|NCT02836054|Procedure|lumbar puncture (LP)|
46034656|NCT02836054|Procedure|brain MRI|
46034657|NCT02835742|Drug|Sargramostim|
46034658|NCT02835742|Drug|Placebo|
46034659|NCT05326360|Drug|Ramosetron Hydrochloride|we injected two additional remosetron doses in different way in experimental groups. In group B, patients received additional ramosetron at 12 hour interval, in group M, patients received additional ramosetron in mixed with the patient controlled analgesia regimen.
45683189|NCT04602728|Behavioral|Back2Life|The Back2Life intervention uses an adaptive treatment approach with module-based treatment sessions selected on the basis of baseline assessment (rather than a fixed treatment approach) to allow flexibility in tailoring treatment components to meet individual family needs. All youth participants will receive the standard 6-session pain coping skills training program, consisting of learning ways to cope with and manage chronic sickle cell pain. The standard program includes topics that were identified by young people with chronic sickle cell pain and their parents as important skills for all youth with chronic pain and sickle cell disease. In addition to the standard 6-session program, youth participants may receive an additional 1 to 4 sessions that may help with specific problems and/or co-morbidities related to pain. At least one parent or guardian is required to attend the sessions with their child.
45683190|NCT05396248|Behavioral|Memory Retraining Exercises|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
45683191|NCT05396248|Behavioral|Placebo Control Memory Exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
45683192|NCT01842620|Drug|Metformin|Oral antidiabetic agent
46034660|NCT00666523|Dietary Supplement|phytalgic|3/day
46034661|NCT00666523|Dietary Supplement|placebo|3/Day
46034662|NCT02838550|Behavioral|Motivational Online Intervention|"The self-administered Motivational Online Intervention developed by the authors was based on the Transtheoretical Model of Change. It attempts to facilitate the decisional balance, the increase of the self-efficacy, and the use of experiential and behavioral processes of change (e.g., consciousness raising, counterconditioning, reinforcement management, stimulus control). The main objective is to deliver information to increase the motivation to practice physical activity and to set individualized goals. It has a total length of 45 minutes, and it is delivered in a web platform at the beginning of the intervention."
46034663|NCT02838550|Behavioral|Pedometer|Wearing a pedometer of new generation that provides motivational messages from time to time to motivate the user to increase the physical activity, as well as information in the screen regarding all-day activity: steps taken, calories burned, distance travelled, floors climbed and active minutes.
46034664|NCT00666601|Drug|TR-700 (active moiety)|A TR-700 solution will be locally administered via a microdialysis probe into the skeletal muscle and subcutanous tissue (just under the skin) at a concentration of approximately 2 µg/mL at a flow rate of 1.5 µL/min for 60 minutes for a total maximum dose of 0.36 µg (0.18 µg per probe).
46034665|NCT00666601|Drug|TR-701 (pro-drug)|Each subject enrolled in the Main study will receive a single oral dose of 600mg TR-701
46034666|NCT01207388|Drug|Blinatumomab|Continuous intravenous infusion
46034667|NCT02835664|Dietary Supplement|Nicotinamide Riboside (Niagen)|
46034668|NCT02835664|Dietary Supplement|Placebo|
46034669|NCT00666913|Other|informational intervention|Data from an archived database of a closed clinical trial is retrieved.
45339474|NCT00918476|Drug|filibuvir + Oral Contraceptives|This is an open-label, fixed sequence study to investigate the effect of filibuvir (600 mg BID on the pharmacokinetics of oral contraceptives steroids. Sixteen subjects who have been on any combination of ethinyl estradiol and levonorgesterol oral contraceptives for at least one consecutive month prior to Period 1 will be enrolled into the study. The study will be conducted over two 28 day menstrual cycles and Day 1 of each period is defined as the first day of dosing OC in each cycle. During the first cycle (Period 1), the subjects will receive OC QD for 21 days and filibuvir BID on Days 22 through 28. During the second cycle (Period 2) the subjects will receive OC QD and filibuvir BID for 21 days. The dosing of filibuvir will start in Period 1 (Days 22 - 28).
46034670|NCT02838472|Drug|Ascorbic Acid|Ascorbic acid administration at a doses of 75-80% of the upper limit of allowance according to IOM
46034671|NCT00666991|Drug|nanoparticulate paclitaxel|This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients. Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced. Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
45339475|NCT00749385|Drug|PN 400|A single tablet containing delayed-release naproxen (500mg) plus immediate-release esomeprazole (20mg)
45339476|NCT00749385|Drug|EC naproxen plus EC esomeprazole|Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule (20mg)
46034672|NCT02835430|Procedure|Coronally advanced flap and PRF with DFDBA|• For Test site: i. Following pre-suturing of coronally advanced flap, DFDBA (Rocky Mountain Particulate Allograft) was placed over the exposed root and adjacent bone surface and subsequently covered by PRF membrane.
46034673|NCT02835430|Procedure|Coronally advanced flap and PRF without DFDBA|. For Control site: i. Following pre-suturing of coronally avanced flap, exposed root and adjacent bone surface was covered by PRF membrane.
46034674|NCT02835508|Drug|JNJ-56021927 60 Milligram|JNJ-56021927 60 mg oral tablet.
46034675|NCT02835508|Drug|JNJ-56021927 120 Milligram|JNJ-56021927 120 mg as 2 tablets of 60 mg.
46034676|NCT02835508|Drug|JNJ-56021927 240 Milligram|JNJ-56021927 240 mg as 4 tablets of 60 mg.
46034677|NCT02838394|Procedure|Dry needling|Acupuncture filiform needles are inserted into myofascial trigger points
46034678|NCT02838394|Other|Sham dry needling|Blunted needles will be pressed against the skin, but no actual penetration will occur
45339477|NCT00749385|Drug|EC naproxen|Enteric-coated naproxen tablet (500mg)
45339478|NCT00749385|Drug|EC esomeprazole|Enteric-coated esomeprazole capsule (20mg)
46034679|NCT00667147|Drug|Weekly Abraxane and Daily Vandetanib|Abraxane once a week for three weeks, followed by one week with no Abraxane. Vandetanib once a day every day for 28 days. This four week period is called a cycle.
46034680|NCT00667147|Drug|Abraxane every three weeks and daily vandetanib|Abraxane on day one of study therapy, followed by 20 days of no Abraxane. Vandetanib once a day every day for 21 days. This three week period is called a cycle.
46034681|NCT02835586|Drug|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery and/or popliteal artery after stenting. Dosing will be based on the lesion surface area and will be calculated using the following formula : 22/7 x diameter (mm) x length (mm) x 3 µg/mm3
46034682|NCT04154215|Diagnostic Test|PET-CT FDG brain scan|"Scans will be performed in Discovery MI PET/CT scanner (by GE). Dynamic FDG PET scan start immediately after a bolus injection of 18F-FDG (0.1 mCi/kg) 5. Dynamic PET scan protocol of 30 min will be follow by a static scan protocol with a duration of 8 min combined with a low dose CT scan.~The radiation exposure of the patients is equal to the radiation exposure during the routine PET-CT FDG brain scan. The only discomfort to the patient is a longer scan duration.~After the scan is concluded the patient will be released with no restrictions. Each of the acquired PET images will undergo visual assessment. In addition, quantification of the image data using Standardized Uptake Values (SUV) and kinetic model. The correlation between the clinical information, visual assessment and quantitative parameters will be tested. Sensitivity and accuracy of the quantification methods will be calculated."
46034683|NCT00911521|Drug|human papillomavirus vaccination (Gardasil)|3 doses of the human papillomavirus vaccines to be given at baseline, month 2 and month 6
46034684|NCT02835352|Other|Essential oils massages|
46034685|NCT02835352|Other|Oil massages|
45339479|NCT02592044|Procedure|peripheral venous cannulation|The 18 gauge venous cannula will be inserted in a peripheral vein on the back of right hand of the patient.
45339480|NCT02592044|Procedure|Aromatherapy with lavender essential oil|The two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
45683193|NCT05687890|Drug|Placebo of SC0062|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
45683194|NCT05687890|Drug|SC0062 low dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
45683195|NCT05687890|Drug|SC0062 medium dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
46034686|NCT02630407|Biological|viscosupplementation|A single 3 ml hyaluronic acid (HA) injection (viscosupplementation) performed the day after ACL reconstruction, after drainage removal
46034687|NCT02630407|Other|Placebo group|A single 3 ml saline injection performed the day after ACL reconstruction, after drainage removal
46034688|NCT04248790|Behavioral|mobile app to improve adherence to PrEP self-management|Access to the mobile app which includes the sex and PrEP diary, information on HIV/STI testing, PrEP reminders and geo-location features.
46034689|NCT00667303|Other|Nasopharyngeal Washes|A total of eight nasopharyngeal washes will be done at the following time points: Prior to conditioning, on the day of admission and thereafter every two weeks until day +100 (Day +14, 28, 42, 56, 70, 84 and 98). To allow for flexibility over the weekends and holidays the specimen may be collected on the scheduled day ± 3 days. The baseline sample obtained prior to conditioning is required for patient to be considered evaluable.
46034690|NCT00667303|Other|Fluorescent antibody detection|For IF (Direct IF for hHRSV and indirect IF for the other viruses), the specimens will be spotted onto glass slides. Samples without respiratory epithelial cells will be considered inconclusive. Labelled antibodies against Flu A, Flu B, HPIV 1 to 3, RSV, hMPV and Adv will be used.
46034691|NCT00667303|Other|Respiratory viral culture|Shell vial culture specimens will be inoculated and incubated for 48 hours. The following RVs: Flu A, Flu B, HPIV 1-3, RSV, Adv and hMPV will be identified on the basis of cytopathic effects in cell cultures and confirmed by staining with fluorescein-conjugated monoclonal antibodies.
46034692|NCT02838238|Drug|Capecitabine|
46034693|NCT02838238|Drug|Placebo|
45339481|NCT02592044|Procedure|Placebo|The two drops of water will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
45339482|NCT00748059|Procedure|Standing or upright tilt|stand upright or tilt table test
45339483|NCT00748059|Procedure|Microneurography|Recording from sympathetic nerve
45339484|NCT00748059|Procedure|QSweat|quantitative sweat testing
45339485|NCT00748059|Device|neck cuff stimulation|Blood pressure receptors in the neck arteries may be stimulated by applying suction through a collar around the neck.
45339486|NCT00748059|Drug|phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine|"IV Pharmacological Testing~phenylephrine 12.5 - 400 ug, isoproterenol 0.1 - 0.4 ug or higher until desired effect, nitroprusside 0.1 - 1.6 ug/kg, propranolol 1.1 mg/min, edrophonium maximum of 10 mg, atropine .01 mg/kg, tyramine 250-4000 ug or higher until desired effect"
45339487|NCT00748059|Drug|clonidine,yohimbine,metoclopramide,alpha-methyldopa|"Oral Pharmacological Testing~clonidine 0.1-0.3 mg, yohimbine 5-10 mg, metoclopramide 10 mg, alpha-methyldopa 62.5 mg, placebo"
45339488|NCT00748059|Procedure|BodPod|Determination of body composition
46034694|NCT00667537|Drug|Radium-223 chloride (Xofigo®, BAY88-8223) injection|Sterile, clear and colourless aqueous solution of radium-223 chloride free of endotoxins, for intravenous administration
46034695|NCT02835040|Other|New model of service delivery|Introduction of a new CAP disease specific clinical team to ensure systematic implementation of standardized treatment protocols (similar to a clinical pathway) for interventions supported by Level-1 evidence.
46034696|NCT02835040|Other|Current practice|Interventions as determined by the treating General Medical team consistent with current usual practice.
46034697|NCT00667771|Drug|Naltrexone|
46034698|NCT01206764|Drug|RAD001|
46034699|NCT04248400|Other|Tai Chi training|A 24 weeks Tai Chi training with three 1-hour section per week
46034700|NCT04248400|Other|Conventional exercise|A 24 weeks conventional exercise training with three 1-hour section per week
46034701|NCT00667927|Drug|Busulfan|See Detailed Description section for description of treatment plan.
46034702|NCT00667927|Drug|Cyclophosphamide|See Detailed Description section for description of treatment plan.
46034703|NCT00667927|Drug|Mesna|See Detailed Description section for description of treatment plan.
46034704|NCT02835118|Drug|Surotomycin|Two oral doses of surotomycin in hard gelatin capsules totaling either 0.5, 1 or 2 g per day, for 14 days
46034705|NCT02835118|Drug|Placebo|Two oral doses of placebo for surotomycin in hard gelatin capsules per day, for 14 days
46034706|NCT00668005|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
46034707|NCT00668005|Drug|Placebo|Matching placebo
46034708|NCT02835196|Device|Optical Elastography|To image skin thickness, Optical Coherence Elastography (OCE)-scanning of 6 body surface areas will be preformed using the Phase-Stabilized Swept Source Optical Coherence Elastography (PhS-SSOCE) system.
45683196|NCT05687890|Drug|SC0062 high dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
45339489|NCT00748059|Procedure|Eye exam|"Examination of pressure in the eye and eyelid fatiguability. The following eyedrops might be used:~0.5% proparacaine (Alcaine, Allergan, Inc)~Fluress (0.4% benoxinate hydrochloride, fluorescein sodium, Akorn, Inc)~0.5%, 1% tropicamide (Mydriacyl, Alcon)~Over-the-counter preservative-free artificial tears~0.25%, 2.5% and 10% phenylephrine (Bausch and Lomb)~1% cyclopentolate hydrochloride (Alcon)"
45339490|NCT00748059|Procedure|Sleep study|Recording of sleep pattern overnight
45683197|NCT04400266|Drug|B+MEL|Buspirone and Melatonin
45683198|NCT04746742|Procedure|Tunneled Femoral Catheter (TFC) group|Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
46034709|NCT02835196|Other|Visual Assessment|Skin thickness will be visually assessed clinically in 6 body surface areas using the the modified Rodnan Skin Score (mRSS). The mRSS uses a 0-3 scale, where 0 = normal, 1= mild thickness, 2 = moderate thickness, and 3 = severe thickness
45339491|NCT00748059|Procedure|Pain response testing|Subjects will rate the quality and intensity of 2 pain tasks.
45339492|NCT00748059|Procedure|Metabolic chamber|Determination of metabolic rate via 24hr stay in whole-room indirect calorimeter
45683199|NCT04746742|Procedure|Femoro-femoral Arteriovenous graft (FF-AVG) group|Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
45683200|NCT04348162|Other|Cocoa flavanols and berries anthocyanins|Effect of cocoa flavanols and berries anthocyanins on cardiovascular and cognitive health
46034710|NCT05333692|Dietary Supplement|Fresubin® Protein Energy DRINK|1-2 bottles of Fresubin® Protein Energy DRINK per day
46034711|NCT05333692|Dietary Supplement|NEPRO® , Abbott|2-4 cans NEPRO® per day
46034712|NCT04154137|Other|Questionnaire|Enrolled patients will fill out a modified version of a previously validated written questionnaire, including two different sections. The first comprises basic demographic information, including age, sex and ethnicity, and a screening section for symptoms consistent with irritable bowel syndrome (IBS) in accordance with the Rome III criteria, also including their past gastrointestinal, allergic and psychiatric history. The second section enquires for self-reported gluten-related symptoms. Participants will be also asked for their use of a gluten-free diet and if they had seen a healthcare professional for their symptoms. A reported diagnosis of celiac disease and wheat allergy in the population group is defined by those who had a doctor diagnosis of celiac disease and wheat allergy and are also taking a gluten-free diet.
46034713|NCT00668161|Behavioral|Exercise|60 minutes/session of aerobic exercise, 6 d/week at 50-50% HHR. All sessions will begin with 10 minutes of stretching and 5 minutes of warm-up, and will end with 5 minutes of cool down.
46034714|NCT00668239|Drug|intravitreous triamcinolone|Intravenous injection of 0.1 ml (4 mg) of triamcinolone acetate was performed through the pars plana in a surgical environment. The medication used was manipulated by the Ophthalmos chemist. This type of formulation is different from the similar American one (Kenalog ®) since it does not use a conservation agent
46034715|NCT00668239|Procedure|laser therapy|pan fotocoaglulation by laser therapy
46034716|NCT00658801|Radiation|Respiratory gated proton beam radiotherapy|"Prescription dose to PTV as according to the following dose escalation schema:~Group 1: Tumor size ≤5cm Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.~Group 2: 5cm <Tumor size ≤10cm Dose level 1: 54 GyE /18 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week."
46034717|NCT04156009|Other|Activated Lavender Elequil aromatabs® (#372)|Activated Lavender aromatherapy tablets wrapped in tape
46034718|NCT04156009|Other|Unactivated Lavender Elequil aromatabs® (#372)|Unactivated Lavender aromatherapy tablets wrapped in tape
45339493|NCT00748059|Procedure|Brain function studies|Questionnaires and computer tasks, an EEG and an MRI may be used to assess brain function.
45339494|NCT00748059|Procedure|Bicycle Exercise Test|Blood pressure and heart rate may be monitored while exercising on a stationary bicycle.
45339495|NCT00576381|Drug|Dexmedetomidine|Dosage Level 1=0.25mcg/kg loading dose, 0.2 mcg/kg/hr infusion Dosage Level 1A= 0.35mcg/kg loading dose, 0.3 mcg/kg/hr infusion Dosage Level 2= 0.5mcg/kg loading dose, 0.4 mcg/kg/hr infusion
46034719|NCT02631499|Procedure|TACE|TACE is performed 4-6 weeks after hepatectomy. Epirubicin and lipiodol are used in TACE.
46034720|NCT02631499|Drug|Epirubicin|Epirubicin is a chemotherapy drug used in TACE
45339496|NCT00748137|Device|ezy-BICC dose calculation card|small laminated table lists the dose of insulin to administer based on BGL and carbohydrate to be consumed - individualised for each study subject
45339497|NCT00748137|Other|Fixed dose|Approach where study subject is prescribed a set amount of carbohydrate to eat each meal and set dose of rapid acting insulin. Minor modifications may be made if the measured BGL is out of target
45339498|NCT02562417|Drug|Normal saline|
45339499|NCT02562417|Drug|IV dexamethasone|
45339500|NCT00748293|Other|Low-residue diet|Commercialized (not yet marketed)low-residue diet
46034721|NCT02631499|Drug|lipiodol|lipiodol is a kind of embolization material used in TACE
46034722|NCT00662233|Drug|cyclophosphamide|
46034723|NCT00662233|Drug|doxorubicin hydrochloride|
46034724|NCT00662233|Drug|etoposide|
46034725|NCT00662233|Drug|ifosfamide|
46034726|NCT00662233|Drug|vincristine sulfate|
45339501|NCT00749619|Other|Catheter Lock Solution Taurolidine and Citrate|
45339502|NCT00749619|Other|Catheter Lock Solution :Taurolidine and Citrate and Heparin|
46034727|NCT00662233|Procedure|adjuvant therapy|
46034728|NCT00662233|Procedure|neoadjuvant therapy|
45339503|NCT00749619|Other|Catheter Lock Solution : Heparin|
45339504|NCT00749697|Other|SPECT scan|SPECT scan measures the amount of radio activity that is remaining in patients' body after the consumption of radio iodine for therapeutic purpose
45339505|NCT02561403|Behavioral|EVO multitask video game|Participants will play a multitasking game for 4 weeks
45339506|NCT02561403|Behavioral|EVO words video game|Participants will play a word puzzle game for 4 weeks
45339507|NCT00752349|Procedure|Ultrasound|To evaluate oral phase swallowing function using submental ultrasound
45339508|NCT00748371|Drug|aspirin|40mg aspirin: one 40-mg aspirin capsule by mouth each morning + one Avicel capsule by mouth each evening
45339509|NCT00748371|Drug|aspirin|1300mg aspirin: one 650-mg capsule by mouth twice daily
45339510|NCT00748371|Drug|placebo|Placebo: one Avicel (cellulose) capsule by mouth twice daily
46034729|NCT00662233|Procedure|therapeutic conventional surgery|
46034730|NCT00662233|Radiation|brachytherapy|
46034731|NCT00662233|Radiation|intraoperative radiation therapy|
46034732|NCT00662233|Radiation|radiation therapy|
46034733|NCT04156243|Biological|CD19 CARvac T cells|CD19 CARvac T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
46034734|NCT00668629|Drug|Lactic acid (Dermacid)|
46034735|NCT02630173|Procedure|Scaling and root planing|Scaling and root planing was done in both the groups
46034736|NCT02630173|Other|Endodontic treatment|In non vital teethRoot canal treatment was completed in two visits. 3% Naocle was used as irritant and calcium hydroxide was used as intracanal medicament .Obturation was done with gutta percha.
46034737|NCT02632357|Other|Spinal Manipulation|
46034738|NCT00658957|Drug|gentamicin-collagen sponge|5 × 5 cm sponge
46034739|NCT00658957|Drug|placebo collagen sponge|5 × 5 cm sponge
46034740|NCT00662467|Drug|aspirin + clopidogrel|Dual therapy
46034741|NCT00662467|Drug|aspirin + clopidogrel + warfarin|Triple therapy
46034742|NCT00668941|Drug|Teriparatide|Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.
46034743|NCT00668941|Drug|Alendronate|Participants will take 70 mg per week of alendronate for 48 months.
46034744|NCT00668941|Dietary Supplement|Calcium|Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.
45339511|NCT03879291|Other|pinpointIQ|The study will utilize physIQ's multivariate analytical methods that detect vital sign relationship changes compared to a patient's individual baseline. Changes in vital signs relationships may be indicative of current or future important clinical events. These changes are indicated through the Multivariate Change Index (MCI), which is a scalar index between 0 and 1, where values close to 0 indicate no significant change from baseline and values close to 1 indicated greater changes from baseline
45339512|NCT00749853|Drug|follicle stimulating hormone|Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
45339513|NCT00749853|Drug|follicle stimulating hormone|No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
46034745|NCT00668941|Dietary Supplement|Vitamin D3|Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.
46034746|NCT00894322|Drug|exenatide once weekly|subcutaneous injection, 10.0 mg, single injection
46034747|NCT00894322|Drug|exenatide once weekly|subcutaneous injection, 2.0 mg, once a week for 12 weeks
46034748|NCT00894322|Other|Placebo|subcutaneous injection, volume equivalent to Cohort 2 experimental intervention, once a week for 12 weeks
46034749|NCT02631265|Other|Exercise 1|Participants will be admitted at IRCM at 14:00. At 15:30, participant's insulin basal rate will be reduced by 80% and participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
46034750|NCT02631265|Other|Exercise 2|Participants will be admitted at IRCM at 14:00. At 15:10, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
46034751|NCT02631265|Other|Exercise 3|Participants will be admitted at IRCM at 14:00. At 14:50, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
46034752|NCT00662623|Behavioral|i-PAP|Internet Intervention based on wireless telemonitoring of CPAP data and patient-centered, collaborative care
46034753|NCT00662623|Behavioral|Usual Care (Standard Care)|Pre-determined clinic visits and telephone support
45339514|NCT00748449|Procedure|Colonoscopy|1 Colonoscopy
45339515|NCT00748449|Procedure|CT-colonography|1 CT-colonography; Procedure/Surgery/Radiation
46034754|NCT00669097|Drug|TKI258|
45339516|NCT02561325|Drug|Sodium Bicarbonate and Sodium chloride|
45339517|NCT02562495|Device|CT Scan and ultrasonography|Up to three measurements (CT scan and Ultrasonography) of the thickness of quadriceps, will be made concurrently .
45339518|NCT00684567|Radiation|Radiotherapy|Radiotherapy will be administered in combination with temozolomide during the concomitant radiotherapy phase. Radiotherapy will consist of a conventionally fractioned regimen, delivering a total dose of 60 Gy in 6 weeks, in a once daily schedule of 2 Gy per fraction, for a total of 30 fractions. Radiation will be provided by a linear accelerator of x ray energy of 4 MV or higher.
45339519|NCT00684567|Drug|Temozolomide|During the concomitant radiotherapy phase (6 weeks), temozolomide will be administered in combination with radiotherapy, once daily at 75 mg/m2/day. Then, during the monotherapy phase, subjects will receive 6 cycles of temozolomide alone. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m2/day, and may be increased to 200 mg/m2/day for Cycle 2 and subsequent cycles depending on nonhematologic toxicity observed and neutrophil and platelet count values. Capsules containing 5 mg, 20 mg, or 100 mg of temozolomide will be combined to achieve each subject's calculated dose.
45339520|NCT00752427|Drug|Paliperidone ER OROS®|
46034755|NCT00633412|Drug|Esomeprazole|20mg oral daily
46034756|NCT00633412|Drug|Ranitidine|150mg oral twice daily
46034757|NCT00633412|Drug|Esomeprazole|40mg oral tablet daily
45339521|NCT04053621|Dietary Supplement|Thiamine pyrophosphate|12 weeks of weekly dose of 1 gram of thiamine pyrophosphate administered in an intravenous manner with saline solution
45339522|NCT04053621|Other|Placebo|12 weeks of weekly dose of 275 ml of saline solution administered in an intravenous manner
45339523|NCT04053621|Drug|Metformin|All participants will continue taking metformin in their previous established tolerated dose for the duration of the study
45339524|NCT00684411|Drug|Imatinib mesylate|
45339525|NCT02561793|Drug|DHEA|Women will receive DHEA 12 weeks before starting IVF/ICSI
46034758|NCT04250116|Drug|NOAC monotherapy|Patients enrolled in the anticoagulation mono therapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 20 mg once daily for 2 years after randomization. In case of renal impairment, reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (15 mg once daily) or Warfarin would be considered.
46034759|NCT04250116|Drug|Dual therapy with apixaban and clopidogrel|Patients enrolled in the dual antithrombotic therapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 15 mg once daily and clopidogrel 75 mg daily for 2 years after randomization. In case of renal impairment, reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (10 mg once daily) or Warfarin would be considered.
46034760|NCT00596635|Dietary Supplement|Once Daily Cranberry Capsule|650mg capsule pure cranberry powder
46034761|NCT00596635|Dietary Supplement|Twice Daily Cranberry Capsules|One 650mg cranberry capsule administered twice per day
46034762|NCT00659113|Drug|cisplatin|
46034763|NCT00659113|Drug|tegafur-gimeracil-oteracil potassium|
46034764|NCT00659113|Other|cytology specimen collection procedure|
46034765|NCT00659113|Procedure|endoscopic biopsy|
46034766|NCT00662701|Procedure|Catheter Ablation|RF ablation with complete circumferential ablation around the right and PVs, optional additional lines between the lower and upper PVs, and towards the mitral valve ring.
46034767|NCT00662701|Procedure|Surgical Ablation|Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
46034768|NCT04159051|Device|Regional Hyperthermia|Regional hyperthermia 1-2×/week to a total number of 7-10 treatments combined with salvage radiotherapy to a total dose of 70 Gy over 7 weeks
45339526|NCT02561793|Drug|Placebo|women will receive a placebo 12 weeks before starting IVF/ICSI
46034769|NCT00662779|Drug|arformoterol|15 mcg arformoterol nebulizer
46034770|NCT00662779|Drug|formoterol|Formoterol 12 mcg/inhalation, dry powder inhaler
46034771|NCT00662779|Drug|placebo|placebo dry powder capsules ( lactose) and placebo normal saline for nebulization
46034772|NCT00669253|Procedure|Er: YAG Laser|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
46034773|NCT00669253|Procedure|Conventional treatment 1(ultrasonic and manual means)|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods : ultrasonic and manual means
46034774|NCT00669253|Procedure|Conventional treatment 2 (ultrasonic and manual means)|Surgery at baseline for all deep pockets using conventional methods: ultrasonic and manual means
46034775|NCT02630329|Procedure|vNOTES adnexectomy|Surgical removal of one or both adnexa by a natural orifice transluminal endoscopic surgical technique using a colpotomy (transvaginal incision)
46034776|NCT02630329|Procedure|Laparoscopic adnexectomy|Surgical removal of one or both adnexa by transabdominal laparoscopy
46034777|NCT00911599|Diagnostic Test|Blood metal ion levels|Blood and urine will be collected and the levels of cobalt and chromium ions will be tested.
46034778|NCT00662935|Procedure|setting-up of an electrode in deep brain|deep brain stimulation of the postero-inferoir hypothalamus
46034779|NCT02630095|Drug|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3, and during the of perioperative period of Endoscopic treatment changing to use Nadroparin Calcium 4100IU／d，subcutaneous.
46034780|NCT02630095|Device|Doppler ultrasound and CT|all patient will take Doppler ultrasound examination every 3 months ；Abdominal CT will be done every 6 months。
46034781|NCT00669487|Drug|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|Truvada(FTC200mg+TDF300mg) every 24 hours + NVP 200 mg every 12 hours orally until week 72
46034782|NCT00669487|Drug|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR S(D4T30mg+3TC150mg+NVP200mg)1 pill orally every 12 hours until week 24 and then switch to GPO-VIR Z
45339527|NCT02562651|Drug|Doxycycline|Doxycycline bid for the first 7 days after primary anterior STEMI
45339528|NCT02562651|Other|Standard care for STEMI|Invasive and medical treatment for STEMI according to guidelines
45339529|NCT00748527|Drug|carboplatin|Given IV
45339530|NCT00748527|Drug|decitabine|Given IV
45339531|NCT00686829|Drug|Vicriviroc maleate|VCV 30 mg tablet once daily by mouth.
45339532|NCT00687297|Drug|vandetanib induction|100 mg daily by mouth
45339533|NCT00687297|Drug|Docetaxel|(75mg/m2) IV (in the vein) on day 1 of a 21-day cycle for 4 cycles or until disease progression
46034783|NCT00669487|Drug|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR Z(AZT250mg+3TC150mg+NVP200mg) 1 pill orally every 12 hours until week 72
46034784|NCT00669565|Drug|Bavituximab|Receive weekly bavituximab at a dose of 3 mg/kg until disease progression, and carboplatin at a dose of AUC = 2 and paclitaxel 100 mg/m2 on days 1, 8, and 15 of a 28-day cycle for up to 6 cycles.
46034785|NCT00669643|Drug|PB 6 doses - Rifampicin and Dapsone|"Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone;~Children: 6 doses;~1 monthly supervised dose: 450 mg Rifampicin + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone"
46034786|NCT00669643|Drug|PB 6 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 6 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
46034787|NCT00669643|Drug|MB 12 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 12 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 12 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
46034788|NCT00669643|Drug|MB 6 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 6 doses~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine~Children: 6 doses~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
46034789|NCT00669721|Drug|law molecular weigth heparin|administration of LMWH as anticoagulation for hemodialysis circuit;nadroparin is administred ad the dosage of 65 IU/kg on starting dialysis and in the arterial hemodialytic line after a washing phase with 2 litres of a heparin-free saline solution 0.9%.
46034790|NCT00669721|Drug|unfractioned heparin|administration of UFH as anticoagulation of hemodialysis circuit; standard heparin ( Sodic Heparin, Vister by Parke-Davis) 1500 IU on starting dialysis and 1500 ± 500 IU in continues intradialytic infusion per dialysis session
46034791|NCT00669799|Drug|gentamyacin|topical internasal
46034792|NCT00669799|Drug|gentamyacin|intranasal
46034793|NCT04158505|Other|non-interventional|This prospective, observational study will be conducted according to each site's routine clinical practice
46034794|NCT00659347|Drug|DOV 21, 947|Capsules, 25 mg, 2 capsules (1 Active/1 Placebo) BID, 2 weeks Capsules, 25 mg, 2 capsules (2 Active) BID, 2 weeks
46034795|NCT00659347|Drug|Placebo|Capsules,25 mg,BID,6weeks
45339534|NCT00687297|Drug|Carboplatin|IV (in the vein) to area under the curve (AUC) of 6 on day 1 of a 21 day cycle, for 4 cycles or until disease progression
45339535|NCT00687297|Drug|Placebo|
45839850|NCT04745052|Other|Clinical observation index|The first is to verify the application effect of intravenous thrombolytic hemorrhage prediction models (HAT, SIT-sICH, THRIVE) in the population of acute ischemic stroke in Guangdong Province, and verify the clinical application effects of existing prediction models. Secondly, analyze the predictive value of clinical indicators, optimize HAT, SIT-sICH, and THRIVE scores, construct an improved HT prediction model, and optimize and improve the existing prediction model. The third is to apply the improved HT prediction model to the clinic, collect clinical data prospectively, evaluate the prediction effect of the model, and evaluate the clinical application effect of the improved prediction model.
45839851|NCT04744896|Device|cryolipolysis(3 max cool shaping)|cryolioplysis applied over abdomen area
45839852|NCT04744896|Device|Treadmill (jkexer focus 8020A)|aerobic training ( high intensity interval training)
45839853|NCT04744506|Device|Tissue Marker Clip|Tissue Marker Clip Placed in Metastatic Lymph Node (Before Neoadjuvant Chemotherapy for Breast Cancer)
45339536|NCT00687297|Drug|Vandetanib maintenance|300 mg daily by mouth
45839854|NCT04744584|Other|Medication reconciliation|MR will be performed directly upon entering the patient's hospital for a first PAH or HTP-Thrombo embolic assessment, just after inclusion. Information regarding the treatments taken by the patient at the time of admission will be retrieved. The entry medication assessment will then be compared with the first medical prescription in order to identify whether medications have been forgotten, prescribed at a different dosage or prescribed when not indicated, etc. All of these differences will be considered medication errors if the reason for the discrepancy is not entered in the patient medical file.
45839855|NCT04744584|Other|Medication reconciliation|After inclusion of the patient, the MR will be carried out retrospectively, that is to say that the information concerning the treatments taken by the patient at the time of the first assessment will be retrieved during the period of the first reassessment (therefore with a delay of 3 to 6 months depending on the deadline for the first assessment). All these discrepancies will be considered medication errors if the reason for the discrepancy was not entered in the patient's computerized medical record (IMR).
46034796|NCT00894166|Drug|Nicotine Patches|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
45339537|NCT00748683|Other|RFID|A RFID tag attached on subjects' clothes 24hr a day during 1 month.
45839856|NCT04744038|Device|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
45339538|NCT00684177|Drug|Retapamulin Ointment, 1%|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
45339539|NCT00684177|Drug|Placebo ointment|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
45339540|NCT00684021|Biological|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
45339541|NCT00684021|Biological|Placebo|One time infusion of 30 ml of HSA (5%)
45339542|NCT00748761|Behavioral|Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered weekly for 12 weeks
45339543|NCT00748761|Behavioral|Waitlist|Contact waitlist weekly for 12 weeks
45339544|NCT04057911|Device|Active NIBS|Cathodal noninvasive brain stimulation will be given for 20 mins.
45339545|NCT04057911|Device|Sham NIBS|The electrode placement will be same, but the electric current will be ramped down 5 seconds after the beginning of the stimulation
45339546|NCT02561871|Biological|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on day 1 and 85 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on day 1 in Group 2.
45339547|NCT02561871|Biological|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on day 169 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on day 85 in Group 2.
45339548|NCT02561871|Drug|Placebo|Participants will receive Intramuscular injection of Placebo control on day 169 in Group 2. Intramuscular injection of Placebo control on day 1, 85 and 169 in Group 3.
45339549|NCT02561949|Behavioral|YRI|Youth Readiness Intervention (YRI) is an innovative, evidence-based mental health intervention to address co-morbid difficulties with externalizing problems (anger/emotion dysregulation) and internalizing problems (hopelessness/anxiety) among violence-affected youth. YRI methodology draws on evidence-based treatment elements commonly used in both cognitive-behavioral intervention and group interpersonal therapy. YRI has cross-cutting efficacy across a range of mental health conditions common in violence-affected youth. YRI will be delivered in 12 sessions over the course of 3 months.
45339550|NCT02561949|Other|Income generating activity program|Income generating activity programming will be carried out by GOAL in partnership with St. George's foundation through use of their current funding. GOAL focuses on supporting people in need by providing healthcare resources, advocating and advancing child protection practices and policies, and administering livelihood programs to empower them improve their lives in a sustainable manner. The St. George's Foundation's addresses child welfare concerns by actively reaching out to homeless and orphaned children. The program is 4 months in length and consists of skills training, soft skills development (primarily in numeracy and literacy), and a cash transfer of $200.
45339551|NCT02562339|Behavioral|SMART-3RP|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
45339552|NCT00686595|Biological|Infliximab|Infliximab 5 mg/kg IV infusion.
45339553|NCT00750009|Other|educational intervention|Patients receive a tailored intervention or generic information
45339554|NCT03879369|Diagnostic Test|Hormonal assay|LH , FSH and Free testosterone index (FTI) levels
45339555|NCT00755703|Biological|Pandemic Influenza Vaccine|Undetermined
45839857|NCT04743882|Other||
45839858|NCT04743648|Behavioral|Innovative Thinking Development Program (ITDP)|With the implementation of the program, nursing students are expected to develop innovative thinking skills.
45839859|NCT04743414|Drug|CTP-543|Itraconazole in solution dosage form
46034797|NCT00894166|Drug|Nicotine patches, then bupropion & nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
46034798|NCT00894166|Drug|Nicotine patches, then varenicline (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
46034799|NCT00894166|Drug|Nicotine patches, then nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
46034800|NCT00894166|Drug|Nicotine patches, then bupropion & nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
46034801|NCT00894166|Drug|Nicotine patches, then varenicline (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
45339556|NCT00755703|Biological|Placebo|
45339557|NCT00752661|Drug|Tramadol Hydrochloride; JNS013|
46034802|NCT00894166|Drug|Nicotine patches, then nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first seven weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
46034803|NCT00880165|Device|Continuous positive airway pressure apparatus|Veterans randomized to both arms who are diagnosed with obstructive sleep apnea will be started on treatment with continuous positive airway pressure.
46034804|NCT02834650|Other|Cardiac MRI with contrast|Cardiac MRI
46034805|NCT02834650|Other|Cardiac MRI without contrast|Cardiac MRI
45839860|NCT04743336|Other|Measuring pocket depth|Probing pocket depth (PPD = distance between gingival margin and bottom of the periodontal pocket)were evaluated in each patient. All periodontal measurements were recorded at six sites around each tooth by a periodontal probe excluding third molar
46034806|NCT02834650|Other|Blood Test|Hematocrit, Creatinine, Troponin, BNP
46034807|NCT02834650|Other|Heart Rate|Holter Monitor
46034808|NCT02834650|Other|Pulmonary Function Test|Pulmonary Function Test
45339558|NCT00576303|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
45339559|NCT00752739|Dietary Supplement|selenium|Given orally
45339560|NCT00752739|Other|placebo|Given orally
45339561|NCT00755781|Drug|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration (up to 3 years)
45839861|NCT04743180|Device|LUMINOR© Paclitaxel eluting balloon|Patients will be treated with the Luminor paclitaxel eluting balloon
45839862|NCT04743258|Procedure|MAXILLARY PREMOLAR EXTRACTION|Patients will undergo bilateral maxillary 1st premolar extraction before bonding followed by leveling & alignment.
45339562|NCT00755859|Drug|steroids plus azathioprine|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months
46034809|NCT02834650|Other|Genetic Testing|Genetic Testing
46034810|NCT02834650|Other|Repeat MRI scan|Repeat MRI scan
46034811|NCT04032223|Procedure|Implant placemet in the mandibular canine regions|Implant placemet in the mandibular canine regions retained by cast metal copings or 3D printed metal copings to deliver Implant Supported telescopic overdenture in the mandible
46034812|NCT00659503|Drug|Ciclesonide|200µg Ciclesonide versus Placebo
46034813|NCT00659503|Drug|Placebo|placebo
46034814|NCT04248556|Other|Health care product|Health care product (gel) - to be applied on the participant's skin
46034815|NCT00663013|Other|Virtual Reality|Virtual reality (VR) gives patients an illusion of going into the 3-D computer generated environment/virtual world. During VR, the subject wears a head-mounted virtual reality helmet that positions two goggle-sized miniature LCD computer screens close to the subject's eyes. Position tracking devices keep the computer informed of changes in the patient's head location. An electro-magnetic head orientation device feeds the x, y, z coordinates of the patient's head to the computer, which can quickly change what the patient sees in virtual reality accordingly. The scenery in VR changes as the patient moves her head orientation (e.g., virtual objects in front of the patient in VR get closer as the patient, wearing the VR helmet, leans forward in the real world).
46034816|NCT02834728|Behavioral|telephone interview|
46034817|NCT04158193|Other|acupuncture|Subjects in acupuncture group will be received acupuncture treatment by inserting LI11, SJ5, SJ9, SJ13, SJ10, HT3, PC2, LI4, and LI15 on the affected limb and RN12, RN9, RN6, RN4, SP9, SP6. Needles will be remained for 30 minutes each time after DeQi sensation, one time a day，three times a week, the treatment will be lasted for 7 weeks.
45339563|NCT00755859|Drug|steroids|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months
45839863|NCT04743258|Procedure|DISTALIZATION|Maxillary arch will be distalized with the help Zygomatic miniplates will be placed bilaterally.
46034818|NCT04158193|Other|sham acupuncture|"Subjects in control group will be treated with non-acupoint shallow needling, points will be selected 1 cm at the radial direction from acupoint LI11, SJ5, SJ9, SJ13, SJ10, LI4, HT3, PC2, LI4, LI15; 2 cm at the left of acupoint RN12, RN9, RN6, RN4; 1 cm at the tibial direction from SP9, SP6.~The needling manipulation is the same as that of the acupuncture group, but only the superficial skin of points are punctured. The depth of needling is less than 0.5 cm, and no manipulation will be performed after puncturing the skin. Needles will be remained for 30 minutes each time,one time a day，three times a week, the treatment will be lasted for 7 weeks."
46034819|NCT02834572|Behavioral|All About Me|Assessment and algorithm to determine recommended HIV testing approach
46034820|NCT02834572|Behavioral|Control|HIV testing information
45339564|NCT00752817|Other|Proficiency-based virtual reality simulation training|Subjects (surgical trainees) will be trained under a proficiency-based virtual reality simulation training programme before performing their first live case
45339565|NCT00752817|Other|Training under the current surgical training programme|Subjects (surgical trainees) will continue to train under the current training methodology offered at their institution before they perform their first live case.
45339566|NCT00756015|Other|Early Motion Protocol|Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
46034821|NCT04158115|Other|Entire Spine Mobilization|8 sessions of Following: -Entire Spinal Mobilization of all spinal segment from C0 to C1 to L5 to S1 (10 reps × 3 sets), - Moist heat: 10 to 15 minutes, - Soft tissue Mobilization, - Exercises : (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
46034822|NCT04158115|Other|Segmental Mobilization|"8 sessions of following -Segmental Mobilization: All lumbar segment from L1 to L2 to L5 to S1 (10 reps × 3 sets) - Moist heat: (10 to 15 minutes), -Soft tissue Mobilization~- Exercises: (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)"
46034823|NCT00670189|Drug|BMS-833923 (XL139)|Capsules, Oral, 30 mg starting; dose escalation, Once daily, 37 days; additional days if receiving benefit
46034824|NCT00663091|Drug|Bacteriophage|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
46034825|NCT00663091|Drug|WPP-201 Bacteriophage|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
46034826|NCT00663091|Drug|Bacteriophages|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
45339567|NCT00756015|Other|Immobilization|Immobilization group: 6 weeks of sling shoulder immobilization. Immediate range of motion of the elbow, forearm, wrist and hand. At 6 weeks, PROM and stretching of the shoulder allowed under therapist direction. At 12 weeks, AAROM and AROM exercises will be initiated and capsular stretching advanced until full ROM achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 4 months post surgery.
45339568|NCT00686517|Biological|Pegylated interferon alfa-2b|1.5 ug/kg/week SC for 12 or 24 weeks
45339569|NCT00686517|Drug|Ribavirin|Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
45339570|NCT00686205|Device|collection of follow-up sample based on PRISM HIV O Plus result|Test blood samples with investigational HIV assay. If results are reactive, donors may be deferred and asked to return for a follow-up blood draw.
45339571|NCT00571701|Drug|celebrex (celecoxib)|Adults: 400 mg celebrex (celecoxib) daily Pediatrics: 100 mg celebrex (celecoxib) daily for weight between 12-25 kg or 200 mg Celebrex (celecoxib) daily for weight >25 kg
45339572|NCT00571701|Drug|placebo|similar appearing capsules containing inert ingredients
45339573|NCT00686127|Drug|Lidoderm patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
45339574|NCT00686127|Drug|Placebo patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
45339575|NCT02561715|Behavioral|Questionnaires|Pre and post deep brain surgery questionnaires
45339576|NCT00718718|Drug|CNTO 136 100 mg|CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.
46034827|NCT00670345|Drug|Tranexamic Acid|Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.
46034828|NCT00670345|Drug|Placebo|Patients belonging to the control group will receive the same volume of saline infusions.
46034829|NCT04153981|Drug|Insulin Glargine|Administered SC
46034830|NCT02631343|Behavioral|KMC|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
46034831|NCT02631343|Other|Essential newborn care|
45339577|NCT00718718|Drug|CNTO 136 50 mg|CNTO 136 50 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
46034832|NCT04153903|Other|OCT, coronary angiography, FFR|Coronary images by OCT and angiography and FFR values will be registered.
45339578|NCT00718718|Drug|CNTO 136 25 mg|CNTO 136 25 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
45339579|NCT00718718|Drug|Placebo|Placebo will be adminstered subcutaneously as per the appropriate randomized arm.
45839864|NCT04742790|Diagnostic Test|Scalp electroencephalography (EEG)|Resting EEG will be recorded before initiation of the combination treatment (visit 1) and 7-10 days after treatment (visit 2). Drug-induced sedation-related changes in the EEG frequency spectrum. Five minutes of resting EEG eyes-open will be recorded in a quiet room while participants are asked to focus on an image displayed on a wall. Then, they will be asked to close their eyes for an additional 2 minutes. The alpha power ratio eyes open/eyes closed will be computed (alpha attenuation coefficient; Kaida et al., 2006). Changes in this coefficient will be used as a measure of drug-induced sedation.
46034833|NCT01165229|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
46034834|NCT01165229|Biological|Placebo|Intramuscular injection.
46034835|NCT00596011|Drug|Polyphenon E|Polyphenon E, at a dose of 400 mgs EGCG (200 mgs BID) for 1 year in men diagnosed with HGPIN and ASAP.
46034836|NCT00596011|Drug|Placebo|Matching placebo BID
45339580|NCT00718718|Drug|Methotrexate|Stable dose of methotrexate will be maintained through Week 24.
45339581|NCT04085822|Device|SMA-001|Intra-dermal injection of SMA-001 and control device.
45339582|NCT00683787|Drug|docetaxel|Given IV once every 3 weeks
45339583|NCT00683787|Drug|vandetanib|Oral vandetanib once daily
45339584|NCT02560935|Drug|Hydroxyurea (Moderate Dose)|The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
45339585|NCT02560935|Drug|Hydroxyurea (Low Dose)|The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
46034837|NCT00670423|Drug|Tacrolimus|Tacrolimus as a continuous IV infusion will begin on day -3. (Levels will be monitored at least every 3 days to target 5-10 ng/mL)
45339586|NCT00723008|Device|Alpha Stim 100 (Cranial Electrotherapy Stimulation)|cranial electrical stimulation 100 microamps
46034838|NCT00670423|Drug|Sirolimus|Sirolimus oral loading dose on day -3, followed by oral daily dose. (Levels will be monitored at least every 3 days to target 3-12 ng/mL)
46034839|NCT00670423|Drug|Bortezomib|"Administered intravenously on day 0 (a minimum of 6 hours post-infusion of PBSC), and on day +3. The following dose levels will be used:~Cohort 1 (3-6 pts): 1 mg/m2 on days 0 and +3~Cohort 2 (3-6 pts): 1.3 mg/m2 on days 0 and +3~Cohort 3 (3-10 pts): 1.6 mg/m2 on days 0 and +3"
46034840|NCT04153825|Device|Transcutaneous Electrical Nerve Stimulation|Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended. The device is set at pulse duration of 50 to 80 μs; pulse frequency of 50 to 100 Hz; low-intensity (paraesthesia, not painful). The patient wears TENS for a 20-minute duration for each knee.
46034841|NCT04153825|Device|Interferential Current|Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. The device is set at carrier frequency 4000 Hz, amplitude modulated frequency (AMF) 100 Hz, scanning frequency 50 Hz, scanning mode 1: 1 s. The patient wears ICF for a 20-minute duration for each knee.
46034842|NCT04153825|Other|Hydrocollator hot-pack|The hot-pack (at a surface temperature of almost 42 °C) is administered on knees while patients are in sitting position with the knees extended. Every session includes 20 minutes of hot-pack for each knee.
46034843|NCT04153825|Device|Sham transcutaneous Electrical Nerve Stimulation|Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended.TENS unit in place but not turned on.The patient wears TENS for a 20-minute duration for each knee.
46034844|NCT04153825|Device|Sham interferential Current|Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. IFC unit in place but not turned on.The patient wears ICF for a 20-minute duration for each knee.
46034845|NCT02632201|Biological|PIK-HER2|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-HER2 cell suspension (1-6×109 PIK-HER2 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
46034846|NCT02632201|Biological|DC-PMAT|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
45339587|NCT00750399|Drug|Ranibizumab|intravitreal ranibizumab monthly for 4 months, and then every month thereafter until month 12.
46034847|NCT00659659|Drug|MEDI-563|1.0 mg/kg IV: MEDI-563
46034848|NCT00659659|Drug|MEDI-563|100 mg, 200 mg SC
46034849|NCT00659659|Other|Placebo Comp.|Placebo SC
46034850|NCT00659659|Other|Placebo|Placebo as a single IV infusion (Certain number of subjects)
46034851|NCT00670501|Drug|teriparatide|40 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
46034852|NCT00670501|Drug|teriparatide|20 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
46034853|NCT00670501|Drug|Placebo|Placebo for subcutaneous injection will be supplied in a prefilled injection device with a cartridge identical in appearance to the LY333334 device.
46034854|NCT00670501|Drug|Calcium Supplement|Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement
46034855|NCT00670501|Drug|Vitamin D Supplement|Approximately 400 to 1200 IU/day of vitamin D will be supplied as open-label oral supplement
45339588|NCT00750399|Drug|ranibizumab|intravitreal ranibizumab 0.5 mg
45339589|NCT00756171|Drug|colesevelam|2 times 3 625 mg tablets daily, 3 weeks
45339590|NCT00756171|Drug|placebo|2 times 3 625mg tablets daily
45339591|NCT00750477|Dietary Supplement|NEM|see Treatment Arms
45339592|NCT00750477|Dietary Supplement|Placebo|Placebo comparator containing inactives
45839865|NCT04742790|Diagnostic Test|Laser-evoked potentials (LEPs)|Laser-evoked potentials (LEPs) will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Short pulses (50-100 ms) of radiant heat generated by a C02 laser stimulator will be applied to the skin of the left or right hand dorm to briefly and selectively activate heat-sensitive pain receptors. A concomitant EEG recordings will be used to measure the amplitude and latency of the elicited laser-evoked potentials. Changes in LEP amplitude (expressed as percentage of change) will be used as a measure of drug-induced effects on the state of the thermonociceptive system.
46034856|NCT02631421|Procedure|Blood Sampling|
45339593|NCT00718640|Drug|Dexamethasone|Dexamethasone 20 mg per day will be administered orally on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-days cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
46034857|NCT02631421|Other|Cardiac MRI|
46034858|NCT05657093|Dietary Supplement|Beetroot Juice|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
46034859|NCT05657093|Combination Product|Placebo|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
46034860|NCT04153669|Behavioral|Exercise-NMES|Exercise-NMES
46034861|NCT04153669|Behavioral|Exercise-No NMES|Exercise-No NMES
46034862|NCT00663247|Device|Mesalazine|3 grams daily for 3 months
46034863|NCT00663247|Drug|Placebo|3 grams daily for 3 months
46034864|NCT02629939|Behavioral|course for learning CPR|
46034865|NCT04158271|Device|Prone Position|In a randomized order we evaluate techniques for securing the airway in paralyzed patients in prone position
46034866|NCT04158271|Device|Laryngeal tube|In a randomized order we evaluate techniques for securing the airway in patients with a failed laryngeal tube
45683201|NCT05658172|Diagnostic Test|Determination of tumormarkers (CA27.29, CEA, CA125)|CA27.29, CEA and CA125 will be measured with the AIA®-CL1200 by TOSOH BIOSCIENCE (TOSOH CORPORATION, Tokyo, Japan). The CL AIA-PACK assays are two-step chemiluminescence enzyme immunoassay kits. CA27.29/CEA/CA125 present in a test sample is bound to the anti- CA27.29/CEA/CA125 mouse monoclonal antibody immobilized on the magnetic microparticles in one cell (Cell-I). After first incubation, the magnetic microparticles are washed and the enzyme-labeled anti- CA27.29/CEA/CA125 mouse monoclonal antibody that has been reconstituted in another cell (Cell-II) is dispensed into Cell-I. After second incubation, the magnetic microparticles are washed again and are incubated with a chemiluminescent substrate, DIFURAT®. The amount of enzyme-labeled antibodies that bind to the magnetic microparticles is directly proportional to the CA27.29/CEA/CA125 concentration in the test sample. A standard curve is constructed, unknown sample concentrations are calculated by using this curve.
46034867|NCT04158271|Device|Endotracheal tube Leackage|In a randomized order we evaluate techniques for securing the airway in paralyzed patients with a endotracheal tube and a cuff leackage
46034868|NCT01163747|Biological|tocilizumab|Intravenous repeating dose
46034869|NCT01163747|Drug|methotrexate|A stable dose of between 7.5 and 25 mg/week, oral or parenteral.
46034870|NCT01163747|Biological|23-Valent Pneumococcal Polysaccharide Vaccine|Intramuscular or subcutaneous injection
45339594|NCT00718640|Drug|Bortezomib|Bortezomib 1.3 milligram per meter^2 (mg/m^2), bolus intravenous injection will be administered on Days 1, 4, 8 and 11 of each 21-day cycle and up to 8 cycles.
46034871|NCT01163747|Biological|Tetanus Toxoid Adsorbed Vaccine|Intramuscular injection
46034872|NCT00663325|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
46034873|NCT00659893|Drug|PEP005 Topical gel|0.05%, two day dose
46034874|NCT02629783|Other|Psychomotor therapy|1 treatment of approximately 45 minutes the first 5 weeks after randomization. The treatment will focus on teaching the patients about body awareness and handling of there shoulder problems in daily living.
46034875|NCT02629783|Other|Physiotherapy|Patients are, in secondary care setting, given 3-5 basic physiotherapy exercises for there shoulder pain, targeting rotator cuff muscles and scapula thoracic muscles. Furthermore they are given advice on seeking further physiotherapy guidance in private setting.
45339595|NCT00756249|Drug|Lu AA24493 (CEPO)|0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset
45339596|NCT00756249|Drug|Placebo|Vials with solution for IV infusion
45339597|NCT02591810|Procedure|Serial casting/splinting|Serial Casting involves applying and removing a series of lightweight casts made of fiberglass. The wrist is monitored as healing occurs.
45339598|NCT02591810|Procedure|Percutaneous fixation|Injury is treated by the percutaneous placement of Kirschner wires to promote healing. This is an invasive procedure, involving the placement of Kirschner wires to stabilize the wrist.
45339599|NCT02591810|Procedure|Foveal repair|Injury is treated by open anatomic foveal repair of the ligaments. This is a surgical procedure.
46034876|NCT02629783|Drug|corticosteroid injection|At baseline, patients with signs of inflammation in the subacromial bursa, can receive a ultrasound guided corticosteroid injection in the bursa
46034877|NCT01163279|Behavioral|Real world strategy approach|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
46034878|NCT01163279|Behavioral|Psychosocial Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sudoku puzzles. Homework will consist of reading assignments related to the session topics.
46034879|NCT04155931|Other|body temperature measurement|Postoperative analgesic and antiemetic requirements, nausea and vomiting were observed in the recovery room at 6, 12 and 24 hours
46034880|NCT02629705|Dietary Supplement|Carrageenan|Carrageenan 250 mg bid supplemented to a standard food
46034881|NCT02629705|Dietary Supplement|Placebo|Placebo (Mannitol/Aerosil) bid supplemented to a standard food
46034882|NCT00670657|Drug|AmBisome|Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
45339600|NCT00753051|Drug|clozapine+haloperidol|clozapine 300-900 mg/d haloperidol 4-60 mg/d
45339601|NCT00753051|Drug|clozapine,electroconvulsive therapy|clozapine 300-900 mg/d electroconvulsive therapy 4-12 times
46034883|NCT01162499|Drug|Exendin-(9-39)|IV infusion of exendin-(9-39) for 5 hours
46034884|NCT01162499|Other|Vehicle|Normal saline (vehicle) infusion for 5 hours at 0.06 mL/kg/hr
46034885|NCT04153513|Drug|Lanolin|Lanolin will be applied by hand in a thin layer to the nipple and areola after every breast feed (approximately every 2 to 3 hours) for a maximum of 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).
46034886|NCT04153513|Other|Mother's milk|After each breast feed (approximately every 2 to 3 hours), a few drops of breast milk will be applyed to the nipple and areola by hand and allow them to air dry. The treatment will last for up to 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).
46034887|NCT00659971|Drug|PAC113|PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
46034888|NCT05657015|Drug|Lepidium Sativum|2 ml of LS in situ gel at baseline
46034889|NCT05657015|Drug|Simvastatin|1.2% of SMV in situ gel at baseline
46034890|NCT04314479|Behavioral|Symptom Assessment and Health Coaching|The intervention condition will involve weekly symptom assessment and health coaching to manage symptoms and to meet the ACS cancer prevention guidelines provided over the telephone by trained health coaches. Participants will be completing the same forms/assessments throughout the study. The content will be built around the Symptom Management Toolkit. The coaching will be dictated by the symptoms the survivor or the support person is experiencing the week of the intervention call. All calls begin with the symptom assessments, only the intervention arm includes intervention coaching that focuses on physical activity, stress management, or eating a healthy diet to improve adherence to the ACS guidelines for cancer prevention. We anticipate coaching sessions will last approximately 20 - 45 minutes.
46034891|NCT02887313|Drug|mFOLFOX6|Patients receive mFOLFOX6 for 4 cycles during neoadjuvant radiotherapy, and after CRT, another 4 cycles of mFOLFOX6 would be given before surgery.
46034892|NCT02887313|Radiation|Radiotherapy|Patietns received preoperative radiotherapy, 1.8-2.0GY/23-25F
46034893|NCT01206140|Other|Laboratory Biomarker Analysis|Correlative studies
46034894|NCT01206140|Drug|Selumetinib|Given PO
46034895|NCT01206140|Drug|Temsirolimus|Given IV
46034896|NCT01162421|Biological|adalimumab|Study drug will be provided to participants in Early Adalimumab arm as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). 40 mg of adalimumab will be administered subcutaneously at Baseline and then every other week for 24 months. Adalimumab may be initiated in participants in standard of care (SOC) arm after a minimum of 6 months of treatment recommended by their study doctor.
46034897|NCT01162421|Drug|Methotrexate|Participants in both arms will receive a methotrexate regimen based on local guidelines and their study doctor's judgment.
46034898|NCT05366387|Device|intrapulmonary percussive ventilation|Intrapulmonary percussive ventilation is a non invasive ventilation technique where small boli or air are delivered, at adjustable frequency and pressure, to the upper airways though a mouthpiece. IPV is currently used in the clinic to aid with airway clearance in neuromuscular and airway diseases.
46034899|NCT05366387|Radiation|delivery of 99mTc-DTPA aerosol|A 99mTc-DTPA aerosol (500 MBq+/-20%, 3 ml volume) is generated with a jet nebuliser (MMAD 4 µm). The aerosol is inhaled by the study subject and lung deposition is imaged by SPECT
46034900|NCT02885519|Behavioral|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment"
45339602|NCT02591108|Device|Neuromuscular Block Aid|Neuromuscular Block Aid, is a quantitative mechansim for collecting the the train-of-four and can be kept in an electronic medical record, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
45683202|NCT05658172|Diagnostic Test|Determination of CTC levels|CTCs will be analyzed using the CellSearch® System (Menarini Silicon Biosystems). The CellSearch® system is designed to enumerate CTCs of epithelial origin (CD45-, EpCAM+, cytokeratin 8+ / 18+ and/or 19+). The basic principle is linking a magnetic ferrofluid reagent that contains i. a. antibodies targeting the EpCAM antigen to CTCs. After steps of immunomagnetic capture and enrichment as well as addition of fluorescent reagents (that contain anti-CK-PE, DAPI and anti-CD45-APC), the automatic dispersion to a magnetic cartridge holder takes place. Via strong magnetic field, the magnetically labeled epithelial cells are attracted to the surface of the cartridge where they can be scanned automatically. Images of events where CK-PE and DAPI fluorescence are co-located are presented to the user for final classification. An event is classified as a tumor cell when its morphological features are consistent with that of a tumor cell and it exhibits the phenotype EpCAM+, CK+, DAPI+ and CD45-.
46034901|NCT02885519|Behavioral|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
45339603|NCT02591108|Device|Standard of Care: Microstim Plus|A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
45683203|NCT05658172|Diagnostic Test|Determination of ctDNA levels|Presence of ctDNA will be analyzed centrally at Inivata Inc. using the RaDaRTM assay. Therefore, primary tumor tissue and peripheral blood specimens will be shipped for centralized analysis to Inivata Inc. RaDaRTM is a tumor-informed approach, beginning with whole exome sequencing of a tumor specimen from a patient's biopsy or surgical resection. SNVs and indels identified from the exome sequencing are prioritized to build a patient specific primer panel of up to 48 tumor-specific somatic variants. Patient specific primers are combined with common SNP primers for NGS for quality control purposes. To detect patient specific ctDNA, NGS testing is performed with the RaDaRTM assay using a multiplex PCR based on the InVision® platform.
45683204|NCT05658172|Other|Biobanking of blood samples|To ensure the possibility of retrospective studies during and after the ongoing study, a biobank will be implemented.
46034902|NCT02885441|Drug|Ketorolac|Ketorolac, 10 mg, 3 times daily from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.
45339604|NCT00753129|Procedure|Prone position with head elevation|Head elevation of 30° in prone position (Ant-Trendelenburg position of the whole bed)
45339605|NCT00756795|Behavioral|Intervention group|"5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.~Structured Interview will be conducted at baseline and post-intervention.~Patients assigned to the Intervention group will be given pedometers to obtain distance walked. In addition, patient will be taught how to keep the Exercise diary to record walking and physical activities.~All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis."
45339606|NCT00753207|Drug|epirubicin hydrochloride|
45339607|NCT00753207|Drug|lapatinib ditosylate|
45339608|NCT00753207|Other|biomarker analysis|
45339609|NCT00753207|Other|immunohistochemistry staining method|
45339610|NCT00753207|Other|liquid chromatography|
45339611|NCT00753207|Other|mass spectrometry|
45339612|NCT00715910|Biological|Nimenrix|One dose, as intramuscular injection
45339613|NCT00715910|Procedure|Blood sampling|Blood samples will be collected from subjects 10-25 years of age as per enrollment in primary study and from subjects in the Nimerix Naive Group at Month 60 (Year 5) and 1 month post booster vaccination (Month 61).
45339614|NCT04056663|Behavioral|Health-Circuit mobile application|Health-Circuit as a collaborative tool between professionals and patient and professionals
45339615|NCT00750711|Procedure|Radiofrequency ablation for atrial flutter by catheters|
45339616|NCT00750789|Dietary Supplement|dates|5 maedjool dates or 7 emery dates per day for 2 weeks each with a washout period of 2 weeks between
45339617|NCT02590484|Procedure|The cervix as a natural tamponade (cervical inversion)|Suturing an inverted lip(s) of the cervix over the bleeding placental bed to control the bleeding.
45339618|NCT04086914|Procedure|Nerve Block|This group will receive a nerve block consisting of 20mL of 5mg/mL ropivicanine and 0.1mL of 10mg'mL dexamethasone.
45339619|NCT00715676|Drug|Placebo|oral, once daily
45339620|NCT00715676|Drug|DP001|oral, once daily
45339621|NCT05163470|Other|early on filed functional rehabilitation|Intervention 1 ,called ''On FI.RE. framework '' included a on filed functional rehabilitation framework ,with early return of the player on the field activities during injury recovery. Involve a specific 5 stages framework of functional rehabilitation on filed. Criteria of inclusion and exclusion for each stage are included based on pain, oedema and range of motion specific to nature of injury . Additional included a daily session planning framework for on field functional rehabilitation with a content ,duration and the description of each content.
45683205|NCT05687656|Device|InnovaMatrix AC porcine placental ECM therapy|All eligible subjects will be treated with a weekly application of sterilized, porcine placental ECM followed by standard of care moist wound therapy and offloading
45683206|NCT03306316|Dietary Supplement|Prebiotic|Prebiotic experimental group
45683207|NCT03306316|Dietary Supplement|Dextrose Control|Dextrose Control
46034903|NCT04314791|Device|Ultrasound evaluation, with grayscale and color Doppler imaging|In pregnant women with previous CS and anterior low-lying or placenta previa, the following three sonographic criteria were assessed: (i) the smallest myometrial thickness in the sagittal plane; (ii) presence of placental lacunae and its grade from 0-3; (iii) bridging vessels using color Doppler. The PAI score (up to 9) was calculated for every patient as described by Rac et al.2015.
46034904|NCT02885597|Drug|Juanbi pill|4g, twice a day, 3month, oral
46034905|NCT02885597|Drug|Juanbi pill placebo|4g, twice a day, 3month, oral
45339622|NCT05163470|Other|traditional on filed functional rehabilitation|Intervention 2 ,called 'traditional rehabilitation' include a on field functional rehabilitation framework ,as the late phase of injury recovery .The framework described as a 5 stages on filed rehabilitation framework based on load monitoring usingGlobal positioning system.No criteria for the player to return to activity on the field cited ,but referred criteria for progression in each stage based on Strength/power depending of the nature of injury.
46034906|NCT02885597|Drug|Methotrexate|5mg, once a week, 3 month, oral
46034907|NCT01188551|Drug|Dexmedetomidine|dexmedetomidine (1 µg/kg) will be administered intranasally
46034908|NCT01188551|Drug|Fentanyl|fentanyl (2 µg/kg) will be administered intranasally
46034909|NCT01188551|Drug|Midazolam|Sedative given pre-op.
46034910|NCT04316429|Other|Egg included vegan phase|: Participants will meet with a registered dietitian and receive instructions to include 2 eggs per day for 6 weeks as part of their otherwise vegan diets. Participants will also receive instructions to preserve an isocaloric condition with the addition of 2 eggs in their diets. Counseling of the study participants will be based on the U.S. Department of Agriculture (USDA) healthy vegetarian meal plans, with modifications to exclude dairy products. [21] Additional resources (e.g., educational materials, recipes, etc.) for adopting and maintaining a vegan diet (with the exception of including eggs) will also be provided.
46034911|NCT04316429|Other|Vegan Phase|The participants will consume a vegan diet for 6 weeks. The study dietitian will provide counseling and sample meal plans based on the USDA healthy vegetarian dietary pattern, with modifications to exclude eggs and dairy products. Additional resources (e.g., educational materials, recipes, etc.) for adopting and maintaining a vegan diet will also be provided.
45339623|NCT00718328|Drug|Simvastatin 80 mg|Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.
46034912|NCT05293379|Other|Connected teleconsultation booth|15-minutes assessment in a connected teleconsultation booth.
45339624|NCT00718328|Drug|Placebo|Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.
45339625|NCT05346848|Drug|Association of darolutamide and EBRT|"Darolutamide will be taken orally at a fixed dose of 600 mg twice daily (1200 mg), on a continuous basis, for a maximum of 6 months. Darolutamide will start at Day 1.~- External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated with standard schedules:~78 Gy with classical 2 Gy/fractions, 5 days/7~Or 60 Gy with 3 Gy/fractions, 5 days/7~Use of IMRT and IGRT is mandatory~Clinical Target Volume Definition according to GETUG Guidelines~Organ at risk dose constraints according to RECORAD"
45683208|NCT04746664|Behavioral|Nutritional counselling|Individual-based nutrition counselling guided with the health belief model (HBM) and the theory of planned behavior (TPB) will be implemented.
45683209|NCT03359356|Drug|Dupilumab|A total of 24 doses
45683210|NCT03359356|Drug|Placebo|A total of 24 doses
45683211|NCT05687422|Procedure|100μm laser spot diameter micropulse laser|100μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
46034913|NCT05287451|Other|RIsk-Reducing Salpingectomy (RRS)|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
46034914|NCT05287451|Other|Risk-Reducing Oophorectomy-RRO|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
46034915|NCT05287451|Other|Risk-Reducing Salpingo-Oophorectomy-RRSO|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
46034916|NCT01161407|Dietary Supplement|1500 mg/d elemental calcium as calcium carbonate|500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium. Given for 21 days in conjunction with a controlled diet.
45683212|NCT05687422|Procedure|200μm laser spot diameter micropulse laser|200μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
45683213|NCT05687344|Drug|NIFEdipine ER|Postpartum BP treatment to <140/90 mmHg
45683214|NCT04760704|Biological|Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration|Specific T cells and specific antibodies assessment
46034917|NCT01161407|Dietary Supplement|Placebo|Placebo for calcium carbonate in same capsule form. Given 3 times per day with meals for 21 days in conjunction with a controlled diet.
45683215|NCT03356860|Drug|Paclitaxel|80mg/m2 IV weekly from week 1 to week12
46034918|NCT01161173|Drug|Erlotinib|Erlotinib was provided in the retail versions of the product.
46034919|NCT01159769|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)|Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis
46034920|NCT05329727|Drug|Angiotensin receptor neprilysin inhibitor (ARNI)|The group with ARNI was defined as patients with HFrEF took ARNI more than 3 months
45683216|NCT03356860|Drug|Epirubicin|90 mg/m2 IV Q 2 weeks from week 14 to week 20
45683217|NCT03356860|Drug|Cyclophosphamide|600 mg/m2 IV Q 2 weeks from week 14 to week 20
45683218|NCT03356860|Drug|Durvalumab|Durvalumab 1500 mg IV at week 14 and 18
45683219|NCT01931839|Drug|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet, oral use
45683220|NCT01931839|Drug|Ivacaftor|Film-coated tablet, oral use
45683221|NCT01842308|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous stem cell transplant
45683222|NCT01842308|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
45683223|NCT01842308|Drug|Carfilzomib|Given IV
45683224|NCT01842308|Other|Laboratory Biomarker Analysis|Correlative studies
45683225|NCT01842308|Drug|Melphalan|Given IV
45683226|NCT01931059|Drug|Risperidone|We gave oral liquid of risperidone one time 1-2 mg depending on subject's weight.
45339626|NCT05346848|Drug|Association of ADT and EBRT|"Treatment by Androgen Deprivation Therapy (ADT) will be prescribed as per market authorization and following investigator judgement. ADT treatment will consist on:~Either LH-RH agonist injection given every 3 months for 6 months, or once for 6 months,~Either LH-RH antagonist given monthly for 6 months~External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated by high dose irradiation in stereotactic conditions:~78 Gy with classical 2 Gy/fractions, 5 days/7~Or 60 Gy with 3 Gy/fractions, 5 days/7~Use of IMRT and IGRT is mandatory~Clinical Target Volume Definition according to GETUG Guidelines~Organ at risk dose constraints according to RECORAD"
45339627|NCT02591186|Procedure|Acupuncture|Participants will receive 3 acupuncture sessions during IVF process
45472801|NCT05569083|Diagnostic Test|Neuropsychological evaluation|"For extensive neuropsychological evaluation the investigators will use the following tools: global measurements (MMSE, Information-Memory-Concentration Test), tasks exploring verbal and spatial short- and long-term memory (Digit Span, Corsi Tapping Test, Five Words and Paired Words Acquisition and Recall after 10 min and 24 hr, Short Story Immediate and Delayed Recall), prospective memory (Rivermead Behavioral Memory Test), attention (Trail Making Test A, Dual Task), language (Token Test, naming pictures, Category Fluency Task, Phonemic Fluency Task), constructional praxis (Copying Drawings and Rey-Osterrieth complex figure) and executive function (Trail Making Test B, Stroop Test, Frontal Assessment Battery, Weigl Test).~To assess independent living skills, the investigators will use two structured interview: Activities of Daily Living Scale (ADL) and Instrumental Activities of Daily Living Scale (IADL)."
45472802|NCT05569083|Diagnostic Test|Assessment of cognitive reserve, depression, personality traits and leisure activities|"In order to estimate premorbid intelligence, all cases will perform TIB test (Test di Intelligenza Breve), an Italian version of the National Adult Reading Test (NART).~To assess personality traits of the subjects, the investigators will use the Big Five Factors Questionnaire (BFFQ), that measures the five factors of emotional stability, energy, conscientiousness, agreeableness and openness to culture and experience.~For cognitive reserve. subjects will perform structured interviewed regarding participation in intellectual, sporting and social activities, in the course of their life.~The presence of depressive symptoms will be evaluated by means of the 22-item Hamilton Depression Rating Scale (HDRS)."
45683227|NCT01931059|Other|Placebo|We gave oral liquid without active risperidone (pt and provider were both double blinded)
45683228|NCT01841762|Drug|Macitentan|Macitentan tablet, dose of 10 mg, once daily
45683229|NCT03301636|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks starting on day 1.
45683230|NCT03301636|Drug|Nivolumab|Nivolumab will be administered intravenously every 2 weeks starting on day 1.
45683231|NCT03301636|Drug|Indoximod|Indoximod will be administered orally every 12 hours starting at Day 1
45683232|NCT01841060|Procedure|Percutaneous radiofrequency ablation (RFA)|Computed tomography (CT) was used to treat tumors under general anesthesia. Thoracic epidural anesthesia was administered in case of contraindication to general anesthesia mostly due to poor respiratory function. All patients were treated with the same multitine electrodes (LeVeen; Boston Scientific, Nattick. MA) measuring 3, 3.5, or 4 cm in diameter and at least 10 mm larger than the diameter of the target tumor. Multiple overlapping ablations were performed, when needed, in different parts of the tumor in order to cover the entire volume.
46034921|NCT05329727|Drug|Renin-Angiotensin System Inhibitor (RAS inhibitor)|The group with RAS inhibitor was defined as patients with HFrEF took RAS inhibitor more than 3 months
46034922|NCT05328791|Behavioral|Dietary and mindfulness intervention|"Dietary intervention: Preparation and follow-up of diet program~Mindfulness intervention: Implementation of cognitive stress reduction program"
46034923|NCT02885207|Biological|Focal epilepsy of unknown cause|"Male or female 18-65 years presenting focal epilepsy on the following arguments:~Crisis with clinical symptoms indicating focal seizure~& / Or crisis or critical focal inter-recorded EEG interpreted by a neurologist with expertise in the field of epilepsy.~From unknown cause:~No evidence of injury (excluding temporal or hyperintensity of hippocampal sclerosis) on brain MRI with focus on regions of interest cuts.~No discharge or generalized photosensitivity recorded over an extended interpreted by a neurologist with expertise in the field of epilepsy video-EEG.~No argument for metabolic or neurodegenerative genetic epilepsy.~Normal neurological examination. Epilepsy that started within a maximum period of 2 years prior to inclusion in the study (including vegetative symptoms of temporal focal seizures).~Without treatment by benzodiazepines or anti-epileptics first-line monotherapy (excluding benzodiazepines)."
46034924|NCT05280119|Device|EchOpen ultra-portable ultrasound device|Depending on the clinical picture, patients are examined to detect the presence or absence of pleural effusion, or intra-abdominal effusion, or to localize the basilic vein
46034925|NCT05280119|Device|Ultrasound device routinely used in the department.|Patients who were first examined with the EchOpen ultra-portable ultrasound device, are secondarily examined with an ultrasound probe used routinely in the department.
46034926|NCT05280119|Procedure|Standard ultrasound examination by an independent referent radiologist|In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating
46034927|NCT04123691|Device|pulse oximetry monitoring|pulse oximetry monitoring as per routine clinical practice
45683233|NCT04414592|Other|human umbilical cord mesenchymal stem cells|Twenty million human umbilical cord mesenchymal stem cells will be immediately injected into the degenerative discs of such patients who are diagnosed with lumbar disc herniation and operated with full endoscopy lumbar discectomy.
45683234|NCT04602494|Drug|Varenicline|varenicline: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
45683235|NCT04602494|Drug|Placebo|Identical placebo: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
46034928|NCT01157897|Biological|VMP001|Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B
46034929|NCT01157897|Other|P. vivax sporozoite challenge|P. vivax sporozoite challenge
45339628|NCT04087070|Device|Biosignal measurements|"Following parameters will be measured by non-invasive electrocardiogram (ECG), photoplethysmograph (PPG), and an accelerometer on the chest and will be used to estimate the biosignal derived blood pressure.~PAT(time between R peak of ECG and beginning of the pulse of PPG)~PEP(time between R peak of ECG and peak of accelerometer signal)~PTT(PAT-PEP)"
45339629|NCT02590874|Drug|Duloxetine|Duloxetine 30 mg per day for 2 weeks. Duloxetine 60 mg per day for 4 months. Duloxetine 30 mg per day for 2 weeks.
45339630|NCT02590874|Drug|Placebo|Placebo 30 mg per day for 2 weeks. Placebo 60 mg per day for 4 months. Placebo 30 mg per day for 2 weeks.
45339631|NCT02590952|Drug|Epitinib|The starting daily dose is 20 mg. Dose escalation will follow daily dose of 40 mg,80 mg, 120 mg, 160 mg, 200 mg, and 250 mg. A 3+3 design applies to this study. Patients will continue taking Epitinib until they experience intolerable adverse events or their diseases are confirmed to be progressed.
46034930|NCT04316507|Procedure|Genetic Counselling and Testing|Oncologist-initiated brief genetic counselling and testing
46034931|NCT01185821|Drug|BAF312|BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.
45339632|NCT00715520|Other|Transcranial Magnetic Stimulation (TMS)|Each TMS training session will begin with a baseline measurement lasting about 30 minutes in which brief magnetic pulses will be generated by the single-pulse and paired pulse TMS stimulator and the responses are recorded with surface EMG electrodes. Participants will be instructed to move their wrist for up to ½ hour. After these measures, rTMS will be applied to the scalp during training. Stimulation will occur at a low rate of different frequencies and different times with respect to the training movement depending on the experimental condition. In the last phase of the session post-training measurements will be done using single TMS pulses. TMS pulses and intensity with be given in random order.
45339633|NCT00715520|Drug|Carbidopa-Levodopa|"Participants will receive one oral dose of carbidopa-levodopa 25mg one hour prior to measuring wrist extension movements.~The order in which Carbidopa-Levodopa is given will be randomized per participant."
46034932|NCT02885285|Behavioral|Spinning Class|Spinning Class twice a week for six weeks.
46034933|NCT02885285|Behavioral|Yoga Class|Yoga Class twice a week for six weeks.
46034934|NCT02885285|Behavioral|Dance Class|Dance Class twice a week for six weeks.
46034935|NCT02885285|Other|No Exercise Class|No exercise class. Subject will continue regular activities for six weeks.
46034936|NCT00893464|Drug|IXAZOMIB|Patients will be administered IXAZOMIB by IV on Days 1, 8, and 15 of a 28-day cycle. The first stage of the study will be initiated at a starting dose of 0.125 mg/m2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established.
45339634|NCT00715520|Drug|Methylphenidate|"Participants will receive one oral dose of methylphenidate 40mg 2 hours prior to measuring wrist extension movements.~The order in which Methylphenidate is given will be randomized per participant."
45339635|NCT00715520|Drug|Amphetamine Sulfate|"Participants will receive one oral dose of amphetamine sulfate 10mg 2 hours prior to measuring wrist extension movements.~The order in which Amphetamine Sulfate is given will be randomized per participant."
46034937|NCT05318326|Drug|placebo group|placebo 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
45683236|NCT03379402|Other|Specimens collection|"On admission: Blood samples 30.01 mL and other specimens (if available) for culture and other diagnostics tests including sputum, throat swab, urine (midstream urine), and pus which is part of routine practice for patients with sepsis at study site.~Day 3: Blood (15 mL) for culture (10 mL) and PCR (5 mL). There will be no blood collection, if patient is discharged before day 3."
45683237|NCT04587050|Diagnostic Test|Human papillomavirus testing|HPV test from cervical sample using Cepheid GeneXpert HPV
45683238|NCT04587050|Diagnostic Test|Cervical cytology|Cervical cytology
46034938|NCT05318326|Drug|Yogliptin 400mg group|Yogliptin 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
46034939|NCT05318326|Drug|Yogliptin 200mg group|Yogliptin 200mg (2 tablet) and placebo 200 mg (2 tablet), Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
45339636|NCT00715520|Drug|Placebo|"Participants will receive one oral tablet of placebo 2 hours prior to measuring wrist extension movements.~The order in which Placebo is given will be randomized per participant."
45339637|NCT00715520|Other|Sham Transcranial Magnetic Stimulation (TMS)|Sham TMS pulses will be randomly administered during TMS sessions.
45339638|NCT00715520|Other|Transcranial Magnetic Stimulation (TMS) Training|TMS surface electromyographic activity will be recorded with surface electrodes mounted on the skin overlaying a forearm muscle. Single pulses of TMS at increasing intensity will be delivered to measure motor cortex excitability. Peak acceleration and TMS evoked responses in the muscle will be measured prior to the training, after completion of the training and again one hour after completion of the training.
45339639|NCT05306132|Drug|ASKC202|Dosage Forms: Tablets; Administration: Oral administration
45339640|NCT05684978|Drug|Perampanel|The purpose of this study is to determine the efficacy of Perampanel, an approved antiseizure medication, in the treatment of refractory status epilepticus (RSE), to identify determinants of outcomes, and establish safety.
46034940|NCT02834962|Procedure|single bundle ACL reconstruction|anterior cruciate ligament reconstruction using single bundle technique
45339641|NCT00756873|Drug|Administration of placebo|Placebo qd orally day 0-14
45339642|NCT00756873|Drug|Administration of etoricoxib|Etoricoxib 90 mg qd orally day 0-14
45339643|NCT00756873|Drug|Administration of etoricoxib|Etoricoxib 120 mg qd orally day 0-7 Etoricoxib 90 mg qd orally day 8-14
45339644|NCT00790205|Drug|Sitagliptin|Sitagliptin, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily.
45339645|NCT00790205|Drug|Placebo|Placebo tablet matching the 50 mg or 100 mg sitagliptin tablet, orally, once daily.
45339646|NCT04056039|Drug|Atorvastatin|Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
45683239|NCT04587050|Diagnostic Test|HPV serology|HPV type specific serology (16/18) using ELISA from serum samples
46034941|NCT02834962|Procedure|double bundle ACL reconstruction|anterior cruciate ligament reconstruction using double bundle technique
46034942|NCT04441060|Other|Distress intervention (CBT & Mindfulness-based program)|Distress intervention is not fully developed yet, but we are working on the development of distress intervention based on CBT & Mindfulness-based program.
46034943|NCT04205110|Diagnostic Test|PET-CT|PET-CT compared to intravascular imaging for assessment of atherosclerotic plaques in stable angina patients
46034944|NCT02834182|Behavioral|IRMf|
46034945|NCT02834182|Behavioral|Mini International Neuropsychiatric Interview|
45339647|NCT04056039|Drug|Colchicine|Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
45683240|NCT05640232|Drug|CDE100 association|Experimental drug.
46034946|NCT02834182|Behavioral|Positive And Negative Syndrom Scale|
46034947|NCT02834182|Behavioral|Young Mania Rating Scale|
46034948|NCT02834182|Behavioral|Hamilton Depression Scale|
46034949|NCT00891904|Biological|cetuximab|Given IV
46034950|NCT00891904|Radiation|stereotactic body radiation therapy|Undergoing Radiotherapy
46034951|NCT02834338|Device|activity tracking for autofeedback|The intervention group receives an unblinded wristband. The handling of the activity trackers is explained to the patients and a predefined mobilization end-point (step-count) for the first five PODs is targeted. The target step-count was set at the 85% quartile obtained from a previous pilot study. The patients are assessed and monitored two times daily between 9 and 11 o'clock AM and between 3 and 5 o'clock PM by a surgical fellow or a study nurse throughout their hospital stay for read-out of the step count, assurance of the proper use and functioning, and for communication of the autofeedback.
46034952|NCT02837926|Other|questionnaire|
45339648|NCT00750945|Other|Music and treadmill walking program|Treadmill with Music cueing training 3 days/wk, plus home music cueing 3 days/wk x 4 weeks
45339649|NCT00750945|Other|Treadmill walking program|Treadmill training 3 days/wk, plus home walking 3 days/wk x 4 weeks
46034953|NCT02837926|Biological|Gardasil vaccine|
45339650|NCT00750945|Other|Home program|Home walking program 6 days/wk x 4 weeks
45339651|NCT04104815|Other|Experimental Thickener|Use to thicken liquids
45339652|NCT00715208|Drug|rituximab|
45339653|NCT00715208|Drug|cyclophosphamide|
45339654|NCT00715208|Drug|doxorubicin|
45339655|NCT00715208|Drug|VELCADE|
45339656|NCT00715208|Drug|prednisone|
45339657|NCT04104503|Drug|Lu AF11167|Lu AF11167 - 2 mg modified release tablets (reference formulation), up to 5 prototype MR tablet formulations (test formulations)
45339658|NCT04104503|Drug|[14C]-Lu AF11167|single iv microdose administered as a 15 minutes infusion
45339659|NCT04104503|Drug|Lu AF11167 MR tablet prototype formulation selected from part A or 1 mg modified release tablet (reference formulation)|Single oral dose
45339660|NCT05186870|Other|Outcome measures|Observational study
45683241|NCT05640232|Drug|Buscopan® Composto association|Active comparator.
46034954|NCT02837926|Biological|Cervarix®|
46034955|NCT02834260|Drug|Dexamethasone implant OZURDEX|
46034956|NCT02834416|Behavioral|Supervised Group Exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
46034957|NCT02834416|Behavioral|Home Based Exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
46034958|NCT02831608|Biological|Influenza vaccine|
46034959|NCT02831608|Biological|Placebo|
46034960|NCT01157351|Drug|paliperidone|flexible dosing as prescribed by the study doctor for 15 months
46034961|NCT01157351|Drug|risperidone|flexible dosing as prescribed by the study doctor for 15 months
46034962|NCT01157351|Drug|haloperidole|flexible dosing as prescribed by the study doctor for 15 months
45683242|NCT04414904|Other|Exposure: Covid-19 infection|Previous history of COVID-19 infection.
45339661|NCT00919178|Biological|DEN4 Vaccine Candidate|"DEN4 Vaccine Candidate~Participants will receive a single immunization on Study Day 0. Vaccine will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
45339662|NCT00919178|Biological|DEN4 Vaccine Placebo|"DEN4 Vaccine Placebo~Participants will receive a single immunization on Study Day 0. Placebo will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
45683243|NCT05627518|Drug|Linaprazan glurate|100 mg
46034963|NCT01157351|Drug|perphenazine|flexible dosing as prescribed by the study doctor for 15 months
46034964|NCT01157351|Drug|aripiprazole|flexible dosing as prescribed by the study doctor for 15 months
46034965|NCT01157351|Drug|quetiapine|flexible dosing as prescribed by the study doctor for 15 months
46034966|NCT01157351|Drug|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 15 months
46034967|NCT01157351|Drug|olanzapine|flexible dosing as prescribed by the study doctor for 15 months
46034968|NCT02834494|Procedure|3D Shear Wave Elastography (SWE)|Ultrasound imaging with Elastography will be performed at the inclusion (T0), after course 1 and course 2 respectively with anthracyclines, at the end of anthracycline treatment and at the end of taxane treatment.
46034969|NCT02834494|Biological|Biopsy|Optional biopsy of breast tumor under neoadjuvant chemotherapy after the course 2 of anthracycline.
46034970|NCT02831686|Drug|Selinexor|
46034971|NCT02831686|Drug|Ixazomib|
46034972|NCT02831686|Drug|Dexamethasone|
46034973|NCT02831530|Drug|Abemaciclib|
46034974|NCT04248478|Other|Eating Behaviours|Patients' eating behaviour will be questioned with Three Factor Eating Questionnaire. The 18-item Three-Factor Eating Questionnaire is a scale that measures three domains of eating behavior: cognitive restraint , uncontrolled eating and emotional eating.
46034975|NCT04248478|Other|Health Status|The effect of fibromyalgia on the daily life of the patients will be questioned with Fibromyalgia Impact Questionnaire (FIQ). The FIQ was developed from information gathered from patient reports, functional status instruments, and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue, and well-being over the past week.
45683244|NCT01814696|Device|MedSentry System|Subjects will use the MedSentry System and electronic pillbox, to manage their medications.
45683245|NCT03301558|Drug|Low dose sodium bicarbonate|1500 mg sodium bicarbonate
45683246|NCT03301558|Drug|High dose sodium bicarbonate|3000 mg sodium bicarbonate
45683247|NCT01970371|Drug|plazomicin|
45683248|NCT01970371|Drug|colistin|
45683249|NCT01970371|Drug|meropenem|
45683250|NCT01970371|Drug|tigecycline|
45683251|NCT01970371|Drug|antibiotic of Investigator's choice|
45683252|NCT03300466|Device|GP0045|Hyaluronic acid gel
46034976|NCT00633490|Drug|apatinib|apatinib is a tablet in the form of 250mg and 100mg and 50mg, orally, daily
46034977|NCT04247932|Behavioral|Active labor market intervention|Behavior change intervention
46034978|NCT02834026|Other|Cicloergometry training|
46034979|NCT02834026|Other|No Cicloergometry training|
46034980|NCT02831452|Other|pelvic floor muscle strength evaluation|
46034981|NCT02831374|Drug|Local anesthesia|The surgical extraction under local anesthesia (2% Lignocaine and 1:100000 Adrenaline) procedure was the same in all patients.
46034982|NCT02831374|Procedure|surgical extraction of impacted third molar|After achieving Local anesthesia using 2% lignocaine hydrochloride with 1:100,000 epinephrine, standard Terrence Ward's incision was placed to raise a full thickness mucoperiosteal flap. Disto-buccal bone was carefully exposed and bone surrounding the buccal aspect of impacted tooth was performed using surgical bur under copious irrigation with 0.9% saline. Tooth was elevated using Coupland elevator and if required situations tooth was sectioned with surgical bur to facilitate its removal. The socket was checked for any tooth or bony debris. The bony margins smoothened using a file and irrigated with 0.9% saline.
46034983|NCT02831374|Biological|Preparation of PRP gel|Before surgery, 10 milliliter of venous blood was collected from the anticubital fossa of the patients forearm and stored into sterile tubes containing anticoagulant (0.5 milliliter citrate phosphate dextrose) from each patient in the experimental group using routine venipuncture procedure. The whole blood is then centrifuged at 1,200 rotations per minute for ten minutes. The supernatant layer obtained was platelet poor plasma and buffy coat was collected in a new sterile tube and centrifuged again at 1,000 rotations per minute for 10 min. The upper half of the supernatant is removed and the lower half is mixed carefully to get platelet rich plasma. Five drops of mixture of 10 % CaCl2 and 1000 Units bovine thrombin to 2 milliliter Platelet rich plasma to obtain the gel form.
46034984|NCT02831374|Procedure|Placing platelet Rich plasma and suturing|Subsequently, platelet rich plasma gel was placed into the extraction sockets of patients in the group A and wound closure was done using simple interrupted 3.0 black silk sutures.
46034985|NCT02831374|Procedure|Suturing|Wound closure was done using simple interrupted 3.0 black silk sutures.
46034986|NCT02831374|Drug|Postoperative medication|Patients were advised regular post extraction and prescribed 500 milligram of paracetemol postoperatively (1 tablet every 6 hours for 2 days).
46034987|NCT02833870|Behavioral|Musical intervention|
46034988|NCT02833870|Behavioral|Non-musical (cooking) intervention|
46034989|NCT02833870|Behavioral|Control with no intervention|
46034990|NCT02833558|Device|PuraStat®|PuraStat® gel is applied through a safe catheter delivery system (via endoscope) over the bleeding point
46034991|NCT02833558|Procedure|Electrocautery|Electrocautery (coagulation current) to stop bleeding during ESD
46034992|NCT02831218|Procedure|QCA and Aspirin|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
46034993|NCT02831218|Procedure|QCA and Clopidogrel|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
45472803|NCT05569083|Diagnostic Test|Clinical-neuropsychological follow-up|For follow-up assessment, each subject will perform a complete clinical evaluation, an extensive neuropsychological evaluation (27 test), assessment of independent living skills (ADL and IADL), estimation of premorbid intelligence (TIB test) and scale for depression (Hamilton Depression Rating Scale - HDRS).
46034994|NCT02831218|Procedure|Imaging guided and Aspirin|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
45339663|NCT05184140|Procedure|Sentinel node detection|"Injection of the radiotracer to infundibulo-pelvic and utero-ovarian ligament in patients with high suspicion of malignancy adnexal mass. Injection of green indocyanine r to infundibulo-pelvic and utero-ovarian stumps only in case of malignancy after the adnexectomy.~Sentinel node exeresis and a complete staging surgery (including pelvic and para-aortic lymphadenectomy) will be performed in patients with ovarian cancer diagnosis."
45472804|NCT05569083|Diagnostic Test|ERP recording|For ERP acquisition the same EEG system that was used for EEG data acquisition will be used. The participants will be administered an ERP test battery with concurrently recorded EEG consisting of a 3-choice vigilance task (3CVT) designed to evaluate sustained attention and standard image recognition memory task (SIR) designed to evaluate attention, encoding, and image recognition memory. In the SIR, images will be chosen as stimuli to distinguish short term from semantic memory loss and extend previous results of image recognition ERP effects.
46034995|NCT02831218|Procedure|Imaging guided and Clopidogrel|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
45339664|NCT04083872|Drug|Reference drug|D744 Cap. 1 Cap., single oral administration under fasting condition
45472805|NCT01160627|Other|Hydration|Saline hydration
45472806|NCT01160627|Drug|Acetylcysteine|Acetylcystein tablets for 2 days
46034996|NCT02831140|Behavioral|Early exercises|"In postoperative phase:~Early exercises: within the first hour ;setting a half bed position, deep breathing and coughing . In the second hour, curbing vagal malaise and performing relaxation movements. In the third hour, walking about 20 to 30 minutes."
46034997|NCT02831140|Behavioral|Removing urinary probe and all catheters.|In postoperative phase : Removing urinary probe and all catheters.
45339665|NCT04083872|Drug|Test drug|CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fasting condition
45339666|NCT05183672|Procedure|Telecare consultation|Using Zoom to communicate with patients
45339667|NCT05183672|Procedure|Usual face-to-face consultation|Face-to-face communication with patients
45339668|NCT05684354|Other|Patient Reported Outcomes (PROs)|"The day before or the morning before surgery, the patient filled the first QoR-15 scale alone or could be helped by one of the investigators in case of questions or difficulties.~The second QoR-15 scale was distributed the day before or the day of discharge from the hospital"
45339669|NCT02590250|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
45472807|NCT01160627|Drug|Sodium bicarbonate|Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours
45472808|NCT01160627|Drug|Combined Acetylcystein and Sodium Bicarbonate|Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours combined with acetylcystein tablets for 2 days
45472809|NCT03985813|Behavioral|Screening Wizard|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
45472810|NCT02731690|Drug|Aceneuramic Acid Extended-Release|oral tablets
45472811|NCT03909581|Procedure|Endoscopic coronary arterial bypass|is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization (50 participants)
46034998|NCT02831140|Behavioral|Early alimentation|In postoperative phase :Early alimentation: in the first hour to the second hour .
45339670|NCT05293418|Other|data collection|data collection from medical records and the microbiological surveillance system of the enrolled patients
45339671|NCT00775463|Drug|treprostinil diethanolamine|oral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID)
45339672|NCT00775463|Drug|placebo|
45339673|NCT02589782|Drug|Bedaquiline|
45339674|NCT02589782|Drug|Pretomanid|
45339675|NCT02589782|Drug|Moxifloxacin|
45339676|NCT02589782|Drug|Linezolid|
45339677|NCT02589782|Drug|Clofazimine|
46034999|NCT02831140|Behavioral|commun interventions|"In preoperative phase: stopping smoking at least 2 weeks, hospitalization and balanced alimentation one day before the surgery.~In peroperative phase : no use of benzodiazepines in the anesthesia , selective intubation , maintaining vital parameters as normal and using a mini invasive surgical approach ( video thoracoscopy , video assisted thoracoscopy , thoracotomy with preservation of the posterior muscles of the chest wall~, preservation of Serratus anterior and the front part of Latissimus Dorsi ).~In postoperative phase : Immediate extubation ( less than 30 minutes from the surgery end) , peridural or paravertebral or intercostal block analgesia , no use of abusive antibiotic , all analgesic drugs are permitted if there are no contraindications and physiotherapy from the 6th hour."
46035000|NCT02833480|Drug|Fluticasone group|
46035001|NCT02833480|Drug|Budesonide group|
45339678|NCT02589782|Drug|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.|
45339679|NCT00587795|Device|StabilAir Wrist Brace|Patient will be placed in a StabilAir Wrist Brace 10-14 days after initial injury and return for follow up visits at 6 weeks; 3, 6, 12 and 24 months.
45339680|NCT00587795|Other|Placement of sugar tong splint or plaster cast|Patients will receive a sugar tong splint or plaster cast for their wrist fracture. They will return for x-rays and an exam at 6 weeks; 3, 6, 12 and 24 months.
45339681|NCT05169320|Device|Subcutaneous implantable loop recorder (ILR) implantation|All patients will undergo subcutaneous implantable loop recorder (ILR) implantation to quantify AF burden 1 month before the ablation procedure and at least 1 year after the ablation procedure.
45339682|NCT05169320|Procedure|Mapping and catheter ablation|Driver regions will be identified during persistent AF using a conventional electroanatomical mapping system, multielectrode mapping catheters, and leading-driver maps generated by novel single-signal algorithms based on an automatic and accurate analysis of the instantaneous amplitude and frequency modulations displayed by atrial signals (iAM and iFM, respectively). Such maps enable the location of the spatiotemporally stable regions that drive persistent AF (leading drivers). Leading-driver regions that can be reasonably targeted/isolated with catheter ablation without high-risk of complications upon radiofrequency delivery will be targeted for ablation.
45339683|NCT05169320|Procedure|Minimally invasive surgical ablation via thoracoscopy|"This procedure will be performed only in those patients whose leading-driver maps in the previous mapping and catheter ablation procedure fulfill the following requirements:~Extensive atrial remodeling who will not likely get any benefit from catheter-based ablation due to too large atrial leading driver areas (≥10-15% of atrial surface), or~Leading drivers located at regions with high-risk of complications upon radiofrequency delivery (e.g. left and right atrial appendages, coronary sinus, in the vicinity [≤5 mm] of the cardiac specific conduction system).~In such patients, the leading-driver regions not completely targeted or not targeted at all in the previous index mapping and catheter ablation procedure, will be specifically ablated/isolated by minimally invasive surgical ablation techniques via thoracoscopy."
45339684|NCT00587639|Device|rTMS Treatment|Active rTMS treatment.
45339685|NCT05167526|Drug|ASP8731|Oral
46035002|NCT02833480|Drug|Formoterol group|
46035003|NCT04248166|Device|Photoacoustic imaging|"Photoacoustic image of thyroid nodule is obtained by using probe of photoacoustic imaging equipment and image data and data are stored in the device.~The patient's examination is the same as the general ultrasound, and the patient is asked to hold his breath for about 3-4 seconds to get the photoacoustic image."
46035004|NCT02833636|Procedure|ACEF score|
46035005|NCT04201054|Drug|Fluconazole|50 mg of fluconazole administered orally in a single dose.
46035006|NCT02833402|Device|InterStim Therapy|Sacral Neuromodulation, delivered by the InterStim® System, offers long-term control of bladder control and bowel control symptoms through modulation of the nerves that help control the pelvic floor and lower urinary tract.
46035007|NCT04247854|Dietary Supplement|Bacillus subtilis probiotic|Bacillus probiotic which contains one confidential ingredient of Bacillus subtilis spores (2 x 1010 CFU/g). Over 5 days of interventional period, the patient receives one tablet (250 mg; 5 x 109 CFU) of probiotic per day.
45339686|NCT05167526|Drug|ASP8731 Matching Placebo|Oral
45472812|NCT03909581|Procedure|Percutaneous Coronary Intervention|will be performed using standard techniques at the discretion of the operator (50 participants)
45683253|NCT03300466|Device|Comparator|Hyaluronic acid gel
45683254|NCT01868594|Drug|Subetta|"Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type I diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
45683255|NCT01868594|Drug|Placebo|"Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type I diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
45683256|NCT04621435|Drug|Gallium-68 labelled (68Ga-) FAP-2286|The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
46035008|NCT04247854|Other|Placebo|Over 5 days of interventional period, the patient receives 1 placebo tablet per day
46035009|NCT01157117|Biological|Placebo for omalizumab|Placebo for omalizumab is injected subcutaneously every 2-4 weeks for 16 months at a volume designed to match that of the verum treatment group (determined by the participant's IgE level and weight).
46035010|NCT01157117|Biological|Omalizumab|Omalizumab is injected subcutaneously every 2-4 weeks for 28 months at a dose determined by the participants IgE level and weight.
46035011|NCT01157117|Drug|Milk powder|Milk powder is ingested orally at a dosage of up to 3.84 grams of of milk protein daily from Month 4 through Month 28 if the Month 28 10 g milk OFC is failed, and through Month 30 if the Month 28 10 g milk OFC is passed.
46035012|NCT04247386|Drug|PEG-Mizone|"The evening before the colonoscopy:60gPEG-4000 was mixed with 0.6LMizone and 0.4L water.~On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 1.2LMizone and 0.8L water."
46035013|NCT04247386|Drug|PEG-ELS|The evening before the colonoscopy:60gPEG-4000 was mixed with 1L water. On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 2L water.
45683257|NCT04621435|Procedure|Positron Emission Tomography (PET) imaging|Participants will be scanned for approximately 30 to 45 minutes
46035014|NCT04334590|Procedure|Cleft Lip/Nose Repair without PSIO|Standard of care surgical repair of cleft lip/nose without PSIO.
45472813|NCT05568849|Diagnostic Test|OCTA measurements|OCTA images will be obtained from the retina at 1-3 time points around the time of children's heart surgery
45683258|NCT04621435|Drug|Copper-64 labeled (64Cu-) FAP-2286|The dose will be 3.5 to 5.5 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
46035015|NCT04334590|Procedure|Presurgical Infant Orthopedic Therapy|Standard of care surgical repair of cleft lip/nose with PSIO.
46035016|NCT02833246|Other|SMS/MMS text messaging|text messaging reminders on oral chemotherapy medication adherence
46035017|NCT02833246|Other|usual care|
46035018|NCT02885051|Procedure|Recording of skin conductance and heart rate variability.|When a procedure of care will be prescribed, installation of the electrodes of measure of the cutaneous conductance on the foot and connection of the NIPE monitor to the cardio-respiratory monitor of the child used in routine. At this stage, beginning of the video recording.
46035019|NCT02833324|Behavioral|Education regarding ambulation|The participants will be educated on the importance of postoperative ambulation during the recovery period.
46035020|NCT02833324|Behavioral|Ambulation reminder alarms|Participants in the intervention arm will receive 5 daily alarms to prompt them to ambulate. Alarms will be set to ring at 9am, 11am, 2pm, 5pm and 9pm. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
46035021|NCT02833324|Other|Fitbit|Participants who are postoperative for colorectal surgery, who have been cleared to ambulate during recover, will be equipped with an off-the-shelf Fitbit device (a wireless activity tracking device) which will record steps taken while the participant is hospitalized. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
46035022|NCT04248088|Behavioral|Gentle Stretching and Education|60 minutes of gentle stretching twice weekly for 6 months
45683259|NCT03300232|Behavioral|Computer-based VC-CBT|Computer-based VC-CBT: Three, one-hour computerized therapy sessions delivered on an interactive computerized platform with therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
45683260|NCT05686876|Drug|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of PsA by PET/CT.
45683261|NCT04171700|Drug|Rucaparib|Oral rucaparib will be administered twice daily. The starting dose will be 600 mg daily (BID).
45683262|NCT01616953|Biological|Ixmyelocel-T|Twelve days after the bone marrow aspiration, alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with the cell therapy (Ixmyelocel-T)
46035023|NCT02833090|Procedure|biomarkers|transthoracic echocardiography, radial, and aortic arterial blood sampling
46035024|NCT02833012|Drug|Caprylic Triglyceride Oil|10 g Caprylic Triglyceride Oil (10.5 mL) at Hour 0 on Day 1
46035025|NCT02833012|Drug|AC-1202|60 g AC-1202 (shaken in 180 mL of water) at Hour 0 on Day 1
46035026|NCT02833012|Drug|Axona|40 g Axona (shaken in 120 mL of water) at Hour 0 on Day 1
46035027|NCT02833012|Drug|AC-1204|40 g AC-1204 (shaken in 120 mL of water) at Hour 0 on Day 1
46035028|NCT00891202|Drug|Eliglustat tartrate|PAP: Eliglustat tartrate (ET) capsule 50 mg orally on Day 1 followed by ET 50 mg capsule twice daily (BID) from Day 2 to Week 4, then either ET 50 mg capsule BID (participants with Genz-99067 [active moiety of ET in plasma] trough plasma concentration >=5 ng/mL) or ET 100 mg capsule BID (participants with Genz-99067 trough plasma concentration <5 ng/mL), up to Week 39. PK assessment at Week 2 used for dose adjustment after Week 4. LTTP: Participants of the eliglustat arm in PAP who completed PAP were included in LTTP and received ET capsule 50 mg BID orally from Day 1 (post Week 39) until Week 43 followed by ET 50 mg or 100 mg capsule BID up to Week 47, then ET 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration <5 ng/mL: next higher dose administered; if >=5 ng/mL: same dose continued) at Week 41 & Week 45, respectively.
46035029|NCT00891202|Drug|Placebo|PAP: Matching placebo capsule once daily on Day 1 followed by matching placebo capsule BID from Day 2 through Week 39. LTTP: Participants of the placebo arm in PAP who completed PAP were included in LTTP and received eliglustat tartrate from Day 1 (post Week 39) up to Week 312. Day 1 (post Week 39) was considered as baseline for LTTP. On Day 1, participants received eliglustat tartrate capsule 50 mg BID orally until Week 43 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 47, then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration <5 ng/mL: next higher dose administered; if >=5 ng/mL: same dose continued) at Week 41 & Week 45, respectively.
45339687|NCT00916175|Dietary Supplement|P1&P2|"First period (4 weeks) intake food product P1&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~Second period, cross over from AG&CC group, 4 weeks intake food product P1&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
46035030|NCT02831062|Other|low protein diet + ketosteril|Patients will follow a diet containing 0.6 g protein/kg per day, phosphorus 5-10 mg/kg/day, Ketosteril 1 capsule per 5 kg body weight/day divided over three doses (max 8 capsules per dose).
45339688|NCT00916175|Dietary Supplement|P1&CC|"First period (4 weeks) intake food product P1&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~Second period, cross over from AG&P2 group, 4 weeks intake food product P1&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
45339689|NCT00916175|Dietary Supplement|AG&P2|"First period (4 weeks) intake food product AG&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~Second period, cross over from P1&CC group, 4 weeks intake food product AG&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
45339690|NCT00916175|Dietary Supplement|AG&CC|"First period (4 weeks) intake food product AG&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~Second period, cross over from P1&P2 group, 4 weeks intake food product AG&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
45339691|NCT00916175|Dietary Supplement|TA (concentrated 5:1 aloe vera gel)|"First period (4 weeks) intake food product TA (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~Second period, cross over from P3 group, 4 weeks intake food product TA (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
45339692|NCT00916175|Dietary Supplement|P3|"First period (4 weeks) intake food product P3 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~Second period, cross over from TA group, 4 weeks intake food product P3 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
45339693|NCT05163782|Device|New ankle foot orthosis with anterior support|New ankle foot orthosis with anterior support developed by Turbomed
45339694|NCT05163782|Device|Ankle foot orthosis with anterior support|Ankle foot orthosis with anterior support from Turbomed
45339695|NCT05163782|Device|Ankle foot orthosis from competitor 1|Ankle foot orthosis with posterior support from competitor 1
45339696|NCT05163782|Device|Ankle foot orthosis from competitor 2|Ankle foot orthosis with posterior support from competitor 2
45472814|NCT03972553|Procedure|Sugarbaker technique for repairing parastomal hernia|The bowel will be brought through the peritoneum lateral to the edge of the retromuscular mesh and then draped over the mesh before bringing it through the anterior fascia medially.
45472815|NCT03972553|Procedure|Keyhole technique for repairing parastomal hernia|The bowel will be brought through defects in the posterior rectus sheath or contiguous peritoneum, mesh, and anterior fascia.
45472816|NCT05567211|Other|Free use of the virtual platform.|Access to the virtual platform + general healthy eating and physical activity recommendations. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
45683263|NCT01616953|Procedure|Autogenous Bone Grafting|Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
45683264|NCT05619718|Behavioral|Awareness, Courage, and Love Groups|Groups based on the Awareness, Courage, and Love framework from functional analytic psychotherapy
45683265|NCT05619718|Other|Mutual Help Meetings|Groups based on treatment as usual where patients gather to discuss how they can help others on the ward, and make requests for how others can help them.
46035031|NCT02830906|Drug|ramosetron|intravenous ramosetron 0.3 mg before spinal anesthesia and intrathecal morphine
46035032|NCT02830906|Drug|Ondansetron|intravenous ondansetron 8 mg before spinal anesthesia and intrathecal morphine
46035033|NCT02832778|Drug|Efavirenz|Efavirenz 400mg
46035034|NCT02832778|Drug|tenofovir /emtricitabine|tenofovir 245 mg/emtricitabine 200mg
46035035|NCT02832778|Drug|tenofovir/lamivudine|tenofovir 245mg/lamivudine 300mg
46035036|NCT02832778|Drug|lamivudine/zidovudine|lamivudine 300mg/zidovudine 600mg
46035037|NCT02832778|Drug|Rifinah or local generics|Rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if <50kg.)
45839866|NCT04742790|Diagnostic Test|Cognitive auditory-evoked potentials (P300)|Cognitive auditory-evoked potentials will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Short-lasting auditory tones will be delivered using a three-stimulus oddball paradigm combining standard tones (90% of stimuli), slightly different target tones that the subject must attend and detect (10% of stimuli), and strongly different distractor non-target tones (10% of stimuli). The stimuli will be delivered binaurally using headphones. Participants will be instructed to press a button when they detect a target tone, and to ignore the standard and distractor non-target tones. The EEG recordings will be used to measure the amplitude and latency of the cognitive P3a and P3b potentials (Komerchero & Polich 1999). Changes in P3a/P3b amplitude will be used as a measure of drug-induced effects on cognition (expressed as percentage of change).
46035038|NCT01185509|Drug|trastuzumab|
45339697|NCT00916487|Dietary Supplement|Fructosin|Three capsules of Fructosin before one of the hydrogen breath tests.
45339698|NCT00774995|Biological|EngerixTM-B|Intramuscular injection, one dose.
45472817|NCT05567211|Other|Personalized nutritional planning based on the Mediterranean diet + physical exercise + use of mobile application.|Access to the virtual platform + nutritional planning based on the Mediterranean diet + physical activity. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
45683266|NCT03293524|Genetic|GS010|GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). GS010 will be administrated via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) as a single baseline intravitreal injection.
45683267|NCT03293524|Drug|Placebo|The placebo is a BSS, sterile, apyrogenic solution and used for ocular surgery. The placebo will be administered via intravitreal injection in a volume of 90 μL.
45683268|NCT01867658|Device|Progel® Pleural Air Leak Sealant|Video-assisted or robotic-assisted surgical lung procedures plus Progel® Pleural Air Leak Sealant
46035039|NCT01185509|Drug|vinorelbine|
46035040|NCT02830984|Procedure|EST+LBD+ENBD|Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
46035041|NCT02830984|Procedure|EST+LBD|Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
46035042|NCT02833168|Other|patient-filled questionnaires|All patients answer selected questionnaires on sleep-related symptoms, sleep quality, daytime performance, and health-related quality of life.
46035043|NCT02833168|Device|spiromanometry|Measurement of forced vital capacity, maximum inspiratory pressure and maximum expiratory pressure
46035044|NCT04247230|Drug|Tetracaine|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
46035045|NCT04247230|Other|Matching placebo (PET500)|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
46035046|NCT04247230|Drug|STUD100|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
46035047|NCT02832934|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
45472818|NCT05567211|Other|Personalized nutritional planning with an extra intake of berries + physical exercise + use of mobile application.|Access to the virtual platform + nutritional planning with an extra supply of antioxidants using red berries + physical activity. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
45472819|NCT01252979|Dietary Supplement|Medium-Chain Triglycerides|Subjects will take supplemental MCT oil 3 times a day for 6 months
46035048|NCT02832934|Drug|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
46035049|NCT04247776|Combination Product|Prehab|Exercise: functional exercises, walking, Fitbit goals Nutrition: handout, supplements (protein, vitamins, minerals) Stress reduction: deep breathing
46035050|NCT04247776|Other|ERAS|Enhanced Recovery After Surgery guidelines are applied.
45472820|NCT05561595|Behavioral|Healing HEARTS|Session topics will include: psychoeducation; myths and stereotypes; cognitive distortions and restructuring; coping strategies; interpersonal effectiveness; self-efficacy; mindfulness and self-compassion; acceptance and positive self-image; disclosure and finding support; stigma in health care; and empowerment and advocacy.
46035051|NCT04247776|Behavioral|Fitbit|Fitbit is worn to monitor step counts.
46035052|NCT05268796|Behavioral|Behavior therapy|Caregivers will be coached either in-person or via telehealth to implement function-based behavioral treatment in 1-hour sessions each week with their child over 12 weeks.
46035053|NCT05268796|Other|Psychoeducation|Caregivers will complete online education modules in 1-hour sessions each week over 12 weeks.
46035054|NCT02830750|Procedure|Ablation|
46035055|NCT02832700|Dietary Supplement|Casein glycomacropeptide|
45472821|NCT05561595|Behavioral|Peer Support|Peer support groups will cover general topics such as symptom management, stress, and social support. Stigma will not be a formal topic of discussion, and group leaders will be trained to avoid initiating conversations about stigma; however, to capture realistic discussions in peer support groups, participants will not be prohibited from discussing the topic should they bring it up.
45472822|NCT04446208|Procedure|Endoscopy|Endoscopic treatment will consist in placement of a metal stent in a patient with early fistula (< 15 days) and/or a large fistula orifice, and no abscess, or double pigtail plastic stents if the fistula is older than 15 days and the orifice is small.
45472823|NCT04075513|Drug|Insulin glargine, 300 U/ml|"Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection"
46035056|NCT02832700|Dietary Supplement|Placebo|
46035057|NCT02832466|Other|Functional Test|Observation of physical function in hemodialysis patients during a period of 6 months
45472824|NCT04075513|Drug|Insulin degludec, 100U/ml|"Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection"
46035058|NCT05223790|Device|Pain measurement during care procedures in neonatal reanimation|Pain measurement during care procedures in neonatal reanimation
46035059|NCT02832232|Other|translational dorsal glide mobilization technique grade III|"Translational dorsal glide mobilization technique grade III of the atlanto-occipital joint, it is a mobilization technique of Orthopedic Manual therapy according to Kaltenborn-Evjenth concept. The aim is to produce a dorsal glide of the occipital on the atlas, which will be held back by the therapist's hand, producing a stretch component of the suboccipital muscles.~And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education."
45339699|NCT00918554|Drug|Methotrexate|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
45339700|NCT00918554|Drug|Placebo|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection of triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
46035060|NCT02832232|Other|pressure maintained suboccipital Inhibition technique|"Pressure maintained suboccipital Inhibition technique is aimed to inhibit the tone of the suboccipital muscles. Although some dorsal occipital glide is produced by the weight of the head itself, the main effect is on the muscles due to dorsally pressure is not added to the occipital.~And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education."
46035061|NCT02832232|Other|Control Group|Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education.
46035062|NCT02830828|Other|Investigation of precision pinch grip control|
46035063|NCT02830516|Other|Measurement of lung elastance by two methods|Measurement of tidal variations in esophageal pressure followed in the same patient by performing a PEEP-step while simultaneously measuring the change in lung volume
45683269|NCT05614180|Procedure|Percutaneous coronary intervention|Patients with a diagnose of coronary chronic total occlusions will be treated by percutaneous coronary intervention, as indicated by the heart-team.
45683270|NCT05613946|Drug|Lumason|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
45683271|NCT05613946|Drug|Optison|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
46035064|NCT04247152|Other|Intraoperative Aberrometry vs preoperative biometry|Hypothesis: Intraoperative aberrometry measures lower levels of astigmatism more accurately than preoperative biometry in patients undergoing cataract surgery.
45472825|NCT04075513|Drug|Background therapy: Rapid acting insulin analogs|Route of administration: SC injection
45472826|NCT03874871|Procedure|Function preserving gastrectomy|Function preserving gastrectomy include pylorus preserving gastrectomy, proximal gastrectomy, and partial gastrectomy.
45683272|NCT05613946|Drug|Definity|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
46035065|NCT02832310|Procedure|valsalva maneuver|the effects of valsalva maneuver on arterial pressure
46035066|NCT02831920|Other|CEUS and targeted biopsies|
46035067|NCT02831920|Other|MRI and targeted biopsies|
46035068|NCT02830672|Procedure|Surgical release A1 pulley for Trigger finger of the hand|
46035069|NCT02832076|Procedure|Subcutaneous negative suction drain for 10 days|
46035070|NCT02832076|Procedure|No subcutaneous drain|
46035071|NCT02831842|Drug|Anti-EGFR-Containing Regimen|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
46035072|NCT02831842|Drug|Bevacizumab-containing regimen|Study protocol does not specify any particular bevacizumab containing regimen. The data will be collected retrospectively.
46035073|NCT02831842|Drug|Chemotherapy|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
46035074|NCT00891046|Drug|Canakinumab|Canakinumab
45339701|NCT05684822|Other|Acupuncture|Acupoint:Taichong, Shenmen, Neiguan points with twice a week for total three weeks
45339702|NCT04104113|Other|Modified Xiang Bei Yang Rong Tang|Modified Xiang Bei Yang Rong Tang is a combination of 15 herbal components and it is available in granules form to be dissolved in hot water for consumption
45339703|NCT04104113|Other|Placebo|Placebo granules contain 5% XBYRT, colourant, bitterant and 95% starch filler
45339704|NCT00713648|Drug|catridecacog|35 IU/kg body weight, i.v. administration, once every 4 weeks
45339705|NCT04102085|Other|no intervention|no intervention
45339706|NCT02590016|Drug|Insulin, Aspart|Insulin aspart Novorapid® Penfill 40 IU/0,4 ml is diluted into 1000ml of 0,9 % sodium chloride (NaCl). Infusion is started at rate 48 ml/l, which equates insulin dosing at rate of 2 IU/h. Glucose infusion is started simultaneously. 5 ml of potassium chloride (KCl) is added to 500 ml of 10 % Glucose solution. Infusion rate is 100 ml/h giving glucose infusion rate of 10 g/l. Plasma glucose level is measured every 1-2 hours and infusion rate of insulin is increased by 6ml/h if plasma glucose is more than 7,5 mmol/l and decreased by 6 mmol/h if plasma glucose is below 4 mmol/l.
45339707|NCT00768053|Drug|Etanercept|Etanercept 50 mg once a week
45339708|NCT00683475|Biological|IMC-A12|IMC-A12 is to be administered as an I.V. infusion, 6 mg/kg over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. IMC-A12 treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
45472827|NCT03874871|Procedure|Standard gastrectomy|Standard gastrectomy include distal gastrectomy and total gastrectomy with standard lymphadenectomy according to the Japanese gastric cancer treatment guideline.
45683273|NCT04401046|Other|Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later|The first survey will include questions relative to sociodemographic characteristics, existence of psychological troubles; living conditions in the Covid19 pandemic context; IES-R, Stait Trait Anxiety, and the fear of a cancer recurrence scales, satisfaction with cancer care and medical status of patients (diagnosis, ongoing treatment, follow-up of the disease).
45683274|NCT03375892|Other|Deep Inspiration Breath Hold during Radiation|The DIBH technique involves the patient breathing to a specified threshold and then holding that level of inspiration during every radiation therapy field delivered.
45683275|NCT03375892|Other|Free breathing during radiation|The patient will be instructed to breathe freely.
45683276|NCT05686798|Biological|Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)|Ad5-yCD/mutTKSR39rep-ADP adenovirus will be injected intratumoral
46035075|NCT02830282|Other|Blood Collection|
46035076|NCT04245982|Procedure|Gingival biopsy|Two gingival biopsies from each participant were collected.
46035077|NCT02830048|Drug|Glibenclamide|
46035078|NCT02830126|Other|Anesthesiology Control Tower Feedback|Clinicians in the Anesthesiology Control Tower will provide extra support for the anesthesiology team in the operating room.
46035079|NCT04245358|Device|Ainara|1g of gel per administration
45339709|NCT00683475|Drug|Mitoxantrone|Mitoxantrone is to be administered as an I.V. infusion, at 12 milligrams/square meter (mg/m^2) over 5-15 minutes on Day 1 during a 3-week (21-day) cycle. Mitoxantrone treatment is to be continued for a maximum of 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m^2) or until there is evidence of disease progression, death, or intolerable toxicity.
45339710|NCT00683475|Drug|Prednisone|Prednisone (5 mg) is to be self-administered PO BID, each day of the 21-day cycle.
45339711|NCT00683475|Biological|IMC-1121B (ramucirumab)|IMC-1121B (ramucirumab) is to be administered as an intravenous (IV) infusion, 6 milligrams/kilogram (mg/kg) over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. Ramucirumab treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
45339712|NCT02589158|Drug|Evotaz|All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days
45339713|NCT02589158|Drug|Rezolsta|All participants will be administered Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
45472828|NCT04619823|Other|Blood sample collection|Blood sample collection Mosquito collection at home
45683277|NCT03291496|Other|Blood Collection Preterm|Blood will be collected on day 4 of life and then approximately every 3 days until 21 days of life. Thereafter, one sample will be collected weekly until discharge. For preterm neonates that have suspected sepsis an additional sample will be collected within 24-48 hours of the initial sepsis evaluation.
46035080|NCT02829892|Device|Light therapy|14-days exposure with an innovative ambient light
46035081|NCT02828800|Other|Cartography of allodynic and hypoasthetic territories|The cartography of allodynic and hypoasthetic territories will be performed by applying a tactile stimulation of an application force of 15g (for allodynia) or 0.7g (for hypoesthesia). Tracings will be plotted on tracing paper layer that will then be evaluated by the VISITRAK® tool (Smith & Nephew), validated method reproducible and standardized, enabling accurate measurement of the area concerned .
46035082|NCT02829970|Behavioral|SUCCEEDS Program|Participants will receive ADHD Psychoeducation, Brief Motivational Interviewing (BMI) and Behavioral Activation for Attention & Alcohol Disorders (BAAAD).
46035083|NCT02829970|Behavioral|Living a Healthy College Lifestyle|Participants will receive ADHD Psychoeducation, BMI and Supportive Counseling (SC).
46035084|NCT02828722|Other|Controlled light and noise|"Purpose: The day-night ratio of the environmental illumination (limit 8 lux) and that of the noise level (limit 20 dBA) must correspond to the necessary value required by a healthy human body as defined by the National Sleep Foundation (USA).~Implementation: Simulation of the daytime period is performed with blue predominant artificial light with colour temperature between 5500 and 8000 K with lux values of 1000-1200 measured at the head of the patient. Simulation of the nighttime period is performed with a sleeping mask and earplugs."
45339714|NCT04083482|Procedure|continous venovenous hemofiltraion|CVVH
45339715|NCT04083716|Drug|ABI-H2158 Reference Formulation|ABI-H2158 tablets Reference Formulation
45339716|NCT04083716|Drug|ABI-H2158 Test Formulation|ABI-H2158 tablets Test Formulation
45339717|NCT00918788|Other|biologic sample preservation procedure|Ex vivo samples of normal and malignant breast tissue; biopsy specimens are then fixed in formalin and submitted for histopathologic studies
45339718|NCT00918788|Other|immunohistochemistry staining method|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H&E staining and IHC). Additional histochemical, immunohistochemical, and fluorescent in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
45339719|NCT00918788|Other|light microscopy|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H&E staining and IHC).
45472829|NCT03388996|Diagnostic Test|microbiomes|16s RNA analysis and microculture of discharges/flushing fluid from vagina, faces and fimbria end of fallopian tube
45472830|NCT03877523|Dietary Supplement|Cocarnit|a metabolic complex
45472831|NCT01313715|Biological|160U /0.5ml|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml, two doses, one month interval
45683278|NCT03291496|Other|Blood Collection Term|A single 250 µl blood sample will be collected once the term neonate is >24 hours old.
45683279|NCT03291496|Other|Adult Blood collection|One Time 1 ml of whole blood collected
45683280|NCT01867580|Device|V.A.C.Ulta with Prontosan instillation|NPWT with instillation of a wound cleanser (Prontosan® Wound Irrigation Solution)
45683281|NCT01867580|Device|V.A.C.Ulta without instillation|NPWT only
46035085|NCT02828722|Other|Controlled nutrition|"In compliance with the standard daily nutrition protocol, nutrition is carried out only during daytime both in case of enteral and parenteral feeding in accordance with European Society for Clinical Nutrition and Metabolism 2016 guidelines.~Nutritional regimen should be stopped for 8 hours/24 at night (non-nutritional period may be depending on the work schedule of the actual ICU) , even if the daily energy/protein target is not reached."
45472832|NCT01313715|Biological|320U /0.5ml|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, one month interval
45683282|NCT05686720|Drug|SZ011 CAR-NK|In the escalation study, the minimum initial dose was 5.0×10^6 cells, then increased to 5.0×10^7 and 2.0×10^8 cells. The infusion is given every 2 weeks.
45683283|NCT04414982|Behavioral|Intervention Values Affirmation|Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.
45683284|NCT04414982|Behavioral|Control Values Affirmation|Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
45683285|NCT04400734|Other|No intervention, observational study|no intervention
46035086|NCT04245592|Dietary Supplement|Extra Virgin Olive Oil|Before beginning the 3-week dietary trial, participants will conduct a 2-week washout period during which they consumed ROO (50 ml daily for 2 weeks) because they are part of a population that consumes olive oil regularly. After thar, patients of this groups will consume 50 ml/day of organic EVOO for 3 weeks. Biochemical markers and clinical parameters in each participant will be determine before and after the 3-week treatment period.
46035087|NCT04245592|Dietary Supplement|Refined Olive Oil|Before beginning the 3-week dietary trial, participants will conduct a 2-week washout period during which they consumed ROO (50 ml daily for 2 weeks) because they are part of a population that consumes olive oil regularly. After thar, patients of this groups will consume 50 ml/day of ROO for 3 weeks. Biochemical markers and clinical parameters in each participant will be determine before and after the 3-week treatment period.
45683286|NCT05604742|Drug|Belimumab (Benlysta)|Belimumab will be administered intravenously every 2 weeks for 3 cycles and then every 4 weeks for a total of 5 cycles
45683287|NCT03290326|Device|Transcranial Alternating Current Stimulation (tACS)|tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
46035088|NCT02828332|Other|Vineland II (VABS -II)|semi-structured interview with a psychologist; Measure 4 areas: Communication, skills of daily living, socialization and skills Motrices
46035089|NCT02828332|Other|Quality of life|Evaluation of the quality of life and comorbidities
46035090|NCT02828566|Drug|IN ketamine|Intranasal ketamine 100 mg/mL solution (10 mg/kg, maximum 800 mg)
45339720|NCT00918788|Other|medical chart review|Medical records are reviewed to obtain information from the pathology report on patient demographics, pathological characteristics of the surgical specimen, and clinical indication for the surgical procedure.
45339721|NCT00918788|Procedure|histopathologic examination|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H&E staining and IHC). Additional histochemical, immunohistochemical, and fluorescent in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
45339722|NCT00918788|Procedure|needle biopsy|Tissue spectra are measured using a portable clinical spectroscopy device with front- and side-viewing optical fiber probes that are inserted into the breast tissue through a hollow biopsy needle.
46035091|NCT02828566|Drug|IV ketamine|Intravenous ketamine 50 mg/mL solution (1 to 1.5 mg/kg, maximum 120 mg)
46035092|NCT02828566|Drug|IN saline 0.9%|Intranasal 0.9% normal saline
45839867|NCT04742790|Diagnostic Test|Cervical somatosensory-evoked potentials|Cervical spinal-cord evoked potentials will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. The responses will be elicited by transcutaneous electrical stimulation of the median nerve. The N13 component of this response is mediated by large myelinated non-nociceptive fibers and reflects a segmental postsynaptic response of dorsal horn interneurons at the level of lumbar spinal cord (Cruccu et al., 2008). Changes in magnitude of the N13 will be used as a measure of drug-induced effects on spinal cord function (expressed as percentage of change).
45339723|NCT00918788|Procedure|spectroscopy|Optical spectra are acquired from ex vivo samples of normal and malignant breast tissue using diffuse reflectance, fluorescence, and Raman spectroscopy. Tissue spectra are measured using a portable clinical spectroscopy device with front- and side-viewing optical fiber probes that are inserted into the breast tissue through a hollow biopsy needle. After the probes are withdrawn through the needle, cutting biopsies are obtained and the tissue is marked at the site of the spectral measurements.
45339724|NCT00756951|Drug|Placebo|Placebo
45472833|NCT01313715|Biological|640U /0.5ml|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml, two doses, one month interval
45472834|NCT01313715|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, one month interval
45839868|NCT04742790|Diagnostic Test|Pupillometry|Pupillometry measurements will be performed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Pupillometry has been proposed as a method to assess opioid pharmacodynamics. The extent of pupil dilatation can provide an index of nociceptive input via autonomic innervation of the iris muscles, while the extent of the attenuation of this pupillary response during exposure to opioid analgesics could provide an index of pharmacological effects reflecting the extent of opioid receptor occupancy in the CNS. Pupillometry (static pupil diameter, variability of pupil diameter [variation coefficient of pupillary dilation, VCPD, Charier et al. 2017]), light-evoked speed of pupil constriction [maximum pupil constriction velocity, PCV, Connely et al., 2014]) will be measured using a handheld pupillometry device routinely used for clinical evaluations.
46035093|NCT02828566|Drug|IV saline 0.9%|Intravenous 0.9% normal saline
46035094|NCT04245046|Drug|Candesartan, Amlodipine, Atorvastatin|compare the pharmacokinetic of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate from reference products given as a multiple dose
45472835|NCT03388918|Device|Telerehabilitation|Blood pressure (A&D Medical UA 767PBT), weight (A&D Medical UC-321PBT), step counters(Fitbit Zip & Charge), sleep sensor (Beddit 3), tablet (iPAD Air 2) & transmitter (Qualcomm Life, QWH-HUB-V1.0E)
45472836|NCT03877679|Drug|Triamcinolone|Triamcenolone +napolycarboxylate
45472837|NCT03877679|Drug|Turmeric paste|Topical turmeric paste (a mixture of curcumin powder and vegetable glycerin base in a ratio of 1:8 by weight) Mix with 85ml carbapol gel (125ml H2O + 0.5g carbapol + triethanolamine 3 drops) prepared in the Faculty of pharmacy-Cairo University
45472838|NCT03330249|Drug|Split Cisplatin|25 mg/m2/day IV infusion at D1 to D4, at D22 to D25, at D43 to D46 during the radiotherapy.
46035095|NCT02828176|Procedure|electric cardiometry|"The following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance.~these parameters are measured on arrival to operating room before subarachnoid block in three different angles of lateral uterine tilt ( 0, 15 and 30 degrees )"
45339725|NCT00756951|Drug|SCV-07|0.02 mg/kg
45339726|NCT00756951|Drug|SCV-07|0.10 mg/kg
45339727|NCT00916253|Drug|Modafinil|"Modafinil is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~during 3 days at home~during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day and 2 driving sessions (one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under treatment (Modafinil)."
45472839|NCT03330249|Drug|Cisplatin|100 mg/m2/day IV infusion at D1, D22 and D43 during the radiotherapy.
46035096|NCT02828176|Procedure|IV line insertion|two Iv lines are inserted and 500cc crystalloid is administered to parturient .
46035097|NCT02828176|Procedure|spinal anesthesia ( subarachnoid block )|Subarachnoid block (SAB) was performed in sitting position under complete asepsis using 25 g spinal needle. SAB was achieved by intrathecal injection of 10 mg hyperbaric bupivacaine plus 25ug fentanyl. Success of SAB was tested within five minutes after drug injection. SAB was considered successful if adequate block reached T4 dermatome.
46035098|NCT02828176|Procedure|electric cardiometry|after SAB the following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance at three different angles of left uterine lilt (0,15,30 degrees)
45339728|NCT00916253|Drug|Placebo|"Placebo is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~during 3 days at home~during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day, and 2 driving sessions ( one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under Placebo."
45339729|NCT04087226|Device|PTFE Retraction Cord|Polytetrafluoroethylene (PTFE) Retraction cord will be gently applied in gingival sulcus with minimal pressure. The intervention will be applied for three minutes in gingival sulcus, followed by a two stage addition silicone impression.
45472840|NCT03330249|Radiation|Radiotherapy|70 Gy in 35 fractions of 2 Gy in non-operated patients and 66 Gy in 33 fractions in post-operative.
45339730|NCT02561637|Behavioral|Case management|
46035099|NCT02829580|Procedure|Echocardiography|Measures by Doppler and study of endothelial function
46035100|NCT02828410|Dietary Supplement|SBI|Serum bovine immunoglobulin protein isolate 10 g twice per day
46035101|NCT02828098|Drug|Part 1: BO-112|Cohorts of three patients per dose level will be treated consecutively in the absence of Dose Limiting Toxicity (DLT).
45339731|NCT02561637|Behavioral|Control group|
45339732|NCT00757029|Genetic|norepinephrine transporter polymorphism,|OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism
45839869|NCT04742790|Diagnostic Test|Saccadic Peak Velocity|The saccadic peak velocity (SPV; m/s) will be measured before before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Saccadic peak velocity is one of the most sensitive parameters for sedation. Recording of eye movements will be performed in a quiet room with dimmed lightning. Average values of saccadic peak velocity (expressed as degrees/second) of all correct saccades will be measured.
45339733|NCT04101929|Drug|Apatinib|Patients receive Apatinib 250mg po qd , Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
45339734|NCT04101929|Drug|S-1 capsule|Patients receive S-1 capsule According to the body surface area <1.25m2 60mg/d, 1.25 ~ 1.5 m2 80 mg/d, > 1.5m2 100mg/d po bid, taking 7 days, stopping for 7 days, 28 days for 1 cycle, Treatment repeats until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
46035102|NCT02828098|Drug|Part 2: BO-112|"BO-112 at a fixed dose will be administered as an intratumoral injection for up to 5 doses over 12 weeks and continue as long as there is benefit.~Nivolumab will be administered as an intravenous infusion every 2 weeks at a dose of 3 mg/kg for up to a total period of one year.~OR Pembrolizumab will be administered as an intravenous infusion every 3 weeks at either 200 mg or at 2 mg/kg depending on the indication, for up to a total period of one year."
46035103|NCT04245124|Other|Strategic Memory Advanced Reasoning Training|SMART focuses on three metacognitive strategies: Strategic Attention, Integrated Reasoning and Innovation.
46035104|NCT04245124|Other|Traditional Cognitive Rehabilitation|Participants randomized to the TCR condition will participate in a clinician-directed intervention that provides manualized, traditional clinician-directed cognitive rehabilitation that was developed for the SCORE trial (Cooper et al., 2017)
46035105|NCT04246450|Device|Implantable Cardioverter Defibrillator (ICD) insertion|Implantation of ICD when arrhythmic risk is deemed high in those with LVEF between 35%-50%, and to all with LVEF<35%. Aim to determine whether risk stratification accuracy can be improved more than that of the current approach regarding primary prevention of sudden cardiac arrhythmic death in nonischemic dilated cardiomyopathy patients (no ICDs to those with LVEF between 35%-50% and ICDs to all with LVEF <35%. In patients in the LVEF <35% groups, ICDs will be used as implantable recorders, to determine whether occurrence of major arrhythmic events (MAEs) can be better predicted by NIRFs/PVS than by LVEF alone.
46035106|NCT04244812|Other|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm."
46035107|NCT04244812|Device|Laser doppler flowmetry|Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena
46035108|NCT02827864|Behavioral|sequentially apply tDCS and MT|The participants in the SEQ group will first receive a-tDCS applied over M1lesioned without any active arm practice for 20 minutes. For the following 20 minutes, the participants will receive the MT, while the electrodes will be remained on the scalp without stimulation (sham tDCS). Then the electrodes will be removed from the scalp, and the participants will continue another 20 minutes of MT without tDCS. The treatment session will be ended with 30 minutes of functional task practice.
46035109|NCT02827864|Behavioral|apply tDCS concurrently|Sham tDCS will be first applied for 20 minutes without active arm practice. Twenty minutes of a-tDCS will then be applied concurrently with MT followed by another 20 minutes of MT without tDCS. The participants will also practice functional tasks for 30 minutes after MT.
46035110|NCT02827864|Behavioral|MT with sham tDCS|The training procedure will be the same as the above 2 groups except that sham tDCS will be provided in the first 40 minutes.
46035111|NCT00633568|Drug|Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
45472841|NCT04652206|Drug|SCO-101|Oral tablets with a strength of 50 mg or 150 mg according to dose level (cohort). Administered for 6 consequtive days in a bi-weekly schedule in each treatment cycle. Treatment until disease progression.
45472842|NCT04652206|Drug|Gemcitabine|Used according to marketing authorisation
45472843|NCT04652206|Drug|Nab paclitaxel|Used according to marketing authorisation
45472844|NCT01269281|Drug|Sumatriptan|Sumatriptan Succinate Tablets 100 mg
46035112|NCT00633568|Drug|Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
45839870|NCT04742790|Diagnostic Test|Adaptive tracking test|The test will be performed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Adaptive tracking is a pursuit-tracking task sensitive to impairment of eye-hand coordination by drugs. It has been proven useful for measuring CNS effects of alcohol, various other psychoactive drugs, and sleep deprivation.
45839871|NCT04742790|Diagnostic Test|Body Sway Test|Body sway will be assessed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment, using a body sway meter and with eyes closed. The body sway meter allows measurement of body movements in a single plane, providing a measure of postural stability. The method has been used to demonstrate effects of sleep deprivation, ethanol and psychoactive drugs. All body movements over a 2-min period are integrated and expressed as millimeters of sway.
46035113|NCT02829424|Drug|Methotrexate|Use of low dose methotrexate (MTX) in psoriasis patients receiving an anti TNF alpha agent
46035114|NCT02829424|Drug|Methotrexate Placebo|Use of placebo- MTX in psoriasis patients receiving anti TNF alpha agent according to the approved indication
46035115|NCT04246294|Device|Continuous Positive Airway Pressure (CPAP)|"CPAP is golden standard treatment for moderate-to-severe sleep apnea with high compliance, effectiveness, and cost-effectiveness.~There will be no interference with standard care."
46035116|NCT02829658|Behavioral|Psychologic test|Assessment by a psychologist including the Structured Interview for Diagnostic and Statistical Manual (DSM)-IV Personality Disorders (SIDP-IV) was given straight to those who had a score above 28. This questionnaire allowed us to distinguish one group of subjects with BPD and a group with other PD (without BPD). Clinical evaluation included Axis I (MINI), Axis II (SIDP-IV), psychopathological features (YSQ-I, Defense Style Questionnaire (DSQ-40), demographic variables and therapeutic alliance (Haq-II).
46035117|NCT02829658|Other|No intervention|No intervention
46035118|NCT02827630|Other|Proteus Discover|FDA cleared Wearable Sensor with Ingestible Sensor and Mobile Device Application
46035119|NCT02827630|Other|Usual Care|Routine medical care including medication titration, adherence counseling, and lifestyle coaching.
46035120|NCT05216692|Procedure|La Tour Hospital Foot Strengthening Protocol|"First exercise : NMES forward lean doming. Doming exercise assisted by NMES placed on the IFM. 8 sec of contraction (6 sec rest) moving the trunk forward. 12 repetitions, 3 sets. Progressive increase of the intensity of NEMS during 4 weeks and increase of body load while decreasing the number of repetitions.~Second exercise : MTP joint flexion. Isometric MTP joint flexion contractions. 4 contractions of 5 sec (10 sec rest), 3 sets. Progressive increase of the number of MVIC during 4 weeks and of increase body load while keeping the same intensity.~Third exercise : Foot-ankle rebound. Multiple jumps with only plantar flexion. Keeping the knee stiff and straight and pushing off the ground with only ankle and MTP plantar flexion by a forefoot contact with the ground. 10 seconds of jump (1 min of rest) during 5 sets. Progressive increase of body load while keeping the same intensity."
45339735|NCT04101929|Drug|Irinotecan|"Patients receive Irinotecan According to the body surface area of 180 mg/m2, ivgg/90min, once every two weeks. Continuous chemotherapy until the criteria for discontinuation of the drug are met (eg, progression of the disease, intolerance of adverse reactions, or withdrawal of informed consent by the patient).~Because the toxicity of apatinib or irinotecan or tigeol in the chemotherapy regimen meets the withdrawal criteria, the drug can be discontinued alone and the exact duration of the trial treatment recorded."
45339736|NCT04083638|Diagnostic Test|IFAB|Intestinal Fatty Acid Binding Protein will be taken from all participants before the tx and after the tx
45339737|NCT00757107|Device|Taperloc Microplasty|primary total hip arthroplasty
45339738|NCT00757107|Device|Taperloc standard|primary total hip arthroplasty
45339739|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -> B -> C. Each of these treatments will be separated by a 7 day washout period.
45339740|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -> C -> B. Each of these treatments will be separated by a 7 day washout period.
45339741|NCT00918632|Drug|AG-013736|A single dose of an FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -> C -> A. Each of these treatments will be separated by a 7 day washout period.
45339742|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -> A -> C. Each of these treatments will be separated by a 7 day washout period.
45683288|NCT05300776|Diagnostic Test|M-ROSE analysis|"The M-ROSE analysis process consists of 3 procudures.~Specimen quality assessment. The BALF undergoes the process of smear, diff-quik stain, gram stain and are analyzed by experts to report the cytoloy and pathogen patterns to determine whether the sample is qualified according to the cell proportions. The qualified BALF samples are: squamous epithelial cell proportion<1%, columnar epithelial cell proportion <5% .~Distinguish infection and colonization. According to the cytoloy pattern, the proportion of neutrophils > 50% often strongly suggests pulmonary bacterial infection; Neutrophil phagocytosis proportion> 5% indicates infection, and phagocytosis of bacteria is the pathogen. Besides, fungal and hyphae can be found under the microscope.~Preliminary identification of infectious pathogens. Identify the infected bacteria and fungi, and the results are gram-positive cocci, gram-positive bacilli, gram-negative cocci, gram-negative bacilli, yeasts and molds."
46035121|NCT05216692|Procedure|Standard Literature Foot Strengthening Protocol|"During the 1st week, the participants will perform the Short foot exercise (SFE) during 3 series of 10 repetitions of 5 seconds of contractions in sitting position. 1 minute of rest will be give between series.~During the 2nd week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in sitting position. 1 minute of rest will be give between series.~During the 3rd week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in standing bipedal position. 1 minute of rest will be give between series.~During the 4th week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in standing unipedal position. 1 minute of rest will be give between series.~The progression of the exercise during the protocol will be based on passing from a sitting position to a unipedal standing position."
46035122|NCT04245826|Other|Change in LCSBs Intake|Effect of changing LCSBs intake
46035123|NCT04245826|Other|Substitute LCSBs for SSBs or Water|Effect of substituting LCSBs for SSBs or Water
46035124|NCT02829736|Procedure|Intraoperative sealing test|A standard 28 Fr chest tube is inserted through the anterior port hole and all port holes are closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
46035125|NCT02829736|Procedure|Standard post-operative chest tube|A regular chest tube is left in the pleura.
46035126|NCT02829736|Procedure|Intraoperative chest tube removal|Chest tube is removed intraoperatively.
46035127|NCT02829346|Drug|Peri-articular tranexamic acid|750 mg of peri-articular TXA, prior to deflating the tourniquet and wound closure
46035128|NCT02829346|Drug|Intravenous tranexamic acid|750 mg of IV TXA, prior to deflating the tourniquet and wound closure
46035129|NCT05210764|Drug|propofol|General anesthesia is induced and maintained mainly with propofol.
46035130|NCT05210764|Drug|sevoflurane|General anesthesia is induced and maintained mainly with sevoflurane.
46035131|NCT05210764|Drug|S-ketamine|General anesthesia is induced mainly with S-ketamine and maintained mainly with propofol.
46035132|NCT00889720|Drug|Varenicline|Varenicline film coated tablets - escalating dose with maximum dose of 1mg bd
46035133|NCT01116648|Drug|Cediranib Maleate|Given PO
46035134|NCT01116648|Drug|Olaparib|Given PO
46035135|NCT04244500|Procedure|swab sampling|Multiplex polymerase chain reaction assay for organisms of upper respiratory tract infections
46035136|NCT02827786|Device|Electromagnetic Acoustic Imaging|Electromagnetic Acoustic imaging (EMA) is a novel experimental platform utilizing the combination of electromagnetic radio frequency (RF) and acoustic waves to enhance ultrasound images. The resultant imaging allows (based on early experimental models) tissue differentiation based on its mechanical and electrical properties. Combined with conventional US scanning, this technology potentially allows high spatial resolution imaging of a target tissue with superimposed high contrast functional information. This is a proof-of-concept pilot study in humans.
46035137|NCT02827552|Other|skin biopsy|skin biopsy performed prior radiation to characterize in blind the individual radiosensitivity of the patient
45339743|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -> A -> B. Each of these treatments will be separated by a 7 day washout period.
46035138|NCT04244734|Other|Usual care treatment|"All evaluations are the same in both groups:~Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment:A daily session from Monday to Friday of 40 minutes according to patient functional status: Passive or active-assisted or active mobilizations, muscle enhancement, respiratory physiotherapy and inspiratory muscle training at 40% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)"
45339744|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -> B -> A. Each of these treatments will be separated by a 7 day washout period.
45339745|NCT00751257|Drug|N-acetylcysteine|2400mg (1200mg b.i.d., 600mg capsules, p.o.)
45339746|NCT00751257|Drug|Placebo|"Identically appearing placebo capsules, packaged in an N-acetylcysteine slurry so that placebo has similar odor as active NAC capsules"
46035139|NCT04244734|Other|New Treatment Protocol-MotoMED®|"Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment: A daily session from Monday to Friday of 40 minutes (5 minutes of warm-up, 30 of training and 5 of cooling). Combined quadriceps / biceps femoris electrotherapy: at 200-350μs intensity. Respiratory physiotherapy with the objectives: Airway permeabilization and inspiratory muscle training at 60% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)"
46035140|NCT02880306|Other|RA|RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria
46035141|NCT02827318|Dietary Supplement|Isomaltulose|75g Isomaltulose (low glycaemic load intervention)
46035142|NCT02827318|Dietary Supplement|Glucose|75g Glucose (high glycaemic load intervention)
46035143|NCT02827318|Dietary Supplement|Sweetened water|Sweetened water will be used as a control
46035144|NCT04309968|Drug|Drug: SYHA1801|Drug: SYHA1801 administered orally
45339747|NCT00753441|Procedure|Surgical bypass|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
45339748|NCT00753441|Procedure|Endoscopic stenting|Placement of a biliary metal stent (in combination with a duodenal metal stent in case of gastric outlet obstruction if necessary)
45339749|NCT05685134|Device|Radiofrequency catheter ablation|Radiofrequency application via catheter to burn the electroanatomic substrate implicated in Brugada syndrome
45339750|NCT05685134|Device|Sham procedure|Venous and epicardial punctions, catheter insertions, programmed electrical stimulation and electroanatomical mapping
45339751|NCT00757185|Drug|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days
45339752|NCT00757185|Drug|methyl testosterone|testosterone, oral administration, day 5 of GnRH administration, 2.5 mg/day
45339753|NCT04084808|Dietary Supplement|Solution ingestion|Subjects will be required to ingest 1 liter of the experimental solution, spread over the 45 minutes of exercise. A first ingestion of 167 mL of solution will be made at rest, right before starting warmup, and another dose (167 mL) after it. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
45339754|NCT04084808|Behavioral|Cognitive flexibility|"Subjects will be required to undergo the Stroop task. They will have to answer as quickly as possible, with push buttons, to a colour stimulus, following specific rules, and get the highest possible number of right answers. The flexibility block will show a pre-signal on a screen in front of the subject (a square or a cross will be shown). The form presented will indicate if the subject must use the colour of the writing, or the word written. Each block will consist of 50 trials, 25% of which switching the condition of answer. During this test, reaction time in milliseconds (ms) as well as the number of right answers will be measured.~This test will be measured before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise."
45339755|NCT04084808|Procedure|Brain oxygenation|"Optic imagery (Near-infrared spectroscopy, or NIRS) is a non-invasive technique allowing a fine investigation of the inner workings of the brain. It allows discrimination of oxygenated hemoglobin from deoxygenated hemoglobin, which informs on the coupling between blood flow and oxygen consumption inside the brain. To measure brain oxygenation with NIRS, optodes will be installed on the subject's skin without glue or transmission gel.~[ Time Frame: During Stroop's task (i.e.before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise). ] Measured with near-infrared spectroscopy (NIRS)."
45339756|NCT04084808|Other|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
45339757|NCT04084808|Procedure|Blood glucose|Blood glucose will be measured with a puncture on the tip of a finger to get a droplet of blood.
46035145|NCT04244578|Device|Active tDCS|Active tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.
46035146|NCT04244578|Device|Sham tDCS|Sham tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), but the current will be applied for 30 s and will be ramped down without the participants awareness.
46035147|NCT02828878|Biological|Allogeneic MPBC transplantation from matched related donor|
46035148|NCT05183464|Biological|saliva samples|Collection of salivary a-amylase during the day (5 times a day: at 8:00 am, 9:00 am,1:00pm, 4:00pm and 8:00pm) with Salivette.
46035149|NCT05183464|Behavioral|Stanford sleepiness scale|"The Stanford Sleepiness Scale evaluates sleepiness at the time of the evaluation. The subjects have to choose the statement best representing their level of sleepiness on a scale ranging from 1 to 7: the higher the score, the higher the sleepiness.~This scale will be submitted to the children before each salivary sampling (5 times a day: at 8:00 am, 9:00 am,1:00pm, 4:00pm and 8:00pm)"
46035150|NCT05183464|Behavioral|Karolinska Sleepiness Scale|"The Karolinska Sleepiness Scale assesses the perceived level of sleepiness at the time of the evaluation on a 9-points scale. The higher the score, the higher the sleepiness.~This scale will be submitted to the children before each salivary sampling (5 times a day: at 8:00 am, 9:00 am,1:00pm, 4:00pm and 8:00pm)"
46035151|NCT05183464|Behavioral|Epworth Sleepiness Scale|"The Adapted Epworth Sleepiness Scale for children in which the item falling asleep while in a car stopped in traffic was replaced by falling asleep at school assesses the risk of falling asleep in 8 daily-life situations estimated on a 4-point Likert scale. The total score is the sum of the scores for the 8 items: a higher score represents greater sleepiness and the pathological threshold is higher than 10.~This scale will be submitted to the children one time, at the onset of the hospitalization."
46035152|NCT05183464|Behavioral|BLAST test|"The BLAST (Bron/Lyon Attention Stability Test) is a computerized attention test evaluating brief lapses of attention with 4 measures: reaction times, errors and two composite measures (Stability and Intensity). The subjects have to detect the presence or the absence of a specific stimulus during approximatively 60 trials for 3 minutes. Normative data are available for both children and adults.~This test is part of the neuropsychological evaluation, conducted the afternoon of the first day of hospitalization. The test is realized at 4:00pm."
46035153|NCT04244422|Other|PIEZOSURGERY VERSUS CONVENTIONAL SURGERY|Piezosurgery: SATLEC ACTEON peizotome 2 (A company of ACTEON Group, France) was used. Conventional surgery with rotary instruments
46035154|NCT02827474|Other|Patient Interview|Patient intervention includes a 30 minute interview prior to their abortion procedure and a follow up phone-interview that will be 10-minutes and held 24-72 hours from the procedure.
46035155|NCT02827474|Other|Provider Interview|For physician participants, providers will be interviewed after completion of the patient's visit and this will be 10-15 minutes.
46035156|NCT02827396|Behavioral|Psychosocial intervention|"This training is aimed at Mothers/Fathers/Caregivers/Grandparents of children with intellectual disabilities.~Individual (for severe mental health problems) or group counseling for similar psychological issues should be a vital ingredient of this program. The package runs for 40 hours. It will run for five days continuously. It's important to promote participatory rather than deductive approach allow a lot of time for questions and discussions."
46035157|NCT04243954|Drug|PCA IV Hydromorphone (continuous dose = 0)|Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose = 0; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
45339758|NCT04084808|Behavioral|Perceived exertion|Perceived exertion will be assessed using 3 scales : Borg (RPE), and DP-15 scale for mental effort (Delignières, Brisswalter, & Legros, 1994). These scales will be administrated at the end of each 3 minute high intensity bout.
46035158|NCT04243954|Drug|PCA IV Hydromorphone (continuous dose ≠ 0)|Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
45683289|NCT03351556|Behavioral|Active Arm 1|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month conditional on visit attendance.
45339759|NCT04084808|Behavioral|High Intensity Interval Training bouts|6 3-minute bouts at 95% of maximal aerobic power will be done on a bike. Each bout will be separated by 3 minutes of passive recovery. The last bout will be followed by 45 minutes of rest.
45339760|NCT00751413|Drug|Comparator: MK0633|A single dose of MK0633 10 mg or 25 mg film coated tablet. Dose will be based on patient weight.
46035159|NCT04243954|Drug|Oral morphine|"Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for d1; the total equianalgesic of the previous 24 hours/2 for day 2 and day 3; 2) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours; 3) Evaluate once every 24 hours"
45339761|NCT00757263|Genetic|polymorphism analysis|
46035160|NCT04244344|Other|fall prevention measures|High fall risk signage, information sheet, High fall risk bracelet, verbal instructions
45339762|NCT00757263|Other|laboratory biomarker analysis|
45339763|NCT00757263|Other|questionnaire administration|
45339764|NCT00919334|Device|Defocus Incorporated Soft Contact (DISC) lens|Use of simultaneous vision bifocal soft contact lenses with myopic defocus to control the progression of myopia
45339765|NCT00751491|Drug|Adenosin|Intracoronary Adenosin 50 microg;
45339766|NCT00751491|Other|placebo|no intervention
45339767|NCT00751491|Drug|Clopidogrel|Clopidogrel 300/600 mg
45339768|NCT05685056|Behavioral|Text messages|Texts with detailed information focusing on nutrition and iodine rich foods specifically, every 3-5 days.
45683290|NCT03351556|Behavioral|Active Arm 2|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month conditional on visit attendance.
46035161|NCT02827240|Other|Oral HIV Self-Testing|The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
46035162|NCT02827942|Drug|vonoprazan 20 mg bid|Vonoprazan is potent acid inhibitor. Vonoprazan 20 mg is dosed twice daily for 1 week.
46035163|NCT02827942|Drug|Amoxicillin 500 mg tid|Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. Then, 500 mg of amoxicillin is dosed three times daily for 1 week.
45339769|NCT02561169|Drug|Oseltamivir|Those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. For patients with a known creatinine clearance < 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
45339770|NCT02561169|Other|Placebo|Those randomized to the control arm will receive 75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir. For patients with a known creatinine clearance < 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
45339771|NCT00753597|Drug|Solu-medrone, Mabthera|125mg, 1gram, twice day 1 and day 15
45339772|NCT00751569|Other|blood donation|obtaining cord blood
45339773|NCT00757341|Drug|SKI-606|
45472845|NCT03385018|Procedure|Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by laparoscopic approach|"Total gastrectomy with D2(D2-10) lymph node dissection by laparoscopic approach~The number of trocars is 6 or less~Roux-en-Y esophagojejunostomy with any stapling method~Enough(negative) margin from tumor~LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~Washing cytology~Frozen biopsy for surgical margin at surgeons discretion~Complete omentectomy for grossly serosa-involved tumor~Combined organ resection only in cholecystectomy and splenectomy~Indwelling nasogastric tube and drainage catheter at surgeons discretion~D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection"
45339774|NCT00751647|Other|Physical Therapy|Treatment
46035164|NCT02827942|Drug|Amoxicillin 750 mg bid|Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. However, the standard regimen in Japan, 750 mg of amoxicillin is dosed twice daily with clarithromycin or metronidazole for 1 week. Then, 750 mg of amoxicillin is dosed twice daily.
45683291|NCT03289936|Device|NIPPV|Non invasive ventilation technique in which PIP and PEEP administration is not synchronized with newborn's respiratory efforts
46035165|NCT02827942|Drug|Clarithromycin 200 mg bid|Clarithromycin is antibiotics. It is involved in the standard first line regimen in Japan. Then, 200 mg of clarithromycin is dosed twice daily for 1 week.
46035166|NCT02827942|Drug|Metronidazole 250 mg bid|Metronidazole is antimicrobial agent. It is involved in the standard second line regimen in Japan. Then, 250 mg of metronidazole is dosed twice daily for 1 week.
45339775|NCT00757419|Drug|AZD3355|capsules, oral, single or twice daily dose
45339776|NCT00757419|Drug|Placebo|To match dosing of AZD3355
45339777|NCT00757497|Behavioral|Electrical Polarization|
45339778|NCT00757653|Device|Hip stem with plasma sprayed porous Ti 6Al4V alloy + plasma sprayed HA|Hip stem with plasma sprayed porous Titanium 6Al4V alloy + plasma sprayed HA
45339779|NCT00757653|Device|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA
45339780|NCT00757653|Device|Hip stem with Interloc Titanium surface + Bonemaster H.A|Hip stem with Interloc Titanium surface + Bonemaster H.A
45339781|NCT03877887|Diagnostic Test|echo cardiogram|Assessment of left ventricular systolic and diastolic function
45339782|NCT00757731|Drug|milnacipran|hard capsule
45339783|NCT00757731|Drug|Placebo|hard capsule
45683292|NCT03289936|Device|SNIPPV|Non invasive ventilation technique in which PIP and PEEP administration is synchronized with newborn's respiratory efforts through an algorithm based on flow detection
45339784|NCT05338892|Other|Non-Interventional|No study treatment will be administered on this study.
46035167|NCT00880087|Procedure|Therapeutic Hypothermia|Participants who are assigned to receive therapeutic hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32° to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36° to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
46035168|NCT00880087|Procedure|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
46035169|NCT02827084|Device|Kinesio Taping|Application of the Kinesio Taping with tension in the vatus mediallis muscle.
45339785|NCT00757809|Drug|neratinib|HKI-272
45339786|NCT00753831|Procedure|Aurosling|Silicon rod to be used in frontalis suspension surgery
46035170|NCT02827084|Device|Placebo|Application of the Kinesio Taping without tension in the vatus mediallis muscle.
45339787|NCT00753909|Drug|Carboplatin|Carboplatin (IV) 3 AUC on day 1 and day 15 every 4 weeks for 6 cycles
45339788|NCT00753909|Drug|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15 every 4 weeks for 6 cycles Followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
45339789|NCT00753909|Drug|Paclitaxel|Paclitaxel (IV) 140 mg/m2,on day 1 and day 15 every 4 weeks for 6 cycles
45339790|NCT04015544|Dietary Supplement|Watermelon|Pureed whole (100%) watermelon
45339791|NCT00685035|Device|HFCWC with higher pressure/variable-frequency settings|Randomized crossover trial of airway clearance therapy comparing sine wave HFCWO with high pressures and variable frequency (pressure 10, frequencies 8,9,10 and pressure 6, frequencies 18,19,20) to low pressure and mid frequency (pressure 5, frequency 12). Subjects will have 2-day washout between airway clearance sessions. All sputum collected during sessions.
45339792|NCT00685035|Device|HFCWC with lower pressure/mid-frequency settings|Subjects will perform pulmonary function tests prior to and following each airway clearance therapy. All sputum produced during, and for 15 minutes following airway clearance therapy will be collected. Subjects will complete a questionnaire addressing the comfort of therapy upon completion of the session.
45339793|NCT02560857|Other|Quantiferon-Monitor assay|The QFT-Monitor assay is a recently developed non-pathogen specific immune assay based on immune activation of both innate and adaptive immunity.
45339794|NCT00753987|Drug|Hypertonic Saline|5 ml of 7% saline will be administered via mask with Pari LC Plus nebuliser and a Pari Ultra Ned compressor.
45339795|NCT00757887|Biological|Exposure to 5 P. falciparum infected mosquitoes|Five Anopheles Stephensi mosquitoes are infected with NF54 P.falciparum. volunteers are exposed to bites for 10 minutes.
45683293|NCT03350386|Drug|FYU-981|Single administration
45683294|NCT03350386|Drug|Oxaprozin|Repeated administration
45683295|NCT04761016|Other|Usual Care|The current I-POP health model includes: 1) BSW HWC primary care medical home (for uninsured or Medicare patients), 2)BSW HWC providing diabetes prevention, nutrition education, weight loss, farm stands, physical activity programming (in collaboration with its onsite City of Dallas Park and Recreation Center), 3) BSW HWC programming at community sites in 75210, 4) Referrals to Parkland Hatcher Station clinic that provides health care to Medicaid patients, 5) Referrals between Parkland Hatcher Station and BSW HWC programming, 6) Community improvement in collaboration with Frazier Revitalization Inc. Individuals will have access to resources within our current, ongoing I-POP Health model, but without CHW navigation between BSW HWC and local service providers. Participants will complete follow-up visits for collection of study measures with study personnel at 6- and 10- months. At the end of the 10-month follow-up period, participants receive an assigned CHW and CHW-navigation.
46035171|NCT00889252|Device|contact lens with ketotifen|K-Lens (generic name not established) and Ketotifen combination drug-device product
46035172|NCT00889252|Device|contact lens|Placebo contact lens
46035173|NCT00670813|Drug|Modafinil (Vigil)|Oral application of 2 x 100 mg Modafinil each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
46035174|NCT00670813|Drug|Placebo|Oral application of 2 x 100 mg Placebo each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
46035175|NCT01110330|Drug|Placebo cream|A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
45339796|NCT00757965|Genetic|polymorphism analysis|
45339797|NCT00757965|Other|laboratory biomarker analysis|
45339798|NCT00757965|Other|questionnaire administration|
45339799|NCT05435079|Device|high-flow oxygen therapy device for tracheotomized patients|From the output end of the automatic pressure-adjustable oxygen flow meter, connect the oxygen suction tube, Venturi, Fisher & Paykel MR850 heated humidifier, RT308 breathing tube with humidification tank, closed sputum suction tube and tracheostomy tube), Adjust the MR850 to invasive automatic transmission, the temperature sensor automatically adjusts and maintains the gas temperature at the inlet of the tracheostomy tube at 37°C according to the feedback temperature, and adjusts the oxygen therapy device according to the gas outflow from the exhalation port of the patient's inspiratory phase. The gas flow rate is 40-60L/min. According to the monitored pulse oxygen saturation (SpO 2 ), the concentration of the venturi valve and the corresponding oxygen flow rate are adjusted to maintain the SpO 2 between 94% and 100%.
45339800|NCT02560155|Drug|Mupirocin 2% nasal ointement|Mupirocin nasal ointement 2x/d for 5 days preoperatively
45339801|NCT02560155|Drug|Chlorhexidine sol 4%|Shower with Chlorhexidine sol 4% once a day for 5 days preoperatively
45339802|NCT05331638|Behavioral|Prostate Cancer Genius App|Participants assigned to use the Prostate Cancer Genius App will receive a combination of (a) scheduled and (b) on-demand content prostate cancer for one month. Scheduled content will be delivered on specific days each week using app notifications. Participants will also receive tailored navigation for ordering a home-based PSA kit, including receiving follow-up information from trained medical professionals about their test results.
45472846|NCT03385018|Procedure|Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by open conventional approach|"Total gastrectomy with D2(D2-10) lymph node dissection by open conventional approach~Roux-en-Y esophagojejunostomy with any stapling method~Enough(negative) margin from tumor~LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~Washing cytology~Frozen biopsy for surgical margin at surgeons discretion~Complete omentectomy for grossly serosa-involved tumor~Indwelling nasogastric tube and drainage catheter at surgeons discretion~D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection"
45339803|NCT05331638|Behavioral|US Prevention Taskforce App|Participants assigned to use the US Prevention Task Force app will download the app from Google Play and will be instructed to use the app for one-month to to become more informed about prostate cancer. They will also be instructed to download a companion app from the Google Play store. This companion app will be used to deliver weekly assessments and order a home-based PSA test kit if the participant chooses to so. Participants assigned to the Prevention Taskforce app will receive a brochure providing details about the purpose of the home-based PSA test.
45683296|NCT04761016|Other|I-POP + CHW navigation|Individuals randomized to this condition will be paired with a CHW to assist with navigation of I-POP Health resources at BSW HWC and entities in local zip codes. CHW navigation will occur through monthly one-on-one follow-up visits for a period of 10-months. Participants will complete study visits for collection of data measures at baseline, 6- and 10- month timepoints. Study participation ends with completion of 10-months data measures.
45339804|NCT00758121|Device|Cardiac Resynchronization Therapy Defibrillator|CRT-D observational study
46035176|NCT01110330|Drug|Ketoconazole 2% cream (formulation F012) (Nizoral)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
46035177|NCT01110330|Drug|Ketoconazole 2% cream (formulation F126)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
46035178|NCT04244188|Other|Collection of datas|Collection of datas: pre- and postoperative scanner and endoprosthesis characteristics
46035179|NCT00663481|Drug|CoFactor|
46035180|NCT00663481|Drug|Leucovorin|
46035181|NCT04308954|Drug|[18F]flumazenil|[18F]flumazenil is a PET radiopharmaceutical that can be used to determine gamma-aminobutyric acid (GABA(A)) receptor density.
45339805|NCT04084340|Procedure|Real transcranial direct current stimulation + therapeutic exercises for urinary incontinence|"Real transcranial direct current stimulation associated with therapeutic exercises for urinary incontinence~tDCS: 20 minutes, 2mA, motor supplementary area anode and supraorbital cathode (ipsilateral to the dominant lower limb).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
45472847|NCT04073407|Dietary Supplement|AXA1957|Amino acids, food study
45472848|NCT04073407|Dietary Supplement|Placebo|placebo
46035182|NCT05016778|Drug|GPRC5D-CAR-T|After enrollment, subjects complete the PBMC apheresis, then complete the Lymphocyte clearance, and then receive the dose climbing test: 1×10e6/kg，3×10e6/kg，6×10e6/kg.
46035183|NCT02881398|Device|mHealth|After randomization and at the time of the initial encounter, study subjects are assessed at the point-of-care with mHealth devices that measure symptoms, functional status, and for structural abnormalities. These devices include activity monitoring for an assessment of a 6-minute walk test, smartphone connected blood pressure, oxymetry and ECG for functional assessments, and structural assessments with handheld-echocardiography and point-of-care BNP. Treatment decisions for an intervention with percutaneous valvuloplasty or valve replacement were performed based on the aggregate of these mHealth findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
45339806|NCT04084340|Procedure|Sham transcranial direct current stimulation + therapeutic exercises for urinary incontinence|"Sham transcranial direct current stimulation + therapeutic exercises for urinary incontinence~tDCS: 20 minutes (30 seconds ON), 2mA, motor supplementary area anode and supraorbital cathode (ipsilateral to the dominant lower limb).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
45339807|NCT02559921|Biological|rhRIG（20 IU/kg）|
45339808|NCT02559921|Biological|rhRIG（40 IU/kg）|
45339809|NCT02559921|Biological|HRIG（20 IU/kg）|
45339810|NCT02559921|Biological|rhRIG（20 IU/kg） and vaccine|
45472849|NCT02778204|Drug|Maraviroc|8 mg/kg oral solution as a single dose.
45472850|NCT02778204|Drug|Maraviroc|8 mg/kg oral solution given twice daily.
45472851|NCT03874403|Procedure|DSA|The changes on DSA on NIVATS and VATS
45472852|NCT01160705|Drug|docetaxel|
45472853|NCT01160705|Genetic|RNA analysis|
45472854|NCT01160705|Genetic|reverse transcriptase-polymerase chain reaction|
45472855|NCT01160705|Other|circulating tumor cell analysis|
45472856|NCT01160705|Other|laboratory biomarker analysis|
45472857|NCT04578028|Drug|ONO-2808|Investigational drug
45472858|NCT04578028|Drug|Placebo|Placebo drug
46035184|NCT02881398|Other|Standard-Care|After randomization and at the time of the initial encounter, study subjects randomized to standard-care underwent a physical examination, 12-lead ECG, radiographic and laboratory tests as warranted and clinically required. Treatment decisions for percutaneous valvuloplasty or valve replacement were based on the aggregate of the standard-care findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
46035185|NCT04243564|Device|Supraglottic device (SGD)|Positioning of SGD as temporary ventilatory device before tracheal intubation
45339811|NCT02559921|Biological|rhRIG（40 IU/kg） and vaccine|
45339812|NCT02559921|Biological|HRIG（20 IU/kg） and vaccine|
45339813|NCT02559921|Biological|placebo and vaccine|
45683297|NCT04279444|Dietary Supplement|BKR-017|BioKier, Inc. is developing colon-targeted, oral formulations of natural gut hormone secretagogues as non-prescription medical foods or supplements for nutritional use for improvement of insulin sensitivity.
45339814|NCT05273762|Device|FlowTriever|Mechanical thrombectomy for pulmonary embolism
45339815|NCT00754143|Drug|FG-3019|Placebo every 2 weeks IV for all infusions
45339816|NCT00754143|Drug|FG-3019|FG-3019 5 mg/kg every 2 weeks IV for all infusions
45339817|NCT00754143|Drug|FG-3019|FG-3019 10 mg/kg IV for infusions on Days 1, 15, 29 and 57 and Placebo IV on Days 43 and 71
45339818|NCT02588768|Device|Photobiomodulation therapy (Phototherapy)|PBMT was applied employing MR4 Laser Therapy Systems manufactured by Multi Radiance Medical, Solon - OH, USA. The cluster emitter contains 12 diodes with four super-pulsed laser diodes (905 nm, 0.3125 mW average power, and 12.5 W peak power for each diode), four red LED diodes (640 nm, 15 mW average power for each diode), and four infrared LEDs diodes (875 nm, 17.5 mW average power for each diode). It was applied in direct contact with the skin to 9 sites on extensor muscles of the knee, 6 sites on knee flexors of the knee, and 2 sites on the calf of both lower limbs. To ensure blinding, the device emitted the same sounds and regardless of the programmed mode (active or placebo).
45339819|NCT04083248|Behavioral|Feasibility group|Same as arm description
45339820|NCT05266040|Drug|Valacyclovir 500 MG|Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Valtrex (valacyclovir 500mg x three times daily for 7 days). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
45339821|NCT05266040|Drug|Placebo|Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Placebo (empty capsule). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
45339822|NCT02588924|Other|Second University of Naples|enrollment of patients with Parkinson's disease; collection of blood samples; measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
46035186|NCT05010460|Drug|Roxadustat|orally 100mg every other day for 5-8 days prior to CABG
46035187|NCT05010460|Drug|Placebo|orally 100mg every other day for 5-8 days prior to CABG
46035188|NCT00596947|Drug|prednisone|In this group, participants had prednisone rapidly decreased until completely eliminated by day 6 after transplant. Participants began on 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20mg on day 5, none from day 6-on.
45472859|NCT04072159|Behavioral|Community Pharmacists Vaccinating Against Cancer|Upon completing informed consent, parents of children who have received Dose 1 of the HPV vaccine at the recent clinical visit will be invited to participate in the study. Upon completing the demographic form and pre-test survey for the study, they will be randomized to intervention or control group. Participants in the intervention group will be asked to complete the additional vaccine doses with their community pharmacist. A provider from the participating clinic will electronically prescribe the HPV vaccine dose. Participants in the control group will be scheduled to return to the clinic (based on the vaccine schedule) to complete the vaccine series. The research team will conduct a follow-up survey six months after baseline for each participant. A sample (n=30) of intervention and control group participants will be invited to participate in an in-depth interview to gauge both parents' and children's' acceptability of this intervention.
45472860|NCT03232281|Drug|Triptorelin Pamoate PR 3-month|15mg/injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections).
45472861|NCT03232281|Drug|Triptorelin Acetate PR 1-month|3.75mg/injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections)
45339823|NCT02588924|Other|Neuromed IRCCS|enrollment of patients with Parkinson's disease; collection of blood samples;
45339824|NCT05684042|Other|Data analysis: Accuracy measurement of the classifications of the distal radius fracture in the fracture database.|An expert panel (3 in-house experienced specialists) carries out a new fracture classification based on the anonymous radiological images in the interface of the REDCap fracture database. The degree of discrepancy between the expert panel and the database in fracture classifications is analyzed. By evaluating the extracted data, it is analyzed how valid the quality of the collected fracture classifications are, which the medical staff carry out in everyday clinical practice.
45339825|NCT05325710|Behavioral|Study nurse intervention|Contact everay 4 months with a dedicated study nurse
45472862|NCT04572126|Behavioral|Mindfulness Intervention|The mindfulness intervention includes strategies to cope with substance cravings based on previously published mindfulness techniques. Examples of strategies presented include paying close attention to sensations, acceptance of cravings, and self-kindness.
45683298|NCT03371056|Biological|Bacteriological analyses on clinical samples performed with swabs|Bacteriological analyses will be performed to assess the InSPIRe kit
45683299|NCT05345548|Diagnostic Test|Cold Pressor test|Cold Pressor test will be done for 3 minute duration maximum
45683300|NCT03283462|Dietary Supplement|Mitopure|Mitopure (Urolithin A) containing softgels
45683301|NCT03283462|Dietary Supplement|Placebo|Placebo containing softgels
46035189|NCT00596947|Drug|rabbit antithymocyte globulin|Participants in both groups received 3 to 5 doses of an intravenous medication to prevent rejection called Thymoglobulin (rabbit antithymocyte globulin) as per our standard of care. This drug was dosed at 1.5 milligrams/killograms per dose and dosing was then based on body weight. The dose was decreased in half or held if the participant had a low white blood cell count or if the participant a low platelet count. The first dose was given intravenously in the operating room and subsequent intravenous doses were administered either while participants were inpatients or outpatients for a total of 3 to 5 doses for a total of up to 6mg/kg. The number of doses was based on transplant kidney function and risk factors for rejection.
45339826|NCT00773747|Drug|Vorinostat|Four 100 mg capsules vorinostat taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
45683302|NCT04400968|Procedure|Auricular therapy|The auricular therapy points were selected following the protocol for dysmenorrhoea described by Oleson (Oleson, 2008). These points were (the name of the European cartography is specified by the name of the point): Shenmen [FT2], uterus [FT5], sympathetic [HI4], kidney [CS6], heart [CI4], endocrine [IT2] and thalamus [PC2].
46035190|NCT00596947|Drug|Tacrolimus|Participants in both groups received tacrolimus per our standard of care. This medication helped to prevent rejection and was initially dosed at 0.1-0.2 milligrams/killograms/day in two divided doses, given orally, based on participant's body weight. We then looked at the trough levels of this medication(the lowest level before the next dose), and aimed to keep the trough level between 5-10 nanograms/milliliter throughout the study.
45839872|NCT04742790|Diagnostic Test|N-back working memory test|"Working memory performance will be assessed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. In this test, a series of letters are shown to the participant on a computer screen. The test includes three conditions with increased working memory load. The 0-back condition simply requires to indicate whether the presented letter is the letter X or another letter. In the 1-back condition, participants are requested to indicate whether the displayed letter is identical to the preceding letter. In the 2-back condition, participants are required indicate whether the letter is repeated with one other letter in between (e.g., B … C … B)."
46035191|NCT00596947|Drug|Prednisone|Participants in this group continued on prednisone indefinitely. Participants began with 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20 mg days 5-9, 15 mg day 10-19, 10 mg day 20-24, 7.5 mg day 25-29, and 5mg from day 30-on indefinitely.
45339827|NCT00773747|Drug|bortezomib|1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
45339828|NCT00773747|Drug|placebo to vorinostat|Four placebo capsules taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
45339829|NCT05123222|Other|ZIKV-SJRP/2016-184 Strain|Zika Virus Strain
45339830|NCT05123222|Other|Experimental: ZIKV-Nicaragua/2016 Strain|Zike Virus Strain
45339831|NCT05123222|Biological|Placebo|Not an active strain of Zika
45339832|NCT04104269|Diagnostic Test|Heart rupture|Free wall rupture and Ventricular septal rupture
45339833|NCT04104191|Device|L-1000AF System|The L-1000AF System is a wrist worn system that analyzes pulse rate data. The system identifies atrial fibrillation rhythms.
45339834|NCT00784277|Drug|oxycodone CR|flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
46035192|NCT00596947|Drug|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone withdrawal group was 1000mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
45339835|NCT00784277|Drug|oxycodone IR|10mg for 14 days
45339836|NCT00784277|Drug|Tapentadol ER (CG5503)|flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
45339837|NCT00784277|Drug|Tapentadol IR (CG5503)|50mg for 14 days
45339838|NCT00784277|Drug|Tapentadol IR (CG5503)|75mg for 14 days
45339839|NCT00784277|Drug|placebo|1 capsule for 14 days
45339840|NCT00784277|Drug|placebo|Tablets and capsules 2 x a day for 28 days
46035193|NCT00596947|Drug|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone maintenance group was 500 mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
46035194|NCT04155697|Drug|2% Chlorohexidine Gluconate soap|Participants will wash hands for 30 seconds with 2% Chlorohexidine Gluconate soap.
46035195|NCT04155697|Drug|62% ethyl alcohol-based hand sanitizer|Participants will apply 62% ethyl alcohol-based hand sanitizer for 30 seconds
46035196|NCT00663559|Drug|Sunitinib|Sunitinib 50mg oral in the morning during 4 weeks with 2 weeks of break.
46035197|NCT04158349|Drug|Oxaliplatin|Subjects will be accrued in cohorts of 3 to 6 subjects per dose level starting at Dose Level 0 (85 mg/m2). Escalation will continue as described in the protocol until DLT stopping rules are met or the highest dose level is reached.
45339841|NCT05116748|Biological|COVID19 mRNA vaccine|Administration of COVID19 mRNA vaccine
45339842|NCT05254964|Procedure|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hour on every working 20 days (4 weeks) during the subacute stroke phase
45339843|NCT05071274|Device|Skinpen Prescision System|Skinpen Precision is an automated nonsurgical micro needling device designed for use by licensed health care practitioners or individuals directed by practitioners. The device incorporates a sterile Microneedle cartridge and Biosheath for single use only.
45339844|NCT05113784|Drug|Meplazumab for Injection|humanized antibody target CD147
45339845|NCT05113784|Drug|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
46035198|NCT04158349|Drug|mFOLFIRI|mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle. 5-Fluorouracil, leucovorin, and irinotecan should be prepared and administered per the package insert and local institutional guidelines.
45339846|NCT02588534|Device|etanercept (ENBREL®) via auto-injector device|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
46035199|NCT00670891|Procedure|oxygen (Hyperbaric Oxygen Therapy)|"Current Accepted Applications of HBOT (2008) Jan 2003, ANDI International~Air or Gas Embolus~Decompression Illness~Carbon Monoxide poising~Clostridial Myonecrosis (Gas Gangrene)~Necrotizing Fasciitis~Crush Injury (Compartment syndromes)~Selected Problem Wounds~Compromised Skin Flaps or Grafts~Refractory Osteomyelitis~Exceptional Anemia due to Blood loss~Osteoradionecrosis~Thermal Burns and Radiation Tissue Damage~Diabetic Wounds~Intra-Cranial Abscess~Brain Injury and other Head Trauma~Cerebral Palsy~High Altitude Sickness~Lyme disease"
45339847|NCT02588534|Other|Etanercept (ENBREL®) via Manual injection|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
45339848|NCT05099822|Drug|CC-97489|Specified dose on specified days
45339849|NCT05099822|Other|Placebo|Specified dose on specified days
45339850|NCT05099276|Drug|Tranexamic Acid Pill|1950 mg tranexamic acid (three capsules) given in post-anesthesia room and three capsules for postop day one and three capsules for postop day two
45339851|NCT05099276|Drug|Placebo|Three capsules of cellulose given in post-anesthesia room and three capsules for postop cay one and three capsules for postop day two
45339852|NCT05103878|Drug|BT051 100mg|Single oral dose of 100mg BT051
45339853|NCT05103878|Drug|BT051 300mg|Single oral dose of 300mg BT051
45339854|NCT05103878|Drug|BT051 700mg|Single oral dose of 700mg BT051
46035200|NCT00888940|Drug|Ecallantide|2.25 mg/L pump prime, 0.13 mg/kg loading dose, 2.25 mg/L constant infusion
45339855|NCT05103878|Drug|BT051 1500mg|Single oral dose of 1500mg BT051
45339856|NCT05103878|Drug|BT051 3500mg|Single oral dose of 3500mg BT051
45339857|NCT05103878|Drug|Matching Placebo|Placebo Matching BT051
45339858|NCT00682929|Drug|Inhaled Cannabis|Participants will be instructed to smoke one cannabis cigarette, daily for 7 weeks.
45339859|NCT00682929|Drug|Oral THC|Participants will be instructed to take two 5 mg dronabinol tablets two hours prior to the inhaled medication, daily for 7 weeks.
45339860|NCT00682929|Drug|Oral Placebo|Participants will be instructed to take two placebo tablets two hours prior to the inhaled medication, daily for 7 weeks.
45339861|NCT00682929|Drug|Inhaled placebo|Participants will be instructed to smoke one placebo cigarette, daily for 7 weeks.
45339862|NCT05094206|Biological|0.75x10^6 cells/kg CAR20.19.22 cells|"Dose escalation: CAR20.19.22 cells will be administered at one of three dose levels either fresh or thawed after cryopreservation by IV injection.~Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6."
45339863|NCT05094206|Biological|1x10^6 cells/kg CAR20.19.22 cells|"CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection.~Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6."
46035201|NCT00888940|Drug|Cyklokapron(R)|1000-mg loading dose followed by a continuous infusion of 400 mg/hr with an additional 500 mg added to the pump prime
46035202|NCT00595621|Device|Enterra Multi-Channel Phased Gastric Pacemaker (MGP-1)|Multi-Channel Phased Gastric Pacemaker (MGP-1)
46035203|NCT02826070|Drug|Telbivudine|Telbivudine, 600mg, oral, daily
46035204|NCT02826070|Drug|Adefovir dipivoxil|Adefovir dipivoxil 10mg, oral, daily
46035205|NCT02826070|Other|off-treatment follow-up|
46035206|NCT00663637|Device|CAM (Complete Airway Management) Catheters|Prior to extubation, endotracheal tube lumen secretions are mechanically removed using CAM Rescue Cath followed by CAM Endotrach Cath.
45839873|NCT04742790|Other|Patient-reported outcomes|Before (visit 1) and 7-10 after (visit 2) initiating the combination treatment, but also daily between the two visits, 14 days, 1 month, 3 months and 6 months after treatment initiation, patient-reported outcomes will be collected to assess clinical effects and side-effects of the combination treatmen These include the short form of the Brief Pain Inventory (BPI), the PROMIS PQ-NEURO score for neuropathic pain, the Stanford Sleepiness Scale (SSS), and the PROMIS Neuro-QOL self-assessment of cognitive functioning.
45839874|NCT04742478|Procedure|Rotational Atherectomy|Rotational atherectomy (RA) has been the most used atherectomy modality since its first inception in1988. RA uses high speed rotation (140,000 - 180,000 rpm) to ablate inelastic plaque, resulting in debris averaging 5µm in size24. The main focus of RA in the era of DES stent has been on plaque modification rather that plaque debulking with more papers showing improved PCI success rates.
45339864|NCT05094206|Biological|2.5x10^6 cells/kg CAR20.19.22 cells|"CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection.~The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6."
45472863|NCT04572126|Behavioral|Control Intervention|The control intervention instructs participants to utilize their own, previously used strategies to cope with substance cravings.
45839875|NCT04742244|Dietary Supplement|Lvemon verbena extract|Each capsule contained 200 mg of lemon verbena extract 2 capsules/day, 14 days
45839876|NCT04742244|Dietary Supplement|maltodextrin|Each capsule contained 0 mg of lemon verbena extract 2 capsules/day, 14 days
45839877|NCT04741854|Device|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
45839878|NCT04741152|Procedure|Pancreatic resection|Different pancreatic resections
45839879|NCT04740840|Drug|Levamlodipine|According to the inclusion criteria of the trial, those who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was treated with 2.5mg levamlodipine to lower blood pressure. Abdominal blood was emptying before the start of the trial and at the first and third month of medication.Data on CRP, TNF-α, IL-6, Lp-PLA2 and ATP were collected.
46035207|NCT05090488|Behavioral|Personal Health Coaching and Diabetes Education in Group|Health coaching was given as face to face with a trained coach from primary health care. Diabetes education in group, with trained educator team from primary health care
46035208|NCT00663715|Other|Observation of the Sciatic Nerve|Ultrasound will be used to determine the location of the Sciatic Nerve using a lateral mid-thigh approach.
46035209|NCT02826226|Device|multiple-breath-washout test|
46035210|NCT02826226|Drug|Bronchodilator Agents|
46035211|NCT00671047|Other|non-interventional|SLE nature history observational
46035212|NCT00671125|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.
46035213|NCT00671125|Drug|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 5 weeks.
46035214|NCT00671125|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
46035215|NCT00671203|Procedure|Reestablish colon blood flow|If ischemia is detected, and the detection in consistent with the physician's clinical view, blood flow to the colon is established using any of the known techniques that would be used had the diagnosis been made in the absence of T-Stat, which include changes in the deployment of stents and/or coils, reanastomosis, reimplantation, or stenting, of obstructed vessels, or other established techniques.
45339865|NCT05094206|Biological|5x10^6 cells/kg CAR20.19.22 cells|"CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection.~The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6."
45339866|NCT05094206|Biological|Dose expansion: The maximum tolerated dose of CAR20.19.22 cells|Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6 cells/kg.
45339867|NCT05237648|Other|Online Voice quality education module|The novel online module the authors developed consists of a patient education on acoustic-perceptual rating of voice quality (CAPE-V), practice rating sample recordings of others' voices, and the patient's self-rating of their own voice in real time during a standard sentence-reading task. The module also includes the Self-Efficacy Scale for Voice Therapy.
45339868|NCT05237648|Other|Vocal hygiene module|The generic online patient education module on vocal hygiene during the waiting period between their initial evaluation and their first therapy session that also includes the Self-Efficacy Scale for Voice Therapy
45472864|NCT04071301|Device|TENA SmartCare Change Indicator|"Each participating subject will be provided with a Change Indicator and absorbent products for the duration of the investigation. Nine types of absorbent products will be used to collect real-life measurement data in order to assess the mathematical algorithms involved in the TENA SmartCare Change Indicator. Each participating subject will be allocated to the type(s) that are considered most suitable.~Gateways will be placed in the resident's rooms as well as in common areas, this to enable full measurement registration."
45839880|NCT04740840|Drug|Amlodipine|According to the inclusion criteria, patients who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was given 5mg amlodipine to lower blood pressure. Fasting blood was collected before the trial and during the first and third months of treatment. CRP, TNF-α, IL-6, Lp-PLA2 and ATP data were collected.
45839881|NCT04740762|Behavioral|Intervention group|The women in the intervention groups were administered a three-session intervention program in addition to the routine care they received.The program encompassed providing the women with an educational booklet, childbirth stories and childbirth videos that were created to reduce their fears of childbirth.The interviews were held a total of three times, in gestational weeks 28-30, 31-33 and 34-36. The duration of the intervention at each visit was 60-80 minutes. Depending on the woman's own preference, she was invited to visit the delivery room at the second or last session and meet the midwives there. The women who did not wish to go to the delivery room were alternatively provided with photographs of the delivery room so they could take a look. Again as part of the education program, the women were given the links to the selected childbirth videos and given the opportunity to watch them.
45839882|NCT04740528|Diagnostic Test|fto gene testing|Blood samples were collected after a 12-h fasting by Prodia Laboratory for DNA isolation and biochemical analysis
46035216|NCT04157803|Diagnostic Test|Acetic acid % spray|"If during a videcolonoscopy a polyp is found with suspicion of tubular, tubulovillious or Serrated adenoma, the endoscopist will proceed to stain it using diffuser and acetic acid at a concentration of 3%. The presence or not of the aceto-whitening reaction will be evaluated, understanding it as the persistence of white staining of the polyp at one minute or three minutes, standing out from the surrounding mucosa.~In case of positive staining it will be considered homogeneous if the staining is uniform on the surface of the polyp or heterogeneous if it is done irregularly."
45472865|NCT03261336|Drug|Calcitriol, Ketoconazole, Hydrocortisone|Calcitriol (0.5 mcg caplets) given in escalating doses, orally QD X3 consecutive days every week Ketoconazole, 200 mg tablets, 2 tablets orally TID Hydrocortisone 20mg AM, 10mg PM orally starting in the evening before the first dose of Calcitriol
45472866|NCT03388840|Biological|Adipose derived stem cells suspention|application of adipose derived stem cells to the engrafted hair in hair transplantation surgery
46035217|NCT04157959|Drug|SHR4640 dose1|Tablet,dose1,QD
45339869|NCT02588690|Procedure|Fingerstick cholesterol test|A finger stick draws approximately four drops of blood. The total cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C), Triglycerides, Low Density Cholesterol (LDL-C), and Glucose tests are done.
45472867|NCT03388840|Biological|Platelet rich plasma|application of autologous platelet rich plasma to the engrafted hair in hair transplantation surgery
45472868|NCT03745417|Biological|Umbilical cord mesenchymal stem cells|Umbilical cord mesenchymal stem cells were infused intravenously at a dose of 2 million cells/kg.
45472869|NCT01269359|Procedure|robotic assisted surgery|Robotic guidance: SpineAssist™ (Mazor Surgical Technologies, Caesarea, Israel), is a bone-mounted miniature robot. It is a semi-active system offering surgical tool guidance while leaving performance of the actual surgical operation, such as the drilling, in the surgeon's hands.
46035218|NCT04157959|Drug|Febuxostat dose2|Tablet,dose2,QD
46035219|NCT04243408|Other|Autologous umbilical cord blood transfusion|single dose of an autologous umbilical cord blood transfusion
46035220|NCT04243408|Other|placebo|The placebo product will consist of the standard ingredients of the acellular content of the UCB unit. It will consist of 20 ml Dextran (Plander 40.000 - 50g/500ml, solution for infusion) and 20 ml of human Albumin 5% (solution for infusion). The volume of placebo product will be 40 ml
46035221|NCT00660283|Drug|Temozolomide|"(Stage I Treatment) Postoperative concomitant limited-field radiation therapy with daily temozolomide (75 mg/m2) must begin between 14 and 28 days from surgery.~7. (Stage II Treatment) temozolomide 150 mg/m2 to be given days 1-7 and 15-21 of a 28 day cycle to begin within 45 days of stop date of concomitant limited field radiation/daily temozolomide (Stage I treatment) up to a maximum of 12 cycles."
46035222|NCT02826148|Other|RAADS-R scale|This scale is a self-administered questionnaire completed by the person himself assisted by a clinician
46035223|NCT00663949|Drug|Captopril|25 mg captopril tablet q8h
45339870|NCT02588690|Other|Atherosclerosis Cardiovascular Disease Risk assessment|"This Risk Estimator enables estimation of 10-year and lifetime risks for atherosclerotic cardiovascular disease (ASCVD), defined as coronary death or nonfatal myocardial infarction, or fatal or nonfatal stroke, based on the Pooled Cohort Equations and lifetime risk prediction tools. The Risk Estimator is intended for use in those without ASCVD with a LDL-cholesterol <190 mg/dL.~The information required to estimate ASCVD risk includes age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure lowering medication use, diabetes status, and smoking status."
45339871|NCT02588690|Procedure|Blood pressure measurement|Blood pressure measurement
45339872|NCT00758199|Drug|Bromfenac|Group 1: Bromfenac BID for 3 weeks Group 2: Bromfenac BID for 6 weeks
45339873|NCT00758199|Drug|Moxifloxacin hydrochloride|Group 1 and Group 2:Moxifloxacin hydrochloride 1 day prior to surgery-continue for six days after surgery.
45339874|NCT00758199|Drug|Prednisolone Acetate|Group 1 and Group 2:Prednisolone Acetate for 3 weeks in a tapering schedule (week 1: TID; week 2: BID, week 3:QD).
45339875|NCT05683808|Drug|Apixaban|Open label
45339876|NCT02559999|Other|Painful tonic stimuli|
45683303|NCT04400968|Procedure|kinesio tape|Before the tape application, the skin surface was removed of hair when needed and cleansed. The tapes were applied at 25% of tension and were placed horizontally covering the area between the antero-superior iliac spines and the postero-superior iliac spines and vertically from the navel to the symphysis pubis. All bandages were adhered to the skin with a technique type I with a space augmentation. The centre of the tape was removed and applied at 25% of tension. Afterwards, the rest of the protector were removed and the laterals anchors of the tape were adhered with no tension. The participant maintained a slight extension of the trunk while the tape was applied on the anterior aspect of the truck and a slight flexion while the tape was applied in the posterior aspect of the trunk.
45683304|NCT04400968|Procedure|Auricular therapy Placebo group|Sham auricular therapy
45683305|NCT04400968|Procedure|kinesio tape Placebo group|Sham kinesio tape
45683306|NCT05686330|Device|Apple Watch|Smartwatch for detecting atrial fibrillation using photoplethysmography (PPG)
45839883|NCT04740450|Device|Kinesio taping|skin colored Kinesio-Tex Gold tape, 50 mm _ 5 m (Kinesio Holding Corp, Albuquerque, NM) tapped in technique described by Gozluklu et al in 2020
46035224|NCT00663949|Drug|Captopril + Pentoxifylline|patients takes captopril tablets 25 mg q8h and pentoxifylline 400 mg q8h
46035225|NCT05076448|Procedure|Gonadal veins resection|"Gonadal veins resection (GVR) was performed open, transperitoneal and retroperitoneal endoscopic methods under general anesthesia.~Open GVR was performed in the Trendelenburg position, on the back with the operating table rotating 30° The retroperitoneal approach was employed in the left and/or right iliac region. The GV was mobilized for 10-12 cm and the vein was resected..~Transperitoneal GVR was performed with 3 ports were placed: one 10-mm port in the umbilical region, one 5-mm port in the left or right iliac region, and one 5-mm port 5 cm below the umbilicus. The GV was mobilized over a length of 10-12 cm and the vessel was resected.~Retroperitoneal GVR was performed with the patient in a lateral position and in the reverse Trendelenburg position. A 10-mm camera port was installed in the lumbar region between the posterior superior iliac spine and the lower edge of the XII rib. The GV was mobilized over a length of 10-12 cm and the vessel was resected."
45339877|NCT02559999|Other|non-painful stimuli|
45339878|NCT00919490|Drug|ABT-333|Tablet, see arms for interventional description
45339879|NCT00919490|Drug|Placebo|Tablet, see arms for interventional description.
45839884|NCT04740450|Device|Wound Tape|skin colored wound tape tapped in technique described by Gozluklu et al in 2020
45339880|NCT05434767|Device|Mobile application|Participants will be instructed on the installation and use of the mobile application on their personal mobile phones. Participants will then have to perform the assigned exercises using the mobile application 3 times daily. Physiotherapists will still perform the required assessment/review, education, and intervention.
45339881|NCT05434767|Other|Standard rehabilitation program|All participants will be seen by physiotherapists in the ward post-TKR surgery and undergo standard inpatient rehabilitation. Patients will be given instructions to perform assigned exercises 3 times daily. Physiotherapists will perform the required assessment/review, education, and intervention.
45339882|NCT05683652|Device|TRAINING BOOKLET|Cancer patients in the intervention group, who will receive immunotherapy for the first time, will be given face-to-face training with the prepared training booklet and followed up by phone. Patients who received immunotherapy after the 1st, 2nd and 3rd cycles, respectively, will be called by phone. The researcher's phone number will be given to the intervention group patients and they will be told that they can call 24/7 if they experience any symptoms. The telephone interview form created by the researcher will be used during the monitoring by telephone.
45839885|NCT04740216|Behavioral|exercise therapy plus jaw device|The mouth-opening rehabilitation exercise lasts for twelve weeks, five days a week, three times a day. Subjects can arrange to perform before or after meals according to personal eating time and preferences. The experimental group performs 30 minutes each time, including 20 minutes of stretching exercises. Ten-minute mouth expander assisted passive exercise.
45339883|NCT05434611|Diagnostic Test|S100A12|The early dynamic detection of S100A12 was used to determine whether it was an auxiliary diagnostic index for Kawasaki disease
45339884|NCT05082116|Drug|turoctocog alfa pegol (N8-GP)|N8-GP will be injected into a vein (intravenous injections) every 4 days in at least 28 weeks
45339885|NCT05081570|Device|telecare consultation|Two tertiary stroke care consultations will be provided by stroke nurses via telecare in 2 months. Consultation content includes provide education on modifying stroke-specific risk factors, disseminate self-management knowledge, reinforce the importance of medication compliance, revise the blood and investigation results, and co-design and follow-up on mutually agreed rehabilitation goals with the subjects. When necessary, the nurse will also refer the stroke survivors to multidisciplinary team members according to the referral guidelines. The nurse will also encourage the patients' family and/or informal caregivers to participate in the consultations.
45339886|NCT02589470|Other|COMETE|Patients of COMETE group will attend 12 individual sessions of cognitive rehabilitation, which are not systematic in usual treatment, and will receive memory exercises via internet to continue cognitive exercizes at home.
45339887|NCT02588378|Procedure|multi-modal cSLO imaging|
45339888|NCT00680745|Drug|dapagliflozin|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
45339889|NCT00680745|Drug|Glimepiride|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
45339890|NCT00680745|Drug|metformin hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
45339891|NCT00680745|Drug|pioglitazone hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
45339892|NCT00680745|Drug|Rosiglitazone|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
45339893|NCT05434377|Other|ergocalciferol supplementation|Participants in both groups will recieve ergocalciferol with different supplementation regimens for 6 months.
45339894|NCT05434377|Other|dialysis techniques|Both groups will have participants treated with maintenance hemodialysis and peritoneal dialysis.
45339895|NCT05434377|Other|sunlight exposure time|Both groups will be advised to receive similar hours of daily sunlight exposure time.
45339896|NCT05428293|Drug|A1: Ibuprofen/Acetaminophen Fixed dose combination oral suspension (Laboratorios Silanes S.A. de C.V.)|Formula : 100 mg/ 125 mg /5mL Pharmaceutical Form: Oral suspension Dosage: 5mL (100 mg/125mg) Administration way: oral
45339897|NCT05428293|Drug|A2: Ibuprofen (Advil®, Pfizer S.A. de C.V.)|Pharmaceutical Form: oral suspension Formula: 2 g/100 mL Dosage: 5 mL(100 mg of Ibuprofen) Administration way: oral
45472870|NCT03960255|Other|Normal standard care|Both groups will receive standardized treatment and care for diabetic foot ulcers
45472871|NCT03919669|Drug|All Subjects|All subjects will be given the experimental tau PET radioligand [18F]MK-6240
46035226|NCT05076448|Procedure|Gonadal vein embolization with coils|"Procedure was performed under local anesthesia with 5.0-10.0 mL of 0.5% lidocaine solution with a patient under intravenous sedation. For the left GV embolization, the transfemoral approach was used, while for the right or both GV embolization, the transjugular approach was used. The vein puncture was performed under ultrasound guidance. The 5F multipurpose angiographic catheters (Cordis; USA), standard 'moving core' J .035 guidewire, and an angled hydrophilic guidewire (Radiofocus; Terumo Corp., Japan) were used. For the GV occlusion, the pushable 0.035 standard stainless steel coils (Gianturco; William Cook, Bjæverskov, Denmark) and 0.035 coils made of Inconel with interwoven long collagen fibrils (MReye; Cook Medical Inc., Bloomington, USA) were used. The diameter of coils was 8-12 mm, and the length was 10-20 cm."
46035227|NCT05076448|Procedure|Endovascular stenting of the common iliac vein (CIV)|"After providing local anesthesia, the left common femoral vein was punctured, a 0.035 guidewire was inserted into the inferior vena cava (IVC), and then a 10F introducer was installed. A balloon catheter was introduced over the guidewire in the left CIV (XXL balloon, Boston Scientific, diameter 14-18, length 40-60 mm), and double balloon dilation of the vessel was performed with a pressure of 6-8 atm. Then, a delivery system was advanced to the area of stenosis in the left CIV, and stent was deployed at the level of confluence of the left CIV and inferior vena cava (IVC) or with a protrusion in the IVC of no more than 1 cm. For better fixation of stent in the venous lumen and prevention of its displacements and migration, a balloon post-dilatation of the stented vessel was performed. In case of residual stenosis, the balloon angioplasty was performed."
46035228|NCT00660439|Behavioral|Narrative Exposure Therapy|"Psychological treatment, with narration of positive and traumatic events in patients history, including in vivo exposure of traumatic events. The narrative is written down by the therapist."
46035229|NCT02825758|Dietary Supplement|ZestiVits|"The study product is a low-carbohydrate, orange flavour, vitamin, mineral and trace element (micronutrient) supplement for use in ketogenic and restricted therapeutic diets, for children aged from 11 years of age and adults.~The recommended dosage of the study product for each subject will be determined and prescribed by a dietitian. This will be based on individual requirements for micronutrient supplementation."
45339898|NCT05428293|Drug|A3: Acetaminophen (Tylenol®, from Janssen-Cilag, S.A. de C.V.)|Pharmaceutical Form: oral suspension Formula: 3.2 g/100 mL Dosage: 3.9 mL (125 mg) Administration way: oral
45339899|NCT05427825|Other|ERAS anesthetic care|The ERAS anesthetic care includes EEG spectrum-guided multimodal anesthesia and HPI-guided hemodynamic therapy.
45339900|NCT05427825|Other|Standard anesthetic care|The standard anesthetic care includes bispectral index guided general anesthesia and arterial line monitored hemodynamic care.
45339901|NCT02561091|Other|Placebo|
45339902|NCT02561091|Drug|AM-111 0.4 mg/ml|
45339903|NCT02561091|Drug|AM-111 0.8 mg/ml|
45472872|NCT03384862|Dietary Supplement|Vitamin B12|5 μg/d vitamin B12 to be given orally. This is a standard nutritional supplement commonly used in the US.
45472873|NCT03384862|Dietary Supplement|Placebo|Placebo pills, with same appearance as intervention pills.
45472874|NCT03384862|Dietary Supplement|Folic Acid|400 μg/d folic acid to be given orally. This is a standard nutritional supplement commonly used in the US.
45472875|NCT03909191|Diagnostic Test|serum HBV RNA|serum HBV RNA level was determined by using HBV-SAT kit at different time point
45472876|NCT05513235|Other|Digital personal health record|The digital personal health record is a mobile application ('app') entitled Caremap. The mobile app will be downloaded and accessible by parents/caregivers to help coordinate care.
45472877|NCT01269437|Drug|Budesonide dry powder inhaler|200mcg per inhalation, twice daily, for 12 weeks
45472878|NCT03636867|Other|data and specimen collection|to identify laboratory, cellular and molecular determinants of clinical success after treatment, several clinical information and specimens will be collected by Authors from each patient
46035230|NCT00888238|Drug|sitagliptin|Single oral dose of sitagliptin 100 mg (2 x 50 mg) tablets followed by the hyperglycemic clamp procedure and meal tolerance test.
45339904|NCT00680121|Drug|Benfotiamine|Benfotiamine 600 mg
45339905|NCT00680121|Drug|Placebo|Placebo
45339906|NCT00754533|Other|Continuous versus interval training|Influence of different exercise training programs
45339907|NCT00754689|Drug|Rimonabant|Tablet, oral administration
45339908|NCT00754689|Drug|Metformin|Tablet, oral administration
45339909|NCT00754689|Drug|placebo|Tablet, oral administration
45339910|NCT05375175|Other|Hybrid Snack|"The intervention will consist of the administration of 20 g of the snack (produced by Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Hybrid snack: combination of legumes in the highest proportion and lean meat.~It will have the following composition:~Ingredients (%):~Chickpea flour 45.40% Natural emulsifier 0.40% Meat 15.50% Olive oil 1.00% Sunflower oil 4.00% Water 22.50% Onion powder 0.30% Garlic powder 0.20% Thyme 0.60% Tomato powder 10.00%"
45472879|NCT04163952|Biological|Panitumumab|Given IV
45472880|NCT04163952|Biological|Talimogene Laherparepvec|Given IM
45472881|NCT03909269|Device|Continuous glucose monitoring|Continuous glucose monitoring five times over 17 weeks
45472882|NCT03909269|Diagnostic Test|Glycaemic markers|Measurement of HbA1c by immunoassay (Roche) and chromatography (TOSOH), including glycated albumin and fructosamine.
45472883|NCT03909269|Radiation|Erythrocyte life span|Erythrocyte life span measured by Crom-51 labelling over 4 weeks
46035231|NCT00888238|Drug|Comparator: Placebo|Single oral dose of 2 tablets placebo to sitagliptin followed by the hyperglycemic clamp procedure and meal tolerance test.
46035232|NCT05660356|Drug|Growth Hormone|Pfizer provided GH therapy
46035233|NCT05660356|Drug|Placebo|Pfizer provided placebo
46035234|NCT00595465|Biological|Japanese Encephalitis purified inactivated vaccine|IC51 6 mcg i.m. injection on Day 0 and Day 28
46035235|NCT02825914|Dietary Supplement|Casein glycomacropeptide (CGMP)|
46035236|NCT02825914|Dietary Supplement|Placebo|
45472884|NCT03909269|Device|Carbon monoxide (CO)-rebreathing method|Measurement of total blood volume, plasma volume and erythrocyte volume
45472885|NCT00462748|Drug|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally, cholesterol lowering medication.
46035237|NCT00671281|Drug|Tranexamic acid|Oral form, 100mg, tid (three times per day), 3 days before/the day of/6 days after the surgery
46035238|NCT00671281|Drug|Placebo|Placebo, Oral form, three times a day, 3 days before/day of/6 days after surgery
45339911|NCT05375175|Other|Meat snack|"The intervention will consist of the administration of 20 g of the snack (produced by Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Snack sausage:~Composed solely of meat from loin tape~It will have the following composition:~Ingredients (%):~Shoulder meat 4 mm 94.13% Low sodium salt 3.30% Maltodextrin 1.65% Spices 0.28% Natural dye 0.64%"
45339912|NCT00767819|Drug|Everolimus|2.5 and 5 mg tablets taken orally and starting dose was 10 mg daily for all patients
46035239|NCT01205438|Drug|LY2127399|120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
45339913|NCT00758277|Drug|levetiracetam (Keppra)|levetiracetam daily application 1500-2000 mg
45339914|NCT00758277|Drug|Placebo|Sugar Pill
45339915|NCT04022447|Drug|Dupilumab|retrospective data collection
45339916|NCT03984617|Other|Emergency visit in a French tertiary Maternity hospital (Maternity of Nancy)|total number of visits (hospitalizations and consultations)
45472886|NCT00462748|Drug|Comparator: atorvastatin|atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally
45472887|NCT00462748|Drug|Comparator: rosuvastatin|rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally.
45472888|NCT03948789|Procedure|Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy|Magnetic Resonance Imaging-controlled high-focussed ultrasound
45472889|NCT03948789|Procedure|Myomectomy (laparoscopic or open surgical)|Myomectomy (laparoscopic or open surgical)
45472890|NCT04206085|Device|Viveve - Active|Radiofrequency and Cryogen-Cooling
45472891|NCT04206085|Device|Viveve - Cryogen-Alone|Cryogen-Cooling
45339917|NCT00584870|Drug|Naproxen|Oral naproxen 500 mg twice daily for Weeks 1-12.
45339918|NCT00584870|Drug|Placebo|Single IV infusion of placebo on Day 1 and placebo for naproxen twice daily for Weeks 1-12.
45339919|NCT00584870|Drug|PF-04383119 (RN624)|Single IV infusion of 200 micrograms/kg RN624 on Day 1
45472892|NCT04206085|Device|Viveve - Sham|Sham
45472893|NCT01253213|Drug|BR55|One to two bolus (2nd bolus optional) of BR55 per patient
45839886|NCT04740216|Behavioral|exercise therapy|the control group performed 20-minute stretching exercises each time.
46035240|NCT01205438|Drug|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.
46035241|NCT01205438|Drug|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
46035242|NCT04155229|Other|Default settings for opioid prescriptions (acetaminophen/hydrocodone, oxycodone, acetaminophen/oxycodone)|"For each of the arms, the investigators modified the default setting for the dispense quantity of study opioids on the electronic medical record settings for discharge prescriptions.~Study drugs include acetaminophen 325mg + hydrocodone 5mg, acetaminophen 325mg + hydrocodone 7.5mg, acetaminophen 325mg + hydrocodone 10mg, oxycodone 5mg, acetaminophen 325mg + oxycodone 5mg, acetaminophen 325mg + oxycodone 10mg."
46035243|NCT04944316|Behavioral|Dietary intervention|Low-fat, plant-based diet
46035244|NCT04944316|Behavioral|Dietary intervention|Portion-controlled diet (compliant with ADA guidelines)
46035245|NCT00664183|Drug|Vitreosolve|Intravitreal injection
46035246|NCT00671359|Drug|TR-701 600mg|TR-701 600mg
46035247|NCT05058898|Other|blood samples|5 mL
46035248|NCT05058898|Other|Scabs and pus samples|if available
45339920|NCT00679341|Drug|Trastuzumab emtansine [Kadcyla]|The total dose depended on the patient's weight on Day 1 of each cycle. Trastuzumab emtansine was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease (or until second disease progression for patients who crossed over), unacceptable toxicity, or study closure, whichever occurred first.
45339921|NCT00679341|Drug|Trastuzumab|The dose of trastuzumab was recalculated if body weight changed by more than ±10% from baseline. Trastuzumab was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
45683307|NCT03368716|Behavioral|Acceptance-based Behavioral Treatment (ABBT)|ABBT is rooted in behavioral therapy but also cultivates self-regulation skills including experiential acceptance of potentially uncomfortable internal experiences (e.g., emotions, cravings), mindful awareness of decision making (e.g., mindful eating), and values clarification and behavioral commitment (e.g., practicing daily physical activity to be a contributing member on a sports team). ABBT has been used effectively to help youth and adults manage various medical and psychological problems. Moreover, components of ABBT have been shown to improve child and adult EF including inhibitory control and cognitive flexibility. Recently, ABBT has been integrated with components of standard behavioral treatment of obesity and applied with robust efficacy to weight management in adults.
45339922|NCT00679341|Drug|Docetaxel|Docetaxel was given at a dose of 75 or 100 mg/m^2 based on the investigator's decision. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
46035249|NCT04153201|Drug|Hydroxychloroquine|Hydroxychloroquine 200 mg daily for patients weighing < 60 kg, hydroxychloroquine 400 mg daily for patients weighing >= 60 kg
45339923|NCT00679263|Drug|MN-221|Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg)
45339924|NCT00679263|Drug|MN-221|Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).
45339925|NCT00679263|Drug|Placebo|Placebo intravenous infusion with dosing volume equivalent to active treatment.
45339926|NCT02588300|Procedure|Drug induced sleep endoscopy|Titration of propofol using a target controlled Infusion pump and description of the upper airway according to the VOTE classification
46035250|NCT05660278|Other|Milk containing A1 and A2 beta-casein|Single dose of milk
46035251|NCT05660278|Other|Milk containing only A2 beta-casein|Single dose of milk
45339927|NCT05227352|Behavioral|Biophilic design experience|Recharge Rooms are immersive, biophilic private spaces featuring multisensory input that is inspired by nature.
45339928|NCT05227196|Drug|Semaglutide D Dose 1|Tablet given orally
45339929|NCT05227196|Drug|Semaglutide D Dose 2|Tablet given orally
45339930|NCT05227196|Drug|Semaglutide D Dose 3|Tablet given orally
45339931|NCT05227196|Drug|Semaglutide Dose 4|Tablet given orally
45472894|NCT05503719|Procedure|Surgical wound closed with an absorbable suture|Patients undergoing median nerve release surgery will get their surgical wound closed with an absorbable suture according to their respective study group.
45683308|NCT05310526|Other|Training Group|Training for prescribing the Brazilian cardioprotective diet
45683309|NCT05686174|Dietary Supplement|MBS217|Soybean Fermented Extract (MBS217)
45683310|NCT05686174|Dietary Supplement|Placebo|Without active ingredient
45683311|NCT05685940|Procedure|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of risankizumab.
46035252|NCT00664261|Behavioral|smoking cessation intervention|
46035253|NCT00664261|Other|cancer prevention|
46035254|NCT00664261|Other|counseling intervention|
46035255|NCT00664261|Other|educational intervention|
46035256|NCT00664261|Other|laboratory biomarker analysis|
46035257|NCT00664261|Other|questionnaire administration|
46035258|NCT00664261|Other|survey administration|
46035259|NCT00664261|Procedure|study of high risk factors|
46035260|NCT04153123|Drug|Epinephrine|
46035261|NCT02825524|Device|Habib™ EndoHBP|During an endoscopic retrograde cholangiography, endobiliary application of radiofrequency through a dedicated probe named Habib.
46035262|NCT00671593|Biological|House Dust Mite|"Dermatophagoides pteronyssinus: nebulized inhaled dosing is every 10 minutes per protocol limits at the following Allergen Concentration , (5 breaths of duration 0.8 seconds using a dosimeter) 0.0 AU, 0.3 AU/ml,~1 AU/ml, 3 AU/ml, 10 AU/ml, 30 AU/ml, 100 AU/ml, 300 AU/ml, 1000 AU/ml, 3000 AU/ml"
46035263|NCT00671593|Biological|Diluent|Greer lab allergen extract diluent (0.5% sodium chloride, 0.25% sodium bicarbonate, 50% glycerin (v/v), and 0.4% phenol)nebulized inhaled dosing is every 10 minutes per protocol limits at the following Diluent Concentration, (5 breaths of duration 0.8 seconds using a dosimeter)
46035264|NCT01104870|Drug|UT-15C|oral
46035265|NCT02887664|Procedure|Blood test|Blood will be drawn from mother's vein and from the cord to test for n-6:n-3 ratio and inflammatory markers: CRP, IL-6, TPO and TNF-alpha markers
46035266|NCT02825368|Biological|MMR|0.5 mL, subcutaneous
46035267|NCT02825368|Biological|Tdap|0.5 mL, intramuscular
46035268|NCT02825368|Other|Diphtherinum®|
46035269|NCT02825368|Other|Pertussinum®|
46035270|NCT02825368|Other|Tetanotxicum®|
46035271|NCT02825368|Other|Morbilinum®|
46035272|NCT02825368|Other|Ourlianum®|
46035273|NCT02825368|Other|Sterile saline|0.5 mL, intramuscular
45339932|NCT05227196|Drug|Semaglutide Dose 5|Tablet given orally
45339933|NCT05227196|Drug|Semaglutide Dose 6|Tablet given orally
45339934|NCT00680043|Drug|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.04 milligram per kilogram (mg/kg); the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
45339935|NCT00680043|Drug|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.08 mg/kg; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
45339936|NCT00680043|Drug|Epoetin Alfa|Participants received Epoetin alfa by intravenous injection three times a week at the starting dose of 50 Units/kg. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
45339937|NCT00918944|Other|Control|"The asthma disease management toolkit available to all practices in the EHR will consist of four elements:~A data entry tool for capturing asthma control data~Standardized documentation templates to facilitate severity classification~Order sets to facilitate ordering controller medications~An asthma care plan that can be supplied to families"
46035274|NCT02825368|Other|Sugar pellets|
46035275|NCT02632279|Dietary Supplement|Tryptophan (TRP) depletion|TRP depletion will be accomplished by administering a TRP-low amino acid protein drink containing 100 g of gelatin powder. The protein mixture consists of 18 amino acids. According to Dutch law, TRP is considered a food supplement and is not registered as a medicine.
45339938|NCT00918944|Other|Intervention|"Three alerts and two reminders will be programmed:~Alert providers to enter asthma severity classification if none is on file~Alert providers to prescribe controller medications for persistent asthma if none on file~Alert providers to complete an asthma care plan if none on file~Remind providers to review the asthma care plan if it is already on file by providing a link to the form~Remind providers that educational content is available on-line by providing a web link"
45339939|NCT02589392|Other|Cetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash|
45472895|NCT05503719|Procedure|Surgical wound closed with a non-absorbable suture|Patients undergoing median nerve release surgery will get their surgical wound closed with a non-absorbable suture according to their respective study group.
45683312|NCT05685940|Procedure|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
46035276|NCT02632279|Dietary Supplement|Placebo|The placebo treatment will consist of an identical amino acid protein drink containing 100 g of gelatin powder to which 1.21g TRP is added.
46035277|NCT02632279|Device|Stimulator ON|Participants will be tested while their stimulator is turned ON
46035278|NCT02632279|Device|Stimulator OFF|Participans will be tested while their stimulator is turned OFF
46035279|NCT02631187|Device|Bielefeld balloon|Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
46035280|NCT02881476|Other|Biological: Cell-based therapy|Human allogeneic Wharton's jelly-derived mesenchymal stem cell transplantation in ALS patients.
46035281|NCT00664339|Biological|Flu Vaccine|Single dose of Flu vaccine by year (1)
46035282|NCT00664339|Other|Conventional medical therapy for heart failure|According with the international guidelines
45339940|NCT02589392|Other|Cetaphil® Restoraderm® body wash|
45339941|NCT02560545|Drug|Cannabis oil|Cannabis oil 20% THC
45472896|NCT01160939|Other|low intensity exercise|exercise protocol with six stages of exercise (1. upper limbs, 2. inferiors, 3. walk 35 m, 4. ½ flight of stairs, 5. walk 200 m 6. a flight of stairs) with intensity between 2-6 metabolic equivalents
45683313|NCT05567458|Drug|Luspatercept|Specified dose on specified days
46035283|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 1
46035284|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 2
46035285|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 3
45339942|NCT02560467|Drug|Echo and myocardial contrast echocardiography perfusion imaging|"Myocardial blood flow will be assessed by myocardial contrast echo. Perfusion at rest and stress will be quantified and compared to patient sx, degree of dysfunction on echo strain imaging, and degree of fibrosis on magnetic resonance imaging (when available) that was ordered as part of routine clinical care.~Myocardial contrast echocardiography will be performed by intravenous administration of ultrasound contrast agent (Definity or Lumason) using FDA-approved dose limits. Vasodilator stress during MCE imaging will be performed using regadenoson at FDA-approved doses."
45472897|NCT01161017|Drug|Amitriptyline|Initial dose of 12.5mg will be given for 2 days. Then, daily 25mg will be taken for additional 8 weeks
45472898|NCT01161017|Drug|Topiramate|For the first 5 days of treatment 25mg is prescribed and should be ingested in one evening dose. For another 5 days, 25g dose should be taken twice a day (morning and evening). For the next 5 days, morning dose will be 25mg; evening dose will be 50mg. For the remaining 6 weeks of treatment, a dose of 50mg twice a day will be advised
46035286|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 4
45472899|NCT03936465|Drug|BMS-986158|BMS-986158 belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
45683314|NCT05567458|Drug|Placebo|Specified dose on specified days
45683315|NCT03344692|Drug|Alirocumab|prefilled pen containing 75 mg of Praluent (Alirocumab) in 1 ml of solution
45683316|NCT03344692|Other|Placebo|prefilled pen containing 1 ml of solution without Praluent
45683317|NCT03343132|Behavioral|Standard locomotor therapy|Typical clinical therapy.
45683318|NCT04278820|Drug|TQA3526|Tablet(s) administered orally once daily
46035287|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 5
46035288|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 6
46035289|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 1
46035290|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 2
46035291|NCT00664417|Biological|Physiological saline|0.5 mL, IM, 2 injections
46035292|NCT04031755|Drug|Minocycline|Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
46035293|NCT04031755|Drug|Placebos|Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
45339943|NCT05352633|Drug|Intensive BP Arm|Participants in the Intensive BP treatment group have a goal of SBP <120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals: Angiotension converting enzyme (ACE)-inhibitors;Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics
45339944|NCT05352633|Drug|Standard BP Arm|Participants in the Standard BP treatment group have a goal of SBP <140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
45339945|NCT05436093|Drug|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
45683319|NCT04278820|Drug|Placebo to match TQA3526|Tablet(s) administered orally once daily
46035294|NCT01104792|Drug|Cariprazine|Cariprazine was supplied in capsules.
46035295|NCT01205126|Drug|Hydromorphone HCl|Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of Titration phase and 28 days of Maintenance phase. Starting dose will be based on participant's previous daily opioid dose.
46035296|NCT01205126|Drug|Oxycodone HCl CR|Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titration phase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
46035297|NCT01205126|Drug|Placebo|Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
46035298|NCT04155307|Device|Anal EndoFLIP®|Anal EndoFLIP® measure to evaluate anal compliance
46035299|NCT04155307|Diagnostic Test|Anal Manometry|Anal Manometry done in standard care
46035300|NCT04155307|Diagnostic Test|Defecography|Defecographydone in standard care
45339946|NCT05436015|Other|Virtual nature-based intervention|"Virtual nature-based intervention is video with Finnish naturepictures and naturesounds shown from a 75 vertical screen monitor"
45683320|NCT05305924|Other|Fulvestrant Run-In|The study is evaluating if a drug holiday (post CDK inhibitors progression) will reset the cell cycle machinery to be responsive to Abemaciclib and Fulvestrant.
46035301|NCT04155307|Diagnostic Test|Electromyogram|Electromyogram done in standard care
45339947|NCT05058092|Device|Immediate Remedee Solution|"D0 to M3: Remedee Solution + medical care~M3 to M6: Remedee Solution without personalized support + medical care~M6 to M9: medical care only"
46035302|NCT00664495|Behavioral|Diet Weight Loss|
45339948|NCT05058092|Device|Delayed Remedee Solution|"D0 to M3: medical care only~M3 to M6: Remedee Solution + medical care~M6 to M9: Remedee Solution without personalized support + medical care"
45339949|NCT05435937|Behavioral|Partnering for change (P4C-Swe)|"P4C focuses on the collaboration and a intersectional partnership between teachers and occupational therapists/special educators to create physical, social and learning environments that facilitate successful participation for all pupils. The intervention tiered model provides interventions in a school context in levels; class, group, and individual level to students with participation restrictions.~Dynamic Performance Analysis (DPA), which focuses on pupils' occupational performance, is used in P4C model to identify and analyze were and why pupils' occupational performance is breaking down in school-based occupations in the natural context, followed by collaboration and coaching between the occupational therapist and teacher in setting up goals, planning, implementing and monitoring intervention at the different intervention levels, to support participation."
45339950|NCT05435937|Behavioral|Treatment as usual|Treatment as usual is provided by the Student health services that consists of a school doctor, school nurse, psychologist and counselor, and staff with special educational competence
45683321|NCT05305924|Other|No Fulvestrant Run-In|The study is evaluating if a drug holiday (post CDK inhibitors progression) will reset the cell cycle machinery to be responsive to Abemaciclib and Fulvestrant.
46035303|NCT00664495|Behavioral|Exercise Weight Loss|
46035304|NCT00664495|Behavioral|Exercise Without Weight Loss|
46035305|NCT00624494|Device|Conventional monitoring|In the CM group, therapy was guided by central venous pressure, mean arterial pressure (MAP) and heart rate (HR)
46035306|NCT00624494|Device|Advanced monitoring|In the AM group by the intrathoracic blood volume index, MAP, HR, central venous oxygen saturation (ScvO2) and cardiac index (CI). The measurements were performed before and during surgery, and at 2, 4 and 6 hrs post-operatively.
46035307|NCT05137314|Drug|PLG0206|PLG0206 is an engineered antibacterial peptide (EAP)
46035308|NCT02629627|Dietary Supplement|Conjugated linoleic acid/Leucine|Conjugated linoleic acid/Leucine capsules, 825mg time daily with the first bite of eat meal during 12 weeks.
46035309|NCT02629627|Drug|Metformin|Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 12 weeks
46035310|NCT02629627|Dietary Supplement|Placebo of ACL/Leucine|Homologate placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) during 12 weeks.
45339951|NCT05057078|Behavioral|mindfulness-based stress reduction program|groups of 10 people will be formed among the patients included in the mindfulness program group. A mindfulness-based stress reduction program will be done once a week for eight weeks and will take approximately 60-120 minutes. A plan will be made with the patients for the day and time of the session. During this process, no application will be made to the control group. Meetings will be held as an online session via Zoom Video Communications.
45339952|NCT02587754|Device|Acupuncture|10 sessions of acupuncture, twice a week over 5 weeks.
45683322|NCT05685862|Device|Laser Speckle Contrast Imaging using the PerfusiX-Imaging device|Patient will undergo the standard-of-care gastric conduit procedure and in addition, peroperative Laser Speckle Contrast Imaging of the gastric conduit and eosophagus will be performed.
45683323|NCT05298436|Other|Follow-up interview|All participants will be followed up at defined time points post-stroke by face-to-face or telephone interview or postal questionnaire.
45683324|NCT05685784|Device|Bytelfies kit - sensor dot|"Participants will be asked to undergo a standard of care gait analysis and PSG whilst simultaneously wearing sensor dots.~GAIT: sensor dots will be placed in the neck, on the chest and one on both ankles.~PSG: sensor dots will be placed on the forehead, chin, chest, abdomen, both legs(tibialis anterior) and an SpO2 device will be placed on the finger middle finger of the non-dominant hand"
45683325|NCT05556148|Drug|Otrivine Congestion Relief|0.1% Nasal Spray (Xylometazoline Hydrochloride)
45683326|NCT05555524|Other|Baby oil|"Before each application~Hand hygiene will be done~Skin care will be done to the affected area and the area is thoroughly dried.~Participants will wear a hospital gown and seated comfortably on their bed.~Gentle massage with the cool baby oil will be applied on the itching area and is continued for 15-20 min.~Message will be applied for three times a week before each hemodialysis session for 12 weeks"
46035311|NCT02629627|Other|Placebo of Metformin|homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks
46035312|NCT00664729|Behavioral|Caloric Restriction|Reduced calorie diet (400 kcal/day deficit)
45339953|NCT00682539|Drug|Bevacizumab (Avastin)|The intravitreal injection of Bevacizumab (Avastin®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
46035313|NCT00664729|Behavioral|Caloric Restriction + Low-Intensity aerobic exercise|400 kcal/day deficit plus 3 days/week aerobic exercise at 45-50% maximal aerobic fitness
46035314|NCT00664729|Behavioral|Caloric Restriction plus High-intensity aerobic exercise|400 kcal/day deficit and 3 d/week of aerobic exercise at 65-75% maximal fitness
46035315|NCT00946647|Drug|Panobinostat (LBH589)|Panobinostat was supplied by Novartis as immediate-release hard gelatin capsules in strengths of 5 mg, 10 mg, and 20 mg packaged in high density polyethylene bottles.
46035316|NCT00946647|Drug|5-Azacytidine|
46035317|NCT04310514|Dietary Supplement|Fructose/glucose/xylitol/saccharose|"Intervention: rehydration with glucose solution. Glucose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~Intervention: rehydration with fructose solution. Fructose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~Intervention: rehydration with xylitol solution. Xylitol will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~Intervention: rehydration with sucrose solution Saccharose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m."
46035318|NCT00671827|Behavioral|Questionnaire|Questionnaires each taking less than 10 minutes to complete.
46035319|NCT05117736|Drug|Sacubitril / Valsartan Oral Tablet|For the first phase of the trial, each patient will be randomized to active therapy (50, 100, or 200 mg bid of Sacubitril/Valsartan based on the run-in phase) or the corresponding placebo (matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan), with the sequence reversed in the second phase.
45683327|NCT05555524|Other|Placebo|"Before each application~Hand hygiene will be done~Skin care will be done to the affected area and the area is thoroughly dried.~Participants will wear a hospital gown and seated comfortably on their bed.~Gentle massage with the cool distilled water will be applied on the itching area and is continued for 15-20 min.~Message will be applied for three times a week before each hemodialysis session for 12 weeks"
45683328|NCT03342586|Diagnostic Test|Resting State fMRI (rsfMRI)|rsfMRI before receiving High-dose chemotherapy with autologous stem cell transplantation/HDC-ASCT (pre-HDC-ASCT), at approximately 3 months (+/- 2 weeks) after HDC-ASCT (early post-HDC-ASCT) and approximately 6months (+/- 2 weeks) after HDC-ASCT (late post-HDC-ASCT).
46035320|NCT05117736|Drug|Placebo|Corresponding placebo: matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan.
46035321|NCT00671905|Procedure|GP ablation|HF stimulation-guided and anatomic ablation of the main right and left atrial GP
46035322|NCT00671905|Procedure|PV isolation|Circumferential PV isolation
46035323|NCT02631967|Procedure|Kono anastomosis|Kono anastomosis
46035324|NCT02631967|Procedure|Stapled side-to-side anastomosis|Stapled side-to-side anastomosis
46035325|NCT04157491|Drug|anlotinib and anti PD-1 antibody|Anti-PD-1 antibody administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus Anlotinib 12 mg administered orally (PO) once daily (QD) Day1-Day14 during each 21-day cycle.
45339954|NCT00682539|Drug|Triamcinolone|The intravitreal injection of triamcinolone (Volon A®) is performed in the operating room under sterile conditions at baseline. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
45339955|NCT00682539|Drug|Sham|Patients receiving sham intravitreal injections do not receive an actual injection of study drug. The injecting physician performing the sham injection will be unmasked to the treatment to the treatment assignment regarding active versus sham. The injecting physician will perform the same pre-injection procedures for the patients receiving bevacizumab or triamcinolone, An empty syringe without a needle will be used in the sham injection. The injecting physician will mimic an intraocular injection by making contact with the conjunctiva and applying pressure without the needle. Immediately following the sham injection, the injecting physician will perform the same post-injection procedures as those performed on patients receiving bevacizumab or triamcinolone.
45339956|NCT00682539|Procedure|Lucentis|The intravitreal injection of Ranibizumab (Lucentis®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.05ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
45339957|NCT02587910|Dietary Supplement|Melanole for GERD treatment|Melanole is given orally as 2 capsules TID 5 minutes before each meal
45472900|NCT03936465|Drug|BMS-986378|BMS-986378 (also known as CC-90010) belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
45339958|NCT02587910|Dietary Supplement|Placebo|Placebo is given orally as 2 capsules TID 5 minutes before each meal
46035326|NCT04157647|Device|CytoSorb|The hemadsorption filter will be included in the CPB circuit between the oxygenator and the venous reservoir. After cardiac surgery, the use of the filter will be continued till 24 hours after the end of surgery.
45339959|NCT00682461|Drug|Nicotine|Marketed nicotine replacement therapy formulation
45683329|NCT03342586|Other|Auditory Attention and Executive Functions Test|"Trail Making Test (Parts A & B): Part A is a timed test of visual scanning and graphomotor speed; AT: 3 minutes. Part B is a timed measure of set-shifting; Administration Time (AT): 5 minutes. Test-retest reliabilities=0.64-0.94.~Brief Test of Attention-BTA assesses auditory working memory; AT: 10 minutes. Test-re-test reliability=0.70.~Controlled Oral Word Association Test-COWAT is a timed measure of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S). The subject is allowed 60 seconds per letter, and the resultant score is the total number of words produced. Test-retest reliability=0.88. AT: 5 minutes."
45683330|NCT03342586|Other|Memory Test|The Hopkins Verbal Learning Test-Revised (HVLT-R): The HVLT-R is a test of verbal learning and memory.
45683331|NCT03342586|Other|Motor Speed Test|Grooved Pegboard Test (GPT)-Dominant Hand and Non-Dominant Hand. It is a timed test of manual dexterity, in which the time to completion is scored separately for each hand.
46035327|NCT04157647|Device|Control|No hemadsorption filter or other treatment will be included in the CPB circuit
46035328|NCT00671983|Procedure|Neurocognitive Testing|
46035329|NCT02629471|Behavioral|response time due to light flash pulses|light flash pulses effect on response time to random targets appearance
46035330|NCT00946101|Biological|MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]|0.5 mL: (intranasal sprayer)
46035331|NCT00946101|Biological|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer
46035332|NCT00664885|Other|Culturally Sensitive Collaborative Treatment|a collaborative care model, for treating depressed patients in general medical care
46035333|NCT00672061|Drug|Ramelteon or Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
46035334|NCT00672217|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBTI)|Six 15-30 minute in-person or phone sessions that incorporate cognitive, behavioral and psycho-educational techniques focused on modifying the perpetuating factors that maintain insomnia.
46035335|NCT00672217|Behavioral|Behavioral Placebo Treatment|Six 15-30 minute in-person or phone sessions that begin with a review of the sleep diary, a general discussion of treatment progress and tabulation of sleep parameters.
46035336|NCT00660751|Drug|Duloxetine|SNRIs
46035337|NCT00664963|Device|Implantation of YUKON Sirolimus-eluting Stent|Implantation of YUKON Sirolimus-eluting Stent
45339960|NCT00682461|Drug|Nicotine|Nicotine prototype
45472901|NCT03874559|Diagnostic Test|Blood Draw|Serum samples will be obtained from each patient enrolled
45472902|NCT04202497|Drug|TAK-418|TAK-418 orally.
45472903|NCT04202497|Drug|[18F]MNI-1054 (radiotracer)|[18F]MNI-1054 injection.
46035338|NCT00664963|Device|Implantation of YUKON Stent (uncoated)|Implantation of YUKON Stent (uncoated)
46035339|NCT00672295|Drug|Dasatinib, Paclitaxel, and Carboplatin|"Dasatinib will be administered as an oral dose (tablet) as per the dose escalation (50 mg everyday - 250 mg everyday)continuously on days 2-21 in the first cycle (3 weeks) therapy and continuously (days 1-21) throughout the remainder of therapy.~Paclitaxel will be administered on a 21-day schedule. Paclitaxel (150-175 mg/m^2) IV infused over 3 hours on day #1 of each cycle.~Carboplatin (AUC=5-6 mg/,l/min) will be infused over 30-60 minutes every cycle via IV on day 1 of every cycle following the paclitaxel administration.~All patients will be followed until disease progression or study withdrawal. In addition, following disease progression, patients will be monitored for delayed toxicity and survival for a period of 5 years and data entered into eDC, unless is withdrawn."
45339961|NCT05684588|Diagnostic Test|Magnetic Resonance|After enrollment a Magnetic Resonance without medium contrast, at 1 year from previous hospitalization
45339962|NCT02589002|Other|Sucralose|
45339963|NCT00755001|Device|BiHapro hip stem with PPS Ti+Plasma HA|BiHapro hip stem with PPS Ti+Plasma HA
45339964|NCT00755001|Device|BiHapro hip stem with PPS Ti+BoneMaster HA|BiHapro hip stem with PPS Ti+BoneMaster HA
45339965|NCT04082546|Procedure|Surgical unroofing of muscle-briged coronary artery|Medical therapy with beta-blockers or calcium-channels blockers
45339966|NCT02560311|Other|observation|
45339967|NCT02587364|Drug|Gemcabene 50 mg|Gemcabene 50 mg once daily (QD)
45339968|NCT02587364|Drug|Gemcabene 150 mg|Gemcabene 150 mg once daily (QD)
45339969|NCT02587364|Drug|Gemcabene 450 mg|Gemcabene 450 mg once daily (QD)
45339970|NCT02587364|Drug|Gemcabene 750/600 mg|Gemcabene 750/600 mg once daily (QD)
45472904|NCT03935685|Drug|Mirtazapine (Remeron)|Eligible patients should start Mirtazapine 15mg and stay there unless not tolerated, If there is no improvement in nausea dose can be increased to 30 mg and respectively 45 mg, 4 days apart. If excessive sleep, dose can be doubled. Patients should not take tryptophan while they are part of the study.
45683332|NCT03342586|Other|Self Reported Quality of Life Questionnaire|The Functional Assessment of Cancer Therapy-Brain Cancer (FACT-BR Version 4) consists of 46 questions with five domains assessing physical well-being, social/family well-being, emotional well-being, functional well being, additional concerns. The neuropsychological and QOL assessments will be performed by a neuropsychologist or by a trained RSA under the neuropsychologist's direct supervision.
46035340|NCT04155073|Behavioral|smoking cessation, early COPD detection, electronic visit|electronic visits (e-visits) for smoking cessation and early detection of chronic obstructive pulmonary disease (COPD)
46035341|NCT04155073|Other|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking
46035342|NCT04154995|Diagnostic Test|Venipuncture|Blood testing at 3, 6 and 12 months
45339971|NCT02587364|Drug|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
45339972|NCT02587364|Drug|Placebo|Placebo once daily (QD)
45339973|NCT00921765|Drug|Saline|Saline single bolus dose followed by saline single bolus dose iv
45339974|NCT00921765|Drug|Saline + Ketamine|Single bolus dose of saline followed by ketamine 0.2 mg/kg bw
45339975|NCT00921765|Drug|Naloxone + Placebo|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
45339976|NCT00921765|Drug|Naloxone + Ketamine|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
45339977|NCT05435781|Drug|Hydrocortisone|Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
45339978|NCT05435781|Drug|Placebo for hydrocortisone|Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
45339979|NCT02560233|Other|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of brain activity in the target region of interest.
45339980|NCT02560233|Other|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
45339981|NCT05435625|Procedure|FCO2|Fractional Carbon dioxide laser
45339982|NCT05435625|Procedure|FRF|Fractional Microneedling Radiofrequency
45339983|NCT00755157|Drug|Docetaxel|Metronomic docetaxel (IV) 30 mg/m2 on days 1, 8, 15 every 4 weeks for 6 cycles maximum
46035343|NCT04154995|Diagnostic Test|Ultrasound Quadriceps Muscles|Ultrasound measurement of quadriceps muscle mass and health
46035344|NCT00665041|Drug|Quinagolide|"• Quinagolide 200 μg/day (dose titration from 50 μg/day to 100 μg/day to 200 μg/day), oral. Quinagolida tablets, 50 mcg.~placebo, oral."
45339984|NCT00755157|Drug|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by (not compulsory) Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
45339985|NCT00919880|Drug|carboplatin+ paclitaxel|carboplatin AUC 2mg/mL*min/week, 3 week cycle up to 4 cycles; paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
45339986|NCT00919880|Drug|paclitaxel|paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
46035345|NCT04153045|Device|Radiograph interpretation for pulmonary abnormalities|"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."
46035346|NCT04152655|Drug|Idebenone|30mg tablets three times a day
46035347|NCT04152655|Drug|Placebo oral tablet|placebo tablets three times a day
45472905|NCT01164917|Drug|AMG811|Twelve subjects will be randomized to receive AMG 811 in Period 1 and will receive AMG 811 Placebo in Period 2. The AMG 811 and AMG 811 Placebo will be administered by injection.
46035348|NCT00672373|Drug|Extract of Ginkgo Biloba (EGb-761 capsules)|EGb-761 240mg/d, 1 capsule(80mg) tid,po,12 weeks; Each capsule contains 19.6mg flavonol glycosides and 4.8mg terpene lactones.
45472906|NCT01164917|Drug|AMG811 Placebo|8 subjects will be randomized to receive AMG 811 Placebo in Period 1 and will receive AMG 811 in Period 2. The AMG 811 Placebo and AMG 811 will be administered by injection
45472907|NCT03297294|Drug|EMA401|capsules, oral
45472908|NCT03297294|Drug|Placebo|Placebo to EMA401 capsules, oral
45472909|NCT03874637|Device|Treament|Placement of the FemPulse System with therapy delivery
45472910|NCT03874637|Device|Sham Control|Placement of the FemPulse System without therapy delivery
46035349|NCT00672373|Drug|Placebo|Wheat flour placebo capsule,1 capsule tid, po,12 weeks
46035350|NCT01109940|Biological|AIN457A|
46035351|NCT00595309|Biological|IC51|IC51, 6 mcg, intramuscular (i.m.) booster vaccination 15 months after the primary immunization
45339987|NCT02560077|Other|placebo|Subject receive the Placebo product (placebo group had same color and smell of treatment groups)
45339988|NCT02560077|Other|cashew apple juice|Subject received the cashew apple juice at dose of 120 mg/day after meal
45339989|NCT02560077|Other|cashew apple juice|Subject received the cashew apple juice at dose of 240 mg/day after meal
45339990|NCT00755313|Biological|trastuzumab|
45339991|NCT00755313|Drug|aromatase inhibition therapy|
45339992|NCT00755313|Drug|carboplatin|
45339993|NCT00755313|Drug|cyclophosphamide|
45339994|NCT00755313|Drug|docetaxel|
45339995|NCT00755313|Drug|doxorubicin hydrochloride|
45339996|NCT00755313|Other|metabolic assessment|
45339997|NCT00755313|Other|questionnaire administration|
45339998|NCT00755313|Other|study of socioeconomic and demographic variables|
45339999|NCT00755313|Procedure|cognitive assessment|
45340000|NCT00755313|Procedure|positron emission tomography|
45340001|NCT00755313|Radiation|fludeoxyglucose F 18|
45683333|NCT03340246|Procedure|Delayed sclerotherapy|See arm descriptions
46035352|NCT00665119|Drug|remifentanil|0.05 mcg.kg-1.min-1 for 30 minutes by continuous endovenous infusion
46035353|NCT00665119|Drug|placebo|NaCl 0.9 %
46035354|NCT05113212|Device|Macular surgery with NGENUITY surgical display system|Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon
46035355|NCT05113212|Device|Macular surgery with standard operating microscope|Patient undergoes VR surgery with visualization using standard operating microscope
46035356|NCT00665197|Radiation|Protracted Course Radiotherapy|External Beam Radiation 30 Gy in 10 fractions
46035357|NCT00665197|Radiation|Short Course Radiotherapy|External Beam Radiation 20 Gy in 5 fractions
46035358|NCT04309890|Other|Arabic version of the Overactive Bladder Symptom Score Questionnaire|All enrolled patients were asked to complete the Arabic OABSS questionnaire in its final edition before and three months after treatment with Solfinasin 5 mg once daily
45472911|NCT01161095|Device|LNG-IUS|Mirena (Bayer)- Levonorgestrel-Intrauterine System
45472912|NCT03238911|Drug|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg)."
45472913|NCT03238911|Drug|Ferric carboxymaltose|"Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial.~Ferric carboxymaltose was administered as 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg)."
46035359|NCT00672529|Dietary Supplement|Orthomolecular Therapy or Placebo Comparator|"The custom formulation proposed in this study comprises Vitamins C, E, B6 and B12, magnesium, selenium, quercetin and fish oil in relatively large doses. It is not at present registered as a natural health product or drug product.~Eligible patients will be randomized to an orthomolecular treatment regime or placebo with a 2:1 randomization ratio and will remain on their randomized treatment for 16 weeks. For the first 8 weeks of the intervention period inhaled corticosteroid treatment will be unchanged. In the remaining 8 weeks dose adjustment will occur every two weeks. Participants will be monitored closely for changes in their lung function."
46035360|NCT02629549|Drug|OTL38|Infusion of OTL38 prior to surgery
46035361|NCT00672607|Drug|extracts of Vitex agnus castus tablets|orally, one tablet daily. Apply for a period of 3 months. Do not interrupt during menses period.
46035362|NCT00672607|Drug|Placebo|Placebo
45340002|NCT00755391|Behavioral|cognitive behavior therapy|The cognitive behavioral therapy used in this study will focus on developing patterns of regular eating, addressing body image issues, and ways to cope with situations that trigger eating disordered behaviors.
45340003|NCT00755391|Behavioral|Supportive Psychotherapy|The supportive psychotherapy treatment used in this study will involve identifying issues underlying your child's eating disorder and giving your child information about the psychological processes that tend to maintain or continue eating disorder symptoms.
45472914|NCT03909113|Dietary Supplement|amino acid based formula|amino acid based formula
45472915|NCT01269515|Drug|Etoricoxib|90 mg QD
45472916|NCT00418834|Drug|ezetimibe and atorvastatin|ezetimibe 10 mg and atorvastatin 10 mg daily for 12 weeks
45340004|NCT04082858|Drug|Ketamine|A sub-anaesthetic dose of ketamine will be administered in twice-weekly infusions
45340005|NCT04082858|Drug|Midazolam|A sub-anaesthetic dose of midazolam will be administered in twice-weekly infusions
45340006|NCT05273307|Dietary Supplement|Miraculin|Given orally
45472917|NCT00418834|Drug|atorvastatin|Atorvastatin 20 mg daily for 6 weeks, and up-titrated to atorvastatin 40 mg daily for an additional 6 weeks
46035363|NCT00665509|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml, trivalent one injection at Day 1
45340007|NCT05273307|Dietary Supplement|Miracle Fruit Placebo Cube|Given orally
45340008|NCT05209815|Behavioral|Questionnaire|Questionnaire
45340009|NCT05213858|Diagnostic Test|CAPS questionnaire|PTSD diagnosis and severity will be done using the CAPS-5 questionnaire.
45340010|NCT05213858|Diagnostic Test|Beck Depression Inventory|depression symptoms will be measured by the BDI-II. The BDI-II consists of 21 items and uses a 0 to 3 severity scale. Total scores range from 0 to 63, with higher scores indicating more severe depression.
45340011|NCT05213858|Diagnostic Test|The Fibromyalgia Impact Questionnaire|The FIQ was developed from information gathered from patient reports, functional status instruments and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue and well-being over the past week.
45340012|NCT05213858|Diagnostic Test|The Pittsburgh Sleep Quality Index|"sleep patterns will be measured using the PSQI. This index assesses the quality and patterns of sleep in adults. It differentiates poor from good sleep quality by measuring seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, the use of sleeping medications and daytime dysfunction over the last month. Items are rated using a 0 to 3 scale. The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality."
45340013|NCT05213858|Diagnostic Test|Depression, Anxiety and Stress Scale-21 items|The DASS-21 is a three-scale self-report questionnaire designed to measure the emotional state of depression, anxiety and stress. Each scale contains 7 items, divided into subscales with similar content. Scores range between 0 and 21 in each subcategory.
45340014|NCT05213858|Diagnostic Test|Traumatic Events Questionnaire|"The TEQ examines experiences of traumatic events (e.g. sexual abuse, accidents and crime) that are considered potential triggers of PTSD symptoms. To assess trauma intensity, respondents provide information for each event that was experienced, as well as their age at the time of the event. The items are measured on a 9-point Likert scale from not at all to severely/extremely. The TEQ has previously been used in Israel."
45472918|NCT00418834|Drug|Placebo (unspecified)|Placebo (unspecified) daily for 12 weeks
45472919|NCT03908957|Drug|Ga68-Dolacga Injection|Ga68-Dolacga Injection, 3.5±0.25 mCi, single dose iv
45472920|NCT03908801|Behavioral|Specialized water dance intervention|Group activity in a warm pool (32-34 °C) led by two SWAN leaders. During each session, nine songs are played and the participants, assisted by a support person, perform dance movements rhythmically to the mood of the music. The songs are chosen to stimulate different movement patterns and to emphasize different emotions.
45472921|NCT01267331|Procedure|bone marrow mononuclear cells injection|Participants will receive direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG.
45340015|NCT05213858|Diagnostic Test|Clinician Administered Dissociative States Scale|The CADSS is a 28-item structured clinical interview to assess state dissociation.
45340016|NCT05213858|Diagnostic Test|A diary will be used for seven consecutive nights|"A diary will be used for seven consecutive nights for the evaluation of:~Mean sleep latency~The number and duration of awakenings.~Subjective total sleep time~Subjective wake after sleep onset~Sleep efficiency"
45340017|NCT05213858|Diagnostic Test|MRI|Brain imaging will include DTI and resting state for structural and functional MRI scanning. Images will be acquired on MAGNETOM Vida 3T Scanner, configured with 64-channel receiver head coils (Siemens Healthcare, Erlangen, Germany) at the Department of Radiology at Shamir Medical Center.
45472922|NCT01267331|Procedure|placebo intramyocardial injection|Participants will receive between 10 and 15 placebo injections that consist of saline and 5% human serum albumin during CABG.
46035364|NCT00672685|Dietary Supplement|omega-3|V0137 CA containing 400 mg docosahexaenoic acid (DHA) - 2 soft capsules once a day, i.e. 800 mg DHA per day for 36 months
46035365|NCT00672685|Behavioral|multi-domain intervention|multi-domain intervention = Nutrition, physical exercise, cognitive training and social activities, and preventive consultations
46035366|NCT00672685|Drug|Placebo|OMEGA-3 placebo
46035367|NCT00595075|Drug|Ramelteon|Ramelteon 8 mg tablet by mouth x 1 dose
46035368|NCT00595075|Drug|placebo|placebo identical in appearance to active experimental drug x 1 dose
46035369|NCT00887224|Drug|Desvenlafaxine succinate sustained release 50 mg|50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.
46035370|NCT00887224|Drug|Desvenlafaxine succinate sustained release 25 mg|25 mg tablet for taper, once daily for 1 week
46035371|NCT00887224|Drug|Placebo|Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.
46035372|NCT00672763|Drug|Colecalciferol D3 (Vigantol Oil)|"Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~Colecalciferol 100,000iU orally once fortnightly for 4 weeks (2 doses)."
45472923|NCT01269671|Drug|Melatonin, Peppermint Oil (mentharil), and Simethicone|Dosing will be dependent on patient's age during time of enrollment. Patients 8-12 years of age will receive Melatonin 3mg tab at night, Peppermint oil 1 capsule (0.2ml) 30-60 minutes prior to meal twice daily, and Simethicone 80mg tab 30-60 minutes prior to meal twice daily. Patients 13-18 years of age will receive Melatonin 3mg tab at night, Peppermint oil 2 capsules (0.4ml) 30-60 minutes prior to meal twice daily, and Simethicone tab 125mg 30-60 minutes prior to meal twice daily
46035373|NCT00672763|Drug|Medium chain triglycerides|"Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~Migliol Oil 5ml oral fortnightly (2 doses)"
46035374|NCT04154449|Drug|Intranasal insulin|Surgical group Received intranasal insulin, the second group surgical Received placebo and the third group is non surgical do not receive anything.
45683334|NCT03340246|Procedure|Immediate phlebectomy|See arm description
46035375|NCT02629081|Other|Controls & Cases|All interventions are standard of care and both controls and cases will be treated the same. IEE results from controls and cases will be compared.
46035376|NCT00661063|Drug|ketamine|ketamine 150 mcg/g bid
46035377|NCT00661063|Drug|vehicle gel|bid - 12 weeks
46035378|NCT00661063|Drug|ketamine + clonidine|ketamine 150mcg/g + clonidine 1% gel bid 12 weeks
46035379|NCT00661063|Drug|clonidine gel 1%|bid 12 weeks
46035380|NCT00665587|Procedure|Cox-MAZE III|Maze procedure according to standards of the department
45683335|NCT04279132|Behavioral|POSTOPERATIVE COGNITIVE DYSFUNCTION|NEURON SPECIFIC ENOLASE LEVELS IN LUMBAR DISC HERNIECTOMY WITH GENERAL ANESTHESIA MODALITIES
46035381|NCT02629237|Other|Multifaceted education|Subjects will be asked to watch a 5-10 min education film and participate in a 10-15 min counseling session with a trained doctor/nurse before glaucoma surgery,and at 1 week and 2 week after surgery.
46035382|NCT02825446|Procedure|angioplasty tibial arteries|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
45340018|NCT05213858|Diagnostic Test|Functional brain imaging|Functional magnetic resonance imaging (fMRI) is widely used to study the operational organization of the human brain. This technology measures brain activity by detecting changes associated with blood oxygenation, using blood-oxygen-level-dependent imaging (BOLD) contrast.
45340019|NCT05213858|Diagnostic Test|EEG analysis|EEG will be obtained using a point-of care device that consists of an EEG-Sense Headset, EEG-Sense Single-Use brush sensors, a pneumatic sensor positioning mechanism, EEG sampling electronics and software. The EEG-Sense Headset is an EEG electrode positioning system that quickly places electrodes in a uniform and consistent manner, to transfer electrophysiological EEG signals from an individual to a suitable EEG data collection device. The device is nonsterile, non-invasive and non-radiation emitting, and was developed for use in healthcare facilities and hospitals. Typical set-up and procedure time is several minutes. The device does not contain biologics, drugs, coatings or any claim of sterility. The EEG-Sense Single-Use brush sensors are made from well-established medical-grade materials; the Headset is made from Nylon 101. Electronic components and harnesses are embedded between two layers of nylon and are attached to each electrode port.
45472924|NCT01269671|Other|Sugar pill|Patients in the placebo group will receive one placebo tab to be taken at night, one placebo capsule to be taken 30-60 minutes prior to meal twice daily, and one placebo tab to be taken 30-60 minutes prior to meal twice daily.
45472925|NCT04407286|Dietary Supplement|Vitamin D3|Oral vitamin D3 capsules
45472926|NCT03276975|Drug|TISSEEL|TISSEEL is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. TISSEEL is effective in heparinized patients
46035383|NCT02825446|Procedure|"angioplasty tibial arteries augmented radio frequency denervation popliteal artery by the useVessix Renal Denervation System Balloon"|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion. Then in 3 portion of the popliteal artery starts ablation by the use Vessix Renal Denervation System Balloon performed radiofrequency denervation. After removal of the balloon, control angiography is performed.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
46035384|NCT04242706|Device|ETTEvac|Endotracheal tube with evacuation lumen without noble metal coating
46035385|NCT04242706|Device|BIP ETTEvac|Endotracheal tube with evacuation lumen with noble metal coating
45472927|NCT03380416|Other|Portfolio Diet|Medium-term (8 weeks ) nutritional intervention
46035386|NCT00672919|Drug|Pioglitazone|Pioglitazone 30 mg to 45 mg, tablets, orally, once daily in combination with stable statin therapy for up to 17 weeks.
45472928|NCT03380416|Other|MUFA Diet|Medium-term (8 weeks ) nutritional intervention used as control
45683336|NCT05552248|Device|LumbarBelt SOFT 300|15 patients will be included in this group and will used the medical device LumbarBelt SOFT 300 during sport practice (at least 2 sport sessions per week), for 12 weeks.
45683337|NCT05552248|Other|Control group LumbarBelt SOFT 300|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device LumbarBelt SOFT 300), for at least 2 sport sessions per week during 12 weeks.
45683338|NCT05552248|Device|LumbarBelt MID 500|15 patients will be included in this group and will used the medical device LumbarBelt MID 500 during sport practice (at least 2 sport sessions per week), for 12 weeks.
45683339|NCT05552248|Other|Control group LumbarBelt MID 500|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device LumbarBelt MID 500), for at least 2 sport sessions per week during 12 weeks.
46035387|NCT01109316|Drug|Insulin lispro 2 day reservoir in-use|Insulin lispro 2 Day (L2D) administered by infusion pump for 8 week treatment period.
46035388|NCT01109316|Drug|Insulin lispro 6 day reservoir in-use|Insulin lispro 6 Day (L6D) administered by infusion pump for 8 week treatment period.
46035389|NCT01109316|Drug|Insulin aspart 6 day reservoir in-use|Insulin aspart 6 Day (A6D) administered by infusion pump for 8 week treatment period.
46035390|NCT02825290|Drug|Choriogonadotropin alfa|
46035391|NCT02825290|Drug|Triptorelin acetate|
46035392|NCT00675961|Behavioral|Brief Counseling Intervention (BCI)|Two-tiered BCI characterized by both primary and secondary interventions. Primary BCI treatment format consists of 6 discussions delivered monthly in the first 6 months of standard TB treatment. 10-15 minutes long. Secondary BCI is delivered on a monthly basis while receiving TB treatment. 5-10 minutes long.
46035393|NCT00675961|Drug|Naltrexone|Opioid antagonist, which decreases the pleasurable response to and craving for alcohol consumption. Oral; single daily dose of 50 mg per day for 6 months.
46035394|NCT00675961|Other|BCI + Naltrexone|Combination of the two previous interventions
46035395|NCT00675961|Behavioral|Treatment as Usual|Services provided by psychologists and narcologists (additions specialists) employed by the Tomsk Oblast TB Services.
45340020|NCT05213858|Diagnostic Test|Autonomic nervous system monitors|"Data will be collected using Empatica's E4 wristband. Each of the study participants will wear the wristband for 7 days.~Data collected from the band will include:~ACC - Data from 3-axis accelerometer sensor in the range [-2g, 2g]. (sampled at 32 Hz) BVP - Data from photoplethysmography (PPG). (sampled at 64 Hz) EDA - Data from the electrodermal activity sensor in μS. (sampled at 4 Hz) IBI - Inter-beat intervals. (intermittent output with 1/64 second resolution) TEMP - Data from temperature sensors, expressed in degrees on the Celsius (°C) scale. (sampled at 4 Hz)"
45472929|NCT01267409|Other|STN stimulation|Manipulating emotional processing of PD patients by high and low frequency stimulation of their subthalamic area (through the 4 DBS contacts) after the surgery
46035396|NCT00887068|Drug|Azacitidine|32 mg/m^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
45683340|NCT05548582|Drug|OxyCODONE 5 mg Oral Tablet|No opioid prescription after laparoscopic hysterectomy
45683341|NCT05548582|Drug|Acetaminophen 500Mg Tab|Standard prescription
45683342|NCT05548582|Drug|Ibuprofen 600 mg|Standard prescription
46035397|NCT00941031|Drug|AIN457|
46035398|NCT00941031|Drug|AIN457A|"Induction with monthly injections - Monthly: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9"
46035399|NCT00941031|Drug|AIN457A|"Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5"
46035400|NCT00941031|Drug|Placebo|"Placebo - Placebo: Placebo administered at weeks 1, 2, 3, 5, 9"
45340021|NCT05198817|Drug|SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection|Firstly Dose Escalation and Dose Expansion of SHR-2002 injection monotherapy should be conducted. After RP2D and MTD of the SHR-2002 injection monotherapy were confirmed, Dose Escalation, Dose Expansion and Efficacy Expansion of SHR-2002 injection in combination with other anti-cancer treatment would be completed, including Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection.
45340022|NCT02587286|Other|Gather app|Participants in the intervention group will receive the Gather Health software free for the duration of the study. Their medication and BG testing goals will be entered into the system and they will receive automated reminders. Their data will be regularly reviewed by study staff and feedback provided.
46035401|NCT04310436|Behavioral|Modifying saccades by looking down to naval.|Paragraphs from list Provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly down to their naval to reset the lateral tongue position.
45340023|NCT00679029|Drug|doxorubicin hydrochloride|Given IV
45340024|NCT00679029|Drug|cyclophosphamide|Given IV
45340025|NCT00679029|Biological|bevacizumab|Given IV
45340026|NCT00679029|Drug|paclitaxel|Given IV
45340027|NCT00679029|Drug|gemcitabine hydrochloride|Given IV
45340028|NCT00679029|Other|laboratory biomarker analysis|Correlative studies
45340029|NCT00679029|Biological|pegfilgrastim|Given subcutaneously
45340030|NCT00919022|Drug|Cyproterone Acetate (Androcur, BAY94-8367)|Patients in regular clinical practice receiving Androcur according to local drug information
45340031|NCT04082156|Device|electrical stimulation|electrical stimulation
45340032|NCT04082156|Device|Sham|no stimulation
45340033|NCT03938571|Procedure|Duodenal Switch|
45340034|NCT05191953|Procedure|Bilateral ultrasound-guided ESPB|"Bilateral ultrasound-guided ESPB (total of 40 ml, 0.25% bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit."
46035402|NCT04310436|Behavioral|Modifying saccades by looking in air.|Paragraphs from list provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly up to reset the lateral tongue position.
46035403|NCT00886834|Drug|Misoprostol|400 micrograms inserted vaginally or buccally, per the participants desire prior to the IUD insertion.
46035404|NCT00886834|Drug|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
46035405|NCT00880009|Drug|Bosutinib|400mg (4x100)mg tablets once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
46035406|NCT00880009|Drug|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
45340035|NCT05191953|Procedure|Bilateral ultrasound-guided ESPB and superficial PIPB|"Bilateral ultrasound-guided ESPB (total of 40 ml, %0.25 bupivacaine) and Superficial PIPB (total of 20 ml, %0.25 bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit."
45340036|NCT02588066|Procedure|Ligamentum teres/falciform-plasty|Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
46035407|NCT00880009|Drug|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
46035408|NCT04242472|Behavioral|SMS-based Mobile Health intervention|Nutritional related SMS text message mobile health intervention will be provided to Tuberculosis patients.
45340037|NCT02559219|Other|Questionniares|
45340038|NCT05004350|Drug|Encorafenib|oral hard capsule
45340039|NCT05004350|Drug|Cetuximab|intravenous infusion
45340040|NCT05004350|Drug|FOLFIRI|"Combination of:~irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous infusion, and 5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion"
46035409|NCT02827006|Procedure|corrective osteotomy distal radius|Opening wedge corrective osteotomy on dorsal malunions of the distal radius. Distraction and correction of deformity.
46035410|NCT00676039|Drug|Venlafaxine|NOVO-Venlafaxine XR 75 mg (NOVOPHARM, Generic)
46035411|NCT00676039|Drug|Gen-Citalopram|Gen-Citalopram 40 mg (Genpharm, Generic)
46035412|NCT00676039|Drug|Effexor XR|Effexor XR 75 mg (Wyeth Pharmaceuticals, Brand Name)
46035413|NCT00676039|Drug|Celexa|Celexa 40 mg (Lundbeck, Brand Name)
45340041|NCT05141955|Other|Group Erector Spinae Plane Block (ESPB)|"Patients will receive general anesthesia initially then bilateral ESPB with a total volume of (0.3-0.4 ml/kg LBW) of bupivacaine 0.25% will be performed (not exceeding toxic dose) 150 mg "
46035414|NCT01104636|Drug|Varenicline|varenicline tablets prescribed as per local German SmPC for 12 weeks duration
45683343|NCT04400422|Dietary Supplement|Lipano formula|Subjects will be asked to take an MCT infant formula to assess the tolerability, compliance and overall acceptability of the product for patient with LCHAD
45683344|NCT05538754|Device|EVO ICL|The EVO ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
46035415|NCT04268511|Procedure|Caudal epidural block group|The linear probe of ultrasound was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone. A 22 Gauge 50 mm echogenic block needle was advanced
46035416|NCT04268511|Procedure|Pudendal nerve block group|A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.
46035417|NCT04931602|Diagnostic Test|Biochemical markers i.e. Serum Ca, PTH, CTX, Albumin, Phosphate, Vitamin D and Bone mineral density Scan|investigations for secondary causes of osteoporosis
46035418|NCT04157023|Device|Simulator-based Training of Direct Ophthalmoscopy|A digital simulator is used to teach the skills of direct ophthalmoscopy
46035419|NCT04157257|Drug|TDF tablet|TDF tablet 300mg QD
45340042|NCT05141955|Other|Group Quadratus Lumborum Block (QLB)|"Patients will receive general anesthesia initially then bilateral QLB with a total volume of (0.3-0.4 ml/kg LBW) of bupivacaine 0.25% will be performed not exceeding toxic dose150 mg "
45340043|NCT05141955|Other|Group (C) (Control group)|Where patients will be operated under general anesthesia.
46035420|NCT04157257|Drug|Entecavir Tablet|Entecavir tablet 0.5mg QD
46035421|NCT04157257|Drug|QL-007|QL-007 tablets 200mg BID
46035422|NCT04243174|Behavioral|SMS Messaging|Patients with type 2 diabetes will be recruited and will start receiving short SMS messages about physical activity, encouraging them to be more active and help them to build a healthy life style routine.
46035423|NCT02852421|Procedure|Single injection paravertebral block|"The patients in single injection group will receive single injection paravertebral block at T3-T4 level with 25 ml of 0.5% ropivacaine and four subcutaneous sham injections"
45340044|NCT02559531|Device|Mobile triage system|A mobile triage system used by EMS providers will be evaluated using standardized clinical vignettes
45340045|NCT05122221|Drug|Fludarabine + Cyclophosphamide|Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 500mg/m²/day×3 days
45340046|NCT05122221|Drug|Interleukin-2|Interleukin-2 20,000,000 IU/time infused within 15 minutes approximately every 8 hours (according to the subject's tolerance, the interval between medications can be extended to 24 hours) for a maximum usage time up to 14 days.
45340047|NCT05122221|Biological|CRTE7A2-01 TCR-T Cell|On day 0, the TCR-T cells will be administered one time, each bag of cell intravenously within 20 minutes.
45340048|NCT05119647|Device|Thrombus Aspiration Catheter(Ton-bridgeMT)|Thrombus Aspiration Catheter is a developed technique for treating acute stroke caused by artery occlusion. The catheter(Ton-bridgeMT) was specially designed for those patients who experience acute stroke within 24 hours.
46035424|NCT02852421|Procedure|Multiple injection paravertebral blocks|"Patients in the multiple injection group will receive five injections of paravertebral blocks from T1 to T5 level. 5 ml of 0.5% ropivacaine was injected at each level."
45340049|NCT02559453|Procedure|Debridement|Removing dead tissue from infected wounds.
45340050|NCT03802305|Device|computerized intraosseous technique (Quicksleeper™)|"The anesthetic solution is administered with a specific equipment allowing the injection step by step:~anesthesia of the interdental papilla,~positioning of the needle and perforating of the interdental space,~Injection of the solution. All of these steps are based on an adjustment of the different part of this equipment."
46035425|NCT02825134|Device|Transcatheter aortic valve replacement|Retrograde transfemoral transcatheter aortic valve replacement with any CE mark approved aortic bioprosthesis with or without concomitant percutaneous coronary intervention.
46035426|NCT02825134|Device|Surgical aortic valve replacement|Conventional surgical aortic valve replacement with a bioprosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest with or without concomitant coronary artery bypass graft surgery.
46035427|NCT04152811|Behavioral|Cooking Matters for Diabetes|Each Cooking Matters course is made up of 6, 2-hour, weekly classes with 15 participants. The curricula is based on the Dietary Guidelines for Americans, MyPlate, the American Diabetes Association Standards of Medical Care in Diabetes 2017 and Medical Nutrition Therapy Evidence Based Guide for Practice/Nutrition Protocol as the foundation for basic nutrition guidelines, then builds upon these ideas using the collective groups' needs and interest to provide interactive lessons to teach cooking, food safety and food resource management with emphasis placed on blood sugar management.
46035428|NCT04152811|Other|Usual Diabetes Care|Usual Diabetes Care
46035429|NCT04152889|Drug|Camrelizumab|Camrelizumab, 200 mg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
46035430|NCT04152889|Drug|S-1|Tegafur-gimeracil-oteracil potassium: 80 - 120 mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.
45340051|NCT03802305|Device|loco-regional anesthesia (IANB technique)|The anesthetic solution is delivered by a needle near to the inferior alveolar nerve before it enters the mandibular foramen.
45340052|NCT00755469|Procedure|Post-conditioning|The post-conditioning protocol consists of performing 4, 30-second PTCA balloon occlusions followed by 30 seconds of reperfusion for a total of 4 minutes. The first balloon inflation occurs immediately after an angioplasty guidewire is placed through the obstruction in the artery and flow is restored. Following this protocol the vessel will be stented as part of usual practice for treatment of acute MI.
45340053|NCT02587442|Drug|RadProtect®|This study will evaluate RadProtect® at sequential, escalating dose levels. Once administration is given, study subjects will be followed during 24 hours of hospitalization according to the final injection timing. All subjects will need to return to the hospital for monitoring at 7+2 days after dosing, and follow-up visits by telephone at Day 3, Day 14+2, and Day 28+2 days will need to be conducted.
45340054|NCT04084184|Drug|HGP1812|Dapagliflozin (Forxiga) 10mg
45340055|NCT04084184|Drug|HGP1602|Dapagliflozin 10mg
45683345|NCT04278430|Device|transcranial direct current stimulation|"The tDCS stimulator (ActivaDose II tDCS Device; IOMED Inc., Salt Lake City, USA) is a standardized instrument used and tested in children. Two tDCS electrodes of dimensions 3 x 3 were used for the brain stimulation. The electrodes were inserted into a wet saline sponge."
45683346|NCT04278430|Device|Sham tDCS|Five children with LSIH were randomly allocated to this group. All participants received sham tDCS for 3 weeks on alternate days and completed 10 treatment sessions. The sham tDCS followed preparatory procedures similar to that used for the experimental group, except that the device was disconnected after the initial increase of the current. Children usually started the activity without noticing that the device was disconnected. The children were assessed at baseline, during the 5th and 10th sessions, and during a follow-up that was scheduled for 4 months later.
46035431|NCT04152889|Drug|Docetaxel|Docetaxel: 40 mg/m^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.
45340056|NCT00755547|Other|Aerobic Exercise Training|All sessions will be designed to elicit a certain degree of energy expenditure that will progressively increase throughout the trial. Adolescents randomized to the vigorous activity group will perform interval sessions that ensure an average heart rate between 70 and 85% of maximal heart rate reserve while those randomized will perform aerobic activity between 40 and 50% of heart rate reserve. The goal for the trial will be to expend a minimum of 350 kcal. The type of exercise will depend on the preference of each participant however, during the supervised sessions walking/jogging on a treadmill or outdoors will be used to elicit exercise intensities. The three activity sessions held at the YMCA-YWCA facilities in Winnipeg and be supervised by a trained kinesiologist who will record heart rate and perceived exertion for each session.
46035432|NCT00602511|Drug|Bortezomib|"Bortezomib 1,3 mg/m2 intravenously on days 1, 4, 8 och 11 of every 3 weeks cycle until maximal response, toxicity or maximum 8 cycles~Dexamethasone 20 mg days 1-2, 4-5, 8-9 and 11-12 during the first 2 cycles, thereafter individualized dose depending on response and toxicity"
45340057|NCT02587052|Drug|Generic tacrolimus|Generic tacrolimus
45340058|NCT02587052|Drug|Prograf|Prograf, the original tacrolimus
45340059|NCT02587130|Drug|Ketamine|ketamine administered in bolus by subcutaneous injection
45340060|NCT00677235|Device|FLAIR Endovascular Stent Graft|Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft
45340061|NCT00677235|Procedure|PTA|Treatment of stenoses with PTA only
45340062|NCT04084418|Other|Control Diet|Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Control diet, the diet will provide 50% of energy from CHO, 15% from protein, and 35% from lipids. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.
45683347|NCT05537974|Procedure|Endotracheal aspiration|Clearance of endotracheal secretions via a catheter.
45683348|NCT05093374|Drug|anti-VEGF agent|"All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~Presence/change of sub- and intraretinal fluid will be assessed objectively by AI software and the results will be provided during the visit to the investigator. The final decision for/against retreatment is always made by the discretion of the clinical investigator. Should the Investigators decision differ from the study protocol, the reason will be indicated in the CRF."
45683349|NCT05093374|Drug|anti-VEGF agent|"All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~In this cohort the amount of retinal fluid will not be assessed by AI software at the time of retreatment."
45683350|NCT05249374|Drug|Recombinant Human Serum Albumin|10 g/bottle (20%, 50 mL)
46035433|NCT00602511|Drug|Thalidomide|"Thalidomide 50 mg/day with dose escalation every 3 weeks until response or toxicity, maximal dose 200 mg/day~Dexamethasone 40 mg/day day 1-4 every 3 weeks for at least 2 courses, thereafter individualized dose depending on response and toxicity"
46035434|NCT02826616|Drug|Trimetazidine|Trimetazidine 60 mg 30min before PCI and 20 mg for 12 months after surgery
46035435|NCT00676117|Drug|Esomeprazole (D961H)|20mg
46035436|NCT00676117|Drug|Loxoprofen|60mg tablet
46035437|NCT05042986|Drug|.[14C]-SKI-O-703|Single oral dose of 200 mg (100 μCi in 200 mg salt [0.5 μCi/mg as salt], equivalent to 100 μCi in 142 mg active [0.7 μCi/mg as active]) of [14C]-SKI-O-703 containing approximately 100 μCi of [14C]-SKI-O-703 per capsule after an overnight fast.
46035438|NCT02852187|Device|SIGNUS MOBIS PEEK Cage|Lumbar Interbody Fusion
45683351|NCT05249374|Drug|Human serum albumin|10 g/bottle (20%, 50 mL)
45683352|NCT05247580|Other|Hicks self-confidence scale, Karasek survey, Maslach Burnout Inventory|Questionnaires (Hicks self-confidence scale, Karasek questionnaire, Maslach Burnout Inventory) sent to hospital staff caregivers before and after (at 3 and 6 months) their SUrVIS training.
45340063|NCT04084418|Other|VLCHF Diet|Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Experimental diet, the diet will provide 10% of energy from CHO, 15% from protein, and 75% from lipids. During the Experimental diet, participants will be provided with a multivitamin to reduce risk of deficiencies due to restrictions on fruits and grain products. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.
45683353|NCT05084638|Drug|Ofatumumab|20mg subcutaneous injection
46035439|NCT02852187|Device|SIGNUS MOBIS II ST Cage|Lumbar Interbody Fusion
46035440|NCT00676273|Device|TVT-Obturator (TVT-O)|sub urethral sling
46035441|NCT00676273|Device|TVT-Secur (TVT-S) (Hammock method)|suburethral sling
45683354|NCT04278742|Other|Patient education|Using a collaborative approach to engage patients in their own care, allowing patients to continue to have full control of their treatment. The clinician and patient co-creates the treatment plan.
45683355|NCT03338218|Drug|Volulyte 6%|Solution for infusion
45683356|NCT03338218|Drug|Ionolyte|Solution for infusion
45683357|NCT04400032|Biological|Mesenchymal Stromal Cells|The Mesenchymal Stromal Cells will be administered intravenously
45683358|NCT05262088|Other|video recording of general movements|"Video recording of general movements of children aged 3-5 days, then 4-5, 8-9, 12-13, 16-17, 20-22 weeks of life.~At the age of 12 weeks of life, an assessment will be made on the Motor Optimality Scale (MOS)."
45683359|NCT05226910|Device|tDCS and intensive therapies|This intervention will consist in the combination of tDCS with CIMT (30 hours) and then with BIT (3 hours and 45 minutes)
46035442|NCT01104558|Drug|Bisoprolol|Bisoprolol will be given in a starting dose of 1.25 milligram (mg) once daily for two weeks and if it is well tolerated, the dose will be increased to 2.5 mg, 3.75 mg, 5 mg once daily in intervals of two weeks, 5 mg daily as a maintenance therapy. If the subject is tolerable, the dose can be increased as 10 mg/day as maximum dose.
46035443|NCT04242160|Other|Modified Clamshell Thoracotomy|Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
46035444|NCT04242160|Other|Left Anterolateral Thoracotomy|Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
46035445|NCT00602589|Drug|Levofloxacin oral suspension; Levofloxacin oral solution; and Levofloxacin marketed tablet formulations|
46035446|NCT00911755|Procedure|Endotracheal Intubation|This study is comparing 2 currently accepted methods of endotracheal intubation: laryngoscopy and videolaryngoscopy
46035447|NCT00911755|Procedure|Endotracheal Intubation|
46035448|NCT02826850|Procedure|Saphenous Nerve|Saphenous nerve neurotomy by radiofrequency, guided by ultrasound.
46035449|NCT02826850|Procedure|Genicular nerves|Genicular nerves neurotomy by radiofrequency, guided by fluoroscopy
46035450|NCT04270071|Drug|Yangxin Shengmai|Yangxin Shengmai Granules
46035451|NCT04270071|Drug|Yangxin Shengmai placebo|Yangxin Shengmai placebo have an identical appearance and scent as the active treatment granules.
46035452|NCT04270071|Drug|nitroglycerin tablets|Be used when angina attack
46035453|NCT04152733|Device|High flow nasal cannula|Oxygen is supplied via high flow nasal cannula. Heated air (2L/kg/min) is administered using Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand).
46035454|NCT02826538|Device|fracture fixation with patient specific guides|Using the preoperative computed tomography scan, a 3D planning of the fracture Fixation is made and patient-specific guides for fracure fixation are produced using a 3D Printer. These Patient-specific guides are used for fracture fixation
46035455|NCT02826538|Device|standard procedure of fracture fixation|the standard procedure of fracure fixation for each fracture localisation is used as a standard of reference
46035456|NCT04152577|Drug|R2-combination chemotherapy|"R2-CHOP/CHOPE/DA-EPOCH/HD MTX~R2-CHOP :~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R2-DA-EPOCH:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R2-HD MTX:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
46035457|NCT04152577|Drug|R-combination chemotherapy|"R-CHOP/CHOPE/DA-EPOCH/HD MTX~R-CHOP :~Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R-DA-EPOCH:~Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R-HD MTX:~Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
46035458|NCT02856087|Drug|High dose Remifentanil|remifentanil infusion at 4ng/ml of Ce
46035459|NCT02856087|Drug|Naloxone|naloxone infusion
45340064|NCT02559141|Drug|Dobutamine|If PPV ≤10%, volume substitution of 500 ml of crystalloids and/or colloids as long as CI was ≥2.5 l/min/m². Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg was achieved by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min).
45340065|NCT05679440|Behavioral|Postural interventions based on pulmonary imaging|The main difference between the intervention group and the control group was the position during oxygen therapy. Patients in the intervention group were placed in the appropriate position for oxygen therapy according to pulmonary imaging, while patients in the control group were placed in the appropriate position for oxygen therapy according to conventional treatment principles and the patient's wishes.
46035460|NCT02856087|Drug|Low dose remifentanil|remifentanil infusion at 1ng/ml of Ce
46035461|NCT02856087|Drug|Normal Saline|normal saline infusion
46035462|NCT02881632|Device|Structured Light Plethysmography (SLP) - Pneumscan|Both healthy infants and bronchiolitis infants will have their chest movements monitored using Structured Light Plethysmography (SLP) performed by a device (Thora-3 Di) using a projector and two cameras. A light pattern of black and white squares is projected on the child's chest and the cameras record how the shape of this pattern changes with breathing. A computer converts this information to show how the child's chest moves during breathing.
46035463|NCT02855931|Procedure|Middle turbinate resection|
46035464|NCT00676429|Drug|Ziprasidone Hydrochloride|Ziprasidone Hydrochloride oral solution, individual titration 5 mg o.d. or 10 mg to 40 mg b.i.d
46035465|NCT00676429|Drug|Placebo|Placebo as oral solution, individually titrated
46035466|NCT02880072|Dietary Supplement|phosphate orally|4 different preparations of phosphate
45340066|NCT04969965|Drug|aumolertinib|EQ143 tablet is an oral solid dosage form manufactured at a strength of 55 mg
45340067|NCT03680625|Device|Passive Distraction|Patients in this group will be offered an iPad® showing a video while they will undergo their pins' removal and/or removal of sutures. There will be videos appropriate for each age group. The child can choose from the videos presented on the iPad® and start watching 5 minutes before the beginning of the procedure to assure similar preparation for both groups.
45683360|NCT05226910|Device|Sham and intensive therapies|This intervention will consist in the combination of sham tDCS with CIMT (30 hours) and then with BIT (3 hours and 45 minutes)
45683361|NCT05524948|Other|Experimental Dentifrice|Dentifrice containing 0.454% stannous fluoride with 0.3% zinc chloride.
45340068|NCT03680625|Device|Virtual Reality Distraction|Patients in this group will be offered virtual reality distraction through the use of Oculus Quest® while they undergo their pins' removal and/or removal of sutures. VR produces a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness symptoms such as nausea, vomiting, headache. The videogame was developed by our team with three levels of difficulty, and approved by pediatric healthcare professionals. The game, oculus head-mounted device and computer will be available in the procedure room and ready for immediate use. The head-mounted device will be adjusted to the head of the child before any procedure and a period of 5 minutes will be allotted prior to pin and/or suture removal in order for the child to get acquainted with the game and immersed in the virtual environment.
45340069|NCT02561013|Device|3M™ Coban™ Custom Fit Compression System|"3M Coban™ Fit is a compression system that consists of two components: 1. A Compression Stocking and 2. Coban™ Fit Sleeve.~The stocking provides compression to the foot and improves wearing comfort in the calf area under the sleeve. The compression sleeve is intended to provide the therapeutic compression to the calf, with the initial fitting to be done by a health-care professional. The compression sleeve is customized according to the anatomy of the patient's leg; both components are designed to be used together."
45340070|NCT02561013|Device|Profore|PROFORE is a multi-layer compression bandaging system developed to apply sustained graduated compression for the management of venous leg ulcers and associated conditions. Multi-layer compression bandaging is the first choice in treatment for venous leg ulcers.
45340071|NCT04081844|Drug|HCP1306|Ezetimibe 10mg / Rosuvastatin 20mg (Rosuzet)
45472930|NCT03125746|Drug|LXI-15029|The investigational product for this study is LXI-15029 capsule, which can be administered orally and the specification included 10 mg and 50 mg. There will be about 6 cohorts during the monotherapy period. LXI-15029 capsules will be administered in a therapeutic cycle of 28 days twice a day orally. The patients will be given LXI-15029 continuously, in a therapeutic cycle of 28 days. Patients will continue therapy with LXI-15029 if good safety and tolerability were assessed by investigators after 1 cycle treatment. The treatment will continue until progression or occurrence of unmanageable toxicity.
45683362|NCT05524948|Other|Reference Dentifrice|Standard fluoride dentifrice containing 0.243% sodium fluoride.
45683363|NCT01839656|Drug|nusinersen|Administered by intrathecal (IT) injection
45683364|NCT03335332|Behavioral|High intensity exercise|The exercise groups will receive identical exercise prescription for the first two months of the intervention, after which the HIE group will incorporate HIIT in their exercise regimen. The reason for this approach is to include a period of general conditioning and progressively increase intensity prior to submitting volunteers to HIE. This approach considers participant safety as arrhythmias may be uncovered during the first two months of MIE training. It will also improve participant compliance by increasing exercise self-efficacy and confidence prior to commencing HIIT.
45683365|NCT03335332|Behavioral|Moderate intensity exercise|A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded. The first few exercise training sessions in both exercise groups (MIE and HIE) will supervised at our hospital based fitness centre until the subject is confident to complete the training independently.
46035467|NCT02856165|Device|High-flow nasal canula oxygen therapy|High-flow nasal canula oxygen therapy (HNF) using Optiflow junior system and AIRVO2 turbine (F&P, NZ) at initial flow to 3l/kg/min (up to a maximum of 20l/min), FiO2 adjusted for SpO2 > 94%.
46035468|NCT02856165|Device|Low-flow oxygen therapy with standard nasal canula|flow adjusted to SpO2 > 94% (up to a maximum of 2l/min).
46035469|NCT02629315|Other|Carnoy's solution|
46035470|NCT02629315|Other|10% neutral buffered formaldehyde|
46035471|NCT04310046|Procedure|PCI before TAVI|TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with iwFR≤0.89 or >90% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.
46035472|NCT04310046|Procedure|PCI after TAVI|TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with iwFR≤0.89 or >90% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.
45340072|NCT04081844|Drug|HGP0904|Amlodipine 5mg(Norvasc)
45683366|NCT05047900|Diagnostic Test|Rapid antigen testing kit|COVID-19 Saliva Antigen Rapid Test Tigsun COVID-19 Speichel Antigen-Schnelltest
46035473|NCT02855853|Other|serious game et virtual reality|
46035474|NCT02855853|Other|Nintendo Wii|
45340073|NCT04081844|Drug|HGP0608|Losartan 100mg(Cozaar)
45340074|NCT04779242|Drug|Omadacycline|IV for injection, oral tablets
45683367|NCT05223868|Drug|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
45683368|NCT05223868|Drug|Placebo|Placebo tablet will be administered orally.
45683369|NCT01839188|Biological|PR5I|Hexavalent PR5I vaccine (DTaP-HB-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed [DTaP], Hepatitis B [HB; Recombinant DNA], Inactivated Poliovirus [IPV], and Haemophilus influenzae type b [Hib] conjugate vaccine [adsorbed]) at 0.5 mL for IM injection (left upper thigh) at 2 and 6 months of age.
46035475|NCT00676507|Biological|Lucanix™|Treatment Arm: Subjects receive Lucanix™ (belagenpumatucel-L) intradermally (ID) once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
46035476|NCT00676507|Other|Placebo Comparator|Control Arm: Subjects receive placebo ID once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
46035477|NCT02880150|Other|Stress test|
46035478|NCT04983186|Device|Wearable sensor and smartphone application|Empatica E4 wearable sensor and custom-made headache smartphone application
46035479|NCT01204658|Biological|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
45340075|NCT04779242|Drug|Moxifloxacin|IV solution, oral tablets
45340076|NCT00676689|Device|SAPIEN Transcatheter Valve Implantation|Device Implantation
45340077|NCT02589314|Device|Mechanical periodontal therapy|
45340078|NCT02589314|Procedure|nonsurgical periodontal therapy|
45340079|NCT04978844|Behavioral|IWOTCH|Arm 1
46035480|NCT01204658|Biological|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
46035481|NCT01204658|Biological|Synflorix|Intramuscular injection
45472931|NCT03125746|Drug|LXI-15029+Exemestane|The combined drug in the combined therapy period of this study (investigational product) is Exemestane tablet (specification 25 mg). Exemestane should be taken at similar time every day in case of multiple doses (Cycle 1 Day 1 to Cycl 1 Day 28). If one dose was missed (e.g., forgetting, vomiting, etc.), this dose could not be made up and should be administered at next scheduled time point. And the dose of LXI-15029 will be determinated by safety review committee after dose escalation
45472932|NCT03877601|Drug|Bevacizumab-IRDye800CW|Topical administration of Bevacizumab-IRDye800CW during the endoscopic procedure.
45472933|NCT03877601|Diagnostic Test|Fluorescence endoscopy|Device: Molecular Fluorescence Endoscopy platform A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope.
45472934|NCT03380338|Behavioral|Combined aerobic and strength exercise|
46035482|NCT01204658|Biological|Prevenar 13|Intramuscular injection
45340080|NCT04978844|Behavioral|Dyadic therapy|Arm 2
45472935|NCT03297216|Drug|17P|Synthetic progestin
46035483|NCT01204658|Biological|Infanrix Hexa (DTPa-HBV-IPV/Hib)|Intramuscular injection
45340081|NCT02587988|Drug|HCP1302|
45472936|NCT03297216|Other|Placebo|Non-active placebo comparator
45472937|NCT03388684|Procedure|Conjoined twin separation surgery|This study included 4 case reports on conjoined twins (CT), 2 male and three female patients; 3 of them were parasitic and one was conjoined. We operated upon 2 parasitic and one conjoined. The 1st case died preoperatively.
46035484|NCT00951483|Drug|Quetiapine-XR|Quetiapine-XR (Seroquel-XR) 50-300mg daily for 12 weeks.
45340082|NCT02587988|Drug|HGP0904|
45340083|NCT02587988|Drug|Placebo (for HCP1302)|
45340084|NCT02587988|Drug|Placebo (for HGP0904)|
45340085|NCT00678795|Drug|Sativex®|"Containing ∆9 tetrahydrocannabinol (THC), 27 mg/ml and cannabidiol (CBD), 25 mg/ml as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours"
45340086|NCT00678795|Drug|Placebo|containing excipients only. Subjects received study medication delivered in 100 µl actuations from a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations in 24 hours.
45340087|NCT04774952|Drug|RMC-5552|RMC-5552 for IV administration
46035485|NCT01104246|Drug|Testerone Transdermal System|Transdermal testosterone applied daily for 4 weeks
46035486|NCT00676741|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46035487|NCT00676741|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46035488|NCT00676741|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46035489|NCT01103778|Drug|Bortezomib (Velcade®)|Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).
45472938|NCT03908645|Device|Artificial intelligence assisted bowel preparation quality scoring system|After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. During the withdrawal process, bowel preparation quality is monitored by AI-associated scoring system. Whenever a sub-score below 2 points is detected, endoscopist will be alarmed up to three times to wash and suck the colonic contents. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
46035490|NCT02855619|Procedure|Martin|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to the higher resistance tolerated by the patient in a set of 6 breaths. Participant repeats 4 sets of 6-10 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2<150)."
46035491|NCT02855619|Procedure|Cader|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to 30% of the Maximal Inspiratory Pressure initially recorded the day of the inclusion. Participant breaths against this resistance during 5 minutes. The resistance is daily increased of 10 % to the higher tolerated.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2<150)."
45340088|NCT00678639|Other|Observation unit care, coupled with cardiac MRI|After Emergency Department (ED) evaluation, patients are randomized to Observation unit care or standard inpatient care. Patients in the observation unit will also undergo a stress cardiac MRI. Patients in the usual care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
45340089|NCT02587208|Device|Plastibell|In the Plastibell group, the size of the device is chosen according to the lateral-lateral diameter of the glans. A dorsal slit incision is made and then the foreskin is pulled up and the Plastibell device placed between the prepuce and the glans. A non-absorbable string was tightly tied around the device and the distal prepuce is removed.
45340090|NCT02587208|Procedure|conventional sleeve|In the sleeve dissection group, a double incision technique on both outer and inner layers of the foreskin is employed. Hemostasis is achieved by bipolar diathermy, and cut edges are sutured with 5/0 rapide vicryl.
45340091|NCT02559063|Behavioral|Vision-based speed of processing training|computerized cognitive tasks addressing vision-based speed of processing
45340092|NCT02559063|Behavioral|Mental leisure activities|computerized cognitive tasks addressing different aspects of executive function
45340093|NCT04836897|Device|PrizValve® valve and transapical delivery system|Transcatheter aortic valve replacement system
45472939|NCT03908645|Device|Conventional human scoring|After receiving standard bowel preparation regimen, patients go through conventional colonoscopy without the AI monitoring device. During the withdrawal process, after washing and sucking the colonic contents according to endoscopist's personal experience, bowel preparation quality is evaluated by human. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
45472940|NCT03125668|Behavioral|Educational Program|At the hospitalization, patients receive the educational program with Power Point®Slides, booklets and orientation about the use of warfarin.
45472941|NCT03125668|Behavioral|Telephone follow-up|"After hospital discharge they receive a telephone follow-up (five calls for six months: 1st call in one week and the others calls month by month until six months).~During the telephone calls the researcher talk with the patient about the topics that were approach in the educational intervention and motivate the patient to follow the recommendations for they have a successful treatment."
45472942|NCT03125668|Behavioral|Face to face counseling|They receive two face to face counseling (1st meeting in three months and the 2nd meeting in six months after hospital discharge). In the face to face counseling the researcher collect the data about anxiety and depression again, health-related quality of life and adverse events related to oral anticoagulation therapy.
45472943|NCT01165073|Dietary Supplement|Osmolite and B.C.A.A.|Feeding inserted into enteral tubes
46035492|NCT02855619|Procedure|EDRIC|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance at 30% of the Maximal Inspiratory Pressure of the day for the first set of 20 breaths with a resistance 's increasment of 10% at each set. Participant repeats 4 sets of 20 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2<150)."
46035493|NCT00673621|Drug|Technosphere Insulin Inhalation Powder|3.0 of human insulin. single dose cartridges filled with 5 or 10 mg of Technosphere Inhalation Powder, containing 15 or 30 u of insulin
46035494|NCT00673621|Drug|Salbutamol (Albuterol)|2 puff = 200 mcg total dose
46035495|NCT00673621|Drug|Methacholine chloride|5mls of methacholine; diluent sodium chloride 0.9%; formulation methacholine chloride in sodium chloride 0.9%
45340094|NCT04190342|Other|control group|A booklet on the self-management of cancer symptoms. After the pilot RCT is completed, if the participants allocated to the control group are interested in practising tai chi, the intervention will be provided
45340095|NCT04190342|Behavioral|tai chi group|Around 60 minutes practising easy tai chi movements/postures twice per week
45472944|NCT01165073|Dietary Supplement|Normal oral intake & supplementation if necessary|Enteral nutrition
45472945|NCT03872219|Combination Product|Nature-based materials|In the intervention arm, theycontain inactive and slowly-growing environmental bacteria and other microbiota. In the placebo arm, they do not contain the microbiota.
45472946|NCT05174104|Procedure|Vestibular Rehabilitation|The home exercise schedule consists of a patient-tailored association of adaptation (without and with the target moving on pitch and yaw planes for 1 min each three times per day), substitution, habituation, and balance and gait exercises. All the unilateral vestibular hypofunction patients will be followed in the clinic twice a week for 4 weeks for 30-45 min and evaluated for adherence. Between supervised sessions, patients will perform a twice-daily home exercise plan for a total of 30-40 min/day
46035496|NCT01103466|Device|Atlas|Altas base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
46035497|NCT01103466|Device|SenSura|SenSura base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
45472947|NCT01165151|Behavioral|behavioral weight loss program|weekly, group-based lifestyle weight loss program
46035498|NCT01103466|Device|Conform 2|Conform 2 base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
45472948|NCT03388528|Dietary Supplement|Low Residue Diet Intervention|All patients will be provided with a LRD plan (< 10g fibre per day) for 12 weeks between visits 2 and 3. They will also be supplemented with multivitamin and mineral tablet or liquid (Forceval) to meet nutrient requirements (prescribed as standard care). The dietitian will provide written and oral information about the LRD and weekly telephone calls to assess patient's progress on the diet.
45472949|NCT03260868|Drug|Insulin glargine, 300 units per milliliter (U/mL)|Self-administered subcutaneous injection using prefilled pen once daily for 24 weeks. Dose titration to achieve fasting self-monitoring of plasma glucose (SMPG) level between 80 and 130 milligram per deciliter (mg/dL).
45472950|NCT03260868|Drug|Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)|Subcutaneous injection.
45472951|NCT01165385|Drug|cisplatin|60, 75 or 100 mg/m2 , day 1 - 3 weekly
45472952|NCT01165385|Drug|Pazopanib|400 mg, 600 mg or 800 mg/day, daily
45472953|NCT03380260|Behavioral|Paranoia Induction|Behavioral procedure involving social exclusion and negative feedback to induce paranoia
45472954|NCT03380182|Other|Acupressure Band|These bands use pressure to stimulate the P6 acupuncture point.
45683370|NCT01839188|Biological|Pediacel®|Pentavalent Pediacel® vaccine (DTaP-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed [DTaP], Inactivated Poliovirus [IPV], and Haemophilus influenzae type b [Hib] conjugate vaccine [adsorbed]) at 0.5 mL for IM injection (left upper thigh) at 4 months of age.
45683371|NCT01839188|Biological|NeisVac-C®|Meningococcal group C (MCC) polysaccharide conjugate vaccine (adsorbed) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
46035499|NCT02627053|Drug|rivaroxaban|
46035500|NCT00945945|Drug|Duloxetine (DLX)|dose daily by mouth
46035501|NCT00945945|Drug|Placebo (PLA)|Placebo Comparator daily by mouth
46035502|NCT01203956|Device|SmartFlex|Device used with smartflex engaged.
46035503|NCT01203956|Device|Standard|
46035504|NCT04150627|Other|deep breathing|Deep breathing maneuver to increase parasympathetic nerve activity
46035505|NCT01103232|Procedure|Experimental group|Electrical muscle stimulation (EMS) of the right wrist flexor muscles was applied. EMS was applied for 20 minutes. Maximum current intensity tolerated was used so as to stimulate the highest possible number of motor unit. The stimulation intensity increased every five minutes during a session. Electrical stimulation was applied for thirty sessions (one session a day, five days a week for six weeks.)
46035506|NCT01103232|Procedure|Control group|Conventional mode of transcutaneous electrical nerve stimulation (TENS) was applied for the control subjects. TENS was applied for 20 minutes. The stimulus intensity was adjusted as the lowest current at which the subject felt only a slight tickling of the impulses. A visible, and palpable muscle contraction was not provided during TENS stimulation. The stimulus intensity was not changed during the first session. Subsequently, TENS was applied at same intensity in all sessions. TENS was applied for thirty sessions (one session a day, five days a week for six weeks).
45340096|NCT04772690|Other|A resource-oriented intervention|The intervention is delivered by an interdisciplinary team of occupational therapist, physiotherapist, nurse, psychologist, physician and social worker. It consists of a five-day residential stay at REHPA and a two-day follow-up stay after seven weeks at home. The residential stays include both workshops and engagement in physical and creative activities.
45340097|NCT03417687|Drug|129Xe MRI|Evaluation of pulmonary function
45340098|NCT03417687|Drug|133 Xe scintigraphy|Evaluation of pulmonary function
45340099|NCT04767698|Drug|Belimumab|200 mg SC weekly for 36 months
45340100|NCT04767698|Drug|Short-course Ocrelizumab|300 mg, two infusions two weeks apart and then 600 mg as a single infusion after six months (only one time) (total of two courses of treatment)
45340101|NCT04767698|Drug|Continued Ocrelizumab|300 mg, two infusions two weeks apart and then 600 mg as a single infusion every six months for a total of 36 months
45683372|NCT01839188|Biological|RotaTeq®|Human-bovine rotavirus reassortants (live) vaccine 2 mL oral administration at 2, 4 and 6 months of age. RotaTeq® administered prior to any other vaccine administration to avoid having the infant participants spit up the RotaTeq® when crying.
46035507|NCT02627287|Device|FlexPen®|For subcutaneously (s.c. under the skin) injection.
46035508|NCT02627287|Device|DV3316 pen-injector|For subcutaneously (s.c. under the skin) injection.
46035509|NCT02627287|Drug|placebo|For subcutaneously (s.c. under the skin) injection
46035510|NCT02853669|Procedure|Ultrasound-guided Lumber Plexus Block|(30 cc of 0.25% of bupivacaine, via a 22-gauge 2-inch Stimuplex A needle) with nerve stimulator confirmation. The type of motor response (e.g., quadriceps, patellar) and the minimum current needed were recorded. Ultrasound pictures (preinjection and postinjection) were obtained to verify proper local anesthetic placement.
46035511|NCT02853669|Procedure|adductor canal block|ultrasound-guided Adductor Canal Block (15 cc of 0.5% of bupivacaine)
46035512|NCT00673699|Procedure|Gastric mucosal biopsy|Using upper gastrointestinal endoscopy with targeting biopsy in patients with dyspepsia
46035513|NCT01112982|Other|Magnetic Resonance Imaging|An Magnetic Resonance Imaging (with and without gadolinium contrast) of index joint will be performed (T1, T2, and STIR images).
46035514|NCT01112982|Drug|Febuxostat|All subjects in the sub-study will be started on febuxostat 40mg daily at baseline. If their serum urate level is > 6.0 at months 1 or 3, then the febuxostat dose will be increased to 80mg daily.
46035515|NCT01112982|Drug|Colchicine|Colchicine will be dosed at 0.6mg by mouth BID for the first three months then 0.6mg daily from months 3 to 6, and then discontinued at month 6.
46035516|NCT01203878|Drug|Photodynamic therapy|Administered 4 weeks after completion of imiquimod therapy
45340102|NCT04785807|Other|Post traumatic, Anxiety and depression evaluation|Family member of person or trust of patient who had a limitation or discontinuation of treatments will be identified and asked to fulfilled a hospitalized anxiety and depression scale and the revised Impact Event scale 7 and 30 days after the limitation or discontinuation of treatments announcement
45340103|NCT04962776|Drug|Low-concentration carbohydrate and nitrates|Patients in the CHON group will be given 400 mL of a clear carbohydrate drink (12.5 g/100 mL maltodextrin, 50 kcal/100 mL) and 2 capsules of beet root extract 1 gm on the evening before surgery (8 hours) and another 200 mL of the carbohydrate drink and 1 capsule of beet root extract 1 gm on the day of surgery, 2 h before anesthesia induction.
45340104|NCT04962776|Drug|Low-concentration carbohydrate|Patients in the CHO group will be given the same carbohydrate drink in the CHON group with 2 placebo capsules with the evening drink and one with the morning drink.
45340105|NCT04962776|Other|Water with placebo capsules|Patients in the W group will be given equivalent volume of drinking water with placebo capsules by evening and in the morning of surgery.
45340106|NCT04707573|Drug|Vadadustat|oral capsules
46035517|NCT01203878|Drug|Imiquimod|Imiquimod 3.75% cream, up to 2 packets, applied topically daily for two 2-week cycles separated by a no-treatment interval of 2-weeks, followed observation
46035518|NCT02853825|Behavioral|Relationship Skill Enhancement|Receive relationship classes with access to parenting, employment services, and financial services.
46035519|NCT00676819|Drug|insulin aspart|
46035520|NCT00676819|Drug|human insulin|
46035521|NCT02851953|Device|Aqueduct-100|
46035522|NCT04151797|Other|Medication therapy management|"The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~Data collection on comorbidities, medication and laboratory results.~A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~A detailed feedback to the geriatrician.~A written report addressed to the attending physician"
46035523|NCT01112514|Drug|indocyanine green|Administered intravenously during endoscopic near-infrared (NIR) imaging
46035524|NCT02629003|Drug|[11C]Cimbi-36|
46035525|NCT02629003|Drug|[11C]Cimbi-36-5|
45472955|NCT03380182|Other|Sham Band|These sham bands are used to make it seem like the band is using pressure to stimulate the P6 acupuncture point.
46035526|NCT00625794|Drug|Nicotine nasal spray|8 weeks or counseling plus 6 weeks of nicotine nasal spray (2 sprays each nostril as needed).
46035527|NCT00625794|Behavioral|Smoking cessation counseling|8 weeks or counseling
45683373|NCT01839188|Biological|Prevenar 13®|Pneumococcal polysaccharide conjugate vaccine [PCV; 13-valent, adsorbed]) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
46035528|NCT02853981|Device|Harmonic scalpel|a method for liver parenchymal transection
46035529|NCT02853981|Device|Kelly clamp crush technique|a method for liver parenchymal transection
46035530|NCT00911911|Procedure|Blood sampling|Taken at different times : inclusion, at the cycle 4 and at the cycle 6 during the neoadjuvant chemotherapy
46035531|NCT00911911|Procedure|BIOPSY|Biopsy at the moment of inclusion, before neoadjuvant chemotherapy
46035532|NCT00911911|Procedure|SURGERY|Surgery after neoadjuvant chemotherapy
46035533|NCT01203098|Drug|DU-176b 15mg|DU-176b 15 mg tablets oral, once daily for 2 weeks initiated within 6 to 24 hours after surgery.
46035534|NCT01203098|Drug|DU-176b 30mg|DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery.
45340107|NCT02589080|Behavioral|Non-invasive sensory feedback|"A non-invasive simple sensory feedback system, which provides the user of a prosthetic hand with sensory feedback on the arm stump. It is mediated by air in a closed loop system connecting silicone pads on the prosthetic hand with pads on the amputation stump. The silicone pads in a tactile display on the amputation stump expand when their corresponding sensor-bulb in the prosthesis is touched, evoking an experience of real touch. Most amputees experience phantom limb sensations and/or phantom limb pain, as well as residual limb stump pain. There is often a map of the phantom hand on the amputation stump, where pressure on specific skin areas result in evoked sensation from specific fingers in the amputated phantom hand. This map is the target for the sensory feedback."
46035535|NCT01203098|Drug|Enoxaparin sodium 20 mg (=2000IU)|Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks initiated within 24 to 36 hours after surgery.
46035536|NCT05032794|Other|Unrestricted diet before colonoscopy|Free diet, without restrictions
46035537|NCT05032794|Other|1-day low residue diet|To follow a diet low in residues / fiber. the day before the colonoscopy.
45683374|NCT05223088|Drug|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 3-6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
45683375|NCT05223088|Drug|Apatinib Mesylate|Participants will receive apatinib, 250mg, qd，every 3 weeks for 2-5 weeks.
45683376|NCT05223088|Drug|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 3-6 weeks.
45683377|NCT05223088|Drug|Tegafur|Participants will receive Tegafur, day 1-14 of every 3 weeks for 3-6 weeks.
45683378|NCT01838876|Drug|Cariprazine|Cariprazine capsules 0.5 mg, 1.0 mg, and 1.5 mg; Cariprazine doses 1.5, 3.0, or 4.5 mg/day (d); patients will be titrated to a starting dose of 3.0 mg/d. Patients can stay on 3.0 mg/d or the dose can be adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability. Oral administration.
45683379|NCT01838876|Drug|Antidepressant Therapy (ADT)|ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its respective FDA approved package insert for each drug
45683380|NCT03279250|Drug|Abiraterone Acetate|Given PO
45683381|NCT03279250|Drug|Apalutamide|Given PO
45683382|NCT03279250|Biological|Gonadotropin-releasing Hormone Analog|Given IM
45683383|NCT03279250|Drug|Prednisone|Given PO
45683384|NCT03279250|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
46035538|NCT05032794|Drug|Bisacodyl 5 MG|If the participant is at risk of inadequate bowel cleansing, defined by a score of Dik et al ≥ 2 it will be given Bisacodyl 5 milgrams bid for 3 days.
46035539|NCT00676975|Drug|Traditional Chinese Medicine|"A herbal extract 17g once daily for 8 weeks for lower dosage, and 34g for higher dosage.~The 20-herb formulation are Agastache rugosa,Fraxinus rhynchophylla, Angelica dahurica,Glycyrrhiza uralensis, Artemisia capillaris, Magnolia officinalis, Atractylodes macrocephala,Paeonia lactiflora, Aucklandia lappa, Plantago asiatica,Bupleurum chinense, Phellodendron amurense, Citrus reticulate, Poria cocos, Codonopsis pilosula, Saposhnikovia diraricata, Coix lacryma-jobi, Schisandra chinensis, Coptis chinensis, Zingiber officinale"
46035540|NCT00676975|Drug|Traditional Chinese Medicine Placebo|Placebo once daily for 8 weeks
46035541|NCT00945555|Drug|Antibacterial agent for the treatment of febrile neutropenia|The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order
45472956|NCT03872141|Diagnostic Test|Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer|Quantitative measures that include additional aspects of peripheral neuropathy, such as pain, thermal allodynia, numbness and tingling are needed. We propose to evaluate several pharmacodynamics biomarkers in patients before and during chemotherapy: changes in nerve conduction velocity and amplitude, quantitative sensory testing (QST), computer based cognitive assessment, and rate of drop-out from treatment. The tests from this list that best correlate with decreased CIPN would be added to EORTC QLQ-CIPN20 scores and will provide an early indication of CIPN and/or CICI.
45683385|NCT01838642|Drug|Ponatinib|Ponatinib tablets will be administered orally, continually, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment will be administered primarily in an outpatient setting.
45683386|NCT05007418|Biological|STI-1492|Anti-CD38 A2 KOKI DAR T cells
45683387|NCT05240170|Device|RIRS|The standard RIRS will be performed using a disposable flexible ureteroscope. Holmium: YAG laser will be used for stone dusting and fragmentation. If indicated, JJ ureteral stent will be placed at the end of the procedure.
46035542|NCT04318184|Procedure|Aerobic exercise|The aerobic exercise protocol was performed 3 times a week for 3 months on the treadmill. Loading periods were performed according to the heart rate maximum using the Karvonen formula (%60-80 Heart rate maximum)
45839887|NCT04740138|Behavioral|Dialectical Behavioral Therapy Skills + Parent Training|"The DBT/Parent training group intervention is a novel integration of three evidence-based treatments (i.e. DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC)). The DBT Skills portion of each session follows the DBT Skills Training Manual Second Edition and DBT Skills Training Handouts and Worksheets Second Edition. DBT Skills portions cover the four modules of traditional DBT Skills: mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness.~PMT portions of the intervention cover: praise, positive interactions and parental attention, reward systems, effective commands, use of consequences, and problem solving. EC portions of the intervention cover: psychoeducation on children's emotional development, teaching children to identify and label emotions, validation of children's emotions, handling children's negative emotions, fostering children's positive emotions and parental modeling of emotion regulation and expression."
45683388|NCT05240170|Device|SWL|Patients who underwent SWL at our institution in the past five years. According to (a) the type of renal anomaly (rotation, position, or rotation/position anomaly), (b) the size of the stone (±5 mm), (c) location of the stone (lower polar or non-lower polar), and (d) density of the stone (>800 HU or ≤800 HU), matched cases will be selected for comparison.
45683389|NCT03269110|Diagnostic Test|SRS 2, CBCL, BRIEF-P|This study does not involve an intervention.
46035543|NCT00673777|Biological|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
46035544|NCT01108458|Drug|Pertuzumab|iv, 840 mg, 420 mg
46035545|NCT01108458|Drug|Erlotinib|PO, 150 mg
46035546|NCT00633646|Dietary Supplement|diets contained different levels of protein|diets contain protein in the range of 0.6-0.8 or 1.0-1.2 g/kg/d
46035547|NCT04318262|Biological|Determination of the clinical and biological characteristics|"clinical data: types of infections (skin and soft tissues, bone and joint, bacteraemia, endocarditis…), delay between clinical signs and hospitalization, number of days of fever, number of days of hospitalization, infectious complications…~biological data: Haemoglobin, Leucocytes, Neutrophils, Creatinine clearance, CRP…"
46035548|NCT04318262|Biological|Description of the antibiotic resistance profile|Determination of MICs of the major anti-staphylococcal antibiotics by the Sensititre technique
46035549|NCT04318262|Biological|Molecular epidemiology of S. lugdunensis infections|Genome sequencing (Illumina technique)
46035550|NCT00680485|Drug|GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg)|
46035551|NCT02851641|Procedure|"pushed mono-canaliculonasal intubation"|
46035552|NCT04242316|Behavioral|Mirror Therapy|Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks. The patients practiced the movements with the unaffected hand (including the shoulder, elbow, wrist, and hand). While watching the reflection of the unaffected hand in the mirror, the patient was then asked to moving the affected hand at the same time to synchronize the movement with the reflection of the unaffected hand. If the patient was unable to move the hand, a therapist would passively assist the movement of the affected hand so as to synchronize it with the reflection of the unaffected hand.
45839888|NCT04740684|Other|Standardized diet|Standardized diet is prepared in a commercial kitchen and packaged in single serve portions to provide to participants to consume for 7 days
46035553|NCT04242316|Behavioral|Bilateral arm training|Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks, but without a mirror. The patients can take a direct view of their paretic hand.
46035554|NCT00680563|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
45340108|NCT04082702|Behavioral|Faith-enhanced diabetes prevention program|The faith-enhanced curriculum was faith-based and developed using CBPR approaches. The Faith-DPP condition included delivery of the DPP. The group intervention was delivered by one to two trained peers from the church and consisted of 16 weekly group meetings followed by 6 bi-monthly or monthly maintenance sessions. The faith enhanced curriculum included five strategies: 1) a mini sermon (~15 min in length) delivered by a pastor (head pastors were required to deliver at least one per month), first lady, or church leader (pastor associate, deacon, elder, etc.), 2) a memory verse, 3) in class or take-home faith activity (application of faith principles), 4) promises to remember, and 5) scripture and prayer integrated into participant curriculum and facilitator materials. These five faith enhancements were developed by the CAB to enhance the DPP's weekly learning objectives, which resulted in faith components specifically linked to each week of DPP content.
46035555|NCT02887508|Behavioral|HINTS Intervention|HINTS is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on sexual risk reduction.
45340109|NCT04082702|Behavioral|Standard diabetes prevention program|The S-DPP condition was faith-placed, a secular program (the DPP) held at an faith-based organization. This condition received the same diabetes prevention program (DPP) as the Faith-DPP, but did not receive any faith enhancements or pastor involvement.
45340110|NCT03301311|Other|Specific Carbohydrate Diet (SCD)|Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.
45472957|NCT03384628|Device|First pair Senofilcon A contact lens|Fit assessment of the first pair contact lenses.
45839889|NCT04740372|Other|No intervention. Method study. Psychometric testing|Patients will fill in the questionnaire followed by an interview (phase IIIA) or a debriefing questionnaire (Phase IIIB)
45839890|NCT04739826|Drug|Flumatinib Mesylate|Flumatinib mesylate tablets 600mg qd
46035556|NCT02887508|Behavioral|Healthy Living Control|The Healthy Living Control is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on non-sexual health topics.
45340111|NCT03301311|Other|Modified Specific Carbohydrate Diet (MSCD)|Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.
45340112|NCT04082624|Behavioral|Nutrition condition|Received nutritional information in in-person PowerPoint presentations.
45340113|NCT04082624|Behavioral|Affective condition|Received information about affective benefits of less sitting in the workplace in in-person PowerPoint presentations.
45340114|NCT04082624|Behavioral|Instrumental condition|Received information about instrumental benefits of less sitting in the workplace in in-person PowerPoint presentations.
45340115|NCT04082624|Behavioral|Self-regulation condition|Learned how to self-regulate behavior to sit less in the workplace in in-person PowerPoint presentations.
46035557|NCT02851719|Other|PFMT with biofeedback + Home PFMT|24 outpatient sessions PFMT with biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
45472958|NCT03384628|Device|Second pair Senofilcon A contact lens|Fit assessment of the second pair of contact lenses.
45472959|NCT03384628|Device|Third pair Senofilcon A contact lens|Fit assessment of the third pair of contact lenses.
45839891|NCT04739826|Drug|Nilotinib Pill|Nilotinib Capsules 300mg bid
46035558|NCT02851719|Other|PFMT without biofeedback + Home PFMT|24 outpatient sessions PFMT without biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
46035559|NCT01108068|Drug|Lithium|lithium will be given for 6 months to patients with OPPG, starting at a low dose of 2.5 mg/kg daily, gradually increasing until a lithium blood level of 0.3-0.6 ng/dl is achieved.
46035560|NCT02851875|Other|Registry|
46035561|NCT00680641|Drug|Simvastatin|40mg of Simvastatin once daily
46035562|NCT00680641|Drug|Placebo|40mg of placebo once daily
46035563|NCT01201850|Drug|Bevacizumab (Avastin®)|Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses. An MRI will be done after the first cycle (3 doses/ 6weeks) and then again at the end of therapy.
46035564|NCT05660122|Drug|Fexuprazan Hydrochloride|Fexuclue Tablet 40mg
46035565|NCT04980144|Drug|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
45839892|NCT04739904|Other|Normoxia|48 hours experimental protocol conducted at sea level
46035566|NCT04980144|Drug|0.1% hyaluronate|0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
46035567|NCT00951171|Procedure|Intrauterine Insemination|The intervention arm will undergo temporary (15 minutes) cervical occlusion with the eliptosphere intracervical catheter. This catheter is typically used to perform saline infusion ultrasounds to image the uterine cavity in our practice.
46035568|NCT00951171|Procedure|IUI with the standard inseminator|The control arm will undergo insemination with the standard inseminator (TOmcat catheter).
45340116|NCT04049253|Drug|Phosphate Buffer Solution|Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
45340117|NCT00919958|Biological|PLX-PAD IM injection|Single treatment; multiple injections
46035569|NCT00677131|Other|Reading the package insert of the drug|package insert of the drug
45340118|NCT03217851|Diagnostic Test|Blood Collection|blood smear and/or rapid diagnostic
45340119|NCT03217851|Diagnostic Test|Dried Blood Spot|Dried Blood Spot on filter paper
45340120|NCT04082000|Drug|BOL-DP-o-04|BOL-DP-o-04
45839893|NCT04739904|Other|Normobaric hypoxia|24 hours experimental protocol conducted in a normobaric hypoxic facility
45839894|NCT04739904|Other|Hypobaric hypoxia|72 hours experimental protocol conducted at terrestrial altitude
45839895|NCT04739748|Diagnostic Test|complete blood picture|Measure the red blood cell distribution width (RDW), the neutrophil-lymphocyte ratio (NLR).
46035570|NCT00677131|Other|Reading the education information provided by the Pharmacy of NTUH|education information
46035571|NCT00677131|Other|Oral education provided by the pharmacist|Oral education provided by the pharmacist
46035572|NCT02825056|Drug|Bupivacaine|Intrathecal local anesthetic drug,Bupivacaine will be delivered in L3-L4 space.
46035573|NCT02825056|Drug|Bupivacaine + Morphine|Intrathecal local anesthetic drug,Bupivacaine and Morphine will be delivered in L3-L4 space.
46035574|NCT02628691|Other|Liver fibrosis progression|A history taking and physical examination focused on hepatic disease and blood sampling for basic hematologic and hepatic function parameters will be performed. Patients will also be referred every year for ultrasound and transient elastography measurements and sampling for some additional liver function tests and measurement of HCV-RNA viral load.
46035575|NCT02826772|Drug|GT0918|anti-tumor activity
45472960|NCT03293394|Device|Anodal bilateral motor cortex and cathodal spinal tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
46035576|NCT00677209|Biological|Injection of autovaccine (Autovaccine Symbiopharm)|increasing dosage schedule, six different concentrations, application over six weeks, 2 weeks break, another six weeks, 2 weeks break, than challenge with inhalative house dust mite extract
46035577|NCT05398640|Biological|Lifileucel|A portion of the patient's tumor is resected and serves as the starting material for manufacturing lifileucel. After preparative NMA-LD, patients are infused with their autologous TIL (lifileucel), followed by a short course of high-dose IL-2.
46035578|NCT02824744|Device|treatment by 2l/min/kg in High Flow Nasal cannula (HFNC)|
45683390|NCT01611194|Drug|Hyperbaric oxygen (HBO2) at 1.5 atms|The Hyperbaric oxygen (HBO2) at 1.5 atms (active) group (hyperbaric oxygen-chamber compressed to 1.5 atm abs and breathing 100% oxygen). Each participant should complete 40 sessions over the course of 12 weeks, one session per day, five per week.
45472961|NCT03293394|Device|Sham bilateral motor cortex and sham spinal tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
45472962|NCT01267487|Drug|Heparin fixed doses|"Fixed doses of 400 units/ kg of patient's body weight before CPB to achieve an ACT > 480 sec. Supplemental doses of 50mg of heparin if ACT <480 sec during CPB.~Reversal doses of protamine in a 1:1 ratio (1mg of protamine for every mg of heparin administered), plus 0.8mg/kg of protamine at the end of the surgery."
45472963|NCT01267487|Drug|PO continuous infusion of Protamine|25mg/hour in IV continuous infusion during first 6 PO hours
45683391|NCT01611194|Drug|Sham control 1.2 atms|The chamber will be compressed with air to 1.2 atm abs to simulate the active group. Participants will don a hood and breathe 21% oxygen (room air). Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
46035579|NCT02824744|Device|treatment by 3l/min/kg in High Flow Nasal cannula (HFNC)|
46035580|NCT00674011|Drug|Bevacizumab|Given as part of standard of care or another research protocol
46035581|NCT02824900|Device|Vibration stimuli to neck muscles|
46035582|NCT02824900|Device|Vibration stimuli to hand|
46035583|NCT02824900|Behavioral|conventional physiotherapy|
46035584|NCT00674089|Dietary Supplement|Vitamin A|Vitamin A 50,000 IU
46035585|NCT00674089|Dietary Supplement|Placebo|Vitamin A Placebo
46035586|NCT01200992|Biological|EN3348|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
45340121|NCT04082000|Drug|Placebo|Placebo
46035587|NCT01200992|Biological|Mitomycin C|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
46035588|NCT02824666|Drug|ATI-9242|"Formulated ATI-9242 will be administered as an IV bolus injection (2mg/mL of ATI-9242 in 40% solution of propylene glycol).~Two doses will be tested: single IV bolus injection of 0.5mg/kg and single IV bolus injection 1.0 mg/kg. In the event that a third cohort is needed the IV bolus injection would be 2.0 mg/kg"
46035589|NCT02824666|Radiation|[18F]Fallypride Imaging|Subjects will be injected with approximately 250 MBq or 6.75 mCi of [18F]Fallypride [5-6 mCi being the typical range of injected dose].
45340122|NCT04610853|Diagnostic Test|rotational thromboelastometry|ROTEM will be conducted and DIC score calculated within 24 hours after the diagnosis of Sepsis as well as on day 3 and 5 of ICU stay
45340123|NCT03205137|Drug|subjects treated with telmisartan/hydrochlorothiazide|subjects treated with telmisartan/hydrochlorothiazide
45340124|NCT03205137|Drug|Subjects treated with Telmisartan and amlodipine|Subjects treated with Telmisartan and amlodipine
45340125|NCT03205137|Drug|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
45340126|NCT03205137|Drug|subjects treated with telmisartan+amlodipine double pill|subjects treated with telmisartan+amlodipine double pill
45683392|NCT05003440|Drug|NNC0385-0434|Participants will get 1 tablet (oral use) of NNC0385-0434 per day for 10 days in either 15, 40 or 100 mg
45683393|NCT05003440|Drug|Placebo|Participants will get 1 tablet (oral use) of placebo per day for 10 days
46035590|NCT00674167|Drug|Docetaxel|Three cycles of chemotherapy will be administered before surgery with docetaxel at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
45340127|NCT04953650|Behavioral|Intermittent fasting|The intervention group is required to perform intermittent fasting for two days. The intermittent fasting method for this group will mimic the Sunnah Muslim fasting; they are allowed to consume food and calorie water without restriction in between dusk and dawn. During the five ad libitum days, they are allowed to have a variety of foods and drinks. Subjects will be informed about healthy food choices; choosing low-fat meat and dairy options, increasing fruit and vegetable intake.
46035591|NCT00674167|Drug|Cisplatin|Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
45340128|NCT04953650|Other|No intervention|The control group will receive education training at the baseline as well, regarding blood pressure and nutrition. They will have usual exercise prior to the intervention. Furthermore, the group will have equal health education through health promotion leaflets which have been issued by the ministry of health.
45340129|NCT05189522|Device|Innova Breeze®-based roadmap|An Innova Breeze® bolus chase acquisition is realized to assess the final result of the Revascularization of the target limb. Both Innova Breeze® bolus chases are required at field of view 30-cm
45472964|NCT01267487|Drug|Heparin and protamine titration|"Titrated doses of heparin during CPB were manually calculated using Bull´s dose-response curve, which was based in periodic assessment of Activated-Coagulation Times (ACT)- baseline ACT, after 2mg/kg of heparin at cannulation and every 15 to 30 minutes during CPB.~Reversal doses of protamine were calculated as a 1:1 ratio of the actual estimated heparin concentration (in mg/kg) at the end of CPB, using the Bull´s dose response curve."
45683394|NCT05181046|Device|Nanodropper adaptor|The Nanodropper adaptor is a sterile medical device that reduces the size of administered eyedrops by coupling to the original bottle.
45683395|NCT05181046|Other|Original eyedrop bottle/No Nanodropper|The original eyedrop bottle dispenses standard eyedrops.
45683396|NCT05505448|Drug|REGN14284|Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
46035592|NCT00674167|Drug|Capecitabine|Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycle.
46035593|NCT02824588|Behavioral|Working Memory Training|Training mental flexibility
46035594|NCT02824588|Behavioral|Internet use|Used as control for time spent on computer
46035595|NCT00680719|Behavioral|IBFT /HIV prevention|Integrated Behavioral and Family Therapy (IBGT) with HIV prevention.
45340130|NCT05189522|Other|Control Group|"2D roadmap guidance is used based on DSA. The treatment of the target lesion is let at the physician discretion. Treatment result of each lesion is checked by a DSA with 1 incidence.~After treatment overall limb assessment will be done through multiple staged DSA.~Finally, the sheath is retrieved and the hemostasis at the puncture site is realized via a manual compression or using a vascular closure device.~DSAs are performed with the injector set at 7mL/s and the volume at 7mL (pressure limit 1000psi) for femoropopliteal assessment. An injector with iodinated contrast (50% of dilution) will be used.~For hospitalized patients, three to five days after the procedure, a blood test is performed to assess the eGFR, as part of the usual care of patients. If the patient is no longer hospitalized, at the time of this examination, the investigating physician has given him an order before his discharge to perform this examination in an analysis laboratory."
46035596|NCT00680719|Behavioral|IBFT|Integrated Behavioral and Family Therapy (IBFT).
45340131|NCT02588144|Procedure|[standard STN]|High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
45340132|NCT02588144|Procedure|[STN+SNr]|high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
45340133|NCT02586740|Procedure|Pulmonary artery rehabilitation|
45340134|NCT04951544|Other|LetSync v1.0|Study B will entail a pilot randomized, controlled trial (RCT) of an mHealth behavioral intervention, LetSync, with 80 couples (N=160) to assess its acceptability, feasibility, and preliminary impact on retention in care and ART adherence as measured by antiretroviral concentrations in hair. Participants in the intervention arm will use LetSync v1.0 for 6 months and provide acceptability and feasibility data. Participants will then continue to use LetSync v1.0 while the Waitlist-Control group begins to use LetSync v2.0.
45340135|NCT04951544|Other|LetSync v2.0|LetSync v2.0 will be developed by taking feedback from participants regarding LetSync v1.0. Participants in the waitlist-control group will be given LetSync v2.0 to use during the last 6 months of the trial.
45340136|NCT02589236|Drug|Cavosonstat|GSNOR inhibitor
45340137|NCT02589236|Drug|Placebo|Control sample with only capsule excipients and fillers
45472965|NCT05173948|Other|Kinesio taping|Kinesio taping: The tape is measured from the sacrum to the 12th thoracic vertebra with forwarding flexion of the trunk. The base is affixed to the insertion in the resting position. The muscle is elongated and the base anchored with skin displacement. The tape is then affixed with 10% stretch paravertebrally over the muscle bundles up to T12. The tape is rubbed with the muscle in the elongated state.
45472966|NCT05173948|Device|Conventional physical therapy|Transcutaneous electrical nerve stimulation device settings, such as the frequency of 80 Hz, the pulse width of 100 µs, and symmetrical biphasic waveform. Four mediums sized (2 × 2 cm) carbon-impregnated rubber cutaneous electrodes were placed bilaterally in a standard dermatomal pattern over the most painful lumbar region. The current intensity was increased up to the patient's perception of paraesthesia. The supervised exercise therapy management consisted of stretching exercises for the back, iliopsoas, gluteal and hamstring muscles, and strengthening exercises for the abdominal and back muscles. Three sets of stretching exercises, each involving a 30-sec hold and 30-sec of rest repeated three times, were performed in three sessions per week over four weeks. One set of strengthening exercises, consisting of 10 repetitions with a 5-sec hold, was performed in three sessions per week over four weeks.
46035597|NCT04150471|Other|RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis|Conventional Q-RT-PCR every 3 months
46035598|NCT00912145|Drug|Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)|
46035599|NCT00680875|Behavioral|Click City|School-based intranet delivery of tobacco use prevention program for 5th and 6th graders using interactive and engaging game-like multi-media technology.
46035600|NCT04243252|Behavioral|Healthy Pantry Program|Food pantries will receive the Healthy Pantry Program online training, which will be completed by at least one pantry staff member and teaches pantry staff a novel traffic-light nutrition labeling system, a multilingual healthy recipe database, and how to use those and other behavioral economic strategies to implement simple interventions in the food pantry to promote client selection of healthier options. Onsite support by a registered dietitian is included.
46035601|NCT04243252|Other|Waitlist Control|Normal food pantry use for duration of the 9-month study period. Control pantries will have access to the Healthy Pantry Program after study is completed.
46035602|NCT04242004|Drug|Docosahexaenoic acid (DHA) capsules|Treatment was provided as 7 omega-3 fatty acid (Lovaza) capsules daily. Each capsule contained 1 g of omega-3 fatty acids with approximately 450 mg of docosahexaenoic acid (DHA).
45340138|NCT04082312|Other|No intervention|No intervention
45340139|NCT04082468|Diagnostic Test|Blood sample collection for coagulation profile|Factor VIII Activity Level, Factor VIII Antigen Level, Interleukin 6, vWF Antigen Level, Thrombin Activity, Protein C Activity, Protein C Antigen Level, CRP, PT/PTT/INR ,T & B lymphocyte panel at above time points
45340140|NCT04739072|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
46035603|NCT04242004|Dietary Supplement|Soy oil capsules|The placebo was identical looking capsules that contained soy oil
46035604|NCT04150237|Other|Simulation training in gastroscopy|Simulation-based training with virtual reality simulation at a Simbionix GI-mentor II endoscopy simulator and procedure training on a phantom.
46035605|NCT02824510|Other|Algorithmic changes in insulin therapy.|Based on SG evolution in first treadmill test, algorithms will evaluate the modifications in insulin therapy required to normalize SG during the second treadmill test.
46035606|NCT02824510|Other|Treadmill exercises|25 min treadmill exercise at 60% of maximal heart rate estimated for age
45340141|NCT04739072|Other|Electronic Health Record Review|Review of medical records
45340142|NCT00920036|Device|StressEraser|A hand-held biofeedback device that facilitates resonant frequency of respiration
45340143|NCT04684550|Drug|Stabilized hypochlorous acid|Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
45340144|NCT04684550|Drug|Placebo|Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
45340145|NCT00678561|Drug|CP-690,550|Topical treatment once daily for 28 days
45340146|NCT00678561|Drug|CP-690,550|Topical treatment once daily for 28 days
45340147|NCT00678561|Drug|CP-690,550|Topical treatment once daily for 28 days
46035607|NCT02824510|Drug|Insulin aspart, glargine and detemir|
46035608|NCT00674245|Drug|Pantoprazole|40 mg once daily for 4 weeks
46035609|NCT00674245|Drug|Pantoprazole|40 mg once daily improves sleep quality in patients with GERD.
46035610|NCT00674245|Drug|placebo|40 mg once daily for 4 weeks
46035611|NCT04194190|Drug|Individual Patient TCR-Transduced PBL|
45340148|NCT00678561|Drug|CP-690,550|Topical treatment twice daily for 28 days
45683397|NCT05505448|Drug|Matching Placebo|Single ascending IV or SC administration per the protocol
46035612|NCT04242082|Diagnostic Test|GLUT 1 gene expression|"GLUT 1 gene expression will done on blood samples taken from three groups using real time PCR.~Pigment epithelium derived factor will used on keratinocytes cell line and compare GLUT 1 gene expression before and after treatment."
45340149|NCT00678561|Drug|CP-690,550|Topical treatment twice daily for 28 days
45683398|NCT01813058|Drug|Tranexamic Acid|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to either:~placebo i.e. saline 0.9% (intravenous injection)~intravenous TXA given as a loading dose over 15 minutes of 50 mg/kg bolus ( within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery."
45683399|NCT01813058|Drug|Placebo|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to:~Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery or~TXA as previously described."
45683400|NCT05163262|Other|sexuality questionnaire|Questionnaire evaluating the sexuality of head trauma victims by comparing their sexual focus, the quality of their relationship, their self-esteem, their mood before the trauma to their current situation
45683401|NCT01867424|Drug|Eovist|0.1 ml/kg Eovist will be administered intravenous (IV) to each patient
45683402|NCT04986514|Other|Bio-banking without genetic analysis|For patients included in SCLERO-BIOBANK study, 2 blood samples will be collected at each SSc evaluation (usually once a year), in addition to the routine care blood collection.
45839896|NCT04739202|Drug|Atezolizumab + Ipatasertib|Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Ipatasertib PO (400 mg per day continuously, starting on cycle 1 day 1). Treatment given until disease progression or unacceptable toxicity.
46035613|NCT00878215|Device|Explorer Liver Image Guided System|
46035614|NCT00878215|Device|Explorer Liver Passive Tracking|
46035615|NCT00878215|Procedure|Liver surgery|-Standard of care
45340150|NCT00678561|Drug|CP-690,550|Topical treatment twice daily for 28 days
45340151|NCT00678561|Drug|Placebo Vehicle|Topical treatment once daily for 28 days
45340152|NCT00678561|Drug|Placebo Vehicle|Topical treatment twice daily for 28 days
45340153|NCT05613296|Drug|Fostamatinib|Patients with Chronic ITP, refractory to other treatment who received at least one dose of Fostamatinib outside clinical trials in Italy will be enrolled and observed for at least 6 months.
46035616|NCT00878215|Procedure|Liver abalation|-Standard of care
46035617|NCT04243018|Behavioral|Acceptance and Commitment Therapy Group Treatment|The intervention presents, a mixture of instruction, discussion, and the use of metaphor and experiential activities designed to sensitise participants to the effects of self-stigma and shame on how they live their lives. This training condition provides instruction and experiences that train participants to notice, and then to override, the very human tendency to categorise and then avoid aversive thoughts and feelings and the people and situations that evoke them. The acceptance and commitment training condition will cover the following topics: (a) introduction to enacted and self-stigma (b) cognitive defusion/behavioural flexibility (c) acceptance vs. avoidance and control of emotions and thoughts and (d) values and committed action.
46035618|NCT04243018|Behavioral|Peer Support Group|The peer support group will allow participants to share and discuss experiences related to their experiences of homelessness, shame and stigma. The group will be facilitated by an expert in facilitating peer support groups with marginalised populations.
46035619|NCT02628847|Drug|sildenafil citrate|
45683403|NCT04601480|Behavioral|Choice Architecture Nudge|During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient will a current opioid prescription. The alerts prompt PCPs to consider tapering the patient's opioid. The alert also displays the MME of the patient's current opioid prescription and automatically calculates what a 10% reduction in MME relative to the current prescription would be. The alert contains options to either cancel the refill order, or to continue with the order.
46035620|NCT02628847|Drug|Placebo|
46035621|NCT04241770|Other|no intervention|no intervention
45340154|NCT04081532|Procedure|surgical removal of superficial peritoneal endometriosis|In the active comparator group patients will have endometriosis lesions removed by ablation or excision. Patients randomised to no surgical treatment arm will not have lesions removed and will only be given diagnosis on whether endometriosis was found or not.
46035622|NCT00677287|Biological|RNF43, TOMM34, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, RNF43 peptide (1mg), TOMM34 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
46035623|NCT05660902|Other|ROM Exercises|The patients were evaluated by the physician, they were put into practice when their condition was stable within the first 72 hours. In addition to their routine treatments, according to the ROM exercise protocol, which was created by taking expert opinions and reviewing the literature ROM exercises were performed by the researcher and health personnel trained by the researcher 3 times a day for 2 weeks, approximately 30 minutes. The movements were started with the upper extremity on the unaffected side and then moved to the affected upper extremity. After the exercise applied to the affected upper extremity was finished, the same exercise was applied to the intact lower extremity and the affected lower extremity. Only the resistance points were mobilized and the exercise applied in each joint was repeated at least three times without applying extra force.
45340155|NCT04732286|Drug|Atezolizumab|Atezolizumab will be administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.
45340156|NCT04732286|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
45683404|NCT04601480|Behavioral|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration & nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
46035624|NCT00674401|Procedure|Radiofrequency catheter ablation|"In case of Paroxysmal AF, patients will be randomized into one of 2 in the study:~Empirical pulmonary vein antrum circumferential isolation, or~High frequency sites ablation in the LA~In case of Persistent AF, patients will be randomized into one of 2 in the study:~Empirical circumferential PV antrum isolation w/out roof line, or~A combined approach involving PV antrum isolation w/out roof line and high frequency sites ablation."
45340157|NCT04731350|Device|radial extracorporeal shock wave|Radial shock wave device, Swiss DolorClast (EMS Electro Medical Systems, Nyon, Switzerland)
45340158|NCT04731350|Device|iontophoresis|Iontophoretic drug delivery system (phoresors II auto model PM850 IOMED):
45340159|NCT04731350|Other|Exercise|strengthening exercise
45472967|NCT01267565|Other|dosage of amylase|4 sets of aspirations on one day per inclusion in the intubated and ventilated patients group and 1 set of aspiration in the non intubated patients group
45839897|NCT04739202|Drug|Atezolizumab + Bevacizumab|Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Bevacizumab IV (15 mg/kg on day 1 of each 21-day cycle). Treatment given until disease progression or unacceptable toxicity.
45472968|NCT03380104|Device|Intradural Spinal Cord Stimulation|The device will be placed percutaneously at the lumbar spine at L2-3 or L3-4 level into the intrathecal CSF space and advanced to the T8-10 disc space. After positioning of the intrathecal lead, the stimulation catheter will be run through a standardized experimental algorithm consisting on various frequencies.
46035625|NCT02824120|Other|Comedy|patients will watch comedy film
46035626|NCT02824120|Other|Documentary|patients will watch a documentary film
45340160|NCT04081766|Behavioral|SUGAR Handshake|"An interactive patient counselling session delivered by a pharmacist which mainly focuses on medication-related instructions towards preventing hypoglycaemia in addition to recommendations about hypoglycemia early recognition, causes, and treatment. The SUGAR Handshake is individualised according to shared decision making and each participant's characteristics.~Components of the SUGAR Handshake intervention will be covered under five main domains:~Signs and symptoms of hypoglycemia.~Understanding the underlying causes of hypoglycaemia such as misuse of anti-diabetic medications.~Good glycaemic control and self-monitoring, which mainly includes instructions on handling the anti-diabetic medications.~Acknowledgement by the patient~Recap and summary~The pictogram contains the main recommendations for easy recall by the participant. Moreover, the intervention will be reinforced by a phone call at week 6 of the inclusion visit."
45340161|NCT04950686|Behavioral|Media Aware for Young Adults|Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults that uses a media literacy education (MLE) approach.
46035627|NCT00677443|Drug|S-1 & Oxaliplatin|S-1 and Oxaliplatin : S-1 80 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
46035628|NCT00677443|Drug|Capecitabine & Oxaliplatin|COX : Capecitabine 1000 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
45683405|NCT05491330|Drug|Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
45683406|NCT05491330|Drug|Nirmatrelvir 150 mg + Ritonavir 100 mg (test)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
45683407|NCT05491330|Drug|Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
46035629|NCT04913584|Behavioral|Cognitive Behavioural Therapy|Cognitive Behavioral Therapy 9 weekly 2-hour online group CBT sessions delivered by trained lay peers.
46035630|NCT00674557|Drug|SOD1 inhibitor ATN-224|
46035631|NCT00674557|Drug|exemestane|
46035632|NCT00674557|Genetic|protein expression analysis|
46035633|NCT00674557|Genetic|proteomic profiling|
46035634|NCT00674557|Other|laboratory biomarker analysis|
46035635|NCT00674557|Other|pharmacological study|
46035636|NCT04259242|Procedure|SRP|scaling and root planing with ultrasonic scaler and manual instruments
45340162|NCT04950686|Behavioral|Health Aware for Young Adults|Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults.
45472969|NCT03380104|Behavioral|Administration of Questionnaires|Subjects will be administered questionnaires to evaluate pain, quality of life, and global function prior the study, at 1 hour after the completion of the study, and at 4 day follow-up appointment.
45683408|NCT04601402|Drug|GEN-001|The capsules taken by mouth once a daily. Each capsule will contain ≥ 1x10^11 colony-forming units (CFU)
46035637|NCT04150003|Behavioral|Pulmonary Rehabilitation program|Structured rehabilitation program of directed exercises
45340163|NCT02587832|Device|HHHFNC|Tri-Anim Vaptherm the Precision Flow, which is a self contained unit that provides flow rates up to or 8 LPM (Infants) of blended oxygen that is heated and humidified
45340164|NCT02587832|Device|NCPAP|Bubble CPAP System.
46035638|NCT04150003|Other|Usual care|Usual care for patients who had suffered a Pulmonary Embolism
45472970|NCT01267643|Drug|Alefacept|"Dose Escalation Schedule~Level -1 5 mg IV once weekly~Level 1 7.5 mg IV once weekly~Level 2 10 mg IV once weekly~Level 3 12.5 mg IV once weekly"
45472971|NCT03620604|Device|Stress urinary incontinence surgery|All patients were treated according to the Urology protocols of our unit. They were patients with stress urinary incontinence refractory to pelvic floor exercises so they underwent surgery
45472972|NCT03388450|Drug|Omega 3|Enteral 1000 mg omega 3 fatty acid.
45472973|NCT03388450|Drug|Placebo|Enteral nutrition without omega 3 fatty acid.
45683409|NCT04601402|Drug|Avelumab|800 mg given by intravenous (IV) infusion once every 2 weeks
45839898|NCT04739514|Other|Exercises for dysphagia rehabilitation|Diet modifications, postural exercises, compensatory exercises, swallowing exercises
45340166|NCT04939142|Combination Product|SVd (Selinexor+Bortezomib+dexamethasone)|Randomized into two treatment Arms in a 2:1 allocation (SVd Arm or Vd Arm): (1) SVd Arm (~100): ATG-010 + (Once a week, QW) + bortezomib (QW) + dexamethasone (BIW)
45340167|NCT04939142|Combination Product|Vd (Bortezomib+dexamethasone)|Vd Arm (~50): Bortezomib (Cycles 1-8 [BIW], Cycles ≥ 9 [QW]) + dexamethasone (Cycles 1-8 [Four times a week], Cycles ≥ 9 [BIW])
45340168|NCT05683340|Drug|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 12 weeks
45472974|NCT03874481|Other|Observation|follow up regularly for MACE
45472975|NCT05173402|Device|dentoalveolar compensation method|orthopedic treatment was performed using the dentoalveolar compensation method with permanent apparatus with a palatal expanding screw
45472976|NCT05173402|Device|face mask|orthopedic treatment was performed using a face mask.
46035639|NCT05660824|Device|Stromal Vascular Fraction infiltration|Procedure to prepare SVF: In the operations room and after aseptic technic, local anesthesia is applied in the liposuction incision site with lidocaine 1% without epinephrine subcutaneously. 60 ml of tumescent solution are injected. After 15-20 minutes waiting, 15 ml of lipoaspiration per side are recollected into a double syringe. This is centrifuged for 4 minutes at 2.500 rpm and the remaining fat is separated from the other fractions. Two 1.4 mm GEMS syringes are attached together, and fat is transferred at least 30 times from one syringe to the other. Syringe content is again centrifugated for 4 minutes. The oil is discarded and approximately 1.5ml SVF fraction remains.
46035640|NCT05660824|Procedure|Plattelet Rich Plasma infiltration|Procedure to prepare PRP: 15 cm of peripheral blood obtained by venipuncture are centrifugated at 5000 RPM during 5 minutes. Using PRP Arthrex kit platelets poor plasma is discarded and 1-3 mm of PRP are ready to be injected
46035641|NCT04150159|Dietary Supplement|FMD Arm|ProLon Fasting Mimicking Diet Plan
45472977|NCT01269827|Drug|Pentoxifylline|Over a period of 4 months, patients of the study group received one PTX tablet (400 mg) orally once a day (at dinner time)
45683410|NCT04601168|Device|kneeSOFT100|During the first two weeks of follow-up, the subject shall not use the device during the sports sessions. The subject shall use the device during the sports sessions for the next 4 weeks (6 weeks of follow-up)
46035642|NCT00677521|Drug|Acarbose|50mg tablet by mouth daily for the first 2 weeks, then twice a day for the next 2 weeks, and then three times a day for the next 8 weeks for a total of 12 weeks.
46035643|NCT00677599|Dietary Supplement|Flavonoid enrichment (cocoa / soy compounds)|Flavonoid compounds from cocoa (including epicatechin) and soy to be consumed for 365days in the experimental intervention (versus placebo consumption). 27g chocolate bar the vehicle for flavonoid enrichment.
46035644|NCT00677599|Dietary Supplement|Flavonoid enrichment (cocoa / soy compounds)|27g placebo chocolate bar to be consumed for 365 days.
45340169|NCT05683340|Drug|Placebo|placebo, tablet, once daily, for 12 weeks
45683411|NCT05160766|Biological|Comirnaty(BTN162b2)|Single booster shot (4th dose) of already approved BioNTech/ Pfizer vaccine that protect against COVID-19 infection
45340170|NCT04931420|Drug|Standard of Care Chemotherapy|"If you have cancer of the stomach or food pipe (esophagus): the preferred chemotherapy regimen includes two or three medications. These drugs include Cisplatin or Oxaliplatin and 5-fluorouracil (5 FU) in combination with Docetaxel.~If you have cancer of the pancreas or ampulla: the preferred chemotherapy medicines include Gemcitabine or a three-drug combination chemotherapy called FOLFIRINOX, which includes 5FU, Leucovorin, Irinotecan, and Oxaliplatin.~If you have bile duct cancers: a combination of Gemcitabine, platinum agents, or fluoropyrimidine will be considered."
46035645|NCT02826304|Procedure|Vaginal hysterectomy|"All the cases were performed by the same surgical team~Incision is made at the anterior cervical lip below the bladder reflection~Anterior peritoneal entry .~Douglas pouch entry.~The uterosacral ligaments and the cardinal ligaments are clamped, divided and ligated .~Uterine artery clamping division and ligation~After securing the uterine A., debulking procedures was performed in the form of bisection, coring or myomectomy~Utero-ovarian and round clamping-division and ligation ( in cases where oophorectomy was performed this part was done at the level of the infundibulo-pelvic ligament).~Hemostasis~The vaginal vault is closed after insertion of intraperitoneal drain and"
46035646|NCT02826304|Procedure|Laparoscopic assisted vaginal hysterectomy|"Uterine manipulator was inserted through the cervix to mobilize the uterus~Veress needle was inserted through the base of the umbilicus~creation of pneumoperitoneum~Insertion of 4 trocars one at the base of umbilicus for the camera and 3 lateral trocars~The round and the utero-ovarian ligament are coagulated and divided.~Dissection through the vesico-uterine space to displace bladder away from the cervix.~Uterine artery was coagulated and divided laparoscopically~anterior colpotomy over the cup of the uterine elevator.~Vaginal part starts with opening of douglas pouch and clamping , division and ligation of uterosacral and cardinal ligaments followed by removal of the uterus and closure of the vault. reinflation to ensure proper hemostasis."
45340171|NCT04931420|Procedure|Video-Assisted Thoracic Surgery (VATS)|If you have lung cancer, you may receive video-assisted thoracic surgery (VATS): a type of minimally invasive thoracic surgery of the chest, performed with a thoracoscope (small videoscope) using small incisions and special instruments to minimize trauma.
46035647|NCT00674713|Other|Acupuncture|
45340172|NCT04931420|Procedure|Lobectomy|"If you have lung cancer, you may receive a lobectomy:~A major/invasive surgical procedure where an entire lobe of your lung is removed."
46035648|NCT00674713|Drug|Ondansetron|
46035649|NCT00674713|Drug|Physiological saline solution|
45472978|NCT01269827|Drug|starch tablets|Over a period of 4 months, patients of the control group received one starch tablet orally once a day (at dinner time)
46035650|NCT00674713|Other|Sham acupuncture|
46035651|NCT00674713|Drug|Ondansetron|
46035652|NCT00674713|Other|Acupuncture at P6 point|
46035653|NCT00674713|Drug|Physiological saline solution|
46035654|NCT00674713|Other|Sham acupuncture|
46035655|NCT04241380|Drug|Anticoagulant Solutions|Patients in this group will received continuous infusion heparin 6 hours postoperatively (initial dose 10 iu/kg/h, dynamic regulation according to ACT 160-180s). After the removal of deep vein catheter, aspirin 5 mg/kg will be given every eight hours subsequently for 3 months.
46035656|NCT04241380|Other|No anticoagulant solutions|They will receive non-coagulant or coagulant treatment according to clinical conditions.
46035657|NCT04241380|Drug|Anticoagulant management|"Continuous infusion heparin (initial dose 10 iu/kg/h and dynamic regulation until the activated coagulation time (ACT) 160-180 s) for a few days.~Aspirin 5 mg/kg will be given every eight hours subsequently for 3 months."
46035658|NCT00677677|Biological|Human papillomavirus quadrivalent vaccine|Patients meeting the inclusion / exclusion criteria will be enrolled from outpatient transplant clinics. Upon enrolment, baseline serum will be obtained and patients will be given the first dose of vaccine. Two months later, serum will again be obtained and the second dose of vaccine will be administered. Finally, at month 6, serum will be obtained and the third dose of vaccine will be given. The final serum samples will be collected at months 7, 12 and 36. At 48 hours and 7 days after each vaccination, patients will be contacted by telephone for local and systemic adverse effect reporting.
46035659|NCT00674791|Biological|OCPM Immunotherapeutic Vaccine|Patients will receive 1 injection into each thigh at each of 6 visits: week 0, week 1, week 2, week 4, week 5, and week 6. The first 9 patients will receive a 100 microgram dose and the second 9 patients a 1 milligram dose of the peptide mixture.
45340173|NCT04931420|Radiation|Consolidative Radiation|A type of radiation treatment used to kill any cancer cells that may be left in the body. It may also include a stem cell transplant or treatment with drugs that kill cancer cells.
46035660|NCT02824354|Drug|Nalmefene (Selincro®) 18 mg tablet|Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
46035661|NCT02824354|Drug|placebo|Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
46035662|NCT00674869|Other|pit and fissure sealant|pit and fissure sealant on one randomized tooth by pair of permanent molar
46035663|NCT04150315|Diagnostic Test|Proteome analysis|Evaluation of specific protein levels in tissue and plasma.
46035664|NCT02823496|Other|Sunscreen Lotion , BAY 987521|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. Formulation A: Y49-103, Formulation B: Y71-150.
46035665|NCT02823496|Other|Untreated skin|One site is patched without treatment as control
45340174|NCT04931420|Radiation|Ablation Treatment|"Depending on the location of you cancer and the state of your cancer after chemotherapy, you may receive on the the following ablation treatments:~-Microwave or Radiofrequency Ablation: Radiofrequency ablation (RFA) and microwave ablation (MWA) are treatments that remove liver tumors by placing a needle through the skin into the tumor. In RFA, high-frequency electrical currents are passed through an electrode in the needle, creating a small region of heat. In MWA, microwaves are created from the needle to create a small region of heat. The heat destroys the liver cancer cells.~-General Tumor Ablation Treatment: a minimally invasive surgical method to treat solid cancers. Special probes are used to burn or freeze cancers without the usual surgery. Doctors use images of your tumor to guide where they place the needle. This requires only a tiny hole, usually less than 3 mm via which the probe is introduced."
45340175|NCT04931420|Procedure|Resection or Excision|Depending on the type of GI cancer you have and the state of your cancer after chemotherapy, you may receive a resection or excision: a surgical procedure that focuses on removing all or part of a tumor/organ/body using a sharp knife (scalpel) or other cutting instrument.
45340176|NCT04931420|Procedure|Peritonectomy|Peritonectomy is a surgery used to remove peritoneal tumors (tumors in the lining of the abdomen/stomach) from a patient. Following surgery, a heated chemotherapy bath (HIPEC) is commonly administered.
45472979|NCT03388372|Biological|Nimotuzumab|Nimotuzumab, 200 mg as 1-hour intravenous infusion once weekly, from first week to last week of RT for a total of 6 times.
45683412|NCT05160766|Biological|Spikevax (mRNA-1273)|Single booster shot (4th dose) of already approved Moderna vaccine that protect against COVID-19 infection
45683413|NCT05157490|Behavioral|Mindfulness training|Guided meditations in the preoperative time period, at least 3 sessions per week, leading up to surgery
45683414|NCT01811732|Drug|Delafloxacin|Delafloxacin
45683415|NCT01811732|Drug|Vancomycin|Vancomycin
46035666|NCT00677755|Drug|mifepristone combined misoprostol|women received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
45340177|NCT04931420|Other|Transarterial Radioembolization|"If you have cancer in your biliary tract (gallbladder, pancreas or liver), you may receive transarterial radioembolization known as TARE.~TARE allows doctors to deliver radiation treatment directly to the liver using a minimally invasive technique that is designed to cause few side effects. TARE allows doctors to thread a catheter through a small incision in the participant's upper thigh through the artery that goes directly to the liver."
46035667|NCT00677755|Drug|misoprostol alone protocol|patients were only administered 0.8 mg of misoprostol orally on day 3.
46035668|NCT00674947|Drug|BIIB015|IV infusion once every 3 weeks until disease progression or unacceptable toxicity
46035669|NCT02628457|Procedure|arthroscopic rotator cuff repair|arthroscopic rotator cuff repair done in all patients to check whether, surgery itself changes the appearance of muscle atrophy in the supraspinatus in all patients irrespective of size of preoperative tendon retraction
45683416|NCT01811732|Drug|Aztreonam|Aztreonam
45683417|NCT01811732|Drug|Placebo|Placebo
45340178|NCT00920114|Biological|blood sample|
45340179|NCT04691570|Drug|ANX005|ANX005 is provided as a solution for IV infusion
46035670|NCT02823418|Procedure|No neuraxial labor analgesia|Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
46035671|NCT02823418|Procedure|Neuraxial labor analgesia|Epidural or combined spinal-epidural labor analgesia will be performed when the cervix is dilated to 1 cm or more and continued until the cervix is fully dilated to 10 cm.
45340180|NCT04691180|Drug|BRII-196 and BRII-198|BRII-196 and BRII-198 given intravenously
45340181|NCT04691180|Drug|Placebo|Placebo given intravenously
45340182|NCT05585528|Procedure|Functional or surgical management in 1st intention|Proportion of patients after rupture of the anterior cruciate ligament of the knee, who will have functional or surgical management in 1st intention
45340183|NCT04912622|Diagnostic Test|Clinical Trial|Retinal image acquisition with Cellularis version 2.0
45340184|NCT04081376|Drug|Hydromorphone Hydrochloride|4 mg of hydromorphone hydrochloride (equivalent to 3.56 mg of hydromorphone) administered orally in a single dose.
45340185|NCT04890158|Other|Prone positioning for a total of 6 hours daily|Prone positioning for 6 hours daily
45340186|NCT00920192|Drug|Foretinib|Phase I starting dose 30 mg/day escalated to 45 mg/day; de-escalated to 30 mg/day. MTD for Phase II dose was 30 mg/day,
45340187|NCT02584400|Drug|Injection with the hypoxia tracer [18F]HX4,|The [18F]HX4 PET scan will be performed, by administrating 444 MBq (12 mCi) [18F]HX4 via a bolus IV injection.
45340188|NCT00676143|Drug|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
45340189|NCT00676143|Drug|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
45340190|NCT02586272|Device|Daifert|
45340191|NCT02586272|Procedure|Control Group|
45340192|NCT02586428|Other|what patients elect noninvasive prenatal testing (NIPT)|what percentages of patients elect noninvasive prenatal testing (NIPT), amniocentesis, or no testing before and after genetic counseling.
45340193|NCT04082390|Dietary Supplement|RELEASE|Dietary supplement
45340194|NCT04082390|Dietary Supplement|Placebo|Placebo
46035672|NCT04149379|Drug|Hyperbaric oxygen|20 sessions of hyperbaric therapy in a pressure chamber at 2,4 absolute atmospheres, 90 minutes per day of breathing 100% medical oxygen through an own mask. Table 14/90.
46035673|NCT02824042|Drug|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine given IV On Day 1 of each 21-day treatment cycle Part 1: Cycle 1 Day 1: 6.5 mg/kg of body weight (BW) Cycle 2 Day 1: 0.6 mg/kg BW Part 2: Cycle 1 Day 1: 6.5 mg/kg BW Cycle 2 Day 1: 6.5 mg/kg BW (planned dose) Continuous treatment: Cycles ≥3 Day 1: 6.5 mg/kg BW once every 3 weeks (Q3W)
46035674|NCT02824042|Drug|Itraconazole|Itraconazole 100 mg oral capsules given by mouth Cycle 1 (Day 18): 200 mg twice daily (BID) (Days 19 - 21): 200 mg once daily (QD) Cycle 2 (Days 1-8): 200 mg QD 12 days in total (Part 1 or Part 2)
46035675|NCT02628925|Device|Nu-DESC DK|Nu-DESC DK as a screening tool is presented to the medical staff and they have to evaluate the tool an evaluate the screening tool on a evaluation form and rates on a 6 step Likert scale.
45340195|NCT02587676|Other|Evatouch Super|The deterioration of RDLs may differ between in vitro conditions and the conditions encountered in denture wearers. We conducted an in vivo study to investigate how resilient denture liners (RDLs) changed in hardness when embedded in complete maxillary dentures worn by patients for one month in a clinical setting. We hypothesized that the hardness one month after application of the RDLs would be affected by the age, the condition of the saliva, the occlusal force, type of denture used, the patients habits related to smoking, drinking, wearing dentures while sleeping, and using a denture cleanser.
45340196|NCT04585022|Device|Magnum, Zimmer Biomet, Warsaw, IN|
46035676|NCT02628301|Dietary Supplement|Hypercaloric diet|Hypercaloric diet consisting of 60% excess calories based on resting energy expenditure (REE). Calories will be provided in the form of snacks in between the ad libitum meals. A subsequent hypocaloric diet will consist of 1.0x resting energy expenditure.
46035677|NCT02628301|Other|Normocaloric diet|Normocaloric diet
46035678|NCT00675181|Drug|Melatonin|5mg per os
46035679|NCT00675181|Drug|Placebo|per os
45340197|NCT04585022|Device|Recap, Zimmer Biomet, Warsaw, IN|
46035680|NCT04241458|Drug|BI 703621|BI 703621
46035681|NCT04241458|Drug|Placebo|Placebo
45340198|NCT03055533|Behavioral|Headsprout reading program|Headsprout is a commercially available, computer-based program reading intervention that can be tailored to meet the individual needs of each child. Participants will have treatment sessions with a trained therapist lasting one to two hours, two to four days a week, for approximately twelve weeks.
45472980|NCT03388372|Drug|Temozolomide|Temozolomide, 75 mg/m2/d was administered orally from the first to the last day of RT. After 4-week break, individualized adjuvant TMZ was given based on MGMT status. The standard 5-day schedule every 4 weeks for six cycles was given for patients with negative MGMT expression. Dose was 150mg/m2 for the first cycle and 200 mg/m2 from the second cycle. The 7-day on/7-day off schedule every 2 weeks for 12 cycles was given for patients with positive MGMT expression. The dose was 100 mg/m2 for the first two cycles and 150 mg/m2 starting from the third cycle.
46035682|NCT04241458|Drug|Midazolam|Midazolam
45472981|NCT03388372|Radiation|Radiotherapy|Fractionated 3D conformal RT was given at 2.0Gy per fraction, 5 daily fractions per week for 6 weeks.
45839899|NCT04739124|Other|Follow-up questionnaires|"The patient normally follows the education program as usual but research specific data is collected:~Biological sampling at the start and end of the education program (glycated hemoglobin).~Retrieval of usage and glycemic balance data from the Libreview online platform (at one week, one month and three months of use)~Iterative questionnaires allowing the study of factors of acceptance, appropriation and use (at the start of the study, at 4 weeks, at 12 weeks)"
46035683|NCT04836988|Other|Three months of digitally delivered osteoarthritis treatment|Digitally delivered osteoarthritis management including education and exercise and weight control if needed
46035684|NCT04836988|Other|Three months of face-to-face delivered osteoarthritis treatment|Face-toface delivered osteoarthritis management including education and exercise and weight control if needed
45340199|NCT02586350|Drug|Anlotinib|
45340200|NCT02586350|Drug|Placebo|Placebo p.o. qd
45340201|NCT04504071|Drug|Dacomitinib|Patients will receive continuous oral therapy with the study drugs (dacomitinib 45 mg) until disease progression or unacceptable toxicity.
45340202|NCT02586194|Drug|ASP015K|Oral
45472982|NCT01161485|Behavioral|HIV Testing and Counseling|A manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening.
45683418|NCT05146648|Device|Gondola AMPS|One treatment session lasts about two minutes and consists of the application of a mechanical pressure pulses on each of the points, one after the other, for a set duration (a few seconds), which is repeated several times in sequence.
45839900|NCT04739124|Other|Interviews|Semi-structured interviews will be carried out during the visits, either face-to-face or remotely.
46035685|NCT00681343|Drug|Thymoglobulin|Induction
46035686|NCT00681343|Drug|Campath-1H|Induction
46035687|NCT00681343|Drug|Daclizumab|Induction
46035688|NCT02823808|Drug|NESINA ACT TAB. 25/15mg|Alogliptin/Pioglitazone 25/15mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
46035689|NCT02823808|Drug|AMARYL-M TAB. 2/500mg|Glymepiride/Metformin 2/500mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
46035690|NCT04241302|Diagnostic Test|Pure Tone Audiogram|A Pure Tone Audiogram is done in a sound proof room in both cases of Free Field Voice Test and Free Field Click Tests to identify the Pure Tone Average (Hearing Threshold Average of 500Hz,1000Hz and 2000Hz).
46035691|NCT04151719|Drug|Methylnaltrexone bromide (MNTX)|Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
46035692|NCT02823886|Other|MRI at D7|The infarct size measured on MRI at 7 days.
46035693|NCT02823886|Biological|Blood samples|Blood samples at H0; H4; H12; H24, H48, D7 and 1 month post MI
46035694|NCT05299255|Drug|Utidelone|Utidelone Versus placebo in Third-line and above treatment of Extensive Small-cell Lung Cancer
46035695|NCT05299255|Drug|Placebo|the placebo as control group.
45472983|NCT01161485|Behavioral|Contingency Management|In voucher-based CM programs, drug users who submit urine samples that are negative for specified drugs are reinforced with vouchers. Based on operant conditioning, CM rewards those who comply with the targeted behavior and does not reward when compliance is not achieved. In this study a mid-value reinforcement CM schedule will be used in order to balance community cost concerns with the need to show comparative efficacy in reducing meth use and concomitant sex risk behaviors in a largely unstudied risk group. Participants in the CM arm will be asked to come to the study site three times a week to leave a urine sample, get the result, and will then be offered a voucher if their urine is clean and given brief verbal feedback.
45340203|NCT04483713|Behavioral|Educational Workshop|"The workshop proposes a review of all stages of EBP which includes approaches to clinical care based on science and the quality of evidence, with the ultimate goal of promoting safe and quality care.~The workshops comprise one for each group with a total workload of six (6) hours divided into two days, lasting three hours each day. The first day will be a theoretical approach and the second day a practical approach.~The workshops with theoretical content and practical classes will be held in rooms of Albert Einstein Hospital.~All participants of both educational strategies will answer the same questionnaires."
45340204|NCT04483713|Behavioral|Educational Workshop plus J. H. N. EBP Guide Tools|"In addition to the workshop. It will follow the same molds as the case of group Educational Workshop plus the Johns Hopkins Nursing Evidence-based Practice guide tools since the beginning of this practical class, when the participant will receive a description of a problem as a basis for elaborating their clinical question, and thus, move on to the next stage.~The tools will be offered in the case of this group: question development, evidence level and quality guide, research evidence assessment tool, individual evidence tool, evidence synthesis and recommendation tool, action planning tool and tool dissemination."
45683419|NCT04591574|Biological|Red Blood Cells (Transfusion)|Participants will receive RBC transfusions in accordance with trial protocol (intervention group) or usual care, which is in accordance with the NICE guidelines
45683420|NCT04400344|Other|No intervention|No intervention
45839901|NCT04739046|Drug|Theragene arm|Theragene®,Ad5-yCD/ mutTKSR39rep-ADP with radiation therapy
45839902|NCT04738656|Dietary Supplement|Diet plan|Mediterranean style is a non-restricted diet plan compared with the open protein diet plan
46035696|NCT02823340|Device|Fractional microneedle RF(United, Peninsula Medical, China)|
45839903|NCT04738266|Diagnostic Test|Amyloid Cardiomyopathy|Echocardiographic red flags of Amyloid Cardiomyopathy to guide the suspicion of disease and to proceed with second level diagnostic work up including cardiac scintigraphy with bone tracers and search of monoclonal component in serum and urine
45839904|NCT04738500|Procedure|PENG Block combinated with PCA|After spinal anesthesia PENG block will be performed
45839905|NCT04738500|Procedure|PCA|PCA will be applied after surgery
46035697|NCT00677911|Behavioral|In-vivo pain catastrophizing induction|All participants underwent a 10-minute in-vivo pain castastrophizing induction.
46035698|NCT02823184|Biological|RNA sample of total leukocytes before start of treatment|RNA sample of total leukocytes before start of treatment
46035699|NCT00677989|Procedure|Laparoscopic appendectomy|laparoscopic appendectomy:did appendectomy by laparoscopic manipulation
46035700|NCT00677989|Procedure|Open appendectomy|open appendectomy: did appendectomy by laparotomy
46035701|NCT02822482|Drug|Copanlisib|Copanlisib will be given at Day 1, Day 8 and Day 15 (1 cycle = 28 days), administered intravenously over 60 minutes, in association with Cetuximab.
45340205|NCT04079660|Diagnostic Test|Capillary blood glucose blood draw|Capillary blood glucose (CBG), HbA1c, fructosamine, albumin, BUN, and creatinine values will be obtained from a blood draw as a standard of care
45340206|NCT02559375|Other|Survey|
45472984|NCT01161485|Behavioral|Strengths-based case management|Strengths-based case management (SBCM) is a specific type of case management that is based on the following principles: 1) clients are most successful when they identify and use their strengths, abilities, and assets; 2) goal-setting is guided by the clients' perceptions of their own needs; 3) the client-case manager relationship is promoted as essential; 4) a creative approach to the use of the community will lead to the discovery of needed resources; and 5) case management is conducted in the community. It differs from more traditional case management models that emphasize resource brokerage and client advocacy in its recognition that only the individual can change his/her behavior.
46035702|NCT02822482|Drug|Cetuximab|Cetuximab will be given weekly at Day 1, Day 8, Day 15 and Day 22 (1 cycle = 28 days), administered intravenously over 120 minutes (Cycle 1 Day 1) or 60 minutes (subsequent infusions), in association with Copanlisib.
46035703|NCT00678067|Dietary Supplement|Docosahexaenoic acid|Soft capsules 500 mg/each; 1 capsule/day for 4 months
46035704|NCT00678067|Dietary Supplement|Docosahexaenoic acid (DHA)+ Eicosapentaenoic acid (EPA)|Soft capsules, 228 mg DHA + 208 mg EPA /each; 1 capsule/day for 4 months
46035705|NCT00678067|Dietary Supplement|Germ oil|Soft capsules, 275 mg linoleic acid + 35 mg linolenic acid + 65 mg oleic acid /each; 1 capsule/day for 4 months
45839906|NCT04738032|Other|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
46035706|NCT00678067|Other|National Cholesterol Education Program (NCEP) Step I Diet|Dietary counselling aimed at achieving NCEP Dietary Guidelines: Total fat intake <30% of total calories, Saturated fat intake <10% of total calories, Polyunsaturated fat intake up to 10% of total calories, monounsaturated fat intake 10-15% of total calories
46035707|NCT04239898|Other|Red cabbage microgreens|2 cups per day
45340207|NCT02584166|Behavioral|multifaceted program|This program present two steps : a first step to revise protocols related to the management of cases (between M5 and M8) and a second step after M8 et M 26, with morbimortality conferences organized every trimester to analyze management with the staff.
45340208|NCT02559843|Dietary Supplement|pomegranate juice|
45340209|NCT02559843|Behavioral|lifestyle modification|
45340210|NCT02586116|Device|nanOss|nanOss Cervical Interbody Fusion Device with nanOss BA bone void filler.
45340211|NCT02586116|Device|C-Plus|C-Plus PEEK IBF Device with autograft
45472985|NCT03379948|Diagnostic Test|blood culture|blood culture to diagnose blood stream infection
46035708|NCT04239898|Other|Red beet microgreens|2 cups per day
45472986|NCT03259308|Drug|Ontamalimab|Participants will receive 1 mL of ontamalimab sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).
45472987|NCT03259308|Drug|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
45472988|NCT01280279|Other|education for behavioral modification|a systematized 30-minutes education program for behavioral modification (SBMP) by watching videos and discussion with a specialized continence nurse practitioner.
45472989|NCT05173246|Drug|JS001|JS001 240mg, ivdrip, d1, Q3w
45472990|NCT05173246|Drug|nab-paclitaxel|nab-paclitaxel 220 mg/m2,ivdrip, d1,d8,Q3w
45340212|NCT00761163|Other|Resistance Exercise|The subjects will complete 2 resistive exercise sessions on non-consecutive days that will be supervised by our laboratory staff. The following exercises will be performed using the Keiser Sports Health equipment in Ismail Health, Exercise, and Nutrition Center: seated row, double leg press, seated leg curl, chest press, and leg extension. The subjects will individually perform 3 sets of 8-10 repetitions at an exercise intensity of 70% of pre-determined maximal strength for these exercises. Each repetition will be performed in a slow (six to eight seconds) uniform fashion, giving equal time to the concentric (muscle shortening) and eccentric (muscle lengthening) portions. One minute of rest will be allowed between sets. The last repetition of the third set of each exercise will be done to voluntary fatigue or the performance of 12 repetitions.
45340213|NCT00761163|Other|Aerobic Exercise|The subjects will complete 2 aerobic exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. The subjects will perform 45 minutes of aerobic exercise on a stationary bike at an exercise intensity of 70% of their heart-rate reserve.
45472991|NCT05173246|Drug|Cisplatin|Cisplatin 75mg/m2, ivdrip,d1,Q3w
45472992|NCT05173246|Drug|Carboplatin|Carboplatin AUC 5,d1,Q3w
45472993|NCT01167101|Drug|Rebamipide|Rebamipide 100mg Tid for 28days
45839907|NCT04738188|Procedure|DEB-TACE|Drug-eluting beads transcatheter arterial chemoembolization
45839908|NCT04738188|Procedure|cTACE|Transcatheter arterial chemoembolization
45472994|NCT01167101|Drug|pantoprazole|pantoprazole 40mg qd for 28days
45472995|NCT01165463|Behavioral|SOPT basic training|10 hours of basic training
45472996|NCT01165463|Behavioral|Crossword Puzzles|Subjects train with puzzles 10 hrs in lab.
45472997|NCT01165463|Behavioral|SOPT booster training|4 hours of subsequent booster-training
45472998|NCT03388216|Biological|Drug: INM004 Dose 1|Stage I- Cohort I: (2mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo) -
45472999|NCT03388216|Biological|Drug: INM004 Dose 2|Stage I- Cohort II: Dose 2 (4mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo)
45473000|NCT03388216|Biological|Drug: INM004- Repeated dose|Stage II: Either 3 doses of 2 mg/kg or 4 mg/kg will be administered every 24 hs. The ratio is 5:1 (investigational product : placebo).
45473001|NCT03388216|Other|Placebo|A placebo infusion will be administered at the same infusion rate as the Drug arm
45473002|NCT01267721|Procedure|Blood sampling|Blood sampling at various time points. Additional 92 mL blood.
45473003|NCT05173090|Drug|Ropivacaïne 0,5% for appendectomy or cholecystectomy surgery|Visual analog scale 15 min after arrival in the recovery room, then H+4, H+6, H+12, H+24 and one week after the operation
45839909|NCT04738188|Device|Drug-eluting Beads|Drug-eluting beads
45839910|NCT04738188|Drug|Epirubicin|Chemotherapy drug for intra-arterial infusion
45340214|NCT00761163|Other|Control (Non-exercise)|The subjects will also complete 2 non-exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. These sessions will consist of incorporating diversionary tasks throughout a 45 minute period consisting of a variety of motor and psychological tasks (tests of hand steadiness, alertness, optical illusions, mental acuity, etc.)
46035709|NCT02628145|Behavioral|Resistance Training Intervention|The RTI group will participate in a periodized RT program on 3 non-consecutive days/week using NSCA and ACSM guidelines and will be designed by a team member who is a NSCA certified strength and conditioning specialist. This program will consist of a full-body, nonlinear periodized program: a training method that has frequent variations in program variables. Intensity variations intensity are based on training phase. E.g., the first portion of 12-week cycle has more moderate and light days as participants adapt to the program. Weeks 1-4 will consist of primarily RT machine exercises and few unilateral and multi-joint light free weight exercise. Weeks 5-8 will incorporate more free-weight exercises that are multi-joint. Weeks 9-12 will incorporate more complex multi-joint movements.
46035710|NCT02628145|Behavioral|Active Control Group|The CON group will meet three times weekly for approximately 12 weeks for light physical activity and stretching.
45340215|NCT02584322|Other|Enhanced Recovery pathway|The enhanced recovery pathway consists of postoperative medical orders including nursing care, investigations and tests, and other peri-operative orders. The enhanced recovery pathway is standardized for all patients, and can be discontinued at any time when clinical judgment mandates (i.e. patient has a severe complication).
45340216|NCT00761241|Drug|Gemcitabine, Docetaxel, 5FU, Oxaliplatin|Gemcitabine: 1000 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8cycles Docetaxel: 40 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8 cycles Gemcitabine/docetaxel will be repeated (based upon initial response) Oxaliplatin: 40 mg/m2 IV on day 1 of each week of radiation 5-FU: 175 mg/m2 continuous infusion on days 1-18 and 29-46 of radiation
45473004|NCT03384550|Behavioral|Self-regulation coaching|Short (2-5 min.) dialogue with the digital coach who provides information relevant for behavioral self-regulation, such as a goal reminder, the distance between the current step count and the goal and strategies to increase daily steps. Participants are randomized to self-regulation coaching or control (no coaching) on a daily basis.
45473005|NCT03384550|Behavioral|Planning|A dialogue with the digital coach who prompts the participant to either formulate action plans (when and where the participant can go for a walk) or coping plans (strategies to respond to barriers for increasing daily steps) for the upcoming week. Participants are randomized on a weekly basis to action planning, coping planning or control (no planning).
45473006|NCT03384550|Behavioral|Financial Incentives|Participants receive CHF 1 ($1) for each day they meet a personalized adaptive step goal.
45473007|NCT03384550|Behavioral|Charity Incentives|Participants donate CHF 1 ($1) to a charity of choice for each day they meet a personalized adaptive step goal.
45473008|NCT03877367|Other|Upper extremity manipulation|An upper extremity (glenohumeral, humeroulnar and radioulnar joints, bilaterally) or a lower extremity (coxofemoral, tibiofemoral, and tibiotalar, bilaterally) manipulation series.
45473009|NCT03877445|Device|exposition half-face|Patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control. The effect of blue light on the melasma lesions will be assessed from Day 1 to Day 6 using chromametry and a modified Melasma Area and Severity Index on standardized photographs
45473010|NCT03388060|Procedure|Ultrasound guided SWL|Ultrasound guided SWL for radiolucent renal stone
46035711|NCT02822326|Biological|CD19-CAR-T2 Cells|
46035712|NCT00675337|Procedure|perineum maintained|infants maintained at the level of the perineum until umbilical cord clamping
45340217|NCT00761241|Biological|Alpha-interferon|Alpha-interferon: injected subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 29, 31, 33, 36, 38, 40, 43 and 46 during radiation therapy
45473011|NCT03388060|Procedure|Dissolution therapy|Alkalinization dissolution therapy for radiolucent renal stone
46035713|NCT00675337|Procedure|abdominal placement|infants placed on the maternal abdomen prior to umbilical cord clamping
46035714|NCT04152265|Procedure|colonoscopy|colonoscopy
45473012|NCT03388060|Procedure|Combined ultrasound guided SWL and dissolution therapy|Combined ultrasound guided SWL and alkalinization dissolution therapy for radiolucent renal stone
45473013|NCT02526953|Drug|Paclitaxel|45 mg/m2, IV, weekly during the radiation. Number of infusions: 5.
46035715|NCT04152265|Other|questionnaires|complete the two questionnaires (Food Frequency Questionnaire (FFQ) and the questionnaire of The World Health Organization Quality of Life (WHOQOL-BREF)
46035716|NCT04152265|Other|demographic data collections|completing the demographic questionnaire
45473014|NCT02526953|Drug|Capecitabine|625 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
46035717|NCT04152265|Other|anthropometric data collections|For the determination of anthropometric data will be used a professional body mass composition analyser (Seca,Hamburg, Germany)
45473015|NCT02526953|Drug|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
45473016|NCT02526953|Drug|Mitomycins|10 mg/m2, IV, on day 1. Number of infusions: 1.
45473017|NCT02526953|Drug|Mitomycins|12 mg/m2, IV, on day 1. Number of infusions: 1.
45473018|NCT02526953|Radiation|Radiotherapy|Dose: 44 Gy on regional nodes, 52-58 Gy on primary tumor, based on T stage
45473019|NCT04343638|Device|conventional nociception control|While Intraoperative opioid will be administered by conventional clinical practice in control arm.
45473020|NCT04343638|Device|ANI monitor guided nociception control|The intraoperative opioid will be administered by maintaining the 4-minute moving average of ANI ≥50 in ANI-monitor guided nociception control arm.
45473021|NCT03874247|Drug|pelubiprofen 45mg|bid for 3 days after meal
45473022|NCT03874247|Drug|pelubiprofen placebo|bid for 3 days after meal
45473023|NCT03379792|Other|DEXA|Measurement of body composition by Dual Energy X-ray Absorptiometry (DEXA)
46035718|NCT04152265|Procedure|Collecte the biological samples|blood and faeces collections
46035719|NCT02822404|Dietary Supplement|Urinary and blood sample for Cystatine dosage|Urinary and blood cystatin C are sampled in patient with nephrotoxic risks before the treatment beginning, after the first course of chemotherapy, in the middle and at the end of the treatment. A follow up assessment is also required at 2 and 5 years. The cystatin C measurements are compared to traditional nephrology markers. Their sampling requires additional blood and urinary collection but involve minimal risks for patient.
46035720|NCT02822248|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-64-R84-070)
46035721|NCT00675493|Drug|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
45340218|NCT00761241|Radiation|Abdominal/pelvic radiation therapy|3-D conformal technique. The dose per fraction will be 180cGy, with a total dose of 5040 cGy in 28 fractions. Radiation therapy will be delivered on days 1-18 and days 29-46
45340219|NCT00761241|Procedure|Pancreaticoduodenectomy|Surgery performed if subject is considered candidate by protocol definition.
45340220|NCT02558907|Other|cognitive evaluation by MMS (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) tests|
45340221|NCT02981979|Drug|Leflunomide 10mg Tab|20mg per day for leflunomide group during the entire study; 20mg per day for control group during the maintenance therapy (start from the 25th week till the end of the study).
45473024|NCT03379792|Other|MRI|Whole body magnetic resonance imaging (MRI)
45340222|NCT02981979|Drug|Prednisone Acetate|basic therapy（start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission.）
45340223|NCT02981979|Drug|Placebos|used in control group during the induced remission therapy for 24 weeks.
45473025|NCT03379792|Other|CGM|A continuous glucose monitor (CGM) will be placed on the participant and will be used as a safety measure to monitor glucose levels.
45473026|NCT03379792|Other|Whole room calorimeters|Whole room indirect calorimetry allows for the simultaneous measure of total energy expenditure and substrate oxidation in a free living environment with multiple activities.
45839911|NCT04737798|Other|oil pulling with coconut oil|using oil pulling therapy with coconut oil
45340224|NCT04081064|Behavioral|10-week exercise programme based on aerobic interval and resistance training|The intervention will take place over 10 weeks. Participants will complete three sessions per week; each sessions will be scheduled at least 24 hours apart. Two sessions per week will consist of aerobic interval exercise and resistance training, and one session per week will consist of aerobic interval exercise only.
45340225|NCT04049409|Drug|CMAB809|CMAB809 will be administered by IV infusion at a single dose of 6mg/kg.
45839912|NCT04737798|Other|oil pulling with sesame oil|using oil pulling therapy with sesame oil
45839913|NCT04737486|Drug|AV-001|AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
45839914|NCT04737486|Other|Placebo|D-PBS
45839915|NCT04737564|Behavioral|Attachment and Biobehavioral Catch-up (ABC10)|"The ABC parenting targets include: nurturing children when they are distressed (Sessions 1 and 2), following the child's lead in play (Sessions 3 and 4), and avoiding harsh or frightening behavior (Sessions 5 and 6). Sessions 7 and 8 help parents consider how their own experiences of being parented affect their sensitivity, and Sessions 9 and 10 consolidate gains with additional practice. Session content focusing on parenting targets is guided by a manual. Additionally, parent coaches make frequent in-the-moment comments (at least once per minute) about parent-child interactions as they occur in session, and use video feedback."
45340226|NCT04049409|Drug|Trastuzumab|Trastuzumab will be administered by IV infusion at a single dose of 6mg/kg.
45340227|NCT04568252|Device|Wristband with millimeter wave emission.|Wristband treatment with millimeter wave emission twice a day for 3 months.
45340228|NCT04568252|Device|Placebo of wristband with millimeter wave emission.|Treatment with a millimeter wave emission wristband placebo twice a day for 3 months.
45340229|NCT00920660|Drug|Placebo|Matching placebo is supplied containing microcrystalline cellulose (Avicel PH 105). Placebo will be administered as eight matched capsules.
45340230|NCT00920660|Drug|0.25g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.25g SRT2104 treatment visit will be administered as one SRT2104 capsule with 7 placebo capsules. Dosing will take place during one of the 6 treatment visits.
45340231|NCT00920660|Drug|Prednisolone|During the last treatment period, subjects will receive 30 mg open-label prednisolone.
45473027|NCT03379792|Other|Dietary counseling|The low carbohydrate diet counseling will be to assist young adult, overweight study participants with Type 1 diabetes in adhering to a lower calorie diet (500 calorie deficit)
45473028|NCT01269983|Other|Fascial Manipulation|8 treatment session in 4 weeks: every week both fascial manipulation and standard physiotherapy
45340232|NCT00920660|Drug|0.5g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.5g SRT2104 treatment visit will be administered as two SRT2104 capsules with 6 placebo capsules. Dosing will take place during one of the 6 treatment visits.
45340233|NCT00920660|Drug|1g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 1g SRT2104 treatment visit will be administered as four SRT2104 capsules with four placebo capsules. Dosing will take place during one of the 6 treatment visits.
45473029|NCT03258762|Drug|Pyrimethamine|Pyrimethamine will be available as 25 mg tablets. Subjects will be orally administered two pyrimethamine tablets on Day 1 in a fasted condition with 240 mL of water.
45473030|NCT03258762|Drug|Calcium folinate|Calcium folinate will be available as 5 mg tablets. Subjects will be orally administered three calcium folinate tablets on Day 1 along with pyrimethamine followed by once daily administration of calcium folinate until Day 8. Each administration will be with 240 mL water.
46035722|NCT04240990|Other|Development of a score and algorithm for TB treatment decision in hospitalised children with SAM.|"The diagnostic strategy will include an initial clinical, radiographic and bacteriological evaluation of all enrolled children:~TB contact history~Suggestive TB symptoms in the previous 4 weeks~Physical examination~Clinical, anthropometric and biochemical assessment of malnutrition~Clinical assessment for other non-dietary causes of malnutrition~Digitalized CXR~Ultra performed on NPA and stool samples, and one gastric aspirate (GA)~Mycobacterial culture performed on two GAs~Abdominal ultrasonography~QuantiFERON®-TB Gold IGRA~Monocyte-to-Lymphocyte Ratio (MLR)~C-Reactive Protein (CRP)~TB diagnosis will be made according to national TB guidelines."
46035723|NCT02627131|Biological|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
45340234|NCT00920660|Drug|2g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 2g SRT2104 treatment visit will be administered as eight SRT2104 capsules. Dosing will take place during one of the 6 treatment visits.
45340235|NCT02903355|Drug|D-methionine|D-methionine, oral liquid suspension
45340236|NCT02903355|Drug|Placebo|Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
46035724|NCT02821936|Procedure|Parametric Imaging|2 parametric PET (one at the inclusion and one at 42 gray of the beginning of radiotherapy)
46035725|NCT04239664|Other|Acceptance Based Telephone Support (ABS+UC)|Support based on Acceptance and Committment Therapy (Hayes, 1999)
45340237|NCT02583464|Drug|Tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
45683421|NCT03327064|Drug|UAB30|9cUAB30 promotes homodimer and heterodimer formation with retinoic acid receptors (RARs), and was shown to inhibit breast tumor development in the N-methyl-N-nitrosourea (MNU)-induced rat mammary gland carcinoma model. The compound has also shown efficacy in rodent models of skin cancer. Dose administration will be 160mg daily for 28 days.
45473031|NCT03871985|Procedure|Subglottic secretion lavage combined with aspiration|Ventilator-associated pneumonia preventive measures were applied to all patients according to VAP bundle. Subglottic secretion lavage combined with aspiration was performed every 4 hours: Underwent preoxygenation before cuff pressure checking, and was maintained between 30 and 35 cmH2O. After aspirating secretions from the mouth, nose, and airway, 2-5 mL distilled sterile water was instilled through the subglottic lumen, and then the negative pressure suction device is connected with the outer opening of the side cavity of endotracheal intubation for suction with a negative pressure of 100 mmHg, and each suction was kept under 15 seconds. Repeat lavage and aspiration until the irrigation fluid is clear. After washing, cuff pressure checking and was maintained between 25 and 30 cmH2O.
45340238|NCT00675597|Drug|Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)|Patients will be treated as follows: vinorelbine (45 mg/m2) + docetaxel (45 mg/m2) intravenously on day 1, followed by pegylated filgrastim 6mg subcutaneously on day 2, delivered every 2 weeks for 8 doses total. Patients who have already received one cycle of cisplatin-based adjuvant chemotherapy need only complete 3 cycles of vinorelbine+docetaxel for a total of 4 cycles of adjuvant chemotherapy. Patients who require post-operative radiation therapy (PORT) will begin PORT after completion of vinorelbine + docetaxel.
45340239|NCT00761397|Behavioral|Interview|15-30 Minute Weekly meeting w/Staff to discuss swallowing exercises
45473032|NCT03871985|Procedure|Subglottic secretion aspiration|Ventilator-associated pneumonia preventive measures were applied to all patients according to VAP bundle. Subglottic secretion aspiration was performed every 4 hours:Underwent preoxygenation before cuff pressure checking ,and was maintained between 25 and 30 cmH2O. After aspirating secretions from the mouth, nose, and airway, the negative pressure suction device is connected with the outer opening of the side cavity of endotracheal intubation for suction with a negative pressure of 100 mmHg, and each suction was kept under 15 seconds. Repeat suction until the secretion is completely absorbed.
45340240|NCT00761397|Behavioral|Phone Call|Phone call follow ups for 4 weeks after last radiation treatment
45340241|NCT00761397|Other|Brochure|Detailed brochure explaining the purpose of the swallowing exercises and a description of how to perform the exercises
45340242|NCT00761397|Other|Questionnaire|Day 1 of study, 10 weeks after starting study, & 12 months after starting study
45683422|NCT03327064|Drug|Placebo|This matches the UAB30 in appearance. Frequency of dosing will be daily for 28 days.
46035726|NCT04240834|Drug|Aspirin|Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
46035727|NCT04240834|Drug|Ticagrelor|Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
46035728|NCT01200758|Drug|Rituximab SC|First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
46035729|NCT01200758|Drug|Rituximab IV|Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.
46035730|NCT01200758|Drug|Cyclophosphamide|Eight cycles of cyclophosphamide (750 mg/m^2 IV) administered every 3 weeks.
46035731|NCT01200758|Drug|Doxorubicin|Eight cycles of doxorubicin (50 mg/m^2 IV) administered every 3 weeks.
46035732|NCT01200758|Drug|Vincristine|Eight cycles of doxorubicin (1.4 mg/m^2 IV) administered every 3 weeks.
46035733|NCT01200758|Drug|Prednisone/Prednisolone|Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.
46035734|NCT02823106|Drug|Verapamil and Citicoline|Single dosing strategy will be used.
46035735|NCT02823106|Other|Placebo|Single matching dosing strategy will be used.
45340243|NCT04292301|Device|STrategically Acquired Gradient Echo (STAGE)|The STAGE package uses conventional 3D gradient echo MR, its magnitude and phase, collected at set parameters which allow for the reconstruction of multiple MR datasets which results in decreased acquisition time, equivalency to conventional MR, and the decrease in scan time allows for a higher standard of wealth within the data acquired.
45683423|NCT04399720|Procedure|Root canal treatment|Root canal treatment using a standard manual k file instrumentation and carrier-based root canal filling technique
46035736|NCT02821858|Drug|Odalasvir (ODV)|ODV 50 mg (1 tablet) in Treatment A, 100 mg (2 tablets of 50 mg) in Treatment B and 300 mg (6 tablets of 50 mg) in Treatment C.
45340244|NCT04255563|Device|DCB treatment|DCB (Sequent® Please) treatment for CAD patients will be enrolled. Intravascular ultrasound (Boston Scientific®) guidance is recommended.
45340245|NCT04078646|Other|Intervention with soy protein isolate|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), with 30 g added soy protein, plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
46035737|NCT02821858|Drug|AL-335|AL-335 400 mg (1 tablet) in Treatment D, 800 mg (2 tablets of 400 mg) in Treatment E and 1200 mg (3 tablets of 400 mg) in Treatment F.
45340246|NCT04078646|Other|Intervention with whey protein|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), with 30 g added whey protein isolate, plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
45340247|NCT04078646|Other|Intervention without protein addition|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
45340248|NCT04049565|Diagnostic Test|Procalcitonin biomarker and CRP biomarker|collecting blood samples to measure serum CRP and Procalcitonin
45340249|NCT02677545|Drug|Ticagrelor|
46035738|NCT02821858|Drug|Placebo|Matching placebo will be administered.
45683424|NCT01836458|Drug|KAE609|Patients will receive KAE609 single dose at a different dose level in each cohort.
45683425|NCT05142358|Device|Continuous Positive Airway Pressure|Use of CPAP device at the start of treatment planning.
45683426|NCT05142358|Other|Deep inspiratory breath hold|Treatment during breath holds leads to longer treatment times for patients and radiation oncology departments
45683427|NCT05142358|Other|Free Breath|Regular breathing
46035739|NCT04240600|Dietary Supplement|Experimental group|2 cans or bottles (200ml)per day, orally
46035740|NCT04240600|Dietary Supplement|Control group|2 cans or bottles (200ml)per day, orally
46035741|NCT00876343|Drug|Aripiprazole (Fixed dose)|administered orally once daily, 3 mg daily, 6 weeks
46035742|NCT00876343|Drug|Aripiprazole (Titrated dose)|administered orally once daily, 3 to 15 mg daily, 6 weeks
46035743|NCT00876343|Drug|Placebo|administered orally once daily, 6 weeks
46035744|NCT02822014|Other|FDG-PET/CT|We performed baseline FDG-PET/CT, another FDG-PET/CT after 2 months of TB treatment and a PET/CT at the end of treatment in 18 HIV/TB patients.
45683428|NCT05139004|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo AHSCT
45683429|NCT05139004|Biological|Basiliximab|Given IV
45683430|NCT05139004|Drug|Fludarabine Phosphate|Given IV
45683431|NCT05139004|Drug|Indium In 111-DOTA-Basiliximab|Given IV
45683432|NCT05139004|Drug|Melphalan|Given IV
45683433|NCT05139004|Biological|Palifermin|Given IV
45683434|NCT05139004|Radiation|Total Lymphoid Irradiation|Undergo TMLI
45683435|NCT05139004|Radiation|Total Marrow Irradiation|Undergo TMLI
45683436|NCT05139004|Biological|Yttrium Y 90 Basiliximab|Given IV
45340250|NCT02677545|Drug|Clopidogrel|
45340251|NCT02677545|Drug|Aspirin|
45473033|NCT03379714|Device|WEB aneurysm embolization system|The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/ iridium radiopaque markers.
45473034|NCT05427669|Drug|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
45473035|NCT05427669|Drug|mFOLFOX6|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
45473036|NCT01280513|Dietary Supplement|High protein intake|30% of energy intake coming from proteins
45473037|NCT01280513|Dietary Supplement|Low Protein intake|9% of energy intake coming from proteins
46035745|NCT04240444|Device|drug-coated balloon Catheter|All eligible subjects will be assigned randomly to study group or control group, receive PTCA.
46035746|NCT04151641|Dietary Supplement|MNGDPF|Standardized mangosteen extract in dry powder form
45473038|NCT03379636|Device|kinesiotape|Application of an elastic beige 5-cm width Leukotape®K (BSN medical, Germany). The first strip, a Y-strip, was applied with 10% to 15% of tension over the deltoid muscle, from origin to insertion with the first tail along the anterior deltoid while the arm was externally rotated and horizontally abducted. The second tail was applied along the posterior deltoid with the arm horizontally adducted and internally rotated. A second strip, an I-strip, was applied for mechanical correction, transversally in the sagittal plane over the acromioclavicular joint with a downward pressure applied to the KT, the arm being at trunk side
45473039|NCT03379636|Device|sham tape|a rigid Leukotape®Classic (BSN medical, Germany) was used. A 5-cm strip was applied transversally under the deltoid tuberosity with no tension and with no direct influence on shoulder area.
45473040|NCT01270373|Drug|FAC x 3 followed by Docetaxel x 3|5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles; followed by Docetaxel 100 mg/m2 every 21 days, for 3 cycles
46035747|NCT04151641|Dietary Supplement|MNGEF|Standardized mangosteen extract in encapsulated form
46035748|NCT02627989|Drug|Diflucortolone valerate (Nerisona)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
45340252|NCT04479644|Drug|BRII-198|BRII-198 given intravenously
45340253|NCT04479644|Drug|Placebo|Placebo given intravenously
45340254|NCT04079426|Other|Sampling of Blood and bronchoalveolar lavage|Multiplex assays for pro- and anti-inflammatory markers and incubation of immune cells isolated from serum and bronchoalveolar lavage fluid of patients with ARDS.
46035749|NCT02627989|Drug|Diflucortolone valerate (Texmeten)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
46035750|NCT02822170|Other|IV amino acids and in-bed cycle ergometry|IV amino acids and in-bed cycle ergometry
45340255|NCT00921921|Drug|HFA-BDP|HFA-BDP 100 mcg bid for 3 weeks, then 400 mcg bid for 3 weeks
45340256|NCT00921921|Drug|Placebo|1 puff bid for 3 weeks, then 1 puff bid for 3 weeks
45340257|NCT02602119|Drug|OTL38|Infusion of OTL38 prior to surgery
45340258|NCT00761475|Procedure|mesh supported closure|onlay mesh supported closure midline laparotomy
45340259|NCT00761475|Procedure|primary closure|primary closure of the midline
45340260|NCT00761475|Procedure|mesh supported closure|sublay mesh supported closure midline laparotomy
46035751|NCT02627209|Other|spectrophotometric assay|measurement of enzyme activity in the serum
46035752|NCT02627209|Other|radial immunodiffusion|measurement of the precipitated ring diameters showing enzyme activity in the serum
46035753|NCT00675649|Biological|CNTO 148 / Golimumab|100 mg sc injection every 4 weeks from week 0 to week 20
46035754|NCT00675649|Biological|placebo|placebo sc injection every 4 weeks from week 0 to week 20
46035755|NCT00633724|Biological|HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 0.5mg, 1.0mg and 3.0mg.
46035756|NCT01107912|Drug|prasugrel|administered orally, daily for 12 days
45473041|NCT01270373|Drug|Docetaxel x 3 followed by FAC x 3|Docetaxel 100 mg/m2 IV every 21 days, for 3 cycles; followed by 5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles
45340261|NCT04477538|Other|Post-mastectomy breast reconstruction physical well-being survey|-The survey will ascertain: function status (BREAST Q - Physical Well Being Module and PROMIS upper extremity function), former interaction with physical or occupational therapy, amount of narcotics taken weekly due to chest/neck/breast pain, amount of Tylenol or similar anti-inflammatories taken weekly due to chest/neck/breast pain, and amount of muscle relaxants taken weekly due to chest/neck/breast pain.
45340262|NCT00675441|Drug|Lenalidomide|10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
45340263|NCT00761553|Other|Dietary supplements with exercise|Resistive exercise along with consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
45340264|NCT00761553|Dietary Supplement|Dietary supplement without exercise|Consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
45340265|NCT02559297|Drug|Sevoflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
45473042|NCT03669237|Procedure|different reconstruction methods|Different reconstruction methods should be performed after sphincter preservation surgery in two groups.The methods include end-to-end anastomosis or end-to-side anastomosis
45473043|NCT03713086|Biological|Rabipur®|3 doses administered IM at Days 1, 8 and 29 in the deltoid region of the arm
45473044|NCT03713086|Biological|Rabies mRNA vaccine CV7202 Dose level 1|1 or 2 doses administered IM at Days 1 and 29 in the deltoid region of the arm
45839916|NCT04737564|Behavioral|Attachment and Biobehavioral Catch-up, Brief (ABC3)|The 3-session Attachment and Biobehavioral Catch-up intervention (ABC 3) is a brief version of the standard protocol. Parents who receive ABC 3 will receive the first 3 sessions of the ABC intervention, which focus on enhancing parental sensitivity (i.e., nurturance to distress, following the child's lead) by providing in-the-moment feedback on parent-child interactions, video feedback, and discussion of manualized content. ABC 3 was adapted from the standard protocol based on modeling of session-by-session data that demonstrated that, on average, most of the change in parental sensitivity happens in the first several sessions of the intervention.
45473045|NCT03713086|Biological|Rabies mRNA vaccine CV7202 Dose level 2|1 or 2 doses administered IM at Days 1 and 29 in the deltoid region of the arm
45473046|NCT03713086|Biological|Rabies mRNA vaccine CV7202 Dose level 3|1 or 2 doses administered IM at Days 1 and 29 in the deltoid region of the arm
45340266|NCT02559297|Drug|Desflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of desflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
45683437|NCT04073992|Behavioral|cognitive behavioral treatment of insomnia|A behavioral modification program consisting of 8 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
45683438|NCT01811186|Drug|Oxycodone/naloxone|Oxycodone/naloxone titration
46035757|NCT01107912|Drug|clopidogrel|Administered orally, daily for 12 days
46035758|NCT01200524|Drug|AZD2423|20 mg tablet
46035759|NCT01200524|Drug|AZD2423|50 mg tablet
46035760|NCT01200524|Drug|Placebo|Placebo
46035761|NCT00678145|Drug|naloxone|Administering naloxone on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
46035762|NCT00678145|Dietary Supplement|fructose|Administering fructose on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
46035763|NCT00678145|Behavioral|exercise|Administering exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
46035764|NCT00678145|Drug|Morphine sulfate|Administering morphine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
46035765|NCT00678145|Drug|Epinephrine|Administering epinephrine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
46035766|NCT04239742|Diagnostic Test|F18-fluciclovine PET/CT|370 MBq ±10% 18F-Fluciclovin + low-dose CT scan, from skull base to pelvis.
46035767|NCT04239742|Diagnostic Test|F18-PSMA-1007 PET/CT|4 MBq/kg ±10% F18-PSMA + low-dose CT scan, from skull base to pelvis
45839917|NCT04737564|Behavioral|Safe Environment for Every Kid (SEEK)|Safe Environment for Every Kid (SEEK) is an evidence-based screening and referral system to facilitate parents' access to services for risk factors for maltreatment, including: mental health, substance abuse, intimate partner violence, harsh parenting, major parental stress, and food insecurity. Parents first complete the SEEK Parent Questionnaire with the help of an outreach worker. Following the SEEK protocol, handouts will be provided that address the identified problems and parents will be referred to partnering organizations in the community. Any additional work is completed by phone. The developer of the intervention, Howard Dubowitz, is a consultant on this application and will provide support around effective implementation.
45839918|NCT04737408|Drug|Rosuvastatin 40mg|Rosuvastatin 40 mg
46035768|NCT05010642|Device|Use of Eko DUO electronic Stethoscope|Auscultation of heart sounds using electronic stethoscope
46035769|NCT02626741|Dietary Supplement|meal replacement group|The participants will receive SlimWell 60 grams per meal for 2 meals per day plus life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
46035770|NCT02626741|Behavioral|control group|The participants will receive only life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
46035771|NCT04317950|Other|Vojta|Reflex locomotion stimulus
45839919|NCT04737174|Drug|ES-481|28-day screening period followed by 4-week dose escalation period followed by 16-week treatment period followed by 4-week dose washout period
45839920|NCT04736784|Other|Food-based - beetroot juice|Beetroot juice containing approximately 340 mg nitrate daily
46035772|NCT04317950|Other|Sham|sham stimulus
46035773|NCT02879916|Drug|Levobupivacaine|Inject 3ml of levobupavacaine into the stellate ganglion area
46035774|NCT02879916|Drug|NaCl 0.9%|Inject 3ml of NaCl 0.9% into the stellate ganglion area
46035775|NCT02690506|Drug|Placebo|
46035776|NCT02690506|Drug|Pregabalin|
46035777|NCT04310280|Drug|Insulin Glargine|Half of the wound surface is injected daily with topical glargine insulin
46035778|NCT04310280|Drug|Saline|Half of the wound surface is injected daily with topical saline solution
46035779|NCT04151407|Drug|Drug 601|Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
46035780|NCT04824118|Diagnostic Test|Thromboelastometry|Point of Care Test for clotting parameters (ClotPro device)
45340267|NCT04176159|Other|MOTOR IMAGERY AND TASK-ORIENTED TRAINING|"The intervention will be divided into two modules. A first module will include activities of activation and relaxation of the body, prediction and sequencing of movement and motor imagery. The second module, task-oriented training, will be divided into analytical work phase (visual coordination, balance, muscular strength, fine motor skills ...), a second phase of integration into specific tasks and, at end, the inclusion of the free (and supervised) practice of a sport.~The investigators will apply 20 sessions of 40 minutes."
45473047|NCT04138680|Behavioral|Active Biofeedback|"The active biofeedback session will be done within the 7T MRI. It will include a pre-training run, 3 training runs, and a post-training run. Each run will be comprised of MOTIVATE and REST trials. During each MOTIVATE trial, subjects will be instructed to generate a heightened state of motivation. Participants will be encouraged to identify strategies that are personally relevant or useful and to monitor the efficacy of the strategies. Subjects will simultaneously view a progress bar on the screen during MOTIVATE trials that represents their VTA activity and they will be trained to try to increase the level of the bar by motivating themselves. For the active VTA biofeedback group, the progress bar will be updated every second to accurately convey level of VTA signal activation. During REST trials, all subjects will be instructed to count backwards. During the post-training 'test' run, subjects will be instructed to use the strategies they found to be most effective."
45340268|NCT01413399|Drug|4 degree chilled saline|4 degree chilled saline up to 2L in the prehospital setting
45340269|NCT04104555|Other|Birthday card|Birthday card sent to participants in the post
45340270|NCT04104555|Device|Prefabricated orthoses|Prefabricated insole
45473048|NCT04138680|Behavioral|Sham Biofeedback|The sham biofeedback session resembles the active condition, however, the thermometer seen during the MOTIVATE trials will represent yoked sham values.
45473049|NCT05172856|Drug|IBI321|IBI321 at a dose no higher than RP2D, D1 IV Q3W.
45473050|NCT01271231|Drug|Scaling and root planing plus placebo|Single session of scaling and root planing using ultrasonic device. placebo tablets 500 mg, 1 tablet every 24 hours for 3 days
45683439|NCT04630756|Drug|AZD4573|AZD4573 will be administered as an absolute (flat) dose, 2-hour (± 15 minutes) IV infusion once weekly (as monotherapy for Module 2 only) and in combination with orally administered acalabrutinib twice daily continuously. For both Part A and Part B of this study, Cycle 1 consists of 5 weeks, with a dose ramp-up. Subsequent cycles are 21 days (3 weeks) with once weekly dosing of AZD4573 in combination with acalabrutinib twice daily continuously (in Module 1 and Module 2, period 2).
45683440|NCT04630756|Drug|Acalabrutinib|Oral Acalabrutinib capsule will be administered twice daily continuously from Day 1 of Cycle 1 Week 1 in combination with AZD4573.
45683441|NCT04414436|Behavioral|GYNEA- digital coping program for women after gynaecological cancer|6 modules with relevant information and tools for coping after cancer
46035781|NCT04824118|Diagnostic Test|Clotting Studies|"Standard laboratory tests for clotting:~International normalised ratio (INR)~Prothrombin time (PT)~adjusted partial thromboplastin time (aPTT)~fibrinogen"
46035782|NCT04824118|Diagnostic Test|Full Blood Count|For platelet count
46035783|NCT04824118|Diagnostic Test|Quantitative hCG|Serum human chorionic gonadotrophin
45683442|NCT03240328|Biological|CAR-T cells|HIV-1 specific chimeric antigen receptor cells
45683443|NCT04746196|Other|Serum galectin-3 concentration was measured.|Serum galectin-3 concentration was measured using a commercial chemiluminescent microparticle immunoassay.
45683444|NCT01866098|Drug|Naltrexone|25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.
46035784|NCT04824118|Diagnostic Test|Pregnancy Test|Point of care urinary pregnancy test
46035785|NCT02627911|Device|Diabeloop System|Insulin delivery
46035786|NCT02627911|Device|Continuous Glucose Monitoring|
46035787|NCT02627911|Device|Accelerometer and heart rate monitor|Monitoring and measurement of physical activity
46035788|NCT02627911|Dietary Supplement|Meals|Calibrated meals for all patients and outstanding dinners for patients being in outstanding meals situation (Centers : Grenoble, Toulouse, Montpellier)
46035789|NCT04239586|Drug|Sulfonylurea|Starting treatment with sulfonylurea class of drug
45340271|NCT04104555|Other|Signposting to multimedia|Signposting to multimedia information in the patient information sheet which is sent to participants in the post as part of the OSTRICH recruitment pack.
45340272|NCT04104555|Other|Usual supportive care - exercises and footwear advice (the comparator)|Active comparator
45473051|NCT01271231|Drug|Scaling and root planing plus azythromycin|Single session of scaling and root planing using ultrasonic device. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
46035790|NCT02628613|Drug|Vinorelbine plus Epirubicin|Evaluate the efficiency and safety of vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations
46035791|NCT02628613|Drug|Paclitaxel plus Epirubicin|standard neoadjuvant chemotherapy
46035792|NCT04239352|Diagnostic Test|Pentraxin 3 ; new biomarker|"Pentraxin (PTX3) is an inflammatory molecule that belongs to a recently identified, well-known C-reactive protein (CRP) family.~PTX3 plasma levels increase in vascular disorders including myocardial infarction and correlate with small vessel vasculitis and outcome or disease activity.~These biological and clinical features of PTX3 have led us to investigate this molecule in preeclampsia, a syndrome characterized by a prominent vascular component."
46035793|NCT04239352|Diagnostic Test|Lipoprotein-associated phospholipase A2 ; new biomarker|Lp-PLA2 is a recently described and potentially useful plasma biomarker associated with cardiovascular diseases. Because of this effect, we will investigate that preeclampsia also be beneficial.
45340273|NCT04049487|Other|Exercise|Both groups will participate in group exercise as previously described
45340274|NCT02558517|Drug|prednisone discontinuation|randomization
45340275|NCT00674973|Drug|Erlotinib|Participants received erlotinib 150 mg tablet orally once daily.
45473052|NCT01271231|Drug|Prophylaxis plus azythromycin|Dental polishing using prophylaxis paste and rubber cups. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
45340276|NCT00674973|Drug|Placebo|Participants received placebo matching to erlotinib 150 mg tablet orally once daily.
45340277|NCT00673179|Drug|Doxorubicin|Pre-Surgery, Regimen 1: IV Over 15 Minutes on Day 1 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV on Day 1 of Weeks 16, 21, and 26; Pre-Surgery, Regimen 2: IV over 15 Minutes on Day 1 of Weeks 1, 4, and 7. Dose 90 mg/m^2.
45340278|NCT00673179|Drug|Cisplatin|Pre-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 16, 21, and 26. Pre-Surgery, Regimen 2: Infusion through an artery over 4 hours on Day 1 of Weeks 1, 4, and 7. Dose 60 mg/m^2/day for 2 days continuous infusion.
45683445|NCT01866098|Drug|Placebo|
45683446|NCT04919356|Genetic|G2019S LRRK2|No cost genetic testing for G2019S LRRK2
45683447|NCT04399798|Drug|Baricitinib|4 mg/day for 7 days
45683448|NCT04897360|Behavioral|Increased breathing|hyperventilation to lower ETCO2
45683449|NCT04897360|Other|sharpened Romberg test (SRT)|Balance test conducted by standing with feet in front of each other, heel-to-toe in line while the right hand is on the left shoulder and the left hand is on the right shoulder.
45340279|NCT00673179|Drug|Methotrexate|Pre-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 4, 5, 9, and 10; Post-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 14, 15, 19, 20, 24, 25, 29, and 30; Post-Surgery, Regimen 2: IV Over 4 Hours on Day 1 of Weeks 14, 15, 20, 21, 26, 27, 32, 33, 38, and 39. Dose 12 gm/m^2, max 20 gm over 4 hours.
45340280|NCT00673179|Drug|Leucovorin|Pre- and Post-Surgery, Regimen 1: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours; Post-Surgery, Regimen 2: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours. Dose 10 mg IV, with 10 mg orally every 6 hours.
45340281|NCT00673179|Drug|Dexrazoxane|Dose 900 mg/m^2 IV Push with doxorubicin. Pre-Surgery, Regimen 2: IV Over 15 minutes on Day 1 of Weeks 1, 4, and 7.
45683450|NCT04889326|Other|Retrospective data and biological samples|Analysis of data and biological samples collected during hospitalization:
45683451|NCT04885972|Drug|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
45683452|NCT04885972|Drug|Zilretta|Zilretta is an extended-release corticosteroid approved to manage osteoarthritis knee pain.
45683453|NCT04885972|Drug|Placebo|Vehicle solution
45683454|NCT04884568|Device|Exufiber|Wound dressed with Exufiber for up to 21 days.
45683455|NCT04039750|Drug|antibiotic rinse with suction|antibiotic rinse with suction
45683456|NCT04039750|Procedure|suction only|no irrigation, suction only
45683457|NCT03264196|Procedure|Open Reduction and Internal Fixation|Surgical treatment of fracture
45683458|NCT03236428|Drug|Daratumumab|Daratumumab is a drug that may kill or stop cancer cells from growing through a variety of mechanisms by attaching to the CD38 molecule
45683459|NCT03985540|Behavioral|Behavorial; memory exercise|Memory training twice a week for 5 weeks.
45683460|NCT03985540|Behavioral|Placebo; memory exercise|Placebo Memory training twice a week for 5 weeks
45683461|NCT03985540|Behavioral|Behavioral: speed exercises|Speed training twice a week for 5 weeks.
46035794|NCT02627833|Other|observation|Record lung function, Lung clearance index, inflammatory status
45683462|NCT03985540|Behavioral|Placebo speed training|Placebo Speed training twice a week for 5 weeks.
45683463|NCT04347772|Dietary Supplement|Oral Nutrition Support|Intensive Nutrition Intervention
46035795|NCT01100034|Drug|Etanercept|Expected duration of 24 weeks as one course
46035796|NCT00675727|Biological|CADI-05|Two intradermal treatments each week for first 4 weeks followed by one intradermal treatment per week for second 4 weeks.
46035797|NCT02822560|Device|pEVAR|percutaneous femoral access using a suture-mediated closure device
46035798|NCT02822560|Procedure|open femoral access|cutdown to femoral artery and surgical closure
46035799|NCT00675805|Device|Infusomat filter (Codan Duofilter-Set V86-P)|An approved filter system may be efficient in retaining complement activating IgG aggregates in IVIG preparations. This effect may reduce complement activation and consecutive inflammation thereby diminishing adverse events during application of intravenous immunoglobulins.
46035800|NCT00675805|Device|IVIG application without filter (Placebo)|Application Intravenous immunoglobulins without filter (Placebo)
45683464|NCT03263026|Drug|Enzastaurin Hydrochloride|R-CHOP + Enzastaurin (Kinenza®) 125 mg
45683465|NCT03263026|Other|R-CHOP + placebo|R-CHOP + placebo
45340282|NCT00673179|Drug|Ifosfamide|Post-Surgery, Regimen 2: IV continuously over 5 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m^2. Dose 2.8 grams m^2/day.
45340283|NCT00673179|Behavioral|Questionnaire|Questionnaires to be completed on 5 different days during the study.
45340284|NCT00673179|Drug|Gemcitabine|IV over 1 hour, every other week.
45340285|NCT00673179|Drug|Sargramostim|Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg) twice a day for 7 days on, 7 days off, beginning the day receive gemcitabine.
45340286|NCT00673179|Procedure|Surgery|Planned limb salvage surgery after 3 courses of doxorubicin + cisplatin (IV) and High-dose methotrexate - at approximately week 12.
45683466|NCT04858360|Drug|Emla 1 hour|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 1 hour.
45683467|NCT04858360|Drug|EMLA 3 hours|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 3 hours.
45340287|NCT00673179|Drug|Mesna|IV continuously over 6 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m^2/day.
45340288|NCT02584088|Other|Ultrasound|The appearance of the post ablative endometrium on transvaginal ultrasound at 2, 6, and 12 months.
45340289|NCT00758433|Drug|Zucapsaicin|Civamide patch 0.0075% q.d. 24 hours for 7 days
45340290|NCT00758433|Drug|Zucapsaicin|Civamide patch 0.0150% q.d. 24 hours for 7 days
46035801|NCT02880930|Dietary Supplement|Fultium-D3 drops (Internis)|Oral daily doses of vitamin D3 (400 IU for 3 months; and 1,000 IU for an additional 3 months)
45340291|NCT00758433|Drug|Placebo patch|Placebo patch q.d. 24 hours for 7 days
45340292|NCT00758511|Procedure|25% Sucrose|orally administrated 25%Sucrose before, during and after heel stick
45340293|NCT00758511|Procedure|facilitated tucking|facilitated tucking before, during and after heel stick
45340294|NCT00758511|Procedure|Sucrose and facilitated tucking|orally administrated 25%sucrose and facilitated tucking before, during and after heel stick
45340295|NCT00584012|Drug|Lovastatin|Given PO
45340296|NCT00584012|Drug|Docetaxel|Given IV
45340297|NCT05435846|Drug|Capmatinib|Given orally
45340298|NCT05435846|Drug|Trametinib|Given orally
45340299|NCT00920270|Drug|nebulized colistin|nebulized colistin 75 mg every 12 hours
45839921|NCT04736784|Other|Food-based - leafy green vegetable juice|Leafy green vegetable juice containing approximately 340 mg nitrate daily
46035802|NCT04770766|Other|Non-medical practitioners|All observational research activity in each cohort is related to the exposure of non-medical practitioners in the Emergency Department or Urgent Treatment Centre
45340300|NCT00920270|Drug|antibiotics|conventional parenteral antibiotics
45340301|NCT04080674|Other|Feed-back controlled deep brain stimulation|Feed-back controlled deep brain stimulation
45340302|NCT04078724|Dietary Supplement|5-HTP|5-HTP that have Good Manufacturing Practice certification will be used and participants will be suggested to be take the 5-HTP supplementation at bedtime.
45340303|NCT04078724|Other|Without 5-HTP|Subject will not take 5-HTP
45340304|NCT02583386|Behavioral|Free From Falls fall prevention program|Eight-week education and exercise program, intended to reduce falls in people with Multiple Sclerosis.
45340305|NCT02583386|Other|Electronic Fall Detector|30 participants will be randomly selected to wear an electronic fall detector during the first 10 weeks of study participation. This fall detector will automatically record any falls occurring while worn.
45340306|NCT04454450|Diagnostic Test|PET/MRI|Imaging will include research PET/MRI of pelvis within 30 days of multiregion tissue collection.For research PET/MRI - standard volumes of gadolinium contrast and fluorodeoxyglucose (FDG) will be administered.
45340307|NCT04454450|Diagnostic Test|Contrast enhanced CT|Standard of care contrast enhanced CT
45473053|NCT04575285|Diagnostic Test|Electroencephalogram (EEG)|EEG measures brain activity by recording the spontaneous brain electrical activity and evoked responses non-invasively from the scalp. Reusable Tangle Free 10mm EEG Cup Electrodes will be placed on the subject's scalp using the 10-20 system montage.
46035803|NCT04148833|Drug|LDE-Paclitaxel|LDE-Paclitaxel at the dose of 175 mg/m2 IV each 21 days for 6 weeks
46035804|NCT04148833|Drug|LDE-Placebo|LDE-Placebo at the dose of 175 mg/m2 IV each 21 days for 6 weeks
46035805|NCT04926246|Drug|R1: Reference Product X|under fasted conditions
46035806|NCT04926246|Drug|T1: Test Product M|under fasted conditions
46035807|NCT04926246|Drug|T2: Test Product N|under fasted conditions
45340308|NCT04537364|Diagnostic Test|combined diagnosis of renal parenchymal damage|"This study is an observational study to evaluate the accuracy of renal parenchymal damage combined diagnosis with no intervention. All patients from the cohort accept MRI-DWI scan，the urinary biomarkers detection, disease gene detection and DMSA scan.~This combined diagnosis includes MRI-DWI scan and the urinary biomarkers detection.~MRI-DWI： All the scans are performed using the MagnetomVerio 3.0T magnetic resonance imaging system from Siemens.~Urinary polypeptide collection: Urine samples requirements: volume between 50-100ml, specific gravity >1.010. Immunomagnetic beads isolation technique is used to collect polypeptide.~The reference standard is DMSA scan: Intravenous injection of 99mTC-DMSA5mCi is followed by anterior and posterior planar imaging of the renal area 1 hour later. The DMSA scan images are read by 2 trained radiologists and confirmed by the special doctor of the center for diagnosis and treatment of renal and urinary diseases at the same time."
46035808|NCT04926246|Drug|T3: Test Product O|under fasted conditions
46035809|NCT04926246|Drug|T4: Test Product O|under fed conditions
46035810|NCT04926246|Drug|R2: Reference Product Y|under fasted conditions
46035811|NCT04926246|Drug|T5: Test Product P|under fasted conditions
46035812|NCT04926246|Drug|T6: Test Product P|under fed conditions
46035813|NCT04926246|Drug|T7: Test Product Q|under fasted conditions
46035814|NCT04926246|Drug|R3: Reference Product Z|under fasted conditions
46035815|NCT04926246|Drug|T8: Test Product S|under fasted conditions
46035816|NCT04926246|Drug|T9: Test Product S|under fed conditions
46035817|NCT04926246|Drug|T10: Test Product U|under fasted conditions
45340309|NCT02585882|Other|Fluoride table salt|
46035818|NCT02821546|Drug|Lactated Ringer's solution|Standard fluid hydration with Lactated Ringer's solution is calculated based on Holiday Segar's equation Aggressive hydration with Lactated Ringer's solution is defined as administration of 150 ml/hour of fluid
46035819|NCT02821702|Device|Vaginal ultrasound|
46035820|NCT02821702|Biological|Blood sample|
46035821|NCT00876265|Device|Belotero|Belotero, injectable hyaluronic acid gel device, implanted into the nasolabial fold in the Treatment Phase of the study (multiple injections of 0.1 to 0.2 mL, up to a maximum of 3 mL over 2 treatment sessions). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered.
46035822|NCT00876265|Device|Zyplast|Zyplast Collagen Implant, an injectable dermal collagen device, implanted into the nasolabial fold in the Treatment Phase of the study (average injection of 1.0 mL). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered. Zyplast was obtained by each site from commercially available supplies.
46035823|NCT04308018|Procedure|S2alar-iliac screws|Caudal end of the instrumentation at iliac bone via S2alar-iliac screws
46035824|NCT04308018|Procedure|S1 screws|Caudal end of the instrumentation at S1
46035825|NCT02690350|Drug|U3-1784|Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated
46035826|NCT02879838|Other|Blood sample|Biobank. Analysis of cytokines and DNA polymorphisms
45340310|NCT04080596|Drug|Dorzagliatin|GKA for T2DM currently under clinical development
45340311|NCT04522154|Diagnostic Test|Magnet resonance imaging|Patients will receive a cardiac magnet resonance tomography before and 3-month after the procedure
45340312|NCT00920738|Other|metabolic assessment|Physical examination, medical history, blood pressure, anthropometrics, laboratory studies and other procedures (body composition, bone density, growth hormone, vascular, functional mobility, body fat assessments, etc).
45340313|NCT00920738|Other|questionnaire administration|Dietary habits will be evaluated using the Youth/ Adolescent Questionnaire (YAQ)and the Modifiable Activity Questionnaire for Adolescents (MAQA) will be used to assess participation in leisure time and competitive activities during the past year will be administered on Day 2.
46035827|NCT02821468|Drug|Droglican|Combined Chondroitin Sulfate 1200 mg + Glucosamine Hydrochloride 1500 mg
46035828|NCT02821468|Drug|Paracetamol or oral NSAIDs excluding COX2 inhibitors|
45340314|NCT02585648|Device|Thealoz Duo Gel and Thealoz Duo eye drops|Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day)
45340315|NCT02585648|Device|Thealoz Duo eye drops|Thealoz Duo eye drops during the day (4 to 6 drops per day)
45340316|NCT02584010|Other|Silicon-based aerosol|Apply twice a day over the postoperative scar
45340317|NCT02584010|Other|Silicon-based gel|Apply twice a day over the postoperative scar
45340318|NCT02585804|Drug|Dapagliflozin|Oral tablet, 10mg, PO, 8 weeks
45340319|NCT02585726|Device|SP-402 VenaSeal™ Closure System|A medical device kit consisting of seven delivery tools and the proprietary VenaSeal™ Adhesive (Medtronic Cardiovascular, Santa Rosa, CA). The device is used to treat venous reflux in lower extremity superficial truncal veins for subjects in the treatment arm..
45340320|NCT04079270|Other|Nutrition intervention|The diet recommendations will be provided by a certified dietitian. Participants will be asked to document their food intake and daily activities including exercise and sleep using a dedicated smartphone app throughout the intervention period.
45340321|NCT04506866|Device|InterStim Micro|Eligible subjects will receive InterStim Micro therapy. Commercial devices will be used within their intended use as described in each geography's approved instructions for use
46035829|NCT04964622|Drug|nurofen|tablet
46035830|NCT04769050|Drug|Docetaxel combined with Trastuzumab±Pertuzumab|Docetaxel, 75 mg/m2 ivgtt d1 q3w Trastuzumab, 6 mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Pertuzumab, 420mg(840mg for initial dose) ivgtt d1 q3w
46035831|NCT04769050|Drug|T-DM1 or Capecitabine combined with Pyrotinib regimen.|T-DM1, 3.6mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Capecitabine, 1250 mg/m2 bid po d1-14 q3w Pyrotinib, 400mg po daily (continuously)
45340322|NCT05674760|Device|Trancutaneous CO2 monitoring (using TCM5 device)|Patients in the Transcutaneous arm will undergo Trancutaneous CO2 monitoring (using TCM5 device)
45340323|NCT05674760|Other|Arterial Blood Gas (ABG) sampling|Arterial Blood Gas (ABG) sampling to monitor CO2 - as per standard practice.
45340324|NCT02582996|Drug|Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.|The subject must manage 02 tablets of Cefalium right after a moderate to severe migraine.
46035832|NCT04309656|Drug|Pretomanid|"Treatment A (reference) = 200 mg given as a single 200 mg tablet (using the immediate release formulation), orally administered.~Treatment B (test) = 200 mg given as four 50-mg tablets (using the dispersible pediatric formulation), orally administered.~Treatment C (test) = single 50-mg dispersible tablet, orally administered.~Treatment D (test) = single 10-mg dispersible tablet, orally administered."
46035833|NCT02821624|Drug|G1T38 (CDK 4/6 Inhibitor)|CDK 4/6 Inhibitor
45340325|NCT02582996|Drug|Acetaminophen|The subject must manage 02 tablets of Tylenol right after a moderate to severe migraine.
45340326|NCT00674817|Drug|400 microgrammes GSK961081|Inhaled GSK961081 administered via Dry Powder Inhaler.
45340327|NCT00674817|Drug|1200 microgrammes GSK961081|Inhaled GSK961081 adminisntered via dry powder inhaler.
45340328|NCT04080440|Procedure|Extubation readiness clinical score|"After treatment of the acute neurological condition, elligibility for a spontaneous breathing trial will be assessed 2 times a day.~In the intervention group, after a successful spontaneous breathing trial in unconscious patients, the score will be evaluated.~If the score is >9, extubation has to be completed"
45473054|NCT04132596|Device|Transcutaneous spinal cord stimulation|Electrical stimulation of the spinal cord via transcutaneous hydrogel electrodes
45473055|NCT04132596|Other|Activity Based Therapy|Physical therapy
46035834|NCT02821624|Drug|Placebo|Placebo
46035835|NCT02879058|Procedure|Intraoperative contact ultrasonography|In patients randomized to myomectomy with contact ultrasonography, the laparoscopic or robotic ultrasound probe will be advanced through an existing port site into the pelvis after traditional myomectomy has been performed. The face of the ultrasound transducer will be guided over the uterus (including open hysterotomy sites) in systematic strokes, taking special care to note locations of myomas that may have been missed by the preceding excision. Additional hysterotomy sites will be made as necessary in order to remove persistent myomas. Any number of additional ultrasound passes and excisions may be performed in order to achieve the most comprehensive removal of myomas.
46035836|NCT02881164|Other|Low glycemic index|Subjects intake a low glycemic index breakfast
46035837|NCT02881164|Other|High glycemic index|Subjects intake a high glycemic index breakfast
46035838|NCT02821390|Drug|Nepafenac Eye Drops|One drop instilled to the eye's cul de sac prior to the intravitreal injection.
46035839|NCT02821390|Drug|Placebo (Artificial Tears)|One drop instilled to the eye's cul de sac prior to the intravitreal injection
46035840|NCT02821312|Drug|DA-8010|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 8 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 8 subject for DA-8010."
46035841|NCT02821312|Drug|Placebo|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 2 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 2 subject for DA-8010."
45340329|NCT04080440|Procedure|Standard of care|"After treatment of the acute neurological condition, elligibility for a spontaneous breathing trial will be assessed 2 times a day.~In the control group, after a successful spontaneous breathing trial in unconscious patients, the extubation will be achieved according to the standard of care"
45683468|NCT04858360|Other|Vehicle cream for 1 hour|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 1 h.
46035842|NCT02821078|Other|4D flow imaging sequence|4D flow imaging sequence
46035843|NCT04240132|Other|Adherence to Hand Hygiene|determine the colonization of microorganisms due to microbial reproduction on the external surface of the distal end of the enteral feeding tube (EFT), hub of the EFT and other feeding system components and assess the relation between the colonization and adherence to hand hygiene practices by nurses and other healthcare workers
46035844|NCT02821156|Drug||Inhaled Nitric Oxide with monitoring by EZ-KINOX device
46035845|NCT02821234|Other|MRI|
46035846|NCT02820922|Procedure|Orthopedic|anesthesia techniques with regard to age, sex, ASA score, anaesthesia technique, comorbidities, surgery diagnosis, length of surgery, complications and admission to intensive care unit after surgery
46035847|NCT02822638|Other|STEMI PATIENT Cohort|PCI
46035848|NCT05659264|Drug|mRNA-0184|mRNA-0184 dispersion for intravenous (IV) infusion
45340330|NCT04078802|Procedure|VNOTES/VH|same as above
45683469|NCT04858360|Other|Vehicle cream for 3 hours|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 3 h.
45683470|NCT04858360|Other|Cowhage|Cowhage spicules are 1-2 mm in length and have a diameter of 1-3 μm. The spicules are inserted by gently rubbing 30-35 spicules into a 1 cm diameter skin area.
46035849|NCT05659264|Drug|Placebo|0.9% sodium chloride (normal saline) injection
45340331|NCT02585570|Drug|Phenylephrine|Patients is received phenylephrine 1.0 mcg/kg/min or 0.5 mcg/kg/min for 5 minutes before being placed in the beach chair position.
46035850|NCT00633958|Drug|18F-FLT|Patients will receive a dose of 18F-FLT through a fresh intravenous catheter as per standard PET procedures. Dosing will be based on age.
46035851|NCT00633958|Radiation|PET Imaging|
45340332|NCT02583932|Drug|Meaning-Making intervention (MMi)|The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis.
45340333|NCT02583932|Behavioral|Empathic Visitor|They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing.
45340334|NCT02583854|Device|RY-STOP hemostasis device|
45473056|NCT03697876|Drug|PRO-165|PRO-165 Chondroitin sulfate 0.18% / sodium hyaluronate 0.2%, ophthalmic gel. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
46035852|NCT02820688|Drug|Bupivacaine 0.25%|
46035853|NCT02820688|Drug|Prilocaine 1%|
45473057|NCT03697876|Drug|Artelac|Artelac® Nightime Gel. 0.2% Carbomer, ophthalmic gel. Made in Germany by: Dr. Gerhard Mann Chem Pharm. Imported and marketed by: Bausch & Lomb México, S.A. de C.V.
45473058|NCT04526691|Drug|Datopotamab deruxtecan|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle (starting datopotamab deruxtecan dose of 4.0 mg/kg)
45473059|NCT04526691|Drug|Pembrolizumab|Intravenous infusion Q3W on Day 1 of each 21-day cycle (fixed pembrolizumab dose 200 mg Q3W)
45473060|NCT04526691|Drug|Carboplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (AUC 5)
45473061|NCT04526691|Drug|Cisplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (75 mg/m^2)
46035854|NCT02820688|Procedure|Infraclavicular Nerve Block|Ultrasound guided infraclavicular nerve block
46035855|NCT02820688|Drug|Bupivacaine 0.167%|
46035856|NCT02820688|Drug|Bupivacaine 0.125%|
46035857|NCT02820688|Drug|Prilocaine 0.66%|
46035858|NCT02820688|Drug|Prilocaine 0.5%|
46035859|NCT02820688|Device|Ultrasound|All nerve blocks will be performed with ultrasound guidance
45340335|NCT02583854|Device|TR-Band, Terumo|
45340336|NCT02583074|Procedure|Stimulation|After surgery, patients in 'Neurostimulation Group' will receive subthalamic nucleus stimulation for 3 months.
45473062|NCT03384394|Device|high-flow nasal cannula oxygen|high-flow nasal cannula oxygen
46035860|NCT02818816|Drug|brimonidine tartrate 0.2%|Alpha adrenergic receptor agonist
46035861|NCT02818816|Other|Carboxymethylcellulose Eye Drops|Ocular lubricants
46035862|NCT02820610|Drug|Dexmedetomidine|2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity
46035863|NCT02820610|Drug|Magnesium Sulfate|2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity
46035864|NCT02820610|Drug|Normal saline 0.9 %|2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
46035865|NCT04751266|Procedure|minimally invasive repair of pectus excavatum|substernal insertion of a metal bar
46035866|NCT04747522|Drug|SARS-CoV-2 vaccine|SARS-CoV-2 vaccines currently on market, i.e. Pfizer/BioNTech and Moderna
46035867|NCT02820532|Device|Protura Treatment table|The treatment couch will be moved according to the respiratory motion of the patient. As a reference first the respiration will be measured without couch motion, than the couch will be switched on and we will evaluate if the respiration changes due to the motion of the couch. This procedure will be repeated once.
46035868|NCT04745728|Drug|Prednisone|1mg/kg/d p.o.which will be tapered after 2 months and discontinued over a 6-12 month period.
46035869|NCT04745728|Drug|Cyclophosphamide|1-2mg/kg/d p.o. with a target accumulated dose of 12g.
46035870|NCT04745728|Drug|Rituximab|1000mg I.V. on D1 and at 6 month. After 6 month, in patients with response but not complete remission, Rituximab could be stopped or repeated with a 6 month-interval (12 month, 18 month, 24 month) until complete remission. Rituximab 1000mg I.V. will be repeated on the 15th day of each Rituximab infusion if CD19+ B cell count>5/ul.
46035871|NCT05658718|Procedure|refractive surgery|refractive surgery
45340337|NCT02583074|Procedure|Sham-stimulation|After surgery, patients in 'sham-stimulation Group' will receive subthalamic nucleus sham-stimulation for 3 months.
45340338|NCT00764907|Drug|asparaginase|Given IV during reinduction
45340339|NCT00764907|Drug|cyclophosphamide|Given IV during reinduction
45683471|NCT04852822|Procedure|Biospecimen Collection|Undergo collection of blood samples
46035872|NCT02818660|Drug|Synachten|To stimulate the adrenals to increase the cortisol Production as much as possible
46035873|NCT05659186|Drug|Tislelizumab|200mg IV Q3W
45340340|NCT00764907|Drug|cytarabine|Given IV during reinduction
45340341|NCT00764907|Drug|daunorubicin hydrochloride|Given IV during reinduction
45340342|NCT00764907|Drug|dexamethasone|Given IV or orally during reinduction
45340343|NCT00764907|Drug|doxorubicin hydrochloride|Given IV during reinduction
45340344|NCT00764907|Drug|etoposide|Given IV during reinduction
45340345|NCT00764907|Drug|ifosfamide|Given IV during reinduction
45340346|NCT00764907|Drug|leucovorin calcium|Given IV during reinduction
45340347|NCT00764907|Drug|mercaptopurine|Given orally during reinduction
45340348|NCT00764907|Drug|methotrexate|Given orally during reinduction
45340349|NCT00764907|Drug|prednisone|Given intrathecally during reinduction
45340350|NCT00764907|Drug|thioguanine|Given orally during reinduction
45340351|NCT00764907|Drug|vincristine sulfate|Given IV during reinduction
45340352|NCT00764907|Drug|vindesine|Given IV during reinduction
45340353|NCT02585492|Other|Head-of-bed elevated 15°|Head-of-bed elevated 15° during 2 hours after delivery.
45683472|NCT04852822|Other|Electronic Health Record Review|Medical records are reviewed
45340354|NCT02585492|Other|Head-of-bed elevated 45°|Head-of-bed elevated 45° during 2 hours after delivery.
45340355|NCT04417946|Behavioral|PrEP messages|The peer leaders and the study staff will post PrEP related health messages
46035874|NCT05659186|Drug|Anlotinib|12mg PO QD
46035875|NCT05659186|Radiation|Radiotherapy|Multimodal Radiotherapy
46035876|NCT01107444|Drug|Docetaxel|Administered intravenously
45340356|NCT04417946|Behavioral|Heath messages|The peer leaders and study staff will post general health messages that are not related to sexual health
45340357|NCT00672633|Drug|Lovaza|Lovaza , 4 grams/day orally for 6 months
45340358|NCT00672633|Drug|Placebo|Corn Oil Pill, 4 pills/day orally for 6 months
46035877|NCT01107444|Drug|LY2181308|Administered intravenously
46035878|NCT04238806|Drug|Desflurane Inhalational agent|Desflurane inhalational agent administration during the whole cardiac surgical operation with cardiopulmonary bypass versus administration of desflurane inhalational agent before and after cardiopulmonary bypass during the whole period of cardiac surgical operation.
45340361|NCT00672555|Procedure|Limberg-flap|Complete excision of the pilonidal sinus and covering of the defect by a Limberg-flap from one buttock
45340362|NCT00758823|Device|Paranix|pediculicide product
45683473|NCT01865552|Biological|SB4|SC administration
45683474|NCT01865552|Biological|EU sourced Enbrel|SC administration
45683475|NCT01865552|Biological|US sourced Enbrel|SC administration
46035879|NCT02820454|Drug|AGuIX|A single intravenous injection on day 1. Dose level 1: 15mg/kg; Dose level 2: 30mg/kg, Dose level 3: 50mg/kg; Dose level 4: 75mg/kg; Dose level 5: 100mg/kg
45340363|NCT00758901|Device|Knee Replacement (with ROCC Knee prosthesis)|Knee Replacement (with ROCC Knee prosthesis)
45340364|NCT02583698|Drug|Carvedilol|
45340365|NCT02583698|Drug|Placebo|
46035880|NCT02820454|Radiation|whole brain radiation therapy|30Gy in 10 sessions of 3Gy (5 days a week in weeks 1-2); first session 4 hours after AGuIX injection.
46035881|NCT05659108|Behavioral|CPR|HIGH QUALITY CPR
45340366|NCT05317143|Other|Evaluation of prostate cancer margins|Evaluation of prostate cancer margins
45340367|NCT00762099|Drug|Pregabalin|Pre-operative dose 150 mg Post-operative dose 75 mg BID
45340368|NCT00762099|Drug|Placebo|Placebo/sugar tabs will look identical to active drug.
45340369|NCT00762255|Drug|Vorinostat|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
45340370|NCT00762255|Drug|Bevacizumab|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
45340371|NCT00762255|Drug|Irinotecan|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
45340372|NCT04078958|Dietary Supplement|Salmon fishmeal|Salmon fishmeal with high protein content
45473063|NCT03384394|Device|Conventional oxygen therapy|oxygen by a standard nasal cannula or nonrebreather mask
45340373|NCT04078958|Dietary Supplement|Whey|Whey with high protein content
45340374|NCT04080206|Drug|188-0551 Spray|Applied topically twice daily for two weeks
45340375|NCT04080206|Drug|RLD|Applied topically twice daily for two weeks
45340376|NCT00765219|Behavioral|CBT|10-12 weekly sessions of CBT in person or over the telephone.
45340377|NCT00765219|Other|Usual Care|Treatment as usual provided by participants' physician(s)
45473064|NCT01280669|Drug|Intravitreal injection 440mcg|Intravitreal injections of sirolimus 440mcg/20mcL at baseline and months 1, 2, 3, 4, and 5.
45340378|NCT02585180|Device|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
45340379|NCT02585180|Device|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
45340380|NCT00765297|Device|fall related movement (stumble) detector|movement pattern (gait,balance) of young subjects recovery of a stumble in young subjects
45340381|NCT00765297|Device|fall related movement characteristic (stumble) detector|age related gait changes influencing movement pattern different pattern to recover from a trip
45340382|NCT02583542|Drug|AZD2014|AZD2014 is a dual inhibitor of both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin insensitive); compared to rapalogues, AZD2014 has a broader range of growth inhibitory activity in preclinical models based on a more profound mTORC1 inhibition and the additional inhibition of mTORC2. AZD2014 is currently in phase 2 studies in renal cell cancers and metastatic breast cancer.
45340383|NCT02583542|Drug|AZD6244|Selumetinib (AZD6244, ARRY-142886) is an orally available, potent, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinases. Selumetinib has demonstrated clinical efficacy in pre-treated KRAS-mutant NSCLC, leading to a significantly improved progression-free survival in combination with docetaxel compared to docetaxel alone.
45340384|NCT02557971|Drug|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) as prescribed in clinical practice.
45340385|NCT02583776|Device|Unblinded - CGM|Data from device will be readable and alarms on
45340386|NCT02583776|Device|Blinded - CGM|Data from device will be blinded and alarms off
45340387|NCT04048785|Other|Behavioral sleep intervention|The intervention consists of an infant behavioral sleep protocol. In the tailored intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings.
45340388|NCT05674682|Procedure|HIV testing|venipuncture or digital puncture for HIV testing
45340389|NCT02557815|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive 10Hz right DLPFC stimulation using Magstim TMS apparatus
45340390|NCT02583620|Genetic|blood sample|A blood test is realized on the subject
45340391|NCT00765453|Other|Bone marrow derived progenitor cells or placebo infusion|Over-the-wire balloon catheter delivers infusion into coronary vessel using a stop-flow technique
45473065|NCT01280669|Drug|Intravitreal injection of sirolimus 880mcg|Intravitreal injection of 880mcg/20mcL sirolimus at baseline and months 2 and 4.
45340392|NCT00765453|Other|Placebo infusion|Placebo infusion
45340393|NCT05332730|Drug|BAT2506 injection|50 mg, subcutaneous administration
45340394|NCT05332730|Drug|Simponi® (EU commercially available product)|50 mg, subcutaneous administration
45340395|NCT05332730|Drug|Simponi® (US commercially available product)|50 mg, subcutaneous administration
45340396|NCT02581904|Device|Prevena Care|The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
45340397|NCT02581904|Device|Dry gauze dressing care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
46035882|NCT02878824|Other|Ethnicity|"As mentioned by Goldberger and Veroff (1995) the concept of ethnicity is also associated with culture and is often used interchangeably with culture as well as with race. Ethnic differences are not necessarily inherited, but they are learned through constant exposure; however have strong genetic influences that explain consequent behavioural differences between different ethnic groups (Chudek & Henrich, 2011). An individual's genetic makeup greatly affects their behaviours (Klahr & Burt, 2014).~In this study, we look at exposure to different ethnicity as exemplified by comparison between two groups of typically-developing children from different ethnicity (Chinese children in Hong Kong and Filipino Children in Hong Kong)."
46035883|NCT02878824|Other|Environment|The living environment has been implicated to have an effect on a person's psychological functioning (Rutter, Picker, Murray & Eaves, 2001) and eventually how behaviour is manifested. The proposed disparity or effects between urban and rural dwelling is built on research that looks at the restorative and calming features of the natural environment, as well as the chaotic organization of the living spaces in urban settings.
45340398|NCT02581826|Drug|Silodosin|α1-adrenoceptor antagonists are distributed not only in the bladder neck, urethra, and prostate, but also in the seminal vesicle and vas deferens. Specifically, the distribution of messenger ribonucleic acid (mRNA) of α1-adrenoceptor antagonists in seminal vesicle and vas deferens is reported to be 75-97%. It is reasonable to use α1-adrenoceptor antagonists with high selectivity for patients with Premature Ejaculation (PE). A new highly selective α1-adrenoceptor antagonists, is strongly associated with dry ejaculation with loss of seminal emission. It had the highest selectivity for the vas deferens compared with other α1-adrenoceptor antagonists.The effectiveness of highly selective α1-adrenoceptor antagonists as a potential therapy for this class of patients was scarcely investigated.
46035884|NCT04627558|Other|stroke patients, balance assessment|validity relability dubousset functional test
45340399|NCT02581826|Drug|Placebo|No column specified.
45340400|NCT00765687|Drug|bisphosphates|any bisphosphate, repeated every 4 weeks for up to 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
46035885|NCT02820376|Other|Differential renal function assessment by 4D CT|Low dose 4D (perfusion) renal acquisition after injection of iodinated contrast medium (ICM) (13 passes every 3 seconds, 3 passes every 10 seconds); estimated additional DLP 400 mGy.cm No additional contrast medium
45340401|NCT04340882|Drug|Docetaxel|Given IV
45340402|NCT04340882|Biological|Pembrolizumab|Given IV
45340403|NCT04340882|Biological|Ramucirumab|Given IV
45340404|NCT00765921|Drug|ranibizumab|Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of surgery for tumor localization and then bimonthly for 22 months (total of 12 injections).
45340405|NCT02583308|Device|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
45340406|NCT02583308|Device|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
45473066|NCT03379558|Drug|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:as per routine practice Route of administration: subcutaneous
45683476|NCT03205072|Device|Spy Glass DS|The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
45683477|NCT04832932|Biological|COVID-19 vaccines|Emergency-use authorized COVID-19 vaccines
45683478|NCT01809314|Drug|Epoetin beta|Treatment will be given according to standard of care and the Summary of Product Characteristics during the study.
45340407|NCT02582606|Other|Regular meal pattern|a 14-day period of eating 6 meal per day
45340408|NCT02582606|Other|Irregular meal pattern|a 14-day period of eating between 3 and 9 meal per day
46035886|NCT00876187|Biological|Tanezumab 20 mg IV|2 IV administrations of tanezumab 20 mg at an 8 week interval
46035887|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
46035888|NCT00876187|Biological|Tanezumab 10 mg IV|2 IV administrations of tanezumab 10 mg at an 8 week interval
45340409|NCT02582762|Drug|Nail gel|apply nail gel on affected nails twice daily for 2 months
45340410|NCT00672477|Drug|Methylnaltrexone|
45340411|NCT00672477|Drug|Placebo|
45340412|NCT04080362|Device|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial neochordae or ege-to-ege repair using MitralStitch System
45473067|NCT01169909|Drug|Ranibizumab|Subtenon injections of Ranibizumab 0.5mg will be given, and repeated twice with 30 day intervals between each dose. Note, after an amendment in February 2011, this dose was increased to 2mg with the same schedule.
45473068|NCT03379480|Behavioral|Yoga arm|Yoga module developed for patients with Schizophrenia
45473069|NCT04502589|Drug|Perampanel Tablet|Subjects will be titrated over 3 weeks to a target dose of 8mg perampanel daily in both groups
45473070|NCT04502589|Drug|Disulfiram|Disulfiram will be kept at 250mg daily
45683479|NCT02984332|Other|Lower limb immobilisation (leg brace)|
45683480|NCT03943498|Drug|Fingolimod|Given PO daily for 4 weeks
45683481|NCT03943498|Drug|Fingolimod Hydrochloride|Given PO
45683482|NCT03943498|Other|Questionnaire Administration|Ancillary studies
45683483|NCT05185024|Dietary Supplement|Ferrous Sulfate Capsules|Once daily dose of one Ferrous Sulfate Capsule for 12 weeks in total.
45683484|NCT05185024|Dietary Supplement|>Your< Iron Forte Capsules|Once daily dose of one >Your< Iron Forte Capsule for 12 weeks in total.
45683485|NCT05185024|Dietary Supplement|>Your< Iron Forte Liquid|Once daily dose of 5 ml of >Your< Iron Forte Liquid for 12 weeks in total.
46035889|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
46035890|NCT00876187|Biological|Tanezumab 5 mg IV|2 IV administrations of tanezumab 5 mg at an 8 week interval
46035891|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
46035892|NCT00876187|Biological|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
46035893|NCT00876187|Drug|Naproxen|Oral naproxen 500 mg twice a day for 16 weeks
46035894|NCT00876187|Biological|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
45340413|NCT02585336|Behavioral|Brief intervention|An interviewer provides health information, elicits motivation to reduce SSB consumption, and helps participants make implementation plans. Booster phone calls occur at 1 week after the intervention visit, and at 2 weeks and 24 weeks following the date on which SSBs sales ended at the participant's work location.
45340414|NCT05319080|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed against the subjects scalp on the left side of the head. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in speech perception.
45340415|NCT00766155|Drug|capecitabine|Given orally
45340416|NCT00766155|Drug|oxaliplatin|Given IV
45340417|NCT05314868|Device|PhotoFix|Surgical repair with patch.
45340418|NCT00766233|Other|Hyperthermal treatment|Hyperthermal treatment one or three times per week for 60 minutes
45340419|NCT02585258|Drug|Prednisolone|capsules 5 mg / day
45340420|NCT02585258|Other|Placebo|capsules 1 / day
45340421|NCT00766311|Other|Gross Motor Function|The Bruinicks-Osteretsky Test of Motor Proficiency Version 2 (BOT-2) will be used to measure participants' motor function. The test is norm- referenced and designed to test motor function in children and adolescents 4 -21 years of age. The motor composite score describes overall motor abilities and is comprised of fine motor control, manual coordination, body coordination, and strength and agility. We will use the total motor composite to describe overall motor function.
45340422|NCT00766311|Other|Knee extension strength|"Maximum isometric knee extension strength will be measured with the subject seated in an adjustable straight-back chair. The pelvis will be fixed by an adjustable strap and the knee flexed to 45 degrees. The participant will exert a maximal voluntary force until their contraction is broken."
45473071|NCT01586663|Device|Serial night time position splint|This group will use a serial night time position splint, adjusted monthly, during three months.
45473072|NCT01586663|Drug|Drug treatment|This patients will keep there drug treatment and will receive their splints on the end of the study.
45473073|NCT05172622|Drug|JP-2266|"Single Ascending Dose: Single administration on Day 1~Food effect cohort: Single administration on Day 1 of each period~Multiple Ascending Dose: Repeated administrations from D1 to D15"
45473074|NCT05172622|Drug|JP-2266 Placebo|"Single Ascending Dose: Single administration on Day 1~Food effect cohort: Single administration on Day 1 of each period~Multiple Ascending Dose: Repeated administrations from D1 to D15"
46035895|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
46035896|NCT04238884|Drug|Voriconazole preemptive genotyping strategy|The patients who finally receives voriconazole will be randomized to receive the dose according to a pharmacogenetic algorithm including CYP2C19 genotype and clinical and demographic information.
46035897|NCT04238884|Drug|Voriconazole clinical practice|The patients who finally receives voriconazole will be randomized to receive the dose according to clinical practice
45340423|NCT00766311|Other|Hand grip strength|Hand grip strength in kilograms will be measured using a Jamar hand held dynamometer (Sammons Preston Rolyan, Nottinghamshire, UK). Participants will be seated with the shoulder at 0-10 degrees and the elbow in 90 degrees of flexion. The forearm will be positioned in neutral. Each participant will complete three trials, and the average used for analysis.
45340424|NCT00766311|Other|Flexibility|Flexibility will be measured by having the participant perform the sit and reach test. A yardstick is placed on a firm flat surface and tape is placed across it at a right angle to the 15 inch mark. The participant sits with the yardstick between the legs with legs extended at right angles to the taped line on the floor. The heels of the feet touch the edge of the taped line and are 10-12 inches apart. The participant reaches forward with both hands as far as possible, keeping the hands parallel. The best value for three trials, in centimeters, at the most distant point of the fingertips is recorded.
45340425|NCT00766311|Other|Ankle range of motion|Ankle dorsiflexion active and passive range of motion will be measured with a goniometer. The goniometer is a reliable and valid measure of active and passive range of motion if the rater uses standard procedures
45683486|NCT05185024|Other|Blank Capsules|Once daily dose of one Blank Capsule (excipients only) for 12 weeks in total.
46035898|NCT01102374|Drug|High Dose Vitamin D|Vitamin D3 100,000 IU monthly
46035899|NCT01102374|Drug|Standard Dose Vitamin D|Vitamin D 12,000 IU monthly
46035900|NCT01102374|Drug|Placebo|Placebo monthly
46035901|NCT01102374|Dietary Supplement|Usual Care|Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
46035902|NCT05658640|Drug|Trametinib|Oral
46035903|NCT05658640|Drug|Dexamethasone|Oral/ Intravenous
46035904|NCT05658640|Drug|Cyclophosphamide|Intravenous
46035905|NCT05658640|Drug|Cytarabine|Intravenous
46035906|NCT05658640|Drug|Intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
45340426|NCT00766311|Other|Aerobic capacity|Participants will complete the modified Cooper test where they walk in a corridor as fast as possible for six minutes. The distance is recorded in meters and can also be used to estimate peak V02
45340427|NCT00766311|Other|Body composition and vital signs|Height, body mass index, waist circumference, and blood pressure will be measured.
45340428|NCT00762489|Other|Temporal artery thermometer temperature|Newborn infants had a temporal artery temperature taken within a few minutes of the axillary and rectal temperatures. The axillary and rectal temperatures are taken via methods which are standard of care.
45340429|NCT04078100|Procedure|Transseptal approach.|surgical approach to the mitral valve through the Fossa Ovalis by way of the right atrium.
45340430|NCT00762567|Drug|phenylephrine HCl|A single dose of a liquid dosage form of phenylephrine HCl 2.5mg/5mL, using a weight-age dosing schedule
45340431|NCT04338620|Drug|camrelizumab、albumin-bound paclitaxel and platinum|Experimental Group：camrelizumab、albumin-bound paclitaxel and platinum. Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg on day1 of each cycle. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle. Platinum included Cisplatin/carboplatin/Nedaplatin
46035907|NCT04238572|Device|Audiovisual distraction device|Evaluate the impact of an audiovisual distraction device on the peroperative opioid consumption
45340432|NCT04338620|Drug|albumin-bound paclitaxel and platinum|"Control group：albumin-bound paclitaxel and platinum. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle.~Platinum included Cisplatin/carboplatin/Nedaplatin"
46035908|NCT04238572|Device|Analgesia nociception index|ANI (Analgesia Nociception Index) will be used for peroperative overall comfort measurement
45473075|NCT04485039|Drug|TPOXX|oral antiviral and phosphate binders
46035909|NCT02880696|Behavioral|Regular stimulation sequence|Vibrotactile stimulation of the right hand with regular intervals and random omissions
46035910|NCT02880696|Behavioral|Random stimulation sequence|Vibrotactile stimulation of the right hand with random intervals and random omissions
46035911|NCT02880696|Device|DCS|Near-infrared imaging of the neurovascular response in the left somatosensory cortex
46035912|NCT04693702|Device|Corneal treatment by a low vision aid device|Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The modulus change produces a change in light distribution onto the retina. Light rays are redirected from dysfunctional areas of the retina to functional areas, thereby improving patient vision.
45340433|NCT00759057|Device|Posterior Pedicle Screw System|Implantation of Posterior Pedicle Screw System
46035913|NCT02818504|Other|Wize Mirror|Interactive mirror which integrates contactless sensors and a touch screen interface to derive a semeiotic model of the face with reference to cardiometabolic risk in healthy subjects
46035914|NCT02818270|Drug|Salbutamol|Salbutamol (albuterol ) was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
45340434|NCT00923234|Drug|Azacitidine|75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles
45473076|NCT03387904|Drug|Anlotinib Plus Irinotecan|Anlotinib QD po.and Irinotecan Day 1,8 ivgtt.
45683487|NCT05185024|Other|Blank Liquid|Once daily dose of 5 ml of Blank Liquid (excipients only) for 12 weeks in total.
45683488|NCT01803464|Device|Low-magnitude vibration|Children will receive a daily low-magnitude vibration treatment.
46035915|NCT02818270|Drug|Acetylcysteine|Acetylcystine was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
46035916|NCT02879760|Biological|Ad-MAGEA3|Intramuscular injection
46035917|NCT02879760|Biological|MG1-MAGEA3|Intravenous infusion
45340435|NCT00923234|Drug|Lenalidomide|10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
46035918|NCT02879760|Biological|Pembrolizumab|Intravenous infusion
45340436|NCT05520710|Behavioral|Cognitive Rehabilitation|A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).
45340437|NCT05520710|Other|Education|Educational materials, designed to help people with traumatic brain injury manage their everyday cognitive challenges will be provided through Zoom video conferencing software.
45473077|NCT03387904|Drug|Irinotecan|Irinotecan Day 1,8 ivgtt
45683489|NCT01803464|Drug|Botox|Children who are candidates to receive Botox as part of their standard of care.
46035919|NCT02818348|Drug|darunavir/cobicistat|800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days
45683490|NCT01808690|Drug|Metformin|
45683491|NCT01808690|Drug|Placebo|
46035920|NCT02818348|Drug|etravirine|400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
46035921|NCT04308876|Other|Manual therapy|Manual therapy includes techniques applied to elbow joints and surrounding tissues
46035922|NCT04308876|Other|Strengthening exercises|Strengthening exercises used in this study includes resistant exercises to increase muscle strength of upper extremity
46035923|NCT00634192|Drug|tobramycin|1x300mg/d inhaled
46035924|NCT00634192|Drug|tobramycin|2x300mg/d inhaled
46035925|NCT02626897|Device|GENEActiv Original Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
46035926|NCT02626897|Device|ActiGraph GT3X Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
45340438|NCT04335110|Behavioral|STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias)|STELLA consists of 8 sessions: 4 sessions one-to-one, with the Care Partner and a Guide, and then 4 sessions with one Guide with up to four Care Partners (total small group will include as few as two and as many as 4 Care Partners) Each weekly session takes about 1 hour. The first four sessions allow for development of the Care Partner-Guide working relationship. In these sessions, the Care Partners identify behaviors (both the person with dementia's and the Care Partner's) which are upsetting to the family. Care Partners will be taught to use an Activator, Behavior, Consequence (ABC) approach to identify activators of behaviors, the behaviors, and consequences of the behaviors. After they identify the ABCs, they will develop a plan to address the behavior and then test it. After the four one-to-one sessions, Care Partners will meet in small groups with a Guide. Effective communication strategies, engagement in pleasant events, and coping will be addressed.
45340439|NCT00674661|Drug|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
45340440|NCT00674661|Device|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
45340441|NCT00766545|Drug|cilostazol|oral tablet 100 mg, twice daily, over 1 year
45340442|NCT00766545|Drug|placebo of cilostazol|oral tablet, 0 mg twice daily, over 1 year
46035927|NCT02879214|Radiation|Simultaneous boost along with chemo|Prior studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3), the studies often use single drug. This study treatment plan will use dose intensify in both chemotherapy and radiation. The chemotherapy have two drugs regimens of mitomycin with cisplatin or taxol with cisplatin along of radiation dose escalate, the RT dose escalation to biological GTV defined by PET scan to dose of 57.50 Gy in 25 fx while the elective volumes are held constant at 45 Gy.
46035928|NCT04238182|Other|wet cupping|This smoker group will receive single wet cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm . Cupping of BL 17 will be done bilaterally.
45340443|NCT00766623|Dietary Supplement|high fat meal|milkshake containing 95g fat
45340444|NCT00766623|Dietary Supplement|control meal|milkshake comparable with a normal breakfast
45340445|NCT00766701|Procedure|Procedure: Spectroscopy and Digital Imaging|Procedure: Spectroscopy and Digital Imaging
45340446|NCT04314128|Diagnostic Test|TOS and TCD|TOS: Transorbital sonography TCD: Transcranial Doppler
45340447|NCT02558205|Radiation|CT Liver Perfusion|Imaging study of liver using injection of Iodine contrast agent done using CT imaging
45340448|NCT02558205|Radiation|PET/CT of liver|PET/CT of liver following Y-90 treatment. PET/CT imaging uses positron decay of Y-90 to detect distribution of Y-90 in the liver.
45340449|NCT00759369|Other|Water prescription|Water prescription in 12 to 16 equally divided doses
45340450|NCT00766779|Procedure|hematopoietic cell transplantation|low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
45340451|NCT00766779|Drug|Non-Transplant treatment approach for consolidation|Patients will receive the treatment that would be otherwise applied at the local institution. The consolidation or maintenance therapy is according to the study group protocol.
45340452|NCT00759447|Device|Genesis and Gemini|3 dimensional breast mammography system
45340453|NCT00759447|Device|Investigational 3D Mammography system|3 dimensional breast mammography system
45340454|NCT02557737|Drug|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
46035929|NCT04238182|Other|dry cupping|The smoker group will receive single dry cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm. Cupping of BL 17 will be done bilaterally.
45340455|NCT00766857|Drug|exenatide|Exenatide 5 mcg BID for 4 weeks, subsequently increased to 10 mcg BID for the remainder of the study (total of 26 weeks).
45340456|NCT00766857|Drug|Insulin glargine|Insulin glargine will be initiated at 10 IU QD, titrated according to fasting blood glucose concentrations based on general protocol-defined guidance.
45340457|NCT02558673|Other|TMAO dietary precursors|
45340458|NCT02558673|Other|Control (or active comparator)|
45473078|NCT01283165|Behavioral|Health education intervention|Health education was conducted in two ways. (1) Teachers were taught how to use the flip chart that contained health education material about parasites. The lessons were done during free periods as this intervention had not been formally fitted into the school syllabus. (2) The research team provided health education to school children. Focus group discussions were conducted by the research team with school children all assembled outside their classes. Health education leaflets were distributed to all school children at the school. Children were asked to share the health information with their friends and families.
46035930|NCT02627755|Device|aScope®|we use the aScope® as a flexible and dirigible guide to facilitate the passage of the endotracheal tube through the vocal cords.
46035931|NCT02627755|Device|Glidescope®|use of Glidescope® in conventional manner to facilitate endotracheal intubation
46035932|NCT02817724|Device|BENECA System|BENECA System is a mobile application whit aims to recover a healthy lifestyle in breast cancer survivors (in terms of energy balance: physical activity and dietary).
46035933|NCT02817724|Other|Supervised-occupational therapy program|It is a comprehensive program that covers most of the physical, cognitive and emotional needs of these patients after oncology treatment from occupational therapy perspective.
45340459|NCT02558283|Device|JUVÉDERM® VOLIFT® with Lidocaine|JUVÉDERM® VOLIFT® with lidocaine injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
45340460|NCT02558283|Device|Restylane®|Restylane® injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
46035934|NCT00681421|Biological|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
45340461|NCT04624256|Procedure|Discussion|Patients and physicians engage in discussion
45340462|NCT04624256|Radiation|Hypofractionated Radiation Therapy|Undergo conventional hypofractionated radiation therapy
45340463|NCT04624256|Radiation|Hypofractionated Radiation Therapy|Undergo moderate hypofractionated radiation therapy
45340464|NCT04624256|Other|Laboratory Biomarker Analysis|Correlative studies
46035935|NCT04614220|Behavioral|Presence of Family member|The correlation between presence of the Family member and the consent for regional anaesthesia for Caesarean Section
45340465|NCT04624256|Other|Quality-of-Life Assessment|Ancillary studies
45340466|NCT04624256|Other|Questionnaire Administration|Ancillary studies
46035936|NCT00684463|Drug|Palonosetron|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent.
45340467|NCT04624256|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45340468|NCT02585102|Other|Recommended Vegetable Intake|Subjects will consume vegetables in amounts recommended by the Dietary Guidelines for Americans
45340469|NCT02585102|Other|Usual Vegetable Intake|Subjects will consume vegetables in their usual amount
45340470|NCT00767013|Other|DSCT, TTE|One assessment each
45340471|NCT00759837|Drug|Bosutinib|
45340472|NCT00767091|Drug|rivastigmine|transdermal patch of rivastigmine of 9.5 mg/day
45340473|NCT00767091|Drug|placebo|transdermal patch of placebo
45340474|NCT00767169|Device|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate compared with uncoated controls in the same mouth.
45340475|NCT05256381|Drug|SOT101|Subcutaneous (SC) injection.
45340476|NCT05256381|Drug|Pembrolizumab|Intravenous (IV) infusion via peripheral or central venous line.
45340477|NCT02582528|Behavioral|Cognitive remediation treatment|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
45340478|NCT02582528|Behavioral|Motivational Interviewing|A client-centered, directive method for enhancing intrinsic motivation to change.
46035937|NCT02817490|Other|patient education program|"The PREDUSED patient education program aims to make the patient actor of his pathology by providing him a box of therapeutic tools in order to: improve his knowledge of the disease, improve the management of pain, fatigue and episodes of instability; learn to communicate about the disease; set realistic goals.~The program includes theoretical information, practical cases, and discussions between participants and professionals.~It is the first patient education program in France for the patients with hypermobility type Ehlers-Danlos Syndrome. It is proposed two times a year. Six patients can participate at each session."
46035938|NCT02817568|Other|Drawing Blood|Drawing Blood for genetic analysis
45473079|NCT03291288|Drug|Tolbutamide|Commercially available tolbutamide
45473080|NCT03291288|Drug|Midazolam|Commercially available midazolam
45473081|NCT03291288|Drug|Pexidartinib|Pexidartinib is formulated as opaque, white, 200-mg capsules
46035939|NCT00678457|Drug|Ondansetron|ondansetron (4 μg/kg b.i.d.)
46035940|NCT00678457|Drug|Olanzapine|olanzapine (9, 18, and 36 μg/kg)
46035941|NCT00678457|Drug|Placebo|placebo
45340479|NCT00767403|Behavioral|Internet Intervention + Stepped Care|"Participants will spend about 1 hour each week for 6 weeks using the Internet Intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program then assigns additional intervention modules based on the difficulties the participants endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses. In addition to automatic emails, participants in this group will also receive additional support based on whether they complete specific intervention milestones."
45340480|NCT00767403|Behavioral|Internet Intervention|"As described in Arm 1 above, participants will spend about 1 hour each week for 6 weeks using the Internet intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program will then assign additional intervention modules based on the difficulties the participant endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses."
45340481|NCT00767403|Behavioral|Patient Education Website|Participants will be given access to a relevant patient education website. It will contain material on managing and treating the behaviors and symptoms of childhood encopresis.
46035942|NCT02817646|Other|Computed tomography scan made for clinical reasons|Patients were included if a computed tomography scan of the abdomen or thorax was made early during intensive care admission (1 day before up to 4 days after admission)
46035943|NCT02817646|Dietary Supplement|Nutrition as per hospital protocol|Patients received enteral and/or parenteral nutrition as per usual hospital protocol
46035944|NCT00678613|Drug|Probiotics and Placebo|The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder. It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs and placebo will be given for one year or till the end points of the study.
45473082|NCT05172310|Drug|68Ga-FAPI-46|"[68Ga] Ga-FAPI-46 Solution for Injection is manufactured at the Karolinska University Hospital Radiopharmacy facilities, for imaging studies with Positron Emission Tomography (PET).~It is a radiolabelled Fibroblast Activation Protein Inhibitor (FAPI) used for PET of a number of different cancer entities.~Depending on the labelling yield 50 - 370 megabecquerel (MBq) of [68Ga] Ga-FAPI-46 Solution for Injection will be administered intravenously 60 minutes prior to whole-body PET image acquisition."
45473083|NCT05172310|Device|PET/CT|"Combined PET and computed tomography (CT) imaging with 68Ga-FAPI-46 will be performed using the same protocol on a Biograph 6 PET/CT scanner (Siemens, Erlangen, Germany) and General Electrics (GE) Discovery 710, Milwaukee, Wisconsin, USA at the Department of Nuclear Medicine, Karolinska Huddinge within 2 weeks before surgery.~PET/CT imaging will be performed in dynamic mode at one bed position centered over the primary tumor for 45 minutes.~At 60 minutes post injection, a whole-body PET will be acquired."
45340482|NCT04383314|Behavioral|10-week exercise program on HA accumulation|A 10-week exercise program with both aerobic and resistance components, based on the American College of Sports Medicine (2010), will be individually prescribed to 25 T2DM patients.Exercise training will be performed on Days 1 and 2 of each week under the supervision of licensed physical therapists. Participants will have the choice of using a treadmill or a recumbent stepper. The physical therapists will monitor blood glucose level, blood pressure, heart rate, and RPE during each exercise session. Participants will be asked to exercise at home on Day 3 of each week, and will not be supervised by the study team.
45340483|NCT00767481|Drug|Travoprost/Brinzolamide|Eye drop suspension, once daily
45340484|NCT00767481|Drug|Cosopt|Eye drop solution, one drop BID
46035945|NCT00678613|Drug|Probiotics and Norfloxacin|The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder.It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs will be given for one year or till the end points of the study.
46035946|NCT02817334|Drug|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
45340485|NCT04306874|Dietary Supplement|Ensure Max Protein|Liquid shake with 30 g protein per serving
45340486|NCT02557893|Behavioral|Resistance exercise|Resistance exercise involved 12-weeks of strength training twice per week
45340487|NCT02557893|Other|Education|Bimonthly pregnancy education classes
45340488|NCT02557893|Other|Wait list|Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
46035947|NCT02626429|Dietary Supplement|Amino acid intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
46035948|NCT02817412|Behavioral|Go/No-Training|
46035949|NCT02817412|Behavioral|Stop-Signal Training|
46035950|NCT02817412|Behavioral|Dot-Probe Paradigm|
46035951|NCT02817412|Behavioral|Generic Response Training|
46035952|NCT04579432|Other|Education|With the training module prepared according to the ADDIE model, the intervention group will be trained on reproductive health and sexual health.
46035953|NCT00678769|Drug|Cixutumumab|Given IV
45340489|NCT00671931|Drug|low dexmedetomidine, low propofol|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 100 MCG/KG/M
45340490|NCT00671931|Drug|high dexmedetomidine, low propofol|Dexmedetomidine loading dose 1.1 MCG/KG ,Propofol infusion 100 MCG/KG/M
45340491|NCT00671931|Drug|Dexmedetomidine|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 200 MCG/KG/M
45340492|NCT00671931|Drug|Dexmedetomidin|Dexmedetomidine loading dose 1.1 MCG/KG.Propofol infusion 200 MCG/KG/M
45340493|NCT00671931|Drug|Dexmedetomidine|Dexmedetomidine loading dose 0.9 mcg/kg,Propofol infusion 140 mcg/kg/min
45340494|NCT00767559|Drug|warfarin|5 mg beginning the night before surgery, followed by 5 mg the PM of surgery*, and then variable daily dose, until day 28 (+/-2 days) from day of surgery follow-up. (target INR 2.0 -2.5)
45683492|NCT03927820|Other|Benefits investigation|The study pharmacist will review the prescribed inhaler for 1) insurance coverage and 2) clinical appropriateness. The pharmacist will conduct a benefits investigation at time of hospital admission. The benefits investigation involves running test claims for inhalers to determine the most cost-effective inhaler for the patient's insurance plan. The study pharmacist will utilize clinical practice guidelines to assess appropriateness of the prescribed inhaler. Based on this review, the study pharmacist will submit a pharmacy consult to the inpatient pharmacist on the patient's healthcare team who will pend the inhaler orders (changing the patient's prescribed inhaler, if necessary) for the prescriber to send to the Meds to Beds discharge pharmacy. The Meds to Beds pharmacist will counsel the patient on inhaler use techniques prior to discharge.
46035954|NCT00678769|Other|Laboratory Biomarker Analysis|Correlative studies
46035955|NCT00678769|Other|Pharmacological Study|Correlative studies
45340495|NCT00767559|Drug|Fondaparinux:|2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day*, or 6-8 hours after epidural catheter removal, and continued until follow up day 28 (+/-2 days) from day of surgery.
45340496|NCT00767559|Drug|warfarin|"Fixed Low Dose warfarin~1 mg daily beginning 7 days preoperative, and continued at 1 mg daily until follow-up 28 day (+/- 2 days) from day of surgery."
45340497|NCT00767637|Drug|Lanthanum Carbonate (BAY77-1931)|BAY77-1931 750mg, in the morning, day and evening
45340498|NCT00767715|Drug|olanzapine|physician determined dose, oral, daily, 5 months
45340499|NCT00767715|Drug|haloperidol|physician determined dose, oral, parenteral (<= 3 days), daily, 5 months
45340500|NCT00767715|Drug|zuclopentixol|physician determined dose, oral, parenteral (<= 3 days), daily, 5 months
45340501|NCT02584946|Other|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa).
45340502|NCT00762957|Drug|TAK-559 and metformin|TAK-559 16 mg, tablets, orally, once daily and metformin stable dose orally, once daily for up to 26 weeks.
45683493|NCT04583618|Biological|Pneumococcal Conjugate Vaccine - formulation 1|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
45683494|NCT04583618|Biological|Pneumococcal Conjugate Vaccine - formulation 2|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
45683495|NCT04583618|Biological|Pneumococcal Conjugate Vaccine - formulation 3|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
46035956|NCT00678769|Drug|Temsirolimus|Given IV
46035957|NCT02817022|Other|developmentally supportive care|DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment
46035958|NCT04146883|Drug|Antibiotics|Post-procedural one-day iv cefazolin then 3-day prophylactic cephalexin
46035959|NCT02817256|Dietary Supplement|Vitamins and Minerals|Multivitamins and Minerals supplementation
46035960|NCT00681577|Biological|URLC10, KOC1, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
46035961|NCT02817100|Drug|BAY1817080|Study part 1: Escalating doses of BAY1817080; single dose administration; solid dosage form (redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food [American breakfast]) Study part 2: Escalating doses of BAY1817080; single dose administration together with an American breakfast; solid dosage form (redosing of BAY1817080 at dose group 1, 2 and 4 together with food [Continental breakfast])
46035962|NCT02817100|Drug|Placebo|Study part 1: Escalating doses of respective placebos; single dose administration; solid dosage form (redosing of placebo at dose group 1 and 2 together with itraconazole; redosing of placebo at dose group 4 together with food [American breakfast]) Study part 2: Escalating doses of respective placebos; single dose administration together with an American breakfast; solid dosage form (redosing of placebo at dose group 1, 2 and together with food [Continental breakfast])
46035963|NCT02817100|Drug|Itraconazole|Redosing of BAY1817080/placebo at dose group 1 and 2 together with itraconazole (study part 1)
46035964|NCT00684697|Dietary Supplement|iron|High, intermediate and low iron dosage orally for 2 months
46035965|NCT02816944|Procedure|EUS-guided laser ablation for refractory neoplasms|
46035966|NCT00678847|Device|KFH NOVO (inactive) + SCT|inactive device (placebo) 2 x 1hour/day for total period of 8 weeks + standardized conventional therapy (SCT)
46035967|NCT00678847|Device|KFH Novo (BEST) + SCT|2 x 1 hour/day bio-electrical stimulation (BEST) for total period for total period of 8 weeks in combination with standardized conventional therapy (SCT)
46035968|NCT02816866|Other|empowered primary care model|mode of survivorship care
46035969|NCT02816866|Other|specialty survivor clinic|mode of survivorship care
46035970|NCT00684853|Drug|bevacizumab|1.25 mg of bevacizumab intravitreal
45340503|NCT00762957|Drug|TAK-559 and metformin|TAK-559 32 mg, tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
46035971|NCT00684853|Drug|vetaporfin|full fluence of vetaporfin
46035972|NCT02816554|Biological|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 10-12 days interval
45340504|NCT00762957|Drug|Metformin|TAK-559 placebo-matching tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
46035973|NCT02816554|Biological|JECEVAX-1|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 1 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
46035974|NCT02816554|Biological|JECEVAX-0.8|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.8 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
45340505|NCT04295720|Device|Transcranial magnetic stimulation (TMS)|"Subjects will undergo testing at baseline prior to TMS treatments and once more at the end of the 2-week intervention.After the conclusion of baseline data acquisition, the research team will analyze each participant's unique structural and functional connectivity patterns to determine stimulation site for TMS in future study sessions.~The subjects will receive 10-sessions (1 session per day, M-F over 2 consecutive weeks).~The treatment itself lasts approximately only 190 seconds."
45473084|NCT03636711|Other|antibiotic protocol, according to a syndromic approach|Description of patients who benefited or not the antibiotic protocol, according to a syndromic approach and analysis of the causes of non-adherence to the protocols
46035975|NCT02816554|Biological|JECEVAX-0.5|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
45683496|NCT04583618|Biological|Pneumococcal 13 - valent conjugate vaccine|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
46035976|NCT02816476|Drug|Daratumumab|
46035977|NCT00678925|Dietary Supplement|Phosphatidylcholine|850 mg per day from 18 weeks pregnancy through 90 days postpartum
46035978|NCT00678925|Dietary Supplement|Corn oil placebo|Placebo capsules containing corn oil given from 18 weeks pregnancy through 90 days postpartum
45340506|NCT00763113|Device|Vanguard PS Knee|Vanguard PS Knee
45340507|NCT00763113|Device|Vanguard CR Knee|Vanguard CR Knee
46035979|NCT04573738|Procedure|Robotic assisted transanal total mesorectal excision|Robotic assisted transanal total mesorectal excision for rectal cancer patients
46035980|NCT04573738|Procedure|Laparoscopic assisted transanal total mesorectal excision|Laparoscopic assisted transanal total mesorectal excision for rectal cancer patients
46035981|NCT00875485|Procedure|Blood sampling|Blood sampling at Years 11, 12, 13, 14, 15 and at the time of challenge dose administration and one month after challenge dose administration.
46035982|NCT00875485|Biological|Additional challenge dose|If a subject became seronegative for anti-HAV antibodies (< 15 mIU/mL) or if anti-HBs antibody concentrations decreased below 10 mIU/mL during the long-term follow-up, immune memory against the antigen was evaluated by administering a challenge dose of the appropriate antigen (vaccine) 6 to 12 months after the Year 15 follow-up time-point.
46035983|NCT04572802|Procedure|Coronary angiography|Coronary angiography was performed in patients with coronary heart disease complicated with type 2 diabetes mellitus
45683497|NCT04583618|Biological|Pneumococcal Vaccine Polyvalent|Pharmaceutical form:Solution for injection Route of administration: intramuscular
45683498|NCT04591054|Device|Extended Vision IOL|Vivity IOL implantation following cataract extraction
45340508|NCT05292014|Device|ANGIOLITE|Patients in whom treatment with ANGIOLITE has been attempted
45340509|NCT02558127|Genetic|Asthma patients|Patients with inclusion criteria, following examinations: a study of lung function measurement of the fraction of nitric oxide in exhaled air, induced sputum, sputum, and extraction of peripheral venous blood for Study of genetic variants in the CFTR gene,skin prick test . The number of eosinophils in peripheral blood by automated cell counting and Total IgE by ELISA were measured. Furthermore, the level of asthma control be assessed by validated symptom questionnaire Asthma Control Test, quality of life is determined by the MiniAQLQ questionnaire.
45473085|NCT03869801|Procedure|erector spinae plane block|Ultrasound-guided bilateral Erector spinae plane (ESP) block performed before the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
45473086|NCT03869801|Procedure|quadratus lumborum block|Ultrasound-guided bilateral Quadratus lumborum (QLB) type 2 block performed before the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
46035984|NCT04237870|Device|Active cTBS|Active cTBS treatment will be delivered at an intensity that is 70% of the resting motor threshold (RMT). cTBS consist of bursts of 3 magnetic pulses at 30 Hz repeating every 200 ms for 300 pulses. cTBS will be repeated twice with 15 min interval. The cTBS sessions last for 4 weeks, 5 times a week. Treatment will be applied to central suleus.
46035985|NCT04237870|Device|Sham|Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
45473087|NCT03869723|Procedure|Virtual planning using customized surgical devices|Preoperative modeling was conducted by obtaining scans of patient maxillofacial skeleton and angioscans of the lower extremities. The planning phase was then carried out by the surgeon and the engineer (from MATERIALISE, Leuven, Belgium) so as to define the clinical and technical parameters of the reconstruction. This stage consisted of discussing and determining osteotomy lines, donor side, anastomosis site, and overall reconstruction contour. Resection was decided by the surgeon. 3D modeling and the manufacture of cutting guides and customized osteosynthesis plates were then undertaken
45473088|NCT03869723|Procedure|Conventional surgery|Classical surgery for mandibular reconstruction with fibula free flap
45473089|NCT04084626|Drug|PD1 antibody|2mg/kg ivgtt on day 1(age<18 years); 200mg ivgtt on day 1(age >=18 years).
46035986|NCT00684931|Other|Imaging|neuropsychological evaluation and Imaging with magnetic resonance (MRI)
46035987|NCT04238104|Other|no intervention|it's only observational study. No interventions.
46035988|NCT04147117|Device|Cervical pessary|Cervical pessary is a silicone ring with a smaller diameter to be fitted around the cervix and a larger diameter to fix the device to the pelvic floor. It modifies the direction of the cervix to the posterior vaginal wall.
46035989|NCT00679003|Behavioral|SLCBT|Social learning and cognitive behavioral therapy
46035990|NCT00679003|Behavioral|ES|Education and support (information about nutrition and gastrointestinal system)
46035991|NCT04547140|Biological|Liquid Alpha1-Proteinase Inhibitor (Human)|Intravenous infusion 120 mg/kg
45340511|NCT00763191|Other|examination of ocular movements|
46035992|NCT04547140|Drug|Placebo|Intravenous infusion
46035993|NCT04547140|Drug|Standard Medical Treatment|SMT
45340512|NCT00763191|Other|MATTIS test|
45340513|NCT00763191|Other|UPDRS test|
45340514|NCT00763191|Other|CRST test|
45340515|NCT00759993|Drug|chromium piccolinate|1000mg tab
45340516|NCT00759993|Drug|placebo for chromium piccolinate|
45340517|NCT00673881|Drug|choline fenofibrate|135 mg choline fenofibrate daily(oral, capsule)
45340518|NCT00763347|Drug|SYR-619|SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.
45340519|NCT00763347|Drug|SYR-619|SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.
45340520|NCT00763347|Drug|SYR-619|SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.
45473090|NCT04084626|Drug|lenalidomide|5mg orally once a day（age<18years) ,day 1-14; 10mg orally once a day(age>=18years), day 1-14.
45340521|NCT00763347|Drug|SYR-619|SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.
45340522|NCT00763347|Drug|Placebo|SYR-619 placebo-matching tablets, orally, once daily for up to 12 weeks.
45473091|NCT03387826|Drug|Ticagrelor 60 mg|Ticagrelor 60 mg twice daily
45340523|NCT00763347|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
45340524|NCT00767793|Drug|Placebo|One drop in each eye every 12 hours for seven days
45473092|NCT03387826|Drug|Prasugrel 5mg|Prasugrel 5 mg once daily
46035994|NCT00679159|Biological|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis
46035995|NCT00679159|Biological|Prevenar|Streptococcus pneumoniae vaccine
45340525|NCT00767793|Drug|INS117548|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
45340526|NCT00767793|Drug|INS117548|One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
45340527|NCT00767793|Drug|INS117548|One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
45340528|NCT00767871|Drug|Lexapro|12 week treatment with lexapro
45340529|NCT04049019|Diagnostic Test|Urine collection through a collecting device (Uridom®) for maximum 1 week|"The child will collect:~Urine at bedtime on a wet and a dry night.~Urine during a wet night through a collecting device.~First morning voided volume following both a wet and a dry night."
45340530|NCT00760149|Drug|Rifampicin in higher doses|Rifampicin 900 mg (study arm 2), and rifampicin 1200 mg (study arm 3)
45340531|NCT00767949|Biological|iSONEP|single intravitreal injection of 0.2, 0.6, 1.0, 1.4 or 1.8 mg/eye
45473093|NCT03869411|Behavioral|supervised aerobic exercise or home-based aerobic exercise|"The aerobic exercise and home exercise programs are consisted of 50 minutes per time, 3 times per weeks and totally 3 months.~The aerobic exercise group will perform the exercise program under one physical therapy and one aerobic dance teacher supervised. The home exercise group will do the exercise program based on ACSM's aerobic exercise recommend, and will used the home exercise record form to make sure their cooperation."
45340532|NCT00671853|Drug|Quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
45340533|NCT00671853|Drug|Placebo for quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
45340534|NCT00760227|Other|Massage Therapy|Patient and parents will meet with a licensed massage therapist at the time of admission. During the session, the therapist will introduce them to the rationale of the massage intervention before moving on to provide the initial massage session. Each session will last approximately 1/2 hour. Massage sessions will be scheduled 3x/week from admission through week +3.
45473094|NCT04016454|Procedure|Intervention|There will be one complete handover
45340535|NCT00760227|Other|Humor Therapy|For this component will will utilize a humor cart, stocked with humorous video shorts, books, gags, props and games.
45340536|NCT00760227|Other|Relaxation Therapy|In the initial session held near the time of admission, parents will meet with the RA therapist, who will describe relaxation response and the benefits of a regular practice of relaxation techniques. They will be led through a modified progressive muscle relaxation induction, using breath awareness and muscle release, followed by guided imagery.
46035996|NCT04237714|Behavioral|Smiling is fun|"Smile is Fun is a self-applied program that combines elements of prevention and psychological treatment for emotional disorders. It is delivered via the Internet and it is based on CBT technics. The program consists of 8 therapeutic modules and includes 3 transversal tools (activity report, calendar, how am I?) to provide feedback and accompany patients during the intervention. The program requires 8 to 10 weeks to complete in its entirety.~The intervention, initially developed in Spain, will be adapted to the Ecuadorian culture including elements of the local population, such as, dialect, personal stories, examples and activities. The Ecuadorian version will be evaluate by health professional and users of public health system of Ecuador."
46035997|NCT04146103|Drug|Novex|Novex® made of Pumpkin Seed Extract 550mg, Soy Germ Isoflavonoids 50 mg and Cranberry 50mg. The dose is 2 tablets/day taken orally.
45340537|NCT00768105|Drug|AZD1656|Dose titration of oral suspension to a tolerable dose in 2-3 dose steps. Investigational product given twice daily for eight days.
45683499|NCT04591054|Device|Neutral Aspheric Monofocal IOL|enVista IOL implantation following cataract extraction
45340538|NCT00768105|Drug|Placebo|Dosing to match AZD1656
45683500|NCT04588870|Device|Pre operative computer based cochlear implant surgical simulation|Prior to surgery, the surgeon will perform virtual cochlear implant surgery on patient specific imaging data within a computer simulation program. The surgeon will be able to iterate the procedure on the simulator until achieving the best electrode array location is achieved with respect to scalar location and modiolar distance. A written and graphical surgical plan will then be developed that the surgeon can use in the actual surgery.
46035998|NCT05654038|Biological|Anti-CD19 UCAR-NK cells|"The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set three different dose levels of UCAR-NK cells:Dose level one: 5-10×10^6/kg; Dose level two:1-2×10^7/kg; Dose level three:2-5×10^7/kg."
46035999|NCT00685009|Drug|Estrogen hormone therapy|Estrogen pill daily
46036000|NCT00685009|Drug|Estrogen plus progesterone hormone therapy|Estrogen plus progesterone hormone therapy pill (Prempro) daily
46036001|NCT00685009|Drug|Placebo|Placebo pill daily
45340539|NCT00768183|Drug|KADIAN Capsule + alcohol (under fasting conditions)|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
45340540|NCT00768183|Drug|KADIAN Capsule + water (under fasting conditions)|Capsules 100mg + 240 mL in 4 shots of 60 mL
45340541|NCT00768183|Drug|morphine sulfate IR oral solution + water|Morphine sulfate IR oral solution + water (under fasting conditions)
45340542|NCT00768183|Drug|KADIAN Capsule + alcohol (under fed conditions)|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
45683501|NCT04413734|Drug|Combination therapy|Triprilumab by intravenous infusion accompanying with Gemcitabine plus Cisplatin
45683502|NCT04413734|Drug|Mono-chemotherapy|Gemcitabine plus Cisplatin by intravenous infusion
46036002|NCT02816086|Other|Interdisciplinary collaboration structure|A pharmacist is integrated in the team surrounding the patient, working by the Integrated Medicines Management (IMM) model. The IMM-model consist of medication reconciliation, medication review, standardized medication reports and counseling patients about their medication at discharge. In addition a phone meeting between the primary care physician and the study pharmacist is added after discharge.
46036003|NCT00679237|Behavioral|smoking cessation|NRT and varenicline
46036004|NCT00679237|Drug|betablocker, diuretics, ACEI, ARB,|blood pressure control according to ESC guidelines
46036005|NCT00679237|Drug|statins, ezetimibe|Cholesterol reduction according to ESC guidelines
46036006|NCT00679237|Behavioral|training|daily walking
45683503|NCT03229798|Drug|Sumatriptan Succinate Oral Tablet|Sumatriptan succinate commercial Imitrex 100 mg tablet
45683504|NCT03229798|Combination Product|Transdermal delivery of sumatriptan succinate|Sumatriptan succinate transdermal drug delivery system
46036007|NCT00679237|Biological|influenza vaccine|vaccine (FLuarix, Influvac etc)
45340543|NCT00763425|Procedure|cold polypectomy|The removal of small colorectal polyps up to 8 mm is performed using cold snare polypectomy.
45340544|NCT00763425|Procedure|conventional polypectomy|The removal of small colorectal polyps up to 8 mm is performed using conventional polypectomy.
45340545|NCT00760305|Behavioral|Pro self pain control programme|A 6 week psychoeducational programme that included three home visits and three phone calls. Patients were taught about pain medication and side effects and about incorrect information regarding cancer pain management
45340546|NCT00768339|Drug|AEG35156 antisense IV infusion|"AEG35156 will be given as a 2-hour intravenous infusion (escalating dose 50, 100, 150, 200, 250 and 300 mg) once weekly on Day 1, Day 8 and Day 15. One cycle of therapy will consist of 21 days. Patients will be treated until disease progression.~Patients must be pretreated for at least three days with allopurinol prior to the first dose of AEG35156 and throughout protocol therapy.~Patients must be hydrated with 1 L of normal saline prior AEG35156 infusion"
45340547|NCT00768417|Behavioral|10 chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 10 times before swallowing.
45340548|NCT00768417|Behavioral|25 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 25 times before swallowing.
45473095|NCT03387748|Behavioral|Gesture elicitation|"Participants are required to gesture with their hands (and not speaking) one by one 30 pictures from the Boston Naming Task which appear on a laptop screen.~Participants retell a cartoon to the researcher~The researcher initiates a 10-min spontaneous conversation.~These three tasks are video-recorded."
45473096|NCT01280747|Other|prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
45473097|NCT01280747|Other|no prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
45473098|NCT01280747|Other|prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
45473099|NCT01280747|Other|no prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
45340549|NCT00768417|Behavioral|40 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 40 times before swallowing.
45340550|NCT02557581|Other|No training|
45340551|NCT02557581|Other|Endurance training|
45340552|NCT02557581|Other|Resistance Training|
45340553|NCT02557581|Drug|Terbutaline|
45473100|NCT03966612|Other|Questionnaires|"Questionnaires about:~Socio-professional situation~Lifestyle~Health~NME 1~specific breast cancer survey~Imaging"
45683505|NCT04808908|Biological|N-803|N-803, provided by ImmunityBio., Inc. will be administered subcutaneously at a dose 6 mcg/kg on Days 0, 21, and 42 (with a dosing window of up to 14 days post the planned dosing day)
46036008|NCT00679237|Drug|metformin, glimepiride, insulin|s.glucose control according to ESC guidelines
46036009|NCT00679237|Behavioral|weight reduction|diet tips
45340554|NCT02557581|Drug|Clenbuterol|
45340555|NCT02557581|Drug|Placebo|
45340556|NCT04077944|Diagnostic Test|maternal serum concentration of trace elements and heavy metals levels|The maternal serum levels of trace elements and heavy metals in both groups were measured using an inductively coupled plasma-mass spectrometry (ICP-MS)
45340557|NCT02558751|Biological|23-valent pneumococcal polysaccharide vaccine|One standard adult dose of the 23-valent pneumococcal polysaccharide vaccine
45473101|NCT03379324|Biological|Superiority of augmented repairs|4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
45473102|NCT03379324|Biological|Fat degeneration of supraspinatus muscle|4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
45473103|NCT03953742|Drug|CPI-200|CPI-200 will be administered via intravenous infusion on Day 1 of a 21-Day cycle
45473104|NCT01167335|Drug|BGG492|
45683506|NCT03927742|Behavioral|Shade + app with messaging|Shade wearable device and application with UV messaging activated
46036010|NCT02816164|Drug|Neupogen|Subcutaneous injections
46036011|NCT02816320|Other|Hospitalization|Patients who were hospitalized in acute care
45473105|NCT01167335|Drug|Placebo|
45473106|NCT03943914|Combination Product|Preventive strategy|In the experimental strategy, NIV is performed after inclusion in patients with moderate hypoxemia, defined by a PaO2/FiO2 ratio < 300 mmHg. The minimally required duration of NIV was 4 hours per day for at least 2 calendar days. The daily duration of NIV can be increased at the discretion of the physician in patients with signs of delayed respiratory failure under HFNC-O2 and improving under NIV. Beyond the first 48 hours, NIV and HFNC-O2 can be stopped and the patient switched to COT if respiratory rate < 25/min and SpO2 > 92% under FiO2 < 30% for at least 6 hours.
46036012|NCT00681733|Drug|Pioglitazone|Pentoxifylline 1200mg/day in 3 divided doses. Pioglitazone 30 mg/day in single dose
46036013|NCT00681733|Drug|Pioglitazone|30 mg OD
46036014|NCT00681733|Drug|Pentoxifylline|1200 mg/d
46036015|NCT02816008|Behavioral|Cognitive rehabilitation training with RGS in the clinic|Daily cognitive training with the Rehabilitation Gaming System (RGS) in the clinic during 6 weeks (5 days per week a 30 minutes).
45340558|NCT02558751|Biological|13-valent pneumococcal conjugate vaccine|One dose of the 13-valent pneumococcal conjugate vaccine, PCV13, followed 8 weeks later by one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23.
45340559|NCT00768573|Drug|sildenafil|Oral suspension of sildenafil.
45340560|NCT02558361|Drug|Treatment with Apremilast|Standard dosing with apremilast (Otezla) will be used. [30mg po BID after initial titration]
45340561|NCT02558595|Dietary Supplement|Niacinamide|
45340562|NCT02558595|Other|Placebo|Placebo pill that matches niacinamide pill is size, shape and color
45340563|NCT02585024|Drug|Cytisine|
45340564|NCT00760695|Drug|dronabinol|tablets, twice daily, for 4 weeks
45340565|NCT00760695|Drug|placebo|tablets, twice daily, for 4 weeks
45683507|NCT03927742|Behavioral|Shape + app without messaging|Shade wearable device and application without UV messaging activated
45340566|NCT04617314|Drug|RC108|RC108 for injection is a novel antibody-drug conjugate, with a c-Met-targeting antibody and a microtube inhibitor.
45340567|NCT04048629|Device|Point-of-care (POC) viral load (VL) testing plus refresher training|VL testing at the first antenatal care visit will occur using POC VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
45340568|NCT04048629|Other|Standard of care central laboratory VL testing plus refresher training|VL testing at the first antenatal care visit will occur using central laboratory VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
45340569|NCT02582372|Drug|Dexmedetomidine and bupivacaine|10 micrograms of dexmedetomidine plus 12,5 mgrs of bupivacaine subarachnoideal
45340570|NCT02582372|Drug|Fentanyl and bupivacaine|25 micrograms of fentanyl plus 12,5 mgrs of bupivacaine subaracnoideal
45340571|NCT03926468|Diagnostic Test|Liquid biopsy|Before onset of treatment, cell-free DNA (cfDNA) is extracted from venous blood sample for next-generation DNA sequencing (NGS) using a commercially available platform (Roche Foundation ACT) For this purpose, 4 x 10 ml of venous blood will be collected from each patient. Two tubes (Streck) will be sent to service provider (Roche), one tube will be used for droplet digital polymerase chain reaction (ddPCR, QX200 Droplet Digital PCR System, BioRad) and ddPRC/NGS analyses and one is collected and stored in Auria Biobank (www.auria.fi) for possible future analyses.
45340572|NCT00768729|Drug|Sirolimus|Oral tablets or liquid taken every 12 hours. Dosage adjusted to attain target trough levels of 8-12 ng/mL. Participants who have maintained such levels at study entry on once daily dosage will be permitted to continue on once daily dosing.
45340573|NCT00768729|Drug|MMF or Azathioprine|600 mg/m2 MMF taken orally daily or Azathioprine orally daily. Dosage of Azathioprine is dependent on weight. MMF or Azathioprine will be reduced by 25% initially and by 25% every 2 months resulting in complete withdrawal by 6 months.
45340574|NCT04266080|Other|Fitbit Inspire HR|assessing step counts
45340575|NCT04266080|Other|Questionaires|Patient-Reported Outcomes Measurement Information System (PROMIS)
45340576|NCT00760773|Drug|Lacidophil (experimental high dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the high dose which will consist of 4 billion CFU (1 active sachet) PO BID (total daily dose = 8 billion CFU) x 5 days.
45340577|NCT00760773|Drug|Lacidophil (experimental standard dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the standard dose which will consist of 4 billion CFU (1 active sachet) PO QAM (total daily dose = 4 billion CFU) plus 1 placebo sachet PO QHS x 5 days.
45340578|NCT00760773|Drug|Placebo|The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated.
45340579|NCT00768807|Device|CPAP (continuous positive airway pressure)|Patients treated by CPAP for 06 months
45340580|NCT04077554|Genetic|gene expression|determination of VEGF gene expression, VEGF gene polymorphism and serum leptin concentration
45340581|NCT00768885|Device|PureVision 1|Currently marketed PureVision soft contact lens.
45340582|NCT00768885|Device|PureVision 2|Alternate design soft contact lens.
45340583|NCT00768963|Drug|ranibizumab|0.5 mg subconjunctival ranibizumab 3 days prior to surgery
45340584|NCT00768963|Drug|ranibizumab|0.5 mg subconjunctival ranibizumab at the time of surgery
45683508|NCT04805944|Drug|Dolutegravir|Dolutegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic et metabolite profiling, stools for microbiota profiling) drawn at follow-up.
45683509|NCT04805944|Drug|Bictegravir|Bictegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
46036016|NCT02816008|Behavioral|Passive/conventional cognitive training at home.|Daily conventional cognitive rehabilitation at home as recommended by the neurologist during 6 weeks (5 days per week a 30 minutes).
45340585|NCT00769041|Drug|moxifloxacin|400mg
45340586|NCT00769041|Drug|avanafil|100mg single dose
46036017|NCT04151329|Biological|BAT1306 and BAT8001 2.4mg/kg|Phase 1 dose titration study of BAT1306 and BAT8001 2.4mg/kg , then choose a proper dose for amplification study based on DLT result
46036018|NCT04151329|Biological|BAT1306 and BAT8001 3.6mg/kg|Phase 1 dose titration study of BAT1306 and BAT8001 3.6mg/kg , then choose a proper dose for amplification study based on DLT result
46036019|NCT02815774|Drug|SP2086|all subjects were given SP2086 50mg only one time.
46036020|NCT00679315|Drug|alfuzosin hydrochloride XL 10mg|One tablet to be taken daily after a meal before bedtime for 8 weeks.
46036021|NCT00679315|Drug|Placebo|One tablet to be taken daily after a meal before bedtime for 8 weeks.
46036022|NCT04049773|Procedure|haemodialysis|haemodialysis, thrice weekly in-center
46036023|NCT02626351|Other|Quality Improvement|In a stepped wedge fashion all 7 PHC clinics will receive QI one by one (exception: the two smallest clinics will be rolled into one step). Each step is of 2 months' duration. The study will commence with baseline data collection across all clinics, before the first randomised clinic receives the QI intervention. The QI intervention involves the following activities at each clinic: [1] Situational Analysis: assessment of clinic needs and gaps in processes that influence the specified study endpoints; [2] Intensive Intervention Phase (2 months): the clinic QI team (healthcare facility staff) with support of CRH QI mentors maps clinic processes and establishes priorities for process improvements through identification of bottlenecks, root-causes and commence plan-do-study-act (PDSA) cycles; [3] Maintenance Phase (duration varies for each clinic based on stepped wedge study design): clinic processes are further improved through iterative PDSA cycles; [4] Follow up.
45473107|NCT03943914|Combination Product|Standard of care|In the control group, patients receive oxygen from nasal cannula or high concentration oxygen mask according to the FiO2 needed to achieve SpO2 > 92%. NIV is initiated only in patients having PaO2/FiO2 ratio < 200 mmHg under COT. A trial of curative NIV is allowed at the discretion of the physician in patients who have signs of delayed respiratory failure and no other organ dysfunction. The non-improvement of respiratory conditions after 1 hour of NIV, the NIV-dependence (≥ 12 consecutive hours) or NIV-intolerance should be considered as criteria for endotracheal intubation.
45340587|NCT00769041|Drug|avanafil|800mg single dose
45340588|NCT00769041|Drug|sugar pill|single dose
45340589|NCT00763659|Dietary Supplement|Lutein/ Zeaxanthin + Omega-3-FA|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
45340590|NCT00763659|Dietary Supplement|Lutein/ Zeaxanthin + Omega-3-FA|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
45340591|NCT00763659|Dietary Supplement|Placebo|0 mg Lutein, Zeaxanthin, Omega-3-FA
45340592|NCT04077476|Behavioral|Online Yoga + Facebook|Each week, the research team will post a prompt for discussion to encourage participation. Prompts will be developed in the beginning stages of the project based on data from the current R34 study and with guidance from consultant Waibel. Participants will be encouraged to post about their experiences with the intervention and stillbirth (emotional support), share resources, (informational support), and offer feedback and advice (appraisal support). Participants will not be required to adhere to certain criteria for engagement (e.g., number of posts, etc.), other than their weekly log in. This is to account for different types of engagement when using social networking as a means of support (e.g., posting, just reading); the benefits of each type of engagement are person-specific. The page will be moderated by members of the research team, who will post prompts and ensure content is updated and appropriate. No members can be added to the group without approval from the research team.
45683510|NCT04805944|Drug|Dolutegravir|Patient having discontinued dolutegravir will be included and samples (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
46036024|NCT02626351|Other|Baseline data collection (active comparator)|Endpoint data collection only
45340593|NCT04077476|Behavioral|Online Yoga|Participants will complete a series of videos covering basic poses and safety techniques, tracked using the Wistia plugin software. Once complete, they will be able to access the library of pre-selected classes (range in time from 10-90 minutes). Participants will be asked to complete at least 60 minutes of yoga per week; participants may choose any classes to yield 60 minutes. Preliminary data from the current R34 study suggests 60 minutes is a feasible amount of time for yoga participation. There is no upper limit to the number of minutes participants can complete.
45340594|NCT00760851|Other|probiotic strain Bb-12|10^9 CFU Bb-12 per 4 oz yogurt
45340595|NCT00760851|Other|no Bb-12|yogurt identical to intervention yogurt, only without Bb-12 added.
45340596|NCT04019678|Procedure|Omission of Axillary dissection|In Group 1 and 2: Axillary dissection won't be performed
46036025|NCT05652400|Other|Exposure to antiretroviral therapy|Outcomes will be compared with regard to current or previous exposure to antiretroviral therapy.
46036026|NCT00679393|Procedure|Open reduction internal fixation|Open reduction internal fixation surgery of severely comminuted calcaneal fracture (Sanders IV).
46036027|NCT00679393|Procedure|Fusion|Primary subtalar fusion of severely comminuted calcaneal fracture (Sanders IV)
46036028|NCT02815852|Other|Women under 40 years old with histological diagnosis of breast cancer|Evaluation of imaging characteristics (ultrasound, mammography and mammary MRI if available) of breast cancer with the corresponding histological reports and assess whether in women <40 years the typical imaging presentation pattern of malignancies observed in women> 40 years are confirmed.
46036029|NCT02816242|Other|concept map teaching|teaching anatomy using concept map to improve critical thinking
46036030|NCT02816242|Other|traditional teaching|teaching anatomy using lecture
46036031|NCT04692298|Other|pulses|kidney beans, pinto beans, lentil, black-eyed pea and chickpea
46036032|NCT02815696|Device|Magnetic Resonance Imaging|Specific MRI sequences (delayed gadolinium-enhanced magnetic resonance imaging of cartilage -dGEMRIC) performed before the surgery, 6 months and 1 year after surgery will allow to measure the following parameters: disc height, total lumbar spine lenght, GAGs concentration.
46036033|NCT02815930|Other|HCU Status|Total healthcare expenditures in the top 5% of Ontarians
46036034|NCT04238962|Drug|Semaglutide (administered by DV3396 pen-injector)|Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 7 weeks
45340597|NCT00770445|Drug|Pioglitazone and insulin|Pioglitazone 15 mg, tablets, orally, twice daily and metformin placebo-matching tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
45340598|NCT00770445|Drug|Pioglitazone and metformin and insulin|Pioglitazone 15 mg, tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
45340599|NCT00770445|Drug|Metformin and insulin|Pioglitazone placebo-matching tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
45340600|NCT04077398|Drug|Ropivacaine 0.5% Injectable Solution|There will be two groups, in order to compare two different sets of volumes with the same amount of drug. we will try to identify if it is better one volume over the other in terms of pain control and consume of opioids, as well the presence or absence of motor weakness.
45340601|NCT00763737|Procedure|Fetoscopic Endoluminal Tracheal Occlusion|prenatal balloon placement at 30-31+6 weeks and removal at 34-34+6 wks
45340602|NCT04239716|Other|regional anesthesia|combination of erector spinae plane block and interscalene block for anesthesia in modified radical mastectomy surgeries with axillary lymph node dissection
45340603|NCT04078256|Other|Proprioceptive exercise program|Group A will carry out two sessions of proprioceptive training per week, in a total of 8 weeks, during the pre-season period (September-October). Each session will last approximately 30 minutes and will include 6 exercises. The execution of the exercises will be supervised by a physiotherapist and a national trainer of athletics.
45340604|NCT04078256|Other|Usual training routine|The subjects of the control group (group B) will be informed so that they do not include any change in their usual training routine.
45340605|NCT05179395|Other|Brasthesis|Brasthesis is a harness that is integrated with an off the shelf sports bra
45340606|NCT04079972|Behavioral|personalized lifestyle intervention|Based on genotype of SNPs potentially relevant to weight control, tailored lifestyle guidance to facilitate weight loss will be provided.
45683511|NCT04805944|Drug|Dolutegravir|Patients starting dolutegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of dolutegravir
46036035|NCT04238962|Drug|Semaglutide (administered by PDS290 pen-injector)|Increasing doses of semaglutide given sc in the stomach for 7 weeks
46036036|NCT01098474|Biological|GSK's investigational vaccine 692342|Intramuscular, 1 or 2 doses
46036037|NCT01098474|Biological|Tritanrix™ HB+Hib|Intramuscular, 3 doses
46036038|NCT01098474|Biological|Prevnar™|Intramuscular, 3 doses
46036039|NCT01098474|Biological|Polio Sabin™|Oral, 3 doses
46036040|NCT01098474|Biological|Menjugate™|Intramuscular, 3 doses
46036041|NCT04238026|Procedure|Distal radial artery approach|Use of distal radial artery approach in coronary angiography and angioplasty
46036042|NCT00633802|Drug|Risperidone|1 mg/d risperidone for 10 weeks or placebo
46036043|NCT04460248|Drug|Zanubrutinib, Lenalidomide and Rituximab (ZR2)|"Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Zanubrutinib, 160 mg bid, po, day 1-21;~Lenalidomide, 25 mg qd, po, day 2-11;~Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days, for a maximum of 2 years."
45340607|NCT04079972|Behavioral|general lifestyle intervention|Regardless of individuals' genetic make-up, general lifestyle guidance to facilitate weight loss will be provided.
45340608|NCT04048707|Drug|Angiotensin II|Intravenous
45473108|NCT03872063|Other|Experimental|The intervention by myofascial induction will consist of the application of two techniques: global technique of myofascial induction of the pectoralis major muscle (once the tissue is placed in tension, the direction of fascia release in that region should be followed and as a result of the release, the caudal hand can move to the pelvis in any direction, to the right or to the left) and telescopic technique for the upper extremity of the subject's dominant arm (gently tractioning the upper limb of the subject, making a slight external rotation, so slow and progressive). The subjects will then perform the eccentric exercises, which will also be done by control group subjects
45473109|NCT03872063|Other|Control|The intervention by eccentric exercises will consist of two exercises using an elastic band. In the supine position, with the elastic band on the contralateral side attached to a fixed body perpendicular to the subject's hand performing a slow and constant movement of external rotation against resistance in an approximately 45 degree arc; holding for 5 seconds and relaxing slowly (perform 3 sets of 12 repetitions). The second exercise, with the elbow in 90 degrees of flexion and a shoulder abduction also of 90 degrees, with the elastic band in front of the subject, executing a movement against resistance performing an external rotation.
45473110|NCT03930966|Diagnostic Test|PDEQ, PCL-5 and demographic survey|Questionnaires
45473111|NCT03871517|Drug|Indobufen|Indobufen inhibits platelet aggregation by reversibly inhibiting the platelet cyclooxygenase enzyme thereby suppressing thromboxane synthesis.
46036044|NCT02819986|Behavioral|Progressive Goal Attainment Program|Behavioural intervention that consists of 10 one hour weekly therapy sessions that focus on goal setting, challenging thoughts about return to work, problem solving, behavioural activation, and resuming occupational roles.
46036045|NCT05658874|Drug|Multimodal Bundle Drugs|multimodal pain therapy
45340609|NCT04048707|Drug|Midodrine|Pill
45340610|NCT04048707|Drug|Octreotide|Subcutaneous
45340611|NCT04048707|Drug|Albumin solution|Intravenous suspension
45473112|NCT03871517|Drug|Aspirin|Aspirin is a salicylate (sa-LIS-il-ate). It works by reducing substances in the body that cause pain, fever, and inflammation.
46036046|NCT05658874|Procedure|Operative Cystoscopy|Evaluate bladder and treat Hunner lesions with kenalog or fulguration as appropriate
46036047|NCT05658874|Behavioral|Behavioral health consultation/therapy|Patient to see behavioral health/psychiatric care
45340612|NCT05346458|Device|Intra coronary rapid-exchange iKOs microcatheter intervention|Patients planned for an invasive coronary physiology (pressure-wire) study and who meet the inclusion criteria and none of the exclusion criteria can be enrolled. Participants will undergo preparation for their clinical procedure (angiogram with pressure wire study) in the normal manner. Arterial cannulation will be performed via the radial or femoral artery) under local anaesthesia. The sheath will be inserted and a pre-procedure blood sample taken for Troponin T level. A coronary angiogram will be performed as per standard clinical practice prior to cannulating the coronary artery to be studied. The pressure studies will be performed sequentially, first with a pressure wire before using the iKOs™ microcatheter. Following withdrawal of the iKOs™ microcatheter. A pressure wire assessment is repeated after the microcatheter is withdrawn. The case will then proceed as clinically indicated. Post-procedure the participant will be managed according to standard clinical practice.
45340613|NCT03925844|Other|Classification according to the cardiovascular risk|All patients are cognitively assessed at the beginning of the study and their cardiovascular risk is calculated. After 5 years of follow-up, patients are re-evaluated cognitively and their cardiovascular risk is recalculated.
45340614|NCT00769353|Behavioral|Primary and Secondary Coping Enhancement Training|A cognitive behavioral therapy designed to help individuals cope with physical illness.
45340615|NCT00769353|Behavioral|Supportive Non-directive Therapy|A non-structured therapy designed to provide a supportive atmosphere in which individuals may discuss concerns and process events in their lives
45340616|NCT00769431|Other|educational intervention|
45473113|NCT03387592|Drug|CPT-11|180 mg/m2
45473114|NCT03387592|Drug|Calcio levofolinate|200 mg/m2
45683512|NCT04805944|Drug|Bictegravir|Patients starting bictegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of bictegravir
45683513|NCT03906292|Drug|Imatinib|Imatinib 400 mg QD and asciminib 60 mg QD
46036048|NCT05658874|Other|Pelvic floor physical therapy|Patient to have evaluation and treatment by a trained pelvic floor physical therapist
46036049|NCT05658874|Other|Usual Urogynecologic care|Usual care from practicing academic Urogynecologist
46036050|NCT05658874|Drug|Bladder Instillation|Intravesical lidocaine, heparin, sodium bicarb, Kenalog, gentamicin
46036051|NCT05658874|Drug|Vaginal estrogen|Topical vaginal estradiol application
46036052|NCT05658874|Drug|Methenamine|UTI prevention/bladder therapeutic
46036053|NCT05658874|Drug|Amitriptyline/Gabapentin|Part of multimodal pain therapy
45340617|NCT00769431|Other|study of socioeconomic and demographic variables|
45473115|NCT03387592|Drug|5-Fluorouracil|400 mg/m2 + 2400 mg/m2
45473116|NCT03387592|Drug|Capecitabine|1500 mg/m2
45473117|NCT03387592|Drug|Temozolomide|200 mg/m2
45473118|NCT01281059|Device|BreathID - Breath Test - 13C Octanoate|
45473119|NCT02501226|Other|Treatment as usual|Treatment as usual consisting of clinical management including assessment of the psychiatric symptoms and subsequent prescription of antidepressants.
45683514|NCT03906292|Drug|Nilotinib 300 mg|Nilotinib 300 mg BID and asciminib 20 mg BID or 40 mg QD
45683515|NCT03906292|Drug|Dasatinib|Dasatinib 100 mg QD and asciminib 80 mg QD
45683516|NCT03906292|Drug|Asciminib|Asciminib 80 mg QD Monotherapy
46036054|NCT04452526|Other|Best Practice|Receive usual care
46036055|NCT04452526|Other|Educational Intervention|Receive educational materials
46036056|NCT04452526|Other|Questionnaire Administration|Ancillary studies
46036057|NCT04452526|Other|Reminder|Receive reminder letter
46036058|NCT02878902|Other|Post implementation|Patient group whose care course was organized by the nurse coordinator of chronic renal failure
45340618|NCT04077632|Device|Transcranial direct current stimulation|tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively.
45340619|NCT00763893|Drug|placebo|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.
45340620|NCT00763893|Drug|Losartan|50 mg/day if < weight 50 kg 100 mg/day if weight > 50 kg
45340621|NCT04019366|Other|Balance Training|Experimental group received balance training on Biodex stability System along with traditional exercise program. During balance training on Biodex, patients were instructed to stand on the platform with bare feet with open eyes and both legs supported. Patients were looking forward to screen having hands hang by the sides. The patients were instructed not to change their feet position and balance the body. The handles were accessible for safety point. But touching the handles cancelled the trail. Total time of training was 10 minutes each set is of 3 minutes with 20 sec rest intervals.
45473120|NCT02501226|Behavioral|ENVIE psychoeducational program|"The intervention will consist of 9 weekly, 90 min sessions led by two animators. The program ENVIE will provide:1.Presentation of the program 2.Education on depressive symptoms. 3.Information about the causes leading to depression. 4.The depression's consequences. 5.Teaching about the last neurobiological and neuroanatomical knowledges about depression, through didactic presentations. 6.How to recognize his own mood state, the prodromal symptoms of relapse. 7.Didactic explanation of the neurobiological action of antidepressant, and other evidence-based medical treatments. 8 and 9. Recommendations about lifestyle and skills of behavioral activation.To enhance the active role of the patient, each session will be accompanied with homework for the patient.~The sessions may be carried out remotely, by videoconference."
45340622|NCT04019366|Other|Conventional Training|Control group has received traditional exercises i.e Quadriceps strength exercises, Hamstrings flexibility exercises and Balance exercises.
45473121|NCT01587053|Other|therapeutic education program|
45473122|NCT03384160|Diagnostic Test|Group 1 -Pain monitor|Use of the anesthetic Mepivacaine 2% in third molar extraction and evaluation in postoperative
45473123|NCT03384160|Diagnostic Test|Group 2 -Pain monitor|Use of the anesthetic Articaine 4% in third molar extraction and evaluation in postoperative
46036059|NCT02819830|Behavioral|Exercise Intervention|Combined strength and aerobic exercise
46036060|NCT02820064|Procedure|duodenal biopsy during gastroduodenal endoscopy|Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.
46036061|NCT01106898|Drug|cyclophosphamide|Given IV
46036062|NCT01106898|Drug|paclitaxel|Given IV
46036063|NCT01106898|Biological|trastuzumab|Given IV
46036064|NCT01106898|Other|laboratory biomarker analysis|Correlative studies
46036065|NCT04425538|Drug|Infliximab|Either infliximab or infliximab-abda will be used at the discretion of the investigator
46036066|NCT04309344|Device|WEREWOLF COBLATION System|The bipolar radiofrequency-based chondroplasty device is used in the COBLATION mode (yellow) with The WEREWOLF system and the wand FLOW 50 in Lo mode (low) which are approved by the FDA for chondroplasty and debridement of the articular cartilage; fibrillations were removed and the surface was smoothed. This low energy and low suction setting minimizes damage to healthy chondrocytes surrounding and is therefore the preferred setting for the removal of articular cartilage.
45340623|NCT00770835|Drug|Pioglitazone and Metformin|Pioglitazone 30 mg, tablets, orally, once daily, metformin stable dose and lifestyle modification for up to 24 weeks.
45340624|NCT00770835|Drug|Glibenclamide and Metformin|Glibenclamide 10 mg, tablets, orally, once daily and metformin stable dose and lifestyle modification for up to 24 weeks.
45473124|NCT01587131|Biological|FVH1 - a DNA-based influenza vaccine|0.9 mg FVH1 vaccine
45473125|NCT03387436|Behavioral|Sham-Intervention|The sham intervention does not target the specific topics of the study intervention group (i.e. no special focus an ACP or end of life communication). Supportive therapy uses common factors of psychotherapy such as elicitation of affect, reflective listening, and feeling understood, but provides no explicit theoretical formulation to the patient. The therapist tries to elicit and validate the patients' affect for instance on the realization that there is no curative treatment option. Supportive therapy has been used as an unspecific control condition in several studies (Cohen et al. 2011; Markowitz et al. 1998). Patients of the sham intervention will be informed about the benefits of advance directives in general.
45683517|NCT04399642|Procedure|Arthroplasty|All patients include in the study will undergo a lowerlimb arthroplasty, primary or revision
45683518|NCT04399564|Device|temporary hemodialysis catheters|Vascular access using temporary vs.long-term hemodialysis catheters
45683519|NCT04399564|Device|long-term hemodialysis catheters|long-term hemodialysis catheters
46036067|NCT04309344|Procedure|control|mechanical debridement
46036068|NCT02879526|Drug|C-CPT|Chidamide 30mg ，twice a week Prednisone 20mg qd Cyclophosphamide 50mg qd Thalidomide 100mg qd
45340625|NCT04228016|Device|Device: nastent™|Patients with Nasal obstruction at night, will be used intrasal stent during 15 nights. These are flexible silicone tubes that are lubricated and easy to insert into the nasal cavities, which would restore the permeability of the nasal cavities.
45340626|NCT00769509|Other|energy expenditure in preterm fed with preterm formula|Assessment of energy expenditure by indirect calorimetry in preterm infant fed with preterm formula 24 hours before measurements.
45340627|NCT00769509|Other|assessment of energy expenditure|assessment of energy expenditure in preterm infant during fed with human milk with fortifier
45340628|NCT04223960|Drug|EA1080|EA1080 Formulation A.
45340629|NCT04223960|Drug|EA1080|EA1080 Formulation B.
45340630|NCT04223960|Drug|EA1080|EA1080 Formulation C.
45340631|NCT04223960|Drug|EA1080|EA1080 Formulation D.
45340632|NCT04223960|Drug|EA1080-matching placebo|EA1080-matching placebo.
45340633|NCT04223960|Drug|EA1080|EA1080 Formulation E.
45683520|NCT03672526|Device|measure of injection pressure by compuflo|injection pressure mesured by Compuflo
45340634|NCT04223960|Drug|EA1080|EA1080 Formulation F.
45340635|NCT00769587|Drug|thalidomide|
46036069|NCT02815306|Device|Polyaxial brace|The Polyaxial brace were made by a technician trained by the China National Disabled Persons Federation. For all patients, gypsum models were prepared first, and then braces were fabricated according to the models. The detailed technique was fully in accordance with the Ponseti method.
45340636|NCT00769665|Other|Systane Ultra|Re-wetting ocular eye drop
45340637|NCT00769665|Other|Sensitive Eyes Rewetting Drops|Re-wetting ocular eye drop
45340638|NCT04077320|Behavioral|Memory Self-Efficacy Training|The intervention will consist of a six-week cognitive behavioral intervention integrating the four pillars of self-efficacy, Mastery, Social Modeling, Coaching, and Physiological Responses (West et al. 2008). Each week will comprise of a 1.5 hour session which focuses on an educational component, discussions and active learning practice activities to apply lesson material. Additionally, participants will be given take home exercises to practice outside a classroom setting. The sessions will be conducted in small groups of 4-6 people.
45340639|NCT04077320|Behavioral|General Education|The active control intervention will be a general education class consisting of real world knowledge and factual information on various topics unrelated to memory. This intervention will follow the same format as the memory self-efficacy training arm. One 1.5 hours session every week for 6 weeks, in small groups.
45340640|NCT00764049|Device|Single pass albumin dialysis|6 hours sessions of albumin dialysis.
45683521|NCT03229174|Drug|Droxidopa|Droxidopa initial dose 100mg TID, titrated in increments of 100mg every 24-48 hours to symptomatic response.
45683522|NCT03229174|Drug|Placebo|Placebo (sugar pill)
45683523|NCT03227926|Drug|Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]|Panitumumab 6 mg/kg in 100 cc 0.9% NaCl solution on Day 1 every two weeks by IV administration over 1 hour.
45683524|NCT03227926|Diagnostic Test|Molecular Screening|Patients without plasmatic evidence of potentially resistant clones harbouring RAS or EGFR-ectodomain mutations in the RML liquid biopsy, will be molecular eligible for the trial phase
45683525|NCT03871816|Other|Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis|Saliva, blood, and/or archival tumor tissue will be collected from the participants with metastatic PC for genomic testing to confirm DRD status.
46036070|NCT04309032|Procedure|retrograde bladder filling with 0.9% normal saline 250cc prior to removal of foley catheter|0.9% NS 250cc was introduced before foley catheter removed for discharge
45340641|NCT04048083|Behavioral|Mental trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement. During each training session they will perform 3 practice trials by following the instructions, after practicing 3 trials, the instructions will be discontinued, and subjects will perform 30 mental movements by following auditory cues.
46036071|NCT04690582|Behavioral|Cognitive Processing Therapy (CPT)|Cognitive processing therapy (CPT) is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of PTSD that have developed after experiencing a variety of traumatic events including child abuse, combat, rape and natural disasters. CPT is generally delivered over 12 sessions and helps patients learn how to challenge and modify unhelpful beliefs related to the trauma. In so doing, the patient creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life. This treatment is strongly recommended for the treatment of PTSD.
46036072|NCT04690582|Behavioral|Crisis Response Plan (CRP)|The crisis response plan (CRP) is a collaborative, patient-centered intervention that is typically handwritten on an index cards and focuses on several key components: (1) warning signs, (2) self-regulatory strategies, (3) reasons for living, (4) sources of social support, and (5) professional and crisis services.
45340642|NCT04048083|Behavioral|Computer-aided trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of visual feedback of reaching-to-grasp movement. During each training session they will be sitting on a chair, in front of a computer screen observing simple tasks of reaching and precision fine grasping of a small object with 4 fingers of virtual upper extremity using the visualization software that will be coded specifically for the purpose of this experiment.
45340643|NCT04048083|Behavioral|Computer-aided and mental trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement that will be supplemented by visual feedback of this task by the visualization software that will be coded specifically for the purpose of this experiment (they will receive trainings that link the features of the two mentioned above types of training (MT and CAT).
45340644|NCT04048083|Other|No trainings|Healthy controls without any kind of training
45340645|NCT05674604|Procedure|Cryoneurolysis|This is on observational study. All participants are already candidate for cryoneurolysis. Cryoneurolysis uses a cold probe to generate an ice ball, which initiates Wallerian Degeneration, a process where axon is destroyed but the epineurium and perineurium remain intact. The treated nerve is able to regenerate over time due to this preserved tube.
45340646|NCT00570921|Drug|Everolimus|Everolimus tablets, two-5 mg tablets a day
45340647|NCT00570921|Drug|Fulvestrant|intramuscular, 500 mg in two divided doses- one on each side- on day 1, then 250mg on day 14, then 250 mg on day 28 and every 4 weeks +/- 3 days thereafter
45340648|NCT04077242|Diagnostic Test|"Hysteroscopic Fallopian tube assessment using the Parryscope technique"|A small amount of air is introduced into the iv tubing by inverting the drip chamber to create air bubbles. When air enters the uterine cavity, a single large air bubble or stream of air bubbles traversing the ostia is considered indicative of tubal patency. At least 10 seconds of intracavitary evaluation is typically performed before air bubble entry to allow pressure equilibration if a hydrosalpinx is present [10]. At least 30 seconds of observation per ostia is performed if patency is not observed.
45340649|NCT04077242|Diagnostic Test|"Hysteroscopic Fallopian tube assessment using the Tubal flow technique"|"a positive flow is defined as the observation of saline directly traversing the ostia, endometrial structures floating toward the ostia, or air bubbles traversing the ostia."
45340650|NCT00769821|Other|questionnaire administration|
45340651|NCT00769821|Procedure|assessment of therapy complications|
46036073|NCT04690582|Behavioral|Safety Planning Intervention (SPI)|The safety planning intervention (SPI) is a suicide-focused intervention typically handwritten on a pre-printed form that includes the following sections: (1) warning signs, (2) internal coping strategies, (3) people and social settings that provide distraction, (4) people who can offer help, (5) professionals or agencies they can contact during a crisis, and (6) making the environment safe.
46036074|NCT04690582|Behavioral|Narrative Assessment|"The narrative assessment is a patient-centered assessment approach in which the clinician invites the patient to share the story of a recent crisis or period of intense emotional distress. Patients are asked to identify the thoughts, emotions, and physical sensations experienced in the time leading up to this crisis, as well as the contextual and environmental characteristics surrounding the crisis. Information obtained from the narrative assessment is then used to help formulate a crisis response plan."
46036075|NCT02878980|Behavioral|Exercise Intervention|Undergo supervised 1-on-1 exercise sessions
46036076|NCT02878980|Other|Laboratory Biomarker Analysis|Correlative studies
45340652|NCT00769821|Procedure|bioimpedance spectroscopy|
46036077|NCT02878980|Other|Quality-of-Life Assessment|Ancillary studies
45340653|NCT00769821|Procedure|quality-of-life assessment|
45340654|NCT04076930|Drug|angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB)|The use of ACEI/ARB within a 90-day after the date of PD initiation (exposure ascertainment window period).
45340655|NCT02557425|Other|No intervention in PROTECT|
46036078|NCT02878980|Other|Questionnaire Administration|Ancillary studies
46036079|NCT04420156|Other|No intervention administered.|Eye exams are standard of care and would be performed regardless of participation in this study.
45340656|NCT05233826|Biological|COVI-VAC|Intranasal, live attenuated vaccine against SARS-CoV-2
45340657|NCT00769899|Drug|AZD7325|Capsule for oral, single dose
45340658|NCT00769899|Drug|Placebo|Placebo capsule for oral, single dose
45340659|NCT00770055|Other|medical chart review|
46036080|NCT02627521|Procedure|PRU guided CABG|Coronary Artery Bypass Surgery
46036081|NCT02627521|Procedure|CABG per standard of care|Coronary Artery Bypass Surgery
46036082|NCT02627521|Device|VerifyNow assay|Platelet reactivity Units by VerifyNow assay
46036083|NCT02627521|Drug|Ticagrelor|Ticagrelor administration prior to randomization
45340660|NCT00770055|Other|questionnaire administration|
45340661|NCT00770055|Other|survey administration|
45340662|NCT00770055|Procedure|psychosocial assessment and care|
45340663|NCT04048317|Drug|HepaSphere Microspheres/Doxorubicin Hydrochloride|"evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of drug-eluting microsphere (25 mg Hepasphere 50-100 micron) loaded with 50 mg doxorubicin solution for 2 hours."
45340664|NCT04048317|Drug|Lipiodol|"evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of prepared mixture of Lipiodol and (Doxorubicin or 5-FU) vary in dosage depend on operator consideration"
45340665|NCT00764283|Device|Tegaderm dressing|Tegaderm dressing is used to secure the epidural catheter for postoperative analgesia
46036084|NCT02627599|Device|Breath Responsive Variable Bolus Oxygen Conserving Device|Mini Electronic Oxygen Conserving Device
46036085|NCT04406974|Procedure|Surgery or treatment for local recurrence|Surgery or treatment for local recurrence
45340666|NCT00764283|Device|Epi-Fix dressing|Epi-Fix dressing is used to secure the epidural catheter for postoperative analgesia
45340667|NCT00764283|Device|Lockit-Plus|Lockit-Plus dressing is used to secure the epidural catheter for postoperative analgesia
45340668|NCT02582294|Other|Questionnaire|
45683526|NCT03227770|Device|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform at least once every two week. The hemoperfusion apparatus will use type HA130 resin hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
45340669|NCT04363034|Biological|Convalescent Plasma|1-2 units (200-400 mL per unit, not to exceed 550 mL total) of ABO compatible, low isohemagglutinin titer, COVID-19 convalescent plasma
45340670|NCT00920504|Behavioral|German PRO-SELF(c) Plus Pain Control Program (PCP)|Educational intervention directed at patients and their family caregivers to reduce cancer pain and related symptoms
45340671|NCT00920504|Other|Standard Care|Patients in the standard care group will receive routine care provided by their treating physicians without any further care concerning the PRO-SELF© PCP. Patients in the standard care group will be seen by a research nurse in their homes at weeks 1, 2, 4, 6, 8 and 10 and telephone interviews will be conducted at weeks 3, 5, 7 and 9 but the focus of the visits and phone calls will be data collection only.
45340672|NCT02584712|Other|Combined Exercise Training|This intervention consisted in 4 weeks of strength, flexibility and aerobic exercises made at the hospital and at home.
45340673|NCT02582450|Other|Patients with haemophilia|Piloting of reliability and validity of the Spanish version of the Veritas-Pro questionnaire.
46036086|NCT04406974|Procedure|Surgery for advanced colorectal cancer|Surgery for advanced colorectal cancer
46036087|NCT02815228|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z43-034)
46036088|NCT00681967|Drug|Gefitinib|250 mg; oral
46036089|NCT00681967|Drug|Gefitinib|250mg; oral
46036090|NCT00685321|Device|H1 deep TMS coil|20 daily deep rTMS treatment
45598867|NCT02346981|Behavioral|Resistance training|Supervised resistance training program was performed on three nonconsecutive days per week at morning period for 12 weeks. The resistance training program included eight exercises in two consecutive sets of 10-15 repetitions until moderate fatigue, except for crunch exercise which was performed on 20 to 30 repetitions without overload. The participants were instructed to perform repetitions at a ratio of 1:2 (concentric and eccentric phases, respectively). Subjects rested for 60- to 90-s between each set and for 2- to 3-min between each exercise. Each subject was individually supervised. Increases of 2-5 % for the upper limb exercises and 5-10 % for the lower limb exercises every time that subjects were able to complete 15 repetitions in both sets.
45683527|NCT03227770|Device|hemodialysis|Blood purification (including low-flux hemodialysis, high-flux hemodialysis, or hemodiafiltration) treatment ≥10 hours per week
45340674|NCT02584556|Drug|systemic chemotherapy|Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks starting 4-6 weeks after hepatic resection.
46036091|NCT00685321|Device|Sham|inactive treatment
46036092|NCT04239118|Combination Product|Complex endoscopic treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets|Complex endoscopic bleeding ulcers treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets
45340675|NCT02584556|Drug|Transcatheter Arterial Chemoembolization|Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou) starting 4-6 weeks after hepatic resection.
45340676|NCT04353986|Drug|Sofosbuvir and Ledipasvir|fixed dose tablet containing 400 mg sofosbuvir and 90 mg ledipasvir
45340677|NCT05208164|Behavioral|Mindfunlness Meditation|Sleep monitoring, mental health promotion and active enrollment/engagement in self-described coping mechanisms
45340678|NCT04077164|Other|No intervention, observational only.|No intervention, this study will use self-report information regarding health, social, and behavioral factors for each member of the couple.
45340679|NCT04077008|Procedure|unilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
45340680|NCT04077008|Procedure|bilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
45340681|NCT05325554|Behavioral|Multimodal rehabilitation|Multimodal rehabilitation
45598868|NCT02289937|Drug|Ropivacaine|
45598869|NCT02289937|Drug|Placebo|
45683528|NCT03227146|Biological|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
45683529|NCT03227146|Biological|STSG|Transplantation of autologous split-thickness skin graft to the control area
46036093|NCT04239118|Procedure|Traditional methods of endoscopic hemostasis|Traditional methods of endoscopic hemostasis were used without the use of platelet-enriched plasma and granular sorbents
45683530|NCT03615742|Other|Placebo|Inhalation of air through a Turbuhaler that contains no medication, as a control.
45683531|NCT03615742|Drug|Budesonide|1.6mg of budesonide from a Turbuhaler.
45683532|NCT03615742|Other|Filtered Air|Exposure to HEPA filtered air, as a control.
45683533|NCT03615742|Other|Diesel Exhaust|Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
45683534|NCT04562194|Device|NeVa Stent Retriever|mechanical neurothrombectomy
46036094|NCT04139941|Diagnostic Test|Test for HCV antibodies with an RDT|Fingerstick whole blood, plasma and serum of each participant is tested with three investigational HCV RDTs and one reference HCV RDT. Plasma is also used for testing with the composite reference standard, HCV viral load and genotyping. All participants are also tested for HIV with an HIV RDT.
46036095|NCT02815150|Dietary Supplement|preoperative oral carbohydrate drink|5% glucose solution 250ml 2-3 hours before surgery
46036096|NCT02814994|Behavioral|tidal volume guided by respiratory system compliance|ventilated with tidal volume guided by respiratory system compliance
45340682|NCT02581436|Other|kSORT assay based follow-up|kSORT assay in pre-established days: 14, 45, 90, 180, 365 and 540 of post transplantation follow-up. If kSORT result is positive maintenance immunosuppressive will be increased (tacrolimus trough levels 12-15 ng/mL, Mofetil Mycophenolate 1.5 mg every 24 hours and prednisone 5 mg/day) and graft biopsy will be obtained. Kidney biopsy will be obtained one mo after treatment as well as kSORT assay. If kSORT result is negative, the maintenance immunosuppressor dosages will remain as established in our institutional guidelines. If after a year of follow-up, the kSORT result is negative, immunosuppression will be decreased (Tacrolimus levels 5 - 10 ng/ml and mofetil mycophenolate 500 mg every 12 hours).
45340683|NCT02581436|Other|Standard follow-up|Surveillance will be the usual, includes creatinine determinations and clinical evaluation as often as established in the institutional protocol. A kidney graft biopsy will be obtained in case of dysfunction (increase in serum creatinine >25% above baseline or 0.3 mg/mL above baseline) or as part of our institutional programmed biopsies (months 3 and 12). Treatment will be established in accordance with biopsy results. In all cases of rejection a kidney biopsy will be obtained one month after initiating treatment. In this control group, samples for kSORT analysis will be collected on pre-established dates for the study, but patient treatment will not be contingent on the assay's results; investigators will be blinded to the result in this control patient group.
45473126|NCT03387436|Behavioral|Study-Intervention|"The design of the study-intervention was influenced by dignity therapy (Chochinov et al. 2005), the End-of-life-Review (Ando et al. 2010) and barriers concerning participation of ACP identified by research (Bollig et al. 2017; Gjerberg et al. 2015). It is the goal of the study-intervention to enhance communication about death related topics of patients and their relatives/caregivers.~Our study intervention extends over six therapeutic sessions. The length of each session will be adjusted to the patients physical condition, it should not exceed 45 minutes in total.~In the first four sessions, patients and relatives will be informed about the relevance of ACP. Potential barriers for an efficient patient-caregiver communication and ACP are discussed. The intervention focuses on encouraging end-of-life communication and on jointly modifying barriers to EOL communication.~The fifth and sixth session focus on ACP based on the standardised concept of beizeiten begleiten."
45340684|NCT00670449|Drug|Fingolimod|Fingolimod was supplied in capsules.
45340685|NCT04168970|Procedure|PSGB|Percutaneous stellate ganglion block: injection of 10 mL of local anaesthetic (lidocaine 2%) at the C6 level using the anatomic technique or the echo-guided technique The anaesthetic that will be used for PSGB is lidocaine.
45340686|NCT04160390|Other|Biospecimen Collection-Blood|Undergo collection of blood
45340687|NCT04160390|Other|Biospecimen Collection-Stool|Undergo collection of stool
45473127|NCT03871673|Dietary Supplement|sweet polvilho|100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
46036097|NCT02814994|Behavioral|low tidal volume|ventilation ventilated with low tidal volume
46036098|NCT00875017|Drug|Lanthanum Carbonate|1 x 1000mg tablet
46036099|NCT00875017|Drug|Sevelamer|3 x 800mg tablets
46036100|NCT04151095|Other|BFR Exercise Training|Participants will complete exercise training on a recumbent bike placed on a 45 degree incline (BFR).
46036101|NCT04151095|Other|CTL Exercise Training|Participants will complete exercise training on a recumbent bike placed on flat ground (CTL).
46036102|NCT02819362|Device|MRI|The magnetic resonance imaging (MRI) will be performed before the two-step surgery: a ductal-MRI sequence (highly weighted sagittal T2) - followed by sequence with axial plane, T2, T1, injection in dynamic sequences, subtractions.
46036103|NCT00679705|Drug|Ritodrine|Ritodrine (Pre-Par), maximum 400 µg/minute, IV
46036104|NCT00679705|Drug|Atosiban|Atosiban (Tractocile), maximum 300 µg/minute, IV
46036105|NCT00679705|Drug|Placebo|Glucose 5%, IV
45340688|NCT00771147|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients with diagnosis of advanced renal cell cancer and decision taken by the investigator to prescribe Nexavar®.
45340689|NCT00771225|Procedure|fascial repair|surgery to treat genital prolapse with fascia repair
45683535|NCT04398472|Behavioral|KIND Challenge|The KIND challenge consists of nominating an activity to complete over a 4 week period. The activities involve doing an activity with others in your neighbourhood. These activities are positive, engaging and feasible to the average individual. Activities adhere to relevant country or state department health and safety guidelines. For example; having a chat with a neighbour online, or bringing in rubbish bins for an elderly neighbour.
46036106|NCT04672486|Behavioral|POD Adventures|"Participants in the intervention arm will receive information about local services/national helplines and a brief problem-solving intervention that is delivered through a smartphone app with telephone guidance from a lay counsellor. The intervention is grounded in stress-coping theory, with a technical focus on practical problem solving. The emphasis on problem solving reflects the primacy of psychosocial stressors in adolescent help-seeking. Moreover, problem-solving is among the most commonly used practice elements in evidence-based psychological interventions for children and adolescents globally.~The content of the app comprises two sections: 'Adventures' which teaches problem-solving concepts and methods through contextually-appropriate games; and 'My POD' which scaffolds the student through the application of step-by-step problem-solving procedures to their own prioritized problems."
46036107|NCT00685555|Behavioral|Switch active lifestyles brought to you by MediaWise|The Switch™ Program is a unique community and family-based behavior change initiative that helps motivate children to change three critical health behaviors that are risk factors for childhood overweight and obesity.
45340690|NCT00771225|Procedure|mesh repair|surgery to genital prolapse with mesh
45340691|NCT04155710|Biological|IOV-2001|Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL). The final investigational product is a cryopreserved cell suspension.
45340692|NCT04155710|Drug|Low dose IL-2|6 doses of subcutaneous (SC) LD-IL-2 (9 MIU every 8-12 hours) will follow the infusion of IOV-2001
45340693|NCT04155710|Drug|High dose IL-2|6 doses of IV HD-IL-2 (600,000 IU/kg Q8-12H will follow the infusion of IOV-2001
45340694|NCT04155710|Drug|IL-2|6 doses of IL-2 will follow the infusion of IOV-2001
45340695|NCT02557659|Device|Zenith Low Profile AAA Endovascular Graft|Treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair
45340696|NCT00775047|Other|Pharmacist-administered|women will receive their injections at a pharmacy by a clinical pharmacist
46036108|NCT00685555|Behavioral|Switch active lifestyles from MediaWise|1300 students (male and female) were recruited through two separate school districts in Lakeville, Minnesota and Cedar Rapids, Iowa. Informed consents went to all students who chose to participate. Demonstration and Control school were randomly selected. Baseline data was collected regarding physical activity, screen time, and nutrition, standard body measurements, and baseline data, and salivary cortisol levels were taken. Parent and teacher surveys were also conducted. After baseline selected demonstration sites and students were provided with information focused on improving healthy behaviors while the control sites served as matched comparison groups.
45473128|NCT03871673|Dietary Supplement|Cornstarch|100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
46036109|NCT02815072|Other|Skin biopsy|A sample of skin (approximately 0.5cm x 0.5cm) from inner thigh area. The skin biopsy will be conducted and completed with a single stitch to close the wound under local anaesthesia to minimise any discomfort. The skin biopsy will be taken by the medical doctor trained in biopsy collection. The tissue sample will be processed and cells will be grown out of them under appropriate conditions. These cells will only be used for laboratory experiments that include experimental transplantation models and laboratory bench-top research.
45340697|NCT00775047|Other|clinic-administered injections|women will return for their injections to the clinic where recruitment took place. They will receive one at 3 months and 6 months.
45340698|NCT00775125|Drug|Telaprevir; Darunavir; Ritonavir; Fosamprenavir|
46036110|NCT04140019|Diagnostic Test|CMR|Early CMR with adenosine stress/rest perfusion before invasive coronary angiography.
45340699|NCT02557503|Drug|Oxaliplatin and fluorouracil|Oxaliplatin and fluorouracil by HAIC on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer after TACE
45473129|NCT04445818|Behavioral|More appreciation|
45473130|NCT04445818|Behavioral|Less criticism|
45473131|NCT04445818|Behavioral|More Fruit and Vegetable|
45473132|NCT03384082|Procedure|hysteroscopic treatment|treatment
46036111|NCT04237948|Device|transcranial direct current stimulation (tDCS)|cerebellar tDCS consists in the application of a low intensity (1-2 mA) steady current through a surface scalp electrode over the cerebellum
46036112|NCT04237948|Behavioral|Physical therapy|Hospitalized patients will undergo a 60 minutes physical treatment improving gait and postural instability for four weeks of time
45473133|NCT04445506|Drug|Dexamethasone|4mg dexamethasone was given to some patients three times daily for 2 days, 2 times daily for 2 days, once daily for 2 days.
45683536|NCT04764292|Device|Contrast-enhanced mammography|supplemental breast cancer screening with contrast-enhanced mammography
46036113|NCT00685633|Drug|bicalutamide|Given orally
46036114|NCT00685633|Drug|enzastaurin hydrochloride|Given orally
46036115|NCT04206670|Device|In-Home Technology System and Questionnaires|Participants self-install the in-home technology system in their homes after enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
45340700|NCT00764439|Drug|Nicotine replacement therapy|Nicotine replacement therapy with Standard NRT user direction
45340701|NCT00764439|Drug|Nicotine replacement therapy|Nicotine replacement therapy with a Novel NRT user direction
45340702|NCT00771303|Other|Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer, lower limb vein ultrasonography and MSCT.|
45473134|NCT01283243|Device|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
45598870|NCT02289937|Device|An ultrasound-guided Nervus cutaneous femoral lateralis blockade will be given postoperatively|
45683537|NCT04764292|Drug|Iodinated Contrast Media (ICM)|supplemental breast cancer screening with contrast-enhanced mammography
46036116|NCT04206670|Device|Waiting Control In-Home Technology System and Questionnaires|Participants self-install the in-home technology system in their homes six months after their enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
45473135|NCT03387358|Device|Nasal bridle securement device for small bore feeding tubes|A Nasal bridle securement device is an alternative method to securing small bore feeding tubes which are most commonly secured with adhesive tape to the nose. A nasal bridle securement device instead secures the feeding tube to a cloth ribbon that is inserted in one nostril, over then nasal bridle and out the other nostril.
45340703|NCT05674526|Biological|WU-NK-101 - Dose Escalation|WU-NK-101 administered on Days 1, 15, 30 and 44
45340704|NCT05674526|Drug|Cetuximab - Dose Escalation|Cetuximab 500mg/m2 administered on Days 29 and 43
45340705|NCT05674526|Biological|WU-NK-101 - Cohort Expansion|WU-NK-101 administered on Days 2 and 16
45473136|NCT03869489|Device|Anodal left dorsolateral prefrontal cortex tDCS stimulation|Anodal tDCS will be applied to the left dorsolateral prefrontal cortex of participants
45473137|NCT03869489|Device|Anodal right dorsolateral prefrontal cortex tDCS stimulation|Anodal tDCS will be applied to the right dorsolateral prefrontal cortex of participants
45473138|NCT03869489|Device|Sham tDCS stimulation|Sham tDCS stimulation will be applied
45473139|NCT03384004|Device|Irrigation Technique 1|Irrigation of root canals for this group will be performed using EndoVac Pure, an Apical Negative Pressure Endodontic Irrigation System intended for the delivery and evacuation of endodontic irrigation solutions during root canal procedures. The Endovac Pure is a negative pressure system that utilizes negative pressure irrigation so irrigants are suctioned apically from the pulp chamber to the apical terminus and then through the dental office High Volume Evacuation (HVE) valve (Hi-VAC) system. Endovac Pure is designed to be used with Sodium Hypochlorite (NaOCl or bleach) and EDTA (Ethylenediaminetetraacetic acid). This will be followed by Ultrasonic activation of the sodium hypochlorite solution using Minendo II ultrasonic unit.
45340706|NCT05674526|Biological|Cetuximab - Cohort Expansion|Cetuximab 500mg/m2 administered on Days 1 and 15
45473140|NCT03384004|Device|Irrigation Technique 2|Irrigation of root canals for this group will be performed using the EndoVac pure system without Ultrasonic irrigation. The Endovac Pure is a negative pressure system that utilizes negative pressure irrigation so irrigants are suctioned apically from the pulp chamber to the apical terminus and then through the dental office High Volume Evacuation (HVE) valve (Hi-VAC) system. Endovac Pure is designed to be used with Sodium Hypochlorite (NaOCl or bleach) and EDTA (Ethylenediaminetetraacetic acid).
46036117|NCT00685711|Biological|Cat-PAD|single, escalating dose intradermal and subcutaneous injections of Cat-PAD
46036118|NCT04371952|Drug|Doxycycline|comparison of doxycycline 200 mg/day to placebo
45340707|NCT02558049|Other|Decision aid|Participants will receive a patient decision aid which outlines the potential benefits and harms of proton pump inhibitor use, as well as the potential benefits and harms of switching to a lower dose of PPI or stopping and using on-demand (only when symptoms occur). The decision aid also allows participants to clarify their values regarding these potential benefits and harms.
45340708|NCT00771381|Drug|18F-FAZA PET scan|Radioactive dose of 18F-FAZA: 110-600 MBq per injection. One pre-treatment injection of 18F-FAZA and PET scan will be permitted per patient.
45473141|NCT01587365|Biological|BMS-962476|
45473142|NCT01587365|Biological|Placebo matching with BMS-962476|
45473143|NCT04445272|Drug|Tocilizumab|Treatment with Tocilizumab
46036119|NCT04371952|Drug|Placebo|Placebo : lactose, 380 mg/gélule
45340709|NCT00771381|Drug|FluGlucoScan Injection (18F-FDB) PET scan|Radioactive dose of 100-700 MBq per injection. A single pre-treatment injection of FluGlucoScan Injection and PET scan will be permitted per patient.
45340710|NCT00771459|Drug|Ropivacaine 0.5 %|Local infiltration analgesia
45340711|NCT00771459|Drug|Isotonic NaCl|Local infiltration analgesia
45340712|NCT00764595|Drug|imatinib mesylate|Imatinib mesylate is administered as oral dose of 400 mg/d once daily after meal until 3 years after enrollment of the last patient.
45340713|NCT00775359|Drug|Fenofibrate 160 mg tablets|
45340714|NCT02557347|Behavioral|Aggressive fluid management|nursing education, dietary advice, extra hypertonic dialysis cycles
45340715|NCT04048005|Diagnostic Test|Fractional flow reserve|
45473144|NCT03383926|Procedure|4.5cm suture|Suture confection of the Tobacco-pouch of 4.5cm from the anal margin.
45473145|NCT03383926|Procedure|6cm suture|Suture confection of the Tobacco-pouch of 6cm from the anal margin.
45598871|NCT03146559|Device|EMG and TENS|Healthy hand EMG signal measured while making voluntarily wrist dorsi flexion will activate TENS, which will be placed on the paretic forearm and will produce wrist dorsi flexion.
45340716|NCT02582138|Other|Multicomponent intervention (MCI)|"The multicomponent intervention will include physical activity (PA), nutrition and information and communications technology (ICT). The PA will be of moderate intensity and will include aerobic, strength, flexibility, and balance training. Walking will be the primary mode of PA .~The nutritional intervention will combine individual nutritional assessment and personalised dietary recommendations to achieve:~a daily total energy intake of 25-30 kcal/kg body weight;~an average protein daily intake between 1.0 and 1.2 g/Kg/body weight.~The ICT component will involve the use of an ad hoc technological device to record actimetry data to support the elaboration of a personalised training programme."
45340717|NCT02582138|Other|Healthy Aging Lifestyle Education (HALE)|The healthy aging lifestyle education programme will be based on a workshop series. Participants will receive information on a variety of topics of relevance to older adults (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
45340718|NCT00775515|Procedure|laparoscopic prostatectomy|laparoscopic prostatectomy
46036120|NCT00682123|Dietary Supplement|19-norandrostendione|"Volunteers recieved 500mL of water containing 5g of creatine monohydrate and either 1.0μg, 2.5μg or 5.0μg of 19-norandrostendione in a single-blind crossover manner.~The amount of 19-norandrostendione administered was trivial, and far less than the amounts shown to be present in many popular dietary supplements. The recommended dosage according to the distributors is 100 mg 2-3 times daily, so the administered daily dose was not more than 0.05% of the recommended dose. This dose has no measurable physiological or pharmacological effects."
45340719|NCT05338502|Drug|Selpercatinib|Administered orally.
46036121|NCT04205734|Diagnostic Test|MTX Assessment|Measurement of Methotrexate Polyglutamate levels.
46036122|NCT04145089|Device|Glidescope video laryngoscopy/ C-MAC video laryngoscopy|usage of said devices according to manual
45473146|NCT01587287|Device|Corneal power measurement|All subjects will be underwent a full ophthalmic examination including vision, auto- and subjective refraction, slit-lamp examination, non-contact tonometry, corneal power measurements with the 8 devices and fundus examination.
45473147|NCT05186025|Drug|MATA trees or MATA grass|Glutaraldehyde-modified and MCT® (MicroCrystalline Tyrosine)-adsorbed allergoids
45340720|NCT05338502|Drug|Ranitidine|Administered orally.
45340721|NCT05338502|Drug|Omeprazole|Administered orally.
46036123|NCT00679861|Behavioral|Counselling Intervention|A personal counselling by the residing practitioner of up to 10 minutes. A follow-up counselling is included for the next regular patient consultation
46036124|NCT00679861|Behavioral|Expert-system intervention|Counselling letter of three to four pages will be generated by an expert-system base on the assessment of the patient. A second and third letter will be generated at follow-up consultations.
45340722|NCT04078334|Other|MATCH|In the first days of hospitalization, the physiotherapist determines the score linked to the patient's mobility profile using of a decisional tree. The PA program has 2 or 3 exercises to be done with or without supervision 3 times per week day during hospitalization. These daily exercises are prescribed by the doctor and taught by the physiotherapist.
45473148|NCT03379012|Drug|Testosterone undecanoate and sunitinib or pazopanib|Testosterone undecanoate (Nebido®) 1,000 mg (4 ml) intramuscular deeply, once before targeted therapy (sunitinib 50 mg 4/2 or pazopanib 800 mg daily)
45473149|NCT03869255|Procedure|Nasal swab|In hospitalized patiens, a nasal swab will be performed within the first 48 hours and on the 7th day. In community patient, only one swab will be performed
45598872|NCT03146559|Device|TENS only|Automatic TENS stimuli to the paretic dorsi flexors (i.e., producing wrist dorsi flexion).
45598873|NCT03446807|Drug|Droxidopa|Droxidopa in 100, 200, and 300mg capsules. Maximum dose to be used in this study is 600mg.
45340723|NCT04078334|Other|PATH|In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decisional tree. When returning home after hospitalization, each PA program includes a daily walk as well as 3 or 4 exercises that can be completed in a 12 to 20 minutes timeframe. These daily exercises are prescribed by the doctor and taught by the physiotherapist in 2 sessions.
45473150|NCT03839667|Behavioral|intensive diet intervention|the participants will be instructed to restrict the total daily calorie intake to 800 kcal by receiving the very-low-calorie meal replacement formula for 2 consecutive days per week. They will be allowed to maintain their normal diet in the remaining 5 days, but need to restrict total intake to 2000 kcal per day.
45473151|NCT03839667|Behavioral|Enhanced physical activity intervention|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
45473152|NCT03839667|Behavioral|Standard education|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on healthy diet and exercise plans, prevention for acute and chronic complications and self-glycemic monitoring.
45473153|NCT01271777|Drug|GFT505 80mg|hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
45473154|NCT01271777|Drug|Placebo|hard gelatin capsules, oral administration, 4 capsules per day before breakfast
45473155|NCT05181579|Other|Manuel therapy|Some sacroiliac manipulation and mobilization techniques will be applied to patients by an experienced physiatrist. Patients in the manual therapy group will receive 3 to 5 sessions of sacroiliac joint manipulation once a week, depending on the treatment response
45598874|NCT03446807|Drug|Placebo Oral Tablet|Placebo capsules to match Droxidopa 100, 200, and 300mg capsules.
45340724|NCT04078334|Other|PATH 2.0|"In the first days of hospitalization, the physiotherapist determines the score linked to the patient's mobility profile using of a decisional tree. The PA program has 2 or 3 exercises to be done with or without supervision 3 times per week day during hospitalization. These daily exercises are prescribed by the doctor and taught by the physiotherapist.~In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decisional tree. When returning home after hospitalization, each PA program includes a daily walk as well as 3 or 4 exercises that can completed in a 12 to 20 minutes timeframe. These daily exercises are prescribed by the doctor and taught by the physiotherapist in 2 sessions."
46036125|NCT02814760|Other|training of emergency professionals to acute stroke management|"The training program aiming at improving the timeliness of care of acute stroke patients in ED was designed for triage ED nurses and ED physicians and it was based on 3 sub-objectives:~Improving knowledge and skills of triage nurses to recognize patients with stroke symptoms~Improving knowledge and skills of ED physicians to recognize stroke symptoms, to realize a good quality neurological examination and be able to measure the NIHSS (National Institute of Health Stroke Score), to have a better understanding of the physiopathology of ischemic stroke and thrombolysis, and to have a better understanding of the consequences of wasted time for patients Developing, together with other hospital professionals involved in acute stroke management, a clinical pathway adapted to the local characteristics an organization (ED organization optimization, management steps, connections between ED, radiology unit and stroke unit, thrombolysis organization)."
45340725|NCT05337722|Behavioral|SFT 2.0|The SFT 2.0 intervention will include the use of the SFT 2.0 smoking cessation app, Motivational Interviewing (MI) counseling, and the support of a peer person
45340726|NCT05337722|Behavioral|Active control|Low dose prenatal and postnatal MI video counseling, defined as one prenatal session and one postnatal session
45473156|NCT05181579|Other|Sacroiliac joint injection|Corticosteroid (1 ml 40 mg methylprednisolone) and local anesthetic (1 ml 1% lidocaine) will be injected into the sacroiliac joint using a 22 G spinal needle, guided by fluoroscopy (C-arm fluoroscopy) by an experienced physiatrist. It will be applied just one time.
45598875|NCT03158181|Other|Non interventional study|None intervention will be conduct on patient. Only the operating room will be randomized to have an intervention or not (Bundle of measure for optimizing the discipline of personnel in the operating room)
45340727|NCT00673257|Other|pharmacological study|pharmacological studies
45598876|NCT03521323|Drug|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
45598877|NCT03521323|Drug|Placebos|Placebos: Saline，Sham operation
45340728|NCT00673257|Procedure|dual x-ray absorptimetry|
45340729|NCT02582060|Other|Thromboelastography/Thromboelastometry-Guided Treatment Regimen|The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
45340730|NCT04344392|Diagnostic Test|Ultrasonographic study|Thyroid hyoid approximation and hyoid anterior replacement during swallowing. Tongue thickness in rest.
45340731|NCT04344392|Diagnostic Test|Videofluoroscopic study temporal parameters|Glossopalatine junction opening and closing time, velopharyngeal junction opening and closing time, laryngeal vestibule opening and closing time, upper esophageal sphincter opening and closing time in seconds.
45340732|NCT04344392|Diagnostic Test|Videofluoroscopic study distance parameters|Hyoid bone horizontal and vertical replacement, thyroid-hyoid approximation (THA) in millimeters.
45340733|NCT02557269|Drug|Xylometazoline - intranasal application|Applied as needed up to 5 consecutive days when prominent congestion
45340734|NCT02557269|Drug|Azelastine - intranasal application|Applied as needed when prominent symptom is rhinorrhea
45340735|NCT02557269|Drug|Mometasone furoate - intranasal application|Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment
45340736|NCT02557269|Drug|Hydroxyl-propyl-methyl cellulose powder - intranasal application|Applied intranasally immediately after every application other intranasal formulation
45340737|NCT02557269|Other|Placebo - Lactose powder|Applied intranasally immediately after every application other intranasal formulation
45340738|NCT02557269|Drug|Bilastine 20 mg|1 tablet per os - as needed
45340739|NCT02557269|Drug|Prednisolone 5 mg|Per os - if needed (only in case of broncial obstruction)
45340740|NCT02581358|Other|Scolioscan (Ultrasound imaging system)|To assess the scoliotic patient, a 3D ultrasound imaging system (the Scolioscan) was developed. The system composes of an ultrasound scanner with a linear probe, a frame structure, an electromagnetic spatial sensing device and a dedicated PC program for imaging and data collection, processing, visualization, analysis, and assessment. The spatial sensor was attached to the ultrasound probe for spatial information collection and calibration. The Scolioscan will generate ultrasound images of the spine for quantitative assessment of the curve deformity in terms of Cobb angles.
45340741|NCT00771771|Other|Early supported discharge with day unit rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in a day unit
45340742|NCT00771771|Other|Early supported discharge with home rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in the patient's home
45340743|NCT00772083|Behavioral|Educational brochure|This brochure will educate anemic blood donors regarding the possible causes of their anemia, and based on age will make recommendations for who should seek consultation with a physician.
45340744|NCT00772083|Behavioral|Standard pamphlet|The BloodCenter of Wisconsin's default action when a potential donor has been found to be anemic is to provide a standard pamphlet with very basic nutritional information.
45340745|NCT00779181|Drug|ADX415|ADX415 taken three times a day to achieve a high total daily dose
45340746|NCT00779181|Drug|ADX415|ADX415 taken three times a day to achieve a mid level total daily dose
45340747|NCT00779181|Drug|ADX415|ADX415 taken three times a day to achieve a low total daily dose
45340748|NCT00779181|Drug|Placebo|Placebo taken three times a day
45340749|NCT00779337|Biological|Autologous AdE1- Latent Membrane Protein CTLs|Total dose 20-800 million CTL given in 4 equal doses (5-200 million CTL) given intravenously, at weekly intervals for the first cohort of 10 patients and twice a week for the second cohort of 10 patients.
45340750|NCT02556411|Drug|LNG-IUS 13,5 mg Levonorgestrel|LNG-IUS
45340751|NCT02556411|Drug|Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg|Levonorgestrel 0,10 mg+ethinylestradiol 0,02 mg oral contraceptive pill in continuous regime
45340752|NCT04085276|Drug|JS001|JS001 240mg, i.v., q3w; Other name: Toripalimab
45340753|NCT04085276|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
45340754|NCT04085276|Drug|Placebo|Placebo, i.v., q3w;
45340755|NCT04085276|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
45340756|NCT00775827|Drug|fenofibrate 160 mg tablets|
45340757|NCT02580032|Other|No treatment given|No treatment given.
45340758|NCT00775905|Drug|amlodipine 10 mg tablet|
45340759|NCT05674448|Biological|HH-003 20mg/kg|HH-003 20mg/kg Q2W intravenously for 24 weeks
46036126|NCT00875797|Dietary Supplement|parenteral glutamine|Dipeptiven, Fresenius Kabi, Graz, Austria was given intravenously through central venous line in a dose up to 30 g per day
46036127|NCT00875797|Dietary Supplement|enteral glutamine|Alitraq, Abbott Laboratories, B.W. Zwolle, the Netherlands was given via nasogastric tube as continuous infusion of enteral diet, dose up to 30 g per day
46036128|NCT04144621|Procedure|ICSI|Intracytoplasmic sperm injection of female partner oocytes with ejaculated sperm selected by density gradient centrifugation
45340760|NCT05674448|Biological|HH-003 3mg/kg|HH-003 3mg/kg Q2W intravenously for 24 weeks
45340761|NCT00772161|Drug|Methylphenidate|Comparison of two extended-release formulations of 20mg Methylphenidate in a cross-over design.
45340762|NCT04075838|Other|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the PTR (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
45340763|NCT00776139|Drug|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet
46036129|NCT04337476|Device|The effects of Pacifier Activated Lullaby in very low birth weigt preterm infants. An italian music therapy intervention|Positive reinforcement is an effective development strategy for improving the feeding skills of preterm infants. A brief intervention with the PAL device with pacifier that reproduces lullabies sung by both parents or by the music therapist could reduce the use of the feeding tube and the length of hospital stay in preterm infants. The aim of this study is not only to evaluate the benefits of positive reinforcement on the nutritional sucking competence of the premature baby, but at the same time to observe its possible effects on its well-being and its clinical stability.
45340764|NCT03810560|Device|laser device Er,Cr:YSGG laser|laser device with open flap debridement
45340765|NCT00779493|Dietary Supplement|curcumin|curcumin 900mg twice daily by mouth
45340766|NCT00779493|Dietary Supplement|placebo|placebo capsule to simulate 900mg curcumin capsule
45340767|NCT00772239|Device|Rotation thromboelastometry (ROTEM)|Coagulation measurement
45340768|NCT00772239|Procedure|Standard coagulation managment procedure|Standard coagulation managment procedure
45340769|NCT00779571|Behavioral|Crispbread|8 week low calorie diet
45340770|NCT02580344|Drug|Ibuprofen|The women will receive 400mg ibuprofen 3 times per day from the first day of the cycle for 5 days
45340771|NCT00779649|Other|MoviPrep Kit|"Diet: At noon the day prior to the procedure, patients will begin a clear liquid diet. Patient will discontinue any ingestion by mouth 4 hours prior to the procedure.~Purgative: Starting at 6pm the evening before the procedure, patient will ingest 250 ml of MoviPrep® at 15 minute intervals until 1 liter is consumed. Following this, an additional 500 ml (approximately 16 oz) of clear liquids will be consumed. The next day, 6 hours before the procedure, the patient will repeat ingestion of one liter MoviPrep® over the course of an hour, again ingesting 250 ml at 15 minute intervals. Patient will then ingest an additional 500 ml (approximately 16 oz) of clear liquid following the MoviPrep® consumption."
45473157|NCT03387202|Procedure|Laparoscopic lateral suspension with mesh|V-shaped ccm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3cmsuperoposterior to the anteriosuperior iliac spine.A grasper is introduced retroperitoneally through the subperitoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Broad ligament is lifted upward and tunnel is practiced in its lower third.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level
46036130|NCT02626195|Dietary Supplement|nutritional support program|"Nutritional support program is briefly described below.~Interval: 5-10 days Contents: admission is required~Calories: 30-35Kg, via enteral or parenteral~Protein: 1.2-1.5g/Kg~Lipid : 1-1.5g/Kg~Mineral and vitamins supply~Blood glucose control~Daily monitoring by dietician and specialized nurse"
45473158|NCT03387202|Diagnostic Test|Transperineal ultrasound|Vaginal length, bladder neck mobility and pelvic floor biometry with anterioposterior hiatal diameter and pelvic organ descent measurements are measured by transperineal ultrasonography to assess anatomic success in the preoperative and at postoperative first third and sixth months if available.
45473159|NCT01281215|Behavioral|Education interventional|The patients will receive pharmaceutical education to know more about asthma, the importance of treatment compliance, the medications used to control the pathology, corrected patients' inhalation techniques and the medication care.
46036131|NCT02814214|Device|ECG+IEGM|Cardiac Resynchronization Therapy programming adjustments
46036132|NCT00685789|Device|acupuncture, deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the deqi sensation.
46036133|NCT00685789|Device|acupuncture Non-manipulation|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
46036134|NCT04329832|Drug|Hydroxychloroquine|Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight < 45 kg or GFR (glomerular filtration rate)<50ml/min). For patients < 45kg, doses will be halved. For patients with GFR<50ml/min, the final dose of hydroxychloroquine will not be administered. If the patient has already received hydroxychloroquine prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
46036135|NCT04329832|Drug|Azithromycin|Patients in the azithromycin arm will receive azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). If the patient has already received azithromycin prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
45340772|NCT00779649|Other|HalfLytely and Bisacodyl Tablets Bowel Prep Kit|"Diet: Patients will refrain from solid food and have only clear liquids starting 8 am on the day before colonoscopy. In addition, patients will consume nothing by mouth, except clear liquids, from the time the preparation is completed until midnight. Patients will be instructed not to eat or drink anything from midnight until after the colonoscopy is completed.~Purgative: At noon on the day prior to colonoscopy patients will swallow (not chew or crush) 2 bisacodyl delayed release tablets (10 mg). Once the initial bowel movement has occurred (1 - 6 hours after taking the bisacodyl tablets), or if there has been no bowel movement, not more than 6 hours after ingestion of the bisacodyl tablets patients will then drink the reconstituted HalfLytely® solution over 1 hour and 20 minutes. Patients will drink one 8-oz glass every 10 minutes until the two liters is completed"
45340773|NCT04074980|Diagnostic Test|Venous and Fingerstick blood draws|Fingerstick sampling to collect blood from subjects Venepuncture to collect blood samples from subjects
45340774|NCT04074980|Diagnostic Test|Venous blood draw|Venepuncture to collect blood samples from subjects
45340775|NCT00776217|Drug|loratadine 10 mg orally disintegrating tablets|
45340776|NCT04990232|Drug|Anakinra or rhIFNγ|In hyper-inflammation anakinra three times daily (every eight hours) for 15 days and sc 0.5 ml N/S 0.9% every other day for 15 days. In immunoparalysis IV 20 ml N/S 0.9% (10ml for patients with creatinine clearance lower than 30ml/min) three times daily (every eight hours) for 15 days and sc rhIFNγ every other day for 15 days.
45683538|NCT01363297|Drug|Inotuzumab Ozogamicin|"Part 1: Administered intravenously as 2 - 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total dose per cycle 0.8 mg/m^2 to 2.0 mg/m^2.~Part 2 Expansion and Part 3 Phase 2: Administered intravenously as 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total initial dose per cycle 1.8 mg/m^2."
46036136|NCT02626273|Radiation|weight loss|
46036137|NCT04237246|Drug|Tacrolimus|"24 hour long acting advegraf"
45340777|NCT04990232|Drug|Placebo|20ml (10ml for patients with creatinine clearance lower than 30ml/min) intravenous (IV) 0.9% saline (N/S) three times daily (every eight hours) for 15 days and 0.5 ml subcutaneous (sc) 1ml 0.9% N/S every other day for a total of 15 days
45340778|NCT00772317|Device|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound
46036138|NCT00680095|Drug|AN2690|AN2690 Solution, 2.5%, Daily for up to 21 days
46036139|NCT00680095|Drug|AN2690|AN2690 Solution, 7.5%, Daily for up to 21 days
46036140|NCT00680095|Drug|AN2690|AN2690 Solution, 5.0%, Daily for up to 21 days
46036141|NCT00680095|Other|AN2690 Solution, Vehicle|AN2690 Solution, Vehicle, Daily for up to 21 days
46036142|NCT00680095|Other|Sodium Lauryl Sulfate, 0.5%|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
46036143|NCT04237168|Diagnostic Test|IgNGS from circulating tumor DNA|3 longitudinal plasma samples will be evaluated at three different time points per patient: 0 (pre-treatment), end of treatment, and at 6 months after treatment.
46036144|NCT00685867|Other|Rapid molecular MRSA test|PCR-based rapid screening for MRSA carriage
45340779|NCT02556957|Behavioral|HealthScouts|
45340780|NCT02556957|Other|Standard of Care|
46036145|NCT00685867|Behavioral|Hand hygiene promotion|"Promotion and monitoring of hand hygiene, with special emphasis on alcohol-based hand rubs and feedback of hand hygiene compliance~Standard precautions (e.g. use of gloves for contacts with wounds and body fluids)~Isolation precautions according to the hospitals' capacity and strategy~Additional basic infection control interventions (if necessary)"
46036146|NCT02814604|Other|Nutrition Rating Systems|Behavioural: Nutrition Rating Systems (shown on a mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product.
46036147|NCT00686023|Procedure|internal fixation (DHS - richard nail)|internal fixation
46036148|NCT00686023|Procedure|internal fixation (inflatable PFN by DISCOTEC)|internal fixation
45340784|NCT02580500|Procedure|epidural catheter|epidural anaesthesia application for spinal catheter will be used
45340785|NCT02580500|Procedure|spinal catheter|spinal anesthesia application for spinal catheter will be used
45473160|NCT05181501|Drug|Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)|"CT103A is a customized, BCMA-targeted genetically modified autologous T cell immunotherapy, which can identify and eliminate malignant and normal cells expressing BCMA. CAR specifically recognizes BCMA with single chain fragment variable (ScFv), and promotes the activation, proliferation, cytokine secretion and target cell killing of CAR-T through the CD3ζ domain. And 4-1BB enhances the expansion and persistence of CT103A.~CT103A will be infused at 1.0×10^6 /kg via intravenous drip within 24h to 72h after chemotherapy conditioning regimen at the recommended infusion rate of 3-5 mL/min."
46036149|NCT02814136|Procedure|Ablation|
46036150|NCT02814058|Drug|zolpidem hemitartarate 1.75 mg - Sequency 1|zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
46036151|NCT02814058|Drug|zolpidem hemitartarate 1.75 mg - Sequency 2|zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
46036152|NCT00680173|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
46036153|NCT04293016|Behavioral|Support as usual|this group receives current best practice which includes participation in ICU support groups and provision of community support resources
46036154|NCT04293016|Behavioral|problem solving therapy|This group will receive one on one therapy based on identifying stressors and solutions to those stressors
45340786|NCT04074200|Procedure|Open Inguinal Hernia Repair|With the patient under anesthesia, a single incision is made in the groin area. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific open approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
45340787|NCT04074200|Procedure|Laparoscopic Inguinal Hernia Repair|With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope (a lighted scope used to visualize the hernia) are inserted to complete the repair. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific laparoscopic approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
45340788|NCT04074200|Device|Robotic-Assisted Inguinal Hernia Repair|With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the procedure. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific robotic-assisted approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
45340789|NCT00667875|Drug|Placebo|placebo
45340790|NCT00667875|Drug|Naltrexone|Naltrexone (25mg or 50 mg per titration schedule)
45340791|NCT00667875|Drug|Naltrexone + Aripiprazole|Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)
45340792|NCT05056610|Other|food antigens on duodenal mucosa|Administration of food antigens on duodenal mucosa and determining the response through confocal laser endomicroscopy
45340793|NCT00779727|Procedure|Placement of drainages|
45340794|NCT02579642|Drug|Ketamine|Low dose ketamine 0.2 mg/kg (or 0.5 mg/kg depending on results of interim analysis) administered with usual induction drugs for ECT
45340795|NCT02579642|Drug|Placebo|Normal saline administered with usual induction drugs for ECT
45473161|NCT03573154|Other|administration of the liquid 1 and then the liquid 2|The patient will received the e-liquid 1 in the first visit and the e-liquid 2 in the second
45473162|NCT03573154|Other|administration of the liquid 2 and then the liquid 1|The patient will received the e-liquid 2 in the first visit and the e-liquid 1 in the second
45473163|NCT01283477|Device|ACUPUNCTURE AT LI11|ACUPUNCTURE AT LI11 FOR 30 MINUTES PRIOR TO INTRATHECAL MORPHINE & LEFT IN PLACE FOR 30 MINUTES
45473164|NCT01283477|Device|SHAM ACUPUNCTURE|SHAM ACUPUNCTURE AT A POINT 2 CM LATERAL TO LI11 30 MINUTES PRIOR TO INTRATHECAL MORPHINE & LEFT IN PLACE FOR 30 MINUTES
45473165|NCT03387124|Other|Breastfed infants|Breastmilk
45473166|NCT03873779|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
46036155|NCT04293016|Behavioral|ICU diary|This group will provided with a structured written diary that includes identification of stressors and development of solutions to those stressors
46036156|NCT05636878|Other|Mobile Intervention Team in Perinatal Psychiatry (EMPPer)|The Mobile Intervention Team in Perinatal Psychiatry consists in going towards the most excluded patients, changing the organization of care compared to the current practice and facilitating access to care for the most vulnerable populations
46036157|NCT00682279|Drug|oral topotecan (SK&F-104864); lapatinib (GW572016)|This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
46036158|NCT02811484|Drug|Exenatide-LAR plus Dapagliflozin placebo|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin placebo x 52 weeks and behavioral therapy.
45340796|NCT00779805|Drug|Pseudoephedrine hydrochloride 120 mg ER tablets|
45340797|NCT00772395|Drug|Risedronate|35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)
45340798|NCT00772395|Drug|Placebo|Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)
45340799|NCT03468998|Device|Socket Grafting with small particle allograft|Small Particle Bone Allograft of 0.25-1.0 mm placed in extraction socket
45340800|NCT03468998|Device|Socket Grafting with large particle allograft|Large Particle Bone Allograft of 1.0-2.0 mm placed in extraction socket
45340801|NCT03468998|Device|Lateral ridge augmentation with small particle allograft|Small Particle Bone Allograft of 0.25-1.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
45340802|NCT03468998|Device|Lateral ridge augmentation with large particle allograft|Large Particle Bone Allograft of 1.0-2.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
45340803|NCT05325398|Dietary Supplement|HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada|"The cohort will consist of 17 patients with NAFLD. Name of the product that will be the source of molecular hydrogen: HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada. It is a nutritional supplement that is a source of molecular hydrogen.~All study participants will drink one tablet dissolved in 0.33 l of tap water every 8 hours.~They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)."
45340804|NCT05325398|Dietary Supplement|placebo|"13 probands in the control group who will receive placebo. All study participants will drink one placebo tablet dissolved in 0.33 l of tap water every 8 hours.~They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)"
45473167|NCT03383848|Device|Medication Management Software|"The OnTrack Medication Management Software allows patients to track the amount of fertility medication they have at home. When they check off their to do list of medications, it decrements the amount they have at home. It allows them to see when they will run out of medication depending on their current doses (which can change daily). Daily use of the software will be 5-10 minutes daily for approximately 21 days."
45473168|NCT01167413|Device|Evaluation by manual Dolorimeter|Patients will be examined by a manual Dolorimeter
45473169|NCT01167413|Other|SIJ imaging|Patients will undergo imaging of the Sacroiliac joint by plain x-ray or MRI and sacroileitis will be documented
45473170|NCT03383302|Radiation|Stereotactic body radiotherapy|Patients will receive a total of 54 Gy if delivered in 3 fractions or 55 Gy if delivered in 5 fractions.
45473171|NCT03383302|Drug|Nivolumab|Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody, that binds to the PD-1 receptor and blocks interaction with its ligands PD-L1 and PD-L2. Nivolumab will be given every 14 days at a flat dose of 240 mg, to be administered as a 30 minute IV infusion.
45473172|NCT01165697|Other|Fluorescein angiography|Fluorescein angiography once every 6 months for 3 years
45473173|NCT03493126|Drug|Estradiol|17β-estradiol vaginal cream
45340805|NCT00667251|Biological|trastuzumab|IV q weekly (loading dose 4mg/kg; subsequent doses 2mg/kg) or IV q 3 weekly (loading dose 8mg/kg, subsequent doses 6mg/kg).
45473174|NCT03493126|Other|Placebo|Compounded placebo cream
46036159|NCT02811484|Drug|Exenatide-LAR plus Dapagliflozin|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin 5 mg x 2 weeks, then 10 mg for 22 weeks and behavioral therapy.
46036160|NCT02811484|Drug|Insulin Titration|Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c>8%
46036161|NCT02811484|Behavioral|Behavioral Therapy|Subjects will be seen by a registered dietitian and receive nutritional and lifestyle counseling according to a web-based weight management program.
46036162|NCT05635084|Drug|YN001|Dose ranges from 2-90mg
46036163|NCT05635084|Drug|Placebo for YN001|5% dextrose injection to mimic the YN001
46036164|NCT00686179|Drug|AZD3480|Capsule, oral, single dose, 6 days
46036165|NCT00686179|Drug|Moxifloxacin|Capsule(encapsulated), oral, single dose
45340806|NCT00667251|Drug|docetaxel|75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).
45340807|NCT00667251|Drug|lapatinib ditosylate|1250 mg po daily (while given with taxane). 1500mg PO daily (when given alone after taxane completion).
45340808|NCT00667251|Drug|paclitaxel|80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.
45340809|NCT04063124|Drug|Dasatinib + Quercetin|Intermittent D+Q administered for 2 days on/14 days off for 12 weeks (6 cycles)
45340810|NCT00776529|Other|Sensorimotor training first, followed by strength exercises|nine sessions of one hour duration
45340811|NCT00776529|Other|Strength exercises and sensorimotor exercises alternated|nine sessions of one hour
46036166|NCT00686179|Drug|PLACEBO|Capsule, oral, single dose
46036167|NCT04139707|Device|Caring4Dementia|A mobile application administered for 30 days, which provides people caring for a person living with dementia with a useful and intuitive tool targeting communication skills.
46036168|NCT04139707|Other|White Paper|The White Paper group will receive a white paper (hard copy and electronically) on the principles of communicating efficiently with persons living with dementia.
45340812|NCT00779883|Biological|ISF35|Subjects participating in this study will receive a single dose of 1x10^8, 3x10^8, or 1x10^9 autologous Ad-ISF35-transduced CLL B cells.
45340813|NCT05673746|Procedure|Acupuncture|acupuncture administration
45473175|NCT01167491|Biological|Physiopathology Endpoint Classification|Blood samples will be collected during a routine medical visit.
45473176|NCT03488758|Other|CMF|Taking a infant formula based on cow milk protein fractions, 4-5 feeds per day given by bottle, 180-210 ml/feed, total 800-900ml per day for one mounth
45473177|NCT03488758|Other|GMF|Taking a infant formula based on whole goat milk, 4-5 feeds per day given by bottle, 180-210 ml/feed, total 800-900ml per day for one mounth
45473178|NCT01283633|Device|Neuromodulation|Neuromodulation as directed via remote presence robotic and experienced clinician for those with neuromodulation systems implanted to treat movement disorders and chronic pain
45473179|NCT01283711|Device|apollo device|RF treatments for wrinkles and rhytides reduction
46036169|NCT02813902|Drug|Heliocare with Fernblock PLE technology|240 mg taken orally daily over the course of 1 year
45340814|NCT05673746|Drug|treatment of physician choice, according to the standard of care|treatment of physician choice, according to the standard of care for the treatment of chemotherapy-induced peripheral neuropathy, including neuropathic pain
46036170|NCT02813902|Other|Sugar Pill|A pill that appears similar to the supplement
45683539|NCT04758598|Device|Direct Selective Laser Trabeculoplasty (DSLT)|DSLT employs frequency-doubled, Q-switched Nd:YAG laser with a wavelength of 532 nm. During the procedure, a laser beam targets the trabecular meshwork (TM) - to improve intraocular fluid outflow. The laser beam is delivered in short nanosecond pulses and the selective cellular effect occurs at the pigmented cells of the TM. This increases the permeability of the TM endothelial cells and thereby increases outflow, resulting in reductions in IOP. In contrast to SLT, the DSLT treatment directs the laser beam directly through the sclera around the limbus without the need for a delivery device (gonioscope lens). Laser treatment lasts for about 2 seconds with about 120 laser shots delivered to the sclera around the limbus.
46036171|NCT00922597|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients undergoing surgery and receiving continuous infusion with Kogenate Bayer according to local drug information.
46036172|NCT02811172|Other|BEhavior of biomarkers during pregnanCy and lactatiOn|
46036173|NCT04151173|Procedure|laparoscopic aspiration/electrocoagulation|laparoscopic aspiration/electrocoagulation of ovarian endometrioma
46036174|NCT04151173|Procedure|laparoscopic cystectomy|laparoscopic cystectomy of ovarian endometrioma
45340815|NCT00772473|Other|subjects personal triptan|Subjects will treat 1 migraine attack with their usual triptan
45340816|NCT00776607|Drug|NovoMix 30|Insulin arm: Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal. Dose will be adjusted in increments of 2-6U depending on fasting glucose level When total dose equals 16 U patient will be started on 4 units with breakfast and continue with 16 units with evening meal. Breakfast and/or evening meal dose will be adjusted where necessary at increments of 2-6 U depending on fasting and/or pre-evening meal glucose level. Patient needs to keep a daily diary of insulin doses taken.
45473180|NCT03257358|Drug|Fingolimod|Commercially available 0.5mg hard capsules, taken orally once per day
45473181|NCT03386656|Drug|Amchafibrin|Tranexamic acid (Amchafibrin) exerts an antihemorrhagic activity by inhibiting the fibrinolytic properties of plasmin.
45473182|NCT03386656|Other|Saline Solution|Placebo
45473183|NCT03871439|Drug|PF-05221304 Formulation A|50mg
45473184|NCT03871439|Drug|PF-05221304 Formulation B|50mg
45473185|NCT03125278|Other|Medication knowledge|Participants will be asked questions over the phone about their medications
45473186|NCT01165853|Other|Glucose|25% dose at 8-week intervention assigned to subjects.
45473187|NCT01165853|Other|Fructose|25% dose at 8-week intervention assigned to subjects.
45473188|NCT03378778|Procedure|Root canal treatment|Root Canal Treatment followed by Ceramic Onlay restoration
46036175|NCT04196218|Other|Driving simulator|Computer simulated driving assessment
46036176|NCT02627365|Behavioral|Individualized, interactive short messaging intervention|An Individualized, interactive short messaging intervention reminding study participants to take antiretroviral medication and report any problems.
46036177|NCT02813746|Dietary Supplement|Fitness program|
46036178|NCT02813746|Behavioral|Stop smoking|
45473189|NCT01281527|Drug|Paliperidone Palmitate|50 - 150 mg eq. every 30 days
45473190|NCT03378700|Behavioral|Brief Hope Intervention|"The present Brief Hope Intervention (BHI) is a four-weeks individual intervention, consisting of four sessions: two face-to-face sessions (1-hour) and two telephone follow up sessions (30 minutes) in between.~The facilitator will guide participants to imagine how they navigate themselves to circumvent possible obstacles and accomplished their set goals and experience positive emotions.~A booklet will be given to the participants for reviewing their planned goals, recording achieved targets and successful experiences."
45473191|NCT03378700|Other|Pre-dialysis Education Group|Pre-dialysis educational class and standard care such as clinic follow up and normal hospital care will be provided. This session is led by clinicians with renal nursing training. The educational class aims at providing information on the treatment modalities for patients with ESRD, signs and symptoms of their illness and the basic advice on the importance of adherence to healthy lifestyle, nutrition and medications. Logistic call and social communication will be offered and initiated by trained nurses in the second week and the third week
45473192|NCT03378622|Other|Anchor|Anchor technique for mesh attachment
45473193|NCT03378622|Other|Suture|Suture technique for mesh attachment
45473194|NCT05171764|Device|Additional Gemstone Spectral Imaging (GSI) cardiac scan|After the subject undergoes the clinically prescribed cardiac Computed Tomography (CT) scan for their diagnostic purposes, the investigational Gemstone Spectral Imaging (GSI) scan will be conducted following the diagnostic CT scan utilizing the same contrast administration.
45473195|NCT03871127|Procedure|Percutaneous coronary intervention|Using sirolimus eluting stent
45473196|NCT03871127|Procedure|coronary artery bypass graft|coronary artery bypass graft
46036179|NCT02813746|Procedure|Endometrial fluid collection|
46036180|NCT00874939|Drug|MK-0249 7.5 mg|4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period
46036181|NCT00874939|Drug|MK-0249 25 mg|5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period
46036182|NCT00874939|Drug|Donepezil 5mg|One 5 mg tablet, single oral dose during each crossover period
46036183|NCT00874939|Drug|Placebo to MK-0249|Five tablets, single oral dose during each crossover period
46036184|NCT00874939|Drug|Placebo to Donepezil|One over-encapsulated capsule, single oral dose during each crossover period
46036185|NCT04268836|Device|Optimal Acuity Clear-K® Low Vision Aid System treatment|The treatment involves irradiation of the cornea with low energy light in a treatment pattern that produces corneal shape change.
45340817|NCT00776607|Drug|Tablet treatment|Step 1: Lifestyle modification. If HbA1c at 7%+ or if on metformin/sulphonylurea go to step 2. Step 2: Glucophage. If HbA1c of 7%-7.5% give 500mg x 1 per day. If HbA1c 7.6%-8.0%, week 1 - 500mg x 1 day and then 500mg x 2 day. If HbA1c 8.0%+ then 500mg x 3 per day (Titrated). If HbA1c remains 7%+ give additional tablet until 2gms per day then progress to Step 3. Step 3: Rosiglitazone. HbA1c of 7%+ give 4 mg per day. If HbA1c remains 7%+ titrate to maximal dose 4 mg twice daily +/-Metformin. If HbA1c remains 7% + for an 3 months move to step 4. Before initiation of Rosiglitazone repeat medical history with special emphasis on cardiovascular disease, if patient has a history of CVD move to Step 4 (insulin). Any adverse events suggestive of heart disease move to step 4. Step 4: Insulin (oral agents will be stopped). Initiation of insulin will the same as for the insulin arm and will follow the protocol detailed in the Insulin arm.
45340818|NCT04054544|Dietary Supplement|Gluten powder 4g|Gluten powder 4g oral BID
45340819|NCT00776685|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained teacher and co-facilitator
45340820|NCT00780039|Drug|Pegylated Liposomal Doxorubicin|Subjects will receive Caleyx 30 mg/m2 intravenously on Day 1 of each 4-week cycle, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
45473197|NCT03378544|Behavioral|mhGAP|The intervention will involve psycho-education to patients on the importance of maintaining interest in activities that they used to do, regular sleep cycles, physical activity and social activity
45473198|NCT01313832|Other|remote ischemic preconditioning (RIPC)|RIPC will be performed by 5-min cycles of lower limb ischemia reperfusion using blood pressure cuff
45473199|NCT03385876|Genetic|Genomic sequencing and molecular diagnostic results, if any|Samples will be stored in the pediatric genomic biorepository. A subset of samples will undergo genetic/genomic analysis.
45473200|NCT01281605|Behavioral|Active titration algorithm|Patients in active titration algorithm group will contact with investigator by telephone weekly to self-adjust the insulin dose till they achieve the target of FPG(<110mg/dl).
46036186|NCT00634348|Drug|Aripiprazole|Oral aripiprazole capsules 15 mg once daily from Days 1-14; thereafter, doses could be adjusted on Days 14 and 21 to 10, 15, or 30 mg once daily; patients treated for 28 days
46036187|NCT00634348|Drug|Ziprasidone|Oral ziprasidone capsules 40 mg twice daily on Day 1, 60 mg twice daily on Day 2, 80 mg twice daily on Days 3-14; thereafter, doses could be adjusted on Days 14 and 21 to 40, 60, or 80 mg twice daily; patients treated for 28 days
45340821|NCT00780039|Drug|Carboplatin|Subjects will receive carboplatin dosed to target AUC of 5 mg/mL.min, intravenously, on Day 1 of each 4-week cycle, after the Caelyx infusion, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
45473201|NCT01281605|Behavioral|Usual titration algorithm|All patients will be instructed to self-measure fasting capillary blood glucose. The dose of insulin detemir will be adjusted based on the average of three consecutive FPG values. the daily insulin dose should be increased by 2 IU/day if the FPG>=110mg/dL, and by 4 IU/day if the FPG>=180 mg/dL without any intervening hypoglycemic episodes; or it should be decreased by 2 or 4 IU/day if the FPG < 70 mg/dL.
45473202|NCT03386422|Behavioral|MSC|Mindfulness and Self-Compassion training
45473203|NCT03386422|Behavioral|CBT|Cognitive-behavioural techniques training
45473204|NCT03871205|Biological|Neoantigen loaded DC vaccine|Patients will be vaccinated with autologous mature dendritic cells loaded with neoantigen, DC vaccine will be injected subcutaneously 6 times, once a week.
45473205|NCT03377062|Diagnostic Test|EEG monitoring|Five-minute of EEG monitoring accompanied with auditory stimulation.
46036188|NCT00680329|Drug|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
45473206|NCT01170143|Drug|Trastuzumab QW, Trastuzumab Q3W|two arms using Trastuzumab QW vs Q3W
45473207|NCT05171530|Drug|Lenvatinib plus taxane drugs|"Drug: Paclitaxel Dose: 135mg/m2 Other Name: PTX~Drug: Docetaxel Dose: 75mg/m2 Other Name: FA~Drug: Lenvatinib Dose: 4mg, 8mg, 12mg,16mg Other Name: FA"
45473208|NCT02936037|Drug|MD1003 100mg capsule|
45473209|NCT02936037|Drug|PLACEBO|an inactive substance
45473210|NCT03288714|Device|Synchronized Transcranial Magnetic Stimulation (sTMS)|sTMS delivers brain stimulation via a continuous magnetic field created by the device and set to the individual patient's intrinsic alpha frequency (IAF).
45473211|NCT03288714|Device|Sham Stimulation|Sham stimulation is designed to look, sound and feel like the investigational device, but does not deliver magnetic stimulation to the brain.
45473212|NCT03869099|Other|Pneumonia Case Management Practices|Standard practices of pneumonia case management at three levels of health care; community level, first level care facility and practitioner level, across Pakistan.
45473213|NCT04068181|Drug|Talimogene laherparepvec|Intralesional injection into injectable cutaneous, subcutaneous and nodal legions.
46036189|NCT00680329|Device|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
46036190|NCT02811016|Drug|Budesonide 200|200 µg inhaled at 7:00 a.m. and 7 p.m.
46036191|NCT02811016|Drug|Budesonide 800|800 µg inhaled at 7:00 a.m. and 7 p.m.
46036192|NCT02811016|Drug|Placebo|Placebo Inhalation at 7:00 a.m. and 7 p.m.
46036193|NCT00686413|Drug|AZD3480|single dose, oral
45340822|NCT03438188|Other|Practice Quit Attempt|Smokers will be studied under 2 conditions: smoking as usual and during a 4 day practice quit attempt.
45473214|NCT04068181|Drug|Pembrolizumab|Intravenous (IV) infusion.
46036194|NCT00686413|Radiation|2-[18F]-F-A85380|Single dose, IV
46036195|NCT02810860|Procedure|Laparoscopic cholecystectomy|Administration of a disease-specific and generic PROMs survey to patients undergoing Laparoscopic Cholecystectomy
46036196|NCT04144309|Procedure|Electroacupuncture (EA) and Auricular Acupressure (AA)|"EA: Ten points will be used, including GV24 (Shenting), GV20 (Baihui), EX-HN1 (Sishenchong), PC6 (Neiguan), CV12 (Zhongwan), CV4 (Guanyuan), ST25 (Tianshu), ST36 (Zusanli), SP6 (Sanyinjiao), KI3 (Taixi).~AA: Vaccaria seeds will be embedded by acupuncturists on three auricular points (Shenmen, Sympathetic and Heart) and maintained between EA treatments."
46036197|NCT04144309|Procedure|Sham Electroacupuncture (SE) and Sham Auricular Acupressure (SA)|"SE: The sham acupuncture treatment procedure, including the acupoint selection principle, sterilization procedure and treatment schedule, will be the same as in the acupuncture treatment group, except that sham points 1 to 2 cm exterior and inferior to the real points will be used, and no needle penetration or electric stimulation will be performed.~SA: Three sham auricular points in the helix region (HX7, HX8, HX9) will be selected. Instead of Vaccaria seeds, soft Junci Medulla (1 to 2 mm in length, dyed black) will be used to mimic real AA with no pressure."
45340823|NCT03436550|Procedure|mpMRI|Multiparametric MRI
45340824|NCT03436550|Procedure|ARFI US|Acoustic radiation force impulse is a type of ultrasound elastography
45340825|NCT00669903|Drug|AZD0328|
45340826|NCT00669903|Drug|Placebo|
45340827|NCT00776763|Drug|Avastin intravitreal injection|1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and proliferative diabetic retinopathy)
45340828|NCT00772551|Drug|Raltegravir and ezetimibe|Group 1: raltegravir 400 mg orally twice daily for 10 days followed by 10 days of raltegravir 400 mg twice daily and ezetimibe 10 mg orally once daily for 10 days followed by a 10 days wash out period and ezetimibe 10 mg once daily for 10 days
46036198|NCT05592262|Drug|SHR2554|On an empty stomach - after meals
45340829|NCT00772551|Drug|Ezetimibe and raltegravir|Group2: ezetimibe 10 mg orally once daily for 10 days followed by ezetimibe 10 mg and raltegravir 400 mg orally twice daily for 10 days followed by a 10 days wash out period and raltegravir 400 mg twice daily for 10 days
45340830|NCT00776841|Drug|Aramchol|1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
45839922|NCT04736238|Procedure|Arthroscopy surgery|The patient receives intraspinal anesthesia or general anesthesia under supine position. Establish an anteromedial channel at the inner side of the tibial anterior tibial tendon at the level of the tibiotalar joint, and establish an anterolateral channel at the lateral angle of the talus. Exploring and clearing the ankle joint and dealing with possible combined injuries, such as talar cartilage injury, ankle impingement, and loose ankle joints. Then observe the lateral sulcus through the anterior medial channel, clean the synovium in the lateral sulcus, and explore the anterior talofibular ligament. A double-line anchor was inserted into the fibula side stop of the anterior talofibular ligament through the anterolateral channel. The anterior talofibular ligament was sutured using an outside-in technique in the anterior inferior safety zone of the distal end of the fibula. Fix the ankle joint with the suture after the dorsiflexion, neutral valgus position.
46036199|NCT05592262|Drug|SHR2554|After meals - on an empty stomach
46036200|NCT00690313|Drug|Vigamox|eye drops 3 times day either 1 or 3 days prior to intravitreal injection
46036201|NCT02810938|Device|Ablation of atrial flutter|Ablation of atrial flutter using IntellaTip Mifi 8 mm technology in combination with Maximum voltage-guided ablation approach
46036202|NCT02626585|Procedure|Postrhinoplasty taping|Postrhinoplasty taping is commonly applied by rhinoplasty surgeons. Following rhinoplasty the nose is generally taped and a (thermoplastic) nasal cast is applied on top of this to make sure the final form of the nose is protected. Postoperatively, this cast is removed at some point. After this, some of the surgeons prefer to tape the nose with nasal tapes such as Micropore (3M) etc. Postrhinoplasty taping is the term used for this. The nose is (generally) taped horizontally with 1/2 inch wide tapes. This is done superiorly from radix to inferiorly to nasal tip. The idea is to compress the nose and to cover it. The duration of postrhinoplasty taping differs according to the preference of the surgeon and the patient
46036203|NCT04237480|Diagnostic Test|serum value 1,25(OH)2 vitamin D|statistical evaluation of the serum values
46036204|NCT04144543|Other|White Noise|The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. The baby was exposed to white noise for 2 minutes before the procedure.
46036205|NCT04144543|Other|Facilitated Tucking|The baby's arms and legs were held in flexed positions close to the midline of the torso in sidelying position, so the baby was able to move his/her extremities. The baby was held in facilitated tucking position for one minute before the procedure.
46036206|NCT04144543|Other|White Noise+Facilitated Tucking|The baby was exposed to white noise for 1 minute before the procedure. The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. At the second minute, when the white noise still continued to play, facilitated tucking was performed at the same time and the baby continued to listen to the white noise for 1 minute while in facilitated tucking position.
46036207|NCT04237324|Procedure|Treatment one side BLE by NAFL|One side of the patient face underwent treatment using the ResurFX module of M22 (Lumenis Co., Yokneam, Israel) randomly.
46036208|NCT04237324|Procedure|Treatment another side BLE by FMR|One side of the patient face underwent treatment using FMR device (INFINI, Lutronic Co., Goyang-si, Korea).
46036209|NCT04144231|Behavioral|iCBT-I|Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I)
46036210|NCT04144231|Behavioral|GCBT-I|Cognitive Behavioral Group Therapy for Insomnia (GCBT-I)
45340831|NCT00776841|Drug|Aramchol|Oral Aramchol at dose 30 mg to 900 mg
45340832|NCT00776841|Drug|Aramchol|Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
45340833|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic euglycemic clamp (90 mg/dl)
45340834|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (70 mg/dl)
46036211|NCT02813434|Biological|florbetapir|18F-AV-45 or 18F-Florbetapir
46036212|NCT04139863|Diagnostic Test|aMMP-8 chairside test|No test
46036213|NCT02810782|Drug|Phenobarbital|Phenobarbital per os
46036214|NCT02810782|Drug|Chlorpromazine|Chlorpromazine per os
46036215|NCT02810782|Drug|Morphine|Morphine per os
45340835|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (60 mg/dl)
45340836|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (50 mg/dl)
46036216|NCT02626117|Device|LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
45473215|NCT05171452|Biological|Urine and stoll samples|Urine collection will be proposed to patient during consultations or medical examinations corresponding to routine care of patients with IBD at the time of prescribing a FC test. The urine sample, as for stool samples, will be collected in an ordinary universal container at any time of the day (no dietary restriction is required). Urine and stool samples should be taken during the same period (for example, the same day, or within a maximum of one week if no change in treatment)
45473216|NCT02526251|Other|observational|No intervention
46036217|NCT02626117|Device|Sham LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. sham LASER deepithelialisation was applied to the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
45340837|NCT04047615|Other|Exercise|An exercise intervention programme will be delivered in each school for an 8 week period. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
45340838|NCT03759392|Drug|Omecamtiv Mecarbil|Oral omecamtiv mecarbil twice daily for up to 20 weeks with dose level determined by periodic blood testing
45340839|NCT03759392|Drug|Placebo|Oral placebo twice daily for up to 20 weeks
45340840|NCT02556879|Biological|Donor specific antibodies|Additional samples for Donor specific antibodies at each visit
45473217|NCT03386188|Device|Transcranial Magnetic Stimulation (TMS)|Transitory inactivation of the posterior parietal cortex and measure of sensorimotor integration.
45839923|NCT04736238|Procedure|BrostrÖm surgery|The patient receives intraspinal anesthesia or general anesthesia under supine position. The first ankle arthroscopy is performed to deal with possible combined injuries, such as talar cartilage injury, ankle impingement, and loose ankle joints. Then, open surgery was performed, and an arc incision was made at the anterior edge of the lateral malleolus to the tip of the fibula. After separating the subcutaneous tissue, the anterolateral joint capsule and talofibular ligament are exposed. A double-line anchor was placed at the fibular side stop of the anterior talofibular ligament. Tighten and suture the anterior talofibular ligament, anterolateral joint capsule, and extensor support belt with an anchor band. Fix the ankle joint with the suture after the dorsiflexion, neutral valgus position.
45340841|NCT02556879|Biological|Serum bank|Additional samples for serum bank at each visit if possible
45340842|NCT02556879|Biological|DNA bank|Additional sample for DNA bank at inclusion visit if possible
45839924|NCT04736160|Other|collect data|The data for this project will be obtained directly from the IVI digital work platform (SIVIS) where the characteristics and scans performed to each patient are recorded. Furthermore, it will be recollected information from the time-lapse incubator. For the current study will be used Embryoscope and Geri time-lapse incubators
45839925|NCT04735848|Dietary Supplement|Iron-supplement application|The participants will take the corresponding amount of iron-supplement supervised at 8am.
45340843|NCT02556879|Procedure|Liver biopsy|Liver biopsy at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
45340844|NCT02556879|Procedure|Liver ultrasounds and Fibroscan|Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
45340845|NCT00777075|Drug|L-arginine|
45340846|NCT00777075|Drug|Placebo|
45340847|NCT00772863|Drug|docetaxel and cisplatin|4 cycles Cisplatin 100 mg/m2 at every 3 weeks, after Cisplatin 4 cycles of docetaxel 100mg/m2 at every 3 weeks
45340848|NCT04075760|Procedure|Coils + Cyanoacrylate Group + beta-blocker|"EUS-combined coiling and cyanoacrylate injection into the feeder vessel of GOV II and IGV I~Patients with Gastric Varices GOV II or IGV I that have never bleed and are of high-risk GV according to Baveno VI consensus will be prophylactically obliterated via the EUS-guided coiling and cyanoacrylate injection. Patients will also be on beta-blocker therapy as indicated in the other group."
46036218|NCT02810626|Device|BrightMatter™ products|"BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.~BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.~BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively."
46036219|NCT04260802|Drug|OC-001|Monotherapy in Phase 1b
45340849|NCT04075760|Drug|beta blocker therapy|A beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was > 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure < 90 mm Hg or pulse rate < 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
45340850|NCT05674058|Other|No intervention|According to clinical practice.
45340851|NCT02580656|Behavioral|Metacognitive Therapy|MCT helps patients to understand the deleterious and counterproductive effects of responding to negative thoughts and feelings with worry and rumination. Treatment aims to enable patients to exert greater metacognitive control over their worry and rumination. The positive and negative metacognitive beliefs that keep perseverative thinking in place are modified, using verbal and behavioural reattribution and through specifically designed therapeutic methods.
45340852|NCT03741920|Device|Personal KinetiGraph™ (PKG™)|"The Personal KinetiGraph™ (PKG™) Movement Recording System was developed by neurologists at the Melbourne-based Florey Institute of Neuroscience and Mental Health. The product is manufactured and marketed by Global Kinetics (GKC).~The Personal KinetiGraph™ (PKG™) Movement Recording System consists of the following:~A wrist-worn data logger designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~An application to configure the data logger and transfer the acquired data at the end of a recording.~A series of algorithms that analyze the uploaded data, producing a report that is delivered to the clinician. The report contains objective data distinguishing the movement patterns consistent with tremor, bradykinesia, dyskinesia and immobility."
45340853|NCT00667719|Drug|Aliskiren|300 mg tablet
45340854|NCT00667719|Drug|Amlodipine|5 mg tablet
45340855|NCT00667719|Drug|Hydrochlorothiazide|12.5 mg and 25 mg capsule
45340856|NCT00922077|Behavioral|standard physical therapy program with emphasis on dynamic balance exercises|
45340857|NCT00777387|Procedure|slow-freeze|Slow-freeze-rapid-thaw procedure of oocytes is characterized by prolonged exposure of the cell to cryoprotectants in a low metabolic state at very low temperatures
46036220|NCT04260802|Drug|OC-001 in Combination|Anti-PD-1/anti-PD-L1 Ab administered per approved prescribing schedule, in Phase 2a
45340858|NCT00777387|Procedure|vitrification|Vitrification is the process by which water is prevented from forming ice due to the viscosity of a highly concentrated cryoprotectant cooled at an extremely rapid rate
45340859|NCT00780351|Device|sustained low efficiency daily hemodiafiltration (SLEDD-f)|vancomycin 15mg/kg IV infusion on day 1 from 6PM to 8PM. Start SLEDD-f on day 2 from 9AM to 5PM.
45340860|NCT03429296|Other|Autohypnosis learning|Patients are taught how to do auto-hypnosis by an hypnotherapist before all along their chemotherapy.
46036221|NCT00875563|Device|Zenith(R) Fenestrated AAA Endovascular Graft|The Zenith(R) Fenestrated AAA Endovascular Graft with the H&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
46036222|NCT04254094|Other|Neuropsychological scales|Basic Activity of Daily Living (BADL) and Instrumental Activities of Daily Living (IADL), Neuropsychiatric Inventory (NPI), Cornell Scale for Depression in Dementia (CSDD), Clinical Dementia Rating Scale (CDR) and defining dementia criteria. Also as part of this study, an MRI examination at baseline and at 18 months follow-up will be performed in the Bordeaux center
46036223|NCT02810548|Procedure|OFD alone|Periodontal surgical cleaning procedure
46036224|NCT02810548|Drug|Platelet rich Fibrin|Natural platelet concentrate rich in growth factors
45340861|NCT00780585|Drug|SCH 900460|Subjects who participated in previous trials of Org 24448 (SCH 900460)
45340862|NCT00780663|Drug|Quarfloxin|IV Quarfloxin 240 mg/m2 daily x5 days every 21 days
46036225|NCT02810548|Drug|Nanohydroxyapatite|Synthetic bone graft
45340863|NCT02581514|Other|Scheduled exams and diagnosis|Scheduled exams and diagnosis circuit as imposed by the algorithm
46036226|NCT01155869|Drug|Depot naltrexone|Depot naltrexone 380 mg. IM monthly
46036227|NCT01155869|Drug|Oral Naltrexone|Naltrexone 50 mg tablet PO daily
46036228|NCT05635006|Other||No special intervention, randomly classify the subjects
46036229|NCT02810470|Dietary Supplement|Fortimel Compact Protein|Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.
46036230|NCT02810470|Dietary Supplement|Fortimel Cream|Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.
45340864|NCT04030910|Other|'LIFEView'|A prototype audiovisual technology in development by Motitech AS.
45340865|NCT00669669|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal IMRT
45340866|NCT00669669|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplant
45340867|NCT00669669|Drug|Carmustine|Given IV
45340868|NCT00669669|Biological|Filgrastim|Given SC
45340869|NCT00669669|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplant
45340870|NCT00669669|Radiation|Intensity-Modulated Radiation Therapy|Undergo 3D conformal IMRT
46036231|NCT00690469|Other|Laboratory Biomarker Analysis|Correlative studies
46036232|NCT00690469|Other|Questionnaire Administration|Ancillary studies
45340871|NCT00669669|Other|Laboratory Biomarker Analysis|Correlative studies
45340872|NCT00669669|Drug|O6-Benzylguanine|Given IV
45340873|NCT00669669|Drug|Plerixafor|Given SC
45340874|NCT00669669|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
45340875|NCT00669669|Drug|Temozolomide|Given PO
45340876|NCT02579564|Drug|Gemcitabine|
45340877|NCT02579564|Drug|Vinorelbine|
45340878|NCT02579564|Drug|Paclitaxel|
45340879|NCT02579564|Drug|Pemetrexed|
45340880|NCT02579564|Drug|Oncorine|
45340881|NCT02579564|Drug|Endostar|
45340882|NCT02579564|Drug|Cisplatin|
45340883|NCT00467779|Drug|cobimetinib|Repeating oral dose
46036233|NCT02810314|Behavioral|neuropsychological battery|neuropsychological battery including cognitive and behavioural tests
46036234|NCT02810314|Other|resting state functional magnetic resonance image (rs-fMRI)|rs-fMRI
46036235|NCT02625493|Other|Questionnaire|Questionnaire containing a Best-worst Scaling scenario
46036236|NCT02813590|Other|Ascitic fluid puncture|
46036237|NCT02813590|Other|Skin swaps from puncture side|
46036238|NCT02813590|Other|Stool samples|
46036239|NCT00690547|Other|muscle activation|activation of the muscle quadriceps femoris
45340884|NCT00467779|Drug|dextromethorphan|In Stage III only: single dose of dextromethorphan
45340885|NCT00467779|Drug|midazolam|In Stage III only: single dose of midazolam
45473218|NCT03386188|Device|Electrical Muscle Activity (EMG)|Electrodes for the collection of EMG activity will be glued on the skin next to the first interosseus dorsalis muscle, the Abductor digiti minimi, the Extensor carpi radialis and the Abductor pollicis brevis. EMG signals will be stored on computer for off-line analysis using Signal © software (Cambridge Electronic Design, Cambridge, UK)
45839926|NCT04735380|Device|TCM-5 Flex monitor connected to a Sensor 84 (Radiometer Medical Aps, Brønshøj, Denmark)|Patients undergo 2-3 hrs of observation while wearing the device.
45839927|NCT04735302|Other|Radiographic Feature|Radiographic rewiev
45839928|NCT04734912|Other|gastroscopy in transnasal techique|All patients with indication for gastroscopy in transnasal technique are included.
46036240|NCT02809924|Other|Simulation-based just-in-time training|Video and low fidelity simulation (Laerdal® Neonatal Intubation Trainer, Laerdal Medical, Toronto, Canada)
46036241|NCT02809924|Other|Video training|Video describing endotracheal intubation
46036242|NCT00690625|Drug|MyoRx Cream (6% Omega 3 Fatty Acid)|1/2 teaspoon 3 times per day for 30 days.
46036243|NCT00690625|Drug|Placebo cream, no Omega 3 fatty acid|Placebo cream, no Omega 3 fatty acid
46036244|NCT02813512|Drug|ADSCs|Autologous ADSCs
45340886|NCT04076306|Other|iSTEP exercise testing|iSTEP 10 minute step test, up and down on a commercial standard 3-height adjustable step Undertaking the 10m-MSWT 20-30 minutes Procedure takes place on testing track at Great Ormond Street Hospital; a 5 minute walk from the Haemophilia Centre. One of the research team accompanies the family with child to the track and will accompany them back to the Centre once testing is finished. Muscle Myometry 10 minutes, carried out by one of the research team at the end of the physiotherapy clinical assessment in the Haemophilia Centre. Wearing of accelerometer (activity/ step counter)7 days Device will be set up and provided at the end of the testing on the day of attendance at clinic. They will be instructed to wear this throughout the week at home when they are awake (at least 8 hours). Haemophilia Joint Health Score (HJHS) - a standardised outcome measure of joint health in people with Haemophilia, undertaken by the Clinical Specialist Physiotherapists in Haemophilia.
45839929|NCT04735146|Other|Adapted physical activity|"Participants in the experimental group will undergo the adapted physical activity program that will be co-designed during phase I of the study.~The 6-week program is aimed at improving the quality of life; increase the physical activity levels according to recommended guidelines; improving body awareness through an educational component; maintain and ameliorate the previous functions (for women previously active) and build the exercise background for sedentary women; increase physical fitness and functional capacity."
45340887|NCT04075214|Device|transcutaneous auricular neurostimulation (tAN)|Phoenix tAN system
45473219|NCT03868865|Behavioral|Integrative mind-body-medicine group program|The mind-body-medicine group program focuses on support in coping with the disease, in lifestyle modification and in reduction of chemotherapy induced side effects. The self-contained modules of the mind-body-medicine group program can be followed in an individual order, to allow adoption to different chemotherapy concepts and continued access is possible. Patients can join in the group program eleven times for six hours each visit. They participate in every one of the eleven modules once.
45839930|NCT04734522|Device|Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating|Subjects will be wearing three different PAL designs with different geometries of the optical progression.
45839931|NCT04734756|Device|Dragonfly Transcatheter Mitral Valve Repair System|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
45839932|NCT04734834|Dietary Supplement|"Prodovite® VMP35"|"Efficacy of Prodovite® VMP35 will be Assessed as Compared to Placebo"
45839933|NCT04734600|Device|Electronic Treadmill device|"group A:PN-7001M Panasonic Treadmill 130 kg, frequency 50 HZ, input voltage AC220 V, input power 100W+_ 10 will usefor aerobic training program ,start by 1pbm grading to 2pbm speed and increase according to patient abilities during sessions ,0% treadmill inclination angle for two month as a total treatment period for study group patients.~Patients in this group will participate in aerobic training as march walking on treadmill for 45 mints duration for session 3 times per week, start with 5 mints warm up beginning and 5 mints cooling down at end session, in addition to their medical program and burger exercises"
46036245|NCT00687037|Drug|Cetylpyridinium chloride|
46036246|NCT02810002|Device|Experimental infantry boot - DEFINITE-REGULATOR|Training: infantry basic training in the experimental boots
46036247|NCT02810002|Device|Control infantry boot|Training: infantry basic training in the control boots
46036248|NCT02625415|Device|Vitamin B6 cream|Topical Vitamin B6 cream
46036249|NCT02625415|Device|Placebo Vitamin B6 cream|Placebo Vitamin B6 cream
46036250|NCT02809768|Drug|Avatrombopag|
46036251|NCT02809768|Drug|Fluconazole|
46036252|NCT02809768|Drug|Itraconazole|
46036253|NCT02809768|Drug|Rifampin|
45839934|NCT04734600|Other|myofascial release technique|"group B:The myofascial release technique group will receive a 45 mints session time, for3 times per week for two months in addition to their medical program and burger exercises. Before the MF will starte, patient will rested in a relaxed prone position for 15 to 30 mints and also after end session time, MF protocol will applied as follow sequence over all period of total treatment sessions (8) week.:~thoracolumbar cross hand facial release technique for at least 5 mints for every barrier depth area, started by one hand will place on high thoracic area with pressure applied cephalic, the other hand was placed directly on the lower lumbo -sacrum area pushing caudal and arms are crossed to maximize as leverage as the barrier sense of softening will occurre and release sense on fascia under hand (release done at transverse alternative with longitudinal direction)alternation same methods to affected leg"
45839935|NCT05314842|Drug|Formocresol|dressing agents in pulpotomized primary molas using formocresol in cariously exposed vital primary molars
45473220|NCT03256578|Device|New Life Box Respiratory Function Monitor|The intervention is the use of a visible New Life Box Respiratory Function Monitor display in infants born between 24 and 27 6/7 weeks gestation receiving PPV for resuscitation after birth.
45473221|NCT04933071|Behavioral|Podcast|A list of podcasts that are specified for each rotation
45839936|NCT05314842|Drug|Premixed bioceramic MTA|dressing agents in pulpotomized primary molas using premixed bioceramic MTA in cariously exposed vital primary molars
45839937|NCT05314530|Behavioral|ReTA-model|Validating the rehabilitation model ReTA
46036254|NCT02813278|Dietary Supplement|simo decoction|Participants allocated to SMD and acupuncture were asked to take oral SMD decoction (Hansen Co., Ltd., Yiyang, Hunan province, China, 10 mL/dose) three times per day beginning on the first day after colorectal resection. They also received bilateral injections of vitamin B1 (50 mg x 2) at the tsusanli acupoint one time per day. This intervention was performed for a total of 5 consecutive days or until flatus.
46036255|NCT02813278|Other|gum chewing|Participants allocated to chewing gum were instructed to chew commercially available sugar-free gum (Extra & Reg, Wm. Wrigley Jr. Co., Ltd., Shanghai, China) three times daily starting on the first postoperative morning. They were instructed to chew the piece of gum for at least 10 min. This intervention was performed for 5 consecutive days or until flatus.
46036256|NCT04138849|Drug|BBT-877 single dose|Oral capsule, single dose.
46036257|NCT04138849|Drug|Placebo single dose|Oral capsule, single dose.
46036258|NCT04223284|Other|D-Limonene|Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% D-Limonene in the nose for 15 minutes
46036259|NCT04223284|Other|SLVO|Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% SLVO in the nose for 15 minutes
45839938|NCT05314140|Diagnostic Test|Coronary artery calcium score evaluation|The evaluation of the coronary artery calcium score will be performed with chest CT scan
45839939|NCT05313984|Device|Sacral neuromodulation|"Sacral neuromodulation: the 2-staged tined lead procedure. (Interstim II therapy, Medtronic).~Stage I: Placement of a tined-lead electrode. 2 - 4 weeks test phase. Stage II: Placement of an implantable pulse generator."
45839940|NCT05313906|Drug|RC48+AK105+cisplatin|RC48 plus AK105 and cisplatin
46036260|NCT00690703|Device|RF ablation (Rita Medical Systems Model 1500x)|computed tomography-guided RF ablation with an expandable electrode needle
46036261|NCT04237090|Drug|Diphenhydramine|Drug identification number : 02369567
46036262|NCT04237090|Drug|Cetirizine|Drug identification number : 02231603
46036263|NCT04237090|Drug|Lactose pill|Natural product number : 00501190
46036264|NCT04237090|Drug|Sodium chloride 0.9%|Drug identification number : 00037796
46036265|NCT00690781|Dietary Supplement|Pulse casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
46036266|NCT00690781|Dietary Supplement|Spread casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
46036267|NCT00690781|Dietary Supplement|Pulse milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
45473222|NCT01283789|Drug|Lapatinib and RAD-001|"Lapatinib will be taken orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease. Patients will take the tablet at bedtime, at the same time each day, in a fasting state.~Everolimus will be taken orally as a once-daily dose of 5 mg (one 5 mg tablet) from study day 1 until progression of disease. Patients will take the tablet at the same time each morning."
45473223|NCT03383068|Drug|Acarbose 100 MG|for metformin uneffective subjects, using acarbose for 3 months
45473224|NCT03383068|Drug|Exenatide|for metformin uneffective subjects, using Exenatide for 3 months
45473225|NCT03383068|Drug|Orlistat|for metformin uneffective subjects, using Orlistatfor 3 months
45473226|NCT03383068|Drug|Metformin|metformin effective subjects,act as control group
45473227|NCT03873701|Diagnostic Test|bedside ultrasonography|Patients suspicious to urinary tract infection with kidney involvement are being examined by ultrasonography to detect hydroneprhosis. The treating clinicians fill out questionnaires to validate the impact of the bedside ultrasonography on the patient care and treatment.
45473228|NCT03227445|Device|ELLIPTA placebo DPI|ELLIPTA is a dry powder inhaler used via oral route. It will be a placebo DPI with two strips with 30 blisters per strip. First strip will contain lactose monohydrate and the second strip will contain lactose monohydrate blended with magnesium stearate.
45473229|NCT03227445|Device|DISKUS placebo DPI|DISKUS is a dry powder inhaler used via oral route. It will be a placebo DPI with one blister strip that will contain lactose monohydrate.
46036268|NCT00690781|Dietary Supplement|Spread milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
46036269|NCT04187794|Other|Interview patient|to investigate an association between literacy level and medication adherence in patients with rheumatic diseases.
46036270|NCT00682669|Behavioral|MBSR|A mindfulness-based stress reduction (MBSR) program consisting of an 8-week, 9-session intervention based on systematic and intensive training in mindfulness meditation and mindful hatha yoga and their application to every day life.
46036271|NCT00682669|Behavioral|HLC|An 8-week program consisting of lectures and discussion of health-related topics.
45839941|NCT05313828|Drug|Acyclovir|acyclovir 4 times /day
46036272|NCT05631184|Behavioral|Self-administered acupressure group|Self-administered acupressure treatment group was developed on the basis of previous systematic reviews and clinical studies of acupuncture and acupressure for depression. It has robust theoretical basis of TCM. The acupoints selected are commonly used for depression according to a recent systematic review and recommended by other clinical practice guidelines.
46036273|NCT05631184|Behavioral|Mental health education group|Mental health education training group was developed based on the materials regarding depression and mental health from the Centre of Health Protection, Department of Health, the Government of Hong Kong SAR and reviewed by a clinical psychologist.
46036274|NCT00682747|Drug|Hyperbaric oxygen|40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen
45473230|NCT03227445|Device|HandiHaler placebo DPI|HandiHaler is a dry powder inhaler used via oral route. It will be a DPI with placebo capsules that will contain lactose monohydrate.
45473231|NCT03227445|Other|Inhaler preference questionnaires|Preference questionnaires will be given to subjects to understand the inhaler preference. There will be 2 types of questionnaire, preference questionnaires 1 and 2, which will be randomized at visit 3 (Day 56).
45473232|NCT03869021|Other|3D printed surgical guide constructed|A printed surgical guide ( to direct through the surgery and make results predictable), the guide is designed by Mimics 19.0, Materialise NV,Belgium and printed with self cure resin
45473233|NCT03869021|Other|free hand surgery|A control group in which patients are randomly assigned and surgeries are planned without surgical guides and performed free handed
45839942|NCT05313828|Drug|Tobramycin|tobramycin 4 times /day
45839943|NCT05313828|Drug|Fluorometholone|Fluorometholone 4 times/ day
46036275|NCT00682825|Behavioral|Bispectral index protocol|Aim to titrate anesthesia to maintain BIS between 40 and 60.
46036276|NCT00682825|Behavioral|End tidal anesthetic gas-guided|Aim to maintain anesthetic gas between 0.7 and 1.3 MAC equivalents
46036277|NCT02809612|Behavioral|Internet-based platform|Internet-based platform with information and training modules based on acceptance and commitment therapy for vulvodynia patients
46036278|NCT00682903|Device|GuardianR|As self monitoring of capillary glucose level is needed to validate those algorithms, we postulate that using a device able to permanently control interstitial glucose readable by both medical team and patient himself (during the session and the 5 following days after discharge) could significantly improve safety and efficiency of such educative session.
46036279|NCT04187248|Drug|Asparaginase|
45839944|NCT05313828|Drug|Sodium Hyaluronate|Sodium Hyaluronate 4 times/day
45839945|NCT05313750|Drug|anti-infective therapy sitafloxacin|anti-infective therapy
45839946|NCT05313750|Drug|anti-infective therapy levofloxacin|anti-infective therapy
45839947|NCT05313126|Other|sterile insect technique (TIS)|Sterile male Aedes albopictus mosquitos are released in the area/neighborhood
45839948|NCT05295420|Procedure|platelet rich plasma|Injection of Platelet Rich Plasma in the female conditions that suffer from SUI
45839949|NCT05290350|Other|OSA|EXPOSURE TO OBSTRUCTIVE SLEEP APNEA
46036280|NCT00912379|Biological|hemoglobin determination|laboratory and non invasive hemoglobin determinations
46036281|NCT02809378|Drug|Palonosetron|newly developed 5-HT3 antagonists with long half life (48 hrs) intravenous administration prior to anesthesia induction
46036282|NCT02809378|Drug|sevoflurane|Inhalational anesthetics Halogenated.
46036283|NCT02809378|Drug|remifentanil|ultra-short acting opioid anesthetics
46036284|NCT02809378|Drug|pentothal sodium|intra-venous anesthetics for anesthesia induction
46036285|NCT02809378|Drug|propofol|intra-venous anesthetics for anesthesia induction and maintenance
46036286|NCT00683059|Drug|Paclitaxel|total dose (mg) = body surface area in m2 x study dose (mg/m2) to be injected into a vein once every 3 weeks over 18 months.
46036287|NCT02813122|Device|x-ray|x-ray for the detection of leaks and bleeding
46036288|NCT05299021|Procedure|Double-point SAPB|After general anesthesia, patients were placed in the lateral position with 90˚ abduction of the upper arm. A high-frequency linear probe (6-13 MHz) of the ultrasound machine was used to identify the fifth rib in the midaxillary line. The anatomic landmarks of the block were identified: latissimus dorsi, serratus anterior, and the intercostal muscles in the fourth and fifth intercostal levels. After sterilization and draping, an 18-gauge needle was introduced craniocaudally at an angle of 45˚ using an in-plane technique. The needle tip was advanced, targeting the plane between the serratus anterior muscle and the fifth rib. Needle position was confirmed by injection of 1-to-2 mL of saline after negative aspiration. And use the same method targeting the plane between the serratus anterior muscle and the third rib.Under real-time visualization, total 30 mL of 0.375% ropivacaine and 1 μ g/kg dexmedetomidine mixture will be injected into the two points with 15 ml separately.
45473234|NCT04067401|Behavioral|Wingman Connect|Wingman-Connect combines group and individual skill training. Group exercises build cohesion, belonging and shared purpose, and promote value of healthy unit, giving and receiving support. Individual skills promote the ability to thrive during transitions, manage stressors and meet career goals, and decrease barriers to utilizing organizational resources (family, health). The training has a total of 22 modules comprised of specific learning objectives and activities. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
45340888|NCT04076774|Device|Wondaleaf Female Condom|Wondaleaf: Wondaleaf is an ultra thin (of 0.02 mm) polyurethane female/male condom (16x8cm) that has folded extended adhesive shields (front 18x18cm, back 18x10cm), which at unfolding covers the entire external genitalia to prevent direct skin contact and exchange of body fluid between sexual partners during intercourse. Insertion of the condom body into the vagina is through use of a small medical grade cotton tissue packed inside the foil package. This is inserted into the end of the condom body and used to push the condom into the vagina. Each condom is individually packaged without prior lubrication. However, lubricant is expected to be used at donning the condom and during sexual intercourse. The lubricant will be supplied in separate packets together with the condom. Unlike latex, polyurethane condoms are unlikely to cause any allergic reaction and are much stronger than conventional latex condoms
45340889|NCT04076774|Device|FC2 Female Condom|FC2: The FC2 is a second-generation female condom manufactured by the Female Health Company (Chicago, IL). The FC2 has US FDA approval and has been granted the CE Mark (Conformité Européenne) of the European Union. The FC2 is the only female condom that has been pre-qualified by the World Health Organisation. The device is similar in design to the FC1, but is made from a synthetic polymer (nitrile) film that is softer and more elastic than the polyurethane of the earlier device. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The outer ring at the open end is rolled from the nitrile material. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal polyurethane ring is removable and serves as the insertion mechanism and anchors the device within the vagina. FC2 measures 180mm in length and 80mm in lay-flat width. The device is pre-lubricated with dimethicone.
45340890|NCT03704480|Drug|Durvalumab|1500mg by intravenous (IV) infusion on D1 until progression or unacceptable toxicity or withdrawal of consent
45473235|NCT04067401|Behavioral|Stress Management|Stress management training reviews the basics of the hypothalamic-pituitary-adrenal axis stress-response system; common experiences of stress (physiological, cognitive, emotional); the impact of chronic stress on the brain and other domains of health; how exercise reduces harmful effects of stress; and relaxation techniques that have been shown to reduce stress and adverse effects of stress on health. Additional modules review the physiological stress response and effects of stress on health; introduces how cognition influences stress responses; common cognitive distortions/attributions are reviewed that affect stress including strategies to strengthen protective cognitive responses. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
45839950|NCT05275530|Behavioral|Active FIT Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about FIT as a screening strategy. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with a FIT, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
45340891|NCT03704480|Drug|Tremelimumab|300mg by IV infusion on D1 at cycle 1 only
45473236|NCT03378310|Drug|BMS-986205 reference tablet|Single, 100 mg oral dose.
45473237|NCT03378310|Drug|BMS-986205 tablet with free base|Single, 100 mg oral dose.
45473238|NCT01283867|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets
46036289|NCT05299021|Procedure|Single-point SAPB|After general anesthesia, patients were placed in the lateral position with 90˚ abduction of the upper arm. A high-frequency linear probe (6-13 MHz) of the ultrasound machine was used to identify the fifth rib in the midaxillary line. The anatomic landmarks of the block were identified: latissimus dorsi, serratus anterior, and the intercostal muscles in the fourth and fifth intercostal levels. After sterilization and draping, an 18-gauge needle was introduced craniocaudally at an angle of 45˚ using an in-plane technique. The needle tip was advanced, targeting the plane between the serratus anterior muscle and the fifth rib. Needle position was confirmed by injection of 1-to-2 mL of saline after negative aspiration.Under real-time visualization, total 30 mL of 0.375% ropivacaine and 0.5μ g/kg dexmedetomidine mixture will be injected.
46036290|NCT01185353|Drug|LY3009104|Administered orally
45839951|NCT05275530|Behavioral|Active Colonoscopy Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about colonoscopy as a screening strategy. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with a colonoscopy, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
45340892|NCT03699254|Drug|Valganciclovir|"Valganciclovir is a L-valyl ester of ganciclovir that exists as a mix of 2 diastereomers. After administration, both are converted to ganciclovir by esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."
45473239|NCT03382990|Device|DES or BMS|DES or BMS placement during the procedure of PCI in patients with AMI is depend on the operator's decision.
46036291|NCT01185353|Drug|Placebo|Administered orally
46036292|NCT01185353|Drug|Methotrexate|Administered orally as background therapy
45473240|NCT02526329|Biological|donor regulatory T lymphocytes|Given IV
46036293|NCT02809300|Biological|blood collection|
45473241|NCT02526329|Other|laboratory biomarker analysis|Correlative studies
45473242|NCT03378232|Dietary Supplement|Placebo Olive Oil|Each participant was instructed to consume the dietary supplement on a daily basis for 12 weeks.
45473243|NCT03378232|Dietary Supplement|High EPA Supplement|Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.
45473244|NCT03378232|Dietary Supplement|High DHA Supplement|Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.
45473245|NCT04250415|Procedure|Surgery|
45473246|NCT01170299|Dietary Supplement|dietary intervention|
45473247|NCT01170299|Other|laboratory biomarker analysis|
45473248|NCT01170299|Procedure|gastrointestinal complications management/prevention|
45473249|NCT01170299|Procedure|management of therapy complications|
45473250|NCT01170299|Radiation|selective external radiation therapy|
46036294|NCT04237402|Other|Hair follicles sampling|The hair follicles will be collected by strand of 5 to 6 hairs approximately in the scalp (centro-parietal part), in order to obtain 20 follicles with epithelial sheath.
45473251|NCT04094298|Drug|FX006 Injection|One injection of extended release triamcinolone. 32 milligram injection of the extended release triamcinolone in a 75:25 ratio of polylactic-co-glycolic acid (PLGA) microspheres to drug load of 25%. The drug product is reconstituted with diluent containing an isotonic, sterile aqueous solution of sodium chloride, carboxymethylcellulose sodium and polysorbate-80 to form a suspension prior to injection.
45473252|NCT03378154|Procedure|Orotracheal intubation in infants with Macintosh|Orotracheal intubation in infants using Macintosh laryngoscope
45473253|NCT03378154|Procedure|Orotracheal intubation in infants with King vision|Orotracheal intubation in infants with King vision videolaryngoscope
45473254|NCT04194151|Drug|Propofol Injection|1, 1.5 or 2 mg/kg of propofol according to the subgroup
45473255|NCT01281761|Drug|cetuximab/irinotecan/simvastatin|D1 Cetuximab 500mg/m2 IV stepwise shortened infusion duration- [C1D1 over 120min, C2D1 over 90min,subsequent dose over 60min] D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV [over 90min] D1-14 Simvastatin 80mg P.O(continuous, daily) every 2weeks
45473256|NCT04280328|Drug|Ciforadenant|100 mg orally twice daily for 28-day cycles
45473257|NCT04280328|Drug|daratumumab|"16 mg/kg administered intravenously as follows based on 28-day cycles:~Cycles 1 - 2: Days 1, 8, 15, and 22~Cycles 3 - 6: Days 1 and 15~Cycles 7 - 24: Day 1"
46036295|NCT00683137|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth once daily on Days 2 through 5
46036296|NCT00683137|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth twice daily on Days 2 through 5
46036297|NCT00683137|Drug|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then placebo on Days 2 through 5
46036298|NCT02809456|Drug|Nicorandil|oral intake
45473258|NCT03385954|Other|Intervention|The distance eduacation group course has a workload of 8 hours and will be developed over 2 weeks. It is suggested that students have a minimum of 1 hour of study per day. The course will consist of work tips, clarifications and procedures for the prevention of RIS/WRMD physical training tips to improve cardiovascular condition and, of strength and flexibility, available literature and theoretical evidence that should be answered through the knowledge acquired in the EAD course of prevention of LERDORT from the HCPA's Physiatrics and Rehabilitation Service. This Course will be available through moodle.
45473259|NCT03385954|Other|Control|will receive a lecture of 30 minutes.
45473260|NCT03820323|Diagnostic Test|POC VL and targeted DRM testing.|Point-of-care Viral Load Testing will be done to ensure that providers and caregivers receive the results with in 24 hours study. Targeted DRM testing will be performed during the initiation of ART and when viremia (VL>1000 copies/mL) is detected.
45473261|NCT03820323|Diagnostic Test|SOC VL testing|SOC VL testing is done at 6 months after ART initiation then every 3 months if unsuppressed, otherwise every 12 months. DRM testing is conducted only if failing 2nd line ART.
45473262|NCT03748147|Drug|Misoprostol|prostaglandin e1
45473263|NCT01580813|Drug|Acipimox|Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
45473264|NCT01580813|Drug|Placebo|Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
45473265|NCT05002504|Diagnostic Test|A series of questions were asked to the children's parents in a virtual questionnaire|A series of questions were asked to the children's parents in a virtual questionnaire on physical characteristics, previous health assessments and observations of their balance and coordination in front of their children
45473266|NCT05002504|Diagnostic Test|"neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI)"|"the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-49%), normal (50-79%) and high (80-100%). Low and high values are considered impairments in one or more of the areas evaluated. Evaluation of the Battelle scale was carried out before and after the therapy sessions."
45473267|NCT05002504|Procedure|Therapy sessions|Seven treatment sessions were carried out with the balance and coordination therapeutic exercise techniques (group 3) most frequently used for the treatment of these pathologies; seven sessions of craniosacral therapy (group 2) as corrective and preventive in possible alterations during infant neurodevelopment and finally seven sessions simulating craniosacral therapy on a placebo group (group 1) as a control of the treatments used.
45473268|NCT03915379|Drug|JNJ-67571244|JNJ-67571244 will be administered.
46036299|NCT05576740|Procedure|Determination of hormone level concentrations|Determination of concentration of 17β-oestradiol (pg/mL), progesterone (ng/mL), LH (mUI/mL), FSH (mUI/mL), prolactin (ng/mL), total testosterone (ng/mL), free testosterone (pmol/L) sex hormone binding globulin (SHBG) (nmol/L), cortisol (μg/dL), T3 (ng/dL), T4 (mcg/dL), TSH (mcU/mL), basal insulin (mcUI/mL) during the early follicular phase, late follicular phase, and mid-luteal phase.
46036300|NCT05576740|Procedure|Jump height determination|by Chronojump contact mat, determine five types of jump in centimeters: Squat jump without additional weight, Squat jump with 50% of body weight, Countermovement jump, Abalakov jump, and Drop jump, during the early follicular phase, late follicular phase, and mid-luteal phase.
45473269|NCT01314183|Other|Exercise|The program starts with a 10 minute aerobic exercise warm-up (treadmill walking or stationary cycling). Subjects then perform a series of strengthening, stretching, and neuromuscular control activities which are core exercises for the program and mandatory. In addition to the above core exercises, therapists have the option to select additional optional exercise activities, based on the initial examination findings. These exercises will address strength or flexibility in the hip, and ankle if impairments are identified in the initial examination.
45839952|NCT05275530|Behavioral|Active Dual Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about FIT Kit and Colonoscopy screening. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with either a FIT or Colonoscopy, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
45340893|NCT03699254|Drug|Ganciclovir|"Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."
46036301|NCT05576740|Procedure|Grip strength determination|measuring of changes in muscle strength by handgrip dynamometer in the hand to be tested (handgrip test) during the early follicular phase, late follicular phase, and mid-luteal phase. Three attempts on each hand.
45340894|NCT00570687|Drug|Technosphere Insulin|Inhalation 15U/30U
45340895|NCT01021891|Drug|Technosphere®/Insulin|
45340896|NCT04075058|Radiation|Hypofractionated Radiation therapy|
46036302|NCT05576740|Procedure|Flexibility determination|measurement of changes in the range of motion of the hamstring musculature, by sit and reach test (cm), during the early follicular phase, late follicular phase, and mid-luteal phase. Three tries.
45683540|NCT04758598|Device|Selective Laser Trabeculoplasty (SLT)|SLT employs frequency doubled Q switched Nd:YAG laser with a wavelength of 532 nm. It is delivered in short nano second pulses and the resulting selective effect to the pigmented cells of the TM, leaving the surrounding non-pigmented cells unaffected. This increases the permeability of the TM endothelial cells and can assist in increasing outflow and hence result in reductions in IOP. The procedure lasts approximately 10 minutes, with delivering 100 separate laser beams through a manually rotated mirrored lens (gonioscope), involving prolonged contact with the participant's eye. This treatment is applied on the cornea through a gonioscopic lens which is used to direct the laser beam to the desired location - the TM (360 degrees of treatment area).
46036303|NCT05576740|Procedure|Indirect maximum oxygen consumption determination|by the Course Navette test, the indirect oxygen consumption is calculated using the formula: VO2max = (6xFA) - 27,4 (FA = Speed of the last stage of the test completed. It takes place during the early follicular phase, late follicular phase, and mid-luteal phase.
45340897|NCT01029223|Drug|ivabradine|
45340898|NCT01029223|Drug|metoprolol|
45340899|NCT01029223|Drug|placebo|
45340900|NCT02556723|Drug|Intravitreal injections of ziv-aflibercept|All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks. No topical or systemic antibiotics will be prescribed (pre- injection or postinjection).
45340901|NCT03412058|Procedure|Biopsy|To be performed prior to anti-PD1/PD-L1 treatment initiation
45340902|NCT03412058|Procedure|Biopsy|To be performed after 42 (±3) days of anti-PD1 or PD-L1 treatment in consenting patients
45340903|NCT03412058|Procedure|Biopsy|To be performed at disease progression if medically feasible
45340904|NCT03836677|Combination Product|BGF|Treatment with Budesonide/Glycopyrronium/FormoterolFumarate
45340905|NCT03836677|Combination Product|GFF|Treatment with Glycopyrronium/Formoterol Fumarate
45340906|NCT00777543|Other|ferulic acid|Ferulic acid is naturally contained in wholegrain bread. Bran is the main source of ferulic acid while is low in white flour. Ferulic acid is mainly covalently bound to fiber and low bioaccessible. The bran is pretreated to increase the bioavailability of ferulic acid by increasing the free ferulic acid released from the food matrix.
45473270|NCT01314183|Other|manual therapy|The manual therapy (MT)techniques are maneuvers that are applied with manual force from the treating therapist. The MT techniques will include a series of accessory motion techniques, manual stretching , and soft tissue manipulation (deep massage to muscles and connective tissues associated with knee function). Core techniques include anterior-posterior and posterior-anterior tibiofemoral translations, superior-inferior and medial-lateral patellofemoral mobilizations, knee flexion and extension mobilizations that may be combined with varus-valgus stresses,medial-lateral tibial rotations, manual stretching of the quadriceps, rectus femoris, hamstring, and gastrocnemius muscles, and soft tissue manipulations of the quadriceps, peri-patellar tissues, hamstring, hip adductors, and gastroc-soleus muscle groups. There are optional MT techniques for the hip, and foot and ankle joints that can be selected by the therapist based on initial examination findings.
45473271|NCT04446364|Other|Ethanolic extract of Aloe vera gel cavity disinfectant|Application of Aloe vera gel after partial caries removal then taking dentin bacterial sample to be sure for reduction of bacterial count (streptococcus mutans and Lactobacillus) in deep cavity then add final restoration
45473272|NCT04446364|Other|Chlorohexadine|2%Chlorohexadine add on deep cavity as cavity disinfection after partial caries removal. Pre and post excavation bacterial count to measure bacterial reduction then add final restoration
45473273|NCT01588535|Drug|benzocaine|benzocaine 10 mg/mL, five drops in affected ear canal each hour as needed
45473274|NCT01588535|Drug|placebo|placebo solution, five drops in affected ear canal each hour as needed
45473275|NCT03637101|Diagnostic Test|Ischemia modified albumin (IMA)|Ischemia modified albumin is a biomarker for cardiac ischemia and acute stroke whether ischemic or hemorrhagic
46036304|NCT05576740|Device|Sensory and pain threshold determination|by electrical muscle stimulator (Digitimer DS7A), during the early follicular phase, late follicular phase, and mid-luteal phase.
46036305|NCT05576740|Other|Physical and mental symptoms associated with the menstrual cycle|By The Daily Record of Severity of Problems (DRSP) questionnaire, during a full menstrual cycle.
46036306|NCT05576740|Device|Daily activity|by accelerometer (GENEActiv) during a full menstrual cylcle: Wrist-worn device measuring accelerations as a measure of daily activity, in cpm, counts per minute.
46036307|NCT05576740|Procedure|Biochemical parameters determination|Determination of concentration of iron (μg/dL), ferritin (ng/mL), and transferrin (mg/dL), during the early follicular phase, late follicular phase, and mid-luteal phase.
46036308|NCT05576740|Procedure|Blood count determination|Determination of concentration of hemoglobin (g/dL), red blood cells (10^6/μL), hematocrit (%), white blood cells (10^3/μl), platelets (10^3/μl), during the early follicular phase, late follicular phase, and mid-luteal phase.
46036309|NCT05576740|Procedure|Body composition parameters determination|Determination of weight (kg), total body water (L), proteins (kg), minerals (kg), body fat mass (kg), body mass index (BMI) (kg/m2), basal metabolic rate (kcal) by Bioelectrical Impedance Analysis, during the early follicular phase, late follicular phase, and mid-luteal phase.
45683541|NCT04757116|Device|iTind|The iTind is implemented for 5-7 days
46036310|NCT05576740|Procedure|Vital signs|Determination of blood pressure (mmHg) and heart rate (bpm) at baseline, one minute and three minutes after the Course Navette test
46036311|NCT05576740|Other|Checking for correct use of contraceptive methods|Pre-test questions about possible forgetfulness or mishandling of the method
46036312|NCT05576740|Procedure|Urinary LH determination|Urine LH test strips are performed from day 8 of the cycle until positive.
46036313|NCT04139473|Procedure|Hepaticojejunostomy / Duct-to-duct anastomosis|
46036314|NCT04139629|Diagnostic Test|antichlamydial antibody test|At the first day of stimulation blood analyses for IgG, IgA and IgM (ELISA) to major chlamydial antigens (anti-C.trachomatis), major outer membrane protein (MOMP) and plasmid-encoded protein (pgp3) will be performed for patients found eligible for the study.
46036315|NCT04139629|Drug|treatment of infertility with ART|COS in gonadotropin-releasing hormone (GnRH) antagonist protocol with IVF/ICSI, fresh ET and, if no pregnancy occurred, frozen/thawed ET (for all embryos resulting from this COS) will be performed.
46036316|NCT04222894|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
45340907|NCT00777543|Dietary Supplement|Treated bran bread|This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
45340908|NCT00777543|Dietary Supplement|wholegrain bread|The control is the wholegrain bread enriched with bran that has not been pretreated
45340909|NCT03410654|Drug|Tacrolimus, Extended Release, (Envarsus Xr)|After conversion of tacrolimus immediate release to tacrolimus extended release.
46036317|NCT04222894|Other|Control Diet|Participants will be asked to continue their usual diets for the 12-week study period.
46036318|NCT00687349|Behavioral|Training Program Intervention|Resident or NP Student receives the educational intervention during 8 half-day sessions.
45473276|NCT03287622|Behavioral|Educational Intervention|This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.
45473277|NCT03287622|Behavioral|Nudge|Behavioral Nudge in this study is a simple, take-home kit (ziplock baggy of used coffee grounds) to be used to dispose of left-over prescription opioids
45473278|NCT04063657|Procedure|External fixator|Patients will be placed in an external fixator followed by open versus closed surgical stabilization of their calcaneus fracture when their soft tissue is appropriate for surgery.
46036319|NCT02813044|Drug|total intravenous anesthesia (TIVA)|In the TIVA group,anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil.
46036320|NCT02813044|Drug|inhalation anesthesia group|In the inhalation anesthesia group, anesthesia is induced by pentothal sodium 4-6mg/kg and remifentanil 1 μg/kg, and then maintained with end-tidal sevoflurane concentration of 0.8 to 1 MAC and continuous infusion of remifentanil at 0.1-0.3μg/kg/min.
46036321|NCT02625883|Other|Interview|Interview by validated Quality-of-life-questionnaire
45473279|NCT04063657|Procedure|Splinting|Patients will be placed in a short leg splint followed by open versus closed surgical stabilization of their calcaneus fracture when their soft tissue is appropriate for surgery.
46036322|NCT04236778|Drug|VE303|The VE303 Drug Product is a live biotherapeutic product (LBP) consisting of 8 clonal human commensal bacterial strains manufactured under GMP conditions.
45683542|NCT04757116|Procedure|UroLift|UroLift is a minimally invasive procedure where permanent implants are placed in the prostate.
45683543|NCT04756804|Drug|70% v/v Isopropyl Alcohol Surgical Solution|Patient preoperative skin preparation
45683544|NCT04756804|Drug|2%w/v Chlorhexidine Gluconate / 70% v/v Isopropyl Alcohol|Patient preoperative skin preparation
45683545|NCT04398394|Device|Cellularis version 1 imaging|Using a new modality for retinal cell imaging, we aim at comparing qualitatively and quantitatively, the morphology of the deepest layer of the retina, the retinal pigment epithelium (RPE) by imaging the people with a prototype instrument (Cellularis version 1).
46036323|NCT04236778|Drug|Oral Vancomycin|Vancomycin, when taken by mouth, is used to treat Clostridium difficile-associated diarrhea.
46036324|NCT00687427|Behavioral|Questionnaires and motor/sensitivity testing|"Group A:~Full assessment (using the various measures described) will be carried out 0-3 weeks since referral.~Treatment will focus on the patient's needs and in accordance with the physicians requests.~Three months post initial treatment re-assessment will be conducted."
45683546|NCT04740268|Device|Straberi|"The patient's entire face will be treated with the Straberi microneedling devise.~The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm"
45683547|NCT03829462|Drug|Regorafenib|regorafenib tab 40 mg i.e 160 mg/day
45683548|NCT03829462|Drug|Irinotecan|irinotecan 120 mg/m2 cycle 1, 150 mg/m2 cycle 2, 180 mg/m2 cycle 3 and more
45683549|NCT03199924|Drug|Diclofenac|Intramuscular injection of 75mg / 3ml of Diclofenac solution
45473280|NCT01165931|Drug|Riociguat (BAY63-2521)|0.1 mg intracoronary infusion through coronary guide catheter. Single dose. Sequential application after initial vasoactive bolus of Adenosine (non-study drug) and Nitroglycerin (non-study drug).
45683550|NCT03199924|Drug|Magnesium Sulfate|intravenous injection of 1 g magnesium solution diluted in 10ml of saline solution administered over 2 minutes
45683551|NCT03199924|Drug|Lidocaine|intravenous injection of 10ml lidocaine 1% solution administered over 2 minutes
45683552|NCT01908907|Dietary Supplement|DHA oil|Therapy Group:DHA oil administered at 50 mg/d (0.18ml) as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
45683553|NCT01908907|Dietary Supplement|(MCT) Control oil|Placebo Group:MCT oil administered at 0.18 ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
45340910|NCT03401840|Radiation|postoperative hypofractionated stereotactic radiotherapy|total dose of 36Gy in 6 fractions over 11-13 days
45340911|NCT02556645|Other|Web-PE Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
45340912|NCT02556645|Other|Therapist-Delivered Present-Centered Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies. It provides a credible comparison therapy to control for nonspecific therapeutic factors so that observed effects of Web-PE can be attributed to its specific ingredients beyond the benefits of good therapy.
45340913|NCT01032421|Procedure|IVF procedure|
45473281|NCT03636945|Other|PET at 18F-FDOPA|18F-fluorodihydroxyphenylalanine (18F-FDOPA) PET imaging
45473282|NCT02970136|Device|OraQuick Swab|OraQuick for oral fluid HIV antibody testing
46036325|NCT00687427|Behavioral|Questionnaires and motor/sensitivity testing|Group B Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
46036326|NCT00687427|Behavioral|Questionnaires and motor/sensitivity testing|Group C Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
45473283|NCT02970136|Device|Fecal Immunochemical Test|Fecal Immunochemical stool test specific for human hemoglobin
45473284|NCT02970136|Device|OraQuick Fingerstick|Patients will be tested for Hepatitis C infection using a fingerstick
45473285|NCT02970136|Other|Standard Screening Tests|Patients will be navigated to a local health center for standard screening tests
45473286|NCT02970136|Device|HPV Self-Sampling Test|Patients will be using swab to check for HPV infection
45473287|NCT02970136|Other|Home Based Screening Tests|Patients will provided screening tests and instructed by Community Health Worker on how to perform home screening tests
45473288|NCT05181111|Device|Wearable Sensor|The sensor measures vital signs including heart rate and respiratory rate, posture and level of physical activity.
45473289|NCT05181111|Other|Usual Care|Usual Care Monitoring
45473290|NCT03441282|Drug|Fentanyl|"After the patient is attached to an ASA non-invasive monitor, a dose (2mcg/kg) of Fentanyl will be administered.~Groups compared would include patients experiencing respiratory depression vs those not experiencing respiratory depression after fentanyl administration. Their samples would be evaluated for any differences in genetic make-up concerning selected, known sequences affecting opioid-induced analgesia."
45683554|NCT04398940|Drug|TQ-B3139|TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.
45683555|NCT04632199|Drug|111In-IPN01087 Low dose|Administered once via slow intravenous injection.
45683556|NCT04632199|Drug|111In-IPN01087 High dose|Administered once via slow intravenous injection.
45683557|NCT03199300|Drug|Anthracyclines|Chemotherapy regimen containing anthracyclines.
45683558|NCT03199300|Drug|Trastuzumab|Systemic treatment including trastuzumab.
45683559|NCT03199300|Drug|Cisplatin|Chemotherapy including cisplatin.
45683560|NCT03199300|Drug|Bleomycin|Chemotherapy including bleomycin.
45683561|NCT03826498|Biological|CP CB-MNC injection|CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.
45683562|NCT03826498|Other|Standard therapy|The standard therapy can include drugs, special psychology training etc.
45683563|NCT04746430|Drug|Dexamethasone|6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms
45683564|NCT03781414|Biological|CFZ533|Comparison with standard of care immunosuppression
46036327|NCT01098240|Drug|CP-601,927|CP-601,927 1-2 mg twice per day, oral 1 mg tablets, for 6 weeks.
46036328|NCT01098240|Other|Placebo|Matching placebo tablets, taken orally, twice per day, for 6 weeks.
45340914|NCT04008758|Diagnostic Test|Ultrasound|Evaluate participant's lung condition using ultrasound. Using lung ultrasound scoring, more than 1 point needs recruitment maneuver
45340915|NCT01021969|Other|Fructose|Subjects consume different amounts of fructose, glucose and sucrose in a crossover design
45340916|NCT04006262|Drug|Nivolumab 10 MG/ML|"Neo-adjuvant treatment : 240 mg intravenous (I.V.) in 30 minutes - every 2 weeks - 6 cycles~Adjuvant treatment : 480mg I.V. in 30 minutes - every 4 weeks - 9 cycles"
45340917|NCT04006262|Drug|Ipilimumab 200 MG in 40 ML Injection|Neo-adjuvant treatment : 1mg/kg over 30 minutes every 6 cycles - 2 cycles
45683565|NCT03781414|Drug|Tacrolimus - MMF - corticosteroids|Standard of care immunosupprevive regimen
45340918|NCT01032499|Drug|oxytetracycline, taro elixir|comparison of treatment efficacy between oxytetracycline and taro elixir
45340919|NCT01032499|Drug|Taro Elixir|Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
45340920|NCT01022047|Drug|Noex|The patients shall use the Noex drug only once a day (one application in each nostril) during the 12 weeks of treatment
45340921|NCT01022047|Drug|Budecort Aqua|The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
46036329|NCT02812888|Drug|thionamide treatment for 3 months|Hyperthyroid patients would received thionamide treatment (methimazole, propylthiouracil, or propranolol) for 3 months, and euthyroidism would be obtained.
46036330|NCT00922675|Procedure|Postconditioning|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting. In the postconditioning group 4 additional balloon inflations separated by 1 minute reperfusion are given, starting after 1 minute of reperfusion.
45340922|NCT01029301|Device|Device: EndyMed Pro System for Skin Tightening|"Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~Pulse energy (J); RF frequency (1MHz); Pulse duration (30 sec); Treatment hand piece (skin tightening);"
45340923|NCT04001036|Drug|1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine|One bag for nocturnal (long-dwell) exchange.
45340924|NCT04001036|Drug|0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine|One to three, daily (short-dwell) exchanges
45340925|NCT01022125|Drug|TMC435|
45340926|NCT01032655|Drug|susceptibility test guided sequential therapy|"susceptibility test driven sequential therapy D1- D7 Nexium ,40mg, bid Amolin, 1gm bid D8-14 Nexium ,, 40mg, bid Flagyl, 500mg, bid~plus either one of the following~Klaricid, 500 mg, bid~Cravit, 250 mg, bid~Tetracycline, 500 mg, bid"
45340927|NCT03654248|Behavioral|Let's Get Organized group intervention|Group intervention aiming to enhance time management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with PowerPoint presentation and a course manual, an information from the group leaders is intermixed with discussion among the participants and tasks to complete.
45340928|NCT03654248|Device|Individual Occupational Therapy|Individual meetings with Occupational Therapist (standard therapy) during a 10-week period. Number of meetings and exact nature of intervention depends on the client's needs and is decided by the treating occupational therapist. Interventions will include prescription or instruction regarding time assistive devices and instructions regarding structure and planning of everyday life.
45340929|NCT03385928|Drug|Tranexamic Acid|Investigational product given within 2 hours of symptom onset
45340930|NCT03385928|Drug|Normal saline|Placebo given within 2 hours of symptom onset
45340931|NCT02581280|Other|Residual blood|Residual blood samples(1~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).
45473291|NCT03377998|Other|skin biopsy|Skin biopsy for measuring tissue levels of the Erythroid differentiation regulator 1 (Erdr1) cytokine will be taken from the lesional skin of patients of vitiligo and from normal skin of healthy controls.
45473292|NCT01274273|Drug|Interleukin-2|2.4 MIU/m2 s.c. two times daily, 5 days per week, weeks 1 and 2, every 28-day-cycle, for a maximum of 9 cycles (i.e.for a maximum of 9 months).
45473293|NCT01274273|Drug|Interferon Alfa-2b|IFN-alfa given as one priming-week of daily IFN 3.0 MIU, followed by up to 9 treatment cycles (i.e. for a maximum of 9 months) with IFN-alfa 3.0 MIU as a fixed dose s.c. once daily - 5 days per week.
45683566|NCT04277650|Other|Machine learning algorithm|machine learning directed identification of radiotherapy or chemoradiotherapy patients at high-risk for emergency department acute care and/or hospitalization
45683567|NCT03832270|Behavioral|Parents InC|Based on social learning theory, Parents InC has been designed specifically for parents of children with an ADHD diagnosis with a particular focus on parenting sense of self competence.
45683568|NCT03832270|Behavioral|Incredible Years|Also based on social learning theory but focus is not specifically on ADHD.
45683569|NCT03258892|Other|Educational Intervention|Receive STG
45683570|NCT03258892|Other|Quality-of-Life Assessment|Ancillary studies
45683571|NCT03258892|Other|Survey Administration|Ancillary studies
46036331|NCT00922675|Procedure|Control intervention|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting.
46036332|NCT04149028|Procedure|PRP injection inside the ovary by laparoscoy. The injection volume is 2 ml|intraovarian injection of 2 mml of PRP by laparoscopic guide
46036333|NCT02809222|Other|Samples|Blood samples
46036334|NCT02809222|Other|Quality of life questionnaire|Questionnaire to assess the quality of life of cancer patients
46036335|NCT04139785|Other|Moodbuster|"Moodbuster intervention comprises three elements: (1) a web-based interface providing the patients access to CBT therapies, (2) a web-based portal for the trial co-ordinator and researchers, where they can view participation, amend modules and send login codes, (3) a mobile phone component which enables daily EMA monitoring of mood state, cognitions, activities, social interaction, and sleep.~The mobile application will be used to capture EMA data."
46036336|NCT02812966|Device|Lutonix|Drug Coated Balloons
46036337|NCT02812966|Device|IN.PACT|Drug Coated Balloons
46036338|NCT00687661|Drug|Bisphosphonate|35mg given orally once weekly for 24 months
45340932|NCT03374072|Behavioral|Siblings FORWARD program|Siblings will participate in a program developed by the researchers designed to engage adults with their autistic sibling and other family members to plan for the future. The Siblings FORWARD program will be implemented by community service providers already working with autistic adults. The program will involve a series individual and joint sessions with siblings and autistic adults using Zoom.
46036339|NCT00687661|Drug|Placebo|identical placebo pill once weekly for 24 months
46036340|NCT02809534|Drug|Anlotinib|Anlotinib p.o. qd
46036341|NCT00687817|Drug|bavituximab plus paclitaxel and carboplatin|Weekly bavituximab dose of 3 mg/kg until disease progression, and up to 6 cycles of carboplatin at a dose of AUC=5 and paclitaxel 175 mg/m2 every 21 days (21-day cycles)
45340933|NCT03374072|Behavioral|Information Only Condition|Siblings will be provided with online information about services for adults with ASD and future planning.
45340934|NCT05673980|Drug|Vitamin D2|Participants in the vitamin D2 group received 200,000 IU of vitamin D2 orally on the first day of the trial and again two weeks later
45340935|NCT05673980|Other|placebo|This group will not do any intervention
45340936|NCT02581124|Drug|JTZ-951|
45340937|NCT02581124|Drug|Lapatinib|
45340938|NCT02580968|Device|electro-acupuncture|electro-acupuncture on acupoints according to the traditional syndrome diagnosis.once per day, for 20 days.
46036342|NCT02809144|Procedure|Nerve block|Nerve block: 31 ml ropivacaine 7.5 mg/ml (Lateral sagittal infraclavicular brachial plexus block) + 4 ml ropivacaine 5 mg/ml (suprascapular nerve block) + 5 ml ropivacaine 5 mg/ml (superficial cervical plexus block)
46036343|NCT02808988|Procedure|periodontal phase 1 therapy|periodontal phase 1 therapy consisted of scaling and root planning with ultrasonic and hand instruments under local anesthesia and gingival crevicular fluid collection by the same investigator.
46036344|NCT02808988|Procedure|gingival crevicular fluid collection|gingival crevicular fluid collection by periopapers
46036345|NCT02808988|Other|zoledronic acid|5 mg/year zoledronic acid (i.v.)
46036346|NCT02625805|Device|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises. Additional EEG monitoring will be performed during performance of a computerized test using MindWave Headset.
46036347|NCT02625805|Device|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
46036348|NCT02625805|Drug|Methylphenidate|Methylphenidate will be administered to each of the study participants in both groups in one of the two days on the study selected randomly.
46036349|NCT00687895|Procedure|Clinical algorithm and microscopy diagnosis of malaria|"Clinical alogarithm~The content of the package included~description of signs and symptoms of malaria disease~history taking relevant to malaria and physical examination~identification of danger signs and severe illness for referral~appropriate treatment~counseling patients on the use of drugs.~Malaria microscopy. contents~make thick blood smears from patients with fever and stain with Giemsa~identify and count malaria parasites~maintain the microscope and store blood slides."
46036350|NCT02808910|Behavioral|Nudged to eat less added salt and more other seasonings|
46036351|NCT02808910|Behavioral|Nudged to avoid foods high in salt content, and to choose foods low in salt content|
45340939|NCT02580968|Drug|flunarizine hydrochloride|flunarizine hydrochloride ，10mg/day，for 20 days。
45340940|NCT03640520|Device|FACETS: Pediatric Resuscitation|Family-centered & Trauma-informed Support in Pediatric Resuscitation (FACETS: Pediatric Resuscitation) is an online skills training module for health care professionals involved in pediatric resuscitation in general EDs. The module combines didactic information and scenario-based learning with opportunities for the learner to practice applying their knowledge of FCC practices at key choice points in realistic pediatric resuscitation case scenarios. Training content is guided by evidence regarding FCC practices that are effective in reducing concurrent and ongoing emotional distress in children and family members, and in promoting child and family involvement and satisfaction with care.
46036352|NCT02808910|Behavioral|Nudged to eat more vegetables|
46036353|NCT02808910|Behavioral|Nudged to eat smaller portions|
45340941|NCT03640520|Device|Control|An online training module in which participants will receive information and policy education about national pediatric readiness standards for all EDs (including a brief mention of family-centered care as one of these standards), with no specific skills training in FCC. The module provides practice-relevant knowledge related to pediatric differences and pediatric readiness
46036354|NCT02808910|Behavioral|Nudged to eat less calorie-dense food|
46036355|NCT00688051|Other|My Life with CF game|Play the game My Life with CF
45340942|NCT03610646|Drug|MYL-1701P|"Subjects will receive intravitreal injections of MYL-1701P throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol."
45340943|NCT03610646|Drug|Eylea|"Subjects will receive intravitreal injections of Eylea throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol."
45340944|NCT04075448|Other|Control|100 grams breakfast cereal
45340945|NCT04075448|Other|50 g Walnut|50 grams walnuts mixed with 50 gram breakfast cereal.
46036356|NCT00688129|Behavioral|KITS Program|This is a 4-month psychosocial intervention for foster children entering kindergarten and their caregivers beginning the summer before kindergarten. The KITS intervention consists of: (a) child therapeutic play groups to facilitate the development of self-regulatory, social, and emergent literacy skills (2 times per week in summer, 1 times per week in the fall); (b) a bi-monthly psychoeducational support group to promote caregiver involvement in the child's emergent literacy and schooling and the use of effective parenting techniques; (c) home- and school-based behavioral consultation on an as needed basis.
45340946|NCT00434161|Drug|Palifermin before only|One bolus IV injection at 60 μg/kg/day, on Days 6, 5 & 4 days before-high dose chemotherapy and one bolus IV injection at 60 μg/kg/day of matched placebo on days 0, 1 & 2 days after-high dose chemotherapy. Minimum of 4 days between before-chemotherapy and after-transplantation dosing.
45340947|NCT00434161|Drug|Placebo|"One bolus IV injection at 60 μg/kg/day of matched placebo on Days 6, 5 & 4 (before-high dose chemotherapy) and on Days 0, 1 & 2 (after-high dose chemotherapy).~Minimum of 4 days between pre-chemotherapy and post-transplantation dosing."
46036357|NCT04117126|Behavioral|Prompted voiding|"Monitoring: This involves asking the incontinent individual, at regular intervals, if he or she needs to use the toilet. The care provider may look for behaviours that the client needs to be toileted (e.g., restlessness, agitation, disrobing), and take the client to the toilet at regular intervals specific to their schedule, rather than routinely every two hours.~Prompting: This process includes prompting the person to use the toilet at regular intervals, and encourages the maintenance of bladder control between prompted voiding sessions.~Praising: This important step is the positive reinforcement of dryness and appropriate toileting, and is the response from the care provider to the individual's success with maintaining bladder control."
46036358|NCT00688207|Drug|Rosiglitazone (Extended Release)|open-label, single, oral, 4mg dose
46036359|NCT02880462|Dietary Supplement|sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
46036360|NCT02880462|Other|placebo|Placebo is made of starch
46036361|NCT00688285|Other|automated clinical alerts|automated clinical alerts in the electronic medical record
46036362|NCT00688285|Other|provider education|PCP education session on CKD
46036363|NCT00688363|Procedure|weekly blood glucose profile|once daily self-control of urinary-glucose
46036364|NCT00688363|Procedure|three-monthly haemoglobin A1c|once daily self-control of urinary-glucose
45340948|NCT00434161|Drug|Palifermin before and after|"One bolus IV injection at 60 μg/kg/day, on Days 6, 5 & 4 (before-high dose chemotherapy) and on Days 0, 1 & 2 (after-high dose chemotherapy).~Minimum of 4 days between before-chemotherapy and after-transplantation dosing."
45340949|NCT00441103|Drug|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week for 40 weeks.
45473294|NCT01274273|Drug|Bevacizumab|Bevacizumab doses of 10 mg per kilogram of body weight, given every two weeks i.v. until disease progression, unacceptable toxicity, withdrawal of consent or a maximum of 1 year following obtaining no evidence of disease (NED).
45340950|NCT00441103|Drug|Placebo|Matching placebo will be administered subcutaneously three times a week for 16 weeks.
45340951|NCT00441103|Drug|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week from Week 17 to Week 40.
45473295|NCT03377920|Device|In-check Dial device (Clement Clarke International Ltd, Harlow, UK)|"pre-bronchodilator spirometry for the measurement of PIFspiro as per ERS/ATS guidelines for standard lung function5 (part of routine clinical follow-up).~5 forced inspiratory manoeuvres using the In-check Dial device G16, set at 5 different resistances (performed in order of increasing resistance), yielding the PIFresist values for the different DPI's"
45473296|NCT04058353|Drug|ELX/TEZ/IVA|FDC tablet for oral administration.
45473297|NCT04058353|Drug|IVA|Mono-tablet for oral administration.
46036365|NCT00688363|Procedure|no blood-glucose self-control|once daily self-control of urinary-glucose
46036366|NCT05575024|Device|oXiris membrane|Perform continuous renal replacement therapy with oXiris membrane
46036367|NCT05575024|Device|Polysulfone membrane|Perform continuous renal replacement therapy with polysulfone membrane
46036368|NCT02812654|Drug|Doxorubicin|Doxorubicin 75mg/m2 (cycle 1,2 and 3)
46036369|NCT02812654|Drug|Ifosfamide|Ifosfamide 9 g/m2 (cycle 1 and 3)
46036370|NCT02812654|Radiation|radiotherapy|radiotherapy: 25 Gy / 5 x 500 cGy/day
46036371|NCT02809066|Other|Sufficient dietary calcium intake in premenstrual syndrome|"Intervention group was ensured to take at least 1000 mg calcium from foods, 700-800 mg of it from dairy and dairy products, according to Recommended Dietary Allowances (RDA), for two months. These foods were;~50 gr kashkaval cheese,~400 ml milk and~150 gr yogurt for each day."
45340952|NCT01029613|Drug|Adalimumab|sc. inj. Humira 40 mg every other week from week 0 to 52
45340953|NCT03540212|Drug|Daclatasvir and sofosbuvir|"Daclatasvir is a DAAs that can inhibit the HCV non-structural (NS) 5A protein when used in combination with other HCV-therapies. It has a linear, non-time-dependent pharmacokinetic profile and nanomolar potency in vitro against HCV genotypes 1-6. It is excreted primarily via faeces, about 88% in an unchanged form while renal excretion accounts for approximately 7% of its elimination.~DOSE OF SOFOSBUVIR: 400 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2.~DOSE OF DACLTASVIR: 60 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2."
45340954|NCT03268057|Drug|VX15/2503 + avelumab|Dose escalation will begin at 5 mg/kg of VX15/2503 and will increase up to 20 mg/kg with a constant dose of avelumab at 10 mg/kg. A recommended phase II dose of VX15/2503 will be determined and then utilized in the expansion phase with 10 mg/kg of avelumab.
45473298|NCT04058353|Drug|TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
45473299|NCT01170455|Device|Macintosh laryngoscope|nasal intubation with macintosh laryngoscope after general anesthesia induction
45473300|NCT01170455|Device|Blind Intubation Device|nasal intubation using Blind Intubation Device after general anesthesia induction
45473301|NCT03226353|Device|somofilcon A|contact lens
46036372|NCT01097694|Drug|Imatinib mesylate|Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.
46036373|NCT01097694|Drug|Placebo|Placebo
46036374|NCT02808754|Procedure|Remote Ischemic Preconditioning|Those randomized to RIPC will undergo a standard protocol of 4 cycles of 5 minutes of forearm ischemia with 5 minutes of reperfusion requiring 35 minutes for an application. Forearm ischemia will be induced by a blood pressure cuff inflated to 200mmHg or at least 15mmHg higher than the systolic pressure if systolic > 185mmHg or until the radial pulse is obliterated. This can occur during anesthesia induction and incision/dissection prior to manipulation or clamping of the carotid.
46036375|NCT00688831|Drug|AZD1305|Solution for iv infusion , single dose
45473302|NCT03226353|Device|omafilcon A|contact lens
45340955|NCT03337100|Behavioral|Co-Dispensing|"Implementation of a naloxone co-dispensing pharmacy program.~The intent of this program is to provide patients prescribed chronic opioid therapy naloxone under the terms of a standing order for potential opioid overdose reversal. Prior to implementing the program, a naloxone standing order will be implemented and pharmacy operational staff will provide training to pharmacy staff about the standing order and a naloxone co-dispensing protocol. Under a co-dispensing protocol, pharmacy staff members will identify opioid prescriptions meeting criteria for co-dispensing, prepare naloxone fills, offer patients naloxone, and provide counseling on its use."
46036376|NCT00688831|Drug|Placebo|NaCl solution for iv infusion, single dose
45340956|NCT01033903|Drug|misoprostol|800 micrograms intravaginally ONCE
45340957|NCT03331094|Procedure|Surgery with graft|arthrodesis with autologous bone graft and using pedicular ilio-sacred EUROS ® screw
45340958|NCT03331094|Procedure|surgery without graft|arthrodesis without bone graft using pedicular ilio-sacred EUROS ® screw
45473303|NCT01274507|Other|Medical tests|All participants will undergo medical tests and will be observed.
45473304|NCT02730598|Device|Hybrid Training System (HTS)|Electrodes (15 cm x 6 cm) will be placed over the quadriceps and electrodes (11 cm x 6 cm) (Sekisui Plastics Co., Tokyo, Japan) will be placed over the hamstrings. Electrical stimulation parameters will be based on a standard Russian waveform in which a 5,000 Hz carrier frequency is modulated at 40 Hz (2.4 ms on, 22.6 ms off) to deliver a rectangular voltage biphasic pulse. Acceleration sensors as a joint motion sensor (EWTS9PD, Home Appliances Development Center Corporate Engineering Division, Appliances Company Panasonic Corporation 2-3-1-2 Noji-higashi,Kusatsu City, Shiga, Japan) is placed on the front of each leg 88mm above the patellar edge. It analyzes the algorithm of each exercise pattern, and stimulates the antagonist of the motion of each bilateral knee joint during exercise. Electrical stimulation intensity will be set to ~50-60% of 1RM based on the subject's tolerance. The subject's tolerance gradually increases, and electrical stimulation intensity is reset every 2 weeks.
45473305|NCT02730598|Device|Sensory TENS|The electrical stimulation intensity will be set under the muscle contraction threshold (but at a level at which the subject can perceive as sensory TENS). Electrical stimulation parameters (i.e. waveform and pulse duration) will be the same of HTS, while the amplitude will be lower. The subject will be stimulated using the same device as for HTS.
45473306|NCT04874415|Behavioral|1RLD|1RLD=One text per day, ramped goal, loss incentive, daily goal time period
45473307|NCT04874415|Behavioral|1RLW|1RLW=One text per day, ramped goal, loss incentive, weekly goal time period.
45473308|NCT04874415|Behavioral|1RGD|1RGD=One text per day, ramped goal, gain incentive, daily goal time period.
45473309|NCT04874415|Behavioral|1RGW|One text per day, ramped goal, gain incentive, weekly goal time period.
45473310|NCT04874415|Behavioral|2RLD|Two texts per day, ramped goal, loss incentive, daily goal time period.
45473311|NCT04874415|Behavioral|2RLW|Two texts per day, ramped goal, loss incentive, weekly goal time period.
46036377|NCT02808832|Behavioral|Educational materials|5-minute video and information sheet with a list of suggested questions to ask the provider
46036378|NCT00688987|Drug|Hydrocortisone|Subjects will receive in random order daily (split) dosing of hydrocortisone: a low dose of 15 mg (10 in AM, 5 in PM); a medium dose of 25 mg (15 in AM, 10 in PM) and high dose of 40 mg (30 in AM, 10 in PM) for 4 months.
45340959|NCT03329924|Other|Activity level measurement by accelerometer|Eligible patients will wear an accelerometer to measure activity levels while in the ICU.
46036379|NCT00688987|Dietary Supplement|Isocaloric Diet|Subjects will eat an isocaloric diet for 4 weeks while taking hydrocortisone
45473312|NCT04874415|Behavioral|2RGD|Two texts per day, ramped goal, gain incentive, daily goal time period.
45473313|NCT04874415|Behavioral|2RGW|Two texts per day, ramped goal, gain incentive, weekly goal time period.
45473314|NCT04874415|Behavioral|1FLD|One text per day, fixed goal, loss incentive, daily weekly goal time period.
45473315|NCT04874415|Behavioral|1FLW|One text per day, fixed goal, loss incentive, weekly goal time period.
45473316|NCT04874415|Behavioral|1FGD|One text per day, fixed goal, gain incentive, daily goal time period.
45473317|NCT04874415|Behavioral|1FGW|One text per day, fixed goal, gain incentive, weekly goal time period.
46036380|NCT02808676|Dietary Supplement|Vitamin D3|Dose: 10000 IU, three times per week, orally.
45340960|NCT00433771|Device|WallFlex™ Biliary Fully Covered Metal Stent placement|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is fully covered with a polymer to reduce the potential for tumor ingrowth into the stent.
45473318|NCT04874415|Behavioral|2FLD|Two texts per day, fixed goal, loss incentive, daily goal time period.
46036381|NCT02808676|Other|Exercises (E)|All participants will complete three (3) group training sessions per week (total 20 weeks), under the supervision of trainers. Each exercise session will last approximately 60 minutes and will happen after the cognitive training/control (CT cCT) session. The exercise session will be a combined aerobic and progressive strengthening exercise. Within each small group of four to eight individuals, participants follow the program tailored to their individual functioning level, with constant monitoring by the trainers. Participants are expected to attend all training sessions and research staff will strongly encourage them to do so.
45473319|NCT04874415|Behavioral|2FLW|Two texts per day, fixed goal, loss incentive, weekly goal time period.
45473320|NCT04874415|Behavioral|2FGD|Two texts per day, fixed goal, gain incentive, daily goal time period.
45473321|NCT04874415|Behavioral|2FGW|Two texts per day, fixed goal, gain incentive, weekly goal time period.
45473322|NCT01167725|Biological|bevacizumab|Given IV
45473323|NCT01167725|Biological|cetuximab|Given IV
45473324|NCT01167725|Drug|FOLFIRI regimen|Given IV
45473325|NCT01167725|Drug|FOLFOX regimen|Given IV
45473326|NCT01167725|Drug|capecitabine|Given IV
45340961|NCT03281954|Drug|Placebo|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + placebo IV Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ placebo IV Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by placebo IV Day 1 every 3 weeks after surgery until 1 year after the first dose."
45473327|NCT01167725|Drug|fluorouracil|Given IV
46036382|NCT02808676|Other|Cognitive Training (CT)|CT intervention will involve computer-based multimodal and multi-domain dual-task training with memory load. A custom-written program, developed for neuro-rehabilitation and used in previous research trials for cognitive and mobility outcomes will be used. Training sessions will take place in groups of four to eight participants before each of the fitness-training session for duration of 30 min max. Participants will perform a concurrent visuo-motor task (dual-task combination) composed of different sets of visual stimuli that have to be identified by tapping designated figures on an digital tablet (IOS or Android system). Participants will perform discrimination tasks involving sets of items (e.g. letters, numbers, animals, vehicles, fruits, celestial bodies).
46036383|NCT02808676|Other|placebo D3|matching placebo for Vitamin D3
46036384|NCT02808676|Other|control cognitive training|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 30 min computer skills training.
46036385|NCT02808676|Other|Placebo exercise|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 60 min of a tone exercise regimen
46036386|NCT04138459|Other|Not an interventional study. This is a qualitative, explorative study of recovery orientation of community mental health services|"Explore recovery orientation of mental health services in a municipality through:~Qualitative, in-depth interviews with service users and mental health professionals and~Observational fieldwork"
45473328|NCT01167725|Drug|irinotecan hydrochloride|Given IV
45473329|NCT01167725|Drug|leucovorin calcium|Given IV
45473330|NCT01167725|Drug|mitomycin C|Given intraperitoneally
45473331|NCT01167725|Drug|oxaliplatin|Given IV
45473332|NCT01167725|Procedure|therapeutic conventional surgery|Patients undergo cytoreductive surgery
46036387|NCT02878746|Device|Robotic mirror therapy|2-dimensional
46036388|NCT02878746|Device|Conventional mirror therapy|2- and 3-dimensional
46036389|NCT00683371|Procedure|Specimen collection|10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
46036390|NCT00683371|Procedure|Specimen collection|10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
45473333|NCT03815695|Drug|FT-4202/Placebo|Healthy volunteer subjects will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
45473334|NCT03815695|Drug|FT-4202|Healthy volunteer subjects will receive FT-4202 with or without food and undergo pharmacokinetic studies
45473335|NCT03815695|Drug|FT-4202/Placebo|SCD subjects will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
45473336|NCT03815695|Drug|FT-4202|SCD subjects will receive FT-4202 and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
45473337|NCT04446130|Drug|Decitabine combined with HAAG Regimen|Decitabine :20mg/m2/d,d1~5, intravenous infusion; Homoharringtonine :1mg/d,d3~16,intravenous infusion; Aclarubicin :10mg/d, d3~d10, intravenous infusion; Cytarabine :10mg/m2,q12h,d3-16, subcutaneous injection; Granulocyte colony-stimulating factor (G-CSF): 50-300μg/d (when WBC counts are less than 20×10^9/L ),subcutaneous injection
45473338|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
45473339|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
46036391|NCT04308798|Procedure|Surgical glove changing|Changing surgical glove after draping and before cementation during total knee arthroplasty
46036392|NCT04138693|Device|G-PUR® 2x 2.0 g oral suspension|Cohort 1: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before and immediately after 204Pb intake
46036393|NCT04138693|Device|G-PUR® 1x 2.0 g oral suspension|Cohort 2: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before 204Pb intake and 100 ml water (placebo) in an opaque drinking bottle immediately after 204Pb intake
45473340|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
45473341|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
45473342|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
45473343|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
45340962|NCT03281954|Drug|Atezolizumab|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + Atezolizumab 1200 mg Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ Atezolizumab 1200 mg Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by Atezolizumab 1200 mg Day 1 every 3 weeks after surgery until 1 year after the first dose."
45340963|NCT03922256|Other|molded brace|The moldable brace utilized in the current study will be pre-fabricated and of the short-arm brace variety , which is primarily indicated for non-displaced fractures of the distal radius or distal ulna. The braces are available in multiple sizes for both right and left hands.
45340964|NCT00433537|Drug|bortezomib|Given IV
46036394|NCT04138693|Device|Placebo oral suspension|Cohort 3: 100 ml of water in an opaque drinking bottle will be orally administered immediately before and after 204Pb intake
46036395|NCT05001282|Drug|ELU001|Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
45340965|NCT00433537|Biological|rituximab|Given IV
46036396|NCT02812498|Other|Teleconsultation|The patients in the consultation group arranged their bookings on a website, where they could also access to web educational courses or to nutritional and psychological counselling
46036397|NCT02812498|Other|Standard|Group of patients followed in a traditional way
46036398|NCT00689065|Drug|CALAA-01|Subjects with solid tumors who satisfy the eligibility criteria will receive two, 21-day cycles of CALAA-01. A cycle will consist of four (4) 30-minute intravenous infusions administered on days 1, 3, 8, and 10 followed by 11 days of rest. If safe, a second 21-day cycle will be administered consisting of infusions on days 22, 24, 29 and 31 followed by 11 days of rest.
46036399|NCT00690937|Drug|Enteric coated sevelamer|Drug treatment
45340966|NCT00433537|Drug|cyclophosphamide|Given IV
45340967|NCT00433537|Drug|doxorubicin hydrochloride|Given IV
45340968|NCT00433537|Drug|vincristine|Given IV
45340969|NCT00433537|Drug|dexamethasone|Given IV
45340970|NCT00433537|Biological|filgrastim|Given SC
45340971|NCT00433537|Biological|pegfilgrastim|Given SC
45340972|NCT00433537|Procedure|Autologous stem cell transplantation (ASCT)|
45340973|NCT05673902|Biological|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
45340974|NCT03935282|Other|AH-HA Tool in the EPIC EHR|The Automated Heart-Health Assessment tool implemented in clinics' EPIC EHR will be used by providers during routine follow-up care appointments.
45340975|NCT02580110|Other|Sucrose|
45340976|NCT02580110|Other|Stevia glycosides|
45340977|NCT02580110|Other|saccharin|
46036400|NCT00690937|Drug|Enteric coated sevelamer|Drug treatment
46036401|NCT00690937|Drug|Colesevelam Cholestagel|Drug comparator
46036402|NCT00690937|Drug|Placebo|Placebo
46036403|NCT00690937|Drug|Placebo|Placebo
45473344|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule immediately after breakfast; correspondingly, one dose of a matched powder-in-capsule placebo will be administered immediately after breakfast.
45473345|NCT03226275|Drug|Bisoprolol-Amlodipine FDC|Participants received a single oral dose of 5 milligram(mg)/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) either on Day 1 or Day 15 under fasting or fed conditions.
45340978|NCT00570765|Drug|Placebo|Matching placebo tablets were administered orally once daily.
46036404|NCT01102140|Drug|POMx, pomegranate polyphenol extract|1000 mg orally once daily.
45473346|NCT03226275|Drug|Bisoprolol|Participants received 5 mg bisoprolol tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.
46036405|NCT01102140|Drug|Sugar Pill|Matching sugar pill
46036406|NCT02690116|Other|Qigong/Tai Chi Easy|Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 8 weeks, with a recommended home practice time of 2 1/2 hours each week.
45340979|NCT00570765|Drug|Obeticholic Acid (OCA)|Starting dose of 10 or 50 mg administered orally once daily, followed by dose titration planned from 10 mg to 25 mg to 50 mg once daily, which could be modified for safety and tolerability issues or to achieve adequate therapeutic response.
45340980|NCT00777621|Other|Calorie Restriction|This group will undergo a 20% reduction in energy intake without any change in energy expenditure.
45340981|NCT00777621|Other|Exercise|This group will undergo a 20% increase in energy expenditure by exercising without any change in energy intake.
45340982|NCT00777621|Other|Calorie Restriction and Exercise|This group will undergo 10% reduction in energy intake and a 10% increase in energy expenditure via exercise.
45340983|NCT00777699|Drug|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; daily dosing
45340984|NCT00777699|Drug|erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
45340985|NCT00667563|Biological|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
45473347|NCT03226275|Drug|Amlodipine|Participants received 5 mg amlodipine tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.
45473348|NCT04189081|Device|dry mouth rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
45340986|NCT00667563|Genetic|DNA analysis|Weeks 0, 2, 10, 26, and 52.
45473349|NCT04189081|Other|Water Control|negative control
45473350|NCT03382756|Dietary Supplement|High fat diet|A diet consisting of more than 900kcal and 35% of fat
45473351|NCT03382756|Drug|CKD-337|Test Drug
46036407|NCT02690116|Other|Sham Qigong|Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 8 weeks, with a recommended home practice time of 2 1/2 hours each week.
46036408|NCT02690116|Other|Educational Support|Class times and at-home readings correspond to dose set for the QG/TCE and SQG class times and home practice. Participants will attend one 60-minute class per week for the 8 weeks, with a recommended home practice time (reading, workbook completion) of 2 1/2 hours each week.
46036409|NCT00689143|Drug|sargramostim|
46036410|NCT02812810|Device|active rTMS|
46036411|NCT02812810|Device|sham rTMS|
45473352|NCT01274819|Other|Dynamic Light|Dynamic Light Application (DLA) is a light application which exposes the subject in the room to a varying light intensity and light temperature during the day thus mimicking a natural daylight exposure.
45473353|NCT04187989|Behavioral|Social Media Intervention|Information will be posted by e-coaches. You can interact with the e-coaches as well as other study members in your group.
45473354|NCT03868553|Other|No intervention|observational study
45340987|NCT00667563|Genetic|polymerase chain reaction|Screening, week 36, and week 52.
45340988|NCT00667563|Other|cytology specimen collection procedure|Screening, week 36, and week 52.
45340989|NCT00667563|Procedure|colposcopic biopsy|Screening, week 36, and week 52.
45340990|NCT00777777|Device|eSVS, saphenous vein supporting mesh|Surgical coronary artery bypass grafting to the right coronary artery and the circumflex coronary artery with saphenous vein grafts, one will be supported by the eSVS(TM).
45340991|NCT00780819|Device|PoleStar N20 intraoperative MRI|low field strength mobile intraoperative MRI system (0,15 Tesla) with local Faraday shielding (using the StarShield system)
45340992|NCT05118477|Device|Ambulatory monitoring system|Patients will use AMS.
45340993|NCT05118477|Device|Active alerting system|Clinical staff alerted if AMS detects deterioration
45340994|NCT00667095|Drug|Botox Instillation|Botox instilled into the bladder via ureteral catheter and retained for up to 30 minutes then spontaneously voided.
45340995|NCT00667095|Drug|DMSO Instillation|DMSO 50% w/w aqueous solution; 50 cubic centimeters instilled into the bladder via ureteral catheter and retained up to 30 minutes then spontaneously voided.
45473355|NCT01170611|Device|PACEMAKER SYMPHONY 2550|
45473356|NCT01166087|Drug|Fluoxetine Hydrochloride|Fluoxetine Hydrocloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories.
45340996|NCT00777933|Drug|tacrolimus|
45340997|NCT00777933|Drug|cyclosporine|
45473357|NCT01170767|Drug|Avastin|Intravitreal injection of bevacizumab at a concentration of 1.25 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
45473358|NCT01170767|Drug|Lucentis|Intravitreal injection of ranibizumab at a concentration of 0.50 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
45340998|NCT00773331|Drug|epoetin beta|As prescribed
45340999|NCT00773331|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms every 4 weeks
45341000|NCT00778011|Drug|Ondansetron|dosage
45341001|NCT00778011|Drug|Ondansetron|4 mg
45341002|NCT00778011|Drug|Metoclopramide|10 mg IV
45473359|NCT01170845|Drug|sivelestat sodium hydrate|saline or sivelestat sodium hydrate intravenously for 7 days starting the beginning of surgery
46036412|NCT02879370|Procedure|Transanal Inspection and management of low ColoRectal Anastomosis|Low anterior resection with total mesorectal excision (TME), either performed open, laparoscopic or robotic Closure of the rectum with linear or curved stapler with transanal inspection Transanal placement of four 2-0 prolene sutures on the rectal stump, respectively 2 at the extremities of the suture line (left and right) and other two 1 cm medial to each of the previous two sutures Circular stapler is introduced, the 4 tails of the prolene stitches are introduced through the windows (2 in the left and 2 in the right side of the instrument) and gently pulled, to obtain a gradual and homogeneous traction of the tissue and elimination of both previous suture lines and doggy ears, then the stapler is fired The termino-terminal anastomosis is carefully inspected A leak test can be performed (if negative the protective stoma is not performed) An eventual leak can be transanally repaired
45473360|NCT01150890|Biological|Brodalumab|Administered as as an intravenous (IV) infusion over at least 30 minutes.
46036413|NCT04139239|Diagnostic Test|Coma Recovery Scale-revision|Patients were assessed by Coma Recovery Scale-revision to detect the DOC patients enrolled by clinicians.
46036414|NCT02808442|Biological|UCART19|
46036415|NCT00683527|Drug|Elemental iron|Iron in the dose of 3-4 mg/kg/day (of elemental iron) PO once daily mixed with expressed breast milk from 14 days of life till the end of study period
46036416|NCT02808598|Behavioral|Breast Cancer Clinical Trials Education Program|The purpose of this study is to test a program designed to increase African American and Hispanic American women's scientific literacy, knowledge of clinical trials, and to facilitate breast cancer clinical trial participation.
46036417|NCT00634426|Procedure|Surgical excision of the metastatic process|Surgical excision of the metastatic process
45341003|NCT02556021|Drug|CJ-12420 50mg|CJ-12420 50mg, tablet, once daily, oral administration for up to 4 weeks
45341004|NCT02556021|Drug|CJ-12420 100mg|CJ-12420 100mg, tablet, once daily, oral administration for up to 4 weeks
45341005|NCT02556021|Drug|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
45341006|NCT00778089|Device|ArteFill® Skin Test|Subjects will receive the ArteFill® Skin Test at Visit 1, Day 0 on the volar forearm. After 30 days, if the test result is negative a second skin test will be administered on the contra volar forearm at Visit, 3, Day 30.
45341007|NCT00773487|Other|Bonchoscopy|Segmental instillation of allergen/Diesel particles; bronchoalveolar lavage
45341008|NCT00433381|Biological|Bevacizumab|Given IV
45341009|NCT00433381|Drug|Irinotecan Hydrochloride|Given IV
45341010|NCT00433381|Drug|Temozolomide|Given orally
45341011|NCT00781053|Drug|P144 cream|P144 cream 0.03% will be used once a day during the whole extension period of 6 months. The patient will apply the cream by him/herself or with a help of a person uniformly in a 10% maximum affected surface until absorption
45473361|NCT01150890|Drug|Placebo|Administered as as an intravenous (IV) infusion over at least 30 minutes.
46036418|NCT00634426|Radiation|Radiotherapy of the metastatic spine process|Standard of care radiotherapy for patients with metastatic epidural spinal cord compression.
46036419|NCT00683683|Behavioral|Knowledge Translation|The multifaceted KT strategy will include 1) local multidisciplinary champions in ED, ICU, and Cardiology 2) A simple protocol for application of hypothermia, tailored to local needs and policy; 3) Identification of perceived and actual barriers to knowledge use; 4) Development of an implementation tool kit and 5) Providing timely feedback on benchmarks for hypothermia and outcomes.
45341012|NCT00773565|Dietary Supplement|Optifast|Formula diet for twelve weeks combined with physical activity and behavioral therapy
45341013|NCT00667017|Biological|RFT5-dgA immunotoxin|
45341014|NCT00667017|Other|fluorescence activated cell sorting|
45341015|NCT00667017|Other|immunohistochemistry staining method|
45341016|NCT00781131|Drug|Pregabalin|pregabalin 75 or 150 mg
45341017|NCT00781131|Drug|Placebo|lactulose placebo
45341018|NCT00778245|Drug|cefprozil 500mg tablets|
45341019|NCT00778323|Procedure|limb remote ischemic preconditioning (LRIPC)|LRIPC consists of three 5-min cycles of right upper limb ischemia induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mmHg,with an intervening 5 min reperfusion during which the cuff is deflated.
45341020|NCT00778401|Drug|Gabapentin tablets 800 mg|
45341021|NCT00773643|Other|biopsy|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
45473362|NCT04057573|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
45473363|NCT04057573|Drug|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
45473364|NCT01167803|Drug|Desflurane|Patients undergo anesthesia using remifentanil associated with desflurane
45473365|NCT01167803|Drug|Xenon|Patients undergo anesthesia using remifentanil associated with xenon
45473366|NCT01167959|Procedure|Roux en Y gastric bypass and lap. gastric banding|Standard RYGB and LAGB procedures
45341022|NCT00773721|Device|CPAP mask|"Current CPAP masks are mainly silicone elastomers, which though well understood and accepted, are often uncomfortable.~Test Units: The test unit is a foam seal component which directly replaces the patients existing silicone mask cushion, and is fitted to the patients existing mask frame.~Subjects will wear the test unit mask, instead of their current CPAP mask, each night whilst sleeping."
45473367|NCT01167959|Behavioral|Prodimed dietary intervention|3 months of using the prodimed diet
45473368|NCT01168037|Device|Endovascular aortic repair with branched/fenestrated stent-graft|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
45473369|NCT01168037|Procedure|Open Surgical Repair|aortic replacement with revascularization of visceral arteries
45473370|NCT01275521|Drug|BONT-A intra-prostatic injection|"• Intra prostatic injection of 200 IU of BONT-A (2 x 100 IU to dilute in 10 cc salted serum), divided into 4 injections, 2 in each prostate lobe for a volume intra injected 2.5 cc per site.~Interruption of the medical therapy 1 month after the injection;"
45473371|NCT01275521|Drug|Optimized medical BPH treatment|Optimization of the medical therapy according to recent guidelines
45341023|NCT00778479|Device|Sepraspray|Max. 10g of Sepraspray
45473372|NCT01275911|Drug|Esmolol|Induction of anesthesia: 1mg/Kg; Maintenance during surgery: 5-15 mcg/kg/min
45473373|NCT01275911|Drug|Remifentanil|At the induction of anesthesia: 1mcg/Kg; Maintenance during surgery: 0.025-0.25mcg/kg/min
45473374|NCT01170923|Device|FDR-PET|FDR-PET performed after 1 cycle of chemotherapy
45473375|NCT01170923|Device|CT|CT performed after 3 cycles of chemotherapy
46036420|NCT00683761|Drug|131I-TM601|In the first study phase (Dose Escalation), patients will be assigned to treatment to between 2-5 doses of 131I-TM601 treatment at a treatment dose of 1.2 mCi/kg of lean body mass (in scaled dosing, this will amount to 0.024 mg TM601 peptide/kg of lean body mass), once weekly (for between 2-5 weeks, depending upon dose cohort). The maximum amount of administered radioactivity per infusion is 100 mCi.
45341024|NCT00666705|Drug|Maraviroc|300 milligrams(mg) every 12 hours Days 6-11
45473376|NCT04054765|Device|videogame|Invite Only VR videogame
45473377|NCT04054765|Other|treatment as usual|treatment as usual
45473378|NCT01166165|Drug|Cholecalciferol|3 tablets of 1000 IU daily for 20 weeks
45473379|NCT01166165|Drug|Placebo|3 placebo tablets daily for 20 weeks
45341025|NCT00666705|Drug|Maraviroc|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
45473380|NCT04017793|Behavioral|Mindfulness Based Stress Reduction|Structured 8-week training program teaching about increased mindfulness strategies and gentle stretching.
45473381|NCT04017793|Behavioral|Relaxation Group|8-weekly group discussion meetings reviewing relaxation techniques and other stress reduction strategies with an emphasis on social support.
45473382|NCT01168193|Other|No intervention|
45473383|NCT03873155|Behavioral|Mindfulness Based Cognitive Therapy|Mindfulness based cognitive group therapy (MBCT) is a structured eight-week programme (although an extra introductory week will be added in the current study) that combines mindfulness-based exercises with cognitive therapy.
45839953|NCT05248464|Other|The Patient Dignity Inventory instrument (PDI)|The PDI is an instrument made up of 25 items integrated into 5 factors that include: symptoms, existential anguish, dependency, peace of mind, and social support, prior to its application, adaptation, and validation will performer
46036421|NCT02812732|Behavioral|DOSE HPV|"The primary goals of the DOSE HPV intervention are to 1) change clinician HPV vaccine recommendations and responses to hesitant parents, and 2) support systems changes to improve the vaccination process. The first four sessions follow a standardized curriculum, while the last three sessions include development and implementation of tailored activities designed to meet individual practice needs.~Sessions 1 and 2 generate motivation for the project through feedback of vaccination rates (Session 1) and education on HPV disease (Session 2). Brief Negotiated Interview (BNI) skills are taught in Sessions 3&4. Action Plans are developed in Session 5. Sessions 6&7, which follow a standard quality improvement format: plan-do-study-act (PDSA) cycles."
46036422|NCT00912457|Drug|donepezil|donepezil 5 mg/day for 14 days followed by donepezil 10 mg/day for 14 days
46036423|NCT00912457|Drug|placebo|placebo 1 p/day for 28 days
46036424|NCT02808286|Behavioral|Hybrid|The hybrid emotion-focused treatment integrates procedures from exposure and dialectical behavior therapy (DBT) with a clear uniting conceptualization focused on targeting underlying processes that maintain co-occurring chronic pain and emotional problems.
46036425|NCT02808286|Behavioral|internet Cognitive Behavior Therapy (iCBT)|A state-of-the-art CBT pain treatment, delivered via the internet.
45839954|NCT05248464|Other|WHOQOL-BREF (quality of life) instrument|The WHOQOL-BREF is a self-report questionnaire which assesses 4 domains of quality of life (QOL): physical health, psychological health, social relationships, and environment, it consists of 24 items.
46036426|NCT04139161|Procedure|Q-Factor Intervention|The intervention period will consist of 12 training sessions across four consecutive weeks, with three training sessions held per week. If pain is not increased or reduced and Rating of Perceived Exertion is ≤12, the participant will progress to the next bout. If pain is increased from the pre-bout pain score, participants will repeat the bout, at the same workrate and Q-Factor settings. Following this fashion, participants will progress through three increasing Q-Factors for each given workrate; Q-Factor 1 (Q1, 192mm), Q2 (234mm), Q3 (276mm). After completing bouts of all three Q-Factors for a given workrate, workrate will be increased by 20 Watts and bouts at each Q-Factor will be repeated. For each training session, participants will complete bouts of cycling until 1) the maximum number of bouts (4 bouts) has been accomplished, 2) self-reported Rating of Perceived Exertion >12, indicating a transition to moderate physical activity, or 3) self-reported pain >5.
46036427|NCT04093492|Other|Preemie Prep for Parents (P3) Outpatient Mobile Intervention|The P3 mobile intervention sends participants text messages according to a schedule based on their gestational age. These text messages contain links to short videos uploaded to the P3 site, focusing on topics related to preterm labor and premature infants.
45473384|NCT04179721|Behavioral|PES-4-BPSD Model|"Staff Training: Dementia Care Education and Training. The PI, with the support of the research team, will spend 12 weeks training the PES/NA staff. Based on the Try This: Best Practices in Nursing Care for Persons with Dementia, the PES staff will receive weekly 20 minute sessions. This study aims to capture the impact of dementia care training on the experience of PES (intervention unit) and NA (control unit) staff to care for patients with dementia. Measures will be completed at baseline, prior to dementia training (T1: baseline), immediately after completion of the training program (T2: 3 months post-baseline) and following the completion of the 1-year intervention period (T3: 12 months post-training)."
45839955|NCT05213910|Dietary Supplement|Lactichoc|dosage form: mix of 8 strains containing 1.2x10^11 CFU frequency, and duration: 2 capsules/day during 10 days
45839956|NCT05213910|Other|Stool sampling|3 stool samples are taken during the study (D0, D10 and D30)
46036428|NCT04093492|Other|ACOG links|Participants in the active control condition will receive links to patient education handouts about preterm birth provided by the American College of Obstetricians and Gynecologists.
46036429|NCT04139083|Procedure|LSC mesh suspension|Long mesh, a synthetic T-shaped mesh (Gynemsh, Ethicon, San Lorenzo, Puerto Rico), is delivered into the pelvic cavity. Bilateral mesh arms are extracted outside trocar wounds bilaterally to stabilize mesh position. The center piece is fixed to the cervix with 5mm ProTack screws (Covidien, New Haven, Connecticut). Fixation is strengthened with Stratafix 2-0 sutures (Ethicon, Norderstedt, Germany), followed by Tisseel fibrin sealant (Baxter, Deerfield, Illinois) for better hemostasis among surrounding tissues. An extraperitoneal tunnel is created along the left round ligament until reaching 2cm medial to the anterior superior iliac spine (ASIS). One arm of the long mesh is pulled out along the tunnel underneath round ligament and fixed with the fascia of oblique abdominis. The same procedure is repeated for the contralateral side. Bilateral round ligaments and the mesh arms are sutured continuously with Stratafix 2-0.
46036430|NCT04139083|Procedure|TVM|Transvaginal mesh kit is delivered into the pelvis via vagina route.
46036431|NCT04200586|Drug|Dapagliflozin|Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground.
46036432|NCT02807974|Drug|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally
45473385|NCT04179721|Behavioral|The attention control condition|"Staff Training: Dementia Care Education and Training. The PI, with the support of the research team, will spend 12 weeks to train the PES/NA staff. Based on the Try This: Best Practices in Nursing Care for Persons with Dementia, the PES staff will receive weekly 20 minute sessions. This study aims to capture the impact of dementia care training on the experience of PES (intervention unit) and NA (control unit) staff to care for patients with dementia. Measures will be completed at baseline, prior to dementia training (T1: baseline), immediately after completion of the training program (T2: 3 months post-baseline) and following the completion of the 1-year intervention period (T3: 12 months post-training)."
45341026|NCT00666705|Drug|Raltegravir|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
45341027|NCT00666705|Drug|Raltegravir|400 milligrams(mg) every 12 hours Days 1-3 Followed by washout Days 4-5
45341028|NCT00433147|Drug|Afegostat tartrate|
45341029|NCT04047849|Drug|Antibiotics, oral Azithromycin and oral Amoxicillin|Azithromycin (500mg day one followed by 250mg per day for 4 more days) and amoxicillin (500mg orally three times daily for 7 days) for a total course of seven days of antibiotic therapy
45473386|NCT01171079|Device|application of oxidized regenerated cellulose|
45341030|NCT04047381|Other|Measurement of Quality of Life|Quality of life will be measured using Atrial Fibrillation Impact Questionnaire, Short Form-36 and Pittsburgh Sleep Quality Index
45473387|NCT03286218|Drug|Lasmiditan|Administered orally
45473388|NCT03286218|Drug|Alprazolam|Administered orally
45473389|NCT03286218|Drug|Placebo|Administered orally
45839957|NCT05201196|Other|Conventional physical therapy|Targeted muscle stretching and Strengthening (flexors, Extensors, abductors, internal and external rotators, of Shoulder, Elbow, forearm (supination & pronation) and hand 10 repetitions×1 set, 4 days/ week. Transcutaneous Electrical nerve Stimulation for 10-20 min, 4 days/ week. Total of 16 sessions were given each consisting of 45 mins.
46036433|NCT02807818|Behavioral|Home visiting Program for Young Pregnant Women|
45341031|NCT04047927|Device|EpiFinder|The EpiFinder is a sensing device intended to assist physicians performing placement of epidural needle analgesic and/or anesthesia injection in a safely and accurately manner. The device is a single use sterile device consisting of a probe (Stylet), an actuator (micro DC motor), IR sensor and Controller. The device is integrated to a standard LOR Syringe and an 18G Tuohy needle and enables to simultaneously work with the standard LOR technique.
45341032|NCT00778557|Drug|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
45341033|NCT00774033|Device|autologous epidermal cells harvesting kits|autologous epidermal cells harvesting kits used for the treatment of acute burn
45341034|NCT00774033|Procedure|classic skin grafts|classic skin grafts used for the treatment of acute burn
45341035|NCT02556567|Other|Fitbit® Charge Heart Rate (HR) wristband|The Investigators will conduct a proof of concept and feasibility study to explore associations between asthma symptoms and sleep patterns and physical activity over an 8-week intervention period among 20 adolescent patients with persistent asthma.
45341036|NCT00778713|Drug|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
45341037|NCT00781209|Procedure|Irradiation plus Stereotactic Radiosurgery|"Posterior Fossa Irradiation-total dose of 37.5 Gy in 2.5 Gy fractions administered via conformal beams.~Radiosurgical boost-total dose administered to each lesion will be titrated to the size of the metastatic focus as follows:~Maximum Tumor Diameter:<2.0 cm; Assigned Dose:24 Gy. Maximum Tumor Diameter:2.1-3.0 cm;Assigned Dose:18 Gy. Maximum Tumor Diameter:3.1-4.0 cm;Assigned Dose:15 Gy."
45473390|NCT01171157|Other|Routine sample collection|Collection of routine nasal/throat swab samples
45473391|NCT03745261|Drug|Salbutamol (Ventolin®)|According to the revised 2017 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol will be used to Group A patients: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
45473392|NCT03745261|Drug|Tiotropium Bromide (Spiriva®)|Tiotropium Bromide Powder for Inhalation will be used to Group B and Group C patients: Tiotropium Bromide Powder for Inhalation(Spiriva®, Boehringer Ingelheim), 18μg/ capsule, 10 capsules. 18μg each time, once daily.
45473393|NCT03745261|Drug|Salmeterol / fluticasone (Seretide®)|Salmeterol / fluticasone will be used to Group D patients: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/250 μg / dose, 60 inhalations. 50/250 μg each time, twice daily.
46036434|NCT04120168|Genetic|Laboratory Tests|"Acid Alpha IgGlucosidase alpha enzyme test for Late Onset Pompe Disease and gene sequencing test from the same sample in samples with low enzyme activity~Genetic Analysis for DMD (only in boys): Detection of dystrophin gene for duplication and deletion with MLPA (Multiplex-ligation dependent probe amplification) and re-screening for other mutations by gene sequencing in patients without MLPA deletion / duplication."
46036435|NCT00874549|Biological|Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
46036436|NCT00874549|Biological|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
46036437|NCT00874549|Biological|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL. Intramuscular
46036438|NCT00874549|Biological|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
46036439|NCT04116814|Diagnostic Test|wall-to-lumen ratio measurement|wall-to-lumen ratio measurement in patients with renal insufficiency
46036440|NCT02807740|Other|Virtual reality|Each session will consist of multiple exercises. These ones are already described, each exercise will be performed by the patient for 4 minutes followed by a 1 minute of rest.
45341038|NCT00781287|Drug|3-drug anti-HIV therapy|3 FDA-approved drugs, including two nucleos(t)ide reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor (Low dose ritonavir can be used to enhance the protease inhibitor and is not considered one of the 3 anti-HIV drugs)
45341039|NCT00781287|Drug|Raltegravir|400 mg BID PO
46036441|NCT02807740|Other|Conventional rehabilitation program|In each C rehabilitation session, patients underwent 3 phases: 1) Warm-up phase: passive mobilization of main joints and muscular strengthen of lower limbs; 2) Active phase (both standing than seated): exercises of motor coordination with upper and lower limbs, balance training, start and stop exercises, deambulation training; 3) cool-down phase (with seated patient): manipulation exercises, mobilization exercises, respiratory exercises.
46036442|NCT02812108|Device|intracranial stent, flow diverter and coils|
45341040|NCT00774111|Drug|GSK1349572|GSK1349572 50 mg in combination with Etravirine
45341041|NCT02557191|Other|Observational study|
45341042|NCT00778791|Drug|metformin HC1 750 mg extended-release tablets|
45473394|NCT03745261|Drug|YCC capsule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Yong Chong Cao (YCC)capsule (Kecai®, Guangdong daguang pharmaceutical group Co., Ltd), 1 g each time, three times a day.
46036443|NCT02807896|Other||This study is cohort.
46036444|NCT02812264|Behavioral|API App|Mobile application that uses API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale
46036445|NCT02812264|Behavioral|Non-API App|Mobile application that does not use API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale.
46036446|NCT02812264|Behavioral|fitness tracker|fitness tracker to monitor physical activity and sleep patterns that is connected to transfer data to app
45341043|NCT00774189|Drug|clarithromycin 250 mg tablets|
45341044|NCT00774423|Drug|Riluzole|50 mg per day during 24 months
45341045|NCT00781521|Drug|ofloxacin otic solution 0.3%|ofloxacin otic solution 0.3% instilled twice a day for seven days
45341046|NCT02557113|Procedure|Vertebroplasty|Fractured Osteoporotic Vertebral Body is Augmented with Injection of Bone Cement
45473395|NCT03745261|Drug|BL capsule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bailing(BL) capsule (Bailing®, Huadong Medicine Co.,Ltd), 1 g each time, three times a day
45473396|NCT01166243|Biological|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
45341047|NCT02557113|Procedure|Cavuplasty|Small Cavity is Created in Fractured Osteoporotic Vertebral Body Prior to Cement Injection
45341048|NCT00778947|Procedure|Harmonic Synergy Dissecting Hook (Harmonic Scalpel)|Harmonic Synergy Dissecting Hook (Harmonic Scalpel) uses ultrasound waves to coagulate and cut in surgery. It is available on the market, holds a CE mark and is coded as a Class IIb medical device.
46036447|NCT02812264|Behavioral|scale|Connected scale that will transfer weight information to app
45341049|NCT00778947|Procedure|Electrocautery Diathermy|Electrosurgery uses high temperatures (150-400oC) and causes obliterative coagulation. Diathermy is the use of high frequency electric current to produce heat. In surgery it is used to cut or destroy tissue and/or to produce coagulation. The electrical frequency produced in diathermy is in the range of 300kHz to 3MHz.
45341050|NCT00774501|Procedure|image guidance with general anesthesia and suspended ventilation during treatment delivery|"All study patients will undergo marker implantation approximately 2 weeks prior to the PET-CT simulation and treatment planning. PET-CT is performed for treatment planning purposes. This part of the process is in routine clinical use at MSKCC.~Three cone beam imaging scans and an IV contrast injection just prior to the first cone beam scan will be added to the standard procedure. The use of these two techniques is investigational.~The treatment delivery will make use of general anesthesia and suspension of mechanical ventilation to render the patient apneic during both target localization and dose delivery. This will allow the dose to be delivered more precisely than the techniques currently in use, thus allowing the use of smaller treatment margins and reducing the high dose exposure of healthy liver tissue. These measures have not previously been used for treatment delivery."
45341051|NCT04047147|Other|Enrollment in the Million Hearts CVD Risk Reduction Model|"The intervention is at a provider organization level and all eligible beneficiaries enrolled by participants will be considered exposed. Intervention organizations receive payments to:~Risk stratify eligible Medicare FFS beneficiaries~Provide CVD care management to high-risk beneficiaries~Collect and report clinical data to CMS via the Million Hearts Data Registry and participate in learning system activities~Participating organizations receive payments for each eligible beneficiary they risk stratify. In model year 1, the organizations receive a fixed payment per beneficiary per month to provide cardiovascular management. In model years 2-5, the organizations receive a risk reduction payment that is scaled based on reductions in 10-year predicted risk scores among their cohort of high-risk beneficiaries."
45341052|NCT04047147|Other|Enrollment in control provider organizations|Control organizations receive payments to collect and report clinical data on their eligible Medicare FFS beneficiaries, but are not asked to calculate CVD risk scores or otherwise change their clinical care.
45341053|NCT00784407|Device|harmonic scalpel device utilized intraoperatively|harmonic scalpel device utilized intraoperatively (FOCUS in group A and HARMONIC ACE in group B patients)
46036448|NCT04236700|Other|Oral clinical exam|Detailed anamnesis, with information regarding the time of sun exposure, protection measures, medical history and application of questionnaires will be carried out. Dental dental and tissue examination should be performed
46036449|NCT02812030|Other|National Eye Institute Visual Functioning Questionnaire|Routine treatment plus visual functioning questionnaires
46036450|NCT02625103|Procedure|Blood sampling|blood samples for s-clozapine and s-desmethyl-clozapine analysis are collected at 10, 11, 12, 13 and 14 hours post evening-clozapine-administration
46036451|NCT02625103|Drug|Clozapine|Registration of the exact time of drug administration. Also postponement of any morning clozapine administration until ended blood sampling.
46036452|NCT02807662|Behavioral|Adapted Seeking Safety Intervention|Intervention participants received Seeking Safety psychosocial education Intervention adapted for prenatal care setting.
45341054|NCT04046913|Behavioral|Dietary education|Intervention: Low food additive diet. Control: Habitual food additive diet
45341055|NCT00784485|Drug|Xolair injections|In addition to Advair Diskus 250/50 or 500/50, subjects will receive 150 to 375 mg subcutaneous injection every 2 or 4 weeks (depending on IgE levels) for 16 weeks.
45473397|NCT01166243|Procedure|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control bleeding.
45473398|NCT03744949|Drug|Remifentanil dose 0.5 ug/kg|Remifentanil will be given (dosage of 0.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
45473399|NCT03744949|Drug|Remifentanil dose 1 ug/kg|Remifentanil will be given (dosage of 1 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
45473400|NCT03744949|Drug|Remifentanil dose 1.5 ug/kg|Remifentanil will be given (dosage of 1.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
45473401|NCT03744949|Drug|Remifentanil dose 2 ug/kg|Remifentanil will be given (dosage of 2 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
46036453|NCT01155479|Drug|Preladenant 2 mg tablet|Preladenant 2 mg oral tablet taken twice daily
46036454|NCT01155479|Drug|Preladenant 5 mg tablet|Preladenant 5 mg oral tablet taken twice daily
46036455|NCT01155479|Drug|Preladenant 10 mg tablet|Preladenant 10 mg oral tablet taken twice daily
46036456|NCT01155479|Drug|Rasagiline 1 mg capsule|Rasagiline 1 mg oral capsule taken once daily
45473402|NCT03870581|Behavioral|AI-based social software management model|a AI-based miniprogram, embedded in the Wechat social software, to manage participants' warfarin therapy, such as dose adjustment, INR monitoring alert, etc.
46036457|NCT01155479|Drug|Placebo for Rasagiline 1 mg capsule|Placebo for rasagiline 1 mg oral capsule taken once daily
46036458|NCT01155479|Drug|Placebo for Preladenant|Placebo for preladenant 2 mg, 5 mg, or 10 mg oral tablet taken twice daily
46036459|NCT04138303|Other|Exercise Protocol|The exercise protocol consists of a nine-week progressive intense-conditioning program involving six consecutive days (Monday-Saturday) of one-hour exercises and one-day rest weekly for a total of 54 days of exercise. Exercises are performed in person as a group with other participating subjects and lead by certified instructors. Exercises will involve a variety of activities ranging from running, cycling, whole-body functional movements, power movements, and open-chain weight lifting with barbells and resistance bands.
46036460|NCT04138303|Other|Calorie-Restrictive Low Carbohydrate Diet (CR-LC)|Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. CR-LC consists of caloric and macronutrient restrictions. Caloric restrictions involves a 40% deficit from calculated total daily energy expenditure. Macronutrient restriction involves a high protein, low carbohydrate diet (35% protein, 25% carbohydrate and 40% fat).
45341056|NCT00781755|Drug|varenicline|.5mg/day for 3 days then titrated to 1.0mg/day for 11 days. A total dosing regimen of 14 days.
45341057|NCT00781755|Behavioral|Adaptation of Motivational Interviewing|2 sessions of behavioral intervention designed to create ambivalence about quitting or plan for a quit attempt if the patient is ready.
45341058|NCT00781833|Device|Radio Frequency Microstimulator|Implantable peripheral muscle microstimulator, delivering controlled pulsatile stimulation to femoral nerves for knee extension and peroneal nerves for dorsiflexion.
45473403|NCT03870581|Behavioral|Human-based social software management model|a Human-based miniprogram, embedded in the Wechat social software, to manage participants' warfarin therapy, such as dose adjustment, INR monitoring alert, etc.
46036461|NCT04138303|Other|Ancestral Diet (AD)|Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. AD consists of consuming only whole foods and avoiding processed foods. Emphasis will be on food quality with no caloric or macronutrient restrictions.
46036462|NCT02807584|Device|ELECT|
46036463|NCT04031131|Drug|Instillagel|Topical Anaesthetic Gel (Instillagel) licensed for rectal administration.
46036464|NCT04031131|Other|KY Gel|Lubricant Gel
46036465|NCT00683839|Behavioral|Brief tobacco counseling|Public health dental professionals provide brief counseling during routine visits based on the Clinical Practice Guidelines 5 As (Ask, Advise, Assess, Assist, Arrange), including offering free Nicotine Replacement Therapy and referral to a Tobacco Quit Line. Pharmacologic: nicotine patch or lozenge maximum 12 week course.
46036466|NCT02807272|Drug|Tipifarnib|Oral tablet
45341059|NCT00774735|Drug|GSK1349572|30 mg given in combination with lopinavir/ritonavir
45341060|NCT00774735|Drug|GSK1349572|30 mg in combination with darunavir/ritonavir
45473404|NCT03224325|Drug|TAK-831 Tablet T2|Tak-831 tablets.
45683572|NCT04277494|Other|Clorethyl cold spray® (Vapocoolant spray)|From the anterior superior of the dominant legs to the spinal iliac, the upper part of the patella will be measured and the center point will be marked. Cold spray will be applied to this point and its surroundings. The ethyl chloride spray bottle will be kept approximately 30 cm from the skin. An ethyl chloride stream will be applied at a 45 ° angle for 15 seconds (Shadgan et al., 2015). Skin temperature and mechanical properties of muscle; will be measured before, immediately after, 2 minutes, 5 minutes and 15 minutes after cold application.
45683573|NCT03642028|Drug|Suvorexant|Suvorexant, a dual orexin receptor antagonist, is the first in a new class of drugs with great promise of addressing insomnia in Veterans with PTSD. Suvorexant targets the orexin neuropeptide system and has been shown to be highly successful in treating insomnia.
46036467|NCT02811796|Other|angio-based FFR estimation|The investigators will acquire specific angiograms to permit angio-based FFR (QFR) calculation. An independent corelab will estimate the QFR value. This value will be related to prognosis to verify if it is able to discriminate those at higher risk of adverse events.
45341061|NCT00666237|Procedure|Tube shunt surgery|The procedure involves implantation of a Baerveldt consisting of a tube that is connected to an end plate. The tube is inserted into the anterior chamber and shunts aqueous humor to the end plate located in the equatorial region of the eye. The aqueous humor is then absorbed by the tissues around the eye.
45341062|NCT00666237|Procedure|Trabeculectomy|The procedure involves removal of a small portion of trabecular meshwork and adjacent tissue under a partial thickness scleral flap. Aqueous humor drains into the subconjunctival space producing a filtering bleb. The aqueous humor then diffuse out of the bleb.
46036468|NCT04138771|Device|An artificial intelligence system for postoperative management of cataract patients|This system can detect multiple postoperative complications of cataract patients and then provide a management strategy.
45341063|NCT00666237|Drug|Mitomycin C|A fluid retaining sponge soaked in 0.4 mg/ml Mitomycin C will be applied in the region of Trabeculectomy site for about 2 minutes
45341064|NCT00774813|Device|Nexalin 1.3mA Device|"3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~Daily receipt of placebo antidepressant"
45341065|NCT00774813|Device|Nexalin 15mA device|"3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~Daily receipt of a placebo antidepressant"
45473405|NCT03224325|Drug|Placebo|TAK-831 placebo-matching suspension.
45473406|NCT03224325|Drug|TAK-831 Suspension|TAK-831 Suspension.
45683574|NCT03642028|Other|Placebo|Visibly matched, equally weighted placebo tablets. In addition to matching in appearance and weight, they will have identical packaging and labeling as randomized, blinded study medication.
46036469|NCT01155323|Device|etafilcon A|1-day soft contact lens
46036470|NCT01155323|Device|omafilcon A|1-day soft contact lens
46036471|NCT02807194|Other|spinal anesthesia|
46036472|NCT02807194|Other|general anesthesia|
45341066|NCT00774813|Drug|placebo device and Citalopram|"3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~Daily receipt of a a SSRI (Citalopram or similar)"
45473407|NCT01277315|Drug|Anakinra|Open Safety and Tolerability study to evaluate a subcutaneous application 100 mg of Anakinra in combination with Riluzol in Amyotrophic Lateral Sclerosis.
45473408|NCT04016779|Drug|Placebo|Placebo will be administered once daily
45473409|NCT04016779|Drug|SPN-812|SPN-812 will be administered once daily and compared to Placebo
45473410|NCT03798951|Other|Prehabilitation|"The patients included in the treatment group will follow a prehabilitation program, based on a physiotherapist, nutritionist and psychologist evaluation. All the treatments will be tailored according the characteristics of each single patient.~The program will have a duration of, at least, 4 weeks."
45473411|NCT03870503|Drug|oxytocin|The patient will be received oxytocin 20 IU by intravenous infusion
46036473|NCT02807194|Procedure|lumbar disc herniation|
45473412|NCT03870503|Drug|oxytocin plus misoprostol|The patient will be received oxytocin 20 IU by intravenous infusion plus 400 mic gm sublingual misoprostol
45473413|NCT03870503|Drug|Carbetocin|The patient received Carbetocin 100 mic gm
45341067|NCT00784797|Drug|mifepristone and misopristol|200 mg mifepristone and after 48 hours vaginal misopristol 800 mgr followed by oral misopristol 400 mgr every 3 hours for maxamum 5 doses
45473414|NCT02857426|Drug|Nivolumab|
45473415|NCT05181033|Drug|Lenvatinib + Letrozole|"Patient will receive letrozole 2.5mg daily plus lenvatinib 14mg daily until disease progression/unacceptable toxicity.~Patient review, safety evaluations, thyroid function monitoring and urine dipstick will be done. Toxicities will be graded using NCI CTCAE toxicity grading vs 4.0. Patient should be discontinued if drug cannot be resumed within 28 days due to toxicities.~Drugs should be withheld when subject has imminent risk to develop hypertensive crisis/has significant risk factors for severe complications of uncontrolled hypertension. Drugs can be resumed once patient received same hypertensive medications for at least 48 hours and the BP is controlled.~Lenvatinib should be withheld for at least 1 week prior to elective surgery, at least 2 weeks after major surgery, until adequate wound healing.~For risk of ONJ, oral dental examination and preventive dentistry should be considered prior to lenvatinib intake.~There is no dose modifications for letrozole."
46036474|NCT00912535|Drug|Quetiapine extended release tablet|Quetiapine extended release tablet of 50-300mg/day
45341068|NCT00784797|Drug|mifepristone and oxytocin|200 mg mifepristone followed 48 hours with high dose oxytocin drip (9 unit per hour)
45341069|NCT00774969|Drug|Metronidazole|Metronidazole 10% ointment three times a day 7 days
46036475|NCT00912535|Drug|Placebo|Placebo orally, as adjunct to the same antidepressant at the same dose.
45341070|NCT00785031|Other|internet based vascular risk factor intervention|The patient and a nurse practitioner create an internet dossier and the patient is instructed on how to use the internet dossier. The internet dossier is mainly meant for the patient: to improve knowledge of vascular risk factors, to give an overview of the actual status of the levels of his/her vascular risk factors and to give guidance and personal advice how to treat risk factors with medication and/or lifestyle.
46036476|NCT02811718|Behavioral|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
46036477|NCT02811718|Behavioral|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
45341071|NCT00785109|Dietary Supplement|Vitamin K supplementation|Daily vitamin K supplementation per os (2 mg once a day)Experimental 1 Placebo Experimental 2
45341072|NCT00662025|Drug|Capecitabine|Capecitabine 1000 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
45341073|NCT00662025|Drug|Sunitinib|Sunitinib 37.5 mg daily, continuous dosing
46036478|NCT04313777|Behavioral|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
45341074|NCT00789945|Other|Control|Study Arm A will consist of patients with Type 1 diabetes who will continue their current intensive insulin therapy regimen with no additional interventions by the investigators. Their primary care providers will continue to manage their diabetes to obtain the best control as possible of their glucose, lipids, and blood pressure. Continuous Glucose Monitoring will be monitored. No timing of premeal insulin administration will be utilized in this arm.
45341075|NCT00789945|Other|Study Arm B|"Study Arm B will include participants with type 1 diabetes which will utilize Timing to adjust their pre-meal insulin dosages. Participants will continue taking their current insulin and will be placed on a continuous glucose monitor."
46036479|NCT04313777|Device|Virtual therapeutic support|8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.
45341076|NCT00785187|Device|exposure to UVB radiation|exposure to UVB radiation for limited time in order to establish subject's minimal erythema dose.
45341077|NCT00785265|Behavioral|Group-Based (GB) Intervention|60-minute group session involving other study patients who have been assigned to this condition and their guests.
45473416|NCT05181033|Drug|Fulvestrant|Patients will be treated with Fulvestrant 500mg injections that are administered into the muscles (intramuscularly). This is injected at 2-weekly interval for the first 3 doses, followed by 4-weekly interval dosing.
45473417|NCT05666765|Drug|Isotretinoin ,silymarin|20mg/day isotretinoin for 3 months. 140 mg/day silymarin for 3 months. 20mg/day isotretinoin and 140mg/day silymarin for 3 months.
45473418|NCT01127256|Drug|zonisamide|Initial dose was 100mg/day, increased by 100mg. The maximum dose was 600mg/day.
45473419|NCT01127256|Drug|carbamazepine|Initial dose was 100mg/day, increased by 200mg every 1 week to 600mg/day. The maximum dose was 1200mg/day.
45473420|NCT01277471|Behavioral|Meal frequency (6 meals vs. 2 meals/day)|6 meals/day for 12 weeks followed by 2 meals/day for 12 weeks at the same caloric restriction (-500 kcal/day)
45341078|NCT00785265|Behavioral|Home-Based (HB) Intervention|60-minute educational intervention in their home, which will be delivered by an African American health educator.
45341079|NCT05013645|Other|Sterilized probiotic LfQi601|Sterilized probiotic topically administered.
45473421|NCT01277471|Behavioral|6 meals/day followed by 2 meals/day|2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
45473422|NCT03059472|Behavioral|Group 1 (Intervention)|"The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
45341080|NCT05013645|Other|Placebo|Gel control product
45473423|NCT03059472|Behavioral|Group 2 (Delayed intervention)|"The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
46036480|NCT04313777|Behavioral|Schultz Autogenic Training|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
46036481|NCT02811874|Behavioral|diabetes education|Diabetes education program includes: 4 theoretical sessions, 60 minutes long, taught once a week for 4 weeks, developed in the form of group classes, and given by one of the authors. The educational program content comprises (1) definition of diabetes, and identification of modifiable risk factors for type 2 diabetes, (2) non-pharmacological treatment, with emphasis on diet and exercise, (3) pharmacological therapy, including mechanism of action and side effects of anti-diabetic medications provided by the Brazilian public health system and (4) an overview of chronic diabetes complications.
46036482|NCT02811874|Behavioral|education in other areas|Four theoretical sessions related to education in other health areas, not related to diabetes, administered during 4 weeks
46036483|NCT02625727|Other|hyaluronic acid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
45341081|NCT00782145|Other|educational intervention|
45341082|NCT00782145|Other|informational intervention|
46036484|NCT02625727|Other|hyaluronic acid combined corticosteroid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
46036485|NCT02884739|Other|Data collection|
45341083|NCT00782145|Other|internet-based intervention|
45341084|NCT00782145|Other|questionnaire administration|
45341085|NCT00782145|Other|study of socioeconomic and demographic variables|
45341086|NCT00782145|Other|survey administration|
45341087|NCT00782145|Procedure|psychosocial assessment and care|
45341088|NCT00782145|Procedure|quality-of-life assessment|
45341089|NCT00782145|Procedure|standard follow-up care|
45341090|NCT00790101|Drug|Risedronate|
46036486|NCT02807116|Drug|Pacritinib|Subjects received a single oral 400-mg dose of pacritinib
46036487|NCT02807116|Drug|Rifampin|Subjects received 600-mg oral doses of rifampin; administered QD following a 7-day washout period
45341091|NCT00790101|Drug|Raloxifene|
45341092|NCT00790101|Other|Placebo|
45341093|NCT02555085|Biological|BIIB063|Single ascending IV dose
45341094|NCT02555085|Other|Placebo|Single dose
45341095|NCT00782301|Drug|maraviroc|maraviroc 150 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
45341096|NCT00782301|Drug|etravirine|etravirine 200 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
45341097|NCT00785343|Device|Reo Go robotic arm trainer|Robotic training with the Reo Go is included with conventional treatment during daily OT sessions
45341098|NCT00785343|Procedure|Conventional Therapy|Occupational therapy that is the current standard of care
45341099|NCT00785421|Drug|enoxaparin|Patients receive GFFC +/- LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.). Pts with KPS < 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) +/- LMWM +/- Enoxaparin 1mg/kg daily s.c. After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) +/- Enoxaparin 40mg/d s.c.
45341100|NCT00785421|Drug|chemotherapy with LMWH - enoxaparin|1-12 weeks: enoxaparin 1g/m², s.c. 12-PD or event: enoxaparin 0,4g s.c.
46036488|NCT02807116|Drug|Pacritinib and Rifampin|On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.
45341101|NCT00785421|Drug|only chemotherapy|observation, no treatment with LMWH
45341102|NCT00790179|Procedure|continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA|"0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.~Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA."
46036489|NCT04313699|Drug|Antiretroviral treatment|The cohort will recruit HIV infected participants who are on antiretroviral treatment
46036490|NCT01155167|Drug|Nitroglycerin and lidocaine|Topical Nitroglycerin and lidocaine
46036491|NCT01155167|Other|Placebo|Placebo
45341103|NCT00790257|Device|"Encapsulated human islets in a Monolayer Cellular Device"|"The product consists of isolated allogeneic human islets of Langerhans formulated in a serum-free transplant media. The islets will be encapsulated in an alginate-based Monolayer Cellular Device.~One device will be transplanted subcutaneously and corresponds to a patch of 1-3cm². One Device per patient. No Retransplantation."
45341104|NCT00785499|Behavioral|Milk Components and Metabolic syndrome|1 liter per day of the test drinks for 3 mo
45341105|NCT00782457|Procedure|RECTAL CANCER RESECTION|
45341106|NCT00790413|Drug|iodine I 131 metaiodobenzylguanidine|
45341107|NCT00790413|Drug|Fludarabine|
45341108|NCT00790413|Drug|Thiotepa|
45683575|NCT04458220|Other|photo and voice obtained|The 3D face scanner and camera is used to obtain 3D or 2-dimensional portrait images of patients in different positions and from different angles.The Hi-Fi Recorder is used to obtain sound samples of patients in different word.
45683576|NCT04277572|Procedure|Aortic valve replacement|Aortic valve surgery
45683577|NCT04430842|Drug|QBS10072S|QBS10072S targets cancers with high LAT1 expression.
45839958|NCT05201196|Other|Task Oriented Training|"Experimental group was given Task oriented protocol including activities such as Table-top polishing, Arm cradling, Reach forward and pick-up or touch an object, Reached sideway to pick-up an object and transferring it to a table in front, Pouring~½ cup of water from a measuring pot into wide mouth glass held in opposite hand, Picking up pen from thumb and first two fingers, lifting a basket and placing it on the table 10 repetitions×1 set for each activity, 4-5days/week. Total of 16 sessions were given each consisting of 45 mins"
45683578|NCT04428580|Other|Online FBT Training|Therapists will receive online training in Family-Based Treatment (FBT)
45683579|NCT04428580|Other|Webinar FBT Training|Therapists will receive webinar training in Family-Based Treatment (FBT)
46036492|NCT02807038|Procedure|Lung function test|Pregnant woman use the individual passive sampler 15 days before the spirometry test at each trimester
45341109|NCT00790413|Procedure|T-cell depletion|
45341110|NCT00790413|Procedure|Haploidentical stem cell transplantation|
45341111|NCT00790413|Procedure|Donor Lymphocyte Infusion|
45341112|NCT00790413|Drug|Rituximab|
45683580|NCT04686838|Behavioral|READyR II: A|Continuous monitoring for anomaly detection and contact phone call when a potential change in care needs is indicated by an anomaly.
45683581|NCT04686838|Behavioral|READyR II: B|Sensors will remain in the home but anomaly detection analysis will not be performed and contact phone calls will be at regular intervals without dynamic tailoring content.
45341113|NCT00790413|Procedure|Co-transplantation of mesenchymal stem cells|
45341114|NCT00785655|Drug|Dermacyd PH_DETINLYN (Lactic Acid)|
45341115|NCT00790491|Behavioral|guidance tool for providers for lifestyle changes|automated guidance tool for medical providers involved in patient encounters addressing lifestyle changes. Addresses dietary and physical activity. Seeks to reduce cardiac disease risk.
45839959|NCT05158530|Other|Aerobic training|Aerobic training ( with cycle ergometer, 5-minute warm-up 15 - 30 minute cycle +5 minute cooldown) 40%-60% intensity calculated through Karvonen formula 3 days/ week
45839960|NCT05158530|Other|Pulmonary Exercises|"4 weeks protocol~Deep breathing Exercises* 10 Reps 3 sets~Postural drainage (10 minutes * 2 sets /day)~Incentive spirometry* 10 Reps 3 sets~Bed activities (Active ankle and hand pumping exercise * 10 Reps 3 sets)"
45839961|NCT05138952|Behavioral|Mindfulness Meditation|"30-day mediation program comprising:~Weekly group mediation tuition and support sessions delivered online. Sessions will last 45-60 minutes and focus on mindfulness meditation theory and techniques, and trouble shooting barriers to practice and engagement.~10-minutes of daily mindfulness meditation practice with the Headspace Inc app."
45683582|NCT04684264|Other|Heart Failure Prevention Clinic|Heart Failure Prevention Clinic is a pharmacist-directed practice in collaboration with an attending cardiologist that uses evidence-based guidelines to optimize medications and lifestyle interventions for heart failure prevention.
45683583|NCT04677010|Other|Cycle exercise|10 weeks of cycle exercise on a cycle ergometer with motor.
45683584|NCT04277806|Behavioral|New Oral feeding process|From the beginning of 32 weeks, try oral feeding once a day, suck pacifier for 10 minutes before feeding. When she/he can finish 50% of the amount of one meal in consecutive two days, and there is no adverse events happened, then we will try oral feeding twice a day. In the same way, in the oral feeding she/he can finish 50% of this meal in consecutive two days, there is no adverse events happened, then we will try three oral feedings three times a day. We wil continue the process until the infant can be fully oral fed by herself/himself.
45341116|NCT00790725|Other|Proportional Assist Ventilation|Proportional Assist Ventilation will be used to ventilate the patients.
45341117|NCT00790725|Other|Pressure Support Ventilation|Pressure Support ventilation will be used to ventilate the patients.
45341118|NCT00785811|Drug|L-arginine aspartate (Targifor)|3g of L-arginine taken orally in a single daily dose for 8 weeks
45341119|NCT00785811|Drug|Placebo L-arginine aspartate (Targifor)|Placebo of L-arginine taken orally in a single daily dose for 8 weeks
45341120|NCT00782613|Drug|4,4-dimethyl-benziso-2H-selenazine|ALT-2074 in a 0.5% cream formulation
45341121|NCT00782613|Drug|Placebo|Placebo in a cream formulation
45341122|NCT00440947|Drug|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV)+ ritoanvir (/r) for 36weeks followed by ABC/3TC + ATV + /r for 48wks followed by optional treatment extension for 60 weeks on the same regimen
45341123|NCT00440947|Drug|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV) + ritonavir (/r) for 36 weeks followed by ABC/3TC + ATV for 48wks followed by optional treatment extension for 60 weeks on the same regimen
45341124|NCT00790881|Drug|Artemether/Lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
45341125|NCT00790881|Drug|Artemether/ lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
45341126|NCT00782691|Other|CT-FDG/PET scan of the head-and-neck region|CT-FDG/PET scan of the head-and-neck region
45473424|NCT03873233|Device|Aisys Carestation ventilator and normal endotracheal tube|Fraction of Inspired Oxygen (FIO2) 0.3 End Expiratory Pressure (EEP) at +5 cm H2O Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 Tidal Volume: 6 mL/kg Zero inspiratory pause Respiratory frequency will be adapted to produce an End-Tidal CO2 35-40 mmHg
45473425|NCT03873233|Device|Evone ventilator and Tritube|Fraction of Inspired Oxygen (FIO2) 0.3 Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 End Expiratory Pressure (EEP) at +5 cm H2O Flow: start with 10 L/min and adjusted along with the peak inspiratory pressure to produce a tidal volume of 6 mL/kg and End-Tidal CO2 35-40 mmHg
45473426|NCT03377842|Drug|FOLFOX regimen|FOLFOX(Oxaliplatin 85 mg/m² IV infusion and leucovorin 200 mg/m² IV infusion， followed by Fluorouracil 400 mg/m² IV bolus , followed by Fluorouracil 600 mg/m²/h IV infusionas a 22-hour continuous infusion). Repeat cycle every 2 weeks for a total of 6 cycl
45473427|NCT03377842|Drug|apatinib and FOLFOX regimen|Apatinib, 500mg p.o. qd, Repeat cycle every 2 weeks for a total of 6 cycles. FOLFOX regime, Repeat cycle every 2 weeks for a total of 6 cycles.
45473428|NCT03668613|Drug|secukinumab low dose|dose depends on the weight group
45473429|NCT03668613|Drug|secukinumab high dose|dose depends on the weight group
45473430|NCT03646812|Other|Glucose Reference 1|Glucose contains 50g of available carbohydrates
46036493|NCT04141111|Device|Continuous Glucose Monitoring (CGM)|"On each visit (baseline, 4, 8, and 12 months), participants received an iPro2 CGM device (MiniMed Medtronic), placed according to the manufacturer's standard procedure. The iPro2 was used each time for 7-days. During this period, patients were asked to perform 4 SMBG measurements daily for calibration (fasting, lunch, dinner, and before bed). Patients received a diary to register food intake, physical activity and medication, SMBG values, and any diabetes-related event (extra consultations, phone calls, etc) in the previous 4 months.~Each time, CGM data was interpreted by an expert clinician, and a report was delivered, within one week, to the respective healthcare team. This report was discussed together by the patient and one member of the healthcare team, either in consultation or by phone, agreeing on any necessary therapeutic changes. If necessary, extra consultations for nutrition, nursing, or education, were scheduled, to address specific needs identified during rCGM review."
45341127|NCT01029769|Drug|Olanzapine or amisulpride|Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding
45341128|NCT02557945|Drug|Gabapentin|Subjects will be treated with 400mg pills of gabapentin , titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
45341129|NCT02557945|Drug|Placebo|Subjects will be treated with 400mg pills of placebo, titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
45341130|NCT05673668|Device|Endovascular Denervation System (Netrod)|The Netrod system is a percutaneous, catheter- based device which uses radiofrequency energy to denervate the sympathetic nerves surrounding the arteries
45341131|NCT03268070|Device|Repetitive TMS over contralateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
45473431|NCT03646812|Other|Glucose Reference 2|Glucose contains 50g of available carbohydrates
45473432|NCT03646812|Other|Glucose Reference 3|Glucose contains 50g of available carbohydrates
45473433|NCT03646812|Other|Semolina Penne|Semolina Penne contains 50g of available carbohydrates
45341132|NCT03268070|Device|Repetitive TMS over ipsilateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over ipsilateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
46036494|NCT02811406|Procedure|Receives IV albumin infusion|"IV albumin 20% 50 mL for every 1L of ascitic fluid drained. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.~If hypotension occurs (defined as fall in systolic blood pressure of > 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains > 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP < 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated."
45341133|NCT03268070|Device|Repetitive TMS over contralateral primary motor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral primary motor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain.Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
45341134|NCT03268070|Device|Sham Repetitive TMS over contralateral premotor cortex.|Sham rTMS will be applied over contralateral premotor cortex. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
45473434|NCT03646812|Other|Wholegrain Penne|Wholegrain Penne contains 50g of available carbohydrates
45473435|NCT03646812|Other|Semolina Spaghetti|Semolina Spaghetti contains 50g of available carbohydrates
45473436|NCT03646812|Other|Wholegrain Spaghetti|Wholegrain Spaghetti contains 50g of available carbohydrates
45473437|NCT03646812|Other|Jasmine Rice|Jasmine Rice contains 50g of available carbohydrates
45473438|NCT03646812|Other|Asian Noodles|Asian Noodles contains 50g of available carbohydrates
45473439|NCT03377764|Procedure|Landmark Technique Control group|Spinal Anesthetic
45473440|NCT03377764|Procedure|Neuroaxial block using Ultrasound Guidance|Ultrasound guided Spinal Anesthetic
45473441|NCT04016311|Behavioral|Mindful Drinking/Eating Intervention|Participants will be individually guided during their dialysis session through: 1) a mindful drinking exercise, a meditation focused on the sensory experience of 3 sips of fluid, along with a discussion of the experience; and 2) a mindful eating exercise with select foods that are recommended for controlling thirst (i.e., hard candy, frozen fruits). Participants will be given directions for mindful drinking/eating and asked to practice mindful drinking/eating as often as possible but least once each day.
45683585|NCT04666402|Other|Blood tests for Single Nucleotide Polymorphisms|This extra test would be performed on participants assessed in the specialist liver clinic. This test would require an extra 5ml of blood to be taken at the time of routine blood tests for clinical purposes.
46036495|NCT02811406|Biological|Do not receive IV albumin infusion|"No IV albumin infusion. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.~If hypotension occurs (defined as fall in systolic blood pressure of > 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains > 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP < 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated."
46036496|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Raw|Low Dose- 70g bar
45341135|NCT03268070|Device|Single TMS over extensor carpi ulnaris spot of motor cortex|Single-pulse TMS will be applied over the extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1) during motor training.TMS uses magnetism to excite neurons near the surface of the brain. TMS pulses will be applied at different strengths (30%-80% maximum stimulator output) and record subsequent activity of the ECU muscle using electromyography (EMG).
46036497|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Raw|High Dose- 100g bar
46036498|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Cooked|Low Dose- 70g bar
46036499|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Cooked|High dose: 100g bar
46036500|NCT00691249|Dietary Supplement|Shredded Wheat|70g bar
45341136|NCT03929666|Drug|ZW25 (Zanidatamab)|"Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC)~Part 2: RD identified in Part 1"
45341137|NCT03929666|Drug|Capecitabine|Administered orally twice daily (PO bid)
45341138|NCT03929666|Drug|Cisplatin|Administered IV
45341139|NCT03929666|Drug|Fluorouracil|Administered IV
46036501|NCT05238155|Drug|antimetabolite|When OLT recipients are discharged following transplantation, they are typically prescribed a triple immunosuppression maintenance regimen, consisting of a calcineurin inhibitor, an antimetabolite, and a corticosteroid. Over the last several years, there have been changes made to this protocol, and the current protocol now suggests
45341140|NCT03929666|Drug|Leucovorin|Administered IV
45341141|NCT03929666|Drug|Oxaliplatin|Administered IV
45341142|NCT03929666|Drug|Bevacizumab|Administered IV
45341143|NCT03929666|Drug|Gemcitabine|Administered IV
45341144|NCT03241082|Device|ultrasound|validation of portable ultrasound to measure body composition
45473442|NCT01277705|Biological|GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine|Intramuscular, single
45341145|NCT00664521|Biological|Rituximab|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3.
45341146|NCT00664521|Drug|Atacicept|Atacicept will be administered at a dose of 150 mg subcutaneously once a week from Week 7 to 32.
45341147|NCT00664521|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously once a week from Week 7 to 32.
45341148|NCT02581046|Procedure|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 3month of the patients|The surgical timing of phacoemulsification is perform at the age of 3 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
45341149|NCT02581046|Procedure|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 6 month of the patients|The surgical timing of phacoemulsification is perform at the age of 6 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
45341150|NCT02581046|Drug|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
45341151|NCT02580890|Device|tDCS active|Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline.
45341152|NCT02580890|Device|tDCS sham|For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
45473443|NCT01277705|Biological|Boostrix™|Intramuscular, single dose
45473444|NCT01277705|Biological|GSK Biologicals' IPV vaccine|Intramuscular, single dose
45473445|NCT01277705|Biological|Revaxis®|Intramuscular, single dose
46036502|NCT01106586|Drug|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
46036503|NCT01106586|Drug|ATV|Atazanavir 300 mg capsule administered orally once daily
45341153|NCT00664209|Drug|clartihromycin, amoxicillin, and omeprazole|clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days
45341154|NCT00664209|Drug|placebo|placebo therapy
45341155|NCT05254977|Drug|Standard Preparation|Any kind of intervention received to reduce adverse effects
46036504|NCT01106586|Drug|Ritonavir|Ritonavir (RTV; /r) 100 mg tablet administered orally once daily
45341156|NCT04074434|Device|Study Watch|Study Watch is a miniaturized physiological data monitoring and data collection device for continuous recording of physiological and environmental data
45341157|NCT00785889|Procedure|water infusion colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
45341158|NCT03192332|Device|Stent-retriever thrombectomy with revascularization device of the Solitaire™ type|Mechanical thrombectomy with a stent-retriever revascularization device
45473446|NCT03377686|Diagnostic Test|inflammation markers in exhaled breath|non-invasive, cross-sectional, assessment of inflammation markers in exhaled breath with various techniques (observational)
45473447|NCT04757337|Drug|Doxorubicin|6 x 3-week cycles corresponding to a maximal duration of 18 weeks
45473448|NCT04757337|Drug|Cyclophosphamide|Until progression up to 24 months
45473449|NCT03868241|Device|Coated devices|Gold-silver-palladium coated devices (endotracheal tube, central venous catheter and urinary catheter) will be used whenever necessary. All three devices are required to be inserted as soon as possible after randomization and need for all three devices are the main inclusion criteria
45473450|NCT03868241|Device|Control|Devices without coating available at each participating intensive care unit
45473451|NCT03921970|Other|ESP block (Group ESP)|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
45473452|NCT03946527|Drug|Lanreotide|Participants will receive lanreotide 120 mg deep subcutaneous injection every 4 weeks (±7 days) for 52 weeks, followed by an extension phase in which all patients will continue to receive lanreotide 120 mg injection every 4 weeks (±7 days) if there is no evidence of disease progression.
46036505|NCT01106586|Drug|FTC/TDF|FTC/TDF 200/300 mg tablet administered orally once daily
46036506|NCT01106586|Drug|Stribild Placebo|Placebo to match Stribild administered orally once daily
46036507|NCT01106586|Drug|ATV Placebo|Placebo to match ATV administered orally once daily
46036508|NCT01106586|Drug|RTV Placebo|Placebo to match RTV administered orally once daily
46036509|NCT01106586|Drug|FTC/TDF Placebo|Placebo to match FTC/TDF administered orally once daily
46036510|NCT02884583|Other|Pulmonary function test|Patients hospitalized for OFC realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes) and static volume assessment, by using body plethysmography, were realized before, during and after the OFC. An exhaled fraction of NO (FeNO) is also realized to characterize asthma.
46036511|NCT00683995|Drug|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
45683586|NCT04666402|Diagnostic Test|Faecal microbiome analysis|This test will be undertaken for all participants who give consent and are assessed through the new liver care pathway, in the community liver assessment clinic. All participants will be given the equipment to take a stool sample at the time of presentation at the community liver assessment clinic and asked to return the sample to the clinic. The sample will be processed to remove genetic material so the microbiome can be identified.
45341159|NCT03192332|Drug|Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA)|Bridging thrombolysis (IV t-PA plus mechanical thrombectomy) according to current European and North American stroke guidelines.
45341160|NCT02555943|Drug|Ledipasvir/Sofosbuvir|Oral direct anti-HCV agent. Ledipasvir/Sofosbuvir(LDV/SOF) 400mg/90mg fixed-dose combination(FDC) tablet, administered orally once daily.
46036512|NCT02806882|Drug|Ceftaroline fosamil|600mg IV infusion
45341161|NCT02555943|Drug|Sofosbuvir and Daclatasvir|TWO oral direct anti-HCV agent: Sofosbuvir(SOF), 400mg tablet administered orally once daily. Daclatavir(DCV), 60mg tablet administered orally once daily.
45341162|NCT02555943|Drug|Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir|VIEKIRA PAK includes ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor.
45341163|NCT02555943|Drug|Entecavir|Nucleoside-inhibitor-treatment-naïve with compensated liver disease (greater than or equal to 16 years old): 0.5 mg once daily.
45341164|NCT02555943|Drug|Tenofovir disoproxil|VIREAD is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.
45839962|NCT04734288|Dietary Supplement|Vit.D3 5000 IU, Immune Active|"The subjects will receive monthly (for either 3 or 6 months):~Vit.D3 5000 and Immune Active. The first phase includes 3 months of treatment and the second phase includes 6 months of treatment.~An in-home Vit.D/ hs-CRP test kit and asked to self-administer a blood collection via fingerstick and return the kits for analysis within a few days.~Two online questionnaires each month and asked to fill them out within a few days. It will either be the Medical Outcomes Study (MOS) Short Form (SF)-36 and the Health Status Baseline or Health Status Follow-up Questionnaire."
45341165|NCT00790959|Behavioral|SASA!|"A community mobilization approach to try to change community and individual attitudes and behaviours that support both the perpetration of violence against women and HIV risk behaviours~The intervention team engages with four major groups of actors: community volunteers selected from the general public; community leaders (e.g. religious, cultural and local council leaders); resource persons (health care providers, police, etc); and institutional leaders. The community volunteers are a key component of the intensive intervention."
45473453|NCT03377608|Drug|Tenofovir Disoproxil Fumarate|Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
45683587|NCT04666402|Diagnostic Test|Serum for diagnostic biomarkers|Blood samples will be taken alongside blood taken for clinical assessment. In total, an extra 5ml of blood. These samples will be used to explore novel blood biomarkers using ELISA and mass-spectroscopy techniques in the University of Manchester.
45839963|NCT04662684|Drug|Rivaroxaban 10 MG|No intervention
45683588|NCT04407442|Drug|Azacitidine|Given IV
45683589|NCT04407442|Biological|Daratumumab|Given SC
46036513|NCT02884817|Drug|Experimental: essential oils and ELA|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the Experimental solution, Listerine Gum Therapy. This oral hygiene routine was repeated for 21d.
45341166|NCT00790959|Other|Control|"Control communities will receive the full SASA! intervention after completion of the SASA! Study.~For the duration of the study, they will receive a less intensive intervention comprising the Division-level elements of SASA! (involving community leaders, resource persons and institutional leaders) without the community volunteers."
45341167|NCT02580812|Other|Clinical and neuropsychological evaluation procedure|WPPSI, NEPSY, Brief, SDQ, Vineland and SCQ evaluation Clinical examination
45341168|NCT04047459|Other|Tissue samples collection and cells isolation|During surgery, leftover samples of bone (femoral head/ trabecular bone tissue) and muscle will be collected. Then they will be sent to the laboratory where isolation of cells will be performed.
45341169|NCT00782847|Behavioral|DiaNe consultation and support program|the DiaNe consultation and support program for clients with diabetic nephropathy consists of 4 sessions at 90-120 minutes conducted every week in a period of 4 weeks
45341170|NCT00785967|Biological|Various vaccines|VAQTA: 1.0ml IM at weeks 24 & 48; Pneumovax 23: 0.5ml IM at screening; Td ADSORBED: 0.5ml IM at screening; phiX174 bacteriophage: 0.02ml/kg body weight IV at weeks 28, 32, 36, 40.
45341171|NCT03923504|Other|Physical Activity Intervention (PAI)|Those who opt-in to attend in-person study visits and to undergo COVID testing will also complete an MRI exam and CPET testing. Participants unwilling to have COVID testing done will only complete an MRI exam and home-based testing. All testing will take place either within 6 weeks of initiating systemic treatments or within 8 weeks of completing radiation then at 3 & 6 months. Patients may participate in 1-2 training sessions per week offered under the direct supervision of a master's level clinical exercise physiologist, as well as 1-2 sessions at home. PAI sessions consist of slow aerobic warm-up, followed by 20 minutes of strength training,15 minutes of progressive intensity aerobic exercise (AE), and then 10 minutes of stretching for cool-down. Participants will have the ability to participate in training sessions facilitated via online channels at home.
45341172|NCT03923504|Other|Healthy Living Control|Patients randomized to the control arm will either attend online sessions via secure video conferencing (e.g. Zoom) or telephone or to come to a centralized meeting location (if safety allows) to participate in organized health workshops. Session attendance will be required 2 times/month (over the 6 months). Make up sessions will be offered for those participants who have to miss a group session. Each session lasts 60 minutes and matches the number of visits made by the PAI group as much as possible.
45341173|NCT02555553|Behavioral|CBT-GSH with Noom Monitor|This intervention is cognitive behavioral treatment with a smartphone application
45341174|NCT00786045|Other|Home Cycling Program|Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
45341175|NCT02631044|Biological|JCAR017 (lisocabtagene maraleucel) single-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
45473454|NCT03377608|Drug|Depo-Provera|Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
45473455|NCT01282073|Drug|Mycophenolate mofetil, low dose steroid|"Mycophenolate Mofetil: Myconol capsule 250mg, Myconol 500 mg bid per day (less than 50kg), 750 ~ 1000 mg bid per day (more than 50kg)~Steroid: Methylprednisone 4mg tablet or Prednisolone 5mg tablet or Deflazacort 6mg tablet. Prednisolone dose: 0.15mg/kg up to a maximum dose of 15mg/day~Duration: 48 weeks"
45473456|NCT01282073|Drug|Cyclosporin, low dose steroid|"Cyclosporin: Implanta soft cap (cyclosporin microemulsion) 25mg/100mg, starting dose of 4mg/kg per day and titrate according to investigator's decision based on cyclosporin trough level (100±50 ng/ml)~Steroid: same dosage with active comparator goup~Duration: 48 weeks"
45473457|NCT04052425|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
45473458|NCT04052425|Drug|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
45473459|NCT03235089|Device|Test Lens|Daily disposable contact lens
45473460|NCT03235089|Device|Control Lens|Focus Dailies All Day Comfort contact lens (nelfilcon A)
46036514|NCT02884817|Other|Placebo|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the 21.6% hydroalcoholic solution. This oral hygiene routine was repeated for 21d.
45341176|NCT02631044|Biological|JCAR017 (lisocabtagene maraleucel) 2-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon product availability, participants will receive study treatment consisting of lymphodepleting chemotherapy followed by two IV doses of JCAR017.
45473461|NCT03377530|Diagnostic Test|Ways to prevent these infections.|"The purpose of this database is to describe the pathogenicity of this germ, the incriminated modes of contamination.~The collaborators studied the factors of poor prognosis and propose ways to prevent these infections."
45473462|NCT03873077|Procedure|local infiltration analgesia|10 mL ropivacaine 7.5 mg/mL and 10 mL lidocaine 10 mg/mL
45473463|NCT03377374|Dietary Supplement|Probiotic|L. reuteri Prodentis oil drops (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) will be given at a dose of 2x108 Colony Forming Units (CFU). Five drops are to be taken twice a day (in the morning and in the evening) giving a daily dose of 4x108 CFU/day.
45473464|NCT03377374|Other|Placebo|Five drops of Placebo taken twice a day (in the morning and in the evening).
45341177|NCT02580578|Other|No Intervention|No intervention is administered in this study.
45341178|NCT02618252|Device|Zonare|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
45473465|NCT03870347|Diagnostic Test|Endoscopic ultrasound|Upper endoscopy using an echoendoscope to obtain ultrasound images of the pancreaticobiliary system and adjacent structures.
45473466|NCT02736526|Procedure|recession or resection of the horizontal extraocular muscles|
45473467|NCT02526173|Procedure|RALP using full nerve sparing technique|RALP using full nerve sparing technique
45473468|NCT02526173|Other|dHACM Application|2x12 sheet of dHACM applied to the neurovascular bundle
45683590|NCT04407442|Drug|Dexamethasone|Given IV or PO
46036515|NCT02884817|Other|Water|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the sterile water, sham comparator. This oral hygiene routine was repeated for 21d.
46036516|NCT02806804|Biological|one dose test vaccine|
46036517|NCT02806804|Biological|one dose commercially available trivalent influenza vaccine|
46036518|NCT02806804|Biological|One dose of Quadrivalent Influenza Virus Vaccine|
46036519|NCT04138537|Other|OB volume|The mean OB volume was calculated in cubic millimeters and compared between the two groups.
46036520|NCT04138537|Other|CCCRC test|CCCRC test was done for olfactory function assessment and compared between the two groups.
45341179|NCT02618252|Device|Veinviewer|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
45341180|NCT02557412|Device|Continuous positive airway pressure|Treatment with nasal CPAP. Treatment begins with an empirical pressure of 8 cmH2O and in a period of three weeks, the pressure is adjusted by automatic titration with AutoSet II (ResMed) device.
45341181|NCT02557412|Behavioral|Intensive lifestyle intervention|Specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% [saturated fats <7% monounsaturated fats up to 20% and polyunsaturated fats <10% ] and proteins: 15-20%) and recommendation to increase daily physical activity, setting a target walking 10,000 steps a day. The patients will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
45341182|NCT02557412|Other|Conventional treatment|Hygiene and diet recommendations on sleep
46036521|NCT02811562|Device|manikin|
46036522|NCT02811562|Device|fiberoptic bronchoscope|
46036523|NCT02811562|Device|pentax-airwayscope|
46036524|NCT04137991|Device|Nol-Index guided analgesia|Monitor that indicates the level of nociception-antinociception balance
46036525|NCT04137991|Other|Standard Analgesia|Administration of remifentanil based guided by heart rate, blood pressure, and experience
46036526|NCT05599048|Drug|Hyperpolarized 13C-Pyruvate|Given IV
46036527|NCT05599048|Procedure|Magnetic Resonance Imaging (MRI)|Imaging procedure
46036528|NCT04031365|Procedure|Acupuncture|Use of sterile, disposable needles in acupuncture
46036529|NCT04031365|Behavioral|Cognitive Behavioral Therapy|psychotherapy
46036530|NCT01155011|Behavioral|Physical Activity|"MIPARC will focus on 3 physical activity goals:~increasing walking behavior through gradually increasing step goals~increasing attendance at available on-site and local aerobic, strength and flexibility classes, as well as prompting stair use,~reducing sedentary behavior. Participants will monitor their steps with a pedometer, daily step logs and progress charts. All participants will have a gradually increasing fixed step goal for each week that will result in an total increase of 3000 steps after 3 months, which they will be supported to maintain for an additional 3 months."
45341183|NCT02542202|Radiation|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
45341184|NCT02487134|Device|TIGR Matrix|Reinforcement of the suture line with resorbable mesh
45341185|NCT02487134|Device|Control|Closure of the abdomen with conventional technique
46036531|NCT01155011|Behavioral|Group educational sessions|Every three weeks, participants will be required to attend a group education session, where researchers will teach behavior change strategies and allow participants to share their experiences and offer support to each other. The group sessions will follow a common format including: a group exercise (e.g. quiz), group discussion of use of behavior change strategies (e.g. overcoming barriers), and will end with a behavior change strategy instruction and goal setting component.
46036532|NCT01155011|Behavioral|Phone counseling call|"To support a tailored intervention delivery, participants will receive 4 individual phone calls (in weeks 2, 5, 8, and 11) from a trained health counselor. The phone call will follow the following format:~health check~step goal check~barrier identification~problem solving~specific goals to achieve target step counts. Counselors will prompt participants to report any adverse events, illnesses, medication changes or counter indicative symptoms. The calls will cease during the second 3 months to allow participants to practice self help techniques while still supported by the group sessions and peer mentoring."
46036533|NCT01155011|Behavioral|Peer Mentoring|"Three peer mentors at each CCRC will be trained in intervention content and delivery, measurement support, and advocacy. The peer mentors will lead a group session once every three weeks for the 6 month intervention period and once a month for the following 6 months. The peer mentors will formulate their own ideas for these sessions but we will suggest they include group walks, group activities and trips to active locations, etc.~The peers will help study staff to answer questions from participants and assist with study compliance and retention. They will also receive advocacy training from a non-profit advocacy organization to conduct walk audits of their CCRC and help mobilize participants to make changes to their community that will increase or improve the opportunities for physical activity."
45341186|NCT02476838|Procedure|Hand Transplantation|microvascular VCA transplant
45683591|NCT03771430|Behavioral|Osteoarthritis education, exercise and CBT|"Osteoarthritis Education~60-min session by AktivA trained PT)~Signs/symptoms, risk factors, weight control, treatment~Importance of physical activity~Appropriate activity & training modalities~Exercise and CBT Support~60-min sessions/week for 12 weeks (a total of 24 sessions) led by AktivA and CBT trained PT)~Warm-up session~Strengthening exercises~Functional exercises~Stretching~Monitoring of CBT progress~Review of CBT lessons learned~Integration of CBT skills~Enhance motivation to continue~Online CBT (iCBT) (10 modules completed at home)~Pain causes & prevention~Pain management~Health promotion & stress reduction at home & work~Adapting for leisure & work~Controlling flare-ups~Maintaining & improving results"
45341187|NCT00440557|Drug|Epoetin alfa 3 times weekly /once weekly|Epoetin alfa will be administered as a SC injections at initial dose of 50 IU/kg (3 times weekly for 22 weeks) and at initial dose of 10000 IU (once weekly for 22 weeks)
45341188|NCT00440557|Drug|Epoetin alfa once weekly|Epoetin alfa will be administered as a SC injection at initial dose of 10000 IU (once weekly for 44 weeks).
45341189|NCT00440557|Drug|Epoetin alfa once every two weeks|Epoetin alfa will be administered as a SC injection at initial dose of 20000 IU (once every 2 weeks for 44 weeks).
46036534|NCT01155011|Behavioral|Policy Change|In order to increase the sustainability of the project, MIPARC will focus on addressing on-site policies and neighborhood factors that are barriers to physical activity. Peers and staff will conduct site inspections to identify these barriers (e.g. lack of facilities, limited opening hours, unsafe sidewalks, etc.) which will be prioritized and presented to CCRC management and community officials.
45341190|NCT05673590|Drug|Utidelone Injection|"Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to Utidelone iv drip at the first day of each cycle. The dose of dexamethasone and diphenhydramine can be halved by the physician based on patient's condition in the following day through the fifth day in each cycle, as detailed in the protocol.~Dexamethasone 8 mg per oral, bid, one day prior to docetaxel iv drip for 3 days.~The treatment group will be treated with Utidelone Injection at 40 mg/m2/d intravenously once daily on days 1-5 in a 21-day cycle until disease progression or an occurrence of intolerable toxicities."
46036535|NCT01155011|Behavioral|Support|A binder of professionally prepared materials will be provided at the beginning of the intervention and are referred to by researchers in the group sessions and phone counseling calls. The materials provide important information to encourage knowledge, self efficacy and realistic expectations.
45341191|NCT05673590|Drug|Docetaxel Injection|"Pretreatment: Dexamethasone should be administered orally for 3 days at 16 mg per day (8 mg twice daily), starting one day before the start of Docetaxel.~The control group will be treated with Docetaxel Injection at 75 mg/m2/d, administered intravenously once on day 1. Patients in this group will be treated in 21-day cycles until disease progression or intolerable toxicities occurs."
45341192|NCT02528227|Other|Know Your Baby Language Curriculum|Early language activities that parents can do with their infants
45341193|NCT02528227|Other|Reading Aloud Language Curriculum|Early language activity that parents can do with their infants
45341194|NCT02528227|Other|Sing A Long Language Curriculum|Early language activity that parents can do with their infants
45341195|NCT02528227|Other|Mimicking First Sounds Language Curriculum|Early language activity that parents can do with their infants
45341196|NCT02528227|Other|Language Games and Narrating Your Day Language Curriculum|Early language activity that parents can do with their infants
45341197|NCT02528227|Other|Feeding Safety|Part of Health and Safety Curriculum
45683592|NCT03771430|Procedure|Total Knee Arthroplasty|Standard total knee arthroplasty will be performed.
45683593|NCT04402138|Drug|Acalabrutinib|Acalabrutinib 100 mg BID will be self-administered orally starting from 100 day (+/- 7 days) Post-BMT on a 28-day schedule, with or without food, until the patient has reached approximately 2 years post-BMT.
46036536|NCT01155011|Behavioral|Tailored environmental resources|Participants will be provided with a set of printed materials relating to the residential and neighborhood environment of their CCRC. A list of step counts for key indoor routes will be provided as well as safe walking route maps for the site an local neighborhood.
45683594|NCT03197662|Drug|Intranasal Oxytocin (IN-OXT)|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
46036537|NCT01155011|Behavioral|Group educational sessions|Lectures will be delivered every three weeks to match the MIPARC intervention schedule. Sessions will include topics such as medications, foot care and nutrition. Physical activity will not e discussed in these sessions but participants will receive informational pamphlets on the benefits of physical activity.
46036538|NCT01155011|Behavioral|Health check phone call|For the first 3 months, control participants will also receive a health check phone call to match the individual attention paid to participants in the MIPARC sites.
46036539|NCT01155011|Behavioral|Pedometer|Participants will also keep the pedometer they wear during the baseline measurement week to satisfy any curiosity about the devices and the step entry criteria. They will be given instructions on its use but will not be taught the benefits of self-monitoring.
46036540|NCT00689689|Device|Fully coated Prodigy stem|Total hip arthroplasty with fully coated Prodigy stem
46036541|NCT00689689|Device|Cemented Endurance Stem|total hip arthroplasty with cemented endurance stem
45341198|NCT02528227|Other|Car Seat Safety|Part of Health and Safety Curriculum
45341199|NCT02528227|Other|Bath Safety|Part of Health and Safety Curriculum
45341200|NCT02528227|Other|Back to Sleep/SIDS prevention|Part of Health and Safety Curriculum
45341201|NCT02528227|Other|Taking a Temperature and Signs of Infection|Part of Health and Safety Curriculum
45341202|NCT02528227|Other|Infection Control Measures and Vaccine Information|Part of Health and Safety Curriculum
45341203|NCT01029847|Drug|Adalimumab|Sc. inj. adalimumab 40 mg every other week for 42 to 48 weeks. At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines.
45341204|NCT01029847|Drug|Placebo|"sc. inj. placebo every other week, week 0, 2, and 4. Sc. inj. adalimumab 40 mg every other week from week 6.~At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines."
45341205|NCT02452268|Drug|NIZ985|Subcutaneous administration of hetIL-15 three times a week for two consecutive weeks
45341206|NCT02452268|Drug|PDR001|• PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
46036542|NCT02806570|Device|Mitral valve repair|
45473469|NCT03125512|Device|Night Shift positional device|Night Shift is a small, positional therapy device that is worn at the back of the neck using a latex free silicone rubber strap. The strap is adjustable and is secured with a magnetic clasp. When a supine position is detected, the device vibrates with increasing intensity till the subject changes to a non-supine position.
46036543|NCT02879292|Other|Spinal anesthesia|Spinal Anesthesia
46036544|NCT00689767|Device|CINATRA™ Coronary Stent System|Bare metal cobalt chromium stent implantation
45341207|NCT05673512|Combination Product|Injection of IAH0968 + CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
45473470|NCT03125512|Device|continuous positive airway pressure|Automated adjusting continuous positive airway pressure
45341208|NCT05673512|Combination Product|PLACEBO+CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
45341209|NCT03872492|Other|Digital Assessment on mobile|"The digital assessment is composed on 5 tests:~My daily survey~My evaluation~My cognition~My emotions~My voice~Data will also be collected passively."
45341210|NCT02524249|Drug|Caffeine|
45341211|NCT02524249|Drug|Placebo (dextrose)|
45473471|NCT01166477|Drug|Lopinavir and ritonavir|The patients will take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
45473472|NCT01166477|Drug|Triple therapy with ritonavir|The patients will continue to take their usual triple therapy, as established in the summary of product characteristics
46036545|NCT00689767|Device|CINATRA™ ISA 247 Coated Coronary Stent System|Drug coated cobalt chromium stent implantation
46036546|NCT04313465|Other|Immediate discharge|Participants discharged after initial blood test for cardiac troponin and risk stratification using the T-MACS decision aid
46036547|NCT02806648|Drug|Palbociclib|Palbociclib
45473473|NCT02725528|Drug|collagenase injection|injection
45473474|NCT02725528|Procedure|limited palmar fasciectomy|surgery
46036548|NCT04138147|Procedure|Superficial cervical plexus with auriculotemporal nerve blocks|Superficial cervical plexus block using 10 ml bupivacaine 0.5%. Auriculotemporal nerve block using 3 ml bupivacaine 0.5%.
46036549|NCT04138147|Procedure|Cervical retrolaminar with auriculotemporal nerve blocks|Cervical retrolaminar block using 10 ml bupivacaine 0.5%. Auriculotemporal nerve block using 3 ml bupivacaine 0.5%.
46036550|NCT04071808|Diagnostic Test|ELISA Test|The levels of orphanin and norepinephrine in blood of diabetic patients with painless myocardial ischemia requiring interventional therapy and diabetic patients without interventional therapy were measured.
46036551|NCT04307784|Dietary Supplement|VD3|VD3 (50.000 IU/week) for 8 weeks
46036552|NCT04307784|Dietary Supplement|Omega-3FA|Omaga-3FA (300 mg/day) for 8 weeks
45341212|NCT01033981|Drug|Sunitinib|Treatment for mRCC as indication approved and physician criterium
45341213|NCT02430194|Drug|lonafarnib|antiviral farnesyl transferase inhibitor
45473475|NCT02714920|Other|CHEMRAD assay|CHEMRAD is a new biomarker research strategy based on three assays that enables the functional characterization of DNA repair capacities.
45341214|NCT02430194|Drug|ritonavir|CYP 3A4 inhibitor, lonafarnib booster
45341215|NCT02430194|Drug|Pegylated interferon-alfa-2a|immunomodulator
45341216|NCT00582608|Drug|131I-8H9|This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m^2 dose [intended specific activity of ~20 mCi/mg protein]
45341217|NCT00582608|Drug|8H9|administration of 50mg/1.73m^2 of unlabeled 8H9.
45341218|NCT02579798|Device|PEEP (positive end-expiratory pressure)|
45341219|NCT02400242|Drug|ACY-241|Dose escalation up to 480 mg administered orally on Days 1-21 of a 28 day cycle.
46036553|NCT04307784|Dietary Supplement|VD3 and Omega-3FA|VD3 (50.000 IU/week) and (Omega-3FA 300 mg /day) for 8 weeks
46036554|NCT04307784|Other|Control|No intervention is given
46036555|NCT00689845|Biological|bleomycin sulfate|Given IV
46036556|NCT00689845|Biological|filgrastim|Given subcutaneously
46036557|NCT00689845|Biological|rituximab|given IV
45473476|NCT02526641|Procedure|Functional Hepatic Nitrogen Clearance (FHNC)|
45473477|NCT02526641|Procedure|Galactose Elimination Capacity (GEC)|
45683595|NCT03197662|Drug|Matched Placebo|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
46036558|NCT00689845|Drug|cyclophosphamide|Given IV
46036559|NCT00689845|Drug|cytarabine|Given subcutaneously
46036560|NCT00689845|Drug|doxorubicin hydrochloride|Given IV
46036561|NCT00689845|Drug|etoposide phosphate|Given IV
46036562|NCT00689845|Drug|ifosfamide|Given IV
46036563|NCT00689845|Drug|methotrexate|Given IV
46036564|NCT00689845|Drug|prednisolone|Given orally
45341220|NCT02400242|Drug|Pomalidomide|4 mg qd dosed on days 1-21 of a 28 day cycle
45341221|NCT02400242|Drug|Dexamethasone|40 mg qd on days 1, 8, 15, 22
45341222|NCT03918824|Other|Data extraction from medical files|Data extraction from medical files
45473478|NCT02526641|Procedure|Liver vein catheterization|
45473479|NCT01282151|Drug|Taxotere|Docetaxel 60 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
45473480|NCT01282151|Drug|Pemetrexed|Pemetrexed 500 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
45473481|NCT03377218|Dietary Supplement|Iodine|Receiving 150 μg iodine (as potassium iodide) daily
45473482|NCT03377218|Dietary Supplement|Iodine + Selenium|Receiving a combination of 150 μg iodine (as potassium iodide) and 100 μg selenium daily
45473483|NCT01168505|Drug|ferric hydroxide saccharate|single dose of 200 mg (2 ampoules), 24-48 hours after administration of chemotherapy for a total of four doses
45473484|NCT03382600|Biological|Pembrolizumab|200 mg Q3W on Day 1 by IV infusion
45473485|NCT03382600|Drug|Oxaliplatin|130 mg/m^2 Q3W on Day 1 by IV infusion
45473486|NCT03382600|Drug|TS-1|40 to 60 mg orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
45473487|NCT03382600|Drug|Cisplatin|60 mg/m^2 Q3W on Day 1 by IV infusion
46036565|NCT00689845|Drug|prednisone|Given orally
46036566|NCT00689845|Drug|vincristine sulfate|Given IV
46036567|NCT00689845|Drug|vindesine|Given IV
46036568|NCT00624767|Drug|Insulin (recombinant human insulin)|Insulin Nasal Spray at doses up to 200 IU.
46036569|NCT00624767|Drug|NovoLog|NovoLog at doses up to 30 IU
45341223|NCT02579330|Device|Coloshield|Coloshield is designed to occlude the rectum during surgery thus enabling the possibility for rectal washout and maintaining a clear operating field. The rod-shaped Instrument contains two silicon balloons which are inflated by means of a catheter. Several holes at the section in between the two balloons are connected to another catheter, which enable negative pressure to be established. By insufflation of the two balloons and establishment of a negative pressure between the balloons by means of connection to a closed drainage bottle the colon is occluded for the duration of surgery.
45473488|NCT01282307|Behavioral|Guided Self-Determination GSD|The method GSD consists of 21 worksheets designed to guide patient and mental health professionals through autonomy-supportive problem solving. The worksheets are filled in by the patient before and between conversations with their community nurse over 10 sessions, approximately 1 hour a session.
46036570|NCT04200820|Diagnostic Test|Trampoline|During trampoline training that participants undergo constant change of vestibular stimulation. This triggers deep proprioception as well as other sensory inputs. This trigger might affect strength, body stability, muscle coordinative responses, joint movement amplitudes and spatial integration
45341224|NCT02579330|Other|Control|In the control group no device is introduced but a rectal washout with 500ml of Saline solution in performed.
45341225|NCT03918902|Behavioral|Qestinnaires|Questionnaires
45341226|NCT03087656|Drug|Ceftriaxone|Intravenous Ceftriaxone will be given during the procedure.
45473489|NCT03377140|Dietary Supplement|Hesperidin|2 capsuls
45473490|NCT03377140|Other|control|2 capsuls
45473491|NCT03868319|Procedure|lung protective ventilation strategy|low tidal volumes and positive end-expiratory pressure mechanical ventilation during robot-assisted laparoscopic radical cystectomy for bladder cancer
45473492|NCT03868319|Procedure|nonprotective ventilation|large tidal volume and zero PEEP mechanical ventilation during robot-assisted laparoscopic radical cystectomy for bladder cancer
45473493|NCT04013191|Drug|Padsevonil|Padsevonil will be administered in predefined dosages.
45683596|NCT04391062|Drug|Gliolan|patient will receive 5-ALA 4 to 6 hours before surgery
46036571|NCT04205981|Other|Aerobic exercise|8-week aerobic exercise (moderate intensity), 5 times per week, 60 min per session. Exercise training under supervision of trained staff.
46036572|NCT02806492|Other|50-100ug phenylephrine before CPB|In this intervention we will administer 50-100 μg phenylephrine to the patient before CPB is started. This intervention will take place when the patient shows hypotension (MAP <60mmHg, according to protocol22). Because of the increase in PVR there will be a baroreceptor-reflex-mediated decrease in CO. On-line, we will quantify the percentage decrease in systemic blood flow (i.e. CO) by using the Modelflow algoritm incorporated in a non-invasive beat-to-beat finger blood pressure monitor. This will allow us to obtain a reference for the decrease in CO to use in the next interventions. Our hypothesis is that CO will decrease because of the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.
45683597|NCT04391062|Device|Intraoperative PDT|"The protocol requires the realization of specific procedures in addition to the usual care.~The intra-operative photodynamic therapy (intraoperative PDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA ( 5-aminolevulinic acid hydrochloride),GLIOLAN drinkable 6h before surgery + lighting of the tumor bed by a red light source (laser with different J/cm²) at the end of resection (Prolonged surgery of 45 minutes)."
46036573|NCT02806492|Other|50-100ug phenylephrine during CPB|In this intervention we will induce only 1 component of the changes at intervention (1), being the increase in MAP of approximately 20 mmHg by administrating 50-100 μg phenylephrine. The CPB enables us to maintain a constant CO and thus eliminating the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.
45341227|NCT03087656|Drug|Levofloxacin|Oral Levofloxacin will be given for 3 days after the procedure.
45341228|NCT03068624|Biological|Aldesleukin|Given SC
45341229|NCT03068624|Biological|Autologous CD8+ SLC45A2-specific T Lymphocytes|Given via hepatic arterial infusion via central catheter
45341230|NCT03068624|Drug|Cyclophosphamide|Given IV
45341231|NCT03068624|Biological|Ipilimumab|Given IV
45341232|NCT03870776|Drug|MAP4343|Daily oral administration of MAP4343
45341233|NCT03870776|Drug|Placebo|Daily oral administration of Placebo
45473494|NCT03872765|Device|Laser surgery|Use of CO2 laser to perform surgeries to treat chronic anal fissure
45473495|NCT01171391|Drug|VA106483|1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
45473496|NCT01171391|Other|Placebo|Placebo on Day 1
45473497|NCT03898726|Biological|laparoscopical l cuff closure|closure of vaginal cuff following hysterectomy
45473498|NCT03867929|Other|25-Hydroxy vitamin D|27.32 is calculated as a cut fo level for 25 hydroxy vitamin D deficiency
45473499|NCT03285594|Drug|Sotagliflozin|"Pharmaceutical form: Tablet~Route of administration: Oral"
45473500|NCT03285594|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
45473501|NCT03285594|Drug|Placebo|"Pharmaceutical form: Tablet~Route of administration: Oral"
45341234|NCT03918668|Behavioral|Women with recent diagnosis of breast cancer|To evaluate dietary habits of a group of women with pre and post-surgical breast cancer
45341235|NCT03014570|Behavioral|EIT-4-BPSD|This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
45341236|NCT03014570|Behavioral|Education-only Control|This arm includes step 2 only of the EIT-4-BPSD. Facilities are provided with education abouthow to provide behavioral interventions for behavioral symptoms associated with dementia. They can have the education face-to-face or via a powerpoint or webinar.
45341237|NCT03869372|Device|rTMS|In subsequent sessions, the same measures of autonomic activity and MEPs will be monitored but different patterns of repetitive TMS (rTMS) will be applied to motor cortex or other areas before the test meal, water or nutrient drink is consumed.
45341238|NCT03005366|Drug|Vernakalant|Initial infusion: 3 mg/kg intravenously over a 10 minute period. For patients weighing ≥ 113 kg, the maximum initial dose will be 339 mg. If conversion to sinus rhythm does not occur within 15 minutes after the end of the initial infusion, a second 10 minute infusion of 2 mg/kg will be administered. For patients weighing ≥ 113 kg, the maximum second infusion will be 226 mg.
45341239|NCT03005366|Drug|Flecainide|2 mg /kg (max 150 mg) intravenously over 10 minutes.
45341240|NCT04073654|Procedure|Placement of dental implants (surgical procedure)|The two study implants have to be placed in the same surgical session according to similar procedures. Implants will be placed in the planned anatomic sites by using a flapless or a miniflap approach. Implants sites will be prepared based on the bone density, and according to the manufacturers's instruction by using the 122 Taper kit (Osstem Implant).
45341241|NCT04076228|Drug|Pembrolizumab|pembrolizumab is a PD-1 inhibitor. Treatment and follow up will be performed at Kiang Wu Hospital in their clinical oncology center. Clinically pathological related information will be recorded.
45341242|NCT02579252|Biological|AADvac1|
45341243|NCT02579252|Drug|Placebo|
45341244|NCT02580734|Dietary Supplement|melatonin|Cross-over randomized clinical trials
45341245|NCT05673434|Biological|TM4SF1-positive chimeric antigen receptor T-cell therapy|"Specification: 50mL/bag. Storage: The prepared CAR T-cells are cryopreserved in a preserving medium . This product is manufactured under the current good manufacture practices (cGMP) conditions, with restrictions on chemical components, free from animal- or human-derived components and confirming to the United States Pharmacopeia (USP)<71> and <85> regulations.~Preservation: The frozen CAR T-cells are preserved in the liquid nitrogen transfer tank.~Usage: The frozen CAR T-cells are preserved at low temperature and transferred to the bedside. The cells are thawed by 36 degrees centigrade to 38 degrees centigrade. water bath. The frozen cells are gently massaged until complete thawing. Then they are transfused back to the patients intravenously. The transfusion will be finished within 10-20 min."
45341246|NCT04073576|Device|AHCL|Closed loop algorithm contained in the MiniMed™ 670G 4.0 pump to be used in the study; includes a modified proportional integrative derivative (PID) model, with insulin feedback, an auto correction bolus feature and additional safety features.
46036574|NCT02806492|Other|decreasing CPB flow|With this intervention we will only create a change in CO, which enables us to eliminate the effect of blood pressure. We will modify CPB flow to achieve the CO decrease (in %) measured at intervention (1) meaning: pre-CPB after the bolus of 50-100 μg phenylephrine. In the case of unexpected increase (in %) of CO measured at intervention (1), we will still decrease CPB flow so we will be able to analyse decrease as well as increase in CPB flow. During this intervention NIRS and TCD MCA will be recorded.
46036575|NCT02806492|Other|Decreasing CPB flow AND 50-100ug phenylephrine|In this intervention we will simulate the 'normal' physiological state when administering phenylephrine. We will modify CPB flow to achieve the percentage change CO as observed during intervention (1) as well as administrate 50-100 μg phenylephrine. We expect to see similar outcomes as in intervention (1). During this intervention NIRS and TCD MCA will be recorded.
45473502|NCT03285594|Drug|Oral Antidiabetes Drugs (OADs)|OADs (including metformin) as prescribed by the investigator as per local labeling.
45683598|NCT03194542|Drug|Luspatercept|Luspatercept is a recombinant fusion protein consisting of a modified form of the extracellular domain of the human active in receptor type IIB linked to the IgG1 Fc domain. Luspatercept, through a mechanism of action different from erythropoietin, works to correct ineffective erythropoiesis by promoting late-stage maturation of erythroblasts.
46036576|NCT02806492|Other|Increasing CPB flow|In this last intervention we will create an increase in MAP without using phenylephrine but only by increasing CO. This enables us to eliminate a possible direct α1-adrenergic effect on the cerebral vasculature. MAP will be raised approximately 20 mmHg by increasing CPB flow 20%. During this intervention NIRS and TCD MCA will be recorded.
46036577|NCT02884895|Device|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction Disposable
45341247|NCT04073576|Device|SAP+PLGM|Sensor Augmented Pump (SAP) Therapy Mode with Predictive Low Glucose Management (PLGM), contained in the the MiniMed™ 670G 4.0 pump to be used in the study.
45341248|NCT02924870|Other|Health education program|"2 sessions, at 15 and 30 days after hospital discharge. The first session will consist of four stages:~Basic formation: basic lung anatomy and physiology, COPD concept, importance of tobacco, diagnostic tests for COPD, and how COPD is treated.~Care in COPD: diet, breathing exercises, physical exercise (walking, cycle, treadmill ...), lifestyle (clothing, hygiene, preening, exercise, rest, sexuality, social relations).~Management of conventional treatment: inhalers, oxygen therapy and smoking cessation.~Action Plan: the patient and the nurse will establish a target about the activities that the patient must perform as well as their frequency and duration, according to WHO guidelines.~Second session: changes from the previous session; compliance with the physical activity plan and the deviation causes; weaknesses of the patient; skills in the management of inhalers, oxygen, and breathing exercises; and a new physical activity plan."
46036578|NCT02884895|Device|Direct Laryngoscopy|Direct Laryngoscopy
46036579|NCT02806258|Radiation|Accelerated partial breast irradiation|To date, there is no report on external beam APBI associated with CT in the neoadjuvant setting.In the NeoAPBI 01 trial, the objective is to demonstrate the efficacy of combined APBI and CT administered sequentially in patients with intermediate ad high risk BC. The hypothesis is that combined PST-sequential APBI may increase the rate of pCR, breast conservation and survival without additional toxicity, as seen with WBI.
46036580|NCT02806258|Drug|Chemotherapy|minimum of six cycles of PST using anthracycline and/or taxane based regimens
46036581|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 5 mcg BID
46036582|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
45473503|NCT01171469|Biological|Dendritic Cells|5, 10 or 15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
46036583|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
46036584|NCT00691405|Drug|Placebo|Placebo inhalation solution BID
46036585|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg QD
46036586|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg QD
46036587|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
46036588|NCT00691405|Drug|Placebo|Placebo inhalation solution QD
46036589|NCT01106430|Drug|Lisdexamfetamine Dimesylate|Oral 30, 50, or 70mg once-daily for 9 weeks
45341249|NCT02924870|Other|Conventional management|Treatment and follow-up according to conventional clinical practice (GesEPOC guidelines), including recommendations on healthy habits and lifestyle.
45341250|NCT00427999|Drug|imatinib mesylate|
45341251|NCT00427999|Drug|Treosulfane|
45341252|NCT00427999|Drug|etoricoxib|
45473504|NCT01171469|Drug|Imiquimod|Imiquimod (INN) is a prescription medication that acts as an immune response modifier. Imiquimod is marketed as 5% Aldara cream in 250 mg packets, providing a total dose of 12.5 mg per packet and sufficient to cover 20 square centimeters. The contents of ½ of a packet will be applied as a thin film to cover approximately 10 square centimeters of skin in the area of the planned vaccination.
45341253|NCT00427999|Drug|pioglitazone|
45341254|NCT00427999|Drug|dexamethasone|
45341255|NCT01032967|Procedure|Esophagectomy|The patients will receive standard open esophagectomy with two-field lymphadenectomy
45473505|NCT03872921|Drug|norUrsodeoxycholic Acid|oral treatment
46036590|NCT01106430|Drug|Atomoxetine Hydrochloride|Oral 10mg to 100mg once-daily for 9 weeks
46036591|NCT02804698|Behavioral|Education intervention|13-week educational and physical activity intervention
46036592|NCT01154231|Drug|Nonacog Alfa (Genetical Recombination)|"Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered this drug.~Patients with hemophilia B are either patients for whom treatment was already started with a blood coagulation factor IX product (Previously treated patients: hereinafter, PTPs) or patients who have no history of treatment with a blood coagulation factor IX product in the past and for whom treatment will be started with this drug for the first time (Previously untreated patients: hereinafter, PUPs).~The definition of PUPs in this survey is Patients in whom the total number of days of administration of a blood coagulation factor IX product other than this drug before administration of this drug was 3 exposure days (actual number of days of administration: hereinafter, EDs) or less."
46036593|NCT02806180|Procedure|Dual Operator Ultrasound Guided IV placement|Second operator holds ultrasound probe.
45341256|NCT01032967|Radiation|Definitive chemoradiation|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
45341257|NCT02881814|Diagnostic Test|Lung and diaphragm ultrasound|The ultrasound physiotherapist/operator performs a lung and diaphragm ultrasound. He is blinded to the patient's status and clinical physiotherapist examination. He/she is not involved in patient management or patient clinical decision-making. The ultrasound findings are recorded in the LUS report. The LUS report is reported to the clinical physiotherapist and to the intensivist. The ultrasound diagnosis(es) is recorded.
45341258|NCT02881814|Diagnostic Test|Lung and diaphragm ultrasound in MV patients|In case of mechanically ventilated patient at St. Vincent Hospital (Sydney, Australia), LUS scan will be performed immediately following intubation. Additionnal LUS scans will be performed 72h after intubation and Immediately prior to or following extubation.
45341259|NCT04836494|Drug|BBP-671|BBP-671, oral suspension
45341260|NCT04836494|Drug|Placebo|Placebo matching BBP-671
45341261|NCT04836494|Drug|BBP-671|BBP-671, tablet
45341262|NCT02579018|Behavioral|One hour supervised exercise session|All participants will participate in a one hour supervised exercise session. Participants will wear a physical activity monitor during the assessment for continuous monitoring of heart rate. Short, intense bouts of exercise will be interspersed with rest periods.
45341263|NCT04825652|Drug|177Lu-PSMA-617|Participants will receive 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles.
46036594|NCT02806180|Procedure|Single Operator Ultrasound Guided IV placement|Single operator holds ultrasound probe and places IV.
46036595|NCT02804776|Drug|Gefitinib|250mg oral daily for 4 weeks
46036596|NCT01154153|Drug|Placebo nasal spray|1 spray/nostril, once daily in the morning, for 8 to 24 days during the screening phase.
45473506|NCT03234465|Biological|AG013|AG013 is made up of genetically modified (GM) bacteria called Lactococcus lactis (L. lactis). Wild type L. lactis are commonly used to produce dairy products including cheeses and milk. To make AG013, the DNA of L. lactis has been changed in the laboratory to secrete a protein called human Trefoil Factor 1 (hTFF1). hTFF1 is normally secreted in saliva and intestines. Trefoil factors have been shown to be important in protecting and healing mucosal tissues, such as the tissue in the mouth, when these tissues are damaged by cancer therapies such as chemotherapy and radiation therapy.
45473507|NCT03234465|Other|Placebo|Subjects assigned to the placebo group will receive appearance- and taste-matched placebo powder.
45473508|NCT03290131|Drug|Arbaclofen|Arbaclofen Extended Release Tablet
45341264|NCT04825652|Drug|PSMA-11|Patients will receive a dose of gallium (68Ga) gozetotide that is 1.8-2.2 MBq/kg of body weight (0.049-0.059 mCi/kg), with a minimum dose of 111 MBq (3mCi) up to a maximum dose of 259 MBq (7 mCi).
45341265|NCT03847220|Diagnostic Test|BOMET-QoL questionnaire|study to evaluate the utility of the BOMET-QoL questionnaire in patients with BC and BM
45341266|NCT00661713|Biological|rMenB+OMV NZ|
45341267|NCT00661713|Biological|Placebo|
46036597|NCT01154153|Drug|Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ)|"Treatment assignment was randomized with stratification by sex and age group (>=2 to <6, >=6 to <12 years old).~For children who were >=2 to <6 years old, 1 spray/nostril (110 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.~For children who were >=6 yrs to <12 years old, either 1 spray/nostril (110 µg TAA-AQ) or 2 sprays/nostril (220 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase."
46036598|NCT01154153|Drug|Placebo nasal spray|"Treatment assignment was randomized with stratification by sex and age group (>=2 to <6, >=6 to <12 years old).~For children who were >=2 to <6 years old, 1 spray/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.~For children who were >= 6 yrs to <12 years old, either 1 spray/nostril or 2 sprays/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase."
45341268|NCT02578472|Drug|JNJ-42847922|JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule*20 mg) in one of the treatment periods.
45341269|NCT02578472|Drug|Zolpidem|Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.
45341270|NCT02578472|Drug|Placebo|Matching Placebo will be administered orally.
45341271|NCT00786123|Dietary Supplement|VSL#3|Dose: 4 capsules of VSL#3 daily for 6 weeks.
45341272|NCT00786123|Dietary Supplement|Placebo|Identical looking preparation of placebo taken at the same dose regimen as the active comparator
45341273|NCT03840902|Drug|M7824|Participants will receive intravenous infusion of 1200 milligram (mg) M7824 over 1 hour every 2 weeks (q2w) during cCRT and up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
45341274|NCT03840902|Drug|Placebo|Participants will receive intravenous infusion of placebo matched to M7824 over 1 hour q2w during cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
45473509|NCT03290131|Drug|Placebo|Placebo comparator
45473510|NCT03870191|Other|Injection of either twin block or trigger point injection.|Study participants will be randomized into either group and will receive the intervention.
45341275|NCT03840902|Drug|Durvalumab|Participants will receive intravenous infusion of durvalumab 10 milligram per kilogram (mg/Kg) over 1 hour q2w up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
45341276|NCT03840902|Drug|Etoposide|Participants will receive etoposide 50 mg/m^2 intravenously over a minimum of 30 minutes up to 60 minutes daily on Day 1 to 5 and Day 29 to 33 during cCRT.
46036599|NCT01154153|Drug|Claritin® Syrup|Children's Claritin® Syrup [5 mg of loratadine per 5 mL] could be taken orally for the relief of AR symptoms throughout the study on an as needed basis, according to the Food and Drug Administration-approved manufacturer's label.
45341277|NCT03840902|Drug|Pemetrexed|Participants will receive pemetrexed at a dose of 500 mg/m^2 intravenously over 10 minutes or according to local standards on Days 1, 22, and 43 during cCRT.
46036600|NCT02806102|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention
45341278|NCT03840902|Drug|Carboplatin|Participants will receive carboplatin intravenously based on area under curve (AUC) 2 over 30 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
45473511|NCT03746353|Procedure|early ileostomy closure|Assigned interventions Conventional closure of ileostomy: Surgical closure of the protective ileostomy 90 or more days after the proctectomy surgery
46036601|NCT02806102|Drug|Dual-antiplatelet therapy|Dual AntiPlatelet Therapy
46036602|NCT02806102|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention
46036603|NCT02806102|Drug|Dual-antiplatelet therapy|Dual AntiPlatelet Therapy
46036604|NCT00691561|Behavioral|Project ABLE|Participants will receive HIV counseling and testing. Those selected for the intervention arm will attend small groups consisting of 10 men who meet once a week for 8 consecutive weeks. The weekly two hour discussion sessions will address HIV risk behavior within a framework of contextual influences that may moderate men's risk reduction motivation and behavior. The factors include identity, stigma, connections to community, and situation factors.
45341279|NCT03840902|Drug|Paclitaxel|Participants will receive paclitaxel intravenously at a dose of 45 mg/m^2 over 60 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
45341280|NCT03840902|Drug|Cisplatin|In combination with etoposide, participants will receive cisplatin 50 mg/m^2 intravenously over 60 minutes on Days 1, 8, 29, and 36 during cCRT. In combination with pemetrexed, participants will receive cisplatin 75 mg/m2 intravenously over 60 minutes on Days 1, 22, and 43 during cCRT.
45341281|NCT03840902|Radiation|Intensity Modulated Radiation Therapy (IMRT)|Participants will receive IMRT 5 fractions per week for about 6 weeks (Total 60 gray [Gy]).
45341282|NCT04047225|Device|THE ANALGESIA NOCICEPTIVE INDEX (ANI)|Utilisation of the ANI during the operation
45341283|NCT00782925|Other|educational program|Educational program will consist of 1, 2-hour, small-group (8-patient) session with a specialist physician in Physical and Rehablilitation Medecine. Workers will be given information about lower back pain, pain and psychosocial risk factors for persistent or recurrent back-related disability
45341284|NCT00782925|Other|exercise program|The exercise program will consist of 5, 90-minute, small-group (8-patient) sessions with a physical therapist. Healthcare workers will be taught exercises including warm-ups, floor exercises, and endurance training. Only one absence will be allowed, otherwise the worker will be considered as non-compliant.
45341285|NCT00782925|Other|Self-led exercises|Self-led exercises to perform as part of a daily exercise routine
45473512|NCT02526485|Procedure|Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
45473513|NCT02695992|Drug|Metoprolol|Dosage 100 mg o.d.
46036605|NCT00684229|Procedure|Regional anesthesia and analgesia|Post-operative analgesia will be epidural bupivacaine and fentanyl as well as intravenous morphine.
45341286|NCT04073888|Procedure|Semen collection|Semen collection for seminogram and spermocytogram
45341287|NCT04072796|Behavioral|Questionnaires|Short Form-36 (SF-36), Barthel Index (BI), Functional Ambulation Category (FAC), Mini-Mental Test (MMT) and Beck Depression Inventory (BDI) questionnaires
45341288|NCT03840668|Device|USB Eye Mask|To evaluate the acceptance of the USB eye mask via questionnaire and also to monitor the use of USB eye mask over a period of 3 months.
45341289|NCT03835975|Biological|13vPnC|Pneumococcal conjugate vaccine
45341290|NCT03835975|Biological|PPSV23|Pneumococcal polysaccharide vaccine
45341291|NCT03835975|Biological|20vPnC|Pneumococcal conjugate vaccine
45341292|NCT04072718|Radiation|Radiotherapy|34 Gy/10#/2wk to the PTV and 40Gy/10#/2 Wk to the PTV SIB with IGRT using Rapid arc technique.
45341293|NCT03838562|Other|Vestibular rehabilitation with virtual reality|"Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Optokinetic application with three-dimensional head-mounted is used in the experimental group."
45473514|NCT02695992|Drug|Diltiazem|Dosage 360 mg o.d.
45598878|NCT03158259|Other|Prehospital diagnosis and treatment|The patient will be diagnosed and treated by anesthesiologist in the mobile stroke unit (MSU). The diagnosis will be NIHSS, CT scans by a CT-scanner fitted in the MSU, and blood-analysis in a mobile lab inside the MSU. All performed by a three-person crew consisting of an anesthesiologist, paramedic and nurse-paramedic. The CT images will be sent to the lokal hospital and contact with neurologist in ward established. A decision to treat will be given in collaboration between the neurologist and anesthesiologist.
46036606|NCT00684229|Drug|general anesthesia followed by opioid analgesia|sevoflurane general anesthesia and postoperative opioid analgesia
46036607|NCT02887001|Other|Pharmacist consultation|
46036608|NCT04236622|Other|Periodontal clinical exam|"The individuals will be submitted to a complete periodontal examination, with measurements obtained at four points per tooth and dental implant (mesial, distal, buccal and lingual / palatal), in all teeth / implants present, except for the third molars, the parameters evaluated will be: Probing Depth, Clinical Insertion Level, Plaque Index, Teeth Bleeding Index. The implants will be evaluated according to the parameters: presence of suppuration, probing depth, bleeding to probing and presence of biofilm around the implants. To perform the clinical examinations, the following instruments will be required: Willians millimeter probe, exploratory probe and clinical mirror.~In all participants, complete periapical radiographic examinations with 14 radiographs will be performed to verify the bone cortical height level and to assist in the periodontal diagnosis."
45341294|NCT03838562|Other|Standard optokinetic stimulator or dynamic visual surround|"Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Standard optokinetic stimulator (stimulopt) or dynamic visual surround (smart equitest) are used in the control group."
45341295|NCT04038086|Diagnostic Test|oral glucose tolerance test|Participants will undergo an 75 gram oral glucose tolerance test. Blood and CSF will be collected in the fasting state before the test and every 30 minutes throughout the test which lasts for 2 hours.
45341296|NCT04038086|Other|circadian rhythm|Blood and CSF will be collected five times throughout the day.
45341297|NCT04038086|Drug|effect of insulin on peptide transport|Blood and CSF will be collected in the fasting state and 15, 30, 60, 120 und 240 min after administration of 160 U of human insulin as nasal spray.
46036609|NCT04313387|Diagnostic Test|Corneal tomography multivariate index derived from a support vector machine (CTMVI).|MATHEMATICAL ALGORITHM: To build the equation extracted from SVM, 58 variables were used, some of them were extracted from the spreadsheet.. After the construction of these 58 feature vectors (FV), an SVM-derived index was created, which was called the corneal tomography multivariate index derived from a support vector machine (CTMVI). Considering that each patient represents a point on a cartesian plane with 58 dimensions (each coordinate representing one of the 58 FV), the role of SVM is to find the hyperplane that best separates the CG, KCG, and VAE-NT G subjects. A hyperplane is algebraically described by a linear equation; in this case, there are 59 coefficients, 58 of which are related to the FV and one independent coefficient representing the bias (which is a possible parallel dislocation of a given hyperplane).
45341298|NCT03177577|Device|Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis.
45341299|NCT03177577|Device|Splint with strengthening exercises|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis and will also be taught two first dorsal interosseous (FDI) strengthening exercises.
45341300|NCT04072640|Drug|Voriconazole 200mg|Induction treatment with voriconazole( 400mg/d)+5FC (100mg/kg/d) for 14 days;
45341301|NCT04072640|Drug|amphotericin B deoxycholate (0.4-0.5mg/kg/d)|Induction treatment with 0.4-0.5mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 28 days
45341302|NCT04072640|Drug|Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)|Induction treatment with 0.7-1.0mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 14 days
45341303|NCT01566487|Drug|Quetiapine fumarate|Quetiapine fumarate tablets 300mg
45341304|NCT04819646|Dietary Supplement|Marine Lipid Oil Concentrate Formulation|Marine Lipid Oil Concentrate softgels
45341305|NCT04819646|Dietary Supplement|Dietary Supplement|Dietary Supplement capsules
45341306|NCT04073264|Procedure|monofilament|In the intervention group,monofilament absorbable suture,will be used.
45341307|NCT04019210|Procedure|MODIFIED TRABECULECTOMY|Rectangular scleral flap
45341308|NCT02576288|Drug|Sitagliptin|anti-inflammatory properties
45341309|NCT02576288|Drug|Placebo|No anti-inflammatory properties
45341310|NCT00427921|Biological|adalimumab|160 mg loading dose, 80 mg at week 2, 40 mg every other week
45341311|NCT04794374|Other|Telerehabilitation|Telerehabilitation will consists of physiotherapist-guided exercises. Exercises will be designed by physiotherapists for COVID-19 survivors using the current guidelines. Exercise brochure will be prepared and will be sent to participants. Repetitions and sets of exercises will be modified according to the patients.
45341312|NCT00432991|Drug|Ephedrine [Synonyms: Ephedra, Ephedrinum]|25 mg, IM (in the muscle), one time
45341313|NCT00432991|Drug|Saline Placebo|0.5 mL, IM (in the muscle), one time
45341314|NCT00432835|Device|Gastric Electrical Stimulator, Enterra, Medtronics, Inc.|All patients received a GES electrode, endoscopically placed and connected to an external device at baseline. The device was turned ON to provide 72 continuous hours of active stimulation and OFF to deactivate stimulation
45598879|NCT03519061|Drug|Budesonide|Nasal saline irrigations with budesonide
45598880|NCT02229773|Drug|BIBB 1464 MS low dose|
45598881|NCT02229773|Drug|Placebo|
45598882|NCT02229773|Drug|Pravastatin|
45341315|NCT00580970|Drug|lovastatin|The HMG-coA reductase inhibitor used in this study will be lovastatin. Dosage: 20 mg/d PO with evening meal. Patients on a higher dose of lovastatin at the time of study entry may continue at that dose level; for patients switching to lovastatin, the dose will be at the discretion of the prescribing physician, but must be at least 20 mg/day.Schedule: begin on the first day of external beam radiation therapy (external beam alone or external beam followed by brachytherapy) or on the day of brachytherapy (brachytherapy alone or brachytherapy followed by external beam radiotherapy) and continue for 12 months. Patients or their third party payers will be expected to cover the cost of the drug.
45341316|NCT04786028|Other|Isatuximab|Brand name for interventional drug is Sarclisa
45341317|NCT01030081|Drug|Amlodipine (Norvasc®)|Amlodipine (Norvasc®), tablet, 5 mg
45473515|NCT05180643|Behavioral|Mindfulness-Based Stress Reduction-based program (MBSR).|The MBSR program is built over 8 weeks (1 information session, 8 group sessions from 2h30 to 3h and 1 full day). A trained MBSR instructor will lead group sessions weekly for approximately 150-210 minutes to teach and demonstrate the practices. Practices include walking/standing/supine meditation, body scanning (drawing attention to various areas of the body such as the right foot or left hand), and simple hatha yoga postures. Exercises are the basis of this group learning with practice time and practice exchange time. Participants are asked to commit to daily meditation at home using audioguides for 40 minutes to 1 hour.
45473516|NCT04050865|Drug|Dexamethasone, 0.4mg|Ophthalmic Insert
45473517|NCT04050865|Device|Placebo plug with no drug|Ophthalmic Insert
45473518|NCT01168661|Behavioral|Yoga|Participants in this intervention arm will practice yoga (physical postures, breathing exercises, and meditation) >= 5 times a week (twice in a supervised group and the rest on their own). Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. They will follow this schedule for 20 weeks.
45473519|NCT01168661|Behavioral|Mindfulness based cog psychotherapy|Participants in this arm will attend a weekly group meeting to practice mindfulness based cognitive psychotherapy. They will also practice >= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
45473520|NCT01168661|Behavioral|Cognitive psychotherapy|Participants in this arm will attend a weekly group meeting to practice cognitive psychotherapy. They will also practice >= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
45473521|NCT03283566|Drug|Hydroxychloroquine|Subjects will receive a pre-transplant 200 mg daily dose of HCQ 30 days before TPAIT and will continue on the drug for 3 months after surgery.
45473522|NCT03283566|Drug|Placebo|Subjects will receive a pre-transplant placebo 30 days before TPAIT and will continue on the placebo for 3 months after surgery.
45473523|NCT03210519|Dietary Supplement|Eleutherococcus senticosus|taken orally once/day for 90 days
46036610|NCT02804620|Behavioral|Peer-led, Empowerment-based Approach to Self-management efforts in Diabetes|The investigators will train patients with type 2 diabetes who are well-controlled and pair them up with participants. Peer leaders will help the participants overcome their problems and teach them how to make changes by 5 step goal setting strategy. The peer leaders never give advice on any medical condition. All the medical questions will be referred to the research team.
46036611|NCT00690079|Drug|AZD1386|Oral admin. of doses at 11 days through a 12 days period. Cmax = 16 mikromol/L and AUCmax = 98 mikromol*h/L
46036612|NCT00690079|Drug|Placebo|Oral admin. of doses at 11 days through a 12 days period.
46036613|NCT05251415|Biological|Blood sampling|Blood will be taken in larger quantity.
46036614|NCT02805712|Other|Verbal Information and Discussion|Intervention patient will receive a outpatient session with a palliative care social worker in the heart failure clinic two weeks post discharge consent focusing on goals of care.
46036615|NCT02805712|Other|Control|The control group will receive usual written care material and a palliative care consult if ordered by physician.
46036616|NCT00874237|Drug|Inhaled loxapine|Inhaled Staccato Loxapine 10 mg single dose
46036617|NCT00874237|Drug|Inhaled placebo|Inhaled Staccato placebo single dose
46036618|NCT00874237|Drug|Oral moxifloxacin|Oral moxifloxacin 400 mg
46036619|NCT00874237|Drug|Oral placebo|Oral placebo similar in appearance to moxifloxacin 400 mg
46036620|NCT02805946|Drug|posaconazole|iv versus oral
45341318|NCT01030081|Drug|Nifedipine GITS (Adalat® XL 30|Nifedipine GITS (Adalat® XL 30), controlled released tablet, 30 mg
45341319|NCT00665925|Drug|Fostamatinib disodium (R935788)|100 mg tablet, orally, twice-a-day
45341320|NCT00665925|Drug|Fostamatinib disodium (R935788)|150 mg tablet, orally, once a day
45341321|NCT00665925|Drug|Placebo|Placebo, orally, either once a day, or twice a day
45341322|NCT02578004|Other|biochemical and molecular analysis|
45341323|NCT02578160|Procedure|inferior alveolar and lingual nerve block procedure|inferior alveolar and lingual nerve block
45341324|NCT02578784|Device|Angioplasty with drug-coated balloon|"Angioplasty with drug-coated balloon Elutax (Aachen Resonance, Germany)"
45341325|NCT02578784|Device|Angioplasty with plain old balloon|"Angioplasty with plain old balloon Sterling (BostonScientific, Switzerland)"
45341326|NCT00426751|Drug|Abciximab|Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
45341327|NCT00426751|Drug|Eptifibatide|Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mdg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
46036621|NCT05544604|Device|Transcranial direct current stimulation|tDCS will be delivered with current strength of 2 mA for 20 min . Current will be applied through two concentric electrodes target electrode; return electrode. First we will fill the electrode cage with an electroconductive gel, and then position the electrodes, with the target electrode over the FDI hotspot, and finally we fasten the electrodes with a tubular net-shaped elastic bandage in mesh tissue, making sure that it will not push the electrode forward or backward. This procedure will aim at reducing contact impedance and at creating a uniform adherence between the whole surface of the electrodes and the scalp, avoiding uneven distribution of the current (Fertonani, 2015). We will position the central electrode (anode) according to the study group over C3 or C4 , the stimulating electrode will be placed on the scalp at T7 or T8 for the insular cortex per the 10-20 (EEG) system.
45341328|NCT02576366|Drug|Voriconazole|
45341329|NCT02576366|Drug|Rifampin|
45341330|NCT01030159|Other|Adult Cancer Patients|Tracking anemia management in Adult Cancer Patients
45341331|NCT01030237|Other|FID 114657|1 drop both eyes four times a day for 6 weeks
45473524|NCT03210519|Other|Placebo|taken orally once/day for 90 days
45473525|NCT01171547|Drug|Daptomycin|once daily over 5 days
45473526|NCT03745183|Other|Senna alata leaf decoction|"Preparation of the akapulko decoction~Remove the leaflets from the rachis of a mature leaf.~Wash the mature leaflets thoroughly to remove dust, dirt and debris.~In the clay, enamel, or stainless steel pot, place one glassful of closely packed chopped leaves (350 ml glass) and add 2 glasses (around 700ml) of clean water . Use the same glass for measuring the leaves and water.~Cook the leaves and bring to a rolling boil.~When the fluid is reduced to half, remove the decoction from the fire and cool slightly.~Strain the mixture using cheesecloth and press the cut leaves in the strainer to make sure to get as much liquid out of them.~Place the liquid in a clean container (bottle/jar with cover). Label the container clearly as Akapulko."
45473527|NCT03872687|Device|single tufted brush with IDB|Subjects in this group will receive a single tufted brush and interdental brushes of an appropriate size that will fit the interdental spaces around the implant.
45473528|NCT03872687|Device|interdental brushes|Subjects in this group will only receive interdental brushes
46036622|NCT04139005|Behavioral|Awareness|The program foundation targets attention and awareness skills that are integral to many conceptions of mindfulness.
45341332|NCT01030237|Other|Soothe XP Lubricant Eye Drops|1 drop both eyes four times a day for 6 weeks
45341333|NCT04046679|Drug|Bleomycin|Skin bleomycin infusion through tattoo machine
45341334|NCT04046679|Other|Saline Solution|Saline solution infusion through tattoo machine
45341335|NCT01323439|Device|Axium™ MicroFX™ PGLA COILS|Axium™ MicroFX™ PGLA COILS to treat aneurysms
45341336|NCT00786279|Other|ethanol|15 gm ethanol daily for 6 months
45341337|NCT00786279|Other|Ethanol-free beverage|0 grams ethanol daily for 6 months.
45341338|NCT01030315|Drug|HM10760A or placebo|Once, 0.04 mcg/kg to 2.0mcg/kg once intravenously
45341339|NCT00791193|Drug|Paliperidone ER|
45341340|NCT00791271|Drug|Decitabine|Starting dose of 10mg/m^2 given daily via intravenous infusion on days 1-5 of 28 day cycle.
45341341|NCT00791271|Drug|Pegylated Interferon Alpha-2b|Starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
45341342|NCT02555163|Device|HoLERBT|Using holmium laser, the tumour will be removed as one piece from its base working underneath the muscle layer
45341343|NCT02555163|Device|cTURBT|using the conventional electrocautery device with the cutting hot loop the tumor will be removed in pieces
45341344|NCT00786357|Behavioral|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
45341345|NCT00786357|Behavioral|Sleep Enhancement Training System|4 week program of readings and relaxation programs
45341346|NCT00791349|Drug|Immediate release (IR) Paliperidone|
45341347|NCT00440401|Drug|fibrinogen (human) + thrombin (human)|
45341348|NCT00440401|Drug|Standard haemostatic treatment in cardiovascular surgery|Any haemostatic fleece material without additional active coagulation stimulating compounds (primarily Surgicel®)
45473529|NCT03851133|Other|Blood Sample Collection|Participants will be asked to donate blood at baseline (+/- 30 days of diagnosis date) and at the time of follow-up (approximately 6 months and approximately 12 months after baseline).
45598883|NCT02229773|Drug|BIBB 1464 MS medium dose|
45598884|NCT02229773|Drug|BIBB 1464 MS high dose|
45473530|NCT03851133|Other|Tumor Sample collection|At the time of tissue biopsy and surgical resection (if applicable), pancreatic tumor tissue and tissue from site of metastasis will be collected.
45473531|NCT03851133|Other|Data Collection|Participants will be asked to complete a 3 page screening tool at the time of their in-person clinic visit, as well as questionnaires at baseline and at 6 and 12 months.
45473532|NCT01166555|Drug|PF-04236921|single subcutaneous dose
45473533|NCT03737305|Device|TMJ Condilar Distraction Device|The patients will perform condylar distraction with the condylar distraction device in an ambulatory basis.
45473534|NCT03737305|Device|Conventional Physical Therapy|Conventional Physical Therapy, performed in office by a experienced physical therapist for the TMJ condition.
45473535|NCT01283945|Drug|Lucitanib|"Oral administration, once daily (qd), in fasting conditions.~Dose escalation - continuous schedule~Dose expansion - continuous or intermittent dosing schedules (i.e. 5 days on/2days off or 21 days on/7 days off)~Dosage form: hard gelatin capsules for oral administration (2.5, 5, 10, 30 and 50 mg strengths)"
45473536|NCT04048681|Behavioral|diet soda|12 oz can of artificially sweetened cola beverage (Diet Coke planned to be used but similar to Diet Pepsi or other Diet Colas)
45683599|NCT04384276|Other|The Weigh Easy System|By use of a small user-friendly luggage scale, the family can easily and safely obtain a weight within the comfort of their own home. Using the Weigh Easy eClipboard, a message will be sent to the family on a weekly basis via Cerner's Message Center that will include a link. The link will be used by parents to enter and submit the patient's current weight. Upon submission, the weight will be transmitted into the patient's EMR after it's reviewed and accepted by a member of the study team. When the weight is received in the system, an alert will be triggered that will notify the study team of its arrival. While the Weigh Easy eClipboard function does qualify as a device, as the investigators will be making clinical decisions based off of the data received through the form, the device is not being used investigationally on this study. The eClipboard function is a standard part of the Cerner framework and has been previously investigated and vetted by for safety and efficacy.
45683600|NCT04384276|Other|Retrospective Control|No interventions will be administered to the historical control group.
45683601|NCT03247582|Drug|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
46036623|NCT04139005|Behavioral|Connection|The Connection module targets skills underlying social connection, which refers to the sense of having close and positively experienced relationships with others in the social world.
46036624|NCT04139005|Behavioral|Insight|The Insight module targets skills underlying dynamic self-inquiry and experiential self-knowledge.
46036625|NCT01153841|Biological|Synflorix™( GSK1024850A)|Intramuscular, 3 doses
46036626|NCT01153841|Biological|Infanrix hexa™|Intramuscular, 3 doses
46036627|NCT02804386|Drug|Sofosbuvir|Sofosbuvir (formerly known as GS-7977) is a direct-acting nucleotide polymerase inhibitor that is being developed as an oral drug for the treatment of chronic HCV infection
45341349|NCT00783003|Drug|GSK233705 and GW642444|Inhaled Long acting muscarinic receptor antagonist (LAMA) and a inhaled Long acting Beta 2 agonist (LABA) both in development as treatment for Chronic Obstructive Pulmonary Disease, taken in combination.
45341350|NCT00783003|Drug|GW642444|Inhaled Long acting Beta 2 agonist (LABA)
45341351|NCT00783003|Drug|GSK233705|Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
45341352|NCT00783003|Drug|Placebo|Matching placebo.
45341353|NCT01034215|Behavioral|Envision the Rhythms of Life Program|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered with trainer present in the room.
45341354|NCT01034215|Behavioral|Envision the Rhythms of Life Program/Distance|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered by videoconference equipment
45473537|NCT04048681|Behavioral|Regular soda|12oz can of regular cola beverage (Coke planned but similar to Pepsi or other regular cola sodas)
45683602|NCT01808612|Drug|Fluoxetine|
46036628|NCT02805868|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
46036629|NCT02805868|Other|Laboratory Biomarker Analysis|Correlative studies
46036630|NCT02805868|Biological|Siltuximab|Given IV
46036631|NCT00691639|Other|Blood Collection Only|Blood Collection Only
46036632|NCT02805634|Other|Nine Hole Test|The Nine Hole Pegs technique is a simple manual dexterity test, commonly used in ergotherapy. The participant tries to place 9 pegs in a 9 holes perforated plate, and then tries to remove them as quickly as possible. The hand must stay in a depression within the plate, thereby insuring a constant distance between the hand and the pegs.
45341355|NCT00791427|Drug|Ranibizumab|0.05 ml of ranibizumab injected into the eye monthly for one year
45341356|NCT00786513|Other|Conventional antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on conventional planktonic antimicrobial susceptibility testing results.
45341357|NCT00786513|Other|Biofilm antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on biofilm antimicrobial susceptibility testing results.
45341358|NCT00791505|Drug|ciprofloxacin|1500 mg a day for 10 days
45341359|NCT00791505|Drug|trimethoprim-sulfamethoxazole|2000 mg a day for 10 days
46036633|NCT02805634|Device|Triple Stimulation Technique|TST (Triple stimulation technique) combines two techniques used in neurologic diagnosis: magnetic stimulation and electroneuromyography. It is based on the principle of two collisions between the descending central stimulation (magnetic stimulation) and the ascending peripheric stimulation. TST allows to better quantify central nervous system diseases. The abnormal amplitude registered by TST is proportional to the intensity of conduction disorders. The evaluation of these disorders is more precise than with the magnetic stimulation technique alone.
45341360|NCT02598960|Drug|BMS-986156|
45341361|NCT02598960|Drug|Nivolumab|
45341362|NCT00426361|Biological|Boostrix ® Polio|One dose of vaccine administered intramuscularly
45341363|NCT00426361|Biological|GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly, with the second and third dose give one month and six months after the first dose respectively
45341364|NCT00665847|Drug|Etravirine (TMC125)|Patients will be dosed by body weight , i.e. 5.2 mg/kg twice daily (b.i.d.) up to a maximum of 200 mg b.i.d. for 48 weeks.
45473538|NCT04048681|Behavioral|Carbonated Water|12oz can of carbonated water (sparking water, selzter water) unflavored
45473539|NCT01171703|Device|femoral-popliteal bypass|Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
45683603|NCT01808612|Drug|Placebo|
45683604|NCT01908829|Drug|mirabegron 25 mg|Mirabegron was supplied as the marketed formulation in the 25 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
45683605|NCT01908829|Drug|mirabegron 50 mg|Mirabegron was supplied as the marketed formulation in the 50 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
45341365|NCT00665847|Drug|Optimized background regimen (OBR)|An investigator-selected optimized background regimen (OBR) comprising of a low-dose ritonavir (rtv)-boosted protease inhibitor (PI) (either lopinavir [LPV], darunavir [DRV], atazanavir [ATV] or saquinavir [SQV]) in combination with nucleos(t)ide reverse transcriptase inhibitor(s) (N[t]RTIs) to be dosed according to the drugs individual package inserts for 48 weeks.
45341366|NCT01030393|Drug|human chorionic gonadotrophin|intrauterine injection of 100 iu (group1) or 200 iu (group2) of hCG before embryo transfer in IVF/ICSI And intrauterine injection of 500 iu hCG before embryo transfer .
45341367|NCT00783081|Drug|K-134|K-134 is given as low dose mid dose and high dose tablets for 26 Weeks.
45341368|NCT00783081|Drug|Cilostazol 100 mg BID|Cilostazol 100mg BID for 26 weeks.
45341369|NCT00783081|Drug|Placebo|Placebo BID for 26 weeks.
45473540|NCT01171703|Device|stent|Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
45473541|NCT03737227|Radiation|Cinematographic recording|Cinematographic recording during flexion and extension of the lumbar spine.
45473542|NCT03870113|Biological|Vaccinated group|Develop highly reactive DC vaccines targeting HPV 16/18 E6/ E7 protein and DC vaccine would be injected to patients once a week, six doses in total.
45473543|NCT01282385|Drug|Simvastatin|simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance
45473544|NCT01282385|Drug|placebo|placebo capsules with external characteristics similar to simvastatin administrated each 24 hours.
45683606|NCT01908829|Drug|solifenacin 5 mg|Solifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food.
45683607|NCT01908829|Drug|solifenacin 10 mg|Solifenacin was provided as the marketed formulation in the 10 mg strength. Medication was taken orally with a glass of water, with or without food.
45683608|NCT01908829|Drug|mirabegron 25 mg matching placebo|Matching placebo of mirabegron OCAS 25 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
45341370|NCT03241056|Behavioral|CBT for Maladaptive Beliefs about Memory|The novel intervention is a manualized 2-session cognitive behavioural therapy. Agenda elements, including psycho-education, discussion prompts, and homework exercises are standardized across participants. In session 1, participants are taught about the cognitive theory of checking, the research support behind this theory, and how it may apply to their own checking behavior. A homework exercise is introduced and practiced to test out this theory. In session 2, the homework results are reviewed. Further education is shared on the nature of memory and the relationship to checking, and a discussion regarding how this applies to the participant's checking then takes place. A second homework exercise is introduced to test this theory.
45341371|NCT03241056|Other|Treatment as Usual|Treatment as Usual (TAU) during patients' time on our waitlist in our clinic will depend on at what point they have been recruited. It may consist of a 2-session group psychoeducational intervention on anxiety, any medications prescribed by their referring physicians, and/or independent therapy/counseling they may be seeking on the side. TAU for community participants will include any treatments they are currently seeking. Information about participation in such interventions will be collected during the course of the study (at each assessment visit) in order to accurately characterize participants' TAU in the current study.
45341372|NCT00426127|Drug|Docetaxel|
45341373|NCT00426127|Drug|Liposomal Doxorubicin|
45341374|NCT00426127|Drug|Enoxaparin|
45341375|NCT02578212|Other|Placebo|
45341376|NCT02578056|Device|Midurethral sling|Anti-urinary incontinence procedure, in a prophylactic way.
45341377|NCT02578056|Procedure|Genital prolapse surgery|Surgical correction of genital prolapse
45341378|NCT00783159|Procedure|Power Training|Power training, Vitamin D substitution
45341379|NCT00783159|Procedure|Strength Training|Strength training, Vitamin D substitution
45341380|NCT00783159|Other|Control|Vitamin D substitution, Lifestyle consultation
45341381|NCT02555709|Drug|VTP-43742|VTP-43742 administered as an oral capsule once daily
45341382|NCT02555709|Drug|Placebo 1|Placebo 1 matching VTP-43742 administered as an oral capsule once daily
45341383|NCT02555709|Drug|Placebo 2|Placebo 2 matching VTP-43742 administered as an oral capsule once daily
46036634|NCT00684385|Drug|ZD1839|250mg administered daily for patients with NSCLC and500mg daily for patients with H&NC. Treatment dispensed to patients on Day 1 and every 12 weeks thereafter until the patient withdraws. Patients with NSCLC will take one tablet at each dose administration; patients with squamous cell H&NC will take two tablets at each dose administration.
46036635|NCT02690038|Drug|Intravenous immunoglobulin (IVIG)|"Baseline Ig < 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization.~Baseline Ig > or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization"
46036636|NCT02690038|Drug|Normal Saline|"Baseline Ig < 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization.~Baseline Ig > or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization"
45341384|NCT02535078|Drug|Tebentafusp (IMCgp100)|soluble gp100-specific T cell receptor with anti-CD3 scFV
45341385|NCT02535078|Drug|durvalumab|anti-PD-L1 monoclonal antibody
45473545|NCT04007107|Drug|Semaglutide (administered by DV3396 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
45473546|NCT04007107|Drug|Semaglutide (administered by PDS290 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
46036637|NCT00691795|Drug|Clonidine or fentanyl|After obtaining consent, the patients will be randomized into two groups using a random allocation table. At the onset of late stage breakthrough pain one arm of patients will receive a mixture of 75 mcg clonidine and 10 mg bupivacaine in 8 ml of volume and the second group will receive 75 mcg fentanyl and 10 mg bupivacaine in 8 ml of volume.
46036638|NCT04136821|Dietary Supplement|Oceanix|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
45473547|NCT01166711|Device|Coroflex Blue (BMS) followed by SeQuent Please (DEB)|"standard techniques will be used~maximal vasodilatation after nitro application~baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)~6 French guiding catheter at least~target lesion will be crossed with standard guidewire~direct stenting at the discretion of the investigator~if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)~full lesion coverage will be ensured (with one or more stents)~only insert assigned stent type~BMS needs to be fully embedded in vessel wall~post-dilation with high pressure is required before treatment with DEB~DEB will be inflated with nominal pressure (balloon equates to vessel diameter)~length of DEB should exceed the BMS by 2-3 mm on each side~if dissection, full length of dissection and optional additional stented area should be treated with additional DEB (to avoid geographic miss)"
46036639|NCT04136821|Other|Resistance Training|6 weeks of supervised and programmed whole body resistance training, performed 3-5 times per week.
46036640|NCT02805556|Drug|BMS-663068|Single oral dose of BMS-663068
45341386|NCT02535078|Drug|tremelimumab|anti-CTLA-4 monoclonal antibody
45341387|NCT04047069|Behavioral|Awareness Training and Person-Centered Occupational Therapy Intervention|Exp. identifying the activities the person wants to do, suggestions to facilitate the activity, arranging the activity according to the needs of the person, arranging the environment so that the environment can be a facilitating factor in the activities the person wants to do.
45341388|NCT04047069|Behavioral|Awareness Training|"Exp.~General information about HD~Approaches to Coping with HD Symptoms~Self care skills (eg hygiene)"
45598885|NCT02296879|Genetic|SAIT301|The treatment period will consist of 21-day cycles. On Day 1 of each cycle, SAIT301 will be administered as an intravenous (IV) infusion.
46036641|NCT02805556|Drug|BMS-626529|Single intravenous dose of [13C]BMS 626529
46036642|NCT04136977|Device|Eustachian tube dilation|Unilateral or bilateral balloon dilation of the Eustachian tube using the FDA-cleared XprESS ENT Dilation System
46036643|NCT04032964|Drug|L19TNF|L19TNF 13 µg/kg i.v. will be administered on day 1, 3 and 5 of each 21-day cycle
46036644|NCT04032964|Drug|DOXORUBICIN|Doxorubicin 75 mg/m2 will be administered on day 1 of each 21-day cycle
46036645|NCT00694291|Drug|Sorafenib|400 mg orally twice daily
46036646|NCT00694291|Drug|Placebo|Matching Placebo
46036647|NCT04100902|Drug|ODACTRA 12 SQ-HDM Sublingual Tablet|Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
46036648|NCT04100902|Drug|Placebo sublingual tablet|Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
45341389|NCT00425503|Drug|PS-341 (bortezomib)|PS-341 is a dipeptidyl boronic acid inhibitor with high specificity for the proteasome developed by Millennium Pharmaceuticals Inc. to treat human malignancies. It is the first member of this class of anti-tumor agents to come to human trials. Patients will receive PS-341 (1.6mg/m2/dose) by intravenous push weekly for 4 consecutive weeks followed by a 24-72 hour rest. This schedule consists of one treatment cycle. Upon the completion of 4 weeks of PS-341 followed by a 24-72 hour rest period, radical prostatectomy will be performed.
45473548|NCT01166711|Device|Coroflex Please (DES)|"standard techniques will be used~maximal vasodilatation after nitro application~baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)~6 French guiding catheter at least~target lesion will be crossed with standard guidewire~direct stenting at the discretion of the investigator~if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)~full lesion coverage will be ensured (with one or more stents)~only insert assigned stent type"
46036649|NCT01153763|Drug|GSK2118436|Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
46036650|NCT00691873|Drug|Placebo|placebo
45341390|NCT00786669|Drug|Bevacizumab|Bevacizumab (IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles
46036651|NCT00691873|Drug|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
46036652|NCT02805322|Device|ARC InstaTemp MD|Measurement of Body Temperature using an Infrared Non-Touch Thermometer - Experimental arm.
45598886|NCT03515863|Genetic|DNA extraction and genetic characterization|Collection of blood samples for DNA extraction and genetic characterization using whole-genome sequencing, and for identification of cellular biomarkers using transcriptomics and mass cytometry.
45598887|NCT03515863|Device|Orbit MRI examination|Orbit MRI examination is performed to confirm the diagnosis of TAO
46036653|NCT02805322|Device|Covidien Genius 2 Tympanic Thermometer|Measurement of Tympanic Temperature using a standard approved method - Control arm.
46036654|NCT02805322|Device|Welch Allen SureTemp Plus Sublingual Thermometer|Measurement of Sublingual Temperature using a standard approved method - Control arm.
46036655|NCT05538052|Drug|Tramadol hydrochloride|Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth
46036656|NCT05538052|Drug|Lidocaine Hydrochloride|Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth
46036657|NCT05298475|Drug|Statin|Medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)
46036658|NCT05298475|Drug|PCSK9 inhibitor|1 injection of PCSK9 inhibitor once a month SC
46036659|NCT05298475|Drug|PCSK9 inhibitor|1 injection of PCSK9 inhibitor twice a month SC
46036660|NCT02884505|Device|Pupillometry|Measures pupillary dynamics in darkness and light conditions
45341391|NCT00786669|Drug|Temozolomide|100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.
45341392|NCT00786669|Drug|Vincristine|1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients <0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).
45341393|NCT00786669|Drug|Irinotecan|90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles
45341394|NCT00786669|Drug|Cefixime|8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity
45341395|NCT01030471|Behavioral|Family-based cognitive-behavioral treatment|Participants will engage in ten weekly sessions aimed at improving depressive symptoms and medication compliance via reducing family conflict and improving communication among family members.
45341396|NCT00786747|Behavioral|Personally tailored computer program|The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).
45341397|NCT00786747|Behavioral|Non-tailored control computer program|This program provides users with non-tailored information about colorectal cancer screening, in their preferred language (English or Spanish).
45473549|NCT04046341|Behavioral|Sleep Well!|The intervention comprehensively addresses poor sleep health behaviors (e.g., use of electronics at bedtime; inconsistent and variable sleep schedules; lack of a bedtime routine) as well as insomnia (difficulty falling and staying asleep; the need for caregiver presence at bedtime) and insufficient sleep in toddlers and preschoolers. Interventionists will use strategies to engage with and empower families, such as motivational interviewing and collaborative problem-solving. Session content will be reinforced via phone calls from interventionists. Families will receive intervention session appointment reminders and information about intervention content (e.g., reminders to follow a bedtime routine) via text message.
45473550|NCT01168739|Dietary Supplement|Quercetin|2g/d dietary quercetin supplementation, 1g taken am; 1g taken pm
45473551|NCT01168739|Dietary Supplement|Placebo|Placebo, performed on same subjects as Quercetin Arm, used to compare results between conditions
45341398|NCT00791739|Drug|trazodone, pregabalin|"phase I (from baseline to week 12): trazodone, in a starting dose of 50 mg at bedtime subsequently adjusted according to drug's efficacy and tolerability~phase II (from week 12 to week 24): addition of pregabalin in a starting dose of 75 mg/day subsequently adjusted according to drug's efficacy and tolerability"
45341399|NCT00425269|Behavioral|lifestyle intervention (diet and physical activity)|The intervention will include a combination of individual counselling group sessions. The intervention groups will be divided into subgroups of 10-12 subjects. Each group will have 10 group sessions on diet/lifestyle in the 6 months the intervention period lasts, and will additionally have the possibility to join a culturally adapted exercise program of low intensity twice a week.
46036661|NCT02884505|Behavioral|Psychomotor Vigilance Task|Response time task measuring neurobehavioral alertness
45341400|NCT02555475|Other|community based hepatitis C care and treatment|
45341401|NCT00791895|Drug|biphasic insulin aspart 30|Treat-to-target dose titration scheme
45341402|NCT01807728|Other|Group 1 Training Program|Up to four group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
45341403|NCT01807728|Other|Group 2 Training Program|Two group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
45341404|NCT04074720|Procedure|Tissue Sample collection|Tissue sample collected following standard of care procedure patient was already scheduled to have
45341405|NCT04074720|Other|Blood Sample Collection|A one time sample of blood will be collected on day of standard of care procedure
45473552|NCT03869879|Other|Feedback-assisted physical therapy|The system uses unobtrusive, wearable, inertial sensors with real-time algorithms to provide real-time feedback on: step time asymmetry, foot clearance, arm swing, trunk lateral range, and foot strike angle during gait.
45473553|NCT03869879|Other|Traditional physical therapy|Therapists will treat these patients with traditional therapeutic modalities and practices.
45598888|NCT03515863|Other|Collection of life style data|Collection of life style data using quality of life questionnaire
45598889|NCT02346669|Procedure|gastroscopy|as detailed in arm description
46036662|NCT02884505|Other|Auditory Evoked Potential|Measure of electroencephalographic response to standardized auditory tones
46036663|NCT02884505|Behavioral|Hypersomnia Severity Index|Self-report measure of hypersomnolence
46036664|NCT02805400|Other|determination of cortical activity|"Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.~For these methods only commercially available CE marked devices will be used."
45341406|NCT04074720|Other|Rectal Swab|optional rectal swab may be collected on day of standard of care procedure
45341407|NCT01030627|Device|Springfusor infusion pump|Women will receive a loading dose and maintenance therapy using an IV infusion administered by the Springfusor® pump. Women will receive a 8 mL loading dose containing 4g magnesium sulfate heptahydrate (MgSO4*7H2O) 50% solution, which is approximately 2 mmoL magnesium/mL. The loading dose of 8mL with 4 g MgSO4 will be administered using the Springfusor® pump. The administration of the loading dose will be immediately followed by a maintenance infusion. The maintenance dose of 4 g (8 cc, 50% MgSO4) will be administered with the Springfusor® pump continuously over four hours. The pump will be started immediately after the initial bolus and the 4g dose repeated (and syringe replaced) every four hours. Maintenance therapy will be administered for at least 24h. Treatment will be discontinued when clinically indicated. Drug administration will be initiated at the sites and, when necessary, the patient will be transferred, with the Springfusor pump in situ, to the local referral site.
45341408|NCT02503722|Other|Laboratory Biomarker Analysis|Correlative studies
45341409|NCT02503722|Drug|Osimertinib|Given PO
46036665|NCT00691951|Drug|budesonide and budesonide/formoterol|
45473554|NCT03744559|Behavioral|Retrieval Extinction Training (RET)|Retrieval extinction training (RET) is a behavioral intervention that involves cue-elicited retrieval followed by extinction training (i.e., massed unreinforced exposure to drug-associated cues). The first element of RET involves briefly presenting drug-associated cues to retrieve drug use memories. The second element, occurring after a brief interval, involves extinction training. It is argued that the initial retrieval of the memories prior to extinction training initiates a period of instability, which is followed by reconsolidation of the memories back into long-term storage. Extinction training during the period of instability is presumed to overwrite the original drug-associated cue with a non-drug-associated cue, to attenuate expression of drug-seeking behavior.
45473555|NCT03744559|Behavioral|Control Retrieval Extinction Training (RET)|The control retrieval extinction training (RET) for the NR-E arms serves as the control intervention to the RET behavioral intervention. The first element of the control RET involves briefly presenting retrieval cues that contain neutral, non-smoking content. The second element, occurring after a brief interval, involves extinction training. Based on findings from the previous NIDA-funded R21, the R-E arm reported a significant 25 percent reduction in cigarettes smoked per day during the follow-up period versus the control NR-E arm.
45598890|NCT02346669|Drug|Fecal Microbiota Transplantation|as detailed in arm description
45598891|NCT02346669|Other|high fat low fiber diet|as detailed in arm description
45598892|NCT02346669|Other|sham diet|as detailed in arm description
46036666|NCT05355233|Other|bebo concept|techniques to remove urinary incontinence
46036667|NCT05355233|Other|diaphragmatic breathing|techniques to remove urinary incontinence
45341410|NCT02503722|Other|Pharmacological Study|Correlative studies
45341411|NCT02503722|Drug|Sapanisertib|Given PO
45341412|NCT00786981|Other|Epidural steroid injection plus physical therapy|Patients in the ESI+PT Group will be treated additionally with a physical therapy program emphasizing lumbar flexion exercises, aerobic and strength/ conditioning exercises, and manual physical therapy as well as receiving up to 3 epidural steroid injection(s) and educational support using The Back Book.
45341413|NCT00786981|Other|Epidural steroid injection|Patients in the ESI Group will be treated with up to 3 epidural steroid injections, educational support, and general care by the treating physician.
45341414|NCT00430573|Drug|D-cycloserine|Single dosage of D-cycloserine is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
45341415|NCT00430573|Drug|Placebo|Single dosage of placebo is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
45598893|NCT02346669|Other|low fat high fiber diet|as detailed in arm description
45598894|NCT03357029|Device|GammaCore Device|GammaCore will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes.
46036668|NCT02805166|Drug|PEG-rhG-CSF|
46036669|NCT02621671|Behavioral|Cognitive interview|
46036670|NCT02621671|Other|Survey|
46036671|NCT04316351|Drug|Toripalimab + Pemetrexed + Anlotinib|"Toripalimab 240 mg iv d1 + anlotinib 12mg po d1-d14 + pemetrexed 500mg / m2 d1 Q3W for 4 cycles, followed by Toripalimab 240mg iv d1 + anlotinib 12mg po d1 + pemetrexed 500mg / m2 d1 Q3W for another 31 cycles (up to a total of 35 cycles).~If there is no disease progression, patients will receive anlotinib po 12mg d1-d14 + pemetrexed 500mg / m2 d1, Q3W for maintenance therapy until PD per RECIST v1.1 or loss of clinical benefit."
46036672|NCT02805244|Drug|JTZ-951, 14C-JTZ-951|
46036673|NCT00694447|Procedure|Acupuncture|
45341416|NCT00783315|Behavioral|Call-Center Directed (CCD) Weight Loss Program|This program will be implemented by trained counselors of Healthways, Inc., and will use telephone, Web, and e-mail contacts to engage participants. There will be no in-person visits.
45341417|NCT00783315|Behavioral|In-Person Directed (IPD) Weight Loss Program|This program will be primarily implemented through in-person visits (including group sessions) with health counselors at Johns Hopkins University. Telephone, Web, and e-mail contacts will occasionally be used.
45341418|NCT00783315|Behavioral|Self-Directed Weight Loss Program|Participants will meet with study staff at the beginning of the study and will receive written information about weight loss.
45341419|NCT04073940|Behavioral|Targeted Ballet Program|All classes will be offered in a set schedule convenient for all participants. Classes will be taught by the PI, who has extensive dance training expertise. The targeted ballet program consists of an initial period of dance movements while sitting in chairs (20min), followed by exercises holding onto the ballet barres mounted to the walls in the Neuroscience of Dance on Health and Disability Laboratory (20min), followed by locomotive dance movements (20min). The dance moves are based on the Ballet I Syllabus of the Royal Academy of Dancing and the Cecchetti Council of America, designed for eight-year-old students with no necessary previous training in ballet.
45341420|NCT00783393|Drug|Temozolomide|Temozolomide orally once daily for 5 consecutive days followed by a 23 day rest period to complete a 28 day treatment cycle. In Cycle 1, temozolomide will be administered at 150 mg/m2/day; in Cycle 2 and subsequent cycles, it will be administered at 100, 150, or 200 mg/m2, depending on hematology test results and adverse events observed.
45341421|NCT00783471|Drug|Erlotinib, Docetaxel|Drug: Erlotinib 150 mg po daily, days 1-12 Drug: Docetaxel 75 mg/m2 IV over 30 min on day 15 Treatment will be repeated every 21 days
45341422|NCT00783471|Drug|Docetaxel, Erlotinib|Drug: Docetaxel 75 mg/m2 IV over 30 min on day 1 Drug: Erlotinib 150 mg po daily, days 4-15 Treatment will be repeated every 21 days
45341423|NCT00792051|Biological|Inactivated influenza vaccine|0.5ml intramuscular single dose
45341424|NCT00792051|Biological|Saline|0.5ml intramuscular, one dose
45341425|NCT00787215|Other|observational: no treatment involved|observational: no treatment involved
45341426|NCT00792129|Device|The Atavi System|"The primary device in the Atavi system is the Flex Posture retractor and accessories such as dilators and an Expander Instrument.~The Atavi System includes instruments used to access the spine by dilation of the overlying tissues, as well as a retracting device that is used to maintain the access. Once the retractor is in place, the visualization components of the system may be used."
45341427|NCT00792207|Other|Virtual Coach software|The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data.
45341428|NCT00792207|Other|Activity monitor and website|The control group will use an activity monitor and a website to track activity levels.
45341429|NCT00787293|Device|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein, anterior interventricular vein.
46036674|NCT02884349|Procedure|RoM assessment|This group will have a CT scan at three months post-operatively instead of the two radiographs, an anterior/posterior pelvis view and a lateral hip view, which are standard care. They will also have a RoM assessment session in the movement analysis laboratory in the hospital at the same time point lasting about one hour, which is additional to standard care.
46036675|NCT04029454|Biological|birth dose vaccination against hepatitis B strategy|"Complex intervention targeting healthcare workers and involving:~training on hepatitis B awareness and management~training on EPI vaccination and cold chain~training on the modalities for the birth dose administration~the use of a monovalent unidose vaccine against Hepatitis B"
46036676|NCT02625337|Drug|Pembrolizumab|
45341430|NCT02460900|Drug|Varenicline|
45341431|NCT02460900|Behavioral|Positively Smoke Free|
45341432|NCT02460900|Drug|Placebo|
45341433|NCT02460900|Behavioral|Standard of Care|
45341434|NCT00787371|Biological|PegIntron (peginterferon alfa-2b)|PegIntron 0.25 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
45341435|NCT00787371|Biological|PegIntron (peginterferon alfa-2b)|PegIntron 0.5 mcg/kg SC QW for 12 weeks
45341436|NCT00787371|Biological|PegIntron (peginterferon alfa-2b)|PegIntron 1.0 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
45341437|NCT00783549|Drug|an undetermined dose of GSK1292263|GSK investigational product or placebo
45341438|NCT00783549|Drug|ascending dose of GSK1292263|Ascending dose based on target exposures or placebo
45341439|NCT00783549|Drug|ascending dose of GSK1292263|An ascending dose based on target exposure
45341440|NCT00783549|Drug|ascending dose of GSK1292263|An ascending dose based on target exposures.
45341441|NCT00783549|Drug|ascending dose of GSK1292263|An ascending dose based on target exposure
46036677|NCT02625337|Drug|Dabrafenib|
46036678|NCT02625337|Drug|Trametinib|
45473556|NCT03744559|Other|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI) will identify patterns of brain activity associated with RET and potentially predictive of treatment outcomes. The fMRI is used during the baseline and 24-hour follow-up test sessions while participants complete a cue-reactivity task. The collection of fMRI data is based on findings from human fear conditioning fMRI studies, in which groups receiving RET in the reconsolidation window exhibited less fear that was associated with attenuated BOLD response in the amygdala, relative to the control. We propose that the R-E arm will evidence attenuated cue reactivity in medial prefrontal cortex, limbic regions and ventral striatum, and that greater reduction in BOLD response in regions of interest will predict decreased smoking.
46036679|NCT02625337|Procedure|Biopsy|Biopsies will be taken during screening, before randomization, at week 8 (only arm 2-4) after 12 weeks, at week 18 and if PD.
45341442|NCT02075840|Drug|Alectinib|Participants will receive alectinib 600 mg orally (four 150 mg capsules) BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
45341443|NCT02075840|Drug|Crizotinib|Participants will receive crizotinib 250 mg capsules orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
45341444|NCT00783627|Procedure|Angiography|Angiography done at the J1 visit
45341445|NCT00430495|Drug|Atacicept|Atacicept was administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 21 weeks.
45341446|NCT00430495|Drug|Atacicept|Atacicept was administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 21 weeks.
45341447|NCT00430495|Drug|Atacicept|Atacicept was administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
45341448|NCT00430495|Drug|Placebo matched to atacicept|Placebo matched to atacicept was administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
45341449|NCT02554695|Drug|placebo|subcutaneous saline injection
45341450|NCT02554695|Drug|denosumab|single subcutaneous injection of denosumab 60 mg
45683609|NCT01908829|Drug|mirabegron 50 mg matching placebo|Matching placebo of mirabegron OCAS 50 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
45341451|NCT00792285|Behavioral|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition calls to health plan members to promote screening
45341452|NCT00792363|Drug|Irinotecan|350 mg/m2 intravenously on day 1 every 3 weeks
45341453|NCT00792363|Drug|Panitumumab|9 mg/kg intravenously on day 1 every 3 weeks
46036680|NCT02625337|Procedure|Blood taking|Blood will be taken for PBMCs during screening (twice), before randomization, at weeks 12 at week 18 and if PD.
46036681|NCT04236310|Drug|SHR6390|SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment for 4 cycles
46036682|NCT04236310|Drug|Anastrozole|Anastrozole 1md, orally once daily for 16 weeks (For premenopausal women, ovarian suppression may be considered)
46036683|NCT04236310|Drug|Pyrotinib|Pyrotinib 400mg once daily for 16 weeks
46036684|NCT04236310|Drug|Trastuzumab|Trastuzumab 6mg/kg (loading dose, 8mg/kg), infusion once every 3-week cycle for 5 cycles.
46036685|NCT02805478|Other|There is no intervention|This is a prospective observational cohort study without any intervention
45341454|NCT00787683|Device|Home-monitoring provided by LUMAX ICD device and CardioMessenger II|All study participants receive an ICD of the Biotronik lumax family. Only participants of the intervention group receive the CardioMessengerII to allow for transmission of regular home monitoring messages. All study participants will be followed for 12 to 24 months (depending on the time of recruitment). The intervention and comparison to be investigated is home-monitoring vs. no home-monitoring. The intervention involves a combination of in-clinic consultations and regular use of home-monitoring services. As part of the modified follow-up schedule of intervention patients compared to standard care, follow-up in-clinic consultations 3, 6, and 18 months after ICD implantation will be replaced by home-monitoring follow-up.
45341455|NCT00425113|Drug|Metronidazole|
45341456|NCT00425113|Procedure|Blood Draw|
45341457|NCT00425113|Procedure|CT Scan|
45341458|NCT00425113|Procedure|PET Scan|
45341459|NCT04895280|Drug|Ketorolac|Ketorolac: will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 30 mg ketorolac x 1
45341460|NCT04895280|Drug|Marcaine|Marcaine (control): will receive an injection of 4 cc 0.25% Marcaine without epinephrine
45341461|NCT04895280|Drug|Kenalog|Kenalog: 4 cc 0.25% Marcaine without epinephrine and 40 mg triamcinolone x 1.
45341462|NCT00792441|Device|intervention group|inspiratory muscle training at 50% of peak negative inspiratory muscle training (PNIP)will be performed with 6 breathe/set, 10 set/day, once a day for 28 days.
45341463|NCT01034293|Dietary Supplement|low feeding frequency (3x)|3 meals a day
45341464|NCT01034293|Dietary Supplement|High feeding frequency (14x)|14 meals a day
45341465|NCT03919032|Other|This is an observational study without intervention|This is an observational study without intervention
45341466|NCT00792519|Behavioral|HIV support group|group support
45341467|NCT00792519|Behavioral|CBT|group cognitive behavioral treatment
45341468|NCT03994783|Drug|Rituximab|2 intravenous infusions of rituximab or approved biosimilar given 14 days +/- 2 days apart.
45341469|NCT03994783|Drug|Methylprednisolone|Intravenous infusion of methylprednisolone
45473557|NCT03744559|Other|No functional magnetic resonance imaging (fMRI)|No functional magnetic resonance imaging (fMRI) serves as the control intervention to the fMRI intervention. Participants who are randomized to the no fMRI intervention or who have a contraindication to MRI will complete an identical cue-reactivity task in a cue-reactivity lab during the baseline and 24-hour follow-up test sessions.
46036686|NCT04134949|Behavioral|Cognitive Behavior Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
46036687|NCT04134949|Behavioral|Mindfulness-Based Cognitive Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
46036688|NCT02804308|Behavioral|Combined Training|
46036689|NCT02805088|Other|Electroencephalographic recordings|
45473558|NCT01171781|Drug|cisplatin (3 weekly)|radiation with cisplatin (100mg/m2) on D1,D22,D43 and followed by adjuvant chemotherapy (3 cycles of FP)
46036690|NCT02805088|Other|neuropsychological evaluation|
46036691|NCT02805088|Other|clinical evaluation of symptoms|
46036692|NCT02621515|Drug|Nivolumab|All patients in this phase 2 trial will receive treatment with nivolumab, a monoclonal antibody against the PD1-receptor on T cells. Dosing will be based on patients' weight (3 mg/kg). It will be administered in an intravenous infusion every 2 weeks and for a maximum of 2 years.
46036693|NCT00912613|Other|ICU Diary|ICU Diary containing daily information of patients condition and treatment with appropriate photographs
45341470|NCT03994783|Drug|Intravenous Immunoglobulin|High dose (2 g/kg total) or Low dose (100 mg/kg, n=7)
45341471|NCT03994783|Procedure|Plasma Exchange|Blood is removed from the patient and filtered to remove the plasma. Red and white blood cells and platelets are returned to the patient with replacement fluid.
45341472|NCT04072536|Device|Electric wheelchair with activated assistance module|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance
46036694|NCT02803918|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45341473|NCT04072536|Device|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with no activated assistance
45341474|NCT00440011|Drug|bimatoprost 0.03% eye drops|bimatoprost 0.03% 1 drop nightly for 3 months
45341475|NCT00440011|Drug|travoprost 0.004% eye drops|travoprost 0.004% 1 drop nightly for 3 months
45341476|NCT03105102|Drug|Placebo for Risankizumab SC|Placebo for Risankizumab SC Subcutaneous (SC) Injection
46036695|NCT02803918|Drug|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
46036696|NCT02803918|Drug|Basal Insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45341477|NCT03105102|Drug|Risankizumab IV|Risankizumab IV Intravenous (IV) infusion
45341478|NCT03105102|Drug|Placebo for Risankizumab IV|Placebo for Risankizumab IV Intravenous (IV) infusion
45341479|NCT03105102|Drug|Risankizumab SC|Risankizumab SC Subcutaneous (SC) injection
45341480|NCT03105102|Drug|Risankizumab On-Body Injector (OBI)|Subcutaneous (SC) injection; on-body injector (OBI)
45341481|NCT00877448|Biological|Adjuvanted Multimeric-001 250 Mcg|
45341482|NCT00877448|Biological|Multimeric-001 250 Mcg|
45341483|NCT00877448|Biological|Phosphate Buffered saline|
45341484|NCT00877448|Biological|Adjuvanted PBS|
45341485|NCT00877448|Biological|Adjuvanted Multimeric-001 500 Mcg|
45341486|NCT00877448|Biological|Multimeric-001 500 Mcg|
45341487|NCT00877448|Biological|Multimeric-001 125 Mcg|
45341488|NCT00783861|Drug|Lactic Acid|Lactic Acid (Dermacyd Femina)
45341489|NCT01034371|Procedure|Minimally invasive direct coronary artery bypass|MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
45341490|NCT01034371|Procedure|PCI-Drug eluting stents|"PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
45341491|NCT01034371|Procedure|Off-pump coronary artery bypass|Procedure: coronary artery bypass without cardiopulmonary Coronary artery bypass surgery with no associated or concomitant surgical procedures, using full median sternotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
45341492|NCT04971213|Device|Non invasive ventilation|Emergency and transport ventilator (Monnal T60, Airliquide, Antony, France)
45341493|NCT04971213|Device|High-flow nasal cannula heated and humidified oxygen|AirVO2 device (Fisher and Paykel, New Zealand)
45341494|NCT00783939|Drug|Lactic Acid|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
45341495|NCT00792675|Other|Aerobic and resistance exercise training|Exercise was performed 3 times per week. It consisted of 30 minutes of treadmill exercise at approximately 85% of heartrate max and 2 sets of 6 resistance weight lifting exercises resulting in volitional fatigue at 12 to 15 repetitions.
45341496|NCT04739930|Procedure|Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation|Autologous bone marrow aspirate will be processed and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to the site of operation in the treatment group
45341497|NCT04739930|Procedure|Control group incision|0.5cm sham incision over the iliac crest
45341498|NCT00788229|Drug|AT01|eye drop for 12 weeks
46036697|NCT02803918|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
46036698|NCT04138069|Other|PLB+Aerobic Bicycling|"Combination of Breathing control and Purse lips breathing technique for 5 minutes at the start of session.~Purse lips breathing with aerobic bicycling for 8 minutes"
46036699|NCT04138069|Other|Aerobic Bicycling|"Breathing control for 5 minutes at the start of session.~Aerobic bicycling for 8 minutes"
46036700|NCT04022356|Device|Feetme Connected Soles|"Walk for 10 meters (and 30meters):~By wearing the European Community (EC) labelled connected soles in patient's shoes, triggered by smartphone- collection of data by smartphone~By being filmed by a camera camera mounted on a tripod (excluding the face) for steps counting (2 observers).~If there is a technical problem during the walk test, this one can be performed 1 time again 1 hour after initial test.This is expected to happen very rarely."
45341499|NCT00788229|Drug|AT02|eye drop for 12 weeks
46036701|NCT02621593|Device|M22-IPL|The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filters that will be used for this evaluation are filters blocking wavelengths of 560 and 595 nm.
45341500|NCT00788229|Drug|AT03|eye drop for 12 weeks
45341501|NCT00788229|Drug|AT04|eye drop for 12 weeks
45341502|NCT01937468|Other|Treg-enriched infusion|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema
45341503|NCT01937468|Drug|Interleukin-2|Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
45341504|NCT00663117|Drug|Naltrexone-HCl|naltrexone 4.5 mg
45341505|NCT00663117|Drug|Placebo|Placebo
45341506|NCT02578628|Other|Patient Engagement|The patient engagement system monitors routine clinical laboratory test results and sends messages to patients and providers when action is indicated, such as when tests are overdue or results require extra clinical attention. Patients receive first class letters directing them to call their provider. Providers receive fax or electronic messages directing them to reach out to the patient to arrange follow-up care.
45341507|NCT04072328|Drug|Propofol|Propofol will be given 0.5 mg/kg bolus initially, and can be administered additionally after a least 30 secs if necessary.
45341508|NCT04072328|Drug|Midazolam|midazolam with propofol
45341509|NCT00792753|Device|Medtronic Endeavor Coronary Stent System|coronary stent implantation
45341510|NCT00792753|Device|DESyne BD Novolimus Stent System|coronary stent implantation
45341511|NCT00792753|Device|DESyne Novolimus Stent System|coronary stent implantation
45341512|NCT00495716|Drug|acyclovir|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
45341513|NCT00495716|Drug|acyclovir|400 mg acyclovir orally twice daily for 1 year
45341514|NCT00793065|Other|Electronic health record (EHR)|Computer-based system that allows physicians to access and manage patient records electronically.
45341515|NCT00793065|Other|Medical Home redesign|Implementation of NCQA Level III Medical Home
45341516|NCT04709432|Procedure|ECMO|ECMO is a form of Extracorporeal Life Support (ECLS) to support either the pulmonary, or both the pulmonary and cardiac systems.
45341517|NCT00788385|Device|ShuntCheck test|
45341518|NCT04704830|Biological|R21/Matrix-M|Adjuvanted malaria vaccine
45473559|NCT01171781|Drug|cisplatin (weekly)|radiation with 7 cycles of cisplatin (40mg/m2) on D1,8,15,22,29,36,43, and followed by adjuvant chemothrapy (FP X3)
46036702|NCT04236466|Device|hyrax appliance|Hyrax will be constructed with bands on maxillary first molars and wire extending on palatal surfaces of teeth till the upper canines.
46036703|NCT04236466|Device|haas appliance|Haas will be constructed with bands on maxillary first molars and wire extending on palatal surfaces of teeth till the upper canines. Acrylic part will be added on palate
45341519|NCT04704830|Biological|Rabies vaccine|Placebo Comparator
45341520|NCT00784017|Drug|asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
45341521|NCT00784017|Drug|recombinant asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
45341522|NCT04074122|Diagnostic Test|Adenosine and epinephrine, isoprenaline provocation|High-resolution electromechanical mapping at baseline and after provocative measures.
45341523|NCT04073342|Genetic|Gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).|Ileal tissue from both group will be tested for gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).
45341524|NCT00570141|Device|OASIS Wound Matrix|OASIS (an acellular biomaterial that supports tissue repair with a scaffold-like matrix having a natural structure and composition).
45341525|NCT01894802|Device|Implantation of CRS Arrays|Two Blackrock Microsystems CRS Arrays will be implanted in the motor cortex and sensory cortex of study participants.
45341526|NCT02579694|Device|Acumed Scapholunate Intercarpal Screw|Evaluation of provisional fixation to allow biologic healing of the scapholunate interval
45341527|NCT02578550|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC)|A single tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg will be administered.
45341528|NCT02578550|Drug|Emtricitabine/tenofovir alafenamide FDC|A single tablet containing FTC 200 mg and TAF 10 mg will be administered.
46036704|NCT00692107|Radiation|Gray|68 Gy vs. 78 Gy
46036705|NCT00692107|Radiation|Gray|68 Gy vs. 78 Gy
45839964|NCT04661202|Other|combined resistance and aerobic exercise training|"A supervised moderate-intensity exercise training session, which will include aerobic exercise with a stationary exercise bike, resistance exercise using dumbbell, theraband band, or gym ball for each major muscle groups and core muscles (including pelvic floor muscle (PFM) training with biofeedback), and stretching exercise, twice a week for 8 weeks. All exercises will be individualized based on participant's heart rate reserve and Rate of Perceived Exertion (RPE). An oximeter and a sphygmomanometer will be used to monitor the heart rate, oxygen saturation and blood pressure of the participants to ensure safety.~A home exercise program will include a walking exercise for 30 minutes per day and a PFM training with the aim of completing 1~3 sets of 8~12 submaximal contraction of PFM by holding 6~10 seconds with 12~20 seconds of rest between each contraction, and it will end with 3 maximal PFM contractions by holding 1~3 seconds 3~6 seconds of rest between each contraction."
45839965|NCT04634682|Dietary Supplement|MYODM|Formulated composition containing Theobroma cacao supplemented with caffeine
45341529|NCT02578550|Drug|Darunavir|A single tablet containing darunavir 800 mg will be administered.
45341530|NCT02578550|Drug|Cobicistat|A single table containing cobistat 150 mg will be administered.
45341531|NCT00788463|Drug|Intranasal Beclomethasone aerosol|Beclomethasone aerosol intranasal, 100ug each nostril, twice daily for 6 months.
45341532|NCT00788463|Drug|Intranasal Beclomethasone spray|Beclomethasone spray intranasal, 100ug each nostril, twice daily for 6 months.
45341533|NCT00579254|Drug|CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)|Patients who have been treated with Caduet 5/10 or 5/20 mg single pill treatment, based on their clinical conditions and latest locally approved packet insert recommendations will be eligible to be enrolled to this study
45473560|NCT01284023|Other|Shaving|Male patients will have the leg hair under each sensor site shaved, using an electric razor, and near infrared spectroscopy monitored for an additional 15 minutes
46036706|NCT02805010|Drug|Abatacept|On Day 1, subjects will receive a single SC dose of abatacept 125mg
46036707|NCT02805010|Other|Placebo|On Day 1, subjects will receive a single SC dose of placebo
46036708|NCT02621437|Other|Osteopathy sessions|- Three osteopathy sessions every 14 days (D13, D27 and D41 post-surgery),
46036709|NCT02621437|Other|phone questionnaires|"Six phone questionnaires (D9, D20, D26, D34, D40 and D48):~pain questionnaire with digital scale,~quality of life survey: SF-12~HAD (Hospital and Anxiety Depression) questionnaire"
46036710|NCT02621281|Device|Kidney Transporter machines|Kidney Transporter gently pumps the special cold solution through the kidney which outside the body.
46036711|NCT02621281|Device|cold storage|The kidneys procurement from the donor will be cold stored using some cold preservation solution.
46036712|NCT02803996|Drug|Aramchol|Part A: Aramchol oral tablets at 400 mg or 600 mg single dose Part B: Aramchol oral tablets at 400 mg or 600 mg multiple dose for 10 consecutive days.
46036713|NCT02803996|Drug|Placebo|Part A: Placebo oral tablets single dose Part B: Placebo oral tablets multiple dose for 10 consecutive days.
46036714|NCT04136431|Other|Programed cryotherapy and continuous passive motion|The intervention group started to use a CPM machine and applied programed cryotherapy intermittently within one hour while returning to the ward on the day of surgery.
45473561|NCT03233529|Drug|Crisaborole ointment 2% BID|Crisaborole ointment 2% BID for 15 days (double blind); additional 28 days (open label)
45473562|NCT03233529|Drug|Placebo ointment (vehicle)|Placebo ointment (vehicle) BID for 15 days (double blind)
45473563|NCT04006171|Diagnostic Test|C type natriuretic peptide|Serum level of CNP in PCOS and healthy women
45341534|NCT02579460|Other|Cessation of Acid Suppressing Medications|Acid suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations are performed while the participant is not on acid-suppressing medications. Endoscopy with biopsies will be performed in all patients on day 0, 7, and 14.
45341535|NCT02574806|Procedure|Blood sample and BNP measurement|Blood sample of umbilical artery from umbilical cord immediately after birth.
45341536|NCT00793221|Device|Implantation of sirolimus-eluting coronary stent|Implantation of sirolimus-eluting coronary stent after dilatation of the coronary occlusion
45341537|NCT00793221|Device|Implantation of everolimus-eluting coronary stent|Implantation of everolimus-eluting coronary stent after dilatation of the coronary occlusion
45341538|NCT02578134|Other|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the symptomatic insertion of the plantar fascia
45473564|NCT01171859|Drug|Doxycycline + Tauroursodeoxycholic acid|doxycycline 100 mg twice a day for 12 months; tauroursodeoxycholic acid 250 mg three times a day for 12 months
45473565|NCT01284101|Device|Use of the Tan Endoglide to insert the donor graft|Using the Tan Endoglide to insert the donor graft into the eye
45473566|NCT01284101|Device|Forceps for delivery of the donor graft|Use of the forceps for delivery of the donor graft into the eye.
45473567|NCT02652468|Drug|Fludarabine Phosphate|Fludarabine will be administered by IV over approximately 30 minutes for 4 days.
45473568|NCT02652468|Drug|Mesna|Given IV over 24 hours starting prior to cyclophosphamide
45473569|NCT02652468|Drug|Cyclophosphamide|Given IV for 2 days
45473570|NCT02652468|Radiation|Total nodal irradiation|Undergo total lymphoid irradiation
45473571|NCT02652468|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
45473572|NCT02652468|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
45473573|NCT02652468|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo TCR alpha-beta/CD19-depleted hematopoietic stem cell transplant
45473574|NCT02652468|Drug|Mycophenolate Mofetil|Given PO
46036715|NCT04136431|Other|Unrogramed cryotherapy and continuous passive motion|A CPM machine and cryotherapy were not applied on the day of surgery while returning to the ward
46036716|NCT02800954|Biological|blood samples|
46036717|NCT02800954|Biological|Bone marow samples|
46036718|NCT00694681|Behavioral|Telephonic care management|Individuals received intensive outreach from care managers, first to help them to enter treatment and then, if treatment began, to remain in it for an appropriate time. Treatment is based on the American Psychiatric Association's Evidence-Based Practice Guidelines for Major Depression, which includes psychotherapy and antidepressant medications. Outreach and care management took place by telephone.
45341539|NCT02578134|Other|Sham US-guided percutaneous electrolysis|The acupuncture needle will be inserted into the symptomatic plantar fascia but no galvanic electrical current will be applied, the equipment will be turn off. Patients will be blinded to the application of galvanic electrical current.
45473575|NCT02652468|Drug|Tacrolimus|Given PO or IV ONLY if graft cell content is over 1 x 10^5 cells/kg ideal BW of the patient
45341540|NCT04072562|Drug|AZD7594|"Treatment A: The study drug is a nebulizer suspension with strength 2.8 mg/mL using 2 mL in the device. The study drug is administered via oral inhalation.~Treatment B: The study drug is a nebulizer suspension with strength 6.3 mg/mL using 2 mL in the device. The study drug was administered via oral inhalation.~Treatment C: The study drug is an inhalation powder. The study drug was administered via oral inhalation."
45341541|NCT00784329|Device|Optical Frequency Domain Imaging (OFDI) System|Optical Frequency Domain Imaging(OFDI)System. Additional biopsy obtained from regions of normal appearing tissue. Up to an additional 20 minutes to standard Bronchoscopy
45341542|NCT04072484|Other|Mild hypoxia|The subject will breathe a gas mixture containing 15% oxygen instead of 21% oxygen.
45341543|NCT00793299|Behavioral|Video Illness Narrative|video
45341544|NCT04072406|Other|Mindfulness meditation|Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
45341545|NCT04072406|Other|Usual care packet|Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
45341546|NCT00788619|Procedure|Transfer of embryos on day 3 or day 5 after fertilization.|Subjects will be allocated at random to the two arms. Group 1 will have two embryos transferred on day 3 based on nitric oxide concentration. Group 2 will have two embryos transferred on day 5 based on morphologic criteria.
45341547|NCT00788619|Procedure|Day 5 transfer|Subjects will have embryo transfer on day 5 after fertilization. Selection of embryos to transfer will be based on morphologic criteria.
45341548|NCT00661089|Drug|Botulinum Toxin Type A - OnabotulinumtoxinA|100-200 units injected into the pectoralis major. The teres major may also be injected if tone is noted in shoulder extensors.
45341549|NCT00661089|Drug|Placebo (Saline)|Equivalent volume of saline without study drug injected into the pectoralis major. Teres major was also injected if tone noted in the shoulder extensors.
45473576|NCT02652468|Biological|Rituximab|Given IV ONLY if graft B cell content exceeds 1 x 10^5 cells/kg ideal BW of the patient
45683610|NCT01908829|Drug|solifenacin 5 mg matching placebo|Matching placebo of solifenacin succinate 5 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
45683611|NCT01908829|Drug|solifenacin 10 mg matching placebo|Matching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
46036719|NCT02800564|Behavioral|Active mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months. Interactive voice response systems (IVRS) will be promoted where listeners can chose to receive pre-recorded audio/voice messages or text messages on mobile phones. Messages will be consistent with the weekly radio program. The topic of the radio program will be discussed in monthly open community meetings. Each individual may choose to participate or not to listen to the radio program, receive the IVRS system, and attend monthly meetings.
45341550|NCT03098082|Device|Actim Pancreatitis|Actim Pancreatitis (Medix Biochemica) is a urine trypsinogen-2 dipstick test (UTDT) that uses trypsinogen-2 as a biomarker for acute pancreatitis.
45473577|NCT03737071|Behavioral|Low Carbohydrate Diet|Ketogenic dietary intervention
45473578|NCT04673877|Drug|Systemic IV Vancomycin|1 g of vancomycin will be delivered intravenously over a period of one hour prior to tourniquet inflation.
45473579|NCT04673877|Procedure|Bier Block|After exsanguination of the limb and elevation of the tourniquet in the prepped and draped patient, Vancomycin will be injected into a superficial vein in the hand, wrist or forearm.
45473580|NCT04673877|Drug|Vancomycin|500 mg diluted in 50 cc normal saline of injection into superficial vein in the hand, wrist or forearm
45683612|NCT04277338|Drug|SPECT|One single injection of 99mTc-HE3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
45683613|NCT01773122|Drug|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
45683614|NCT01773122|Drug|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
46036720|NCT02800564|Behavioral|Passive mass media approach|These communities will be exposed to twice weekly radio programming for up to 18 months only.
45683615|NCT01773122|Drug|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
46036721|NCT04236232|Diagnostic Test|Thyroid function|Thyroid function,Lipid Profile, systolic Blood pressure ,diastolic blood pressure .Body Mass Index ,CRP,Echocardiography،ECG, Ultrasonography of Carotid artery
45341551|NCT01773278|Drug|Antioxidants|Patients will be prescribed the drug DEKAS plus at a dose based on age and weight. The effects of the treatment will be monitored by serial ERG, ABR, oxysterol levels and clinical findings. Blood levels of 25-Oh vitamin D will be monitored to prevent toxicity.
45341552|NCT01773278|Drug|Cholesterol|Patients with SLOS typically have cholesterol deficiency. They will be treated with cholesterol supplementation to keep cholesterol levels > 100 mg/dl if possible
45341553|NCT00788853|Other|No treatment given|No treatment is given
45341554|NCT04071002|Other|12 weeks physical therapy programme|The programme include contrast bath, bandage, massage, active exercises, resistive exercises.
45341555|NCT00788931|Drug|IV LBH589|
45341556|NCT00788931|Drug|Oral LBH589|
45341557|NCT00788931|Drug|trastuzumab|
45341558|NCT00788931|Drug|paclitaxel|
45341559|NCT00709514|Drug|DCB-WH1 ointment|DCB-WH1 ointment (1.25%), topically applied twice daily
45341560|NCT00709514|Drug|Placebo|Placebo
45341561|NCT00386906|Procedure|Sentinel Lymph Node Mapping and Biopsy|Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
45341562|NCT04458194|Other|Standard Care|Standard Care is used as a control condition. Cancer survivors assigned to this arm continue to receive standard care from their medical providers.
46036722|NCT02803762|Drug|Pacritinib|400 mg [14C]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose following at least a 10-hour fast (not including water) on Day 1
46036723|NCT00871741|Biological|GSK2202083A vaccine|Intramuscular, three doses
46036724|NCT00871741|Biological|Infanrix hexa|Intramuscular, three doses
46036725|NCT00871741|Biological|Menjugate|Intramuscular, two doses
45341563|NCT04458194|Behavioral|YOCAS©® yoga|Yoga for Cancer Survivors, YOCAS©®, intervention is a low to moderate intensity mode of exercise that draws from two basic types of yoga; gentle Hatha and Restorative yoga. The program includes specific physical postures and mindfulness exercises focused on breathing and meditation. Cancer survivors will participate in 8 virtual YOCAS sessions (75 minutes/session, 2 times a week for 4 weeks) delivered via an electronic platform (e.g., Zoom)
45341564|NCT00709670|Procedure|MSCT and stress echocardiography|tests MSCT and stress echocardiography
45473581|NCT01284179|Behavioral|Home Hypnotherapy|Each session contains the following elements: (1) trance induction consisting of narrowing the focus of attention and eye-closure, (2) trance deepening through imagery, guided dissociation from the here-and-now and graded suggestions of change in mental state, (3) vivid guided imagery that engages all the senses and implies improved health, well-being and a sense of strength and personal power, (4) therapeutic suggestions and imagery, both direct and indirect, for enhanced chest comfort, overall physical comfort and mental well-being and immunity to discomfort, that is suggested will last beyond termination of the session and become more noticeable and permanent over time, and (5) trance termination through direct suggestions and counting.
45473582|NCT01284179|Behavioral|Educational|Educational recordings regarding FCP and FGIDs.
45473583|NCT05179590|Other|Quality of Dream|"Patients frequently report having dreams during general anesthesia, and the dreams are often reported to be pleasant dreams.~However, factors associated with the quality of dreams during general anesthesia have not been clarifed. The aim of this study was to determine the relationships between the quality of dreams during general anesthesia and perioperative factors.~This prospective observational study included patients scheduled for elective surgery under general anesthesia."
45683616|NCT01773122|Drug|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
45683617|NCT01808534|Drug|palifosfamide|Given IV
45341565|NCT00709748|Device|Empi Select TENS Device|The Empi Select TENS device delivers therapeutic electrical currents at various frequencies (intensities) and periods of time for the treatment of pain.
45341566|NCT00709748|Device|Placebo|Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
45341567|NCT02574650|Device|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) delivered by a percutaneous transcatheter procedure.
45341568|NCT04072094|Procedure|Minimally Invasive Locking Plate Fixation|Patients randomized to the Minimally Invasive Locking Plate Fixation arm will be treated with plate fixation. The plate may be applied in a percutaneous fashion. Any combination of locked and/or non-locked screws may be used.
45683618|NCT04353154|Diagnostic Test|Spartan Cube Point-of Care Covid-19 test|Throat and nasal swab for COVID-19 point-of-care test.
45683619|NCT01808222|Drug|FACBC|Participants will receive a bolus of anti-[18F]FACBC injected IV over 1-2 minutes. The dosage will be approximately 10.0 millicuries (mCi) (3.70 x 108 becquerel (Bq)).
45683620|NCT04660435|Diagnostic Test|Thymidine kinase activity|DiviTum® assay determines the enzymatic activity of TK in serum samples
46036726|NCT02800408|Other|Whole grain high-BCX maize|The whole grain orange maize will be milled and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
46036727|NCT02800408|Other|Refined grain high-BCX maize|The refined grain orange maize will be degermed, milled, and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
46036728|NCT02800408|Other|Whole grain white maize|The whole grain white maize will be milled and prepared into muffins to be consumed daily. Muffins will contain minimal beta-cryptoxanthin, matched for dry maize weight.
46036729|NCT02800720|Behavioral|Meditation Awareness Training|8 Week Meditation Intervention
45341569|NCT04072094|Procedure|Intramedullary Nail Fixation|Patients randomized to the Intramedullary Nail Fixation arm will be receive a standard locked intramedullary nail fixation. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with a reamed technique.
45341570|NCT02577848|Drug|GLP-1|GLP-1 were taken daily for 7 days
45341571|NCT02577848|Drug|Placebo|Placebo were taken daily for 7 days
46036730|NCT02800720|Behavioral|Cognitive Behavioral Therapy for Groups|8 week intervention based on Cognitive Behavioral Theory
46036731|NCT02625025|Procedure|Low pression pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 8 mm Hg during pneumoperitoneum creation and insertion of trocars."
46036732|NCT02625025|Procedure|Standard Pression Pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 12 mm Hg during pneumoperitoneum creation and insertion of trocars."
46036733|NCT02625025|Procedure|Single Port Access Laparoscopy|Laparoscopy surgery with use of only one incision of 2 cm in the umbilicus in order to threat benign adnexal pathology
46036734|NCT00692263|Drug|escitalopram and tramadol|10 mg escitalopram for 3 days 20 mg escitalopram for 6 days 150 mg tramadol as a single dose on day 9
45341572|NCT00582426|Drug|Octreotide Long Acting Release|Patients will receive the first dose of Octreotide LAR (30 mg) at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR (with an interval of 28 days between them), until first-line chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first.
45473584|NCT03736993|Other|Additional blood sampling|Establish predictive markers for early disease progression after complete surgical resection in patients with stage I to IIIA NSCLC.
46036735|NCT00692263|Drug|placebo|placebo identical for 10 mg/ 20 mg escitalopram and 150 mg tramadol
45341573|NCT00582426|Other|Standard Treatment|Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
45341574|NCT02574572|Biological|Autologous mesenchymal cells transplantation|All patients will undergo laminectomy and autologous mesenchymal cells injection into the lesion area.
45341575|NCT02575898|Other|First Session|Creative Practice and Positive Re-enforcement
45473585|NCT01166789|Drug|Lubiprostone|48ug daily taken as 24ug capsules twice per day, in morning and evening.
45473586|NCT01166789|Drug|Placebo|2 capsules daily, taken in morning and evening
45473587|NCT01314339|Drug|Desloratadine|Desloratadine Tablets, 5 mg
45473588|NCT05179512|Drug|Tiotropium|Tiotropium dispensing claim is used as the reference group.
45473589|NCT05179512|Drug|salmeterol-fluticasone|Salmeterol/Fluticasone dispensing claim is used as the exposure group.
45473590|NCT03736915|Procedure|Injection using 1 cc of NaCl 0.9%|The injection will be using SIMPLE block technique using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
45473591|NCT03736915|Other|Patient Preference Question|Patient is asked at the end of each injection which injection they prefer
46036736|NCT00692263|Drug|placebo and tramadol|9 days of placebo equivalent to 10 / 20 mg escitalopram, one single dose of 150 mg tramadol on day 9
46036737|NCT02800486|Drug|Intra-arterial Cetuximab|
46036738|NCT02800486|Drug|Intra-arterial Mannitol|
46036739|NCT02800486|Radiation|Hypofractionated re-irradiation|
46036740|NCT00694759|Drug|pioglitazone|30 mg for 2 weeks, then 45 mg daily
46036741|NCT00694759|Drug|metformin|500mg twice daily for 1 week, then 1000 mg twice daily
46036742|NCT00694759|Drug|placebo|capsule twice daily
46036743|NCT02803840|Radiation|Low-dose radiotherapy|2 x 2 Gy on symptomatic sites only
46036744|NCT00694837|Drug|nelfinavir|The start dose of nelfinavir in phase 1 is 1000mg BID. The maximum administered dose, if no DLT occurs, will be1250 mg BID (2500mg). Nelfinavir will be administered 1 week before start of the chemoradiotherapy until the last day of chemoradiotherapy.
46036745|NCT02800252|Drug|Placebo|One-stage full-mouth periodontal ultrasonic debridement plus placebo intervention
45341576|NCT02575898|Other|Second Session|Disease Related
45341577|NCT02575898|Behavioral|Third through Sixth Sessions|Life Review and Legacy
45341578|NCT04019184|Drug|L-Alanyl/L-Glutamine|Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the investigational drug
45341579|NCT04019184|Drug|Placebo|Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the placebo
45341580|NCT00709982|Drug|Norgestimate; Ethinyl Estradiol; Folic acid|
45341581|NCT02387970|Procedure|Immediate provisionalization|Stage one protocol: Individuals will receive temporary crowns at the same day as implant surgery, and a final restoration at four months after surgery.
45341582|NCT02387970|Procedure|Delayed provisionalization|Stage two protocol: Individuals will receive temporary crowns 3 months after implant surgery, and a final restoration at four months after surgery.
45341583|NCT02387970|Device|NobelParallel CC implant|Supports the comprehensive range of dental prosthetics as well as full range of prefabricated abutments.
45341584|NCT02387970|Device|Dental crown|"A tooth-shaped cap that is placed over a tooth or implant for teeth restoration and improvement in appearance."
45341585|NCT00710060|Behavioral|Community Popular Opinion Leader (C-POL)|The C-POL intervention will teach identified opinion leaders to share personalized HIV prevention messages in conversations with peers in an effort to change community norms. Opinion leaders will be taught skills for sharing HIV risk-reduction messages during four to five weekly training sessions. At least 15% of the community population will be trained as opinion leaders. After the initial training, opinion leaders will attend six to nine booster sessions over the next 2 years to reinforce and support continued conversation efforts.
45341586|NCT00710060|Behavioral|HIV/STD educational materials|Communities will receive HIV/STD educational materials and treatment referral information to distribute to community members.
45341587|NCT04070690|Procedure|Concentration of dialysate bicarbonate|Adjust the dialysate bicarbonate concentration
45341588|NCT03086850|Behavioral|Promotion of daily physical activity with a pedometer|"Patients will receive an ONwalk 100 pedometer (GEONAUTE, France) and will be instructed how to use it. They will be encouraged to be more active by using the pedometer to measure the number of steps walked daily and to record this in a diary, together with any information related to their clinical condition. Based on the cumulative step count for each day and the mean value since the last visit, patients will receive a task to increase their steps per day by the next appointment according to the next protocol:~<6000 steps/day: increase by 3000 steps/day~6000 - 10000 steps/day: reach 10000 steps/day~> 10000 steps/day: maintain or increase steps"
45341589|NCT03086850|Other|Conventional treatment|Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
45683621|NCT03221140|Drug|Outpatient parenteral antimicrobial therapy|Administration of intravenous antimicrobials on an outpatient basis
45683622|NCT04343482|Device|wearable vital signs sensor|vital signs monitoring during maternal non-stress testing
45683623|NCT01772576|Device|Reliance 4-Front lead implantation|The patients selected for participation should be from the investigator's general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.
45839966|NCT04614480|Genetic|Exome analysis|Exome analysis of tumor DNA and constitutional DNA in patients included in 1st line treatment
45839967|NCT04531410|Dietary Supplement|linoleic acid supplementation|Oils given daily at morning meal with extra enzymes
46036746|NCT02800252|Drug|3g omega-3 plus 100mg aspirin daily for 60 days|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
46036747|NCT02800252|Drug|omega-3 plus aspirin before periodontal therapy|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days before periodontal therapy
46036748|NCT02621359|Drug|Nitazoxanide|Nitazoxanide 500 mg twice daily
46036749|NCT02621359|Drug|Levofloxacin|Levofloxacin 500 mg once daily
46036750|NCT02621359|Drug|Doxycyclin|Doxycyclin 100 mg twice daily
45341590|NCT00710138|Dietary Supplement|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
45341591|NCT04072172|Device|Mole Freckle Pen|Insulated micro steel needle use current: 5V / 1A of 5-speed free adjustment.5
45341592|NCT00580034|Drug|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Patient Evaluation: Will occur 2-3 times per week by physical exam for toxicity through day 45."
45341593|NCT00580034|Procedure|Donor Apheresis|Donor will receive Granulocyte colony-stimulating factor (G-CSF) 10-16 mcg/kg/d subcutaneously (dose will be rounded to the nearest whole vial size and may be divided into twice daily dosing). Granulocyte-macrophage colony-stimulating factor (GM-CSF) 15 mcg/kg/d subcutaneous or similar growth factor for donor mobilization. Donors will receive at least 3-6 doses of daily growth factor until adequate cells are mobilized.
45341594|NCT00710216|Drug|Lamivudine|100 mg/day
45341595|NCT00710216|Drug|Telbivudine|600 mg/day
45341596|NCT02575820|Procedure|Old red blood cells transfusion|Red blood cells (shelf life > 14 days) transfusion during the operation (total hip replacement arthroplasty)
45341597|NCT02575820|Procedure|New red blood cells transfusion|Red blood cells (shelf life =< 14 days) transfusion during the operation (total hip replacement arthroplasty)
45341598|NCT02577692|Other|Oxygen|breathing oxygen
45473592|NCT03736915|Other|Questionnaires|Patient is asked to answer questionairres at the end of each injection
45473593|NCT01168817|Drug|BAY60-4552 plus Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 10 mg plus BAY60-4552 1.0 mg)
46036751|NCT02621359|Drug|Omeprazole|Omeprazole 40 mg twice daily
46036752|NCT02800018|Other|risk factors|investigators will analyze if certain risk factors will influence the progression of the encephalopathy
45341599|NCT02577692|Other|Ambient|breathing ambient air
45341600|NCT03913598|Other|patient questionnaire|self-administered patient questionnaire regarding the different aspects of internet and social media use in dermatology patients
45473594|NCT01168817|Drug|Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 20 mg)
45473595|NCT01168817|Drug|Placebo|Treatment with 3 tablets once daily for 4 weeks (Placebo)
45839968|NCT04531410|Dietary Supplement|oleic acid supplementation|Oils given at morning meal with extra enzymes
45839969|NCT04497246|Other|Questionnaire|Data collection by means of various questionnaires
46036753|NCT01152437|Drug|BIBW 2992|Patients receive BIBW 2992 tablets once daily, and can reduce dose for adverse event management
46036754|NCT01152437|Drug|Cetuximab|Patients receive cetuximab intravenously, once a week, every week
45341601|NCT00710294|Device|CVRx Rheos Baroreflex Hypertension Therapy System|"The pulse generator, which is similar to a pacemaker, is typically implanted under the skin below the collarbone.~Two small leads from the device are wrapped around the carotid arteries on both sides of the neck and connected to the pulse generator."
45341602|NCT00710372|Biological|CYT006-AngQb|s.c. injection
45341603|NCT00773513|Drug|Darbepoetin Alfa|Darbepoetin alfa will be administered as per approved label.
45473596|NCT04523649|Device|Remote atrial fibrillation screening with handheld single lead ECG recorder|Patients in this group will be given a handheld single lead ECG recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China) and a patient-facing smartphone application specially designed for the study, and they will be requested to record daily ECG and certain vital measurement.
45473597|NCT03639961|Behavioral|Integrated leading, managing and governing for results model|Integrated leading, managing and governing for results model is an intervention launched to improve institutional delivery.
45341604|NCT00773513|Drug|Epoetin Alfa|Epoetin alfa will be administered as per approved label.
45473598|NCT03639961|Behavioral|Traditional model|Traditional model is a health service delivery model already in place in the government health system.
45473599|NCT03612258|Diagnostic Test|Functional Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging scans will be completed to assess neural responses to painful, non-painful sensory, and emotion-eliciting stimuli.
45473600|NCT01279811|Other|Crossover of vasopressors|"To evaluate the effect of different vasopressor agents on SCPP, a crossover intervention will be conducted on patients requiring either NORepinephrine or DOPamine post-operatively, once daily for 5 days while the catheter is in place. A subject on NORepinephrine will be switched over to DOPamine for 1 hr, and then switched back to NORepinephrine. Likewise, a subject on DOPamine will be switched over to NORepinephrine for 1 hr, and then switched back to DOPamine. Subjects on both vasopressors will have DOPamine stopped for 1 hr and NORepinephrine titrated up to maintain the same MAP for 1 hr, and then brought back to the original levels of both vasopressors. On the following day, the reverse will be carried out, with a stoppage of the NORepinephrine and maintenance solely on DOPamine."
45473601|NCT04043143|Other|Arm 1 Prescription As Usual|At the time of writing the discharge prescription for a patient the provider will receive a best practice alert (BPA) to consider prescribing the usual medications for pain management after discharge.
45473602|NCT04043143|Other|Arm 2 Prescription Tool Intervention|The best practice alert (BPA) Prescription Tool will only make a suggestion to the provider if the patient may be considered for a lower post-discharge opioid dose. Providers may still choose to prescribe a higher dose as clinically indicated.
45473603|NCT01168895|Drug|Cipro Inhale (Ciprofloxacin, BAYQ3939)|32.5 mg ciprofloxacin corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
45473604|NCT01168895|Drug|Cipro Inhale (Ciprofloxacin, BAYQ3939)|48.75 mg ciprofloxacin corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
45473605|NCT05572398|Behavioral|STAC-T|Middle school participants will complete online modules to learn about anti-bullying techniques and bystander intervention.
45473606|NCT01169129|Other|surgery|resection of brain metastases
45473607|NCT01169129|Radiation|radiosurgery|radiosurgery to brain metastases
45341605|NCT00773513|Drug|Epoetin Beta|Epoetin beta will be administered as per approved label.
45341606|NCT00773513|Drug|methoxy polyethylene glycol-epoetin beta|Participants who are currently not being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta administered at a starting dose of 0.6 mcg/kg body weight once every 2 weeks. Participants who are currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta at a dose of 120, 200 or 360 mcg once monthly (based on ESA dose administered in Week -1)
45473608|NCT03736837|Drug|Anlotinib Plus Icotinib|"Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent."
45473609|NCT02526407|Behavioral|Singing|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will learn songs with their babies and help to create new musical material together.
45473610|NCT02526407|Behavioral|Group play|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will take part in group play activities.
45473611|NCT04041895|Other|Audio speech recording|Audio recording of speech sample from subject description of Cookie-Theft image.
45839970|NCT04442256|Drug|Dupilumab|All patients will be administered subcutaneous doses of dupilumab in a biweekly fashion.
45341607|NCT00710528|Drug|CAL-101|CAL-101 50, 100, 150, 200, 350 mg capsules BID for 28 days CAL-101 150, 300 mg QD for 28 days CAL-101 150 mg BID 3 weeks on 1 week off for 28 days
45341608|NCT04070612|Other|Blood sample|A blood sample of 2 times 2 to 5 ml additional maximum
46036755|NCT02800174|Device|Smart nitinol stent implantation|Before intervention, clopidogrel (75 mg/d), aspirin (100 mg/d) and atorvastatin (40 mg/d) were prescribed. One week later, aortic arch and aortocranial angiography were performed under general anesthesia to determine the site, range and extent of the lesion and the status of the cerebral microcirculation, and consequently to inform the treatment strategy and the selection of the correct size of self-expanding nitinol stent system.
45341609|NCT00711074|Drug|AZD5672|single dose 200mg aqueous solution
45341610|NCT02574416|Other|There is no intervention|The study is observational and there is no intervention
45341611|NCT00711152|Other|Protocol-driven care under JADE Program|The JADE Program uses the state of the art of information technology to facilitate evidence-based clinical protocol by a multidisciplinary team. There is an internet on-line and computer record system to facilitate the day-to-day management of people with diabetes.
45341612|NCT00711152|Other|Additional support by CHW|Patients will receive additional support by a trained community health worker (CHW). Guided by the personalized report with embedded decision support, the CHW will reinforce treatment adherence and self care after each clinic visit.
45341613|NCT00711230|Biological|DermaVir|
45341614|NCT00711230|Biological|Placebo|glucose/dextrose
45341615|NCT00711308|Drug|tinzaparin|tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
45473612|NCT03523806|Behavioral|Solution-Focused Coaching in Pediatric Rehabilitation|A coaching model for children with disabilities, with a strong theoretical basis, and ability to be customized to children and families' resources, environmental settings, child age and developmental stage
45473613|NCT03745105|Drug|Dexamethasone sodium phosphate|prophylactic intraligamentary supplemental injection of 0.4 ml of 8 mg/2 mL dexamethasone.
46036756|NCT02800174|Drug|antiplatelet drug|Patients with carotid artery stenosis treated conservatively were commenced on an indefinite course of one or more oral antiplatelet drugs. The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.
45341616|NCT00711308|Drug|acenocoumarol|acenocoumarol for 6 months
45341617|NCT02601911|Drug|Ketorolac Tromethamine|10 mg Ketorolac tromethamine is applied 45 minutes before the injection.
45341618|NCT02601911|Drug|Acetaminophen|10 mg Ketorolac tromethamine/ 1000mg Acetaminophen application before injection.
46036757|NCT04137913|Behavioral|Musical arts intervention|A 6-week group music class that incorporates listening, theory, performance, and creation of music.
45341619|NCT02601911|Other|Placebo|This group receive the caplet including placebo 45 minutes before the injection.
45341620|NCT00711386|Drug|GSK706769|50mg, 100mg, 200mg, or 400mg
45341621|NCT00711386|Other|Placebo|Placebo
45341622|NCT04101773|Procedure|RBL versus sutured mucopexy versus haemorrhoidectomy.|All 3 interventions are part of Dutch usual care, and serve as each other's control.
46036758|NCT02800330|Drug|Esomeprazole 40mg concomitantly|During phase B the patients will use esomeprazole 40mg concomitantly with regorafenib for 5 days.
45341623|NCT00711542|Biological|autologous bone marrow-derived progenitor cells|intracoronary infusion of autologous bone marrow-derived progenitor cells isolated from 50 ml bone marrow aspirate
45341624|NCT00711542|Biological|placebo medium|intracoronary infusion of placebo medium
45341625|NCT04104347|Other|Metacognitive training (MCT)|Metacognitive Training (MCT) was first developed in Germany in 2007 by Steffen Moritz and Todd Woodward (Moritz & Woodward, 2007) targeting positive psychotic symptoms of patients with schizophrenia. MCT aims to change cognitive biases leading to delusional beliefs and consists of ten group sessions focused on different topics (Modules) as follows: Attributional Style (Module 1), Jumping to Conclusions (Modules 2 and 7), Changing Beliefs (Module 3), Empathy (Modules 4 and 6), Memory (Modules 5), Depression and Self-Esteem (Module 8) and two additional modules, namely Self-Esteem (Module 9) and Stigma (Module 10). Modules 8 (Self-Esteem), 9 (Self-Esteem) and 10 (Stigma) can be delivered together as one session so the intervention totals eight weekly group (3-10 participants) sessions. The MCT manual is available at: http://www.uke.de/mkt and was directly supervised by Steffen Moritz.
45341626|NCT04104347|Other|Support group|Controls will attend eight weekly support groups. Seven group sessions will focus on the following topics: 1) basic activities of daily living (BADL), 2) instrumental activities of daily living (IADL), 3) physical health, 4) press-based work, 5) psychoeducation on emotions, 6) psychoeducation on illness, 7) social and family relationships. One additional session will give participants some time to openly raise general issues and concerns which were not discussed during the above sessions. Controls will be encouraged to attend these group sessions from which they are likely to benefit. While not an intervention as such, this should turn into enough incentive to reach similar attendance rates in both arms of the RCT.
45341627|NCT00711620|Drug|Thymosin alpha 1|1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.
45341628|NCT00581828|Drug|Vitamin D|50,000 IU po qd for 15 days and 50,000 IU po twice month for 10 months (until final study visit at one year)
45341629|NCT02577380|Behavioral|IPV/GBV HTC|Participants will be interviewed after receiving their services.
45341630|NCT02577614|Drug|FEIBA|Administration of FEIBA after cardiopulmonary bypass
45341631|NCT02577614|Drug|Normal Saline|Administration of placebo after cardiopulmonary bypass
45341632|NCT02577458|Drug|CM082|CM082 tablets taken orally once a day on 28-day cycles
45341633|NCT02577458|Drug|Everolimus|Everolimus tablets taken orally once a day on 28-day cycles
45341634|NCT00767039|Drug|Survanta (beractant)|beractant 4.0 ml/kg/dose (100 mg phospholipid/kg/dose, intratracheal, every 6-12 hours as needed for respiratory distress syndrome for initial and subsequent doses, maximum of 4 doses)
46036759|NCT02800330|Drug|Esomeprazole 40mg before|During phase C the patients will use esomeprazole 40mg 3 hours before regorafenib for 5 days.
46036760|NCT02800330|Drug|Regorafenib 160mg or 120mg|Patients will use regorafenib 160mg or 120mg during all phases (A, B, C)
46036761|NCT02799862|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered in accordance with the SmPC of Nab-Paclitaxel.
46036762|NCT02799862|Drug|Carboplatin|Carboplatin will be administered as combination partner of Nab-Paclitaxel in accordance with SmPC of Nab-Paclitaxel.
45341635|NCT00767039|Drug|Curosurf (poractant)|poractant alfa 2.5 ml/kg/dose initial (200 mg phospholipid/kg), and 1.25 ml/kg/dose subsequent (100 mg/kg/subsequent dose), intratracheal, every 12-24 hours as needed for respiratory distress syndrome, maximum of 3 doses)
46036763|NCT01151579|Drug|Levalbuterol|inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg
45341636|NCT01640522|Other|Collaborative Care|Collaborative care intervention to manage cancer-related symptoms
45473614|NCT03745105|Drug|Piroxicam Injectable Solution|prophylactic intraligamentary supplemental injection of 0.4 mL of 20 mg mL-1 piroxicam
45473615|NCT03745105|Drug|Mepivacaine HCL|prophylactic intraligamentary supplemental injection 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml
45473616|NCT01282541|Drug|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transconjunctivally into the palpebral lobe of the lacrimal gland once
45473617|NCT01282541|Drug|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transcutaneously into the orbital lobe of the lacrimal gland once
46036764|NCT01151579|Drug|Albuterol|Nebulized albuterol 2.5mg
46036765|NCT00694915|Biological|Mycobacterium w|Immunomodulator
45341637|NCT01640522|Other|Enhanced usual Care|
46036766|NCT00694915|Biological|BCG (Bacillus Calmette-Guerin)|Immunotherapeutic agent
45341638|NCT04071938|Other|Teaching to GPs|Educational modules on bladder, bowel and skin-care, and pain management will be provided to participating GPs by Spinal Cord Injury specialists
46036767|NCT02800096|Behavioral|Gambling Internet intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
45341639|NCT04071938|Other|Site visits to GP practices|Visits by specialized nurses to the participating GPs at their practices to support the establishment of specialized care on-site
45341640|NCT01572506|Drug|Biotin RBC survival|
45473618|NCT03744325|Dietary Supplement|Hen's egg OIT|Increasing doses of egg white protein administered orally
45473619|NCT01169363|Genetic|proteomic profiling|
45473620|NCT01169363|Other|flow cytometry|
45473621|NCT01169363|Other|laboratory biomarker analysis|
46036768|NCT02800096|Behavioral|MoodGYM|Internet intervention for depression and anxiety - MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
46036769|NCT00694993|Drug|GSK1004723|GSK1004723 will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
46036770|NCT00694993|Drug|Placebo|Placebo will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
46036771|NCT02803450|Procedure|Epidural needle|Medication administration via epidural needle.
45341641|NCT00662649|Drug|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
45341642|NCT00662649|Drug|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
45341643|NCT02577770|Device|acupuncture|therapeutic acupuncture treatment with actual needles
45683624|NCT03192358|Diagnostic Test|Videofluoroscopic Swallowing Examination|During the videofluoroscopy, subjects will take up to 21 sips of liquid, ranging in thickness from thin (like water), to extremely-thick (like pudding or custard). The liquids will be mixed with E-Z-Paque barium sulfate, to allow it to be visible on the x-ray.
45341644|NCT02577770|Dietary Supplement|200mg caffeine|8g coffee, po
45341645|NCT02577770|Dietary Supplement|400mg caffeine|16g coffee, po
45341646|NCT02577770|Dietary Supplement|Decaffeinated|decaffeinated coffee, po
45341647|NCT00766493|Device|GORE® Embolic Filter|Embolic protection during carotid stenting
45341648|NCT00129896|Drug|Myocet|Myocet®: 60-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles
46036772|NCT02803450|Procedure|Catheter Administration|Medication administration via epidural catheter.
46036773|NCT02803450|Procedure|Standard of Care Epidural Administration|Medication administered at higher concentration, lower volume via epidural catheter.
46036774|NCT00692497|Behavioral|one stop (Electronic standardised referrals and appointment bookings)|The one stop strategy is a set of interventions directed at GPs referring to the University Hospital. The interventions include: Guidelines for referral, standardised electronic referrals, booking for outpatient surgery and a patient information form.
46036775|NCT02803528|Drug|Biodentine|Biodentine is going to be used as the direct pulp capping material
46036776|NCT02803528|Drug|MTA|MTA is going to be used as the direct pulp capping material in the second group
46036777|NCT04136041|Device|Smartphone Application|The experimental group will watch movies using the Smartphone application for at least 10 min a day for 5 weeks.
46036778|NCT01097616|Drug|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants <65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
45341649|NCT00129896|Drug|Taxotere|Taxotere® 70-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles
45341650|NCT00129896|Drug|Herceptin|Herceptin® (4) 2 mg/kg (vía IV) Semanal for 6 cycles
46036779|NCT01097616|Drug|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants <65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
45341651|NCT02602535|Behavioral|Mindfulness-Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
45839971|NCT04175106|Other|a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value|"150 g of a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
45341652|NCT02602535|Behavioral|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
45341653|NCT02574338|Device|Foley's Catheter|intracervical extraamniotic Foley's catheter
45341654|NCT02574338|Drug|prostaglandin E1 analogue|intravaginal misoprostol
45341655|NCT03070392|Biological|IMCgp100|IMCgp100 is to be administered at 20 mcg cycle 1 day1, then 30 mcg cycle 1 day 8, then 68 mcg cycle 1 day 15 and weekly thereafter by IV infusion over 15 minutes until confirmed disease progression or unacceptable toxicity
45341656|NCT03070392|Drug|Dacarbazine|Dacarbazine is to be administered at 1,000 mg/m2 of body surface area IV infusion every 3 weeks until disease progression or unacceptable toxicity
45341657|NCT03070392|Biological|Ipilimumab|Ipilimumab is to be administered at 3 mg/kg IV infusion over 90 minutes every 3 weeks for a total of 4 treatments
45341658|NCT03070392|Biological|Pembrolizumab|Pembrolizumab is to be administered at 2 mg/kg IV infusion up to a maximum of 200 mg administered Intravenously over 30 minutes every 3 weeks or 200 mg fixed dose administered intravenously every 3 weeks where approved locally until confirmed disease progression or unacceptable toxicity
45341659|NCT00711698|Procedure|Patient controlled analgesia|Patients in this arm will be treated with a bolus of narcotic followed by PCA
45341660|NCT00711698|Drug|nurse-administered intermittent IV bolus opioid therapy (NAIBOD)|In this arm patients will receive the current standard of care of IV bolus narcotic therapy
45341661|NCT00784043|Device|Cochlear Implant|Bilateral Implantation in children
45341662|NCT02555241|Behavioral|Mand Training|The mand training component of treatment will consist of behavioral principles designed to increase the participant's Mean Length of Utterances (MLU) when manding.
45341663|NCT02555241|Behavioral|Matrix|The matrix training component of treatment will consist of behavioral principles designed to teach labeling of noun-verb and color-shape combinations using matrix training.
45341664|NCT02555241|Behavioral|Stimulus Equivalence Training|The stimulus equivalence training component of treatment is designed to examine the emergence of untrained skills following the training of relational skills.
45341665|NCT04071548|Other|HIIT Exercise|"HIIT exercise bike protocol~3 minute warm up~Intervals of 10x 60 sec of 80-95% of heart rate reserve Heart rate reserve = Max Heart rate - Resting Heart rate § Max heart rate = 220-age~10x60 second Recovery period~5 minute cool-down"
45341666|NCT00789087|Procedure|Videothoracoscopic talc poudrage (VT).|Videothoracoscopic talc poudrage
45341667|NCT00789087|Procedure|Talc slurry through a chest tube (DT).|Talc slurry through a chest tube
45341668|NCT00711776|Drug|New formulation|New formulation of Aciclovir Cream 5% scheduled to be substituted to Current formulation in Japan
45341669|NCT00711776|Drug|Current formulation|Current formulation of Aciclovir Cream 5% in Japan
45341670|NCT00795171|Drug|Docetaxel * Sunitinib|docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
45341671|NCT00795171|Drug|Docetaxel|docetaxel 75mg/m2 day1 q 21d x 4 cycles
45341672|NCT00795171|Drug|Docetaxel|Docetaxel 75mg/m2 q21d for 4 cycles
45341673|NCT00711854|Drug|trimethoprim-sulfamethoxazole (TMP-SMX)|TMP-SMX (160 mg TMP/ 800 mg SMX IV or PO 3x daily)
45341674|NCT00711854|Drug|Linezolid|Linezolid (600 mg IV or PO twice daily)
46036780|NCT01097616|Drug|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants <65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
46036781|NCT02799628|Behavioral|intervention|intervention with recommendation and therapist introduction
46036782|NCT02799628|Other|placebo|low back pain education, and physical therapy 3 times per week
45341675|NCT00711854|Drug|Rifampicin|Rifampicin (600 mg IV or PO once daily)
45341676|NCT00795249|Behavioral|smoking cessation|After baseline examination, the group is asked to quit smoking for 2 weeks.
45341677|NCT00795327|Device|Sculptra (Poly-L-Lactic Acid Dermal Implant)|Drug Device study
46036783|NCT00695071|Drug|Itraconazole|Oral
46036784|NCT04047823|Device|a digital Infrared thermography (FLIR E5 Serial No.63985976）|Measurements were taken during radiation and additionally two weeks after radiotherapy weekly. Temperature change was measured by thermal infrared imager (FLIR) for 4 test areas within the supraclavicular radiation field and on an opposite non-irradiated area, which was outlined using a specific software package (FLIR Systems 6.3.17227.1001).
46036785|NCT02799550|Biological|allogeneic CART-19|allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19)
46036786|NCT00695149|Procedure|Transplantation of bone marrow stromal cell|
46036787|NCT04137679|Radiation|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
46036788|NCT04137679|Procedure|Neoadjuvant Radiochemotherapy followed by surgery|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
46036789|NCT04939428|Drug|Molnupiravir|Four molnupiravir 200 mg capsules taken by mouth.
45341678|NCT00773279|Device|FlexTouch®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
45341679|NCT00773279|Device|FlexPen®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
45341680|NCT05003882|Other|Commercially available, orally ingestible CBD product|botanically-derived CBD extract product
45341681|NCT00795405|Behavioral|Exposure to sporting events|Exposure to sporting events
46036790|NCT04939428|Drug|Placebo|Placebo capsule matched to molnupiravir 200 mg capsules taken by mouth.
46036791|NCT02621125|Dietary Supplement|Fertilix|daily supplementation
46036792|NCT02621125|Other|Placebo|Placebo
45341682|NCT00795405|Behavioral|No exposure to sporting events|No exposure to sporting events
45341683|NCT02579304|Procedure|transbronchial lung cryobiopsy|bronchoscopic sampling
45341684|NCT04046211|Drug|Hydrogen|Gas exposure for 24, 48 or 72 hours via high flow nasal cannula.
46036793|NCT00695227|Diagnostic Test|Screening for Barrett's Esophagus|
46036794|NCT02799394|Other|Activity modification, exercises and gradual return to sport|
46036795|NCT00692575|Behavioral|Problem-solving, education based telephone counseling|Caregivers are contacted every 2 weeks for 16-20 weeks after discharge of TBI survivor home. A caregiver support specialist provides telephone counseling based on a problem-solving, educational model.
46036796|NCT00692575|Other|No Intervention|The control group will receive standard of care, i.e., typical resources and/or supports offered to caregivers of persons with TBI.
45341685|NCT00712088|Behavioral|Project ICARE|Group-level intervention (Project ICARE)
45341686|NCT00712088|Behavioral|HCT|Offer of HIV counseling and testing
45341687|NCT02579226|Drug|AZD2811|The study will be conducted in 2 parts, dose-escalation (A) and dose-expansion (B). All patients in both parts of the study with receive AZD2811.
45341688|NCT00795483|Drug|Zoledronic acid|Zoledronic Acid 5mg/year
45473622|NCT03745027|Diagnostic Test|in vitro fertilization|All patients underwent gonadotropin-releasing hormone agonist (GnRHa) treatment for in vitro fertilization and Follicular fluid sialic acid levels are measured.
45473623|NCT03744247|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
46036797|NCT02803294|Procedure|transcatheter aortic valve replacement|
46036798|NCT00871429|Other|Lindi skin care products|"Subjects will then be instructed to apply all three products daily for 1 month.~The products include: Lindi Skin soothing balm (product A), Lindi Skin face serum (product B, and Lindi Skin face wash (product C)."
45341689|NCT00795483|Behavioral|Lifestyle modifications|Lifestyle modifications
45341690|NCT00795483|Drug|Zoledronic acid|Zoledronic acid (5mg/2years)
45341691|NCT00712400|Drug|Latanoprost 0.005%, Xalatan®|Substance: Latanoprost 0.005%, Xalatan® (Pharmacia Austria Ges.m.b.H. Oberlaaer Straße 251, 1101 Vienna) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
45341692|NCT00712400|Drug|Placebo|Substance: Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
45341693|NCT00766415|Drug|AZD1981|Oral tablet, twice daily, 4 weeks treatment
45341694|NCT00766415|Drug|Placebo|Placebo
45341695|NCT04071834|Diagnostic Test|ELISA|Detection of blood orphanin and norepinephrine in patients
45341696|NCT00712478|Drug|insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
45473624|NCT03744247|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
45473625|NCT03744247|Drug|Placebo|Intravenously every 2 weeks
45473626|NCT01282619|Drug|Huperzine A|Sustained-Release Tablet, 400µg once a day, 24 weeks
45473627|NCT01282619|Drug|huperzine A|Tablet, 200µg twice a day, 24 weeks
46036799|NCT02803216|Drug|standard triple region|ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).
46036800|NCT02803216|Drug|2-week Xiang-sha-liu-jun decoction|2-week Xiang-sha-liu-jun decoction, bid.
46036801|NCT02803216|Drug|4-week Xiang-sha-liu-jun decoction|4-week Xiang-sha-liu-jun decoction, bid.
46036802|NCT02624635|Other|Manual Therapy|The scheme established for that intervention is as follows: joint manipulation passive ankle and foot, myofascial release technique (gastrocnemius, soleus muscle and plantar fascia), neural mobilization (nerve tibial) and stretching the plantar region and sural triceps, following the recommendations described by Mcpoil et al. (2008).
46036803|NCT02624635|Other|Manual Therapy and Hip Strengthening|It will be done the same treatment performed in group 1 plus the strengthening of the muscles of the hip (iliac muscle, psoas, gluteus maximus, gluteus medius and gluteus minimus) and the treatment schedule established for this intervention is the use of exercises with progressive resistance. Will be performed 3 sets of 10 reps with 30 seconds rest between each set, according to the guidelines of the American College of Sports Medicine (ACSM, 2014). The home exercises consist of repeating the same procedures performed for supervised strengthening. The calculation of the ideal individual load will be carried by Brzycki formula, i.e. one repetition maximum (1RM) = weight ÷ [1.0278 - (0.0278 x number of repetitions)] as was used by (Shirazi et al., 2007).
45341697|NCT03015792|Drug|Dexamethasone|Given PO
45473628|NCT01282619|Drug|Placebo|placebo orally twice a day
46036804|NCT04308408|Behavioral|Guideline Daily Amounts|All food items displayed the corresponding GDA label in the lower left corner of the front of the package.
46036805|NCT04308408|Behavioral|Multiple Traffic Light|All food items displayed the corresponding MTL label in the lower left corner of the front of the package.
46036806|NCT04308408|Behavioral|Warning Labels|"Food products were labeled with High in labels In the lower left corner of the front of the package. In total, 37 of the 60 food products in the shopping site did not display a WL."
46036807|NCT04308408|Behavioral|Video|Participants viewed a short (less than 1 min) video explaining how to interpret the label.
46036808|NCT02799316|Other|HBV core antibodies testing. • Real time PCR testing.|"HBV core antibodies testing in HBV surface antigen negative patients.~Real time PCR testing for those having positive HBc antibodies."
46036809|NCT04015999|Dietary Supplement|Microbiota Directed Complementary Food (MDCF)|MDCF2 with four complementary food ingredients (rationale: lead with evidence from Pre-POC clinical trials to optimize lead microbiota-directed complementary food prototypes for their ability to repair microbiota immaturity and positive effects on growth)
45473629|NCT01282697|Drug|Combined administration of irinotecan and rapamycin|This phase I trial is a dose escalation study of irinotecan + rapamycin with a 3+3 statistical design.
45473630|NCT03283098|Drug|Etelcalcetide|Etelcalcetide was supplied as a sterile, preservative-free, aqueous solution in a single-use 3 mL glass vial.
45473631|NCT03283098|Drug|Placebo|Placebo supplied to match active intervention.
46036810|NCT04015999|Dietary Supplement|Ready to Use Supplementary Food (RUSF)|Rice-lentil based RUSF (rationale: reference standard of care for MAM; based on knowledge of its effects on the gut microbiota or microbiota immaturity)
46036811|NCT04936932|Device|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser
46036812|NCT04936932|Device|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser
46036813|NCT02803372|Other|Goal-directed circulatory management|In addition to routine monitoring, invasive LiDCOrapid is used to monitor MAP, SVV and CI. Intraoperative circulatory management is performed according to the goal-directed principal, i.e., to maintain MAP > 95 mmHg, SVV < 6%, and CI 3.0-4.0 L/min/m2, started from renal artery clamping and maintained until the end of surgery. Crystalloid solution is firstly infused to maintain SVV at the target level, dobutamine and/or noradrenaline are then infused to maintain MAP and CI at the target levels.
45341698|NCT03015792|Drug|Ibrutinib|Given PO
45473632|NCT03655951|Behavioral|Web-based resource on adolescent sexual health|Web-based resource on adolescent sexual health than the intervention.
46036814|NCT02803372|Other|Routine circulatory management|Routine monitoring is performed, which include invasive blood pressure and urine output. Intraoperative circulatory management is performed according to routine practice, i.e., to maintain blood pressure within 20% from baseline level and urine output > 0.5 ml/kg/h by infusing crystalloid solution and administering vasoactive drugs when considered necessary.
46036815|NCT00695383|Behavioral|Bedside cycle exercise therapy|A 20-minute cycling exercise session is performed 5 days a week using a bedside cycle ergometer. Patients can cycle passively and actively against increasing resistance. Besides this, patients receive the standard physiotherapy program as in arm 2
45341699|NCT03015792|Other|Laboratory Biomarker Analysis|Correlative studies
45473633|NCT03655951|Behavioral|Alternate web-based resource on adolescent sexual health|This is a different web-based resource on adolescent sexual health than the intervention.
45473634|NCT01169597|Drug|prednisone|prednisone 12.5 mg daily po
45341700|NCT03015792|Drug|Lenalidomide|Given PO
45341701|NCT03015792|Other|Pharmacological Study|Correlative studies
46036816|NCT00695383|Behavioral|Standard physiotherapy program|The standard physiotherapy program consists of daily chest physiotherapy and a mobilization session on 5 days per week.
46036817|NCT04933890|Device|Use of Eko DUO electronic stethoscope|Auscultation of heart sounds using electronic stethoscope
45341702|NCT03015792|Other|Quality-of-Life Assessment|Ancillary studies
45341703|NCT00789165|Drug|quinidine|quinidine at highest tolerated dose. Expected doses are hydroquinidine 600 - 900 mg daily.
45341704|NCT00789165|Drug|no therapy|No therapy; this is not a placebo-controlled trial
46036818|NCT02803684|Other|MRI examination with tensor diffusion protocol acquisition. No injection needed.|standard MRI examination
46036819|NCT00625950|Procedure|ENDOMETRIAL BIOPSY|Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.
46036820|NCT02620969|Other|Blood and dialysate sampling|Blood and dialysate sampling
46036821|NCT02799238|Biological|ALECSAT|3 doses of ALECSAT/4 weeks followed by ALECSAT/3 months
45341705|NCT00712556|Radiation|fluorine 18-fludeoxyglucose positron emission tomography|fluorine 18-fludeoxyglucose is a radioactive isotope used in PET to detect cancer tumors
45341706|NCT00795561|Procedure|Day care|Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.
45341707|NCT00795561|Procedure|Inpatient|Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
45341708|NCT04659122|Biological|AT-100|reconstituted AT-100 for intratracheal administration
45341709|NCT00772967|Drug|Naproxen|Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
45341710|NCT00772967|Drug|Placebo|Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
45341711|NCT00772967|Drug|Ultracet|Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
45341712|NCT02363010|Behavioral|Gold Standard Behavior Therapy for Weight Loss|Group- based behavioral treatment for weight loss and weight loss maintenance, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
45341713|NCT02363010|Behavioral|Behavior Therapy for Weight Loss with Physical Activity Emphasis|Group-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
45341714|NCT02363010|Behavioral|Acceptance-based Behavior Therapy for Weight Loss with PA emphasis|Group-based, acceptance-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
45341715|NCT00793377|Drug|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen|Adriamycin will be given at a dose 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles.Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
45341716|NCT00793377|Drug|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid|Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
46036822|NCT02799238|Radiation|Radiotherapy|Radiotherapy 5 days/week for 6 weeks
46036823|NCT02799238|Drug|Temozolomide|Temozolomide daily for 6 weeks followed by 6 cycles 5days/4weeks
46036824|NCT00692653|Behavioral|P4|Tailored online decision support system for prostate cancer treatment decision making
46036825|NCT02798926|Device|polyethylene bag|The infant will be wrapped in a polyethylene bag 15 min before starting central venous catheter placement
46036826|NCT02620813|Drug|Tretinoin|Subjects will apply 0.5% tretinoin cream nightly to their face for a total of 12 weeks.
45341717|NCT01419704|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
45341718|NCT00789243|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
45341719|NCT00712634|Biological|CMVpp65-A*0201 peptide vaccine|Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
45341720|NCT00662259|Drug|Alprazolam (Xanax)|Drug dose will be fixed across patients: alprazolam 0.5 mg b.i.d escalating to 1.0 mg b.i.d. The treatment duration will be approximately 28 days (4 weeks).
45473635|NCT02527798|Drug|Furosemide Cohort 1|furosemide 1 mg/kg q 24 hours IV or 2 mg/kg q 24 hours enterally Cohorts will be enrolled sequentially after a safety review.
45341721|NCT00662259|Drug|Placebo|Placebo, bid, p.o. for 28 +/- 2 days.
45473636|NCT02527798|Drug|Furosemide Cohort 2|furosemide 1 mg/kg q 6 hours IV or 2 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
45839972|NCT04175106|Other|a standard commercially available blueberry variety (i.e., cultivar)|"150 g of a standard commercially available blueberry variety (i.e., cultivar).~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
46036827|NCT02620813|Drug|Isotretinoin|Subjects will take isotretinoin as prescribed by their dermatologist.
46036828|NCT02803060|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formaulation number- SR15-62 -Z15-038).
45341722|NCT04070222|Other|Hysteroscopy|"Three groups of patients will be enrolled: Natural labour group, Cesarean scar group and Cesarean with diverticulum (PCSD) group;~Hysteroscopy will be carried out for uterine cavity examine and the specimen collection for further microflora analysis and inflammation marker detection;~ART will be carried out with standard protocol and the clinical outcome will be recorded;~The primary outcome of the study is the comparation of species and communities of uterine microflora and inflammatory markers of the female uterus among three groups. The secondary outcome is biochemical pregnancy rate, clinical pregnancy rate, embryo implantation rate and live birth rate."
45341723|NCT00712790|Drug|Sorafenib|Tablet, 400mg orally, twice daily
45473637|NCT02527798|Drug|Furosemide Cohort 3|furosemide 2 mg/kg q 6 hours IV or 4 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
46036829|NCT00695461|Dietary Supplement|Lactobacillus plantarum 299v in oatmeal drink|Bacteria in a concentration of 10(9) CFU/ml
46036830|NCT00695461|Dietary Supplement|Oatmeal drink|Oatmeal drink as in arm 1 but without bacteria added.
45473638|NCT02527798|Other|Placebo|Sugar water will be administered in a equivalent volume as drug intervention.
46036831|NCT02798848|Device|Tablet computer|iPad
45341724|NCT00712790|Radiation|SIR-Spheres|one time treatment and capped at 3.0 Gbq
45341725|NCT02990130|Other|Observational|
45341726|NCT02574104|Other|Simulate a functional NICU prior to moving patients|Test translation of care paradigms in the new environment a priori. Invest significant time and resources into scenario design, staffing, preparing and orchestration the simulations. 80-160 staff participate in simulations, discover and resolve latent safety threats
45341727|NCT02577744|Other|Noninvasive Ventilation|Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.
45341728|NCT02577744|Other|Expiratory Positive Air Pressure|EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.
45341729|NCT00712868|Drug|Lactic acid|Once a day
45473639|NCT01282775|Behavioral|WEB + Environment|Participants receive weekly lessons via the Web along with additional tools for weight loss support
45473640|NCT01282775|Behavioral|WEB + Cash Incentive for Weight Loss|Participants are paid cash based on the percent weight lost at 3, 6, and 12 months.
46036832|NCT00692731|Dietary Supplement|500 mL/day of a beverage providing approximately 625 mg catechins|Subjects were asked to consume 500 mL/day of a beverage providing approximately 625 mg catechins
46036833|NCT00692731|Other|Control beverage matched for energy and caffeine content|500 mL/day of a control beverage
46036834|NCT02624401|Drug|Dexmedetomidine|Intravenous infusion
46036835|NCT02624401|Drug|Propofol|Intravenous infusion
46036836|NCT02624401|Drug|S-ketamine|Intravenous infusion
46036837|NCT02624401|Drug|Sevoflurane|Inhalation
46036838|NCT02624401|Drug|Placebo|Intravenous infusion of saline (Ringer's Acetate)
45341730|NCT02966886|Procedure|Eccentric Reaming|"Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric (high side) anterior reaming to within < 10 degrees of neutral glenoid version."
45341731|NCT02966886|Procedure|Augmented Glenoid Component Implantation|Patients will undergo standard glenoid preparation and implantation of a posteriorly augmented glenoid component. The degree of posterior augment will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version.
45341732|NCT02966886|Procedure|Posterior Glenoid Bone Grafting|Patient will undergo a total shoulder arthroplasty as per standard technique. Glenoid version will be restored to within 10 degrees of neutral with a posterior glenoid bone graft. The bone graft will be harvested from the humeral head and fixed to the posterior glenoid with mini-fragment screws.
45341733|NCT00660699|Drug|Gemcitabine|
45341734|NCT00660699|Drug|Docetaxel|
45341735|NCT00660699|Radiation|Radiation|
45341736|NCT02577068|Drug|Nefopam|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
45473641|NCT05178498|Procedure|Follow-Up|Undergo follow up
45473642|NCT05178498|Procedure|Physical Examination|Complete physical measurements
45473643|NCT05178498|Other|Questionnaire Administration|Complete questionnaires
45473644|NCT01282853|Procedure|endoscopic biopsy|endoscopic biopsy for rapid urease test
45473645|NCT01282853|Procedure|endoscopic biopsy|endoscopic biopsy for rapid urease test
46036839|NCT03952234|Drug|L-Citrulline|To determine the safest maximum dose of L-Citrulline which could be used as a potential treatment for adults with disorder of energy metabolism called MELAS
45341737|NCT02577068|Drug|Propacetamol|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
45341738|NCT02576834|Behavioral|Cognitive Therapy for Suicide Prevention|10 sessions of cognitive therapy for suicide prevention provided, along with optional 9 booster sessions + SAU
45341739|NCT02576834|Other|Services as Usual|Services as usually provided in the community
45341740|NCT01364480|Device|Implantation of NeuroPort Arrays in the motor cortex|Two Blackrock Microsystems NeuroPort Arrays will be implanted in the motor cortex of study participants.
45341741|NCT00582114|Drug|Lisinopril|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to <140/90 mm Hg.
45341742|NCT00582114|Drug|Atenolol|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to <140/90 mm Hg.
45341743|NCT04071080|Drug|fluorescein sodium|Fluorescein sodium in 500mL Gatorade
45341744|NCT04071080|Drug|Placebo|500mL Gatorade
45341745|NCT01719666|Procedure|MPFL reconstruction and lateral retinaculum release|MPFL is performed with a standard technique using gracilis tendon. A tunnel is performed at the femoral part with a bioabsorbable screw fixation and 2 bundles with suture fixation at the patellar side
45341746|NCT01719666|Procedure|conventional surgery|conventional surgery: MPFL reconstruction
45341747|NCT00582036|Drug|Regular Insulin|Use of sliding scale insulin as per Appendix 1
45341748|NCT00582036|Device|Deployment of the MiniMed Paradigm monitoring device|Automated insulin delivery system
45473646|NCT01282853|Procedure|endoscopic biopsy|endoscopic biopsy for rapid urease test
45473647|NCT03382444|Procedure|Cognitive Assessment|Each patient with have a 2 hour cognitive assessment at baseline, 3months after starting renal replacement therapy and 12 months after starting renal replacement therapy
46036840|NCT02624557|Drug|Alpelisib|Subjects will receive a single dose of 300 mg alpelisib.
46036841|NCT02802748|Drug|Oral Vinorelbine|Metronomic Schedule of Vinorelbine administered orally in a schedule monday-wednesday-friday, tuesday-thursday-saturday, etc
46036842|NCT02802748|Drug|Letrozole|Letrozole will be administered orally at 2.5 mg QD for 3 weeks.
46036843|NCT00695617|Drug|trisodiumcitrate|trisodiumcitrate 1.035 M
46036844|NCT00695617|Drug|trisodiumcitrate|trisodiumcitrate 1.035 M
46036845|NCT02798614|Device|10-day cast|Removal of plaster cast fixation 10 days after reduction
46036846|NCT02620891|Device|helium oxygen mixture|
46036847|NCT02798692|Biological|Low dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
46036848|NCT02798692|Biological|Medium dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
45341749|NCT00581360|Drug|doxorubicin and bortezomib|Patients will be treated with bortezomib 1.3 mg/m2, intravenously on days 1, 4, 8 and 11, and doxorubicin 20 mg/m2, intravenously on days 1 and 8, every 21 days. Zinecard will be added at the 8th cycle and all subsequent cycles with doxorubicin. After the completion of 14 cycles, if there is no progression, bortezomib once a week at a dose of 1.6 mg/m2 on days 1,8,15, every 28 days, will be administered alone. Treatment will continue unless disease progression or intolerable toxicity emerges.
45341750|NCT05673564|Procedure|Anatomical Resection|Based upon the segmental anatomy of the liver according to Couinaud system, AR was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these. NAR, known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
45473648|NCT03382444|Diagnostic Test|Depression and Quality of Life Assessment|Each patient with have a 2 hour depression and QOL assessment at baseline, 3months after starting renal replacement therapy and 12 months after starting renal replacement therpay
45839973|NCT04175106|Other|"a minimally processed blueberry-rich protein bar"|"A minimally processed blueberry-rich protein bar matched to the phytonutrient content of the 150 g of the non-traditional blueberry.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
46036849|NCT02798692|Biological|High dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
46036850|NCT02798692|Biological|Placebo|Three intra muscular administrations at Day 0, Month 1 and Month 3. The diluent is used as placebo.
46036851|NCT02620735|Device|Fit bit Device|Use of the fit bit flex for the duration of the study. Measures steps and sleep. Health Coaching
46036852|NCT02620735|Behavioral|Exercise Only|12 week exercise program
46036853|NCT02620735|Behavioral|Connected Wellness HealthCoach Software|Use of the app on Smart-phones and an online platform. Measures the following factors: Mood, Pain, energy,exercise not picked up by Fit bit.
46036854|NCT02620735|Behavioral|Health Coaching|10 over the phone health coaching sessions.
46036855|NCT02798770|Other|No Intervention Foreseen|
45473649|NCT05331911|Drug|Propofol|total intravenous anesthesia with propofol for the partial hepatectomy of hepatocellular carcinoma.
45473650|NCT05331911|Drug|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC).
45473651|NCT03188991|Drug|NanoPac®|NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)
45473652|NCT03857542|Drug|Pilocarpine HCl Ophthalmic Solution|Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
45473653|NCT03857542|Other|Vehicle|Vehicle, one drop in each eye, once daily, for up to 30 days.
46036856|NCT04235452|Diagnostic Test|Somatosensory evoked potential|"Stimulation of the right and left median nerves for each subject were carried out with electrical square wave pulses of 0.2 ms duration applied at a rate of 5 HZ. with cathode proximally. The intensity of the stimulus was adjusted to produce minimal twitches of the thumb (1-2 cm thumb movement). Five hundred (500) stimuli were delivered. The recording electrode picked up the responses. They were then summated and averaged.~The final evoked potential was then displayed on the screen. When two reproducible SEPs responses were obtained the data was accepted for analysis. The graph was printed out on paper, for the purpose of simplification only one response was printed out."
46036857|NCT01151345|Drug|TILACEM|At 08:00 hours on day 1, CIF-BIOTEC personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
45839974|NCT04175106|Other|a control beverage of matched-nutritive content|"The matched nutritive content of the blueberry-rich protein bar will be dissolved in whey protein~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
46036858|NCT01151345|Drug|ANGIOTROFIN|At 08:00 hours on day 1, CIF-BIOTEC Pharmacy personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
46036859|NCT02802904|Other|Diet: Palm olein IV64|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat Palm Olein IV64 which was incorporated into daily snacks (~50g of test fats, brownies (~15g test fat each) for breakfast and 4 pieces cookies (~5g test fat each) with low fat palm olein based background diet daily.
46036860|NCT02802904|Other|Diet: Cocoa butter|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat cocoa butter which was incorporated into daily snacks (~50g of test fats, brownies (~15g test fat each) for breakfast and 4 pieces cookies (~5g test fat each) with low fat palm olein based background diet daily.
45839975|NCT04081428|Radiation|Stereotactic Body Radiotherapy|Daily collection of breath and blood before and after each of the 5 radiotherapy treatment sessions. Before and after daily cone beam CT image collection
46036861|NCT02802904|Other|Diet: Virgin olive oil|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat virgin olive oil which incorporated into daily snacks (~50g of test fats, brownies (~15g test fat each) for breakfast and 4 pieces cookies (~5g test fat each) with low fat palm olein based background diet daily.
45341751|NCT02574182|Radiation|Brain MRI|"Brain MRI (Magnetic Resonance Imaging) brain is a painless test that allows to visualize the different brain structures.~Korvit, device made up of 2 shoes which reproduces the feeling to go. The Korvit® system appears possible to analyze the activated cerebral zones and to thus try to better understand the operation of the brain during walk.~The GAITRite is a carpet for recording the walking operating parameters"
45341752|NCT01650792|Drug|Aspirin|
46036862|NCT05502250|Drug|gemcitabine, cisplatin and tislelizumab|"All patients will receive 2 cycles of gemcitabine and cisplatin (GP) + tislelizumab. Each cycle lasts 21 days. Treatment is given through an IV line on day 1 and 8.~After 2 cycles a FDG-PET-CT scan will be performed. Patients who respond well will proceed with 2 additional cycles of GP + tislelizumab . Patients with insufficient response will stop with the study treatment and they will continue treatment according to local practice.~After 4 cycles of GP + tislelizumab another FDG-PET-CT scan will be performed. If this scan shows that the disease is under control (metabolic complete remission) patients will proceed with 13 cycles of tislelizumab consolidation treatment (21 day cycles). Treatment is given on day 1 through an IV line."
45341753|NCT00713180|Procedure|Pterygium excision followed by grafting|Pterygium will be excised followed by either free conjunctival or limbal conjunctival graft obtained from the upper part of the globe. The graft will be kept in place by sutures
45473654|NCT01172717|Drug|Panitumumab|Panitumumab will be given by intravenous infusion at a dose of 9 mg/kg on day 1 of study and then every 3 weeks until progression of disease
45473655|NCT01172795|Behavioral|Relaxation session|30 minutes relaxation session (audiotape)
45473656|NCT01172795|Behavioral|Neurocognitive test battery|the psychomotor vigilance task, span task and the stroop task on computer
45341754|NCT03918018|Device|BORA Band SpO2 Validation Study|"Qualified healthy volunteers will be enrolled into the study. Subjects will recline for the study. Reference sensor(s) will be placed on each subject to evaluate the SpO2 accuracy and performance. Shield material may be used between any adjacent finger sensors to prevent optical crosstalk.~Simultaneous data collection will be set up for device under test and the control pulse oximeter. The data from the test device will be collected by the sponsor or trained Clinimark Study staff. Data will be collected for 1 second intervals data analysis. The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.~The investigational device will only be placed on the wrist. The control pulse oximeter may be alternated through fingers between subjects."
45341755|NCT05673122|Device|Implant(Flotecno)|"The implants It has a tapered body design and Sandblasting with Large grit that facilitates the osseointergration process.~made in Italy Flotecno srl via.Turati,38 20121 MILANO (Italia)"
45341756|NCT00660387|Drug|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
45341757|NCT00660387|Drug|Placebo Gel|
45341758|NCT00660387|Drug|Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets|
45341759|NCT00660387|Drug|Placebo (PBO) oral capsules|
45341760|NCT00660387|Device|CADD-Legacy® 1400 ambulatory infusion pump|
45341761|NCT00660387|Device|PEG tube|percutaneous endoscopic gastrostomy tube
45341762|NCT00660387|Device|J-tube|jejunal tube
45341763|NCT00582738|Drug|CsA-TAC (standard Treatment)|Continuation of current immunosuppressive regimen (continuation of CNI with or without MPA, with or without steroids) / no everolimus introduction.
45341764|NCT00582738|Drug|Everolimus|Hepatitis C recurrence after orthotopic liver transplantation (OLT)
45341765|NCT00713336|Drug|ZD4054|ZD4054 10mg Tablet
45341766|NCT00713336|Drug|Moxifloxacin|400 mg capsule
45341767|NCT00713336|Drug|ZD4054 Placebo|3 tablets
45341768|NCT00713336|Drug|Moxifloxacin placebo|1 capsule
45341769|NCT00713336|Drug|ZD4054 Placebo|2 tablets
45341770|NCT00713336|Drug|ZD4054|30mg tablet
45341771|NCT00713336|Drug|ZD4054|10mg tablet
46036863|NCT02798302|Other|Flush rate oxygen using a standard flowmeter (Precision Medical, 8MFA). See description for details. This is specific.|A standard oxygen flowmeter will be fully opened and oxygen will be administered for three minutes.
46036864|NCT02798146|Other|blood collection|Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
46036865|NCT02802670|Drug|[14C]-GDC-0810|Participants will receive a single 300-mg dose of GDC-0810 containing approximately 100 microcuries of [14C]-labeled GDC-0810 on Day 1.
46036866|NCT02802826|Behavioral|Tailored Exercise Prescription|The intervention is a walking- based exercise prescription with the aim of a graduated increase in exercise to achieve national guidelines (i.e. Over 150mins of moderate intensity exercise over a week).
46036867|NCT02798068|Drug|Solu-medrol or placebo administration|patients will receive 500mg of methylprednisolone in 100ml NaCl 0,9% or placebo (100ml NaCl 0,9%) at anesthesia induction
45341772|NCT00789711|Drug|biphasic insulin aspart 30|Evaluation of the safety profile and effectiveness of biphasic insulin aspart 30 in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
45341773|NCT00789711|Drug|insulin detemir|Evaluation of the safety profile and effectiveness of insulin detemir in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
45341774|NCT00713726|Drug|FentanyL|Fentanyl: 1 µg/kg/h for preterm infants and 2 µg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
45341775|NCT00713726|Drug|Tramadol|Tramadol: 0.1 mg/kg/h for preterm infants and 0.2 mg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
45341776|NCT00772889|Biological|Influenza vaccine GSK2186877A|One intramuscularly injection at Day 0
46036868|NCT02802358|Procedure|Surgery or non-invasive procedure (reduction of the fracture, immobilization, stabilization)|
46036869|NCT02802436|Procedure|Extraction with socket graft|Extraction will be done as usual standard of care to preserve socket walls. Sockets will be measured at all 4 line angles for depth with the same periodontal probe, Buccal-Lingual dimension will be measured prior to graft placement. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used for both sites. Volume of graft used will be recorded. Both sites will be filled slightly below marginal bone level (1mm). Test site will be injected with Bioactive Agent. At 3 levels apical 1/3rd, middle 1/3rd and coronal 1/3rd. Control site will be injected with saline (or vehicle) at same levels. Occlusal orifice will be closed with Collagen plug adjusted for depth to meet free gingival margins and then sutured with 4-0 PGA (Vicryl)
46036870|NCT02797912|Other|No intervention|
46036871|NCT02802280|Other|Cardiovascular risk in HCV patients|"Cardiovascular risk assessement (through Flow-mediated vasodilatation FMV, measurement of endothelial function biomarkers, carotid ultrasound, etc.)~This is a prospective study. The only intervention planned will consist of performing different tests that define the individual cardiovascular risk. These tests will be carried out on a single group cohort at different times.~Notwithstanding, the investigators will record the exposure to DAA to assess any change in CVR.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
46036872|NCT04235842|Other|Physical Exercise|Moderate-intensity continuous exercise training performed at cycle ergometer.
45341777|NCT00772889|Biological|GSK Biologicals' Fluarix™|One intramuscularly injection at Day 0
45341778|NCT00795795|Procedure|Preimplantation Genetic Screening|Preimplantation Genetic Screening
45341779|NCT00795795|Procedure|IVF without PGS|IVF without PGS
45341780|NCT05325983|Other|lemonade ice cubes|Mixing 1 part lemon juice and 6 parts boiling water, make 10ml lemonade ice cubes. The experimental group was given a 10ml lemonade ice cube. The ice cubes were weighed first and then given. The subjects were required to hold the lemonade ice cube in their mouths without breaking them, and not to swallow saliva. 45 seconds after the intervention is given, the nurse will use tweezers to take out the ice cube from the subject's mouth and weigh it , and then place the dry cotton swab at the opening of the sublingual gland in the oral cavity, take it out after 1 minute, and collect saliva, the recorded saliva volume = the collected saliva volume minus (10 ml ice cube weight minus the remaining ice cube weight); The experimental group was given a brand new 10ml lemonade ice cube. At 90 seconds, 135 seconds and 180 seconds, the above saliva collection method was repeated for a total of 5 times of saliva collection.
46036873|NCT04235842|Other|High-intensity interval training performed at cycle ergometer.|High-intensity interval training performed at cycle ergometer.
45473657|NCT03382366|Diagnostic Test|Blood sampling, risk of fall evaluation, and MR acquisition.|Data will be collected on 1) bone/muscle metabolism through blood sampling, 2) risk of fall through OAK device; 3) muscle quality through MR acquisition.
45473658|NCT03209973|Drug|Tislelizumab|Administered as specified in the treatment arm
45473659|NCT03751631|Drug|Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)|Fixed combination tropicamide 1%-phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
45473660|NCT03751631|Drug|Tropicamide 1% ophthalmic solution (TR)|Tropicamide 1% ophthalmic solution administered with the Optejet microdose dispenser
45341781|NCT05325983|Other|water ice cubes|make 10ml water ice cubes. The control group was given a 10ml water ice cube. The ice cubes were weighed first and then given. The subjects were required to hold the water ice cube in their mouths without breaking them, and not to swallow saliva. 45 seconds after the intervention is given, the nurse will use tweezers to take out the ice cube from the subject's mouth and weigh it , and then place the dry cotton swab at the opening of the sublingual gland in the oral cavity, take it out after 1 minute, and collect saliva, the recorded saliva volume = the collected saliva volume minus (10 ml ice cube weight minus the remaining ice cube weight); The control group was given a brand new 10ml water ice cube. At 90 seconds, 135 seconds and 180 seconds, the above saliva collection method was repeated for a total of 5 times of saliva collection.
46036874|NCT00593827|Drug|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 16 mg/m^2 was administered as a 1-hour IV continuous infusion on Days 1, 8, and 15 in a 28-day cycle until progressive disease or intolerable toxicity.
45341782|NCT00800553|Drug|donepezil|5mg o.m. p.o. for approx. 2 weeks
45341783|NCT00800553|Drug|Placebo|5mg of placebo for approx. 2 weeks
45341784|NCT04103801|Dietary Supplement|Sucrose|Participants in the intervention group were given 2 ml dose of 50% sucrose solution and participants in the placebo group were given 2 ml dose of sterile water. Both groups were administered slowly over 30 seconds sublingually via needle-less syringe immediately prior to the immunization injections.
45341785|NCT00793767|Drug|erythropoietin|bolus of 400 IU/kg
45341786|NCT00793767|Drug|placebo (saline)|i.v
45341787|NCT04103723|Procedure|Preoperative premedication|Every patient with or without a preoperative premedication with midazolam before surgery.
45341788|NCT00796029|Drug|14C-paliperidone|
45341789|NCT00793845|Drug|Cyclophosphamide|First HDCT
45341790|NCT00793845|Drug|Etoposide|First HDCT
45341791|NCT00793845|Drug|Carboplatin|First HDCT
45341792|NCT00793845|Drug|Thiotepa|Second HDCT
45341793|NCT00793845|Drug|Melphalan|Second HDCT
45341794|NCT00793845|Radiation|Total body irradiation|Second HDCT
45341795|NCT04099745|Device|CGM|Continuous Glucose Monitoring System
45341796|NCT04099745|Device|FGM|Flash glucose monitoring System
45341797|NCT00800709|Drug|Memantine|Initially memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day
46036875|NCT00593827|Drug|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 40 mg/m^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day cycle provided the subject met the retreatment criteria.
46036876|NCT02797834|Procedure|Endometrial fluid collection|
46036877|NCT02797756|Procedure|Esophago-gastro-duodenoscopy (EGD) with biopsy|
46036878|NCT02797756|Procedure|Esophageal Impedance Monitoring (EIM)|
46036879|NCT02797600|Behavioral|Questionnaires|Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. The questions are standardized and taken from either nationally recognized surveys, CARE I surveys, or represent validated survey items.
45341798|NCT00916331|Procedure|subcutaneous indwelling|vacuum drainage is indwelled in subcutaneous layer
45341799|NCT00916331|Procedure|intraarticular indwelling|vacuum drainage is indwelled in intraarticular space
45341800|NCT00793923|Drug|ranibizumab and dexamethasone|Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
45341801|NCT00793923|Drug|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab
45341802|NCT01247324|Drug|Interferon beta-1a|
45341803|NCT01247324|Drug|Ocrelizumab-matching placebo|
45341804|NCT01247324|Drug|Ocrelizumab|
45341805|NCT01247324|Drug|Interferon beta-1a-matching placebo|
45341806|NCT00772577|Drug|Aliskiren Hydrochlorothiazide|Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks
45341807|NCT00772577|Drug|Ramipril|Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks
46036880|NCT02797600|Other|Biological Samples|All biological samples will be collected at the time of the clinical Pap smear for the controls, and will be collected for the Arm 2 (newly diagnosed) during a scheduled clinic visit. For those individuals in Arm 1, biological samples will be collected during a scheduled visit with the research staff.
46036881|NCT04135105|Other|Normal hearing group|Observational
45341808|NCT02345850|Procedure|Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
46036882|NCT02797444|Other|semi-structured interviews|
46036883|NCT04136119|Other|questionnaire|survey exploring practice of vitamin and micronutrient supplementation
46036884|NCT02797366|Radiation|Proton radiotherapy|
45341809|NCT02345850|Procedure|Mobilized CD34-selected Peripheral Blood Stem Cell graft|Mobilized CD34-selected PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
45341810|NCT02345850|Procedure|Unmanipulated Bone Marrow Graft with Cyclophosphamide|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
45473661|NCT03751631|Drug|Phenylephrine 2.5% ophthalmic solution (PE)|Phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
45839976|NCT04044144|Dietary Supplement|Probiotic Dietary Supplement|Dietary supplement containing a combination of 8 probiotic strains
46036885|NCT00692887|Device|PHP - Preferential Hyperacuity Perimeter (Foresee)|computerized test
46036886|NCT02801890|Biological|Intravenous injection|Intravenous injection of stem cell or placebo to the patients with The patients with ultra filtration failure (UFF) .
46036887|NCT02801812|Device|nailfold capillaroscopy|Detection by nailfold capillaroscopy of capillary abnormalities in patients with Systemic Lupus Erythematosus and comparison with healthy controls at enrolment
46036888|NCT00695851|Drug|PCK3145|i.v. bolus either 15 mg/m2 weekly of PCK3145.
46036889|NCT00695851|Drug|PCK3145|by i.v. bolus 7.5 mg/m2 twice per week of PCK3145
46036890|NCT02797210|Device|Continuous theta-burst stimulation|
46036891|NCT02624323|Procedure|Real-time ultrasound-guided central vein catheterization.|
46036892|NCT02796820|Drug|Huaier Granule|Huaier Granule is continuously taken three times per day, 20g per time.
46036893|NCT04135885|Drug|Folic Acid|The patient was continuously taking 7 ml of a brown sugar aqueous solution containing a certain amount of folic acid for 7 days before surgery (0.3 mg/d for children with 1-3 years old and 0.4 mg/d for children aged 4 to 5, once a day). After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0~20 points, and the score ≥10 points is defined as the recovery period).
46036894|NCT04135885|Drug|Placebos|Patients in the placebo group received 20 ml of an aqueous solution of brown sugar with the same concentration as the intervention group on the 7th day before surgery. After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0~20 points, and the score ≥10 points is defined as the recovery period).
46036895|NCT02801968|Procedure|Tap block|
46036896|NCT02801968|Other|intravenous analgesia|
46036897|NCT00696865|Drug|AZD2624|oral suspension, 3 doses
46036898|NCT00696865|Drug|Placebo|
46036899|NCT02802046|Radiation|Computed tomographic angiography of coronary artery|
45341811|NCT02345850|Drug|Cyclophosphamide|"Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide 50 mg/kg will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
46036900|NCT02620657|Other|Non interventional study|Non interventional study
46036901|NCT02801734|Other|EQUIP|Patients in the EQUIP intervention group will receive four face-to-face sessions. The focus of these sessions is to equip patients with the skills and strategies needed to cope with common symptoms experienced by lung cancer patients.
46036902|NCT02624011|Behavioral|7 days of habitual physical activity followed by 7 days of reduced physical activity|Young, active participants will undergo a 7 day period of habitual physical activity followed by a 7 day period of step reduction and exercise cessation.
46036903|NCT02796898|Drug|SM88 (Cohort 1)|"Tyrosine Isomers - 230 mg qd~Phenytoin - 50 mg qd.~Methoxsalen - 10 mg qd~Sirolimus - 0.5 mg qd"
46036904|NCT02796898|Drug|SM88 (Cohort 2)|"Tyrosine Isomers - 460 mg (230 mg bid)~Phenytoin - 50 mg qd~Methoxsalen - 10 mg qd~Sirolimus - 0.5 mg qd"
45341812|NCT02345850|Drug|Tacrolimus|Tacrolimus will be given orally or intravenously per institutional standards starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels, with a target of 5-15 ng/ml. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
46036905|NCT00693043|Drug|lidocaine hydrochloride|Study group will have up to 2 mg/kg of Lidocaine administered to the skin and additional Lidocaine(3mg/kg)infused through an atomizer using a specialized tip attached to the sterile leur lock syringe into the pleural cavity. The Intrapleural lidocaine dose will be given in a fixed dose of 3 mg/kg. Serum levels will be obtained at 30, 60, and 120 minutes after initial intradermal administration
46036906|NCT00695929|Drug|Levosimendan|Intravenous injection
46036907|NCT00695929|Drug|Milrinone|Intravenous injection
46036908|NCT04235296|Biological|epidermal growth factor|Residual wounds from the same person were divided into control group and experimental group. The epidermal growth factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days.
46036909|NCT04235296|Biological|mesenchymal stem cell conditioned medium-derived pleiotropic factor|Residual wounds from the same person were divided into control group and experimental group. The pleiotropic factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days.
46036910|NCT02624167|Drug|NW-3509A|Patients will be given oral doses of 15, 20 and 25 mg BID of NW-3509A
46036911|NCT02624167|Drug|Placebo|Patients will be given oral dose of matching Placebo
45341813|NCT02345850|Drug|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m^2 IV bolus on Day +1, and 10 mg/m^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate should be given at least 24 hours after the hematopoietic stem cell infusion. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices. Leucovorin rescue is allowed according to institutional practices.
45341814|NCT00800787|Biological|Nabi-HB|"Hepatitis b Immune Globulin (Human)(Nabi-HB) 312 IU/L per dose administered subcutaneously.~Dosage will be according to each patients body weight, as follow:~< 75 kg: 500 IU weekly ( may be increase to 1,000 IU weekly if anti-HBs levels are <150 IU/ML > 75 Kg: 1,000 IU weekly"
45341815|NCT04099433|Dietary Supplement|Vivomixx|Individuals in the interventional arm will undergo daily oral intake of probiotic supplement
45341816|NCT04099433|Other|Placebo|Individuals in the placebo arm will undergo daily oral intake of placebo supplement
46036912|NCT02796976|Other|Training or control condition|Participants get a 12 week high intensity and walking-based interval training which is adapted to their individual physical fitness level or a general recommendation on physical activity according to European Guidelines.
46036913|NCT02620501|Drug|Lidocaine|topical lidocaine
46036914|NCT02620501|Drug|Placebo|0.45% Normal Saline
46036915|NCT02796742|Other|Collecting samples from all patients presenting with SSTIs requiring drainage|The study will be conducted by microbiology laboratories. Before the start of the study, each participating laboratory will send an information letter to its corresponding emergency departments to increase vigilance of clinicians in collecting samples from all patients presenting with SSTIs; this will improve the level of inclusion. Each participating lab will also insure connection to local representation of the project for ethical clearance, collection of clinical data and SSTI specimen.
45341817|NCT04045977|Behavioral|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
46036916|NCT00693121|Drug|Amantadine hydrochloride|100mg administered orally twice daily x 14 days
45341818|NCT04045977|Device|Virtual therapeutic support|"8 sessions of VR therapy (each of them 20 minutes long).~As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work."
45341819|NCT04045977|Behavioral|Standard therapeutic support|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
45598895|NCT03357029|Device|Sham Device|Sham device will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes. The sham device is identical in appearance, weight, visual and audible feedback, and user application and control but did not deliver electrical stimulations.
46036917|NCT00693121|Drug|Placebo capsule|capsule, identical to amantadine hydrochloride capsule, administered twice daily x 14 days
46036918|NCT02796586|Other|Counseling|Participants will be randomly assigned to group versus individual contraceptive counseling
46036919|NCT04134793|Procedure|radiofrequency ablation|bipolar radiofrequency ablation by ablation forceps
46036920|NCT02801500|Device|Magnetic Compressive Anastomosis|The magnetic compressive anastomosis device will be used to complete the anastomosis during bilioenteric anastomosis.
46036921|NCT02801500|Procedure|Manual Anastomosis|A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
46036922|NCT02801344|Dietary Supplement|Normal|test drink which contains low amount of amino acids (0.14 g/kg/day)
46036923|NCT02801344|Dietary Supplement|Moderate|test drink which contains moderate amount of amino acids (0.40 g/kg/day)
46036924|NCT02801344|Dietary Supplement|High|test drink which contains high amount of amino acids (1.03 g/kg/day)
46036925|NCT02801344|Other|Controlled-diet|the diet containing 0.8 g protein /kg/day
46036926|NCT02620423|Biological|REOLYSIN®|4.5x10E10 TCID50 1 hour intravenous infusion, administered on Day 1 and 2 of a 21-day cycle
46036927|NCT02620423|Drug|Chemotherapy|Patients may be treated with one of three chemotherapy backbone regimens. The decision on the chemotherapy backbone is based on physician preference.This includes either: a) Gemcitabine or b) Irinotecan or c)Leucovorin followed by 5-fluorouracil
46036928|NCT02620423|Drug|Gemcitabine|1000 mg/m2 intravenous infusion over 30 minutes on Day 1 of a 21-day cycle or
46036929|NCT02620423|Drug|Irinotecan|125 mg/m2 intravenous infusion over 90 minutes on Day 1 of a 21-day cyle or
46036930|NCT02620423|Drug|Leucovorin|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
45473662|NCT03736525|Behavioral|Design For Wellness (DWELL)|Design for wellness is an online Facebook intervention. During 3 months intervention period, participants in the intervention group will be exposed to contents on their newsfeed (posts on Facebook wall), and also be expected and encouraged to create new content themselves. The contents will be interactive and involve different modes of delivery, as audio and video, to reinforce active learning. Participants will be part of DWELL Facebook group community and will be empowered to read and control cues in the environment, by developing skills to enhance their self-efficacy.
46036931|NCT02620423|Drug|5-fluorouracil|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
45473663|NCT03736525|Behavioral|Wait list control group|Wait list control group will get no intervention during the study period. Participants will answer questionnaires pre, mid and post intervention. A delayed form of the intervention will be available to them after the close of the study.
46036932|NCT02620423|Drug|Pembrolizumab|Pembrolizumab, 2 mg/kg intravenous infusion 30 minutes on Day 8 of a 21-day cycle
45341820|NCT04021667|Other|educational intervention|İndividual and Group Breastfeeding Education:It was taken into consideration that mothers and fathers who do not have breastfeeding experience in the antenatal period feel better in terms of their perception of the education given, and education is provided with adult education principles.Breastfeeding training slides, cloth nipple model, dummy dolls were used during the training and lecture, demonstration and application and breastfeeding training were provided.At the end of the training, they were given time to ask questions and their feedback was received.Control Group:Routine procedures in the clinic were performed for the mother and father candidates.The data of the mother and father who came to the hospital for antenatal follow-up and control were collected in four stages.
45473664|NCT05179941|Procedure|Perfusion with Indocyanine green|Infusion of Indocyanine green to determine perfusion of the subscapularis tendon change after tenotomy vs peel technique and subsequent intra-operative repair.
46036933|NCT02796430|Other|Time needed to start indirect calorimetry measurement|Comparison of the time needed to start EE measurements by the new calorimeter and the currently used calorimeter, including the time needed for calibration, patient data input, connection to the ventilator circuit.
45341821|NCT04101305|Diagnostic Test|IsoPic|Biomimetic circulating epithelial cell enrichment followed by epithelial cell detection and single cell DNA sampling and sequencing
45341822|NCT04100993|Other|No intervention used|No intervention used
45341823|NCT04099043|Device|Cascade Continuous Glucose Monitoring System|Continuous Glucose Monitoring for 15 days
45341824|NCT04073550|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
45341825|NCT04073550|Drug|Placebos|Anlotinib blank analog capsule.
45341826|NCT04073550|Drug|Topotecan|A topoisomerase I inhibitor.
45341827|NCT02576600|Device|Videopupillometer Algiscan|pupillary diameter measurement every five minutes per-operatively
45341828|NCT02576600|Other|Standard practice|remifentanil administration left to the discretion of the anesthesiologist in charge according to standard practice
45341829|NCT02576600|Drug|Propofol|TCI
45341830|NCT02576600|Drug|Remifentanil|TCI
45341831|NCT02863770|Other|EUS enhanced with contrast to evaluate pancreas|Patients will receive intravenous contrast during EUS to assess whether it increases diagnostic yield of the examination
45341832|NCT00713804|Behavioral|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
45341833|NCT00713804|Behavioral|Educational Booklet|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
45341834|NCT02329470|Procedure|Withdrawal of continuous positive airway pressure treatment|Withdrawal of continuous positive airway pressure treatment
45341835|NCT00796185|Drug|Paliperidone ER|
45341836|NCT02848092|Behavioral|FOCAL+|Weekly for 5 weeks, teens complete a computer training program designed to train teens to limit the length of glances away from the roadway. On a computer, the top portion of the screen plays a simulated video drive while the bottom half of the screen contains a map. Teens complete tasks that require switching between the 2 halves of the screen. While doing so, they receive feedback regarding how long they are looking away from the driving portion of the screen. After each session of computerized FOCAL training, teens will complete two 5-minute simulated drives. During the drives, teens will be cued to a complete a visual search task which will require them to divert their gaze from the road. Eye tracking goggles will monitor eye glances and provide real time auditory feedback when a visual glance away from the roadway exceeds 2 secs.
45473665|NCT01172951|Other|Oral glucose tolerance test|75g anhydrous glucose powder mixed with 100mls water
46036934|NCT02796430|Other|Indirect calorimetry measurement|Comparison of EE measurements by the new calorimeter and the currently used calorimeter when using different mechanical ventilators, different ventilation modes, different patient conditions and severity
45473666|NCT01172951|Other|Oral lipid tolerance test|150ml drink composed of 2 commercially available high fat products
45473667|NCT03667599|Other|home care|This is the interventional arm where patients receive the transplant care in their homes.
46036935|NCT00696007|Drug|Gemcitabine and cisplatin|"Neoadjuvant chemotherapy (gemcitabine and cisplatin) administered before Nephroureterectomy.~Chemotherapy regimen of three cycles of gemcitabine and cisplatin, dosed over a 3 month period Each cycle would consist of gemcitabine and cisplatin on day 1, with two other doses of gemcitabine on day 8 and day 15.~Gemcitabine dosing would be 1,000 mg/m² and cisplatin would be dosed at 70 mg/m²"
46036936|NCT00696007|Other|Retrospective comparison|60 retrospective historical cohort group of subjects who have undergone a radical nephroureterectomy over the past five years
46036937|NCT02796508|Behavioral|Experimental: Non-action video game training|PSI2013-41409R. Effects of video game training on behavioral and neuroimaging measures of attention and memory
45473668|NCT03688711|Drug|Dasiglucagon|Glucagon analogue
45473669|NCT03688711|Drug|Placebo|Placebo for dasiglucagon
46036938|NCT02796508|Behavioral|Active Comparator: Non-cognitive video game training|16 training sessions with The Sims over 8-10 weeks in small groups
46036939|NCT02624089|Drug|Ropivacaine|Ropivicaine will be administered via in-line nebulization using the Aeroneb Pro™ system
45341837|NCT02848092|Other|Rules of The road|Weekly for 5 weeks, teens will perform computer-based training regarding traffic codes, laws, and rules of the road. After each computerized training, teens will complete two 5-minute drives. This time in the driving simulator will be contextualized as a time for them to practice the rules of the road they learned during training. Importantly, teens in the sham intervention group will complete the same distraction tasks but will NOT receive any feedback regarding their eye gaze during simulated driving.
45473670|NCT03866681|Drug|sirolimus|The dose of sirolimus is adjusted according to monitored serum concentration, maintain Rapamycin concentration ranging from 4 to 10ng/ml.Warfarin was administered orally at a dose of 1mg per day for a year,then gradually reduced to stop.
46036940|NCT02624089|Drug|Normal saline|Normal saline will be administered via in-line nebulization using the Aeroneb Pro™ system
46036941|NCT02801422|Other|fMRI|
46036942|NCT02624245|Other|Conventional Physical Therapy|
46036943|NCT02796196|Other|Medical Chart Review|Review of medical chart
46036944|NCT02796196|Device|Monitoring Device|Wearable physical activity monitoring device
46036945|NCT02796196|Procedure|Physical Therapy|Undergo primarily self-directed physical therapy
45839977|NCT04014660|Dietary Supplement|Probiotic|The probiotic product consists of two different bacterial strains, L.plantarum Heal 9 and L.paracasei 8700:2
46036946|NCT00696943|Drug|([18F]-ML-10)|[18F]-ML-10 was administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The radiation dose of [18F]-ML-10 administered at each session was 300-500 MBq (8.1-13.5 mCi).
46036947|NCT02796040|Device|MRI|
46036948|NCT00693199|Drug|amlodipine|amlodipine 5mg once daily for 28 days
46036949|NCT00693199|Drug|terazosin|terazosin 2 mg once daily for 28 days
46036950|NCT00693199|Drug|amlodipine plus terazosin|amlodipine 5 mg plus terazosin 2 mg once daily for 28days
46036951|NCT02795962|Other|Direct transfer to an Endovascular Center|Cluster randomized controlled study: allocation to active or no intervention arm will be performed accordingly to a pre-established temporal sequence
46036952|NCT02623777|Dietary Supplement|Arabinoxylan oligosaccharides|Arabinoxylan oligosaccharides administered
46036953|NCT02623777|Dietary Supplement|Short chain fatty acids|Short chain fatty acids administered
46036954|NCT04135651|Procedure|Paratracheal pressure|To apply paratracheal pressure, the thumb was placed over the left side of the trachea cephalad to the clavicle and medial to the sternocleidomastoid muscle.
46036955|NCT04135651|Procedure|Cricoid pressure|To apply cricoid pressure, the crocoid cartilage was compressed with a single-handed three-finger maneuvre towards the vertebral bodies.
46036956|NCT02796118|Drug|ASP2151|Oral
46036957|NCT02796118|Drug|Placebo|Oral
46036958|NCT02795884|Drug|intercalation therapy using pemetrexed, cisplatin and erlotinib|During the intercalation phase of the initial 12-week period, erlotinib is to be orally administered at the dose of 150 mg daily from Day 8 to Day 21 at every cycle of 21 days. During the maintenance phase after 12 weeks, it is orally administered at the cycle of 28 days without a wash-out period at the dose of 150 mg daily for one year. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1. Pemetrexed 500 mg/m2 will be diluted in 100 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 minutes. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1.
46036959|NCT02795884|Drug|Vinorelbine, cisplatin|Vinorelbine 25mg/m2 will be diluted in 50 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 6 to 10 minutes and then wash the catheter using 100 ml of 0.9% saline solution. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes.
46036960|NCT02795728|Other|Application of the GIC based sealant|Application of the GIC based sealant was carried out according to the manufacturer's instructions.
46036961|NCT02795728|Other|Resin based sealant|Application of the resin based sealant on the occlusal surfaces was carried out as per the manufacturer s recommendations.
45341838|NCT04070066|Other|Digital didactic environment|Students assigned to this group will receive access to a digital didactic environment where they will have at their disposal the exchange transfusion guide and a complete video explaining the indications, the preparation of supplies and the newborn for the procedure, the management of medical devices required and a step-by-step description of the exchange transfusion technique. Finally, the student will see an integrated clinical case. This video will be developed by the neonatology and paediatric medical education teaching team in the simulation laboratory of the university using neonatal high-fidelity simulators, a simulated mother and the necessary medical equipment and supplies.
46036962|NCT02800798|Other|Preeclampsia positive|
45341839|NCT04070066|Other|• Simulated scenario|The educational intervention will be developed with the students, led by the neonatology teacher, in the simulation laboratory. For the training, neonatal high-fidelity simulators, clinical history and paraclinical exams, necessary supplies for the procedure, a simulated mother, a professional nurse and a nursing assistant will be available. Training will take place in individual skill stations (identification of indications, communication, management of medical devices and procedures) and in integrated clinical scenarios.
45341840|NCT00660309|Drug|Aliskiren|Aliskiren 300 mg tablets
45341841|NCT00660309|Drug|Irbesartan|Irbesartan 300 mg tablets
45341842|NCT00660309|Drug|Captopril|Captopril 25 mg tablet
46036963|NCT02795572|Dietary Supplement|Vitamin D|Vitamin D 2000 IU oral once daily
46036964|NCT02795572|Dietary Supplement|Vitamin B6|Vitamin B6 100 mg oral once daily
46036965|NCT02795572|Dietary Supplement|Vitamin B12|Vitamin B12 100 mcg oral once daily
46036966|NCT02795572|Dietary Supplement|Omega-3 Fatty Acids|Omega-3 Fatty Acids 900 mg oral three times a day (600 mg EPA, 300 mg DHA)
46036967|NCT02795650|Drug|Personalised treatment|Personalised treatments include chemotherapy, targeted therapy, immunotherapy or others based on the previous test results, chosen from a database that include more than 2000 different drugs.
46036968|NCT02795650|Drug|Treatment chosen per investigator´s judge|Investigators are allowed to chose what they consider the best standard treatment option for their patients.
46036969|NCT02800876|Other|CT-acquisition|
46036970|NCT02795494|Behavioral|WOMAC questionnaire at baseline|Patient-reported pain, stiffness and physical function outcome score
46036971|NCT02795494|Behavioral|ASK-P questionnaire at baseline|Patient-reported activity level score
46036972|NCT02795494|Behavioral|WOMAC questionnaire at 2 weeks|Patient-reported pain, stiffness and physical function outcome score
46036973|NCT02801188|Drug|Bupivacaine|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.
45473671|NCT03188055|Other|Best Case/Worst Case communication tool|"The communication tool promotes dialogue and patient deliberation, and supports shared decision making in the context of life-limiting illness. Building on a conceptual model of shared decision-making proposed and the practice of scenario planning our intervention is designed to lead to a discussion of patient preferences and consideration of outcomes.~The surgeon verbally describes the best case, worst case, and most likely outcomes for each treatment option-incorporating rich narrative from clinical experience and translation of probabilistic information-while drawing a diagram of those options. The surgeon also writes details about each option on the diagram. The narrative and graphic help family and patients formulate and express preferences."
45473672|NCT03866915|Diagnostic Test|Aortic pulse wave velocity measurement|Aortic pulse pulse wave velocity (AoPWV) measured by photoplethysmography
46036974|NCT02801188|Drug|Mixture of bupivacaine and dexmedetomidine|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye, and1 ug/kg of dexmedetomidine
45473673|NCT03866915|Diagnostic Test|6 minutes walking test|This test is performed routinely in the pre-rehabilitation units or in external anesthesiology consultations during the preoperative visit. In essence, it consists in measuring the maximum distance the patient is able to walk in 6 minutes, in a short walk in a corridor, simultaneously assessing the heart rate, oxygen saturation and the degree of dyspnea. In general, healthy people can walk between 400 and 700 meters in 6 minutes, depending on age, height and sex.
45839978|NCT04014660|Dietary Supplement|Placebo|The placebo supplement consists of corn starch only.
45839979|NCT04713930|Drug|JNJ-61393215|JNJ-61393215 will be administered orally.
45839980|NCT04713930|Drug|Placebo|Placebo will be administered orally.
45839981|NCT04713696|Other|Functional training|Functional training refers to exercises that targets the muscles of the lumbopelvic-hip complex in order for them to more appropriately support and control the spine.
46036975|NCT04236076|Device|PulseHaler|PulseHaler™ is a pulsating positive expiratory pressure ventilation device for treatment of COPD. PulseHaler™ is pre-programmed to deliver airflow at pre-defined frequencies, ranging from 3.5 Hertz (Hz) to 55Hz, and for pre-defined lengths of time.
46036976|NCT04236076|Device|Sham - control|Sham device has the same look as PulseHaler and is set to deliver nominal pressure but it does not contain the active pulsating components.
46036977|NCT04235920|Diagnostic Test|Montreal Cognitive Assessment (MoCA)|This scale evaluates different domains of cognition like attention, orientation, memory, language, visuoconstructional capacities, and lastly, executive functions. MoCA is a thirty point test with a score of 25 or less considered as abnormal impaired cognition
46036978|NCT02795260|Biological|Bacillus Calmette - Guerin|The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of BCG .
46036979|NCT02795260|Biological|placebo of Bacillus Calmette - Guerin|The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of placebo of BCG .
45341843|NCT04578002|Other|prehospital telemedical triage|Prehospital Triage of Patients with Suspected Stroke Using Onsite Mobile Telemedicine approach (interactive video and audio streaming). In patients with suspected stroke, a prehospital patient evaluation by end-to-end encrypted real-time audio- and video streaming from the pre-hospital setting to an in-hospital stroke physician, located at the University hospital of Basel, is requested and initiated (telestroke-path). The process is supervised and evaluated by an in-hospital stroke physician in real-time. Patients considered having an acute stroke will be directly transferred to cerebral imaging via CT. All other patients will follow conventional stroke path.
45341844|NCT02845518|Procedure|Cardiac magnetic resonance imaging (cMRI)|"Right ventricular contouring and indexed aortic flow measurement from cMRI will be performed locally with the dedicated software used in clinical practice by the physicians of each centre. Cardiac index and RVEF will be derived from these measures. MRI interpretation will be performed blind with respect of clinical and RHC data.~A self-administered questionnaire made up of 2 Likert scales will be given to all patients on visits V1, V2 or V3 and V9.~To constitute a biobank for diagnosis and prognosis purposes blood samples will be taken at visits V1, V2 or V3 and V9."
45341845|NCT04925388|Other|rapid molecular diagnosis|peritoneal samples will be analysed using Unyvero IAI test
45341846|NCT04925388|Other|conventional method analysis|peritoneal samples will be analysed using conventional method
45341847|NCT04046133|Drug|Pembrolizumab|Pembrolizumab, an immune checkpoint inhibitor, concomitantly with standard CRT in patients with locally advanced T3/4 anal cancer.
45341848|NCT02257554|Behavioral|education|Discussion of surgical expectations with patients
45341849|NCT00794079|Dietary Supplement|omega-3 fatty acids|4 grams per day for 8 weeks
45341850|NCT00794079|Dietary Supplement|corn oil|4 grams per day for 8 weeks
45341851|NCT02573714|Drug|Ketamine|Intranasal ketamine (concentration: 50 mg/ml, dose: 1 mg/kg) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes > 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
45839982|NCT04713696|Other|Routine training|Routine training refers to general exercises that perform before and after practice, including jogging, stretching and strengthening exercises for upper and lower extremities
45341852|NCT02573714|Drug|Normal Saline|Intranasal normal saline (placebo: volume-matched with intranasal ketamine) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes > 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
46036980|NCT02801032|Drug|Tadalafil|"Single dose, 20 mg capsule p.o. minimum one week apart from placebo.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention."
46036981|NCT02801032|Drug|Placebo|"Single dose, matching capsule p.o. minimum one week apart from active treatment.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention."
46036982|NCT05442190|Drug|Hypericin|SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment.
46036983|NCT05442190|Drug|Placebo|Placebo ointment is identical to SGX302 ointment (color matched) but it does not contain hypericin.
46036984|NCT05441332|Other|EOS Radiation|One EOS exam of lower extremities
46036985|NCT02795416|Drug|"Secukinumab Cosentyx TM"|"Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.~First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month"
46036986|NCT02790658|Dietary Supplement|Intake of grumixama juice|In the morning of experimental day after 10 h fasting, the volunteers have been collect the first urine in the morning and it was collected the blood before the intake of grumixama juice, after they drink the juice (0 min), it was collected blood at the times: 15 min, 30 min, 60 min,120 min, 240 min and 24 h; and it was also collected urine at the period: 0 -1h, 1 - 2h, 2 - 4h, 4 - 6 h, 6 - 12 h, 12 - 14 h, the first urine in the morning in the second day (24 h). During the period in the first 4 h of experiment the volunteers only intake the juice.
46036987|NCT02795026|Procedure|Manual therapy|Myofascial trigger point release technique is a technique used to help ease tight muscles. This technique involves palpating the tight muscle for the 'knot'/trigger point and gently applying pressure for 30-60 seconds to help ease out the trigger point.
45341853|NCT02573714|Other|Standard Pain Therapy|Typical management strategy for pediatric sickle cell disease vasoocclusive crises including acetaminophen/paracetamol, ibuprofen, oral opioids, and injectable opioids depending on pain severity.
46036988|NCT02795026|Procedure|Trigger point dry needling|Trigger point dry needling is a treatment technique involving the use of a single, disposable, fine filament acupuncture needle. Here the tight muscle is palpated and the acupuncture needle is directed towards the trigger point. The insertion of the needle is not felt, however the twitch reflex elicited to ease off the trigger point can be felt . This can be sore, but lasts only for a few seconds. Trans-perineal trigger point dry needling is an effective dry needling technique for the pelvic floor muscles done externally, targeting the trigger points in the pelvic floor muscles.
46036989|NCT02689960|Drug|100mg prednisone suppository|vaginal administration of 100mg prednisone suppository (Rectodelt)
45341854|NCT02573714|Other|Pediatric Quality of Life - Sickle Cell Disease Module|Standardized quality of life assessment performed 2-3 weeks post intranasal medication administration to evaluate pain management and severity of symptoms after discharge from the hospital.
46036990|NCT01150097|Drug|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
45341855|NCT02573714|Other|Faces Pain Scale - Revised|All patients will answer the FPS-R at 0 minutes (immediately prior to receiving intranasal medication), 30 minutes, 60 minutes, and 120 minutes to assess current pain status.
45341856|NCT00794235|Drug|Sorafenib (Nexavar), Dacarbazine (DTIC)|"Sorafenib: 2x400 mg daily PO (2 tablets (200 mg each) each AM and PM). DAY 1-56.~DTIC: 1-hour IV infusion 1000mg/m2 DAY 14 and 42."
45341857|NCT00800943|Biological|Alemtuzumab (Campath-1H)|Campath is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg,10mg,and 30mg, administered subcutaneously (SC) (if tolerated). When escalation to 30 mg dose is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 8 weeks
46036991|NCT01150097|Drug|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
46036992|NCT01150097|Drug|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
45473674|NCT04035577|Behavioral|Mobile self-help intervention|During the trial, participants will use Intellicare apps for up to 8 weeks and will be invited to provide feedback about their experience at two follow-up time points: weeks 4 and 8. All participants will first undergo initial assessments that will include a series of online questionnaires about their mood. Eligible participants will receive up to 8 weeks of access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
46036993|NCT01150097|Drug|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
45473675|NCT02416492|Biological|SB623 cells|SB623 cells will be implanted in the peri-infarct area using stereotactic surgery.
45473676|NCT02416492|Procedure|Sham Control|Sham Surgery
46036994|NCT01150097|Drug|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
45473677|NCT01284569|Biological|ALX-0061|Intravenous administration, single dose (0.3-1-3-6-8 mg/kg) or multiple dose (Biologically effective dose, once every 4 weeks or once every 8 weeks, for 24 weeks)
45341858|NCT00714116|Drug|SBI-087|Single IV or SC dose of SBI-087
45473678|NCT01284569|Biological|Placebo|Intravenous administration, single dose or multiple dose (once every 4 weeks or once every 8 weeks, for 12(/24) weeks; switch to ALX-0061 in weeks 13-24 if no response after first 12 weeks)
46036995|NCT01150097|Drug|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6. The corticosteroids were not specified in the protocol because they were adminsitered to the participants according to local practice as part of standard of care.
45341859|NCT00801021|Drug|Frio Mouth Rinse|Rinse with 15ml twice daily then expectorate
45341860|NCT00796341|Procedure|PIPELLE ENDOMETRIAL SAMPLING|Pipelle endometrial sampling will be done twice between 7th to 10th day and 24th to 26th d in the cycle prior to IVF.
45341861|NCT02575664|Drug|Buprenorphine|Buprenorphine 5 microg/h/7 days
45341862|NCT02575664|Drug|Placebo|Placebo patch
45341863|NCT02554539|Procedure|Endometrial fluid aspiration|Patient will undergo a biopsy to aspirate endometrial fluid from the uterine cavity
45473679|NCT01172015|Other|blood samples|
45473680|NCT03736369|Drug|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily for up to 8 weeks
46036996|NCT02790190|Other|Radiotherapy dose|
46036997|NCT02794948|Other|Chinese medicine granules (HuYang Yang Kun Formula)|Take Chinese medicine granules (HuYang Yang Kun Formula), 1 sack every time,twice a day Take DHEA(dehydroepiandrosterone) placebo,1 capsule every time ,once a day. Treatment for 3 months Both Chinese Medicine formula granules and DHEA placebo were produced by Jiangyin Medical &pharmaceutical limited company in Jiangsu province
46036998|NCT02794948|Dietary Supplement|dehydroepiandrosterone|The DHEA( dehydroepiandrosterone)25mg,1 capsule every time once a day. Take Chinese medicine granules placebo , 1 sack every time,twice a day Treatment is 3 months. DHEA were produced by General Nutrition Center(GNC)company in America and The placebo granules of Chinese Medicine were produced by Jiangyin Medical &pharmaceutical limited company in Jiangsu province.
45473681|NCT03736369|Drug|DWP14012 40mg placebo|DWP14012 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
46036999|NCT01149863|Drug|Plerixafor|Plerixafor 240 mcg/kg SC will be administered daily starting on the first day of stem cell apheresis, up to a total of 4 doses.
46037000|NCT02794792|Drug|Ipragliflozin L-proline|Oral
46037001|NCT02794792|Drug|Metformin|Oral
45341864|NCT02576522|Radiation|brain metastatic patients|Surgery followed by hypofractionated intensity modulated radiation therapy (IMRT) using VMAT approach
45341865|NCT00796497|Drug|ondansetron|ondansetron hydrochloride (oral solution) dosage of 0.25 mg twice a day for 6 weeks followed by 0,5 mg twice a day for 6 weeks for a total observation period of 12 weeks.
45341866|NCT00714194|Procedure|Normal continuous sedation|Normal continuous sedation.
45341867|NCT00714194|Other|Daily interruption of continuous sedation|Withdrawal of normal continuous sedation with Lorazepam, Midazolam, and Propofol from 7:00 am to 8:00 am daily until continuous sedation discontinuation.
45341868|NCT00796575|Drug|CS-8080|CS-8080 1mg tablets, 3 tablets administered 1 times per day
45341869|NCT00796575|Drug|placebo tablets|placebo tablets matching active
45341870|NCT00796575|Drug|CS-8080|CS-8080 5 mg tablets, 2 tablets administered 1 times per day
45341871|NCT00796575|Drug|CS-8080|CS-8080 5 mg tablets, 4 tablets administered 1 times per day
45341872|NCT04330820|Drug|Venetoclax Oral Tablet|"This study will investigate the combination of a fixed maximum venetoclax dose with increasing cytarabine doses plus mitoxantrone in a fixed dose in phase I. In Phase II cytarabine will be given at MDT or RP2D that assessed in phase I.~The venetoclax dose of 400 mg will be reached by a ramp up over 3 days. Parallel chemotherapy with cytarabine and mitoxantrone will start on day 3."
45341873|NCT00801177|Biological|IMC-11F8|"Cohort 1~100 mg I.V."
45341874|NCT00801177|Biological|IMC-11F8|"Cohort 2~200 mg I.V."
45473682|NCT03736369|Drug|Esomeprazole 40mg|Esomeprazole 40mg tablet, orally, once daily for up to 8 weeks
45473683|NCT03736369|Drug|Esomeprazole 40mg placebo|Esomeprazole 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
45473684|NCT03605667|Drug|troriluzole|Oral BHV-4157 will be given daily for up to 48 weeks
45473685|NCT03605667|Drug|Placebo oral capsule|Oral matching placebo will be given daily for up to 48 weeks
45473686|NCT03867695|Drug|Ropivacaine|At the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered.
45341875|NCT00801177|Biological|IMC-11F8|"Cohort 3~400 mg I.V."
46037002|NCT02794792|Drug|Placebo|Oral
45341876|NCT00801177|Biological|IMC-11F8 I.V.|"Cohort 4~600 mg I.V."
46037003|NCT01149473|Drug|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
46037004|NCT01149473|Drug|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
46037005|NCT02790268|Procedure|Lens Subluxation Surgery|Surgical Intervention to include Cionni Ring implantation and in-the-bag IOL implantation
45341877|NCT00801177|Biological|IMC-11F8|"Cohort 5~800 mg I.V."
45341878|NCT00801177|Biological|IMC-11F8|"Cohort 6~1000 mg I.V."
45341879|NCT00801177|Biological|IMC-11F8|"Cohort 1~100 mg I.V."
46037006|NCT00872989|Drug|docetaxel|Given IV
46037007|NCT00872989|Drug|vandetanib|Given orally
46037008|NCT02794714|Drug|Deep neuromuscular blockade|Deep neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction of anesthesia with intermittent boluses of 0.15 - 0.2 mg/kg to maintain a Post Tetanic Count (PTC) of 1-2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 4mg/kg.
46037009|NCT02794714|Drug|Moderate neuromuscular blockade|Moderate neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction with intermittent boluses of 0.15 - 0.2 mg/kg to maintain Train of Four Count (TOFC) of 2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 2mg/kg.
46037010|NCT02790112|Other|GnRHas|"Influence of early adiposity rebound, genetic polymorphisms and GnRHa treatment on long-term outcome of treated and untreated girls with idiopathic central precocious compared to a control group.~puberty."
45341880|NCT00801177|Biological|IMC-11F8|"Cohort 2~200 mg I.V."
45341881|NCT00801177|Biological|IMC-11F8|"Cohort 3~400 mg I.V."
45341882|NCT00801177|Biological|IMC-11F8|"Cohort 4~600 mg I.V."
45341883|NCT00801177|Biological|IMC-11F8|"Cohort 5~800 mg I.V."
45341884|NCT00801177|Biological|IMC-11F8|"Cohort 6~1000 mg I.V."
45341885|NCT00581100|Drug|etanercept|"Subjects randomized to Arm 1 shall be treated with ETN 50 mg twice weekly for 12 weeks reducing thereafter to ETN 50 mg once weekly to 24 weeks.~Subjects randomized to Arm 2 shall be treated with ETN 50 mg once weekly for the entire 24 week treatment period."
45341886|NCT02554461|Other|advise for exercices given by team staff|"To respond to questions asked:~it is not the investigator who decides on the intervention, but the daily team staff (e.g. trainer, coach, PT,.....). So no predetermined intervention is provided"
45341887|NCT00579098|Drug|Atorvastatin|80 mg tablet taken by mouth daily for 90 days
45341888|NCT00579098|Drug|Placebo|Placebo tablet taken by mouth once daily for 90 days
45341889|NCT00794391|Behavioral|Motivational interviewing|Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller & Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
45341890|NCT00794391|Behavioral|Educational intervention|The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
46037011|NCT04234750|Biological|mesenchymal stem cell conditioned medium-derived pleiotropic factor|After the patient is enrolled, when the patient's condition is stable, he is ready to undergo skin transplantation. For the donor site, an electric dermatome was used to remove the skin. The two donor areas of the same patient were divided into a pleiotropic factor group and a blank group randomly. After placing a coarse mesh vaseline oil gauze, then cover a certain thickness of sterile gauze and pressure bandage.
46037012|NCT01148771|Drug|ertapenem|1 gram IV bolus every 24 hours (q24h) for 3 days
46037013|NCT01148771|Drug|ertapenem|1 gram 30 minute infusion q24h for 3 days
45473687|NCT03867695|Drug|sterile saline|Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution
46037014|NCT05429008|Drug|HMPL-A83 injection|Day 1,8,15,22 dose; 28 day treatment cycles.
46037015|NCT01148693|Drug|gentamicin|10mg per 10ml of contrast media
46037016|NCT01148693|Drug|Placebo|Distilled water
46037017|NCT00693355|Other|Sodium butyrate|sodium butyrate
46037018|NCT00693355|Other|NaCl|NaCl
45341891|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
45341892|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
46037019|NCT04114552|Other|questionnaires|"6 weeks after the trauma,during the call, an oral questionnaire will be proposed to collect data on patients' management since they have left the emergency department.~After the call, socio-demographic characteristics, trauma mechanism, medics management will be extracted from the patient's medical records"
45473688|NCT02412046|Procedure|Muscle biopsy|
45473689|NCT03124654|Behavioral|Education|Patients will receive several questionnaires to fill in. Knowledge about NOACs will be assessed with a newly developped questionnaire and an educational program will be dispensed while analysing the answers (reactive educational program).
46037020|NCT02620111|Dietary Supplement|Whey protein high in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein high in leucin
46037021|NCT02620111|Dietary Supplement|Whey protein normal in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein normal in leucin.
45341893|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
46037022|NCT02883959|Other|music therapy|Music therapy will be delivered through headphones during nursing procedures (toilet and/or surgical dressings): from initiation up to 30 minutes after the end of procedure.
46037023|NCT00696085|Behavioral|Brief motivational intervention|The women who have positive alcohol screening questionnaires and a random sample of women who screen negative are entered into the next phase of the study. They have blood drawn for the markers of alcohol use, are told of the results and are given brief intervention about alcohol use.
45341894|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
45341895|NCT00801255|Drug|RO5024048|500mg po bid/100mg po q8h for 7 days
45341896|NCT00801255|Drug|danoprevir|500mg po bid/100mg po q8h for 14 days
45341897|NCT00801255|Drug|danoprevir|1000mg po bid/100mg po q8h for 14 days\n500mg po bid/200mg po q8h for 14 days
45341898|NCT00801255|Drug|danoprevir|1000mg po bid/200mg po q8h for 14 days
45341899|NCT00801255|Drug|danoprevir|1000mg/600mg po twice daily for 14 days
45473690|NCT01172171|Drug|Melatonin, N-acetyl-5-methoxytryptamine|The investigators will give the randomized patients 10 ml of 0,1 mg/ml melatonin intracoronarily and 490 ml of 0,1 mg/ml (49 mg) melatonin.
46037024|NCT02794558|Device|ExAblate MRgFUS|"MR images of the breast will be obtained for lesion localization purposes. The breast surgeon or the radiologist will make a treatment plan or map. Sonication at therapeutic power level will be performed on multiple overlapping points successively until sonication of the target volume has been completed.~Follow-up evaluation will be made within 14 to 21 days after the MRgFUS treatment."
45341900|NCT00801255|Drug|danoprevir|1000mg/900mg po twice daily for 14 days
45341901|NCT04893590|Behavioral|Fatigue self-management SMS intervention|Participants will set up an initial goal for the SMS intervention related to fatigue management, and prior to beginning the intervention they will be trained to use the SMS system. Participants will receive text messages each day, providing tips and techniques to help self-manage fatigue. Weekly the participants will be asked to provide feedback regarding their fatigue levels and their patient activation will be re-assessed at the halfway point of intervention.
46037025|NCT00693433|Drug|dexamethasone|Given orally
46037026|NCT00693433|Drug|temsirolimus|Given IV
46037027|NCT00693433|Other|laboratory biomarker analysis|Correlative studies
46037028|NCT02794090|Behavioral|Usual care, individual visits|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
45341902|NCT02577588|Biological|re-activated T cells|autologous reactivated T cells against p53
45473691|NCT01172171|Drug|Isotonic saline, Natrium chloride|The randomized patients will be given 10 ml of isotonic saline intracoronarily and 490 ml intravenously.
45473692|NCT03655717|Drug|Dronabinol|Dronabinol at physician determined doses of 10-80mg designed to produce intoxication.
46037029|NCT02794090|Behavioral|Telephone coaching|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
46037030|NCT05414422|Drug|PCN-101|Concentrate for solution for infusion
46037031|NCT05414422|Drug|Placebo|Concentrate for solution for infusion
46037032|NCT00872599|Drug|fenofibrate|Subjects will be randomized to receive either fenofibrate 160 mg/day or matching placebo for five days by mouth.
46037033|NCT00872599|Drug|Placebo|Subjects will be randomized to receive placebo or fenofibrate for five days by mouth
45341903|NCT02554305|Device|fusion oxygenation system|The fusion oxygenation system is a novel design of the pump oxygenator used in cardiopulmonary bypass, integrating multiple new engineering concepts that have altered its performance profile.
45341904|NCT02554305|Device|Affinity oxygenation system|The affinity oxygenation system is the classical pump oxygenator used in cardiopulmonary bypass surgeries
45341905|NCT04069988|Behavioral|Baduanjin program|This exercise program aimed to increase patient participation and control their metabolic parameters and body mass index through Baduanjin program. The entire program continued for 6 months (March to October 2016), and the intervention was performed for 60 min 3 times for 12-weeks; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warmup, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
45341906|NCT02577666|Behavioral|Ecologically Based Therapy|6 months of community reinforcement approach and case management, 3 months of rental assistance for housing
45341907|NCT02577666|Behavioral|Housing Only|receives 3 months of project supported rental assistance
45341908|NCT02577666|Behavioral|Treatment as Usual|receives services as normally offered within the community
45341909|NCT00796731|Drug|SAR3419|administered by intravenous infusion
46037034|NCT04233658|Drug|Placebo|3x2 capsules / day
45341910|NCT04891328|Other|Intensive therapy program|The intensive therapy program consists of physical therapy, occupational therapy, and speech therapy 3-6 hours x 4-5 days/week for 4 weeks. The individual therapies received will vary with the child/caregiver goals and be based on neuroplasticity and motor learning principles.
45341911|NCT00794625|Drug|Valproate|Standard therapeutic doses of valproate, set according to valproic acid blood level, for 8 weeks
46037035|NCT04233658|Drug|Cynara Scolymus|3x2 capsules / day
45341912|NCT00794625|Drug|Risperidone|Standard therapeutic doses of risperidone for 8 weeks
45341913|NCT00794625|Drug|Placebo|An inactive substance at identical dosing to active treatments for 8 weeks
45341914|NCT00794625|Drug|Stimulant medication|Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine
45341915|NCT00794625|Behavioral|Behavioral family counseling|Weekly behavioral counseling with a therapist
45341916|NCT00714350|Behavioral|New ICU Display Visualization|
45341917|NCT02577432|Drug|fentanyl|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
45341918|NCT02577432|Drug|fentanyl|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
45341919|NCT02577432|Drug|Hyperbaric bupivacaine|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
45473693|NCT03655717|Drug|Ethanol|Oral Ethanol, dosed to obtain a breath alcohol concentration (BrAC) of approximately 0.05 BrAC (equal to 1-2 standard drinks).
45341920|NCT02577432|Drug|hyperbaric bupivacaine|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
45473694|NCT03655717|Drug|Placebo dronabinol|Identical in appearance to active dronabinol (overencapsulation of both active and placebo dronabinol)
45473695|NCT03655717|Drug|Placebo ethanol|Placebo ethanol will consist of diet soda used in the active ethanol condition with 0.25ml ethanol floated on top to provide the odor of ethanol and blind the study drug.
46037036|NCT05411302|Other|Mental health supportive text messages|Text4Support program was developed based on knowledge from randomized controlled trials conducted in Ireland and Alberta and from evaluations of the Text4Mood program. The diagnostic-specific approach is based on an analysis of service data, which suggested that diagnostic clusters for individuals accessing mental health services into 6 categories: mood disorders, anxiety disorders, schizophrenia and other psychotic disorders, substance use disorders, adjustment disorders and personality disorders. Thus, text message content will focus on 2 dimensions. General range includes messages of self-care, social support, hope, affirmation, and recovery. Specific content will focus on managing symptoms related to the conditions described above. As a component of scalability and inclusiveness, text message content can also be customized based on end-user characteristics. We will explore content that is sensitive to needs based on age group, cultural identity and gender identity.
45341921|NCT02577276|Device|Tele-motion rehabilitation system|Tele-motion rehabilitation system: Interventions include functional therapeutic exercise and real-time feedback. Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
45473696|NCT03382288|Device|EYESTAR 900|EYESTAR 900 is an optical biometry device used to create a geometrical representation of the eye by means of optical interferometry. The experimental intervention is an optical, non-contact examination with the investigational device EYESTAR 900.
46037037|NCT00693511|Behavioral|Circuit Training|Circuit Training (aerobic + strength training 2 times per week for 16 weeks)
46037038|NCT00693511|Behavioral|Circuit training + motivational interviewing|Circuit training (aerobic + strength training 2 times per week for 16 weeks) + motivational interviewing (4 individual + 4 group sessions)
45341922|NCT00794703|Drug|micafungin (Mycamine)|Intravenous
45341923|NCT00794703|Drug|itraconazole|oral
45341924|NCT02575430|Other|No treatment: retrospective chart review|
45341925|NCT00772031|Drug|propranolol LA|Propranolol LA up to 240 mg/day
45341926|NCT00772031|Drug|topiramate|Topiramate is an effective, safe and generally well-tolerated drug used for treating chronic migraine. It is becoming the standard treatment among headache specialists.
45341927|NCT00772031|Drug|placebo|an inactive substance
45341928|NCT02576262|Procedure|TCT，HPV，colposcopic inspection|
45341929|NCT00801411|Drug|cyclophosphamide|Given IV
45341930|NCT00801411|Drug|docetaxel|Given IV
45341931|NCT00801411|Drug|doxorubicin hydrochloride|Given IV
45341932|NCT02579148|Biological|HUCMSC injection|The subjects will receive intracavernous injection of HUCMSC.'
45341933|NCT02579148|Biological|collagen scaffolds/HUCMSC injection|The subjects will receive intracavernous injection of the mixture of collagen scaffolds and HUCMSC respectively.'
45341934|NCT04577066|Other|GA2|15 volunteers will receive 50 GA2-infected mosquito bites. The GA2 parasite is a new genetically attenuated Plasmodium falciparum parasite, which arrests development in the liver and should not be able to cause malaria in humans.
45341935|NCT04577066|Other|GA1|10 volunteers will receive 50 GA1-infected mosquito bites. The GA1 parasite is a genetically attenuated Plasmodium falciparum parasite, which arrests development in the liver and is not able to cause malaria in humans.
45473697|NCT03222531|Drug|sofosbuvir/velpatasvir|Drug: sofobuvir/velpatasvir
45473698|NCT03382210|Other|Enhanced recovery protocol|Standardized enhanced recovery protocol including 21 perioperative items.
45341936|NCT04577066|Other|Placebo|5 volunteers will receive 50 uninfected mosquito bites.
45341937|NCT00794859|Drug|Sorafenib|400mg twice daily
45341938|NCT00714506|Behavioral|Diet and physical activity|lifestyle weight reduction - low fat eating, low calorie and physical activity
46037039|NCT02623621|Drug|chemotherapy plus bevacizumab|Every chemotherapy regimen combined with bevacizumab is allowed
46037040|NCT00693589|Drug|folic acid, vitamin B12 and B6 and rosuvastatin|Vitamin supplementation with folic acid 1mg/d, vitamin B12 0.4mg/d and B6 10mg/d po for 6 weeks alone vs. rosuvastatin 10mg/d for 6 weeks alone and thereafter combined treatment for 6 weeks
46037041|NCT04233736|Procedure|Bilateral lumbar erector spinae plane block|Bilateral lumbar erector spinae plane blocks performed under ultrasound guidance
45341939|NCT00714506|Other|Physical activity control|physical activity plus successful aging health education
45341940|NCT00580866|Device|JAS Brace|For approximately 6 weeks after surgery, the brace will be utilized for a period of 30 minutes, 3 times per day. Participants will also receive physical therapy 3 times per week.
45341941|NCT04940013|Drug|Misoprostol|Study participants are given misoprostol alone for menstrual regulation.
45341942|NCT00801567|Device|Magnetic resonance spectroscopy (MRS)|90-minute magnetic resonance scan.
45341943|NCT00771953|Drug|apricoxib|Oral apricoxib tablets will be provided as white or off-white film-coated tablets available in 100mg strength to be taken every day
45341944|NCT00771953|Drug|Placebo|Oral placebo tablets will be provided as white or off-white film-coated tablets to be taken every day
45341945|NCT00771953|Drug|Docetaxel or Pemetrexed|Docetaxel 75mg/m2 or Pemetrexed 500mg/m2 given as an IV infusion every 21 days. TheTreating physician will determine chemotherapy drug as per his usual practice.
45341946|NCT02576028|Other|Fascial Manipulation® (FM)|Fascial Manipulation® (FM) is a manual therapy that focus on the deep muscular fascia. This technique considers the fascia as a three-dimensional continuum. The mainstay of this manual technique lies in the identification of specific localised areas of the fascia, defined Center of Coordination (CC), where the gliding of the subcutis should be preserved to avoid biomechanical in-coordination of the surrounding muscles. The method is performed by applying a deep friction over the CCs that result more altered at the clinical palpation
46037042|NCT02620267|Device|tDCS Stimulation|Subjects will receive tDCS stimulation over the auditory cortex for 20 min. For anodal stimulation the anode electrodes will be placed over the auditory cortex. For cathodal stimulation, the cathode electrodes will be placed over the auditory cortex. For sham stimulation, the anode electrodes will be placed over the auditory cortex and current turned on for 30 sec before being turned off to simulate the sensation of active stimulation.
46037043|NCT02794168|Drug|VAS203|Treatment
46037044|NCT02794168|Drug|Saline|Placebo
45341947|NCT02576028|Other|standard active exercises|two sessions of 45 minutes of active exercises
46037045|NCT02793934|Other|Scales|"For stroke patients there are used scales:~Modified Rankin Scale, NIH Stroke Scale , Glasgow Coma Scale, Dysphagia Severity, Rating Scale Speech or Language Impairment Severity Rating Scale, Modified Rivermead Mobility Index, Berg Balance Scale, Modified Ashworth Scale, Medical Research Council Scale, Frenchay Arm Test, Montreal Cognitive Assessment Scale, Spielberger Scale, Beck's Depression Inventory, Visual Analogue Scale, Functional Independence Measure For patients after AMI: Rankin scale, GRACE scale, MoCA, VAS, Hospital scale of anxiety and depression, Canadian classification if stenocardia~For patients after THR:~The pain of the operated joint on VAS scores The Harris scale (the total amount), Scale Lequesne (total), Hospital scale of anxiety"
46037046|NCT02793934|Other|New model of rehabilitation|
46037047|NCT02793934|Other|Old model of rehabilitation|
46037048|NCT02793934|Other|ICF reader|
46037049|NCT01148537|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10, 20, and 2 * 20 mcg/h.
45341948|NCT00714584|Drug|Naltrexone HCl.|
45341949|NCT02554227|Other|Cytokine Profile and suPAR|Routine blood collection will be carried out directly before surgery and also during the stationary hospitalization on day 4 and day 10. Additional blood collection will be done after 6 weeks and 3 months during the follow-up.
45473699|NCT03221517|Other|Standardized meal with a glucose challenge test|Postprandial glucose and insulin response
46037050|NCT01148537|Drug|Matching placebo transdermal patch|Placebo transdermal patch to match BTDS 5, 10, 20, and 2 * 20.
46037051|NCT01148537|Drug|Avelox (moxifloxacin hydrochloride) tablet|Moxifloxacin 400 mg tablet; 1 tablet taken orally on days 6 and 13
46037052|NCT02794324|Procedure|Voluntary deep-inspiratory breath hold|Patients undergoing scanning in v_DIBH will be positioned supine with arms extended on a MedTec breast board. They will be monitored visually on screen and will be given a buzzer to press when they have taken a breath. CT images will be obtained during DIBH. If the patient needs to release their breath, they will be asked to press the buzzer a second time. Patients will be closely monitored by radiographers via CCTV.
46037053|NCT02794324|Procedure|Active-breathing-controlled deep-inspiratory breathhold|Patients undergoing scanning in ABC_DIBH will be positioned supine with arms extended on a MedTec breast board to which an activated-breathing control device (Elekta, Crawley, UK) has been attached. They will breathe through the device. During ABC_DIBH, CT images will be obtained.
46037054|NCT02794324|Procedure|Prone treatment|Patients undergoing scanning in a prone position will lie on a customised prone treatment platform. CT images will be acquired under free-breathing conditions.
46037055|NCT02794324|Device|Active-breathing-controlled deep-inspiratory breathhold|The ABC unit allows for temporary and reproducible immobilization of internal thoracic structures by monitoring the patient's breathing cycle and implementing a breath hold at a predefined lung volume level. The device consists of a mouthpiece connected to a pneumotachometer via a bidirectional valve and tubing. The air flow across the pneumotachometer is integrated and displayed on a computer monitor. The computer also controls a scissor valve which, when enabled, restricts air flow through the system, enabling the breath hold phase. The mouthpiece and air filter are patient specific, as is a nose clip that is used to ensure that patients are breathing through the device.
46037056|NCT02789722|Other|Yerba Mate Extract|Yerba Mate extract capsules 750 mg
45341950|NCT03988127|Diagnostic Test|Perfusion index|The perfusion index (PI) is the ratio of the pulsatile to the non-pulsatile blood flow in peripheral tissue. It represents a non-invasive measure of peripheral perfusion that can be continuously obtained from a pulse oximeter. We observe changes in PI before and after painful stimulation in intubated critically ill patients.
45341951|NCT00714662|Device|high flux hemodialyzer (FX-60, FX-80 or FX-100)|three sessions per week
45341952|NCT02553837|Biological|Hantavax injection|A single 0.5mL dose intramuscular or subcutaneous injection
46037057|NCT02789722|Other|Placebo|Take 3 capsules, 3 times daily for 28 days.
46037058|NCT02793778|Drug|CROWN|A nutritionally based therapy, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
46037059|NCT02793778|Drug|CROWN Placebo|Placebo, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
46037060|NCT02793544|Drug|Fludarabine|"Fludarabine 30 mg/m2/day (adjusted for renal function) is administered over a 30-60 minute IV infusion on Days -6 through -2 (maximum cumulative dose, 150 mg/m2).~The body surface area (BSA) for fludarabine dosing is based on adjusted ideal body weight (IBW) (Appendix K).~creatinine clearance may change during the days fludarabine is given. Adjustment in fludarabine dose due to creatinine changes during conditioning is permitted."
46037061|NCT02793544|Drug|Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5|"Cy 14.5 mg/kg/day is administered as a 1-2 hour IV infusion on Days -6 and -5 after hydration.~Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Hydration prior to Cy may be given according to institutional guideline.~Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
46037062|NCT02793544|Radiation|Total Body Irradiation (TBI) 200cGy on Day -1|"200 cGy TBI is administered in a single fraction on Day -1.~Radiation sources, dose rates, and shielding follow institutional practice."
45341953|NCT00621244|Drug|LBH589|
45341954|NCT02553759|Other|Actions observed|Patients observed movements without realize them. After this actions, movements will be imagined by patients
45341955|NCT04021901|Device|balloon dilatation|"The balloon catheter (BD U30) was placed through narrow ureter along the guide wire, and the balloon was pressurized to 25 atm until the bee waist sign disappeared on the balloon or the narrow section was seen under the endoscope. Dilation, expansion for 10 min, and then through the endoscope to observe the stenosis of the stenosis (stenosis of the stenosis of the visible adipose tissue)"
46037063|NCT02793544|Procedure|Infusion of non-T-cell depleted bone marrow on Day 0|"On Day 0, the harvested bone marrow is infused.~Donor bone marrow will be harvested with a target yield of 4 x 108 nucleated cells/kg recipient weight.~The lowest acceptable nucleated cells yield is 1.5 x 108 cells/kg recipient weight."
46037064|NCT02793544|Drug|Busulfan|"Busulfan ≥ 9mg/kg total dose (IV or PO) on Days -6, -5, -4, -3 (PK monitoring required to achieve a daily area under the curve (AUC) target of 4800-5300 μM*min (Perkins et al., 2012))~Busulfan dosing is based on adjusted IBW (Appendix K)"
45473700|NCT03124498|Biological|CIK Cell|Autologous cytokine-induced killer (CIK) cell
46037065|NCT02793544|Drug|Cyclophosphamide 50mg/kg/day IV on Days -2,-1|"Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -2 and -1 after hydration.~Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Hydration prior to Cy may be given according to institutional guideline.~Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
46037066|NCT02793544|Drug|Cyclophosphamide 50mg/kg/day IV on Days -5,-4|"Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -5 and -4 after hydration.~Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Hydration prior to Cy may be given according to institutional guideline.~Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
45839983|NCT04713384|Device|Integrative tele-rehalitation of chronic stroke survivors using custom therapeutic games|20 sessions of playing therapeutic games using both arms while siting at a table at home. Arms hold either generic game controllers, or BrightBrainer therapeutic controllers. Sessions involve a variety of games that train motor and cognitive function in an integrative way. The games are rendered by the BrightBrainer system. Games adapt and are winnable, benefiting well-being (reducing depression). Each session may generate many hundreds of arm repetitions, finger movement and grasps, depending on session duration. Data on arm reach as well as game outcomes and vitals are uploaded to an secure server. These data allow researchers to remotely monitor compliance to protocol and longitudinal progress. Caregivers are present at each session, and provide feedback as well as subjective ratings of the system.
46037067|NCT02793544|Radiation|Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1|"200cGy TBI is administered in twice daily on Days -3, -2, and -1.~Radiation sources, dose rates, and shielding follow institutional practice."
45341956|NCT00801645|Behavioral|Exercise|The exercise groups engage in aerobic exercise training three 60-minute sessions per week for 12 weeks, in addition of school physical education. Training sessions consist of 30 minutes of aerobic exercise (walking, running, games, swimming), followed by strength training and stretching.
45473701|NCT01172249|Drug|Glucosamine sulfate + chondroitin sulfate - MANTECORP|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
45839984|NCT04712682|Other|Assessment of neck posture.|pain, pain threshold, CVA angle, muscle strenght test, joint position sense test
45839985|NCT04712916|Behavioral|Health education|Individualized education intervention on medication use, appropriate diet and physical activity was explained to participants. Participants were guided on achieving recommended metabolic equivalent per week (MET) physical activity considering their health status and daily activities. Furthermore, participants were guided on appropriate dietary recommendation and resolving non-adherence behaviour to medication(s), diet and physical activity.
45839986|NCT04708002|Other|early integrated palliative approach model|From the construction of a common vision of palliative care between actors inside and outside the nursing home to the sustainability of palliative care in nursing home.
45341957|NCT00916409|Device|NovoTTF-100A device|patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
45473702|NCT01172249|Drug|Glucosamine sulfate + chondroitin sulfate - CONDROFLEX|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
46037068|NCT02793544|Drug|Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4|"Cy 50mg/kg IV, over 1-2 hours (depending on volume), is given on Day+3 (ideally between 60 and 72 hours after bone marrow infusion) and on Day+4 (approximately 24 hours after Day+3 Cy).~Hydration with Cy, management of volume status, and monitoring for hemorrhagic cystitis will follow institutional standards.~Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Cy is dosed according to IBW, unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual body weight."
46037069|NCT02793544|Drug|Sirolimus|"Sirolimus dosing is based on adjusted IBW (Appendix K).~Sirolimus prophylaxis is discontinued after the last dose on Day+180, or may be continued if there is GVHD.~For subjects ≥ 18 years old:~A one-time sirolimus loading dose, 6 mg PO, is given on Day+5, at least 24 hours after Cy completion.~Sirolimus is then continued at a maintenance dose (starting dose 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by high performance liquid chromatography (HPLC) or immunoassay.~For subjects < 18 years old:~A one-time sirolimus loading dose, 3 mg/m2 PO with the dose not to exceed 6 mg, is given on Day+5, at least 24 hours after Cy completion.~Sirolimus is then continued at a maintenance dose (starting dose 1 mg/m2 PO QD, maximum 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by HPLC or immunoassay."
45598896|NCT02293291|Dietary Supplement|Lithium Water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in GWI"
46037070|NCT02793544|Drug|Mycophenolate mofetil|"MMF begins on Day+5, at least 24 hours after completion of PTCy. MMF dose is 15 mg/kg PO TID (adjusted IBW (Appendix K)) with total daily dose not to exceed 3 grams (i.e. maximum 1 g PO TID).~An equivalent IV dose (1:1 conversion) may instead be given. MMF prophylaxis is discontinued after the last dose on Day+35, or may be continued if there is GVHD."
46037071|NCT02793544|Drug|G-CSF|"Granulocyte-colony stimulating factor (G-CSF): filgrastim or a biosimilar begins on Day+5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously (SC) (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is ≥ 1,000/mm3 over the course of 3 consecutive days.~Additional G-CSF may be administered as warranted."
46037072|NCT02793544|Drug|Pre-HCT Mesna on Days -6 and -5|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
46037073|NCT02793544|Drug|Pre-HCT Mesna on Days -2 and -1|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
46037074|NCT02793544|Drug|Pre-HCT Mesna on Days -5 and -4|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
46037075|NCT02793544|Drug|Post-HCT Mesna|"Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy on Day+3 and Day+4.~Mesna is dosed according to IBW, unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual body weight."
46037076|NCT02793388|Drug|Supervised primaquine treatment|Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided supervised every other day.
46037077|NCT02793388|Drug|Unsupervised primaquine treatment|Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided unsupervised.
46037078|NCT02793310|Procedure|DMEK|The intervention group will receive cornea transplantation by DMEK
46037079|NCT02793310|Procedure|DSAEK|The usual care / control group will receive cornea transplantation by DSAEK
45341958|NCT00916409|Drug|Temozolomide|"maintenance Temozolomide will be administered according to the approved dosing scheme as follows: Maintenance Phase Cycle 1: Four weeks after completing the Temozolomide + Radiotherapy phase, Temozolomide is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose is escalated to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles."
45839987|NCT04708080|Procedure|thoracic epidural analgesia|A thoracic epidural catheter is routinely placed in patients undergoing open heart surgery in our hospital, at least 1 hour before heparin administration during the operation. After standard monitoring (ECG, SpO2, NIBP) is applied to the patients in the operating room, sedoanalgesia is provided with 1-3mg of midazolam and 50-100mcg of fentanyl. Then, by providing sterilization conditions, an epidural catheter is inserted through the T5-T6 interval with Tuohy needle. After confirming the location of the epidural catheter, 25mg / 10ml bupivacaine is administered as a bolus and then 3ml / hour bupivacaine infusion is started from the solution prepared as 3mg / ml and continues until the 48th postoperative hour. On the postoperative 2nd day, the catheter is removed 10-12 hours after LMWH administration and 2-4 hours after UFH, as recommended by the guidelines, paying attention to the anticoagulant administration times applied to the patients.
45839988|NCT04707924|Device|Er:YAG laser|Treatment of scars with fractional Er:YAG 2940nm laser.
46037080|NCT02689882|Dietary Supplement|nicotinamide riboside|Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.
45598897|NCT03157557|Behavioral|Lifestyle treatment|Lifestyle treatment
45598898|NCT04305275|Drug|SAGE-324|SAGE-324 oral tablet
45598899|NCT04305275|Drug|SAGE-324 Placebo|SAGE-324 matched placebo oral tablet
46037081|NCT02789644|Drug|Ursodeoxycholic Acid|Day 1: Ursodeoxycholic acid 400mg or 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
46037082|NCT04234594|Drug|QL1203|6 mg/kg intravenous (IV) infusion only once，on the first day.
46037083|NCT04234594|Drug|Vectibix®|6 mg/kg intravenous (IV) infusion only once，on the first day.
46037084|NCT02789488|Dietary Supplement|Fenugreek seeds extract 500 mg|Furocyst one caps BID
46037085|NCT02793076|Other|Bollywood Dance|8 week Bollywood Dance Program
45598900|NCT05231031|Behavioral|Aerobic exercise|continuous aerobic exercise on a treadmill
45341959|NCT00714740|Drug|acetazolamide|acetazolamide 2 times 250mg per day
45341960|NCT00659529|Drug|sildenafil|Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.
45839989|NCT04707456|Other|Training operator|"After recruitment, the participants were divided into two groups to perform first-trimester ultrasound scan by two different levels of proficiency.~First group : operator has experience more than 3 years in NT scan and second trimester ultrasound scan Second group : operator has experience less than 3 years in NT scan and second trimester ultrasound scan"
45839990|NCT04707612|Other|No intervention.|No intervention.
45839991|NCT04707378|Device|repetitive transcranial magnetic stimulation(rTMS)|Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
45839992|NCT04706988|Other|Treatment of asthma according to GINA guideline|Pharmacological treatment depending on level of control of asthma
45839993|NCT04706832|Device|Thoracic Splanchnic Magnetic Neuromodulation Therapy|ThorS-MagNT is performed by low-frequency, low-intensity repetitive magnetic stimulation bilaterally around T7-8 intervertebral space twice a day for 5 days with a total 1200 magnetic stimulations per treatment session at 1 Hz.
45839994|NCT04706286|Drug|CKD-501, D759, D150|CKD-501 0.5 mg 1T, D759 100 mg 1T and D150 1000 mg 1T, single oral administration under fed condition
45839995|NCT04706286|Drug|CKD-393 0.5/100/1000 mg|CKD-393 0.5/100/1000 mg 1T, single oral administration under fed condition
45839996|NCT04706052|Other|Superficial Parotidectomy|Classical procedure for pleomorphic adenoma of the parotid gland is superficial parotidectomy around the world. This study only observed the outcome with reference to facial nerve morbidity
45839997|NCT05140122|Drug|Multiple|We will collect information on all medications taken by the caregiver and the person they care for.
46037086|NCT04233346|Drug|Ponatinib|CP-CML patients will be randomized into 30 mg and 45 mg dose groups at the ratio of 1:1,each group taken orally once daily. Other patients taken 45mg orally once daily.
45839998|NCT05140122|Other|Multiple|We will collect information on all forms of therapy or medical intervention taken by the caregiver and the person they care for.
46037087|NCT03806608|Procedure|Crestal|Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
46037088|NCT03806608|Procedure|Subcrestal|Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
46037089|NCT01148459|Biological|GSK Biological's Investigational Malaria Vaccine 257049|All infants enrolled to group A will receive 3 doses of the experimental vaccine. The vaccine will be administered intramuscularly.
46037090|NCT01148459|Biological|Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);|"To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly"
46037091|NCT01148459|Biological|Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).|"To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly."
46037092|NCT02789254|Biological|FLYSYN|"Cohort 1:~Patient 1-3: FLYSYN 0.5 mg/m² BSA* day 1~Cohort 2:~Patient 4-6: FLYSYN 0.5 mg/m² BSA day 1 FLYSYN 1.0 mg/m² BSA day 2~Cohort 3:~Patient 7-9: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 4.5 mg/m² BSA day 2~Cohort 4:~Patient 10-12 and 13-18: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 14.5 mg/m² BSA day 2~Cohort 5:~Patient 19-21: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 44.5 mg/m² BSA day 2~Cohort 6:~Patient 22-24 and 25-31: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 14.5 mg/m² BSA day 2, FLYSYN 15 mg/m² BSA day 15, FLYSYN 15 mg/m² BSA day 29~* The maximum upper limit for calculation of antibody dose is fixed at a body surface of 2.0 m², even if the calculated body surface exceeds this. In this study DLT are defined as the following treatment-related adverse events or laboratory abnormalities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03."
45839999|NCT05139966|Drug|Mouthwash Product|The participants were requested to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study).
45598901|NCT05231031|Behavioral|breathing exercise|continuous aerobic exercise plus breathing exercise (Mindfulness)
45840000|NCT05138718|Diagnostic Test|18F-FDG PET/CT|Perform a 18F-FDG PET/CT to patients with history of myocardial infarction
45840001|NCT05138640|Other|Not applicable. The study is designed as an observational cohort study|Not applicable. The study is desigend as an observational cohort study
45683625|NCT03192358|Other|Tongue Strength Measurement|"We will measure tongue strength using a tongue pressure measurement system called the Iowa Oral Performance Instrument (IOPI). A small disposable bulb filled with air will be placed in the mouth, just behind the front teeth. Participants will be asked to press their tongue upwards against the bulb as hard as they can, three (3) times at the front of the tongue and three (3) times at the back of the tongue (i.e., total of six (6) maximum isometric tongue presses). Participants will also be asked to swallow their saliva with the bulb placed in their mouth, three (3) times.~Tongue pressure measurement will be completed twice in the data collection session - once at the beginning, and once at the end (following the videofluoroscopy)."
45683626|NCT03218800|Combination Product|Ertapenem|"Dose: 1g per day if creatinine clearance > 30mL/min or 500 mg per day if creatinine clearance < 30mL/min.~Dilution: 50 ml saline solution. Duration 30 minutes."
46037093|NCT03913234|Drug|Ribociclib, Trastuzumab, Letrozole|Phase IB: letrozole 2.5mg (fixed dose), trastuzumab (8mg/kg loading followed by 6mg/kg q 3weeks, fixed dose) plus ribociclib (dose escalation from 200mg to 600mg) to identify recommended phase iI dose (RPIID) Phase II: letrozole, trastuzumab (same as phase IB) plus ribocicilb RPIID
46037094|NCT02792842|Drug|ART-123 (3-day ART)|ART-123 380 U/kg infusion once daily on days 1-3 in each cycle
46037095|NCT02792842|Drug|ART-123 (1-day ART)|ART-123 380 U/kg infusion once on day 1 and placebo infusion once daily on days 2-3 in each cycle
45341961|NCT02575508|Drug|Fluorouracil|Given IV
45683627|NCT01802216|Procedure|Scaling and root planing|non-surgical periodontal disease treatment
45683628|NCT01802216|Drug|Minocycline|antibiotic microspheres
45683629|NCT04760158|Other|Exercise|Participants of this study exercised strengthening and stretching 3 days a week for 6 weeks
46037096|NCT02792842|Drug|Placebo|Placebo infusion once daily on days 1-3 in each cycle
46037097|NCT03854500|Drug|Tenecteplase|0.4 mg/kg single bolus intravenously
46037098|NCT03854500|Drug|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
46037099|NCT02792998|Drug|IW-1701|IW-1701 Tablet
46037100|NCT02792998|Drug|Placebo|Matching Placebo Tablet
46037101|NCT02792920|Device|CoCr-EES|
46037102|NCT02792608|Behavioral|Mindfulness-based Therapy|MBT will be delivered in group format, 135 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
46037103|NCT02792686|Drug|ABX464|Single Administration
46037104|NCT02792374|Other|Psychological Measurement|Measurement of psychological status in three levels: discrete symptom level, dimensional level, global level as measured by the scale
46037105|NCT02792530|Other|Dietary consultation|Dietary consultation for sodium restriction to decrease dietary intake to 2 grams/day less than the patients consume currently
45341962|NCT02575508|Drug|Irinotecan Hydrochloride|Given IV
45598902|NCT05231031|Behavioral|Relaxation training|continuous aerobic exercise plus relaxation training
46037106|NCT02792296|Other|Project: EVO Monitor|Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
45341963|NCT02575508|Other|Laboratory Biomarker Analysis|Correlative studies
45341964|NCT02575508|Drug|Oxaliplatin|Given IV
45341965|NCT02575508|Drug|pan FGFR Kinase Inhibitor BGJ398|Given IV
45341966|NCT02575508|Other|Pharmacological Study|Correlative studies
45598903|NCT02347215|Other|Quality of Life assessment|Seattle Angina Questionnaire and other questionnaires.
45598904|NCT02347215|Procedure|Stress imaging|Stress imaging
45598905|NCT03337451|Drug|OPN-305|Patients will receive study drug every 4 weeks
46037107|NCT02791984|Device|Fluid challenge with 250 ml of Ringer Lactate|"Fluid challenge with 250 ml of Ringer Lactate over less than 2 minutes, intra-venous, help by a syringe of 50 ml.~Measure of peak velocity before and after the fluid challenge"
45341967|NCT00795015|Drug|insulin regular IV infusion|IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
45341968|NCT00795015|Drug|IV insulin infusion|IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
45341969|NCT04045899|Device|Proseal LMA|The Proseal Laryngeal Mask Airway (p-LMA) has a dual cuff modified to provide better sealing, and a drainage tube for gastric tube insertion. These features attribute in increasing the safety of the p-LMA when used with positive pressure ventilation.
45341970|NCT04045899|Device|Air-Q LMA|Air-Q LMA has a self-pressurizing cuff which inflates to adequate pressure during positive pressure ventilation thus eliminating the adverse effects of cuff over inflation associated with the use of Supraglottic airway device with an inflatable cuff.
45341971|NCT04045899|Device|Ambu AuraGain LMA|The AmbuAuraGain™ is a disposable, preformed second generation SAD, anatomically curved with integrated gastric access and intubation capability, taking patient safety and airway management efficiency to a new level.
45341972|NCT02575586|Device|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle moving the needle up and down ten times."
46037108|NCT02789332|Drug|PwO|paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (PwO) (65 patients)
46037109|NCT02789332|Drug|PwCb|paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (PwCb) (37 patients)
46037110|NCT02789332|Drug|EC|both Arms followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.
46037111|NCT02789332|Procedure|Surgery after neoadjuvant Therapy|In both study arms, treatment will be given until surgery, disease progression, unacceptable toxicity, or withdrawal of consent of the patients.
46037112|NCT02789332|Other|Stratification|Hormone-receptor status (HR+ vs HR-) Age < 40 years vs >= 40 years
46037113|NCT02792140|Drug|Naltrexone|one week
46037114|NCT02792140|Other|Placebo|one week
45341973|NCT02575586|Device|Control-Dry Needling|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle moving the needle up and down ten times."
45598906|NCT03515707|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
45598907|NCT03515707|Drug|Busulfan|Given IV or oral
45598908|NCT03515707|Drug|Etoposide|Given IV
45598909|NCT03515707|Other|Laboratory Biomarker Analysis|Correlative studies
46037115|NCT04234282|Procedure|Manual Physical Therapy|Orthopedic manual physical therapy targeting the knee joint and soft tissues with complementary exercises targeted at their impairment.
46037116|NCT02791594|Drug|Pembrolizumab|
46037117|NCT02791750|Other|questionnary of quality of life|
46037118|NCT04234516|Drug|Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film|3 x 8 mg sublingual buprenorphine/naloxone films wrapped inside one Listerine strip at 8 pm daily + oral placebo pills q.i.d.
46037119|NCT04234516|Drug|Morphine Sulfate 30 mg|oral morphine sulphate 30 mg immediate release tablets q.i.d. + two sublingual Listerine strips at 8 pm
45683630|NCT03621904|Drug|Hormonal Antineoplastics|Hormonal therapy used for treatment in endometrial cancer patients
45598910|NCT04214639|Drug|IDP-126 Gel|IDP-126 Gel applied topically to the face once daily for 12 weeks.
45683631|NCT04330378|Other|Hospital-at-home|As per experimental arm
45598911|NCT04214639|Drug|IDP-126 Vehicle Gel|IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
45598912|NCT02346513|Device|Ceramic on Metal Articulation|Patients have THA with ceramic on metal articulation
45598913|NCT02346513|Device|Non-Ceramic on Metal Articulation|Patients have THA with non-ceramic on metal articulation
45598914|NCT02296957|Procedure|Hypnosedative discontinuation|Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
45598915|NCT02346591|Behavioral|Jauntly|Mobile app designed to encourage positive emotion-enhancing and stress reduction activities.
45683632|NCT04330378|Other|Usual in-hospital care|As per control arm
45683633|NCT01808144|Drug|lesinurad|Tablets, 400 mg once daily (QD)
45683634|NCT01808144|Drug|lesinurad|Tablets, 200 mg QD
45683635|NCT01808144|Drug|febuxostat|Tabletsm 80 mg QD
45683636|NCT01801982|Other|non-interventional|non-interventional
45683637|NCT02085070|Drug|MK-3475|IV MK-3475
46037120|NCT02791672|Behavioral|Discharge within 24 hours|If both the physician and patient have no concerns within 24 hours of a Latissimus Dorsi Flap breast reconstruction the patient will be discharged home and enrolled in the cohort group.
46037121|NCT02789566|Drug|Primaquine|Primaquine 30 mg taken after meal in the morning.
45840002|NCT05138562|Drug|Placebo Comparator: Placebo|4 x placebo capsules, QD
45840003|NCT05138562|Drug|Active Comparator: TU2670 320mg|320mg (80mg x 4), QD
45840004|NCT05138562|Drug|Active Comparator: TU2670 240mg|240mg (80mg x 3 + placebo x 1), QD
46037122|NCT03889522|Diagnostic Test|Bioelectrical Impedance Analysis|BIA is a radiation-free and clinically accessible measure of body composition [47, 49]. An electrode is placed on the youth's extremities and they are asked to sit for 10 minutes. The youth's height and weight is manually inputted and the measure is obtained (approx. 90 seconds to complete). BIA sends a low level of electrical current through the body and measures the impedance to the current based on fat, muscle, bones providing a measure of body composition.
46037123|NCT03889522|Diagnostic Test|Total Body Dual-energy X-ray Absorptiometry|The DXA total body scan provides measurements of percent body fat, lean and fat free mass throughout the body. Youth lay on a table while the machine moves around them. The process takes about 3 minutes and 20 seconds.
46037124|NCT03889522|Diagnostic Test|Blood draw|Blood will be drawn to assess the following labs: HbA1c, leptin, lipid panel and comprehensive metabolic panel.
46037125|NCT02791360|Other|Brain MRI|
46037126|NCT00872521|Drug|PAD induction|"Open Label Treatment:~Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1, 4, 8 & 11), Doxorubicin 20 mg/m2 i.v. (D1 & 4), Dexamethasone 20 mg p.o. (D1, 2, 4, 5, 8 , 9, 11 & 12)"
46037127|NCT04234438|Device|SL-MPL treatment protocol was performed with a 577 nm yellow laser (EasyRet, Quantel Medical, Cedex, France)|Macular laser treatment was applied after pupil dilation and topical anesthesia. Laser application was performed with a Mainster Standard contact laser lens (Volk Optical, Mentor, OH, USA). To determine the appropriate personalized calibration value, single-spot test shot was applied under the green filter to a non-edematous area of the macula outside the temporal vascular arcade. The laser power was gradually increased until it formed a barely visible laser spot. The power of the micropulse pattern laser was set at 50% of the power needed to form a barely visible laser spot. Laser parameters used were 200 ms duration, 160 µm spot diameter, low operating cycle (5%), and zero spacing with 5x5 pattern shape. SL-MPL was applied to the areas where edema was detected in OCT and examination.
45341974|NCT00714818|Behavioral|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required
45598916|NCT02346591|Behavioral|Online stress management information|Online educational information about stress management
46037128|NCT02791282|Other|Index test: functional dynamic contrast enhanced (DCE)-MRI|Index test: functional dynamic contrast enhanced (DCE)-MRI Reference test: Ventilation-perfusion (VQ) single-photon emission computed tomography (SPECT) Follow-up per patient: clinical assessment after 6-12 months
45598917|NCT02298205|Other|Asthma controller medication (Beclomethasone) adjustment strategy|The participant will adjust the dose of Beclomethasone based on symptoms
46037129|NCT02791126|Other|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
46037130|NCT02791126|Other|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
46037131|NCT04048213|Other|questionnaire|questionnaire send to the parents
45341975|NCT00714818|Behavioral|Genetic Counseling|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
46037132|NCT02790814|Device|Moyo strap-on|Continous measurements
45341976|NCT00843700|Behavioral|Interpersonal Psychotherapy-Trauma in Community Settings|Interpersonal Psychotherapy-Trauma in Community Settings (IPT-TCS) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of depressed patients with trauma histories seen in community settings.
45341977|NCT00843700|Behavioral|Treatment as Usual|Individual psychotherapy following usual care practice in a community mental health center.
45341978|NCT00796887|Drug|Extended-Release Niacin|500mg tablet once daily
45341979|NCT00796887|Drug|Extended-Release Niacin|1000mg tablet once daily
45341980|NCT00796887|Drug|Placebo|Placebo tablet once daily
45341981|NCT00578942|Drug|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Subject Evaluation will occur 2-3 times per week by physical exam for toxicity through day 45."
45341982|NCT00835822|Drug|Venocur Triplex®|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
45598918|NCT02298205|Other|Provider-based adjustment|The provider will adjust the dose of Beclomethasone based on the participant's asthma control at their encounter with them
46037133|NCT02790814|Device|Hand-held fetoscope|Intermittent measurements
46037134|NCT00693667|Drug|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. Three tablets per day will be taken orally before bedtime.
46037135|NCT02791048|Behavioral|Music therapy|"Music therapy is a clinical intervention conducted by qualified therapists who use shared music-making and improvisation to engage and interact with the client (s) in order to work towards specific therapeutic objectives.~This is the aim of sessions, rather than the teaching or utilising of any musical skills, and clients do not have to have any prior musical training or experience whatsoever in order to participate in and benefit from music therapy. The intervention is client-led and the therapist will guide the patient in a range of strategies and activities appropriate to the therapeutic aims in place. Sessions can be individual, or family members can also be involved if appropriate and desired."
46037136|NCT00697021|Drug|Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG|Non- responders to Aspirin or Plavix shown on TEG analysis will be treated by doubling of Aspirin (200mg) and/or Plavix (150mg) dosage
46037137|NCT00697021|Drug|Aspirin 100mg and Plavix 75mg|Responders to standard dual antiplatelet therapy as observed by TEG analysis will continue standard doses of Aspirin and Plavix
46037138|NCT02790892|Behavioral|Art therapy - pre and post test measures|12 weeks of 90 minutes of art therapy with pre and post test measures to determine changes in social support and levels of diabetes distress
46037139|NCT02620345|Drug|Dydrogesterone M ( case 1 )|"Dydrogesterone Multivitamin nature~Fibroids / Women Pregnancy ( discovered fibroids during pregnancy ) Dydrogesterone Multivitamin nature.~1tablet/24 hours/day (to 4 weeks after postpartum)"
46037140|NCT02620345|Drug|Dydrogesterone M ( case 2 )|"Dydrogesterone Multivitamin nature~Fibroids/ Women of Reproductive age ( discovered fibroids )~1tablet/24 hours/day ( from discovered fibroids through 6 months)"
46037141|NCT02790970|Device|PReDicT Test|PReDicT Test, when completed 7-9 days after starting antidepressant treatment, is able to predict a patient's subsequent response to that antidepressant treatment 4-6 weeks later
45598919|NCT03307577|Drug|UHE-101 Cream|Topical cream containing investigational drug at a concentration of 1%
46037142|NCT02790970|Other|Treatment as Usual|Patients treated by the clinician conventionally using signs and symptoms to determine treatment changes or medication changes.
46037143|NCT02623543|Device|OrthoK|
46037144|NCT00696163|Drug|biphasic insulin aspart 30|Being an observational study, dose of NovoMix 30 will be according to treating physician's discretion
46037145|NCT02790502|Device|Food Photography Application©|Group testing RFPM as method of recording plate waste
45840005|NCT05138562|Drug|Active Comparator: TU2670 120mg|120mg (80mg x 1 + 20mg x 2 + placebo x 1), QD
46037146|NCT02790580|Drug|Dose-dense doxorubicin/cyclophosphamide + sunitinib|"Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0) Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease."
45598920|NCT03307577|Other|Vehicle Cream|Topical cream containing no drug (i.e., placebo)
45598921|NCT03514771|Device|Fraxel DUAL 1550/1927|
45598922|NCT03514771|Drug|oral isotretinoin|oral isotretinoin
45598923|NCT03514771|Drug|oral valacyclovir|Oral valacyclovir
45598924|NCT02346279|Other|Questionnaires, EDSS, physical test|6 Meter timed walking test, Nine Hole Peg Test, Berg balance Scale, MSQPT, HAQUAMS, Transition Questionnaire for Patients, Transition Questionnaire for Therapists, EDSS, 6 Minute Walking Test
45598925|NCT02298283|Drug|brentuximab vedotin|is 1.8 mg/kg administrated by IV infusion
46037147|NCT02790580|Drug|Dose-dense doxorubicin/cyclophosphamide|"Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease."
46037148|NCT00693823|Procedure|Femoral-popliteal Bypass|Surgical placement of a prosthetic graft in the thigh from the groin to the knee
46037149|NCT00693823|Device|Angioplasty and stent placement with Viabahn covered stent-graft(W.L. Gore & Associates, Flagstff, Arizona) of superficial femoral artery|Placement of an ePTFE covered stent graft within the superficial femoral artery in the thigh through a needle hole percutaneously
46037150|NCT02788864|Drug|Arterakine (DHA/piperaquine)|"Stage 1: Parasite Clearance~Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)"
46037151|NCT02788864|Drug|Placebo|"Stage 1: Parasite Clearance~Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Placebo (visually matched to Arterakine (DHA/piperaquine) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)"
46037152|NCT05298787|Drug|RLS-0071|RLS-0071 is administered as an IV infusion
46037153|NCT05298787|Drug|Saline Placebo|Placebo is administered as an IV infusion
45341983|NCT00835822|Drug|placebo|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
45341984|NCT02553213|Other|Laparoscopic sleeve gastrectomy|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
46037154|NCT04137055|Drug|ZSP0678-10mg|ZSP0678 tablet administered orally under fasted condition
46037155|NCT04137055|Drug|ZSP0678-30mg|ZSP0678 tablets administered orally under fasted condition
46037156|NCT04137055|Drug|ZSP0678-60mg|ZSP0678 tablets administered orally under fasted condition
45341985|NCT02553213|Other|Laparoscopic Roux-en-Y gastric bypass|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
45341986|NCT02553213|Other|Caloric restriction diet|Patients of the control group do not undergo surgical treatment. They undergo a caloric restriction diet for 5 days. This diet is adapted to the postoperative diet of the patients included in the two other groups.
45341987|NCT02553213|Other|easy digestible diet|
46037157|NCT04137055|Drug|ZSP0678-120mg|ZSP0678 tablets administered orally under fasted condition
46037158|NCT04137055|Drug|ZSP0678-180mg|ZSP0678 tablets administered orally under fasted condition
46037159|NCT04137055|Drug|ZSP0678-240mg|ZSP0678 tablets administered orally under fasted condition
45341988|NCT02575274|Procedure|Surgical flaps|Surgical intervention will be performed with full thickness mucoperiostal flaps to obtain access in the bone defects. All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%.
45341989|NCT00843934|Drug|epirubicin|Arm E: Suspension is prepared before arterial infusion as follows: Epirubicin is dissolved with water-soluble, non-ionized contrast medium then mixed with Lipiodol by pumping. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of EPI and Lipiodol are 60mg/m2 and 0.3mL/Kg, respectively.
45341990|NCT00843934|Drug|Cisplatin|Arm C: Suspension is prepared before arterial infusion as follows: Cisplatin (Water soluble CDDP: IA CALL) is mixed with Lipiodol. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of Cisplatin and Lipiodol are 65mg/m2 and 0.3mL/Kg, respectively.
46037160|NCT04137055|Drug|ZSP0678-320mg|ZSP0678 tablets administered orally under fasted condition
46037161|NCT04137055|Drug|ZSP0678|ZSP0678 tablets administered orally under fasted or fed condition
45341991|NCT00805701|Drug|avodart|0.5 avodart once daily for 13 weeks
45341992|NCT00805701|Drug|Placebo|placebo
45683638|NCT01808066|Device|Groundskeeper|Groundskeeper is a product developed for helping players develop skills to increase focus and attention. The game is played on small Sifteo Cubes that have sensors that react to you and each other. There are new games that might help children with ADHD and Autism learn to better focus and keep attention on a task.
45683639|NCT01604343|Drug|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 50.
45683640|NCT01604343|Drug|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 104.
46037162|NCT04137055|Drug|ZSP0678-Dose 1|ZSP0678 tablets administered orally once daily for 14 Days
46037163|NCT04137055|Drug|ZSP0678-Dose 2|ZSP0678 tablets administered orally once daily for 14 Days
46037164|NCT04137055|Drug|ZSP0678-Dose 3|ZSP0678 tablets administered orally once daily for 14 Days
46037165|NCT04137055|Drug|ZSP0678 Placebo|Participants will receive placebo matching to ZSP0678 orally.
46037166|NCT02788786|Drug|Chlorhexidine|non-alcoholic chlorhexidine gluconate antiseptic mouth rinse
46037167|NCT02788786|Drug|Cetylpyridinium chloride|non-alcoholic cetylpyridinium chloride antiseptic mouth rinse
46037168|NCT02788786|Drug|Salt and Water|salt and water mix oral rinse
46037169|NCT00693901|Behavioral|Community-based participatory research (CBPR)|CBPR will involve park advisory boards and community members in the research process, including the park assessments and data analysis. The assessment research will be used to inform use of discretionary funds for park programming and facilities in the hopes of increasing community physical activity. Park directors will be provided with analysis of descriptive information and community feedback to help improve outreach, park programming, and features to attract more park users and increase physical activity.
46037170|NCT00693901|Behavioral|Director-only|Park directors will be provided with descriptive information on park use and community feedback. They will also receive assistance on how to improve outreach, programming, and park features that will increase park use and physical activity. These parks will not take part in any assessments.
46037171|NCT03668236|Drug|Isotonic crystalloids|"Types of fluid to be used in both intervention groups:~IV fluids given for circulatory impairment: Only isotonic crystalloids are to be used as per the Scandinavian guideline for fluid resuscitation~Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used~Fluids used for dehydration: Water or isotonic glucose should be used~Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency, including water in the case of severe hypernatremia~Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy"
46037172|NCT02623465|Drug|Insulin Lispro|Administered subcutaneously (SC)
45840006|NCT00575016|Biological|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 and botulinum toxin Type A injection 200 U > Week 12; injection into the detrusor
45840007|NCT00575016|Biological|botulinum toxin Type A (50U); botulinum toxin Type A (200U)|botulinum toxin Type A 50 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
45840008|NCT00575016|Biological|botulinum toxin Type A (100U); botulinum toxin Type A (200U)|botulinum toxin Type A 100 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
45840009|NCT00575016|Biological|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
46037173|NCT00693979|Device|TAXUS Element Stent or TAXUS Express Stent|Paclitaxel was selected as the drug to coat the stent because it is known to prevent the uncontrolled cell growth that contributes to the narrowing of artery, by interfering with the ability of cells to divide and multiply. Because of these properties, it has been used as a drug for the treatment of various types of cancer. Cancer patients are given paclitaxel as a solution into the vein. For this study, paclitaxel will be administered locally to the wall of coronary artery as a coating on the stent. Cancer patients receive a dose of paclitaxel approximately 1100 - 1400 times greater than the dose used in the coating of the stent. It is highly unlikely that levels of paclitaxel in the blood would be measurable or have effects anywhere beyond the heart.
45341993|NCT02547610|Device|The imaging biomarkers determined by MR-PET|Combining PET and MRI, namely MR/PET, has the benefit of evaluating tissue metabolism with PET and at the same time evaluating tissue morphology/functional information with MR.
45683641|NCT01604343|Drug|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 52 through Week 104.
45683642|NCT01604343|Drug|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 104.
45840010|NCT00577512|Drug|DTPACE|"Dexamethasone 200 mg Intravenous Infusion Piggy-Back (IVPB) Days 1-7~Thalidomide 200 mg by mouth (PO) Days 1-7~Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency)~Adriamycin 15 mg/m2 Days 1-4~Cyclophosphamide 600 mg/m2 Days 1-4~Etoposide 60 mg/m2 Days 1-4"
45341994|NCT00805779|Device|MagPro R30|Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil. The figure eight coil is placed directly over the posterior tibial nerve and the MagPro R30 will be activated. The coil will stimulate the posterior tibial nerve at 20 pulses per second for a 30 minute session.
45598926|NCT02298283|Drug|Cyclophosphamide|1250 mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
45598927|NCT02298283|Drug|Adriamycin|35mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
45598928|NCT02298283|Drug|Oncovin|1.4 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
45598929|NCT02298283|Drug|Bleomycin|10 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
45598930|NCT02298283|Drug|Etoposide|200 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D3 of 2 BEACOPP cycles, every 3 weeks
45341995|NCT00714896|Behavioral|Stepped-Care|"stage-based expert system written intervention at baseline and 3 months~in-person stage appropriate counseling at baseline and 3 months~telephone counseling sessions at weeks 2,4 and 8,~as-needed brief check-in calls on or 2 days after quit date for those who have set a quit date; and/or check-in calls on days with anticipated high risk situations for former smokers or those who have quit smoking during the study~optional NRT nicotine replacement therapy in the forms of patch, gum or lozenge for current smokers who are ready to quit smoking and/or for former smokers who report significantly strong smoking urges"
45341996|NCT00714896|Behavioral|Control|Referral list to smoking cessation classes at Kaiser and the California Smokers Helpline
45341997|NCT04042948|Drug|Tylenol|when we decide to remove the drainage tube, we ask the patient to take a pill of tylenol, and another pill in 12h later
45341998|NCT00796965|Drug|AZD7268|Solution/Capsule, Oral, once daily
45341999|NCT00796965|Drug|Placebo|
45342000|NCT04566302|Device|SECM Skin Imaging|Consented Participants will be asked to allow their forearm to be imaged by the dermatoscope on the same skin/lesions as a control comparison. We will be trying to image pigmented skin/lesions present on the forearm. This will be followed by imaging using the SECM Skin imaging device
45342001|NCT00765245|Drug|Lenalidomide|Orally once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
45342002|NCT00765245|Drug|Lenalidomide|Lenalidomide 20 mg daily, Days 1-21, followed by 7 days rest (28-day cycle). Cycles will be repeated every 28 days for a total of 12 cycles
45683643|NCT01604343|Drug|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 104.
45683644|NCT01801436|Drug|Bortezomib|Bortezomib 1.3 mg per (m^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
45840011|NCT00577590|Drug|Metformin|Metformin is taken alone
45342003|NCT00765245|Drug|Rituximab|Rituximab 375 mg/m2 intravenously (IV) starting on Day 8, Cycle 1 of lenalidomide. Rituximab will be repeated on Day 8 of odd numbered cycles (Cycles 1, 3, 5, 7, 9, and 11) for a total of 6 doses from randomization.
45342004|NCT02546518|Device|Moniri Otovent|Please see Arm Description.
45840012|NCT00577590|Drug|Rosiglitazone|Rosiglitizone is taken with Metformin
45598931|NCT02298283|Drug|Procarbazine|100 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
45598932|NCT02298283|Drug|Prednisone|40 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
45598933|NCT02298283|Drug|G-CSF|5 µg/kg/j, SC, D9 until GB 1.0x109/L
46037174|NCT04232800|Drug|Riboflavin|The intervention will consist of 100mg riboflavin (vitamin B2) given in three time daily dosing.
45598934|NCT02298283|Radiation|30 Grays|30 Gy radiation of sites initially diagnoses + 6Gy for residual sites, 3 to 4 weeks after D1 of BEACOPP cycle 2.
45683645|NCT01771250|Biological|Insulin Peglispro|Daily doses administered SC.
46037175|NCT04232800|Other|Placebo|An inert, standard placebo in identical capsules to primary intervention.
46037176|NCT01148225|Drug|adalimumab|Adalimumab, pre-filled syringe, administered by SC injection
46037177|NCT02623387|Procedure|Ultrasound guided paravertebral block|Paravertebral blocks is a regional anaesthetic technique in which thoracic spinal nerves are inhibited for post operative analgesia in patients undergoing breast surgery. The site of injection can be determined using anatomical landmarks (standard) or using ultrasound guidance.
46037178|NCT02788240|Drug|Peg GCSF|
46037179|NCT02788240|Biological|20% Albumin|
46037180|NCT02788240|Dietary Supplement|Nutrition|
45683646|NCT01771250|Biological|Insulin Glargine|Daily doses administered SC.
46037181|NCT02788240|Other|Bowel wash|
46037182|NCT02788240|Drug|Terlipressin 1- 4mg,if indicated|
46037183|NCT02788240|Drug|Meropenem or Imepenem, if indicated|
46037184|NCT02788240|Drug|Placebo|
46037185|NCT02788162|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation Number - X71-144)
46037186|NCT04134715|Drug|PF-06826647|100 mg tablet
46037187|NCT04134715|Drug|Oral Contraceptive (OC)|OC in the form of 1 PORTIA (30 µg EE and 150 µg LN) or equivalent tablet
46037188|NCT04136899|Other|Dukes scale|collection of questionnaires
46037189|NCT02788006|Drug|Regorafenib 160 mg|
46037190|NCT00694057|Drug|HE3286|HE3286 10 mg per day (5 mg BID)
46037191|NCT00694057|Drug|Placebo|Placebo capsules BID
46037192|NCT02884115|Drug|benzathine penicillin|
45598935|NCT02346357|Procedure|Obturator Nerve Block|Ultrasound-guided obturator nerve block with 20 mL of treatment drug (Ropivacaine 0.5% [local anesthetic]) 30 minutes prior to induction of anesthesia.
45840013|NCT00577590|Drug|Lovaza|Lovaza is taken with Metformin
46037193|NCT00696319|Other|Exercise protocol with perturbation exercises.|Perturbation exercises are exercises for balance and stability that involves perturbations of the surface through use of custom made equipment (a rollerboard, a rockerboard and a platform).
46037194|NCT00696319|Other|Exercise protocol with traditional exercises for stability and balance.|The exercise protocol will consist of exercises for balance and stability that do not include sudden disturbances or perturbations to the surface.
46037195|NCT01190891|Procedure|Manual Physical Therapy|Same as arm description
46037196|NCT01190891|Procedure|Corticosteroid Injection|Dose represents a glucocorticoid potency of 400 hydrocortisone equivalents/injection (mg).
45598936|NCT02346357|Drug|Ropivacaine|
46037197|NCT00871975|Device|Urodynamics + TETRA - NIRS|Urodynamics will be performed as per standard of care for patients enrolled, whereby one catheter is inserted into the bladder and one in the rectum to analyze bladder filling, storage and voiding conditions via pressures measured and urine flow rates detected by a uroflowmeter. Tetra-NIRS will be concurrently performed where Tetra-NIRS unit uses near infrared light at 3 different wavelengths to measure changes in haemoglobin and cytochrome. A patch is applied externally to measure these changes in the detrusor muscle of the human bladder wall. This process is similar to what is used for cerebral and muscle oxygenation monitoring (e.g., pulse oximetry). Previous clinical feasibility studies have identified a correlation between the changes in haemoglobin and cytochrome and the pressure values obtained during urodynamics procedures.
46037198|NCT00694213|Biological|VCL-IPM1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
46037199|NCT00694213|Biological|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
46037200|NCT00694213|Biological|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
45683647|NCT01770860|Device|6660|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
46037201|NCT00694213|Biological|PBS|IM, 1 mL, 2 injections, 0 and 21 days
46037202|NCT04134403|Drug|STASIS|Hydrocortisone sodium succinate, 50 mg, every 6 hours, 7 days or until ICU discharge Thiamine, 200 mg, every 12 hours, 4 days or until ICU discharge Ascorbic acid, 1,500 mg, every 6 hours, 4 days or until ICU discharge
46037203|NCT01190813|Drug|Levodopa/Carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
45598937|NCT02346357|Drug|Placebo Saline|
45598938|NCT03146247|Drug|Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet|All patients are scheduled to receive Apremilast with a titration phase of one week, followed by 23 weeks of regular treatment.
45598939|NCT03263273|Drug|1% Topical Minocycline Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
45598940|NCT03263273|Drug|3% Topical Minocycline Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
46037204|NCT01190813|Drug|Placebo|Oral placebo tid
46037205|NCT01190813|Other|Patching|Two hours of daily patching
46037206|NCT03641326|Drug|Sunitinib|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest until there is disease progression or development of intolerable side effects.
46037207|NCT03641326|Device|wGT3x-BT|Participants will given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
45683648|NCT01770860|Device|4314|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
45683649|NCT01770860|Device|8336|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
45683650|NCT01770860|Device|4840|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
45683651|NCT03568708|Drug|Transdermal Estrogen|In an open-label fashion, participants with POI will receive transdermal estradiol (beginning at a dose of 25 µg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).
45342005|NCT02546518|Device|Tympanostomy tube in the ear drum|Insertion of tympanostomy tube/Grommet in the ear drums.
45342006|NCT00801879|Drug|Mupirocin calcium ointment, 2%|0.25 g in each nostril twice daily for 5 days (given monthly for up to 8 months)
45840014|NCT00578214|Drug|Randomized Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. In the randomized arm, patients received a single-dose administration of 5 ml (10 mg) of the midazolam syrup.
46037208|NCT03721510|Biological|PGT121 + VRC07-523LS|PGT121 + VRC07-523LS, dose 30 mg/kg each, given intravenously
46037209|NCT03721510|Biological|PGT121 + VRC07-523LS + PGDM1400|PGT121 + VRC07-523LS + PGDM1400, dose 20 mg/kg each, given intravenously
46037210|NCT02788942|Procedure|Removing from Epigastric port|The cholecystectomy material will be removed from epigastric port. This will be experimental group. Port site infection rates will be measured
46037211|NCT04313309|Other|Integrative Yoga Therapy|Individualised intervention developed, consists of a six one to one sessions with patients, followed by home self practiced sessions. The intervention includes yoga movements, yoga breathing, relaxation techniques, reasoning, and other techniques designed to enhance awareness and acceptance of the psychological factors underlying the chronic pain problem.
46037212|NCT00870727|Drug|Aripiprazole oral product|Minimum dose of 2 mg per day to a maximum dose of 20 mg per day over 8-weeks of treatment.
46037213|NCT00870727|Drug|Placebo oral capsule|Placebo will be identical in size and appearance to study drug.
45342007|NCT00801879|Drug|Placebo ointment|Placebo ointment 0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
45598941|NCT03263273|Other|Topical Vehicle Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the vehicle intervention
45598942|NCT02293369|Procedure|Cuff closure via vaginal route|Vaginal cuff will be closed via vaginal route during total laparoscopic hysterectomy.
45598943|NCT02293369|Procedure|Cuff closure via laparoscopic route|Vaginal cuff will be closed via laparoscopic route during total laparoscopic hysterectomy.
45342008|NCT00718484|Drug|Palifosfamide Tris and Doxorubicin|On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
45342009|NCT00718484|Drug|Doxorubicin|On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
45342010|NCT00841126|Drug|Magnesium iron hydroxycarbonate|500 mg tablets, administered orally: initial dosage 500 or 1000 mg (total daily dose 1500 or 3000 mg) depending on serum phosphate concentration, titrated to a maximum DAILY dose of 9000 mg). The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 3000 mg.
45342011|NCT00841126|Drug|Lanthanum carbonate|750 mg chewable tablets, administered orally: initial dosage 750 mg up to 3-times daily (total daily dose 2250 mg), titrated to a maximum SINGLE dose of 1500 mg (DAILY dose 3750 mg). The total daily dose should be divided and taken with meals.
45342012|NCT00841126|Drug|Placebo|0 mg (500 mg-size) tablets, administered orally: The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 6 tablets.
45342013|NCT02553369|Other|Biological sample collection|A blood sample is collected during a follow up visit for HIV infection.
45342014|NCT03987113|Other|Plasma concentration analysis during and after ex-vivo pulmonary reconditioning|The pulmonary endothelial dysfunction will be evaluated with plasma concentration of heparan sulphate, syndecan-1, endothelin-1 and i-NOS.
45473703|NCT03744169|Diagnostic Test|Lung ultrasound|A point-of-care lung ultrasound exam will be performed on admission (no later than 14 hours following admission, allowing for participant stabilization and care) to the PICU and within 6 hours of any escalation in mechanical ventilatory support without interrupting clinical care, by study investigators blinded to participant history, physical examination, and diagnostic testing/imaging and who are not involved in the clinical management of the participant. Investigators will use a six-zone standardized scanning protocol with pattern analysis to form a diagnosis for the cause of the participant's respiratory failure. Images will be acquired by pediatric critical care trainees and saved online; accuracy of diagnoses based on the ultrasound exam will be evaluated by a expert sonographer offline.
45342015|NCT02575040|Biological|Fecal microbiota transplantation|Fecal microbiota transplantation to patients with ulcerative colitis and Crohn disease
45342016|NCT03987347|Other|Observational|People who are enrolled in the Canadian Longitudinal Study on Aging. Participants undergo repeated waves of the same standardized data collection every three years. All participants are also contacted by telephone 18 months after baseline assessment to complete the Maintaining Contact Questionnaire.
45473704|NCT03744169|Diagnostic Test|Clinical exam|Following morning ICU rounds, the PICU fellow or attending physician caring for the participant will be asked for his/her interpretation of the most recent chest radiograph and his/her diagnosis concerning the etiology of the participant's acute respiratory failure. This clinical diagnosis will be compared to ultrasound findings.
46037214|NCT02787928|Drug|Intrathecal hydromorphone|Intrathecal hydromorphone will be administered in an up/down dosage fashion. A successful dose will be defined as a patient not requiring additional narcotic pain medication outside of the standard VCU order set, which includes PRN oxycodone 5 and 10 mg every 4 hours and a one time PRN 1 mg hydromorphone IV. Failure of a dose will be if patient requires additional narcotic pain medication outside of these parameters
45342017|NCT00805857|Drug|Tipranavir|
45342018|NCT00718562|Drug|AMN107|
45342019|NCT00801957|Drug|tacrolimus ointment 0.03%|topical application
45342020|NCT00801957|Drug|hydrocortisone acetate ointment 1%|topical application
45342021|NCT00801957|Drug|hydrocortisone butyrate ointment 0.1%|topical application
45342022|NCT00801957|Biological|Meningitec|im injection
45342023|NCT00801957|Biological|AC VAX|im injection
45342024|NCT02572544|Device|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|Wearing multiple and single pinhole glasses
45342025|NCT02547688|Device|Nasal High Flow|
45342026|NCT00714974|Device|BIS|Sedation dosing based on BIS value, oer treating physician discretion.
45342027|NCT00836134|Procedure|rectus sheath block|ultrasound-guided rectus sheath block using 0.2ml/kg 0.25% bupivacaine bilaterally prior to skin incision
45342028|NCT00836134|Procedure|local anesthetic infiltration|Wound infiltration using 0.4ml/kg 0.25% bupivacaine by the surgeon at the end of surgery
45473705|NCT03744169|Diagnostic Test|Chest x-ray|Results of chest x-ray will be collected for comparison with ultrasound findings.
45342029|NCT00715052|Procedure|Hyperbaric Oxygen Therapy (HBOT)|40 consecutive one hour treatments at 1.5 ATA with 100% O2
46037215|NCT02617069|Biological|botulinum toxin injection|
46037216|NCT02617069|Biological|0.9% normal saline injection|
45342030|NCT00782795|Drug|Pioglitazone|Participants randomized to pioglitazone receive 30 mg taken once daily for 48 weeks.
45342031|NCT00782795|Drug|Placebo|
45473706|NCT03139227|Procedure|Bio specimen Collection|Patients undergo collection of blood and urine
45473707|NCT03139227|Dietary Supplement|Dietary Intervention|Consume celery-banana bread
46037217|NCT02617069|Device|Implantable loop recorder|
45342032|NCT00841282|Procedure|Colonoscopy for colorectal cancer screening|
45342033|NCT00841282|Procedure|Water Infusion Colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
45342034|NCT00841282|Procedure|Air insufflation colonoscopy|Conventional colonoscopy with air insufflation
45342035|NCT00715130|Behavioral|Energy Balance|We propose to develop and test a comprehensive intervention that will provide simple strategies related to dietary intake and energy expenditure that individuals can follow to achieve a balance in their energy intake and expenditure, while simultaneously changing structural and environmental cues to focus on promoting information, social support and opportunities for managing energy intake and increasing physical activity.
45342036|NCT00841360|Other|Index Recruiter|Participants agree to recruit at least two female friends from their friendship network to undergo HIV screening.
45473708|NCT03139227|Other|Laboratory Biomarker Analysis|Correlative studies
45598944|NCT03146325|Drug|BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE|A 14-day quadruple Hp eradication therapy consisting of: omeprazole (20 mg twice daily) plus 3 capsules q.i.d., each containing 420 mg of bismuth subcitrate potassium, 375 mg of metronidazole and 375 mg of tetracycline hydrochloride, for 14 days
46037218|NCT02788630|Behavioral|Sleep hygiene counseling|The mothers of the eligible infants will be visited at home and will be invited to participate at the study. To those who sign the Consent Form (CF) a following visit will be scheduled to within 5 days. Between CF signature and the 5-day visit, the enrolled children will use an actigraph-device in the leg and the mothers will fill out a sleep diary registering the times of the day the child is asleep, awake, napping, and feeding. At the 5-day visit the child allocation in the trial (intervention or control group) will be uncovered and the sleep recommendations will be delivered to mothers in the intervention group. Phone calls on days 6 and 7 and a home visit on day 8 will be paid to support mothers for possible difficulties in implementing the recommendations.
45598945|NCT03146325|Drug|MATCHING PLACEBO|TO BE PREPARED BY LICENSED COMPOUNDING PHARMACY
46037219|NCT02619877|Biological|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
46037220|NCT02619877|Other|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer
46037221|NCT02788552|Drug|Thiamine Hydrochloride|Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.
46037222|NCT04135339|Other|Eccentric exercise|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure eccentric contraction.
45598946|NCT03518905|Device|Radiofrequency ablation|Radiofrequency ablation is performed using the Barrx Channel endoscopic catheter (Medtronic, Dublin, Republic of Ireland) generating an energy density level of 12 Joule/cm2. The energy is applied using a simplified protocol of three ablations without removal of coagulated tissue. The device is used on a routinely basis all around the world and already approved. The ablation catheter is applied through the working channel of the endoscope.
45840015|NCT00578214|Other|Placebo|The placebo was prepared as a color- and texture-matched cherry flavored syrup without midazolam.
46037223|NCT04135339|Other|Concentric exercise.|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure concentric contraction.
46037224|NCT04135339|Other|Isometric exercise.|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure isometric contraction.
46037225|NCT01147055|Drug|crizotinib|Treatment A: a single 250-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
45342037|NCT00841360|Other|Friendship Network Member|Participants are recruited by Index Recruiters to enroll in study and receive HIV screening and complete a questionnaire either on Facilitators of HIV Screening or Barriers to HIV Screening.
45342038|NCT02573558|Drug|Dexmedetomidine|
46037226|NCT01147055|Drug|rifampin|Treatment B: 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 1 to Day 14.
46037227|NCT01147055|Drug|crizotinib|Treatment B: A single 250-mg dose of crizotinib will be administered in the fasted state on Day 9 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
46037228|NCT05388916|Other|Cosentyx|Prospective observational cohort study. There is no treatment allocation. Patients administered Cosentyx by prescription will be enrolled.
45342039|NCT02573558|Drug|Propofol|
45342040|NCT00656799|Drug|sugammadex|At 15 minutes after administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was administered.
45342041|NCT00656799|Drug|Rocuronium|After achieving stable anesthesia an IV single bolus dose of 0.6 mg/kg rocuronium was administered
45342042|NCT00764699|Drug|rhIGF (Increlex)|rhIGF will be administered as a subcutaneous injection per the following schema: First 2 weeks: 40 mcg/kg BID; Weeks 3 and 4: 80 mcg/kg BID; Subsequent weeks: 120 mcg/kg BID.
45342043|NCT02547142|Other|Early Palliative Care|Metastatic esophageal cancer patients that receive early palliative care along with standard oncological care
45342044|NCT00715286|Other|timing of surgery|Surgery is followed by chemotherapy
45342045|NCT00715286|Other|timing of surgery|Chemotherapy is followed by surgery
45342046|NCT00844012|Drug|Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a continuous regimen.
45342047|NCT00844012|Drug|Cyclic OC (clormadinone acetate plus ethinil-estradiol)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a cyclic regimen.
45342048|NCT02574962|Drug|H.P. Acthar® Gel|
45342049|NCT00802035|Drug|Baclofen IR|30 mg; single dose
45342050|NCT00802035|Drug|Baclofen ER|30 mg; single dose
45598947|NCT03518905|Procedure|esophagoscopy|Patients receive an esophagoscopy without radiofrequency ablation under sedation
46037229|NCT03705754|Device|carbon black suspension colonic tattoo injection|Examine the SPOT syringe to verify that the pigment is fully suspended. A 23 or 25 G sclerotherapy needle is recommended for this procedure, attach the syringe and prime with SPOT. After injection catheter is primed, manoeuver with the endoscope for optimal injection position and inject tangentially, at a 30-40˚ angle to the mucosa and create a saline bleb to find the submucosal plane prior to injecting SPOT to reduce risk of intramural injection. Document both the depth of scope and anatomic location of each tattoo and the ink consumption as well. Place injection 2-3 cm distal (downstream) of the area of interest. Use 0.5-0.75 mL per injection site and no more than 8 mL per patient. Place SPOT tattoos in 3-4 quadrants around the lumen to increase likelihood of visualisation.
45473709|NCT03867461|Procedure|Venous Sinus Stenting|Venous sinus stenting is performed under general anesthesia. Patients are loaded with aspirin and clopidogrel before the procedure. After induction, the right femoral vein is accessed and an 8 F sheath is placed. Intravenous heparin is administered. A 0.070-0.088 guide catheter is navigated into the ipsilateral jugular vein near the jugular bulb. Pre-stenting manometry is performed in every patient. To do so, a Renegade Hi-Flo microcatheter is navigated into the superior sagittal sinus and then used to measure ipsilateral venous pressures across the site of outflow obstruction (this will be the time point where the study intervention will be performed).
45342051|NCT00836212|Drug|Reducing dose of Lopinavir|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
45342052|NCT00836212|Drug|Reducing dose of efavirenz|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
45473710|NCT03867461|Other|Adjustment to end-tidal carbon dioxide concentrations ( 38-40 mmHg range)|End-tidal carbon dioxide concentrations will be adjusted to fall in the End-tidal carbon dioxide concentrations will be adjusted to fall in the 38-40 mmHg range
45473711|NCT03867461|Other|Adjustment to Mean Arterial Pressure (100-110 mmHg range)|Mean arterial pressure will be adjusted to fall in the 100-110 mmHg range
45342053|NCT04069676|Other|EEG|EEG, ECG and EDR record during a behavioral task
46037230|NCT02623231|Drug|Escitalopram|Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
46037231|NCT02623231|Drug|placebo|group # 2 Will include 50 patients , who will receive placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
46037232|NCT04232878|Drug|CVL-936|CVL-936
46037233|NCT04232878|Drug|Matching Placebo|Placebo matching CVL-936
45683652|NCT04305106|Drug|Bevacizumab|Bevacizumab (7.5mg/kg BW) + Saline (100ml) Bevacizumab will be administered in a single dose with no less than 90 minutes of intravenous infusion under ECG monitoring.
45840016|NCT00578214|Drug|Local Anesthesia|Lidocaine 1% with 1:100,000 epinephrine
45840017|NCT00578214|Drug|Prospective Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. Dosing in the prospective arm was based on weight (>45 to 77 kg, 10 mg; >77 to 100 kg, 15 mg; greater than or equal to 100 kg, 20 mg). In the prospective arm patients were given additional doses of midazolam as necessary (in 5 mg increments) to achieve and maintain the desired level of anxiolysis.
45840018|NCT00580398|Behavioral|Smoking cessation counseling|Median of 9 tobacco treatment counseling sessions conducted in person or by telephone.
46037234|NCT02623153|Drug|Oxaliplatin|oxaliplatin 130 mg/m2
45473712|NCT03867461|Other|Adjustment to Mean Arterial Pressure (60-80 mmHg range)|Mean arterial pressure will be adjusted to fall in the 60-80 mmHg range
45683653|NCT04305106|Other|Placebo|Placebo (7.5mg/kg BW) + Saline (100ml) The placebo drug will be administered in a single dose with no less than 90 minutes of intravenous infusion under ECG monitoring.
46037235|NCT02623153|Drug|capecitabine|capecitabine of 1000 mg/m2
46037236|NCT02623153|Drug|S1|S1 of 40 mg/m2
46037237|NCT02623153|Drug|Docetaxel|docetaxel 40 mg/m2
46037238|NCT04316195|Diagnostic Test|Assessment of the bulbocavernosus reflex|"According to the International Standards for Neurological Classification of Spinal Cord : The standard examination consists of the contraction of the bulbocavernous muscle following stimulation of the glans of the penis in men and of the clitoris in women.~By electromyography: The electromyography consists to stimulate the bulbocavernosus reflex with a bipolar probe apply on the glans for men, and on the clitoris in women. A surface electrode will be positioned on the right or left bulbocavernous muscle at the base of the penis (or vagina) and the anus for recording. The bulbocavernous reflex will be obtained by stimulation at a frequency of 1.5Hz and an amplitude of 14 to 47 mA."
46037239|NCT02616913|Other|R,R-monatin|Each subject consumes test article R,R-monatin (150 mg) in one of 3 treatment periods
45342054|NCT00782717|Drug|Nepafenac ophthalmic suspension, 0.1% (NEVANAC)|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery.
46037240|NCT02616913|Other|Moxifloxacin|Each subject consumes moxifloxacin (400 mg; positive control) in one of 3 treatment periods
45473713|NCT03867461|Other|Adjustment to end-tidal carbon dioxide concentrations (24-26 mmHg range)|End-tidal carbon dioxide concentrations will be adjusted to fall in the 24-26 mmHg range
45342055|NCT00782717|Other|Nepafenac ophthalmic suspension vehicle|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
45473714|NCT05153733|Device|RIFRAM implant|Participants will receive the newly developed, patient-specific RIfRaM mandibular implant.
45473715|NCT03385642|Device|ChondroMimetic|ChondroMimetic is a single-use, biphasic implant that serves as an osteochondral scaffold for the repair of cartilage defects in the knee
45473716|NCT03621813|Behavioral|Exercise Rehabilitation|This training is designed to improve fitness, target the major muscle groups for strength, and to improve balance. Aerobic exercise of walking on a treadmill will be performed. Thera-Bands will be used for resistance exercise for the lower and upper body. Balance program includes core exercises (stepping, weight shifts, etc.) and other progressive exercises.
45473717|NCT03621813|Other|Control|Participants are instructed to maintain current activity level and are monitored for changes.
45473718|NCT03867071|Other|recombinant erythropoietin injection|Intravenous injection of 300 international units (IU) per kg (kg) of recombinant erythropoietin with a maximum of 20.000 IU, daily for a maximum of 10 days (D0 to D9).
45342056|NCT00782717|Drug|Prednisolone acetate ophthalmic suspension (OMNIPRED)|One drop in the study eye 4 times daily (morning, late morning, late afternoon, and bedtime)for two weeks postsurgery.
45342057|NCT00656175|Drug|raltegravir|raltegravir
45342058|NCT02572622|Other|non -surgical spinal decompression therapy|it is a kind of traction therapy, it has an special traction design which can provide intermittent traction as to herniation levels.
45342059|NCT02572622|Other|deep friction massage,|deep friction massage is a kind of massage targeting deep muscles for decreasing pain and increasing function
45473719|NCT03867071|Other|placebo injection|Intravenous injection 0,9% saline solution.
45473720|NCT03382132|Behavioral|momHealth|Mobile health program delivered via an iPad. Program delivers information and support related to breastfeeding education, Ten Steps of the Baby Friendly Hospital Initiative, healthy eating and active living topics, and depression prevention information.
45473721|NCT03382132|Behavioral|Standard of Care|Participants will receive standard health care via their prenatal provider, including routine prenatal education and postpartum support.
45473722|NCT04032613|Other|Vascular Access Navigation and Education Quality Improvement Program|A Vascular Access Navigation and Education Quality Improvement Program implemented in the Geisinger Danville, PA chronic kidney disease clinic. Participants complete questionnaires to assess their vascular access care knowledge and confidence before and after the implementation of the quality improvement program.
45598948|NCT04189133|Drug|Lutropin alfa|daily increasing dosages of lutropin alfa
46037241|NCT02616913|Other|Placebo|Each subject consumes placebo in one of 3 treatment periods
45473723|NCT01172327|Behavioral|Multicomponent exercise|This intervention is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks. The active intervention phase is 12 weeks.
45473724|NCT01172327|Behavioral|Nutrition|This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks. The active intervention lasts for 12 weeks.
45473725|NCT03375502|Drug|Varicella Vaccine|The subject will receive investigational product or comparator.
45473726|NCT01284413|Drug|S-1, Gemcitabine, Cisplatin|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
45473727|NCT03376984|Combination Product|ND and AMOX modified Gutta Percha|Gutta percha reinforced and modified with 5 nm diameter nanodiamonds and amoxicillin
45342060|NCT02572622|Other|electrotherapy|electrotherapy is consist of hot pack, ultrasound and TENS. electrotherapy agents were help decreasing pain, increasing metabolism of tissues.
45473728|NCT03376984|Device|Gutta Percha|Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
45473729|NCT03867149|Other|neuroimaging|neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI
45473730|NCT03867149|Other|Neuropsychological assessment|neuropsychological assessment of memory, language, executive functions and mood
45840019|NCT00580398|Drug|varenicline|varenicline (1mg bid, with initial titration up over week 1) for 12 weeks
45342061|NCT02572622|Other|exercise|special lumbar stabilization exercises were applied in advanced protocol.
45473731|NCT05152017|Biological|Flu-M Quadro [inactivated split influenza vaccine] with preservative|solution for intramuscular injection, 0.5 ml
45473732|NCT05152017|Biological|Flu-M Quadro [inactivated split influenza vaccine] without preservative|solution for intramuscular injection, 0.5 ml
45473733|NCT05152017|Biological|Placebo|solution for intramuscular injection, 0.5 ml
45473734|NCT03866993|Biological|AK105|IV infusion
45473735|NCT03866993|Drug|Paclitaxel|IV infusion
45473736|NCT03866993|Drug|Carboplatin|IV infusion
45473737|NCT03866993|Drug|Placebo|IV infusion
45598949|NCT04189133|Drug|Human chorionic gonadotropin|human chorionic gonadotropin increasing administration
46037242|NCT03701230|Other|low temperature rota-flush solution|Patients with severe calcified lesions undergoing RA were performed with low temperature rota-flush solution. The investigators used thermal insulation equipment to keep rota-flush solution at 0～5℃. The EKG and blood pressure were monitored during the RA procedure. After RA, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
46037243|NCT02884037|Drug|Rifaximin group 1|Rifaximin: 1100mg/day, 550 mg tablets 1 × 2 before meals
46037244|NCT04233502|Drug|Melatonin|prolonged release 1 mg and 5 mg mini-tablets coated odorless and tasteless to facilitate swallowing
45342062|NCT02601599|Behavioral|Motivational interviewing|"The medical student will deliver a brief (approximately 15 minute) consultation with the patient that is based on principles of social cognitive theory and motivational interviewing. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy (via a chart sticker).~Each student will counsel 1-3 smokers each over the 8-month academic period, with student training and intervention staggered over this time. Students will also re-contact the smoker at 1-week post-discharge via telephone or personal follow-up, to provide further support."
45342063|NCT02572466|Other|Hemodialysis|ESRD group received long-term hemodialysis
45342064|NCT00797121|Procedure|Preoperative biliary drainage|Percutaneous transhepatic biliary drainage(PTBD) is performed under the guidance of ultrasound. The duration may be around four weeks to make the total bilirubin of patients lower than 85μmol/L.
45473738|NCT03376906|Procedure|HIIE 1|In the HIIE 1 session, all the subjects performed 10 stimuli of 1 min at high intensity (92% of VO2Max) with passive recovery (without exercise) of 1 min.
45840020|NCT00581256|Radiation|IMRT|All patients treated with the optimized plan will be treated to the entire target volume to 52.2 Gy in 1.74 Gy fractions, which is biologically equivalent to 50 Gy in 2 Gy fractions. This fractionation scheme will allow the boost of 10 Gy to be incorporated into the planning directive and to be delivered simultaneously with the treatment to the remaining target volume.
46037245|NCT04233502|Drug|Placebo|Placebo melatonin
46037246|NCT01146665|Behavioral|Computer-based PAF|This intervention includes standard medical care followed by receipt of computer-based Personalized Assessment Feedback (PAF). PAF is a type of brief intervention that targets norm misperceptions, for example summarizing a person's drinking in comparison to the average male or female in the general population. Theoretically, such normative feedback corrects norm misperceptions and motivates drinkers to re-evaluate their consumption patterns.
46037247|NCT01146665|Behavioral|Computer-based Sham|This intervention includes standard medical care followed by receipt of a computer-based sham. The sham is similar in format and duration as the computer-based Personalized Assessment Feedback but will engage youth in nutrition and exercise-related questions.
46037248|NCT03679078|Dietary Supplement|IDDSI nutritional supplement drink|ready-to-use nutritional supplement drink to be taken daily for 28 days
46037249|NCT00696475|Drug|Diazoxide choline|
45598950|NCT03518749|Other|1mA tDCS|transcranial direct current stimulation with the intensity of 1mA
46037250|NCT00696475|Drug|Diazoxide choline|
46037251|NCT00696475|Drug|Diazoxide choline|
46037252|NCT00696475|Drug|Placebo|
46037253|NCT03628066|Drug|Letrozole|Letrozole 2.5 mg by mouth daily for 24 weeks
46037254|NCT03628066|Drug|Palbociclib|Palbociclib 125mg by mouth daily for 21 days per 28-day cycle (21 days on, 7 days off) for 24 weeks
46037255|NCT03628066|Drug|Goserelin|Goserelin 3.6mg subcutaneous injection x 1 on Day 1 of each 28-day cycle for 24 weeks
46037256|NCT03628066|Diagnostic Test|Oncotype DX Breast Recurrence Score|Prior to assignment to Arm 1 the Oncotype DX diagnostic test will be conducted on diagnostic tissue to assign a recurrence score for stratification to cohort 1 or 2.
46037257|NCT02616757|Device|Sunlight Omnisense Quantitative Ultrasound|Ultrasound
46037258|NCT00625079|Drug|sildenafil|the dose of sildenafil will be 20mg three times per day (orally)
46037259|NCT02788318|Other|Brain samples|Collected in patients died
46037260|NCT02788318|Other|Skin samples|Collected in patients died
46037261|NCT02619721|Device|PINS SNS|
46037262|NCT04133389|Other|Growth mindset of personality educational intervention|This is a brief online educational intervention that teaches growth mindset of personality. The intervention includes pictures, text, videos, and questions administered through Qualtrics survey software.
46037263|NCT04133389|Other|Growth mindset of athletic ability educational intervention|This is a brief online educational intervention that teaches growth mindset of athletic ability. The intervention includes pictures, text, videos, and questions administered through Qualtrics survey software.
46037264|NCT02787616|Genetic|buccal swab|cheek swab for DNA sampling
46037265|NCT02787772|Procedure|Elective Hernia repair|abdominal wall hernia repair using onlay mesh.
46037266|NCT02616835|Device|theta-burst TMS|This protocol involves short periods of pulse delivery in combination with long periods of silent intervals.
46037267|NCT02616835|Device|sham theta-burst TMS|This protocol delivers theta-burst pulses from a sham device (i.e. at same speed and timeframe but without the magnetic output)
46037268|NCT01145885|Drug|BI 6727|PLK-1 inhibitor
46037269|NCT02787538|Behavioral|US-ANSWER-2 decision aid|US-ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
45473739|NCT03376906|Procedure|HIIE 3|In the HIIE 3 session, the subjects performed the same stimulus of the HIIE1, but with passive recovery of 3 min. Both protocols started with a warm-up of 5 min at 50% of the VO2Peak performed on a T2-100 GE Healthcare® treadmill (Lynn Medical, Wixon, Michigan, USA).
46037270|NCT02787538|Behavioral|Control group (Online medication guide)|Standard online medication guide.
46037271|NCT02616991|Procedure|computed tomography venography|systematically performing computed tomography venography in addition to thoracic computed tomography angiography
46037272|NCT02786992|Drug|Misoprostol|
46037273|NCT02786992|Drug|Oxytocin|
46037274|NCT02786992|Drug|Carbetocin|
45342065|NCT00715364|Drug|NTx™-265: rhCG, then rEPO|"rhCG 385 µg, SC, on Day 1, 3, and 5 of study participation, then~rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation"
45342066|NCT00715364|Drug|Saline Placebo|"Saline SC, on Day 1, 3, and 5 of study participation, then~Saline IV, on Day 7, 8, and 9 of study participation"
45598951|NCT03518749|Other|2mA tDCS|transcranial direct current stimulation with the intensity of 2mA
46037275|NCT02786992|Drug|Placebo|
46037276|NCT02617303|Procedure|OTAGO's exercises|The intervention is based on OTAGO's program, consisting of a set of aerobic exercises affecting gait, balance, stability and are adapted for older people to support them both in groups and individually. The program lasts 6 weeks (2 sessions per week) and is followed by a loyalty phase to consolidate the exercise program. Falls and fractures will be monitored quarterly for 15 months.
46037277|NCT02617303|Procedure|COMMON PRACTICE|Normal medical treatment will be provided by family physicians and nurses.
45342067|NCT02601677|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral Nucleus accumbens/Anterior Limb of Internal Capsule
45342068|NCT02601677|Drug|Fluoxetine|Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
45342069|NCT04558112|Drug|L-DOPA|two gel capsules with 100mg L-DOPA (with 25 mg carbidopa to inhibit peripheral decarboxylase)
45342070|NCT04558112|Drug|Placebo|two gel capsules of placebo
45598952|NCT03518749|Behavioral|Cognitive control training|cognitive control training with the PASAT
45342071|NCT00620776|Behavioral|Cognitive Behavioral Therapy|This cognitive behavioral therapy for GAD has a cognitive restructuring component and an applied relaxation component. Patients will be educated about the nature of anxiety and be trained in the recognition and monitoring of situational, physiological, cognitive, and behavioral cues associated with anxious responding. They will be guided through copings skill rehearsals in addition to imaginal and in vivo exposure to anxiety cues. This cognitive behavioral treatment will consist of 1 to 1.5 hour sessions of psychotherapy, which will be held once weekly over a period of 12 weeks.
45342072|NCT00620776|Drug|Venlafaxine XR|Venlafaxine XR, 75-225 mg/d, oral administration. 14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).
45342073|NCT05479097|Drug|Anti-Hypertensive|Based on information entered by the CHWs into the CommCare application designed for this study, the application will provide recommendations (and underlying rationale for these recommendations) for prescription of antihypertensives (amlodipine and/or losartan OR enalapril) and medications to reduce cardiovascular risk (aspirin and atorvastatin) if indicated, lifestyle modification, and referral to the supervising physician if indicated for potential complications of hypertension.
45342074|NCT00656019|Drug|Vitamin D|0, 2000, 4000, and 6000 IU per day orally
45342075|NCT04282226|Device|active transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS device will be attached to the left aspect of the neck to stimulate the cervical branch of the vagal nerve and connected to an MR safe electrical stimulator.
45342076|NCT04282226|Device|sham transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS device will be attached to anatomically distinct from the cervical branch of the vagal nerve.
46037278|NCT02884193|Procedure|Brief Cooling|Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
45473740|NCT03376906|Procedure|Control|In the control session, participants remained seated for 30 min. During HIIE 1 and 2, HR and RPE were assessed immediately after stimulus intervals (ten measurements at each HIIE). In all sessions, the subjects remained in supine position to obtain hemodynamic measurements which were obtained before and at 10 min, 30 min and 60 min after the HIIE and control sessions.
45473741|NCT05142735|Dietary Supplement|N-Acetylcysteine|2000 mg (4 x 500-mg tablets) every morning
45473742|NCT05142735|Dietary Supplement|Placebo|4 placebo tablets every morning
46037279|NCT02884193|Procedure|Prolonged Cold|Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the NCV.
46037280|NCT02884193|Procedure|Sham Ice Bag|"Placebo application through an ice bag empty."
46037281|NCT02787460|Behavioral|Behavioral Text Messages|
46037282|NCT04232644|Drug|ADAIR 10mg IR capsules|manipulated ADAIR IR 3x10 mg capsules
46037283|NCT04232644|Drug|Crushed d-amphetamine sulfate IR tablets|crushed d-amphetamine sulfate IR 6 x 5 mg tablets
45342077|NCT00841438|Drug|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
46037284|NCT02622529|Other|Screening through questionnaires|Distribution of Questionnaires to every participant within the single existent Arm at three times.
46037285|NCT03557788|Drug|Rifaximin Oral Tablet|PO 550mg TDS for 2 weeks
46037286|NCT04133155|Drug|nab paclitaxel plus gemcitabine|Nab-paclitaxel 125 mg/m2 weekly for 3 weeks, every 4 weeks Gemcitabine 1000 mg/m2 weekly for 3 weeks, every 4 weeks
45342078|NCT00841438|Drug|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
45342079|NCT04046367|Behavioral|Prehabilitation|Prehabilitation: The intervention of a physiotherapist will be added to the components of the control group. Patients will receive practical instructions on aerobic and resistance physical activity, as well as training of their inspiratory muscles.
45342080|NCT04046367|Behavioral|Control|Standard group intervention. Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, as well as standard instructions to increase physical activity.
45342081|NCT00782483|Device|ThermoVision A20M Infrared Camera|FLIR Systems, Boston, MA. This is a non invasive passive thermal imaging device with less than minimal risk to subjects and staff.
46037287|NCT01190267|Drug|asenapine|asenapine 2.5 mg or 5.0 mg sublingual tablets, administered BID
45342082|NCT00782483|Device|ScleroPLUS|Sclerolaser, Candela Corp., Wayland, MA. This laser is approved by the food and drug administration (FDA) for treating PWS lesions and will be used as labeled.
45342083|NCT00782483|Device|3D Digital Camera|3dMD, Atlanta, GA. Approved by the food and drug administration (FDA) for imaging patients and will be used as labeled.
45342084|NCT02573090|Procedure|Non-invasive resin based fissure sealing|The dentists use resin based fissure sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
45342085|NCT02573090|Procedure|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
46037288|NCT02622763|Biological|Tolerogenic Dendritic Cells|Intralesional administration
46037289|NCT02787382|Device|echocardiographic examination|"Patients will undergo echocardiography (us) starting at the time of the first referral and every 3-4 weeks until delivery and at the 2-7th day birth. Cardiac scans of fifty pregnant women the healthy women from the group will serve as controls at the 2-7th day birth. Cardiac scans of fifty pregnant women and the healthy women from the group will serve as controls~EXPECTED RESULTS Subtle myocardial deformation abnormalities are expected to be commonly found in fetuses and infants with CMV infection."
46037290|NCT03279874|Other|Interviews|Semi-structured one-on-one interviews
46037291|NCT00869089|Drug|CC-10004|30mg,oral medication, BID, for 24 weeks (60mg total DAILY)
46037292|NCT01190189|Biological|GSK580299 (Cervarix)|3-dose schedule intramuscularly vaccination
45342086|NCT04798521|Other|Tele-HCV|Patients will be prescribed HCV medication treatment for 4 weeks at a time. The study pharmacist will check in with the participant by telephone or telemedicine visit at week 0, week 4, and end of treatment to 1) determine general medication tolerance, 2) assess quality of adherence and 3) dispense medications. Peers will assist participants in keeping telehealth appointments and navigating medication pick up or storage. HCV labs will be repeated at 12 weeks post end of treatment and results will be relayed to the participant in the SVR12 follow up visit with the research assistant, along with follow up surveys. Those successfully achieving SVR12 will be counseled on ongoing harm reduction methods. Those showing persistent HCV viremia at 12 weeks post treatment will be referred to community-based HCV treatment providers for treatment re-initiation.
45473743|NCT01172405|Drug|Ibuprofen plus caffeine|One or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
46037293|NCT04232488|Procedure|coronary angiography using distal radial artery|Patients undergoing coronary angiography with or without percutaneous coronary intervention will be catheterised using distal radial artery ('snuff box'); color doppler will be performed after 3 months to estimate eventual occlusion of the radial artery
46037294|NCT04232488|Procedure|coronary angiography using proximal radial artery|Patients undergoing coronary angiography with or without percutaneous coronary intervention will be catheterised using proximal radial artery; color doppler will be performed after 3 months to estimate eventual occlusion of the radial artery
46037295|NCT02616367|Drug|liposomal bupivacaine Periarticular injection|Liposomal bupivacaine used for a periarticular injection in the knee
46037296|NCT02616367|Drug|Ropivacaine Periarticular Injection|Periarticular Injection for the knee with ropivacaine
45473744|NCT01172405|Drug|Ibuprofen|One or two tablets of ibuprofen 400 mg when presenting headache.
46037297|NCT05347264|Other|gun massager|15 to 20 minutes along with hot pack.
46037298|NCT05347264|Other|transverse friction massage|15 to 20 minutes along with hot pack.
46037299|NCT04200118|Other|Observational|non intervention
46037300|NCT04200040|Biological|OrienX010 injection|"OrienX010 to be used in this study have been developed and manufactured by OrienGene Biotechnology Ltd.~Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd."
46037301|NCT04200040|Drug|Dacarbazine (DTIC)|Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd.
46037302|NCT00871117|Biological|GSK Biologicals'Kinrix®|One dose as intramuscular injection at visit 1
46037303|NCT00871117|Biological|Merck and Company's MMRII|One dose as subcutaneous injection at visit 1
46037304|NCT00871117|Biological|Merck and Company's Varivax|One dose as subcutaneous injection at visit 1 or at visit 2
46037305|NCT05346796|Behavioral|Survivorship Care Plan-Personal Health Record (SCP-PHR)|The SCP-PHR tool is an online portal that is intended to help cancer survivors manage their survivorship care.
46037306|NCT04232722|Drug|Arsenicals|As4 S4
46037307|NCT02787070|Drug|PQ supervised|
46037308|NCT02787070|Drug|PQ unsupervised|
46037309|NCT02622685|Drug|DWP10292|Drug: DWP10292 tablets, oral administration, multiple administration
46037310|NCT02622685|Drug|DWP10292 Placebo|Placebo tablets, oral administration, multiple administrations
46037311|NCT02622685|Drug|Ursodeoxycholic acid (UDCA)|Drug: Ursodeoxycholic acid (UDCA) tablets, oral administration, multiple administration
46037312|NCT02622685|Drug|UDCA Placebo|Placebo tablets, oral administration, multiple administrations
46037313|NCT02622607|Drug|Zoledronic acid|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride)
46037314|NCT02622841|Procedure|BLEND|Stereotactic bodyradiotherapy and surgical stabilization within 48 hours.
46037315|NCT02622451|Behavioral|Teen Intervene|Teen Intervene (TI) is an early intervention program for 12-19 year olds who display early stages of alcohol or drug use. TI uses motivational interviewing, goal setting, and skill training to foster the internal development of responsible decision-making with the goal of choosing attitudes and behaviors that are healthier alternatives to drug use behaviors.
45342087|NCT04798521|Other|Community Linkage to Care|Following study inclusion and enrollment, research staff will refer the participant to a local community health clinic to engage in hepatitis C care and seek treatment. Peers will assist patients to engage with local primary care and health plan resources and will receive an information sheet on optional clinics to attend and questions to ask their provider.
45342088|NCT05505227|Behavioral|Stigma-reduction training|While the details will be finalized by the intervention working group after the key modifiable features of OUD-stigma among rural HCPs are isolated in Aim 1, our intervention will include several new elements that distinguish it from existing stigma-reduction interventions. The prototype intervention includes several modules aimed at decreasing stigma, increasing knowledge about medications for OUD, and increasing willingness to prescribe buprenorphine (see Table 3) among rural HCPs currently in practice.
45598953|NCT02346123|Genetic|Gathering of samples of genetic material|The samples will be obtained from peripheral blood mononuclear cells and the genotyping of the polymorphisms will be done by real time PCR.
45598954|NCT03514693|Procedure|PVI|Ipsilateral circumferential PVI is the recommended PVI strategy. The success of PVI is defined as the achievement of the dissociation of PV potentials in all PVs. Disappearance of PV potentials is reconfirmed at the end of the procedure, a minimum of 20 minutes after the initial success of PVI.
46037316|NCT02622451|Behavioral|Everyday Parenting|Everyday Parenting is a family-focused intervention that works with parents to provide environmental scaffolding necessary to help teens gradually internalize decision-making skills that reinforce and promote healthy lifestyle alternatives.
46037317|NCT02619565|Other|blood samples|blood samples at Day 0 and also if there is an evolution of the disease
46037318|NCT03181750|Behavioral|Patient Navigator Intervention Group|Bicultural, bilingual navigators conducting home visits with patients and caregivers.
46037319|NCT02616445|Drug|UE2343|"UE2343~10mg, 20, 35mg~twice daily for 9 days"
46037320|NCT02616445|Drug|Placebo|"10mg, 20, 35mg~twice daily for 9 days"
46037321|NCT02616445|Drug|Placebo|"Cross-over study~single dose administered twice (on day 1 and day 8)~study duration 17 days"
45342089|NCT05505227|Behavioral|Placebo|HCPs affiliated with clinics in the control arm will receive no training but will be provided with a link to the SAMHSA website where prescribers can learn more about buprenorphine prescribing and apply to receive an X-waiver.
45342090|NCT02546830|Device|FreeO2 v2.2 active|"Automatic adjustment of oxygen through the Free O2 device.~FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
45342091|NCT02546830|Device|FreeO2 v2.2 with manual oxygenation|"Manual adjustment of oxygen without the assistance of the FreeO2 device.~Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
45342092|NCT00802269|Procedure|Retinal laser photocoagulation|Retinal laser photocoagulation using a 532 nm laser
45342093|NCT02601443|Device|Cervical Pessary|
46037322|NCT02616445|Drug|UE2343|"Cross-over study~UE2343~single dose administered twice (on day 1 and day 8)~study duration 17 days"
45342094|NCT02573480|Behavioral|Wraparound care|Wraparound care starts by linking an individual with a support worker who works with them to address risk factors and empower the individual to make positive choices. It not only includes connecting the youth with existing community resources such as education, employment, cultural services and substance counselling, it also helps build problem-solving skills, coping skills, and self-efficacy of the youth and family members. The support worker provides mentorship to the youth. Mentorship both teaches and emulates appropriate behaviours with respect to attitudes and behaviours associated with violence.
45342095|NCT00841516|Other|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection.
46037323|NCT02616445|Drug|UE2343|"UE2343~twice daily for 3 days~single dose on day 4"
46037324|NCT02622373|Device|PEA POD Infant Body Composition System|The non-invasive device used in this study to measure a baby's body composition is a called a Pea Pod. The Pea Pod is a quick, safe, non-invasive and reliable bedside procedure used to measure changes in infant body composition.
46037325|NCT02787226|Drug|Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension.
46037326|NCT02787226|Drug|Continuous Perineural Ropivicaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine.
46037327|NCT00697567|Biological|Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant|Intramuscular injection, 3 doses
46037328|NCT00697567|Biological|Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant|Intramuscular injection, 3 doses
46037329|NCT02787148|Behavioral|Cognitive behavioral therapy|
45342096|NCT00841516|Biological|rBet v1-FV|Placebo was given the same way as a subcutaneous (just under the skin) injection.
45342097|NCT03985163|Other|Patient Reported Outcomes Electronic Survey|This study does not include a drug, test, behavioral or medical procedure intervention; participants will be asked to complete three surveys
45342098|NCT04069832|Behavioral|Single-Session Consultation|A single, goal-directed consultation session based on Solution-Focused Brief Therapy (SFBT). SFBT is an evidence-based therapy approach that is primarily focused on the client's present problems and their immediate future. When using SFBT in a single-session the aim of the intervention becomes empowering the client to take the smallest possible steps towards their desired future.
45598955|NCT03514693|Procedure|PVI plus additional ablation|In addition to PVI, CFAE ablation, linear ablation, or both; the choice of which is decided by the physician
45598956|NCT02233049|Drug|Erlotinib|
45598957|NCT02233049|Drug|Everolimus|
46037330|NCT02616289|Other|Topical emollient (Sun Flower seed oil)|3 g of oil per kg of infant's weight at study entry of Sunflower Seed oil (SSO) will be applied three times per day at regularly spaced intervals (8-hour intervals) for 10 days. Oil will not be applied to the face (to avoid the possibility of any accidental aspiration or ingestion), ears or under the hairline. Care will be taken to not injure the skin during the massage treatment. The child's anal area will be washed prior to application to avoid the spread fecal flora from the anal region (to which the oil will be applied to last). Prior to bathing the child a minimum of 3-4 hours should have elapsed following the application of the SSO. The amount of oil required will be calculated based on the child's weight and the required amount weighed out each time.
45598958|NCT02233049|Drug|Dasatinib|
45598959|NCT02350725|Drug|Furosemide injection solution for subcutaneous administration (80 mg)|
45598960|NCT02350725|Drug|Oral Furosemide tablets (80 mg)|
45598961|NCT02297035|Behavioral|Behavioural testing|
45598962|NCT02297035|Other|Brain imaging|MRI, PET
46037331|NCT03421756|Drug|Alemtuzumab|Alemtuzumab is a non-myeloablative pre-transplant conditioning regimen. Non-myeloablative therapy uses doses of chemotherapy and radiation to weaken (but not destroy) the patients bone marrow and immune system, while still allowing their body will accept the donor's stem cells. Alemtuzumab will be given 7 days prior to stem cell infusion at 0.03 mg/kg IV, 6 days prior to stem cell infusion at 0.1 mg/kg IV, and 5 thru 3 days prior to stem cell infusion at 0.3 mg/kg IV.
45342099|NCT00841594|Drug|nitroglycerin 0.9 % (MXQ-503)|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
46037332|NCT03421756|Radiation|Total Body Irradiation|300 cGy will be administered in a single fraction on Day - 2. TBI is used commonly as part of pre-transplant conditioning in a variety of settings.
45342100|NCT00841594|Drug|Nitroglycerin ointment 2%, USP|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
45342101|NCT04068974|Drug|Camrelizumab (SHR-1210)|Anticancer T-cell activity is regulated by multiple suppressive mechanisms, including tumour-expressed programmed cell death ligand 1 (PD-L1) signalling to the T-cell inhibitory receptor (programmed death protein 1 [PD-1]). Monoclonal antibodies like SHR-1210 that can block this pathway.
46037333|NCT03421756|Drug|Sirolimus|Sirolimus will be used for the prevention of graft-verus-host disease and will begin on Day - 1.
46037334|NCT00870103|Drug|Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops|1 drop every 6 hours into the study eye
46037335|NCT02619487|Other|text message to parent only|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
46037336|NCT02619487|Other|text message to parent and adolescent|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
46037337|NCT03365752|Drug|Chloroprocaine|A spinal anesthetic with 2% chloroprocaine (2cc or 40 mg) will be performed
45342102|NCT04068974|Drug|Apatinib|Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2.
45342103|NCT00836290|Behavioral|Pre-Release (Group 1)|Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
45342104|NCT00836290|Behavioral|Post-release (Group 2)|Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
45342105|NCT00782171|Device|SLActive dental implant|"Straumann® SLActive implants will be placed. Implants in Arm 1 will be restored with a temporary restoration on the day of surgery.~Implants in Arm 2 will receive healing caps immediately after surgery and a provisional restoration will be placed between day 28 to day 34 post-surgery.~In both arms, the final restoration will be placed between 140 and 160 days (20 to 23 weeks) post-surgery."
45598963|NCT02297035|Genetic|Genetic screening|APOE, Progranulin
46037338|NCT03365752|Drug|Mepivacaine|A spinal anesthetic with 1.5% Mepivacaine (3cc or 45 mg) will be performed
46037339|NCT03365752|Drug|General Anesthetics|General anesthetics will be administered intravenously
46037340|NCT02622217|Behavioral|Sleep deprivation|
46037341|NCT04133467|Other|scalp block|intravenous acetaminophen according to the body weight, plus intravenous tramadol 1 mg/kg)
46037342|NCT02619643|Device|Transcranial Magnetic Stimulation (Magstim)|
46037343|NCT04232410|Diagnostic Test|Drug induced sleep endoscopy|DISE is performed in a semi-dark, silent operating theatre, starting with the patient in supine position. To first induce sleep, an IV bolus of midazolam (1.5 mg) is administered. Then, a flexible fiberoptic nasopharyngoscope (Olympus END-GP, 3.7 mm diameter, Olympus Europe GmbH, Hamburg, Germany) is inserted through one of the nostrils. Either at the start of the examination or while holding the scope at the level of the palate, propofol (2.0-3.0 µg/ml) will be administered via a target-controlled infusion (TCI) pump. Sleep occurrence is confirmed using the additional EEG measurement.
46037344|NCT04232410|Diagnostic Test|Measurement of critical closing pressure of the uppper airway|After sleep onset, the CPAP pressure well be increased until no flow limitations are observed. This pressure is called the holding pressure and is used as a base for all the following measurements for that individual OSA patient. After observing sleep stage 2 or 3, the holding pressure is reduced abruptly by 1 cmH2O during expiration for 5 breaths. Then the pressure is set back to the holding pressure for the duration of 1 minute. This procedure is repeated until obstructive sleep apnea is noted.
46037345|NCT02616133|Other|chart abstraction|abstraction of breast cancer patients with de-identified data
46037346|NCT02785666|Drug|grazoprevir/elbasvir, ribavirin|To investigate the virological efficacy and safety of grazoprevir/elbasvir ±ribavirin for HIV/HCV-coinfected MSM with a GT 1 and/or 4 infection
45598964|NCT02350959|Drug|Atorvastatin|in moderate dosea statin group, atorvastatin 10mg will be used and maintained until follow up angiography
45598965|NCT02350959|Drug|Atorvastatin|in high dose statin group, atorvastatin 40mg will be used and maintained until follow up angiography
45683654|NCT04305106|Other|Standard care|Standard care, including prophylactic doses of low molecular weight heparin or unfractionated heparin without contraindications, and therapeutic doses of anticoagulants with the evidence of thrombosis risk or occurrence.
45598966|NCT04088357|Drug|TolaSure Topical Gel|TolaSure topical gel is applied to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.
46037347|NCT02785666|Behavioral|Behavioural Intervention|To counsel the targeted population with a behavioral intervention regarding the reduction of sexual risk behaviour and recreational drug use.
46037348|NCT01145417|Drug|pregabalin (Lyrica)|150 mg-600 mg/day (twice daily)
45473745|NCT03381976|Other|Intervention 2X/week (G2X)|Participants performed resistance training (RT) composed of eight exercises performed for one set of 10-15 repetition maximum (RM). The rest interval between exercises was 2-3 min. Participants were instructed to control the speed of movement in the ratio of 1:2 for concentric and eccentric muscle actions, respectively. The progression of training loads in each exercise occurred, when a participant completed 15 repetitions in two consecutive sessions, with increases of 2-5% in exercises for the upper limbs, and 5-10% in exercises for the lower limbs. At the end of each session, one static stretching exercise at the point of discomfort for 15 seconds was performed for all major muscle groups for a total of exercises. Participants were asked not to perform any other type of organized physical exercise during the entire study period.
46037349|NCT02622139|Device|Multispectral Optoacoustic Tomography (MSOT)|MSOT for the evaluation of disease activity in IBD patients
46037350|NCT04232332|Drug|Recombinant human nerve growth factor injection,experimental|Intramuscular injection once on the first day according to dose requirements
46037351|NCT04232332|Drug|Recombinant human nerve growth factor injection,single dose|Intramuscular injection once on the first day according to dose requirements
46037352|NCT04232332|Drug|Recombinant human nerve growth factor injection,multiple dose|Intramuscular injection once daily for 7 days according to dose requirements
46037353|NCT04135183|Procedure|changes of Pneumonia Severity Score|assessing effectiveness of CAP treatment by using continuous pneumonia severity score
46037354|NCT02785276|Device|AutoFuser Pain Pump|Closed loop local anaesthetic infusion system
46037355|NCT02785276|Drug|Ropivacaine|Commonly used local anaesthetic drug
46037356|NCT02785276|Other|Normal Saline (0.9%)|Normal saline is a sterile, non-pyrogenic solution for fluid and electrolyte replenishment for intravenous administration. This will be the solution used for the intraperitoneal infusion in the placebo/control group.
46037357|NCT00696553|Other|Tailored Nutrition Intervention|Provision of individualized nutrition counseling and nutrition support using oral liquid nutrition supplements and/or liquid enteral supplements
46037358|NCT00696553|Behavioral|Nutrition plus Exercise|Nutrition plus Exercise
46037359|NCT04316039|Drug|Temozolomide|Concurrent chemotherapy is to receive oral temozolomide, 75 mg/m2 per day, during radiation therapy. Adjuvant chemotherapy will be treated with six cycles of temozolomide, 150 to 200 mg/m2 per day for five consecutive days, repeated every 4 weeks. There is a 28-day break during radiotherapy and adjuvant temozolomide.
45342106|NCT02572700|Other|Clinical examination, blood sampling, ultrasonic assessment, and questionnaires|Visits include clinical examination, questionnaires (pain, comorbidity, lifestyle, work status) and ultrasonography of joints and entheses, blood samples, and only at baseline x-ray of hands and feet.
46037360|NCT04316039|Radiation|intensity modulated radiation therapy|The radiation dose is 50-54 Gy given in 25-30 fractions (1.8-2.0 Gy once daily, 5 days per week).
46037361|NCT04199416|Device|mRehab app|The mRehab app will be an interactive system with a user-friendly graphical user interface to provide multiple motivational functions that engage individuals in their prescribed home exercises. The app will contain video-based lower limb strengthening and aerobic exercise materials, health information, and motivational functions to increase their access to rehabilitation and care resources to augment their self-management ability.
46037362|NCT04199416|Device|Sham app|The sham app will only contain educational components and text-based exercise recommendations.
45598967|NCT04088357|Drug|Topical Vehicle Gel|TolaSure Vehicle Gel is applied topically to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.
45342107|NCT00836368|Dietary Supplement|gamma-tocopherol|oral doses 1,200 mg of gamma tocopherol (2 capsules of the gamma tocopherol enriched vitamin E preparation)
45598968|NCT02297113|Device|Macintosh blade|conventional endotracheal intubation
45598969|NCT02297113|Device|C-MAC videolaryngoscope|
45598970|NCT02350803|Device|mini plate|in the intervention group, 4 L shaped titanium mini plates with 16 screws were fixed immediately after distraction phase and removal of distraction ossteogenesis to prevent the relapse after distraction
45683655|NCT01603875|Biological|New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).|new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention
45683656|NCT01770392|Drug|Nintedanib|single dose administration
45683657|NCT01770392|Drug|Rifampicin|single dose once daily for 7 days
45683658|NCT01770392|Drug|Nintedanib|single dose administration
45683659|NCT02020564|Behavioral|Speed of Processing Training|
45683660|NCT02020564|Behavioral|Placebo Control|
45683661|NCT01603641|Biological|Botulinum Toxin Type A|Participants received intramuscular injections of botulinum toxin Type A into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
45683662|NCT02018692|Dietary Supplement|Alga Dunaliella Bardawil powder|9 cis beta carotene rich Alga Dunaliella Bardawil powder
45683663|NCT02018692|Dietary Supplement|Placebo:Starch|Starch powder
45683664|NCT03492112|Device|HCV RNA Point of Care|Participants attending needle syringe programmes in Australia will be screened for hepatitis C using the finger-stick whole blood GeneXpert HCV RNA cartridge.
45683665|NCT03492112|Drug|Sofosbuvir/velpatasvir|Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
45683666|NCT03492112|Drug|Glecaprevir/pibrentasvir|Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
45683667|NCT04397380|Device|Thermography|Measure Temperature using Thermal Camera
45683668|NCT04397380|Device|Tympanic Temperature|Measure Temperature using Tympanic Temperature
45683669|NCT01556763|Drug|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
45683670|NCT01556763|Drug|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
45683671|NCT01556763|Drug|Placebo|Matching placebo was administered as one capsule per day for 21 days.
45683672|NCT01556763|Drug|Antipsychotic therapy|Concomitant therapy with antipsychotic medication (aripiprazole [10 to 30 mg/day], olanzapine [10 to 20 mg/day], paliperidone [3 to 12 mg/day], or risperidone [2 to 16 mg/day]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.
45683673|NCT04397458|Drug|Saline|0.9% saline on each side
45683674|NCT04397458|Drug|Bupivacaine|0.25% bupivacaine (50mg) on each side
45683675|NCT04397458|Drug|Dexamethasone|3mg preservative-free dexamethasone on each side
45473746|NCT03381976|Other|Intervention 3X/week (G3X)|Participants performed resistance training (RT) composed of eight exercises performed for one set of 10-15 repetition maximum (RM). The rest interval between exercises was 2-3 min. Participants were instructed to control the speed of movement in the ratio of 1:2 for concentric and eccentric muscle actions, respectively. The progression of training loads in each exercise occurred, when a participant completed 15 repetitions in two consecutive sessions, with increases of 2-5% in exercises for the upper limbs, and 5-10% in exercises for the lower limbs. At the end of each session, one static stretching exercise at the point of discomfort for 15 seconds was performed for all major muscle groups for a total of exercises. Participants were asked not to perform any other type of organized physical exercise during the entire study period.
46037363|NCT00697645|Device|Deep TMS (Transcranial magnetic stimulation)|All participants will receive standard medical and rehabilitation therapy for stroke without any restrictions. In addition, patients recruited for the study will receive 7 sessions of TMS with the Brainsway device delivered over the motor strip of the affected hemisphere. Each session will last for 15 minutes and the brain will be stimulated at 10Hz. Each TMS train will contain 20 pulses (2 seconds) and the inter train interval will be 20 seconds. Each session will contain 40 trains. Sessions will begin on day 3-5 after stroke onset and will be given every day, excluding weekends, for 10 days. All deep TMS will be performed in a dedicated room under the observation of an unblinded investigator. Patients will be monitored daily until discharge from the hospital, or until the end of the treatment, whichever is earlier. All assessments will be performed by investigators blinded to the therapy group.
46037364|NCT00697645|Device|Brainsway Deep TMS|Deep TMS applied over the motor strip
46037365|NCT02786680|Behavioral|stroop test in condition DBS off|Patients were evaluated in DBS Off
46037366|NCT02786680|Behavioral|stroop test in condition DBS on|Patients were evaluated in DBS On
46037367|NCT00697723|Procedure|Transit-time flowmetry|Transit-time flowmetry during 1:1 IABP assistance and when IABP is turned off
46037368|NCT01144715|Device|Hand Mentor (TM) robotic stroke therapy device|The goal of the Hand Mentor ™ (TM) device is to improve Active Range of Motion in the distal musculature of the paretic limb of patients with stroke. Development of HM patient protocols are based on basic principles of motor learning: the protocols actively engage the patient in activities, progressively increase task difficulty based on patient performance, actively assist patient if necessary (i.e. patient is not passive), provide meaningful feedback at regular intervals, require sensorimotor integration and incorporate the use of tasks that that are intended to transfer to distal motor performance.
46037369|NCT01144715|Device|Home Therapy Program|Subjects in the control group will be instructed in a self administered home therapy program
45473747|NCT02966691|Other|VisioCyt® diagnostic test|The cytology slides obtained from the current practice will be compared to the slides obtained with the Visiocyt protocol, for each arm.
46037370|NCT00696631|Drug|Dronedarone (SR33589)|oral administration
46037371|NCT00696631|Drug|Placebo|oral administration
46037372|NCT04198324|Procedure|Closure of the uterus with endometrium at the time of cesarean|Closure of the uterus at the time of primary cesarean will be performed with suturing the endometrium.
46037373|NCT04198324|Procedure|Closure of the uterus without endometrium at the time of cesarean|Closure of the uterus at the time of primary cesarean will be performed without suturing the endometrium.
46037374|NCT02615977|Behavioral|Zooming Joystick Task|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
45473748|NCT01166867|Device|Photo-plethysmography monitoring|monitoring vital sign in infant
45473749|NCT04000165|Drug|AG-348|This is a nonrandomized, intra-patient dose escalating clinical study. AG-348 will be administered starting at 5 mg twice a day, increasing to 20 mg twice a day, to maximum 50 mg or 100 mg twice a day. Dosing period is every 2 weeks at each dose level. Dose taper will start on Day 42 (50 mg) or Day 56 (100 mg) with dose reduced over 12 to 15 days.
45342108|NCT00718796|Other|Naturopathic medicine. May include: fish oil, plant sterols, soluble fiber, cinnamon, coQ10 and exercise|Individualized according to needs of each participant and willingness to comply. Intervention to include lifestyle modification, dietary changes and supplementation using natural health products as recommended by naturopathic practitioner.
45473750|NCT03376828|Device|Macintosh laryngoscopy|Endotracheal intubation time using the Macintosh laryngoscope
45473751|NCT03376828|Device|C-Mac Videolaryngoscope|Endotracheal intubation time using the C-Mac Videolaryngoscope
45473752|NCT02526563|Procedure|ropivicaine|Blood draws to measure serum ropivicaine
45683676|NCT04397146|Dietary Supplement|Oral Nutrition Supplement (ONS)|Consumption of a portion of 300-320kcal (based on a standard single serve for ONS products) with a two hour follow-up. Products include: 2 Prototype Oral Nutrition Supplements (ONS) with 2.4kcal/ml and respectively 9.6% protein and 14.4% protein; 6 Commercially available Oral Nutrition Supplements with varying energy and protein levels.
45683677|NCT04398316|Drug|Lidocaine Iv|2 mg/kg over 5 minutes
45683678|NCT04398316|Drug|HYDROmorphone Injection|1 mg over 5 minutes
45473753|NCT03375424|Biological|vedolizumab|duration of disease and kind of therapy
45473754|NCT01172483|Procedure|general practice in primary care and education|education of chronic disorders in PC
45473755|NCT01172483|Other|Multimodal community program|The intervention was an 8-week programme of MMPP combined with DWR, delivered by physiotherapists in groups of 8 to 10 participants. One-hour sessions were conducted 3 times per week, consisting of DWR and an individualised MMPP of therapeutic exercises combined with education based on cognitive-behavioural principles. Each session was comprised of 30 minutes of land-based exercise followed by 20 minutes of DWR, with an additional 10 minutes of warm-up and cool-down time. Deep water running stimulates running using a flotation device in water levels over head height. During the first two weeks of the intervention, participants undertook a low-intensity adaptation interval to learn proper exercise technique. For the remaining six weeks, participants were instructed to maintain a constant speed to achieve the prescribed HRAT. If experiencing pain while exercising, participants were asked to temporarily reduce intensity and return to target HR as capable.
45473756|NCT03187197|Drug|Pradaxa®|Dabigatran etexilate
45473757|NCT03375346|Device|Whole body vibration|whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.
45473758|NCT03375346|Other|Exercise|maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees
45473759|NCT01284647|Drug|Teprenone capsule and placebo of sucralfate|Teprenone 1 capsule (50mg)+placebo of sucralfate 4tab, tid×8 weeks.
45683679|NCT01576575|Drug|Buprenorphine Control|Control (no pretreatment) - intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)
45683680|NCT01576575|Drug|Buprenorphine + Rifampin|Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine
45342109|NCT00718796|Other|Conventional medical treatment (Atorvastatin,Fluvastatin,Lovastatin,Pravastatin,Rosuvastatin,Simvastatin)|Will vary according to individual - not standardized and likely to include statins.
45342110|NCT00844168|Drug|sorafenib tosylate|Given orally
45342111|NCT00844168|Other|laboratory biomarker analysis|Correlative studies
46037375|NCT02615977|Behavioral|Zooming Joystick Task (Placebo)|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
45473760|NCT01284647|Drug|Sucralfate and placebo of teprenone|Placebo of teprenone 1 capsule+ sucralfate 4 tab(1.0), tid×8 weeks
45342112|NCT02573168|Genetic|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
45683681|NCT01576575|Drug|Buprenorphine + Grapefruit juice|Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine
46037376|NCT01189487|Drug|ampicillin sodium/sulbactam sodium|ampicillin sodium/sulbactam sodium is administered 12g/day (3 g four times a day) intravenously for 3 to 14 days
46037377|NCT02786602|Genetic|pyrosequencing|
46037378|NCT02621905|Drug|Sporanox|At least 2 capsules twice a day for 3 weeks
45342113|NCT02573168|Genetic|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
45342114|NCT02573168|Other|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
45342115|NCT00836446|Other|physical activity|physical activity routines 5 times a weeks for 12 weeks.
45342116|NCT00841750|Procedure|Do not leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, an air leak proof will take place and if no air leak is noted, the surgical incisions for thoracoscopy ports will be closed without leaving a chest tube inserted in the pleural cavity of the patient.
45342117|NCT00841750|Procedure|Do leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, a chest tube will be inserted in the pleural cavity of the patient through the inferior surgical incision for thoracoscopy port; the rest of the incisions will be closed.
45342118|NCT02574884|Procedure|Blood sample (act specific of blood withdrawal for the study)|Specific intervention : blood sample (3x7 ml in total)
45342119|NCT00836524|Procedure|ultrasound|4 ultrasound examinations during pregnancy and every time a blood sample is colletted. blood sample from the mother and the umbilical cord is collected as well
45342120|NCT00764465|Drug|Maraviroc|300 mg BID
45342121|NCT00764465|Drug|Fosamprenavir|1400 mg BID, 700 mg BID or 1400 mg QD
45342122|NCT00764465|Drug|Ritonavir|100 mg BID, 100 mg QD
45342123|NCT02546752|Other|THEO|THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). THEO is the intervention in this study.
45342124|NCT00715832|Biological|Dendritic Cell Vaccination|Autologous dendritic dells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally
45473761|NCT04000009|Drug|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
45473762|NCT03381898|Behavioral|Telehealth Exercise, speech therapy, medication management|Telehealth exercise once per week, speech therapy 4 times per week, medication management once per week
45683682|NCT01576575|Drug|Buprenorphine + Ketoconazole|Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine
45683683|NCT05051566|Drug|LY3502970|Administered orally.
46037379|NCT02621905|Drug|Lozanoc|At least 2 capsules twice a day for 3 weeks
46037380|NCT02785198|Device|Passive knee extensor machine|The passive training machine, moves both legs from flexion to extension and back, 60 times per minute in 1 hour, 3 times per week. ROM is 60 degrees
46037381|NCT04134247|Drug|PD-1 combined with chemotherapy|"PD-1 200 mg，d1; Rituximab 375mg/m2，d0（ the same as the chemotherapy group）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3"
46037382|NCT04134247|Drug|chemotherapy|"Rituximab 375mg/m2，d0（ Except for patients who relapsed within12 months after the last application of rituximab）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3"
46037383|NCT04232098|Other|Heat to ankle|Heat administered via hot water to ankle level
46037384|NCT04232098|Other|Heat to calf|Heat administered via hot water to calf level
45683684|NCT05051566|Drug|Esomeprazole|Administered orally.
45473763|NCT01280045|Procedure|VAGINAL HYSTERECTOMY|GOSERELINE ACETATE 10.8 MG FOR THREE MONTHS; ANASTROZOL ACETATE FOR THREE MONTHS
45473764|NCT03282240|Biological|QIV-HD|0.7 mL-dose was administered intramuscularly (IM) into the upper arm area.
45473765|NCT03282240|Biological|Licensed TIV-HD1|0.5 mL-dose was administered IM into the upper arm area.
45473766|NCT03282240|Biological|Investigational TIV-HD2|0.5 mL-dose was administered IM into the upper arm area.
46037385|NCT01106352|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection.
46037386|NCT01106352|Drug|Docetaxel|Docetaxel (75 mg/m^2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m^2 is allowed as per the approved docetaxel label.
45342125|NCT05525117|Behavioral|covivio (additional to treatment as usual)|Covivio is a dialogue-based online psychological intervention for patients with type 2 diabetes. This intervention includes elements that address disease literacy, physical activity and exercise, dieting and nutritional principles, coping with depression, etc. Content is adapted to users needs using interactive dialogues, illustrations and audio files. Participants may also continue with their usual treatment.
45342126|NCT05525117|Other|treatment as usual|Participants may continue with any treatment that they require (treatment as usual)
45342127|NCT04069598|Diagnostic Test|Statin intolerance test|Statin intolerance test
45342128|NCT00836602|Drug|BMS-779788|Oral Solution, Oral, 1 mg, Once daily, 7 days
45342129|NCT00836602|Drug|BMS-779788|Oral Solution, Oral, 2 mg, Once daily, 7 days
45342130|NCT00836602|Drug|BMS-779788|Oral Solution, Oral, <= 4 mg, Once daily, 7 days
45473767|NCT01177865|Other|informational intervention|
45473768|NCT01177865|Other|questionnaire administration|
45473769|NCT03185949|Device|Endobar Infusion Catheter System|Bariatric embolization with microspheres using Endobar Infusion Catheter System
45473770|NCT03185949|Behavioral|Behavioral therapy|Healthy diet and exercise
45683685|NCT01555983|Drug|Vaporization of Cannabis|Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC
46037387|NCT01144403|Drug|Cyclophosphamide|as prescribed, 6 cycles
45342131|NCT00836602|Drug|Placebo|Oral Solution, Oral, 0 mg, Once daily, 7 days
45473771|NCT01284725|Drug|mycophenolate mofetil or azathioprine|
45473772|NCT01284725|Other|immunosuppressive treatment discontinuation|
46037388|NCT01144403|Drug|Fludarabine|as prescribed, 6 cycles
46037389|NCT01144403|Drug|Mitoxantrone|as prescribed, 6 cycles
46037390|NCT01144403|Drug|Rituximab|375 mg/m^2 intravenously, Day 1 of each 28-day cycle, up to 8 cycles
46037391|NCT03071926|Drug|Pegylated Liposomal Doxorubicin|20 mg, qw, first 6 weeks ,every 8 weeks
45342132|NCT00655863|Drug|Alogliptin and Pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.
45683686|NCT01576341|Drug|HX575 epoetin alfa (Sandoz)|Eligible patients are scheduled to receive HX575 (INN: Epoetin alfa) as a solution for injection in order to achieve or maintain the correction of renal anemia.
45683687|NCT04276090|Device|Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.|Patients will undergo surgical hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.
45683688|NCT04276090|Drug|Hepatic artery infusion pump floxuridine and dexamethasone|Patients will receive infusion of floxuridine (FUDR) and dexamethasone via hepatic artery infusion through the implanted pump
46037392|NCT02619331|Procedure|Allergy test reading|Reading of allergy skin tests (in response to allergen extracts or histamine or negative control) by HSL-DI versus direct observer evaluation (CWFM)
46037393|NCT03061552|Diagnostic Test|sonographic measurement of inferior vena cava diameter|pre-dialysis measurement of inferior vena cava diameter using echocardiography
46037394|NCT02883647|Drug|Entecavir or Tenofovir|Patients in retreatment group receive nucleos(t)ide analogs therapy (Entecavir 0.5mg/d or Tenofovir 300mg/d) again
46037395|NCT02621827|Other|Oral dose of stable isotope labeled 25(OH)D3|At each measurement, women are given an oral dose of stable isotope labelled 25(OH)D3. Blood and urine samples are collected at baseline and on day 21 post-dose. Additional blood samples are collected post-dose on days 6,9,24,27 and 30.
46037396|NCT02615899|Other|Matched: Targeted (specific) balance exercise interventions|
46037397|NCT02615899|Other|Mismatched: Untargeted (non-specific) balance exercise interventions|
46037398|NCT02703922|Other|color Doppler ultrasound and TAB in case of CDU negative|Screening with color Doppler ultrasound followed by TAB in case of CDU negative
46037399|NCT00625157|Drug|ASF 1096 0.5 % cream|
46037400|NCT00625157|Drug|ASF 1096 placebo cream|
46037401|NCT01143389|Drug|Riboflavin|Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
46037402|NCT01143389|Device|UVX light|UVX 365 nm wavelength light source is applied with continued application of riboflavin.
46037403|NCT00868231|Drug|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 15 days.
46037404|NCT00868231|Drug|Tiotropium 18 μg once-daily|Tiotropium 18 μg once-daily via inhalation by Handihaler® dry powder inhaler: 1 puff in the morning for 15 days.
46037405|NCT00868231|Drug|Placebo|Inhaled placebo: 1 puff in the morning (placebo to tiotropium) or in the morning and evening (placebo to aclidnium) for 15 days.
46037406|NCT04231864|Biological|Durvalumab|Given intravenously (IV)
46037407|NCT04231864|Drug|Epacadostat|Given orally (PO)
46037408|NCT01101438|Drug|metformin hydrochloride|Given orally
46037409|NCT01101438|Other|placebo|Given orally
46037410|NCT02786524|Behavioral|Specialized Symptom Management and Supportive Care|Based on Patients who score 5 or higher on the Baseline Patient Palliative Care Survey that will identify patients that will most benefit from specialty palliative care
46037411|NCT02883803|Biological|Injection of mesenchymal stem cells|Injection of mesenchymal stem cells
46037412|NCT02883803|Biological|Injection of albumin alone|Injection of albumin alone
46037413|NCT00698347|Device|M2a-Magnum™ Hip System|
46037414|NCT04130581|Other|Transcranial Magnetic Stimulation (TMS)|TMS is a safe and non-invasive technique, which involves the generation of brief magnetic pulses applied to the head through a coil. The magnetic pulses pass through the scalp and skull and induce weak electric currents in the neural tissue directly underneath the coil. When TMS is applied in repetitive, patterned trains of pulses (rTMS), it can induce cortical plasticity specifically in the targeted brain region.
46037415|NCT02784886|Biological|Women at high risk of MAP|Blood sample
46037416|NCT02614573|Device|CoagucheckXSR Capillary INR measures|"We will be using the CoagucheckXSR device for capillary INR measures performed by nurses every 7 days during the 6 months of the study, plus after related intercurrent events.~If capillary INR is <2 or >3 (with a tolerance of 1.9 to 3.1 given the margin of measurement inaccuracy of the coagulometer), then a classic venous measure is performed. If both tests agree, adaptation of treatment as indicated. If slightly discordant results, then the INR values are considered discordant and the decision to adjust the treatment dose and the next monitoring date for venous INR is made based on the value of the venous INR, according to the predefined protocol. If clinically significant discordance (> 0.3), a venous INR is reperformed within 24 hours and if the discrepancy persists, dose adjustment is made according to the venous INR and the predefined protocol.~If capillary INR is > 4, then verification by venous measure and refer to general practitioner."
46037417|NCT02614495|Drug|Surufatinib|Patients receive oral Sulfatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
46037418|NCT01143077|Drug|Lurasidone HCl|Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks
46037419|NCT02786446|Drug|Lidocaine gel,|2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
46037420|NCT02786446|Drug|Naproxen Sodium|Tab Naproxen sadium 550 mg per oral will be given to patients 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
45342133|NCT00655863|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
45342134|NCT00655863|Drug|Placebo|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
45342135|NCT00718874|Other|Dietary|modification of macronutrient content
45342136|NCT05672030|Other|Non-Interventional|No intervention.
45342137|NCT02572310|Device|Simplex High Viscosity Bone Cement|high viscosity bone cement for total knee replacement
45342138|NCT00836680|Device|Colorectal Stent|"Diagnosis of an internal rectal prolapse:~The device will be introduced and placed into the patient via a proctoscopic procedure. After that the doctor can measure and determine the internal rectal prolapse. After the diagnosis results have been received, the device will be removed from the patient via proctoscopic examination. The whole procedure will take approx. 5 minutes.~An additional X-ray examination procedure with the use of contrast media will be made for the determination of a pelvic floor ptosis and for the determination of an internal hernia into the Douglas pouch."
45473773|NCT03655405|Other|Individual Deprescribing Intervention|The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.
45342139|NCT00718952|Drug|Vardenafil|vardenafil tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
45342140|NCT00718952|Drug|Placebo|Placebo tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
45683689|NCT04276090|Drug|Systemic chemotherapy for colorectal liver metastases|Patients will receive disease-appropriate systemic chemotherapy for colorectal liver metastases (FOLFOX, FOLFIRI, or irinotecan/oxaliplatin, or panitumumab if KRAS/NRAS wild type)
46037421|NCT02786446|Drug|Lidocaine gel and Naproxen Sodium|Tab Naproxen sodium 550 mg per oral will be given to patients 45 minutes before ESWL and 2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
46037422|NCT02618941|Biological|AFFITOPE® PD01A|s.c. injection
45342141|NCT00718952|Drug|Vardenafil|Patients in all the 2 arms will take vardenafil tablet 5mg twice-daily orally from week 13 to week 24(open-label).
45342142|NCT00719030|Dietary Supplement|Pomegranate pill|Pomegranate extract pill
45342143|NCT00719030|Dietary Supplement|Pomegranate pill placebo|Pomegranate pill placebo
45342144|NCT00844246|Other|Developmental screening using ASQ and MCHAT|In the SRS intervention arm subjects will complete developmental screening tools with a school readiness specialist at their 9, 18, 24 and 30 month well child visits and then complete their well child visit with their primary care clinician to discuss the results.
45683690|NCT04276090|Drug|Systemic chemotherapy for intrahepatic cholangiocarcinoma|Patients will receive disease-appropriate systemic chemotherapy for intrahepatic cholangiocarcinoma (gemcitabine/oxaliplatin or gemcitabine alone)
45683691|NCT03451630|Behavioral|High-Touch|Intensive, in-person support.
46037423|NCT02784964|Biological|Elixcyte 8 ml|ADSC 6.4*10^7 cells, allogeneic injection
46037424|NCT02784964|Device|Hya Joint Plus|Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc.
46037425|NCT02784964|Biological|Elixcyte 4 ml|ADSC 3.2*10^7 cells, allogeneic injection
45473774|NCT03510598|Device|The ZELTIQ CoolSculpting System|The CoolSculpting machine will be used to perform the treatments.
45473775|NCT03510598|Drug|Kybella 20 MG in 2 ML Injection|Injectable drug called KYBELLA® (deoxycholic acid)
46037426|NCT02784964|Biological|Elixcyte 2 ml|ADSC 1.6*10^7 cells, allogeneic injection
46037427|NCT02619019|Drug|Dexamethasone|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
46037428|NCT02619019|Drug|Pethidine|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
46037429|NCT02619019|Drug|Normal saline|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
45342145|NCT00844246|Other|Developmental screening using ASQ and MCHAT|Subjects who are randomized to PCP arm will be screened for developmental delays by their Primary Care Clinician at their 9, 18, 24 and 30 month well child visits. The corresponding screening tools may be mailed to the study participants 2 weeks before the scheduled well child visits. Those who do not complete the screening tools or those who did not receive them in the mail will then complete the questionnaire in the office prior to seeing their doctor or with their doctor. The PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI referral will be completed, at the discretion of the provider with the approval of the caregiver , if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
45342146|NCT00781937|Drug|liraglutide|Liraglutide 3.0 mg per day administered in a 6.0 mg/mL, 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
45342147|NCT00781937|Drug|placebo|Liraglutide placebo 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
45342148|NCT00802581|Procedure|Circumferential spread of local anesthetic|The anesthetist will ensure, under ultrasound guidance, that local anesthetic (1 mL of 1% lidocaine) surrounds the sciatic nerve.
45473776|NCT01173107|Drug|colchicine|colchicine 1T tid
45473777|NCT03376750|Behavioral|CO - OP|CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance
45473778|NCT03860441|Other|Computerized cognitive training|Intervention used CogniFit platform with Personalized brain training sub-option
45473779|NCT04656210|Radiation|MRI|Non conventional MRI (35 minutes)
45473780|NCT04656210|Other|neuropsychological tests|Standardized and quantified neuropsychological assessment
46037430|NCT02957032|Drug|F16IL2|"All patients first receive an initial run-in dose of 30 Mio IU of F16IL2 on day 1 and escalating doses of F16IL2 on day 1, 8, 15 and 22.~Treatment will be repeated every 28 days for up to three cycles."
46037431|NCT02957032|Drug|cytarabine|Patients will be treated with cytarabine (5 mg twice daily s.c. for 10 days). Treatment will be repeated every 28 days for up to three cycles.
46037432|NCT02615587|Drug|Standard of care in AF in Denmark|As used in clinical practice, analysed as per drug class, not separate drugs.
46037433|NCT02786368|Behavioral|Control group|A comparison group; no intervention for year 1, EHFP after 1 year of program implementation.
45473781|NCT03736291|Device|Repetitive transcranial magnetic stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a widely used non-invasive neuromodulation technique that induces excitatory changes in the cerebral cortex stimulated by repeated pulsed magnetic fields on the scalp.
45683692|NCT03451630|Behavioral|High-Tech|Remote care management and self-directed digital tools.
45683693|NCT03451630|Behavioral|Usual Care/Optimal Discharge Planning|Transition to other Health Plan disease management programs.
46037434|NCT02786368|Behavioral|EHFP group|Intervention group: training; inputs cost-sharing for EHFP activities.
46037435|NCT02615821|Behavioral|Mental Contrasting|n the mental contrasting activity participants will be asked by the researcher to consider the best outcome associated with engaging in physical activity, as well as the obstacles they may encounter while completing the activity. The first question will ask participants to name the most positive outcome of realizing their goal (e.g., feeling more awake during classes; weight loss). The second question will ask participants to name the most critical obstacle (e.g., feeling tired; rain) to reaching their goal.
46037436|NCT04307160|Procedure|Bilateral lateral rectus recession|All patients will undergo bilateral lateral rectus recession according to standard tables. In the younger age group, the amount of lateral rectus recession will be reduced by 0.5 mm. in those with inferior oblique overaction, inferior oblique recession will be performed
45683694|NCT04247464|Procedure|Fasting|Food intake restriction
45683695|NCT04241224|Device|Atherectomy|Endovascular treatment of peripheral arterial disease
45473782|NCT03381820|Other|instrumental folk music|The music was composed and edited by a professor of Folk Musical Department, Faculty of Arts, Khon Kaen University. There were total of 6 songs, 32-minute length. The music was slow-instrumental, 60-80 beats per minute and ranged between 40-60 decibel levels.
45683696|NCT04226248|Drug|Rivastigmine Transdermal System|Rivastigmine Trandermal Patches applied once a day for up to 12 months
46037437|NCT02956798|Radiation|Stereotactic ablative body radiation (SABR)|SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
46037438|NCT02947516|Procedure|Endoscopic ultrasound-guided liver biopsy|Participants will undergo endoscopic ultrasound per standard technique, with liver biopsy performed at that time.
46037439|NCT02947516|Procedure|Percutaneous liver biopsy|Participants will undergo percutaneous liver biopsy per standard protocol.
46037440|NCT01096446|Drug|Intravenous Fat Emulsions|Control Group: 0.5 grams/kg/day Experimental Group: 2 grams/kg/day
46037441|NCT00864721|Drug|Sutent|Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
45473783|NCT03222141|Device|TAVR Implantation of the THV Prosthesis|Patients with TAVR implantation
45473784|NCT01313598|Drug|GLPG0187|continuous IV infusion
45683697|NCT04226248|Other|Placebo Transdermal System|Placebo Trandermal Patches applied once a day for up to 12 months
45683698|NCT01892722|Drug|Interferon beta-1a|Administration once weekly via i.m. injections.
45342149|NCT00802581|Procedure|Non-circumferential spread of local anesthetic|"The anesthetist will perform a single shot injection of local anesthetic (1 mL of 1% lidocaine) near the sciatic nerve under ultrasound guidance, without ensuring circumferential spread around the nerve."
45473785|NCT03744091|Drug|P1|10 mg or 20 mg of THC:THCa
45473786|NCT03376594|Drug|Benjakul Extract|30 patients taking Benjakul Extract dosage 100 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
46037442|NCT05308420|Procedure|Pericapsular nerve group (PENG) block|A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and 20ml 0.5% levobupivacaine with 2mg (0.5ml) dexamethasone injected (total volume of injectate 20.5ml) between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule
46037443|NCT05308420|Procedure|Spinal anesthesia|Spinal anesthesia will be performed at the level of the presumed interspace in-between the third and fourth lumbar vertebrae by introducing a 27 gauge pencil-point spinal needle and 15mg of levobupivacaine (3ml) injected intrathecally
46037444|NCT05308420|Drug|Intrathecal morphine|100 micrograms of preservative free morphine diluted to a volume of 0.5ml is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
45342150|NCT00842062|Device|MyoScience Tissue Remodeling Device|Percutaneous treatment with the MyoScience device
45342151|NCT00836836|Other|Modified Atkins diet|"Modified Atkins Diet administration~Carbohydrates intake will be restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~Fats (e.g. cream, butter, oils, ghee) encouraged.~Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~Clear carbohydrate-fluids not restricted.~Calcium and multivitamin supplementation will be provided."
45342152|NCT00797589|Drug|HES|20ml/kg as prime fluid
45342153|NCT00797589|Drug|Ringer lactate|
45473787|NCT03376594|Drug|Loratadine|30 patients taking Loratadine dosage 10 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
45473788|NCT03863873|Procedure|Platelet-Rich Plasma Injection Group|Platelet-Rich Plasma Injection Group
45840021|NCT00581256|Radiation|3D|All patients treated using the best standard technique will receive 50 Gy in 2 Gy fractions or 50.4 Gy in 1.8 Gy fractions to the entire target volume delivering one treatment per day, five fractions per week (excluding holidays). A boost of 10 Gy to the tumor bed of an intact breast will be delivered. Patients treated to the chest wall will receive a 10Gy scar boost if mastectomy margins are positive in a patient with Stage II disease or if the patient was originally diagnosed with T3 or T4 (Stage III) disease
45840022|NCT00582660|Drug|Celecoxib|400 mg twice a day for 7 days prior to surgery
45342154|NCT00719108|Biological|Wosulin R|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
45840023|NCT00582660|Drug|Placebo|one tablet of placebo will be given for 7 days prior to surgery
45473789|NCT05572164|Procedure|TRADITIONAL EPIDURAL|epidural technique used for intraoperative analgesia (the EPL group; local anesthetics will be delivered via epidural catheter guided by SPI to provide intraoperative analgesia)
46037445|NCT05308420|Procedure|Sham PENG block|A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and a placebo solution consisting of 20.5ml 0.9%NaCl injected between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule
46037446|NCT05308420|Drug|Intrathecal placebo|0.5ml of placebo solution (0.9%NaCl) is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
46037447|NCT04927338|Dietary Supplement|BacoMind® (Bacopa monnieri standardized extract)|BacoMind® (Bacopa monnieri standardized extract) 300 mg daily capsule.
46037448|NCT04927338|Drug|Placebo|Daily placebo capsule identical in size, color, and shape to that of the Bacopa capsules.
46037449|NCT02615665|Procedure|Hepatic resection|Removal of a part of the liver during surgery
46037450|NCT02897050|Drug|Docetaxel|Docetaxel 75mg/m2, iv, d1 or 100mg/m2, iv, d1
46037451|NCT02897050|Drug|Capecitabine|Capecitabine 1200mg/m2/d, po, d1-d21
46037452|NCT02897050|Drug|Cyclophosphamide (tablet)|Cyclophosphamide 50 mg/d, po, d1-d21
46037453|NCT02897050|Drug|Fluorouracil|Fluorouracil 500mg/m2, iv, d1
46037454|NCT02897050|Drug|Epirubicin|Epirubicin 100mg/m2, iv, d1
46037455|NCT02897050|Drug|Cyclophosphamide (injection)|Cyclophosphamide 500mg/m2, iv, d1
46037456|NCT02619097|Drug|Pegol-sihematide injection|single dose
46037457|NCT01095666|Drug|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
46037458|NCT01095666|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
46037459|NCT01095666|Drug|Metformin|Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks
46037460|NCT01095666|Drug|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
46037461|NCT01095666|Drug|Pioglitazone|Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
46037462|NCT04132765|Other|Drooling Impact Scale|A scale with 10 items which are scored with visual analog scale from1 to 10. Drooling impact increases with increased scores.
46037463|NCT04132765|Other|Drooling Frequency and Severity Scale|In this scale, parents or care givers were asked to rate the severity and frequency of drooling, classifying severity of drooling using a 5-level domain ranging from 1 (dry) to 5 (profuse drooling). The frequency of drooling was classified using a 4-level domain ranging from 1(no drooling) to 4 (constant drooling)
45342155|NCT00719108|Biological|Actrapid|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
46037464|NCT04132765|Other|The Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD™)|A quality of life scale that measure caregivers' perspectives on the health status, comfort, well being, and ease of caregiving of children with severe developmental disabilities. CPCHILD consists of 36 items distributed over six sections representing the following domains: (1) Personal Care (eight items); (2) Positioning, Transfer, and Mobility (eight items); (3) Communication and Social Interaction (seven items); (4) Comfort, Emotions, and Behaviour (nine items); (5) Health (three items); and (6) Overall Quality Of Life (one item). For the sections which involve the performance of skills, the degree of difficulty of accomplishing each task or activity was rated on a 7-point ordinal scale anchored by 0 ('No problem at all') to 6 ('Impossible').
45342156|NCT00842140|Drug|oral contraceptive|oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate)once a day for 12 months
45342157|NCT00842140|Drug|Oral contraceptive plus spironolactone|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
45840024|NCT00582894|Drug|Busulfex, Fludarabine, ALemtuzumab|Busulfex 3.2 mg/kg/day for 2 days infused over 3 hours, Days -6 and Day-5 Fludarabine 30 mg/m2/day for 5 days on Day -6 to D-2 Alemtuzumab 10 mg/day IV on Days -5 to -1
45840025|NCT00583050|Device|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
45840026|NCT00583908|Device|senofilcon A|toric contact lens
45840027|NCT00583908|Device|balafilcon A toric|toric contact lens
46037465|NCT04132765|Other|Drooling Quotient (DQ)|DQ is a semi-quantitative method that assesses the presence of newly formed saliva on the lips every 15 seconds with 40 observations in 10 minutes, expressed as a percentage based on the ratio between the number of observed drooling episodes and the total number of observations.
45683699|NCT01892722|Drug|Fingolimod|"Administrated orally once daily:~0.5 mg capsule for patients over 40 kg or 0.25 mg capsule for patients 40 kg or less."
46037466|NCT04132765|Other|Patient and caregiver visual analog scale (VAS) for drooling|Patients will be asked to score their children's drooling severity on a visual analog scale (0-100 mm, 0 none to 100 severe)
46037467|NCT04132765|Other|Functional Oral Intake Scale (FOIS)|Functional Oral Intake Scale (FOIS) which is a 7-point ordinal scale document the functional level of oral intake of food and liquid.
46037468|NCT04132765|Other|number of bibs daily used|Parents will be asked their children's number of bibs daily used.
45342158|NCT00842140|Drug|Oral contraceptive plus metformin|Oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg of metformin
45342159|NCT00806169|Drug|triamcinolone and bevacizumab|
45342160|NCT02572232|Device|Combitube, Easytube, Laryngeal masks|Supraglottic airway device
45342161|NCT00844324|Drug|Candesartan cilexetil|Formulation:Oral suspensionStrength:1 mg/mLDose: 32 mg, single dose
45342162|NCT00844324|Drug|Candesartan cilexetil|Formulation:Oral suspensionStrength:1.6 mg/mLDose: 32 mg, single dose
45342163|NCT02572154|Other|Blood and sperm samples|20 ml of blood and sperm samples for sperm DNA fragmentation exploration
45342164|NCT00802815|Drug|Etanercept|50 milligrams subcutaneously every week
45342165|NCT04100759|Drug|Sildenafil 50 mg Oral Tablet|Sildenafil 50 mg Oral Tablet
45342166|NCT00836914|Drug|CAL-101|CAL-101 100mg capsules administered orally twice a day (BID) for 7 days
45683700|NCT01892722|Drug|Placebo capsule|Matching placebo capsule required for double-dummy masking to blind formulations.
46037469|NCT04132765|Other|number of hospital admissions per year related to respiratory infections|Parents will be asked their children's number of hospital admissions per year related to respiratory infections.
46037470|NCT04132765|Other|Gross Motor Function Classification System (GMFCS)|The GMFCS describes self-initiated movement and use of assistive devices (walkers, crutches, canes, wheelchairs) for mobility during an individual's usual activity.
45342167|NCT00836914|Drug|Placebo|Placebo capsules administered orally BID for 7 days
45683701|NCT01892722|Drug|Placebo i.m. injection|Matching placebo i.m. injection required for double-dummy masking to blind formulations.
46037471|NCT04132765|Other|Manual Ability Classification System (MACS)|The MACS is also a simple, five-point ordinal classification system and was designed for use in children ages 4-18 years. The MACS is a validated measure in cerebral palsy that can be used to classify a child's typical use of both hands and upper limbs.
46037472|NCT04132765|Other|Communication Function Classification System (CFCS)|The CFCS is a simple, five-point ordinal classification system that assesses everyday communication (not optimal communication) of children with cerebral palsy.
45342168|NCT04124042|Biological|XT-150|plasmid DNA
45342169|NCT04124042|Drug|Placebo|Placebo is a sterile phosphate-buffered saline
45342170|NCT05180175|Drug|Top down treatment if patient at high risk|Patients with an increased risk of poor disease course (as defined by a serum protein signature at diagnosis), will be treated with a top down treatment strategy.
45683702|NCT03411070|Device|Implanted Medical Device|Undergo SCOUT reflector placement
45683703|NCT03411070|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45840028|NCT00583908|Device|lotrafilcon B toric|toric contact lens
45840029|NCT00583908|Device|omafilcon A|toric contact lens
45840030|NCT00584220|Device|senofilcon A toric|contact lens
45840031|NCT00584220|Device|alphafilcon A toric|contact lens
46037473|NCT04132765|Other|Eating and Drinking Ability Classification System (EDACS)|EDACS is a measure to assess eating and drinking ability for children with CP, ages 3 and older. This classification is a simple five-point ordinal system.
46037474|NCT04231474|Device|Urodynamic testing|All data were obtained using the MMS Alfa 4T by the same urologist with use of an 8 Charr catheter.
46037475|NCT02615431|Other|MitraClip Intervention|
45840032|NCT00584922|Procedure|Endoscopy in group I (all patients)|Post procedure endoscopy, omeprazole 40 mg BID, sucralfate 1 gm BID for 2-4 weeks.
46037476|NCT05338840|Other|MULLIGAN ROTATIONAL MOVEMENT|12 sessions over 6 weeks
46037477|NCT05338840|Other|Medial gapping technique|12 sessions over 6 weeks
46037478|NCT02618863|Device|Cricoid pressure|Applying cricoid pressure and testing its effectiveness using gastric tube . in addition , by using the cricometer , the CP 50 is defined and compared in both gender
46037479|NCT05302180|Other|Pain neuroscience education|"The online pain neuroscience education program will be based on the model proposed by the Pain Research Group, available in http://pesquisaemdor.com.br, which presents the Path of Recovery. In our program we will hold 10 meetings: (1) conversation with the group, (2) acceptance and pain education, (3) continuation about pain education, (4) sleep hygiene, (5) pharmacological assistance, (6) recognizing stress and negative emotions, (7) increasing positive coping in lifestyle, (8) exercises, (9) communication, and (10) prevention of recurrence. The program will be offered by synchronous meetings; asynchronous (videos) and e-book."
45342171|NCT00844402|Drug|Atorvastatin|oral, 10 mg, daily, 48 weeks
45342172|NCT04117412|Other|Exercise|Same participants will undergo different one bout of exercise protocols
45342173|NCT00802971|Dietary Supplement|FOS|Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
45342174|NCT02546908|Other|No Intervention|This is an observational study. No study medication is provided will be provided as part of participation. Participants disease status, overall survival (OS), PFS, MFS, SRE-free survival, and time to castration (TTC) will be analyzed according to treatments prescribed while enrolled in the registry. All treatment decisions will be made at the discretion of the investigator or treating physician.
45342175|NCT04115852|Behavioral|fmri|functional magnetic resonance imaging
45342176|NCT00806247|Drug|tapentadol HCl|
45342177|NCT00803127|Device|vs-sense|detection swab
45342178|NCT00797745|Biological|peginterferon alfa 2b|1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
45342179|NCT00797745|Drug|ribavirin|ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
46037480|NCT05302180|Other|Usual care|All participants will receive usual care in one of the five physiotherapy clinics accredited to SUS, according to availability of scheduling in the services. The usual care consists of 10 sessions of physical therapy, that is mainly composed by kinesiotherapy and electrothermophototherapy.
46037481|NCT01100658|Drug|Methylphenidate|1 capsule each day for 1 week, .3 mg/kg dose.
46037482|NCT01100658|Drug|Placebo|1 capsule per day for 1 week.
46037483|NCT02618785|Procedure|hysterosalpingography|Starting procedure by using largest appropriate speculum for maximum cervical exposure. Cleanse the cervix with povidone iodine. A tenaculum was applied to the anterior cervix to help for stabilization and counter-traction. Then insert a sterile Rubin's cannula into the cervix uteri. A scout radiograph of the pelvis was obtained with the catheter in place before contrast material was instilled. After that the water soluble contrast media was slowly instilled through the cannula appropriate volume range 10-15 ml., with fluoroscopic images obtained intermittently to evaluate the uterus, fallopian tubes and tubal patency
46037484|NCT05296720|Behavioral|Tactile stimulation|Participants are asked to react as fast as possible to a tactile stimulation
46037485|NCT02618707|Other|Lactate|Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
45342180|NCT00797745|Drug|SCH 900518|SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
46037486|NCT05276908|Procedure|Thoracolumbar interfascial plane block (TLIP)Technique|A curvilinear array ultrasound probe (Siemens ACUSON X300 Ultrasound System) will be placed at the targeted lumbar level.The corresponding spinous process and interspinal muscles will be identified, and the probe will be slided laterally to identify the longissimus muscle and iliocostalis muscle. Under ultrasound guidance, A 38-mm 22-gauge (22-G, 50-mm 'Stimuplex; BBraun, Melsung, Germany) regional block needle will be advanced in plane to the ultrasound beam in a medial to lateral orientation through the belly of longissimus muscle toward the iliocostalis muscle. Hydro-dissection with 2-3 ml of isotonic saline solution will confirm the correct needle tip position and, after negative aspiration, 0.25 % bupivacaine will be injected slowly whilst carefully monitoring the spread of local anesthetic into the fascial plane between the longissimus and iliocostalis muscles. The same procedure will be repeated on the contralateral side.
46037487|NCT05276908|Procedure|Anesthetic Management|"Induction:~Induction of general anesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of atracurium.~Maintenance:~Anesthesia will be maintained with inhaled isoflurane 0.8% in oxygen enriched air (FiO2=0.5). Maintenance doses of 0.1 m\kg atracurium will be provided every 30 minutes. Then the patient will be placed in prone position."
46037488|NCT05276908|Drug|Bupivacaine Injection 10ml|patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 20 ml 0.25%bupivacaine (10 ml on each side).
46037489|NCT05276908|Drug|Bupivacaine Injection 20ml|patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 40 ml 0.25%bupivacaine (20 ml on each side).
45683704|NCT03331978|Behavioral|Rise - Treatment Education|Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if <85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
45683705|NCT04398004|Drug|Clarithromycin|Treatment with 500 mg Clarithromycin orally twice daily for seven days
45683706|NCT03284242|Procedure|Apheresis|Collect white blood cells to isolate Treg cells for expansion. Once the blood cells are collected the cells will be cultured in the laboratory and will be expanded. After approximately 3 weeks in culture, the cells will have increased in number and be ready for the autologous Treg cell infusion.
46037490|NCT02785978|Drug|Levodopa acute challenge|"Inclusion visit (simultaneous video + ActiMyo recording):~Levodopa acute challenge and 2 hours of recording and medical monitoring"
46037491|NCT02785978|Other|Controlled environment tests (series of tasks of everyday life)|"Inclusion visit (simultaneous video + ActiMyo recording):~Controlled environment tests (series of tasks of everyday life)"
45342181|NCT00797745|Drug|ritonavir|Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
46037492|NCT02785978|Other|Standardized scales: MDS-UPDRS (Part II to IV) and RDRS|"Inclusion visit (simultaneous video + ActiMyo recording):~Standardized scales: MDS-UPDRS (Part II to IV) and RDRS"
46037493|NCT02785978|Device|ActiMyo recording|Continuous activity recording with ActiMyo during the 2 weeks of study participation
46037494|NCT02785978|Other|Diary completion|Daily patient logbook completion during the 2 weeks of study participation
46037495|NCT02786056|Other|Lung MRI examination|Lung MRI examination is performed for approximately 30 min on a 3T machine (Achieva 3T, Philips) using UTE sequences, both during free breathing with image synchronisation using an echo-navigator, and during an end-inspiratory and end-expiratory pauses. In the 10 first subjects, the MR protocol is optimized in order to maximize MRI parenchymal signal intensity, signal-to-noise ratio and contrast-to-noise ratio. The final image acquisition parameters will be applied in the following 30 subjects in order to assess the outcomes of the study.
46037496|NCT02786212|Drug|Dexmedetomidine|
46037497|NCT02786212|Drug|Normal Saline|
46037498|NCT05273710|Other|Regular toast and juice|Participants consume a single test meal composed of regular whole wheat toast and apple juice, and zinc absorption is measured.
45342182|NCT04070846|Drug|[14C] LC350189|Carbon-14 labelded LC350189
46037499|NCT05273710|Other|High phytate toast and juice|Participants consume a single test meal composed of high phytate whole wheat toast and apple juice, and zinc absorption is measured.
45683707|NCT01687413|Radiation|Intensity-modulated radiation therapy (IMRT)|
46037500|NCT05273710|Other|Regular toast and juice, with folic acid|Participants consume a single test meal composed of regular whole wheat toast and apple juice, with 400 mcg folic acid; and zinc absorption is measured.
46037501|NCT02784808|Drug|Biological DMARDs|Participants will receive biologic DMARDs as per standard of CARE. The choice of specific biologic DMARD will be at the descretion of treating physician.
45683708|NCT01687413|Drug|Cisplatin|
45683709|NCT04181320|Device|Venous Leg Ulcer Standard of Care with Granulox|Granulox will be added as an adjunct therapy to defined standard of care in subjects with predominantly venous leg ulcers.
45683710|NCT01555671|Drug|Meperidine|0.5 ml meperidine injection intravenously injected in randomly selected patients
45683711|NCT01555671|Drug|Saline|0.5 ml saline solution injection intravenously injected in randomly selected patients
46037502|NCT02784808|Drug|Non-Biologic DMARDs|Participants will receive non-biologic DMARDs as per standard of care. The choice of specific non-biologic DMARD will be at the descretion of treating physician.
45342183|NCT00659373|Drug|Tamoxifen|
45683712|NCT03255616|Other|mechanical stimulation|mechanical non-painful low- and high pressure stimuli to thoracolumbar segments of healthy subjects and low back pain patients
46037503|NCT02784652|Drug|Zoledronic acid|Zoledronic acid: every 4 weeks, 6 times, 4.0 mg iv
45683713|NCT03255616|Other|vibrotactile stimulation|non-painful vibrotactile stimulation within a frequency range between 20-150Hz to thoracolumbar segments of healthy subjects and low back pain patients
45683714|NCT03226756|Drug|Nivolumab Injection|Nivolumab 3 mg/kg, every 2 weeks
45683715|NCT01801358|Drug|AEB071|Twice-daily doses of AEB071 for a cycle of 28-days, given without interruption (continuous cycles)
45342184|NCT00659373|Drug|triptorelin|
45683716|NCT01801358|Drug|MEK162|Twice-daily doses of MEK162 for a cycle of 28-days, given without interruption (continuous cycles)
46037504|NCT02784652|Radiation|Radiotherapy|Radiotherapy: 5 days/ week, 3 Gy * 10-13 fractions or 4 Gy * 5 fractions,
46037505|NCT04231630|Other|Prolacta|Will receive outpatient supplementation with donor human milk product added to mother's own milk
45342185|NCT00659373|Drug|Exemestane|
45342186|NCT00837070|Procedure|Percutaneous zygapophyseal cyst rupture|Patients will be treated by introducing a 20G spinal needle in the inferior joint recess of the zygapophyseal joint.1 ml of celestone-chronodose,1 ml of Marcain 5 mg/ml and 1-3 ml of contrast media:Omnipaque 240 will be injected until the cyst ruptures.
45342187|NCT00716378|Behavioral|Teen Passenger Presence|
45342188|NCT00719342|Drug|Oxygen + Carbondioxide|Mixture of 92 % oxygen and 8 % carbon dioxide for inhalation
46037506|NCT02784730|Procedure|Iterative PICC placement|Intervention is the catheterisation strategy (not the device)
45683717|NCT01807598|Drug|Brentuximab vedotin|
45683718|NCT01801280|Drug|Mycophenolate sodium|Daily dose: 720mg, 1080mg, 1440mg. Application alone or together with Pantozol®.
45683719|NCT01801280|Drug|Pantoprazole|Daily dose: 40mg. Application together with CellCept® or Myfortic® .
46037507|NCT02784730|Procedure|Long term PAC placement|Intervention is the catheterisation strategy (not the device)
46037508|NCT02786290|Device|Zenflow Spring System|The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
45683720|NCT01801280|Drug|Mycophenolate mofetil|Daily dose: 1000mg, 1500mg, 2000mg. Application alone or with Pantozol® .
46037509|NCT04231552|Drug|Camrelizumab|Radiotherapy with CAPOX+ Camrelizumab following surgical therapy Radiation: 25 Gy/5 fractions CAPOX (2 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine:Dose of 2000mg/m2,14days, q3w Camrelizumab (2 cycles): 200mg on day 1 of each cycle, q3w Surgical therapy: the resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
45473790|NCT05572164|Procedure|DURAL PUNCTURE EPIDURAL|group on whom dural puncture epidural technique used for intraoperative analgesia ( the DPL group; local anesthetics will be delivered via an epidural catheter placed after a dural pucture performed with the SPI guidance to provide intraoperative analgesia)
45473791|NCT03381664|Drug|AVP-923|capsule
45473792|NCT04029961|Other|Video Education|Prior to their CT simulation, participants will receive education on radiation therapy in the form of a video.
45473793|NCT04029961|Other|VR-based Education|Prior to their CT simulation, participants will receive education on radiation therapy in the form of an immersive VR program delivered through a head-mounted display (HMD).
45473794|NCT03863561|Behavioral|Diabetes self-management education (DSME) program|Diabetes educators customized care paths for their patients based on their individual responses to the SCPI questions. Patients met with an educator five to seven times over the course of three to four months.
45473795|NCT05126979|Biological|Inactivated Split Influenza Vaccine|
45473796|NCT05126979|Biological|Placebo|
46037510|NCT02785744|Other|Gaucher disease DNA mutation analysis|
46037511|NCT01100502|Drug|brentuximab vedotin|Every 21 days by IV infusion (1.8 mg/kg)
46037512|NCT01100502|Drug|placebo|Every 21 days by IV infusion
46037513|NCT02784418|Procedure|Chronic Total Occlusion Percutaneous Coronary Intervention|Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice
45473797|NCT04060758|Drug|PA5108 Latanoprost FA SR Ocular Implant|Ocular Implant
45473798|NCT03376438|Other|Prospective observational cohorts|Patients with AF or SVT that is significant enough to consider prenatal treatment are eligible for enrollment. Management decisions are made at each patient encounter by the primary physician based on clinical findings and may include: 1) no antiarrhythmic treatment; 2) transplacental antiarrhythmic treatment; 3) direct fetal antiarrhythmic treatment; 4) delivery. Patients enrolled in the FAST Registry will be followed from the time of enrollment until the baby is discharged after birth.
46037514|NCT02784418|Procedure|Sham Procedure|Sham Procedure: Bilateral arterial access, without angiography or PCI being performed
46037515|NCT02784340|Drug|Dexamethasone|16 mg Dexamethasone IV drip
46037516|NCT02784340|Drug|Dexamethasone|16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
45473799|NCT03484455|Device|Hypothermic machine perfusion|Organ Recovery Systems LifePort® Liver Transporter (LLT) System and Vasosol® Machine Perfusion Solution
46037517|NCT02784340|Drug|Saline (IV fluids)|IV fluids 500 cc saline infusion
46037518|NCT02784340|Drug|Bupivicaine and Fentany|
46037519|NCT02784340|Device|25G spinal needles|
46037520|NCT02785822|Drug|hMG-HP|Ovarian stimulation with hMG-HP (150 IU / day)
46037521|NCT02785822|Drug|hFSH-HP|Ovarian stimulation with hFSH-HP (150 IU / day)
46037522|NCT02389036|Drug|SDD Oral Paste|A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx
46037523|NCT02389036|Drug|SDD Gastric Suspension|2. A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10 ^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube
45342189|NCT00719342|Other|full field flickering light at 12.5 Hz|1 minute stimulation with full field flickering light at 12.5 Hz during measurement of vessel diameters and measurement of blood flow.
45342190|NCT00842452|Drug|topotecan hydrochloride|Patients receive oral topotecan hydrochloride on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
45342191|NCT00842452|Other|pharmacological study|Patients treated at the maximum tolerated dose undergo blood sample collection periodically on day 1 of course 1 for pharmacokinetic studies.
45342192|NCT02552745|Drug|parecoxib sodium|parecoxib sodium was administered postoperatively, when transcatheter arterial embolization finished.
46037524|NCT02389036|Drug|Intravenous Antibiotic|A four-day course of an intravenous antibiotic in patients not already receiving a therapeutic antibiotic
46037525|NCT02878512|Procedure|PCNL under General Anesthesia|Patients undergoing percutaneous Nephrolithotomy received General anesthesia.
46037526|NCT02878512|Procedure|Segmental Epidural Anesthesia|Patients undergoing PCNL surgery received Segmental epidural anesthesia with 0.5% bupivacaine.
46037527|NCT04302246|Genetic|Biological testing on sequential blood sample|Biological characterization of various immune function and blood circulating leukocytes phenotyping before liver transplantation and therafter at day-3, -7, -14 postoperatively and if septic complication occurs.
45473800|NCT03484455|Device|Static cold storage|Static cold storage (standard of care)
46037528|NCT03677986|Behavioral|Video DOT+|Participants will receive financial incentives for recording and submitting videos of themselves taking their daily buprenorphine dose.
45473801|NCT03863405|Drug|Metformin|metformin 850 mg bid for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2
45473802|NCT03863405|Drug|Conventional DMARDs|methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
45473803|NCT03863405|Drug|Placebo Oral Tablet|oral tablet
45473804|NCT03637218|Other|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
46037529|NCT04900740|Device|Catheter fixation with surgical stitch|The catheter will be fixed using the standard procedure - surgical stitch.
45473805|NCT03637218|Other|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
45473806|NCT03997825|Device|Basivertebral Nerve (BVN) Ablation|Single follow-up visit of previously treated participants from the SMART trial.
45473807|NCT03866369|Drug|Moxifloxacin|Single oral dose at D-8
45473808|NCT03866369|Drug|Placebo|Single oral dose at D-1
45473809|NCT03866369|Drug|Lanifibranor|Single daily oral dose during 14 days
45473810|NCT03866369|Drug|Placebo|Single daily oral dose during 14 days
45473811|NCT05120661|Other|food product|a food product containing 50 gram carbohydrates
45473812|NCT05178264|Drug|SARS-CoV-2 vaccines|All patients treated at least with 1 SARS-CoV-2 vaccine
45473813|NCT01284803|Behavioral|an educational intervention|To elaborate an educational program for the management of depression in primary care
46037530|NCT04900740|Device|Catheter fixation with glue (cyanoacrylate tissue glue Secure PortIV)|The catheter will be fixed using the experimental procedure - novel surgical glue.
45683721|NCT01769456|Behavioral|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
46037531|NCT04847856|Behavioral|Diabetic care Information, education, and communication intervention will be delivered by relevant and trained health animators working in chronic care clinic.|The training sessions and the IEC materials were adapted from John Hopkins University studies on self-care for diabetic patients.
46037532|NCT04306614|Procedure|Endobronchial Ultrasound guided Transbronchial Fine Needle Aspiration|Bronchoscopic procedure to allow for sampling mediastinal lymphadenopathy or proximal lung tumours under real-time ultrasound guidance.
46037533|NCT04231006|Radiation|High dose rate brachytherapy|High dose rate brachytherapy will be delivered to the site of recurrence within the prostate gland based on MRI and PSMA PET/CT
46037534|NCT01094886|Drug|Rivaroxaban|10mg tablet daily, receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
46037535|NCT04231240|Device|Measure of ACT with IStat|Measure of ACT with a point of care device named IStat
46037536|NCT02784028|Other|SGM-101|Administration of SGM-101 prior surgery
46037537|NCT02782234|Behavioral|Contract management|
46037538|NCT01094808|Drug|Pregabalin|FDA approved medication (capsules) at 75 mg and 200 mg doses
45683722|NCT01769456|Drug|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
45683723|NCT01769378|Drug|Placebo|Administered SQ
46037539|NCT01094808|Drug|Placebo|Placebo capsules
46037540|NCT01094808|Other|Bowel preparation|Polyethylene glycol electrolyte solution bowel preparation
46037541|NCT00864253|Drug|ABI-007|Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
45683724|NCT01769378|Drug|Dulaglutide|Administered SQ
46037542|NCT00864253|Drug|Dacarbazine|Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
46037543|NCT02782312|Drug|ICS+LABA|Seretide is inhaled for one year
46037544|NCT02782312|Other|routine therapy|routine therapy for one year
46037545|NCT01094730|Device|galyfilcon A prototype lens|Experimental silicone hydrogel contact lens
45473814|NCT05177952|Other|Blood Flow Restriction|Resistance training with BFR
46037546|NCT01094730|Device|marketed galyfilcon A lens|Marketed silicone hydrogel contact lens.
46037547|NCT04229758|Drug|Anticoagulants|DOAC for the prevention of thromboembolic events in patients with non-valvular AF or VTE.
45683725|NCT01769378|Drug|Glimepiride|Administered PO
46037548|NCT04307706|Behavioral|Acceptance and Commitment Therapy|The Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in six sessions. The duration of each session lasted on average 60-90 minutes. A session was held for each parent once a week.
45473815|NCT05177952|Other|Standard of Care|Resistance Training with no BFR
45473816|NCT03124576|Device|Implantable loop recorder|Continuous rhythm monitoring Medtronic
45683726|NCT01807520|Biological|Secukinumab|Study treatment was provided in pre-filled 1 mL syringes.
45683727|NCT01807520|Biological|Placebo|Placebo was provided in pre-filled 1 mL syringes.
45683728|NCT01806896|Drug|PF-02545920|"Dose will be titrated up every 2 days by 5mg increments: 5mg Days 1-2, 10mg days 3-4, 15mg days 5-6, and reach 20 mg from Days 7 to Day28.~Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Treatment for 28 days."
46037549|NCT04230538|Device|DJO Walker|
46037550|NCT04230538|Device|Traditional plaster cast|
46037551|NCT02783794|Drug|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
46037552|NCT02783794|Drug|Placebo|Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
46037553|NCT00698425|Other|EyeGate II® Drug Delivery System|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
46037554|NCT00698425|Drug|Citrate buffer|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
46037555|NCT02614417|Other|Polysomnography|One night polysomnography performed using standard techniques and scored in accordance with American Academy of Sleep Medicine standards. Polysomnography monitors sleep by electroencephalography (F4-A1, C4-M1, O2-M1 F3-M2, C3-M2, O1-A2), electro-myography (submental and tibialis anterior muscles), electro-oculography, nasal flow, respiratory effort, pulse oximetry and transcutaneous carbon dioxide partial pressure.
45342193|NCT02547844|Drug|efavirenz + emtricitabina + tenofovir|
45342194|NCT02547844|Drug|rilpivirina + emtricitabina + tenofovir|
45342195|NCT00439777|Drug|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
45342196|NCT00439777|Drug|Enoxaparin overlapping with and followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 hr before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
45342197|NCT00842686|Drug|bevacizumab, capecitabine|bevacizumab 5mg/kg days -15,1,15,29 capecitabine 1250 mg/square m/day during radiotherapy radiotherapy 50,4 Gy (1,8 Gy per fraction)
45342198|NCT04045821|Drug|AMD3100|Subjects in this arm will have AMD3100 administered per the standard dosing regimen of 0.24 mg/kg actual body weight subcutaneous x1 dose
45342199|NCT04045821|Drug|Normal saline|Subjects in this arm will have a placebo of normal saline administered subcutaneously x1 dose
45342200|NCT04045821|Procedure|dilation and curettage|all participants will undergo routine D&C procedure
45342201|NCT04068584|Other|Smart Angel|Patient issued with a tablet with the Smart Angel application to monitor clinical signs and symptoms
45342202|NCT00842842|Procedure|tack fixation of mesh|tack fixation of mesh
46037556|NCT05342506|Drug|Toripalimab + ScTIL|Toripalimab (80 mg iv) 24 hours before or concomitantly with ScTIL 3-5x10^9 intravenous reinfusion.
46037557|NCT05242198|Procedure|Robotic prostatectomy|patients who will undergo robotic prostatectomy
46037558|NCT04230616|Procedure|total knee arthroplasty|total knee arthroplasty
45473817|NCT03860675|Diagnostic Test|Assessment of walking-related fatigability|participants perform two six-minute walking test (6MWT), with 3-5 days in between. Before and after the 6MWT, three screenings test (spasticity, muscle strength, balance) are executed and the participants have to indicate the severity of eleven possible symptoms (= symptom inventory, SI) on a VAS scale. These screening tests and SI are continued every 10 minutes for half an hour. During a third test session, participants perform a 6-minute vigilance alphabet test in rest and while doing a 6MWT to investigate the relationship between cognitive and motor fatigability.
46037559|NCT04230616|Radiation|CT scan|The first 52 participants will recieve a pre- and postoperative CT scan of the hip, knee and ankle.
45342203|NCT00842842|Procedure|glue fixation of mesh|glue fixation of mesh
46037560|NCT04230850|Other|Static Cupping|Two cups will be applied unilaterally to the lumbar paraspinals. The skin will be elevated to 1.5 cm ensuring standardized pressure. Cups will remain on the treatment area statically for 4 minutes prior to removal. Another 4 minute bout of identical treatment to the contralateral side will follow. (Participants will be equally dispersed into three treatment groups via stratified randomization).
46037561|NCT04230850|Other|Dynamic Cupping|One cup will be applied ipsilaterally, raising skin to 1.2 cm of standard pressure. The cup will be continuously moved in a sweeping motion between L1 and L5 within a defined width. This process will be repeated on the other side. Each side will be treated for 4 minutes dynamically for a total treatment duration of 8 minutes. (Participants will be equally dispersed into three treatment groups via stratified randomization).
45342204|NCT00803439|Drug|Clobetasol Propionate 0.05% Foam-Reference Product|Small amount applied and evaluated over the course of two days
45342205|NCT00803439|Drug|Clobetasol Propionate 0.05% Foam-Test product|Small amount applied and evaluated over the course of two days
45342206|NCT00844636|Device|Sharp needle|
45342207|NCT00844636|Device|Blunt needles|
45342208|NCT02575196|Device|Non-invasive cerebral flow monitoring|As soon as possible after ROSC, c-flow monitor will be connected to the patient, recording cerebral flow index for the first 72 hours following ROSC. All other relevant clinical data will be recorded.
45342209|NCT00806481|Drug|Sevelamer carbonate|Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks
45342210|NCT00806481|Drug|Placebo|Treatment group: treatment with tablets of placebo three times daily for 36 weeks
45342211|NCT02546596|Device|Electro-hyperthermia|Addition of electro-hyperthermia to radiation
45342212|NCT00709436|Drug|PMI-150 (intranasal ketamine)|PMI-150 (intranasal ketamine) at time 0 and scheduled times thereafter.
45342213|NCT00709436|Drug|Placebo|Placebo (intranasal) at time 0 and scheduled times thereafter.
45342214|NCT00803673|Drug|100mcg|100mcg '719
45342215|NCT00803673|Drug|500mcg|500mcg '719
45342216|NCT00803673|Drug|1000mcg|1000mcg '719
45342217|NCT00803673|Drug|Placebo|Placebo '719
45473818|NCT04024891|Drug|Phentolamine Mesylate Ophthalmic Solution 1%|1% phentolamine mesylate ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
45342218|NCT00844792|Dietary Supplement|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
45342219|NCT00844792|Drug|Placebo|Twice a day with meals.
45473819|NCT04024891|Other|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
45683729|NCT01806896|Drug|Placebo|"- Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days."
45342220|NCT04017195|Drug|EVRA patch (NGMN+EE) (Treatment A) (Reference)|A single transdermal contraceptive patch of EVRA (NGMN + EE) will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
45342221|NCT04017195|Drug|High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)|A single transdermal contraceptive HMW PIB (NGMN + EE) patch will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
45342222|NCT00719420|Drug|Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole)|Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid with or without omeprazole 20 mg bid for 14 days
45342223|NCT00719420|Drug|Clarithromycin, Amoxicillin, Omeprazole|Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
45342224|NCT00797901|Other|Collaborative Care|
45342225|NCT00844870|Behavioral|stabilization training|training of arm function with the trunk stabilized
45342226|NCT00844870|Behavioral|auditory training group|response to an auditory signal
45342227|NCT00719498|Drug|Epo-alpha|
45342228|NCT00803829|Other|Synbiotic (Synergy1/B. longum)|Probiotic Bifidobacterium longum Prebiotic Synergy 1
45342229|NCT00716612|Drug|Coenzyme Q 10|PO Coenzyme Q 10 120 mg QD
45342230|NCT00716612|Drug|Placebo control|po Placebo QD
46037562|NCT04230850|Other|Stretching|The stretching program performed will involve a double knee to chest stretch, cat stretch, camel stretch, and pelvic tilts. Participants will receive a 30 second rest break between each of the four stretches. (Participants will be equally dispersed into three treatment groups via stratified randomization).
45342231|NCT00842920|Drug|Simvastatin 60 mg|60 mg once daily
46037563|NCT05240638|Device|TD Drainage|Image-guided percutaneous cannulation of the TD and drainage with an endovascular catheter (microcatheter)
45342232|NCT00842920|Drug|Placebo|one tablet once daily
45342233|NCT00842920|Drug|Simvastatin 20 mg|20 mg once daily
45342234|NCT00806559|Other|Re-designed room|In the redesigned room patients and clinicians are sitting at a single table in a different configuration compared to the usual clinical exam room, with the doctor at the computer and two chairs for the patient and family/friends.
45342235|NCT00806559|Other|Control room|This is the usual clinical room for a clinical visit, with physician at desk and chairs along the wall for patient/family.
45342236|NCT00716690|Procedure|Multi donor stem cell transplantation|stem cell transplantation from 2 donors
46037564|NCT00638092|Drug|sodium iodide|sodium iodide 30 micrograms/kg/day, daily dose, from randomisation (within 42 hours of birth) to 34 corrected weeks gestation
46037565|NCT00638092|Drug|Sodium Chloride|Sodium Chloride 30 micrograms/kg/day, daily dose, from randomisation (from within 42 hours of birth)to 34 corrected weeks gestation
45342237|NCT03850054|Procedure|AADI glaucoma shunt|"Implantation of the nonvalved AADI glaucoma shunt instead of the Bearveldt tube shunt, in eyes with intractable glaucoma.~It is not a RCT study, but a prospective evaluation of the AADI device, and the study has been approved as a quality control study at the Department of Ophthalmology, at Odense University Hospital"
45342238|NCT02552979|Other|atopic patch test|
46037566|NCT04230772|Procedure|Natural Orifice Specimen Extraction Surgery|In the experimental group, patients will be performed robotic colorectal resection with natural orifice specimen extraction.
46037567|NCT04230772|Procedure|Traditional Robotic-assisted Surgery|In the active comparator group, patients will be performed traditional robotic-assisted colorectal resection.
46037568|NCT05342272|Drug|Betaine taurine PVP gel|At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of GUM Hydral® gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
45342239|NCT00722774|Biological|H2N2 1960 AA ca recombinant vaccine|Approximately 0.2 ml of 10^7 TCID50 doses of vaccine administered intranasally
45342240|NCT03118063|Diagnostic Test|Evaluation of pain by algometry|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
45342241|NCT00842998|Drug|Trastuzumab or Lapatinib|Trastuzumab: loading dose 8 mg/kg iv in 90 min.followed by weekly doses of 2 mg/kg Lapatinib: 1500 mg/die orally
46037569|NCT05342272|Drug|Xylitol, Lactoperoxidase, Lysozyme, Lactoferrin|At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of Biotene® Oral Balance gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
46037570|NCT05173012|Drug|SAGE-324|SAGE-324 oral tablets.
45473820|NCT03381586|Drug|ALT-803|Subjects randomized to Group A (n=8) will receive ALT-803 at a concentration of 1.0 mg/mL and subjects randomized to Group B (n=8) will receive ALT-803 at a concentration of 2.0 mg/mL. Subjects will receive a single 10 µg/kg subQ dose of ALT-803 on Day 1 of study period 1. After a rest period, subjects will receive a single 20 µg/kg subQ dose of ALT-803 on Day 1 of study period 2.
45473821|NCT01178021|Drug|Chloroquine|Chloroquine 10 mg/kg on day 0 & 1 and 5mg/kg on day 2
45473822|NCT01178021|Drug|Chloroquine/Primaquine|Chloroquine 10 mg/kg on day 0 & 1 and 5mg/kg on day 2 Primaquine (if given) 0.25mg/kg/day for 14 days
46037571|NCT05173012|Drug|SAGE-324 Matched Placebo|SAGE-324 matched placebo oral tablets.
46037572|NCT04230460|Drug|Cannabis (THC) (Inhaled) Placebo|Cannabis vapor is produced from 500 mg of dried plant material (placebo) (0% THC). Participants will inhale ad libitum over 10 minutes.
46037573|NCT04230460|Drug|Cannabis (High% THC) (Inhaled)|Cannabis vapor is produced from 500 mg of dried plant material (7.5% THC). Participants will inhale ad libitum over 10 minutes.
46037574|NCT04230460|Drug|Cannabis (Very High% THC) (Inhaled)|Cannabis vapor is produced from 500 mg of dried plant material (12.5% THC). Participants will inhale ad libitum over 10 minutes.
46037575|NCT04230460|Drug|Alcohol (oral)|Subjects will be dosed to achieve a 0.05% Blood Alcohol Concentration (BAC), so the amount of alcohol consumed will be calculated to produce a peak BAC of 0.065%. Subjects will be served three equal-sized drinks, 10-minutes apart, and be instructed to pace each drink evenly over the 10-minute period.
45342242|NCT00806637|Procedure|Vessel sealing system uvulopalatoplasty (VSSU)|Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
45342243|NCT00806637|Procedure|Uvulopalatal flap (UPF)|Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
45342244|NCT00716768|Procedure|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
46037576|NCT01593202|Behavioral|Dialectical behavior therapy|"16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus & Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
45342245|NCT00716768|Procedure|Open Inguinal Hernia Repair|Open Inguinal Hernia Repair
45342246|NCT01034449|Other|allogeneic transplant|ex vivo amplification of a unit of placental blood for transplantation
45342247|NCT00716846|Drug|simvastatin|10mg, 2 weeks
45342248|NCT00716846|Drug|atorvastatin|10mg
45342249|NCT00716846|Drug|pitavastatin|2mg
45473823|NCT03250182|Drug|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations per use as instructed per the protocol.
45473824|NCT03381508|Device|Brizzy continuous positive pressure device|Patients are treated with the Brizzy continuous positive pressure device, including pneumotachograph.
46037577|NCT01593202|Behavioral|Enhanced usual care|16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive. family and/or pharmacological treatment as needed.
46037578|NCT05238376|Behavioral|Exercise training|12 weeks of high intensity interval training (HIIT) (3x/week) and resistance training (2x/week)
46037579|NCT02783638|Drug|YHD1119|2 by 2
46037580|NCT02783638|Drug|Lyrica|2 by 2
46037581|NCT04229524|Procedure|Fluorescence angiography|After the tube and stomach were made during surgery, the predetermined anastomosis position was marked with sutures in advance according to the doctor's experience, and then 0.04ml / kg indocyanine green injection was injected into the central vein. Next, dynamic observation and recording of the tube-gastric anastomosis area in 136 seconds using a fluorescent imaging system with a fixed focal length till the fluorescence reaching range and intensity. If the average value of the fluorescence value of the anastomosis position is greater than 30, then the anastomosis position may be according to the original plan or moved to the proximal part. If the average fluorescence value of the predetermined anastomosis position is less than 30, the anastomosis must move to proximal part ensure anastomosis with fluorescence value at least> 30.
46037582|NCT02783326|Other|Rehabilitation|Pulmonary rehabilitation, exercise in COPD individuals and health individuals
45473825|NCT01173263|Other|BIS 70 maintained|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 70.
45473826|NCT01173263|Other|BIS level 50|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 50.
46037583|NCT02782000|Other|lessons,long-term supervision and message|
45473827|NCT01173263|Other|BIS 35|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 35.
46037584|NCT02782000|Other|lessons,short-term supervision and message|
46037585|NCT04230070|Drug|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Bioequivalence
46037586|NCT04230070|Drug|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product|Bioequivalence
46037587|NCT02782078|Biological|Clindamycin and rifampicin dosages|blood samples for clindamycin and rifampicin dosages (for each patient)
46037588|NCT01293682|Drug|Calcitriol|In pill form, 45 micrograms once a week for 12 weeks
45473828|NCT05177874|Device|Traumacel FAM Trium|Absorbable Hemostat (oxidized non-regenerated cellulose)
45473829|NCT05177874|Device|Surgicel Fibrillar|Absorbable Hemostat (oxidized regenerated cellulose)
45473830|NCT03381430|Drug|Gefitinib|Gefitinib 250 mg/day oral daily
45473831|NCT01288157|Drug|Golimumab|Single dose of 100 mg subcutaneously
45473832|NCT01288157|Drug|Golimumab|Single dose of 50 mg subcutaneously
46037589|NCT02782156|Other|Process evaluation|Adherence to screening and action algorithm
46037590|NCT05342116|Other|Nestle Preload|1 sachet of Preload (50g) diluted with 400ml of water, to be consumed 2 to 4 hours prior to the endoscopy.
46037591|NCT05342116|Other|Water|400ml of water to be consumed 2 to 4 hours prior to the endoscopy.
46037592|NCT04229446|Behavioral|Music based caregiving|The intervention (MBC) consists of daily individualized prerecorded music integrated with activity with about 30 minutes duration, combined with a one hour active session in groups twice weekly. The music will be selected based on individualized preferences from the patients or their family. The music will also be adapted to the day rhythm; awakening in the morning, support activities during the day, or for sleep in the evening. The healthcare worker will bring playback equipment e.g. a CD-player to the patient room. In addition will two weekly sessions in groups be performed (each on one hour) with music and movement.
45473833|NCT03993379|Drug|CX-072|CX-072 in combination with ipilimumab
45473834|NCT03993379|Drug|Ipilimumab|CX-072 in combination with ipilimumab
45473835|NCT01284881|Device|MRA|daily wear overnight
45473836|NCT03376282|Other|Hyperbaric Oxygen oxygen therapy (HBOT)|60 daily sessions, 5 days/week, 120 minutes each, 100% oxygen at 2ATA.
45473837|NCT03866291|Other|No intervention, observational|See above
45473838|NCT01173419|Device|VNUS RF ClosureFAST|VNUS® RF ClosureFAST is a minimally invasive varicose vein treatment procedure that uses radiofrequency energy (electricity) to heat, collapse and seal off the targeted blood vessels.
46037593|NCT02782936|Other|measurement of the work of breathing|"We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. A gas mask has been used mask (C4, Airboss Defence, Bromont, Canada).~Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Each condition lasted 10 minutes, data of the last 2 minutes at a steady state has been considered for analyses."
45342250|NCT00797979|Device|Skull Grip bone fixation|Skull Grip bone fixation
46037594|NCT02782936|Device|Gas mask|During the conditions that involved a gas mask, the measurement of the work of breathing is achieved with a oesophageal catheter and two disposable pneumotachs. While the oesophageal catheter has been fixed to the mandibular with an hypo-allergic tape, the two pneumotachs are hooked respectively on the canister and exhalation port of the gas mask. Investigators have induced the hypoxemia with a mixture nitreous and medical gas in a plastic bag that has been setted up to the canister. The FiO2 level has been kept to 14 percent.
46037595|NCT02782858|Drug|GNbAC1|Monthly IV repeated dose
46037596|NCT02782858|Drug|Placebo|Monthly IV repeated dose
46037597|NCT00864097|Biological|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 16)
45342251|NCT00797979|Device|sutures|Standard skull bon flap fixation, sutures
46037598|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
46037599|NCT00864097|Biological|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 16)
45473839|NCT01173419|Device|VenaCure EVLT NeverTouch|Endovenous Laser Treatment (EVLT) uses laser energy, which is a highly concentrated beam of light to treat varicose veins.
45473840|NCT03866447|Drug|Vitamin D analog|Patients will be clinically and photographically evaluated at baseline and at each follow up visit every month for 3 months. Any local or systemic clinical side effects of the medications will be noted during each follow up visit.
46037600|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
45342252|NCT00620854|Drug|Recombinant Salmon Calcitonin (rsCT)|Single dose of a nasal spray or one of two doses of tablets, randomized to visits 2, 3, and 4.
45342253|NCT00620854|Drug|Oral Tablet|0.15 mgs recombinant salmon calcitonin, single oral dose
45473841|NCT03866447|Drug|Adapalene|Patients will be clinically and photographically evaluated at baseline and at each follow up visit every
45473842|NCT03370120|Drug|Padsevonil|"Pharmaceutical Form: film-coated tablet~Route of Administration: Oral use"
45473843|NCT03247686|Drug|RSLV-132|RNase Fc fusion protein
45473844|NCT03247686|Drug|Placebo|Placebo
46037601|NCT00864097|Biological|tanezumab|IV tanezumab 2.5 mg every 8 weeks (through Week 16)
46037602|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
46037603|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
46037604|NCT00864097|Other|IV placebo|IV placebo to match tanezumab every 8 weeks (through Week 16)
46037605|NCT04230226|Dietary Supplement|Pre-workout plus and protein recovery plus|Study products consumed prior and after exercise
46037606|NCT04230226|Other|Placebo|Placebo product consumed prior and after exercise
46037607|NCT02782624|Drug|Empagliflozin|5 days of treatment with 5 mg BI 10773 bid until steady state
45342254|NCT00620854|Drug|Oral Tablet|0.2mgs recombinant salmon calcitonin, single oral tablet
45342255|NCT00620854|Drug|Nasal Spray|200 IU recombinant salmon calcitonin, single intranasal spray
45342256|NCT05672966|Biological|Human papillomavirus (HPV) Vaccine|0.5mL, Intramuscular
46037608|NCT02782624|Drug|Empagliflozin|5 days of treatment with 10 mg BI 10773 qd until steady state
46037609|NCT02781766|Other|Thrombin generation measurement.|
46037610|NCT02781688|Behavioral|Physical Activity|"Self-monitoring: Subjects will be provided with a commercially available activity monitor (i.e., Fitbit) and instructed to wear the device daily.~Active Living counseling: The Active Living counseling program will consists of 12 weekly group educational sessions, facilitated by project interventionists. These sessions will involve discussion of topics related to increasing physical activity, including: identifying and overcoming barriers, setting goals, social support, and time management.~Facility Access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills, stationary bikes, etc.)."
46037611|NCT00887536|Drug|bevacizumab|bevacizumab 15 mg/kg IV every 21 days for 6 cycles followed by bevacizumab 15 mg/kg IV every 21 days until 1 year following the first dose of bevacizumab
46037612|NCT00887536|Drug|docetaxel|docetaxel 75 mg/m2 IV every 21 days for 6 cycles
46037613|NCT00887536|Drug|doxorubicin|doxorubicin 50 mg/m2 IV every 21 days for 6 cycles
46037614|NCT00887536|Drug|cyclophosphamide|"Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles"
46037615|NCT00887536|Drug|pegfilgrastim|pegfilgrastim 6 mg subcutaneous (SC) Day 2 every 21 days for 6 cycles [filgrastim (Neupogen®) 5 mcg/kg Days 2-10 may be given in lieu of pegfilgrastim (Neulasta®), but pegfilgrastim is preferred.]
46037616|NCT02614339|Drug|metformin|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer and receive an additional prescription metformin. Metformin will be prescribed 1g/day (500mg, 2 table/day, or 1000mg, 1 table/day). After adjustment period for 1month, patients who do not have side effects will be taken metformin for additional 47 months (total 48months including the adjustment period).
45342257|NCT05672966|Biological|Placebo|0.5mL, Intramuscular
45342258|NCT00716924|Drug|Clopidogrel|300 mg
45342259|NCT00716924|Drug|Clopidogrel|600 mg
45342260|NCT00430027|Drug|Capecitabine|Given 650 mg/m^2 BID on days of ration therapy, 825 mg/m^2 day 1-14, day 15-20 off x 4
45342261|NCT00430027|Drug|Oxaliplatin|Oxaliplatin 30 mg/m^2, 130mg/m2 IV Q 21 days x 4
45342262|NCT00430027|Drug|Cetuximab|Initial Cetuximab 400 mg/m^2 IV starting no earlier than 8 weeks and no later than 10 weeks after surgical resection
45473845|NCT05160324|Procedure|Removal of axillary lymph nodes.|Axillary dissection in patients with positive sentinel lymph node
45473846|NCT05160324|Procedure|Preservation of axillary lymph nodes|Preservation of axillary lymph nodes in patients with positive sentinel lymph node
46037617|NCT02614339|Drug|control|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer.
46037618|NCT00697333|Procedure|restriction of radiotherapy to FDG-PET positive areas only|Restriction of target volumes to areas positive in positron emission tomography using fluoro-deoxy-glucose
46037619|NCT04132687|Procedure|autologous blood patch therapy|use autologous blood as blood patch therapy in persistent air leak
46037620|NCT02618395|Drug|SPARC001A|
46037621|NCT02618395|Drug|SPARC001B|
46037622|NCT02618395|Drug|Reference001 - Hydrocodone|Hydrocodone-acetaminophen
46037623|NCT01183013|Drug|Pioglitazone 15 mg|Pioglitazone Capsules 15 mg once daily for 30 weeks followed by Pioglitazone Capsules 30 mg once daily for up to 54 weeks
45473847|NCT03990649|Drug|Soticlestat|Soticlestat tablets
45683730|NCT01806896|Drug|PF-02545920|"5mg dose~Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days."
45473848|NCT03990649|Drug|Placebo|Soticlestat matching placebo tablets
46037624|NCT01183013|Drug|Pioglitazone 45 mg|Pioglitazone Capsules 30 mg once daily for 6 weeks followed by Pioglitazone Capsules 45 mg once daily for up to 78 weeks
46037625|NCT01183013|Drug|Pioglitazone 30 mg|Pioglitazone Capsules 30 mg once daily for up to 84 weeks
46037626|NCT01183013|Drug|Linagliptin 5mg / Pioglitazone 45 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg Tablets once daily for 6 weeks followed by Linagliptin 5mg low dose / Pioglitazone 45 mg FDC Tablets once daily for up to 78 weeks
46037627|NCT01183013|Drug|Linagliptin 5mg / Pioglitazone 30 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 84 weeks
46037628|NCT01183013|Drug|Linagliptin 5mg|Linagliptin 5mg Tablets low dose once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
45473849|NCT01175291|Drug|MK-0646|ARM A will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil [5-FU] + Bevacizumab) + MK-0646 (Investigational).
45683731|NCT01806896|Drug|Placebo|"Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days."
45683732|NCT01768676|Drug|avanafil|100 mg
45683733|NCT01768676|Drug|Placebo|
45683734|NCT01555125|Drug|secukinumab 150 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 150 mg treatment as open label for the remainder of the extension treatment period
46037629|NCT01183013|Drug|Linagliptin 5mg / Pioglitazone 15 mg FDC|Linagliptin 5mg low dose / Pioglitazone 15 mg FDC Tablets once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
46037630|NCT04129801|Other|Isokinetic Dynamometer|Participants then executed two series of four uninterrupted repetitions of Ext and Flex of both legs, first with the dominant member and subsequently with the non-dominant member, at an angular velocity of 60o/s, with a 60-second interval between series.
45342263|NCT04043182|Procedure|ultrassound|The treatment protocol will consist of 10 sessions, lasting 20 minutes. The energy level corresponding to 59 J / cm2 (177 J / cm2) and frequency of 3 MHZ, applied in the anterior region of the abdomen, in a quadrant previously delimited with a ballpoint pen, will be used. The flanks (lateral of the abdomen) will not be treated.
46037631|NCT04129801|Other|Bioimpedance|Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).
46037632|NCT02618629|Drug|14C-Z-215|Single oral dose of 20mg Z-215 and 14C-Z-215 solution
46037633|NCT04132609|Behavioral|Cognitive bias modification|: In CBM, the task presentation and timing is the same as attentional bias, except the probe always replaces the neutral word. It ensures that: 1) the duration of CBM and control training should not differ; 2) CBM and control participants receive equal practice on the motoric aspects of the task; and 3) CBM and control participants are exposed to the same word cues. Based on previous data, duration of CBM and control trainings will be about 10 minutes.
45342266|NCT04043260|Device|Advisor Pro|The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
45342267|NCT00717080|Procedure|IOL surgery|IOL surgery using capsular tension ring (AURORING)
45342268|NCT00717080|Procedure|IOL surgery|IOL surgery without CTR
45342269|NCT04766229|Combination Product|Citalopram +/- Gabapentin + Sleepio + support person|All participants will receive citalopram and/or gabapentin to manage vasomotor symptoms of menopause and will get access to digital CBT for insomnia and be asked to identify a support person
45342270|NCT04068506|Drug|Gabapentin 600 mg Tab|Gabapentin 600 mg Tab is a drug of choice for treating postoperative pain.
45342271|NCT03871335|Diagnostic Test|Investigation of the work-related musculoskeletal disorders|Structured questionnaires will be used to determine the prevalence of the work-related musculoskeletal disorders and work-related factor. Photogrammetric method will be used to evaluate working posture.
46037634|NCT04132609|Behavioral|Standard attentional bias|"the standard attentional bias task, a drug or pain-related word is presented next to a neutral word for 500ms. Subsequently, a probe (i.e., a q or p) replaces the drug/pain word or the neutral word at an equal rate. The participant's task is to indicate the location of the probe as quickly as possible by pressing q or p. Attentional bias is calculated from the difference in reaction times (i.e., neutral cue minus drug/pain cue) to indicate the location of the probe, with higher values indicating greater attentional bias. For all tasks, opioid and pain words will be presented in separate blocks in counterbalanced order. Neutral words paired with opioid or pain words will be matched for length and frequency of use in the English language."
45342272|NCT00851188|Behavioral|Internet CBT self-help|Internet based Cognitive behavioral self-help method for insomnia
45473850|NCT01175291|Drug|Placebo|ARM B will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil [5-FU] + Bevacizumab) + placebo: standard of care chemotherapy plus placebo.
46037635|NCT04132531|Procedure|Bariatric (weight loss) surgery|Surgical intervention for weight reduction, whereby the stomach is resected and the gastrointestinal tract is rerouted in the case of Roux-en-y gastric bypass, or the stomach is only resected in the case of sleeve gastrectomy.
46037636|NCT02615197|Behavioral|Dialectical Behavior Therapy|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
46037637|NCT02615197|Behavioral|Dialectical Behavior Therapy Prolonged Exposure protocol|Includes an adapted version of Prolonged Exposure therapy for PTSD.
46037638|NCT04229212|Device|hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State)|In the drained group, a hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State) was placed beneath the fascia of the gluteus muscle, surrounding the entry point of the nail at the fracture site.
46037639|NCT02618473|Other|non-seloken|regarding the guidelines patients receive seloken before the cardiac CT scan to lower the heart rate during the scan. The intervention in this study is to avoid the medication with seloken before the scan, and to investigate if the use of a new motion correction scan algorithm can compensate for the absence of the seloken.
45342273|NCT00851188|Behavioral|CBT self-help booklet|Cognitive behavioral self-help method for insomnia via booklet
45342274|NCT00851188|Other|Waiting list|Waiting list
45342275|NCT04068740|Procedure|Surgical treatment of valvular heart disease|Valve replacement or repair
45342276|NCT04068740|Diagnostic Test|Virtual treatment|Virtual valve replacement or repair surgery
45342277|NCT00803907|Drug|Imiquimod 5% cream|Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average)
45342278|NCT00843154|Drug|Candesartan and standard chronic heart disease therapy|Candesartan 4mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for two weeks; then Candesartan increased up to 32mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
45342279|NCT00843154|Drug|Standard chronic heart disease therapy|Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
45342280|NCT00803985|Procedure|Total Extraperitoneal repair (TEP)|Operation for primary inguinal hernias i men
45342281|NCT00803985|Procedure|Lichtenstein|Operation for primary inguinal hernias i men
46037640|NCT00634660|Drug|rAvPAL-PEG|rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.
45342282|NCT00429793|Drug|temsirolimus|Given IV
45342283|NCT00851266|Biological|V512|"Subjects received 1 of 8 formulations of the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6:~1) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 2) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 3) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 4) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 5) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX; 6) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 7) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 8) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX;"
45342284|NCT00851266|Biological|Comparator: Placebo to V512|Subjects received placebo to the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6.
45473851|NCT03863717|Other|Arm Endurance Exercise Training|Pulmonary Rehabilitation Program including Upper Limb Endurance Exercise Training with arm cycle ergometer
46037641|NCT02886767|Other|skin to skin contact|The researchers facilitated initial SSC between intervention-group participants and their infants within 24 hours of birthing under conditions that did not adversely affect spontaneous mother-infant SSC nor interfere with the early initiation of breastfeeding. Because it is standard practice to discharge vaginal-birth mothers on the third postpartum day, this study implemented the intervention during the first three postpartum days for both vaginal and cesarean birth cases.
46037642|NCT00922753|Other|VS|Spontaneous breathing of 100% oxygen in a facemask for 3 minutes
46037643|NCT00922753|Other|AI-4/PEEP-4|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes
46037644|NCT00922753|Other|AI-6/PEEP-4|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 6 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes.
45473852|NCT03863717|Other|Control|Pulmonary Rehabilitation Program without Upper Limb Endurance Exercise Training
46037645|NCT05141500|Device|STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS|"Reprocessed noninvasive pulse oximeters~1859 & 2329~MAX-A & MAX-N"
46037646|NCT04312373|Other|Ankle Foot Orthosis|"According to the SCED methodology, patients were fitted with ankle foot orthosis intermittently, during 4 phases, in the following order : without orthosis (A1), with orthosis (B1), again without orthosis (A2) and again with orthosis (B2).~All the phases were carried out over one day."
46037647|NCT02618239|Dietary Supplement|Bimuno Galacto-oligo-saccharide|
46037648|NCT05341102|Drug|LY3556050|Administered orally.
46037649|NCT05341102|Drug|Placebo|Administered orally.
46037650|NCT02615041|Drug|Meropenem|1 g in 100 ml of normal saline solution and administered via bolus injection Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 hh after 3rd dose of meropenem
46037651|NCT02615041|Drug|Meropenem|"1 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and~1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
46037652|NCT02615041|Drug|Meropenem|"2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
46037653|NCT04229602|Drug|Venlafaxine Hydrochloride Sustained-Release Capsules 75 mg|A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.
46037654|NCT04229602|Drug|EFEXOR® XR|EFEXOR® XR (75mg) produced by Pfizer Ireland Pharmaceuticals(held by Pfizer Healthcare Ireland, distributed by Wyeth pharmaceutical co. LTD)
46037655|NCT05298163|Drug|Calcitriol capsules|Calcitriol under the name of Oscal, 0.25 mcg/day (minimum dose) will be given for 6 months, starting at the day of the time when inclusion criteria have been met.
46037656|NCT05298163|Drug|Placebo|One placebo capsule matching the active drug will be given per day for 6 months, starting at the day of the time when inclusion criteria have been met
46037657|NCT05133232|Device|SynPhNe physio-neuro platform|"The SynPhNe device training protocol lasting approximately 60 mins:~Preparation for setup (~5 mins)~Instruction video led warm up with active single and multi-joint movements - (~20 mins): • Wrist extension and flexion• Fingers extension and flexion• Arm pronation and supination• Open grasp and close grasp • Open pinch and close pinch• Pronate and close grasp/ supinate and open grasp~Rest break - (~5 mins)~Video led task practice as per the tasks below (any 4 tasks only) - (~30 mins) • Grasp, lift and transfer water bottle using cylindrical grasp• Grasp lift and transfer pen using pinch grip• Flip pages of a book using lateral pinch grip• Use chopsticks to lift, transfer and place a small object• grasp doorknob and turn clockwise/anticlockwise, spoon scoop to pick up macaroni, open/ close a cylindrical jar, put object in pouch while holding it open and close it, fold/crease/tear a A4 size paper or fold handkerchief, reach a basket at different heights with an object."
46037658|NCT01141283|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
45683735|NCT01555125|Drug|secukinumab 300 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 300 mg treatment as open label for the remainder of the extension treatment period
45683736|NCT01555125|Drug|placebo|Subjects who were on placebo at Week 52 cannot continue in the extension treatment period
45683737|NCT01768286|Drug|LDV/SOF|Ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg fixed-dose combination (FDC) tablet administered orally once daily
45683738|NCT01768286|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45683739|NCT01800968|Drug|Liraglutide|Active Drug
45683740|NCT01800968|Drug|Placebo|Placebo
45683741|NCT01799720|Dietary Supplement|Less oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 1 took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet, . Follow-up 30 days
46037659|NCT01141283|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
45473853|NCT05572008|Behavioral|Protein nutrition in paediatric Crohn's disease|"All participants (N = 40) will undergo the same study procedures:~Eating behaviour questionnaire(s) completion Duration: 5 minutes Frequency 2 Dietary intake data via online computerised recall Duration: 60 minutes Frequency: 3 Collection of blood sample via venepuncture Duration: 15 minutes Frequency 1 Strength Tests Duration: 30 minutes Frequency: 1~Half the participants (N = 20) will return for two more visits and will undergo the following procedures:~MRI Scan Duration: 30 minutes Frequency: 1 Consumption of intrinsically labelled protein Duration: 15 minutes Frequency: 1 Insertion of cannulae into hand Duration: 15 minutes Frequency: 1 Collection of blood sample via cannulae (for protein digestion and inflammatory markers and study endpoints outlined below) Duration: 1 minute Frequency: 17"
45473854|NCT03230266|Procedure|Collection of intra-peritoneal catheters for insulin infusion|Collection of intra-peritoneal catheters for insulin infusion
45473855|NCT03732469|Drug|Acetaminophen|Rectal acetaminophen will be administered to the intervention group at the conclusion of the oocyte retrieval.
45473856|NCT03732469|Drug|Fentanyl|Weight-based IV Fentanyl as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
45473857|NCT03732469|Drug|Propofol|Weight-based IV Propofol as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
45473858|NCT01175447|Drug|S-1|S-1 was administered on days 1-14 and 29-42 at the following dosages: 60, 70, and 80mg/m(2)/day
46037660|NCT01141283|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
46037661|NCT05340946|Procedure|general anaesthesia|intraoperative general anaesthesia followed by postoperative IV patient analgesia
45473859|NCT02519998|Other|Concussion|Study groups are differentiated based on presence of concussion. No intervention is being made in either population (observational study)
46037662|NCT05340946|Procedure|spinal anaesthesia|patient received spinal followed by continuous ultrasound guided femoral never block.
46037663|NCT00863707|Drug|Regadenoson|IV
45473862|NCT01313988|Dietary Supplement|Plant sterols and fish oil|4 weeks intervention, 3 times daily
45473863|NCT01313988|Dietary Supplement|Plant sterols|4 weeks intervention, 3 times daily
46037664|NCT00863707|Drug|Placebo|IV
46037665|NCT05340634|Dietary Supplement|Metionac|Metionac is a food suplement composed by 200 mg of SAMe, 100 mg of NAC, 75 mg of ALA and 0,65 mg of vitamin B6 per tablet for 6 months
46037666|NCT05340634|Drug|Oral contraceptive|Drospirenone 4 mg once a day
46037667|NCT02886689|Drug|TNF-alpha antagonist and other biotherapy|
46037668|NCT04181086|Procedure|surgical excision of intracranial cavernoma|microvascular excision of intracranial cavernoma
45342285|NCT04067570|Radiation|SBRT|Stereotactic body radiation therapy, or SBRT, is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue
45473864|NCT01313988|Dietary Supplement|Placebo|4 weeks, 3 times daily
45473865|NCT03743857|Procedure|Manual Therapy|AP ankle mobilization
45473866|NCT03863327|Other|No intervention|There will be no intervention as a part of this protocol.
46037669|NCT05367479|Drug|Antibiotic|Peri-operative, intravenous antibiotic for surgical site infection
46037670|NCT02614105|Procedure|Pelvic floor muscle training|16 weeks of group-based exercise
46037671|NCT02614105|Procedure|Cough-suppression therapy|Group and individual sessions of respiratory physiotherapy with focus on techniques to suppress cough
46037672|NCT02614105|Other|Control|Brief information only
46037673|NCT02780830|Drug|AZD2014|AZD2014 will be supplied as oral tablets. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week.
46037674|NCT02780830|Drug|Ibrutinib|Ibrutinib will be provided in hard gelatin capsules in opaque high-density polyethylene bottles. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.
45342286|NCT00806871|Drug|Methylprednisolone 40 mg|"Depo-medrol 40 mg , suspension, injection in the carpal tunnel, one time use~1 ml 40 mg Methylprednisolone + 1 ml 10mg Lidocaine + 1 ml saline"
45342287|NCT00806871|Drug|Methylprednisolone 80 mg|"Depo-medrol 80 mg , suspension, injection in the carpal tunnel, one time use.~2 ml 80mg Methylprednisolone + 1 ml 10mg Lidocaine"
45342288|NCT00806871|Drug|Sodium chloride|"Saline solution 0,9%, injection in the carpal tunnel, one time use~1 ml 10 mg Lidocaine + 2 ml saline"
45342289|NCT00717158|Behavioral|Usual medical care|
45473867|NCT03381352|Radiation|Chemo-radiotherapy with IMRT technique|IMRT radiation technique; 50.4-54Gy/25F
45473868|NCT03381352|Drug|Capecitabine|Capecitabine 825mg/m2 PO BID
46037675|NCT04187807|Drug|Melatonin 5 mg|Placebo
46037676|NCT02780752|Drug|hymecromone|Oral Hymecromone
45840033|NCT00585780|Drug|Prazosin Tablet|Target medication dosing was three times/day (t.i.d. dosing) with 5 mg in the morning, 5 mg in the afternoon and 6 mg at night reached at the end of the 2-week period, and maintained at this or their highest tolerated dose until week 11, followed by a 5-day taper in week 12, as in previous research.The titration schedule was as follows: 1 mg dose at bedtime for 2 nights, followed by a 1mg dose morning and night (8 AM/8 PM) on day 3, then 2 mg dose t.i.d., on days 4-6, 3 mg dose (2 pills each) morning and afternoon, and 4 mg dose (2 pills) at night for days 7-9, increased to 4 mg dosing t.i.d. on days 10-13, and from day 14 through week 11, 5 mg (1 pill) each in the morning and afternoon, and 6 mg for the night (2 pills) dose. This was followed by a 5-day taper in week 12. Patients were initiated on study medication upon presenting with a negative breathalyzer without any minimum pre-treatment alcohol abstinence period prior to medication initiation.
45840034|NCT00585780|Drug|Placebo Tablet|Placebo tablets identical in appearance and dosing schedule as the active study medication was utilized
45473869|NCT03381352|Drug|Mitomycin C|Mitomycin C 10mg/m2 D1,29 iv
45473870|NCT05571930|Procedure|Secondary TEVAR after initial FET procedure|Under general anesthesia, via percutaneous femoral access, the investigators implant a TEVAR in the endovascular part of a FET. This secondary connexion is indicated in case distal thoracic aortic involvement such as aneurysm or dissection.
45473871|NCT01175525|Drug|CROMOLYN|Cromolyn 200mg (dissolved in water) given 4 times a day
45473872|NCT01175525|Drug|sugar pill|sugar pill Dissolved in water taken 4 times daily 30 minutes prior to meals
45840035|NCT00586170|Device|EBI Bone Healing System|10 hours of treatment per day for up to 24 weeks
46037677|NCT02781298|Dietary Supplement|New Infant Cereal|The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
46037678|NCT02781298|Dietary Supplement|Multicereals Infant Cereal|The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
45840036|NCT00586170|Device|Placebo Device|10 hours of treatment per day for up to 24 weeks
46037679|NCT05168033|Other|Motor imagery training|Mentally imagine to perform rehabilitation exercises or sport-specific tasks without generating actual motor output.
46037680|NCT05168033|Other|Classic rehabilitation|Classic rehabilitation after anterior cruciate ligament reconstruction focusing on regaining mobility, stability and strength of the knee joint and return to sport.
45473873|NCT05571852|Device|CogniFit's CCT Post COVID-19|The computerized cognitive training (CCT) program is tailored to each person's specific cognitive strengths and weaknesses detected in the Cognitive Assessment Battery (CAB)™ PRO (CogniFit Inc., San Francisco, US; https://www.cognifit.com/cab) by a patented Individualized Training System™ (ITS) software.
46037681|NCT04132297|Behavioral|Asthma Academy|The Asthma Academy is a one hour virtual training that includes providing information about asthma, asthma medications, communicating with healthcare providers and navigating healthcare resources.
45473874|NCT03375190|Other|Dressing|Transparent film dressing (TegadermTM CHG Chlorhexidine Gluconate IV Securement Dressing, 3M Health Care, St. Paul, MN, USA) alone
46037682|NCT04132297|Behavioral|Telehealth Visit|The telehealth Visit will be conduct by a trained Doctor of Nurse Practice (DNP) student via a scheduled meeting through zoom on the participant's smart phone or computer. The visit will last about one hour wherein participant will be asked about their asthma knowledge and will be given information about asthma.
46037683|NCT01094184|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 10 mg/kg Q2W or 15 mg/kg Q3W as intravenous infusion.
46037684|NCT01094184|Drug|Paclitaxel|Paclitaxel will be administered as intravenous infusion Q1W as per discretion of the treating physician.
45683742|NCT01799720|Dietary Supplement|More oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 2 took 2 capsules/day of one of the more oxidized oil (containing 300 mg EPA + DHA) and diet . Follow-up 30 days
45840037|NCT00586170|Procedure|Surgery|Open Reduction and Internal Fixation of the nonunion site
45342290|NCT00717158|Behavioral|Lifestyle Case management|Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
45342291|NCT00855400|Procedure|Laminectomy and bone marrow stem cells transplantation|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
45342292|NCT00855400|Procedure|Autologous bone marrow cells collection|Autologous bone marrow cells collection under sedation. Sixty mL are obtained and processed through a ficoll gradient.
45840038|NCT00586482|Drug|Nicotine Lozenge|Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day and a 2 minute behavioral intervention. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.
46037685|NCT01094184|Drug|Docetaxel|Docetaxel will be administered as intravenous infusion Q3W as per discretion of the treating physician. Protocol amendment 2 (dated 17-Feb-2011) removed the option to choose docetaxel.
45840039|NCT00586482|Drug|Placebo Lozenge|Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day and a 2 minute behavioral intervention.
46037686|NCT00697879|Drug|CHR-3996|Once daily oral ingestion of capsules (5, 10, 20 or 40 mg), dose depending on cohort, treatment cycle of 28 days
45473875|NCT03375190|Other|Dressing + adhesive|Transparent film dressing + topical skin adhesive (SwiftSetTM Topical Skin Adhesive, CovidienTM Devon, UK) at insertion site
46037687|NCT02780908|Other|Graded exercise testing|All graded exercise tests will be performed on electromagnetically controlled cycle-ergometer Ergo Bike Premium. The testing protocol will commence with a 10-min resting period, to obtain the resting cardio-respiratory values, followed by a 5-min warm up at a work rate of 60 W. Thereafter the workload will increase every fourth minute by 40 W. The participants will be required to maintain a cadence of 60·min-1 throughout the whole test. The test is terminated when the participant is unable to maintain the assigned cadence.
46037688|NCT02780908|Other|Resting testing|The resting test will be performed in supine position with participants breathing normoxic air (FiO2=0.21) for 30 min and hypoxic gas for the subsequent 30-min (FiO2=0.120). During the whole protocol duration the respiration, local blood flow, ECG and EEG will be measured non-invasively.
46037689|NCT01134731|Drug|paliperidone|1-5 mg daily (QD)
46037690|NCT01134731|Drug|lithium|300-1500mg QD
45342293|NCT00798213|Drug|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21 day cycle until disease progression.
45342294|NCT00798213|Drug|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 9 mg/m2 IV on Day 1 and Day 15.
45342295|NCT04069208|Drug|Idarubicin and cytarabine induction|Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days
45342296|NCT04042246|Behavioral|Information Provision|Provide the information on the importance of the vaccination and tailored vaccination schedule
45342297|NCT04067258|Diagnostic Test|EDI-OCT|"EDI-OCT (enhanced depth imaging spectral domain optical coherence tomography) wiil be performed in all study participants.~Three sets of measurements in the macular (horizontal and vertical) and peripapillary area will be averaged."
45473876|NCT03375190|Other|Experimental: Dressing + adhesive + strips (parallel)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed parallel to long axis of catheter
45473877|NCT03375190|Other|Experimental: Dressing + adhesive + strips (perpend)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed perpendicular to long axis of catheter
45473878|NCT03375190|Other|Experimental: Dressing + adhesive + strips + benzoin|Transparent film dressing + topical skin adhesive + skin closure strips + topical benzoin (Compound Tincture of Benzoin USP 10%, Professional Disposables International, Inc., Orangeburg, NY, USA) spread in a 12 centimeter by 14 centimeter area around the insertion site
46037691|NCT01134731|Drug|Placebo|1-5 placebo capsules
46037692|NCT04132063|Drug|Generic levetiracetam|Generic levetiracetam tablet as the same dose as original levetiracetam tablet at the switching date
46037693|NCT05340556|Genetic|Blood sample|Blood sample of 12 ml EDTA plasma.
46037694|NCT05340556|Genetic|Swap test|receive swab tests for collecting cells from the oral mucosa
46037695|NCT04127071|Procedure|Ultrasound-guided Needle Aspiration Procedure|The intervention under investigation utilizes an ultrasound-guided needle to less invasively drain an abscess.
46037696|NCT04127071|Procedure|Incision and Drainage (I&D)|The current standard procedure to drain an abscess of purulent material.
45342298|NCT00807027|Drug|Activated T lymphocyte(Immuncell-LC)|"Efficacy/Effects: Removal of minimal residual cancer after removal of brain tumors and relapse prevention~Method of administration and quantity: Test Drug: Per 60kg of average adult body weight, administer 100mg that contains 109~2x1010 lymphocytes for one hour intravenously. (Duration of administration can be controlled based on patient conditions)"
45473879|NCT03375190|Other|Experimental: Dressing + adhesive + strips + spray|Transparent film dressing + topical skin adhesive + skin closure strips + medical adhesive spray (AdaptTM Medical Adhesive, Hollister Incorporated, Libertyville, IL, USA) in a 12 centimeter by 14 centimeter area around the insertion site
45840040|NCT00586482|Behavioral|Abstinence Advisement|A brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times.
46037697|NCT01141205|Biological|AFO-18|18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)
46037698|NCT01141205|Drug|Saline|1.2 ml saline intramuscularly
45342299|NCT00424645|Drug|Voraxaze (Glucarpidase)|50 units/kg IV within 12 hours of study eligibility being confirmed.
45342300|NCT00424645|Drug|Placebo|Administered by IV within 12 hours of study eligibility being confirmed.
45342301|NCT00845104|Drug|fludarabine phosphate|Given IV
45342302|NCT00845104|Biological|rituximab|Given IV
45342303|NCT00845104|Biological|bevacizumab|Given IV
46037699|NCT02618317|Drug|Heparin Lock Solution|Just after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
46037700|NCT02618317|Drug|Trissodium Citrate 30%|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
45342304|NCT00845104|Other|laboratory biomarker analysis|Correlative studies
45342305|NCT00845104|Other|flow cytometry|Correlative studies
45342306|NCT00845104|Genetic|polymerase chain reaction|Correlative studies
45342307|NCT00845104|Genetic|fluorescence in situ hybridization|Correlative studies
45342308|NCT00804063|Procedure|drawing blood sample|fasting blood sample
45683743|NCT01799720|Drug|Hypercholesterolemic diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 3 only received the diet and no capsules. Follow-up 30 days
46037701|NCT02618317|Drug|Minocycline-EDTA 30 mg/ml - 3 mg/ml|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
46037702|NCT02781376|Other|CHICA OSA|Computer decision support system module that assesses snoring, assesses additional OSA symptoms, provides guideline-based recommendation to PCPs, and reassesses for residual OSA symptoms.
45342309|NCT02553681|Device|roflufocon D contact lenses|HPT treated rigid contact lenses
45342310|NCT02553681|Device|RGP contact lenses made from roflufocon D|
45342311|NCT01034605|Dietary Supplement|PinnoThin|6.0 gram of the oil extract from the korean pine nut (PinnoThin) as a single dose
45683744|NCT01687257|Drug|SOF|SOF 400 mg tablet administered orally once daily
46037703|NCT02781376|Other|Snoring Identification Only|Computer decision support system module that assesses snoring and alerts the PCP when caregivers endorse snoring.
46037704|NCT02614963|Drug|Clostridium Butyricum|Irritable bowel syndrome patients treated with Clostridium Butyricum
46037705|NCT02614963|Drug|placebo|Irritable bowel syndrome patients treated with placebo
46037706|NCT01140503|Drug|Apremilast|Apremilast 20mg PO BID
46037707|NCT02689726|Drug|GTL001+|
46037708|NCT02689726|Drug|Aldara|5% imiquimod cream
45342312|NCT03994939|Behavioral|Families Talking Together (FTT)|FTT is an evidence-based program designed to increase parent-adolescent communication about sex in order to delay sexual debut and prevent negative SRH outcomes in young adolescents (aged 10 to 14). The FTT intervention has been delivered with efficacy in multiple settings, including schools and clinics (Guilamo-Ramos et al., 2011a; Guilamo-Ramos et al., 2011b).
45342313|NCT00763451|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
45683745|NCT01687257|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
46037709|NCT00863317|Drug|montelukast sodium|4mg granules daily for 14 days
46037710|NCT00863317|Other|sucrose|table sugar as placebo daily for 14 days
46037711|NCT02883413|Behavioral|CRT + Teach the Parent|CRT sessions will occur for 45-60 minutes every day (excluding weekends) for 6-8 days while adolescents are in hospital. Adolescents will be given homework and asked to practice tasks each day.
46037712|NCT02883413|Behavioral|CRT + Contact Control|Adolescents will be asked to spend 3-4 sessions with their parents engaging in fun activities (games, coloring, trivia). Adolescents will be able to choose 2 tasks from a list and be asked to engage in those tasks with their parents.
46037713|NCT02744092|Drug|Rivaroxaban|Anticoagulation therapy.
45342314|NCT00763451|Drug|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
45342315|NCT00763451|Device|Pen auto-injector|
45342316|NCT00763451|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
45342317|NCT00762762|Drug|Triclosan/copolymer/fluoride|Brush whole mouth 2x/day for 12 months with triclosan/copolymer/fluoride toothpaste. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
45342318|NCT00762762|Drug|Fluoride|Swished around whole mouth twice daily for 12 months. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
45342319|NCT00424489|Biological|Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation
45342320|NCT00424489|Drug|Cyclophosphamide|
45342321|NCT00424489|Drug|ATG (rabbit)|
45473880|NCT03735355|Procedure|Surgery|Surgical resection of fibrostenotic area
45473881|NCT03735355|Procedure|TTS balloon dilation|Dilation of a stricture using TTS balloon
45473882|NCT01175603|Behavioral|Mothers and Babies Course (Adapted for Baltimore Home Visiting Programs)|6 weekly 2-hour cognitive-behavioral intervention sessions held in group format
46037714|NCT02744092|Drug|Apixaban|Anticoagulation therapy.
46037715|NCT02744092|Drug|Edoxaban|Anticoagulation therapy.
45342322|NCT00424489|Drug|Mesna|
45342323|NCT00424489|Drug|Methylprednisolone|
45342324|NCT00424489|Drug|G-CSF|
45342325|NCT00578864|Drug|Protracted Oral Etoposide|"Cisplatin with Oral Protracted Etoposide for cycles 1, 2 and 4~Day 1 - 5~Hour 0: Etoposide 50 mg/m2 po daily~Hours 1 to 7: Cisplatin 40 mg/m2~Day 6 - 14~Etoposide 50 mg/m2 po once daily"
46037716|NCT02744092|Drug|Dabigatran|Anticoagulation therapy.
46037717|NCT02744092|Drug|Warfarin|Anticoagulation therapy.
46037718|NCT02744092|Drug|Dalteparin|Anticoagulation therapy.
46037719|NCT02744092|Drug|Enoxaparin|Anticoagulation therapy.
46037720|NCT02744092|Drug|Fondaparinux|Anticoagulation therapy.
46037721|NCT01200368|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL per dose, 4 doses
46037722|NCT01200368|Biological|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
46037723|NCT01200368|Biological|7-valent pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
46037724|NCT01200368|Biological|DTaP|0.5 mL per dose, 4 doses
46037725|NCT01200368|Biological|DTaP|0.5 mL per dose, 4 doses
46037726|NCT00697957|Behavioral|Exercise|Progressive impact exercise
45473883|NCT04818424|Device|Soft exosuit|A soft exosuit is a textile-based wearable robot that is worn on the paretic ankle. Soft exosuits provide assistive torques through retraction of Bowden cables that connect distally to anchor points on front and back of the ankle, assisting with dorsiflexion during swing for foot clearance, and plantarflexion during late stance to assist with propulsion, respectively. Exosuit assistance is provided synchronously based on the wearer's gait, as detected by integrated inertial measurement units.
45840041|NCT05247216|Drug|Hemay007 800 mg QD group|daily oral administrtion of Hemay007 800 mg QD for 12 weeks, 4 tablets of 200mg Hemay007 and 2 tablets of placebo.
46037727|NCT02878668|Procedure|hepatopancreatobiliary surgery|hepatopancreatobiliary surgery
46037728|NCT04125121|Drug|Sevoflurane-propofol|General anaesthesia with a maintenance phase of two hours duration with either sevoflurane or propofol.
45840042|NCT05247216|Drug|Hemay007 1200 mg QD group|daily oral administrtion of Hemay007 1200 mg QD for 12 weeks, 6 tablets of 200mg Hemay007.
46037729|NCT02618083|Device|color Doppler ultrasound|pre-operative blood flow velocity measurement with a color Doppler ultrasound device
46037730|NCT01079130|Drug|Indacaterol|Once daily via Concept1, a single-dose dry powder inhaler (SDDPI) for two week. Dosage varies according to randomization scheme.
46037731|NCT01079130|Drug|Salmeterol|50 µg Salmeterol twice daily in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.
45342326|NCT00578864|Drug|Doxorubicin|"Given together with cyclophosphamide for cycle 3 and 5 of induction chemotherapy Day 1 and 2~Hours 0 to 6: Cyclophosphamide 2000 mg/m2 (67 mg/kg if < 12 kg) with Mesna 400 mg/m2 (13 mg/kg if < 12 kg) in D5½NS 600 mL/m2 IV over 6 hours to run at 100 mL/m2/hr~Hours 6 to 6.25: Doxorubicin 37.5 mg/m2 (1.25 mg/kg if < 12 kg) IV over 15 minutes"
45342327|NCT00578864|Drug|IV Bolus Etoposide|"Cisplatin with Bolus IV Etoposide~Day 1~Hours 0 to 6: Cisplatin 40 mg/m2~Days 2, 3, 4:~Hours 0 to 1: Etoposide 200 mg/m2 Hours 1 to 7: Cisplatin 40 mg/m2~Day 5:~Hours 0 to 6: Cisplatin 40 mg/m2"
45342328|NCT00578864|Drug|Cisplatin|Cycle 1, 2, and 4
45473884|NCT04818424|Behavioral|Gait training without exosuits|Control intervention will implement gait training without exosuits. Other elements of intervention are similarly structured as with REAL, with the only exception of using exosuits.
45473885|NCT03185481|Drug|1 mg QD to 15 mg QD PF-06649751|Up titration from 1 mg QD to 15 mg QD PF-06649751
46037732|NCT01079130|Drug|Placebo to Indacaterol|Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI.
45473886|NCT03185481|Drug|3 mg QD to 15 mg QD PF-06649751|Up titration from 3 mg QD to 15 mg QD PF-06649751
46037733|NCT01079130|Drug|Placebo to Salmeterol|Placebo to Salmeterol twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI).
45342329|NCT00578864|Drug|Cyclophosphamide|Cycle 3 and 5 with doxorubicin
45342330|NCT00578864|Drug|Mesna|Standard weight-based dosing with cyclophosphamide
45342331|NCT00578864|Drug|Hematopoietic Factor|Standard weight-based dosing after cycle 3 and 5 and if needed for neutropenic recovery after cycles 1,2 and 4
45342332|NCT00578864|Procedure|Primary tumor resection|Resection of primary tumor after cycle 3, 4, or 5 as clinically appropriate
45342333|NCT01034683|Drug|lobaplatin , 5-FU ,leucovorin|Participants received 2-hour lobaplatin (30 mg/m2 on day 1) and a 2-hour infusion of leucovorin (LV; 200 mg/m2 on days 1-5) followed by a 4-hour infusion of 5-FU (650 mg/m2 on days 1-5). Treatment was repeated every 21 days.
45342334|NCT02579070|Device|DFUPS|The DFUPS device is a two-camera instrument for capturing images of feet.
45342335|NCT00717470|Drug|Prograf®|oral
45342336|NCT00717470|Drug|Advagraf®|oral
45342337|NCT00717470|Drug|Mycophenolate Mofetil|oral
45342338|NCT00717470|Drug|Simulect|oral
45473887|NCT03185481|Drug|7 mg QD to 15 mg QD PF-06649751|Up titration from 7 mg QD to 15 mg QD PF-06649751
46037734|NCT05341570|Drug|BPI-21668|Subjects will receive BPI-21668 until disease progression
46037735|NCT05117632|Drug|ALTO-100 PO tablet|one tablet twice daily
46037736|NCT05113264|Device|'Penny' via Memora Platform|"The overall objective of this study is to evaluate the feasibility and safety of a novel SMS text- based intervention of an Algorithmically Driven Augmented Intelligence chatbot, Penny. This chat bot will walk patients through how and when to take their oral chemotherapies, as well as provide real-time management of side effects Grade II or less, and escalate to the clinical team side effects of Grade III or more, as based on the Common Terminology Criteria for Adverse Events (CTCAE), for patients that have a gastrointestinal (GI) cancer."
45342339|NCT00717470|Drug|methylprednisolone / prednisone|oral
45342340|NCT02577198|Other|Medilogy Decision Support System (MediDSS)|Italian translation of Evidence-Based Medicine electronic Decision Support (EBMeDS), a set of rules (scripts) based on Evidence Based Medicine guidelines and applied to structured health data. MediDSS further includes knowledge from Swedish, Finnish, INteraction X-referencing (SFINX), a drug-drug interaction database containing concise evidence-based information of about 18,000 drug interactions and adverse events. MediDSS is integrated with local reminders.
45342341|NCT00631566|Drug|Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%|"BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649).~pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration.~Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days."
45342342|NCT00631566|Drug|Placebo|Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.
45473888|NCT03185481|Drug|15 mg QD PF-06649751|15 mg QD PF-06649751 remaining at 15 mg QD PF-06649751
45473889|NCT03185481|Drug|1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study)|Up titration from 1 mg QD to 7 mg QD PF-06649751 for subject at 1 mg QD who were blindly de-escalated in the parent study
45473890|NCT03185481|Drug|3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)|Up titration from 3 mg QD to 7 mg QD PF-06649751 for 3 mg QD subjects who were blindly de-escalated in parent study
45840043|NCT05247216|Drug|Hemay007 600 mg QD group|daily oral administrtion of Hemay007 600 mg QD for 12 weeks, 3 tablets of 200mg Hemay007 and 3 tablets of placebo.
45342343|NCT04067414|Biological|BZ019|"Subjects will be enrolled in three dose-groups:~Dose 1: 1×10^6/kg CAR+ cells; Dose 2: 3×10^6/kg CAR+ cells; Dose 3: 6×10^6/kg CAR+ cells."
45473891|NCT03185481|Drug|7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)|7 mg QD to remain at 7 mg QD PF-06649751 for subjects who were blindly de-escalated in parent study
46037737|NCT02689414|Procedure|Remote ischaemic preconditioning|Ischaemia is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 200 mm Hg or to a value that is 20 mm Hg greater than the patient's systolic blood pressure - if the patient's systolic blood pressure is more than 180 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
46037738|NCT02689414|Procedure|Control to RIPC|Venous pressure is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 10-20 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
46037739|NCT01078974|Drug|pomalidomide|Taken orally once a day
45342344|NCT00717548|Behavioral|Narrative Exposure Therapy|Trauma-Focused short term intervention (8-12 sessions)
45342345|NCT00722852|Drug|ketoprofen in Diractin®|100 mg (b.i.d.)
45342346|NCT00722852|Drug|Placebo|100 mg (b.i.d.)
46037740|NCT01078974|Drug|dexamethasone|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
46037741|NCT01078974|Drug|rituximab|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
45342347|NCT04838418|Procedure|Optic nerve sheath diameter measured by transorbital ultrasound|Optic nerve sheath diameter measured 3 mm behind eyeball. For every eyeball 2 measurements in axial and 2 measurements in sagital projections are performed. Summary value for every eyeball is arithmetic mean from these 4 measurements.
46037742|NCT04307082|Drug|[14C]-Ibrexafungerp|Radio-labeled Ibrexafungerp, single dose.
46037743|NCT05105308|Behavioral|Family Assisted Diet (FAD)|A behavioral intervention consisting of helping parents renourish their child and conduct food exposures with new foods.
45342348|NCT00770315|Biological|Ambrosia artemisiifolia allergen extract (Amb a 1-U)|Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.
45342349|NCT00770315|Biological|Placebo|Placebo matching Ambrosia artemisiifolia allergen extract rapidly dissolving tablet, administered sublingually once daily
45342350|NCT04071600|Drug|Neuropeptide Y|Intranasal
45342351|NCT04071600|Other|Placebo|intranasal
45342352|NCT05657444|Drug|Tenecteplase|intra-arterial tenecteplase during endovascular treatment
45473892|NCT03185481|Drug|15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD|7mg QD PF-06649751 for subjects assigned to 15 mg QD who were blindly de-escalated to 7 mg QD PF-06649751 in parent study
45683746|NCT01806740|Drug|Gadoterate meglumine|Gadoterate meglumine was administered at a dose of 0.1 mmol/kg (0.2 mL/kg) using a power injector, in an intravenous bolus at a rate of 3 mL/sec.
45473893|NCT03863249|Procedure|SCALE AND ROOT PLANING|"SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~Each session will be carried out with the following materials: - Ultrasound device (SONICflex 2003 / L) and curettes (Hu-Friedy Manufacturing, Illinois, USA)."
45683747|NCT01687101|Drug|STOPAIN topical gel|STOPAIN topical gel is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
45683748|NCT01968967|Drug|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
45683749|NCT01968967|Other|Placebo|subcutaneous injection every 2 weeks for 12 months
45683750|NCT01554579|Drug|Gefapixant|BID
45683751|NCT01554579|Drug|Sugar Pill|Placebo
45683752|NCT01806662|Drug|Ustekinumab|Injection of monoclonal antibody against the p40 subunit of IL-12/23
45683753|NCT01806662|Other|Placebo|Injection of placebo
45840044|NCT05247216|Drug|Hemay007 placebo group|daily oral administrtion of placebo for 12 weeks 6 tablets of placebo.
45840045|NCT03708354|Drug|placebo softgel|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
46037744|NCT05105308|Behavioral|Feeling and Body Investigator_ARFID Division|A sensory and somatic focused intervention that educates children about feelings and bodily sensations, in-session exposures to body and food sensations, different strategies to improve generalization while at home, and strategies to help them understand and track experiences exploring food.
45683754|NCT01930123|Drug|intravenous fructose challenge|"Patients will be admitted to our Duke Clinical Research Unit (DCRU) at least 12 hours prior to morning intravenous fructose challenge. All patients will have a standard meal in order to control for dietary composition and calorie intake prior to intravenous fructose challenge. Patients will be NPO (nothing by mouth) after midnight for morning IV fructose MR biomarker measures. Patients with suspected NAFLD will have had an historical standard of care liver biopsy in the past and will have IV fructose Magnetic Resonance biomarker measures in the morning."
46037745|NCT02877576|Procedure|Implantation of mixed intracerebral electrodes|"5 macro electrodes with micro electrodes are implanted in internal temporal structures (amygdala, anterior and posterior hippocampus, rhinal cortex, posterior para-hippocampal gyrus).~Each electrode has 8 microcontacts, each recording the activity of 0 to 3 neurons (activity of 0 to 120 neurons/patient)."
45342353|NCT04072302|Drug|KAF156|100 mg tablet, 20 mg tablet, 50 mg tablet
45342354|NCT04072302|Drug|Placebo|100 mg tablet, 20 mg tablet, 50 mg tablet
46037746|NCT02877576|Behavioral|Face detection|Visualization of images of 60 unknown faces and 60 objects that are not faces (object, house, scene, animal, plant, word, letter…). Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.
46037747|NCT02877576|Behavioral|Face individualization|"Visualization of images of celebrities (persons known by patient), showed randomly. Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.~Several celebrities are showed, with for each the presentation of 60 images different from that celebrity. 1 to 3 celebrities are showed (60 to 180 total images)."
45342355|NCT04103411|Other|24h-Ambulatory Blood Pressure|Effect of High Intensity Interval Training compared to Hydrochlorothiazide on ambulatory Blood Pressure.
45342356|NCT00525720|Drug|Brachytherapy|Brachytherapy implant procedure lasting 1-2 hours.
45342357|NCT00525720|Behavioral|Questionnaire|Questionnaires taking 30 total minutes.
45342358|NCT01410942|Other|Placebo|Capsules by mouth twice daily.
45342359|NCT01410942|Drug|Methylphenidate|Starting dose 5 mg by mouth twice daily.
45342360|NCT01410942|Behavioral|Counseling Sessions|8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each.
45342361|NCT01410942|Other|Sham Exercise|Participants in placebo/sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
45342362|NCT01410942|Other|Standardized Exercise Intervention Program|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist.
45683755|NCT01930123|Other|Blood Draw|Fasting bloodwork will be obtained before and after the IV fructose challenge.
45683756|NCT01930045|Drug|Raltegravir (ISENTRESS™)|Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.
45683757|NCT01930045|Drug|MAALOX (MAL)|MAL (or generic equivalent) 20 mL oral single dose on Day 1
46037748|NCT02878200|Biological|dihydroartemisinin-piperaquine|A treatment course of DHAP consists of three doses taken daily. Treatment doses for household members will be prepared based on measured weight
45342363|NCT01410942|Other|Cognitive Behavioral Therapy (CBT)|8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
45342364|NCT00587171|Device|Patching|2 hours daily patching
45342365|NCT00587171|Procedure|Near activities|30 minutes daily near activities at home
45342366|NCT00587171|Procedure|Active vision therapy|30 minutes of daily at-home active vision therapy and a weekly 45 minute in-office active vision therapy session
45342367|NCT00587171|Procedure|Control vision therapy|30 minutes of daily at-home control vision therapy and a weekly 45 minute in-office control vision therapy session
46037749|NCT05340088|Procedure|Retrograde intrarenal surgery after DJ stent placement|Patients who underwent RIRC for 2-4 weeks after DJ stent placement for passive dilatation
46037750|NCT04302012|Procedure|Color fundus photography|Subjects will undergo fundus photography before and/or after administration of mydriatic agent
46037751|NCT04302012|Drug|Mydriatic Agent|Subjects may be administered mydriatic medication to dilate their pupils.
46037752|NCT02780518|Device|Airvo|Applying high flow nasal oxygen
45342368|NCT04833426|Drug|Testosterone gel|Topical gel containing testosterone
45342369|NCT04833426|Drug|Placebo|Topical gel without active substance
45342370|NCT02576964|Drug|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m^2 twice daily on Days 1 to 14 of each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
45342371|NCT02576964|Drug|Peginterferon alfa-2a|Participants will receive SC peginterferon alfa-2a, 180 mcg every week during each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
46037753|NCT04306770|Other|OPTIMUM programme|"OPTIMUM programme encompass of telehealth service to support the patient. Study participants will be given devices (Bluetooth-enabled blood pressure machine, weighing scale and glucometer) to monitor their parameters at home. Care team will use the Phillips Vital Health to perform tele-monitoring, tele-management (individualized on-line health coaching and timely interventions), and to deliver education content."
46037754|NCT05098834|Device|ENLIGHT 2100 ventilatory electrical impedance tomograph|The ENLIGHT 2100 system will remain connected to the patient for data acquisition from immediately prior to initiation of the ERT until up to 24 hours following extubation.
46037755|NCT00869557|Drug|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR once daily (QD) + placebo to match Atripla once daily prior to bedtime (QHS)
45342372|NCT00763139|Drug|Pioglitazone|45 mg by mouth once a day for 8 weeks
46037756|NCT00869557|Drug|Atripla|Atripla (EFV 150 mg/FTC 200mg/TDF 300 mg) STR QHS + placebo to match Stribild QD
45342373|NCT00763139|Drug|Placebo|By mouth once a day for 8 weeks
45342374|NCT04074408|Procedure|stereotactic surgery|stereotactic aspiration surgery
45342375|NCT04074408|Biological|hUMSCs|single intracavitary infusion 1 day after stereotactic aspiration surgery
45342376|NCT04074408|Biological|placebo|single intracavitary infusion 1 day after stereotactic aspiration surgery
45342377|NCT01366092|Drug|Interleukin-2|Daily subcutaneous IL-2 (1 x 10^6 IU/m^2/day) for self-administration for 12 weeks followed by 4-week hiatus
45342378|NCT00781859|Drug|125 µg Ocriplasmin|125µg ocriplasmin intravitreal injection
45473894|NCT03863249|Drug|ADJUNTIVE ANTIBIOTICS|"The antimicrobial adjunctive agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit.~The antibiotic will be selected among AMOXICILIN, METRONIDAZOLE, AMOXICILIN + METRONIDAZOLE AND AZITROMYCIN."
45473895|NCT03863249|Diagnostic Test|MICROBIAL SAMPLING|"Before treatment, the 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~The subgingival microbiota will be harvested from the sampling sites 2 months after the completion of active therapy."
45342379|NCT00781859|Drug|Placebo|Placebo intravitreal injection
45342380|NCT02576886|Device|Gamma Camera|All images acquired with the General Electric Discovery 530c
45342381|NCT02576886|Procedure|Prone Imaging|
45342382|NCT04100915|Other|No Intervention|There is no intervention for this study
45683758|NCT04631263|Device|Hyaluronic Acid|Injectable gel. Chin correction and augmentation for retrusion
45342383|NCT01344252|Drug|Lidocaine|We will made anesthesia with topical lidocaine and compared with subtenon anesthesia
45342384|NCT04101383|Drug|RinGlar®|Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg
46037757|NCT02878356|Behavioral|Regular MI-training|Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities
46037758|NCT02878356|Behavioral|Regular MI-training + supervision half|Regular MI-training followed by six individual MI-supervision sessions at monthly intervals based on only the behavior counts component of MITI (n= 58)
46037759|NCT02878356|Behavioral|Regular MI-training + supervision full|Regular MI-training followed by MI-supervision based on both the behavior counts and the five global dimensions of MITI (n= 58)
46037760|NCT02780596|Other|Item1|Does CHILD NAME often wake one or more times during the night?
45342385|NCT04101383|Drug|Lantus®|Single subcutaneous administration of Lantus® in dose 0.6 Units/kg
45342386|NCT02576808|Drug|Ginger extract|Ginger extract capsule at dose of 250 mg two times a day after meal daily for 42 days
45342387|NCT02576808|Drug|Loratadine|Loratadine tablet at dose of 10 mg one times a day after morning meal daily for 42 days
45342388|NCT04100681|Device|Active FlowOx™|Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
45683759|NCT01929343|Drug|lidocaine following cue-induced craving|as described in Arm Description
45683760|NCT01929343|Drug|lidocaine following neutral stimulus|as described in Arm Description
45683761|NCT01929343|Drug|saline|as described in Arm Description
45683762|NCT01968811|Device|Avance Foam dressing kit|
46037761|NCT02780596|Other|Item2|Does CHILD NAME often wake one or more times per night, and does and adult go to him/her?
46037762|NCT02780596|Other|Item3|Do you think CHILD'S SLEEP is a problem?
46037763|NCT02780596|Other|Item4|Do you think CHILD NAME has a sleep problem?
46037764|NCT02780596|Other|Item5|Do you have any concerns about CHILD NAME'S sleep?
46037765|NCT02877420|Other|Non-Technical Skills Training Curriculum|
46037766|NCT02877420|Other|Conventional Simulation Training Group|
45342389|NCT04100681|Device|Sham FlowOx™ (Placebo)|Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
46037767|NCT01200290|Drug|LY2127399|120 milligrams (mg) administered subcutaneously every 4 weeks for 20 weeks. A loading dose of 240 mg will be given as the first dose of the study medication
46037768|NCT02781142|Other|Motor imagery training|The motor imagery training will be designed for the individual basis with following standard protocols. It will be applied two times a week for 8 weeks. The first one and/or two sessions will be performed in the clinic, the other will be performed at the patients' home with a video-conference telerehabilitation technique.
45342390|NCT04098965|Other|Pysiotherapy techniques|manual therapy techniques, postural re-education and muscle strengthening
45342391|NCT04098965|Other|physician treatment|hygienic-dietary recommendations, Kegel exercises and pain relievers
45342392|NCT02576730|Procedure|ORIF|surgery for foot and ankle fractures
45342393|NCT04098887|Radiation|Lattice stereotactic body radiation therapy|For Lattice SBRT, the daily prescription dose will be 20 Gy to be delivered to the PTV_2000 with a simultaneous integrated boost of 66.7 Gy to be delivered to the PTV_6670 over 5 fractions (4 Gy and 13.2 Gy to the PTV_2000 and PTV_6670, respectively).
45342394|NCT04100603|Other|No Intervention|There is no intervention for this study
46037769|NCT04131985|Procedure|Erector Spina Block|After the C7 spinous protrusion is prepared as sterile as T10, the erector spina muscle is seen at the T7 level on the same side as the hernia with the convex probe and block is applied with 0.25% bupivacaine (20 cc).
46037770|NCT05052372|Drug|Balversa|BALVERSA® is a prescription medicine used to treat adults with bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery
46037771|NCT02618005|Dietary Supplement|Probiotic capsule|Continuously take five capsules containing freeze-dried LcS on ISS for four weeks, from four weeks before the return (R-4W) to one day before the return (R-1d)
46037772|NCT02781064|Drug|Atorvastatin 20mg|Atorvastatin and matching placebo to be taken in a randomised order for 12 months
46037773|NCT02781064|Drug|Placebo|Atorvastatin and matching placebo to be taken in a randomised order for 12 months
46037774|NCT04205682|Drug|Cannabidiol|CBD capsules administered BD for 4-days (800-1200 mg/day), placebo day 5
46037775|NCT04205682|Drug|Placebo|Placebo capsules administered BD for 5 days
46037776|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, Subcutaneous (SC)
45342395|NCT00580788|Drug|PTHrP (1-36)|IND # 49,175
46037777|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, SC
46037778|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, SC
45342396|NCT02576106|Device|Cryoablation|
45342397|NCT02575872|Behavioral|Exercise Intervention|Participate in physical activity behavioral intervention
45342398|NCT04071678|Behavioral|Careful examination during endoscopic procedures to identify lesions|When the AI model alarms, check carefully to confirm the lesion
45683763|NCT01806584|Biological|SRM003|One time implant (3 SRM003 pieces) on surgery day.
46037779|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, Subcutaneous (SC)
46037780|NCT01134263|Biological|Placebo: NaCl 0.9%|0.5 ml, SC
46037781|NCT00626184|Drug|4 dose levels of ALV003|4 dose levels of ALV003 vs placebo
46037782|NCT00634738|Procedure|Ischemic Compression (thumb Pressure)|Pressure, one thumb on the other, applied on the trigger points
46037783|NCT02780440|Behavioral|Traditional Home Based Exercise Program|Subjects in the control group will receive a traditional home Occupational Training exercise program as per conventional OT guidelines with the same home program duration.
46037784|NCT02780440|Behavioral|Unimanual Home Based Mirror Therapy Program|The affected hand will remain still in the mirror box, the unaffected hand will perform the exercises while the subject watches the mirror reflection.
46037785|NCT02780440|Behavioral|Bimanual Home Based Mirror Therapy Program|The affected hand in the mirror box will best mimic the unaffected hand, while also watching the mirror reflection.
46037786|NCT05339776|Behavioral|Hand Lateralization Test|Before hand lateralization test, participants will be evaluated. Both groups (Amputees and Control) will complete hand lateralization test for at least 10 days. The test will be sent each day on an online system. Participants' performances will be recorded via online system. After hand lateralization test, participants will be evaluated.
45498032|NCT05411991|Drug|Intravenous canrenoate 200 mg OD|At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa <80 mmol/L), intravenous canrenoate 200 mg OD is provided. Canrenoate is never administered in case of hypotonic hyponatremia with serum sodium concentration <135 mmol/L or if serum potassium levels are >5.5 mmol/L. If canrenoate is administered, oral mineralocorticoid receptor drugs are temporarily withhold until switch to oral diuretic treatment.
46037856|NCT02780050|Other|core muscle activation using physical fitness|"2 instructors, they had physical therapy (PT) certificate, take an exam for subject's muscle strength of each muscle. After that time, subjects take a rest for 10 minutes. Researchers educate to subjects for high quality CPR including 5 to 6cm compression depth, 100 to 120 beat per minute (bpm) rate, complete chest recoil. Subjects perform chest compression to manikin with skill reporting system during 4min under guidance of 110 bpm metronome sound (first chest compression). After 1st chest compression, subjects take a rest during an hour and carry out PT. PT consist of 30 second plank for 3 sets, 12 times bridge for 3 sets and 20 times leg extension for 3 sets. Subjects take a rest during 30 seconds between sets, 1 minute every 3 sets.~After PT completion, subjects take a rest during 10 minutes, and then perform 2nd chest compression in the same way of 1st chest compression. Researchers record subject's chest compression depth and rate in 1st and 2nd chest compression."
45474019|NCT04948905|Other|Evaluation using the Self-Defining Memory Questionnaire|"This questionnaire consists of 3 pages. Page 1 gives a clear, concise definition of a memory that defines the self. This enlightens the subject on what is expected and helps him/her consider the phenomenological characteristics of the Self-Defining Memory. Page 2 recalls the 6 essential characteristics of the Self-Defining Memory. Page 3 allows the practical application of what has been understood about the questionnaire. At least 3 memories are asked of the participants. Each memory is rated as follows : On a scale of 0 - 6 for each of the following emotions, participants note how they feel when recalling each memory. Happy, Sad, Angry, Fearful, Surprised, Ashamed,Disgusted,Guilty, Interested, Embarrassed, Contemptful, Proud. 0 = not at all, 3 = Moderately and 6 = Extremely.~Participants must then use the same scale to indicate the vividness and importance of the memory.~They must also note the approximate number of years ago the memory took place (to the nearest whole number)."
45474020|NCT03381573|Drug|Roflumilast|Roflumilast
45694521|NCT01588951|Drug|Cytarabine consolidation|Cytarabine-based consolidation per institutional standards.
45381968|NCT05498792|Drug|CBL0137|Patient will be enrolled at 3 dose levels of CBL 0137, dose level -1 (320 mg/m²), dose level 1 (400 mg/m²), dose level 2 (540 mg/m²)
45694522|NCT01588951|Drug|Allogeneic transplant|Allogeneic stem cell transplant per institutional standards.
46037857|NCT00634894|Drug|Femara|2.5 mg by mouth daily x 12 weeks
45381969|NCT05498792|Drug|Ipilimumab|Patient will be on Ipilimumab (1 mg/kg)
45381970|NCT05498792|Drug|Nivolumab|Patient will be on Nivolumab (3 mg/kg)
45381971|NCT05492214|Procedure|Delayed cord clamping (30s)|The same as that stated in arm descriptions.
45381972|NCT05492214|Procedure|Delayed cord clamping (60s)|The same as that stated in arm descriptions.
45381973|NCT05492214|Procedure|Delayed cord clamping (90s)|The same as that stated in arm descriptions.
45381974|NCT05490134|Drug|Naloxone|A 0.15 mg/kg bolus dose of naloxone in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
46037858|NCT00634894|Drug|Placebo|Placebo capsule by mouth daily x 12 weeks
46037859|NCT04963738|Drug|JNJ-73763989|JNJ-73763989 will be administered as a single SC injection.
46037860|NCT04228120|Behavioral|self-regulation programme|The programme consisted of one 20-to-30-minute, face-to-face individual education session related to self-regulation and problem-solving processes that was performed in accordance with the patient's plan. Furthermore, eight 15- to 20-minute telephone follow-up counselling sessions were delivered twice per week for four weeks.
45381975|NCT05490134|Drug|Saline|0.15mg/kg bolus of normal saline in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
46037861|NCT02779270|Drug|BAY987518|"Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.~Formulation: V27-104"
46037862|NCT02779270|Drug|Sunscreen Lotion (U77-030 Control)|Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.
46037863|NCT02779894|Other|Remote control of patients|Diagnosis outside the hospital (3 Home PR) CPAP (if needed) titration at home REmote control of patient's during 3 months by video or phonoconference
46037864|NCT04228900|Dietary Supplement|Individualized plan for improvement of nutrition|For each participant we will make a plan, describing different items the can improve their nutritional status: enrichment of food, dental care,
46037865|NCT04228900|Drug|Systematic drug review|Consider altering medication list if the patient has symptoms that may be attributed to adverse drug effects, in particular side effects as nausea, dry mouth or loss of appetite, and if drug-drug interactions or drug-disease interactions are likely to occur. Recommended changes in patient's medication list will be presented for the family physician who will hold the final decision to implement the suggested adjustments.
46037866|NCT01078662|Drug|olaparib|Tablets Oral BID
46037867|NCT04227886|Radiation|Radiation|Neoadjuvant radiotherapy consisted of 50 Gy in 25 fractions using intensity-modulated radiotherapy to the primary tumor and to mesorectal, presacral, and internal iliac lymph nodes.
46037868|NCT04227886|Drug|Capecitabine-Irinotecan Combination|The concurrent chemotherapy consists of capecitabine 625 mg/m2 twice daily 5 days per week and combined with weekly irinotecan. The irinotecan dose was used based on UGT1A1 genotype of 80mg/m2 for UGT1A1*1*1 or 65mg/m2 for UGT1A1*1*28 weekly, followed by a cycle of XELIRI.
46037869|NCT02200978|Drug|ATO|Given IV
46037870|NCT02200978|Drug|RIF|Given orally
46037871|NCT02200978|Drug|ATRA|Given orally
46037872|NCT02200978|Drug|mitoxantrone|Given IV
46037873|NCT02200978|Drug|Ara-C|Given IV
46037874|NCT02200978|Drug|MTX|Given orally
46037875|NCT02200978|Drug|6MP|Given orally
46037876|NCT02200978|Other|intrathecal injection|Ara-C and dexamethasone
46037877|NCT02779192|Drug|SPI-1005 200mg|Oral SPI-1005 capsules, 200 mg ebselen, twice daily, 7 days
46037878|NCT02779192|Drug|SPI-1005 400mg|Oral SPI-1005 capsules, 400 mg ebselen, twice daily, 7 days
46037879|NCT02779192|Drug|Placebo|Oral SPI-1005 capsules, 0 mg ebselen, twice daily, 7 days
46037880|NCT05020210|Drug|Sivelestat sodium|Patients were treated with Sivelestat Sodium within 72 hours of the diagnosis of ARDS.
46037881|NCT04227808|Drug|Lenvima 4 mg Oral Capsule|The participants will receive treatment with lenvatinib for 12 months after recruitment or until disease recurrence, intolerance AEs, or death. In case of treatment-related adverse effects, interruption or reduction is allowed.
46037882|NCT04963426|Behavioral|Behavioral interventions targeting multiple risk behaviors as well as protective factors|Depending on the baseline data and prioritization of actions, behavioral interventions related to the following topics will be implemented: alcohol use, dietary behaviors, drug use, hygiene, mental health, physical activity, protective factors, sexual behaviors, tobacco use, violence and unintentional injury.
46037883|NCT04963426|Other|School-level interventions targeting the school environment and system|Depending on the baseline data and prioritization of actions, and based on the Global Standards for Health Promoting Schools, school-level interventions related to the following will be implemented: school policies and resources, school governance and leadership, school and community partnerships, school curriculum, school social-emotional environment, school physical environment, school health services
46037884|NCT01091454|Drug|brostallicin|Given IV
46037885|NCT01091454|Drug|cisplatin|Given IV
46037886|NCT04960072|Biological|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10^9-5x10^10 autologous TILs to patients i.v. in 30-120 minutes.
46037887|NCT01140347|Biological|Placebo|8 mg/kg IV every 2 weeks
45381976|NCT05487677|Procedure|BioBrace Augmentation|During shoulder replacement surgery, the subscapularis (rotator cuff muscle) is sometimes repaired back again. This will be stitched and augmented with a BioBrace. The Biobrace is a biocomposite scaffold meaning both synthetic and biologic, compared to other traditional implants that are either synthetic or biologic. The stitch in the BioBrace group will be anchored to and reinforced by this material.
45381977|NCT05487677|Procedure|Standard Repair with Sutures|During shoulder replacement surgery, the Subscapularis (rotator cuff muscle) is sometimes repaired back again. This is usually repaired with stitches per standard of care treatment.
46037888|NCT01140347|Biological|Ramucirumab DP (IMC-1121B)|8 milligrams/kilogram (mg/kg) intravenous (IV) every 2 weeks
45474021|NCT03369964|Drug|Atezolizumab|"In Cohort A1, Atezolizumab will be administered, 1200 mg IV, every 3 weeks starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV, starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2 , In Cycle 2-8, Atezolizumab will be administered, 1200 mg IV on day 1 of each 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV starting on Cycle 9; Day 1 of each 21 day cycle"
45474022|NCT03369964|Drug|Emactuzumab|"In Cohort A1, Emactuzumab will be administered 1000 mg IV, every 3 weeks, starting on Cycle 1; Day 1 of a 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV, starting on Cycle 1 Day 1 of a 21 day cycle.~In Cohort A2, in cycle 2-8, Emactuzumab will be administered 1000 mg IV, on day 1 of each 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV starting on Cycle 9; on Day 1 of each 21 day cycle"
46037889|NCT01140347|Other|BSC|Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.
46037890|NCT02779114|Drug|Control group|Stable dosage of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
46037891|NCT02779114|Other|Reduction group 1|Dose reduction of 50% for 12 months of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
46037892|NCT02779114|Other|Reduction group 2|Dose reduction of 50% of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®) for 6 months and if they are still in remission therapy will be discontinued.
46037893|NCT04227964|Device|Enamel matrix derivative, bone replacement graft, barrier membrane|
46037894|NCT04227964|Procedure|Tooth extraction and replacement|
46037895|NCT02779036|Procedure|Task-oriented home exercise|Structured, walking related task-oriented home exercise program with three progressive steps, at moderate to high intensity, 60 minutes per session, three sessions per week for total 8 weeks.
46037896|NCT02779036|Procedure|Usual Physiotherapy Care|Deficits-oriented free active and resisted lower extremity exercises with bicycling and overground walking , 60 minutes per session, three sessions per week for total 8 weeks.
46037897|NCT02878278|Drug|Chidamide BIW|Chidamide is given 30mg, twice a week
46037898|NCT02878278|Drug|Chidamide QD|Chidamide is given 10mg,QD
46037899|NCT02883101|Behavioral|Pulmonary Rehabilitation|"The Rehabilitation Programme will include the following :~i. Patient education ii. Exercise training iii. Ventilator and breathing exercises"
46037900|NCT05209126|Dietary Supplement|Beetroot juice|Acute effects of beetroot juice ingestion on neuromuscular performance in female rugby players
46037901|NCT05224739|Procedure|Minimally Invasive Liver Resection|laparoscopic and robotic liver resections
46037902|NCT04227652|Drug|Ibuprofen administration|Administration of ibuprofen, according to treatment recommendations - per orally, into the nasogastric tube, or in the form of a suppository
46037903|NCT02883569|Procedure|open or endoscopic discectomy|FDA approved surgical procedures
46037904|NCT02883569|Procedure|epidural block|epidural block
46037905|NCT02883569|Other|exercise|educated exercise
46037906|NCT02883569|Drug|ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac|FDA approved medication such as ibuprofen, naxoprofen etc.
46037907|NCT02883569|Procedure|decompression|FDA approved surgical procedure such as lamiectom and, laminotomy
46037908|NCT02883569|Procedure|instrumentation and fusion|FDA approved surgical procedure such as PLIF, ALIF, DLIF, OLI and TLIF
46037909|NCT02883569|Drug|codeine, oxycontine, IRcodone, Tramadol|FDA approved opioid drug such as codeine, oxycontin, IRcodon
46037910|NCT02883569|Procedure|epidural adhesiolysis|FDA approved epidural adhesiolysis with catheter or endoscope
46037911|NCT04306224|Biological|IMC-002|IMC-002 blocks the interaction between CD47 and SIRPα.
46037912|NCT02883023|Other|Electrosclerotherapy|Combination of intralesional bleomycin sclerotherapy and electroporation
46037913|NCT02883023|Drug|Intralesional bleomycin injection|Local intralesional injections with bleomycin
46037914|NCT02778958|Drug|paracetamol|"iv paracetamol flakon, 1 gram infusion at 30 min;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
45474023|NCT03369964|Drug|Obinutuzumab|"In Cohort A2, Obinutuzumab will be administered 1000 mg IV starting on Cycle 1; Day 1 of a 21 day cycle~In Cohort A2, Obinutuzumab will be administered again on days 8 and 15 (Cycle 1) of a 21 day cycle~In Cohort A2, in cycle 2-8, Obinutuzumab will be administered 1000 mg IV on day 1 of each 21 day cycle"
46037915|NCT02778958|Drug|ibuprofen|"iv ibuprofen flakon, 800 mg;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
45474024|NCT01288391|Drug|NNC 0128-0000-2011|Single dose of 100 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
46037916|NCT01197560|Drug|Lenalidomide|Lenalidomide 25 mg orally for 21/28 days until Diffuse Large B-Cell Lymphoma (DLBCL) progressive disease. For patients with Creatinine Clearance ≥ 30 mL/min but < 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
46037917|NCT01197560|Drug|Gemcitabine|Suggested starting doses and regimens for Gemcitabine is 1,250 mg/m^2 intravenous (IV) administration on days 1, 8, 15 every 28 days for 6 Cycles or 1,000 mg/m^2 IV days 1 and 15 every 28 days for 6 Cycles
46037918|NCT01197560|Drug|Oxaliplatin|Suggested starting dose and regimen for Oxaliplatin is 100 mg/m^2 IV day 1 for 21 days for 6 Cycles
46037919|NCT01197560|Drug|Rituximab|Suggested starting dose for Rituximab is 375 mg/m^2 IV days 1, 8, 15, 22 during Cycle 1, and if stable disease at Week 12, also on Day 1 of Cycles 4, 6, 8, and 10 (CD20+ patients only)
46037920|NCT01197560|Drug|Etoposide|"Suggested starting doses for Etoposide are:~100 mg/m^2 IV days 1-5 every 28 days for 6 Cycles, or 100 mg/m^2 IV days 1-3 every 28 days for 6 Cycles, or 50 mg/m^2 oral days 1-21 every 28 days for 6 Cycles, or 50 mg/m^2 oral days 1-14 every 28 days for 6 Cycles, or 50 mg/m^2 oral days 1-10 every 28 days for 6 Cycles"
46037921|NCT04227418|Device|12 lead ECG monitoring|Rate, Rhythm, QTc and PR interval will be assessed
46037922|NCT04227418|Device|6 lead ECG monitoring|Rate, Rhythm, QTc and PR interval will be assessed
46037923|NCT04227418|Device|Hand held ECG monitoring|Handheld ECG machines are portable, inexpensive, hand held devices that provide a 'real-time' rhythm strip, equivalent to lead I or II on a 12 lead machine, depending on how the device is held. The rhythm strip is displayed on a computer tablet or mobile phone, and are compatible with both android and iPhone platforms. To perform the test the patient places their fingers/thigh, or alternatively the device can be placed directly on the patient's chest. The process does not require the patient to be exposed, can be done in a seated position (negating the need an examination couch) and their ease of use and portability means they could be readily used in memory clinics or community settings.
46037924|NCT05005390|Device|TTIP ventilation then mask ventilation|In TTIP ventilation, an endotracheal tube is inserted via the nostril or oral cavity and subsequently advanced until the tip of the tube reaches approximately the level of the glottis.
46037925|NCT05005390|Device|Mask Ventilation then TTIP ventilation|In mask ventilation, a mask is placed over the nose and mouth.
46037926|NCT04228666|Biological|HB-adMSCs|Four IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety laboratory tests follow-up on weeks 4, 8, 13, 26, and 52; inflammation and amyloid markers follow-up on weeks 13 and 52; MMSE and ADCS-ADL follow-up on weeks 13, 19, 26, 33, 40, 46 and 52; Altoida NMI follow-up will occur weekly from week 0 to week 52; CDR follow-up will occur weeks 4, 10, 13, 19, 26, 33, 40, 46 and 52; C-SSRS follow-up will occur on weeks 4, 10, 26, and 52; Amyloid PET imaging follow-up occurs week 26 and 52;
46037927|NCT04227574|Other|Zero Time Exercise training + WhatsApp anti-inertia reminders|"Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.~In addition, WhatsApp anti-inertia reminders will be sent daily by the research assistant to remind and encourage the participants to practice the Zero Time Exercise."
46037928|NCT04227574|Other|Zero Time Exercise training alone|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
46037929|NCT04196140|Device|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
46037930|NCT05199142|Drug|SDI-118|SDI-118 Powder in Capsules (PiC) are presented as Drug Substance in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules. No excipients are added.
46037931|NCT05199142|Drug|Placebo|The Matching Placebo for SDI-118 PiC is equivalent dose of mannitol (an inert excipient) in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules.
46037932|NCT04940572|Drug|Depakine|Refer to arm description.
46037933|NCT05320978|Device|Hand grip test, computed tomography|A hand grip test, abdominal computed tomography are performed before surgery.
46037934|NCT05315362|Device|solid microneedle skin patch|intradermal vaccination with a skin patch
46037935|NCT05315362|Biological|mRNA-1273|administration of mRNA-1273 vaccine
46037936|NCT05315362|Device|standard needle|intramuscular vaccination with a standard needle
46037937|NCT02778568|Behavioral|Resistance training|Resistance training exercises
46037938|NCT02778568|Behavioral|Control|Stretching exercises
46037939|NCT04227496|Device|Auditory disturbances|A sound will be played from a portable device (smartphone) during movement
46037940|NCT01133405|Drug|LY2886721|Oral capsules
45474025|NCT01288391|Drug|NNC 0128-0000-2011|Single dose of 200 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
46037941|NCT01133405|Drug|Placebo|Oral capsules
45474026|NCT03375658|Other|PDWS Intervension|Patients admitted to the emergency department in the intervention period will have their vital values presented on the PDWS in addition to existing patient monitoring systems
45847547|NCT04404114|Diagnostic Test|Shear wave elastography to distinguish CKD from normal kidney|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
46037942|NCT02779816|Device|Pen device|Adaptive pen device
46037943|NCT01196078|Drug|erlotinib [Tarceva]|150 mg, orally once a day for up to 6 cycles of 21 days each
46037944|NCT01196078|Drug|vinorelbine|60 mg/m2, orally on days 1 and 8 of cycle 1, 80 mg/m2 for the other cycles
46037945|NCT05314660|Drug|38 % silver diamine fluoride|Application of 38% SDF on carious dentine lesions.
46037946|NCT05314660|Procedure|Atraumatic restorative technique|Hand excavation of carious dentine followed by application of Glass ionomer
46037947|NCT05314660|Procedure|Ultra conservative dentistry|Removal of soft dentine and enlarging of cavity to control bio film
46037948|NCT05314036|Other|Standardized test meal|During this study visit, a standardized test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 2 hours after test meal.
46037949|NCT01133171|Behavioral|Nurse Alone|Patients received two in-person counseling sessions by a research nurse, approximately 3-7 months apart, in methods for controlling cardiovascular risk factors.
46037950|NCT01133171|Behavioral|Dashboard Plus Nurse|Patients receive two in-person counseling sessions, six months apart, in methods for controlling cardiovascular risk factors and were asked to use a computerized dashboard to enter values for the risk factors and observe the effects of the risk factors on the overall cardiovascular risk.
46037951|NCT01195844|Biological|Rotavirus Vaccine|This is an observational study evaluating hospitalizations and the medical care for the treatment of diarrhea from rotavirus infection in children < 5 years of age; however, any rotavirus vaccines used in the children presenting with rotavirus-attributed diarrhea were evaluated, as well the prevalent rotavirus serotypes in this sample for future vaccine development.
46037952|NCT02883725|Other|data collection|
46037953|NCT04920292|Drug|Oxfendazole|Oxfendazole is a benzimidazole anthelminthic drug.
46037954|NCT04920292|Drug|Placebo|The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.
46037955|NCT02779972|Other|Echo stress test|Echo stress test
46037956|NCT04312685|Device|Prometra II Programmable Pump system - Flowonix Medical|This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump
46037957|NCT02779738|Drug|Merestinib|Administered orally
46037958|NCT04317872|Drug|High dose of peri-operative intravenous dexamethasone|25mg aacidexam is administered during induction followed by 10mg on the ward after 12 hours
46037959|NCT04317872|Drug|Low dose of peri-operative intravenous dexamethasone|10mg aacidexam is administered during induction followed by placebo on the ward after 12 hours
46037960|NCT04227262|Other|MIRROR THERAPY|The children were instructed to sitting on chair and a mirror is placed in midsagittal plane of the child, with the normal limb in front of mirror and the affected limb is blocked so the patient see only the reflected movement of the sound limb (non affected).
46037961|NCT01132547|Drug|cyproheptadine hydrochloride|Given orally
46037962|NCT01132547|Other|placebo|Given orally
46037963|NCT01194830|Drug|Linagliptin|Active drug 1 tablet PO QD
46037964|NCT01194830|Drug|Placebo|1 Tablet PO QD
46037965|NCT05074888|Drug|Prospekta|Oral administration.
46037966|NCT05074888|Drug|Placebo|Oral administration.
46037967|NCT04228510|Procedure|2D speckle tracking echocardiography|"Global and segmental strain and strain rate in longitudinal and circumferential directions will be detected after PPCI; before discharge. The LV circumferential strains and strain rates will be determined from the short-axis views at the basal, middle, and apical levels, and longitudinal strains and strain rates will be determined from the apical 2-, 3-, and 4-chamber views of the LV.~Segmental longitudinal strains equal to -15% or closer to 0 will be considered abnormal (injured segments). The average segmental longitudinal strain and strain rate of the abnormal segments is defined as the injury longitudinal strain (InjLS) and injury longitudinal systolic strain rate (InjLSRs)."
46037968|NCT02778334|Other|survey|"Patients who accept will be seen in maintenance during hospitalization in Neuro-Vascular Unit (UNV) (T0 = 4 to 7 days post-stroke)~At the time of the release of the UNV two groups:~patients who return home and~patients who continued hospitalization in rehabilitation. Depression, anxiety, quality of life and coping strategies will be assessed by self-administered questionnaires. A first phase of ambulatory (ESM / EMA) will also take place following the (UNV) output: 5 times a day for 7 days patients will respond to questions evaluating depression, anxiety and coping strategies. Patients will answer these questions via a smartphone app (issues ESM).~Another ambulatory phase on the same model as that performed at T1 (5 times daily for 7 days) accompanied by a self-assessment of depression, anxiety, coping strategies and quality of life will made 2 months post-stroke (T2).~The last time the study will take place 4 months after stroke onset (T3)."
46037969|NCT02778178|Drug|ropivacaine plus clonidine|20 mL ropivacaine 3.75 mg/ml + 75 µg clonidine, per side
46037970|NCT02778178|Drug|Placebo|20 mL saline 0.9%, per side
46037971|NCT02778178|Device|ultrasound|
46037972|NCT02887586|Other|auricular needling|Patients will be treated with auricular needling for 4 weeks. 4-8 specific auricular acupoints are selected unilaterally at a time, and alternate to another side every 2-3 days, treatment will last for 4 consecutive weeks. The following 4 ear acupoints points will be selected for every patient: Ear Shenmen, Stoma, Spleen, and Subcortex. Other ear acupoints including Triple Energizer, Liver, Sympathetic Nerve and Smallintestine will be selected based on the condition of patients. Treatment will be performed by a registered Chinese medicine practitioner.
46037973|NCT04228432|Other|Dedicated and coordinated monitoring|"Coordinated monitoring performed by a dedicated nurse: consultation before hormonotherapy initiation~Monitoring at home over a period of 6 months using an e-monitoring tool: assessment of adverse events and completion of GIRERD questionnaire at week 3 and week 6."
46037974|NCT01194440|Drug|letrozole|Given orally
46037975|NCT01194440|Drug|zoledronic acid|Given IV
46037976|NCT04228588|Drug|Mepolizumab 100 MG [Nucala]|Mepolizumab 100mg, SC, every 4 weeks
46037977|NCT04823052|Drug|Sulindac (HLX-0201), dose strength 1|Sulindac (HLX-0201) Capsule
46037978|NCT04823052|Drug|Sulindac (HLX-0201), dose strength 2|Sulindac (HLX-0201) Capsule
46037979|NCT04823052|Drug|Placebo|Placebo Capsule
46037980|NCT04823052|Drug|Gaboxadol (HLX-0206)|Gaboxadol (HLX-0206) Capsule
46037981|NCT05048992|Other|ELDOA method|group A will receive
46037982|NCT05048992|Other|Post-facilitation stretching|Group B will receive
46037983|NCT04114474|Diagnostic Test|TRANSTHORACIC ECHOCARDIOGRAPY|TTE (Vivid I echocardiography machine General Electric Healthcare, Milwaukee, WI, USA) with a 3S-RS (1.5-3.6 MHz) transthoracic probe). was done by professional anesthesiologist following the :Hemodynamic Echocardiography Assessment in Real Time ( HEART) protocol. According to the clinical findings of TTE patients may be either free or have one or more of the following haemodynamic states normal, empty, vasodilated ,left ventricular systolic or diastolic failure, left ventricular systolic and diastolic failure, and right ventricular failure, valve stenosis or regurgitation of at least moderate severity
46037984|NCT05258500|Other|Ghostly app|For the Ghostly app, we include three different trainings (standard, cluster set 1, cluster set 2). The standard training consists of three sets in which twelve muscle contractions are performed with 120 seconds of rest between each set. Each set of twelve contractions will be considered as one level in the game that needs to be ended before taking rest of 120s. Subsequently, the 'Cluster set 1' training is based on the training modalities of cluster set training since evidence shows that similar results can be obtained using cluster set training compared to standard training. The Cluster sets 1 and 2 also consist of 3 sets of twelve repetitions, but with ten seconds of rest between each contraction or 30 seconds of rest after three consecutive contractions respectively. The intensity at which will be trained is 75% of maximum voluntary contraction.
46037985|NCT05258500|Other|Blood flow restriction|Patients will complete four sets of 15 repetitions, with each contraction lasting three seconds. Similar to the first experimental group and control group, the training intensity will be set at 100%MVC with two minutes of rest between sets. The cuff pressure will be set at 50% of arterial occlusion pressure.
46037986|NCT05258500|Other|Leaflet|This training program will be matched with the Ghostly game in terms of repetitions, sets and inter-set rest and will be given to the patient to complete without supervision of the therapist.
46037987|NCT00951015|Drug|GSK1349572|investigational HIV-1 integrase inhibitor
46037988|NCT00951015|Drug|efavirenz|approved therapy for HIV-1 infection, used as an internal study control
46037989|NCT01139021|Biological|rMenB+OMV NZ|Subjects will be assigned to a study group based on the group assignment in the parent study (follow-on subjects). In addition, one group of naïve age-matched subjects will be recruited at the same study sites. Subjects who had received 4 doses of rMenB+OMV NZ will have one visit including one blood draw. Subjects who had received two catch-up doses in V72P13E1 will receive a third dose boost and will have 3 blood samples drawn. Naïve subjects will receive two catch-up doses and have 3 blood samples drawn.
46037990|NCT02777866|Drug|Infiltration of 0.5% Bupivacaine|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
46037991|NCT02777866|Drug|Placebo: Infiltration of 0.9% Saline Solution|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound
46037992|NCT00626262|Drug|Esomeprazole|Oral and Intravenous
46037993|NCT02876796|Drug|GS-0976|Capsule(s) administered orally
46037994|NCT02876796|Drug|Placebo|Capsule(s) administered orally
46037995|NCT02876796|Other|1-13C acetate|10 g ± 0.25 g in 1000 mL 0.45% saline solution administered intravenously for 19 hours
46037996|NCT02876796|Other|Fructose solution|Fructose solution administered orally under fasted conditions immediately after study drug and every 30 minutes for a total of 20 doses
46037997|NCT04980820|Other|No mask|The participant is asked to wear no mask for 10 minutes.
46037998|NCT04980820|Device|Filtering face mask 2 (FFP2)|The participant is asked to wear a FFP2 mask for 1 hour during work.
46037999|NCT04980820|Device|Filtering face mask 3 (FFP3)|The participant is asked to wear a FFP3 mask for 1 hour during work.
46038000|NCT02876562|Procedure|root coverage with collagen matrix|the material used is a porcine derived native collagen matrix which serves an alternative to connective tissue graft. the material is 1.5 mm in thickness with a specific tissue surface to allow for cell migration and a fibrous outer layer. it has a resorption time of 6 months.
46038001|NCT02779660|Procedure|Remote ischemic preconditioning (RIPC)|RIPC will be induced by the application of 3 short episodes (5 minutes) of forearm ischemia by cuff sphygmomanometer inflation separated by 5 minutes of reperfusion.
46038002|NCT02779660|Procedure|sham-intervention|In the control group the cuff will be inflated for 3 times at 10 mm Hg for 5 minutes with 5-minute intervals
46038003|NCT05153447|Behavioral|M-Tech|M-Tech involves the use of a mobile app delivery platform to several interventions. The components of M-Tech include: 1) Hybrid in-person and telehealth visits with oncology providers; 2) Disease-specific education videos; 3) Activity level monitoring via a wearable device with promotion of physical activity; 4) Symptom monitoring with provision of self-management strategies, and 5) Medication management.
46038004|NCT05153447|Other|Usual Care|Participants randomized to the usual care arm will receive standard of care.
46038005|NCT01193660|Biological|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion (total nucleated cells > 3x10^7/kg) intravenously under non-myeloablative immunosuppression (maintaining blood level of cyclosporine as 100-200ng/mL for 1 month).
46038006|NCT01193660|Drug|Erythropoietin Injection|Erythropoietin will be given as the schedule of twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times.
46038007|NCT01193660|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They received two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 5 months.
46038008|NCT01193660|Other|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood will be given except the Experimental arm. Placebo Umbilical Cord Blood was made using peripheral blood. Participants and Investigators maintained as blind.
46038009|NCT01193660|Other|Placebo Erythropoietin|Placebo Erythropoietin containing Normal Saline
46038010|NCT04298814|Other|severe covid-19 pneumonia with ET|severe covid-19 pneumonia undergoing endotracheal intubation
46038011|NCT02778022|Behavioral|PriCARE|PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE utilizes the 3 P skills (Praise, Paraphrase and Point-out-Behavior) and includes a trauma and stress education component. The training starts with parenting skills focused on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second phase of the training teaches techniques for giving children effective commands in order to set age-appropriate limits. We piloted PriCARE and demonstrated promising findings. The PriCARE intervention has been slightly modified from the pilot version to increase engagement and attendance.
45381978|NCT05487664|Device|Transcutaneous Auricular Neruostimulation (tAN)|The intervention we are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets both the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN, a branch of the trigeminal nerve).
46038012|NCT04306068|Other|Plyometric protocol|"Each session will last 20 minutes, with 2 sessions a week, over a period of 5 weeks. The intervention will last 20 minutes, which consists of a 4-station circuit.~Exercise 1: jump on the rope, with your feet together at a moderate pace. Exercise 2: In standing with hands on the hip and hip flexion (one foot in front). Knee flexion and dorsal ankle flexion, with straight trunk. Alternate legs.~Exercise 3: box jump (jump on the box with both feet at the same time). Exercise 4: depth jumps from box to antoher box (jump on the box with both feet at the same time and when falling, immediately jump to the other box).~1 minute with 30 seconds between sets."
46038013|NCT02777788|Drug|JinFuKang|treated with chemotherapy
46038014|NCT02777788|Drug|XingZaoRuanJian|treated with chemotherapy
46038015|NCT02777788|Drug|pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin|
46038016|NCT02856009|Other|completion of a quality of life questionnaire|
46038017|NCT01076166|Drug|clarithromycin (Klacid) granules for oral suspension|clarithromycin (Klacid) Granules for Oral Suspension
46038018|NCT00631059|Other|Hem(A)+ Technology|The purpose of the study is to test patients blood. A blood draw will be taken and examined with Hem(A)+ technology.
46038019|NCT02777710|Drug|Pexidartinib|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
46038020|NCT02777710|Drug|Durvalumab|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
46038021|NCT02853747|Behavioral|high-intensity-interval-training|12 weeks of walking-based HIIT training
46038022|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~4 doses starting from 121 to < 212 days of age"
46038023|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~3 doses starting from 212 days to < 12 months of age"
46038024|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~2 doses starting from 12 months to < 24 months of age"
46038025|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~1 dose starting from 24 months to < 72 months of age"
46038026|NCT00602901|Other|HVLA-SM|High-velocity low amplitude spinal manipulation (HVLA-SM)
46038027|NCT00602901|Other|LVVA-SM|Low-velocity variable amplitude spinal manipulation (LVVA-SM)
46038028|NCT00602901|Drug|Usual medical care|Celebrex: po, 200mg, qd, six weeks; Aleve: po, 220mg, bid, six weeks; Bextra: po, 10mg, qd, six weeks; Naproxen: po, 500mg, bid, six weeks.
46038029|NCT02777476|Device|B-Lite- Light Weight Breast Implants|
46038030|NCT04874350|Drug|LPCN 1148|LPCN 1148 is an oral capsule product containing an ester prodrug of bioidentical testosterone, designed to enable absorption via intestinal lymphatics.
46038031|NCT04874350|Drug|Placebo|Oral matching placebo capsule
46038032|NCT00945477|Drug|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks
46038033|NCT02777398|Procedure|Trans-Quadrant Channel Surgery|Patients in the experimental group will be general anaesthetized and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Kirschner wire will be used to identify the position of the Quadrant channel with X-ray. After disinfection and draping, an incision of 3cm long and 2-3cm lateral to midline on the tumor side will be made. Soft tissues will be separated. Graded dilators will be used to establish Quadrant channel. Kerrison clamps will be used to expose the very local posterior spinal structures. Vertebral plate will be windowed with power drill to expose dural mater, and tumors will be removed with microsurgical techniques. Hemostasis will be performed after resection. Dural mater will be closed by titanium clips, and close incision by layers.
46038034|NCT02777398|Procedure|Conventional Open Surgery|Patients in the control group will be general anaesthetized during operation and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Surgeons will locate the lesion by X-ray. After disinfection and draping, the midline incision of 7-10 cm and centered by the lesion segment will be made. Soft tissues will be cut and separated to expose posterior structure of spine. The root of spinal process and half of the vertebral plate on tumor side of certain segments will be removed. The dural mater will be opened. Then surgeons will remove tumor with microsurgical techniques. Hemostasis will be precisely performed after resection, and dural mater will be closed by suturing. Incision will be closed by layers. Drainage would be placed if necessary.
46038035|NCT01135719|Procedure|LASIK and PRK|Wavefront-guided versus wavefront-optimized LASIK or PRK.
46038036|NCT01076088|Drug|Sitagliptin 50 mg|Sitagliptin 50 mg tablet twice a day, prior to the morning and evening meal, for 24 weeks.
46038037|NCT01076088|Drug|Metformin 500 mg|Metformin 500 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
46038038|NCT01076088|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg once daily for 24 weeks.
46038039|NCT01076088|Drug|Placebo|Matching placebo tablets to sitagliptin or metformin for 24 weeks.
46038040|NCT01076088|Drug|Metformin 850 mg|Metformin 850 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
46038041|NCT05021458|Other|Gong's mobilization|Ten patients will be treated with Gong's mobilization.
46038042|NCT05021458|Other|SNAG|: Ten patients will be treated with SNAGs
45381979|NCT05486260|Dietary Supplement|DMB lowest dose|Intake of 150 mg of DMB
46038043|NCT01652235|Device|Zenith® p-Branch® or Zenith® Fenestrated AAA Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
45381980|NCT05486260|Dietary Supplement|DMB highest dose|Intake of 300 mg of DMB
46038044|NCT02776462|Device|EyeBox CNS|
46038045|NCT02776384|Other|Observational study|
46038046|NCT02777632|Procedure|Living donor liver transplantation|
46038047|NCT05014204|Device|The Endogenex Device|The Endogenex device is designed to induce duodenal mucosal regeneration using pulsed electric field. The Endogenex procedure is a non-surgical, endoscopic procedure.
46038048|NCT02777320|Drug|paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
46038049|NCT02777320|Drug|Ibuprofen|400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
46038050|NCT04226326|Other|Directly measure microvascular function using direct coronary flow measurements|The study will enroll subjects who have been scheduled for a clinically-indicated cardiac catheterization, and will evaluate coronary microvascular function in all subjects meeting inclusion criteria with a coronary flow wire. Evaluation of coronary microvascular function may be performed using indirect methods, however the rationale behind the present study is to directly measure microvascular function using direct coronary flow measurements, since the subjects in the study are to undergo a clinically-indicated cardiac catheterization. The overall purpose of the study is to define the presence and severity of coronary microvascular dysfunction subjects with CTO.
46038051|NCT04226560|Device|41% Silicone Hydrogel Soft Contact Lenses(SHSCL)|Silicone Hydrogel
46038052|NCT04226560|Device|ACUVUE® VITA™ (senofilcon C) Brand (Soft) Contact Lens|Senofilcon C (USFDA Device License #K160212)
46038053|NCT04226560|Other|Contact Lens Care Product|Cefatrizine (propylene Glycol), Sodium Citrate (sodium Citrate Tribasic), Sodium Chloride, Sodium Borate (sodium Biboratesodium Tetraborate, Polyquaternium -1, Hydrochloric Acid, Sodium Hydroxide, Water Purified ( Eq to Aqueous Purified Or Purified Water ), Tetronic 1304, Myristamidopropyl Dimethylamine, Nonanoyl Ethylenediaminetriacetic Acid
46038054|NCT04226560|Other|Contact Lens Case|"Alcon Soft (hydrophilic) Contact Lens Case (Non-Sterile)"
46038055|NCT01193348|Drug|Eculizumab|Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient growth is possible.
46038056|NCT00945321|Drug|aprepitant 165 mg|Single dose of aprepitant 165 mg tablet in the fasted state during treatment period 1,2, or 3.
46038057|NCT00945321|Drug|Comparator: aprepitant 185 mg|Single dose of aprepitant 185 mg tablet in the fasted state during treatment period 1, 2, or 3.
46038058|NCT00945321|Drug|Comparator: fosaprepitant 150 mg|Single dose of fosaprepitant 150 mg intravenous infusion in the fasted state during treatment period 1,2, or 3.
46038059|NCT00945321|Drug|Comparator: aprepitant with food|Single dose of aprepitant 165 mg or 185 mg tablet in the fed state during treatment period 4.
46038060|NCT02776228|Drug|Brotizolam|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg brotizolam once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
46038061|NCT02776228|Drug|placebo|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg LACTOSE once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
46038062|NCT04990492|Diagnostic Test|Paper GAD 7|The paper based GAD 7 that is commonly accepted at clinics
46038063|NCT04990492|Diagnostic Test|Voice Administered GAD 7|This is the voice based GAD 7 that is administered through a Mirror device equipped with Amazon Alexa software.
46038064|NCT00631215|Procedure|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy: 1.3 atmospheres of pressure, 100%0xygen by face mask, for 60 minutes
46038065|NCT04872790|Drug|Dasatinib|Given PO
46038066|NCT04872790|Drug|Methotrexate|Given IT
46038067|NCT04872790|Drug|Prednisone|Given PO
46038068|NCT04872790|Biological|Rituximab|Given IV
46038069|NCT04872790|Drug|Venetoclax|Given PO
46038070|NCT05382728|Drug|TY-9591|"The dose of TY-9591 is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
46038071|NCT05382728|Drug|placebo Osimertinib|"The dose of placebo Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
46038072|NCT05382728|Drug|Osimertinib|"The dose of Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
46038073|NCT05382728|Drug|placebo TY-9591|"The dose of placebo TY-9591 is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
45381981|NCT05486260|Dietary Supplement|Strawberry lyophilisate|Intake of 300 mg of strawberry lyophilisate
46038074|NCT00945243|Device|Zero-P|The Zero-P PEEK is a stand-alone device intended for use in cervical interbody fusion. The device consists of a plate and a spacer with four rigid screws to provide similar stability to a traditional cervical plate and interbody spacer. It is intended for use in skeletally mature patients with symptomatic cervical disc disease (SCDD) with accompanying radicular symptoms, at one level from C3 to C7.
46038075|NCT01192412|Procedure|Intervention is blood pressure management approach|1) 'Less tight' control. The dBP treatment goal is 100 mmHg. For safety, if dBP is >105 mmHg, then antihypertensive medication must be started or increased in dose. For dBP <100 mmHg, antihypertensive therapy should be decreased in dose or stopped, as appropriate. The intervention will be applied until delivery.
46038076|NCT01192412|Procedure|Intervention is blood pressure management approach.|'Tight' control. The dBP treatment goal is 85 mmHg. For safety, if dBP is <80 mmHg, then antihypertensive medication must be decreased in dose or discontinued. If dBP is >85 mmHg, then antihypertensive therapy should be started or increased in dose. The intervention will be applied until delivery.
46038077|NCT04226092|Device|GPSkin Barrier Pro|This study is a pilot study to determine if this device produces similar readings than Aquaflux AF200 for TEWL/skin barrier on patients with and without atopic dematitis (AD).
46038078|NCT04226092|Device|Aquaflux AF200|This study is a pilot study to determine if this device produces similar readings than GPSkin Barrier Pro for TEWL/skin barrier on patients with and without atopic dematitis (AD).
46038079|NCT04868578|Dietary Supplement|study treatment PPI|patient take PPI every day during 12 months
46038080|NCT04868578|Dietary Supplement|Placebo comparator|patient take PPI placebo every day during 12 months
46038081|NCT02777164|Device|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
46038082|NCT04931134|Device|Trigeminal nerve stimulation - active|Active trigeminal nerve stimulation
46038083|NCT04931134|Device|Trigeminal nerve stimulation - sham|Sham trigeminal nerve stimulation
46038084|NCT01192178|Drug|FLOVENT™ DISKUS™ 100 mcg BID|FLOVENT™ DISKUS™ 100 mcg, one inhalation twice daily (BID) from the DISKUS device from randomization through the end of study (week 16).
46038085|NCT01192178|Drug|ADVAIR™ DISKUS™ 100/50 mcg BID|ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a 100 mcg fluticasone propionate and a 50 mcg salmeterol. One inhalation from the DISKUS device twice daily (BID) from randomization through end of study (week 16).
46038086|NCT02777008|Drug|CTP-543|
46038087|NCT02777008|Drug|Placebo for CTP-543|
46038088|NCT02855775|Other|additional blood sample|blood sample every 3 weeks
46038089|NCT02775994|Drug|Canakinumab|interleukin beta (IL-1) antagonist
46038090|NCT01192100|Behavioral|Breakfast Skipping|Participants will continue to skip breakfast each morning.
46038091|NCT01192100|Behavioral|Normal Protein Breakfast Meals|Participants will consume normal protein breakfast meals each morning.
46038092|NCT01192100|Behavioral|Protein-rich Breakfast Meals|Participants will consume protein-rich breakfast meals each morning.
46038093|NCT04193566|Drug|Forxiga|"Forxiga®, dapagliflozin 10 mg film-coated tablet.~For further information please refer to:~https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf.~Common side effects include hypoglycemia, hypotension, elevated hematocrite, dyslipidemia, back pain, dizziness, skin rash, urinary tract infection, vulvovaginitis and dehydration. Very rare incidents of ketoacidosis have been observed. Side effects have only been observed after use in longer periods and not in single-dose usage, as planned in the present study. A dose of 50 mg has been chosen to achieve optimal efficacy. Once-per-day doses of dapagliflozin for 12 weeks of 2.5 mg, 5 mg, 10 mg, 20 mg and 50 mg have been demonstrated to be relatively safe across the mentioned doses (20) and no apparent risk is expected from instituting two single-doses of 50 mg dapagliflozin."
46038094|NCT00869401|Drug|dasatinib|Given orally
46038095|NCT00869401|Drug|temozolomide|Given orally
46038096|NCT00869401|Other|placebo|Given orally
46038097|NCT00869401|Radiation|radiation therapy|Radiation therapy is performed as 30 fractions of 200 cGy for a total of 6000 cGy.
46038098|NCT04226482|Device|New Device|Laparoscopic appendectomy using new ultrasonic shears.
45847548|NCT04170894|Other|Periods of Apnea|Periods of apnea throughout atrial fibrillation ablation.
46038099|NCT04226482|Device|Used Device|Laparoscopic appendectomy using reprocessed ultrasonic shears.
46038100|NCT04823104|Other|Home visitation|Home visitation for pregnancy follow-up
46038101|NCT01076010|Drug|Tivozanib|Tivozanib capsules, administered orally, on a dosing schedule of 3 weeks of treatment (beginning on Day 1) followed by 1 week off treatment. One cycle was defined as 4 weeks of treatment.
46038102|NCT01076010|Drug|Sorafenib|Sorafenib tablets, 400 mg twice daily, administered orally for 4 weeks (1 cycle = 4 weeks). One cycle was defined as 4 weeks of treatment. Cycles were repeated every 4 weeks.
46038103|NCT02775838|Drug|Indocyanine green|perioperative application of Indocyanine green (ICG)
46038104|NCT04122391|Other|sound level volume|Noise level during cardiac arrest
46038105|NCT02776852|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number: SR15-43-Y65-158)
46038106|NCT02775604|Behavioral|Video based/Therapists' rating of comprehensive-home-fall-hazard-checklist (vt-CHFHC)|The participant will use GoPro technology and follow standardized instructions to inspect each room of their house. They will navigate through their home wearing the GoPro camera, recording images about their home and their usual activities and use a talk-aloud approach to describe what they are doing and seeing. The evaluator will provide no feedback during the assessments.
46038107|NCT02775604|Behavioral|Paper based/Patient self-rating of comprehensive-home-fall-hazard-checklist (pp-CHFHC)|A paper version of CHFHC and other self-reported documents will be completed by the participants in their homes based on standardized verbal instruction provided by the research staff.
46038108|NCT04305990|Device|Demand-driven delivery method|The gas delivery device is set to the demand-driven setting. Patients must inspire through their nose to trigger the flow of gas.
46038109|NCT04305990|Device|Free-flow delivery method|The gas delivery device is set to a free-flow setting. Gas flows through the system at a rate determined by the operator. Standard flow rate is 6 liters per minute. Patients do not need to inspire through their nose to trigger the flow of gas.
45847549|NCT04170894|Other|Control Arm - No Periods of Apnea|Standard of care atrial fibrillation ablation.
46038110|NCT02614651|Procedure|Find visual comfort threshold related to light intensity|"In this testing session, the patient's visual comfort threshold related to light intensity will be determined. Test sessions are kept under 45 minutes.~The subject is sitting in front of a keyboard and a computer screen. He/she is invited to recognize letters successively displayed in the center of the screen, this center is marked with a black cross. Each letter appearance is preceded by a beep. The subject must click on the space bar on the keyboard as soon as he/she recognizes the letter, then gives his/her answer orally."
46038111|NCT02614651|Procedure|Find the size of the visual field|For these tests, the subject is seated at a table, 1.5m from a wall. It features a computer keyboard. It projects an image on the wall, using to a video projector. An image moving towards a target (along 16 different trajectories) is used to evaluate the size of the visual field.
46038112|NCT02614651|Procedure|Effectiveness of brightness control|"During this testing session, the investigators seek to evaluate the effectiveness of the algorithms used to control the brightness.~The subject is in a room with four different computers. The subject is asked to identify the objects displayed on different computer monitors in the room: he/she must press a key on the keyboard when he/she detects an object and state aloud the nature of the object."
46038113|NCT02614651|Procedure|Performance of color correction|"During this session, the investigators try to assess the performance for the color vision correction (saturation and hue).~The subject, while wearing the virtual reality glasses + camera performs a test (twice) that requires matching colored dots (i.e. a Farnsworth test) under controlled light conditions."
46038114|NCT02614651|Device|Vuzix Wrap 1200DX virtural reality glasses|The other interventions are performed with the use of virtual reality glasses, specifically the Vuzix Wrap 1200DX. In case of technical difficulties, the latter can be swapped with the Oculus Rift model or another model. The associated webcameras are from Logitech, and the exact model used can vary and does not carry any importance for this research.
46038115|NCT04225780|Drug|Low-dose IL-2 and ganciclovir|If patients are eligible, which CMV-DNA are more than 10^3 copies, it will be randomly distributed in low-dose IL-2 and ganciclovir group, or ganciclovir group. Low-dose IL-2 is defined as 1 million IU per day subcutaneously.
46038116|NCT04045171|Drug|Tacrolimus|Tacrolimus, oral, 0.05-0.075 mg/kg/d, Q12h, 6～12 months
46038117|NCT04816864|Diagnostic Test|extracardiac vagal nerve stimulation (ECANS) + EPS|"The study intervention will consist of 3 steps, all of which will be performed under general anesthesia:~EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing.~ECANS of the right and the left vagus nerve (from the right and left internal jugular vein, respectively; patients will be randomized to start from the right or the left side) performed during: 1) the patient's spontaneous heart rhythm (if present); 2) HB/LBB pacing with permanently programmed impulse parameters; 3) HB/LBB pacing at a pacing threshold of +0.1 V; and 4) 5 minutes after intravenous injection of atropine (0.02-0.04 mg/kg).~EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing."
46038118|NCT02877966|Dietary Supplement|Amixea|Amixea is a mixture of amino acids. It consists mainly of essential amino acids (EAA) that cannot be synthesized de novo by the organism, and therefore must be supplied in its diet.
46038119|NCT02877966|Other|Placebo|
46038120|NCT04226014|Procedure|Endoscopic ultrasound|Echo-endoscopy ultrasound is an examination that presents little risk. However, any medical act, exploration, intervention even conducted under conditions of competence and safety in accordance with current data of medicine and the regulations in force, conceals a risk of complications. In particular, esophageal perforations can occur. They are often favored by underlying lesions (tumor, diverticulum, anatomical variants ...). Other complications are possible such as cardiovascular, respiratory or infectious disorders, as with any anesthesia.
46038121|NCT02618161|Radiation|HDR Brachytherapy|HDR Brachytherapy, a single dose of 15 Gy delivered to prostate
46038122|NCT02618161|Radiation|External beam Radiotherapy|External beam Radiotherapy, a dose of 46 Gy in 23 fractions delivered to prostate
46038123|NCT04226404|Other|CSD1905-11|Flavor variant CSD1905-11 of a 4.8% nicotine ENDS product
46038124|NCT04226404|Other|CSD1905-12|Flavor variant CSD1905-12 of a 4.8% nicotine ENDS product
46038125|NCT04226404|Other|CSD1905-13|Flavor variant CSD1905-13 of a 4.8% nicotine ENDS product
46038126|NCT04226404|Other|CSD1905-14|Flavor variant CSD1905-14 of a 4.8% nicotine ENDS product
46038127|NCT04226404|Other|CSD1905-15|Flavor variant CSD1905-15 of a 4.8% nicotine ENDS product
46038128|NCT04226404|Other|CSD1905-16|Flavor variant CSD1905-16 of a 4.8% nicotine ENDS product
46038129|NCT04226404|Other|CSD1905-17|Flavor variant CSD1905-17 of a 4.8% nicotine ENDS product
46038130|NCT00698113|Procedure|Massage|"Children will receive a 10-15 minute massage seated (clothed), or in bed (clothed or unclothed) each day using the following protocol: stroking, effleurage, petrissage, muscle squeezing, effleurage, stroking. Massaged areas can include the back, arms and legs.~Parents will receive a one hour educational session with a Massage Therapist, a DVD, and written materials that all illustrate the required protocol."
46038131|NCT00698113|Other|Journaling|Children will complete weekly journals about their feelings. These journals will either be drawn or written based on the preference of the child. Parents will complete a weekly journal outlining the number of massages given to their child, barriers that prevented massage, and their experience of giving the massage.
46038132|NCT01075152|Drug|efavirenz|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
46038133|NCT01075152|Biological|nucleoside|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
46038134|NCT02775526|Procedure|TOT|70 patients
46038135|NCT02775526|Procedure|TVT|70 patients
46038136|NCT02775526|Procedure|Burch Colposuspension|70 patients
46038137|NCT04134637|Device|ultrasound|in the PIFB group linear ultrasound (Philips clear vue350,Philips healthcare,Andover MAO1810,USA,Machine Identification number:1385,Nile medical center,service@nilemed.net) probe will be used.
46038138|NCT04134637|Drug|Bupivacaine Hydrochloride 5 MG/ML|twenty milliliters of a solution of 0.25% bupivacaine in the PIFB group
46038139|NCT04133857|Other|aerobic exercise|aerobic exercise HIIT : High intensity interval training SSMIT : Steady state moderate intensity training
46038140|NCT02877186|Other|commercially-available diet soda|Subjects are asked to consume diet soda three times daily for one week.
46038141|NCT02877186|Other|carbonated water (control)|Subjects are asked to consume carbonated water three times daily for one week.
46055815|NCT03973645|Other|Patient presenting peritonitis managed with fungal research during year 2016|Patient presenting a peritoneal fungal with panfungal PCR and BDG compared to Peritonitis score (PS) and microbiological (ED direct fungal examination)
46055816|NCT02598037|Dietary Supplement|Test meal|The test meal will contain the following features: 50% carbohydrate, 20% protein and 30% of total fat, and will be admnistrada after drawing blood fasting for 12 hours.
46038142|NCT04225858|Procedure|Omission of sentinel lymph node biopsy|No sentinel lymph node biopsy will be performed in clinically node-negative triple-negative or HER2-positive breast cancer patients with a radiologic complete response on MRI. Participants will be asked to complete quality of life questionnaires at baseline (prior to surgery), 6 months, 1, 3 and 5 years follow-up. A control group consisting of 100 clinically node-negative patients receiving standard treatment will be used to compare QoL scores. This group consists of patients that do not wish to participate in the experimental group (i.e., no sentinel node lymph node biopsy) or patients that are not eligible.
46038143|NCT02617849|Drug|Pembrolizumab|200 mg IV every 3 weeks
46038144|NCT02617849|Drug|Carboplatin|AUC=6, every 3 weeks x 4
46038145|NCT02617849|Drug|Paclitaxel|175 mg/m2, every 3 weeks x 4
46038146|NCT02775448|Drug|Carduus marianus 6cH|
46038147|NCT02775448|Drug|Carduus marianus 12cH|
46038148|NCT02775448|Drug|Carduus marianus 30cH|
46038149|NCT02775448|Drug|Placebo|
46038150|NCT02775448|Behavioral|Exercise|aerobic exercise, 30 minutes, daily
46038151|NCT02775448|Other|Diet|1600 calories
46038152|NCT00950859|Drug|GSK1349572 (Cohort I)|50 mg once daily
46038153|NCT00950859|Drug|GSK1349572 (Cohort II)|50 mg twice daily
46038154|NCT02775292|Biological|Aldesleukin|Given SC
46038155|NCT02775292|Drug|Cyclophosphamide|Given IV
46038156|NCT02775292|Drug|Fludarabine Phosphate|Given IV
46038157|NCT02775292|Other|Laboratory Biomarker Analysis|Correlative studies
46038158|NCT02775292|Biological|Nivolumab|Given IV
46038159|NCT02775292|Biological|NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL|Given IV
46038160|NCT02775292|Biological|NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine|Given ID
46038161|NCT02775292|Procedure|Positron Emission Tomography|Correlative studies
46038162|NCT00862849|Drug|Insulin Lispro|
46038163|NCT00862849|Drug|Regular Human Insulin|
46038164|NCT00862849|Drug|rHuPH20|
46038165|NCT01090050|Drug|Sumatriptan/Naproxen Sodium|Each tablet of Sumatriptan/Naproxen Sodium for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
46038166|NCT01090050|Drug|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
46038167|NCT02776618|Procedure|running subcuticular closure of excisional defect|Excisional defects will be repaired with deep polyglactin 910 sutures, followed by each half of the wound given randomly assigned subcuticular superficial closure as described in the treatment arms.
46038168|NCT00944229|Drug|LOVAZA (Omega-3)|LOVAZA 4 gm q24 for 8 weeks Each 1-gram capsule of LOVAZA (omega-3-acid ethyl esters) contains at least 900 mg of the ethyl esters of omega-3 fatty acids. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 mg).
46038169|NCT00944229|Drug|Placebo|4 capsules of placebo every 24 hours
46038170|NCT02775370|Drug|Apatinib Mesylate|Apatinib Mesylate will be administered orally at 500 mg once daily for 5 consecutive days, and this was followed by a 2-day rest every week; each cycle consisted of 28 days
46038171|NCT00698893|Biological|Herpes simplex candidate (gD) vaccine GSK208141|Intramuscular injection, 2 doses, 2 different formulations (with and without MPL)
46038172|NCT04225468|Behavioral|ACL Opioid Exposure Reduction Program|Subjects will engage in a brief, educational which includes information about the appropriate use of opioid pain medication, exposure and tolerance, the definition of misuse and opioid-related harms, how to wean off medication, alternative pain management strategies, and appropriate disposal of leftover medication.
46038173|NCT02855307|Other|60-minute exercise|Patients will be admitted at the research clinical facility at 6:30. The artificial pancreas intervention will start at 7:00. A standardized breakfast will be served at 8:00. At 9:30, patients will performed a 60-minute exercise on the ergocycle at 60% of VO2 max. At 11:30, patients will be switched to standard insulin pump therapy and a lunch will be served. Patients will be discharged after lunch consumption.
46038174|NCT02855307|Device|Insulin pump|Patient's insulin pump will be used to infuse insulin.
46038175|NCT02855307|Device|Dexcom G4 Platinum glucose sensor|The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
46038176|NCT02855307|Drug|Insulin|Patient's usual fast-acting insulin analog will be used.
46038177|NCT02855307|Other|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) will be infused using the patient's pump. The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom Inc.) will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
46038178|NCT01077960|Biological|Serostim|Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
46038179|NCT04225234|Other|Financial incentives|"Depending on their level of participation or weight loss outcomes, participants will have the opportunity to receive between $60-$120 (over 12 months), on average, regardless of program assignment.~Regardless of which incentive program that participants are randomized to, they will receive the incentaHEALTH weight loss program intervention. incentaHEALTH is an technology-supported multi-component coaching intervention for weight loss includes a website, objective weight assessment using HIPAA-compliant kiosks, daily social cognitive theory-based email and text message support, and online access to health coaches. The intervention encourages increased intake of fruit, vegetables, lean protein, and complex carbohydrates while monitoring portion sizes."
45474027|NCT02525705|Biological|Oral Glucose|1.75g/kg of glucose is orally taken by the patient. Capillary glycemia is systematically realised before ingestion (H0) and after 30, 60, 90, 120, 180 and 240 min and/or if clinical signs of hypoglycemia are presented by the patient.
45474028|NCT03184077|Procedure|Laceration Repair with Polyglactin 910|Polyglactin 910 suture for laceration repair
45474029|NCT03184077|Procedure|Laceration Repair with poliglecaprone 25|poliglecaprone 25 suture for laceration repair
45474030|NCT03245736|Drug|Tisotumab Vedotin|All patients in the trial will be administered tisotumab vedotin (HuMax-TF-ADC).
46038180|NCT04269369|Drug|5-Fluorouracil|"The aim of this study is to investigate if the systematic implementation of pre-emptive geno- and phenotyping, and therefore a dose reduction based on the French guidelines and the literature during the first month of treatment, reduces grade 3 or greater toxicity in patients treated with 5-FU or capecitabine. Therefore a dosing table was obtained by combining the results of the study by Henricks et al., Launay et al. and Yang et al. and the recommendations from the French HAS guideline. The treatment schedule then will be discussed by the team of doctors and paramedics at the weekly MOC (multidisciplinary cancer consultation). Complementary, the pharmacist provides dose advice with regard to the start of 5-FU or capecitabine treatment.~In a subgroup, the group of patients with genotype wild type and phenotype intermediate metabolizer, a comparison will be made between group A with dosage according to French guidelines and group B with dosage according to literature."
46038181|NCT02776696|Device|Advanced Hybrid Closed Loop System|
46038182|NCT02776696|Device|Hybrid Closed Loop System|
46038183|NCT02776540|Drug|Clopidogrel|there is 2 groups one group will receive 900 mg Clopidogrel and the other will receive 600 mg Clopidogrel
46038184|NCT02776540|Drug|Aspirin|there's another group will receive 400 mg Aspirin
46038185|NCT00944697|Drug|Oxycodone Naloxone|Oxycodone Naloxone tablets
46038186|NCT00944697|Drug|Placebo tablets|Placebo Oxycodone Naloxone tablets
46038187|NCT02772796|Drug|SENS-218|Oral Administration
46038188|NCT00626652|Drug|K201 Injection|single intravenous infusion of Dose 1 - 10 or placebo (saline) or single oral capsule Dose A or placebo capsule
46038189|NCT02775136|Device|HS-1000 recording|
46038190|NCT05307276|Other|Heliox|"Participants will then complete 1 FAM (#V3) to Neuromuscular Function Assessment (PRE-POST), Pre- and Post- Exercise Ventilatory Function Assessment, and a Constant Load Ergocycle Test to Tolerance Limit (intensity fixed at 90% of the maximum aerobic power, PMA). The following two experimental visits (#V4 and #V5) will replicate the tests described in #V3. However, during the constant load exercise, participants will breathe either ambient air or heliox (a mixture in which the nitrogen in the air is replaced by the inert gas helium) in a random order. During a final Experiential Visit (#V6), participants will replicate the Medical Gas Administration visit but the exercise will be interrupted when a similar amount of time/work as the ambient air condition is achieved."
46038191|NCT05307276|Other|Air|Following the selection visit (#V0) to verify the inclusion and non-inclusion criteria, participants will make 2 visits (#V1 and #V2) including in particular a Respiratory Functional Exploration (EFR) and a triangular VO2 MAX estimation test in Ambient Air or Heliox conditions (depending on randomization).
46038192|NCT02878122|Procedure|Cancer treatment|Chemotherapy and laparoscopic surgery
46038193|NCT04878172|Device|TempSure Firm|The TempSure firm will be used on the abdomen for non-invasive lipolysis.
46038194|NCT04306926|Drug|TQB2450|TQB2450 1200mg administered IV on Day 1 of each 21-day cycle.
46038195|NCT04306926|Radiation|SBRT|Give according to the location of the lesion and clinical condition.
46038196|NCT04807348|Drug|Chiglitazar 32mg|Administrated once daily
46038197|NCT04807348|Drug|Chiglitazar 48mg|Administrated once daily
46038198|NCT04807348|Drug|Placebo|Placebo of Chiglitazar
46038199|NCT04807348|Drug|Metformin Hydrochloride|most tolerable dose
46038200|NCT01075074|Procedure|Transversus abdominis plane block|A regional block performed in the transversus abdominis plane of the abdomen, used to provide anesthesia and analgesia for the abdominal region.
46038201|NCT04224922|Drug|Paclitaxel|
46038202|NCT04224922|Drug|Carboplatinum|
46038203|NCT04224922|Drug|Epirubicin|
46038204|NCT04224922|Drug|Cyclophosphamide|
46038205|NCT00626418|Drug|Aplindore|Tablets 0.05, 0.1, 0.2, 0.3, 0.5 and 0.7 mg QD for up to 6 nights
46038206|NCT00626418|Drug|Placebo|Placebo tablets
46038207|NCT02877030|Other|Video game|The protocol sensorimotor exercises consist of a virtual game that attaches to the Nintendo Wii and using arrows that are thrown from above, players must perform weight-shifting movements in the Nintendo platform to the target be directed to the trajectory the arrows. The goal is to catch as many arrows.
46038208|NCT02877888|Drug|fluoride varnish 22600ppm|topical application on teeth every 6months
46038209|NCT02772640|Drug|Rosuvastatin and Ezetimibe morning or evening administration|"Timing of the drug administration:~morning -> evening evening -> morning"
46038210|NCT02877342|Other|Pre-hospital notification|Pre-hospital notification smartphone/tablet application in the form of an Android program that will be used by ambulance clinicians to notify emergency departments of selected hospitals of an impending arrival of a patient.
46038211|NCT02877810|Other|Telemedicine|Telemedicine is a live, interactive, audiovisual teleconferencing system.
46038212|NCT02877810|Other|Telephone|Consultations will be given over telephone.
46038213|NCT02772484|Device|HS-1000|
46038214|NCT02876952|Other|HIGH VOLUME (HV) Supervised exercise|"Supervised exercise two nonconsecutive days per week (day 1-on the treadmill, day 2-on the bike) for 16 weeks. High-intensity interval training (HIIT) protocol on the treadmill: 5-min warm-up at a moderate-intensity, before walking 2 intervals of 4 min at high-intensity interspersed with intervals of 3 min of walking at moderate-intensity. 1-4 min cool-down at moderate-intensity.~HIIT protocol on the bike: 5 to 10-min warm-up at moderate intensity. After that, 4 repetitions (1rep = 30 s high-intensity followed by 60 s moderate-intensity) and gradually increased to 16 repetitions in HV-HIIT week by week. 5-10 min cool-down at moderate-intensity"
46038215|NCT02876952|Other|Mediterranean Diet Recommendations|"Participants will be interviewed regarding their usual eating habits. They will receive practical information about which are the Mediterranean Diet (DMed) foods according to the model proposed in the PREDIMED trial. Medical doctors or nurses will give this information.~Before starting the program of intervention, participants will assist to an informative talk in which benefits for the health of the DMed will be exposed and general information about food composition, frequencies of consumption, etc. will be explained.~Nutritional management: Diet reviews and body mass control will be performed every two weeks to assess the body composition and adherence to treatment. In the event of poor compliance strategies will be addressed for its correction."
46038216|NCT02876952|Other|Physical Activity Recommendations|Participants will be advised to perform, without supervision, moderate to high-intensity dynamic aerobic exercise (walking, jogging, cycling or swimming) 3-5 days per week, following an adequate warm-up of 5-15 min, at moderate to high intensity (below the ischemic threshold) for a period of 20 to 40 min (not including warm-up and cool-down) followed by a cool-down period of 5-10min. Participants will receive information related to heart rate values regarding moderate and high exercise intensity domains for the self monitoring of exercise intensity.
46038217|NCT02876952|Other|LOW VOLUME (LW) Supervised exercise|Supervised exercise two nonconsecutive days per week (one day on the treadmill, and the second one on the bike) for 16 weeks. HIIT protocol on the treadmill: 5-min warm-up at a moderate-intensity, before walking 2 intervals of 4 min at high-intensity interspersed with intervals of 3 min of walking at moderate-intensity. The training session will end with a 1-4 min cool-down period at moderate-intensity. Total exercise time of 20min HIIT protocol on the bike: 10-min warm-up at moderate intensity. After that, participants will cycle for 4 repetitions (1rep = 30 s high-intensity followed by 60 s moderate-intensity) and gradually increased to 8 repetitions in LV-HIIT week by week. The training session will end with a 5-10 min cool-down period at moderate-intensity.
46038218|NCT02772406|Device|Linked Color Imaging|
46038219|NCT02772406|Device|white light imaging|
46038220|NCT02772718|Drug|XOMA 358 single dose level A|XOMA 358 single dose level A administered by intravenous infusion
46038221|NCT02772718|Drug|XOMA 358 single dose level B|XOMA 358 single dose level B administered by an intravenous infusion
46038222|NCT02772718|Drug|XOMA 358 single dose level C|XOMA 358 single dose level C administered by an intravenous infusion
46038223|NCT02772718|Drug|XOMA 358 multiple dose level 1|XOMA 358 multiple dose level 1 administered by an intravenous infusion
46038224|NCT00866281|Drug|midostaurin|Midostaurin 25 mg/mL oral solution was provided in bottles of 50 mL, administered with water. The pediatric starting dose of midostaurin was set at 30 mg/m2 bid and was not to exceed 60 mg/m2 bid.
46038225|NCT02772016|Drug|Colla corii asini|15 g of Colla corii asini in powder form daily for 4 weeks
46038226|NCT04225000|Other|Exercise Group|Control group included 6 different exercises to treat participants having PFPS. These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. These all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This exercise protocol was for 4 weeks and 3 sessions per week.
46038227|NCT04225000|Other|Mobilization Group|"Experimental group included Anterior-Posterior (AP) tibiofemoral joint mobilization and all 6 exercises suggested controlled group for treating participants having PFPS; 3 sessions of mobilizations per week and total 4 weeks.~These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. Theses all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week."
46038228|NCT04121611|Drug|Unfractionated heparin|"Intravenous unfractionated heparin (UFH) infusion within 6 hours of EVT with target activated partial thromboplastin time (aPTT) 64-86~Anticoagulation to continue for minimum of 48 hours (can be maintained on UFH aPTT 64-86 or transitioned to low-molecular weight heparin (LMWH) Enoxaparin 1mg/kg)"
46038229|NCT04121611|Drug|Acetylsalicylic Acid (ASA)|"Acetylsalicylic Acid (ASA) 325mg PO/PR/NG loading dose < 2 hours of EVT completion~ASA 81mg PO OD maintenance dose"
46038230|NCT02617615|Drug|MB-110|MB-110 is a novel, potent, and selective HCV inhibitor against the NS5A protein. In the preclinical studies, MB-110 demonstrated picomolar EC50s towards various genotypes and favorable pharmacokinetic properties to support the once daily dosing regimen.
46038231|NCT02617615|Drug|Placebo|It will be identical in appearance and similar in weight to the MB-110 hard-gel capsule.
46038232|NCT02772250|Behavioral|telephone re-education(TRE)|Subjects who are randomized into this group receive regular instructions at the time of their appointment to discuss colonoscopy (a nurse provides education of 5 minutes and meanwhilet sent a bookle to the patient) and a TRE which was conducted by one investigator at 15:00-17:00 on the day before colonoscopy.
46038233|NCT02772250|Behavioral|face-to-face re-education (FFRE)|Subjects who are randomized into this group receive regular instructions on the day of their appointment to discuss colonoscopy and also a FFRE which was conducted by a investigator on the same-day of procedure at hospital.
46038234|NCT02614885|Device|RFA|Radiofrequency ablation of the cavity walls of a simulated lumpectomy in the excised prophylactic mastectomy tissue.
46038235|NCT02772172|Device|Surgical Template|
46038236|NCT02772094|Biological|Single arm, open-label|"Biological: ADCTA-G. Biological: autologous DC loaded with irradiated autologous tumor cells. Biological: dendritic cell vaccine. Drug: 180mg/m2•per day temozolomide prior and concomitant with radiotherapy. Radiotherapy: Local ionizing radiation 200 centigray(cGy)/day, 5 successive days per week for 6 weeks, total dose of 6000 cGy.~Drug: Adjuvant chemotherapy-temozolomide (TMZ) monthly cycle, 200mg/m2•per day continued for 5 days in the beginning of every month, 6 cycles of TMZ."
46038237|NCT02771860|Drug|denosumab|60mg sc
46038238|NCT02771860|Drug|Placebo|identical syringe
46038239|NCT02771860|Dietary Supplement|Calcium/Vit D supplementation|Daily dosage Calcium 1000mg / Vit D 880 IU
46038240|NCT02771782|Biological|BCG vaccine (SSI)|
46038241|NCT02771782|Biological|TDaP-IPV vaccine|
46038242|NCT02771392|Drug|Ophthalmic Tetracaine|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
46038243|NCT02771392|Other|Normal Saline|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
46038244|NCT02771470|Drug|Probiotics|Microbial composition using probiotic
46038245|NCT02771470|Drug|placebo|Microbiota modulation using placebo
46038246|NCT02696746|Other|Observation|No intervention
46038247|NCT02771704|Other|Silver Diamine fluoride|
46038248|NCT02771704|Other|Potassium iodide|
46038249|NCT02771704|Other|Chlorhexidine|
46038250|NCT02771704|Other|Silver diamine fluoride and potassium iodide|
46038251|NCT02771704|Other|Physiological saline|
46038252|NCT02771548|Procedure|Anterior Cruciate Ligament Reconstruction|
46038253|NCT02771314|Drug|AZD9291|AZD9291, 80 mg (tablets) once daily, administered orally in the fasted state
46038254|NCT02771002|Device|Peripheral Perfusion index by Carescape Patientenmonitor|Peripheral Perfusion index measured with pulse-oximetry by Carescape Patientenmonitor
46038255|NCT04732780|Other|No intervention|No intervention
46038256|NCT02771158|Drug|Midodrine|midodrine is metabolized to an active metabolite, desglymidodrine, which is an alpha adrenergic antagonist that causes vasoconstriction of both venous and arterial vasculature, thereby increasing blood pressure
46038257|NCT02771158|Drug|placebo|placebo will be administered to double blind the study
46038258|NCT02771080|Procedure|Cardiac surgery|
46038259|NCT02770924|Device|AT LISA TRI TORIC|phacoemulsification with IOL implantation
46038260|NCT02770924|Device|AT LISA TRI|phacoemulsification with IOL implantation
46038261|NCT02770534|Procedure|blood test|10mls extra mls of blood taken during usual phlebotomy procedures
46038262|NCT02770768|Drug|Flibanserin|Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
46038263|NCT02770768|Drug|Placebo|Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
46038264|NCT02770690|Drug|ethyl chloride spray|apply the spray for 5 seconds on the dorsal hand before propofol iv injection
46038265|NCT02770690|Drug|lidocaine|apply lidocaine under the tourniquet state before propofol iv injection
46038266|NCT02770690|Drug|placebo|apply normal saline before propofol iv injection
46038267|NCT02770378|Drug|Temozolomide|Patients will receive temozolomide at a dose of 20 mg/m² BSA twice daily with start day 1 during induction and treatment cycles
46038268|NCT02770378|Drug|Aprepitant|Patients will receive aprepitant at a dose of 80 mg p.o. once daily with start day 1 during induction and treatment cycles
46038269|NCT02770378|Drug|Minocycline|Induction cycle day 3-4: minocycline 50 mg p.o. twice daily from day 19-20; minocycline 100 mg p.o. twice daily during treatment cycle 1-12 (28 days); minocycline 100 mg p.o. twice daily
46038270|NCT02770378|Drug|Disulfiram|Induction cycle day 5-6: disulfiram 250 mg p.o. once daily from day 21-22; disulfiram 250 mg p.o. twice daily during treatment cycle 1-12 (28 days); disulfiram 250 mg p.o. twice daily
46038271|NCT02770378|Drug|Celecoxib|Induction cycle day 1-35: day 7-8: celecoxib 200 mg p.o. twice daily from day 23-24; celecoxib 400 mg p.o. twice daily during treatment cycle 1-12 (28 days); celecoxib 400 mg p.o.twice daily
46038272|NCT02770378|Drug|Sertraline|Induction cycle day 1-35: day 9-10: sertraline 50 mg p.o. twice daily, day 31-32: sertraline 100 mg p.o. twice daily; treatment cycle 1-12: sertraline 100 mg p.o. twice daily
46038273|NCT02770378|Drug|Captopril|Induction cycle day 1-35: day 11-12: captopril 25 mg p.o. twice daily, day 25-26: captopril 50 mg p.o. twice daily; treatment cycle 1-12 (28 days): captopril 50 mg p.o. twice daily
46038274|NCT02770378|Drug|Itraconazole|Induction cycle day 1-35: day 13-14: itraconazole 200 mg p.o. once daily day 27-28; itraconazole 200 mg p.o. twice daily; treatment cycle 1-12 (28 days): itraconazole 200 mg p.o.twice daily
46038275|NCT02770378|Drug|Ritonavir|Induction cycle day 1-35: day 15-16: ritonavir 200 mg p.o. once daily, day 29-30: ritonavir 200 mg p.o. twice daily, day 35: ritonavir 400 mg p.o. twice daily; treatment cycle 1-12 (28 days): ritonavir 400 mg p.o. twice daily
46038276|NCT02770378|Drug|Auranofin|Induction cycle day 1-35: day 17-18: auranofin 3 mg p.o. once daily, day 33-34 auranofin 3 mg p.o. twice daily; treatment cycle 1-12 auranofin 3 mg p.o. twice daily
46038277|NCT02770456|Dietary Supplement|High dose fish oil|Four 0.72-gram gelatine capsules per day with fish oil providing 2.0 g/d lc-n3FA
46038278|NCT02770456|Dietary Supplement|Low dose fish oil|Four 0.72-gram gelatine capsules per day with a mixture of fish oil and olive oil providing 0.5 g/d lc-n3FA
46038279|NCT02770456|Dietary Supplement|Olive oil|Four 0.72-gram gelatine capsules per day with olive oil providing 0 g/d lc-n3FA
46038280|NCT02770222|Drug|Selexipag|Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)
46038281|NCT02770222|Drug|Gemfibrozil|Gemfibrozil film-coated tablet of 600 mg administered orally b.i.d. from Day 1 to Day 9
46038282|NCT02770222|Drug|Rifampicin|Rifampicin film-coated tablet of 600 mg administered orally o.d.from Day 1 to Day 9
46038283|NCT02770144|Behavioral|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
46038284|NCT02770144|Behavioral|Access to Referral to Social Services|
46038285|NCT00943917|Other|ITCA 650|ITCA 650 (continuous delivery of exenatide in DUROS)
46038286|NCT00943917|Drug|Exenatide Injection|twice daily (BID) injections of exenatide commercially available Byetta: 5 mcg/dose first 12 weeks then 10 mcg/dose for 8 weeks
46038287|NCT00943917|Other|Ex Inj/ITCA 650|twice-daily (BID) exenatide injection: 5 mcg/dose for 4 weeks then 10 mcg/dose for 8 weeks, followed by ITCA 650
46038288|NCT04780620|Other|Parent Intervention Group|Parents will be involved in 8 weekly sessions.
46038289|NCT02769832|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2, day 1, 8 q 21 days
46038290|NCT02769832|Drug|Gemcitabine|Gemcitabine 1000 mg/m2, day 1, 8 q 21 days
46038291|NCT02876250|Drug|Cyclosporine A|a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
46038292|NCT02876250|Drug|Placebo|a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
46038293|NCT02769910|Drug|Capsaicin 24 Hours|Dermal patches for transdermal application of Capsaicin, applied for 24 hours
46038294|NCT02769910|Drug|Capsaicin 1 Hour|Dermal patches for transdermal application of Capsaicin, applied for 1 hour
46038295|NCT02769910|Other|Qutenza Demo Patch|Dermal patches mimicking active Qutenza patches. Used as control in comparison of Capsaicin efficacy. Applied for 24 hours.
46038296|NCT02876484|Drug|Colesevelam|
46038297|NCT02876484|Drug|Chenodeoxycholic Acid|
46038298|NCT02876484|Other|Water|
46038299|NCT02851485|Drug|GLPG1972 600 mg oral solution fasted|dosing after overnight fasting
46038300|NCT02851485|Drug|GLPG1972 600 mg oral tablet fasted|dosing after overnight fasting
46038301|NCT02851485|Drug|GLPG1972 600 mg oral tablet fed|dosing after high-fat high-calorie breakfast
46038302|NCT04779372|Behavioral|smartphone-based dCBT-I from a Wechat applet|Participants will receive 6-week smartphone-based dCBT-I from a Wechat applet.
46038303|NCT04779372|Behavioral|sleep education|Participants will receive sleep education like the advices getting from common sleep clinic.
46038304|NCT02696668|Other|modified FaME|Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors. The components of the FaME programme include specific falls management strategies, such as bone loading, gait, dynamic posture, balance, reaction and co-ordination training, functional floor activities to improve coping skills and confidence.
45498033|NCT05411991|Other|Maintenance infusion|A maintenance infusion with 500 mL dextrose 5% and 3 g MgSO4 is started at an infusion rate of 20 mL/h upon the moment of first protocol-specified administration of intravenous diuretics and continued until switch to oral diuretic therapy. 40 mmol KCl is added if serum potassium levels are <4 mmol/L. In case of hypotonic hyponatremia with serum sodium concentration <130 mmol/L, dextrose 5% will not be provided and MgSO4 will be administered in 50 mL of normal saline (NaCl 0.9%).
46038305|NCT02696668|Other|Multisensory|"Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors.Participants will receive an initial assessment by the research physiotherapists to determine the most appropriate interventions for each participant. Interventions used will include:~Limits of stability training with eyes open / eyes closed~Self induced movement strategies with eyes open / eyes closed~Gaze stability exercises in sitting / standing / walking~Sensory integration~Habituation exercises"
46038306|NCT04297722|Other|Dairy products|Dairy consumption including total dairy, full-fat dairy, low-fat dairy, total milk, full-fat milk, low-fat milk, total yogurt, full-fat yogurt, low-fat yogurt, total cheese, hard cheese and fresh cheese
46038307|NCT02769598|Device|ANI Index for Hospitalized children|Each file consists of a simultaneous recording of an ECG signal, according to usual practice, coupled with a record of ANI Index (Analgesia Nociception Index) by MetroDoloris®. The ECG signals and the ANI index are recorded simultaneously on a computer.
46038308|NCT04297644|Other|There is no intervention|There is no intervention
46038309|NCT02769676|Other|3-week visit|The intervention will be an additional visit to the usual postpartum care provider at 3-weeks postpartum.
46038310|NCT02769676|Other|usual care|Participants in the usual care arm will receive no additional interventions.
46038311|NCT02876094|Drug|celecoxib|dose-response
46038312|NCT00603135|Drug|first-line i/v-levetiracetam|No effect after 30 min, standard therapy with f.e. lorazepam for NCSE
45498034|NCT05411991|Drug|Oral potassium supplements|If serum potassium levels are <3.5 mmol/L at any time during the administration of intravenous diuretics, oral potassium supplements are provided as needed to keep serum potassium levels >4 mmol/L
45498035|NCT05411991|Other|Intravenous hypertonic saline|In case of hypotonic hyponatremia with serum sodium concentration <125 mmol/L, a bolus of 150 mL hypertonic saline 3% is administered and repeated OD if necessary, until sodium levels are ≥135 mmol/L.
46038313|NCT02769754|Device|Hemopatch|Hemopatch will be apply once the standard surgical hemostasis is achieved.
46038314|NCT02769754|Other|Control|No additional treatment will be applied after performing the usual surgical hemostasis.
46038315|NCT02769286|Drug|Osimertinib|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from circulating tumor DNA
46038316|NCT02855073|Biological|ReJoinTM|adipose derived mesenchymal progeinitor cells
46038317|NCT02855073|Drug|Sodium Hyaluronate|Sodium Hyaluronate Injection
46038318|NCT01077024|Other|Smoking-cessation treatment|Smoking cessation treatment includes four components: 1. brief weekly individual smoking-cessation counseling study weeks 1-10; 2. extended-release (XL) bupropion (300 mg/day)study weeks 1-10; 3. nicotine inhaler (6-16 cartridges per day ad libitum)during the post-quit treatment phase; 4. prize-based contingency management during the post-quit treatment phase.
46038319|NCT02769130|Drug|Losartan|Losartan is given for 12 months
46038320|NCT02768896|Behavioral|Baseline|Patients will walk naturally with EEG measuring brain waves
46038321|NCT02768896|Behavioral|visual stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses
46038322|NCT02768896|Behavioral|Auditory stimuli|Patients will walk naturally with EEG measuring brain waves while hearing an auditory stimuli
46038323|NCT02768896|Behavioral|Visual and auditory stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses and hearing an auditory stimuli simultaneously
46055817|NCT02751567|Other|BAY987516|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
46055818|NCT02751567|Other|Untreated skin|One site is patched without treatment as control
45694523|NCT01709383|Device|Transcranial Direct Current Stimulation|The tDCS treatments will be applied bilaterally, with the anodal electrode placed on the left temple and the cathodal electrode placed on the right temple. The tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
46038324|NCT02853357|Other|Manipulation|"Middle Thoracic: Participants are placed in the supine position with their arms over their chest. The clinician rolls the participant to their side and places the fulcrum at the desired thoracic segment and the participant is rolled back onto the clinician's hand. The participant is instructed to take a deep breath. As the participant is exhaling, the clinician uses his body to push through the participant's arms to perform a high velocity thrust in an anterior to posterior directed force. Lower Thoracic: With the patient in a prone position, the clinician achieves a skin lock with both pisiforms over the transverse processes of the target vertebra. The clinician then uses his body to push down through his arms to perform a high-velocity, low-amplitude posterior to anterior thrust."
46038325|NCT02853357|Other|Sham Manipulation|The participants are positioned in prone and the clinician's hands are placed with the pisiforms of each hand over the transverse processes of the target vertebra. The clinician will only apply minimal pressure and slide the hands across the skin to mimic the manipulative thrust. This sham procedure has been shown to be an adequate sham comparator for spinal manipulative therapy (SMT) with similar expectations and believability as SMT active treatment
46038326|NCT02853357|Other|Core Strengthening Exercises|Both groups will receive the following exercises at each visit. The core strengthening (core strengthening) exercises are a standard protocol used by Richardson et al and Franca et al which are proposed to target muscles responsible for segmental stabilization, specifically the transverse abdominis (TrA) and the lumbar multifidi (LM). Exercises will include: TrA exercises in 4 point kneeling and in supine with flexed knee, LM exercises in prone, and co-contraction of TrA and LM in upright position. Three sets of 15 repetitions will be done for each exercise.
46038327|NCT04858698|Device|Ultrasound / Echocardiography|Ultrasound will be used to guide vascular access and to place a lead into the right ventricle.
46038328|NCT02769208|Device|Central air handling unit air purification technologies|As described in the arm descriptions, the interventions involve changing the baseline pre-filter + HEPA + ESP conditions by removing either just the ESP or both the ESP and the HEPA for a five week period.
46038329|NCT02769052|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy through self-applied device .
46038330|NCT02768740|Drug|Hydrocortisone hemisuccinate|In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
46038331|NCT01089582|Other|No intervention|
46038332|NCT00603213|Procedure|Blood Volume Analysis, Echocardiogram|"Blood Volume Analysis: The use of radioactive tracer to determine plasma volume and red cell mass.~Echocardiogram is an ultrasound of the heart."
46038333|NCT02768974|Drug|OPRX-106|Oral delivery, once daily.
46038334|NCT02851095|Drug|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.
46038335|NCT02851095|Drug|Canagliflozin|Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
46038336|NCT02851095|Drug|Metformin Extended Release (XR)|Participants will receive 2 metformin XR tablets of each 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
46038337|NCT04224532|Procedure|Pneumoperitoneum Timing (Before Positioning)|Before Reverse Trendelenburg Position
46038338|NCT04224532|Procedure|Pneumoperitoneum Timing (After Positioning)|After Reverse Trendelenburg Position
46055819|NCT00917449|Drug|L-arginine|Oral L-arginine (3.2 gr bid)for 18 months
46055820|NCT00917449|Drug|Placebo|Oral Placebo BID for 18 months
45474031|NCT03369886|Diagnostic Test|Optical Coherence Tomography Angiography (OCTA)|The images will be obtained using a commercial swept-source OCT (SS-OCT) device (DRI OCT Atlantis; Topcon, Tokyo, Japan). SS-OCT uses infrared light, wavelength of 1050 nm which is longer than conventional SD-OCT, at 100,000 A-scans per second. This longer infrared light source has advantages of deep signal penetration through the retina and choroid. Its axial and transversal resolution is 7 and 20 μm in tissue, respectively. Volumetric OCT scans were taken from 6 × 6 mm cubes. Each cube consists of 320 clusters of 4 repeated B-scans centered on the fovea. Moving objects (mostly blood flows) are detected by measuring intensity fluctuations from these repeatedly scanned OCT images. Automated segmentation was performed by OCT software to separate each layer of the retina. The en-face images of the superficial capillary network were derived from an en-face slab, ranged from the internal limiting membrane (ILM) to the inner border of the inner nuclear layer (INL).
45474032|NCT03375411|Device|Stent INC1|Coronary intervention with conventional angioplasty technique but with a novel bare metal stent.
46038339|NCT00580515|Behavioral|Family Focused Group Therapy|6 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months.
46055821|NCT02754687|Drug|Placebo|Placebo with capsules that look like the 11β-MNTDC capsules but with no active ingredients
46055822|NCT02754687|Drug|11βmethyl nortestosterone dodecylcarbonate|Escalating doses of 100, 200, 400, and 800 mg 11β-MNTDC
46055823|NCT02597335|Radiation|Spectro-MRI|Spectro-MRI for D-2HG detection
46055824|NCT02597335|Other|Dosage of free circulating plasmatic DNA|
46055825|NCT02597335|Other|Dosage of D-2HG in the urine|
46038340|NCT00580515|Behavioral|Family Focused Group Therapy|10 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months
46038341|NCT00580515|Behavioral|Standard of Care|Standard of Care Families assigned to the Usual Care Condition will receive standard psychosocial care which is based on the following patterns: Social work consultations are routinely provided to the cancer patients, but relatives are only seen during admissions or upon request.
46038342|NCT02876874|Drug|indocyanine green(ICG)|ICG will be injected into the dorsal of hand/foot
46038343|NCT02768818|Dietary Supplement|Probiotic VIVOMIXX™|The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
45474033|NCT01173809|Drug|Amiodarone|Patient will continue taking Amiodarone before, during and after ablation (8 weeks post-ablation).
45474034|NCT01173809|Drug|Amiodarone|Amiodarone therapy will be stopped at least 5-months before ablation procedure and ablation will be performed off Amiodarone. Patients will not take Amiodarone during the blanking period (8 weeks post-ablation).
45474035|NCT03375580|Dietary Supplement|TLC|transform life custom (TLC)
45474036|NCT03375580|Drug|metformin|0.5g metformin group，PO tid
46038344|NCT02768818|Dietary Supplement|Placebo|The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
46038345|NCT02876016|Device|functional MRI|locate the cerebral bases in functional imaging
46038346|NCT00862459|Drug|Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
46038347|NCT00862459|Drug|Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
46038348|NCT00862459|Drug|Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
46038349|NCT00862459|Drug|OptiMARK~0.1 mmol/kg BW|Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
45840201|NCT00675558|Procedure|Initial Surgery|"NO patients had initial abdominal laparoscopic surgery at study entry, during which research fat biopsies were obtained, completing their participation.~MO patients had initial laparoscopic bariatric surgery (gastric bypass, adjustable gastric band, or sleeve gastrectomy) and fat biopsies at entry, completing their participation.~All 30 SMO patients had initial laparoscopic bariatric surgery (sleeve gastrectomy) & fat biopsies. The first 10 to lose 100 lbs but who needed further surgery to reach optimal weight and who consented to further surgery underwent a 2nd laparoscopic bariatric surgery (either a biliopancreatic diversion with duodenal switch or a Roux-en-Y gastric bypass) and biopsies. The interval between surgeries averaged 15 mos. and the weight loss 55 kg. 30 SMO patients were initially enrolled to insure that 10 would complete 2 surgeries. When 10 had had their 2nd operation, the study was considered complete, and the remaining 20 SMO participants were so notified."
45840202|NCT00675558|Procedure|Second Bariatric Surgery|A second bariatric procedure was performed on only 10 of the original 30 Super-morbidly Obese (SMO) subjects.
45840203|NCT00675792|Drug|Sugammadex|Participants received 4 mg/kg sugammadex at 1-2 Post Tetanic Counts (PTCs) or better after the last dose of rocuronium bromide.
46038350|NCT00580047|Drug|Zoledronic Acid|4mg IV Annually
45840204|NCT00675792|Drug|Neostigmine|Participants received 50 µg/kg neostigmine combined with 10 µg/kg glycopyrrolate after the last dose of rocuronium bromide as per standard of care.
45840205|NCT00675792|Drug|Rocuronium|Participants received a single intubation bolus dose of 0.6 mg/kg rocuronium bromide, followed if necessary to maintain neuromuscular blockade by one or more single bolus dose(s) of 0.15 mg/kg rocuronium bromide.
46038351|NCT00580047|Combination Product|Calcium with vitamin D|1200 mg Calcium with 800 International Units of vitamin D
46038352|NCT00580047|Drug|Alendronate|70mg weekly
46038353|NCT01074450|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
46038354|NCT01074450|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
46038355|NCT02768428|Other|Video-Audio Media|each arm spends 15 mins for watching the video or study the handbooks
46038356|NCT00603369|Behavioral|group intervention|13-session intervention
46038357|NCT00603369|Behavioral|group intervention|2-session intervention
46038358|NCT02853279|Behavioral|Interval exercise training|"Interval exercise sessions (INT) involving work:recovery ratios of 40 s at 70% delta work-rate followed by 80 s active recovery at 20 W. 70% delta (∆) is 70% of the difference between work rate peak (WRpeak) and work rate at the lactate threshold (WRLT) calculated as:~70%∆ =0.7(〖WR〗_peak- 〖WR〗_LT )+ 〖WR〗_LT~Where WR is work rate, LT is lactate threshold)~Each session was for 30 min and this was undertaken twice per week for 12 weeks. One home based exercise session was incorporated per week."
45840206|NCT00676182|Other|Telerehabilitation|Rehabilitation via computer assisted internet capabilities
45840207|NCT00676572|Other|Fiberoptic bronchoscopy; blood test|Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells
45840208|NCT00676806|Biological|Umbilical Cord Blood After Myeloablative Conditioning|cyclophosphamide (60mg/m2 days -6 & -5), fludarabine (25 mg/m2 days -7, -6, & -5) and total body irradiation (days -3, -2, & -1, total 1200 cGy) followed by cord blood infusion on day 0.
45840209|NCT00676806|Biological|Umbilical Cord Blood After Reduced-Intensity Conditioning|Extracorporeal Photopheresis (days -8 & -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 & -4), total body irradiation (days -3 & -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.
46038359|NCT02853279|Behavioral|Continuous exercise training (CON)|Exercise sessions involved cycling at 20%∆ work-rate peak for the duration of the session. This work-rate was chosen so that all participants in the group would be exercising in the heavy-intensity domain. To enable participants in the CON exercise group to complete the same amount of work (kJ) as the participants in the INT exercise group, the amount of work that would be completed if the CON participants completed an INT exercise session was calculated. Participants exercised for 26 min (varying to match interval group) twice per week for 12 weeks.
46038360|NCT02768116|Procedure|Sirolimus Drug-eluting Stent via Active Transfer of Plaque|
46038361|NCT02768116|Procedure|Sirolimus Drug-eluting Stent implantation via Provisional T Stenting|
46038362|NCT02768272|Device|PCEA vs PIEB|We evaluate the relation between the distribution of L-bupivacaine plus fentanyl in the epidural space and the incedence of breaktrough pain during labor
45840210|NCT00677898|Behavioral|Patient-centered computerized tool|A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects
45840211|NCT00677898|Behavioral|Written educational materials|Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
46038363|NCT02768272|Procedure|Epidural vs CSE|We evaluate the relation between the type of epidural technique and the incedence of breaktrough pain during labor
45840212|NCT00678444|Other|Educational video|Watching an educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
45840213|NCT00678834|Dietary Supplement|To surgery patients, Tocopherol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
45840214|NCT00678834|Dietary Supplement|Tocotrienol to healthy subjects.|200 mg to take orally two times a day (400 mg a day).
46055826|NCT02754453|Behavioral|Behavioral lifestyle intervention|20 session lifestyle behavioral intervention with the goal of altering diet and physical activity and decreasing problematic behaviors associated with weight regain and session behavioral intervention addressing increasing physical activity, improving adherence to dietary recommendations and altering problematic eating behaviors.
46055827|NCT04254315|Behavioral|Group based cognitive therapy|"Patients are informed about the Optima program in the inclusion interview, and patients are participating in groups of maximum 4 persons. Each of the 5 session has a duration of 1,5 - 2 hours.~The psychologist have developed the content of each session, with attention to thoughts and feelings regarding the current situation after a heart-condition, and the effects on life conditions. Patients get the tools to overcoming the difficulties, they experience, f.x. anxiety and stress.~When other hospitals are joining the Optima project, the project nurse and psychologist are training the hospital staff as well as supervising."
46055828|NCT04220151|Genetic|DNA methylation|DNA methylation will be measured by real time polymerase chain reaction
46055829|NCT05429775|Drug|Budesonide|single dose of 2 mg oral suspension formulation administered orally under fasting conditions
46055830|NCT02754219|Drug|Evogliptin|DPP4-inhibitor, Evogliptin
46055831|NCT05429619|Device|OnCall mobile health peer support app|"Mobile health platform that provides anonymous access to peer support services that has been co-design by and for Canadian public safety personnel. OnCall is for frontline public safety providers; features include links to mental health self-assessment tools, a wellness toolbox, tips to cope articles and peer wisdom videos, and options to reach out to a peer support provider of their choice via telephone or text. The OnCallSupport app is for the peer support providers which includes a list of resources and an opportunity to create post-action reports following the peer support encounter. Connections are made to peer support via a telephone service that disguises the contact information of both parties. The app platform includes options to complete feedback surveys related to the app and to the peer support encounter."
46055832|NCT04232631|Device|IntraOx Vioptix|Vascular imaging device
46055833|NCT04232631|Device|Hyperview, HyperMed Imaging|Vascular imaging device
46055834|NCT04232631|Device|Snapshot NIH, Kent Imaging|Vascular imaging device
46055835|NCT05429385|Drug|HLX70|Single-dose, intravenous infusion
46055836|NCT05429385|Drug|Placebo|Single-dose, intravenous infusion
46055837|NCT02753829|Procedure|Cardiovascular rehabilitation program using Kinect of Xbox|"Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks."
46055838|NCT02753829|Procedure|Cardiovascular rehabilitation program using paper manual|"Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks."
46055839|NCT02753829|Other|Educational component|It was only given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks.
46055840|NCT04220073|Biological|JS005 (recombinant humanized monoclonal antibody against IL-17A)|JS005
46055841|NCT04220073|Drug|placebo|placebo
46055842|NCT02753907|Dietary Supplement|Low LA|Individuals who replaced 10 mL soy oil with one apple
46055843|NCT02753907|Dietary Supplement|High LA|Individuals who reduced 1/3 cup of cooked refined rice and consumed 9.9g (9 of 1.1g capsules, 3 capsules at every 3 meals a day) of soy oil as a supplement
46055844|NCT02753985|Other|Survey|
46038364|NCT04269681|Device|High Flow Nasal Cannula|"Experimental intervention (HFNC) The HFNC (AIRVO 2 - Fisher & Paykel Healthcare, Auckland, New Zealand) consists of a device that allows FiO2 adjustable from 21 to 100% and that delivers a flow of humidified and heated gas up to 60 l / min and 37 degrees C of temperature.~The HFNC will be offered until resolution of the ARF or until decision by the assisting team and the patient and/or their legal guardian, for the suspension of the treatment due to intolerance, and/or worsening of the discomfort and / or dyspnea.~The HFNC should be offered to the patient in ARF as follows:~Initial parameters: Flow 45 ml / L, FiO2 50%, AIRVO 37oC temperature;~Titrate the flow up to 60ml / L or up to the maximum tolerated;~Titrate FiO2 to maintain SatO2 between 92% to 98%, starting with 50%;~Keep the AIRVO temperature at 37oC, if not possible, acceptable down to 34oC."
45840215|NCT00678834|Dietary Supplement|To surgery patients, Tocotrienol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
45840216|NCT00679380|Procedure|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
46038365|NCT04269681|Other|Standard respiratory support|The patient randomized to standard respiratory support will be placed on conventional low flow oxygen therapy according to the center's standard of care aiming at SpO2 90 - 98% and improvement of dyspnea. For cases refractory to oxygen therapy, keeping SpO2 below 90% or if dyspnea does not improve, non-invasive positive pressure ventilation (NIPPV) may be offered at the discretion of the assistant team. NIPPV will be performed with the patient in a supine position at 45 degrees. The mask will be facial (oronasal or full face) with an appropriate size for each patient and adapted in a way to minimize leakage. A hydrocolloid dressing can be placed over the nose in order to avoid ulcerations and increase comfort. The NIPPV will be performed with the help of a ventilator with inspiratory and expiratory circuits or with Bilevel devices with a single circuit and exhalation valve according to the availability of each center.
46038366|NCT00635284|Drug|ABI-009|nab-rapamycin
45840217|NCT00679380|Drug|Budesonide MMX® 6 mg|6 mg/day, 6 mg tablets
45840218|NCT00679380|Drug|Budesonide MMX® 9 mg|9 mg/day, 9 mg tablets
46038367|NCT02854839|Biological|MG4101|MG4101 is ex vivo-expanded, allogeneic natural killer cells. MG4101 were manufactured from normal healthy donor who underwent lymphopheresis under good manufacturing practice (GMP) conditions.
46038368|NCT02768350|Procedure|Ventilator hyperinflation technique|"Hyperinflation using a ventilator or ventilator hyperinflation technique (VHI) was developed from the manual hyperinflation (MHI) technique. There is no need to disconnect the patient when using the VHI technique and consequently there is no loss of PEEP and little or no risk of the adverse effects associated with MHI."
46038369|NCT02768350|Procedure|Conventional treatment|Conventional treatments are the routine treatment that patients were received from the physical therapist who take care them. The routine treatments are consist of chest physical therapy techniques (i.e. vibration, positioning, etc.) and others treatment (i.e. passive movement).
45474037|NCT03375580|Drug|Compound Zhenzhu Tiaozhi capsule|Compound Zhenzhu Tiaozhi capsules consist of eight Chinese herbal medications, such as Ligustrum lucidum, Atractylodes macrocephala, Radix Salviae Miltiorrhizae, pseudo-ginseng, Astragalus membranaceus.
45474038|NCT03375580|Drug|Simvastatin|20mg simvastatin, PO qn
45474039|NCT03340896|Drug|Docetaxel|Docetaxel 75 mg / m² administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion of one hour followed by cisplatin 75 mg / m² administered on day 1 hour infusion followed by 5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
45474040|NCT03340896|Drug|Cisplatin|Cisplatin: 75 mg/m² for experimental arm and 100mg/m² for comparator arm administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion.
45474041|NCT03340896|Drug|Fluorouracil|5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
45474042|NCT03340896|Radiation|radiotherapy|Radiotherapy : 70Gy (2Gy/day) for 7 weeks.
45474043|NCT03282981|Drug|Timolol|Topical application of Timolol on non-healing diabetic foot ulcers
45474044|NCT03282981|Drug|Non biologically active gel|Topical application of non biologically active gel (Hydrogel- standard of care) on non-healing diabetic foot ulcers
45840219|NCT00679380|Drug|Entocort EC® 3 mg|9 mg/day, 3 mg tablets
45840220|NCT00679380|Drug|Placebo|Placebo
45840221|NCT00680706|Drug|Thiamine|Thiamine (100 mg) in 50 ml D5W, x 2.
45840222|NCT00680706|Drug|Placebo|D5W (50 ml)
45474045|NCT01286831|Drug|[14C]GW642444|Single 200μg dose of [14C]GW642444 given on Day 1.
45474046|NCT03124186|Device|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
45474047|NCT02855710|Other|Rhythm workers training Perceptive timing|Perceptive timing training
45474048|NCT02855710|Other|Rhythm workers training sensorimotor timing|Sensorimotor timing training
45474049|NCT02855710|Other|No Rhythm workers training|No training
45474050|NCT01286909|Dietary Supplement|LaFlavon|two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months
45474051|NCT02954887|Drug|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
45474052|NCT03183063|Device|4DCT and SPECT/CT|Each patient will receive two 4DCT followed by SPECT/CT.
46038370|NCT04131595|Biological|MVA-BN-WEV Dose 1|1 x 10^7 Inf.U MVA-BN-WEV vaccine
46038371|NCT04131595|Biological|MVA-BN-WEV Dose 2|1 x 10^8 Inf.U MVA-BN-WEV vaccine
46038372|NCT04131595|Biological|MVA-BN-WEV Dose 3|2 x 10^8 Inf.U MVA-BN-WEV vaccine.
46038373|NCT00699049|Drug|Alpha blocker|oral
45474053|NCT03183063|Device|4DCT with BiPAP and SPECT/CT|Each patient will receive two 4DCT, with the second scan obtained with positive pressure breathing via BiPAP, followed by SPECT/CT
45474054|NCT03183063|Device|4DCT with CTA in suspected PE|Each patient will receive 4DCT before or after CTA for suspected PE
45474055|NCT05155722|Drug|BAT1308|A 21 day treatment cycle was administered every 3 weeks (Q3W) on day 1 of each cycle. Six consecutive dosing cycles are recommended for the dose escalation phase. In the extended study phase, after the end of the 6th treatment cycle, after the risk and benefit are evaluated by the investigator in combination with the clinical practice, if the subjects are still in a state of clinical benefit (including CR, PR and SD), the investigator can decide to appropriately extend the treatment of BAT1308. Until disease progression, unacceptable toxicity, withdrawal of informed consent, loss of follow-up, death, acceptance of new antitumor therapy, termination of treatment by investigator evaluation, or 12 months after initial administration, whichever is the earliest.
45474056|NCT03860129|Drug|Isoflurane|Group A: Isoflurane (0.5 MAC)
45474057|NCT03860129|Drug|Sevoflurane|Group B: Sevoflurane (0.5 MAC)
45474058|NCT03860129|Drug|Desflurane|Group C: Desflurane (0.5 MAC)
46038374|NCT00699049|Drug|placebo|oral
46038375|NCT00699049|Drug|solifenacin|oral
46038376|NCT04131283|Drug|Epinephrine|Vasoconstrictor solution is applied on the surface of the attached gingiva and on the gingival sulcus.
46038377|NCT02768038|Other|Observational|Blood, stool ja biopsy specimens
46038378|NCT04224454|Other|Questionnaire|"Questionnaire was adapted from questionnaires used by the French national agency Institut de Veille Sanitaire to study vaccination coverage and were completed with the assistance of one fellow to limit missing data."
46038379|NCT02614027|Other|Evaluation of metabolic syndrome|Evaluation and analytical determinations of the different components of the syndrome
46038380|NCT02614027|Other|Evaluation of changes in fat by DXA while on current therapy|Comparison of changes in fat (visceral and subcutaneous) by dual X-ray absorptiometry since therapy initiation
46038381|NCT02617693|Behavioral|lifestyle intervention|Evaluation of lifestyle intervention combining behavioural change councelling and utilisation of E-health platform. The intervention consists of a combination of behaviour change counselling and support through six contact-points with CHPs (community health promoter) and access to a personalised mobile application.
45474059|NCT03374098|Behavioral|Home Visitiation|"The home visit component of the intervention will involve a visit to participants' homes by a social worker, who will assist patients dealing with other health and social problems. Participants will be followed for a minimum of 10 weeks, and additional follow-up visits will be at the discretion of the social worker. They will work with community partners and refer patients when appropriate.~Community partners could include: Domestic violence services, employment placement, benefit enrollment, community action agency (bill pay, utilities), ACA enrollment, homeless shelter, housing authority, re-housing program"
46038382|NCT02617693|Other|standard antenatal care|Standard of care for pre-pregnancy health. Subjects will be reminded of their endpoint measurement visit towards the end of the intervention period through a phone call.
45474060|NCT03374098|Behavioral|Education|"The education component of the intervention will include attending a class once per week for 3 weeks. Classes will be led by a dietician, and may also involve other members of an interdisciplinary team including nurse practitioners, health educators, and community members. Education sessions will be held at 5:30pm on Mondays or Tuesdays, and participants will be provided with a meal. Topics will include:~Week 1 (5:30-6:30pm): Importance of self-management of disease, glucometer testing for blood sugars and using home blood pressure monitors, diabetes medication review~Week 2 (5:30-7:00pm): Diabetes and Healthy Eating and Exercise - carbohydrate counting, portion control, lifestyle activity, and exercise demonstration activity~Week 3 (5:30-6:30pm): Grocery shopping guidelines, label reading, hands on cooking demo"
46038383|NCT02696980|Device|Positive Expiratory Pressure|Patient will exhale against positive expiratory pressure 0 mm or 10 mm while inhaling methacholine
45474061|NCT03720678|Drug|etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
45474062|NCT03720678|Drug|mFOLFOX|Oxaliplatin, Leucovorin and 5-fluorouracil given as part of standard mFOLFOX chemotherapy regimen
45498036|NCT05411991|Other|Switch to oral diuretic therapy|"Upon complete resolution of clinical signs of fluid overload with UNa <80 mmol/L, intravenous diuretics are switched to an oral schedule including:~Loop diuretics with dose & frequency at the discretion of the treating physician~Chlorthalidone 50 mg if added for diuretic resistance at any time during the intravenous diuretic phase~Spironolactone 25 mg or another equivalent mineralocorticoid receptor antagonist"
45498037|NCT05411991|Other|Usual AHF care|It is recommended to administer an intravenous loop diuretic dose at least BID (or through continuous infusion), with the aim of achieving a urine output 3-5 L per day until the patient is considered in an optimal volume status as is recommended by current guidelines.
46038384|NCT02767648|Other|proteomic urine analysis|proteomic urine analysis
46038385|NCT00943761|Drug|Vaniprevir 600 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, four in the morning and four in the evening, for 48 weeks
46038386|NCT00943761|Drug|Vaniprevir 300 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, two in the morning and two in the evening, for 48 weeks
46038387|NCT00943761|Drug|Pegylated interferon|Prefilled syringe containing 180 µg/0.5 mL peg-IFN, for weekly subcutaneous injection, for 48 weeks
45840223|NCT00682734|Drug|metoclopramide|metoclopramide 20 mg
46038388|NCT00943761|Drug|Ribavirin|Oral tablets containing 200 mg RBV, 5 or 6 tablets, dosage based on the participant's weight (<75 kg or ≥75 kg, respectively), for 48 weeks
46038389|NCT02617771|Drug|Vitamin D3|from October to March, a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year
46038390|NCT02696590|Dietary Supplement|Vitamin D3|two forms of vitamin D3 (Oral versus injection) were compared in MS and healthy groups.
46038391|NCT02617459|Drug|Levobetaxolol eye drops|one drop per time; twice daily
45498038|NCT03815604|Behavioral|Independent Housing and Support (IHS)|Direct placement of people with SMI in an independent accommodation in the community, usually in a flat rented by the service user. Support is provided by a coach according to individual needs in a permanent housing situation without time limit.
46038392|NCT02617459|Drug|Betaxolol eye drops|one drop per time; twice daily
46038393|NCT02854995|Procedure|circumcision|(i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce. The two study team members performing the surgery in this trial (HC and SK) will be free to choose the method of circumcision (e.g. guillotine vs. sleeve) as this is not thought to influence outcome. The foreskin will be sent for histological analysis.
45694524|NCT01709383|Device|Sham Stimulation|The sham tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
46038394|NCT02854995|Procedure|preputioplasty with intralesional injection of triamcinolone:|(ii) preputioplasty with intralesional injection of triamcinolone: this will be performed as described by Wilkinson et al.[5] Briefly, longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile. A biopsy of an area of affected foreskin will be sent for histological analysis. The intention will be to perform three incisions (tri-radiate) but the final decision on how many will be made by the operating surgeon and based on the appearance of the prepuce and result of initial incision(s). Once the prepuce is felt to be freely retractile, 1 - 3 mL of triamcinolone (Adcortyl Bristol-Myers Squibb 10 mg/mL) will be injected intradermally around the circumference of the affected foreskin using a 25-gauge needle.
46038395|NCT04192786|Other|Standard physiotherapy program+50 Hz local vibration|Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (50 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.
46038396|NCT04192786|Other|Standard physiotherapy program+100 Hz local vibration|Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (100 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.
45498039|NCT03815604|Behavioral|Residential Care Settings and other Treatment as Usual (RCS/TAU)|Placement in a common residential home or supportive housing setting with the aim to gain psycho-social stability before being able to maintain independent housing.
45840224|NCT00682734|Drug|metoclopramide|metoclopramide 40 mg
46038397|NCT04192786|Other|Standard physiotherapy program|Standard physiotherapy program (strength, balance, gait exercises) for 60 minutes will be performed 3 days a week for 8 weeks.
46038398|NCT02767726|Device|non-invasive multimodal imaging|
46038399|NCT02696512|Drug|Polypharmacy using FDA-approved products|Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12, Methylfolate, Rasagiline, Amantadine, Naltrexone and Levodopa/carbidopa.
46038400|NCT02696512|Device|Median Nerve Stimulation (MNS)|40 cycle/second (gamma range) asymmetric, 2 ms wavebands with 300 µs bursts at 20 milliamps bilaterally (randomized left arm and right arm sequencing algorithm) applied 20 seconds on and 40 seconds off for 8 hours per day.
45342575|NCT05810467|Other|Active Surveillance|"Active surveillance (AS) is an accepted management strategy for men diagnosed with low risk PrCa, generally defined as PSA <10ng/ml and Gleason score of ≤6 and clinical stage T1 to T2a. Occasionally, a minority of men with Gleason 3+4 disease are included, though majority of those included in AS studies have Gleason 3+3 disease or less.~Men in AS studies have repeated biopsies based on various criteria including PSA velocity, repeat biopsy at set time points and change noted on digital rectal examination (DRE), biopsy or MRI imaging. Progression of disease has been defined in various ways in different studies, generally, using criteria of Gleason upgrade to greater than Gleason 3+3, evidence of Gleason 4 or Gleason 5 disease, >50% involvement of any one biopsy core, and greater than 2 cores positive on repeat biopsy. Percentages of men on AS who have upgrade on repeat biopsy have been found to be 19-34%; this may differ in our cohort of men with increased genetic risk for PrCa."
46038401|NCT02696512|Dietary Supplement|Nutraceutical Supplementation|Battery of nutraceuticals provided through a 12-week schedule including: Acidophilus, Alpha-Lipoic Acid, Acetyl L-Carnitine,
45498040|NCT03808506|Diagnostic Test|Fecal calprotectin|Stool test to look at baseline burden of inflammation
46038402|NCT02696512|Other|Standard of Care|Standard of Care treatment
46038403|NCT00949533|Drug|Oseltamivir|Standard dose (30 - 75 mg orally bid) or double dose (60 - 150 mg orally bid); for 5 days
46038404|NCT02767414|Device|Respirio Flu Test|The Respirio Flu Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
45498041|NCT03686436|Device|ocular coherence tomography|imaging by ocular coherence tomography
45498042|NCT04140708|Behavioral|Exercise--Rock Steady Boxing class|Rock Steady Boxing is a class designed specifically for those with Parkinsonism and movement difficulty using explosive and fine tuned movements as well as cognitive learning skills.
45840225|NCT00682734|Drug|metoclopramide|metoclopramide 10 mg
46038405|NCT02767414|Device|eLab Flu Test|The eLab Flu Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasopharyngeal swab samples. The eLab Flu Test generates a result within 10 minutes.
46038406|NCT02767414|Device|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
46038407|NCT02767258|Device|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
45840226|NCT00682734|Drug|Diphenhydramine 25mg|Diphenhydramine 25mg, administered as an intravenous drip over 20 minutes
45840227|NCT00683046|Drug|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3,.
46038408|NCT02767258|Device|VIDISIC® GEL|Carbomer based gel, used in the treatment of dry eye.
46038409|NCT04224376|Device|App based Serious Gaming with the Genu Sport knee trainer|The Genu Sport knee trainer has a strength monitoring unit with three integrated sensors which is placed in the popliteal area and a tablet with the application which allows to transfer the raised force into the game modus. Each training session in our study takes around 5 minutes and is performed autonomously by the patient in his bed with 45° degrees of upper body evaluation while the patient holds the tablet in both hands. By simply pushing his knee downward onto the measuring unit the patient can apply the force.
45342576|NCT05810454|Device|iPACES (interactive Physical and Cognitive Exercise System)|"iPACES involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations."
45342577|NCT05810454|Device|PACE (Physical and Cognitive Exercise)|"PACE involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations."
45342578|NCT05810441|Other|Evaluation of diagnostic accuracy of anti-ttg-m|Mucosal anti-ttg evaluated in intestinal biopsy samples
45381982|NCT05483270|Biological|the timing of embryo transfer in freeze-all cycles|"Immediate FET group Freeze-all embryo transfer will be carried out in the menstrual cycle immediately following oocyte retrieval.~Postponed FET group Freeze-all embryo transfer will be carried out during the second menstrual cycle to 6 months after oocyte retrieval."
45381983|NCT05479812|Drug|WTX-124|Investigation Product Monotherapy
45381984|NCT05479812|Drug|Pembrolizumab|Investigation Product in combination with approved therapy
46038410|NCT02854761|Drug|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
46038411|NCT00866047|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
46038412|NCT01706692|Biological|Adalimumab|all dosages, frequencies and durations prescribed
46038413|NCT01706692|Biological|Etanercept|all dosages, frequencies and durations prescribed
46038414|NCT01706692|Biological|Infliximab|all dosages, frequencies and durations prescribed
46038415|NCT01706692|Biological|Ustekinumab|all dosages, frequencies and durations prescribed
46038416|NCT01706692|Drug|Cyclosporine A|all dosages, frequencies and durations prescribed
46038417|NCT01706692|Drug|Fumaric acids|all dosages, frequencies and durations prescribed
46038418|NCT01706692|Drug|Methotrexate|all dosages, frequencies and durations prescribed
46038419|NCT01706692|Drug|Other anti-psoriatic systemic treatments|all dosages, frequencies and durations prescribed
46038420|NCT02767336|Device|Blood Glucose Monitoring System.|In vitro diagnostic medical device
46038421|NCT02617537|Drug|EE20/DRSP(YAZ,BAY86-5300)|0.02 mg EE (β-CDC)/3 mg DRSP for 24 days and placebo tablets for 4 days per 28-day intake cycle
46038422|NCT02617537|Drug|Placebo|Matching placebo tablets for 28 days per 28-day intake cycle
46038423|NCT04719442|Behavioral|Building Healthy Families|Building Healthy Families (BHF) is a family based obesity treatment program which includes key behavior change strategies including goal setting for both behavior change and weight loss, self-monitoring, rewards/contingency management, role modeling, and stimulus control/ modifying the environment. BHF includes a minimum of 32 contact hours consisting of three main program components: nutrition education, behavior modification, and physical activity. Participants and parents are expected to attend 12 continuous weeks of education (2 hours/session) followed by 12 weeks of relapse prevention refresher courses. Relapse prevention refresher sessions are every three weeks for one hour to re-evaluate goals, discuss rewards/contingency management and changes in stimulus control with seasonal changes and holidays. A final follow-up check-in session is conducted at 12 months for approximately 1 hour.
45498043|NCT03686358|Procedure|Renal artery angioplasty|"Patients meeting the inclusion criteria were selected from the medical records of renal angioplasty performed at the Rennes University Hospital between 01/01/2010 and 12/31/2013. Each selected patient will receive a notice by mail of information. In the absence of opposition from them within a two weeks, the processing of their data will begin :~Evaluation of the results at 3 years of renal angioplasty on atherosclerotic stenosis performed at Rennes University Hospital~Evaluation of indications of renal angioplasty on stenosis atherosclerosis performed after 2009 at Rennes University Hospital~Identification of prognostic factors"
46038424|NCT00869323|Biological|rituximab|375 mg/m^2 intravenously on Days 1,8, 15 and 22
46038425|NCT00869323|Drug|bortezomib|1.3 mg/m^2 intravenous bolus days 1, 8, 15 and 22
45381985|NCT05478252|Drug|Semaglutide J|Participants will initially receive 0.25 mg subcutaneous injections of semaglutide J OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
45381986|NCT05478252|Drug|Semaglutide B|Participants will initially receive 0.25 mg subcutaneous injections of semaglutide B OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
46038426|NCT02775058|Device|synergoss Pxx|dental grafting
46038427|NCT02774980|Behavioral|Recurrent depression|
46038428|NCT02767102|Other|Red wine with melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine rich in MLT (10 ng mL-1)
45840228|NCT00683046|Drug|Melphalan|Melphalan 140 mg/m2 IV on day -2.
46038429|NCT02767102|Other|Red wine without melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine without MLT
46038430|NCT02774902|Drug|TAK-438|TAK-438 tablets
46038431|NCT02774902|Drug|Clarithromycin|Clarithromycin tablets
46038432|NCT04662970|Device|Device programming|Non-invasive electrophysiology with 65 ECG leads will be performed in 16 different device programming
46038433|NCT02766946|Device|Ultrasound|An ultrasound of the right diaphragm will be performed on day 1, day 3, day 5 and day 10
46038434|NCT02766946|Device|Ultrasound|An ultrasound of the pectoral muscle will be performed on day 1, day 3, day 5 and day 10
45498044|NCT03686280|Other|Clinical evaluation|A clinical evaluation of the balance and the walk: is carried out by one of the coordinating physiotherapists of the center where the patient realizes his rehabilitation. The latter performs, according to the functional level of the patient, the following tests: Berg balance scale, FAC, PASS, TUG, 10MWT, 6MWT, paretic lower limb traction index , LBA, SSA and SSV, measurement of spasticity and sensitivity(D0, D30 and D90)
45840229|NCT00683046|Drug|Stem cells|Stem cell infusion on day 0.
46038435|NCT02766946|Other|Neuromyopathy score|A neuromyopathy score will be assessed on the extubation day
46038436|NCT02766946|Other|Respiratory performances|An assessment of the respiratory performances will be done on the extubation day, including higher expiratory pressure, higher inspiratory pressure, and occlusion pressure
46038437|NCT02766868|Drug|FACE-Flu/Bu/Cy|Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
46038438|NCT02774434|Device|JM-105|Measurement of TcB via the JM-105 device
46038439|NCT02767024|Drug|Sodium nitroprusside|Sodium nitroprusside is a medication used to lower blood pressure.
46038440|NCT02767024|Drug|Dobutamine|Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the ÃŸ receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects.
46038441|NCT02767024|Drug|Furosemide|Furosemide is a prescription drug used to treat hypertension (high blood pressure) and edema. Learn about side effects, warnings, dosage, and more.
46038442|NCT02766790|Dietary Supplement|TA-65MD|TA-65, a purified small molecule extracted from Astragalus root
46038443|NCT02766790|Other|Placebo|Placebo, an inactive formulation
46038444|NCT04793776|Behavioral|Manage Emotions to Reduce Aggression|MERA begins with education about the adaptive nature of emotions, how childhood and military experiences can influence emotion regulation, and how combat requires different emotion regulation strategies than most civilian environments. MERA use modeling and practice with feedback to teach cognitive-behavioral and acceptance-based emotion regulation skills.
46038445|NCT04793776|Behavioral|Present Centered Psychotherapy|PCT will serve as the comparison group. PCT assists Veterans in understanding and coping with current difficulties, such as aggression, but does not provide systematic training in emotion regulation skills.
46038446|NCT02774200|Drug|Apatinib|Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
46038447|NCT02766712|Procedure|Pace During 1st Half of Lesion|
46038448|NCT02766712|Procedure|Pace During 2nd Half of Lesion|
46038449|NCT01192022|Biological|TachoSil®|Intraoperative application as secondary hemostatic treatment
45498045|NCT03686280|Other|Intervention - with Robot|16 sessions of 45 minutes of reeducation with robot of the walk and the procedure to follow with the same patient for the same phase of rehabilitation of the balance and the walk or of several of them (Annex 3b), at the rate of 3 at 5 sessions per week, for 4 weeks and according to predefined exercises
46038450|NCT01192022|Device|Surgicel® Original|Intraoperative application as secondary hemostatic treatment
46038451|NCT02766634|Biological|Filgrastim Hospira (US)|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
46038452|NCT02766634|Biological|U.S.-approved Neupogen®|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
46038453|NCT04857190|Device|Parker Flex-it Directional Stylet|Parker Flex-it Directional Stylet
46038454|NCT04857190|Device|Conventional Malleable Stylet|Conventional Malleable Stylet
46038455|NCT02774044|Drug|Cadisurf|Cadisurf Intratracheal suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural lung extract containing phospholipids and surfactant-associated proteins. The resulting composition provides 25 mg/mL phospholipids and less than 1.0 mg/ml protein. It is suspended in 0.9% sodium chloride solution. Cadisurf contains no preservatives. Each ml of Cadisurf contains 25 mg of phospholipids. It is a creamy white suspension supplied in single-use glass vials containing 8 mL (200 mg phospholipids).
46038456|NCT02774044|Drug|Survanta|
46038457|NCT00635206|Device|BiPap auto with Fi Flex|"MinEPAP = 4 cmH2O for prescribed CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP > 10 cmH2O)~MaxIPAP = 25 cm H2O~MinPS = 2 cm H2O (cannot be adjusted)~MaxPS = 8 cm H2O~Bi-Flex setting of 3"
46038458|NCT00635206|Device|Standard CPAP|CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP > 10 cmH2O)
46038459|NCT02766556|Drug|dexmedetomidine|ISB with ropivacaine with dexmedetomidine or normal saline
46038460|NCT02766556|Procedure|ISB|ISB with ropivacaine with dexmedetomidine or normal saline
46038461|NCT02766556|Drug|Ropivacaine|ISB with ropivacaine with dexmedetomidine or normal saline
45342579|NCT05810428|Procedure|GKRS-VR training|One month after radiosurgery, GKRS-VR subjects will receive neuromodulation treatment twice a week (30' per time), for 8 consecutive weeks followed by 9 months of remote rehabilitation. GKRS-VR group will perform neuromodulation based on VR sensorimotor rehabilitation using an immersive system developed ad-hoc. Treatments will include voluntary mimic movements reinforced by VR augmented feedback, consisting in the reflection of a real-time avatar animation, multiplied when needed, associated with different targets to reach based on specific facial gestures. The execution of motion multiplier on avatar will be allowed in order to personalize treatments, emphasizing a graded exposure to pain perception. In addition, the investigators will develop a dedicated mobile-application for remote rehabilitation with the aim of prescribing VR augmented feedback home exercises and immersive VR pain neuromodulation.
45498046|NCT03686280|Other|Intervention - without Robot|16 sessions of 45 minutes of reeducation without robot of the walk and the procedure to follow with the same patient for the same phase of rehabilitation of the balance and the walk or of several of them (Annex 3b), at the rate of 3 at 5 sessions per week, for 4 weeks and according to predefined exercises
46038462|NCT01191944|Drug|pramipexole immediate release tablet|0.375mg-4.5mg(daily dose), three times a day
46038463|NCT01191944|Drug|pramipexole extended release tablet|0.375mg-4.5mg, once a day
46038464|NCT02774512|Drug|Nilotinib|Each patient will receive nilotinib 800 mg/day every day for 7 days. Study treatment will be taken twice a day (400 mg - 2 capsules) by oral route with an interval of approximately 12 hours between two doses and should not be taken with food. The entire capsule should be swallowed with water. No food should be consumed for 2 hours before taking the drug and for at least 1 hour after it.
46038465|NCT04224844|Other|Erector spinae plane block|The block will be performed before the surgery. The spinous process of T2 or T3 wil be identified by an ultrasound guide, with the probe positioned longitudinally. A block needle will be inserted in the caudo-cephal direction. After the injection site is confirmed by 3 ml of physiological solution and correct position of the needle tip is confirmed, bupivacaine will be injected. The patients assigned to this group will also receive an intravenous patient-controlled analgesia device containing tramadol postoperatively.
45342580|NCT05810428|Procedure|Control Group|Control Group will undergo only radiosurgery with no rehabilitation and they will perform only clinical evaluation at study entry, after three months and one year.
45342581|NCT05810415|Diagnostic Test|Renin levels and lactic acid levels|Sampling of blood for measuring renin and lactate
45342582|NCT05810389|Combination Product|Fluoride|Application methods of delivery of topical fluoride
45342583|NCT05810376|Behavioral|Digital-based physical activity intervention|The digital behavioral program comprises goal planning, motivational messages and video calls, social support, and routine follow-up of weekly goals.
46038466|NCT04224844|Other|Control group|Control group will receive only patient-controlled analgesia device containing tramadol. No block will be performed.
45342584|NCT05810376|Other|Patient education and exercise|Patient education will include information on osteoarthritis, prognosis, pain management, importance of physical activity and exercise. The exercise program will include warm up, stretching and strengthening.
45342585|NCT05810337|Dietary Supplement|Splenda drink|4.5g Splenda containing 1% sucralose, 95% maltodextrin, dissolved in 250ml water and consumed with a high carbohydrate breakfast.
45342586|NCT05810337|Dietary Supplement|Maltodextrin drink|4.5g maltodextrin dissolved in 250ml water and consumed with a high carbohydrate breakfast.
45840230|NCT00683046|Drug|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
46038467|NCT02773888|Device|HS-1000|
46038468|NCT04223908|Other|observational : questionnaries for assessment of health burden|The French IN-FOCUS study was designed to capture current and retrospective data in FCS or MCS. Patients were called by the participating centers and were proposed to answer a paper questionnaire or to connect to a web-based questionnaire The questionnaire was divided into sections specifically assessing various domains of their experience: demographic data, signs, symptoms and complications of the disease, healthcare circuit, management, relationship with healthcare providers, and burden of the disease on daily life. (Details are available as supplementary material S1). The questionnaire focused on symptoms because the interest of quality of life assessment tools is debated in rare diseases with episodic manifestations. Indeed, most of these tools refer to a limited recall period.
45342587|NCT05810337|Dietary Supplement|High carbohydrate breakfast|Meal consisting of 30g cereal with 100ml skimmed milk, 1.5 slices white toast with 12g margarine, providing 386kcal, 61.4g carbohydrate, 10.4g protein and 10.1g fat.
45342588|NCT05810324|Drug|18F-FAPI|Each patient receive a single intravenous injection of 18F-FAPI, and undergo PET/CT scan within specified time.
45342589|NCT05810298|Other|Asana Practice|Yogasana training will be comprised of active movements when standing. Spine and limbs stretches eccentrically respecting the movement patterns of body without pushing limits. Transition in between poses will be synchronized with breathing pattern in zero resistance flow. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of standing poses training will last for 4 weeks.
45342590|NCT05810298|Other|Pranayam Practice (Rhythmic regulated breathing)|Breathing exercises will be comprised of diaphragmatic breathing, holding the breath after inhaling deeply and exhaling passively or exhaling actively by contracting abdominal muscles and inhaling passively. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of breathing exercises will last for 4 weeks.
45342591|NCT05810298|Behavioral|Smoking Education Program|The aim of the education is to increase awareness of subjects who are chronical smokers. The subject education will be performed at least once via face to face interview. Education topics will be covered basic information about harmful effects of habitual smoking and how to reduce the side effects of nicotine withdrawal.
45342592|NCT05810272|Behavioral|Metabolic Trial|Participants will undergo a metabolic trial to assess for their anabolic response to a protein-carbohydrate meal.
45498047|NCT03686280|Other|quality of life assessment|A quality of life assessment: SIS questionnaire completed by the patient, the results of which will be reported in the observation book by the coordinating physiotherapist who carried out the evaluations described above. (D0, D30 and D90)
46038469|NCT01191788|Behavioral|Group Cognitive Behavioral Therapy|16 two hour sessions of group CBT
45342593|NCT05810272|Behavioral|15 sit-to-stands with calf raises|Participants (n=10; 5F/5M) will be randomized to perform 15 sit-to-stands with calf raises every 30 minutes for the 4 hour duration between muscle biopsies
45342594|NCT05810259|Device|Caravan Wellness app|Caravan Wellness is a digital platform that offers brief mindfulness and light to moderate physical activity modules, among many others (e.g., Pilates, Yoga, Barre, meditation, etc.), to enhance overall individual well-being.
45342595|NCT05810207|Procedure|Colorectal resection|Patients undergoing a colorectal resection with the construction of a primary anastomosis
46038470|NCT01191788|Behavioral|Group CBT for Depression|16 of group CBT for depression delivered in 2 hour groups for up to 8 weeks by a trained substance abuse treatment counselor
45342596|NCT05810142|Drug|furquimatinib and sintilimab|furquimatinib and sintilimab
45342597|NCT05810129|Other|Cross-education training|Concentric-eccentric cross training in a 6-week immobilization period + 12-week standard kinesic therapy (2 times a week)
46038471|NCT00940875|Drug|erlotinib [Tarceva]|150mg po on days 15-28 of each 4 week cycle
46038472|NCT00940875|Drug|gemcitabine|1250mg/m2/day on days 1 and 8 of each 4 week cycle
46038473|NCT00940875|Drug|gemcitabine|1000mg/m2/day on days 1, 8 and 15 of each 4 week cycle
46038474|NCT02766322|Other|Oral Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
45342598|NCT05810129|Other|Cross-education training|Eccentric cross training in immobilization period of 6 weeks + Standard kinesic therapy of 12 weeks (2 times a week)
45342599|NCT05810116|Drug|Levagen+|Daily dose of 1-2 capsules (1 capsule containing 350mg Levagen+ equivalent to 300mg PEA)
45342600|NCT05810116|Drug|Microcrystalline cellulose|Daily dose of 1-2 capsules (1 capsule containing 350mg)
46038475|NCT02766322|Other|Oral Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol).
45342601|NCT05810103|Drug|DP303c|DP303c injection, 3.0 mg/kg, every 3 weeks.
46038476|NCT02766322|Other|Intravenous Alcohol Challenge Test (Clamp)|Subjects will be evaluated with an alcohol clamp (i.e. alcohol will be infused intravenously until reaching 60mg/dl and this blood alcohol concentration will be kept constant for two hours). We will record subjective responses to alcohol throughout different times of the clamp.
45342602|NCT05810090|Procedure|Total knee arthroplasty|patient who received a TKA in our hospital
45342603|NCT05810012|Drug|PENG block|10ml of 0.125% isobaric bupivacaine injected
45342604|NCT05810012|Drug|FICB Block|20ml of 0.125% isobaric bupivacaine injected
46038477|NCT02766322|Other|Intravenous Alcohol Self-administration Test|"Subjects will be asked to press a button (work) to receive either a drink or saline through an IV catheter. The amount of alcohol infused after earning their reward will be based on their body composition and will raise their blood alcohol level by 10 mg/dl (eight time less than the legal limit for driving). We will set a safety limit to 150 mg/dl so that subjects will not be allowed to work for alcohol until their blood alcohol levels go below that limit."
45498048|NCT03686280|Other|An assessment of patient acceptance of robotic rehabilitation|An assessment of patient acceptance of robotic rehabilitation (for patients in the robot group): self-questionnaire to be filled in by the patient (before carrying out the gait tests in order to avoid influence the results) (D30 ans D90)
45498049|NCT03686280|Other|cognitive assessment|An evaluation of cognitive functions (between D0 and D30): research dysexual cognitive-behavioural syndrome, hemineglect visio-spatial, memory disorders. Done by a doctor evaluator.
46038478|NCT05656898|Device|Piezocision+GaALAs diode laser|After seven weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\point) 10 seconds per point will be applied on each tooth of the six maxillary anterior teeth .
46038479|NCT05656898|Device|Piezocision|Vertical soft-tissue incisions will be made on the buccal and palatal gingiva. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.
46038480|NCT05656898|Device|Orthodontic fixed appliance|Closed nickel-titanium coil springs applying 250 g of force per side will be used for retraction of the maxillary anterior teeth.
46038481|NCT00624572|Drug|chlorexidine|Chlorexidine gel 1% during 7 days inside root canals
46038482|NCT02851173|Device|LLLT|The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA).
45342605|NCT05809999|Procedure|Standard colonoscopy with targeted biopsies|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
45342606|NCT05809986|Other|Ofatumumab|There is no treatment allocation. Ofatumumab will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
45342607|NCT05809973|Diagnostic Test|VISA tool|Validation of VISA
46038483|NCT02851173|Device|Placebo|The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA). However, the placebo group will receive approximately 1/12th of the cumulative energy density as the treatment group.
46038484|NCT02774122|Device|CAABT|CAABT was an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
45474063|NCT05240703|Device|Stabilization splint treatment|The stabilization splints were made of heat-cured acrylic by the same dental technician. The occlusion of the splint was defined in the centric relation occlusion using wax (Astynax, Associated Dental Products Ltd, UK). The patients were instructed to use the splint every night during the course of the study. The patients were instructed to perform a standardized program for masticatory muscle exercises. At the beginning of the training program, active mouth openings, laterotrusive movements and protrusive movements were performed. The mandible was held in the maximal positions for a few seconds on each movement. Thereafter, these movements were made towards resistance (using the patient's own fingers). After jaw exercises, the patients were suggested to open the jaw wide, stretching it with fingers a few times for 10 to 20 seconds. These movements were repeated 7 to 10 times per training session, and the sessions were performed 2-3 times per day.
46038485|NCT02774122|Device|masking therapy|Masking intervention was a standard monophone tinnitus masking therapy.
45474064|NCT03865901|Diagnostic Test|Mellitus GCD59 Test|An ELISA for screening for the risk of gestational diabetes
46038486|NCT02851017|Other|Exercise|This study is designed to examine and comparing there intervention program on postural control, flow and technology acceptance in young healthy adults.
46038487|NCT05656274|Drug|JS1-1-01|Oral tables
46038488|NCT05656274|Drug|Placebo|Oral tables
46038489|NCT02773810|Other|Integrated Family Planning Services|Women who agree to enrollment will undergo our intervention, which will include an educational intervention and free on-site provision of all reversible contraceptive options, including LARC. This educational 5 intervention will be a one-on-one educational session on all available methods of contraception, with an emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the importance of planning a pregnancy in women with medical conditions requiring anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning counseling and provision will provide all counseling and discussions in Kiswahili. Women will then be offered free, on-site provision of whichever contraceptive method they choose by a trained provider.
46038490|NCT05656118|Device|Genoss® DCB|Paclitaxel coated balloon with a shellac plus vitamin E excipient
46038491|NCT02766010|Device|TensorTip|Non Invasive screening of various physiological and hematological parameters.
45474065|NCT03369808|Biological|7.5μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
46038492|NCT04317560|Procedure|Arthrocentesis|2 guiding points have been created on the skin. The first one is 10 mm in front of the tragus and 2 mm below the tragus line. The second guide point is on the same line, 20 mm in front of the tragus and 6 mm below. After the auriculotemporal nerve block was made, the first 20 gauge needle was inserted from the first point. 2mL Ringer's Lactate solution is injected into the temporomandibular joint area, and then a second 20 gauge needle is entered from the second guide point determined before and pressurized washing is performed with 100 mL of 5% lactate solution to enter the first needle and exit from the second needle.
45474066|NCT03369808|Biological|Phosphate Buffer Solution|0.5ml phosphate buffer solution
46038493|NCT04317560|Procedure|injectable platelet rich fibrin injection|2 tubes of blood were collected from the patients with the help of vacuumed 10 mL special liquid PRF tubes (Choukroun I-PRF Collection Tubes, Dr. Choukroun) after arthrocentesis. Blood tubes were centrifuged at 700rpm for 3 minutes. 3 mL of liquid PRF was obtained at the top of each tube. I-PRF was injected into the joint areas of all patients in the experimental group, with a maximum dose of 2 mL per joint.
46038494|NCT04192708|Procedure|intercostal nerve block under direct vision|When the intercostal nerve is adequated exposed，a surgeon use a 5ml syringe to perform the block and the needle is tilted 15 degree cephalad and advanced towards the caudal rim of the lib，and penetration depth is about 5mm.Then 1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.
46038495|NCT04192708|Procedure|intercostal nerve block under ultrasound guidance|After induction ，an ultrasonographic probe (M-Turbo with the L25 transducer; SonoSite Inc.) is used to scan laterally from the midaxillary line to identify the required anatomic landmarks, while the patients are in a lateral decubitus position. The ribs are identified as hyperechoic streaks, while the pleura appeared as hyperechoic lines between and below the ribs.The needle was advanced towards the caudal rim of the rib until the distal tip is just between the innermost and inner intercostal muscle.1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.
45474067|NCT03369808|Biological|Aluminum Hydroxide Adjuvant|0.5ml aluminum hydroxide adjuvant
45474068|NCT03369808|Biological|15μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
46038496|NCT04192708|Procedure|paravertebral block under ultrasound guidance|"Paravertebral block is performed between the thoracic segments T7-8,A linear ultrasound transducer (M-Turbo with the L25×transducer; SonoSite Inc.) is placed to parallel the T7 transverse process so as to identify the T7 spinous process，the T7 transverse process and 7th lib.Then move the probe caudally until the thoracic paravertebral space (TPVS) which is bounded by transverse process,pleura and internal intercostal membrane.Using in-plane technique, we advance the 20-gauge needle(Becton Dickinson Infusion Therapy Sysstems Inc.Sandy,Utah 84070,USA.1.88，1.1×48mm) until the needle tip penetrates the internal intercostal membrane,9ml mixture of 1% lidocaine and 1/200000 epinephrine after no blood or gas is aspirated.Both PVB and ultrasound-guided ICNB is performed by the same anesthesiologist"
45342608|NCT05809960|Other|Nursing support program|It was discussed about the operation and surgical menopause that the woman will undergo after hospitalization for the operation. Education was given including the problems experienced during menopause and the approaches used to cope with them. Progressive relaxation exercises were taught and practiced. In order to carry out these procedures, an interview of approximately 45-60 minutes was held with each woman. During the program, four planned meetings were held. One of them was face-to-face and the others were phone calls. During the phone calls, the symptoms experienced by the women and their coping methods were discussed and the questions of the women were answered. The average of each phone call was 20-30 minutes.
45474069|NCT03369808|Biological|30μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
46038497|NCT05655728|Drug|Metformin|The participants will receive treatment of metformin (initial dose of 500 mg/day, within 2 weeks reaching the maximum tolerated dose [maximum: 1500 mg/day]).
46038498|NCT05655728|Other|Placebo|The participants will receive treatment of placebo.
46038499|NCT02773654|Other|Healthy Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
46038500|NCT02773654|Other|Symptomatic Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
45342609|NCT05809960|Other|Routine nursing care|Routine nursing care was given to the control group. The clinical routine has not been exceeded. It includes discharge training for the surgery.
46038501|NCT02887430|Other|foot reflexology therapy|standard care and foot reflexology
46038502|NCT00940485|Drug|entecavir|0.5mg po daily for 8 weeks
46038503|NCT00940485|Drug|entecavir|0.5mg po daily for 48 weeks
46038504|NCT00940485|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
45342610|NCT05809908|Drug|Tricaprilin|"Each dose of IMP will be administered orally 30 minutes after completing a meal.~There is 1 g of tricaprilin per 2 ml of AC-OLE-01-VA.~Subjects will titrate from 5 g twice a day to 20 g twice a day, 40 g total daily dose of tricaprilin; 80 ml total daily dose of AC-OLE-01-VA, over the course of 3 weeks."
45474070|NCT03734575|Device|ClariCore System|The user will perform a standard trans-perineal biopsy and collect a number of biopsy cores as per standard practice.
46038505|NCT02696356|Biological|GRN-1201|GRN-1201 is a vaccine comprised of 4 peptides
46038506|NCT02765932|Procedure|Dummy Movements|The placebo group will be asked to perform the same touch technique and count backwards from 50 while removing petals from a flower. Patients will also perform these techniques before rehab and sleep.
45694525|NCT01588405|Drug|UT-15C SR|Subjects will transition in the hospital from Remodulin to UT-15C SR within 5 days of the start of the transition. The dose of Remodulin will be decreased as the dose of UT-15C SR is increased over the 5 days. Once subjects have been transitioned from Remodulin, the dose of UT-15C SR will continue to be modified / titrated to the appropriate optimal dose for that subject throughout the rest of the study.
46038507|NCT02765932|Procedure|Psychosensory Therapy|The research assistant will administer one of the several psychosensory touch techniques prior to surgery. This will involve the touching of upper arms, palms, and a visualization process. This will last no longer than 10 minutes. These techniques will also be performed by the patients prior to any rehab sessions and before going to sleep. The patients will be asked to perform these touch techniques with the eyes closed and imaging having no pain. The patients will also be asked to keep a record of all medications.
46038508|NCT05655494|Behavioral|ALEX Research Portal|Adaptive and patient-centered virtual community health educator providing users with culturally relevant information about clinical trial participation and connection to patient registries.
45694526|NCT01923311|Drug|EVG|Tablet (s) or tablet (s) for oral suspension (if unable to swallow) will be administered orally once daily
45694527|NCT01923311|Drug|Background regimen|Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants < 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed.
46038509|NCT02773186|Other|monitoring cerebral oxygen saturation|Children undergoing urological surgery also required of locoregional blockade. Anesthetic induction was achieved with high concentration sevoflurane 6-8% (Sevorane®, Abbvie) and oxygen 50%. Anesthetic maintenance was done with sevoflurane 2-3%, 50% O2/air mixture, fentanyl 1 µg.kg.-1 iv, and rocuronium 0.3 µg.kg.-1 iv if required. Electrocardiogram (ECG), non-invasive arterial pressure, pulse oximetry, end-tidal carbon dioxide and cerebral NIRS oximetry was monitoring by using an INVOSTM5100 (Somanetics Corporation, Troy, MI, USA).
45342611|NCT05809908|Drug|Placebo|"Each dose of IMP will be administered orally 30 minutes after completing a meal.~Subjects will titrate from 5 g twice a day to 20 g twice a day, 40 g total daily dose of safflower oil; 80 ml total daily dose of placebo, over the course of 3 weeks."
46038510|NCT05655416|Procedure|Endovenous chemical ablation with Trendelenburg's operation (eCAT)|Endovenous chemical ablation with trendelenburg's operation (e CAT) is a method for the treatment of varicose veins
45342612|NCT05809895|Drug|Ociperlimab|900 mg intravenously (IV) every 3 weeks (Q3W)
45342613|NCT05809895|Drug|Tislelizumab|200 mg intravenously (IV) Q3W
45342614|NCT05809895|Drug|Paclitaxel|90 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
45342615|NCT05809895|Drug|Nab-paclitaxel|100 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
45342616|NCT05809895|Drug|Carboplatin|AUC 2 intravenously (IV) on Days 1 and 8 every 21 days
45342617|NCT05809895|Drug|Placebo|normal saline intravenously (IV) Q3W
45342618|NCT05809895|Drug|Pembrolizumab|200 mg intravenously (IV) Q3W
45342619|NCT05809895|Drug|Gemcitabine|1000 mg/m2 intravenously (IV) on Days 1 and 8 every 21 days
45474071|NCT04630626|Device|Simplify Disc|The Simplify Disc is a cervical artificial disc manufactured from polyether ether ketone (PEEK) endplates and a mobile, zirconia-toughened alumina ceramic core.
46038511|NCT02854683|Drug|Normal Saline|1 liter of intravenous saline will be delivered over 1 hour
46038512|NCT02854683|Dietary Supplement|Oral Rehydration Solution|1 liter of ORS solution given by mouth
46038513|NCT04317248|Drug|Cyclophosphamide|Intravenous drip，250mg/m^2 per time，two days before each times of MSDCV therapy，total 6 times, in order to improve the immunosuppressive microenvironment of tumor，reduce CD4+CD25+FOXP3+regulatory T cells (Tregs）
46038514|NCT04317248|Biological|Multiple Signals loaded Dendritic Cells Vaccine|one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, intravenous driptotal 6 times;
46038515|NCT02765776|Other|Observational retrospective cohort to describe RAL data|"This is an observational retrospective cohort in real world to describe RAL data, including NUC-sparing regimens, in aged HIV patients.~In this retrospective analysis all naïve patients on raltegravir-based regimens and all patients switched to raltegravir-based regimens will be considered. For raltegravir-based regimens the investigators mean raltegravir as third agent in a triple regimen with NRTIs and also raltegravir-based regimens in NUC-sparing therapies. Data will be collected from medical records. The Time horizon for patient follow-up for outcome is at least 12 months."
46038516|NCT05655338|Device|antimicrobial photodynamic therapy|
45342620|NCT05809882|Device|"Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil"|frequency range, 20 Hz; 90% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times
45342621|NCT05809882|Device|"Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil"|frequency range, 20 Hz，60% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times. But with no stimulating energy output.
45342622|NCT05809869|Drug|Durvalumab|Durvalumab 1500mg intravenous infusion on week 1, 5, 9, 13, 17, 21 and 25 for a total of 7 cycles
46038517|NCT05655338|Drug|systemic antibiotics|
46038518|NCT00943605|Device|Scalpel and Traditional Electrosurgery|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
45342623|NCT05809869|Drug|Tremelimumab|Tremelimumab 300mg intravenous infusion on week 1 only.
45342624|NCT05809869|Radiation|Yttrium-90 radioembolisation|Yttrium-90 radioembolisation on week 2 only.
45342625|NCT05809856|Device|GrOwnValve - novel heart valve replacement approach|The autologous GrOwnValve is implanted into a stent before it is implanted via minimal-invasive transcatheter technique into the patients with high-grade pulmonary valve insufficiency and right ventricular dilatation. Control intervention/Reference test: Since the study is designed for investigating the safety of the procedure, there will not be a control group. However, the outcomes will be compared as a non-inferiority analysis with the standard of current medical care (Edwards SAPIEN 3 or Medtronic's Melody, both bioprosthetic transcatheter pulmonary valves).
45342626|NCT05809843|Device|hybrid artificial pancreas systems (CSII)|artificial device that adjust the patient's glycemic levels with insulin doses appropriate to the patient's blood glucose
46038519|NCT00943605|Device|PEAK PlasmaBlade|The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
46038520|NCT02765620|Other|drug&radiation|"Early treatment response assessment: using baseline data and early follow-up data~Evaluate treatment response: using baseline data, early follow-up data and final data~Compare PERCIST to RECIST criteria: correlation analysis~Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot)"
46038521|NCT05655260|Other|Comparison of adjuvant therapies|"Chemotherapy (paclitaxel-carboplatin) vs. chemoradiotherapy (paclitaxel-carboplatin followed by whole pelvic radiotherapy)~Patients assigned to chemotherapy receive paclitaxel (175 mg/m2) and carboplatin (area under curve, 5) every 3 weeks for 6 cycles. The pelvic radiotherapy dose is 45 to 50.4 Gy over 5 to 6 weeks (1.8 Gy per day for 25 to 28 fractions)."
45342627|NCT05809817|Procedure|Periodontal treatment|Scaling and root planing
45342628|NCT05809804|Drug|Esketamine|The initial dose of esketamine was set as 0.06 mg / kg, and the injection time of esketamine was 5 s. One minute after injection of esketamine, sufentanil 0.4 μg / kg was injected within 5 s, and the number of coughs within 1 min after injection was recorded. According to the evaluation of sufentanil-induced cough, the dose of esketamine was adjusted. If the patient had no cough ( negative reaction ), the dose of esketamine in the next patient was reduced until the cough reaction occurred. If the patient had a cough reaction ( positive reaction ), the dose of esketamine in the next patient was increased until the cough disappeared. The dose ratio of adjacent esketamine was 1.1. Each group was selected from the previous patient with positive reaction until the 7 groups of positive and negative reactions appeared alternately, and the test was completed.
45474072|NCT01178255|Drug|homeopathic q-potencies|individualised homeopathic medicines
45474073|NCT01178255|Drug|Placebo|placebo
45474074|NCT01178255|Other|homeopathic case history taking type I|one special homeopathic technique for case history taking
45474075|NCT01178255|Other|homeopathic case history type II|another type of homeopathic case history taking
45474076|NCT03374020|Device|Notal OCT|Imaging using Notal OCT
45474077|NCT03182829|Diagnostic Test|DOAC Dipstick|"Patients collect a sample of urine for analysis.~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. [Epub ahead of print]"
45498050|NCT03686280|Other|An evaluation of how to use the robot|An evaluation of the robot's modalities of use (for patients in the robot group): time of use, distance travelled, walking speed, exercise duration, percentage of regulated suspension, number of breaks, average length of breaks, total length of breaks. (D30)
46038522|NCT05655260|Other|Comparison of adjuvant therapies|"Vaginal brachytherapy vs. whole pelvic radiotherapy~Patients randomized to vaginal brachytherapy receive cuff brachytherapy at 21 Gy in 3 fractions of 7 Gy at 0.5 cm depth. The pelvic radiotherapy dose is 45 to 50.4 Gy over 5 to 6 weeks (1.8 Gy per day for 25 to 28 fractions)."
46038523|NCT02773420|Procedure|HET Application|The HET device is a modified anoscope equipped with LED lighting, a tissue clamping mechanism and a bipolar energy source used to treat multiple hemorrhoidal columns in one sitting. Three columns of hemorrhoids were treated with 2 heat energy applications per column
45342629|NCT05809765|Other|8-week breath training program|The participants were asked to be seated comfortably and raise their heads by 30° with the guidance of the investigator. During the inspiration process, the participants' abdomens bulged. They then held their breaths for 5 seconds before exhaling from their mouths for twice the duration of inspiration. Breath training was performed five times each hour throughout the three-hour duration of each dialysis session. In sum, the experimental group performed Triflow breath training 15 times during each dialysis session. The experimental group and the control group were randomly assigned by a coin toss.
46038524|NCT05655104|Other|Couplet Care|In the Couplet Care model, the parents are provided access to the infant stabilisation room and encouragement for early skin-to-skin contact, mothers receive their postpartum care in the same NICU room with the infant, and fathers/partners also have a bed in the same NICU room.
46038525|NCT00604227|Other|Hypoxic Exposure|ascent to 4559 m within 24 h without prior acclimatization
46038526|NCT02772874|Other|No intervention|No intervention
46038527|NCT02887352|Other|assessment of problem-solving ability|
46038528|NCT00603603|Other|80% inhaled oxygen via non-rebreather mask|Patients randomized to treatment group will receive 80% inhaled oxygen via a non-rebreather face mask during their cesarean section and for 2 hours afterwards.
46038529|NCT00603603|Other|30% inhaled oxygen via nasal cannula|Patients randomized to treatment group will receive 30% inhaled oxygen via a nasal cannula (standard of care)during their cesarean section.
46038530|NCT01132313|Drug|BI 207127|28 weeks, high dose, TID
46038531|NCT01132313|Drug|BI 201335|40 weeks, QD
46038532|NCT01132313|Drug|BI 207127|4 weeks, low dose TID
46038533|NCT01132313|Drug|BI 201335|24 weeks, QD
46038534|NCT01132313|Drug|Ribavirin|16 weeks, according to label
46038535|NCT01132313|Drug|Ribavirin|28 weeks, according to label
46038536|NCT01132313|Drug|Ribavirin|28 weeks, according to label
46038537|NCT01132313|Drug|BI 207127|40 weeks, high dose, TID
46038538|NCT01132313|Drug|BI 207127|24 weeks, very high dose, BID
46038539|NCT01132313|Drug|BI 207127|16 weeks, standard dose, BID
46038540|NCT01132313|Drug|BI 201335|24 weeks, QD
46038541|NCT01132313|Drug|Ribavirin|48 weeks, according to label
46038542|NCT01132313|Drug|Ribavirin|40 weeks, according to label
46038543|NCT01132313|Drug|BI 207127|16 weeks, high dose, TID
46038544|NCT01132313|Drug|BI 207127|28 weeks, high dose, TID
45342630|NCT05809726|Other|Manual lymph drainage|one session 20 minutes
45342631|NCT05809713|Other|Technology-enabled Team Care|Patients randomized to the TTC arm will receive telehealth-enabled team-based care. The team will include a physician and/or advanced practice provider, a pharmacist with Certified Pharmacist Practitioner (CPP) status or similar skills in NC, and will incorporate brief nutritionist-directed lifestyle behaviors counseling (DASH diet; exercise) initially delivered every other week by phone for two months, followed by monthly calls (once SBP values achieve individualized goal and remain stable for 14 days) over 12 months supported by cellular enabled home BP monitoring.
45498051|NCT02957942|Device|1Hz repetitive transcranial magnetic stimulation (rTMS)|1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)
46038545|NCT01132313|Drug|BI 201335|28 weeks, QD
46038546|NCT01132313|Drug|BI 201335|16 weeks, QD
46038547|NCT01132313|Drug|Ribavirin|24 weeks, according to label
46038548|NCT01132313|Drug|BI 201335|24 weeks, QD
46038549|NCT01132313|Drug|BI 201335|28 weeks, QD
46038550|NCT01132313|Drug|BI 207127|24 weeks, standard dose, BID
46038551|NCT01132313|Drug|BI 201335|24 weeks, QD
46038552|NCT01132313|Drug|BI 201335|16 weeks, QD
46038553|NCT01132313|Drug|BI 207127|16 weeks, high dose, BID
46038554|NCT01132313|Drug|BI 201335|24 weeks, QD
46038555|NCT01132313|Drug|Ribavirin|16 weeks, according to label
46038556|NCT01132313|Drug|Ribavirin|16 weeks, according to label
46038557|NCT01132313|Drug|BI 207217|28 weeks, high dose BID
46038558|NCT01132313|Drug|BI 201335|16 weeks, QD
46038559|NCT01132313|Drug|BI 207127|24 weeks, high dose, TID
46038560|NCT01132313|Drug|Ribavirin|48 weeks, according to label
46038561|NCT01132313|Drug|BI 207127|4 weeks, high dose, TID
46038562|NCT01132313|Drug|BI 201335|28 weeks, QD
46038563|NCT01132313|Drug|Ribavirin|24 weeks, according to label
46038564|NCT01132313|Drug|Ribavirin|24 weeks, according to label
46038565|NCT00422565|Device|Endeavor, Medtronic|Zotarolimus-eluting stent
46038566|NCT00422565|Device|Cypher, Cordis|Sirolimus-eluting stent
46038567|NCT00422565|Device|Taxus Liberte, Boston Scientific|Paclitaxel-eluting stent
45683942|NCT04107519|Behavioral|Goal-Directed Resilience Training|This pilot study seeks to test the efficacy of a resilience skills training intervention for former football players who experience chronic pain. Between 20 to 48 eligible and consented participants from the Atlanta area will be identified (with a goal of 40 completing the study). They will undergo a pre-training test session and will then be randomized to either the Immediate GRIT (ImT) training intervention or the Delayed Training (DeT) control. The immediate (ImT) group will be trained for 4 weeks with 2 biweekly sessions. At the end of GRIT training they will be post-tested. The delayed (DeT) group wait during these 4 weeks and do not receive training. At the end of the 4-week waiting period, they will also be post-tested. At this point, they will be offered GRIT training for 4 weeks with 2 biweekly sessions. At the end of their training, they will be given a second post-testing. This process will then be repeated for two additional groups of 5-12 lmT and 5-12 DeT participants.
45342632|NCT05809713|Other|Enhanced Usual Care|Patients randomized to the enhanced usual care (EUC) arm will receive telehealth enabled home BP monitoring equipment including set-up and instruction and basic hypertension-specific lifestyle (diet, exercise) instruction and materials at baseline, but will not receive telehealth-enabled team-based care, active home BP monitoring by a pharmacist, or detailed DASH intensive lifestyle counseling.
45683943|NCT04107285|Behavioral|neurocognitive evaluations|The test battery consists of validated and reliable measures of attention, executive functions and memory.
46038568|NCT04316936|Drug|Omidria|phenylephrine 1% and ketorolac 0.3% intraocular solution
46038569|NCT04316936|Drug|Dextenza (dexamethasone ophthalmic insert) 0.4mg|intracanalicular dexamethasone insert
46038570|NCT04316936|Drug|Dexycu, 9% Intraocular Suspension|dexamethasone intraocular suspension
46038571|NCT04316936|Drug|Prednisolone Acetate 1%|standard postoperative ophthalmic drop regimen
46038572|NCT02772952|Other|Control Intervention|Control Intervention: review medication + adequacy of diet + health education (physical activity recommendation (within a comprehensive advice on healthy lifestyles)
46038573|NCT02772952|Other|Multimodal Intervention|Multimodal Intervention: therapeutic exercise + review medication + adequacy of diet + health education program
46038574|NCT02850627|Drug|Tongguan capsule|eligible participants were randomized to receive Tongguan capsule ( 1.5 g/day for six months immediately after PCI)
46038575|NCT02850627|Drug|placebo capsule|eligible participants were randomized to receive placebo capsule ( 1.5 g/day for six months immediately after PCI)
46038576|NCT02765386|Device|Hybrid fittings for cochlear implant recipients|
46038577|NCT02850861|Device|Condylar reductor|A new surgical instrument was designed to assist the surgeons to perform condylar fracture reduction.
46038578|NCT05658068|Behavioral|SAFE Spaces training and coaching|Staff in facilities assigned to the intervention are eligible to receive evidence-based programming in suicide detection and prevention (Shield of Care; SOC) and wellness skill-building (Skills for Life) through training and personalized coaching. Multiple training sessions will be offered to small groups of staff in-person in residential facilities and paired with personalized in-person and virtual coaching.
46038579|NCT00861757|Drug|Tadalafil|by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks
45683944|NCT04107285|Diagnostic Test|brain MRIs|Patients will undergo baseline and follow-up research MRIs in the same scanner at MSKCC (3 Tesla scanner (GE, Discovery 750W, USA) with a GEM HNU 24-channel head coil) (total scan duration=15 minutes).
46038580|NCT00861757|Drug|Placebo|PO, QD (30 min after meal) for 12 weeks
46038581|NCT00861757|Drug|Tamsulosin|PO, QD (30 min after meal) for 12 weeks
46038582|NCT02762734|Other|MEDIA|"The intervention for the group MEDIA is a keeping in touch intervention through sending of SMS (or mail or other new media). The patient will receive 6 SMS (or mail or other new media) during 6 months after the suicide attempt. The first one 7 days after the suicide attempt and the last one after 6 months. The first SMS (or mail or other new media) is sent soon after the suicide attempt because studies on adult suicide attempters underline the importance of an early start for the connectedness measures. The text message are evolving in time, and are adapted to the genre of the adolescent."
46038583|NCT02850783|Procedure|89Zr-nanocoll and Indocyanine Green|
46038584|NCT05657912|Device|ECG monitoring|Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
46038585|NCT00604305|Device|Acrysof|Monofocal IOL
46038586|NCT00604305|Device|Acuity's AIOL|Accommodating IOL
46038587|NCT05657756|Device|Randomize clinical trial using hand dynamometer|Our research article involves 100 patients aged over 18 years old with ASAI&II divided into two groups, 50 patients will receive atracurium (0.5 mg/kg) and 30 patients receive Rocuronium (0.6 mg/kg). All of our patients will be undergoing elective laparoscopic surgery for cholecystectomy; the patients will randomly select to receive standard anesthesia induction with propofol (2 mg/kg), fentanyl (1-2 mcg/kg), and isoflurane 1.2 Mac, except muscle relaxant. Neuromuscular will monitoring by Train-of-Four (TOF) during surgery.
45683945|NCT04107285|Other|Blood samples|Blood samples will be collected at each time point (Day -1, day 0, day 1, day 3, day 5, day 7, day 10, day of neurotoxicity onset, and 3-4 months post- CART).
45683946|NCT04122183|Other|iManage (my hearing loss)|An internet-based decision coaching guide to help an individual decide if they wish to visit an audiologist.
46038588|NCT01131455|Biological|Autologous Concentrated Plasma|Autologous blood products have created a growing interest for use in a number of orthopedic therapies. The healing effects of plasma are supported by growth factors released by platelets. These growth factors induce a healing process wherever they are applied. The Arthrex ACP System is a cost-effective method of concentrating growth factors for therapeutic use.
46038589|NCT02765542|Other|Automated disease assessment & self-care support phone calls|Automated disease assessment & self-care support phone calls for up to 12 weeks.
45683947|NCT01968031|Drug|Istradefylline 40 mg|Istradefylline 40 mg and placebo
45683948|NCT01968031|Drug|Istradefylline 20 mg|Istradefylline 20 mg and placebo
45683949|NCT01968031|Drug|Placebo|Placebo
46038590|NCT05657600|Behavioral|Sociodemographic profile, quality of life, sleep, fatigue, physical function and balance assessments|Respiratory functions are assessed with a portable spirometer according to the criteria of the American Thoracic Society and European Respiratory Society. Measures the physical, mental, social, and environmental well-being were tested to understand the quality of life. The quality of sleep, delayed sleep, sleep disorders, usage of sleeping pills, and loss of functionality during the day were assessed. The balance and static standing capability of the participants were tested. The functional reach of participants were tested by expecting them to lean forwardly as far as they can without taking a step, nor rising their heels. The fatigue feeling of the participants as everyday life were assessed. The posture of the participants was assessed on 13 regions at anterior, posterior and lateral views.
46038591|NCT05657600|Other|Video-based yoga|Video-based yoga
45342633|NCT05809674|Device|Polarization sensitive optical coherence tomography (PS-OCT)|The PS-OCT is a prototype, also known as an early version of a medical device, specially developed by the Ocular Imaging Research Group, Singapore Eye Research Institute, for prediction of myopia progression. It has not been approved for use in any other country. There is currently no method to identify who is at risk of myopia progression. The PS-OCT device will provide the capabilities of OCT scleral biomarkers, which may have the potential to identify individuals at high risk for myopia.
45342634|NCT05809661|Behavioral|implementation of the nurse navigation program|Adult patients with intestinal stoma were contacted continuously for 6 months.
46038592|NCT05657600|Other|Face-to-face yoga|Face-to-face yoga
46038593|NCT05657600|Other|physical exercise|physical exercise
45342635|NCT05809635|Other|Natural History Study|Longitudinal assessment of participants with BEST1 Vitelliform Macular Dystrophy
45342636|NCT05809622|Behavioral|Elbow focused rehabilitation|"Patient education~Activity modification~2 days/week, 8 weeks in total~Exercises for the wrist extensor tendon, especially the extensor carpi radialis brevis (EKRB) (stretching + strengthening)"
45342637|NCT05809622|Behavioral|Scapular and rotator cuff muscles strengthening|"Patient education~Activity modification~2 days/week, 8 weeks in total~Exercises for the wrist extensor tendon, especially the extensor carpi radialis brevis (EKRB) (stretching + strengthening)~Scapular stabilizer muscle + rotator cuff (RM) strengthening"
45683950|NCT01684215|Drug|PD-0332991|PD-0332991 (100 mg or 125 mg) will be orally administered once a day for 3 weeks followed by 1 week off treatment, in the morning on an empty stomach. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
45694528|NCT01603615|Biological|Botulinum Toxin Type A|Participants received intramuscular injections of botulinum Toxin Type A in the upper and/or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
46038594|NCT02762812|Biological|BCD-055|
46038595|NCT02762812|Biological|Remicade®|
46038596|NCT05657522|Device|Rapid molar intruder|The rapid molar intruder was applied.
46038597|NCT02762890|Drug|Deep neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Post-tetanic count 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 4 mg/kg will be administered to reverse neuromuscular blockade.
46038598|NCT02762890|Drug|Moderate neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Train-of-four 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
46038599|NCT00698191|Biological|Allogeneic MSC (AlloMSC)|"Intervention:~Cyclophosphamide will be administered intravenously at at total dose of 0.8-1.8g 24 hours before transplantation.~Allogeneic bone marrow derived mesenchymal stem cells (matched family donors)will be infused intravenously at 106 cells/kg body weight"
45683951|NCT01684215|Drug|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
46038600|NCT01138007|Drug|323U66 SR 150 mg tablet|323U66 SR 150 mg tablet is orally administered once in the morning and/or once in the evening during the teatment phase.
46038601|NCT01138007|Drug|323U66 SR 150 mg placebo tablet|323U66 SR 150 mg placebo tablet is orally administered once in the evening and/or once in the morning during the teatment phase.
45342638|NCT05809609|Drug|Ketamine Hydrochloride|Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who fail to respond to at least two antidepressant trials of adequate dose and duration.
45342639|NCT05809609|Other|No intervention (placebo)|Placebo injection (0.9% sodium chloride)
45683952|NCT01684215|Drug|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
45683953|NCT01684215|Drug|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
45694529|NCT04626947|Biological|Bezlotoxumab|Bezlotoxumab infusion
46038602|NCT04223128|Procedure|Ultrasound guided transversus abdominis plane block|Using an 18 G Tuohy needle (80 mm Smiths medical Portex®) and the layers of the abdominal wall will be identified guided by superficial high-frequency 45 mm linear array ultrasound probe (13 MHz) as described by McDonnell and colleagues.(1) Twenty millilitre of 0.25% bupivacaine will be injected slowly after careful aspiration to ensure no vascular injury has occurred. Successful injection will produce an echo-lucent space between the muscle layers (internal oblique and transversus abdominis). All TAP blocks will be performed by the same anesthetist.
46038603|NCT05375864|Other|Absorption test|Paracetamol's administration (1 gram) - 48 hours after oseltamivir administration.
46038604|NCT02613715|Dietary Supplement|Blackberry juice with 12% ethanol|
46038605|NCT02613715|Dietary Supplement|Blackberry juice|
46038606|NCT02762968|Dietary Supplement|Placebo|Placebo capsules similar to the experimental treatments.
46038607|NCT02762968|Dietary Supplement|HMB|Capsules containing calcium HMB.
46038608|NCT02762968|Dietary Supplement|BC30|Bacillus Coagulans GBI-30, 6086 (BC30) mixed in water.
46038609|NCT02613559|Biological|TK001|Intravitreal Injection
46038610|NCT02762656|Drug|Lidocaine|Lidocaine drip during surgery
46038611|NCT05657210|Genetic|Mutation|
46038612|NCT02613637|Other|Registry|
46038613|NCT02764996|Device|Acupuncture|
45683954|NCT01684215|Drug|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
45683955|NCT01908205|Drug|Intranasal Oxytocin|
45683956|NCT01908205|Drug|Placebo|
46038614|NCT05657132|Drug|herbal intracanal medication paste|study the effect of costus herbal paste on enterococcus faecalis bacteria
46038615|NCT05657132|Drug|Meta paste|compare the effect of Costus paste with meta paste in reducing the number of enterococcus faecalis
46038616|NCT02765152|Other|Conventional Physical Therapy|Combination of joint mobility exercises, specific exercises for muscle strength and motor coordination exercises, unilateral and bilateral motor tasks as well as task-oriented training of the upper limb with a focus on functional tasks. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week)
45342640|NCT05809557|Other|Chemotherapy toxicity tool|"CARG is an EMR based tool that informs medical oncologists visiting a patient for the first time of potential risk of chemotherapy toxicity. This intervention will make available a simple calculator which includes: Gender, Height and weight, Cancer Subtype, Hemoglobin, How is your hearing (with hearing aid, if needed)?, Number of falls in the past 6 months, Can you take your own medicines, Does your health limit you in walking one block., During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting with friends, relatives, etc.)? and Glomerular filtration rate.~The CARG chemotoxicity calculator will be built into the patient navigator and its use will be assessed on a monthly basis and used to inform iteration."
45342641|NCT05809557|Other|Oncology Consultation|Oncologists will consult new patient with a new diagnosis of cancer.
46038617|NCT02765152|Other|Discrete movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The starting point of the movement and its target are predetermined. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
45342642|NCT05809544|Device|WELT-IP|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
45840231|NCT00683826|Dietary Supplement|L-Leucine 8gr|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 8 grams of leucine.
45342643|NCT05809544|Device|Sham|Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
45342644|NCT05809518|Drug|Propofol injection|sedation after cardiac surgery
45342645|NCT05809518|Drug|Dexmedetomidine injection|sedation after cardiac surgery
45840232|NCT00683826|Other|Liquid meal|Liquid meal preparation (contents): Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. The placebo group will have the same drinks listed above with no leucine incorporated.
45342646|NCT05809518|Drug|Dexmedetomidine and Propofol|sedation after cardiac surgery
45381987|NCT05476458|Radiation|White Light Imaging|white light imaging is often the preferred option for poem surgery due to its effective results. However, it also comes with some drawbacks that make it difficult to identify areas of bleeding, unlike RDI, WLI cannot enhance the visibility of deep vessels This can lead to longer haemostasis time as the physician must wait for a longer period before stopping the bleeding. This can make it challenging as it may lead to excessive bleeding. This makes RDI a potential solution for those seeking a more accurate approach to treatment.
45342647|NCT05809492|Other|step test|"The step speed of 18 steps/min was chosen for the first level because it is suitable for all subjects and prevents them from being too fast at the end of the test.~the slow standardized initial tempo at Level 1 of 72 beats/min allowed familiarity with the coordinated cascading technology of the tests (step up and down in time with the metronome beat). Regular replacement of the leading leg was encouraged to prevent unilateral leg fatigue and November muscle pain.~pwCF selected 1-minute stage times for each level in accordance with the maximum exercise test (CPET) recommendations in 18; at each new level, the test speed was increased by two steps / minute to ensure a progressive change in exercise parameters; a suitable end test time of 16 minutes was achieved along with an initial speed of 18 steps/min. The fast pace of 194 beats/min (48 steps/min at Level 16), which was eventually reached, it was physically possible to perform safely."
45840233|NCT00683826|Dietary Supplement|L-Leucine 4g|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 4 grams of leucine.
45342648|NCT05809479|Other|No intervention|No intervention
45342649|NCT05809466|Other|Vegan diet|A self-composed 12 week fully plant-based diet
45342650|NCT05809466|Other|Resistance exercise|Biweekly resistance exercise for 12 weeks
45342651|NCT05809466|Other|Omnivorous diet|Habitual diet containing both animal- and plant-based food products
45342652|NCT05809440|Other|20-minute mindful breathing session|A 20-minute mindful breathing session guided by a trained medical doctor. The session consisted of four 5-minute breathing exercises done consecutively. Participants were instructed to close their eyes and bring their attention to their breathing, and re-direct their attention back to their breathing once they were distracted.
45342653|NCT05809414|Device|Transcranial Magnetic Stimulation|"TMS is a technique for electrical stimulation of brain tissue by generating a magnetic field, which modulates neural activity at the stimulation site and in interconnected neural networks.~The treatment will be applied to the left dorsolateral prefrontal region. Each patient will receive 3 sessions per week of approximately 10 minutes for 6 weeks.~In the case of TMS sham, a placebo coil will be used, which is indistinguishable from the therapeutic one. In addition, the sessions will be carried out with the same frequency, so the patient will be unaware of the treatment they are receiving."
45683957|NCT04121325|Device|Enterra|To measure validated and subjective pain scores among patients with an existing GES device, and who have a trial of new settings directed at abdominal pain and compare their pain scores to each patient baseline symptoms, done with their previous GES settings.
45683958|NCT03911739|Drug|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
45683959|NCT03911739|Drug|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
45683960|NCT01549041|Drug|Asenapine 10 mg daily in the evening|The total daily dose of Asenapine will be given once daily in the evening
45683961|NCT01549041|Drug|Asenapine 5 mg twice daily|Asenapine will be given in two doses, 5 mg in the morning and 5 mg in the evening, daily
46038618|NCT02765152|Other|Rhythmic movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The movement begins in a predetermined starting point, directed to a target and returns to the starting point. This activity is performed several times with rhythmic movements. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
45840234|NCT00684138|Device|ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens|Intraocular Lens
45342654|NCT05809414|Drug|Amantadine Hydrochloride 100 mg (milligrams) Oral Capsule|"It will be used at a dose of 100 mg, 1 capsule a day for 1 week, followed by 2 daily doses of 100 mg until completing 6 weeks in total. After completing the treatment phase, the dose will be de-escalated (1 capsule a day for 5 days and discontinued).~In the case of placebo amantadine capsules, they will have the same organoleptic characteristics as amantadine. The start, maintenance and de-escalation pattern will be identical."
46038619|NCT00865345|Device|MMT-7003 subcutaneous glucose sensor|All subjects will use the glucose sensor, randomized to participate in a 12-hour frequent (15-minute) blood glucose sampling period on one of six days of sensor wear. Blood samples will be analyzed using a laboratory standard (YSI) for comparison to the glucose sensor to evaluate accuracy.
45342655|NCT05809401|Behavioral|Pragmatic Rehabilitation|A series of behavioral activities to improve specific pragmatic abilities in patients
46038620|NCT01131299|Other|Placebo|2 tablets PO 3 times a day for 12-14 weeks
46038621|NCT01131299|Drug|Alpha cyclodextrin|2g PO 3 times a day for 12-14 weeks
45342656|NCT05809401|Behavioral|Neuropsychological Rehabilitation|A series of behavioral activities to improve general aspect of cognition, with a specific focus on attentional abilities.
45683962|NCT04106115|Drug|Durvalumab|1500 mg IV infusion every 4 weeks for up to 7 doses
45683963|NCT04106115|Biological|S-488210/S-488211|S-488210/S-488211 is given as a 1 mL subcutaneous (SC) injection of S-488210/Montanide emulsion and a 1 mL SC injection of S-488211/Montanide emulsion starting the day after first dose of durvalumab and continuing weekly for 6 doses and then every 2 weeks for a further 9 doses
45683964|NCT01907815|Drug|Akt Inhibitor GSK2141795|Given PO
45683965|NCT01907815|Other|Laboratory Biomarker Analysis|Correlative studies
45683966|NCT01907815|Drug|Trametinib|Given PO
45683967|NCT01548573|Drug|Dexamethasone|Given PO
45840235|NCT00684138|Device|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens|Intraocular Lens
46038622|NCT02762422|Other|Phlebotomy|Removal of 500 cc of blood via forearm vein
46038623|NCT04316858|Drug|Sodium phosphate|90ml of sodium phosphate will be added to 800ml of solvent( water or zero calorie carbonated drink) and taken in divided doses one day prior to procedure. Whole solution will be finished 3 -4 hours before colonoscopy.
46038624|NCT04316858|Dietary Supplement|Water|800 ml of water will be added to 90 ml of sodium phosphate to facilitate its intake by the patients preparatory to colonoscopy
46038625|NCT04316858|Dietary Supplement|Zero calorie carbonated drink|800 ml of zero calorie diet cola will be added to 90 ml of sodium phosphate to facilitate its intake by the patients preparatory to colonoscopy
46038626|NCT02614807|Dietary Supplement|Nepro|The intervention is a dietary protein supplement. In the elderly hypertensive patient (assuming body weight of 70 kg) with mild to moderate hyponatremia free water excess is around 2.5 L. One bottle of Nepro/day will generate about 120 mosm to be excreted via urine. Given limited and mostly fixed urinary dilution and concentration between 300 and 800 mosm/L in the elderly and very elderly, one bottle of Nepro a day will result in an extra 400 ml of urine for a net loss of 163 ml of free water. Thus over the period of 2 to 4 weeks the calculated free water excess should be completely eliminated.
45381988|NCT05476458|Radiation|Red Light Imaging|Red dichromatic imaging (RDI) is a next-generation image enhancement technique which works by employing green, amber and red wavelengths. Greenlight(520-550nm) can visualize small blood vessels in superficial tissue without extending deep into the mucosa. Amber(595-610nm) and red light (620-640nm) can penetrate deep into the tissue owing to low scattering property. The blood vessels in the deeper tissues absorb the amber light because of strong affinity with hemoglobin. Even though red light can penetrate deep into the tissue, it is weakly absorbed by hemoglobin. Hence the reflected light contains red light and amber light without attenuation.
45683968|NCT01548573|Procedure|Tandem autologous stem cell transplant|
46038627|NCT04555720|Behavioral|Interdisciplinary Visit|If assigned to the interdisciplinary group, participants will see social work, physical therapy, occupational therapy, speech therapy, and pharmacy in a scheduled rotation for about 45 minutes each. After these evaluations, the team meets with the participants doctor for a discussion of treatment. After this meeting, the participants doctor will meet to discuss a treatment plan and make recommendations.
45683969|NCT01548573|Drug|Cisplatin|Given IV
45683970|NCT01548573|Drug|Doxorubicin|Given IV
45683971|NCT01548573|Drug|Cyclophosphamide|Given IV or PO
45683972|NCT01548573|Drug|Etoposide|Given IV
45683973|NCT01548573|Drug|Bortezomib|Given IV
45683974|NCT01548573|Drug|Thalidomide|Given PO
46038628|NCT04119895|Other|Neuromuscular electrical stimulation and core stabilization exercise|"In NMES group, the amplitude of the electrical current will be set at the highest level subject can tolerate.~The lumbar stabilization mode of the device will be used. This mode consists of three phases; warming, contraction and recovery phases. The duration will be set to 35 minutes. In the first 2 minutes (warming phase), frequency is 6 Hz. Contraction phase includes consecutive cycles of contractile frequency of 40 Hz for 6 seconds and the rest frequency of 4 Hz for 12 seconds, lasting a total of 30 minutes. The last 3 minutes (recovery phase) frequency is 3 Hz. The ramp up time is 2 seconds and the ramp down time is 1 second"
46038629|NCT04119895|Other|Sham neuromuscular electrical stimulation and core stabilization exercise|In sham NMES group, the amplitude of the electrical current will be set at a minimum level which does not stimulate any contraction.
45683975|NCT01548573|Drug|Melphalan|Given IV
46038630|NCT02764840|Other|isokinetic dynamometer|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain. The first stage of the study will be crossover. The second will be split, one arm carry out the procedures in the elastic tube and the other in isokinetic dynamometer.
45342657|NCT05809375|Other|Coping Skills Training|In the intervention, it was acted in a way to include the educational content determined by the International Headache Association and with a problem-solving perspective. The coping skills training contents in the literature were combined, and the CST prepared by including the most used and related contents will be given. CST includes a targeted therapy specifically developed for this study to address the needs and expectations of individuals with migraine. The targeted CST was designed by the authors, consisting of an occupational therapist, and two physiotherapists with clinical, and academic experience. It is planned as a total of eight sessions, and two sessions per week. CST includes giving information about migraine, activity tempo, progressive muscle relaxation exercise, stress management, social participation, leisure time management, general evaluation of the program, and home program.
46038631|NCT02764840|Other|elastic tube|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain.
46038632|NCT00637325|Drug|trastuzumab|In the maintenance study trastuzumab will be administrated once every 3 weeks at the dose of 6 mg/kg by intravenous infusion over 90 minutes until progression of disease. In the 2nd line study, to accomplish the schedule of concomitant second line chemotherapy, trastuzumab will be given on a weekly (2 mg/kg) or a 3-weekly (6 mg/kg).
46038633|NCT02762344|Drug|heparin|routinary heparin administration during coronary angiography/PCI
45683976|NCT01907737|Other|Active tDCS|Active tDCS will be applied with the anode positioned over the ipsilesional M1 and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
46038634|NCT04316780|Other|Retrospective observational study- no intervention to occur.|Subject data will be grouped based on the anti-fibrotic medication at the time of lung transplant listing eligibility and when medication was stopped relative to the transplant.
46038635|NCT02764684|Drug|Probiotic|The probiotic strain Lactobacillus rhamnosus will be self-administrated twice a day, one capsule in the morning and one in the evening for eight weeks.
45342658|NCT05809349|Device|transcranial magnetic stimulation|The stimulation intensity will be 80% resting motor threshold (RMT). The theta burst stimulation (cTBS) with a frequency at 50Hz, repeated at 5Hz, are delivered in a duration of 33.2s with the number of stimulation pulses of 600. Two groups of stimulation will be repeated in each cerebellar dentate nucleus with an interval of 5 min in each group. The treatment will last for 2 weeks, with 5 times per week.
46038636|NCT05657054|Other|Exercise Intervention Targeting Hip Strengthening|An initial 16-week exercise intervention of 45 minutes of training 3 times a week in the patient's own home or at a rehabilitation center. Patients will be instructed by a physiotherapist during the first 3 sessions, in order to be able to perform the exercises at home. Subsequently, there are physiotherapist-supervised sessions once every second week. The delivery of the supervised sessions is based on the patient's preferences, either by physical attendance or remotely in the patient's home. The intervention will consist of 4 exercises adapted from the NEMEX program targeting lower extremity muscle strength, stability, postural function, and postural orientation. Progression is made when an exercise is performed with good sensorimotor control and good performance quality and with minimal exertion and adequate movement control. Progression is primarily provided by 3 levels of difficulty and secondly by varying the number of repetitions or where possible, by increasing the weight load.
45342659|NCT05809336|Drug|Inosine 0.2g orally 3 times/day|inosine + PD-1/PD-L1 inhibitor ± chemotherapy/targeting,
45342660|NCT05809336|Drug|PD-1/PD-L1 inhibitor ,chemotherapy/targeting|PD-1/PD-L1 inhibitor ± chemotherapy/targeting
45342661|NCT05809323|Other|Exercise Intervention Group|Patients will be educated on methods of self-evaluating exertion and cardiovascular effort by assessing respiratory rate and perceived exertion. Next, patients will be given options for cardiovascular activities and complete at a moderate level of activity for a minimum of 150 minutes per week. Patients will perform a combination of exercises under the supervision of a physical therapist until a mod intensity level is reached and sustained. Patients will be taught to use the activity tracker to record their heart rate, activity, and PES. Patients will have a phone call every week to assess status, answer questions, and provide guidance on progressing intensity or duration of exercise. At the end of 12 weeks all patients will return for re-assessment.
45342662|NCT05809323|Other|Control Group|Patients in the control group will be instructed to continue with baseline physical activities over the duration of the study and be given instructions on the use of the activity tracker. At the end of 12 weeks all patients will return for re-assessment.
45342663|NCT05809271|Drug|MDMA 120 mg + MDMA 60 mg|An oral dose of 120 mg racemic MDMA will be administered followed by a second dose of 60 mg racemic MDMA two hours later.
45342664|NCT05809271|Drug|MDMA 120 mg + placebo|An oral dose of 120 mg racemic MDMA will be administered followed by a placebo two hours later.
45342665|NCT05809271|Drug|Placebo|An oral placebo will be administered followed by a placebo two hours later.
45342666|NCT05809258|Procedure|Supraclavicular block|brachial plexus nerve block by supraclavicular route
45342667|NCT05809258|Procedure|Axillary block|brachial plexus nerve block by axillary route
45342668|NCT05809245|Procedure|Corneal neurotization|Autologous sural nerve will be harvested or cadaveric nerve graft will be coapted to an intact sensory branch of the trigeminal nerve. The nerve will be separated into fascicles which will be tunneled under the conjunctiva around the cornea near the limbus.
45342669|NCT05809232|Other|CARES-guided Group|Participants randomised to the CARES-guided arm will have their CARES-score calculated and entered into the Pre-Anesthesia Assessment electronic form within the Electronic Medical Records (EMR). This score and its relevant advisories will be prominently displayed on this electronic form. (Participants on this arm will receive this intervention in addition to the routine practice).
46038637|NCT05657054|Other|Usual Care|The intervention will consist of a rehabilitation intervention corresponding to standard care in the participating municipalities (i.e. content and duration of intervention). The intervention will be delivered individually or as group training, based on a clinical assessment of the individual patients' needs. The intervention can be supported by home-based exercises following instruction from a physiotherapist, supplemented by the provision of written information or access to a virtual training program. The intervention occurs in either the rehabilitation center's gym or the patient's home. The training sessions may consist of some of the following parameters: Strength training, stretching, functional training e.g. walking and stair climbing, stability training, balance training, endurance training, and gait correction.
46038638|NCT01130831|Drug|Lanthanum carbonate|
46038639|NCT02764450|Device|Astralis 10 HPM|The cavity to be filled is in quadrant I or III
46038640|NCT02764450|Device|Astralis 10 RM|The cavity to be filled is in quadrant II or IV
46038641|NCT05304416|Diagnostic Test|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
46038642|NCT05304416|Diagnostic Test|Simultaneous FEES and Videofluoroscopy instrumental swallowing exam|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism. The participant will be asked to perform some voicing tasks, once completed, a videofluoroscopic swallowing exam will occur at the same time. This is like a moving x-ray of the participant swallowing foods and liquids (barium).
46038643|NCT05304416|Diagnostic Test|Videofluoroscopy instrumental swallowing exam (VFSS)|This is like a moving x-ray of the participant swallowing foods and liquids (barium).
46038644|NCT05304416|Other|Voluntary Cough Peak Expiratory Flow (PEF) Testing|Cough PEF will be performed to index a participant's physiologic airway defense capacity and strength. Testing will occur with the participant seated upright at 90 degrees using an analog peak flow meter with a one-way expiratory valve that prevents a participant from breathing air in from the device to reduce contamination.
45840236|NCT00685932|Device|Mobius Retractor|The Mobius retractor is a dual ring elastic self retaining retractor that is inserted into the abdominal cavity after the peritoneal incision has been established. It is then left in place during the hysterotomy incision, delivery of the fetus, hysterotomy repair, inspection and irrigation.
45840237|NCT00687102|Drug|tamoxifen|oral tamoxifen plus placebo daily for 5 years
45840238|NCT00687102|Drug|raloxifene|oral raloxifene plus placebo daily for 5 years
46038645|NCT05304416|Other|Reflex Cough Screen|Participants will be seated upright and administered reflex cough testing via a disposable adult aerosol mask with an attached nebulizer that contains a solution to elicit a cough response.
46038646|NCT05304416|Other|Lingual Pressure Testing|Lingual strength will be evaluated using the Iowa Oral Pressure Instrument (IOPI). Participants will be seated upright, and the SLP will place the IOPI air-filled sensing bulb in the midline anterior position on the participant's tongue, posterior to the alveolar ridge.
45683977|NCT01907737|Other|Active PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
45683978|NCT01907737|Other|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
45381989|NCT05475613|Procedure|Downstaging procedures containing immunotherapy|Anti-PD-1 inhibitor will be given every 3-4 weeks intravenously according to the manufacturer's instruction. Other combination regimens, such as locoregional therapies or targeted therapies will be given to patients according to the protocol decided by the multidisciplinary team of Centers.
45683979|NCT01907737|Other|Sham PNS|No current will be delivered to the radial, ulnar and median nerves.
45683980|NCT01570491|Other|ultrasound-guided spinal anesthesia|ultrasound-guided technique for block placement
45683981|NCT01570491|Other|standard spinal anesthesia|Anesthesiologist will use standard technique for placement of spinal block.
45840239|NCT00688662|Procedure|ERCP with sphincterotomy|cutting the biliary sphincter muscle (sphincterotomy)
45840240|NCT00688662|Procedure|ERCP without sphincterotomy|ERCP with sphincter manometry, but no sphincterotomy
45840241|NCT00690924|Drug|calcitriol|Oral
45840242|NCT00690924|Other|laboratory biomarker analysis|Correlative Study
45840243|NCT00690924|Other|pharmacological study|Correlative Study
45840244|NCT00691002|Drug|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
46038647|NCT05304416|Diagnostic Test|Speech Testing|"Speech assessment will occur with the participant comfortably seated headset microphone with a lapel windscreen connected to a TASCAM DR40 to allow for high-quality audio recordings. Individuals will be asked to perform two maximal performance speech tasks that include vowel prolongation of /a/, and a Diadochokinetic (DDK) rate task to examine SMR for production of the word buttercup."
45342670|NCT05809206|Other|Glutes maximus strength protocol|"The subjects attended physical therapy two times. Per week for a total of 10 visits. Each session lasted approximately 30 minutes. In the first five sessions, subjects performed the following exercises to strengthen the gluteus maximus: bilateral bridge, unilateral bridge, and non-weight-bearing hip extension in prone with the knee flexed at 90 degrees. In the next five sessions, abduction and external rotation in a quadruped (fire hydrant exercise) and weight-bearing hip extension (known as deadlift exercise) were added. Each exercise was performed for 10 repetitions. Elastic resistance was added to the fire hydrant, hip extension in prone and dead lift exercises to allow each subject to perform at a 10-repetition maximum. The resistance for each subject was adjusted weekly as needed. The exercise program was performed under direct supervision only during the physical therapy sessions."
45498052|NCT04059354|Behavioral|Speech therapy addressing phonology and motor learning|Determine the efficacy of a newly devised intensive speech treatment plan (DS-DxTx) focusing on vowels that combines efficacious treatment approaches to use with individuals with Down syndrome. The phonological speech intervention, Phonological Cycles approach, is designed for use with children with highly unintelligible speech and the speech motor learning intervention, Script training is a functional treatment to promote phrase level productions. Both approaches are documented to be efficacious with other speech disorders. The proposed approach takes into account the multiple deficits commonly present in individuals with DS, and based on the acoustic and perceptual finding on vowels from our VTLab. Acoustic and perceptual measures will be used to assess treatment efficacy.
45498053|NCT03640910|Device|OT Equators® (Rhein83)|Attachment systems to retain an implant overdenture
45840245|NCT00691002|Drug|LEO 80190 Vehicle|
45840246|NCT00691002|Drug|Hydrocortisone|
45840247|NCT00691002|Drug|Calcipotriol|
46038648|NCT04663282|Drug|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
46038649|NCT04663282|Drug|Insulin Degludec|Insulin Degludec injected subcutaneously once daily. Treat-to-target dose titration during the trial
45342671|NCT05809206|Other|Gluteus medius strength program|"Strengthening exercises for Gluteus Medius subdivisions:~The anterior GMED exercise: side lying abduction exercise The middle GMED exercise: wall press Exercise The posterior GMED exercise: was the pelvic drop exercise"
45342672|NCT05809206|Other|Corrective Exercises|"The following low back corrective exercises were given:~To stretch the tight lower back muscles: Seated Forward Bend and Full Squat held for 5 sec and Repeated for 3 times, once a day.~To strengthen the weak lower abdomen: Draw in and Reverse Crunch 3 seconds, repeated 5 times, once a day.~To stretch the tight hip flexors: held for 10-15 seconds repeated 5 times on both legs, once a day.~To stretch the tight quadriceps: held for 3 seconds, repeated 5 times on each side, once a day.~To strengthen weak hamstrings: Kick Butts 2 sec, repeated 8 times, once a day."
45840248|NCT00693498|Biological|Standard leukoreduced irradiated blood cell transfusion|standard vs washed blood cell transfusions
45342673|NCT05809206|Device|Ultrasound|US was administered in continuous mode at PSIS with patient in prone lying position, with a frequency of 1 MHz and intensity of 0.8 W/cm2 for 5 minutes every alternating day
46038650|NCT02764606|Biological|Serum and plasma samples|Serum and plasma are collected at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases.
46038651|NCT01130597|Drug|patiromer|Active investigational drug
46038652|NCT01130597|Drug|spironolactone|
46038653|NCT02762188|Device|Genotype analysis|"After signing informed consent, a blood sample is taken and DNA extracted according to standard procedures. The samples are genotyped with the Mass Array iPlex Gold. Processing of the data is done using the previously described protocol by Lambrechts and co.~Statistical analysis will be done to evaluate the association between the different genetic variants and the clinical outcomes collected during the standard of care follow-up for ARMD."
45381990|NCT05475613|Procedure|Liver transplantation|Patients with successful downstaging therapy at the end of the observation phase will enroll and undergo liver transplantation unless major medical or oncological contraindications should occur during the waiting phase.
45381991|NCT05463198|Device|CM-1600|Subjects undergoing blood donation will be connected to the CM-1600 device.
45381992|NCT05462795|Diagnostic Test|Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule|10 cc of blood is collected at one time point, which is prior to biopsy procedure
45840249|NCT00693498|Biological|Washed leukoreduced irradiated blood cell transfusions|washed leukoreduced irradiated blood cell transfusions
46038654|NCT02761876|Behavioral|Mentor farmer training (Malawi)|Mentor farmers, 1 man, 1 woman, from each village will participate in a field visit to and training by existing mentor farmers in Malawi. Only the intervention arm of this study will receive mentor farmer training in Malawi, delayed intervention arm will receive mentor farmer training from farmers participating in the initial intervention in Tanzania.
46038655|NCT02761876|Behavioral|Mentor farmer training (Singida, Tanzania)|Mentor farmers will receive training in Singida, Tanzania on agroecology practices, climate change, nutrition, and gender equality. Intervention villages will receive training in 2016. Delayed intervention villages will receive training in 2019.
45840250|NCT00693654|Drug|Sarna|Active Ingredient: Pramoxine Hydrochloride Inactive ingredients:Benzyl Alcohol, Carbomer 940, Cetyl Alcohol, Dimethicone, Glyceryl Stearate (&) PEG-100 Stearate, Isopropyl Myristate, Petrolatum, PEG 8 Stearate, Purified Water, Stearic Acid, Sodium Hydroxide
46038656|NCT02761876|Behavioral|Mentor farmer visits and facilitation|Mentor farmers will conduct monthly visits to participating households and support the households in conducting experimentation with agroecological practices and/or new behavior regarding nutrition and gender equality. Quarterly meetings among farmers within each village will be held to discuss progress and challenges of household experimentations. Intervention households will receive support and facilitation for approximately 2 years. Delayed intervention households will receive support and facilitation for approximately 6 months after end line survey.
45840251|NCT00693654|Drug|Cetaphil|Purified Water, Glycerin, Hydrogenated Polyisobutene, Cetearyl Alcohol, Ceteareth 20, Macadamia Nut Oil, Dimethicone, Tocopheryl Acetate, Stearoxytrimethylsilane, Stearyl Alcohol, Panthenol, Farnesol, Benzyl Alcohol, Phenoxyethanol, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Sodium Hydroxide, Citric Acid
45840252|NCT00695292|Drug|irinotecan|irinotecan 60 mg/m2 intravenously (IV) on Days 1, 8, and 15
45840253|NCT00695292|Drug|Carboplatin|carboplatin AUC=4 on Day 1
45342674|NCT05809193|Behavioral|Family-Focused Therapy|"After the patient and family are informed, they are included in the therapy group on a voluntary basis. After evaluation by independent evaluators, therapy sessions are started by therapists.~Session 1: Goal Setting, Treatment Overview, Symptoms, Vulnerability Stress Model Session 2: Stress and Coping Skills, Optional treatment: Regulation of sleep habits, Relaxation exercises Session 3: Optimizing Family Support; Prevention Plan, Drug compliance Session 4: Overview of Communication Skills; Expressing Positive Feelings, Active Listening Session 5: Making a Positive Request, Communication Clarity Session 6: Expressing Negative Feelings Session 7: Introduction to Problem Solving Skills Session 8 and 9: Problem Solving Skills, Termination of Treatment The same psychometric assessment will be repeated before and after FFT. Intra-group comparisons will be made. Also study groups will be compared using time by group interactions to investigate the differences in therapy response."
45498054|NCT03640910|Device|Locator® (Zest)|Attachment systems to retain an implant overdenture
45840254|NCT00695292|Drug|sunitinib|sunitinib 25 mg orally (PO) daily after initial chemotherapy
45840255|NCT00696618|Drug|Fleet Enema|hyper-osmolar preparation
45840256|NCT00696618|Drug|tap water enema|hypo-osmolar preparation
45840257|NCT00696618|Drug|Normosol-R enema|iso-osmolar preparation
46038657|NCT02696278|Other|Lesson about vegetables|During the introductory period, children will receive a lesson about vegetables 3 days a week for 3 weeks.
46038658|NCT02696278|Other|Vegetables|During the introductory period, children will be served vegetables 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive vegetables everyday for 3 weeks during snack time at their daycare center.
45694530|NCT01905683|Drug|IncobotulinumtoxinA (16-20 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total dose per injection cycle: up to 500 units; Mode of administration: intramuscular injection into spastic muscles.
45840258|NCT00700440|Drug|C225 (cetuximab)|one week before and then weekly during radiotherapy
45342675|NCT05809167|Drug|VEN+AZA+Modified BUCY|"Venetoclax: 200mg/day*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day*7days."
45840259|NCT00701376|Other|liver biopsy|Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
46038659|NCT02696278|Other|Hummus|During the introductory period, children will be served hummus, depending on their group assignment, 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive hummus, depending on their group assignment, everyday for 3 weeks during snack time at their daycare center.
45342676|NCT05809154|Diagnostic Test|Video-Urodynamics|Minimal invasive Urodynamic examination: Cystomanometry for the assessment of the bladder storage phase and a pressure-flow for the assessment of the voiding phase. By a thin transurethral catheter, body warm fluid is filled in to the bladder and at the same time is the intravesical and abdominal pressure traced with a computer system. The pelvic floor muscle activity is assessed at the same time using EMG surface electrodes.
46038660|NCT05163119|Behavioral|Commercial Cellphone-Blocking App (Active)|The Fleetsafer app, which is a commercial cellphone app that uses a cellphone's standard sensors and function to block handheld cellphone use while driving, will be downloaded on the participant's smartphone.
45840260|NCT00702780|Drug|escitalopram|5 mg/day for 2 weeks, 10 mg/day for 2 weeks and 20 mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
45342677|NCT05809141|Diagnostic Test|thromboelastography|Thromboelastography (TEG), a whole blood viscoelastic test. TEG detects the clotting time, clotting kinetics and clot stability to more comprehensively evaluate haemostatic status by several parameters, mainly including reactive time (R), kinetic time (K), angle (α), maximum amplitude (MA) and lysis-30 .
46038661|NCT05163119|Behavioral|Driving Mode|"Apple's Do Not Disturb driving mode provided by Apple for iPhones or Google Do Not Disturb, Verizon Messages +, Android Auto or have another app, called LifeSaver installed on their Android phone (collectively referred to as driving modes; the specific driving mode for participants in this arm will be determined based on smartphone type and service provider)."
45840261|NCT00702780|Drug|placebo|5mg/day for 2 weeks, 10mg/day for 2 weeks and 20mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
46038662|NCT00939003|Biological|Adalimumab|40 mg every other week up to Week 12
46038663|NCT00939003|Biological|Placebo|Placebo every other week up to Week 12
46038664|NCT00939003|Biological|Open-label Adalimumab|40 mg every other week, Week 12 through Week 156
45840262|NCT00704028|Drug|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
45840263|NCT00704028|Drug|Iron Dextran|As determined by the investigator to a maximum cumulative dose of 2,250 mg.
45840264|NCT00704262|Drug|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
45840265|NCT00706446|Drug|tiotropium bromide|tiotropium bromide one inhalation a day for one year, along with inhaled steroids at variable dosing based on patient's prior inhaled steroid dosing and treating physician's judgement.
46038665|NCT01188668|Drug|Aripiprazole|Period 1-Aripiprazole 5mg on study day 1.
46038666|NCT01188668|Drug|Aripiprazole + desvenlafaxine succinate sustained release|Period 2-Desvenlafaxine SR 100mg on days 1-19 with coadministration of Aripiprazole 5mg on day 7.
46038667|NCT02882945|Other|Group A|150 healthy blood donors without a family history of diabetes mellitus were enrolled in the study.
46038668|NCT02882945|Other|Group B|200 cases of type 2 DM without complications were enrolled in the study.
46038669|NCT02882945|Other|Group C|120 cases of type 2 DM with macroangiopathy complication were enrolled in the study.. Among the group C subjects, 65 individuals had CHD; 55 patients had cerebrovascular disease (CVD); and 30 subjects had a combination of peripheral vascular diseases (PVD) and CHD.
46038670|NCT04524286|Other|Interviews only.|Interviews will be conducted with childbearing women and midwives.
46038671|NCT04192084|Procedure|microvascular partial toe transfer|we will perform microvascular partial toe transfer for patients with traumatic amputation of one or more digits
46038672|NCT01130051|Drug|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
46038673|NCT01130051|Drug|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
46038674|NCT05301998|Other|Skin and thickness measurement/breast MRI|"Patient will be installed in dorsal decubitus position. Measurements will be performed at 3 sites on one breast: at the areola, above the areola and below. Measurements will be performed by a single gynecologist using a cutometer provided by TIMC-IMAG laboratory of Grenoble. Three measurements will be performed at each site. Duration of measurements will be approximately 15 minutes.~Measurement of skin thickness will be performed using an ultrasound device available in obstetrics/gynecology consultation department. The measurement will be performed at 3 sites. The duration of the measurements will be of approximately 10 minutes.~Among the 200 patients, 10 patients who should benefit from a breast MRI as part of their follow-up, will have a breast MRI in 3 different positions: prone (standard protocol) and two additional acquisitions (as part of the research) in dorsal and right lateral decubitus. This examination will be scheduled in the senology department of the Lapeyronie Hospital"
46038675|NCT00865189|Drug|Bevacizumab|Bevacizumab will be administered at the fixed dose of 5 milligrams per kilogram (mg/kg) as an IV infusion over 30 to 90 minutes.
46038676|NCT00865189|Drug|Oxaliplatin|Oxaliplatin will be administered at a dose of 85 milligrams per square meter (mg/m^2) as a 2-hour IV infusion.
46038677|NCT00865189|Drug|Folinic Acid|Folinic acid will be administered at a dose of 200 mg/m^2 as a 2-hour infusion.
46038678|NCT00865189|Drug|5-fluorouracil|5-fluorouracil will be administered at a dose of 400 mg/m^2 as an IV bolus, then at a dose of 600 mg/m^2 as a continuous infusion for 22 hours in Phase 1, and will be administered at a dose of 225 mg/m^2 as a 24-hour infusion, 5 days a week, for 5 weeks in Phase 2.
46038679|NCT00865189|Radiation|Preoperative Radiotherapy|Radiotherapy will be delivered in fraction of 1.8 gray per day (Gy/day), 5 days a week for 5 weeks, i.e., a total dose of 45 Gy will be administered in 25 fractions over a period of 33 days.
46038680|NCT00865189|Procedure|Surgery|Radical rectal excision based on the TME technique.
46038681|NCT02762032|Dietary Supplement|PrimaVie Herbal Supplement 125|125 mg to take BID for 14 weeks in Arm 1
45342678|NCT05809128|Other|surgery for breast cancer and imaging test evaluations|At the time of surgery, having completed the evaluation extemporaneous of the surgical piece, tissue samples will be collected to be stored from the material exceeding the completion of the patients' diagnosis. In addition, paramenters that can be extracted from radiodiagnostic images will be evaluated
45840266|NCT00706446|Drug|Salmeterol|salmeterol diskus 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
46038682|NCT02762032|Dietary Supplement|PrimaVie Herbal Supplement 250|250 mg to take BID for 14 weeks in Arm 2
45342679|NCT05809102|Procedure|repair of flexor tendon in Zone II|Repair of Zone II flexor tendon of the hand using minimal incisions instead of whole tendon exposure
45342680|NCT05809076|Device|real tACS|tACS is a non-invasive method to induce brain modulation. It will be applied at a frequency of 40 Hz (gamma-tACS) with a peak-to-peak intensity of 2 mA. During the real tACS condition, the alternating current will be administered for 20 minutes.
46038683|NCT02762032|Drug|Placebo|Placebo supplement to take BID for 14 weeks in Arm 3
46038684|NCT02764372|Behavioral|Serious games|Participants played serious games developed for Kinect in the the EU FP7 STREP Project REHAB@HOME N. 306113
46038685|NCT02764372|Behavioral|Exergames|Participants played exergames existent in the Wii game console
46038686|NCT05362292|Drug|Tolterodine Tartrate ER|Anticholinergic
46038687|NCT05362292|Drug|Mirabegron|Beta-3-adrenergic agonist
46038688|NCT05362292|Drug|Placebo|matching placebo pill
46038689|NCT04311905|Device|Diode laser|Diode laser activated irrigation
45342681|NCT05809076|Device|sham tACS|In the sham tACS condition, the current will be delivered only for the first 30 seconds and then stopped, in order to simulate the same somatosensory sensations as real tACS, but without inducing modulation.
45342682|NCT05809063|Other|observational|document the number , disease pattern& outcome of neonates admitted to the neonatal intensive care units
45342683|NCT05809050|Diagnostic Test|BM aspirate|Bone Marrow aspiration & Examination
45342684|NCT05809037|Device|transcutaneous auricular vagus nerve stimulation|In addition to the conventional rehabilitation program, non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, noninvasive auricular stimulation will be applied, stimulation frequency is 10 Hz, pulse width is 300 µs, and biphasic.
46038690|NCT04311905|Other|Placebo|mock Laser activated irrigation
45342685|NCT05809037|Device|Sham stimulation|In addition to the conventional rehabilitation program, sham vagus nerve stimulation (0 mA) will be applied to the participants in the control group. Non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, and noninvasive auricular stimulation will be applied.
45342686|NCT05809024|Drug|letrozole|Hormone receptor positive,HER2 negative participants will receive letrozole as neoadjuvant endocrine therapy，if don't work, CDK4/6 Inhibitor was added.
45342687|NCT05808998|Radiation|Stereotactic body radiotherapy|Stereotactic body radiotherapy using TomoTherapy
45342688|NCT05808985|Drug|sodium butyrate|Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭, per day)
45840267|NCT00706446|Drug|Formoterol|formoterol aerolizer 12 mcg 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
45342689|NCT05808972|Drug|Sodium chloride 0.9% (SC)|This trial looks specifically at the type of hydratation liquid. The patients included will receive SC. The volume, frequency of fluid administration and other severe DKA therapies, such as insulin therapy and electrolytes, are prescribed similarly. The intervention will continue for 48 hours from admission to the ICU with a blood gas control (including base excess) + Blood glucose + ionogram (Na, K, chlorine) + lactates on admission (or H0), H6, H12, H24 and H48.
46038691|NCT00697489|Procedure|correction of POP plus preventive continence procedure|
46038692|NCT00697489|Procedure|POP surgery followed by eventual incontinence procedure|
46038693|NCT02764216|Radiation|Elective mucosal irradiaton|Patients will elective mucosal irradiaton based on nodal station, EBV/HPV status, RPN status etc. IMRT will be adopted.
46038694|NCT00698269|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46038695|NCT00698269|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46038696|NCT00698269|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46038697|NCT01182194|Drug|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
46038698|NCT01182194|Drug|YAZ®|3 mg/0.02 mg Tablets
45342690|NCT05808972|Drug|Ringer lactate (RL)|The intervention will continue for 48 hours from admission to the ICU with a blood gas control (including base excess) + Blood glucose + ionogram (Na, K, chlorine) + lactates on admission (or H0), H6, H12, H24 and H48.
46038699|NCT02761798|Device|Automated Mobile Interactive Audiometer|iPad game
45342691|NCT05808946|Drug|Alpha-Lipoic Acid|1200 mg of ALA daily (given as two 600 mg capsules once daily)
45342692|NCT05808946|Drug|Sepsis Supportive Care|Appropriate IV fluid, Appropriate antibiotic, Vasopressors if needed, Mechanical ventilation if needed
45342693|NCT05808907|Other|Questionnaire|A novel TAVI PROMs questionnaire will be created by us and used for this study.
45342694|NCT05808894|Procedure|extended pancreatic neck transection during laparoscopic pancreaticoduodenectomy|Transect the pancreatic neck at ≥5mm and ≤10mm beyond the left side of the portal vein.
45840268|NCT00706446|Drug|Fluticasone propionate|Either fluticasone propionate diskus 100 mcg 1 puff twice a day or fluticasone propionate aersol in 44 mcg, 110 mcg, 2 puffs twice a day OR fluticasone propionate 220 mcg 2 puffs once a day for one year, depending on which dose the patient was on before the start of the trial.
45840269|NCT00706446|Drug|budesonide|Either budesonide 90 mcg 2 puffs twice a day or 180 mcg 2 puffs twice a day for one year, depending on which dose the patient was on before the start of the trial.
45840270|NCT00706836|Drug|Pregabalin 50mg|One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan
45840271|NCT00706836|Drug|Pregabalin 200 MG|One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan
45840272|NCT00706836|Drug|placebo|One dose of matched oral placebo to be administered one hour prior to fMRI scan
46038700|NCT04133779|Procedure|neurological examination, Kurtzke EDSS, Barthel scale, ecocolor-Doppler|For the subjects diagnosed with MS (group A), who did not need to be in a period of clinical relapse of the disease (at least 30 days from the last clinical relapse), the duration and the form of the disease was indicated (CIS, RR, SP or PP). The Investigator has submitted these subjects to a neurological examination which included the standard neurological examination, the Kurtzke EDSS (Kurtzke Expanded Disability Status Scale) comprising the functional systems of Kurtzke and the Barthel scale. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
45498055|NCT03686046|Other|Exploratory use|Participants will be accompanied by a researcher while wearing the open-source speech processing platform as a hearing aid - adjusted to their needs using a widely accepted Fitting prescription. Using a hand-held controller, they will readjust to their liking as the acoustic conditions change. After returning to the laboratory, they will complete speech perception tests using under their self-selected amplification conditions and respond to a structured interview dealing with perceived performance of the device and its acceptability as a hearing aid during possible field studies.
45840273|NCT00708942|Drug|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Suppository HAL 100 mg for 3-7 hours application
45840274|NCT00708942|Drug|Placebo|Placebo suppository, for 3-7 hours application
45840275|NCT00708942|Drug|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Ointment HAL 100 mg for 5 hours application
45840276|NCT00708942|Drug|Placebo|Placebo ointment for 5 hours application
46038701|NCT04133779|Procedure|neurological evaluation, ecocolor-Doppler|For the subjects affected by OND and ONDi, as in the groups C and D respectively, the Investigator has performed, beside the anamnesis and the physical examination, a specific neurological evaluation which included the compilation of the Barthel scale for the disability evaluation. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for performing the ecocolor-Doppler examination which was performed in blind.
46038702|NCT04133779|Procedure|medical history, vital signs, ecocolor-Doppler|For the healthy subjects (HC) of the group B, the Investigator has solely performed the medical history and a check of the vital signs, reporting the demographic and clinical data of the subjects. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
45342695|NCT05808868|Other|Screening|"The detailed management is not different from that usually practiced in our department.~Each patient benefits from an ENT consultation where an interrogation is carried out concerning the sleep disorders, the answer to the usual questionnaires screening for sleep disorders, a detailed ENT clinical examination including a nasofibroscopy. Each patient then benefits from a sleep recording by ventilatory polygraph."
46038703|NCT04268667|Other|Spinal manipulation|Application of upper cervical spine thrust joint manipulation or application of a full combination of cervical, cervico-thoracic and thoracic spine thrust joint manipulation.
46038704|NCT02764294|Other|Music Group|Music group was listened to a music of their choise with a headset. The music intervention was started about 10-15 minutes before cystoscopy and continued during the whole procedure. Types of music were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
46038705|NCT02764294|Other|Stress Ball Group|"Music group was given stress ball into both their palms about 10-15 minutes before cystoscopy. Participants were instructed to squeeze the balls twice after counting up to five and repeat it until the end of the procedure."
45342696|NCT05808855|Procedure|two-component skin adhesive Glubran Tiss 2®|After subcutaneous stitches with 4-0 Coated VicrylTM Plus PS-2, 3/8 (Ethicon Inc., USA); a two-component skin adhesive, 0.35 mL of Glubran Tiss 2® (GEM S.r.l., Viareggio, Italy), will be applied in the open wound. Before bandaging, subjects will rest for 20 seconds for a polymerization process.
45342697|NCT05808855|Procedure|skin stitched with transcutaneous nylon suture|The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0
45683982|NCT04118517|Other|Using intrinsically labelled bean protein to assess bioavailability of amino acids in healthy adults|The intervention comprises a test meal of intrinsically deuterium labelled stewed common bean with rice. The meal is mixed with a reference protein (Universally labelled 13C-spirulina, 12 mg/kg) and 13C6-Phenylalanine (0.05mg/kg) which is divided into equal mini meals and fed hourly over 8 hours. Protein in the total meal provides 15% of the energy intake with the labelled bean contributing >50% of the protein.
46038706|NCT02764294|Other|DVD Group|DVD group was started to be watched a DVD of their choise about 10-15 minutes before cystoscopy and continued during the whole procedure.
45342698|NCT05808361|Other|exercises|"The complex of therapeutic exercises included exercises in the initial position lying, sitting and standing. In active and static motor modes under the control of saturation, blood pressure, heart rate and respiratory rate.~The complex included breathing exercises with the inclusion of compensatory respiratory muscles, elements of sound and drainage gymnastics, and diaphragmatic breathing. Therapeutic gymnastics was carried out in the form of individual lessons with an exercise therapy instructor, a course of 10 procedures, daily, the duration was 20 minutes."
45342699|NCT05808361|Other|massage|Hardware massage in the electrostatic field with a frequency of 30/60 Hz of the chest area consisted of 10 procedures, daily, the duration of the procedure was 20 minutes.
45342700|NCT05808283|Other|preoperative anemia frequency|patients who applied to the outpatient clinic prospectively for 3 months
45342701|NCT05808140|Drug|Indocyanine Green|Preoperatively, a single dose of intravenous indocyanine green is administered
45342702|NCT05808140|Device|Fluorescence imaging|Use of a spinal endoscopic fluorescent imaging system to assist surgeons in identifying and protecting nerve roots intraoperatively
45342703|NCT05807971|Drug|ATH-063|12.5 and 50 mg Capsules, anticipated dose range to be from 25 to 250 mg.
45342704|NCT05807971|Drug|Placebo|Identical capsule to the drug without the active ingredient.
46038707|NCT04131205|Diagnostic Test|Magnetic Resonance Imaging|We will assess the role of magnetic resonance (MR) in mHE diagnosis with emphasis on multimodal imaging technique
46038708|NCT05381571|Other|Motivating reminiscence physical therapy|The jDome BikeAround system involves participants using a stationary bike while their selected location is displayed in front of them on a domed projector screen using Google Street View. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.
46038709|NCT02764060|Device|Tongue scraper|The patients were instructed to start cleaning the tongue by two pulling strokes along the median sulcus of the tongue, followed by two pulling strokes along the lateral edges of the tongue.
45342705|NCT05807698|Behavioral|laughter therapy|Assigned Interventions Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
45342706|NCT05806567|Drug|Belumosudil|Pharmaceutical form: Tablet; Route of administration: Oral
45342707|NCT05806567|Drug|UGT1A1 victim drug|Pharmaceutical form: Tablet; Route of administration: Oral
45342708|NCT05806567|Drug|P-gp victim drug|Pharmaceutical form: Capsule; Route of administration: Oral
45342709|NCT05806567|Drug|OATP1B1/BCRP victim drug|Pharmaceutical form: Tablet; Route of administration: Oral
45342710|NCT05806450|Behavioral|Intervention|Structured online intervention consists of three weekly sessions of cognitive therapy and psychoeducation about child sleep
45342711|NCT05806450|Other|Active control condition|Psychoeducation about basic sleep structure and sleep hygiene
45683983|NCT04117425|Biological|biological collection|"Blood collection at each trimester of pregnancy, delivery and post partum visit or at medical interruption.~Collection of saliva at each trimester of pregnancy and post partum visit. Collection of cord blood and amniotic fluid at delivery or at medical interruption."
45683984|NCT01929109|Drug|LY2409021|Administered orally
46038710|NCT02764060|Device|Toothbrush|The patients who were assigned to the tooth brush group were taught to perform three forward and backward strokes along the median sulcus and at each lateral part of the tongue.
45342712|NCT05806242|Other|Italian Validation of the Italian Elderly Mobility Scale (EMS-I)|Two physiotherapists independently evaluate the same enrolled patient with the Italian Elderly Mobility Scale (EMS-I) and Barthel Index
45342713|NCT05806073|Procedure|Elective neck dissection|patient underwent elective neck dissection(level I-III) as initial treatment, along with the excision of the primary tumor
45342714|NCT05806073|Procedure|Therapeutic neck dissection|patient underwent Therapeutic neck dissection(level I-V) as initial treatment, along with the excision of the primary tumor
45342715|NCT05802420|Drug|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
45342716|NCT05802407|Drug|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
45342717|NCT05802394|Drug|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
45342718|NCT05798923|Drug|LAM-001|LAM-001 (inhaled sirolimus), in blister pack containing 100 mcg capsule per dose to be administered once per day using a commercially available device (Plastiape RS01 dry powder inhaler Model 7)
45342719|NCT05797272|Procedure|in-utero HSCT|Pregnant women who are diagnosed to have BHFS affected fetuses and opt for continuation of pregnancy will undergo in-utero HSCT.
45342720|NCT05783050|Device|Wei Nasal Jet Tube|The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices.
45683985|NCT01518153|Drug|Fludarabine|40 mg/m^2 by vein on Day -6 to -3.
45683986|NCT01518153|Drug|Melphalan|140 mg/m^2 by vein on Day -2.
46038711|NCT01181726|Drug|Estradiol/Norethindrone acetate|1 mg/0.5 mg Tablets
46038712|NCT01181726|Drug|Activella®|1 mg/0.5 mg Tablets
46038713|NCT01137071|Biological|Monoclonal antibody Hu3S193|"30 mg/m2 of Monoclonal antibody Hu3S193, IV as a single agent every two weeks, in a total of 12 doses (treatment period duration: 23 weeks). Anti-Lewis Y humanized monoclonal antibody designated orphan drug by the FDA on March 09, 2012 for the treatment of ovarian cancer, not yet approved for the orphan designation."
45342721|NCT05783050|Device|Nasal Cannula Oxygen Support|The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices.
45342722|NCT05778786|Device|Acuvue Oasys 1 Day for Astigmatism|CONTROL
45342723|NCT05778786|Device|TRA100/TRA200 series toric contact lens with HEVL-blocking chromophore|TEST
45342724|NCT05776914|Biological|Donor Fecal Microbiota Transplantation|Single fecal microbiota transplantation using 50 gm of freeze-thawed donor stool
45683987|NCT01518153|Drug|Alemtuzumab|50 mg by vein on Day -1.
45683988|NCT01518153|Procedure|Stem Cell Infusion|Reduced intensity stem cell transplant on Day 0.
45840277|NCT00709878|Procedure|Skin Biopsy of Skin Rash Secondary to EGFRI Use|Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.
45342725|NCT05776914|Biological|Autologous Fecal Microbiota Transplantation|Single fecal microbiota transplantation using 50 gm of stool collected from the same individual
45342726|NCT05773456|Other|Sushi and wakame salad|One serving of mixed sushi and wakame salad
45342727|NCT05770349|Procedure|coronary artery bypass grafting|Coronary artery bypass grafting
45342728|NCT05767840|Other|psychological interventions|"mhGap-IG Depression and self-harm module. For participants identified as has having depression, following interventions will be offered depending on nature of the participants.~Khushi Aur Khatoon - for the treatment of depression and anxiety~Learning through Play Plus - 10-session group intervention that integrates parental information about child development and Cognitive Behavior Therapy~Problem management Plus (PM+) - PM+ is for adults suffering from symptoms of common mental health problems , as well as self-identified practical problems.~Cohort identified as having a recent history of self-harm will receive; Culturally Adapted Manual Assisted Problem Solving Intervention (CMAP) - This intervention is a manual-assisted intervention, adapted from a self-help guide called Life After Self-Harm."
45342729|NCT05766163|Device|DaVinci RARP|Assisted-robotic radical prostatectomy.
45342730|NCT05766163|Device|Hugo RARP|Assisted-robotic radical prostatectomy.
46038714|NCT04046419|Other|Turkish validity and reliability|"Explanation of the Turkish version of the scale.~Translating the Turkish version of the scale into English to ensure consistency with the original scale.~First application of scales to participants.~Second application of the scales to the participants.~Statistical analysis and scaling"
46038715|NCT00603681|Drug|Polyethylene glycol 4000|powder for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
46038716|NCT00603681|Drug|Polyethylene glycol 4000 with electrolytes|granules for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
45342731|NCT05766163|Device|Versius RARP|Assisted-robotic radical prostatectomy.
45342732|NCT05764876|Drug|Linezolid Oral Tablet|Oral tablet of linezolid 10mg/kg every 8 hours for 7 days.
45342733|NCT05764876|Drug|Azithromycin Oral Tablet|Oral tablet of azithromycin 30mg/kg maximum 2gr single dose.
45342734|NCT05760690|Procedure|Retro-Auricular Single-Site Endoscopic Thyroidectomy|The strap muscles and the sternocleidomastoid muscle were separated. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified，A lobe of thyroid specimen and central lymph nodes were dissected.
45342735|NCT05760690|Procedure|Transoral Endoscopic Thyroidectomy Vestibular Approach|The patient was placed in a supine position with slight neck extension under nasotracheal intubation. The mouth was garbled with povidone iodine before surgery. Three laparoscopic ports (a 10- to 15-mm port at midline and two 5-mm ports at the lateral junction between the canine and first premolar teeth)were inserted under the lower lip at the oral vestibular area.The strap muscleswere separated in the midline to expose the thyroid and trachea. The recurrent laryngeal nerve (RLN) was identified at the insertion to the larynx, then followed downandparallel tothe trachea inferiorly.
45381993|NCT05462795|Diagnostic Test|Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection|10 cc of blood is collected at three time points: 1) before surgery; 2) 4-6 weeks post surgery; and 3) 6 months post surgery
45840278|NCT00710814|Drug|Leptin|Leptin self-administered subcutaneously at 0.05 mg/kg body weight twice each day
46038717|NCT00699127|Behavioral|Lecture|Lecture of information regarding prematurity, NICU hospitalization, etc.
46038718|NCT02763904|Dietary Supplement|Intensive nutritional counseling|Dietary counseling + energy-dense oral nutritional supplements since admission
46038719|NCT02763904|Other|Dietary counseling|Dietary counseling alone. In case of inadequate energy intake patients will receive oral nutritional supplements since day 8 from admission (after the evaluation of the primary end point)
45342736|NCT05760690|Procedure|Transareola Endoscopic Thyroidectomy|The patient was in supine position. Incision was made inside the right areola and a 10mm puncture device was placed, subcutaneous separation rod was used to separate the space, and a 30° endoscope was introduced, puncture device was placed in a 5mm incision on the left areola, ultrasonic knife free flap was used, subcutaneous separation space was placed in the upper sternal segment, and a 5mm puncture device was placed outside the right areola. The anterior cervical flap was further dissociated to establish a space. The median cervical line was cut to cut off the isthmus of the thyroid, and the tracheal fascia ligament of the thyroid was separated and the nerve was exposed to protect the nerves. Then remove the lobe of thyroid and central lymph nodes
46038720|NCT02853045|Drug|period with drug (trade name) then period with generic|"The list of drugs is detailed in the study description"
46038721|NCT02853045|Drug|period with generic then period with drug (trade name)|"The list of drugs is detailed in the study description"
45342739|NCT05753904|Procedure|Conjoint Tendon Resection|For conjoint tendon resection in the experimental group, the conjoint tendon will be released completely via a transverse incision made at a level 2 cm distal to the coracoid process for the patients assigned the conjoint resection group. Electrocautery will be used for the resection, and the underlying muscular portion of the conjoint tendon will be preserved.
45342740|NCT05749341|Diagnostic Test|Three-Dimensional Poly(dimethylsiloxane) Scaffold|The rest blood samples from patients with and without endometriosis (No. 20 VS 20) would be collected for testing on a Microchip Embedded with Three-Dimensional Poly(dimethylsiloxane) Scaffold.
45342741|NCT05748678|Device|Compression pants|"Patients will have 3D photos taken each week of each buttock and thigh separately. A lymph scanner will also be used for each section to provide a percentage of water content. Weight will also be taken for each visit.~The first 2 weeks the patients will wear their regular pants, and from weeks 3-7 wear the compression pants provided. Weeks 8-9 the patients will be asked to resume to regular pants again"
45498056|NCT03682380|Drug|Seltorexant High Dose|In Part 1, Part 2, and Part 3 (3A and 3C), Seltorexant high dose (either a high dose tablet or two low dose tablets) will be administered orally.
45498057|NCT03682380|Drug|Seltorexant Low Dose|In Part 3 (3B and 3C), Seltorexant low dose will be administered orally.
45498058|NCT03640442|Other|Modified ramped position|This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.
46038722|NCT04131049|Other|High GI calculated by CC (CHGI)|This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
46038723|NCT04131049|Other|Low GI calculated by CC (CLGI)|This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
46038724|NCT04131049|Other|High GI calculated by FII (FHGI)|This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
46038725|NCT04131049|Other|Low GI calculated by FII (FLGI)|This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
46038726|NCT04658368|Procedure|Primary TMR|TMR procedure as part of the primary major limb amputation surgery
46038727|NCT04658368|Procedure|Secondary TMR|TMR procedure subsequent to major limb amputation surgery
45342742|NCT05747118|Behavioral|Physical training|A 12 week supervised training intervention with 1 hour physical training two times a week.
46038728|NCT00603759|Drug|celecoxib|100 mg qid
45342743|NCT05744310|Device|Long term mechanical ventilation support|Patients that choose life prolonging treatment with long term mechanical ventilation support
45342744|NCT05744310|Device|No long term mechanical ventilation support|Patients that decline life prolonging treatment with long term mechanical ventilation support
45342745|NCT05743699|Behavioral|Bright Horizons|Bright Horizons is a brief substance use intervention delivered by Research Program Assistants.
45342746|NCT05743699|Behavioral|Case Management|Placebo condition
45342747|NCT05741190|Device|Pentacam Imaging|Imaging of the corneal surface
45342748|NCT05737576|Drug|HR011408 injection; NovoRapid®|HR011408 injection, administered subcutaneously in dose 1. NovoRapid®, administered subcutaneously in dose 1.
45342749|NCT05737576|Drug|NovoRapid®；HR011408 injection|NovoRapid®, administered subcutaneously in dose 1. HR011408 injection, administered subcutaneously in dose 1.
45342750|NCT05737576|Drug|HR011408 injection; NovoRapid®|HR011408 injection, administered subcutaneously in dose 2. NovoRapid®, administered subcutaneously in dose 2.
45342751|NCT05737576|Drug|NovoRapid®；HR011408 injection|NovoRapid®, administered subcutaneously in dose 2. HR011408 injection, administered subcutaneously in dose 2.
46038729|NCT00603759|Drug|placebo|1 cap qid
46038730|NCT04130815|Drug|Inhaled furosemide|4ml of 10mg/ml solution of furosemide nebulized with small and large droplet sizes and inhaled with different breathing patterns
46038731|NCT02761564|Other|Red blood cell tranfusion|Red blood cell transfusion according to transfusion guidelines.
46038732|NCT02761564|Other|ScvO2 measure|ScvO2 (oximetry) is measured at the distal lumen of the central venous catheter placed in the superior vena cava. Transfusion is performed if ScvO2 is inferior or equal to 65%.
46038733|NCT04256265|Drug|Risdiplam|Risdiplam will be administered orally once daily
46038734|NCT04316624|Drug|C-CAR066|Single infusion of C-CAR066 at a target dose of 1.0-9.0x 10^6 CAR+T cells/kg. Divided into three dose levels: low (1.0-3.0×10^6 CAR+T cells/kg), medium (3.0-6.0×10^6 CAR+T cells/kg) and high (6.0-9.0×10^6 CAR+T cells/kg).
46038735|NCT02763982|Other|Physical evaluation|
46038736|NCT04312061|Drug|oral tramadol|oral tramadol tablet 5o mg given 1 hour before LNG-IUD insertion
46038737|NCT04312061|Drug|Placebo oral tablet|oral placebo tablet given 1 hour before LNG-IUD insertion
46038738|NCT02852811|Other|Group education|Intervention involving two education session with topics common in menopause transition.
46038739|NCT00860743|Drug|Antioxidant cocktail|120 mg of Coenzyme Q10 (orally), 800 mg of Superoxide Dismutase (orally), 400 IU of Vitamin E (orally) before exposure to intermittent hypoxia. Two doses of 1 g of Vitamin C in 50 cc of saline IV (in the vein) before and after exposure to intermittent hypoxia.
46038740|NCT04317170|Other|Music|Participants will be played Frederic Chopin's piano sonatas through a headphone device prior to and during injection of local anesthesia during their routine standard of care dermatologic procedure
46038741|NCT02761720|Other|No Intervention|
46038742|NCT04311593|Diagnostic Test|CD4, CD19, CD38, CD56 and CD11b|measuring CD markers by flowcytometry
45342752|NCT05734560|Drug|D2C7-IT|D2C7-IT will be dosed at 166,075 ng in 36 mL.
45342753|NCT05734560|Drug|2141-V11|2141-V11 will be dosed at 3 mg in 3.5 mL for CED administration. 2141-V11 in the cervical perilymphatic subcutaneous area will be dosed at 2 mg.
45342754|NCT05723458|Combination Product|Cream|A cream containing Turmeric, Black Seeds, Flaxseed, and Medicago Sativa
45342755|NCT05723458|Drug|Placebo|Placebo cream containing vaseline
45342756|NCT05722535|Behavioral|Media Discussion and Planning Tool (MDPT)|An interactive, web-based tool to support within-family media use planning will be developed and shared with families.
45474078|NCT05571384|Behavioral|high intensity body-weight circuit|"Bodyweight and suspension training equipment (TRX® Fit System) with modified movements. Modified Squats: participants will be instructed to hold the handles of the band with arms extended, participants will then lean back in a standing position and perform a squat within a comfortable range of motion while weight is being distributed to the band. Modified Rows: participants will grab the bands with arms and legs extended. They will find a comfortable angle by which to perform a row (pulling the handles to the rib cage) with arms at a 45-degree angle. Modified Push-Ups: perform push-ups on their knees with a flat back and hands underneath their shoulders. They will be instructed to lower their chest towards the ground in a controlled manner and as far as comfort will allow them. Modified Crunches: participants will lay on their back with feet approximately 8-10 inches from their buttocks, and asked to lift their shoulders slightly off the ground."
46038743|NCT01186796|Drug|Fulvestrant|"Secretagogue combinations are assigned in randomized double-blind order within-subject to include the following four conditions:~(i)L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by 5 mL bolus of NS at 1000 h; (ii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH and Ghrelin (both at dose of 0.3 mcg/kg bolus i.v.) at 1000 h; (iii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH (0.3 μg/kg bolus i.v.) at 1000 h; (iv) L-arginine infusion (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by Ghrelin (0.3 μg/kg bolus i.v.) at 1000 h.~**Ghrelin dosage is based on 70 kg subject.Total exposure of Ghrelin will be 42 mcg total dose for 2 subject visits (21 mcg per visit)."
45474079|NCT05571384|Behavioral|traditional exercise intervention (TEI)|150 min a week of moderate aerobic exercise
45474080|NCT03363724|Other|HaGuide version 1.0 software module|
45683989|NCT01518153|Drug|Tacrolimus|0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35.
45342757|NCT05721651|Drug|Fruquintinib+PD-1|"This is a one-arm, prospective, exploratory clinical study, including patients with advanced HER-2-negative gastric cancer (including gastroesophageal junction adenocarcinoma) who received first-line immunization combined with standard chemotherapy (RECIST 1.1 criteria) and were treated with fruquintinib（4mg orally, once daily for 3 wks on/1 wk off ）combined with PD-1 antibody. Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.~PD-1: Nivolumab(360mg IV d1, Q3W）；Sintilimab(200mg IV d1, Q3W）；Tislelizumab(200mg IV d1, Q3W） can be selected;"
45342758|NCT05720988|Drug|Azacitidine|Given SC
45342759|NCT05720988|Biological|Tagraxofusp-erzs|Given IV
46038744|NCT05383131|Drug|HEC585|Mulltiple doses of HEC585 for up to 10 days
46038745|NCT05383131|Drug|Pirfenidone|Mulltiple doses of Pirfenidone for up to 3 days
45683990|NCT01518153|Drug|Methotrexate|5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6.
46038746|NCT05383131|Drug|Nintedanib|Mulltiple doses of Nintedanib for up to 7 days
46038747|NCT02763670|Other|PRETICARD patient care management|"A standardized and specialized network to take care of the severe cardiac insufficiency:~An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~At 1 months, consultations and acts realized by health professionals specialized (one hospital day care)~At 2 months, a therapeutic education program for heart failure patients, approved by the Rhône-Alpes regional public health authorities (week hospital: two days and one night).~At 6 and 18 months, one cardiology consultation~At 12 and 24 months, consultations and acts realized by health professionals specialized (one hospital day care)"
46038748|NCT02763670|Other|"As usual  patient care management"|"Conventional management of heart failure patients is defined in the guide HAS (Haute Autorité de Santé) care course. Patient follow-up, however, is defined by the patient's physician and / or cardiologist at the waning of his hospitalization, according to the usual practice for patients with stage II, III or IV NYHA.~According to these recommendations, the patient should see his cardiologist at least once a year.~Usual practices are:~An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~At 12 months, a cardiologic consultation. For the study, three evaluation points are programmed: two by phone at 6 and 18 months, two by a consultation at 24 months. This interview aimed to evaluate the number of hospitalization, consultations and acts realized by health professionals specialized (the information in the logbook)."
46038749|NCT04119817|Dietary Supplement|Mucosave® capsules|400 mg/day of Mucosave® capsules for a period of 8 weeks, once a day.
45342763|NCT05717504|Device|Implantable Loop Recorder|Patients will be implanted with a loop recorder. Patients will be given the choice of remove the loop recorder after the 12-months follow-up visit or at the end of its battery life (approximately 3 years)
45342764|NCT05717504|Other|Quality of life survey|A quality of life survey will be performed at the end of the follow-up period. The survey will be done over the phone or in person if the follow-up visit is in person.
46038750|NCT04119817|Dietary Supplement|Placebo|400 mg/day of placebo capsules for a period of 8 weeks, once a day.
45342765|NCT05717478|Combination Product|rhBMP-2-BBM|Alveolar socket is filled with granules of bovine bone mineral (1.0-0.25 mm) loaded with human recombinant bone morphogenetic protein 2
45342766|NCT05717478|Device|Bio-Oss+Bio-Gide|Alveolar socket is filled with granules of bovine bone mineral (Bio-Oss 1.0-0.25 mm) and covered with porcine collagen barrier membrane (Bio-Gide)
45342767|NCT05717439|Diagnostic Test|CAPS-5 Assessment|A validated, semi-structured clinical interview to assess core PTSD symptoms
45342768|NCT05717439|Diagnostic Test|Senseye DT|Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.
45342769|NCT05716763|Drug|Tramadol Hydrochloride 5 MG/ML Oral Solution|50mg (10mL) single dose
46038751|NCT01136915|Drug|Iopamidol 370|one time administration for PCI
46038752|NCT01136915|Drug|Iodixanol 320|Iodixanol 320 single injection for percutaneous coronary injection
46038753|NCT02761486|Drug|Aspirin|325mg aspirin per day
45342770|NCT05716763|Drug|Tramadol Hydrochloride 100 MG/ML Oral Solution (Contramal(r))|50mg (20 drops) single dose
46038754|NCT02761486|Drug|Placebo|placebo in matching capsules
45342771|NCT05716503|Device|Negative Pressure Wound Therapy (NPWT)|Patients Will Receive negative pressure wound therapy dressings before skin grafting to prepare the wound bed and after skin grafting.
45342772|NCT05716503|Other|Ordinary dressings with antibiotic ointment and gauze|Patients will Receive once daily dressing with antibiotic ointment and gauze before and after skin grafting.
45342773|NCT05716217|Other|Arm training|Daily arm training program
45342774|NCT05716009|Drug|Dose Escalation -tagraxofusp-erzs|Sequential dose levels of tagraxofusp-erzs dependent on patient response. Fixed doses of gemtuzumab ozogamicin 3mg/m2/day on days 1, 4, and 7 of cycle 1 then on Day 1 or all subsequent cycles for a total of 3 cycles.
45342775|NCT05716009|Drug|Dose Expansion at RP2D -tagraxofusp-erzs|Following the dose escalation portion, the expansion dose and schedule (RP2D) will be determined. Patients will continue to receive fixed doses of gemtuzumab ozogamicin 3mg/m2/day on days 1, 4, and 7 of cycle 1 then on Day 1 or all subsequent cycles for a total of 3 cycles.
45342776|NCT05715736|Drug|APB-R3|APB-R3 is formulated as a sterile solution containing APB-R3 as the active substance administered intravenously.
45342777|NCT05715736|Drug|Placebo|0.90% Normal Saline only
45342778|NCT05710055|Dietary Supplement|Study product A (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
45342779|NCT05710055|Dietary Supplement|Study product B (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
45342780|NCT05710055|Dietary Supplement|Study product C (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
45342781|NCT05710055|Dietary Supplement|Study product D|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
46038755|NCT02617225|Behavioral|DHaAL Intervention|"This group handwashing program is for rural elementary schools to institutionalize the practice of handwashing before mid-day meal consumption and after use of toilets by harnessing the theory of social peer pressure.~DHaAL intervention consists of: (1) capacity building of school teachers to implement group handwashing; (2) installing group handwashing station; (3) generating demand among students to wash hands in group; and (4) establishing systems to sustain handwashing infrastructure and behaviors."
46038756|NCT02617225|Behavioral|DHaAL + CFSS Intervention|In addition to support under DHaAL, several intervention schools receive a more holistic and participatory support that focuses on health, safety, nutrition status, and psychological wellbeing of the children, and thus can also influence handwashing practices (and other WASH facilities). CFSS provides capacity building support and establishes systems to improve school environment, learning outcome, teachers capacity, and physical education for children.
46038757|NCT04268589|Other|virtual reality game|routine
46038758|NCT02882789|Drug|LCB01-0371|Cohort1 & 3: Placebo-controlled, Single ascending dose administration
45342786|NCT05704296|Procedure|Y-composite grafting|Saphenous vein is used as a Y-composite graft during coronary artery bypass grafting
45342787|NCT05704296|Procedure|Aortocoronary grafting|Saphenous vein is used as an aortocoronary graft during coronary artery bypass grafting
45342788|NCT05703841|Drug|JNJ-77242113|JNJ-77242113 will be administered orally as an immediate-release (IR) file-coated tablet.
45342789|NCT05700942|Device|High Dose Intervention-tsDCS|Subjects will receive a high dose tsDCS (2.5mA, 30 mins) LT (4x/week, 5 weeks)
45342790|NCT05700942|Device|Low Dose Intervention-tsDCS|Subjects will receive a low dose tsDCS (2.5mA, 30 mins) LT (4xweek/ 5 weeks)
45342791|NCT05697718|Biological|MSC|a single injection dose i.v.
45342792|NCT05696938|Dietary Supplement|Wonderlab Nicotinamide Drink|Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
45342793|NCT05696938|Dietary Supplement|Ordinary Drink|Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
45342794|NCT05695508|Drug|Teclistamab (Tec)|Subcutaneous administration of Teclistamab
45342795|NCT05695508|Drug|Daratumumab|Subcutaneous administration of Daratumumab
45342796|NCT05695508|Drug|Dexamethasone|administered i.v. or orally
45342797|NCT05695508|Drug|Lenalidomide|Administration oral
45342798|NCT05695508|Drug|Bortezomib|Subcutaneous administration
46038759|NCT02882789|Drug|LCB01-0371 400mg|Cohort 2: Crossover designed administration
46038760|NCT02617381|Other|questionnaire|assessing the sensitivity and specificity of a simple structured questionnaire
45342799|NCT05691062|Device|Titanium Fusion Device|Titanium fusion device will be utilized for one-level lumbar fusion.
45342800|NCT05691062|Device|PEEK Fusion Device|PEEK fusion device will be utilized for one-level lumbar fusion.
46038761|NCT00940017|Drug|anidulafungin and voriconazole|Subjects will be admitted to the clinical research unit on Day 0. Subjects will receive anidulafungin intravenously in a loading dose of 200 mg on Day 1, followed by maintenance doses of 100 mg Q24h on Day 2 and Day 3. Simultaneously, using a separate intravenous access, subjects will receive voriconazole in a loading dose of 6 mg/kg Q12h on Day 1, followed by a maintenance dose of 4 mg/kg Q12h on Day 2, and a 4 mg/kg morning dose on Day 3.
46038762|NCT01129583|Drug|Botulinum Toxin Type A|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
46038763|NCT01129583|Drug|Saline|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
45840279|NCT00710814|Other|Placebo|Sterile water equal in volume to that of the metreleptin dose calculated for each individual self-administered subcutaneously twice each day
45840280|NCT00711828|Drug|Bortezomib|Given IV
45342801|NCT05690113|Procedure|CATS scale|During the inclusion visit (J0), enrolled children will complete the CATS scale as well as the SCARED (Screen for Child Anxiety and Related Disorders). Their parents will also complete the CATS and the SDQ (Strength and Difficulties Questionnaire).
45342802|NCT05689307|Device|SIVA-MVP|Participants receive a small, wearable data recorder, wear it during the day and charge it on the nightstand during sleep for 14x24 hours. The encrypted, recorded segments are uploaded to a server. The server provides a secure environment where the segments are decrypted after receiving the required keys from the patient's SIVA smartphone application. The decrypted segments are then classified as cough by a machine learning algorithm. Participants respond to questions on a smartphone once a day for additional context data. The audio data from the first 24 hours after the patient started wearing the device are used for the validation of the performance of the cough detection algorithm.
45342803|NCT05687383|Device|Safe breastfeeding pillow|A randomized controlled trial
45342804|NCT05682092|Dietary Supplement|WonderLab Collagen Tripeptide Drink|the participant in this arm will use the assigned product 25ml one time, twice a day.
45474081|NCT02525237|Drug|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
45474082|NCT02525237|Drug|S-1|S-1 (40 mg/m2 qd days 1-14 q3w p.o.) until disease progression or intolerable toxicity
45474083|NCT02974647|Drug|Ruxolitinib|
45474084|NCT03369652|Behavioral|Medication review|Conducted by the pharmacist and discussed with hospital physician
45498059|NCT03640442|Other|Ramped position|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
45840281|NCT00711828|Biological|Rituximab|Given IV
45840282|NCT00711828|Drug|Cyclophosphamide|Given PO
45840283|NCT00711828|Drug|Dexamethasone|Given PO
45840284|NCT00711828|Other|Questionnaire Administration|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
45840285|NCT00711828|Other|Quality-of-Life Assessment|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
45840286|NCT00712296|Drug|ASHMI 4|4 capsules orally twice a day
45840287|NCT00712296|Drug|ASHMI 12|12 capsules orally twice a day
45840288|NCT00712296|Drug|Placebo|Placebo 6 capsules twice a day
46038764|NCT01186328|Drug|EZN-3042|Dose will be assigned at study entry. To be given as a 2 hour intravenous infusion on days -5, -2, 8, 15, 22 and 29. Dose levels: L0 (level zero): 1.5 mg/kg, L1: 2.5 mg/kg, L2: 5 mg/kg, L3: 6.5 mg/kg
46038765|NCT01186328|Drug|Cytarabine|"Given intrathecally on day -6. Patients who may have received intrathecal chemotherapy within 7 days of day 0 as part of their prior maintenance chemotherapy (e.g. before the diagnosis of relapse) or as part of the diagnostic workup will not receive this dose of IT cytarabine. If given, dose is defined by age:~1-1.99 years: 30 mg 2-2.99 years: 50 mg~Greater than or equal to 3 years: 70 mg.~Cytarabine is also part of the triple intrathecal therapy given to CNS 3 patients on Days 8, 15, 22 and 29. Dose is defined by age:~- 1.99 years: 16 mg~- 2.99 years: 20 mg~- 8.99 years: 24 mg~Greater than or equal to 9 years: 30 mg"
46038766|NCT01186328|Drug|Doxorubicin|60 mg/m2/day given intravenous infusion (IV) over 15 minutes on day 1.
45342805|NCT05682092|Dietary Supplement|Ordinary Drink|the participant in this arm will use the assigned product 25ml one time, twice a day.
45342806|NCT05679908|Drug|TNX-1900|Patients will spray TNX-1900 once into each nostril.
45342807|NCT05679908|Drug|Placebo Nasal Spray|Patients will spray placebo nasal spray once into each nostril.
45342808|NCT05679648|Diagnostic Test|ultrasonography|studying degree of steatosis
45342809|NCT05678491|Other|Endoscopic mucosal band ligation|The mucosa in 3/4 of the circumference of the gastroesophageal junction and cardia will be treated with mucosal band ligation left in place. This will be done during upper endoscopy in sedation. It is the endoscopic procedure that is being investigated.
45342810|NCT05678465|Procedure|Non-fixation of the mesh|3D-shaped, anatomical, standard, polypropylene mesh without fixation.
45342811|NCT05678465|Procedure|Fixation of the mesh|Glue fixation of lightweight, macroporous, polypropylene mesh.
45342812|NCT05678088|Behavioral|Oropharyngeal Exercises|The participant will practice exercises designed to strengthen the tongue and pharyngeal muscles
45342813|NCT05678088|Behavioral|Sham Exercises|The participant will practice exercises that have no impact on oropharyngeal (e.g., base of the tongue) muscle strength.
45342814|NCT05676177|Diagnostic Test|Ultra Low Dose CT|"Two immediately consecutive scans with either one or two breath-holds~First scan (ULD_DECT_1) 140 kilovolt peak (kVp) - fixed current 10 or 20 milliampere (mA) (if body mass index (BMI)>30), that is 5 or 10 mAs~Second scan (ULD_DECT_2) 80 kVp - fixed current 20 or 40 mA (if BMI>30), that is 10 or 20 mAs"
45342815|NCT05676177|Diagnostic Test|Fat quantification MRI|Dual echo scans, as well as proton density fat fraction (PDFF) scans, will be performed to assess liver fat fraction
45342816|NCT05668039|Procedure|Enhanced external counterpulsation|15 one-hour sessions during 15 weeks of enhanced external counterpulsation.
46038767|NCT01186328|Drug|Prednisone|40 mg/m2/day divided BID or TID given orally on days 1 through 29. For patients who are unable to tolerate prednisone orally, substitute IV methylprednisolone at 80% of the oral prednisone dose.
46038768|NCT01186328|Drug|Vincristine|1.5 mg/m2/day (maximum dose 2 mg) given intravenous push over 1 minute or infusion via mini-bag as per institutional policy on days 1, 8, 15 and 22.
46038769|NCT01186328|Drug|PEG-asparaginase|2500 IU/m2 intramuscular injection on days 2, 9, 16, 23. If available, Erwinia L-asparaginase may be substituted for pegaspargase in patients with clinically significant prior allergies to pegaspargase.
46038770|NCT01186328|Drug|Methotrexate|"Given intrathecally to patients with CNS1 or CNS2 disease at the dose defined by age below on days 15 and 36:~1-1.99 years: 8 mg 2-2.99 years: 10 mg 3-8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg~Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~- 1.99 years: 8 mg~- 2.99 years: 10 mg~- 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg"
46038771|NCT01186328|Drug|Hydrocortisone|"Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~- 1.99 years: 8 mg~- 2.99 years: 10 mg~- 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg"
45474085|NCT01173887|Drug|VCAP/AMP/VECP(mLSG15)|VCAP(Vincristine Sulfate, Cyclophosphamide Hydrate, Doxorubicin Hydrochloride, Prednisolone); AMP(Doxorubicin Hydrochloride, Ranimustine, Prednisolone); VECP(Vindesine Sulfate, Etoposide, Carboplatin, Prednisolone)
46038772|NCT00848497|Drug|Testim®|Testim® 5 g of gel (one tube) containing 50 mg of testosterone once daily. This was the dose given to the patient which he started.
46038773|NCT00848497|Other|Placebo Testim®|Placebo Testim® 5 g of gel (one tube)
46038774|NCT00848497|Drug|Viagra®|Viagra 25mg was the dose given to the patient which he started.
46038775|NCT02763592|Drug|Lidocaine|The aim of this study is to evaluate the impact of 5% lidocaine medicated plaster on allodynic symptoms of localized neuropathic pain after knee surgery
46038776|NCT02763592|Other|placebo plaster|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo. Pain intensity and pain relief, sleep and quality of life and osteoarthritis severity are also assessed.
46038777|NCT04268043|Device|flexible laryngeal airway mask|Ventilation with flexible laryngeal mask airway
46038778|NCT04268043|Device|proseal laryngeal mask airway|Ventilation with proseal laryngeal mask airway
45342823|NCT05657665|Other|Observational measurements of skin tone|Objective and subjective skin tone measurements will be performed.
45342824|NCT05655052|Device|Virtual Reality (VR) Group|"At the beginning of the study, the women who applied for the IUD procedure will be interviewed, and then the following procedures will be applied; Informed consent of all women will be obtained about the study.~An introductory information form will be filled in for women in all three groups.~While the Intervention Group 1 IUD is being applied, a nature video will be watched with Virtual Glasses.~Distraction Cards will be shown while the Intervention Group 2 IUD is being administered.~The Control Group will be given routine IUD application and care."
45342825|NCT05655052|Device|Group using distraction cards|"At the beginning of the study, the women who applied for the IUD procedure will be interviewed, and then the following procedures will be applied; Informed consent of all women will be obtained about the study.~An introductory information form will be filled in for women in all three groups.~While the Intervention Group 1 IUD is being applied, a nature video will be watched with Virtual Glasses.~Distraction Cards will be shown while the Intervention Group 2 IUD is being administered.~The Control Group will be given routine IUD application and care."
45342826|NCT05653427|Drug|Amivantamab|Amivantamab will be administered intravenously.
46038779|NCT02882867|Other|Injuries in Swedish Youth Athletics. The KLUB-study.|
45342828|NCT05651321|Other|Samples materials of basic taste stimuli and enteral nutrition preparations|Samples materials of basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) and six different flavored enteral nutrition preparations.
45342829|NCT05649176|Other|Diet without soy|The diet is designed to moderate the blood glucose response with a similar macronutrient composition as the experimental diet but does not contain soy.
45474086|NCT01173887|Biological|KW-0761|VCAP/AMP/VECP(mLSG15) + KW-0761
45474087|NCT04524052|Drug|DWRX2003|Intramuscularly injection at pre-defined injection sites
45474088|NCT04524052|Drug|Placebo|Intramuscularly injection at pre-defined injection sites
46038780|NCT02763748|Procedure|Laparoscopic endoscopy combined surgery|
46038781|NCT02763748|Procedure|laparoscopic and endoscopic cooperative surgery|
46038782|NCT02763748|Procedure|Single-arch laparoscopic and endoscopic cooperative surgery|
46038783|NCT04268355|Behavioral|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action plan during Week 7. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
46038784|NCT00857623|Drug|AZD2066|Capsule, once daily, 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28.
46038785|NCT00857623|Drug|Placebo|Capsule, once daily
45342830|NCT05649176|Other|Diet with soy|The diet is designed to moderate the blood glucose response with a similar macronutrient composition as the comparator diet but contains soy.
45342831|NCT05648435|Diagnostic Test|Lithium measures|Measurements of lithium levels in blood and urine
46038786|NCT04312607|Diagnostic Test|BCR-ABL gene PCR|peripheral blood sampling for detection of Philadelphia chromosome and flowcytometry for detection of CD26 positive stem cells
46038787|NCT02761096|Device|acupuncture|"Acupuncture, electroacupuncture, and intradermal acupuncture will be performed at every session.~Sterile disposable stainless steel acupuncture needles (0.25 mm × 30 mm) will be used. Acupuncture needles will be inserted bilaterally at the following acupuncture points: LI4, LI11, PC6, ST36, GB39 and LR3, and GV20. If GV20 is close to the surgical site, this acupoint may be excluded.~An electric stimulator will be connected to the handle of each needle at LI4, LI11, ST36, and LR3 and a current of 5 Hz will be applied.~After the needles are removed, intradermal acupuncture needles with tape (DB130A; 0.25 mm × 1.5mm) will be inserted at the same acupoints (LI4, LI11, PC6, ST36, GB39, and LR3 bilaterally, and GV20) and left in place until the next session."
45342832|NCT05647096|Device|NucleoCapture device|100ml NucleoCapture selective DNA adsorber
45342833|NCT05645497|Procedure|Surgery with FACET FIXATION implants|Surgical treatment of degenerative lumbar spinal stenosis by lumbar decompression with FACET FIXATION implants
45342834|NCT05645497|Procedure|Surgery with Pedicle Screw|Surgical treatment of degenerative lumbar spinal stenosis by lumbar decompression with Pedicle Screw
45342835|NCT05645341|Diagnostic Test|screening system for ocular surface malignant tumors|Develop an intelligent screening system for ocular surface malignant tumors, apply it to the mobile terminal for real-world verification and large-scale general screening, and test its effect on assisting doctors in the diagnosis and treatment of rare diseases.
45342836|NCT05642767|Diagnostic Test|culture on cetrimide agar|Samples will be inoculated on cetrimide agar using the plating out technique.
45342837|NCT05642767|Diagnostic Test|Staining with Gram stain|colonies on cetrimide agar will be spread on glass slide and stained by gram stain
45342838|NCT05642767|Diagnostic Test|Antibiotic sensitivity testing|Antibiotic sensitivity testing will be done by disc diffusion method according to CLSI
45342839|NCT05642767|Diagnostic Test|Molecular detection to efflux genes and some virulence genes|Molecular detection to efflux genes and some virulence genes by conventional PCR
45342840|NCT05639829|Behavioral|Time-restricted eating|Restriction of calorie intake to an 8-hour window, with water only fasting in the remaining 16 hours of the 24-hour period
45342841|NCT05635656|Device|Digital symptom mapping and biofeedback treatment|Digital symptom mapping and biofeedback treatment
45381994|NCT05462795|Diagnostic Test|Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer|10 cc of blood is collected at one time point
45381995|NCT05462795|Diagnostic Test|Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease|30 cc of blood is collected at one time point
46038788|NCT02761096|Other|conventional treatment|The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery and includes stabilizing vital signs, pain control, prevention and treatment of infections, and other IV fluid or drug therapy required based on the condition of the patient.
46038789|NCT01185782|Drug|Gonalef® (Follitropin alfa)|Subcutaneous administration of follitropin alfa at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
46038790|NCT01185782|Drug|Purified pituitary gonadotropin (Fertinorm-P®)|Subcutaneous administration of purified pituitary gonadotropin at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
46038791|NCT04119349|Behavioral|Extra counseling|Participants will be given an extra 15-minute prenatal counseling before their first-trimester scan. The extra counseling, which is the intervention in the experimental group, consists of an explanation of all screening techniques for chromosomal abnormalities, including the first trimester combined test, cfDNA testing, invasive testing, and no screening at all.
46038792|NCT02761174|Drug|Brimonidine|Patients receive brimonidine to half of their face, whereas the other half receives no treatment and thereby patients are their own control
46038793|NCT02761174|Other|IPL+air-cooling|IPL+air-cooling are applied to the whole face and the control side thereby only receives IPL+air-cooling
45342842|NCT05633823|Other|Mobile Application Game Training|"Mobile application game training can be used interactively with smartphones and tablets.~A user account will be created after the application is downloaded to the mobile phone/tablet.~After logging into the application, the map of the game will be displayed.~The game will start with the first level of the game consisting of 5 levels.~At each level, first of all, educational videos prepared in the form of short (1-2 minutes) animations will be watched. The number of videos varies between 1 and 3.~After watching the videos, interactive games will be played.~Children are required to complete each stage in the game, and each stage is planned to take approximately 7-10 minutes.~After passing the first level, children will be able to move on to the next level of games and will not be able to move on to the next level until the previous level is finished."
45381996|NCT05460273|Drug|Datopotamab Deruxtecan (Dato-DXd)|Dato-DXd is an antibody-drug conjugate (ADC) that binds to TROP2.
45381997|NCT05457842|Drug|pudexacianinium chloride|Subcutaneous or subareolar (breast cancer) or intradermal or peritumoral (melanoma)
45381998|NCT05454033|Device|JUVÉDERM® VOLITE™|Injection, intradermal
46038794|NCT01129115|Behavioral|Nonexercise control group|Participants randomized to the nonexercise control group will be asked to maintain their current level of physical activity during the 26-week active study period. They will perform outcome assessments and receive the same telephone checks as the exercise group at baseline, 26 and 52 weeks. The purpose of including a non-exercise control group is to allow adequate comparisons with the low, medium and high exercise dose groups on changes in cognitive and physiologic outcome measures.
46038795|NCT01129115|Behavioral|Aerobic Exercise Group 1|The 50% group will perform 75 minutes a week of moderate intensity exercise spread over 3 days.
46038796|NCT01129115|Behavioral|Aerobic Exercise Group 2|The 100% group will perform 150 minutes a week of exercise over 3 - 5 days
46038797|NCT01129115|Behavioral|Aerobic Exercise Group 3|The 150% group will perform 225 minutes a week of exercise over 4 - 5 days.
46038798|NCT04119583|Device|U-shape Automatic Electric Toothbrush|The U-shape Automatic Electric Toothbrush will be applied for 30-45 seconds on the teeth of both arches without the use of toothpaste.
46038799|NCT04119583|Other|Usual home toothbrushing procedure|Usual home toothbrushing procedure either with manual or electric toothbrush without the use of toothpaste.
46038800|NCT04119583|Other|Conventional Electric Toothbrush|The Conventional Electric Toothbrush will be applied for 2 minutes on the teeth of both arches without the use of toothpaste.
46038801|NCT04222738|Dietary Supplement|GINOFF1|The intervention lasted for six weeks and consisted of the administration of powdered ginger extracts in the form of capsules at a dose of 2g/day.
46038802|NCT04119661|Device|Max-i-Probe|Using Max-i-Probe as endodontic needle during syringe irrigation
46038803|NCT04119661|Device|NaviTip|Using NaviTip as endodontic needle during syringe irrigation
46038804|NCT04315922|Diagnostic Test|Microbiome and Plasma Characterisation|Flow Cytometry, Mass-Spectometry, Shotgun-Sequencing
46038805|NCT04312217|Behavioral|Medical clowning|Medical clowning
45342843|NCT05633537|Procedure|pulpectomy procedure and the clinical evaluation|in this study, pulpectomy procedure was performed in a single visit and the root canals were filled with different obturating materials. The clinical follow up evaluation was carried out after three, six and twelve months after pulpectomy procedures. The teeth were clinically evaluated each follow up visit for the following clinical features: absence of spontaneous pain, no tenderness with percussion, no abnormal mobility and absence of swelling & sinus or fistula. If the tooth exhibited any one of above clinical features, the pulpectomy was considered to be a failure (F); otherwise, it was regarded as clinical success (S).
45342844|NCT05633537|Radiation|radiographic evaluation|Radiographic evaluation was performed immediately after teeth restoration (base line radiograph), then after three, six and twelve months. The parallel periapical technique was performed using the rinn (XCP) periapical film holder and a long cone which was mounted to the x-ray tube. The criteria for radiographic success were no evidence of extensive pathologic root resorption, reduction or no change in pre-operative pathologic inter-radicular radiolucency and no evidence of new postoperative pathologic radiolucency.
45474089|NCT02525159|Dietary Supplement|DIM pills|Two pills of BioResponse DIM® 150 are equal to 75 mg of DIM pure
45683991|NCT01518153|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
45840289|NCT00712530|Biological|DermaVir|DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.
45474090|NCT02525159|Other|Placebo Pill|Placebo pills, proportionate by the same provider, vials and pills were the same size, shape and material containing the DIM pills
45474091|NCT03373942|Other|Choroidal thickness measurements with SD-OCT device|
45840290|NCT00712530|Drug|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
45474092|NCT03865823|Procedure|pus sample|A pus sample from the fistula will be taken by the doctor during this first consultation or, failing that, in the operating room before disinfection.
45474093|NCT03369574|Drug|Reslizumab|reslizumab administration
45474094|NCT03278028|Drug|A-101 Topical Solution|A-101 Topical Solution
45683992|NCT01518153|Procedure|Low Dose Donor T-Cells|Planned Donor Lymphocyte Infusion CD3+ cells: 3 * 106 CD3+ cells/kg between Day +56 and +64.
45683993|NCT01518153|Procedure|High Dose Donor T-Cells|Planned Donor Lymphocyte Infusion CD3+ cells: 1 * 107 CD3+ cells/kg between Day +56 and +64.
45683994|NCT01906489|Drug|AKB-6548|Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
46038806|NCT04116307|Dietary Supplement|Polymethylsiloxane|
46038807|NCT04116307|Dietary Supplement|Lactobacillus reuteri|
46038808|NCT02763436|Procedure|physiological-based cord clamping|The cord of the newborn infant is clamped after establishing stable breathing efforts. The suspected time ranges from 2-4 minutes.
46038809|NCT04311359|Drug|Drugs, Generic|All drugs having 19 or more Brain Oedema cases reported to the FAERS database
46038810|NCT02882555|Behavioral|Exercise|6 min running on a motor-driven tredmill in a climate room (18-20°C, humidity <10 mg/l). Tredmill speed and slope are adjusted to increase heart rate to about 80 % of maximum value predicted for age (= 210 - age in years) during the first 2-3 min and pursued until the end of exercise (3-4 min). Heart rate is measured during the whole exercise.
46038811|NCT02882555|Drug|Capsaicin|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
46038812|NCT02882555|Drug|Normal saline|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
45840291|NCT00715104|Biological|Sipuleucel-T with Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
45840292|NCT00715104|Biological|Sipuleucel-T without Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
45840293|NCT00715650|Behavioral|Benefits Counseling|Benefits counseling is designed to improve the quality of life of disability applicants by accomplishing two functions: 1) Providing information concerning what vocational rehabilitation services are available and how they will affect receipt of disability payments, 2) Amplifying applicants' existing motivation to engage in work and related-activities, using a Motivational Interviewing approach.
46038813|NCT02761018|Behavioral|Behavioral: Fitness Tracker|will use a fitness tracker but will not be able to see other participant's data
46038814|NCT02761018|Behavioral|Fitness Tracker|will use a fitness tracker and will be able to see other member's daily and weekly results
46038815|NCT04119427|Device|ultrasonic therapeutic apparatus 1|After installing the disposable treatment head coat, the transplanted kidney was treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Patients were treated twice a week for 6 weeks.
45342845|NCT05628194|Other|Observational/Survery|MSM participants will complete a one-time survey, delivered in an e-format. Survey will be accessible via Meta-based social media platforms (Facebook, Instagram).
45342846|NCT05626166|Drug|Placebo|placebo tablets twice daily
45342847|NCT05626166|Drug|Diosmin|diosmin 600 mg twice daily
45840294|NCT00715650|Behavioral|VA Orientation|VA Orientation is designed to provide the Veteran with information regarding the services available, how to access the services and where the service is located on the VA campus.
45840295|NCT00715728|Device|Intraoperative warming with Bair Hugger forced air system|Intraoperative warming with Bair Hugger forced air system
45342848|NCT05624138|Drug|Placebo tablets|12 cycles of modified FOLFOX-6 regimen (Oxaliplatin, Fluorouracil, calcium leucovorin) with 2 mg placebo tablets
45840296|NCT00715728|Device|Intraoperative warming with Hotdog resistive heating system|Intraoperative warming with Hotdog resistive heating system
45342849|NCT05624138|Drug|Ketotifen Oral Tablet|ketotifen is a potent anti histaminic drug that may prevent oxaliplatin induced peripheral neuropathy and mucositis and will be administered 2 mg daily along with the 12 cycles of modified Folfox-6 regimen
46038816|NCT04119427|Device|ultrasonic therapeutic apparatus 2|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
45381999|NCT05454033|Other|Control|No-treatment control
46038817|NCT02763358|Device|Bite Counter|This study is a 15-week assessment of the possible utility of a wrist-worn device, the Bite Counter, in assisting the weight loss behavior change efforts of overweight and obese individuals. The Bite Counter tracks and analyzes wrist motions to identify those associated with taking bites of food and drinking beverages. It also has a step-counter feature. This study is designed to determine if using the Bite Counter with specific goals to reduce the numbers of bites and increase the numbers of steps will result in those changes.
46038818|NCT00699361|Drug|Pantoprazole|Pantoprazole 160 mg I.V.
46038819|NCT00699361|Drug|Pantoprazole|Pantoprazole 160 mg intravenously (IV)
45382000|NCT05453968|Drug|Berotralstat|Administered orally once daily at a weight-based dose in up to 4 cohorts
46038820|NCT01185704|Drug|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 1 (Day 0 of stimulation period [S0]) until r-hCG day (at least 2 follicles >=17 mm)
46038821|NCT01185704|Drug|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 7 (Day 6 of stimulation period [S6]) until r-hCG day (at least 2 follicles >=19 mm)
45342850|NCT05619796|Procedure|pulpectomy procedure|single visit pulpectomy was performed under strict aseptic conditions by a single operator. Peri-operative evaluation was done using intraoral digital senso. The teeth were anesthetized with 2% mepivacaine with 1:20,000 levonordefrin & isolated using rubber dam. caries was removed using no. 330 round carbide burs in high-speed contra angle headpiece. Access opening was gained & the roof of the pulp chamber was removed. Working length was determined by apex locator, then confirmed by periapical radiograph. Working length will be determined 1 mm shorter than apex. mechanical preparation was done using the tested files according to each group. Then, canals were irrigated with 1% sodium hypochlorite between each file followed by irrigation with normal saline. The root canals were dried using paper points & root canals were filled with Metapex. Intermediate restorative material was placed, and the tooth was restored with a preformed stainless-steel crown in the same appointment.
46038822|NCT01185704|Drug|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day
45342851|NCT05619796|Radiation|Post-operative Cone Beam Computed Tomography|"post-operative CBCT image was taken after completing the procedure with fixed exposure parameters (120 Kv, 5mA and 0.125mm voxel size) using smallest field of view (8D, 8Hcm) to improve spatial resolution. The CBCT images were obtained by using 3D module of On Demand Dental software (version 1.0 (build 1.0.10.7462),× 64 Edition, copyright 2004-2017 Cybermed, Korea and license key 670094709).~The Immediate post-operative CBCT was taken to evaluate the quality of root canal filling by two trained pediatric dentists, blinded to instrumentation technique ."
45342852|NCT05619796|Other|Post-operative pain assessment|The parents of the children were given a questionnaire to record the intensity of postoperative pain at six, twelve, twenty-four and forty-eight hours after the pulpectomy procedure. A nursing officer who was blind to the study groups, had trained all parents on how to record the postoperative pain. The four-point pain intensity scale was used to record postoperative pain (figure 5). This scale categorizes pain as follows: (1) no pain; (2) slight pain; (3) moderate pain; and (4) severe pain. To ensure standardization, the same parent was asked to record the child's pain intensity at all time intervals. To reduce the possibility of the parents failing to record the pain at a given time, the investigator also recorded findings via telephonic conversation with the parents. The children returned to the department two days after the pulpectomy procedure with their completed questionnaire form.
45342853|NCT05610800|Drug|Exenatide 2 milligram (mg) Injection|Exenatide will be purchased commercially as Bydureon for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 14 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
45342854|NCT05610800|Drug|Placebo|Sterile saline (0.9%) will serve as the placebo for exenatide. The placebo will be administered 2 mg subcutaneously using insulin syringes.
45342855|NCT05610800|Drug|Nicotine patch|"Nicotine patches will be purchased commercially and dispensed during clinic visits for one week of use.~Participants who smoke >10 cigarettes/day will receive 21 mg patches for the first 12 weeks, 14 mg patches for week 13, and 7 mg patches for week 14.~Participants who smoke 5-10 cigarettes per day will receive 14 mg patches for the first 12 weeks and 7 mg patches for weeks 13 and 14."
45342856|NCT05610800|Behavioral|Smoking Cessation Counseling|Participants will receive brief individual behavioral smoking cessation counseling that consist of weekly in-person sessions and 2 brief (10-15 min) supportive phone calls (once pre-quit and again 3-days post-quit), spanning the 14-week active treatment phase. Counseling will be provided by master's level clinicians who will receive at least 8 hours of initial training.
45342857|NCT05606159|Dietary Supplement|Bacillus velezensis DSM 33864|1 probiotic capsule to be taken orally once a day, with breakfast, once a day for 8 weeks.
45342858|NCT05606159|Dietary Supplement|Placebo|1 microcrystalline cellulose-containing placebo capsule to be taken orally once a day with breakfast, for 8 weeks.
45474095|NCT03278028|Drug|A-101 Vehicle Solution|A-101 Vehicle Solution
45474096|NCT01176149|Behavioral|SMBG plus intensive education|
45474097|NCT02651740|Drug|Rifaximin|400mg tid* 3d
45840297|NCT00715884|Device|CYPHER® ELITE™ Sirolimus-Eluting Stent System|Drug eluting stent
45840298|NCT00715884|Device|CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System|Drug eluting stent
46038823|NCT01185704|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period [S1]) until r-hCG day
46038824|NCT01128959|Drug|Intravenous Carbamazepine (IV CBZ)|10 mg/mL of IV CBZ dissolved in 250 mg/mL of Captisol® (sulfobutylether-beta-cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by IV infusion every 6 hours.
45342859|NCT05605080|Device|Gelfoam|Use Gelfoam as a hemostatic agent after anal surgery.
45342860|NCT05605080|Other|Bosmin gauze|Use bosmin gauze as a hemostatic agent after anal surgery.
45342861|NCT05601544|Device|ACUVUE OASYS 1-Day|Sphere CONTROL
45342862|NCT05601544|Device|ACUVUE OASYS MAX 1-Day|Sphere TEST
46038825|NCT04222582|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a weak current (2mA direct current) to temporarily excite or inhibit underlying brain regions with small electrodes placed on the scalp.
46038826|NCT04119739|Other|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
46038827|NCT04119739|Drug|Ibuprofen|Oral tablets
46038828|NCT02760706|Device|Computed Tomography scan|
46038829|NCT00625235|Dietary Supplement|VLED followed by a high protein or high carbohydrate diet|
46038830|NCT04206098|Other|Factors associated with Hospital admission for an Acute Exacerbation Chronic Obstructive Pulmonary Disease (AECOPD)|Develop a descriptive predictive model fo factors that influence clinical characteristic of patients that require hospital admission
46038831|NCT02763514|Dietary Supplement|3 g PronovaPure 150:500 EE EU|
46038832|NCT02763514|Dietary Supplement|3 g PronovaPure 500:200 EE EU|
46038833|NCT02763514|Dietary Supplement|3 g Placebo|
46038834|NCT00859573|Drug|Modafinil|400 mg/day
46038835|NCT00859573|Drug|Placebo|inactive substance
45342863|NCT05601544|Device|ACUVUE OASYS Multifocal|Multifocal CONTROL
45342864|NCT05601544|Device|ACUVUE OASYS MAX 1-Day Multifocal|Multifocal TEST
45342865|NCT05601544|Device|ACUVUE OASYS 1-Day for Astigmatism|Toric CONTROL
45342866|NCT05601544|Device|senofilcon A based contact lens (toric) with new UV/HEV filter|Toric TEST
45342867|NCT05597930|Device|Wrist and Thumb orthosis|Custom 3D printed thumb and wrist orthosis
45342868|NCT05596383|Dietary Supplement|Vitamin D 5000 IU|Intervention vitamin D 5000 IU per day, duration six months, dosage form chewable tablet
45342869|NCT05596383|Dietary Supplement|Placebo|Placebo
45342870|NCT05594745|Drug|Lifitegrast Ophthalmic|eyedrop
45342871|NCT05594745|Drug|Systane Free|eyedrop
45342872|NCT05594745|Device|Lipiflow|thermal pulsation
45342873|NCT05592717|Drug|Yutiq|YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye.
45342874|NCT05592561|Other|mental stress task|The stress protocol used for this experiment utilized a cognitive challenge and a previously studied virtual reality active shooter drill (VR-ASD). The cognitive challenge included a modified version of the Stroop challenge (2 min) and mental arithmetic calculations (2 min) presented to the subject via e-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh, PA, USA). Immediately upon completion of the cognitive challenge, the subjects completed the VR-ASD scenario (~2 min) followed by the same cognitive challenge with different questions (another 4 min). The total duration was ~10 min.
45342875|NCT05592548|Device|cold atmospheric plasma|Cold atmospheric plasma will be generated on the skin surface using an electric device
46038836|NCT04312295|Behavioral|ACP-SCT program|The ACP-SCT program was designed to improve nurses' knowledge and competence in discussing ACP with Chronic Kidney Disease patients.
45382006|NCT05449340|Device|BEAUTIFY application|Interview with the coordinating nurse in the postoperative period to install the BEAUTIFY application on the patient's smartphone and to train her to record any Patients will monitor their symptoms weekly. In case of toxicity grade > 2, the nurse will contact the patient for further information.
45382007|NCT05443724|Drug|CVL-231 30 mg|Oral tablets
45382008|NCT05443126|Drug|EP0031|EP0031 is a potent next-generation selective RET-inhibitor (SRI)
45382009|NCT05443035|Procedure|Antimicrobial PDT and Papacarie Deproteinization|Selective removal of carious tissue with curette + antimicrobial PDT (methylene blue 5 Evilux, Color index 52015, Fórmula & Ação + red laser at 660 nm) + deproteinization of enamel with Papacárie DuoTM + restoration.
45382010|NCT05443035|Procedure|Conventional caries treatment|Selective removal of carious tissue with curette + restoration.
45382011|NCT05443035|Procedure|Antimicrobial PDT and 5% NaOCl Deproteinization|Selective removal of carious tissue with curette + application of methylene blue and low-level laser (aPDT) + deproteinization of adjacent enamel with 5% NaOCl + restoration.
45382012|NCT05440201|Other|Amount of anticoagulant Clexane|Change (increase/decrease) the amount of Clexane administered at the dialysis start.
45382013|NCT05438940|Behavioral|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
45382014|NCT05438940|Behavioral|Nutrition Counseling|Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth
45382015|NCT05438940|Behavioral|Survey|Participants will take a survey at baseline and weeks 4,8,12 & 16. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
45342876|NCT05590962|Other|EHR Nudge|Clinicians in Arm 1 (intervention) will receive a EHR notification with option to opt-out for palliative care referral for any eligible high-risk patient, defined by a risk score ≥3 for Stage IV cancer patients and ≥5 for Stage III cancer patients. If the risk score is above 8, they will be scheduled within 2 weeks, and all other patients will be scheduled within 4 weeks. Clinician will have the option to opt-out for any patient by responding to the notification which will be sent to the research coordinator. If the clinician does not respond, the research coordinator will approach patient via telephone, explain the rationale for referral based on a predetermined script, and offer and schedule an outpatient or telemedicine palliative care consultation per patient preference. Follow-up visits will occur at the discretion of the palliative care clinician, usually monthly.
46038837|NCT02760940|Drug|oral liposomal iron|After screening, anemic patients will be treated during 8 weeks with 28mg of oral liposomal iron per day and then the investigators will report data assessing the tolerability and efficacy of oral liposomal iron treatment in these patients.
45342877|NCT05585320|Drug|IMM-1-104|Once-daily, oral tablet administered in 28-day cycles until treatment discontinuation criteria are met
46038838|NCT01136291|Other|physical exercise|"The exercise protocol was done under supervision once a week. Pregnant women have been told to do some exercise three more times during the week unsupervised and may be the protocol of exercises or walk in mild to moderate intensity.~The exercise protocol lasted 50 minutes with 10 minutes of stretching overall, 30 minutes of exercise for muscle strengthening and 10 minutes of relaxation.~These women also received nutrition counseling and prenatal care."
46038839|NCT02763280|Dietary Supplement|Ginseng extract 1g|Ginseng extract 1g, parallel design
46038840|NCT02763280|Dietary Supplement|Ginseng extract 3g|Ginseng extract 3g, parallel design
46038841|NCT02763280|Dietary Supplement|Placebo|placebo, parallel design
46038842|NCT02758444|Dietary Supplement|Micronutrient Powder (MNP) + 15 mg Zn|Children will have the supplement powder added to one meal on study day 1. Absorption of zinc from this meal will be measured using zinc stable isotope techniques.
45342878|NCT05584241|Behavioral|Diagnostic Disclosure Protocol|Personalized disclosure on cognitive test results and research diagnosis, plus post-disclosure dementia risk reduction counseling.
45474098|NCT02651740|Procedure|Fecal microbiota transplantation|Using filtered fresh donor stool, 100-200ml per time throuth enteral nutrition tube for at least one time
46038843|NCT02758444|Dietary Supplement|MNP + 10 mg Zn|Same as above except MNP will contain 10 mg Zn
46038844|NCT02758444|Dietary Supplement|MNP + 5 mg Zn|Same as above except MNP will contain 5 mg Zn
46038845|NCT02758444|Dietary Supplement|MNP without Zn|Same as above except MNP will not contain Zn
46038846|NCT02760784|Behavioral|Early weight bearing|The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
46038847|NCT02695966|Procedure|Whipples Surgery|Whipples Surgery
46038848|NCT01185548|Drug|Tolbutamide|Administered orally
45342879|NCT05584241|Behavioral|Biomarker Disclosure Protocol|Participants receive information about their cognitive test results and research diagnosis just like in the diagnostic disclosure protocol. In addition, participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging. PET is a type of imaging biomarker (Aß-PET and tau PET) for clinical diagnosis of Alzheimer's disease. These actions are followed by post-disclosure dementia risk reduction counseling.
45342880|NCT05580783|Other|Test meal labelled with 54Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 54Fe
45342881|NCT05580783|Other|Test meal labelled with 57Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 57Fe
45342882|NCT05580783|Other|Test meal labelled with 58Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 58Fe
45342883|NCT05580159|Biological|SW-BIC-213|The patient will take a single 25 μg dose mRNA vaccine SW-BIC-213.
45342884|NCT05580159|Biological|SARS-Cov-2 Vaccina(Vero Cell ) Inactivated|The patient will take a third dose of COVID-19 Inactivated vaccine.
45342885|NCT05579938|Dietary Supplement|Enzyme-containing lozenge|A lozenge containing 3 active enzymes
45342886|NCT05579938|Dietary Supplement|Placebo lozenge|Identical placebo lozenge
45342887|NCT05578274|Radiation|SBRT + LDRT|"SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions.~LDRT is planned to irradiate EQD2 (α/β=10) 6 Gy to lesions, considering the scattered dose caused by SBRT.~If there are non-irradiated lesions, they are defined as internal control, and the total dose is limited to 0.5 Gy or less.~CTV allows up to 5 mm margin for GTV, and 3-10mm for PTV margin from CTV. It is planned that the iso-dose line corresponding to the prescribed dose contains at least 90% of PTV and 95% of GTV."
45342888|NCT05578274|Radiation|SBRT alone|"SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions."
45474099|NCT03862547|Diagnostic Test|A peripheral blood sample from the cubital vein|"Evaluation of NGF and Cytokine levels A portion of each blood sample and medium conditioned by PBMC will be used for the enzyme immunoassay of NGF and pro and anti-inflammatory cytokine levels (TNF alfa and IL-10).~Expression analysis of TrKA and p75NTR receptors and intracellular cytokines in PBMCs The remaining part of each blood sample and PBMC of the in vitro experiment will be used for the cytofluorimetric evaluation of the expression of TrKA, p75NTR and the pro and anti-inflammatory cytokines and reactive oxygen species."
45474100|NCT03181503|Drug|CD14152 Dose A|3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
46038849|NCT01185548|Drug|Tasisulam|Administered intravenously
46038850|NCT01128569|Drug|Fluticasone Furoate|FF
46038851|NCT01128569|Drug|FF/Vilanterol (VI; GW642444M)|FF/VI
46038852|NCT01128569|Drug|Placebo|Placebo Inhaler
45342889|NCT05570851|Behavioral|Alcohol Cessation Text Messages|Intervention condition will consist of a text message program designed to promote alcohol cessation tailored to HNC patients and targeted to VA or Civilian populations in addition to usual-care-advice.
46038853|NCT02696044|Drug|triheptanoin|Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.
46038854|NCT05130827|Drug|Plinabulin|40mg flat dose IV infusion, infused over approximately 30 minutes starting between 1-3 hours after stem cell infusion on day 0.
46038855|NCT04582942|Drug|PEG|Patients began to drink 1 L of PEG at 8:00 PM on the day before colonoscopy at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took the remaining 2 L of PEG 4-6 hours before colonoscopy.
46038856|NCT04582942|Drug|PEG+lactulose|On the day before colonoscopy , Patients took 45 mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took 45 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.
46038857|NCT02883179|Drug|lidocaine injection|anhydrous solution
45683995|NCT01906489|Drug|Placebo|Oral Placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
45683996|NCT04620343|Procedure|A: Breathing advice with bio-feedback|Information and breathing advice with biofeedback will serve as an active comparator in this study, and time allowed for IBA and biofeedback in this study will be max 30 min. The teaching will be provided by the attending physician and the test leader. The session will follow a strict checklist. After the laryngoscope has been secured in correct position the patient will be shown his/her larynx on the screen, providing the patient with basic knowledge on laryngeal anatomy and function in a calm atmosphere before the CLE-test. After, the patients will be trained to make any symptoms abate, and a good breathing posture and how to optimally use their breathing muscles.
45840299|NCT00715962|Behavioral|Behavioral intervention|Using social cognitive theory, participants in the walking program group will be encouraged to complete a brief diary about out of bed activities like sitting up for meals of walks to the bathroom. They will be provided with information regarding the importance of being out of bed a praise for any attempts. They will be asked to set out of bed time activity goals daily. The control group will have a diary to track visitors.
45840300|NCT00715962|Other|Walking Intervention|Participants in the walking program will be assisted to walk twice a day by trained staff. Those in the control group will be visited twice a day for friendly visits only
45840301|NCT00715962|Other|Friendly visits|The control group will receive twice daily friendly visits and will be asked to complete a diary each day of the people who visit them in the hospital.
45840302|NCT00716586|Drug|2% dorzolamide|Carbonic anhydrase inhibitor, Trusopt (2% dorzolamide)
45840303|NCT00716742|Drug|bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%|1 drop in eye(s) every evening
45694531|NCT01921829|Drug|Protocolized Diuretic Strategy|"The Protocolized Diuretic Strategy will administer diuretics according to an algorithm based on based on the stepped pharmacologic care arm used by the CARRESS-HF trial investigators. This algorithm targets a relatively aggressive goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide)."
45694532|NCT04416113|Procedure|photobiomodulation and photodynamic therapy|antiviral treatment
45694533|NCT04619615|Other|Asynchronous self-directed digital training|Resident participants will be able to complete the digital training at their own pace.
45840304|NCT00716820|Drug|SUNITINIB MALATE|"SUTENT capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition."
46038858|NCT02883179|Drug|lidocaine-prilocaine cream|topical cream
46038859|NCT02758366|Drug|Doxorubicin|
46038860|NCT05125601|Other|The Parents' Evaluation of Aural/Oral Performance of Children (PEACH)|The Parents' Evaluation of Aural/Oral Performance of Children (PEACH) will be completed once.
46038861|NCT04577326|Drug|cyclophosphamide|A preconditioning regimen of one dose of intravenous (IV) cyclophosphamide 1.5 g/m^2 will be administered 2-7 days before the infusion.
46038862|NCT04577326|Biological|CAR T cells|A single dose of M28z1XXPD1DNR CAR T cells will be instilled into the pleural cavity via a pleural catheter or through an interventional radiology-guided needle. Cohorts of 3 patients will be treated at each dose level, up to a maximum of 3 x 10^7 T cells/kg or until the MTD has been reached.
46038863|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with normal renal function (CLcr >80 mL/min)
45840305|NCT00717054|Drug|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
45840306|NCT00717054|Drug|Scopolamine|Scopolamine transdermal applied to skin behind the ear one hour prior to surgery
45840307|NCT00717288|Drug|Detemir|Detemir dosed at 50% of calculated basal insulin infusion requirements
45840308|NCT00717288|Drug|Detemir|Detemir dosed at 65% of calculated basal insulin infusion requirements
46038864|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with mild renal impairment (CLcr 50 - 80 mL/min)
46038865|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with moderate renal impairment (CLcr 30 - <50 mL/min)
45694534|NCT04619615|Other|Synchronous large group online workshop|Resident participants will complete the digital training platform in real time over the course of a one day, live workshop (4.5 hours of online instruction).
45694535|NCT01904903|Drug|Trastuzumab|HER2 therapy
46038866|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with severe renal impairment (CLcr <30 mL/min and not on hemodialysis)
46038867|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally as 2 single doses of 300 mg (2.4 mL x 125 mg/mL) each in subjects with end stage renal disease undergoing hemodialysis. Washout period of 21 days between each dose
45840309|NCT00717288|Drug|Detemir|Detemir dosed at 80% of calculated basal insulin infusion requirements
45840310|NCT00717912|Other|Experimental sweetener syrup|3 glucose and insulin responses with experimental sweetener syrup : 50 grams of digestible carbohydrate plus fiber
46038868|NCT02758288|Other|New Protocol - BK viremia or BK virus nephropathy|Data collected prospectively that will follow new clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
46038869|NCT02758288|Other|Standard Protocol - BK viremia or BK virus nephropathy|Data collected retrospectively that followed standard clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
45840311|NCT00717912|Other|Classical sweetener syrup|1 glucose and insulin responses with classical sweetener syrup : 50 grams of digestible carbohydrate plus fiber
45474101|NCT03181503|Drug|CD14152 placebo|3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
45694536|NCT01904903|Drug|Pertuzumab|HER2 therapy
45694537|NCT01904903|Drug|Ado Trastuzumab Emtansine|HER2 therapy
45840312|NCT00717912|Other|Classical sugar syrup|3 glucose and insulin responses with classical sugar syrup : 50 grams of digestible carbohydrate plus fiber
45840313|NCT00718302|Device|Antiglide Plate|A plate is placed behind the broken ankle and secured with screws
45840314|NCT00718302|Device|Lateral Plate|A metal plate is placed to the side of the broken ankle and is secured with screws
45840315|NCT00719160|Drug|esomeprazole|2 Interventions with esomeprazole 20 mg twice a day for 9 days vs. a placebo for 9 days while on a high protein diet
45474102|NCT03363568|Behavioral|Adaptive Inhibitory Control Training|Playing computerized stop-signal reaction time tasks that had been modified to increase in difficulty as performance increased.
45474103|NCT03363568|Behavioral|Non-adaptive Inhibitory Control Training|Playing computerized stop-signal reactions time tasks that do not change in difficulty level (non-adaptive).
45498060|NCT03690492|Other|The Box 2.0|Patients in the intervention arm will receive a Box with several devices that is hypothesized to allow for better and earlier detection of complications after cardiac surgery.
45498061|NCT03690414|Drug|Experimental BHVI2|Experimental BHVI2 eye drops
45694538|NCT01921517|Device|Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months at a frequency of 30 Hz and acceleration of 0.3 g.
45694539|NCT01921517|Device|Sham Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months using a sham device.
45840316|NCT00719160|Drug|Placebo|Placebo 20 mg twice a day for 9 days
45840317|NCT00720330|Drug|ropivacaine|10 ml 0.5% ropivacaine plus epinephrine will be injected at T11 and L1 as described above (20 ml total) using intravenous midazolam (1-2 mg) and fentanyl (0.5-1 mcg/kg) for sedation
45840318|NCT00720330|Drug|Lidocaine/Ketamine|Patients will receive a general anesthetic consisting of intravenous induction with lidocaine (1.5 mg/kg), propofol (1.5-2.5 mg/kg), ketamine (0.25 mg/kg), fentanyl (1 mcg/kg), and midazolam (1-2 mg).
45840319|NCT00720330|Other|placebo|placebo
45840320|NCT00721188|Drug|Venofer|Single dose of 7mg intravenous (IV) of iron per kg of body weight for a maximum of 200mg iron IV.
45840321|NCT00721500|Device|etafilcon A|contact lens
45840322|NCT00721500|Device|narafilcon A|contact lens
45840323|NCT00722124|Drug|S-Adenosyl-L-Methionine|800 mg dose per day for 8 weeks
45840324|NCT00722124|Drug|S-Adenosyl-L-Methionine|1600 mg per day for 8 weeks
45840325|NCT00722124|Other|placebo|4 pills (2 in the AM and 2 in the PM) of placebos for 8 weeks
45840326|NCT00722436|Drug|Tranexamic acid|100 mg/kg load, then 10 mg/kg/hr
45840327|NCT00722436|Drug|saline|Placebo
45840328|NCT00724308|Other|Telephone Care Coordination|The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
45694540|NCT01921205|Drug|Lacosamide|"Subjects <30 kg (LCM oral solution): 4 mg/kg - 6 mg/kg BID ( 8mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to <50 kg (LCM oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (LCM tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)"
45694541|NCT01921205|Other|Placebo|"Subjects <30 kg (placebo oral solution): 4 mg/kg - 6 mg/kg BID (8 mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to <50 kg (placebo oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (placebo tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)"
46038870|NCT01128413|Device|Cheetah NICOM® PLRT|Cheetah NICOM® (non-invasive cardiac output monitoring)PLRT (passive leg raise testing) protocol: The patient while in a semi-recumbent position (legs level, torso up 45 degrees) will have 3 minutes of stroke volume and cardiac index monitoring. Following the 3 minutes, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) for 3 minutes of stroke volume and cardiac index monitoring. NICOM® PLRT will be performed within 10 minutes after any fluid bolus in both arms with results blinded to the Routine Care arm. If saline locked or maintenance IV fluid rate, NICOM® PLRT will be performed every 30 minutes in both arms with results blinded to the Routine Care arm.
46038871|NCT01128413|Device|USCOM ® (Ultrasound Cardiac Output Monitor)|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have simultaneous USCOM® stroke volume and cardiac index monitoring. Following the 3 minutes of Cheetah NICOM® PLRT semi-recumbent positioning, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) and have simultaneous USCOM® stroke volume and cardiac index monitoring. USCOM® monitoring will be blinded to the Routine Care arm unless used as part of a provider's routine practice. USCOM® changes in SVI or CI with PLRT will be calculated after the patient leaves the ED.
45342890|NCT05570851|Behavioral|Usual Care|Control condition will consist of a provider-delivered alcohol cessation intervention with usual-care-advice.
45342891|NCT05568953|Biological|Stamaril|Stamaril is licensed by the Health Sciences Authority (HSA), Singapore. The vaccine are manufactured by Sanofi Pasteur and sourced from Sanofi Pasteur's local distributor.
45342892|NCT05568953|Biological|Imojev|Imojev is licensed by the Health Sciences Authority (HSA), Singapore. The vaccine are manufactured by Sanofi Pasteur and sourced from Sanofi Pasteur's local distributor.
45342893|NCT05568953|Biological|Ixiaro|Ixiaro is licensed by the Health Sciences Authority (HSA), Singapore. The Ixiaro vaccines are manufactured by Valneva and sourced from local distributor, Aenon Pharmaceuticals SEA Pte Ltd.
45840329|NCT00724308|Other|Telephone Care Coordination with state Quitline|"The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state Quitline; and (4) follow-up at 2 and 6 months to check the patient's smoking status."
45342894|NCT05564052|Drug|Ibrutinib|Ibrutinib capsules will be administered orally.
45342895|NCT05564052|Drug|Lenalidomide|Lenalidomide capsules will be administered orally.
45342896|NCT05564052|Drug|Rituximab|Rituximab will be administered IV.
45498062|NCT03690414|Drug|Atropine sulfate 0.02% eye drops|Atropine eye drops
45694542|NCT01920893|Drug|Placebo (for dupilumab)|Solution for injection; Subcutaneous injection.
45694543|NCT01920893|Drug|Dupilumab|Solution for injection; Subcutaneous injection.
45840330|NCT00724464|Biological|PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b)|Prior to enrollment in the study, PegIntron was to be administered at a dose of 1.5 μg/kg/week subcutaneously in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
45840331|NCT00724464|Drug|Rebetol (ribavirin)|Prior to enrollment in the study, Rebetol was to be administered at a dose of 800-1200 mg/day orally in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
46038872|NCT01128413|Device|Inferior Vena Cava (IVC) Ultrasound Collapsibility|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have a simultaneous 6-12 second ultrasound recording of their IVC. These recordings will be reviewed later by an ultrasonographer and graded for volume responsiveness. The reviewing ultrasonographer will be blinded to the Cheetah NICOM® PLRT results.
45840332|NCT00726414|Drug|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
46038873|NCT01128413|Behavioral|CURVES Questionnaire|The CURVES (CardiovascUlar Response & Volume Estimation in Shock) Questionnaire consists of multiple provider questions aimed at defining the presumed shock etiology and anticipated responses to interventions. This will be administered to both arms.
46038874|NCT01128413|Biological|Lactate Clearance|Lactate samples will be drawn at time 0, 1, 3, & 6 hours (or at ED departure if before 6 hours). Time 0 lactate will be revealed to the Routine Care arm and subsequent lactates revealed to the Routine Care arm only if serial lactates are part of the provider's routine practice.
45694544|NCT01920893|Drug|Mometasone furoate nasal spray|Nasal spray, 2 actuations in each nostril twice daily.
45840333|NCT00726414|Drug|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
45840334|NCT00727740|Drug|Indomethacin|Indomethacin 100 mg liquid suspension (25 mg/5 ml) which is 20 cc of suspension is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
45694545|NCT01709305|Drug|Metformin|Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily; administered with food.
45694546|NCT01709305|Drug|Sitagliptin|Sitagliptin, 100 mg oral tablet, once daily (QD); administered with or without food
45694547|NCT01709305|Drug|Acarbose|Acarbose, 50 mg oral tablets, TID (150 mg total daily dose); administered with the first bite of each main meal.
45694548|NCT01709305|Drug|Repaglinide|Repaglinide, 0.5 mg and/or 1 mg oral tablets, TID (up to 16 mg daily); administered within 30 minutes of each meal.
46038875|NCT01128413|Biological|500ml Normal Saline Bolus|Patients randomized to the experimental arm and having a >/= 15% change in stroke volume index (SVI) or cardiac index (CI) via Cheetah NICOM®PLRT will be given a 500ml normal saline fluid bolus.
45342897|NCT05564052|Drug|Bortezomib|Bortezomib will be administered either intravenously or subcutaneously.
45342898|NCT05563896|Other|No intervention|No intervention
45342899|NCT05563233|Other|Helfer skin tap technique|Using the Helfer skin tap technique during intramuscular injection to the ventrogluteal region.
45342900|NCT05563233|Device|Shot Blocker|Shot Blocker will be used during intramuscular injection to be applied to the ventrogluteal region.
45474104|NCT03277794|Behavioral|HOP-C|Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.
46038876|NCT01128413|Biological|Clinician Discretion Intravenous Fluid Management|Clinicians caring for patients randomized to the Routine Care arm will within 10 minutes after any fluid bolus be asked to decide via their clinical discretion if they want to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate. If the patient is on a saline lock or maintenance fluid rate, clinicians will be asked every 30 minutes to decide via their clinical discretion to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate.
45342901|NCT05558085|Behavioral|Expanded Food and Nutrition Education Program (EFNEP)|Subjects will participate in nine hands-on EFNEP lessons to teach nutrition, healthy lifestyle choices, physical activity, food preparation, food safety, and food resource management.
45342902|NCT05556200|Drug|Anti-PD-1 monoclonal antibody|Camrelizumab 200 mg, iv, d1, q3W (3 mg/kg if weight <50 kg)
45342903|NCT05556200|Drug|VEGFR2 Tyrosine Kinase Inhibitor|Apatinib 250 mg, po, qd
45342904|NCT05554133|Device|High Resolution Microendoscope (HRME)|The High Resolution Microendoscope (HRME) take pictures of a very small area of the lining of the mouth, about the size of a pencil tip, but at high magnification.
45694549|NCT01709305|Drug|Glimepiride|Glimepiride, 1 mg and/or 2 mg oral tablets, QD (up to 6 mg daily); administered before the first main meal of the day
46038877|NCT02760628|Behavioral|The First Twenty (TF20)|TF20 is an online wellness program for firefighters focused on improving cardiovascular risk factors through behavioral changes.
45342905|NCT05554133|Device|Optical Mapping Scope|The optical mapping scope displays a wide area of the lining of the mouth (about the size of the top of a soda can) by shining different colors of light into the mouth and taking pictures.
45498063|NCT03690414|Combination Product|Combination eye drops|Combination eye drops with experimental BHVI2 plus 0.02% atropine
45694550|NCT01709305|Drug|Gliclazide|Gliclazide, 30 mg oral tablets, QD or BID (30 mg to 120 mg total daily dose); administered with meal.
45694551|NCT01684423|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Subjects were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days.
46038878|NCT02760628|Behavioral|Life Simple 7 (LS7)|LS7 is a wellness program designed and implemented by the American Heart Association focused on improving cardiovascular health.
45342906|NCT05554133|Drug|Proflavine hemisulfate|A coloring substance (a fluorescent dye which glows green in the dark), called proflavine hemisulfate, will be painted on areas of the mouth with a cotton tip applicator to help improve the pictures
45342907|NCT05553691|Drug|SPL026|Intravenous
45342908|NCT05553080|Genetic|Immunohistochemistry|immunohistochemical staining of colorectal carcinoma specimens by anti human fascin antibody.
45342909|NCT05549622|Other|Low-soluble fiber diet|12 older adults (>65y) will be randomized to consume the USDA Guidelines for fiber intake (10g of total fiber/1000 calories), as the low-soluble fiber diet
45342910|NCT05549622|Other|High-soluble fiber diet|12 older adults (>65y) will be randomized to consume 34-35g of total fiber/1000 calories, as the high-soluble fiber diet
45342911|NCT05542212|Device|Transcranial Magenetic Stimulation|Intermittent Theta Burst Stimulation (iTBS) treatment plan: iTBS treatment for the left dlPFC were used for a total of 20 treatments (one time each Monday to Friday, continuous treatment for 4 weeks).
45342912|NCT05542212|Device|Sham Transcranial Magenetic Stimulation|Sham stimulation: The coil angle is set at 90° to the scalp for Sham stimulation of the left dlPFC for a total of 20 treatments (one time each Monday to Friday, continuous treatment for 4 weeks).
46038879|NCT01185080|Drug|AZD8848|Nasal spray solution, intranasal, three times weekly for one month
46038880|NCT01185080|Drug|Placebo|Nasal spray solution, intranasal, three times weekly for one month
46038881|NCT01185080|Drug|AZD8848 and placebo|Nasal spray solution, intranasal, three times weekly for one month
45474105|NCT03277794|Behavioral|Transitional Case Management Only|Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
46038882|NCT00625313|Device|HMY Model YA-60BB IOL|Following phacoemulsification cataract extraction, insertion of a Hoya HMY posterior chamber intraocular lens will be performed.
46038883|NCT02882399|Other|Shortystrap|
46038884|NCT04498156|Other|No intervention|No intervention, observational study
46038885|NCT02760550|Other|No intervention|Participants of all three groups completed a questionnaire.
46038886|NCT01128179|Drug|Lanthanum carbonate|1000 mg in chewable tablets administered three times a day (for a total of 3000 mg/day) for 12 weeks
46038887|NCT01128179|Drug|Placebo|Matching placebo chewable tablets administered 3 times a day for 12 weeks
46038888|NCT02883257|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will include core mandatory modules of key effective components (e.g., behavioural activation, cognitive restructuring) and optional elements to address individual maintaining factors (e.g., coping and social skills training, perfectionism and self-criticism).
46038889|NCT01181102|Drug|edoxaban|
46038890|NCT01181102|Drug|enoxaparin sodium|
46038891|NCT02757820|Device|LMA Classic|Patients will be anesthetized using Classic laryngeal mask airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air.
46038892|NCT02757820|Device|i- gel|Patients will be anesthetized using I-gel LMA with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
46038893|NCT02757820|Device|Air-Q|Patients will be anesthetized using Air-Q_ ILA, with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
46038894|NCT00858637|Drug|MCI-196|Tablets of 3 g to 12 g/day (3 times a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
46038895|NCT00858637|Drug|Placebo of Simvastatin|Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
45474106|NCT03862391|Drug|Analgesics|while patients are in the PACU after general anesthesia, if patients' VAS scores are higher than 3, we will give them 50 mg of deksketoprofen as analgesic.
45498064|NCT02959970|Drug|dapsone gel|Dapsone (ACZONE) 7.5% gel topically once daily.
46038896|NCT00858637|Drug|Simvastatin|Tablets of 10 mg to 40 mg/day (once a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
46038897|NCT00858637|Drug|Placebo of MCI-196|Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
46038898|NCT04221646|Device|BTL-899|Treatment with study device.
46038899|NCT02760394|Device|HBOT|40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.
46038900|NCT04221334|Device|Electric Toothbrush|Electric Toothbrush used to remove dental plaque and resolve gingivitis
46038901|NCT04221334|Other|oral health care application|phone application that shows the user brushing efficiency real time
46038902|NCT00699439|Other|Paper-based asthma flow diagram|If a patient is identified as having an asthma exacerbation by the Bayesian Network, the patients will be randomized to either arm A or B. If in A, the paper-based flow-chart will be printed out to place on the chart.
46038903|NCT04173520|Drug|DDA|Follow up after SVR
46038904|NCT02760316|Drug|AZD9567 10 mg|Oral suspension Multiple doses 5 days of treatment Once daily
46038905|NCT02760316|Drug|AZD9567 20 mg|Oral suspension Multiple doses 5 days of treatment Once daily
46038906|NCT02760316|Drug|AZD9567 40 mg|Oral suspension Multiple doses 5 days of treatment Once daily
46038907|NCT02760316|Drug|AZD9567 80 mg|Oral suspension Multiple doses 5 days of treatment Once daily
46038908|NCT02760316|Drug|Prednisolone 20 mg|Oral Multiple doses 5 days of treatment Once daily
46038909|NCT02760316|Drug|AZD9567 125 mg|Oral Multiple doses 5 days of treatment Once daily
46038910|NCT02760316|Drug|AZD9567 155 mg|Oral Multiple doses 5 days of treatment Once daily
46038911|NCT02760316|Drug|Prednisolone 5 mg|Oral Multiple doses 5 days of treatment Once daily
46038912|NCT02760316|Drug|Prednisolone 40 mg|Oral Multiple doses 5 days of treatment Once daily
46038913|NCT00858403|Drug|Dasatinib|Take tablets of Dasatinib by mouth once a day.
46038914|NCT02760238|Other|Observational|
46038915|NCT02760472|Drug|SMOFlipid|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
46038916|NCT02760472|Drug|Clinoleic|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
46038917|NCT00858247|Dietary Supplement|Vitamin D3|One arm would receive vitamin D3 at a dose of 400 IU by mouth once daily for 12 weeks and the other arm would receive vitamin D3 as a single oral daily dose of 2000 IU for 12 weeks.
46038918|NCT04222348|Drug|Metformin|850-2550 mg every 24h.
46038919|NCT04222348|Drug|Insulin Detemir|Insulin detemir associated or not with rapid insulin analogue (aspart) according to individual glycemic controls.
46038920|NCT04222114|Drug|Catumaxomab|The starting dose of catumaxomab for intra-peritoneal infusion will be 10μg, gradually increased to 20μg, 50μg and 150μg, respectively. From the second cycle, catumaxomab will be changed to 20μg,50μg,150μg on days 1,4 and 8.
46038921|NCT04222114|Drug|The treatment of investigator choice|the localized supportive treatment which has been approved or recommended by local gastric cancer guidance to treat the peritoneal metastasis.
46038922|NCT02757976|Device|Conventional CRT|Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization. Conscious sedation or general anesthesia can be used for the implant procedure. The device will be implanted in a facility that has the capacity to perform coronary sinus venography at the time of implantation. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum (R wave > 7 mV, pacing threshold < 1.5 V at a pulse-width of 0.5 ms). The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches, avoiding the LV apex and scar region identified by pre-implant imaging.
46038923|NCT02757976|Device|LV endocardial CRT|Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame, and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach, using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Special care will be taken to avoid the LV apex and transmural scar identified by pre-implant imaging.
45342913|NCT05540106|Behavioral|Nature Coloring Packet|Coloring packet containing nature scenes
45342914|NCT05540106|Behavioral|Geometric Shape Coloring Packet|Coloring packet containing geometric shapes
45342915|NCT05540106|Behavioral|Activity Book|Pages containing word searches, connect the dots, etc.
45342916|NCT05540106|Behavioral|Blank Paper and Pencil|Blank sheets of paper and a pencil.
45342917|NCT05540080|Device|BTL-899|Treatment with applicators C4/C5 to the BTL-899 system.
45342918|NCT05536154|Drug|Etoposide|Day 1~Day 2: 75mg/m^2
45342919|NCT05536154|Drug|Cytarabine|Day 1~Day 2: 200mg/m^2, q12h
45342920|NCT05536154|Drug|PEG-rhG-CSF|Day 6: 6mg
45342921|NCT05532215|Drug|Misoprostol|The misoprostol tablets to be used in the study will be of the same brand and batch
45342922|NCT05532215|Drug|Oxytocin|The oxytocin ampoules to be used in the study will be of the same brand and batch
45342927|NCT05528497|Other|VR+|Use of a virtual reality helmet during ovocyte retrieval
45342928|NCT05525026|Device|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
45342929|NCT05524766|Device|BTL-785-7 Treatment|Treatment with BTL-785F device (BTL-785-7 applicator) for improvement of overall facial appearance and muscle tone in patients injected with botulinum toxin.
45342930|NCT05524740|Device|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for improvement of the structure of facial muscles.
45342931|NCT05524662|Device|BTL-785-7|Treatment with BTL-785F device (BTL-785-7 applicator) for non-invasive facial rejuvenation.
45382021|NCT05435066|Diagnostic Test|Harbinger Health Test|This trial will be used to test the ability of the Harbinger Health test to detect cancer using blood-based biomarkers in a large cohort of patients with cancer and matched asymptomatic controls. The asymptomatic controls will be followed for up to 2 years
45382022|NCT05426785|Device|1:1 ratio for Treatment Group and Control Group|Randomization also will be performed at latest 10 days after ICD implantation, and the specified device programming settings for the allocated group will be set after successful implantation of the investigational devices.
45382023|NCT05422885|Drug|Dasatinib|Dasatinib 100 mg for 2 consecutive days, every two weeks for 12 weeks
46038924|NCT00838435|Drug|sapropterin dihydrochloride|A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
46038925|NCT02760160|Other|Reconstituted grape powder|To prevent UV-induced skin cancers. Each subject's will have one arm exposed to 6 separate doses of UV (J/m2) [114, 217, 343, 500, 619, 848].
46038926|NCT02757586|Genetic|shRNA|Using shRNA interfered the expression of the gene of CLL
46038927|NCT04111042|Device|stenting|stenting procedure in patients diagnosed malignant large bowel occlusion
45342932|NCT05521568|Diagnostic Test|Index test: Abbott ID NOW STREP A 2|The test under evaluation ('index test') is the rapid molecular test for Group A streptococcus Abbott ID NOW STREP A 2 (performed on saliva samples instead of throat swabs). This test was chosen because of its ease of use and several previous evaluations showing high diagnostic accuracy on throat swabs. The test gives a result after 2 to 6 minutes and will be performed by primary care practitioners participating in the study, in their office, using salivary swabs instead of throat swabs. Investigators will receive one session of specific training prior to the study. Saliva samples will be collected using the cotton swab that comes within the test packages. Index test results will not be used for patient management. Clinicians performing the rapid saliva test will not be blinded to clinical information.
45382024|NCT05422885|Drug|Quercetin|Quercetin 1,250 mg for 2 consecutive days, every two weeks for 12 weeks
45840335|NCT00727740|Drug|Placebo suspension|A placebo suspension which is made by the Investigational Drug Service (IDS) by adding the appropriate dye coloring to normal saline so that the appearance is identical to the indomethacin suspension. The placebo solution is also instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the placebo suspension, the catheter is flushed with 5 cc of normal saline.
45840336|NCT00728910|Drug|Atorvastatin|10 mg QD for 4 weeks
45840337|NCT00728910|Drug|ABT335|135 mg QD added to atorvastatin for 8 weeks
45840338|NCT00728910|Drug|ER Niacin|2000 mg QD added to atorvastatin and ABT335 for 10 weeks
45840339|NCT00729846|Drug|Bevacizumab|Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
45840340|NCT00729846|Device|verteporfin photodynamic therapy reduced fluence|Patients will receive combination verteporfin photodynamic therapy with stand fluence [600mW/cm2].
45840341|NCT00729846|Device|verteporfin photodynamic therapy standardfluence|Patients will receive combination verteporfin with photodynamic therapy at standard fluence [600mw/cm2].
46038928|NCT02757664|Device|Shock Wave Therapy|Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
45840342|NCT00729924|Drug|Raltegravir|400mg orally every 12 hours for 7 days
46038929|NCT02757664|Other|Eccentric Exercises|12 weeks, starting on the same day of the first appliance. The patient will practice the exercises standing on tiptoes and will perform exercises of passive ankle extension (dorsiflexion), three series of 15 repetitions, with the knee stretched, and three series of 15 repetitions with the knee flexed by 20 degrees.
46038930|NCT02757664|Device|Placebo|Placing of the apparatus´ therapeutic head with the support that impedes the shock wave propagation directly on the appliance field; Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
45382026|NCT05418049|Drug|Baclofen|30mg - Supplied as 10mg and 20mg tablets
45382027|NCT05418049|Drug|Memantine|two 10 mg tablets
45382028|NCT05418049|Drug|Roflumilast|250 mcg capsule
45382029|NCT05418049|Drug|Placebo|Placebo pill
45840343|NCT00731094|Behavioral|Expert system-based physical activity counseling|The intervention included 14 mailings to participants that involved completion of physical activity questionnaires printed on forms that were scanned into a computerized expert system program to generate individually-tailored feedback messages and related manuals based on the Stages of Motivational Readiness for Change Model. Newsletters providing additional support and suggestions for increasing physical activity were also part of the mailing program.
46038931|NCT02757508|Dietary Supplement|protein powder supplement|
46038932|NCT02757508|Dietary Supplement|Vitamins/minerals|
46038933|NCT02760082|Other|Qualitative evaluation|
45694552|NCT01684423|Drug|Active comparator|Subjects received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
45342933|NCT05521568|Diagnostic Test|Reference standard test: Composite of culture and PCR-based tests based on a throat swab|"Throat samples will be obtained by use of a double-swab collection-transportation system :~Swab #1 will be used to perform the rapid antigen detection test (see below)~Swab #2 will be held at ambient temperature and sent within 72 hours to Robert Debre Hospital microbiology laboratory. Throat swabs will be used to perform throat cultures using standard techniques (PMID: 22768060). Throat swabs will also be used to perform a PCR specific for Group A streptococcus (PMID: 23465407). Samples with a positive culture and/or a positive PCR test result will be classified as reference-standard-positives. Samples with a negative culture and a negative PCR will be classified as reference-standard-negatives. Investigators will be blinded to clinical data, including the result of the rapid antigen detection test and the rapid saliva test."
45342934|NCT05521568|Diagnostic Test|Comparator test: Rapid antigen detection test (usual care)|As per usual care, all children will undergo a rapid antigen detection test (StreptAtest, Biosynex), using Swab#1 (see above). This rapid antigen detection test is the one used in France and is the only commercial kit that is officially recommended by the National Health Insurance system. It detects Lancefield's Group A antigen, which is specific to Group A Streptococcus. The test will be performed by investigators, during consultation time. Clinicians performing the rapid antigen detection test will not be blinded to clinical information.
46038934|NCT04435678|Diagnostic Test|ALEX² test using the MAX 45k automated laboratory system|"The ALEX² test system is a quantitative in vitro diagnostic (IVD) test for the measurement of allergen specific IgE (sIgE) and a semi-quantitative in vitro diagnostic test for the measurement of total IgE (tIgE) in human serum or plasma (exception EDTA plasma).~The MAX 45k analyzer is intended for an automated in-vitro diagnostics use for quantitative determination of allergen specific Immunoglobulin E and semi-quantitative determination of total IgE. The MAX 45k is suitable for human serum or plasma (Heparin, Citrat, but no EDTA). MAX 45k is intended to be used only in conjunction with RAPTOR SERVER analysis software and ALEX based technology arrays."
46038935|NCT04574362|Drug|Rimegepant|One 75mg orally disintegrating tablet
46038936|NCT04574362|Drug|Placebo|Matching placebo
45342942|NCT05520502|Other|PILATES EXERCISE|12 WEEKS, 3 SESSIONS A WEEK 36 SESSIONS IN A TOTAL OF PLANNED MAT 1 PILATES EXERCISES
45382030|NCT05417126|Biological|Gene Therapy-vMCO-010|The vMCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
45474107|NCT03862391|Drug|Antiemetics|while patients are in the PACU after general anesthesia, if patient' Nausea and vomiting scores are higher than 1, we will give them 4 mg of ondansetron
45474108|NCT03369496|Other|Social capital; Neighborhood environment|Observational study examining the relationship among neighborhood environment, social capital and health among Montreal adults
45694553|NCT01684423|Drug|Rivaroxaban (BAY59-7939) suspension|Subjects aged were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily.
45342943|NCT05519423|Behavioral|Physical Activity Incentive Program|Physical Activity Incentive (PAI) programs, which is a method used in preventive health services, are recommended by a number of public health institutions, including the World Health Organization, thanks to the universal access and high potential of health services. PAI is defined as offering verbal or written advice/guidance to encourage the individual to increase their current level of physical activity.
45342944|NCT05516654|Diagnostic Test|Routine bacteriological cultures|culture of different samples on different culture media as nutrient agar, blood agar, MacConkey agar, EMB agar, TSI
45694554|NCT01709227|Drug|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output <1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output >1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
45840344|NCT00731640|Device|ReSTOR|AcrySof ReSTOR +4 Intraocular Lens (IOL) unilaterally implanted
45840345|NCT00731874|Drug|Tacrolimus|Dosed to achieve target trough concentrations.
46038937|NCT04422730|Behavioral|Psychological evaluation|Patients will be answer to validated test about how they feel. Psychological interview is also possible depending on patients availability. The different answers will be compared between the four groups
45694555|NCT01709227|Procedure|Peritoneal Dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management and discontinuation will be directed by CICU attending and Nephrology service.
45694556|NCT01684033|Device|Opti-Free® PureMoist® MPDS|
45342945|NCT05516654|Diagnostic Test|Identification of the organism and antibiotic sensitivity will be done by VITEK II|Automated identification of the organism and antibiotic sensitivity will be done by VITEK II
45694557|NCT01684033|Device|Biotrue™ MPS|
46038938|NCT04568902|Drug|H3B-6545|H3B-6545 oral tablets.
46038939|NCT04568902|Drug|Antihistamine|Systemic antihistamine oral drug such as fexofenadine, loratadine and cetirizine.
46038940|NCT02757196|Drug|Rituximab plus methylprednisolone|rituximab （1000mg IV day1, week 3, week 17 , and week 19）
46038941|NCT02757196|Drug|methylprednisolone|1mg/kg, oral or IV; begin to reduce at week 4, reduce 8mg every 2 weeks, then another 8 weeks later reduce 2-4mg every 2-4 weeks
45694558|NCT01684033|Device|Habitual contact lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
45474109|NCT03862313|Device|active-rtACS treatment|For the active-rtACS treatment arm, a CE-certificated proprietary class IIa medical device will be used to apply transorbital symmetrical rectangular current pulses in bursts (NextWave® 1.1 system; EBS Technologies GmbH, Germany). The stimulation protocol will be patient-individualized, with a stimulation current strength of 125% of the phosphene threshold recorded during 5Hz stimulation and stimulation frequencies between the individual's EEG alpha frequency and their flicker fusion frequency.
45474110|NCT03862313|Device|sham-rtACS treatment|For the sham-rtACS treatment arm, exactly the same medical device, setup, time schedule, etc. will be used as for the patients of the active-rtACS arm. However, sham-treated patients will receive no actual current stimulation during the therapy sessions.
45840346|NCT00732030|Device|Toric IOL (SN60T3)|Each enrolled eye implanted with the AcrySof Toric Model SN60T3 intraocular lens (IOL) for the treatment of cataract.
46038942|NCT04403698|Drug|Alendronate Effervescent Oral Tablet|At the earliest three months but no later than four months after the last denosumab injection, subjects will be randomized to effervescent alendronate administered for either 24 or 48 weeks
46038943|NCT02759770|Other|no intervention|This is a clinical observational study, no intervention was included.
46038944|NCT02759926|Drug|Denatonium benzoate|
46038945|NCT02759926|Drug|Quinine hydrochloride|
46038946|NCT02759926|Drug|Tap water|
45840347|NCT00732654|Drug|Milk Protein Extract Immunotherapy goal of 4mg/day|Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
45840348|NCT00732654|Drug|Milk Protein Extract Immunotherapy goal of 7mg/day|Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
46038947|NCT02759536|Radiation|Boronophenylalanine and IHNI-based BNCT|Patients will be infused Boronophenylalanine (BPA)-fructose solution intravenously at a dose of 350mg/kg over 90 minutes. After BPA infusion, patients will receive neutron irradiation in IHNI for a certain period of time based on his boron bio-distribution curve and BPA concentration in the blood.
45342946|NCT05516654|Diagnostic Test|Detection of biofilm formation|Detection of Biofilm formation to the collected organism by tissue culture plate method.
46038948|NCT04221256|Drug|Administration of SSRI escitalopram|Participants will be administered 5, 10 or 20mg of SRRI escitalopram prior to paired associative stimulation
46038949|NCT04221256|Behavioral|Paired Associative stimulation|Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.
46038950|NCT04221256|Drug|Administration of Placebo|Participants will be administered a placebo prior to paired associative stimulation
46038951|NCT00838201|Drug|Denosumab|60 mg SC of Denosumab will be administered on study day 1, month 6, month 12, and month 18
46038952|NCT02695888|Behavioral|Risky Driving Prevention|The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
46038953|NCT02695888|Behavioral|Teen Healthy Living|The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
45683997|NCT04620343|Procedure|B: Breathing advice with bio-feedback, Inspiratory muscle training (IMT)|Breathing advise and IMT. The inspiratory muscle training (IMT) will build on the information the patients have obtained during the IBA and biofeedback session. The IMT will focus on training endurance and coordination of the PCA muscle, aiming to reduce fatigue of the abducting capacity of the larynx and to enhance coordination and create a sense of laryngeal control. When performing the IMT sessions, it is of utmost importance that a functional diaphragmatic breathing pattern has been established, and that this breathing pattern is maintained throughout all the IMT sessions. Once the patient has demonstrated that he/she is able to perform breathing according to these principles, the IMT session will follow a detailed protocol while wearing a flexible laryngoscope and settings and techniques are adjusted to ensure max open larynx. The patient will perform IMT training at home as instructed and have video meetings one and three weeks after initial training to observe progress.
45840349|NCT00732654|Drug|Milk Powder Immunotherapy goal dose 2000 mg/day|Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
45840350|NCT00732654|Drug|Milk Powder Immunotherapy goal dose 1000mg/day|Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
45840351|NCT00733278|Device|Copper IUD ( ParaGard Intrauterine Contraceptive Device)|Intraoperative placement of copper IUD at time of C-section
46038954|NCT02757118|Drug|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
46038955|NCT02757118|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
45342947|NCT05516654|Diagnostic Test|Molecular detection by PCR|Molecular detection of Type VI Secretion System genes, capsular serotyping( k1, k2), and FimH genes by PCR.
45342948|NCT05511181|Device|BioWave|The BioWave device is called BioWaveGO. It is a FDA 510(k) cleared high frequency sinusoidal neurostimulator
46038956|NCT04222036|Other|Translating the Questionnaire into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the index and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
45342949|NCT05511181|Device|TENS|The TENS device is called Intensity 5000. It is a FDA 510(k) cleared TENS device
46038957|NCT04222036|Other|Validity|The scale will be applied by face-to-face technique and convergent (moderate-high correlation with optimism measure) and distant (low correlation with depression and anxiety measures) validity will be evaluated.
45342950|NCT05510089|Drug|Etoposide|D1~D2: 75mg/m^2
45342951|NCT05510089|Drug|Cytarabine|D1~D2: 300mg/m^2, q12h
45342952|NCT05510089|Drug|PEG-rhG-CSF|D6: 6mg
45342953|NCT05509972|Device|total knee prosthesis implantation|Total Knee Arthroplasty (TKA) represents a well-established, reliable and successful treatment option for end-stage bicompartmental osteoarthritis or comparable conditions even in young patients compromised by knee pain and limitations of daily living
45342954|NCT05509322|Other|Subsidy for fertility consult|Some participants will receive a subsidy when they purchase the fertility consult.
45342955|NCT05509322|Other|Invitation to purchase fertility consult|Some participants will receive an invitation from their health center to purchase an at-home fertility consult.
45342956|NCT05505552|Dietary Supplement|Vitamin K|1 mg/day phylloquinone (vitamin K1)
46038958|NCT04222036|Other|Reliability|The reliability of the materials will be tested with Cronbach alpha.
46038959|NCT00837967|Drug|Symbicort Turbuhaler|160/4.5μg for 3 days
45840352|NCT00733356|Drug|Vyvanse|Subjects will participate in an open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day) during the week leading up to their final visit. During the study subjects will take their prescribed dose once a day in the morning with breakfast.
45840353|NCT00733512|Device|ReSTOR|Patients were implanted with the AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL) in one or both eyes for treatment of cataract.
46038960|NCT00837967|Drug|Terbutaline Turbuhaler|0.4 mg for 3 days
45840354|NCT00735306|Drug|Avastin|Avastin 10 mg/kg IV on days 1, 15 and 29 Begins the first day of radiation therapy
45840355|NCT00735306|Drug|Tarceva|Daily by mouth per assigned dose, for 5.5 weeks Begins the first day of radiation therapy
45840356|NCT00735306|Radiation|Radiation Therapy|Radiation to the pancreas Monday through Friday for 28 treatments
45840357|NCT00735462|Drug|2.5% imiquimod cream|2.5% imiquimod cream applied daily to wart areas for up to 8 weeks.
46038961|NCT02759614|Drug|Bevacizumab|Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle and Erlotinib orally once daily at 150mg/day
46038962|NCT02759614|Drug|Erlotinib|Erlotinib 150mg, orally once a day
45342957|NCT05505552|Dietary Supplement|Placebo|Placebo capsule once daily
45342958|NCT05505240|Other|Respiratory analysis at cold temperature|Respiratory analysis at an ambient temperature of 18°C
45342959|NCT05505240|Other|Respiratory analysis at room temperature|Respiratory analysis at an ambient temperature of 22°C
45342960|NCT05505240|Other|Respiratory analysis at thermoneutral temperature|Respiratory analysis at an ambient temperature of 28°C
46038963|NCT02757040|Drug|Ibrutinib combined with As2O3|arsenic trioxide combined with ibrutinib in CLL
46038964|NCT02757040|Drug|ibrutinib|ibrutinib
46038965|NCT00635440|Device|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day.The amplitude of the electrical stimuli in the stimulated leg was adjusted to ensure maximum tolerable muscle contraction.
46038966|NCT00635440|Device|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day. Current was increased until the patient could feel a tingling sensation but no muscle contraction was visible or palpable.
46038967|NCT04563130|Behavioral|Cryocompression|Cryocompression will be administered using ice bags and compression socks/ surgical gloves
45342961|NCT05505240|Other|Respiratory analysis at hot temperature|Respiratory analysis at an ambient temperature of 38°C
45342962|NCT05500014|Other|Biofortified potato, not genetically modified|Cooked potato, not genetically modified, with the addition of an acqueous solution of 57FeSO4 (3 mg in total).
45342963|NCT05495932|Diagnostic Test|blood sample|blood sample taken to measure serum mepolizumab concentration at baseline, 1 month and 6 months during study follow-up
46038968|NCT02756884|Biological|LoFU and aADSC|Administration of low frequency ultrasound prior to administration of autologous adipose derived stem cells.
46038969|NCT02756884|Biological|adipose derived stem cells|control arm will only received the adipose derived stem cells.
46038970|NCT02759224|Drug|BRI-1501|
46038971|NCT02759224|Drug|Lafutidine|
46038972|NCT02759224|Drug|Irsogladine maleate|
45342964|NCT05492630|Drug|HEC73077 tablets|"Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
45342965|NCT05492630|Drug|HEC73077 placebo tablets|"Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
45342966|NCT05492383|Device|TAVI|Patients with severe symptomatic AS undergoing Transcatheter aortic valve implantation (TAVI)
45342969|NCT05487820|Device|IscAlert|Insertion of a CO2- and temperature sensor(s) in the reconstructed flap.
45342970|NCT05486975|Biological|CT0591CP Cells|CT0591CP cells
45342971|NCT05479474|Biological|Platelet rich plasma|"Patients will undergo a blood draw (12 tsp) to prepare the PRP infusion. The use of a centrifuge and an Arteriocyte Magellan kit are necessary for the PRP preparation. After injection of local anesthesia, PRP will be injected into each testicle.~On the third month after the testicular PRP procedure, a TESE will be performed~If the procedure is successful a new IVF cycle using the sperm procured from the procedure will be done."
45342972|NCT05478915|Procedure|discectomy of the TMJ disc|removal of the TMJ disc
45342973|NCT05478915|Procedure|TMJ discopexy|fixation of the TMJ disc
45342974|NCT05473520|Drug|Doxycycline|A dose of 100 mg twice daily of doxycycline based on the recommended dose for adults which is commonly used for bacterial infections such as rickettsial infection, lyme disease and pelvic inflammatory disease.
45342975|NCT05473520|Drug|Placebo|Placebo + standard anti-tuberculous treatment
45840358|NCT00735462|Drug|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks
45840359|NCT00735462|Drug|Placebo cream|Placebo cream applied daily to wart areas for up to 8 weeks
45342976|NCT05471947|Drug|15% Trichloroacetic acid + 3% glycolic acid|Treatment of the hand with an over-the-counter chemical peel containing 15% trichloroacetic acid + 3% glycolic acid
45342977|NCT05468567|Diagnostic Test|SPHERE protocol : Spatial hearing performances test|Participants will be instructed to localize a sound emitted in their environment using a virtual reality setup (SPHEAR protocol).
45342978|NCT05468567|Diagnostic Test|French Matrix Test : audiology test of speech in noise perception|Intelligibility threshold is the signal-to-noise ratio (in decibels) for which the subject can repeat 50% of the words heard in a dichotic listening.
45840360|NCT00735618|Other|Guided Relaxation|Following 5 minute questionnaire, 15 minute rest and 5 minute heart rhythm recording, 15 minute relaxation program (listening via headphone to audio recording) to be completed by second heart rhythm recording and same questionnaire. Entire procedure 45-60 minutes.
45840361|NCT00736242|Biological|PEG-IFN alfa-2b|Peginterferon alfa-2b administered subcutaneously at a dose 1.5 ug/kg/week, according to the European Medicines Agency (EMEA)-approved labeling
45840362|NCT00736242|Drug|RBV|Ribavirin administered at a dose of 800-1200 mg/day (on a weight-basis) according to the EMEA-approved labeling
45840363|NCT00736632|Drug|Vitamin D3|Cholecalciferol 4000 units orally daily Calcium carbonate 500 mg orally twice daily
46038973|NCT04221724|Other|Multicomponent physical exercise program|"The intervention consists of a combined multicomponent exercise program (EP) carried out for 6 months that includes strength, balance, flexibility and functional exercises aimed to improve functioning on daily life activities. The EP will be divided into two parts:~The first 3 months the EP aims to restore the physical condition through the multicomponent exercise program. This program will comprise of upper and lower body strengthening exercises, using external weights for 2-3sets of 8-12repetitions at a progressive intensity of 30-50% of 1RM. In addition, static balance and flexibility exercise will be performed.~From 3th to 6th months, the objective will be to improve autonomy through the functional EP. Strength exercises intensity will be increased to 60-70% of 1-RM, 2-3sets of 8-12repetitions. Attention tasks, temporal space dissociation and dynamic balance exercises will be added to increase the intensity in balance exercises. Flexibility and fine handle will be also performed"
46038974|NCT02756806|Device|Picosecond Q-switched laser|Each subject will receive laser treatments with Enlighten laser
46038975|NCT02756728|Biological|BI-505|Treatment with BI-505 10 mg/kg bi-weekly infusion, up to 9 doses over 4 months
46038976|NCT02756728|Other|High dose melphalan|High dose melphalan (HDM)
46038977|NCT02756728|Other|Autologous stem cell transplantation|Autologous stem cell transplantation (ASCT)
45840364|NCT00736632|Drug|Placebo|Placebo pill orally daily Calcium carbonate 500 mg twice daily
45840365|NCT00737178|Device|CuT380A|Comparison of different timing of IUD insertion
46038978|NCT02759068|Behavioral|sounds and odors|presentation of sounds and odors
46038979|NCT00638170|Biological|Cranberry juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
46038980|NCT00638170|Biological|Placebo juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
46038981|NCT00635518|Behavioral|Ten Steps for Healthy Feeding children programme|Ten Steps for Healthy Feeding children
46038982|NCT04586920|Drug|LY3509754|Administered orally
46038983|NCT04586920|Drug|Placebo|Administered orally
46038984|NCT04586920|Drug|Itraconazole|Administered orally
46038985|NCT04586920|Drug|Midazolam|Administered orally
46038986|NCT02756494|Biological|Ischemic Stroke|Ischemic Stroke in Chinese Young Adults
46038987|NCT02758990|Dietary Supplement|Vitamin A|Subjects will be asked to increase vitamin A intake by 8000 International Units per day.
46038988|NCT02758990|Dietary Supplement|Vitamin B6|Subjects will be asked to increase vitamin B6 intake by 50 mg per day.
46038989|NCT02758990|Dietary Supplement|Vitamin C|Subjects will be asked to increase vitamin C intake by 500 mg per day.
46038990|NCT02758990|Dietary Supplement|Nicotinamide|Subjects will be asked to increase Nicotinamide intake by 500 mg per day.
46038991|NCT02758990|Dietary Supplement|Vitamin D3|Subjects will be asked to increase Vitamin D3 intake by 1000 International Units per day.
46038992|NCT02758990|Dietary Supplement|Vitamin E|Subjects will be asked to increase vitamin E intake by 400 International Units per day.
46038993|NCT02758990|Other|Broccoli|Subjects will be asked to increase broccoli intake by 8 fluid ounces (~91 grams) per day.
45342979|NCT05468567|Behavioral|SSQ15 questionnaire of life : (The Speech, Spatial and Other Qualities of Hearing Scale)|The SSQ questionnaire is a clinical subjective scale that allows evaluating of hearing performances in daily life. The questionnaire is divided into 3 main items (A: speech; B: spatial hearing; C: other qualities of hearing) comprising questions with rating scores out of ten.
46038994|NCT02758990|Other|Spinach|Subjects will be asked to increase spinach intake by 8 fluid ounces (~30 grams) per day.
46038995|NCT02758990|Dietary Supplement|Caffeine|Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.
45840366|NCT00738426|Device|Erchonia ML Scanner (MLS)|Red diode low level laser light energy.
45840367|NCT00738426|Device|Sham device|non-therapeutic light energy output
46038996|NCT02758990|Other|Coffee|Subjects will be asked to increase coffee intake by drinking 2 cups (177 mL each) of coffee per day.
46038997|NCT02758990|Device|Axon Eyewear|Subjects will be asked to utilize the therapeutic eyewear when exposed to bright or fluorescent light.
46038998|NCT02758990|Other|Chocolate|Subjects will be asked to increase chocolate intake by eating 57g per day.
46038999|NCT02756416|Device|MRI brain|Standard MRI brain will be performed on each participant to look at brain structure and exclude complications of RCVS (if any).
46039000|NCT02756416|Device|ASL-MRI brain|ASL-MRI is a non-contrast scan used to measure cortical cerebral blood flow (CBF) in areas supplied by major arteries (Circle of Willis).
46039001|NCT02756416|Device|MRA brain|MR angiography scan looks at blood vessels structure. We expect to see constriction (narrowing) of the major arteries in RCVS cases.
46039002|NCT02758912|Drug|оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg|
46039003|NCT02758756|Other|Massage|Treatments will be on a massage table and last up to 75 minutes. We do not specify what will occur during the massage treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. We specify that energy healing techniques not be used, because that is our research comparison condition. We also specify that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
45840368|NCT00739752|Behavioral|Non-Framed-Offered|Subjects received information only and are offered the vaccine.
45342980|NCT05468502|Drug|Human umbilical cord mesenchymal stem cell injection|Different doses of human umbilical cord mesenchymal stem cell injection were infused to the focus of patients with idiopathic pulmonary fibrosis through bronchoscope, and the tolerance of subjects to different doses of human umbilical cord mesenchymal stem cell injection was observed, and the curative effect was preliminarily observed.
45683998|NCT04620343|Procedure|C: Breathing advice with bio-feedback, Speech Therapy|The training period with the speech therapist takes three days, divided into 6 sessions. The training is continued at home, implementing the techniques during physical activity and at rest. The aim of the speech therapy is to help the patients to develop a strategy on how to control his/her larynx during exercise, and to be able to continue exercising without experiencing dramatic EILO incidents. They will be informed that the best approach is to start practicing while performing low to moderate intensity exercise, and then gradually increase the intensity as they become more confident. It will be emphasized that the new breathing technique they are about to adopt will need to be repeated until it becomes adapted as a part of their automated breathing pattern. Patients will be followed up with video meetings one and three weeks after initial training to observe progress.
46039004|NCT02758756|Other|Reiki|Reiki treatments will be provided by Reiki Masters on a massage table and last up to 75 minutes. We will not specify what will occur during the Reiki treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. That being said, we will ask that two specific things be kept to a minimum. The first is that we ask that Swedish massage techniques not be used, because that is our research comparison condition. The second is that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
45840369|NCT00739752|Behavioral|Non-Framed-Recommended|Subjects receive information only and are recommended the vaccine.
45840370|NCT00739752|Behavioral|Gain-Framed-Offered|Subjects receive gain-framed messages and are offered the vaccine.
45840371|NCT00739752|Behavioral|Gain-Framed-Recommended|Subjects receive gain-framed messages and are recommended the vaccine.
45840372|NCT00739752|Behavioral|Loss-Framed-Offered|Subjects receive loss-framed messages and are offered the vaccine.
46039005|NCT02756104|Other|phenotyping Tcells|Collecting blood for analyses of the T cells phenotypes
45342981|NCT05466032|Other|Osteopathic Manual Manipulation (OMM) Curriculum|Osteopathic medical students are enrolled in the OMM curriculum while masters students are not enrolled.
45342982|NCT05465681|Drug|HR20013 for injection；dexamethason|"HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy.~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
45342983|NCT05463601|Drug|Mecapegfilgrastim|Mecapegfilgrastim
45342984|NCT05463601|Drug|dalpiciclib|dalpiciclib
45474111|NCT03363490|Behavioral|Self-management program|Self-management diary will record the frequency of pain, fatigue and injury of knee joint due to knee OA, if patients maintain proper activities, it will be also recorded by an smart phone APP. Patients diet and intake calorie will also be recorded in the diary，which help clinicians to adjust their diet, control their body weight.
46039006|NCT02756104|Other|Supplementation in vitamin D|Supplementation in vitamin D for the patients who are deficient on vitamin D
45342985|NCT05463601|Drug|exemestane, fulvestrant, letrozole, tamoxifen|endocrine therapy
45342986|NCT05462015|Behavioral|elastic-band exercises|The training content includes 5 minutes of warm-up exercise, 20 minutes of elastic-band resistance training, and 10 minutes of cool-down exercise.
45342987|NCT05462015|Behavioral|regular rehabilitation|The training content includes 5-minute warm-up exercise, 20-minute upper and lower extremity muscle strengthening, and 10-minute cool-down exercise
45342988|NCT05457725|Behavioral|rtfMRI-guided Neurofeedback Training|Real-time functional magnetic resonance imaging guided neurofeedback is a non-invasive procedure that provides a visual of participants' current blood oxygen-level-dependent (BOLD) signal in response to a specific task or stimulus in a targeted brain region relative to a control region. Participants use real-time neurofeedback to modulate targeted BOLD signals in their own brain. This technique is used in Study 3. The study does not assess change in a health condition. It evaluates the effect of real-time functional magnetic resonance imaging guided neurofeedback (vs. sham neurofeedback) on trust-related learning in older adults.
45342989|NCT05457725|Behavioral|Sham Control|Sham control is the neurofeedback that was previously recorded from a patient, a non-invasive procedure used as a placebo
45474112|NCT03363490|Behavioral|Neuromuscular exercise therapy|The exercise therapy is basically combined with neuromuscular training and anti resistance training. The aim is to improve the stability of the joints, enhance sensory motor control of lower extremities, reconstruct neutral position line. The exercise mode, frequency, intensity and duration will be adjusted individually through monitoring patient's pain.
45474113|NCT03363490|Behavioral|Health education|All four groups of patient will receive two times of health education in the first week.
45474114|NCT02509702|Behavioral|Connected to Care|10 health educative SMSs' sent once a month 5 SMS-reminders for follow-up appointment sent on days -14, -7, -1 pre- follow-up appointment, and +1, +7 post follow-up appointment
45474115|NCT03859583|Dietary Supplement|Capsaicin|4 tsp of cayenne in a breakfast omelette
46039007|NCT02755870|Other|CNM-Au8|Clene's technology integrates nanotechnology, materials science, plasma conditioning (corona discharge), and hydro-electrocrystallization to create a new nanocatalytic drug class
45474116|NCT03859583|Dietary Supplement|Control|breakfast omelette without cayenne pepper
45474117|NCT03369262|Drug|OBE022|Oral
45474118|NCT03369262|Drug|Placebos|Oral
45474119|NCT03369262|Drug|Atosiban|I.V.
45683999|NCT04620343|Procedure|D: Breathing advice with bio-feedback, IMT and Speech Therapy|All treatments as described above.
46039008|NCT02755870|Other|Placebo|Placebo oral suspension which matches the volume of the experimental nanocrystal suspension
45684000|NCT04620343|Procedure|A: If CLE-test unchanged, additional IMT and Speech Therapy|All treatments as described above.
46039009|NCT02756026|Dietary Supplement|Multiple micronutrient supplement (Nutri-Fem)|Multiple micronutrient supplement (Nutri-Fem) manufactured by Thorne, containing the Recommended Dietary Intake (RDA).
46039010|NCT02755714|Drug|Ipratropium bromide spray|The patient will - or will not - receive Ipratropium bromide spray (MDI) 20 μg given through a plastic spacer two puffs 1 hour before a continuous laryngoscopy exercise test (CLE-test)
46039011|NCT02755792|Behavioral|Calligraphy Training|
45840373|NCT00739752|Behavioral|Loss-Framed-Recommended|Subjects receive loss-framed messages and are recommended the vaccine.
46039012|NCT02755792|Behavioral|iPad Training|
46039013|NCT02758678|Biological|A single 2 ml heparinised peripheral blood sample|A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. Serum separation and Raman spectroscopy analysis:
46039014|NCT02758522|Drug|Once-daily Insulin|Patients will receive NPH insulin in a once-daily regimen. The starting dose is calculate according to body mass index (BMI): 0.3 U/kg for BMI < 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the once-daily regimen will be administered subcutaneously before breakfast. Regular insulin subcutaneously wil be given in three equally divided doses before each meal.
46039015|NCT02758522|Drug|Twice-daily Insulin|Patients receive NPH insulin in twice-daily regimen. The starting dose is calculated according to body mass index (BMI): 0.3 U/kg for BMI < 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will de fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the twice-daily regimen will be administered subcutaneously before breakfast and before dinner. Regular insulin will be given in three equally divided doses before each meal.
45474120|NCT03862235|Diagnostic Test|Cardiovascular Magnetic Resonance|The patients underwent to CMR examination on a Philips Achieve 1.5 device. Images were acquired coupled to the electrocardiogram and during respiratory pause, in four chambers, short axis and long axis of the left ventricle, in the same exact location in different sequences. A gradient - echo sequence (steady-state free precession) was used to evaluate cardiac function (functional evaluation). We will also evaluate T1 weighted images (T1 -relaxation times) and T2, performed sequentially, through spin-echo pulse (black-blood), triple inversion recovery sequence, for the morphological evaluation
45694559|NCT00878644|Procedure|Therapeutic Hypothermia|Participants who are assigned to receive hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32 to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36 to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
45342992|NCT05446766|Behavioral|Self-guided Exposure-based Digital Intervention for Health Anxiety|"An 8-week self-guided internet based CBT intervention which consists of text, exercises, examples and automated support. The format, potentially more accessible compared to traditional ICBT, will be developed with the aim to enhance treatment comprehension and motivation in the participants. The program consists of eight modules (chapters) where the main therapeutic focus is exposure with response prevention.~Participant will be interviewed before the program starts, after 8 weeks and 3 months after the program ends. If in need for technical support, participant will be able to ask for assistance via the program and will then be contacted by a clinician via telephone within a couple of days."
46039016|NCT02758522|Drug|Triple-daily Insulin|Patients receive NPH insulin in a triple-daily regimen. The starting dose was calculated according to body mass index (BMI): 0.3 U/kg for BMI < 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the triple daily regimen will be administered subcutaneously before each meal. Regular insulin will be given in three equally divided doses before each meal.
46039017|NCT02758600|Other|Cycle ergometer exercise rehabilitation protocol|Patients will be submitted to a progressive and moderate exercise protocol with a portable cycle ergometer.
46039018|NCT00942357|Drug|Carboplatin|Given IV
45342995|NCT05442437|Biological|hUCMSCs|Human umbilical cord mesenchymal stem cell preparation, 100ml/ bag, containing 2.5×107 cells, 5.0×107 cells, 1.0 x 108 cells
45694560|NCT00878644|Other|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
46039019|NCT00942357|Drug|Cisplatin|Given IV
46039020|NCT00942357|Radiation|Internal Radiation Therapy|Undergo brachytherapy
46039021|NCT00942357|Drug|Paclitaxel|Given IV
46039022|NCT00942357|Other|Quality-of-Life Assessment|Ancillary studies
46039023|NCT00942357|Radiation|Radiation Therapy|Undergo radiation therapy
46039024|NCT02755402|Device|Xpert HCV Viral load|HCV viral load testing
46039025|NCT02755402|Device|Transient elastography|Evaluation of liver fibrosis
46039026|NCT02755480|Device|Ultralow Dose Thoracic Computed Tomography|Ultralow dose chest CT (uLDCTT) at a radiation dose comparable to 2 chest X-rays
46039027|NCT02755324|Biological|male Schistosoma mansoni cercariae|Viable male Schistosoma mansoni cercariae of the Puerto Rican strain
46039028|NCT02755558|Behavioral|Low energy density|Low energy density milk served
46039029|NCT02755558|Behavioral|High energy density|High energy density milk served
46039030|NCT02755558|Behavioral|Small portion|Small portion of milk served
45342996|NCT05441501|Drug|JNJ-80038114|JNJ-80038114 will be administered.
45342997|NCT05441280|Drug|pimavanserin|pimavanserin 34mg PO at bedtime
45342998|NCT05441280|Other|Placebo|The placebo is a pill that looks like a study medication but has no medication in it
46039031|NCT02755558|Behavioral|Large portion|Large portion of milk served
45342999|NCT05438082|Drug|Antibiotic Prophylaxis|This trial will contain two arms in which patients will be randomized to receive one dose of either Trimethoprim (if < 2 months) or Trimethoprim-Sulfamethoxazole (if ≥ 2 months) or placebo in suspension. Dosing regimen for the active treatment (Trimethoprim) will be based on weight (5mg/kg of Trimethoprim component) with a maximum dosage of 320mg
45343000|NCT05438082|Other|Placebo|The placebo group will receive an equal volume of placebo suspension that has been developed to have the same colour and taste as the antibiotic to preserve blinding.
45343001|NCT05436197|Behavioral|PLAYshop Program|The intervention includes: 1. Educational Training - the 60 min virtual/hybrid workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities with their child. 2. Distribution of Education Resources- Parents will be provided with physical literacy and physical activity printed resources. 3. Material resources -parents will also be provided a bag of inexpensive active play equipment (e.g., ball, bean bag, balloons). 4. Provide Follow-up Support- After the workshop, participants will gain access to an app with an online toolkit including new active play ideas, tips, and equipment they can make at home for active play. Additionally, participants will receive four bi-weekly booster lessons that include key workshop messages, support and encouragement for parents, reflection and check-in questions, and new activities to try with their child.
45343002|NCT05433129|Procedure|Transient hyperemic response|The transient hyperemic response will be tested via carotid compression method. This test will consist of 5 carotid compressions lasting 5 seconds each with a 60 seconds interval between each compression to allow normalization of the CBF to precompression levels, and the total time for this block would be 6 minutes. The ipsilateral common carotid artery will be compressed for this method, and the response of the middle cerebral artery (MCA) blood flow velocity will be assessed using transcranial doppler (TCD) probe (EMS-9D, Delica). The carotid compressions will only be accepted when there is no further decrease in blood flow velocity can be achieved and stable conditions remained during the whole period of the compression. Otherwise, the compression will be terminated and repeated again after 60 seconds. Satisfactory compression is typically considered to result in a reduction in MCA velocity of 50%, at a minimum.
45694561|NCT05312086|Other|MRI|"Performing the muscle MRI requires the cooperation of the child in order to remain lying down and motionless throughout the duration of the MRI, about 45 minutes.~Performing MRI does not require the injection of contrast products or radiopharmaceuticals."
46039032|NCT02752828|Drug|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
46039033|NCT02752828|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
46039034|NCT02752828|Drug|Oral anti-diabetic drugs|"Pharmaceutical form: tablet~Route of administration: oral"
46039035|NCT02755636|Behavioral|PCPHC|Mobile-delivered health risk intervention (HRI), computer-tailored interventions (CTIs), text messages; provider-delivered one-on-one session guided by clinical dashboard
46039036|NCT02755636|Other|Usual care|Primary care as usual
46039037|NCT02753062|Drug|bendamustine, rituximab|subjects will receive rituximab 375mg/m2 on day 1 and bendamustine 120mg/m2 by intravenous infusion on day 2 and 3 in the first cycle. From the 2nd to 6th cycle, rituximab will be administered subcutaneously at a fixed dose of 1400mg and bendamustine 120mg/m2 by intravenous infusion on day 1 following administration of rituximab and day 2.
46039038|NCT00939783|Drug|Dimebon|Tablet for oral administration
46039039|NCT02752594|Biological|probiotic|Probiotic was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
46039040|NCT02752594|Other|placebo|placebo was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
46039041|NCT02755246|Dietary Supplement|Polyamine supplementation|3 months of polyamine supplementation (3 capsules/day)
46039042|NCT02755246|Dietary Supplement|Placebo supplementation|3 months of placebo intake (3 capsules/day)
46039043|NCT04220710|Diagnostic Test|DNA extraction and methylation detection|DNA extraction and methylation detection
45684001|NCT04620343|Procedure|Surgery 1: Supraglottoplasty - full procedure under general anesthesia|Endoscopic supraglottoplasty with carbon dioxide laser and cold steel microlaryngeal instruments. The patient is intubated with an armored laser-tube which is positioned in the posterior midline to protect this area from laser injury. The laryngoscope is positioned into the vallecula and the surgery is visualized through an operation-microscope. CO2-laser beams of 2-4W focused with micro spot is utilized. Releasing incisions are made at the anterior border of both AEFs. The depth of the incisions are limited to the cranial border of the ventricular folds. The cuneiform tubercles including their surrounding mucosa are removed in a circular pattern before the two incisions are adjoined, thus creating a drop shaped excision. Care is taken to avoid scarring. It is recommended to protect the posterior commissure and the piriform sinus with wet tissue cloths. In case of perioperative edema of the laryngeal mucosa, corticosteroids are administrated to prevent laryngeal edema post-operatively.
46039044|NCT00602199|Drug|ABT-510|
46039045|NCT00602199|Other|immunoenzyme technique|
46039046|NCT00602199|Other|immunohistochemistry staining method|
46039047|NCT00602199|Other|laboratory biomarker analysis|
45474121|NCT03862235|Diagnostic Test|Transthoracic echocardiography|The images were collected by the Vivid E9. The patients were submitted to one-dimensional (M-mode), two-dimensional (B-mode), and three-dimensional (three-dimensional) echocardiographic studies. The images obtained were associated with pulsed, continuous and color Doppler.
46039048|NCT00602199|Other|pharmacological study|
46039049|NCT00602199|Procedure|biopsy|
46039050|NCT02755168|Procedure|External Pop-Out Cesarean Section|During fetal head extraction, the obstetrician puts four fingers of his right hand on the lower segment at uterovesical pouch. The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not on directly on the fetal head. While the palmar aspect of the fingers was facing the lower segment they were pushed deep below the fetal head.
45343003|NCT05433129|Procedure|Orthostatic challenge|The orthostatic challenge response will be evaluated by lying-to-sit and sit-to-stand methods 5 times where sitting and standing positions will be held for 3 minutes each for a total block time of 35 minutes. A baseline in lying position will be collected at the start of the block, then the position will be changed from lying to sit for 3 minutes and then position will be changed to standing for another 3 minutes.
45343004|NCT05433129|Procedure|Vascular chemo-reactivity|vascular chemo-reactivity will be assessed by varying CO2 concentrations through slow and fast breathing exercises with Capnostream 35 Portable Respiratory Monitor (Medtronic Canada) to monitor EtCO2 through nose clip. The breathing trials will occur two times and each of them will have fast and slow trials along with an interval of normal breathing. First time, the normal, fast and slow breathing trials will be 2.5 minutes long while the second time, these breathing trials will be 1.5 minutes long. The normal respiratory rate for adults is 12 breaths/minute, the target slow respiratory rate will be 5 breaths/minute and fast respiratory rate will be 25 breaths/minute as set by metronome. It has been shown that the EtCO2 has a 10% increase during hypoventilation and almost 50% decrease during hyperventilation compared to normal breathing.
46039051|NCT02755168|Procedure|Classic technique|During fetal head extraction, the obstetrician puts four fingers of his right hand inside the uterus.
46039052|NCT04221100|Device|Radiograph interpretation for pulmonary abnormalities|"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."
45474122|NCT03276078|Drug|Aclidinium Bromide/Formoterol Fumarate 400/12μg BID|Aclidinium bromide/formoterol fumarate 400/12μg administered by inhalation via the Genuair® multidose dry powder inhaler, twice daily (morning and evening) for 5 days
45474123|NCT01288547|Dietary Supplement|theobromine|700 mg theobromine in gelatin capsules given one time only
45474124|NCT01288547|Dietary Supplement|Caffeine|120 mg caffeine in capsules given one time only
46039053|NCT02754934|Other|Cervical range of motion|Patients will fill out the Neck Disability Index, Visual Analogue Pain Rating Scale and the Self-administered Neck range of motion questionnaire.
46039054|NCT04289740|Behavioral|7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals|Patients assigned to the experimental group will receive 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals over a 12 week period
45474125|NCT01288547|Dietary Supplement|caffeine + theobromine|120 mg caffeine and 700 mg theobromine in capsules given one time only
45474126|NCT01288547|Dietary Supplement|placebo|cellulose in capsules given one time only
45474127|NCT03180801|Biological|adjuvanted FLU-v|Subcutaneous injection in the upper arm with 500mcg of FLU-v as 0.5ml emulsion in 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51
45474128|NCT03180801|Biological|adjuvanted placebo|Subcutaneous injection in the upper arm with 0.5ml emulsion made of 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51
45474129|NCT03180801|Other|Influenza challenge|On day 0, administration with an intranasal sprayer of 1ml of PBS containing 10(7) TCID50 of Influenza A 2009 H1N1 human virus manufactured under GMP in certified Vero cells.
45840374|NCT00740376|Device|Uniglide Mobile Bearing Unicondylar Knee System|Uniglide Mobile Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo)that articulates with a mobile bearing tibial construct comprised of a cobalt chromium molybdenum (CoCrMo)tibial base plate and ultra high molecular weight polyethylene (UHMWPE) meniscal insert. The femoral component has been cleared as part of the fixed bearing version in K050764. The investigational portion of this device is the mobile bearing tibial construct (tibial tray and meniscal insert).
46039055|NCT04289740|Behavioral|a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure plus same number of sessions as the experimental intervention.|The control group will receive a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure. This intervention will have the same number of sessions as the experimental intervention and last anywhere from 60 to 90 minutes, depending on the session.
46039056|NCT02754700|Other|Neuromuscular Training|Standardized, comprehensive neuromuscular training
45343005|NCT05433129|Procedure|Neurovascular coupling|The fourth block will evaluate the neurovascular coupling using Automated Neuropsychological Assessment Metrics (ANAM) General Neuropsychological Screening (GNS) Clinical Toolkit which contains 5 tests explained as follows 1) Standard Continuous Performance test will assess sustained attention, concentration and working memory. 2) Manikin test will assess 3D spatial rotation ability, left-right orientation, problem solving and attention. 3) Pursuit Tracking test will measure the visuo-motor control. 4) Switching test will assess divided attention, mental flexibility, and executive function. 5) Stroop test will assess the processing speed, selective attention, interference, and executive functioning with three trial blocks.
46039057|NCT02754700|Other|Hip Focused ROBUST Training|Biofeedback training focused on the hip extensors
45343006|NCT05432245|Device|Phacoemulsification combined with minimally invasive glaucoma surgery (MIGS)|The cataract surgery will be performed first and if successful, only then will the MINIject be placed into supraciliary space.
46039058|NCT02754700|Other|Knee Focused ROBUST Training|Biofeedback training focused on knee abduction
45684002|NCT04620343|Procedure|Surgery 2: Supraglottoplasty - mini-invasive procedure under general anesthesia|"Endoscopic supraglottoplasty with carbon dioxide laser. The patients are intubated with an armored laser-tube, which is positioned in the posterior midline to protect this area from laser injury. The laryngoscope (Benjamin/Lindholm) is positioned into the vallecula and the surgery is visualized through an operation-microscope. CO2-laser beams of 2-4W focused with micro spot are utilized. Four punctures will be made along the lateral borders of both aryepiglottic folds bilateral, thus creating a row of small punctures parallel to the rim of the aryepiglottic folds. The punctions should not be deeper than the incision in the full procedure (above); i.e. less than 5 millimeter, and care must be taken to avoid heat affecting the nervus recurrens posteriorly. Care is taken to avoid scarring and collateral thermal injury. It is recommended to protect the posterior commissure and the piriform sinus with wet tissue cloths. No antibiotic prophylaxis is administered."
45684003|NCT01517373|Drug|Placebo|Combination of tablets and capsules, a total of 3 pills/dose, administered once daily for 84-days
45684004|NCT01517373|Drug|PF-04937319 10 mg|Combination of tablets and capsules, dose of 10 mg, a total of 3 pills/dose, administered once daily for 84-days
46039059|NCT04220788|Other|Enhanced pharmacist service|Calculation of cardiovascular risk by an online tool for discussion on the CVD risk. Pharmacist will also provide ducation on cardiovascular risk factors and healthy lifestyle. Any prescription adaptation(s), and/or recommendations where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation will be initiated
46039060|NCT04220788|Other|Usual care|Participants in the arm will receive their care from their respective nurse, doctor or pharmacists as per usual clinic practice
46039061|NCT02752360|Procedure|Biodegradable Stenting Anastomoses|Biodegradable Stenting Anastomoses(BSA) is a new method and device which helps to make intestinal anastomosis easily. According to the measurement of intestinal canal diameter, chose an appropriate size of BSA and use the Seromuscular layer Purse-string Suture to stitch with an absorbable line (VCP311, Ethicon, Inc.) away from the end 0.5 to 1.0 cm and not knot temporarily, then open and sterilize intestinal canal fully, and place the BSA into the intestinal canal at appropriate position before tightening knot. Last, the interrupted whole layer inversion suture is used to fix.
45343007|NCT05428956|Procedure|Single Inhalation technique|Single maximal inhalation with breath hold technique
45343008|NCT05428956|Procedure|Tidal inhalation technique|5 tidal breaths technique
45343009|NCT05427162|Drug|Prostacyclin Receptor Agonist|Prostacyclin receptor agonist will be administered.
46039062|NCT02752360|Procedure|Double-layer Hand Sutures|Double-layer Hand Sutures(DHS)is a surgery way that is to use the single-layer continous Hand Sutures,then Lembert to stitch with an absorbable line (VCP311, Ethicon, Inc.).
45474130|NCT03373864|Procedure|Unilateral spinal anesthesia|Unilateral spinal anesthesia with hypobaric local anesthesia allowing a lateralized anesthesia of the fractured limb.
45474131|NCT03373864|Procedure|General anesthesia|General anesthesia following the latest recommendations for elderly patients (SFAR 2017)
45474132|NCT03373786|Drug|RG012|RG012 in 0.3% sodium chloride
45684005|NCT01517373|Drug|PF-04937319 50 mg|Combination of tablets and capsules, dose of 50 mg, a total of 3 pills/dose, administered once daily for 84-days
45840375|NCT00740376|Device|Uniglide Fixed Bearing Unicondylar Knee System|Uniglide Fixed Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo) that articulates with a one piece ultra high molecular weight polyethylene (UHMWPE) tibial bearing (K050764).
45840376|NCT00741156|Drug|Enalaprilat|Enalaprilat will be administered intravenously i.v. 0.005 - 0.01 mg/kg i.v. over 1 minute
45343011|NCT05424679|Behavioral|Safety Planning Intervention|The Safety Planning Intervention is a brief intervention that directly targets suicide risk with demonstrated efficacy and is a recommended best practice for suicide prevention. The intervention aims to provide participants with an individualized set of steps that can be used progressively to both reduce risk and maintain safety when under particular stress. It also includes a series of brief telephone calls to revise the safety plan and facilitate connections to care. The study team will adapt the intervention to target a larger range of mental health distress.
45382031|NCT05415670|Diagnostic Test|Whole-genome Methylation Sequencing(GM-seq)|A Whole-genome Methylation detection method, which can analyze the genome-wide, single base resolution methylation of tissue / blood samples, and is used to develop a benign and malignant classification model for Pulmonary Nodule.
45382032|NCT05414500|Drug|Mogamulizumab|Administered IV
46039063|NCT00635596|Biological|MT110|MT110 treatment as continuous intravenous infusion over at least 28 days with increasing doses
46039064|NCT04527796|Other|Rehabilitation|"During the rehabilitation program a multidisciplinary team, consisting of a pneumologist, dietician, psychologist, social worker and several physiotherapists, coach the cystic fibrosis patients.~The physiotherapists help with autogenic drainage and aerosol therapy (2-3 times/day) and supervise physical activity (5, 1-hour lasting, training sessions/week: swimming 2, Fitness training 2, 1 session of choice). The dietician calculates basal and theoretical energy needs . A carbohydrate-rich snack before exercise, to improve exercise tolerance and a carbohydrate-protein-rich snack afterwards to improve recuperation is provided."
46039065|NCT02752204|Drug|AZD 2014|AZD2014 125mg BD - 2 days on 5 days off in a 28 day cycle
45382033|NCT05414500|Drug|Brentuximab vedotin|Administered IV
46039066|NCT02752204|Drug|Rituximab|Rituximab 375mg/m2 will be administered intravenously on day 1 of a 28 day cycle for a total of 6 cycles.
46039067|NCT04220398|Drug|Neoadjuvant chemotherapy combined with hormone therapy|Docetaxel 75mg/m2 IV (every 3 weeks) +Prednisone 5mg BID orally + HT (Bicalutamide Tablets, 50mg QD orally; Goserelin, 3.6mg, subcutaneous injection, q28d), 4-6 cycles
46039068|NCT04220398|Drug|Neoadjuvant hormone therapy|HT (Bicalutamide Tablets, 50mg QD orally; Goserelin, 3.6mg, subcutaneous injection, q28d), 3-6 cycles
46039069|NCT04220398|Procedure|Radical Prostatectomy (RP)+ extended lymph node dissection|"Radical Prostatectomy (RP)+ extended lymph node dissection: Within three months after neoadjuvant treatment.~Treatment after prostatectomy: There will not have any drug treatment after surgery until disease progression.~Pelvic lymph node dissection is required to reach the level of bilateral iliac artery. If the postoperative pathology indicated positive incisional margin or pelvic lymph node metastasis, pelvic adjuvant radiotherapy should be performed within 3 months after surgery."
46039070|NCT02752126|Radiation|Conventional radiotherapy|Patients will receive standard palliative radiation in dose of 30Gy in 10 fractions, or 20Gy in 5 fractions.
46039071|NCT02752126|Radiation|Esophageal-Sparing Intensity-Modulated Radiotherapy|Patients will receive esophageal-sparing intensity-modulated radiotherapy, of 30Gy in 10 fractions or 20Gy in 5 fractions.
45343012|NCT05424679|Behavioral|Caring Contacts|Caring contacts is a cost and time effective suicide prevention intervention. It traditionally utilizes letters and postcards that are sent to an individual to remind them that they are cared about and that they matter. Research suggests that this intervention significantly reduces the likelihood of dying by suicide and suicide attempt over a person's lifetime. This intervention has the potential to reach more individuals at risk in the community. In this study, the research team will allow participants to receive these messages by postcard/MMS and will adapt the intervention to align with cultural values.
45343013|NCT05418283|Behavioral|Exercise|1 hour of aerobic exercise will be applied 3 days a week for 12 weeks.
45343014|NCT05414448|Device|ENDOCUFF|ENDOCUFF mucousal exposure device will be used during withdrawal process of the colonoscopy.
45343015|NCT05410561|Behavioral|Enhanced Usual Care (EUC)|EUC will comprise one session of brief psychoeducation and referral information to alcohol use disorder (AUD) treatment.
45343016|NCT05410561|Behavioral|TeleTx intervention|TeleTx will consist of an initial session and then 8 ~counseling sessions.
45343017|NCT05410249|Diagnostic Test|Serum IL10 By ELISA|measurement Of IL10 by ELISA
45343018|NCT05410249|Diagnostic Test|SNP -3279 A/C of FOXP3|Genotyping of -6054 del/ATT will be performed using the real-time polymerase chain reaction.
46039072|NCT04220944|Drug|Sintilimab|Sintilimab (200mg) was administered intravenously over 30-60 min every 3 weeks.
45343019|NCT05410249|Diagnostic Test|SNP-924 A/G Of FOXP3|Genotyping of -924 A/G polymorphisms was performed using the real-time polymerase chain reaction.
45343020|NCT05408091|Drug|TRL345, a human monoclonal antibody|Anti-Human Cytomegalovirus (HCMV) IgG1κ Human Monoclonal Antibody
45343021|NCT05397379|Drug|HEC96719|Oral tablets
45343022|NCT05397379|Drug|Placebo|Comparator
45343023|NCT05396014|Behavioral|Enhanced Self-Care (ESC)|The Enhanced Self-Care intervention will be comprised of educational modules on evidence-based cognitive-behavioral self-management skills for pain. These modules will be provided digitally for self-administration over a period of 12 weeks. There will be no therapist associated with the delivery of these educational materials; however, after the first four modules, email or text messages will be used to make personalized recommendations for accessing additional modules based upon identified problems from the baseline assessment. Additionally, the walking program module will utilize Fitbit step tracking to allow participants to monitor their walking progress.
45343024|NCT05396014|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT is a form of cognitive behavioral therapy that is well established for the treatment of chronic pain. The goal of ACT is to build psychological flexibility thereby interrupting pain avoidance behavior patterns. Participants randomized to ACT will take part in 12 sessions over the course of 12 weeks. Sessions will be delivered as a combination of 4 remote face-to-face visits with a therapist and 8 therapist-supported online sessions (self-directed online modules supported by provider coaching). Online sessions will focus on helping participants accept pain, connect with negative thoughts and emotions, develop mindfulness and identify and commit to values and goals that are important to them. During face-to-face sessions with the therapist, participants will be encouraged to share their experience of skills practice and mastery, provide examples of skill use at home, and describe what barriers they encountered.
45343025|NCT05396014|Behavioral|Evidence-Based Exercise and Manual Therapy (EBEM)|Licensed physical therapists (PTs) or Doctors of Chiropractic (DCs) will rely on evidence-based guidance to direct decision-making on the particular type of manual and exercise therapy that may be best suited to an individual study participant. Special attention will be paid to the clinician's choice of language in regard to the purpose and expected outcomes of manual therapy in order to avoid enhancing catastrophizing ideations or preference for passive interventions. A total of 10 sessions will be provided over an 8-week treatment period. Two sessions per week are provided in the first two weeks followed by weekly sessions over the next 6 weeks. Treatment sessions will last approximately 60 minutes each.
45343026|NCT05396014|Drug|Duloxetine|Duloxetine is a serotonin norepinephrine reuptake inhibitor (SNRI) that is FDA-approved for use in Chronic Low-Back Pain, and, as such, is included as a recommended therapy in nearly all current treatment guidelines for low back pain. Study participants will be treated with duloxetine for 12 weeks during the active treatment phase. At the time of randomization, the approved drug pharmacy at each study site will dispense between 185 and 192 duloxetine 30 mg capsules and provide to participants. This will ensure enough capsules to maintain up to a 60 mg dosage through the 12-week intervention phase and to taper the dose in the 13th week if needed.
45343027|NCT05395416|Drug|HEC74647PA+HEC110114|administered orally once daily for 12 weeks
45343028|NCT05395416|Drug|Placebo|administered orally once daily for 12 weeks
45684006|NCT01517373|Drug|PF-04937319 100 mg|Combination of tablets and capsules, dose of 100 mg, a total of 3 pills/dose, administered once daily for 84-days
46039073|NCT04220944|Procedure|Microwave Ablation|The ablation area should covered at least two thirds the size of the nodules.
46039074|NCT04220944|Procedure|TACE|Patient was treated with epirubicin lipiodol emulsion(Epirubicin 40mg, Lipiodol 10ml).Embolic materials such as gelfoam or microsphere was aslo administered until complete stasis in segmental or subsegmental arterial branches.
46039075|NCT04221022|Other|Light physical activity|Each session started with leisure walk, duration of which was set to 35 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
45684007|NCT01517373|Drug|Glimepiride|Combination of tablets and capsules, dose of up to 6 mg, a total of 3 pills/dose, administered once daily for 84-days
46039076|NCT04221022|Other|Moderate physical activity|Each session started with brisk walk, duration of which was set to 30 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
45684008|NCT01517295|Drug|Hydrocodone|Dose: Standard prescribed dose Frequency: Once Duration: Once
45684009|NCT01541865|Device|Renal Denervation|percutaneous renal denervation using the Vessix RF balloon catheter
45684010|NCT01541397|Drug|Sapropterin|20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy
46039077|NCT04221022|Other|Vigorous physical activity|Each session started with jogging, duration of which was set to 15 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
45684011|NCT04104321|Drug|Aramchol|Aramchol 300 mg BID
46039078|NCT02754622|Other|Observational Group|Indirect calorimetry measurement during Physical Rehabilitation. Observing planned physical rehabilitation session to determine the rehabilitation activity achieved with IC utilised to determine the number of calories used per session
46039079|NCT02752516|Drug|Anlotinib|Anlotinib QD po. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
45684012|NCT04104321|Drug|Placebo|Placebo BID
45684013|NCT04104165|Device|Foley Catheter|Foley catheter used for treatment of urinary retention
45684014|NCT04103775|Behavioral|Cognitive Remediation|See Cognitive Remediation Arm description.
45840377|NCT00741390|Device|BD/33G|BD Lancet device/BD 33G lancets (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
45840378|NCT00741390|Device|OTM / 33G|OneTouch® Mini Lancet device / BD 33G lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
45840379|NCT00741390|Device|OTU/28G|OneTouch® UltraSoft® Lancet device/OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ BGM) and OneTouch® Ultra® test strips)
45343029|NCT05395195|Drug|Erythropoietin|Erythropoietin injections (500u/kg) x 9 doses
45343030|NCT05395195|Other|Supportive neonatal intensive care|Neonatal intensive care monitoring and support including ventilatory and inotropic support as clinically indicated
45343031|NCT05394207|Dietary Supplement|L. casei DG® (Lactobacillus paracasei CNCM I-1572)|L. casei DG® (Lactobacillus paracasei CNCM I-1572) containing 8 billion of live cells daily + Vitamin D 4.000 U.I. daily.
45684015|NCT04103775|Behavioral|Active Control|See Active Control Arm description.
45684016|NCT01548417|Drug|Korlym (mifepristone)|600 mg/day, oral pill, 7 days
45684017|NCT01548417|Drug|Sugar Pill|600 mg/day, oral pill, 7 days
45684018|NCT01546857|Drug|Placebo|Normal Saline
45840380|NCT00741390|Device|ACC/28G|Accu-Chek® Softclix Lancet device/Accu-Chek® Softclix 28G Lancet (BGM measured with Accu-Chek® Advantage BGM and Accu-Chek® Comfort Curve test strip)
45840381|NCT00741390|Device|OTM/28G|OneTouch® Mini Lancet device / OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
45840382|NCT00741468|Drug|Proellex|2, 25 mg Proellex capsules administered daily
45840383|NCT00741468|Drug|CYP1A2 probe|Caffeine (200 mg)
45840384|NCT00741468|Drug|CYP2C9 probe|Tolbutamide (250 mg)
46039080|NCT04278352|Behavioral|Mindfulness Based Relapse Prevention|The intervention is a group skills training program that is delivered once weekly for eight weeks. Content focuses on mindfulness and cognitive-behavioral relapse prevention skills, including psychoeducation, experiential exercises, and between session homework assignments.
46039081|NCT02751892|Behavioral|Active lifestyle programme|The intervention is an activity lifestyle programme to increase physical activity behaviour post-intervention and to facilitate behaviour change maintenance at 3 months post-intervention.
45343032|NCT05394207|Other|placebo|The comparator product is an identical matching placebo daily + Vitamin D 4.000 U.I. daily.
45343033|NCT05391360|Drug|Freethiadine tablets(part I)|Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
45343034|NCT05391360|Drug|Freethiadine tablets (part II)|once or twice daily for consecutive 28 days
46039082|NCT02754466|Other|Subjective vs objective criteria in selective excavation|Subjective vs Objective criteria (Polymer burs) to perform selective excavation of dentin caries in deep lesions
46039083|NCT02754466|Other|Glass-ionomer vs Bulk fill composites in the ART approach|High-viscosity glass-ionomer vs Bulk fill composite to restore shallow and medium depth dentin lesions using the ART approach
45343035|NCT05391360|Drug|Freethiadine placebo tablets|Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
46039084|NCT02754232|Other|Telemedical training|Intervention will involve resistance training and anaerobic training
46039085|NCT04220632|Drug|Itacitinib|at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.
45840385|NCT00741468|Drug|CYP2C19 probe|Omeprazole (20 mg)
45840386|NCT00741468|Drug|CYP2D6 probe|Dextromethorphan (30 mg)
46039086|NCT04220632|Drug|Prednisone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
45343036|NCT05391360|Drug|entecavir tablets|once daily for consecutive 28 days
45382034|NCT05414175|Drug|Mavacamten|Specified dose on specified days
45382035|NCT05414019|Other|Mini-screw|7 patients will receive an intrusive force delivered by elastics from 2 mini-screws between mandibular lateral incisor and mandibular canine.
45382036|NCT05414019|Other|Utility arch|7 patients will receive an intrusive force delivered by intrusive utility arch.
45382037|NCT05414019|Other|Nitinol reverse curve wire|7 patients will receive an intrusive force delivered by Nitinol reverse curve wire
45382038|NCT05411484|Drug|NanoDOX® Hydrogel|NanoDOX® Hydrogel (Doxycycline Monohydrate USP) will be applied on the areas of the skin previously treated by the Co2 Ablative Fractional Laser and also on a small non treated area of the subject's skin
45382039|NCT05411484|Device|CO2 Ablative Fractionla Laser|CO2 Ablative Fractional Laser will be applied to healthy skin areas
45382040|NCT05409846|Diagnostic Test|Alfa-galactosidase activity and genetic testing for Fabry diagnosis|Dry blood spot analysis and blood sample (if necessary)
46039087|NCT04220632|Drug|Methylprednisolone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
45840387|NCT00741468|Drug|CYP3A4 probe|Midazolam (2mg)
45840388|NCT00741858|Procedure|Duragen duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duragen)
45840389|NCT00741858|Procedure|Duraguard duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duraguard)
45840390|NCT00742170|Device|Electroacupuncture|Participants are randomly assigned to receive either active or sham electroacupuncture using the Han's Acupoint Nerve Stimulator (HANS) device. The HANS method uses a non-invasive device that emits a constant electric current transcutaneously via skin electrodes to stimulate relevant acupoints: Heku (LI4) / Laogong (P8) on one hand and Neiguan (P6) / Waiguan (TE 5) on the opposite arm. Stimulation is delivered in the dense-and-disperse mode, alternating between 2 and 100 Hz at 3-second intervals. Participants receive thrice daily treatments for 4 days during inpatient opioid detoxification.
45840391|NCT00742872|Drug|Mosapride Citrate|One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.
46039088|NCT02751970|Procedure|Dental restoration|Methacrylate resins will be used to complement the cavity restoration after of adhesive procedure
46039089|NCT02751970|Procedure|3 step ER|Enamel and dentin will be conditioning with 35% phosphoric acid, then applied primer, and then applied adhesive resin.
45840392|NCT00742872|Drug|Placebo|One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.
45840393|NCT00743262|Device|Provox voice prosthesis|The current voice prosthesis (Provox ActiValve)of the patients will be removed and a new prosthesis (Provox Vega) will be inserted
46039090|NCT02751970|Procedure|2 step ER|Enamel and dentin will be conditioning with 35% of phosphoric acid, then applied primer/adhesive resin.
46039091|NCT02751970|Procedure|2 step SE|Enamel and dentin will be conditioning with acidic primer, then applied primer/adhesive resin.
46039092|NCT02751970|Procedure|1 step SE|Enamel and dentin will be conditioning with acidic primer/adhesive resin.
46039093|NCT02752438|Device|HFOV|HFOV is a kind of respiratory support with a rate higher than physiological but with lesser volume.
46039094|NCT00939627|Biological|cetuximab|Given IV
46039095|NCT00939627|Other|placebo|Given orally
46039096|NCT00939627|Drug|sorafenib tosylate|Given orally
45840394|NCT00743574|Dietary Supplement|Vitamin D2 (Ergocalciferol)|50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
46039097|NCT00939627|Other|laboratory biomarker analysis|Correlative studies
46039098|NCT00939627|Procedure|quality-of-life assessment|Ancillary studies
46039099|NCT02752282|Other|Anticipatory Counseling|Anticipatory Counseling provides information on expected side-effects that may change or go away over time, or stay for the duration of the treatment. Anticipatory counseling can also help patients understand when their side-effects are normal and when to seek medical attention.
45343040|NCT05386407|Diagnostic Test|telemedically guided oropharyngeal + nasal (OP+N) self-sampling (GSS) and nasopharyngeal (NP) or OP+N sampling performed by health care professionals (HCP)|"After giving informed consent by signing the consent form, patients will be randomized to either OP+N GSS - or to OP+N USS.~After performing either procedure, they will continue to be sampled by HCP OP+N and HCP NP."
46039100|NCT02752282|Other|Cancer Screening Guidelines|Anticipatory Counseling on United States Preventative Services Task Force (USPSTF) updated pap screening guidelines
46039101|NCT05382741|Drug|Durvalumab Injection for intravenous use 500 mg vial solution for infusion|MEDI4736
46039102|NCT05382741|Drug|Regorafenib 30 mg capsules|BAY73-4506
46039103|NCT05090007|Device|magnetic resonance image|Imaging data were collected in a strong magnetic field
46039104|NCT05090007|Other|gut microbiota|gut microbiota
45343046|NCT05374993|Device|3TBA|Induce third molar tooth bud agenesis
45684019|NCT01546857|Drug|Gapabentin|400mg orally at 9pm day of surgery and the first evening post operatively.
45694562|NCT05235490|Other|Non intervention|"Data study with inclusion of patients and retrospective clinical data collection, combining :~Proofreading by radiologist of the CT scan performed (within 2 months prior to surgical intervention)~Proofreading by iBiopsy® of the CT scan performed (within 2 months prior to surgical intervention)~Proofreading of tumor sample slides by pathologists~Patients follow-up (imaging, clinical)~Recurrence-free survival"
45840395|NCT00743574|Drug|Medroxyprogesterone (Provera)|10mg, PO, daily for ten days
45840396|NCT00743574|Dietary Supplement|Vitamin D3 (Cholecalciferol)|2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
45840397|NCT00743574|Dietary Supplement|Elemental Calcium|1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
46039105|NCT02754076|Drug|AX 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
46039106|NCT05381415|Other|Inhalation of bronchodilation therapy at FRC|"the patient will be asked to inhale the bronchodilator (salbutamol pMDI, 400 µg) with a spacer from FRC (functional residual capacity, in a random order, with the assistance of an operator. The spacer will be connected to a Fleish flowmeter placed in series with the pMDI device.~The valve included in the spacer will guarantee that only the air inhaled by the patient will pass through the flowmeter, reducing the risk of contamination. In both cases a low inspiratory flux and a period of apnea after inhalation of 10 seconds will be used. Before and after the administration it will be asked to the patient to execute a spirometry, a plethysmography, a lung diffusion test, and the NEP technique. These will allow the characterization of the bronchodilator effect in terms of static and dynamic volumes, heterogeneity of ventilation distribution and volume of closure, expiration flux-limitation."
45343047|NCT05374980|Dietary Supplement|Yogurt|Drink a bottle of 200ml yogurt every morning and evening for 8 weeks
45343048|NCT05374980|Dietary Supplement|Placebo|Drink a bottle of 200ml placebo every morning and evening for 8 weeks
45343049|NCT05372887|Drug|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
45343050|NCT05372887|Drug|Placebo|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
45343051|NCT05372523|Diagnostic Test|CAPS-5 Assessment|A validated, semi-structured clinical interview to assess core PTSD symptoms
45694563|NCT04129138|Other|Survey Administration|Complete survey
46039107|NCT05381415|Other|Inhalation of bronchodilation therapy at RV|"the patient will be asked to inhale the bronchodilator (salbutamol pMDI, 400 µg) with a spacer from VR , with the assistance of an operator. The spacer will be connected to a Fleish flowmeter placed in series with the pMDI device.~The valve included in the spacer will guarantee that only the air inhaled by the patient will pass through the flowmeter, reducing the risk of contamination. In both cases a low inspiratory flux and a period of apnea after inhalation of 10 seconds will be used. Before and after the administration it will be asked to the patient to execute a spirometry, a plethysmography, a lung diffusion test, and the NEP technique. These will allow the characterization of the bronchodilator effect in terms of static and dynamic volumes, heterogeneity of ventilation distribution and volume of closure, expiration flux-limitation."
46039108|NCT04220554|Other|Improved support by health-care professionals|Improved support to patients prescribed topical antipsoriatic drugs
45840398|NCT00743730|Other|Pain and standard side effect management for PNCA with basal method.|"Comparing pain management and parent and nurse satisfaction with medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure."
46039109|NCT04220476|Radiation|Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. They will undergo tumor Immunogenic-SBRT(I-SBRT) days 1-12 (+/-2 days, to enable inclusion of holidays). During the week preceding day 1, they will undergo simulation and planning for radiotherapy. Each oligometastatic lesion will be treated with I-SBRT every 48 hours. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions
46039110|NCT04220476|Drug|Letrozole 2.5Mg Tab|All patients start standard therapy with oral letrozole (Femara), day 1 of the study.
46039111|NCT04220476|Drug|Palbociclib 125mg|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
45694564|NCT00878878|Drug|Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)|"Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison."
45343052|NCT05372523|Diagnostic Test|Senseye OBCI|Using a machine learning algorithm, Senseye's DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.
45694565|NCT00878878|Drug|Dextrose|"Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison."
45840399|NCT00743730|Other|Pain and standard side effect management with PNCA without basal|"Comparing pain management and parent nurse satisfaction with pain mediation delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure."
46039112|NCT00937833|Procedure|Prostatectomy|
46039113|NCT00937833|Device|Surgisis Male Sling|
46039114|NCT02695810|Drug|Dapagliflozin|10 mg per day as monotherapy for 13 weeks
46039115|NCT02695810|Drug|Metformin|2 x 850 mg per day as monotherapy for 13 weeks
46039116|NCT02695810|Behavioral|Exercise|Interval training, 5 times per week, 30 min per session
45343053|NCT05371743|Diagnostic Test|Plasma RNA isolation, qPCR analysis of micro RNA|qPCR will be performed using Taqman microRNA assays (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. Total RNAs going to be used to make cDNAs using TaqMan microRNA RT Kit. Diluted cDNAs were mixed with TaqMan Universal PCR Master Mix (No AmpErase UNG). Taqman miRNA assay will run in the 7500 Real-Time PCR System (Applied Biosystems). miR-39 also will be used as an exogenous control. All assays will be done in triplicates. The expression levels will be evaluated using the comparative cycle threshold (∆∆_Ct) method
46039117|NCT04204161|Biological|CAR-T19/CAR-T22|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.The recommand dose is 1x10^5/kg-2.5x10^8/kg .
46039118|NCT02753764|Drug|AZD7624|
46039119|NCT02753764|Drug|prednisone|oral prednisone 20 mg bid for one week
46039120|NCT02753764|Drug|Placebo|
46039121|NCT05382429|Procedure|OWHTO|OWHTO Surgical procedure For the OWHTO Surgical procedure, only medial split biplanar osteotomy performed.
46039122|NCT05382429|Procedure|CWHTO|CWHTO Surgical procedure For the OWHTO Surgical procedure, only lateral closure osteotomy was performed.
46039123|NCT02695654|Drug|Levobupivacaine|14 ml of 0,25 % Levobupivacaine
46039124|NCT02695654|Drug|Clonidine|Clonidine 100 mcg
46039125|NCT02751736|Dietary Supplement|CJLP243|Perioperative administration till postoperative weeks 3
46039126|NCT02751736|Dietary Supplement|Placebo|Perioperative administration till postoperative weeks 3
45840400|NCT00743730|Other|Pain and standard side effect management with IV on an as needed basis method.|"Comparing pain management and parent and nurse satisfaction with pain medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol."
46039127|NCT02751658|Other|mouth swab|Levy to make inside of the mouth with a swab on the day of admission to hospital and the day of release at the patients in the Otorhinolaryngology
45343054|NCT05371743|Diagnostic Test|estimation of serum level of IL2|"2ml of patient serum will be used to measure IL 2 in patients with different groups by ELISA technique.~The techniques will be done in the central research laboratory in Sohag university hospital"
45343055|NCT05371743|Diagnostic Test|estimation of serum level of IL17|"2ml of patient serum will be used to measure IL17 in patients with different groups by ELISA technique.~The techniques will be done in the central research laboratory in Sohag university hospital"
45343056|NCT05366764|Drug|SAR443765|solution for injection
45343057|NCT05366764|Drug|Placebo|solution for injection
45343058|NCT05366764|Drug|Salbutamol or levosalbutamol|metered dose inhaler
45343059|NCT05366166|Biological|Pembrolizumab|In the induction phase, participants will receive a single intravenous infusion of pembrolizumab 400 mg prior to chemoradiotherapy. In the Maintenance Phase, participants will receive pembrolizumab 400 mg every 42 days for 8 cycles.
45840401|NCT00745290|Drug|Bupivacaine HCl|200 mg bupivacaine HCl
45840402|NCT00745290|Drug|SKY0402|600 mg SKY0402 (study drug).
45840403|NCT00748410|Drug|SB-656933|7 days repeat dose
45840404|NCT00748956|Drug|Low dose NPY|50nmol, administered intranasally
45840405|NCT00748956|Drug|High dose NPY|100nmol administered intranasally
45840406|NCT00748956|Drug|Placebo|placebo comparator (0nmol)) administered intranasally
45840407|NCT00749268|Device|AbsorbaTack|Comparison of different devices for mesh fixation. This intervention arm has absorbable tacks as the method of hernia mesh fixation. Application is during hernia repair and tacks will essentially absorb within the body after 1 year.
45840408|NCT00749268|Device|ProTack|Comparison of different devices for mesh fixation. This intervention is a permanent tack for hernia mesh fixation. Application is during hernia repair and the tacks will remain in the body.
45840409|NCT00750282|Drug|Florbetaben (BAY94-9172)|Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions
46039128|NCT00635674|Device|CPAP device - REMstar Plus, Respironics, Murrysville, USA|continuous positive airway pressure device with heated humidification
46039129|NCT02696122|Procedure|Local Group|General anesthesia willl be induced with propofol 2 mg mg. kg-1 and alfentanyl 30 mcg.kg-1. Once an appropriate depth of anesthesia had been obtained, a laryngeal mask airway (LMA) will be positioned. The anesthesia will be maintained by propofol 4 to 5 mg. kg-1.h-1. Ventilation will controlled by adjusting the flow volume and respiratory rate to keep the end-tidal CO2 level (PETCO2) between 30 and 40 mmHg. For local anesthesia, approximately 50 ml of 0.5% ropivacaive will infiltrated along the line of incision in the subcutaneous plane, followed by peripheral nerve block technique (e.g., ilioinguinal-hypogastric nerve block) and local wound infiltration at the fascial level.
45343060|NCT05366166|Drug|Olaparib|In the induction phase, participants will receive daily oral olaparib 150 mg two times a day for 3 weeks prior to chemoradiotherapy. In the Maintenance Phase, participants will receive daily olaparib 150 mg two times a day for up to 48 weeks.
46039130|NCT02696122|Procedure|Spinal anesthesia|Spinal puncture will be performed with the patient in the sitting position, using 27G disposable Quincke needles (B. Braun, Meisungen, AG). After obtaining CSF, 15 mg of 0.5% hyperbaric bupivacaine will be injected.
45840410|NCT00750360|Biological|FluarixTM|All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).
46039131|NCT02753608|Other|Collection of exhaled breath condensate|An sampling device (authorized for this use) will be connected to the expiratory line of the ventilator. Exhaled breath condensates accumulate in a cooled container.
46039132|NCT01135511|Drug|CP-690,550 Eye drops|Ophthalmic topical solution, low dose, dosed once/day, 8 weeks
46039133|NCT01135511|Drug|CP-690,550 Eye drops|Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks
46039134|NCT01135511|Drug|CP-690,550 Eye drops|Ophthalmic topical solution, high dose, dosed once/day, 8 weeks
46039135|NCT01135511|Drug|CP-690,550 Eye drops-vehicle|Ophthalmic topical solution, vehicle, dosed once/day, 8 weeks
46039136|NCT01135511|Drug|Sodium Hyaluronate|Ophthalmic topical solution, dosed 6 times/day, 8 weeks
46039137|NCT02753140|Drug|Cetuximab|
46039138|NCT02753140|Radiation|radiation|
46039139|NCT02753140|Drug|Docetaxel|
46039140|NCT02753140|Drug|Cisplatin|
46039141|NCT02753218|Drug|Midazolam|
46039142|NCT02753218|Drug|LEO 32731|
46039143|NCT05429554|Drug|Vildagliptin|observe the effect of vildagliptin on cognitive function and cardiovascular in diabetic patients
46039144|NCT04220164|Other|Education and inform the optimal threshold of LDL-C levels|Physicians educate patients and provide a clear information about optimal LDL-C value according to individual patient's condition according to current guidelines
46039145|NCT05429398|Drug|Linperlisib Tablet|"Linperlisib Tablet Oral administration, once a day, for 21 consecutive days as a treatment cycle;~Camrelizumab for Injection 200 mg intravenously every 3 weeks. Camrelizumab should be administered prior to Linperlisib."
46039146|NCT04220086|Procedure|Pediatric massage therapy|Children with ASD will receive pediatric massage therapy twice a week for 12 consecutive weeks by professional pediatric massage doctor. In addition, they will receive parent provided pediatric massage therapy at home after their parents received the professional pediatric massage therapy training. The frequency of pediatric massage will not be more than once every day and each session last about 30 minutes.
46039147|NCT04220086|Procedure|Usual care|Including Applied Behavior Analysis (ABA), Educational intervention, Interpersonal development intervention.
46039148|NCT04220086|Other|No intervention|No intervention for healthy controls
46039149|NCT04088968|Behavioral|Prehabilitation|Patients screened positive for minimun 1 SNAP factor will be offered enrollment in the study and have an individualized plan for the prehabilitation intervention.
46039150|NCT05429086|Drug|Remimazolam combined propofol|Remimazolam combined propofol
46039151|NCT05429086|Drug|Remimazolam|remimazolam only
46039152|NCT05429086|Drug|Propofol|propofol only
46039153|NCT04219930|Diagnostic Test|Expression of nucleotide protein -3|Expression of nucleotide protein -3 will be measured in serum by ELISA
46039154|NCT04486066|Behavioral|Mindfulness-Based Stress Reduction|In MBSR, participants meet by video for 2 hours per week for 8 weeks in a group format and receive instruction in mindfulness meditation according to a standardized curriculum, are given daily homework, participate in group discussions, and can ask questions.
46039155|NCT04486066|Behavioral|Cognitive Behavioral Therapy for Chronic Pain|Cognitive Behavioral Therapy (CBT) is the most widely used non-pharmacologic intervention for chronic pain and a version of CBT specifically addressing chronic pain (CBT-CP) has been developed for use in VA with Veterans. Fundamentally, CBT is an approach that seeks to ameliorate dysfunctional relationships between an individual's thoughts, feelings, and behaviors to improve functioning and quality of life. At our site, the CBT-CP format has been adapted for clinical use (i.e., as part of usual clinical care) to 8 video sessions in a group format, while retaining all essential elements.
46039156|NCT04486066|Other|Usual Care|Veterans randomized to usual care will continue to be followed by their usual care providers for all medical and mental health care. This can include continued use of medications, specialty referrals and other usual elements of care. They will be asked to not enroll in the specific MBSR or CBT-CP interventions during the 8-month study period, but can attend other groups interventions, such as CBT-Insomnia, Acceptance and Commitment Therapy for Chronic Pain, and other groups for chronic pain and PTSD as directed by their treating providers. They can also enroll in MBSR or CBT-CP at the completion of the study.
46039157|NCT00638248|Drug|Desmoteplase|Desmoteplase 90µg/kg BW i.v. bolus
46039158|NCT00638248|Drug|Desmoteplase|Desmoteplase 125 µg/kg BW i.v. bolus
46039159|NCT00638248|Drug|Placebo|Placebo i.v. bolus
46039160|NCT04219306|Other|Alert on dispatchers screen 'Suspect cardiac arrest'|Alert on dispatchers screen 'Suspect cardiac arrest'
46039161|NCT04056208|Drug|Pistachio|Unsalted pistachios
46039162|NCT04056208|Other|Usual care|Advice and resources will be provided
46039163|NCT04219150|Device|Electrical cardiometry|Four sensors of EC will be applied : first approximately 5 cm above the base of the neck, second on the base of neck, third on the lower thorax at the level of the xiphoid and the fourth one on the lower thorax approximately 5 cm below the 3rd electrode at the level of anterior axillary line. The EC monitor (Electrical Cardiometry monitor, ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, serial number 1725303) will be connected to the sensor cable and the patient data will be fed. Corrected flow time (FTC) and stroke volume (SV) will be measured continuously in less than 30 seconds after placing the sensors and inputting the height and weight.
46039164|NCT04219150|Drug|"Fluid and Catheter Treatment Trial FACTT Lite"|The FACTT Lite provided three possible instructions determined by the CVP and urine output: furosemide administration, fluid bolus, or no intervention. FACTT Lite contained instructions to withhold furosemide until the patient achieved a mean arterial pressure greater than 60 mmHg off of vasopressors for at least 12 h.
46039165|NCT04220242|Other|Video recordings with analysis thereafter applied|Recordings of surgical assessments in order to develop a model for Artificial Intelligence analysis
46039166|NCT04220242|Other|Examination of microsections of tissue excised for the purposes of cancer resection|Microscopic examination including by near-infrared examination of some of the tissue excised for the purposes of cancer resection to examine cellular mechanisms of fluorescence uptake and distribution
45343061|NCT05366166|Drug|Cisplatin|"In the chemoradiation phase, participants will receive weekly intravenous cisplatin infusion, 40 mg/m2 over 7 weeks.~In the chemoradiation phase, standard of care radiation therapy and chemotherapy will be administered, for a total of 7 weeks. Radiation therapy is done on daily basis (excluding weekends), and chemotherapy therapy will involve cisplatin infusion once weekly."
45343062|NCT05366166|Radiation|IMRT (intensity modulated radiation therapy)|In the chemoradiation phase, participants will receive 70 Gray external beam radiotherapy, at 2 Gray/fraction dose, 35 fractions, delivered once a day, on weekdays, using Intensity Modulated Radiotherapy Treatments or proton radiotherapy techniques, over 7 weeks.
46039167|NCT04220242|Other|Cancer organoid development and testing|Some tissue will be taken from the specimens excised for the purposes of the cancer operation to develop experimental models of cancer tissue to allow examination of mechanisms of uptake and distribution of the fluorophores in cancer
45343064|NCT05359835|Drug|Calcium DTPA and Zinc DTPA|Intravenous administration of 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by 900 mL of normal saline infusion over about 90 minutes, followed by 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by infusion of the remaining 100 mL of normal saline over about 10 minutes. Procedure repeated with Zn-DTPA the following day. Two-day procedure repeated at an interval of one week or more for a total of six 2-day treatment sessions.
45343065|NCT05357378|Device|Hip Innovation Technology Reverse Hip Replacement System|Implantation of the Investigational Device is performed using standard surgical procedures for THA, as described in the Instructions for Use (IFU). The control hip systems will be implanted in accordance with their respective IFU, which are also in line with standard surgical approaches for THA.
45382041|NCT05409833|Diagnostic Test|Synovial biopsy and Cardiac scintigraphy with [99mTc]Tc-DPD|Congo red and Immunohistochemical analysis and/or Mass spectrometry analysis
45840411|NCT00751530|Drug|raltegravir|New combination ART incorporating raltegravir with other ARVs.
46039168|NCT04468204|Device|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.
45382042|NCT05409534|Other|Backward Walking (Exercise group)|The participant will apply a maximum of 40-50 minutes of exercise, including 10 minutes of warm-up exercise, 30 minutes of backward walking training and 10 minutes of cooling-off exercise. The maximum time to do backward walking training will be 30 minutes. In the backward walking exercise, 1 set will take 5 minutes. The maximum number of sets that can be made will be 6 sets. No more than 6 sets will be made.
46039169|NCT04468204|Device|Sham SinuSonic Device|Sham positive expiratory pressure intervention using the SinuSonic Device.
46039170|NCT04219462|Device|active extracorporeal shock wave|Ultrasound gel was used as a coupling agent, and the applicator of extracorpral shock wave therapy (ESWT) will be held perpendicular to the treatment surface throughout the treatment. Men in this group (n= 20) men receive ESWT twice weekly for 3 consecutive weeks and repeated after a 3-week rest period, for a total of 12 treatment sessions. The patients will receive ESWT for 15 minutes at an energy level of 0.09 and a frequency of 120 shocks/min (1800 pulses per session). Shockwaves were delivered to the distal, mid, and proximal penile shaft, as well as to the left and right crura + 5 mg sildnafil once daily for 3 months
46039171|NCT04219462|Device|sham extracorporeal shock wave|twenty men will receive sham treatment underwent identical therapy with ESWT application with a similar appearance and sound as the active extracorporal shock wave therapy (ESWT), although shock wave propagation to the tissue wills be blocked by a metal plate that will inserted into the sham applicator + sildenafil 5mg once daily for 3 months.
46039172|NCT04219852|Other|data collection|data collection
46039173|NCT04467736|Device|Gengigel Forte©|Gengigel (hyaluronic acid) will be administered by the patient 3 times per day during 7 days following alveolar ridge preservation
46039174|NCT04218994|Other|Flossing technique|Subjects instructed on flossing technique
46039175|NCT05428228|Other|TP1|Participants will be administered TP1 during one of the experimental visits.
46039176|NCT05428228|Other|TP2|Participants will be administered TP2 during one of the experimental visits.
46039177|NCT05428228|Other|Placebo|Participants will be administered placebo during one of the experimental visits.
46039178|NCT04219228|Diagnostic Test|Ophthalmic examinations|Ophthalmic examinations include visual acuity, cover test and ocular dominance, noncycloplegic autorefraction, cycloplegia, ocular biometric measurements, cycloplegic auto-refraction, subjective refraction, and anterior and posterior segment examination.
46039179|NCT04219228|Device|Wearable devices|Physical activity, light intensity, and visual information will be measured with wearable devices.
46039180|NCT05422144|Device|Antimicrobial Skin & Wound Cleanser (AWC)|BIAKŌS™ Antimicrobial Skin & Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site. BIAKŌS™ Antimicrobial Skin and Wound Cleanser is a pure, colorless, isotonic cleanser that is safe. The preservative, polyhexamethylene biguanide (PHMB), at a concentration of 0.1% w/w is added to the product to inhibit the growth of microorganisms such as Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA). and fungus Candida albicans within the product.
46039181|NCT05422144|Device|Antimicrobial Wound Gel (AWG)|"BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel. The gel provides preservative properties through the antimicrobial polyhexamethylene biguanide (PHMB).~BIAKŌS Antimicrobial Wound Gel:~Resists microbial colonization within the gel during shelf storage.~Provides an amorphous gel covering.~Facilitates autolytic debridement through a moist wound environment. Wounds experience some level of autolytic debridement in which the body's own enzymes breakdown necrotic tissue."
46039182|NCT01180790|Drug|ACH-0141625 (Sovaprevir)|200 mg oral capsule once daily
46039183|NCT01180790|Drug|ACH-0141625 (Sovaprevir)|400 mg oral capsule once daily
46039184|NCT01180790|Drug|ACH-0141625 (Sovaprevir)|800 mg oral capsule once daily
46039185|NCT01180790|Drug|Placebo|Powder in capsule once daily
46039186|NCT01180790|Drug|Pegylated Interferon alpha-2a|180 ug once a week by subcutaneous injection
46039187|NCT01180790|Drug|Ribavirin|400 mg or 600 mg (am) and 600 mg (pm) capsules taken orally twice daily
45694566|NCT05311696|Other|psychoeducation|The program consists of psychoeducational material regarding PTSD, demonstration of various stress management techniques, and social cohesion activities
46039188|NCT05308004|Other|Palliative Care Consultation|Trained provider will discuss illness trajectories, establish and communicate patient-directed goals that guide health care decisions, identify and treat illness-related symptoms, and identify psycho-spiritual needs and approaches to mitigate suffering
46039189|NCT00624728|Radiation|18F Fluorothymidine PET CT|"18 FLT will be provided by the Laboratoire des Radiopharmaceutiques- Université Bordeaux2, Hôpital Xavier Arnozan and prepared according to the method described by Grierson and Shields ( Grierson J, Shields A. Nucl Med Biol 27 :143-156 ; 2000).~Specific activity of 18FLT will be more than 37 GBq/µmol (>1Ci/µmol) corrected for decay at the end of bombardment of cyclotron target. Before tracer injection to patients, each dosis will be tested for pH and for radiochemical purity (> 95%) via HPLC technique and thin layer chromatography.~18FLT dosis will be injected intravenously to the patients (10 mL of salted isotonic solution with less than 10 % (v/v) of ethanol (USP). Administrated activity will be calculated estimating total body surface of patient (2,6 MBq/kg ou 0,07 mCi/kg) with maximal activity of 185 MBq.~PET acquisition will be realized as follows : Dynamic acquisition in 3D mode for 35 min, Iterative reconstruction (OSEM) with and without attenuation correction."
45840412|NCT00753636|Drug|Dynacirc CR (Isradipine)|Dynacirc CR is given by the recommended schedule for titration. Subjects start on a 5mg dose and are increased in increments of 5mg every 2 weeks provided that the subjects do not have significant adverse events or symptomatic orthostatic hypotension.
45840413|NCT00753948|Drug|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
46039190|NCT01184846|Biological|10% liquid formulation of human immunoglobulin|
46039191|NCT05346692|Other|Survey Administration|Complete Survey
46039192|NCT05346692|Other|Interview|Complete Interview
45343066|NCT05357378|Device|Already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.|"Control Arm subjects will receive one of the already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.~DePuy Synthes Corail® Total Hip System in combination with Pinnacle® Complete Acetabular Hip System.~Zimmer Biomet Taperloc® Complete Hip System in combination with G7® Acetabular System.~Stryker Accolade® II femoral stem in combination with Stryker Trident® II acetabular cup.~Smith & Nephew Anthology® Total Hip System in combination with R3® Acetabular System."
45343067|NCT05355207|Drug|TRL1068|A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
45343068|NCT05355051|Drug|Azacytidine|Given by Vein (IV)
45343069|NCT05355051|Drug|Pembrolizumab|Given by Vein (IV)
46039193|NCT05346692|Other|Text Message-Based Navigation Intervention|Complete mindfulness intervention
45343070|NCT05349292|Other|ANH|one group will be managed with ANH and the other without (control group)
46039194|NCT05346692|Other|Interview|Complete interview
46039195|NCT01180400|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
46039196|NCT01180400|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
46039197|NCT04316000|Other|Initial Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) before the initial endoscopic procedure.
45343076|NCT05337280|Device|Imagio OA/US|Imagio optoacoustic/ultrasound
45840414|NCT00754494|Drug|erlotinib hydrochloride|Given PO
45840415|NCT00754494|Other|placebo|Given PO
45840416|NCT00754494|Other|laboratory biomarker analysis|Correlative studies
45840417|NCT00755040|Drug|cyclosporine ophthalmic emulsion|Given as eye drops
46039198|NCT04316000|Procedure|Endoscopic band ligation without resection of the subpetihelial tumour.|Correct application of the elastic band in the subepithelial tumor, achieving its removal by self-amputation in the 4-6 weeks endoscopic ultrasonography (EUS) control.
46039199|NCT04316000|Other|1-2 Months Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1-2 months of the initial endoscopic procedure, knowing whether the tumor has either been removed or not, is a benign entity or has not been observed.
46039200|NCT04316000|Other|1 Year Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1 year of the initial endoscopic procedure, knowing whether the tumor has either been removed or not.
46039201|NCT01180244|Device|Noninvasive cortical electrical stimulation|Subjects will receive 22 sessions of the intervention protocol, twice per week for a total of 11 weeks. The signal stimulation used in this study utilizes amplitude modulation to shape a high frequency carrier signal, nominally greater than 10 kilohertz, into the form of one or more low frequency components, nominally less than 40 hertz. Exact protocol is set in software and is the same for all participants in the active treatment arm.
45343077|NCT05335148|Drug|oral colchicine(0.6 mg) once a day|The standard of care arm will receive a placebo colchicine pill once a day
45343078|NCT05329623|Drug|JDQ443|All the participants will receive a single oral dose of JDQ443.
45343081|NCT05319041|Drug|Wei's Qi Ju Gan Lu Formula|"The formulation, Wei's Qi Ju Gan Lu Formula, is initiated by the senior TCM collaborator, Prof Wei QP, is formulated to treat the dry eye patients with liver-kidney yin deficiency. The treatment regulation aims to nourish the Liver and Kidney, enrich yin deficiency, in order to promote tears production, hence treatment of Dry Eye."
45343082|NCT05319041|Drug|Placebo|0.5g maltodextrin without any herbs medicine
45343083|NCT05314933|Drug|2-Deoxyglucose|Intranasal administration
45343084|NCT05314933|Other|Placebo|Intranasal administration
45343085|NCT05314335|Other|Reflexology socks+walking|Patients should wear reflexology socks; Wearing clothes and walking 30 minutes after breakfast and dinner for 30 minutes 3 days a week (Monday, Wednesday and Friday)
45840418|NCT00755040|Other|placebo|Given as eye drops
45840419|NCT00755274|Biological|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
45840420|NCT00755274|Biological|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
46039202|NCT01180244|Device|Sham treatment|Subjects in the placebo group will receive the exact same experience as those in the active treatment group. However, the device will not output any electrical stimulation signal.
46039203|NCT01191086|Drug|USL255|
46039204|NCT04316312|Device|Threshold inspiratory muscle trainer|Threshold inspiratory muscle trainer will be set between 15% to 30% of maximal inspiratory pressure.
45840421|NCT00756600|Drug|Regional Anesthesia|Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.
45840422|NCT00756600|Drug|General Anesthesia|Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.
45840423|NCT00756678|Drug|Lubricant Eye Drops (Optive™)|1 drop in both eyes as needed for 7 days'
45840424|NCT00756678|Drug|Lubricating Eye Drops (blink® Tears)|1 drop in both eyes as needed for 7 days
46039205|NCT01088412|Drug|Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)|Dose, frequency and duration at discretion of attending physician.
46039206|NCT04198714|Procedure|Pudendal block|Administration of a pudendal block at the conclusion of vaginal surgery.
46039207|NCT00635752|Other|TF-CBT|TF-CBT sessions will include trauma-focused treatment, and will teach participants behavioral and coping skills.
46039208|NCT00635752|Other|Treatment as Usual (TAU)|Participants will receive regular therapy as is usually practiced in clinics
45343086|NCT05314335|Other|Just walking|Patients will be instructed to walk for 30 minutes, 3 days a week (Monday, Wednesday, and Friday), 30 minutes after breakfast and dinner. Patients will be asked to continue the application for 4 weeks.
45343087|NCT05313152|Drug|TAVO103A|TAVO103A single ascending dose IV infusion.
45840425|NCT00758550|Device|AcrySof® Toric IOL|AcrySof® Toric Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
46039209|NCT04218916|Drug|Rhodiola Rosea Capsules|0.28g per capsule, 0.56g once (2 capsules), three times a day
45343088|NCT05313152|Other|Placebo|Placebo single ascending dose IV infusion.
45343089|NCT05310071|Drug|Aducanumab|Administered as specified in the treatment arm.
45343090|NCT05310071|Drug|Placebo|Administered as specified in the treatment arm.
45343091|NCT05308225|Biological|STI-6129|Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor
45684020|NCT04767867|Other|Pre-oxygenation|"Induction of anaesthesia after 2mins 45 seconds of pre-oxygenation with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions commenced until study conclusion.~Positive pressure ventilation commenced at Sp02 92%. Failure to intubate the patient during the first minute of apnoea results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after one minute of apnoea, and every two minutes during the apnoeic period."
45840426|NCT00758550|Device|AcrySof Natural|AcrySof Natural Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
46039210|NCT04218916|Drug|Placebo|2 placebo capsules once, three times a day
46039211|NCT05383924|Procedure|postplacental IUD insertion|"patients will have immediate postplacental IUD insertion as follows: The IUD is inserted after removal of the placenta and after the uterus has become hemostatic. After initiating closure of the uterine incision, the IUD is placed at the top of uterine fundus manually. Before closing the uterine incision, the strings are placed gently in the lower uterine segment manually. After this is accomplished, the uterine incision closure can be completed. The strings will usually descend spontaneously through the cervix during the puerperal period. If the cervix is closed, it'll be dilated from above with ring forceps. Strings can be passed through the cervix with ring forceps. If this is done, the surgeon will recheck to make sure IUD remains at the fundus of the uterus prior to closing the uterine incision. Strings can be trimmed at a follow-up visit.~Ultrasound will be done after the CS to ensure proper placement of the IUD."
45343092|NCT05303844|Drug|H101|H101 intratumorally injection starts at day 0.
46039212|NCT05383924|Procedure|delayed IUD insertion|cesarean section will be done, then contacts will be taken to arrange for delayed IUD insertion at the 6th week postpartum visit as follows: Prepare IUD prior to starting procedure Place vaginal speculum then prepare vaginal wall with betadine Apply tenaculum at anterior cervical position then insert and remove uterine sound Place IUD according to package insert then cut threads 2-3 cm from cervical os. Ultrasound will be done to ensure proper placement of the IUD.
45343093|NCT05303844|Drug|Tislelizumab|Tislelizumab will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
46039213|NCT01076400|Drug|MK-1775|MK-1775 capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
46039214|NCT01076400|Drug|Topotecan|Topotecan is administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3.
46039215|NCT01076400|Drug|Cisplatin|Cisplatin is administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
46039216|NCT01076400|Drug|Placebo to MK-1775|Placebo to MK-1775 capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
45343097|NCT05297019|Procedure|Hyperbaric Oxygen Therapy|hyperbaric oxygen therapy
45343098|NCT05294549|Other|Caring Contact|The Caring Contact intervention is an email with messages of hope, support and resource information sent to patients post-discharge from psychiatric hospitalization.
45343099|NCT05291754|Device|PEEK Cranioplasty|3D printed PEEK skull implant
45343100|NCT05291182|Drug|SY-4835|WEE1 inhibitor
46039217|NCT04948840|Biological|Blood sampling|Blood sample of 7 mL whole venous blood in an EDTA citrate tube (4.5 mL) and a PAXgene Blood RNA tube (2.5 mL).
45343101|NCT05287087|Behavioral|My Symptoms 1 (MySt-1)|"The patients will get access to an eHealth programme consisting of:~A questionnaire including the BDS checklist~A brief introductory animation about how to understand symptoms in general~Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~A brief animation about the interaction of body and mind.~These four provisions are identical to the first part of the MySt-2."
46039218|NCT05318560|Drug|Lidocaine 2% Injectable Solution|for MPS
46039219|NCT05318560|Drug|Ozone|for MPS
45343102|NCT05287087|Behavioral|My Symptoms 2 (MySt-2)|"The patients will get access to an eHealth programme consisting of:~A questionnaire including the BDS checklist~A brief introductory animation about how to understand symptoms in general~Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~A brief animation about the interaction of body and mind.~Thorough symptom explanations~Physical energy (focus on sleep, diet and activity)~Values and choices (focus on meaning and existential issues)~Emotional health (focus on emotion regulation)~Mental energy (focus on stress regulation and thinking)~After 4-6 weeks, the patient will see the GP for a follow-up consultation."
45343103|NCT05280574|Device|GE Portrait Monitor|All patients will be monitored
45343104|NCT05280574|Device|GE Portrait Monitoring with intervened by clinician|Monitoring might be intervened if clinician believe that the alarm is clinically meaningful
45343105|NCT05280574|Device|GE Portrait Monitoring randomized to blinded or unblinded|Without intervention
45343106|NCT05279313|Drug|Centanafadine Hydrochloride|Capsule
45343107|NCT05278598|Procedure|Erector Spinae Plane Block|"After skin sterilization, ESP block will be performed at the level of T9. A curvilinear high-frequency ultrasound transducer will be placed sagittal 3 cm lateral to T9 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. Sonographic confirmation of the local anesthetic spread will be seen as an anechoic shadow in the paravertebral spaces from T7 to T12.~This procedure will be done on both sides."
45382043|NCT05409534|Other|Forward Walking (Control Group)|The participant will apply a maximum of 40-50 minutes of exercise, including 10 minutes of warm-up exercise, 30 minutes of forward walking training and 10 minutes of cooling-off exercise as the home exercise programme.
46039220|NCT05318560|Other|stretching exercise|for MPS
46039221|NCT04171258|Drug|Botulinum toxin type A injection|Experimental
46039222|NCT04171258|Drug|Botulinum Toxin Type A Injection [Botox]|Active Comparator
46039223|NCT04165564|Other|Institutional standard of care|Institutional standard of care may involve the use of LungRADS (screening setting) or Fleischner criteria (either combined 2005, 2013 or 2017 guidelines)
46039224|NCT04165564|Other|Biosamples of airway and blood|Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
45840427|NCT00758784|Drug|bromfenac ophthalmic solution 0.06%|bromfenac ophthalmic solution 0.06% bilaterally twice a day
46039225|NCT05247814|Genetic|Pharmacogenomic testing of a panel of important pharmacogenes to detect genetic variants and evaluate the association between genetically predicted and measured drug metabolism|All planned interventions are explorative analyses of biological and genetic risk profiles that can contribute to patients' individual risk for adverse drug reactions, i.e. due to variability in drug metabolism
46039226|NCT05247814|Other|Adverse Drug Reaction detection|During appointments in the university outpatient clinic, patients will undergo a comprehensive adverse drug reaction (ADR) assessment based on an ADR diary they were handed at enrolment
46039227|NCT05247814|Other|Falls Efficacy Scale International (FES-I)|The FES-I wil be obtained to estimate fear of falling
46039228|NCT02695576|Procedure|Lumbar Fusion Surgery|Interbody fusion with fixation
46039229|NCT02695576|Other|Physiotherapy|Examination by physiotherapist, motivation of the patient, training in body awareness, physical activity/Qigong, training in water, outdoor pole work, circle training, stabilization training, massage, stretching, lessons and practice in ergonomics.
45382044|NCT05409378|Device|The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)|Aortic valve replacement with the HLT Meridian TAVR Valve to treat aortic regurgitation
45840428|NCT00758862|Drug|2% TD1414 Cream|Application 3 times daily for 7 days
45840429|NCT00759096|Device|RESTOR IOL Model SA60D3|Implanted into the study eye following cataract extraction surgery
46039230|NCT02695576|Other|Cognitive behavioral therapy|Individual and group lessons performed by psychologists.
46039231|NCT01086384|Drug|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
46039232|NCT01086384|Drug|Fluticasone furoate|Inhaled corticosteroid
46039233|NCT04115644|Drug|Ketorolac|Group 2 (ketorolac): will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml
46039234|NCT04115644|Drug|Marcaine (placebo)|Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine
46039235|NCT04115644|Drug|Kenalog|Group 3 (kenalog): 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone.
46039236|NCT00635986|Drug|Fentanyl|100 mcg Fentanyl intravenous or epidural route
46039237|NCT04866784|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is a non-pharmacologic intervention for acute and chronic pain. This treatment involves the application of electric current through the skin; it is safe, easy to use, and inexpensive
46039238|NCT01127633|Drug|Solanezumab|400 mg of solanezumab administered once every 4 weeks by intravenous infusion (IV) for up to 8 years.
46039239|NCT01127633|Drug|Placebo|Participants were from feeder studies (LZAM or LZAN). Placebo administered intravenously every 4 weeks through Week 80.
46039240|NCT04799626|Drug|biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc|biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc extended infusion time or continuous infusion for 24 hours;Tigecycline changed standard does for treatment.
46039241|NCT02751112|Biological|Predictor' kit|Realization of the Predictor' kit on the blood of donor of HSC, in the frame of a graft, to predict a aGvH reaction on recipient patient.
45474133|NCT01176227|Dietary Supplement|Kyodophilus multi-strain probiotic capsules|"The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:~Lactobacillus gasseri KS-13 1.2~Bifidobacterium bifidum G9-1 0.15~Bifidobacterium longum MM-2 0.15~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
45840430|NCT00759330|Drug|Placebo Tape (Arm 1)|Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
46039242|NCT00636064|Drug|Parecoxib Sodium/Valdecoxib|Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
45840431|NCT00759330|Drug|Flurbiprofen Tape (Arm 2)|Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
45343108|NCT05278598|Procedure|Thoracic Paravertebral Plane Block|"After skin sterilization, curvilinear high-frequency ultrasound transducer will be used to visualize the T10 paravertebral space in the paramedian sagittal plane. An injection into the paravertebral space will spread to multiple adjacent dermatomes, so exact identification of a specific level will be not necessary. A 22-gauge spinal needle will be inserted in-plane relative to the ultrasound probe and slowly be directed from lateral to medial until its tip was located at the apex of the paravertebral space and the endpoint for successful block will be anterior displacement of the pleura by injected local anesthetic where a single injection of 30 ml of 0.25% bupivacaine will be injected.~This procedure will be done on both sides."
45343109|NCT05278598|Procedure|Quadratus Lumborum Plane Block|"After skin sterilization, curvilinear high-frequency ultrasound transducer will be positioned horizontally in the anterior axillary line halfway between the subcostal margin and iliac crest, to locate the triple abdominal muscle layers, then the probe will be relocated subsequently to the posterior axillary line until the quadratus lumborum muscle could be visualized with its attachment to the lateral edge of the transverse process of the L4 vertebral body. With the psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process, this is a well-recognizable pattern of a shamrock with three leaves. A 22-gauge spinal needle will be inserted in-plane relative to the ultrasound probe passing in posterior to anterior direction through the quadratus lumborum to reach the border between it and psoas major, where 30 ml of 0.25% bupivacaine will be injected.~This procedure will be done on both sides."
45343110|NCT05278364|Drug|SY-5007|a RET selective Inhibitor
45343111|NCT05277844|Radiation|Local Consolidative Radiation Therapy|Local consolidative radiation therapy to loco-regional disease and all Oligometastatic sites in addition to TKI
45343112|NCT05277844|Drug|TKI|TKI
46039243|NCT00636064|Drug|Placebo/Valdecoxib|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
46039244|NCT00636064|Other|Placebo/Placebo|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral placebo matched to valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
46039245|NCT01122173|Device|Ablation|Atrial fibrillation ablation procedure
46039246|NCT02751034|Device|Neuramis® Deep Lidocaine|HA filler
46039247|NCT02751034|Device|Restylane® PERLANE-L|HA filler
46039248|NCT02750878|Other|Informational Handout|
46039249|NCT04217668|Drug|Isosorbide Mononitrate 60 MG|1 tablet Isosorbide Mononitrate 60 mg administrated orally.
46039250|NCT01127165|Drug|zonisamide low dose group|Initial dose was 2mg/kg/day, increased after 1~2 weeks to 3~4mg/kg/day.
46039251|NCT01127165|Drug|zonisamide high dose group|Initial dose was 2mg/kg/day, increased after 2~4 weeks to 6~8mg/kg/day.
46039252|NCT02750722|Device|Flutter®|Acute exercise with Flutter® breathing therapy.
46039253|NCT02750722|Device|No Flutter®|Acute exercise without Flutter® breathing therapy.
46039254|NCT04110106|Other|no intervention|All participants were evaluated with the PDQ-39, and the severity of PD was recorded according to the H&Y scale by a neurologist.
46039255|NCT04335292|Drug|Osimertinib First-Line|Osimertinib, 80 mg, oral, daily
46039256|NCT04335292|Drug|Platinum + Pemetrexed Chemotherapy Second-Line|Platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed are prescribed as per institutional standards.
46039257|NCT04335292|Drug|Osimertinib Third-Line|Rechallenge with osimertinib, 80 mg, oral, daily
46039258|NCT00941733|Device|IN.PACT Amphirion|Balloon Angioplasty
46039259|NCT00941733|Device|Standard PTA|Balloon Angioplasty
45343118|NCT05274659|Drug|KJ103|Recombinant Immunoglobulin G Cleaving Enzyme
45343119|NCT05274659|Drug|Placebo|Placebo
45382046|NCT05406193|Other|Patient-centred complex intervention in complicated multimorbidity (CIM2)|CIM2 is the second version of the Patient-centred complex intervention in complicated multimorbidity
45382047|NCT05404529|Drug|Tavapadon|Oral tablets
45343120|NCT05274061|Behavioral|Accelerated, Intensive, Multi-Couple Cognitive Behavioral Couples Therapy|AIM-CBCT consists of an accelerated, 2-day delivery of the first 7 sessions of CBCT for PTSD and is comprised of (a) psychoeducation about PTSD and relationship functioning; (b) instruction in conflict management skills; (c) instruction in effective communication skills with an emphasis on the identification and sharing of emotions to decrease emotional numbing and increase emotional intimacy; (d) discussion of the importance of approaching, rather than avoiding, difficult situations and identification of places, situations, people, and feelings that the couple has heretofore avoided as a result of PTSD; (e) instruction in identification of thoughts and related feelings that can maintain PTSD and relationship distress and strategies to increase cognitive flexibility, and (f) instruction in problem-solving skills to generate couple-level approach behaviors and guidance in how to select activities that double as opportunities to approach feared situations and engage in positive bonding.
45343121|NCT05272137|Device|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
45343122|NCT05270668|Drug|PRA023 IV|PRA023 administered at timepoints as directed by the protocol
45343123|NCT05270668|Device|Companion diagnostic ( CDx)|CDx+ or CDx-
45343124|NCT05270668|Drug|Placebo|Placebo
46039260|NCT04278508|Drug|Progesterone|To determine if different serum P levels on FET day are associated with different clinical pregnancy rates (CPR)
45343126|NCT05263739|Drug|ESG206|Administered via intravenous (IV) infusion
45343127|NCT05262621|Other|progressive muscle relaxation|Practice muscle relaxation for 20 minutes once/a day
45343128|NCT05262621|Other|Listening to relaxing music once/day|Right after practising progressive muscle relaxation, the participants will listen to relaxing music for 20 minutes
45343129|NCT05260606|Diagnostic Test|F-18 FDG PET/CT|"1st scan: pre-Tx, ICI Tx must be started within 35 days after 1st scan.~2nd scan: interim~Pembrolizumab or atezolizumab: after the 2nd Tx cycle to before the start of the 3rd Tx cycle~Nivolumab: after the 3rd Tx cycle to before the start of the 4th Tx cycle~3rd scan: optional (3rd scan can be performed when disease progression is suspected)~Imaging~Fasting: at least 6 hours~Blood glucose level: < 200 mg/dL~F-18 FDG 0.14 mCi/kg (IV)~Image acquisition: 1 hr after FDG injection, CT images are acquired. After CT scan, PET images are acquired and attenuation-corrected PET images are reconstructed based on the CT image data.~PET/CT: Discovery MIDR or MI (GE Healthcare, Chicago, Illinois, USA)~First and second scans have to be performed with same scan."
45343130|NCT05260164|Device|HIFEM+RF|Combination of High-Intensity Focused Electromagnetic Field (HIFEM) and a high radio frequency (RF) field.
46039261|NCT04454242|Other|Expiratory muscle trainig|This exercise will be used to strengthen forced expiratory muscles.
46039262|NCT05382351|Drug|Entecavir|Entecavir group will receive entecavir orally once a day, 0.5mg each time, and fasting for 2h before and after taking the medicine
45343131|NCT05257538|Other|FMT|Fecal microbiota transfer from a healthy and tested volunteer
45343132|NCT05257538|Other|placebo enema|colored water enema
46039263|NCT05382351|Drug|Entecavir combined with Tenofovir Amibufenamide|Entecavir combined with Tenofovir Amibufenamide group will be treated with entecavir and tenofovir amibufenamide. Entecavir is administered in the same way as before. enofovir amibufenamide orally 25mg once a day with meals
45343134|NCT05251337|Drug|Essential oils|Participants will receive Wyndmere Naturals, Inc. aromatherapy patches. The hydrogel adhesive patches are infused with essential oil for inhaled aromatherapy treatment. The aromatherapy patches provide an occlusive barrier that is hypoallergenic, allowing essential oils to be inhaled without coming in direct contact with the skin. Participants indicating nausea/vomiting is their symptom of concern will receive peppermint aromatherapy patches (or mandarin if peppermint sensitivity). Participants indicating anxiety is their symptom of concern will receive lavender aromatherapy patches.
46039264|NCT04218760|Drug|Isosorbide Mononitrate 60 MG Extended Release Oral Tablet [Imdur]|1 tablet Isosorbide Mononitrate 60 mg administrated orally.
46039265|NCT04218760|Other|Blood sample|3 blood samples from a periferal vein, two for RNA and one for metabolomics are taken right before administration of isosorbide mononitrate, 3 hours after administration of isosorbide mononitrate and again 5 hours after administration of isosorbide mononitrate.
46039266|NCT02750488|Drug|BAY987517|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
46039267|NCT02750488|Other|Untreated skin|One site is patched without treatment as control
45343135|NCT05251337|Drug|Placebo|Patients assigned to either control group (nausea/vomiting or anxiety) will receive Wyndmere Naturals non-scented patches (i.e., blank hydrogel adhesive patches without essential oil infusion).
46039268|NCT00604539|Drug|Chondroitin sulphate (Condrosan)|800 mg (two capsules of 400 mg each) taken once a day for one year
45840432|NCT00759330|Drug|Placebo Tape (Arm 3)|Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
46039269|NCT00604539|Drug|Placebo|Two placebo capsules taken once a day for six months followed by an additional six month treatment of 800 mg (two capsules of 400 mg of Chondroitin sulphate each) taken once a day
46039270|NCT02750254|Drug|Fludarabine|
46039271|NCT02750254|Radiation|Fractionated total body irradiation|
46039272|NCT02750254|Drug|Busulfan|
46039273|NCT02750254|Drug|Cyclophosphamide|
46039274|NCT02750254|Radiation|Single dose total body irradiation|
45840433|NCT00759330|Drug|Flurbiprofen Tape (Arm 4)|Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
45840434|NCT00759408|Drug|BQ-123|6-120 µg/min
45840435|NCT00759642|Drug|lapatinib|lapatinib 1500 mg PO daily
46039275|NCT02750254|Drug|Melphalan|
46039276|NCT02750254|Drug|Granulocyte-colony stimulating factor|
46039277|NCT02750254|Procedure|Stem cell transplant|
46039278|NCT02750254|Drug|Azacitidine|
45684021|NCT01540851|Behavioral|Care Navigator|Subjects assigned to the Care Navigator intervention group will receive 10 calls from a care navigator after discharge from the hospital for 5 months after their total knee replacement.
45684022|NCT01540851|Other|Standard Post-Operative TKA Care|Subjects assigned to the Standard Post-Operative TKA Care group will receive the current standard of care for post-operative care
45684023|NCT01516749|Drug|anakinra|Anakinra is supplied in individual pre-filled glass syringes 100mg/0.67mL each. It will be injected subcutaneously once daily for 8 continuous weeks.
45684024|NCT01516437|Procedure|Blood collection|Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.
45684025|NCT01516437|Procedure|Swab collection|Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).
45840436|NCT00759798|Drug|Fludarabine|25 mg/m^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
45840437|NCT00759798|Drug|Cyclophosphamide|250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
45343140|NCT05249998|Other|Program combing APA, Nutrition, and Therapeutic Education|Patients will benefit from the activities already proposed as part of the usual practice and in addition a multidisciplinary staff will take place in order to interpret the assessments of the patients included and to direct the patients according to their phenotypic profile towards the different programmes of adapted physical activity.
45343141|NCT05248672|Drug|CT1812|Study Drug
45684026|NCT01516437|Procedure|Sputum collection|Sputum collection at Day 0 and at exacerbation visits (COPD subjects)
45840438|NCT00759798|Drug|Rituximab|"375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)"
46039279|NCT04218604|Procedure|Personalized atrial fibrillation ablation|Atrial fibrillation (AF) ablation adapting the ablation index (AI) target in a point-by-point manner, according the local left atrial wall thickness (LAWT), as measured by multidetector cardiac tomography (MDCT)
46039280|NCT00941655|Drug|Oxaliplatin|"Oxaliplatin 460 mg/m^2 diluted in 2.0 L/m^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.~Systemic chemotherapy - Oxaliplatin 85 mg/m^2 over 120 minutes,"
46039281|NCT00941655|Drug|Irinotecan|Irinotecan 165 mg/m^2 IV over 90 minutes
46039282|NCT00941655|Drug|5-Fluorouracil|"Surgery and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m^2 intravenous (IV) over 5 minutes.~systemic chemotherapy -3200 mg/m^2 continuous intravenous over 48 hours."
46039283|NCT00941655|Drug|Leucovorin|"surgery and heated intraperitoneal chemotherapy -20 mg/m^2 intravenous over 5 minutes.~systemic chemotherapy - 200 mg/m^2 intravenous over 120 minutes."
45684027|NCT01515423|Drug|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
45684028|NCT01515423|Drug|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
45684029|NCT01515423|Drug|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
45684030|NCT01515423|Drug|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
45840439|NCT00760578|Drug|Placebo|Once daily, oral
45840440|NCT00760578|Drug|Pioglitazone|Once daily, oral
45840441|NCT00760578|Drug|MSDC-0160 90 mg|Once daily, oral
45840442|NCT00760578|Drug|MSDC-0160 220 mg|Once daily, oral
45840443|NCT00761202|Drug|A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®|Eyedrops as required, but at least 3 times per day
45840444|NCT00761202|Drug|Sodium hyaluronate|Eyedrops as required, but at least 3 times per day
46039284|NCT00941655|Procedure|Gastrectomy and/or metastasectomy|"Gastrectomy: tumor resection and a bypass; palliative treatment for pain, bleeding, obstruction and/or if deemed in the best interest of the patient.~Metastasectomy: anatomical segmental resection to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible, followed by systemic chemotherapy."
46039285|NCT00605787|Drug|Tetradecylthioacetic acid (TTA)|1000mg capsules once daily for 28 days
46039286|NCT00939393|Device|FESS instruments with or without balloon treatment|Intervention with metal instruments with or without balloon treatment
45343150|NCT05242458|Drug|Ustekinumab|No interventions will be administered as a part of this study. Participants will receive ustekinumab as per their routine clinical practice.
45343151|NCT05242445|Drug|Cetrelimab|Cetrelimab (Dose 1 and Dose 2) will be administered via SC injection or as an IV infusion.
45343152|NCT05242445|Drug|Placebo|Placebo will be administered via SC injection or as an IV infusion.
45684031|NCT01515423|Drug|Placebo (20% Intralipid)|Form= injection, route= intramuscular use. One injection monthly when not receiving active medication for 48 weeks.
46039287|NCT00939393|Device|Balloon Sinuplasty|Balloon dilatation of sinuses
45343153|NCT05236946|Radiation|Stereotactic radiosurgery/whole brain radiotherapy|SRS/ WBRT for asymptomatic brain metastases depending on the number of brain metastases
45343154|NCT05236946|Drug|Tyrosine kinase inhibitor|TKI
45343155|NCT05234424|Other|THRIVE|During general anesthesia, apneic oxygenation with a high flow nasal oxygen system is applied for 10 minutes. Video laryngoscopy will be performed to achieve similar airway patency.
45343156|NCT05222932|Biological|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
45343157|NCT05222932|Drug|Avelumab|Anti-PDL1 antibody
45343158|NCT05218655|Drug|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm description.
45684032|NCT01515423|Drug|PP1M 50 mg eq.|Type= exact number, unit= mg eq., number= 50, form= injection, route= intramuscular use. One injection every month for 48 weeks.
45684033|NCT01515423|Drug|PP1M 75 mg eq.|Type= exact number, unit= mg eq., number= 75, form= injection, route= intramuscular use. One injection every month for 48 weeks.
45684034|NCT01515423|Drug|PP1M 100 mg eq.|Type= exact number, unit= mg eq., number= 100, form= injection, route= intramuscular use. One injection every month for 48 weeks.
45684035|NCT01515423|Drug|PP1M 150 mg eq.|Type= exact number, unit= mg eq., number= 150, form= injection, route= intramuscular use. One injection every month for 48 weeks.
46039288|NCT05382273|Behavioral|T-Break Guide|"The T-Break Guide was designed to help people complete a 21-day break from cannabis. For each day of the break, the Guide offers inspiration in the form of a quote, reflections based on likely experiences occurring at that point during the break, advice on ways to overcome challenges, alternative activities in which to engage, and encouragement.~The first week focuses on physical symptoms of cannabis withdrawal (e.g., sleep, appetite).~The second week focuses on the emotional experience (e.g., anxiety, boredom).~The third week focuses on behavioral aspects (e.g., examining patterns, connections).~The T-Break Guide follows the Motivational Interviewing principles of affirmation and autonomy."
46039289|NCT05382195|Other|hospital anxiety and depression scale|questionare on patients with multiple sclerosis
45343159|NCT05216419|Drug|Cholecalciferol|"Since the concentration of D-mac 30,000 IU in the body reaches the maximum in the body around 1 to 3 weeks after administration, the drug is taken once 15 days before the surgery so that the vitamin D3 concentration is maximized at the time of surgery.~In the case of the control group, there is no drug to be taken."
45382048|NCT05403554|Biological|NI-1801|All treatments will be administered in 28-day cycles. Each subject will receive the assigned dose of NI-1801 on Cycle 1, Day 1. Subsequent doses will be given once weekly (QW) in Cycles 1 and 2 (e.g., Days 1, 8, 15, and 22), and once every two weeks (Q2W) in Cycles 3 through 6 (e.g., Days 1 and 15). NI-1801 treatment can extend beyond 6 cycles for those patients who do not have disease progression.
45474134|NCT01176227|Dietary Supplement|Kyodophilus Matching Placebo Capsules|Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.
46039290|NCT04441996|Biological|Therapeutic plasma exchange (TPE)|Participants will receive two treatments of TPE with frozen plasma (FP) replacement on two sequential days (Day 2 and Day 3). All procedures will be performed by the apheresis staff at the hospital sites, following institutional standard operating procedures. FP will be obtained from American Red Cross or LifeSouth Community Blood centers.
45382049|NCT05403450|Drug|Tolinapant|Capsule for oral administration
45474135|NCT04597320|Drug|Fentanyl|"The fentanyl group was prepared by 1ug/kg fentanyl in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer."
45474136|NCT04597320|Drug|Esketamine|"The esketamine group was prepared by 0.5mg/kg esketamine in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer."
46039291|NCT04441996|Other|Standard of care|Participants will continue to receive standard of care and be closely monitored by ICU team for any change in clinical status, and any adverse events directly related to study intervention will be reported to the study investigator.
46039292|NCT04267965|Procedure|parathyroidectomy plus bilateral thymectomy and autotransplantation|Patients should receive total parathyroidectomy plus bilateral thymectomy and autotransplantation
45382050|NCT05403450|Drug|Decitabine + Cedazuridine|Tablet for oral administration
45382051|NCT05400369|Drug|Sitafloxacin|Oral administration, 50 mg tablets
45382052|NCT05400369|Drug|Moxifloxacin Hydrochloride|Oral administration, 400 mg tablets
45474137|NCT04597320|Drug|Midazolam|"Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg."
45474138|NCT03373708|Drug|Epirubicin|100mg/m2
45474139|NCT03373708|Drug|Cyclophosphamide|600mg/m2
45474140|NCT03373708|Drug|Docetaxel|75mg/m2(TC), 100mg/m2(EC-T)
45474141|NCT03373708|Drug|Goserelin acetate|3.6mg every month
46039293|NCT05380869|Diagnostic Test|Point-of-care Test|to test Point-of-care procalcitonin in suspected pneumonia
46039294|NCT02750020|Other|Questionnaire|Current study is a retrospective telephone survey based on questionnaires. It aims to investigate the level of public support on current and future tobacco control measures and taxation policies and to address the timely impacts of smoke-free policies, substantiate public support on further tobacco control measures and assist COSH in shaping policy direction for government. The telephone survey will be conducted by a telephone survey agent under the monitor of applicants.
46039295|NCT04190836|Behavioral|Self-Managed Exercise Strategy|The intervention is a personalised supported self-management intervention which emphasises dynamic, progressively loaded exercises for the shoulder. The intervention consisted of 1-5 individual sessions provided over 3 months, with a duration of 1 hour for the first session and 45 minutes for the following. The participants will have the opportunity to contact the physiotherapist by phone, text message or e-mail for advice during the treatment period (12 weeks). The personalised supported self-management intervention will be based on the components of the self-management framework, provided by Lorig and Holman (2003). The five self-management skills and the operationalization of these will be described when publishing the study. For specific content reporting of the self managed exercises we will follow the Consensus on Exercise Reporting Template.
46039296|NCT00936117|Drug|Posaconazole|200 mg (liquid) by mouth 3 times per day.
45382053|NCT05398237|Other|Solar Simulated Light (SSL)|Acute SSL will be delivered to sun damaged skin at a rate of two-times the minimal erythema dose of each individual subject. Minimal erythema dose is defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 22-26 hours post-exposure.
46039297|NCT04218682|Behavioral|Shadow's Edge Mobile Application Gameplay|6 weeks of individual, interactive game play of the Shadow's Edge mobile app.
45382054|NCT05395442|Diagnostic Test|Training on web-based diabetic foot care based on the Health Belief Model|Training on web-based diabetic foot care based on the Health Belief Model will be implemented.Four materials will be used in the research, namely the Introductory Information Form, the Foot Care Behavior Scale, the Diabetic Foot Care Self-Efficacy Scale.
46039298|NCT04267653|Drug|Lactoferrin Bovine|treatment for 30 days
46039299|NCT04267653|Drug|Ferrous Sulfate|treatment for 30 days
45474142|NCT03373708|Drug|Tamoxifen|10mg twice daily oral
45474143|NCT03373708|Drug|Letrozole|2.5mg every daily oral
45474144|NCT01173965|Device|MEA|Microwave endometrial ablation device
45474145|NCT01173965|Device|Novasure|Bipolar impedence control system
46039300|NCT04088500|Biological|Nivolumab|Specific dose on specific days
46039301|NCT04088500|Biological|Ipilimumab|Specific dose on specific days
45343160|NCT05212714|Device|taVNS|The non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) device that will be used in this study is a wearable TENS unit called the Vorso STIM100 System. The Vorso system consists of a wearable, external stimulator, a neural interface ear piece, and an arm band designed to be safe for human contact. The external stimulator generates electrical pulses that are transcutaneously delivered to the auricular branch of the vagus nerve through the ear canal. The ear piece contains 4 electrodes that carry current from the external stimulator to the auricular branch of vagus nerve. The external stimulator connects to a flexible arm band that attaches to the upper arm for ease of use during each stimulation session. The type of stimulation (including shape, frequency, pulse width, amplitude, total charge, and energy delivered) is comparable to the levels applied by commercially available TENS stimulators. The sham control group will not receive any stimulation.
45343161|NCT05205863|Biological|Cofact|Human prothrombin complex concentrate
46039302|NCT05379153|Device|Laser Therapy|Undergo vaginal fractional CO2 laser therapy
46039303|NCT05379153|Device|Sham Intervention|Undergo placebo procedure
46039304|NCT05379153|Other|Questionnaire Administration|Ancillary studies
45474146|NCT03363412|Device|PTFE-covered stent grafts|Creation of a small diameter intrahepatic shunt between portal and hepatic veins.
46039305|NCT05379153|Other|Quality of Life Assessment|Ancillary studies
45343165|NCT05200897|Device|Transdermal trigeminal electrical neuromodulation(Cefaly)|The Cefaly device delivers electrical micro-impulses through a self-adhesive electrode which is placed over the participant's forehead, where the supratrochlear and supraorbital branches of the ophthalmic division of the trigeminal nerve are located. Rectangular, biphasic impulses with an electrical mean equal to zero are transmitted. The impulse width is 250μs, frequency is 60Hz, and the maximum intensity of 16mA is over 14 minutes
45840445|NCT00761592|Biological|Botulinum Toxin Type A 900kDa|6 to 16 injections, with maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
45840446|NCT00761592|Biological|Botulinum Toxin Type A 150kDa|6 to 16 injections, with a maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
45343166|NCT05199441|Drug|Dihydroxydibutylether group|This group takes 1.500 mg/day of dihydroxydibutylether for 8 weeks.
45343167|NCT05199441|Drug|Control group placebo|This group takes 1,500 mg/day of placebo for 8 weeks.
45840447|NCT00762216|Device|AcrySof® Toric intraocular lens|Implantation of the AcrySof Toric intraocular lens (IOL) into the eye following cataract extraction surgery
45840448|NCT00762450|Drug|Triclosan, Fluoride|Rinse 3 times daily with assigned toothpaste slurry
45840449|NCT00762450|Drug|fluoride|Rinse 3 times daily with assigned toothpaste slurry
46039306|NCT04218214|Other|LIFE-DM Group (Integrated Depression and Livelihood Group Intervention)|Livelihood Integration for Effective Depression Management (LIFE-DM) program aims to address the dual challenges of poverty and depression by integrating evidence-based treatment for depression management and microfinance services. The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and access to microfinance loans. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union. The intervention generally lasts about 3-4 months.
46039307|NCT05379075|Other|26 styles of Chen Taichi training based on Relaxation guidelines|The arms and legs and the spine should rotate follow the arrow tips in order to cause a stretch reflex slightly. And then, the exerciser should use relaxation skills to eliminate the stretch reflex, such as exhaling, drop the control of body
46039308|NCT05379075|Other|26 styles of Chen Taichi training based on Coordination guidelines|"When the posture needs to open the arms should accompany with inhale and when the posture needs to close the arms should accompany with exhale. Similarly, if the arm is lifting should accompany with inhale, and the put down should accompany with exhale."
46039309|NCT02750098|Other|Glucose measurement|"Elective cataract surgery~Blood glucose measurement - glucometer~Aqueous humor glucose measurement - at beginning of cataract surgery - glucometer~Perioperative Hemoglobin A1c level - blood laboratory test"
46039310|NCT01082874|Drug|Active Clonidine|Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.
46039311|NCT01082874|Drug|Placebo Clonidine|Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.
46039312|NCT01082874|Drug|Active ASA|Pre-op (goal 2-4 hours): 2 x 100mg oral tablets. Post-op: patients ingest one tablet a day (100 mg ASA) for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
46039313|NCT01082874|Drug|Placebo ASA|Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
46039314|NCT04009408|Device|Expiratory muscle strength therapy (EMST150, Aspire LLC)|Active therapy calibrated to the participant's maximum expiratory pressure
46039315|NCT00933543|Drug|Visonac PDT (MAL PDT)|Cream application followed by illumination with red light.
45343172|NCT05196529|Other|Inspiratory muscle training|All participants will undergo inspiratory muscle training.
45343173|NCT05196464|Behavioral|Acceptance and Commitment Therapy (ACT) Workshop|ACT workshops are single-day workshops that last 5-6 hours. The workshops will 1) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from unhelpful thoughts) and strategies to willingly face experiences that cannot be changed; and 2) Committed Action Training to help Veterans clarify what matters most to them (e.g., valued domains including family, friends, spirituality, career) and what they want to stand for in life, how they want to behave, and what strengths and qualities they want to develop. Within this context, the workshop will encourage engagement in, rather than avoidance of, actions consistent with valued directions, including engagement in healthcare. Workshop participants will be given homework related to implementing a key coping skill.
45343174|NCT05196464|Behavioral|Treatment as usual (TAU)|TAU will consist of a consult to a mental health provider at their rural clinic. The patient will then be scheduled for an intake and offered traditional mental health treatment options. Treatment options are likely to include outpatient individual psychotherapy, psychotherapy groups, or medication management.
46039316|NCT00933543|Drug|Vehicle cream (placebo)|Cream application followed by illumination with red light.
45382056|NCT05393986|Drug|CT048 Autologous Injection (CT048)|up to 3 times CT048 Autologous Injection infusion
45840450|NCT00762450|Drug|Fluoride, triclosan, amino acid|Rinse 3 times daily with assigned toothpaste slurry
45840451|NCT00762528|Drug|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
45840452|NCT00762528|Drug|Sodium monofluorophosphate toothpaste|Twice daily usage
45840453|NCT00765570|Radiation|Spatially Fractioned Radiation Therapy|evaluate response to radiation therapy by a large bulky tumor influenced by adding a single dose of 15 Gy grid radiotherapy.
45840454|NCT00765570|Radiation|Treatment Group 1|one treatment of Grid therapy followed by 15 treatments with standard radiation
45840455|NCT00765570|Radiation|Standard radiation|15 Standard radiation treatments
45840456|NCT00765570|Radiation|Standard radiation|standard radiation treatment
45840457|NCT00765648|Drug|nicardipine intravenous|nicardipine intravenous 5 mg/hour titrated every 5 minutes by 2.5 mg/hour until target systolic blood pressure range (TSBPR) is reached or maximum dose of 15 mg/hour is achieved.Following achievement of target systolic blood pressure range the infusion rate should be decreased to 3 mg/hour
46039317|NCT00933543|Procedure|PDT|Photodynamic Therapy - Light dose 37 J/cm2
46039318|NCT02695498|Other|Mindfulness Based Stress Reduction|"MBSR is a standardized course in mindfulness mediation and yoga. The participants will meet weekly for 8 weeks for 2.5 hours, plus a mindfulness retreat day (approximately 6 hours) after the 6th class [9 total classes.] Mindfulness is cultivated through meditation, body scan (sequential attention to parts of the body), and mindful movement (bodily awareness during gentle stretching, based on yoga). The instructor also gives information about stress and stress relief."
46039319|NCT02695498|Other|Migraine/stress Education|The participants will be educated about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
46039320|NCT02749942|Device|AutoRIC: Remote Ischemic Conditioning|"4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG) using the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
46039321|NCT02749942|Device|AutoRIC: Sham device treatment|"4 cycles of 5 minute forearm sham treatment (no ischemia/reperfusion, 0 mmHG pressure) with the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
46039322|NCT00607503|Drug|Terbutaline|"Each subject will be treated with terbutaline for 21-28 days following the initiation of treatment during the CRC admission.~Subjects weighing between 25 and 45 kg will be treated with a nightly oral dose of 2.5 mg and subjects who weigh more than 45 kg will be treated with 3.75 mg.~The standard 2.5 mg terbutaline tablets available in a pharmacy will be used in the study, with subjects taking either 1 or 1.5 tablets nightly."
46039323|NCT04264533|Drug|VC|12g Vitamin C will be infused in the experimental group twice a day for 7 days by the infusion pump with a speed of 12ml/h.
46039324|NCT04264533|Drug|Sterile Water for Injection|50ml sterile water for injection will be infused in the placebo comparator group twice a day for 7 days by the infusion pump with a speed of 12ml/h.
46039325|NCT02750176|Other|Closed chain exercises|Closed-chain strengthening will be performed with the shoulder moving over a fixed hand. Resistance will be provided by body weight against gravity. To off-load and progress the amount of body-weight resistance, elastic bands will be used to support body weight using a exercise frame. Patients will perform 6 exercises.
45840458|NCT00765648|Drug|Labetalol|Labetalol: bolus therapy to start at 20 mg intravenous injection over 2 minutes, may repeat 20mg, 40mg or 80mg injections every 10 minutes until target systolic blood pressure range(TSBPR)is reached or a maximum of 300 mg is injected.
46039326|NCT01082328|Drug|Kuvan®|Kuvan® (sapropterin dihydrochloride) oral solution 20 milligram per kilogram (mg/kg) will be given once daily for 28 +/- 1 days.
45840459|NCT00766116|Drug|5-Azacitidine|Given in cohorts of 3 starting with 2 doses of 5-azacitidine. The doses of 5-azacitidine will be escalated to 4 and then 6 doses if the dose escalation rules permit.
45840460|NCT00766116|Drug|Gemtuzumab ozogamicin|Mylotarg given 2 times over 2 weeks
46039327|NCT04172584|Behavioral|correct use of the contraceptions|know the emergency contraception and how to use
46039328|NCT03796000|Procedure|tissue samples, blood and stool sample|Tissue samples from gastroscopy/colonoscopy.
46039329|NCT02749786|Other|Skin Biopsy|Skin biopsies will be performed via the Keys punch technique from normal facial skin.
46039330|NCT04218058|Procedure|reduction of zygomatic arch in zygomaticomaxillary complex fracture|ultrasound guided reduction of zygomatic arch
45840461|NCT00767364|Biological|Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)|Oral vaccine for prevention of rotavirus infection, 3 dose series
45840462|NCT00769314|Drug|Acyclovir Lauriad|50 mg muco-adhesive buccal tablets, single application on the gum
45840463|NCT00769314|Drug|Placebo|50 mg muco-adhesive buccal tablets, single application on the gum
45840464|NCT00769392|Drug|Proparacaine Ophthalmic|Drops of Proparacaine on the eye, administered as described in the package insert
45840465|NCT00769392|Drug|Tetracaine Ophthalmic|Drops of Tetracaine on the eye, administered as described in the package insert
45840466|NCT00769392|Drug|Lidocaine 4%|A cotton sponge(pledget)soaked with Lidocaine 4% placed over the conjunctiva
45840467|NCT00769392|Drug|Lidocaine 2% Injectable Solution|A subconjunctival injection of Lidocaine 2%
45474147|NCT04007796|Behavioral|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
45474148|NCT04007796|Behavioral|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
45474149|NCT03363334|Drug|Fostamatinib disodium 100 mg|Fostamatinib Disodium tablet 100 mg PO bid (morning and evening)
45474150|NCT03363334|Drug|Fostamatinib disodium 150 mg|Fostamatinib Disodium tablet 150 mg PO bid (morning and evening)
45474151|NCT03742271|Device|senofilcon A|TEST Lens
45474152|NCT03214224|Device|remote pulmonary function testing|Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
45474153|NCT03214224|Device|standard pulmonary function testing|Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
45474154|NCT03123562|Combination Product|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear Cells
45474155|NCT05280353|Other|Glubran 2|Application of Glubran 2 sealant (liquid) in axillary hollow
46039331|NCT04217434|Procedure|400 µm fibre length will be used in continuous contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 400 µm fibre length will be used in continuous contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
45382057|NCT05393518|Behavioral|Anxiety-induced task|Subjects will be asked to describe their most anxious thoughts and write each of them in a detailed scenario. The scenarios will be based on the answers to the Worry and Anxiety Questionnaire, in order to validate the procedure by a standardized examination. During the task, the scenarios will be successively presented to the subjects, on a digital computer medium in written and oral format. Subjects will be asked to actively focus on these negative thoughts with maximum concern, without seeking to control their emotions.
45382058|NCT05393518|Behavioral|Neuropsychiatric assessment|Screening for depression and anxiety
45382059|NCT05391477|Device|GI-Genius artificial intelligence|The software allows for the real-time characterization of framed polyps during a colonoscopy classifying them on adenoma or non-adenoma.
45474156|NCT05571228|Behavioral|Self-stigma intervention|Be Outspoken and Overcome Stigmatizing Thoughts (BOOST) is a group-based intervention integrating cognitive behavioural therapy (CBT) and peer support to reduce or prevent the internalization of stigma in early psychosis. The BOOST group will last for 4 weeks and consists of two 1-hour sessions per week. Participants will be assessed prior to the first group, following the final group, six months after the group ends, and twelve months after the group ends.
45382060|NCT05389709|Drug|Iberogast (STW5-II, BAY98-7410)|Survey without any intervention assigned in the study.
45382061|NCT05388760|Drug|Tralokinumab|A loading dose under the skin (s.c.) at first treatment visit and then injections in accordance with a pre-defined schedule for 16 weeks (initial treatment) followed by a maintenance treatment for 52 weeks (open-label treatment).
45684036|NCT00637156|Device|PRESTIGE LP device at two adjacent levels|PRESTIGE LP is a prosthetic device intended to replace a damaged disc in the cervical spine and intended to act as an intervertebral body spacer rather than a fusion device. It is inserted using an anterior surgical approach.
45684037|NCT00637156|Device|Bi-level fusion with ATLANTIS Cervical Plate System|Bi-level anterior cervical fusion procedure involving cortical ring allograft and the ATLANTIS Cervical Plate System.
45684038|NCT00637000|Drug|Buprenorphine soluble film|Buprenorphine soluble film strips administered sublingually with doses escalated from 12 mg per day up to 24 mg daily for 5 days of total treatment.
45684039|NCT00637000|Drug|Buprenorphine/naloxone film strip|Buprenorphine/naloxone soluble film strips administered sublingually with doses escalated from 12 mg buprenorphine/3 mg naloxone to 24 mg buprenorphine /6 mg naloxone daily for 5 days of total treatment.
45684040|NCT00637000|Drug|Placebo|Placebo soluble film administered on the same schedule as active treatment to maintain the study blind.
45382062|NCT05387707|Drug|difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg tablets administered twice daily
45382063|NCT05387707|Drug|difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg tablets administered twice daily
45382064|NCT05387707|Drug|TCS Cream|TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
45684041|NCT01515189|Biological|Ipilimumab|
45684042|NCT04767399|Behavioral|protaper next|rotary systems used on patients need root canal treatment
45684043|NCT01546623|Drug|TAP-144-SR(6M)|
45684044|NCT01546623|Drug|TAP-144-SR(3M)|
45382065|NCT05387707|Drug|Placebo|Oral Placebo tablets administered twice daily
45382066|NCT05387707|Drug|Vehicle Cream|Vehicle Cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
45684045|NCT01546155|Radiation|PET imaging|Up to a 120 minute PET scan using [11C]diprenorphine as the radiotracer
46039332|NCT04217434|Procedure|400 µm fibre length will be used in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 400µm fibre length will be used pulsed contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
45474157|NCT03369184|Drug|Oxygen gas|The intervention is administered as previously described. The duration of intervention is 10 minutes.
46039333|NCT04217434|Procedure|300 µm fibre length will be used in continuous mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 300 µm fibre length will be used continous contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
45343175|NCT05195866|Diagnostic Test|CRP POCT (C-reactive protein point of care test)|"CRP POCT equipment will be supplied at healthcare centers, along with a short training in use and interpretation supporting the clinical evaluation of the child. It will be communicated that CRP levels less than 10 indicate that the disease is not severe, and antibiotics is most likely not needed, if between 10 and 50, that antibiotics might be needed, and if more than 50 that it is likely that they are needed. With CRP between 10-50 the HCW are instructed to take the clinical picture into account together with the value of the test.~The training will also include knowledge of CRP pharmacodynamics and cases where a low CRP might need to be interpreted cautiously, e.g. a history of fever lasting less than 24 hrs. HCWs will be instructed to use CRP POCT for all patients in the intervention group and use the information to guide diagnosis and treatment choice. We will use Aidian (Copenhagen, Denmark) QuickRead go CRP POCT set-up."
45474158|NCT03369184|Other|Ambient air|Administered similarly to treatment arm, via an open face mask and during 10 minutes
45343176|NCT05192226|Behavioral|Counterfactual Strategy|Participants in this intervention condition will think about their past and identify how a less than desirable physical activity event could have turned out better using counterfactual thinking (i.e., If only I... then....). After identifying actions they could have taken to reach a better outcome in their physical activity event, they will then apply those thoughts to the future upcoming week so they can be realized.
45343177|NCT05191485|Other|Qualitative interviews|We will conduct semi-structured interviews with target patients, patients' representatives and other stakeholders to assess their decisional needs. The cognitive debriefing interview will start afterwards, and participants will answer probing questions asked by interviewers about DA_LCMT 1.0. Then the field testing interviews will conducted one-on-one structured interviews.
45474159|NCT01174277|Other|Collection of blood sample|Participation involves collection of blood sample at baseline, 2, 4, 6 and 12 months regardless of whether or not patients continue on treatment.
45474160|NCT03123952|Drug|ABT-414|ABT-414 will be administered by intravenous infusion
45684046|NCT00636610|Drug|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules in 3 different strengths, 25 mg, 125 mg, and 150 mg.
45684047|NCT00636610|Drug|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
45684048|NCT00636610|Drug|Bevacizumab|Bevacizumab 5 mg/kg was administered intravenously (IV) over 90 minutes for the first infusion, shortening to 60 and 30 minutes for subsequent infusions.
45474161|NCT03865745|Dietary Supplement|Korean Red Ginseng|Take one pack of the product (3g) once a day for 24 weeks
45474162|NCT03373630|Device|Midline catheter|The catheter will be inserted according to usual practices, after the enrollment of the patient in the study. The follow-up will last until the removal of the catheter, which will also be done according to usual practices. Following the removal, bacteriologic analyses will be performed in order to diagnose any prospective infection.
45474163|NCT03180645|Other|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
45474164|NCT03180645|Other|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
45474165|NCT03180645|Other|No treatment|No treatment
46039334|NCT04217434|Procedure|300 µm fibre length will be used in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 300 µm fibre length will be used pulsed contact mode at a power setting of 1.5 - 3W. .Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
46039335|NCT04217512|Drug|Pantoprazole low dose|Pantoprazole 0.6 mg/kg
45343178|NCT05187195|Other|Home-based telerehabilitation with exercise videos|Balance, walking, strengthening, posture videos etc. taken in different positions will be uploaded to the telerehabilitation system. A personalized exercise program will be created from these exercises. This program will be defined to the account of the patient and the follow-up of the person will be carried out through the system.
45343179|NCT05187195|Other|Exercise brochure|Photos and explanations of exercises taken in different positions such as balance, walking, strengthening, posture etc. will be uploaded to the telerehabilitation system. A personalized exercise brochure will be created from these exercises. This program will be defined for the patient's account and the patient will be asked to follow the exercises with this brochure.
45474166|NCT03124030|Procedure|simple dental extraction|dental extraction is performed by an expert oral surgeon within 20 minutes. Non-resorbable suture are applied
45474167|NCT03750695|Behavioral|Resistance exercise|One acute exercise session of resistance exercise (40 minutes including 3 sets of 8-10 repetitions at the participant's 10 repetition maximum load of upper and lower extremity exercise
45343180|NCT05180136|Dietary Supplement|Rice bran extract group|Rice bran extract 1,000 mg/day for 8 weeks
45474168|NCT03750695|Behavioral|Aerobic Exercise|One acute session of aerobic exercise (40 minutes of cycle ergometry exercise at 70% of VO2peak)
45474169|NCT03750695|Behavioral|Rest|40 minutes of quiet rest in semi-recumbent position
45474170|NCT02519530|Behavioral|Teen Outreach Program|The Teen Outreach Program (TOP) is a positive youth development program that uses weekly educational peer group sessions, Community Service Learning (CSL), and positive adult guidance to help youth in grades 6-12 build healthy behaviors, life skills, and a sense of purpose. For this study, TOP was implemented in traditional public high schools in Florida and delivered by local health department staff, who were trained and certified as TOP facilitators. Youth enrolled in these classes received the TOP intervention in addition to, not as a replacement for, all business-as-usual curriculum content.
45474171|NCT05010213|Other|Educational intervention|Educational intervention
45474172|NCT03373552|Diagnostic Test|Platelet function assay|Platelet function assay
45474173|NCT03373474|Other|local distribution points association|"Participants will receive acupuncture treatments using the local points set plus the local-addition points set (local distribution association) described below. Warming acupuncture will be applied at HT2, LI11, and TE9 if permitted.~Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Local-addition points set: LU5, PC3, SI7, TE4, TE3, HT2, TE10, LI15, and 2 other points according to the symptom on the affected arm."
45474174|NCT03373474|Other|local-distal points association|"Participants will receive acupuncture treatments using the local points set plus the distal points set (local-distal association) described below. Warming acupuncture will be applied similarly to the local distribution group, with the addition of Ren6, Ren9, bilateral SP9, and LI11 on the unaffected arm.~Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Distal points set: TE5, LI11, HT3, TE13 on the unaffected arm; CV4, CV6, CV9, CV12, bilateral SP6 and SP9."
45474175|NCT02518906|Behavioral|Adolescent Identity Treatment|"Integrative Approach for the treatment of adolescents with Personality Disorder.~Manual was published in 2013."
45474176|NCT02518906|Behavioral|DBT-A|Dialectic Behavioral Treatment for Adolescents is the most commonly used Approach for the Treatment of adolescents with Boderline Personality Disorder
45474177|NCT02519608|Drug|Aspirin 100 mg|Patients with COPD and SCAD undergoing PCI and stent implantation will receive aspirin
45474178|NCT02519608|Drug|Ticagrelor|Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + ticagrelor (loading dose 180 mg + maintenance 90 mg x2)
45474179|NCT02519608|Drug|Clopidogrel|Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + clopidogrel (loading dose 600 mg + maintenance 75 mg)
45474180|NCT03699930|Device|tDCS|Anodal or sham tDCS will be applied to the scalp.
45474181|NCT03699930|Behavioral|Speech and language therapy|A trained speech pathologist will administer the speech and language therapy.
45474182|NCT03363178|Biological|GC3107|BCG Vaccine, 0.1mL
45474183|NCT05181852|Drug|IP2015, dose 1|Active
45474184|NCT05181852|Drug|IP2015, dose 2|Active
45474185|NCT05181852|Drug|Placebo|Placebo
45474186|NCT05181852|Drug|Pregabalin|Comparator
46039336|NCT04217512|Drug|Pantoprazole high dose|Pantoprazole 1.6 mg\kg
46039337|NCT04217512|Other|Standard hydration|Standard hydration alone
46039338|NCT04217512|Drug|Cisplatin|Cisplatin
46039339|NCT02749708|Drug|IRX5183|IRX5183 will be administered orally daily on days 1-28 of each cycle for 2 cycles of induction. In the phase I part of the study, there will be 3 dose levels (dose level 1 [DL1] with 50 mg, DL2 with 75 mg, and DL3 with 100 mg), with 1 additional dose level to be only used if excessive toxicity noted at the DL1. There will be no intra-patient dose escalation. A phase II portion of the study was originally planned, but the study was terminated prior to phase II enrollment.
46039340|NCT03632434|Device|transcranial direct current stimulation|tDCS generates a small electric current which modulates how easy it is for active brain cells to discharge. The device is a neoprene cap worn over the head, and in the cap there are two electrodes, which are small metal discs, where the current comes from.
46039341|NCT02749552|Behavioral|Acceptance and Commitment Therapy|weight-related interventions using values, acceptance, and mindfulness based on Acceptance and Commitment Therapy
46039342|NCT04217980|Diagnostic Test|Lung ultrasonography (LUS) or Chest X ray (CXR)|pediatrician researcher (PR) will conduct a LUS or CXR at admission time as a first test of lung image depending on randomized group.
46039343|NCT01079988|Drug|Cyclosporins|Starting dose 4.0 - 5.1 mg/kg/day until clinical improvement. Upon clinical improvement, cyclosporin dose to be tapered by 50% every two weeks.
46039344|NCT01079988|Drug|Retinoids|Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.
46039345|NCT01079988|Drug|Systemic corticosteroids|Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.
46039346|NCT01079988|Drug|Methotrexate|Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.
45343181|NCT05180136|Dietary Supplement|Control group|Placebo 1,000 mg/day for 8 weeks
45343182|NCT05177770|Drug|SRF617|SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39.
45343183|NCT05177770|Drug|etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
46039347|NCT01079988|Drug|Systemic corticosteroids/methotrexate|Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks.
45343184|NCT05177770|Drug|zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
46039348|NCT03974152|Other|Subox Mini C with Avail 18 mg nicotine salt (protonated)|Participants will be instructed to take one puff of the Subox Mini C with Avail 18 mg nicotine salt (protonated) liquid every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
46039349|NCT03974152|Other|Subox Mini C with Avail 18 mg nicotine (unprotonated)|Participants will be instructed to take one puff of the Subox Mini C with Avail 18 mg nicotine (unprotonated) liquid every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
45343185|NCT05175313|Radiation|transthoracic ultrasonography|"lung ultrasonography~Diaphragm and respiratory muscle ultrasound~inferior vena cava ultrasound"
45343186|NCT05175313|Device|spirometry|pulmonary function test : FVC, FEV1, FEV1/FVC will be measured.
45343187|NCT05175053|Other|Renal replacement therapy|Continuous renal replacement therapy using continuous venovenous hemodiafiltration (CVVHDF)
45343188|NCT05175053|Other|Best medical management|The best medical management continues until the patient meets absolute indication of renal replacement therapy
45343189|NCT05174975|Behavioral|App-based Positive Psychological Intervention|The PPI has included a 12-week PPI lessons. Each lesson has separated into 3 parts: introduction, activity, and feedback. Diabetes-related health education will include the basic knowledge of diabetes, diet, and exercise related videos. Physical records include record of daily blood sugar, blood pressure, HbA1c, diet, and exercise. In terms of dietary records, the amount of carbohydrates of each food will be calculate automatically after documented. Exercise records documents the burn of calories of each exercise (per 30 minutes). Both unit of dietary and exercise are based on Health Promotion Administration's criteria in Taiwan. Moreover, participants are available to have one-on-one instant online consultation with their diabetes educators via App.
45343190|NCT05170399|Biological|PNEUMOVAX 23|Pneumococcal Polysaccharide Vaccine (PPSV23)
45343191|NCT05170399|Biological|Fluarix|Annual Influenza Vaccine
45343192|NCT05170399|Biological|FluLaval|Annual Influenza Vaccine
45343193|NCT05170399|Biological|Pfizer-COVID-19 Vaccine|COVID-19 Vaccine
45840468|NCT00770874|Drug|S-1 + Cisplatin (arm A)|S-1 will be administered orally, twice daily from Day 1 through Day 14 followed by a recovery period from Days 15 through Day 21. Initial dose of S-1 will be determined according to the patient's body surface area (80 to 120 mg/day). On Day 1, Cisplatin 50 mg/m2 will be administered intravenously (IV). This regimen is to be repeated every 3 weeks.
45840469|NCT00770874|Drug|Cisplatin (arm B)|Cisplatin 50 mg/m2 will be administered intravenously (IV) on Day 1, repeated every 3 weeks.
46039350|NCT03974152|Other|Own brand cigarette|Participants will be instructed to take one puff of a cigarette matching their typical brand every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
46039351|NCT02876718|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|No specified dosing or dosage in the study. The treatment decision falls within current practice and the prescription of the medicines is clearly separated from the decision to include the patient in the study.
45343194|NCT05170399|Biological|Heplisav -B|Recombinant, adjuvanted Hepatitis (HepB-CpG)
45343195|NCT05170399|Biological|PREVNAR 13|Pneumococcal Conjugate Vaccine (PCV13)
45343196|NCT05170399|Biological|Afluria|Annual Influenza Vaccine
45343197|NCT05170399|Biological|Flucelvax|Annual Influenza Vaccine
45343198|NCT05170399|Biological|Shingrix|Recombinant, adjuvanted Zoster Vaccine (RZV)
45343199|NCT05170399|Biological|Fluzone|Annual Influenza Vaccine
46039352|NCT03508570|Biological|Ipilimumab|Given i.p.
46039353|NCT03508570|Other|Laboratory Biomarker Analysis|Correlative studies
46039354|NCT03508570|Biological|Nivolumab|Given i.p.
46039355|NCT03508570|Other|Pharmacokinetic Study|Correlative studies
46039356|NCT04218370|Procedure|Dialysis|Dialysis treatment, either in the form of hemodialysis or continuous renal replacement therapy (if patient develops hemodynamic instability)
46039357|NCT04217122|Other|strawberry powder|Participants consume 2 packages of standard strawberry powder (13 g x 2) daily for 4 weeks
46039358|NCT04217122|Other|placebo powder|Participants consume 2 packages of placebo powder (13 g x 2) daily for 4 weeks
46039359|NCT01074216|Drug|vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)|Patients will be given vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units) three times per week until the target vitamin D level of 40 ng/ml is achieved, and vitamin D3 maintenance initiated at 2,000 International Units daily thereafter.
46039360|NCT04217044|Diagnostic Test|Histopathology images based prediction of molecular pathology|Histopathology images based prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI
46039361|NCT04218136|Biological|Blood samples|A minimum of 4 blood samples and a maximum of 6 blood samples will be collected. Venous return blood samples collected as part of routine monitoring of patients for bioclinical parameters. Samples will be collected before start of the infusion and end of the infusion
46039362|NCT01079832|Radiation|stereotactic radiosurgery|Radiation will be delivered in 3 fractions. The dose level will range between 500 to 800cGy per fraction at the discretion of the treating radiation oncologist
46039363|NCT01079832|Procedure|quality-of-life assessment|Ancillary studies
46039364|NCT02749630|Drug|Placebo|Matching placebo to UTTR1147A administered intravenously
46039365|NCT02749630|Drug|UTTR1147A|Escalating doses of intravenously administered UTTR1147A
46039366|NCT00626730|Procedure|adjuvant therapy|
46039367|NCT00626730|Radiation|radiation therapy|
46039368|NCT03209128|Radiation|Irradiation prophyllactique cérébrale|Irradiation prophyllactique cérébrale
46039369|NCT04788342|Device|pulse wave recording, echocardiography.|pulse wave recording using a single-channel electrocardiogram cardiomonitor with photoplethysmography, conducting echocardiography according to a standard protocol with the determination of systolic function of the left ventricle
46039370|NCT04216732|Other|Blood Pressure Measurement|Undergo blood pressure measurement
46039371|NCT04216732|Other|Questionnaire Administration|Complete questionnaires
46039372|NCT02749318|Genetic|IL-1 genetic test for risk of severe periodontitis|DNA obtained by cheek swab analyzed for four variations (SNPs) in the IL-1beta gene to determine whether patient is at elevated risk for more severe periodontal disease.
46039373|NCT03199144|Drug|Chemotherapy|3 cycles of Gemzar-Abraxane
46039374|NCT03199144|Radiation|Stereotactic radiotherapy|Stereotactic radiation treatment delivering 30 Gy in 5 fractions over 9 days
46039375|NCT03199144|Procedure|Surgery|Whipple procedure will be the recommended procedure but will be modified according to the initial tumor location
46039376|NCT04306536|Dietary Supplement|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
46039377|NCT04304664|Other|Mindfulness- Based Intervention|"Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment."
45474187|NCT03373396|Diagnostic Test|Blood samples|Collected data will contain epidemiological and biological data, blood samples with chlordecone dosage.
46039378|NCT00636142|Biological|Infliximab|5 mg/kg body weight, maximal dose 500 mg; intravenous administration
45474188|NCT04584684|Other|Saline|Saline placebo rinse
45474189|NCT04584684|Drug|1.5% w/v Hydrogen Peroxide|Over-the-counter antiseptic mouth rinse
45474190|NCT04584684|Drug|0.12% Chlorohexidine Gluconate|Dentist prescribed antimicrobial mouth rinse
45474191|NCT04584684|Drug|27% Ethanol plus essential oils|Over-the-counter antiseptic mouth rinse
45474192|NCT04584684|Drug|0.5% w/v Povidone-iodide|Over-the-counter antiseptic mouth rinse
45474193|NCT04584684|Drug|0.075% Cetylpyridinium Chloride|Over-the-counter antiseptic mouth rinse
45474194|NCT03369106|Other|Composite severity score calculation|Neurological examination, cognitive testing, and MRI exam
46039379|NCT04305522|Dietary Supplement|Probiotic 1|Probiotic mixture with maltodextrin as a carrier.
45474195|NCT03748823|Combination Product|Ravulizumab OBDS|The ravulizumab OBDS is a biological-device combination product consisting of a prefilled cartridge containing ravulizumab SC and an on-body injector.
45474196|NCT03748823|Biological|Ravulizumab|Administered by IV infusion. Ravulizumab IV doses will be based on participant body weight.
45474197|NCT03369028|Other|2D and 3D image of infants´ faces|2D and 3D image of infants´ faces
46039380|NCT04305522|Dietary Supplement|Placebo|Placebo comparator with maltodextrin as a carrier.
46039381|NCT04305522|Dietary Supplement|Probiotic 2|Probiotic mixture with maltodextrin as a carrier.
46039382|NCT02499562|Drug|Hydronidone|The investigational products in the test groups and control group shall be orally taken 30 minutes before meals for 52 continuous weeks. There are respectively 60 cases in the test group I, II, III and the control group, totally 240 cases.
46039383|NCT02499562|Drug|Placebo|
46039384|NCT02499562|Drug|Entecavir|
45343202|NCT05155059|Device|MagStim|Bursts of three at 50Hz with an inter burst interval of 200 ms will be given for 190 seconds and this session will be repeated 3 times with 20 minutes between each session in one day. The set of 3 sessions will be repeated 5 times in 5 consecutive days.
45343203|NCT05155059|Other|Sham Comparator|Sham TMS stimulation using a sham coil
45343204|NCT05150626|Drug|DBPR108 tablets|Drug: DBPR108, tablets, oral
45343205|NCT05149625|Device|Dexcom G6|continuous glucose monitoring device
45343206|NCT05148780|Diagnostic Test|Nasal Swab Sample|Nasal swab sample will be used to screen participants for detection of viral pathogens. No intervention or study drug will be administered as part of this study.
46039385|NCT02877654|Procedure|colonoscopy with biopsies in the left colon to assess intestinal permeability|"Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin; occludin and ZO-1.~One blood sample is taken to assess plasmatic zonulin (ELISA kit)."
45343207|NCT05144737|Behavioral|The Diabetes Prevention Program|The multicomponent intervention will focus on intensive lifestyle modification delivered by the Lifestyle Coach. The Lifestyle Coach of African origin will be responsible for delivering the intensive lifestyle intervention and implementing the adapted diabetes prevention program (DPP) curriculum.
45343208|NCT05138822|Drug|GSK3882347|GSK3882347 will be administered on each dosing day.
46039386|NCT02749240|Other|Youth Empowerment Seminar, YES!|An 8-week innovative bio-psycho-social program.
46039387|NCT04304430|Drug|Dapagliflozin|Initiation of dapagliflozin according to clinical indication
46039388|NCT04304430|Drug|DPP-4 inhibitor|Initiation of DPP-4i according to clinical indication
45343209|NCT05138822|Drug|Nitrofurantoin|Nitrofurantoin will be administered on each dosing day.
45343210|NCT05138822|Drug|Placebo|Placebo matching study drug (GSK3882347) or Nitrofurantoin will be administered on each dosing day.
45343211|NCT05138250|Drug|Mepolizumab 100 MG|participants will receive 100mg of mepolizumab every 4 weeks for 52 weeks
45343212|NCT05137392|Other|oral hygiene instruction|The treatment process is identical for both test and control groups except for the methods of oral hygiene instructions. In the control group, the participants will receive the following oral hygiene instructions at completion of debridement, at week-1 and week-3. In the test group, apart from the standard oral hygiene instructions at completion of debridement, at week-1 and week-3 , additional analysis of brushing data and provision of targeted brief interventions will be provided on a daily basis for the first week, 3 times/week until week 6 and once a week thereafter until 6 months after the debridement.
45343213|NCT05128409|Drug|XKH001 Injection|0.5mg/kg: 3Subjects,1Sentinel Participants 1.67mg/kg: 6Subjects, ,1Sentinel Participants 3.34mg/kg: 6Subjects,1Sentinel Participants 5.0mg/kg: 6Subjects, ,1Sentinel Participants 10.0mg/kg: 6Subjects,1Sentinel Participants
45343214|NCT05128409|Drug|XKH001Placebo Injection|1.67mg/kg: 2Subjects,1Sentinel Participants 3.34mg/kg: 2Subjects,1Sentinel Participants 5.0mg/kg: 2Subjects,1Sentinel Participants 10.0mg/kg: 2Subjects, 1Sentinel Participants
46039389|NCT04216966|Device|Control group|No intervention was given
46039390|NCT04216966|Device|Gracey Curette|Lingual surface of tooth was debrided by Gracey Rigid curette
46039391|NCT04216966|Device|After Five|Lingual surface of tooth was debrided by After Five Rigid curette
46039392|NCT04216966|Device|Mini Five|Lingual surface of tooth was debrided by Mini Five Rigid curette
46039393|NCT02875002|Drug|volasertib|Volasertib (BI6727) is a small molecule inhibitor of the polo-like kinase 1 (PLK1) protein. Infusion for 60 minutes. Dosing will start at 25 mg/m^2, is schedule to increase to 100mg/m^2, and be administered on days 1 and 8 of each 28-day cycle.
46039394|NCT02875002|Drug|belinostat|Belinostat is a histone deacetylase inhibitor. Infusion will take 30 minutes. Dosing will start at 600 mg/m^2 , is scheduled to increase to 1000 mg/m^2, and will be administered on days 1,2,3 and 8,9,10 of each 28-day cycle.
46039395|NCT02749396|Drug|Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
46039396|NCT02749396|Drug|Extavia (interferon beta-1b), Novartis Pharma AG|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
46039397|NCT02749396|Drug|Rebif (interferon beta-1a), Merck Serono Europe Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
46039398|NCT02749396|Drug|Plegridy (peginterferon beta-1a), Biogen Idec Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
46039399|NCT02749396|Drug|Avonex (interferon beta-1a), Biogen Idec Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
46039400|NCT02749396|Drug|MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
46039401|NCT02749396|Other|No MSDMDs therapy (control)|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
46039402|NCT04745910|Drug|Pegloticase|Given IV
45343215|NCT05126927|Biological|68Ga-NODAGA-SNA006|A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors
46039403|NCT04745910|Drug|Rasburicase|Given IV
46039404|NCT04305132|Device|Electroconvulsive therapy|Thymatron System IV electroconvulsive therapy device
46039405|NCT00627120|Drug|VGX-1027|Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.
46039406|NCT02749162|Drug|Dexamethasone phosphate|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
46039407|NCT02749162|Drug|Paracetamol|After the block regression, at the first analgetic request the patients received the analgesia protocol
45343216|NCT05126797|Other|Questionnaire Administration|Ancillary studies
45343217|NCT05126797|Device|Stent Device|Wear customized 3D printed oral stent
45343218|NCT05126524|Other|NO INTERVENTION|Observational study, no intervention performed
46039408|NCT02749162|Drug|Morphine|After the block regression, at the first analgetic request the patients received the analgesia protocol
45343220|NCT05126030|Device|Topaz TTVR System|Transcatheter tricuspid heart valve replacement
45343221|NCT05123807|Other|Cytoreductive surgery|(an operation to remove as much tumor tissue as possible) with hyperthermic intraperitoneal chemotherapy
45840470|NCT00771264|Device|Urgent PC Neuromodulation System|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
46039409|NCT02749162|Drug|Lidocaine|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
46039410|NCT02749162|Drug|Ropivacaine|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
46039411|NCT02874612|Other|Psychosocial Survey Questionnaires|Young adults with Type 1 Diabetes Mellitus will be invited to participate in a observational study in which they complete psychosocial measures immediately after completing a readiness transition survey and then again 1 year later.
46039412|NCT02041234|Procedure|Roux-en-Y Gastric Bypass (RYGB)|Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
46039413|NCT02041234|Drug|Incretin analogues|Incretin analogues: Liraglutide up to 1.8 mg daily
46039414|NCT02041234|Drug|Xenical|Xenical: Up to 120 mg tds
46039415|NCT02041234|Drug|SGLT2 inhibitors|SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily
46039416|NCT02041234|Drug|DPP-4 Inhibitors|Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily
45343222|NCT05121454|Device|Serenno Sentinel, model Alpha 2.0, software version: 8.0|intra-abdominal pressure measurements compared to a Foley Manometer at different insufflation pressures between 5 and 25 cmH20 at 30seconds intervals.
45343223|NCT05118568|Device|Histolog Scanner|imaging of fresh lumpectomy specimens with the Histolog Scanner, confocal microscopy scanning medical imaging device
45343224|NCT05117034|Drug|Morphine|Intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure.
45343225|NCT05117034|Drug|Nacl 0.9%|Intraoperative intravenous administration of 0.08 ml/kg NaCl 0.9% at dura closure.
45343226|NCT05115838|Drug|Islatravir|ISL 47, 52, or 57 mg implantable rod placed subdermally on the upper arm.
45343227|NCT05115838|Drug|Placebo|Placebo implantable rod placed subdermally on the upper arm.
45343228|NCT05112939|Drug|RPV LA|RPV LA will be administered at different formulations.
45343229|NCT05112939|Drug|CAB LA|CAB LA will be administered at formulation 3.
45343230|NCT05110105|Behavioral|Interactive board game health education|The interactive board game includes risk factors, symptoms, and acute management of stroke. It's a card game combined with (1) addition and subtraction game (risk factors). (2) gestures game (symptoms) (3) matching game (acute management), but in traditional Chinese. The game was implemented in a group (2~6 individuals) for 40 minutes.
45343231|NCT05110105|Behavioral|Conventional health education|The health education flier was made refer to medical institutions, e.g., hospitals or clinics, the stroke prevention video was collected from the internet. Participants were assigned to read the health education flier for 20 minutes. Then watch the stroke prevention video for 20 minutes.
45343232|NCT05109078|Drug|[14C]- Rongliflozin|Patients will receive single dose of orally [14C]- Rongliflozin on Day 1
45343233|NCT05108766|Drug|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC. Each PFS contains 1 mL of solution, tildrakizumab 100 mg/mL.
45343234|NCT05108766|Drug|Placebo|Matching placebo to tildrakizumab administered SC
45343235|NCT05106777|Drug|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 21-day cycle.
45343236|NCT05103475|Behavioral|Rage Against the Pain (RAP)|The RAP program curriculum will mirror that of the Hatha Yoga classes, but will differ from this traditional yoga practice in a number of ways: (1) the classes will be set to rock/heavy metal music; (2) meditation will not be incorporated; (3) yoga terms will not be used to describe the poses/movements (rather, poses will be cued in plain descriptive English terms); (4) the culminating activity for the class will be called a 'cool down' (rather than the typical relaxation/meditation exercise used in yoga, referred to as savasana).
45382067|NCT05380076|Other|Mindfulness meditation|6 minutes of watching a video tape made for the study that inspire mindfulness like meditation just before entering the examination circuit.
45840471|NCT00772590|Drug|Raltegravir|Tablets, 400mg, twice daily
45840472|NCT00772590|Drug|Hyper-immune Bovine Colostrum|Tablet, 1800mg, twice daily
45840473|NCT00772590|Other|raltegravir placebo|One tablet, twice daily
45840474|NCT00772590|Other|Hyper-immune Bovine Colostrum placebo|Three tablets twice daily
45840475|NCT00772590|Drug|raltegravir and hyper-immune bovine colostrum|400mg twice daily raltegravir and 1800mg twice daily of hyper-immune bovine colostrum
46039417|NCT04305210|Drug|F-18 PMPBB3|In this study we will enroll 20 healthy controls, 20 amnestic mild cognitive impairment patients (aMCI), 20 mild-moderate dementia due to AD patients and 10 other dementia such as frontotemporal dementia patients. All of the subjects will receive 18F-PM-PBB3 tau PET scan, and 18F-flobetapir (AV-45) amyloid PET scan, brain magnetic resonance images and clinical evaluation.
46039418|NCT04305210|Drug|18F-florbetapir|18F-florbetapir
45840476|NCT00773370|Behavioral|APA-Stroke|Exercise program design specifically for individuals with residual hemiparetic gait deficits due to stroke. Exercises are progressive, beginning with a 5 minute walk at the beginning and end of each class and gradually progressing to a 15 minute walk at the beginning and end of each class. Exercises focus on walking and are designed to improve walking ability and balance. Program includes a homework component.
46039419|NCT04217824|Procedure|pilonidal sinus excision|Closure of the defect in pilonidal sinus excision with one of the randomly selected flap methods.
46039420|NCT02749006|Device|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of bipolar depression.
46039421|NCT02749006|Device|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
46039422|NCT01072344|Drug|Chamomile (Matricaria recutita)|500 mg 3 times daily
46039423|NCT02695732|Drug|Carvedilol|Carvedilol is started at a dose of 6.25 mg/d, and titrated to a maximum dose of 12.5 mg/d.Doses are increased every 7 days until ABPsys is not less than 95 mm Hg and HR is not less than 55 bpm.
46039424|NCT02695732|Device|endoscopy|Patients receiving endoscopic therapy (either endoscopic ligation or cyanoacrylate injection) every 4 weeks until eradication of varices.
46039425|NCT02751268|Drug|Normal Saline|Bilateral infraorbital and infratrochlear nerve block before general anesthesia with normal saline
46039426|NCT02751268|Drug|Ropivacaine|Bilateral infraorbital and infratrochlear nerve block before general anesthesia with 0.5% ropivacaine
46039427|NCT02751190|Procedure|Totally ExtraPeritoneal (TEP) repair|
46039428|NCT02751190|Procedure|TransAbdominal PrePeritoneal (TAPP) repair|
46039429|NCT02751190|Procedure|Open anterior mesh repair|
46039430|NCT02751190|Procedure|Open Anterior Non Mesh|
46039431|NCT02751190|Procedure|Combined anterior and posterior repair|
46039432|NCT02751190|Procedure|Open preperitoneal mesh repair|
46039433|NCT02748772|Drug|Two Anti-angiogenesis Drugs（Endostar and Thalidomide）|Endostar:30 mg/d, CIV (continous intravenous pumping) on day 7 of each 21 day cycle，5 days before the chemotherapy is the first day; Thalidomide:100-200mg/d,PO (peros) on day 14 of each 21 day cycle Number of Cycles: 6 cycle or progression or unacceptable toxicity develops.
46039434|NCT02748772|Drug|Pure chemotherapy（Xelox）|"CapeOX (also called XELOX) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin.~Oxaliplatin 130mg/m2 IV over 2 hours,day1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks Number of Cycles: 6 cycle or progression or unacceptable toxicity develops."
46039435|NCT02750956|Procedure|Non-surgical periodontal treatment|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
46039436|NCT02748850|Biological|blood sample|a blood sample 20 milliliter
46039437|NCT02748850|Biological|Stem cell donation|The volume of stem cells remained in the tube is recovered
46039438|NCT02747056|Other|clinical, psychological and neuropsychological assessment|the subjects will do 3 tests about executive functions, complete 3 questionnaires about autism and 3 questionnaires about the self concept
46039439|NCT02747056|Other|Autobiographical memories Assessment|The investigators will ask subjects to tell autobiographical memories freely first and, secondly, to specify participants'characteristics by answering focused questions.
46039440|NCT02747056|Other|Autobiographical memories assessment characteristics|During the second time point, the investigators will ask subjects to say the self statements which define them. Then, subjects will have to tell and to specify the characteristics of the autobiographical memories linked to these self statements.
46039441|NCT01071954|Biological|Romiplostim|Administered by subcutaneous injection once a week.
45840477|NCT00773370|Behavioral|Sittercise|Not stroke specific. This less vigorous exercise program consists of seated exercise focusing on stretching to improve general range of movement and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework.
46039442|NCT04406272|Drug|VB11|Intravenously administered type of gene therapy that works by blocking the process of blood-vessel creation. Disrupting a cancer from growing blood vessels, might slow the growth of the cancer or shrink it.
46039443|NCT04406272|Procedure|Surgery|Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.
46039444|NCT04406272|Other|Placebo|Intravenous solution that has no therapeutic effect, used as a control in testing investigational drug.
46039445|NCT04406272|Drug|Bevacizumab|A type of antibody, Bevacizumab is intravenously administered and works by binding to and disrupting the vascular endothelial growth factor (VEGF). VEGF is a signal protein produced by cells that stimulates the formation of blood vessels. By disrupting VEGF, Bevacizumab helps to prevent the growth and maintenance of tumor blood vessels.
45343237|NCT05103475|Behavioral|Treatment as Usual|The 'treatment as usual' class will be conducted in the style of the yoga classes currently being offered to Veterans at the Hines VA Hospital, which is a program akin to Hatha yoga with chair modifications available to all Veterans who choose/need to use them.
45343238|NCT05096208|Biological|RSVpreF (Group 1)|RSV vaccine (RSVpreF)
45474198|NCT03373318|Drug|Human albumin|Single dose as a primer for the CEC, in sufficient quantity to reach a concentration of 4% of the total volume of priming.
45840478|NCT00773604|Device|Medtronic implantable deep brain stimulation (DBS) system|surgical placement of deep brain stimulation system for treatment of dystonia
46039446|NCT02746978|Other|Peer directed education|No drug or device is included. The intervention of interest is the redesigned approach to inpatient education that follows the Stanford chronic disease self management approach which includes peer-led problem solving discussions compared to traditional didactic education lectures provided by nurse educators
46039447|NCT02746978|Other|Patient Engagement Portal|No drug or device interventions. The Engagement Portal is populated by electronic medication record information (demographics, medications, supplies) then owned/maintained by patient after discharge. This approach to managing information and conditions associated with injury will be compared to the traditional approach of providing patients with a large instruction manual to carry home with them.
45343239|NCT05096208|Biological|RSVpreF (Group 2)|RSV vaccine (RSVpreF)
45343240|NCT05096208|Biological|RSVpreF (Group 3)|RSV vaccine (RSVpreF)
45343241|NCT05096208|Biological|Placebo|Placebo
45343242|NCT05093920|Drug|Doxorubicin-Eluting Beads|"The patients will be categorized in two randomized groups; c-TACE group (A) and DEB-TACE group (B).~After patient counseling and obtaining a written consent to participate in the study, both groups will be subjected to the interventional procedure according to patient group; Group A; Lipidol-Doxorubicin emulsion material followed by gel foam embolic material will be injected through the catheter directly into tumor feeding vessels through transarterial catheter.~Group B; Doxorubicin-Eluting Beads will be injected through the catheter directly into tumor feeding vessels through transarterial catheter."
45343243|NCT05090345|Other|Biorepository Trial|participating in this arm, peripheral blood specimen(s) will be obtained at 8 specified time-points.
45343244|NCT05089318|Dietary Supplement|Flexofytol PLUS|2 tablets in the morning and in the evening for minimum 6 weeks.
45343245|NCT05088863|Other|flaxseed|40g of flaxseed per day
45343246|NCT05085288|Device|Intermittent electrical stimulation system (IES) treatment and turning patient every two hours|The investigators propose to assess whether addition of the IES system and the use of the standard of care procedure of turning the patient every two hours reduces the morbidity of sacral and ischial pressure injuries by decreasing progression of stage 1 or stage 2 ulcers or facilitates their healing compared to standard wound care in an inpatient critical care population.
45343247|NCT05085288|Other|Turning population every two hours|The investigators propose to assess whether standard of care of turning the patient every two hours reduces the morbidity of sacral and ischial pressure injuries.
45474199|NCT03373318|Drug|Plasmalyte|The dose and the speed of administration depend on the age, weight, clinical and biological status of the patient and the concomitant treatment. The recommended dose for adults, the elderly and adolescents: from 500 ml to 3 liters / 24 hours.
45840479|NCT00775944|Behavioral|Proactive telephone support|Pro-active telephone counselling allows for repeated, sequenced calls to be made by quitline counsellors to smokers and for counselling to be provided during accepted calls.
45840480|NCT00775944|Behavioral|Reactive (standard) telephone support|Reactive counselling usually involves the provision of evidence-based information to support quit attempts without any or with only very brief counselling to accompany it.
45343248|NCT05080946|Drug|Aspirin 325mg|"Participants will receive a tablet of 325mg aspirin that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery."
45343249|NCT05080946|Drug|Placebo|"Participants will receive a placebo tablet that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery."
45474200|NCT03124420|Drug|Lansoprazole|Group A: lansoprazole 30 mg b.i.d. for 7 days Group B: lansoprazole 30 mg b.i.d. for 14 days
45474201|NCT03124420|Drug|Amoxicillin|Group A: amoxicillin 1 g b.i.d. for 7 days Group B: amoxicillin 1 g b.i.d. for 14 days
45474202|NCT03124420|Drug|Clarithromycin|Group A: clarithromycin 500 mg b.i.d. for 7 days Group B: clarithromycin 500 mg b.i.d. for 14 days
45474203|NCT03231228|Drug|Cefazolin 1 g Infusion|1 g cefazolin infusion for pediatric surgical subjects weighing ≥25 to <60 kg
45474204|NCT03231228|Drug|Cefazolin 2 g Infusion|2 g cefazolin infusion for pediatric surgical subjects weighing at least 60 kg
45840481|NCT00775944|Drug|Offer of voucher for cost-free Nicotine Replacement Therapy|Offer of voucher for cost-free Nicotine Replacement Therapy over the telephone
45840482|NCT00780234|Procedure|fluorescence bronchoscopy|examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.
46039448|NCT04216888|Drug|Ketamine Hydrochloride|Intranasal administration of 40mg ketamine hydrochloride using an intranasal mucosal atomization device
45840483|NCT00780234|Procedure|quantitative high resolution CT scan|High resolution CT scan of the chest
46039449|NCT02746744|Drug|Rituximab|Infusion of Mabthera/Rituximab every 6 months
46039450|NCT02746744|Drug|Dimethyl fumarate|Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
46039451|NCT02746744|Drug|Sodium Chloride solution|Placebo/Sham infusion every 6 months so that the examining physician (blinded) should not know which patient gets Mabthera or Tecfidera
45382068|NCT05380076|Other|Mobilization of inner resources|6 minutes of watching a video tape made for the study that provide psychological stimulation just before entering the examination circuit
45382069|NCT05380076|Other|Biofeedback|6 minutes of relaxing breathing exercise coupled with heart rate variability biofeedback guided on eMWave Pro software on a computer just before entering the examination circuit.
45382070|NCT05379634|Drug|Nipocalimab|Nipocalimab will be administered intravenously in double-blind period and LTE period.
45382071|NCT05379634|Other|Placebo|Nipocalimab matching placebo will be administered intravenously in double-blind period.
45847550|NCT04063956|Behavioral|multi-domain internet-based adaptive training program|The training paradigms include a time perception task, visual search task, rapid serial presentation task, delayed match to sample task, paired-associate recall task, attention span task, digit span task, go-no go task, Stroop task, task switching, auditory span task and n-back working memory task. Each task has several difficulty levels. The tasks are grouped in different cognitive domains including: processing speed, attention, perception, long-term memory, working memory, calculation, executive control, reasoning, and problem-solving. Participants in the cognitive training group will complete 40 min of training daily, 4 days a week for 12 weeks. When a high accuracy (80%) is achieved for each task, the level of difficulty will be upgraded for that task.
46039452|NCT02748304|Other|control|just follow up
46039453|NCT02748304|Drug|sorafenib|sorafenib 400mg bid po
46039454|NCT02748304|Drug|aspirin|aspirin 100mg qd po
46039455|NCT02748382|Other|higher chloride crystalloid|Normal saline
46039456|NCT02748382|Other|higher chloride albumin|5% Octalbin
46039457|NCT02748382|Other|lower chloride crystalloid|Ringers Lactate
45840484|NCT00780234|Drug|PIOGLITAZONE VS. PLACEBO 30 mg|"Patients will be randomized to receive either pioglitazone or placebo. Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator-~activated receptor-gamma agonist. It is FDA approved for the treatment of Type II diabetes. It has been previously administered to non-diabetic subjects. The most common side effect of pioglitazone is fluid retention and modest weight gain. There is a potential risk that pioglitazone may cause an elevation in liver enzymes and more serious hepatotoxicity (rare). There is risk of edema and weight gain associated with pioglitazone therapy. 5% experienced peripheral edema in clinical trials. fluid retention may result in new onset heart failure or exacerbation of existing heart failure. Small risk of hypoglycemia, anemia, myalgia, bone fracture, headache, and macular retinal edema exists. There is insufficient information to confirm its safety in Pregnancy/Breastfeeding. Bladder cancer is more serious but rare."
45840485|NCT00781950|Dietary Supplement|Flaxseed|30 grams of milled flaxseed per day in food products or on its own.
46039458|NCT02748382|Other|lower chloride albumin|5% Plasbumin
45840486|NCT00781950|Dietary Supplement|Placebo|Wheat and Mixed Dietary Oils
46039459|NCT02746822|Other||
46039460|NCT02746666|Behavioral|Pharmacist's behavioral intervention|Pharmacist's 30 min counselling on antiemetic therapy, causes of nausea or vomiting and ways to prevent them during chemotherapy.
46039461|NCT02746900|Procedure|Cervical cerclage|McDonald cervical cerclage
45840487|NCT00784524|Biological|allogeneic large multivalent immunogen breast cancer vaccine|Allogeneic large multivalent immunogen breast cancer vaccine (1 x 10^7, 5-μm silica spheres) will be given as an intradermal injection every 28 days (+/- 3 days). Each vaccine dose will be 0.2 ml.
45840488|NCT00784524|Biological|aldesleukin|Subcutaneous aldesleukin (10 x 10^6 International Units) will be given on day 7 and day 8 after each LMI injection.
45840489|NCT00785772|Drug|Gabapentin|100-200mg once a day
46039462|NCT04216654|Diagnostic Test|ELISA (enzyme-linked immunosorbent assay)|ELISA Principle. Enzyme-linked Immunosorbent Assays (ELISAs) combine the specificity of antibodies with the sensitivity of simple enzyme assays, by using antibodies or antigens coupled to an easily-assayed enzyme. ELISAs can provide a useful measurement of antigen or antibody concentration.
46039463|NCT02748148|Other|Medication therapy management|Implementation of a systematic approach to evidence- and personalized-based medicine through a pharmacist-guided medication therapy management service
45474205|NCT01176383|Genetic|Respiragene test and risk score|This 12 gene test used with other data (family history, age and spirometry result) to calculate lifetime risk of lung cancer in smokers who do not quit smoking. This intervention is expected to be a motivator to quit.
45474206|NCT03363100|Behavioral|Digital health Partnership program|The program pairs patients with their own certified diabetes educator coach who will guide the patient through a personalized program that leverages a proven educational curriculum combined with proven patient engagement methods.
46039464|NCT02746432|Drug|Hyper insulinemic euglycemic clamp|After obtaining a baseline preoperative lab set blood glucose value, 2 U/kg bolus of insulin (Human regular insulin) to be administered IV followed by an infusion of 2 U/ kg/min.fiver - Ten minutes after starting the insulin infusion, and when the blood glucose is <6.1 mmol /L (110 mg /dL). an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered. In the operating room, blood glucose levels were measured every 5-15 minutes, and the dextrose infusion rate was adjusted to maintain arterial glycemia between 3.5 and 6.1 mmol/L (63-110 mg/dL). timed intra operative lab assessment to be obtained.
46039465|NCT02746354|Other|The MySupport tool|Utilization of the MySupport tool, a tailored patient-centered assessment
46039466|NCT02746276|Drug|Ceftriaxone|Ceftriaxone is active against a broad spectrum of gram positive and gram negative bacteria, including intracellular bacteria (e.g. Salmonellae, Staphylococci). Its antibacterial effect is dependent on time above the minimum inhibitory concentration(MIC). Ceftriaxone is highly protein-bound and elimination depends on glomerular filtration rate. In severely ill adults, elimination is highly variable. Alteration in plasma proteins, volume of distribution and renal function in sick severely malnourished children could significantly alter pharmacokinetics (PK). Despite several published studies on the PK of ceftriaxone in children, none have included severe malnutrition.
45474207|NCT03363022|Drug|Standard Medical Treatment|Standard Medical Treatment includes antibiotics,CRRT (Continuous Renal replacement Therapy),Liver Dialysis.
45840490|NCT00785772|Drug|Gabapentin|200-500mg once a day
45840491|NCT00785772|Drug|Gabapentin|400-1000mg (200-500 mg twice a day)
45840492|NCT00787332|Drug|Desirudin or Argatroban®|Desirudin 15mg SC Argatroban® IV dosing per Package Insert
45840493|NCT00787722|Procedure|Hematopoietic Stem Cell Transplantation|Infusion of participant's own stem cells
45840494|NCT00787722|Drug|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
45840495|NCT00787722|Drug|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
45840496|NCT00787722|Drug|rATG|A rabbit polyclonal antibody to lymphocytes
45840497|NCT00787722|Drug|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
45840498|NCT00787722|Drug|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
45840499|NCT00787722|Drug|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
45343250|NCT05078853|Device|Point of care assay for thyroglobulin (POC-Tg) evaluation of a suspected cervical lymph node|"FNA Clinic: When a bloody material is seen in the needle, 100 µL of 0.9% saline is drawn via the needle into the syringe. The aspirate is then transferred into an Eppendorf tube. 40 µL is aspirated from the Eppendorf tube and dripped into the middle of the sample well of the POC-Tg kit. Two drops of the buffer are then dispensed into the middle of the sample well. The result of the POC-Tg is obtained and documented after 10 minutes. To compare the accuracy of the POC-Tg kit to the formal immunoassay for Tg, 0.9% saline is added to the aspirate that was left in the Eppendorf tube to a final volume of 0.6 mL. This volume is transferred into a gel containing tube and sent to the clinical laboratory that performs Tg measurement.~Operating room: When an indeterminate or suspicious LN is found, the LN is dissected and evaluated by both the formal evaluation and the POC-Tg. Following dissection of the LN, the ex-vivo POC-Tg is conducted as described above."
45343251|NCT05077982|Diagnostic Test|Spirometry|Spirometry to assess lung function
45840500|NCT00788892|Drug|CPX-351|
45840501|NCT00788892|Drug|Cytarabine|
45343252|NCT05077982|Diagnostic Test|6-minute walk|Exercise tolerance
45343253|NCT05074498|Drug|TB006|intravenous infusion
45840502|NCT00788892|Drug|Daunorubicin|
45840503|NCT00789672|Drug|levodopa/carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation)
45840504|NCT00789672|Device|patching|2 hours daily patching
45840505|NCT00789672|Drug|levodopa/carbidopa|Oral levodopa 0.51mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation)
45840506|NCT00789750|Drug|Colesevelam|Colesevelam 625 mg tablets
45840507|NCT00789750|Drug|Placebo|Placebo tablets appearing to be colesevelam
45840508|NCT00789750|Drug|Pioglitazone|30 mg or 45 mg pioglitazone therapy
45840509|NCT00790062|Drug|Oxytocin|See arms
45840510|NCT00793572|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo transplantation
45840511|NCT00793572|Drug|Bortezomib|Given SC
45840512|NCT00793572|Drug|Cyclosporine|Given IV
45840513|NCT00793572|Drug|Cyclosporine|Given PO
45840514|NCT00793572|Drug|Fludarabine Phosphate|Given IV
45840515|NCT00793572|Other|Laboratory Biomarker Analysis|Correlative studies
46039467|NCT02746276|Drug|Metronidazole|Metronidazole is effective against Giardia, which is common amongst children with SAM; and against other anaerobic infections, including small bowel bacterial overgrowth and Clostridium difficile colitis. Small cohort studies suggest there may be benefits for nutritional recovery. However, metronidazole can cause nausea and anorexia, potentially impairing recovery from malnutrition and may also cause liver and neurological toxicity. Changes in body composition as well as metabolic and drug elimination mechanisms may alter the potential toxicity or effective dose.
46039468|NCT05629936|Other|digital interdisciplinary intervention|Digital medication interview, comprehensive medication review, interdisciplinary patient team discussion followed by a MTO-plan, follow-ups
45684049|NCT00636610|Drug|Modified FOLFOX|Following administration of bevacizumab, patients received oxaliplatin 85 mg/m^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m^2 (d,I-racemic form, or 200 mg/m^2 I-isomer form) IV administered over 120 minutes, then fluorouracil 400 mg/m^2 administered as an IV bolus, then 2400 mg/m^2 administered as a continuous IV infusion over 46 hours.
45840516|NCT00793572|Drug|Melphalan|Given IV
46039469|NCT02747602|Drug|AC-1204|40 g (120 mL) AC-1204 administered 30 minutes after the start of a standard breakfast.
45684050|NCT00636610|Drug|FOLFIRI|Following administration of bevacizumab, patients received irinotecan 180 mg/m^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m^2 (d,I-racemic form, or 200 mg/m^2 I-isomer form) administered IV over 120 minutes, then fluorouracil 400 mg/m^2 administered as an IV bolus, then fluorouracil 2400 mg/m^2 administered as a continuous IV infusion over 46 hours.
45840517|NCT00793572|Drug|Mycophenolate Mofetil|Given PO
46039470|NCT02747602|Drug|caprylic triglyceride oil (standard breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.
46039471|NCT02747602|Drug|caprylic triglyceride oil (high fat breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.
46039472|NCT02745964|Device|LMA supreme|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
46039473|NCT02745964|Device|I-gel|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
46039474|NCT02746042|Drug|Sinupret extract coated tablets|1 coated tablet 3 times a day for 16-weeks (1-1-1)
46039475|NCT02746042|Drug|Placebo coated tablets|1 coated tablet 3 times a day for 16-weeks (1-1-1)
46039476|NCT02748226|Procedure|endovascular treatment|endovascular treatment
46039477|NCT02747680|Other|hypoglycemia (low blood sugar) in MRI|hypoglycemia (low blood sugar) in MRI
46039478|NCT02746198|Other|probiotic dairy drink|
46039479|NCT02746198|Other|acidified milk|
46039480|NCT02745886|Drug|metformin 0.85 twice daily for 6 months|
46039481|NCT02745886|Behavioral|Calorie restriction|
46039482|NCT02747446|Dietary Supplement|added sugar|isocaloric substitution of added sugars (honey or FG) for starch
46039483|NCT02745652|Device|pulsed electromagnetic field|it is a magnetic device for magneto-therapy, it has an appliance, motorized bed, and applicable large solenoids which can be moved in 4 different positions according to the treatment area, and the additional small solenoid for hand treatment with 30 cm diameter
45343254|NCT05074498|Drug|Placebo|intravenous infusion
45382072|NCT05379634|Drug|Glucocorticoids|Prednisone or equivalent will be administered orally as Glucocorticoid.
46039484|NCT02745652|Device|Therapeutic ultrasound|Ultrasound is applied using a transducer or applicator that is in direct contact with the patient's skin. Gel is a medium which is used on all surfaces of the head to reduce friction and assist transmission of the ultrasonic waves
46039485|NCT02747524|Other|Vita Mamba peanut butter paste|
46039486|NCT02747212|Device|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue that placed on a measurements experiment platform.
46039487|NCT02747290|Drug|68Ga-NOTA-BBN-RGD|68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
46039488|NCT02747368|Device|Ocusweep system|Comparison of Ocusweep system to conventional visual acuity, contrast sensitivity and visual field testing.
46039489|NCT02745808|Biological|HUC-MSCs|The subjects will receive intracavernous injection of HUCMSC.
46039490|NCT02745808|Biological|Injectable Collagen Scaffold + HUC-MSCs|The subjects will receive intracavernous injection of the mixture of injectable collagen scaffold and HUC-MSCs.
46039491|NCT05629780|Drug|Resuscitation fluid|Cristalloid fluids given as a resuscitational intervention
46039492|NCT02747134|Behavioral|Emotion Regulation and Mindfulness skills|
46039493|NCT02745574|Procedure|Combined maneuver|Combined maneuver (Intraperitoneal normal saline infusion and Pulmonary recruitment maneuver): the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity. Then, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
46039494|NCT02745574|Procedure|Intraperitoneal infusion|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity.
46039495|NCT02745496|Procedure|TRUS Biopsy|Standard of Care Treatment
45840518|NCT00793572|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
45840519|NCT00793572|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
45840520|NCT00793572|Procedure|Syngeneic Bone Marrow Transplantation|Undergo transplantation
46039496|NCT02745496|Procedure|TRUS/FUSION Biopsy|Interventional Treatment
45840521|NCT00793572|Radiation|Total-Body Irradiation|Undergo radiotherapy
45840522|NCT00793650|Drug|Bortezomib|Escalating doses of bortezomib 1.0, 1.3, or 1.6 mg/m2 in Arm A and Arm B.
45840523|NCT00793650|Drug|Melphalan|"All patients received melphalan (100 mg/m^2/day × 2; days~-3 and -2), for a total dose of 200 mg/m^2."
45343255|NCT05070013|Device|Deep Brain Stimulation|All subjects will undergo three 1-week conditions of stimulation during nighttime sleep over the course of three consecutive weeks of in-home sleep: adaptive stimulation, open-loop stimulation and no stimulation.
45382073|NCT05376241|Behavioral|Survey|Identify the prevalence and predictors of negative and positive reactions to evidence about mammography benefits and harms, and consequences for decision-making and trust.
45840524|NCT00793650|Procedure|Autologous PBSC Transplant|Day 0 consists of the stem cell infusion.
45840525|NCT00794508|Biological|ADA gene transfer|Autologous CD34+ cells transduced with the retroviral vector MND-ADA, carrying the human ADA gene.
45840526|NCT00795210|Drug|Growth hormone|Recombinant Human Growth Hormone (Teva pharmaceuticals), with one arm receiving 6mcg/kg SC once daily for two weeks and the other arm receiving 2mg SC once daily for two weeks
45840527|NCT00795210|Drug|Growth Hormone Releasing Hormone|Tesamorelin (GHRH) 2mg SC QD x 2 weeks
46039497|NCT02745730|Other|Glucose|
46039498|NCT02745730|Other|Fructose|
46039499|NCT02745730|Other|Sucralose|
46039500|NCT02745730|Other|Allulose|
46039501|NCT02742142|Other|water as placebo|topical application of water as a placebo in the control arm
46039502|NCT02742142|Drug|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
46039503|NCT02742064|Other|Cogito Companion Mobile Phone Application|
46039504|NCT04357756|Drug|YH001|YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G.
46039505|NCT04357756|Drug|Toripalimab|Toripalimab will be administered by intravenously (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle.
46039506|NCT00636298|Drug|Bevacizumab, cetuximab|"Cetuximab - 400 mg/m2 loading, then 250 mg/m2 weekly~Bevacizumab - 10 mg/kg every 2 weeks"
46039507|NCT05629624|Dietary Supplement|Chickpea based RUSF|One group will receive locally produced RUSF, approximate at 50-100 kcal/kg/day, two of 50g packets daily (42) until anthropometric recovery ( WHZ > - 1SD) has been achieved or for maximum 3 months then immediately 1 packet / day SQLNS will be given throughout the study till the end of 2 years of follow-up.
45474208|NCT03363022|Other|Fecal Microbiota Transplant|"Fecal Microbiota Transplant Stool specimen (preferably Bristol Stool Type 3 or 4) with a weight of ∼50 g will be considered adequate.~250 mL sterile normal saline will be added to the stool sample and homogenized with a blender for 2-4minutes in pulses of 30 seconds with 10 seconds wait in between each pulse.~Enema to be held for 30 minutes."
45684051|NCT01923220|Drug|HO/02/02 20µg|Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
46039508|NCT05629624|Dietary Supplement|E-RUSF|The other group will receive the E-RUSF at 50-100 kcal/kg/day which in this age group approximates one 92 g sachet daily until anthropometric recovery ( WHZ > - 1SD) has been achieved or for a of maximum 3 months, then immediately E-SQLNS 1 packet daily provided throughout the study till the end of 2 years of follow-up.
45474209|NCT03363022|Other|Placebo|Placebo will be identical and non medicinal to the Fecal Microbiota Transplant
45474210|NCT03510468|Drug|Vemlidy (tenofivir alafenamide)|Each tablet of Vemlidy contains 25 mg of tenofivir alafenamide.
45684052|NCT01923220|Other|Aloe Vera Jel|To be applied topically once daily
45694567|NCT00879034|Drug|Lonafarnib|Lonafarnib capsules are to be orally administered twice per day approximately every 12 hours. Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Dose levels are 150, 115, 90 and 70 mg/m2. Patients experiencing significant drug related grade 3 or 4 toxicity and not responding to therapy interruption or supportive care measures will be dose reduced by one dose level.
45694568|NCT00879034|Drug|Zoledronic Acid|Zoledronic acid will be administered intravenously at week one of this treatment trial. Week one administration will consist of one infusion over a 30 minute period, 0.0125 mg/kg body weight.
46039509|NCT05629624|Dietary Supplement|Outcome reference group/RUSF|We will also recruit 70 three-year-old previously untreated MAM children WHZ <-2 and ≥-3 z-score, and/or MUAC <12.5 and ≥11.5 cm as an outcome reference group for a singular assessment. All children (both case & control) will undergo a baseline nutritional, medical, biological and neuropsychological assessment (EF, ER, EEG and fNIRS). After all the assessments chick-pea based RUSF will be given for 2 months for nutritional rehabilitation.
46039510|NCT02741908|Behavioral|Calorie counting diet|
45343256|NCT05069727|Procedure|Regular Protocol with advanced carbohydrate counting|"Review 3 Days CGM data in Manual Mode~Carb Ratio by formula 360 / TDD~Finetune ICR~Target 100 or 110 mg/dl~AIT: 2-3 hour~Insulin Bolus for meal (advanced carb counting)~The parameters will be set using clinical assessment and fine-tuned if needed on F-up visits.~Follow up visits will be scheduled Day 7, 14,28, 56 and 84 after enabling SmartGuard (AHCL use)."
45343257|NCT05069727|Procedure|Simplified Protocol with fixed carbohydrate content|"Review 3 Days CGM data in Manual Mode~Carb Ratio by formula 360 / TDD ICR 8-10 (TDD 40-60) ICR 5-7 (TDD >60)~Target 100 mg/dl~AIT: 2 hours~Insulin Bolus for meal (Thee sets of meal set of meals announcement carbs will be provided) Regular meal: Total Carbs per Day x 0.6 / 3 Large meal: Total Carbs per Day x 0.6 / 3 x 1.5 Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5~Total carbs per day will be calculated as average on 7-days Food Logbook diary, provided by participant, one week before AHCL initiation.~The parameters will be fixed and fine-tuned only in case of hypoglycemia on F-up visits."
45343258|NCT05068752|Drug|Vemurafenib|Vemurafenib 480 mg PO BID daily given with Sorafenib 200 mg PO BID
45840528|NCT00795288|Drug|Simvastatin, 80 mg/day for 21 days|Active treatment group
46039511|NCT02741908|Behavioral|Fixed diet plan|
46039512|NCT02745340|Other|Acetate by Citrate substitution and vice versa|substitution of acetate by citrate in dialysis fluid
46039513|NCT02745106|Procedure|Radiofrequency pulmonary artery denervation|Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
45694569|NCT00879034|Drug|Pravastatin|Pravastatin will begin at 5 mg by mouth once daily for children weighing less than 10 kg, and 10 mg by mouth once daily for children weighing 10 kg or greater.
45343259|NCT05068752|Drug|Sorafenib|Sorafenib 200 mg PO BID and Vemurafenib 480 mg PO BID daily
45343260|NCT05064436|Drug|11C-BMS-986196|Specified dose on specified days
45343261|NCT05064358|Drug|Belantamab mafodotin|Belantamab mafodotin will be administered.
45343262|NCT05060471|Drug|Toripalimab|Four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab.
45343263|NCT05052879|Drug|Toronto association|Toronto association coated tablet, 20 mg + 30 mg or 20 mg + 60 mg, oral, 2 hours before the sexual intercourse.
45343264|NCT05052879|Drug|Tadalafil|Tadalafil coated tablet, 20 mg, oral, 2 hours before the sexual intercourse.
45343265|NCT05052879|Other|Tadalafil placebo|Tadalafil placebo coated tablet, oral, 2 hours before the sexual intercourse.
45343266|NCT05052879|Other|Toronto association placebo|Toronto association placebo coated tablet, oral, 2 hours before the sexual intercourse.
45343267|NCT05049707|Drug|IV magnesium sulfate|15 grams magnesium in 500 cc normal saline delivered at a rate of 15 mg/kg/hr
45694570|NCT04089202|Other|eConsult|Completion of electronic consult utilizing data collected from flash glucose monitoring
45840529|NCT00795288|Drug|placebo|Control group
45694571|NCT04089202|Other|Standard of care|Care by the Endocrinologist is provided as would typically be done, taking into account patient factors and preferences.
45694572|NCT04088890|Drug|Fludarabine|Fludarabine 30 mg/m2
45694573|NCT04088890|Drug|Cyclophosphamide|Cyclophosphamide 500 mg/m2
45840530|NCT00795366|Drug|arginine vasopressin|Titrated to cerebral perfusion pressure greater than 60 mm Hg
45343268|NCT05049707|Other|Placebo|500 cc normal saline delivered in equivalent rates as the treatment group
45474211|NCT03510468|Drug|Priftin (rifapentine)|Each tablet of Priftin contains 150 mg of rifapentine. Participants who weigh 45 to < 50 kg will take 750 mg (5 tablets), and participants who weigh (Bullet) 50 kg will take 900 mg (6 tablets).
46039514|NCT02745106|Device|Ablation catheter|4MM RF CONDUCTR (MULTI-CURVE) SERIES ABLATION CATHETER Standart procedure for radiofrequency ablation: Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
45343269|NCT05047068|Device|OCS Heart System|"The TransMedics® OCS Heart System is a portable system available for ex-vivo maintenance of a donor heart in a metabolically active and beating state.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation."
45343270|NCT05043805|Drug|Dextromethorphan|add on therapy
46039515|NCT02745106|Device|Swan-Ganz catheter for right heart catheterization|"Standart procedure of right catheterization:~punction of right jugular vein with Seldinger technique, introducer placement~insertion of Swan-Ganz catheter via introducer in jugular vein under fluoroscopic control and wave form of monitor's curve.~positioning of swan-ganz catheter in pulmonary artery~direct central hemodynamics measurements: systolic/diastolic/mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac output (thermodilution technique)~calculating of indirect parameters (pulmonary vascular resistance)"
46039516|NCT02741752|Procedure|Decortication|cortical bone perforation
46039517|NCT02695264|Device|HS-1000 recording|
45474212|NCT03510468|Drug|Isoniazid|Each tablet of generic INH is formulated as 100 or 300 mg of the drug.
46039518|NCT02745262|Other|Collect retrospectively the follow-up data|Collect retrospectively the follow-up data. Each patient is called in order to request data authorization, to complete and track information.
46039519|NCT02741674|Procedure|Roux-en-y gastric bypass (RYGB) - historical|Participant has had RYGB, as identified using existing data
46039520|NCT02741674|Procedure|Adjustable gastric banding (AGB) - historical|Participant has had AGB, as identified using existing data
45343271|NCT05043805|Other|placebo|add on therapy
45343272|NCT05042687|Drug|Tc99m sestamibi|Given by IV
45343273|NCT05036109|Drug|Aspirin|by mouth every day for up to 90 days
45474213|NCT03510468|Dietary Supplement|Pyridoxine|Each tablet of pyridoxine contains 50 mg of Vitamin B6.
45474214|NCT01178645|Drug|Busulfan, etoposide, cytarabine, and melphalan|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
45474215|NCT03368950|Other|Online Mindfulness Course|An online mindfulness course guiding participants through all elements of Mindfulness-Based Cognitive Therapy (MBCT) and Mindfulness-Based Stress Reduction (MBSR). Ten easy-to-follow sessions with videos and interactive exercises led by leading mindfulness trainers.
46039521|NCT02741674|Procedure|Sleeve gastrectomy (SG) - historical|Participant has had SG, as identified using existing data
46039522|NCT02695186|Procedure|Gastroscopy|Gastroscopy and biopsies, as well as blood sample collection
46039523|NCT02744950|Procedure|Pulley stitches|
46039524|NCT02744950|Procedure|Intermediate Repair|
45343274|NCT05036109|Drug|Vitamin D|by mouth every day for up to 90 days
45343275|NCT05036109|Dietary Supplement|Diet|Patients will receive counseling promoting a plant-based diet and avoidance of Western dietary patterns in a one on one session with a licensed dietitian prior to day 1.
45343276|NCT05036109|Other|Physical Activity|The exercise goal is to increase recreational physical activity from baseline by at least 10 MET hours per week, which is equivalent to 150 minutes of moderate activity weekly
45343277|NCT05036109|Behavioral|Behavioral Support Counseling Sessions|Patients will undergo a one-on-one counseling session prior to day 1
46039525|NCT02695108|Other|classical approach for neck pain|Patients with mechanical neck pain were instructed to do cervical exercise
46039526|NCT02695108|Other|scapular exercise on neck pain|Patients with mechanical neck pain were instructed to do scapular stabilization and cervical exercise
45343278|NCT05033483|Dietary Supplement|Ferrous Fumarate|Gelatin capsule containing 200 mg ferrous fumarate and microcrystalline cellulose
45343279|NCT05033483|Dietary Supplement|Placebo|Gelatin capsule containing microcrystalline cellulose
45840531|NCT00795366|Drug|Standard catecholamine|Titrated catecholamine of attending physicians preference to cerebral perfusion pressure greater than 60 mm Hg.
45343280|NCT05026047|Other|HPV self-sampling|HPV self-sampling in HIV-positive women
45343281|NCT05013918|Other|Observational study|No intervention
45847551|NCT04063956|Behavioral|active-control program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
46039527|NCT02695030|Device|Low Profile Visualized Intraluminal Support Device|LVIS device is intended for use with bare platinum embolic coils for the treatment of unruptured, wide neck, intracranial, saccular aneurysms.
46039528|NCT02744716|Drug|Aspirin|low dose of Aspirin after operation
46039529|NCT02744716|Device|intrauterine balloon|insert intrauterine balloon after operation
46039530|NCT02741362|Other|Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs|
46039531|NCT02741362|Other|Lipoaspiration|
46039532|NCT00837811|Biological|LY2127399|60 milligrams [(mg) with potential for dose escalation to 120 mg] subcutaneously every 4 weeks for 48 weeks
46039533|NCT02744794|Device|Dermal Cooling System|Treatment with cryotherapy.
46039534|NCT02744872|Drug|Felodipine|Felodipine 10 mg once daily or identical placebo
46039535|NCT02744872|Drug|Placebo|Placebo
46039536|NCT02741206|Behavioral|Bellevue ROSE Intervention|
46039537|NCT02741206|Behavioral|Psycho-education session and usual, Standard of care Control|Psycho Education and usual, standard of care
46039538|NCT02741206|Behavioral|One Psycho-education session and usual, standard of care Control|
46039539|NCT02744638|Other|probiotic yoghurt|verum is a liquid probiotic yoghurt containing all four probiotics as described in the arm description. Study participants consume daily two bottles (125g) during an intervention period of four weeks.
46039540|NCT02744638|Other|chemically acidified milk|Placebo is chemically acidified milk without bacterial strains. Study participants consume daily two bottles (125g) during an intervention period of four weeks (randomly assigned).
45847552|NCT04024878|Drug|Nivolumab|Nivolumab (Opdivo®) is an antibody. An antibody is a common type of protein produced by the body that the immune system uses to find and destroy foreign molecules.
45847553|NCT04024878|Biological|NeoVax|"The vaccine will consist of up to 20 peptides as well as a drug that activates the immune system called Poly-ICLC. Poly-ICLC (also called Hiltonol) is an experimental viral mimic and an activator of immunity"
46039541|NCT02744638|Drug|Arilin|2 tablets Arilin 500mg for 7 days
46039542|NCT02744560|Dietary Supplement|spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
46039543|NCT00703417|Device|magnetic Resonance Imaging|MRI of the calcaneus, the distal tibia, the distal radius and also lower back.
45343282|NCT05008185|Procedure|Regenerative Peripheral Nerve Interface (RPNI) surgery|Surgeons will perform neuroma resection and RPNI creation using a free muscle graft from the brachioradialis muscle harvested through a small separate incision
45343283|NCT05008185|Procedure|Traction Neurectomy|Surgeons will perform neuroma resection and traction neurectomy,
45343284|NCT05007964|Device|Spatz4 Adjustable Balloon System|The Spatz4 Adjustable Balloon System is designed to assist weight loss by partially filling the stomach and inducing satiety. The intragastrical balloon is implanted endoscopically for up to 12 months.
45343285|NCT04999969|Drug|AZD0171|AZD0171
46039544|NCT00703417|Device|Computed Tomography|CT scan of the lower back and hip
46039545|NCT00703417|Device|High resolution peripheral quantitative computed tomography|HR-pQCT of the distal radius and distal tibia
45343286|NCT04999969|Drug|Durvalumab|Durvalumab
45343287|NCT04999969|Drug|Gemcitabine|Chemotherapy (Standard-of-Care)
45343288|NCT04999969|Drug|Nab-paclitaxel|Chemotherapy (Standard-of-Care)
45343289|NCT04998396|Biological|AAV9 BBP-812|Sterile solution for injection for 1-time use via volumetric infusion pump
45343290|NCT04997187|Dietary Supplement|Bacillus coagulans group|Bacillus coagulans 400 mg/day for 12 weeks
46039546|NCT05629078|Device|Toric intraocular lens Zeiss AT TORBI|Intraocular lenses are medical devices that are implanted in patients during cataract surgery. At Plymouth University NHS trust the standard lens is a monofocal non-Toric lens unless the patient has astigmatism greater than 4.00D. This study involves implantation of a toric lens in the intervention group where astigmatism is greater than 1.00D. The lens is called the toric IOLS- Zeiss AT TORBI, will be implanted bilaterally instead of standard monofocal IOLs- Zeiss CT ASPHINA, used in routine cataract surgery within NHS.
45343291|NCT04997187|Dietary Supplement|Control group|Placebo 400 mg/day for 12 weeks
46039547|NCT02744404|Device|POC EID|
45343292|NCT04992247|Biological|COVI-MSC|"2, 4 or 6 MSC vials (approximately 15 million cells/vial) will be intravenously infused on Day 0, Day 2, or Day 4 depending on assignment to treatment group.~Group A: 2 MSC vials infused on D0 and 2 vials of placebo on D2 and D4~Group B: 2 MSC vials infused on D0 and D2 and 2 vials of placebo on D4~Group C: 2 MSC vials infused on D0 and D4 and 2 vials of placebo on D2~Group D: 2 MSC vials infused on D0, D2 and D4"
45343293|NCT04992247|Biological|Placebo|6 vials of placebo will be intravenously infused on Day 0, Day 2, or Day 4.
45343294|NCT04986501|Device|MucoPEG|Experimental
45343295|NCT04986501|Device|Biotene|Active Comparator
45474216|NCT03674892|Device|TrueTear™ intranasal neurostimulator (ITN)|Subject will place the tips of the ITN into both nostrils simultaneously. Subject will be asked to apply it for 3 minutes [could be modified if need be], daily.
46039548|NCT02744326|Behavioral|Text message reminders|Patients assigned to the intervention group will receive a series of 7 to 10 text message reminders to schedule or attend their follow-up appointment.
45474217|NCT02525315|Device|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
45474218|NCT05181774|Diagnostic Test|Proteomics|Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
46039549|NCT02740894|Drug|Gefitinib|
46039550|NCT00857389|Drug|Thiotepa|5 mg/kg through a central venous catheter (CVC) over 2 hours on Day -8.
46039551|NCT00857389|Drug|Clofarabine|40 mg/m^2 through a central venous catheter (CVC) over 1 hour daily on 4 consecutive days (Days -6 through -3).
46039552|NCT00857389|Drug|Busulfan|"Test dose of 0.5 mg/kg through a central venous catheter (CVC)over 30 minutes on Day -7.~High dose 5,000 µMol-min through a central venous catheter (CVC) over 3 hours on Days -5, -4, and -3."
46039553|NCT00857389|Procedure|Allogeneic Stem Cell Transplantation|Infusion of stem cells through through a central venous catheter (CVC) On Day 0.
46039554|NCT00857389|Drug|Thymoglobulin (ATG)|1.25 mg/kg by vein on Day -4 and 1.75 mg/kg on Day -3.
46039555|NCT00857389|Drug|G-CSF (Filgrastim)|5 µg/kg Injection under the skin once a day, starting 1 week after transplant, until blood cell levels return to normal.
46039556|NCT00857389|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered as indicated after transplant day 90, if no GVHD is present. Tacrolimus is adjusted trough level of 5-15 ng/mL.
46039557|NCT00857389|Drug|Methotrexate|5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant. The Day 11 methotrexate dose may be held as indicated if mucositis is present.
46039558|NCT00857389|Drug|Cyclophosphamide|Post haploidentical stem cell transplant participants: 50 mg/kg by vein on Days + 3 and + 4.
46039559|NCT00857389|Drug|Mesna|Post haploidentical stem cell transplant participants: 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses.
45343296|NCT04982913|Drug|HEC116094|Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
45343297|NCT04981899|Drug|Nivolumab|6 infusions of nivolumab at a fixed dose of 40 mg, 14 days apart, and infusion of nivolumab on day 0 of the NICE-40.
45343298|NCT04981899|Drug|Ifosfamide|5000 mg / m2, 24-hour infusion on day 2 of the NICE-40.
45343299|NCT04981899|Drug|Carboplatin|Optimized to get AUC = 5 (max. 800 mg) on day 2 of the NICE-40.
45343300|NCT04981899|Drug|Etoposide|100 mg / m2 intravenously on 1-3 days of the NICE-40.
45343301|NCT04980703|Device|Grain moxibustion|Take Baihui(GV20), apply vaseline on the acupoint, knead moxa villi into grain size, put it on GV20, and ignite it with incense. When the patient feels burning or a little pain, put out moxa with gauze and keep for 10 seconds, so as to ensure enough heat to be penetrated into the acupoint. There are 3 cones for the first six times and 5 cones for the last six times . After the treatment of GV20, the patient will be in prone position. Select bilateral Xinshu(BL15) and Pishu(BL20) and operate the same as that of GV20. 3 times a week, 12 times in all. During the trial, patients with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.).
45343302|NCT04980703|Device|Sham grain moxibustion|Take Baihui(GV20), apply vaseline on the acupoint, knead moxa villi into grain size, put it on GV20, and ignite it with incense. When the moxa burns to half （the patient hasn't feel hot or feel a little hot）, take the moxa away with tweezers. There are 3 cones for the first six times and 5 cones for the last six times . After the treatment of GV20, the patient will be in prone position. Select bilateral Xinshu(BL15) and Pishu(BL20) and operate the same as that of GV20. 3 times a week, 12 times in all. During the trial, patients with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.).
45474219|NCT05181774|Diagnostic Test|Metabolomics|Metabolomic data were obtained by UPLC-QTOF/MS platform.
45847554|NCT04024878|Procedure|Core Needle Biopsy|Surgical procedure
46039560|NCT02741050|Behavioral|Tailored Physical Activity Intervention|The Tailored Internet intervention is based on constructs of the Transtheoretical Model (TTM) and Social Cognitive Theory (SCT). During the 6-month intervention period, participants will receive monthly mailed questionnaires that assess current motivational readiness for physical activity and other TTM and SCT constructs (e.g., process of change, self-efficacy) and monthly logs to record their current activity.
45343303|NCT04980703|Other|Standard care|Participants in the wait-list control with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.). And after waiting for 12 weeks, these patients will be treated with the same grain moxibustion as the grain moxibustion group.
45343304|NCT04977830|Device|Xenon-129|Patients will undergo a hyperpolarized MRI with administered Xenon gas
45474220|NCT03368872|Other|Astaxanthin formulation|Astaxanthin formulation containing AstaReal® astaxanthin (Haematococcus pluvialis algae extract), tocotrienol, and zinc will be orally administered starting on Day 1 until Day 120
45474221|NCT03368872|Other|Placebo|Placebo will be orally administered starting on Day 1 until Day 120.
45474222|NCT03368872|Other|Exercise training|The subjects will undergo interval treadmill incline protocol (target 85% HR max, 3 times a week for 40 to 60 minutes) starting on Day 31 until Day 120.
45474223|NCT01178723|Dietary Supplement|breakfast size|"The research group will receive instructions to eat a large breakfast, Dividing the total daily calories recommended to the patient to: breakfast - 1/8 of the total daily calories , lunch - 1/3 of the total daily calories and supper- 1/3 of the total daily calories.~(the rest of the calories will be snacks between the meals) In contrast, the control group that will receive instructions to eat a small breakfast.~Dividing the total daily calories recommended to the patient to: breakfast - 1/3 of the total daily calories , lunch - 1/4 of the total daily calories and supper- 1/4 of the total daily calories (the rest of the calories will snacks between the meals).~The instructions will be adapted to each patient individually"
45474224|NCT05570760|Device|Adaptos®Ortho Wedge (bone grafting surgery)|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation. A synthetic bone graft will be used as a bone void filler in the osteotomy defect. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 10 months.
46039561|NCT02741050|Behavioral|Standard of Care|Those assigned to the control group will continue to receive standard of care through the Family Medicine clinic. This currently entails commonly accepted medication treatment strategies, educational materials and counseling for self-management and medication adherence, screening for depression or other conditions that would impair self-management, and national and state quality of care guidelines for lab testing and control targets (HbA1c, lipids, blood pressure). Participants in the control group will also receive monthly questionnaires on topics other than physical activity (e.g. diet) to fill out and return in order to have the same opportunities for compensation as those in the intervention condition.
46039562|NCT03873376|Behavioral|Opt-in; Receive offer to order self-sampling kit|Women in the opt-in arm receive an offer to order a HPV self-sampling kit, in addition to information about the study. Women who order, receive a kit that includes a self-sampling brush (Evalyn, Rovers Medical Devices), with instructions for use and a pre-paid envelope for returning the brush for HPV testing. The women are also informed that they can attend ordinary screening, i.e. performed by a physician. Women who choose self-sampling and test positive for high-risk HPV will be 1:1 allocated to follow-up by their general practitioner or a gynecologist. Women who test negative for high-risk HPV return to the ordinary screening program
45343305|NCT04976621|Behavioral|Behavioral Activation|BA is a brief behavioral treatment that helps people define goals, create and execute plans to attain them, and engage in meaningful activities. BA protocol components include: goal setting (especially for activities that promote social connectedness), creation of a plan (broken down into steps), strategies for implementation of steps, identification of potential barriers, tactics to overcome them, activity monitoring and scheduling, and emotion regulation strategies. The BA intervention will be delivered in 6 sessions over 3 months by Occupational Therapists trained in BA for post-TBI depression. BA sessions will be conducted in an office at the VA rehabilitation clinic or the home, depending on the veteran's preference.
45343306|NCT04976621|Other|Treatment as Usual|Treatment as Usual refers to usual care provided by the VA medical center.
45474225|NCT05570760|Procedure|OWHTO without bone grafting|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation, without bone grafting. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 10 months.
45474226|NCT05570760|Device|chronOS® Wedge (bone grafting surgery)|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation. A synthetic bone graft will be used as a bone void filler in the osteotomy defect. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 10 months.
45474227|NCT04525768|Diagnostic Test|JAK2 mutation test|Patients with portal caver cavernoma will be divided into two groups by the result of JAK2 mutation test
45474228|NCT01174355|Drug|ND0801|Confidential
45474229|NCT03213366|Behavioral|E-PrEP- Peer-Led Intervention about PrEP|Intervention contents and targets were informed by a systematic review of PrEP barriers and facilitators, a locally conducted qualitative study, and key informant and peer leader inputs. The contents were developed or adapted by study staff and peer leaders. Components and associated text have been designed to engage participants in online discussions about PrEP and related health and social topics. Posts will also include information about linkage-to-care, and insurance access. New contents will be posted almost daily.
45474230|NCT03213366|Behavioral|BxNow - General Health Campaign|BxNow will focus on general health topics unrelated to HIV or sexual health (i.e. fitness, nutrition, smoking), as chosen by PLs. Contents will be developed or adapted by PLs and posted almost daily. Posts will also include information about linkage-to-care and insurance access. At the end of the intervention, BxNow participants will be exposed to E-PrEP components at the end of the trial.
45474231|NCT04525924|Device|bright light therapy|please see arm description
45684053|NCT00635050|Drug|Doxil, Paclitaxel, Cyclophosphamide, Avastin|"Regimen A: Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3 . Patients who experience <pCR to primary chemotherapy will receive an additional year of Avastin 15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation.~Regimen B: Doxil 30 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3. Patients who experience <pCR to primary chemotherapy will receive an additional year of Avastin15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation."
46039563|NCT03873376|Behavioral|Opt-out; Receive self-sampling kit unsolicited|Women in the opt-out arm receive the self-sampling kit directly, without having ordered it themselves. The kit has the same contents, and the follow-up is the same, as that described for the opt-in arm.
45343307|NCT04967872|Other|Implementing risk management and control plan for the elderly during perioperative period|Visualization technology is used for preoperative evaluation, anesthesia management, bedside real-time monitoring and intervention, etc., to achieve accurate perioperative management of elderly patients and whole-process whole-person management
46039564|NCT03873376|Behavioral|Control; Receive open reminder to be screened by physician|Similar to the procedure of the national screening program, women in the control arm receive a reminder to be screened by their general practitioner, and continues in the ordinary screening program
45474232|NCT01285505|Drug|alprazolam commercial sublingual formulation|0.5 mg tablet, single dose
45343308|NCT04960059|Other|No intervention|This is an observational study
45684054|NCT05240404|Drug|Toripalimab|toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after ablation for six months
45343309|NCT04956887|Behavioral|AKL-T01|The study intervention, AKL-T01 (Akili Interactive), is a digital, app-based intervention designed to target and improve cognition through an engaging video game-based software experience delivered on an iPad.
45343310|NCT04956887|Other|Control Group|Patients assigned to the control group will receive no intervention, as is typical for those with Covid-19 with respect to cognitive functioning
45343311|NCT04956081|Device|Neuro-navigated Transcranial Magnetic Stimulation (TMS)|TMS delivered to a target within the left- dorsolateral prefrontal cortex (L-DLPFC)
45343312|NCT04955600|Other|Implementation Study|Implementation of digital technology in two different care settings from both patients, informal caregivers, and healthcare professional's perspective.
45343313|NCT04929600|Drug|sacubitril/valsartan|Sacubitril/valsartan oral tablets (200mg) one pill a day + matching placebo of amlodipine one pill a day.
46039565|NCT03868930|Behavioral|STEP-Home|This group will meet for 2 hours a week for 12 weeks. The core skills of Emotional Regulation (ER) (45-minutes) and Problem Solving (PS) (45-minutes) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention Training (AT) augments PS and ER core skills and is interspersed throughout group and individual sessions.
45343314|NCT04929600|Drug|Amlodipine|Amlodipine oral tablets (5mg) one pill a day + matching placebo of sacubitril/valsartan one pill a day.
45343315|NCT04925648|Drug|Dasatinib|Dasatinib 100mg once daily orally for 14 Days
45343316|NCT04925648|Drug|Darolutamide|Darolumatide 600 mg twice daily orally for 14 Days
45684055|NCT05240404|Procedure|Thermal ablation|The ablation operation was performed under local or compound anesthesia and guided by ultrasonography (US) or computed tomography (CT). To ensure complete destruction of the tumor, the ablation area must exceed the tumor boundary 1.0 cm.
45684056|NCT01923376|Drug|Lactulose|If randomized to this group, subjects will receive 10 - 30 grams of lactulose per standard of care
45684057|NCT01923376|Drug|Polyethylene Glycol 3350|If subject is randomized to this group, one time dose of one gallon polyethylene glycol 3350 will be given at the time of enrollment
45343317|NCT04921059|Diagnostic Test|Active Stand|The participant is asked to lie down for 10 mins without moving or speaking. A heart rate monitor is attached while the participant is lying down. They are then asked to stand up as quickly as possible and to remain standing unassisted for 3 minutes. The participant will be asked to describe any symptoms at 1 and 3 minutes after standing. Blood pressure and heart rate will be monitored constantly throughout the test.
46039566|NCT03868930|Behavioral|PCGT|The PCGT group will also meet for 2 hours a week for 12 weeks. It is a nonspecific and supportive intervention to control for the nonspecific benefits of the group experience (e.g., therapist contact, instillation of hope, expectation of improvement). It will focus on identifying and discussing current life stressors that contribute to reintegration difficulties, psychoeducation, and promotion of wellness and physical health.
46039567|NCT02744482|Drug|risedronate|risedrante tablet (75 mg)
45343320|NCT04916600|Device|NET|NET is an investigational device that received CE-Mark in April 2009 as a Class IIa active medical device
45343321|NCT04910295|Drug|COVID-19 vaccine|Subjects will be vaccinated with COVID-19 vaccines approved in Korea. Data on specific vaccines will be gathered.
45343322|NCT04908553|Drug|Remimazolam Tosilate for Injection 0.1mg/kg|Remimazolam Tosilate for Injection 0.1mg/kg at induction
45343323|NCT04908553|Drug|Remimazolam Tosilate for Injection 0.15mg/kg|Remimazolam Tosilate for Injection 0.15mg/kg at induction
45343324|NCT04908553|Drug|Remimazolam Tosilate for Injection 0.2mg/kg|Remimazolam Tosilate for Injection 0.2mg/kg at induction
46039568|NCT02744482|Drug|placebo|risedrante placebo tablet (75 mg)
46039569|NCT02744248|Drug|IOP Injection|IOP Injection 20 mg Fe/ml, intravenous injection
46039570|NCT02744248|Drug|0.9% normal saline|0.9% normal saline 10 ml, intravenous injection
46039571|NCT01071798|Drug|Rituximab|As prescribed by physician
46039572|NCT02744170|Device|1 continuous flow oxygen supplementation|This oxygen Supplementation is used in special order
45343325|NCT04907669|Other|Brief contact intervention|"The BCI in this study is a series of structured messages, and messages will be delivered to participants by pushing feeds through WeChat and an iOS/Android application developed for this study. If participants did not use smartphones, messages will be delivered by mobile text messages or by phone calls. Though the final details are yet to be determined by the CBPR study, the investigators expect to structure messages into six components including introduction, greetings for previous complains, mental health promotion, encouragement, and coping strategies, remind of treatment and subsequent visit, and crisis intervention resource.~Noted, the same messages will also be sent to patients' LHSs."
45684058|NCT05246566|Other|Routine care|"The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge."
45684059|NCT05245786|Biological|Copper Cu 64 Anti-CEA Monoclonal Antibody M5A|Given IV
45343326|NCT04906174|Other|Electronic Health Record Review|Medical records are reviewed
45343327|NCT04904536|Drug|Atorvastatin|40mg atorvastatin + standard care daily for 18 months.Atorvastatin 40mg has TGA approval for general marketing for the treatment of hypercholesterolaemia and cardiovascular prevention under a number of manufacturer names.The study medication selected will be the atorvastatin 40mg (Apotex) which is scored, and allows down-titration to 20mg should a participant develop symptoms.The study medication will be packaged, labelled and dispensed directly to particpants by the Syntro Health pharmacy in Australia. A comparable atorvastatin 40mg is being sourced in Chile, and will be dispensed from the pharmacy of the Clínica Alemana de Santiago.
45343328|NCT04904536|Other|Standard Care|Standard care for neurological symptoms as a result of COVID-19 infection.
45343329|NCT04899479|Drug|SGLT2 inhibitor|In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
45343330|NCT04899479|Other|Control|In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
45474233|NCT01285505|Drug|alprazolam test sublingual tablet|0.5 mg tablet, single dose
45474234|NCT01285583|Drug|TRO19622|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
45684060|NCT05245786|Procedure|Imaging Technique|Undergo imaging
46039573|NCT02744170|Device|2 demand delivery liquid oxygen supplementation|This oxygen Supplementation is used in special order
46039574|NCT02744170|Device|3 demand delivery oxygen supplementation via concentrator|This oxygen Supplementation is used in special order
46039575|NCT00857311|Biological|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10^9 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
46039576|NCT00857311|Biological|Comparator: Placebo|1.0 mL intramuscular injection of Placebo at Day 1 and Weeks 4 and 26
45840532|NCT00796302|Drug|Methylphenidate HCl|"For children weighing less than 25 kg, the dose will be titrated at 18 mg for the first 7 days, 36 mg for the next 4 days, and, if needed, 54 mg for the next 4 days. For children weighing more than 25 kg, the dose will be titrated at 18 mg for the first 4 days, 36 mg for the next 3 days, 54 mg for the next 4 days, and 72 mg for the next 3 days.~Once the child's optimal dose is established, he or she will continue on that dose for the rest of the 21-week trial.~One pill is taken once daily."
45474235|NCT04525612|Diagnostic Test|68Ga-BNU-PSMA|Each patient receive a single intravenous injection of 68Ga-BNU-PSMA, and undergo PET/CT scan within specified time.
45684061|NCT00634504|Drug|glucarpidase, high-dose methotrexate, leucovorin|single intravenous dose
46039577|NCT00857311|Biological|Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed|0.5 mL Open Label Tetanus and Diptheria Toxoids Adsorbed (Td) intramuscular injection at Day 1 only
46039578|NCT00857311|Biological|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10^10 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
46039579|NCT05629000|Procedure|Carotid revascularization|All patients received carotid revascularization surgery at Peking Union Medical College Hospital.
45343331|NCT04899024|Behavioral|PARTI|PARTI will provide positive affect skills. Each 1-hour session delivered via Zoom consists of a didactic portion with in vivo skills practice and participants are asked to complete home practice of the skills between sessions. Many sessions include formal exercises that have been utilized in Mindfulness-Based Relapse Prevention to cultivate mindfulness and meta-cognitive awareness.
45343332|NCT04899024|Behavioral|Attention-Control|Attention-Control will provide a core set of coping and affect measures as well as neutral writing exercises. Each 1-hour attention-control session will be administered via Zoom.
45343333|NCT04899024|Behavioral|Contingency Management for PrEP Adherence|Participants will complete a 12-week contingency management protocol via their smartphone that consists of uploading brief videos taking PrEP medications up to four times per week. Total possible contingency management incentive for completing 48 observed PrEP doses is $360.
45343334|NCT04895293|Drug|RBM-007 Injectable Solution|Sterile solution
45343335|NCT04861844|Behavioral|mindfulness training|phone based mindfulness training on 4 consecutive days
45474236|NCT04523896|Radiation|Real time High-Dose-Rate prostate brachytherapy in combination with stereotactic prostate radiotherapy|"- Brachytherapy: Real time HDR prostate brachytherapy using a MRI-trans-rectal ultrasound image fusion protocol: single fraction of 15 Gy.~Planning software: Oncentra prostate (Nucletron)~- External beam radiotherapy: Stereotactic ablative radiation therapy (SABR): 5 session in 5 consecutive days, 5 Gy per fraction to the prostate.~Intra-fraction gold seeds monitoring using Auto beam Hold solution (Varian) Planning software: Eclipse (Varian)."
45474237|NCT01287299|Other|Low Glycemic Load diet|Pregnant women were counseled to consume a diet with a glycemic load per 1000 kcal of less than 55.
45474238|NCT01287299|Other|Low Fat Diet|Pregnant women were counseled to consume diets providing less than 25% of the energy as fat.
45474239|NCT03637140|Device|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
45474240|NCT03637140|Device|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask"
45474241|NCT03372850|Drug|HIP1601|Test Drug
45474242|NCT03372850|Drug|HGP1705|Reference Drug
45684062|NCT00634504|Drug|high-dose methotrexate, leucovorin|standard of care, leucovorin every 6 hours
45684063|NCT04396522|Device|noninvasively Bio-electrical Impedance Analysis (BIA)|By means of noninvasively Bio-electrical Impedance Analysis (BIA) to measure body composition, which divides body weight into different components such as lean body mass and fat mass.
45684064|NCT03101254|Drug|LY3022855|LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor
45684065|NCT03101254|Drug|Vemurafenib|Vemurafenib is a BRAF inhibitor that works by blocking altered BRAF proteins from stimulating the growth of melanoma cancer cells
46039580|NCT05629000|Diagnostic Test|MRI-PWI|Multi-modal MRI before and after surgery.
46039581|NCT05629000|Diagnostic Test|CTA|CTA before and after surgery.
46039582|NCT05629000|Diagnostic Test|PET/MRI|PET/MRI before surgery.
46039583|NCT05629000|Diagnostic Test|Ultrasound|Ultrasound before and after surgery.
46039584|NCT04118881|Other|Ear Acupuncture|Auricular Acupuncture (AA) is a micro-system of acupuncture and moxibustion initiated by Chinese and French doctors. All acupoints are distributed in the ear. In the treatment of perioperative patients, ear needle is far away from the surgical wound and its minimally invasive and tolerable position has obvious advantages over body needle.AA can regulate the function of corresponding organs at acupoints. The theoretical basis of TCM is holistic concept and syndrome differentiation and treatment.AA can prevent and treat perioperative nausea and vomiting. A number of randomized controlled trials and retrospective studies have confirmed that AA has obvious advantages in preventing nausea and vomiting in perioperative period compared with routine prevention, and its possible mechanism is ear-directed stimulation of the ear branch of vagus nerve, thereby enhancing gastrointestinal motility and accelerating gastric emptying.
45684066|NCT03101254|Drug|Cobimetinib|Cobimetinib works by blocking a protein called MEK that has been known to promote melanoma growth
45684067|NCT04396054|Device|Lag Screws|Method of internal fixation
46039585|NCT02875626|Drug|Infracyanine|In the beginning of the intervention, a periareolar injection of the Infracyanine will be carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).
46039586|NCT02744014|Behavioral|Add-on Therapy for Axial Spondyloarthritis|
45684068|NCT04396054|Device|double Y-shaped plates|Method of internal fixation
45684069|NCT00634114|Drug|Esomeprazole|10mg once daily oral administration
45684070|NCT00634114|Drug|Esomeprazole|20mg once daily oral administration
45684071|NCT00634114|Drug|Omeprazole|10mg once daily oral administration
45684072|NCT00634036|Drug|pioglitazone|pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
45684073|NCT00634036|Drug|placebo|matching placebo (inert tablet)
46039587|NCT02874768|Drug|Dexmedetomidine|Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 ~ 0.7 mcg/kg/h)
46039588|NCT02874768|Drug|Propofol|Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 ~ 1.6 mg/kg/h)
46039589|NCT04118647|Drug|Wu-Chu-Yu tang|Wu-Chu-Yu tang at a rate of 3.0 g three times per day for 28 days.
45684074|NCT05241496|Diagnostic Test|The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration|Lidocaine in spray form is a simple and convenient local anaesthetic with minimal adverse effects and is often used in dentistry for oral mucosal anaesthesia during minor surgical interventions. The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration. Lidocaine acts by stabilization of the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action (Hüseyin Aksoy et al. ,2016 ) .
45684075|NCT01545375|Biological|Pneumococcal vaccine GSK2189242A|4 doses administered intramuscularly
46039590|NCT02740738|Device|Wagner Pain Algometer|applied at a 90 degree angle to the skin at a constant rate of 10kPa/s to minimize the impact of the examiner's reaction time on recorded pain thresholds
46039591|NCT02740738|Device|Dynamometer|Dominant Hand Grip strength measured by the average of 3 attempts
46039592|NCT04118725|Diagnostic Test|Pulmonary function test|Diaphragmatic electromyography with measurement of transdiaphragmatic pressure in cases of dyspnea and/or abnormal pulmonary function test (maximum inspiratory pressure and/or lying/seating low vital capacity ratio)
45343336|NCT04861844|Behavioral|active listening|The active listening intervention script asks the participant to attend by relaxing their body and visualizing themself in various exotic locations and narratives described in the script; it also asks the participant to rate their attention level of various points. The active listening scripts were compiled from National Geographic article excerpts (taken from the public domain)
45343337|NCT04861415|Radiation|Sterotactic Body Radiotherapy|Hypofractionated stereotactic radiation treatment.
45343338|NCT04861415|Radiation|Conventionally Fractionated Radiation|External beam radiation therapy treatment
45343339|NCT04859426|Drug|DBPR108 tablets|Drug: DBPR108, tablet, oral
45684076|NCT01545375|Biological|Placebo|4 doses administered intramuscularly
45684077|NCT01545375|Biological|Prevnar 13®|4 doses administered intramuscularly
45684078|NCT01545375|Biological|PedvaxHIB®|4 doses administered intramuscularly
46039593|NCT05629312|Procedure|Maxillary expansion|The upper jaw is expanded with a removable expansion plate
46039594|NCT05629312|Procedure|Extraction of deciduous upper canines|Both deciduous upper canines are extracted in this group
46039595|NCT00857233|Drug|Memantine|20 mg oral tablets once daily
46039596|NCT05628922|Drug|Toripalimab|"Early Responders: They receive the second and third cycle of induction chemotherapy (GP regimen), followed by cisplatin-based concurrent chemoradiation.~Intermediate Responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w * 2 cycles), followed by cisplatin-based concurrent chemoradiation.~Late responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w * 2 cycles), followed by cisplatin-based concurrent chemoradiation. At 4-6 weeks post-chemoradiation, they received adjuvant capecitabine and toripalimab for 6 months."
46039597|NCT05628922|Other|Induction chemotherapy and concurrent chemoradiation|"Induction chemotherapy (GP regimen) and cisplatin-based concurrent chemoradiation.~GP regimen: Gemcitabine 1.0 g d1,d8, cisplatin 25mg/m2 d1-3 q3w Cisplatin based chemotherapy: cisplatin 80mg/m2 given in three consecutive days, q3w * 2 cycles."
46039598|NCT02740426|Drug|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of ureteroscopy.
46039599|NCT00856999|Drug|Botox|Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups
45684079|NCT04396912|Procedure|Total thyroidectomy|Patients with thyroid diseases either benign (e.g. multinodular goitre) or malign (e.g. thyroid carcinoma) will be prepared for total thyroidectomy procedure and will be enrolled.
45684080|NCT05242978|Other|Nutrition|acute single dose nutrition intervention
45684081|NCT03159676|Radiation|Proton beam|Proton beam
45684082|NCT01539837|Drug|Deferiprone 20mg|20mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
46039600|NCT02743624|Procedure|Variation of the level of pressure support during the mechanical ventilation|The pressure support of the patient was changed form the baseline to 20 cmH20 and then stepwise decreased to 2 cmH20,
45474243|NCT01178879|Behavioral|Telehealth consultation|"The consultations are structured as outpatient sessions immediately after discharge. The content of the education deals with the regular treatment, prevention of exacerbation and how to live with the illness. The aim of the counseling is to increase the patient's empowerment and competence to take action. The patients have the consultations for 7 days followed by a telephone call. Each session is organized and individualised according to the patient's wishes and needs for education and counselling.~The equipment consists of a computer with web camera, microphone and measurement equipment. A button to contact to the nurse at the hospital, an alarm button and a volume button. The results are transferred to the hospital by a secure internet line."
45474244|NCT04525066|Drug|Hyaluronic acid|Patients in the treatment group received hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
45474245|NCT04525066|Other|No Hyaluronic Acid Injection Injection|Patients in the placebo group did not receive hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
45474246|NCT01178957|Other|Hyperglycemia|Hyperglycemia with a blood glucose of 15 mmol/L
45474247|NCT03362788|Drug|VKA|VKA plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
45474248|NCT03362788|Drug|NOAC|NOAC plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
45684083|NCT01539837|Drug|Placebo|Feriprox placebo administered orally at the same dosing volume as the 20mg/kg/day feriprox per day
45684084|NCT01539837|Drug|Deferiprone 30mg|30mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
46039601|NCT02743546|Drug|Duvortuxizumab|Duvortuxizumab will be administered at starting dose of 15 nanogram per kilogram (ng/kg) as an intravenous (IV) infusion during Part 1 (Dose Optimization) and at RP2D level determined in Part 1 during Part 2 (Dose Expansion). Participants will receive duvortuxizumab either with or without a priming dose. Participants who receive a priming dose will have infusions on Days 1, 8, and 22 of an initial 35-day cycle and then on Days 1 and 15 of 28-day cycles thereafter. Participants who do not receive a priming dose will have infusions on Days 1 and 15 of 28-day cycles.
46039602|NCT02743546|Drug|Ibrutinib|Ibrutinib will be administered at 560 milligram per day (mg/day) orally once daily during Part 1 (Dose Optimization) and at a dose of 420 mg/day (for participants with CLL) or 560 mg/day (for participants with DLBCL, FL, or MCL) during Part 2 (Dose Expansion). In Part 1, ibrutinib will be initiated on Day 1 of the initial treatment cycle. In Part 2, ibrutinib will be initiated on Day -7 prior to the initial treatment cycle.
45343340|NCT04857463|Other|Nutritional supplement drink|At the intervention period (0th to 12th week of the experiment), In addition to nutrition and health education, subjects were provided with 2 bottles of commercially available oral nutritional supplements (Meiji Mei Balance, Meiji Co., Ltd., Tokyo, Japan) every day, between lunch and dinner and before bedtime.
46039603|NCT01071252|Drug|AIN457|
46039604|NCT01071252|Drug|Placebo|
46039605|NCT02743234|Other|Fecal microbiota transplantation|FMT follows 4-10 days of vancomycin 125 mg x 4 daily
46039606|NCT02743234|Drug|Fidaxomicin|Fidaxomicin 200 mg x 2 daily for 10 days
46039607|NCT02743234|Drug|Vancomycin|Vancomycin 125 mg x 4 daily for 10 days
45474249|NCT03859505|Device|Placebo PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated in a single session and they will receive a total dose of 0 J.
45343341|NCT04857463|Other|Nutritional education|At the intervention period (0th to 12th week of the experiment) , subjects will be given regular nutrition education by a qualified clinical dietitian to ensure the effectiveness of nutrition education, in order for the nutrition education group to benefit from participating in this trial, the subjects will also be provided with the same nutritional products after the trial
45343342|NCT04852367|Device|Focused Ultrasound|Focused ultrasound targetting the tumour at subablative powers, to facilitate drug release
45343343|NCT04852367|Drug|Doxorubicin|Doxorubicin infusion
45474250|NCT03859505|Device|Active PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated in a single session and will receive a total dose of 220.05 J.
46039608|NCT02740270|Drug|GWN323|
46039609|NCT02740270|Drug|PDR001|
46039610|NCT00856843|Drug|BLI800|Solution for oral administration prior to colonoscopy
45343344|NCT04852367|Drug|ThermoDox|ThermoDox infusion
45343345|NCT04850703|Device|Transcranial Radom Noise Stimulation|tRNS against Dapoxetine in LPE patients
45343346|NCT04850703|Drug|Take Dapoxetine|Dapoxetine against tRNS in LPE patients
45343347|NCT04850703|Combination Product|Comparation EEG changes between Sham Group against tRNS and Dapoxetin participants|Compare EEG parameters like Theta Rhythm and Coherence between three groups of participants: sham, tRNS participants and Dapoxetine participants groups.
45343348|NCT04850703|Diagnostic Test|Compare LPE EEG endophenotype between participants and healthy controls|Define as precisely as possible the electrophysiological endophenotype of Longlife Premature Ejaculation, using healthy humans who do not express the LPE EEG endophenotype
46039611|NCT00856843|Drug|Polyethylene glycol 3350 based bowel preparation|Solution for oral administration prior to colonoscopy
46039612|NCT02875782|Behavioral|Smoking cessation and DM specific component intervention|A brief stage-matched smoking cessation intervention plus a DM-specific leaflet on smoking cessation
45343349|NCT04848337|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
45343350|NCT04848337|Drug|Lenvatinib|Lenvatinib 20 mg orally daily.
45343351|NCT04843787|Drug|SLV213|SLV213 oral capsule (200mg) BID
45343352|NCT04843787|Drug|SLV213|SLV213 oral capsule (400mg) BID
45343353|NCT04843787|Drug|SLV213|SLV213 oral capsule (800mg) QD
45343354|NCT04843787|Drug|Placebo|Placebo oral capsule (200mg) BID
46039613|NCT02875782|Behavioral|Control group|A simple, brief advice and a self-help general leaflet on smoking cessation
46039614|NCT02740348|Behavioral|ZocDoc Assistance|Research assistant sets up a follow-up appointment for a subject with a primary care doctor using ZocDoc
46039615|NCT02740348|Behavioral|ZocDoc Information|Providing ZocDoc information to subjects so that they can make a follow-up appointment with a primary care doctor themselves
46039616|NCT02740192|Procedure|Adductor Canal Block|Post-op adductor canal block using Bupivacaine
46039617|NCT02740192|Procedure|Periarticular Injection|Intra-op periarticular injection of Ropivacaine
45343355|NCT04843787|Drug|Placebo|Placebo oral capsule (400mg) BID
45343356|NCT04843787|Drug|Placebo|Placebo oral capsule (800mg) QD
45343357|NCT04842448|Drug|Hyperbaric oxygen|Hyperbaric oxygen 240 kPa for 90 minutes (with 10 min compression time, 2 air bakes and 10 minutes decompression time).
45343358|NCT04842448|Procedure|Sham treatment|Sham treatment 134-120 kPa Air (with 5 min compression time, and 5 min decompression to 120 kPa, two air brakes will be reported to the subjects)
45343359|NCT04837586|Other|Standard Care|Individuals will receive standard care for their obesity through the Pediatric Weight Management Clinic.
45343360|NCT04837586|Device|Simple Scale|Individuals will be encouraged to perform daily weighing at home on a simple scale.
45343361|NCT04837586|Device|EHR-Connected Scale|Individuals will be encouraged to perform daily weighing at home on a Smart scale that connects to the EHR. Clinic staff will review weight entries in the EHR and provide feedback.
45343362|NCT04836520|Drug|SHR6390+anatrozole|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
45474251|NCT03368794|Behavioral|Active treatment referral of opioid overdose survivors to long-term treatment|Telephone alert and outreach for inclusion, assessment and intake into long-term evidence-based treatment of the substance use disorder.
45684085|NCT03156790|Drug|Spectrila®|3 intravenous doses of 10 000 U/m² BSA each during induction phase I of the underlying BRALL 2014 treatment protocol on Days 21, 23 and 25. Additionally, the subjects (standard risk subjects only) will receive doses of 10 000 U/m² BSA each on Days 2, 4, 6, 9, 11 and 13 of the consolidation phase II, III and VI of BRALL 2014 treatment protocol.
45684086|NCT03153982|Drug|Ruxolitinib|15 mg or 20 mg (three or four 5 mg tablets) by mouth twice daily
45684087|NCT01539759|Device|Immediate Postplacental Placement of an IUD during cesarean delivery|Women randomized to this arm will have an IUD placed during their cesarean delivery, immediately after delivery of the placenta
45684088|NCT03153202|Drug|Ibrutinib|once daily oral intake ibrutinib
45343363|NCT04824417|Drug|Itraconazole 200 mg|Control
45343364|NCT04824417|Drug|Voriconazole 200mg|Comparator
45343365|NCT04810299|Other|Aromatherapy|Aromatherapy; It is one of the complementary therapy methods defined as the therapeutic use of essential oils obtained from parts of plants such as root, seed, leaf, flower, shell with appropriate methods.
45343366|NCT04810299|Other|Classical foot massage|Classical foot massage; It is defined as a massage technique based on the principle of systematic relaxation
45343367|NCT04807231|Biological|Blood withdrawal|Blood withdrawal in order to perform a bioavailable testosterone RIA (Radio-Immuno Assay).
45684089|NCT03153202|Drug|Pembrolizumab|200mg IV pembrolizumab on Day 1 of each cycle
45684090|NCT04410081|Drug|14C-lazertinib|A single oral dose of 14C-lazertinib will be administered.
45684091|NCT03153124|Other|Respiratory muscle training|The intervention group will perform three months of intradialytic training of a physical therapy protocol with PowerBreath
45684092|NCT01923610|Biological|Experimental|"Biological/Vaccine: MVA-B Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~-~ 1 x 10e8 pfu/ml 3 immunisations at week 0, 4 and 16"
46039618|NCT02740192|Drug|Ropivacaine|Ropivacaine was used for the periarticular injection
45474252|NCT03368794|Behavioral|Control|Written information from ambulance staff to the patient about how to seek treatment. Patient is able to contact the research treatment facility through a specific phone number, making it possible to study treatment entry in the information-only control condition.
46039619|NCT02740192|Drug|Bupivacaine|Bupivacaine was used for the periarticular injection
46039620|NCT02743156|Procedure|IVUS-guided PCI|intravascular ultrasound-guided percutaneous coronary intervention
46039621|NCT02743156|Procedure|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention. This is the conventional treatment.
46039622|NCT02743390|Biological|Infliximab|Monoclonal antibody biologic drug that inhibits tumour necrosis factor alpha (TNF-α), 3 mg/kg for 2 hours (250mL)
46039623|NCT02743390|Other|Saline|Saline for 2 hours (250mL)
46039624|NCT00856609|Drug|Byetta (exenatide)|Exenatide is an injectable medication
46039625|NCT00856609|Behavioral|Weight loss|Because response to weight loss
46039626|NCT00856609|Other|Metabolic Chamber|The subject stays in the small room
46039627|NCT00856609|Drug|Placebo|
46039628|NCT02739958|Drug|Propofol group|Anesthesia is maintained with continuous infusion of propofol 1.5-2mg/kg/h and dexmedetomidine 0.2-1ug/kg/h.
45684093|NCT01923766|Drug|Cytotoxic T lymphocytes (CTLs).|"This Phase I dose-escalation trial is designed to evaluate the safety of donor-derived cytotoxic T lymphocytes (CTLs). Dose escalation is guided by the modified continual reassessment method (mCRM) in order to determine the maximum tolerated dose (MTD). For each group, MTD is defined as the dose at which the probability of DLT is at most 21%. Four dose levels are being evaluated namely, 5x106 cells/m2, 1.0x107 cells/m2, 1.5x107 cells/m2 and 2.5x107 cells/m2 with prior probabilities of toxicity estimated at 5%, 7.1%, 10% and 21%, respectively.~Two patients are allocated in each cohort and are followed for 30 days post IV injection for evaluation of DLTs. The trial continues until a minimum of 12 patients have been treated and stop when the maximum 18 patients have been treated."
45684094|NCT05246410|Device|Spot stent system|Spot stent system designed and produced by Acotec
46039629|NCT02739958|Drug|Isoflurane group|Anesthesia was maintained with isoflurane at a concentration of 2-2.5%. fentanyl 50 ug increments
46039630|NCT02740036|Device|Hearing Aid (Successor of Phonak Audéo V90)|Successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90.
46039631|NCT02739802|Drug|Coppertone(BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.Formulation number - SR16-02.
46039632|NCT02739880|Device|DESIRIAL® (Intra-mucosal Injections of Cross-linked Hyaluronic Acid)|"Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule~The intervention is Intended for intra-mucosal injection in women for biostimulation / rehydration of the surface layers of the lining of the genital areas, vaginal hypotrophies and / or treatment of female sexual dysfunction related to subsidence G spot or area of Gräfenberg .~Following disinfection and topical anesthesia (lidocaine gel), the vesitbule is injected using a multi-point technique. The optimal volume of DESIRIAL® to be used for injection into the vestibule is approximately 0.3 ml in total."
45474253|NCT03862001|Behavioral|LungCARE|"The LungCARE intervention involves patient and PCP components. The patient component consists of watching a short, educational video, answering questions about lung cancer screening preferences, and receiving a patient report and handout.~The PCP component consists of receiving a similar report (physician report) prior to the patient visit. This report is based on the patient's risk factors and lung cancer screening preferences. It contains additional information about documenting discussions related to risk, screening, and referrals in the electronic medical record system."
45343368|NCT04806399|Other|Educational Materials and Decision Counseling|Participants in the active comparator arm will receive an introductory letter and lung cancer screening educational materials. A site care coordinator will contact each participant post receiving materials.
45343369|NCT04802070|Drug|Autologous CIK|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory (4 dose levels)
45474254|NCT02518828|Other|High SpO2|SpO2 range ≥96%
45474255|NCT02518828|Other|Low SpO2|SpO2 range 90-92%
45474256|NCT03862079|Other|Best Practice|Given standard of care
45474257|NCT03862079|Procedure|Fecal Microbiota Transplantation|Undergo FMT
45474258|NCT03862079|Drug|Nystatin|Given PO
45474259|NCT03862079|Drug|Piperacillin-Tazobactam|Given PO
45343370|NCT04797143|Device|multidisciplinary consultation program|The multidisciplinary consultation program (MCP) was divided into 3 steps: the first step involved a consultation with an oncologist, the second step involved a consultation with an oncology pharmacist, and the third step involved a meeting with a coordinating nurse (CN). The CN put in place a regular telephone follow-up with the patient, a few days later (7 to 15 days), to ensure adherence and tolerance of the oral anticancer treatment (OAT).
45343371|NCT04791956|Dietary Supplement|Prebiotic|Daily intake of Inulin-type fructans from chicory
45474260|NCT03362632|Drug|Antibiotics|This is an observation study, no specific antibiotics will be indicated during treatment.
45474261|NCT03213210|Device|easy-graft CLASSIC (beta-Tricalcium Phosphate)|easy-graft will be grafted to the bone defect supporting a dental implant and covered by polylactide membrane to facilitate regeneration of new bone and healthy attachment to stabilize the dental implant.
45474262|NCT01179035|Other|Transitions Clinic - parolee-targeted care|Subjects receive ongoing primary care from the Transitions Clinic versus ongoing primary care in the San Francisco Department of Public Health affiliated primary care network.
45343372|NCT04791956|Dietary Supplement|Placebo|Daily intake of maltodextrin
45474263|NCT01179035|Other|Expedited Primary Care|Following randomization, subjects receive ongoing primary care in the San Francisco Department of Public Health affiliated primary care network. Appointments are expedited with safety-net primary care providers.
45343373|NCT04788940|Procedure|Percutaneous Coronary Intervention|Patients with AMI who underwent PCI and CMR at index hospitalization and 6-month follow-up
45343374|NCT04783077|Behavioral|WhatsApp|Participants assigned to the WhatsApp group will receive weekly messages developed by communication specialists aimed to motivate blood donation, be encouraged to discuss their blood donation experiences, and share their own motivations for donating blood in a moderated, closed group over a six-month duration. The moderator will provide guidelines on acceptable use of WhatsApp in the group, including images they can or cannot share. Participants will also receive standard NBSG communications for first-time donors.
46039633|NCT01071096|Drug|OnabotulinumtoxinA|"Minimum dose of 155 U OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache symptoms with a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional 40 U OnabotulinumtoxinA Purified Neurotoxin Complex may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
45343375|NCT04783077|Behavioral|Control|Participants in this group will receive the standard NBSG communications for first-time donors: 1) a thank you phone call and 2) and a reminder phone call two-weeks prior to the second blood donation eligibility. The second blood donation eligibility is four months after the first donation.
45343376|NCT04783077|Behavioral|Docu-drama|Participants will be exposed to a document-drama related to blood donation.
45343377|NCT04782531|Other|peripheral ECG|Subjects will be placed in supine position. The systematic use of a headset will reduce the noise inherent to the machine. A cardiac synchronization system using peripheral ECG allows the synchronization with the subject's heart rate.
45343378|NCT04782531|Other|Standard MRI|Standard MRI examination using a torso coil consists of morphological and phase-contrast flow sequences(standard and EPI acquisitions).
45343379|NCT04777877|Other|Pain Neuroscience Education delivered via a Virtual Reality Headset|Pain educational videos (5) and guided imagery 360 degree nature videos (5)
45343380|NCT04771091|Diagnostic Test|Mesure of head-perineum distance by transperineal ultrasound|A mesure of head-perineum distance by ultrasound will be realized at the beginning of maternal pushing efforts by a junior gynecologist
46039634|NCT01071096|Drug|Saline|"155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache using a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional Saline may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
46039635|NCT02742844|Biological|APZ2 application|Application of IMP on patients wound.
46039636|NCT02739646|Device|Functional MRI scan|7.0 Tesla functional MRI scan
46039637|NCT02739568|Drug|Pitolisant (BF2.649)|
46039638|NCT02739568|Drug|Placebo|
45474264|NCT03372772|Drug|Levocarnitine|Levocarnitine syrup- Oral supplementation about 2000mg/ day for 8 weeks
45474265|NCT01235494|Other|polarised 3 helium|1 inhalation (= 1 litre)
45474266|NCT01174433|Device|Tryton|Percutaneous coronary intervention of a bifurcation lesion, with a Tryton bifurcation coronary stent for the side branch and a drug-eluting coronary stent for the main branch
45474267|NCT02932878|Drug|DSXS topical|topical treatment
45474268|NCT01093066|Drug|optimal TURB|The TURB will always try to be optically complete.
45684095|NCT05246410|Device|Self-expanding peripheral stent system|Self-expanding peripheral stent system designed and produced by Ev3, Inc
46039639|NCT02742688|Dietary Supplement|Pyrus pyrifolia var. culta(Makino) NaKai peel extract|Pyrus pyrifolia var. culta(Makino) NaKai peel extract(4g/day)
46039640|NCT02742688|Dietary Supplement|Placebo|Placebo(4g/day)
45684096|NCT03831724|Device|EndoFLIP™ System with FLIP Topography Module|The EndoFLIP system with the EF-322N catheter will be used. The EndoFLIP system is a tool that assesses esophageal, esophago-gastric junction (EGJ)/lower esophageal sphincter (LES), and pylorus function. It allows the measurement of LES and pylorus distensibility as well as esophageal contractile activity in response to distension. The system uses impedance planimetry to measure luminal cross-sectional area (CSA) along an axial plane during volume-controlled distention.
45343381|NCT04765150|Procedure|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
45343382|NCT04765150|Other|Electronic Health Record Review|Medical charts are reviewed
46039641|NCT02742610|Behavioral|Mindfulness with Contingency Management|
45684097|NCT01923844|Drug|exogenous surfactant|Preparations of poractantalfa (Curosurf, 200 mg/kg) (n = 15) or beractant (Survanta, 100 mg/kg) (n = 15) were administered in a consecutive randomized manner within the first 6 h of life. During the procedure, the tube was disconnected from the ventilator. The patient's head was held in a neutral position and surfactant preparations were given in two bolus fractions. Manual ventilation was given for 2 min after each dose. After the second dose, the endotracheal tube was reconnected and the physician (D.T.) observed the infant for 30-60 s until the oxygen saturation reached > 90% on pulse oximetry. Thereafter, the peak inspiratory pressure of the 6 ventilator was reduced by 1-2 mmH2O.
46039642|NCT02742610|Behavioral|Active Control|
46039643|NCT02739724|Procedure|Adnexal surgery|
46039644|NCT00856375|Drug|NKTR-102|IV every 3 weeks
46039645|NCT00856375|Drug|irinotecan|IV every 3 weeks
46039646|NCT02739490|Procedure|Core Training Group|Performs oriented exercise segmental stabilization lumbar-pelvic.
46039647|NCT01070784|Drug|Symbicort Turbuhaler (Budesonide/formoterol)|2 x 160/4.5 microgram, inhalation, bid, 52 weeks
46039648|NCT01070784|Drug|Drug: any available COPD treatment; investigator to decide|According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision
46039649|NCT02694874|Drug|Rosiglitazone|This is the experimental drug, rosiglitazone, being tested against placebo to assess its efficacy as an adjunctive treatment for severe malaria
46039650|NCT02694874|Drug|Placebo|This is the placebo control
46039651|NCT00837577|Drug|Comparator: Placebo|Placebo to sitagliptin once daily for 12 weeks (double-blind period)
45343383|NCT04753021|Other|Exercise|Progressively increasing training load
45343384|NCT04751422|Other|Electronic Health Record Review|Medical data is collected
45343385|NCT04727996|Drug|Sitravatinib|120 mg will be administered orally once daily
45343386|NCT04727996|Drug|Tislelizumab|200 mg will be administered intravenously (IV) once every 3 weeks
45343387|NCT04725110|Drug|Instilled T3|The first dose of T3 (50 micrograms in 10 mls volume BID) will be instilled by an investigator or under their direct supervision within 48 hours of obtaining consent after verifying that the patient is not too unstable to treat at that time. T3 doses will be given in 50 mcg doses twice daily for 4 days.
45343388|NCT04725110|Other|Placebo Therapy|A placebo therapy will be instilled into the lungs by the investigator or under their direct supervision within 48 hours of obtaining consent after verifying that the patient is not too unstable to treat at that time. Doses will be given twice daily for 4 days.
46039652|NCT00837577|Drug|Sitagliptin|"Sitagliptin/Sitagliptin arm only: Sitagliptin 50 mg once daily orally before breakfast for 12 weeks (double-blind period).~Both arms: Sitagliptin 50 mg once daily orally before breakfast for 40 weeks (open-label period). The dose of sitagliptin was increased up to 100 mg for participants who had an inadequate response to sitagliptin 50mg after treatment Week 20."
45474269|NCT03859271|Behavioral|Brief motivational interviewing|Children and parents will receive BMI and instant messaging delivered by a trained research nurse. At the time of recruitment, both children and parents will receive an education talk on the significance of and misconceptions about regular physical activity for cancer survivors and strategies for overcoming barriers to engaging in physical activity. Parents will then receive a face-to-face BMI to motivate their children to engage in regular physical activity. Parents will also be encouraged to motivate their children to intensify their physical activity levels progressively, with the ultimate goal of achieving the Global Recommendations on Physical Activity on Health suggested by the World Health Organization. Additionally, they will be invited to download a mobile health application from the Centre for Health Protection, Department of Health, HKSAR website that contains information on physical activity.
45474270|NCT03859271|Behavioral|Placebo control|Children and parents will receive the education talk on physical activity and ask to download the mobile health application that contains information on physical activity at the time of recruitment similar to the intervention group. However, parents will not receive BMI and instant messaging throughout the study period.
45343389|NCT04720781|Drug|Vonoprazan|Vonoprazan (20mg/day) is prescribed for 4 weeks.
45847555|NCT04004520|Behavioral|Virtual Reality with Meditation|The Guided Meditation Virtual Reality is a mindfulness meditation app provided on a virtual reality platform that includes a 10 minute audio meditation for relaxation along with a 3D visualization of natural settings (e.g. forest, beach, mountain).
46039653|NCT00837577|Drug|Voglibose|"All participants received a stable dose of voglibose, in~accordance with the package insert, throughout the study."
46039654|NCT02742220|Other|Isometric Handgrip Training Group|Intervention period will last eight weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of four unilateral sets (dominant arm) with two minutes of isometric contraction, with 30% of maximum voluntary contraction, and four minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. Visits will be scheduled at weeks 1 and 5 to provide feedback to individuals, discuss possible problems during the training and adjust the intensity of the exercise. In addition the patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.
45343390|NCT04720781|Drug|Esomeprazole|esomeprazole (20mg/day)
46039655|NCT02742220|Other|Control Group|Intervention period will last eight weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
45474271|NCT03368638|Other|Physical therapy intervention|Double knee to chest stretches, hip extension mobilization, neural mobilizations, home exercises program
45343391|NCT04704700|Device|repair of a cuff tear|Group (Treatment): Arthroscopic Implantation of the System InSpace on a repaired rotator cuff tendon
45343392|NCT04704700|Device|repair of a cuff tear|Group (Control): standard Arthroscopic repair of the cuff rotator
45343393|NCT04702139|Device|shoulder arthroplastis|- Group (Treatment): Placement of the Game-Ready splint immediately after surgery for 12 hours. They will then be put on the standard splint which they will keep for 2 weeks as for the other group but without ice packs.
45343394|NCT04702139|Device|shoulder arthroplastis|- Group (Control): Placement of a standard splint immediately after surgery for 2 weeks with ice packs to be used for an average of 8 days.
45343395|NCT04695327|Biological|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
45474272|NCT01179269|Drug|Pazopanib plus Paclitaxel|Pazopanib daily and weekly paclitaxel IV
45343396|NCT04692623|Drug|Moxifloxacin 400mg|Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
45343397|NCT04692623|Drug|Gemifloxacin 320 MG|Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
45474273|NCT03230292|Drug|Bimekizumab|Bimekizumab will be administered subcutaneously in 2 different doses.
45474274|NCT01174511|Drug|A -1 Cool Cream,Vaselin ointment|A- 1 Cool Cream applied to flexural aspects of the upper and lower limb on the one site of patient and placebo (Vaseline ointment) applied to other site of the upper and lower limb in the itch patient. Applying the ointment will be a regular time, twice a day for 5 consecutive days
45684098|NCT03128164|Drug|HMPL-689|Two strengths of HMPL-689 capsules (2.5 mg and 10 mg) will be used for clinical studies. The drug products are capsules.
45847556|NCT04004520|Behavioral|Audio Control|The UCLA Mindful App is an audio only mindfulness meditation for relaxation called Breath, Sound, Body Meditation that is 12 minutes in length.
45343398|NCT04691037|Diagnostic Test|CCTA|All patients underwent CCTA according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary.
45343399|NCT04690608|Drug|Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1|suprachoroidal injection of the drug in cases of resistant diabetic macular edema and central retinal vein occlusion
45474275|NCT00165724|Drug|Donepezil Hydrochloride|
45474276|NCT01287455|Drug|"Vitamin D3 as BABY D3"|drops, 70 drops (= 14000 units), once weekly for 6 weeks
45684099|NCT00633022|Drug|LOSMAPIMOD 7.5 MG|GW856553 tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised GW856553X active substance. Tablets are available containing 7.5 mg of GW856553X and are packed into high-density polyethylene (HDPE) bottles.
45684100|NCT00633022|Drug|Placebo|Placebo tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised substance to visually match the active GW856553 tablets are also available. Tablets are packed into high-density polyethylene (HDPE) bottles.
45684101|NCT04396600|Behavioral|MinnRAP Peer Support Program|"The behavioral intervention consists of 1) pairing healthcare workers into Battle Buddies who maintain daily dialogue to detect stress and anxiety and 2) assigning a mental health consultant to each department to facilitate Battle Buddies and provide both small group sessions and individual psychological triage/referrals."
45840533|NCT00796302|Drug|Risperidone|"For children weighing less than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 16, the child's dose may be increased to 2.0 mg a day. On Day 22, the child's dose may be increased to 2.5 mg a day.~For children weighing more than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1.0 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 12, the child's dose may be increased to 2.0 mg a day. On Day 15, the child's dose may be increased to 2.5 mg a day. On Day 18, the child's dose may be increased to 3 mg a day. On Day 23, the child's dose may be increased to 3.5 mg a day."
45840534|NCT00796302|Behavioral|Parent Management Training (PMT)|PMT will include individual parent sessions held weekly for 9 weeks, with two booster sessions to be completed during the 3-month extension. Sessions will include development of problem-solving skills and behavior management strategies, practice activities, and role-playing with the behavioral therapist.
45840535|NCT00796302|Drug|Placebo|One pill will be taken once daily for the first 4 days and then twice daily until Week 21.
45840536|NCT00796926|Drug|Systane Ultra eyedrops|Four times a day
45840537|NCT00796926|Drug|Refresh eye drops|Four times a day
45343400|NCT04686435|Other|Non-surgical treatment such as physiotherapy, exercise, corticosteroid injection, medication, acupuncture|Treatment consisting of different non-surgical interventions as recommended by the orthopedic specialist and decided upon in shared decision making with the patient
45343401|NCT04686435|Procedure|Surgery|Surgery can consist of rotator cuff repair, Bankart repair, subacromial decompression, biceps tenodesis or tenotomy, acromioclavicular joint resection.
45343402|NCT04684238|Drug|Midazolam|Solution for Injection/Infusion
45343403|NCT04684238|Drug|Isoflurane|Inhalation vapour, liquid. Isoflurane delivered by the AnaConDa-S (Anaesthetic Conserving Device)
45343404|NCT04664101|Behavioral|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT)|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT) The intervention consists of high intensity interval training, consisting of a 30-minute exercise session that includes 10 x 1-minute intervals of high intensity 3x/week (e.g., Monday, Wednesday, Friday) and supplemented with 2 sessions per week of strength, balance, and mobility exercises (e.g., Tuesday, Thursday). Exercise will be supported by an activity tracker, which will allow study personnel to track patient heart rates during exercise on a daily basis, allowing them to provide individualized feedback and coaching.
45343405|NCT04664101|Other|Comparator|Patients randomized to the control arm will receive the same technology platform and education on exercise options, including HIIT, but will return home to exercise as they see fit without personalized instruction and coaching. They will be remotely monitored, but will not receive feedback unless any adverse events are noted
46039656|NCT02742298|Device|Muscle ultrasound|Ultrasound images of limb muscles will be collected.
45343407|NCT04638543|Drug|ABP-671|ABP-671 Tablet
45343408|NCT04638543|Drug|Placebo|Placebo
45343409|NCT04633057|Drug|TJ101|TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive TJ101 1.2 mg/kg once a week until 52 weeks back site, investigator evaluate effectiveness and safety.
45343410|NCT04633057|Drug|NordiFlex|TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive Recombinant Human Somatropin Injection 0.034 mg/kg once a day, until 52 weeks back site, investigator evaluate effectiveness and safety.
45474277|NCT01287455|Other|placebo|drops, 70 placebo drops, once weekly for 6 weeks
45343411|NCT04629833|Biological|MC0518|MC0518 will be intravenously infused immediately after thawing.
45343412|NCT04629833|Biological|BAT|BAT including MMF, ECP, ATG, everolimus, and RUX will be administered based on Investigator's decision.
45343413|NCT04628377|Device|Angiography-drived Index of Microcirculatory Resistance|"From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation."
45343414|NCT04621019|Device|BTL-785F|Treatment with study device.
45343415|NCT04607005|Drug|Mepolizumab|Mepolizumab will be available as a clear to opalescent, colorless solution for SC injection in a single-use, safety syringe at a unit dose strength of 100 mg/milliliters (mL).
45474278|NCT04527172|Diagnostic Test|neuromuscular ultrasound|ultrasound to visualize the peripheral nerves of lupus patients and to compare it with results of the raditional electrophysiological studies
45474279|NCT03865433|Other|Aerobic Exercise|Sub-symptom threshold aerobic exercise at a dose of 30 minutes per day, five days per week.
45474280|NCT03865433|Other|Placebo/Stretching|A detailed, progressive stretching program to be performed for approximately 20-30 minutes per day, five days per week
46039657|NCT02742298|Other|Electrical Impedance Myography|A painless current passes through the skin and surface electrodes are used to record the impedance through muscle.
45498065|NCT03690258|Device|Variable load exercise|This study is being conducted to determine whether variable load training approach (nHANCE™ squat - more data available at http://nhance.se/) is an effective countermeasure to attenuate for rapid declines in muscle power, function, that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, safety guidelines and protocols could be developed aimed at reducing health risks in seniors. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system.
46039658|NCT01070550|Drug|Peginterferon alfa-2a (Pegasys®)|Peginterferon (PEG-IFN) alfa-2a Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
46039659|NCT02742376|Other|Soft surface|A sponge rectangle used in physiotherapy will be placed on the floor,
46039660|NCT02742376|Other|Floor|A marked path on the floor where the subject is instructed to walk.
46039661|NCT02742376|Other|Kyboot shoes|Special shoes will be worn by the subject.
45474281|NCT03368560|Other|Sudarshan Kriya Yoga|Sudarshan Kriya Yoga (SKY): A 12-week training course conducted by certified instructors from the Art of Living Foundation. SKY training will take place in group-format (group sizes of 8-15 participants) in an appropriately sized and accessible community hall in London, Ontario.SKY training involves attending a week-long (5 days) course that teaches the basic principles of SKY over 2.5-3 hour daily sessions. This will be followed by once weekly follow up sessions (90 min/wk) for 3 weeks and then bimonthly sessions (every 2 weeks) for the next 8 weeks. In addition, participants will be asked to practice SKY at home daily (25 min/day) throughout the duration of the study period and log practice frequency and any other noteworthy observations in a log sheet that will be provided to them . Nutritional snacks will be provided during the 5 day SKY training course.
45840538|NCT00798018|Drug|2% lidocaine|lidocaine: 2%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
45343416|NCT04607005|Drug|Placebo|Placebo will be available as a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe
45343417|NCT04607005|Drug|Standard of care|Participants will continue to receive Standard of care as they are used to before entry in the study.
45343418|NCT04598399|Behavioral|Mindfulness Based Relapse Prevention|7 x 60-120 minute sessions with different themes: Automatic pilot/triggers/relapse/high-risk situations/ mindfulness in daily life. There will be a welcoming time, with a focus on at-home practice and difficulties, a theoretical presentation of new concepts, practical meditation exercises and a debriefing.
45343419|NCT04598399|Behavioral|Relaxation/ meditation|7 x 60-120 minute sessions each with a different sound from nature with unguided, closed relaxation group with a maximum of 12 participants
45474282|NCT04965090|Drug|Amivantamab|Amivantamab 1050mg IV once weekly for the first 28 days (Cycle 1) and every other week thereafter. For subjects who weigh ≥80 kg, they will receive 350mg IV on C1D1 and 1050 mg on C1D2. They will continue to receive amivantamab 1400 IV once weekly for the first 28 days and every other week thereafter. Each cycle is 28 days in length.
45840539|NCT00798018|Drug|placebo|Air injected into the cuff to seal the space between the trachea and the tube at minimal volume
45840540|NCT00798018|Drug|1% tetracaine|tetracaine: 1%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
46039662|NCT02739178|Other|GSF Intervention|Intervention utilizes community-based demand generation matched with supply side improvements to improve access and use of sanitation facilities in rural communities. This is complimented with multi-stakeholder engagement to promote cooperation and coordination with national, state, and local stakeholders.
46039663|NCT04189900|Drug|Triptorelin|Subjects receive a single subcutaneous dose of 0,1 mg of Triptorelin acetate.
46039664|NCT00848107|Drug|treprostinil diethanolamine|sustained release tablet; BID dosing; up to 16 mg BID
45343420|NCT04594070|Drug|Ferrous sulfate|Iron supplementation
45343421|NCT04592094|Device|Blueback® Physio|Blueback® Physio is monitoring the activation level of the transversus abdominis muscle in real time during the exercises
45343422|NCT04586348|Combination Product|Low Iodine Supplement|Multivitamin and mineral supplement with reduced iodine
45343423|NCT04586348|Combination Product|Standard Iodine Supplement|Multivitamin and mineral supplement with standard amount of iodine to match current leading brands of prenatal supplements
45343424|NCT04577001|Drug|Letrozole|2.5 mg orally daily for 6 months
45343425|NCT04577001|Drug|Placebo|No active ingredient taken orally daily for 6 months
45343426|NCT04576078|Drug|Oral nefopam|Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h. Oral nefopam is prepared ex-tempore from the intravenous formulation adding a taste masking compound by a non-caring nurse following detailed instructions.
45343427|NCT04576078|Drug|Placebo|Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h. Oral placebo is prepared ex-tempore with a taste masking compound by a non-charge nurse following detailed instructions
46039665|NCT02739334|Behavioral|ENRICH|The intervention, called ENRICH (Encouraging Nurturing Responsiveness to Improve Child Health), is a 10-week home-based parent-centered curriculum designed to facilitate parents' mastery of skills for interacting with their toddler to increase opportunities for healthy eating and activity. Each weekly session is a 60 minute session implemented by a trained coach.
46039666|NCT02739334|Behavioral|Control - monthly handouts|The control group receives monthly handouts (one per month) for 3 months that provides information on various topics including child cognitive and language development and child behaviors as it pertains to 2 and 3 year old children.
46039667|NCT00703495|Device|transcranial oxygen saturation measurement (INVOS Somanetics 5100C)|rSO2 measurement
46039668|NCT02739256|Procedure|Retrograde voiding trial|A bladder test is performed after surgery for prolapse to make sure the patient can empty their bladder prior to discharge from the hospital. The test consists of filling the bladder with 300 mL of water and removing the catheter. Then the patient voids.
46039669|NCT04030741|Drug|Meronem and flagyl|meronem and flagy
46039670|NCT04030741|Procedure|Appendectomy|Appendectomy as treatment for acute appendicitis
45474283|NCT04965090|Drug|Lazertinib|Lazertinib 240 mg orally once daily and take this continuously, starting C1D1. For patients who weigh <80 kg, on C1D1, patients will receive amivantamab 350 mg IV, with 700 mg given on C1D2.
45474284|NCT03859817|Other|Comparison of eGFR values and ketonemia in diabetic patients|To verify if there is a correlation between the level of ketones and an alteration of the renal function in the diabetic patient, the values of the prognostic markers indicated in the protocol and the data downloaded by the glucometers will be evaluated in addition to the blood tests of the patients
45474285|NCT03865511|Drug|TAGRISSO® 80mg (Osimertinib)|Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.
45474286|NCT03865511|Genetic|Tumor biopsies|"Tumor biopsies performed at baseline and clinical progression will be processed (fixed) on site, and sent to Nantes University Hospital for analysis.~The following analysis will be performed:~Analyses performed on a regular basis, in order to allow subsequent inclusion in other clinical trials :~C797S testing (digital PCR)~MET amplification (dPCR/FISH)~Histological examination of the tissue sample (to identify small cell transformation)~Expression of proteins by immunohistochemistry: PD-L1 (Ventana SP263 antibody); CD73 ; CD4; CD8.~At the end of inclusions, deep sequencing analysis to identify acquired mutations and copy number variations (amplifications)."
45840541|NCT00798018|Drug|N.S|0.9% Normal saline injected into the cuff to seal the space between the trachea and the tube at minimal volume
46039671|NCT03689140|Behavioral|Smoke Free Together - App-only|Pregnant smokers and their life partners will use a smoking cessation app.
46039672|NCT03689140|Behavioral|Smoke Free Together - Telemedicine counseling only|Pregnant smokers and their life partners will use telemedicine, real time video counseling on smoking cessation
46039673|NCT03689140|Behavioral|Smoke Free Together - app + telemedicine|Pregnant smokers and their life partners will use telemedicine and an app for smoking cessation
45840542|NCT00798486|Device|A1C Test Kit|Subjects tested 3 times with A1C test kits. Two tests were performed by the subject and the third test was performed by a healthcare professional (HCP). All results were compared to results from a laboratory glucose analyzer (TOSOH).
46039674|NCT04298632|Behavioral|Safety Education Program|this is a pesticide safety education program
45343428|NCT04565457|Device|Research CBCT|Each study participant will receive one additional CBCT scan, with 2D antiscatter grid in place. This is the only intervention in the study, referred as research CBCT scan, and it will be performed on one of the days during the participant's radiation treatment course. This additional research CBCT scan will be used strictly for the objectives of this study. It will not be used as part of the standard clinical care, such as imaging guidance of participant's radiation treatment or diagnostic purposes. To deliver participant's radiation treatment under CBCT guidance, a standard clinical CBCT scan will be acquired, as in standard clinical care protocols.
45343429|NCT04561557|Biological|CT103A cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT103A cells, during which cyclophosphamide will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT103A cells by intravenous (IV) infusion. The initial dose of 0.5×106 CAR+ T cells/kg will be infused on day 0.
45498066|NCT03921996|Procedure|Radical prostatectomy (RP) followed by ePLND|ePLND is performed either before or after radical prostatectomy and includes the removal of all nodal and fibro-fatty tissue
46039675|NCT00636376|Procedure|Place HOB in alternate positions from 0-50 degrees.|Patients will receive an US while the HOB(Elevation of the head of bed) is 30 degrees(baseline) then they will increase the angle to 40 degrees, then 50 degrees. Another US will be done then in 20, 10, and o degree angles. Then another US will be done
46039676|NCT02736760|Drug|Daylight photodynamic therapy using Methylaminolevulinate (MAL)|"In the Daylight photodynamic therapy arm the patients will apply a sunscreen to the whole face which is followed by lesion preparation of AKs. Following this, MAL will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours.~5 photodynamic therapy treatment sessions (visits 1-5) will be performed within 18 months."
45474287|NCT03865511|Genetic|ctDNA analysis|"ctDNA analysis by Collection of plasma (two 10-ml Streck tubes) at each time point indicated in the trial.~These samples will be sent at room temperature by courier to the central laboratory (Nantes University Hospital). There they will be centrifuged, and plasma will be frozen (-80°C).~Analyses :~Detection of the EGFR activating mutation in plasma at baseline By dPCR (characterization of patients enrolled)~Detection of the EGFR activating mutation at d7 and m1 by dPCR (early detection of response to osimertinib)~Analysis of the plasma samples collected at clinical progression in order to identify acquired mechanisms of resistance by NGS (and comparison with analysis of the biopsies).~Kinetics studies of the alterations"
45343430|NCT04561557|Drug|Cyclophosphamide and fludarabine|"Subjects will receive one 3-day cycle of lymphodepletion starting 4 days prior to CT103A infusion on Day 0.~Subjects will be given IV infusion of cyclophosphamide 500 mg/m2/day on day -4, -3 and -2, and fludarabine 30 mg/m2 over 30 minutes administered immediately after cyclophosphamide."
46039677|NCT02736760|Procedure|Cryosurgery|In the control group, cryosurgery as standard reference therapy will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. Cryosurgery of AK lesions will be investigated as standard reference therapy. Single freeze-thaw cryosurgery is performed using an open spraying procedure with liquid nitrogen with nozzle size C. After formation of an ice-ball of the required size, freeze time starts. Freeze time should lie between 5 s and 10 s.
45474288|NCT03362554|Behavioral|Controlled diet and exercise.|"The intervention will involve 3 weeks of a diet and exercise program designed to cause a net energy decrease of 7000 kcal/week compared to habitual behaviour. This will be achieved through:~Five exercise sessions per week at 70% VO2 max, using 400 kcal per session.~Reduction of their standard diet by 5000 kcal per week~Before and after this intervention period participants will take part in a trial day which includes measurement of body composition (using DEXA) and blood sugar control (oral glucose tolerance test). Samples of blood, adipose, skeletal muscle and faeces will also be taken."
45684102|NCT01923922|Radiation|CT Perfusion|The CT perfusion scan will be performed on a multi-detector CT scanner at the time of routine preoperative neuronavigation imaging. A non-contrast CT head scan will be acquired to localize the tumour. Four 5 mm thick slices will be selected at the level of the tumour. Multiple images will be acquired at each levels starting 5 sec after the injection of 50 cc of non-ionic iodinated contrast media at a rate of 4 cc/sec. The acquisition parameters will be 80 kVp and 100 mA. The images will be acquired every second for a total of 110 sec. The post- processing will be performed and parameters will be calculated using regions of interest in the areas of tumour showing the highest perfusion values. Another region of interest will be placed in the contralateral normal looking white matter.
45684103|NCT01929304|Other|Survey|
45684104|NCT01924000|Drug|Minoxidil lotion 1%|Minoxidil lotion 1% is applied twice daily to one eyebrow.
45684105|NCT01924000|Drug|Placebo|
45684106|NCT01924078|Drug|Capecitabine|metronomic use: capecitabine 500mg/tid
45684107|NCT01924078|Drug|aromatase Inhibitors (AIs)|Anastrozole 1mg/day p.o,Exemestane 25mg/day,Letrozole 2.5mg/day p.o.
45684108|NCT01929616|Drug|regorafenib|Patients will receive 160 mg regorafenib 1/day 3 weeks out of 4.
45684109|NCT01929694|Dietary Supplement|Berocca Boost|
45343431|NCT04561375|Drug|Sufentanil|30 µg tablet of sublingual sufentanil
45343432|NCT04561375|Drug|Fentanyl|50 µg fentanyl
45343433|NCT04561258|Biological|AGT103-T|An autologous, genetically modified PBMC product enriched with HIV-specific and resistant CD4 T cells
45343434|NCT04560127|Drug|Camrelizumab combination with Apatinib|Apatinib (250mg p.o. q.d.) combined with Camrelizumab (200mg, iv, q2w)
45684110|NCT01929694|Dietary Supplement|Placebo|
45684111|NCT01924156|Biological|adenovirus-transfected DC + CIK|adenovirus-transfected DC vaccine plus CIK cells
46039678|NCT02736838|Device|tcpO2|Skin oxygenation will be measured by tcpO2, and microvascular flow with Laser Doppler. Measurements will be made inserting probes in sacrum, trochanters, elbows and heels, before and after the end of each decubitus lying period, and in every position and angle. Pressure: Continuous pressure measurements will be made in sacrum, trochanters, elbows and heels. Measures will be carried out at sessions separated at intervals of 7 days, with 0 to 4 hours of experimental exposure to pressure, different bed angles (0º, 30º, 45º), and lateral decubitus tilts (30, 90). Bioimpedance will be performed at baseline early in the morning, fasting and after emptying the bladder. Subjects will be lying without clothes, in a supine position on the bed, with a distance of at least 25 cm between thighs. The measurement will be made in single frequency mode (50 kHz , 400 μARMS) with a tetrapolar electrode arrangement.
45474289|NCT03368482|Behavioral|Brain Gym Exercises|"Participants in the BrainGym Exercises group performed six of the following BG exercises in every training session they took part in: Cross Crawl, Gravity Glider, Arm Activation, Belly Breathing, Hook-ups, Think of an X, Lazy Eights, Elephant, Space Buttons, The Owl, Energy Yawn, Balance Buttons and The Energizer. All exercises were executed from a sitting position but following the main tenets of the Brain Gym® work routine."
46039679|NCT02736838|Device|Laser Doppler|
46039680|NCT05620108|Procedure|Endotracheal Intubation at TOFC=1|Intubation using a video laryngoscopy will be performed after train-of-four (TOFC) stimulation indicates neuromuscular blockade
46039681|NCT05620108|Procedure|Endotracheal Intubation 2 minutes after rocuronium administration|Intubation using a video laryngoscopy will be performed 2 minutes after administration of rocuronium at 0.6 mg/kg (usual current clinical routine)
45343435|NCT04555616|Behavioral|Standard Environmental Design|Participants' caregivers will receive set script of physical environmental modifications (i.e., declutter living space, reduce background noise, increase natural light), and social environment training script will include caregiving techniques: training for calming demeanor (emotional contagion), needs-driven care to decrease behavioral disruption, and accepting and accommodating approach to behavioral disruption. A pre-selected sensory stimulation kit will be provided to each participants' caregiver for administration throughout the day.
45474290|NCT03368482|Behavioral|Standard exercise program for institutionalized older adults.|Participants in the Standard Exercise group took part in a traditional physical exercise program designed for institutionalized elderly people aimed at increasing their range of mobility and coordination, specifically focused on the lower limbs.
45343436|NCT04555616|Behavioral|Individual Environmental Design|Participants' caregivers will receive set script of physical environmental modifications and social environment training script in a standard protocol. Following initial assessments, individualized sensory stimulation kits will be developed using subjects' preferred sensory stimuli (as determined by the Adult Sensory Profile assessment and informant report) and will be provided via caregiver administration throughout the day to promote maintained behavioral regulation.
45343437|NCT04555616|Behavioral|Placebo|Participants' caregivers will receive a set script of placebo modifications.
45684112|NCT01929850|Procedure|Laparscopic Sleeve Gastrectomy|The laparoscopic sleeve gastrectomy involves the placement of 5 trocars. A leak check may be performed at the same time by insufflating with a gastroscope with the remnant gastric section submerged in irrigation fluid and by infusing sterile methylene blue through a nasogastric tube. The staple line may be oversewn (3-0 Vicryl, Ethicon), only along the bleeding and leakage areas, or areas with the potential for such complications. A nasogastric decompression tube placed to monitor bleeding and an intraperitoneal drain was placed under an anastomotic stoma.
45684113|NCT01929850|Behavioral|Weight Watchers Program|Intensive medically supervised nutritional and exercise therapy
45684114|NCT00630994|Drug|Dacogen|
46039682|NCT00856297|Biological|MenACWY-CRM conjugate vaccine|
45343438|NCT04553536|Drug|Esketamine, Sulfentanil or/and Remifentanil|The esketamine or the opioids will be intravenously injected or infused to the patients with propofol and one of the muscle relaxants to induce and maitain general anesthesia.
45474291|NCT03865355|Other|Non- interventional|Translational, observational study
45474292|NCT03362398|Drug|Omarigliptin 25 mg|Once weekly new anti-diabetic drug approved only in Japan
45474293|NCT03362398|Drug|Trelagliptin 100 mg|Once weekly new anti-diabetic drug approved only in Japan
45684115|NCT00630838|Drug|VSL#3|"Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (360 billion bacteria or 4 sachets) of VSL#3 will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (180 billion bacteria or 2 sachets) daily in the same amount of formula or breast milk.~E.2.6. Time of start of probiotics: Probiotic vs. placebo will begin once the infant has reached full oral feeding."
45684116|NCT00630838|Drug|Placebo|Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
45343439|NCT04549337|Behavioral|Exercise training|"Feasibility and safety of 3 different training protocols will be tested. Therefore the intervention is three different exercise protocols (4X4, 6X1, and 10-20-30). The exercise workload is set according to the patients HRmax or wattmax from a VO2max test at the baseline testing. All training protocols have a duration of 38 minutes and start with a 10-minute warm up and a 3-7-minute cool-down period. The intervals in the training protocols are interspersed with a 3-minute active rest. Therefore the three exercise protocols are matched on duration, and they all fall within the category of high-intensity-interval training.~The accumulated time spend with a heart rate >85% of HR max will be evaluated to determine the intensity."
45343440|NCT04541914|Diagnostic Test|5-gene classification model|Peripheral blood marker-based molecular diagnostic method for AMR in ABOiKT
45343441|NCT04540900|Biological|KB301|non-integrating HSV-1 vector expressing human type III collagen
45343442|NCT04540900|Other|Placebo|sterile isotonic saline
45474294|NCT03865199|Behavioral|Narrative Intervention|"Participants in the intervention group will first view a digital story on a tablet with headphones that will combine a fictional patient's abortion story with basic medical and social facts regarding abortion. After viewing the narrative, participants will be asked to write a narrative either on a tablet provided or on paper with the prompt: Patients have different thoughts and feelings about their experiences when they have this procedure. Tell a story (about yourself or someone else, real or imaginary) that might help another patient feel supported."
45474295|NCT03498612|Other|Laboratory Biomarker Analysis|Correlative studies
46039683|NCT00856297|Biological|Licensed comparator|
45684117|NCT03126214|Drug|Anticoagulants|Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with the Canadian Cardiovascular Society Guidelines for Atrial Fibrillation.
46039684|NCT02875470|Device|Intensiv Perio Set|Diamond burs for root planing
46039685|NCT02875470|Device|Gracey curette|
45474296|NCT03498612|Biological|Pembrolizumab|Given IV
45474297|NCT01287533|Drug|Ibandronate|monthly dosage of ibandronate 150mg
46039686|NCT02738944|Behavioral|Telepsychiatry Collaborative Care|The telepsychiatrist will also conduct an initial consultation with the patient via interactive video to establish the diagnosis and recommend medications to prescribe. Onsite primary care providers prescribe psychotropic medications. Onsite care managers work with patients either face-to-face or by phone to promote adherence to treatment and assess treatment response. Care managers provide Behavioral Activation either face-to-face or by phone. Care managers have weekly provider-to-provider consultations with the telepsychiatrist to review treatment plans for patients not responding to treatment. The telepsychiatrist will make revised treatment recommendations to the primary care provider.
45474298|NCT01287533|Drug|Placebo|monthly dosage of placebo
45474299|NCT03488628|Other|Noninvasive ventilation|Noninvasive ventilation delivered through a face mask, in alternace with satandard nasal oxygen therapy over the first 24 hours
45343443|NCT04540211|Drug|Atezolizumab|Atezolizumab at a fixed dose of 1200 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
45343444|NCT04540211|Drug|Tiragolumab|Tiragolumab at a fixed dose of 600 mg administered by IV infusion every Q3W on Day 1 of each 21-day cycle.
45474300|NCT03488628|Other|High-Flow Nasal Oxygen therapy|High-Flow Nasal Oxygen therapy delivered continuously over the first 24 hours by the AIRVO2® device (Fisher & Paykel Healthcare,New Zealand) through nasal canula.
45474301|NCT03859349|Diagnostic Test|Selective Targeted Sampling|After CLNS assessment, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
45343445|NCT04540211|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
45343446|NCT04540211|Drug|Cisplatin|Cisplatin 60-80 mg/m^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
45343447|NCT04540211|Drug|Atezolizumab Matching Placebo|Atezolizumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
45684118|NCT03126136|Device|Nicom (TM)|Heart rate, arterial pressure and cardiac output measurements (monitor NICOM) performed in the dorsal decubitus position and in the left lateral decubitus
45474302|NCT03859349|Diagnostic Test|Systematic Sampling|Following routine biopsy of lymph nodes, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
45684119|NCT01924234|Drug|Morphine|
45343448|NCT04540211|Drug|Tiragolumab Matching Placebo|Tiragolumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
45343449|NCT04537429|Drug|Eptinezumab|up to four iv infusions of eptinezumab
45343450|NCT04536532|Drug|HEC121120 tablets|"single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
45343451|NCT04536532|Drug|HEC121120 placebo tablets|"single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
45343452|NCT04536532|Drug|entecavir tablets|Patients with chronic hepatitis B：Administered Entecavir orally once daily for consecutive 28 days in fasted state
45840543|NCT00798720|Drug|vorinostat|400 mg by mouth once daily for days 1-14 of each 21 day cycle
46039687|NCT02738944|Behavioral|Telepsychiatry Enhanced Referral|"The offsite telepsychiatrist and/or telepsychologist delivers the treatment via interactive video to patients located at primary care clinics. Telepsychiatrists/telepsychologists administer symptom rating scales at each session. The first encounter will be with the telepsychiatrist to establish diagnosis and develop a treatment plan consisting of algorithm-informed medication management and/or evidence-based psychotherapy. The telepsychiatrists will prescribe medications. Psychotherapy options include Cognitive Processing Therapy and Cognitive Behavioral Therapy.~If a patient does not engage in treatment (<=2 encounters) in the first six months, they will be randomized a second time to continued Telepsychiatry Enhanced Referral or Telephone Enhanced Referral for the second six months. Phone Enhanced Referral involves delivering psychiatric and/or psychological treatment (either initially or exclusively) by telephone to patients in their home."
45343453|NCT04536532|Drug|entecavir placebo tablets|Patients with chronic hepatitis B：Administered Entecavir placebo orally once daily for consecutive 28 days in fasted state
45343454|NCT04535986|Drug|Ensifentrine|"• Dosage Formulation: Ensifentrine Nebulizer suspension~Dosage 3mg~Frequency: Twice Daily~Study to randomize 800 patients in total~Subjects randomized to the 24-week subset will enroll 400 patients (1:1 ensifentrine (3 mg): placebo)~Subjects randomized to the 48-week subset will enroll approximately 400 patients randomized 3:1 ensifentrine (3 mg): placebo."
45343455|NCT04535986|Drug|Placebo|"• Dosage Formulation: Ensifentrine Nebulizer suspension~Dosage 3mg~Frequency: Twice Daily~Study to randomize 800 patients in total~Subjects randomized to the 24-week subset will enroll 400 patients (1:1 ensifentrine (3 mg): placebo)~Subjects randomized to the 48-week subset will enroll approximately 400 patients randomized 3:1 ensifentrine (3 mg): placebo."
45343456|NCT04533503|Device|HF-OCT Imaging with the Vis-Rx Micro-Imaging Catheter|Intracoronary HF-OCT imaging of the target lesion(s) during the procedure.
45343457|NCT04528693|Behavioral|Circuit training (combination of strength and endurance exercises)|The intervention will last 3 months, exercises will take place 3 times a week and will consist of strength exercises, interspersed with bouts of endurance exercise carried out on circuit machines integrated with the Milon computer software for a total of 30 minutes per session.
45474303|NCT03372616|Diagnostic Test|Invasive left ventricular diastolic function assessment|Left ventricular (LV) polyethylene catheter was inserted into left ventricular to directly measure LV filling pressure.
45474304|NCT03372616|Diagnostic Test|Invasive aortic blood pressure measurement|Aortic blood pressure will be measured with polyethylene catheter in aortic root.
45498067|NCT03921996|Procedure|Radical prostatectomy (RP) only|Radical prostatectomy
45684120|NCT01924234|Drug|Remifentanil|
45684121|NCT01924312|Behavioral|Heart Health Intervention|A specialty CVD Risk Clinic will focus on education and individualized treatment programs to modify vascular risks in each subject using the methods developed, tested and shown to successfully reduce multiple CVD risk factors in the HeartHealth Program (HRSA grant, 1D1ARH1606, phase I and 2).
45840544|NCT00798720|Drug|bortezomib|1.3 mg/m2 IV on days 1, 4, 8, 11 of each 21 day cycle
45840545|NCT00799578|Drug|Cysteamine|Drug is in enteric-coated capsule form. The dosage will begin at 1g/m-squared body surface area with a maximum dose of 1000mg twice daily. Treatment period is 3-6 months.
45343458|NCT04526158|Behavioral|Mobile+Group LAMP Mindfulness-Based Intervention|The Mobile+Group LAMP Mindfulness-Based Intervention (MBI) condition consists of eight 90-minute weekly group sessions, delivered via secure video-conferencing. The first session is preceded by a 90-minute technical session introducing the video-conference system and other logistics. The program consists of educational and instructional videos presented by a trained mindfulness instructor interspersed with workbook reflections and group discussions, and daily practice exercises that participants do on their own. A trained facilitator (who is not required to be an expert in mindfulness) leads the group. Participants also have access to a mobile app and a study website, with the same educational and instructional videos that are presented in the group sessions, and the accompanying workbook.
45343459|NCT04526158|Behavioral|Mobile LAMP Mindfulness-Based Intervention|The Mobile LAMP MBI consists of 8 self-paced, 30- to 60-minute weekly sessions, delivered on a mobile app and available on the study website, with an accompanying workbook. The program consists of educational and instructional videos presented by a trained mindfulness instructor, with workbook reflections and daily practice exercises that participants do on their own (the same content used in Mobile+Group LAMP). Participants also participate in 3 engagement phone calls with a facilitator. The 1st call (45-60 minutes), held at the beginning of the program, includes technical and logistical information on engaging with mobile app, website, and workbook; and discussion of goals, challenges and plans for practice. The 2nd (middle of program) and 3rd call (end of program) are 25-45 minutes long and address technical/logistical issues and discussion of goals, progress, plans for practice and strategies to address challenges.
46039688|NCT04304898|Other|Home spirometry|"Patients will perform daily home spirometry for three months with a Bluetooth-enabled validated, CE-marked home spirometer (Spiro bank Smart, MIR, Italy). Subsequently, patients will perform weekly home spirometry for two years in total. During this period, patients will be asked to perform three measurements each week on the same day.~Hospital-based spirometry will be performed according to international guidelines.~Patients will complete patient-reported outcomes (PROMs) online in the secured application every six months."
45684122|NCT00630058|Drug|MP-424(H), PEG-IFN-a-2b, RBV|MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
45343460|NCT04525950|Procedure|Navio|New generation computer navigation with haptics and robotics
45343461|NCT04525950|Procedure|Conventional|Total knee arthroplasty using conventional instruments
45474305|NCT03372616|Diagnostic Test|Non-Invasive left ventricular diastolic function assessment|Echocardiography will be performed in all participants to assess left ventricular diastolic function non-invasively.
45474306|NCT03372616|Diagnostic Test|Non-Invasive aortic blood pressure measurement|Three devices (Sphygmocor [AtCor Medical, Australia], PulsePen [DiaTecne SRL, Italy], and Mobil-O-Graph [IEM, Germany] ) will be used to assess aortic blood pressure non-invasively when participants are undergoing invasive aortic blood pressure measurement.
45684123|NCT00630058|Drug|MP-424 (L), PEG-IFN-a-2b, RBV|MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
46039689|NCT02875938|Behavioral|Simultaneous music and reading lyrics|music with sung lyrics simultaneously with silent reading of the lyrics.
46039690|NCT02875938|Behavioral|Priming with music|priming with music and sung lyrics followed by reading of the lyrics.
46039691|NCT02875938|Behavioral|Control|control condition using reading materials without music.
45684124|NCT01925794|Device|COBRA PzF|
45684125|NCT01927198|Drug|Placebo|
45684126|NCT01927198|Drug|RDEA3170 5 mg|
45684127|NCT01927198|Drug|RDEA3170 10 mg|
45684128|NCT01927198|Drug|RDEA3170 12.5 mg|
45684129|NCT01924468|Drug|Oral methylphenidate and Oral haloperidol|
46039692|NCT02736604|Drug|nitrous oxide anesthesia|General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with Nitrous Oxide and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
46039693|NCT02736604|Drug|air anesthesia|General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with air and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
45343462|NCT04518566|Behavioral|Nudges|Behavioral nudges will be delivered to patients' FitBit device through adaptive intervention platform via notification syncing. To ensure the delivered nudges are timely and personalized, predictive nudges will be developed based on patterns in patients' sociodemographic, clinical and baseline activity tracking. These nudges will be sent automatically to patients upon specific triggers. The nudges will also be assessed for its effectiveness in behavior change. For example, a predictive nudge to encourage patients to take a short walk after detecting long periods of sedentary time will be assessed for its effects by step counts data after delivery of nudge. An iterative approach will be used to generate an effective set of nudges and its most appropriate delivery times for specific activity patterns.
46039694|NCT02736604|Device|laryngeal mask airway (LMA Supreme Size 3/4|
46039695|NCT02736604|Drug|sevoflurane|
45343463|NCT04513145|Drug|Ropivacaine injection|Ropivacaine is a local anesthetic that is FDA approved for local anesthetic nerve block.
45343464|NCT04513145|Drug|Saline Injection|Saline will be used as a placebo injection
45343465|NCT04513145|Procedure|Total Knee Arthroplasty|All subjects participating in this study will undergo primary total knee arthroplasty
45343466|NCT04509115|Drug|Short-acting opioid prescription for acute pain|Patients not currently using opioids who receive a new short-acting opioid prescription as part of routine care for acute pain will be recruited and followed prospectively for 180 days.
45343467|NCT04508634|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
45343468|NCT04508634|Drug|Metformin Pill|Metformin 1000mg bid
45343469|NCT04507074|Device|lumbar traction therapy|The application of traction forces on the traction table (ST6567P-SEERSMEDICAL) will last 30 minutes a day for 4 weeks (continuous traction mode with a maximum strength of 30% of the patient's body weight).
45343470|NCT04504981|Behavioral|Y2Prevent|Y2Prevent (Y2P) is a groupl level intervention that consists of 7 weekly group sessions focused on helping young African American men who have sex with men (AAYMSM) identify life goals and safeguard their health to achieve those goals
45343471|NCT04504721|Other|light therapy|The intervention will take 8 weeks with 30 minutes exposure at awakening to blue-enriched white light.
45343472|NCT04504422|Device|transcranial Direct Current Stimulation (tDCS)|tDCS was applied for 20 minutes through two saline-soaked sponge electrodes (diameter 6cm) using the YMS-201B (Ybrain Inc, South Korea).
45343473|NCT04490512|Biological|FluBHPVE6E7|Multiple subcutaneous, intradermal or intramuscular administrations
45343474|NCT04489771|Drug|Belzutifan|Oral administration
45343475|NCT04484194|Behavioral|Check Yourself - Oncology|A validated AYA-targeted electronic health assessment (eHA) screening tool for use in oncology clinics.
45343476|NCT04480502|Biological|Envafolimab|PD-L1 single domain antibody for subcutaneous injection.
45343477|NCT04480502|Drug|Ipilimumab|CTLA-4 monoclonal antibody
45474307|NCT01179425|Other|Cognitive stressor|The Paced Auditory Serial Addition Task (PASAT-C), has been modified for use as a computerized laboratory-based stressor. Single digits are presented, and the patient must add each new digit to the one immediately prior to it and click on the appropriate answer. Failure to do so in the allotted time results in a noxious error sound.
45343478|NCT04470726|Drug|AIV001|Intradermal/intratumoral
45343479|NCT04468334|Device|LARIAT + PVI|LAA ligation with the LARIAT System initially performed followed by adjunctive PVI catheter ablation (RF or cryoballoon) in staged procedures
45474308|NCT03372538|Procedure|cesarean section or cesarean hysterectomy|upper segment cesarean section and or cesarean hysteroctomy
45474309|NCT01176539|Device|Non-Contact Respiratory Rate Monitor|"The Non-Contact Respiratory Rate Monitor provides a measurement of respiratory rate at a single point in time for neonates, pediatrics and adults.~The Non-Contact Respiratory Rate Monitor provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults."
46039696|NCT02613013|Device|neodymium:yttrium-aluminum- garnet laser|a neodymium:yttrium-aluminum- garnet laser was used to perform the LPI
46039697|NCT02613013|Device|frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser|a frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser was used to perform the LPIP
46039698|NCT02613013|Drug|Pilocarpine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
46039699|NCT02613013|Procedure|LPIP plus LPI|LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure.
45684130|NCT03536416|Behavioral|My Asthma in School|The intervention will include three arms. During the theatre workshop, the children will watch a theatre performance, and engage in a discussion at the end of the play, about what they have watched. The self-management workshops will cover a range of topics identified as barriers to self-management in our earlier study, and will be delivered to children with asthma only. The control group will receive usual care during the intervention.
46039700|NCT02613013|Drug|Proparacaine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
46039701|NCT02613013|Procedure|LPI|LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris >0.1mm. and patency was determined by direct visualization of the posterior chamber.
46039702|NCT04304976|Device|ROBERT®|Robotic Rehabilitation intervention ROBERT®, designed for early, and supplementary therapy of patients.
46039703|NCT02738710|Procedure|transumbilical incision|incision within umbilicus
46039704|NCT02738710|Procedure|Infra umbilical incision|incision about 1 cm below umbilicus
46039705|NCT04306510|Procedure|Blood samples for immunoglobulins|Following an injection of TEGSEDI as prescribed by their physician per the product label, patients will have additional blood tests at 1, 2, 4, 8 and 24 hours post injection for immunoglubulins at a clinic visit every 4 months for up to 2 years.
46039706|NCT04306510|Procedure|Blood samples for inflammatory markers|Following an injection of TEGSEDI as prescribed by their physician per the product label, patients will have additional blood tests at 1, 2, 4, 8 and 24 hours post injection for inflammatory markers at a clinic visit every 4 months for up to 2 years.
46039707|NCT04306510|Procedure|Blood samples for anti-drug antibodies|Patients taking TEGSEDI as prescribed by their physician per the product label, patients will have additional blood samples for anti-drug antibodies at various time-points as indicated in the event of hypersensitivity reactions.
46039708|NCT02611921|Drug|Ketamine|Ketamine will be compounded into a mucosal atomization device and self-administered or administered with assistance of a caregiver/study coordinator
46039709|NCT02611921|Drug|Placebo|Placebo will delivered as an atomized saline spray which will be self-administered or administered with assistance of a caregiver/study coordinator
46039710|NCT02736448|Drug|Capecitabine|oral low dose of capecitabine
46039711|NCT02736448|Drug|Lu-PRRT|Lu-PRRT (at 3.7Gbq per cycle x 7 cycles)
46039712|NCT02736448|Drug|SS-LAR|long acting octreotide or lanreotide
46039713|NCT00701077|Drug|3,4-Di-amino-Pyridine|a single 20 mg dosing
45343480|NCT04455867|Behavioral|Diabetes Exercise and Healthy Lifestyle Program|The program combines exercise, education and healthy lifestyle behaviour changes. Participants will begin the program with a cardiopulmonary exercise assessment. Then the team will create a personalized program of exercise based on functional abilities and personal goals. Participants will attend 1 supervised exercise class a week, which includes a warm-up and stretching routine, aerobic exercise (walking, stationary cycling or elliptical machine), resistance training and an educational session. This program also offers peer-to-peer support and encourages participants to carry out their own exercise program at home 4 more times per week and to keep a weekly exercise diary to help them with their progress.
45343481|NCT04455867|Other|Outpatient care|Participants receive usual care from outpatient services, which may include Endocrinology, Family Medicine, or Diabetes Education
45343482|NCT04453072|Other|Interview|Participate in interviews
46039714|NCT00701077|Drug|placebo|placebo
46039715|NCT02738476|Procedure|Patellofemoral arthroplasty|
45343483|NCT04453072|Other|Media Intervention|Receive iPhone with W8Loss2Go app
45343484|NCT04453072|Other|Questionnaire Administration|Complete questionnaires
45684131|NCT01924546|Other|Water|1.5 L bottle of water provided in the morning of the school day, with refills provided during the course of the day.
45684132|NCT01923064|Drug|Lipiodol|endoscopic injection of lipiodol + cyanoacrylate + lipiodol for gastric varices
45684133|NCT01923064|Drug|Lauromacrogol|endoscopic injection of lauromacrogol + cyanoacrylate + lauromacrogol for gastric varices
45684134|NCT01924624|Drug|Thalidomide|Patients in the Adjuvant group were given oral Thalidomide(at a dose of 100 mg per day) continuously during the follow-up period
45684135|NCT01924702|Behavioral|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
45684136|NCT01924702|Device|transcranial direct current stimulation|1mA anodal over M1 primary motor cortex for 20min with 35cm/2 electrode, Cathode (100cm/2) contralateral
45343485|NCT04453072|Other|Scale Device|Receive body scale and food scale
45343486|NCT04453072|Behavioral|Telephone-Based Intervention|Receive telephone calls
45343487|NCT04453072|Other|Text Message|Receive text message
45343488|NCT04447092|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 iv D1, 8, 15 (every 4 weeks)
45474310|NCT03368404|Device|CBL-102 eye drops|CBL-102 eye drops, 3 to 6 times per day for 3 months
45474311|NCT03368404|Device|Vismed Multi eye drops|Vismed Multi eye drops, 3 to 6 times per day for 3 months
45684137|NCT01929382|Drug|interferon gamma 1b|Standard therapy vs dose titration
45684138|NCT01924780|Device|Stimulation 10 minutes|NEMOS transvagal stimuli 10 minutes
45684139|NCT01924780|Device|NEMOS transvagal stimulation 60 minutes|NEMOS Device stimulation in 60 minutes
45684140|NCT01924780|Device|NEMOS Device sham stimulation 10 minutes|
45684141|NCT00981448|Dietary Supplement|Zinc acetate|50mg of elemental zinc to be administered 2 times daily orally for 14 days.
45684142|NCT01926184|Behavioral|Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS)|5-session integrative intervention to improve positive affect as well as boost and extend the effectiveness of contingency management (CM).
45684143|NCT01926184|Behavioral|Contingency Management (CM)|12-week CM protocol that provides escalating monetary reinforcement for biological evidence of methamphetamine abstinence. Delivered as the standard of care for non-treatment-seeking methamphetamine-using MSM in San Francisco. Delivered to both the intervention and attention-control arms
46039716|NCT00703651|Biological|Inactivated, split-virion influenza vaccine|0.1 mL, ID. 1 injection/year for 3 years
45343489|NCT04447092|Drug|Nab-paclitaxel|Nab-paclitaxel 125 mg/m2 iv D1, 8, 15 (every 4 weeks)
45343490|NCT04447092|Drug|Pembrolizumab|Pembrolizumab ( 200 ) mg iv D1 (every 3 weeks)
45343491|NCT04447092|Drug|Oxaliplatin|Oxaliplatin 65 mg/m2 iv over 2 hours D1 (every 2 weeks)
45343492|NCT04447092|Drug|Leucovorin|Leucovorin 400 mg/m2 iv D1 (every 2 weeks)
45343493|NCT04447092|Drug|Irinotecan|Irinotecan 140 mg/m2 iv over 1.5 hours D1 (every 2 weeks)
45343494|NCT04447092|Drug|5FU|5-FU 2400 mg/m2 iv over 46 hours D1 (every 2 weeks)
45840546|NCT00799812|Drug|CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once).|3 swabsticks topically applied at the same time to intact skin
46039717|NCT00703651|Biological|Inactivated, split-virion influenza vaccine|0.1 mL, ID. 1 injection/year for 3 years.
45684144|NCT01924858|Drug|GSK2647544 oral|GSK2647544 100 mg will be supplied as a size 0 swedish orange hard gelatin capsules filled with white/slightly colored granule. Subjects will receive a single oral dose of GSK2647544 100 mg (2 X 50mg capsules) with 150 mL of tepid water approximately 2 hours prior to the IV infusion of [18F]-GSK2647544 and a PET scan.
46039718|NCT00703651|Biological|Inactivated, split-virion influenza vaccine|0.5 mL, IM. 1 injection/year for 3 years
45684145|NCT01924858|Drug|[18F]GSK2647544 IV bolus|[18F]GSK2647544 will be supplied as a clear, colourless solution free from visible particle. A maximum dose up to 2 mg with a maximum dose volume of 25 mL will be administered as IV bolus over 60 seconds.
45684146|NCT04395820|Diagnostic Test|Lung function test|MBW
46039719|NCT01046136|Drug|guaifenesin (Mucinex)|bid 7 days
46039720|NCT01046136|Drug|placebo|bid 7 days
46039721|NCT02736682|Drug|Single dose antibiotic|Single dose arm receive 2g of IV Ceftriaxone and 500 mgs ofIntra venous Metronidazole given to the mothers 30-60 minutes pre operative.
46039722|NCT02736682|Drug|Multiple dose antibiotic|Multiple dose arm receive 1 g of IV Cetriaxone plus 500 mgs during surgery and there after IV ceftriaxone once a day for 3 days and IV Metronidazole 500mgs during surgery and there after every 8 hours for 3 days.
45684147|NCT04395820|Diagnostic Test|Imaging|MP-MRI
46039723|NCT02736292|Behavioral|Mindfulness Practices for Healthcare Professionals|
46039724|NCT00701155|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the actual clinical evaluation
46039725|NCT02874690|Drug|Methylphenidate|single dose methylphenidate; 0.3mg/kg, up to 20mg, rounded to the nearest 2.5mg
46039726|NCT02874690|Drug|Placebo|Placebo pill identical in appearance to methylphenidate
45474312|NCT03859037|Other|Umbilical cord milking|100 babies will have squeezing of blood from umbilical cord towards baby
45474313|NCT03362320|Procedure|double layer fixation|
45474314|NCT03362320|Procedure|single layer fixation|
46039727|NCT02736214|Behavioral|Reproductive Life Plan (RLP)|A structured discussion based on the RLP, including information about reproduction and a brochure with the same information.
46039728|NCT05298007|Device|High definition transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
45474315|NCT01287689|Other|Immunoglobulin G (IgG)|Not applicable. All interventions are at the discretion of the investigator. All marketed IgG formulations can be documented.
45474316|NCT03228420|Device|Senza HF10 Therapy|Senza 10kHz Spinal Cord Stimulation
45474317|NCT03228420|Other|CMM|Conventional Medical Management
45474318|NCT03368326|Diagnostic Test|Critical-Care Pain Observation Tool (CPOT)|The CPOT includes 4 behaviors: (1) facial expression, (2) body movements, (3) compliance with the ventilator, and (4) muscle tension. Each behavior is rated from 0 to 2 for a possible total score ranging from 0 to 8.
45684148|NCT04395742|Other|Data collection|Only data collection
45684149|NCT00989950|Drug|Daytrana|Daytrana patch 10-30 mg administered once daily for 9hr
45684150|NCT00989950|Drug|Daytrana|Daytrana 10-30 mg worn once daily for 10 hr wear
45684151|NCT00989950|Drug|Daytrana|Daytrana 10-30 mg worn once daily for 11 hr
46039729|NCT05298007|Device|sham high definition transcranial direct current stimulation|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
46039730|NCT02738242|Device|Novus system|The Novus system is a FES based neuroprosthesis, which intended to provide ankle dorsiflexion and knee flexion or extension in individuals with foot drop and thigh muscle weakness, following an upper motor neuron injury or disease.
45474319|NCT03859115|Procedure|TENS (transcutaneous electrical nerve stimulation)|transcutaneous nerve stimulation with electrical pulse generation
45474320|NCT03859115|Procedure|sham intervention|sham stimulation without electrical pulse generation
45474321|NCT03362242|Drug|ARO-AAT Injection|Single or multiple doses of ARO-AAT by subcutaneous (sc) injections
45474322|NCT03362242|Other|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
45684152|NCT00989950|Drug|Daytrana|Daytrana 10-30 mg worn once daily for 12 hrs
45840547|NCT00799812|Drug|CHG 2% w/v & IPA 70% v/v swab applied sequentially|Chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; 3 swabsticks applied sequentially to intact skin.
45343495|NCT04437134|Other|On-line exercise and education|"Exercise:~Exercise is performed twice weekly for 6 weeks. Each exercise session lasts approximately 60 min. and consists of three parts; warm-up (10 min.), neuromuscular exercises (40 min.), and cool-down/stretching (10 min.). The neuromuscular exercises include exercises for core stability, postural orientation, function and leg muscle strength. Exercises are performed in 2-3 sets with 10-15 repetitions with three levels of difficulty described. The exercises follow the standardized GLA:D exercise protocol. Patients are instructed in how to use alternative equipment at home for each exercise if necessary prior to the first on-line exercise session.~Education:~Patients attend two to three on-line educational sessions at the start of each GLA:D program. The educational sessions focus on disease-management and self-help strategies, including OA disease features and symptoms, treatment options, and exercise and physical activity as treatment."
45343496|NCT04437134|Other|On-site exercise and education|"Exercise:~Exercise is performed twice weekly for 6 weeks. Each exercise session lasts approximately 60 min. and consists of three parts; warm-up (10 min.), neuromuscular exercises (40 min.), and cool-down/stretching (10 min.). The neuromuscular exercises include exercises for core stability, postural orientation, function and leg muscle strength. Exercises are performed in 2-3 sets with 10-15 repetitions with three levels of difficulty described. The exercises follow the standardized GLA:D exercise protocol. The exercise sessions are delivered at physiotherapy clinics in Denmark.~Education:~Patients attend two to three on-site educational sessions at the start of each GLA:D program. The educational sessions focus on disease-management and self-help strategies, The educational sessions focus on disease-management and self-help strategies, including OA disease features and symptoms, treatment options, and exercise and physical activity as treatment."
45343497|NCT04433780|Drug|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination switched from either EFV/TDF/FTC or DTG/TDF/3TC
46039731|NCT02738632|Drug|Telmisartan/Amlodipine+Hydrochlorothiazide|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg 1 Tab.QD"
46039732|NCT02738632|Drug|Telmisartan/Amlodipine|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg Placebo 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg Placebo 1 Tab.QD"
45684153|NCT01924936|Behavioral|DBT Online Program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
46039733|NCT02738632|Drug|Placebo for Hydrochlorothiazide|
46039734|NCT01070394|Drug|LDX Treatment|30 mg, 50mg, or 70 mg. Oral capsule, once a day, for 12 weeks.
46039735|NCT00836953|Biological|Influenza virus vaccine (Pediatric formulation)|0.25 mL, Intramuscular
46039736|NCT02736058|Device|Trans- abdominal sonography|
46039737|NCT02736058|Device|Trans-vaginal sonography|
46039738|NCT02736058|Procedure|post-operative pathological specimen examination|
46039739|NCT00703807|Drug|Topotecan|Dose escalation, 5 dose levels, 1.5 mg/m2 - 2.3 mg/m2, PO day 1-5 every 21 days
46039740|NCT00703807|Drug|RAD001|Dose level -1, 5 mg qod Dose level 1, 5 mg qod Dose level 2, 5 mg qd Dose level 3, 5 mg qd DOse level 4, 10 mg qd
45684154|NCT04276012|Other|Multifactorial intervention|Psychoeducational intervention, recommendations on life style and diet, medication adherence and changes in pharmacological strategy
45343500|NCT04422951|Behavioral|Wise interventions -- values self-affirmation and growth mindset -- plus usual care behavioral treatment|Addition of two wise wise social psychological interventions-growth mindset and self-affirmation-to a 6-month usual care behavioral intervention for weight control in children with obesity
45343501|NCT04422951|Behavioral|Education plus usual care behavioral treatment|6-month health education plus usual care behavioral intervention for weight control in children with obesity
45343502|NCT04414813|Biological|Human Amniotic Epithelial Stem Cells|Stereotactic transplantation of hAESCs for participants with PD.
45343503|NCT04410575|Other|Standard Pharmacist Care|Standard pharmacy care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians)
45684155|NCT03121456|Other|18F-FDG PET SCAN|REALIZATION OF INITIAL 18F-FDG PET SCAN (PRE THERAPEUTIC), THEN BETWEEN CYCLE 2 DAY 10 AND CYCLE 3 DAY 1
45684156|NCT03121456|Other|MRI DIFFUSION|REALIZATION OF INITIAL MRI DIFFUSION WITHIN 7 DAYS AFTER INITIAL 18F-FDG PET SCAN, THEN WITHIN 7 DAYS AFTER 18F-FDG PET SCAN 1.
45684157|NCT01925092|Drug|mifepristone|tablets
45343504|NCT04410575|Other|Reviewed Questionnaire tool results with participant|Pharmacist reviews results of the patient-administered PHQ-9 and/or GAD-7 questionnaire tool, at the scheduled follow-up appointment
45343505|NCT04410575|Other|Patient Clinical Assessment|Pharmacist conducts clinical assessment of the participant's major depressive disorder and/or generalized anxiety, which can include: appearance, current mood, sleeping patterns, mental health, medical history, social history, family history, relationship with others, suicidal ideation, previous suicide attempts or hospitalizations, current employment status
45343506|NCT04410575|Other|Psychotherapy Referral|Pharmacist initiates collaboration with physician to arrange referral for psychotherapy, including: psychologist, social worker, counsellor, psychiatrist
45498068|NCT03690180|Diagnostic Test|serum magnesium|assessment of serum magnesium in all patients
45684158|NCT03121378|Other|Blood sample 1|Blood taken before prosthesis implantation
45684159|NCT03121378|Other|Blood sample 2|Blood taken after prosthesis implantation
45684160|NCT01920256|Other|Remote, personalized type 2 diabetes care.|Diabetes and comorbidities will be managed with 1 clinic visit per year and frequent adjustments made remotely.
45684161|NCT01920256|Other|Usual Endocrine care.|Diabetes and comorbidities management will provided by an endocrinologist
45684162|NCT04347850|Other|blood sample|Collection
45684163|NCT01925248|Dietary Supplement|Whey protein|Whey protein group participants will take supplement drinks that contain whey protein, daily before breakfast and before dinner for 3 months.
45684164|NCT01925248|Dietary Supplement|Placebo group|Placebo group participants will take supplement drinks that do not contain whey protein, daily before breakfast and before dinner for 3 months.
46039741|NCT03649438|Drug|131 I-Metaiodobenzylguanidine|"Minimum dose of 10 mCi/kg for patients without a stem cell source whose renal function is above the upper limit of normal but still meets eligibility criteria.~Dose of 12 mCi/kg for patients without a stem cell source with normal renal function and meets other eligibility criteria.~Dose of > 12 mCi/kg to 18 mCi/kg maximum at investigator's discretion for patients meeting eligibility criteria with stem cells available."
45684165|NCT01905943|Drug|Bendamustine|Bendamustine: 90 milligram per millilitre square (mg/m^2) IV over 60 minutes once daily (QD) Day 1-2 in participants previously untreated or 70 mg/m^2 I.V. over 60 minutes QD Day 1-2 in participants with relapsed/refractory disease. In non-fit participants only, investigators may opt at their own discretion to use lower initial doses of bendamustine, i.e., bendamustine 70 mg/m^2 in previously untreated participants, and bendamustine 50 mg/m^2 in relapsed/refractory subjects (over 60 minutes qd Day 1-2 for each administration).
45684166|NCT01905943|Drug|Chlorambucil|Chlorambucil 0.5 mg/kg p.o. qd on Day 1 and Day 15 in non-fit participants only.
45684167|NCT01905943|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m^2 p.o. QD Day 1-3 in fit participants only.
45684168|NCT01905943|Drug|Fludarabine|Fludarabine 25 mg/m^2 I.V. over 30 minutes QD Day 1-3 or Fludarabine 40 mg/m^2 per os (p.o.) QD Day 1-3 in fit participants only.
46039742|NCT03649438|Drug|Potassium Iodide|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection.
46039743|NCT03649438|Drug|G-csf|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally >5000). This will start 24 hours after stem cell infusion (if stem cells are to be infused).
45684169|NCT01905943|Drug|Obinutuzumab|Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.
46039744|NCT02738554|Other|Treatment cessation|Cessation of nucleoside analogue therapy following European Association for the Study of the Liver guidelines
45343507|NCT04410575|Other|Pharmacist initiated interim telephone follow-up with participant|Interim telephone follow-up conducted by the pharmacist since the last in-person follow-up & a minimum of 1-2 weeks after the last in-person follow-up that involved a dose adjustment, prescribing of adjunctive medication, or discontinuation of therapy (Note: a telephone follow-up does not replace the scheduled in-person follow-up)
46039745|NCT00701233|Drug|Botulinum toxin|45 units Botox injected into Carpal Tunnel once
46039746|NCT00701233|Drug|Corticosteroid injection into Carpal Tunnel|40 mg Triamcinolone with one mL 1% lidocaine injected once into Carpal Tunnel
45343508|NCT04410575|Other|Communication update with physician after participant contact|Pharmacist provides communication update (fax or electronic charting) with the participant's physician after contact with the participant
45343509|NCT04410575|Other|Medication Counselling and Educational Support|Pharmacist provides medication related counselling and educational support to participant
45343510|NCT04410575|Other|Non-medication Counselling|Pharmacist provides non-medication related counselling and educational support to participant
45343511|NCT04410575|Other|Identification of drug interaction|Pharmacist identification of drug interaction related to medication for major depressive disorder and/or generalized anxiety
45684170|NCT01905553|Drug|SSP-004184SS|Disodium salt
46039747|NCT03645694|Device|Social Support Aid|Please see earlier; the social support aid technology consists of a smartphone with a facial recognition software application and a smartwatch. Up to 1,000 individuals can be enrolled in the facial recognition application. Enrollment includes typing individuals names and relationships of the person with memory concern into the application and taking pictures of PWMC's faces at multiple angles. Once enrolled and in view of the smartphone's camera, the SSA's application recognizes the individual's face and alerts the smartwatch. The watch then vibrates and displays the individuals' name and relationship to the PWMC.
45684171|NCT04629625|Biological|End-range mobilization|End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension
46039748|NCT03633058|Drug|Ketamine|oral ketamine dosed twice daily for 5 days
46039749|NCT01070316|Drug|Everolimus|Everolimus is available in tablet form. The starting dose will be 5 mg/m2/day, rounded to the nearest 2.5 mg/dose, to be taken daily. After two weeks, serum trough level will be measured and dose adjusted according to the following algorithm If Blood trough level is less than 2.5 ng/ml than increase dose by 5 mg/m2/day; If Blood trough level is 2.5-5.0 ng/ml than increase dose by 2.5 mg/m2/day; If Blood trough level is 5.1-10.0 ng/ml than increase dose by 0 mg/m2/day (no change); If Blood trough level is 10.1-15.0 ng/ml than decrease dose by 2.5 mg/m2/day
46039750|NCT02735824|Procedure|blood sampling and skin biopsy|Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
45684172|NCT04629625|Biological|Non end-range mobilization|Non end-range mobilization performed in tibiofemoral joints' loose position
45343512|NCT04410575|Other|Identification of drug adverse effect|Pharmacist identification of adverse effect related to medication for major depressive disorder and/or generalized anxiety
45343513|NCT04410575|Other|Identification of severe deterioration|Pharmacist identification of participant severe deterioration (i.e. suicide attempt)
45343514|NCT04410575|Other|Pharmacist-to-physician recommendation for medication adjustment, change to alternative, add-on, or deprescribing|Pharmacist collaborates, discusses, and makes recommendations to physician re: treatment plan for MDD and/or GAD (as per CANMAT guidelines), which can include: medication dose adjustment, change to alternative medication, add-on, or deprescribing
45343515|NCT04410575|Other|Pharmacist initiated medication adjustment, change to alternative, add-on, or deprescribing|Pharmacist initiated alteration to treatment plan for MDD and/or GAD (as per CANMAT guidelines), which can include: medication dose adjustment, change to alternative medication, add-on, or deprescribing
45343516|NCT04398524|Drug|ISA101b|ISA101b 4 times plus cemiplimab every 3 weeks for up to 24 months
45343517|NCT04379921|Device|Apple Watch and App|Participants in the Apple Watch and App arm will receive an Apple Watch and download an App (NeuroCoach). The Apple Watch and App are used for this study to record patient's mobility information (e.g., step counts, heart rate, stairs climbed, distance traveled) as well as provide an additional platform for patients to complete questionnaires.
45343518|NCT04375826|Device|Epidural patient controlled analgesia|The device is connected to the epidural catheter prior to surgery and drug administration is started during surgery. The continuous infusion rate is 4 ml / hr. When the button is pressed, 2 ml is additionally administered and the lock time is 20 minutes.
45343519|NCT04375826|Device|Preperitoneal analgesia and IV-PCA|During surgery, the preperitoneal analgesia catheters are inserted into the preperitoneal space and these catheters are connected to the pump with ropivacaine.
46039751|NCT02735824|Procedure|blood sampling or mouth swap|specimen will be used for genetic testing, results compared to patients
45343520|NCT04371224|Drug|Irinotecan Liposomal Injection [Onivyde]|both arm
46039752|NCT02735824|Procedure|blood sampling|Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
46039753|NCT02737774|Drug|Icotinib|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin. After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
45343521|NCT04371224|Drug|Capecitabine|NaliCap
45343522|NCT04371224|Drug|5-fluorouracil|NAPOLI
46039754|NCT02737774|Drug|Pemetrexed/Carboplatin|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin (standard solution, 3 weeks for a cycle of chemotherapy : pemetrexed 500mg/m2 iv , 4 cycles. carboplatin AUC=5 iv ,4 cycles.). After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
45343523|NCT04371224|Drug|Leucovorin|NAPOLI
46039755|NCT02735590|Drug|Isoniazid|Participants in the Treatment Arm will receive high dose Isoniazid - 15mg per kg body weight, rounded up to the nearest 100 mg; maximum dose 900 mg with Pyridoxine supplementation (25mg).
45343524|NCT04368663|Drug|Japanese traditional medicine group|TJ-134 (7.5g/day) or lactomin (3g/day) is administered for 8 weeks.
45343525|NCT04368455|Behavioral|Virtual Immersive Communication Training on Recommending Immunizations (VICTORI)|An intervention that includes a self-directed app based curriculum and virtual reality simulations, designed to increase the strength and consistency of HPV vaccine recommendations among clinicians.
45684173|NCT04629625|Biological|Placebo|Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension
45684174|NCT01929031|Drug|ibuprofen + caffeine|FDC tablet
45684175|NCT01929031|Drug|ibuprofen|tablet.
45684176|NCT01929031|Drug|ibuprofen|tablet
45684177|NCT01929031|Drug|caffeine|tablet
45343526|NCT04368455|Behavioral|HPV Same Way Same Day App|An intervention that includes a self-directed app based curriculum
45343527|NCT04363242|Biological|SYN125|Administered by IV infusion
46039756|NCT02735590|Drug|Rifapentine|Rifapentine based on body weight (>32kg - 50kg: 750 mg; >50kg: 900 mg), given weekly as 12 directly observed treatment (DOT) oral doses, ideally with food, over 3 months.
45474323|NCT05181306|Procedure|Robotic-assisted Total Gastrectomy with D2 Lymphadenectomy|Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and excluding T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
46039757|NCT05626348|Drug|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
45498069|NCT03623880|Behavioral|Unified Protocol|The unified protocol is a form of cognitive behavior therapy focused on helping the person reduce emotional distress through cognitive changes and behavioral skills. Exercises included confronting emotional-driven behaviors and mindfulness activities.
45684178|NCT01929031|Drug|ibuprofen + caffeine|Fixed Dose Combination (FDC) tablet
46039758|NCT05626348|Drug|Methotrexate|Methotrexate，10mg, po, quaque week (qw) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
45343528|NCT04363242|Biological|SYN004|Administered by IV infusion
46039759|NCT05626348|Drug|Adalimumab Injection|Adalimumab Injection，40mg，iH，every two weeks (q2w) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
46039760|NCT05626348|Drug|Leflunomide|Leflunomide，20mg, po, quaque day (qd) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
46039761|NCT05626348|Drug|Hydroxychloroquine|Hydroxychloroquine，200mg, po, twice per day (bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
45343529|NCT04343183|Device|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy delivered at a specific uniformed pressure and duration.
45343530|NCT04329364|Combination Product|Laser Haemorrhoidoplasty (LAH)|Using a laser diode to cause coagulative necrosis to the haemorrhoidal cushion
45343531|NCT04329364|Procedure|Open milligan-morgan conventional haemorrhoidectomy|conventional excisional haemorrhoidectomy
45343532|NCT04327336|Device|Manual Non invasive ventilation titration|Manual Group: during a complete polysomnography, adding transcutaneous capnography and the basic ventilators curves, the ventilators setting will be adjusted in order to correct respiratory events and patient-ventilator asyncrony. A 10 hours face-to-face investigator training meeting is programmed before opening the inclusion period.
45343533|NCT04327336|Device|Automatic Non invasive ventilation titration|Automatic Group: the A40 ventilator in the automatic AVAPS mode will be adjusted in order to achieve 8-10 ml/kg of ideal weight.
45684179|NCT01929031|Drug|placebo|tablet
45684180|NCT01929031|Drug|placebo|tablet
45684181|NCT01929031|Drug|caffeine|tablet
45343534|NCT04318964|Biological|TAEST16001 cells|"The patients in the dose increasing part and the expanding part received the intravenous reinfusion of TAEST16001 cells on the 5th day (i.e. the interval was 4 days) after the lymphocyte elimination chemotherapy: If the dose level of reinfusion was 1 and 2, the planned total amount of TAEST16001cells (calculated by TCR-T positive cells) was given a single reinfusion on the 1st day of the study. If the dose level of reinfusion was 3 and 4,then the total amount of TAEST16001cells (calculated by TCR-T positive cells) was planned to be reinjected in 60% and 40% proportion on the first and second day of the study.~After the first reinfusion of TAEST16001 cells, the patients will be given a small dose of IL-2 subcutaneously (study day 1 to day 14), 500000 U / time. The first injection will be carried out within 30 minutes after the cell reinfusion, twice a day (interval 10-12 hours), for 14 days."
46039762|NCT02737696|Behavioral|Web-based prescription opioid prevention for adolescents|The intervention focuses on individual skills factors (e.g., promoting accurate knowledge about risks), as well as peer and societal influences on prescription opioid abuse (e.g., training skills to refuse offers to misuse opioids). When accessing the program, users see pictures of youth who have been in treatment for opioid dependence, and may choose to click on links to: 1) listen to or read real stories of problematic involvement with prescription opioids, 2) view youth' trajectories of important decision points related to prescription opioid misuse, 3) view videos that provide key information or teaches a skill that might help a young person make healthier choices (e.g., refusing offers to misuse prescription opioids), 4) or take quizzes to assess information/skill acquisition.
45474324|NCT05181306|Procedure|Laparoscopic-assisted Total Gastrectomy with D2 Lymphadenectomy|Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and excluding T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
45474325|NCT03372694|Behavioral|Rehabilitation Training|Patients will be trained in one month after operation. Rehabilitation training will be carried out between every two cycles of chemotherapy. Rehabilitation training is mainly composed of gymnastics qigong, which has long been regarded as a form of rehabilitation in Traditonal Chinese Medicine. According to the poor pulmonary function of patients with lung cancer after operation, Liu Zi Jue lung exercise is chosen to strengthen the pulmonary function of the human body in Chinese traditional health culture. Liu Zi Jue lung exercise intervention will be lead by an expert instructor, five times a week, 15 min/time.
45474326|NCT03372694|Drug|TCM|four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.
45474327|NCT03372694|Other|Rehabilitation Education|General health education
45684182|NCT01929031|Drug|ibuprofen|tablet
45343535|NCT04306900|Combination Product|TTX-030, budigalimab and mFOLFOX6|Dose and schedule per protocol
45343536|NCT04306900|Combination Product|TTX-030, budigalimab and docetaxel|Dose and schedule per protocol
45343537|NCT04306900|Combination Product|TTX-030 and mFOLFOX6|Dose and schedule per protocol
45684183|NCT01929031|Drug|ibuprofen + caffeine|FDC tablet
45684184|NCT00989092|Biological|darbepoetin alfa|Administered subcutaneously.
45343538|NCT04306900|Combination Product|TTX-030 and budigalimab|Dose and schedule per protocol
45343539|NCT04306900|Combination Product|TTX-030, budigalimab, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
45343540|NCT04306900|Combination Product|TTX-030 and pembrolizumab|Dose and schedule per protocol
45343541|NCT04306900|Combination Product|TTX-030, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
45840548|NCT00799812|Drug|Aqueous CHG 4% w/v applied according to mfr's directions|Chlorhexidine gluconate 4% w/v in an aqueous base applied according to mfr's directions. Step 1) 5 ml of Hibiclens applied to a sterile gauze pad. Step 2) Product applied to treatment area on intact skin for 2 minutes. Area dried with sterile towel or sterile gauze. Steps 1 and 2 repeated.
45840549|NCT00799812|Other|Sterile swabstick with sterile water (3 @ once)|3 sterile swabsticks wetted with sterile water topically applied to intact skin at the same time.
46039763|NCT02737696|Behavioral|JustThinkTwice.gov website (DEA)|The JustThinkTwice.com website is educational (a large percentage of the website content focuses on opioids) with a menu including: Drug Information, True Stories (of youth who have lost their lives to drugs), Consequences, Facts/Statistics, Videos (e.g., the Life of an Opiate Addict, and Synthetic Drugs), and a brief Quiz.
45343542|NCT04306900|Combination Product|Budigalimab and mFOLFOX6|Dose and schedule per protocol
45343543|NCT04296604|Device|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
45343544|NCT04288687|Drug|Niraparib Pill|Niraparib 200 mg by mouth daily (2 x 100 mg pills)
45343545|NCT04278235|Drug|Elezanumab|Solution for intravenous (IV) infusion
45343546|NCT04271579|Procedure|Salvage Lymphnode dissection|"A salvage lymphnode dissection is performed in all study patients (both arms)using standard surgical techniques (openly or DaVinci).In patients who were randomized to the bilateral pelvic lymphnode dissection group, a salvage lymphadenectomy was also performed on the opposite side with resection of the corresponding fields that were removed on the PSMA-PET positive side (th Blinding must be guaranteed during pathological assessment)"
45343547|NCT04269512|Procedure|lymph node dissection|At least 10 lymph nodes must be removed.
46039764|NCT02738320|Other|NHCPlus|A decision-aid tool that will interface with Nursing Home Compare and improve consumers' ability to assimilate and incorporate the information into their process of choosing a nursing home.
45343548|NCT04269161|Device|Automatic control of inspired oxygen|A device will be used to automatically adjust the blend of oxygen and air with the ability to return to manual control as needed.
45343549|NCT04259047|Behavioral|Diabetes Regulation for Eyesight and Memory|Participants randomized to DREAM will have 11 in-home visits over 2 years with a CHW, and 4 telehealth visits with a DM nurse educator.
45343550|NCT04259047|Behavioral|Enhanced Usual Care|Participants in this group will have 11 in-home CHW visits over 24 months to control for attention. During these visits, the CHW will provide general diabetes education. There will be no telehealth visits.
46039765|NCT02737384|Biological|Depletion in CD45RA graft donor|"Experimental treatment: negative fraction after CD34+ selection from PBSC graft is depleted of naïve CD45RA+ cells. this fraction is reinjected to the recipient and is the experimental product.~Conditioning regimen:~Up-front ATG from D-14 toD-11 Busulphan IV from D-8 to -5 Fludarabine from D-7 to D-4 Thiothepa D-3 to D-2~Graft: CD34+ cells positively selected cells from PBSC of the donor~Post transplant immunosuppression: ciclosporin started at D-1 to D+100"
45343551|NCT04257994|Diagnostic Test|obtaining a buccal smear sample|A sample will be taken from the inside of the participants' cheeks using a soft brush
46039766|NCT03512392|Other|Conservative fluid and deresuscitation strategy|Conservative administration of intravenous fluid and active deresuscitation using diuretics or renal replacement therapy for eligible patients
45343552|NCT04245228|Behavioral|Wellness Coach|Trained in motivational interviewing who will call the patient weekly for 12 sessions for an approximately 30-minute intervention
46039767|NCT03512392|Other|Usual care strategy|Usual care at the discretion of the clinical team
45343553|NCT04231708|Drug|Yohimbine + Hydrocortisone|Yohimbine (54mg bulk powder inside capsule) administered in combination with Hydrocortisone (20mg tablet inside capsule)
45343554|NCT04231708|Device|Active rTMS|10Hz rTMS over the left dlPFC
45343555|NCT04231708|Drug|Placebo|lactose (inside capsule)
45343556|NCT04231708|Device|Sham rTMS|inactive stimulation over the left dlPFC
45343557|NCT04229992|Dietary Supplement|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
45343558|NCT04229992|Dietary Supplement|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
45343559|NCT04229472|Diagnostic Test|High density electrophysiological mapping|Recording of electrophysiological data using a high density contact catheter during pacing at the time of catheter ablation for atrial fibrillation.
45343560|NCT04229472|Diagnostic Test|Cardiac Magnetic Resonance Imaging|Late gadolinium enhance cardiac magnetic resonance imaging (in AcQMap group only)
45840550|NCT00799812|Other|Sterile swabstick with sterile water (one-at-a-time)|Sterile swabsticks wetted with sterile water topically applied to intact skin one-at-a-time.
45343561|NCT04221230|Drug|BTRX-335140|Active Drug
46039768|NCT02735668|Other|Shoulder Conventional Exercises|"The protocol consists in:~• Flexibility and Strengthening Exercises of the shoulder muscles conventionally performed in shoulder pathology treatment:~Mobilisation Joint Exercises.~Isometrics and Resisted Exercises (elastic bands)."
46039769|NCT02735668|Other|Multimodal Physiotherapy|"The protocol consists in:~Dry Needling in active myofascial trigger points related to shoulder joint (optimal hygiene and disinfection before and after needling). Special care in muscles located in the arm in women with axillary node dissection.~If Upper Limb Neural Tension Test is positive, neurodynamic techniques will be included."
45343562|NCT04221230|Drug|Placebo|Placebo
45343563|NCT04218786|Drug|Colchicine|The tablet will be given once daily for the span of the study
46039770|NCT02735668|Other|Scapular exercises|"The protocol consists in:~Scapula-focused exercises: based on evaluation of scapular dyskinesis and Kinetic Medial Rotation Test as well as inherent characteristics of each woman, individualized scapular exercises were prescribed based on a motor control approach with emphasis on obtaining a neutral scapular orientation."
45343564|NCT04218786|Drug|Placebo oral tablet|The tablet will be given once daily for the span of the study
45343565|NCT04216524|Drug|Cyclophosphamide|Given IV
45343566|NCT04216524|Drug|Cytarabine|Given IT or IV
46039771|NCT02735668|Behavioral|Therapeutic Education|"The protocol consists in:~Therapeutic Education about chronic shoulder pain using a slide show, anatomical models, providing information and analysis of real clinical cases."
45684185|NCT00988858|Drug|LY2603618|150 milligram per square meter (mg/m^2) intravenously on Day 2 of each 21 day cycle repeating every 21 days for a minimum of 2 cycles continuing until disease progression
45684186|NCT00988858|Drug|Pemetrexed|500 mg/m^2 intravenously on Day 1 of each 21 Day cycle repeating every 21 days for a minimum of 2 cycles or until disease progression
45684187|NCT01920334|Drug|Zolpidem CR 12.5mg|Patients will be given zolpidem CR 12.5mg each night for, at least, 3 consecutive nights, including the first night on the Cardiac ICU, when the undergo a full-night polysomnography
45684188|NCT01920334|Drug|Placebo|Patients will receive placebo pills at night, according to their usual sleep time, from the first night on the Cardiac ICU, until their hospital discharge
45684189|NCT04395352|Device|Endocuff Vision (ECV)|Detachable disposable (single-use) device that fits over the distal colonoscope end.
45840551|NCT00801138|Drug|saline|2 ml 0.9% saline (placebo)
45840552|NCT00801138|Drug|Dexamethasone|dexamethasone 8 mg (2 ml)
45840553|NCT00801138|Drug|ropivacaine|30 ml 0.5% ropivacaine
45343567|NCT04216524|Drug|Dexamethasone|Given PO or IV
45343568|NCT04216524|Drug|Doxorubicin|Given IV
45343569|NCT04216524|Drug|Mercaptopurine|Given PO
45343570|NCT04216524|Drug|Methotrexate|Given IT, IV, or PO
45343571|NCT04216524|Drug|Methylprednisolone|Given IV
45343572|NCT04216524|Drug|Prednisone|Given PO
45343573|NCT04216524|Biological|Rituximab|Given IV
45343574|NCT04216524|Biological|Tagraxofusp-erzs|Given IV
45343575|NCT04216524|Drug|Venetoclax|Given PO
45343576|NCT04216524|Drug|Vincristine|Given IV
45343577|NCT04211129|Other|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.
45474328|NCT03372694|Drug|placebo|four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe，with the same color, smell，taste, weight and package
45474329|NCT01179503|Dietary Supplement|calcium|600 mg calcium carbonate twice daily (total of 1200 mg/day) for 4 months
45840554|NCT00801138|Drug|Bupivacaine|30 ml 0.5% bupivacaine
45840555|NCT00801684|Drug|Placebo|Supplied as an empty size-2 capsule and administered as a single dose via C2S inhaler.
45840556|NCT00801684|Drug|TrIP-2D|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
45343578|NCT04211129|Other|Sham acupuncture|Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
45840557|NCT00801684|Drug|TrIP-2SS|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
46039772|NCT02735434|Behavioral|Internet-based ACT|The guided internet program consists of 7 modules activated consecutively over a period of 12 weeks. The content is written psycho education, patient videos, audio-exercises and behavioural exposure exercises. The program is therapist-guided; hence all patients will receive support from primarily the same therapist during the 12 weeks.
45343579|NCT04202692|Device|Hyaluronic acid with chondroitin sulphate and magnesium trisilicate, 1100 mg melt in mouth tablet|1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks
45343580|NCT04202692|Device|Placebo 1100 mg, identically-looking melt in mouth tablet|1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks
45343581|NCT04201119|Device|Oxiris|Oxiris membrane used on the Prismaflex device (Baxter) dedicated to that type of membrane at blood pump flow of 450 ml min-1
45343582|NCT04198831|Other|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and CV8, CV12 and bilateral ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.
45343583|NCT04198831|Other|Sham acupuncture|Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and CV8, CV12 and bilateral ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
45840558|NCT00801684|Drug|TrIP-2D|Trospium inhalation powder containing 400 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
45840559|NCT00801684|Drug|TrIP-2SS + Foradil|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
45343584|NCT04198818|Drug|HH2710|HH2710 is a small molecule that potently inhibits both ERK1 and ERK2 protein kinases in the nanomolar range. The kinase selectivity assessment towards a panel of over 400 protein kinases showed that HH2710 barely inhibited other kinases at a concentration up to 1 μM, except the substantial inhibition against ERK1 (MAPK1), ERK2 (MAPK2) and the MAPK pathway upstream kinases MEK and RAF proteins.
46039773|NCT02735434|Other|Internet-based discussion forum|The online discussion forum consists of 7 themes touching upon the impact of health anxiety and the patients own coping strategies. The themes are activated consecutively over a period of 12 weeks. The discussion forum is text-based, and only patients will participate in the discussion. The written discussions will be reviewed by a professional for ethical reasons. The discussion forum aims to control for the effect of attention and contacts to the health care system. After 9 months patients in the discussion forum are offered active treatment, but not as part of the research project.
46039774|NCT02737228|Drug|CG200745 PPA|CG200745 PPA IV every week three times per cycle (4 weeks)
45343585|NCT04195542|Other|Questionnaire|questionnaire assessing knowledge of the need to take vitamin B9 supplementation in women in the periconceptional period and the reasons why this supplementation is carried out or not
45343586|NCT04192825|Procedure|surgical treatment|surgical drainage and/or surgical reconstruction procedures to anoperineal suppurations according to the doctor's decision
45343587|NCT04187820|Other|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. In the acupuncture group, Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustIon.
45343588|NCT04177758|Drug|Vitamin D|Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.
45343589|NCT04177758|Drug|Control|Patients randomized to the control will receive a placebo
45343590|NCT04172805|Drug|anlotinib and toripalimab|Anlotinib 12mg orally per day, two weeks on , one week off; 240 mg of toripalimab (fixed dose) every three weeks. Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment.
45343591|NCT04168112|Drug|Dextenza|Placement of intracanalicular dexamethasone insert for post-crosslinking inflammation and pain
45343592|NCT04168112|Drug|Prednisolone Acetate|post-crosslinking eye drop prednisolone acetate given in a tapering schedule over 1 month
46039775|NCT02737228|Drug|Gemcitabine|1000 mg/m^2 intravenously every week three times per cycle (4 weeks)
46039776|NCT02737228|Drug|Erlotinib|100 mg per oral daily per cycle (4 weeks)
45343593|NCT04159909|Device|Transcutaneous Nerve Stimulation|510(K) number: K110390 vagus nerve for 5 minutes twice a day for 4 consecutive days
45343594|NCT04159909|Device|Sham Stimulation|sham stimulation (no electrical current) for 5 minutes twice a day for 4 consecutive days
45343595|NCT04150458|Drug|18F-fluorocholine PET/CT.|18F-fluorocholine positron emission tomography / computed tomography
46039777|NCT01126541|Drug|rituximab|Arm A: 1000 mg IV (one infusion) every 2 months \nArm B: 2 x 1000 mg IV (2 infusions) every 2 months
46039778|NCT02735278|Other|different test paradigms|
46039779|NCT05578300|Diagnostic Test|Thrombus analyses|Physical, histology, biochemical or protein expressions of the thrombi obtained from thrombectomy procedures may contain information regarding the etiology of stroke and relevant disease pathology. The investigators shall store the thrombus, if any, yielded from thrombectomy procedures for future analyses.
46039780|NCT05578300|Diagnostic Test|Imaging assessment|All imaging data will be deidentified before assessment. Plain computer tomography of the brain (CT brain), CT angiography (CTA), CT perfusion (CTP), magnetic resonance imaging of the brain (MRI), digital subtraction imaging (DSA) will be analysed. The investigators shall blind the assessors from treatment choice and outcome in all analyses that require human assessment.
45343596|NCT04148482|Other|Dietary intervention|To investigate whether individuals with divergent genetic susceptibility have different food preferences and have differential post-prandial glycemic and metabolomics responses to a standardized or an election meal.
45474330|NCT01179503|Dietary Supplement|Vitamin D plus calcium|1000 IU of vitamin D3 twice daily (for a total of 2000 IU/day) plus 600 mg calcium carbonate twice daily (for a total of 1200 mg/day)
46039781|NCT02737150|Device|CoreValve Evolut R|
46039782|NCT02737150|Device|Edwards Sapien 3|
45343597|NCT04147208|Drug|GLS4|Administered GLS4 120 mg orally three times daily in fed state
45343598|NCT04147208|Drug|RTV|Administered RTV 100 mg orally three times daily in fed state
45343599|NCT04147208|Drug|ETV|Administered orally ETV 0.5 mg once daily in fasted state
46039783|NCT02737150|Procedure|Local anesthesia with conscious sedation|
46039784|NCT02737150|Procedure|General anesthesia|
46039785|NCT02736916|Radiation|HS-WBRT PCI|LD-SCLC patients with HS-WBRT PCI
46039786|NCT02736916|Radiation|Conventional PCI|LD-SCLC patients with conventional PCI
45343600|NCT04140487|Drug|Azacitidine|Given IV
45343601|NCT04140487|Drug|Gilteritinib|Given PO
45840560|NCT00803010|Drug|Tacrolimus (TAC)|Tacrolimus: administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.
45343602|NCT04140487|Drug|Venetoclax|Given PO
45684190|NCT03096418|Drug|Paclitaxel|Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.
46039787|NCT02735356|Drug|Itraconazole|Applied topically
45840561|NCT00803010|Drug|Methotrexate (MTX)|Methotrexate: administered on day 1 at dose of 15 mg/m^2, and a dose of 10 mg/m^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.
46039788|NCT02735356|Other|Placebo|Applied topically
46039789|NCT00625469|Drug|bosentan|62.5mg orally bid for first month, followed by 125mg bid thereafter
45840562|NCT00803010|Drug|Rapamycin (RAPA)|Rapamycin: initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.
45840563|NCT00803400|Drug|Alprazolam|"The patients assigned to the pharmacological plan will receive 4 mg alprazolam daily for 12 weeks. Two weeks after the first interview they have their first baseline psychiatric control, where all the patients are tested.~Then, at the same visit, all the patients are indicated 4 mg of alprazolam. The dose is gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12."
46039790|NCT05577910|Device|Vectored thermal pulsation (VTP) therapy|VTP purchased from TearScience®️ is an automated thermal pulsation system that is designed to heat and simultaneously evacuate the meibomian gland contents. It is performed by the unmasked treating investigators as described by the equipment manufacturer. In brief, one to two drops of topical anesthesia are applied prior to the bilateral application of the activators. The inner portion of the activator applies a constant temperature of 42.5°C to the tarsal conjunctiva of upper and lower eyelids. Simultaneously, the outer portion of the activator applies directional, pulsatile pressure to the external eyelid surfaces (maximum 6 psi) for the 12-minute treatment cycle. Participants will receive one session of VTP treatment only (month 0).
46039791|NCT05577910|Device|Intense pulsed light with meibomian gland expression (IPL+MGX) therapy|"IPL is delivered using the proprietary dry eye mode setting of the Lumenis®️ M22TM system per the Toyos protocol. Pulse intensity (11-14 J/cm2) is inversely related to the Fitzpatrick skin phototype of each participant and will be used for the same patient throughout the study. IPL will be delivered to four overlapping zones inferior to each eye and a fifth pulse applied temporally adjacent to the lateral canthus four times. Both eyelids are closed and sealed with IPL-Aid disposable eye shields. MGX is immediately performed on both upper and lower eyelids of each eye and pain will be minimized by topical anesthetic. Participants will receive four-session IPL and MGX treatment (month 0, 1, 2 ,3)."
46039792|NCT05577910|Behavioral|Eyelid Warm Compress Therapy (EW)|EW using warm wet towel to each eye is performed twice daily for 10 mins. A treatment diary will be given for patients randomized to EW for daily recording which will be reviewed and recorded by the unmasked study coordinator at each study visit.
46039793|NCT05577910|Drug|Topical eye drops (Hypromellose, 3mg/ml)|All patients will be given one single topical lubricant (Hypromellose, 3mg/ml) to be used as frequently as needed from recruitment to study exit (total 16 months).
45343603|NCT04140344|Other|Text Message Group|The intervention group will receive automated text messages every day for the first week, and every other day for the second week post-operatively. The text messages will follow a series of pre-defined standardized scripts (Appendix 3) with embedded hyperlinks to a video from the providers with further advice. The patient is directed not to respond to the text messages, but to call for any questions or concerns. The text message group will receive a 30-day post-operative phone call to evaluate: number of ED visits, hospital readmissions, and to re-administer the questionnaires completed at baseline visit. Other data to be collected may include the following: number of phone calls to provider, MyChart messages to provider, pain medications, and new problems like pain and infection.
46039794|NCT04311125|Procedure|Mini posterior approach Total Hip Replacement|Total hip replacement in patients suffering from hip osteoarthritis using the mini posterior approach
45343604|NCT04137510|Device|Percutaneous coronary intervention|It's a non-surgical procedure that uses a catheter to place a stent into a coronary blood vessel in order to open up the vessel.
45343605|NCT04120688|Device|3D generated tooth replica|3D generated tooth replicas are compared to conventional procedure
45343606|NCT04114227|Behavioral|Acceptance and Commitment Therapy adapted for Cystic Fibrosis (ACT with CF)|Subjects learn new ways to manage uncomfortable experiences and feelings and to engage in positive behaviors
45684191|NCT01920490|Device|GUILT-INCREASE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
45684192|NCT01920490|Device|GUILT-STABILIZE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
45684193|NCT04275622|Behavioral|Lifestyle including optimal exercise and diet modification.|The intervention group will receive diet education and be given exercise suggestion.
45343607|NCT04114227|Behavioral|Supportive Psychotherapy (Treatment as Usual Control)|Subjects talk about their experiences to date in a cohort of adult Cystic Fibrosis patients.
45343608|NCT04085991|Drug|131I-PSMA-1095 Radioligand Therapy (RLT)|Intravenous injection of 100 mCi of 131I-PSMA-1095, Q8 weeks up to a maximum of 4 doses.
45343609|NCT04077281|Other|Medication Coordinated care|"Clinical Pharmacology & Toxicology consult~CPT team completes detailed circle of care communication~Telemedicine followup by CPT team (approximately 48 hrs post-discharge & 1 week to1 month post-discharge)"
46039795|NCT04311125|Procedure|Anterior approach total hip replacement without a traction table|Mini Anterior approach total hip replacement in patients suffering from hip osteoarthritis without the aid of a traction table
45343610|NCT04072991|Other|dietary therapy|participants will undertake a four week diet as part of their IBS treatment
45343611|NCT04072354|Drug|SEP-363856 50mg|SEP-363856 50mg tablet dosed once daily
45343612|NCT04072354|Drug|SEP-363856 75mg|SEP-363856 75mg tablet dosed once daily
45343613|NCT04072354|Drug|Placebo|Placebo tablet dosed once daily
46039796|NCT04311125|Procedure|Anterior approach total hip replacement with a traction table|Mini Anterior approach total hip replacement in patients suffering from hip osteoarthritis with the aid of a traction table
46039797|NCT00637481|Drug|atorvastatin calcium|Given orally
45343614|NCT04067726|Drug|Denosumab|Denosumab is commercially available and will be provided at no cost to participants.
46039798|NCT00637481|Other|laboratory biomarker analysis|Correlative studies
46039799|NCT00637559|Drug|Esomeprazole Magnesium|
45343615|NCT04067726|Drug|Placebo|Placebo will be made available as 1 mL sterile, non-pyrogenic water solution in a single-use prefilled syringe.
45343616|NCT04067726|Drug|Calcium|-Participants will be instructed to take calcium (600 mg) daily for 12 months between baseline examination and 12- month mammographic breast density examination.
45343617|NCT04067726|Drug|Vitamin D3|Participants will be instructed to take vitamin D3 (800 IU) supplements daily for 12 months between baseline examination and 12- month mammographic breast density examination.
45343618|NCT04067726|Procedure|Core needle biopsy|Baseline and 12 months
45343619|NCT04067726|Procedure|Blood draw|Baseline and 12 months
45343620|NCT04053517|Other|Medical Chart Review|Medical chart is reviewed
45343621|NCT04053517|Other|Quality-of-Life Assessment|Ancillary studies
45343622|NCT04053517|Other|Questionnaire Administration|Ancillary studies
46039800|NCT02736994|Drug|PIP toothbrush cleaner® (Chrisal, Lommel, Belgium).|Probiotic
46039801|NCT02736994|Drug|Corega Tabs Anti-bacteria®|Cleansing tablet -Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)
46039802|NCT02736994|Other|Water|Water
46039803|NCT04310969|Device|MiBoFlo Thermoflo|Each treatment for each eye takes 10 minutes and is treated every two weeks for a total of three times. The device was preheated to 42.2℃ and the eyelid was cleaned and smeared with a small amount of ultrasound gel in order to reduce friction between the device and eyelid skin. Then massage the outer skin of the upper and lower eyelids for a period of 10 minutes. The patient's eyes keep closed during therapy.
45474331|NCT03368248|Other|Survey|A survey was conducted among all professionals in neonatal resuscitation services : doctors (senior and intern), paramedics (managers, pediatric nurses, auxiliaries and nurses, psychomotor therapists) and psychologists. The survey was based on a questionnaire, which was offered to all professionals, both medical and non-medical. All questions were closed, and a free comment area was proposed at the end. The questionnaire was preceded by a comment recalling the objectives of the study, the voluntary and individual nature of participation, and insisted on respect for anonymity. It consisted of 49 questions, allowing 197 possible answers. For most questions, several answers could be chosen.
45343623|NCT04047771|Drug|SCB-313|Intraperitoneal injection, 3 doses on D1,D4,D7，21 days for 1 cycle
45343624|NCT04040348|Biological|Approximately 100 million cells allogeneic hMSC|Umbilical cord-derived, allogeneic hMSC administered intravenously at a dose of approximately 100 million cells per infusion.
45343625|NCT04025931|Drug|chidamide and toripalimab|"The eligible patients with advanced soft tissue sarcoma were treated with chidamide combined with toripalimb. Chidamide 30mg orally twice a week;~Toripalimab 240 mg (fixed dose) every three weeks.~Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment."
45343626|NCT04008706|Drug|Acalabrutinib|Acalabrutinib will be administered as one 100 mg capsule taken orally, twice daily with 8 ounces (approximately 240 mL) of water.
45474332|NCT03117049|Drug|ONO-4538|360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
45498070|NCT03623880|Behavioral|Supportive Therapy|Supportive therapy seeks to improve self-esteem, aid the patient with problem solving, and provide structured support using empathetic listening.
45684194|NCT01920646|Other|ALV|Random allocation of children of two rural farm schools per grade to receive either 300 gram cooked ALVs and school meal starch or the normal school meal as daily meal (5 days/weeks) for 3 months.
45684195|NCT00986986|Drug|extended release niacin|Active arm subjects will start extended release niacin (Niaspan) at 500 mg per night (by mouth once a daily) and titrate to a maximum tolerated dose (not exceeding 1500 mg per night (by mouth once a day) for 12 weeks. Titration will depend on patient tolerability of Niaspan.
45684196|NCT01925482|Drug|6%CO2, 25%O2, balance N2|exposure of middle ear to gas
46039804|NCT04310969|Procedure|forceful expression of the meibomian glands|Utilize a cotton swab on the inner surface of the eyelid and the another cotton swab on the outer lid to apply force
46039805|NCT04310969|Device|LipiFlow|LipiFlow treatment applies heat to the palpebral surface of eyelids while simultaneously applying graded pulsatile pressure to the outer eyelid surfaces, thereby expressing the meibomian glands during heating.
45684197|NCT01925482|Drug|6% CO2, 0%O2, balance N2|exposure of middle ear to gas
45684198|NCT01925482|Drug|20%CO2, 6%O2, balance N2|exposure of middle ear to gas
45684199|NCT01925482|Drug|0%CO2, 6%O2, balance N2|exposure of middle ear to gas
46039806|NCT05577208|Device|"Symplicity Spyral multi-electrode renal denervation catheter and Symplicity G3 generator (Renal Denervation System)"|Minimally invasive percutaneous interventional therapy aimed to modulate the sympathetic nervous system through endovascular ablation of both renal arteries
46039807|NCT04311047|Diagnostic Test|USPIO-enhanced MRI|Administration of USPIO contrast 24-36 hours before MRI scan of the abdomen to detect lymph node metastases.
45474333|NCT03117049|Drug|Carboplatin|Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
46039808|NCT05553730|Behavioral|Digital Buddy program|Six months of ICT and psychoeducation delivered by youth mentors via an e-learning platform
45343627|NCT04003103|Drug|Islatravir|Islatravir 30 mg capsules taken by mouth.
45343628|NCT04003103|Drug|Placebo|Placebo capsules taken by mouth.
45343629|NCT03999216|Drug|Loop Diuretics vs. loop + thiazide diuretics|Participants will receive the diuretic type as determined by the randomized group assignment starting within the first 24 hours of hospital admission and continuing for up to 72 hours. All other treatments are left to the discretion of the treatment team, as this is a pragmatic randomized trial.
45474334|NCT03117049|Drug|Paclitaxel|Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
45474335|NCT03117049|Drug|Bevacizumab|Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
46039809|NCT00836875|Drug|Voriconazole|"All subjects will receive voriconazole for a minimum of 6 weeks and a maximum of 12 weeks. All subjects must receive intravenous (IV) voriconazole for the first week of therapy.~Group 1: Subjects 2 to 11 years old and subjects 12 to 14 years old with low body weight (<50 kg) will receive 9 mg/kg IV every 12 hours (q12h) on day 1, then 8 mg/kg IV q12h starting day 2. If there is a significant clinical improvement after the first week of IV therapy, subjects may be switched to the step-down oral regimen (9 mg/kg PO q12h with a maximum dose of 350 mg PO q12h) at the discretion of the investigator.~Group 2: Subjects 12 to 17 years old (excluding 12-14-year-olds weighing <50 kg) will receive 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h starting day 2. Similar to Group 1, subjects may be switched to the step-down oral regimen (200 mg PO q12h) at the discretion of the investigator. Oral voriconazole can be administered as tablet or oral suspension."
46039810|NCT02732314|Drug|Investigational OTC Cream|
45343630|NCT03996850|Procedure|Computed Tomography|Undergo SPECT/CT
45343631|NCT03996850|Other|Questionnaire Administration|Ancillary studies
46039811|NCT02732314|Other|Cosmetic Eczema Cream|
45343632|NCT03996850|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
45474336|NCT03117049|Drug|Placebo|Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
45474337|NCT03372304|Drug|Ropivacaine 0.2%|Perineural infusion of Ropivacaine 0.2% using a peripheral nerve block catheter and a portable infusion pump.
46039812|NCT02732314|Drug|0.05% Desonide Cream|
45343633|NCT03996850|Radiation|Technetium Tc-99m Sestamibi|Given IV
45343634|NCT03989401|Other|Multimedia video health education|The experimental group conducted multimedia video education while admission.
45343635|NCT03978611|Drug|Relatlimab|Specified dose on specified days
45343636|NCT03978611|Drug|Ipilimumab|Specified dose on specified days
45474338|NCT02525081|Drug|Ramipril (ACE-inhibitor)|up to 10 mg
46039813|NCT02732314|Other|Placebo Cream|
45343637|NCT03971617|Drug|Hydrogen|each hydrogen tablet contains 80mg magnesium
45343638|NCT03971617|Drug|Placebo oral tablet|matching placebo tablet
45343639|NCT03965585|Procedure|in-office hysteroscopy|in-office hysteroscopy with miniaturized instruments
45684200|NCT01925482|Drug|6% CO2, 6%O2, balance N2|exposure of middle ear to gas
45684201|NCT01925482|Drug|6%CO2, 6%O2, 0%N2, balance argon|exposure of middle ear to gas
45694574|NCT04088890|Drug|CD22 CAR|Autologous T cells transduced with lentiviral vector (CD22.BB.Z) Chimeric Antigen Receptor (CD22 CAR). Autologous CD22 CAR T cells will be administered intravenously at Dose Level 1 in subjects with ALL. Autologous CD22-CAR T cells will be administered in 3 escalating doses (Dose Level 1, 2, and 3) in subjects with aggressive B-cell NHL to determine MTD/RP2D
45694575|NCT00879190|Drug|Unasyn|Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.
45343640|NCT03964909|Procedure|Functional Magnetic Resonance Imaging|Undergo fMRI
45343641|NCT03964909|Procedure|Magnetic Resonance Imaging|Undergo CVR MRI
45343642|NCT03964909|Procedure|Resting State Functional Connectivity Magnetic Resonance Imaging|Undergo rs-fMRI
45474339|NCT02525081|Drug|placebo|up to 10 mg
45498071|NCT03682146|Procedure|Prostatectomy|Comparison of robot-assisted and conventional laparoscopic radical prostatectomy
45498072|NCT03681990|Drug|3M CHG/IPA Prep|Apply topically to intact skin
45474340|NCT05566548|Diagnostic Test|Liquid Chromatography-Mass Spectrometry Method to identify bilirubin molecular species|It will determine the concentration of the different molecular species of bilirubin and examine the pattern of increase present in patients with liver cirrhosis who develop hepatic encephalopathy and acute-on-chronic liver failure (ACLF) compared to other groups like patients with liver cirrhosis and healthy people.
45474341|NCT02525003|Dietary Supplement|Vitamin D2|Experimental group 2: daily vitamin D2 supplement 25ug/d for 8 weeks
45474342|NCT02525003|Dietary Supplement|Vitamin D3|Experimental group 3: daily vitamin D3 supplement 25ug/d for 8 weeks
45694576|NCT00879190|Drug|Ampicillin/gentamicin|Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.
46039814|NCT01125917|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
45474343|NCT02525003|Other|Vitamin D2 fortified bread|Experimental group 4: vitamin D2 fortified bread containing 25 µg of vitamin D2/d (bread dose 87g/d) and placebo pill for 8 weeks
45694577|NCT01903811|Drug|Carfilzomib|Given IV
45474344|NCT03367936|Behavioral|One-on-one Session|Participants will receive a 45-minute one-on-one behavioral lifestyle program for a healthful lifestyle and weight loss.
45474345|NCT03367936|Behavioral|Self-monitoring|Participants will receive an orientation on how to self-monitor using the smartphone and other devises
45474346|NCT03367936|Behavioral|Feedback|Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings
45498073|NCT03681834|Other|Data collection|Data on the effectiveness and safety of the Cor-Knot® knotting device
45694578|NCT01903811|Drug|Dexamethasone|Given IV
45694579|NCT01903811|Other|Laboratory Biomarker Analysis|Correlative studies
45694580|NCT00880360|Drug|Ontak|Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.
45694581|NCT01709149|Drug|CK-2017357|CK-2017357 125 mg tablets twice daily
46039815|NCT01125917|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
46039816|NCT01125917|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
46039817|NCT02732236|Other|Rituximab|Cohort observation study
46039818|NCT02734966|Drug|Magnesium Isoglycyrrhizinate Injection 100mg OD|Magnesium Isoglycyrrhizinate Injection 100mg OD
46039819|NCT02734966|Drug|Magnesium Isoglycyrrhizinate Injection 200mg OD|Magnesium Isoglycyrrhizinate Injection 200mg OD for 4 weeks
46039820|NCT02734966|Drug|Tiopronin Injection|Tiopronin Injection 200mg OD
46039821|NCT00847561|Behavioral|Family-based CBT|Eight, 1-hour weekly sessions with a trained clinician.
46039822|NCT00847561|Behavioral|Information Monitoring|Packet providing information on strategies for coping with anxiety
45474347|NCT03464448|Drug|Teriflunomide|AUBAGIO® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), which inhibits pyrimidine de novo synthesis by blocking the enzyme dihydroorotate dehydrogenase.
45343643|NCT03959683|Device|Trilogy Lithotrite|The Trilogy has been FDA cleared for fragmentation of urinary tract calculi in the kidney, ureter, and bladder. Trilogy is a combined piezoelectric/pneumatic device capable of fragmenting calculi and aspirating stone debris. The novel technology in Trilogy has been demonstrated in bench testing to more quickly disintegrate stones compared to other devices.
45343644|NCT03959683|Device|The ShockPulse-SE Lithotripsy System|The ShockPulse-SE System is an electromechanical device capable of fragmenting calculi and aspirating stone debris. The novel technology in the ShockPulse-SE Lithotripsy System uses a single transducer and proprietary ShockPulse technology to generate both low-frequency mechanical impacts and high-frequency ultrasonic energy which quickly disintegrates stones.
45343645|NCT03958929|Other|Educational Video|The film follows the journey of an elderly patient scheduled to undergo glaucoma surgery, beginning with a face-to-face Q&A health session with an eye doctor. After surgery, the patient talks about his post-operative eyesight and discusses the benefits of early diagnosis and glaucoma surgery for treatment with his community.
45474348|NCT01179581|Drug|GLPG0634|single ascending doses, oral solution (1 to 10 mg/dose) and capsules (10 to 200 mg/dose)
46039823|NCT05552638|Other|Telecare|The University of Kentucky (UK) will embed telehealth stations at community-based senior centers. Individuals who utilize these telehealth stations will be invited to complete a demographic survey prior to their telehealth appointment. Following their appointment, they will be invited to complete a semi-structured interview with the research team. Participants who elect to use telehealth station will be doing so as telehealth visits already scheduled with patients as Standard of Care (SOC). The telehealth station in the senior center will be used to increase ease and access to telehealth should the patient/provider choose to use such an approach (for example, in instances when the patient does not have sufficient technology, internet access, or capability to operate telehealth at home).
45474349|NCT01179581|Drug|placebo|single dose, oral solution or capsule (matching corresponding study medication)
45474350|NCT01179581|Drug|GLPG0634|multiple dose, capsule, 10 days
45474351|NCT01179581|Drug|placebo|multiple dose, capsule, 10 days
45474352|NCT03362008|Drug|Zeropix|administration of Zeropix
45474353|NCT03362008|Drug|Champix®|administration of Champix®
45474354|NCT05556798|Drug|Belantamab Mafodotin|Belantamab mafodotin will be administered via IV infusion in an outpatient setting on Day 1 of Cycles 1-3. Treatment with belantamab mafodotin will be given at an initial dose of 1.0 mg/kg. The study will have a 3+3 dose escalation design for belantamab mafodotin. Belantamab mafodotin dose levels are 1.0 mg/kg, 1.4 mg/kg, and 1.9 mg/kg
45474355|NCT05556798|Drug|Nirogacestat|1:1 randomization between nirogacestat 100mg BID or 100 mg QD during the 4 day run-in period. Treatment with nirogacestat will be 100mg BID continuously during each cycle for all subjects.
45498074|NCT04690413|Device|NOWDx COVID-19 Test|The investigational device is the NOWDx COVID-19 Test.
45694582|NCT01709149|Other|Placebo tablets|Tablets
45694583|NCT01709149|Drug|Riluzole|Tablets
45343646|NCT03945448|Drug|Single dose liposomal Amphotericin and Fluconazole|Intravenous Single dose of 10mg/kg of Ambisome and fluconazole as per WHO guidelines for six months.
45343647|NCT03945448|Drug|Fluconazole|Fluconazole 800mg for 2 weeks,400mg for 8 weeks and 200mg up to six months
45343648|NCT03941873|Drug|Sitravatinib|Study participants will receive sitravatinib capsule once daily
45343649|NCT03941873|Drug|Sitravatinib plus Tislelizumab|Study participants will receive sitravatinib capsule once daily and in combination with tislelizumab IV once every 3 weeks.
45694584|NCT05216926|Other|Timing of preventive action based on prediction model|Timing of preventive action based on prediction model
45694585|NCT05216926|Other|Hypoglycaemia treatment at hypoglycaemia (usual care)|Hypoglycaemia treatment at hypoglycaemia (usual care)
45343650|NCT03941873|Drug|Sitravatinib|Study participants will receive sitravatinib capsule once daily.
45343651|NCT03941873|Drug|Sitravatinib and tislelizumab|Study participants will receive sitravatinib capsule once daily and in combination with tislelizumab IV once every 3 weeks.
45343652|NCT03941873|Drug|Sitravatinib and tislelizumab|Study participants will receive sitravatinib capsule once daily and in combination with tislelizumab IV once every 3 weeks.
45343653|NCT03941873|Drug|Sitravatinib and tislelizumab|Study participants will receive sitravatinib capsule once daily and in combination with tislelizumab IV once every 3 weeks.
45343654|NCT03941587|Drug|Aflibercept + reduced fluence photodynamic therapy (RF-PDT)|Aflibercept dosage of 2mg in 0.05ml along with intravenous infusion of Verteporfin (6mg/m2)followed by laser light at a dosage of 25Joule/cm2
46039824|NCT05569837|Other|Regular meal pattern|6 meals every day
45343655|NCT03941587|Drug|Aflibercept + sham reduced fluence photodynamic therapy (RF-PDT)|Aflibercept dosage of 2mg in 0.05ml along with sham photodynamic therapy
45343656|NCT03941171|Procedure|PAO|PAO will be performed as the trans-sartorial approach or the anterior pelvic approach.
45343657|NCT03941171|Other|Usual care after PAO|Patients commence post-operative rehabilitation as usual and follow the rehabilitation program guided by a physiotherapist specialized in hip problems until 4 months after the operation.
45474356|NCT03858959|Device|topical agent|"HBX protocol consisted in product application into the periodontal pocket (starting from the base) with a delivery syringe, second saline solution irrigation after 60 seconds to flush-out the product and Teflon-curettes debridement to remove the deposits.~CHX protocol consisted in Teflon-curettes debridement to remove the deposits, associated with a first saline solution irrigation, and product application into the periodontal pocket (starting from the base) with a delivery syringe."
46039825|NCT05569837|Other|Irregular meal pattern|It consists of consuming a different number of meals every day (between 3 and 9).
45343658|NCT03941171|Other|PRT|4 months of partly supervised progressive resistance training 2 times per week. After these 4 months (16 weeks), patients receive a free membership to a fitness center near their home address and are encouraged to train on their own 2 times per week until 12 months follow-up with one supervised session per month. The PRT program involves 10-min of warm up followed by 50-min of bilateral resistance exercises including sets of squats, hip extension, hip flexion, and hip abduction.
45343659|NCT03935763|Other|observational disease study|observation of routine clinical practices in mCRC
46039826|NCT01121549|Drug|Aromasin|25 mg daily continuously
45474357|NCT03123406|Drug|Cinacalcet HCl|Administer Cinacalcet HCL to all subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL in real-world period from 33rd to 52nd week.
45343660|NCT03930524|Behavioral|Personalized Normative Feedback (PNF)|Personalized normative feedback is generated by a process in which: (1) baseline surveys gather respondent information; (2) a computer program links the data with algorithms to select feedback messages; (3) a format for feedback presentation is specified; and (4) the program generates output. Norms will focus on prevalence of drinking, consuming 4/5+ drinks, total number of drinks consumed each week, and maximum drinks consumed. Normative information will be from the national Monitoring the Future (MTF) study college student sample and the University of Minnesota Twin Cities campus. Students will be sent a link to a website where they see their own personal responses in the feedback. Feedback will detail quantity and frequency of drinking (a) reported by the participant him/herself, (b) according to the participant's perception of the descriptive norm for drinking quantity and frequency for the reference group, and (c) reflecting the actual descriptive norm for the reference group.
45343661|NCT03930524|Behavioral|Self-Monitoring (SM)|Students will be asked to self-report their alcohol use every 2 weeks in response to two main questions (frequency of 4/5+ drinking in the past 2 weeks, frequency of past 2-week 8/10+ drinking), as well as consequences of their drinking. The therapeutic role of SM is two-fold. First, SM facilitates deliberate attention to and reflection on the person's actions, the conditions under which these actions occur, and their consequences (Bandura, 1998; Kanfer, 1970). Hence, SM of drinking behaviors and consequences has the potential to promote awareness of problematic drinking and need for health services. Second, SM affords the opportunity to obtain ongoing information concerning the target behavior, which can be used to inform timely intervention decisions (Nahum-Shani et al., 2016)
45474358|NCT05554770|Diagnostic Test|Examinations in a TRV chair|Positional tests (Dix-Hallpike and SRT) traditionally used to diagnose BPPV uwith a TRV chair.
45498075|NCT02740335|Drug|Octaplex|OCTAPLEX will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (~3 units/kg/min), up to a maximum rate of 8.4 mL/min (~210 units/min).
46039827|NCT02732002|Procedure|OCBRA ( Objective Criteria Based REhabilitation Algorithm|The patient will complete the initial functional and clinical evaluation in the medical room and laboratory. Afterwards, all the gathered information will be assembled to generate the patient-specific functional and clinical status-based rehabilitation program. This program will be generated in conjunction with the physical therapy staff. For each of the functional or clinical deficits observed during the examination, the physical therapist will identify the precise exercise and goal-based progression from a previously standardized goal-based rehabilitation algorithm adapted from previously published investigations targeting this issue
46039828|NCT00847405|Drug|Sumatriptan Succinate|100 mg Tablets
46039829|NCT00847405|Drug|Imitrex®|100 mg Tablet
45343662|NCT03930524|Behavioral|Web-BASICS|Web-BASICS is delivered online and responds to individual participant input with the same motivational information and feedback as used in the in-person BASICS intervention. In-person BASICS content (Dimeff et. al., 1999) was developed for online use in studies conducted by Drs. Larimer and Lee (e.g., LaBrie et al., 2013; Lee et al., 2014; Neighbors et al., 2012a). Web-BASICS feedback contains text and graphical feedback regarding students' reported drinking quantity, frequency, peak alcohol consumption, and blood alcohol content (BAC), risks for alcohol problems based on participant family history and consumption patterns, protective behaviors the participant already uses and others he/she might consider, and a tips page with a BAC chart, information on reduced-risk drinking, and where to get more information. Participants can print and/or view their individualized content online for up to 3 months.
46039830|NCT04118413|Other|erector spinae plane block|Erector espine plane block will be administrated bilaterally to this group at low thoracic level (Th11).
45343663|NCT03930524|Behavioral|Health Promotion Consultation|A health promotion consultation via a campus clinic is a confidential exploration of student drug and alcohol use. Health Promotion Consultants help students assess how their alcohol and other substance use affects their life and learn how to make healthier decisions.
45343664|NCT03930524|Behavioral|M-Bridge Online Health Coach|A health coach will correspond with students via a secure online chat platform, utilizing motivational interviewing strategies to encourage students to consider their values and goals, the possibility of behavior change, and available services. The goal of the dialogue is to motivate the student to access alcohol use interventions (Web-BASICS or an in-person health promotion consultation).
46039831|NCT05147987|Device|Hands free wearable breast pump|Use of a supplementary breast pump which can be discreetly worn and is hands free
45343665|NCT03923322|Drug|Botanical Tincture|Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. Participants randomized to Botanical Tincture will have a 2-week withdrawal period. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
45343666|NCT03923322|Other|Placebo|Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
45343667|NCT03921528|Biological|SRK-015|SRK-015 is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that binds to human pro/latent myostatin with high affinity. SRK-015 will be administered every 4 weeks by intravenous infusion.
45343668|NCT03917420|Drug|Tenofovir 300Mg Oral Tablet|Once daily dose of the combo tab x 5 days pre-sampling
45343669|NCT03917420|Drug|Emtricitabine 200 MG|Once daily dose of the combo tab x 5 days pre-sampling
45343670|NCT03917147|Procedure|Office Hysteroscopy|Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Histopathological examination was conducted to confirm the diagnosis.
45474359|NCT03361930|Device|Ankle-foot orthosis|"Two custom ankle-foot orthoses for the involved lower leg; cast, rectified and fitted by same certified orthotist to reduce clinician variability.~The cast is rectified according to the specifications of Hylton (1987) to produce tone-reducing features in the foot plate; the tone-reducing ankle-foot orthosis is manufactured on this cast. The orthotist then remodels the cast with a flat foot plate; the plain ankle-foot orthosis is then manufactured."
45474360|NCT01179659|Drug|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
45474361|NCT05547672|Device|UroMems artificial urinary sphincter|Implantation of the device
46039832|NCT03268096|Device|Cerebral MRI and Optical Coherence Tomography|Clinical and paraclinical assessment (cerebral MRI and Optical Coherence Tomography) will be carried out on the same day. Paraclinical evaluation consists in the realization of additional MRI sequences in order to obtain more precise information on brain lesions (unconventional parameters). An optical coherence tomography will also be performed for both eyes to describe the thickness of the different layers of the retina.
46039833|NCT02734654|Procedure|remote ischemic preconditioning (RIPC)|Remote ischemic preconditioning: The limb RIPC was applied after the induction of anaesthesia and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on a thigh and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff on a thigh.
46039834|NCT04115995|Diagnostic Test|Dynamic infrared thermography (DIRT) and indocyanine green fluorescence angiography (ICG-FA)|DIRT and ICG FA are used intraoperatively to evaluate perfusion of the perforators and the anastomosis. Both technique are compared in their ability to visualize perfusion.
46039835|NCT02881931|Behavioral|FuRST 2.0|Cognitive Pre-testing of new Functional Rating Scale
45343671|NCT03913195|Drug|ibalizumab-uiyk|Ibalizumab-uiyk is an IgG4 monoclonal antibody targeting domain 2 of the extracellular portion of the CD4 protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.
45474362|NCT03858725|Drug|D569 Tab.|D569 Tab. 1T single oral administration under fasting condition
45343672|NCT03913104|Drug|Mifepristone|Patients will have MifeprexⓇ (mifepristone) shipped to a preferred address via an online mail order pharmacy rather than standard care at clinic visit.
45474363|NCT03858725|Drug|CKD-374 5mg Tab.|CKD-374(Tofacitinib) 5mg Tab. 1T single oral administration under fasting condition
45474364|NCT04523818|Drug|Capecitabine|Given PO
45474365|NCT04523818|Drug|Fluorouracil|Given IV
45474366|NCT04523818|Radiation|Radiation Therapy|Undergo radiation therapy
45343673|NCT03902067|Biological|UC-MSC|0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5x10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability>80%, and endotoxin<0.1 EU， at the concentration of 2x10(7) cells/ml.
45343674|NCT03902067|Biological|Control Group|Routine treatment without catheter infusion
45343675|NCT03892720|Other|Quality-of-Life Assessment|Ancillary studies
45343676|NCT03892720|Other|Questionnaire Administration|Ancillary studies
45343677|NCT03892720|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45474367|NCT04523818|Procedure|Therapeutic Surgical Procedure|Undergo standard of care surgery
45474368|NCT03361774|Drug|Dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride).|"Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth.~Participants will be permitted to rinse with tap water post-brushing if they wish to."
45474369|NCT03361774|Drug|Dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride).|Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth. Participants will be permitted to rinse with tap water post-brushing if they wish to.
45474370|NCT03746483|Drug|MS1819|MS1819, an oral, non-systemic, that is non-enterically-coated. It is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.
45343678|NCT03891784|Drug|Abemaciclib|Given PO
45343679|NCT03890068|Drug|Anlotinib Hydrochloride|48 subjects with advanced soft tissue sarcoma will receive anlotinib at a dose of 12 mg once daily (day1-14 PO) in 21-day cycles until disease progression (defined by RECIST version 1.1) or unacceptable toxicity.
45343680|NCT03886077|Drug|glecaprevir/pibrentasivir|12 weeks of oral open label glecaprevir/pibrentasivir (Dose 3 tablets daily per package label).
45343681|NCT03884556|Drug|TTX-030|Variable dose and schedule
45474371|NCT03746483|Drug|Porcine PERT|Porcine PERT is being used as a comparator to MS1819 as a second drug/intervention
45474372|NCT04523740|Drug|Placebo|Patients who use regular paracetamol will now receive 6 to 8 tablets of placebo per day for 2 weeks
45474373|NCT04523740|Drug|Paracetamol|Patients who use regular paracetamol will now receive 6 to 8 tablets of 500 mg paracetamol per day for 2 weeks
45474374|NCT03410706|Drug|Rivaroxaban(Xarelto, BAY 59-7939)|The dosage and the anticoagulation duration is decided by investigators. As list in product information, the PE treatment dosage of rivaroxaban is 15mg bid for first 21 days and then 20mg qd. If CrCl is 30-49 ml/min and bleeding risk is over VTE recurrence risk, 20mg qd can be replaced with 15mg qd.
45343682|NCT03884556|Drug|Pembrolizumab|Dose and schedule per standard of care
45343683|NCT03884556|Drug|Gemcitabine|Dose and schedule per standard of care
45343684|NCT03884556|Drug|nab paclitaxel|Dose and schedule per standard of care
45343685|NCT03883165|Other|high-intensity neck strengthening|"All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions.~Participants will perform a standardized set of general resistance exercises targeting the chest, shoulders, back, upper and lower extremities, and core. Additionally, they will also perform a higher number of repetitions of manual resistance neck strengthening exercises in sagittal plane flexion and extension, coronal plane lateral flexion in both directions, and axial plane rotation in both directions,as well as dumbbell shoulder shrugs."
46039836|NCT02731846|Drug|Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler(2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Umeclidinium 62.5 mcg and Vilanterol 25 mcg per blister), administered as one inhalation of FF/UMEC/VI (100/62.5/25 mcg) once-daily in the morning
45343686|NCT03883165|Other|Control group|"All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions.~Participants will perform a standardized set of general resistance exercises targeting only the chest, shoulders, back, upper and lower extremities, and core, without resistance exercises specifically targeting the neck."
45840564|NCT00803400|Drug|Alprazolam + Aerobic exercise|"The patients assigned to exercise have to pass an ergometric test to determine their functional capacity expressed in METs for future exercise indication.~Two weeks after the first interview they have their first baseline psychiatric control and at the same time they are indicated a 4 mg dose of alprazolam, gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.~Then they follow a protocolized aerobic exercise plan for this study during 12 weeks.~The type of selected exercise consists of a rapid walk for 30 minutes divided in stages.~After each stage the patient has to control his own heart frequency that has to be between 50 and 75% of their maximum to assure an aerobic condition (American Cardiological Association)."
45840565|NCT00804648|Drug|Timolol Maleate in Sorbate|0.5%
45343687|NCT03870815|Procedure|CABG|Patients who undergoing CABG
45343688|NCT03870815|Procedure|PCI|Patients who undergoing PCI with DES
45343689|NCT03853473|Procedure|Remote Ischemic Preconditioning|Remote Ischemic Preconditioning (RIPC) occurs when a limb is made transiently ischemic (5 minutes) using a simple blood pressure cuff. We are proposing that study participants in the RIPC group perform the intervention daily at home for at least 14 days prior to scheduled surgery. They will inflate a blood pressure cuff on the upper portion of their nondominant arm, inflate it to 225 mmHg for 5 minutes, release the cuff for 5 minutes, and repeat this 5 times (for a total of 45 minutes). A study coordinator will monitor compliance with phone calls and daily log sheets that must be filled out.
45343690|NCT03845244|Device|Flow reduction first|-10L/min q 1hr
45343691|NCT03845244|Device|FiO2 reduction first|- 0.1 q 1hr
45343692|NCT03845244|Device|Simultaneous (flow and FiO2) reduction|-10L/min and -0.1 q 1hr
45343693|NCT03844568|Device|nocturnal nasal continuous positive airway pressure|applying nasal continuous positive airway pressure at 7.5-10cmH2O for at least 4 hours during nighttime
45343694|NCT03841760|Diagnostic Test|PSMA PET/CT|"For 18F-DCFPyL PET/CT: Approximately 9 mCi (333MBq) of 18F-DCFPyL is injected intravenously. Approximately 60-90 minutes following 18F-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the toes.~For 68Ga-PSMA-11 PET/CT: Approximately 2.5 MBq/kg (0.068 mCi/kg) of 68Ga-PSMA, up to a maximum of 300 MBq (8 mCi), is injected intravenously. Approximately 60 minutes following 68Ga-PSMA injection, CT and PET images are consecutively acquired from the base of the skull to toes."
45343695|NCT03833102|Other|biological analysis|ST types will be determined for all individualized bacterial strains. For all the bacterial strains, RNAs expression will be analyzed at three different growth phases: early exponential phase, mid exponential phase and early stationary phase. Expression of RNAIII and SprD will be evaluated by quantitative polymerase chain reaction.
45343696|NCT03832322|Procedure|Water exchange colonoscopy|During back-to-back colonoscopy, the first examination was completed with water exchange during insertion and CO2 insufflation during withdrawal. The second examination was completed with CO2 insufflation during both the insertion and withdrawal.
46039837|NCT02731846|Drug|Fluticasone furoate 100 mcg + Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler (2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Vilanterol 25 mcg per blister), administered as one inhalation of FF/VI (100/25 mcg) once-daily in the morning
46039838|NCT02731846|Drug|Umeclidinium 62.5 mcg|Dry white powder delivered via ELLIPTA inhaler (1 strip with 30 blisters containing Umeclidinium 62.5 mcg, administered as one inhalation once-daily in the morning
45694586|NCT05214196|Drug|Hypochlorous Acid 0.02% Soln,Top (Crystaline) (HClO)|SARS-CoV-2 sample was obtained from COVID-19 patients by rinsing the mouth and throat with 5 ml of isotonic saline before and 30 minutes after rinsing. In the hypochlorous acid group, 20 ml of HClO was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the povidone-iodine group, 20 ml of PVP-I was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the saline group, 20 ml of saline was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants.
46039839|NCT02731846|Device|Placebo ELLIPTA inhaler|Placebo will be administered via ELLIPTA inhaler. Dry white powder administered as one inhalation each morning (1 strip with 30 blisters containing placebo)
45343697|NCT03832322|Procedure|CO2 insufflation colonoscopy|During back-to-back colonoscopy, the first examination was completed with CO2 insufflation during both the insertion and withdrawal. The second examination was also completed with CO2 insufflation during both the insertion and withdrawal.
46039840|NCT02731846|Drug|Albuterol/Salbutamol|Albuterol/salbutamol will be administered via metered-dose inhaler (MDI) with a spacer as needed throughout the study as a rescue medication
45343698|NCT03828968|Diagnostic Test|bladder scan|Measurement of vesical volume by bladder scan
45343699|NCT03825822|Behavioral|ImPaC Resource Intervention (INT)|"A Change Team will lead the implementation process of the ImPaC Resource using the steps:~Step 1: Complete a checklist to ensure its members can commit to responsibilities.~Step 2: Reflect on the unit's readiness for change.~Step 3: Perform an audit on 10 to 15 medical charts.~Step 4: Identify a practice change based on audit results (pain assessment or pain treatment). Develop an aim statement for the practice change.~Step 5: Select the KT strategies and plan the implementation.~Step 6: Perform an audit on 10 to 15 medical charts.~Step 7: Examine the effectiveness of the implementation and decide on the aim and KT strategies for the next cycle of change."
45343700|NCT03825822|Other|Standard Practice (SP)|The SP arm will continue as usual with their standard pain practices and will be offered the intervention 6 months after randomization and completion of data collection.
45474375|NCT04523662|Drug|Camrelizumab Apatinib Mesylas|This study intends to use the PD-1 antibody carrelizumab combined with apatinib and radiotherapy to treat patients with advanced liver cancer with extrahepatic metastasis
45474376|NCT04266522|Other|Informational Intervention|Receive printed materials
45474377|NCT04266522|Other|Counseling|Receive direct physicist interactions to describe the technical aspects of the treatment
45840566|NCT00804648|Drug|Timolol hemihydrate|0.5%
45840567|NCT00804648|Drug|Timolol maleate gel forming solution|0.5%
46039841|NCT00836095|Device|Supreme Laryngeal mask airway|Supreme Laryngeal mask airway is a new, single use laryngeal mask airway variant
45343701|NCT03802656|Device|Anterior Vertebral Body Tethering|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
45694587|NCT05213026|Procedure|Regenerative endodontics|Regenerative endodontic procedure with 3 Mix-MP
45694588|NCT01568593|Device|T2750|1 drop in each eye 3 to 6 times daily during 84 days
46039842|NCT00836095|Device|Proseal laryngeal mask airway|Proseal is a multiple use, variant of the laryngeal mask airway
46039843|NCT05564455|Other|Biometry with Kane formula|Kane formulae for intraocular lens (IOL) power calculation in cataract patients
45474378|NCT04266522|Other|Questionnaire Administration|Ancillary studies
45474379|NCT03746405|Device|repetitive transcranial magnetic stimulation|excitatory 5Hz rTMS will be used
45684202|NCT04275466|Procedure|necrotic cavity lavage|"At least two 30- to 36-Fr drainage tubes will be placed into each necrotic cavity. One of these drainage tubes will be used as the lavage tube; the other tube is designed for drainage.~Lavage will begin on the first day after debridement, and the relevant indices will be evaluated every 7 days to decide whether to continue the lavage.~1200 mL of normal saline will be lavaged into each necrotic cavity every day at a speed of 200 mL/h for 3 hours each time and for a total of two times. The start times of lavage will be 08:00 and 20:00.~The lavage and drainage volumes of the first hour and second hour of each lavage session will be calculated. The lavage of the next hour will be stopped if the lavage volume minus the drainage volume is >100 mL.~Lavage will be suspended if abdominal pain and distention occur, the maximum body temperature is >38.5ºC, or the abdominal pressure is ≥15 mmHg during the lavage procedure."
45343702|NCT03797482|Procedure|Intra-operative Tumor Tissue Biopsy|The changing pattern of gene expression during surgery has never been studied. This could be an effect of acute hypoxia that sets in the tumour during surgery or could be a surgical response. To study these changes happening in the tumour during surgery, we are taking serial biopsies during surgery, one at the beginning, one midway during surgery and one at the end of surgery. These samples will be snap frozen and stored at -80 deg celsius in biorepository for future analysis.
45343703|NCT03781973|Behavioral|Data platform +Quality Performance feedback reports|Teams from each of the participating sites will attend the webinars. Each site will share an example of a QI initiative that they are executing and describe the success and challenges.
45343704|NCT03773003|Dietary Supplement|Probiotics|"The administered probiotics are readily available on the market and contain~Bifidobacterium breve, B. infantis, B. lactis, B. longum~Lactobacillus acidophilus, L. bulgaricus, L. casei, L. crispatus, L. fermentum, L. paracasei, L. plantarum, L. reuteri, L. rhamnosus, L. salivarius~Streptococcus thermophilus"
45343705|NCT03773003|Dietary Supplement|Placebo|Identically looking to verum, containing corn starch.
45343706|NCT03766438|Behavioral|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
45343707|NCT03765307|Device|SyMap Bronchial Ablation System|The Bronchial Ablation is performed using SyMap Bronchial Ablation System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
45343708|NCT03765307|Device|Boston Scientific Alair System|The Bronchial Thermoplasty is performed using Boston Scientific Alair System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
45343709|NCT03755154|Drug|S65487- initial scheme|S65487 is administered as single agent via i.v. infusion once a week on a 3-week cycle.
45840568|NCT00805038|Behavioral|Transplant navigator|Navigator will provide help to patients in completing specific steps in transplant process.
46039844|NCT05564455|Other|Biometry with SRK-T formula|Sanders Retzlaff Kraff theoretical (SRK T) formulae for intraocular lens (IOL) power calculation in cataract patients
46039845|NCT02731924|Procedure|Ultrasound for Appendicitis|Point-of-care ultrasound to evaluate emergency department patients for suspected appendicitis
46039846|NCT02731768|Behavioral|Standard|Participants will receive an evidence-based behavioral weight control program focused on physical activity and reducing caloric intake. They will be provided with a Fitbit Zip and digital body weight scale for self-monitoring of physical activity and body weight, respectively.They will track caloric intake via the MyFitnessPal smartphone application. They will have access to a study website and attend weekly, in-person group counseling sessions.
46039847|NCT02731768|Behavioral|Social support-enhanced|Participants will receive the same intervention components as the Standard group.Participants will also be provided with two extra Fitbit Zips and digital body weight scales to share with up to two persons in their social circle who will be invited to serve as their support partners.
45343710|NCT03755154|Drug|S65487 - alternative scheme|S65487 is administered in 3 to 5 i.v. infusions the first week of each cycle then once a week on the rest of the 3-week cycle.
46039848|NCT02731768|Device|Fitbit Zip|
45684203|NCT01904773|Drug|AZD5213 and placebo|low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules
45684204|NCT01928719|Drug|Reduced Nicotine Content Cigarettes|Cigarettes contain 11.6, 7.4, 3.3, 1.4, 0.7, and 0.2 mg nicotine per cigarette
45684205|NCT01928719|Drug|Same Nicotine Content Cigarettes|about 11.6 mg nicotine per cigarette
45684206|NCT00986674|Biological|cixutumumab|Given IV
45684207|NCT00986674|Drug|carboplatin|Given IV
45684208|NCT00986674|Drug|paclitaxel|Given IV
45684209|NCT00986674|Biological|cetuximab|Given IV
45684210|NCT00986440|Drug|CS-7017|CS-7017
45684211|NCT00986440|Drug|Placebo|Placebo
45684212|NCT01904383|Drug|Trazenta|1 tablet of 5 mg Trazenta tablets once daily
45684213|NCT01920880|Other|Quantitative Sensory Testing analysis|
46039849|NCT02731768|Device|Digital body weight scale|
46039850|NCT02694484|Other|Blood and stool samples|Blood sample at Day 1 and blood and stool sample at the next visit
46039851|NCT04248712|Drug|Famotidine|40 mg tab twice daily by mouth for 12 week duration
45684214|NCT03118492|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
45343711|NCT03734705|Behavioral|Imaginal Exposure Writing|Imaginal exposure is a psychotherapy strategy that has been studied and shown to be helpful in the improvement of symptoms (e.g., anxiety, worry) for other psychiatric conditions, including excessive worry and obsessive-compulsive disorder symptoms.
46039852|NCT04248712|Drug|Loratadine|10 mg tab once daily by mouth for 12 week duration
45343712|NCT03734705|Other|Neutral Writing|Used in prior research as a control condition for imaginal exposure. Neutral writing will involve writing about what one would do on a day off work or school.
45343713|NCT03720119|Drug|Lidocaine Hydrochloride|As per clinical practice, a local treatment with ORTODERMINA® over a 14-day period (once a day) was prescribed. ORTODERMINA® contains 5% of lidocaine hydrochloride.
45343714|NCT03715712|Other|standardized blood pressure management|Standardized blood pressure management of a mean blood pressure > 65mmHg and a systolic blood pressure of < 160mmHg using norepinephrine continuous infusion
45343715|NCT03715712|Other|Individualized blood pressure management|Individualized blood pressure management of 20% within the preoperative ward blood pressure using norepinephrine continuous infusion
45343716|NCT03713528|Drug|Intraoperative Intraosseous Vancomycin|After debridement and irrigation the interventional group will receive intraosseous vancomycin 500mg in 150ml of normal saline. This solution will be prepared by the hospital pharmacy and administered via an EZ-IO intraosseous cannula. 75ccs of the vancomycin solution will be injected as a bolus. Subsequent to this the remaining 75ccs will be placed in the distal femur just proximal to the femoral component evenly split between the medial and lateral femoral condyles in knees.
45343717|NCT03709511|Other|Cardiac rehabilitation|perioperative rehabilitation consists of education, inspiratory muscle training, active cycle of breathing techniques, and early mobilization.
45474380|NCT03746405|Device|Sham repetitive transcranial magnetic stimulation|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
45684215|NCT03118492|Drug|Cyclophosphamide|Given IV
45684216|NCT03118492|Drug|Fludarabine|Given IV
45684217|NCT03118492|Biological|Glycosylated Recombinant Human G-CSF AVI-014|Given IV
45684218|NCT03118492|Other|Laboratory Biomarker Analysis|Correlative studies
45684219|NCT03118492|Drug|Melphalan|Given IV
45684220|NCT03118492|Drug|Mycophenolate Mofetil|Given PO
45684221|NCT03118492|Drug|Tacrolimus|Given IV or PO
45684222|NCT03118492|Radiation|Total-Body Irradiation|Undergo TBI
45684223|NCT01904149|Drug|Placebo|Placebo single oral dose (first 8 hours)
45684224|NCT01904149|Drug|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
45684225|NCT01904149|Drug|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
45684226|NCT01904149|Drug|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol single oral dose (first 8 hours)
45684227|NCT01904149|Drug|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)
45684228|NCT01904149|Drug|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
46039853|NCT04248712|Drug|Placebo|Contains no active ingredient
46039854|NCT02734732|Drug|Trimethoprim/Sulfamethoxazole|
46039855|NCT02734732|Drug|Ciprofloxacin|
46039856|NCT00835237|Biological|Boostrix®|Intramuscular, single dose.
46039857|NCT00835237|Biological|Decavac™|Intramuscular, single dose.
45474381|NCT02518672|Dietary Supplement|MAG-DHA|MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
45343718|NCT03708562|Device|everlinQ endoAVF System|The everlinQ device is a single-use disposable device. The everlinQ catheter system consists of two flexible, magnetic catheters. Once the catheters are properly inserted and aligned, the magnets contained in each catheter attract to one another, approximating the vessels while simultaneously aligning the electrode with the backstop. Radiofrequency (RF) energy is delivered to the electrode whereby the arterio-venous fistula (AVF) is created.
45343719|NCT03705845|Drug|placebo softgel|Each placebo softgel of 430 mg olive oil will contain no TT or tocopherols at detectable levels.
45343720|NCT03705845|Drug|DeltaGold® Tocotrienol 70%|DeltaGold® Tocotrienol 70% contains 430 mg tocotrienol (90% δ-tocotrienol + 10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
45343721|NCT03673176|Radiation|Stereotactic Ablative Radiotherapy (SABR)|The prescribed dose will be 45 Gy in three fractions of 15 Gy, on each side that is treated.
46039858|NCT02731378|Drug|Erythropoietins (EPO)|A routine dose 10,000 IU of EPO, three times weekly by subcutaneous injections.
45343722|NCT03669718|Biological|ISA101b|Every 3 weeks for a total of 3 times
45343723|NCT03669718|Drug|Cemiplimab|Every 3 weeks for up to 24 months
45343724|NCT03669718|Other|Placebo|Every 3 weeks for a total of 3 times
45343725|NCT03668457|Behavioral|Intervention to Patients|"Multifaceted intervention consisting of:~A collaborative care management intervention, including depression education, medication management and behavioral activation.~Use of a medication reminder mobile app."
45343726|NCT03668457|Behavioral|Intervention to Psychiatrists|Educational intervention consisting of theoretical and practical sessions to to improve communication and negotiation abilities, and to develop skills to promote patient-centered care and shared decision-making.
45343727|NCT03668457|Other|Control|Other: Usual care Usual care for depressive disorder received in mental health units
45343728|NCT03668197|Biological|microbiological analysis|microbiological analysis of the peritoneal fluid
45343729|NCT03668184|Other|preeclampsia|occurrence of pre-eclampsia
45474382|NCT02518672|Dietary Supplement|Placebo|Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
45474383|NCT03372226|Behavioral|Online self-help program|The program consists of 10 modules with many interactional exercises and homework-sheets. Themes that are addressed in the online-program are for example self-esteem, sleep hygiene, problem solving strategies, mindfulness-based relaxation and attention exercises as well as gambling-specific topics such as money/debt management and impulse control. In addition, the user learns to modify negative and gambling-specific thought distortions, to integrate positive activities into his/her daily routine, strategies to deal with the urge to play as well as ways to regulate debts and to prevent relapse.
45474384|NCT03226392|Drug|QAW039|QAW039 once daily
45474385|NCT03226392|Drug|Placebo|Placebo once daily
45474386|NCT03372070|Device|cNEP|soft silicon collar applied to anterior neck with negative pressure
46039859|NCT02731378|Drug|Aggressive iron dextran supplementation|Iron dextran 100 mg, BIW, through 90 minutes of IV infusion, for the first consecutive 5 weeks
46039860|NCT02731378|Drug|Erythropoietins (EPO)|Doubling EPO dosage to 20,000 IU, three times weekly by subcutaneous injections with a maximum of 5 doses
46039861|NCT02731378|Drug|Sustained iron dextran supplementation|Iron dextran 200 mg, Q3W, through 90 minutes of IV infusion and a maximum of 5 doses
45474387|NCT03371992|Drug|Nivolumab|Nivolumab, pembrolizumab or atezolizumab will be administered as per the established standard of care for the eligible population.
45684229|NCT01904149|Drug|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
45343730|NCT03649555|Drug|[18F]-FTC-146|Two 5 mCi [18F]-FTC-146 doses will be administered intravenously on two separate scan days at least one week apart (total per study = 10 mCi) Participants who complete both test days will receive 10 mCi total dose; however, if a participant is unable to return for a second test day due to unforeseen circumstances, they will receive 5 mCi total dose.
45343731|NCT03644966|Dietary Supplement|Bifidobacterium infantis|Probiotics
45840569|NCT00805038|Behavioral|Usual care|Nephrologists and dialysis facilities will provide usual care regarding access to transplantation.
46039862|NCT00704119|Drug|RhuDex®|"Treatment A.1: 31.65 mg RhuDex® once N=12~Treatment A.2: 63.33 mg RhuDex® once N=12~Treatment A.3: 126.63 mg RhuDex® once N=12~Treatment A.4: 253.26 mg RhuDex® once N=12~Treatment B.1: 31.65 mg RhuDex® once N=12~Treatment B.2: selected dose of RhuDex® once N=12~Treatment C: selected dose of RhuDex® once N=12~Treatment D: selected dose of RhuDex® twice daily for 6 days N=12"
45343732|NCT03644966|Other|Placebo|Sugar pill manufactured to mimic probiotic tablet
45343733|NCT03644966|Drug|Antibiotics|Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women
46039863|NCT02731456|Other|altitude exposure|altitude exposure
46039864|NCT04118335|Other|Black Mulberry Syrup|The individuals in the intervention group gargled with 5 ml black mulberry syrup and waited average one minute and then swallow it.
45684232|NCT00986362|Drug|Ocriplasmin|175µg ocriplasmin intravitreal injection
45684233|NCT00986362|Drug|Placebo|Placebo intravitreal injection
45684234|NCT01925560|Other|Agave Inulin|3x3 Latin square with 3 periods
45684235|NCT01925560|Other|Placebo|control- 0 (zero) grams/day inulin
45840570|NCT00806598|Drug|Thymoglobulin|"3.5 or 2.5 mg/kg/day IV for 5 days~Aplastic anemia patients receive 3.5 mg/kg/day for 5 days~MDS patients <55 years receive 3.5 mg/kg/day for 5 days~MDS patients >55 years receive 2.5 mg/kg/day for 5 days"
46039865|NCT02731534|Drug|Z-213|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
45343734|NCT03642990|Drug|Nicotinamide Riboside|Capsule
45343735|NCT03639311|Drug|CAB LA|Administered CAB LA (600 mg) Q2M, as intramuscular injection.
45343736|NCT03639311|Drug|RPV LA|Administered RPV LA (900 mg), Q2M, as intramuscular injection.
45343737|NCT03639311|Drug|RPV|Oral dose of RPV 25 mg, administered once daily from Day 1 up to Month 12
45343738|NCT03639311|Drug|DTG|Oral dose of DTG 50 mg administered once daily from Day 1 up to Month 12.
45474388|NCT03371992|Diagnostic Test|3D-EX|Analysis of drug-mediated changes in the tumor microenvironment.
45684236|NCT01890421|Drug|Gadobutrol (Gadovist, Gadavist, BAY86-4875)|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
45684237|NCT01925638|Drug|BAY86-9766|
45684238|NCT01925638|Drug|Ketoconazole|
45343739|NCT03636438|Other|No Intervention|No Intervention
45840571|NCT00806598|Drug|Cyclosporine|5 mg/kg orally for 6 months; start after completing thymoglobulin.
45474389|NCT03371992|Other|Evaluation of Response by RECIST|Evaluation of tumor response using the set of published rules to determine if a tumor has responded, is stable or progressed during treatments.
45498076|NCT02740335|Drug|Beriplex P/N (Kcentra)|Beriplex® P/N (Kcentra) will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (~3 units/kg/min), up to a maximum rate of 8.4 mL/min (~210 units/min).
45684239|NCT01925716|Other|Corn oil|corn oil 56 g/day for 21 days
45684240|NCT01925716|Other|Olive oil|olive oil 56 g /day for 21 days
45684241|NCT03092284|Biological|Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)|Direct intramyocardial injection of CSCC_ASC
45684242|NCT03092284|Biological|Placebo|Saline
45684243|NCT00985738|Drug|Dutasteride|Dutasteride will be administered at 0.5 mg dose and it will be given every day (QD), for approximately 3 months, followed by 3D mapping biopsy.
45684244|NCT00985738|Other|Placebo|The placebo group will receive the same standard of care as the intervention group, but instead of receiving the intervention drug, Dutasteride, participants will receive a placebo drug for the same 3 month period.
46039866|NCT02731534|Drug|Saccharated Ferric Oxide|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV two or three times per week
46039867|NCT04115917|Device|Schocket scleral depressor|Scleral Depression on eye with Schocket scleral depressor
46039868|NCT04115917|Device|Cotton tipped applicator|Scleral Depression on eye with cotton tipped applicator
46039869|NCT02734420|Drug|PapacarieMBlue and PDT|Initial periapical and interproximal radiographs Microbiological sample with otoscope curette to standardize volume of carious tissue; Application on PapacarieMBlue (addition of toluidine blue) for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with non-cutting curette; No removal of carious tissue on pulp floor; Irradiation of dental tissue for one minute on a single point; Second microbiological sample of remaining dentin with curette; Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE); Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
45684245|NCT01928485|Other|active surveillance|Undergo active surveillance
46039870|NCT02734420|Drug|Toluidine Blue O and PDT|Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette;Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
45684246|NCT01928485|Drug|Sunphenon|Given PO
45684247|NCT01928485|Other|laboratory biomarker analysis|Correlative studies
45684248|NCT01928485|Other|Questionnaire Administration|Ancillary studies
46039871|NCT02734420|Device|Laser|
45684249|NCT00985504|Drug|Duloxetine|60-120 milligrams (mg) taken once daily (QD) by mouth (po) for 8 weeks; with option for additional 2 weeks.
45684250|NCT00985504|Drug|Escitalopram|10-20 mg taken QD po for 8 weeks; with option for additional 2 weeks.
45684251|NCT01921036|Procedure|traditional cardiac rehabilitation|mutifactoral cardiac rehabilitation
45684252|NCT01921036|Procedure|combined exercise|Moderate endurance and resistance exercise once a week over six months
45684253|NCT01921192|Drug|Folic Acid, vit B6 and B12|
45684254|NCT01921192|Drug|Placebo|
45694589|NCT01568593|Device|Vismed|1 drop in each eye 3 to 6 times daily during 84 days
46039872|NCT04117867|Behavioral|Patiens with intraoperative hypotension|In this study, we will use four previously defined thresholds for intraoperative hypotension: two absolute thresholds (MAP less than 50 mmHg and MAP less than 60 mmHg) and two relative thresholds to the baseline MAP (a decrease of 30% or more and a decrease of 40% or more). A definition of baseline value most frequently reported was the arterial blood pressure before the induction of anesthesia. Therefore, the baseline MAP used in calculating the relative thresholds is defined as the mean MAP of all available blood pressure measurements before induction of anesthesia in the operating room.
46039873|NCT02731066|Other|Standard pro|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d.
46039874|NCT02731066|Other|High pro|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d.
46039875|NCT02731066|Other|carbo bev|During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing ~1.8 g carbohydrate/min.
45684255|NCT04275388|Drug|Xiyanping injection|Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet /Ritonavir tablet or Alpha-interferon nebulization or Abidor Hydrochloride,
45684256|NCT04275388|Drug|Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization;Abidor Hydrochloride
45684257|NCT03467698|Device|Active tDCS|Real stimulation
45684258|NCT03467698|Device|Sham tDCS|Sham stimulation
45684259|NCT01921426|Drug|GC4419|GC4419 is a novel, highly stable manganese-containing macrocyclic ligand complex with a molecular weight of 483, whose activity mimics that of naturally occurring superoxide dismutase (SOD) enzymes. It is therefore a prototype of a new class of drugs termed selective SOD mimetics. GC4419 selectively removes superoxide anions without reacting with other reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite.
45684260|NCT03458962|Genetic|Genetic Enrollees|Identification of new genetic diagnoses in children with multiple congenital anomalies, developmental delay, autism, seizures, intellectual disabilities, neurodegenerative disorders and metabolic illness. Samples and data will be stored in a pediatric biorepository. A subset of samples will undergo genetic/genomic analysis.
45684261|NCT01926106|Device|nIPPV|one of the twins was randomly allocated to nIPPV
46039876|NCT02731066|Other|placebo bev|During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
46039877|NCT04118257|Dietary Supplement|Sugary beverage: Fruit juice|Participants consumed 100% fruit juice (~710mL) daily for three weeks, along with their habitual diets.
45498077|NCT03690102|Other|T-CPR|Participants receive telephone instructions in cardiopulmonary resuscitation (T-CPR) from the Emergency Medical Services in Copenhagen during the cardiac arrest scenario test.
45684262|NCT01926106|Device|nCPAP|another of the twins was allocated to nCPAP
45694590|NCT05311228|Drug|Azithromycin Powder|Azithromicyn intravena for 14 days
45840572|NCT00806598|Drug|Methylprednisolone|1 mg/kg/day IV for 5 days, given before each dose of thymoglobulin.
46039878|NCT04118257|Dietary Supplement|Sugary beverage: Soda|Participants consumed soda (~710mL) daily for three weeks, along with their habitual diets.
46039879|NCT04118257|Dietary Supplement|Control: Water|Participants consumed water (~710mL) daily for three weeks, along with their habitual diets.
45343740|NCT03633825|Behavioral|Brief help-seeking barrier reduction intervention|The BRI was designed to overcome common concerns and misconceptions (i.e., barriers) related to using crisis services. It works by first asking the user about what potential barriers may keep them from using the crisis service referrals, and then, based on the user's response, by providing information intended to help the user overcome the potential barrier(s) they selected. By exploring the menu of barriers, users could read brief messages designed to dispel common misconceptions or concerns related to each barrier. For example, a common concern among Koko users was that calls to lifelines invariably result in visits by the police or other emergency services. Users who feared this possibility could tap on the associated button and learn that active rescues such as these are extremely rare, and occur in less than one percent of all cases. Whenever possible, we used language throughout the intervention to help validate the experiences of the users.
46039880|NCT01072500|Behavioral|Physical Activity|The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.
45343741|NCT03630146|Behavioral|iPeer2Peer program|In addition to standard care, youth in the experimental group will receive the iPeer2Peer Program. The iPeer2Peer program is a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with IBD aged 18-25 years) who have learned to function successfully with their disease. Mentors will encourage youth to develop and engage in disease self-management skills and provide social support.
45343742|NCT03630146|Other|Waitlist control|The control group will receive standard care but without the iPeer2Peer Program.
45343743|NCT03609853|Drug|Placebo|Placebo vapor (distilled water)
46039881|NCT01072500|Behavioral|Successful Aging|The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
45840573|NCT00806598|Drug|G-CSF|5 microgram/kg subcutaneously daily up to 3 months, start after thymoglobulin.
46039882|NCT02731222|Other|observational cross-sect. analytical inferential unicentric|collecting data from patients of the Service of Angiology and Vascular Surgery of the Hospital de Sant Pau
46039883|NCT00704275|Drug|0.05% cyclosporin eye drop|bid dosage for 4 months
45840574|NCT00806676|Drug|Gardasil® Vaccine (FDA-approved vaccination regimen)|Standard Gardasil® 3-dose regimen (0.5 mL/dose; doses at 0, 2 and 6 months) delivered to females with chronic kidney disease 9-21 years of age.
45343744|NCT03609853|Drug|Vaporized THC, limonene, or THC and limonene|Acute drug exposure
45343745|NCT03608410|Other|Weekly Internet based PRO questionnaires|If core symptoms worsen and exceeds a predefined threshold, a PRO-notification is sent to the hospital.
45343746|NCT03582475|Drug|Carboplatin|Given IV
45343747|NCT03582475|Drug|Cisplatin|Given IV
45343748|NCT03582475|Drug|Docetaxel|Given IV
45343749|NCT03582475|Drug|Etoposide|Given IV
45343750|NCT03582475|Biological|Pembrolizumab|Given IV
45343751|NCT03579784|Drug|Paclitaxel|Paclitaxel 80 mg/m2 mg iv on D1, D8, D15 Every 4 weeks
45840575|NCT00807768|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo pelvic radiation therapy
45840576|NCT00807768|Drug|Carboplatin|Given IV
45840577|NCT00807768|Radiation|Intensity-Modulated Radiation Therapy|Undergo pelvic radiation therapy
45840578|NCT00807768|Radiation|Internal Radiation Therapy|Undergo vaginal cuff brachytherapy
45840579|NCT00807768|Other|Laboratory Biomarker Analysis|Correlative studies
45840580|NCT00807768|Drug|Paclitaxel|Given IV
45840581|NCT00807768|Other|Quality-of-Life Assessment|Ancillary studies
45343752|NCT03579784|Drug|Olaparib|Olaparib 150mg bid on D1-28 Every 4 weeks
45343753|NCT03579784|Drug|Durvalumab|Durvalumab 1.5 g iv on D1 Every 4 weeks
46039884|NCT02734342|Other|exercise|Participants will be asked to attend eight exercise sessions within a group class environment that will last for 1 hour. The exercise programme has been developed through clinical and research evidence. During the hour, a 5 minute warm up followed by 14 exercises specific to strengthening the lower limb and improving aerobic capacity. Each exercise will be timed for two minutes with the participant reporting number of repetitions counted. A cool down will be completed at the end of the class. After each exercise class, the participant will be advised to have a recovery day to prevent overloading (De Carlo & Armstrong, 2010). Progression of exercises will be patient led. Participants will attend twice per week for four weeks.
46039885|NCT00847015|Drug|Sunitinib|Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period.
46039886|NCT00847015|Drug|Gemcitabine|Gemcitabine 1,000 mg/m^2
45498078|NCT03690102|Other|ERC standardized BLS course|Participants will receive and complete the standardized course in basic life support (BLS) from European Resuscitation Council (ERC).
45840582|NCT00807768|Other|Questionnaire Administration|Ancillary studies
46039887|NCT00847015|Drug|cisplatin|cisplatin 35 mg/m^2 will be administered intravenously on days 1 and 8.
45343754|NCT03571984|Behavioral|Moving on ABC Plus|The intervention has two components. CBT Moving on After Breast Cancer
45343755|NCT03564678|Dietary Supplement|Levocarnitine|Given IV
45343756|NCT03564678|Drug|Vitamin B Complex|Given PO
45343757|NCT03564171|Combination Product|Prehabilitation|stress counseling, exercise, nutritional counseling, smoking cessation counseling
45343758|NCT03560037|Device|Endocuff Vision Assisted Colonoscopy|Detachable device that is fixed to the end of colonoscope. The device has single-row of soft, hair-like projections that flatten colonic folds during colonoscope withdrawal which can aid in detection of colon polyps.
45343759|NCT03553563|Drug|D961H capsule 10mg|All Groups can select either capsule or sachet during the study.
45498079|NCT03580369|Biological|Ligelizumab|Liquid in vial
45498080|NCT03580369|Biological|Omalizumab|Lyophilized powder for solution in vial
45498081|NCT03580369|Other|Placebo|Liquid in vial
46039888|NCT04302792|Behavioral|Texture-modified foods for cancer patients (Stage 2)|Participants (cancer patients that require texture-modified foods) will be expected to evaluate a maximum of three meals over a 2-weeks period.
46039889|NCT04302792|Behavioral|Taste-optimised foods for cancer patients (Stage 3)|Participants (cancer patients with taste & smell alterations) will be expected to evaluate three foods at home over a period of one month.
46039890|NCT05438680|Dietary Supplement|The bovine colostrum ( trade name : baby steps sachets, 300mg )|"The bovine colostrum sachets will be used in a dose of 3.5ml/kg/ day , starting from the first 3 days after birth, for 14 days.~Enteral route, either through nasogastric tube or orally."
46039891|NCT05438680|Dietary Supplement|Placebo|distilled water with no bovine colostrum
46039892|NCT00627354|Drug|etoposide|
45840583|NCT00808470|Drug|beta-carotene, vitamins C and E, magnesium|"6 mint-flavored tablets per day, taken once daily~total daily dose label claim: micronutrient combination of 500 mg vitamin C (magnesium ascorbate), 315 mg magnesium (magnesium citrate, magnesium ascorbate, magnesium stearate), 267 mg vitamin E (d-α-tocopherol acetate), and 18 mg beta carotene."
46039893|NCT00627354|Drug|mitoxantrone hydrochloride|
46039894|NCT00627354|Drug|prednisone|
46039895|NCT00627354|Drug|vinorelbine tartrate|
45343760|NCT03553563|Drug|D961H sachet 10mg|All Groups can select either capsule or sachet during the study.
45343761|NCT03548103|Dietary Supplement|Green tea extract|Green tea extract 500 mg tid for 16 weeks
45343762|NCT03548103|Dietary Supplement|Placebo|Placebo tid for 16 weeks
45343763|NCT03542760|Drug|Methylene Blue|Administration of methylene blue as per the treating physician's diagnosis and the acute care facility's standard of care
45343764|NCT03530397|Biological|MEDI5752|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.
45343765|NCT03530397|Drug|Pemetrexed|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
46039896|NCT02612935|Device|Lumosity|Lumosity offers a suite of online games focused on stimulating cognitive domains of attention, memory, cognitive flexibility, problem solving, and speed of processing. The Lumosity program may be well suited for cognitive remediation in individuals with MS.
46039897|NCT00704431|Drug|SB-480848 (darapladib)|160 mg darapladib
46039898|NCT02734186|Drug|Praziquantel|Anthelminthic
45343766|NCT03530397|Drug|Carboplatin|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
46039899|NCT00704509|Drug|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
45343767|NCT03530397|Biological|Pembrolizumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
45343768|NCT03530397|Drug|Paclitaxel or Nab-Paclitaxel|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
45840584|NCT00808470|Other|Placebo|6 mint-flavored tablets per day, containing inactive substances including mannitol, peppermint flavor, sucralose, color prep, iron oxide yellow synthetic, stearic acid (vegetable grade), and silicon dioxide colloidal.
45840585|NCT00810498|Device|Trilogy|Exposure for one hour on the Trilogy ventilator
46039900|NCT00704509|Drug|Placebo|Encapsulated tablets, orally, 12 weeks
45343769|NCT03515304|Drug|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
45840586|NCT00810498|Device|Standard of Care|Exposure to participants current ventilator
45343770|NCT03515304|Drug|Placebo|Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
45343771|NCT03513653|Diagnostic Test|Echocardiography with speckle-tracking imaging|"Measurement of left ventricular ejection fraction and global longitudinal strain~Measurement of left atrial reservoir strain (peak atrial longitudinal strain)~Measurement of right ventricular global longitudinal strain"
45343772|NCT03503643|Device|Hemigland Cryoablation|Hemigland cryoablation for the treatment of prostate cancer
45840587|NCT00810576|Drug|Vorinostat|Dose of 200 mg by mouth twice daily on days 1-14 of each 21-day study.
45840588|NCT00810576|Drug|Bortezomib|Dose of 1.3 mg/m^2 by vein on days 1, 4, 8, and 11 of a 21 day cycle.
45840589|NCT00810888|Drug|recombinant activated factor VII|Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
45840590|NCT00810888|Drug|placebo|An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)
45840591|NCT00811434|Drug|Lactulose|1.5cc/kg/day po for three months
45840592|NCT00811434|Drug|placebo|1.5 ml sugar water/kg day for three months
45840593|NCT00812604|Drug|Ping On Ointment|Ping On Ointment
45840594|NCT00812604|Drug|Vaseline|Placebo
46039901|NCT00704509|Drug|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
46039902|NCT02730910|Other|Purple Wheat Crackers|Whole grain crackers manufactured with purple wheat
46039903|NCT02730910|Other|Purple Wheat Granola Bars|Whole grain granola bars manufactured with purple wheat
46039904|NCT02730832|Other|Questionnaires completed at D0|
46039905|NCT02730832|Other|Questionnaires completed at D15 (test-retest for 30 patients)|
46039906|NCT02733952|Drug|Tranexamic Acid|
45343773|NCT03496792|Other|Tilt + external pressure|In Visit 1, the anti-shock trousers will be inflated to 20, 40, or 60 mmHg. BP will be measured 3 times from the brachial artery. Then the table will be tilted head up to a maximum of 70o for up to 10 min, while BP will be measured from the brachial artery at 1 min intervals. The tilt table is returned to 0o and the resting supine baseline BP will be collected. Then, the anti-shock trousers will be inflated to a different pressure (20, 40, or 60 mmHg) and the head up tilt will be repeated. Repetitions at the various pressures will be performed in a random order with suitable resting intervals in between the tilting bouts.
45343774|NCT03496792|Other|Tilt + no external pressure.|In Visit 1, the anti-shock trousers will NOT be inflated. Auscultatory BP will be measured 3 times from the brachial artery. Thereafter, the table will be tilted head up to a maximum of 70o for up to 10 min, while BP will be measured from the brachial artery at 1 min intervals.
45343775|NCT03496792|Other|Limb occlusion + negative pressure|In Visit 2, a cuff will be placed on the thigh of a leg that is sealed in an airtight pressure tank. After the cuff is inflated to 250 mmHg, the pressure in the tank will be reduced to -100mmHg for 2 minutes. The application of negative pressure creates a suction effect on the leg, and leads to an overall increase in pressure gradient across the blood vessel wall and induces vascular distension.
45474390|NCT03371914|Behavioral|Management training and data feedback|The management training will consist of a variety of management topics, such as financial, workplace and staff management. The training will include a number of tools that the managers will be expected to bring back with them and use regularly at their site. There will be monthly refresher trainings for the managers via an online platform, where participants will interact about the topics covered in the training and others relevant to their work as managers. Participants will also receive monthly visualizations that compare the data that they enter via tablet monthly to both (1) their baseline data, and (2) to other sites' data. Outcomes that will be measured and reported back to sites include cost per client tested, number of condoms distributed, and number of FSW reached by educational interventions.
45343776|NCT03496792|Other|Limb occlusion + no negative pressure|In Visit 2, a cuff will be placed on the thigh of a leg that is sealed in an airtight pressure tank. The cuff is inflated to 250 mmHg for 2 minutes, but the pressure in the tank is not changed.
45474391|NCT03371758|Other|skin biopsy|Punch skin biopsy will be taken from the lesional and non-lesional skin of vitiligo patients as well as healthy skin of controls.
46039907|NCT02733952|Procedure|Pericervical Tourniquet|
45343777|NCT03487224|Device|MRI with fMRI frequency|Functional magnetic resonance imaging or fMRI measures brain activity by detecting changes in blood flow. Participants will do cognitive tasks during fMRI.
45474392|NCT03205371|Biological|MenACYW conjugate vaccine|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; 0.5 milliliter (mL), Intramuscular
45474393|NCT03205371|Biological|MMR|Measles, Mumps, and Rubella Virus Vaccine Live; 0.5 mL, Subcutaneous
45474394|NCT03205371|Biological|Varicella|Varicella Virus Vaccine Live; 0.5 mL, Subcutaneous
45474395|NCT03205371|Biological|DTaP-IPV-HB-Hib|Diphtheria, Tetanus, Pertussis (acellular component), Hepatitis B, Poliomyelitis (inactivated), and Haemophilus influenzae type-b conjugate vaccine (adsorbed); 0.5 mL, Intramuscular
45474396|NCT03205371|Biological|PCV13|Pneumococcal 13-valent Conjugate Vaccine; 0.5 mL, Intramuscular
45474397|NCT03371680|Drug|Injection of 1-13 Carbon Leucine and deuterated water|All patients received a constant intravenous infusion of 1 g 1-13 Carbon Leucine (Cambridge Isotope Laboratories, Andover, MA) dissolved in saline for 24 h. Deuterated water (Cambridge Isotope Laboratories, Andover, MA) was administered as a 25 ml bolus at the study start and then, every 12 hours over the next 36 hours, as intermittent boluses corresponding to 0.0625% of fluid intake, to maintain steady state of deuterium enrichment in body water
45474398|NCT03371524|Other|Cardiac Echography|While routine cardiac echography is performed on patients with calcified aortic valve, a 30 second loop is recorded.
45474399|NCT03371446|Genetic|oral epithelial cells obtained by rinsing with 3% sucrose|rinsing with 3% sucrose, for a single time of collection, patients received periodontal treatment after collection and data analysis.
46039908|NCT02694796|Behavioral|Physical activity program after a balneotherapy|workshop during the balneotherapy associated to an automated program of physical activity after the end of the balneotherapy available during 12 months
46039909|NCT05435170|Drug|linerixibat|linerixibat will be administered per the treatment sequence
46039910|NCT02733640|Drug|Pantoprazole|pantoprazole 40 mg once-daily
46039911|NCT02733640|Drug|Ranitidine|ranitidine 150 mg twice-daily
45474400|NCT03371290|Other|Mirror Therapy|The healthy UE will be positioned in front of the mirror and the paretic UE behind it, enabling the patient to observe the movements of the healthy limb through the mirror, interpreting that image as the affected limb. The MT protocol will be composed of active bimanual exercises of range of motion and functional exercises. Three sets of 15 repetitions will be performed for each exercise with a 20 seconds interval between each series, for 30 minutes. The exercises: 1) Elbow flexion/extension; 2) Wrist flexion/extension in neutral position; 3) Fingers flexion/extension in neutral position; 4) Forearm pronation/supination; 5) Roll the ball with hands; 6) Squeezing the sponge; 7) Drag a towel in anteroposterior direction; 8) Opponency of fingers; 9) Climb the mirror with the fingers (similar to walking the spider).
45343778|NCT03479554|Other|Early antihypertensive treatment|"The CATIS 2 trial is designed to test BP reduction strategies-early antihypertensive treatment vs. delayed antihypertensive treatment-rather than test the efficacy of individual antihypertensive drugs. Several antihypertensive agents, including angiotensin-converting enzyme inhibitors, calcium channel blockers, and diuretics will be used in the trial.~BP-lowering treatment will start immediately after randomization in the early antihypertensive treatment group. The target treatment goals are:~Step 1 (within 24 hours after randomization): To lower systolic BP by 10-20% with an average of 15% (but systolic BP not lower than 130 mmHg and diastolic BP not lower than 80 mmHg) within the first 24 hours after randomization based on the participant's admission BP levels.~Step 2 (within 7 days after randomization): To achieve systolic BP below 140 mmHg (but not lower than 120 mmHg) and diastolic BP below 90 mmHg (but not lower than 70 mmHg) and maintain this BP level afterward."
45474401|NCT03371290|Other|Control Intervention|"In the control intervention, patients will be performed the same bimanual activities proposed by the MT protocol, but without the reflector side of the mirror. The mirror will be placed in the same position as the MT intervention. However, the subject will have access to the non-reflective side of the mirror, directly visualizing the movement of his healthy arm.~Both interventions will be performed a single session of MT or control composed of 30 minutes of exercises. The participants who will be first assigned to the MT intervention, after 4-weeks washout period, will be performed the same procedures, but in the control intervention. Likewise, patients who will be first allocated to control intervention, after 4-weeks of washout, will be performed the same procedures, however in MT intervention."
46039912|NCT02730520|Other|Retrospective analysis of patient files|The results of the allergen skin tests will be encoded as the edema diameter. The allergenicity score (mean of the skin reactivities for each allergen) will be compared between each age groups. The impact of tabagism, gender, BMI and residential area on the allergic reactivity will also be assessed in the overall population and within each age group.
46039913|NCT02730676|Other|Electronic Cigarette #1|VUSE® Digital Vapor Cigarettes (original flavor, 29 mg nicotine)
46039914|NCT02730676|Other|Electronic Cigarette #2|VUSE® Digital Vapor Cigarettes (menthol flavor, 29 mg nicotine)
46039915|NCT00855595|Drug|Azelaic acid (Finacea, BAY39-6251)|Participants received topical azelaic acid gel 15% twice daily for 12 weeks
46039916|NCT00855595|Drug|Metronidazole (Metrogel)|Participants received topical metronidazole 1% gel once daily for 12 weeks
46039917|NCT00855595|Drug|Doxycycline (Oracea)|Participants received systemic doxycycline 40 mg once daily for 12 week
46039918|NCT05434858|Other|Dual-energy CT (DECT) and ultrasound|DECT and ultrasound will be performed to clarify the pathological mechanisms responsible for the transition from asymptomatic crystalline deposition to gout, and the mechanisms involved in the transition from hyperuricemia to de novo crystalline deposition.
45343779|NCT03479554|Other|Delayed antihypertensive treatment|All home antihypertensive medications will be discontinued in the first seven days after randomization. Study participants will receive antihypertensive treatment on day eight after randomization and will target systolic BP <140 mmHg (but not lower than 120 mmHg) and diastolic BP <90 mmHg (but not lower than 70 mmHg) in two weeks. A BP check-up visit will be conducted in two weeks. If BP treatment goal is not achieved, antihypertensive medication will be titrated or a new medication will be added.
45343780|NCT03477292|Drug|Duration of antibiotic|Duration of antibiotic for treatment of VAP
45343781|NCT03471650|Drug|18F-DCFPyL Injection|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
45474402|NCT03367858|Behavioral|Motivational Interviewing (MI)|
45474403|NCT03367858|Behavioral|Brief Adolescent Mindfulness (BAM)|
45474404|NCT03682705|Drug|Elsubrutinib|Elsubrutinib capsule will be administered orally.
45474405|NCT03682705|Drug|Upadacitinib|Upadacitinib tablet will be administered orally.
45684263|NCT01921504|Device|Acupuncture|"Acupuncture treatment~Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~Needling details 2a) Number of needle insertions per subject per session: 9-19 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Spleen(SP)4, Conception Vessel(CV)12 Optional points - Gallbladder(GB)21, Small Intestine(SI)14, Pericardium(PC)6, External points of Hand and Neck(EX-HN)5, Stomach(ST)34 2c) Depth: 5 ~ 30mm 2d) Response sought: 'Deqi' 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 25 X 30 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
45343782|NCT03465540|Drug|AMG 397|AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.
46039919|NCT02733718|Device|NIRS (near-infrared spectroscopy)|mesenteric oxygenisation measurement
46039920|NCT05433532|Drug|Azacitidine|Azacitidine: 75mg/m2 qd, d1-d7, subcutaneous injection
45343783|NCT03465540|Drug|Dexamethasone|Dexamethasone will be administered intravenously (IV) or orally on Days 1, 8, 15, and 22 of each 28-day cycle.
45343784|NCT03465540|Drug|Azacitidine|Azacitidine will be administered intravenously (IV) or subcutaneously (SC) daily for the first 7 days of a 28-day cycle.
45343785|NCT03462316|Biological|NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）|NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）
45343786|NCT03460769|Other|Data Management and Monitoring|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC).
45343787|NCT03441204|Drug|LTOT 24 h/day|LTOT prescribed for 24 h/day.
45474406|NCT03682705|Drug|Placebo for elsubrutinib|Placebo capsule for elsubrutinib will be administered orally.
45474407|NCT03682705|Drug|Placebo for upadacitinib|Placebo tablet for upadacitinib will be administered orally.
45474408|NCT03361618|Dietary Supplement|Zinc Sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
45474409|NCT01314495|Drug|Abatacept|Abatacept will be administrated as a 30 minute intravenous infusion.
45474410|NCT01314495|Drug|Inactive infusion|Placebo will be administered as a 30 minute intravenous infusion.
45474411|NCT03367780|Device|PSMA PET/CT-scan|PSMA PET is a new diagnostic instrument which can visualize the presence of vital acinar cells in salivary gland locations throughout the head and neck, with a sensitive and quantitative signal.
45474412|NCT03361540|Drug|ASP8302|ASP8302 will be administered orally.
45474413|NCT03361540|Drug|Placebo|Placebo will be administered orally.
45474414|NCT04943367|Device|TEAS|Transcutaneous electrical acupuncture stimulation
45474415|NCT04539561|Device|PiQo4 Laser System|PiQo4 Laser System for treatment of hand pigmentation
45474416|NCT03123484|Drug|β-elemene|β-elemene：400-600mg + 5%GS 500ml,ivgtt,qd, continuously 45days
45474417|NCT03123484|Drug|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual
45474418|NCT02519764|Other|Hydration when thirsty.|Volunteers in this arm habitually follow a hydration protocol that advises hydration when thirst is felt.
45474419|NCT02519764|Other|Not hydration when thirsty|"Volunteers in this arm habitually follow any other kind of hydration protocol, i.e. not a hydration when thirsty protocol."
45840595|NCT00812838|Drug|100 units of Botulinum Toxin Type A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
45840596|NCT00812838|Other|Preservative free normal saline|Approximately 20 to 30 injections of 10cc of preservative free normal saline given with a 20 gage needle directly into the penile plaque
45840597|NCT00812838|Drug|100 units Botulinum Toxin A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
45840598|NCT00812916|Procedure|RF ablation, using specialized CFAE software|RF ablation
46039921|NCT05433532|Drug|Venetoclax|Venetoclax: 100mg d1, 200mg d2, 300mg d3, 400mg d4-d14 or 21, oral (Adjusted according to the peripheral blood BCR/ABL1 results on day 14)
45474420|NCT03179787|Drug|Aripiprazole oral product|oral administration of aripiprazole
45474421|NCT03367468|Other|Exercise|Strengthening exercises ( extrinsic and intrinsic foot muscles) Stretcthing exercises (plantar fascia, plantar flexor muscles)
45474422|NCT03367468|Other|Mobilization|Antero-posterior gliding, talocrural traction, metatarsal mobilization
45474423|NCT03745937|Drug|MEDI0382|Subcutaneous dose of MEDI0382 will be up-titrated weekly once daily up to 8 weeks during the uptitration period and thereafter once daily in 3-week TEP.
45840599|NCT00814788|Drug|Bicalutamide|50 mg oral tablet daily
46039922|NCT05433532|Drug|Flumatinib|Flumatinib: 600mg qd, d4-d21, oral
46039923|NCT00855439|Drug|Exenatide|Exenatide is given according to current FDA prescribing guidelines. Exenatide and other diabetes medications will be titrated in order to achieve optimal blood glucose levels
46039924|NCT00855439|Drug|Glargine|Subjects will take 1 daily injection of insulin glargine in manner consistent with current prescribing guidelines. Glargine and other diabetes medications will be adjusted to achieve optimal levels of blood sugar control
46039925|NCT01064856|Biological|Adalimumab|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing adalimumab 40 mg/0.8 mL. Study drug was SC self-administered eow at approximately the same time of day.
46039926|NCT01064856|Biological|Placebo|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing matching placebo for adalimumab. Study drug was SC self-administered eow at approximately the same time of day.
46039927|NCT02730442|Drug|F901318|Administration of F901318 intravenously
45840600|NCT00814788|Drug|Everolimus|10 mg oral capsule daily
45343788|NCT03441204|Drug|LTOT 15h/day|: LTOT prescribed for 15 h/day. The patient is instructed to use LTOT during sleep and not to use LTOT for about 9 hours during daytime, totalling 15 h/day.
45343789|NCT03437798|Other|Disease status|Women who reported periodontal disease diagnosis/condition
45474424|NCT03745937|Drug|Placebo|Subcutaneous dose of placebo matched to MEDI0382 will be administered once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.
45474425|NCT02956057|Drug|Polyethylene Glycols|
45474426|NCT02956057|Drug|Natrium picosulfate / Magnesium citrate|
46039928|NCT02730442|Drug|Fluconazole|Oral administration
46039929|NCT02733874|Drug|Compound Clobetasol Propionate Ointment|
46039930|NCT02733874|Drug|Calcipotriol Betamethasone Ointment|
46039931|NCT02730364|Drug|Paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C|One sachet is provided for each participant randomized to the Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.
45474427|NCT02956057|Drug|Polyethylene glycol / Ascorbic acid|
45840601|NCT00815490|Device|Desaturation|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
46039932|NCT02730052|Device|Omron 9200T plus Telemonitoring|Telemonitoring of the self-measured blood pressure at home. After each blood pressure measurement the values are transmitted to and stored into a central station where a condensed weekly report is elaborated and delivered to the doctor (investigator).
45343790|NCT03420404|Other|TCM physician involved collaborative care model (TCMCMC)|"TCM physician delivered acupuncture as well as history taking, physical examination, non-pharmacological advice and communications with rheumatologists.~Acupuncture procedures: After eliciting the deqi sensation, the needles will be left in place for 30 minutes. The acupuncture treatment will be done 2-3 times a week, with 5 sessions constituting a treatment course. There will be a break of 1 week in between each acupuncture course. Patients in the intervention arm will undergo 2 treatment courses (or 10 sessions) in total."
46039933|NCT02730052|Device|Omron 9200T without Telemonitoring|Self-measured blood pressure at home and register the values in a diary card. Participants will perform 2 consecutive blood pressure measurements twice a day for a 7 day period, previous to the visit to the doctor's (investigator) office.
45343791|NCT03408353|Procedure|Biospecimen Collection|Undergo collection of blood samples
46039934|NCT00846391|Drug|MK8245 5 mg (twice a day) b.i.d.|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 5 mg b.i.d. treatment group took 2 capsules of MK8245 2.5 mg in the morning and 2 capsules of MK8245 2.5 mg in the evening."
46039935|NCT00846391|Drug|MK8245 50 mg b.i.d.|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 50 mg b.i.d. treatment group took 2 capsules of MK8245 25 mg in the morning and 2 capsules of MK8245 25 mg in the evening."
45343792|NCT03408353|Procedure|Mammography|Undergo standard of care mammography
46039936|NCT00846391|Drug|Placebo|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the placebo treatment group took 2 capsules of placebo matching MK8245 capsules in the morning and 2 placebo capsules matching MK8245 capsules in the evening."
46039937|NCT00636454|Behavioral|Coping skills training (CST) for chronic pain|Participants will attend 10 sessions lasting between 45 and 60 minutes each. Topics will include relaxation training, managing activity cycles, and changing thought patterns to reduce the negative effects of pain.
46039938|NCT00636454|Other|Usual care|Participants will receive the care usually given to patients with knee or hip OA.
45343793|NCT03408353|Other|Questionnaire Administration|Complete questionnaires
45343794|NCT03368547|Procedure|Computed Tomography|Undergo PET/CT scan
45343795|NCT03368547|Radiation|Gallium Ga 68 Gozetotide|Given IV
45343796|NCT03368547|Procedure|Positron Emission Tomography|Undergo PET/CT scan
45343797|NCT03338309|Other|Instantaneous wave-free ratio measurement|Instantaneous wave-free ratio measurement in order to evaluate functional significance of epicardial stenosis
45343798|NCT03337620|Device|Tx360|Tx360 used to deliver active and placebo drug interventions to SPG.
45474428|NCT03179319|Behavioral|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
45474429|NCT04526392|Other|Questionnaire|Pubertal course questionnaire
45847557|NCT04004520|Behavioral|Virtual reality Control|The Looking Glass Virtual Reality is a stereographic 3D photo viewer provided on a virtual reality platform featuring photos from around the world dating back to approximately a century ago that participants will view for 10 minutes.
46039939|NCT01042392|Drug|Aliskiren|150 mg Aliskiren as film-coated tablet
46039940|NCT01042392|Drug|Ramipril|Ramipril 5 mg was given in capsule form.
46039941|NCT01042392|Drug|Matching placebo to Aliskiren|The tablet of matching placebo to aliskiren 150 mg for period I and III. In period II, matching placebo to Aliskiren was given to Ramipril active treatment arm.
45684264|NCT01921582|Drug|Methylphenidate|"Weekly appointments with study psychiatrists for the first four weeks, and then biweekly appointments for the last eight weeks.~Intervention will consist of medication as well as components of Med-Plus treatment (e.g., medication management, general support, and compliance enhancement strategies)."
46039942|NCT01042392|Drug|Matching placebo to Ramipril|The placebo capsule to ramipril 5 mg for period I and III. In period II, matching placebo to Ramipril was given to Aliskiren active treatment arm.
46039943|NCT00704665|Drug|Relaxin|10 ug/kg/day or 25 ug/kg/day
45474430|NCT04526470|Drug|Alpelisib|Dose level -2: 200 mg PO once daily / Dose level -1: 200 mg PO once daily / Dose level 0: 250 mg PO once daily / Dose level 1: 300 mg PO once daily
45474431|NCT04526470|Drug|Paclitaxel|Dose level -2: 60 mg/m2 IV on day 1, 8, and 15 / Dose level -1: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 0: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 1: 70 mg/m2 IV on day 1, 8, and 15
45474432|NCT01314651|Behavioral|Stimulus Control and Sleep Restriction|5 instructions in stimulus control and individually-tailored sleep restriction
46039944|NCT00704665|Drug|Relaxin|Placebo
45684265|NCT01921582|Behavioral|Cognitive Behavioral Therapy|"Cognitive Behavior Therapy will include three phases:~Phase 1 undertakes to eliminate binge episodes and introduce a 'regular' pattern of eating;~Phase 2 aims to reduce food intake and restructure eating-related cognitions;~Phase 3 focuses upon relapse prevention"
45684266|NCT02984098|Drug|Dextrose|before heel lance, 2ml oral dextrose gel 25%or 40% was administered, and pain related intensity was evaluated with premature infant pain profile scale
46039945|NCT02694952|Biological|FAV-Africa|Polyspecific antivenom immunoglobulin F(ab)'2 fragments of equine origin manufactured by Sanofi Pasteur, S.A., Lyon, France. Per undiluted 1 ml, the multivalent serum contains ≥25 times the LD50 for mice exposed to venom of Bitis gabonica, Bitis arietans, Echis leucogaster, Echis ocellatus, Naja haje, Dendroaspis polylepis, Dendroaspis viridis, and Dendroaspis jamesoni, as well as ≥20 times the LD50 for mice exposed to venom of Naja melanoleuca and Naja nigricollis.
46039946|NCT02694952|Biological|EchiTabPlus-ICP|Polyspecific antivenom immunoglobulin of equine origin manufactured by the Clodomiro Picado Institute, San Jose, Costa Rica. Each 10 ml of undiluted antivenom contains enough antibody fragments to neutralize 30 mg of Echis ocellatus venom, 20 mg of Bitis arietans venom and 5 mg of Naga nigricollis venom.
46039947|NCT00913315|Drug|tolterodine|4 mg of tolterodine ER
46039948|NCT00913315|Drug|tamsulosin|0.4 mg of tamsulosin once a day for 8 weeks
46039949|NCT00913315|Drug|placebo|placebo once a day for 8 weeks
46039950|NCT00701857|Drug|cisplatin|Standard weekly dose
46039951|NCT00701857|Drug|Pemetrexed|Biweekly pemetrexed dose escalation
46039952|NCT00701857|Radiation|radiation therapy|Weekly standard dose radiation therapy
45474433|NCT01314651|Behavioral|Lifestyle Modification|5 instructions in changing general lifestyle habits (maintaining consistent liquid intake, range of motion exercises, eating a serving of protein in the morning, etc.)
45343799|NCT03336931|Diagnostic Test|Molecular profiling and drug testing|"Laboratory analysis including:~A. Tumour molecular profiling: targeted whole exon variant analysis, whole genome (DNA) and transcriptome (RNA) sequencing, methylation analysis, proteomics analysis, immunohistochemistry B. In vitro high-throughput drug sensitivity testing C. In vivo drug testing using patient-derived xenograft (PDX) models D. Liquid biopsies~Multi-disciplinary Tumour Board case discussion~Recommendation of personalised therapy"
45343800|NCT03319407|Device|EPAD monitoring system|EPAD system will be used as part of routine care
45343801|NCT03306706|Dietary Supplement|Whole pea muffins|2 muffins containing whole peas
45343802|NCT03306706|Dietary Supplement|Split pea muffins|2 muffins containing split peas
45343803|NCT03306706|Dietary Supplement|Wheat muffins|2 muffins containing wheat
45343804|NCT03289923|Device|Sham TMS + Cognitive therapy|Placebo Transcranial Magnetic Stimulation with cognitive therapy
45343805|NCT03289923|Device|Active TMS + Cognitive therapy|Active Transcranial Magnetic Stimulation with cognitive therapy.
45343806|NCT03275974|Biological|Carbon C 11 Glutamine|Given by IV
45474434|NCT03361384|Drug|Alcohol|
45474435|NCT03361384|Other|Placebo (non-alcoholic beverage)|
46039953|NCT02730286|Other|observational study|application of several standard instruments in patients with rheumatoid arthritis
45474436|NCT03858569|Procedure|active management of third stage of labor|Active management of the third stage of the labor will be done administering oxytocin and cord traction.
45474437|NCT02519374|Drug|Placebo (including Maltodextrin)|
45474438|NCT02519374|Drug|PROMITOR® (including Maltodextrin)|Investigational product dose 1
46039954|NCT02733484|Dietary Supplement|Probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
46039955|NCT02733484|Dietary Supplement|Placebo|the patients in this arm will receive placebo intervention
46039956|NCT02694640|Behavioral|Reach Plus|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will no longer receive calls from RTR coaches and will be encouraged to use the heart rate monitors and pedometers during exercise. Participants will continue to complete their exercise logs and receive feedback reports from study staff."
46039957|NCT02694640|Behavioral|Reach Plus Phone|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, these participants will have the opportunity to continue to receive support calls from their coach. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
46039958|NCT02694640|Behavioral|Reach Plus Message|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will receive messages by email or text to motivate, prompt and reinforce continued exercise. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
45343807|NCT03275974|Biological|Fluorine F 18 L-glutamate Derivative BAY94-9392|Given by IV
45343808|NCT03275974|Procedure|Positron Emission Tomography|Undergo PET scan
45343809|NCT03275974|Procedure|Blood Draw|Undergo venous blood draws
45343810|NCT03270150|Device|BTL-899|BTL-899
45343811|NCT03262155|Biological|Blood test|
45343812|NCT03246061|Device|Intracept System|BVN ablation using radiofrequency energy
45343813|NCT03246061|Other|Standard Care|Non-surgical standard care
45474439|NCT02519374|Drug|PROMITOR® (including Maltodextrin)|Investigational product dose 2
45474440|NCT02519374|Drug|PROMITOR® (including Maltodextrin)|Investigational product dose 3
46039959|NCT02733328|Procedure|CPB Surgery|
46039960|NCT05420272|Behavioral|Trunk performance and endurance lower extremity biomechanic|Trunk performance and endurance lower extremity biomechanic
45474441|NCT01176695|Drug|fish oil containing lipid emulsion|medium chain triglycerides, long chain triglycerides, omega-3 fatty acid containing triglycerides
45343814|NCT03217227|Other|Cardiovascular Magnetic Resonance Imaging with Exercise Bike|A rest scan is performed and a gadolinium contrast may be administered during the scan (depending on the kidney function). After the rest scan is completed, images of the subject's heart during exercise via cycling in the supine position, will be scanned.
45474442|NCT01176695|Drug|MCT/LCT containing lipid emulsion|medium chain triglycerides, long chain triglycerides
45474443|NCT03361150|Procedure|HIT|Both exercise protocol will be personalized, 3 times per week, 40-min exercise. HIT alternates a series of high-intensity bouts with relief period. MCT is continuous exercise with a constant intensity below anaerobic threshold.
45474444|NCT03361150|Procedure|MCT|Both exercise protocol will be personalized, 3 times per week, 40-min exercise. MCT is continuous exercise with a constant intensity below anaerobic threshold.
45474445|NCT03861455|Drug|Dupilumab|patient receive dupilumab 300 mg every 2 weeks after a 600 mg-loading dose of dupilumab on day 0
45840602|NCT00816348|Drug|Omegaven|Omegaven® will be initiated at a dose of 0.5 gram/kg/day and is infused over 24 hours for 1-2 days, and then advanced to 1 gram/kg/day. Omegaven® will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven® will continue until weaned from PN. Monotherapy with Omegaven® can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/kg/day, advancing to 1 gm/kg/day.
45474446|NCT03861455|Drug|placebo|patient receive placebo
45474447|NCT04526626|Device|Radiofrequency ablation for treatment of lower limb varicose veins (ClosureFast, Medtronic)|Thermal injury to long saphenous vein
45474448|NCT03367390|Device|AID System|AID system
45474449|NCT03367390|Drug|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
45474450|NCT01179893|Biological|IVIG|Intravenous immunoglobulin
45474451|NCT01179893|Procedure|PLEX|Plasma exchange: removal of pathogenic antibodies and constituents and replacement with albumin.
45474452|NCT04526080|Device|TheraBionic Device|Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three courses of 60-minute treatments per day, administered in the morning, at noon and in the evening at the patient's home, with the exception of the first 60-minute treatment, which will be delivered at the research site. Each 6-week treatment period will be considered a cycle of treatment. For subjects who are randomized to the active arm, the device will be programmed with hepatocellular carcinoma-specific modulation frequencies and will be activated for more than 200 one-hour treatment sessions.
45474453|NCT04526080|Device|Placebo Device|Subjects who are randomized to receive placebo, will receive the same instructions and a similar device. The placebo device will look and sound the same as the active device, but will not deliver the modulation frequencies. For subjects randomized to the placebo arm, the device will not emit any hepatocellular carcinoma-modulation frequencies and will be activated for more than 200 one-hour treatment sessions.
45474454|NCT01176851|Drug|Glycopyrrolate|Single administration of Glyco pMDI 100 µg
45840603|NCT00817596|Device|Infusion Pump (Prometra)|Implantation of pump/catheter for infusion of morphine into the intrathecal space
45840604|NCT00820872|Biological|trastuzumab|
45840605|NCT00820872|Drug|carboplatin|
46039961|NCT02729662|Drug|Tolvaptan|"Before administration of tolvaptan~TKV・Liver capacity: Once/year (an additional measurement within 3 months before start of administration)~24-hour urine collection・Hematology/urinalysis: Once/year~Physical findings: Blood pressure and medical interview at ambulatory visit~Hospitalization for education and examination at the start of tolvaptan administration~24-hour urine collection・Hematology/urinalysis・Inulin clearance~Physical findings: Body weight, blood pressure~Adverse Events~After administration of tolvaptan~TKV・Liver capacity・inulin clearance: Once/year~24-hour urine collection: Once/6 months~Hematology/urinalysis: Once/month in principle~Physical findings: Blood pressure and medical interview at ambulatory visit~Adverse Events"
45474455|NCT01176851|Drug|Glycopyrrolate|Single administration of Glyco pMDI 100 µg after charcoal ingestion
45474456|NCT01176851|Drug|Glycopyrrolate|Single intravenous injection of glycopyrrolate 100 µg
45343815|NCT03217227|Procedure|Cardiac Catheterization|"It is a procedure to diagnose and treat cardiovascular diseases by inserting a long and thin tube known as a catheter into the artery or vein in the neck, groin or arm and threaded through the blood vessels to the heart.~A coronary angiogram is also performed during the procedure where an invisible contrast dye (only visible in the X-rays) is injected through the catheter and X-ray images scanned will show the flow of the dye through the heart arteries to determine any blockages in the arteries.~In the case where there is severe narrowings, fractional flow reserve (FFR) may be performed to measure the pressure in the coronary arteries.~If there is no significant narrowing lesions, the interventionist may perform additional flow resistance measurements of the small vessels to further investigate the cause of angina"
45343816|NCT03217227|Other|Retinal Photography (Optional)|The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
45840606|NCT00820872|Drug|docetaxel|
45840607|NCT00820872|Drug|lapatinib ditosylate|
45343817|NCT03217227|Diagnostic Test|I123 MIBG Scintigraphy (Optional)|"The test studies the cardiac sympathetic signalling that may help to identify patients with high risks of adverse events. The scan consists of 2 acquisitions of images 3-4 hours apart.~For this study, only patients without clinically significant lesions (diagnosed via the cardiac catetherisation and have normal FFR results) will undergo this test."
45343818|NCT03216798|Other|questionnaires survey|The questionnaires will be self-administered and anonymous. Information obtained from the questionnaire will not contain identifiable information of patients, CBO staff or health care workers.
45840608|NCT00821184|Drug|Vesicare (solifenacin)|5mg po qd
46039962|NCT04203082|Behavioral|Exposure Intervention|Single session intervention of psychoeducation + exposure treatment to the operating room and procedural steps of a cesarean delivery
45474457|NCT02519218|Device|Ellipse Technologies Intramedullary High Tibial Osteotomy Nail System|
45474458|NCT01176929|Other|Usual treatment and Prevention program|"Prevention program of recurrent suicidal acts includes three interventions:~A series of three telephone calls ( the second week , one month and three months after discharge from hospital )~A systematic telephone contact with the referring physician~A telephone helpline for people who made a suicide attempt and referring physicians."
45840609|NCT00821184|Behavioral|Vesicare (solifenacin) plus behavioral modification|5 mg dose po once daily plus behavioral modification
46039963|NCT04203082|Other|Usual Care|Standard of care for education about the cesarean /delivery planning varies across the two hospitals. At Children's Hospital Colorado, anesthesiologists are included in the delivery planning meetings where the patients have the opportunity to review anesthetic technique and ask questions.
46039964|NCT03195244|Other|Aquatic Physical Therapy|Swim Whisperer's Aquatic Therapy Sessions
46039965|NCT05406232|Procedure|Biopsy|Undergo tumor punch biopsy
46039966|NCT05406232|Procedure|Biospecimen Collection|Undergo blood sample collection
46039967|NCT05406232|Radiation|Radiation Therapy|Undergo RT
45343819|NCT03185455|Other|Remote (text based) surveillance|Women with hypertensive disorders of pregnancy with access to a cell phone with unlimited text message capabilities will be randomized to either office visit blood pressure checks after discharge or receive a blood pressure cuff and text in blood pressures for two weeks postpartum using a standardized, HIPAA compliant, physician derived automated platform.
45343820|NCT03182075|Behavioral|Computerized Training|OCD participants will receive 14 sessions of training via computer within 3 weeks.
46039968|NCT03194854|Behavioral|Fun For Wellness (FFW)|FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
46039969|NCT02733250|Biological|Pembrolizumab|200mg IV Day 1 of each 21 cycles
45343821|NCT03179969|Other|paravalvular leak|Observational study on patients with paravalvular leak
45343822|NCT03177044|Behavioral|Behavioural treatment|2 to 6 sessions of behavioural training with a pelvic floor physiotherapist
45343823|NCT03159923|Other|Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.|Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.
45343824|NCT03152903|Biological|VPM1002 (Recombinant BCG Vaccine)|"VPM1002 is a formulated, lyophilized cake of live recombinant Mycobacterium bovis rBCGÄureC::Hly+; VPM1002.~VPM1002 is the active pharmaceutical ingredient. It is a genetically modified BCG vaccine derived from the Mycobacterium bovis BCG subtype Prague characterized as rBCGÄureC::Hly+. Single dose of VPM1002 is administered intradermally."
45840610|NCT05237154|Other|Intervention with intermittent fasting.|Intervention with fasting protocol of alternate days 2 days a week and the other days with ad libitum consumption. Restricted food in 25% of the total daily needs on the days of the intermittent fasting protocol, with 18 hours of fasting and 6 hours of restricted feeding (18:6).
46039970|NCT02733250|Drug|Nab-Paclitaxel|100mg/m2 IV Day 1, 8 and 15 of every 21 day cycles
46039971|NCT02733094|Drug|Secukinumab|
46039972|NCT03188068|Drug|Sirolimus|Oral administration
46039973|NCT03188068|Drug|Prednisolone|Oral administered with sirolimus
46039974|NCT03304600|Device|Active stimulation|Patients will receive a tDCS stimulation during 30 mn with an intensity of 2 milliampere (mA).
45343825|NCT03152903|Other|Placebo|Single dose of Placebo is administered intradermally.
46039975|NCT03304600|Device|Sham stimulation|Patients will receive a Sham stimulation during 30 mn
46039976|NCT02729506|Procedure|Transarterial Radioembolization|Yttrium-90 radioembolization (90Y) is a relatively new technique involving the trans-arterial administration of glass or resin microspheres loaded with Yttrium-90, a β-emitting isotope, delivering selective internal radiation to the tumor.
46039977|NCT02729506|Procedure|Transarterial Chemoembolization using drug-eluting beads|"TACE is a procedure in which a catheter is introduced into the branches of the hepatic artery supplying the tumor. Embolic material and chemotherapeutic agents are deployed through the catheter directly into the tumor vasculature. This technique potentially enhances the cytotoxic effect by inducing ischemia and retention of the therapeutic agent in the vicinity of the tumor.~The drug-eluting beads (DEBs) enable standardization of TACE since DEBs act as both an occluding agent as well as a drug-loaded carrier, achieving local ischemia and cytotoxic death of the tumor with one device."
46039978|NCT02732782|Other|Isometric exercise|
46039979|NCT02732782|Other|Eccentric exercise|
46039980|NCT05379400|Other|Portable air cleaner (PAC)|Commercially available Portable air cleaners (PAC) contain carbon filters that reduce volatile organic carbons and can reduce odors. Because of this, the researchers will remove the carbon filters from all air purifiers to preserve blinding. This will be done by unblinded research staff and devices will be labelled with an ID number to preserve blinding of the rest of the research team.
46039981|NCT05379400|Other|Sham Portable air cleaner (PAC)|Sham Portable air cleaner (PAC) are commercially available portable air cleaners with the carbon filters and the HEPA filters removed. This will be done by unblinded research staff and devices will be labelled with an ID number to preserve blinding of the rest of the research team.
45474459|NCT01176929|Other|Usual Treatment|Usual Treatment
45474460|NCT04526236|Drug|Methadone Injectable Product|Perioperative use of placebo for pain management and remifentanil during the surgery.
45684267|NCT03398902|Behavioral|Sleep extension|Based on CBTI principles, the instructor will prescribe bed times and wake times each week to allow for gradual increases in sleep opportunity.
46039982|NCT02729428|Device|MRI|Participants will undergo an MRI scan
45343826|NCT03152890|Drug|Insulin|If blood glucose level after reperfusion of liver graft exceeds 180 mg/dL, the insulin dose proposed by the linear mixed effects analysis is given as a bolus.
45343827|NCT03148600|Behavioral|Pelvic floor and bowel behavioural training|Physiotherapist-led pelvic floor muscle and bowel behavioural training
45343828|NCT03148600|Other|Standard arm|Standard medical and nursing care
45343829|NCT03141255|Device|IVTM™ System|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
45343830|NCT03141255|Device|Quattro® Catheter|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
45343831|NCT03139162|Other|Swiss RAI-HC assessment|RAI-HC assessments done by trained nurses in clinical routine
45343832|NCT03125811|Other|Inhaled Isopropyl Alcohol (IPA)|Three doses within 60 minutes. Doses will occur at 0 minutes, 30 minutes, and 60 minutes. Each dose consists of 3 inhalations of one IPA prep pad. A new prep pad is used at each dose.
45343833|NCT03125811|Drug|Oral Dissolvable Tablet Zofran (ondansetron)|Single dose 4 mg tablet at 0 minutes.
45343834|NCT03123029|Drug|Venetoclax|Venetoclax will be administered orally.
45474461|NCT03627091|Drug|Ontamalimab|SC injection of 25 mg or 75 mg ontamalimab will be administered using a prefilled syringe.
45474462|NCT03627091|Other|Placebo|SC injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
45474463|NCT01179971|Dietary Supplement|Fish oil, gamma-linolenic acid|3 g/d DHA + EPA
45474464|NCT04526314|Other|observational|observational
45684268|NCT03398902|Other|Habitual sleep|The study team member will monitor and encourage participants to keep bedtimes and wake times that matched their baseline bedtimes and wake times.
45684269|NCT00985426|Biological|HEPLISAV-B|Intramuscular (IM) injections of HEPLISAV-B at Weeks 0, 4, and 24
45684270|NCT00985426|Biological|Engerix-B|Intramuscular (IM) injections at Weeks 0, 4, 8, and 24
45684271|NCT00985426|Other|Placebo|Placebo(saline) intramuscular (IM) injection at Week 8
46039983|NCT02732548|Other|Negative Pressure Wound Therapy (NPWT)|
46039984|NCT02732548|Other|MIRODERM Application(s)|
46039985|NCT02732548|Other|Standard Care|wound measurement, debridement, photography of wound, moist wound environment, infection management, nutritional support
46039986|NCT03303664|Other|IMPROVE Protocol|Comprehensive pain management protocol
46039987|NCT02729272|Procedure|Laparoscopic colpotomy by ultrasonic ESD|In this intervention, laparoscopic colpotomy was performed by ultrasonic ESD (Harmonic Synergy Hook Blades; Ethicon Endo-Surgery, Cincinnati, OH, USA).
46039988|NCT02729272|Procedure|Laparoscopic colpotomy by monopolar ESD|In this intervention, laparoscopic colpotomy was performed by monopolar ESD (hook electrode with 90 watts of unmodulated current; Karl Storz, Tuttlingen, Germany).
46039989|NCT02729272|Device|Monopolar ESD|
46039990|NCT02729272|Device|Ultrasonic ESD|
46039991|NCT02732470|Other|Qi Gong|The aim of this study is to evaluate the effects of Qi Gong on quality if life in patients with Systemic Lupus Erythematosus
46039992|NCT03170362|Other|Pharmacogenetic Test|The intervention is a battery of pharmacogenetic test results that mostly affect the metabolism of antidepressants and other medications.
45343835|NCT03118531|Device|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System(34/38 mm)|The stenting procedure should be performed according to the Instructions for Use that is provided with each 34/38 mm Resolute Integrity stent.
45343836|NCT03117933|Drug|Olaparib|Tablet, 100mg and 150mg
45343837|NCT03117933|Drug|Cediranib|Tablet 15mg and 20mg
45343838|NCT03117933|Drug|Paclitaxel|Intravenous (IV)
45474465|NCT04237584|Drug|Enzalutamide during Lead-in Period|Participants will receive 12 weeks open-label lead-in ARB (enzalutamide) that will continue after double-blind randomization to radium-223 or placebo.
45474466|NCT04237584|Drug|Lead-in Enzalutamide followed by Radium-223/Enzalutamide|After a 12-week lead-in period of open-label enzalutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label enzalutamide.
46039993|NCT02732158|Other|Nutrition Products|a sachet containing AN777and amino acids; a carotenoid capsule
46039994|NCT02727166|Dietary Supplement|Inulin|Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
45343839|NCT03091231|Diagnostic Test|mpUS multiparametric Ultrasound|compare the mpUS to other methods
45684272|NCT00985192|Drug|everolimus|
45684273|NCT00985192|Other|laboratory biomarker analysis|
45684274|NCT03392662|Device|Hemopatch|Patients received product at the discretion of their surgeon.
45684275|NCT03390010|Drug|Misoprostol + syntocinon and using extra uterotonic drugs when needed ; methergine|medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
45684276|NCT03390010|Drug|Syntocinon and using extra uterotonic drugs when needed ; methergine carboprost|medical prophylaxis against postpartum atony and postpartum hemorage by giving syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
46039995|NCT02727166|Dietary Supplement|Maltodextrine|Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
46039996|NCT03112408|Behavioral|Forward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in the same direction as the saccade in order to induce an adaptive increase of saccade amplitude ('forward adaptation')
46039997|NCT03112408|Behavioral|Backward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in a direction opposite to the saccade in order to induce an adaptive decrease of saccade amplitude ('backward adaptation')
45684277|NCT00985114|Device|EndoBarrier|EndoBarrier implant
45474467|NCT04237584|Drug|Lead-in Enzalutamide followed by Placebo/Enzalutamide|After a 12-week lead-in period of open-label enzalutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label enzalutamide.
45684278|NCT00985114|Behavioral|Diet + Lifestyle Counseling|Multidisciplinary lifestyle and nutritional counseling
45684279|NCT00984568|Biological|Infliximab|Infliximab intravenous infusion at a dose of 5 mg/kg.
45684280|NCT00984568|Drug|Prednisolone|Oral prednisolone 40 mg/day or 1 mg/kg/day depending upon participant response.
45684281|NCT00984568|Drug|5-aminosalicylic acid|5-ASA administered orally at a dose of 2 g/day.
45684282|NCT00984568|Drug|Azathioprine|AZA administered orally at a dose of 2.0-2.5 mg/kg/day.
45684283|NCT02984176|Drug|Simethicone Tab 40 mg|3 tablets of Simethicone Tab 40 mg (one tablet after each meal) and to fast overnight the day before the operation.
46039998|NCT03112408|Behavioral|Execution of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in forward and backward adaptation conditions)
46039999|NCT03112408|Behavioral|Generation of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in adaptation condition)
46040000|NCT02727088|Procedure|Pulpotomy|Conservative pulp management (experimental treatment): ablation of the coronal part of the pulp
46040001|NCT02727088|Procedure|Pulpectomy|ablation of the whole dental pulp, preparation and filling of the whole root canal system
46040002|NCT02727244|Procedure|urgent or elective cesarean section|a kind of surgical procedure to deliver a baby
45684284|NCT02984176|Drug|Placebo Tablets|3 tablets of Placebo Tablets (one tablet after each meal) and to fast overnight the day before the operation.
45684285|NCT03075280|Procedure|400ml high carbohydrate liquid diet before ERCP|400ml high carbohydrate liquid diet uptake 2 hours before ERCP
45684286|NCT01921738|Drug|1% Azithromycin gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
45684287|NCT01921738|Drug|Azithromycin|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
45684288|NCT01921738|Drug|placebo gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
45684289|NCT01921738|Drug|placebo capsule|Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
45684290|NCT01921816|Device|Prismocitrate 18/0, Prism0cal|Subjects on continuous hemodiafiltration will ordinarily receive heparin as the anticoagulation. In our study, regional citrate anticoagulation with Prismacitrate is used to replace heparin. Citrate has been shown in study to be safer than heparin with reduced bleeding risk
46040003|NCT02728960|Procedure|MRI of the Brain (No Contrast) Scan|DSI data will be acquired on 3T Tim Trio System (Siemens) using a 32-channel coil
46040004|NCT02726932|Other|No intervention, merely observational|
45343840|NCT03088579|Device|GammaTile seed loader|Patients are chosen based on symptomatic tumor/radiographic finding of a surgically accessible mass. Surgery will be done in usual fashion. A cavity will be left where the tumor was. Size of operative bed will be measured using a surgical dissector and standard operating room ruler. A sheet of surgical fabric may be used to estimate size of cavity. If pathology is positive the study treatment will continue. If not, patient will not be on trial. If patient is eligible, radiation oncologist will form custom implants using a seed(s) of Cesium-131, with other biocompatible materials used to achieve maximum dosimetric conformality. Surgeon will place constructs into cavity until the operative bed is fully addressed. Implant is not expected to migrate. Surgicel, bioglue or similar material may be used to secure seeds. Wound will be closed in standard fashion. The last 10 patients will be asked to participate in an effort to gauge costs related to radiation portion of treatment.
45343841|NCT03088553|Drug|Therapeutic Drug Monitoring|Trough concentration of ganciclovir and viral load measurement at each follow-up visit.
45343842|NCT03077243|Radiation|Intensity Modulated Radiotherapy (IMRT) - deintensified|60 Gy at 2 Gy/fx
45343843|NCT03077243|Radiation|Intensity Modulated Radiotherapy (IMRT) - standard|70 Gy at 2 Gy/fx
45343844|NCT03077243|Drug|Cisplatin (or alternative) - deintensified|The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 total doses.
45343845|NCT03077243|Drug|Cisplatin (or alternative) - standard|The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 7 total doses.
45343846|NCT03077243|Procedure|Assessment for surgical evaluation|Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
45343847|NCT03062085|Other|Cataract|The genetic and environmental factors concerning to the pathogenesis of cataract in the three groups.
45343848|NCT03055897|Device|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
45343849|NCT03055832|Device|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
46040005|NCT02728882|Biological|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
46040006|NCT01064310|Drug|pazopanib|oral anti-angiogenic treatment
46040007|NCT01064310|Drug|sunitinib|oral anti-angiogenic treatment
46040008|NCT00627276|Dietary Supplement|omega-3 fatty acid|Oral, 3 times daily
45474468|NCT04237584|Drug|Darolutamide during Lead-in Period|Participants will receive 12 weeks open-label lead-in darolutamide that will continue after double-blind randomization to radium-223 or placebo.
45474469|NCT04237584|Drug|Lead-in Darolutamide followed by Radium-223/Darolutamide|After a 12-week lead-in period of open-label darolutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label darolutamide.
45474470|NCT04237584|Drug|Lead-in Darolutamide followed by Placebo/Darolutamide|After a 12-week lead-in period of open-label darolutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label darolutamide.
45474471|NCT02893787|Other|Speckle Tracking Echocardiography|Echocardiography analyses
45840611|NCT05237154|Other|Intervention with high-intensity interval training.|Intervention with high-intensity interval training, 3x per week, with intensity maintained between 70-85% of maximum heart rate.
45474472|NCT02519296|Behavioral|Prolonged Exposure Therapy|8 sessions with prolonged exposure therapy and fMRI.
45474473|NCT02519296|Behavioral|Observation|fMRI.
45840612|NCT05236842|Drug|Sulthiame|oral intake of tablets
45840613|NCT05236686|Procedure|Hepato-celiac lymphadenectomy|Hepato-celiac lymphadenectomy in the treatment of epithelial ovarian cancer, with a maximum cytoreduction, in the circumstance of primarily diagnosed advanced epithelial ovarian cancer (primary debulking surgery or interval debulking surgery) and of platinum-sensitive recurrent ovarian cancer (no more than 4 lines of therapy).
46040009|NCT00627276|Other|placebo|Oral, 3 times daily
45343850|NCT03055832|Device|LipiFlow Pulsation System|Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
45343851|NCT03052595|Diagnostic Test|Oral glucose tolerance test|Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load
45343852|NCT03052595|Diagnostic Test|Testing of autonomous nervous system function|Autonomous nervous system function will be assessed using a battery of tests (orthostasis, Valsalva manoeuvre, heart rate variability recording, blood hormone levels, ect.)
45343853|NCT03052595|Diagnostic Test|Stroop test|Stroop test will be used to test cognitive function
45343854|NCT03052049|Device|Prostate Artery Embolization|The PAE procedure will be completed on all enrolled patients in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Bead Block microspheres to slow/block blood flow to the prostate.
46040010|NCT02726854|Drug|Apatinib|Patients with pancreatic cancer who are failed of receiving first-line chemotherapy and cannot tolerate second-line chemotherapy or unwilling to receive second-line chemotherapy will receive Apatinib Tablets (850mg once daily, orally) 30 minutes after meal with warm water. Take 28 days as a cycle, patients will receive this treatment until they have got disease progressed.
45343855|NCT03048877|Drug|Apatinib Oral Tablet|Apatinib Mesylate Tablets
45343856|NCT03048877|Drug|Placebo Oral Tablet|Placebo Oral Tablet
45343857|NCT03032575|Behavioral|SEARCH010/RV254|
45343858|NCT02951351|Drug|Proparacaine|Extra proparacaine will be applied to the conjunctival surface to determine its role in patient experience.
45343859|NCT02951351|Procedure|Conjunctival culture|Conjunctival cultures will be performed to ensure that the intervention does not interfere with antisepsis.
45474474|NCT02519296|Device|fMRI|Functional Magnetic Resonance Imaging of the brain
45840614|NCT05235906|Drug|Surufatinib+Sintilimab|Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody Sintilimab injected intravenously 200mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
46040011|NCT04724928|Radiation|Metastasis directed therapy (MDT)|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Concurrently, the oligometastasis will be treated with stereotactic body radiotherapy or metastasectomy.
46040012|NCT04724928|Drug|Immunotherapy|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards immunotherapy will be initiated and regular follow up will be performed.
46040013|NCT04724928|Procedure|Standard of care|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards regular follow up is performed.
46040014|NCT02728570|Other|High Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing high levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
45474475|NCT01177085|Behavioral|Weight-loss and weight-maintenance diets|Participants will be given a personalized diet plan, with or without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
46040015|NCT02728570|Other|Low Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing low levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
46040016|NCT02728492|Drug|Quisinostat|
46040017|NCT02728492|Drug|Paclitaxel|
45343860|NCT02940925|Other|Drug: Taxol,cisplatin and capecitabine|Taxol, cisplatin and capecitabine as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
46040018|NCT02728492|Drug|Carboplatin|
46040019|NCT02728492|Drug|Gemcitabine|
45343861|NCT02940925|Other|Drug: Cisplatin and 5-Fluorouracil|Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
45343862|NCT02915705|Biological|burosumab|solution for subcutaneous (SC) injection
45343863|NCT02915705|Drug|Oral Phosphate Supplement|oral tablet; oral solution; oral powder
45343864|NCT02915705|Drug|active vitamin D|tablet, oral solution
45343865|NCT02891278|Drug|Sertraline|"Sertraline is a selective serotonin reuptake inhibitor (SSRI) that is FDA approved to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder.~Sertraline will be administered orally twice a day starting on day -3. Sertraline will be administered at one of 4 pre-defined dose levels in the following dose-escalation: 50 mg daily, 50 mg twice a day, 50 mg every morning (QAM) and 100 mg every evening (QPM), 100 mg twice a day. 100 mg QAM and 150 mg QPM."
45343866|NCT02891278|Drug|Cytosine arabinoside|"Cytarabine is a cytotoxic chemotherapy approved for use in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelogenous leukemia. It is also approved to prevent and treat meningeal leukemia. Cytarabine kills cells in S-phase through inhibition of DNA polymerase, as well as by halting DNA synthesis after its incorporation into DNA.~Cytosine arabinoside (Ara-C) will be administered as a 72 hour intravenous continuous infusion (IVCI) beginning Day 1 of therapy and again beginning Day 10 of therapy. The total dose of ara-C for each 72 hour period is 2 gm/m2 (0.667 gm/m2/24 hours)."
45474476|NCT04525378|Other|Mesenchymal stromal cell-based therapy|Intravenous administration of MSCs, performed as single dose (high dose group) or repeated after 48 h (low doses; intermediate dose)
45474477|NCT05507424|Procedure|Prone Positioning|Newborn will be prone position for 30-60 seconds during delayed umbilical cord clamping
45840615|NCT05235594|Device|Wearable sensor|The patients will be asked to wear a smart shirt. The shirt is designed with multiple sensors and electrodes fully embedded which engender 6 different measurement flows continuously. The smart t-shirt system is washable, and patients can wash and dry this t-shirt anytime, thus the shirt can be worn repeatedly.
46040020|NCT02728492|Drug|Cisplatin|
46040021|NCT02726776|Other|Suspension in a harness|
45474478|NCT05507424|Procedure|Supine Positioning|Newborn will be supine position for 30-60 seconds during delayed umbilical cord clamping
45474479|NCT03858803|Behavioral|Families Matter 2|Parents training in communication, youth sexual development, parental monitoring, parental use of positive reinforcement, risks facing adolescents and their management.
46040022|NCT02726776|Other|Climbing|
46040023|NCT02726152|Procedure|Polymer clips for closure of the appendiceal stump|Application of polymer clips to the appendiceal stump
46040024|NCT02726152|Procedure|Endoloops for closure of the appendiceal stump|Application of endoloops to the appendiceal stump
45343867|NCT02891278|Procedure|allogeneic stem cell transplantation|Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to a patient after high-intensity chemotherapy or radiation.
45343868|NCT02843308|Behavioral|Facilitated group therapy with behavioral practice; 18 weeks|Facilitated group therapy for hoarding disorder with behavioral practice
45343869|NCT02807181|Drug|Cisplatin-gemcitabine|Systemic chemotherapy
45343870|NCT02807181|Device|Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)|SIR-Spheres microspheres followed by systemic chemotherapy
46040025|NCT02726308|Drug|Dexamethasone|5 mg I.V. Dexamethasone just before induction
46040026|NCT02726308|Drug|10 ml/kg Ringer's lactate|Intra-operative 10 ml/kg Ringer's lactate solution .
46040027|NCT02726308|Drug|30 ml/kg Ringer's lactate|Intra-operative 30 ml/kg Ringer's lactate solution .
46040028|NCT02728414|Dietary Supplement|probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
46040029|NCT02728414|Dietary Supplement|placebo|the patients in this arm will receive placebo intervention
45343871|NCT02771275|Device|Harpoon Medical Device|It is expected that the Harpoon Medical transapical suturing device will be a valuable treatment alternative for patients suffering from mitral valve regurgitation because it can access the left ventricle with a small shaft or via a small valved introducer with a secure anchoring mechanism that can be deployed anywhere on the mitral valve leaflet.
45840616|NCT05215860|Behavioral|Tobacco and areca nut cessation counselling with standard management for Oral Potentially Malignant Disorders|WHO toolkit for Tobacco cessation (5A's and 5R's model)
45840617|NCT05215860|Other|visual exposure to personal intraoral photographs of oral lesions at baseline and review|Chairside digital intraoral photographs of oral potentially malignant disorder with smart phone and showing the photograph to the participant explaining the abnormal areas of concern
46040030|NCT01037244|Drug|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
46040031|NCT01037244|Drug|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
46040032|NCT03058588|Genetic|Analysis with molecular biology|Molecular screening by next generation sequencing (NGS) platform, for known and unknown mutations potentially associated with the disease
46040033|NCT00833989|Drug|GSK249320|I.V. infusion
46040034|NCT00833989|Drug|PLACEBO|Placebo
46040035|NCT02728180|Drug|Xingnaojing injection|Xingnaojing injection (20 ml), IV (in the vein), every 12 hours for 10 days.
46040036|NCT02728180|Other|Standard care|Guidelines-based standard care for acute ischemic stroke.
45343872|NCT02768870|Device|Harpoon Artificial ePTFE Chords|It is anticipated that use of the Harpoon device could achieve similar outcomes to open cardiac surgery while decreasing the invasiveness of mitral valve repair.
46040037|NCT02873832|Biological|Blood sample|
46040038|NCT02873832|Other|Flow cytometry|
46040039|NCT02873832|Other|western blot|
46040040|NCT02728024|Other|Missing items, Errors in Completion, Difficulties|
46040041|NCT00627432|Drug|gemcitabine hydrochloride|
45343873|NCT02761811|Device|SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator|Radiofrequency ablation of renal arterial sympathetic nerves
46040042|NCT00627432|Drug|oxaliplatin|
45343874|NCT02750618|Biological|Burosumab|solution for subcutaneous injection
45343875|NCT02745002|Device|navigated bronchoscopy|
45684291|NCT04395976|Other|Ayurveda|The Ayurveda intervention is multimodal and following the principles of Ayurveda as a whole medical system, each participants will be treated with individualised care. From the range of proven Ayurvedic Herbs, combination will be decided based on individual participants, his symptoms and his personality.
45343876|NCT02716116|Drug|TAK-788|TAK-788 capsules.
45474480|NCT03858803|Behavioral|Living as a Safer Teen|Prevention intervention for adolescents 13-18 that provides information, motivation, and behavioral skills to prevent STIs, HIV, and unplanned pregnancy.
45474481|NCT03371134|Biological|Harvesting of muscular biopsies|Muscular biopsies will be harvested during surgery; them satellite cells will be isolated and characterized in vitro.
45840618|NCT05206812|Drug|durvalumab|"durvalumab 1500 mg QD*~Surgery within 1 to 8 weeks - 4 cycles of durvalumab 1500 mg/m2 (Day 1, Day 8)+cisplatin 80 mg/m2 (Day 1) q3wks -durvalumab 1500 mg q4wks (Maximum of 10 cycles)"
45840619|NCT05174988|Procedure|Angle stitch|Surgeon will use 0 polyglactin 910 suture on a tapered needle to place figure of 8 sutures on both (left and right) vaginal cuff apexes.
45840620|NCT05172648|Other|oral spry|Pour sterile distilled water into a 30ml small-capacity spray bottle and spray 4 times at the patient's mouth. They are on the tongue and under the tongue, the left side and the right side of the mouth. The same spray bottle is used by the same person. Consistent dosage and strength.
46040043|NCT02726230|Behavioral|Ananya|The Ananya program was developed and implemented via a partnership of the Bill and Melinda Gates Foundation and the Government of Bihar as a means of improving reproductive, maternal, newborn and child health (RMNCH) outcomes in the state, in particular focusing on improving health behaviors and service utilization in the final trimester of pregnancy and early postpartum period. Ananya was designed as a series of supply- and demand-side efforts to improve health. Efforts were focused on strengthening outreach services in quantity and quality, improving quality of facility services, and mobilizing communities to improve health behaviors. The Ananya program included training, mobilizing, and monitoring of government frontline health workers (FLWs, including anganwadi workers- AWWS, auxiliary nurse midwives- ANMs, and community health workers-ASHAs) to increase quantity and quality of home visits for RMNH screenings and services, and media messages to increase demand for services.
45343877|NCT02616432|Device|Tomosynthesis|Three-dimensional imaging of both breasts in standard CC and MLO views
45343878|NCT02552823|Other|Group1|
45343879|NCT02552823|Other|Group2|
45343880|NCT02537431|Biological|burosumab|solution for subcutaneous injection
45343881|NCT02526160|Biological|burosumab|solution for SC injection
45343882|NCT02526160|Other|Placebo|saline solution for SC injection
45343883|NCT02515383|Other|Interview|Complete cognitive debriefing interview
45343884|NCT02515383|Other|Quality-of-Life Assessment|Ancillary studies
45343885|NCT02515383|Other|Questionnaire Administration|Complete MDASI questionnaire
45343886|NCT02454543|Procedure|Radical prostatectomy|Study participants randomized in the intervention arm receive best systemic therapy in addition to radical prostatectomy with extended lymphadenectomy. It is not crucial whether the radical prostatectomy is performed open or robot-assisted.
45343887|NCT02454543|Drug|Best systemic therapy|"For the antiandrogenic therapy a non-steroidal antiandrogen (e.g. flutamide, bicalutamide) or a gonadotropin-releasing hormone (GnRH) analogues (e.g. goserelin, leuprolide) are available.~The selection of best systemic therapy is up to the judgment of the treating urologist."
45474482|NCT05180916|Device|TVNS|Cerbomed NEMOS
45474483|NCT03360994|Other|WATChmAN Active Surveillance|WATChmAN Active Surveillance uses an electronic tool used to provide active surveillance care to testicular cancer patients. This virtual active surveillance care is delivered with an identical schedule to in-person care without the need to come into clinic.
45684292|NCT03092050|Behavioral|Guided Imagery and Mindfulness|This is a behavioral intervention using guided imagery and mindfulness techniques.
45684293|NCT03092050|Behavioral|Facilitated Discussion|This is a behavioral intervention that involves discussion and group support.
45684294|NCT01926418|Behavioral|Planning tasks|"Implementation intentions: Participants are asked to specify when, where and how they plan to use condoms in the future.~Executive function training aims to improve planning ability and therefore aims to increase condom use planning."
45684295|NCT00984256|Drug|Atovaquone Proguanil|Volunteers will receive doses of atovaquone/proguanil (Malarone) or matching sugar pills.
46040044|NCT02727946|Other|optimal resuscitation|optimal resuscitation to achieve mean arterial blood pressure above 65 mmHG , Central venous pressure more than 8 mmHg , urine out put more than 0.5 ml /Kg/hour
45343888|NCT02432196|Device|Harpoon Medical Device|It is expected that the Harpoon Medical transapical suturing device will be a valuable treatment alternative for patients suffering from mitral valve regurgitation because it can access the left ventricle with a small shaft or via a small valved introducer with a secure anchoring mechanism that can be deployed anywhere on the mitral valve leaflet.
45343889|NCT02430740|Drug|recFSH|
45343890|NCT02384512|Drug|Azilect®|AZILECT® 1mg Tablets
45343891|NCT02366494|Drug|Bicalutamide|ANDROGEN BLOCKADE
45343892|NCT02366494|Drug|Leuprolide|ANDROGEN BLOCKADE
45343893|NCT02366494|Drug|Goserelin|ANDROGEN BLOCKADE
45343894|NCT02366494|Drug|Triptorelin|ANDROGEN BLOCKADE
45343895|NCT02366494|Drug|Docetaxel|Chemo hormonal therapy
45343896|NCT02366494|Drug|Abiraterone|Chemo hormonal therapy
45474484|NCT03360994|Other|In-person Active Surveillance|In-person active surveillance is the current recommended management option for all Stage I testicular cancer patients at Princess Margaret. Patients are monitored clinically with imaging and blood work, and active treatment only begins if relapse occurs.
45684296|NCT00984256|Other|Procedure - malaria challenge|2) Procedure- Malaria Challenge- Volunteers will be exposed to bites of infectious mosquitoes with the intention of causing malaria infection. Volunteers infected with malaria will undergo approved treatments for malaria.
45684297|NCT00984022|Device|Type of dressing - Iodoform|Dressing for packing a cutaneous abscess
45684298|NCT00984022|Device|Type of dressing - Aquacel|Aquacel dressing
45343897|NCT02366494|Drug|Apalutamide|Nonsteroidal antiandrogen medication
45343898|NCT02366494|Drug|Enzalutamide|Nonsteroidal antiandrogen medication
45343899|NCT02333136|Device|raman spectroscopy (LighTouch)|near infrared light will be shone upon a fingerbed capillary and light scatter measured using in vivo raman spectroscpy
45343900|NCT02311933|Drug|Endoxifen Hydrochloride|Given PO
45343901|NCT02311933|Other|Laboratory Biomarker Analysis|Correlative studies
45343902|NCT02311933|Other|Pharmacological Study|Correlative studies
45343903|NCT02311933|Drug|Tamoxifen Citrate|Given PO
45474485|NCT01177163|Drug|Placebo|one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
45474486|NCT01177163|Drug|JNJ 28431754 300 mg/placebo|one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
45684299|NCT01926574|Behavioral|long rehabilitation program|
45684300|NCT01926574|Behavioral|short rehabilitation program|
45684301|NCT01926574|Behavioral|Acceptance and commitment therapy (ACT)|
45684302|NCT01922128|Drug|MC-1101, Placebo|One drop 0.5%; MC-1101; One drop 1.0% MC-1101, One drop Placebo
45684303|NCT01890265|Drug|Pamrevlumab|Solution for infusion
45684304|NCT01890265|Drug|Placebo|Solution for infusion
45684305|NCT01890265|Drug|Sub-Study: Pirfenidone|Pirfenidone concomitant therapy will not be provided by the Sponsor.
45684306|NCT01890265|Drug|Sub-Study: Nintedanib|Nintedanib concomitant therapy will not be provided by the Sponsor.
46040045|NCT01037088|Drug|Mild dose cannabis|3.53% THC by weight
46040046|NCT01037088|Drug|Low dose cannabis|1.29% THC by weight
46040047|NCT01037088|Drug|Cannabis|0.00% THC by weight
46040048|NCT02727790|Device|Stimulator|
46040049|NCT04189120|Procedure|Thoracic epidural analgesia , superficial serratus plane block and deep serratus plane block|neuroaxial thoracic epidural analgesia and regional analgesia supeficial and deep serratus plane blocks
46040050|NCT02725996|Biological|NK cells|Adjuvant adoptive immune therapy using NK cell 4 times
46040051|NCT02725996|Other|Curative therapy|Patients who had undergone curative treatment(surgical resection or radiofrequency ablation for HCC of pretreatment clinical stage I or II were eligible for this study with no adjuvant treatment
46040052|NCT02725762|Device|LT-300 Active (PBM)|
46040053|NCT02725762|Device|LT-300 Inactive (Sham)|
46040054|NCT02727712|Procedure|bilateral thoracic paravertebral block|group A under TPVB((TPVB T2/3+T5/6) by ropivacaine(0.3%,10ml*4)program
45343904|NCT02296450|Behavioral|Quality of Life (QoL) Assessment|Per physician's discretion, the patient (or, if applicable, patient's family member/ spouse/ caregiver for FDLQI) will complete one or more of the following dermatology-specific QoL instruments: Skindex-16, Skindex-29 DLQI (Dermatology Life Quality Index), FDLQI (Family DLQI) - for patient's family member/spouse/caregiver ONLY, CDLQI (Children's DLQI;Cartoon version) - for patient's under the age of 18 ONLY-written, CDLQI (Children's DLQI; Cartoon version) - for patients under the age of 18 ONLY - cartoon version, FACT-G (Functional Assessment of Cancer Thearpy-General), FACT-Melanoma (Functional Assessment of Cancer Therapy-Melanoma), SCI (Skin Cancer Index) FACT-EGFRI-18 (Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor-18), HFS-14 (Hand-Foot Syndrome) OMWQ (Oral Mucositis Weekly Questionnaire), ESTEEM, Hairdex , Skindex-29 modified for hair loss, Itchy QoL,CADS (Chemotherapy-induced alopecia distress scale)
45343905|NCT02257229|Procedure|Surgical|Surgery only
45343906|NCT02257229|Procedure|Non-Surgical|non-surgical methods such as, casting, bracing, physical therapy, and other.
46040055|NCT02727712|Device|Transesophageal Echocardiography（TEE）|"Apply Transesophageal Echocardiography（TEE）after anesthesia induction and draw 400ml autologous blood (Haemonetics®)used for the postoperative transfusion;~Goal-directed fluid management"
45343907|NCT02257229|Procedure|Non-surgical + surgical|Combination of non-surgical methods subsequently followed by surgery
45343908|NCT02244788|Device|SR™ PIP|
45840621|NCT05172648|Other|Cotton swab|Moisten the mouth with sterile distilled water with an oral cotton swab.
45840622|NCT05131152|Drug|Cyclosporine|0.05% cyclosporine Eye Drops; Sodium Hyaluronate Eye Drops, 0.02% Fluoromethalone Eye Drops.
46040056|NCT02727712|Device|Lung protection measure during the surgery（Dräger Primus）|Protective ventilation strategy(Low tidal volume about 6~7ml/kg, joint use of PEEP)
45343909|NCT02163577|Biological|burosumab|solution for SC injection
45343910|NCT02157610|Behavioral|Self-Help Materials|Participants receive free self-help materials mailed at baseline, 6, and 12 months. and a referral to the Oklahoma Quitline.
45343911|NCT02157610|Drug|Nicotine Patch|Participants receive a 12-week supply of nicotine patch. Nicotine patch regime based on participant's self-reported smoking rate. Participants who smoke >10 cigarettes/day receive 8 weeks of 21 mg, 2 week of 14 mg, and 2 week of 7 mg patches. Those who smoke <10 cigarettes/day receive 8 weeks of 14 mg and 4 weeks of 7 mg patches.
45343912|NCT02157610|Behavioral|REDCap|REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months.
46040057|NCT02727712|Drug|Anesthesia drugs during the surgery|"Bilateral thoracic paravertebral block before induction of anesthesia;~Fast channel anesthesia • Induction use Sufentanil 0.5~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2~0.6mg/kg; ②. Maintain use Sufentanil Hydrochloride for Injection 0.01~0.04ug/kg•min, Sevoflurane 0.5~1.5MAC（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg•h,Vecuronium 0.06~0.12mg/kg•h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over."
46040058|NCT02727712|Procedure|thoracic paravertebral block|group B under(TPVB T3/4)by ropivacaine(0.3%,20ml*2)program
45343913|NCT02157610|Procedure|Saliva Test|Saliva test performed at 3, 6, 12, and 18 months.
45343914|NCT02157610|Behavioral|Telephone Counseling Sessions|6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
45840623|NCT05131152|Device|oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy|oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy
46040059|NCT04118101|Drug|ESPB block|A total of 25 ml bupivacaine 0.5% will be injected into the ESP.
46040060|NCT04118101|Other|control|no ESPB will be given.
46040061|NCT02727868|Genetic|blood samples|
46040062|NCT01042236|Drug|Fesoterodine|Fesoterodine 4 mg and 8 mg and placebo - each dosed for 7 days with 7 day washout between dosing periods
46040063|NCT02725918|Drug|Pemetrexed|500 mg/m2,iv,d1,q3w,until PD
46040064|NCT02725918|Drug|Cisplatin|75 mg/m2,iv,d1,q3w,×4 cycles
45343915|NCT02157610|Drug|Nicotine lozenge|Participants receive a 12-week supply of nicotine lozenges. All participants receive 12 weeks of 2mg lozenges.
45343916|NCT02152254|Drug|Targeted Therapy Based on Molecular Profiling|Molecular profiling results are used to assign targeted therapy. Patients receive targeted therapy by participating in a Phase I or a Phase II clinical trial. If a clinical trial is not available, and a commercially available targeted therapy exists (Food and Drug Administration [FDA]-approved for another indication), patients can receive the FDA-approved drug.
45343917|NCT02152254|Drug|Standard-of-Care Therapy|Standard-of-care treatment regimen will be left to the discretion of the treating physician.
45343918|NCT02138617|Drug|5-Fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours, Day 1 and Day 15 .
45343919|NCT02138617|Drug|Leucovorin|200-400 mg/m2 IV over 2 hours, Day 1 and Day 15
45343920|NCT02138617|Drug|Irinotecan|IV infusion over 90 minutes, dosed at 180, 260 or 310 mg/m2 based on genotype.
45343921|NCT02138617|Drug|Bevacizumab|Bevacizumab (5 mg/kg IV infused as per institutional policy, IV, Day 1, 15)
45343922|NCT02078869|Drug|Progesterone in oil|Daily administration of 50 mg of IM Progesterone
45343923|NCT02078869|Drug|vaginal progesterone suppositories|Vaginal Promterium 200 mg , 3 times a day
45343924|NCT02070705|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
45343925|NCT02070705|Drug|Ferumoxytol|Given IV
45343926|NCT01946815|Drug|Atorvastatin|Lipitor dose titration will be followed by the result of LDL lab test until it meets the target level of LDL. IVUS(optional) and FFR during follow up CAG in 12 months will be measured to evaluate the effect of lipitor.
45343927|NCT01943318|Procedure|Liver biopsy|Histologic evaluation
45343928|NCT01943318|Device|Hepatic venous pressure gradient (HVPG) measurement|Hepatic venous pressure gradient (HVPG) measurement
45343929|NCT01937156|Drug|SP-01 (Granisetron Transdermal Delivery System)|SP-01 will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days.
45343930|NCT01937156|Drug|Granisetron Hydrochloride Tablet|Granisetron hydrochloride 1 mg tablets will be administered 1 hour before administration of chemotherapy at the first time, then taken 12 hours after the first dose later; 2 mg/day bid, for ≥ 2 days.
45343931|NCT01876524|Device|Transcranial Random Noise Stimulation|Random Noise Stimulation between 100 and 500 Hz and 400-500 microAmperes are applied over head in particular areas
45343932|NCT01821131|Other|muffin|
45343933|NCT01805804|Drug|placebo/valsartan|
45343934|NCT01718873|Drug|Bevacizumab|5 mg/kg every 2 weeks for up to 24 weeks. After 24 weeks, those patients without disease progression will receive bevacizumab 7.5 mg/kg every 3 weeks until progression of disease or unacceptable toxicity.
45343935|NCT01718873|Drug|Oxaliplatin|85mg/m2 IV every 2 weeks for up to 24 weeks
45343936|NCT01718873|Drug|levo-folinic acid|200 mg/m2 IV before 5-fluorouracil infusion, every 2 weeks up to 24 weeks
45840624|NCT05110872|Behavioral|Cigarette flavor restricted and e-cigarette flavor restricted|"Tobacco cigarettes will be available in the Experimental Tobacco Marketplace~Tobacco-flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
45840625|NCT05110872|Behavioral|Cigarette flavor restricted and e-cigarette flavor unrestricted|"Tobacco cigarettes will be available in the Experimental Tobacco Marketplace~Tobacco-flavored and a range of flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
45343937|NCT01718873|Drug|5-fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV infusion over 46 hours, every 2 weeks for up to 24 weeks (given in mFOLFOX-6 schedule)
45343938|NCT01718873|Drug|Capecitabine|1000mg/m2 by mouth, twice a day for 10 days, every 2 weeks for up to 24 weeks(given in mOXXEL schedule)
45343939|NCT01612351|Drug|Carboplatin|Weekly carboplatin given intravenously for 6 weeks during induction chemotherapy.
45343940|NCT01612351|Drug|Paclitaxel|Weekly paclitaxel given intravenously prior to carboplatin infusion for 6 weeks during induction chemotherapy.
45343941|NCT01612351|Drug|Lapatinib|Lapatinib (1000mg) taken by mouth once a day either one hour before or one hour after a meal for 6 weeks during induction chemotherapy. Participants deemed high risk following transoral surgery will additionally take lapatinib daily concurrently with their chemoradiation therapy.
45343942|NCT01612351|Drug|Cisplatin|Weekly cisplatin given intravenously for 6 weeks concurrent with ipsilateral radiation. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
45343943|NCT01612351|Drug|Cisplatin|Cisplatin given once every 3 week cycle intravenously for 5-7 weeks concurrent with bilateral radiation and daily lapatinib. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
45343944|NCT01612351|Radiation|Ipsilateral Radiation|After transoral surgery, subjects deemed medium risk will receive ipsilateral radiation as per standard of care 5 days/week for 6 weeks concurrent with weekly cisplatin.
45343945|NCT01612351|Radiation|Bilateral Radiation|After transoral surgery, subjects deemed high risk will receive bilateral radiation as per standard of care 5 days/week for 5-7 weeks concurrent with cisplatin every 3 weeks and daily lapatinib.
45840626|NCT05110872|Behavioral|Cigarette flavor unrestricted and e-cigarette flavor restricted|"Tobacco and menthol cigarettes will be available in the Experimental Tobacco Marketplace~Tobacco-flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
46040065|NCT02727634|Other|Comparison cardiac power and cardiac power output at different time points in the perioperative period|The intervention is a comparison between two methods of calculating the heart's energy delivery, cardiac power, measured in watts. A tertiary measurement is calculation of arterioventricular coupling. All patients will have cardiac power output calculated through the use of Doppler echocardiography. The echocardiography based cardiac output will be done through the velocity time integral of the left ventricular outflow tract (LVOT). This will be compared against total power as measured by our Ultrapower approach which involves instantaneous doppler measurement of cardiac output through LVOT multiplied with simultaneous radial artery pressure. This and ejection fraction (for calculation of ventriculoarterial coupling) will be recorded at rest in neutral position preoperatively, directly post operatively and the day after operation. Directly postoperatively the power measurements will also be repeated in Trendelenburg and anti Trendelenburg position.
45343946|NCT01612351|Procedure|Transoral Surgery|Transoral resection by robotic or microscopic approach, which will be at the discretion of the treating surgeon.
45474487|NCT01177163|Drug|JNJ 28431754 100 mg/placebo|one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
45684307|NCT01926652|Drug|candesartan cilexetil 32mg, amlodipine 10mg|"Part A: Treatment A (candesartan), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.~Part B: Treatment A (Amlodipine), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover."
45840627|NCT05110872|Behavioral|Cigarette flavor unrestricted and e-cigarette flavor unrestricted|"Tobacco and menthol cigarettes will be available in the Experimental Tobacco Marketplace~Tobacco-flavored and a range of flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
45343948|NCT01543698|Drug|LGX818|
45343949|NCT01543698|Drug|MEK162|
45343950|NCT01543698|Drug|LEE011|
45343951|NCT01511250|Biological|TDV|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
45343952|NCT01511250|Biological|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
45343953|NCT01424566|Drug|Nabiximols|
45343954|NCT01424566|Drug|Placebo (GA-0034)|
45343955|NCT01367561|Drug|Naloxone|
45847558|NCT03821376|Drug|Contrast enhanced ultrasound with Lumason|Following consent, they will undergo contrast enhanced ultrasound of their known renal mass(es). This will be performed at University hospital following intravenous administration of Lumason (2.5 mL per injection, maximum of 2 injections per mass).
45343956|NCT01367561|Drug|IV Methylnaltrexone (MNTX)|
45343957|NCT01367561|Drug|Placebo|
45343958|NCT01361607|Drug|Nabiximols|
45474488|NCT05180604|Behavioral|experience learning programs of eHealth care|The experience learning programs of eHealth care was included six sections of activities. Six activities were conducted based on eHealth literacy framework and experience learning theory to improve patients' abilities to engage in eHealth care service. The outcome indicators were eHealth literacy, patient health engagement, the acceptance of eHealth care, eHealth usage status, and their learning experience
46040066|NCT02725606|Biological|Pegylated Recombinant Human G-CSF|subcutaneous
46040067|NCT02725606|Biological|GW003|subcutaneous
46040068|NCT02725684|Other|Observational study, no intervention|Observational study, no intervention
45343959|NCT01361607|Drug|Placebo (GA-0034)|
46040069|NCT02725450|Behavioral|Motor Imagery + Psychomotor Battery of fine motor skills|Subjects were randomly divided in two groups: a control group and an experimental one. The study procedures were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month. Motor imagery sessions were added on in the experimental group. Participants on the experimental group were asked to mentally imagine themselves recreating tasks they had performed earlier on the initial assessment.
46040070|NCT02725450|Behavioral|Psychomotor Battery of fine motor skills Practice|Subjects were randomly divided in two groups: in the control group were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month.
46040071|NCT04168060|Procedure|Crura dissection|The diaphragmatic crura, one of two tendon structures below the diaphragm, will be removed during the laparoscopic sleeve gastrectomy.
45343960|NCT01337089|Drug|Nabiximols|
45847559|NCT03686514|Biological|FLUARIX QUADRIVALENT|The FDA-approved, quadrivalent seasonal influenza vaccine that will be administered contains four distinct strains, two influenza A viruses and two influenza B viruses.
45343961|NCT01297400|Drug|Investigational Drug, MW-III|Topical application, twice a day
45343962|NCT01297400|Drug|Silvadene® Cream 1% [Silver Sulfadiazine]|Topical application, twice a day
45343963|NCT01276587|Drug|Vitamin D3|Oral vitamin D3 100,000 IU administered monthly for six months in children and adolescents with sickle cell disease
45343964|NCT01217580|Drug|0.5% ropivacaine|20ml each side of the hip of 0.5% ropivacaine into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
45474489|NCT03367234|Behavioral|Individual Therapy Sessions|One-on-one sessions with a counselor
46040072|NCT04168060|Procedure|Sleeve gastrectomy|Surgical weight-loss procedure in which the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature.
45343965|NCT01217580|Drug|0.9% sodium chloride|20ml each side of the hip of 0.9% sodium chloride into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
45343966|NCT00981396|Behavioral|EFT (Emotional Freedom Techniques)|EFT is a brief but efficacious stress-reduction intervention. It combines exposure, cognitive structuring, and somatic stimulation.
45343967|NCT00981396|Behavioral|CBT (Cognitive Behavioral Therapy)|CBT is a behavioral intervention that seeks to challenge and change negative client cognitions about events and life circumstances.
45343968|NCT00802646|Drug|saline|intrathecal preservative free normal saline, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested
45847560|NCT03314688|Behavioral|Dietary/Physical Activity intervention|Motivational counseling to follow established dietary and exercise guidelines.
45847561|NCT03314688|Behavioral|Usual Care|Standard follow-up care and educational materials. Lifestyle counseling offered at the conclusion of the trial.
46040073|NCT04168060|Procedure|Hiatal hernia repair|This involves tightening the opening in your diaphragm with stitches to keep your stomach from bulging upward through the opening in the muscle wall.
45343969|NCT00802646|Drug|fentanyl/bupivacaine/epinephrine|intrathecal 0.125% fentanyl/bupivacaine/epinephrine, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested The mother will then receive a new bag of fentanyl/bupivacaine/epinephrine.
45343970|NCT00505245|Other|Interview|Complete interview
45343971|NCT00505245|Other|Quality-of-Life Assessment|Complete quality of life assessment
45343972|NCT00505245|Other|Questionnaire Administration|Complete questionnaires
45343973|NCT00473707|Procedure|Active management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
45343974|NCT00473707|Procedure|Expectant management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
45343975|NCT00473707|Drug|Oxytocin and gentle cord traction with fundal massage|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
46040074|NCT02725294|Other|This is an observational study without an intervention|Not applicable. This is an observational study without an intervention.
46040075|NCT02727478|Other|HiBalance training program|The program consists of physiotherapist led highly challenging balance exercises, which are adapted and progressed on both a group and individual basis throughout the training period.
46040076|NCT00592501|Radiation|Proton/Photon Radiotherapy|Given once a day, five days a week, for seven weeks.
46040077|NCT00592501|Drug|Cisplatin|Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.
45684308|NCT03073954|Other|Working memory training|"The working memory intervention training programme consists of a domain-general cognitive working memory training programme. One training session will take 20 to 30 minutes, and participants will have to complete approximately 40 cognitive training sessions.~The sham treatment is the same as the intervention training however it does not increase in difficulty. Participants are presented with the same task at the same level of difficulty over and over again. Thus a training effect is not expected."
46040078|NCT00592501|Drug|Fluorouracil|Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.
46040079|NCT02727556|Behavioral|visual images|
45684309|NCT03073954|Behavioral|Standardised healthy lifestyle coaching|Participants will receive standardised healthy living coaching focusing on healthy diet and daily physical activity.
45343976|NCT00473707|Drug|Oxytocin|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
45343977|NCT00279500|Device|Argus 16 Retinal Stimulation System|The chronic retinal stimulation system is an implantable electronic device designed to provide electrical stimulation of the retina in order to elicit visual percepts in blind subjects.
45343978|NCT00233675|Drug|GABITRIL (tiagabine hydrochloride; CEP-6671)|
45684310|NCT01926730|Other|Restriction diet|Selected food items will be limited in the participants diet
45684311|NCT03070444|Device|CTC retainer|The CTC retainer consists of 0.8 hard Remanium® wire (Dentaurum, Germany) and is bonded with Tetric Flow (Ivoclar Vivadent, Liechtenstein) to the lower canines directly after debonding.
45684312|NCT03070444|Device|Essix retainer maxilla|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
45684313|NCT03070444|Device|Essix retainer mandible|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
46040080|NCT03097666|Device|C2 CRYOBALLOON SWIPE ABLATION SYSTEM|"The C2 CryoBalloon Swipe Ablation System (CryoBalloon Swipe) is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal diagnostic endoscopes."
46040081|NCT03072862|Device|Commercial Nucleus Cochlear Implant Systems|Commercially available Nucleus Cochlear Implant Systems, including Data Logging functionality
46040082|NCT02721628|Procedure|Epi-keratoplasty|Femtosecond laser assisted Epi-keratoplasty
46040083|NCT02721628|Procedure|Collagen Cross-Linking|Collagen Cross-Linking: Standard procedure, which is descriptor bellows: Corneal epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes
46040084|NCT02721628|Device|Femtosecond laser|Use in the epic-keratoplasty surgery
46040085|NCT02721472|Procedure|micro- and macro-circulatory vascular remodelling measures not practice in routine care|Vascular measures : reactive hyperaemia index (RHI) assessed by Endo-PAT, central aortic blood pressure, aortic augmentation index, carotid-femoral pulse wave velocity
45343979|NCT00202774|Drug|(capecitabine, oxaliplatin, 5-fluorouracil)|
45343980|NCT00114530|Biological|mHSCT|Hematopoietic progenitors were mobilized with G-CSF. After leukapheresis and CD34+ cell enrichment, the autologous product was cryopreserved. Fractionated TBI (800 cGy), CY (120 mg/kg) and equine antithymocyte globulin (90 mg/kg) were administered as previously reported (References provided in citation section of this ClinicalTrials.gov record: PubMed ID: 17452515 citation and 2.) PubMed ID: 12176878 citation).
45343981|NCT00114530|Drug|cyclophosphamide|An initial intravenous dose of 500 mg/m^2 was followed by 11 infusions of 750 mg/m^2 with mesna given for bladder protection.
45343982|NCT00107744|Dietary Supplement|Soy protein-milk protein-carbohydrate|40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
45343983|NCT00107744|Dietary Supplement|Milk protein-carbohydrate-soy protein|40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
45684314|NCT03070444|Procedure|Alginate impression|Alginate impressions are taken to made the cuspid-to-cuspid and Essix retainers, respectively. Dental casts are obtained at the debond appointment and at the follow-up visits after 6, 18 and 60 months.
45684315|NCT03070444|Other|Questionnaire|A questionnaire is completed at the follow-up visits.
45684316|NCT03110926|Drug|mFOLFOX6|Induction Chemotherapy
46040086|NCT02721472|Procedure|Biological measures not practice in routine care|Biological measures : Plasma DNA level, NETs (plasma nucleosome levels), Microparticules (MPs) (total, associated with red blood cells, neutrophils, platelets), haem (total and bound to MPs), Myeloperoxydase and elastase activity, neutrophils/DNA, Annexin A5, RNA and TSP1
46040087|NCT02721394|Behavioral|Functional Communication Training|Functional Communication Training (which aims to teach the child a communicative alternative to challenging behaviour) implemented by either the researcher or family carer.
46040088|NCT01040832|Drug|Cetuximab|Cetuximab weekly (initial dose 400 milligram per square meter [mg/m^2] over 120 minutes followed by 250 mg/m^2 intravenous infusion over 60 minutes) will be administered in 3-week treatment cycle until disease progression. The total treatment period will be approximately 18 months.
46040089|NCT01040832|Drug|EMD 1201081|EMD 1201081 weekly (0.32 milligram per kilogram [mg/kg] by subcutaneous injection) will be administered in 3-week treatment cycle until disease progression. Subjects who will discontinue cetuximab due to toxicity in cetuximab monotherapy, could continue to receive EMD 1201081 monotherapy until disease progression. The total treatment period will be approximately 18 months.
46040090|NCT02721550|Drug|Sodium Glycididazole|800mg/m2，dissolved in 100ml physiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 4 weeks course.
46040091|NCT02721238|Biological|20% Albumin|
46040092|NCT02721238|Other|Plasmalyte|
46040093|NCT02721004|Drug|Tocilizumab|Tocilizumab administered as an intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.
46040094|NCT02721160|Other|Nutrition PBF|"Nutrition PBF focuses on children under five years old. It follows the standard PBF model in Burundi and combines quantitative indicators to encourage an increase in service delivery (see Table below) and qualitative indicators. Quality of nutrition activities is assessed quarterly, and a bonus or penalty is applied to subsidies received by the facilities according to their quality score.~Table: Incentivized indicators~CHW level~nb of cases screened and referred to HC for acute malnutrition (AM)~nb of classes promoting good nutrition~HC level~nb of cases screened and cared for severe and moderate AM~nb of growth follow-ups~Hospital level~nb of treated severe AM cases with complications~length of the stay~All hospitals with nutrition services fall under the Nutrition PBF program. At lower levels, only HCs in the intervention group and the CHW that refer to them are subject to the Nutrition PBF."
45343984|NCT00107744|Dietary Supplement|Carbohydrate-soy protein-milk protein|40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks.
45343985|NCT00845338|Drug|Darifenacin (BAY79-4998)|Darifenacin 7,5mg tablets once daily for 14 days, darifenacin 7,5mg or 15mg once daily for 14 consecutive days
45343986|NCT00711360|Device|Intrathoracic impedance measurement|Intrathoracic impedance measurement by cardiac resynchronization therapy (CRT) devices and implantable cardioverter defibrillators (ICDs) (Lumax 540)
45343987|NCT00855634|Procedure|Resection of metastases|resection of the primary tumor, followed by resection of the liver metastasis/metastases
45343988|NCT00855634|Procedure|Resection of infiltrated veins|resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic
45684317|NCT03110926|Combination Product|Chemoradiation|Chemoradiation
45684318|NCT01928329|Drug|Exenatide (Bydureon®)|
45684319|NCT01928329|Drug|Placebo|
45684320|NCT01922206|Behavioral|TRACK Intervention|"TRACK Intervention~3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child"
45684321|NCT01922284|Biological|DNA|8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54
45684322|NCT01922284|Biological|MVA-C|1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54
45343989|NCT05673174|Diagnostic Test|Non-Invasive Estimation of Left Ventricular Diastolic Pressure|Modified blood pressure cuff used to detect arterial waveforms used for the estimation of LVDP
45343990|NCT00923962|Drug|Glucagon like peptide-1|0,1 pmol/kg/min
46040095|NCT04302090|Other|Regulated expiratory method|This method was originally a postpartum abdomino-perineal rehabilitation technique. It allows a functional abdominal rehabilitation by combining a regulated breath in a specific mouthpiece and an abdominal stimulation triggered by this same breath. The use of this method was extended to labor and childbirth. In fact, the application of the method during labor is based on the use of a flow regulating device (Winner Flow + URO-MG®). By regulating the flow of breath during a uterine contraction, it allows better pain management.
45343991|NCT00923962|Drug|Adenosine|20-40 microgram/minute
45343992|NCT00711438|Behavioral|Breathlessness Intervention Service (BIS)|BIS consists of a clinical specialist physiotherapist & palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social & physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); & pharmacological review. This BIS seeks to enhance self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs & allied health professionals (with medical consent).
45684323|NCT01922284|Biological|CN54rgp140|100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54
45684324|NCT01922284|Biological|GLA-AF|5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant
45684325|NCT01890109|Biological|Erenumab|Administered via subcutaneous injection.
45840628|NCT04982718|Diagnostic Test|OraQuick® HCV Self-Test|"Self-testing will be performed using the OraQuick® HCV Self-Test manufactured by OraSure Technologies Inc., USA. Modified IFU developed by the manufacturer will be used to adapt the below professional use kits to a self-test: the OraQuick® HCV Rapid Antibody Test is prequalified by WHO and CE marked for professional use (sensitivity 98.1%, specificity 99.6%).~As it is not approved for self-test use in Malaysia, the OraQuick® HCV Self-Test kits provided to participants in the intervention group will be labelled for Research Use Only (RUO) and test results will not be used for patient management."
45474490|NCT03367234|Behavioral|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy techniques delivered by a behavioral health consultant (BHC)
45474491|NCT03367234|Behavioral|Medication-Assisted Treatment|Buprenorphine or Extended-Release Naltrexone
45474492|NCT03367234|Behavioral|Peer Recovery Specialist Support|Individual and/or group sessions with a certified peer recovery specialist
45474493|NCT03367234|Behavioral|Group Therapy Sessions|Group therapy sessions
45474494|NCT03367234|Behavioral|Psychiatric Consultation|Access to psychiatric consultation
45474495|NCT03367234|Behavioral|Contingency Management|Rewards for engagement in specified recovery behaviors
45684326|NCT01890109|Drug|Placebo|Administered via subcutaneous injection
45684327|NCT03108976|Other|Behavioral assessments|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
45684328|NCT03108976|Other|Magnetoencephalography (MEG)|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
45474496|NCT02524925|Procedure|fast track protocol|Evaluation of postoperative stress
45474497|NCT03918642|Behavioral|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
46040096|NCT04304196|Other|TEMPO|TEMPO is designed as a 7- to 10-week, web-based intervention containing 5 modules to pace patient-caregiver dyads' learning, avoid information overload, and allow sufficient practice time in-between modules . Each module is organized along six key components: needs assessment, tailored information and skills training, goal setting and action planning, motivational and social support, monitoring, automated feedback, and addressing time demands. Overall, modules aim to a) increase dyads' confidence in using strategies to address key psychosocial issues in the acute survivorship phase (e.g., dealing with stress and worry, communicating with partner and family, uncertainty management) and b) assist dyads in developing the self-regulatory skills necessary to meet the physical activity guidelines. Each module specifies a series of online (i.e. didactic material and interactive worksheets) and offline activities (i.e. practicing the proposed skills).
46040097|NCT04304196|Other|Usual care|Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team, but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices). Participants will be given access to the TEMPO website after having completed their final questionnaire, as thanks for participating.
46040098|NCT02832856|Behavioral|Healthy Relationship Education|RS+ is a widely-implemented healthy relationship education curriculum that aligns with the Georgia Department of Education performance standards in health education. The full curriculum features 12 lessons covering such topics as healthy relationships, dating violence prevention, communication skills, conflict management, and decision making.
45343993|NCT00711438|Behavioral|Best supportive care (Standard care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory) which may include specialist nurse input, and primary care services.
45847562|NCT03004248|Biological|Botulinum Toxins, Type A|Intramuscular Injection
45847563|NCT02529930|Biological|VB10.16 Immunotherapy (DNA vaccine)|Patients will receive 3 vaccinations of 3 mg VB10.16 at the pre-specified time points. VB10.16 will be administered intramuscularly in the area over the lateral deltoid muscle.
45343994|NCT02575092|Drug|Enalapril Maleate Tablets(as the program-based antihypertension)|
45343995|NCT02575092|Drug|Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension)|
45684329|NCT03108976|Other|Magnetic Resonance Imaging (MRI)|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
45684330|NCT03069976|Drug|Metronidazole|Flagyl x 14 days.
46040099|NCT02832856|Behavioral|Job Readiness Curriculum|"Beginning to Work it Out (BWIO) assists youth who are preparing for first-time employment. Topics include recognizing how personal beliefs and behaviors may be perceived in the workplace, as well as soft skills such as emotional self-management and problem-solving skills."
45343996|NCT02575092|Drug|Placebo|
45343997|NCT00851578|Device|WATCHMAN|WATCHMAN LAA Closure Device
45474498|NCT03918642|Behavioral|Cognitive Behavior Therapy|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
46040100|NCT02720770|Drug|norditropine simplex|
46040101|NCT02733406|Other|Target Controlled Infusion|
46040102|NCT02733406|Other|Velocity Controlled Infusion|
45847564|NCT00039780|Drug|BNP7787|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
46040103|NCT02720926|Drug|Xeloda,|Capecitabine (xeloda): 2000mg/m2, twice a day on Day 1-14;
45343998|NCT04097470|Drug|Decitabine|Decitabine dosage 20mg/m2 i.v.
45343999|NCT04097470|Drug|Midostaurin|Midostaurin 50 mg b.i.d.
45344000|NCT02575014|Drug|Preoperative hyperbaric oxygen|Subjects undergoing preoperative HBOT will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator, for two days. The two days will be the day of and the day immediately prior to the operation.
45474499|NCT03741335|Other|Resistance Training|Participants attend supervised, group-based moderate-intensity strength training program 3 times per week for 60 minutes per session.
46040104|NCT02720926|Drug|Oxaliplatin|Oxaliplatin: 130mg/m2 day 1 every 21days
46040105|NCT02720926|Drug|TKI258|4 dose levels of TKI258: 200mg, 300mg, 400mg, 500mg once daily, 5days on and 2 days off;
46040106|NCT00854581|Biological|PEG-interferon alfa-2b|Administered subcutaneously.
45344001|NCT04041934|Dietary Supplement|tryptophan|Each experimental session will be carried out over a week. Adolescents will take part randomly in three sessions. In order to limit inter-individual differences, the diet of the first 3 days will be fixed to the RDA followed by 3 days where dietary intake will be supplemented with different protein (PROT REF : ratio = 0,04 PROT1 : ratio = 0,07, session PROT2 : ratio = 0,11). Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio of proteins taken varies-double-blind between sessions. All proteins had the same dose and packages. Neither the researcher nor the participants were aware of the quality of the protein.
46040107|NCT00854581|Biological|Interferon alfa-2b|Administered intravenously.
45344002|NCT02573142|Behavioral|Bull City Healthy and Fit|Integrated model of child obesity treatment including clinical care plus community-based program for family-based experiential learning of healthy habits.
45344003|NCT02573142|Behavioral|Healthy Lifestyles Clinic|Clinic-only model of care including clinical care and educational materials
45344004|NCT02574234|Other|Determination of apelin and inflammatory cytokines|A blood sample will be conducted at baseline, on day 1 and day 7 post operative to meter inflammatory cytokines (IL1B, IL1-ra, IL6) and apelin.
45344005|NCT02574234|Other|Assessment of cognitive functions|Evaluation of preoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale.
45344006|NCT02574234|Other|Liquid sampling cerebrospinal|Determination of the concentrations of inflammatory cytokines and apelin in cerebrospinal fluid perioperatively.
46040108|NCT00854581|Drug|Valproic Acid|Administered orally.
45344007|NCT02574234|Other|Postoperative delirium research|Using the scale Confusion Assessment Method (CAM) for screening and delirium diagnosis. This research will be daily lasted, during the first 7 days postoperative.
45344008|NCT02574234|Other|Residual cognitive dysfunction research|Evaluation of postoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale realised on day 1 and day 7 postoperative. Realization of the IQCODE and IADL three months after the operation in a telephone interview.
45474500|NCT03741335|Other|Stretching|Participants attend a supervised, group-based supervised flexibility program 3 times per week for 60 minutes per session
45474501|NCT03741335|Other|Tai Chi|Participants attend a supervised, group-based tai ji quan program where they perform an integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements 3 times per week for 60 minutes per session.
46040109|NCT00854581|Drug|Zidovudine|Administered intravenously during Induction Therapy; orally during Maintenance Therapy in all Phases (1, 2A and 2B).
46040110|NCT02720458|Other|Standardized gradual hypnotic taper|The gradual hypnotic taper is standardized and is adjusted depending on the hypnotic treatment and the initial weekly dose. The practitioner will give to the patient a calendar for the taper period with the specific dose for each day (name of hypnotic, quantity and dose of pills).
45344009|NCT00845494|Behavioral|cognitive behavioral intervention|The intervention will consist of an hour of cognitive behavioral education. The first 15 minutes spent discussing cases examples of medication errors. The next 15 minutes will include identifying old rules or assumptions nurses have about medication history obtainment. The next 15 minutes will be utilized reviewing a medication tool to be used, and the last 15 minutes will be discussing techniques to help nurse obtain information from elderly patients.
45847565|NCT00039780|Drug|Placebo|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
46040111|NCT02720458|Behavioral|Short-term simple self-help program|"The short-term simple self-help program consists in:~Restriction of time in bed~Stimulus control instructions~The restriction of time in bed would be delivered by an e-health tool (web site). The patient will have to connect to the web site with an individual connexion password. He will connect every day to complete an on-line sleep diary during the period of the simple short-term behavioural program (5 weeks). After this period, patients will have the choice to continue connecting to the website and using the program or to stop using the program."
45344010|NCT00855790|Other|evaluate the effectiveness of the RJ4 biopsy forcep versus the RJ3 biopsy forcep|Use of either the RJ3 or RJ4 biopsy forcep for colon polypectomy. will evaluate the effectiveness of removal of polyps less than 6 mm.
45474502|NCT03370978|Behavioral|Text Messaging|"To communicate with intervention patients after discharge from the ED, we will use a bidirectional text messaging service provided by another physician's research group within the University of Iowa. The nurse navigator will enter the patient's study identification number, first and last name and cell phone onto a secure study website established by this research group.~Patients will, as previously mentioned, have had their cell phone number tested in the text messaging system prior to leaving the Emergency Department (this includes the control group).~Patient's will receive a text message 3 days, and 1 day, prior to their scheduled follow-up appointment with Family Medicine (this appointment having been scheduled through the Emergency Department Nurse Navigators). Each text message will remind the patient of the date/time of their appointment, and provide them a link containing a map with the location of their appointment."
45684331|NCT00982930|Drug|Tobramycin inhalation powder|Tobramycin inhalation powder, 112 mg (4 capsules of 28 mg), inhalation capsules, b.i.d.
45684332|NCT03091816|Device|Computed Tomography Perfusion Imaging|Undergo DPCT
45684333|NCT03091816|Other|Laboratory Biomarker Analysis|Correlative studies
45684334|NCT03091816|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
46040112|NCT02720614|Radiation|Hypofractionated radiation/chemotherapy|Procedure: Radiation Therapy Drug: Vinorelbine Drug: Carboplatin Drug: Paclitaxel Drug: Cisplatin
46040113|NCT02720380|Other|Buteyko|Intervention will be held twice a week during 3 weeks.
45344011|NCT04197336|Device|Bariatric Embolization of Arteries with imaging visible Embolics|The BEATLES study is an investigator-initiated, prospective, doubleblind, randomized, sham-controlled study that will assess the impact of bariatric embolization on the systemic levels of obesity related hormones and, as a consequence, on weight loss. The goal of this study is to help treat obesity combining a lifestyle program and a minimally invasive, angiographic (i.e., through blood vessels) approach.
45344012|NCT04197336|Other|Control Arm|Participants randomized to the control arm will follow the same screening and pre-procedure assessment, and will also take the same pre-procedure medications. The procedural team instead will follow a prescribed simulated protocol that will mimic an actual embolization procedure.
45344013|NCT04042090|Device|Reducept, virtual reality|The VR serious game Reducept is a novel psychological VR intervention for treating chronic pain. It incorporates several psychological therapies into one application: hypnotherapy, mindfulness, ACT and EMDR. Reducept has been made in co-creation with patients, researchers, psychologists and developers and can be installed and played on a VR goggles. It consists of an education module and three games.
45344014|NCT04069650|Procedure|Free flap|Free flap reconstruction of the oral cavity
45344015|NCT00851734|Drug|voclosporin ophthalmic solution|0.02%, 0.2% t.i.d. or b.i.d.
45344016|NCT00716040|Behavioral|Social-psycho intervention to improve adherence to HAART|The intervention focus on the notion of scenes and scenarios to examine and discussing the experience of taking ARV medicines. In principle, such an approach provides a tool for conscientization, action and the invention of novel group and individual repertoires that may result in individual mobilization for improving adherence to treatment and reducing his/her vulnerability.
45344017|NCT00716040|Other|Usual care|The control group will be submitted to the usual care of the health service
45344018|NCT04019028|Device|low frequency rTMS + Navigation System|1Hz low-frequency rTMS stimulation over primary motor area using navigation system
46040114|NCT02720380|Other|Asthma education|Educational interventions in relation to asthma will be given to children assigned to the control group.
46040115|NCT00833911|Drug|Tramadol Once A Day|
45344019|NCT04019028|Device|only low frequency rTMS|1Hz low-frequency rTMS stimulation over primary motor area
45344020|NCT04019028|Device|Sham low frequency rTMS + Navigation System|1Hz low-frequency sham rTMS stimulation over primary motor area using navigation system
45344021|NCT00845572|Behavioral|Consta Club|Biweekly group for patients receiving Risperdal Consta injections. Each 45 minute group includes socialization time, goal-setting, illness and medication education, and refreshments.
45344022|NCT00851812|Behavioral|Exercise|Standard care monitoring
45344023|NCT00851812|Behavioral|Progressive walking and resistance exercise treatment|Home-based exercise : Progressive walking and resistance program
46040116|NCT02719756|Drug|Metformin|Metformin tablets 1000 mg
46040117|NCT02719756|Drug|Dapagliflozin|Dapagliflozin 10 mg tablets
46040118|NCT02719756|Drug|Metformin up-titration|
46040119|NCT02719678|Other|General health checks|The intervention group is invited to up to three general health checks over a 10-year period
45344024|NCT00711906|Drug|Cotrimoxazole|Cotrimoxazole
45344025|NCT00711906|Drug|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine
45344026|NCT00851968|Procedure|Pringle's Maneuver|The entire hilar pedicle was encircled with a rubber tape to perform a Pringle maneuver with a tourniquet.
45684335|NCT03088540|Drug|Pemetrexed|Patients will be administered pemetrexed chemotherapy as per protocol with either cisplatin or carboplatin
45684336|NCT03088540|Drug|Paclitaxel|Patients will be administered paclitaxel chemotherapy as per protocol with either cisplatin or carboplatin
46040120|NCT01125293|Drug|Everolimus|
46040121|NCT01125293|Drug|Rituximab|
46040122|NCT01125293|Drug|Bortezomib|
45847566|NCT05101746|Drug|Nitric Oxide (NO) 20 part per million (ppm)|Nitric oxide will be mixed into the gas flow of the cardiopulmonary bypass (CPB) oxygenator, which will be kept at 1-3 L/min to allow for the desired NO delivery rate. NO levels will be maintained at 20ppm using a NO delivery system (INOmax, Mallinckrodt).
46040123|NCT02702986|Procedure|immunostimulating Interstitial Laser Thermotherapy|Through a laparotomy a laser device will be inserted into the locally advanced pancreatic cancer.
46040124|NCT02702986|Device|Laser|
45684337|NCT03088540|Drug|Gemcitabine|Patients will be administered gemcitabine chemotherapy as per protocol with either cisplatin or carboplatin
45684338|NCT03088540|Drug|Cisplatin|Administered with either Pemetrexed, Paclitaxel or gemcitabine.
46040125|NCT02719912|Device|mitral valve replacement|transcatheter mitral valve replacement
46040126|NCT05111483|Other|Tupler technique|"The subjects with DRA will receive Tupler's technique treatment plan for 18 weeks in which four steps will be followed.~Repositioning with diastasis rehab splint :~Protect the connective tissue~Tupler's technique exercises (elevators, contractions, standing pelvic tilt, head lifts, leg slides, low back stretch) with 10 repetitions for each exercise.~Diastasis safe exercises program to maintain the gains"
45344027|NCT00851968|Procedure|Hemihepatic vascular Clamping|The portal vein,hepatic artery ,and biliary duct were dissected in the hilum by opening the peritoneal fascia. Either the right or left portal pedicle was isolated and encircled with a tourniquet or clamped with Shatinsky clamp. Separate clamping of accessory left hepatic artery was performed when present in controlling the left hemihepatic portal traid.
45684339|NCT03088540|Drug|Carboplatin|Administered with either Pemetrexed, Paclitaxel or gemcitabine.
45684340|NCT03088540|Drug|cemiplimab|Patients will be administered cemiplimab as per protocol.
45684341|NCT03069664|Procedure|ERCP|endoscopic retrograde cholangiopancreatography
45684342|NCT03069664|Device|Covered Self-expandable Metal Stent|Pancreatic duct stent
45684343|NCT05602168|Other|experimental:Acute leukemia/myelodysplastic or myeloproliferative disease|blood sampling, bone marrow aspirate and buccal swab
46040127|NCT05111483|Other|conventional therapy|"The subjects with DRA will receive conventional physical therapy treatment for 16 weeks in which researcher will follow these steps:~Tie a scarf around abdomen while performing exercises~Exercise program for diastasis recti abdominal muscles; sit ups, reverse sit ups, reverse trunk twist and U-seat exercises. (10 repetitions for each exercise)~Respiratory rehabilitation manoeuvre"
46040128|NCT02719834|Drug|Acetaminophen|Acetaminophen (regular strength) will be provided in two capsules: 325 mg, take two capsules 3 times/day for 28 days (1,950 maximum daily dose). Capsules will be labeled to maintain blinding.
46040129|NCT02719834|Other|Placebo|The placebo will be provided in the same type of capsules as the acetaminophen. Two capsules, given 3x a day for 28 days. Capsules will be labeled to maintain binding.
46040130|NCT04311203|Behavioral|Mental Health First Aid|The intervention has 3 parts:1.Two-day MHFA training provided by MHFA England. A manualised programme designed to provide individuals with: an in-depth understanding of mental health and the factors that can affect wellbeing, practical skills to spot triggers and signs of mental health issues, confidence to step in, reassure and support a person in distress, enhanced interpersonal skills such as non-judgemental listening, knowledge to help someone recover their health by guiding them to further support - whether that's self-help resources, through their employer, the NHS, or a mix. 2.Raising awareness of the presence of MHFA in the organisation. 3.The application of MHFA to participants in the workplace using the manualised five-stage approach, ALGEE: Approach the person, assess and assist with any crisis; Listen and communicate non-judgementally; Give support and information; Encourage the person to get appropriate professional help and Encourage them to seek other forms of support.
46040131|NCT02719600|Behavioral|Virtual reality|Evaluation of observational motor learning using virtual reality
46040132|NCT02719288|Other|CLARIX® CORD 1K graft|
46040133|NCT02719210|Biological|High Volume Plasma Exchange|
46040134|NCT02719210|Drug|Hypertonic 3% saline|
45684344|NCT00981682|Drug|SER120|once a day treatment of nocturia
46040135|NCT02719210|Drug|Mannitol|
46040136|NCT02719210|Device|Elective positive pressure ventilation|
45684345|NCT01903993|Drug|Docetaxel|Participants received starting dose of 75 mg/m^2 every three week (q3w) until disease progression, unacceptable toxicity or death. Dose modifications were according to the locally approved label. Participants randomized to receive docetaxel had to be premedicated with corticosteroids according to local practice.
46040137|NCT02719132|Drug|Dapagliflozin|Dapagliflozin, 10 mg
46040138|NCT02719132|Drug|Metformin|Metformin, up to 2500 mg
46040139|NCT02719054|Behavioral|Cognitive behavioral therapy: Alter of negative thinking, positive thinking and social support and psychosocial stimulation: play stimulation and parenting|"A:Cognitive Behavioral Therapy specifically focused on changing thinking style toward positive and not associated with any medication. CBT found to be effective in managing or treating not only depression, also a variety of other conditions-e.g. mood, personality, stress, eating habit, tic etc.~B: Psycho social stimulation will follow a set of culturally appropriate, semi-structured, child's age appropriate curriculum."
46040140|NCT02718820|Drug|Docetaxel|Docetaxel 75mg/m2; q21
46040141|NCT02718820|Drug|Pembrolizumab|Pembrolizumab 200mg, q21
46040142|NCT02718976|Procedure|Ultrasound/MR image fusion guided lumbar plexus block (Shamrock)|
46040143|NCT02718976|Procedure|Ultrasound guided lumbar plexus block (Shamrock)|
46040144|NCT02718976|Drug|Lidocaine-epinephrine added gadoterate meglumine|Perineural injection of 20 ml 2% lidocaine with 0.0005% epinephrine added 1 ml of gadoterate meglumine (0.13 ml) and sodium chloride (NaCl, 0.87 ml). The 1 ml of gadoterate meglumine-NaCl is added to the local anesthetic prior to the perineural injection in order to enhance visualization of the local anesthetic on MRI scanning after the intervention.
46040145|NCT02718664|Other|Test meal (breakfast)|Standardized test meal, in accordance with high-fat and high-calorie meal as described in the FDA guidance, but ingredients are changed to Dutch standards and ingredients are added that are expected to have the largest effects on dihydrouracil and uracil levels
46040146|NCT02718742|Other|Laboratory Biomarker Analysis|Correlative studies
46040147|NCT02718742|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
45344028|NCT00851968|Procedure|Portal vein occlusion|The proper hepatic artery was dissected first from the duodenohepatic ligament, portal pedicle was blocked with a rubber encircled through the posterior wall of proper hepatic artery and the bottom of duodenohepatic ligament.When aberrant hepatic arteries emerging from the superior mesenteric artery are found in duodenohepatic ligament ,they should be dissected and kept unobstructed.
46040148|NCT02718742|Other|Quality-of-Life Assessment|Ancillary studies
46040149|NCT02718508|Behavioral|eParenting|The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
46040150|NCT02718430|Drug|VXM01|Oral immunotherapy targeting VEGFR2
46040151|NCT02718352|Other|Naturalistic Prospective Cohort|Follow subjects through 1 year of naturalistic buprenorphine treatment
45847567|NCT05101746|Other|Standard of care cardiopulmonary bypass|Cardiopulmonary bypass (CPB) will be performed using the departmental guidelines and standards. CPB will be performed using in a nonpulsatile flow with the System 1 Heart Lung Machine (Terumo Cardiovascular Systems, Ann Arbor, Mich). The maximum perfusion flow will be 200 ml/kg/minute. Blood pressure management will be selected based on the patient age and procedure. Temperature management will be to cool the patient 32 celsius (C).
45344029|NCT04502550|Drug|Propofol|Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.
46040152|NCT02718274|Device|OraQuick ADVANCE HIV I/II test kits, packaged for self-use (manufactured in Thailand)|Community based distribution of self-tests
46040153|NCT02718274|Other|Home-based initiation of ARVs|Home-based initiation of ARVs by study nurse linked to follow-up at clinic
46040154|NCT02717884|Drug|tranylcypromine|"TCP p.o., daily either 20, 40**, 60**, 80** mg/day, (28d/cycle)~**TCP doses will be slowly increased during cycle 1 and slowly decreased at end of treatment (for details see study protocol)"
46040155|NCT02717884|Drug|all-trans retinoic acid|45mg/m2 (days 10-28), CAVE: ATRA will be administered without interruption until inclusively cycle 3. At the beginning of the cycle 4 a nine-day break corresponding to the first nine days of the AraC treatment will be performed, thereafter the ATRA-therapy will be continued with a nine-day interruption every fourth cycle. That means that the therapy in cycles 1, 4, 7, 10, 13 etc. In other cycles ATRA will be given without interruption
46040156|NCT02717884|Drug|cytarabine|40mg s.c. (days 1-10)
46040157|NCT02718196|Behavioral|Sleep Training smartphone application|Every evening the application provides a list of the planned bedtime activities as well as the recommended bedtime. The steps are 1) positive bedtime routine 2) bedtime fading 3)addressing nocturnal feeding 4) extinction protocol
46040158|NCT04100512|Device|Oscillating Positive Expiratory Pressure Device|Aerobika® Oscillating Positive Expiratory Pressure (OPEP) device is a drug-free, easy to use, hand-held device with a proprietary pressure-oscillation dynamic that provides intermittent resistance and creates positive pressure and oscillations simultaneously. The Aerobika® OPEP device opens weak or collapsed airways to mobilize and assist mucociliary clearance to the upper airways where it can be coughed out.
46040159|NCT04100512|Device|Incentive spirometry|An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
46040160|NCT02717572|Radiation|Fludeoxyglucose F 18|
46040161|NCT02717572|Device|Positron Emission Tomography|
46040162|NCT02717572|Device|Computerized Tomography|
46040163|NCT02717572|Device|Magnetic Resonance Imaging|
46040164|NCT05041192|Dietary Supplement|Synaquell|7.9 grams of Synaquell are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
46040165|NCT05041192|Dietary Supplement|Placebo|7.9 grams of a placebo (that looks, smells, and tastes like Synaquell) are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
46040166|NCT02717806|Behavioral|PATHway|Patients will use the PATHway platform for 6 months
46040167|NCT02717026|Device|Optical coherence tomography|Sections including the retinal vasculature will be taken.
46040168|NCT02717026|Device|Fluorescein angiography|Video fluorescein angiography from one eye of each subject will be performed
46040169|NCT02717026|Device|Fundus photography|30 and 50 degree fundus images
46040170|NCT01121393|Drug|Gemcitabine+Cisplatin|Gemcitabine d1,8, Cisplatin d1, 21 days as a course, up to 6 courses.
46040171|NCT01121393|Drug|BIBW 2992|starting dose is 40 mg, in the event of no or minimal drug-related adverse events after one course, the dose will be increased to 50mg. in the event of certain drug related Adverse Event (AE), dose reduction will be increments of 10 mg, with the lowest dose being 20mg.
46040172|NCT02717338|Behavioral|Competence|Participants will be assigned to review our donor coping website that combines text, videos, and interactive features to directly address common donor fears and to offer advice on empirically-validated strategies to reduce fear, pain, and syncopal reactions.
46040173|NCT02717338|Behavioral|Autonomy|Participants will be assigned to receive a brief telephone interview that we have developed that encourages blood donors to reflect upon their unique motivations for giving and how the act of donating is consistent with their broader life goals and values.
46040174|NCT02717338|Behavioral|Relatedness|Participants will be asked to join a closed Facebook group for one month. The group encourages participants to discuss their experiences with blood donation, including such things as posting images of their donations and/or reasons for donating. Posts will be designed to encourage social interaction around donation experiences, identity formation and group affiliation.
45344030|NCT04227184|Drug|Trospium|Drug to treat overactive bladder
45344031|NCT04227184|Drug|Placebo oral tablet|Placebo tablet containing no active drug
46040175|NCT02717260|Device|transcranial random noise stimulation (tRNS) (Starstim)|subjects are stimulated 3 times in a day by transcranial random noise stimulation (tRNS) (Starstim). each 20 minutes stimulation are separated by a period of at least 30 minutes. before and after each stimulation, inhibition is evaluated by cognitive tests: go nogo test, stroop test, Hayling test and by the BIS 10 scale. During the stimulation, subjects compleat the STAXI and STAI scales. Cognitive tests are repeated 24 hours and 8 days after the stimulation to evaluate duration of the effect. Possible side effects will be notified throughout the protocol.
46040176|NCT02717182|Other|interviews|interviews
46040177|NCT02882477|Drug|Deferiprone|
45847568|NCT04961034|Procedure|kasai portoenterostomy|surgical creation of stoma between porta hepatis and jejunal loop
45847569|NCT04951518|Other|VAN Stroke Scale|V.A.N Stroke Assessment measures unilateral weakness with visual deficits, aphasia, and neglect in possible stroke patients
46040178|NCT02882477|Drug|Acetylcysteine|
46040179|NCT02882477|Drug|Sitagliptin and Metformin|
46040180|NCT04081168|Device|Stereotactic Body Radiotherapy|Patients will undergo Stereotactic Body Radiotherapy (SBRT)
46040181|NCT04081168|Device|Microwave Ablation|Patients will undergo Microwave Ablation (MWA)
46040182|NCT02716870|Other|Fructose-containing Sugars|An intervention in which calories from fructose-containing sugars are substituted, added, or subtracted in the diet
45684346|NCT01903993|Drug|Atezolizumab|Participants received atezolizumab of 1200 mg (equivalent to an average body weight-based dose of 15 milligram per kilogram [mg/kg]) which was administered by IV infusion q3w on Day 1 of each 21 day cycle. Participants were allowed to continue treatment beyond progression per response evaluation criteria in solid tumors (RECIST) v1.1 if they were experiencing clinical benefit per investigator, did not have a decline in performance status, did not have signs or symptoms of unequivocal progression, did not have tumor progression at critical sites, and signed an informed consent signature page acknowledging deferment any standard treatment options that may exist in favor of continuing atezolizumab.
45840629|NCT04982718|Diagnostic Test|First Response® HCV Self-Test|"Self-testing will be performed using the First Response® HCV Card Test (Self Test) manufactured by Premier Medical Corporation, India. Modified IFU developed by the manufacturer will be used to adapt the below professional use kits to a self-test: the First Response® HCV Card Test is CE-marked and currently under WHO review for professional use (sensitivity 100%, specificity 100%).~As it is not approved for self-test use in Malaysia, the First Response® HCV Self-Test kits provided to participants in the intervention group will be labelled for Research Use Only (RUO) and test results will not be used for patient management."
46040183|NCT04163224|Device|RibFix Advantage|Class II device in the United States; consists of bridges (with locking posts) and locking caps for the thoracoscopic fixation and stabilization of ribs. These implants are manufactured from commercially pure titanium and titanium alloys. When fully assembled, the bridge plate is placed on the underside of the rib (pleural cortex); the threaded locking posts extend through pre-drilled holes in the rib, and the locking caps are fixed to the locking post on the anterior (cutaneous) side of the rib. The combined threaded locking post and cap provides for fixation of the bridge and stabilization of the fracture.
45344036|NCT04018950|Drug|ETX2514|intravenous infusion
45344037|NCT04018950|Drug|14C-ETX2514|intravenous infusion
45344038|NCT00845806|Other|MRI|All subjects will be asked to lay in an MRI for about an hour while reading Arabic diacritic characters
45344039|NCT00709410|Biological|rBS-WC vaccine|1 mg of recombinant cholera toxin B subunit and approximately 1 x 10^11 of inactivated whole cells of Vibrio cholerae O1 Inaba and Ogawa, classic and El Tor strains (6). The rBS-WC vaccine is supplied as 3 ml single-dose vials each with a sachet of sodium bicarbonate buffer. Buffer solution will be prepared by dissolving the sachets in drinking water (150 ml water for each sachet of sodium bicarbonate). The full dose of vaccine will be mixed with 40, 75, or 150 ml of buffer solution for persons 2 to 4 years, 5 to 11 years, and over 11 years old, respectively. The vaccine is recommended to be given in two doses with an interval of at least seven days and protection is conferred 7 to 10 days after the second dose.
45344040|NCT02545972|Drug|tacrolimus extended release|daily dosing of tacrolimus
45344041|NCT02574780|Other|complex physical therapy|Compare the standard treatment of lymphedema, by complex physical therapy versus TFC associated with the upper limbs strengthening exercises.
45344042|NCT02574780|Other|Evaluate treatment of lymphedema, with in the quality of life and depression|evaluate through the questionnaires fatigue and quality of life of patients with lymphedema (FACT- F and Inventory BECK)
45344043|NCT00852046|Drug|Dexmedetomidine|IV solution, 0.2 mcg/kg/hr or 0.6 mcg/kg/hr for a max of 5 days
45344044|NCT02573064|Drug|Colistin|
45344045|NCT02573064|Drug|Tigecycline|
45344046|NCT02573064|Drug|Vancomycin|
45344047|NCT00845884|Drug|Docetaxel, Cisplatin, Capecitabine, Bevacizumab|"Docetaxel 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~Cisplatin 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~Capecitabine 1,600 mg/m2/d PO, divided into two daily doses, on Days 1-14, Q:21 days.~Bevacizumab 7.5 mg/kg IV, on Day 1, Q:21 days."
45684347|NCT00981292|Dietary Supplement|EGCG|Acute oral administration of capsules containing either: 0mg, 135mg or 270mg. One dosage administered on each of three separate study days.
46040184|NCT02716792|Drug|Ibandronate|Participants will receive ibandronate, 6 mg via IV infusion, every 3 weeks for up to 9 cycles. The infusion interval will be either 15 or 60 minutes depending upon treatment group assignment every 3 weeks (9 treatment cycles in total).
45684348|NCT00981292|Dietary Supplement|Placebo|Pharmaceutical grade silica was utilized as placebo
45684349|NCT03065140|Other|Training or detraining|A period of detraining or a supervised exercise program.
45684350|NCT01927042|Behavioral|ECHOs plus TAU|A self-help DVD that provides information for carers on eating disorders and teaches coping strategies to carers.
45684351|NCT01927042|Behavioral|Treatment as Usual|Treatment as Usual at the Eating Disorder Services includes group psychotherapy and skills training, nutritional counselling, and meal support.
45840630|NCT04956276|Drug|ALXN1830|Administered as an SC infusion.
45840631|NCT04956276|Drug|Placebo|Administered as an SC infusion.
45684352|NCT01927510|Behavioral|Early mobilisation|
45498082|NCT03685812|Diagnostic Test|Autocad software|The participants will be prepared for image-capture data collection by putting four squared markers on leg and thigh.Each subject will extend his/her leg and make two angles from the resting position (90º) to the full extension, photos will be taken. The tested leg passively moved by the researcher through 20° to 60° of knee extension, the participant will be instructed to actively move that leg to the target angle and hold it in this position another photograph will be taken. The angles will be measured using the AutoCAD software. Knee JPS measurements will also be collected using an IKD by same steps
45684353|NCT00980044|Drug|Tramadol|Oral Medication
46040185|NCT02716636|Procedure|Slow placement of the tenaculum|Slow placement of the tenaculum on the cervix
45684354|NCT00980044|Drug|Placebo|Oral Medication
46040186|NCT02694016|Procedure|Remote ischemic preconditioning|A blood pressure cuff is placed around the right leg on the level of the thigh. Randomization is performed after this, using sealed envelopes with covariate balancing for age and sex. Regardless of the outcome of the randomization the cuff is left in place so as not to give any indication of which group the patient belongs to. If the patient is randomized into the remote ischemic preconditioning group (RIPC) then four (4) cycles of five (5) minute inflation are given after induction. Each cycle is followed by a five (5) minute interval of reperfusion. Cuff pressure should be 200mgHg at least (RRsyt + 100mmgHg) during the inflation periods.
45344048|NCT02574936|Procedure|A new surgical technique|"Description of a new surgical technique in pilonidal sinüs surgery in order to reduce dead space volume.~A flap extending across the cut (Karydakis) is prepared in medial edge of the wound, 1 cm deep and 2 to 3 cm to be towards the interior. Prepared flap is shifted to the medial and sutured to presacral fascia with vicryl 2/0. To reduce the volume of the dead space formed in the lateral, 5 mm skin is excised along the incision in the flap side. Skin is approximated with sutures in the form of intermittent, using 2/0 poliprolen. No drain used"
45344049|NCT00923806|Biological|PG13-CEA_TCR (Anti-CEA TCR PBL)|
45344050|NCT00923806|Drug|Aldesleukin|720,000 IU/kg intravenous over 15 minutes every 8 hours for up to 5 days
45344051|NCT00848068|Other|FID 114657|artificial tears
45344052|NCT00848068|Other|OPTIVE Lubricant Eye Drops|artificial tears
45344053|NCT00711984|Device|Herkulink renal artery Stent|renal artery stent
45344054|NCT00711984|Other|best medical therapy|All patients will receive best medical therapy according to current guidelines consisting in antihypertensive, antiplatelet, antidiabetic and lipid-lowering medication and in recommendation of lifestyle modification
45344055|NCT00856102|Behavioral|Exercise|Home-base walking program
45344056|NCT00856102|Behavioral|Control|Usual care
45498083|NCT05390151|Procedure|Laser treatment of anal fistula|using a radial laserprobe to treat transsphincteric fistula
45684355|NCT03049306|Drug|Propranolol Oral Tablet|Patients will receive Propranolol LA 80 mg PO at 7 PM before sleep (on CPAP withdrawal nights only)
45684356|NCT03049306|Drug|Placebo Oral Tablet|Patients will receive Placebo tablet at 7 PM before sleep (on CPAP withdrawal nights only)
45684357|NCT03049306|Device|CPAP|Patients will sleep in the lab wearing CPAP
45474503|NCT03858881|Behavioral|PROJECT PERSONALITY|"PROJECT PERSONALITY is self-administered by youth via Qualtrics and is 30 minutes in duration. The intervention includes five elements: 1. An introduction to the brain, including a lesson on neuroplasticity (how and why our behaviors are controlled by thoughts and feelings in the brains, which have potential for change); 2. Testimonials from older youths who describe their views that people's traits are malleable, given the brain's plasticity; 3. Additional vignettes written by older youths, describing times when they used growth mindsets to persevere through social and emotional setbacks; 4. A summary of selected scientific studies suggesting that personality can, and often does, change in positive ways over time; and 5. An exercise in which the participants write notes to younger students, drawing on scientific information to describe the malleability of people's personal traits"
45344057|NCT00718536|Drug|Addition of raltegravir 800 mg QD to HAART|Addition of raltegravir 800 mg QD to HAART
45344058|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses were suspensions of drug candidate. Doses were administered once daily for 10 consecutive days.
45344059|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
45344060|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
45344061|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
45498084|NCT05390151|Procedure|RAF|current golden standard in transsphincteric fistula surgery
45498085|NCT03689790|Procedure|sleeve gastrectomy|sleeve gastrectomy
46040187|NCT02359318|Procedure|Resin infiltration|Resin infiltration is done according to manufactures´ instructions after de-bonding of old brackets and prior bonding of new brackets.
46040188|NCT02359318|Procedure|Bonding and debonding of brackets.|Brackets (Gemini metal brackets (3M Unitek) are bonded and de-bonded by one clinician (Roberto Vogel) and using the same bonding and de-bonding techniques and materials for all patients. All brackets were finally de-bonded at the end of the treatment, with silicon impressions taken before adhesive removal.
46040189|NCT02716558|Other|ART Sealant Application|application of the ART sealant using high viscosity glass inomer cements.
45344062|NCT02572674|Other|Experimental follow up|Neuropsychological assessment (intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function)
45344063|NCT02572674|Genetic|Genetic sample|Blood samples
45344064|NCT00856336|Drug|DMXAA|DMXAA, given intravenously over 20 minutes. Patients were to each undergo six doses of treatment at weekly intervals, receiving each of six doses (300, 600, 1200, 1800, 2400 and 3000 mg/m2)
45344065|NCT00712062|Drug|Pemetrexed|500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
45344066|NCT00848146|Procedure|Endoscopically assisted Laparoscopic Cholecystectomy Surgery|Using endoscopic instruments a small incision will be made in the gastric wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The gallbladder will be removed through the stomach and out of the mouth. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the gastrotomy.
45498086|NCT03689790|Procedure|gastric bypass|gastric bypass
45498087|NCT03681756|Behavioral|WALK|Walking program
45498088|NCT05567757|Biological|Arteriovenous conduit implant|Study subjects will be implanted with an arteriovenous shunt for hemodialysis access in the upper extremity
46040190|NCT02716558|Other|Resin sealant application|application of the moisture tolerant sealant according to the manufacturers instructions.
46040191|NCT02716402|Radiation|Cerebral MRI and V/Q SPECT/CT|Cerebral MRI and V/Q SPECT/CT
45840632|NCT04946994|Behavioral|HIIT|The participant will walk/jog for 50 continuous minutes at 55% VO2peak. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 4 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
45344067|NCT04103970|Behavioral|Graded Activity and Pain Education (GAPE)|"GAPE is based on a cognitive behavioral perspective that human behavior is affected by behavioral, cognitive and affective factors, this include the patient's perception of and response to pain. The perspective is a psycho-social perspective which amplify and interact with the individual patient's pathology.~The overall theoretical perspective in GAPE is that fear of movement and/or lack of self-efficacy for exercise can potentially lead to disuse and sedentary behavior, a perspective modified from the fear-avoidance model. In this modified version the patients´ and the physiotherapists´ former experiences, knowledge, and beliefs are factors influencing on the patients´ experience of pain and thereby their self-efficacy for exercise and fear of movement."
46040192|NCT02716480|Behavioral|Mobility coaching|"The intensive follow-up for the patients of Mobility Coaching  arm will consist on a monthly remote coaching of 20 to 30 minutes led by a Mobility coach. The web platform allows self-administration of a questionnaire to establish patient's diagnosis of mobility to enable personalized coaching. The web platform can also track the parameters collected by connected devices (pedometer and connected scale), organize appointments with patients and ensure the traceability of exchanges with patients. A smartphone application tracks different modes of locomotion used."
46040193|NCT02716480|Behavioral|Diet coaching|"The intensive follow-up for the patients of Diet Coaching  arm will consist on a monthly remote coaching of 20 to 30 minutes led by dietitian trained in the care of patients undergoing bariatric surgery."
46040194|NCT04964596|Diagnostic Test|colonoscopy|colonoscopy
46040195|NCT04964596|Diagnostic Test|FIT test|faecal immunochemical test
46040196|NCT04964596|Diagnostic Test|CT colonography|noninvasive medical imaging technique that uses computed tomography to visualize the interior of the colon and rectum especially to screen for polyps or cancerous growths
46040197|NCT04964284|Biological|rhTSH|rhTSH (0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH
46040198|NCT04964284|Radiation|Radioiodine (131I)|Patients were given an ablative dose of 131I (30 mCi±1.5 mCi).
46040199|NCT02716168|Other|Shared video consultation between patient, general practitioner and oncologist|At the start of the patients chemotherapy treatment a shared video consultation between the patient, general practitioner and oncologist will bee arranged. The video consultation should address distribution of roles, comorbidity, medicine, depression and anxiety symptoms, relatives and social resources.
46040200|NCT04896346|Other|Punch biopsy|punch biopsies will be used for histologic analysis and biochemical assays
46040201|NCT04896346|Other|non-invasive photography, assessments, and measurements|photography, scar questionnaires, pain and itch assessments, and non-invasive measurements of scar including color, stiffness, and elasticity
45474504|NCT03858881|Behavioral|VR PERSONALITY PROJECT|The VR PERSONALITY PROJECT contains similar elements as PROJECT PERSONALITY, including a lesson on neuroplasticity; testimonials from older youths; information about research on the malleability of personal traits; and an exercise wherein the participant provides advice to a student in the VR environment who has experienced a peer-related setback. Content is delivered by characters in the VR environment (hired/filmed actors) who guide youths through the program, providing scientific information and personal stories. Completion time is 30-40 minutes. The key difference between the VR and web-based mindset intervention is the delivery system, and by extension the level of immersion each program offers. The VR program is designed to be immersive, fun and interactive; youth choose to speak to various scientists and students within the VR environment and navigate themselves from scene to scene. In the online program, participants automatically view a series of text-based activities.
46040202|NCT02716090|Drug|Adapalene and Benzoyl peroxide Dalap Duo®|
45840633|NCT04946994|Behavioral|CME|The participant will walk/jog for 50 continuous minutes at 55% VO2peak. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 4 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
46040203|NCT02716090|Drug|Adapalene and Benzoyl peroxide Epiduo®|
46040204|NCT02715934|Other|Glucose to Goal|The Glucose to Goal intervention applies elements of the Patient Centered Medical Home (i.e., practice design, decision support, population management, etc) to diabetes education services and operationalizes the current DSME objectives in the primary care setting.
46040205|NCT02715934|Other|Usual Care|The control group will follow the traditional DMSE delivery model, which includes primary care providers referring patients to an outpatient, hospital-based diabetes educator for DSME, but in a passive manner (i.e., without proactive patient identification), which is the usual process for referrals.
46040206|NCT01227616|Drug|Ferumoxytol|IV Ferumoxytol
46040207|NCT01227616|Drug|Iron Sucrose|IV Iron Sucrose
46040208|NCT02715544|Other|Healthy lifestyle|The families will receive a designed for these purposes intervention
46040209|NCT02715544|Other|physical activity and dietary guidelines|The families will receive a designed for these purposes intervention
46040210|NCT04189276|Biological|ETV/TDF+T101 No.1|Patients will be injected with T101 once on Day1 (Week0), Day8 (Week1), Day15 (Week2), Day106 (Week15), Day113 (Week16), Day120 (Week17), Day211 (Week30), Day218 (Week31), Day225 (Week32), Day316 (Week45), Day323 (Week46), Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.
46040211|NCT04189276|Biological|ETV/TDF+T101 No.2|Patients will be injected with T101 once on Day1 (Week0), Day106 (Week15), Day211 (Week30), Day316 (Week45); ETV or TDF will be administrated once each day successively until Day420.
46040212|NCT04189276|Biological|ETV or TDF|Patients will be administrated ETV or TDF once each day successively until Day420.
46040213|NCT04189276|Biological|ETV/TDF+Peg-IFNα-2b|Patients will be administrated Peg-IFNα-2b successively once a week until Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.
45684358|NCT05601934|Other|Neurophysiological Facilitation Techniques|Increased enlargement of the ribs during inspiration and increased movement in the epigastric region and tone of the abdominal muscles also decreased respiratory rate are some of the changes that occur after these stimuli. In addition to these, involuntary increase in cough, sputum production also decrease in pathological sounds felt on auscultation, decrease in aspiration requirement, rapid return in chest wall stabilization and improvement in respiratory pattern can be observed after application with this application, positive and long-term effective results can be seen in a short time.
45344068|NCT02545816|Device|Bispectral index (BIS) EEG monitoring|The Bispectral Index (BIS) EEG monitor is a simplified EEG monitoring device which was originally designed to monitor the depth of hypnosis during general anesthesia. It does this by analyzing changes in the processed electroencephalogram (EEG) which occur with the hypnotic state and creating a measure (or index) indicative of these changes. A number between 0 and 100 is derived, with values above 70 associated with an awake state. The monitor also provides a single channel EEG, an electromyogram (EMG) and an index of signal quality (SQI), all in real time.
45344069|NCT00712140|Biological|trastuzumab|Given IV
45344070|NCT00712140|Drug|parenteral chemotherapy|per the local institutional protocols either concurrently with or sequentially to trastuzumab
45344071|NCT02546206|Dietary Supplement|Probiotic Yoghurt|Probiotic yoghurt consumption
45344072|NCT02546206|Dietary Supplement|Natural Yoghurt|Natural yoghurt consumption
45344073|NCT02545738|Drug|Liraglutide|active treatment
45344074|NCT02545738|Drug|placebo|placebo
45344075|NCT00712218|Procedure|No Lymphadenectomy (LNE)|No lymphadenectomy is performed in patients of the control group
46040214|NCT00956488|Behavioral|Treadmill Exercise|The intervention will consist of 30 minutes of exercise, performed 3 times per week for 8 weeks (24 sessions). Patient will walk on a treadmill with up to 40% of their body weight supported by a body weight support system with an overhead harness. The training session duration will be 60 minutes consisting of six intervals of 5 minutes exercise, interspersed with 6 intervals of 5 minutes rest to avoid overwork weakness and fatigue. Five minute exercise intervals should be sufficient for patients to reach a steady state. Patients will build up their endurance to this training level at their own pace as tolerated. Walking speed will be determined as tolerated by each patient. Exercise intensity will be guided by each patient's own perception of exertion, but not to exceed level 12-13 (mild to moderate) on the modified Borg perceived exertion scale, and by oxygen saturation (Sa O2) ≥ 90% monitor by handheld pulse Oximeter.
46040215|NCT02714998|Drug|Methotrexate|single dose systemic methotrexate administration (50 mg/m2)
46040216|NCT02714998|Procedure|salpingectomy|Laparoscopic unilateral salpingectomy
46040217|NCT04162054|Other|Observational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).|Observational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).
46040218|NCT00765310|Dietary Supplement|R-alpha lipoic acid|600 mg in morning on empty stomach (two 300 mg capsules)
46040219|NCT00765310|Dietary Supplement|Placebo|two capsules once daily in morning on empty stomach
46040220|NCT02715154|Drug|Dexmedetomidine|The dexmedetomidine groups (n = 20 ) will receive i.v. infusion of 0.5 μg/kg of solution containing 5 µg/mL of dexmedetomidine, at 10 min after the level of anesthesia completed. Followed with 0.1ml/kg/hr continuous infusion until the closure of the abdominal.The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
45344076|NCT00712218|Procedure|Lymphadenectomy (LNE)|Patients allocated to the lymphadenectomy group undergo systematic lymphadenectomy in addition to surgery for complete resection. Complete mobilization of the colon by resection of the paracolic gutters is necessary for the preparation of the lymphadenectomy. Afterwards the peritoneum has to be opened until the Treitzsche's Band for visualization of the renal vein. Systematic pelvic and para-aortic lymphadenectomy is based on anatomical studies and defined according to a recently published single centre series as systematic resection of lymph nodes in the following regions [24, ].
46040221|NCT02715154|Drug|Placebo|The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
46040222|NCT02715232|Drug|Testosterone|100mg testosterone undecanoat every 8-12 weeks, or alternatively 50mg testosterone transdermally, or 50mg testosterone creme
46040223|NCT02715232|Drug|Lynestrenol|2-3 tablets/day, if menstruation still occurs
46040224|NCT02715232|Drug|Cyproterone Acetate|25mg daily
46040225|NCT02715232|Drug|Estradiol|75 microgram transdermal therapeutic system twice a week, or p.o. estradiol 2x2mg/day, or estradiol gel 1,5-3mg
46040226|NCT02715232|Drug|Triptorelin acetate|4,12mg every 4-6 weeks (powder for suspension for injection s.c. or i.m.
46040227|NCT04035226|Other|No intervention|No intervention will be administered as a part of this study.
45684361|NCT01927588|Drug|Everolimus+Tacrolimus+Prednisone|Certican, introduced at Day7 post transplant + TACreduced + Steroids.
46040228|NCT02714608|Drug|Ginsenoside H dripping pills|Experimental: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
46040229|NCT02714608|Drug|Ginsenoside H dripping pills+Placebo|Experimental: Drug: Ginsenoside H dripping pills+Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
46040230|NCT02714608|Drug|Placebo|Placebo Comparator: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
46040231|NCT00643864|Behavioral|mirror training|"Training will be performed one-on-one by an investigator in a quiet room, one hour a day, five days a week, for four weeks. Attendance will be recorded. The mirror-box apparatus consists of an 18 x 24 vertical mirror secured in the center of a wooden platform. During training, the mirror-box will be placed on a table in front of the subject so that the mirror is perpendicular to the chest, slightly lateral of midline. Subjects will be asked to attend to the mirror reflection of their unaffected hand performing a series of tasks, while keeping their affected limb still. At the end of the four week training period, posttests will be administered by the same Occupational Therapist who performed the pretests."
46040232|NCT02693860|Drug|huJ591|Antibody is derived from a hybridoma originally produced in the Weill Medical College Laboratory of Urological Oncology. Treatment with 100 mg of HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of <5 mg/minute.
46040233|NCT02693860|Drug|89Zr-J591|Drug product is manufactured by the radiochemistry staff of Citigroup Biomedical Imaging Center (CBIC) research core facility. Radiolabeling of DFO-huJ591 with 89Zr is achieved by the addition of 89Zr-oxalate to the DFO-huJ591 in ammonium acetate buffer.
45474505|NCT03858881|Behavioral|SHARING FEELINGS PROGRAM|The web-based supportive therapy (ST) intervention, called the Sharing Feelings Program, is delivered via Qualtrics, self-administered by youth, and 30 minutes in duration. It aims to encourage youths to identify and express feelings to close others and does not teach specific skills or beliefs. It is designed to control for nonspecific aspects of intervention, including engagement in a technology-based program. It mirrors the web-based growth mindset intervention as closely as possible, including vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family.
46040234|NCT02714686|Behavioral|Radio Mass Media Family Planning Campaign|Short daily spots, weekly interactive shows, testimonies, and interviews with experts and community leaders on contraception and family planning
45382074|NCT05371834|Device|Microwave Treatment (Swift System)|"Localized microwave energy applied to the wart lesion. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).~For common warts (usually hands, elbow, knees): Treatment starts at 6W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeated on the same wart as is tolerable (3-5 repetitions).~For plantar warts: Treatment starts at 8W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeat on the same wart as is tolerable (3-5 repetitions).~Less power for a longer time will result in a more gradual temperature rise. Higher power for a shorter time will result in a more immediate temperature rise."
45474506|NCT04524988|Procedure|Laparoscopic Simulation Training|All participants underwent 2.5h of training with one of two laparoscopic simulation trainers (FLS or EMIG).
46040235|NCT02714842|Drug|Radiolabelled Diclofenac Tablet A|Delayed release diclofenac sodium tablet (50 mg)
46040236|NCT02714842|Drug|Radiolabelled Diclofenac tablet B|Delayed release diclofenac sodium tablet (50 mg)
45474507|NCT03224598|Drug|A-101 Topical Solution 40%|A-101 Topical Solution 40%
46040237|NCT02714842|Drug|Radiolabelled Diclofenac tablet C|Delayed release diclofenac sodium tablet (25 mg)
46040238|NCT02714842|Drug|Diclofenac|Enteric coated delayed release diclofenac sodium tablet (50 mg)
46040239|NCT02714530|Drug|Erlotinib|Tarceva daily during radiotherapy course
46040240|NCT02714530|Radiation|Radiation|Radiotherapy
46040241|NCT02714452|Behavioral|Person-centred care|Person-centred and thriving promoting care
46040242|NCT02714296|Drug|Nutridrink 200 ml|Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
46040243|NCT02714296|Dietary Supplement|Nutridrink compact protein|2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
46040244|NCT02714374|Biological|GL-ONC1|"Dose and Regimen:~Single dose group: Cohort 1 dose is 1 × 109 pfu~Multiple dose groups:~Cohort 2 dose is 1 × 109 pfu × 5 consecutive days~Cohorts 3 and 4 dose is 2 × 109 pfu × 5 consecutive days~Cohorts 5 and 6 dose escalates at 2,3,5,5,5 × 109 pfu.~Route: GL-ONC1 is delivered as a bolus IV injection."
46040245|NCT04010266|Device|RelieVRx headset|RelieVRx is a virtual reality therapy intended as adjunctive treatment for acute surgical pain
45344077|NCT00848224|Behavioral|systems-based and pharmacist-mediated program|Patients in the SI were seen by a study pharmacists prior to discharge to establish a relationship with the patient, explain the pharmacist's role in the study, provide education about all discharge medications and a medication card listing all medications and their manner of use, and set the framework for the follow-up telephone calls. Patients received pharmacist-delivered adherence counseling telephone contacts that took place at two weeks following discharge, and at months 1, 3, 6, and 9 oriented towards assisting patients to remain adherent to prescribed lipid-lowering and other medications, and also towards ensuring that all patients were either documented to be at the LDL-C goal, or were assisted to reach the goal by facilitating the scheduling of repeat lipid measurement as needed and providing information, guidelines and prompts to the patient's physician or nurse practitioner.
45344078|NCT00848302|Drug|L-arginine|30 patients will receive either 50, 100 or 500mg L-arginine supplementation infused via a end-hole catheter
45344079|NCT02572596|Drug|rhTPO|rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.
46040246|NCT04010266|Drug|multi-modality pain management|combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids
46040247|NCT02714140|Behavioral|PB-HCT +|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all EXISTING HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
45344080|NCT02572596|Drug|CTX|CTX 2.5/m2 for 2 days.
45684362|NCT01927588|Drug|Mycophenolate+Tacrolimus+Prednisone|Myfortic + Tacrolimus full + Steroids, as control arm.
46040248|NCT02714140|Behavioral|PB-HCT -|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible HIV testing options for each participant and select 3 PB-HCT options that are less preferred than the common option
46040249|NCT02714140|Behavioral|Economic incentive|Participants will be re-contacted three months after being offered PB-HCT options. Participants will be reminded of the options, and offered an incentive to present for testing using any of the PB-HCT options or the common option.
46040250|NCT02714140|Behavioral|PB-HCT ++|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible ENHANCED HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
45344081|NCT02572596|Drug|-CSF|10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
46040251|NCT02714140|Behavioral|SMS Reminder|Participants will receive an SMS reminder to test.
45344082|NCT00718614|Procedure|Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.|Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.
45344083|NCT04069728|Other|Explanation with 3D printed fistula model|Explanation of fistula and surgery using a 3D printed model of an anal fistula that depicts the anatomy of the anal canal, the path of the anal fistula and its relation to anatomic structures.
45344084|NCT04069728|Other|Standard explanation|Explanation of fistula and treatment using words, diagrams and MRI images as per consultant choice. Standard clinical care.
45344085|NCT00712374|Drug|sulfadoxine-pyrimethamine plus amodiaquine|"SP+AQ on three occasions during the malaria transmission season~Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine"
45344086|NCT02573220|Biological|Cetuximab|Given IV
45684363|NCT05601466|Drug|QN-023a|NK cell therapy
45684364|NCT05601466|Drug|Cyclophosphamid|Lympho-conditioning Agent
45684365|NCT05601466|Drug|Fludarabine|Lympho-conditioning Agent
45684366|NCT05601466|Drug|Cytarabine|Lympho-conditioning Agent
45684367|NCT01903837|Drug|Samidorphan (Low Dose)|Tablets taken once daily
45684368|NCT01903837|Drug|Samidorphan (Medium Dose)|Tablets taken once daily
45684369|NCT01903837|Drug|Samidorphan (High Dose)|Tablets taken once daily
45684370|NCT01903837|Drug|Placebo|Tablets taken once daily
46040252|NCT04742452|Procedure|Superior Capusular Reconstruction|Superior capsular reconstruction is one treatment option for massive and irreparable rotator cuff tears. The superior shoulder capsule, a thin membranous structure located on the inferior surface of the supraspinatus and infraspinatus muscles, is often torn in this type of rotator cuff tear. In superior capsular reconstruction, this structure is reconstructed with acellular dermal allograft.
45684371|NCT01903837|Drug|Olanzapine|Tablets taken once daily
46040253|NCT04742452|Procedure|Partial Rotator Cuff Repair|Partial rotator cuff repair can be performed, in conjunction with other procedures such as subacromial decompression and biceps tenodesis, when a rotator cuff tear is not amenable to a complete repair.
46040254|NCT02713906|Device|X-Ray Knee Guide group|
46040255|NCT02713984|Biological|Anti-HER2 CAR-T|HER-2-targeting CAR-T cells infusion in HER2 positive cancers
46040256|NCT02713672|Other|Dose adjustment according to genotype|Patients in the intervention group received a dose adjustment according to their CYP2D6 or CYP2C19 genotype based on guidelines of the KNMP
45344087|NCT02573220|Drug|Fluorouracil|Given IV
45344088|NCT02573220|Drug|Irinotecan Hydrochloride|Given IV
45684372|NCT01927666|Dietary Supplement|100mg glucoraphanin|The extent of ITC excretion in urine from a capsule delivered dose of glucoraphanin
45684373|NCT00982696|Biological|Opioid Growth Factor|250ug per kilogram weekly IV infusions
46040257|NCT02713750|Other|reversible contraceptive methods|"Consistent male condom use only~Consistent female condom use only~Hormonal contraception, combined oral contraceptive pills and male/female condom~Hormonal contraception, progestin only depot medroxyprogesterone acetate (DMPA) injectable and male/female condom~Hormonal contraception , progestin only hormonal implant and male/female condom~Intrauterine device and male/female condom"
45344089|NCT02573220|Drug|Leucovorin Calcium|Given IV
45344090|NCT00712452|Other|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
45684374|NCT00982150|Drug|Talampanel|50mg capsules tid
45684375|NCT02984254|Device|Womac|Answer Womac questionnaires at baseline, 1 month, 3 months and 1 year
45684376|NCT02984254|Device|Lequesne|Answer Lequesne questionnaires at baseline, 1 month, 3 months and 1 year
45684377|NCT02984254|Device|Timed-up-and-go (TUG)|Perform Timed-up-and-go (TUG) at baseline, 1 month, 3 months and 1 year
45684378|NCT02984254|Device|five-times-sit-to-stand-test (FTSST)|Perform the five-times-sit-to-stand-test (FTSST) at baseline, 1 month, 3 months and 1 year
46040258|NCT04738162|Drug|5-Aminolevulinic Acid Hydrochloride, Oral|Application of 5-ALA oral solution (20mg/kg bw) 4 hours (range 3.5-4.5 hours) prior to anesthesia followed by fluorescence-guided tumor resection Tumor resection is performed conventionally using a surgical microscope. A change from white light to blue light is possible at anytime to make the fluorescence visible
46040259|NCT04000906|Drug|Nab paclitaxel|Dose escalation (7.5 mg/m2, 15 mg/m2, 25 mg/m2, 37.5 mg/m2, 52.5 mg/m2 and 70 mg/m2)
46040260|NCT04000906|Drug|Cisplatin|10.5 mg/m2
46040261|NCT04729504|Behavioral|Adapted Project BRAVE|A culturally and linguistically adapted Project BRAVE is web-based single session intervention that is about 30 minutes in length. The session is designed to focus on targeting child anxiety symptoms in the multilingual and diverse families in Miami-Dade.
46040262|NCT00636766|Drug|atorvastatin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
46040263|NCT00636766|Drug|rimonabant|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
45382075|NCT05371834|Device|Cryotherapy|Local application of Cryotherapy. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).
45684379|NCT02984254|Device|Six-minute walk test.|Perform six-minute walk test at baseline, 3 months and 1 year
45684380|NCT02984254|Device|functional patellofemoral neoprene brace|Use the functional patellofemoral neoprene brace for 2 hours/day minimum - 12 hours/day maximum
45382076|NCT05369676|Drug|SSD8432 dose 1/Ritonavir|Cohort 1:SSD8432/ritonavir or placebo, on day 1 ~day5，BID；
45382077|NCT05369676|Drug|SSD8432 dose 2/Ritonavir|Cohort 2:SSD8432/ritonavir or placebo, on day 1 ~day5，BID；
45474508|NCT03370900|Other|Testing|Participants either received 20 case testing with or without feedback
46040264|NCT00636766|Drug|rosiglitazone|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
46040265|NCT00636766|Drug|metformin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
46040266|NCT02713360|Behavioral|Cognitive Therapy|
45474509|NCT03681691|Drug|Estradiol patch|transdermal 17β-estradiol patch
46040267|NCT03998176|Drug|Bictegravir/emtricitabine/tenofovir alafenamide|B/F/TAF single tablet formulation
45474510|NCT01289171|Drug|Glycolic acid|Those who met the study criteria commenced once daily use of 15% glycolic acid lotion to the face and/or dorsal hands, with an increase to twice daily application as tolerated after two weeks of use.
46040268|NCT02713282|Drug|Paliperidone palmitate 3 month formulation (PP3M)|Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq) up to 525 mg eq based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
46040269|NCT00611104|Dietary Supplement|standardized freeze-dried table grape powder|
46040270|NCT00611104|Other|laboratory biomarker analysis|
46040271|NCT00611104|Other|pharmacological study|
46040272|NCT02713516|Other|Virtual Reality|Use of virtual reality to deliver exposure therapy
46040273|NCT02713048|Other|Blood sample collection|Eight blood samples in each patient within 48 hours to perform Troponin I measurement.
46040274|NCT00611260|Behavioral|Vipassana Meditation practice and instruction|2-3 instructed meditation sessions per week in addition to standard medical care.
46040275|NCT00611260|Other|Standard Medical Care|Standard medical care for patients with congestive heart failure plus implanted cardiac defibrillators.
46040276|NCT02712970|Procedure|pit-picking technique|midline pits were excised removing a minimal amount of tissue (with a margin of skin of <1 mm). Incision of 1-2 cm in length was performed parallel to the most convenient side of the midline to be curetted of the chronic abscess cavity. All infected granulation tissue and hair were removed. After establishing hemostasis, the area of the excised midline pits was approximated by absorbable sutures.
45474511|NCT03370822|Device|MONICA AN24 device|Application of MONICA AN24 device and recording for the longest period of fetal heart rate recording possible (limited by battery life)
45684381|NCT02984254|Device|neoprene sleeve brace.|Use the neoprene sleeve brace for 2 hours/day minimum - 12 hours/day maximum
45474512|NCT01177319|Drug|Glutathione|
45474513|NCT03360760|Drug|Doxorubicin|60mg/m^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
45474514|NCT03360760|Drug|Cisplatin|100mg/m^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
45474515|NCT03360760|Drug|Methotrexate|High dose of methotrexate (8-12g/m^2), in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
45694591|NCT04382014|Dietary Supplement|MAG fish oil + Curcumin OR Rice bran oil + Curcumin OR Curcumin extract|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) curcumin combined with MAG fish oil as a carrier, 2) curcumin combined with rice bran oil as a carrier, and 3) curcumin extract.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24h after taking the supplement. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
46040277|NCT02712970|Procedure|Bascom Cleft Lift|The upper end of the incision was made 1-2 cm lateral to the midline on the more affected side and this was continued vertically over a distance of 1-2 mm from the midline pits. The lower end was fashioned from the midline in a V-shape in order to prevent a dog-ear deformity. The skin on this side of the natal cleft was then elevated and excised. The skin on the opposite side was undermined to the distance required to allow primary closure of the defect away from the midline without tension. Sinus tissue and its extensions were excised. The incision was then closed subcuticularly by absorbable polyglecaprone (3-0), after which a few interrupted mattress polyglecaprone (3-0) buttress sutures were also inserted.
46040278|NCT02712970|Procedure|Rhomboid excision with the Limberg Flap|The area to be excised was mapped on the skin in a rhomboid form, and the flap was designed. The skin incision was deepened to the postsacral fascia. The flap was fully mobilized and transposed medially to fill the defect without tension. The wound was closed in two layers: the subcutaneous tissue with absorbable (2/0 polyglactin) sutures and the skin with nonabsorbable (3/0 polypropylene) interrupted mattress suture
46040279|NCT02712970|Procedure|Other flap techniques|Bascom Cleft lift as described above, Rhomboid excision with the Limberg Flap as described above, V-Y advancement flap, Z-Plasty
46040280|NCT03987568|Other|Blood draws|Blood draws at two specified timepoints - the first is during the MRI and the second is scheduled during participant's prostatectomy.
46040281|NCT03987568|Diagnostic Test|Magnetic resonance imaging (MRI)|At the beginning of study magnetic resonance imaging MRI will be completed.
46040282|NCT02712892|Genetic|Non Interventional Study|
46040283|NCT02693782|Dietary Supplement|Placebo|15 g/day maltodextrin in 3 portions of 5 g.
46040284|NCT02693782|Dietary Supplement|Fibre supplement|15 g/day Wheat Bran Extract in 3 portions of 5 g.
46040285|NCT00611338|Behavioral|HIV Skills-based Prevention|
46040286|NCT04188886|Other|Practice survey|Practice survey on
45344091|NCT00712452|Other|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
45344092|NCT00712452|Other|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
45344093|NCT04070274|Procedure|different types of surgery platforms|58 patients with lateral calcaneus surgeries are divided into the control group of 29 patients and the experimental group with 29 patients. The traditional lateral method and calcaneus lateral surgery platforms are separately applied in the groups.
45344094|NCT02572440|Procedure|Sorin XTRA/Sorin Group,|
45382078|NCT05364372|Behavioral|Symptom assessment only|Dyads will receive 12 weekly phone calls to assess symptom management.
45382079|NCT05364372|Behavioral|Symptom management and lifestyle intervention|Survivor and caregiver dyads will work together with a coach to establish diet and physical activity change SMART goals. Motivational interviewing based weekly coaching sessions will review symptom management and goal attainment and then enact strategies to modify goals to be more relevant and achievable.
45382080|NCT05363176|Behavioral|Cognitive-Behavioral Therapy for Treatment Seeking|CBT delivered over the course of 1, ~45 minute sessions delivered via telehealth.
45382081|NCT05363176|Behavioral|Pain treatment education|Pain treatment education describes a variety of pain treatments offered in the VA. It is delivered over the course of 1, ~45 minute session delivered via telehealth
46040287|NCT02712580|Device|First investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light.
45344095|NCT00718848|Procedure|Incentre nocturnal hemodialysis|This is a hemodialysis schedule that consists of 3 weekly hemodialysis sessions administered overnight (8 hours/session) in-hospital.
46040288|NCT02712580|Device|Second investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light.
46040289|NCT02712580|Device|ES Wetling W200 Placebo with white light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
45344096|NCT00718848|Procedure|Remaining on conventional hemodialysis|These patients will remain on their current conventional hemodialysis schedule that consists of 4 hours/session, 3 sessions/week.
45344097|NCT00618982|Drug|Sorafenib (Nexavar, BAY43-9006)|The initial dose of sorafenib will be 400 mg bid administered orally, on a continuous basis. A treatment cycle is considered to be 28 days. Intrapatient dose escalation will occur according to the following schedule, providing no grade 3 or 4 toxicities are observed (except for alopecia, nausea and vomiting); Day 1-28 400 mg bid, Day 29-56 600 mg bid, Day 57 onwards 800 mg bid. Subjects will continue on treatment until progression, unacceptable toxicity, subject withdraws consent or the decision is taken to stop the study following the analysis of response rates.
46040290|NCT02712580|Device|ES Wetling W200 Placebo with red light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
45344098|NCT00716352|Behavioral|Educational intervention programme|
45474516|NCT03360760|Drug|Ifosfamide|12g/m^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
46040291|NCT00611416|Dietary Supplement|green tea|different catechin combinations
46040292|NCT00611416|Dietary Supplement|Mix of catechins and caffeine|3 tablet a day
46040293|NCT00611416|Dietary Supplement|EGCG|3 tablets a day
46040294|NCT00611416|Dietary Supplement|EGC|3 tablets a day
46040295|NCT00611416|Dietary Supplement|Caffeine|3 tablets a day
46040296|NCT00611416|Dietary Supplement|Placebo|3 tablets a day
45344099|NCT03948048|Device|ECMO|ECMO is used to intervene septic shock and refractory septic shock
45344100|NCT02544880|Drug|Tadalafil|Tadalafil tablets administered by mouth. Dose will be between 10 to 20 mg adjusted depending on patient's body weight. On course 1, Tadalafil will be administered daily for 19 consecutive days. On Course 2 through 4, Tadalafil will be administered daily for 14 consecutive days. No Tadalafil will be provided on Course 5.
45344101|NCT02544880|Biological|Anti-MUC1 Vaccine|300 uL Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb. Anti-MUC1 vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
45474517|NCT03360760|Procedure|definitive surgery|Including limb-sparing procedure and amputation
45474518|NCT03360760|Other|pre surgical chemotherapy|chemotherapy that given before definitive surgery
45474519|NCT01285661|Drug|Sodium warfarin|Patients with early vein recanalization, as shown by ultrasonography, and repeatedly negative D-dimer will have anticoagulation discontinued. They will be followed-up for up to 4 years after recruitment in order to assess the rate of recurrent symptomatic VTE. In all other patients anticoagulation will not be discontinued.
46040297|NCT02712658|Drug|Terbutaline|K+ transport and Ca2+ release and uptake function are stimulated by administration of terbutaline
46040298|NCT02712658|Drug|Placebo|
46040299|NCT02712736|Other|quality of life survey|subjects with PSC will be administered a survey to assess their quality of life
46040300|NCT00611494|Drug|MMF|Gradual optimization of drug dosage, as clinically tolerated.
46040301|NCT00611494|Drug|EC-MPS|Conversion from MMF to EC-MPS. Gradual optimization of drug dosage, as clinically tolerated.
46040302|NCT02712502|Drug|Levofloxacin|"Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.~Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
46040303|NCT02712502|Drug|Amoxicillin-Potassium Clavulanate Combination|"Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.~• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
46040304|NCT02712346|Drug|Ambrisentan|Ambrisentan 5 milligrams a day or a placebo (sugar pill) for twelve weeks
46040305|NCT02712346|Drug|Placebo|One inactive pill daily for twelve weeks
46040306|NCT02712190|Device|High-frequency non-invasive ventilation|Comparison of 2 different settings of HF-NIV
46040307|NCT04617028|Drug|Jaktinib|Jaktinib Hydrochloride Tablets administered orally twice daily
46040308|NCT04617028|Drug|Placebo to match Hydroxycarbamide|Placebo to match Hydroxycarbamide Tablets administered orally twice daily
45344102|NCT02544880|Biological|Anti-Influenza Vaccine|300 uL Anti-Influenza vaccine will be administered intramuscularly in the left upper limb. Anti-Influenza vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
45344103|NCT02544880|Other|Tadalafil Placebo|Placebo tablets mimicking Tadalafil administered by mouth. On course 1, Tadalafil Placebo will be administered daily for 19 consecutive days. On Course 2 through 4, Tadalafil placebo will be administered daily for 14 consecutive days. No Tadalafil Placebo will be provided on Course 5.
45694592|NCT01683565|Drug|LCPUFA oil supplement|"2.5mL per day for 90 days~Daily Dose: EPA (338mg) + DHA (225mg) + GLA (83mg) + OA (200mg)"
46040309|NCT04617028|Drug|Hydroxycarbamide Tablets|Hydroxycarbamide Tablets administered orally twice daily
46040310|NCT04617028|Drug|Placebo to match Jaktinib|Placebo to match Jaktinib Tablets administered orally twice daily
46040311|NCT02712268|Other|Checklist|Introduction of a 5-point checklist to be used by all physicians on the internal medicine wards to review and adapt the medications of the patient.
46040312|NCT02712034|Behavioral|MAT + A-CHESS|"Subjects randomized to MAT + A-CHESS will receive MAT plus the A-CHESS recovery support system which provides:~Self-directed, interactive modules that teach basic recovery support, harm-reduction, and psychosocial functioning skills.~The latest information about addiction and recovery support, monitoring prompts, and peer and family support.~Advice on where to go for help and on how to make the best use of health and human services; and~A way to talk with experts in the area of addiction and other study participants by sending anonymous messages in the A-CHESS discussion groups.~A way to keep your health care team up to date through reports based on information entered into A-CHESS (i.e. alcohol and drug use, depression, MAT side effects)."
45474520|NCT02935842|Other|Specific SL-therapy|Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.
45344104|NCT02544880|Other|Anti-MUC1 Vaccine Placebo|Placebo for Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb. Placebo for Anti-MUC1 vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5..
45474521|NCT02935842|Other|Rhythmic Balance-Movement Training (rBMT)|Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.
45474522|NCT03360682|Drug|Lamivudine 300 MG|Lamivudine 300 MG/day (48 weeks)
45474523|NCT03360682|Drug|Abacavir 600 MG|Abacavir 600 MG/day (48 weeks)
45474524|NCT03360682|Drug|Dolutegravir 50 mg|Dolutegravir 50 MG/day (48 weeks)
45474525|NCT03360682|Drug|Tenofovir Disoproxil 245Mg Tablet|Tenofovir 245 MG/day (48 weeks)
45474526|NCT03360682|Drug|Emtricitabine 200 MG|Emtricitabine 200 MG/day (48 weeks)
46040313|NCT02712034|Other|MAT|"Patients will receive treatment consisting of a recovery plan, appropriate pharmacology, routine urine screens, and regularly scheduled behavioral interventions, such as monthly group counseling sessions or sessions with a recovery coach. Appropriate pharmacology may include methadone; naltrexone; buprenorphine; and in the case of overdose, naloxone; and other medications and combinations of medications as part of the patient's standard clinical care."
46040314|NCT02711722|Device|Neurally adjusted ventilatory assist|"Ventilation supported by NAVA~Blood gas analysis~Respiratory Parameters At the end of the study step Neuro-Ventilatory Efficiency and Neuro-Mechanical Efficiency are measured."
45344105|NCT02544880|Other|Standard of Care Treatment|Treatment according to prescribed standard of care regimen.
45344106|NCT02544880|Other|Anti-Influenza Vaccine Placebo|Placebo for Anti-Influenza vaccine will be administered intramuscularly in the left upper limb. Placebo for Anti-Influenza vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
45344107|NCT00856570|Drug|warfarin|Oral
45474527|NCT01180205|Drug|Telmisartan|Telmisartan (80 mg ,Tablets, QD, p.o., 26 weeks)
46040315|NCT02711722|Device|PScli1|Pressure support set by clinicians prior to inclusion
46040316|NCT02711722|Device|PScli2|Pressure support at the same level as prior to the study
46040317|NCT04161742|Device|Nevisense|Nevisense measures electrical impedance of skin lesions and provides an output called the electrical impedance spectroscopy (EIS) score
45344108|NCT00856570|Drug|YM178|Oral
45344109|NCT04068870|Behavioral|Contraceptive management program|The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) incentivized visits.
45344110|NCT00852280|Device|Treatment of 1/2 of skin graft with pulsed-dye laser|Pulsed-dye laser will be applied to 1/2 of the seam of the skin graft, using a 10mm spot size, and sufficient pulse-width and fluency to induce purpura.
45344111|NCT00719004|Procedure|Ultrasound of the foot|These volunteers will have one ultrasound scan of each foot
45344112|NCT00856648|Device|SmartPill ingestion and monitoring|The SmartPill device will be ingested and remotely monitored until it is excreted in a normal bowel movement.
45344113|NCT00856804|Drug|thalidomide|Open-label pilot study analyzing the impact of adding thalidomide (200 mg/d)to SOC on 12 weeks virological response in patients with chronic hepatitis C and interferon resistance.
45344114|NCT00712608|Other|Infant formula|Marketed cow's milk base infant formula 20 kcal/oz
45344115|NCT00712608|Other|Infant formula|cow's milk based infant formula with prebiotics, different level of fatty acids and fat and a different calcium source
45344116|NCT00712608|Other|Cow's milk infant formula|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
45344117|NCT00856882|Dietary Supplement|soy protein|
45344118|NCT00856882|Dietary Supplement|isoflavones|
45344119|NCT00856882|Dietary Supplement|milk protein|
45344120|NCT00712686|Drug|Aripiprazole|Tablets, Oral, 15-30 mg, once daily, 140 weeks
45474528|NCT01180205|Drug|Amlodipine|Amlodpine 5 mg po 14 days, the forced - titration to 10 mg po for 24 weeks
45344121|NCT00712686|Drug|Olanzapine|Capsule, Oral, 10-20 mg, once daily, 140 weeks
45474529|NCT01180205|Drug|Olmesartan medoxomil|Olmesartan 40 mg po for 26 weeks
46040318|NCT02711566|Device|Physioassistant: Haptic training|Subjects in the Haptic training arm had to perform fast-and-accurate reaching movements in different directions. reaching was mediated by a virtual 'tool', consisting of a virtual point mass (m=5 kg) connected to the subjects' hand through a linear spring (stiffness range: Km=200-500 N/m). An additional spring (stiffness range: Kr = 20-70 N/m) was connected between hand a starting point to resist movements. Subjects were instructed to move the virtual point mass as fast as possible through suitable hand motions, so that the mass ends up and stops on the 'target' area.
46040319|NCT02711566|Device|Physioassistant: Sensorimotor training|Subjects in the Sensorimotor training arm had to perform fast-and-accurate reaching movements in different directions. The manipulandum was only used to record hand movements, but throughout the movement it generated no forces.
46040320|NCT02711488|Behavioral|Intervention group|"The proposed intervention will focus on encouraging students to change their eating habits and food consumption over 9 months (from March to November). Monthly 1-h sessions in the classroom will be given by the class teacher, and includes playing games, staging theater sketches, watching movies and puppet shows, and writing and drawing contests. The activities were designed to discourage students from consuming sugar-sweetened beverages as well as getting them to replace snacks, particularly processed foods (especially cookies) with fresh fruit or healthy homemade food. To reinforce the messages of the in-class nutritional sessions, a set of messages will be sent to the families in the form of illustrated booklets and recipes.~The secondary prevention strategy at households will be developed for those with excessive weight. The family will receive additional motivation to change these behaviors, using the community health agents as the encourager."
46040321|NCT02711410|Drug|Clopidogrel|
45344122|NCT04041856|Drug|Povidone Ophthalmic|Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis
45344123|NCT00856960|Drug|Aliskiren|Single dose of four 150 mg tablets (600 mg total) Aliskiren in one of three study periods. There will be at least 10 days between each study period.
45344124|NCT00856960|Drug|Aliskiren|Single dose of one 150 mg tablet of Aliskiren in one of three study periods. There will be at least 10 days between each study period.
45474530|NCT01180205|Drug|Hydrochlorothiazide|HCT 12,5 mg po for 14 days, then 25 mg po for 24 weeks
45474531|NCT04523506|Biological|Botulinum toxin(Botox)|This study will evaluate the use of botulinum toxin for reduced oral aperture in scleroderma patients. Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase.
45694593|NCT01683565|Other|Canola Oil Placebo|2.5mL per day for 90 days
45694594|NCT00882778|Drug|eptacog alfa (activated)|Retrospective data collection of the use of activated recombinant human factor VII as prophylaxis in haemophilia patients with inhibitors
46040322|NCT02711176|Drug|Nexium|Patients in experimental group will receive the 14 day single dose of Nexium 40 mg daily
46040323|NCT02711176|Drug|Tinafas|Patients in experimental group will receive the 14 day single dose regimen of Tinafas 1 g daily
46040324|NCT02711176|Drug|Tavanex|Patients in experimental group will receive the 14 day single dose of Tavanex 500 mg daily
45344125|NCT00856960|Drug|Comparator: Losartan|Single dose of one 100 mg tablet Losartan in one of three study periods. There will be at least 10 days between each study period.
46040325|NCT02711176|Drug|Lanzol|Patients in active comparator group will receive the 14 day lansoprazole (Lanzol) 30 mg twice daily
46040326|NCT02711176|Drug|Klacid|Patients in active comparator group will receive the 14 day clarithromycin (Klacid) 500 mg twice daily twice daily
46040327|NCT02711176|Drug|Iramox|Patients in active comparator group will receive the 14 day amoxicillin (Iramox) 1 g twice daily
46040328|NCT02711098|Biological|"Inflammatory biomarkers dosage Hypothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management between 33°C and 37°C.
45344126|NCT00856960|Drug|Comparator: Placebo to Aliskiren|Three or four tablets placebo to Aliskiren 150 mg in one of three study periods. There will be at least 10 days between each study period.
45344127|NCT00856960|Drug|Comparator: Placebo to Losartan|Single dose of placebo to Losartan 100 mg in one of three study periods. There will be at least 10 days between each study period.
45344128|NCT00712764|Drug|Adenosine|
45344129|NCT00712764|Drug|Placebo|
45344130|NCT03911622|Device|MRI|medical device that is used as an imaging tool for soft tissues
45344131|NCT00848458|Other|Iontophoresis|iontophoresis with 15% azelaic acid gel twice weekly
45344132|NCT00848458|Other|Azelaic acid cream|topical treatment with 20% azelaic acid cream twice daily
45344133|NCT00578786|Drug|ambrisentan|2.5, 5.0 or 10.0 mg ambrisentan po, qd, long-term
45344134|NCT00424255|Drug|Lapatinib|Dual ErbB1/2 inhibitor
45694595|NCT00892606|Drug|Methadone|Patients will receive 0.2 mg/kg of methadone IV immediately after intubation
45694596|NCT00892606|Drug|Morphine|Patients will receive 0.2 mg/kg of morphine IV immediately after intubation
45694597|NCT04416035|Biological|TRS003|TRS003 will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Each cycle is 3 weeks.
45344135|NCT00424255|Radiation|Chemoradiation|Radiation plus platinum based chemotherapy
45474532|NCT01174589|Other|Strength training|to compare if there is a difference between 6 or 12 weeks of physical strength training
45474533|NCT03370744|Diagnostic Test|Neuropsychological scale|Neuropsychological scale, including mini-mental state examination (MMSE), Montreal cognitive assessment (MoCA), clinical dementia rating scales (CDR) and so on
45694598|NCT04416035|Biological|China-approved Bevacizumab|China-approved bevacizumab will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W).Each cycle is 3 weeks.
45694599|NCT04416035|Drug|Carboplatin|Carboplatin will be administered at an AUC 6 mg/mL/ min (the maximum dose capped at 900 mg) by IV infusion (over 15 - 30 minutes) Q3W on Day 1 of each cycle.
45344136|NCT00424255|Other|Placebo|Placebo
46040329|NCT02711098|Biological|"Inflammatory biomarkers dosage Normothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management at 37°C.
46040330|NCT00611650|Drug|defined green tea catechin extract|Given orally
46040331|NCT00611650|Other|placebo|Given orally
46040332|NCT02711332|Other|capillary blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
46040333|NCT02711332|Other|venous blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
46040334|NCT02711020|Behavioral|Cognitive Behavioral Therapy|Patients assigned to this arm will receive a maximum of 18 1-hour sessions of Cognitive Behavioral Therapy following the intervention techniques included in various group therapy manuals for patients with fibromyalgia, plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. Techniques are adapted to individual format in the following modules: (1) Psychoeducation, (2) Relaxation, (3) Behavioral Activation, (4) Cognitive Restructuring, (5) Problem solving, (6) Assertiveness Training, and (7) Relapse Prevention.
45344137|NCT03910764|Other|no intervention|Investigators review patients' medical records and collect personal data, underlying diseases, indwelling catheter duration, laboratory data, diagnosis, treatment and prognosis.
45344138|NCT00852358|Drug|laronidase|For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.
45474534|NCT01180283|Drug|lodenafil carbonate|Dosage: lodenafil carbonate 80mg once a day. It should be taken between 6 and 2 hours before the sexual intercounter.
45474535|NCT01285739|Other|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
45474536|NCT01285739|Other|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
45474537|NCT01177475|Other|blood samples , feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants received mother's native milk or substitute.
45344139|NCT02574156|Drug|Insulin|All patients will receive insulin. However, the infusion flow will be different according to the group.
45344140|NCT00848692|Drug|Rituximab|Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart
45344141|NCT00848692|Drug|Saline (NaCl 0,9 %) (placebo)|Two infusions of saline (NaCl 0,9 %) given two weeks apart
45344142|NCT00712842|Other|Ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters and laser Doppler velocimetry
45344143|NCT00848770|Drug|Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)|"Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS).~NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min.~NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min."
45474538|NCT01177475|Other|blood samples, feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants continued mother's native milk or received substitute.
45474539|NCT04525846|Other|PFMT|"program of PFMT consist of contract and hold pelvic floor muscle 10 seconds and relax 10 seconds 20 times per set totally 3 set per day~follow up by telephone once a week about compliance of program PFMT, general symptoms, notice recording book~at third trimester evaluate UI by questionaire (UDI-6, IIQ-7)"
45684382|NCT01903525|Drug|Docosahexaenoic acid (DHA)|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
45344144|NCT00848770|Drug|Esmolol, NPS or NOR|We use one of the three drug to manipulate the systolic arterial pressure
45344145|NCT00848770|Drug|manipulation of SAP|Esmolol or NPS or NOR
45344146|NCT04070118|Procedure|Measure niche thickness with ultrasound|in patients with previous cesarean section who applied to the emergency department with pain and underwent surgery; Measure niche thickness before operation
45344147|NCT00717704|Drug|ixabepilone|by vein once every 3 weeks
45344148|NCT00717704|Drug|Dasatinib|by mouth once daily
45694600|NCT04416035|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 200 mg/m^2 by IV infusion (over 3 hours) Q3W on Day 1 of each cycle
45840634|NCT04905342|Drug|NVP-1805|orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4) (NVP-1805 80/10/20.8mg)
45474540|NCT04525846|Other|non PFMT|Randomized to non PFMT group follow up and evaluate UI at third trimester sames as intervention group
45474541|NCT05179980|Other|Assessment|Evaluation of clinical-surgical competencies with a previously validated instrument.
45840635|NCT04905342|Drug|NVP-1805-R1and NVP-1805-R2|orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4) (NVP-1805-R1 80mg, NVP-1805-R2 10/20.8mg)
45840636|NCT04900116|Drug|Bupivacaine HCl 0.5 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.5% bupivacaine using a 22 gauge 10 mm block needle.
46040335|NCT02711020|Behavioral|Personal Construct Therapy|"Patients will receive a maximum of 18 1-hour sessions of Personal Constructs Therapy plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. The intervention will follow a protocol designed specifically for this project based on the clinical experience of a previous pilot study. It will consist of 4 stages: (1) Analysis of patient's request, goals setting, identification of the main dilemmas, and other personal meanings relevant for self and others' construction; (2) feedback on the assessment results and problem reframing in terms of a dilemma and/or other personal meanings; (3) work on the dilemmas and/or other aspects of the self and others' construction; and (4) end of the therapeutic process outlining personal projects and future perspectives."
45474542|NCT01287845|Drug|BAY1075553|Cancer patients, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
45474543|NCT01287845|Drug|BAY1075553|Healthy volunteers for dosimetry, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
45474544|NCT03360604|Dietary Supplement|Low Glycaemic Diet|This intervention is a diet consisting of a Low GI breakfast, lunch and snack meal.
45474545|NCT03360604|Dietary Supplement|High Glycaemic Diet|This intervention is a diet consisting of a High GI breakfast, lunch and snack meal.
45474546|NCT03867084|Biological|Pembrolizumab|IV infusion of Pembrolizumab 200 mg.
45474547|NCT03867084|Drug|Placebo|IV infusion of 0.9% normal saline.
45474548|NCT03860831|Drug|Ketamine + midazolam|Group IN received intranasal midazolam (0.2 mg/kg) +ketamine (5mg/kg). Group IM received intramuscular midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.
46040336|NCT02710786|Procedure|Gastric bypass|Gastric bypass surgery, i.e., small gastric pouch and excluded main stomach
46040337|NCT02710942|Behavioral|SPHERE|
46040338|NCT02710942|Behavioral|PRISM|
46040339|NCT02710708|Drug|EE20/DRSP (YAZ, BAY86-5300)|YAZ (DRSP 3 mg/EE 20 µg), oral route, 6 cycles of 28 days per cycle, each cycle comprising 24 days of active tablets followed by 4 days of placebo tablets
46040340|NCT02710552|Drug|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 5 mg, indapamide 1,25 and amlodipine 5 mg
46040341|NCT02710552|Drug|Reaptan (perindopril, amlodipine)|Fixed combination of perindopril 10 mg and amlodipine 5 mg
45684383|NCT01903525|Drug|Placebo|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
45684384|NCT00981526|Drug|Telmisartan|"Telmisartan 40mg/day for the first 2 weeks.~Telmisartan 80mg/day for the next 10 weeks."
45684385|NCT00981526|Drug|Placebo|Placebo (plus existing clozapine or olanzapine treatment) for 12 weeks.
45684386|NCT00981526|Drug|Clozapine|Clozapine (plus telmisartan or placebo) for 12 weeks.
45684387|NCT00981526|Drug|Olanzapine|Olanzapine (plus telmisartan or placebo) for 12 weeks.
45840637|NCT04900116|Drug|Bupivacaine HCl 0.25 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.25% bupivacaine using a 22 gauge 10 mm block needle.
46040342|NCT02710396|Drug|Pembrolizumab|"Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2 (programmed cell death (PD) proteins).~Pembrolizumab 200 mg will be administered IV every 3 weeks."
46040343|NCT02710396|Drug|Carboplatin|Carboplatin AUC (area under curve (AUC)) = 5 IV on day 1 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
46040344|NCT02710396|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2 IV on days 1, 8 and 15 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
46040345|NCT02710396|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
45840638|NCT04900116|Drug|Bupivacaine HCl 0.125 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.125% bupivacaine using a 22 gauge 10 mm block needle.
45840639|NCT04900116|Drug|NaCl 0.9%|In this group, US guided PENG block will be performed with 20 ml %0.9 NaCl solution using a 22 gauge 10 mm block needle (Control Group).
46040346|NCT04564768|Behavioral|Online Mindfulness-Based Cancer Recovery (MBCR)|Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools.
46040347|NCT02710318|Behavioral|Electronic immunization alert|Immunization alert in the electronic health record
46040348|NCT02710162|Device|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flanged rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) used.
46040349|NCT02710162|Device|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
45840640|NCT04699890|Other|Blood sampling, questionnaires and specific exams|Patients will have additionnal blood samples, answer to self-questionnaires and will performed an electrocardiogram and an echocardiography if not performed in routine care.
46040350|NCT02710162|Device|Electrical Impedance Myography|The SFB7 Bioimpedance device measures the function of the tongue by calculating measures of reactance, resistance and phase once a custom electrode array is placed on the midline of the subject's tongue for approximately 2 seconds.
45344149|NCT00713076|Other|Polyquaternium-preserved Multi-purpose Lens Cleaning Solution 109182|Lens Cleaning Solution Formulation Identification Number 109182
45344150|NCT00713154|Drug|MTS-01|MTS-01 7% gel in 100 ml tubes, two 100 ml tubes prior to each radiation treatment
45344151|NCT00713154|Drug|Placebo|Placebo gel in 100 ml tube, two 100 ml tubes prior to each radiation treatment
45344152|NCT00620074|Drug|voriconazole|Subjects with creatinine clearance at least 50 ml/min will receive initial treatment with IV (loading dose of 6 mg/kg Q12h followed by maintenance dose of 4 mg/kg Q12h) or oral (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h). Subjects with creatinine clearance <50 ml/min will receive oral voriconazole (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h).
45840641|NCT04694976|Biological|25-OH Vitamin D measure|As a complement to the off-study prescription, the investigator are taking two 1 mL tubes of extra blood to measure vitamin D, calcium, phosphorus, parathyroid hormone (PTH) and creatinine.
45840642|NCT04690530|Procedure|mechanical ventilation|mechanical vantilation will be performed
45840643|NCT04690530|Drug|Sedation|sedation wil be performed
46040351|NCT02710162|Drug|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
46040352|NCT02710162|Procedure|Videofluoroscopic Swallowing Study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
46040353|NCT02710162|Procedure|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
45344153|NCT00620074|Drug|anidulafungin|Loading dose of 200 mg QD followed by maintenance dose of 100 mg QD for up to a total of 28 days therapy
45344154|NCT01033435|Other|No intervention|
45344155|NCT04069130|Drug|400 mg of BIA 5-1058|1 x 400 mg capsule Oral, Fasted
45344156|NCT04042012|Other|Eccentric exercise|soleus eccentric exercise
45344157|NCT04042012|Other|PNE|the application of galvanic current
45344158|NCT04042012|Other|Combined|soleus eccentric exercise and PNE
45344159|NCT00719238|Behavioral|Nutrition plus education|Nutritional instruction in small groups plus education
45344160|NCT00719238|Behavioral|Education only|Educational video and pamphlets
45344161|NCT02571296|Drug|micronized progesterone|Oral
45344162|NCT02571296|Drug|Placebo|Oral
45344163|NCT00857038|Drug|Doxycycline|Doxycycline tablets, 100mg daily
45344164|NCT00857038|Drug|Placebo|Placebo tablets 100mg
45344165|NCT00719316|Drug|Aliskiren|Aliskiren 300mg per day for 6 weeks
45840644|NCT04640298|Device|Cingal|CINGAL® is a chemically cross-linked sodium hyaluronate combined with Triamcinolone Hexacetonide supplied as a 4-mL unit dose in a 5-mL glass syringe.
45840645|NCT04603248|Drug|Nivolumab|Nivolumab 3mg/kg treatment will be given every 2 weeks up to progression or unacceptable toxicity
45840646|NCT04340700|Drug|THC or Placebo|A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber. The first THC dose is 8 mg, followed by approximately three doses of 2 mg each. Placebo will also be administered through a Volcano Vaporizer via inhalation. The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.
46040354|NCT02710162|Other|Swallowing Related Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
46040355|NCT02710162|Other|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
46040356|NCT02710162|Other|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised|The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) will be used to track global disease progression in participants.
46040357|NCT02710162|Other|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
45474549|NCT03360526|Device|PICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. (Selecting an individual bound sperm with enhanced genetic and developmental integrity ensures that the sperm selected is the optimal sperm from the sample for oocyte injection.
46040358|NCT02710162|Other|Communicative Effectiveness Survey|The Communication Effectiveness Survey (CES) will be used for participant reporting of communication abilities across different speech contexts.
46040359|NCT02710162|Other|The Center for Neurologic Studies Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
46040360|NCT02709928|Drug|TD-0714|
46040361|NCT02709928|Drug|Placebo|
45344166|NCT00720200|Behavioral|Facilitator-Based intervention|Family Members receiving facilitator-based intervention
45344167|NCT00720200|Behavioral|Usual Care|Family Members receiving usual care/clinical interaction
45344168|NCT03926988|Device|NeVa Stent Retriever|mechanical neurothrombectomy
45344169|NCT00857116|Drug|Albendazole|Albendazole 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
45344170|NCT00857116|Drug|Placebo|Placebo 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
45474550|NCT03360526|Procedure|TESA|"Patients will undergo TESA which is performed by sticking a needle in the testis and aspirating fluid and tissue with negative pressure then examine the sample for presence of motile~sperms followed by sample processing and oocyte injection."
45474551|NCT01064479|Drug|Carboplatin|Given IV
45474552|NCT01064479|Drug|Cisplatin|Given IV
45474553|NCT01064479|Drug|Docetaxel|Given IV
45840647|NCT04213248|Drug|Umbilical Mesenchymal Stem Cells derived Exosomes|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by UMSC-exo 10ug/drop, four times a day for 14 days. The follow-up visit will be 12 weeks.
45840648|NCT04033224|Device|Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)|Every center will prescribe EBPT with commercial membranes in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
45840649|NCT03936270|Drug|Palbociclib 125mg|The Palbociclib capsules supplied for this study contains 75 mg, 100 mg or 125 mg of Palbociclib. It must be taken orally 125 mg once daily for 21 consecutive days followed by 7 days off treatment (Schedule 3/1) to comprise a complete cycle of 28 days.
45840650|NCT03936270|Drug|Letrozole 2.5mg|Letrozole will be supplied as a 2.5 mg film-coated tablet. It must be taken at the recommended dose of 2.5 mg once daily.
46040362|NCT02710006|Procedure|Sonohysterography|Sonohysterography, also known as saline infusion sonography, is a special, minimally invasive ultrasound technique. Sonohysterography is a technique in which fluid is injected through the cervix into the uterus, and ultrasound is used to. It provides pictures of the inside of a woman's uterus. Three-dimensional sonohysterography is based on volumetric scanning of uterus and its cavity during saline infusion.
46040363|NCT00611728|Drug|SU011248 & Irinotecan|"Sutent given in daily oral manner for 1st 4 wks of each 6wk cycle. You will not take any Sutent during last 14 days of each 6 wk cycle. CPT-11 will be given intravenously over 1 & 1/2 hrs on 1st day of each cycle & then again on days 14 & 28.~Sutent is approved for adult subjects w some forms of kidney cancer. It is considered investigational for brain tumors. Dosing will begin on day 1 of cycle 1 & continue daily for 4 wks by mouth.~Irinotecan is approved for adult subjects with some forms of colorectal cancer. It is also considered investigational for brain tumors. Irinotecan dose will depend on your height & weight. Irinotecan will be given intravenously over 90 min on days 1, 14 & 28 of 6wk cycle.~You will be seen in clinic approximately every 42 days for 1st 3 cycles of study drug, & then every other cycle thereafter. Your brain MRI examination will be done within 1 wk prior to completion of cycles 1-3, & then within 1 week prior to completion of every other cycle."
46040364|NCT04497610|Diagnostic Test|Breath sample|Patient will blow into a tube 5 times.
46040365|NCT02709850|Drug|IONIS ANGPTL3-LRx|
46040366|NCT02709850|Drug|Placebo|0.9%NaCl, water, riboflavin
46040367|NCT02709772|Behavioral|Electronic Record Alert|Electronic alert within the medical record indicating the ordered test or treatment may be inappropriate. The provider can indicate why the test or treatment is appropriate and complete the order.
46040368|NCT02709304|Drug|Lidocaine gel|Gel used for insertion of urinary catheter containing local anesthetic to determine if patients have less discomfort postoperatively when this is used
46040369|NCT02709304|Drug|standard gel|Standard gel that is used to insert a urinary catheter that does not contain local anesthetic
46040370|NCT04189666|Drug|Rivastigmine Transdermal System [Exelon]|compare the ability of the drug in preventing postoperative delirium
45344171|NCT00717782|Procedure|injection of botulinum toxin|Patients received a 0·6-ml injection of a solution containing 30 units botulinum toxin into the internal anal sphincter
45344172|NCT00717782|Procedure|injection of saline|Patients received a 0·6-ml injection of a saline solution into the internal anal sphincter
45344173|NCT00719394|Drug|GSI 136|
45344174|NCT00719394|Drug|placebo|
46040371|NCT04189666|Drug|Melatonin|compare the ability of the drug in preventing postoperative delirium
46040372|NCT03944512|Drug|Pravastatin|20 mg Pravastatin taken daily
46040373|NCT03944512|Other|Placebo|Identical appearing placebo pill
45344175|NCT00857194|Procedure|2 hour Oral Glucose Tolerance Test|Fasting baseline blood samples will be drawn for analysis of insulin and glucose. A 75-gram glucose solution will be administered and subjects remain sedentary for 2 hours. After 2 hours, blood is drawn to analyze post-load insulin and glucose levels.
45344176|NCT00857194|Procedure|Fat Meal Test|A fasting blood draw is performed for analysis of lipids, insulin, and glucose. Subjects ingest a high fat meal (milkshake made from heavy whipping cream and premium ice cream) within 15 minutes. Postprandial blood draws at 2, 4, and 6 hours are made for analysis of lipids, insulin, and glucose.
45344177|NCT04011410|Drug|Hydroxychloroquine Sulfate 200Mg Tab|Twice daily for 90-days, administered two weeks prior to radiation/surgery of oligometastatic lesions
45382082|NCT05362903|Other|Inclisiran|Prospective observational cohort study. There is no treatment allocation. Patients administered Inclisiran by prescription will be enrolled.
45684388|NCT05601310|Device|liquid chromatography-mass spectrometry (LC/MS) analysis|To obtain a complete metabolic profile, untargeted metabolomics analysis was conducted by using UPLC-MS. Chromatographic separation was accomplished in an Thermo Vanquish system equipped with an ACQUITY UPLC®HSS T3 (150×2.1 mm, 1.8 µm, Waters, USA) column maintained at 40 ℃. The temperature of the autosampler was 8 ℃. The ESI-MSn experiments were executed on the Thermo Q Exactive mass spectrometer with the spray voltage of 3.5 kV and -2.5 kV in positive and negative modes, respectively. The capillary temperature was 325℃. The analyzer scanned over a mass range of m/z 81-1 000 for full scan at a mass resolution of 70 000. The normalized collision energy was 30 eV(19606840). The detected ions were all under isotopic calibration with the accurate masses of the reference standards.
45840651|NCT03878394|Other|aerobic exercise and balance exercises|The first group will be prescribed aerobic exercise and balance exercises as home exercise. Participants in this group will perform 30 min moderate walking exercises and balance exercises. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Exercises will be held once a day for 3 days per week over 6 weeks.Exercise will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
46040374|NCT04160338|Device|specular microscopy|"An informed written consent will be obtained from all patients that will be included in this study. Patients in this study will undergo specular microscopic examination of corneal endothelium before CXL procedure.~Patients will be assigned to undergo accelerated (epithelium-off ,transepithelial ) CXL .~Follow up specular microscopy will be done 3 months and 6 months after corneal collagen cross linking procedure ."
45474554|NCT01064479|Drug|Erlotinib Hydrochloride|Given PO
45684389|NCT01927900|Dietary Supplement|HMO|
45684390|NCT01927900|Dietary Supplement|Glucose|
45684391|NCT04274920|Other|Bioactive Glass|Bioactive glass was incorporated in resin composite and its adhesive
45684392|NCT04274920|Other|Light cured calcium hydroxide|Light cured calcium hydroxide
45684393|NCT04274842|Other|observation by D-OCT|observation by D-OCT before, after, 1-3 days after, and 1 month after IPL treatment
46040375|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation I
46040376|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation II
45684394|NCT04274608|Drug|Botulinum toxin type A|Intragastric injection of Botulinum toxin type A
46040377|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation III
46040378|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation IV
45684395|NCT04274608|Behavioral|Weight Management Program|12 week weight management program
45684396|NCT05601076|Procedure|fixed with the triple-buffer system|The steps were as follows: i) elastic cotton tape (3M 2733-25 Japan Ltd., Tokyo, Japan) was used at the proximal 15 cm from the incision, with 5 × 2.5 cm pieces glued to the skin and fixed with the drainage tube using surgical knots; ii) the distal end of the ligation was fixed using the same method, while the ligation position was higher than the first; iii) the ligature point was fixed next to the elastic soft cotton tape (5 × 5 cm), using the high-platform method to fix the drainage tube, with the drainage tube curved; and iv) the drainage tube between the two fixed points was inserted with a specific radian.
45344178|NCT03847870|Diagnostic Test|MORU in-house ELISA test followed by IFA if positive|An in-house rickettsial IgG ELISA test will be used for this study to determine previous rickettsial infections by measuring IgG levels. All specimens will be tested for IgG antibodies using ELISA tests for scrub typhus (Orientia tsutsugamushi strains Karp, Kato, Gilliam and TA716), murine typhus (Rickettsia typhi strain type Wilmington), and spotted fever rickettsiosis (Rickettsia honei and Rickettsia conorii). If the sample tests positive, it will be retested for the same antigens using the IFA test. The sample will be considered positive if both the ELISA and the IFA are positive.
45344179|NCT00717938|Drug|cisplatinum or carboplatin and e.g.etoposide.|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. Treatment will be given every three weeks for 4-6 cycles according to local variants.
45344180|NCT00717938|Drug|cisplatinum or carboplatin and e.g.etoposide+enoxaparin|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
45344181|NCT04068558|Device|VNI-NAVA/sNIPPV|Ventilation of the child in NIV-NAVA for 2 hours then ventilation of the child in sNIPPV for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
45344182|NCT04068558|Device|sNIPPV/VNI-NAVA|Ventilation of the child in sNIPPV for 2 hours then ventilation of the child in NIV-NAVA for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
46040379|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation V
46040380|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation VI
46040381|NCT00937521|Biological|Control|Control
46040382|NCT00937521|Biological|Meningococcal B vaccine with antipyretic|Vaccine candidate formulation I with antipyretic
46040383|NCT02709460|Procedure|Lateral occlusion|Lateral occlusion close to the internal Iliac artery
46040384|NCT02709460|Procedure|Cervical occlusion|Cervical occlusion of the uterine artery
46040385|NCT02709382|Drug|Cefepime and Tazobactam combination|
46040386|NCT02708992|Drug|Azithromycin|
46040387|NCT02708992|Drug|Cefixime|
46040388|NCT02709070|Procedure|resection|hepatectomy for HCC
46040389|NCT02709070|Procedure|highly-purified CTL|hepatectomy first, followed by highly-purified CTL treatment
46040390|NCT02708914|Biological|UB-851|UB-851 (rhEPO) has been developed as a biosimilar product to Eprex®.
45344183|NCT04068090|Other|Patient Questionnaires|FACT-Ntx, EORTC-CIPN20
46040391|NCT02708914|Biological|Eprex|Eprex® is chosen as the comparator.
46040392|NCT02709148|Device|Activa PC+S|DBS
46040393|NCT00611962|Drug|Oxaliplatin, Paclitaxel|"Oxaliplatin was provided in clear glass vials sealed with a rubber stopper and an aluminum seal with a flip-off cover. Each vial contained 50 or 100 mg of active ingredient with 450 or 900 mg, respectively, of lactose monohydrate as excipient~Paclitaxel was supplied as single dose vials of 30 mg/5 mL or 100 mg/17 mL."
46040394|NCT05380791|Other|Follow-up visits|Regular follow-up visits to record information about the patient's surgery and routine post-operative examinations
46040395|NCT05380713|Drug|Cyclophosphamide|Cyclophosphamide will be applied in the neoadjuvant setting
46040396|NCT05380713|Drug|Tremelimumab|tremelimumab-durvalumab in adjuvant setting
46040397|NCT05380713|Drug|Durvalumab|tremelimumab-durvalumab in adjuvant setting
46040398|NCT00606099|Drug|telbivudine|To compare the rate and pattern of treatment-emergent Hepatitis B virus (HBV) viral genotypic mutations after 24 weeks of treatment.
46040399|NCT00606099|Drug|adefovir dipivoxil|Active Comparator
46040400|NCT02708602|Genetic|β2AR polymorphism|
46040401|NCT00935883|Drug|Eculizumab|"Induction Period: patient will receive eculizumab 600 mg or 900 mg via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by 900 mg or 1200 mg eculizumab for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive eculizumab 900 mg or 1200 mg via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
46040402|NCT00935883|Drug|Saline|"Induction Period: patient will receive saline via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by saline for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive saline via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
45344184|NCT04068090|Other|Blood Collection|biomarker analysis
45344185|NCT00857428|Drug|oxymorphone|Tablets
45344186|NCT00857428|Drug|Oxymorphone|40 mg tablets
46040403|NCT02708446|Drug|Mifepristone|200mg oral mifepristone to both study arms
46040404|NCT02708446|Drug|Buccal misoprostol|doses of buccal misoprostol every 3 hours beginning 24 hours after mifepristone
46040405|NCT02708446|Drug|Sublingual misoprostol|doses of sublingual misoprostol every 3 hours beginning 24 hours after mifepristone
46040406|NCT03913078|Behavioral|Group Fitness|Traditional Group Fitness consisting of aerobic and strength exercises performed in a group setting and led by a trained instructor.
46040407|NCT03913078|Behavioral|PlayFit|Modified sports fitness exercise program consisting of games played in groups and led by a trained instructor.
46040408|NCT02708056|Drug|Sugammadex|
46040409|NCT04426708|Drug|HMS5552|single dose of HMS5552 25mg
46040410|NCT05305209|Other|Intervention group|The patients will receive 12 minutes of intravaginal application with an average power of 1 watios and total applied energy of 720J and an extracavitary application for 4 minutes with an average power of 3 watios and a total dose of 720J with all effects at 200%, twice a week for 6 weeks.
46040411|NCT05305209|Other|Control Group|The patients will receive 12 minutes of intravaginal application and 4 minutes of extracavitary application, twice a week for 6 weeks. The difference compared to the intervention of group 1 is that the device will be off and therefore will not emit energy.
46040412|NCT05378919|Radiation|Radiotherapy 50 Gy|Radiotherapy 50 Gy 5 radiations per week of 2 Gy for 5 weeks
45344187|NCT02572778|Procedure|Local biopsy in the tumor|A tumor biopsy of 0.5 cm2 or more will be collected from every patient during surgery or endoscopy after informed consent and if there is enough material after review by the pathologist.
45344188|NCT04069494|Other|questionnaires|Two questionnaires in patients and another two questionnaires in carer.
45474555|NCT01064479|Other|Laboratory Biomarker Analysis|Optional correlative studies
46040413|NCT05378919|Drug|Fluorouracil/folic acid|Fluorouracil 400 mg/m² D1-4 and folic acid 20mg/m2 D1-4 the first and fifth weeks of radiotherapy
46040414|NCT05378919|Drug|Chemotherapy in regimen with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4)|oxaliplatin: 85 mg/m² in 2 hours at D1; folinic acid: 100 mg/m² simultaneously in 2 hours at D1 and D2 during the Oxaliplatin; bolus 5-fluorouracil (5-FU) 400mg/m² D1+D2; infusion 5-fluorouracil (5-FU): 600 mg/m² continuous infusion during 22hours at D1 and D2, every 14 days during 42 months (8 cycles).
46040415|NCT05378919|Radiation|Radiotherapy 50 Gy|"Chemoradiotherapy 5 weeks (50 Grays (Gy), 2 Gy/session; 25 fractions) + fluorouracil/leucovorin 400 mg/m² 1-4 day the first and fifth weeks of radiotherapy.~FOLOFX4 will be administrated for 8 cycles over a 16 week period. Patients will undergo re-staging within 6 weeks of their 8th cycle of FOLFOX. This will include MRI of the pelvis. If the reassessment reveals that there has been no disease progression compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection, the patient will proceed to definitive rectal cancer surgery within 8 weeks from the last chemotherapy dose. If the surgical oncologist's reassessment reveals that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous fluorouracil."
46040416|NCT00607581|Drug|cyclophosphamide|cyclophosphamide: 500 mg orally on days 1, 8, 15
45684397|NCT05601076|Procedure|fixed using the conventional lifting platform method|In terms of the control group, two lines of flexible cotton tape (3M 2733-25 Japan Ltd., Tokyo, Japan) measuring 10 × 2.5 cm were used, and the drainage tube was fixed parallel to the long axis and glued to the middle-position 360° winding tube once the drainage tube was 0.5 cm higher than the surrounding skin. Next, the drainage tube was fixed at both ends to the patient's skin using adhesive tape. Then, the tube and the adhesive plaster were overlapped vertically and horizontally, the tube was inserted, the adhesive plaster was added, and then the chest tube was fixed on the adhesive plaster by knotting the interspersed cotton rope, which was equal to indirectly fixing the tube on the patient's skin
45344189|NCT04018768|Other|ibuprofen 600 mg|MRN ending in an EVEN # will receive ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN) and oxycodone/acetaminophen (Percocet) 5 mg/325 mg for pain that is not adequately controlled by the ibuprofen.
45344190|NCT04018768|Other|Oxycodone/acetaminophen (Percocet) 5 mg/325|MRN ending in an ODD #: will receive the current standard of care postoperative pain management, which is Percocet 5 mg/325 mg every 6 hours PRN.
45344191|NCT03518060|Drug|Juluca|Juluca is a combination of dolutegravir (INSTI) and rilpivirine (NNRTI).
45344192|NCT00719784|Device|Vibration Response Imaging|Recordings will be then performed using the VRI device (Deep Breeze™, Or Akiva, Israel). Forty-two sensors that are assembled on 2 planar arrays will be placed on subject's back. Each row of 3 sensors is held in place by silicone cups that are coupled to the patient's back by a computer-controlled low vacuum seal.
46040417|NCT00607581|Drug|lenalidomide|lenalidomide: 15 mg orally on days 1-21
46040418|NCT00607581|Drug|dexamethasone|dexamethasone: 40 mg orally on days on days 1, 8, 15, 22
46040419|NCT02707900|Drug|Vorinostat|"At Step 2 (Enrollment) - subjects receive two paired oral doses of Vorinostat (VOR) 400 mg.~Step 5 - Approximately 7- 10 days after the 4th dose of AGS-004 in Step 4 (Visit 11), ten (10) doses of VOR 400 mg will be administered at 72 hour intervals.~Steps 6 - 7 & EOS visit - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 6) followed by 10 doses of VOR 400 mg PO (Step 7)."
46040420|NCT02707900|Biological|AGS-004|"Step 4 - AGS-004 vaccination. AGS-004 product will be delivered in three intradermal injections of 0.2 mL (0.6 mL total volume) for a total of 1.2 x 10-7 viable cells. AGS-004 will be administered every 3 weeks for 4 doses.~Steps 6 - 7 & EOS visit - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 6) followed by 10 doses of VOR 400 mg PO (Step 7)."
46040421|NCT05380479|Drug|Mirtazapine|mirtazaine15 mg tablet daily for 8 weeks.
46040422|NCT05380479|Drug|Megestrol Acetate|megestrol acetate 160 mg tablet daily for 8 weeks.
46040423|NCT02707822|Other|Clinical and genetic factors|
46040424|NCT00936975|Radiation|Fluorine F 18 Sodium Fluoride|Undergo fluorine F 18 sodium fluoride PET scan
46040425|NCT02707744|Other|no intervention|
45474556|NCT01064479|Other|Pharmacological Study|Optional correlative studies
45474557|NCT01064479|Other|Placebo|Given PO
46040426|NCT05378841|Procedure|Surgical Denervation|This is an outpatient procedure performed under local anesthesia (depending on the anesthesiologist's decision), which lasts about 30 minutes.
46040427|NCT02707978|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
46040428|NCT00604929|Dietary Supplement|carbohydrate and protein|The intake of carbohydrate and protein during endurance type exercise
45344193|NCT00848848|Biological|Trivalent Influenza Vaccine|1 dose of Trivalent Influenza Vaccine
45474558|NCT01064479|Other|Quality-of-Life Assessment|Ancillary studies
46040429|NCT04410718|Other|Glycaemic levels|Glycaemic levels during admission for COVID-19
46040430|NCT02707510|Other|Growing Resiliency And CouragE with Cancer™ (GRACE)|GRACE is a 6 week curriculum which includes themes illustrated via PowerPoint slides with semi-structured delivery, video presentations, a variety of mindfulness meditation practices, and selected readings that serve to reflect and capture the theme for the week of the curriculum.
46040431|NCT02707354|Device|Probe based confocal laser endomicroscopy (Cellvizio)|"The probe is a miniaturized microscope in the form of a fiber which is inserted through the endoscope and brought into contact with the mucosa. It thus allows for a live virtual biopsy, that is to say, obtaining real-time microscopic virtual image of the mucosa. It requires an intra-veinous injection of 5 mL of 10% fluorescein diluted in 50 cc of saline serum. The images obtained during the examination will be recorded via the endomicroscopy console so that two endoscopists blinded from the macroscopic and histological findings can review the data."
46040432|NCT04335682|Drug|Darolutamide|Patients randomized to darolutamide.
46040433|NCT04335682|Drug|Enzalutamide|Patients randomized to enzalutamide.
45344194|NCT00848848|Biological|Trivalent Influenza Vaccine + high A|1 dose of Trivalent Influenza Vaccine with high A content
45344195|NCT00848848|Biological|Trivalent Influenza Vaccine + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ¼ dose adjuvant
46040434|NCT02707120|Drug|PRGF-Endoret|Active treatment will be PRP eye drops obtained by the PRGF-Endoret system.
46040435|NCT02707120|Drug|Artificial tears eye-drops|Artificial tear moisturizing eyedrops (Hidrathea®, Nacl 0.9 % solution without preservatives).
46040436|NCT02706808|Dietary Supplement|'resistance starch for CKD|Intervention period (6 weeks): Group A - patients will receive 6 cookies/day containing resistant starch (18g/day); Group B - patients will receive 6 cookies/day containing placebo
45344196|NCT00848848|Biological|Trivalent Influenza Vaccine + high A + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ¼ dose adjuvant
45344197|NCT00848848|Biological|Trivalent Influenza Vaccine + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ½ dose adjuvant
45344198|NCT00848848|Biological|Trivalent Influenza Vaccine + high A + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ½ dose adjuvant
46040437|NCT02706808|Dietary Supplement|Placebo|Intervention period (6 weeks): Group B - patients will receive 6 cookies/day containing resistant starch (18g/day); Group A - patients will receive 6 cookies/day containing placebo
46040438|NCT02693470|Drug|Ustekinumab|50 patients with severe psoriasis received ustekinumab 45mg at 0 and 1 month. There were 50 healthy controls. The levels of circulating CD31 and CD41a positive microparticles are measured. In patients with psoriasis, the investigators measure microparticles in the baseline and 4 months after ustekinumab. For control group, the investigators measure microparticles in the baseline.
45474559|NCT01180439|Device|Adjustment of ventilator settings (device)|Decrease in pressure support, increase in respiratory back-up rate, increase in expiratory positive airway pressure (EPAP) to counteract effect of PEEPi, and adjustment of cycling (at higher percentage of peak inspiratory flow)
45474560|NCT03639883|Drug|AIV001|Intradermal injection
46040439|NCT00936897|Drug|Ibandronate|Ibandronate 150mg PO QM (tablet)
46040440|NCT00936897|Drug|Denosumab|denosumab 60mg SC Q6M (pre-filled syringe)
45344199|NCT00848848|Biological|Trivalent Influenza Vaccine + adjuvant|1 dose of Trivalent Influenza Vaccine plus adjuvant
45344200|NCT00848848|Biological|Trivalent Influenza Vaccine + high A + adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus adjuvant
45344201|NCT00848848|Biological|Trivalent Influenza Vaccine intradermal dose|1 dose of Trivalent Influenza Vaccine intradermal dose
45344202|NCT00848848|Biological|Trivalent Influenza Vaccine + high A intradermal dose|1 intradermal dose of Trivalent Influenza Vaccine + high A
45344203|NCT04069364|Behavioral|TinnitusTipps|Self-helf tips for managing chronic tinnitus will be given via smartphones.
45344204|NCT02573922|Drug|oxycodone-naloxone|
45344205|NCT02573922|Drug|Oxycodone|
45474561|NCT04218708|Other|Nicotine patch and gum|Nicotine patch and gum will be given to subjects in the Nicotine replacement therapy cohort every visit after providing exhaled CO/Saliva cotinine test.
45474562|NCT04218708|Behavioral|Minnesota Nicotine Withdrawal Scale (MNWS)|The MNWS assesses symptoms associated with nicotine withdrawal (i.e., craving, irritability, anxiety, difficulty concentrating, restlessness, increased appetite or weight gain, depression, and insomnia).
45474563|NCT04218708|Behavioral|ASSIST (the Alcohol, Smoking and Substance Involvement Screening)|The ASSIST is the Alcohol, Smoking and Substance Involvement Screening Test. It is a brief screening questionnaire to find out about people's use of psychoactive substances (alcohol, smoking and substance involvement).
45474564|NCT04218708|Behavioral|Counseling|At each study visit, participants will receive counseling protocol that will be based on effective counseling manuals. The PI will train the research assistant who will assist the PI in tailoring the manual to the target group: counseling will cover health education, social support issues, and motivational enhancement to improve self-efficacy while addressing other aspects known to contribute to smoking among PLWHA (e.g., tips on dealing with depression and feeling stigmatized particularly in relation to HIV).
45474565|NCT04218708|Other|NIDA Standardized Research E-cigarettes (SREC)|"NIDA SREC has a case with a liquid tank. The e-liquid is supplied in sealed disposable cartridges that deliver >300 puffs / cartridge. The SREC uses a battery recharged via a micro USB port. A single charge is designed to outlast the capacity of an e-liquid cartridge. The e-liquid is tobacco flavored and contains nicotine."
45474566|NCT01177631|Procedure|Operation|Operation for clinically evaluated resectable hepatocelluar carcinoma. Compare the different expression of protein between tumor, non-tumor and tumor with vascular invasion part.
45474567|NCT03360448|Drug|Ad5.hAC6|1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
46040441|NCT02706418|Procedure|Clinical Massage Therapy|
46040442|NCT00607659|Other|No intervention, only observational|No intervention, only observational
46040443|NCT02706340|Other|No intervention - observational study only|
46040444|NCT04266561|Other|hernia repair|Two 3-mm needle holders were used for stitching the wide IIR. Then the suture was continued along the upper margin of IIR, but in a deeper plane to include the peritoneum and the deeper fascia transversalis.
46040445|NCT02706184|Drug|E. coli Nissle suspension|Patients receive E. coli Nissle suspension
46040446|NCT02706184|Drug|Placebo|Placebo
46040447|NCT04264689|Procedure|serratus anterior block|ultrasound guided block
46040448|NCT04264689|Procedure|thoracic epidural|thoracic epidural
46040449|NCT04264689|Procedure|erector spinae block|ultrasound guided block
45344206|NCT00852436|Drug|pregabalin|Pregabalin capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
45344207|NCT00852436|Drug|placebo|Placebo capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
45344208|NCT02574000|Other|ShoulderQ which is a shoulder pain questionnaire|Questions regarding shoulder pain at rest, during movement and at night with visual analogue scales. Factors affecting shoulder pain.
45474568|NCT03360448|Drug|Placebo|1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
45474569|NCT01288001|Drug|Ostenil plus|2% Sodium Hyaluronate plus Mannitol injection
45474570|NCT03732313|Procedure|Central toenail resection|Using local aneasthesia, resection of central part of toenail with germinal matrix.
45474571|NCT03732313|Procedure|Wedge toenail resection|Using local anaesthesia,we remove lateral part of toenail .
46040450|NCT05265676|Drug|Enoxaparin Sodium (Venus Remedies Limited)|The test drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Venus Remedies Limited, India
46040451|NCT05265676|Drug|Enoxaparin Sodium (Sanofi)|The reference drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Sanofi, Germany
46040452|NCT00606333|Device|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the Conor Cobalt Chromium Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
45344209|NCT02574000|Other|Clinical shoulder examination|Shoulder-Hand-Score (measuring pain, oedema, passive range of movement), muscle strength (using Oxford scale and National Institute of Health Stroke Scale (NIHSS) upper limbe motor and shoulder joint palpation (recording subluxation and soft-tissue pain).
45344210|NCT04068350|Other|Pain questionnaire|Pain questionnaire, 3 months after surgery
46040453|NCT00606333|Device|Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
45344211|NCT00857662|Device|Onyx|Embolization
46040454|NCT03886714|Diagnostic Test|Screening for Fabry disease|Screening for the α-galactosidase (GAL) enzyme activity (men + women) and plasma Lyso globotriaosylsphingosine (GL3, women) for the diagnosis of Fabry disease.
46040455|NCT03886714|Diagnostic Test|Screen for α-galactosidase mutation|If necessary (positive for GAL), genetic confirmation tests for Fabry disease will be performed (men + women).
46040456|NCT04264611|Other|Experimental: Short Foot Exercise Group|Short foot exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
45684398|NCT05600998|Drug|Camrelizumab|Subjects will receive carilizumab every three weeks, with alozantinib 20 mg orally daily for 9 weeks
46040457|NCT04264611|Other|Experimental: Towel Curl Exercise Group|Towel curl exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
45344212|NCT00857662|Device|TRUFILL|Embolization
45344213|NCT02573844|Drug|Proklama|
45344214|NCT02573844|Drug|Placebo|
45344215|NCT02545894|Behavioral|Cognitive therapy|"The tasks are:~visually tracking a picture as it moves across the computer screen~pressing a button every time a picture is seen on the screen~pressing a button every time a specific picture is seen on the screen~Pressing a button every time a specific sound is heard~Matching objects to a picture~Matching gestures to objects~Matching two connected objects~Sorting objects by categories~Matching sounds to objects~Complete the category and odd on out with objects~Choosing target objects by pointing~Choosing objects to complete the category by pointing"
45684399|NCT05607940|Procedure|blood volume loss based blood transfusion|Blood transfusion is indicated based on the estimated intraoperative blood loss. When intraoperative blood loss exceeds 400ml, blood transfusion begin. At the end of the operation, we ensure that the volume of blood transfusion is no greater than the anticipated blood loss.
46040458|NCT05265442|Drug|Methadone|titration of Zoryon (methadone): increase of posology untill pain relieved is reached
45344216|NCT00424177|Drug|eltrombopag|experimental
45344217|NCT04068116|Procedure|Primary per-cutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention including balloon angioplasty & coronary stent deployment as needed +/- post-conditioning (for post-conditioning arm) making 4 cycles of repeated occlusion & reperfusion 30-second each by inflation/deflation of an appropriately sized PTCA (percutaneous transluminal coronary angioplasty) balloon
45344218|NCT00716430|Behavioral|Quality Improvement Programme|Quality Improvement training programme
45344219|NCT00720512|Biological|bevacizumab|Given IV
45344220|NCT00720512|Drug|fluorouracil|Given IV
45344221|NCT00720512|Drug|irinotecan hydrochloride|Given IV
45344222|NCT00720512|Drug|leucovorin calcium|Given IV
45344223|NCT00720512|Drug|oxaliplatin|Given IV
45344224|NCT04069286|Drug|Oral Aroeira/ Amoxicillin/ Claritromycin|Oral Aroeira (Schinus terebinthifolius Raddi, 640mg/tablet) 1 tablet, twice day, 12/12 hours + Amoxicillin 2 tablets of 500mg, twice day, 12/12 hours, + Claritromycin, 1 tablet of 500mg, twice day, 12/12 hours, for 14 days.
46040459|NCT05265130|Drug|YiQiFuMai|YQFM is a redeveloped preparation based on the traditional Chinese medicine formula Sheng-Mai-San, which is widely used in clinical practice in China, mainly for the microcirculatory disturbance-related diseases.
46040460|NCT05265130|Drug|0.9% Normal Saline 250ml|0.9% Normal Saline 250ml IV, about 40 drops per min.
45684400|NCT05607940|Procedure|hemoglobin concentration based blood transfusion|Blood transfusion is indicated based on the intraoperative hemoglobin concentration. Intraoperative blood transfusion begins when hemoglobin concentration is blow 70g/L. Intraoperative blood transfusion stops when hemoglobin concentration reaches 80g/L
46040461|NCT02691117|Drug|garlic concentrate|Topical application of GarlicRich gel on the scalp areas affected with alopecia areata once a day for 6 months
46040462|NCT02693626|Behavioral|intensive cessation message|Mobile phone-based text message （three to five messages per day） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
45344225|NCT04069286|Drug|Omeprazole/ Amoxicillin/ Claritromycin|Omeprazole 1 tablet of 20mg, twice day, 12/12 hours + Amoxicillin 2 tablets of 500mg, twice day, 12/12 hours, + Claritromycin, 1 tablet of 500mg, twice day, 12/12 hours, for 14 days.
45344226|NCT00716508|Procedure|Repair with transpatellar tunnels|Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.
45344227|NCT00716508|Procedure|Repair with suture anchors.|Repair with suture anchors: The insertion points for the three suture anchors will be marked with electrocautery. The anchors will be placed approximately 2 mm from the articulate surface; placing them too superficially may increased the joint reactive force and lead to abnormal patella femora joint mechanics. Pilot holes will be drilled with a 3.2-mm drill bit parallel to the patella, avoiding penetration of the articular surface. Three Suture anchors (Arthrex, Naples FL) will be threaded with two No. 5 Fiberwire (Arthrex, Naples FL) sutures and will be inserted and deployed in the pilot holes in the usual manner.
45344228|NCT04069442|Other|This is a non-interventional study|This is a non-interventional study
45344229|NCT03992846|Drug|75 mg linzagolix tablet|For oral administration once daily
45344230|NCT03992846|Drug|200 mg linzagolix tablet|For oral administration once daily
45344231|NCT03992846|Drug|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
46040463|NCT02693626|Behavioral|Not intensive cessation message|Mobile phone-based text message （three to five messages per week） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
45344232|NCT03992846|Drug|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
45344233|NCT03992846|Drug|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
45344234|NCT03992846|Drug|Placebo capsule to match Add-back capsule|For oral administration once daily
46040464|NCT04266405|Dietary Supplement|Placebo drink|consume 1 bottle (50 mL) per day for 28 days
46040465|NCT04266405|Dietary Supplement|Collagen Cubilose Drink|consume 1 bottle (50 mL) per day for 28 days
46040466|NCT05264662|Drug|Adacel (Tdap)|Administer Adacel to hiv infected and hiv uninfected pregnant mothers
46040467|NCT00606411|Drug|Topiramate or Placebo|25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules
46040468|NCT00631293|Dietary Supplement|lactisole|administration of lactisole followed by placebo
45344235|NCT00713622|Drug|Zonisamide|Capsules of 25mg, 50mg and 100mg zonisamide will be supplied. Dosing will be twice a day.
45344236|NCT00713622|Drug|Sodium valproate|Crushable tablets of 100mg and enteric coated tablets of 200mg and 500mg will be supplied. Dosing will start at 600mg/day, increasing to the minimally effective dose, the maximum tolerated dose, or 2500mg/day, whichever is the lowest.
46040469|NCT00631293|Other|placebo|administration of placebo followed by lactisole
46040470|NCT00612196|Drug|TB-402|Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes
46040471|NCT00612196|Drug|Placebo|
45344237|NCT00719940|Behavioral|Cognitive behavioral therapy|1-15 individual sessions of 50-60 min. to apply 1-15 manualized tinnitus specific cognitive behavioral therapy interventions structured by the tinnitus care disease management program
45344238|NCT00719940|Other|Waiting group|No intervention
45344239|NCT00718172|Procedure|Liver Biopsy|
46040472|NCT00607737|Drug|insulin detemir|3 cutaneous injections
46040473|NCT00607737|Drug|saline|3 cutaneous injections
46040474|NCT05264428|Dietary Supplement|Honey|Participants need to drink honey every day for four weeks.
46040475|NCT05264428|Dietary Supplement|Water|Participants need to drink water every day for four weeks.
45344240|NCT00718172|Drug|Peginterferon &amp; Ribavirin for Hepatitis C|
45344241|NCT00718172|Drug|Pre-treatment Ribavirin|
46040476|NCT05264272|Other|Prospective serological assays|"Investigators will measure the levels of hemogram, AST, ALT, Bilirubine-total,Platelet, ALP, rGT, Albumin, GluAC, HBA1C, Albumin, INR, AFP, Creatinine, eGFR, HBsAg, quantitative HBsAg, anti-HBc, HBeAg, anti-HBe, HBV DNA, HBV genotype, anti-HDV, HDV RNA, and HDV RNA genotype at the enrollment of the study.~BMI data, and Child-Pugh score (in cirrhotic patients) at the enrollment of the study. The smoking status, alcohol, coffee and green tea consumption, diabetes, family history of HCC will be collected."
46040477|NCT05264272|Other|Retrospective serological assays|"Investigators will measure hemogram, AST, ALT, Bilirubine-total,Platelet, ALP, rGT, Albumin, GluAC, HBA1C, Albumin, INR, AFP, Creatinine, eGFR, HBsAg, quantitative HBsAg, anti-HBc, HBeAg, anti-HBe, HBV DNA, HBV genotype, anti-HDV, HDV RNA, HDV RNA genotype BMI data, and Child-Pugh score (in cirrhotic patients) at the enrollment of the study.~The smoking status, alcohol, coffee and green tea consumption, diabetes, family history of HCC will be collected."
46040478|NCT01120691|Drug|QVA149|QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
46040479|NCT01120691|Drug|NVA237|NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
46040480|NCT01120691|Drug|tiotropium|Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
46040481|NCT01120691|Drug|Salbutamol/albuterol|As needed throughout the study
46040482|NCT04281784|Behavioral|EHR-based Clinician Jumpstart|The Jumpstart Guide is a communication-priming intervention for clinicians that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The one-page Jumpstart Guide provides information to the clinician about prior advance care planning documentation and code status derived from the EHR. The Jumpstart Guides includes tips to improve goals-of-care communication.
46040483|NCT04231318|Drug|Cingal|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH)
46040484|NCT04231318|Drug|Triamcinolone Hexacetonide - Lederlon|20 mg/ml supplied as 1 mL unit dose of Triamcinolone Hexacetonide
46040485|NCT04231318|Drug|Placebo|0.9% Saline
46040486|NCT00612274|Drug|tacrolimus|Tacrolimus will be administered at a dose of .02mg/kg/d IVCI beginning day -3 until able to take oral medicines reliably. Blood levels will be maintained at 5-10 ng/ml. The oral dose will be 4 times the IV dose. Tacrolimus will be converted to oral dosing prior to hospital discharge. Tacrolimus will be continued until 4 months post transplant (day +120) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
46040487|NCT00612274|Drug|Sirolimus|Sirolimus will be administered as a 12 mg oral loading dose on day -3 followed by 4mg daily. Sirolimus levels will be obtained on day +0 and then at least twice weekly to maintain a trough serum level of 3-12 ng/ml. Sirolimus will be continued until 5 months post transplant (day +150) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
46040488|NCT00612274|Drug|Methotrexate|Methotrexate, dose #1 will be administered on day +1 post transplantation, as an IV bolus, provided at least 24 hours have elapsed following infusion of donor stem cells at a dose of 10mg/m2. Dose #2 of Methotrexate will be administered 48 hours later, as IV bolus on day +3 at a dose of 5mg/m2.
46040489|NCT05263882|Drug|Gemcitabine combined with eribulin|"Eribulin mesylate injection, specification: 2ml: 1mg/piece. Usage and dosage: 1.4mg/m2, intravenous bolus injection within 2-5 minutes, 21 days as a cycle, once on the 1st and 8th day of each cycle.~Gemcitabine hydrochloride for injection, specification: 200mg: 1g/piece. Usage and dosage: administer gemcitabine (1000 mg/m2) intravenously over 30 minutes on the 1st and 8th day of every 21 days treatment cycle.~The above combination regimen takes 21 days as a treatment cycle, and the efficacy is evaluated every 2 treatment cycles. The drug is continued until the disease progresses or intolerable adverse reactions occur."
46040490|NCT02725138|Dietary Supplement|Probiotic|Probiotic containing Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
46040491|NCT02725138|Other|Placebo|Placebo without Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
46040492|NCT05261230|Behavioral|Vedic Counselling|Trauma focused Vedic Counselling intervention was delivered by trained and experienced therapist of Yoga and Vedanta.12-week sessions were provided on one to one bases on personalised approach.
46040493|NCT05261230|Behavioral|Standard Care|The active control group received standard psychosocial care provided by the participating psychologists and psychiatrists.
46040494|NCT05261152|Drug|drug product: capsules are containing S. boulardii, administered twice daily (250 mg)|Randomisation: 1:1 Capsules containing S. boulardii twice daily (250 mg) or indistinguishable capsules containing placebo twice daily.
46040495|NCT05261074|Other|No intervention|No intervention (retrospective study)
46040496|NCT05260996|Other|Pilot Group|12 Weeks, 1-1 Hour Session Per Week for 10 Total Curriculum Sessions,including 1 Week of Orientation and 1 Week of Debriefing/Program Graduation.
46040497|NCT02724904|Procedure|Allogeneic stem cell transplantation|Reduced intensity allogeneic stem cell transplantation from a fully matched related or unrelated donor
46040498|NCT02724904|Drug|Fludarabine|Standard Treatment
46040499|NCT02724904|Drug|Thiotepa|Standard Treatment
46040500|NCT02724904|Drug|Methotrexate|IV Bolus
46040501|NCT00935493|Drug|Guanfacine|Guanfacine 0.1 mg po qhs
46040502|NCT00935493|Drug|Guanfacine|Guanfacine 0.5 mg po qhs
46040503|NCT00935493|Drug|Placebo|Placebo po qhs
46040504|NCT05380245|Drug|Voriconazole 200 mg x 2 Tablets|Name of medication of Reference Formulation: Tablets Voriconazole Vfend®, 200 mg by Pfizer, Inc. (USA), (Batch No: 00005505; Mfg. date 09/2016).
46040505|NCT05380245|Drug|Clarithromycin 500 mg x 1Tablets|Name of medication of Intervention Formulation: Tablet Klaricid, 500 mg by Abbott, Lab Pvt. Ltd. (Karachi, Pakistan), Batch No: 81573XU; Mfg. date 10/2017.
45344242|NCT00720018|Drug|NP101 Sumatriptan Iontophoretic Transdermal Patch|NP101 transdermal patch delivering sumatriptan for 4 hours.
45344243|NCT00716664|Other|A treatment series of gentle joint and muscle movements|Undertaken by a physiotherapist, weekly, for six weeks
45474572|NCT03360370|Other|Ages & Stages Questionnaires, Third Edition in French (ASQ-3™)|"This questionnaire screens 5 neurodevelopmental areas (communication, gross motor, fine motor, problem solving and personal-social); 30 items per questionnaire about the child's abilities are evaluated.~It takes about 15-20 minutes. Data are collecting and a scoring by a professional is provided. Follow-up action is taken for children at risk. Medical and surgical history is also collected to detect risk factors for neurodevelopmental disorders among neonatal data, characteristics of congenital heart disease and first surgery, and other comorbidities."
45474573|NCT03667326|Drug|Aspirin tablet|Low dose aspirin, 81mg tablets, PO
46040506|NCT03856996|Biological|Stable CH505TF gp120|Administered by IM injection in the deltoid of the non-dominant arm
46040507|NCT03856996|Biological|Transient CH505TF gp120|Administered by IM injection in the deltoid of the non-dominant arm
46040508|NCT03856996|Biological|Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)|Admixed with Stable CH505TF gp120 or Transient CH505TF gp120 for IM injection in the deltoid of the non-dominant arm
45344244|NCT00716664|Other|Control group measurements|The control group are measured using the same outcome measures at the same time intervals, but receive no active intervention
45344245|NCT03992456|Biological|Panitumumab|Given IV
45344246|NCT03992456|Other|Quality-of-Life Assessment|Ancillary studies
45344247|NCT03992456|Other|Questionnaire Administration|Ancillary studies
45344248|NCT03992456|Drug|Regorafenib|Given PO
45474574|NCT03667326|Drug|Placebo oral capsule|Placebo oral capsule, PO
45344249|NCT03992456|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
45344250|NCT00618826|Drug|Paclitaxel|Patients will be premedicated with dexamethasone and diphenhydramine hydrochloride. Patients will received 150mg of paclitaxel via IV over 120 mins.
45344251|NCT00618826|Drug|Gemcitabine|Patients will receive 1500mg of Gemcitabine via IV over 30-60 minutes. Gemcitabine will be given after Paclitaxel.
46040509|NCT05378685|Procedure|Endotracheal intubation|The patient is intubated using a laryngoscope and cuffed endotracheal tube. The selection and size of the equipment is at the discretion of the pediatric cardiac anesthesiologist.
46040510|NCT03853252|Other|Skin biopsy|Skin biopsy on a location preliminarily anesthetized Disinfection protocol Combined required blood tests (HIV, Hepatitis B)
46040511|NCT05378607|Behavioral|Incentivization based on gradually increasing, externally chosen adherence goals|Wisepill data on adherence will be collected remotely. Every three months, participants have a chance to participate in a prize drawing for an airtime reward of 500, 5,000, or 10,000 Ugandan Shillings if adherence matches or exceeds the subgoal chosen by the study coordinator. Subgoals will gradually increase from the participant's baseline adherence up to 90%. Prize drawings can be done during regularly scheduled clinic visits if the participant has a visit corresponding to the 3-month mark or remotely via SMS text message.
45474575|NCT03860519|Behavioral|Electronic Medication Monitors on ICS and SABA - Active Mode|"The patients in the intervention group will have sensors that are active, so that these patients receive reminders about when to use their inhalers medications."
46040512|NCT05378607|Behavioral|End of year 1 adherence prize drawing|Participants will have a chance to participate in a prize drawing at the end of year 1 with larger prize amounts of up to 20,000 Ugandan Shillings (approximately $6), where eligibility is based on reaching 90% in the three months preceding the end of year 1.
46040513|NCT05378607|Behavioral|SMS motivational messages + reminder of prize drawing|Participants will receive weekly motivational messages with a reminder of their upcoming prize drawing throughout year 1 of the study.
45344252|NCT00618826|Drug|Avastin|10mg/kg will be given via IV over 90 mins (1st dose). Patients must remain under supervision for 1 hr after completion of the initial dose of Avastin. If no side effects occur, shortened, 60-min 2nd infusion, the post-infusion observation period for the subsequent infusions may be shortened to 20 minutes, and eliminated entirely with the fourth and subsequent infusions.
45474576|NCT03860519|Behavioral|Electronic Medication Monitors on ICS and SABA - Silent Mode|"The patients in the control group will have sensors that are silent, so that these patients do not receive reminders about when to use their inhalers medications."
46040514|NCT05378607|Behavioral|Year 2 re-allocation based on year 1 performance|In Year 2 of the study, participants who have reached 90% by the end of year 1 will no longer be given sub-goals and instead will be eligible for prize drawings if they maintain the fixed level of 90% or higher. Those who have not reached 90% by the end of year 1 will be allocated to the intervention group that showed the highest effectiveness in year 1.
46040515|NCT05378607|Behavioral|End of Year 2 viral suppression prize drawing|Participants will have a chance to participate in a prize drawing at the end of Year 2 with larger prize amounts of up to 20,000 Ugandan Shillings (approximately $6), where eligibility is based on achieving viral suppression by the end of Year 2.
46040516|NCT05378607|Behavioral|Incentivization based on gradually increasing self-chosen adherence goals|Wisepill data on adherence will be collected remotely. Every three months, participants have a chance to participate in a prize drawing for an airtime reward of 500, 5,000, or 10,000 Ugandan Shillings if adherence matches or exceeds the self-chosen subgoal. While self-chosen, subgoals are subject to a minimum threshold determined by baseline adherence working towards 90% adherence. Prize drawings can be done during regularly scheduled clinic visits if the participant has a visit corresponding to the 3-month mark or remotely via SMS text message.
46040517|NCT05378607|Behavioral|Incentivization based on a fixed adherence goal|Wisepill data on adherence will be collected remotely. Every three months, participants have a chance to participate in a prize drawing for an airtime reward of 500, 5,000 or 10,000 Ugandan Shillings if adherence matches or exceeds the fixed adherence goal of 90%. Prize drawings can be done during regularly scheduled clinic visits if the participant has a visit corresponding to the 3-month mark or remotely via SMS text message.
46040518|NCT05378607|Behavioral|SMS motivational messages|The control group will also receive weekly motivational messages but without the reminder of the upcoming prize drawing.
46040519|NCT02724826|Behavioral|Qigong therapy|Medical qigong
46040520|NCT02724826|Behavioral|Exercise therapy|Regular exercise
46040521|NCT00605241|Drug|GSK598809|Drug
46040522|NCT04173442|Drug|dupilumab|Dupilumab cohort
46040523|NCT04266171|Behavioral|Diet education based on CGMS data|Intervention group will receive diet education based on CGMS data, using post prandial glucose response, calculated by incremental area under curve of glucose level. Control group will receive conventional diabetes diet education without CGMS data.
46040524|NCT04266171|Behavioral|Conventional diet education|Control group will receive conventional diabetes diet education without CGMS data.
46040525|NCT05289375|Drug|Vacucis autovaccine|A sample will be taken from all participants in group T following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory. After 1 month from the sample collection, the laboratory will send in a container/dispenser (with the same appearance in both groups) to the T group will be administered the complete autovaccine ((with two applications per day for 7 weeks)
45344253|NCT02572362|Other|No intervention in this retrospective study|No Intervention in this retrospective Analysis. All patients included did receive Radiation therapy Independent of this study
45344254|NCT00718250|Biological|RFUSIN2-AML1|AML cell vaccine alone. x4 doses 3 weeks apart
45344255|NCT00718250|Biological|Donor leukocyte infusion (DLI)|1 dose 1x107/kg
45344256|NCT00718250|Biological|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x 4 doses 3 weeks apart Donor leukocyte infusion 1x107/kg x 1 dose
45344257|NCT00718250|Biological|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x4 doses 3 weeks apart Donor leukocyte infusion 1x108/kg x1 dose
45344258|NCT00720174|Biological|Cixutumumab|Given IV
45344259|NCT00720174|Drug|Doxorubicin Hydrochloride|Given IV
45344260|NCT00720174|Other|Laboratory Biomarker Analysis|Correlative studies
45344261|NCT00857740|Behavioral|Education|Education about the neurophysiology of pain
45344262|NCT04041544|Drug|SN1011|SN1011 will be supplied to the Pharmacy as 25 mg and 100 mg capsules.
45474577|NCT03860519|Behavioral|Asthma App Tracking of ICS/SABA Usage - Active Mode|Patients in the intervention group will have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
45344263|NCT04041544|Drug|SN1011 placebo|The placebo to be used in this study will be identical to SN1011, minus the active ingredient.
45474578|NCT03860519|Behavioral|Asthma App Tracking of ICS/SABA Usage - Silent Mode|Patients in the control group will not have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
45344264|NCT00722930|Drug|Y90 Ibritumomab Tiuxetan|Consolidation with Y90 Ibritumomab Tiuxetan
45344265|NCT00713778|Procedure|Ovarian cystectomy|Laparoscopic ovarian cystectomy using bipolar
46040526|NCT05289375|Drug|Placebo|A sample will be taken from all participants in group P following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory (as in group T). After 1 month from the collection of the sample, the laboratory will send it in a container/dispenser (with the same appearance in both groups). The content in group P will receive a placebo in the same dosage and temporality as group T, it will be the same except for the active ingredient, that is, only thimerosal, methylcellulose, sodium chloride and orange essence.
46040527|NCT00935259|Drug|Simvastatin|40 mg once daily for 2 weeks
46040528|NCT00935259|Drug|Placebo|Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks
46040529|NCT02937766|Drug|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
46040530|NCT02937766|Drug|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
46040531|NCT02724748|Behavioral|Educational intervention|Educational intervention for staff members will encourage collaboration between patients, relatives and staff members. Skills, intellectual resources, motivation and encouragement among staff members to make changes on the unit will be supported. More detailed content of the intervention to be used in each unit will be tailored based on preparatory phase of the study and individual needs of the unit. The educational intervention will be carried out beside usual care.
46040532|NCT05260450|Device|1064 nm Nd:YAG-laser therapy|"All interventions and mycological tests for each subject were performed over the course of one day.~After subjects were included, toenails with a clinical suspicion of OM were tested for fungal infection by culture and microscopy. At the same time, nail clippings from said toenails were obtained and randomised into one of two treatment groups, i.e., group A and group B.~The nail clippings were then treated with a 1064 nm Nd:YAG-laser with laser settings as specified by the treatment groups. All nail clippings were treated only once.~Immediately after treatment, nail clippings were again tested for fungal infection by culture and microscopy."
46040533|NCT00606567|Other|Methods for monitoring patients with ICD's|Intervention comparing 2 different methods of monitoring patients with ICDs; at home monitoring vs. quarterly monitoring in the clinic.
46040534|NCT03830320|Drug|[64Cu]FBP8|Injection of Copper-64 radiopeptide to detect thrombosis
46040535|NCT03830320|Device|PET/MR|Whole body imaging using Siemens mMR PET/MR scanner
46040536|NCT03830320|Procedure|Blood Collection|A total of 9 cc of blood sampled before, during, and after imaging for clinical chemistry
46040537|NCT03830320|Procedure|Electrocardiogram|A standard 12-lead ECG will be obtained pre-and-post injection with radiotracer
45344266|NCT00713778|Procedure|Ovarian cystectomy|Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
45344267|NCT00713778|Procedure|Ovarian cystectomy|Laparotomic ovarian cystectomy using suture
45344268|NCT00849004|Other|silicone gel|silicone gel
45344269|NCT00849004|Other|silicone sheet|silicone sheet
45344270|NCT00849004|Other|paper tape|paper tape
45344271|NCT03834740|Drug|Ribociclib|Ribociclib administered orally in 5 daily doses prior to resection
45344272|NCT03834740|Drug|Everolimus|Everolimus administered orally in 5 daily doses prior to resection
45344273|NCT00849082|Drug|cyproterone acetate|
45344274|NCT00849082|Drug|goserelin acetate|
45344275|NCT00849082|Radiation|radiation therapy|
45344276|NCT00713856|Procedure|Custom PRK with iris registration|PRK
45344277|NCT00713856|Procedure|Conventional PRK|PRK
45344278|NCT02545582|Device|VITARIA System|Implantable vagus nerve stimulator
45344279|NCT00713934|Biological|CD133|portal vein infusion of CD133+ cells
45344280|NCT00713934|Biological|BM-MNC|portal vein infusion of BM-MNC
45344281|NCT00849160|Drug|darunavir|darunavir/r 800/100 mg once daily by oral route, 48 weeks of treatment
45474579|NCT03860519|Behavioral|NorthShore Connect Real Time ICS and SABA Usage Feedback - Yes|Patients in the intervention will receive feedback from the Research Nurse about their medication use and asthma control status.
46040538|NCT04267419|Diagnostic Test|salivary biomarker|MDA and NO as salivary biomarkers
46040539|NCT05378451|Procedure|Totally Extraperitoneal Groin Hernia Repair|"Patients will undergo totally extraperitoneal groin hernia repair, by a single senior experimented surgeon and without modifications from the routine clinical practice due to study inclusion. TEP approach will be assessed by placement of 3 trocars in the lower midline. Preperitoneal space will be dissected under direct vision using Spacemaker Dissection Balloon (Applied Medical®). Systematic complete dissection of the myopectineal orifice, Retzius and Bogros spaces will be performed to identify all potential sites of hernia formation. It will be used a laparoscopic self-fixating mesh (ProGrip™). Preperitoneal instillation of local anesthesia (15 mL of 0.5% bupivacaine) will be placed placed by the surgeon under direct visualization into triangle of pain. Local anesthesia (levobupivacaine 10mL 1%) will be applied in all the incisions."
46040540|NCT03829540|Biological|CD4CAR|CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose (total dose of up to ~4x106 T Cells/KG)
46040541|NCT00606645|Biological|XmAb2513|Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, or 12 mg/kg in sequential dose cohorts.
46040542|NCT02724670|Radiation|IGRT|MR-based IGRT
46040543|NCT04267341|Other|Timed Up and Go Test|It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again
46040544|NCT04267341|Other|10 Meter Walk Test|10 Meter Walk Test measures the time required to complete straight walk of 10 meters distance
46040545|NCT04267341|Other|Purdue Pegboard Test|Purdue Pegboard test evaluates the fine manuel dexterity
46040546|NCT02724514|Other|non-invasive image & bioimpedance based techniques|Ultrasound scans, bioimpedance measurements, clinical photographs and questionnaires will be performed before and after the massage.
46040547|NCT05260372|Diagnostic Test|Quantification of donor-derived cell-free DNA|Quantification of ddcfDNA on serial plasma samples during follow-up after lung transplantation
46040548|NCT04264377|Procedure|Bronchoscopy|Bronchoscopy for retrieval of airway cells
45684401|NCT04394728|Drug|Trabectedin|1.3 mg/m2 with a top-dose of 2.6 mg per cycle, via a central venous catheter as a 24-hour infusion every 21 days.All patients received premedication with dexamethasone 20 mg i.v. 30 min before administration of trabectedin.
45344282|NCT00714012|Other|observational|presented with paper-based sets, web based sets or human simulator based set of questionnaires designed to identify the users' experience level and optimal visual or auditory elements for each specific domain.
46040549|NCT05260294|Procedure|Epidural space identification with cervical epidural steroid injection employing CST and LORT.|Cervical epidural procedure and epidural space recognition were performed utilizing the fluoroscopy only method. With this technique, needle navigation from the skin toward the epidural space is performed under contralateral oblique fluoroscopy. With the needle at the ventral interlaminar line, the contrast spread technique was employed for epidural space identification. After radiological confirmation of the epidural spread, LOR was tested using an Epidrum® device (Exmoor Innovations Ltd., Somerset, UK). Subsequently, accompanied by the radiology assistant, I observed the Epidrum for 30 seconds or more; if the Epidrum deflated, thus confirming LOR, the result was positive. However, if the device remained inflated, the result was reported as negative. The collected data was then analyzed.
46040550|NCT00606723|Biological|Hematopoietic stem cells from bone marrow or peripheral blood|> = 2 x 10*8 nucleated cells (WBC)/kg body weight of the recipient or rather > = 4 x 10*6 nucleated CD34+ cells / kg body weight are required for engraftment. Suspension of stem cells is administered via intravenous infusion.
46040551|NCT03826576|Behavioral|Multicomponent intervention|"The multicomponent intervention will be consist of:~Training of the restaurant staff (waiters and cookers) about Mediterranean and Healthy Diet and food allergens,~Nutritional and food allergen analysis of the menu of the restaurant~Improvement of the menu to follow the Mediterranian diet standards (AMED criteria), the nutritional quality of the menu and the adaptations of the menu for food allergies and food intolerances~Marketing campaign about healthy and food allergen adapted menus in the restaurants"
45344283|NCT00857974|Other|Physical Activity|The intervention is an individualized, structured, moderate intensity home-based physical activity program. During the first 12 weeks the program will focus on lower extremity strengthening, and thereafter incorporate cardiovascular activity. The target duration of activity is 150 minutes per week, i.e., 20-30 min on most days of the week. However, the program is adjusted based on each participant's progression, initial level of physical fitness and will be modified in response to illness, injury, or physical symptoms.
45344284|NCT00720252|Device|Ultrasound|To measure intratracheal flow volume (and peak velocity) displaced during breathing cycle in premature fetuses.
45344285|NCT00720590|Drug|Atazanavir|400 mg of atazanavir (two 200-mg capsules) per day for 4 weeks
45474580|NCT03860519|Behavioral|NorthShore Connect Real Time ICS and SABA Usage Feedback - No|Patients in the intervention will not receive feedback from the Research Nurse about their medication use and asthma control status.
45684402|NCT03831412|Behavioral|CBT-I|Targeting insomnia symptoms to reduce suicidal ideation and sleep problems related to traumatic experience.
45684403|NCT03831412|Behavioral|ERRT|Targeting post-trauma nightmares to reduce suicidal ideation and sleep problems related to traumatic experience.
45684404|NCT05607706|Behavioral|Exposure to maternal odor|Exposure to maternal odor; the shirt worn by the mother is put in the baby's incubator, kangaroo care; mother lays her baby naked between her breasts
46040552|NCT00607971|Drug|Renzapride|All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
45344286|NCT00720590|Drug|Lopinavir/ritonavir|400 mg/100 mg of lopinavir/ritonavir (three soft-gel capsules, each containing 133.3 mg lopinavir and 33.3 mg ritonavir) twice per day with food for 4 weeks
45344287|NCT00720590|Drug|Placebo|Daily dose of placebo for 4 weeks
46040553|NCT02724436|Procedure|TACE|
46040554|NCT02724436|Procedure|radioembolization with Y-90|radioembolization with Y-90
46040555|NCT01120379|Device|XIENCE V® EECSS|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
45474581|NCT03860519|Behavioral|Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - Yes|Patients in the intervention group will receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
45344288|NCT00852514|Device|Bioelectrical impedance-guide dry weight reduction|for optimal determination of fluid status, monthly BIA was performed to monitor fluid status and avoid dehydration
45344289|NCT00718406|Drug|Metoprolol|
45344290|NCT00718406|Drug|metoprolol plus morphine|
45344291|NCT02572206|Radiation|PET/SPECT Scan|PET scan will be performed on a mCT scanner.
45344292|NCT02572206|Device|MRI scan|Structural MRI will be obtained to permit co-registration of PET images.
45474582|NCT03860519|Behavioral|Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - No|Patients in the control group will not receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
45474583|NCT03370666|Other|HFNT|High flow nasal therapy
45474584|NCT03370666|Other|NIV|Noninvasive ventilation
46040556|NCT02724358|Procedure|TACE|iodized oil (5ml) + Pirarubicin (20mg)
46040557|NCT02724358|Drug|Rg3|20mg, BID, maintained though Month 12.
46040558|NCT02724358|Other|TACE + Rg3|
46040559|NCT02724358|Procedure|protective therapy|standard liver protective therapy
45344293|NCT00849238|Drug|mycophenolate mofetil|
45344294|NCT05374070|Dietary Supplement|Streptococcus salivarius K12 Powder 1 Billion colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as lozenges for local delivery in the oral cavity to provide oral health benefits. In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
45344295|NCT05374070|Dietary Supplement|Streptococcus salivarius K12 Powder (1 Billion colony forming units /g) with a prebiotic included|In this study, a powder formulation containing Streptococcus salivarius K12 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
46040560|NCT05260138|Other|Gentle Body message|The intervention group received gentle body massage twice/day and position change from supine to lateral every two hours under the phototherapy for three consecutive days in addition to routine NICU care.
46040561|NCT05260138|Other|Routine NICU Care|received the conventional NICU care of infants undergoing phototherapy. Phototherapy was given by single Blue LEDs emitting light in a narrow spectrum (450-470 nm). Initially, phototherapy lamps were checked and adjusted at the height of 30 cm from the neonates who were kept naked in the incubator/crib except for the reproductive organs with shielded eyes. The neonates were positioned supine under the phototherapy. The treatment was given continuously, except while feeding and nursing for 30 minutes every 3 hours. The neonates' skin was cleaned with warm water without applying any sorts of ointments oils or creams. They were also observed for signs of dehydration.
46040562|NCT00608049|Behavioral|High carbohydrate and low glycemic index (GI) diet|The high carbohydrate and low GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
46040563|NCT00608049|Behavioral|Low carbohydrate and low GI diet|The low carbohydrate and low GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
45344296|NCT05374070|Dietary Supplement|Streptococcus salivarius M18 Powder (1 Billion colony forming units /g)|In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
45474585|NCT03734341|Device|EZ START Titration|"The auto CPAP device gradually increases air pressure night-by-night until the preset therapeutic pressure is reached.~Pressure range: from 5 to 14 cmH2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication).~Titration pressure: fixed pressure that reduces rAHI below 10, mask leak below 10% of the session, time session above 4 hours."
45474586|NCT03734341|Device|APAP Titration|"The auto CPAP device continuously adjusts the pressure in real time to the minimum pressure needed to maintain upper airway patency at any moment. Pressure range: 5 to 14 cm H2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication).~Titration pressure: visual analysis pressure that reduces rAHI below 10 during 90% of the session, mask leak below 10% of the session, therapeutic session above 4 hours."
45474587|NCT05163132|Device|Shearwave elastography|Shear wave elastography is an ultrasound applied technique used to measure tissue stiffness as a result of a disease. So, it can be used to evaluate liver stiffness as a result of liver cirrhosis
45344297|NCT05374070|Dietary Supplement|Streptococcus salivarius M18 Powder (1 Billion colony forming units /g) with a prebiotic included|In this study, a powder formulation containing S. salivarius M18 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
46040564|NCT00608049|Behavioral|High carbohydrate and high GI diet|The high carbohydrate and high GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
45344298|NCT00720408|Drug|Prograf-XL|oral
45344299|NCT00720408|Drug|Prograf|oral
45344300|NCT00720408|Drug|MMF|oral
46040565|NCT00608049|Behavioral|Low carbohydrate and high GI diet|The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
45344301|NCT00849316|Drug|insulin aspart|Safety and effectiveness data collection in connection with the use of the drug NovoRapid™ in patients with coexisting diabetes and chronic kidney disease in daily clinical practice.
46040566|NCT05259748|Behavioral|Psychoeducation Based on the Transtheoretical Model on Healthy Lifestyle Behaviors|Healthy lifestyle behaviours psychoeducation programme, based on the Transtheoretical Model, with 6 sessions (healthcare responsibility, nutrition, physical activity, spiritual development, interpersonal relationships, stress management) was applied to the intervention group for 6 weeks as three days in the weekdays and two sessions in a day. Psychoeducation was carried out by the researcher on the same day but within different time zones. Each psychoeducation session took 90-120 minutes with the breaks taken considering the participants' mood. After completing six sessions, the behavioural change identification form and Healthy Lifestyle Behaviors Scale II were applied to the intervention group again.
46040567|NCT05104463|Drug|CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107|CST-2032 and matching placebo white tablets, CST-107 and matching placebo yellow tablets
46040568|NCT02724202|Drug|Curcumin|Curcumin is supplied as soft-gel capsule. It is a micronized rhizome extract containing phospholipids and 500mg of pure curcuminoids (95% curcumin, 5% desmethoxycurcumin) suspended in turmeric essential oil.
46040569|NCT02724202|Drug|5-flurorouracil|Fluorouracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Fluorouracil is classified as an antimetabolite.
45474588|NCT03261323|Procedure|Immediate Breast Reconstruction|Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery. Reconstruction will be attempted immediately after mastectomy.
45344302|NCT00852670|Drug|ACT-128800|ACT-128800 administered orally once daily
45344303|NCT00852670|Drug|Placebo|Matching placebo capsules administered orally once daily
45344304|NCT00717210|Drug|Temozolomide|200 mg/m2 body surface on days 1-5 every 28 days for 8 cycles; and again for another 4 cycles at primary progression
45344305|NCT00717210|Radiation|Focal radiotherapy|54-60 Gy in 28-30 fractions over 6-7 weeks
45344306|NCT00723086|Drug|docetaxel (XRP6976)|combined treatment with prednisolone
45344307|NCT00720486|Behavioral|Juvenile Justice Anger Management (JJAM) for Girls|JJAM will include two 1.5-hour group treatment sessions per week for 8 weeks. JJAM sessions will be manual based and will be designed to help youth develop skills in the following areas: identifying different types of physical and relational aggression, recognizing early warning signs of anger, avoiding anger-provoking situations, managing anger to prevent aggression, solving problems, communicating about anger-related events, and repairing relationships damaged by anger-related behaviors.
46040570|NCT04265859|Behavioral|Cognitive Behavioral Training|The CBT-based regulation training involves using a cognitive strategy that instructs participants to reappraise situations in positive or less negative ways.
45474589|NCT03261323|Procedure|Delayed Breast Reconstruction|Risk reduction strategies on smoking, weight, and chronic disease control will be offered. The individual risk will be recalculated every three months. Delayed breast reconstruction will be offered when core cancer therapies (mastectomy, chemotherapy and radiation) are complete. Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery.
45474590|NCT03261323|Other|Breast-Q questionnaire|Developed out of Memorial Sloan-Kettering Institute for Cancer Research, this questionnaire is designed to create a patient-reported outcome measure to provide quantifiable information about the impact and effectiveness of breast surgery. In this study it will be used for quality of life assessment
45344308|NCT00720486|Behavioral|Treatment as usual|Treatment as usual will include standard activities in the female juvenile justice program.
45344309|NCT00858286|Other|Spirometry, PEF measurements and diary cards to evaluate control of Asthma|No intervention is made with the existing therapy, but patient will perform spirometry and PEF evaluations together with a registration of control of asthma in diary cards and health economic parameters in questionnaires
45344310|NCT04018378|Drug|varenicline tartrate 1mg (HGP1604, R) - varenicline oxalate 1mg (HIP1502, T), RT|varenicline tartrate 1mg (HGP1604) was used as a reference drug and varenicline oxalate 1mg (HIP1502) was used as a test drug.
45474591|NCT04525300|Drug|Liraglutide|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
46040571|NCT04265859|Behavioral|Mindfulness|The MBT-based regulation training involves using a mindfulness strategy that instructs participants to notice and accept their feelings without judgment or intent to act upon them.
45344311|NCT04018378|Drug|varenicline oxalate 1mg (HIP1502, T) - varenicline tartrate 1mg (HGP1604, R), TR|varenicline tartrate 1mg (HGP1604) was used as a reference drug and varenicline oxalate 1mg (HIP1502) was used as a test drug.
46040572|NCT01120067|Behavioral|Intensive Treatment|Participants randomized to the Intensive Treatment condition will attend 6 bi-weekly outpatient therapy sessions conducted in an individual format of 90 minutes in duration.
46040573|NCT01120067|Behavioral|Treatment as Usual|Treatment as Usual.
46040574|NCT02724280|Device|WLE and then LCI|The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
46040575|NCT02724280|Device|LCI and then WLE|The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
46040576|NCT05282043|Other|Evaluation of Pulmonary and Extrapulmonary Impacts of COVID-19 on Young Adults|Participants' upper extremity and lower extremity muscle strength, 6-minute walking distance, O2 saturation, posture evaluation, spirometric evaluation, pain threshold, pain intensity, dyspnea, and leg fatigue measurements will be recorded. In addition to these measurements, general fatigue, quality of life, depression, physical activity level, sleep quality parameters will be evaluated and the data obtained will be analyzed with appropriate statistical methods.
46040577|NCT00605397|Radiation|PET Imaging With Cu-64 Labeled Trastuzumab|The first 8 patients enrolled will undergo two complete PET studies, up to 3-6 weeks apart, to assess for reproducibility of measures of tracer uptake into individual organs and known sites of metastatic disease.
46040578|NCT00605397|Radiation|PET Imaging With Cu-64 Labeled Trastuzumab|The remaining 20 patients will undergo one PET study.
45474592|NCT04525300|Drug|placebo|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
45474593|NCT03865121|Drug|Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)|Patients will receive incremental doses of Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) starting with 3 bilateral puffs per day (3 mg total) for 3 days, followed by 5 bilateral puffs per day (5 mg) for 3 days, followed by 8 bilateral puffs per day (8 mg) for 4 days, followed by 10 bilateral puffs per day (10 mg) for 10 days.
45474594|NCT03680911|Drug|N Acetyl Cysteine|2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
46040579|NCT00625547|Drug|cabergoline|Cabergoline oral tablets: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 3 mg daily if patient experienced insufficient efficacy without impairing adverse events
45474595|NCT03680911|Drug|Placebo oral capsule|2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
45474596|NCT03370588|Drug|dexmedetomidine|Group A: dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum. Group B: Saline infusion during same time period.
45474597|NCT03370588|Drug|Normal saline|Group B: Saline infusion during same time period.
45474598|NCT05156814|Drug|Femoston® 1, Femoston® 2|Femoston® 1 (1 mg estradiol / 10 mg dydrogesterone), Femoston® 2 (2 mg estradiol / 10 mg dydrogesterone)
45344312|NCT05373602|Diagnostic Test|LARS questionnaire|Eligible participants were issued with LARS questionnaire (Chinese version) by E-mail, message, phone or face to face interview.
45344313|NCT05373524|Biological|Biological analysis|Rheopheresis using plasma separation and plasma filtration, coupled to hemodialysis
45344314|NCT00849550|Drug|capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)|bevacizumab IV, capecitabine oral, oxaliplatin IV, RAD001 oral
45344315|NCT04018976|Device|AVACEN 100|The AVACEN 100 pulls a -30mmHg vacuum around the hand from the wrist down and applies heat (108 Fahrenheit) to the palm
45344316|NCT04018976|Device|AVACEN 100 heat only|The AVACEN 100 applies heat (108 Fahrenheit) to the palm
45344317|NCT04018976|Device|AVACEN 100 sham|The AVACEN 100 does not provide heat or vacuum
45344318|NCT05373368|Behavioral|multi purpose activities|
45684405|NCT05607628|Combination Product|Low Calorie Animal Protein Meals|Consume reduced calorie ready meals with animal proteins to substitute participants' two main meals/day plus a serving of malted beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
45684406|NCT05607628|Combination Product|Low Calorie Plant Protein Meals|Consume reduced calorie ready meals with plant proteins to substitute participants' two main meals/day plus a serving of soy-based plant protein beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
46040580|NCT00625547|Drug|levodopa|Levodopa oral capsules: 25 mg twice daily on Days 1 to 3, 50 mg twice daily on Days 4 to 7, 100 mg twice daily on Days 8 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 150 mg twice daily if patient experienced insufficient efficacy without impairing adverse events
46040581|NCT05241340|Drug|Sasanlimab|Sasanlimab (PF-06801591) is a recombinant humanized monoclonal antibody (immunoglobulin gamma-4 with kappa light chains, IgG4 kappa) directed against programmed death 1 (PD-1). Manufactured by Pfizer, Inc.
46040582|NCT05241340|Radiation|Stereotactic Body Radiation Therapy|This current study is designed to deliver a biologically equivalent dose of 43.2Gy using a strategy of HD hypo-fractionated radiation therapy 8Gy x 3 in combination with Sasanlimab
45344319|NCT03816488|Drug|Metformin|Metformin (usual dose) administered 2 h before surgery
45344320|NCT03816488|Drug|Salsalate|Salsalate 1.5 g administered 2 h before surgery
45344321|NCT00858676|Drug|acarbose|50mg acarbose 3 times a day PO. duration: one year
45684407|NCT05607472|Other|blood sampling|blood samples for bio collection
46040583|NCT05241340|Procedure|Radical Cystectomy + pelvic lymph node dissection + urinary diversion|"This will include a cysto-prostatectomy in males or a radical cystectomy with anterior exenteration in females, bilateral pelvic lymph node dissection, and creation of a urinary diversion (ileal conduit, Indiana pouch or orthotopic neo-bladder). Robotic assisted or open surgery will be permitted.~Because there is currently equipoise regarding standard or extended template pelvic lymph node dissection, the limits of node dissection will not be protocol mandated. In the standard template, nodal packets will include the common iliac, external iliac, internal iliac (or hypogastric) and obturator nodes. Patients receiving an extended template will have the standard nodes with the addition of the para-aortic, para-caval, pre-sacral, and pre-sciatic node packets. The decision for urinary diversion is multifactorial involving patient factors (e.g., adequate renal function) and preference; thus, it will be made on a case-by-case basis."
46040584|NCT04265469|Other|Diabetic foot education|Give Diabetic foot education via mobile phone
46040585|NCT05240326|Other|exercise training group|All exercise program will be applied during supervised session by a physiotherapist. Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks. The program consisted of 10 minutes warm-up exercises, clinical pilates-based exercises on mat for 40 minutes and 10 minutes relaxation and stretching exercises.
45344322|NCT00720668|Procedure|radiofrequency ablation|radiofrequency ablation for HCC
45344323|NCT00858754|Drug|methylnaltrexone|
45344324|NCT00858754|Drug|placebo|
45344325|NCT00723164|Drug|Fentanyl and Midazolam|A combination of fentanyl 0.6 ug/kg and midazolam 9 ug/kg, to which NaCl was added to obtain a volume of 2.5 mL (group FM) injected IV, 5 minutes prior inhalation induction of anesthesia with sevoflurane
45344326|NCT00723164|Drug|NaCl|NaCl 0.9% 2.5 ml intravenous (IV), 5 minutes prior inhalation induction of anesthesia with sevoflurane.
45344327|NCT00849706|Other|Study participants will work their regular shifts, and tested after night shifts.No shifts will be added because of the study.|Night shifts in our medical center are working 8 hours from 23:00 to 7:00 the following day for nurses, and working overnight (24h) for doctors.
45344328|NCT00858910|Other|Motor imagery (MI) training|MI training encloses the internal rehearsal of a known motor skill without any overt motor output.
45344329|NCT00858910|Other|Control intervention|"The control intervention encloses relaxation and breathing exercises, and information about:~the disease (stroke),~therapy options,~self-help groups and their offers for support,~helping aids for independent living at home."
45344330|NCT00852826|Procedure|Standard axillary lymphadenectomy|Standard axillary lymphadenectomy
45474599|NCT05156814|Drug|Duphaston|Duphaston®, 10 mg
45474600|NCT05156814|Drug|Klimadynon|Cimicifuga racemosa rhizomatum extract
45474601|NCT05156814|Drug|Divigel|Divigel, 0.1%
45474602|NCT03250013|Drug|ADHD medications|
45344331|NCT00852826|Procedure|Collagen sponge coated with human coagulation factors|Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
46040586|NCT05240326|Other|control training group|The control group will be followed up as a home program by giving the relaxation exercises. Patients will be asked to do the exercises regularly for 3 days/week, 1 sessions/day, for eight weeks. Patients in the control group will be followed up by phone once a week.
45684408|NCT05607472|Other|questionnary of health estate during 18 month|clinical exam Charlson comorbidity classification questionaries : SHERE and EHAD (emotional evaluation), SF-12, EQ-5D-5L, MFIS-5 (Fatigue evaluation) during 18 months
45684409|NCT04759378|Diagnostic Test|Upper endoscopy, esophageal manometry, 24-hour pH monitoring|upper endoscopy determines if there are structural abnormalities in upper Git. esophageal manometry determines if there are motility disorders. 24-hour pH monitoring determines if acid reflux is present or not, and specifies its rate and duration.
46040587|NCT02881853|Drug|XmAb7195|
46040588|NCT02881853|Drug|Placebo|
45344332|NCT00723242|Drug|Viraferon-peg and Rebetol|
46040589|NCT02724046|Drug|Ciprofloxacin|Single-dose oral ciprofloxacin
45344333|NCT02545426|Other|Change the dialysate calcium concentration|The dialysate calcium concentration will be changed according to the prior concentration
45344334|NCT00720824|Behavioral|Topical anesthetic and hypnotic distraction|Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions.
45344335|NCT00720824|Behavioral|Office routine|Standard vaccine administration
45344336|NCT05373290|Other|there is no intervention in the study|there is no intervention in the study
45344337|NCT05373134|Drug|Pentoxifylline|400mg OD x 1 week, 400mg BD x 1 week then increased to 400mg TDS and continued
45344338|NCT05373134|Other|Placebo|Placebo
45344339|NCT00723320|Drug|Atorvastatin|atorvastatin 10mg/d
45344340|NCT00723320|Behavioral|Aggressive lifestyle intervention|aggressive lifestyle intervention
45344341|NCT00578448|Drug|Belatacept|IV infusion
45344342|NCT05373056|Behavioral|Scapular program|the patient will be in prone. With the elbow extended, begin by raising the shoulder above the head, keeping the upper extremity in line with the fibers of the lower trapezius. The participant will then remain pronated with the elbow flexed at 90 degrees and the shoulder abducted and externally rotated. Starting from this position, you should exert the force towards external rotation and then return to internal rotation. For the last exercise, the subject will be placed in a standing position holding the elastic band with one hand while the other end will fix it to the ground, while stepping on it with the foot. You will start the movement with a shoulder elevation in the plane of the scapula above 120 degrees and then perform the eccentric returning to the starting position.
45474603|NCT03367078|Device|Anodal tDCS|Anodal tDCS, on L-DLPFC area, is started 2 weeks after admission to the sABI Operative Unit with: one session per day (in the morning), possibly for 5 consecutive days per week (from Monday to Friday), for 2 consecutive weeks. Each tDCS session lasts 20 minutes. Current intensity is 1 mA during the first week, 2 mA in the second week
45474604|NCT03367078|Other|Usual care|Usual care of DOC patients
45474605|NCT03370432|Other|Observational|Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews
45474606|NCT01174667|Procedure|Specific massage for fascial release|Patient will receive a 3 minute massage to reduce restrictions in the lumbodorsal fascia.
46040590|NCT05379621|Other|COVID-19 infection|All persons of legal age or not resident in the Alpes-Maritimes between 03/01/2021 and 14/02/2021 with a COVID-19 diagnosis.
46040591|NCT02724124|Other|Static Stretching|3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
46040592|NCT02724124|Other|warm up|Warm-up for 10 minutes at 70-80% of maximum heart rate.
46040593|NCT02724124|Other|static stretching + warm up|3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets + Warm-up for 10 minutes at 70-80% of maximum heart rate.
45344343|NCT05373056|Behavioral|Conventional program|They will be performing a combination of concentric-eccentric type contractions adding an isometric contraction
46040594|NCT02724124|Other|warm up+static stretching|Warm-up for 10 minutes at 70-80% of maximum heart rate + 3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
46040595|NCT02724124|Other|Control|No intervention
46040596|NCT00608127|Device|LupusorbTM|Single treatment
46040597|NCT04265547|Behavioral|Breast Cancer Risk Reduction Household Intervention|This study will focus the intervention on ways at the individual level to reduce sources of Polycyclic Aromatic Hydrocarbons (through cooking methods, exposure to cigarette smoking, indoor air filters) and also individual ways to reduce sources of other Endocrine Disrupting Chemicals. Mother-daughter pairs will partake in an educational session at the baseline visit, covering topics on reading labels, cleaning habits, and cooking methods for reducing exposures. Participants will also be introduced to free resources for consumer product safety information. The intervention arm will receive a 6-month supply of soap, lotion, deodorant, lip balm, a mop, cleaning cloths, and an air filter to take home with them. Pairs in both study arms will return for a second clinic visit 6 months after the pre-intervention visit for blood and urine sample collection, Optical Spectroscopy measurement, and questionnaire completion. The control arm will be offered the intervention products at this time.
46040598|NCT01124045|Drug|Difluprednate ophthalmic emulsion, 0.05%|Topical ocular administration
45344344|NCT05372978|Behavioral|Cash transfer|Participants will receive a one-time unconditional cash transfer of $8,500.
45344345|NCT03845790|Other|Blood and microdialysis samples|Blood and microdialisys pharmacocinetic samples on one of the two antibiotics prescribed in routine use
45344346|NCT02571764|Other|Nutritional Oats Cookie|
45344347|NCT02572128|Other|Fortified rice|"Study 1: Hot or cold extruded rice fortified test meals fortified with Ferric Pyrophosphate and Zinc oxide will be administered - subjects serve as their own controls.~Study 2: Hot extruded rice or coated rice fortified with Ferric Pyrophosphate and Zinc Oxide will be administered.~Regular rice fortified with Ferrous Sulfate (FeSO4) will act as a control in study 2."
45344348|NCT03786926|Drug|HMPL-689|HMPL-689 is a PI3Kδ inhibitor
45344349|NCT02572050|Procedure|Distal Gastrectomy with D2 LND|Robotic Distal Gastrectomy with D2 lymphadenectomy(#7, #8a, #9, #11p, #12a in Japanese Classification) for patient with stage II or III gastric cancer
45344350|NCT00720564|Drug|arsenic trioxide|
45344351|NCT00720564|Drug|temozolomide|
45344352|NCT00720564|Procedure|adjuvant therapy|
45344353|NCT00720564|Radiation|intensity-modulated radiation therapy|
45344354|NCT00720564|Radiation|radiation therapy|
45344355|NCT04070430|Other|2 weeks of partial weight bearing on crutches|Following surgery, patients will be instructed by their surgeon to use crutches for 2 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
46040599|NCT01124045|Drug|Prednisolone acetate ophthalmic suspension, 1.0%|Topical ocular administration
46040600|NCT04265391|Dietary Supplement|cookies|Either snakehead fish cookies or standard cookies were given to subjects 75g per day.
45344356|NCT04070430|Other|4 weeks of partial weight bearing on crutches|Following surgery, patients will be instructed by their surgeon to use crutches for 4 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
45474607|NCT01174667|Other|Quiet non-instructed rest for 3 minutes|Patient will lay quietly without any instructions on how to relax.
45344357|NCT00578318|Behavioral|Motivational Interviewing Active|Patients received 2 sessions of an in-person talk based intervention utilizing culturally relevant Motivational Interviewing.
45344358|NCT00714090|Other|active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed|"active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.~active rTMS : 5 sessions per week for 2 to 6 weeks"
45474608|NCT03224130|Other|Nurse Phone Call|We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a one-time nurse phone call, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants), in improving pediatric patient transitions from hospital to home
45684410|NCT04219696|Other|Reactive balance training|A research physiotherapist will oversee reactive balance training (RBT) to ensure consistent RBT delivery across participants. Training strategies will be individualized to each participant, based on their balance impairments and rehabilitation goals. The RBT program includes multi-directional 'internal' and 'external' balance perturbations. Internal perturbations are achieved by asking the participant to complete tasks that challenge balance control, such that they lose balance when attempting to perform the task (e.g., kicking a soccer ball). External perturbation are delivered manually using a push or pull from the physiotherapist. As participants improve their reactive balance control, difficulty will be increased by shifting task requirements along a continuum from stable to mobile, and from predictable to unpredictable, and by increasing perturbation magnitude or imposing sensory or environmental challenges.
45474609|NCT03224130|Other|Standard of Care|Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.
45474610|NCT04001842|Other|Surgical reconstruction of the mandible using an axially vascularized bone construct|Surgically reconstructing defects of the mandible using reconstruction plate and Titanium mesh filled with an artificial bone substitute to form a bone construct. This construct will be vascularized at the same operation using a vein graft from the forearm. The vein graft will be microsurgically connected to an artery and vein within the facial/neck region to provide a vascular supply to the construct (arterio venous loop)
46040601|NCT01123889|Biological|platelet rich plasma injection|45 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP). Under sterile conditions, patients will receive a 5 cc PRP injection (consisting of their own PRP) with 1 cc of 1% lidocaine and 1 cc of 0.5% ropivacaine into the subacromial space, administered by an orthopedic surgeon. This will be done using a posterior lateral approach. The patient will be monitored for 10 minutes in clinic for adverse reactions.
45474611|NCT03858413|Diagnostic Test|No intervention|No intervention
46040602|NCT01123889|Drug|corticosteroid injection|Under sterile conditions, patients will receive a 5cc injection consisting of 2cc 1% lidocaine, 2cc 0.5% ropivacaine, and 1cc kenalog corticosteroid (40mg/cc) into the subacromial space utilizing a posterior lateral approach. Patients will be observed for 10 min in clinic for any adverse reactions.
46040603|NCT05226208|Diagnostic Test|Visual analogue scale (VAS)|In the postpartum period all patients filled VAS and underwent interviews from the 1st to the 3rd day after delivery.
46040604|NCT05226208|Diagnostic Test|General anxiety scale (GAD-2) and survey|In the postpartum period all patients filled survey with GAD-2 and underwent interviews from the 1st to the 3rd day after delivery.
46040605|NCT05379543|Other|Echocardiography|Echocardiography is performed using a GE Vingmed Ultrasound System (GE Healthcare, Horten, Norway), by an experienced expert. Morphological and functional parameters of the heart are measured in a consistent manner.
45474612|NCT03864887|Procedure|Oxygen supply of high-low-high procedure|The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2 (phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).
45694601|NCT04381858|Drug|Plasma from COVID-19 convalescent patient|"Infusion of 400 ml (2 units) of plasma.~Plasma donated from convalescent patients will be extracted in strict compliance with the following criteria:~History of a clinical event with symptoms attributed to COVID-19 and a positive PCR test for COVID-19~Further confirmation of a negative PCR test for COVID-19~In order to be eligible plasma donors must complete at least 14 days after the last negative PCR in the absence of any symptom attributable to COVID-19 infection~IgG antibodies for COVID-19 must be confirmed POSITIVE when a qualitative assay is being used~When quantification of IgG antibodies for COVID-19 is available a title > 1: 640 will be required for inclusion.~Apheresis will be used as the only method for plasma extraction."
45344359|NCT00714090|Other|active rTMS -repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and sham venlafaxine|active rTMS : 5 sessions per week for 2 to 6 weeks sham venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
45344360|NCT00714090|Other|sham rTMS- repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and active venlafaxine|sham rTMS : 5 sessions per week for 2 to 6 weeks active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
45344361|NCT04067024|Procedure|Local anesthesia made by surgeon|infiltration with local anesthetics
45344362|NCT04067024|Procedure|Regional anesthesia group|Pecs block I and Supraclavicular nerf block
45344363|NCT00717444|Behavioral|contingency management|"contingency management for abstinence plus 12-step facilitation therapy~prizes awarded for target behaviors"
45344364|NCT00717444|Behavioral|contingency management|"contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities~prizes awarded for target behaviors"
45694602|NCT04381858|Drug|Human immunoglobulin|Human immunoglobulin 0.3 gr/kg/day (5 doses)
46040606|NCT02723968|Other|glucose solution at a dose of 1.75 g/kg (up to a maximum of 75 g) for the OGTT and glucose solution at a dose of 0.5 g/kg (up to a maximum of 35 g) was injected in 2.5-3 min for the IGTT|At the first visit at day 1an OGTT will be performed then the CGMS is implanted. Capillary glycaemia will be taken four times a day to set up the CGMS. A second visit is scheduled at day 4, where the intravenous glucose tolerance test is performed as well as the HbA1C level.
46040607|NCT02723968|Procedure|HGPIV diagnosis test|
46040608|NCT02723968|Procedure|HOMAR-IR diagnosis test|
46040609|NCT00606879|Drug|SGX523 Capsules|This is a dose escalation study
45344365|NCT05364710|Dietary Supplement|Transfer factor from colostrum ultrafiltrate|Proteins that confer immune protection, isolated from cow colostrum ultrafiltrate and used to promote immune health and surveillance.
45344366|NCT00618748|Drug|Olanzapine|5-20 mg/day, oral, daily
45382083|NCT05361343|Other|1. Nutrition; 2. Physical activity; 3. Hypoxic training; 4. Menthal heals improvement|"Nutrition: intermittent fasting;~Physical activity: medium-intensity or high-intensity physical activity;~Hypoxic training (at least three per visit to the center);~correction of hygiene and sleep duration, relaxation techniques, cognitive behavioral therapy for insomnia.~Individual motivational counseling."
45840652|NCT03878394|Other|aerobic exercise and balance exercises with cognitive exercises|The second group will be prescribed cognitive tasks combined with aerobic exercise and balance exercises as home exercises. Participants in this group will have 30 minutes of moderate intensity exercise and cognitive tasks combined with balance exercises. Participants will be asked to count backwards from 20 during the walk and then count back the days of the week back and repeat it for 30 minutes. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Patients will be asked to count backwards from 20 to count the days of the week backwards during balance exercises. Exercises will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
45684411|NCT05606770|Behavioral|Structured Exercise|Participants assigned to Structured Exercise will be provided with twice weekly strengthening exercise classes, delivered through the digital platform. The exercise classes will follow a circuit class style, in order to target a moderate-vigorous exercise intensity. Classes will gradually progress in intensity throughout the program. Classes will include a full body warm up followed by a circuit of eight strengthening exercises. This will be repeated for increasing sets and adding resistance through the use of resistance bands . Exercises will involve simple full body exercises and movements for each major muscle group. This will ensure that exercises that can be completed regardless of possible unilateral weakness or physical impairment. During each session, participants will be reminded to reach their targeted weekly step count goals. The structured exercise component is informed by international clinical guidelines (Kleindorfer et al 2021 and Billinger et al 2021).
45694603|NCT04381390|Dietary Supplement|Whole egg and resistance training|This intervention consisted of whole egg consumption concomitant with 12 weeks of resistance training. Subject ingested three whole eggs per day immediately after resistance training.
45382084|NCT05360498|Behavioral|Adaptive Symptom Management and Survivorship Handbook (SMSH) and Telephone Interpersonal Counseling (TIP-C)|This group will get weekly calls for 16 weeks and two follow-up assessments. Participants will be asked to rate their symptoms on a 0-10 scale at each call. This group will receive the SMSH, a printed evidence-based self-care management handbook with specific modules, that will be directed to use for symptoms rated 4 or higher on a 0-10 scale. For symptoms ≥7, participants will be asked to report the symptom to their provider. At each weekly call, participants will be asked: if they tried symptom self-management strategies and, if yes, which strategies were used. These calls will take 10-15 minutes. If during 8 weeks of SMSH, either the survivor or caregiver have distress (symptoms 4 or greater on a 0-10 scale) for any two consecutive weeks during weeks 2-8, TIP-C will be added for the dyad for 8 weeks. The addition of TIP-C can start between weeks 4 and 9. Dyads will continue the SMSH in addition to the TIPC. TIP-C calls will take 35-45 minutes.
45474613|NCT03864887|Procedure|Oxygen supply of low-high-low procedure|The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).
45474614|NCT03864887|Device|Optical monitor for hemodynamic parameter.|Near infrared spectroscopy probes of tow wavelengths were attached on the subjects' foreheat to detect the changes of hemodynamic parameters.
45684412|NCT05606770|Behavioral|Lifestyle Physical Activity|The Lifestyle PA component was developed using the Behaviour Change Wheel (BCW) Guide to Designing Interventions and is underpinned by the COM-B model of behavior change (Michie et al., 2014). This posits that people need capability(C), opportunity(O), and motivation(M) to perform a behavior(B). The aim of the Lifestyle PA component is to increase the capability, opportunity, and motivation of participants to reach their daily step count goals. To achieve this the 3 stages of the BCW intervention design process were followed. The first stage, understanding the behaviour, is done through a review of the literature and primary qualitative research(Cardy et al., 2022). This stage identifies the change objectives of the intervention. Stage 2 requires the selection of intervention functions and the policies that would support them. The final stage is defining the content of the intervention using behaviour change techniques (BCTs) and selecting their mode of delivery.
45344367|NCT04067544|Device|Acupuncture|"The manualized acupuncture treatment (AT) intervention will be designed by Dr. Budhathoki and Dr. Taylor-Swanson and administered by Dr. Budhathoki and members of Huntsman acupuncture team. Ten sessions of AT will be delivered: twice per week for 2 weeks, thereafter once per week for six weeks, with a total of 9 treatments during a two-month course. Each session will last 45-60 minutes, with acupuncture needles retained 30-40 minutes. A minimum of 8 treatments must be received by each participant with no more than 9 days' gap between treatments permitted. Concurrent medications are allowed as prescribed and will be tracked in the study and analyzed as potential confounders.~Participants in the study will undergo study interview and fMRI at the following two time points: within 9 days after baseline following enrollment and within one week of acupuncture treatment completion."
45684413|NCT01927861|Drug|somatropin|Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.
45684414|NCT05606536|Drug|Crystalloid Solutions|Locally approved crystalloid solution will be given at the predefined infusion rate
45344368|NCT00723476|Behavioral|Family Centered Advanced Care Planning (FCACP) sessions|FCACP will include three 60- to 90-minute weekly sessions. Sessions consisting of structured conversations with HIV infected adolescents, their proxies, and trained facilitators will aim to enhance quality of life by integrating effective end-of-life (EOL) care and minimizing depression and anxiety. The three sessions will consist of a structured EOL survey, an FCACP interview, and a family problem-solving lesson.
45344369|NCT00723476|Behavioral|Health education control sessions|Health education control sessions will include three 60- to 90-minute sessions and will involve adolescents with HIV/AIDS and their proxies. Topics covered during sessions will include developmental history, planning for the future, and safety tips.
45344370|NCT02570906|Device|Zephyr BioPatch|Remote patient monitoring devices: BioPatch™ (ZephyrLIFE Hospital System™)
45344371|NCT00717600|Dietary Supplement|Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1|2x10^9 cfu of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1 administered daily via a single orally ingested freeze-dried capsule.
45344372|NCT00721058|Other|CT-scan|A pre-operative CT-scan will be made
45344373|NCT00720720|Dietary Supplement|plant sterol enriched margarine|Each group will have to consume 20 grams of margarines (either placebo or enriched in plant sterols) in one or two catches per day, for 8 weeks.
45684415|NCT05600218|Drug|No intervention - Observational study|Real life drug evaluation
45840653|NCT03763656|Drug|Hydroxyurea|Oral Hydroxyurea
45344374|NCT00720720|Dietary Supplement|placebo margarine|
45344375|NCT00850018|Procedure|Monthly blood transfusion regimen|Participants will receive blood transfusions at 3- to 4-week intervals for 6 months for the treatment of SCD-related anemia; the total number of transfusions that participants will receive will vary between six and eight.
45344376|NCT00850018|Behavioral|Usual care|Participants will receive usual care for the treatment of SCD.
45474615|NCT03370354|Behavioral|Observational|Ask patients about sleep quality and identify reasons of troubled sleeping patterns in the units.
45474616|NCT03367000|Dietary Supplement|Ceprolac|The supplement was packed into two ~15g sachets in powder form of a 90-94% whey protein isolate and hydrolysed whey. The protein powder was dissolved in 75-100ml water at room temperature and was ingested post meal once daily.
45474617|NCT03367000|Other|Dietary counseling (DC)|Received standard dietary counseling at baseline and month 6.
45474618|NCT03366922|Dietary Supplement|Artemisia Annua, Moringa oleifera|As described above
45840654|NCT03419676|Device|Hemopatch|Collagen patch derived from bovine dermis, coated with NHS-PEG, applied covering the pancreaticojejunostomy after pancreatoduodenectomy once the anastomosis is completed.
45840655|NCT03166722|Other|Control group|SpO2 and HR monitoring and routine treatment during immediate transition
45344377|NCT00721370|Device|NIR imaging system|Optical imaging parameter optimization (field-of-view, NIR excitation fluence rate, camera integration time) and system ergonomics.
45344378|NCT03566160|Device|Cryobiopsy probe, administered to study participants|Cryobiopsy probe as a tool for gastrointestinal biopsy
45344379|NCT04067102|Drug|Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|Paclitaxel for injection (albumin binding)260mg/m2，I.v., d1；carboplatin AUC=5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment
45344380|NCT04067102|Drug|paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|Paclitaxel 175mg/m2, I.v., d1； Carboplatin injection AUC 5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment protocol by the researcher
45344381|NCT00859144|Behavioral|Be Proud! Be Responsible!|This intervention consists of highly structured modules that involve group discussions, videos, games, brainstorming, experiential exercises, and skill building activities. The program encourages participants to be proud of themselves and their community, to behave responsibly for themselves and their community, and to consider their goals for the future and how risk behaviors may interfere with the attainment of their goals.
45474619|NCT03370198|Biological|NKR-2 cells|NKR-2 cells will be administered (hepatic transarterial administration) every 2 weeks (14 days) for a total of 3 administrations within 4 weeks (28 days)
45474620|NCT01289405|Device|Continuous Positive Airway Pressure (CPAP)|mechanical splint to open airway during sleep, considered the gold standard treatment for patients with obstructive sleep apnea
45474621|NCT03366688|Drug|IBI306|Cohort 1: 25 mg Subcutaneous(SC) (this cohort is open label without placebo); Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
45474622|NCT03366688|Drug|placebo|Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
45474623|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
45474624|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
45840656|NCT03166722|Device|Study group|Cerebral NIRS measurement with INVOS 5100 during immediate transition in addition to SpO2 and HR monitoring
45840657|NCT02682888|Behavioral|trait anxiety scale|splitting subjects into 2 groups according to scores of the trait anxiety scale
45840658|NCT02682888|Drug|Oxytocin|intranasal administration of oxytocin
45840659|NCT02682888|Drug|Placebo|intranasal administration of placebo
45474625|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
45474626|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
45474627|NCT04522570|Device|Laser ablation|Single session with Diode laser ablation system; one or two applicators will be used for treatments; one to three illuminations; fixed output power of 3 watts (W); pullback technique; delivered energy: 1200-1800 Joules (J) varying according to tumor volume; treatment under local anesthesia +- conscious or moderate sedation;
45684416|NCT05601232|Radiation|BNCT|Patients will be infused SPM-011 intravenously at a dose of 200mg/kg/hr over 2 hours. Thereafter, patient will be infused SPM-011 intravenously at a dose of 100mg/kg/hr and will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
45344382|NCT00859144|Behavioral|Becoming A Responsible Teen (BART)|This program consists of highly structured modules administered using intervention manuals in community-based settings. Each intervention session involves group discussion, videos, games, presentations, demonstrations, role plays, and practice. Youth learn problem solving, decision-making, communication, condom negotiation and use skills, and behavioral self-management. Youth also meet with HIV infected peers to promote risk recognition and improve their perception of vulnerability.
45344383|NCT00859144|Behavioral|Reducing the Risk|This program consists of instruction on developing social skills to reduce sexual risk-taking behavior and role plays to practice and model skills. Additional activities-such as teaching decision making and assertive communication skills, offering encouragement to obtain relevant health information from stores and clinics, and asking parents about their views on abstinence and birth control-support the premise that students should avoid unprotected intercourse, either by remaining abstinent or using contraceptives.
45344384|NCT04067154|Diagnostic Test|ALPE|Measurement of CT scan at PEEP of 5, 20 and 45 cm H2O Measurement of gas exchange by model-based method and FiO2 titration at PEEP of 5 and 20 cm H2O
45474628|NCT04522570|Device|Cryoablation|Single session with Argon-based cryoablation system; one 17 Gauge (G) V-probe applicator will be used for treatments; fixed gas delivery of 100%; treatment under local anesthesia +- conscious or moderate sedation;
45684417|NCT05603572|Drug|KAT-101|oral dosage form
45684418|NCT05603572|Drug|KAT-201|IT dosage form
45684419|NCT05603182|Drug|PRA052|PRA052
45684420|NCT05603182|Other|Placebo|Placebo
45694604|NCT04381390|Dietary Supplement|Egg whites and resistance training|This intervention consisted of egg white consumption concomitant with 12 weeks of resistance training. Subject ingested an isonitrogenous quantity of six egg whites per day immediately after resistance training.
45694605|NCT04088422|Procedure|peripheral blood collection|peripheral blood collection at treatment start, interm PET/CT, end of treatment PET/CT, one-year and two-year follow-up and or progression or relapse
45840660|NCT02641236|Drug|Vancomycin-polymyxin B|
45474629|NCT04522570|Device|Radiofrequency ablation|Single session with radiofrequency generator; one 17 Gauge (G) V-tip applicator with a 1 to 4cm active tip; moving-shot technique or multiple overlapping shot technique with 60 Watts (W) output power; treatment under local anesthesia +- conscious or moderate sedation;
45474630|NCT01180517|Procedure|Percutaneous coronary intervention (PCI)|balloon angioplasty
45474631|NCT01180517|Procedure|PCI|balloon angioplasty
45344385|NCT05311202|Behavioral|low-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 20 minutes of two sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
45684421|NCT05602948|Behavioral|'Run, Jump & Fun' intervention|"The intervention can be designed e.g. to consist of morning sessions each schoolday (except days with PE) or with different time slots at different weekdays. Activities are mainly conducted by school personnel, but can be supplemented by activity sessions during recess once a week lead by older students. Further, to create variation and inspire teachers, external PA parties, for example instructors from local sports clubs are invited to conduct sessions for the students and deliver teaching materials.~To align with the aim of the Danish school system, activities must have a pedagogical purpose.~Both the Run, jump & fun and the Move & learn interventions have a set of strategies underpinning implementation (see Move & Learn for more details).~Both interventions will be grounded in Self-Determination Theory and all activities will be designed to be motivating and enjoyable for all children including those neither particularly fit nor enthusiastic about PA."
46040610|NCT00605631|Device|Cardiac pacing using any Guidant/Boston Scientific Implantable ICD or CRT-D System and any Guidant/Boston Scientific Intracardiac Lead System|No specific device model is required - any FDA-approved, market-released Guidant/Boston Scientific implantable ICD or CRT-D system and any FDA-approved, market-released Guidant/Boston Scientific intracardiac lead system may be implanted as part of MENDMI.
45474632|NCT03680521|Drug|Sitravatinib|Sitravatinib oral capsule administered daily for 6-8 weeks in segments 1 and 2.
45474633|NCT03680521|Drug|Nivolumab|Nivolumab administered as 240 mg IV every 2 weeks for 4-6 weeks in segment 2.
46040611|NCT02723890|Device|Tyto Device|
45344386|NCT05311202|Behavioral|moderate-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 30 minutes of three sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
46040612|NCT00606957|Dietary Supplement|Vitamin D3 (cholecalciferol)|Vitamin D will be taken orally, 10,000 IU (0.25 mg) three times per week.
45474634|NCT03358420|Diagnostic Test|Immunohistochemical staining|Pathological liver slides to be immunohistochemically stained for alpha-defensin
46040613|NCT02723656|Behavioral|Online Referral NYS Quitline|Care coordinator will make an online referral to the NYS Quitline.
45474635|NCT03864809|Behavioral|sleep disturbance|we observe sleep disturbance among patients with psoriasis and atopic dermatitis and control group
45474636|NCT03358342|Other|ePneumonia CDS|ePneumonia clinical decision support system for community-onset pneumonia
45474637|NCT03858257|Device|High flow nasal oxygen|The Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand) will be used.
45474638|NCT03858257|Device|Standard oxygenation|Supplemental oxygen through a facemask.
45474639|NCT03679741|Device|CONTROL Lens|Acuvue OASYS
45474640|NCT03679741|Device|TEST Lens|senofilcon A
46040614|NCT02723656|Behavioral|Tobacco cessation counseling and coordination of cessation medications|Care coordinator will obtain verbal consent to transfer the patient to the NYS Quitline via 3-way call (warm transfer). The care coordinator will also assist the patient in obtaining NRT from a regular care provider, then call the patient every three months for 12 months to assess current smoking and offer to help smokers obtain additional cessation counseling and medications.
46040615|NCT05192512|Drug|TQB2928 injection|TQB2928 injection is a CD47 Blocker.
46040616|NCT00934947|Drug|Propranolol|40 mg
46040617|NCT00934947|Drug|Placebo|sugar pill
46040618|NCT00934947|Drug|Propanolol|120 mg twice per day
46040619|NCT05191810|Behavioral|Educational information|Educational information about non-pharmacological supporting treatment of functional constipation, involving recommendation of adequate for age fluid intake
46040620|NCT02723578|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days
45474641|NCT03360058|Behavioral|Small Talk Big Difference Immediate access training|Immediate access to 1 hour online training and supporting print materials for implementation in primary care practice
45474642|NCT03360058|Behavioral|Small Talk Big Difference delayed access training|Delayed access (by 4 months) to 1 hour online training and supporting print materials for implementation in primary care practice
46040621|NCT02723578|Drug|Erlotinib|Erlotinib 150 mg PO once daily on days 1-21 every 21 days
46040622|NCT04267263|Behavioral|Self-guided lifestyle intervention|The intervention will consist of one 60-minute group based online session, adapted specifically for young men based previous work with young adults, followed by a self-guided program for 12-weeks. Participants will receive a tool kit that includes evidence-based resources (scale for self-weighing, handouts that will include free self-monitoring apps and strategies for no-cost exercise, sample meal plans and meal planning tips, and tips for healthy living that emphasize risk areas) to assist them during the self-guided phase, as well as weekly health risk text messages.
45344387|NCT05311202|Behavioral|high-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 40 minutes of four sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
45344388|NCT05311202|Behavioral|moderate-volume low-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 35 minutes of four sets of low intensity resistance exercise with 20 repetitions; (3) 5 minutes of cool down
45344389|NCT05311202|Behavioral|Control group|Reading a book related to cognitive function & exercise for 40 minutes
45344390|NCT00859300|Genetic|Blood sample|Blood sample Determination of genetic background
45344391|NCT00859300|Genetic|Blood sample|Blood sample Determination of genetic background
45474643|NCT01289327|Drug|Sedation with Propofol or Midazolam+Alfentanil for FFB|Sedation was started with intravenous injection of a bolus of 2-4 mg midazolam and 0.5 mg alfentanil or 20-50 mg propofol. It was maintained with intermittent boluses of 1-3 mg intravenous midazolam or 0.5 mg intravenous alfentanil, according to clinical judgment, or with boluses of 10-20 mg intravenous propofol, administered at short intervals (~2 minutes) or according to clinical judgment.
45474644|NCT03359980|Drug|fecal microbiota transfer|transfer of fecal microbiota from healthy donors to the patients
45474645|NCT03857789|Other|Questionnaire|A 40 question frailty questionnaire.
45474646|NCT02446405|Drug|Enzalutamide|
45474647|NCT02446405|Drug|NSAA|
45474648|NCT02446405|Drug|LHRHA or Surgical Castration|
46040623|NCT01123655|Drug|APLA12|Intervention: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
45474649|NCT03359902|Device|Transcutaneous vagal nerve stimulation|Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device at 20Hz, 100 μs pulse width
45344392|NCT05659290|Drug|Fruquintinib alternating with Bevacizumab plus Capecitabine|Maintenance therapy with Fruquintinib 5mg, orally, once daily, d1-14, 2 weeks on/ 1 week off, q3w, followed by Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 6 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).
45474650|NCT03359902|Device|Sham stimulation|Sham stimulation will be performed using electrodes placed on earlobe
45684422|NCT05602948|Behavioral|'Move & Learn' intervention|"The physical activities in Move & Learn are closely linked to the subject curricula. The bodily integrating in the learning task can vary between high bodily engagement and less demanding activities.~Both the Run, jump & fun and the Move & learn interventions have a set of strategies underpinning implementation. These strategies include; 1) Initial workshops and follow-up courses for school personnel to ensure ownership, empowerment and knowledge in order to implement the interventions, 2) Teaching materials and resources, like posters, booklets etc., 3) A set of core principles for the two different interventions to ensure that the interventions are implemented as intended, and 4) Mandatory school meetings for staff and heads to ensure motivation.~Both interventions will be grounded in Self-Determination Theory and all activities will be designed to be motivating and enjoyable for all children including those neither particularly fit nor enthusiastic about PA."
46040624|NCT01123655|Drug|Placebo|Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
46040625|NCT05185258|Drug|Enstilar|Topical foam
46040626|NCT05185258|Drug|Placebo-vehicle|Topical foam
45344393|NCT05659290|Drug|Bevacizumab plus Capecitabine|Maintenance therapy with Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 3 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).
45344394|NCT00852982|Behavioral|Exercise|Nordic walking, with walking poles, five hours per week during four months
46040627|NCT05379465|Other|No intervention|No intervention was done.
45344395|NCT02571504|Behavioral|Plasticity-based Adaptive Cognitive Remediation (PACR)|Web-based cognitive training program focused on improving attention and executive function (designed by Posit Science)
45344396|NCT05304494|Other|Biomarker tests for participant profiling|Combination of digital and physical tests to objectify measures relevant for breathlessness
45344397|NCT00859378|Device|Cemented semiendoprosthesis|Application of a cemented semiendoprosthesis (Basis, Smith & Nephew)
45344398|NCT00859378|Device|non-cemented|Patients are treated with a non-cemented semiendoprosthesis (Biomet Taperloc, Biomet Inc.)
45344399|NCT00717678|Drug|Prograf-XL|oral
45344400|NCT00717678|Drug|Prograf|oral
46040628|NCT04189198|Drug|Articaine|Supraclavicular block with 30 ml articaine 2%
45344401|NCT00717678|Drug|MMF|oral
45474651|NCT03858023|Other|Hippotherapy|The hippotherapy program consists of 2 sessions per week for 15 weeks. One session is 30-minute session. The program involves 2 therapists and 3 personnel for safety issues.
45474652|NCT03366610|Other|Non-interventional|Non-interventional
45474653|NCT01181063|Drug|Budesonide/formoterol 320/9 μg and 400/12 μg inhalers|Budesonide/formoterol 320/9 μg and 400/12 μg in different kind of inhalers and Symbicort Turbuhaler forte 320/9 μg. Ech subject will be randomly allocation to 4 of 5 products, a single dose administration of each product
45474654|NCT03359824|Other|Exercise|
45474655|NCT03678103|Device|INVSENSOR00029|Noninvasive pulse oximeter sensor
45474656|NCT03358264|Dietary Supplement|L-citrulline|Amino acid supplement
46040629|NCT04189198|Drug|Bupivacaine|Supraclavicular block with 30 ml bupivacaine 0.5%
46040630|NCT04253535|Other|questionnaries|Study on questionnaries
46040631|NCT00608361|Drug|Dasatinib|Given PO
46040632|NCT00608361|Other|Pharmacological Study|Correlative studies
46040633|NCT04311281|Biological|[F-18]FDDNP-PET|[F-18]FDDNP, or 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2- naphthyl}ethylidene)malononitrile, is a positron emission tomography (PET) radiotracer developed for the in vivo visualization of tau and amyloid-beta (Aβ) deposition in the brain.
45344402|NCT00859534|Drug|afamelanotide|16mg afamelanotide, one dose for the duration of the clincial trial
45344403|NCT05050682|Drug|PF-07304814|PF-07304814 is an anti-viral, formulated for intravenous delivery
45344404|NCT00853138|Behavioral|cognitive-behavioral therapy|"In addition to standard medical care, the children and parents in the family CBT condition will also receive education about chronic pain, pain behaviors and operant strategies as well as training in coping skills using an interactive, engaging format on the Internet.~The Internet site will consist of three main sections: child treatment modules, parent treatment modules, and diary tracking. All users will complete 8 treatment modules (one per week) over the 8-week treatment period. Each module will require approximately 30-40 minutes to complete. There is separate specific content of the intervention for child users and for parent users.~Assignments are incorporated into each module for the participant to work on during the treatment week."
45344405|NCT04067466|Dietary Supplement|Fiber product|Fiber product with inulin, maltodextrin, gum guar and plum powder.
45344406|NCT04067466|Dietary Supplement|Control product|Placebo product with maltodextrin and plum powder
45344407|NCT02571842|Drug|Intravenous Rituximab|- 375 mg/m2 rituximab be prescribed 4 consecutive monthly
45474657|NCT03858179|Device|PBMT|PBMT will be applied bilaterally using the direct contact method with light pressure on the skin to 6 sites of the anterior thigh (2 medial, 2 lateral, and 2 central). A 12-diode cluster, with 4 905-nm laser diodes (12.5W peak power for each diode), 4 875-nm LED diodes (17.5 mW mean power for each diode), and 4 640-nm LED diodes (15 mW mean power for each diode), manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used to apply the PBMT. The dose used for applications during the training and/or detraining periods will be 30 Joules (J) per site (180 J per thigh). PBMT will be applied before each workout and during the detraining period, depending on the group to which the volunteers are allocated.
45474658|NCT03858179|Device|Placebo|Placebo PBMT will be applied bilaterally using the direct contact method with light pressure on the skin to 6 sites of the anterior thigh (2 medial, 2 lateral, and 2 central). The placebo PBMT will per performed using the dose of 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). Placebo PBMT will be applied before each workout and during the detraining period, depending on the group to which the volunteers are allocated.
45684423|NCT03831178|Dietary Supplement|Docosahexaenoic acid (DHA)|Participants will take 11 capsules of DHA oil for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
45684424|NCT03831178|Drug|Placebo oral capsule|Participants will take 11 capsules of placebo (corn/soy oil blend) for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
45684425|NCT03353272|Behavioral|Patient Engagement Education and Restructuring of Cognitions|This protocol, informed by principles of CBT, involves three components: 1) engagement, 2) education and 3) cognitive restructuring and behavioral activation. A health coach who is responsible for engaging patients, educating them about pain modulatory mechanisms, and reinforcing cognitive and behavioral coping skills, will deliver the PEERC protocol.
45694606|NCT05117086|Behavioral|DASH diet|Nutrition education and counseling on DASH diet, behavioral and lifestyle modifications
45344408|NCT02571842|Drug|ACEI/ARB and corticosteroids|"ACEI or ARB will be prescribed as high as tolerable dose.~Prednisolone will be prescribed starting as 0.5 mg/kg/day then taper off to 5 mg/day within 6-8 weeks"
46040634|NCT02694406|Device|MRI perfusion|contrast-enhanced MR imaging including perfusion weighted imaging (PWI)
45344409|NCT02546284|Drug|lenzilumab|
45344410|NCT02572830|Behavioral|Delayed Bilateral Eye Movements|Bilateral Eye Movements followed by a 10 min delay after reactivation of fear-memory.
45344411|NCT02572830|Behavioral|Undelayed Bilateral Eye Movement|Bilateral Eye Movements followed by no delay after reactivation of fear-memory. reactivation of the fear memory trace during which the reactivated memory is assumed to be in a labile state.
46040635|NCT00934791|Drug|Tacrolimus|Tacrolimus 6-10 mg/day (maintain trough levels of 8-10 ng/mL)
45344412|NCT00721448|Drug|AZD6140|90mg tablet, oral, once daily for the first day and twice daily from day 4 to 9
45344413|NCT00721448|Drug|AZD6140|90 x 2 mg tablets, oral, once daily for the first day and twice daily from day 4 to 9
46040636|NCT00934791|Drug|Sirolimus|Sirolimus 3-5 mg/day (maintain high-performance liquid chromatography (HPLC) blood level 10-15 ng/mL)
46040637|NCT00934791|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 750 mg twice daily
46040638|NCT00934791|Drug|Prednisone|Prednisone tapered to 5 mg/day by day 92
45344414|NCT00720954|Procedure|Ct-guided pleural needle biopsy|Biopsy of pleura
45344415|NCT00720954|Procedure|Thoracoscopy|Biopsy of pleura
45344416|NCT02570828|Device|Thermal Imaging|FLIR ONE attachment to an iPhone
45344417|NCT00853216|Drug|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose fasting
45344418|NCT00853216|Drug|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose fasting
45344419|NCT02571062|Drug|Fexinidazole|
45344420|NCT04069338|Procedure|Lithotripter|Patients receive standard of care treatment for their urolithiasis using one of two lithotripter machines
45344421|NCT00859768|Other|Questionnaire administration|The patient receives the SIPP at two different time points during their RT period. The first time point is before the first consultation with the radiotherapist (before starting RT) and the second time point is before the last consultation with the radiotherapist at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care.
45474659|NCT03366532|Other|Dietary assessments|We use food frequency questionnaires to collect and update intake of foods and nutrients in observational studies. No intervention is involved.
45474660|NCT03639805|Other|Music therapy program MUSIC CARE® + standard care|Administration of a specific music therapy program (U method) delivered through headphones from an iPad, under the direction of trained nurses. The program will be proposed 3 times a day and will last 20 minutes at each session.
46040639|NCT02882165|Other|Medical review|"A personalised, medical review will be conducted by a respiratory-trained Clinical Fellow. The Clinical Fellow will address any changes needed to optimise their lung health, any comorbidities and social situation. Education will be provided with regards to the COPD diagnosis, identifying and treating exacerbations, inhaler technique, smoking cessation and nutrition. The review will ensure any secondary prevention needs have been addressed and suggest onward referral to other services in primary or secondary care as the patient requires.~A follow up appointment will be booked during the initial appointment; to take place four to eight weeks later to identify and act upon any new clinical issues relevant to the patient's COPD and to follow up any clinical issues previously identified"
46040640|NCT02723812|Biological|GCFLU® Influenza vaccine (Split virion, Inactivated)|
46040641|NCT05268159|Other|Cognitive assessment|Assessment of unilateral spatial neglect, attention, executive functions and memory
46040642|NCT04310267|Device|Petit typeface mask|(Intraoral) Hyrax expander for maxilary sutures disarticulation through expansion, (Extraoral) Face mask for generating maxillary protraction forces and head gear face-bow to act as a connector between both intra and extra oral parts.
45344422|NCT04961528|Drug|Tranexamic Acid 500 MG|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 500 mg x 3/day (= 500 mg / 8 hours) Treatments duration: 5 days"
45344423|NCT04961528|Drug|Terlipressin|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 1 mg x 3/day (= 1 mg / 8 hours) Treatments duration: 5 days"
45474661|NCT03639805|Other|standard care of vaso-occlusive crises|administration of standard care only
45474662|NCT01180595|Device|Trabecular Metal Modular Tibial Total Knee Component|The modular design of the Trabecular Metal Total Knee allows for increased options for physicians however, it is not clear how this modular feature will affect fixation since it may compromise some of the advantages of the original TM Monoblock tibial component.
45474663|NCT01180595|Device|Trabecular Metal Monoblock Tibial Total Knee Component|
45474664|NCT03358186|Procedure|surgically treated periprosthetic femur fracture|patients with surgically treated periprosthetic femur fracture
45474665|NCT02596997|Drug|Brincidofovir|Up to 100mg Brincidofovir twice weekly, not to exceed a total dose of 200mg each week
45474666|NCT04522258|Dietary Supplement|Dietary fiber|Fermentable cereal bran
45474667|NCT04522258|Dietary Supplement|Placebo|Refined cereal flour
45684426|NCT05602870|Diagnostic Test|non invasive evaluation of liver fibrosis by transient elastography (Fibroscan ®)|A Fibroscan will be performed and the result will be given to the patient. A follow-up will be organized in the event of a diagnosis of severe fibrosis. If the serologies for hepatitis B and C cannont be recovered, patient will be able to benfit from a rapid diagnostic orientation test (TROD) (minimally invasive capillary venous sampling at the fingertip) for these 2 serologies.
45344424|NCT04961528|Drug|Placebo|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 5ml x 3/day (= 5 ml / 8 hours) Treatments duration: 5 days."
45344425|NCT00721032|Procedure|MRI guided VT ablation|Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia (VT)
45344426|NCT00721032|Drug|Increased dose of amiodarone|"Increase the dose of amiodarone according to the following scheme:~current dose -> new dose 100 once daily (QD) -> 200 QD; 200 QD -> 400 QD; 300 QD -> 600 QD; 400 QD -> 600 QD"
45474668|NCT03649477|Drug|3.2 mg intranasal carbetocin|three times per day with meals
45474669|NCT03649477|Drug|9.6 mg intranasal carbetocin|three times per day with meals
45474670|NCT03649477|Drug|placebo|three times per day with meals
45474671|NCT01181219|Procedure|CXL without epithelial removal|UV-radiation of a Riboflavin saturated cornea without prior epithelial removal
46040643|NCT02723422|Procedure|Prehabilitation visit/increased physical therapy post-TAVR|Prior to TAVR, patients randomized to the intervention arm will meet with a licensed physical therapist for a 30-minute session in the ambulatory setting. Following TAVR, patients randomized to the intervention arm will receive 4 days per week of home-based physical therapy by a licensed physical therapist working for Revival Home Health Care
45684427|NCT01927627|Drug|enzalutamide|oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
46040644|NCT02723422|Procedure|Standard of Care Arm|Patients randomized to the usual care arm will receive home-based physical therapy for 2 days per week by Revival Home Health Care, which is the current standard of care.
46040645|NCT00605709|Drug|API 31510 Topical Cream|Topical treatments to lesion twice daily of randomized treatments.
46040646|NCT02882009|Drug|Gantenerumab|Gantenerumab as a HCLF will be administered via SC injection according to assigned treatment sequence.
46040647|NCT02882009|Drug|Placebo|Gantenerumab Placebo solution will be administered via SC injection according to assigned treatment sequence.
46040648|NCT00636688|Behavioral|Lifestyle - detailed advice|Detailed advice about how to achieve a loss of 10% or more in their total body weight by reducing caloric intake and increasing their level of physical activity
46040649|NCT00636688|Behavioral|Control - general information|General information about healthy food choices and exercise
46040650|NCT00607035|Drug|Olmesartan medoxomil ＋Azelnidipine|The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
46040651|NCT00607035|Drug|Olmesartan medoxomil + Hydrochlorothiazide|The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
46040652|NCT05060081|Other|Pilates exercise program group|Pilates exercise program group will do a warm-up for 10 minutes and then perform five exercises includes standing footwork, hundreds with knee straight, articulating bridge, rolling like a ball, plank for 25 minutes. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
46040653|NCT05060081|Other|Traditional plank exercise program group|Traditional plank exercise program group will do a warm-up for 10 minutes and then perform five exercises includes prone bridge, side bridge, supine bridge on exercise ball, prone bridge on exercise ball, superman on exercise ball. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
46040654|NCT02723266|Behavioral|STOPPING-GDM|Educational counseling and skills building Intervention
46040655|NCT00608439|Drug|Centella asiatica selected triterpenes (CAST)|Drug provided to subjects in 60 mg capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52.
45474672|NCT01181219|Procedure|CXL with epithelial removal|UV-radiation of a Riboflavin saturated cornea after surgical epithelial removal has been performed
45474673|NCT03359746|Drug|Grazoprevir/Elbasvir|Medication for treatment of patient
45474674|NCT03359668|Diagnostic Test|Use of IV contrast during head and neck CT|Use of IV contrast during head and neck CT
45684428|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with advanced solid tumors.
45684429|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with sarcoma.
46040656|NCT00608439|Other|Placebo|"Placebo provided to subjects in 60 mg color-matched capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52."
46040657|NCT02693236|Biological|adenovirus-transfected autologous DC vaccine plus CIK cells|
46040658|NCT04265313|Other|Measurement of Quality of Life|Quality of life will be measured using The Neck Dissection Impairment Index, Modified Constant-Murley Score, Short Form-36 Health Survey version-2.0.
45684430|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with Malignant head and neck tumor.
46040659|NCT02722954|Drug|Demcizumab|Drug: Demcizumab at starting dose of 2.5mg/kg administered intravenously (IV).
45344427|NCT00859846|Procedure|Arterial line placement|"The following measures will be collected and compared.~Time (in seconds) required for successful placement of the arterial line. This is the time elapsed between either palpation or placement of ultrasound probe on the patient's wrist and the successful demonstration of arterial waveform on the anesthesia monitor.~number of attempts, defined as forward advancements of needle, required to cannulate the artery.~number of separate skin punctures.~number of arteries into which entry is attempted."
46040660|NCT02722954|Drug|Pembrolizumab|Drug: Pembrolizumab administered 2mg/kg IV every 3 weeks
45684431|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with breast cancer.
45684432|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with esophagus cancer.
45684433|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with lung cancer.
46040661|NCT01119443|Drug|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
45344428|NCT00723866|Other|BtxA+mCIMT|The combination group receive BtxA+mCIMT for 2 hours/day, 3 days/week for 3 months.
45344429|NCT00723866|Other|BtxA+ conventional rehabilitation|The control group received for 2 hours/day, 3 days/week for 3 months.
45382085|NCT05360498|Behavioral|NCI Brochure|The attention control arm will receive an NCI brochure: Facing Forward: Life After Cancer Treatment. This group will also get weekly calls for 16 weeks and complete two exit interviews. The NCI brochure will not be address, the purpose of these calls will only be to record participant's symptoms throughout the study. These calls will take about 10 minutes or less.
45684434|NCT05602792|Biological|T3011|T3011 will be administered through intratumoral injection in patients with non-melanoma skin cancer.
45684435|NCT04629469|Diagnostic Test|Hyperfine MRI|• Patients who have a standard of care MRI, CT or US will undergo a low-field MRI utilizing Hyperfine either at the patient's bedside or in the department of Radiology. Results of the Hyperfine MRI will not be used for clinical care and will only be available to members of the research team for review.
46040662|NCT01119443|Drug|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
46040663|NCT04262973|Other|education|six-hour dementia care course
46040664|NCT04262973|Other|education and workshop|six-hour dementia care course, half-day interprofessional education workshop, and interprofessional practice
45684436|NCT04394104|Other|Survey|No intervention is being administered.
45684437|NCT01889251|Drug|Ocriplasmin|
45684438|NCT01889251|Drug|Sham injection|
45684439|NCT05602714|Other|Collection Data|
45684440|NCT05602558|Biological|LYB001|The antigen consists of receptor-binding domain (RBD) from wild-type SARS-CoV-2 displaying on virus-like particle (VLP) vector, adjuvanted with aluminium hydroxide.
45684441|NCT05602558|Biological|Placebo|Aluminium hydroxide adjuvant
45684442|NCT04394338|Other|self-gripping mesh placement with plastic sheath in laparoscopic inguinal hernia|to apply these to the mesh graft placement process. In the first step, plastic sheaths self-gripping mesh placement with plastic sheathwere prepared configuration with the standard 9cmx15cm self-gripping mesh. Then the meshes were folded and unfolded over or under the plastic sheaths.
45684443|NCT01616563|Behavioral|Dietary Intervention|Nutrition assessment, review of the basic principles of dietary intervention for metabolic syndrome with an emphasis on the clinical risk factors identified for each individual, joint goal setting to determine what dietary changes are feasible, considering intention and barriers to dietary behaviour change.
46040665|NCT05091268|Behavioral|Exercise|"All participants will attend a four-hour pain education session including gynecologist, psychologist, sexologist, and physiotherapist at Akershus University Hospital.~The education will be held twice, with half of the participants at the time. The training group will then attend a 60 minutes weekly group training session led by a physiotherapist with specialist training in women's health over a period of four months. In addition, participants will perform a progressive home exercise program performed daily over the same period. The focus will be general strength training using own body weight and cardiovascular fitness (walking, low-impact aerobic exercise), stretching, and relaxation"
46040666|NCT00625859|Drug|GSK189075|GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.
46040667|NCT00625859|Drug|Bupropion|Bupropion will be available as sustained release film-coated tablets with a dose of 150 milligrams administered orally.
46040668|NCT00625859|Drug|Placebo|Placebo tablets will be given to subjects.
46040669|NCT02723110|Other|4 Hour Frequently Sampled Oral Glucose Tolerance Test|Blood glucose level(BGL) every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
46040670|NCT02723110|Other|Isoglycaemic Clamp|Glucose infusion over 4 hours to reproduce OGTT glucose curve to allow measurement of incretin effect. BGL every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
46040671|NCT04262739|Drug|NYH817G|Subject will orally administer NYH817G (15 mg) during the cycles(21 days)
46040672|NCT04262739|Drug|NYH100P|Subject will orally administer NYH100P (100 mg) during the cycles(21 days)
46040673|NCT04262739|Drug|NYH817G and NYH100P|Subject will orally administer NYH817G (15 mg) and NYH100P (100 mg) during the cycles(21 days)
46040674|NCT02691195|Drug|Ropivacaine|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.
45382086|NCT05356195|Biological|CTX001|Administered by intravenous infusion following myeloablative conditioning with busulfan.
46040675|NCT02691195|Drug|0.9% Nacl|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
45382087|NCT05352763|Drug|simufilam|simufilam 100 mg oral tablets
45382088|NCT05350800|Drug|BMS-986369|Specified dose on specified days
46040676|NCT02723032|Device|OxyFrame|Validation of a miniaturized pulse oximetry sensor for integration into the frame of oxygen delivery glasses.
45382091|NCT05346653|Drug|SGLT2i|dapagliflozin (10 mg daily)
45382092|NCT05346653|Other|No SGLT2i|No SGLT2i
46040677|NCT02722876|Other|Contralateral Rehabilitation|Patients will undergo resistance training of the thigh musculature of the non-injured (contralateral) limb 3 times per week. The exercises will consist of unilateral: knee extensions; knee flexions and; leg-press, all performed on commercially-available resistance training machines. To optimise strength gains, patients will work to the 5 repetition-maximum rule (Kraemer et al. 2002); 3 sets of each exercise will be performed and a 2-minute rest will separate each set. Sessions will take no longer than 15-20 minutes, including rest.
46040678|NCT02722876|Other|Placebo flexibility exercise|Patients will perform 'placebo' flexibility training of the upper limb, which will involve a time-matched stretching programme targeting the latissimus dorsi, triceps brachii, biceps brachii, trapezius and pectoral muscles of both limbs. Each stretch will be performed twice, held for 20-30 seconds each time and will be followed by a 30-second rest (McCrary et al. 2015)
45344430|NCT04069182|Behavioral|Behavioral Activation Therapy|Behavioral Activation Therapy (BAT) has its origins in Cognitive Behavioral Therapy. In BAT, the patient monitors his emotions and daily activities, as a behavioral element. It seeks to increase the number of pleasant activities and increase interactions with the environment. The BAT considers positive reinforcement as the main intervention strategy. The treatment focuses on helping patients to systematically increase contact with their life's reward sources and solve their problems through procedures that focus on activation and on processes that inhibit it such as escape, avoidance behaviors and ruminant thoughts. It is a brief treatment consisting of 10 to 12 sessions spaced weekly (one hour per session), the first sessions are an explanation of the treatment and depression. Subsequent sessions are based on a collaborative work where the therapist and the patient work together to find activities that are according to the needs of the patient.
45344431|NCT00850252|Device|Lifeline|Surgical arteriovenous fistula formation with the use of Lifeline blood vessel
46040679|NCT04131946|Other|Community-Based (Intervention Arm)|Community dispensed FIT
45344432|NCT00853294|Drug|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose fasting
45344433|NCT00853294|Drug|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose fasting
45344434|NCT03246230|Biological|Hepatitis B vaccine (HBV)|Licensed pediatric HBV vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
45344435|NCT03246230|Biological|Bacillus Calmette-Guérin (BCG)|Licensed BCG vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
45344436|NCT00717834|Biological|Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant|Two intramuscular injections of either 1.25 µg, 2.5 µg, 5 µg or 10 µg on Days 0 and 21, with a booster vaccination to follow 180 days after the first.
45344437|NCT00658359|Drug|Cyclosporine|Standard of care
45344438|NCT00658359|Drug|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
45344439|NCT00658359|Drug|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
45344440|NCT00721266|Drug|RO5083945|Administered iv, either weekly, every 2 weeks or every 3 weeks, at escalating doses (with a starting dose of 50mg weekly (Part 1)). Recommended dose administered iv, either weekly, every 2 weeks or every 3 weeks (Part 2).
45344441|NCT00853450|Drug|AZD6482|Single intravenous infusion during a maximum of 5 hours
45344442|NCT00853450|Drug|Clopidogrel|Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7.
46040680|NCT03808090|Other|Normal Individuals|Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver
46040681|NCT03808090|Other|Calcium Oxalate Kidney Stone Formers|Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver
46040682|NCT03808090|Other|Type 2 Diabetes|Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver
45344443|NCT00853450|Drug|ASA|75 mg orally once daily during 7 days in each treatment arm
45344444|NCT04066790|Drug|Pyrotinib|Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.
46040683|NCT03808090|Other|Type 2 diabetic kidney stone formers|Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver
45344445|NCT04066790|Drug|nab-Paclitaxel|Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
45344446|NCT04066790|Drug|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 9, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab
45344447|NCT04066790|Drug|EC chemotherapy|epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks 4 cycles (Cycles 5-8)
45344448|NCT04066790|Procedure|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
45344449|NCT03477552|Device|Accuvein V400 device|Sickle cell patients who need a new vein puncture in order to infuse them will benefit of AccuveinV400 device to illuminate their venous network
45344450|NCT03477552|Other|Routine procedure|In the control group, the nurse proceeds as usual to infuse the patient (visual identification in the light of the chamber and palpation)
45474675|NCT01180673|Behavioral|MINT-TLC|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension, which recommend weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. Seniors will attend weekly group classes conducted by trained research assistants for the first 12 weeks (intensive phase); followed by three individual motivational interview (MINT) sessions that will occur monthly over the next three months (extended phase); and finally each senior will receive three bi-monthly booster MINT sessions in the remaining six months (maintenance phase).
45684444|NCT01616563|Behavioral|Exercise Prescription and Fitness Program|Exercise tests (aerobic fitness, muscular and flexibility tests) recommended by the Canadian Society of Exercise Physiology (CSEP), followed by an individualized exercise plan including fitness assessments.
46040684|NCT02722642|Biological|Bronchial basal cells|Patients will receive 10^6 (1 million) /Kg/person cells of clinical grade bronchial basal cells (BBCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
45344451|NCT00860080|Drug|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. The substance is formulated in a viscous solution of sodium hyaluronate. 10, 20, and 40 mg PXL01 will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
45344452|NCT00860080|Drug|Placebo|Placebo is prepared by dilution of sodium hyaluronate using 0.9% sodium chloride solution. The concentration of sodium hyaluronate is 15 mg/ml after dilution. Placebo will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
46040685|NCT02722720|Procedure|Transradial carotid artery stenting|The radial artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
46040686|NCT02722720|Procedure|Transfemoral carotid artery stenting|The common femoral artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
45344453|NCT00721526|Drug|disulfiram plus lorazepam|Disulfiram 500mg three times weekly lorazepam 0.5-2.0 mg three times daily
45344454|NCT00721604|Drug|fluid administration|two consecutive infusions of 6% hydroxyethyl starch at the dosage 7 ml/kg over 30 minutes (total 14 ml/kg in 60 minutes)
45344455|NCT00850330|Other|on line software to detect DI early on|Patients hospital records will be reviewed on the day of admission to assess all their indication using on line software to early detect drug interactions.
45344456|NCT02571192|Drug|SHP626|single oral dose 50mg SHP626 with approximately 5.95 μCi RAD
45344457|NCT02571192|Radiation|5.95 μCi RAD|
45344458|NCT00724022|Drug|Basiliximab, Tacrolimus, MMF, Prednisolon|Control group. Therapy with Prednisolon.
45344459|NCT00724022|Drug|Basiliximab, Tacrolimus, MMF|No Prednisolon after 7 days
45344460|NCT00724022|Drug|Tacrolimus, MMF, rATG|Induction therapy: rATG instead of Basiliximab. No Prednisolon.
46040687|NCT01111019|Drug|Recombinant human growth hormone (r-hGH)|Subjects will receive a single subcutaneous injection of recombinant human growth hormone (r-hGH) equivalent to a dose of 0.057 milligram per kilogram per day (mg/kg/day). The dose will be subsequently adjusted during the trial and subjects will be treated for at least 3 years or until near final height is reached.
46040688|NCT02883400|Drug|Spironolactone|spironolactone 25 mg up to 50 mg
46040689|NCT01119287|Drug|Dexamethasone 0.1% ophthalmic suspension|Maxidex
46040690|NCT01119287|Drug|Olopatadine hydrochloride 0.1% ophthalmic solution|Patanol
46040691|NCT01119287|Other|Inactive ingredients, used as placebo|Tears Naturale II
46040692|NCT04970992|Drug|DZ-002|DZ-002 Injection
45344461|NCT00850408|Procedure|Repetitive Transcranial Magnetic Stimulation|For real rTMS,1200 pulses will be delivered at a frequency of 1Hz, with an intensity equal to the 115% of the motor threshold as established at baseline. For Sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo coil will be used, which provides acoustic and sensory stimulation like the real coil but does not stimulate neural tissue. 20-minute Real and Sham stimulation sessions will be administered bi-weekly for a period of 4 weeks
45344462|NCT00721344|Drug|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 20mg
45344463|NCT00721344|Drug|Moxifloxacin|Tablets 400mg
45344464|NCT00721344|Drug|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 40mg
45344465|NCT00721344|Drug|Placebo|Placebo cartridges
45344466|NCT04076020|Behavioral|Relational agent/AliveCor Kardia - Intervention Group|Use of the relational agent and Kardia daily for 120 days.
45344467|NCT04076020|Behavioral|Usual Care|Use of the WebMD app daily for 120 days.
45344468|NCT00717990|Drug|Capecitabine|Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
45344469|NCT00717990|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg intravenous (IV) on day 1 every 3 weeks for 6 cycles
45344470|NCT00717990|Drug|Irinotecan|Irinotecan 250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
45344471|NCT00853528|Other|questionnaire administration|prior to radiosurgery, at radiosurgery completion, and then at subsequent follow-ups (3, 6, 9, 12, 18, and 24 months after treatment
45344472|NCT00853528|Procedure|diffusion tensor imaging|prior to initiating CyberKnife radiosurgery, at 6 weeks after CyberKnife therapy, and at 6 months after CyberKnife therapy
46040693|NCT02694172|Other|Fiber rich cereal bars|Two cereals per day and per subject for 4 weeks
45344473|NCT00853528|Procedure|functional magnetic resonance imaging|prior to CyberKnife, at 6 weeks, and 3 months after CyberKnife?, every 3 months for the first year, and every 6 months thereafter
45344474|NCT00853528|Radiation|hypo-fractionated SRS|two to three consecutive daily sessions within one week for 3 cohorts- Cohort 1 = 21 Gy; Cohort 2 = 24 Gy; Cohort 3 = 27 Gy
45840661|NCT02402088|Behavioral|Stress Imagery|"The stress imagery script will be based on subjects' description of a recent personal stressful event that they had experienced as most stressful. Most stressful is determined by having the subjects rate the perceived stress experienced by them on a 10-point Likert scale where 1=not at all stressful and 10=the most stress they felt recently in their life. Only situations rated as 8 or above on this scale are accepted as appropriate for script development. Examples of acceptable stressful situations include breakup with significant other, a verbal argument with a significant other or family member or unemployment-related stress, such as being fired or laid off from work."
45840662|NCT02402088|Behavioral|Food Cue Imagery|A food cue script will be developed from the subjects' experience of eating their most favorite foods. Examples include ordering pizza, cooking a favorite meal, or going out to a restaurant.
46040694|NCT01110707|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Subjects will receive subcutaneous injection of recombinant human follicular stimulating hormone (r-hFSH) 300-450 International Units (IU) administered after pituitary desensitization according to the ovarian response with gonadotrophin-releasing hormone agonist (GnRH-a; at a dose of 0.1 milligram per day [mg/day]).
46040695|NCT01110707|Drug|Recombinant human luteinizing hormone (r-hLH)|Subjects will receive subcutaneous injection of recombinant human luteinizing hormone (r-hLH) 150 IU/day until the end of ovarian stimulation.
45344475|NCT00853528|Radiation|single-fraction SRS|two to three consecutive daily sessions within one week for 3 cohorts- for 3 cohorts- Cohort 1 = 16 Gy; Cohort 2 = 18 Gy; Cohort 3 = 20 Gy
45474676|NCT01180673|Behavioral|Control Condition|"Seniors randomized to the control arm will receive a single individual brief advice session on therapeutic lifestyle changes recommended for blood pressure reduction. In addition, they will be given print versions of the NHLBI publications Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan. Sessions will be delivered by trained research assistants."
46040696|NCT03772600|Device|Dexcom G6 CGM|Use of Dexcom G6
46040697|NCT04931368|Drug|Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix|De-escalated induction treatment with R/HD-MTX and two courses of MATRix
46040698|NCT04931368|Drug|Control intervention: four courses of MATRix|Patients receive four courses of MATRix as induction treatment.
45344476|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
45474677|NCT01310101|Drug|ofatumumab plus dexamethasone|"Dose and schedule~Cycle 1:~Ofatumumab: 300 mg as an i.v. infusion on day 1 of the cycle; Ofatumumab: 2000 mg as an i.v. infusion on days 8, 15, 22; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18~Cycles 2 to 6 (cycles every 28 days):~Ofatumumab: 1000 mg i.v. infusion on day 1, 8, 15 and 22 of the cycle; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18"
45684445|NCT05602324|Dietary Supplement|Lauric Acid and Berberine|intervention (15 ml lauric acid + 1000 mg berberine) will be provided daily to participants in this arm for the duration of time that they receive enteral nutrition for a period of 14 days maximum
45684446|NCT05600608|Dietary Supplement|Oral Stimulant Drink|please see description of the drink in the arm/ group section
45684447|NCT01616173|Drug|Dexamethasone|IV dexamethsone 8mg in 50mL (diluted in NS)
45684448|NCT01616173|Drug|Dexamethasone|8mg/2mL
45344477|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
45344478|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
45344479|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
45474678|NCT03864497|Procedure|Myocardial perfusion imaging|
45474679|NCT03359512|Device|qCON monitor|supervision by qCON monitor of the depth of anesthesia
45684449|NCT01616173|Drug|Saline|2mL
45684450|NCT05609734|Other|no intervention, only observational retrospective study|no intervention, only observational retrospective study
45344480|NCT04878302|Behavioral|Combination of Comprehensive Behavioral Intervention for Tics (CBIT) and Evidence-based interventions for co-occurring diagnoses (i.e., Cognitive Behavioral Therapy, Behavioral Parent Training)|Families assigned to the immediate treatment group will receive the telehealth-based Taming Tics Together protocol(created using well-established, evidence-based treatment protocols), which includes group (parent/caregiver-only, child/teen-only) and individualized one-to-one sessions to address tics and co-occurring diagnoses.
45344481|NCT00850486|Device|Exercise test with HyperQ technology|High frequency components of the QRS complex within the ECG signal are analyzed off-line to provide an indication of ischemia induced depolarization abnormalities
45684451|NCT05609500|Behavioral|Warfarin dosage adjustment model|Warfarin dosage adjustment model use to predict the initiation and the maintenance dose of warfarin. Variation of warfarin dose during stable maintenance phase for the same patient might be influenced more by temporal factors such as modification of drug regimens that utilize the CYP450 pathway, or dietary vitamin K intake
45344482|NCT02572986|Drug|Permethrin|
45344483|NCT00853684|Drug|OXCE|Oxaliplatin 130 mg/m2 iv drip D1, Capecitabine 1000 mg/m2 bid d1-14. Every three weeks.
45840663|NCT02402088|Behavioral|Neutral-Relaxing|A neutral-relaxing script will be developed from the subjects' commonly experienced neutral-relaxing situations, such as a trip to the beach or park.
45344484|NCT00853684|Drug|Endostar|Endostar 7.5 mg/m2 iv drip D1-14. Every 3 weeks.
45840664|NCT00625638|Behavioral|Interactive Voice Response System|Phone calls made once daily, each taking about 3-5 minutes to complete.
45344485|NCT01474148|Device|IRS-8 (8-Channel implanted stimulator-telemeter)|Surgical implantation of the 8-channel neuroprosthesis
45344486|NCT00853918|Other|$20 cash|$20 cash incentive mailed with survey
45684452|NCT03044392|Other|Next Bolus Interval|Next Bolus Interval 15, 30, or 45 minutes
45840665|NCT00625638|Other|Standard Care|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
45840666|NCT00284700|Drug|Iron|
46040699|NCT02694250|Device|DTRAX® Cervical Cage with DTRAX Bone Screw|DTRAX Cervical Cage is an intervertebral fusion device that provides mechanical support to the spine. DTRAX Cervical Cage is intended to be used in cervical spine fusion surgery. DTRAX Bone Screw is indicated for use in arthrodesis and provides supplemental fixation. .
46040700|NCT01119131|Drug|Vitamin D3|Vitamin D3 at 10,000 IU a day
46040701|NCT01119131|Dietary Supplement|calcium|1000mg calcium daily
45840667|NCT00142272|Drug|Ciprofloxacin|
45840668|NCT00821886|Drug|Ixabepilone|Ixabepilone 40mg/m2 IV infusion over 3 hours on day 1 of cycles 1-6 (all treatment cycles are 21 days in length)
45840669|NCT00821886|Drug|Trastuzumab|Trastuzumab 8mg/kg IV over 90 minutes for the first infusion (Cycle 1, Day 1) with a 60 minute post-infusion observation period. Subsequent infusions (Day 1 of Cycles 2-6 with all cycles being 21 days in length) 6mg/kg over 30 minutes if the previous dose was well tolerated; peri-operative trastuzumab 6mg/kg IV every 3-4 weeks; post-operative trastuzumab 6mg/kg IV day 1 every 3 weeks until week 52
46040702|NCT01119131|Other|Placebo|A placebo pill with similar appearance to the vitamin D3 will be given to those in the placebo arm
45344487|NCT00853918|Other|$50 cash|$50 cash incentive mailed with survey
45344488|NCT00853918|Other|$50 check|$50 check incentive mailed with survey
45344489|NCT00853918|Other|$100 check|$100 check incentive mailed with survey
45474680|NCT03639727|Diagnostic Test|Citric acid aerosol bronchial challenge|Inhalation challenge by citric acid aerosol to investigate the subject's cough sensitivity
45684453|NCT03044314|Drug|Illoprost and nitric oxide administration|Iloprost will be administered by the I-neb ultrasonic nebulizer (Respironics, Cedar Grove, New Jersey) with a disposable attachment that allows for administration to a supine patient at a concentration of 10 µg/ml with a 10 minute dose of 2.5 µg and then repeated to a cumulative dose of 5.0 µg if tolerated.
45474681|NCT03639727|Diagnostic Test|Mannitol aerosol bronchial challenge|Inhalation challenge by mannitol aerosol to investigate the subject's cough sensitivity
45474682|NCT01180751|Radiation|[18F]-Fluorodeoxyglucose|With each Positron Emission Tomography/Computed Tomography (PET/CT)scan an intravenous administration of radioactive glucose (FDG)is given. This is a weight dependent dosage.
45474683|NCT01181297|Other|Extensively Hydrolyzed Formula with a Probiotic|
45474684|NCT01181297|Other|Extensively Hydrolyzed Formula without a Probiotic|
45840670|NCT00821886|Drug|Carboplatin|Carboplatin AUC=6 IV per institutional guidelines on Day 1 of Cycles 1-6 (all treatment cycles are 21 days in length)
46040703|NCT00636922|Drug|RAD001(Everolimus)|In this study, 5-azacitidine will be administered sc for 7 doses over 9 days in a 28 day cycle. Everolimus will be administered orally with the first dose starting on day 5 (first Friday) of each cycle and continued until day 21 of each cycle. Patients will be treated with combined azacitidine + Everolimus for a minimum of 6 cycles and until at least 2 cycles after documentation of CR. Upon cessation of azacitidine, the patient will be permitted to take Everolimus maintenance therapy until progression at the investigator's discretion.
46040704|NCT02722252|Device|Embryoscope|
46040705|NCT02722252|Device|Embryo culture system without incorporated camera|
45474685|NCT01180829|Behavioral|Personalized feedback text messages|A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking.
45474686|NCT01180829|Behavioral|Consciousness raising text messages|A series of 12 text messages, each of which consists of an item designed to get the person to think about his or her drinking
45474687|NCT03677869|Device|Intraocular gas (C3F8)|Intraocular gas (C3F8) injection
45474688|NCT04523272|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
45474689|NCT04523272|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
45474690|NCT04523272|Drug|Sunitinib|A multi-target receptor tyrosine kinase inhibitor.
46040706|NCT02722096|Drug|Axillary block anesthesia with Ropivacaine and Lidocaine|Axillary brachial plexus block anesthesia with injection of Ropivacaine and Lidocaine will be performed by anesthetist 30 to 45 minutes before surgery
45474691|NCT01289561|Drug|Alcohol + Caffeine Beverage|14 g alcohol per 180 ml total beverage combined with 60 mg caffeine per 180 ml total beverage. The alcohol and caffeine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
45474692|NCT01289561|Drug|Alcohol + Caffeine-placebo|14 g alcohol per 180 ml total beverage combined with 2.2 mg quinine per 180 ml total beverage. The alcohol and quinine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
46040707|NCT02722096|Drug|Local anesthesia with Ropivacaine and Lidocaine|Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
45474693|NCT03366376|Radiation|WBRT with hippocampus-sparing and SIB|"Radiotherapy could be delivered in 5, 8, or 10 fractions according to participating investigator's choice. The prescribed doses are as below;~Fractions 5fxs 8fxs 10fxs Whole brain 20 Gy 24 Gy 25 Gy Gross tumor 30 Gy 40 Gy 40 Gy"
45474694|NCT03855527|Drug|Silver Diamine Fluoride|SDF will be applied as a cavity disinfected after atraumatic restorative technique (Antimicrobial effect)
45344490|NCT02570360|Behavioral|exercise|The EX participants will engage in supervised, individual treadmill exercise 3xs/wk at the UW Natatorium. Sessions will consist of a 5-minute warm-up followed by 30 minutes of a moderate to moderately-high intensity exercise and then finish with a 5-minute cool down. Questionnaires will be completed before and after exercise on a weekly basis.
45344491|NCT02570360|Behavioral|treatment-as-usual|The control (standard care) participants will come to the UW-Natatorium on a weekly basis to complete questionnaires.
45344492|NCT00723060|Drug|escitalopram|escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)
45344493|NCT00860236|Other|Psycoeducation/counseling|2 days of education on mechanisms of illness and coping strategies
45344494|NCT00860236|Behavioral|Cognitive behavioural therapy|4 days intensive training in understanding and behavioural changes
45840671|NCT00821964|Drug|imiquimod|Given topically
45840672|NCT00821964|Drug|Abraxane|Given IV
45840673|NCT00821964|Other|laboratory biomarker analysis|Correlative studies
45840674|NCT00821964|Genetic|RNA analysis|Correlative studies
45840675|NCT00821964|Other|immunoenzyme technique|Correlative studies
45684454|NCT03040102|Other|Hospice Video Educational Tool|it's a 6 minute video regarding hospice care
45684455|NCT03040102|Other|Standard of Care|Standard of Care practice is used
45684456|NCT04168372|Other|High fructose, fructose labeled meal|Liquid meal containing high fructose (16% of energy), labeled with 2-13C fructose
46040708|NCT04893538|Diagnostic Test|First analysis: Lymphocyte count > or = 1500 cells per microlitre, second analysis: IPS < 3 and third analysis: Lymphocyte/Monocyte ratio > or = 2.9|Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS
45684457|NCT04168372|Other|High fructose, pyruvate labeled meal|Liquid meal containing high fructose (16% of energy), labeled with 2-13C pyruvate
46040709|NCT04893538|Diagnostic Test|First analysis: Lymphocyte count < 1500 cells per microlitre, second analysis: IPS > or = 3 and third analysis: Lymphocyte/Monocyte ratio < 2.9|Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS
46040710|NCT04862962|Drug|Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose|Oral Tablets 10 mg/10 mg or 20 mg/10 mg
45474695|NCT03855527|Drug|Chlorhexidine|Chlorhexidine will be applied as a cavity disinfected after atraumatic restorative technique (Antimicrobial effect)
46040711|NCT01118975|Drug|Vorinostat|"300 mg 4 days on then 3 days off~As defined in the protocol, the dose of vorinostat was increased to 400 mg 4 days on then 3 days off in the pilot phase because the adverse event threshold was not met. In the Phase II cohort, the dose of vorinistat was 400 mg 4 days on and 3 days off."
45684458|NCT04168372|Other|Low fructose, fructose labeled meal|Liquid meals containing low fructose (6% of energy), labeled with 2-13C fructose
46040712|NCT01118975|Drug|Lapatinib|1,250 mg once daily
46040713|NCT02722018|Drug|GDC-0810 Phase II Tablet|Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
46040714|NCT02722018|Drug|GDC-0810 Phase III Prototype Tablet|Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
46040715|NCT04310111|Procedure|EUS-RFA|Use EUS-RFA to treat unresectable pancreatic cancer
46040716|NCT02721940|Procedure|Control group|Patients in the control group will be subjected to arthroscopic debridement and microfracture surgery.
46040717|NCT02721940|Biological|Mononuclear Cells|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
46040718|NCT02721940|Biological|Platelets|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
46040719|NCT02721940|Drug|Zoledronic Acid|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
46040720|NCT02721940|Drug|Normal saline|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
46040721|NCT04851340|Other|Cow's Milk|Participants will consume 200 mL, 300 mL, and 400 mL of 1% bovine milk during the diet challenge which occurs on three consecutive days of the study. The first day of the diet challenge participants consume 200 mL, the second day 300 mL and the third day 400 mL.
46040722|NCT04851340|Other|Soy Milk|Participants will consume 200 mL, 300 mL, and 400 mL of soy milk during the diet challenge which occurs on three consecutive days of the study. The first day of the diet challenge participants consume 200 mL, the second day 300 mL and the third day 400 mL.
46040723|NCT04829422|Drug|Lazertinib 240 mg|The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
46040724|NCT04094350|Other|ACF with a seed-and-recruit model|The intervention will take place for 12 months. In the intervention clusters, potential seeds - TB survivors, people living with HIV, and household contacts of people with TB - will be approached by the research team. Seeds will be trained and act as recruiters in the community to refer presumptive TB cases to the attached health centers. The research team will work with staff at the health centers to facilitate screening and enrollment of recruits who are diagnosed with TB to care. New people with TB who have the potential to be a recruiter will be invited and trained to recruit their peers in the community who may have TB for TB screening. Seeds will be trained to identify people who may have TB and equipped with health promotion skills to impart knowledge and practices about TB. We will follow-up all people with TB referred by seeds for six months from the treatment initiation.
46040725|NCT04094350|Other|ACF targeting household and neighborhood contacts|In this arm, community health volunteers will recruit household contacts of people with TB and TB survivors diagnosed during the preceding two years. Immediate neighbors (10 nearest households) of the index cases (people with TB) who are symptomatic will also be invited by the community health volunteers to the screening session. Next nearest households within the same village will be approached if the number of presumptive TB cases in the 10 nearest households is low. The one-off screening session will be held at the nearest health center on specific days. Presumptive TB cases will be screened for symptoms on-site, and chest x-ray (CXR) will be taken. Sputum samples from presumptive TB cases with abnormal (CXR) will be collected for GeneXpert testing. Test results will be communicated to the newly diagnosed people with TB, and they will be referred to the health centers for treatment and follow-up.
45840676|NCT00822354|Drug|Tadalafil|Subjects will be randomized to receive either tadalafil for the first month followed by placebo or placebo for the first month and followed by tadalafil
45840677|NCT00822510|Behavioral|Telephone Interpersonal Counseling|Telephone delivered 8 week education and counseling intervention based on interpersonal psychotherapy.
45474696|NCT03855527|Procedure|Atraumatic Restorative Treatment without Disinfection|Atraumatic Restorative Technique will be performed without cavity disinfection
45474698|NCT03864263|Other||
45474699|NCT03366064|Biological|Pemetrexed and donor-derived NK cell infusion|Patients are administered with donor-derived NK cells one week after pemetrexed infusion
45840678|NCT00822510|Behavioral|Telephone delivered education only|Telephone delivered 8 week educational intervention on prostate cancer health, side effects, physical activity, diet, smoking cessation
45840679|NCT00822588|Device|Sangvia® System|Sangvia® Intra- and Post-op System
45840680|NCT00824070|Drug|Besifloxacin hydrochloride|Instill besifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
45840681|NCT00824070|Drug|moxifloxacin hydrochloride|Instill moxifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
45840682|NCT00824070|Drug|gatifloxacin|Instill gatifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
45474700|NCT03677401|Drug|5mg Serlopitant Tablets|Serlopitant Tablets
45474701|NCT03677401|Drug|Placebo Tablets|Placebo Tablets
45474702|NCT02525393|Device|tDCS|Stroke rehabilitation performed with the aid of a transcranial electrical stimulation device.
45474703|NCT02525393|Device|rTMS|Stroke rehabilitation performed with the aid of a repetitive transcranial magnetic stimulation device.
45474704|NCT02525393|Device|Sham|Stroke sham stimulation performed with the aid of a transcranial electrical stimulation device.
46040726|NCT04094350|Other|ACF targeting the older population using mobile screening units|The outreach team will conduct training and sensitization of the target population of the activities. The schedule of a one-off screening session will be made known to the communities in the districts before the screening day. Each person who visits the screening session will be screened. Demographic information and presence of TB symptoms will be collected at registration by a trained staff. A chest x-ray will then be performed on-site for all persons exhibiting TB symptoms and all elderly aged 55 and above regardless of symptoms. When CXR findings are abnormal, sputum samples will be collected for GeneXpert testing on-site as well. Test results will be communicated to the participants on the spot or via phone calls, and people with TB will be referred for treatment and follow-up at the health center where screening is conducted or a center of their choice. Should the health center of their choice do not fall within the selected sites, follow-up will be conducted via phone calls.
45840683|NCT00824460|Drug|1.25 g PA21 (250 mg iron)|Daily dose of 1.25 g PA21 (1 tablet/day) for 6 weeks. One PA21 tablet will be taken orally with the largest meal of the day.
46040727|NCT04094350|Other|Passive case finding|Passive case finding (PCF) strategy is a default setup in the national health system. PCF relies on the self-presentation of presumptive TB cases to the health centers to be diagnosed with TB.
46040728|NCT01110239|Procedure|remote limb preconditioning|3 cycles of up to 10 minutes leg ischemia
45474705|NCT03359278|Procedure|open reduction and internal fixation|The volar approach was used for open reduction and internal fixation of distal radius fractures
45684459|NCT04168372|Other|Low fructose, pyruvate labeled meal|Liquid meal containing low fructose (6% of energy), labeled with 2-13C pyruvate
45684460|NCT05609032|Behavioral|Sense2Quit App|Participants in the intervention arm will receive access to Sense2Quit, a smartphone app that links to a smartwatch.
45684461|NCT05608720|Behavioral|Information Booklet|Information Booklet prior to the dental visit
45840684|NCT00824460|Drug|5.0 g PA21 (1,000 mg iron)|Daily dose of 5.0 g PA21 (4 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with the largest meal of the day, and one PA21 tablet will be taken orally with each of the two smaller main meals of the day (3 meals per day).
46040729|NCT02721862|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid, is FDA approved for the reduction in gallstone formation in obese patients undergoing rapid weight loss.Ursofalk is indicated in the treatment of primary biliary cirrhosis (PBC) and for the dissolution of radiolucent gallstones in patients with a functioning gall bladder.
45474706|NCT03357874|Drug|Clopidogrel|600 mg loading dose of clopidogrel as pretreatment followed by 75 mg daily for 12 months (52 weeks).
45474707|NCT03357874|Drug|Ticagrelor|patients will receive a 180 mg loading dose as pretreatment of PCI followed by 90 mg bi-daily for 12 months (52 weeks).
45474708|NCT03855293|Procedure|Rhexis protection shield|In the study group the anterior capsule will be used as a protection shield during pacoemulsifikation and removed after the phacoemulsifikation
45474709|NCT01286051|Drug|Follistim administration|adminstation of FSH for ovulation induction
46040730|NCT02721862|Drug|Placebo|The placebo has the same color and size as the ursodeoxycholic acid 250 mg pill
46040731|NCT02721862|Radiation|Gallbladder Ultrasound|Each patient will undergo a total of three abdominal ultrasounds (at 6 months, at 12 months, and at 18 months after sleeve gastrectomy) to check for gallstones. Patients should be gallstone free on an initial ultrasound to satisfy the study inclusion criteria. Ultrasound testing is radiation free and does not pose any additional risk to the subjects.
45474710|NCT01286051|Drug|Follistim plus Ganirelix|Follistim plus single injection of ganirelix
45474711|NCT03357796|Drug|LY03005|80 mg, oral tablets, single dose
45474712|NCT03357796|Drug|Pristiq|50 mg, oral tablets, single dose
45474713|NCT02359513|Drug|Antidepressants|bulimic patients are treated during 3 months
45474714|NCT02359513|Drug|Positron Emission Tomography (PET)|PET scan using [18F]MPPF is performed before and after (3 months)antidepressant treatment
45474715|NCT01184495|Drug|Epoetin Alfa-BioManguinhos|Subcutaneous administration of EPO-BioManguinhos
45474716|NCT01184495|Drug|Epoetin Alfa-BioSimilar|Subcutaneous administration of EPO-BioSimilar
45474717|NCT04522024|Procedure|Epicardial focal cryoablation|Epicardial focal cryoablation on the left atrium around right upper pulmonary vein area
45474718|NCT04522024|Procedure|Mei Mini Maze procedure|Unilateral thoracoscopic epicardial ablation by radiofrequency energy from left side
45474719|NCT03218787|Device|XIENCE|Subjects who received XIENCE family stent systems will be included.
45474720|NCT03218787|Drug|DAPT|"3-month clear subjects who receive 3-month DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for > 7 consecutive days.~Subject who are 3-month clear will discontinue P2Y12 inhibitor after 3-month visit, but continue taking aspirin through 12-month follow-up. Subjects who are not eligible for early P2Y12 inhibitor discontinuation will be treated per site standard of care."
46040732|NCT00612898|Drug|apricitabine|800mg BID apricitabine orally for 48 weeks
45474721|NCT03639649|Diagnostic Test|STHLM3|
45474722|NCT03365986|Diagnostic Test|genetic screening|Patients receive genetic test to see whether they have germline cancer susceptibility gene mutations
46040733|NCT00612898|Drug|lamivudine|150mg BID lamivudine orally for 48 weeks
45474723|NCT03640039|Procedure|3d strut plate.|Under general anathesia fracture will be exposed and fixed with 3d srut plate.Wound closed in standered fashion. patient will be released from operating room with out IMMF.
46040734|NCT01118663|Drug|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free)|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free) {new formulation} 200 mg/kg in 1000 ml diluent over 4 hours; then 100 mg/kg in 1000 ml diluent over 16 hours
46040735|NCT01118663|Drug|Acetadote|Acetadote [old formulation] 150 mg/kg in 200 mL diluent over 60 minutes; then Acetadote 50 mg/kg in 500 mL diluent over 4 hours; then Acetadote 100 mg/kg in 1000 mL diluent over 16 hours.
46040736|NCT02721706|Other|CIPA nutritional screening tool|The new nutritional screening tool termed CIPA includes Control of food Intake, Protein, and Anthropometry (CIPA) results positive when at least one of the following parameters is met: control of food intake for 72 h <50%, serum albumin <3 g/dl, body mass index <18.5 kg/m2 or mid-upper arm circumference ≤ 22.5 cm.
45474724|NCT03864575|Drug|Celecoxib 400 mg|Celecoxib 400 mg/day in combination with nivolumab fixed dose
46040737|NCT04049656|Device|HFVI|Subjects in the HFVI intervention group will be monitored in the same manner as the control group, but the HFVI monitor display will also be available to the anesthesia provider in real time. Bolus doses of 25ug or 50 ug of fentanyl will be recommended to be administered when the HFVI values begin to decrease below 50, and as needed based on the judgment of the clinician responsible for the case. All anesthetic medications that are given, patient events, and vital sign recordings will be included in the anesthetic record and data collection forms.
45474725|NCT03357718|Drug|Precedex|2 µg/kg oral
45474726|NCT03357718|Drug|Midazolam|0.5 mg/kg
45474727|NCT01184651|Behavioral|Questionnaires/Interviews|Girls answer questions about activities and interests, school, feelings about being a girl, stage of physical development, and family relationships during a home interview , provide saliva samples, and participate in phone interviews to answer questions about daily activities .
45474728|NCT01184651|Behavioral|Questionnaires/Interviews|Parents complete questionnaires about their daughter's activities, interests, and behaviors, educational goals, family demographics and relationships, grades, diagnosis and treatment of her CAH, their own activities, interests, and thoughts and feelings about being male or female. Parents answer questions during phone interviews about their daughters daily activities.
46040738|NCT02721784|Device|mpMRI/VERDICT|Combined MRI sequences of T2, DCE, Diffusion and VERDICT
46040739|NCT02721784|Radiation|External Beam Radiotherapy|78Gy (Gray) to Prostate +/- Pelvic
46040740|NCT01118351|Drug|sunitinib malate|Given orally
46040741|NCT01118351|Other|immunohistochemistry staining method|Correlative studies
46040742|NCT01118351|Other|TdT-mediated dUTP nick end labeling assay|Correlative studies
46040743|NCT01118351|Other|light microscopy|Correlative studies
45344495|NCT00724100|Drug|ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)|Starting dose is 1.2 mg/m2. Standard dose increase, in the absence of limiting toxicity, is 50%. Each dose of ALB 109564(a) will be administered by intravenous infusion once every 3 weeks (21-day cycle) over a period of time up to approximately 30 minutes. Number of cycles: Maximum of 12, until disease progression, or unacceptable toxicity develops. Greater than 12 cycles if disease has not progressed after 12 cycles, with Investigator's and Sponsor's approvals.
45344496|NCT04069416|Procedure|living donor liver transplantation|liver graft from a living donor
45344497|NCT00860392|Drug|Stable isotope tracer (13-C(4)-BHB)|A stable isotope tracer (13-C(4)-BHB), a commercially available lipid emulsion, and heparin will be administered intravenously. Ketone body concentrations will be measured before beginning the infusion, at approx. 135 minutes, and at approx. 255 minutes.
45684462|NCT05608642|Other|Intravenous hydration|500 cc intravenous serum for 1 hour in the first group service consists of patients who have been given.
46040744|NCT01118351|Other|laboratory biomarker analysis|Correlative studies
46040745|NCT01110005|Other|D5 Lactated Ringer's Solution (D5LR)|D5LR IV fluid
46040746|NCT01110005|Other|Lactated Ringer's Solution (LR)|LR IV fluid
46040747|NCT04188496|Other|Pulmonary Function Test group|The interventional group received the same conventional Chest physiotherapy Techniques for 30 minutes followed by 10 minutes rest. The patients then received additional 15 minutes protocol of thoracic joint mobilization
46040748|NCT04188496|Other|Control Group|received conventional Chest physiotherapy Techniques for 30 minutes (including deep breathing, diaphragmatic breathing exercises, Self-stretching exercises for accessory respiratory muscles, Respiratory Resistance training by incentive spirometer) followed by 10 min rest.
46040749|NCT04034134|Drug|Jaktinib Hydrochloride Tablets|50 mg twice-daily (BID)
45474729|NCT04521790|Other|support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
45474730|NCT05239923|Biological|Bacillus subtilis|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.
45344498|NCT02571816|Drug|ASP2215|oral
45344499|NCT00850798|Drug|Intensive glycemic control|Intensive glycemic control
45344500|NCT00850798|Drug|Conservative glycemic control|OADs and insulin
46040750|NCT04034134|Drug|Jaktinib Hydrochloride Tablets|150 mg quaque die (QD)
46040751|NCT04034134|Drug|Jaktinib Hydrochloride Tablets|200 mg quaque die (QD)
46040752|NCT02693314|Dietary Supplement|Jarro-Dophilus EPS® (5 billion CFU/capsule)|One capsule containing 5 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
46040753|NCT02693314|Dietary Supplement|Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule)|One capsule containing 25 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
46040754|NCT02693314|Dietary Supplement|Placebo|One capsule (containing potato starch, magnesium stearate and ascorbic acid) will be taken once a day for a period of 28 days.
46040755|NCT02693392|Drug|Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]|"Patients receiving either of the following oral hypoglycemic agents~Sulfonylurea based oral hypoglycemic agents~Metformin based oral hypoglycemic agents~Metformin plus Sulfonylurea based oral hypoglycemic agents"
45344501|NCT02572908|Other|Sourdough wheat bread|
45344502|NCT02572908|Other|Regular yeast baked toast bread|
45344503|NCT02572908|Other|Gluten-free diet|Gluten-free diet excluding even oats and buckwheat. Rice, quinoa, corn and potato allowed as grains/pseudo-grains
45344504|NCT02571140|Drug|Teriparatide|subcutaneous standard injection
45344505|NCT02571140|Drug|Oral PTH (1-34)|Different optimization of API
45344506|NCT00854074|Device|ElectroCore RMS-1100 Resolution Motility System™|An electrical neurostimulation signal will be applied to the spine
46040756|NCT02693392|Dietary Supplement|Fenugreek Seed extract|Patients recruited in the study arm will receive Capsule Fenfuro 500 milligram twice daily for 12 weeks as add-on intervention to the pre-specified oral hypoglycemic agents therapy
46040757|NCT04175626|Device|Orsiro DES|Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
46040758|NCT00613054|Drug|Zactima, Gleevec, Hydroxyurea|"Pts will start treatment on day 1 of cycle 1 w Zactima, imatinib mesylate & hydroxyurea. All 3 agents administered in continuous daily, oral manner. Imatinib mesylate dose 400 mg/day for pts not on EIAEDs & 1000 mg/day for pts on EIAEDs based on previous studies demonstrating that pts on EIAEDs require significantly higher doses of imatinib mesylate & that such doses are safe & well tolerated. Dose of hydroxyurea 500 mg twice day. Dose level of Zactima will be increased in successive cohorts of pts as described below.~Cohorts of 3-6 pts will accrue at each dose level until MTD is defined. Each cohort will consist of a mini of 3 newly enrolled pts. Intra-patient dose escalation is not permitted. Cohorts may be expanded at any dose level for further elaboration of safety & pharmacokinetic parameters as required.~Treatment cycle is defined as daily administration of Zactima + imatinib mesylate & hydroxyurea for 28 days for purpose of scheduling evaluations."
45474731|NCT04521400|Drug|High dose Interferon-beta 1a|High dose IFN-β1a (Recigen) (Subcutaneous injections of 88μg (24,000 IU) on days 1, 3, 6)
45474732|NCT04521400|Drug|Lopinavir/Ritonavir|Lopinavir/Ritonavir (Kaletra) [IFN-β1a group] (400mg/100 mg twice a day for 10 days
46040759|NCT04687696|Other|Post Isometric Relaxation Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform an isometric contraction for 5 seconds in the horizontal abduction direction with 20% of the maximum muscle strength. After the relaxation, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between contractions.This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
45474733|NCT04521400|Drug|Low dose Interferon-beta 1a|Low doseIFN-β1a (Recigen) (Subcutaneous injections of 44μg (12,000 IU) on days 1, 3, 6)
45474734|NCT01184807|Drug|OPB-51602|OPB-51602 at a dose of 2, 5, 10, 20, 40, 60, 80, or 100 mg/day,will be orally administered to subjects once daily for 2 weeks in each cycle of treatment in Dose Escalation Stage.A 2-day treatment-free interval will occur on Days 2 and 3 for PK sampling. Study drug administration will resume on Day 4 and continue until Day 17 in cycle 1.In Expansion stage part 1, OPB-51602 will be administered at recommend dose (4mg) for 3 weeks per cycle 9 2 weeks treatment and 1 week washout). There is also 2-day treatment free interval between Day 1 and Day 4 for PK sampling in cycle 1.In Expansion stage part 2, subject dosing will be started on Day 1 without 2-day treatment free interval and continued until Day 28 at recommend dose (4mg) first in Cycle 1. The same subjects will be treated at MTD(5mg)from cycle 2 onwards for 4 weeks per cycle.
45474735|NCT01184963|Dietary Supplement|High protein diet|High protein diet (30% protein, 40% carbohydrate, 30% lipid)
46040760|NCT04687696|Other|Isolytic Stretching Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform a contraction in the horizontal abduction direction with 20% of the maximum muscle strength. When the muscle contraction occurs, the arm will be moved quickly in 2-4 seconds towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretches. This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
45840685|NCT00824460|Drug|7.5 g PA21 (1,500 mg iron)|Daily dose of 7.5 g PA21 (6 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with each of the three main meals of the day (3 meals per day).
46040761|NCT04687696|Other|Static Stretching Group Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier. Then, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretching exercises. This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
46040762|NCT04167436|Other|Prehabilitation|A minimum of four weeks of prehabilitation with exercise three times a week, protein and vitamin supplements, dietitian consultation and medical optimization prior to surgery.
45344507|NCT04068324|Dietary Supplement|New Care No Nil Per Os|"The product name NoNPO is from South Korean company Well life. It contains carbohydrate and is frequently used in preoperative fasting patients in order to alleviate patients' discomfort resulting from empty stomach and thirst. It is also known to decrease insulin resistant."
46040763|NCT00613132|Drug|Gleevec, RAD001, and Hydroxyurea|Dose of Gleevec will be 400 mg in 1st cohort & will be increased to 600 mg po/day & then to 400 mg bid in successive cohorts. Prescribed dose should be administered orally, w large glass of water. Pts should not eat large or high fat meal within 1 hour before or after gleevec dosing. Doses of 600 mg or less should be administered once daily, whereas doses greater than 600 mg should be administered as equal doses twice day. It is recommended that pts take their prescribed Gleevec at same time that they take their prescribed RAD001 & hydroxyurea, however, 30-60 minute interval between agents is acceptable if required for practical or other compliance issues.
46040764|NCT03733990|Biological|FP-1305 (bexmarilimab)|The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
46040765|NCT03712852|Procedure|PRF+CAF treated patients|Patients will be treated by coronally advanced flap with addition of PRF membrane
46040766|NCT03712852|Procedure|SCTG+ CAF treated patients|Patients will be treated by coronally advanced flap with addition of SCTG graft
46040767|NCT03712852|Procedure|CAF treated patients|Patients will be treated by coronally advanced flap
46040768|NCT00613444|Device|LumaCare LC-122M non-coherent light source|Subjects will receive a series of up to 6 treatment sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, light treatment parameters will be within the guidelines normally used clinically for red-light non-coherrent light sources, and thus fluences used will not exceed 75 J/cm2.
46040769|NCT04143100|Other|Survey|For our primary analysis (multiple regression) scores on the GAD-7, BAI and PHQ-9 will be used to predict dialysis adherence, as defined as minutes reduced (total dialysis prescribed -total actual time on machine) while controlling for age and gender.
45840686|NCT00824460|Drug|10.0 g PA21 (2,000 mg iron)|Daily dose of 10.0 g PA21 (8 tablets/day) for 6 weeks. Four PA21 tablets will be taken orally with the largest meal of the day, and two PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
46040770|NCT04558216|Drug|Vonoprazan|20 mg tablets administered orally
46040771|NCT04558216|Drug|Rifampin|600 mg (Two 300 mg capsules)
46040772|NCT04132180|Other|Early Mobilization|Range of motion exercises of the upper extremity will be performed under the guidance of the physical therapy team starting on post-operative day 1.
46040773|NCT04132180|Other|Late Mobilization|The patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint until post-operative day 5.
46040774|NCT04120870|Drug|Etomidate Injection 0.2 mg/kg|The induction agent of rapid sequence intubation is etomidate. 0.2 mg/kg
46040775|NCT04120870|Drug|Ketamine injection 2 mg/kg|The induction agent of rapid sequence intubation is ketamine. 2 mg/kg
46040776|NCT01118117|Device|Misago™ Self-Expanding Stent System|Transcatheter placement of an intravascular stent(s)
46040777|NCT00613522|Other|polygraphic study|"Berlin scale will be measured. A polygraphic study will be performed to subjects with a Berlin scale > 2.~Patients stroke characteristics will be recorded (initial severity, stroke mechanism) at baseline and stroke outcome will be evaluated at 3 months (stroke recurrence and functional outcome).~Controls will be evaluated at 3 months using a phone interview"
46040778|NCT04310657|Diagnostic Test|mNGS|Metagenomics second generation sequencing technology
46040779|NCT03747562|Drug|Gabapentin|Gabapentin will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, gabapentin capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, gabapentin powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
46040780|NCT03747562|Other|Placebo|Placebo will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, placebo capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, placebo powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
45344508|NCT02570204|Behavioral|Self-assessment|Patients enrolled into the study will do a multi-level pregnancy test (MLPT) at enrollment, and will receive one MLPT to do at home one week after taking mifepristone and misoprostol. They will be instructed to call the study site if the at-home MLPT result do not decline, or if they experience any abortion complications.
45840687|NCT00824460|Drug|12.5 g PA21 (2,500 mg iron)|Daily dose of 12.5 g PA21 (10 tablets/day) for 6 weeks. Four tablets will be taken orally with the largest meal of the day, and three PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
45344509|NCT00721656|Drug|Placebo|
45344510|NCT00721656|Drug|KLS-0611|
45344511|NCT04066712|Drug|LC350189 200 mg|Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7
45344512|NCT02571686|Device|Surveyor S4|
45840688|NCT00824460|Drug|Sevelamer hydrochloride|Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets/day) for 6 weeks. Two Sevelamer tablets will be taken orally with each of the three main meals of the day (3 meals per day).
45840689|NCT00824538|Drug|sunitinib malate|
46040781|NCT04510246|Behavioral|Enhanced case management|"The health care worker will offer support to the GP for all aspects of the cascade of hepatitis C care including:~Further testing advice~Awareness that treatment can be prescribed by the general practitioner~Conducting pre-treatment work-up assessment~DAA prescription guidelines, including linkage to specialist consultation~Providing treatment support~Advising on testing process for cure~Advising on post-cure management including methods of follow-up to manage risks (e.g. harm minimisation, reducing re-infection risk, opioid substitution therapy)~Linking GP to resources for patients with cirrhosis or other concerns to specialist support for ongoing management.~The GP will be offered the option of the DoH specialist to contact the patient directly with the GP's consent to notify them of their result and to educate them on testing and treatment options and referral back to their GP."
46040782|NCT01109849|Behavioral|behavior therapy|combination of individual and group parent training plus school consultation
46040783|NCT01109849|Drug|Extended release (ER) methylphenidate product|medication to be taken daily for duration of study unless assigned to weight promotion arm
45684463|NCT05608642|Other|Intravenous prednisolone|The second group consisted of patients who were given 80 mg intravenous prednisolone for the first 4 days and then gradually reduced doses of prednisolone in the following days.
46040784|NCT01109849|Other|monitoring|monthly weight, height and BMI checks
45684464|NCT05608642|Other|Intravenous lidocaine|The third group includes patients in whom 2 mg/kg of intravenous lidocaine is given by 1-hour infusion.
45684465|NCT05608564|Procedure|Piperacillin and Tazobactam in gel form|After non-surgical periodontal treatment, the test group will receive local antibiotics.
45684466|NCT05608564|Procedure|Amoxicillin and Metronidazole|After non-surgical periodontal treatment, the control group will receive systemic antibiotics.
46040785|NCT01109849|Other|drug holiday|switch from seven day a week dosing to medication only on school days
46040786|NCT01109849|Dietary Supplement|caloric supplement|continue current ADHD regimen and add one 8oz liquid caloric supplement at night
46040787|NCT04094662|Drug|Mirogabalin|Mirogabalin tablets for oral administration
46040788|NCT04094662|Drug|Placebo|Matching placebo tablets for oral administration
46040789|NCT01061736|Drug|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
46040790|NCT01061736|Drug|Placebo (for sarilumab)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
46040791|NCT01061736|Drug|Methotrexate|Same weekly dose as received prior to enrollment
46040792|NCT01061736|Drug|Folic Acid|According to local standard
45684467|NCT03036904|Drug|Venetoclax|Venetoclax will be administered orally on days 3-12 in cycle 1, and days 1-10 with all subsequent cycles except dose level -1. If dose level -1 is required, venetoclax will be administered on days 3-7 in cycle 1 and 1-5 with subsequent cycles.
45344513|NCT00723216|Drug|enoxaparin|20 mg twice a day
45684468|NCT03036904|Drug|Rituximab|Rituximab will be administered as an IV infusion at 375 mg/m2 on day 1 of each cycle of DA-EPOCH-R, immediately prior to the start of chemotherapy. Oral pre-medication 650 mg of acetaminophen and 50-100 mg diphenhydramine hydrochloride will be administered 30 to 60 minutes prior to starting each infusion of rituximab. The first rituximab infusion should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr. If this rate of escalation is well tolerated the second and subsequent infusions can begin at a rate of 100 mg/hr and increase in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. CAUTION: DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS.
45684469|NCT03036904|Drug|Etoposide|Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
45684470|NCT03036904|Drug|Vincristine Sulfate|Vincristine Sulfate will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
45840690|NCT00824538|Other|flow cytometry|
45684471|NCT03036904|Drug|Cyclophosphamide|Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
45684472|NCT03036904|Drug|Prednisone|Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
45684473|NCT03036904|Drug|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
46040793|NCT04083820|Drug|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
45684474|NCT05608486|Device|aerSleep II|The aerSleep® II System includes a soft silicone collar, which is placed on the anterior neck. Integrated with the collar is a vacuum pump module (VPM), which cordlessly powers the generation of negative pressure within the collar's cavity. This negative pressure pulls the underlying tissues forward, maintaining airway patency.
46040794|NCT02881463|Other|therapeutical exercises|Participants of experimental group performs daily an 8-week home therapeutical exercise program. Exercises are periodized by weeks (1-8 weeks). The aim of program is the leg muscle strengthening using an elastic band (Thera-Band, System of Progressive Exercise, USA), body balance training, and leg muscle stretching.
45684475|NCT02983942|Dietary Supplement|ketogenic diet|Ketogenic diet is given to maintain blood ketone level above 2 mmol/L.
45684476|NCT02983942|Dietary Supplement|Routine diet|Routine diet is given without blood ketone requirement
45684477|NCT05608096|Device|Hemoperfusion|Commercial membrane for extracorporeal blood purification (hemoperfusion)
45684478|NCT03035500|Other|Educational Intervention|Receive health education
46040795|NCT02881541|Procedure|Enhanced support|
45684479|NCT03035500|Other|Laboratory Biomarker Analysis|Correlative studies
45684480|NCT03035500|Other|Long-term Follow-up|Undergo long-term follow-up using survivorship care plan
45684481|NCT03035500|Other|Quality-of-Life Assessment|Ancillary studies
45684482|NCT03035500|Other|Questionnaire Administration|Ancillary studies
45684483|NCT05604898|Drug|Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection|608 will be administered subcutaneously.
45684484|NCT05604898|Other|Placebo|Participants will receive Placebo to maintain the blinding of the Investigational Medicinal Products.
46040796|NCT02881541|Procedure|Usual care|
46040797|NCT04058782|Other|Imaging evaluation for vascular assessment|At 1month after MI, Blood sample for total blood, plasma and PBMC collection, ECG, 3D-trans thoracic echocardiography for ventriculo-arterial coupling assessment, Vascular doppler for peripheral artery disease assessment, Arterial stiffness evaluation, Bilateral transcranial doppler for HITS evaluation
46040798|NCT01117337|Procedure|Mesh Fixation|Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed to any structure
46040799|NCT04465162|Other|Radiation Therapy|Undergo radiation therapy
46040800|NCT05034497|Drug|186RNL|"All participants will be required to have an Ommaya Reservoir and a CSF Flow Study.~Participants will receive a single 5cc dose of 186RNL via Ommaya Reservoir."
46040801|NCT05033873|Other|Universal Exercise Unit Therapy (UEU)|Standing, walk standing, half standing, kneel standing, half kneel standing, quadruped position, three point quadruped , alternative quadruped , transitions, walking all these will be done in Universal Exercise Unit with a standardized protocol regimen.
45684485|NCT05604898|Drug|Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection|608 will be provided at pre-specified time intervals.
45684486|NCT05604898|Other|Placebo|Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
45840691|NCT00824538|Other|immunohistochemistry staining method|
45840692|NCT00824538|Other|laboratory biomarker analysis|
46040802|NCT05033873|Other|Sling Exercise Therapt (SET)|"The patient's bilateral knee joints/feet will be suspended by a rope belt, and then the patient's pelvis will be elevated and maintained in supine or lateral position, adding flexion and extension training to lower limb if permitted.~In supine or lateral position, with patient's head, trunk and pelvis fixed, the therapist will use appropriate elastic bands to assist patient's limbs to do passive-power assisted-power resistance training in all directions (bending, stretch, outreach, and adduction).~The patient's chest and abdomen will be suspended by a wide elastic band, positioned him-self in the prone position with the fulcrum of bilateral elbows and knees, and then the torso swayed in all directions, therapists could assist~Target elbow and wrist will be suspended, according to the patient's ability to do passive/active open and close chain movement"
46040803|NCT05033873|Other|Routine Physical Therapy / Control Group|"Control group will receive routine physiotherapy with duration one hour including~Active and passive joint movement~Muscle strength training~Bridging exercises~Balance training in sitting and standing positions, according to the patients' functional state.~Weight bearing exercises on affected Limbs"
46040804|NCT02874378|Drug|Dexmedetomidine|
46040805|NCT02874378|Drug|0.9%NaCl solution|
45840693|NCT00825318|Procedure|Ultrafiltration|Frequency of ultrafiltration is increased from the conventional 3 times a week to 6 times a week.
46040806|NCT01108523|Device|HP828-101|
46040807|NCT04635228|Device|Biodesign Otologic Repair Graft|The Biodesign Otologic Repair Graft is intended for use as grafting material for tympanic membrane perforation closure.
45344514|NCT00723216|Other|Physical prophylaxis|
45840694|NCT00825786|Drug|Ropivacaine|ropivacaine (15 ml).
45840695|NCT00825786|Drug|Mepivacaine|One syringe will contain mepivacaine (15 ml)
45474736|NCT01184963|Dietary Supplement|Normal protein diet|Normal protein diet (15% protein, 55% carbohydrate, 30% lipid
45474737|NCT01348087|Drug|AFQ056|The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths, identical in appearance, will be used.
46040808|NCT04633434|Device|The Talk Parenting Skill for Alexa|In a 6-week session, families will use at home a prototype Bedtime Routine module of the Talk Parenting program, a smart speaker app designed to provide parents with in-situ experiential support for building positive family routines. The prototype Bedtime Routine module of Talk Parenting will guide families in creating a healthy bedtime routine to foster healthy sleep habits, provide experiential practice in self-regulation skills, and promote a positive parent-child relationship.
46040809|NCT01035606|Behavioral|training in goal-directed attention regulation|training in goal-directed attention regulation
46040810|NCT01035606|Behavioral|brain health education|brain health education workshops
45344515|NCT00619918|Drug|Nebulized 3% saline|4 ml inhaled q8h
45344516|NCT00619918|Drug|Placebo|normal saline
45344517|NCT00724178|Dietary Supplement|cholecalciferol plus calcium carbonate|oral calciferol 100,000 IU by mouth bimonthly and calcium carbonate (1 gr) by mouth daily
45344518|NCT02571270|Other|Combined aerobic and resistance physical training program|
45344519|NCT04800536|Other|Rapidly declining plasma glucose|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Rapid plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
45344520|NCT04800536|Other|Slowly declining plasma glucose|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Slow plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
45344521|NCT02546050|Drug|Metformin|
45344522|NCT00721812|Drug|GSK1399686|Safety and tolerability dose escalation in normal human volunteers
45344523|NCT04800224|Drug|Standardized Brazilian Green Propolis Extract|900mg/day of Standardized Brazilian Green Propolis Extract for 10 days.
46040811|NCT01035606|Behavioral|computer-assisted training in goal-directed attention regulation|computer-assisted training in goal-directed attention regulation, with trainer guidance and cognitive games to practice skills
46040812|NCT01117181|Drug|Methylphenidate|The target dose is 20 mg per day provided as two 10 mg doses administered orally. Patients will start by taking 10 mg daily (two 5 mg over-encapsulated tablets) for three days, at which time the dose will be increased to 20 mg per day (four 5 mg over-encapsulated tablets). In the event of significant side-effects, the dose will be reduced to a minimum of 10 mg per day. The study drug will be administered for 6 weeks.
45840696|NCT00826020|Drug|Omegaven™|10% Omegaven™, 50 or 100 mL bottle; 1gram/kg/day and is infused over 12-24 hours.
46040813|NCT01117181|Drug|placebo|Patients will start with two capsules of placebo for three days, at which time the dose will be increased to four capsules. The dose may be reduced to a minimum of two capsules per day if there appears to be significant side-effects. Placebo will be administered for 6 weeks.
46040814|NCT01117181|Other|Psychosocial intervention|"The psychosocial intervention will consist of three components: a counseling session, the provision of education materials, and 24-hour availability for crises.~The counseling session, in which a trained study clinician will counsel the primary caregiver, lasts approximately 20-30 minutes, and consists of the following elements:~Review and adjustment of the patient and caregiver supportive care plans~Emotional support and opportunity to ventilate feelings~Counseling regarding specific caregiving skills~Assistance with problem solving of specific issues that the caregiver brings to the sessions~Answers for questions regarding the educational materials~The educational materials will consist of a copy of the book The 36-Hour Day"
46040815|NCT04302714|Procedure|Hysteroscopic injection|Hysteroscopic injection
45840697|NCT00826800|Drug|FOLFOX and bevacizumab|The patient will receive six treatments, two weeks apart. On each treatment day you will get Oxaliplatin, 5-FU,Leucovorin. On the first four treatments you will also get Bevacizumab (Avastin). These drugs are given through a Mediport. They will be given in an outpatient chemotherapy unit. Each tx will take about 4 hours. A pump for the 5-FU is worn around your waist. This drug is given over 2 days. Part II: Colon Cancer Surgery is standard practice, and is not a research procedure.Part III: Post-operative Re-Evaluation and Recovery The doctor will decide on the type of chemotherapy based on how the patient responded to the first chemotherapy. The plan will be for the patient to get 6 more doses of FOLFOX, without any further bevacizumab, unless your doctor finds a reason to do otherwise.
46040816|NCT04302714|Procedure|Cervical injection|Cervical injection
46040817|NCT02881619|Drug|Etodolac|The patient will receive a single-dose of Etodolac (400 mg) one hour before the bleaching procedure.
46040818|NCT02881619|Drug|Placebo|The patient will receive a single-dose of placebo one hour before the bleaching procedure.
46040819|NCT04303806|Drug|rosuvastatin|receive rosuvastatin orally once daily.
45840698|NCT00830076|Drug|sitagliptin phosphate|Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods.
46040820|NCT02882087|Drug|Placebo plus MTX|All patients had a foundation MTX therapy.The researchers evaluated the efficacy of the patient in 12 week.study investigator evaluate the patients of curative effect . The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
46040821|NCT02882087|Drug|RC18 160 mg plus MTX|
45840699|NCT00830076|Drug|metformin hydrochloride|Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washout between treatment periods.
45840700|NCT00830076|Drug|Comparator: placebo sitagliptin|Placebo to sitagliptin 100 mg in the morning on Days 1 and 2. There will be a 7-day washout between treatment periods.
46040822|NCT04303884|Drug|Pembrolizumab Injection [Keytruda]|Pembrolizumab administration at a fix dose of 200 mg every 3 weeks
46040823|NCT00625625|Drug|isosulfan blue|
46040824|NCT00625625|Genetic|polymerase chain reaction|
46040825|NCT00625625|Other|diagnostic laboratory biomarker analysis|
46040826|NCT00625625|Other|immunohistochemistry staining method|
46040827|NCT00625625|Procedure|diagnostic lymphadenectomy|
46040828|NCT00625625|Procedure|therapeutic conventional surgery|
46040829|NCT00625625|Procedure|therapeutic lymphadenectomy|
46040830|NCT05032547|Behavioral|Therapist-supported digitally delivered transdiagnostic emotion regulation treatment|Please see description of experimental arm (arm one)
46040831|NCT05032547|Behavioral|Therapist-supported digitally delivered supportive treatment|Please see description of active comparator arm (arm two)
46040832|NCT01040130|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
46040833|NCT01040130|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
45344524|NCT04800224|Drug|Placebo|900mg/day of Placebo for 10 days.
45344525|NCT00860548|Drug|currently available therapy in the community|Participants will receive telephone calls every 3 months for approximately 44 months for the purpose of outcome surveys
45344526|NCT00718068|Drug|Sterile Potassium Chloride Concentrate|Continuous infusion, 40mmol in 40ml, starting at 10ml/hr, rate altered according to serum potassium level checked 2 hourly
45344527|NCT00718068|Drug|Sterile Potassium Chloride Concentrate|By intermittent infusion, 20mmol diluted in 100ml 0.9% NaCl, administered over 60 mins, serum potassium level checked 2 hourly, and repeat doses administered as appropriate
45684487|NCT01544595|Drug|Secukinumab (AIN457)|"Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions."
45344528|NCT00718146|Biological|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
45684488|NCT01544595|Drug|Placebo|Placebo
45840701|NCT00830076|Drug|Comparator: placebo metformin|Placebo to metformin 500 mg tablet in the morning and evening on Day 1 and two placebo to metformin 500 mg tablets (1000 mg total dose) in the morning of Day 2. There will be a 7-day wash out between treatment periods.
46040834|NCT01040130|Drug|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
46040835|NCT01040130|Drug|Olodaterol (BI 1744)|Comparison of low and high dose
46040836|NCT01040130|Drug|Olodaterol (BI 1744) Placebo|Placebo that represents olodaterol
46040837|NCT05012969|Device|Hipstop bandage|12 weeks use of a bandage to prevent hip dislocations in patients with previous dislocations
46040838|NCT00932451|Drug|PF-02341066|PF-02341066, 250 mg BID, will be administered orally on a continuous schedule
45344529|NCT00718146|Biological|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
45840702|NCT00830232|Device|closed-cell stent (Xact stent)|"Patients enrolled in this study arm underwent for carotid stenting using closed stent cell. The graft used in this groups was the Xact closed-cell stent. This type of device is rigid device with dense conposition of the nitinol rigns.~Carotid stenting was used on standard fashion using filters as embolic protection device."
46040839|NCT02874456|Other|virus detection|Men will give semen, urine and blood specimens 7 days after the beginning of clinical signs and 11, 20, 30, 60 and 90 days after. ZIKV RNA will be detected in seminal plasma, native semen cells and processed spermatozoa.
46040840|NCT01039584|Drug|Butoconazole Nitrate Vaginal Cream|vaginal cream
46040841|NCT01039584|Drug|Placebo|vaginal cream
46040842|NCT01039584|Drug|Gynazole 1 vaginal cream|vaginal cream
46040843|NCT05297682|Device|anesthesia with propofol|General anesthesia with propofol
46040844|NCT01108055|Drug|Pazopanib (GW786034)|Cycle of 28 days. Pazopanib: 800mg/day
45474738|NCT01185041|Dietary Supplement|Watermelon Extract|6 weeks of watermelon extract taken in two doses of 3g each per day (6g per day)containing L-citrulline/L-arginine (4/2 g)
45474739|NCT03864185|Biological|Rituximab (genetical recombination)|Administer 375 mg/m2 of rituximab (genetical recombination) IV infusion once weekly for 4 doses.
46040845|NCT01108055|Drug|Paclitaxel|Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15
46040846|NCT05082545|Drug|SHR-2002 and SHR-1316|Cohort study
45344530|NCT00860626|Drug|interferon α plus nucleoside analogue|Standard dose of interferon is used for 12 weeks. On 12th week of treatment, HBV DNA is still detectable (>1000 copies/ml), or HBeAg is still positive. And lamivudine is added for 3 months. After nucleoside analogue is added for 3 months, HBV DNA is tested again. If negative, stop nucleoside analogue and use interferon alone for another 6 months or longer. If HBV DNA is still positive, change to another nucleoside analogue or add another nucleoside analogue.
45344531|NCT00860626|Drug|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is still detectable (>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
45344532|NCT00860626|Drug|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is undetectable, or HBeAg is negative. And interferon is continued alone for another 9 months.
45344533|NCT00724256|Drug|ceftibuten|ceftibuten 9mg/kg once a day for 7 days.
45474740|NCT03864185|Other|Placebo|Administer placebo IV infusion once weekly for 4 doses.
45474741|NCT03365830|Diagnostic Test|FertQol, Beck's Depression Inventory, Beck's Anxiety Inventory|These 3 scale will be given to patients to fill up who takes infertility treatments
45474742|NCT01347931|Device|NIOV System|Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.
45474743|NCT01347931|Device|Standard Oxygen Cannula|Supplemental oxygen via a standard oxygen cannula connected to a portable oxygen cylinder
46040847|NCT00609375|Drug|cefepime|Administration of cefepime in continuous infusion (3 Gr over 24 hours) for 7-14 days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.
45474744|NCT01174979|Drug|Caroverin|treatment with eardrops 2 times for 48 hours
45474745|NCT01185119|Drug|native glp-1 (7-36)|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
46040848|NCT00609375|Drug|cefepime|Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for 7-14 days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours
46040849|NCT01107899|Drug|clopidogrel|taken orally, day one, single dose
45344534|NCT00724256|Drug|ceftibuten|ceftibuten 9mg/kg once a day for 10 days.
45344535|NCT04041466|Diagnostic Test|AF detection by ECG|Single-lead ECG with Withings watch HWA08 and reference 12-lead ECG
46040850|NCT01107899|Drug|prasugrel|taken orally, day one, single dose
46040851|NCT04264299|Procedure|T tube drainage|closure of common bile duct over T tube
46040852|NCT04264299|Procedure|Primary closure|Primary closure of common bile duct
46040853|NCT04264299|Procedure|Antegrade stenting|Closure of common bile duct over antegrade plastic biliary stent
46040854|NCT04265157|Procedure|Surgical technique surgical occlusion|Occlusion of hepatoduodenal ligament by clamp or occlusive bands
46040855|NCT05259735|Combination Product|Clinical Guideline based Management|Clinical guidline based management will be done for Type 2 diabetes Mellitus
46040856|NCT05259735|Other|Comparator|In this arm usual management of T2DM without any clinical guideline
45344536|NCT04067934|Behavioral|Jumping Exercise programme|Four weeks of three jumping-based exercise sessions per week. These sessions will involve basic jumping movements, with approximately 50-100 jumps per session; incorporating 20-30 minutes of exercise.
45344537|NCT04752722|Drug|EG-70|Patients will receive up to four cycles of EG-70 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes.One cycle lasts approximately 12 weeks and consists of either a 2-dose (Day 1 and Day 8) or 4-dose (Day 1, Day 8, Day 29 and Day 36) regimen.
45344538|NCT04752722|Drug|EG-70|Cohort 1 and Cohort 2: Patients will receive up to 4 cycles of EG-70 at the RP2D defined in Phase 1 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes. One cycle lasts approximately 12 weeks).
45344539|NCT00860704|Drug|fluidotherapy with ringer-lactate|a bolus of 250ml ringer-lactate is administered, if there is fluid demand monitored by the Esophageal Doppler
45344540|NCT04742660|Drug|Ammonium Glycyrrhizinate|In control group, we assess the incidence and severity of PONV when participants are aministered ramosetron and placebo. In intervention group, the outcomes are assessed as a result of administration of ramosetron and glycyrrhizin.
45474746|NCT03357640|Drug|combined oral contraceptive pills|one package of oral contraception (Cilest containing norgestimate 250 microgram + ethinyl estradiol 35 microgram)
46040857|NCT01115933|Device|XIENCE PRIME SV EECSS|Patients receiving XIENCE PRIME SV EECSS
46040858|NCT01107743|Drug|Amlodipine/Atorvastatin|"Amlodipine and Atorvastatin combination Tablet is indicated in following subjects for whom treatment with both amlodipine and atorvastatin is appropriate.~Subjects with concurrent hypertension or angina pectoris and hypercholesterolemia or familial hypercholesterolemia Indications for amlodipine and atorvastatin.~For oral use, amlodipine and atorvastatin combination tablet is given once daily. Dosage must be individualized based on dosage and administration for each individual component.~Amlodipine~Hypertension Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose.~Angina pectoris For oral use, the usual adult dosage is 5 mg of amlodipine once daily. Atorvastatin~Hypercholesterolemia For oral use, the usual adult dosage is 10-20 mg of atorvastatin once daily.~Familial hypercholesterolemia For oral use, the usual adult dosage is 10-40 mg of atorvastatin once daily."
45344541|NCT00860782|Behavioral|Parent Educational Support|Parents will attend 45-minute educational sessions that will focus on providing them with information regarding SCD and how they can best help their child perform better in school.
45344542|NCT04069260|Drug|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
46040859|NCT01059864|Drug|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
46040860|NCT01059864|Drug|Atorvastatin|Starting at Week 6 and continuing through Week 12 atorvastatin 10 mg oral tablets administered once daily
45344543|NCT04734938|Dietary Supplement|Huel Powder|Huel is made of an ultra-fine blend of sustainable ingredients. Oats, rice, peas, coconut, flaxseed, and our unique mix of vitamins and nutrients to provide you a meal with all the carbohydrates, protein, essential fats, fibre, and all the 26 essential vitamins and minerals your body needs to thrive. Volunteers will consume only Huel as their food source for the final four weeks of the study.
45344544|NCT00860860|Drug|TF2|TF2: 75-300 mg
45344545|NCT00860860|Drug|IMP-288 labeled with In111 and Lu177|IMP-288: 100 microgram
45344546|NCT02571894|Other|Subclinical cardiotoxicity surveillance and treatment|Intervention arm receives cardiology assessment and intervention.
45344547|NCT01089296|Other|Individually customized physiotherapy|Main elements in the intervention are postural support and facilitating techniques. The intervention will be carried out twice a day over a three-week period if the infant's condition allows it. The length of each treatment session will be adjusted dependent on the infant's response and condition. Maximum treatment time is 10 minutes.
46040861|NCT01059864|Drug|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
46040862|NCT01059864|Drug|Atorvastatin Placebo|Starting at Week 6 and continuing through Week 12 atorvastatin placebo tablets administered once daily
46040863|NCT04310033|Other|Questionnaires|Quality of life questionary: 36-Item Short Form Survey Instrument (36-SF) at 3 and 6 months from inclusion By phone
46040864|NCT04309955|Procedure|pigtail catheter|After inserting the chest tube, add a pigtail catheter into the posterior axillary lines of the 7th intercostal.
46040865|NCT02880917|Device|tDCS-Sham|Sham tDCS will involve an identical electrode montage, with stimulation ceasing after a 30-second ramp-up period to provide equivalent scalp sensation.
45344548|NCT04041388|Other|Conebeam CT|medical imaging technique consisting of X-ray computed tomography where the X-rays are divergent, forming a cone
45344549|NCT00854152|Drug|GDC-0980|Escalating repeating dose
45344550|NCT00721890|Dietary Supplement|Double-Brewed Green Tea|liquid, 4 celsius; 500 mL ID, 3 hours after meals and 1 hour before next meal; duration: to the first of the following events: 18 months or relapse
45344551|NCT01005914|Drug|cyclophosphamide|Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
45344552|NCT01005914|Drug|cytarabine|Day 2 & 3: 3g/m2 IV over 2 hours q12 X 4
45474747|NCT01185197|Drug|Myfortic plus low-dose steroid|Prednisolone: 0.25 mg/kg/day for 8 weeks then 0.15 mg/kg/day for 8 weeks then 0.1 mg/kg/day for 8 weeks then off Myfortic: 720 mg b.i.d. (540 mg b.i.d. if body weight less than 60 kg) for 24 weeks then off
45474748|NCT01185197|Drug|Prednisolone|1 mg/kg/day to be tapered over a period of 24 weeks at the discretion of the attending physician
45684489|NCT05600842|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|IMRT will be given in 30 daily fractions at 2 Gy per fraction (60 Gy total) beginning Day 1; Six fractions will be delivered per week. High risk patients will receive induction chemotherapy with 2 cycles of carboplatin and paclitaxel.
46040866|NCT02880917|Device|tDCS-Active|tDCS was delivered using the anode electrode positioned over the left dorsolateral prefrontal cortex (DLPFE) and the cathode electrode at supra orbital right region. The electrodes were placed into a 25-35 cm2 square sponge immersed in saline solution for better current conductivity. Current density used was 2 mA and electrodes attached to the scalp were sustained by rubber band.
46040867|NCT02880917|Other|Cognitive training|. The cognitive training consisted of an online application of a Dual N-Back task .The Training will last for 8 days.
46040868|NCT01035138|Drug|semagacestat|140mg administered orally, once daily for 24 months; dose reduction to 100mg or 60 mg possible due to intolerability
46040869|NCT03739840|Drug|Padsevonil|Padsevonil in different dosages.
46040870|NCT03739840|Drug|Placebo|Placebo will be provided matching padsevonil.
46040871|NCT04301700|Behavioral|mindfullness and relaxation|three arms: mindfullness and relaxation
46040872|NCT02875236|Drug|OctaplasLG®|"OctaplasLG is an donor plasma product pooled from approximately 1000 single donor units. It possesses unique features when compared to standard fresh frozen plasma, such as having standardized concentrations of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen free. The manufacturing method of OctaplasLG removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation by immune neutralization. OctaplasLG should reduce the inflammatory hit on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma."
45344553|NCT01005914|Drug|dexamethasone|Day 1-4; 11-14: 40 mg daily
45344554|NCT01005914|Drug|doxorubicin hydrochloride|Day 4: 50 mg/m2 IV over 2 hours
45344555|NCT01005914|Drug|imatinib mesylate|600 mg/day
45344556|NCT01005914|Drug|methotrexate|Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
45344557|NCT01005914|Drug|methylprednisolone|Day 1-3: 50mg IV BID
45344558|NCT01005914|Drug|pegaspargase|Day 3/Day4: 2,500 IU/ m2 IV
45344559|NCT01005914|Drug|vincristine sulfate|Day 4 & 11: 2 mg IV
45344560|NCT00854230|Drug|Naltrexone|Naltrexone dose 25-100mg
46040873|NCT02875236|Drug|Ringer-acetat|Crystalloid used as standard of care.
46040874|NCT01039428|Dietary Supplement|HS219|Chewing for 30 min three time a day far after meal
46040875|NCT01039428|Dietary Supplement|Placebo|Chewing for 30 min three times a day far after meal
46040876|NCT00613600|Dietary Supplement|Glucomannan|Two 665 mg capsules of glucomannan three times a day for 8 weeks
45344561|NCT04067076|Other|Self-administered evaluation questionnaire|Smartphone app with MeMind questionnaires
45344562|NCT00861016|Drug|metoprolol succinate prolonged-release tablet and felodipine|a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally
45344563|NCT04018144|Diagnostic Test|Gingiva Biopsy Sampling|Gingival samples of healthy individuals were collected by gingivectomy or crown lengthening procedure in the routine treatment protocol or before orthodontically indicated tooth extraction. Gingival samples of periodontitis patients were obtained during the scaling and root planning procedure. Posterior maxillary teeth (#4, #5, #6, and #7) were chosen for gingival sampling.
45474749|NCT03733873|Drug|Desmopressin|take desmopressin for 3 months
45474750|NCT03733873|Drug|Suoquan|take Suoquan mixture for 3 months
45474751|NCT03365674|Device|Vibration|Vibration applied with vibrator switch-on state (100Hz)
45474752|NCT03365674|Device|Placebo vibration|Vibrator applied with switch-off state
45474753|NCT02524691|Device|Use of Rapid Immunoassay Tests for the Detection of PROM|Patient will undergo both rapid immunoassay tests for the detection of PROM and the standard of care for the diagnosis of PROM using a sterile speculum (SSE). Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of rapid immunoassay tests. The provider conducting the SSE will be blinded to the results of the rapid immunoassay tests.
46040877|NCT00613600|Dietary Supplement|Inert microcrystalline cellulose|Two capsules of inert microcrystalline cellulose three times a day for eight weeks
46040878|NCT03962608|Device|Yaq-001|Study patients will be dosed daily with 8g of product Yaq-001 for a period of 48 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 54 weeks, including the screening (up to 45 days), treatment (48 weeks) and 7-day follow up period.
46040879|NCT03962608|Device|Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 48 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 54 weeks, including the screening (up to 45 days), treatment (48 weeks) and 7-day follow up period.
45474754|NCT03733795|Other|TCD|Transcranial Doppler will be used to measure brain blood flow in the middle cerebral artery.
45474755|NCT03357484|Procedure|Leukocyte- and platelet rich fibrin|Prior to surgery, two 9 ml glass-coated tubes (Intra-Spin, Intra-Lock International, Boca Raton, USA) of patient venous blood were collected. Tubes were transferred to a centrifuge (Andreas Hettich GmbH & Co.KG, Tuttlingen, Germany) and processed for 12 minutes at 2800 rpm to prepare L-PRF.
45344564|NCT04697966|Behavioral|Mindfulness (Headspace) App|"The Headspace app consists of guided mindfulness meditations and is available for both Apple iOS and Android devices. For the proposed study, participants will be instructed to complete the app's most popular introductory program which consists of three levels (Basics 1-3), with each level comprising 10 sessions (30 in total) over 30 days. The program is intended to introduce the key principles and techniques of mindfulness (including focused meditation on the breath, body scanning, and noting), and strategies for applying mindfulness to daily life."
45344565|NCT04697966|Behavioral|"Active Control Condition (Recharge condition delivered in Headspace app)"|"The majority of prior research on mindfulness interventions has relied on single-arm designs or wait-list controls conditions, rather than active control conditions. Accordingly, we will include a structurally-equivalent active control condition, delivered via the same Headspace app. Specifically, the control condition will consist of 30 guided Recharge sessions led by Andy Puddicombe (i.e., structurally equivalent to the Mindfulness app). The sessions are the same length as the interventions (Basics) sessions and also delivered via the Headspace app, thus closely matching the mindfulness intervention across key attributes. Specifically, user flow through the app is identical in both the mindfulness and control conditions, differing only in session content. The Recharge sessions include guide reflections, guided positive imagery, problem solving and daily planning. The chosen excerpts exclude any content which feature guided mindfulness exercises."
45474756|NCT03357484|Procedure|Blood clot|Natural blood clot formed within extraction socket
45474757|NCT01290965|Drug|Placebo|Oral tablet given once or three times daily for 15 consecutive days
45474758|NCT01290965|Drug|SCY-635|oral capsule
46040880|NCT01034358|Biological|Human Papillomavirus Vaccine|0.5mL intramuscular for 3 doses at 0, 2, and 6 months
46040881|NCT03470818|Other|Preparatory instructional videos (flipped classroom model)|"The intervention consists in the provision of preparatory instruction about the medical knowledge required to complete the task work of the upcoming simulated acute care clinical situation. The format used to convey this off-loaded educational content will be short (approximately 15 minutes) narrated video PowerPoint presentations; every relevant medical situation incorporated in the simulation case will have a dedicated video presentation.~These videos will be available to the intervention group participants on a web-based platform one week prior to the simulation session"
45344566|NCT00718380|Drug|ABT-869|2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.
46040882|NCT03470818|Other|Sham video|"Participants in the control group will be called to watch an online video prior to the simulation activity. However, this video presentation will not have any form of information regarding the upcoming simulation case; it will be an introductory video discussing the capacities of the simulation facility. This will limit any unwanted snowball effect where discussion between research participants could lead the control group participants to inquire about a video presentation that they would not exposed to."
46040883|NCT04302402|Drug|Rifaximin|Rifaximin has been demonstrated in multiple IBS studies, through a postulated effect on the gut microbiota, to improve the symptoms of pain and bloating, which are important symptoms in subjects with functional dyspepsia
46040884|NCT04302402|Drug|Placebo|Similar looking placebo
45344567|NCT02553291|Behavioral|SystemCHANGE|
45474759|NCT03733639|Drug|Tisseel|Reinforcement of esophagojejunal anastomoses after total gastrectomy with the product.
45474760|NCT03733639|Device|No Tisseel|No reinforcement of esophagojejunal anastomoses after total gastrectomy
45684490|NCT04759534|Biological|protein convertase subtilisin/kexin type 9 inhibitor|IBI306 is a kind of protein convertase subtilisin/kexin type 9 inhibitor.Received abdominal subcutaneous injection of IBI306 150 mg Q2W or 300 mg Q4W
45344568|NCT02553291|Behavioral|Control|
45344569|NCT04683068|Behavioral|Message comparison|Message comparison
45344570|NCT00851032|Other|Molecular Profiling Analyses|Molecular profiling analyses from advanced cancer participants' stored tissue bank samples.
45474761|NCT03357406|Procedure|ultrasound implant site preparation|piezoelectric bone surgery will be used to create implant bone ostectomy
45840703|NCT00830232|Device|Open-cell stent (Acculink carotid)|"Patients enrolled in this study arm underwent for carotid stenting using open stent cell stents. This type of stent is a tube shaped graft composed of flexible nitinol rings. The device used in this group was the Acculinx open-cell stent.~Stenting procedure eas performed on standard fashion.Filters were used as embolic protection device."
45840704|NCT00830310|Behavioral|Psychoeducation module|"Individuals will be assigned the psychoeducation module if they are identified as having opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes towards drugs in general, or lack of information about mood stabilizers operationalized as a score of 1 or higher on any of these AMSQ subscales. Additionally, those individuals who are non-adherent/sub-optimally adherent because of stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments will be assigned to participate in the psychoeducation module (ROMI stigma item or complementary/alternative treatment supplemental item)."
46040885|NCT03935620|Behavioral|Enhanced Milieu teaching|"Enhanced Milieu Teaching (EMT) an evidence-based, naturalistic language intervention that has been optimized to address the specific language and communication deficits associated with DS. EMT is a parent-implemented intervention that involves home-visits during which clinicians teach parents to support their child learning language during typical parent-child interactions at home (play with toys, music, book reading, and snack time). Clinicians follow an evidence-based instructional framework called Teach-Model-Coach-Review to teach parents language support strategies."
46040886|NCT04408300|Procedure|Ophthalmological exam|Retinophotography, OCT-A (Optical Coherence Tomography- Angiography), OCT-B scan (Optical Coherence Tomography B Scan), Measurement of corrected visual acuity in ETDRS (Early Treatment Diabetic Retinopathy Study), Measurement of intraocular pressure, adaptive optics
46040887|NCT03931408|Drug|Gentamicin Sulfate|Gentamicin will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
45840705|NCT00830310|Behavioral|Substance use module|Individuals will be assigned the substance use module if they endorse the ROMI substance use item or if substance use is identified as problematic on the clinician assessment.
45474762|NCT03357406|Procedure|conventional implant site preparation|twist drills will be used to create implant bone ostectomy
45474763|NCT01291043|Other|Shiatsu|8-week treatment with two Shiatsu sessions per week (50-minute duration)
45474764|NCT03358966|Other|Doubly-labelled water technique|
45344571|NCT05632250|Device|ConvaFoam|ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. These dressings are designed to manage excess exudate levels which may further damage the wound bed and surrounding skin. Patient's wounds will be assessed and a dressing from the above will be applied as part of their normal standard of care. The wounds will be assessed on a weekly basis for up to 12 weeks.
45694607|NCT01903031|Device|Nuvaring|NuvaRing is made of ethylene vinylacetate copolymers (28% and 9% vinylacetate) and magnesium stearate, is latex free, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. NuvaRing has an outer diameter of 54 mm and a cross-sectional diameter of 4mm. Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). After being in place for the first 21 days of the study, the ring may be removed after the day 21 study visit evaluations have been completed.
46040888|NCT03931408|Other|Placebo instillation (saline alone)|Saline will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
46040889|NCT03931408|Other|No instillation|Participants will not receive an instillation of gentamicin or saline alone, but instead will continue standard of care. Participants will be assessed at the pre-, mid- and post-intervention time points.
46040890|NCT03398824|Drug|metformin HCl|Receive metformin HCl
46040891|NCT01033734|Drug|oseltamivir [Tamiflu]|5-day course (10 doses), intravenous administration, may be switched to oral administration at the discretion of the investigator; up to 5 additional days of treatment possible.
46040892|NCT03792256|Drug|Palbociclib|Given PO (or via NG- tube)
46040893|NCT03792256|Drug|Cytarabine|Given intrathecally (IT)
46040894|NCT03792256|Drug|Methotrexate|Given intrathecally (IT)
46040895|NCT03792256|Drug|Hydrocortisone|Given IT
46040896|NCT03792256|Drug|Doxorubicin|Given intravenously (IV)
46040897|NCT03792256|Drug|Prednisolone|Either prednisone or prednisolone is given PO
45344572|NCT00807105|Device|H-coil dTMS|treatment with deep TMS stimulation.
45344573|NCT00854386|Drug|liberal fluid administration|patients in the liberal group (LG) will receive 8 ml/kg•hr of ringer lactate (RL) solution
45344574|NCT00854386|Drug|restrictive fluid administration|Patients in the restrictive group (RG) will receive 2 ml/kg•hr of Ringer Lactate (RL) solution throughout the intraoperative period
45344575|NCT00804219|Biological|TBE vaccination and influenza vaccination|FSME-Immun, 0,5 ml, i.m., 1x Inflexal 0,5 ml, i.m., 1x
45694608|NCT01903031|Drug|EFV|Participants received EFV 600 mg daily with two or more NRTIs
46040898|NCT03792256|Drug|Vincristine|Given IV
46040899|NCT03792256|Drug|Pegaspargase|Given IV
46040900|NCT03792256|Drug|Hydrocortisone|Given intrathecally (IT)
46040901|NCT03792256|Drug|Prednisone|Either prednisone or prednisolone is given PO
46040902|NCT04301856|Drug|CFTR Modulators|CFTR modulators as recommended in routine care by the french health authorities
45344576|NCT00723684|Other|Placebo EEG Neurofeedback|"The placebo EEG-neurofeedback group will get an identical procedure as the real EEG-Neurofeedback, but with feedback on a EEG signal simulation. The placebo group will not be rewarded on their real-time EEG but on a random, simulated EEG; known to be effective for this purpose (Utrecht University, study in progress).~In the protocol selection the electrode position and rewarding versus inhibition of the treatment frequency band or bands will be individually created. The first 30 seconds of the treatment will start on a predetermined fixed threshold value for all treatment subjects."
46040903|NCT00613288|Drug|Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo|"The trial is a double blinded, randomised cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young male participants will receive the GnRH-agonist leuprorelide 7,5 mg s.c. 3 weeks before examination on 3 occasions, and a fourth day without intervention.~The four days will include treatment on the examination day, Day 1 with:~Placebo (hypogonadism after leuprorelide injection)~Testosterone gel 50 mg applicated in the morning at 06.00 am (physiologic substitution - after leuprorelide injection).~Testosterone gel 150 mg applicated in the morning at 06.00 am (supra-physiologic substitution - after leuprorelide injection).~No treatment."
45344577|NCT00723684|Other|EEG-Neurofeedback|The EEG-neurofeedback group will receive feedback on their real-time EEG-signal (brain activity). The treatment group will be rewarded, by brightening (i.e. not being blackened of) the feedback screen. Rewards will be given to the subjects when their digitally filtered frequency EEG activity meets the criteria in the 'percentage time over threshold' parameter. The 'percentage time over threshold' parameter will be auto-adjusted on the digitally filtered real-time EEG every 30 seconds, and the percentage parameter will be kept as a constant over all participants during the entire study (i.e. not adjusted during treatment based on individual capabilities).
45344578|NCT00851110|Procedure|stem cell reinfusion|hematopoietic stem cell reinfusion
45344579|NCT00851110|Drug|Chemotherapy|High-dose chemotherapy consisting of cyclophosphamide, thiotepa and carboplatin
46040904|NCT03711838|Dietary Supplement|N-Acetylcysteine|N-Acetylcysteine in a powder form diluted in a 250 ml drink containing 248 ml water and 2 ml of natural, non-caloric, flavoring-sweetener containing sucralose.
46040905|NCT03711838|Dietary Supplement|Placebo|Placebo consisted of 248 ml water and 2 ml of natural, non-caloric, flavoring-sweetener containing sucralose.
45344580|NCT00798291|Other|Ad lib diet and Control placebo|one packet with water two times a day
45344581|NCT00798291|Other|Ad lib diet and An 777|one packet with water two times a day
45344582|NCT00798291|Other|Ad lib diet/ placebo/ exercise|one packet with water two times a day; resistance training three times a week
45344583|NCT00798291|Other|Ad lib diet; AN 777; exercise|one packet with water two times a day; resistance training three times a week
45344584|NCT03650088|Behavioral|Behavioral weight loss with digital tools|Participants will monitor their diet in a study smart phone app using a 'traffic light' approach where foods are categorized as red (high fat and/or calorie), yellow (moderate fat/calorie, high nutrient), or green (low fat/calorie, high nutrient) and adhere to a red food limit recommendation, weigh daily on a digital scale whose data syncs to the study app, gradually increase physical activity and track it using a wearable device for which data is also synced to the app, and monitor blood glucose using Continuous Glucose Monitoring. Participants will meet weekly with a trained interventionist for behavioral lessons (adapted from Diabetes Prevention Program curriculum) and counseling.
45694609|NCT01903031|Drug|ATV/r|Participants received ATV/r 300 mg/ 100 mg daily with tenofovir and one or more additional NRTIs
46040906|NCT00613678|Behavioral|Activity Strategy Training|The AST component will involve training in specific behavioral and environmental strategies to facilitate performance in daily activities and routines. The activity strategy training group sessions will use education, group discussion, and demonstration and practice of techniques to facilitate activity performance. Homework assignments will be given after many of the sessions to practice and reinforce concepts learned.
45344585|NCT00721916|Drug|SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
45344586|NCT00721916|Drug|mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle l-LV 200 mg/m2 iv. for 2 hr on day 1 5-FU 400 mg/m2 bolus on day 1 5-FU 2400 mg/m2 ci for 46 hr (day 1, 2hr～48hr)
45344587|NCT02552901|Drug|0.1 mg/kg ICG Dose|least efficacious dose
45840706|NCT00830310|Behavioral|Improved communication/rapport with provider module|"Individuals will be assigned the provider communication/rapport module if they are identified as having fear of side effects operationalized as a score of 1 or higher on these AMSQ items. Additionally, those individuals who are non-adherent/suboptimally adherent because of concern regarding change in appearance appearing medicated or who experience side-effect-related distress as identified by the ROMI will be assigned the provider communication module."
45840707|NCT00830310|Behavioral|Medication routines management module|"Individuals will be assigned the medication routines management module if they are identified as having difficulties with medication routines operationalized as a score of 1 or higher on this AMSQ sub-scale, or if they are identified as experiencing outside opposition to medications by the ROMI."
45684491|NCT05606224|Behavioral|internet-based mindfulness intervention for emotional distress|The internet-based self-help version of the Mindfulness Intervention for Emotional Distress (iMIED) program integrates rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth-brushing) were retrieved from MBIs. In addition, iMIED selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks.
46040907|NCT00613678|Behavioral|Education|The health education program is based on educational materials from the Arthritis Foundation.
45344588|NCT02552901|Drug|0.5 mg/kg ICG dose|per package insert
46040908|NCT03656848|Diagnostic Test|QFR|QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two angiographic projections.
45684492|NCT04392700|Drug|Tenofovir disoproxil fumarate 300mg|Take the medicine once a day ，300mg/d
45474765|NCT03358966|Other|Resting Energy Expenditure|Resting energy expenditure represents the amount of calories required for a 24-hour period by the body during a non-active period.
45684493|NCT04392700|Drug|Entecavir 0.5 mg|Take the medicine once a day，0.5 mg/d
45474766|NCT03733561|Drug|LY03003|LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)
45474767|NCT03733561|Drug|Neupro 4Mg/24Hr Transdermal Patch|neupro patch
45474768|NCT03358888|Drug|Multi-modal with as needed opioids|Multi-modal with as needed oxycodone and tramadol provided for break-through pain
45684494|NCT01539525|Behavioral|Motivational Interview|Motivational Interview provided by either a Nurse or Computer
45840708|NCT00830388|Drug|Ketoconazole 2% Foam|Ketoconazole 2% Foam, twice daily application to affected areas for 4 weeks.
45840709|NCT00831480|Drug|everolimus|everolimus 10 mg PO once daily for 3-5 weeks followed by removal of the kidney. Everolimus will begin again between 2 to 4 weeks after surgery.
45684495|NCT01539525|Other|Treatment as Usual|Subjects given a brochure listing relevant recovery resources in the local area.
46040909|NCT03656848|Diagnostic Test|Angiography|Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries
46040910|NCT04275778|Drug|Plaquenil 200Mg Tablet|Hydroxychloroquine will be taken at a dosage of 400 mg / day until delivery
45840710|NCT00832338|Drug|Docetaxel with Cytoxan|Docetaxel 75 mg/m² plus cytoxan 600 mg/m² every 3 weeks for 6 cycles.
45840711|NCT00832338|Drug|Dexamethasone|Dexamethasone 4 mg BID PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel.
45840712|NCT00834210|Drug|Dapsone|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
45840713|NCT00834210|Drug|Tazarotene|Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
46040911|NCT04275778|Drug|Placebo oral tablet|placebo will be taken at a dosage of 400 mg / day until delivery
45840714|NCT00834288|Drug|Tramadol HCl|1x200 mg Tramadol HCl OAD tablet daily
45840715|NCT00834288|Drug|Tramadol HCl|1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly
45840716|NCT00834678|Drug|bendamustine|100 or 120 mg/m2 IV on days 1 and 2
45840717|NCT00834678|Drug|erlotinib|100 or 150 mg po on days 5 - 21 of each 28 day cycle
45684496|NCT02960620|Device|TheraSphere Treatment|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
45684497|NCT02960308|Radiation|Computed Tomography Perfusion Imaging|Undergo WNCTP scan
45684498|NCT04274452|Biological|efgartigimod|Intravenous infusion of efgartigimod
45684499|NCT04274452|Other|Placebo|Intravenous infusion of placebo
45684500|NCT03827902|Device|Telcare 2.0 BGM|Blood glucose meter that uploads blood glucose measurements to a cloud server that providers can access and use to monitor patients' glycemic trends.
45684501|NCT03828058|Drug|Envarsus XR|Envarsus XR to be administered orally, once a day. Dosage will be adjusted as determined by trough blood levels.
45474769|NCT03358888|Drug|Multi-modal with one week of opioids offered|Multi-modal with only one week of oxycodone and tramadol provided for emergency pain relief only
45474770|NCT03358888|Drug|Standard of Care|This arm follows standard of care post-operative pain management with oxycodone, tramadol, and acetametophin
45684502|NCT03828058|Drug|Prograf|Prograf 2 mg BID to be administered orally, twice a day. Dosage will be adjusted as determined by trough blood levels.
45684503|NCT03827590|Drug|Test|three times a day for five days
45840718|NCT00834678|Drug|Maintenance erlotinib|150 mg po daily (days 1 - 28 of 28 day cycle)
45840719|NCT00835224|Drug|L-NAME|A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
46040912|NCT04260880|Other|periodontal status in mild depression patients|Assessment of periodontal status in mild depression patients
46040913|NCT04260880|Other|periodontal status in moderate depression patients|Assessment of periodontal status in moderate depression patients
46040914|NCT04260880|Other|periodontal status in systemically healthy patients|Assessment of periodontal status in systemically healthy patients
45684504|NCT03827590|Drug|Active Comparator Control 1|three times a day for five days
45840720|NCT00835224|Drug|Midodrine|To treat low blood pressure.
45840721|NCT00835224|Drug|Placebo|A pill with an inactive substance that looks like the study drug.
45840722|NCT00835926|Biological|Influenza virus vaccine|0.5 mL, Intramuscular
45840723|NCT00835926|Biological|Influenza virus vaccine|0.5 mL, Intramuscular
45840724|NCT00837252|Drug|Finasteride|Participants received 5mg of oral finasteride daily for three months.
45840725|NCT00839982|Drug|clofarabine|Given PO
45840726|NCT00839982|Drug|cytarabine|Given SC
46040915|NCT01115855|Drug|Eplerenone|Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily
45684505|NCT03827590|Drug|Active Comparator Control 2|three times a day for five days
46040916|NCT01115855|Drug|Placebo|Placebo once daily or every once daily
46040917|NCT03669094|Dietary Supplement|Lactobacillus salivarius V4II-90|7 months intervention study: with a screening period of 12 weeks after which participants GBS+ women will be randomized and start the orally intake of 1 capsule per day of the Lactobacillus salivarius V4II-90 (1*10E9 CFU) probiotic supplement over a 12 weeks period. A visit will then be completed one month after delivery.
46040918|NCT03669094|Dietary Supplement|Placebo|7 months intervention study: with a screening period of 12 weeks after which participants GBS+ women will be randomized and start the orally intake of 1 capsule per day of the placebo supplement over a 12 weeks period. A visit will then be completed one month after delivery.
46040919|NCT03615508|Drug|10% phenylephrine|10% phenylephrine is a drug that can be used to dilate patient's eyes at their yearly eye examination. All enrolled subjects will receive this drug for their eye dilation.
46040920|NCT05331976|Diagnostic Test|Proof Lab Test System|Includes the Proof Lab Reader and the Proof Lab COVID-19 Test Kit containing: Proof Lab COVID-19 Test Cartridge, Sample Vial, Sample Swab, Exact Volume Transfer Pipette
46040921|NCT05288296|Device|dynamic taping|"The intervention of dynamic tape can improve the LESS, which also means that we may reduce the probability of ACL injury through the intervention of dynamic tape.~By establish a native model of single-leg and double-leg LESS can predict the occurrence of ACL injury early and further prevent it."
45684506|NCT03827590|Drug|Placebo|three times a day for five days
45684507|NCT03827668|Drug|PF-06650833 alone|In Period 1, Days 1-5, participants will receive PF-06650833 once daily alone.
45684508|NCT03827668|Drug|PF-06651600 alone|In Period 2, Days 1-7, participants will receive PF-06651600 once daily alone.
45684509|NCT03827668|Drug|PF-06650833 together with PF-06651600|In Period 2, Days 8-12, participants will receive PF-06650833 once daily together with PF-06650833 once daily.
45684510|NCT02958280|Behavioral|Fit&Sober App|Fit&Sober is a smartphone-based physical activity app that includes multilevel strategies for increasing physical activity for patients with AUDs in early recovery.
45694610|NCT01903031|Drug|TDF|Participants received 300 mg of tenofovir in Arm C
46040922|NCT00614068|Behavioral|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT sessions will include trauma-focused treatment and will teach participants behavioral management and coping skills to overcome their PTSD.
46040923|NCT00614068|Behavioral|Treatment as usual (TAU)|TAU outpatient sessions will include routine community care and nontrauma-focused therapy.
46040924|NCT05274802|Drug|ALS-4|Single dose of ALS-4 before Breakfast
46040925|NCT05274802|Drug|Placebo|Single dose of placebo before Breakfast
45344589|NCT00861172|Procedure|3T MR scanner|"The follow-up will be scheduled for one year; it will consist in a weekly MR examination during the first two months, and subsequently on the 6th and the 12th months.~We will perform for each MRI exploration an intravenous injection of contrast agents: gadobutrol (gadovist 1,0 mmol/ml) which is a stable agent with a cyclic structure. This agent is few responsible for NFS, given their low capacity to liberate gadolinium GD3+ in tissues.~The same imaging protocol will be performed for each MR examination. Evaluation of creatinemia will be used before inclusion and during the 1st, 3rd, 5th, 7th, 9th, and the 10th MRI examination. Thus we will take advantage of catheter to perform the creatinemia blood test and to reduce the discomfort produced by the injection."
45344590|NCT00721994|Device|Cormet Hip Resurfacing System|Cormet Hip Resurfacing System
46040926|NCT05274802|Drug|ALS-4|Dose three separate times in crossover fashion: (1) fasted morning dose; (2) fed morning dose; (3) fasted evening dose
45344591|NCT04068714|Procedure|Type of aneurysm repair|In open surgery repair group, aneurysm repair was performed by open surgery including aortobifemoral bypass, aorto-bi-iliac bypass and tubular aortic bypass. In endovascular repair (EVAR group), aneurysm correction was performed by percutaneous approach, femoral cutdowns and aorto-uni-iliac EVARs with femorofemoral bypass.
45344592|NCT00861250|Drug|bortezomib + dexamethasone|Bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4, 9-12 in cycles 1- 2, then bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4 in cycles 3-4, total number of cycles is 4, followed by HDT with ASCT
45344593|NCT00807183|Other|woodstove|installation of new EPA-certified woodstove
45344594|NCT00807183|Other|inactive air filter|air filter units without filter in place
45344595|NCT00807183|Other|Active air filter|air filter units correctly operating
45344596|NCT00722150|Drug|Artesunate|2 mg/kg/day x 7 days
45344597|NCT00722150|Drug|Artesunate|4 mg/kg/day x 7 days
45474771|NCT03733405|Behavioral|Postpartum Visit at 6 Weeks|The patient will be scheduled for a routine postpartum visit at the standard time interval. Each postpartum visit will consist of the standard interview and physical examination. The purpose of this visit is for routine postpartum care. If she has a medical complication during delivery, she may be recommended to schedule an additional earlier visit.
45474772|NCT03733405|Behavioral|Postpartum Visit at 2 Weeks|The patient will be scheduled for an earlier postpartum visit in addition to the standard time interval. Each postpartum visit will consist of the standard interview and physical examination. The purpose of this visit is for routine postpartum care. If she has a medical complication during delivery, she may be recommended to schedule an additional earlier visit.
45474773|NCT03864029|Drug|KUVAN|retrospective data on the effectiveness of past treatment with KUVAN®. It includes blood Phe level, physical development status, intelligence development status, etc., during treatment with KUVAN
45474774|NCT03365518|Behavioral|Cognitive Behavioural Therapy (CBT)|Sessions consist of CBT tools as well as sex therapy techniques and education. The CBT treatment was adapted from the mindfulness-based treatment, but all mentions of mindfulness have been replaced with CBT principles. The therapeutic content presented in this treatment arm is manualized.
45684511|NCT02958280|Behavioral|Brief Advice|Participants randomized to the BA only condition will meet for a 30-minute discussion with a research staff member. In this session, participants will receive information about the public health guidelines for physical activity, the benefits of physical activity for physical and mental health, as well as sobriety, strategies for getting started as well as instruction on gradually increasing physical activity
45684512|NCT01513551|Biological|Pneumococcal Conjugate Vaccine (V114)|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
45344598|NCT00722150|Drug|Artesunate|6 mg/kg/day x 7 days
46040927|NCT05274802|Drug|ALS-4|Multiple dose of ALS-4 up to two times daily
46040928|NCT05274802|Drug|Placebo|Multiple dose of placebo up to two times daily
45344599|NCT02571738|Biological|CHAM|The treatment indication is for chronic diabetic foot ulcers that can accommodate up to one 5cm x 5cm piece of CHAM
45344600|NCT02571738|Other|Control|Standard of Care
45344601|NCT00861094|Drug|cisplatin|
45344602|NCT00861094|Drug|5-FU|
45344603|NCT00861094|Drug|oxaliplatin|
45344604|NCT00861094|Radiation|radiation therapy|
45344605|NCT00861094|Drug|Folinic Acid|
46040929|NCT02880995|Device|PET scan|The patient group and the healthy control group will undergo PET scan at the baseline. the investigators are going to measure striatal dopamine synthesis capacity using [18 fluorine(F)]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a >30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
46040930|NCT02880995|Behavioral|clinical scale|Patient group should complete clinical scales at baseline and 6 week.
46040931|NCT02880995|Drug|6 weeks of treatment with amisulpride|The investigators are going to measure striatal dopamine synthesis capacity using [18 fluorine(F)]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a >30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
45344606|NCT02554149|Radiation|Radiological measurement of femoral stem version|particular radiographs( lateral decubitus view) and CT scans
45344607|NCT00722228|Biological|Autologous or Allogeneic tumor cells|Five vaccine doses, injected subcutaneously at 3-week intervals. Each dose is composed of irradiated and DNP-conjugated tumor cells.
45344608|NCT00807261|Drug|Gemcitabine and Docetaxel|"Drug and schedule~Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min (D1, D8)~Docetaxel 35 mg/m2 IV (D1, D8) .. every 21 days~Dose modification~Treatment should be delayed if the ANC<1,500/ mm3, or if the platelet count <75,000/mm3 on the first day of the next cycle.~Gemcitabine & docetaxel are omitted on day 8, when ANC is less than 1000/mm3 or platelet count is less than 50,000/mm3; it is reduced by 25% if the ANC is between 1,000 and 1,500/mm3 or the platelet count is between 50,000 and 75,000/mm3 Study design Treatment should consist of at least 2 cycles unless rapid disease progression or unacceptable toxicities occur after one cycle of chemotherapy.~Patients with response or no change will receive 2 additional cycles."
46040932|NCT03522064|Drug|Testosterone Enanthate 100 MG/ML Injectable Solution|Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL.
45344609|NCT04019106|Drug|Budesonide in bovine lipid extract surfactant (BLES)|Budesonide in bovine lipid extract surfactant
46040933|NCT03522064|Drug|Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5|Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL. Carboplatin as per standard procedures
45474775|NCT03365518|Behavioral|Mindfulness-Based Therapy|The mindfulness-based treatment was developed based on pre-existing mindfulness-based cognitive therapy treatment groups for sexual dysfunction developed by Dr. Lori Brotto at the University of British Columbia Sexual Health Laboratory, mindfulness in Sex therapy and Intimate Relationships (MSIR) treatment group developed by Kocsis and Newbury-Helps (2016), and expert input. Sessions consist of mindfulness-based training as well as sex therapy techniques and education. The therapeutic content presented in this treatment arm is manualized.
45684513|NCT01513551|Biological|PNEUMOVAX® 23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose.
45684514|NCT01513551|Biological|PREVNAR 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
45344610|NCT02571608|Drug|Metformin|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
45344611|NCT02571608|Drug|Placebo|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
45344612|NCT00865072|Drug|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
45684515|NCT03827434|Device|Continuous glucose Monitoring Devices and Clarity Software|Patients with DM2 at the intervention group will be managed by Continuous glucose Monitoring and Clarity software
45684516|NCT03827434|Other|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
46040934|NCT01115309|Device|XprESS Balloon Device|Sinus dilation completed with the XprESS Balloon Device with or without additional endoscopic sinus surgery procedures (dilation of the frontal recesses, maxillary ostia, and/or sphenoid sinus ostia).
46040935|NCT03517228|Device|BAUM device|The robotic manipulator will be placed at the start of each case. The manipulator will be cleaned and sanitized using the same process as other reusable OR devices. Feasibility will be determined by the rate of successful robotic manipulator docking and if the manipulation of the uterus was successful for the duration of the procedure. The V-Care is an FDA approved uterine manipulator which will attach to the investigational BAUM. Placement of a BAUM will be noted on the operative note.
46040936|NCT04310579|Drug|Oxycodone and Midazolam|"In one period subjects receive oxycodone 10-15 mg immediate release (IR) and placebo IV 1x per day.~In a second period (randomized cross-over), subjects receive midazolam 0.0375-0.075 mg/kg IV and oral placebo tablet 1x per day.~In a third period (randomized cross-over), subjects receive oxycodone 10-15 mg IR tablet and 0.0375-0.075 mg/kg midazolam IV 1x per day.~In a fourth period (randomized cross-over), subjects receive oral placebo tablet and placebo IV 1x per day."
46040937|NCT04310579|Drug|Oxycodone, Paroxetine, and Quetiapine|"In one period, subjects receive: oxycodone 10-15 mg IR tablet 1x per day and oral placebo 3x per day on Days 1 and 5; and oral placebo 3x per day on Days 2-4.~In a second period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, paroxetine 40 mg tablet 1x per day, and oral placebo 1x per day on Days 1 and 5; and paroxetine 40 mg tablet 1x per day and oral placebo 2x per day on Days 2-4.~In a third period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, quetiapine 50 mg tablet 2x per day, and oral placebo 1x per day on Day 1; quetiapine 100 mg (2x50 mg tablets) 2x per day and oral placebo 1x per day on Day 2; quetiapine 150 mg (3x50 mg tablets) 2x per day and oral placebo 1x per day on Day 3; quetiapine 200 mg (4x50 mg tablets) 2x per day and oral placebo 1x per day on Day 4; and quetiapine 200 mg (4x50 mg tablets) 1x per day and oral placebo 1x per day on Day 5."
45474776|NCT01291121|Procedure|Intravitreal expansile gas and ranibizumab injection|Intravitreal expansile gas (0.3 cc C3F8) and 0.5mg ranibizumab at day 0 Additional 3 monthly loading injection of intravitreal ranibizumab Additional injection of ranibizumab as needed
45474777|NCT05666401|Procedure|follicle diameter and duration of procedure|to investigate if smaller follicles thrive embryos as the bigger follicles
45474778|NCT03357328|Other|Therapy light room|See group description
45474779|NCT03357328|Other|Standard light|See group description
45474780|NCT01185275|Device|Alair system|Bronchial thermoplasty
45474781|NCT03365440|Device|esoECG-3D catheter|Recording of esophageal ECGs with the investigational medical device (IMD). Recording of respiration with a commercial breathing sensor.
45474782|NCT01185431|Dietary Supplement|Ficus carica (Fig paste)|Ficus carica paste 300g/day
45474783|NCT01185431|Dietary Supplement|Placebo (Placebo paste)|Placebo composition 300g/day
45344613|NCT00865072|Drug|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
46040938|NCT04188340|Behavioral|Su-Man formula massage oil|bergamot massage oil:dilute bergamot essential oil(0.5%) with almond oil Su-Man formula massage oil: mixed 4 different essential oil include bergamot, red mandarin, petit grain bigarade, spikenard and diluted with almond oil 5%.
45344614|NCT00798447|Drug|MLF 541|22-24 h i.v. infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
45344615|NCT00798447|Drug|Lipofundin MCT|22-24 h iv.infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
46040939|NCT05244538|Device|Virtual reality distraction|Patients will be exposed to a virtual reality representing a forest walk. A reduction of at least 50 percent in the remifentanil and propofol doses required for oocyte retrieval is expected.
45344616|NCT02571660|Drug|GINA treatment fot asthma +vit.D low supplementation dose|Dose of 400 IU of vitamin D3 every 24 hours for 1 year + the standard treatment for asthma,
45344617|NCT02571660|Drug|GINA treatment fot asthma +vit.D high supplementation dose|Dose of 1600 IU of vitamin D3 be allocated each 24 hours for 1 year + standard treatment for asthma
45344618|NCT00722306|Drug|PD 0200390|Extemporaneous solution of C14 Labelled PD 0200390 60 mg single dose
45344619|NCT00804297|Drug|Octreotide (drug)|
45344620|NCT00722384|Drug|bevasiranib|
45344621|NCT00722384|Drug|bevasiranib|The first three patients enrolled will receive 0.1 mg Cand5 in the study eye, the next three patients enrolled will receive 0.33 mg Cand5 in the study eye, the following three patients enrolled will receive 1.0 mg Cand5 in the study eye, the following three patients enrolled will receive 1.5 mg Cand5 in the study eye, and the remaining three patients enrolled will receive 3.0 mg Cand5 in the study eye. The third patient enrolled at each dose level will complete their two-week visit before the next dose level group may be treated.
45474784|NCT01187849|Drug|Metformin|Volunteers will be given Metformin or placebo for 1 month, once daily.
45474785|NCT01187849|Drug|Placebo|Volunteers will be given Metformin or placebo for 1 month, once daily
45474786|NCT03358810|Device|PES|The PES system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Phagenyx® Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation.
45474787|NCT02524535|Other|Therapeutic alliance|
46040940|NCT05244538|Drug|Propofol-remifentanil sedation|"Target controlled infusion (TCI) of remifentanil will be started at an effect concentration (Ce) of 1.5 ng/mL and TCI propofol at Ce 1.5 ug/mL.~The concentration of remifentanil will be adjusted in 0.5 ng/ml increments based on hand sign from the patient with a maximum effect concentration of remifentanil at 2.5 ng/ml."
46040941|NCT03504826|Device|Hybrid Assistive Limb (HAL)|Intensive training with the HAL consisting of two components to the intervention session that include: 1) locomotor treadmill training with the HAL device and 2) locomotor training over ground without the HAL device. All training will be overseen by a licensed physical therapist.
46040942|NCT05175742|Biological|PTX-COVID19-B|Sterile solution for injection
45344622|NCT00804375|Drug|2PX|cutaneous solution to be applied twice daily for 84 days
45344623|NCT00804375|Drug|Placebo|cutaneous solution to be applied twice daily for 84 days
45344624|NCT04067700|Procedure|Invasive coronary treatment|Coronary artery bypass surgery or percutaneous coronary intervention.
45474788|NCT03358732|Device|endometrial navigation one day before the embyo transfer using IUI catheter ,|one day before the actual ET, the participants, in the study group, were taken into the operating room with a moderately full bladder at 10 am. The patient was placed in the lithotomy position and a sterile speculum was inserted into the vagina. The cervix was cleaned with sterile swabs and sterile water, and a mock transfer was performed using a soft catheter (Wallace Intrauterine Insemination Catheter; Sims Portex Ltd., Hythe, Kent, UK). The catheter has an outer sheet with memory , to aid insertion, and a soft inner catheter with atraumatic tip. Under ultrasound guidance, only the soft inner catheter was introduced beyond the internal cervical os till it was 0.5 cm from the fundus. It was, then, gently withdrawn out of the uterus, and the speculum was removed.
46040943|NCT05175742|Biological|Pfizer-BioNTech COVID-19 vaccine|Sterile solution for injection
45474789|NCT03358654|Drug|mesenchymal stem cells from umbilical cord|inject mesenchymal stem cells from umbilical cord，and the patients will be followed up at 1, 2, 3, and 6 months after the injection.
45474790|NCT04927871|Behavioral|Total Diet Replacement (TDR)|The nutritionist will provide a total diet replacement (TDR) with Low-Energy Liquid-Diet (LELD - 811 kcal/day, 64 g protein, 132 g carbohydrate, 6 g fat) and the food reintroduction for two months.
46040944|NCT05175742|Biological|Placebo|0.9% sodium chloride (normal saline) injection
46040945|NCT03638128|Drug|Denosumab|Solution for injection
46040946|NCT03638128|Drug|Alternative osteoporosis medications|Alternative osteoporosis medication/s at the discretion of the investigator.
46040947|NCT03306082|Other|Image-Guided Cochlear Implant Programming|Post Cochlear Implant surgery, participant will receive traditional activation and programming per routine. IGCIP will be used to offer alternative programming of the implant.
46040948|NCT00614146|Device|MARS device|10 treatments with the MARS system during the first three weeks after enrollment of 5-8 hours each.
45840727|NCT00842946|Behavioral|Exposure w/ Acceptance-Based Rationale|"Treatment focuses on the ineffectiveness of participants' past attempts to control or reduce their anxiety in public speaking situations. Acceptance of one's private experiences (thoughts, feelings, sensations) will be introduced. Willingness to experience unwanted thoughts and feelings while simultaneously engaging in valued activities, especially those related to public speaking, is stressed. Techniques designed to foster psychological acceptance are practiced prior to and during exposure exercises, as well as assigned for homework between sessions."
46040949|NCT00614146|Procedure|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
45344625|NCT00865228|Drug|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
45344626|NCT00865228|Drug|Lapaquistat acetate|Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate 100 mg, tablets, orally, once daily in the evening for up to six weeks.
46040950|NCT00614146|Procedure|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
46040951|NCT03555838|Other|transcranial direct current stimulation|Transcranial direct current stimulation, a form of neuromodulation that uses a low direct current delivered via sponge electrodes on the head.
45344627|NCT00865228|Drug|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily in the morning and Lapaquistat acetate 50 mg, tablets, orally, once daily in the evening for up to six weeks.
45344628|NCT00865228|Drug|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
45344629|NCT00724412|Other|Systane|Dry Eye relief eye drops
45344630|NCT00724412|Other|Optive|Dry Eye relief eye drops
45344631|NCT00722202|Drug|ERB-257|
45344632|NCT00722202|Other|placebo|
45344633|NCT00724490|Procedure|Deep Brain Stimulation|Unilateral Deep Brain Stimulation in the right Nucleus Accumbens
45344634|NCT00723762|Procedure|Specimen collection|A blood sample and a spot urine sample will be obtained from all eligible patients receiving VPA at the start of the study.
45344635|NCT00861328|Drug|ON 01910.Na and irinotecan|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety evaluation.~The suggested starting dose of Irinotecan is 180 mg/m2 administered by intravenous (IV) infusion over 90 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
45474791|NCT04927871|Behavioral|Medical Nutritional Therapy (MNT)|The nutritionist will provide Medical Nutritional Therapy (MNT) using the transcultural Diabetes Nutritional Algorithm (tDNA) Toolkit adapted for Venezuela for four months.
46040952|NCT03555838|Other|sham transcranial direct current stimulation|an inactive or placebo version of transcranial direct current stimulation placed on the head via sponge electrodes.
46040953|NCT05108194|Behavioral|SMS Personalized Sleep Intervention|"All participants will be enrolled in the intervention to evaluate the feasibility and acceptability of the SMS-PSI. After the data training and validation phase, participants will be provided with at least one and up to three daily text messages that offer users a specific strategy based on strategies from CBTi. All participants will have access to a user dashboard, which is a web-app that includes personalized sleep-tracking information and the opportunity to customize their messaging. The person-level acceptability and adherence to the sleep strategies will be evaluated via self-report endorsement from daily diary and whether users added suggestions to their calendars. Both adherence and acceptability will be collected and integrated with the selection algorithm to optimize subsequent SMS suggestions."
46040954|NCT05042440|Drug|Efanesoctocog alfa|Solution for injection Intravenous
46040955|NCT05042440|Drug|Octocog alfa|Solution for injection Intravenous
45474792|NCT04927871|Behavioral|Diabetes Prevention Program 4 months|The coach will provide a group-based Diabetes Prevention Program (DPP) version in weekly encounters during 4-months.
45474793|NCT04927871|Behavioral|Diabetes Prevention Program|The coach will provide a group-based Diabetes Prevention Program (DPP) version in weekly encounters during 6-months.
45474794|NCT03365284|Device|Smart Kneebrace with a smart phone app|Smart Kneebrace will be used during the rehabilitation. Patients wearing the Smart KneeBrace are able to know their daily activity summary and exercise performance during rehabilitation training through a smart phone app.
45474795|NCT03365284|Other|regular rehabilitation procedure|regular rehabilitation procedure, especially muscle strengthening exercises
46040956|NCT05042440|Drug|Rurioctocog alfa pegol|Solution for injection Intravenous
45344636|NCT00861328|Drug|ON 01910.Na and oxaliplatin|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety review of the combination regimen in the previous cohort.~The suggested starting dose of Oxaliplatin is 85 mg/m2 administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
45344637|NCT00722462|Procedure|Active acupuncture|Acupuncture 25 minutes before and after embryo transfer
45344638|NCT00722462|Procedure|Sham acupuncture|Acupuncture at neutral points, 25 minutes before and after embryo transfer
46040957|NCT05084963|Drug|IRL201104|lyophilised powder for reconstitution for IV dosing
46040958|NCT05084963|Drug|Placebo|Matching placebo for IRL201104
45684517|NCT03827122|Drug|onabotulinumtoxinA|Experimental group we will use BTX-A administration group. All patients (Male/Female) with bruxism associated with chronic pain in masseter muscles bilaterally Patients will have treatment with 20 units of BOTOX, (Allergan Inc.) per side will be injected at three points into masseter muscle bilaterally.
45684518|NCT02956642|Device|Livongo Health System|Participants will be asked to use the Livongo Health System to manage their blood glucose.
45684519|NCT02956642|Device|iHealth Glucose Meter|Participants will be asked to use the iHealth Glucose Meter to take blood glucose measurements.
46040959|NCT03529630|Other|Inverted syringe|Application of mild suction over the mother's inverted nipple using an inverted syringe before each breastfeeding.
46040960|NCT04940026|Drug|amcenestrant|Tablet Oral
46040961|NCT04940026|Drug|[14C]-SAR439859 microtracer|Solution for infusion Intravenous
45684520|NCT03827356|Device|Inspiratory muscle trainer (IMT)|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).
45684521|NCT03827200|Drug|Ambrisentan|Ambrisentan will be administered subcutaneously at the Hospital on the days of HVPG deterination and taken orally at home between visits.
45684522|NCT02983630|Other|Penicillin allergy testing|The standard protocol for testing for penicillin hypersensitivity, including initial skin testing with prick and intradermal evaluation followed by oral challenge if skin testing is negative.
45344639|NCT02570880|Other|glycemic index (glucose-solution, bread samples)|All participants will test 2 breads, prepared with different fermentation times of dough, both breads will be tested in duplicate. Methode: International Organization for Standardization / Final Draft International Standard 26642, Food products - Determination of the glycaemic index (GI) and recommendation for food classification
45344640|NCT00724646|Other|Survey|3 individual surveys
45344641|NCT00724646|Other|Focus group|Focus group discussions facilitated by a psychologist
45344642|NCT00618514|Device|Bright Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber with a fitted ceramic tip on the end. Treatment performed on one leg.
45344643|NCT00618514|Device|Bare Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber readily available on the market with a bare tip on the end. Treatment performed on one leg.
45684523|NCT03827278|Drug|Voriconazole|"6mg/kg bid, was given on the first day, followed by intravenous 4mg/kg bid for 6 days, followed by oral Valconazole 200mg bid for at least 6 months.~Amphotericin B sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until CD4+ T cells are greater than 100 cells/L for at least 6 months"
46040962|NCT04940026|Drug|[14C]-SAR439859|Powder for oral solution Oral
46040963|NCT03481660|Drug|Brolucizumab|Intravitreal injection
46040964|NCT03481660|Drug|Aflibercept|Intravitreal injection
45684524|NCT03826732|Behavioral|Guided self-help based on ACT|ACT-based self-help book and regular support by trained facilitators
46040965|NCT04825912|Behavioral|Self System Therapy for Older Adults with Advanced Lung Cancer (SST-LC) Resilience|The SST-LC is a brief structured intervention deliverable by video conference. The SST-LC Resilience protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors. The focus will be to test measures of resilience during the intervention period.
46040966|NCT03614026|Behavioral|Teachers and Parents as Partners|Family-school partnership intervention
46040967|NCT03448120|Procedure|Acupuncture|Six needled will be inserted in six already defined acupoints along the non-dominant upper limb for a period of 30 minutes.
46040968|NCT03448120|Procedure|Dry needling|Six needles will be inserted in six predefined points along the volunteers non-dominant biceps brachialis for 30 minutes.
46040969|NCT00614224|Behavioral|treadmill exercise training|3 months (3 times/week) progressive graded aerobic treadmill training with a duration of 10-45 min per training session
46040970|NCT04748926|Drug|rilzabrutinib SAR444671|Pharmaceutical form: caplet Route of administration: oral
45684525|NCT01513473|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
46040971|NCT04748926|Drug|rilzabrutinib SAR444671|Pharmaceutical form: Oral Formulation 1 tablets Route of administration: oral
45684526|NCT01513473|Drug|insulin detemir|Injected subcutaneously (under the skin) once or twice daily. Dose individually adjusted.
46040972|NCT04748926|Drug|rilzabrutinib SAR444671|Pharmaceutical form: Oral Formulation 2 tablets Route of administration: oral
46040973|NCT03261076|Behavioral|Strategies Enhancing Reading in Older Underperf. Students|Strategies for Enhancing Reading in Older Underperf. Students (SERIOUS) combines two scientific, research based intervention programs, each meeting specific need of youth in detention: (1) Stevenson Reading Program, manualized and uniquely suited to students with phonological awareness, attention, and memory difficulties that may impact reading; and (2) Dr. Sharon Vaughn's well-documented, validated program, explicitly designed for older, severely reading-impaired students. SERIOUS also includes: (3) metacognitive strategies for self-regulated learning, and (4) A gamified extension of the intervention on a SmartPhone, designed to reinforce word-level skills (e.g., decoding, automaticity, and vocabulary), and including features efficacious for learning.
46040974|NCT03221218|Other|Enhanced screening-informed follow up letter|Family Physicians will be sent a letter that includes their screening test results and associated symptom-specific recommendations from the Ontario Neurotrauma Foundation clinical practice guidelines.
46040975|NCT00614302|Drug|TPV|
46040976|NCT05345236|Drug|Aflibercept|Intravitreal (IVT) injection
46040977|NCT04586530|Behavioral|Memory and Attention Adaptation Training (MAAT)|A cognitive-behavioral therapy (CBT) for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors.
45684527|NCT01513473|Drug|insulin aspart|Injected subcutaneously (under the skin) as mealtime bolus insulin. Dose individually adjusted.
45684528|NCT04346368|Biological|BM-MSCs|Participants will receive conventional treatment plus BM-MSCs(1*10E6 /kg body weight intravenously at Day 1).
46040978|NCT04586530|Behavioral|Supportive Therapy (ST)|Standard attention control condition therapy for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors.
46040979|NCT02692690|Device|Stimulette r4x|
46040980|NCT02692534|Other|Urine cocaine negative|Preoperative urine cocaine negative
46040981|NCT02692534|Other|Urine cocaine positive|Preoperative urine cocaine positive
46040982|NCT04153318|Device|full-field optical coherence tomography|Pancreatic tissue sample obtained by EUS-FNB will be used for FFOCT imaging. The Images will be sent to trained pathologists for diagnosis. The same tissue sample will be sent to the pathology department for routine histological examination. Compare the diagnoses made by the 2 different methods.
46040983|NCT04413370|Diagnostic Test|Dry eye diagnostic test|The artificial intelligent dry eye screening platform
46040984|NCT05344768|Other|aerobic exercise|Moderate intensity aerobic exercise training will be applied.
46040985|NCT05344768|Other|high-intensity interval exercise training|High-intensity interval exercise training will be applied.
46040986|NCT05344768|Other|resistance exercise training|resistance exercise training will be applied
45474796|NCT01187927|Biological|Cervarix®|Administered according to the prescribing information in the locally approved label by the authorities.
45684529|NCT04346368|Biological|Placebo|Placebo
45684530|NCT03826810|Radiation|aPDT|For the aPDT the PapacarieMblue (Fórmula e Ação) was used. It was left for 5 minutes in the cavity. The carious tissue was removed and the application of the PapacarieMblue was repeated. The tissue was then irradiated in a single spot with a red laser, of wavelength of 660 nm, for 300 s, with the energy of 500mJ. These parameters were also applied in the vestibular root of the teeth, to try and prevent sensitivity.
45684531|NCT03826810|Procedure|ART|Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.
46040987|NCT00613912|Other|Magnetic Resonance Imaging|"Morphological sequences~Arterial Spin Labelling (Perfusion)~Spectroscopy: anterior cingulate cortex Naa, Cho, Cr, Myo-inositol, glutamate TE 30 Reference voxel in Parietal white matter"
46040988|NCT05344612|Radiation|CT Coronary Angiography|Upfront ct-coronary angiography
46040989|NCT04336618|Device|Liver MultiScan|The LiverMultiscan is a quick 15 minute, contrast free, non-invasive MRI scan that provides 3 liver metrics
46040990|NCT05344534|Behavioral|Leadership and Organizational Change for Implementation|LOCI is data driven leadership development and coaching for clinic managers and working with agency executives and middle managers to foster a strategic implementation climate
45344644|NCT04067804|Behavioral|Dynamic Adaptation Process|The Dynamic Adaptation Process draws from implementation science frameworks and methods, including the Exploration, Preparation, Implementation, and Sustainment model, to organize planning and implementation activities. The Dynamic Adaptation Process is a structured methodology designed to integrate new interventions within complex systems, such as schools.
45344645|NCT00854542|Behavioral|Telepsychiatry-based Culturally Sensitive Collaborative Treatment|T-CSCT: Patients in Group A will receive T-CSCT, which consists of Telepsychiatry-based Culturally Sensitive Psychiatry Assessment using the Engagement Interview Protocol (EIP) plus Care Management.
46040991|NCT00614536|Drug|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12weeks
46040992|NCT05344300|Other|Temperature-measurement in lungs under sauna bath|Through a bronchoscopy procedure under an 88-92℃ environment, the air temperature is measured in the 1st, 2nd and 3rd bronchial segment, at 4th and 5th bronchial segment and at 6th-10th bronchial segment in resp. the right and left lung. The temperature is measured at time: 0 seconds (s), 15 s, 30 s, 45 s, 60 s, 75 s, 90 s, 105 s, 120 s, 135 s and 150 s.
45344646|NCT00722540|Drug|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
45344647|NCT00722540|Drug|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
45344648|NCT00722540|Drug|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
45344649|NCT00722540|Drug|NNC126-0083|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
45344650|NCT00722540|Drug|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
45344651|NCT00722540|Drug|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
45344652|NCT00722540|Drug|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
45344653|NCT00722540|Drug|placebo|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
45344654|NCT00722540|Drug|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
45344655|NCT00722540|Drug|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
45344656|NCT00861406|Drug|Pegylated Interferon-Alfa 2b (PEG Intron)|"Group 1:~6 mcg/kg by injection under skin once weekly for 4 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 20 weeks.~Group 2:~6 mcg/kg by injection under skin once weekly for 8 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 16 weeks.~Group 3:~6 mcg/kg by injection under skin once weekly for 12 weeks followed by Maintenance Phase of 3 mcg/kg weekly for 12 weeks."
45344657|NCT00861406|Drug|GP-100 Peptide Vaccine|Injection under skin once every 3 weeks (Weeks 1, 4, 7, 10, 13, 16, 19, and 22), for a total of 8 injections.
45344658|NCT04261790|Drug|Ocrelizumab|Patients will be treated with two courses of ocrelizumab (Ocrevus) 600mg/course, for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience the return of the disease activity can go back on the medication.
45344659|NCT00861484|Drug|GSK958108|Coated Tablets 1 mg
45344660|NCT00861484|Drug|Placebo|Coated tablets
45344661|NCT04018742|Other|Surgical puncture|Investigators propose to collect 20 abscesses. A collection of abscesses is performed systematically during the diagnostic for bacteriological analysis. There will be no further examination.
46040993|NCT05344222|Device|Infrared LED|The participants in the active photobiomodulation group will be irradiated with infrared LED at a wavelength of 850 nm perpendicular to the surface of the skin in gentle stationary contact at three extraoral points. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
46040994|NCT05344222|Device|Similar device - Infrared ED|For the participants in the sham group, a device with a similar appearance will be used that did not emit radiation. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
46040995|NCT04333654|Drug|Hydroxychloroquine SAR321068|Pharmaceutical form:Tablet Route of administration: Oral
46040996|NCT04333654|Drug|Placebo|Pharmaceutical form:Tablet Route of administration: Oral
46040997|NCT01059630|Drug|Obinutuzumab|IV infusion.
46040998|NCT01059630|Drug|Bendamustine|IV infusion.
46040999|NCT05344144|Other|Emotional Freedom Technique|EFT was applied to pregnant women with a history of prenatal loss twice, one week apart, by the researcher. Between the two treatments, they were given personalized homework (on waking up in the morning and before going to sleep at night) for self-administration.
46041000|NCT05344144|Other|Music|Music practice was applied to the pregnant women with a history of prenatal loss twice, one week apart, by the researcher. For one week after the first application, the music application was applied by the pregnant woman once a day/for 30 minutes, and the researcher was reminded by phone message.
46041001|NCT04314700|Device|OCT- based investigational imaging device|Excised breast lumpectomy tissue will be imaged and images reviewed on an investigational Wide-Field OCT (WF-OCT) device.
45344662|NCT00865384|Drug|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
45344663|NCT00865384|Drug|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under non-fasting conditions
45344664|NCT00724724|Drug|Butylphthalide Soft Capsules|Butylphthalide Soft Capsules: 2 tablets Bid for 1 year Aspirin: 100mg for 1 year
45344665|NCT00724724|Drug|Aspirin|Aspirin 100mg Qd for 1 year
45344666|NCT00865462|Drug|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fed conditions
45344667|NCT00865462|Drug|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
45344668|NCT04042558|Drug|Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab|4 cycles of induction every 3 weeks of cisplatine,pemetrexed, atezolizumab + bevacizumab and patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed +/- Bevacizumab administered at the same dosage on 3-week cycles
45344669|NCT04042558|Drug|Carboplatin + Pemetrexed + Atezolizumab|Carboplatin + Pemetrexed + Atezolizumab
45344670|NCT04130204|Drug|DYV700|Proprietary transdermal delivery platform
45344671|NCT04130204|Drug|Placebo|Vehicle transdermal delivery platform
45344672|NCT04130204|Drug|Colchicine 0.6 mg|Standard of care, 2 tablets (1.2 mg) loading dose followed by 1 tablet (0.6 mg) 1 hour later at onset of gout flare.
45344673|NCT00723918|Drug|SAB378|SAB 15 mg per day for 5 days, the 15 mg BID (twice a day) for 5 days, then 15 mg TID (three times a day) to end of 28-day treatment period, in combination with active methadone 5 mg BID for 5 days, then 5 mg TID for 5 days, to maximum of 10 mg TID until end of 28-day treatment period
45344674|NCT00723918|Drug|methadone|Methadone 5 mg BID (twice a day) for 5 days, then 5 mg TID (three times a day) for 5 days, to maximum of 10 mg TID, in combination with SAB placebo or SAB active drug titrated as above, to end of 28-day treatment period.
45474797|NCT04522882|Device|Actimetry|Actimetry will be performed at home to measure physical activity, sleep duration and patient chronotype for 7 days.
45684532|NCT03826654|Dietary Supplement|fortified oil|35 g fortified sunflower oil
46041002|NCT04226170|Drug|DAS-001|ondansetron + pyridostigmine
46041003|NCT05343910|Other|Aroma massage|The older adult participants in the experimental group were applied aroma massage through gentle movements with slight pressure for 15 min a day, five days a week for three weeks.
46041004|NCT05343676|Device|ultrasonography|"For assessment of LNS ( cervical , axillary and inguinal LNS ), The choice of transducer is an important consideration when evaluating lymph nodes as higher frequencies provide better resolution for superficial structures~For color Doppler assessment of the lymph nodes, scanning will be done using the slow frame rate, low pulse repetition frequency~Assessment features including lymph node location, size, shape, border, echogenicity, calcifications, necrosis or cystic change, and adjacent soft tissue edema"
45344675|NCT00723918|Drug|SAB placebo|an inactive substance
45344676|NCT00723918|Drug|Methadone placebo|Methadone placebo
45344677|NCT00722618|Behavioral|Written materials, telephone based education|4 new written materials, 15-20 minute educational session by telephone
45344678|NCT00722618|Other|Written materials|2 written materials available on public website
45344679|NCT05373888|Device|Flexima®/Softima® stoma bags|"One piece stoma bags for enterostomates available as:~Closed (flat and convex)~Drainable with Roll'Up (flat and convex)~High flow with tape outlet (flat)"
45344680|NCT00865540|Drug|prednisolone acetate 1%|1 drop every 8h two days before surgery
45344681|NCT00865540|Drug|ketorolac tromethamine 0.4%|1 drop every 8h two days before surgery
45344682|NCT00865540|Drug|nepafenac 0.1%|1 drop every 8h two days before surgery
45344683|NCT00865540|Drug|methylcellulose 0.5%|1 drop every 8h two days before surgery
45474798|NCT04522882|Other|Questionnaires|Patients will complete food and medication intake questionnaires for 7 days.
45474799|NCT04522882|Other|Glucose level and insulin administration|Continuous subcutaneous glucose level (measured by continuous glucose monitor (CGM)) and the insulin doses delivered by the insulin pump will be collected for 7 days .
45344684|NCT00723996|Behavioral|Behavioral Study in Women|A Randomized study to assess the knowledge of womens health related issues
46041005|NCT04200976|Behavioral|Tele-CABA|"Tele-CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of Tele-CABA focus on learning about TBI and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.~The Tele-CABA intervention will be delivered over 10 weekly, 60-minute telephone sessions."
45474800|NCT01185665|Device|TENS|Transcutaneous Electrical Nerve Stimulator
46041006|NCT04200976|Behavioral|Usual Care|Participants in the UC group will continue to receive their regular medical, psychiatric, and psychotherapeutic care.
46041007|NCT04192240|Other|WB Training with external feedback|WB during sit-to-stand and stepping with external feedback, follow by overground walking.
46041008|NCT04192240|Other|WB Training without external feedback|WB during sit-to-stand and stepping without external feedback, follow by overground walking.
45344685|NCT04066556|Other|Brain CT imaging|"The investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. The investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.~Cut-off values in thrombus volume and Hounsfield unit according to non-contrast CT images~Cut-off values in areas of irreversible changes according to non-contrast CT images~Cut-off values in occlusion sites and collateral scores according to CT angiographies~Cut-off values of consolidated CT imaging index including clot, core, and collateral score~Cut-off values of comorbidity index~Medical care expenses according to comorbidity index in patients who received intravenous thrombolytic treatment and/or endovascular recanalization treatments."
45344686|NCT00865618|Drug|Eplerenone 50 mg Tablets Sandoz Inc., USA|
46041009|NCT05343520|Behavioral|Pelvic floor muscle exercises|Pelvic floor muscle exercises were applied to the pregnant women in the experimental group from the 30th gestational week to the 6th postpartum week.
45474801|NCT01185665|Device|Sham-TENS|TENS without electrical output, from the outside not different from a normal TENS
46041010|NCT04672980|Drug|RTX-321|RTX-321 monotherapy
46041011|NCT04143958|Drug|agalsidase beta (GZ419828)|Pharmaceutical form:Powder for concentrate for solution for infusion Route of administration: Intravenous (IV) infusion,
46041012|NCT04143958|Drug|agalsidase alfa|Pharmaceutical form:concentrate for solution for infusion Route of administration: Intravenous (IV) infusion
46041013|NCT04303338|Procedure|Masotherapy with neural tension and masotherapy with non-neural tension|To compare the effectiveness of masotherapy with neural tension and masotherapy with non-neural tension
46041014|NCT04142086|Biological|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
46041015|NCT04142086|Biological|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
46041016|NCT04142086|Biological|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
46041017|NCT04142086|Biological|Yellow fever vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
46041018|NCT04643184|Other|Management Program|Joint management between the geriatric and cardiology team of the geriatric syndromes and heart failure. Education of the patient and their caregiver, preparing them for the transition of care.
45344687|NCT00865618|Drug|Inspra 50 mg Tablets GD Searle LLC, USA|
45344688|NCT02570594|Other|questionary|
45474802|NCT03123718|Drug|Intrathecal methotrexate|Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.
45684533|NCT03826654|Dietary Supplement|Placebo|plain oil
45344689|NCT00722280|Procedure|Hand Transplantation|"This program is the primary site for a novel immune modulation protocol for hand and/or forearm transplantation using donor bone marrow stem cells. This protocol, otherwise called the Pittsburgh Protocol has been published and implemented in 8 hand/forearm transplantations. The Pittsburgh hand transplant program is the only center that has experience with the Pittsburgh Protocol to reduce the number and dosing of immunosuppressive drugs used to prevent rejection of hand/forearm transplants."
45344690|NCT00655629|Drug|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10 mg orodispersible tablet (ODT)
45344691|NCT00655629|Drug|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
45344692|NCT00865696|Drug|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
45344693|NCT00865696|Drug|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under fasting conditions
45344694|NCT00724802|Dietary Supplement|GTA (Glyceryl triacetate)|0.5 gr/kg x2/day syrup two times a day with increasing dose each 3 days till max 5gr /kg each day for 6 months
45344695|NCT00724802|Drug|GTA glyceryl triacetate|0.5 gr/kg twice a day with increase of 0.5 gr/kg every 3 days up to 5 gr/kg
45344696|NCT05373732|Behavioral|meditation|meditation practice 20 minutes twice a day at home and attending classes at the clinic.
45344697|NCT05373732|Behavioral|Health education control|didactic based classes in CVD risk factor reduction and prevention
45344698|NCT02545114|Drug|Tolvaptan|Use of Tolvaptan to treat SIADH-induced hyponatremia in selected patients with acute neurological injuries.
45344699|NCT00722696|Other|physical training|8 weeks of hiking downwards. For the opposite way, a cable car will be used.
45344700|NCT02570568|Device|Veinlite|Veinlite is a device that emits red light. It provides a non-invasive technique of inserting intra-venous cannula. Placing it onto the skin will cause the outlines of the veins to show up.
46041019|NCT05343442|Procedure|Percutaneous tracheostomy|"Guidewire dilating forceps (Grigges') technique was the method which has been applied during our work. Proper positioning: patient's neck was extended as much as possible by placing a rolled towel between the shoulder blades, the patient's neck and the bed were maintained in neutral position. The operative site was sterilized before draping with 10% povidone iodine solution. Lidocaine 2% was used as local anesthetic prior to beginning the intervention.~Transverse (1 cm) skin incision was made midway between the cricoid cartilage and the suprasternal notch, i.e., opposite the 2nd - 3rd or 3rd - 4th tracheal rings. Blunt dissection of subcutaneous fat and pre-tracheal tissue with mosquito clamp in a vertical direction was done till the tracheal rings were palpable."
46041020|NCT02874222|Other|surveys completed by subject|Cohort study designed to validate previously identified associations between 10 specific SNPs and discontinuation of treatment with AIs due to the development of MSS among women with breast cancer.
45344701|NCT02570568|Device|Pen-torch Transillumination|Pen-torch Transillumination is a non-invasive technique that utilizes 2 pen-torches to provide illumination.The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up
45344702|NCT02570568|Procedure|Conventional Venepuncture|This involves the conventional method of identifying veins suitable for venepuncture, which involves visualization and palpation.
46041021|NCT03583684|Behavioral|Pivotal Response Treatment Program (PRT-P)|The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.
45840728|NCT00842946|Behavioral|Exposure w/ Habituation-Based Rationale|Exposure to feared public speaking situations are accompanied by explanations of behavioral principles, including classical/operant conditioning and habituation. The process of associating public speaking situations with unwanted feelings of anxiety will be discussed, as well as negative reinforcement of escape and avoidance behaviors. The underlying principle of habituation is reviewed. When engaging in exposure exercises (both in session and assigned homework exercises), participants will be encouraged to remain in the feared speaking situation until their subjective ratings of anxiety decrease.
46041022|NCT05333302|Biological|CD19 CAR-T-cells|One dose of CD19 CAR-T cells (1*10e6 CAR+ T-cells/kg) by intravenous infusion.
46041023|NCT05333302|Drug|Tocilizumab|Before 1h of CAR-T cells infusion a patient receive tocilizumab (8 mg/kg).
46041024|NCT05343208|Diagnostic Test|EFP Psychometric assessment to determine level of afflication|Patients were asked to complete a psychometric assessment in relation to their psychological wellbeing. Results were presented to the patient and validdated by the patient.
45344703|NCT00861562|Drug|Imescard water smartweed composed pills|01 pill at every 8 hours for 5 days.
45684534|NCT03109990|Drug|Dexmedetomidine|Patients in the experimental group will receive Dexmedetomidine during surgery.
45840729|NCT00843180|Other|massage|one to three massages per week by massage practitioner additional massages by resident parent who is being taught to massage her/his child
46041025|NCT03456778|Procedure|Ultrasound-guided Percutaneous Tenotomy with Platelet-Rich Plasma (PRP)|Using an aseptic procedure, 7 cubic centimeters (cc) of blood will be collected and processed for the PRP injection. The site to be injected will be prepared with isopropyl alcohol and then sprayed with ethyl chloride to achieve cutaneous anesthesia. Next, with continuous sonographic visualization, the skin and subcutaneous tissues overlying the tendon will be infiltrated with 0.5% bupivacaine and 1% sodium bicarbonate (50 milliequivalents (mEq)/50 mL) via a 25-gauge hypodermic needle. Once adequate anesthesia is achieved, a 20-gauge needle will be used to repeatedly fenestrate the tendinotic portion of the tendon along the long plane. Any calcifications within the substance of the tendon will be mechanically fragmented. When the region of interest has been treated, a PRP injection (5 cc) will be delivered.
46041026|NCT03664882|Drug|Fexofenadine M016455|Pharmaceutical form: tablet Route of administration: oral
46041027|NCT03664882|Drug|Placebo|Pharmaceutical form: tablet Route of administration: oral
45344704|NCT00861562|Drug|Placebo|01 pill at every 8 hours for 5 days, with the exact same appearance as the other intervention.
45344705|NCT00724880|Drug|Clopidogrel|Clopidogrel is stopped 5 days prior to surgery
45344706|NCT00724880|Drug|Clopidogrel|Clopidogrel is stopped 3 days prior to surgery
45344707|NCT00724880|Drug|Clopidogrel|Clopidogrel is stopped 0 days prior to surgery
45344708|NCT02571348|Procedure|micro-osteoperforation|micro-osteoperforation with mini implant at different interval
45344709|NCT00854698|Other|exercise training|subjects are asked to exercise 20 or 30 minutes.
46041028|NCT03951142|Drug|Losartan|This trial is open-label; therefore, the participant, the trial site personnel, the Sponsor and/or designee are not blinded to treatment. Drug identity (name, strength) is included in the label text. Storage, handling and preparation requirements will be handled in concordance with the Pharmacy Manual for losartan.
45684535|NCT03109990|Drug|Saline|Patients in the control group will receive saline but not Dexmedetomidine during surgery.
45840730|NCT00845130|Biological|ascorbic acid (Vitamin C)|ascorbic acid IV 1 g/kg
46041029|NCT03642964|Drug|CTC-501|pramipexole IR, given with ondansetron
46041030|NCT03903016|Drug|Insulin Lispro SAR342434|Pharmaceutical form:solution for injection Route of administration: subcutaneous
45344710|NCT00854698|Other|subjects are asked to exercise during 20 or 30 minutes|subjects are asked to exercise during 20 or 30 minutes
45344711|NCT04067882|Other|Genetic signature|The RNA will be extracted from the tumor sample with a special kit and a q-PCR will be performed. In order to quantify the genetic expression, the comparative method called Cycle threshold or Crossing point will be used.
46041031|NCT03903016|Drug|Insulin Lispro SAR342434|Pharmaceutical form:solution for injection Route of administration: subcutaneous
45344712|NCT00804453|Device|Cartridge blood set|Once a week
45344713|NCT00804453|Device|Standard blood line|Once a week
45684536|NCT03826420|Behavioral|SCF Supervision with Secure Confinement Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves secure confinement.
45684537|NCT03826420|Behavioral|SCF Supervision with Work Release Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves work-release.
45684538|NCT03826420|Behavioral|SCF Supervision with GPS Supervision Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves GPS supervision.
45840731|NCT00848016|Drug|R-(-)-gossypol acetic acid|Participants take 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
45840732|NCT00848172|Drug|Octanoic Acid|4mg/kg
45840733|NCT00848172|Drug|Placebo|identical capsules
45840734|NCT00849810|Drug|Metoprolol|Metoprolol tablets 25-200 mg daily times four weeks. Nebivolol daily for 4-5 weeks
45840735|NCT00849810|Drug|Nebivolol|5 - 20 mg daily, at a stable dose for 4 to 5 weeks
45840736|NCT00856050|Drug|letrozole|Taken orally once a day continuously
45344714|NCT00724074|Device|On-Q PainBuster with Bupivacaine|On-Q PainBuster continuous wound infusion analgesia system, using bupivacaine as the local anaesthetic
46041032|NCT03571750|Behavioral|Building Stronger Allies|"BSA was developed to model the educational and behavioral techniques commonly employed in the treatment of individuals with mood psychopathology. The psychoeducation portion uses Cognitive Behavioral Therapy principles to correct problematic ideas and behaviors related to PB/TB. More specifically, the program was designed to correct myths regarding PB/TB. The program emphasizes the idea that social interaction is a critical need, just like other basic needs such as the need for food and water. Participants are taught that negative beliefs about being isolated and being a burden are usually inaccurate. Following this, behavioral activation techniques are introduced as a way to decrease isolation and feelings of burdensomeness."
45344715|NCT00724074|Device|Usual Care|Usual Care
45474803|NCT03123718|Drug|High-dose intravenous methotrexate|"Intravenous administration of 1st and 2nd doses of methotrexate 3g/m2 on day 15 of 2nd and 6th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.~* Dose of intravenous methotrexate will be reduced to 2g/m2 for patients aged >70 years."
45684539|NCT03825562|Behavioral|acceptance and commitment therapy, ACT|
45840737|NCT00857532|Drug|florbetapir F 18|10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
45840738|NCT00858390|Dietary Supplement|enteral feeding with Oxepa® and Glutasolve®|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
45840739|NCT00858468|Biological|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
45840740|NCT00858468|Biological|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
46041033|NCT03571750|Behavioral|Health Education Training|In the HET condition, participants will spend approximately the same amount of time with a program that will present information regarding the importance and benefits of a maintaining a healthy lifestyle and then will provide guidelines to achieve a healthy lifestyle. HET is shown to engage participants with beneficial information while being inert with respect to the risk mechanisms of interest (i.e., PB/TB). The program covers a number of health related topics including: diet, alcohol use, water consumption, exercise, and sleep. The program reviews with the Participants how to monitor their own daily health habits, which will be reinforced by the Smartphone application.
46041034|NCT03521362|Device|MyT1DHero|MyT1DHero is an app with two separate interfaces, one for the parent and one for the child, that work together to help them communicate about diabetes management. The child receives system reminders to enter their blood glucose numbers, and parents receive a notification about each blood glucose test their child enters. Parents are also able to use the app to communicate with their child about their plan for care. The app has customizable blood glucose reminders and ranges, videos of support from other adolescents with T1D, snack lists, and other educational information on T1D.
46041035|NCT03521362|Device|Other T1D Mobile App|A mobile app will be used in this control/comparison group that only has blood sugar testing reminders and logging capabilities. There will be no other components of the app.
45344716|NCT00854776|Drug|lansoprazole|30 mg once daily
45344717|NCT00854776|Drug|aluminum hydroxide 334 mg and Mg hydroxide 166 mg|1 tablet once daily
45344718|NCT00798525|Drug|Argatroban|Argatra (Argatroban) will be diluted to 0.6 mg/ml and 0.5 µg/kg/min will be administered continuously in patients without liver disfunction. In patients with liver disfunction, defined by a bilirubin of > 4mg/dl, argatroban will be administered as a continuous infusion of 0,25 µg/kg/min with a final concentration of 0,3 mg/ml.
45344719|NCT00798525|Drug|Lepirudin|Refludan (Lepirudin) will be diluted to a final concentration of 0.1mg/ml and initiated as a continuous infusion of 5µg/kg/h in patients with continuous renal replacement therapy. In patients with moderate renal impairment (Creatinine ≥1,3 mg/dl) a final concentration 0,2 mg/ml of will be used to provide continuous infusion of 10 µg/kg/h. Patients without renal impairment (Creatinine < 1,3 mg/dl) will receive a continuous infusion of 50 µg/kg/h by a final concentration of 1 mg/ml of Lepirudin.
45344720|NCT02571374|Dietary Supplement|symbiotic group|this group received sachets of symbiotic
45344721|NCT02571374|Dietary Supplement|placebo group|this group received placebo
45474804|NCT01185743|Drug|olanzapine|olanzapine 10mg od + placebo od
45684540|NCT03071536|Drug|Furosemide Injection|Furosemide 1.5 mg/kg intravenously at 3 hours post-reperfusion of kidney allograft
45684541|NCT01513317|Drug|Siltuximab|15 mg/kg administered as a 1-hour intravenous infusion every 4 weeks
45684542|NCT01513317|Drug|Placebo|Administered as a 1-hour intravenous infusion every 4 weeks
45684543|NCT01513317|Drug|Best supportive care (BSC)|Best supportive care according to local standards and guidelines
45694611|NCT01903031|Drug|NRTIs|Participants received two or more NRTIs in Arm B and one or more NRTIs in Arm C
45694612|NCT00883168|Drug|Placebo|Placebo
45694613|NCT00883168|Drug|azelastineHcl|azelastine hydrochloride 548 mg
45840741|NCT00858858|Drug|Ursodeoxycholic Acid|8 weeks of oral UDCA treatment 10 mg/kg qd
46041036|NCT03514732|Drug|MELATONIN (MELATL07959)|Pharmaceutical form:Capsule Route of administration: Oral
46041037|NCT03800836|Drug|Ipatasertib|Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28 day cycle for all arms except for arms F1/F2 where it will be administered at a dose of 300 milligrams (mg) orally daily for the first two cycles and 400 mg for the remaining three cycles.
46041038|NCT03800836|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m^2) as IV infusion on Days 1, 8, and 15 of each 28 day cycle for all arms, with the exceptions of Arms F1, F2, G1 and G2, where it will be also administered on Day 22 as well, of each 28 day cycle.
46041039|NCT03800836|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 840 mg on Days 1 and 15 of each 28 day cycle for all arms, although in Arms C1/C2, it will be administered on Day 15 of Cycle 1 followed by Days 1 and 15 in subsequent cycles.
46041040|NCT03800836|Drug|Nab-Paclitaxel|Nab-paclitaxel will be administered by IV infusion at a dose of 100 mg/m^2 on Days 1, 8, and 15 of each 28 day cycle.
46041041|NCT03800836|Drug|AC|AC (Doxorubicin and Cyclophosphamide) will be administered by IV infusion at 60 mg/m^2 and 600 mg/m^2 respectively on Days 1 and 15 of Cycles 1 and 2 for Arms F1, F2, G1 and G2.
46041042|NCT01976182|Drug|Methotrexate|methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take, during 4 months.
45344722|NCT00861640|Drug|Intravenous Omeprazole|Intravenous Omeprazole 1amp qd (every day)
45840742|NCT00859950|Device|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is a method of respiratory ventilation which is accepted as the gold standard to treat Obstructive Sleep Apnea (OSA). Subjects found to have OSA after the Nocturnal Polysomnography (NPSG) will be trained in the use of CPAP and will be instructed to use CPAP every night for 30 nights. These subjects will then return for a post-treatment blood draw.
46041043|NCT01976182|Drug|Cyclophosphamide|cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take, during 4 months.
46041044|NCT00932373|Drug|trastuzumab-MCC-DM1|Intravenous escalating dose
45344723|NCT00861640|Drug|Oral Rabeprazole|Oral Rabeprazole 1 bid
45344724|NCT00724230|Drug|PegIntron (peginterferon alfa-2b; SCH 54031)|"PegIntron administered in accordance with approved labeling~Subcutaneous injection once weekly for 24 weeks."
45344725|NCT00724230|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered orally twice daily in accordance with approved labeling. Dosing duration 24 weeks.
45344726|NCT04066322|Procedure|system treatment and surgery|to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to receive Synchronous resection of primary tumor and metastasis. after surgery, the investigator decide further treatments.
45344727|NCT04066322|Other|system treatment|to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to continue take system treatment.
45344728|NCT00861718|Drug|AZD7268|Capsule, Oral, QD
45344729|NCT00861718|Drug|AZD7268|Capsule, Oral, BID
46041045|NCT03511690|Behavioral|BRCA-Gist|"BRCA-gist is an innovative Intelligent Tutoring System intervention that uses avatars to emulate tailored one-to-one human tutoring and includes the bottom-line meaning of risk messages. BRCA-gist is designed to provide the same information contained in four modules from the NCI webpages: breast cancer and metastasis, risk factors, genetic mutation testing, and the consequences of testing."
46041046|NCT04265235|Other|Home-based exercise program|see 'arm' section
45344730|NCT00861718|Drug|Placebo|Capsule, Oral BID
45344731|NCT00725036|Drug|inhaled human insulin|
45344732|NCT00725036|Drug|insulin aspart|
45840743|NCT00862446|Drug|Omegaven|1 gram/kg/day daily until on feeds
45344733|NCT00725036|Drug|insulin NPH|
45344734|NCT00865774|Behavioral|Quantity Frequency Model|The quantitative intervention involves emphasis on tracking and measuring the number of drinks on a weekly basis.
45344735|NCT00865774|Behavioral|Targets Subjective Drunkenness|Explores factors leading to drunkenness and alternative coping strategies for healthier function.
45344736|NCT00724386|Drug|Paclitaxel|1-hour IV infusion once weekly for 12 to 14 weeks
45344737|NCT00724386|Drug|Vinorelbine|escalating doses administered intravenously over 6-10 minutes for 12-14 weeks
45344738|NCT00724386|Drug|Filgrastim|"daily injections for 6 days beginning on day 2 of second week on study and then every other week (weeks 2, 4, 6, 8, 12).~For the final dose cohort, administration on chemotherapy only weeks, only if dose reduction or dose delay required by subject"
45344739|NCT00724386|Radiation|Radiation|Radiotherapy for 5 consecutive days every other week (weeks 1, 3, 5, 7, 9, 11, 13)starting on same day as first dose of protocol chemotherapy
45344740|NCT00865852|Drug|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
45344741|NCT00865852|Drug|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
45344742|NCT02571114|Dietary Supplement|Saskatoon Berry Frozen Yogurt|Frozen yogurt containing a defined amount of powder prepared from Saskatoon berries (serving size = 25 g available carbohydrate)
45344743|NCT02571114|Dietary Supplement|Frozen Yogurt|Unflavoured frozen yogurt (serving size = 25 g available carbohydrate)
45344744|NCT02571114|Dietary Supplement|Control 1|White bread (serving size = 25 g available carbohydrate)
45344745|NCT02571114|Dietary Supplement|Control 2|White bread (serving size = 25 g available carbohydrate)
45840744|NCT00864084|Other|Pulmonary rehabilitation|Pulmonary rehabilitation involves the prescription of customized exercise programs and education on disease management.
45344746|NCT00725114|Biological|Tetrodotoxin|30 µg twice daily for 4 days
45344747|NCT00725114|Biological|Placebo|2 mL subcutaneous injection twice daily for 4 days
45474805|NCT01185743|Drug|ziprasidone|ziprasidone 40mg td
45474806|NCT01185743|Drug|placebo|placebo td
45474807|NCT04445038|Drug|610|Recombinant anti-IL-5 Humanized Monoclonal Antibody
45840745|NCT00864708|Device|radio frequency-controlled (RF) Microstimulator (RFM) Gait System|Fully Implanted FES system to assist patient with gait component practice
45840746|NCT00866034|Drug|Cetrotide (Ovarian stimulation)|Fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2
45474808|NCT04445038|Drug|Placebo|Placebo
45840747|NCT00866034|Drug|Cetrotide (Ovarian stimulation)|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6.
45840748|NCT00868140|Drug|pioglitazone|pioglitazone 45 mg
45840749|NCT00868140|Drug|Placebo|placebo daily
45684544|NCT03825484|Drug|Erdafitinib|Participants will start erdafitinib 8 milligram (mg) (formulated as tablets with 3 mg, 4 mg and 5 mg dosages) orally once daily until disease progression, intolerable toxicity, withdrawal of consent or decision by the doctor to discontinue treatment. Dose will be up-titrated to 9 mg based on serum phosphate levels and if there is no drug-related toxicity.
45684545|NCT03825250|Drug|Sodium Valproate|Treatment with Sodium Valproate vs. Control Discovery phase - 4 arms: 15 mg/kg for 1-2 weeks; 15mg/kg for 4-6 weeks; 25 mg/kg for 4-6 weeks; Control Efficiency phase - 2 arms: Treatment group selected from previous phase; Control
45474809|NCT01188005|Device|n-CPAP|administration of continuous positive airway pressure through a nasal device
46041047|NCT03509506|Behavioral|App Group|"The participants will be educated to use the HFHS application to monitor their daily vital signs (HR, BP, body weight), physical activity, and medications for 4 weeks.~The research team will monitor their data entry remotely via the HFHS App. The team will text the participant via the App if one or more of following conditions is noted:~The vital signs show undesired readings~The records on the HFHS App show that the participant did not take the medications as the schedule says~In addition, the team will call the participant 3 days later to follow up regarding the participant's action towards the text message that the team sent."
46041048|NCT04265079|Other|Additional weight at hand|Added weight of an inactive hand orthosis (300 gram)
46041049|NCT05353881|Other|No intervention|No intervention
45474810|NCT01188005|Device|Oxygen supplementation|Oxygen supplementation (3L) through nasal spectacles
45684546|NCT02983474|Procedure|cholecystectomy|"Laparoscopic surgery~Reverse Trendelenburg position~Skin incision and trocar insertion~CO2 gas insufflation~Intra-abdominal inspection and gallbladder exposure~Gallbladder traction~Calot triangle exposure~Cystic artery and cystic duct isolation~Gallbladder bed dissection~Bleeding control~Gallbladder extraction~Trocar removal and wound closure~Open surgery~Supine position~Skin incision~Intra-abdominal inspection and gallbladder exposure~5. Gallbladder traction 6. Calot triangle exposure 7. Cystic artery and cystic duct isolation 8. Gallbladder bed dissection 9. Gallbladder extraction 10. Bleeding control 11. Wound closure"
45684547|NCT04105179|Device|Zimmer NexGen LPS-Flex|Patients will be randomly assigned to 1 of 2 devices
46041050|NCT04265001|Drug|Hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash|Topical mouthwash used three times daily for one week and patients were not allowed to eat or drink for one hour after rinsing.
45684548|NCT04105179|Device|Smith & Nephew Journey II|Patients will be randomly assigned to 1 of 2 devices
45684549|NCT03066310|Diagnostic Test|Next generation sequencing|The obtained DNA from the urine, blood and tumor (optional) will be tested by next generation sequencing for each arm.
45684550|NCT03825640|Behavioral|CARE|Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.
45840750|NCT00868218|Biological|Influenza vaccine|"Influenza virus strain:~avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14"
45840751|NCT00868374|Drug|Quetiapine XR|Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
45840752|NCT00868374|Drug|Placebo|Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
45840753|NCT00868452|Drug|lurasidone + (lithium or divalproex)|lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7.
45474811|NCT01188005|Drug|Vitamin A, Vitamin C, Vitamin E, Allopurinol, N-Acetylcysteine|Vitamin A 50,000 IU, Vitamin C 1000 mg , Vitamin E 200 mg, Allopurinol 600 mg, N-Acetylcysteine 2 g. Duration is set for 60 days
45474812|NCT03645421|Drug|MEDI0382 100 μg|Solution for injection in 1.0 mL pre-filled syringe, 100 μg per dose, 1 dose
45474813|NCT03645421|Drug|MEDI0382 200 μg|Solution for injection in 1.0 mL pre filled syringe 200 μg per dose, 1 dose
45474814|NCT03645421|Drug|MEDI0382 300 μg|Solution for injection in 1.0 mL pre filled syringe, 300 μg per dose, 1 dose
45474815|NCT03645421|Drug|PlaceboA|1.0 mL liquid formulation per Vial
45474816|NCT03645421|Drug|MEDI0382 50 ug|Solution for injection, 1.0 mL per vial, 50 ug
45474817|NCT03645421|Drug|PlaceboB|Solution for injection in 1.0 mL pre-filled syringe.
45684551|NCT03825328|Drug|Albumin-bound paclitaxel|Albumin-bound paclitaxel is paclitaxel formulated as albumin-bound nanoparticles with a mean particle size of approximately 130 nanometers.
46041051|NCT03488290|Behavioral|LTP Plus TF-CBT|Experimental: LTP Plus TF-CBT LTP Plus TF-CBT group participants will receive group intervention by masters' level trained facilitators weekly during the first two months and then fortnightly. It comprises of two components i.e. LTP and TF CBT. LTP aims at enabling parents to improve their child's psychosocial development by educating about child development and the importance of mother-child play. TF CBT aim is to modify excessively negative appraisals of the trauma and its sequelae by careful questioning
46041052|NCT03488290|Other|Treatment as Usual|The Treatment as Usual group will receive routine care
46041053|NCT04263753|Procedure|Bladder conservative surgery in placenta accretta|"After control of both superior vesical vessels Finding a fresh noninvaded plan between isthmocervical junction and posterior bladder wall aided by filling the bladder 150 cc saline Then cervical stump control sutures and severing the specimen above the clamps~* Now the placenta is only attached to the bladder , apply intestinal clamp or foley cath on the bladder below the level of invasion if feasible to reduce bleeding~* cut through the placenta, heavy back flow bleeding of old blood stored in the placenta will be noticed , but there is no hemodynamic change since the cervical stump is already severed~, dissect the bladder with a large safety margin cutting through the placenta.. Then in cases with hematuria saline irrigation of the bladder is usually enough to clear the hematuria 15 out of 20"
45474818|NCT04445194|Biological|Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
45474819|NCT04445194|Biological|Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
45474820|NCT04445194|Biological|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
45474821|NCT03853031|Procedure|LVEDA cm2 guided intraoperative fluid in TEE /Study Group|Placement of Transoesophageal echocardiography probe in TEE group to measure Left ventricular end diastolic area cm2
45474822|NCT03853031|Procedure|CVP guided intraoperative fluid in CVP / Control group|Ultrasound guided Internal Jugular Vein catheter placement in CVP group to measure CVP value cms H2O .
45684552|NCT03825328|Drug|S-1|a combination preparation of tegafur, gimeracil, and oteracil potassium
45840754|NCT00868452|Drug|Placebo + (lithium or divalproex)|20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7
45840755|NCT00869622|Drug|Risedronate|35 mgs/week + calcium and vit d
45840756|NCT00869622|Drug|Placebo + Calcium and Vitamin D|sugar pill + calcium 1200mgs/day and vitamin d at least 800IU
45840757|NCT00871260|Drug|regadenoson|Subjects in open label group will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus) as contrast.
45840758|NCT00874614|Radiation|Ultratrace® Iobenguane I131|Each subject will be administered 3 mCi to 6 mCi Ultratrace® Iobenguane I 131, referred to as the Imaging Dose, to confirm that subject meets radiological entry criteria and to establish dosimetry. All subjects meeting entry criteria will then receive the investigational product referred to as the Therapeutic Dose (500 mCi or 8 mCi/kg if the subject weighs 62.5 kg or less) of Ultratrace Iobenguane I 131, followed by imaging at 7 days post infusion or upon discharge from isolation. The Therapeutic Doses will be adjusted equally if warranted by results of the dosimetry evaluation. At least 3 months later, subjects will receive the second Therapeutic Dose.
45684553|NCT03825328|Drug|Oxaliplatin|The compound features a square planar platinum(II) center. In contrast to cisplatin and carboplatin, oxaliplatin features the bidentate ligand 1,2-diaminocyclohexane in place of the two monodentate ammine ligands. It also features a bidentate oxalate group.
45684554|NCT03825328|Drug|Gemcitabine|Gemcitabine is a synthetic pyrimidine nucleoside prodrug-a nucleoside analog in which the hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms.
45684555|NCT03057184|Behavioral|Intervention|The intervention will consist of 8 weekly sessions, with a duration of 90 minutes. Although each intervention is adapted to the specific behavioral problems
45840759|NCT00875550|Drug|Dexmedetomidine|Study drug titrated up or down to maintain target UMSS range.
45840760|NCT00875550|Drug|Midazolam|Rescue medication for sedation according to UMSS scores
45840761|NCT00875550|Drug|Fentanyl|Rescue medication for pain based on UMSS scores
45840762|NCT00875550|Drug|Morphine|Rescue medication for pain based on UMSS scores.
45840763|NCT00878436|Drug|Panobinostat|
45840764|NCT00878436|Drug|Bicalutamide|
45840765|NCT00878826|Drug|Enoxaparin|"Drug: Enoxaparin 40 mg every morning until 36 weeks gestation. Drug: Enoxaparin 1 mg per kg every morning until 36 weeks gestation. Dose will increase at wt. increases.~Drug: Enoxaparin dose taken by patient when enrolled until 36 weeks gestation."
46041054|NCT03463486|Behavioral|Physical activity|50min of endurance training combined with 50min of calisthenics; 1-3x/wekk; 6weeks up to 1year
45474823|NCT04445350|Other|External Focus Of Attention|Instructions and feedback are used to direct the learner's focus to an external source (e.g. the effect the intended movement has) promoting long-term learning by stimulating automatic cognitive control processes.
45474824|NCT04445350|Other|Internal Focus Of Attention|In contrast, adopting an internal focus of attention (e.g. focus on specific body areal) can disrupt automatic control processes and interfere automatic movement.
45474825|NCT01291199|Drug|vardenafil|10 mg p.o. bid for 6 weeks
46041055|NCT00607347|Other|Glucose|Oral Glucose Tolerance Test
46041056|NCT02692300|Procedure|EEG-Guided Group|Device: Bispectral Index (BIS) processed electroencephalogram or MASIMO or NeuroSENSE
46041057|NCT00608595|Drug|celecoxib|Will be administered orally 400 mg po BID starting 5 days prior to planned surgical resection.
45474826|NCT01291199|Drug|Placebo|Placebo p.o. 6 weeks bid
45474827|NCT04521010|Other|COVID-19 pandemic|The aim of the study was to evaluate the staff absenteeism in the initial period of the COVID-19 pandemic at Wiktor Dega Orthopedic and Rehabilitation Clinical Hospital in Poznań Poznań as well as to assess the level of performance of medical services that were assigned to the Hospital under contract with National Health Fund, the payer of public health services in Poland.
46041058|NCT00608595|Genetic|gene expression analysis|not noted
46041059|NCT00608595|Genetic|protein expression analysis|Not noted
46041060|NCT00608595|Other|immunohistochemistry staining method|not noted
46041061|NCT00608595|Other|laboratory biomarker analysis|not noted
46041062|NCT00608595|Other|mass spectrometry|
46041063|NCT00608595|Procedure|biopsy|At the time of preoperative evaluation by surgeon as well as one week after administration of Celecoxib.
46041064|NCT00608595|Procedure|neoadjuvant therapy|not noted
45344748|NCT02545192|Device|Low Field Magnetic Stimulation|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1000Hz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. A fully detailed description of the electromagnetic field distribution and waveform has been presented in the IDE submission to the FDA (and determined to be a non-significant risk device).
45344749|NCT00724542|Drug|Voglibose tablets|0.2mg Tid
45840766|NCT00879060|Drug|Spironolactone|spironolactone 50mg daily
46041065|NCT00608595|Procedure|therapeutic conventional surgery|not noted
45474828|NCT02524613|Other|Pelvis CT scan|
46041066|NCT00614770|Procedure|standard of care colonoscopy|"Standard White Light Colonoscopy~one exam per patient"
46041067|NCT00614770|Procedure|colonoscopy|"Narrow Band Imaging Colonoscopy~one exam per patient"
46041068|NCT00614770|Procedure|standard of care colonoscopy|"High Definition White Light Colonoscopy~one exam per patient"
45344750|NCT03089840|Device|OrganOx metra|Following the routine retrieval procedure at the donor hospital the liver will be flushed with cold preservation solution and prepared for cannulation. The donor organ is then placed on the OrganOx metra device and will be perfused with warmed solution. The OrganOx metra device containing the donor organ is then transported to the recipient transplant centre. The donor liver is then removed from the device and flushed with standard of care preservation solution. Alternatively, where more practical, the livers will be transported to the University of Alberta hospital with ≤ 6 hours of cold storage and then placed on the metra™ for ≥ 4 hours. Implantation and reperfusion of the liver proceed as per the usual practice of the recipient transplant centre.
45474829|NCT04444726|Device|Ultra Violet A Device.+ Topical medical treatment|"Hands of the patient are irradiated in the UVA device after soaking for 20 minutes into 10 litres of water containing psoralen meladenine capsule."
45474830|NCT04444726|Device|Iontophoresis device + Topical medical treatment|Tap-water iontophoresis was given 3 times weekly for 10 min. The direct current level was slowly increased, guided by the occurrence of tingling sensations. The maximum level was 30 mA.
45474831|NCT04444726|Drug|"Topical medical treatment (Betamethasone dipropionate 0.05%  diprolene  )"|thin film of the cream is being applied to the affected areas for 2 times per day.
45474832|NCT03733327|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days-7 to -4.
45840767|NCT00879060|Drug|Placebo|inactive placebo pill daily
45840768|NCT00880230|Device|Scuba Iliac Stent System|The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.
45840769|NCT00880464|Biological|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS
45840770|NCT00882102|Drug|Decitabine|Decitabine 20 mg/m^2 IV over 1-1/2 hours daily for 5 days.
45840771|NCT00882102|Drug|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 3 mg/m^2 IV on day 5.
45840772|NCT00884052|Drug|Low dose levetiracetam|20 mg/kg loading dose; 5 mg/kg daily for 7 days.
45840773|NCT00884052|Drug|High dose levetiracetam|40 mg/kg IV load; 10 mg/kg/day maintenance
46041069|NCT03761134|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
46041070|NCT03761134|Drug|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
46041071|NCT03761134|Drug|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
46041072|NCT03761134|Drug|sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
45840774|NCT00884754|Device|GlideScope rigid stylet|Patients will be intubated either with a rigid stylet meant to be used with the GlideScope, or with a standard malleable stylet used with other modalities of intubation.
45474833|NCT03733327|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
46041073|NCT05241717|Behavioral|Web-based Management of Adolescent Pain (WebMAP)|Participants will be asked to complete one module per week, which are approximately 20 minutes in length. Survivors and parents will be asked to spend approximately 4.5 hours each over the course of the intervention on WebMAP including 4 hours to complete the modules and 30 minutes total corresponding with a coach. Each week, patients log into WebMAP to learn a new skill and practice that skill for 1 week to allow time for skills acquisition. WebMAP consists of two separate, password-protected programs including one for adolescents and one for parents (http://webmap2.com).
45684556|NCT03825016|Drug|Lidocaine Hydrochloride|Lidocaine infusion on hystroscopic media during office hystroscopy
45474834|NCT03733327|Drug|Etoposide (VP-16)|Etoposide was administered at 15 mg/kg/day on days -3 to -2.
45474835|NCT01188083|Dietary Supplement|Fructose Drink|Fructose Based beverage 8 oz
45474836|NCT01188083|Dietary Supplement|Glucose Drink|Glucose Based beverage 8 oz per drink x 3 per day x 4 weeks
45474837|NCT03365206|Other|Questionnaire on practices and knowledge in terms of oral hygiene|Questionnaire on practices and knowledge in terms of oral hygiene during a dental consultation
45684557|NCT03825016|Drug|Diclofenac Sodium|Oral Diclofenac Sodium
45694614|NCT00883168|Drug|fluticasone propionate|fluticasone propionate 200 mcg
45694615|NCT00883168|Drug|azelastine Hcl/fluticasone propionate|azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg
45694616|NCT01616693|Dietary Supplement|Probiotic|A capsule that contains at least 1 x 10^9 Lactobacillus rhamnosus GG organisms per capsule. The contents of this capsule were given once daily orally.
46041074|NCT01055496|Drug|inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone|"Day 1:~Rituximab at 375 mg/m2 Cyclophosphamide at 375 mg/m2 (cohort 1), 550mg/m2 (cohort 2), 750 mg/m2 (cohort 3, 4) Vincristine at 1.4 mg/m2 (max 2 mg)~Day 2 Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2, 3), 1.3 mg/m2 (cohort 4)~Days 1-5:~Prednisone at 40 mg/m2~Each cycle is 3 weeks, with a maximum of 6 cycles total."
46041075|NCT01055496|Drug|inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone|"Day 1:~Rituximab at 375 mg/m2 Gemcitabine at 500 mg/m2 (cohort 1, 2b, 3b), 1000mg/m2 (cohort 2a, 3a, 4, 5) Cisplatin at 37.5 mg/m2 (cohort 1, 2a), 50mg/m2 (cohort 2b, 3a), 75mg/m2 (cohort 3b, 4, 5)~Day 2:~Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2a, 2b, 3a, 3b, 4), 1.3mg/m2 (cohort 5)~Days 1-4:~Dexamethasone at 40 mg~Each cycle is 3 weeks, with a maximum of 6 cycles total."
45474838|NCT03733171|Drug|PLATELET RICH PLASMA|PRP was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
46041076|NCT03436498|Drug|Insulin aspart SAR341402|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
46041077|NCT03436498|Drug|Insulin aspart|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
45344751|NCT00724620|Biological|Peginterferon alfa-2b (SCH 054031)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
45344752|NCT00724620|Drug|Ribavirin (SCH 018908)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
45474839|NCT03733171|Drug|diluted epinephrine|diluted epinephrine was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
45474840|NCT03733171|Device|hemoclips|diluted epinephrine was injected followed by application of hemoclips
45474841|NCT03207750|Biological|Rotarix|Two doses administered orally according to a 0, 2 month schedule as per the immunization schedule for HRV vaccine administration in the US.
45474842|NCT03207750|Biological|Pediarix|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
45474843|NCT03207750|Biological|Hiberix|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
46041078|NCT00609453|Behavioral|Brief Behavioral Activation Treatment for Depression|Weekly individual therapy sessions
46041079|NCT03435952|Drug|Pembrolizumab|200 mg by intravenous infusion starting on Day 0, and continuing every 3 weeks for up to 12 months.
46041080|NCT03435952|Biological|Clostridium Novyi-NT|"Participants given a single dose of Clostridium Novyi-NT by intratumoral injection on Day 8.~Clostridium Novyi-NT administered starting with Cohort 1 at a dose of 3 x 10^4 spores followed by dose escalation."
46041081|NCT03435952|Drug|Doxycycline|Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT
46041082|NCT04262193|Drug|Suvorexant|In each group, the participant will take 1 tablet (placebo, 10mg or 20mg) 30 minutes before bedtime.
46041083|NCT04262193|Drug|Suvorexant Placebo|Suvorexant Placebo
46041084|NCT01055262|Device|Heatwrap 1|8 hours continuous topically-applied heat
46041085|NCT00609531|Drug|Citalopram|Pill, 5-20mg once a day for twelve weeks
46041086|NCT00609531|Drug|Placebo|Placebo pill once a day for twelve weeks
46041087|NCT03414736|Drug|SAR425899|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
46041088|NCT04301466|Drug|Qi Zhi Tong Luo capsule|Patients were receiveed Qi Zhi Tong Luo Capsule 4 capsules, 2 times per day for 24 weeks. QZTL capsule, a traditional Chinese medicine. Each capsule was weighted 0.5g.
46041089|NCT04301466|Drug|Placebos|Patients were allocated to placebo, 4 capsules, 2 times per day for 24 weeks.To preserve blinding, the placebo had an identical taste and appearance to the experimental drugs. Placebo (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
46041090|NCT04264923|Other|HyGIeaCare Prep|Each patient will have up to 5 stool specimens for evaluation by a lab for microbial contents.
45344753|NCT00866008|Drug|Ovarian stimulation|"Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment~Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG."
45344754|NCT00722514|Behavioral|patient education|"complex individual antiinflammatory rehabilitation program during inpatient rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally~Patient education 6 x 90 Minutes"
45344755|NCT00722514|Behavioral|Standard Care|"complex individual antiinflammatory rehabilitation program during inpatient~complex individual medical rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally~further 6 treatments from available disciplines(e.g. massage, electrotherapy, bath)"
45344756|NCT00866086|Other|questionnaire administration|
45344757|NCT00866086|Procedure|computed tomography|
45344758|NCT00866086|Radiation|radiation therapy treatment planning/simulation|
45344759|NCT02571426|Drug|Sevoflurane|anesthetic agent
45344760|NCT02571426|Drug|propofol|anesthetic agent
45344761|NCT03491540|Drug|Sennosides colonic preparation|"Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1"
45344762|NCT03491540|Drug|Oral Gentamycin|"Oral gentamycin:~Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials"
45344763|NCT03491540|Drug|Oral Ornidazole|"Oral ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets"
45344764|NCT03491540|Drug|Oral Placebo Gentamycin|"Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1"
45344765|NCT03491540|Drug|Oral Placebo Ornidazole|"Placebo for oral ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablets per day) on day -2 and day -1"
46041091|NCT03406000|Drug|INSULIN GLARGINE (U300)|"Pharmaceutical form: Solution for Injection~Route of administration: Subcutaneous injection"
45344766|NCT00861796|Drug|CYR-101|Experimental arm
45344767|NCT00861796|Drug|Placebo|Placebo comparator
45344768|NCT00722670|Behavioral|Woman-focused intervention|Participants in this group received a four individual sessions of the woman-focused intervention, in addition to services that were part of their substance abuse treatment program
45344769|NCT00722670|Behavioral|Treatment as Usual|Participants in this group only received services that were part of their substance abuse treatment program
45344770|NCT00854854|Biological|TKCell|"TKCell 150ml IV for 7times after each FOLFOX-4 regimen :~From the second cycle of FOLFOX4(start Day1),TKCell is administered in Day3 and Day8.In the third cycle of FOLFOX4(Day1),TKCell is administered in Day3 and Day8.In the fourth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the fifth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the sixth cycle of FOLFOX4(Day1),TKCell is administered in Day8"
45344771|NCT05373030|Biological|Recombinant adenovirus type-5-vectored COVID-19 vaccine|One dose COVID-19 vaccine
46041092|NCT02874300|Other|High intensity supervision arm|The higher-intensity supervision arm will comprise 6 occupational therapist (OT) home visits and 5 physiotherapist visits (1,1,2,2,6,12,18,24,30,36 and 52) plus supervised support from a rehabilitation support worker (RSW) twice a week for 3 months, once a week for 3 months, once a fortnight for 3 months and once a month for 3 months. Initially, and at review and progression points, the RSW will visit jointly with the therapists.
45474844|NCT03207750|Biological|Prevenar 13|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
45474845|NCT04444570|Device|Continuous glycemia measuring device (Dexcom) implantation into the subcutaneous tissue|14 days before the date of the surgery and after the surgery patient will have implemented the device for continuous glycemia measurement (Dexcom). During standard control visit 14 days after the surgery for skin sutures removal the device will be taken out and data of whole period of time will be collected
45344772|NCT00854932|Other|Procalcitonin-guided decision making|In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PDT values are within the normal range.
45344773|NCT02570802|Procedure|Ultrasonographic examination|
45474846|NCT03854981|Behavioral|Exercise|Subjects will be asked to exercise 5 days/week in addition to receiving standard care before bariatric surgery.
45474847|NCT03854981|Procedure|Standard Care|Standard preoperative care of bariatric surgery
45474848|NCT04521322|Drug|Iota-Carrageenan|Participants will received a nasal spray with Iota-Carrageenan or placebo 4 times a day during 21 days
45474849|NCT03674281|Device|SAP|Subjects will wear their own personal insulin pump and will wear the study CGM (Dexcom G6).
45474850|NCT03674281|Device|CLC|The Tandem t:slim X2 is an insulin pump with software (Control-IQ Technology) that helps regulate blood glucose more optimally, based on data received from the Dexcom G6 CGM.
46041093|NCT02874300|Other|Moderate intensity supervision arm|The moderate-intensity supervision arm will be based on an ongoing Australian trial (83, 112). There will be 6 OT home visits and 5 physiotherapist visits (weeks 1,1,2,3,4,5,6,7,8,10,12) and three OT telephone calls (weeks 9,10,11). Participants will be expected to exercise independently in-between supervised sessions.
46041094|NCT04262037|Diagnostic Test|lung ultrasound|Lung ultrasound will be performed after induction of anesthesia and at the end of the operation with a 5-MHz curved array probe (MindrayDC-N6; Mindray; Shenzhen, China
45474851|NCT04523038|Diagnostic Test|S-Albumin|Preoperative serum albumin levels
45474852|NCT01188161|Device|Rotating Chair|Subjects will be spun in rotating chair
45474853|NCT03365050|Other|No Intervention Given|No Intervention to be given
46041095|NCT01052844|Drug|Placebo|Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
46041096|NCT01052844|Drug|Gabapentin|Gabapentin 300mg, orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
46041097|NCT04261881|Dietary Supplement|ATP-Fuel|5 capsules daily with breakfast and 5 capsules daily with lunch
46041098|NCT04261881|Dietary Supplement|ATP-II|3 capsules daily with breakfast
46041099|NCT04261881|Dietary Supplement|ATP-II|3 capsules daily with breakfast and 3 capsules daily with lunch
45474854|NCT01185977|Drug|Fluoxetine|one-week single-blind PBO-lead-in phase, FLX 10 mg/d for 4 days then 20 mg/d of FLX thereafter
45474855|NCT01185977|Drug|Placebo|One pill of PBO for 4 days then two pills of PBO thereafter
45474856|NCT03673345|Biological|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N3) and 2 influenza B subtypes (B Yamata lineage B Victoria lineage).
45684558|NCT02948842|Drug|Clostridium Histolyticum Collagenase|0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture. This is based on 0.25 mL residual fluid that remains within the lumen of the injeTAK syringe. Thus, by adding the additional 0.25 mL of XIAFLEX® as a chase, we are expecting the original total of 0.08 mL of XIAFLEX® to be injected into the area of scarring.
46041100|NCT05319795|Behavioral|Effortful Swallow Maneuver|Repeated practice of the Effortful Swallowing Maneuver generated by pushing the tongue with increased effort against the palate at the point of swallow initiation.
46041101|NCT04261647|Other|kinesio-taping techniques.|
46041102|NCT04261647|Other|Pelvic floor exercise|
46041103|NCT04261647|Other|traditional physical therapy program , stretching of piriformis. iliopsoas, clam shell exercise,seat cushioning and seat kitz.|
46041104|NCT03679936|Diagnostic Test|PET/CT dynamic scan|This study is designed to evaluate the patients who are first diagnosed with non-small cell lung cancer (NSCLC)，for 18 F-FDG PET/CT dynamic scanning and primary tumors and/or metastases in biopsy, than find the inner link of the tumor imaging findings, genomics and histopathologic characteristics, discuss diagnostic value of 18 F-FDG PET/CT dynamic imaging in metastatic non-small cell lung cancer (NSCLC). At the same time, evaluating the ability of 18 F-FDG PET/CT dynamic imaging to differentiating multiple primary lung cancer from intrapulmonary metastases.
46041105|NCT05063487|Other|Return of recent classification|As part of routine HIV case-based surveillance in Rwanda, blood samples are collected for recency testing on the Rapid Test for Recent Infection (RTRI) assay and viral load testing for all newly diagnosed people living with HIV. Results of a recent classification (i.e., having acquired an HIV infection within the last year) will be returned to study participants during a scheduled 1-month visit following initial HIV diagnosis.
46041106|NCT05063487|Other|Return of long-term classification|As part of routine HIV case-based surveillance in Rwanda, blood samples are collected for recency testing on the Rapid Test for Recent Infection (RTRI) assay and viral load testing for all newly diagnosed people living with HIV. Results of a long-term classification (i.e., having acquired an HIV infection more than one year ago) will be returned to study participants during the scheduled 1-month visit following initial HIV diagnosis.
46041107|NCT02932618|Biological|von Willebrand factor (Recombinant)|Lyophilized powder and solvent to prepare solution for injection.
46041108|NCT02932618|Biological|Antihemophilic Factor (Recombinant)|Packaged in single boxes with 2 glass vials, with one vial containing the lyophilized ADVATE and the second vial containing the diluent.
46041109|NCT04261803|Biological|salivary sample|spit of saliva in a tube
46041110|NCT04261803|Biological|blood test|2millilitter blood test
46041111|NCT01049412|Drug|LY2605541|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
46041112|NCT01049412|Drug|Insulin glargine|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
45840775|NCT00884910|Device|Provox Vega voice prosthesis 22.5 Fr|The patients' current Provox2 voice prosthesis will be removed and the new Provox Vega voice prosthesis will be inserted.
45840776|NCT00885768|Procedure|angiography|all patients undergoing coronary angiography with VISIPAQUE and if they had coronary stenosis then renal artery angiography will be done. the dose of contrast will be chosen according to renal function and clinical conditions which will be varied from 75 to 300 ml.
45684559|NCT02948842|Other|Saline|0.08ml of injectable normal saline
46041113|NCT02692378|Drug|sodium bicarbonate 500mg capsules|Defined by active substance and brand names not specified in protocol
46041114|NCT02692456|Device|Double needle celiac neurolysis (DNCN)|CT guided celiac neurolysis will be performed using 2 needles inserted on each sides of aorta where patient was positioned in prone position
46041115|NCT02692456|Device|Single needle celiac neurolysis (SNCN)|CT guided celiac neurolysis will be performed through advancing a single needle to justfront of the aorta near the origin of celiac trunk where patient placed in lateral position
46041116|NCT04302480|Other|Worksheets for ASP|The ASP intervention will cover the harms and misleading marketing strategies of ASPs and other related information.
46041117|NCT04302480|Other|Worksheets for SSB|The SSB intervention will cover the general information on SSBs, such as the sugar content of SSBs, nutrition labels and the harms of SSBs.
45344774|NCT00578292|Drug|Busulfan|"4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg~Days -9 through -6"
45684560|NCT04392466|Other|walking on the treadmill|Participants will walk on the treadmill under single task, cognitive dual task and motor dual task conditions.
46041118|NCT04302480|Other|E-messages for ASP|In the subsequent month after the main intervention, students in the ASP group will receive 4-6 e-messages on ASPs, after which students will be invited to complete a 1-month follow-up assessment.
46041119|NCT04302480|Other|E-messages for SSB|In the subsequent month after the main intervention, students in the SSB group will receive 4-6 e-messages on SSBs, after which students will be invited to complete a 1-month follow-up assessment.
46041120|NCT02873988|Other|bronchial epithelial cell culture|
45344775|NCT00578292|Drug|Fludarabine|30mg/m2 Day -5 through Day -2
46041121|NCT05494918|Drug|JSKN003|JSKN003 is to be administered via intravenous (IV) dose
45344776|NCT00578292|Drug|Campath 1H|Per institutional guidelines Days -5 through -2
45344777|NCT00578292|Drug|Cyclophosphamide|50 mg/kg Days -5 through -2
45344778|NCT00578292|Drug|MESNA|10 mg/kg x 5 Days -5 through -2
45344779|NCT00861874|Drug|Decitabine|20 mg/m2 IV, Days 1-5
45344780|NCT00861874|Drug|Rapamycin|Dose level 1 = 2mg/daily, Dose level 2 = 4mg/daily, Dose level 3 = 6mg/daily. Oral, Days 6-26
45344781|NCT03765242|Other|Non-Interventional|Non-Interventional
45344782|NCT05372874|Drug|Direct Acting Antivirals|hepatitis C patients will be treated by direct acting antiviral drugs (DAAs)for 12 weeks.
46041122|NCT04593498|Diagnostic Test|Holter recording|Holter recording with Zenicor Flex ECG during 14 days.
46041123|NCT04593498|Diagnostic Test|Echocardiography (Echo)|Echocardiography: Comprehensive transthoracic echocardiography with special focus on atrial dimension and function.
45344783|NCT02544646|Other|Changes in Ocular rigidity|measured before the operation and 28±7 days after the operation
45344784|NCT00725192|Behavioral|Cognitive Processing Therapy|Clients will receive between 12 sessions of Cognitive Processing Therapy.
45344785|NCT00725192|Behavioral|Hypnosis|PArticipants will receive 3 sessions of hypnosis to specifically target sleep impairment.
45474857|NCT04521244|Other|Thrust joint lumbar manipulation|Moist Hot pack of 14/15' over lumbar region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45οC.Bilateral Thrust Manipulation of Lumbar Spine from L1-L5 Baseline Algometer for springing force tolerance and Lumbar Inclinometry using dual inclinometer for lumbar flexion, extension and goniometer for lumbar side bending.These pre and post intervention values were mentioned in questionnaire. The participants were administered with thrust and non-thrust manipulation of the lumbar spine and data was collected again immediately after the interventions without any delay.
45840777|NCT00886236|Drug|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Gabapentin 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
45684561|NCT03043924|Drug|Cyproterone Acetate + estradiol|"PCOS will receive:~50mg cyproterone acetate (Androcur®) in combination with p.o. 2mg estradiol daily"
46041124|NCT04593498|Diagnostic Test|Blood sample|Blood sample: 2 x 10 ml EDTA plasma sampled from venous blood at index and at 21 months. Troponin T, NTproBNP, Na, K, Creatinine. Sample for Biobank for future analysis.
46041125|NCT04593498|Diagnostic Test|24 hour ambulatory blood pressure monitoring And Arteriograph|To assess artery stiffness.
45684562|NCT03043924|Drug|Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet|Healthy volunteers receive combined oral contraceptive (COC) consisting 0.02 mg ethinylestradiol and 0.1mg of progestins (Leeloo Gé®)
45684563|NCT03824548|Other|this is non-intervention study, there is no intervention drug or device in this study.|this is exactly a non-interventional study, no intervention during the whole study.
46041126|NCT02584426|Device|Ultrasonic Distribution of Cefazolin|
46041127|NCT00934089|Drug|PF-04217329|Topical ocular solution, once-daily for 14 days
46041128|NCT00934089|Drug|latanoprost vehicle|Topical ocular solution, once-daily for 14 days
46041129|NCT00934089|Drug|PF-04217329|Topical ocular solution, once-daily for 14 days
46041130|NCT00934089|Drug|latanoprost|Topical ocular solution, once-daily for 14 days
46041131|NCT05333068|Procedure|PCI revascularization strategy based on combined FFR and OCT assessment|PCI revascularization strategy based on combined FFR and OCT assessment All FFR ≤ 0.75 and Vulnerable plaque will be treated. VP defined as TCFA ( cap thickness ≤ 75 micron); Ruptured plaque; or Plaque erosion with > 70 % AS or MLA < 2.5 mm2.
46041132|NCT05333068|Procedure|PCI revascularization strategy based FFR assessment|PCI revascularization strategy based FFR assessment (all lesions with FFR≤0.80 will be treated)
45344786|NCT04067856|Drug|Bevacizumab Injection|Intravitreal injection
45344787|NCT00866164|Device|Prometra Programmable Pump|Implantation of Prometra Pump for delivery of intrathecal morphine for the treatment of chronic intractable pain
45344788|NCT00570063|Drug|PF-02545920|Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days
45344789|NCT00570063|Drug|Placebo|Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days.
45344790|NCT05372796|Other|IASTM|instrument-assisted soft tissue mobilization
45344791|NCT05372796|Other|home exercise|home exercise
45344792|NCT05372796|Device|Chattanooga direct Tens device (DJO UK Ltd, Guildford Surrey, United Kingdom)|OTES (Occipital Transcutenous Electric Stimulation)
45344793|NCT04042714|Drug|All patients- TAS-102|Patients will receive TAS-102, Orally, BID for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest treatment cycle. Treatment may continue until disease progresses, intolerable toxicity is developed, or if the patient becomes pregnant or dies.
45344794|NCT03401918|Diagnostic Test|Uterine ERA and microbiome testing|Uterine fluid and endometrial biopsy collection to test uterine endometrial receptivity array and microbiome.
45344795|NCT03401918|Drug|Oral antibiotics and vaginal probiotics|For subjects with abnormal microbiome results, oral antibiotics and vaginal probiotic treatment will be offered followed by a repeat uterine microbiome biopsy.
45344796|NCT05227378|Biological|neoantigen tumor vaccine with or without PD-1/L1|personalized neoantigen tumor vaccine with or without PD-1/L1
45382093|NCT05340959|Device|Devices: Osstell®, Periotest® and AnyCheck®.|"Osstell®: is a device that measure implant stability and based on resonance frequency analysis (RFA). Due to stiffness in the interface between the implant surface and the bone smart peg will vibrates accordingly. the more dense bone the higher stability, the higher frequency and higher Implant Stability Quotient (ISQ) value which is from 1-100.~Periotest®: is a device used to assess osseointegration of dental implants, so it measure implant stability . it is based on damping effect of implant. Showing the measurement digitally on a scale from -8 (low mobility) to 50 (high mobility) PTV units.~AnyCheck®: this is an implant stability meter that measures the stiffness of alveolar bone-implant interface through a tapping motion. Showing the measurement on a scale from 30 (low stability) to 85 (high stability)."
45694617|NCT01616693|Dietary Supplement|Zinc|Zinc sulphate syrup is zinc sulphate heptahydrate (concentration 1mg/ml). 5 ml of this suspension was given once daily orally.
46041133|NCT01032174|Drug|Azithromycin SR|Azithromycin SR, 2.0 g by mouth (PO) x 1
46041134|NCT01032174|Drug|Amoxiclav 1000 mg|Amoxiclav 1000 mg x twice daily, 10 days
46041135|NCT03344146|Behavioral|Medication intake reminders|Acoustic and visual alarm at predefined DOAC-intake timepoints.
45840778|NCT00886236|Drug|Placebo|Placebo 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
46041136|NCT03344146|Behavioral|Pillbox use and counselling|All patients will be counselled based on their previous electronically recorded adherence data and will be given a multicompartment pillbox für daily use
45840779|NCT00886236|Drug|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
45382094|NCT05335889|Device|eButton|The eButton is a wearable camera that takes pictures every 6 seconds of whatever is in front of participants. The recorded data are processed by algorithms to determine food names, volumes, and nutrient value of the consumed food (e.g., grams of carbohydrates). The eButton is a wearable device containing a multicore microprocessor, a rechargeable battery capable of 10-15 hours of continuous operation (upon a flexible choice of battery capacity), a miniSD card for data storage.
45694618|NCT01616693|Dietary Supplement|Probiotic placebo|The probiotic placebo was manufactured by the same company that manufactured the probiotic and contained inulin powder but no Lactobacillus rhamnosus GG. The contents of the capsule were given once daily orally.
45840780|NCT00886626|Drug|Exenatide|Exenatide, subcutaneous injection, 10 mcg, twice per day
45694619|NCT01616693|Dietary Supplement|Zinc placebo|The zinc placebo excluded the zinc sulphate but contained lactose and was diluted to match the taste. 5 ml of this suspension was given orally once daily.
46041137|NCT03434392|Diagnostic Test|Quantitative Sensory Test 1|Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.
45694620|NCT01616693|Biological|Rotavirus vaccine|1 ml Rotarix®, a lyophilized human rotavirus vaccine reconstituted with calcium carbonate buffer provided orally at 6 and 10 weeks.
45694621|NCT01616693|Biological|Oral polio vaccine|A liquid trivalent polio vaccine provided orally at 6 and 10 weeks.
45694622|NCT00883246|Device|SilverHawk & TurboHawk Peripheral Plaque Excision System|Removal of atherosclerotic plaque from artery walls.
46041138|NCT03434392|Diagnostic Test|Quantitative Sensory Test 2|Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.
45474858|NCT04521244|Other|Lumbar mobilization|Moist Hot pack of 14/15' from L1 where ribcage ends up to the region of gluteal folds for 15 mins. Non Thrust Manipulation for 30 seconds Using Kaltenborn grade 3 (Stretch rotation mobilization).Baseline Algometer for springing force tolerance and Lumbar Inclinometry using dual inclinometerfor lumbar flexion, extension and goniometer for lumbar side bending. These pre and post intervention values were mentioned in questionnaire. The participants were administered with thrust and non-thrust manipulation of the lumbar spine and data was collected again immediately after the interventions without any delay.
45344797|NCT03249350|Behavioral|Standard Contingency Management (CM)|"CM utilizes behavior modification & cognitive behavioral strategies to target adolescent substance use. Protocol components are as follows: (a) The provider introduces CM to the youth and caregiver and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the youth and caregiver; (d) Concurrently, a point and level system contract is established with the family, which provides the youth with rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks."
45474859|NCT03854825|Procedure|Cardiac surgery|
45840781|NCT00886704|Dietary Supplement|500 mg eicosapentaenoic (EPA) plus docosahexaenoic acids (DHA)|"Composition of active convenience drink (smartfish): 200 ml drink, enriched with 940 mg omega-3 fatty acids, of which 200 mg are EPA, 300 mg DHA and 100 mg DPA, slightly carbonized..~Energy content 486 kJ (116 kcal), protein 0.6 g, Carbohydrates 22 g, total fat 4 g, of which 0.6 g saturated fatty acids, 1.8 g monounsaturates, 1.4 g polyunsaturates. Vitamin D 0.85 ug.~Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil."
46041139|NCT03434392|Diagnostic Test|Quantitative Sensory Test 3|Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
46041140|NCT02704780|Drug|Misoprostol|2 regimes of misoprostol 400 microgram and 800 microgram injections used for 2 groups of women
45474860|NCT03223662|Other|Chemoradiotherapy|Chemotherapy: Carboplatin (AUC=2)x5 and Paclitaxel (50 mg/m(2))x5 for two cycles. Radiation: a total dose of 40.4 Gray (Gy) will be given in 23 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.
45840782|NCT00886704|Dietary Supplement|Control convenience drink|Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.
45840783|NCT00887562|Drug|Idebenone|900 mg/day for 1 month
45840784|NCT00887562|Drug|Idebenone|2250 mg/day for 1 month
45840785|NCT00887562|Other|Placebo|Placebo - No idebenone
46041141|NCT00933933|Device|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the normal healthy population or pregnant female population at risk for HIV infection are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw.
46041142|NCT00933933|Device|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the at risk population are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw when possible.
46041143|NCT02704546|Drug|Methylphenidate|oral capsules (per os) each containing 10mg Methylphenidate.
46041144|NCT02704546|Drug|Placebo|capsules identical in shape, colour and size to the Ritalin® capsules, which contain only the inactive ingredients of the same formulation.
45474861|NCT03223662|Procedure|Esophagectomy|Minimally-invasive esophagectomy (RAMIE) or traditional open approach if necessary.
46041145|NCT01032018|Behavioral|Problem Solving Therapy|Problem Solving Therapy (PST) will be administered by a trained provider. The concepts of PST will be taught to the participant in the first session and reinforced across subsequent sessions. Sessions will last between 30 and 60 minutes each and continue weekly for the duration of the study (6 months).
46041146|NCT01032018|Drug|Sertraline, citalopram, or bupropion|"Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week,with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated. If a patient cannot tolerate a particular treatment (i.e., intolerable side effects even with careful titration and clinical management), a switch to an alternative antidepressant or PST-PC after 2-4 weeks and 'restart' step 1.~Sertraline: 25-150qam Citalopram: 10-40qam Bupropion: 100-450qam"
45684564|NCT03824314|Drug|Midazolam|2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
45684565|NCT03824314|Drug|Fentanyl|2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
45684566|NCT03824392|Biological|ATYR1923 1.0 mg/kg or placebo|ATYR1923 participants to receive ATYR1923 1.0 mg/kg IV every 4 weeks; Placebo participants to receive placebo IV every 4 weeks
45684567|NCT03824392|Biological|ATYR1923 3.0 mg/kg or placebo|ATYR1923 participants to receive ATYR1923 3.0 mg/kg IV every 4 weeks; Placebo participants to receive placebo IV every 4 weeks
46041147|NCT01032018|Other|Standard care|Participants will receive standard of care from the current physicians
46041148|NCT05332912|Behavioral|Spatial Ability Experience|Participants will engage in puzzle construction, block play, visual search, hide and seek
46041149|NCT04264221|Behavioral|New management mode|"New management mode intervention: Pharmaceutical care~SMS text messages and Phone Calls~Behavioural Educational leaflet~Self-Administered Therapy A financial incentive for mobile use"
45474862|NCT03364972|Device|Cataract surgery|Conventional small-incision phacoemulsification cataract surgery with insertion of intraocular lens implant
45684568|NCT03824392|Biological|ATYR1923 5.0 mg/kg or placebo|ATYR1923 participants to receive ATYR1923 5.0 mg/kg IV every 4 weeks; Placebo participants to receive placebo IV every 4 weeks
45684569|NCT02976922|Dietary Supplement|Probiotic lozenge|10 patients with RAS are randomised to active treatment with probiotic lozenge, one lozenge twice daily for 3 months and other 10 patients with RAS are randomised to treatment with placebo lozenge, one lozenge twice daily for 3 months.
45684570|NCT02946658|Procedure|lipoaspiration|Closed syringe harvesting subdermal fat
45684571|NCT02946658|Procedure|ADcSVF|Isolation of AD-cSVF
45684572|NCT02946658|Procedure|Normal Saline IV|Normal Saline IV containing AD-cSVF
45684573|NCT03824002|Drug|Dulaglutide|Diabetes therapy with dulaglutide and various combinations of insulin, metformin, glinides
45684574|NCT03824002|Drug|Aspart insulin|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
45684575|NCT03824002|Drug|Glargine|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
45684576|NCT03824002|Drug|Metformin|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
46041150|NCT00609687|Procedure|Diagnostic Vitrectomy|"Three-port, 20-gauge pars plana vitrectomy instrumentation was utilized. An infusion line was inserted into one sclerotomy and secured to the globe. A second sclerotomy was made, and a fiberoptic light pipe was immediately inserted to minimize vitreous egress. A third sclerotomy was created, and the vitreous cutter was inserted. To obtain an undiluted vitreous sample, the vitreous was cut mechanically with the vitreous cutter, while the assistant surgeon simultaneously manually aspirated the vitreous. After sufficient undiluted sample was obtained, infusion fluid was allowed to enter the eye and a diluted vitreous sample was obtained in a similar manner. The samples were personally carried to the clinical laboratories by the operating surgeon.~Vitreous fluid analysis was guided by clinical suspicion based on the pre-operative differential diagnosis and the intraoperative posterior segment appearance."
46041151|NCT00614848|Device|Endeavor drug eluting coronary stent|Zotarolimus coated coronary stent (10ug/mm)
46041152|NCT01031706|Drug|Hypertonic Saline|inhaled HS (6% NaCl, 4mL) three times a day for 28 days
46041153|NCT01031706|Drug|Placebo|4 ml 0.12% NaCl inhaled three times a day x 28 days
46041154|NCT04260165|Procedure|Proximal Row Carpectomy|Excision of the proximal carpal row - the scaphoid, lunate and triquetrum
45344798|NCT03249350|Behavioral|Enhanced Contingency Management (CM+)|The CM+ protocol adds the behavioral assessment and teaching system from Parent Management Training Oregon (PMTO) to standard CM to enhance parent's skill acquisition more intensely. PMTO's behavioral assessment and teaching system uses three processes to bring about changes in parenting: daily parent reports on youth behavior, anti-coercive problem-solving, and structured learning and in vivo practice of new parenting techniques.
45344799|NCT02570646|Behavioral|QA-DDS|QuitAdvisorDDS is a point-of-care software tool to facilitate implementation of evidence-based tobacco treatment interventions in dental care settings.
45344800|NCT00725348|Drug|Talarozole|1.0 mg oral dose per day
45474863|NCT03852641|Other|Length of feeding|Feeds will be given via nasogastric tube over 15-30 min versus 2 hr
45474864|NCT03357172|Biological|Blood Sample|Additional blood sample before graft, D0, D7, D15, D21, D30, D60, D90, D180, Y1, Y2
45684577|NCT03824002|Drug|Repaglinide|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
45344801|NCT02545348|Procedure|Sentinel Lymph Node Biopsy|First, the detection of the sentinel node will be preformed at the beginning of the surgery. Differents detection methods are use and the efficacy of each will be recorded. Second, dissection and extraction of the sentinel node will be performed, to send it to the frozen section examination. Third, other lymph node could be removed if the surgeon evaluate that it is feasible and necessary. In this group, the false negative rate will be also evaluate.
46041155|NCT04260165|Procedure|Four-corner fusion|Scaphoid excision and four-corner fusion with cannulated headless compression screws/dorsal plate
45344802|NCT03083288|Drug|[18F]FluorThanatrace|[18F]FluorThanatrace is a radiotracer for PET/CT
46041156|NCT05331261|Procedure|Total knee replacanent surgery|Breath exercises
45344803|NCT00724776|Biological|Albinterferon alfa 2b|recombinant human albumin-interferon alfa fusion protein, 600-1800mcg single dose by S.C. on Day 0
45344804|NCT05325216|Procedure|POPRC+OIN|Pelvic-organ preserving radical cystectomy with orthotopic ileal neobladder
45344805|NCT05325216|Procedure|SRC+OIN|Standard radical cystectomy with orthotopic ileal neobladder
45344806|NCT00866632|Behavioral|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in a group setting for 11 sessions, for 1 to 1.5 hours/session.
45344807|NCT00866632|Behavioral|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in one-on-one via the telephone across 11 sessions, for 1 to 1.5 hours/session.
45474865|NCT03357172|Biological|Bone marrow aspiration|Additional bone marrow aspiration before graft, D30, D90, Y1
45344808|NCT00577772|Drug|Xifaxan|Open-Label Treatment at 400 mg by mouth, 3 times a day, for 7 days; only for those symptomatic and positive SBBO patients.
45474866|NCT03357172|Biological|Blood sample|Before donation
45474867|NCT03357172|Biological|Allogeneic hematopoietic stem cell sample|Allogeneic hematopoietic stem cell sample
45474868|NCT03952806|Drug|Verdiperstat|300mg 2 -oral- capsules, BID
45474869|NCT03952806|Drug|Placebo|Matching placebo
46041157|NCT00627510|Other|Routine psychiatric inpatient treatment|Routine psychiatric inpatient treatment. This is not an interventional study.
46041158|NCT05484934|Procedure|Regenerative post mastectomy surgery|Implantation of the Nipple-Areolar Complex (NAC) Reconstruction Using a Decellularized Donor NAC Graft (DCLNAC)
46041159|NCT05118243|Other|Control cracker|The gut symptoms caused by control crackers are studied in IBS persons
45474870|NCT01181453|Device|Dermagraft|Weekly application of Dermagraft(R) with standard care
46041160|NCT05118243|Other|Enzyme-treated cracker|The gut symptoms caused by enzyme-treated crackers are studied in IBS persons
46041161|NCT02873910|Dietary Supplement|IQP-AS-119|
45474871|NCT01181453|Other|Comparator|Weekly application of standard care
46041162|NCT02873910|Dietary Supplement|Placebo|
46041163|NCT05479006|Device|Transcranial direct current stimulation (high- definition)|20 minutes, 2 mA stimulation.
46041164|NCT02704234|Other|Active Acupuncture|Active Acupuncture two times per week for 5 weeks
46041165|NCT02704234|Other|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
46041166|NCT00927069|Drug|Adalimumab every other week|Adalimumab 40mg injection every other week for 24 weeks
46041167|NCT00927069|Drug|Adalimumab Every Week|Adalimumab 40mg injection every week for the last 12 weeks of study.
45684578|NCT03823846|Drug|Routine Dezocine injection|Dezocine 10mg were intramuscular injected at 8:00am, 4:00pm and 12:00pm.
45684579|NCT03823846|Drug|Adjusted Dezocine injection|Dezocine 10mg were intramuscular injected at at 6:00am, 2:00pm and 10:00pm.
45684580|NCT03823846|Drug|Routine Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at 9:00am, 4:00pm and 12:00pm.
46041168|NCT01031628|Drug|Imatinib mesylate|400 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
45344809|NCT00577772|Device|SmartPill|The SmartPill is a single-use, ingestible capsule that utilizes sensor technology to measure pressure, pH and temperature throughout the entire GI tract. The ACT-1 (SmartPill) GI Monitoring System includes an ingestible capsule, a receiver and video display software.
45344810|NCT00577772|Procedure|Lactulose hydrogen breath test (H_2BT)|A hydrogen breath test provides information about the digestion of certain sugars or carbohydrates, such as milk sugar (lactose) or fruit sugar (fructose). The test is also used for detecting abnormal growth of bacteria within the small bowel by having the patient ingest lactulose.
45344811|NCT00578136|Drug|Bupivacaine|Bupivacaine, 0.25%, dose amount is weight based, injection is divided per dise with rectus sheath injection or with local infiltration of the operative area.
45684581|NCT03823846|Drug|Adjusted Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at at 6:00am, 2:00pm and 10:00pm.
45684582|NCT03823846|Other|postoperative rehabilitation|Rehabilitation was conducted at 8:00am and 2:00pm.
45684583|NCT03823846|Drug|normal analgesia pump administration|Dose of analgesia pump was added if needed.
45840786|NCT00887640|Drug|Temsirolimus|dosage form: IV dosage, frequency and duration: 25mg weekly until clinical progression
46041169|NCT01031628|Drug|Imatinib mesylate|600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
46041170|NCT01031628|Drug|Imatinib mesylate|400, 600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
46041171|NCT02704468|Other|CAVI and FGF-21|FGf-21 and CAVI was measured in renal transplant patients group and study correlation with arterial stiffness
45684584|NCT03823846|Drug|adjusted analgesia pump administration|Dose of analgesia pump was added if needed. Add one dose of analgesia pump 10 minutes before rehabilitation.
45840787|NCT00887640|Drug|Diphenhydramine|Dosage form: IV or PO Dosage, frequency and duration: 25-50mg, 30 minutes prior to Temsirolimus infusion
46041172|NCT00609843|Other|Lipiodol demarcation of the bladder tumour|1-3 drops of Lipiodol Ultra Fluid (iodine 38%W/W) will be injected into the submucosa on 4 locations around the bladder tumour. The procedure is done once during a planned cystoscopy approximately a week before the planning CT.
46041173|NCT02691988|Other|ICS withdrawal|Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG) and inhaled corticosteroids are withdrawn.
45840788|NCT00889200|Drug|eszopiclone|6 weeks standard oral therapy
45344812|NCT00861952|Other|Neuragen|2-3 drops applied topically 2-3 times per day as needed over a 3 month period
45344813|NCT00861952|Other|Mineral oil|Ad lib use of mineral (scent and color matched to Neuragen) applied topically 2-3 times per day in 2-3 drops per application
45344814|NCT04065698|Drug|RV521|Single doses of RV521 administered as the drug in capsule formulation when fed and as the dry powder blend formulation dispersed in water when fed and whilst fasting, each on a separate dosing day.
45344815|NCT00655551|Drug|lacosamide|Single loading intravenous (iv) lacosamide 200 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 200 mg/day (100 mg twice daily) for 6.5 days
45344816|NCT00655551|Drug|lacosamide|Single loading intravenous (iv) lacosamide 300 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 300 mg/day (150 mg twice daily) for 6.5 days
45344817|NCT00655551|Drug|lacosamide|Single loading intravenous (iv) lacosamide 400 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 400 mg/day (200 mg twice daily) for 6.5 days
46041174|NCT02691988|Other|Usual care|Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG)
46041175|NCT01031004|Device|narafilcon B|contact lens
45344818|NCT00855088|Drug|darunavir|Healthy male volunteers will take darunavir 600 mg orally twice daily for 15 doses (8 days)
45344819|NCT00855088|Drug|Ritonavir|Healthy male volunteers will take ritonavir 100 mg orally twice daily for 15 doses (8 days)
45344820|NCT00855088|Drug|Etravirine|Healthy male volunteers will take etravirine 200 mg orally twice daily for 15 doses (8 days)
45344821|NCT00725426|Drug|Bosutinib|
45344822|NCT02553603|Drug|Growth Hormone Releasing Hormone (GHRH)|Growth Hormone Releasing Hormone (GHRH) 1mg/day for 10 weeks
45840789|NCT00889512|Drug|Luveris fixed dose|Luveris 75IU daily throughout ovarian stimulation
45684585|NCT02908750|Drug|Fexofenadine tablet dosing|Fexofenadine (P-gp substrate) 120mg taken once daily on Days 1 in Treatment Period 1 and Day 1 and Day 39 in Treatment Period 2
45684586|NCT02908750|Drug|Osimertininb tablet dosing|Osimertininb 80 mg taken once daily on Day 1 and Days 4 to 41 in Treatment Period 2
45684587|NCT03823612|Drug|Clinpro Tooth Creme|The participant will be instructed to Place a pea-sized amount of Clinpro Tooth Crème on a soft bristled toothbrush and brush teeth for at least two minutes then after brushing the patient will rinse out his mouth with water and spit out. It will be used twice daily at first in the morning and before sleep.
46041176|NCT01031004|Device|etafilcon A|contact lens
46041177|NCT04261335|Biological|CL2020 cells|1.5 million or 15 million cells, IV on day 5 to 14 of birth
46041178|NCT01904656|Behavioral|"Get Behind your health"|"Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
45344823|NCT02553603|Drug|Placebo Growth Hormone Releasing Hormone|Placebo GHRH to be given once daily for 10 weeks
45344824|NCT03334500|Device|[18F]FluorThanatrace|Fluorine-18 labeled FluorThanatrace [18F]FTT can be synthesized with high specific activity so the quantity of mass injected with the radiopharmaceutical is < 10 μg.
45344825|NCT03334500|Drug|Poly(ADP Ribose) Polymerase 1|Poly(ADP-ribose) polymerase (PARP) is a family of enzymes involved in base excision repair (the repair of DNA single-strand breaks) and alternative end joining (repair of DNA double-strand breaks). The molecular basis of PARP1 inhibitor function may depend on the dual roles of PARP1 as a modulator of gene transcription in addition to DNA damage repair 3.
45344826|NCT00730184|Dietary Supplement|potassium bicarbonate|90 mmol/d given as 4 tablets after each meal, with a full glass of water
45344827|NCT00730184|Dietary Supplement|Placebo (microcrystalline cellulose)|Given as 4 tablets after each meal, with a full glass of water
45344828|NCT03846622|Other|Calculation of scoring systems for bleeding|
45344829|NCT00807339|Radiation|Stereotactic radiation|Dose escalation three consecutive treatments
45344830|NCT00807339|Device|CyberKnife Robotic Radiosurgery System|
45344831|NCT03314766|Device|IC-8 IOL|Patients previously implanted with an IC-8 IOL contralaterally or bilaterally will be evaluated for their long-term visual functions and overall satisfaction at least 12 months post-implantation
45344832|NCT00730262|Drug|TLN-4601|14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period
45344833|NCT00862030|Procedure|CT- simulation scan|Patients who are receiving standard palliative radiotherapy planned under x-rays will also undergo 1 CT-simulation scan which they would otherwise not require. The planning x-rays and CT scan will then be compared dosimetrically
45344834|NCT00804531|Drug|Visipaque - Hydrocortancyl|Visipaque 320 mg I/ml - 1 ml intra-discal route Hydrocortancyl 25 mg/ml - 1 ml intra-discal route
45694623|NCT04415645|Drug|[14C]-VVZ-149|A single IV infusion of radio-labeled VVZ-149
45694624|NCT00893074|Drug|Dronabinol 30mg/day|10mg dronabinol administered 3x/day for 5 days
45840790|NCT00889512|Drug|Luveris increasing dose|Luveris 75IU until estradiol level reaches 250 pg/ml then increasing to 75IU BID for two days, then TID until hCG
45840791|NCT00889824|Device|balance prosthesis|vibrotactile stimulation
45840792|NCT00890682|Drug|SKY0402|Local infiltration of 8cc SKY0402
45840793|NCT00890682|Drug|Placebo|Local infiltration of 8cc Placebo
45840794|NCT00890916|Device|FIRSTHAND System|Implanted neuroprosthesis with myoelectric control and electrical stimulation of multiple channels.
46041179|NCT01904656|Behavioral|Peaches|"Participants are exposed to a Healthy Eating! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
46041180|NCT00608673|Drug|Pimecrolimus 1% cream|a very thin coat of pimecrolimus 1% cream, twice daily topically to the facial lesions of discoid lupus erythematosus
46041181|NCT00608673|Drug|betamethasone valerate 0.1% cream|A very thin coat of betamethasone valerate 0.1% cream, twice daily to facial lesions of discoid lupus erythematosus for 8 weeks.
46041182|NCT02704000|Behavioral|Home visiting program (Jamaica curriculum)|Agents will deliver bi-weekly home-visits following the curriculum developed for the Jamaica intervention study by Susan Walker and colleagues. This curriculum foresees age-appropriate tasks assigned to the caregiver during each visit.
46041183|NCT01622062|Biological|PVRV|0.1 mL, 4 site 'one week' (4-4-4-0-0) administered intradermally
46041184|NCT01622062|Biological|PVRV and pERIG Favirab®|0.1 mL of vaccine administered intradermally in 4 site 'one week' (4-4-4-0-0) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
45344835|NCT00804531|Drug|Placebo comparator|Visipaque - 320 mg I/ml - 1 ml in intra-discal route
45344836|NCT00725088|Behavioral|Exercise training|Exercise training
45344837|NCT00866710|Other|Exercise-based behavioral therapy|Participants will be taught pelvic floor muscle exercises as well as urge suppression strategies to overcome the urge to void. In the first 20 participants, computer-assisted biofeedback will also be utilized to help participants identify the pelvic floor muscles and contract and relax these muscles while keeping the abdominal muscles relaxed
45474872|NCT01291355|Other|Specific maternal position during the labor|"women allocated to intervention group will be invited to adopt a posture all fours type:support on the knees, torso tilted forward, back stretched for a minimum of 10 minutes. A cushion is placed between the legs of the woman to limit the cuts."
45474873|NCT03358498|Other|The Medical Outcomes Short-Form 36-Item Health Survey (SF-36v2) It|"SF-36v2 is questionnaire comprising 36items measuring eight dimensions of general HRQOL: physical functioning 10 items, physical health problems 4 items, bodily pain 2 items, general health perceptions 5 items, vitality 4 items, social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health 5 items.~."
45474874|NCT01186055|Behavioral|Smoking Cessation Counseling|Participants shall all receive 8 weeks (6 weeks) of group or individual counseling during their quit attempt.
45474875|NCT03857399|Drug|Caspofungin|Considering the possibility of fungal infection, we take empiric therapy for the patients with persistent fever and agranulocytosis using caspofungin for injection.
45694625|NCT00893074|Drug|Dronabinol 60mg/day|20mg dronabinol administered 3x/day for 5 days
45694626|NCT00893074|Drug|Dronabinol 120mg/day|40mg dronabinol administered 3x/day for 5 days
45694627|NCT00893074|Drug|Placebo|placebo dronabinol administered 3x/day for 5 days
46041185|NCT01622062|Biological|PVRV and pERIG Favirab®|0.1 mL of vaccine administered intradermally in 2-site TRC (2-2-2-0-2) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
45840795|NCT00892710|Drug|Pemetrexed|500 mg/m2 IV given over 10 minutes every 21 days
45840796|NCT00892710|Drug|Bevacizumab|15 mg/kg IV every 21 days
46041186|NCT02873676|Behavioral|nutritional intervention|The intervention is made up of nutrition supplements and dietary pattern modification, which includes whey 30g/d(plus three times every week),vitamin D 1000IU, omega-3 fatty acid (DHA1200mg and EPA 800mg)
46041187|NCT02873676|Behavioral|resistance training program|The training program involve warm-up exercise, muscle strength training and relaxing
46041188|NCT02873676|Behavioral|lifestyle modification project|Lifestyle modification project is made up of multi-dimensional intensive nutritional intervention and resistance training
45840797|NCT00892710|Drug|Carboplatin|AUC=5 IV every 21 days
45840798|NCT00894504|Drug|Panitumumab|6 mg/kg IV on Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
46041189|NCT02873676|Behavioral|control|The intervention involve dietary pattern modification and protein intake standardization
46041190|NCT04263519|Drug|Tacrolimus|Oral Immunosuppressant
45840799|NCT00894504|Drug|Carboplatin|AUC=2.5 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
46041191|NCT04215718|Procedure|fistulotomy and marsupialization|the anal fistula was laid open and the the wound edges was marsupialized using vicryle 3\0 sutures
46041192|NCT04215718|Procedure|fistulectomy and wound closure|anal fistula was excised with both openings and the wound was closed
45344838|NCT00807729|Procedure|ERCP|Endoscopic Retrograde Cholangiopancreatography Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. If choledocholithiasis was detected or suspected at the time of ERCP, a sphincterotomy was undertaken so that gallstones could be extracted using a balloon catheter or retrieval basket. Small bowel gas was aspirated endoscopically as much as possible at the conclusion of the ERCP. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
45344839|NCT00807729|Procedure|LapCBDE|LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
46041193|NCT00609921|Drug|ARQ197|treatment
45344840|NCT00866866|Drug|N-Acetyl Cysteine|600 mg PO BID
45344841|NCT00866866|Drug|Placebo|1 tab PO BID
45344842|NCT00804765|Other|Therapeutic education|Intensive training individual and collective teaching
45344843|NCT00804765|Other|Follow-up|classical follow-up with two individual consultations
45344844|NCT00855244|Other|Diagnostic exams|Growth hormone stimulation testing, oral glucose tolerance test, hyperinsulinemic euglycemic clamp
45344845|NCT00312728|Drug|bevacizumab|15 mg/kg intravenously (IV) on the first day of each 21- to 28-day cycle (± 4 days); the interval between infusions could not be < 17 days, but could extend beyond 28 days if chemotherapy was delayed to allow recovery from toxicity.
45382095|NCT05335889|Device|Continuous Glucose Monitoring (CGM)|The use of this device provides ambulatory glucose profiles, giving graphic and quantitative information on 24-hour glucose patterns. It does not require finger-prick testing for calibration. The system consists of a reader and a sensor (35 mm x 5 mm). The sensor is applied to the back of a person's arm. The sensor automatically measures interstitial glucose at 15-minute intervals during daily activities like work, sleep, eating, and exercise. It is able to store blocks of glucose data for 14 days.
45694628|NCT00884806|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses
45694629|NCT00884806|Device|Etafilcon A contact lens (ACUVUE® 2™)|Commercially marketed hydrogel contact lens for daily wear use
45694630|NCT00884806|Device|Senofilcon A contact lens (ACUVUE® OASYS™)|Commercially marketed silicone hydrogel contact lens for daily wear use
45840800|NCT00894504|Drug|Gemcitabine|1500 mg/m2 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
46041194|NCT02704078|Device|EBUS-TBNA|EBUS-TBNA - Patients in the Active comparator arm shall undergo mediastinal lymph node aspiration transtracheally using the EBUS scope
46041195|NCT02704078|Device|EUS-B-FNA|EUS-B-FNA - Patients in the experimental arm EUS-B-FNA shall undergo mediastinal lymph node aspiration transesophageally using the EBUS scope
46041196|NCT00637650|Procedure|Ureteroscopy, Holmium Laser lithotripsy and active retrieval of fragments|
46041197|NCT00637650|Procedure|Ureteroscopy, Holmium laser lithotripsy, no intent to retrieve any remaining fragment|
46041198|NCT00637767|Drug|melphalan|
46041199|NCT00637767|Procedure|autologous hematopoietic stem cell transplantation|
46041200|NCT00637767|Radiation|yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183|
46041201|NCT03570190|Other|Coordinator|"A THV coordinator will be responsible for communication with the patients and the caregivers as well as for monitoring medical documentation and treatment pathways. The registry will consist of 3 phases:~Determination of the status quo~Dedicated reflection and training followed by implementation of tailored changes~Determination of the effect"
46041202|NCT05101629|Drug|Pembrolizumab|Pembrolizumab 200 mg, IV, over 30 minutes every 3 weeks
45694631|NCT00884806|Device|Lotrafilcon B contact lens (O2 OPTIX®)|Commercially marketed silicone hydrogel contact lens for daily wear use
45344846|NCT00312728|Drug|First-Line Chemotherapy Agents|"Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was administered on Days 1 and 8 of every cycle. Agents were administered as a platinum doublet, or erlotinib alone, at the investigator's discretion. Chemotherapy was administered for a total of 6 planned cycles (up to 8 cycles with prior approval from the Medical Monitor), followed by single-agent bevacizumab therapy. The chemotherapy regimen was to be consistent throughout the study. Erlotinib was administered orally daily.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
45382096|NCT05335863|Dietary Supplement|Oral Nutritional Supplement|Participants must consume 416 mL of ONS FontActiv® DiaBest HP / HC vanilla flavor. A maximum time of 10 min will be given to consume the entire product.
45382097|NCT05335863|Dietary Supplement|Glucose|Participants must consume a 50 g glucose solution in 10 min to obtain the ares under the curve (AUC) data from glucose consumption
46041203|NCT05101629|Drug|Lenvatinib Capsules|Lenvatinib 8 mg for BW < 60 kg / 12 mg for BW ≥ 60 kg oral, once daily for 3 weeks
46041204|NCT01280500|Behavioral|electronic medical record|Decision Support, Asthma Action Plans, and Population Management Reporting (EAP)
46041205|NCT01280500|Other|Integrated Approach to Care|Patients within the IAC group will also receive their own copy of an asthma action plan to allow for some degree of self-management support. In addition, IAC practices receive assistance from a practice coach trained in practice redesign and rapid cycle process improvement.
46041206|NCT01280500|Other|usual care|No EMR
46041207|NCT01280500|Other|Shared Decision Making|The research team will develop the SDM intervention during the first 6 months of the study. The team will model this intervention on the randomized control trial performed by Dr. Sandra Wilson and colleagues within the Kaiser Permanente Clinics in California and Oregon
46041208|NCT01280500|Other|school based care|the research team will start an electronic data capture system linking school data and the clinical EMR (Cerner Power Chart) that will be implemented over the first year. Flow of data between schools and the hospital system will allow the children who have a regular source of care as well as those without a medical home to be treated with a unified asthma program by the school nurse and the hospital system.
46041209|NCT05100849|Procedure|Kinect-based cognitive training|The Kinect-based group will be involved in the standard treatment protocol and will perform a 14-sessions cognitive training program that consists of instrumental activities of daily living simulations. The cognitive training content will be projected onto a wall and patients will interact with the content, i.e., the selection of the appropriate response, through movement (kinect).
46041210|NCT05100849|Procedure|Tablet-based cognitive training|The Tablet-based group will be involved in the standard treatment protocol and will perform a 14-sessions cognitive training program that consists of instrumental activities of daily living simulations. Patients will interact with the cognitive training content through a tablet.
46041211|NCT01221688|Procedure|Axillar Sentinel lymph node biopsy|Group 2 : Patients without proven axillary involved nodes will undergo SLNB and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLNB alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.
46041212|NCT01221688|Procedure|SLNB and complete level I-II axillary lymphadenectomy|group 1 : patients with proven involved axillary nodes will undergo SLNB and complete level I-II axillary lymphadenectomy.
45344847|NCT00312728|Drug|Second-Line Chemotherapy Agents|"Erlotinib, pemetrexed, docetaxel, or chemotherapy at the investigator's discretion. Erlotinib was administered orally daily; pemetrexed and docetaxel were administered IV on Day 1 of every 21-day cycle. Single-agent bevacizumab therapy could be continued at the investigator's discretion if the second-line agent was discontinued.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
45344848|NCT00804921|Drug|bevacizumab|
45344849|NCT00804921|Procedure|anterior chamber paracentesis|
46041213|NCT00609999|Drug|Erlotinib and Dasatinib|You will begin study drug regimen on day 1 of cycle 1 w Dasatinib. If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected. Erlotinib will be begin after initial Dasatinib PK assessments are collected & will continue to be administered w Dasatinib on continuous daily dosing schedule. Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 & at end of cycle 1. If you are not undergoing Dasatinib PK collections you will begin both Dasatinib & Erlotinib together on day 1 of cycle 1. Both drugs will be given in continuous daily oral manner. Cycle is defined as Dasatinib & Erlotinib given daily for 28 days for purpose of scheduling evaluations.
46041214|NCT00951652|Behavioral|CBT|
46041215|NCT00951652|Other|Interpersonal and emotional processing therapy|
46041216|NCT00951652|Behavioral|supportive listening|
45344850|NCT00804921|Drug|acetazolamide|
45344851|NCT00804921|Drug|brimonidine|
45344852|NCT00866944|Drug|Adecatumumab|Adecatumumab,6-9mg/kg, every 14 days, 24 cycles
45344853|NCT00866944|Drug|Adecatumumab and FOLFOX|FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles
45344854|NCT00866944|Drug|FOLFOX 4|FOLFOX 4, every 14 days, 12 cycles
45344855|NCT00922155|Device|guide sheath|The guide sheath (GS) was originally the balloon covered sheath (MAJ-643R, external diameter 2.6mm) of the EBUS probe. The two ends of the balloon covered sheath were cut and trimmed. The EBUS probe was covered with guide sheath and then inserted through the working channel to the targeted bronchus.
45344856|NCT00798681|Dietary Supplement|RTU TPN with olive oil as the primary lipid source|RTU will be provided as a 3 in 1 TPN ready-to-use TPN system in industrialized bags with 2.000 ml. The number of calories will be adjusted in accordance with patients' individual needs.
45344857|NCT00798681|Other|CNF Parenteral nutrition|CNF parenteral nutrition made with olive oil as the primary source of lipids
45344858|NCT00798681|Other|CNF parenteral nutrition|3 in 1 CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
45344859|NCT00577824|Drug|exenatide|subcutaneous injection, 5mcg, twice a day
45344860|NCT00577824|Drug|exenatide|subcutaneous injection, 10mcg, twice a day
45344861|NCT00577824|Drug|placebo|subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day
45344862|NCT02632448|Drug|LY2880070|Capsules
45344863|NCT02632448|Drug|Gemcitabine|50 to 600 milligrams per square meter of body surface area (mg/m2)
45344864|NCT04046289|Dietary Supplement|Low Calcium Milk|50 mg calcium/day
45344865|NCT04046289|Dietary Supplement|Regular Calcium Milk|400 mg/day
45344866|NCT04046289|Dietary Supplement|Probiotic 1|regular calcium milk + probiotic
45684588|NCT03823612|Drug|GC tooth mousse|The participant will be instructed to squeeze a small amount of GC Tooth Mousse out onto a clean finger. A cotton tip, swab or custom tray are suitable application methods as it will Applied directly onto his tooth surfaces and leave undisturbed for three minutes then he will be instructed to Spread any residual crème around the mouth with his tongue and hold for a further one to two minutes then the participant will expectorate thoroughly and if possible he should avoid rinsing. Any GC Tooth Mousse remaining in the mouth can be left to gradually dissipate. The participant will be instructed to avoid eating or drinking for 30 minutes following application.
46041217|NCT00608751|Radiation|IMRT|
46041218|NCT03539380|Drug|TRx0237|TRx0237 8 mg/day, with flexible dosing after 3 months (4-20 mg/day)
46041219|NCT00931515|Device|NuBac|NuBac device implanted at the L4/5 level.
45344867|NCT04046289|Dietary Supplement|Probiotic 2|regular calcium milk + probiotic
45344868|NCT02554071|Other|Pharmacist - Smoking Cessation Support|Intervention mirrors clinical practice with smoking cessation counselling -- patients receive smoking cessation product at no cost and pharmacists are paid flat fee for providing counselling
45344869|NCT00855322|Other|Gym exercise group intervention|Gym based circuit class
45344870|NCT00855322|Other|Hydrotherapy group exercise intervention|Hydrotherapy group exercise class
45344871|NCT00855322|Other|Control group|No intervention
45344872|NCT00807807|Dietary Supplement|Folic Acid|100 mcg, 400 mcg, 1000 mcg, or 2000 mcg of folic acid once a day for 6 weeks
45694632|NCT00884806|Device|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
45694633|NCT05086354|Behavioral|JUMP|Warm-up, stretching, jumping rope, cool-down
46041220|NCT00931515|Device|Prodisc-L|Prodisc-L implanted at the L4/5 level.
46041221|NCT02703766|Behavioral|overfeeding induced weight gain|
46041222|NCT00823108|Drug|GIK|12 hour infusion of GIK solution
46041223|NCT04259619|Device|Low-Level Laser Therapy|The low-level laser emits monochromatic, coherent, bundled laser light. In each therapy a energy dose of 2-4 Joul (J) / centimeter (cm)^2 is applied over a duration of about 30 seconds using level 1 (20 percent of maximum output) of the 350 milliwatt (mW) device.
45344873|NCT00807807|Drug|Placebo Folic Acid|Placebo folic acid once a day for 6 weeks
45344874|NCT05333406|Drug|EN001|"EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10^5 cells/kg"
46041224|NCT04259619|Device|Placebo Therapy|The intervention is conducted identically to the low-level laser therapy but the placebo laser that is used emits only red light that is polychromatic, leading to a reduction in energy being emitted and therewith to no or a smaller effect.
46041225|NCT00627250|Drug|Amantadine|Amantadine 100 mg every morning and 12 noon
45344875|NCT05333406|Drug|EN001|"EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group B (High dose): 2.5x10^6 cells/kg"
45344876|NCT00867256|Device|Large Diameter Metal on Metal|
45344877|NCT00805077|Procedure|mechanical ventilation|mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP
46041226|NCT05330949|Diagnostic Test|Optical coherence Tomography Angiography, Uterine artry doppler|vascular changes in retina by OCT angiography and uterine artry doppler in the first and second trimesters
46041227|NCT04301232|Other|Modified Aldrete Scoring System (mASS)|Activity( Moves all extremities, Moves two extremities, Unable to move extremities), Respiration( Breathes deeply, coughs freely, Dyspneic, shallow or limited breathing, Apneic), Circulation (blood pressure) ( 20 mm Hg > preanesthetic level, 20 - 50 mm Hg > preanesthetic level, 50 mm Hg > preanesthetic level), Consciousness (Fully awake, Arousable on calling, Not responding), Oxygen saturation( SpO2 > 92% on room air, Supplemental O2 required to maintain SpO2 > 90%,SpO2 < 90% with O2 supplementation), scoring is done as 2,1,0, respectively. A score of 9 or more would be required for a patient after general anesthesia for discharge
46041228|NCT04301232|Other|White's Fast-Track Scoring System (WFTSS)|Physical activity (Able to move all extremities on command, ,Some weakness in movement of extremities, Unable to voluntarily move extremities),Respiratory stability(Able to breathe deeply,Tachypnea,Dyspneic),Hemodynamic stability; (Blood pressure(MAP)<15%, Blood pressure 15-30%, Blood pressure>30%, Level of consciousness,(Awake&orientated Arousable with minimal stimulation, Responsive only to tactile stimulation),Oxygen saturation status(Maintains value>90% on room air, Requires supplemental oxygen, Saturation<90% with supplemental oxygen), Postoperative pain assessment(None or mild discomfort, Moderate to severe pain controlled with analgesics, Persistent severe pain), Postoperative emetic symptoms(None or mild nausea w/no active vomiting, Transient vomiting or retching, Persistent moderate to severe nausea&vomiting), Scoring is done as 2,1,0, respectively. A minimal score of 12(with no score<1 in any individual category)would be required for a patient after general anesthesia
45344878|NCT00805077|Other|tidal volume|tidal volume of 10 ml/kg of ideal body weight without PEEP
45344879|NCT03011814|Biological|Durvalumab|Given IV
45344880|NCT03011814|Other|Laboratory Biomarker Analysis|Correlative studies
45344881|NCT03011814|Drug|Lenalidomide|Given PO
45344882|NCT00870298|Drug|Trimethoprim/Sulfamethoxazole and Warfarin|
46041229|NCT04301232|Other|SPEEDS criteria|"Extremity movement (moves all four) Y/N, Stable vital signs( SBP > 90 and < 180, HR > 50 and < 110) Y/N, Dialogue (oriented person/place) Y/N, Oxygen saturation >90% in roExtremity movement (moves all four) Y/N, Stable vital signs( SBP > 90 and < 180, HR > 50 and < 110) Y/N, Dialogue (oriented person/place) Y/N, Oxygen saturation >90% in room air Y/N, Pain Control (VAS < 4) Y/N, Emesis Control Y/N. A patient must have a response of yes to all parameters to progress to phase II recovery"
46041230|NCT05232279|Drug|Testofen 300mg|Testofen in capsule form - To be taken as a 300mg dosage (2 capsules) once daily for 12 weeks.
45344883|NCT00730340|Procedure|Closure of the Tonsillar Fossa|We hypothesize that closure of the tonsillar fossa decreases the morbidity of pain by decreasing exposure of the raw operative bed to oral secretions, mediation, and oral intake, and decreases the morbidity of post-operative hemorrhage by having the operative wound closed.
46041231|NCT05232279|Drug|Testofen 600mg|Testofen in capsule form - To be taken as a 600mg dosage (2 capsules) once daily for 12 weeks.
46041232|NCT05232279|Drug|Placebo comparator|The placebo will consist of maltodextrin and will appear identical to the Testofen capsules. The placebo will be administered as per the active treatment - 2 capsules once daily for 12 weeks.
46041233|NCT02692144|Other|Test Cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
46041234|NCT04300374|Other|The Paediatric Anaesthesia Emergence Delirium scale assesment which was recorded postoperatively|routine remifentanil infusion during general anesthesia
46041235|NCT02703376|Drug|Oral Prednisone|Intakes of Oral Prednisone for 12 weeks after balloon dilations
46041236|NCT04259697|Other|Clinical pilates|Clinical pilates exercises will be performed progressively. The duration of each exercise session will be an average of 40 minutes initially and then will be increased to 60 minutes as the program progress.
46041237|NCT04259697|Other|Whole body vibration|Whole body vibration exercises will be performed using the Power Plate pro5 AIRdaptive machine.The duration of each exercise session will be an average of 20 minutes initially and then will be increased to 30 minutes as the program progress.
46041238|NCT04301388|Procedure|Transvaginal ultrasound|Transvaginal ultrasound to measure cervical length if persist regular uterine contraction
45474876|NCT04520620|Drug|Lovenox 40 MG in 0.4 mL Prefilled Syringe|"Patients with a high thrombotic risk:~In patients with a BMI included between < 30 kg/m² and > 30 kg/m² without added thrombotic risk factor:~Enoxaparin 40 milligrams, (4,000 IU) twice daily subcutaneously (SC) for the entire duration of the intensive care hospitalization~if weight > 120 kg, enoxaparin 60 milligrams (6000 IU) twice daily subcutaneously for the entire duration of the intensive care hospitalization~Patients with a very high thrombotic risk:~In patients with a BMI > 30 kg/m2 with added thrombotic risk factor (active cancer, recent personal history of thromboembolic event), or if iterative or unusual catheter thromboses, or if marked inflammatory syndrome and/or hypercoagulability (e.g. fibrinogen > 8 g/L or D-Dimer > 3 μg/ml or 3000 ng/ml)~* Enoxaparin sodium curative at a dose of 100 IU/kg/12h subcutaneously (SC) not to exceed a dose of 100 mg/12 hours"
45474877|NCT04520620|Device|Ultrasound of the lower limbs|A 4-point compression ultrasound will be performed. In case of suspicion, an angiologist will perform to check the absence of legs thrombosis.
45684589|NCT03823924|Procedure|Bone mineral density (BMD)|"The bone mineral density (BMD) performed by DXA, which will allow the analysis of bone density (mg / cm²) at the lumbar spine (BMD L1 to L4) and the total hip (non-dominant).~This examination will also allow an analysis of the body composition at the same time (lean mass, fat mass and bone mass for the whole body)."
46041239|NCT00615394|Procedure|intramyocardial bone marrow stem cells implantation|Patients with previous diagnosis of non-ischemic dilated cardiomyopathy. were included. Bone-marrow was collected from in the antero-superior iliac crest and mononuclear stem-cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Surgical technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5 ml), in the anterior, lateral, posterior and apical faces of the left ventricle(average 9.6 ± 2.6 x 107 cells). After the procedure, the patients were kept in the post-operative intensive care unit for a minimum period of 24 hours. They were released from the hospital in a period that varied from five to seven days.
45344884|NCT00730340|Procedure|Tonsillectomy with open fossa|SOP for a tonsillectomy.
45344885|NCT00805155|Drug|Mometasone Furoate 0.1% Topical Lotion-Reference Product|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
45344886|NCT00805155|Drug|Mometasone Furoate 0.1% Topical Lotion-Test product 1|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
45474878|NCT03857633|Diagnostic Test|Cardiac MRI 1 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
45344887|NCT00805155|Drug|Mometasone Furoate 0.1% Topical Lotion-Test Product 2|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
45344888|NCT04016350|Behavioral|Exercise training with Inulin Propionate Ester|Supervised moderate intensity exercise training combined with Inulin Propionate Ester supplementation conducted for 4 weeks.
45344889|NCT04016350|Behavioral|Exercise training with placebo|Supervised moderate intensity exercise training combined with placebo conducted for 4 weeks
45344890|NCT00725166|Other|Skeletal muscle aging|"W1 - Blood test~Maximal voluntary contraction of quadriceps~Hydrostatic weighing~W2 - Maximal metabolic test using a cycloergometer~W3 - Muscular biopsy"
45344891|NCT02575742|Device|3D-Transit system|
45344892|NCT00807963|Drug|rHuPH20|recombinant human hyaluronidase PH20 injection
45474879|NCT03857633|Diagnostic Test|Cardiac MRI 2 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
45344893|NCT00807963|Drug|zoledronic acid|subcutaneous injection
45344894|NCT05227066|Other|adding lower extremity weights|All children in the two groups received physical therapy protocol for 30 minutes in addition to half kg of sandbags weights attached for each leg
45474880|NCT03857633|Diagnostic Test|Cardiac MRI 3 - Without Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps.~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
45684590|NCT04273906|Procedure|End-range mobilization|End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension
45684591|NCT04273906|Procedure|Placebo technique|Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension
45684592|NCT02942368|Device|tDCS|Transcranial direct current stimulation with placement of the anode over the F3 region of the scalp and the cathode over the right supraorbital region.
45684593|NCT02834104|Device|RMI|
45684594|NCT02834104|Other|myocardial biopsy|
45344895|NCT05227066|Other|traditional physical therapy group|traditional physical therapy group
45344896|NCT05210634|Dietary Supplement|THCv|THCv in MCT oil
45344897|NCT00730418|Drug|Doxazosin|Treatment with doxazosin 4mg daily for 24 mos
45344898|NCT00730418|Drug|Doxazosin|Treatment with doxazosin 8mg daily for 24 mos
45684595|NCT02834104|Biological|blood sample|
45684596|NCT03823222|Dietary Supplement|Duckweed protein|20 grams isolated protein
45684597|NCT03823222|Dietary Supplement|Whey protein|20 grams isolated protein
45684598|NCT03823066|Device|Coach Pepper|Robot Peppers's height is 1.20 meters and it weighs 28 kilograms. Pepper will be called Coach Pepper, because it is connected, via web interfaces, with a theratainment app including cognitive and physical training
45684599|NCT02810704|Drug|Enteric Coated Aspirin|
45344899|NCT00805233|Drug|combination ranibizumab + bromfenac|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months. Plus one drop of bromfenac in the study eye twice per day, each day, for 12 months.
45344900|NCT00805233|Drug|ranibizumab injection alone|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months
45840801|NCT00894738|Procedure|Testing (MRS, US, DEXA, blood tests)|Magnetic Resonance Spectroscopy (MRS) of the liver to determine hepatic triglyceride content; ultrasound (US) of the carotid artery to determine intima-media thickness; dual energy X-ray absorptiometry (DEXA) to determine body composition; fasting lipids, fasting insulin, C-reactive protein, liver enzymes and fibrinogen levels.
45344901|NCT00725244|Device|Bipolar eletrocoagulation|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
45344902|NCT00725244|Device|Argon Plasma Coagulation|"Argon plasma coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort."
45344903|NCT02569502|Drug|enfuvirtide|Participants will receive a total daily dose of 180mg of enfurtide administered twice daily as a subcutaneous injection.
45684600|NCT02810704|Drug|Warfarin|
45684601|NCT02810704|Drug|Rivaroxaban|
45840802|NCT00895752|Drug|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
45684602|NCT04392076|Procedure|Image Guided Ablation|Image Guided Ablation with RFA, MWA or CRYO of Renal Cancer
45684603|NCT02790424|Device|Imaging devices|technological adjustment tests
45684604|NCT02738398|Radiation|FDG PET/CT|
45684605|NCT02735902|Drug|Vitamin K antagonist or direct oral anticoagulant treatment|"The Vitamin K antagonist or direct oral anticoagulant treatment will be administered to obtain an International Normalized Ratio between 2 and 3 as recommended if the treatment is AVK.~The Direct oral anticoagulant treatment : Apixaban 5 mg x2 or 2.5 mg X2, Edoxaban 30 ou 60 mg"
45684606|NCT02735902|Drug|Aspirin|"Daily dose is between 75 mg and 100 mg.~Allergic reactions to aspirin may be observed in rare cases. In case of suspicion of allergy, treatment with aspirin is stopped."
45840803|NCT00895830|Drug|APD405|IV
45840804|NCT00895830|Drug|Placebo|IV
46041240|NCT02873442|Procedure|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～ 40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
45684607|NCT03822988|Other|no intervention, only complete a survey|we will ask patients to answer to a survey
45684608|NCT03822754|Biological|sIPV-bOPV-bOPV vaccination schedule|Single intramuscular injection of the experimental sIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Vaccine Technology Co., Ltd. The poliovirus (Live) vaccine type I & type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
45684609|NCT03822754|Biological|wIPV-bOPV-bOPV vaccination schedule|Single intramuscular injection of the control wIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively.The control wild strain inactivated poliovirus vaccine (wIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I & type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
46041241|NCT02873442|Biological|Precision Cells|"DC cell suspension (1×107 DC+ physiological saline~+ 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PMAT/PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
46041242|NCT04261179|Drug|Lymphoseek|50 μg microgram(s), timepoint: 30-60 minutes
46041243|NCT04261179|Drug|Nanocoll|500 μg microgram(s), timepoint: 30-60 minutes
45382098|NCT05331105|Drug|HL-085|"IIa: HL-085 capsule 9mg administered orally twice daily in a continuous 21-day treatment cycle. If required, dosing schedule can be adjusted to 12mg BID, 6mg BID, or other dosage regimens.~IIb: HL-085 at the recommended dose or dosage regimen."
46041244|NCT03501706|Behavioral|Sequenced Recall of Digits--Auditory|Auditory digit sequence AT memory component.
45382099|NCT05329649|Biological|CTX001|Administered by intravenous infusion following myeloablative conditioning with busulfan.
45684610|NCT03822676|Device|Prophylactic pancreatic stent|Prophylactic pancreatic stent before segmental pancreatic surgery
46041245|NCT03501706|Behavioral|Sequenced Reverse Recall of Digits--Auditory|Reversed auditory digit sequence AT memory component.
46041246|NCT03501706|Behavioral|Sequenced Recall of Words--Visual|Visual word sequence AT memory component
46041247|NCT03501706|Behavioral|Verbal Memory--Visual|word recognition AT memory component
45382100|NCT05329493|Device|Cooling digit device application|Cooling digit device will be applied on subject's right hand ( fifth finger).
46041248|NCT04582500|Drug|Iohexol|Iohexol (Omnipaque; GE Healthcare, Milwaukee, WI) is a low-osmolar non-ionic iodinated contrast agent that is approved by the FDA for oral use. It is routinely used orally for CT scans of the abdomen and pelvis, and has been used experimentally in CTC. Iohexol is better tolerated by patients and has a better safety profile than hyperosmolar iodinated and barium based contrast agents.
45344904|NCT00798837|Radiation|Intraprostatic maximal simultaneous boost|"Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~The prescription dose will be 73.7 Gy in 28 fractions~A simultaneous intraprostatic boost will be given to as much of the CTV as possible without contravening OAR dose constraints."
45344905|NCT03906136|Biological|Secukinumab/Adalimumab-Biosimilar|Secukinumab 150 mg, s.c. Secukinumab 300 mg, s.c. Adalimumab-Biosimilar, s.c.
45344906|NCT03906136|Other|Standard-of-care|Patients will receive treatment according to local practice standards by their treating physician following the current treatment recommendations.
45344907|NCT02569580|Device|Topically|"use the No More medical device as anti lice treatment"
45344908|NCT00725400|Other|Cetuximab and Radiation Therapy|Patients will receive Cetuximab and Radiation Therapy. Patients will receive a dose of Cetuximab through Intravenous (IV). The initial dose is 400 mg/m2 administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min) and weekly dose is 250 mg/m2 infused over 60 minutes (maximum infusion rate 10 mg/min) until disease progression or unacceptable toxicity. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
45344909|NCT00725400|Procedure|Surgery and Radiation Therapy|Patients will undergo Surgery before or after Radiation Therapy. Colorectal Cancer Surgery are Colon resection (Colectomy), Rectum resection (Proctectomy), Colostomy, and Radiofrequency ablation. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
45344910|NCT00798915|Drug|Placebo|Intravenous infusion of 1% human albumin in normal saline
45344911|NCT00798915|Drug|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
45344912|NCT00798915|Drug|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
45344913|NCT00798915|Drug|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
45344914|NCT00730496|Procedure|uterine cavity injection of day 2 embryo culture supernatant|On the day 2, the embryos were translated from the old dish to a new dish with fresh media and cultured continuously. In study group, the embryo culture supernatant at the old dish were aspirated by using embryo transfer catheter (COOK-5000, Australia) and injected into the patient's uterine cavity. But in the control group, this intervention was not done. Conventional ET was performed on the third day of embryo culture for both groups.
45344915|NCT00798993|Other|Structured Exercise program|30 minutes on an exercise bicycle during every dialysis
45344916|NCT00798993|Drug|Cholecalciferol (25-Hydroxyvitamin D)|Cholecalciferol 2000U per day will be given for duration of study to all participants
45344917|NCT00798993|Other|Usual exercise|Participants randomised to this arm at 3 months will continue on their usual exercise routine for the remaining 3 months
45344918|NCT00725582|Drug|IMA-026|
45684611|NCT02926222|Drug|Regorafenib|Regorafenib is formulated as tablets of 40mg for oral administration.
45684612|NCT02926222|Drug|Lomustine|Lomustine is formulated as tablets of 40mg for oral administration.
45840805|NCT00896064|Biological|Pneumococcal vaccine GSK2189242A (formulation 1)|One dose will be administered intramuscularly at Study Day 0.
46041249|NCT00610077|Drug|Letrozole|Tablet Letrozole 2.5 mg once a day for 5 days for 3 cycles
46041250|NCT00610077|Drug|Clomiphene citrate|Clomiphene citrate 100 mg or 150 mg once a day for 5 days in 3 cycles
46041251|NCT00823576|Drug|Ropivacaine|Compare the evolution of the postoperative levels of pain until J2, in the scheduled lumbar surgery between 2 groups of patients, one receiving a single bolus of analgesic, one receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.
45344919|NCT00725582|Other|Placebo|
45344920|NCT00862108|Drug|Methylphenidate|mg/kg dose: 0.7~1.2mg/kg PO daily morning intake 8 weeks
45344921|NCT04041154|Behavioral|Cognitive Fatigue|Participants will perform a cognitively demanding task (spatial attention task), repeatedly, to induce cognitive fatigue.
45474881|NCT03857633|Diagnostic Test|Cardiac MRI 3 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
45344922|NCT04041154|Behavioral|Physical Fatigue|Participants will perform a physically demanding task (grip force exertion task), repeatedly, to induce cognitive fatigue.
45344923|NCT04041154|Behavioral|Rewarding Stimuli|Reward-associated stimuli will be used to study how reward-induced changes in motivational state influence effort choices.
46041252|NCT01028352|Drug|Duloxetine|"Patients will be treated with open-label duloxetine:~30 mg daily x 7 days, then~60 mg daily x 3 weeks, then~If a patient believes she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will continue taking 60 mg daily for weeks 5-8~If a patient does not believe she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will have the option of increasing the dose to 60 mg twice daily for weeks 5-8.~After completion of 8 weeks of therapy, patients who wish to discontinue therapy will taper off the drug over 1 week (50% decrease for 4 days, then additional 50% decrease for 3 days). Patients may continue therapy off-study at the discretion of their treating physician."
46041253|NCT03172780|Drug|Diclofenac sodium gel 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
45344924|NCT00862264|Drug|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
45344925|NCT02569424|Behavioral|Patient's position|Supine or Trendelenburg strict -20°)
45344926|NCT00870376|Other|biomarkers|To define a biomarker or combination of overactive bladder syndrome
45344927|NCT02844660|Biological|EpiCord|Weekly application of EpiCord and standard of care (moist wound therapy and offloading)
45344928|NCT02844660|Other|Standard of Care|moist wound therapy and offloading
45344929|NCT00730574|Dietary Supplement|Vitamin B12 + Folic Acid|Trial group would get daily treatment of 1 mg Vitamin B12 combined with 5 mg Folic Acid
45344930|NCT02570048|Device|Mutebutton intervention|Participants are asked to use the MuteButton daily for 30-40 minutes.They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollypop' sensor that sits on the anterior section (tip) of the tongue.
45344931|NCT00870532|Drug|oral vinorelbine|The patients will be divided into 3 cohorts (15 patients per cohort), each cohort receiving a fixed metronomic (thrice a week) dose of oral vinorelbine at 60 mg/week, 90 mg/week, and 120 mg/week respectively. We should arrive at 3 different MTDs from the 3 cohorts.
45344932|NCT00870532|Drug|sorafenib|Each patient within each cohort will receive a starting dose of sorafenib at 200 mg bid for 4 weeks. In the absence of dose-limiting toxicities, the dose of sorafenib will be escalated to 400 mg bid for another 4 weeks, 600 mg bid for 4 weeks and then finally 800 mg bid. We should arrive at 3 different MTDs from the 3 cohorts.
45344933|NCT02771496|Other|Other: observational only- no intervention|Other: observational only- no intervention
45344934|NCT05121402|Drug|TLL018|a TYK2/JAK1 inhibitor
45344935|NCT05121402|Other|Placebo|a TLL018 Placebo
45344936|NCT00867724|Device|Aer-O-Scope Colonoscopy|Screening Colonoscopy
45474882|NCT03857633|Diagnostic Test|Peripheral Whole Blood Samples|20ml EDTA whole blood samples - collected sequentially during study - max 8 time points
45344937|NCT02570516|Procedure|Colonoscopy|A double colonoscopy is performed in a back-to-back design using NBI chromoendoscopy then indigo carmine in each patient.
45344938|NCT00725478|Drug|Piribedil|
45474883|NCT03357016|Other|Training programs|High Intensity Interval Training program (HIIT) vs. Moderate Intensity Continuous Training program (MICT) vs. High Intensity Interval Training program + Resistance Training program (HIIT+RT)
45474884|NCT03857711|Procedure|Conventional CABG|Coronary artery bypass grafting
45344939|NCT00730652|Biological|MDX-1411|Single dose of MDX-1411 (fully human monoclonal antibody) will be administered as an intravenous (i.v.) infusion every 7 days for up to a total of 5 doses.
45344940|NCT01951274|Drug|VPD-737|NK1 Receptor Antagonist
45344941|NCT01951274|Drug|Placebo|
45344942|NCT00725556|Other|Speech Therapy|Speech Therapy
45344943|NCT03355794|Drug|ribociclib|Oral capsule or liquid formula
45344944|NCT03355794|Drug|Everolimus|Oral tablets or dispersible tablets
46041254|NCT03172780|Drug|Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
45344945|NCT01487174|Drug|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
45344946|NCT01487174|Drug|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
46041255|NCT03172780|Drug|Placebo gel|Vehicle Gel 4 gm, 4 times a day for 4 weeks
46041256|NCT00929643|Other|no intervention|success of the initial empiric treatment
45344947|NCT00725634|Biological|AV-299|AV-299 monotherapy will be given as intravenous infusion in dose-escalation cohorts at 2, 5, 10, and 20 mg/kg. Once the RP2D has been determined the cohort may be expanded to include up to 12 patients for safety assessment and enriched with up to 12 additional Multiple Myeloma patients.
45344948|NCT00725634|Biological|AV-299 + erlotinib|AV-299 will be given as intravenous infusion at RP2D in combination with erlotinib (150 mg daily). Once the combination-RP2D has been determined the cohort may be expanded to include up to 12 additional patients.
45344949|NCT01248806|Radiation|Low dose CT scan|A low dose CT scan of the lungs is performed after the inclusion of the patient in the study and if negative for active disease, a CT scan if performed once per year for whole period of follow-up
45344950|NCT00617344|Biological|Tetravalent CYD Dengue Vaccine , 5555 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively.
45344951|NCT00617344|Biological|Tetravalent CYD Dengue Vaccine , 5553 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
45474885|NCT03857711|Procedure|CABG+ PVI|CABG+ prophylactic epicardial bipolar radiofrequency isolation of the pulmonary veins
45474886|NCT03857711|Procedure|CABG+ PVI+amiodarone|CABG+PVI+amiodarone (CABG+RFA + class III antiarrhythmic drug- amiodarone)
45474887|NCT03857711|Procedure|CABG+amiodarone|
46041257|NCT05011617|Device|Non-intubation and monitoring anesthesia care (MAC)|Non-intubation and monitoring anesthesia care (MAC) consisted of non-intubation technique, local anesthesia at the site of sternotomy, sedation with dexmedetomidine, analgesia with remifentanil/sufentanil, and electroacupuncture.
46041258|NCT02703298|Drug|TRX-818 capsules|
46041259|NCT04259385|Behavioral|Exposure to sugar-sweetened beverage warning labels|Graphic images of the amount of sugar (randomly assigned teaspoons, packets, or cubes) and text warning labels
46041260|NCT04259385|Behavioral|Exposure to beverage calorie information|Calories for sugar-sweetened and non-sugar-sweetened beverages
45474888|NCT04524676|Procedure|Individualized Treatment|Patients under evaluation including hepatic venous pressure gradient (HVPG) and contrast-enhanced computed tomography of portal venous. For those patients with a HVPG ≥12mmHg or with extraluminal para-gastric vein will under transjugular intrahepatic portosystemic shunt and others receive endoscopic treatment.
46041261|NCT03169972|Biological|ADYNOVATE|Antihemophilic Factor (Recombinant), PEGylated
45344952|NCT00617344|Biological|Tetravalent CYD Dengue Vaccine, 4444 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
46041262|NCT04261101|Other|Test-enhanced learning|Test-enhanced learning with short answers of questions regarding diabetes and adrenal
46041263|NCT03101488|Drug|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
45474889|NCT03364816|Procedure|TDR|total artificial disc replacement
45344953|NCT02570724|Drug|"injection of HES  Voluven® "|Injection into the epidural space of 15 to 30 ml Voluven ® at a rate of 1 ml / about 5 seconds.
45344954|NCT02570724|Biological|blood patch|
45344955|NCT00725738|Genetic|Stem Cell Transplantation|"1-2 million of CD34 cells injected through the infarct related artery by PTCA over-the-wire catheter during multiple sequences of balloon artery occlusion with a mean duration of 30 minutes."
45344956|NCT00862342|Drug|Bevacizumab (Avastin)|Bevacizumab plus chemotherapy (chemotherapy will be chosen by physician's decision)
45344957|NCT01956084|Drug|LMP1/2 CTLs (Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2"
45344958|NCT01956084|Drug|LMP1/2 CTLs (Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2"
46041264|NCT02924116|Device|Bioboosti|Subjects will place the device on the palm of their hand for 8 minutes. There is a light on the device that changes to indicate that the 8 minutes have passed. They will then place it on the palm of the other hand and keep it there for 8 minutes. Alternating 8-minute cycles between hands will be done up to 6 times.
46041265|NCT00926367|Drug|Clindamycin and benzoyl peroxide|Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide gel. This contains a topical antibiotic and benzoyl peroxide gel.
46041266|NCT00926367|Drug|benzoyl peroxide 2.5% and adapalene 0.1% gel|Once-daily applications, to the randomized side of the face either left or right,benzoyl peroxide and adapalene gel
45344959|NCT00732212|Device|Doppler endoscopic ultrasound probe for blood flow detection|Used for blood flow detection
45344960|NCT00732212|Other|Standard endoscopic hemostasis|Per current treatment guidelines for non-variceal UGI lesions - based upon stigmata of hemorrhage & visual cues for risk stratification and completion of endoscopic treatment.
45344961|NCT00870610|Procedure|retrograde jugular venous cannulation|Retrograde cannulation of jugular vein and intermittent sampling of venous blood from cerebral circulation before, during and after hypothermia.
45344962|NCT00730808|Dietary Supplement|PreOP Booster (food for special medical purposes)|3x1 dosage is given prior to surgery: 2x1 the day prior to surgery; 1x1 3-4h prior to initiation of anaesthesia;
46041267|NCT02703142|Procedure|Patients after esophagectomy|postoperative endoscopic evaluation
46041268|NCT04261023|Drug|Orencia 125 MG Per 1 ML Prefilled Syringe|Abatacept sub-cutaneous injection 125mg at week 0 and once weekly thereafter for a maximum of 48 weeks
46041269|NCT05086341|Device|My COPD|In addition to usual care, participants in the intervention group will initially meet with a physiotherapist to set up an individualized exercise program and physical activity plan. Participants will also receive a device instruction manual and a one hour of face-to-face training on how to use My COPD. The 12-week intervention is home-based, and self-managed with support from physiotherapist via My COPD. In addition to warm-up exercises, the exercise program comprises five exercises targeting major muscle groups, as well as, balance and aerobic exercise, to be conducted at least twice weekly. Via My COPD, the physiotherapists can follow activities and progress the exercise program, and the physiotherapist and the participants can contact each other. Throughout the intervention period, technical support will be available.
46041270|NCT01114529|Drug|Everolimus|Early CNI to everolimus conversion
45344963|NCT02544724|Biological|NM-IL-12|Single SC administration of NM-IL-12 will be administered at least 48 hours after completion of the last chemotherapy dose of each cycle
45344964|NCT00867880|Drug|IVIb|800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8
45344965|NCT03248310|Behavioral|Quality of Life Assessments|Upper Limb Lymphedema (ULL-27), Lymphedema Life Impact Scale, version 2 (LLISv2), LYMQOL-Leg.
45344966|NCT04040374|Diagnostic Test|AI-based diagnosis|AI-based diagnosis will be performed based on analysis of endoscopic images (Olympus Optical, Tokyo, Japan). The investigators will use the Single Shot MultiBox Detector (SSD), a deep neural network architecture (https://arxiv.org/abs/1512.02325), and an optimal diagnostic cutoff from a prior report2. The AI system reviewed endoscopy images and reported those in which gastric cancer was detected, together with the coordinates (X, Y) of the lesions.
45344967|NCT04040374|Diagnostic Test|The expert endoscopists-based diagnosis|The expert endoscopists are two physicians with experience of more than 20,000 endoscopies. The expert endoscopists will review the endoscopy images of each patient for 5 min. They will then report endoscopy images in which gastric cancer was detected and manually annotate the lesions in those images.
45344968|NCT00862420|Drug|clopidogrel (SR25990)|oral administration (tablets)
46041271|NCT01114529|Drug|Prograf or Neoral|Active CNI-based control (Prograf or Neoral)
45344969|NCT00862420|Drug|ticlopidine|oral administration (tablets)
45840806|NCT00896064|Biological|Pneumococcal vaccine GSK2189242A (formulation 2)|One dose will be administered intramuscularly at Study Day 0.
46041272|NCT00926289|Drug|Telmisartan|Telmisartan 80mg
45840807|NCT00896298|Drug|Leptin|Leptin injected subcutaneously twice a day, to be administered at 100% of the estimated replacement dose during the first month, which is a dosage of 0.03mg/kg for female children, 0.04mg/kg for adult females, and0.02 mg/kg for all males, and then at 200% subsequently, or placebo.
45840808|NCT00896298|Drug|Placebo|Sugar pill
45840809|NCT00898560|Drug|eslicarbazepine acetate and Microginon®|"eslicarbazepine acetate: once-daily oral dose of 800 mg on days 1- 15 of treatment period.~Microginon®: single oral dose on day 14 of treatment period"
45840810|NCT00898560|Drug|Microginon®|Single oral dose of Microginon® (30ug ethinyloestradiol and 150ug levonorgestrel)
45840811|NCT00899574|Drug|Imiquimod|"Each treatment cycle consists of 8 weeks.~Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.~Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease."
45840812|NCT00900666|Drug|placebo|A total of 2 cc sterile normal saline: will be injected in 0.5 cc aliquots into 4 different injectate sites within the rectus femoris (with EMG guidance) of the involved limb.
45840813|NCT00900666|Drug|botulinum toxin A (BTX-A)|200 Units BTX-A reconstituted with 2 cc sterile normal saline in 100:1 ratio. Teflon-coated EMG guidance for confirmation of injection into the Rectus femoris muscle in addition to utilizing standardized injection landmarks, the solution will be injected in 0.5 cc aliquots into 4 different injectate sites within the muscle.
46041273|NCT00926289|Drug|Telmisartan|Telmisartan 80mg
46041274|NCT00926289|Drug|Hydrochlorothiazide|Hydrochlorothiazide25mg
46041275|NCT02707276|Device|Active Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic treatment being investigated for its effects on mood. It uses magnetic fields that are a fraction of the strength but at a higher frequency than the electromagnetic fields used in transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT)
45344970|NCT00321698|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|Group 1=radiation only; All men in all Arms/Groups receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)
45344971|NCT00321698|Drug|Docetaxel+IMRT|"Group 2=IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation; Phase II with no phase I dose-limiting toxicities=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
45344972|NCT05226052|Dietary Supplement|Saccharomyces boulardii (Floratil 600mg)|PGIC and PGIS assessment
45344973|NCT05226052|Dietary Supplement|3 capsules of placebo|PGIC and PGIS assessment
46041276|NCT02707276|Device|Sham Low Field Magnetic Stimulation|The sham treatment does not provide any electromagnetic stimulation. However, it is designed so that it cannot be differentiated from the active treatment by producing mimicking sounds.
46041277|NCT02699398|Behavioral|Domiciliary VR-based motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
45344974|NCT02569944|Procedure|Bladder stimulation|"Patients included in this arm were stimulated to collect urine with bladder stimulation technique. This technique consists in a tapping movement in the suprapubic area, followed by a circular massage in sacral zone. This sequence lasts one minute and it is repeated five times.~No other procedure, drug or device was done/used in this patients."
45344975|NCT02569944|Procedure|Perineal bag|Patients included in this arm were placed a perineal bag to collect urine sample. No other procedure, drug or device was done/used in this patients.
46041278|NCT02699398|Behavioral|Domiciliary occupational therapy for motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
45344976|NCT00725894|Device|Pediatric Locking Nail|The nail is pre contoured with a nine-degree anterior bow and is universal for right and left femoral.
45344977|NCT02544568|Other|Meals|At 4 different occasions the participants will receive meals with the same amount of calories and different composition of fat, protein, carbohydrate and fiber.The composition of the meals is: Low-fat / high-carbohydrate meal (18 E% proteins, 28 E% fat and 54% carbohydrates), high-fat meal (18 E% protein, 50 E% fat and 31 E% carbohydrate), high-protein meal (40 E% protein, 30 E% fat and 30 E% carbohydrates) and low-fat / high-carbohydrate and high fiber (18 E% proteins, 28 E% fat and 54 E% carbohydrates and 15 gram of fibers).
45344978|NCT03317964|Other|Saliva sample|Extract sample of saliva only once
45344979|NCT02569970|Drug|fluoxetine 20 mg|"Fluoxetine 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label."
45344980|NCT02569970|Drug|placebo 20 mg|"Placebo 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label."
45344981|NCT00867958|Device|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
45344982|NCT04066998|Other|Tears sampling|Tears sampling
45344983|NCT04066998|Other|Lashes sampling|Lashes sampling
45344984|NCT00868036|Procedure|Patch Testing|"Patch testing will be performed with a modified North American Contact Dermatitis Group (NACDG) standard series, cosmetics/preservative, fragrance, and textile series in all patients. Based on patient history, other appropriate allergen series will be added. After two days, patches will be removed and the areas will be inspected for type IV hypersensitivity reactions including papules, edema or vesicles.~Results will be graded and interpreted at a delayed read, 3-4 days after allergens are placed with patch testing."
45344985|NCT00725972|Other|Augment O2 Delivery by hemodynamic protocol|Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.
45344986|NCT00725972|Procedure|High Risk Surgery|Patients with same characteristics as Experimental Group having same types of Surgery but no change to usual anesthetic care
45344987|NCT00725790|Drug|Vardenafil|"10 mg vardenafil on demand treatment for first 4 weeks.~A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period.~A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period."
45344988|NCT00725790|Drug|Placebo|"10 mg placebo on demand treatment for first 4 weeks.~A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period.~A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period."
46041279|NCT04309643|Drug|CTP-543|Investigational Drug
46041280|NCT04309643|Drug|Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)|Oral contraceptive in the form of 1 fixed combination tablet of Seasonique or generic equivalent (0.03 mg EE / 0.15 mg LNG)
46041281|NCT02881073|Other|Maternal plasma PlGF quantification|A point of care test performed on maternal plasma, to quantify the level of the protein PlGF (placental growth factor) in the serum of the pregnant woman with suspected pre eclampsia to help the clinician in stratifying the level of further care for her in her pregnancy
46041282|NCT03208036|Device|TDCS|1 mA of anodal stimulation will be applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training for 20 minutes
45344989|NCT00862498|Other|Written Disclosure|Five sessions, each spaced 1 week apart, during which participants are asked to write about their motor vehicle accident for 30 minutes. The first session of the intervention also involves a description of common reactions to a motor vehicle accident and the rationale for this treatment.
45344990|NCT00731276|Drug|irinotecan hydrochloride|
45344991|NCT00731276|Other|pharmacogenomic studies|
45344992|NCT00731276|Other|pharmacological study|
46041283|NCT03208036|Device|Sham Stimulation|Participants will receive 20 seconds of 1 mA anodal stimulation applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training to mimic the effect of the active condition
45474890|NCT03672097|Drug|Prasugrel|Prasugrel, oral tablets, containing 3.75 mg per tablet
45840814|NCT00900822|Device|Straumann Bone Ceramic|Granules applied once during surgery
46041284|NCT03208036|Behavioral|Cognitive Remediation|Participants complete 60 minutes of computer-based cognitive training. All tasks are adaptable in terms of difficulty and require working memory skills. Sessions always begin with N-back and complex span tasks completed concurrent with tDCS or sham stimulation. Other tasks selected from Happy Neuron software and experimental working memory tasks are used throughout the protocol.
46041285|NCT03208036|Behavioral|Bridging Group|Participants complete 45 minutes of activities and discussion to practice engaging cognitive skills through performance of everyday activities and to learn strategies to use cognitive abilities most effectively. Curriculum generated from Action-based Cognitive Remediation and Compensatory Cognitive Training intervention manuals.
45840815|NCT00900822|Device|BioOss|Granules that are applied once during surgery
46041286|NCT04259307|Drug|Omapone Peri 724mL or Winuf Peri 654mL|Additional intravenous nutrition of 500 kcal per day for 3 weeks
46041287|NCT00926211|Device|ARTAS™ System|Hair harvest using a computer-assisted system
46041288|NCT00926211|Procedure|Manual Hair Harvest|Hair harvesting via the manual technique
46041289|NCT04310813|Diagnostic Test|Multimodal spectroscopic analysis|During time of bladder or prostate resection, freshly excised cold cup biopsies of both bladder cancer or healthy bladder mucosa were taken and sent for inspection through label-free multimodal fiber optic spectroscopy (MFOS) within 30 minutes
45344993|NCT00725868|Other|Data private hospitals, angioplasty, sampling of blood|"Data private hospitals : Age, sex, index of body mass, factors of cardiovascular risk, medical surgical histories, treatment before and after the angioplasty, the renal insufficiency~coronary angioplasty~Sampling of blood : Before the angioplasty, 6 hours after the angioplasty and 24 hours after the angioplasty. A numeration of the proparents circulants (hématopoietics, PEC) and a numeration of CEC are made"
46041290|NCT03188146|Drug|Ursodeoxycholic Acid|Standard care of PBC patients
45344994|NCT00868114|Biological|KLH-pulsed autologous dendritic cell vaccine|5 X10e7 KLH-pulsed autologous dendritic cell vaccine once weekly times three weeks
45344995|NCT00731354|Device|Suction-assisted Lipoplasty|Standard Suction-assisted lipoplasty will be performed on one side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
45344996|NCT00731354|Device|VASER-assisted lipoplasty|VASER-assisted lipoplasty will be performed on the opposite side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
45344997|NCT00725946|Drug|Iodine-124|
45684613|NCT01453816|Procedure|Harvesting and Isolation of Stem cells|Adipose-Derived Stem Cells (ASCs) will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the renal artery and intravenously.
45684614|NCT04273282|Drug|Dexycu intracameral dexamethasone|To evaluate the safety and ocular efficacy of Dexycu.
45344998|NCT00725946|Radiation|PET/CT with Iodine-124|
45344999|NCT02569346|Drug|Triumeq|Single-dose Triumeq as a whole tablet
45684615|NCT04273282|Drug|Prednisolone Acetate|To evaluate the safety and ocular efficacy, and patient acceptance of post cataract surgery drug treatment regimen that minimizes topical medications.
46041291|NCT00610233|Procedure|deep brain stimulation ON|deep brain stimulation in the ON state
46041292|NCT00610233|Procedure|Deep brain stimulation OFF|Urodynamic investigation with deep brain stimulation in the OFF state
46041293|NCT02880839|Device|Partial cervical lamina excision group|Patients with cervical fracture were assigned to undergo partial cervical lamina excision and cervical pedicle screw internal fixation.
46041294|NCT02880839|Device|Pipeline-dredge discharge group|Patients with cervical fracture were assigned to undergo pipeline-dredge discharge and cervical pedicle screw internal fixation.
46041295|NCT02880839|Device|Digital navigation group|Patients with cervical fracture were assigned to undergo digital navigation assisted cervical pedicle screw placement.
46041296|NCT02699320|Other|Complications|Not involved
46041297|NCT04259073|Drug|Pregabalin 150mg|two capsules, one is placebo, the other correspond to pregabalin 150 mg ingested orally one hour before cesarean section
46041298|NCT04259073|Drug|Placebos|two capsules filled with sugar ingested orally one hour before cesarean section
46041299|NCT04259073|Drug|Pregabalin 300mg|two capsules of pregabalin 150 mg ingested orally one hour before cesarean section
46041300|NCT04303793|Device|Percutaneous PDA closure|transcatheter patent ductus arteriosus closure
45345000|NCT02569346|Drug|Triumeq crushed + breakfast|Single-dose crushed and suspended tablet of Triumeq
46041301|NCT00609063|Drug|Atorvastatin|80-mg atorvastatin capsules taken daily for 6 months
46041302|NCT00609063|Drug|Placebo|Placebo capsules taken daily for 6 months
46041303|NCT02703064|Dietary Supplement|Furocyst|Furocyst caps BD
46041304|NCT01114373|Drug|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 24mg of time release melatonin pills (3 x 8mg) to be taken orally at night for 4 weeks.
46041305|NCT01114373|Drug|Placebo|Subjects will receive placebo pills (3 pills) to be taken orally once per night for 4 weeks.
46041306|NCT02699476|Behavioral|Psycho-Social Therapy|
46041307|NCT02699476|Device|Cognitive Behavioral Computer Training|
46041308|NCT02699476|Behavioral|Interactive Trainer-Subject Sessions|
46041309|NCT02699476|Device|Active Control Games|
46041310|NCT00925899|Drug|Melatonin|20 mg melatonin orally every evening about 1 hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of melatonin followed by one week of placebo, or the other way around), the participant may receive melatonin for 6 weeks.
46041311|NCT00925899|Drug|Placebo|Placebo tablet orally every evening about one hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of placebo followed by one week of melatonin, or the other way around), the participant may receive melatonin for 6 weeks.
45474891|NCT04520542|Other|Acupressure Application|Acupressure was administered in a semi-sitting or supine position where the woman felt comfortable and the researcher could perform the practice comfortably to the acupressure points. The application was performed on the determined acupressure points by considering the direction of the meridian in a certain order. It was performed with the administration order of Spleen 6th point (SP 6) and Large Intestine 4th point (Li 4). In total, the administration was performed with 4 acupressure points including 2 points in the upper/lower extremity along with the parallel points in each intervention.
45474892|NCT04444960|Procedure|percutaneous coronary intervention|Intracoronary physiology and imaging-guided intervention strategy versus angiography-guided intervention strategy for complex high-risk coronary heart disease patients
45474893|NCT03847896|Combination Product|Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose)|Budesonide/albuterol sulfate pressurized metered dose inhaler (BDA MDI) 160/180 micrograms (μg), given as 2 inhalations of BDA MDI 80/90 μg, four times a day (QID)
45684616|NCT04391530|Behavioral|emotional freedom technique, breathing therapy|emotional freedom technique, breathing therapy
45684617|NCT01453972|Behavioral|Long distanse moderate training|Moderate exercise
45345001|NCT02569346|Drug|Triumeq crushed + drip feed|Drip feed followed by single-dose crushed and suspended tablet of Triumeq
45345002|NCT04066842|Other|Observation|Evaluation of Vitamin D levels and correlation of Vitamin D levels level with periodontal and cardiovascular disease
45345003|NCT00731432|Drug|Transmucosal Herbal Periodontal Patch (THPP)|Patch applied to oral gingiva
45345004|NCT00731432|Drug|Placebo Patch|Identical in shape and texture to treatment patch
45684618|NCT01453972|Behavioral|Long interval training|High-intensity exercise, long duration
45345005|NCT00726102|Other|Meat|2 0z of locally available meat per day
45345006|NCT00726102|Other|Cereal|Daily provision of cereal to infants from 6-18 mos
45684619|NCT01453972|Behavioral|Short interval training|High intensity exercise, short duration
45345007|NCT00726102|Other|fortified rice cereal|Daily provision of fortified cereal to infants 6-18 months of age
45345008|NCT00731510|Dietary Supplement|Carbohydrate energy drink|Complex carbohydrates including maltodextrin (97%) dissolved in water to make a a 10% solution, or dissolved in 25mL gels. Ad libitum. Twenty two days.
45345009|NCT00731510|Dietary Supplement|Aspartame|Aspartame dissolved in water, ad libitum, 22 days.
45345010|NCT00726804|Drug|Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)|Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.
45345011|NCT00726908|Dietary Supplement|Low carbohydrate|43% CHO
45345012|NCT00726960|Drug|aprepitant|Oral, 125 mg once daily for one week
45345013|NCT00726960|Drug|Pseudo-placebo - buprenorphine|Randomized to receive either 8 mg sublingual tablets or 0.4 mg sublingual tablets
45345014|NCT00726128|Device|VueLock™ Anterior Cervical Plate|Implanted in subjects having an ACDF (Anterior cervical discectomy and fusion)
45474894|NCT03847896|Combination Product|Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose)|Budesonide/albuterol sulfate pressurized metered dose inhaler (BDA MDI) 80/180 micrograms (μg), given as 2 inhalations of BDA MDI 40/90 μg, four times a day (QID)
45684620|NCT01454206|Behavioral|iSBIRT|"Participants will be screened for substance use, view information about the health effects of substance use on the computer, and receive advice from the primary care provider regarding the health effects of substance use. Those found to be at high risk will complete an internet-based program encouraging them to change their substance use."
45684621|NCT01454440|Drug|Eptifibatide|Intravenous eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure) vs placebo.
45684622|NCT01454518|Procedure|Infiltration of local anesthetic|30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
45684623|NCT01454518|Procedure|Normal Saline Injection|injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
46041312|NCT02601586|Drug|PR Oxycodone|PR Oxycodone
46041313|NCT02601586|Drug|Levodopa|Levodopa
46041314|NCT02601586|Drug|Oxycodone Placebo|Placebo of PR Oxycodone
46041315|NCT02601586|Drug|Levodopa placebo|
46041316|NCT00609141|Biological|cixutumumab|Given IV
46041317|NCT00609141|Other|pharmacological study|Correlative studies
46041318|NCT00609141|Other|laboratory biomarker analysis|Correlative studies
46041319|NCT00615862|Other|Observational study; no interventions|Validated questionnaires will be administered. Blood samples will be analyzed for levels of immune markers as well as cortisol. This is an observational study and patients will not undergo any treatment as part of study participation. Patients will not receive medications or other interventions if they participate in the study. Blood samples analyzed are from samples remaining in the hospital laboratory that were collected as part of routine patient care and destined to be discarded.
45345015|NCT02570958|Drug|Indocyanine Green|In the operating room ENB will be used to locate the targeted lung tumor. Once the tumor is located, the surgeon will advance a bronchoscope to the tumor, a needle will be passed through the bronchoscope, and the tumor will be injected with 100-150 micro liters of ICG solution at 0.125mg/mL concentration. The tumor is expected to fluoresce using the da Vinci Firefly robotic camera, giving off a bright green hue. Wedge resection of the fluorescent part of the lung will then be performed. The excised specimen will be sent for immediate pathologist analysis. If the tumor is found within the specimen, and the specimen margins are free of tumor cells, then the procedure will be completed. If the tumor cannot be targeted or visualized, or if the tumor is not found in the pathological specimen, or if the margins of the specimen contain tumor cells, then a formal anatomical lobectomy or segmental resection of the lung will be performed to ensure that the tumor is completely excised.
45345016|NCT00731744|Procedure|Normal full-term deliveries|Normal full-term deliveries by standard procedures according to institutional guidelines
45345017|NCT02570412|Drug|aldoxorubicin|aldoxorubicin administered at 350 mg/m2
45684624|NCT01454674|Other|2, 5 & 10 Vegetable doses|2,5 & 10 serving dose/day combination of fresh lettuce mix, baby carrots, red bell peppers & tomatoes consumed for 3 week intervals
45345018|NCT00726206|Other|Electroencephalogram, recording the movements|Electroencephalogram, recording the movements of the child, RMI, Transfontanel Imaging
45684625|NCT01454986|Drug|ALXN1007|Single dose, IV
45684626|NCT01454986|Other|Placebo|Single dose, IV
45684627|NCT02983084|Device|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed appliance
45684628|NCT01455142|Drug|insulin degludec/insulin aspart|Single injection of each formulation. The dose level will be 0.5 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
45345019|NCT02202590|Device|SECM Capsule|Imaging of the esophagus using the SECM capsule and system
45345020|NCT00727038|Drug|Ranibizumab (Lucentis)|0.5 mg ranibizumab intravitreal injection single dose administration
45345021|NCT00727116|Behavioral|PA Abusive Head Trauma Prevention Program: State-wide|Upon the birth of the child in a Pennsylvania hospital, all parents (mothers, and whenever possible, fathers or father figures) will be asked to read written materials and view an 8-minute video on the dangers of violent infant shaking. Parent education materials contain four key messages: crying is a normal infant behavior, how to keep calm when an infant is crying, how to help calm a crying infant, how to select other caregivers for your infant. Parents will be asked to voluntarily sign a commitment statement affirming their receipt and understanding of the materials.
45345022|NCT00727116|Behavioral|PA Abusive Head Trauma Prevention Program Booster: Central PA|All primary care providers serving families of newborns in half of the counties in Central PA will be asked to provide all parents of newborns at the 2-, 4-, and 6-month immunization visits another set of written materials about violent infant shaking and voluntarily sign a response form that they read and understood the materials.
45345023|NCT04018586|Device|AVACEN 100|AVACEN 100 pulls a -30mmHg vacuum around hand from wrist down and applies heat (108 farenheit) to the palm and will be applied for 30 minutes
45345024|NCT04018586|Device|AVACEN 100 Heat Only|AVACEN 100 applies heat (108 Fahrenheit) to the palm and will be applied for 30 minutes
45345025|NCT04018586|Device|AVACEN Sham|AVACEN 100 neither heats nor pulls a vacuum to hand
45684629|NCT01455298|Other|Transient Elastography and fibrotest|a Transient Elastography and an ultrasound are performed.
45345026|NCT00726258|Drug|ketamine|ketamine with various concentrations
45345027|NCT00726258|Drug|placebo|physiological serum
45345028|NCT02950766|Drug|NeoVax|combination of Neoantigen peptides and poly-ICLC
45474895|NCT03847896|Drug|Budesonide metered dose inhaler / BD MDI 160 µg|Budesonide pressurized metered dose inhaler (BD MDI) 160 micrograms (μg), given as 2 inhalations of BD MDI 80 μg, four times a day (QID)
45684630|NCT01455376|Drug|hyperosmolar sodium lactate|Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
45684631|NCT01455532|Drug|Iniparib (SAR240550-BSI-201)|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
45684632|NCT01455532|Drug|Gemcitabine|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
45684633|NCT01455532|Drug|Carboplatin|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
45684634|NCT01455532|Drug|Placlitaxel|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
45684635|NCT01455532|Drug|Pegylated liposomal doxorubicin|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
46041320|NCT05330715|Other|Management|Comparison if different strategies to manage acute emergencies in the pre-hospital setting.
45345029|NCT02950766|Drug|Ipilimumab|local administration of ipilimumab
46041321|NCT02702830|Other|Cardiopulmonary Exercise Testing|Undergo CPET
46041322|NCT02702830|Device|Magnetic Resonance Imaging|Undergo MRI
46041323|NCT05208957|Other|No intervention|No intervention
46041324|NCT02702908|Other||Historical Reference group.
45345030|NCT00727142|Procedure|Surgical treatment|Insertion of a functioning shunt
45345031|NCT04793802|Other|PHYSIO|session of physiotherapy
45345032|NCT02569814|Drug|Fimasartan/Amlodipine/Rosuvastatin|
45345033|NCT02569814|Drug|Fimasartan/Amlodipine|
45345034|NCT02569814|Drug|Rosuvastatin|
45345035|NCT00726492|Other|Continuous short wave diathermy (CSWD)|CSWD applied twice a week for 4 weeks
45345036|NCT00726492|Other|Hydrotherapy|Hydrotherapy (exercise in water) attended twice a week for 4 weeks
45345037|NCT00726570|Device|Sequential compression device therapy|"Pneumatic stockings will be applied to patients.~Pressures ranging from 12 to 40 mmHg will be applied at different levels of the lower limb for 40-second cycles at 2-minute intervals. Therapy will continue until the morning after surgery."
45474896|NCT03847896|Drug|Albuterol sulfate metered dose inhaler / AS MDI 180 μg|Albuterol sulfate pressurized metered dose inhaler (AS MDI) 180 micrograms (μg), given as 2 inhalations of AS MDI 90 μg, four times a day (QID)
45474897|NCT03847896|Other|Placebo metered-dose inhaler / Placebo MDI|Placebo pressurized metered dose inhaler (Placebo MDI), given as 2 inhalations of Placebo MDI, four times a day (QID)
45474898|NCT01186289|Drug|atorvastatin|high dose atorvastatin therapy (80 mg/day) beginning 48 to 72-hours preoperatively and continuing until 6-weeks postoperatively
45345038|NCT00726570|Drug|Dalteparin|"2500 UI qd if ≤ 50 kg body weight~5000 UI qd if > 50 kg"
45345039|NCT00726570|Procedure|TEG|"A 2-ml blood sample will be used for each exam. A full analysis will be run both with and without heparinase at each time point.~TEG analyses will be run at:~Patient admission (before SCD start)~40-60 min after admission~Morning after surgery"
45345040|NCT00726726|Drug|Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)|Capsules + Tablets + Oral solution, Oral, Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg once daily, Day 1, 1 Day
45345041|NCT00726726|Drug|BMS-708163|Capsules, Oral, 150 mg, once daily, days 6-15, 10 Days
45345042|NCT00726726|Drug|BMS-708163 + Cooperstown Cocktail|Capsules + tablets + Oral solution, Oral, BMS-708163: 150 mg + Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg, BMS-708163, once daily, days 16-20 midazolam,warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan once daily on Day 16, 5 Days
45345043|NCT00731978|Procedure|Restricted intraoperative fluid management|Intraoperative fluid management guided by Sto2.
45345044|NCT00727350|Radiation|Fractionated stereotactic body radiation therapy|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
45345045|NCT00732056|Drug|GRN163L|25% dose escalation infused over 2 hours weekly
45345046|NCT00654381|Drug|BI 1356|5 mg/daily
45345047|NCT00654381|Drug|BI 1356|10 mg/daily
45345048|NCT00654381|Drug|voglibose placebo|three times daily
45474899|NCT04444648|Combination Product|No intervention|No intervention
45474900|NCT03670537|Diagnostic Test|Iron parameters|Serum iron, total iron binding capacity, TSAT (Fe/TIBC), serum ferritin
45474901|NCT03364504|Other|urine collection|3 urine collections during 24 hours
46041325|NCT00610389|Biological|immunotherapy with dendritic cells|We will administer four daily doses (repeated every 24 hours)o dendritic cells in two cycles one month apart. We will administer systemic treatment with PEG-IFN alfa and GM-CSF to potentiate activity.
45345049|NCT00654381|Drug|BI 1356 placebo|once daily
45345050|NCT00654381|Drug|voglibose|0.6 mg/daily
45345051|NCT00727428|Biological|FluLaval® TF|One IM injection.
45345052|NCT02089880|Device|C-brace|The participant will receive 6 sessions of training over a one month period in using the C-brace in all levels of functional gait. The participant will then continue use of the C-brace for one month following training. The C-Brace from Otto Bock is an orthosis that controls throughout stance and swing phases of gait with a micro-processor (MP) controlled knee.
45474902|NCT04509388|Other|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
45345053|NCT02089880|Device|Stance control orthosis|The participant will receive 6 sessions of training over a one month period in using his current stance control knee-ankle-foot orthosis (SCO) in all levels of functional gait. The participant will then continue use of the SCO for one month following training. The SCO controls the knee by maintaining it straight and extended during the stance phase of gait.
45345054|NCT00727584|Radiation|radiation therapy|Patients undergo external beam radiotherapy
45474903|NCT01291823|Drug|gefitinib|gefitinib 250mg/day
45345055|NCT04018482|Other|Povidone Iodine|FDA-approved disinfectant for intravitreal injections
45474904|NCT01291823|Radiation|Thoracic radiotherapy|Thoracic radiotherapy 54-60Gy over 30 fraction
45474905|NCT03354676|Other|MetS+|Data processing from Patient Medical Files
45474906|NCT03354676|Other|MetS-|Data processing from Patient Medical Files
45474907|NCT01181765|Biological|Infliximab 5 mg/kg body weight infused over 2 hours|Subjects will receive IV Infusion of infliximab 5 mg/kg body weight at Week 0, Week 2, Week 6, Week 14 and Week 22 as per the approved Canadian product monograph of infliximab.
45684636|NCT01455688|Drug|early HAART|Initiation of HAART within 5 days of ICU admission
45684637|NCT01455688|Drug|Late HAART|Initiation of HAART after ICU discharge
46041326|NCT01114217|Drug|Ferumoxytol|IV Ferumoxytol
46041327|NCT01030536|Drug|CAT-8015 20 mcg/kg|Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
45345056|NCT04018482|Other|Hypochlorous Acid|FDA-approved disinfectant for intravitreal injections
45345057|NCT00808041|Device|Dedicated breast computed tomography imaging|Pre- and post-contrast enhancement acquisition of breast CT images of tumor-containing breast every two months.
45345058|NCT00727454|Device|CPAP|Continuous Positive Airway Pressure (CPAP) during sleep for 3 months.
45345059|NCT00727454|Device|No treatment|No treatment
45474908|NCT04509310|Device|Active Bodysuits|The wear trial period will be 9-12 months for each subject depending on the active biofeedback training progress. The bodysuits should provide active biofeedback training to the users. By incorporating the IMU sensors, the body alignment in the sagittal or coronal planes can be detected to provide feedback to the users via a wireless platform. This training will be customized to each individual user and will achieve a uniform body alignment goal that benefits the user. The participants will be assessed using the Scoliosis Research Society questionnaire (SRS-22r), the Oswestry Disability Index (ODI) and health-related quality-of-life (HRQOL) measures.
45474909|NCT01186445|Drug|morphine chlorhydrate|1mg of morphine chlorhydrate dilute in 3ml of saline solution, intracoronary injection, just before reperfusion
45474910|NCT01186445|Drug|saline solution|3 ml of saline solution , intracoronary injection during reperfusion
45684638|NCT01455844|Drug|CaPre (TM)|CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.
45684639|NCT01455844|Other|Placebo|2.0g Placebo (Microcrystalline cellulose) daily for 12 weeks
45684640|NCT01455844|Drug|CaPre (TM)|CaPre™ 2.0g daily for 12 weeks
46041328|NCT01030536|Drug|CAT-8015 30 mcg/kg|Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
46041329|NCT01030536|Drug|CAT-8015 40 mcg/kg|Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
45474911|NCT03356938|Behavioral|Sleep restriction|Restricted sleep to 5 hours / night for 5 days prior to sleep laboratory examination
45474912|NCT03356938|Behavioral|Sleep deprivation|Sleep deprivation during first night of sleep laboratory examination
45684641|NCT01455922|Drug|ITCA 650|ITCA 650 is exenatide in DUROS
45684642|NCT01455922|Drug|glimepiride|glimepiride will be up-titrated to 8 mg/day over first 13 weeks
45345060|NCT00727662|Other|Iyengar Yoga|The poses and breathing techniques to be used in this study are based on sequences developed by B.K.S. Iyengar for breast cancer survivors who suffer from fatigue. Women will start with simple versions of the poses and progress to more advanced versions over the course of the intervention.
45345061|NCT00727662|Other|Wellness Seminar Series|The Wellness Seminar Series consists of lectures on key topics, followed by group discussion. This series will focus entirely on cancer survivorship, including sessions on quality of life, side effects of cancer treatment, stress, nutrition and psychosocial issues.
45684643|NCT01456156|Radiation|postoperative radiotherapy|IMRT or 3DCRT, 50-60Gy to the tumor bed
45684644|NCT04391140|Other|Prone position|HFNC set to a SpO2 of 90-95% combined with prone position. At least 2 sessions of 30 minutes or more will be performed daily.
46041330|NCT01030536|Drug|CAT-8015 50 mcg/kg|Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
46041331|NCT01030536|Drug|CAT-8015 60 mcg/kg|Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
46041332|NCT05330637|Other|Climate and environment in Sanya|Sanya have unique island climate and environment campared with the north of China, with a feature of warm, moist and long-sunshine.
45345062|NCT00805311|Procedure|Carotid Endarterectomy|CEA involves a neck incision and physical removal of the plaque from the inside of the artery
45345063|NCT00805311|Drug|atorvastatin, aspirin, losartan, amlodipine|aspirin 100 mg/day, atorvastatin 10 mg/day, losartan 50 mg/day, amlodipine 5 mg/day
45345064|NCT00726440|Device|Navigator®|Patients will be encouraged to use the Navigator® all the time and to modify their treatment according to the device measurments. Patients will also follow and educational process in order to adapt insulin doses according to each sensor data
45345065|NCT00726440|Device|Navigator®|Patients will follow the same educational process as group1 concerning insulin doses adaptation.The duration of the use of the devicewill be determined at the consultation every each 3 months.
45345066|NCT00726440|Device|Placebo|Patients will have their usual follow up with self-monitoring blood glucose
45345067|NCT04474314|Drug|IMR-687|Oral administration of once daily IMR-687
45345068|NCT04474314|Drug|Placebo|Oral administration of once daily Placebo
45474913|NCT03739333|Other|11C-Methionine PET-MRI|Implementation 11C-Methionine PET-MRI performed for each patient in one place (department of nuclear medicine of Hospices Civils de Lyon). The 11C-Methionine PET-MRI will be performed after radiochemotherapy in patients with MRI suspicious of pseudoprogression.
45684645|NCT01456234|Drug|Oseltamivir|Oseltamivir 75 mg BID
45684646|NCT01456312|Drug|Peginterferon alfa-2a|Duration and combination
45684647|NCT01456312|Drug|Entecavir|combination
45684648|NCT02542696|Drug|APL-130277|"Used to treat up to 5 OFF episodes per day"
45684649|NCT05587114|Diagnostic Test|frozen blood plasma samples|Analysis of various biomarkers using frozen blood samples
45840816|NCT00902226|Drug|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
46041333|NCT01030458|Drug|amlodipine 5/10 mg per day plus valsartan 160 mg/day|Amlodipine 5/10 mg/day plus valsartan 160 mg/day, once daily, in the morning
46041334|NCT01030458|Drug|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day, once daily, in the morning
46041335|NCT02692222|Other|Calculation of PPV and CO with two methods|
46041336|NCT02702674|Drug|propranolol|propranolol 20 mg given before induction of labor
46041337|NCT02702674|Drug|placebo|starch tablet containing no active drug material given before induction of labor
46041338|NCT02702674|Drug|Oxytocin|intravenous infusion of oxytocin
46041339|NCT00930969|Device|ICD|Subjects implanted with an ICD.
46041340|NCT02702752|Other|DYNASDY|Measurement of SDF-1 alpha levels i patients' blood samples.
46041341|NCT01114139|Drug|Ferumoxytol|IV Ferumoxytol
45345069|NCT00808119|Drug|RTI-336 (CTDP 31862)|The RTI-336 drug product is formulated as hard, white, gelatin capsules. The dosage levels are 0.3, 1.0, and 3.0 mg (Cohort 1) and 6.0, 12.0, and 20.0 mg (Cohort 2). Subjects will receive a single dose of the study drug on study day 1.
45345070|NCT00732290|Drug|Clopidogrel then fluoxetine+clopidogrel|D1 : clopidogrel (Plavix) 600mg (8 tablets) one time D45 to D48 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D49 : 20mg Fluoxetine + 600mg Clopidogrel
45345071|NCT00732290|Drug|Fluoxetine+clopidogrel then clopidogrel|D1 to D4 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D5: 20mg Fluoxetine + Clopidogrel (Plavix) 600mg (8 tablets) one time D49 : Clopidogrel 600mg one time
45840817|NCT00903162|Drug|leuprolide|Given intramuscularly beginning on day 1 and then either 7.5 mg every month or 22.5 mg every 3 months for two years
46041342|NCT01114139|Other|Placebo|IV Placebo
45345072|NCT02569788|Radiation|Carbon ion radiotherapy (CIRT)|Five dose levels (55GyE, 57.5GyE, 60GyE, 62.5GyE, 65GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 65 GyE are safely delivered, the recommended dose (or 65 GyE) will be the prescribed dose in the Phase II part of the study. Ninty-five percent (95%) of the isodose line should cover the GTV+3~5mm.
45684650|NCT01456468|Drug|Oral all-trans retinoic acid (ATRA)|"The subjects will continue to take their current dose of UDCA (15 mg/kg/day), as per ongoing clinical care, and need to be on a stable dose of UDCA for at least six months prior to enrollment.~The specific intervention is the addition of daily oral ATRA (45 mg/m^2) divided into 2 doses. To increase adherence to the dosing regimen, the drug will be compounded by the Research Pharmacies of Yale and Mayo into 2 formulations (30 mg and 40 mg capsules), and an Investigational New Drug (IND) permit was obtained for this process."
45684651|NCT01456546|Drug|Proguanil|2x350 mg Malarone followed by 3 days of blood- and urine sampling
45684652|NCT01456546|Drug|Clopidogrel|2x300 mg Plavix followed by 7 hours days of blood sampling
45684653|NCT01456624|Drug|Megace|800mg
45345073|NCT03906344|Drug|INCB052793|
46041343|NCT02699242|Device|Simulator (ORSIM) training|The simulator/intervention group will undergo training on the virtual reality bronchoscopic simulator (ORSIM) for 60 minutes before the subjects perform the 2nd Fiber optic intubation
45684654|NCT01456624|Drug|DW-ES(B)|625mg
45684655|NCT01456702|Procedure|risk stratification group|goal-directed volume therapy due to svv measurement or volume therapy via standard operated procedures in dependence of cardiac risk factores
45684656|NCT01456858|Other|Insecticide Treated Polyethylene Sheeting|Insecticide Treated Polyethylene Sheeting is based on the standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. During manufacture the pyrethroid insecticide, deltamethrin, is extruded with the polyethylene into three-ply laminated sheets, comprising an inner low-density laminate and two, outer high-density laminates. The insecticide release characteristics enable the deltamethrin to diffuse slowly to the outer surfaces and to become available for pick-up by any insect that lands on the surface.
45840818|NCT00903162|Drug|letrozole|Taken orally once a day 6-8 weeks after initial leuprolide administration
46041344|NCT01027884|Drug|Placebo|Placebo (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
46041345|NCT01027884|Drug|Idebenone|Idebenone (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
46041346|NCT02699164|Device|DRX 9000, Axiom Worldwide, Tampa, Florida|non-surgical spinal decompression therapy consist 18 traction cycles. Traction force applied herniation levels according to Magnetic Resonance Imaging (MRI).
46041347|NCT02699164|Other|physiotherapy|electrotherapy was used. electrotherapy consisted of 20 minutes of hot-pack, 20 minutes of TENS and 5 minutes of ultrasound.
45345074|NCT00730002|Procedure|Magnetic Resonance Angiography (MRA)|As part of the Magnetic Resonance(MR) scan, you will need to lie still on a padded MR table inside the MR machine for about 15 minutes at a time while MR studies are being performed on you. The total time for the clinical portion of the MR study is approximately 35-40 minutes and there will be an additional 30 minutes for the research related MR studies. The total time you will spend on the MR table for this research will seldom be more than one hour.
45345075|NCT00730002|Procedure|Magnetic resonance imaging|MR spectroscopy
46041348|NCT02699164|Other|spinal stabilization exercise|spinal stabilization exercises started elementary exercises. According to patient tolerance, exercise program reestablished.
45345076|NCT00730002|Procedure|MRA|MRA of the brain
45345077|NCT00730002|Procedure|MRA|
45345078|NCT00730002|Procedure|diffusion Imaging|MRA of the Brain
45345079|NCT00730002|Procedure|perfusion imaging.|MRA of the brain
45345080|NCT04460664|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
45345081|NCT02570334|Other|HIV-infected children initiated antiretroviral treatment within the first 7 months of life|All arms will recieve a thourough clinical evaluation : Global motor development (Touwen test), global cognitive development (K-ABC II test), visual (Log Mar Char) and hearing (full ear nose and throat examination) impediments as well as a questionnaire concerning socioeconomic situation, medical history of the child and mother, and HIV treatment and follow up information.
45345082|NCT00732446|Drug|Moxifloxacin and Dexamethasone combined|moxifloxacin 0,5% qid and dexamethasone 0,1% qid combined
45684657|NCT01456858|Other|Untreated Plastic Sheeting|Standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. Standard untreated plastic sheeting is Identical to ITPS but without the incorporation of insecticide.
45684658|NCT01457092|Device|FC Nitinol SEMS (Niti-S, TaeWoong Medical Co., Korea)|Placement of self-expandable metal stents
46041349|NCT02699008|Drug|Clopidogrel|Antiplatelet agent
46041350|NCT02699008|Drug|Ticagrelor|New P2Y12 receptor inhibitor antiplatelet agent
46041351|NCT00627666|Biological|anti-thymocyte globulin|
46041352|NCT00627666|Drug|busulfan|
46041353|NCT00627666|Drug|fludarabine phosphate|
46041354|NCT00627666|Drug|leucovorin calcium|
46041355|NCT00627666|Drug|methotrexate|
46041356|NCT00627666|Procedure|allogeneic bone marrow transplantation|
46041357|NCT00627666|Procedure|allogeneic hematopoietic stem cell transplantation|
46041358|NCT00627666|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
46041359|NCT03387514|Drug|PSMA-based 18F-DCFPyL PET tracer for PET/CT exams|"18F-DCFPyL whole body PET/CT scan administered at the following timepoints:~PET1 - Prior to scheduled nephrectomy~PET2 - to establish a new baseline PET before systemic therapy~PET2A - Post-surgery and prior to start of standard of care systemic therapy~PET2B - 12-16 weeks from start of first line systemic therapy (immune-based or anti-angiogenic)~PET3 - If first line systemic therapy did not include anti-angiogenesis therapy and new systemic therapy does include anti-angiogenesis therapy~PET3A - Prior to start of additional anti-angiogenesis therapy~PET3B - 12-16 weeks from the start of additional anti-angiogenesis therapy~PET4 - obtained at clinical progression or 2 years following initial systemic therapy"
45684659|NCT01457170|Drug|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
46041360|NCT01113749|Other|Feeding Options in Dementia Decision Aid|Structured decision aid on feeding options in dementia care with prompting to share information in discussion with primary treating health care provider.
46041361|NCT01022580|Drug|Infasurf surfactant (ONY, Inc.)|Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
46041362|NCT01022580|Drug|Sham (No Treatment)|Late doses of Sham (No treatment) will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
46041363|NCT02698930|Drug|dexmedetomidine|Randomly selected patients of the dexmedetomidine group are given intravenous 0.4mcg/kg/h of dexmedetomidine from the beginning of the anesthesia to postoperative 1 day.
46041364|NCT02698930|Drug|Normal saline|Group given intravenous 0.4mcg/kg/h of normal saline from the beginning of the anesthesia to postoperative 1 day.
45345083|NCT00732446|Drug|Moxifloxacin|moxifloxacin 0,5% qid and
45345084|NCT00732446|Drug|Dexamethasone|dexamethasone 0,1% qid
46041365|NCT02880683|Device|NeuroTronik CANS Therapy System|
46041366|NCT04215094|Diagnostic Test|postoperative fever, serum procalcitonin, C-reactive protein and white blood cell coun|All patients in Intracranial Infection group were cured with antibiotic treatment
46041367|NCT02698852|Device|BuMA Supreme|Stent platform: cobalt-chromium alloy
46041368|NCT00615082|Behavioral|Mindfulness-Based Stress Reduction|An 8-week course led by an experienced instructor in a group format of up to 15 people. Participants in the MBSR course learn mindfulness meditation techniques and simple yoga exercises such as stretching.
46041369|NCT00615082|Behavioral|Caregiver Education & Social Support|An 8-week course led by experienced instructors in a group format of up to 15 people. Participants in the CESS course learn about a variety of important issues related to elder care and receive social and emotional support in a group discussion format.
45345085|NCT04065672|Drug|Low-dose IL-2|One million units of rhIL-2 was administered subcutaneously five days every week for 4 weeks and then twice a week for 8 weeks. All patients were followed up for 3 months after treatment.
46041370|NCT01107353|Drug|Imipramine Pamoate|75 mg capsule
45345086|NCT00732524|Drug|Glipizide|Glipizide XL 10 mg once daily 30 mins before breakfast
45345087|NCT00732524|Drug|Glipizide and Glargine|Glipizide XL 10 mg daily 30 minutes before breakfast Insulin Glargine 10 units subcutaneously at bedtime daily
45345088|NCT00657267|Drug|Temozolomide|Taken orally daily for the first three weeks of a four-week cycle.
45684660|NCT01457170|Drug|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
46041371|NCT02702206|Drug|corticosteroids|under US guidance, 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
46041372|NCT02702206|Drug|hyaluronic acid|under US guidance, 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine
46041373|NCT02702206|Drug|normal saline|under US guidance, 2.5ml normal saline (placebo group). 0.5ml distilled water and 1ml 1% lidocaine
46041374|NCT01107197|Dietary Supplement|Enriched nutrition formula|oral formula enriched in arginine, zinc and antioxidant oligoelements
46041375|NCT01107197|Dietary Supplement|Control formula|Isonitrogenous isocaloric oral formula
46041376|NCT04216186|Drug|Atomoxetine|Atomoxetine once daily
46041377|NCT04216186|Drug|Coenzyme Q|Coenzyme Q once daily
46041378|NCT02702440|Other|Liquid calories from sugars|
46041379|NCT02881697|Other|Adipose tissue sampling|
45345092|NCT00733850|Drug|Kanglaite Injection plus gemcitabine|Intravenous repeating dose
45345093|NCT00733850|Drug|Gemcitabine|Intravenous repeating dose
45684661|NCT01457170|Drug|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
45345094|NCT00727818|Device|guided bone regeneration|
45345095|NCT04016961|Other|AAT - Dog|therapy dog added to inpatient PT and OT session
45345096|NCT04016961|Other|TAU - No Dog|PT and OT as usual without the addition of therapy dog
45345097|NCT03146442|Behavioral|Breakfast|For 6 months, the participants will either skip breakfast or will habitually consume a NP or HP breakfast every day.
45345098|NCT00732602|Other|GIP-infusion|
45345099|NCT00732602|Other|Sodium-chloride|
45345100|NCT00732602|Other|GLP-2 infusion|
45345101|NCT00808197|Procedure|ocular blood flow measurement|Ocular blood flow will be determined by non-invasive methods, including laser Doppler flowmetry and laser interferometry
45345102|NCT00727896|Behavioral|Pre-coded messages|Earlier life style modification and existing drug therapy was used and now SMS is added as a tool for reminder
45345103|NCT00727896|Drug|Diabetes Treatment|Life style modification and drug therapy
45345104|NCT00727766|Drug|Clofarabine|
46041380|NCT02698540|Other|Nutritional Supplement|High calorie, high protein peptide based
46041381|NCT02698696|Other|ECo program|
46041382|NCT02698696|Other|CRT program|
46041383|NCT02698696|Other|Supportive psychotherapy|
46041384|NCT01989598|Other|Laboratory Biomarker Analysis|Correlative studies
46041385|NCT01989598|Other|Pharmacological Study|Correlative studies
46041386|NCT01989598|Drug|Trametinib|Given PO
46041387|NCT01989598|Drug|Uprosertib|Given PO
46041388|NCT04214938|Other|Intranasal solutions application were done including one solution for per patient before nasoendoscopy procedure according to randomization|Hypertonic sea water, Vemcaine, Otrivine, and a placebo were applied by intranasal before the nasoendoscopy procedure for improving the field of view of clinician and reducing the patient discomfort.
46041389|NCT02702050|Other|Mechanical stimulation (LPG system; Cellu M6 Integral I)|For the mechanical stimulation group, an additional ten-minute mechanical stimulation will be provided in each of the twelve sessions of convention treatment program. The device produced skin lift through suction via a treatment head with 2 rollers installed. It was a non-invasive technique which aimed to mobilize soft tissues by creating skin folds and stretching the underlying soft tissues while manipulating the treatment head according to protocol.
45345105|NCT00799071|Drug|posaconazole (PSZ)|Intake of PSZ oral suspension 40mg/ml twice daily with food. Starting dose is based on bodyweight. The dosage will be adjusted if the exposure is not adequate based on PSZ trough level on Day 10 and 20.
45345106|NCT00730080|Drug|Sapropterin (Kuvan)|20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
45345107|NCT02569268|Other|Questionnaires and follow-up|Detecting the vascular functional parameters, questionnaire and follow-up: For 2 years or the occurrence of vascular events end time, including cardiovascular events (acute myocardial infarction, angina, coronary reperfusion therapy), stroke, heart failure, peripheral vascular disease.
45345108|NCT04066920|Drug|IBER salvage chemotherapy followed by ibrutinib maintenance therapy|Induction therapy with IBER (up to 6 cycles) [ Ibrutinib 560 mg/d on D1-21 + Rituximab 375 mg/m2 on D1 (on D1/8/15 in C1) + Ifosfamide 3.75 g/m2 on D2 + Etoposide 100 mg/m2 on D2-4 ], followed by ibrutinib 560 mg/d maintenance therapy for up to 6 months
45345109|NCT00732836|Drug|HAI Abraxane|Escalating doses (beginning dose 180 mg/m^2) starting Day 1, Cycle 2 and later via hepatic arterial infusion (HAI) following IV Abraxane in Day 1, Cycle 1 for 21 day cycles.
45345110|NCT00732836|Procedure|Hepatic Artery Catheter|On each day of treatment for Cycles 2-4, hepatic artery catheter placement completed by interventional radiology.
45345111|NCT00732836|Drug|IV Abraxane|Intravenous (IV) Abraxane only in Cycle 1 (up to Dose Level 4 of 260 mg/m^2), infused over 60 minutes or 4 hours Day 1 of 21 day cycle.
46041390|NCT02702050|Other|Conventional treatment|Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises, within a 6-week period (i.e., two sessions per week)
45345112|NCT00799149|Drug|Gabapentin, Etoricoxib, Sugar pill|Control (Sugar pill) or gabapentin (1200 mg) or etoricoxib (120 mg) administered 30-90 min before the patient entered the operating room with a sip of water. Subsequent doses of the oral study drugs were administered on the mornings (08H00) of the first, second, and third postoperative days. .
45345113|NCT00733928|Device|PFC Sigma knee with all-poly tibial component|Orthopaedic implant for total knee replacement with an all-polyethylene tibial component
45345114|NCT00733928|Device|PFC Sigma knee with metal backed tibia|Orthopaedic implant for total knee replacement with a metal-backed tibial component
45345115|NCT00805623|Dietary Supplement|sucrose|1 cc of sucrose 33.5% with or without pacifier
45345116|NCT04280172|Other|Cultural Competence Education|Cultural competence education for participants in the intervention group comprises of completion of an online learning module and participation in an eight-hour training day. The educational content includes various topics related to cultural and linguistic diversity and cultural competence in mentoring.
45345117|NCT04280172|Other|Standard Mentoring Education|Participants in the control group will not receive the educational intervention but will participate in standard mentoring education. This education is offered in an online learning environment and participants can complete the education at their own pace. The educational content focuses on general issues related to mentoring and does not contain topics specific to cultural competence in mentoring.
45345118|NCT00732914|Drug|Sunitinib (Sutent)|Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity), followed by sorafenib 400 mg BID
45345119|NCT00732914|Drug|Sorafenib (Nexavar)|Sorafenib 400 mg BID, followed by Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity)
45345120|NCT00728052|Drug|GSK598809|GSK598809 capsules will be available with dose strengths of 5 milligrams and 25 milligrams, administered orally with water.
45345121|NCT00728052|Drug|Placebo|Placebo capsules will be administered orally with water.
45345122|NCT00808275|Dietary Supplement|Dietary calcium|Dairy and non-dairy calcium provided as a part of diet in the amounts of 500 mg/day and 1500 mg/day. Diet contained 70% of daily caloric requirements.
45345123|NCT00727922|Drug|Mangafodipir|Mangafodipir (0.5 ml/kg) is administered as a 30 minutes infusion just after each administration of oxaliplatin. The oxaliplatin dose (85 to 100 mg/m²) and the length of the infusion (2 hours) are the same that before the inclusion and modifications are not authorized during all the study participation. During 4 months (8 administrations).
45345124|NCT00809289|Drug|esreboxetine|Once daily administration of 4mg esreboxetine for 3 days, followed by 8mg esreboxetine for 3 days, followed by 10mg esreboxetine for 3 days. Drug will be administered double-blind.
45345125|NCT00809289|Drug|placebo|Once daily administration of placebo for 9 days. Placebo will be administered double blind
45684662|NCT01457170|Drug|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
46041391|NCT00615160|Drug|PTK787/ZK 222584|PTK-ZK capsules taken orally with a daily flat dose of 1250 mg
46041392|NCT00615160|Drug|Dacarbazine|Dacarbazine 850 mg/m² on day 1 q4w
46041393|NCT02702362|Device|transcranial direct current stimulation|anodal transcranial direct current stimulation on the precuneus cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session.
46041394|NCT02702284|Behavioral|Advance Directives|These subject's will have a research assistant (RA) review and walk through the advance directives brochure. The RA will read all of the brochure to the patient and prompt for questions. In addition, a link to an educational video on advance directives. The advance directive link will be either texted or emailed or given in paper per the subject's preference.
45345126|NCT00809289|Drug|moxifloxacin|Once daily administration of placebo for 8 days followed by open label single oral dose of 400mg moxifloxacin on day 9
46041395|NCT02702284|Behavioral|Advance Directives without assistance|This group of subjects will be provided with the advance directive and then referred to clinic staff for assistance.
46041396|NCT01112579|Device|Medtronic PrimeADVANCED Neurostimulator|Heart failure therapy
46041397|NCT01112579|Device|Medtronic PrimeADVANCED Neurostimulator|Medical management
46041398|NCT04215484|Diagnostic Test|serum BNP assessment|serum BNP assessment in pregnant women with placenta previa, associated or not to a suspected abnormal placental invasion, compared to a control group
46041399|NCT02698618|Procedure|Diagnostic|"Pre-PCI and treatment:~At hospital admission: all consecutive patients referred for coronary angiography in stable ischemic heart disease will undergo a complete physical examination, Electrocardiogram (ECG) and laboratory blood testing including cardiac troponin and kinase mioband. Subjects will be investigated to confirm or diagnose existing diabetic or pre-diabetic status.~At the time of diagnostic catheterization After informed consent, diabetic or pre-diabetic patients with at least one stenosis with a Fractional Flow Reserve value (FFR) ≤ 0.80 fulfilling all the inclusion/exclusion criteria will be included in the trial.At the same time, a multimodal physiology assessment, including Coronary Flow Reserve (CFR) and Index of Microcirculatory Resistance (IMR) will be measured."
46041400|NCT02698618|Drug|Randomization|Randomization: patients will be randomly assigned (with 1:1 ratio) to receive either Clopidogrel or Ticagrelor before their clinically-indicated Percutaneous Coronary Intervention (PCI). Either a loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours) or a loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg will be administered according to their randomization. Additionally the groups will be balanced according to obesity prevalence [Body Mass Index (BMI) ≥30 kg/m2] with the implementation of a dedicated randomization list.
46041401|NCT02698618|Procedure|PCI|"Pre-PCI: multimodal physiological evaluation: FFR, CFR, IMR will be repeated~PCI: For all the patients undergoing PCI, the use of unfractioned heparin (UHF) will be allowed at the time of PCI; UFH be administered with a target on Activated Clotting Time (ACT) of 200-250 s. The PCI procedures will be performed by standard technique using only second generation Drug Eluting Stents (DES). In all cases, balloon pre-dilatation will be performed before stent implantation using a semi-compliant balloon with a diameter lower than a 75% of the distal reference diameter of the vessel to avoid confounders Post-dilation will be performed according to clinical practice although it will be not mandatory.~Post-PCI: After stent implantation/s, multimodal physiological evaluation will be re-performed (FFR, CFR, IMR)."
45345127|NCT02570256|Behavioral|Deficit-fields to reduce error|Stroke survivors exhibit error in both reaching extent and abnormal curvatures of motion. Prior error augmentation techniques multiply error by a constant at each instant during movement. However, magnification of spurious errors may provoke over-compensation. We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
45345128|NCT02570256|Behavioral|Deficit-fields to expand range of motion|Motor deficits manifest in the workspace limitations of joints, i.e. reduced range of motion, uneven extension-flexion, inter-joint coupling, and unwanted synergies. Our work builds upon these ideas by augmenting self-directed movement for training coordination. We found that amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
45345129|NCT02570256|Behavioral|Deficit-fields to improve function|Clinicians have recognized the benefits of training on everyday tasks (Hubbard, Parsons et al. 2009), as well as practice with whole-body actions (Boehme 1988; Bohannon 1995). However, typical robotic systems have only a single contact point and cannot drive the multiple joints involved in functional tasks. Visual distortions (e.g. a shift, rotation or stretch) can promote adaptation even without forces. Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
45684663|NCT01457404|Behavioral|Integrated Cognitive Behavioral Therapy|Individual or group ICBT, approx. 12 sessions, one session per week
45684664|NCT01457404|Behavioral|Treatment-as-usual|Individual or group therapy as usual within the SATP or PTSD clinics at the PVAMC
45840819|NCT00903162|Drug|zoledronic acid|If desired, given intravenously every 6 months for a total of 4 injections (optional)
45345130|NCT02569034|Other|Functional Magnetic Resonance Imaging|"Both groups will have the fMRI performed once. The fMRI will be use to to dissociate activity associated with both reward wanting and reward liking using the EEfRT. Learning more about the brain basis of components of anhedonia in both young and older adults is important in the context of previous research showing that risk-taking behavior and reward sensitivity changes with age, enhancing the knowledge of anhedonia."
46041402|NCT02698462|Other|Family history questionnaire|All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT (cut-off value 275 ng/ml) and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
45345131|NCT02569034|Other|Effort-Expenditure for Rewards Task|"Both groups with have the EEfRT performed once. The EEfRT is an effort-based decision-making task that measures reward wanting, in contrast to commonly used anhedonia questionnaires, which focus on reward liking. This novel task may provide a useful measure of components of anhedonia in older adults and in different patient populations."
45345132|NCT05623722|Procedure|Erector spinae plane block|Ultrasound-guided erector spinae plane block is performed at thoracic (T) level 8. An 18F catheter is placed on both sides of the thoracic vertebra deep into the erector spinae, and a bolus of 20 ml of 0.375% ropivacaine is administered bilaterally. Then, a continuous infusion of 20 ml of 0.375% ropivacaine on each side is followed at a rate of 2 ml/h every 12 hours. The intervention ends on day 7 or ceases when the patient is discharged from the ICU, died, or withdrew their consent.
45345133|NCT02552667|Drug|HCP1102+HGP0711Placebo|Coadministration of HCP1102 with HGP0711 Placebo for 4-week
45345134|NCT02552667|Drug|HCP1102Placebo+HGP0711|Coadministration of HCP1102 Placebo with HGP0711 for 4-week
45684665|NCT01457482|Other|Art Therapy and therapeutic conversations|Treatment consists of five sessions of Art Therapy given by an authorised Art Therapist and therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
45684666|NCT01457482|Other|Therapeutic conversations|Therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
45684667|NCT01457560|Biological|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
46041403|NCT02698150|Device|HERMES tablet|Tablet, sensors and wearables for daily collection of clinical data
45345135|NCT00728000|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV on day 1 and day 15 over 30mins.
45345136|NCT00728000|Drug|Oxaliplatin|100mg/m2 IV on days 1 and 15 given over 120 mins.
45345137|NCT00728000|Drug|Erlotinib|100mg/day PO on days 1-14 and 15-28
46041404|NCT01112267|Drug|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 tablet containing 75 mg of tramadol HCl and 650 mg of acetaminophen, once daily on Days 1to 3, then 1 tablet twice daily on Days 4 to 7
45345138|NCT04066530|Drug|AD-203|AD-203 administered two times daily for two weeks
45345139|NCT04066530|Drug|Mucosta tab.|Mucosta tab. administered three times daily for two weeks
45345140|NCT00808431|Behavioral|Lifestyle counseling|3 month skills building program emphasizing parent training, behavior modification training, nutrition education, and physical activity promotion
45345141|NCT02569190|Device|Walkbot|Robot assisted gait training
45345142|NCT04235556|Behavioral|Care pathway unit|Patients from the prospective cohort will have their health care scheduled by the care pathway unit.
45345143|NCT00809367|Other|Collection of Leukemia Cells|Collection of leukemia cells either by 1) routine blood draw 2) bone marrow aspirate or 3) leukopheresis
45345144|NCT00728208|Drug|GSK372475|1.5mg for 28 days
45345145|NCT02552433|Dietary Supplement|protein intake assessment and optimisation|
45345146|NCT00733070|Device|CiTop™ ExPander™ Guidewire|Chronic Total Occlusion guidewire
45684668|NCT01457560|Biological|OPV|One dose administered orally
46041405|NCT01112267|Drug|Placebo|Participants will receive 1 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 4 to 7
46041406|NCT01112267|Drug|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 or 2 tablets containing 75 mg of tramadol HCl and 650 mg of acetaminophen, twice daily on Days 8 to 28
46041407|NCT01112267|Drug|Placebo|Prticipants will receive 1 or 2 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 8 to 28
45345147|NCT02905422|Behavioral|H.E.A.L.T.H. II Intervention|12 month study with 6 month intervention phase and 6 month follow up phase. Participants will receive bi-weekly educational information pertaining to weight loss during the intervention phase. Participants will use online website to monitor weight, access meal plans, access weight loss information, and access fitness plans.
45684669|NCT04758442|Other|Additional blood sample|Included subjects will provided three blood samples to follow vancomycin concentration
45684670|NCT01457638|Procedure|Inferior turbinate surgery|During rhinoseptoplasty inferior turbinate submucosal cauterization is performed.
46041408|NCT04216030|Other|High Fe IP meal labelled with Fe-58|500 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days
46041409|NCT04216030|Other|Control OFSP meal labelled with Fe-57|500 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days
46041410|NCT00616096|Procedure|immunoadsorption|"First cycle: week 1, day 1-5~Second cycle: week 5, day 1-5"
46041411|NCT00925587|Drug|darbepoetin alfa|Drug administered either Q2W or QM using a prefilled syringe. Allowable doses of: 10, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200, 300, 400 or 600 mcg.
46041412|NCT02698306|Drug|Dexamethasone|Dexamethasone
46041413|NCT02698306|Drug|Diclofenac Sodium|Diclofenac Sodium
45345148|NCT04065620|Diagnostic Test|ambulatory blood pressure measurement|24-hour ABPM will be made using validated devices, following ABPM device should be programmed to take measurements every 30 minutes . Patients will be instructed in their use. Periods of activity and rest will be pre-determined in short windows: for Asian and European Countries daytime period will be defined between 10:00 and 8:00 pm; and night-time period between 00:00 am and 6:00 am. For Latin American Countries daytime period will be defined between 08:00 and 06:00 pm; and night-time period between 00:00 am and 6:00 am. For Africa daytime period will be defined between 08:00 and 06:00 pm; and night-time period between 11 PM and 5 AM In addition, the duration of ABPM (hours), the percentage of valid readings, and the mean SBP/DBP values during periods of activity, rest and in 24 hours will be recorded. Records with a duration <24 hours, those without one good reading per hour and those with <70% of satisfactory readings will be excluded
45345149|NCT00730314|Procedure|Hematopoietic stem cell transplantation|hematopoietic stem cell transplantation conditioning regimen depending on graft source
45345150|NCT02553993|Device|Wii Fit(30 Mins)|Receive Wi Fit games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
45345151|NCT02553993|Device|Tetrax biofeedback(30 Mins)|Receive Tetrax biofeedback games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
45345152|NCT02553993|Other|Conventional weight-shifting(30 Mins)|Receive weight-shifting exercise training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
45345153|NCT04065230|Drug|Tenofovir Alafenamide Fumarate tablets|Eligible hepatitis B pregnant women are given TAF antiviral therapy (25mg, oral, 1/day) at 24-28 weeks of gestation until one month after delivery.
45345154|NCT00728078|Drug|thalidomide|thalidomide 50mg tid for 6 months
45684671|NCT01457638|Procedure|No iInferior turbinate surgery|During rhinoseptoplasty no intervention is done in inferior turbinates
45684672|NCT01457716|Drug|Budesonide|Single inhalation
45684673|NCT01457716|Drug|Formoterol|Single inhalation
46041414|NCT02698228|Drug|Bupivacaine (femoral nerve block)|0.5% bupivacaine
46041415|NCT02698228|Drug|Morphine|Intravenous injection of 0.1mg/kg of morphine
46041416|NCT02698228|Device|Ultrasound|
45684674|NCT01457716|Device|Easyhaler|Inhaler device
46041417|NCT02698072|Other|Therapeutic exercise|20-25 minutes aerobic exercise, 20-25 minutes strength exercise and 10-15 minutes stretch exercise.
46041418|NCT02698072|Device|Dry needling|Dry needling needle AGUPUNT®
46041419|NCT02698072|Device|Sham dry needling|Sham dry needling DONGBANG-ACUPRIME®
45345155|NCT00653991|Behavioral|SOLVE-IT|SOLVE-IT, a video game using computer-generated virtual agents, is the next generation of interactive media aimed at reducing risky sex among young MSM. Participants will interact in a virtual environment that focuses upon HIV prevention in a dating context.
45345156|NCT04786106|Drug|Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH)|Men in this cohort would receive the full series of 8 Xiaflex injections: 2 injections separated by 1-3 days, repeated 3 additional times with 6 week breaks between treatments.
45345157|NCT04786106|Procedure|Penile Plication Surgery|Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures <70 degrees; I&G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I&G) will ultimately be decided based on the primary investigator's clinical judgment.
45345158|NCT04786106|Procedure|Incision and Grafting (I&G) Surgery|Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures <70 degrees; I&G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I&G) will ultimately be decided based on the primary investigator's clinical judgment.
45345159|NCT04786106|Device|RestoreX Penile Traction Device|RestoreX is a Class I PTT device developed by PathRight Medical, is registered with the FDA, and has randomized controlled data demonstrating efficacy when used for the treatment of PD.
45345160|NCT02561988|Drug|Avapritinib|
45345161|NCT04066088|Other|Placebo|Placebo will be administered same times as GXR
45345162|NCT04066088|Drug|Guanfacine extended release (GXR)|The starting dose for all subjects will be 1 mg per day. If the medication is well-tolerated, the dose can be raised to 2 mg until day 28 and increased to 3mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed; the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8, the study will be unblinded and subjects will continue treatment for 8 more weeks.
45345163|NCT00799461|Other|internet-based intervention|Delayed access to online educational information and resources for managing long term complications of hematopoietic cell transplantation
45345164|NCT00799461|Other|questionnaire administration|Completion of questions in an online format
45345165|NCT00799461|Procedure|psychosocial assessment and care|Assessment and care of psychosocial aspects
45684675|NCT01457716|Device|Turbohaler Forte|Inhaler device
45684676|NCT01457872|Behavioral|Strength-based case management|Strength-based case management
45345166|NCT00799461|Procedure|assessment of therapy complications|Evaluation of complications of treatment
45345167|NCT00799461|Procedure|management of therapy complications|Managing therapy complications
45345168|NCT00799461|Procedure|fatigue assessment and management|Assessing and managing fatigue
45345169|NCT00799461|Other|counseling intervention|Counseling provided via telephone
45684677|NCT01457872|Behavioral|Control condition - referral only|Referral only
45684678|NCT04391218|Other|Multidisciplinary Approach Group|Geriatricians will introduce medication review data on a Clinical Decision Support System, that will help both pharmacists and physicians in medication reconciliation, highligting potentially inappropriate prescriptions according to Beers' criteria and STOPP/START criteria, and potential controindicated and major Drug-Drug Interactions according to Micromedex. Before Hospital at Home discharge, nurses will instruct patients and/or caregivers to the use of an App, where daily drug therapy at discharge will be inserted and scheduled. This App will automatically create an alert everytime a drug dose needs to be taken, alongside an image of the specific drug packaging. The App will register if and when the patient actually takes the drug, or the reason for the delayed/missed dose.
46041420|NCT00616174|Procedure|Active warming with Bair Hugger blanket|Standard care at BC Women's Hospital plus a Bair Hugger full access underbody blanket model 635 (Health Canada Licence # 12692) warmed by Bair Hugger temperature management unit model 750. Patient will lie on the underbody blanket and it will be turned on once patient is supine on operating table following the insertion of anesthetic. The warming device will be set to the medium temperature setting (380C). Warming will continue until the end of surgery unless otherwise requested by the mother.
46041421|NCT02702128|Drug|Tranexamic Acid|1g of tranexamic acid on 1 hour and 1g of tranexamic acid on 8 hours
45684679|NCT04391296|Procedure|Arm I (Prepectoral), Arm II (Subpectoral)|"Arm I (Prepectoral)De-epithelialized skin flaps are made from the inferior pole of breast skin and soft tissue. The implant pocket is shaped by fixing a sufficiently large amount of ADM to the medial surface of the mastectomy pocket, the upper edge of the pectoralis major muscle and the de-epithelial skin flap. The implant is located in the prepectoral mastectomy pocket and the ADM anchored to the chest wall, serratus fascia, and de-epithelial skin flaps. The pectoralis major muscle is located in the anatomical location behind the ADM.~Arm II (Subpectoral)The pectoralis major muscle is dissected from the thorax to create sufficient space for the implant to be placed behind the pectoralis major muscle. Implant pockets are made by suturing the lower part of the elevated pectoralis major muscle to the top of the de-epithelial skin flap and the ADM patch to the skin flap, the pectoralis major muscle, and the lateral thoracic fascia."
45684680|NCT04346602|Other|all treatment about COVID-2019|All patients with COVID-2019 would receive treatment provided by the government and should comply with relevant laws and regulations.
46041422|NCT02702128|Drug|saline solution|30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
46041423|NCT05194683|Behavioral|Relational Letter Writing|The intervention consists of two interviews and a between-session writing task. In the first session, couples will be interviewed regarding their relationship story and preferences. Between the two sessions, each couple member will write a letter from their relationship point of view. In the second interview, the task is reviewed and paths for relationship improvement are outlined.
46041424|NCT00610545|Drug|Atorvastatin|Atorvastatin 80 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
46041425|NCT00610545|Drug|Atorvastatin|Atorvastatin 20 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
46041426|NCT00193414|Drug|Pemetrexed|500mg/m2 IV over 10 min, Day 1, prior to gemcitabine
46041427|NCT00193414|Drug|Gemcitabine|1500mg/m2, 30min IV
46041428|NCT05330559|Other|Fluid MAX group|to evaluate and compare with the histopathological analysis the various margin-assessment systems, including ultrasound, florescence, brightfield vision, new optical filters and microscope image post-processing systems, for the treatment of High Grade Gliomas (HGGs)
45345170|NCT02570178|Other|balance training|Participants complete 2 sessions per week for 30 minutes each, over a period of three months and are distributed in groups of four individuals carrying out the exercises at once.The groups were led by monitors who had received standardized training. Each participant was barefoot on the balance board, carrying out the different exercises in the balance area of the Wii Fit™ game, according to the indications made on the screen.Eight out of the nine balance exercises were used from the Wii Fit™ game (balance bubble, soccer heading, ski jump, table tilt, ski slalom, penguin slide, snowboard slalom, tightrope walk);.The number of repetitions of each exercise varied depending on the skill of the participants but the total time dedicated to each exercise was the same for all group participants.
45345171|NCT00733148|Drug|dosing of insulin|Dosing od insulin is calculated by a computer based algorithm
45684681|NCT01458028|Drug|BAY85-3934|Single doses of 20 mg BAY85-3934 as tablet
46041429|NCT04970511|Behavioral|BBAT (Basic Body Awareness Therapy)|The group I: BBAT Face-to-Face Training (60 min) will be provided.
46041430|NCT04970511|Behavioral|Online BBAT training|The group II: Online BBAT training (60 min) will be provided.
46041431|NCT02701972|Device|BACE Device|Implanted BACE device
46041432|NCT02701816|Device|innova stent (Boston scientific)|
46041433|NCT04260711|Drug|DMT|Discontinuation of patients' own disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)
46041434|NCT00610623|Drug|azithromycin|300 mg/day, IV from day 1 to 20
46041435|NCT00610623|Drug|placebo|once per day, IV from day 1 to 20
46041436|NCT02701660|Device|electronic medication dispenser (medido)|Automated dispense of medication through an electronic dispenser
46041437|NCT04214782|Diagnostic Test|Artificial Intelligence Enabled Transvaginal Ultrasound Imaging algorithm|AI Enabled Transvaginal Ultrasound diagnosis for ovarian cancer
45345172|NCT00730392|Drug|Etanercept|The study drug was provided in lyophilized 10 mg vials to be reconstituted with 1 ml of diluent/vial and was administered at a dose of 0.4 mg/Kg up to maximum dose of 25 mg/dose SC twice weekly
45345173|NCT00730392|Drug|Placebo|administered at 0.4 mg/Kg/dose SC up to 25 mg max twice weekly
45345174|NCT00809601|Device|Insertion of a specific type of ventilation tube through the tympanic membrane|"The ventilation tubes are tested using one type in one ear and another type as an active comparator in the other ear.~The investigators will test in total 4 different kinds of tubes. Four different combinations of tubes will be tested.~The first combination will test:~Shepard tube (double flanged, Fluoroplastic) vs Donaldson tube (double flanged, silicone)~The second combination will test:~Straight tube (single flanged, Fluoroplastic) vs Armstrong (single flanged, silicone)~The third combination will test:~Armstrong (single flanged, silicone) vs Donaldson tube (double flanged, silicone)~The fourth combination will test:~Straight tube (single flanged, Fluoroplastic) vs Shepard tube (double flanged, Fluoroplastic)"
45345175|NCT00730470|Drug|U3-1287 (AMG888)|IV Infusion Dose Escalation (Part 1) - 5 Dose Cohorts Dose Expansion (Part 2) - 30 patients
45345176|NCT00734084|Device|Preservation Unicompartmental Knee|Minimally invasive orthopaedic implant for single compartment knee arthritis
45345177|NCT01528046|Drug|Vincristine|Vincristine (VCR) = 1.5 mg/m^2/day (maximum dose 2 mg), days 1 and 8, administered as intravenous (IV) bolus over 1-5 minutes
45345178|NCT01528046|Drug|Irinotecan|Irinotecan (IRN) = 50 mg/m^2/day, days 1-5, IV over 60 minutes
45345179|NCT01528046|Drug|Temozolomide|Temozolomide (TEM) = 50 mg/m^2/day by mouth (PO) Days 1-5
45345180|NCT01528046|Drug|Metformin|Metformin (MET) = dose as per dose escalation, divided twice a day (BID), PO continuously for the 21 day cycle.
45684682|NCT01458028|Drug|Placebo|Single dose of placebo tablet matching the 20 mg BAY85-3934 tablet
46041438|NCT02697994|Other|Sterile Water|0.1 ml intracutaneous sterile water injections into the skin surrounding the Michaelis rhomboid over the sacral area.
46041439|NCT02697994|Other|Dry Injections|dry injections into the skin surrounding the Michaelis rhomboid over the sacral area.
46041440|NCT02697838|Drug|Apatinib|Apatinib (850 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
45345181|NCT00652899|Biological|Allopurinol|All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.
45345182|NCT00652899|Drug|Cyclophosphamide|60 mg/m^2 on Days 4 and 5 preceding natural killer cell infusion.
45345183|NCT00652899|Drug|Fludarabine phosphate|25 mg/m^2 on Days 6 through 2 preceding natural killer cell infusion.
45345184|NCT00652899|Radiation|total-body irradiation|200 cGy Day 1 preceding natural killer cell infusion.
45345185|NCT00652899|Biological|Allogeneic natural killer cells|Given day 0 - dose of 1.5-8.0 * 10^7/kg
45345186|NCT00652899|Biological|Aldesleukin|10 MU 3 times/week for a total of 6 doses beginning Day 0
45345187|NCT04147962|Device|intense pulsed light (usual practice)|collection data : parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light
45345188|NCT00734240|Drug|ISIS 353512|50 mg via 2 hour IV infusion, single dose
45345189|NCT00734240|Drug|ISIS 353512|50 mg via 2 hour IV infusion, 6 doses over 22 days
45345190|NCT00734240|Drug|ISIS 353512|50 mg via SC injection, single dose
45345191|NCT00734240|Drug|ISIS 353512|50 mg via SC injection, 6 doses over 22 days
45345192|NCT00734240|Drug|ISIS 353512|2 hour IV infusion, 50 mg on day 3, 100 mg on day 5, and 200 mg on day 8
45345193|NCT00734240|Drug|ISIS 353512|100 mg via 2 hour IV infusion, single dose
45345194|NCT00734240|Drug|ISIS 353512|200 mg via 2 hour IV infusion, single dose
45345195|NCT00734240|Drug|ISIS 353512|100 mg via SC injection, single dose
45684683|NCT01458262|Other|systemic and cerebral oxymetry|oxymetry measurement using near infrared spectroscopy
46041441|NCT02697838|Drug|Paclitaxel-based chemotherapeutic regimens|"Paclitaxel-based chemotherapeutic regimens including:~The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~The PF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~Paclitaxel 80mg/m2 d1，d8，d15，repeating the cycle every 28 days~other paclitaxel-based regimens"
46041442|NCT02697682|Biological|injection with the stromal vascular fraction (SVF) of adipose tissue|Description of the active treatment The active treatment is an intra-articular injection with the stromal vascular fraction (SVF) harvested from the patient's own abdominal subcutaneous fatty tissue. SVF is harvested using the Lipogems system.
45345196|NCT00734240|Drug|ISIS 353512|200 mg via SC injection, single-dose
45345197|NCT00734240|Drug|ISIS 353512|100 mg via 2 hour IV infusion, 6 doses over 22 days
45345198|NCT00734240|Drug|ISIS 353512|200 mg via 2 hour IV infusion, 6 doses over 22 days
45345199|NCT00734240|Drug|ISIS 353512|100 mg via SC injection, 6 doses over 22 days
45345200|NCT00734240|Drug|ISIS 353512|200 mg via SC injection, 6 doses over 22 days
45345201|NCT00734240|Drug|ISIS 353512|100 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or oral placebo
45345202|NCT00734240|Drug|ISIS 353512|200 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or steroid
45345203|NCT00734240|Drug|ISIS 353512|2 hour IV infusion, 50 mg on day 1, 100 mg on day 3, 100 mg on day 5 and 200mg on day 8
45345204|NCT04066452|Diagnostic Test|Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP).|Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP) to evaluate the degree of cardiac uptake from 0 to 3 degrees.
45345205|NCT04066452|Diagnostic Test|Proteinogram and serum immunoglobulins. Light chains free in serum -Freelite-. Immunofixation in serum and urine|Analysis to rule out the presence of monoclonal protein in blood and urine.
45345206|NCT00733382|Drug|dexamethazone|injection form, 8 miligram, injected once
45345207|NCT00728442|Device|ONCODOC LOGICIEL|Introduction of a computer-based decision support system in the medical decision process
45345208|NCT00733460|Drug|BFPET|
45345209|NCT00728520|Drug|Azacitidine|Azacitidine 75 mg/m2 daily IV or subcutaneously (SQ) for 5 days, every 4 weeks for a minimum of 4 cycles.
45684684|NCT02892682|Other|BLOOD TEST|
45684685|NCT01458496|Behavioral|Health Coaching|The intervention will take approximately six months to complete. A combination of group and individual face-to-face meetings will be used. Participants will be divided into groups of 20 for group meetings. Groups will be brought together for a group coaching session at the beginning and the end of the coaching process (i.e., intervention). Each participant will also receive four individual coaching sessions with the health coach and will be able to avail of three one-hour telephone coaching sessions during the six month intervention. Participants will be encouraged to utilize telephone coaching for key support periods.
45345210|NCT04065308|Drug|Drug Combinations|"Daratumumab plus DCEP,combination therapy is administered total of three cycles,every 4weeks(28 days).~Daratumuamb 16mg/kg body weight in 500mL (the first dose,16mg/kg body weight in 1000mL) Weeks 1 to 8: weekly Weeks 9-24 : every 2 weeks if ASCT ineligible or PR but Plasmacytoma response <CR: every 2 weeks for 12weeks and then every 4 weeks for 8weeks (Total of 8 times, additional administration of daratumumab) if ASCT eligible: From 6 to 12 weeks after ASCT, administration of daratumumab is initiated within 12 weeks of ASCT and twice a month for 12 weeks and then every a months for 8 weeks. (Total of 8 additional administration of daratumumab after ASCT)~dexamethasone :40mg/day D1-4, intravenous~cyclophosphamide: 400mg/m2 D1-4, intravenous~etoposide: 40mg/m2 D1-4, intravenous~cisplatin : 7mg/m2 D1-4, intravenous Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle"
45345211|NCT00733538|Drug|zometa|patients receiving treatment during their follow-up
46041443|NCT02697526|Other|Terumo|
45684686|NCT01458652|Drug|Kremezin|Kremezin is an oral adsorbent, 9g/day in treatment arm
46041444|NCT02697526|Other|Tensoplast|
45684687|NCT01458886|Drug|BI 54903 MD|2 puffs b.i.d. via Respimat inhaler
45684688|NCT01458886|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
45684689|NCT01458886|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
45684690|NCT01458886|Drug|BI 54903|2 puffs LD b.i.d. via Respimat inhaler
45684691|NCT02880982|Dietary Supplement|Cholecalciferol|Weekly oral softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3)
45684692|NCT02880982|Other|Placebo|Weekly oral placebo softgel capsule
45684693|NCT01458964|Drug|Quetiapine|100 mg (peach colored oblong tablet) and 200 mg (yellow colored oblong tablet)
46041445|NCT02690428|Device|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
46041446|NCT00928707|Drug|GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea|50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy
46041447|NCT00928707|Drug|GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea|50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy
46041448|NCT02706106|Device|Knee brace|Patients will be prepared to receive the device of knee brace with or without a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
46041449|NCT02697760|Radiation|thallium-201|Thallium (Tl-201) myocardial single photon emission tomography, dynamic imaging
45684694|NCT01459120|Other|Door-to-door|Health workers propose the integrated service package including VCT at the peoples' homes (home-based testing).
46041450|NCT04956705|Dietary Supplement|Vitamin D and calcium|Either as tablets, droplets or sprays. Preferably daily doses of 20 µg of vitamin D and 800-1000 mg of calcium as recommended.
45684695|NCT01459120|Other|Pitso|"Health care workers propose the integrated service package including VCT through community gatherings (Pitso)."
46041451|NCT04260633|Device|Dental Monitoring assisted aligner change, 12-hour tray wear time and VPro+ are the interventions for the trial.|"The current standard of care for clear aligner use as suggested by Invisalign is unclear as to how frequently aligners should be changed. We suspect that the frequency for aligner change as determined by the orthodontist using Dental Monitoring will be variable for every participant.~Vpro+ is an adjunctive therapeutic tool for clear aligner treatment. It is proposed to deliver high frequency vibrations to reduce treatment time and pain associated with clear aligners.~Align Technology suggests 22-hour wear time for clear aligner therapy. Participants in two arms of the study will be asked to wear the trays for about half the recommended wear time to assess whether night-time aligner wear will be sufficient for successful treatment."
45345212|NCT00730548|Behavioral|Device triggered remote telephone contact because of Care Alert|Care Alerts on, physician will be notified in case of an Care Alert. Depending on the outcome of the telephone contact drug adjustment and / or further interventions can be prescribed
46041452|NCT02705950|Drug|Intrathecal baclofen bolus|An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level.
46041453|NCT02705950|Other|Placebo|1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
46041454|NCT04951323|Drug|anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)|Participants will receive the COVID-19 mRNA Vaccine BNT162b2 (Comirnaty®). The vaccine is administered intramuscularly after dilution as a series of two doses at least 21 days apart.
46041455|NCT02705872|Drug|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml/h|Continuous epidural perfusion: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml with a 10ml/hour rate
46041456|NCT02705872|Drug|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml each 60 minutes|Injection of programmed intermittent boluses in the epidural space, without continuous perfusion, of the same solution (Chirocaine 0.07% + Sufentanil 0.3 mcg/ml): 10ml each 60 minutes
46041457|NCT04215016|Biological|Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells|Humanized anti-CD19 and CD20 bispecific autologous CAR-T cells injection: the first dose is 1.0×106 /kg, the second dose is 3.0×106 /kg, and the third dose is 8.0×106 /kg. Patients will receive lymphodepleting chemotherapy at least 1 week before CAR-T cell infusion.
45345213|NCT00728156|Drug|clopidogrel|75 milligrams, oral, clopidogrel, one tablet daily, for seven days after the baseline chamber study.
45684696|NCT01459198|Biological|RSV MEDI ΔM2-2 vaccine|Given intranasally once at a baseline study visit, at a dose of 10^5 or 10^6 plaque-forming units (PFU), depending on study arm.
45684697|NCT01459198|Biological|Placebo vaccine|Given intranasally once at a baseline study visit
45345214|NCT00728156|Drug|placebo|Placebo: Hydroxy methyl cellulose, similar in weight to the active medication 75 mgs, oral tablets, once a day
45345215|NCT02569554|Drug|PF-06463922|each subject will receive 4 single oral doses of 100 mg PF-06463922 (treatment A: tablets without food; treatment B: tablets with food; treatment C: tablets without food with rabeprazole; treatment D: oral solution without food). There will be at least 10 days washout period between consecutive PF-06463922 single dose.
46041458|NCT02701894|Dietary Supplement|Alpha-Linolenic Acid|Meta-Analysis of Randomized Controlled Trials
46041459|NCT02706028|Device|underwater ultrasound|underwater US therapy with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
45345216|NCT02569554|Drug|rabeprazole|20 mg daily tablets in the evening for 5 days and Pf-06463922 on the morning of day 6 in treatment C.
45345217|NCT00728234|Device|aEEG recording|weekly recordings with aEEG
45684698|NCT01459276|Biological|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
45684699|NCT01459276|Biological|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
45345218|NCT02523066|Device|Magna Ease|This study is non-intervention
45345219|NCT00734318|Drug|Flutiform 250/10 micrograms|
45345220|NCT00734318|Drug|Flutiform 50/5 micrograms|
45345221|NCT00734318|Drug|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|
45345222|NCT00734318|Drug|Flixotide pMDI 250 micrograms|
45345223|NCT04052412|Drug|18F-AraG|All arms of the study will receive an injection of 18F-AraG while on the PET imaging system. Following a 6 minute scan over the heart to acquire input function data, the patient will undergo a 1 hour multi-pass whole-body dynamic PET/CT acquisition to gather whole-body biodistribution data.
45345224|NCT00733616|Drug|DOX: Docetaxel, oxaliplatin, Capecitabine|"Docetaxel 40 mg/m2, iv infusion 60 minutes, day 1~Oxaliplatin 80 mg/m2, iv infusion 120 minutes, day 1~Capecitabine 625 mg/m2, bid, oral, continuous~6 cycles, every 3 weeks~Capecitabine will be given same dose (625mg/m2/bid) continuous in case no toxicity (no dose adjustment)"
45345225|NCT00728832|Drug|DepoDur (extended-release epidural morphine)|DepoDur with on demand boluses of IV fentanyl PCA
45345226|NCT00734396|Procedure|Mesenchymal stem cell infusion|MSC infusion: two doses of 1-2x106 MSCs per kilogram body weight, intravenously, 7 days apart.
45345227|NCT03924804|Drug|Ringer's solution acetate|Intravenous infusion of 2 ml/kg Ringer's solution acetate within 1 hour after induction.
45345228|NCT03924804|Drug|Ringer's solution acetate|Intravenous infusion of 8ml/kg Ringer's solution acetate within 1 hour after induction.
45345229|NCT03924804|Drug|Ringer's solution acetate|Intravenous infusion of 16ml/kg Ringer's solution acetate within 1 hour after induction.
45684700|NCT02490904|Drug|Eplerenone|Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours
45684701|NCT02490904|Drug|Placebo|Double-blinded Placebo administered for 4 days at 25mg every 12 hours
45684702|NCT01459432|Other|Venepuncture and blood sample collection.|Venepuncture and blood sample collection.
45684703|NCT01459510|Behavioral|Play Nicely Program|Multi media educational intervention
45684704|NCT04390984|Drug|Apatinib Mesylate, Gefitinib|Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.
45840820|NCT00904488|Drug|Addition of oral Metolazone|Addition of oral metolazone 5 mg daily to continued current dose of intravenous bolus furosemide
46041460|NCT02706028|Device|sham underwater ultrasound|ULTRON home OE-302® device is not turned on
46041461|NCT02701348|Other|Shearwave elastography|Patients with primary breast cancer receiving neoadjuvant letrozole will undergo radiological assessment with digital mammogram, ultrasound (US) including shearwave elastography (SWE). These will be performed at 3 monthly intervals until surgical intervention is considered feasible.
46041462|NCT02701348|Drug|Letrozole|Patients will be receiving neoadjuvant letrozole as standard therapy for breast cancer
45345230|NCT00733694|Device|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
46041463|NCT02701348|Procedure|Breast core biopsy|Core biopsies will be taken at diagnosis, and at the time of surgery to allow biological assessment of changes in tumour
45684705|NCT02878408|Genetic|Blood sampling|supplementary blood sampling for analysis of: immuno-genetic, inflammatory process, retro-viruses activity, Questionaries about environment risk factors
45684706|NCT01459900|Procedure|Renal artery ablation|Catheter based renal denervation by applying low power radiofrequency to the renal artery using the Ardian Medtronic Simplicity Catheter, introduced by femoral artery access.
46041464|NCT02701348|Other|Magnetic Resonance Imaging|Breast MRI scans will be performed at time of diagnosis and prior to surgery to allow comparison of MRI change and response to treatment
45345231|NCT00733772|Dietary Supplement|flaxseed|30 grams/day of flaxseed for 12 weeks
45345232|NCT00733772|Behavioral|Health lifestyle counseling|Health lifestyle counseling accroding to AHA reccommendation
45345233|NCT00728312|Drug|Aripiprazole|12 week comparison of active medication (aripiprazole 5-15 mg per day) versus Placebo (placebo look-alike 5-15 mg per day)
45345234|NCT00728312|Drug|Placebo|12 week comparison of placebo 5-15 mg per day (pill which contains no active medication) versus active medication (aripiprazole 5-15 mg per day)
45345235|NCT00728390|Drug|PF-00299804|CP-751,871 at recommended dose on Day 1 and 2 of cycle 1, then on Day 1 every 3 weeks; and PF-00299804 orally at recommended dose once daily.
45345236|NCT00734552|Dietary Supplement|α-Keto Acid with low protein diet|"Compound α-Keto Acid: The daily dose of compound α-Keto Acid is 0.1/kg/d. The total daily dose will be divided into three times a day.~Low Protein Diet: Diet contain protein 0.8g/kg/d."
46041465|NCT02701426|Behavioral|physical activity and nutritional counseling|The program will last 12 weeks, and will include three workshops on diet of the pregnant and lactating women, and the young child. Physical activity sessions will be offered once a week.
45345237|NCT00734552|Dietary Supplement|Normal protein diet|Diet contain protein 1.0-1.2 g/kg/d.
45345238|NCT00728546|Drug|Isoniazid (Rifinah)|The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
45345239|NCT02568722|Other|Standard RRT initiation|"In the absence of kidney function recovery, the initiation of RRT will be permitted if one of the following develops:~serum potassium ≥ 6.0 mmol/L; pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol/L; evidence of severe respiratory failure, based on a PaO2/FiO2 ≤ 200 and clinical perception of volume overload; and/or persistent AKI > 72 hours following the time of randomization."
45345240|NCT02568722|Other|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
45684707|NCT01459900|Procedure|Renal angiography|Renal angiography by femoral access.
45684708|NCT02877394|Device|Squatting Assist Device|The Squatty Potty is a 7 inch tall stool to assist subjects in maintaining a squatting position while using a toilet. While sitting on the toilet, the subject supports her feet on the Squatty Potty.
46041466|NCT00615706|Other|No intervention|no intervention
46041467|NCT02700880|Device|LifeVest|LifeVest monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy.
46041468|NCT00930813|Device|Lutonix Catheter|Paclitaxel Coated Balloon Catheter
46041469|NCT00930813|Device|Standard uncoated Balloon Angioplasty Catheter|plain, uncoated angioplasty balloon catheter
46041470|NCT05324800|Dietary Supplement|Curcuma Longa Extract Mixture|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
46041471|NCT05324800|Dietary Supplement|placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
46041472|NCT04216108|Device|Vitrectomy (23G gauge needle)|Vitrectomy surgery with 23G gauge needle technique
46041473|NCT04216108|Device|Vitrectomy (27G gauge needle)|Vitrectomy surgery with 27G gauge needle technique
46041474|NCT04215796|Device|ReX-C system|CFTR modulators are dispensed to patients via ReX-C system
45684709|NCT02877394|Device|Sham Squatting Assist Device|This stool will be 2 inches tall and be similar in appearance to the Squatty Potty. While sitting on the toilet, the subject supports her feet on the 2 inch high stool.
45684710|NCT01459978|Other|CUmulative SUM (CUSUM) Chart|"Intervention is described as follows:~Step 1: Implementation of the CUmulative SUM (CUSUM)control chart using available medical data Step 2: Submission of monthly results to the coordinator of each participating center (if CUmulative SUM (CUSUM) results period).~Step 3: When an alarm is generated, the steering committee will meet with maternity staff to find the causes of these alerts and propose"
45345241|NCT00738686|Device|Intracoronary stent implantation|Taxus stent implantation in patients with multivessel coronary artery disease
45684711|NCT02874898|Behavioral|Brief Imaginal Exposure|Psychoeducation and imaginal exposure components of full prolonged exposure, in which patients relive the trauma vividly and process thoughts and feelings related to it
46041475|NCT05330481|Other|Moderate-intensity (relative) exercise with glucose ingestion|120 minutes of cycling at 95% of lactate threshold ingesting 90 g/h of glucose
46041476|NCT05330481|Other|Moderate-intensity (absolute) exercise with glucose ingestion|120 minutes of cycling at a power matched to participant in the <70 kg body mass group, ingesting 90 g/h of glucose
46041477|NCT02700958|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes.
46041478|NCT02700958|Procedure|SHAM Remote ischemic preconditioning|SHAM Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC-SHAM will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes
46041479|NCT04215328|Dietary Supplement|Mixed-Meal|Per 250ml bottle: 220 calories, protein 9g, carbohydrate 33g (15g sugar), fat 6g, sodium 190mg, potassium 390mg; 500mLs by tube daily in 4 doses
46041480|NCT04215328|Dietary Supplement|Electrolyte Solution|Electrolyte Solution 500mLs by tube daily in 4 doses
46041481|NCT04258527|Drug|Pemigatinib|Pemigatinib will be self-administered as at 13.5mg a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule.
46041482|NCT00615238|Behavioral|Diet plus continuous bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform 4 30-60 minute aerobic workouts per week
46041483|NCT00615238|Behavioral|Diet plus short bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform short 10 minutes bouts of aerobic exercise 4 times per week
46041484|NCT00615238|Behavioral|Diet plus moderate lifestyle activity|Patients consumed a 1200 kcal/d diet and were instructed to accumulate moderate intensity physical activity on most days of the week.
46041485|NCT04946799|Behavioral|Low-intensity training combined with blood flow restriction (LI-BFR)|Participants (n=20) receives low intensity exercise intervention on a cycle ergometer (at 40% of heart rate reserve), with compression belts attached on both thighs, during exercise the belts are inflated with 50% of the participant's arterial occlusion pressure. Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. The compression belt is deflated during the rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
46041486|NCT04946799|Behavioral|High-intensity aerobic exercise (HI)|Participants (n=20) receives high intensity aerobic exercise intervention on a cycle ergometer (at 70% of heart rate reserve). Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
46041487|NCT04946799|Behavioral|Low intensity exercise (LI)|Participants (n=20) receives low intensity exercise intervention on a cycle ergometer (at 40% of heart rate reserve). Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
46041488|NCT00610779|Dietary Supplement|mixture of aromatic essential oils.|1% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the nose.
46041489|NCT00610779|Dietary Supplement|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the nose.
46041490|NCT02700724|Other|Immediate Surgery|
46041491|NCT02700724|Other|Observation|
46041492|NCT02700724|Procedure|Surveillance Cystoscopy and Urinary Cytology|Cytology and cystoscopy are done at the same time
46041493|NCT04258371|Drug|Dapagliflozin 10 MG|Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
46041494|NCT04258371|Drug|Placebo oral tablet|Placebo once daily for 12 weeks
46041495|NCT00609219|Biological|autologous EBV specific CTLs|"30-40cc of peripheral blood will be used to generate EBV specific CTLs~Group One:~Day 0 - 2 x 10^7 cells/m2 Day 14 - 2 x 10^7 cells/m2~Group Two:~Day 0 - 2 x 10^7 cells/m2 Day 14 - 1 x 10^8 cells/m2~Group Three:~Day 0 - 1 x 10^8 cells/m2 Day 14 - 2 x 10^8 cells/m2"
46041496|NCT00930579|Drug|Metformin|1500 mg per day, divided 500 mg in the morning and 1000 mg in the evening, for at least two weeks prior to surgery
46041497|NCT03367156|Drug|Dexamethasone|Given PO
46041498|NCT03367156|Other|Placebo|Given PO
45345242|NCT04064216|Procedure|Laparoscopic surgery|Patients that will undergo robot assisted laparoscopic surgery and conventional laparoscopic surgery for benign gynecologic disorders will answer 4 questionnaires to assess patient satisfaction, quality of life and cosmesis
45345243|NCT00617890|Biological|robatumumab|Robatumumab IV every two weeks until disease progression.
45345244|NCT04066010|Other|Mobile application (BP-n-Me)|"The mobile app consisted of a series of features including (1) calendar reminders of when to take medications and the patient's antihypertensive medication regimen (2) a Call your Pharmacist button specific to patient's pharmacy, (3) a BP log in which the patient could enter blood pressure values that were automatically compared to goal values, (4) counseling points for lifestyle and adherence factors individually tailored to each patient and (5) lifestyle and medication adherence surveys."
45345245|NCT00730626|Dietary Supplement|Yogurt with 1X10E9 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E9 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
45345246|NCT00730626|Dietary Supplement|Yogurt with 1X10E10 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E10 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
45684712|NCT02873806|Procedure|Implantation of two iStent inject micro-bypass stents|- Implantation of two trabecular micro-bypass stents (iStent inject) in a standalone procedure (i.e., without cataract surgery).
45684713|NCT02873806|Drug|Topical travoprost|- Topical travoprost (0.004%, 1 drop each evening in study eye) started on postoperative Day 1.
45345247|NCT00730626|Dietary Supplement|Yogurt Placebo|100g of yogurt placebo containing no probiotics and no green tea extract, once a day for 10 weeks.
46041499|NCT03367156|Other|Questionnaire Administration|Ancillary studies
46041500|NCT00609297|Other|medical chart review|The Research Nurse will conduct a chart review after the patient's death.
45345248|NCT00870766|Procedure|Abdominal contrast-enhanced CT scanning|Contrast-enhanced (iohexol 350 mgI/ml, 100 ml IV) CT scanning
45345249|NCT00728780|Drug|ABT-143|once
45345250|NCT00728780|Drug|ABT-335 and rosuvastatin|once
45684714|NCT02873806|Device|Two iStent inject micro-bypass stents|- Two trabecular micro-bypass stents (iStent inject) implanted in a standalone procedure.
45684715|NCT02873806|Drug|Tobramycin|"Topical antibiotic (tobramycin):~1 drop four (4) times per day in the study eye for one week (in cases of allergy or contraindication, Polytrim (polymyxin B sulfate + trimethoprim sulfate ophthalmic solution, USP, or equivalent) may be used as an alternative medication) ."
46041501|NCT00609297|Other|questionnaire administration|The questionnaires will be completed at the end of week 1, week 2 and week 4.
46041502|NCT00609297|Other|survey administration|Given to patient and caregivers throughout the study
46041503|NCT04257981|Device|Brain stimulator v3.0|Brain stimulator v3.0 will be used to deliver 1.5 mA current over the scalp corresponding to the primary motor cortex. The current will be delivered via two surface electrodes 5 × 5 cm placed on the scalp, validated by the previous research
46041504|NCT04257981|Other|Sham Comparator: Control group|The sham set-up will follow a similar protocol as the experimental group but the intensity of the current will be ceased after 30 seconds of stimulation. Participants in the Sham group will feel the identical sensation as the experimental group and will be unable to differentiate between actual and sham tDCS such procedure is validated in earlier studies
46041505|NCT04260555|Drug|DW1601|Total 7 days of treatment and The daily dose is tid. (DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml)
45345251|NCT00870844|Drug|Lu AA24493 (CEPO)|0.5 to 50.0 mcg/kg body weight, IV, within 0 to 48 hrs from symptom onset
46041506|NCT04260555|Drug|DW16011|Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml)
46041507|NCT04260555|Drug|DW16012|Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml)
46041508|NCT04260321|Device|AI|Artificial intelligence colonoscopy
46041509|NCT02700568|Drug|axitinib|Initial dose of axitinib: 5 mg orally twice a day. Maintenance dose of axitinib: Increase or decrease dose based on individual safety and tolerability. Dose range of axitinib: 2 to 10 mg twice a day.
45474914|NCT05183100|Procedure|Tibial Nerve Neurodynamics|The patient will lie supine with the trunk and neck in neutral position. During the first stage, participants will receive passive straight leg raise of the affected side held for 20 seconds for 3 repetitions. In the second stage, hip adduction and internal rotation, ankle dorsiflexion, and ankle eversion are added in the straight leg raise position. Slow oscillations of the ankle movement for 1 minute will be applied, followed by holding the position for 20 seconds, for 3 repetitions. In the third stage, the head of the patient will be held in flexion with pillows while the same oscillation procedure as the second stage is performed. There will be a 2-minute rest between the stages.
45345252|NCT00870844|Drug|Placebo|Vials with solution for IV infusion
45345253|NCT00734708|Drug|Trafermin (genetical recombination)|Administered to the bone defect during flap operation
45345254|NCT00734708|Drug|Placebo|Control
45345255|NCT04066296|Drug|Liposomal bupivacaine|Injection of either liposomal bupivicaine or standard local anesthetic during surgical procedure.
45345256|NCT02341014|Drug|Carfilzomib|The initial dose of carfilzomib (cycle 1, day 1) given to any patient regardless of dose level must be 20mg/m2 . All subsequent doses of carfilzomib will be based on the patient's dose level.
45345257|NCT02341014|Drug|Romidepsin|
45345258|NCT02341014|Drug|Lenalidomide|
46041510|NCT00925353|Drug|4% lidocaine gel|1 ounce 4% lidocaine gel on skin of breasts and chest wall for 1 hour under occlusion, then removed with warm water
45345259|NCT00738764|Biological|PDL192|Humanized anti-TWEAK receptor monoclonal IgG1 antibody
45840821|NCT00904488|Drug|Furosemide dose escalation|Furosemide dose escalation via either IV bolus (2-2.5 x current dose) or continuous infusion (2-2.5 x current dose administered over previous 24 hours)
45840822|NCT00905580|Drug|Pregabalin|Pregabalin 150 mg orally
46041511|NCT02700646|Behavioral|Developmental recommendations|
46041512|NCT02700646|Behavioral|Standard care|standard care
45345260|NCT00730782|Biological|PfAMA-1-FVO[25-545]|Subcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1
45345261|NCT00868426|Drug|Budesonide/Formoterol Batch 1|Single, inhaled dose
45345262|NCT00868426|Drug|Budesonide/Formoterol Batch 2|Single, inhaled dose
45345263|NCT00868426|Drug|Budesonide/Formoterol Batch 1 and charcoal|Single, inhaled dose
45345264|NCT03872856|Device|BP-ICAN|"One of two home blood pressure monitor devices will be used.~Omron 7 Series Wrist cuff~Omron 10 Series Upper Arm cuff"
45345265|NCT00870922|Procedure|Active release techniques|Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
45345266|NCT00868504|Other|no intervention|no intervention
45345267|NCT03853746|Drug|Ocrelizumab|Patient will be treated with two courses of ocrelizumab (Ocrevus) for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience return of the disease activity can go back on the medication.
45345268|NCT00868582|Other|PET scanning in cancer|Collection of institutional practice PET imaging data
45474915|NCT05183100|Procedure|Lying in supine|Lying in supine position for about 13 minutes.
45474916|NCT04520464|Diagnostic Test|Cervical samples for identification of HR-HPV DNA via real-time PCTR.|Identification of HR-HPV DNA via real-time PCTR.
46041513|NCT02705560|Other|Cow´s milk (3.9% fat, pasteurized)|600 ml full fat milk (organic, pasteurized, 400 kcal)
46041514|NCT02705560|Other|hard, yellow cheese|100 g Swiss cheese (Le Gruyère medium ripe, 400 kcal)
46041515|NCT02705560|Other|Soy based drink|600 ml Soy drink (540 ml soy milk (232 kcal) supplemented with 60 ml soy and plant based cream (167 kcal)
46041516|NCT04203615|Device|Transcranial magnetic stimulation- sham rTMS|Transcranial magnetic stimulation- sham figure-eight coil will be used for stimulation. This sham coil will generate only clicking noise and will not generate any magnetic field.
46041517|NCT04203615|Device|Transcranial magnetic stimulation- real rTMS|Transcranial magnetic stimulation- figure-eight coil will be used for stimulation. 1 Hz stimulation, 100% of Resting Motor Threshold will be used.
46041518|NCT02705482|Biological|MEDI0562|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
46041519|NCT02705482|Biological|Tremelimumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
46041520|NCT02705482|Biological|Durvalumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
46041521|NCT00615316|Drug|Guaraná|Guaraná extract 75mg/day
45345269|NCT03037242|Procedure|Transtibial pullout technique|Evaluating radographs
46041522|NCT00615316|Drug|Placebo|Placebo 1tab/d
46041523|NCT05036655|Procedure|Perioperative glycemic management pathway|The PGMP is a shared-care pathway. It starts at the decision to undergo surgery, and includes preoperative planning, intraoperative management, the postoperative inpatient stay, and post-admission coordination of care to manage patients undergoing surgery based on a logic model for postoperative hyperglycemia. The PGMP identifies patients at high-risk of postoperative hyperglycemia at the time of surgical triaging using hemoglobin A1c (HbA1c) screening, based on Diabetes Canada recommendations. HbA1c screening estimates an individual's three-month average blood glucose, and is used to screen, diagnose, and titrate medications for diabetes. The PGMP then guides team members to monitor blood glucose postoperatively using POCT, and to manage hyperglycemia in high-risk patients using standardized care plans.
45345270|NCT00868660|Drug|ZP1848|sc. bolus
45345271|NCT00712166|Drug|AZLI 75 mg three times daily (TID)|
45345272|NCT00712166|Drug|Placebo three times daily (TID)|
46041524|NCT00611013|Device|Magnetic Resonance Imaging|Some participants may receive MRI contrast agent, 0.1 mmol/kg
46041525|NCT04215172|Drug|Macrolides|administration of azithromycin three times weekly for six months
45345273|NCT00868738|Dietary Supplement|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
45345274|NCT00652743|Biological|Pandemic influenza vaccine GSK1562902A|IM administration
46041526|NCT02700490|Behavioral|Psychotherapy|"Behaviour Therapy or Cognitive Behaviour Therapy which forms service as usual in primary care centres in Indonesia."
46041527|NCT04260399|Other|Lavender Aromatherapy|Participants in the experimental group will be passively exposed to lavender essential oil
46041528|NCT04260399|Other|Placebo Aromatherapy|Participants in the control group will be passively exposed to saline water aromatherapy
45345275|NCT00730860|Procedure|radiofrequency ablation associated with TACE|treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
45474917|NCT04520230|Drug|Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid|inhaled corticosteroid (ICS)plus long acting B2-agonist (LABA) (Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid ).
45474918|NCT04520230|Drug|Tiotropium 18 mcg capsule inhaled once daily + Budesonide|inhaled corticosteroid (ICS) plus long acting anticholinergic (LAAC) (Tiotropium 18 mcg capsule inhaled once daily + Budesonide ).
46041529|NCT02705638|Drug|Rituximab|All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15.
46041530|NCT02705638|Drug|Lenalidomide|All subjects will receive Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
45345276|NCT00730860|Procedure|radiofrequency ablation only|treatment of hepatocellular carcinoma by radiofrequency ablation only
45345277|NCT00868816|Drug|12 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200 mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 12 cycles
45345278|NCT00868816|Drug|8 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 8 cycles
45345279|NCT02569866|Drug|Cephalexin|Capsules containing cephalexin/500mg
45345280|NCT02569866|Drug|Placebo|Capsules containing placebo/500mg
45345281|NCT00868894|Drug|DE-104 medium concentration|Topical ocular application
46041531|NCT04877223|Other|No intervention|No intervention
46041532|NCT02705170|Procedure|index of microvascular resistance|Measurement of the index of microvascular resistance in the left anterior descending artery
46041533|NCT04260009|Drug|Brigatinib|Brigatinib tablets
46041534|NCT04260009|Drug|Brigatinib AAF|Brigatinib age-appropriate formulation (AAF)
46041535|NCT02705092|Other|Subliminal priming with subliminal reward stimuli|Positive words as subliminal reward (displayed for 17 ms).
46041536|NCT02705092|Other|Subliminal priming with supraliminal reward stimuli|Positive words as supraliminal reward (displayed for 150 ms).
46041537|NCT04257825|Device|Chili Sleep System|A mattress pad that cools or warms bed to maintain a constant temperature.
46041538|NCT02700256|Behavioral|survey|All patients will submit a baseline survey following enrollment onto study. After successful completion of the AXR or 24-hour discharge pathway, the consented patient will be contacted by email or telephone for 5 days following discharge from surgery.
46041539|NCT02692066|Biological|varicella vaccine|
46041540|NCT02691910|Drug|Chloroquine|10mg/kg on day 0 and 7.5mg/kg on days 1 and 2. Total dose, 25 mg base/kg. Tablet containing 150mg of base.
45474919|NCT04520230|Drug|Formoterol/Tiotropium|long acting B2-agonist (LABA) plus long acting anticholinergic (LAAC).
45684716|NCT02873806|Drug|Dexamethasone|"Topical anti-inflammatory medication (dexamethasone ophthalmic suspension 0.1%):~Week 1: 1 drop four (4) times per day in the study eye~Week 2: 1 drop three (3) times per day in the study eye~Week 3: 1 drop two (2) times per day in the study eye~Week 4: 1 drop one (1) time per day in the study eye"
46041541|NCT02691910|Drug|Primaquine|0.5 mg/kg once a day, for seven days. Total dose, 3.5mg/kg.
46041542|NCT04215250|Other|andropulous method|Counts the CVC depth using specific equation
46041543|NCT04215250|Device|ECG|Using ECG to monitor the insertion of the CVC
46041544|NCT02705326|Device|Opti-Speech|Uses visual feedback of the tongue's motion to guide speech sound production
46041545|NCT02700802|Other|Feed1st|Feed1st is a unique hospital-based hunger mitigation program that, since 2010, has operated low-cost, self-serve food pantries at Comer Children's Hospital. All parents and caregivers with a hospitalized child have 24/7 free access to these self-serve pantries with the option to eat food in the pantry, carry out as much food as needed, and contribute back to the pantry with food, volunteerism, or other resources. The program also offers free phone/text/email navigation for food support and other basic needs resources. We aim to conduct a 3-arm, randomized comparative effectiveness study to evaluate the impact, versus usual care, of two alternative referral strategies to increase Feed1st program utilization and impact.
46041546|NCT02705014|Drug|Gonadotropin-releasing Hormone|A regimen of pulsatile GnRH (Fengyuan pharmaceutical company, Anhui province, China) administered subcutaneous via a portable infusion pump (Weichuang Medical Science Company, Shanghai city, China) at a 90-minute interval. The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L ( 200-500 ng/dL).
46041547|NCT02700178|Other|Biofeedback|The visual biofeedback will consist of line or shape targets on a screen that the participants will aim to achieve with your movements. The auditory cues will be a tone or multiple tones to alert them when to move and/or when targets have been achieved. During the biofeedback session the study staff may also provide verbal cues and feedback.
46041548|NCT02704624|Dietary Supplement|Vitamin D|investigate the relationship between musculoskeletal manifestations, in Crohn population, and the hypovitaminosis D
45345282|NCT00868894|Drug|DE-104 high concentration|Topical ocular application
45684717|NCT01890382|Dietary Supplement|Whey protein|30 g in total; twice a day (morning and evening)
46041549|NCT02704624|Other|Placebo|compare the musculoskeletal manifestations of the Placebo group with the group receiving Vitamin D
46041550|NCT02701114|Procedure|Proximal Adductor Canal Block|Continuous Nerve Block
46041551|NCT02701114|Procedure|Distal Adductor Canal Block|Continuous Nerve Block
45345283|NCT00868894|Drug|Placebo|Topical ocular application
46041552|NCT02700100|Device|Bioabsorbable Pulmonary Valved Conduit (PV-001)|"The Bioabsorbable Pulmonary Valved (PV) Conduit (PV-001) is a polymer-based medical device, with a total length of 8 cm with inner diameters of 16 or 18 mm. The valve itself is formed by three leaflets, incorporated within the conduit wall.~The PV conduit is used for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT) in patients with any of the following congenital heart malformations:~Tetralogy of Fallot~Truncus Arteriosus~Pulmonary Atresia~Transposition of Great Arteries with Ventricular Septal Defect (VSD)~Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes~The PV conduit can also be used for replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits."
45345284|NCT00868894|Drug|0.005% latanoprost|Topical ocular application
45345285|NCT00730938|Drug|cefuroxime|intracameral cefuroxime 0.1 ml
45345286|NCT00730938|Drug|Saline placebo|0.1 ml of Ringers lactate
45345287|NCT00712010|Other|Whey protein native|Whey protein native against the 6 other arms
45345288|NCT00712010|Other|Whey protein microgels|Whey protein microgels versus the six other arms
45345289|NCT00712010|Other|Hydrolyzed whey protein|versus the six other arms
45345290|NCT00712010|Other|Casein native|versus the six other arms
45345291|NCT00712010|Other|Hydrolyzed casein|versus the six other arms
45345292|NCT00712010|Other|Total milk protein native|versus the six other arms
45345293|NCT00712010|Other|Hydrolyzed milk protein|versus the six other arms
45345294|NCT00731016|Drug|Zoledronic acid, pravastatin|"Pravastatin : 10 mg daily~Zoledronic acid : slow (30 mn) intravenous injections, diluted into 50 ml of saline solution following this schedule :~injection 1, S1: 0.0125 mg/kg of zoledronic acid~injection 2, S6: 0.025 mg/kg of zoledronic acid~injection 3, S12 and following, trimestrial basis, 0.05 mg/kg of zoledronic acid"
45345295|NCT00868972|Procedure|Percutaneous renal stenting intervention|Percutaneous renal stenting intervention
45345296|NCT00868972|Device|Distal embolic protection|Distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
45345297|NCT00799539|Drug|bortezomib|From cycles 1-4, 1.3mg/m^2 on days 1,4,8,11,22,25,29,and 32 of each 6-week cycle
45345298|NCT00799539|Drug|bortezomib|From cycles 5-9, 1.3mg/m^2 on days 1, 8, 22, and 29 of each 6-week cycle
45345299|NCT00799539|Drug|melphalan|9 mg/m^2 once daily on days 1-4 of each 6-week cycle
45345300|NCT00799539|Drug|prednisone|60 mg/m^2 once daily on days 1-4 of each 6-week cycle
45345301|NCT00731172|Drug|glatiramer acetate|20 mg daily subcutaneous injection through week 12
45345302|NCT00731172|Drug|placebo|subcutaneous daiky injection through week 12
45345303|NCT00799695|Behavioral|phone call contact|A sample of subjects who had not completed their annual diabetic screening exams were contacted by phone and offered appointments for eye exams
45345304|NCT00869284|Drug|CEEP regimen|cyclophosphamide 1200 mg/m² intravenously on day 1 (d1), epirubicin 100 mg/m² intravenously on d1, vindesine 3 mg/m² intravenously on d1 and prednisone 80 mg/m² orally or intravenously on d1-5, with two weeks intervals
45840823|NCT00905580|Drug|Vitamin Complex (placebo)|Vitamin Complex 150 mg orally
45345305|NCT00869284|Procedure|Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)|"The conditioning regimen of the first HDT was mitoxantrone 45 mg/m² intravenously on d1 + cytarabine 1000 mg/m² by a 3-hour infusion every 12 hours from d1-4.~The conditioning regimen of the second HDT started d30 to d45 after the first stem cell infusion, and consisted of 1200 cGy total body irradiation (TBI) in 6 twice daily 200 cGy fractionated doses with a 800 cGy pulmonary shielding, followed by CBV: carmustine 300 mg/m² intravenously on d4, etoposide 200 mg/m² intravenously on d5-8 and cyclophosphamide 1500 mg/m² intravenously on d5-8."
45474920|NCT05155410|Dietary Supplement|Exogenous Ketone Monoester|Participants will consume 15g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.
46041553|NCT04213846|Behavioral|Experimental: Mobile Alcohol Expectancy Challenge (mAEC)|Participants randomized to the mAEC condition will receive daily intervention messages two times a day for three weeks in the mobile app. The intervention uses participants' own daily responses to personalize messages, when appropriate, that challenges their personal expectations of alcohol's positive effects on mood, social facilitation, and tension reduction, as well as aggression and risk-taking. The intervention messages also focus on intentions to drink and pharmacologically-delayed negative effects. Intervention Messages in general will include feedback based on selected assessment items, weekly summaries generated from the daily assessments, general psycho-educational messages and videos about alcohol, and a toolbox with supplemental information (e.g., personal BAC calculators, resources).
45474921|NCT05155410|Dietary Supplement|Placebo|Participants will consume an equivalent volume (30ml) of the active intervention supplement 15 minutes prior to each meal for 14 days. All meals will be provided throughout the 14-day placebo supplementation period.
45474922|NCT03619837|Drug|Sofosbuvir/Velpatasvir|Sofosbuvir/Velpatasvir starting early post-transplant for total of 12 weeks.
45474923|NCT03619837|Drug|Sofosbuvir/Velpatasvir/Voxilaprevir|"Only for patients who fail initial treatment with Sofosbuvir/Velpatasvir.~Dosage: 400mg/100mg/100mg daily for 12 weeks."
45474924|NCT03852485|Device|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
46041554|NCT02700022|Drug|Alisertib|Dose escalation of alisertib: level 1 - 20 mg, level 2 - 30 mg, level 3 - 40 mg PO BID on Days 1-5 of six 21-day cycles, combined with R-EPOCH Rituximab, IV infusion on day 1 of each cycle; Etoposide, IV infusion for 96 hours on days 1, 2, 3, and 4 Doxorubicin, IV infusion for 96 hours on days 1, 2, 3, and 4 Vincristine, IV infusion for 96 hours on days 1, 2, 3, and 4 Cyclophosphamide, IV infusion for 15 minutes on day 5 Prednisone, PO daily on days 1, 2, 3, 4, and 5
46041555|NCT02699944|Device|ECG Vest Optimization|As part of a standard and clinically indicated CRT optimization procedure utilize an ECG Vest as one modality for collecting information to determine best device programming.
46041556|NCT02699788|Device|Multifunction Cardiogram|
45345306|NCT00738842|Drug|AZD6140|Oral tablets taken bid for 5 days
45345307|NCT00738842|Drug|Placebo to match AZD6140|Oral tablets taken bid for 5 days
45474925|NCT03364426|Other|No intervention|No intervention - this is was an observational, cross-sectional study to identify potential risk factors associated with stunting
45474926|NCT03852563|Drug|BAY207543 (Bepanthol)|Product is applied to one hemiface.
45474927|NCT03852563|Other|Semisolid vaseline|Product is applied to one hemiface.
45474928|NCT03356782|Biological|Sarcoma-specific CAR-T cells|1 infusion, for 1x10^6~1x10^7 cells/kg via IV
45474929|NCT03739255|Device|Cacicol20|Cacicol20 is supplied as a sterile single-dose solution of alpha 1-6 poly-carboxymethyl glucose sulfate One drop is instilled at each application to impregnate cornea.
46041557|NCT02699710|Drug|Folic Acid|Folic acid will be administered orally as tablet at a single dose of 5 mg.
46041558|NCT02699710|Drug|GDC-0853|GDC-0853 will be administered orally as tablet or capsule at a dose of 200 mg.
46041559|NCT02699710|Drug|Methotrexate|Methotrexate will be administered orally as tablet at a single dose of 7.5 mg.
46041560|NCT02699710|Drug|Rabeprazole|Rabeprazole will be administered orally as tablet at a dose of 20 mg.
46041561|NCT00618670|Behavioral|Walking Exercise|Three times per week for 3 months
46041562|NCT00618670|Behavioral|Control--Resistance Training|Three times per week for 3 months
46041563|NCT04212520|Other|No intervention|No intervention
46041564|NCT05119348|Other|STOPCOV|Fieldworkers delivered an infection mitigation intervention which consisted of personal protective equipment and messaging on managing COVID19 and reducing onward transmission of SARS-CoV-2 infection.
46041565|NCT00618904|Dietary Supplement|Probiotics - Lactobacillus and bifidobacterium|Probiotics administered bid for 6 weeks.
46041566|NCT00618904|Dietary Supplement|Placebo|Placebo administered bid for 6 weeks.
46041567|NCT05324722|Other|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
46041568|NCT05324722|Other|cross body stretch|crossbody stretch performed by an individual
45345308|NCT00809913|Drug|short treatment (ciprofloxacin)|7 days of antibiotic treatment for febrile urinary tract infection / acute pyelonephritis compared to standard treatment of 14 days
45684718|NCT01890382|Dietary Supplement|whey plus creatine|whey protein combined with creatine (30 g and 6.0 g in total; twice a day, respectively)
46041569|NCT05324644|Behavioral|Motivational interview|In the first interviews with the students; It is planned to provide information about acquaintance and research, fill in the scales in 10-15 minutes, make CO measurements, and also conduct an average of 20-40 minutes of motivational interviews in the intervention group. In the second interview in the 1st month, it is planned to summarize the first interview, fill in the scales in 3-5 minutes, make the CO measurements in 10-15 minutes or get the measurement results and apply motivational interview in the average of 20-40 minutes. In the third interview in the 3rd month, it is planned to summarize the second interview in 3-5 min, fill in the scales in 10-15 minutes, make CO measurements or get the measurement results and to apply motivational interviews for an average of 20-40 minutes. In the last interview in the 6th month, it is planned to summarize the 3rd-month interview, to apply the scales for approximately 10-15 minutes, to make CO measurements or to get the measurement results.
46041570|NCT05324488|Other|No intervention|In this registry no intervention is carried out
46041571|NCT04214704|Device|Genteel lancing device|Painless lancing device that helps to improve and assess self-monitoring frequency and HbA1c respectively
45474930|NCT03739255|Device|Placebo|Ocluac is artificial tear which contains Hydroxypropylmethyl Cellulose and Sodium Chloride, It is presented in a 0.4 mL vial. One drop is delivered at each application.
45474931|NCT01188317|Drug|aleglitazar|repeated daily doses
46041572|NCT04214704|Device|Conventional lancing device|Conventional lancing device
46041573|NCT03140488|Drug|Oxytocin|Patients will be randomized to low dose or high dose oxytocin for induction of labor.
46041574|NCT05324020|Behavioral|Medication adherence eHealth intervention|"The eHealth intervention consists a Medication Event Monitoring Systems (MEMS®) Helping Hand and MEMS Adherence Software application. The eHealth intervention will support BCS to adhere to their OHT (i) by alerting them to take their OHT, and (ii) by allowing patient-physician communication.~The eHealth intervention comprises a questionnaire that should be filled-out weekly and that informs about the presence and severity of side effects. These data are collected in real-time and monitored on a weekly basis by the clinical research nurse (CRN) in charge of the study. In case of an alert, meaning recurrent non-adherence and/or reporting of side-effects, the CRN will contact the breast cancer nurse (BCN) in charge of the patient. Thus the BCN will contact the patient by phone to check on their health status and together define the future procedures (behavioral strategies)."
45684719|NCT01890382|Dietary Supplement|leucine supplementation|7.5 g/d in total; three times per day
45684720|NCT01890382|Dietary Supplement|soy protein|30 g in total; twice a day
45684721|NCT01890382|Dietary Supplement|creatine|6.0 g in total; twice a day
45684722|NCT01890382|Dietary Supplement|placebo|
45684723|NCT01890616|Device|SmartPill ingestion|The participant would ingest the SmartPill and wear the data receiver for up to 5 days.
45345309|NCT00729222|Drug|Comparator: Placebo|rolofylline placebo IV infusion over 4 hours.
45345310|NCT00729222|Drug|rolofylline|rolofylline 30 mg IV infusion over 4 hours.
45345311|NCT03896386|Other|Use of seizure diary|"The participants will press the alert button when they witness and alerting behaviour on their dogs or the Seizure button when they had experienced a seizure. We will receive this information live through the app back-end"
45684724|NCT01890772|Drug|Telaprevir|
45684725|NCT01890772|Drug|Peginterferon alfa-2a|
45684726|NCT01890772|Drug|Ribavirin|
45684727|NCT01890772|Dietary Supplement|Vitamin D|
45840824|NCT00908388|Device|GORE TAG® Thoracic Endoprosthesis|Endoprosthetic Implant
45345312|NCT00734786|Other|Wrinkle cream application|Single application on the crow's feet wrinkles. Placebo cream will be applied on one side, the active cream on the other side.
45345313|NCT00729300|Drug|placebo|placebo daily
45345314|NCT00729300|Drug|disulfiram|250mg daily
45345315|NCT00808743|Drug|Celecoxib|Celecoxib: 400mg twice daily, orally, 6 months
45345316|NCT00808743|Drug|Ursodeoxycholic acid|"Ursodeoxycholic acid: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses"
45345317|NCT00808743|Drug|Placebo|"Placebo: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses"
45345318|NCT00869596|Drug|fluticasone propionate|Single dose of fluticasone 440 mcg (2 x 220 mcg) or 1980 mcg (9 x 220 mcg) by metered dose inhaler in two of three treatment periods
45345319|NCT00869596|Drug|Comparator: Placebo to fluticasone|Single dose of placebo to fluticasone (9 x 0 mcg) by metered dose inhaler in one of three treatment periods
45345320|NCT00869596|Drug|Comparator: Lipopolysaccharide (LPS)|20,000 EU LPS by inhalation 1 hour postdose of fluticasone or placebo in each of three treatment periods
45345321|NCT00869596|Drug|Comparator: albuterol|Albuterol two 100 mcg inhalations by metered dose inhaler prior to sputum induction at screening, twice during each of the three treatment periods, and at the post-study follow up visit.
46041575|NCT00616408|Drug|Octreotide-LAR|Initial dose is 20 mg every 28 d for three months, then the dose is down-titrated to 10 mg/q28d if GH levels are below 1 ng/ml, up-titrated to 30 mg/q28d if GH levels are above 10 ng/ml and remains to 20 mg/q28 d if GH is between 1-10 ng/ml
46041576|NCT03093610|Procedure|Traditional|Removal of the chest tube after air leakage has ceased and fluid drainage is 200ml/24h or less.
46041577|NCT03093610|Procedure|Test|Removal of the chest tube after air leakage has ceased and fluid drainage is 5ml/kg/24h or less.
45345322|NCT03743376|Biological|UB-421(25 mg/kg) Q2W|Monoclonal antibody by IV infusion plus standard ART
45345323|NCT03743376|Biological|UB-421(25 mg/kg) Q4W|Monoclonal antibody by IV infusion plus standard ART
45345324|NCT00734864|Drug|enzyme-inducing anti-epileptic drugs|Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
45345325|NCT00734864|Drug|enzyme-inducing anti-epileptic drugs|Subjects NOT taking EIAEDs (CYP-3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
45345326|NCT00869674|Procedure|GeneSearch™ Breast Lymph Node (BLN) Assay|"Each of the sentinal lymph node will be divided in half according to cutting scheme.~Half of the sentinal lymph node will be tested using rountine pathological method as normal practice, half of the node will have GeneSearch BLN testing."
45345327|NCT03728478|Drug|Etanercept|Patients will receive etanercept subcutaneously at a dose of 0.8 mg/kg weekly (up to a maximum dose of 50 mg weekly).
45345328|NCT03728478|Drug|Methotrexate|Methotrexate will be administered subcutaneously, in a single weekly dose of 15 mg/m2 (max 20 mg).
45474932|NCT01188317|Drug|placebo|repeated daily doses
46041578|NCT05323942|Other|Education and Exercise Therapy Group|"82 children were evaluated. Among those, 37 volunteered children were trained and demonstrated in practice about bruxism, parafunctional oral habits, sleep hygiene education, and 5x5 therapeutic exercises. Therapeutic exercises program 5x5 included breathing exercises, head-neck, and scapular posture exercises which included jaw muscle and neck muscle stretching and strengthening exercises. They were asked to repeat each exercise with 5 set and 5 times a day for 8 weeks.~Sleep hygiene education was given to parents and children with explanation of the parafunctional oral habits to raise awareness about being conscious about the oral habits. Sleep hygiene education includes routines about bedtime, sleeping room environment, and timing for exercise."
46041579|NCT03088150|Procedure|Thermal ablation|Patients will undergo either radiofrequency ablation (RFA) or microwave ablation (MWA).
45345329|NCT03728478|Drug|Intra-articular corticosteroid injections|Triamcinolone hexacetonide and methylprednisolone acetate doses depend on the affected joint.
46041580|NCT03088150|Procedure|Surgical resection|In case of randomization to surgical resection, the surgeon will remove all target lesions as well as all additional unablatable lesions.
45474933|NCT01188317|Drug|ibuprofen|repeated daily doses
45474934|NCT03356704|Other|no intervention|Observational study
45684728|NCT01890850|Other|Retrospective database study using administrative claims data|Data collection from OptumInsight proprietary research database which contains enrollment and claims data for individuals enrolled in commercial health plans.
46041581|NCT02691754|Other|free paracetamol|General Practitioners can prescribe paracetamol and the patient had to pick up the drug at the local hospital.
45345330|NCT00738998|Behavioral|Questionnaire|Questionnaires about pain and other symptoms, quality of life, and ability to work will be completed.
45345331|NCT00738998|Other|Phone Calls|A telephone system will call every 2 weeks so that you can rate your symptoms and how they interfere with daily activities. Each call will take about 5 minutes.
45345332|NCT00653523|Drug|Ezetimibe|Ezetimibe 10 mg once daily
45345333|NCT00653523|Drug|Simvastatin|Simvastatin 20 mg daily
45345334|NCT00869752|Biological|anti-IGF-1R recombinant monoclonal antibody MK-0646|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
45345335|NCT00869752|Drug|cisplatin|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
45345336|NCT00869752|Drug|etoposide|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
45345337|NCT00739076|Behavioral|Virtual Reality|Using Virtual Reality for pain control
45345338|NCT00869830|Other|biofeedback therapy|biofeedback therapy was applied using the surface electromyography (EMG) method with a perianal sensor (Perry, Elan, SRS Medical Systems, Redmond, WA, USA) and biofeedback PC equipment (Orion, Platinum, SRS Medical Systems, Inc., Redmond, WA, USA).
45345339|NCT00799851|Device|Variceal band ligation|
45345340|NCT00799851|Drug|cyanoacrylate injection|cyanoacrylate injection
45345341|NCT02544412|Behavioral|novel mindfulness-based well-being training|
45345342|NCT02717442|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
45345343|NCT02717442|Drug|Placebo|Single intratympanic injection of placebo
45345344|NCT00799929|Other|in vitro fertilization (IVF/ICSI)|
45345345|NCT00734942|Other|support service|"professional partners for communication~befriending with other families concerned~information and education (about illness, symptoms, first aid, caring)~free-time activities and time out~homework assistance~administrative advise~support for everyday life"
45684729|NCT02816788|Behavioral|Equine Assisted Therapy (EAT)|Psychotherapy incorporating use of equines (Equine Assisted Therapy; EAT) to facilitate therapy to improve the social, emotional and psychological well-being of participants and alleviate PTSD symptoms.
46041582|NCT02691676|Drug|Plasmalyte|Parenteral administration of Plasmalyte initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
46041583|NCT02691676|Drug|Ringerfundin|Parenteral administration of Ringerfundin initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
46041584|NCT00616486|Device|repetitive transcranial magnetic stimulation|6 weeks of stimulation with RMT frequency 1Hz, intensity 110% of RMT for 20 minutes, 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
46041585|NCT00616486|Device|sham (placebo)|Sham treatment will mimic active treatment mentioned above.
45345346|NCT00862732|Behavioral|Cognitive behavioural therapy|Will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
45345347|NCT00862732|Other|Treatment as usual|Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
45345348|NCT00808977|Drug|Dersalazine sodium|Dersalazine sodium 2400 mg daily
46041586|NCT05321602|Drug|LY03010 156 mg treatment group, deltoid|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
46041587|NCT05321602|Drug|LY03010 156 mg treatment group, gluteal|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
46041588|NCT05321602|Drug|LY03010 351 mg treatment group, deltoid|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
45345349|NCT00808977|Drug|Mesalazine|Mesalazine 2400 mg daily
45345350|NCT00808977|Drug|Placebo|Placebo matching active and experimental treatments
45345351|NCT04065854|Behavioral|Intervention|Assessment, tailored strength and balance exercise programme, activity analysis and risk enablement advice, and assessment for environmental hazards. Tailored adherence support and supervision.
45345352|NCT02544334|Procedure|Dental Plaque|All participants will have dental plaque removed from different tooth surfaces for supragingival.
46041589|NCT05321602|Drug|LY03010 351 mg treatment group, gluteal|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
46041590|NCT05318872|Device|ENDOSWIR|Patients were enrolled for surgery of their cancer and give their consents to the participation to that study. Characteristics of anonymized patient (sex, age, medical history, and tumoral characteristics) will be collected. During surgery, the excisional specimen will be sent in a fresh state for pathological examination (gold standard). The pathologist will determine 10 zones on a cross-section of the specimen which will be analyzed by SWIR, and compared between the two techniques.
45345353|NCT02544334|Other|Multi-dimensional health assessment questionnaire (MDHAQ)|The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.
45345354|NCT02544334|Other|Saliva Collection|All participants will have a saliva collection.
45345355|NCT00800007|Drug|ANZ-521|3x10^7 cfu or 3x10^8 cfu ANZ-521 in 250 mL, IV over 2 hours, every 28 days for up to 3 doses.
46041591|NCT01106651|Drug|Canagliflozin 100 mg|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
46041592|NCT01106651|Drug|Canagliflozin 300 mg|One 300 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
45345356|NCT00800007|Drug|Placebo|250 mL normal saline, IV over 2 hours, every 28 days for up to 3 doses.
45345357|NCT00739232|Drug|HSD-016|
45345358|NCT00739232|Other|placebo|
45345359|NCT02569008|Drug|Fluid challenge with Compound Sodium Lactate|Infusion of the mentioned dose of Compound sodium Lactate over 5 minutes intravenously.
45345360|NCT00735020|Biological|Adjuvanted Influenza Vaccine|1 dose of Adjuvanted Influenza Vaccine
45345361|NCT00735020|Biological|Influenza Vaccine|1 dose of Influenza Vaccine
46041593|NCT01106651|Drug|Antihyperglycemic agent(s)|Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4] inhibitors, metformin, insulin [all types]) and their combinations (sulfonylurea agent and insulin [all types], metformin and insulin [all types], metformin and sulfonylurea, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4]) are used as per protocol specifications.
46041594|NCT01106651|Drug|Placebo|One matching placebo capsule orally once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
45345362|NCT03869151|Diagnostic Test|CBC|lymphocyte and monocyte count
46041595|NCT00637078|Other|Treatment algorithm:caduet, Amlodipine, ACEI-ARB combo dose, a-blocker, b-blocker or spironolactone, dyslipidemic therapy with ezetamide|initial treatment with a low dose diuretic/ACE-inhibitor or ARB combination followed by a low dose DHP-CCB/statin combination
46041596|NCT05323162|Other|encapsulated autologous fecal microbiota transplantation|Individuals will recieve encapsulated freezedried own fecal microbiota to potentially extingish auto-immunity directed against the residual beta cell fraction
46041597|NCT05323006|Other|scapular stabilization exercises|the effect of the scapular stabilization exercise on the clavicular motion on the adolescent girls
46041598|NCT04214470|Other|No intervention|There is no intervention for this study
46041599|NCT00616564|Drug|GM-CSF|Concomitant Priming with GM-CSF
46041600|NCT04214314|Behavioral|NeuronUp APT attentional program|NeuronUp APT attentional program consists of 4 types of attention with 20 activities each and 5 different levels of difficulty per activity. These 20 activities will be divided into two blocks (block A or block B) of 10 activities each and then, randomly, participants will be administered one block or another. The administration of the entire program is approximately one month and a half or 2 months per patient, with sessions of one hour, 3 times per week.
46041601|NCT05003609|Other|Early Rehabilitation|The intervention involves a progression of rehabilitation exercises with the objective of rehabilitating the patient at the highest level of exercise possible for the patient for the longest period of time that can be tolerated (up to 60 mins) at each session. The intervention will be administered 5 days per week (weekdays) while the patient remains in ICU, censored at 28 days after randomisation.
46041602|NCT00625781|Drug|Insulin aspart and Insulin human (isophane)|Insulin treatment if fasting p-glucose >5.0 mmol/l or post meal value >6.5 mmol/l according to study protocol.
46041603|NCT05111951|Behavioral|Telehealth-delivered physical exercise and support for physical activity|Telehealth-delivered physical exercise sessions, prescription of an individual exercise-regime and support for physical activity through behavior change techniques.
46041604|NCT05111951|Behavioral|Physical activity on prescription|Telehealth-delivered physical activity on prescription in accordance with the core elements of the Swedish model for physical activity on prescription.
45684730|NCT01891006|Device|Negative Pressure Wound Therapy|The Negative Pressure Wound Therapy are changed on the 2. day and removed on the 4. day after the re-operation.
45684731|NCT01891006|Other|Standard wound dressing|The standard wound dressing is a a hydrofiber or alginate dressing used for open wounds
46041605|NCT02867644|Other|standard care|Patients coming for preoperative breast assessment will have standard care.
46041606|NCT02867644|Other|standard care + conversational hypnosis|Patients coming for preoperative breast assessment will have standard care with conversational hypnosis
46041607|NCT02880449|Behavioral|Intervention|A PA promoting intervention which provides education, social support and information about local opportunities for PA to pre-existing groups of older women living in socio-economically disadvantaged areas
46041608|NCT01027650|Drug|AGN208397 intravitreal injection|AGN208397 intravitreal injection on Day 1.
46041609|NCT01027650|Drug|dexamethasone intravitreal implant|Dexamethasone 700 ug intravitreal implant on Day 1.
46041610|NCT02880527|Other|Patients with polymyositis / dermatomyositis|"recruitment of patients with polymyositis / dermatomyositis using :~medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;~general practitioners~the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )~5) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association"
46041611|NCT05322772|Device|ECG|ii. 12 leads ECG: 12 leads ECG will be done to all infants & children using (FUKUDA DENSHI, CARDIMAX, model FCP 7101). The electrocardiograms will be reviewed through the creation of descriptive reports and determination of the following variables: heart rate, QRS duration, The QT interval was measured from the onset of the QRS complex to the end of the T wave, defined by the return of the terminal T wave to the isoelectric T-P baseline. When U waves were present, the end of the T wave will be taken as the nadir between the T and U waves. Then QT interval will be corrected for heart rate using Bazett's formula Interpretation of every ECG paper
45684732|NCT04272112|Combination Product|IPS e.max CAD, Ivoclar Vivadent|Type: monolithic lithium-disilicate glass ceramic
45684733|NCT04272112|Combination Product|BruxZir, Glidewell|Type: high translucent zirconia
45474935|NCT03739177|Diagnostic Test|Onco4D Biodynamic Chemotherapy Selection Assay|The Onco4D Biodynamic Chemotherapy Selection Assay uses Motility Contrast Tomography (MCT) to measure ex-vivo fresh tumor biopsy response when challenged by an array of chemotherapeutic agents. A machine learning algorithm uses the MCT datastream to predict in vivo tumor response or non response to chemotherapy.
46041612|NCT05000567|Other|12 week nordic hamstring exercise program|12 weeks progressive eccentric strength training program targetting the hamstring muscles.
46041613|NCT04214548|Other|No Intervention|There is no intervention for this study
45474936|NCT03206970|Drug|Zanubrutinib|Administered as specified in the treatment arm.
45474937|NCT04520386|Drug|OMT-111|Pre-filled Syringe
45474938|NCT03739021|Drug|Exparel|Single shot of the Bupivacaine Liposome, and then we follow up with patient in the recovery room with traditional common pain management. MME (milligram morphine equivalent) will be collected.
45474939|NCT03739021|Drug|Ropivacaine|Continuous infusion of Ropivacaine via catheter, and then we follow up with patient in the recovery room with traditional common pain management. MME (milligram morphine equivalent) will be collected.
45474940|NCT01588145|Drug|HM61713|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
45684734|NCT04272112|Combination Product|BruxZir*, Glidewell|Type: high translucent zirconia with a mini-veneer of porcelain
46041614|NCT04309331|Dietary Supplement|Motion|Amino acid based protein substitute
46041615|NCT00616876|Drug|Lactulose|Babies in the study group received lactulose in a dose of 1% in their entire mother's breast milk or preterm formula feeds (1 gram per 100 ml feeds, based on the daily volume of feeds, and evenly distributed between all the feeds for the entire duration of their hospital stay). 67% lactulose in the original preparation (Laevolac, Fresenius Kabi, Austria) was diluted by distilled water to 33.5% preparation in the pharmacy in strict sterile conditions under hood. Just before feeding the nurses added the required volume of this 33.5% lactulose solution to the ordered volume of feed to generate a final concentration of 1% lactulose in each feed.
46041616|NCT00616876|Dietary Supplement|Dextrose|Babies in the control groups were given equal volumes of the comparable placebo in all their preterm formula feeds at final concentration of 1% dextrose. The 33.5% dextrose placebo solution was prepared by dissolving dextrose (Dextrose Pulv. USP.24/BP, Roquette Frores 6280, Lestrem, France) in distilled water under heat to the point of near boiling under the same strict sterile conditions in the pharmacy. This gave a placebo solution that looked similar in color, odor and liquidity to the study solution of 33.5% lactulose. Dark bottles were used to further blind the medical team as to what solution was the baby given.
46041617|NCT01106027|Drug|Eculizumab|Eculizumab 900 mg and 1200 mg, administered intravenously (IV)
46041618|NCT00616954|Drug|ATG-F|ATG-f
46041619|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
46041620|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
45345363|NCT04065906|Behavioral|NIRS neurofeedback|Neurofeedback as a treatment for ADHD can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
46041621|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
46041622|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
45840825|NCT00908466|Drug|Sirolimus (rapamycin)|Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.
46041623|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
46041624|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
46041625|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
46041626|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
46041627|NCT00927927|Drug|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
46041628|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
46041629|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
46041630|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
46041631|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
46041632|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
46041633|NCT00927927|Drug|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
46041634|NCT04257513|Diagnostic Test|Brain MRI|Neurological and Cognitive evaluation; Brain MRI
46041635|NCT01027416|Drug|Tamoxifen|Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks
46041636|NCT04259931|Diagnostic Test|microbiome analysis|gut microbiome composition of C. difficile infected patients with relapsing (basal, at the end of first treatment, at the begin of the relapses and at four and twelve weeks after definitive treatment) and non-relapsing ( basal and four and twelve week after treatment) , will be analyzed.
45345364|NCT04065906|Drug|Methylphenidate or Tomoxetine|Methylphenidate is the first line drug of ADHD Tomoxetine is the second line drug of ADHD
45345365|NCT02544256|Procedure|Mild hypothermia|Mild hypothermia during surgical clipping of brain aneurysm will be reached by cooling to body temperature 33,8° C - 34,8° and this temperature maintained up to the end of microcirculation measurement after aneurysm clipping.
45345366|NCT00739388|Drug|azacytidine|100 mg/m2/day s.c. on days 1-5 of a 28-day cycle
45474941|NCT03363958|Procedure|Remote Ischemic Preconditioning with Postconditioning|Three cycles of 5 minutes of ischemia and 5 minutes of reperfusion of lower leg 24 hours, immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
46041637|NCT04300842|Device|smart bracelet|to measure the stress, fatigue, and activity.
46041638|NCT05331495|Device|Intraoperative Hemoperfusion|During the operation, the hemoperfusion device and the membrane oxygenator of the extracorporeal circulation device were operated in parallel.
45345367|NCT00809211|Drug|nilotinib|
45345368|NCT00809211|Genetic|cytogenetic analysis|
45345369|NCT00809211|Genetic|mutation analysis|
45345370|NCT00809211|Genetic|polymerase chain reaction|
45474942|NCT03363958|Procedure|Sham RIPC procedure|Three cycles of 5 minutes of inflation and 5 minutes of deflation of artificial lower leg immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
45474943|NCT03738943|Drug|Adenosine Triphosphate|See arm/group descriptions
46041639|NCT02873520|Drug|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
46041640|NCT02873520|Biological|Precision Cell Immunotherapy|DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
45474944|NCT03738943|Drug|Acetylcholine|See arm/group descriptions
45474945|NCT03738943|Drug|Sodium Nitroprusside|See arm/group descriptions
45474946|NCT03738943|Drug|Adenosine Diphosphate|See arm/group descriptions
45474947|NCT03738943|Drug|Adenosine Monophosphate|See arm/group descriptions
45684735|NCT04272346|Behavioral|Writing for others|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart, and participants will be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
46041641|NCT05026203|Drug|Ketamine Hydrochloride|Ketamine hydrochloride 0.5 mg/kg intravenous administer in 40 minutes per day for 3 consecutive days
46041642|NCT05026203|Drug|Midazolam|Midazolam
45840826|NCT00908466|Drug|Sirolimus (rapamycin)|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
45474948|NCT03738943|Drug|Uridine Triphosphate|See arm/group descriptions
45474949|NCT03738943|Drug|Adenosine|See arm/group descriptions
45474950|NCT03738943|Drug|Vitamin B 6|See arm/group descriptions
45474951|NCT03738943|Drug|Pyridoxal 5'-Phosphate|See arm/group descriptions
45840827|NCT00909324|Drug|Pre-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting 5 days prior to LASIK surgery and continuing through 1 month after LASIK surgery.
45345371|NCT00809211|Other|pharmacological study|
45345372|NCT00862888|Drug|PF-00446687|Single 200mg dose as an oral solution
45345373|NCT00862888|Drug|Placebo|Placebo for oral solution
45345374|NCT00862888|Drug|Placebo|Placebo for tablet
45345375|NCT00862888|Drug|Sildenafil|Single oral dose 100 mg tablet
45345376|NCT00862888|Drug|PF-00446687|Single 125 mg dose as an oral solution
45345377|NCT00862888|Drug|PF-00446687|Single 175 mg dose as an oral solution
45345378|NCT00862888|Drug|PF-00446687|Single 20 mg dose as an oral solution
45345379|NCT00862888|Drug|Placebo|Placebo for oral solution
45345380|NCT00862888|Drug|Placebo|Placebo for tablet
45345381|NCT00862888|Drug|Sildenafil|Single oral dose 100 mg tablet
45345382|NCT00729456|Other|Education|Patients receive a single session, one-to-one workshop (carers may be included if appropriate) in their own home, lasting 60 - 120 minutes.
45345383|NCT00800085|Drug|glucose 20%|maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals
46041643|NCT00923559|Other|Treatment as Usual at Child Health Centre|Treatment as usual (TAU) involved scheduled nurse calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The nurse is encouraged to promote attachment and to detect postnatal depressions. Mothers might be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Within the TAU framework, additional treatment might be initiated by the nurse or the mother. This was registered at the end-point interview.
45345384|NCT00731250|Drug|SB-705498|Subjects will be administered a single dose of 400 mg SB-705498
45345385|NCT00731250|Drug|Placebo|Subjects will be administered SB-705498 matching placebo tablets
45474952|NCT05126082|Behavioral|PedsBP CDS|The PedsBP CDS is a sophisticated web-based electronic health record (EHR)-linked tool that can be used to address barriers and improve the identification and management of elevated blood pressure (BP) and hypertension (HT) in children and adolescents by providing patient-specific clinical care recommendations in real time and in accordance with national guidelines for BP management in youth.
46041644|NCT00923559|Other|Mother-Infant Psychoanalytic treatment (MIP)|MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. In the study, the analysts strived to recruit the baby for an emotional interchange, though this did not imply any belief that the infant would understand verbal communication. Rather, the analyst addressed the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst took care in enrolling the participant mother. This was to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her space to vent her own frustration, depression and anxiety.
46041645|NCT01015638|Drug|Clindamycin and BPO 5% gel|Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.
46041646|NCT01015638|Drug|Clindamycin phosphate and benzoyl peroxide 2.5% gel.|Once daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel
46041647|NCT04257591|Other|hamstring strengthening|A progressive and individualized hamstring strengthening protocol
46041648|NCT01022502|Drug|refined indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
46041649|NCT01022502|Drug|crude indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
46041650|NCT04907877|Dietary Supplement|Probiotic|Probiotic will be taken 1 time a day before breakfast for 28 days.
46041651|NCT04907877|Dietary Supplement|Placebo|Placebo will be taken 1 time a day before breakfast for 28 days.
46041652|NCT02872506|Drug|Anti TNF|Patients are admitted to day hospital with blood test less than 7 days. In the absence of contraindications, hydrocortisone infusion 200 mg will be conducted for 15 minutes followed by anti-TNF treatment infusion over 2 hours for the first three sessions. The following infusions of anti-TNF therapy will be on the same terms without hydrocortisone, every 4 to 8 weeks, in doses of 5-10mg/kg. Adverse effect most frequently reported was URTI. The most serious adverse reactions, were a reactivation of hepatitis B, congestive heart failure, serious infection, serum hypersensitivity reactions, blood diseases, systemic lupus erythematosus / lupus-like syndrome, demyelinating disorders, hepatobiliary metabolism disorders. The QOL will be assessed by IBDQ score at the inclusion visit before the first infusion and at 6 months.
46041653|NCT02872506|Procedure|ileocecal resection|The operation is performed by laparoscopy or laparotomy. Hospital stay is on average 6 days. Preparation for the intervention is sometimes required 3 weeks to 1 month before the procedure to avoid risk situations.The main risk of the intervention is the anastomotic fistula. This risk of anastomotic leakage mainly concerns malnourished patients operated within the context of abdominal sepsis (abscess). An assessment protocol of post-operative pain, every 3 hours, is now well codified in routine surgery. The QOL will be assessed by the IBDQ score before surgery and at 6 months.
45345386|NCT00731250|Other|Caspaicin|Subjects will be challenged with 0.5 µg, 5.0 µg and 50 µg intranasal dose
45345387|NCT04041076|Procedure|Major surgical operation|Surgical operation with magnitude defined as major or ultra-major
45345388|NCT00735098|Other|KBA exercise|KBA exercise protocol, 3 times per week for 8 weeks
45345389|NCT00735098|Other|strength training exercise|strength training exercise, 3 times per week for 8 weeks
45345390|NCT00735098|Other|KBA and strength training|KBA and strength training exercise, 3 times per week for 8 weeks
45345391|NCT00735098|Other|Control group|8 week control group
45345392|NCT00800163|Other|ED Activation/Immediate Transfer|ED Physician Activation and Immediate Transfer Protocol - see Circulation. 2007;116:67-76
45345393|NCT00731328|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|infusion of mobilized donor hematopoietic progenitor cells
45345394|NCT00729170|Dietary Supplement|Supplementation of milk (35% more calcium)|The supplement provides 1000 mg of calcium and 250 kcal daily.
45345395|NCT00871078|Device|Optical Coherence Tomography (OCT)|Macular and retinal nerve fiber layer OCT (Stratus OCT, Carl Zeiss Meditec, Dublin, CA) will be performed both in patients and controls
45345396|NCT00871078|Device|Frequency Doubling Technology (FDT) perimeter|24-2 FDT Threshold (Humphrey Matrix, Carl Zeiss Meditec, Dublin CA; Welch-Allyn, Skaneateles, NY) will be performed both in patients and controls.
45345397|NCT04065594|Procedure|PRP dressing|PRP dressing gel dressings for treatment of chronic ulcer
45345398|NCT04065594|Procedure|conventional ordinary dressing|conventional ordinary dressing for treatment of chronic ulcer
45345399|NCT00735176|Procedure|Cervical arthroplasty|Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
45345400|NCT00735176|Procedure|Anterior cervical discectomy and fusion (ACDF)|Anterior cervical discectomy and decompression, followed by insertion of a PEEK cage, which induces fusion.
46041654|NCT05331417|Diagnostic Test|Patients with herpes-simplex infection requiring bronchoscopy|Due to the observational design of the study, no study-specific interventions are performed. The indication for bronchoscopy is determined by the responsible ICU physicians. Except for the above mentioned laboratory analyses, the treatment of the patients is completely guided by the responsible ICU physicians.
45345401|NCT00862966|Other|citrate|comparison of different catheter lock solutions
45345402|NCT00862966|Other|heparin|comparison of different lock solutions
45345403|NCT02569320|Drug|Dexamethasone|Given PO
45345404|NCT02569320|Drug|HDAC Inhibitor AR-42|Given PO
46041655|NCT00627744|Drug|Sitagliptin|BE 1 receives Placebo tablets od during 12 weeks BE 2 receives Sitagliptin tablets 100 mg od during 12 weeks
46041656|NCT01105091|Drug|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
46041657|NCT01105091|Drug|Flolan®|Per Prescribing Information
45345405|NCT02569320|Other|Laboratory Biomarker Analysis|Correlative studies
45474953|NCT01588223|Other|Lipid identification|The lipids are identified using Mass Spectrometry
45345406|NCT02569320|Drug|Pomalidomide|Given PO
45345407|NCT00739466|Drug|Liposomal Alendronate|IV in a single low dose during the index procedure (coronary stent implantation) over 2 hours
45345408|NCT00739466|Drug|Liposomal Alendronate|IV in a single high dose during the index procedure (coronary stent implantation) over 2 hours
45345409|NCT00739466|Drug|Saline infusion (placebo)|IV saline infusion during the index procedure (coronary stent implantation) over 2 hours
45345410|NCT02544178|Radiation|brain radiotherapy|effect of cerebral radiotherapy on neurocognitive state
45345411|NCT00863044|Procedure|Apnea|Ventilation will be stopped for the duration of the anastomosis as it's done currently. At all other times during the surgery, the ventilatory parameters will be adjusted to maintain a PaCO2 between 40 and 45 mmHg.
45345412|NCT00863044|Procedure|High frequency ventilation|The patients will be ventilated using a tidal volume of 1.5 ml per Kg and a respiratory rate of 100 per minute for as long as the surgeon needs to perform the distal anastomosis of the coronaries.
45345413|NCT00739544|Other|1|Testing with thermal sensor testing device, von Frey filaments, cotton wisp, turning fork, pressure gauge device
45345414|NCT00735332|Drug|TLN-232|21 day continuous IV administration of TLN-232 followed by a 7-day recovery period
45345415|NCT00869908|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
45345416|NCT00869908|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
45345417|NCT00869908|Drug|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
45474954|NCT04520152|Device|FreeFlowMedical Lung Tensioning Device|Bronchoscopic lung tensioning device implantation
46041658|NCT04257435|Behavioral|Positive Psychological Group Treatment|Positive psychological group treatment will involve engagement in traditional behavioral health treatment, as well as a group treatment focusing on previously researched exercises that have been demonstrated to relate to reduced depression and increased positive emotionality (Seligman, Rashid, Parks, et al., 2005; Seligman, Rashid, & Parks, 2006; Rashid, 2015).
46041659|NCT04257435|Behavioral|Traditional Behavioral Health Treatment|Treatment will include traditional individual behavioral health treatment, involving CBT-based therapeutic interventions for presenting diagnoses (typically depression, anxiety, or PTSD-related symptomatology).
46041660|NCT04253301|Device|InnoVein Valve Treatment|Subjects will have the InnoVein Valve implanted
46041661|NCT00628056|Drug|Perhexiline|Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks
45345418|NCT00734058|Device|Laser MAZE by Ablation of Cardiac Tissue|The protocol calls for the creation of the pulmonary vein isolation lesion through the use of the SOLAR™. The additional lesions are to be created using the ATRILAZE™. At surgeon discretion, the ganglia may be ablated and left and right atrial appendages may be removed.
45345419|NCT00739622|Drug|TMC278|
45345420|NCT00731562|Drug|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fasted conditions
45474955|NCT01588301|Behavioral|Attending for cervical cytology|A further invitation to attend for cervical cytology are going to be sent by mail to women
45474956|NCT01588301|Behavioral|Kit for Self-collected vaginal sample|Kit for self-collected vaginal sample are going to be directly sent at women's home
45474957|NCT04520308|Drug|Dupilumab Only Product|SC injections of 300 mg dupilumab every 2 weeks for 24 weeks following a loading dose of 600 mg on day 1
45474958|NCT03644173|Behavioral|Personal Resilience Empowerment Program including 5 sessions with health coaches|5 coaching sessions that will take place either in-person or over the phone with a research nurse (RN)-Health Coach. During the sessions, the health coach will focus on introducing the 5 pillars of health and well-being: sleep, activity, purpose, nutrition and resilience. Will introduce breathing techniques participants and will teach patients how to acquire mind-body skills to assist in stress management, learn to thrive by building resilience, feel empowered to manage their health, gain self-care skills to decrease anxiety, pain and nausea naturally, control the stress response and trigger the relaxation response to promote well-being and discover what foods fuel the body in preparation for healing, during recovery and overall health.
46041662|NCT00924729|Drug|Moxifloxacin 0.5% ophthalmic solution|Administer moxifloxacin study drug prior to cataract surgery.
46041663|NCT00924729|Drug|Besifloxacin 0.6% ophthalmic suspension|Administer besifloxacin study drug prior to cataract surgery.
45684736|NCT04272346|Behavioral|Processing + writing for others|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart. For the first three writing sessions, participants will write their deepest thoughts and feelings regarding cancer diagnosis and treatment. In the final writing session, participants will be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
46041664|NCT01099709|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken with food.
46041665|NCT01099709|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken with food.
46041666|NCT04257357|Behavioral|8-weeks supervised exercise program|Please refer to group description
46041667|NCT04257357|Behavioral|Active control|Please refer to group description
46041668|NCT01099397|Other|Oral glucose tolerance test|For assessment of dysglycemia, 75 grams of glucose solution by mouth at 3 PEAR study visits for all enrolled participants: baseline, single drug therapy assessment, and dual drug therapy assessment.
45345421|NCT00731562|Drug|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fed conditions
45345422|NCT00870064|Procedure|Formal Operative Treatment|Children randomized to the OR arm will be taken to the OR within 24 hours for irrigation and debridement and appropriate bone management.
45345423|NCT00870064|Procedure|Emergency Department Treatment|Children in the ED arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics.
45345424|NCT00734136|Procedure|Blood Draws and a hepatectomy specimen|"Pre operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons).~Blood draw during surgery(1.5 ml serum, 1.5 ml EDTA)from Hepatic Artery, Hepatic Vein, and Portal Vein.~Wedge section of Hepatectomy specimen following resection in surgical subjects(tested for the same factors)"
45345425|NCT00734136|Procedure|Blood draw - pre operative standard of care|Pre-operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons) from peripheral vein
45345426|NCT00739778|Other|food - novel sweetener|concentration to be isosweet with 4.7% sucrose
45345427|NCT00739778|Other|food vehicle blank|water blank
46041669|NCT04907019|Drug|rifampicin，SY-004|"On the morning of D1, the subjects will take orally 80 mg of SY-004 Capsules on an empty stomach.Fasting will be performed within 4 hours after taking the medicine. From D8 to D14, the subjects will take orally 600 mg rifampicin before breakfast every day. On the day of D15, the subjects will take orally 600 mg rifampicin and 80 mg SY-004 Capsules on an empty stomach.~From D16 to D21, subjects will take orally 600 mg of rifampicin before breakfast every day.The patient can be discharged from the hospital after completing the safety examination on D22."
46041670|NCT01022424|Drug|OPC-41061|Repeated oral administration at doses of 15 mg twice daily (morning and evening)
46041671|NCT05329857|Drug|Metformin and Vildagliptin 1000/50 mg|50 mg Vildagliptin + 1000 mg Metformin as single-dose per study period
46041672|NCT04981041|Drug|Prasugrel or Ticagrelor|Escalated antiplatelet therapy with a potent P2Y12- inhibitor for one month in patients with atrial fibrillation and indication for treatment non-vitamin K antagonist oral anticoagulants (NOACs)
46041673|NCT04981041|Drug|Clopidogrel|Clopidogrel and NOAC
46041674|NCT01026948|Drug|Dinoprostone|Propess© vaginal delivery system consists of a non-biodegradable polymeric drug delivery device containing 10 mg Dinoprostone (PGE2) dispersed throughout its hydrogel matrix. The retrieval vaginal insert expands to twice its size and releases a continuous and predictable dose of Dinoprostone at a rate of approximately 0.3 mg/hr over 24 hours (4-5 mg PGE2 over 12 hours) in women with intact membranes whereas release is higher and more variable in women with premature rupture of membranes.
46041675|NCT01026948|Device|Monica AN 24|AN24 Monica is a portable, battery powered device designed to passively monitor a pregnant mother and unborn baby. The device is attached via a suitable cable assembly which in turn attaches to 5 standard disposable electrodes placed on the abdomen of a pregnant woman and is intended for use in either the home or hospital environment.
46041676|NCT05038332|Radiation|Ultra-hypofractionated radiation therapy|34 Gy in 5 fractions to prostate bed, every other day, M-F, ~2 weeks (25 Gy in 5 fractions to pelvic lymph nodes if included)
46041677|NCT05038332|Radiation|Moderately Hypo-fractionated Radiation Therapy|55 Gy in 20 fractions to prostate bed, daily, M-F, 4 weeks (42 Gy in 20 fractions to pelvic lymph nodes if included)
46041678|NCT04951089|Device|i-gel Supraglottic device insertion|i-gel insertion for oxygenation
46041679|NCT04951089|Device|Air-Q SP 3G Supraglottic device insertion|Air-Q SP 3G insertion for oxygenation
46041680|NCT05033652|Other|WARNING KD|"Within 48h of detecting an abnormal creatinemia value (GFR<30 or AKIN2 and AKIN3), the biology laboratory will communicate the patient's information to the WARNING KD team. This team consists of one nephrologist and one clinical pharmacist who will trigger the initial management in the department and then, if the patient has a persistant warning signal during hospitalization, define the patient's course of treatment for discharge. Patients requiring special care will be oriented towards a nephrologist and the patient's GP will be alerted to the benefit of addressing the patient to a nephrologist for multidisciplinary management with a therapeutic project according to the recommendations for good therapeutic practices."
46041681|NCT01104779|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
45345428|NCT00739778|Other|food - sweetener, positive control|4.7% sucrose in water
45345429|NCT00739778|Other|food - sweetener, negative control|non-cariogenic sweetener at concentration isosweet with 4.7% sucrose
45684737|NCT04272346|Behavioral|Facts-only writing|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart. Unlike the previous conditions, participants will not be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
46041682|NCT01104779|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
45345430|NCT00731718|Device|lousebuster|Subject serves as own control the length of treatment is approximately 30 minutes for full head treatment
45345431|NCT04695392|Other|R2 Bundle|"During the intervention phase subjects will receive R2.~Focused effort to replicate the child's pre-hospitalization daily routine (bedtime/wake time, bedtime/arousal routine, nap time, feeding schedule, active periods),~Cycled day-night lighting and modulation of sound to match the child's routine,~Minimal yet effective sedation using a nurse-implemented goal-directed sedation plan (RESTORE),~Night fasting with bolus enteral daytime feedings,~Early, developmentally-appropriate, progressive exercise and mobility (PICU Up!),~Continuity in nursing care, and~Parent diaries."
45345432|NCT00870142|Drug|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fasting conditions
45345433|NCT00870142|Drug|Norvasc® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fasting conditions
46041683|NCT00918957|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder as produced by a modified manufacturing process TIP. TIP was provided in hard capsules each containing 28 mg active ingredient (tobramycin); Capsules were packaged in blister cards and administered by the T-326 Inhaler.
46041684|NCT00918957|Drug|Placebo|Placebo inhalation powder consisting of the excipients used for TIP. Placebo was provided in hard capsules, containing 20 mg placebo powder, which were packaged in blister cards, matching in appearance to TIP. Capsules were administered by the T-326 Inhaler.
46041685|NCT04308161|Drug|vitamin D oral gel|vitamin D is a fat soluble vitamin which has important calcemic roles in the body regarding bone homeostasis and calcium/phosphorus balance. Recently, the non-calcemic roles of vitamin D as anti-inflammatory, anti-oxidant and immuno-regulatory functions have been widely reported.So, we tried to use it for prevention of radiation induced oral mucositis
46041686|NCT04308161|Drug|Miconazole Topical Gel|topical anti fungal agent
46041687|NCT04308161|Drug|BBC oral spray|Topical anesthetics and anti-inflammatory agent
46041688|NCT04308161|Drug|Oracure gel|Topical analgesic gel
46041689|NCT04308161|Other|Alkamisr sachets|Sodium bicarbonate mouthwash
46041690|NCT04939467|Drug|Pirfenidone 267 mg Oral Tablet|Fixed sequence use of active product, TID
46041691|NCT04939467|Drug|Nintedanib 150 mg Oral Capsule|Fixed sequence use of active product, BID
46041692|NCT04939467|Drug|BLD-0409 750 mg Oral Tablet|Fixed sequence use of active product, QD
46041693|NCT01015560|Drug|anti-CCR2 monoclonal antibody MLN1202|
46041694|NCT01015560|Genetic|polymorphism analysis|
46041695|NCT01015560|Other|laboratory biomarker analysis|
46041696|NCT02878889|Drug|S-1|
46041697|NCT04581174|Diagnostic Test|24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated|Patients with the 1st degree of hypertrophy according to Camacho, 2nd degree of hypertrophy according to Camacho, 3rd degree of hypertrophy according to Camacho, 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
46041698|NCT02879045|Other|Elasticity Belly® oil|We will enroll about 50 Nulliparous women randomly, who are in their second trimester of pregnancy. We divide each of the volunteer's abdomen skin into two parts through medioventral line, one of the abdomen skin will receive the elasticity Belly® oil to prevent striae gravidarum, and the other side will use the Clarins® oil. Volunteers apply these two kinds of oil daily until birth. We'll take abdomen pictures before and after interventions, and the occurrence of striae on abdominal skin and its severity will be evaluated as our primary end point of the study.
46041699|NCT04253223|Biological|REMD-477|REMD-477 will be administered as a subcutaneous injection for three weekly doses
46041700|NCT00918879|Drug|Saxagliptin|Oral tablet, once daily for 24 weeks
45345434|NCT00731796|Device|Functional Outcome Measure|Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
45684738|NCT01891084|Drug|Paracetamol|Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose.
45684739|NCT01891084|Drug|Placebo|(Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose.
46041701|NCT00918879|Drug|Placebo|Oral tablet, once daily for 24 weeks
46041702|NCT04874805|Other|Measurement of oxygen saturation|Measurement of oxygen saturation by pulse oximetry once a day, at 6 a.m., for a minimum of 3 days, thanks to three pulse oximeters (1 measurement point per device/day), in parallel with a synchronous sampling, programmed as part of the usual care, of arterial gasometry.
46041703|NCT01026792|Drug|Temsirolimus|Given IV
46041704|NCT01026792|Other|Laboratory Biomarker Analysis|Correlative studies
46041705|NCT01026324|Drug|dinaciclib|Given IV
46041706|NCT01026324|Other|pharmacological study|Correlative studies
46041707|NCT01026324|Other|laboratory biomarker analysis|Correlative studies
46041708|NCT04300686|Biological|Tocilizumab|"The tocilizumab group is prescribed with tocilizumab (8mg/kg.qm.ivgtt.) for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated (remission), then the usage of tocilizumab is maintained for another 24 weeks, otherwise (resistant), patients would be given adalimumab (40mg.bim.IH.) for 24 weeks instead."
45345435|NCT00870220|Drug|Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch|GH will be maintained at 0.05mg/kg/d, adjusted every 3 months. Estradiol 14mcg patch will be applied for 10 days/month for the first 6 months in Group 2. Estradiol 25mcg patch will be applied for 10 days/month for the second 6 months in Group 2, and for the first 6 months in Group 3. Estradiol 25mcg patch will be applied for 3 weeks per month for the second 6 months in Group 3.
46041709|NCT04300686|Biological|Adalimumab|"The adalimumab group is prescribed with adalimumab (40mg.bim.IH) for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated (remission), then the usage of adalimumab would be maintained for another 24 weeks, otherwise (resistant), patients would be given tocilizumab (8mg/kg.qm.ivgtt.) for 24 weeks instead."
45345436|NCT00735410|Biological|Seasonal Influenza Vaccine|1 dose of Split influenza vaccine
46041710|NCT04299282|Device|CanGaroo|CIED ECM envelope
46041711|NCT01098539|Biological|albiglutide|albiglutide weekly subcutaneous injection + sitagliptin matching placebo
46041712|NCT01098539|Drug|sitagliptin|albiglutide matching placebo + sitagliptin (25mg, 50mg or 100mg depending on level of renal impairment)
46041713|NCT04922723|Drug|Daratumumab|Daratumumab will be administered by IV infusion to subjects in combination with current therapeutic strategies of surgical resection followed by a course of Temozolomide and radiation therapy.
46041714|NCT02880215|Behavioral|Attention Bias Modification|Behavioral intervention designed to decrease negative attention bias.
46041715|NCT02880215|Behavioral|Cognitive Control Training|Behavioral intervention designed to improve sustained attention.
46041716|NCT01098461|Biological|albiglutide|subcutaneous injection of albiglutide
45684740|NCT01891084|Drug|Backup NSAID ibuprofen|Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable.
45684741|NCT01891474|Device|U-health care|voice inception technique based U-healthcare service
46041717|NCT01098461|Biological|placebo|subcutaneous injection of placebo to match albiglutide
46041718|NCT01098305|Drug|Varenicline|Participants will be randomized to receive varenicline or placebo for 12 weeks. The dosing regimen consistent with FDA guidelines will be used: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
46041719|NCT01098305|Behavioral|Counseling|All participants will be provided with a structured behavioral counseling program, involving 6 counseling sessions by a trained NDDTC counselor. This will be a manual-based intervention and revised as needed for cultural relevance and sensitivity by Dr. Stigler. The intervention is designed to enhance awareness of the harmful effects of smokeless tobacco, assist the person in developing skills to quit and avoid relapse, and instruct the smokeless tobacco user on medication adherence, as recommended by experts in the field.
46041720|NCT00833833|Drug|Pomalidomide|1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply
46041721|NCT00833833|Drug|Dexamethasone|oral dexamethasone
45345437|NCT00729768|Drug|basiliximab|2 intravenous doses
45345438|NCT00729768|Drug|efalizumab|Subcutaneous repeating dose
45345439|NCT00729768|Drug|mycophenolate mofetil|Oral repeating dose
45345440|NCT00729768|Drug|corticosteroids|Repeating doses
45345441|NCT00729768|Drug|cyclosporine|Oral repeating dose
45684742|NCT01891708|Other|bevacizumab, standard chemotherapy and radiation|the dose and application model of the three intervention are not specified by the sponsor who just observe the efficacy of the combination application of the three in non small cell lung cancer patients with brain metastasis once enrolled.
45345442|NCT00739856|Procedure|Electroconvulsive Therapy|ECT was administered using the MECTA-SR1 apparatus. The current amplitude was 800 mA, pulse width was 1.5 ms, and pulse frequency was 50 Hz. Stimulus duration was increased as required to elicit an adequate seizure, defined as at least 25 s with EEG monitoring. The ECT course was fixed, and comprised 6 treatments administered with bitemporal electrode placement at a twice-weekly frequency
45345443|NCT00734370|Behavioral|Virtual Reality Exposure Therapy for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~Psycho-education, breathing training and cognitive restructuring~Virtual reality Exposure to agoraphobic situations and interoceptive exposure~Relapse prevention"
45345444|NCT00734370|Behavioral|Standard exposure in vivo for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~Psycho-education, breathing training and cognitive restructuring~Standard exposure in vivo to agoraphobic situations and interoceptive exposure~Relapse prevention (according to the protocol of Craske & Barlow)"
45345445|NCT00871156|Drug|Chloroquine, Tafenoquine|Chloroquine and Tafenoquine
45345446|NCT00871156|Drug|Placebo|Placebo
45345447|NCT00734448|Dietary Supplement|myo-inositol|2 g twice a day until delivery
45345448|NCT00735488|Other|Observational|Summary of data
45345449|NCT04039906|Device|Removal of needle with using ANDYs|"ANDY will be provided to medical staffs to be use in removal needles from syringes during 7 days~Record the time required for the needle removal procedure by photographing the needle removal procedure during 24 hours/7 days.~Identify the number of syringes processed by ANDY.~After 3rd week, do survey and interview 15 people selected by the convenient sample method. By interviewing, collect information of overall experience after using automated needle processing system, how long their hospital working experience is, and other information or systems the interviewees felt those are necessary."
45345450|NCT02128152|Device|Ekso exoskeleton|
45345451|NCT04064372|Behavioral|Mindful response to adversity brief training|Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of mindfulness, equanimity, and non-judgment, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
45345452|NCT04064372|Behavioral|Strengths-based response to adversity brief training|Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of strengths-based, narrative self-analysis, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
46041722|NCT00833833|Drug|Aspirin|As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.
46041723|NCT04308083|Procedure|dental implant placement|Implants will be placed according to the manufacturer recommendations. Implants will be placed at 1.5 to 2.0 mm from the adjacent natural tooth. However, these distances will be directed by the prosthetic crown needed and they will be recorded in the CRF.
46041724|NCT02878733|Drug|Albumin|patients that had either received any volume of 5% albumin in addition to at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.)
46041725|NCT01098071|Drug|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months
46041726|NCT04307771|Behavioral|m-Health application|Dental Buddy is a mobile application that has been designed to improve oral hygiene maintenance behaviours in teenagers
46041727|NCT02612545|Drug|Dihydroartemisinin-piperaquine (DHA-PPQ)|Co-formulated anti-malarial drug used as standard of care treatment for uncomplicated malaria in Cambodia
46041728|NCT02612545|Drug|Mefloquine (MQ)|ACT partner drug
45840828|NCT00909324|Drug|Post-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting on the day of LASIK surgery and continuing through 1 month after surgery.
46041729|NCT02878577|Device|fMRI|fMRI scans, mapping brain connectivity using EEG in combination with eye-tracking technology (Brain Network Activation (BNA) technology developed by ELMINDA), characterizing of cortical layers using magnetic resonance (the CoLI technology developed by Tel-Aviv University), and Diffusion Tensor Imaging (DTI) imaging (imaging of brain tracks).
46041730|NCT00704743|Device|Cylindrical cast|Arm cast/immobilization technique for wrist fracture
46041731|NCT00704743|Device|Modified sugar tong cast|Arm cast/immobilization technique for wrist fracture
45345453|NCT00876226|Drug|Citalopram|"Citalopram pharmacokinetics will be studies in subjects with short bowel syndrome.~Citalopram 20mg orally will be given to the subjects and on the seventh day blood will be drawn at hours 0,1,2,3,4,6,8,12,16 and 24 hours post-dose."
45345454|NCT05555342|Procedure|Irreversible electroporation (IRE) ablation|IRE will be performed using the NanoKnife or Aliya System. CT or cone-beam CT will be used to direct electrode placement.
46041732|NCT00704743|Device|Volar dorsal splint|Arm cast/immobilization technique for wrist fracture
46041733|NCT01097057|Drug|Carboplatin|Given IV
45345455|NCT05555342|Radiation|Radiation Therapy|Moderate-dose radiation therapy to the target tumor(s) in 1 fraction.
45840829|NCT00911586|Drug|Testosterone undecanoate|
46041734|NCT01097057|Drug|Etoposide|Given IV
46041735|NCT01097057|Biological|Filgrastim|Given SC
46041736|NCT01097057|Drug|Ifosfamide|Given IV
46041737|NCT01097057|Procedure|Leukapheresis|Given through catheter
46041738|NCT01097057|Drug|Plerixafor|Given SC
46041739|NCT01097057|Biological|Rituximab|Given IV
46041740|NCT02612701|Other|Cigarettes|Subjects will smoke a standard cigarette (yield: tar 12 mg, nicotine 1 mg)
46041741|NCT02612701|Other|E-cigarettes (nicotine free e-liquid)|Subjects will smoke nicotine free e-liquid with an e-cigarette.
46041742|NCT02612701|Other|E-cigarettes (low nicotine e-liquid)|Subjects will smoke low nicotine (4-6 mg/mL) e-liquid with an e-cigarette.
46041743|NCT02612701|Other|E-cigarettes (high nicotine e-liquid)|Subjects will smoke low nicotine (18-24 mg/mL) e-liquid with an e-cigarette.
45840830|NCT00911742|Drug|Tramadol Contramid OAD|1 Tramadol Contramid OAD 200 mg tablet as a single dose
46041744|NCT05065463|Drug|AZD8233|Participants will receive a single subcutaneous (SC) dose of AZD8233 into the region of the abdomen.
46041745|NCT02878811|Other|Observational study|This is a non-interventional study, patients receive their usual treatment as determined by the physician.
46041746|NCT01022112|Drug|TA-7284-Low|TA-7284-Low
46041747|NCT01022112|Drug|TA-7284-Low-middle|TA-7284-Low-middle
46041748|NCT01022112|Drug|TA-7284-High-middle|TA-7284-High-middle
46041749|NCT01022112|Drug|TA-7284-High|TA-7284-High
46041750|NCT01022112|Drug|Placebo|Placebo
46041751|NCT04299204|Procedure|Percutaneous nephrolitotomy|Pediatric PCNL
46041752|NCT04298892|Other|clinical data and sample collection|Patients with hematologic malignancies and disorders will be asked to donate part of the samples collected as per clinical practice for the management of their disease for the aims of this study. In addition, patients will be asked to donate one oral swab sample, and urine samples. Collection of these additional samples is a non-invasive procedure with no associated risks for patients. Clinical data (demographics including ethnicity, stage of disease, concise treatment history, cytogenetic reports, and molecular data if available, as routinely performed during diagnosis procedures) will be collected.
46041753|NCT01096667|Drug|Placebo to Ertuglilflozin 1 or 5 mg|Placebo to ertuglilflozin tablet 1 or 5 mg once daily for 28 days
46041754|NCT01096667|Drug|Ertugliflozin 1 mg|Ertugliflozin tablet 1 mg once daily for 28 days
46041755|NCT01096667|Drug|Ertugliflozin 5 mg|Ertugliflozin tablet 5 mg once daily for 28 days
45345456|NCT00734526|Drug|Temozolomide|"Groups 1 & 2: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 & 4: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
45345457|NCT00734526|Radiation|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
45345458|NCT00734526|Drug|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
45345459|NCT00729404|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+2.1mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles)
45840831|NCT00911742|Drug|Zytram|1 Zytram 200 mg tablet as a single dose
45840832|NCT00911898|Drug|MM-111|For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV
45840833|NCT00912990|Drug|Cisatracurium|One intravenous dose: 0.2mg/kg/dose
46041756|NCT01096667|Drug|Ertugliflozin 25 mg|Ertugliflozin tablet 25 mg once daily for 28 days
46041757|NCT01096667|Drug|HCTZ 12.5mg|Hydrocholorthiazide (HCTZ) 12.5 mg capsule once daily for 28 days
46041758|NCT01096667|Drug|Placebo to HCTZ|Placebo to HCTZ 12.5 mg capsule once daily for 28 days
46041759|NCT01096667|Drug|Placebo to ertuglilflozin 25 mg|Placebo to ertuglilflozin tablet 25 mg once daily for 28 days
46041760|NCT01014624|Drug|Prasugrel|"Prasugrel 10mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria."
45345460|NCT00729404|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+1.05 mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles
45684743|NCT01891786|Behavioral|Self-Management Intervention|The SMI will incorporate a discussion to introduce self-management and why it is important, and about problems associated with reducing CHD risk and managing type 2 diabetes. Specific topics addressed will include health behaviours to reduce CHD risk and manage diabetes including diet and exercise, as well as behaviours specific to managing diabetes, including medication adherence and self-care behaviours (e.g. footcare). Sessions are patient-directed and employ a shared decision-making approach, such that participants work with one another and the practice nurse facilitator to identify specific problems that they wish to address, and to identify solutions and approaches to managing their diabetes and CHD risk
46041761|NCT01014624|Drug|Clopidogrel|"Clopidogrel 75 mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria."
46041762|NCT01021878|Other|icodextrin|glucose sparing dialysis solution
46041763|NCT01021878|Other|Dianeal|glucose based dialysis solution
46041764|NCT02872428|Drug|Valproic Acid|By infusion over 1 hour
45345461|NCT00876304|Drug|PF-04802540|Multiple ascending doses for 10 days; planned doses include capsules totaling 5 mg and 20 mg every 12 hours, with additional doses determined based on accumulating data
45345462|NCT00876304|Drug|Placebo|Placebo capsules every 12 hours for 10 days
45684744|NCT01891786|Behavioral|Risk Result|Participants will receive in-person personalised feedback about their combined genetic and lifestyle 10 year risk for developing CHD.
46041765|NCT02872428|Drug|Isotonic saline solution|By infusion over 1 hour
45684745|NCT01891942|Procedure|twitch by magstim|
45345463|NCT00735722|Device|HIFU AF Ablation|Concomitant left atrial ablation using High Intensity Focused Ultrasound (HIFU)
45345464|NCT00731952|Drug|Velcade and Vorinostat|Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
45345465|NCT04065932|Drug|BMS-986165-01|Participants will receive BMS- 986165 -01 in prototype formulation
45684746|NCT01892098|Dietary Supplement|Zinc Sulfate|9mg elemental zinc via 23mg zinc sulfate/day
46041766|NCT02873364|Drug|Vitamin D3 (High dose)|Daily 4000 unites vitamin D
46041767|NCT02873364|Drug|Vitamin D3 (Low dose)|Daily 600 unites vitamin D
46041768|NCT02872740|Procedure|Embolization of Left Gastric Artery|Left gastric artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
46041769|NCT02872740|Procedure|Embolization of Gastroepiploic Artery|Gastroepiploic artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
46041770|NCT02871960|Procedure|Robotic and Laparoscopic Colectomy|
46041771|NCT00628290|Drug|Cannabidiol|Capsules, 3 times daily, 200 mg, 4 weeks
46041772|NCT00628290|Drug|Amisulpride|Capsules, 3 times daily, 200 mg, 4 weeks
46041773|NCT04559412|Device|Sofusa DoseConnect|25 to 50 mg Enbrel® administered by the Sofusa® DoseConnect™ delivery system once weekly for 12 weeks
46041774|NCT04559412|Drug|Enbrel|25 to 50 mg Enbrel® administered by the Sofusa® DoseConnect™ delivery system once weekly for 12 weeks
45684747|NCT01892098|Dietary Supplement|Placebo|Cellulose pill given as placebo
46041775|NCT00854113|Drug|EGT0001474|Oral ascending doses given daily as capsules for up to 14 days
45684748|NCT01892176|Dietary Supplement|coenzyme q10|400mg/day, 800mg/day, 1200/day and 2400mg/day
45684749|NCT01892254|Drug|Metformin|Metformin, 2x 2 tablets a day, 500 mg tablets
46041776|NCT00854113|Drug|Placebo|Placebo to match EGT0001474
46041777|NCT04553640|Other|Group A/Intervention Curriculum|Virtual patient cases and feedback
46041778|NCT04553640|Other|Group B/Control Curriculum|Online articles on dizziness and emergency department clinical experience
46041779|NCT02872584|Drug|Prednisone|prednisone treatment as required by dermatological condition (pemphigus/pemphigoid)
46041780|NCT00704821|Drug|PTC299|Oral
46041781|NCT00704821|Drug|Docetaxel|Intravenous infusion
46041782|NCT00704899|Procedure|Physiotherapy|Structured exercise regimen
46041783|NCT00704899|Drug|Amitryptiline|Amitryptiline 25mg once daily
45345466|NCT04065932|Drug|BMS-986165 Tablet|Participants will receive BMS-986165 in tablet form.
45345467|NCT04065932|Drug|Famotidine|Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine
45684750|NCT01892254|Drug|Placebo|Placebo (to metformin)
45840834|NCT00912990|Drug|Normal saline|One Intravenous dose
46041784|NCT00845845|Drug|Omega-3-acid ethyl esters (Lovaza)|4 milligrams daily omega-3-acid ethyl esters (Lovaza) with dietary counseling for 24 weeks.
46041785|NCT00845845|Drug|Placebo|Daily placebo with dietary counseling for 24 weeks.
45345468|NCT00871312|Device|Topical wound oxygen therapy|90 minutes 4 days per week Active Topical Oxygen Therapy
45345469|NCT00871312|Device|Topical wound oxygen Placebo|90 mins per day 4 days per week Placebo Therapy
45345470|NCT00740012|Other|Continuous glucose monitoring|Glucoday S (microdialysis system). Continuous glucose monitoring all three nights
45345471|NCT00740012|Other|alarm- clock intervention, patient perform blood glucose self monitoring|Alarm clock intervention at midnight, 2 a.m., 4 a.m. and 6:45 a.m.
46041786|NCT01104701|Drug|exenatide once weekly|subcutaneous injection, 2 mg, once a week
46041787|NCT01104701|Drug|exenatide once monthly suspension|subcutaneous injection, low dose, once a month
46041788|NCT01104701|Drug|exenatide once monthly suspension|subcutaneous injection, medium dose, once a month
46041789|NCT01104701|Drug|exenatide once monthly suspension|subcutaneous injection, high dose, once a month
45345472|NCT00740012|Other|nurse intervention|Nurse intervention: gently drawing capillary sample (blood glucose)at midnight, 2 a.m., 4 a.m. and 6:45 a.m. .
45694634|NCT00885742|Biological|FXIII Concentrate (Human)|"Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who did not complete the pharmacokinetic study (Factor XIII Study BI71023_2002 [NCT00883090]) will initially receive FXIII Concentrate (Human) at a dose of 40 U/kg by intravenous (IV) infusion."
45840835|NCT00913068|Procedure|Transverse Abdominal Plan (TAP)|An injectable anesthetic is introduced to a specific anatomic area where the sensory neurons supplying the operative field.
45345473|NCT00740012|Other|Taking the patients pulse|In nights (a) and (b) the doctoral candidate takes the patients pulse 5-7 minutes after the alarm clock or the nurse.
45840836|NCT00913068|Procedure|standard post op pain control|opiates
46041790|NCT00833755|Drug|Ketamine|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
46041791|NCT00833755|Drug|Placebos|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
45345474|NCT00740012|Other|Venous blood drawing|Venous blood drawing for the determination of epinephrine, norepinephrine, cortisol, glucagon, growth hormone, and prolactin (determined by specific immunoassays at Biocientia laboratories, Jena, Germany) (6-10 minutes after midnight, 2 a.m., 4 a.m. and 6:45 a.m.)in night (a) and (b)
45345475|NCT00740012|Other|Other capillary sample|5-7 minutes after the alarm clock or the nurse the doctoral candidate takes another capillary sample for a laboratory glucose determination (EBIOS, Eppendorf, Hamburg, Germany) analyzer.
45345476|NCT04064268|Dietary Supplement|Whey|45 g whey + 20 g maltodextrin
45694635|NCT04964440|Device|Pure-EP|Advanced Signal Acquisition and Processing
45694636|NCT05319262|Radiation|Pink noise exposure|Continuous pink noise sound exposure at 45 dBA, throughout the whole night
45694637|NCT05319262|Radiation|Traffic noise|120 traffic noise events (40 each of road, rail and aircraft), introduced at maximum sound pressure levels ranging between 45-65 dB LAS.max.
45694638|NCT00887458|Drug|Itraconazole 200 mg|Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
45840837|NCT00914862|Drug|Ramelteon|Ramelteon tablets, orally for one day only.
46041792|NCT01021332|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|oral
45694639|NCT00887458|Drug|Itraconazole 300mg|Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
46041793|NCT01021332|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)|oral
46041794|NCT00704977|Procedure|pterygium surgery using alcohol 20% for tissue separation and bare sclera as wound closure technique|"The eye operated is disinfected and covered according routine protocol.~Tightly applying well above the pterygium area. Instilling alcohol 20% into the well and holding for 40-60 seconds. Absorbing alcohol by applicator and abundant irrigation with BSS.~Pterygium separation starting 2 mm centrally from the edges of the tissue. Excising the pterygium tissue at the base. Applying mytomycin C for 2.5 min+ abundant irrigation with BSS.~Wound closure by by technique described in each arm.~Bandage with chloramphenicol ointment or with Maxitrol ointment (Dexamethasone/Neomycin/Polymyxin B Eye Ointment.~Postoperative treatment include :antibiotic and steroid eyedrop treatment at least 2 weeks.~Follow up at 1 week, 1 month, 3 months, 6 months, 1 year. If additional follow upvisits are needed - they will be accomplished according the patients condition and needs."
46041795|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
46041796|NCT00923091|Drug|Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
46041797|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
45345477|NCT04064268|Dietary Supplement|3-OHB + Whey|50 g ketone + 45 g whey + 20 g maltodextrin
45345478|NCT00740090|Drug|AMA1-C1/Alhydrogel plus CPG 7909|
45345479|NCT04039672|Procedure|Skin biopsy|5mm skin metastasis or primary melanoma biopsy
45345480|NCT00738660|Drug|Telmisartan, Ramipril|80 mg of telmisartan administered for 8weeks,followed by addition of ramipril 10 mg for further 8weeks
45345481|NCT00740168|Drug|bevacizumab treatment|single infusion 10 mg/kg
45345482|NCT05225974|Drug|Liraglutide injection|At a single dose of 0.6 mg of Liraglutide injection by subcutaneous injection
45345483|NCT05225974|Drug|Liraglutide injection(Victoza®)|At a single dose of 0.6 mg of Liraglutide injection(Victoza®) by subcutaneous injection
45840838|NCT00915798|Behavioral|Cigarette smoking|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking a cigarette.
45840839|NCT00915798|Behavioral|Abstinence|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.
45840840|NCT00915954|Diagnostic Test|Oral Glucose Tolerance Test|Participants will have their blood drawn for a baseline value and then will be asked to drink a beverage with 75 grams of sugar. Blood will then be drawn every 30 minutes for 2 hours.
46041798|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
45345484|NCT01139970|Other|Laboratory Biomarker Analysis|Correlative studies
45345485|NCT01139970|Other|Pharmacological Study|Correlative studies
45345486|NCT01139970|Drug|Temozolomide|Given PO
45345487|NCT01139970|Drug|Veliparib|Given PO
45840841|NCT00915954|Diagnostic Test|Subcutaneous administration of recombinant human IGF-1|Participants will receive a subcutaneous injection of recombinant human IGF-1 followed by a series of blood draws.
45345488|NCT00740246|Drug|VIT-45|
45345489|NCT00729638|Drug|RAD001|Dose levels will change: Taken orally either every other day for the first three weeks of each cycle or taken every day for the first three weeks of each cycle.
45345490|NCT00729638|Drug|lenalidomide|Dose level will vary: taken orally 30-60 minutes after taking RAD001 every day for the first three weeks of each cycle.
45345491|NCT00734682|Drug|Nanoliposomal CPT-11|Depending on UGT1A1 genotyping status, patients are either given a starting dose of 120 mg/m^2 (wild type) or 60 mg/m^2 IV q3 weeks.
45840842|NCT00915954|Diagnostic Test|Placebo|Participants will receive a subcutaneous injection of saline followed by a series of blood draws.
45840843|NCT00916032|Biological|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|Participants will receive 3000 IU Advate using one 3000 IU potency vial dissolved in 5 mL diluent followed by two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total) or the alternate sequence
46041799|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
46041800|NCT00923091|Drug|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day
46041801|NCT00923091|Drug|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day.
46041802|NCT00923091|Drug|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day.
46041803|NCT04030819|Behavioral|schema therapy|The intervention is the schema therapy focuses on the management of anxiety and is based on self-efficacy, self-management . It consists of 20 once-weekly sessions of 90 minutes (with a 15 Min break), with homework activities between the sessions
46041804|NCT04115683|Other|Dual Task Training|45 minutes of dual task training consisting of motor activities (walking, balance... etc.) with combination of cognitive activities (spelling words, image description, nomination, word generation, counting... etc.) at sime time.
46041805|NCT04115683|Other|Single Task Training|45 minutes of single task training consisting of same motor activities (walking, balance... etc.)
46041806|NCT04299126|Device|high absorption pad for blood and pus|High absorption pad for blood and pus will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
46041807|NCT04299126|Device|commercial wound dressing|Commercial wound dressing will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
46041808|NCT00853957|Drug|Aliskiren/Amlodipine|Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
46041809|NCT00853957|Drug|Amlodipine|Amlodipine 5 mg titrated to 10mg
46041810|NCT04571034|Procedure|Sham Therapeutic Ultrasound|A standard ultrasound machine (Vectratm by Chattanooga Group, Inc.) with inactive probe will be used to deliver sham massage.
46041811|NCT04571034|Procedure|Medium-Intensity Roller Massage|This group will receive a single bout of roller massage at medium intensity (25 newtons of force directed perpendicular to the surface of the thigh).
46041812|NCT04571034|Procedure|High-Intensity Roller Massage|This group will receive a single bout of roller massage at medium intensity (45 newtons of force directed perpendicular to the surface of the thigh).
46041813|NCT01021020|Drug|Colchicine|0.6mg tablet administered after a fast of at least 10 hours
45345492|NCT00876538|Drug|Olesoxime (TRO19622)|2 capsules of TRO19622 (330 mg) once day with the noon meal
45345493|NCT00876538|Drug|Placebo Control|Placebo Control 2 capsules once day with the noon meal
45345494|NCT00732108|Drug|topiramate|50mg orally for 2 weeks, then 100mg orally for 6 weeks
45345495|NCT00732108|Drug|lactulose placebo pill|1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
45345496|NCT00735800|Behavioral|Family Intervention:Telephone Tracking Support- Caregiver|Family-based problem solving treatment
45345497|NCT00735800|Behavioral|Telephone Support|Supportive telephone counseling about caregiving
45345498|NCT00876616|Drug|Tacrolimus+Mycophenolate mofetil|FK506 4mg/d,MMF 1.0g/d
45345499|NCT00876616|Drug|Cyclophosphamide|CTX 0.75g/m2 BSA
45345500|NCT04064502|Diagnostic Test|CHRONIC ANKLE INSTABILITY AND ASSOCIATED FACTORS:|Questionnaire including sociodemographic information, general medical condition, history of orthopedic surgery, pain intensity, and the number of painful areas of the foot.
45345501|NCT00729716|Biological|BioCart™II|A cartilage biopsy will be harvested from patients during arthroscopy and used for chondrocyte isolation, culture and future implantation. Subjects will also have about 80 ml venous blood drawn for autologous cell culture medium. Two-four weeks following biopsy harvest, BioCart™II will be implanted into the cartilage defect after careful debridement via miniarthrotomy.
45345502|NCT00729716|Procedure|Microfracture|MF procedure will be carried out according to accepted practice. After careful debridement multiple perforations, or microfractures, are made in the subchondral bone using an awl. The released bone marrow forms a clot at the lesion site which is an enriched environment for new tissue formation. With the subject's consent a cartilage biopsy will be taken (at least 150 mg) and about 80 ml venous blood withdrawn. This will be used for chondrocyte culture and cryopreservation in case a later BioCart™II implantation is required after failure of the microfracture procedure.
45345503|NCT00863200|Behavioral|Telephone Intervention|Symptom information will be collected using an automated telephone system, approximately 5 minutes per week.
45345504|NCT00863200|Behavioral|Questionnaires & Interviews|3 questionnaires and one-on-one interviews during 3 regularly scheduled clinic visits.
45345505|NCT00734760|Behavioral|education|face-to-face education and counseling intervention
45345506|NCT00740324|Drug|NPO-11|20 mg butylscopolammonium bromide after administration of NPO-11
45345507|NCT00740324|Drug|NPO-11|NPO-11 after administration of NPO-11
45345508|NCT00740324|Drug|NPO-11|1 mg glucagons after administration of NPO-11
45684751|NCT01892332|Drug|epidural block with lidocaine and fentanyl|"The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting concentration of lidocaine was 1.5 % mixed with fentanyl 75 ug. All patients receive 13mL of lidocaine with fentanyl 75ug. The concentration of lidocaine for subsequent patients is determined by the outcome in the previous patient according to up and down sequential allocation in 0.1% increments. In the case of block failure, the concentration of lidocaine was increased by 0.1%.~Conversely, block success resulted in a reduction in concentration by 0.1%."
46041814|NCT01021020|Drug|Colchicine|0.6mg tablet administered after a standardized high-fat, high-calorie breakfast
46041815|NCT01021020|Drug|Colchicine/Probenecid|0.5mg/500mg tablet administered after a fast of at least 10 hours
46041816|NCT04256187|Other|Qualitative interview|Qualitative interviews to sample the patient's feelings, experiences and thoughts risen by the treatments in the program.
45345509|NCT00871468|Procedure|superior plate|Open reduction internal fixation (ORIF) clavicle with superior plate
45345510|NCT00871468|Procedure|anterior-inferior plate|ORIF clavicle with anterior inferior plate
45345511|NCT00738738|Drug|PD-0332334|Dosage from: 50-100 mg oral capsule Dosage and frequency: 50-350 mg once or twice a day Duration: 6 months
45345512|NCT00735956|Behavioral|Counseling|Handouts, referrals and brief counseling sessions are given after determination of early alcohol abuse has been assessed.
45345513|NCT04040998|Behavioral|Compensatory Cognitive Training|Teach the participants compensatory cognitive skills and strategies
46041817|NCT00833053|Drug|Infliximab|Infliximab 5 mg/kg body weight intravenous infusion given every 6 weeks
45345514|NCT05575440|Procedure|Computed Tomography|Undergo a PET/CT scan
45345515|NCT05575440|Radiation|Fluorine F 18 Tetrafluoroborate|Given IV
45345516|NCT05575440|Procedure|Positron Emission Tomography|Undergo a PET/CT scan
45345517|NCT05575440|Other|Survey Administration|Ancillary studies
45345518|NCT00863278|Procedure|pulsed dye laser treatment|On one side of the face according to Arm placement.
45345519|NCT00863278|Drug|Kligman's Trio|The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.
45345520|NCT00740558|Procedure|Activator methods technique|Chiropractic adjustment by a manually assisted mechanical force
45345521|NCT00740558|Procedure|Traditional chiropractic adjustment|Lumbar roll according to the Diversified technique of chiropractic adjusting
45345522|NCT03784924|Diagnostic Test|MRI prostate|MRI and laboratory biomarkers
46041818|NCT00833053|Drug|Infliximab and methotrexate|Infliximab 5 mg/kg body weight intravenous infusion (given every 8 weeks) plus methotrexate 7.5 mg orally (once weekly)
46041819|NCT02873130|Behavioral|Telepractice Global Voice Prevention Model|
46041820|NCT02873130|Behavioral|In-person Global Voice Prevention Model|
46041821|NCT02873130|Behavioral|Telepractice, Vocal Hygiene and Vocal Education|
46041822|NCT04255953|Behavioral|behavioral telehealth|Participants will receive 24 weekly group phone counseling sessions. Each session will last approximately 60 minutes and begin with an open-ended check-in question, followed by review of weekly self-monitoring data, question and answer time, and end with a new didactic topic of the week addressing diet, physical activity, or behavior change topics. Participants will be instructed to follow a diet that is reduced to 1200-1500 kcal/day and includes ≥ 5 fruit and vegetable (FV) servings per day, <25% kcal from fat, and 20-30 g of fiber. Physical activity will be gradually increased through a guided home-based program. Throughout the intervention, self-monitoring will be emphasized as a key behavioral weight loss strategy.
45345523|NCT00729794|Drug|Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone|"Combination Treatment~Administration of vasopressin, epinephrine, and methylprednisolone during CPR, and of stress dose hydrocortisone after CPR"
46041823|NCT04255953|Other|Treatment as Usual|Treatment as Usual
46041824|NCT04299984|Procedure|Open Conversion after EVAR|"See Open Conversions group description."
46041825|NCT04299984|Procedure|SemiConversion after EVAR|"See SemiConversions group description."
46041826|NCT05329467|Other|Validation of Faces Thermomether Scale|Participants are introduced to all three painscales and are asked to rate their pain with each and one of them according to instructions for each scale
46041827|NCT04256031|Other|Assessment|The structured questionnaire, Visual Analogue Scale, Copenhagen Neck Functional Disability Scale, Shoulder Disability Questionnaire, World Health Organization Quality of Life Instrument-Short Form, and Smartphone Addiction Scale-Short Version will be applied to all participants respectively. Lastly, posture analysis will be performed to all participants by using the New York Posture Rating Chart.
46041828|NCT04245735|Diagnostic Test|perfusion index|To test the objective role of perfusion index in assessing the success of the peripheral nerve block in children under sedation.
46041829|NCT04253067|Device|Active fCO2 laser treatment|The laser probe is inserted into the vagina. Laser treatment is delivered at 6 points at each level of the vaginal wall (12, 2, 4, 6, and 10 o'clock positions). Delivery begins at the most proximal and the probe is retracted by 1 cm and another row of laser treatments are delivered. The number of levels is determined by the patient's vaginal length.
45345524|NCT00729794|Drug|Standard CPR Protocol with Epinephrine and two Placebos|Patients receive advanced life support according to the Guidelines for Resuscitation 2005
45345525|NCT00871546|Drug|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21-day cycle until disease progression.
45345526|NCT00871546|Drug|Bortezomib|Bortezomib 1.3 mg/m2 IV on Days 1, 4, 8, and 11 of each 21-day cycle until disease progression.
45345527|NCT00871546|Biological|Alemtuzumab|Alemtuzumab dose-titrated to the goal maintenance dose of 30 mg/day IV or SC three times a week on alternate days for a total of 12 weeks.
45345528|NCT03778294|Procedure|Computed Tomography|Undergo PET/CT
45345529|NCT03778294|Other|Fluorodopa F 18|Given IV
45345530|NCT03778294|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
45345531|NCT03778294|Procedure|Positron Emission Tomography|Undergo PET/CT or PET/MRI
46041830|NCT04253067|Device|Sham fCO2 laser treatment|The laser probe is inserted into the vagina. The laser will remain in standby mode during the treatment preventing laser exposure. The treatment will appear to be the same as the active treatment with the probe starting at the most proximal and following the same 6 points of treatment delivery. The probe is retracted in the same manner and another row of treatment is simulated. The machine maintains a low humming noise while in standby mode. No active laser treatment is delivered.
45345532|NCT03778294|Radiation|Proton Beam Radiation Therapy|Receive proton beam RT
45345533|NCT03778294|Other|Quality-of-Life Assessment|Ancillary studies
45345534|NCT03778294|Other|Questionnaire Administration|Ancillary studies
45684752|NCT01892488|Drug|Sultamicillin|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Experimental intervention:~Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD."
46041831|NCT04252989|Other|data collection|"Demographic data: age, sex~Ophthalmological history: refraction of parents, previous refractions~Ophthalmological data at each examination: intra-ocular pression, objective refraction after fog, cycloplegia with SKIACOL, slit lamp, dilated eye exam, biometrics~Potential undesirable events (halos, photophobia...)"
45345535|NCT03778294|Drug|Temozolomide|Drug
45345536|NCT00732186|Biological|Ipilimumab|IV Solution, IV, 10 mg/kg, (if dose reduction necessary at 3 mg/kg), Every three weeks for the first 10 weeks, with a booster at week 22, Up to 38 weeks depending on response
45345537|NCT04064996|Other|Routine rehabilitation program patient education|"Patient education~All the patients were assessed with Wagner Classification, Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathy Examination (DNE) score, Visual Analogue Scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS), hand-held dynamometer, range of motion measurements, Semmes-Weinstein monofilament, two point discrimination test, circumference measurements, Foot and Ankle Ability Measure(FAAM), 6-minute walk test (6MWT) before and after the treatment."
45382101|NCT05328323|Other|questionnaire application|"Participants will be asked to fill in the Physical Activity and Social Support Scale (PASSS) adapted into Turkish. Evaluations of the participants will be made in the form of an online survey via Google Forms. Multidimensional Scale of Perceived Social Support and International Physical Activity Questionnaire will be used for construct validity of the scale, and SF-12 physical and mental component summary scores will be used for convergent and divergent validity. The questionnaire will be repeated every 7-14 days in order to perform the test-retest analysis of the questionnaire."
46041832|NCT01020786|Drug|Pemetrexed|"Induction Therapy: 500 milligrams per square meter (mg/m^2) given intravenously (IV) on Day 1 of every 21-day cycle for 4 cycles.~Maintenance Therapy: 500 mg/m^2 given IV on Day 1 of every 21-day cycle until disease progression or unacceptable toxicity."
46041833|NCT01020786|Drug|Carboplatin|Dosage equal to area under the curve (AUC)6 milligrams per milliliter per minute (mg/mL/min) for participant, given IV on Day 1 of every 21-day cycle for 4 cycles.
46041834|NCT00918645|Drug|41 Ca|single oral 1.2 microgram dose of 41Ca; the first two recruited study subjects will also receive an oral dose of stable calcium isotope (46Ca) to compare initial kinetics with prior work.
45345538|NCT04064996|Other|Routine rehabilitation program + foot exercise training|"In addition to the patient education , foot exercise training will be performed. Patients will be applied exercise training consisted of aerobic, strengthening, sensory training and stretching exercises for 3 days/week, 8 weeks.~All the patients were assessed with Wagner Classification, Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathy Examination (DNE) score, Visual Analogue Scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS) ,hand-held dynamometer,range of motion measurements, Semmes-Weinstein monofilament, two point discrimination test,circumference measurements, Foot and Ankle Ability Measure(FAAM), 6-minute walk test (6MWT) before and after the treatment."
45345539|NCT00729872|Biological|AG011|Capsules (low, mid or high dose), twice daily for 28 days, combined with Enema (low, mid or high dose respectively), once daily for 28 days.
46041835|NCT04255719|Procedure|DBS|Unilateral DBS for treatment of patients with PD
45345540|NCT00729872|Other|Placebo|Capsules (matching placebo for low, mid or high dose), twice daily for 28 days, combined with Enema (matching placebo for low, mid or high dose respectively), once daily for 28 days.
45345541|NCT04039828|Drug|Zinc Sulfate Dispersible Tablet 20 mg (Elemental Zinc 20 mg as Zinc Sulfate Monohydrate / Tablet)|Half of the tablet (10 mg) for 3 to 6 months old children and one tablet (20 mg) daily for > 6 to 59 months old children. The tablet will be dissolved in a teaspoon of safe water or breast milk and administered once daily for 10 days.
46041836|NCT00922935|Device|Cresco|Cresco components loading 10 days post surgery
46041837|NCT00922935|Device|Cresco|Cresco loading at 6-8 weeks post surgery
46041838|NCT00922935|Device|Straumann components|Straumann components loading 6-8 weeks post surgery
46041839|NCT01020474|Drug|placebo|matching placebo capsules twice daily.
46041840|NCT01020474|Drug|pregabalin (Lyrica)|75-450mg/day pregabalin dose optimised at start of study
46041841|NCT02872818|Drug|17β estradiol hemihydrate|4mg/kg/day for 20 days
46041842|NCT02872818|Drug|Metformin|50 mg/kg/day last 10 days
46041843|NCT02872818|Drug|medroxyprogesterone acetate|1mg/kg/day last 10 days
46041844|NCT00922779|Drug|peginterferon alfa-2a [Pegasys]|180micrograms sc weekly for 12-48 weeks
46041845|NCT00922779|Drug|ribavirin|800mg, or 1000-1200mg, po daily (dependent on HCV genotype and body weight)
46041846|NCT04205448|Behavioral|Physical exercize|10 weeks group exercize followed by community-based voluntary exercize
46041847|NCT04532892|Dietary Supplement|Meta 18.06 Day and Meta 18.06 Night|5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 & V4) and calls for antistress advices and adverse events, concomitant medication reporting & compliance (V1 & V3)
45345542|NCT00876772|Drug|Olanzapine|Randomized, placebo-controlled, parallel group trial to evaluate the effectiveness and tolerability of an oral dose of 10 mg Olanzapine in combination with Riluzole for the treatment of Loss of Appetite in patients with amyotrophic lateral sclerosis (ALS)
45382104|NCT05328180|Other|Sodium bicarbonate|A 50/50 solution of lidocaine with adrenalin 1% and bupivacaine with adrenalin 0.5% is buffered with 7.5% sodium bicarbonate in 1:10.
45382105|NCT05328180|Other|Control arm|A 50/50 solution of lidocaine with adrenalin 1% and bupivacaine with adrenalin 0.5%.
45382106|NCT05327010|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
45382107|NCT05327010|Procedure|Biopsy|Undergo tumor biopsy
45382108|NCT05327010|Procedure|Biospecimen Collection|Undergo blood sample collection
45382109|NCT05327010|Procedure|Diagnostic Imaging|Undergo diagnostic imaging
45382110|NCT05327010|Drug|Talazoparib|Given PO
45382111|NCT05326412|Drug|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
45382112|NCT05325047|Procedure|Intensive speech rehabilitation|Combination an e-health device allowing the patient to self-rehabilitate with a face-to-face approach of accompaniment and support of the patient by the speech therapist.
45382113|NCT05324826|Device|Butterfly Network handheld ultrasound|Patients would be examined with a handheld US machine which would allow for dynamic imaging chairside and could easily be integrated into both hospital-based and private clinical practices. This would allow the patient to benefit from realtime imaging and a faster preliminary diagnosis with virtually no additional risks.
45382114|NCT05321940|Biological|STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells|Autologous human ultraviolet (UV)-irradiated (dead) leukemia cells loaded with STAVs administered via intravenous injection. Each treatment will administer 5 ml via syringe.
45382115|NCT05321940|Biological|Dendritic Cell Vaccine|15-20 Million mature dendritic cells per dose administered via intravenous injection.
45382116|NCT05316493|Behavioral|Intensive Lifestyle Intervention (ILI)|dietary guidance, exercise guidance, lifestyle intervention
45382117|NCT05316493|Drug|Megestrol Acetate 160 MG Oral Tablet|enrolled participants will take Megestrol Acetate 160mg daily
45382118|NCT05316493|Drug|Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg|enrolled patients will be treated with LNG-IUS.
45382119|NCT05316467|Behavioral|Intensive Lifestyle Intervention (ILI)|"dietary guidance~exercise guidance~lifestyle intervention"
45382120|NCT05316467|Drug|Megestrol Acetate 160 MG Oral Tablet|enrolled participants will take Megestrol Acetate 160mg daily
46041848|NCT04532892|Dietary Supplement|Placebo Meta 18.06 Day and Placebo Meta 18.06 Night|5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 & V4) and calls for antistress advices and adverse events, concomitant medication reporting & compliance (V1 & V3)
46041849|NCT00924651|Behavioral|exercise|home based walking and progressive resistance training exercise
46041850|NCT04528680|Device|Sonication for opening of blood-brain barrier|Implantation of SC-9 device and repeat activation of 9 ultrasound emitters during i.v. injection of microbubbles
46041851|NCT04528680|Drug|Chemotherapy, albumin-bound paclitaxel|Intravenous infusion of ABX over 30 minutes
46041852|NCT04528680|Drug|Chemotherapy, carboplatin|Intravenous infusion of carboplatin over 30 minutes
46041853|NCT04570410|Procedure|primary focal resection plus lymph node dissection|Primary radical resection plus lymph node dissection was performed in patients with oligometastatic urothelial carcinoma
46041854|NCT04570410|Drug|Tislelizumab|Tislelizumab IV infusion of 200 mg Q3W
46041855|NCT04570410|Drug|Gemcitabine plus cisplatin|GC (Gemcitabine plus cisplatin): Gemcitabine 1000mg/m2 D1,D8 iv every 3 weeks Cisplatin70mg/m2,D2,3,4 iv every 3 weeks
46041856|NCT04203771|Dietary Supplement|Probiotic AB-DENTALAC|Orodispersible tablets containing Lactobacillus plantarum [now Lactoplantibacillus plantarum] KABP051 (CECT7481) and Lactobacillus brevis [now Levilactobacillus brevis] KABP052 (CECT7480) as active ingredients, at a minimum dose of 5x10^8 cfu each, and sorbitol (E420) and guar gum (E412) as excipients, taken b.i.d. for 7 days.
46041857|NCT04203771|Other|Placebo|Orodispersible tablets made of sorbitol (E420) and guar gum (E412), taken b.i.d for 7 days.
46041858|NCT04203771|Procedure|Surgical removal of mandibular third molars at baseline|Surgical removal of both mandibular third molars, performed under intravenous sedation and loco-regional anesthesia (Articaine Hydrochloride 4% with Epinephrine 1:100.000), after having undergone a professional oral cleaning.
46041859|NCT04203771|Drug|Ibuprofen|Ibuprofen syrup at 20-30 mg/Kg of body weight, orally every 8 hours (t.i.d), for 7 days
45345543|NCT00729950|Biological|MDX-010|Subjects will be treated with transfectoma-derived MDX-010 at 2.8 or 5 mg/kg/dose, or with hybridoma-derived MDX-010 at 3 mg/kg/dose administered on Days 1, 57, and 85. The 2.8, 3, and 5 mg/kg dosage cohorts may be initiated concurrently. Additionally, 6 subjects per cohort will receive single doses of transfectoma-derived MDX-010 at 7.5, 10, 15, and 20 mg/kg.
45345544|NCT04063826|Device|PET MRI|All participants will have a liver scan
45345545|NCT00616018|Drug|acetaminophen|4 g/day for 10 consecutive days
45345546|NCT04064970|Behavioral|patient acceptable symptom state (PASS)|The Severity Index for Urinary Incontinence, which documents incontinence frequency and severity, pelvic floor distress, patient global impression of severity and improvement, physical function, depression, sleep disturbance, anxiety, global health and ability to participate in social roles and activities.
45345547|NCT00740948|Drug|Rituximab (mabthera) Injection|2 * 1g of Rituximab at the 1st day and at the 14th day.
45345548|NCT00740948|Drug|Placebo: NaCl 0.9% or Glucose 5%|2* 250ml of NaCl 0.9% or Glucose 5% at the 1st day and at the 14th day.
45345549|NCT00871702|Genetic|CD34-TK75 transduced donor lymphocytes|
45345550|NCT00871702|Radiation|Sub Study - 18 FHBG PET/CT Scans|Three 18 FHBG PET/CT Scans will be performed first one at pre-DLI infusion, second 14 days post-DLI infusion and third 30 days post-DLI infusion - patients #3 - #8
46041860|NCT04256733|Biological|Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer|Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through the Koko Digidoser nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. The concentration will never exceed 1000 micromolar. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
46041861|NCT04256733|Biological|Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer|Participants will be repeatedly exposed to a sub-threshold dose of aerosolized capsaicin through the KoKo Digidoser nebulizer during treatment sessions. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
46041862|NCT00627588|Biological|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
46041863|NCT00627588|Biological|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
46041864|NCT00922623|Device|Belotero®|Hyaluronic acid dermal filler, Belotero®, single use syringe, injected into mid to deep dermal layer
46041865|NCT01025232|Drug|Ranibizumab|Intravitreal Injection of 2.0mg formulation
46041866|NCT05321199|Drug|Tranexamic acid|Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to be effective in reducing blood loss and the need for transfusions after several orthopaedic surgeries.
45345553|NCT00732342|Behavioral|Contingency Management|Prizes given for targeted behavior of abstinence
45345554|NCT00876850|Drug|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
45345555|NCT00876850|Drug|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400mg tablets and pre-mixed 400mg IV infusion solution
45345556|NCT00734916|Dietary Supplement|Parenteral lipid emulsion (Omegaven)|Omegaven 10%, 0.2g/kg/hr i.v.during 1 hour on 3 consecutive days
45345557|NCT00734916|Dietary Supplement|Parenteral lipid emulsion (Intralipid)|Intralipid 10%, 0.2g/kg/hr i.v. during 1 hour on 3 consecutive days
45345558|NCT00734916|Dietary Supplement|Parental lipid emulsion (Saline 0.9%)|Placebo (Saline 0.9%), same volume/hr as lipid emulsions
45345559|NCT00872092|Other|Stable-isotope labeled lactose ureide breath test|2 g 13C-labeled lactose ureide orally
45382122|NCT05310539|Other|assessment of the early recovery after wedge resection surgery|To assess the early recovery will be used 1 minute sit to stand, Numeric Rating scale to assess pain, incentive spirometer to assess vital capacity, Borg modified scale to assess dyspnea.
45382123|NCT05309928|Drug|Amoxicillin|medication administration
45345560|NCT00738816|Other|Systematic medication review and advisory notes|Within 24 hours of admission a pharmacist retrieve medication histories from patients included in the intervention group. Medication histories will be obtained from - medical records, medication charts, patients electronical medication profile, interview with patients and if necessary contact to the patients general practitioner. The obtained medication history will be discussed with a physician specialized in pharmacology and an advisory note with suggested changes to the patients medication is added to the medical record. The orthopedic physicians are not obliged to follow the suggested changes
46041867|NCT04300452|Drug|Carbetocin|Administration of Carbetocin after placental detachment
45345561|NCT00877084|Other|Resistance training|Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.
45345562|NCT00877084|Other|Usual care|usual care according to clinical pathway for COPD, No training
46041868|NCT04300452|Drug|Ergometrine Maleate|Administration of ergometrin after placental detachment
45684753|NCT01892488|Drug|Placebo|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Control intervention:~Placebo for 5 days as supplement to standard of care for patients with AE-COPD"
45684754|NCT04390204|Other|intervenions|"Motor control exercises~A supervised home self-rehabilitation program"
45684755|NCT02809690|Device|CAT|Undergo 18F-FMAU PET/CT
46041869|NCT04252755|Behavioral|EEG Neurofeedback|Participants will undergo a baseline (pre) session, then be scheduled for 8 sessions of NFB, and finish with another session (post) after completion of all NFB sessions.
46041870|NCT01025154|Drug|Clofarabine|Induction Cycle: 20 mg/m^2 IV over approximately 1 hour daily for 5 days (days 1-5)
45684756|NCT02809690|Drug|18F-FMAU|Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT
45684757|NCT02809690|Other|Laboratory Biomarker Analysis|Correlative studies
46041871|NCT01025154|Drug|Idarubicin|Induction Cycle: 10 mg/m^2 IV over approximately 30 minutes daily for 3 days (days 1-3), following clofarabine by 1 to 2 hours
45684758|NCT02809690|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
45684759|NCT02809690|Device|Positron Emission Tomography|Undergo 18F-FMAU PET/CT
45684760|NCT02809690|Device|Ultrasound|Undergo TRUS-guided biopsy
45684761|NCT01892566|Other|mHealth Intervention|See arm description
45684762|NCT01892644|Drug|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution, 10 mg/kg/day, once daily for 12 months
45684763|NCT01892644|Other|Venesection|Treated with venesection every 8-10 day for 12 months, or until serum-ferritin has been reduced to about 50 µg/L.
45345563|NCT00735150|Behavioral|questionnaire, interview|You will be asked to make a one-time visit to MSKCC. At that research visit, you will be asked to complete a short questionnaire about your knowledge of various reproductive technologies relevant to individuals at hereditary risk. Then you will watch a short presentation about these reproductive technologies and complete a second brief questionnaire to assess your understanding of the presentation. Afterwards, you will meet with an interviewer one-on-one for about one hour, during which time you may share your thoughts and feelings about the use of these reproductive technologies.
45345564|NCT05157412|Drug|Doxycycline 100 mg Oral Tablet|Oral Doxycycline will be added to prednisolone as a comparison to using prednisolone as a sole therapy for the treatment of nasal polyps associated with chronic rhinosinusitis
45345565|NCT05157412|Drug|Prednisolone 20 mg|Prednisolone will be used in both arms as a sole therapy in one and together with doxycycline in the other
45345566|NCT00732420|Drug|topotecan|Topoisomerase I inhibition.
45345567|NCT00732420|Drug|pazopanib|Tyrosine kinase inhibitor
45345568|NCT00877162|Behavioral|Controlled crying and routines|Behavioural (teaching and support)
45345569|NCT00877240|Behavioral|Behavioral intervention-to determine the effectiveness of a general intervention on healthy living habits of IDF staff|the program consists of 3 times a week of physical activity, nutrition advice, weight lodd program, stress workshop and smoking cessation workshop
45345570|NCT04719156|Drug|Indocyanine green solution administered at 2.0mg/kg.|Dosing of ICG to be administered at 2.0mg/kg, two hours prior to surgery.
45345571|NCT04719156|Device|Stryker SPY-PHI Imaging Device|The SPY-PHI system is used with the ICG dye to provide fluorescence images.
45345572|NCT00863590|Drug|odanacatib|[Intervention Name: odanacatib (Panel A)] Panel A: Odanacatib tablets will be administered to male subjects in rising single doses of 2, 10, 50, 200, or 400 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
45684764|NCT01892644|Drug|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution starting with 10 mg/kg/day, once daily for 2 weeks and thereafter 20 mg/kg/day for 11,5 months.
45684765|NCT01892878|Procedure|VerteLoc|Single Arm
45684766|NCT01892956|Other|Nutritional intervention|"2 dietary interventions~personalized diet based on algorithm predictions of glucose response to foods~Mediterranean-style diet"
45840844|NCT00919932|Behavioral|Paper and pen homework|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The homework will be done on a preprinted form which is assigned weekly and reviewed with their therapists at weekly sessions for 4 weeks.
45684767|NCT01893034|Procedure|Arthroscopic treatment of femoroacetabular impingement|
45684768|NCT01893034|Other|Physiotherapy and activity modification|
45684769|NCT02804230|Device|Neuro Ablation - Functional|MR-Guided Focused Ultrasound
45684770|NCT01901653|Drug|Rovalpituzumab tesirine (SC16LD6.5)|
46041872|NCT01025154|Drug|Cytarabine|Induction Cycle: 1 g/m^2 IV over approximately 2 hours daily for 5 days (days 1-5), follow clofarabine by 3 to 6 hours.
46041873|NCT04252833|Drug|CT-044|CT-044 HCl is a reactive species decomposition accelerant
46041874|NCT04252911|Other|Bispectral index score|Bis value from two sites gives similar results
46041875|NCT04252365|Drug|Sintilimab|Given i.v.
46041876|NCT04252365|Drug|Pembrolizumab|Given i.v.
46041877|NCT04256499|Procedure|Acute water load test|The acute water load test consists in administering orally 20 mL/kg (of body weight) of water (ingested in less than 30 min) and then follow (during 4 to 6 hours) blood and urine parameters.
46041878|NCT04256577|Diagnostic Test|serum ceramides level in blood|Serum ceramides ( sphingolipid measurement, plasma (EDTA as anticoagulant) and serum separation was performed immediately after blood drawing by two-time scentrifugation at 750 x g for 5 min (4°C). Lipid extraction from plasma and/or serum samples (10 µl each) and subsequent LC-MS/MS)
46041879|NCT04252443|Other|Evaluation of nurses' knowledge and attitudes about opioid analgesics working in a university hospital|Interventions involving nurses' pharmacological level
46041880|NCT00832819|Drug|E7080|Drug: E7080 will be administered orally starting at a dose of 6 mg twice daily during the 7-day run-in period and for 3 weeks (Cycle 1).
46041881|NCT00832819|Drug|E7080|Maximum tolerated dose determined in the Dose-Escalation Cohort will be administered to the Expansion Cohort. After E7080 is taken on Day 1, paclitaxel (200 mg/m2) will be administered intravenously (IV), followed by IV carboplatin (AUC 6.0 min/mg/mL).
46041882|NCT00832819|Drug|Paclitaxel|Paclitaxel (200 mg/m2) will be administered intravenously (IV) on Day 1 after administration of E7080.
46041883|NCT00832819|Drug|Carboplatin|Carboplatin (AUC 6.0 min/mg/mL) will be administered IV on Day 1 after administration of E7080 and Paclitaxel.
46041884|NCT04820361|Drug|Cannabis sativa L., folium cum flore|Muscle Relaxation
45345573|NCT00863590|Drug|Comparator: odanacatib (Panel B)|Panel B: Odanacatib tablets will be administered to male subjects in rising single doses of 5, 25 (fasting), 100, 25 (fed), or 600 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
45345574|NCT00863590|Drug|Comparator: odanacatib (Panel C)|Panel C: Odanacatib tablets will be administered to female subjects in rising single doses of 50 or 100 mg over 2 treatment periods. Half of the subjects will receive placebo to odanacatib in one of the 2 treatment periods. There will be at least 7 days between each treatment period.
45345575|NCT00863590|Drug|Comparator: odanacatib (Panel D)|Panel D: Odanacatib tablets or placebo to odancatib will be administered to male subjects in rising single doses of 100, 200, or 300 mg following a high-fat breakfast over 3 treatment periods. Three of twelve subjects will receive placebo to odanacatib in all 3 treatment periods. There will be at least 10 days between each treatment period.
45345576|NCT00735228|Device|Artificial pancreas|Artificial endocrine pancreas (NIKKISO Company)
45345577|NCT04040842|Diagnostic Test|Patients undergoing low anterior resection|Patients before the surgery and one year after the surgery will be assessed with questionnaire.
45345578|NCT03843892|Drug|OFEV|twice daily
45345579|NCT00739128|Biological|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscular at zero, one and six months intervals
45840845|NCT00919932|Device|Text message system homework.|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The novel text-messaging system allows homework to be submitted directly through an adolescent's cellular phone, includes text-messaged homework reminder prompts, and collates all homework for therapists to review with patients during therapy sessions. This is assigned and reviewed weekly for 4 weeks.
45345580|NCT00739128|Biological|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intradermally in the deltoid region at zero, one and six months intervals
45345581|NCT00863668|Drug|Efavirenz + Tenofovir DF/Emtricitabine|600mg QD for 52 weeks + 300mg/200mg QD for 52 weeks
45345582|NCT00863668|Drug|Raltegravir + Tenofovir DF/Emtricitabine|400mg BID for 52 weeks + 300mg/200mg QD for 52 weeks
45345583|NCT00863668|Procedure|Colonoscopy with biopsies|Day 0, Day 2, Day 7, Day 14, Week 52
45345584|NCT00863668|Procedure|Inguinal Lymph Node Excision|Day 0, Day 2, Day 7, Day 14, Week 52
45345585|NCT00739206|Drug|SAR97276A|Dose based on body weight
45345586|NCT00735540|Other|Observational|Data summary only
45345587|NCT00739284|Device|nephrostomy tube and ureteral stent|
45345588|NCT00872248|Procedure|Spinal anesthesia|Procedures of spinal anesthesia with bupivacaine 0.5%, 10-15mg
45345589|NCT00872248|Procedure|Epidural anesthesia|Procedures of epidural anesthesia with ropivacaine 0.75%, 75-120mg
45345590|NCT00732576|Dietary Supplement|menaquinone-7|capsule consisting of 10, 20 or 45 µg menaquinone-7 per day during 8 weeks
45345591|NCT00732576|Dietary Supplement|fish oil|9 fish oil capsules equivalent to 3 gram per day of n-3 polyunsaturated fatty acids during 12 weeks
45345592|NCT00732576|Dietary Supplement|krill oil|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) during 12 weeks
45345593|NCT00863902|Drug|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
45345594|NCT00863902|Drug|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fed conditions
45345595|NCT00732732|Dietary Supplement|Green banana powder|Green banana in powder form, 10 grams/ day for children below 10 kg, 20 grams for those weighing 10 Kg or more. Protocol Modified on Aug 5th 2009 to give 20 grams irrespective of age.
45345596|NCT00732732|Other|Microcrystalline cellulose|Microcrystalline cellulose 10 gm/ day for subjects below 10 kg in weight, 20 gms/ day for those weighing 10 Kg or more
45345597|NCT00732810|Drug|SCH 727965|SCH 727965 50 mg/m^2 IV on Day 1 of each 21 day cycle until disease progression.
45345598|NCT00732810|Drug|Capecitabine|Capecitabine 1250 mg/m^2 orally twice daily from Day 1 to Day 14 of each 21 day cycle until disease progression.
45345599|NCT00732810|Drug|Erlotinib|Erlotinib 150 mg orally once daily until disease progression.
45345600|NCT00732888|Drug|Nilotinib Hydrochloride|Dosage form: capsules Dosage: 400 mg (2 x 200 mg capsule) Frequency & duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
45345601|NCT00732888|Dietary Supplement|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
45345602|NCT00732966|Drug|losartan|with losartan 50 mg once daily for one month
45345603|NCT00732966|Drug|valsartan|valsartan 160 mg once daily
45345604|NCT00739440|Biological|serum antiscorpion|The dose may be required for the patient according to clinical manifestations and evolution
45345605|NCT02568618|Genetic|Pain Medication DNA Insight (TM) test|The DNA insight test uses saliva to test the metabolism of certain pain and mental health medications to determine if the subject is a poor metabolizer, intermediate metabolizer or ultrarapid metabolizer.
45345606|NCT00735774|Drug|11C-ORM-13070|Single dose of i.v. solution
45345607|NCT03901560|Other|Music Therapy|
45345608|NCT00735852|Drug|Decapeptyl SR 11.25mg|11.25 mgs, Intra muscular (IM) every 3 months for 2 years
45345609|NCT00739518|Procedure|MRI|Neurological MRI with new technology evaluation. The new technology may involve software or MRI scanning sequences. This is a long term research study that focuses on new technology that is constantly being created.
45345610|NCT00424021|Drug|ambrisentan|1, 2.5, 5, and 10 mg ambrisentan given orally once daily
45345611|NCT00733044|Behavioral|Specialized Care|The intervention consists of the integration of integral tinnitus management provided by a specialized tinnitus centre in the health care system. The tinnitus centre offers care following a stepped-care approach with two levels. The first level of intervention consists of audiological diagnostics and intervention, a tinnitus educational group session and a individual consult with a clinical psychologist. For patients with mild complaints this basic intervention is expected to suffice. For patients with moderate to severe complaints a second level of intervention exists. This level of intervention consists of combinations of the following therapies: Cognitive Behavioural Therapy (CBT), Attention Diversion (AD), exposure techniques, and Relaxation Therapy (RT).
45345612|NCT00733044|Other|Usual Care|Usual care consists of a standardized version of treatment that is currently applied in peripheral audiological centres throughout the Netherlands. A telephone survey was conducted amongst all audiological centres (n=28) in the Netherlands. The results of this survey determined the content of the usual care treatment protocol in the current study. The treatment consists of audiological diagnostics and intervention and, if necessary, one or more consults with a social worker with a maximum of ten one hour sessions.
45345613|NCT00735930|Drug|Alvocidib Hydrochloride|Given IV
45345614|NCT00735930|Drug|Lenalidomide|Given PO
45345615|NCT00735930|Other|Pharmacological Study|Correlative studies
45345616|NCT00735930|Other|Laboratory Biomarker Analysis|Correlative studies
45345617|NCT03902262|Procedure|appendicectomy|
45345618|NCT00736008|Other|Observational|Data summary only
45345619|NCT00736086|Device|Vessel Closure (StarClose™)|
45345620|NCT00617734|Biological|IMC-A12 (cixutumumab)|IMC-A12 10 milligrams per kilogram (mg/kg) over one hour every two weeks. A cycle is defined as four weeks of therapy. Participants will continue on study until evidence of progressive disease, or unacceptable toxicity develops.
45345621|NCT00617734|Biological|cetuximab (Erbitux ®)|IMC-A12 10 mg/kg over one hour followed by cetuximab 500 milligrams per square meter (mg/m^2) over two hours. This sequence will be repeated every two weeks. Participants will continue on study until evidence of progressive disease or unacceptable toxicity develops.
45684771|NCT01925989|Biological|LY2605541|Administered SQ
45684772|NCT01925989|Biological|Insulin Glargine|Administered SQ
45345622|NCT00733122|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 mL of GARDASIL as intramuscular injections at the Day 1, Month 2, and Month 6 visits.
45345623|NCT00733200|Procedure|Minor or Major Liver Resection|
46041885|NCT04820361|Drug|Placebo|Muscle Relaxation
46041886|NCT04819737|Procedure|SC MRI|SC MRI (Averaged Magnetization Inversion Recovery Acquisitions (AMIRA), standard conventional SC MRI sequences, additional sequences for spinal cord MRI (sagittal-2D or 3D short tau inversion recovery, sagittal-2D or 3D phase-sensitive inversion recovery, 3D magnetization prepared 2 rapid acquisition gradient echoes (MPRAGE)). To evaluate the presences of ongoing inflammation (acute or chronic) in the SC of patients, 3D MPRAGE and 3D fluid-attenuated inversion recovery images after intravenous gadolinium (Gd) contrast administration (0.1 mmol per kg body weight) will be acquired.
46041887|NCT04819737|Other|patient questionnaire|12-item multiple sclerosis walking scale (MSWS-12) questionnaire: self-report measure of the impact of MS on the individual's walking ability
46041888|NCT04256655|Drug|cohort 1 0.225g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
46041889|NCT04256655|Drug|Cohort 2 0.75g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
46041890|NCT04256655|Drug|Cohort 3 2.25 g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
45345624|NCT00877318|Device|SCAD information system|Cardiac rehabilitation at home by telemedicine
45345625|NCT00577460|Drug|Pramipexole|Pramipexole ER 0.375 -4.5 mg
46041891|NCT05320497|Device|Transparent cap|Add a self-made transparent cap (made by cutting a silicone drainage tube) to the end of the SpyGlass choledochoscope, and then perform routine choledochoscopy and biopsy operations
46041892|NCT00853723|Drug|Parathyroid hormone related protein (1-36)|PTHrP (1-36) 400 micrograms / day administered subcutaneously for 3 months
45345626|NCT00577460|Drug|Placebo|Placebo tablets identical to Pramipexole ER tablets
45684773|NCT01901419|Drug|Nitroglycerin infusion|Nitroglycerin infusion during rewarming
46041893|NCT00853723|Drug|Parathyroid hormone related protein(1-36)|PTHrP(1-36)600 micrograms subcutaneously administered daily for 3 months
45840846|NCT00922194|Drug|Extended Release Metformin|0.5g twice a day to 2g twice a day for at least 12 months or more
45345627|NCT00877396|Biological|Influenza vaccination|Influenza vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose (0.5 mL) 4 weeks later.
45345628|NCT00877396|Biological|Hepatitis A Vaccine|Hepatitis vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose ( saline- 0.5 mL) 4 weeks later.
45345629|NCT00877474|Drug|PM01183|Vials containing 0.2 mg of PM01183 as powder for concentrate for solution for infusion
45345630|NCT00872326|Procedure|Autologous Bone Marrow Mononuclear Cells|Infusion > 80 millions mononuclear cells. Intraarterial administration at popliteal artery level. Infusion during 3 minutes with antegrade blockage of arterial flow.
45345631|NCT00736112|Other|Food Allergy Testing|Food Allergy Diagnosis - blood drawn for food allergy testing at the time of surgery (bilateral myringotomy with tympanostomy tubes +/- adenoidectomy)
45684774|NCT02798536|Drug|LMB-100|Administered intravenous (IV) on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles (Arms A1 and A2) or 2 cycles (Arms B1 and B2)
45684775|NCT02798536|Drug|nab-paclitaxel|Arms B1 and B2 only. Administered intravenous (IV) on days 1 and 8 of each 21 day cycle for up to 6 cycles
45684776|NCT01901341|Drug|CB-5945|
45684777|NCT01901341|Drug|Placebo|
46041894|NCT00853723|Drug|Parathyroid hormone (1-34)|PTH(1-34)20 micrograms subcutaneously administered daily for 3 months
46041895|NCT01104545|Drug|MK-3614|
46041896|NCT01104545|Drug|Comparator: Placebo|
45345632|NCT00736112|Procedure|Adenoidectomy|Adenoidectomy to remove adenoid tissue. (Are adenoids a factor in OME (otitis media with effusion) or is food allergy diagnosis and treatment able to significantly prevent ROM (recurrent otitis media) after the tubes fall out?)
46041897|NCT04117789|Behavioral|Therapist-guided internet-delivered cognitive behavior therapy for depression in adolescents|Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program with therapist support via an internet platform.
45345633|NCT00736112|Procedure|BMT|The standard protocol for children presenting with initial Chronic OME is to perform a BMT
45345634|NCT00863980|Drug|Micardis (Telmisartan)|40-80 mg/day oral administration
45345635|NCT00863980|Drug|Blopress (Candesartan)|8-12 mg/day oral administration
45345636|NCT00415519|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
45345637|NCT00415519|Drug|Placebo of MCI-186|Two ampoules of Placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
46041898|NCT04117789|Behavioral|Self-guided internet-delivered cognitive behavior therapy for depression in adolescents|Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program without therapist support via an internet platform.
46041899|NCT04117789|Other|Treatment as usual|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical or the combination of both.
45345638|NCT05741294|Drug|Tirbanibulin 2.5 mg ointment|Participants will apply tirbanibulin 2.5 mg ointment topically for 5 consecutive days over 25 square centimeters (cm^2) of the face or scalp.
45684778|NCT04758286|Procedure|Emergency surgical procedures|COVID-19 patients who had presented to the Emergency Department were evaluated for their emergency surgical conditions and were managed appropriately
46041900|NCT00918255|Biological|adalimumab|Subcutaneous injection using prefilled syringe containing adalimumab 40 mg in 0.8 milliliters
46041901|NCT00918255|Drug|Placebo|Subcutaneous injection using prefilled syringe containing 0.8 milliliters
45684779|NCT01453660|Other|Endo-PAT2000 testing|Endo-PAT2000 testing is done six times during the study. Baseline Assessment Time 1 Cycle 1, Day 1 (Pre-chemotherapy)Time 2 Cycle 1, Day 1 (After 1st dose of cisplatin), Time 3 Cycle 1, Day 2 (Before second cisplatin dose of cycle 1), Time 4 Cycle 1, Day 5 (After last cisplatin dose of cycle 1), End-of-Study Assessment Time 5 (14-34 weeks from Time 1; e.g., 1-12 weeks following completion of the last cycle of first-line chemotherapy) Long-Term Follow Up Assessment Time 6 (24-30 months from Time 1)
46041902|NCT04252131|Drug|cassia seed tablet|traditional Chinese herbs
46041903|NCT04252209|Other|natural herbs of coconut, aloe vera, and pepperint|mixture of herbal oils of coconut, peppermint, aloe vera
46041904|NCT04252209|Other|carboxy methyl cellulose|a moisturizing gel contained 3%carboxy methyl cellulose, 3% peppermint essential oil, 10% propylene glycol, 0.1% potassium sorbate, and water up to 100%.
45840847|NCT00923598|Drug|0.1% and 0.4% perineural ropivicaine|Patients will be randomized to one of two groups: Ropivicaine 0.1% infusion on the right leg and Ropivicaine 0.4% infusion on the left leg, or Ropivicaine 0.4% infusion on the right leg and Ropiviciane 0.1% infusion on the left leg for treatment of postoperative pain following bilateral TKA. Both groups will receive the same total dose of medication and will have the infusion for the two days following surgery.
46041905|NCT04252053|Other|Pilates Based Core Stabilization Training|Pilates-based core stabilization training (PBCST) is a controlled form of exercise provided improvement in stabilization of abdominal and back muscles.
46041906|NCT04252053|Other|Home based exercise|Home exercises which include pilates based core stabilization training will be structured for the people with MS according to their physical condition and will perform at home by them.
45474959|NCT04509154|Other|Multimodal pain therapy|For the elaboration of the contents of the multi-component treatment of the mobile device application (APP), a set of guidelines has been developed for the care of one's own health, based on scientific evidence and adapted to the language of citizens, applying participatory methodology (Loewenson et al. 2014) and consensus, both by professionals (physicians,, nurses, psychologists, pharmacists, social educators and health professionals), and expert patients, who guarantee their validity, allowing the analysis and selection of the interventions that respond to the health problem. This intervention consists in the implementation of a protocol of standard activities of the interactive psychosocial therapy type.
45474960|NCT04509154|Other|Standardized treatment.|Face-to-face health education sessions led by nurses and physicians, with the possibility to have access to a non-interactive website with pain management materials from a self-help approach.
45840848|NCT00923910|Drug|WT1 Peptide-Pulsed Dendritic Cells|
45840849|NCT00923910|Drug|Donor Lymphocytes|Lymphocytes from donors (related or unrelated) collected via lymphapheresis.
46041907|NCT01096589|Device|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
46041908|NCT01096589|Device|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
46041909|NCT01096589|Device|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
46041910|NCT01096589|Device|Comprilan|Commercial short-stretch bandage (Comprilan; BSN Medical Ltd, Hull, U.K).
46041911|NCT04252521|Drug|metoclopramide|10 mg Metpamid in 100 ml normal saline solution
46041912|NCT04252521|Drug|dexketoprofen trometamol|50 mg dexketoprofen trometamol in 100 ml normal saline solution
46041913|NCT04252521|Drug|metoclopramide+dexketoprofen trometamol|10 mg metoclopramide+50 mg dexketoprofen trometamol in 100 ml normal saline solution
46041914|NCT04819659|Device|Pharyngeal packing|Placing gauze-like material in the nasal cavity to absorb blood or other fluids right after tracheal intubation.
45474961|NCT03854669|Device|pain reporting accuracy|pain reporting accuracy will be assessed by the Focused Analgesia Selection Task (FAST) procedure. The FAST is based on recording a subject's pain reports in response to repeated administration of thermal noxious stimuli of various intensities, applied on the non-dominant arm with the Medoc® Thermal Sensory Analyzer II. The subjects will receive 1 of 7 designated temperatures (44°C, 45°C, 46°C, 47°C, 48°C, 49°C, and 50°C), each presented 7 times in a random block-ordered design (49 stimuli in total).
45840850|NCT00923910|Drug|IL-4|water-soluble protein; this study will use GMCSF (granulocyte macrophage colony stimulating factor)/IL-4 generated monocyte derived dendritic cells
45840851|NCT00923910|Drug|KLH|Neoantigen known to induce helper responses; will be used concurrently as a vaccine adjuvant and control antigen.
45840852|NCT00923910|Drug|WT1 Peptides|dendritic cell vaccine
45840853|NCT00923910|Drug|Endotoxin|Purified lipopolysaccharide prepared from E.Coli 0:113
45840854|NCT00923910|Drug|Diphenhydramine|Pre-medication
45840855|NCT00923910|Drug|Acetaminophen|Pre-medication
45840856|NCT00924066|Drug|Ixempra (Ixabepilone (BMS-247550) )|Participants received Ixabepilone 6mg/m^2 for a total of 30mg/m^2 inpatient or outpatient intravenously over an hour on the first five days of each 21 day cycle.
46041915|NCT04918745|Device|Cochlear Vestibular Implant (CVI)|"The Cochlear Vestibular Implant (CVI) is a modified cochlear implant (CI) which also incorporates a vestibular component (VI) in order to restore both hearing and vestibular function. Three vestibular stimulation algorithms will be compared in a randomized order (3 treatments x 3 periods, = 6 arms). These stimulation algorithms are:~A - Baseline stimulation, no modulation stimulation~B - Baseline stimulation, modulated stimulation~C - Reduced baseline stimulation, modulated stimulation"
46041916|NCT00845065|Drug|Boceprevir|800 mg, using SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
46041917|NCT00845065|Other|Placebo|800 mg, using placebo matching SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
46041918|NCT00845065|Biological|Peginterferon alfa-2a|Peginterferon alfa-2a, pre-filled syringes, given 180 μg/week subcutaneously (SC) for 48 weeks
45345639|NCT00736268|Behavioral|Telephone-based Enhanced Coping Skills Training (CST)|Telephone-based Enhanced Coping Skills Training (CST) intervention will systematically train participants (and caregivers) in the use of coping skills for symptom management (i.e. activity pacing, pleasant activity scheduling, communications, relaxation, goal setting, imagery, calming self-statements, problem solving, and preventing and dealing with setbacks). Participants in the CST condition will receive 12 weekly 30 minute telephone sessions followed by 2 bi-weekly booster sessions for training in symptom management strategies. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
45345640|NCT00736268|Other|Usual Medical Care and COPD education and symptom monitoring (UMC)|COPD usual care plus education and symptom monitoring control condition will participate in a weekly 15 minute phone call followed by 2 bi-weekly phone calls, assessing their health status and providing them with support and COPD education. COPD Education topics include types of lung disease, oxygen use, medication management, preventing infection, managing daily activities, and nutrition. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
45474962|NCT03178851|Biological|Atezolizumab|Atezolizumab, 840 mg intravenously every two weeks (Q2W) on Days 1 and 15 of each 28-day cycle, until loss of clinical benefit
45474963|NCT03178851|Drug|Cobimetinib|Cobimetinib, 60 mg orally once daily (QD) on Days 1-21 of each 28-day cycle, until loss of clinical benefit
46041919|NCT00845065|Drug|Ribavirin|"Ribavirin 200-mg capsules, weight-based dosing~<75 kg, 1000 mg/day orally (PO), divided twice daily (BID)~>=75 kg, 1200 mg/day PO, divided BID~for 48 weeks"
46041920|NCT04772001|Drug|Hydrochloride anlotinib|Hydrochloride anlotinib is a small molecular anti-angiogenesis drug with multiple targets. It will be taken at a starting dose of 12 mg for 14 days. Then participants will rest for 7 days and start a new cycles. At most of 3 cycles will be administrated. If intolerable toxicity happen, dosage of 10mg or 8mg will be taken.
46041921|NCT04772001|Drug|cis Platinum/carboplatin|Concurrent chemotherapy will be administrated weekly during radiation for a total of 5-6 doses. Cisplatin of 40mg/m2 will be the most preferred regime. For patients with intolerable toxicity of cisplatin, carboplatin of AUC 2 will be the alternative drug.
46041922|NCT04772001|Radiation|External beam radiotherapy and brachytherapy|Radiation will be given by external beam of 45Gy total dose and 3D-brachytherapy of 30Gy/5F or 28Gy/4F. Duration of radiotherapy will be no more than 8 weeks.
46041923|NCT02880059|Device|Cardiorepiratory Polygraphy|Sleep apnea screening by out-of-center polysomnography/polygraphy
46041924|NCT00702091|Drug|Ramipril|10 mg capsule
46041925|NCT00626171|Procedure|Allergen Challenge|Allergen challenge
46041926|NCT00832585|Drug|Alefacept|Alefacept 15mg IM every week for 12 weeks
46041927|NCT00918567|Drug|atomoxetine|open label treatment dosed up to 1.8mg/kg/day
46041928|NCT00918567|Behavioral|Behavior Modification Therapy|8 week behavioral modification course with school consultation, parenting groups using COPE and child social skills group
45345641|NCT01323907|Drug|Omegaven IV lipid emulsion|For infants meeting inclusion criteria and whose guardians consent to participation, Omegaven will be initiated at the dose of 0.5gram/kg/day and is infused over 24 hours for 1-2 days and then advanced to 1 gram/kg/day. Omegaven will be infused intravenously through a central or peripheral catheter alone or in conjunction with parenteral nutrition.
45345642|NCT01323985|Drug|GSK2315698|5mg-400mg IV (in the vein) single dose over 1-4 hours
45684780|NCT01453660|Other|Endo-PAT2000 testing|Time 1: A baseline assessment will be performed in the fasting state including Endo-PAT2000, vital signs, waist circumference, fasting blood draw, & urine sample. This will be considered Day 1 of the study for this group of patients. Time 2 (2-5 hours from Time 1): Two to five hours after Time 1, patients will undergo assessment of blood pressure & heart rate, including orthostatics & Endo-PAT2000 testing. Time 5 -- End of Study visit (14-34 weeks from Time 1): At a time point 14 to 34 weeks later than Time 1 patients will undergo study testing in the fasting state. This includes Endo-PAT2000 testing, vital signs including orthostatics, waist circumference, fasting blood draw, & urine sample. The Surgery-Only Group will not have any assessment at Time 3 (Day 2) or Time 4 (Day 5) due to logistical concerns. Long-Term Follow Up Assessment Time 6 (24-30 months following Time 1)
45684781|NCT04757896|Procedure|Lateral costoclavicular approach|USG guided lateral costoclavicular approach for brachial plexus block
45684782|NCT04757896|Procedure|Medial costoclavicular approach|USG guided medial costoclavicular approach for brachial plexus block
45684783|NCT01615939|Drug|Bupivacaine|Bupivacaine 0.625% with epinephrine 1:300,000
45684784|NCT01615939|Drug|Ropivacaine|0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr.
46041929|NCT04255797|Behavioral|baby massage|The steps are as follows:1. Monitor the physiological indicators before massage, 2. Assist premature babies to lie on prone, take off their clothes and diapers, and then apply the baby's massage oil to the hands of both parents to warm them. 3. In the incubator, slight pressure touch the baby's body with warm palms and fingers.
46041930|NCT05252325|Device|hyaluronic acid plus lidocaine|local injection for correction of nasolabials fold
46041931|NCT05252325|Device|hyaluronic acid without lidocaine|local injection for correction of nasolabial folds
46041932|NCT04255641|Other|time lapse analysis|grading of the embryos before freezing using time lapse/
46041933|NCT04770051|Procedure|Percutaneous inferior cervical sympathetic block|The procedure will be performed while the patient was awake and under fluoroscopic guidance. A total of 3 ml of 1% lidocaine will be infiltrated to anesthetize the skin and subcutaneous tissues down to the left common carotid artery. A 22 gauge × 3.5 inch BD™ Quincke spinal needle will be introduced at the level of the body of the sixth cervical vertebra, medial to the left common carotid artery. The needle will be advanced until it reached the junction between the body and transverse process of the sixth cervical vertebra. Contrast injection will be used to demonstrate the position of the needle anterior to the paravertebral muscles, with spread along the axis of the interfascial compartment (Figure 1). A total of 20 ml of 0.25% bupivacaine (Marcaine, Hospira, Lake Forest, IL) will be injected over 10 min through the needle. The effectiveness of sympathetic blockade will be confirmed by postprocedure development of ptosis and miosis in the left eye.
46041934|NCT05252091|Drug|herombopag olamine tablets|The first day of chemotherapy was d1, and the drug was started from d-5, 5 days before chemotherapy, with oral herombopag 5 mg/day for a maximum of 14 days. After chemotherapy, when the thrombocytopenia rises to ≥200×109/L, drug discontinuation can be considered
46041935|NCT01024920|Drug|BIBF 1120|VEGF inhibitor
46041936|NCT01024920|Drug|sunitinib|VEGF inhibitor
46041937|NCT00832117|Drug|Ixabepilone|Escalation: Solution, intravenous (IV), 32-40 mg/m2, every 3 weeks, approximately 6 months
46041938|NCT00832117|Drug|Cisplatin|Escalation: Solution, IV, 60-100 mg/m2, every 3 weeks, approximately 6 months
46041939|NCT00832117|Drug|Ixabepilone|Expansion: Solution, IV, 32 mg/m2, every 3 weeks, approximately 6 months
46041940|NCT00832117|Drug|Cisplatin|Expansion: Solution, IV, 60-80 mg/m2, every 3 weeks, approximately 6 months
46041941|NCT02873052|Device|MyoVista|The clinical set up of MyoVista™ is identical to that of a traditional 12-lead ECG but it obtains and processes signal information in a way that permits much greater resolution of the electrical activity associated with the myocardium MyoVista.
46041942|NCT02611843|Behavioral|Peer-Supported Web CBT|
46041943|NCT02611843|Behavioral|Self-Managed Web CBT|
46041944|NCT02872272|Drug|Treatment with Amikacin|Aminoglycosides. Blood sampling for pharmacokinetic evaluation
46041945|NCT02872896|Procedure|Orthopedic, urologic or general surgery|Patients having orthopedic, urologic or general surgery may have the ClearSight device; patients having orthopedic, urologic or general surgery may have the non-ClearSight device to monitor subject blood pressure during surgery
46041946|NCT02612467|Other|Stratified care|"Patients are stratified according to the SBT subgroups (low, medium and high risk) and the appropriate matched intervention will be delivered accordingly.~Low risk: Reassuring information. Onwards referral, investigation or further treatment is not recommended Medium risk: In addition to reassuring information patients receive evidence based individualised treatment focusing on restoring function (targeting back pain, leg pain, co-morbid pain and disability) High risk : In addition to medium risk treatment patients will receive individualised psychologically informed physiotherapy aiming to reduce pain and disability."
46041947|NCT02612467|Other|Current care|Treatment based on clinical judgement, clinical need and patient preferences. No access to guidance tools.
46041948|NCT04205292|Procedure|hysteroscopic|Women in the intervention group will receive an inpatient treatment with two-dose of Methotrexate followed by hysteroscopic resection under ultrasound guidance
46041949|NCT01104311|Procedure|Aggressive BP lowering|adjust the amount and number of antihypertensive drugs to lowering of systolic blood pressure to target level
46041950|NCT01104311|Procedure|modest blood pressure lowering|adjust the amount and number of antihypertensive drugs
45345643|NCT01323985|Drug|GSK2315698|IV (in the vein) single dose over 24 hours, in two sessions
45345644|NCT02568176|Drug|Midazolam|Single oral dose of midazolam 6 mg Day 1 and Day 17.
45345645|NCT02568176|Drug|Esketamine|Intranasal esketamine will be self-administered 5 times during 15 days.
45345646|NCT02568176|Drug|Bupropion|Single oral dose of bupropion 150 mg on Day 1 and 19.
46041951|NCT02612389|Other|Meditative Movement taught via DVD|Gentle movement with attention to posture and breathing with emphasis on interoceptive awareness and self regulation.
46041952|NCT04205214|Behavioral|Integrative Cognitive Behavioural Therapy|This intervention involves the psychological intervention of Cognitive Behavioural Therapy. This intervention also includes third wave psychological interventions of Mindfulness and Narrative Therapy which has been found to be helpful for people with chronic health conditions and chronic skin conditions.
46041953|NCT00702247|Procedure|Hematopoietic Stem Cell Transplantation|
45345647|NCT01033591|Behavioral|Supervised progressive exercise program with an aerobic and a strength component + Optimized treatment|Three month supervised progressive exercise program with an aerobic (high intensity intervals) and a strength component; and the programme will continue linked with community resources for 9 months
45345648|NCT01033591|Behavioral|Optimized treatment according to the European Society of Cardiology guidelines|Optimized treatment according to the European Society of Cardiology guidelines
45345649|NCT03899870|Procedure|Rectal resection|Patients underwent anterior or low anterior resection. Patients with tumors in the lower third of the rectum where anal sphincters could not be preserved underwent abdominoperineal resection. In majority of the cases, inferior mesenteric artery (IMA) was ligated caudal to the origin of the left colic artery. For the tumors of the upper rectum, partial excision of the mesorectum was performed up to the minimum of 5 cm from the inferior aspect of the tumor. For the tumors of the middle and low rectum a total mesorectum excision was done with the minimum distal mucosal margin of 1 to 2 cm. Ileostomy was performed in cases where colon was poorly prepared, anastomotic leak test was positive or colonel anastomosis was made. In most of the cases, open surgery was performed. Laparoscopic surgery was performed in selected cases. Wide local excision was performed in selected cases with T1 tumors without locoregional lymphadenopathy.
45345650|NCT03899870|Drug|Neoadjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered neoadjuvant therapy. In the neoadjuvant therapy, we used 45 Gy in 25 fractions with concurrent 5-fluorouracil [5-FU] and patients were operated 8 to 10 weeks after neoadjuvant therapy. In some cases, especially the elderly patients with multiple co-morbidities, we used short-course pelvic radiation therapy which included 25 Gy in 5 fractions over 1 week.
45345651|NCT03899870|Drug|Adjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered adjuvant therapy. In most of the cases, FOLFOX (leucovorin, 5-FU, oxaliplatin) regimen was used and for elderly patients who could not tolerated this regimen, we used oral capecitabine.
45684785|NCT02789878|Drug|Goserelin|Androgen Deprivation Therapy
46041954|NCT00831493|Radiation|Chemoradiation (Radiation Therapy)|Dose of 50.4 Gy in 1.8 Gy fractions in 28 fractions, Monday to Friday, Weeks 1 to 6.
46041955|NCT00831493|Drug|Vorinostat|Starting Dose of 200 mg orally once daily, Monday to Friday, Weeks 1 to 6.
45345652|NCT00741182|Drug|rhPTH(1-34)|Injection of 20 micrograms per day in eight weeks
45345653|NCT00872404|Drug|CP-751,871|20mg/kg/3 weeks
45345654|NCT00423943|Drug|modafinil|200 milligrams daily dose
45345655|NCT00423943|Drug|Placebos|capsule containing placebo
45345656|NCT00736346|Behavioral|Brief cognitive-behavioral treatment for Panic Disorder|One two-hour session of cognitive-behavior therapy for panic disorder
45345657|NCT00736346|Behavioral|Cognitive-Behavior Therapy for Panic Disorder|Seven one-hour sessions of cognitive-behavior therapy for panic disorder
45345658|NCT00736346|Drug|paroxetine|40 mg die, for 6 months
45345659|NCT00864058|Drug|Gabapentin 400 mg capsules|A: Experimental Subjects received Actavis formulated products under fasting conditions
45345660|NCT00864058|Drug|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
45345661|NCT00864136|Drug|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for treatment of menorrhagia
45684786|NCT02789878|Drug|Prednisone|Corticosteroid
45684787|NCT02789878|Drug|Abiraterone|CYP17 inhibitor
45684788|NCT02789878|Drug|Apalutamide|Androgen-receptor antagonist
45684789|NCT01901185|Drug|Etanercept / Autoinjector A|Autoinjector A, a hand-held, reusable electromechanical device, and a single-use, disposable cassette preassembled with an etanercept 50-mg liquid prefilled syringe (PFS).
45684790|NCT01893424|Drug|Sativex buccal spray|buccal spray
46041956|NCT00853567|Drug|Proellex|25 mg oral daily dose vs. 50 mg oral daily dose vs. placebo
46041957|NCT00853567|Other|placebo|Placebo
46041958|NCT00853489|Device|recombinant bone morphogenetic protein 2|Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft
46041959|NCT00853489|Procedure|Autogenous iliac crest bone graft|Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.
46041960|NCT00705445|Dietary Supplement|Micronutrient Supplementation without Zinc|This will contain Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D and Folic Acid
46041961|NCT00705445|Dietary Supplement|Micronutrient Supplementation with Zinc|This will contain Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid. Additionally, this will also contain 10 mg elemental Zinc Sulphate.
46041962|NCT00705445|Other|Nutritional Counselling and Education|This will contain Nutritional Counselling and Education.
46041963|NCT02879981|Drug|Guaifenesin|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
46041964|NCT02879981|Drug|Sulfamethoxazole|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
46041965|NCT02879981|Drug|Trimethoprim|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
46041966|NCT04307693|Drug|Lopinavir/ritonavir|Lopinavir / Ritonavir tablet
46041967|NCT04307693|Drug|Hydroxychloroquine sulfate|Hydroxychloroquine sulfate tablet
45345662|NCT00864136|Drug|Conventional medical treatment|Women using combined oral contraceptives, oral/injectable progestogens, non-steroidal anti-inflammatory drug
46041968|NCT02878421|Device|electronic cigarette + 16mg nicotine & flavor|comparison of different strengths of nicotine
46041969|NCT02878421|Other|electronic cigarette + 0mg nicotine & flavor|comparison of different strengths of nicotine
45345663|NCT00864136|Drug|Conventional medical treatment|Women using anti-fibrinolytic agent for treatment of menorrhagia
45474964|NCT03178851|Biological|Atezolizumab|Atezolizumab, 840 mg intravenously on Day 15 of Cycle 1; thereafter Q2W on Days 1 and 15 of Cycle 2 and all subsequent 28-day cycles, until loss of clinical benefit
46041970|NCT02878421|Other|Tobacco cigarette|Participant to remain on traditional cigarettes for 28 days
46041971|NCT02878187|Device|Doppler|"Color Doppler ultrasound will be used to demonstrate the main ascending branches of left and right uterine arteries as they cross over the hypogastric vessels just before they enter the uterus at the uterine-cervical junction. The high pass filter was set at 125 Hz and the uterine artery will be obtained immediately after the crossing of the hypogastric artery. The sample volume will be placed on the artery with an angle of about 0°. After detection of blood flow and visu¬alization of the waveform of the uterine artery, five blood flow indices will be automatically cal¬culated:~The pulsatility index The resistance index The peak systolic velocity ; The end-diastolic velocity The time-averaged maximum"
46041972|NCT04307303|Device|abdominal functional electrical stimulation|functional electrical stimulation of the abdominal muscles
45840857|NCT00924612|Drug|Oral testosterone undecanoate (containing 300 mg T)|
46041973|NCT02879903|Procedure|Periodontal treatment|"An experienced periodontist will be performed clinical periodontal parameters, including Plaque Index, Bleeding On Probe, Pocket Probing Depth, Gingival Recession, Clinical Attachment Level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.~Quadrant scaling and root planning will be weekly performed on each patient under local anesthesia using periodontal curettes and ultrasonic scalers. The maintenance therapy will be included professional plaque control and Scaling and root planing in recurrent periodontal pockets."
45345664|NCT05742308|Behavioral|Laughter yoga|Laughter yoga program was composed of four steps. The first step, which took 10 minutes, had warm-up exercises including gentle stretching and hand clapping. The second step, which included deep breathing exercises and hand clapping, took 5 minutes. The third step involved children's games and laughter exercises. The sessions included a combination of different laughter exercises. The last step, which included yoga nidra took 5 minutes.
46041974|NCT02879903|Procedure|Microbiological collect|Biofilm will be collected with the paper point to analyse presence of Porphyromonas gingivalis fimbrial subunit gene type I, II, III, IV and V.
46041975|NCT02879903|Procedure|Questionnaire|Age will be expressed in years Sex -female and male, will be expressed in percentage. Time of cigarette consumption - will be expressed in years
46041976|NCT04308941|Diagnostic Test|Intraocular pressure|The intraocular pressure will be measured using one of three devices
46041977|NCT04307459|Other|standard operating procedures|standard operating procedures represented by continuous positive airway pressure (CPAP) therapy or non invasive ventilation, pharmacological treatment as antiviral and antibiotic drugs, bronchodilators, xanthines, enteral nutrition, hydration.
45345665|NCT00864214|Drug|bioidentical hormone (Biest)|Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
45345666|NCT00864214|Drug|bioidentical hormone (Biest)|Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
45345667|NCT00864214|Drug|bioidentical hormone (Biest)|Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
45345668|NCT00864214|Drug|bioidentical hormone (Vivelle-Dot)|Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
46041978|NCT04974671|Radiation|Stereotactic Body Radiation Therapy|1-5 fraction Stereotactic Body Radiation Therapy to all sites of progression
46041979|NCT01019694|Drug|Combivent CFC-MDI|36/206 mcg Four times a day (QID)
46041980|NCT01019694|Drug|Combivent Respimat 20/100 mcg|Open label randomized parallel
46041981|NCT01019694|Drug|Atrovent HFA 42 mcg + Albuterol HFA 200 mcg|Open label randomized parallel
46041982|NCT00831415|Drug|desvenlafaxine succinate sustained release tablets|25-mg or 50-mg DVS SR tablets taken orally, once daily, at the same time each day. 100 mg dose will be supplied as 2 tablets of 50-mg tablet.
46041983|NCT01095653|Drug|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
45345669|NCT05742230|Drug|Henagliflozin 10 mg|Participants will receive 10 mg single oral tablets orally once daily.
45345670|NCT05742230|Drug|blank control|standard treatment
45345671|NCT00872482|Drug|nimotuzumab|Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
45345672|NCT05741138|Other|Core strengthening|"Plank 1-3 sets of 10-15 reps per side at a slow tempo Side plank Draw in and lift, holding for 5 seconds with purposeful engagement of the core and leg musculature. Keep the head, shoulders, hips, knees and feet in a straight line.~Bridges - Lie supine with your knees bent and the feet flat on the floor. Lift your pelvis off the ground while supporting on your feet and shoulders. The bridge can be progressed by lifting one foot off the ground end extending the knee Leg rises - Lie on your back with your legs straight and your arms by your sides. Then lift one leg 4 inches of the ground. Your back has to stay flat on the floor. Don't allow it to arch. Alternate. The exercise can be progressed by lifting both legs at the same time."
45474965|NCT03178851|Biological|Atezolizumab|Atezolizumab, 1200 mg intravenously every three weeks (Q3W) on Day 1 of each 21-day cycle, until loss of clinical benefit
45840858|NCT00925782|Drug|Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection|Patients will be randomized to receive 100 mg/m2 of Melphalan HCL for Injection (Propylene Glycol-Free) on Day -3 and Alkeran for Injection on Day -2 prior to ASCT.
45840859|NCT00925782|Drug|Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)|Patients will be randomized to receive 100 mg/m2 of Alkeran for Injection on Day -3 and Melphalan HCL for Injection (Propylene Glycol-Free)on Day -2 prior to ASCT.
46041984|NCT01095653|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
46041985|NCT01095653|Drug|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
46041986|NCT01095653|Drug|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
46041987|NCT00913159|Procedure|Extracorporeal Shock Wave Lithotripsy (ESWL)|Using electric shock wave to treat urolithiasis
46041988|NCT00920907|Biological|Ipilimumab|Solution, Intravenous, 10 mg/kg, Every 3 weeks (up to 4 doses) in induction phase, every 12 weeks in maintenance phase, 48 weeks
46041989|NCT00705601|Procedure|PSG|PSG (polysomnography) for adaptation night, day 2 evening, and day 3 evening--used to identify suitable Nonrestorative Sleep candidates to participate in focus groups.
46041990|NCT01103141|Device|Micropuncture needle set|Groin access for vascular intervention
46041991|NCT01103141|Device|Standard gauge-18 needle set|Groin access for vascular intervention
45345673|NCT05741138|Other|Conventional treatment|Hot pack and TENS for 10 minutes (lumbar region and calf muscles) Ultrasound for 10 mins (lumbar region and calf muscles) Gentle passive stretching (calf muscles) Isometric exercises (lumbar region)
45684791|NCT01893424|Drug|CBD-THC-Piperine-PNL capsule|a capsule containing Cannabidiol and Tetrahydrocannabinol combination
45684792|NCT02788708|Drug|Lenvatinib Mesylate|Given PO
45684793|NCT02788708|Drug|Paclitaxel|Given IV
45345674|NCT00428389|Drug|Rivastigmine 5 cm^2 transdermal patch|Rivastigmine 5 cm^2 patch size, loaded with 9 mg and providing 4.6 mg rivastigmine per 24 hours.
45684794|NCT02788708|Other|Pharmacological Study|Correlative studies
45684795|NCT01888003|Drug|Iron sucrose|AMG patients will receive a standardized and well-accepted intravenous dose of 200 mg of iron sucrose (Venofer®) at -14 days and -7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb < 13.0 g/dL and hematocrit between 30% and 39%, for males and females). An additional dose will be given on postoperative day 2.
45840860|NCT00925938|Drug|misoprostol|One vaginal insert containing 100, 200, 400, 800, 1200, 1600 mcg misoprostol administered intravaginally one time and remain in place for 18 - 24 hours prior to the hysteroscopy procedure. An adaptive design will be used to determine whether to escalate or reduce the dose, starting with MVPI 400 mcg.
45684796|NCT01888003|Drug|Epoetin Alfa|AMG patients will receive a standardized and well-accepted subcutaneous dose of 40,000 IU of epoetin alfa (PROCRIT®) plus an intravenous dose of 200 mg of iron sucrose (Venofer®) at -14 days and -7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb < 13.0 g/dL and hematocrit between 30% and 39%, for males and females).
45345675|NCT00428389|Drug|Rivastigmine 10 cm^2 transdermal patch|Rivastigmine 10 cm^2 patch size loaded with 18 mg and providing 9.5 mg rivastigmine per 24 hours.
45684797|NCT01888003|Other|Blood Transfusion|An evidence-based, goal-directed blood transfusion protocol will be applied in AMG, CTG, and NAG patients during and after their surgical procedure to control for health provider variation in transfusion criteria and practices. This blood conservation protocol will consist primarily of the application of a restrictive transfusion trigger (Hgb < 8 g/dl) (21,22) but will also take into consideration the patient's intraoperative estimated allowable blood loss and hemodynamic stability.
45345676|NCT00736424|Device|Itrel II™ and Soletra™ Epilepsy Control System|Bilateral neurostimulation of the anterior nucleus of the thalamus
45345677|NCT00616642|Drug|rosiglitazone maleate|Given orally
45345678|NCT02568488|Drug|Metformin|850 mg orally twice daily for 6 months
45345679|NCT01324063|Biological|sargramostim|
45345680|NCT01324063|Drug|amsacrine|
45345681|NCT01324063|Drug|cytarabine|
45345682|NCT01324063|Drug|daunorubicin hydrochloride|
45345683|NCT01324063|Procedure|quality-of-life assessment|
45345684|NCT00923624|Other|attention control|9 informational email messages sent by study staff about the features of the shared electronic medical record system and how to use them.
45345685|NCT00923624|Behavioral|adherence intervention|9 messages tailored by the study nurse and guided by the IMB model
45345686|NCT03994549|Drug|Dual GLP-1/GLP-2 Receptor agonists|Eight ascending doses of ZP7570
45345687|NCT00736658|Drug|AZD1386|Oral admin. of doses at 11 days through a 12 days period.
45345688|NCT00736658|Drug|Placebo|Oral admin. of doses at 11 days through a 12 days period.
46041992|NCT00700297|Drug|Colchicine|100 mg Colchicine per day for 4 months
46041993|NCT00700297|Drug|Placebo|One tablet placebo per day for 4 months
46041994|NCT05298501|Other|No intervention/exposure|No interventions/exposures will be administered or evaluated
46041995|NCT04307147|Drug|Capecitabine|Oral capecitabine (at a dose of 1250 mg/m², twice per day, on days 1 to 14) every 3 weeks for 4 cycles.
46041996|NCT04307147|Drug|Vinorelbine|Intravenous vinorelbine (at a dose of 25 mg/m² on day 1, day 8) every 3 weeks for 4 cycles.
46041997|NCT00844831|Drug|Lubiprostone|24 mcg bid for 28 days
45474966|NCT03733015|Device|repetitive transcranial magnetic stimulation|Repetitive transcranial Magnetic Stimulation (rTMS) can be used to temporary modify the brain activity.
45474967|NCT01291979|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
45474968|NCT01291979|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
46041998|NCT02878343|Behavioral|Incentives|Daily lottery type incentives tied to achievement of weight loss goals
46041999|NCT02878343|Behavioral|Environmental strategies|Individually tailored environmental strategies around food intake and physical activity; automated text/emails sent from study website platform
46042000|NCT04117633|Device|Laparoscopy|Laparoscopic Procedures for Rectopexy
46042001|NCT00920829|Drug|Naltrexone 50 Mg|Naltrexone 25 or 50 mg per titration schedule
46042002|NCT00920829|Drug|Placebo|placebo
46042003|NCT04306835|Behavioral|Cognitive behavioural therapy for insomnia|a technique for treating insomnia without medications
46042004|NCT04117555|Diagnostic Test|Pupil response to light stimuli|Objective and accurate measurement of pupillary responses to light stimuli
46042005|NCT05010876|Drug|C1 Inhibitor Human|standard care + 1000 units of C1 inhibitor during 2 slow infusions of 500 units
46042006|NCT05010876|Drug|Icatibant Injection|a single injection of 30 mg subcutaneously
45840861|NCT00925938|Drug|placebo|placebo
46042007|NCT05010876|Other|Placebo|The placebo will be physiological serum presented in forms mimicking the C1-Inhibitor and the icatibant.
46042008|NCT04307069|Drug|Oxytocin|The drug wil be adminisrate for augmentation of labor at admission.
46042009|NCT04251741|Diagnostic Test|Adalimumab trough concentration|In the 'drug concentration guided' group, switching to subsequent biological is based on adalimumab trough concentration
46042010|NCT04251741|Other|Usual care|In the usual care group, switch to subsequent biological is based on secondary randomisation
45684798|NCT02784496|Other|Long-term Follow-up|Undergo follow-up assessment
45684799|NCT02784496|Other|Quality-of-Life Assessment|Ancillary studies
45684800|NCT02784496|Drug|Ruxolitinib|Given PO
46042011|NCT02878265|Dietary Supplement|Vitamin A|Vitamin A supplements
46042012|NCT02878265|Dietary Supplement|Vitamin A and ZInc|Combination of vitamin A and zinc supplements
45684801|NCT02783950|Other|Decipher Prostate Cancer Classifier|The Decipher test (GenomeDx Biosciences, San Diego, CA) is a genomic test that predicts high grade disease, the probability of metastasis and prostate cancer-specific mortality for men with prostate cancer.
45840862|NCT00926952|Drug|Methylaminolevulinate (Metvix, Metvixia)|2-4 g of cream applied to entire face at Day 0 for 90 minutes without occlusion prior to light treatment. If any actinic keratoses remained after 4 weeks the treatment was repeated at Week 4.
45840863|NCT00926952|Device|Photodynamic Therapy (Aktilite)|Device set to 37 J/cm². Red light wavelength is approximately 630 nm.
46042013|NCT02878265|Dietary Supplement|Vitamin A , Zinc and Multivitamin|Combination of vitamin A, zinc and multivitamins
46042014|NCT00831181|Drug|5-FU|5-FU: continuous infusion via portable pump during all RT (approximately 33 days)
45345689|NCT05225896|Genetic|Description of clinical characteristic and genetic tumors|"This is a non-interventional study involving clinical data and biological samples (DNA). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study."
45345690|NCT00872560|Device|NovoFine® needle 6 mm|
45345691|NCT00872560|Device|NovoFine® needle 8 mm|
45474969|NCT04443634|Procedure|Ultrasound Guided Adductor Canal Block|It will be performed at the midthigh level, approximately halfway between the superior anterior iliac spine and the patella, a high-frequency linear ultrasound (US) transducer 5-12 MHz probe. Underneath the sartorius muscle the femoral artery was identified, with the vein just inferior and the saphenous nerve just lateral to the artery. From the lateral side of the transducer a 10-cm, 18-gauge Tuohy needle (Braun Medical, Melsungen, Germany) was inserted in plane, through the Sartorius muscle. With the tip of the Tuohy needle placed just underneath the vasto-adductor membrane and lateral to the artery and the saphenous nerve, 20 ml local anesthetic mixture will be injected to expand the adductor canal. the volume of local anesthetic will be selected according to the studied group
45474970|NCT04443634|Procedure|Ultrasound Guided Saphenous Nerve Block|"It will be performed at the intermuscular plane between the sartorius and the vasus medialis muscles at the lower third of the thigh.~The US probe will be positioned on the front of the lower part of the thigh immediately above the patella to see both the patella (hyperechoic curved line) and vastus medialis infront of it (closer to skin). The probe is then moved medially over the vastus medialis till we see the end of the muscle and we see an intermuscular plane between it and Sartorius muscle. A 20 guage spinal needle will be then passed in an in plane direction within the substance of vastus medialis muscle and then pass within the vastus medialis until it faces the intermuscular plane between VM muscle and Sartorius. Once the needle tip is located in close proximity to the target structures, gentle aspiration will be performed followed by 20 ml local anesthetic will be injected."
45474971|NCT04443634|Procedure|General anesthesia|"General anesthesia was induced by propofol 1-2 mg/kg fentanyle 100micg and laryngeal mask was inserted. Maintanace of anesthesia was performed by sevoflurane 2-3%.~Then the surgical procedure started. All patients had arthroscopic knee surgery( ACL repair) surgery under tourniquet control.~Immediately after end the surgical procedure, either ACB or combined ACB and saphenous nerve block distal to adductor canal were performed according to randomization."
45474972|NCT04443634|Drug|Bupivacaine 20 ml|20ml bupivacaine 0.5%
45474973|NCT04443634|Drug|Bupivacaine 30ml|30ml bupivacaine 0.5%
46042015|NCT00831181|Drug|Oxaliplatin|Oxaliplatin: 50mg/m2 weekly dosing during RT (Day 1)
46042016|NCT00831181|Drug|leucovorin|Folinic Acid (Leucovorin): 400 mg/m2; 2-hour IV infusion simultaneously with oxaliplatin
46042017|NCT00831181|Procedure|mesorectal excision|mesorectal excision
45345692|NCT04645394|Dietary Supplement|Aronia melanocarpa|Administered once (acute study)
45345693|NCT04645394|Dietary Supplement|Fermented Aronia Melanocarpa high dose|Administered once (acute study)
46042018|NCT01023672|Drug|Armodafinil|150-250 mg armodafinil by mouth daily
46042019|NCT04251429|Other|CPH-NEW Healthy Workplace Participatory Program|A participatory program for increasing effectiveness of occupational health and safety committees or peer-led employee teams through root cause analysis, prioritizing health and safety needs for effective problem-solving, identifying feasible interventions, and presenting these to senior leadership. Interventions are selected and implemented by leadership and evaluated by both teams.
46042020|NCT05252013|Other|Experimental: Bean Hull Bread|The bean hull bread will deliver 21.96 g of fibre. Volunteers will consume a roll of bean hull bread (155g/portion) served with 25g of raspberry jam.
46042021|NCT05252013|Other|Experimental: Plain Bread|The control bread will deliver 4.53 g of fibre. Volunteers will consume a roll of plain bread (122g/portion) served with 25g of raspberry jam.
45345694|NCT04645394|Dietary Supplement|Fermented Aronia Melanocarpa low dose|Administered once (acute study)
45345695|NCT04645394|Dietary Supplement|Placebo|Administered once (acute study)
45345696|NCT01589029|Drug|CANAKINUMAB (ILARIS®)|subcutaneous injection every 8 weeks
45345697|NCT00877786|Behavioral|Cognitive Behavioral Group Therapy|Cognitive behavioral therapy (CBT) is a form of psychotherapy that addresses the links between thoughts, emotions and behaviors.
45345698|NCT02568332|Biological|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
45345699|NCT02568332|Biological|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
45345700|NCT01033669|Device|CRC-749|There is no drug being used. This is a device.
45345701|NCT01033669|Device|Diskus|There is no drug being used. This is a device.
45345702|NCT01033669|Device|Twisthaler|There is no drug being used. This is a device.
45345703|NCT01033669|Device|Miat Monohaler|There is no drug being used. This is a device.
45684802|NCT02783560|Behavioral|The Sleep Train Program|This modular behavioral sleep intervention includes required modules on sleep routines and sleep habits, and optional modules on bedtime problems, fears, anxiety, and independent sleep.
45684803|NCT02783560|Behavioral|The Family Mealtimes Program|This modular behavioral mealtime intervention includes required modules on mealtime routines and healthy mealtime habits, and optional modules on picky eating and mealtime behavior difficulties.
46042022|NCT00705835|Biological|rsPSMA protein plus Alhydrogel® vaccine|The assigned dose of rsPSMA protein plus Alhydrogel® vaccine will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4-week break and then a fourth vaccination during week 7. The vaccination site will rotate to a different quadrant with each administration.
46042023|NCT01094171|Biological|Poliorix TM|Intramuscular administration, 3 doses
46042024|NCT01094171|Biological|Infanrix TM|Intramuscular administration, 3 doses
46042025|NCT00702637|Drug|Modafinil|
46042026|NCT05251935|Other|Foot Muscle Exercise Protocol|Foot Muscle Exercise was given for 3 days per week for 40 minutes for the period of 6 months including home program
45345704|NCT00872638|Procedure|Eversion|Surgical incisions will be closed in such a manner so as to evert the wound edges.
45345705|NCT00872638|Procedure|Approximation|Surgical incisions will be closed in such a manner so that wound edges are approximated exactly, i.e. without eversion.
45345706|NCT00877864|Behavioral|High volume combined aerobic/resistance exercise|High volume combined aerobic/resistance exercise
45474974|NCT04443634|Drug|Bupivacaine 10ml|10ml bupivacaine 0.5%
46042027|NCT05251935|Combination Product|Arch Support Insole and One Leg Balance Activities|Arch Support Insoles were provided that the child had to wear for 5 hours per day thrice weekly for 6 months plus performed one leg balance activities
45345707|NCT00877864|Behavioral|Low volume combined aerobic/resistance exercise|Low volume combined aerobic/resistance exercise
45345708|NCT00877864|Behavioral|High volume combined A/R exercise, printouts, pedometers|High volume combined aerobic/resistance exercise, printouts, pedometers
45596414|NCT03531541|Device|CJM|The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation to the tissue barrier to perform a high-velocity low-amplitude manipulation (thrust). If the patient does not experience joint cavitation during the maneuver, two more attempts will be made. If no sound occurs on the third attempt, the joints will be considered manipulated.
45684804|NCT02780128|Procedure|Biopsy|Needle or incisional tumor biopsy
46042028|NCT01093625|Device|Narafilcon B Contact Lens|
46042029|NCT01093625|Device|Spectacles|spectacle wearers
46042030|NCT01023516|Drug|AZD9668|2 x 30 mg oral tablets bd for 12 weeks
46042031|NCT01023516|Drug|Placebo|2 x matched placebo to oral tablet bd for 12 weeks
46042032|NCT04786275|Drug|Fentanyl|Standard dose of 2 ug/kg after tetanic stimulation.
46042033|NCT04786275|Other|Tetanic stimulation|Standard tetanic stimulation will be used as the stimulus to evaluate response of the intraoperative pain index (NoL) at a standard fentanyl dose.
45345709|NCT00877864|Behavioral|Low volume combined A/R exercise, printouts, pedometers|Low volume combined aerobic/resistance exercise, printouts, pedometers
45345710|NCT00877864|Behavioral|Printed PA information, pedometers and step log group|Printed PA information, pedometers and step log group
45345711|NCT00877864|Behavioral|Control|No exercise program provided by the study
45345712|NCT00736736|Other|Additional Hip Muscle Strengthening to Leg Press Exercise|
45345713|NCT00736736|Other|Leg Press Exercise|
46042034|NCT00844753|Drug|atomoxetine|atomoxetine
45345714|NCT00864448|Drug|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
45345715|NCT00864448|Drug|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fasting conditions
45596415|NCT03531541|Device|Placebo TENS|The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value. Participants will be informed that TENS can cause a slight tingling sensation or any sensation during the procedure. They will be asked every 5 minutes if they are comfortable, without increasing intensity as in the active TENS group
45684805|NCT02780128|Genetic|Next Generation Sequencing|Tumor tissue will be sent to Foundation Medicine laboratory for molecular profiling.
46042035|NCT00844753|Drug|Placebo|Placebo + parent management treatment
46042036|NCT00844753|Behavioral|Parent Management Training|
45345716|NCT00406315|Drug|ziprasidone|Days 1-3: 40 mg twice a day (BID); Days 4-7: 60 mg BID; Day 8: 80 mg BID; Flexible dose between 40-80 mg BID (adjustable up to 40 mg daily/week) for the remainder of the 16-week treatment phase and continuing throughout the 16-week follow-up phase
45684806|NCT02780128|Procedure|Tumor Scans|Participants will undergo different types of scans to look at your tumor. These scans include CT (computerized tomography), MIBG (meta-iodobenzylguanidine) PET (positron emission tomography), and MRI (magnetic resonance imaging). Participants may have more than one type of scan.
46042037|NCT02878109|Device|Post-treatment phase group|4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)
46042038|NCT02878109|Device|Pre-treatment phase group|4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)
45345717|NCT05740904|Other|New defocus spectacle lenses|The children in the new defocus spectacle lens group will wear new defocus spectacle and receive follow-up examinations every half year.
45345718|NCT05740904|Other|Convenional aspheric single-vision spectacle lenses|The children in the convenional aspheric spectacle lenses group will wear conventional aspheric single-vision spectacle and receive follow-up examinations every half year.
45345719|NCT00872716|Drug|Quetiapine XR|100 mg single-dose Quetiapine XR
46042039|NCT05525611|Drug|Cabergoline 0.5 MG|Cabergoline 0.5 mg once a week in 12 weeks
46042040|NCT05525611|Other|Placebo|Placebo once a week in 12 weeks
46042041|NCT04309175|Device|base rate programming of a permanent cardiac pacemaker|Base rate of a subject's pacemaker is set to a slower, and after wash-out, to a faster pacing rate (Slow-Fast Arm) or to a faster, and after wash-out, to a slower pacing rate (Fast-Slow Arm)
45345720|NCT00872716|Other|Placebo|Placebo
45345721|NCT05740826|Device|Algometer|The algometer head was applied to the trigger point of selected muscles at an angle of 90° and, increasing the pressure at a speed of about 100g/s, three measurements were made. Each measurement stoped at the first sensation of pain
45345722|NCT00864526|Drug|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under fasting conditions
45345723|NCT00864526|Drug|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under fasting conditions
46042042|NCT00830947|Device|OrthoAccel Device|The OA device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
45684807|NCT02780128|Procedure|Bone marrow Tests|Participants will have needles inserted through their hip bone to remove fluid from inside the bone marrow. This test determines if participants have tumor in the bone marrow.
45345724|NCT02568410|Procedure|coronary artery bypass grafting using cardiopulmonary bypass|no study intervention. Study cohort will undergo coronary artery bypass grafting using cardiopulmonary bypass according to standard practices at DUMC
46042043|NCT00830947|Device|Sham Device|Inactive sham device that is held in the mouth for 20 minutes.
45345725|NCT00864604|Drug|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions
45345726|NCT00864604|Drug|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fed conditions
45345727|NCT04064138|Procedure|Peritoneal block|At the beginning of surgery, immediately after insertion of the first port 2 mg/kg lidocaine and 25mg/kg magnesium sulfate and 1/200 000 epinephrine in a total volume 50 ml (completed with saline .9%) will be given intra-peritoneal 10 min before the surgeon proceeds . At the end of the surgery another similar lidocaine-magnesium-epinephrine injection will be instillated before removal of the last port and the drain will be kept closed for 30 min.
45345728|NCT04064138|Procedure|Ultrasound guided erector spinae plane block|Before general anesthesia, ESPB will be performed under ultrasound guidance. The linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. The patient's skin will be anesthetized with 3 mL of 2% lidocaine. A 21 gauge 10cm needle will be inserted using an in plane superior to inferior. The tip of the needle will be placed into the facial plane on the deep aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process on ultrasonographical imaging. The calculated dose of lidocaine (2mg/kg) with 150 mg MgSo4 and 1/200 000 epinephrine will be injected on each side.
45345729|NCT04064138|Other|General anesthesia|General anesthesia
45345730|NCT01323751|Drug|ACY-1215|Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle
45345731|NCT00878020|Drug|BMS-830216|Capsules, Oral, Single Dose, 1 day
45345732|NCT00878020|Drug|Placebo|Capsules, Oral, 0mg, Single Dose, 1 day
46042044|NCT05524129|Other|rehabilitation exercise|Conventional rehabilitation exercise.
46042045|NCT05524129|Other|electrotherapy|A middle frequency electro-therapy
46042046|NCT01018992|Drug|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
46042047|NCT01018992|Drug|Placebo|Matching placebo, oral administration, 1 pill/day for 6 weeks
45345733|NCT00878020|Drug|BMS-830216|Capsules, Oral, Single Dose on Day 1, Period 1 and Day 1, Period 2, 2 days
45345734|NCT00878020|Drug|Placebo|Capsules, Oral, 0mg, Single Dose, on Day 1, Period 1 and Day 1, Period 2, 2 days
45345735|NCT05741996|Behavioral|Taping|Taping types and brace acute effects for knee osteoartritis
46042048|NCT00628368|Genetic|gene expression analysis|
45345736|NCT00872794|Device|DePuy ASR™ Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
45345737|NCT00878176|Procedure|First stage tined lead procedure|bilateral first stage tined lead placement
45345738|NCT00711594|Drug|BIBW 2992 MA2 40mg/day|Phase I step: Increased dose cohorts from low dose to MTD
45345739|NCT00711594|Drug|BIBW 2992 MA2 50mg/day|Phase I step: Increased dose cohorts from low dose to MTD
46042049|NCT00628368|Genetic|mutation analysis|
46042050|NCT00628368|Genetic|polymorphism analysis|
46042051|NCT00628368|Other|laboratory biomarker analysis|
46042052|NCT00628368|Procedure|biopsy|
46042053|NCT00628368|Procedure|endoscopic biopsy|
46042054|NCT02872350|Device|Abdominal ultrasound|Techniques and predictive characteristics of the combination abdominal ultrasound abdomen and shot in the prognostic assessment of ECUN in premature under 33SA.
46042055|NCT00917553|Drug|doxycycline monohydrate|50 mg
46042056|NCT00917553|Drug|Placebo|Cellulose Placebo Capsule
46042057|NCT04809909|Procedure|Peripheral stimulation of acupuncture points (PSAP)|Electrode leads will be implanted at Bladder 25-bilateral (BL25), the acupoint commonly used for relief of chronic Low Back Pain in standardized acupuncture.
46042058|NCT04809909|Procedure|Peripheral nerve field stimulation (PNFS)|Electrode leads will be implanted at the region of pain.
45345740|NCT00711594|Drug|BIBW 2992 MA2 20mg/day|Phase I step: Increased dose cohorts from low dose to MTD
45345741|NCT00711594|Drug|BIBW 2992 QD|Phase II step: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs.
46042059|NCT05251857|Behavioral|Animation Education Program Applied to Laparoscopic Sleeve Gastrectomy Patients|Behavioral: Animation Education Program The investigators will apply Animation Education Program.
45345742|NCT02543866|Biological|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
45474975|NCT03643159|Combination Product|Abilify MyCite - Digital Medicine System|The Abilify MyCite system is a drug-device combination product comprised of aripiprazole (an atypical antipsychotic) tablets embedded with a sensor that communicates with a patch (wearable sensor) and a medical software application with collected information (ingestion, mood, activity, rest) tracked and summarized for participants, healthcare providers, and potential caregivers. Abilify MyCite is intended to track drug ingestion and is indicated for the treatment of adults with schizophrenia (SCH), bipolar 1 disorder (BP1) (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with major depressive disorder (MDD).
45474976|NCT03643159|Drug|Aripiprazole or other oral antipsychotics|For the treatment of adults with SCH, BP1 (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with MDD.
46042060|NCT04747509|Other|Blackburn exercises|"Experimental group will include Blackburn exercises and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include prone horizontal abduction neutral and with full external rotation, prone horizontal scaption neutral and with full external rotation, prone horizontal external rotation, prone horizontal extension. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set."
45345743|NCT00872872|Drug|AZT/3TC 2 weeks after delivery|AZT/3TC 300/150mg will be given every 12 hours for 1 week after NVP discontinuation in arm 1 and for 2 weeks after NVP discontinuation in arm 2.
45345744|NCT00864760|Drug|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
45345745|NCT00864760|Drug|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
45345746|NCT03743662|Radiation|Re-irradiation (RT)|Re-RT will start on day 28 +/- 5 days for 5 fractions of 600cGy every other day over a 2-week period.
45345747|NCT03743662|Drug|Bevacizumab|Bevacizumab if deemed beneficial by the investigator, will be started at the initiation of re-RT and continued for three doses in the medical arm. Patients in the surgical arm will omit the first bevacizumab dose to assure adequate wound healing after surgery and receive two doses. Bevacizumab will be dosed at 10mg/kg and given intravenously on day 28 (medical arm only), day 42 and day 56. Following day 56, further bevacizumab doses can be given every two weeks at the discretion of the treating physician.
45474977|NCT03205566|Drug|Raltegravir 400Mg Tab|bd for 7 days
45474978|NCT03205566|Drug|Lamivudine 150Mg Tablet|+ Raltegravir 400Mg tablet bd for 7 days
45474979|NCT01181999|Drug|rituximab|A dose of 375mg/m2 rituximab will be administered intravenously on day 1 of first to fourth R-CHOP chemotherapy and on day 1, 8, 15, 22 of each augmentation chemotherapy.
45345748|NCT03743662|Drug|Nivolumab|"Nivolumab will be started at enrollment and each patient will receive two doses of nivolumab prior to radiation.~Nivolumab will be dosed at 3mg/kg given intravenously before re-RT (day 1 +/- 5 and 14 +/- 5) and when given with bevacizumab if deemed beneficial by the investigator, (day 28 +/- 5 (medical arm only), day 42 +/- 5, and day 56 +/-5). Nivolumab will be dosed based on body weight while combined with re-radiation and bevacizumab for safety considerations to reduce adverse events. Single agent nivolumab will be given at 240mg flat dose every 2 weeks thereafter until disease progression, withdrawal, adverse event, or death."
46042061|NCT04747509|Other|Conventional Physical therapy|"Control group will include conventional physical therapy and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include push-ups on a stable surface, upward rotation shrugs and resisted scapular retraction. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set."
46042062|NCT04255251|Drug|Silver Diammine Fluoride|Subjects will receive SDF around their crown margins every 6 months for next 3 years.
46042063|NCT04255251|Drug|Fluoride Varnishes|Subjects will receive SDF around their crown margins every 6 months for next 3 years.
45345749|NCT03743662|Procedure|Re-resection|Re-resection will be performed in the surgical arm at day 14 (+/- 5 days).
45345750|NCT00710762|Drug|BIBF1120|
45345751|NCT00710762|Drug|Placebo|
46042064|NCT04856163|Behavioral|Telelactation support|Participants will get unlimited access (through 24 weeks postpartum) to video calls with lactation consultants who are available 24/7. Participants can use the service as demanded.
46042065|NCT04859439|Drug|DBPR108 tablets|Drug: DBPR108, tablet, oral
45345752|NCT05137912|Biological|Immunotherapy|"Patients within this intervention group will be histologically confirmed to have resectable non small cell lung cancer with stage II-IIIA.~Patients may receive single agent immunotherapy or immunotherapy combined with chemotherapy."
45345753|NCT00736814|Drug|carboplatin|Given intravenously
45345754|NCT00736814|Drug|docetaxel|Given intravenously
45345755|NCT00736814|Drug|gemcitabine hydrochloride|Given intravenously
45345756|NCT00736814|Drug|vinorelbine tartrate|Given intravenously
45345757|NCT04063904|Drug|Mifepristone|One 200 mg pill (oral)
46042066|NCT04855851|Procedure|PAIN NEUROSCIENCE EDUCATION AND STRENGTH TRAINING|The subjects of this group will receive an amount of six sessions that will be applied within 12 weeks. Every 15 days, the subjects will come for a consultation to receive a PNE session and review of the exercise program, which will be carried out 3 times a week for 12 weeks.
46042067|NCT04855851|Procedure|USUAL CARE|"Aerobic exercises will consist of a standard table of low intensity stretching exercises, commonly prescribed to fibromyalgia patients. There will be three series of 30 seconds of each stretch, having a total duration of approximately 40 minutes. Each session will be held twice a week, following the recommendations of the American College of Sport Medicine. Monitoring will be performed every 15 days by a physiotherapist."
45345758|NCT04063904|Drug|Misoprostol|Two 400 mcg pills (sublingual)
45345759|NCT00573430|Drug|Candesartan Cilexetil|8 mg oral once daily dose
45345760|NCT00573430|Drug|Candesartan Cilexetil|16 mg oral once daily dose
46042068|NCT01018680|Drug|Duloxetine|30 milligrams (mg) taken by mouth, once daily for 1 week, followed by 60 to 120 mg taken by mouth, once daily for 9 weeks.
46042069|NCT01018680|Drug|Placebo|Taken by mouth, once daily for 10 weeks
45345761|NCT00573430|Drug|Candesartan Cilexetil 32mg|32 mg oral once daily dose
46042070|NCT04255017|Drug|Abidol hydrochloride|Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.
46042071|NCT04255017|Drug|Oseltamivir|Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.
46042072|NCT04255017|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.
45345762|NCT00711516|Drug|Armodafinil|Armodafinil once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
45345763|NCT00711516|Drug|Placebo|Matching Placebo dosed once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
45345764|NCT05741762|Other|Retrospective chart review|The retrospective chart review will be done for patient admitted into ICU between 01/06/2017 to 01/06/2022
45345765|NCT00864838|Drug|Acetazolamide|250 mg 1 hour before intravitreal injection
45345766|NCT00864838|Drug|Brimonidine tartarate|1 drop 1 hour before intravitreal injection
46042073|NCT04255173|Diagnostic Test|Body mass index|Body mass index is calculated as a ratio of height and weight, expressed as kg/m2
46042074|NCT04255173|Diagnostic Test|waist circumference|waist circumference is measured as cm
46042075|NCT04255173|Diagnostic Test|hip circumference|hip circumference is measured as cm
46042076|NCT04255173|Diagnostic Test|height|height is measured as cm
46042077|NCT04255173|Diagnostic Test|Fat percentage|Fat percentage and skeletal muscle mass (SMM) was calculated by using bioimpedance analysis (BIA) (Tanita TBF 300; Tanita Corp., Tokyo, Japan).
46042078|NCT04255173|Diagnostic Test|Skeletal muscle index|Skeletal muscle index (SMI) was calculated from BIA-based skeletal muscle mass with a formula as SMM/height [m2].
45345767|NCT00864838|Procedure|Anterior chamber paracentesis|Immediately after bevacizumab injection
46042079|NCT04255173|Diagnostic Test|A body shape index (ABSI)|ABSI is measured as waist circumference (m) / (BMI(kg)2/3x Height(m)5/6)
45345768|NCT05740748|Drug|Tezepelumab|tezepelumab 210 mg sc q4wks for 20 weeks
45345769|NCT05740748|Drug|Placebo|placebo sc q4wks for 20 weeks
45345770|NCT00873028|Other|In Hospital Cardiopulmonary Rehabilitation|The program consisted of bronchial hygiene characterized by detachment and removal of secretions and respiratory exercises which were applied in the respiratory muscles in order to strengthen and increase the resistance. Patients were instructed to maintain diaphragmatic breathing, at a rate of 12 to 18 breaths per minute during EPAP mask use, and the expiratory pressure was increased progressively in the following fashion: 3-8 cm H2O during 3-12 minutes. Also, they performed flexion/extension of hip and knee, active free exercises for upper limbs, ambulation exercise and ascent/descend of stairs
45345771|NCT04039516|Drug|Lutathera|A total of 4 infusions of Lutathera to be administered every 8 weeks.
45345772|NCT00873106|Device|Optical coherence tomography|Stratus OCT: fast radial lines 3D OCT-1000: radial 2048 and 3D OCT Cirrus HD OCT: 3D OCT
45345773|NCT05741684|Behavioral|Internet-delivered Cognitive Behavioral Therapy|iCBT was administered in an unguided fashion without human therapeutic support. Participants were instructed to progress through the eight core modules over an 8-week period. The modules comprised psychoeducational content centered around CBT, aimed at promoting the development of skills such as self-monitoring of emotions, cognitive distancing, cognitive reframing/restructuring, problem-solving, and mindfulness. In the event of technical difficulties during the intervention, participants were able to seek assistance.
45474980|NCT03363880|Other|trauma treatment team|Establishing the trauma management system included a trauma treatment team. The severe trauma treatment team will be composed by the physicians from departments of emergency, orthopedic trauma, urology, cardiothoracic surgery, neurosurgery, general surgery, anesthesiology, and ICU.
45474981|NCT03363880|Other|Basic experimental settings|Establishing the trauma management system without a trauma treatment team.
45474982|NCT03732937|Diagnostic Test|Ultrasonography|Ultrasonography with biometry and TCD measurement
45474983|NCT04523974|Procedure|Preemptive Surgical Intervention and Precise Efficacy Evaluation of CKD-SHPT|"Preemptive surgical intervention for CKD-SHPT patients with poor calcium and phosphorus metabolism controlled by drugs;~Rapid immunoreactive parathyroid hormone detection technology during peri-operative period."
45474984|NCT03854435|Other|Heart rate assessment (stethoscope)|Immediately after birth heart rate will be evaluated by auscultation
45474985|NCT03854435|Other|Heart assessment (umbilical cord palpation)|Immediately after birth heart rate will be evaluated by palpation of the umbilical cord
46042080|NCT04255173|Diagnostic Test|Dual energy x ray absorptiometry (DXA)|Osteoporosis is diagnosed with DXA scores. According to the T-scores calculated from femur neck (FN) and lumbar spine (LS), subjects divided into 3 groups as following: a) normal: T-score is greater than -1 SD (standard deviation), b) osteopenia: T-score is between -1 and -2.5 SD, c) osteoporosis: T-score is lower than -2.5 SD.
46042081|NCT04255173|Diagnostic Test|The Rapid Assessment of Physical Activity (RAPA) aerobic assessment|Physical activity levels of patients were evaluated with The Rapid Assessment of Physical Activity (RAPA) aerobic assessment. Patients divided into 5 groups as following: 1 = sedentary, 2 = underactive, 3 = regular underactive (light activities), 4 = regular underactive, and 5 = regular active).
46042082|NCT04255095|Procedure|experiment|Treatment was randomly selected according to preoperative grouping. After ERCP, naso-pancreatic drainage was chosen as treatment。
46042083|NCT04255095|Procedure|control|Treatment was randomly selected according to preoperative grouping. After ERCP, nasobiliary drainage was chosen as treatment。
46042084|NCT04592991|Diagnostic Test|Aortoiliac Occlusive Disease Group - PET-CT imaging with injection of 64Cu-DOTA-ECL1i|Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with non-aneurysmal, atherosclerotic aortoiliac occlusive disease (n=3) will be enrolled in Aim 2A and undergo Cu-64 DOTA-ECL1i PET/CT.
45345774|NCT05741684|Behavioral|Attention Bias Modification|The Dot-Probe Paradigm was utilized within the Attention Bias Modification procedure. The training sessions were comprised of 96 trials, which included facial expression photos depicting happiness, neutrality, and sadness, sourced from four male and four female actors. A fixed cross (+) was presented on the computer screen's center for a duration of 500 milliseconds before each stimulus display, followed by the presentation of two images portraying distinct emotional expressions, which persisted for 500 milliseconds. After the disappearance of the images, an arrow appeared in the location where they had been displayed, and participants were instructed to select the arrow that corresponded with the presented arrow. In the ABM procedure, the arrow was consistently presented following the display of a more positive facial expression, such that in the instance of a sad-neutral face pair, the arrow would always appear in the location of the neutral facial expression image.
45345775|NCT00615550|Drug|progesterone|8% vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
45474986|NCT04509232|Procedure|Silver diamine fluoride|"Group A~Excavation of soft carious dentin will be done to minimize the staining.~The selected teeth should be cleaned, dried and isolated. Vaselline should be applied to surrounding soft tissues to avoid their staining.-~38% Silver diamine fluoride will be applied to carious lesions by microbrush~Apply gentle flow of air until medicament is dry, Try to keep isolated for three minutes,remove excess SDF with cotton pellet to decrease systemic absorption.~After silver diamine fluoride application Assessement of parental acceptance to staining will be done though a 5 point likert scale For anterior and posterior teeth separately ."
45345776|NCT00615550|Drug|placebo|vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
45684808|NCT02780128|Other|Physical Exam|The exam includes taking participant weight, height, blood pressure, heart rate and respiratory rate and performing a examination of the participants body. The investigators may also check the participants vision with an eye chart.
45684809|NCT02780128|Other|Eye Exam|Participants will have their eyes will be evaluated using different instruments. Participants will also be asked to read an eye chart. The exams will take about 15 minutes.
46042085|NCT04592991|Diagnostic Test|AAA Group- PET-CT imaging with injection of 64Cu-DOTA-ECL1i|Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with Abdominal aortic aneurysm (AAA) (n=5) will be enrolled in Aim 2B and undergo Cu-64 DOTA-ECL1i PET/CT and contrast-enhanced CT angiography between 7-14 days of their scheduled elective open repair surgery.
45345777|NCT00186888|Procedure|Enucleation|"Enucleation (possibly associated with all treatment strata/arms. For Stratum A, patients with bilateral disease will have surgery to remove the advanced eye before chemotherapy, or patients that have disease progression after chemotherapy may have surgery to remove the affected eye.~For Stratum B, Surgical removal of the affected eye may be required in cases of disease progression For Stratum C, first intervention is removal of the affected eye."
45474987|NCT04509232|Procedure|Silver diamine fluoride and glass ionomer|"38% Silver diamine fluoride will be applied by the same protocol as in group A Then Glass Ionomer restoration is applied~Parental acceptance to staining will be assessed thought 5 point likert scale after application of SDF and once more after application of Glass Ionomer restoration."
46042086|NCT01012440|Device|PEM Flex Solo II PET Scanner|Subjects will receive bilateral (both sides) breast and axillary PEM scans.
46042087|NCT01012440|Device|MRI scan|Subjects will receive bilateral (both sides) breast and axillary MRI scans.
46042088|NCT00916929|Device|Impedance Monitoring Feature|Algorithm in cardiac device that measures intra-thoracic impedance from the implanted leads
46042089|NCT04299750|Procedure|Tooth extraction and Alveolar ridge preservation|Tooth extraction and alveolar ridge preservation with deproteinized bovine bone mineral and a collagen matrix seal
46042090|NCT04299750|Procedure|Tooth extraction|Tooth extraction and socket natural healing
46042091|NCT04299516|Procedure|Two-team simultaneous bilateral total knee arthroplasty|Bilateral total knee arthroplasty can be performed in three different ways: single-stage, two-team simultaneous bilateral total knee arthroplasty; single-stage, one-surgeon, and two-stage bilateral total knee arthroplasty. Two surgeons will operate simultaneously on one side for two-team SBA.
46042092|NCT04299516|Procedure|Single-team simultaneous bilateral total knee arthroplasty|One surgeon will operate sequentially on both sides for one-surgeon SBA
46042093|NCT02872194|Drug|BAY987516, Y55-170|10 uL in one eye
46042094|NCT02872194|Drug|BAY987516, X72-151|10 uL in one eye
46042095|NCT02872194|Drug|BAY987516, Y49-034|10 uL in one eye
46042096|NCT02872194|Drug|Standard shampoo mixture (control)|10 uL in one eye
46042097|NCT04298736|Procedure|Bariatric Surgery|laparoscopic Roux-en-Y gastric bypass or laparoscopic Sleeve Gastrectomy
46042098|NCT04298736|Behavioral|Lifestyle modification|guided low-calorie diet and physical activity.
46042099|NCT02871336|Other|Data collection|
46042100|NCT00844597|Drug|AVI-4658 for Injection|AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.
46042101|NCT01017120|Drug|Tazarotene Foam|Tazarotene foam once a day application to the face
46042102|NCT01017120|Drug|Vehicle Foam|Vehicle Foam once a day application to the face
45345778|NCT00186888|Drug|Vincristine, Carboplatin|(Stratum A subjects receive 8 courses every 3-4 weeks, Stratum B subjects receive this combination for Courses 3, 4, 6, 7, 9, and 10 after the window, if they respond to window therapy) Vincristine dosage< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1.
46042103|NCT04297410|Radiation|177Lu-PSMA-I&T Radionuclide|Each patient will receive two single doses of 7.4 GBq 177-Lu-PSMA-I&T treatments. The treatments will be given intravenously, 2 weeks apart starting 12 weeks prior to radical prostatectomy.
46042104|NCT04298580|Procedure|PVB block|PVB block before surgery versus after surgery
46042105|NCT02872038|Drug|Cefepime|Cefepime intraperitoneal continuous dosing
46042106|NCT02872038|Drug|Cefazolin plus Ceftazidime|
46042107|NCT02871804|Procedure|combined resection of the splenic vein|combined resection of the splenic vein with the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
46042108|NCT02871804|Procedure|separated resection of the splenic vein|separated resection of the splenic vein from the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
46042109|NCT04298424|Other|PLSM|The program was designed for implementation over 4 consecutive weeks, with groups of 6-8 people each attending one 60-90-minute class per week. Peer leaders lead the groups to promote interaction, sharing, and support, and assist in goal setting to address behavior-related health problems, and thereby the development and implementation of strategies to achieve suitable, sustainable, and feasible self-management behavior.
45684810|NCT02780128|Other|Labs|Standard blood tests will be done to measure different types of blood cells, to measure the amount of certain substances, and tests to check how well liver and kidneys are working. When possible, the investigators will take blood from the participants central line. If this is not possible, the investigators will take blood from a vein in the participants arm. First, the investigators will put some cream on the skin so that drawing blood will not be painful. Then the investigators will put a thin needle into the vein to draw the blood.
45684811|NCT02780128|Other|Pregnancy Test|If the participant is 11 years old or older or has already started having periods, the participant will be asked to take a pregnancy test before starting this study. The results will be shared with the participant but not with the participants' parent(s). We strongly encourage the participant to share the results with the parents. If the participant is found to be pregnant, the participant will not be able to continue participation in the study. About 1 teaspoon of blood (or urine if a urine test) will be needed.
45474988|NCT02935452|Behavioral|GENIE - social networking tool|GENIE is a way to help people think about the links they have with others to manage a health problem (local groups, friends, acquaintances, family members, professionals) and to reflect on their involvement in health and wellness activities and their ability to live an ordinary life with a long term condition. By using GENIE and thinking or talking through the GENIE mapping tool, individuals can visualize their network and can reflect on connections that provide value and resources for managing and where there are gaps in support- this might be social, practical or emotional as well as specifically related to a health condition.
45345779|NCT00186888|Procedure|Focal Therapies|Method will be at the discretion of the treating team, used after second course of chemotherapy. Cryotherapy- freezing of affected tissue, Laser photocoagulation- using lasers to destroy affected tissue, Thermotherapy and thermochemotherapy- using heat or heat/chemotherapy combination to destroy diseased tissue, and Episcleral plaque brachytherapy- radiation insertions in the diseased area to destroy affected tissue.
45474989|NCT03732235|Device|TACE+ systemic Bevacizumab|PEG embolics
45345780|NCT00186888|Radiation|External Beam Radiation|44-46 Gy administered using standard practices , limiting dose to normal tissues to subjects with recurrent or progressive disease not considered controllable with focal treatments, Stratum B subjects with suspected active disease after completing therapy, or patients considered to have high-risk disease.
45474990|NCT03732235|Drug|FOLFIRI+Bevacizumab|antiangiogenic factor
45474991|NCT03732235|Device|TACE|PEG embolics
46042110|NCT04298346|Other|no intervention|no intervention
45474992|NCT01289951|Drug|Raltegravir 400 mg/12hours|
45345781|NCT00186888|Drug|Vincristine and Topotecan|(Stratum B subjects receive two up-front courses of vincristine and topotecan, given in 21-day intervals, then those who respond receive 3 additional courses (courses 5, 8, and 11) after the window. Dosages are the same for both window and subsequent courses: Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Topotecan: TSE of 140 ± 20 ng/ml*hr, daily for 5 consecutive days, infused over 30 minutes.
45474993|NCT01289951|Drug|Raltegravir 400 mg/12hours|
45345782|NCT00186888|Drug|Vincristine + Carboplatin + Etoposide|"Stratum B patients that do not respond to window receive 6 courses of this combination.~Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, < 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3"
45474994|NCT03178773|Behavioral|TExT-MED|messages designed to inspire motivation and behavior change
45474995|NCT03178773|Behavioral|FANS|SMS delivered messages to family members to improve social support
45474996|NCT04508920|Other|Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA)|Interventions were recorded in two groups of patients, who were randomly selected, in two different periods of time. The basal group was intervened from 15 May to 15 June 2019, a pandemic-free period. The outbreak group from 15 May to 15 June 2020, corresponding to increased activity of contagiousness and mortality associated with COVID-19, in general population in Mexico14 Basal measurement was performed in a face to face method. In Outbreak period, under social isolation conditions, patients were evaluated by telephone. The assessments were performed out by medical staff with specialized training, with evaluations to which patients were accustomed by regular cohort assessments. The questions were ordered and systematized in a patient evaluation, care, and follow-up guide (appendix). A causality association question of emotional distress perception was added. We recorded mortality and rehospitalization
46042111|NCT01016964|Device|HairMax LaserComb 2009 model 12 beam|HairMax LaserComb
46042112|NCT01016964|Device|Sham Device|Sham Device
46042113|NCT00627900|Device|bare metal stent|implantation of a bare metal stent
46042114|NCT00627900|Device|Cypher-Stent (Implantation of a sirolimus-eluting stent)|Implantation of a sirolimus-eluting stent
46042115|NCT04299360|Device|Cardiac Resynchronization Therapy device programming|Implanted CRT-D devices settings will be programmed based on the best acute hemodynamic response assessed non-invasively
46042116|NCT02996110|Biological|Nivolumab|Specified Dose on Specified Days
46042117|NCT02996110|Biological|Ipilimumab|Specified Dose on Specified Days
46042118|NCT02996110|Biological|Relatlimab|Specified Dose on Specified Days
45345783|NCT00186888|Drug|vincristine, cyclophosphamide, and doxorubicin|(High risk Stratum C patients in courses 2, 4, and 6 after enucleation, intermediate risk stratum C patients for four consecutive courses after enucleation) Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Cyclophosphamide: < 12 months of age: 40 mg/kg i.v. day 1, ≥ 12 months of age: 1,200 mg/m2 i.v. day 1, MESNA 200 mg/m2 at 0, 3, 6, and 9 hours Doxorubicin < 12 months of age: 1.5 mg/kg i.v. day 1, ≥ 12 months of age: 45 mg/m2 i.v. day 1
45474997|NCT01188473|Other|NPPV plus standard of care|Patients in the NPPV group were fitted with a nasal mask with gel seals (Comfortgel Masks, Respironics) and placed on the BiPAP Machine (Vision Bipap, Respironics). To optimize patient cooperation, the mask was initially applied manually to the patient's face. After a short adaptation period, it was firmly applied on the face by head straps to minimize air leak without causing skin injury. Pressures were initially set low for comfort and acceptance while being placed on the machine. The inspiratory positive airway pressure (IPAP) was gradually increased to 8 cm H2O in order to achieve a tidal volume of 6-9 ml/kg and the end expiratory positive airway pressure (EPAP) to 5 cm H 2O. These settings remained unchanged throughout the study period.
45684812|NCT02780128|Behavioral|Interviews|A team member will take the participant's medical history, along with a listing of any medications that are being taken. Throughout the study, participants will be asked to report if they think that anything bad has happened as a result of the study.
45684813|NCT02780128|Other|ECG|This is a test of electrical activity of the heart. The investigators will put electrodes (sticky pads attached to wires) on the participant's chest, arms and legs. The electrocardiogram (ECG) will not be uncomfortable, but the participant will have to lie still. It does not hurt and takes about 15 minutes.
46042119|NCT02996110|Drug|BMS-986205|Specified Dose on Specified Days
46042120|NCT02996110|Drug|BMS-813160|Specified Dose on Specified Days
46042121|NCT04213768|Procedure|Lateral rectus plication|The technique is the same as resection up to the muscle suturing, in the next step, the sutures is passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle is folded anteriorly by Stevens muscle hook during tightening and fixing the sutures. At the end, conjunctiva is repaired by Vicryl 8-0.
46042122|NCT04213768|Procedure|Lateral rectus Resection|Following conjunctiva and tendon capsule incision, lateral rectus is hooked and dissected from its surrounding tissues. Then, the muscle is sutured according to the amount of supposed resection from lateral rectus insertion by Vicryl 6-0 (polyglation 910, coated Vicryl®, Ethicon, Blue Ash, OH). Afterwards, the muscle is cut at 1mm anterior to these sutures and the residual muscle is re-sutured to the sclera at its primary insertion. Finally the conjunctiva is repaired using Vicryl 8-0.
45345784|NCT00186888|Drug|Vincristine, Carboplatin and Etoposide|High risk Stratum C patients in courses 1, 3, and 5 after enucleation: Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, < 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3
45474998|NCT03764592|Other|radiofrequency ablation|Symptomatic patients whose substrates were identified will undergo catheter ablation; asymptomatic patients will be followed without undergoing catheter ablation.
45840864|NCT00927264|Behavioral|Motivational Interviewing Intervention for ETS Reduction|The intervention is designed to motivate caregivers to reduce a child's ETS exposure by establishing a complete home and car smoking ban and by considering smoking cessation. Caregivers will receive 2 home visits & 2 telephone session, both with a health counselor. Caregivers will be provided with feedback on air nicotine levels and child salivary cotinine levels. The main target for the intervention will be the primary caregiver of the child because the primary caregiver is ultimately responsible for protecting the child from ETS exposure. Any and all household members may participate in the intervention visits but are not required to do so.
46042123|NCT00916617|Drug|bapineuzumab|5 mg/week subcutaneous bapineuzumab
46042124|NCT04214236|Device|ciNPT group|Closed-incision negative pressure therapy (ciNPT) will be applied for 7 day using continuous suction at 125 mmHg. To deliver ciNPT we will use a commercially available, FDA-approved device, used according to the manufacturer' indications (PREVENA™ Incision Management System (KCI, San Antonio, Texas, USA). After the first 7 post-operative days, subjects will discontinue the ciNPT and follow a standard wound care protocol.
46042125|NCT04214236|Other|Control group|Standard non-adherent surgical dressing (Vaseline petrolatum gauze) will be used for management of incisional wounds in the control group. Dressing changes will be performed per standard wound care protocol.
46042126|NCT01103063|Drug|Azithromycin plus chloroquine|combination tablet of 250mg azithromycin/155 chloroquine, Once daily PO for three days per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
46042127|NCT01103063|Drug|sulfadoxine-pyrimethamine|Fansidar tablet (500 mg sulfadoxine /25 mg pyrimethamine), once daily, PO, single dose per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
46042128|NCT04214158|Other|Assessment|Assessment
46042129|NCT02987998|Drug|Cisplatin|Cisplatin (50mg/m2 IV D1, 8, 29, 36)
46042130|NCT02987998|Drug|Etoposide|Etoposide (50mg/m2 IV D1-5, 29-33)
46042131|NCT02987998|Drug|Pembrolizumab|Pembrolizumab (200mg IV D1, 21, 42)
45474999|NCT03738787|Procedure|Pancreatic duct occlusion with Neoprene|Pancreatic duct occlusion of the pancreatic stump with Neoprene-based glue after Pancreatoduodenectomy.
45475000|NCT03738787|Procedure|Pancreato-Jejunal anastomosis|Standardized pancreato-jejunal anastomosis after Pancreatoduodenectomy
45475001|NCT01186523|Other|Long Term Energy Balance|To see if there is a variance in weight loss and energy balance between men and women with similar energy expenditure over an extended period of time.
45475002|NCT04508608|Diagnostic Test|Stress Gated blood pool SPECT|"After labeling of red blood cells in vivo, a sequential series of acquisition is carried out at rest and during increasing doses of dobutamine (5/10/15 μg / kg / min). The duration of acquisition is 300 seconds.~The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast Cadmium zinc telluride (CZT) detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)"
45840865|NCT00927264|Behavioral|Educational Program for ETS Reduction|An Environmental Protection Agency-based educational program that will consist of information about reducing tobacco smoke exposure.
45684814|NCT02780128|Other|Echocardiogram|The participant will have an ultrasound of the heart taken to assess heart function. The investigators will put some gel on the skin and use a machine to take pictures of the heart.
45684815|NCT02780128|Drug|Ribociclib|Participants will take ribociclib once per day orally for Days 1-21 of a 28-day cycle.
46042132|NCT02987998|Drug|Radiation|Radiation (1.8Gy/D to 45Gy in 25 fractions)
46042133|NCT04141306|Other|Administrative data|Evaluation of month and year of birth, sex, referent doctor and surgeon
46042134|NCT04141306|Other|Clinical data|Evaluation of diagnostic circumstances, vital status at last follow up
46042135|NCT04141306|Other|Histological data|Evaluation of Pathology report of thyroid surgery
46042136|NCT04141306|Other|Imaging data|Evaluation of scintigraphy, MRI, scan
46042137|NCT04141306|Other|Biological data|Evaluation of thyroglobulin, antithyroglobulin antibodies
46042138|NCT04141306|Other|Further treatment|Evaluation of surgery, radiotherapy, targeted therapy
46042139|NCT04213378|Device|Paclitaxel eluting PTCA balloon|Treatment of coronary in-stent re-stenosis with paclitaxel eluting PTCA balloon
46042140|NCT04213378|Device|SeQuent® Please paclitaxel eluting balloon|Treatment of coronary in-stent re-stenosis with SeQuent® Please paclitaxel eluting balloon
46042141|NCT02879591|Other|Social Skills training with Avatar therapist|
46042142|NCT00617032|Genetic|tgAAC94 gene therapy vector|Single Dose 1x10^10 DNase resistant particles (DRP) / mL joint volume
46042143|NCT00617032|Genetic|tgAAC94 gene therapy vector|Single dose 1x10^11 DNase resistant particles (DRP) / mL joint volume
46042144|NCT00617032|Genetic|tgAAC94 placebo|Single dose
46042145|NCT02877953|Behavioral|the prevention of complications post-TIPS|Continuous nursing through telephone follow-up, family visits, and WeChat guided patients to prevent gastrointestinal bleeding, infection and constipation ,intake quality low-protein diet, recognize minimal encephalopathy, monitor blood ammonia, return visit regularly, deal with adverse drug reactions of anticoagulant.
46042146|NCT04213924|Drug|Bupivacaine HCl 0.5 % in 10 ml and 2 % lidocaine in 10 ml|Erector spinae plane block, 30 min before the ESWL procedure.
46042147|NCT04213924|Drug|5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously|5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously, 30 min before the ESWL procedure.
46042148|NCT04964297|Device|Obtaining bowel gas samples|"The Perf-AlertTM prototype consists of a 15 x 13 x 7 unit containing gas sensors and valves, a small box containing a one-way, ultra-low pressure pump, user controls (buttons), and software algorithms, which control the operation of the device. It is used in conjunction with a single-use, disposable kit of sterile tubing and filters used for sample collection. The sensing unit will be connected via a sterile tube/filter set to any trocar port in use during the procedure. At specific time points during surgery, a one-way valve will be opened, and the unit's pump turned on and withdrawing a small amount of gas from the abdominal cavity. The system is configured that sample collection, transport, analysis, and feedback occur in a single step such that sample collection and sensor feedback occur in real-time. A standard laptop running an analytical software program is connected to the unit to record and log sensor readings."
46042149|NCT00616720|Biological|aldesleukin|
46042150|NCT00616720|Biological|idiotype-pulsed autologous dendritic cell vaccine APC8020|
46042151|NCT00616720|Biological|recombinant interferon gamma|
45684816|NCT02780128|Drug|Ceritinib|Participants will take ceritinib once per day orally for 28 days of a 28-day cycle.
45840866|NCT00927576|Behavioral|Digit span testing|Testing of short-term verbal memory with digit span
45840867|NCT00927576|Behavioral|Spatial span testing|Testing of short-term visuospatial memory with spatial span.
46042152|NCT00616720|Genetic|polymerase chain reaction|
46042153|NCT00616720|Genetic|reverse transcriptase-polymerase chain reaction|
46042154|NCT00616720|Other|flow cytometry|
46042155|NCT00616720|Other|laboratory biomarker analysis|
46042156|NCT01091675|Drug|Etoricoxib|Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.
46042157|NCT00620230|Drug|NVP-VAK694|
46042158|NCT00620230|Drug|NVP-VAK694|
46042159|NCT00617110|Other|live attenuated influenza virus (LAIV) with clean air|Allergic subjects will be exposed to air followed by administration of live attenuated influenza virus
46042160|NCT00617110|Other|LAIV and diesel exhaust particles|subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
46042161|NCT04140370|Other|There is no intervention|There is no intervention
46042162|NCT02739412|Biological|Interleukin-2|Subjects will self-administer low dose IL-2 as subQ injection (0.30 MIU per meter squared body surface area) for 4 weeks.
46042163|NCT04213612|Drug|pegylated liposomal doxorubicin, cyclophosphamide, vincristine,|PLD 40mg/m2 ; PLD 50mg/m2 ; PLD 60mg/m2 ; Maximum tolerated dose； Dose-limiting toxicity
46042164|NCT01091519|Other|Toviaz(fesoterodine) plus educational materials|Educational materials including the Self-Assessment Goal Achievement (SAGA) tool to support dialogue.
46042165|NCT01091519|Other|Toviaz(fesoterodine) without educational materials|No educational materials
46042166|NCT02703220|Other|Hyperoxia/oxygen|The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure
46042167|NCT02703220|Drug|Acetazolamide|Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 5 days. On the final 2 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
46042168|NCT02703220|Drug|Finasteride|Elderly males with sleep apnea and adequate testosterone levels will ingest placebo vs finasteride, at 5 mg a day for 1 month (mo). After 1 mo, while still on the drug, on the final 2 consecutive nights, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG. Blood tests will be performed to check sex hormone levels. A washout period of 1 month prior to cross-over to the alternate arm (placebo).
46042169|NCT00620308|Drug|CD-NP|One of two dosage levels (20 ng/kg/min and another level to be finalized) as a continuous intravenous infusion for four hours
45840868|NCT00927576|Behavioral|Finger tapping|Testing motor speed with a finger tapping test.
46042170|NCT00620308|Drug|Placebo|Dextrose 5% in water (the vehicle)
45345785|NCT00186888|Procedure|Periocular carboplatin|Periocular (subtenon) carboplatin 20 mg, one injection, in courses 5, 8, and 11 in patients responding to the VT window, and in courses 1, 3, and 6 of VCE in patients not responding to the VT window, when active vitreous disease is present. Carboplatin 20 mg will be diluted in 2 mL of NS or D5W and given by subtenon administration while the patient is under general anesthesia.
45345786|NCT00186888|Other|G-CSF|G-CSF (5 mcg/kg/day), will be administered starting 24-36 hours after the completion of each course of chemotherapy, for 7 to 10 days, until ANC is > 2,000/mL in one occasion after the expected nadir.
46042171|NCT02878031|Drug|Oral amoxicillin for CI pneumonia|"CHW management of chest indrawing (CI) pneumonia in children 2-59 months old using oral amoxicillin, given in the following age specific dosage:~2 months ≤ children age <12 months (4 - <10kg): one (1) tablet 250mg dispersible amoxicillin twice daily (morning and evening) for 5 days.~12 months≥ children age <3 years (10 kg - <14 kg): two (2) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days.~≥ 3 years of age children <5 years (14kg - 19kg): three (3) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days."
45840869|NCT00927576|Behavioral|Simple reaction time|Testing the time to respond to the appearance of a visual stimulus.
45840870|NCT00927576|Behavioral|Choice reaction time|Testing the time needed to discriminate and respond to different visual stimuli.
45840871|NCT00927576|Behavioral|Verbal fluency|Evaluating how many words are produced in 90s.
45345787|NCT04039594|Device|VA ECMO|VA ECMO for cardiopulmonary support
45840872|NCT00927576|Behavioral|Verbal list learning|Evaluating short-term memory, learning, and memory interference in the recall of 12-word lists, presented three times. Evaluating long-term memory and recognition after a 20 min interval.
45475003|NCT04508608|Diagnostic Test|Dynamic SPECT|"The passage of a radiopharmaceutical bolus through the cavities of the heart and myocardium at rest and during infusion of adenosine at a dosage of 140 mcg / kg / min (for 4 minutes) is recorded.~At the peak of the stress test (after 2 minutes of administration of adenosine), a 5 ml bolus (dose 260-444 MBq) of 99mTc-methoxyisobutylisonitrile (MIBI) is administered at a rate of 1 ml / s. Immediately after the end of tracer administration, 30 ml of 0.9% sodium chloride (NaCl) is infused. A scintigraphic recording of the study begins 5 seconds before the administration of the radiopharmaceutical.~The next day, the study at rest is carried out. Scintigraphic images are recorded in tomographic mode with ECG synchronization for 600 s, at list mode.~The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast CZT detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)"
45345788|NCT00873184|Behavioral|Massage Therapy|The setting for massage intervention will take place at The Duke Center for Living (DCL). . The massage therapists at the DCL work closely with physicians to design appropriate interventions for patients who are receiving treatment at DUMC, including cancer patients. All DCL therapists have completed more than 600 hours of training, are nationally certified and hold a North Carolina license to practice massage. These types include Swedish, deep muscle, myofascial release, trigger point, acupressure, Bowen Technique, sports massage and chair massage.
45345789|NCT05127538|Diagnostic Test|Gait analysis|Gait analysis Zebris Rehawalk (Zebris Medical GmbH, Germany) computerized gait evaluation system is used to assess the kinetic and kinematic analysis of the gait. The system consists of a treadmill and a computer. For gait assessment, patients walk at their preferred comfortable walking speed.
45345790|NCT05127538|Diagnostic Test|Balance Assessment|Static and dynamic balance Static and dynamic balance and stability limit values are evaluated with the E-LINK FP3 Force Plate (Biometrics Ltd, United Kingdom) system. The device consists of a computer and a platform on which individuals can place their feet. For static balance measurement, individuals are asked to place their feet on the marked places on the platform and hold an object on the computer screen at a fixed point for 30 seconds without support from their hands. For dynamic balance, individuals need to follow a moving object on the computer screen for 30 seconds by putting their body weight forward, backward, and sideways with their feet.
45345791|NCT00736164|Dietary Supplement|selenomethionine|Given orally
46042172|NCT00572962|Procedure|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
45684817|NCT01893502|Behavioral|Telephone counselling from Quitline|
46042173|NCT02879669|Biological|ONCOS-102|
46042174|NCT02879669|Drug|Pemetrexed/cisplatin (carboplatin)|
46042175|NCT02879669|Drug|Cyclophosphamide|
45345792|NCT00736164|Other|placebo|Given orally
45684818|NCT02775214|Device|Video Laryngoscopy|
45684819|NCT02773732|Drug|Ciprofloxacin 750 MG|750 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
46042176|NCT04213690|Other|No Intervention|There is no intervention for this study
46042177|NCT05339321|Genetic|SCG101|SCG101 is an autologous HBV-specific T cell receptor engineered T cell therapy.
46042178|NCT05339321|Biological|PD1/PD-L1 checkpoint inhibitor|Commercially approved for HCC treatment.
46042179|NCT00516724|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
45345793|NCT00739830|Drug|ridaforolimus|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
45684820|NCT02773732|Drug|Etoposide|Etoposide 200 mg will be taken orally once daily on Days 2 to 8 of each 28-day cycle.
45684821|NCT02773732|Drug|Ciprofloxacin 1000 MG|1000 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
46042180|NCT00516724|Drug|Carboplatin|intravenous injection
46042181|NCT00516724|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
45684822|NCT02773732|Drug|Ciprofloxacin 500 mg|500 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
45684823|NCT02773498|Procedure|conventional TESE|usual procedure for sperm extraction
45684824|NCT02773498|Procedure|Micro TESE|procedure of extraction is performed under the operating microscope
45684825|NCT04390126|Other|life questionnaires|Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)
46042182|NCT00516724|Drug|Paclitaxel|Intravenous injection
45345794|NCT00739830|Drug|medroxyprogesterone acetate tablets OR megestrol acetate|oral medroxyprogesterone acetate tablets 200 mg daily OR oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily)
45345795|NCT00739830|Drug|chemotherapy|Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
45684826|NCT04390126|Other|questionnaire|1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease
45684827|NCT02769520|Drug|Pembrolizumab|200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression
46042183|NCT00516724|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
46042184|NCT00516724|Drug|Paclitaxel + Carboplatin|Intravenous injection
46042185|NCT04875533|Biological|20vPnC|20vPnC
46042186|NCT04875533|Other|Saline|Saline
46042187|NCT04875533|Biological|13vPnC|Pneumococcal conjugate vaccine
46042188|NCT04875533|Biological|PPSV23|Pneumococcal polysaccharide vaccine
46042189|NCT00620386|Device|Bonfils|Endotracheal intubation using Bonfils Intubating Fiberscope
45345796|NCT05111782|Other|Symptom Modulation Approach, Movement Control Approach, Functional Optimization Approach|Based on the patients' symptoms and level of disability, either symptom modulation or movement control or functional optimization exercises will be used. The exercises will be provided on alternate days for a duration of 30 minutes in each session preceded by electrotherapeutic modalities for pain relief and muscle relaxation. These modalities will be given for 15 min in each session. The total no. of sessions will be based on the patient's progress for a maximum of 4 weeks.
45345797|NCT00577382|Drug|Sunitinib|
45345798|NCT00733434|Drug|Prostaglandin E1|PGE 1 80mcg/500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
45840873|NCT00927576|Behavioral|Trail making test|Evaluating visuomotor speed and executive function in Trail Making Tests, A and B. In the first, subjects connect successive numbers with the mouse. In the second, they connect numbers and letters in alternation.
45840874|NCT00927576|Behavioral|Design fluency|Subjects create the maximal number of 4-line patterns in 90 s.
45840875|NCT00927576|Behavioral|Questionnaire completion|Question completion time is measured on each question of the Post-Traumatic Stress Disorder check list (PCL) and on the cognitive failures questionnaire.
46042190|NCT00620386|Device|Macintosh|Endotracheal intubation using Macintosh laryngoscopy
46042191|NCT00918333|Drug|panobinostat|Given PO
46042192|NCT00918333|Drug|everolimus|Given PO
46042193|NCT00918333|Other|laboratory biomarker analysis|Correlative studies
46042194|NCT00918333|Other|pharmacological study|Correlative studies
46042195|NCT04929730|Other|Nephrology care bundle|Nephrology care bundle
46042196|NCT01091363|Behavioral|Standard|10 minute brief cessation counseling
46042197|NCT01091363|Behavioral|Deep Cultural|Deep culturally tailored cognitive behavioral therapy
46042198|NCT04910542|Other|Epi-Net Intervention|The Epidemiological Intelligence Network Intervention (Epi-Net) is a group of field epidemiology tools for test, trace and isolate using a community-based approach. The overall goal of Epi-Net is to increase uptake of COVID-19 testing and prevention practices among socially vulnerable communities in Puerto Rico. The intervention intends to impact COVID-19 risk perception, decrease COVID-19 testing barriers, increase testing uptake and increase health promotion strategies.
46042199|NCT04306757|Device|Evone|Airway ventilation device
46042200|NCT04306757|Device|Primus|Airway ventilation device
45345799|NCT00733434|Other|Saline|500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
45345800|NCT04039282|Device|myfood24|online website for dietary analysis
45840876|NCT00927888|Drug|Bupivacaine Block|Bupivacaine local anesthesia block prior to start of FESS procedure.
46042201|NCT00617266|Other|tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
46042202|NCT00617266|Other|Tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
46042203|NCT00617266|Other|Tobacco cessation intervention|Distribution of pamphlets containing information on the hazards of tobacco
46042204|NCT00617266|Other|Tobacco cessation intervention|Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
46042205|NCT01090973|Drug|LBH589|"The LBH589 capsule(s) should be swallowed by mouth with a glass of water (8 ounces noncarbonated) in the morning. The daily dose of LBH589 should be taken at approximately the same time each day. Patients should avoid eating grapefruit, Seville (sour) orange or drinking grapefruit juice or Seville orange juice during the study.~After 2 cycles of treatment, if patients do not demonstrate a partial response or complete response (all of the tumor is gone) to the therapy they will be removed from the study. If patients do obtain a partial (the tumor(s) have decreased in size or number but there are still tumors present) or complete response then treatment will continue until their disease progresses."
45840877|NCT00927888|Drug|Placebo|placebo is identical in appearance in comparison to active drug.
46042206|NCT04755933|Behavioral|Raising Confident Children Course|An online learning tool consisting of 8 different modular components, designed to reduce the transmission of anxiety from parents to children. The modular components include: a core starter about anxiety, the role of avoidance, using play to develop childrens confidence, using Emotion Coaching with children, managing difficult behaviour, the role of sleep, exercise and diet, reducing overprotection, modelling confident behaviour and managing difficult behaviour.
46042207|NCT02607904|Drug|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
45475004|NCT03732157|Procedure|outpatient management of parathyroidectomy|The patient is discharged from hospital the same day of the parathyroidectomy intervention instead of conventional management (stay overnight in hospital)
45475005|NCT03732157|Procedure|conventional management of parathyroidectomy|The patient stays overnight in hospital after intervention
45840878|NCT00928200|Drug|Erwinase|"The dose of Erwinase will be assigned at study entry. The first dose of Erwinase wil be given between Days 3-5 and will continue on a M-W-F schedule for a total of 10 doses.~Erwinase will be administered as a 2-hour intravenous infusion."
46042208|NCT04604925|Behavioral|Remote patient monitoring for hypertension|Intervention involves practices making available remote physiologic monitoring treatment management services allowable under Medicare for blood pressure (and weight if desired) to Medicare patients in the practice when ordered by the patient's clinician.
46042209|NCT05295394|Drug|Dolutegravir plus lamivudine|Dolutegravir 50 mg QD plus lamivudine 300 mg QD
45840879|NCT00928200|Drug|Vincristine|1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22
45840880|NCT00928200|Drug|Dexamethasone|10 mg/m2/day divided BID. Give by mouth days 1-14.
45840881|NCT00928200|Drug|Doxorubicin|60 mg/m2/day IV over 15 minutes on day 1
45840882|NCT00928200|Drug|Cytarabine|Given Intrathecally at the dose defined by age on day 1. 30 mg for age 1-1.99 50 mg for age 2-2.99 70 mg for age 3 and older
45684828|NCT02764528|Behavioral|Clinic|Pregnant women will receive handwashing promotion from a trained facility-based health care worker during her regular antenatal visit at a healthcare clinic. To the extent feasible, everyone accompanying the pregnant woman will be invited to take part in the behavior change communication session. The participant will be provided with several bars of soap to take home and she will be encouraged to maintain a designated place for washing hands (with soap and water) at the home. A poster indicating the key events for handwashing with soap will be posted at the clinic and smaller posters will be given to the participant to post in her home. A system will be established to send regular SMS messages to the participant promote handwashing with soap during the neonatal period.
46042210|NCT01090739|Device|TOPAS Treatment for Fecal Incontinence|The TOPAS Treatment for Fecal Incontinence is implanted using a minimally invasive trans-obturator approach; two needle passers deliver the sling assembly. Two small posterior incisions facilitate the post-anal placement of the mesh.
46042211|NCT02871648|Drug|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
46042212|NCT02871648|Drug|Fludrocortisone|Fludrocortisone 0.1 mg
46042213|NCT02871648|Drug|Eplerenone|Epleronone 100 mg
46042214|NCT04873024|Device|cMAP Flow V 2.0|"Breathing data collected by the device will be processed by a machine learning algorithm to predict obstructive apnea events. When obstructive apnea events are predicted, the algorithm triggers the CPAP device to respond to the apnea event ahead of its onset.~For the control treatment, the device will operate as its conventional treatment."
46042215|NCT00637845|Drug|Esomeprazole Magnesium|40mg once daily
46042216|NCT00637845|Drug|Lansoprazole|30mg twice daily
45475006|NCT03713034|Other|PlayTest!|Participants in the PlayTest! intervention arm played the game on their assigned iPads once per week for an hour over the course of 4-5 weeks.
46042217|NCT04297878|Dietary Supplement|probiotic supplement Streptococcus salivarius K12 (Bactoblis®)|Probiotic food supplement
45475007|NCT03713034|Other|Control games|Participants in the control arm played the games on their assigned iPads once per week for an hour over the course of 4-5 weeks.
45475008|NCT01182077|Drug|ASP015K|Oral
45840883|NCT00928200|Drug|Methotrexate|Given Intrathecally to all patients who are CNS 1 or 2 at study entry. Dose defined by age. Given on day 15 8mg for age 1-1.99 10 mg for age 2-2.99 12 mg for age 3-8.99 15 mg for age 9 and older
45840884|NCT00928200|Drug|Triple Intrathecal Therapy|Methotrexate, Cytarabine and Hydrocortisone given Intrathecally on day 8, 15 and 22 for patients who are CNS 3 at study entry. Doses determined by age.
45475009|NCT01182077|Drug|Midazolam|Oral
45475010|NCT03356314|Other|MRI between 30-35 GA|MRI between 30-35 GA
46042218|NCT04209712|Biological|haploid allogeneic NK cell therapy|NK cells will be intravenously infused to the patient for 2 days, with following subcutaneously injection of Interleukin-2.
46042219|NCT04738695|Diagnostic Test|Point-of-care rapid anti-SARS-CoV-2 antibody test (Orient Gene Biotech) and Dry Blood Spot collection (Euroimmun)|Bimonthly finger pricks with collection of 1-10 drops of capillary blood for detection of anti-SARS-CoV-2 immune markers
46042220|NCT02497300|Drug|Spironolactone|
46042221|NCT02497300|Drug|Amiloride|
45475011|NCT03356314|Other|Pediatric surgeon meeting|Pediatric surgeon meeting
45475012|NCT03356314|Other|Postnatal abdominal ultrasound, barium enema and upper gastrointestinal|Postnatal abdominal ultrasound, barium enema and upper gastrointestinal
45475013|NCT03356314|Other|+/- prophylactic surgery|+/- prophylactic surgery
45475014|NCT03854513|Device|dialysis machine|A machine used in dialysis that filters a patient's blood to remove excess water and waste products when the kidneys are damaged
45840885|NCT00928200|Drug|Dexrazoxane|Due to the limited availability of Dexrazoxane (Zinecard®), treatment will be at the discretion of the treating physician. Dose should be 600 mg/m2 as a IV push immediately prior to anthracycline dose (the elapsed time from the beginning of the dexrazoxane dose to the end of the anthracycline infusion should be 30 minutes or less).
46042222|NCT04254471|Drug|AL3810|5mgQD, 7.5mgQD, 10mgQD
46042223|NCT04254471|Drug|carboplatin + etoposide|Carboplatin and etoposide are background treatment.
46042224|NCT04254471|Drug|Placebo|Placebo
46042225|NCT04299672|Procedure|Postural reconstruction|Interventions are described in group descriptions
46042226|NCT04817020|Other|%2 Klorheksidin|Effect on phlebitis
45475015|NCT02519062|Other|No intervention|This is a retrospective study
45475016|NCT03218397|Device|Accelerate PhenoTest™ BC Kit|Rapid identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX)
45475017|NCT03218397|Device|Standard Culture and AST|Standard culture and antimicrobial susceptibility testing (AST)
45475018|NCT03618823|Drug|Oxycodone|Oxycodone will be prescribed at a dose in the range of 0.025 mg/kg to 0.10 mg/kg every four hours or as needed for adequate pain management. The total supply will be limited to seven days. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
45345801|NCT05740670|Other|Dr. Kellyann's Bone Broth|Participants will have two bone broth phases, each three weeks in length. Bone broth phases will be separated by a one-week maintenance phase. A one-week maintenance phase will also occur after the second bone broth phase. Each week of a broth phase will consist of five feeding days and five fasting days. On feeding days, participants will consume one packet of bone broth, twice each day, as snacks between meals. On fasting days, participants will consume one packet of bone broth every two hours for a total of seven packets each day.
45345802|NCT00736320|Drug|ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)|chemotherapy with 2 cycles of ABVD (day 1 + 15)
45345803|NCT00736320|Radiation|20 Gy IFRT (Involved Field Radiotherapy)|20 Gy Involved Field Radiotherapy
45475019|NCT03618823|Drug|Ibuprofen|Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
45475020|NCT03618823|Drug|Acetaminophen|Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
46042227|NCT00631527|Drug|Leuprolide|Injections given through a needle in the muscle every 3 months.
46042228|NCT00631527|Drug|Goserelin|Subcutaneous injections given once every 3 months.
46042229|NCT00631527|Drug|Sunitinib Malate|Starting dose of 12.5 mg by mouth daily for 4 weeks
46042230|NCT00631527|Drug|Casodex|Once a day by mouth for 2 weeks.
46042231|NCT00631527|Radiation|Radiation Therapy (RT)|Radiation treatment once daily over a period of 8 weeks.
46042232|NCT00620620|Drug|Inhaled placebo|Inhaled Staccato Placebo
46042233|NCT00620620|Drug|Inhaled Zaleplon 0.5 mg|Inhaled Staccato Zaleplon 0.5 mg
46042234|NCT00620620|Drug|Inhaled Zaleplon 1 mg|Inhaled Staccato Zaleplon 1 mg
46042235|NCT00620620|Drug|Inhaled Zaleplon 2 mg|Inhaled Staccato Zaleplon 2 mg
46042236|NCT00620620|Drug|Inhaled Zaleplon 4 mg|Inhaled Staccato Zaleplon 4 mg
46042237|NCT04209556|Drug|PF-06826647 100 mg QD|Investigational Product
46042238|NCT04209556|Drug|PF-06826647 300 mg QD|Investigational Product
46042239|NCT04209556|Drug|PF-06826647 600 mg QD|Investigational Product
46042240|NCT04209556|Drug|Placebo|Matched Placebo
46042241|NCT04209556|Drug|PF-6826647 400 mg QD|Investigational Product
45475021|NCT01188629|Behavioral|Safety Training|IT intervention focuses on safety in the home.
46042242|NCT00916383|Drug|350 mg Donepezil Transdermal Patch|Active and placebo patches will be applied to opposite sides for 7 days.
45475022|NCT01188629|Behavioral|Personal Health Partner and Counseling (PHP+C)|The PHP intervention will have three primary functional areas: 1) pre-visit assessment and counseling; 2) EHR data exchange with clinician review; and 3) post-visit follow-up, re-assessment, and counseling.
45475023|NCT04504786|Other|Vitality acupunch (VA) exercise program|The VA had three phases and took 40 minutes to complete.
45475024|NCT04504786|Other|Control|Participants maintained their daily activities.
46042243|NCT00916383|Drug|Placebo Patch|Active and placebo patches will be applied to opposite sides for 7 days.
45475025|NCT01188707|Drug|Belinostat and Erlotinib|"The design of the first phase is a 3 +3 phase I trial. The Belinostat dose will start at 500 mg and will be increased with 250 mg until a maximum dose of 1500 mg, administered daily in 2/3 weeks. Each patient will at the same time receive 150 mg of Erlotinib daily continously.~When the patient is enrolled at one dose level, there will be no further dose escalation for that individual patient.~3 patients will be treated at each dose level."
45475026|NCT03356158|Biological|CPGJ602|Injection, q.w., 20 mg: 100 ml
45475027|NCT03356158|Biological|Cetuximab|Injection, q.w., 20 mg: 100 ml
45840886|NCT00929838|Behavioral|Diabetes Knowledge/Information|This group will receive telephone-delivered diabetes knowledge/information lasting 30 minutes for 12 weeks.
45840887|NCT00929838|Behavioral|Motivation/Behavioral Skills|This intervention consists of patient activation, patient empowerment, and behavioral skills training delivered via telephone lasting 30 minutes every week for 12 weeks.
45475028|NCT05048706|Device|Laser lithotripsy (SP TLF)|Laser lithotripsy of urinary calculi using the Super Pulse Thulium fiber laser (SP TLF)
45840888|NCT00929838|Behavioral|Combined Intervention|This group will receive all components of the diabetes knowledge/information and the motivation/behavioral skills interventions via telephone lasting 30 minutes every week for 12 weeks.
46042244|NCT00617500|Other|flower therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
46042245|NCT00617500|Other|therapeutic touch|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
46042246|NCT00617500|Other|auricular therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
46042247|NCT00617500|Drug|Hormones|Estradiol 1 mg and a drospirenone 2mg/day (3 months)
46042248|NCT04845555|Other|Observation of the association between clotting factor level and risk of bleeding whilst physical activity|"The participants of this study will be monitored for a period of twelve months regarding individual clotting factor level, bleeding episodes as well as type and intensity of physical activity. By doing so, bleeding events, factor consumption as well as the course of the individual factor clotting factor level will be documented via the mobile application myPKFiT. This individual factor treatment regime will be compared with the retrospective treatment outcome in the last twelve months before the first study visit."
46042249|NCT04254003|Device|DT1 Toric contact lenses|Delefilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)
45475029|NCT05048706|Device|Laser lithotripsy (Ho:YAG)|Laser lithotripsy of urinary calculi using the standard Holmium: Yttrium-Aluminium-Garnet (Ho:YAG) laser.
45684829|NCT02764528|Behavioral|Clinic + home|Women will receive all components of the clinic-based handwashing promotion in addition to handwashing promotion during 3-4 home visits before their expected delivery date and during the neonatal period from a community health volunteer. All household members present will be invited to join in the session, with emphasis on including all caregivers of the neonate.
45684830|NCT02764528|Behavioral|Clinic + home + handwashing device|Women will receive all components of the clinic + home-based handwashing promotion intervention in addition to one handwashing device (i.e. tap and basin to use as a handwashing station) during the first home visit by the community health volunteer. The community health volunteer will work with the woman and her family to identify the location where the neonate will be most of the time in order to position the handwashing station as close to the neonate as possible.
45684831|NCT02762266|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45684832|NCT02762266|Procedure|Transarterial Chemoembolization|Undergo TACE
45345804|NCT00878566|Other|Enhanced pharmacist care|The primary intervention will be enhanced pharmacist care. Pharmacists will assess patients with regards to cardiovascular risk reduction including reviewing BP control, treatment goals and determining lifestyle modifications for the patient to undertake to help manage their BP. The pharmacist will also review the patient's current hypertensive therapy regimen and decide on the options for improvement of BP control (lifestyle modification, increase dose, additional BP medications), and implementation of these strategies.
45840889|NCT00929838|Behavioral|Usual Care|This group will receive telephone-delivered general health education lasting 30 minutes for 12 weeks to control for attention and content.
45345805|NCT00878566|Other|Usual Care|Patients randomized to usual care will receive a wallet card for BP readings, pamphlet on BP and usual pharmacist and physician care. Patients will be seen at 12 weeks for interim BP measurement only. Both groups of patients will be seen at 24 weeks for BP measurement.
45840890|NCT00931164|Drug|Sodium Oxybate|dosage is by weight
45345806|NCT04065282|Drug|Sintilimab|3 cycles before radical surgery
45345807|NCT04065282|Drug|Oxaliplatin|85mg/m2 Q3W, 3 cycles perioperation
45345808|NCT04065282|Drug|Capecitabine|1000mg/m2 bid po D1~14 Q3W, 3 cycles perioperation
45345809|NCT00873262|Drug|Skin test panel and desensitization kit|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the appropriate hormone at the same concentration as it was used in the skin test as follows:~Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml"
45475030|NCT03738709|Behavioral|Falls prevention and education giving a demonstration of the usage of technical assistance.|"Ecological trail to work on balance and walking.~Technical assistance presentation and try-outs within the therapeutic apartment.~Discussion on the perceived feelings over the exercises and the technical assistance submitted.~Falls Education and prevention, screening of the dangerous activities and education on the safe behaviours."
45475031|NCT03854591|Other|No intervention|No intervention
45684833|NCT02762266|Drug|embolic agent|". Acceptable embolic agents include:~Gelatin sponge (gelfoam)~Polyvinyl alcohol (PVA) particles~Microspheres / Embolic beads"
45684834|NCT02762266|Drug|lipiodol|
45684835|NCT02752750|Other|MRI|MR imaging (MRI) at 3 Tesla
45684836|NCT02735512|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and urine samples
45684837|NCT02735512|Other|Laboratory Biomarker Analysis|Samples undergo MDSC clinical assay
45684838|NCT02735122|Drug|acetaminophen Tablet|2 test acetaminophen 500 mg tablets
45345810|NCT00873262|Drug|Skin test panel and solvent|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the solvent as follows:~Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml"
45345811|NCT00739986|Drug|Semapimod|semapimod 60 mg IV x 1 day, placebo x 2 days
45840891|NCT00931242|Drug|Apremilast|Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
45345812|NCT00739986|Drug|Semapimod|Semapimod 60 mg IV x 3 days
45345813|NCT00739986|Drug|Placebo|placebo IV x 3 days
45345814|NCT00736970|Drug|ridaforolimus|10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus.
45345815|NCT00736970|Drug|trastuzumab|single intravenous infusion every week; initial dose of 4 mg/kg over 90 minutes, then 2 mg/kg over 30 minutes
45345816|NCT00879736|Behavioral|THT PACE Training|Patient training
45345817|NCT00879736|Behavioral|THT PACE Training|Patient training
45345818|NCT00879736|Other|placebo|
45345819|NCT00873340|Drug|Interferon-1beta (Betaseron, BAY86-5046)|Patients with a first demyelinating event suggestive of MS, as well as patients with remittent recurrent MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS) will be observed.
45345820|NCT00740064|Drug|Raltegravir and Abacavir/Lamivudine|Raltegravir 400mg BID Abacavir/Lamivudine 1 tablet QD
45345821|NCT00736398|Procedure|Spinal fusion|Spinal fusion
45840892|NCT00932022|Drug|Trospium Chloride, Extended Release (XR)|Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.
45840893|NCT00932022|Other|placebo|Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
46042250|NCT04254003|Device|AO1DfA contact lenses|Senofilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)
45345822|NCT00614926|Drug|Modafinil|Dose schedule: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day as clinically indicated, in the absence of dose-limiting side effects. Dose is daily, in A.M., for 4 weeks.
45345823|NCT00614926|Drug|Placebo|Placebo capsules are administered on the same schedule as active drug: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day in the absence of clinical improvement and dose limiting side effects. Dose is daily, in A.M.
45345824|NCT00873418|Behavioral|Coping skills training|16 weekly telephone session using to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
45345825|NCT00873496|Drug|Hydroxychloroquine|
45345826|NCT04040140|Other|APA Treatment|Light touch using vaccaria seeds on corresponding ear points related to patient's pain.
45345827|NCT00879892|Drug|xenon|Gas, 24 hour inhalation, en tidal target concentration 40%
45345828|NCT00879892|Other|Hypothermia|24 hour, target core temperature 33
45345829|NCT00095784|Drug|Decitabine|Given SC
45345830|NCT00095784|Other|Laboratory Biomarker Analysis|Correlative studies
45345831|NCT00873574|Biological|Blood samples and buccal swabs|Peripheral blood samples (35 ml) and buccal swabs
45475032|NCT05239689|Biological|CD38 CAR T-cells|Drug: CD38 CAR T-cells Each subject receive CD38 CAR T-cells by intravenous infusion Other Name: CD38 CAR T-cells injection
46042251|NCT04703998|Procedure|Arthroscopic rotator cuff repair|A double-row rotator cuff repair will be performed.
46042252|NCT04703998|Biological|platelet rich plasma|A single dose of 10 ml of autologous platelet rich plasma at the bone-tendon interfase will be administered.
46042253|NCT04254081|Drug|Buprenorphine 0.15 MG|Buprenorphine 0.15mg solution will be added to a 20mL 1% buffered lidocaine solution (paracervical block) which will be administered in the paracervical space prior to osmotic dilator insertion.
46042254|NCT04254081|Drug|Lidocaine 1% Injectable Solution|20mL of 1% buffered lidocaine solution (paracervical block) will be administered in the paracervical space prior to osmotic dilator insertion.
45475033|NCT03356080|Drug|Decitabine|Decitabine,iv,0.1-0.2mg/kg, Day1-Day3 per week,up to 3 weeks
45345832|NCT00878956|Drug|Sodium Bicarbonate|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
45475034|NCT03356080|Drug|Cytarabine|cytarabine, iv,15mg/m2 q12h, Day1-Day10
45475035|NCT03356080|Drug|All-transretinoic acid|All-transretinoic acid, 45mg/d Day4-Day6;15mg/d Day7-Day20
45475036|NCT03356080|Drug|G-CSF|G-CSF 300ug,sc,Day 0 until CR is achieved
45475037|NCT01290107|Genetic|DNA analysis|
46042255|NCT04209478|Drug|Tramadol hydrochloride|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration
45475038|NCT01290107|Genetic|gene rearrangement analysis|
45475039|NCT01290107|Genetic|microarray analysis|
45475040|NCT01290107|Genetic|polymerase chain reaction|
45475041|NCT01290107|Other|immunological diagnostic method|
45475042|NCT01290107|Other|laboratory biomarker analysis|
45475043|NCT03640507|Drug|Chlorhexidine-alcohol|Intervention is a 30-second vaginal preparation or topical wash with three chlorhexidine-alcohol 0.5% solution-soaked sponge sticks.
45475044|NCT03640507|Drug|Povidine-iodine|Intervention is a 30-second vaginal preparation or topical wash with three povidine-iodine 10% solution-soaked sponge sticks.
46042256|NCT05252715|Biological|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 meningococcal polysaccharide combined with tetanus toxoid.
45475045|NCT03640507|Drug|Sterile saline|Intervention is a 30-second vaginal preparation or topical wash with three sterile saline-soaked sponge sticks.
46042257|NCT05252715|Biological|Meningococcal A and C Polysaccharide Conjugate Vaccine|Single intramuscular dose contains 10 µg each of Serogroup A and C meningococcal polysaccharide combined with tetanus toxoid.
46042258|NCT00617578|Device|ATP One Shot ON|"The new antitachycardia pacing algorithm ATP One Shot attempts to terminate fast VT by one ATP sequence and thus avoid defibrillation shock delivery"
46042259|NCT00617578|Device|ATP One Shot OFF|Standard defibrillation shock delivery
45475046|NCT02467413|Drug|BAC|(vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof)
45684839|NCT02735122|Drug|acetaminophen Caplet|2 commercial acetaminophen 500 mg caplets
46042260|NCT05252637|Procedure|Laparoscopic Fascial Posterior Vagina Duplication|Laparoscopic Fascial Posterior Vagina Duplication with absorbable sutures for posterior prolapse (plus standard Sacral Colpopexy)
46042261|NCT04209244|Dietary Supplement|Eskimo-3 Pure Fish Oil|Dosage: 10 ml/day (2.6 g EPA+DHA)
46042262|NCT04209244|Dietary Supplement|Rapeseed Oil|Dosage: 10 ml/day (0 g EPA+DHA)
46042263|NCT05251623|Other|walking program|Subjects in PG walked to target steps daily with pedometer for 6 weeks
46042264|NCT04209166|Drug|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|Patients will be treated with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
46042265|NCT04209166|Drug|SSRIs/SNRIs+Mood Stabilizer|Patients will be treated with Mood Stabilizer combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
45475047|NCT02467413|Other|BAC Matched Vehicle|BAC Matched Vehicle
45475048|NCT02937636|Other|Stannous fluoride|Experimental dentifrice containing 0.454% w/w stannous fluoride & 0.0721% w/w sodium fluoride containing1450 parts per million (ppm) fluoride
45475049|NCT02937636|Other|Sodium monofluorophosphate|Dentifrice containing 0.14% w/w sodium monofluorophosphate containing1400 ppm fluoride
45684840|NCT02735122|Drug|ibuprofen Liquid-filled capsule|2 commercial ibuprofen 200 mg Liquid-filled capsules
46042266|NCT04209166|Drug|SSRIs/SNRIs+Quetiapine|Patients will be treated with Quetiapine combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
46042267|NCT04209166|Drug|Usual Treatment|Patients' treatment will be decided by the clinical doctor.
46042268|NCT00916305|Other|Modified Audio video|An audio video modified to mimic noise induced hearing loss after one night at a loud club
46042269|NCT00916305|Other|Unmodified audio video|An audio video with unaltered music
45684841|NCT02735122|Drug|Placebo Tablet|2 placebo tablets
45684842|NCT02735122|Drug|Placebo Caplet|2 placebo caplets
45684843|NCT02735122|Drug|Placebo Liquid-filled capsule|2 placebo Liquid-filled capsules
45684844|NCT02734888|Other|No drug or device, only a test. The test is called a PET/CT|A single PET/CT scan will be performed
45684845|NCT02726542|Drug|somatropin|Norditropin (growth hormone) given by injection using a pen-device
46042270|NCT02446444|Drug|Enzalutamide|
46042271|NCT02446444|Drug|Conventional NSAA|
45345833|NCT00878956|Drug|Sodium Chloride|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
45475050|NCT03356002|Device|C-Scan System|"Each subject will ingest the capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~To evaluate the safety of the C-Scan Capsule System procedure"
46042272|NCT02446444|Drug|LHRHA|
45475051|NCT05212259|Drug|Collagen type II (40 mg/day)|4 capsules per day
45684846|NCT02722798|Drug|KRN23|Doses may be titrated to achieve the target peak serum phosphorus range
46042273|NCT02446444|Radiation|External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)|
45345834|NCT00740142|Drug|L-ornithine-L-aspartate and lactulose|L-ornithine-L-aspartate 1 sachet(3 grams)3 times a day for 7 days
45345835|NCT00740142|Drug|placebo and lactulose|placebo 3 times a day for 7 days
45475052|NCT05212259|Drug|Collagen type II (80mg/day)|4 capsules per day
46042274|NCT04253925|Other|Kegel exercises|global postural correction exercises
46042275|NCT04766008|Drug|Metformin|Diabetic patients treated with metformin undergoing coronary angiography will not suspend metformin before and after PCI.
46042276|NCT00916149|Drug|levetiracetam|The dosage of levetiracetam will begin at 500mg twice per day (bid) for the first 4 days, and increase by 500mg every 5 days thereafter until a goal of 1500mg bid is reached. The subject will then remain on levetiracetam at 1500mg bid for 8 weeks, until the conclusion of the study. Medication will be supplied in 500mg tablets, to be taken orally.
45345836|NCT00873652|Biological|Engerix B®, a recombinant hepatitis B vaccine|Single 0.5 ml dose intramuscularly into the deltoid muscle
45345837|NCT02568774|Other|Traditional Acupuncture|Treatment is based on the traditional Chinese medicine theory for treating overactive bladder. Qi-transforming function of bladder is regulated by experienced Chinese medicine practitioner.
45345838|NCT02568774|Other|Usual Care|Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
46042277|NCT00916149|Drug|Lamotrigine|"The drug will be supplied in 25, 100 and 150mg tablets, to be taken orally per the titration schedule below:~The regimen will begin at 25mg once per day for the first two weeks, and increase to 50mg once per day during weeks 3 and 4. In week 5, the subject will take 50mg twice per day (bid). The dosage will increase to 50mg in the morning and 100mg at night during week 6. During week 7 the subject will take 100mg bid. During week 8, the subject will take 100mg in the morning and 150mg at night. At week 9, the subject will reach the target dose of 150mg bid. The subject will then remain on lamotrigine at 150mg bid for 7 weeks, until the conclusion of the study."
46042278|NCT04742920|Device|Middle Meningeal Artery Embolization|MMA embolization using the Onyx™ non-adhesive liquid embolic agent within 72 hours after randomization in addition to standard management
46042279|NCT04742920|Procedure|Standard Management|"Procedure : Surgical Management Surgical evacuation of the subdural hematoma~Other: Conservative Management Standard medical management: drug treatment and/or observation"
45345839|NCT04039048|Device|cerebellar transcranial direct current stimulation|Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 20 minutes with a 2mA current.
45345840|NCT04039048|Device|Sham cerebellar transcranial direct current stimulation|Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 30 seconds with a 2mA current.
46042280|NCT00631761|Other|educational workshop|The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas.
45345841|NCT04039048|Other|Balance training|Balance training will be performed through the Biodex Balance System for 20 minutes.
45345842|NCT00423319|Drug|Enoxaparin|Subcutaneous, 40 mg, once daily, 5 weeks
45475053|NCT05212259|Drug|Collagen type II (120 mg/day)|4 capsules per day
45345843|NCT00423319|Drug|Apixaban|Oral tablets, 2.5 mg, twice daily, 5weeks
45475054|NCT05212259|Drug|Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)|4 capsules per day
45475055|NCT05212259|Drug|Placebo|4 capsules per day
45684847|NCT02720848|Device|Stiffening wire|The stiffening wire will be inserted into the double/single balloon enteroscope.
45684848|NCT02720848|Device|Standard technique|The double/single balloon enteroscope will be used without the stiffening wire as per standard technique.
46042281|NCT00631761|Other|no intervention (usual resident activities)|usual activities
46042282|NCT00617656|Drug|Cisplatin, Docetaxel|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both on day 1, every 21 days. Total number of cycles: 6
46042283|NCT00617656|Drug|Gemcitabine, Cisplatin|Gemcitabine 1250 mg/m2, days 1 and 8, and Cisplatin 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
46042284|NCT00617656|Drug|Docetaxel, Cisplatin|Docetaxel 75 mg/m2 and Cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total number of cycles: 6
46042285|NCT00617656|Drug|Docetaxel|Docetaxel 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
45684849|NCT02718118|Device|Dysport reconstituted at 1.5 mL (0.05 mL/injection)|Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
46042286|NCT00620932|Behavioral|Exercise|Patients will be randomly assigned to groups and will either be given an exercise program individually tailored to them for them to participate in for 6 months or else be wait-listed for 6 months and remain on whatever exercise regimen they were already on.
46042287|NCT00175162|Device|Osteopal G vs. Refobacin-Palacos R bone cement|Bone cement
46042288|NCT04690660|Other|Data collection for parameters of organ damage (cardiac and renal blood markers)|Blood results will be taken out of next routine venipuncture. Routinely collected standard parameters are a blood count, chemistry panel including renal parameters and electrolytes, lipid profile and a HbA1c as well as albumin/creatinine and protein/creatinine ratio in urine.
46042289|NCT04690660|Other|Data collection for blood pressure (BP)|Clinic blood pressure and 24hour BP Measurements
46042290|NCT04690660|Other|Home-based blood pressure management (substudy)|Subjects participating in home-based blood pressure management via telemonitoring will receive a free HekaHealth application (App) for the structured assessment of HBPM.
46042291|NCT04690660|Other|Biomarker Profiles (substudy)|Substudy where possible cardiac, renal and pregnancy related biomarkers will be additionally analyzed. The following biomarkers will be analyzed: N terminal (NT)-proBNP, Troponin, elevated mid-regional pro-atrial natriuretic peptide (ANP), elevated mid-regional pro adrenomedullin (ADM), soluble fms-like tyrosine kinase (sFlt-1), and placenta growth factor (PlGF).
46042292|NCT04690660|Other|Data collection on patient reported outcomes|Data collection on patient reported outcomes (Questionnaire EQ-5D, Questionnaire for App based monitoring )
46042293|NCT00621010|Drug|CTS21166 (ZPQ-21166)|"Cohort 1: (7.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 2: (22.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 3: (45 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 4: (90 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 5: (150 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 6: (225 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days,proceed to Part B.~Cohort 7: (225 mg): Up to 10 subjects, open label, 3 hour infusion"
46042294|NCT00621088|Procedure|Intertan|Operations performed either with a Sliding Hip Screw or a nail (Intertan)
45345844|NCT00423319|Drug|Enoxaparin-matching placebo|Administered as injection
45684850|NCT02718118|Device|Dysport reconstituted at 2.5 mL (0.08 mL/injection)|Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
45345845|NCT00423319|Drug|Apixaban-matching placebo|Administered as oral tablets
45345846|NCT05224492|Drug|Sulforaphane|40 mg of Sulforaphane powder once daily.
45345847|NCT05224492|Other|Placebo|Placebo
45345848|NCT00733668|Drug|Quetiapine fumarate (Seroquel)|300 mg, PO, 100 mg morning, 200 mg evening, 4 weeks
45345849|NCT00879112|Drug|MB07811|Oral
45345850|NCT00879112|Drug|Placebo|Oral
45345851|NCT00736710|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
45345852|NCT00736710|Procedure|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
45345853|NCT04039126|Drug|CHEMICAL PLEURODESIS WITH POVIDONE-IODINE-TETRACYCLINE COMBINATION|Pleurodesis is the obliteration of the pleural cavity by inducing adhesions of the visceral and parietal pleural layers, mostly used in patients with pleural effusions, pneumothorax (18). The use of pleurodesis to induce pleural symphysis between the pleural layers dates backs to the beginning of the 20th century by Benthune(19) and has continued to evolve with different Thoracic surgeons and researchers still looking for the ideal pleurodesis agent.
45345854|NCT04039126|Drug|CHEMICAL PLEURODESIS WITH POVIDONE-IODINE ALONE|20mls of 10% povidone-iodine (Wosan Solution Povidone-Iodine Usp 10%, Jawa International Limited) is mixed with 10mls of 1% xylocaine and 30mls of water for injection added to the mixture, making also a total volume of 60mls of the the single pleurodesis agents alone, which will be instilled into the pleural space via the closed thoracotomy tube.
45345855|NCT00880126|Behavioral|Community Development Teams|CDTs bring together counties who are implementing a new practice
45345856|NCT00880204|Behavioral|ESS-EMCH training|"The trainings of the ESS-EMCH programme are based on two well-tried and tested structured training methodologies of Advanced Pediatric Life Support (APLS) and Management of Obstetric Emergencies and Trauma (MOET)."
45345857|NCT00873808|Drug|clodronate disodium|
45345858|NCT00873808|Drug|demeclocycline hydrochloride|
45345859|NCT00873808|Drug|ibandronate sodium|
45345860|NCT00873808|Drug|tetracycline hydrochloride|
45345861|NCT00873808|Drug|zoledronic acid|
45345862|NCT00873808|Other|laboratory biomarker analysis|
45345863|NCT00873808|Procedure|adjuvant therapy|
46042295|NCT04648540|Drug|Dexmedetomidine 0.5 mic/kg/h|"In Group I (OFA) the following drugs will be administered preoperatively:~Acetaminophen 1 gm and Ketorolac 30 mg in 100 mL i.v. over 10 minutes Dexmedetomidine loading dose of 0.5 mic/kg i.v. over 10 minutes Lidocaine loading dose of 1.5 mg/kg i.v. over 10 minutes~The following drugs will be administered as a continuous infusion throughout the operation:~Dexmedetomidine 0.5 mic/kg/h~Lidocaine 0.5 mg/kg/h~The following drugs will be administered postoperatively:~Acetaminophen 1 gm/6h ketorolac 30 mg/8h Pregabalin 150 mg once at night Celecoxib 200 mg/24 hours"
46042296|NCT04648540|Drug|Fentanyl 1 mic/kg/hr|In Group II (OA) patients will receive a continuous infusion of Fentanyl (1 mic/kg/h) Morphine 0.1 mg/kg PRN will be administered every 8 hours for postoperative analgesia
46042297|NCT04213222|Drug|Bevacizumab|bevacizumab combined with chemotherapy
45475056|NCT05239611|Drug|Exercise|The intervention for all participants will be delivered by two pulmonary rehabilitation coaches (PR-coach) including a registered respiratory therapist and clinical registered dietitian who've been trained in exercise training as recommended by the AACVPR and American College of Sports Medicine (ACSM). Each TR participant will be assigned a PR-coach, and receive one weekly exercise consulting session during the 12-week intervention.
45345864|NCT00873808|Procedure|computed tomography|
45345865|NCT00873808|Procedure|dual x-ray absorptiometry|
45345866|NCT04064190|Drug|Vactosertib(TEW-7197)/ Durvalumab|Vactosertib (PO) in combination with Durvalumab (IV) every 4 weeks
45345867|NCT00873886|Drug|Oseltamivir (Tamiflu)|"The following procedures will be performed on two occasions: once at least three days prior to the scheduled pregnancy termination procedure and again about eight weeks after the termination procedure.~A) Subject will take 75 mg of oseltamivir pill by mouth~B) Multiple blood draws (1 teaspoon each) over the next 48 hours after taking oseltamivir. Urine samples also will be collected."
45345868|NCT00873886|Procedure|Blood Draws|Two blood draws (1 teaspoon each) will be performed: once during third trimester of pregnancy and again about eight weeks after delivery.
45475057|NCT02518360|Other|Osteopathic|Body adjustment in three sessions (20 minutes/session).
45475058|NCT02518360|Other|Auto Stretching|The patients realize auto stretching in three sessions (20 minutes/session).
45475059|NCT03732079|Diagnostic Test|Ultrasound|Ultrasound to measure the IVC diameter. The IVC diameter will be measured in the inspirium and the expirium, and the collapsibility index will be recorded.
45475060|NCT03354442|Device|Modified Fixed Mandibular Retractor Appliance|All patients with Class III malocclusion will be treated using the Modified Fixed Mandibular Retractor Appliance
46042298|NCT04638478|Other|PRECODE-MRI|Patients with meningioma WHO I tumours treated with radiotherapy will be included, undergoing extensive cognitive testing combined with advanced brain MRI scans just before, 3 and 24 months after radiotherapy
45345869|NCT00736788|Drug|AZD1704|single dose oral suspension, 4 different dose levels
45345870|NCT00736788|Drug|Placebo|single dose oral suspension
45475061|NCT03638635|Drug|Bupivacaine|Abdominal injection of bupivacaine into fascial layer.
45475062|NCT03638635|Drug|Bupivacaine liposome|Abdominal injection of bupivacaine liposome into fascial layer.
45475063|NCT03854279|Device|tonsillar dissection|The tonsils will be removed by bizact device
45345871|NCT00740454|Other|Lower limb veins compression ultrasonography|Distal and proximal lower limb veins compression ultrasonography
45345872|NCT00880282|Biological|cixutumumab|Given IV
45345873|NCT00880282|Drug|temsirolimus|Given IV
45345874|NCT00880282|Other|pharmacological study|Correlative studies
45475064|NCT03204981|Device|Intramural Needle Ablation|The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.
45475065|NCT03204981|Procedure|Ablation|standard ablation
45345875|NCT00880282|Other|laboratory biomarker analysis|Correlative studies
45345876|NCT00740532|Genetic|Gene mutation analyses and FISH|FISH and mutation analyses of multiple genes
45345877|NCT00879268|Device|Vasosol Organ Perfusion Solution and Medtronic Portable Bypass System|Utilization of Vasosol with Medtronic System for Machine Preservation of the Liver for Liver Transplantation
45475066|NCT03354364|Dietary Supplement|Pea hull fiber|Snacks containing 15 g/day of ground pea hulls.
45475067|NCT03354364|Dietary Supplement|Control|Snacks without added fiber.
45345878|NCT05741268|Behavioral|Dialectical behavior therapy|14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in 14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in the following sequence 1. Mindfulness , 2. Emotion Regulation , 3. Distress Tolerance and 4. Interpersonal effectiveness.
45345879|NCT00879346|Drug|AZD8931|160mg oral single dose (4 x 40mg tablets)
45475068|NCT03354286|Behavioral|Developmental & Technological Demands|Education and training related to use of CGM in this age group
45475069|NCT03354286|Behavioral|Distress Reduction|Education and training on reducing distress
45345880|NCT00874042|Drug|Treatment with ARQ 197 in combination with gemcitabine|"Enrollment of an initial cohort of 3 or 6 patients will follow the traditional 3 + 3 dose escalation scheme. These patients will be treated with ARQ 197 and gemcitabine. ARQ 197 will be administered by mouth BID continuously. Gemcitabine will be administered by intravenous infusion over 30 minutes once weekly for 3 consecutive weeks followed by a week of rest."
45475070|NCT03354286|Behavioral|Nutrition, Set Point, & C:I Ratio|Education and training on how to use the HCL system to dose for different kinds of foods to improve glycemic control
45345881|NCT00736866|Drug|Acetylcysteine|Acetylcysteine: 1200 mg every 12 hours for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
45345882|NCT00736866|Drug|Placebo|Placebo of Acetylcysteine: every 12 hours PO, for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
45475071|NCT03354286|Behavioral|Hypoglycemia management|Education and training on reducing worries of hypoglycemia
45475072|NCT03354286|Behavioral|Minimal Intervention|Minimal intervention to simulate standard care - serves as the control group
45475073|NCT03205488|Drug|Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)|2 capsules taken once daily
45475074|NCT03205488|Drug|Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)|2 capsules taken once daily
45475075|NCT03205488|Drug|Placebo|2 capsules taken once daily
45475076|NCT01662609|Procedure|Endoscopic Ultrasound (EUS)|Ultrasound scope will be passed through the participant's mouth into their stomach and their pancreas will be evaluated completely by the ultrasound scope. If an abnormality is found in their pancreas, a biopsy may be performed to obtain a diagnosis.
45475077|NCT01587755|Other|TTOP|Patient is taken care of in an intensified, optimised manner
45345883|NCT00879424|Dietary Supplement|cholecalciferol (vitamin D)|"1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops."
45475078|NCT01587755|Other|non-TTOP|Standard medical care
45345884|NCT00879424|Dietary Supplement|Placebo|"1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops."
45345885|NCT05741112|Device|Wearable device|The treatment group will receive their wearable device and the enhanced education at the start of the study. Their outcomes will be compared with the control group who will receive at 3 months.
45345886|NCT00710684|Drug|SB-742457 15mg|SB-742457 - 15mg added to existing donepezil treatment
45345887|NCT00710684|Drug|SB-742457 35mg|SB-742457 - 35mg added to existing donepezil
45345888|NCT00710684|Drug|Placebo|Placebo added to existing donepezil
45345889|NCT00710684|Drug|donepezil 5-10mg|existing donepezil treatment
45475079|NCT02518516|Drug|Rosuvastatin (≥10 mg)|"Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed >120 days of the index date (i.e. no exposure within 120 days of the index date)."
45475080|NCT02518516|Drug|Atorvastatin (≥20 mg)|"Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
45345890|NCT00874198|Procedure|Ventriculo-peritoneal Shunt|Surgical implantation of a ventriculo-peritoneal cerebrospinal fluid shunt with an adjustable valve system using the Codman-Hakim programmable valve system [pressure settings: 30 - 200 mmH20]
45345891|NCT00740688|Procedure|Logan Basic Apex Contact|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
45345892|NCT00740688|Procedure|Sham Logan Basic apex contact|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
45345893|NCT00710606|Drug|NuvaRing|Obese subjects (BMI 30-39.9) will receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
45345894|NCT00710606|Drug|NuvaRing|Normal weight subjects will also receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
45345895|NCT00713544|Drug|AZD5672|20 mg oral, once daily
45345896|NCT00713544|Drug|Etanercept|50 mg, subcutaneous injection, weekly
45345897|NCT00713544|Drug|Placebo|placebo, oral, once daily
45345898|NCT00713544|Drug|AZD5672|50 mg oral, once daily
45345899|NCT00713544|Drug|AZD5672|100 mg oral, once daily
46042299|NCT00621166|Drug|generic lopinavir/ritonavir|"Patients will start with lopinavir/ritonavir new formulation 400/100 mg bid with a low fat diet plus 2 nucleoside reverse transcriptase inhibitors (NRTIs). The choice of the 2 NRTIs is at the discretion of the investigator, though in general the use of zidovudine+lamivudine (300/150mg Combivir®) is recommended. If patients can be included at or before gestational week 20, a 12h pharmacokinetic curve will be recorded at week 20 (± 2 weeks)(Group 1). There should be a minimum of 2 weeks between start of lopinavir and pharmacokinetic recording. If they are included after week 20, the first 12h pharmacokinetic curve will be recorded at gestational week 33 (± 2 weeks)(Group 2). For the patients in both groups a 12 hr curve will be recorded.~Subjects in Group 1 will be offered to conduct a second 12h pharmacokinetic curve at week 20 (± 2 weeks), but this is only optional. Both groups will be asked to participate in the post partum curve, again this is optional."
46042300|NCT04563832|Other|Standardized respiratory management program|Bronchial decluttering education, respiratory physiotherapy, specialized medical follow-up for 2 years
46042301|NCT04563832|Other|CoughAssist|self-administered mechanical in-exsufflation - CoughAssist (2 x 15 min per day, 5 days per week for 2 years)
46042302|NCT04555798|Drug|Meropenem Injection|patients of both groups given meropenam 1 gram every 8 hours till we collect the sputum culture
46042303|NCT04555798|Device|A-V ECMO|Only patients of group B connected to A-V ECMO for two weeks
45345900|NCT00713544|Drug|AZD5672|150 mg oral, once daily
46042304|NCT04549090|Drug|QL (quadratus lumborum) block administration|Fo the QL block group, they will be receiving bilateral QL block. A total of 40ml of 0.25% bupivacaine (Marcaine) and 10ml of liposomal bupivacaine (Exparel) will be administered
46042305|NCT00617812|Biological|Shan5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
46042306|NCT04515550|Diagnostic Test|lumbar puncture|Some participants will have an optional lumbar puncture
45345901|NCT05741450|Device|Monthly Replacement Spherical Silicone Hydrogel Contact Lens 1|Monthly Replacement Spherical Silicone Hydrogel Contact Lens 1 - first period of 15 minutes
45345902|NCT05741450|Device|Daily Disposable Spherical Silicone Hydrogel Contact Lens 2|Daily Disposable Spherical Silicone Hydrogel Contact Lens 2 - second period of 15 minutes
45345903|NCT00737126|Drug|Folic acid|Administration of a daily tablet containing 5 mg of folic acid for 4 months.
45345904|NCT00737126|Drug|Placebo|Administration of an oral placebo pill
45345905|NCT04063436|Device|New nasal pillows mask with PAP therapy|Participants will be placed in the experimental arm for 14±5 days, during which they will be using the new nasal pillows mask for PAP therapy.
45345906|NCT00740766|Behavioral|Food diary and behavioral model|"The monitored group is to be placed on a prenatal nutritional program consisting of 18 to 24 kcal. per kg. (according to the patient's actual weight) with monitoring each visit.~The patients will be weighed each prenatal visit with the monitored patients weighed and blinded to their actual weight (being weighed with her back to the scale). The monitored patients will be requested not to weigh at home and all patients will be asked to wear similar clothing at each visit.~All intervention (monitored) group women will be asked to record in a diary all of the foods eaten during each day. These records will be reviewed at each prenatal visit. Six weeks after delivery, the patient will be weighed and will then exit the study. The food diary notebooks will be collected from each patient at the end of the study."
45345907|NCT00415363|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression
45345908|NCT00415363|Drug|placebo|oral, daily
45345909|NCT04063046|Drug|General anesthesia|General anesthesia is induced with propofol (0.5-2mg / kg), remifentanil (4-8㎍ / kg / hr) and rocuronium (0.4 ~ 0.6 mg / kg) involving laryngeal mask(supraglottic airway device) insertion or endotracheal intubation. Anesthesia is maintained with 1.0-2.5% sevoflurane and remifentanil.
45345910|NCT04063046|Drug|Peripheral nerve block|ultrasound-guided popliteal sciatic nerve block is performed
45345911|NCT00740844|Device|Intermittent pneumatic compression of the lower limbs|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
45345912|NCT05529056|Drug|Atropine Sulfate 01|Atropine sulfate 01 ophthalmic solution
45345913|NCT05529056|Drug|Atropine Sulfate 02|Atropine sulfate 02 ophthalmic solution
45345914|NCT05529056|Drug|Atropine Sulfate 03|Atropine sulfate 03 ophthalmic solution
45345915|NCT05529056|Drug|Placebo|Placebo ophthalmic solution
46042307|NCT00617968|Drug|DOCETAXEL|
46042308|NCT00621400|Drug|Lenalidomide|5 mg/day, orally for 21 days with 7 days rest (28 day cycle) for the first cohort; or 10mg/day, orally for 21 days with 7 days rest (28 day cycle) for the second cohort, 15mg/day, orally for 21 days with 7 days rest (28 day cycle) for the third cohort or 20mg/day, orally for 21 days with 7 days rest (28 day cycle) for the last and fourth cohort
46042309|NCT00621400|Drug|Melphalan|0,18mg/Kg/day from day 1- 4
46042310|NCT00621400|Drug|Dexamethasone|40mg/day from day 1- 4.
45345916|NCT00740922|Drug|Sterile becaplermin gel vs. sterile placebo gel treatment 1|Becaplermin gel 100 µg/g versus placebo gel (up to 12 applications).
45345917|NCT05523440|Drug|Bevacizumab|Bevacizumab infusion.
45345918|NCT05523440|Drug|Niraparib|Niraparib oral capsule.
46042311|NCT04208932|Drug|SSRIs|Selective Serotonin Reuptake Inhibitors
45345919|NCT05740514|Behavioral|Exercise|Exercise training.
45345920|NCT05740514|Behavioral|De-training|Exercise de-training via unilateral knee immobilization.
45345921|NCT00741000|Procedure|Cervical Stairstep|Cervical low force mobilization procedure.
45345922|NCT05740436|Other|Geriatric rehabilitation program based on CGA|Geriatric rehabilitation program based on CGA will be performed under physicians tight control for 21 days and will include physical activity, psychological training, diet correction, adaptation measures, polypragmasia correction.
45345923|NCT00741078|Drug|statin, amlodipine|
45345924|NCT02568800|Drug|Prolonged Cefepime Infusion|Cefepime infusion should last at least 4 hours with the aide of an infusion bomb
45345925|NCT02568800|Drug|Usual Cefepime Infusion|Cefepime infusion occurs directly without the aide of an infusion bomb, lasting roughly thirty minutes
45345926|NCT00415051|Biological|RVF MP-12|Administer 1 ml SQ
45345927|NCT00741234|Drug|SB939|SB939 taken orally in a 4-week cycle.
45345928|NCT00741234|Drug|Azacitidine|Azacitidine taken orally with SB939 in a 4-week cycle
46042312|NCT02691364|Procedure|Blood withdrawal|
46042313|NCT04428190|Dietary Supplement|Human Milk Oligosaccharides (HMO)|Sachet containing 10 grams of HMO
46042314|NCT04428190|Other|Placebo|Sachet manufactured to mimic 10g of HMO
46042315|NCT04208854|Drug|Vinorelbine|"Vinorelbine 40 mg (2 cps of 20 mg) three times a week (Monday. Wednesday, Friday), for the first 2 weeks.~Starting from the third week, in the absence of any severe toxicity (≥ 3) and in the opinion of the clinician, the dosage can be increased to 50 mg (1 cps from 30 + 1 cps from 20 mg), three times a week ( Monday, Wednesday, Friday) continuously.~The dosage of 40 or 50 mg is continued until progression, patient refusal or unacceptable toxicity (in the clinician's opinion)."
46042316|NCT01090427|Drug|Ustekinumab - Half-Standard Dosage|Ustekinumab 0.375 mg/kg, 22.5 mg, or 45 mg based on body weight, administered subcutaneously (under the skin) at Weeks 0, 4, 16, 28, and 40.
46042317|NCT01090427|Drug|Ustekinumab - Standard Dosage|Ustekinumab 0.75 mg/kg, 45 mg, or 90 mg based on body weight administered subcutaneously at Weeks 0, 4, 16, 28, and 40.
45475081|NCT02518516|Drug|Simvastatin (≥40 mg)|"Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
46042318|NCT01090427|Other|Placebo|Placebo administered subcutaneously at Weeks 0 and 4 or at Week 12.
45345929|NCT00741312|Behavioral|Regular aerobic physical exercise|"Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.~The exercise-program follows the ACOG and ACSM exercise prescription. Aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate) measured by the 6-20 Borg's rating scale. Each session starts with a 5 minutes of warm up, followed by 30 minutes of aerobic activity, including 5 minutes cool down. This is followed by 15 minutes of circuit strength training of the upper limbs, lower limbs, and deep abdominal stabilization muscles. The last 5 minutes consists of stretching and relaxation exercises."
45840894|NCT00934596|Procedure|Lund de-airing technique|In these patients the pleura will be opened on both sides and the ventilator will be disconnected before aorta is cross-clamped and cardioplegia administered. At the conclusion of the surgical procedure, the LV preload will first now be successively increased. When no air is seen on TEE monitoring in the left heart (LA, LV & Aorta), half the calculated minute ventilation with 100% oxygen and a PEEP of 5 cm H2O will be started. Deairing will be continued and when the TEE shows no or minimal air in left heart, full ventilation with unchanged PEEP will be restored. The patient will be weaned successively from the CPB. When TEE will show no air in the left heart, the de-airing will be considered complete.
46042319|NCT04208776|Drug|Propranolol|maximum tolerated dose of propranolol with initial dosage of 20mg once a day and uptitrating every 2nd day by 20 mg.
46042320|NCT04208776|Drug|Midodrine|It will be started at 2.5mg TDS and will be uptitrated every 2nd day to a max of 10mg TDS to attain a MAP of atleast 70mm Hg and then uptitate the beta blocker simulataneously to attain the target heart rate
46042321|NCT04379752|Device|Cold-atmospeheric pressure plasma activated aqueous-alcohol solution treatment|Cold plasma is generated and applied to carrier liquid. Subjects are provided with the liquid to apply to the treated area
45345930|NCT00741312|Behavioral|Activities of daily living|Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist.
45345931|NCT02568228|Dietary Supplement|Krill oil|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
45345932|NCT02568228|Other|Lean and fatty fish|The fish group will be open labeled.
45840895|NCT00934596|Drug|carbon-dioxide insufflation|In these patients (n=10) the pleurae will not be opened. During aortic cross-clamp period the ventilator will be adjusted to provide dead space ventilation only i.e. 5cm PEEP, ventilator frequency 5/min and the minute ventilation = 1,5 liter. Fio2 = 50%. The operating field will be insufflated with Co2 at a flow rate of 10 L / minute starting 2 minutes before cardiac cannulation and continued until 10 minutes after termination of the CPB.At the end of the cardioplegic arrest, the de-airing procedure is similar to that in the Lund de-airing group.
45345933|NCT02568228|Dietary Supplement|Placebo capsules|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
45345934|NCT02568306|Drug|NNC0165-1562|Administered subcutaneously (s.c., under the skin) single dose [SD] or multiple dose [MD] with daily dosing.
46042322|NCT04324762|Behavioral|targetted implementation strategies|strategies at the individual and institutional level to promote implementation of an evidenced based innovation and de-implementation of an unnecessary, low value diagnostic test.
46042323|NCT02879435|Drug|Bupivacaine|pre-operative wound infiltration with 10 ml of numbing medicine
45684851|NCT01893580|Behavioral|Experimental: 1. Experimental|"Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:~Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.~Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
45840896|NCT00935064|Drug|Aliskiren|Pill, 300 mg, once daily, for 6 weeks
46042324|NCT02879435|Other|Placebo|pre-operative wound infiltration with 10 ml of sterile water
46042325|NCT05662774|Diagnostic Test|Ultrasound contrast agent (Sonovue)|Patients are diagnosed by intravenous injection of ultrasound contrast on the first day of admission and information is collected by diagnostic ultrasound instruments
46042326|NCT02879513|Drug|Paclitaxel|
46042327|NCT02879513|Drug|Cisplatin|
46042328|NCT02879513|Drug|Epirubicin|
46042329|NCT02879513|Drug|Cyclophosphamide|
46042330|NCT02879513|Drug|5-fluoruracil|
46042331|NCT04874207|Drug|Regorafenib|Dose adaptation at the beginning of cycle 2 and cycle 3 after regorafenib dosage at day 15
46042332|NCT00621478|Drug|lorazepam or diazepam|"Administration instructions will ask to deliver 0.04 ml per kilogram of child's weight of the study medication up to a maximum of 1.6 ml. 0.04 ml/kg (maximum dose 1.6 ml) will deliver 0.1 mg/kg of lorazepam (maximum dose 4 mg) and 0.2 mg/kg of diazepam (maximum dose 8 mg). Half of this dose can be repeated in 5 minutes if the patient is still convulsing.~The medication will be administered as a slow IV push."
46042333|NCT00621556|Drug|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
46042334|NCT04872413|Procedure|Biospecimen Collection|Undergo blood, saliva or tissue sample collection
46042335|NCT04872413|Other|Follow-Up|Undergo follow-up
46042336|NCT00618046|Drug|Oxcarbazepine|
46042337|NCT04308551|Drug|Indobufen|Indobufen Tablets
46042338|NCT04308551|Drug|Aspirin|Aspirin Tablets
45840897|NCT00935064|Other|Placebo|Placebo orally one tablet once a day for 6 weeks.
46042339|NCT04209010|Procedure|one-stage technique|breast reconstruction in one stage using silicone implant and acellular dermal matrix.
46042340|NCT04306991|Device|Auscultation using an electronic stethoscope (EKO CORE 4)|"Auscultation using an electronic stethoscope (EKO CORE 4). Record of at least 3 cardiac cycles.~Measurement of cardiac output using echocardiography."
46042341|NCT04212988|Procedure|Increase the SCO2 value|The interwention process will be started once the SCO2 value below ideal levels (80% of the basic level or 50% of absolute value), by adjusting the position of extracorporeal circulation arteriovenous catheter, balancing arterial pressure, increasing oxygen supply , adjusting pump speed ,etc.
46042342|NCT04306913|Drug|Esmolol|esmolol 250 mg in cardioplegia solution every 25 minutes
46042343|NCT04306913|Drug|Potassium Cardioplegic Solution|15 meq potassium added to cardioplegia solution
46042344|NCT02299414|Drug|Anti-hypertensive therapy|1st line anti-hypertensive (Labetalol or Nifedipine ER) started; escalate to maximum dose and a preferred 2nd line medication if needed (nifedipine ER or Labetalol)
45345935|NCT02568306|Drug|placebo|Administered subcutaneously (s.c., under the skin) single dose [SD]) or multiple dose [MD] with daily dosing.
45345936|NCT00713258|Drug|Parathyroid hormone (PTH) (1-84)|100 µg PTH(1-84) daily
45345937|NCT00713258|Drug|Alendronate|70 mg alendronate weekly
45345938|NCT00710034|Other|Oral tobacco|Snus
45345939|NCT00710034|Drug|Nicotine Gum|4 mg Nicotine gum
45345940|NCT02567942|Drug|propofol group|Patient will be anesthetized by using propofol infusion during operation
45345941|NCT02567942|Drug|sevoflurane group|Patient will be anesthetized by using sevoflurane inhalation during operation
46042345|NCT02299414|Other|No anti-hypertensive therapy (unless BP is severe)|Treatment will not be started if blood pressure remains <160/105; for blood pressure ≥160/105, treatment with labetalol or Nifedipine ER will be initiated and maintained at lowest dose needed to keep blood pressure under 160/105.
46042346|NCT02877875|Behavioral|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC (Chorpita & Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with Attention-deficit/hyperactivity disorder (ADHD). MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
45345942|NCT00414973|Drug|Teriparatide|Subcutaneous, 20 micrograms/day, 24 weeks
45345943|NCT00414973|Drug|Salmon Calcitonin|Intranasal, 200 International Units (IU)/day, 24 weeks
45345944|NCT00423085|Drug|Rivastigmine transdermal patch|"Rivastigmine transdermal patch was provided in the following sizes and doses:~2.5 cm^2 (4.5 mg), 5 cm^2 (9 mg), 7.5 cm^2 (13.5 mg), and 10 cm^2 (18 mg). The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day."
45345945|NCT00423085|Drug|Placebo|Placebo transdermal patch was provided in the following sizes: 2.5 cm^2, 5 cm^2, 7.5 cm^2 and 10 cm^2. The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.
45345946|NCT00414661|Drug|CP-690,550|Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
45345947|NCT01608451|Drug|Cholecalciferol|Inj Arachitol 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
45345948|NCT01608451|Drug|Inj. Progesterone|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
45345949|NCT00405067|Drug|BMS-201038 (AEGR-733)|
45345950|NCT00405067|Drug|Ezetimibe|
45345951|NCT00708708|Drug|etanercept (Enbrel®)|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
45345952|NCT00404755|Drug|escitalopram|Escitalopram: wk 1: 10 mg/d; wks 2-3: 20 mg/d; wk4: 30 mg/d; wks 5-6: 40 mg/d
45345953|NCT00404755|Drug|bupropion|bupropion XL 150 mg/d increasing as tolerated and not remitted by 150 mg/d to maximal dose of 450 mg/d
45345954|NCT00404755|Drug|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then 50 mg increase/week to 300 mg/d; all dose increases if tolerated and not remitted
45345955|NCT03742453|Diagnostic Test|contrast-enhanced ultrasound|CEUS is performed using SonoVue (Bracco, Milan, Italy) intravenous administration in eligible participants within a month before/after EOB-MRI.
45840898|NCT00935766|Drug|Omega-3|Subjects meeting eligibility criteria will be randomized to receive a supply of omega-3-acid ethyl esters or placebo, and instructed to take 4 capsules daily. A 3-month supply of study drug will be given following randomization and at 3, 6, and 9 months. Subjects will be asked to bring unused supplies to each quarterly visit for ascertainment of adherence.
45840899|NCT00935766|Drug|Placebo|
45345956|NCT03742453|Diagnostic Test|EOB-MRI|EOB-MRI is performed using standard dose of hepatocyte specific contrast media (primovist or eovist) according to standard protocol of our institution.
45345957|NCT03904381|Drug|5-fluorouracil|5-fluorouracil subconjunctival injections were a first-choice therapy for bleb failure and were administered according to predetermined criteria.
45345958|NCT03904381|Procedure|Transconjunctival needling|Transconjunctival needling was administered according to predetermined criteria.
45345959|NCT03904381|Procedure|Transconjunctival revision|Transconjunctival revision was administered according to predetermined criteria.
45345960|NCT02568150|Biological|Single group, open-label|
45345961|NCT01535911|Other|Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)|Adult subjects with newly diagnosed glioblastoma will be referred to the study. Residual tumor size will be determined using MRI imaging. Subjects will be placed on ERKD while they are being treated with radiation therapy and standard of care chemotherapy. After completion of radiation therapy, tumor size will be determined using MRI. If the tumor has decreased in size or remained the same (stable disease), the subjects will be continued on the ERKD for an additional 6 weeks. Total calories consumed by each subject will be targeted to 20 to 25 kcal/kg/day. If the tumor has decreased in size or the size has remained the same then subjects will be continued on the ERKD for as additional 6 weeks and a repeat MRI will be obtained.
45345962|NCT00737256|Drug|Aripiprazole|15-30 mg
45345963|NCT00737256|Drug|Perphenazine|8-16 mg
45345964|NCT00614614|Biological|GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)|One dose in the booster phase as intramuscular injection
46042347|NCT02877875|Other|Monitoring and Feedback System|For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Feelings Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.
46042348|NCT02877875|Behavioral|Treatment as usual|Treatment in the UC condition will use the procedures therapists (e.g., school counselors) and their supervisors consider appropriate and believe to be effective.
46042349|NCT04309097|Behavioral|Digital intervention|"REAP is a live-streaming platform that allows users to shoot short videos or photos related to their physical exercise or eye relaxation (e.g., staring out of the window) using their smartphones. The app has been optimised to be used with the iPhone or Android.~When taking a online course recess, students will have access to the REAP platform that allows them to watch stay-at-home workout videos developed by exercise physiologists. Students will then be asked to create their own workout videos/photos and upload them to the live-streaming platform. When upload is completed, students will receive instant motivational messages to increase their engagement with the program."
46042350|NCT04309097|Behavioral|Information-only intervention|Participants will have access to online health information and stay-at-home workout videos.
46042351|NCT04115488|Biological|Intravenous (IV) infusions|Intravenous (IV) infusions of a dose of 300mg, every 4 weeks with a total of 12 doses
45345965|NCT00614614|Biological|GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)|Three doses in the priming phase and, for Menhibrix 2 Group, one dose in the booster phase as intramuscular injection
45345966|NCT00614614|Biological|Infanrix®|One dose as intramuscular injection
45345967|NCT00614614|Biological|ActHIB®|Three doses in the priming phase as intramuscular injection
45345968|NCT00614614|Biological|Pediarix®|Three doses in the priming phase as intramuscular injection
45345969|NCT00713310|Drug|Asacol 400 mg|"High dose:~17-<33 kg = 3 Asacol 400mg in morning and 2 Asacol 400 in PM, 33-<54 kg = 5 Asacol 400mg in morning and 4 Asacol 400 in PM, 54-<90 kg = 6 Asacol 400mg in morning and 6 Asacol 400 in PM"
45345970|NCT00713310|Drug|Asacol 400 mg|"Low dose:~17-<33 kg = 2 Asacol 400mg + 1 placebo in morning and 1 Asacol 400 +1 placebo in PM, 33-<54 kg = 3 Asacol 400mg +2 placebo in morning and 2 Asacol 400 + 2 placebo in PM, 54-<90 kg = 3 Asacol 400mg + 3 placebo in morning and 3 Asacol 400mg + 3 placebo in PM"
45345971|NCT00737334|Device|EEGo, BIS, FORE-SIGHT cerebral oximeter|"The EEGo monitor, BIS monitor, and FORE-SIGHT cerebral oximeter will be used for cerebral monitoring of all patients. A comparison of the three monitors will be done. For EEGo monitoring, five bipolar electrodes will be placed per International 1020 system. For BIS monitoring, the BIS quattro sensor will be placed on the forehead in usual fashion. For FORE-SIGHT monitoring, the two sensor strips will be placed on the forehead in usual fashion.~All patients will have their ipsilateral Internal Jugular vein cannulated by the surgeon intraoperatively with a 16g IV cannula, through which a Portex multi-orifice epidural catheter will then be placed."
45345972|NCT05740488|Drug|Apalutamide|240mg, po, qd
45345973|NCT05740488|Drug|89Sr|100~150MBq(based on weight), iv, q90d
46042352|NCT01016262|Drug|MAX-002|MAX-002 suppository 1 gram (g) rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the open-label (OL) phase.
45345974|NCT05740488|Drug|Luteinizing Hormone-Releasing Hormone Analog|sc, 3.6mg, q30d or 10.8mg, q90d
45840900|NCT00937794|Behavioral|Neurobehavioral testing|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to assess his neurodevelopmental status using a standardized battery of neurobehavioral testing.
46042353|NCT01016262|Drug|Placebo|Matching placebo suppository rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
46042354|NCT01016262|Drug|Canasa®|Canasa® suppository 1 g rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
46042355|NCT00625937|Drug|cisplatin|
46042356|NCT00625937|Drug|docetaxel|
45345975|NCT05740410|Device|ClotTriever Catheter|Treatment of iliofemoral deep vein thrombosis with the ClotTriever catheter
45345976|NCT00874354|Drug|Intracoronary Transplantation of Bone Marrow Stem Cells|Intracoronary application of autologous bone marrow-derived mononuclear cells in infarct artery 3 - 14 days after PCI for acute myocardial infarction.
45345977|NCT05742126|Drug|HSK36273|Multiple continuous IV infusion ascending doses for 5 days
45345978|NCT05742126|Drug|Placebo|Matching placebo
45345979|NCT05742126|Drug|Heparin sodium injection|Matching positive control
46042357|NCT00625937|Drug|tegafur-gimeracil-oteracil potassium|
46042358|NCT00625937|Radiation|radiation therapy|
46042359|NCT00621634|Dietary Supplement|Omega-3 fish oil capsules (including DHA)|Fish oil capsules of 1000 mg ea., including DHA 460-540 mg/capsule 2 capsules TID daily at mealtime for 12 consecutive weeks
45840901|NCT00937794|Other|Visual and auditory assessments|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to evaluate his visual and auditory function.
45345980|NCT00737412|Other|Probiotic: Bio-K+ CL1285|The probiotic Bio-K+ CL1285 RX®, a mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
45345981|NCT00737412|Other|Placebo|Matching capsules devoid of microorganisms
45345982|NCT00882856|Drug|Bisoprolol|"Bisoprolol Vitabalnas 10 mg once daily"
45345983|NCT00882856|Drug|Placebo|placebo
45345984|NCT02568462|Device|AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
45345985|NCT00882934|Other|Induction to efficient treatment|Informative letters.
45345986|NCT00882934|Other|Doubt to the efficacy of treatment|Informative letters.
45345987|NCT00882934|Other|Induction to ineffective treatment|Informative letters
45345988|NCT00874588|Biological|HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 1.0mg and 3.0mg.
46042360|NCT00621634|Dietary Supplement|Placebo|Corn/Soybean (1:1) placebo 1000 mg capsules 2 capsules TID daily at mealtime for 12 consecutive weeks
46042361|NCT04870853|Other|Electronic Health Record Review|Medical records reviewed
46042362|NCT05662696|Other|Raabta Telemonitoring Program (Mobile Application)|Raabta is a smartphone application that will allow pregnant women at high-risk for preeclampsia to measure and record daily blood pressure readings and self-reported symptoms. An algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated alert self-care message based on their measurements and reported symptoms.
45345989|NCT04064658|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
46042363|NCT01001910|Drug|Carboplatin|Given IV
46042364|NCT01001910|Other|Laboratory Biomarker Analysis|Correlative studies
46042365|NCT01001910|Drug|Pemetrexed Disodium|Given IV
45345990|NCT04064658|Procedure|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
45345991|NCT04064658|Procedure|Encephaloduroarteriosynangiosis|Encephaloduroarteriosynangiosis is an indirect revascularization surgery of moyamoya disease
45345992|NCT00883012|Biological|Trivalent sub-unit influenza vaccine|"Composition per 0.5 ml dose:~Active substance:~Split Influenza virus*, inactivated Strains for 2009 Southern hemisphere A/Brisbane/59/2007- like (H1N1) 15 micrograms**, A/Brisbane/10/2007 (H3N2) - like strain (A/Brisbane/10/2007 (IVR-147) 15 micrograms**, B/Florida/4/2006 - like strain (B/Brisbane/3/2007)15 micrograms** Two doses, one month apart"
45345993|NCT00883012|Biological|Saline, 0.5ml|Saline IMI, 0.5ml. Two doses one month apart
45345994|NCT00737490|Other|"Sequential Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)"|"Echocardiographically guided optimized device programming: specifically sequential BiV pacing. Sequential Arm~Using one of the FDA approved St. Jude devices, depending on MD preference."
45840902|NCT00939120|Drug|Tolterodine ER 4mg|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4 mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
46042366|NCT04308629|Other|Transcranial direct current stimulation|
46042367|NCT00621712|Device|GamCath® central venous catheter|choice of catheter type
46042368|NCT00621712|Device|GamCath Dolphin® Protect central venous catheter|choice of catheter type
45345995|NCT00737490|Other|"Simultaneous Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)"|"simultaneous BiV pacing.~Using one of the FDA approved St. Jude devices, depending on MD preference."
45345996|NCT00737646|Behavioral|Usual care|No intervention will be conducted in this arm of the study.
45345997|NCT00737646|Behavioral|Clinic-focused intervention|The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff. The provider training sessions will include the presentation of CRC screening statistics and information, and will be heavily interactive and skills-based. The provider training sessions will also focus on the provision of tools for improving clinical staff- and clinician-patient interactions about CRC screening and for office system changes/improvements to identify eligible patients and to track screening.
46042369|NCT04308317|Drug|Tetrandrine|Tetrandrine 60mg QD for 1week
46042370|NCT04212208|Device|IV cannulation|IV cannulation in the preoperative period
46042371|NCT04212130|Other|BCA method for assessing environmental cleanliness|"Evaluating the effectiveness and usability of BCA method which is a new approach in evaluating the effectiveness of environmental cleanliness in intensive care units.~In this study, fluorecan labeling, microbiological sampling and BCA methods will be compared in order to evaluate the effectiveness and usability of BCA method"
46042372|NCT01009554|Device|Potassium Oxylate Mouthwash|Rinse with 10 mL for 60 seconds, twice daily after brushing in usual manner with a sodium fluoride dentifrice
46042373|NCT01009554|Drug|Sodium Fluoride Dentifrice|Brush in usual manner, twice daily, with a sodium fluoride dentifrice
46042374|NCT04211896|Drug|Anlotinib|Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.
46042375|NCT04211896|Drug|Nivolumab|Nivolumab will be given at a dose of 240 mg every 2 weeks (Odd Cycles: Days 1 and 15 and Even Cycles Day 8) per 21 day Cycle.
46042376|NCT02012374|Behavioral|Intensive Language Action Therapy|
46042377|NCT04188184|Drug|Tranexamic Acid|received topical 1 gram of TXA diluted in 200 ml of normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
46042378|NCT04188184|Drug|Epinephrine|received Epinephrine 1 mg diluted in 200 ml normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
46042379|NCT04044040|Behavioral|Symptom screening with Targeted Early Palliative care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
45345998|NCT00737646|Behavioral|Clinic- and patient-focused|This arm will combine the clinic-focused intervention and the patient-focused intervention. The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff as described in Arm 2. The patient-focused intervention includes sending a CRC screening education packet (CDC-developed educational text tailored for use within the study sites), accompanied by a letter from the patient's physician, to patients meeting study inclusion criteria.
45345999|NCT00880672|Drug|dutasteride|5mg, oral, daily, 2-4 weeks
45346000|NCT04064034|Other|Lateral Flow Assay (LFA)|Test to detect the Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein
45346001|NCT00874666|Other|crushed garlic clove|1 gram crushed garlic in gelatin capsules, one dose once every 2-16 weeks
45346002|NCT00874666|Dietary Supplement|garlic powder tablet|tablets, dose to contain 1 gram of garlic powder, consume one dose once every two weeks for up to 52 weeks
45346003|NCT03900546|Device|MostCare|CO measurement using echocardiography and PRAM before and after noradrenaline dose change due to clinical reason
45346004|NCT00737724|Drug|Simultaneous ARV and antiMTB|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
45346005|NCT00737724|Drug|Deferred RV and antiMTB treatment|Receives only antituberculosis therapy and 2 months afterwards antiretroviral therapy
45346006|NCT00880828|Other|FIR cervical collar with Acetaminophen|FIR cervical collar with Acetaminophen QID/PRN for 4 weeks
45346007|NCT00880828|Other|Conservative cervical collar with Acetaminophen|Conservative cervical collar with Acetaminophen QID/PRN for 4 weeks
45346008|NCT00880828|Drug|Acetaminophen only|Acetaminophen QID/PRN for 4 weeks
45346009|NCT04440202|Behavioral|Conventional sea bream|Participants initially randomized to this intervention arm will be provided with a total of 8 conventional sea bream fillets and will be asked to consume them twice weekly for 1 month. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 1-month wash-out period (no fish consumption), participants will cross over to the other intervention arm.
45346010|NCT04440202|Behavioral|Enriched sea bream|Participants initially randomized to this intervention arm will be provided with a total of 8 enriched sea bream fillets and will be asked to consume them twice weekly for 1 month. Enriched sea bream fillets will be produced by a fish farming company from fish bread with a diet enriched with a fraction of bioactive polar lipids extracted from olive oil by-products. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 1-month wash-out period (no fish consumption), participants will cross over to the other intervention arm.
46042380|NCT04472442|Procedure|Intermittent hypoxia|"Acute intermittent treatment (AIH) will be initiated using an oxygen generator (Model HYP-123, Hypoxico Inc, New York, NY, and participants will be seated comfortably and fitted with a non-rebreather mask. AIH (using 9% O2) will be provided in 60 s intervals and repeated 15 times with alternating 60 s intervals of normoxia (21% O2). Continuous pulse oximetry (Masimo 7, Irvine CA) will be monitored to ensure oxygen saturation of 82-85%. Signs and symptoms of distress with AIH exposure will be noted throughout, with HR and blood pressure taken every 3-5 minutes and documented.~High-intensity training will then be performed (40 min of walking training up to 70-80% maximum heart rate within 1 hr)."
46042381|NCT04472442|Procedure|Sham hypoxia|"Sham acute intermittent treatment (sham AIH) will be initiated using an oxygen generator (Model HYP-123, Hypoxico Inc, New York, NY, and participants will be seated comfortably and fitted with a non-rebreather mask. Sham AIH (using 20% O2) will be provided in 60 s intervals and repeated 15 times with alternating 60 s intervals of normoxia (21% O2). Continuous pulse oximetry (Masimo 7, Irvine CA) will be monitored to ensure oxygen saturation of 82-85%. Signs and symptoms of distress with AIH exposure will be noted throughout, with HR and blood pressure taken every 3-5 minutes and documented.~High-intensity training will then be performed (40 min of walking training up to 70-80% maximum heart rate within 1 hr)."
45346011|NCT05741970|Procedure|Scaling and root planing|Each tooth with inflammation symptoms was cleaned with scalers, curettes and ultrasonic devices routinely.
45346012|NCT00883402|Procedure|CEA, CAS|Carotid Artery Stenting (CAS) Carotid endarterectomy (CEA)
45346013|NCT00422461|Drug|placebo|placebo, oral, tablets, once daily, for 28 days
45346014|NCT00422461|Drug|PF-00489791|PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days
45346015|NCT00422461|Drug|PF-00489791|PF-00489791 4 mg, oral, tablets, once daily, for 28 days
45346016|NCT00422461|Drug|PF-00489791|PF-00489791 10 mg, oral, tablets, once daily, for 28 days
45346017|NCT04346134|Procedure|mini-PNL|Percutaneous nephrolithotomy using miniature nephroscope. The procedure will be performed under general or spinal anesthesia under fluoroscopy guidance.
46042382|NCT04016662|Device|Tandom t:slim X2 with HCL or PLGS|"The system components include the t:slim X2 with Control-IQ Technology and the Dexcom CGM G6. The modular control algorithm has a safety supervision module that limits insulin delivery to prevent hypoglycemia at all times. The algorithm gradually decreases hyperglycemia from bedtime to reach a target of 120 mg/dL by waking time. During awake hours, the control algorithm attempts to maintain glucose within a target range (112.5 to 160 mg/dL) with meal time insulin boluses delivered based on usual bolus procedures undertaken by patients on an insulin pump (Hybrid closed loop).~The system components include the t:slim X2 with with Basal-IQ Technology and the Dexcom CGM G6. The PLGS System is able to stop and resume basal insulin delivery automatically in response to predicted or low sensor glucose values, thereby reducing the incidence and duration of hypoglycemic episodes. The pump includes the hypoglycemia minimization strategy that will issue insulin delivery commands."
46042383|NCT04495218|Biological|Blood samples|Performed a 10 ml blood sample (2 unnamed samples of 5ml) in each of the 100 patients included.
45346018|NCT04346134|Procedure|SWL|Extracorporal shockwave lithotripsy using Dornier SII lithotripter. the procedure will be performed under sedoanalgesia, and fluoroscopy will be used for stone localization; for a maximum of 3 SWL session.
45840903|NCT00939120|Drug|Placebo|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
45346019|NCT00712920|Drug|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 1644 mcg
45346020|NCT00712920|Drug|0.1% azelastine hydrochloride|0.1% azelastine hydrochloride 1096 mcg
45346021|NCT00712920|Drug|Placebo|Placebo
45346022|NCT01037647|Other|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp, duration 5 hours, plasma glucose 5 mmol/l, insulin dosage 1,0 mU•kg FFM/min, human insulin (Actrapid; Novo Nordisk A/S).
45346023|NCT00874744|Drug|Bevacizumab|1.25mg bevacizumab (0.05ml)
45346024|NCT00874744|Drug|Triamcinolone acetonide|4.0 mg Triamcinolone acetonide injection
45346025|NCT03993769|Other|A19010-F|A snus product
45346026|NCT03993769|Other|B19010-F|A snus product
45346027|NCT04038658|Behavioral|Move-It|
45346028|NCT05736744|Drug|MgSO4|The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.
45346029|NCT05736744|Drug|Rocuronium Bromide|Rocuronium will be administered for intubation at a dose of 0.45-0.6 mg/kg IV and Maintenance at a dose of 0.1-0.2 mg/kg IV on fixed interval
45346030|NCT05736744|Drug|Cis-Atracurium|Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals.
45346031|NCT04270084|Behavioral|Alive-Family|All participants receive lifestyle modification through use of m-health app
45346032|NCT00920868|Drug|dasatinib|dasatinib at 50 mg PO BID)
45346033|NCT00920868|Drug|bevacizumab|7.5 mg/kg IV day 1
45346034|NCT00920868|Drug|Oxaliplatin|130 mg/m2 IV day 1
45346035|NCT00920868|Drug|Capecitabine|850 mg/m2 PO BID on days 1-14
45346036|NCT00880984|Device|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
45346037|NCT00874900|Other|Educational game|"Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to the game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department."
45346038|NCT00874900|Other|Educational game + motivational interview|"Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to this game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department (ED).Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques."
45346039|NCT00874900|Other|Motivational interview|Participant randomized to this group will receive standard care for the treatment of their asthma, including an education asthma booklet developed by Seattle Children's. Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques.
45346040|NCT00881062|Drug|Proellex|A single oral dose administered after at least a 10 hour fast
45346041|NCT05741814|Drug|Propofol|Gynecologist guided individualised propofol only sedation
45346042|NCT04721626|Drug|Chlorhexidine Gluconate|"Preoperative: The patient's dentition, or mandibular alveolus in the absence of dentition, will be brushed for two minutes with 0.12% chlorhexidine gluconate.~Intraoperative: The wound will be irrigated for 60 seconds with 0.05% chlorhexidine after it is irrigated with povidone-iodine.~Postoperative: Patients will swish and spit/suction 15mL 0.12% Chlorhexidine Gluconate (CHG) oral rinses for 30 seconds every six hours for two days (8 total administrations)"
45346043|NCT04721626|Drug|Povidone-iodine|"Preoperative: The oral cavity and oropharyngeal mucosa as well as the nasal vestibules will be coated with 5% povidone-iodine which will stand for at least three minutes prior to incision.~Intraoperative: The wound will be irrigated for 60 seconds with 10% povidone-iodine."
45346044|NCT04721626|Drug|Tetracycline Ointment|Postoperative: ~10g 3% tetracycline ointment will be placed into the oral cavity to coat the dorsal tongue and any oral suture lines every six hours for two days (8 total doses).
45346045|NCT04064892|Behavioral|Exercise Intervention|The intervention will use peer mentors, motivational interviewing, and technology (Fitbit, Fitbit Coach App, & Fitbit message board) to support behavior change. All participants will receive phone or video calls from their peer mentors every other week, and interact with their peer mentor and other participants through a private Fitbit message board at least weekly. Peer mentors will use Fitbit data to identify participants who need additional support to increase their activity.
45346046|NCT00881140|Drug|mifepristone vaginal tablets|Daily use of 10 mg administrated per vagina for 3 months
45346047|NCT05741736|Behavioral|five-days small group-based lifestyle modification program|healthy lifestyle, based on the promotion of a particular dietary pattern, regular physical activity, psychological support, education, and small group intervention results in weight loss
45840904|NCT00939120|Drug|Pre-randomization Dutasteride|All participants were on Dutasteride 0.5mg orally once daily prior to randomization.
45346048|NCT00883636|Other|Cardiovascular Assessment|Measure of BNP, and Pro-BNP Complete 2 Dimensional Echocardiogram with Doppler evaluation including determination of, Left Ventricular mass, Ejection fraction, Midwall fractional shortening, velocity of early and late diastolic transmitral flow, and measurement of E/A ratio, Ratio of end-systolic wall stress to rate corrected velocity of circumferential fiber shortening.
45475082|NCT02518516|Drug|Fluvastatin|"Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
45346049|NCT00883636|Other|Renal Assessment|Complete a metabolic panel, CMP. Calculation of glomerular filtration rate, GFR, measure of urinary total protein, albumin and creatinine excretion in a first morning urine sample, 24 hour blood pressure monitoring,
45346050|NCT00883636|Other|Genetic Evaluation|All patients will undergo genetic screening for all known podocyte gene mutations.
45475083|NCT02518516|Drug|Pravastatin|"Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to pravastatin will be defined as a prescription for any dose of pravastatin (ATC C10AA03) dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
45840905|NCT00939198|Biological|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
45475084|NCT02518516|Drug|Lovastatin|"Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to lovastatin will be defined as a prescription for any dose of lovastatin (ATC C10AA02) dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
45840906|NCT00939900|Drug|zoledronic acid (aclasta)|Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period
45346051|NCT05733702|Other|All participants will be asked to provide data and samples for collection and analysis.|During the first year from the date of inclusion, data related to demographics, lifestyle, laboratory and physical examinations will be collected at baseline, at 3 months, and at 12 months. Patient-Reported Outcomes (PROs) with voice recordings will be collected at different time points in-between clinical visits using the Colive application. Participants will be asked to provide biological samples (i.e., blood, dried blood spots and stool are mandatory; saliva, urine and hair are optional), tissue samples from endoscopic biopsy and imaging data (if performed as per standard of care) at three timepoints (baseline; 3 months; 12 months). One unscheduled visit may be included in the study in case of occurrence of flare or treatment change.A long-term follow-up (starting from month 12 and up to 4 years after month 12) will include the collection of medical data on a yearly basis, collection of PROs with voice recording every 6 months and continuous collection of data using the smartwatch.
45346052|NCT00883714|Other|Supervised exercise|The patients will carry out a daily exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The patients will be supervised by medical personnel.
45840907|NCT00940290|Other|Graded Clinical Recommendation|Graded recommendation in reference to a clinical condition written as it would be in a clinical practice guideline
45840908|NCT00940446|Device|Insorb staples|absorbable staples required for wound closure
45840909|NCT00940446|Device|metal staples (Ethicon metal stapler)|wound closure with metal staples
45840910|NCT00943098|Drug|Diclofenac HPBCD s.c. 75mg/ml|1 single injection at day of dental surgical extraction
45346053|NCT00883714|Other|Exercise Instruction|The patients will receive instructions about exercise and will have access to a bike ergometer to work out. However, they will not receive daily supervision or participate in a structured exercise program.
45346054|NCT05733078|Drug|Vitamin C|The patient in test group will be provided vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The patients who wish to continue at the end of 12 weeks will be provided another 12 weeks supply of vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for with thyroid function tests and clinical score assessed at the end of week 24.
45840911|NCT00943098|Drug|Voltarol 75mg/3ml i.m.|1 single injection at day of dental surgical extraction
45840912|NCT00943488|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
45840913|NCT00943800|Drug|Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)|Fludarabine is given through the vein daily for 5 days. Melphalan is given through the vein daily for 2 days. ATG is given every day in the vein for four days.
45840914|NCT00943800|Procedure|Stem Cell Transplant|Infusion of haploidentical donor, umbilical cord blood
45840915|NCT00943800|Procedure|Stem Cells Collections|Haploidentical cells will be T-cell depleted using the Miltenyi Clinimax device.
45840916|NCT00943800|Drug|Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)|Fludarabine is given through the vein daily for 5 days. Thiotepa is given through the vein daily for 2 days. ATG is given through the vein every other day for 4 days. TBI is given twice a day for 3 days.
46042384|NCT05093764|Device|VIV TAVR with BVF using TCEP|The insertion and retrieval of the SENTINEL device is performed at the time of the patients TAVR procedure in the same setting while they are sedated under moderate sedation or general anesthesia depending on the case. The device is inserted at the initiation of the procedure through 6F right radial artery access and the filters are positioned in the left common carotid artery and brachiocephalic artery. After deployment, the usual TAVR procedure is performed. At the conclusion of the procedure, the SENTINEL device is extracted and hemostasis is achieved at the radial access site in the usual fashion with patent hemostasis.
46042385|NCT01006590|Drug|Saxagliptin|5 mg, oral tablet, once daily
45346055|NCT05733078|Drug|Oral Rehydration Salt Formulations|The patients in control group will have a oral rehydration effervescent tablet to take with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The control group will then be provided vitamin C (intervention) effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks to see if there is any difference on biochemical testing or clinical scores.
45346056|NCT00883792|Procedure|Colonoscopy|Once-only colonoscopy screening
45346057|NCT00874978|Drug|lenalidomide|Oral lenalidomide 10mg (two 5mg capsules) daily on days 1-21 every 28 days for up to 6 cycles.
45840917|NCT00943800|Drug|Fludarabine, Busulfan, and ATG|Fludarabine is given through the vein daily for 5 days. Busulfan is given through the vein daily for 4 days. ATG is given through the vein every other day for 4 days.
45840918|NCT00943878|Biological|Trivalent inactivated influenza vaccine|Licensed trivalent influenza vaccine (TIV) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
45840919|NCT00943878|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine, 15 mcg per dose, administered as a single 0.5 milliliters (mL) intramuscular injection in the deltoid muscle.
45840920|NCT00943878|Drug|Placebo|Normal saline (placebo control) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
45840921|NCT00945282|Drug|GSK2248761|GSK2248761 30 mg capsule once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
46042386|NCT01006590|Drug|Metformin|500 mg, oral tablet, 1 or 2 additional tablets per day added to background therapy
46042387|NCT02010112|Other|Breath Test Collection bags|Breath Collection bags will be used to collect breath of subjects before and after ingestion of 13-C breath test substrate
46042388|NCT00619138|Behavioral|individual cognitive-behavioural therapy|1 session per week for 12 weeks
46042389|NCT00619138|Behavioral|stepped care model|three steps: short psycho-education, a 10 weeks Internet-based self-help program, 12 weeks individual cognitive-behavioural therapy
46042390|NCT04212832|Drug|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
46042391|NCT04212832|Other|Standard pain|Standard pain follow up and monitorization
45475085|NCT02518516|Drug|Atorvastatin (<20mg)|"Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for <20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for <20 mg of atorvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
45840922|NCT00945282|Drug|Lopinavir/ritonavir|Lopinavir 400 mg and ritonovir 100 mg every 12 hours for 28 days. Lopinavir/ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class. Kaletra is a trademark of Abbott Laboratories.
45840923|NCT00945282|Drug|HAART|Highly Active Antiretroviral therapy of the doctor's choice.
45840924|NCT00945282|Drug|Placebo|Placebo is a capsule with no drug in it.
45840925|NCT00945282|Drug|GSK2248761|GSK2248761 10 mg -20 mg or 40 mg - 90 mg once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
45475086|NCT02518516|Drug|Simvastatin (<40 mg)|"Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for <40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for <40 mg simvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
46042392|NCT04211974|Diagnostic Test|whole-exome sequencing|"Fresh frozen or formalin-fixed, paraffin-embedded samples were obtained from patients following resection along with matching peripheral blood samples.~whole-exome sequencing will be performed to identify mutations in tumor tissue and matching blood"
46042393|NCT00621790|Drug|fenoldopam|fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min)for up to 4 days
46042394|NCT00621790|Drug|placebo|placebo
46042395|NCT00618124|Drug|SU011248; Capecitabine|Dose finding study using SU011248 daily by oral capsule in a continuous regimen or administered for 4 out of every 6 weeks (Schedule 4/2) or 2 out of every 3 weeks (Schedule 2/1), with capecitabine administered 2 out of every 3 weeks until progression or unacceptable toxicity.
46042396|NCT02252380|Device|Transcranial ExAblate System|MR Guided Focused Ultrasound
46042397|NCT05067946|Biological|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
46042398|NCT05067946|Other|Placebo|GX-19N formulation buffer
45346058|NCT04063254|Radiation|Stereotactic Radiotherapy|"High Dose (Arm A): Stereotactic radiotherapy with 12 or 16 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).~Standard-dose (Arm B): Stereotactic radiotherapy with 8 or 10 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc)."
45346059|NCT00737880|Other|Organ perfusion during pancreas procurement|Usage of UW or HTK perfusion solution during in situ abdominal organ perfusion in multi-organ procurement
45346060|NCT05728632|Drug|Nebivolol|Nebivolol, capsule, 5 mg once daily, for 12 months
46042399|NCT00621868|Drug|ipragliflozin|Oral
46042400|NCT00621868|Drug|Placebo|Oral
46042401|NCT02246374|Device|ExAblate Transcranial System|ExAblate Transcranial System subthalamotomy for symptoms of Parkinson's Disease
46042402|NCT01882660|Drug|Decitabine|
46042403|NCT05662618|Procedure|Percutaneous selective arteriography of peripheral arteries|Treatment of stenosis or occlusion of superficial femoral artery and/or popliteal artery with rapamycin coated balloon catheter.
46042404|NCT05662618|Procedure|Percutaneous selective arteriography of peripheral arteries|Paclitaxel coated balloon catheter for the treatment of stenosis or occlusion of superficial femoral artery and/or popliteal artery.
46042405|NCT02216500|Dietary Supplement|Ketogenic Therapy|Ketogenic Therapy is based on a ratio of fat: protein+carbohydrate in which protein intake is adequate, fat intake is high, and carbohydrate intake is minimal.
46042406|NCT01001832|Drug|Intravenous (IV) abatacept|IV vial, 125-mg infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141.
45684852|NCT01893580|Behavioral|Experimental: 2. Experimental|"Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery. Intervention consists of:~Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.~Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
45840926|NCT00945594|Device|Cystoscopy|A 16 F flexible cysto urethroscope (Storz, Culver city, CA) is used for flexible cystoscopy. When rigid cystoscopy is performed, a 17F, 70° scope (Storz, Culver city, CA)
45840927|NCT00945750|Drug|Famotidine FCT|Famotidine 20 mg oral film-coated tablet taken once daily
45346061|NCT05728632|Drug|Placebo|Placebo, capsule, once daily, for 12 months
45346062|NCT04180540|Device|Percutaneous Closure|The PerClose Proglide system will be used to deliver a suture to close the venous puncture following completion of ablation for treatment of atrial fibrillation.
45346063|NCT04180540|Other|Manual Compression|"Manual compression is the standard method of attaining hemostasis following ablation for treatment of atrial fibrillation. Manual compression may be performed with or without figure of eight suture for hemostasis at the discretion of the treating physician)."
45346064|NCT04063722|Procedure|modified Benelli procedure|use of modified Benelli procedure for surgical treatment of gynecomastia
45346065|NCT05741580|Procedure|Evolution of symptoms|percentage of patients with improvement in their symptoms
45346066|NCT05741502|Drug|Clozapine|We will monitor inflammatory/immune marker labs periodically
45840928|NCT00945750|Drug|Famotidine CT|Famotidine 20 mg oral chewable tablet taken once daily
45840929|NCT00947310|Device|Standard ICD programming|Standard ICD programming
45346067|NCT05741502|Drug|Antipsychotics,Other (non-Clozapine)|We will monitor inflammatory/immune marker labs periodically
45840930|NCT00947310|Device|High rate cutoff|Programming of a high rate cutoff
45840931|NCT00947310|Device|Long delay|Programming of a prolonged delay
45840932|NCT00948090|Drug|IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)|Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant.
45346068|NCT05727072|Drug|LY3848575|Administered IV.
45346069|NCT05727072|Drug|LY3848575|Administered SC.
45346070|NCT05727072|Drug|Placebo|Administered IV.
45346071|NCT05727072|Drug|Placebo|Administered SC.
45346072|NCT05577936|Device|XPERIENCE Advanced Surgical Irrigation|A clear, colorless, aqueous solution that is indicated for use in the cleansing and removal of debris, including microorganisms, from wounds. Soak for 3 minutes for a total volume of 1L
45346073|NCT05577936|Other|Standard of Care Irrigation|17.5 mL povidone-iodine with 500 mL normal saline: solution (0.35%) for 3 minutes for a total volume of 1L (including a normal saline rinse)
45346074|NCT00612586|Drug|Enzastaurin|1125 milligram (mg) loading dose, then 250 mg twice daily, oral up to 1 year (yr) or until progressive disease
45346075|NCT00612586|Drug|Placebo|oral, daily (up to 1 yr or until progressive disease)
45346076|NCT00612586|Drug|Leucovorin (LV)|400 milligram per meter squared (mg/m^2) intravenously (IV), Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
45346077|NCT00612586|Drug|5-fluorouracil (5-FU)|400 mg/m^2 bolus then 2400 mg/m^2 IV over 46 hours, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
45346078|NCT00612586|Drug|Bevacizumab (Bev)|5 milligram per kilogram (mg/kg) IV, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
45346079|NCT05576922|Other|Prosthetic-surgical approach + autogenous graft|Coronally advanced flap with an autogenous graft (CTG)
45346080|NCT05576922|Other|Prosthetic-surgical approach + graft substitute|Coronally advanced flap with a graft substitute (collagen matrix and rhPDGF-BB)
45346081|NCT05741424|Diagnostic Test|Innovative diagnostic technologies|Samples from patients positive for Gram-negative bacteremia will be analyzed using the new BacT/Alert® VIRTUO®, BioFire® BCID2 and REVEAL® diagnostic solutions
45346082|NCT05741424|Diagnostic Test|Reference diagnostic technique|Analysis of samples using diffusion on Mueller Hinton (MH) agar medium according to EUCAST.
45346083|NCT00883870|Drug|mesenchymal stem cells|Intramuscular injection
45346084|NCT00883870|Drug|Plasmalyte A|Intramuscular injection
45346085|NCT04038892|Other|Conventional Chest Physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.
45346086|NCT04038892|Other|Nintendo Wii Fit Based Exercise Training|Nintendo Wii Fit based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (yoga games; deep breathing and half moon etc.), aerobic exercises for 30 minutes (aerobic games; Twisting and Squat, Step Plus, Jogging Plus and Hula Hoop etc.) and cooling exercises in 5 minutes (yoga games; deep breathing and half moon etc.).
45346087|NCT04038892|Other|BreathingLabs Breathing Games Based Exercise Training|BreathingLabs Breathing Games based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (respiratory control exerice and coughing techniques), breathing games exercises for 30 minutes (breathing games; Kite, Balloon, Pluto, Butterflies and Plane etc.) and cooling exercises in 5 minutes (respiratory control exerice and coughing techniques).
45840933|NCT00948792|Procedure|Short platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets administered over 30 minutes
45346091|NCT00614380|Drug|telmisartan/amlodipine 40/5 mg fixed combination|
45346092|NCT00614380|Drug|telmisartan/amlodipine 80/5 mg fixed combination|
45346093|NCT05525130|Dietary Supplement|Food supplement|FagolitosPlus® is an authorized food supplement that contains hydroxycitric acid, vitamin complexes and ions.
45346094|NCT05525130|Dietary Supplement|Placebo|Placebo has a composition that makes the weight and organoleptic characteristics are identical to FagolitosPlus®.
45840934|NCT00948792|Procedure|Long platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets given over two hours.
45840935|NCT00950352|Drug|Citicoline|Subjects will be given 1g citicoline twice daily for a total of 8-9 weeks.
45840936|NCT00950352|Drug|Placebo|Subjects will be given 1 capsule of placebo twice daily for 8-9 weeks. They will be taking the same quantity as the citicoline group.
45346095|NCT05507190|Other|Self-management of post COVID-19 respiratory outcomes|Intervention: using the participants' initial assessment, personal characteristics, main complaints/needs and goals, the therapist will adjust the exercise plan and personalize the recommendations (e.g. maximum heart rate) as well as instruct the patients about safety precautions (how to pace themselves, when to seek professional or emergency care). Participants will be encouraged to wear the smart shirt as much as they want during the 6 weeks (29), but at a minimum of 1-hour a day (M-F) including while performing the recommended exercises (30-45 min/3 times a week). They should self-monitor their biometric values trying to reach/stay within the target values while wearing the shirt using Hexoskin app installed on an iPad provided by the research team or on the participants' personal device if preferred.
45346096|NCT02567994|Drug|Teneligliptin|Subjects will visit the center on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.
45346097|NCT00738192|Drug|Fentanyl citrate|Fentanyl 0.5 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
45346098|NCT00738192|Drug|Sufentanil citrate|Sufentanil 0.05 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
45346099|NCT00738192|Drug|Butorphanol tartrate|Butorphanol 0.01 mg/kg delivered intravenously immediate at the end of remifentanil pump finished
45346100|NCT00875134|Other|Verbal prompt|Patient hears a voice recording
46042407|NCT01001832|Drug|Subcutaneous (SC) abatacept|Solution in prefilled syringes, SC, 125 mg, once weekly, for 169 days and then for 52 weeks
45346101|NCT00875134|Other|Skin Stimulus|Patient receives either a skin stimulus
45346102|NCT05697978|Device|Monofocal intraocular lens Clareon (Alcon LLC)|monofocal aspheric lens implanted in eyes of patient during routine cataract surgery
45346103|NCT05500170|Dietary Supplement|Nicotinamide riboside|Nicotinamide riboside (NR) is a form of vitamin B3, which is found in fruits, vegetables, meat, and milk. NR is converted into nicotinamide adenosine dinucleotide NAD+. Low NAD+ levels have been linked to Alzheimer's disease and sleep disturbances.
46042408|NCT01873456|Other|multifactorial nutritional intervention|
45346104|NCT05500170|Dietary Supplement|Placebo|The placebo pill will contain micro cellulose powder.
46042409|NCT01851694|Drug|GLP-1|Each subject in this arm will receive GLP-1 infusion and a placebo infusion during a GPA test.
46042410|NCT01851694|Drug|GIP|Each subject in this arm will receive GIP infusion and placebo during a GPA test.
46042411|NCT01001598|Drug|danazol|Dosage is done according to weight; capsules are 50, 100, 200 mg
46042412|NCT04208620|Drug|Placebo|Placebo administered subcutaneously
46042413|NCT04208620|Drug|Cotadutide|Cotadutide administered subcutaneously
46042414|NCT01006356|Drug|Hydromorphone HCl OROS|Hydromorphone HCl OROS 8 mg once daily for 2 weeks.
45346105|NCT04681534|Device|AlphaDBS System|AlphaDBS can be programmed with two different types of stimulation: conventional DBS and adaptive DBS, that automatically adjusts the energy delivered to patient using a biosignal, local field potential (LFP), in a close loop configuration.
45346106|NCT05484804|Other|Data Accountability and Transparency|Collaboration with Practice Facilitators; Maternal Early Warning System; Disparities Dashboard; Racial Equity Training
45346107|NCT05484804|Other|Community-Based Doula (CBD) Support|Community-Based Doula support for high-risk patients; Racial Equity Training
45346108|NCT00883948|Behavioral|Minimal (Trophic) Feeding|Upon admission to the ICU, enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
45684853|NCT01893580|Behavioral|Experimental: 3. Experimental|"Early postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:~Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
45840937|NCT00953862|Drug|Atomoxetine|In Phase II, atomoxetine was dispensed beginning at 25 mg/day. Dose was adjusted based on clinical response and tolerability over a 4-week period up to 120mg/day and held constant at the optimized level for the final 6 weeks of the trial.
46042415|NCT03836092|Procedure|Radiofrequency ablation|RF applications were delivered with a maximal temperature of 43°C at the catheter tip (SmartTouch Navistar Thermocool catheter) and at the power between 25-50 watts. The primary end points during RF ablation were either complete elimination of areas with CFAE or conversion of AF to normal sinus rhythm (SR). When areas with CFAE were completely eliminated but the atrial arrhythmias persisted (organized atrial flutter or atrial tachycardia), they were subsequently mapped and ablated (occasionally in conjunction with ibutilide, 1 - 2 mgs intravenously over 10 minutes).
46042416|NCT04213066|Device|Portable tablet|Each training session was limited to 15 minutes a day, 5 days a week. The entire training period was 6 months.
46042417|NCT01089725|Biological|Placebo IV|1 ml of placebo administered SC and IV once every 8 weeks.
46042418|NCT01089725|Biological|Placebo SC|1 ml of placebo administered SC and IV once every 8 weeks.
46042419|NCT01089725|Biological|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
46042420|NCT01089725|Biological|Placebo IV|1 ml placebo administered IV every 8 weeks
46042421|NCT01089725|Biological|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
46042422|NCT01089725|Biological|Placebo IV|1ml placebo administered IV every 8 weeks
46042423|NCT01089725|Biological|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
46042424|NCT01089725|Biological|Placebo IV|1ml placebo administered IV every 8 weeks
46042425|NCT01089725|Biological|Tanezumab IV|1 ml tanezumab injection IV administered every 8 weeks
46042426|NCT01089725|Biological|Placebo SC|1ml placebo administered SC every 8 weeks
46042427|NCT01190930|Drug|Cyclophosphamide|Given IV
46042428|NCT01190930|Drug|Cytarabine|Given IT, IV, or SC
46042429|NCT01190930|Drug|Dexamethasone|Given orally (PO) or IV
46042430|NCT01190930|Drug|Doxorubicin Hydrochloride|Given IV
45346109|NCT00883948|Behavioral|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
45346110|NCT05695326|Behavioral|3D printing technology learning program|The study is aimed to evaluate a 3D printing technology learning program for rehabilitation professionals
45346111|NCT00738348|Drug|sivelstat|sivelstat sodiumhydrate
45840938|NCT00955032|Device|High-Frequency Repetitive Transcranial Magnetic Stimulation|In patients randomized to receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of MEP threshold, respectively.
46042431|NCT01190930|Other|Laboratory Biomarker Analysis|Correlative studies
46042432|NCT01190930|Drug|Leucovorin Calcium|Given PO
46042433|NCT01190930|Drug|Mercaptopurine|Given PO
46042434|NCT01190930|Drug|Methotrexate|Given IT, PO, or IV
45346112|NCT00738348|Drug|glucose|glucose
45346113|NCT00884026|Device|AIx measurement with a Sphygmacor TM|All subjects will have their AIx measured prior to surgery. After 30 subjects are recruited, they will be split into 2 groups. Group 1 will be those subjects who developed hypotension, and Group 2 will be those subjects who did not develop hypotension. We will then look at the preoperative measured AIx to determine whether there is a baseline difference between the two groups. A threshold value of the AIx with the best sensitivity and specificity for prediction of hypotension will then be determined.
45346114|NCT00884026|Device|AIx measurement with a Sphygmacor TM|The second part of the study will then use the threshold AIx value found from the subjects who developed hypotension from the first 30 subjects to prospectively predict hypotension after spinal anesthesia in another 60 subjects
45346115|NCT05678946|Other|Integrated face-to-face rehabilitation and telerehabilitation|Kela´s integrated face-to-face rehabilitation and telerehabilitation services for family caregivers include two 5-day periods of face-to-face rehabilitation and a 12-week telerehabilitation period between them. It is for those over the age of 18 who work as family caregivers on a daily basis and need support, tools, and coaching to understand and overcome the challenges posed by the care situation. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation. The service, provided free of charge, is carried out in a Finnish rehabilitation centre and online over a period of 8 months, and it is implemented by a multidisciplinary team of rehabilitation experts. During the 12-week telerehabilitation period, the service providers utilise The Own Path, an acceptance and commitment therapy -based guided web intervention found beneficial for older Finnish family caregivers (Lappalainen et al. 2021). Telerehabilitation is independent of time and place.
45346116|NCT05678946|Other|Social Holidays|MTLH's Social Holidays for family caregivers are 5-day holidays in a Finnish hotel, spa, sports institute, or rehabilitation centre. The theme, content, and level of available assistance in Social Holidays vary, and the rehabilitation concept is lighter than that of Kela's rehabilitation services. Social Holidays include full-board accommodation and holiday activities, e.g. lectures, group discussions, instructed exercise, and a pampering treatment. MTLH organises Social Holidays for family caregivers as well as family caregivers and care recipients. The participants cover their travel expenses and pay a fixed sum of €125. Other than that, Social Holidays are provided free of charge. Social Holidays are intended for family caregivers who need recreational activities, rest, and peer support.
46042435|NCT01190930|Drug|Pegaspargase|Given IV
46042436|NCT01190930|Other|Quality-of-Life Assessment|Ancillary studies
46042437|NCT01190930|Other|Questionnaire Administration|Ancillary studies
46042438|NCT01190930|Drug|Thioguanine|Given PO
46042439|NCT01190930|Drug|Vincristine Sulfate|Given IV
46042440|NCT05662462|Device|DEXCOM G6 PRO Continuous Glucose Monitor|Participants in the intervention arm will be provided with DEXCOM® G6 PRO CGM sensors and transmitters. The Dexcom G6 CGM system is accurate and safe in pregnant individuals with diabetes. Participants will be taught how to place and remove CGM sensors by a trained research nurse, and will be given sensors to change themselves at home every 10 days. Of note, the DEXCOM® G6 PRO can be applied as a patch on the abdomen, arm, or upper buttocks, is well-tolerated in pregnancy, and does not require calibration. Our mHealth app will allow for wireless synchronization with the CGM sensor so that data are seamlessly reported back to the healthcare team.
45346117|NCT05678946|Other|Face-to-face rehabilitation|Kela's rehabilitation services for family caregivers and the care recipients include three 5-day periods of face-to-face rehabilitation, which are carried out in a Finnish rehabilitation centre over a 10-month period and implemented by a multidisciplinary team of rehabilitation experts. The rehabilitation services for family caregivers and the care recipients are provided free of charge. The service is intended for persons over the age of 18 who work as family caregivers on a daily basis with or without family caregiver support and who need support, tools, and coaching to understand and overcome the challenges posed by the care situation. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation.
45346118|NCT00875290|Device|Real-time glucose sensor|Children assigned to this intervention will use a real-time sensor continuously
45346119|NCT00884104|Drug|Solifenacin|Oral
45346120|NCT04140214|Drug|Hypertonic saline|Nebulized hypertonic saline solution (6%)
46042441|NCT05662462|Device|Patient mHealth app linked to a provider dashboard|The mHealth app is based on our team's prototype intervention developed at our study site. The mHealth app provides diverse functions, including education, reminders, care goals, care pathway recommendations, CGM data and PROs reporting and monitoring, messaging and video conferencing, and a calendar function. Content is based on clinical guidelines for diabetes in pregnancy. Participants will be directed to appropriate resources and online learning to help them navigate the app and its resources. PROs in the mHealth app will be embedded to address health and social needs, and rule-based algorithms will provide tailored care goals, show care pathways, and establish the frequency of elicited PROs.
46042442|NCT05662462|Behavioral|Care team coaching for medical and social needs (HUB)|"Participants will be screened at enrollment and throughout the intervention for social needs using a survey adapted from validated instruments, such as the Accountable Health Communities Health-Related Social Needs Screening Tool. The care team will refer participants with affirmative responses to the HUB through the provider dashboard to address social needs (e.g., food insecurity, housing, employment). HUB community health workers will perform comprehensive social needs assessments and connect participants to community resources through care pathways, a defined action plan addressing patient needs which is recorded and tracked."
46042443|NCT05662462|Device|Provider dashboard|The ACHIEVE intervention will include a bi-directional dashboard that displays information about individuals, including priority care goals and pathways, and recommendations generated via PROMPT. Healthcare team members can access the dashboard embedded within a portal to modify or update information and close the loop on participant tasks. The dashboard will present recommendations for participant goals and pathways provided by the PROMPT algorithms. Providers can use these recommendations or manually select ones for the participant. Providers can sequence goals and pathways by level of complexity. Both the HUB and the healthcare team can perform ongoing assessments of HUB pathway selections and assess recurring needs through the provider dashboard.
46042444|NCT00622102|Behavioral|Lottery arm (Lottery and Med-eMonitor)|Lottery and Med-eMonitor
46042445|NCT00622102|Behavioral|Non-Lottery (Med-eMonitor only)|Med-eMonitor only
46042446|NCT05662384|Other|No intervention is planned|Observational study, no intervention
46042447|NCT00619216|Drug|Mycophenolic Acid (Myfortic)|Equimolar conversion from mycophenolate mofetil to mycophenolic acid
46042448|NCT00619372|Drug|OKT3|0.2 mg OKT3, PO (in the mouth) on day 1 through 5.
46042449|NCT00619372|Drug|OKT3, GC|0.2 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
45346121|NCT04140214|Drug|Carbocysteine 750 MG|Carbocisteine tablet
45346122|NCT00612508|Drug|Desogen (ethinyl estradiol and desogestrel)|1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol
45346123|NCT00612508|Drug|NuvaRing (ethinyl estradiol and etonogestrel)|Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring
45346124|NCT00881218|Drug|Regadenoson|Regadenoson 400 micrograms will be administered IV bolus via an antecubital cannula.
45684854|NCT01893580|Behavioral|Other: 4. Usual care|"Exercise in a team initiated six weeks after surgery consisting of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.~The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks. The next eight weeks the intensity increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
45684855|NCT02718040|Device|Emervel Classic and/or Deep Treatment Group|"Severity of Wrinkle Severity treated by product type:~Emervel Classic:~Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 2/2, 2/3 or 3/3; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 2/2, 2/3 or 3/3~Emervel Deep Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 3/3, 3/4 or 4/4; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 3/3, 3/4 or 4/4~Both products may be used in the same subject, but only in different anatomic locations. The same study product should be used within the same wrinkle or fold type (e.g., left and right NLFs treated with the same product)"
46042450|NCT00619372|Drug|OKT3|1 mg OKT3, PO (in the mouth) on day 1 through 5
46042451|NCT00619372|Drug|OKT3, GC|1 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
46042452|NCT00619372|Drug|OKT3|5 mg OKT3, PO (in the mouth) on day 1 through 5
46042453|NCT00619372|Drug|GC|7.5 mg GC, PO (in the mouth) on day 1 through 5
46042454|NCT02879279|Device|Amadeo, Pablo, Diego and Motore.|In the robotic rehabilitation group, patients will be treated with the following systems: Amadeo, Pablo and Diego (Tyromotion GmbH, Austria), and Motore (Humanware, Italy). A ratio of one therapist to every 3 or 4 patients will be used, depending on the patient's severity. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
46042455|NCT02879279|Other|Conventional rehabilitation|In the conventional rehabilitation group, patients will undergo a conventional treatment with a ratio of one therapist to one patient. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
45346125|NCT00613834|Drug|Lidocaine|5 ml intrauterine infusion of 4% lidocaine using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
45346126|NCT00613834|Drug|Sterile Saline|5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
45346127|NCT00875368|Drug|maraviroc|maraviroc dose dependent on co-medication
45346128|NCT00875368|Drug|Placebo|Placebo drug
45346129|NCT00884182|Biological|A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine|0.5 mL, Intramuscular
45346130|NCT00875446|Drug|PLACEBO|Placebo
45346131|NCT00875446|Drug|GSK1223249|I.V Infusion
46042456|NCT00618202|Drug|Balsalazide|
46042457|NCT02877719|Other|Questionnaires|Participants were asked to respond to the Chinese version of the Center for Epidemiologic Studies Depression Scale for Children, the Rosenberg self-esteem scale, and the Pediatric Quality of Life Inventory.
46042458|NCT00619450|Other|3D C-arm CT scan|The patient will be given an intravenous contrast dye and then hold their breath for 15 seconds while pictures are taken. The equipment used to take the pictures is like an arch that will rotate around the body. As the arch rotates, it will collect the pictures of the heart. These pictures will then be used to compute a three-dimensional image of the heart. The physicians will then continue with the planned procedure. The three-dimensional images will be reconstructed and available for the doctor to view during the case. The images will also be examined after the procedure by the physician.
45346132|NCT03920098|Other|Nutrition and mental health during pregnancy|Altered metabolic milieu is defined as a fasting glucose level >100 mg/dL at the first trimester of pregnancy by national guidelines. Altered metabolic milieu during the second trimester (24-28 weeks of pregnancy) is defined as a fasting glucose levels > 92 mg/dL and/or plasma glucose levels > 153 mg/dL two hours after load in the oral glucose tolerance test according to ADA guidelines or a fasting glucose >100 mg/dL and/or > 140 mg/dL two hours after load in the oral glucose tolerance test according to national guidelines. The COVID-19 pandemic is considered as a natural nutritional and mental health exposure.
46042459|NCT00626015|Biological|PEP-3-KLH conjugate vaccine|Given intradermally
45346133|NCT03912298|Other|Opioid Taper Pain perception|Pain Responses: The primary dependent variable, pain, will be measured using two highly reliable and valid pain induction techniques, the CPT and QST, employing procedures consistent with those described in the literature. Order of pain testing will vary, and three aspects of the pain response will be captured at each study session: evoked pain; temporal summation; and conditioned pain modulation, which map on to the hypothesized peripheral, spinal and supra-spinal mechanisms of OIH. Protocols for each assay have been uploaded.
45346134|NCT02543710|Procedure|Biomarker (ER/PR) guided lymphadenectomy|"Lymphadenectomy in the pelvis and para-aortic, will, for patients who are considered otherwise low risk (endometrioid tumours grade 1 or 2, or grade 3 with <50% myometrial infiltration (MI), with no sign of extrauterine disease), be dependent on the preoperative hormone receptor status (ER and PR).~Patients will be defined low risk when endometrioid, grade 1 or 2, or grade 3 with <50% MI, AND positive hormone receptor status for both ER AND PR. These patients will not undergo lymphadenectomy.~Patients with endometrioid tumours grade 1 or 2, or grade 3 <50% MI,, with either negative ER or PR status, are defined high risk and will undergo pelvic and para-aortic lymphadenectomy as part of their surgical procedure.~Patients will receive routine clinical follow-up for 5 years. Follow-up data will be collected for the study, focusing on survival and recurrence of disease. All patients will, as part of the study fill out validated quality of life questionnaires (QoL) at follow-up."
45684856|NCT02717962|Drug|VAL-083, Dianhydrogalactitol|The dosing regimen for patients will be VAL-083 (30 mg/m2) administered IV for 3 consecutive days at the beginning of every 21-day cycle. Patients will continue to receive VAL 083, for up to 12, 21-day treatment cycles or until they fulfill one of the criteria for study discontinuation.
45684857|NCT01893658|Drug|Omalizumab|administration of a single dose together with the standard treatment
46042460|NCT00626015|Biological|daclizumab|Given IV
45684858|NCT01893658|Drug|Prednisone|standard treatment
46042461|NCT00626015|Drug|temozolomide|Given by mouth.
46042462|NCT00626015|Other|placebo|Given IV
45684859|NCT02703610|Drug|Oxycodone/acetaminophen|Patients will be discharged home with a 3 day supply of oxycodone/acetaminophen
45684860|NCT02703610|Drug|Ibuprofen/acetaminophen|Patients will be discharged home with a 3 day supply of ibuprofen/acetaminophen
46042463|NCT00626015|Biological|PEP-3-KLH|Basiliximab 20 mg IV over 30 minutes with PEP-3-KLH vaccine # 1 only.
46042464|NCT03787498|Drug|PLX2853|Tablets
46042465|NCT02879201|Procedure|Slow efficiency dialysis|Slow dialysis 4 times weekly 8 hours CVVHDF predilution mode
46042466|NCT00618280|Drug|nicotine nasal spray|0,5 mg nicotine nasal spray or placebo (pepperspray)
46042467|NCT01101191|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken without food.
46042468|NCT01101191|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken without food.
46042469|NCT04212754|Other|Exposure: human development index of country|Primary comparison: Between country groups defined by human development index.
45346135|NCT02543710|Drug|Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer|"A 5mm tissue biopsy will be analysed for stathmin level in the recurrence as well as urine and a second 5mm biopsy on termination of study participation. The second biopsy could help explain why patients have stopped responding to the treatment. Determination of stathmin level both from the tissue and the urine will take place at the pathology department. Stathmin serves as an integrated biomarker, which enables a central biomarker analysis at Haukeland university hospital. Stathmin level is defined as high with an immunohistochemical score 9 (max score). All other scores are considered low. Pre-treatment all patients undergo CT or MRI, maximum 1 month prior to treatment start.~During treatment, urine and bloods will be collected every treatment cycle (weekly basis). Imaging will take place every 8 treatment cycles. Treatment will continue until disease progression."
45475087|NCT03350464|Device|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
45346136|NCT00884260|Drug|Levonorgestrel IUS (LCS, BAY86-5028)|In Vitro release rate: 12µg LNG/24h
46042470|NCT02879357|Behavioral|Training|"Clinician training~System for patient selection~System of triggering and tracking conversations~Training on how to use the Serious Illness Care Guide, a guide for patients about initiating conversations with family members about end-of-life goals and values~Longitudinal Medical Record (LMR) documentation module to serve as a Single source of truth about advance care preferences in the LMR."
46042471|NCT00622258|Drug|Everolmus|
45346137|NCT04038814|Procedure|Routine prevention of VAP|Enhanced hand hygiene protocol, tube cuff pressure monitoring ( set on 25-30 mm Hg) every 12 hours and every time when we suspected under or over distention, fast withdrawal of sedation, moderate supportive mechanical ventilation ( tidal volume (VT) 5-8 ml/kg ideal body weight (IBW), positive end expiratory pressure (PEEP) 3-5 cmH2O, Plateau pressure (Ppl) < 25 cm H2O, normocapnia ), Proton Pump Inhibitors (PPIs) reduction, Selective oral decontamination (SOD) every 8 hours - 0,2% chlorhexidine digluconate mouthwash, Closed Tracheal Suction System (CTSS) - changed every 7 day, 30-45% lifting of the thorax
45346138|NCT04038814|Procedure|Modified prevention of VAP|"3 modifications of the routine bundle in the prevention of VAP:~Endotracheal tube ( Shiley Evac Endotracheal tube with TaperGuard Cuff) and tracheostomy tubes (Tracheostomy Tube Cuffed Seal Guard) instead of regular tubes,~Automatic, continuous tube cuff pressure monitoring ( Covidien Shiley M Pressure Control Automatic Cuff Controller ( 25-30 mmHg),~Automatic continuous subglottic secretion drainage"
45346139|NCT00881296|Drug|gemcitabine and carboplatin|Gemcitabine 1000mg/m2, DIV on day 1 and 15 of each 28 day cycle. Carboplatin AUC=3, DIV on day 1 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles.
45346140|NCT00881296|Drug|Gemcitabine|Gemcitabine 1000mg/m2, DIV on day 1, 8 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles
45346141|NCT02543788|Procedure|• Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG|
45475088|NCT00454467|Procedure|Baseline Questionnaire|Patients will fill out a baseline questionnaire prior to surgery.
46042472|NCT01812616|Drug|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
46042473|NCT01812616|Drug|Placebo|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and Food, Drugs & Cosmetics (FD&C)certified color additives; FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
46042474|NCT00618358|Device|Vascular Sealant System|The Vascular Sealant System is intended for use in vascular reconstructions to achieve adjunctive hemostasis by mechanically sealing areas of leakage.
46042475|NCT00618358|Other|Gelfoam/Thrombin|
46042476|NCT04212676|Other|Body Awareness Therapy|The BAT for the participants was based on the works of Roxendal and Dropsy. Activities include relaxation exercises, breathing exercises, floor exercises for trunk and pelvic movements, weight transfer using extremities and proprioceptive movements. Movements will be made in various positions to determine the centerline of the body. All exercises will be started in the supine position to maximize proprioceptive motion feedback and minimize energy requirements during tasks. Movements will be taught in a series of lessons over a period of 8 weeks with advance advancement of selected movements depending on participant comfort.
45346142|NCT02543632|Device|Parachute Implant System|The CardioKinetix Parachute Implant partitions an enlarged ventricle into dynamic and static chambers. The static chamber is a portion of the left ventricular volume that is taken out of circulation. Stresses placed on the partitioned myocardium and the forces transmitted to the apical segment are decreased both in diastole and systole, eliminating the forces responsible for left ventricular dilation. In addition to this regional unloading, the reduction in size of the dynamic chamber results in a decrease of the myocardial stress in the normal myocardium via Laplace Law, providing a global unloading of the ventricle.
45346143|NCT00884338|Other|Endurance exercise|The patients will carry out an endurance exercise program consisting of walking on a treadmill for 30 to 40 minutes at a speed corresponding to 80% of the maximum heart rate
45475089|NCT00454467|Procedure|Operative Data|Type of prosthesis and other operative data will be uploaded into our database.
45346144|NCT00884338|Other|Counseling|Counseling about exercise and behavioural techniques to reduce fatigue
46042477|NCT04212676|Other|Pulmonary Rehabilitation|Diaphragmatic breathing exercise Thoracic expansion exercises (Chest breathing and bilateral segmental breathing exercises) Inductive spirometry (Triflo®) exercise Cough development techniques
46042478|NCT01178762|Drug|Azithromycin|Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
46042479|NCT03629236|Other|GrafixPL|Debridement, GrafixPL application, dressing application, standard compression therapy
46042480|NCT03629236|Other|Control|Debridement, dressing application, standard compression therapy
45346145|NCT00881374|Drug|LACTIC ACID(ND)|Dermacyd Infantile (Lactic Acid)
45475090|NCT00454467|Procedure|Intra-operative data will be collected post-operatively|Research assistants will post-operatively collect data from patient charts.
45475091|NCT00454467|Procedure|In-hospital post-operative data will be collected|Research assistants will collect information about hospital stay from patient charts.
45475092|NCT00454467|Procedure|Satisfaction data will be extracted from Press/Ganey and on follow-up questionnaires|Follow-up questionnaires will be mailed to participants.
46042481|NCT03563560|Drug|Alvocidib|ACM regimen:30 mg/60 mg, 30-minute intravenous (IV) infusion, followed 4-hour IV infusion from Day 1 to Day 3 A+7+3 regimen: recommended dose (RD), 30-minute IV infusion, followed 4-hour IV infusion from Day 1 to Day 3
46042482|NCT03563560|Drug|Cytarabine|300 or 667 mg/m2/day, 72-hour continuous IV infusion starting on Day 6 (ACM regimen)
46042483|NCT03563560|Drug|Mitoxantrone|14 or 40 mg/m2/day, IV infusion over 1 hour to 2 hours at 12 hours after the end of DSP-AraC administration (acceptable range + 3 hours)
46042484|NCT03563560|Drug|Cytarabine|100 mg/m2/day, continuous IV infusion for 7 days from Day 5 to Day 11 (A+7+3 regimen)
46042485|NCT03563560|Drug|Daunorubicine|60 mg/m2/day, 30-minute IV infusion for 3 days from Day 5 to Day 7
45475093|NCT00454467|Procedure|Cost Data|Cost Data will be collected via hospital billing databases.
45475094|NCT00454467|Procedure|Follow-up questionnaires|Participants will be mailed follow-up questionnaires.
45475095|NCT04508686|Drug|Capecitabine, camrelizumab|This is a single-arm study with all patients receiving these two drugs.
45475096|NCT03852095|Other|minor trauma|following the management of the patient's fracture in the emergency department, the patients / parents are recalled 2 months (J60) after the visit to the emergency room, and are interviewed by following the pre-established interrogation form, which checks the good agreement of the patient. treatment performed with the given sheet and recommendations, and assesses the satisfaction.
46042486|NCT01178294|Biological|OBI-1|Intravenous infusion
45346146|NCT00613366|Drug|Misoprostol|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
45346147|NCT00613366|Dietary Supplement|Magnesium Oxide|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
45346148|NCT00875602|Device|EverOn (EarlySense) contactless monitoring device|Hospitalized patients on the study unit are monitored by a contactless device
45346149|NCT00875680|Device|autoPPC|To test the efficacy of autoPPC machines on residual sleep-related events during a one night autotitration polysomnography.
46042487|NCT01799044|Device|Irreversible electroporation (IRE)|Tumor ablation with irreversible electroporation with the NanoKnife
45475097|NCT03852173|Behavioral|Wasserschulen|"Schools receive following materials and trainings:~one training sessions for teachers (at the beginning of the intervention)~refillable water bottles for each school student~drying rack for water bottles for each classroom~educational material for each class and for school events~informational material for parents"
45346150|NCT00612352|Drug|Ethanol High Dose, Ethanol Low Dose, and Placebo|Three test days will involve administration of placebo, ethanol high dose (BrAc=100mg%) or ethanol low dose (BrAc=40mg%)intravenously for approximately 20 minutes, until the target BrAc is achieved. Once BrAc is achieved (40mg% or 100mg%) it will be maintained using a clamp procedure for 60 minutes.
45346151|NCT00884416|Drug|Sorafenib dose escalation|Sorafenib dose escalation scheme: 3 first patients: 200 mg/d, if dose limiting toxicities (DLT) not reached: 3 patients at 200 mg BID, if no DLT reached: 3 patients at 400 mg bid
45346152|NCT04675996|Drug|INT-1B3|60-min i.v. infusions twice per week in 21-day cycles
45475098|NCT02518438|Drug|Tramadol|A preprepared 20 ml solution was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
46042488|NCT00619606|Device|TwinGuard|A system consisting of an endoscopic bite block that fits together with a nasal cannula. After gastroscopy, the bite block is discarded leaving the patient receiving oxygen in recovery.An optional carbon dioxide sampling device fits with the TwinGuard in endoscopy to monitor expired air.
46042489|NCT00619606|Device|Standard endoscopic bite block|Placed in the mouth during gastroscopy to protect the endoscope and the patient's teeth
46042490|NCT00619606|Device|Standard nasal cannula|Delivers oxygen to the nose. Tubing runs from the nose around the back of the ears and under the chin which then runs to an oxygen source.
46042491|NCT00619606|Device|CO2 sample line|Samples expired air from a patients nose. Tubing is connected to a capnograph.
46042492|NCT01178138|Drug|Prazosin|Prazosin or oral placebo given before methamphetamine or iv placebo to determine effects of prazosin on methamphetamine.
46042493|NCT04211428|Other|No intervention|There is no intervention for this study
46042494|NCT00618592|Dietary Supplement|PreOp carbohydrate drink|800 mL of PreOp evening before surgery, 400 mL at least two hours before surgery
46042495|NCT04206254|Biological|gp96|heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells.
46042496|NCT04206410|Dietary Supplement|Probiotic|Multispecies probiotic mixture administered to patients according to the randomization list
46042497|NCT04206410|Dietary Supplement|Maltodextrin|Maltodextrin as placebo
45346153|NCT00875758|Procedure|Removal of CSF through ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile + 2 standard deviations. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
46042498|NCT05662150|Diagnostic Test|Low frequency repetitive stimulation|Neuromuscular transmission was tested by using short-lasting low frequency RNS (10 stimuli at 3 Hz). The test was applied on the abductor digiti minimi (ADM), anterior tibial, orbiculis oculi, trapezius, anconeus and EDB muscles of one side, in this particular order, by supramaximal stimulation of the corresponding nerve.
45346154|NCT00875758|Procedure|Removal of CSF through a ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
46042499|NCT02558530|Other|Low carbohydrate diet|Isocaloric, carbohydrate restricted diet 14 days
45346155|NCT04018300|Dietary Supplement|Ferrous sulfate|65 mg Fe as ferrous sulfate
46042500|NCT04208542|Drug|ESP block|Ultrasound guided Erector spinae block (ESP) will perform.
46042501|NCT01190228|Biological|JE-CV Vaccine|0.5 mL (single dose), Subcutaneous
46042502|NCT01190228|Biological|Varicella Vaccine|0.5 mL (single dose), Subcutaneous
46042503|NCT01009086|Drug|Placebo|SC injections
46042504|NCT01009086|Drug|Ustekinumab 45 mg|SC injections
46042505|NCT01009086|Drug|Ustekinumab 90 mg|SC injections
46042506|NCT05662072|Behavioral|Motor imagery|Mental imagery of respiratory exercises
46042507|NCT05662072|Behavioral|Action observation|Action observation of respiratory exercises
46042508|NCT05662072|Other|Placebo Intervention|Placebo observation
46042509|NCT02519140|Drug|Cook Medical EMR Gel|Cook Medical EMR Gel will be injected submucosally into ex-vivo gastric or colonic tissue specimens
45346156|NCT04018300|Dietary Supplement|Aspiron|65 mg Fe as iron-enriched koji culture, called AspironTM
46042510|NCT01190150|Drug|tranexamic acid|Either one or two modified-immediate release tranexamic acid tablets (0.65 g each) taken orally, administered with 240 mL of water, as a single dose, at approximately 8 AM.
45346157|NCT04018300|Other|Placebo|Contains maltodextrin.
45346158|NCT00875914|Procedure|RF-ablation|4mm-tip catheter manually guided vs magneticallly navigated
45346159|NCT02543164|Other|REFERENCE: white bread|"Determination of glycemic response after consumption of white bread:~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
46042511|NCT04211662|Behavioral|Tailored Multidimensional Intervention. the tailored intervention will be implemented through 6 months using a multidimensional approach (skill building, psychoeducation and peer support).|Skill-building can be defined as training the family caregivers the following skills (1) hands-on training in such skills as positioning, transferring and mobility techniques and assistance with activities of daily living; (2) coping strategies and stress management (3) communicating with healthcare professionals. Psycho-education is teaching and provision the family caregivers the knowledge and information regarding stroke (stroke definition, types of stroke, risk factors, prevention of recurrent stroke, medication management, stroke complications and measures for prevention and management of these complications). Besides, family caregivers will be taught and given the knowledge and information regarding managing stroke survivors' emotions and behaviors. Peer support can be defined as engaging the family caregivers of stroke survivors in interactions with their peers for support and exchanging advices and experiences.
46042512|NCT04315688|Drug|insulin degludec|Treatment with Tresiba® with or without anti-diabetes medication (as per local label), as prescribed by the participant's physician. The study population will include adult patients with type 2 diabetes, both insulin naïve and previously insulin treated, for whom the treating physician has decided to initiate treatment with Tresiba®, independent of the decision to include the patient in the study.
45475099|NCT04521556|Procedure|Epidural anesthesia with light general anesthesia|"Epidural anaesthesia: mixture of ropivacaine 6.5 mg/ml and fentanyl 8.3 μg/ml.~Light general anesthesia: isoflurane in mixture of 50/50 of nitrous oxide and oxygen to achieve Minimum alveolar concentration between 0.6 and 0.8."
45346160|NCT02543164|Other|TEST: b-glucan enriched bread|"Determination of glycemic response after consumption of bread enriched with barley beta-glucans (Test A) :~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
45346161|NCT00884494|Drug|Ghrelin infusion to assess effects on insulin sensitivity|
45346162|NCT00875992|Device|ETN with ASLS|Angle stable locking of ETN using ASLS
45346163|NCT00875992|Device|ETN locked with conventional locking bolts|Conventional surgical procedure
45684861|NCT02692768|Other|Live Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive live music relaxation and education for practice using a CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
45346164|NCT00881686|Drug|adenosine|1.5mg/Kg adenosine will be administered intravenously before surgery
45346165|NCT00885508|Drug|Lenalidomide|"Induction treatment Lenalidomide 10 mg once daily PO during 3 weeks . in combination with classical 7+3 chemotherapy.~Consolidation treatment 6 monthly courses of : Lenalidomide 10 mg/ d during the first 2 weeks in combination with classical 5+1 consolidation chemotherapy~Maintenance treatment Lenalidomide 10 mg/d 2 weeks every month until relapse~In absence of toxicity, 20 additionnal patients will be included with lenalidomide dose of 25mg/J, then 20 other additionnals patients with Lenalidomide 50mg/J"
45346166|NCT02543086|Drug|KAE609|Study drug
45346167|NCT02543086|Drug|Piperaquine Phosphate|Pre-administration of Piperaquine Phosphate will be done to eliminate the asexual form of the parasite and induce gametocytaemia before characterizing the activity of KAE609 in clearing sexual blood stage parasites from the blood of healthy subjects in the Induced Blood Stage Malaria Challenge model in Part B of study
45346168|NCT00885586|Device|Sham-laser acupuncture|Laser irradiation is faked, approaching a non-functioning laser pen.
45346169|NCT00885586|Drug|gabapentine|Patients in this arm are treated individually with gabapentine 900 mg/d - 3600 mg/d, according to the recommended scheme given by the manufacturer
45346170|NCT00885586|Procedure|Acupuncture|The needle acupuncture technique used in this trial is performed according the traditional way (TCM) using expendable needles.
45346171|NCT02543242|Device|InToneTM (InControl Medical, LLC) - Medical Device|
45346172|NCT02543008|Procedure|Physical activity plus thoracic mobilization|Information already included in arm/group descriptions.
45346173|NCT02543008|Procedure|Physical activity|Information already included in arm/group descriptions.
45346174|NCT02543008|Procedure|Placebo|Information already included in arm/group descriptions.
45346175|NCT02542930|Radiation|Radiotherapy|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
45475100|NCT04521556|Procedure|Postoperative epidural analgesia|Before the end of operation was given 4 ml of the mixture of ropivacaine 4.4 mg/ml and morphine 0.8mg/ml. Epidural analgesia was continued for next 24 hours with a mixture of ropivacaine 2.2 mg/ml and morphine 0.4 mg/ml.
45684862|NCT02692768|Other|Recorded Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive explanation for using the recorded routine on CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
45684863|NCT02692768|Other|Control|Patients will receive standard of care without any music therapy intervention. These patients will have pain and anxiety measures taken at the same contact points as the music therapy intervention groups.
45346176|NCT02542930|Drug|Thymalfasin|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin; Thymalfasin treatment is given twice a week with an interval of 3-4 days each week.
45346177|NCT00704730|Drug|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths administered orally daily
45346178|NCT00704730|Drug|Placebo|Gelatin capsules color and size-matched to XL184 capsules administered orally daily
45346179|NCT00881764|Procedure|Inguinal hernia surgery|Non-experimental procedure
45346180|NCT00881764|Procedure|General anesthesia|Non-experimental procedure/treatment
45346181|NCT04038034|Dietary Supplement|CoQ10- MINIACTIVES|COQUN oral formulation 100 mg BID
45346182|NCT04038034|Dietary Supplement|Placebo|Placebo
45346183|NCT04037878|Procedure|Transversus Abdominis Plane Block(TAP Block)|Under ultrasound guidance, a 22 gauge stimuplex needle will be used to approach the transversus abdominis plane and 20ml of 0.25% Bupivicaine will be infiltrated into the TAP space. This procedure will be performed on either sides once anesthesia is induced.
45346184|NCT04037878|Procedure|Intra-peritoneal infiltration|Before skin closure, the surgeon will infiltrate the peritoneal cavity using a mixture of bupivicaine and epinephrine
45346185|NCT04037878|Drug|PCIA Tramadol|All patients will be given patient controlled intravenous analgesia using Tramadol as the drug
45346186|NCT00881842|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
45346187|NCT02542852|Drug|atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg|Switch to single arm treatment atazanavir-ritonavir 300-100 mg + dolutegravir 50 mg therapy for 24 weeks
45346188|NCT05668416|Other|education|The training includes brochures and oral training prepared by the researchers in line with the literature and the training given in the hospital. Education brochure (Day surgery training brochure); An educational brochure was prepared by the researchers in line with the literature and practices in the institution. The brochure was composed of 3 sections: pre-operative, on the day of the operation and after the operation.
45346189|NCT00651261|Drug|cytarabine|Given IV
45346190|NCT00651261|Drug|daunorubicin|Given IV
45346191|NCT00651261|Drug|midostaurin|Given orally
45346192|NCT00651261|Other|placebo|Given orally
45346193|NCT00651261|Drug|dexamethasone acetate|ocular medication administration
45346194|NCT00885820|Drug|Tacrolimus|Oral
45346195|NCT00885820|Drug|MMF|Oral
45346196|NCT00885820|Drug|Corticosteroids (Prednisone)|Oral
45475101|NCT04521556|Procedure|General anesthesia|"Maintaining general anesthesia: nitrous oxide and oxygen in mixture 50/50 and isoflurane to achieve minimum alveolar concentration between 0.8 and 1.~Fentanyl loading dose: 6-8 μg/kg. Additional fentanyl doses were given incrementally."
45475102|NCT04521556|Drug|Continuous intravenous analgesia|Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
45346197|NCT05481216|Other|COVID-19|Diagnosed with COVID-19 infection
45346198|NCT05481216|Other|HIV-1 infection|Diagnosed with HIV-1 infection
45346199|NCT02542618|Behavioral|Inquiry Based Stress Reduction (IBSR)|
45346200|NCT02542618|Behavioral|Cognitive Behavioral Therapy (CBT)|
45346201|NCT02542774|Other|No intervention is given.|This study is based on the analysis of linked electronic health records (CALIBER dataset)
45346202|NCT02567838|Drug|Lidocaine gel|Instillagel (2% lidocaine) was administered rectally prior to probe insertion.
45346203|NCT02567838|Drug|Placebo|Placebo (Aquagel) was administered rectally prior to probe insertion.
45346204|NCT00885898|Procedure|Non-invasive-ventilation|increased oxygen fraction, continuous positive pressure ventilation, if necessary pressure support ventilation or even intermittent positive pressure ventilation
45346205|NCT00885898|Procedure|conventional treatment|oxygen, diuretics, bronchodilators, positive inotropic drugs
45346206|NCT05462574|Other|No Intervention|No Intervention
45346207|NCT00651183|Drug|Pramipexole immediate release|
45346208|NCT00810381|Drug|Nitroglycerin|intravenous infusion; 0, 0.125, 0.25, 0.5, 1 and 2 µg/kg/min; 20 minutes per infusion step
45346209|NCT00810381|Drug|Isosorbide-Dinitrate|intravenous infusion; 0, 0.5, 1, 2, 4, and 6 µg/kg/min; 20 minutes per infusion step
46042513|NCT05210062|Other|Iterative exposure to suxamethonium during ECT sessions|"The study is divided into 2 phases: phase P and phase E. Phase P: 10 patients to be included in 1 month with a unique dose of suxamethonium during one session of ECT. One blood sample will be taken from patients before their index ECT session. The objective is to evaluate the feasibility of antibody detection relative to the main objective of the study, to ensure the number of patients to include in phase E (analysis in the following month). Depending on the frequency of antibodies detected, particularly IgG4, the number of patients required for phase E will be revised. If no antibodies are detected, the study will be discontinued.~Phase E: 60 patients to be included in 12 months with 5 blood samples: before the first session of ECT (S0), at 2 weeks (S2), at 4 weeks (S4), between 6 - 14 weeks (preferably at S10) and at 6 months (M6). Only first-time patients or those not having been exposed to ECT in the past 10 years will be included in this phase."
45346210|NCT00810381|Drug|Sodium-nitroprusside|intravenous infusion; 0, 0.25, 0.5, 1, 2, and 4 µg/kg/min; 20 minutes per infusion step
45346211|NCT00810381|Drug|Physiologic saline solution (control substance)|intravenous infusion, infusion period 120 minutes
45346212|NCT02553057|Device|mechanical ventilation|
45346213|NCT00800319|Drug|RDC-0313|Oral solution given in 5, 15, 25, 50, and 75 mg single doses
45346214|NCT00800319|Drug|Placebo|Volume matched placebo; oral solution; single dose
45346215|NCT00813501|Biological|immunosuppressive therapy|
45346216|NCT00813501|Other|immunological diagnostic method|
45346217|NCT00813501|Procedure|allogeneic hematopoietic stem cell transplantation|
45346218|NCT00699972|Drug|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
45346219|NCT00699972|Drug|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
45346220|NCT00699972|Drug|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
45346221|NCT00800475|Drug|Gemfibrozil Tablets|
45346222|NCT00810849|Drug|Prednisolone|Prednisolone and placebo will be supplied as 5 mg identical tablets and given at a dosage of 120 mg/day in the first week, followed by 90 mg/day in the second week, 60 mg/day in the third week, 30 mg/day in the fourth week, 15 mg/day in the fifth week, and 5 mg/day in the sixth week.
45346223|NCT00810849|Biological|Mycobacterium w immunotherapy|Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months). Patients in the control arm of the Mycobacterium w comparison will receive a similar regime of placebo injections of normal saline in identically-packaged vials.
45346224|NCT00922311|Drug|Aliskiren|Titrate from 150 mg daily to 300 mg daily
45684864|NCT02688556|Drug|cyclosporine|
45684865|NCT02688556|Drug|vehicle of OTX-101|
45346225|NCT00810927|Procedure|Suction cup application|he IOP will be raised by a 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
45346226|NCT00810927|Procedure|Laser Doppler flowmetry|Measurement of choroidal blood flow
45346227|NCT00810927|Procedure|Measurement of intraocular pressure|
46042514|NCT01001520|Drug|Tolcapone|"Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period."
45346228|NCT00813657|Behavioral|Exercise|Women in the intervention group were enrolled in three sessions/week of individually supervised, resistance exercise training performed over the second and third trimester of pregnancy (in total 26 weeks, ~80 training sessions). Heart rate (HR) was carefully and individually controlled (≤80% of age-predicted maximum HR value, 220-age) through a heart rate monitor during the training sessions. In brief, each session consisted of 35-40 minutes of exercise divided in a light intensity (≤60% maximal heart rate) warm-up period (~8 minutes), followed by toning and very light resistance exercises (~20 minutes) and a light intensity cool-down (~8 minutes) period. Resistance exercises were performed with barbells (≤3kg per exercise) or low-to-medium resistance bands (Therabands).
46042515|NCT01001520|Drug|Placebo|"Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period."
45475105|NCT03204279|Drug|Netupitant|Netupitant 1.33 mg/kg oral suspension up to a maximum of 100 mg
45346229|NCT00811005|Radiation|8-methoxypsoralen or 5- methoxypsoralen|"Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
45346230|NCT00811005|Radiation|8-methoxypsoralen or 5methoxypsoralen|"PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
45346231|NCT00813735|Drug|Eszopiclone|Eszopiclone 2mg daily at bedtime
45475106|NCT03204279|Drug|Palonosetron|Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
45475107|NCT03204279|Drug|Netupitant|Netupitant 4 mg/kg oral suspension up to a maximum of 300 mg
45346232|NCT00813735|Drug|Placebo|Placebo daily at bedtime
45475108|NCT03204279|Drug|Palonosetron|Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
45475109|NCT02524301|Drug|Positron Emission Tomography using [11C]diprenorphine|PET using [11C]diprenorphine
45475110|NCT03122782|Drug|Topical application Tranexamic acid|Tranexamic acid (TXA) will be injected to distinction media during hysteroscopy in myomectomy
46042516|NCT00619840|Drug|methylphenidate hydrochloride|sustained release, 10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
46042517|NCT00619840|Drug|Placebo|10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
45346233|NCT00813735|Drug|Escitalopram|Escitalopram 10mg or 20mg
45346234|NCT05066217|Drug|Clemizole HCl|Double-Blind Randomized
45346235|NCT05066217|Drug|Placebo to match EPX-100|Double-Blind Randomized
45346236|NCT00811083|Drug|DMSA - dimercaptosuccinic acid|dose of 10 mg/kg bodyweight 3 doses/day, for 3 days, followed by 11 days off
45346237|NCT00642759|Drug|carboplatin|Given by infusion on day 1 of each 3 week cycle for a maximum of 6 cycles
45346238|NCT00642759|Drug|Nab-paclitaxel|Given by infusion once weekly (days 1, 8 and 15) of each three week cycle for a maximum of 6 cycles
45475111|NCT03122782|Drug|Placebo (Normal saline)|5ml of normal saline will be added to every 500 ml of distension media
45475112|NCT04938414|Diagnostic Test|Lumbar puncture|Lumbar puncture to obtain the cerebrospinal fluid and for diagnostic test
46042518|NCT02871258|Device|The MetaNeb® System|
45346239|NCT00642759|Drug|Bevacizumab|IV infusion
45346240|NCT00813891|Drug|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week prior to PDT with verteporfin
45346241|NCT00813891|Drug|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week after PDT with verteporfin
45346242|NCT00813891|Drug|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab with no accompanying PDT with verteporfin
45346243|NCT00817557|Drug|Loteprednol|Anti-inflammatory
45346244|NCT00817557|Other|Rewetter|
45475113|NCT01291433|Drug|Pentoxifylline placebo|Placebo for pentoxifylline 400 mg, 1 cp twice a day (7d/7)
45475114|NCT01291433|Drug|Pentoxifylline|Pentoxifylline 400 mg: 1 cp twice a day (7d/7)
46042519|NCT04463082|Procedure|Intravenous administration of fluids|Intravenous administration of fluids (20ml/kg, but the maximum volume will be limited up to 500ml) within 60 minutes.
45475115|NCT01291433|Drug|Tocopherol acetate|Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
45475116|NCT01291433|Drug|Clodronic Acid|Clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
45475117|NCT01291433|Drug|Tocopherol placebo|Placebo for Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
45475118|NCT01291433|Drug|Clodronate placebo|Placebo for clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
45475119|NCT04832841|Diagnostic Test|anti-spike SARS-CoV-2 IgG|Immunochemiluminescent assay by DiaSorin S.p.A. Italy
45346245|NCT00811161|Device|Airgent|HA needle free injection, 3-4 treatments, 3-4 weeks apart
45346246|NCT00611026|Drug|Tolterodine ER|The tolterodine treatment will be 4 mg once daily(QD) for 12 weeks.
45346247|NCT00611026|Drug|Placebo|Placebo treatment will be once daily(QD) for 12 weeks.
45346248|NCT00611026|Drug|Fesoterodine|The fesoterodine treatment will start with 4 mg once daily(QD) for 1 week followed by a forced dose-escalation to 8mg once daily(QD) for 11 weeks.
45346249|NCT00813969|Biological|Autologous mesenchymal stem cell transplantation|A single IV infusion of up to 2 million cells per kg based on the MSC numbers achieved after culture expansion
45346250|NCT02552589|Other|Amine fluoride|toothpaste
45346251|NCT02552589|Other|Placebo|toothpaste
45346252|NCT00811239|Drug|Bungarus multicinctus-candidus Antivenom|Five to ten ampoules of antivenom, depending on severity of muscle paralysis, were diluted with isotonic glucose solution to have total 50 ml and infused intravenously by electric pump during one hour. After a period of 6-8 hours, a second infusion was administered, under similar condition to the first, if no clinical improvement or adverse reaction had been noted. The patients also received supportive care such as intubation, ventilation...if necessary.
45346253|NCT00811239|Other|Supportive Care|Supportive Care only (endotracheal intubation, mechanical ventilation...)
45346254|NCT00814047|Drug|Yohimbine hydrochloride|
45346255|NCT00646113|Device|OsseoSpeed™ TX 3.0S|OsseoSpeed™ TX 3.0 mm diameter
45346256|NCT00814125|Drug|Anastrozole (Arimidex)|1mg, orally, once daily
45346257|NCT00814125|Drug|Tamoxifen (Nolvadex)|20mg, orally, once daily
45346258|NCT00814125|Drug|Nolvadex placebo|
45346259|NCT00814125|Drug|Arimidex placebo|
45475120|NCT04517422|Dietary Supplement|Probiotics|Combination of Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, and Pediococcus acidilactici CECT 7483
45475121|NCT04517422|Other|Placebo|Combination of maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0
45475122|NCT01314144|Drug|Bupivacaine|intraoperative wound soakage with 20ml of 0.5% bupivacaine with epinephrine and continuous infusion of 4ml/hr of 0.2% bupivacaine for 48 hours postoperatively
45346260|NCT04016883|Other|Problem Solving Therapy offered through a web platform|Problem Solving Therapy offered through a web platform. There will be four sessions, during the first four weeks of treatment, and subsequent sessions are dedicated to refining problem-solving skills. Participants set treatment goals; different ways to reach goals are discussed and evaluated; action plans are created, and its effectiveness is evaluated to achieve the objectives. Participants are expected to implement plans and apply the problem-solving model to additional problems between sessions. In the last two sessions, participants create a relapse prevention plan using the problem-solving therapy model.
45346261|NCT04016883|Other|Conventional web platform|The conventional web platform, which will contain the general content on stress coping techniques.
45346262|NCT00817713|Drug|Praziquantel, Ivermectin, Albendazole|"Standard HIV care plus triple anthelminthic treatment~Praziquantel 2400mg single dose~Ivermectin 12 mg, single dose~Albendazole 400mg, 2 doses in 1 day~All drugs given at baseline, after 6 months and after 12 months."
45346263|NCT00422383|Drug|rituximab [MabThera/Rituxan]|500mg iv in days 1 and 15, and 500mg iv on days 168 and 182
45346264|NCT00422383|Drug|rituximab [MabThera/Rituxan]|500mg iv on days 1 and 15, and 1000mg iv on days 168 and 182
45346265|NCT00422383|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15 and 1000mg iv (or placebo in UK)on days 168 and 182
45346266|NCT00814281|Other|placebo|Placebo
45346267|NCT00814281|Drug|Montelukast|10 mg ingested orally 1 hour prior to exercise testing
45346268|NCT00817791|Device|Hyperbaric oxygen pretreatment (GR2200)|2 hours/day,5 days before surgery
46042520|NCT02344108|Device|Inspire® Upper Airway Simulation System (Model 3028 IPG )|Subjects will be implanted with a hypoglossal nerve stimulator. Safety and efficacy of implantation will be evaluated.
45346269|NCT00811551|Device|CRT-D (Intra-thoracic Impedance Monitoring)|Diagnostic Feature in CRT-D device that emits a sub-threshold pulse to measure resistance between two electrodes.
45346270|NCT02542540|Other|Training with Nintendo Wii console|Children with OI and draining for 3 months using Nintendo Wii console
45346271|NCT00811629|Other|sRAGE|The purpose of this observational prospective study is to determine wether sRAGE could be used in an ICU setting as a potential diagnostic and prognostic marker during ALI/ARDS, regardless of associated severe sepsis or septic shock
45684866|NCT01925209|Drug|BYM338/bimagrumab|BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
45684867|NCT01925209|Drug|Placebo|Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
45684868|NCT02684032|Drug|Gedatolisib|Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.
46042521|NCT04415658|Drug|Thyroxine|Infusion prepared by mixing 500 μg of drug in 500-ml of normal saline (i.e. concentration of 1 μg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 μg/hour (30 ml/hour) for twelve hours.
45346272|NCT02542228|Other|questionnaire survey|The HR-QOL PIDD survey will be administered to the patient by the site PI or the study coordinator. A second survey will be handed to the patient to take home with them and completed at 48-120 hrs. after the clinic visit. The study coordinator will contact the patient during this period to ensure that the patient completes this second survey and returns it to the local study site. A case report form (CRF) of their clinical condition and demographics will be collected at the time of informed consent.
45346273|NCT00814359|Drug|Combination of Magic Mouthwash Plus Sucralfate|"Magic mouthwash will contain diphenhydramine powder 375mg, dexamethasone injection 2.8mg, and nystatin suspension 50ml (1000 units/ml) diluted to a total volume of 250ml with sterile water.~The concentration of the sucralfate suspension will be 1g/5ml.~Patients will be instructed to rinse first with 5ml of the magic mouthwash solution for 2 minutes then swallow, followed by rinsing with 5ml of the sucralfate suspension for 2 minutes before swallowing, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy."
45475123|NCT01182155|Procedure|Exhaled Breath Sampling|Standard of care
45475124|NCT04516798|Other|vibration|local and whole-body vibration were applied
46042522|NCT04415658|Drug|Saline|The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours.
46042523|NCT02871024|Device|Toraymyxin|Toraymyxin is an extracorporeal hemoperfusion device designed to reduce blood endotoxin levels in sepsis
46042524|NCT01189604|Drug|Placebo|Infusion of placebo, same infusion rates as for arm 2
46042525|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.17 mg/kg for 3 minutes followed by maintenance with 25 µg/kg/minute
45475125|NCT01186601|Drug|PET tracer (BAY94-9392)|A radioactive dose of 300 MBq of the study drug with a total quantity of </= 0.1 mg will be administered as slow intravenous bolus injection over up to 60 seconds
45346274|NCT00814359|Drug|0.15% Benzydamine HCl|Patients will rinse with 15ml of 1.5mg/ml benzydamine HCl for 2 minutes then expectorate the solution, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy.
45346275|NCT00817869|Other|New flooring|8.3mm thick vinyl floor covering with foam backing, manufactured by Tarkett and installed by Tyndale Flooring Ltd.
45346276|NCT00612040|Drug|insulin degludec|Formulation 1: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
45684869|NCT02684032|Drug|Palbociclib|Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.
45346277|NCT00612040|Drug|insulin degludec|Formulation 2: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
45346278|NCT00612040|Drug|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
45346279|NCT00612040|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily
45346280|NCT00422227|Drug|Etanercept , Methotrexate|"Etanercept: 25 mg twice weekly over 16 weeks, SC~Methotrexate: > 7.5 mg/week and no more than 25 mg/week, PO"
45346281|NCT00422227|Drug|Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide|"Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO~Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO~Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day~Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily"
45346282|NCT02551497|Drug|CNV1014802|
45475126|NCT03354208|Other|blood sampling|small volume blood sampling, according to local laws, is not categorized as intervention (observational study)
45475127|NCT03173547|Drug|146-9251 cream|146-9251 cream contains an active drug and is applied topically.
45475128|NCT03173547|Drug|Vehicle cream|Vehicle cream does not contain an active drug and is applied topically.
45475129|NCT01314378|Behavioral|Mindfulness Training|Eight session intensive behavioral training program for smokers
45475130|NCT01314378|Behavioral|Cognitive-Behavioral Therapy|Eight session intensive behavioral intervention for smokers
45346283|NCT00811785|Drug|Copper Histidine|Daily subcutaneous injections for three years
45346284|NCT00814515|Drug|NOVA22007 (Ciclosporin 0.1%)|Ciclosporin 0.1% Ophthalmic Emulsions
45346285|NCT00814515|Drug|NOVA22007|Vehicle
45346286|NCT00814593|Biological|lymphokine-activated killer cells|Instilled into the tumor bed cavity
45346287|NCT00814593|Drug|polifeprosan 20 with carmustine implant|Intracranial placement
45346288|NCT02542306|Drug|fibrinogen concentrate|Investigators administered fibrinogen concentrate when the plasma fibrinogen level was below 1.5 g/L at 5 minutes after protamine reversal and completion of surgical hemostasis in patients, who comprised the fibrinogen concentrate-treated group.
45346289|NCT00817947|Device|High frequency chest wall oscillation|Airway clearance using high frequency chest wall oscillation ('The Vest')
45346290|NCT00421993|Drug|Adapalene/Benzoyl Peroxide|Topical Gel, One application daily in the evening for 12 weeks
45684870|NCT02684032|Drug|Letrozole|Letrozole at 2.5 mg daily
45684871|NCT02684032|Drug|Fulvestrant|Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.
45684872|NCT01614925|Device|Emdogain|Periodontal surgery with the additional use of Straumann® Emdogain
46042526|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.33 mg/kg for 3 minutes followed by maintenance with 50 µg/kg/minute
45346291|NCT00421993|Drug|Adapalene|Topical Gel,One application daily in the evening for 12 weeks
45346292|NCT00421993|Drug|Benzoyl Peroxide|Topical Gel, one application daily in the evening for 12 weeks
45346293|NCT00421993|Drug|Topical Gel Vehicle|Topical Gel Vehicle,one application daily in the evening for 12 weeks
45346294|NCT00884884|Drug|Double Placebo|1 capsule daily
45346295|NCT00884884|Drug|Aripiprazole 15, placebo|15 mg Aripiprazole daily plus placebo daily
45346296|NCT00884884|Drug|Aripiprazole 7.5, Placebo|Aripiprazole 7.5 mg daily plus Placebo daily
45684873|NCT01614925|Procedure|Periodontal surgery|Periodontal surgery alone
45684874|NCT02388178|Drug|Control toothpaste containing no anti-cavity ingredients|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
46042527|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 3 minutes followed by maintenance with 75 µg/kg/minute
46042528|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.8 mg/kg for 3 minutes followed by maintenance with 120 µg/kg/minute
46042529|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 1 minutes followed by maintenance with 75 µg/kg/minute
46042530|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 5 minutes followed by maintenance with 75 µg/kg/minute
46042531|NCT02697058|Biological|BAX2398 + 5-FU/calcium levofolinate|BAX2398 (a liposomal formulation of irinotecan) in combination with 5-FU/calcium levofolinate
46042532|NCT02697058|Drug|5-FU/calcium levofolinate|5-FU/calcium levofolinate alone
45684875|NCT02388178|Drug|Experimental toothpaste containing fluoride and amino acid (arginine)|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
45684876|NCT02388178|Drug|Fluoride toothpaste containing fluoride as the anti-cavity ingredient|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
46042533|NCT04294524|Other|Sleep apnea treatment|Sleep apnea treatment as decided according to routine practice. This may be Continuous positive airway pressure (CPAP) or wearing a mandibular advancement device (MAD).
46042534|NCT05661994|Dietary Supplement|Omega-3 fatty acid supplementation|"Patients with CAD were divided into the Omega-3 Group (n:16) and Control Group (n:18) to evaluate the effects of omega-3 FA supplementation on biochemical parameters, especially serum fetuin-A, anthropometric measurements, and nutritional status. 1.560 mg/day omega-3 FA supplementation was applied for 8 weeks to 16 participants with CAD included in the omega-3 group."
46042535|NCT04294602|Other|Exercise|Exercise therapy intended in reducing muscle spasm, improving coordination of the mastication muscles and alter the jaw closure pattern.
46042536|NCT04294602|Other|Low Level Laser Therapy|LLLT (max output power: 1200mW, wavelength: 808 nm, dosage: 10j/ cm2 Electronica Pagani Laser Tower Light, Italy) 2.5-4j/TrP dosage was applied to MTrP or sensitive points.
45346297|NCT00884884|Drug|Topiramate 100, Placebo|Topiramate 100 mg daily plus Placebo daily
45346298|NCT00884884|Drug|Topiramate 200, Placebo|Topiramate 200 mg daily plus Placebo daily
45346299|NCT00884884|Drug|Topiramate 100, Aripiprazole 15|Topiramate 100 mg daily plus Aripiprazole 15mg daily
46042537|NCT04294602|Other|Manuel Pressure Release|MPR technique is a noninvasive method based on pressure on the trigger point in accordance with the patient's tolerance and technique applies supine position relax as much as possible, manuel pressure applied trigger point in neck and mactication muscles
46042538|NCT04294602|Other|Patient Education|Some suggestions were made to TMD people who should pay attention to in daily life. These suggestions were given in writing.
46042539|NCT02696824|Behavioral|Cognitive Behavioral Therapy for Adherence and Depression|"This treatment involves integrating CBT for depression with CBT for adherence following our Life-Steps approach."
46042540|NCT04296786|Drug|Sintilimab|200mg intravenously on day 1, every 21 days for 1 cycle, 96 weeks for protocol treatment
46042541|NCT04296786|Drug|Chidamide|20mg po per week continuously
46042542|NCT00622414|Biological|ziv-aflibercept|Given IV
45346300|NCT00884884|Drug|Topiramate 100, Aripiprazole 7.5|Topiramate 100 mg daily plus Aripiprazole 7.5mg daily
45346301|NCT00884884|Drug|Topiramate 100, Aripiprazole 15mg|Topiramate 100 mg daily plus Aripiprazole 15mg daily
45346302|NCT00884884|Drug|Topiramate 200, Aripiprazole 7.5mg|Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
45346303|NCT00884884|Drug|Topiramate 200, Aripiprazole 15|Topiramate 200mg daily plus Aripiprazole 15mg daily
45346304|NCT00818025|Behavioral|Pocket PATH (Personal Assistant for Tracking Health)|Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
46042543|NCT01008696|Drug|Rabeprazole|Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
46042544|NCT01008696|Drug|Lansoprazole|Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
46042545|NCT01955980|Drug|Budesonide|Inhalation
46042546|NCT01955980|Drug|Budesonide|Nasal Spray
46042547|NCT02870478|Drug|Atropine|Dosing frequency comparison, using atropine sulfate 1% solution diluted to 0.01% and 0.05% by Leiter's Compounding Pharmacy
46042548|NCT00622492|Other|echocardiography Doppler sonography, blood and urine sampling|data registration and collection at standard intervals from directly before cannulation until 24 hours after decannulation from ECMO
46042549|NCT05661838|Procedure|transfusion|transfusion
46042550|NCT04296162|Drug|Vinorelbine|Vinorelbine chemotherapy (oral)
46042551|NCT04296162|Drug|Capecitabine|Capecitabine chemotherapy (oral)
46042552|NCT04296162|Drug|Trastuzumab|Trastuzumab target therapy
46042553|NCT00619996|Drug|Sorafenib (Nexavar)|"Sorafenib 400 mg bid orally continuously~Sorafenib will be administered from the start of treatment in combination with Docetaxel until progression of disease."
46042554|NCT00619996|Drug|Docetaxel|Docetaxel 75 mg/mq ev g1 every 21 days. Docetaxel will be administered for a maximum of 9 cycles.
46042555|NCT02870790|Drug|TDF/FTC|one pill daily
46042556|NCT05028400|Device|Laser speckle contrast imaging (LSCI)|LSCI videos will be recorded automatically intraoperatively in each patient before, during, and after ICGA and/or FA in the same surgical field of view to guarantee comparability of the methods.
46042557|NCT05661526|Other|Bloodpoly board game|Blood transfusion training given by Bloodpoly board game
45346305|NCT00884962|Device|Polymeric Lung Volume Reduction System (PLVR)|20ml (each) of polymer will be injected into 2, 3 or 4 subsegments during the first treatment. Eligible patients may have 20ml (each) of polymer will be injected into 2 or 3 subsegments during the second treatment.
45346306|NCT00814749|Procedure|midureteral sling|midureteral sling
45346307|NCT00814749|Other|surgical therapy or conservative|midureteral sling or conservative; medication, physiotherapy
45346308|NCT01037725|Drug|AZD5847|"Part A - Oral doses given to approximately 6 cohorts of 8 subjects (6 on active and 2 on placebo) on Day 1.~Part B - Oral doses of AZD5847 given to 1 cohort of 8 subjects on Days 1 and 8 in either a fasted state or with a high fat meal"
45346309|NCT01037725|Drug|Placebo to AZD5847|In Part A - Single oral doses of AZD5847placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) on Day 1
45346310|NCT02551029|Other|Capsaicin|
45346311|NCT02551029|Other|Placebo|
46042558|NCT05661526|Other|Text-to-speech group|Blood transfusion training given by text-to-speech
46042559|NCT00622570|Drug|Pentobarbital|10 mg/kg in 30 minutes; then 5 mg/kg/h during 3 hours; then 1 mg/kg/h
46042560|NCT00622570|Drug|thiopental|"2 mg/kg in bolus; if ICP is not below 20 mmHg then 3 mg/kg in bolus; if ICP is not below 20 mmHg it can be administrated a third bolus of 5 mg/kg.~Maintenance: 3 mg/kg/h in perfusion"
46042561|NCT04208308|Dietary Supplement|Chia seeds supplementation (25 g)|Dosage: 1 daily dose energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg
46042562|NCT04208308|Dietary Supplement|Chia seeds supplementation (15 g)|Dosage: 1 daily dose energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg
45346312|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 0% of MF59.
45346313|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 25% of MF59.
45475131|NCT01182233|Radiation|Total Skeletal Irradiation|Escalating doses of TSI starting at 200cGy (escalating up to 400cGy unless maximum tolerated dose is determined in lower dose level) in cohort 1 over 5 days followed by high dose melphalan and cytoprotection followed by autologous hematopoietic stem cell transplant
46042563|NCT04208308|Dietary Supplement|Combine supplementation: chia seeds (15g) and fish oil Maxi Cor 70+20|"Chia seeds - 1 daily dose Fish oil TID~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
45475132|NCT03350308|Other|hemodialysis|The main objective is to establish a statistical predictive model of the risk of intradialytic hypotension during hemodialysis (HD) or hemodiafiltration (HDF) sessions based on the measurement of residual blood volume and excess extracellular hydration
45475133|NCT02954653|Biological|PF-06747143|PF 06747143 is a humanized IgG1 monoclonal antibody (mAb) that is an antagonist of CXCR4.
45346314|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 50% of MF59.
46042564|NCT04208308|Dietary Supplement|Fish oil supplementation|"TID~Daily dose:~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)"
46042565|NCT01473004|Device|Sir-Spheres®|Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.
45346315|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 100% of MF59.
45475134|NCT02954653|Drug|Cytarabine|100-200 mg/m2 continuous infusion for 7 days)
45475135|NCT02954653|Drug|Daunorubicin|60-90 mg/m2 daily for 3 days
46042566|NCT05368792|Dietary Supplement|Complex Carbohydrate (PREcovery)|Each serving of the complex carbohydrate drink is a clear, colorless, 12.5% maltodextrin drink with a citrus taste, prepared by mixing 54 g of powder (50g carbohydrate) with 400mL of cold water. Participants will consume 2 servings of the complex carbohydrate drink the evening before colonoscopy (100g carbohydrate, 800mL fluid), and 1 serving 2 hours before their colonoscopy (50g carbohydrate, 400mL fluid)
46042567|NCT04141072|Diagnostic Test|Shrunken Pore Syndrome|eGFR Cystatin C ≤ 60% of eGFR Creatinine
46042568|NCT00925678|Drug|DSP-3025|
46042569|NCT00925678|Drug|Placebo|
46042570|NCT00890266|Procedure|Collagen cross-linking with hypotonic riboflavin|Topical anaesthesia, corneal epithelial debridement, application of hypotonic riboflavin 0.1% solution (20 minutes), application of UV light (30 minutes).
46042571|NCT04208152|Drug|anle138b|capsule containing excipient and anle138b
46042572|NCT04208152|Drug|Placebo|matching placebo capsule containing excipient
45346316|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 0% of MF59.
45346317|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 25% of MF59.
45346318|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 50% of MF59.
45346319|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 100% of MF59.
45475136|NCT02954653|Drug|Azacitidine|75 mg/m2 sub-cutaneous or intravenous for 7 days)
45475137|NCT02954653|Drug|Decitabine|20 mg/m2 continuous intravenous infusion for 5 days in a 4-week schedule
45475138|NCT04504084|Other|Decision aid|Patient Decision Aid is a tool that helps patient with ureteral stone become involved in decision making on choosing treatment for ureteral stone. Patient Decision Aid provides information about the options and outcomes, and by clarifying personal values.
45475139|NCT01186679|Procedure|laminectomy|surgical laminectomy with glial scar resection
45475140|NCT01186679|Procedure|Intrathecal|direct into the CSF through lumbar puncture
45346320|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 0% of MF59.
45346321|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 25% of MF59.
46042573|NCT00622804|Procedure|Billroth-II (B-II)|After conventional distal gastrectomy with lymphadenectomy, jejunum of a distal segment from 10 to 20cm from Treitz is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done.
46042574|NCT00622804|Procedure|Roux en Y gastrojejunostomy (RY-GJ)|After conventional distal gastrectomy with lymphadenectomy, jejunum is transected in the segment from 10 to 20 cm, and then distal end is transposed in a way of retro-colon to perform anastomosis using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done. The resected proximal jejunum and the portion of jejunum distal 45 cm from gastrojejunostomy are anastomosed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture.
46042575|NCT00622804|Procedure|uncut Roux en Y gastrojejunostomy|After conventional distal gastrectomy with lymphadenectomy, jejunum of distal segment 45 cm from Treitz ligament is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture. After anastomosis, afferent loop distal 5cm is obstructed using non-cutting stapler or hand sawing suture. And then, distal jejunum 10 cm from obstructive portion and efferent jejunal loop distal 45 cm from gastrojejunostomy are anastomosed in a manner of side to side followed by reinforcement suture.
46042576|NCT05367934|Behavioral|Therapeutic Touch|Therapeutic Touch for stress
46042577|NCT05661760|Behavioral|interdisciplinary multimodal pain treatment|A combination of physical and psychosocial treatment methods is employed, including Emotional Awareness and Expression Therapy (EAET), Pain Neuroscience Education (PNE), Acceptance and Commitment Therapy (ACT), graded activity, exposure in vivo, and experiential learning through physical training.
45346322|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 50% of MF59.
45346323|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 100% of MF59.
45346324|NCT00413959|Drug|VELCADE®|1.6 mg/m^2 of Velcade® given intravenously on days 1, 8, 15 and 22.
45346325|NCT00413959|Drug|Rituximab|375 mg/m^2 of Rituximab given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
45346326|NCT00413959|Drug|Cyclophosphamide|400 mg/m^2 of Cyclophosphamide given orally on days 1-4 of each cycle.
45346327|NCT00413959|Drug|Decadron|40 mg given orally on days 1, 2, 8, 9, 15, 16, 22 and 23
45346328|NCT00814905|Drug|saline|A saline infusion after delivery (one dose)
45346329|NCT00814905|Drug|ampicillin gentamicin|one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following their vaginal delivery
45346330|NCT00814905|Drug|Ampicillin gentamicin clindamycin|one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
45346331|NCT00814905|Drug|ampicillin gentamicin clindamycin|ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
45475141|NCT03173313|Device|Intravascular permissive hypothermia as an adjunct to PCI|Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI) -or- Standard of Care for PCI
45475142|NCT04895748|Drug|DFF332|Hif2alpha inhibitor
46042578|NCT04210960|Radiation|Magentic resonanace imaging|The brain MR imaging examinations were done by using a 3 tesla scanner (Acheiva; Philips Medical Systems, Best, Netherlands). All patients were examined in the supine position using head coil. Routine images (T2, T1, FLAIR) and double inversion recovery sequence (DIR) were done to all patients: repetition time (TR) _ 9583 sec, echo time (TE) _ 25 sec, inversion time (TI) _ 3400 sec, IR delay _ 325 sec, echo train length (ETL) _ 17, 50 contiguous axial slices, thickness _ 3 mm, matrix size 240× 142 mm2, field of view (FOV) 230× 184 mm2.
45346332|NCT00645567|Device|Unassisted Manual Transfer|No device assistance
45346333|NCT00645567|Device|Standard Transfer Board|Flat surface board
45346334|NCT00645567|Device|Glide n' Go|Flip down power lift chair
45346335|NCT00645567|Device|Easy Reach lift|Original chair is converted to a chair that swivels out of the vehicle and lowers to wheelchair height
45346336|NCT00645567|Device|Ryno lift|Lift for the wheelchair
45346337|NCT00611884|Drug|insulin glargine|Treat-to-target dose titration scheme, s.c. injection.
45346338|NCT00611884|Drug|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, once daily
45346339|NCT00611884|Drug|insulin degludec|Formulation E: Treat-to-target dose titration scheme, s.c. injection, once daily
45346340|NCT00611884|Drug|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, 3 times weekly
45346341|NCT00611884|Drug|metformin|Tablets, 1500-2000 mg/day
45346342|NCT03867825|Device|Non-invasive hemodynamic monitoring|Impedance cardiography
45346343|NCT00420745|Biological|Rotarix™|Two-dose oral vaccination.
45475143|NCT04895748|Drug|RAD001|mTOR inhibitor
45475144|NCT04895748|Drug|PDR001|anti-PD-1
45475145|NCT04895748|Drug|NIR178|Adenosine A2A antagonist receptor
45475146|NCT04508374|Procedure|1470 nm intra-lesional diode laser treatment of right HS tunnel|Ten patients: 1470 nm intra-lesional diode laser treatment of right HS-tunnel randomized to active treatment.
45475147|NCT04508374|Procedure|1470 nm intra-lesional diode laser treatment of left HS tunnel|Ten patients: 1470 nm intra-lesional diode laser treatment of left HS-tunnel randomized to active treatment.
45475148|NCT01182389|Procedure|Robotic VT Ablation|Robotic VT Ablation
45475149|NCT01182389|Other|Conventional Therapy|Review of ICD programming to ensure that detection and therapy will occur appropriately
45475150|NCT05218473|Diagnostic Test|Prolonged ECG monitoring|Using 14-day continuous electrocardiography patch monitoring to increase the detection rate of paroxysmal atrial fibrillation in acute ischemic stroke patients without known atrial fibrillation.
45475151|NCT05218473|Diagnostic Test|Conventional procedure group|Using serial 12-lead electrocardiograms once daily for five days or conventional 24-h Holter monitoring to detect new atrial fibrillation
45475152|NCT01182467|Radiation|PET-CT scan|PET-CT scan performed at baseline to determine SUV-max
45475153|NCT04508452|Drug|Capecitabine-Oxaliplatin-Irinotecan-Bevacizumab Combination|CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; Administered every 2 weeks.
46042579|NCT04210960|Radiation|Magentic resonanace spectroscopy|Magnetic Resonance (MR) spectroscopy is a noninvasive diagnostic test for measuring biochemical changes in the brain.While magnetic resonance imaging (MRI) identifies the anatomical location of a lesion, MR spectroscopy compares the chemical composition of normal brain tissue with abnormal brain tissue. This test can also be used to detect tissue changes in stroke and epilepsy.
46042580|NCT04211038|Device|inspiratory threshold load device|"Before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~And then, the healthy subjects will be increased the neural respiratory drive by increasing the pressure in a water-sealed inspiratory threshold loading device. At last, all subjects will do Incremental cycle ergometry test with the assisstance of NPPV."
45475154|NCT02524223|Other|Systematic HPV DNA assay in semen and cervicovaginal scrape|Screening of HPV status at the genital level of males enrolled in MAP program.
45475155|NCT02524223|Other|Systematic HPV DNA cervicovaginal scrape|Screening of HPV status at the genital level of females enrolled in MAP program.
45475156|NCT02524223|Other|systematic HPV Status in newborns in case of pregnancy|
45475157|NCT03355846|Drug|Centella|after meals twice a day for 15 days
45475158|NCT03355846|Drug|Proctocella|after hygiene treatment for 4 weeks;
45475159|NCT03355846|Drug|Flavonil® cps|after meals twice a day for 15 days
45475160|NCT03355846|Drug|Flavonil® Cream|"treatment for 4 weeks;~."
45346344|NCT00420745|Biological|Placebo|Two-dose oral administration
45346345|NCT00611806|Dietary Supplement|Folic Acid|Folic acid 2mg po daily
45475161|NCT03355846|Drug|Rectalgan Mousse|for 4 weeks
45346346|NCT00611806|Dietary Supplement|B12|B12 400 micrograms po daily
46042581|NCT04187638|Dietary Supplement|Olive oil|Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
45346347|NCT00611806|Other|Placebo|1 capsule po daily
45346348|NCT00413413|Drug|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily
45346349|NCT00413413|Drug|Valsartan 80 mg|1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
45346350|NCT00413413|Drug|Valsartan 160 mg|1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
45346351|NCT00886132|Drug|Sunitinib|37.5 mg taken orally, daily every 28-day cycles
45346352|NCT01040455|Drug|Lansoprazole|lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
45346353|NCT01040455|Drug|placebo|placebo once daily for eight weeks
45346354|NCT01040611|Behavioral|Music therapy|Patients who fit the inclusion criteria were random assigned to either experimental or control group. Patients in experimental group could choose a piece of CD and listen to music with earphone for 30 minutes. Patients in control group just rest for 30 minutes. The procedure was implemented once a day, and sustained for total 5 days.
45475162|NCT03215667|Device|easy-graft CLASSIC (beta-Tricalcium Phosphate)|easy-graft will be grafted to a single extraction socket and covered by polylactide membrane to facilitate regeneration of new bone in order to preserve alveolar ridge dimensions.
45475163|NCT04870788|Behavioral|Mindfulness Relaxation|Participate in mindfulness program
46042582|NCT04187638|Dietary Supplement|Butter|Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
46042583|NCT04211116|Device|Central venous line insertion|Pediatric patients indicated to central venous line insertion
45346355|NCT01040767|Other|Didactic training in basic ultrasound and the EFAST|Physicians in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
45346356|NCT01040923|Device|CardioSond Cardiac Sonospectrographic Analyzer|The CardioSond is a completely noninvasive, FDA 510(k) cleared digital electronic stethoscope designed to detect heart sounds and murmurs using ultrasensitive acoustic technology.
45346357|NCT01041001|Biological|Cartistem|allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product
45346358|NCT01041001|Procedure|Microfracture treatment|
45346359|NCT01041157|Other|Resistance training|Neck muscle trainings effect on botulinum toxin efficiency
45346360|NCT01041235|Drug|ATI-1123 (active drug = docetaxel)|Dose escalation starting at 15 mg/m2 given once every 3 weeks via IV
45346361|NCT01041313|Drug|Memantine|7 days prior to surgery, start taking 5mg memantine daily; 4 days prior to surgery, increase dose to 5mg twice daily; 2 days prior to surgery, increase dose to 10mg in the morning, and 5 mg in the evening; on the day of surgery, increase dose to 10mg twice daily, and continue on this dose until 14 days after surgery.
45346362|NCT01041313|Drug|Placebo|7 days prior to surgery, start taking one placebo tablet daily; 4 days prior to surgery, increase dose to one placebo tablet twice daily; 2 days prior to surgery, increase dose to 2 placebo tablets in the morning, and one placebo tablet in the evening; on the day of surgery, increase dose to 2 placebo tablets in the morning and 1 placebo tablet in the evening. On the first day after surgery through 14 days after surgery, take 1 placebo tablet twice daily.
45346363|NCT01041391|Procedure|Discectomy-lumbar spine|Lumbar intervertebral discectomy performed on patients with herniated disc that chose to have surgical intervention
45475164|NCT04870788|Other|Quality-of-Life Assessment|Ancillary studies
45475165|NCT04870788|Other|Questionnaire Administration|Ancillary studies
45475166|NCT03856853|Drug|Pirfenidone|pirfenidone for SSc-ILD treatment
45475167|NCT03856853|Other|placebo|as control
46042584|NCT04187950|Dietary Supplement|Yogurt with B. lactis and added honey|The intervention condition will utilize a commercially available yogurt (Activia) that contains Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of yogurt with honey twice daily for 14 days.
45346364|NCT03760939|Other|Clinical and economical evaluation|Evaluation of the clinical and the economical impact of a colorectal surgery
45346365|NCT00610714|Drug|AZD0530|oral once daily dose
45346366|NCT00610714|Drug|Carboplatin|intravenous injection
45346367|NCT00610714|Drug|Paclitaxel|intravenous infusion
45475168|NCT03732703|Drug|Abemaciclib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Abemaciclib and Dexamethasone for the first 2 cycles. Abemaciclib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
45475169|NCT03732703|Drug|Enasidenib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Enasidenib and Dexamethasone for the first 2 cycles. Enasidenib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
45346368|NCT00403585|Drug|adefovir dipivoxil 10mg|
45475170|NCT03732703|Drug|Cobimetinib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Cobimetinib and Dexamethasone for the first 2 cycles. Cobimetinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
45346369|NCT04038112|Other|psychological therapy Method of Levels (MOL)|Transdiagnostic, cognitive psychological therapy Method of Levels (MOL)
45346370|NCT00886210|Procedure|intra abdominal drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
45346371|NCT00886210|Procedure|LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group no drain at the end of operation.
45346372|NCT00645411|Biological|Cell culture-derived influenza subunit vaccine (cTIV)|One 0.5 ml injection of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
45346373|NCT00645411|Biological|Egg derived influenza subunit vaccine (eTIV)|One 0.5 ml injection of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
45475171|NCT03732703|Drug|Erdafitinib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Erdafitinib and Dexamethasone for the first 2 cycles. Erdafitinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
45475172|NCT03732703|Drug|Venetoclax, dexamethasone, ixazomib, pomalidomide|Patients with t(11;14) translocation will be enrolled in arm E1 and randomized to the venetoclax or the IPd control arm. Patients with relapsed Multiple Myeloma will receive Venetoclax, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
45346374|NCT00645411|Biological|Cell culture-derived influenza subunit vaccine (cTIV)|Two 0.5 mL injections,of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm, administered four weeks apart.
45475173|NCT03732703|Drug|Daratumumab, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Daratumumab, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
45475174|NCT03732703|Drug|Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Belantamab mafodotin, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
45475175|NCT03732703|Drug|Selinexor, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Selinexor, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
45475176|NCT03636555|Drug|Oxytocin|Oxytocin will be given in an intranasal spray (Syntocinon Spray) twice daily (10 insufflations, 1.0 mL, 40 IU/dose) for 12 weeks
46042585|NCT04187950|Dietary Supplement|Yogurt with heat-inactivated B. lactis and added cane sugar|The control condition will utilize a commercially available yogurt (Activia) following heat inactivation of the probiotic Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of the heat-inactivated yogurt with added cane sugar twice daily for 14 days.The added cane sugar will be an isocaloric amount to the honey.
46042586|NCT02691832|Device|"Dräger double sensor"|"The Dräger Double Sensor is a novel non-invasive device for assessing core body temperature."
45346375|NCT00645411|Biological|Egg derived influenza subunit vaccine (eTIV)|Two 0.5 mL injections of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm,administered four weeks apart.
45346376|NCT04037644|Procedure|Fluid loading with Albumin|Fluid loading with 200 ml of 4% Albumin to reverse acute circulatory failure
45346377|NCT04037644|Procedure|Fluid loading with Ringer Lactate|Fluid loading with 5 ml per kg of actual body weight to reverse acute circulatory failure
45475177|NCT03636555|Drug|Placebo|Placebo solution (contained all the ingredients in Syntocinon Spray except for oxytocin) will be given as an intranasal spray twice daily (10 insufflations, 1.0 mL/dose) for 12 weeks
45475178|NCT03636984|Drug|recombinant TNF-α receptor: IgG Fc fusion protein|50mg weekly
45346378|NCT00403273|Drug|Botulinum toxin A|100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
45346379|NCT00403273|Drug|Normal Saline|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
45346380|NCT00885274|Drug|Pico-Salax|Both doses of Pico-Salax taken the evening prior to colonoscopy
45475179|NCT01186757|Drug|PF-03715455|PF-03715455 1.6 mg BID
45346381|NCT00885274|Drug|Split Dose Pico-Salax|One dose of Pico-Salax taken the evening prior to colonoscopy and the other the morning of the procedure.
45346382|NCT00885430|Drug|Pico-Salax|Two sachets of Pico-Salax given 5 hours apart
45346383|NCT00886366|Drug|AZD6714|Oral single doses a-h suspension
45346384|NCT00886366|Drug|Placebo|Oral single doses suspension
45346385|NCT00886366|Drug|AZD6714|Oral single doses a-d suspension
45346386|NCT00886366|Drug|AZD6714|Oral single doses d and g suspension
45346387|NCT00886444|Drug|Ferucarbotran (Resovist)|single time intravenous bolus injection of a contrast agent
45346388|NCT00888550|Procedure|Post-Op Splinting|Splint will applied post-operatively and will remain on for two weeks
45475180|NCT01186757|Drug|PF-03715455|PF-03715455 4mg BID
45346389|NCT00888550|Procedure|No Splinting|Patient will be discharged post-operatively without a splint on their lower leg.
45346390|NCT00888706|Behavioral|Control Condition|The group participated in the usual nursing home activities and routines.
45346391|NCT00888706|Behavioral|Individualized Social Activities (ISA)|The group received individualized social activities one hour daily, during usual brief daytime napping episodes, between 9 am to 5 pm in brief 15-30 minute intervals five days a week.
45346392|NCT00888706|Behavioral|Physical Resistance Training and Walking (PRT/walking)|The group participated in high intensity PRT to the hip and arm extensors (three sets of eight repetitions per muscle per group, approximately 40 minutes) plus 10 minutes of warm-up and 10 minutes of cool-down on Monday, Wednesday and Friday afternoons for one hour (between 2-5pm). On Tuesdays and Thursdays, participants walked with a research assistant for as long as the participant could walk for up to 60 minutes.
45346393|NCT00888706|Behavioral|Combined ISA/PRT/walking|The group had one hour of ISA in the morning or afternoon and one hour of PRT/walking in the afternoon from 2-5pm five days a week. This group received interventions for 2 hours per day.
45346394|NCT00402727|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
45346395|NCT00402727|Drug|Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid|Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
45346396|NCT04037722|Dietary Supplement|Whey|45 g whey + 20 g maltodextrin
45346397|NCT04037722|Dietary Supplement|3-OHB + Whey|50 g ketone + 45 g whey + 20 g maltodextrin
45346398|NCT02541916|Other|Controlled weaning of immunosuppression|At week 0 patients have liver biopsy and liver functional tests (LFTs). Week 1-4 medication reduction to 1.5mg Tacrolimus (Tac) daily or 150mg Cyclosporine A (CsA). At week 4 LFTs. Week 5-8 medication reduction to 1mg Tac / 100mg CsA. Week 8 LFTs. Week 9-12 reduction to 0.5mg Tac/ 50mg CsA. Week 12 LFTs. Week 13-16 reduction to 0mg. Week 16 liver biopsy & LFTs. Weekly LFTs performed Week 17-20. Monthly LFTs for the next 3 months. LFTs every 3 months for monitoring.
45346399|NCT00923494|Drug|20 ml of ropivacaine 0.5%|Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
45475181|NCT01186757|Drug|PF-03715455|PF-03715455 10 mg BID
45475182|NCT01186757|Drug|Placebo|Placebo
45475183|NCT03123016|Drug|Apremilast|Apremilast 30 mg orally, twice daily. (oral tablet)
45475184|NCT03123016|Procedure|NB-UVB phototherapy|treatment with narrowband UVB two to three times weekly to one half of their body for a total of 16 weeks
45475185|NCT01182545|Procedure|Ventilation|Mechanical ventilation was conducted in all the patients with a Datex-Ohmeda Aestiva/5 Smart Ventilator (Madison, WI) through a rebreathing circuit incorporating a CO2 absorber, a heat and moisture exchanger using volume-controlled mode with an inspiratory to expiratory ratio of 1:2.5, and positive end-expiratory pressure (PEEP) of 5 cm H2O. Plateau pressure was kept as low as possible with an upper limit of 30 cm H2O, and the absence of auto-PEEP was ensured by a drop of the expiratory flow to zero on the flow-time curve.
45475186|NCT03636477|Biological|Ad-RTS-hIL-12|"2.0 x 10^11 viral particles (vp) per injection~intratumoral injection of Ad-RTS-hIL-12"
45475187|NCT03636477|Drug|veledimex|"2 doses (10mg/day, 20mg/day)~15 oral daily doses of veledimex"
45475188|NCT03636477|Drug|Nivolumab|"2 doses (1mg/kg, 3mg/kg)~Every 2 weeks"
45475189|NCT03667014|Drug|Dupilumab|Dupilumab treatment
45475190|NCT03123094|Drug|BI 655130|single dose
45475191|NCT03123094|Drug|Placebo|single dose
45475192|NCT03732001|Drug|Anlotinib combined Docetaxel|Anlotinib ( 12mg, QD, PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2, IV, d1, 21 days per cycle)
45475193|NCT03732001|Drug|Docetaxel|Docetaxel (75mg/m2, IV, d1, 21 days per cycle)
45346400|NCT00923494|Drug|30 ml of ropivacaine 0.5%|Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
45346401|NCT00923494|Drug|40 ml of ropivacaine 0.5%|Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
46042587|NCT01176968|Drug|Eplerenone|Maximum dose of 2x25 mg film coated tablets per day for the duration of the study (approximately 18 months maximum). Lower doses may be administered determined by blood biochemistry data.
45346402|NCT00886522|Procedure|Intrabone cord blood infusion|"Myeloablative conditioning regimen (MAC):~i.v. Busulfan 12.8 mg/kg, Cyclophosphamide 120 mg/kg, ATG-Fresenius 30 mg/kg~Reduced intensity conditioning regimen (RIC):~Tiothepa 10 mg/kg, Fludarabine 100 mg/kg, Cyclophosphamide 100 mg/kg, ATG-Fresenius 30 mg/kg~GVHD prophylaxis:~Cyclosporine 1 mg/kg since day -7 to +120, Mycophenolate 15 mg kg x 2 since day +1 to +27"
45346403|NCT00402649|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated influenza A/H5N1 vaccine administered via intramuscular (IM) injection; dosage 45-mcg.
45346404|NCT00888784|Procedure|Endoscopic Cyanoacrylate injection|Endoscopic Cyanoacrylate injection in gastric varix
45346405|NCT00888784|Drug|beta-blocker (propranolol)|Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure <90 mm Hg or pulse rate <55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
45346406|NCT00886678|Drug|pemetrexed|500 mg/m2, IV, q 21 days x 2 cycles
45346407|NCT00886678|Drug|carboplatin|AUC=5,IV,q 21 days x 2 cycles
45346408|NCT00886678|Radiation|thoracic radiation|66 Gy over 33 fractions
45346409|NCT00886756|Drug|AZD8529|Oral
45346410|NCT00886756|Drug|Placebo|Oral
45346411|NCT00402337|Drug|linaclotide acetate|oral, once daily.
45346412|NCT00402337|Drug|Matching placebo|oral, once daily
46042588|NCT01176968|Drug|Placebo|Matching placebo tablets
46042589|NCT04211584|Device|transradial interventions|percutaneous coronary interventions in stable patients - diagnostic and treatment
46042590|NCT02697370|Drug|Pharmacokinetic based dosage change|Pharmacokinetic based dosing of factor VIII prophylaxis treatment compared to standard prophylactic regimens based on weight.Prophylaxis is prescribed according to routine clinical practice with prophylaxis prescribed on alternate days to maintain predicted target trough of ≥1.5 IU/dL based on sparse blood sampling and Bayesian pharmacokinetic estimation
45346413|NCT00888862|Drug|Desvenlafaxine Succinate|Desvenlafaxine Succinate, 50-100mg/day for 8 weeks
45346414|NCT00886912|Other|hypoxia|training in simulated altitude in a hypoxic chamber (normobaric hypoxia)
45346415|NCT00886912|Other|normoxia|training under normoxic conditions
45346416|NCT04037332|Other|Blood sample (combined with malaria RDT) followed by gentoyping analysis|Finger-prick blood samples collected from children with signs of severe febrile illness and a positive mRDT presenting to community-based providers and referral facilities ; analysis for mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domain
45346417|NCT00886990|Drug|ritonavir-boosted PI-based second line treatments|single PI boosted by low dose ritonavir
45346418|NCT00886990|Drug|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
46042591|NCT02691442|Drug|Ropivacaine 0.75%|The investigators adminster 5ml of Ropivacaine 0.75% in an ultrasound-guided inter scalene nerve block
45346419|NCT00650091|Drug|N-acetylcysteine (NAC)|Participants will receive 600 mg of NAC three times a day.
45475194|NCT01186835|Procedure|Combination Botulinum Toxin A and Hyaluronic Acid|One side of subject's face will randomly be assigned combination treatment.
45346420|NCT00650091|Drug|Placebo|Participants will receive placebo each day.
45346421|NCT00889018|Drug|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 560 mg/m2 (18.6 mg/kg for children £36 months old). .
45346422|NCT00889018|Drug|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 750 mg/m2 (25 mg/kg for children £36 months old).
45346423|NCT00889096|Drug|propranolol|Oral administration of 80 mg propranolol (1 gelatine capsules; content: 2 tablets of Obsidan® 40 mg Tablets) or placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
45346424|NCT00889096|Drug|placebo|Oral administration of placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
45346425|NCT00818103|Drug|atorvastatin|Atorvastatin 40mg p.o. qn for 2 years
45346426|NCT00818103|Drug|β-interferon|β-interferon 50ug i.m. qod for 2 years
46042592|NCT02691442|Drug|Levobupivacaine 0.5%|The investigators adminster 5ml of Levobupivacaine 0.5% in an ultrasound-guided inter scalene nerve block
45475195|NCT01186835|Procedure|Botulinum Toxin A|Other side of subjects face with receive Botulinum Toxin A treatment alone.
46042593|NCT02691442|Drug|Levobupivacaine 0.5% + epinephrin 1/200000|The investigators adminster 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in an ultrasound-guided inter scalene nerve block
45346427|NCT00818103|Drug|EPO|EPO 10000U i.h. bid for 5 days
46042594|NCT00622648|Drug|Enoxaparin|40 mg once daily for 6 to 14 days (10 ± 4 days)
46042595|NCT00622648|Drug|Placebo|Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
45346428|NCT00642369|Drug|quetiapine fumarate|600-750mg/day
45346429|NCT00642369|Drug|haloperidol|6-40mg/day
45346430|NCT04037098|Dietary Supplement|Magnesium lactate.|2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months
45346431|NCT04037098|Dietary Supplement|Placebo|2 tablets orally every 12 hours of on inert placebo for three months
45475196|NCT03649464|Drug|OKN-007|"Dose escalation/PK cohort (Phase Ib): 1000mg twice daily (BID), 1000mg thrice daily (TID), 1500mg thrice daily (TID).~Expansion cohort (Phase 2): MTD defined in the dose escalation (Phase Ib) study."
45475197|NCT04812951|Drug|CycloSPORINE Ophthalmic 0.1% Ophthalmic Emulsion|one cyclosporine 0.1% eye drop twice a day for 30 preoperative days
46042596|NCT04316234|Other|Passive vape|On days with passive vape, 2-3 vapers in an adjacent chamber were vaping by turn, and vape was passed on to the exposure chamber continuously .
46042597|NCT04208386|Drug|JNJ-73763989|JNJ-73763989 will be administered SC under fasted condition.
46042598|NCT02886806|Other|BIS XP, Covidien, Ireland|Closed loop for propofol and remifentanil using BIS XP TM, Covidien, Ireland
46042599|NCT02886806|Other|EV-1000 TM, Edwards Lifesciences, Irvine, California, USA|Closed loop for fluid perfusion using EV-1000 TM, Edwards Lifesciences, Irvine, CA, USA
46042600|NCT02687854|Drug|Apixaban|As prescribed by treating physicians
46042601|NCT02687854|Drug|Vitamin K antagonist|As prescribed by treating physicians
46042602|NCT03991468|Diagnostic Test|Whole Slide Imaging|Scanning of a glass slide to create a digital image that can be viewed on a monitor
45346432|NCT02551575|Drug|Treatment of MTX and HCQ|"Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 2 times a day, oral, for 24 weeks. Qingre Huoxue granule placebo: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation placebo: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks."
45346433|NCT02551575|Drug|Treatment of TCM|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine placebo: 200mg, 3 times a day, oral, for 24 weeks."
45346434|NCT02551575|Drug|Integrative Medicine|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 3 times a day, oral, for 24 weeks."
45346435|NCT02541448|Device|SurgiQuest AIRSEAL® Insufflation System (AIS)|"The SurgiQuest AirSeal Optical Trocar & Cannula System with integrated Insufflator DPIS 2000 (the DPIS 2000 System) is intended for use in diagnostic and/or therapeutic endoscopic procedures to distend the peritoneal cavity by filling it with gas (establish and maintain pneumoperitoneum), to establish and maintain a path of entry for endoscopic instruments, and to evacuate surgical smoke. The trocar of the DPIS 2000 System is indicated for use with or without visualization."
45346436|NCT02552043|Other|Nintendo Wii exercise program|The aerobic training protocol was designed to improve muscular strength, body endurance and flexibility (involved activities as: running, up the knees, butt kickers, etc.). The game used has a strap pouch to hold the Nunchuk© controller placed on the thigh that detects the lower body movements, and also features a number of exercise options supervised by a virtual personal trainer
45346437|NCT02541994|Device|Pachette3|Central corneal thickness will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
45346438|NCT02541994|Device|Lenstar-Think|Axial length will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
45346439|NCT00889408|Biological|DT2219ARL|anti-CD19/CD22 bispecific ligand-directed toxin DT2219ARL
45475198|NCT04812951|Device|cationorm eye drops|one cationorm eye drop twice a day for 30 preoperative days
46042603|NCT03991468|Diagnostic Test|Light Microscopy|Use of traditional light microscopy per institutional standard practice
46042604|NCT01006122|Drug|Placebo|Patients receiving placebo will undergo the same procedures as those receiving active treatment. Each patient will receive matching placebo tablets in a fixed dose escalation schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at 1.0 mg; decrease to 0.5 mg or increase to 2.0 mg based upon the clinicians judgment regarding efficacy and side effects at the 1.0 dose level. The patient will then remain at the determined dose for a 3 week stable dosing period, with a 7 (-2/+ 9) day wash out and then crossover to repeat the same sequence for the second arm of the study.
45346440|NCT00887614|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
45346441|NCT00889564|Device|HeRO Vascular Access Device|Long-term subcutaneous vascular access device for hemodialysis
45346442|NCT01154335|Drug|OSI-906|Dose Level 1: 50 mg Twice a Day, cycle-28 days Dose Level 2: 100 mg Twice a Day, cycle-28 days Dose Level 2a: 100 mg Twice a Day, cycle-28 days
45346443|NCT01154335|Drug|Everolimus|Dose Level 1: 5mg Daily, cycle-28 days Dose Level 2: 10mg Daily, cycle-28 days Dose Level 2a: 5mg Daily, cycle-28 days
45346444|NCT00889642|Device|Iontophoretic Drug Delivery System with Lidocaine/Epinephrine|Active- 10.5% Lidocaine/0.179% Epinephrine
45346445|NCT00889642|Device|Iontophoretic Drug Delivery System with Epinephrine|Placebo- 0.179% Epinephrine
45346446|NCT02541526|Drug|Mirtazapine|One capsule (15 mg) oral mirtazepine daily will be started on day six of treatment for a period of 3 days followed by two capsules (30 mg) daily for a period of four months
45346447|NCT02541526|Drug|Placebo|Similar capsule containing placebo will be started on day six of treatment for a period of 3 days followed by two capsules of placebo daily for a period of four months
45346448|NCT01037959|Drug|Norfloxacin|400 mg/day (per os) for 6 months
46042605|NCT01006122|Drug|PF-03654746|Each patient will receive PF-03654746 tablets in a fixed dose titration schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at the 1.0 mg dose; decrease to 0.50 mg or increase to 2.0 mg based upon the clinician's judgement regarding efficacy and side effects at the 1.0 mg dose. The patient will remain at the determined dose for a 3 week stable dosing period.
46042606|NCT02687698|Other|Ketogenic diet|The proposed ketogenic diet will concern a low glucidic diet with 60-70% of lipidic intake and 20-30% of proteins.
46042607|NCT02689570|Other|observational|no interventions; observational study
46042608|NCT00639028|Other|Ankle echography|Ankle echography
46042609|NCT00639028|Other|Ankle echography + stress radiography|Ankle echography + stress radiography
46042610|NCT00639028|Other|stress radiography|ankle stress radiography
45346449|NCT01037959|Drug|Placebo|1 pill/day (per os) for 6 months
46042611|NCT04186156|Drug|KA2507|KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
46042612|NCT01005966|Drug|Sodium Fluoride Toothpaste|Test product
46042613|NCT01005966|Drug|Amine Fluoride Toothpaste|Test product
45346450|NCT00887692|Behavioral|prone and supine position|patients will be treated alternating daily between prone and supine position for breast radiotherapy.
45346451|NCT01038037|Drug|Carboplatin|i.v. day 1: AUC 5 x (GFR + 25) mg q3w
46042614|NCT01005966|Drug|Sodium monofluorophosphate/Sodium Fluoride Toothpaste|test product
45346452|NCT01038037|Drug|Vinorelbine|i.v. day 1: 30 mg/m2 q3w Orally day 8: 60 mg/m2 q3w
45346453|NCT01038037|Drug|panitumumab|i.v. day 1: 9 mg/kg q3w
45346454|NCT01038115|Procedure|Atrial fibrillation ablation|Comparison of three different techniques for pulmonary vein isolation
45346455|NCT00645099|Drug|olanzapine|10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months
46042615|NCT01005966|Drug|Placebo|placebo and washout treatment
46042616|NCT01005966|Drug|675 ppmf toothpaste|dose response
45346456|NCT00645099|Drug|paliperidone ER|6-mg or 9-mg tablet once daily flexible dosing for 6 months
45346457|NCT04401982|Drug|Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks|Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks will be administered
46042617|NCT03937960|Other|Carbohydrate restricted group|Prescribed low carbohydrate diet with set recipes
45346458|NCT01038271|Other|Standard Palliative Care Group|Participant is referred to the Palliative Care Team at any time.
45346459|NCT01038271|Other|Integrated Palliative Care Intervention|Participant meets with the Palliative Care Team within 3 weeks of being randomized
46042618|NCT03937960|Other|Standard low fat diet|Diet with less than 20% total calorie intake from dietary fats
46042619|NCT01005732|Device|Custom fabricated pressure garments|Cloth garments designed to apply 17-24 mmHg pressure to the 1/2 the burn wound and <5 mmHg to the other half, to be worn 23 hours per day until wounds mature, approximately 12 months
46042620|NCT00628680|Device|AAT-023 solution (Zuragen)|Amount equal to the catheter lumen plus 0.3mL. Three times per week (after each Hemodialysis) for 26 weeks
46042621|NCT00628680|Drug|Heparin|Hepaarin 5000 units diluted with normal saline to the exact catheter lumen volume.
46042622|NCT00603382|Drug|GW685698X|GW685698X
46042623|NCT00603382|Drug|Placebo|placebo comparator
46042624|NCT01176266|Drug|asfotase alfa|
46042625|NCT01182428|Device|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
46042626|NCT01182428|Device|CYPHER SELECT|XIENCE V® / XIENCE PRIME™ to CYPHER SELECT in female patients with de novo coronary artery lesions
45346460|NCT01038349|Other|Avise PG - Diagnostic test|Eligible patients will receive an Avise PG test
45346461|NCT00889954|Biological|TGFBeta resistant HER2/EBV-CTLs|"Each patient will receive one injection of the TGFBeta resistant HER2/EBV-specific CTLs. Each pt will be followed for 6 weeks after the CTL infusion for evaluation of dose limiting toxicity (DLT).~Patients may receive up to six additional doses of the T cells at 6 to 12 weeks intervals."
46042627|NCT00603304|Drug|Saw Palmetto - first 24 weeks|Participants will take one 320 mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
46042628|NCT00603304|Drug|Placebo - first 24 weeks|Participants will take one 320 mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
46042629|NCT00603304|Drug|Saw Palmetto - weeks 24 - 48|Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
46042630|NCT00603304|Drug|Placebo - weeks 24 - 48|Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a placebo for 24 weeks.
46042631|NCT00603304|Drug|Saw Palmetto - weeks 48 - 72|Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
46042632|NCT00603304|Drug|Placebo - weeks 48 - 72|Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
46042633|NCT01176032|Drug|Aliskiren|Aliskiren 300 mg film coated tablets
46042634|NCT01176032|Drug|Losartan|Losartan 100 mg tablets
46042635|NCT01176032|Drug|Amlodipine|Amlodipine 5mg was given to patients who did not achieve the required blood pressure (<140/90 mmHg) after 8 weeks (visit 3)of treatment at the maximum doses of study medication in addition to the study medication in order to reach the required BP. at visit 4 (week 18) the dose of amlodipine was increased to 10mg if the required level (<140/90 mmHg) was still not achieved.
46042636|NCT01176032|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 12.5mg was prescribed at visit 5 (week 26) if the required values (<140/90 mmHg) had not been reached.
45346462|NCT04601623|Other|Sonoelastography|This diagnostic test would be executed by a physician who has experiences of using Siemens Acuson S2000 ultrasound system for more than three year. The examination includes two of four rotator cuff muscles, listed as follows, supraspinatus muscle and infraspinatus muscle. Linear transducer (4-9 MHz) would be used for the whole test. The probe would be positioned along the longitudinal axis of the muscle belly. Compressive sonoelastography technique is used for semiquantitative analysis. In order to maintain the quality of images, quality factor needs to be over or equal to 60. The quantitative analysis was performed by shear wave sonoelastography and the region of interest (ROI) would be divided into four quadrants. The physicians will measure the shear wave velocity at the center point of each quadrant.
45346463|NCT00887770|Drug|AZD5672|12 x 50mg tablet, oral, single dose
45346464|NCT00887770|Drug|Moxifloxacin|1 x 400mg capsule, oral, single dose
45346465|NCT00887770|Drug|placebo|12 x matched to AZD5672 50 mg tablet
45346466|NCT00887770|Drug|AZD5672|3 x 50mg tablet, oral. single dose
45346467|NCT00887770|Drug|placebo|9 x matched to AZD5672 50mg tablet
45475199|NCT04508296|Diagnostic Test|Goal directed de-escalation therapy|Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT in the case of GEDVI > 650 mL/m2 or EVLWI > 10 mL/kg depending on the randomization group. The primary goal of de-escalation was to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI < 650 mL/m2 or EVLWI < 10 mL/kg, the target fluid balance was in the range of 0 to +3000 mL
45684877|NCT02384668|Dietary Supplement|Cholecalciferol|One tablet per day. The duration of the intervention period is between 24-36 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18(-24) months after randomisation. Vitamin D supplementation will continue 12 months after withdrawal of ATD treatment or until relapse of Graves' Disease if this occurs prior.
45346468|NCT00887770|Drug|placebo|1 x matched to Moxifloxacin capsule
45346469|NCT01038505|Drug|Tacrolimus, Myfortic and Sirolimus|Immunosuppressive drugs
46042637|NCT02691598|Drug|Infusion|Dexmedetomidine Hydrochloride or normal saline 4ug/ml；0.05ml/kg.h infusion for 24hours
46042638|NCT01008618|Drug|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
45346470|NCT00890032|Biological|BTSC mRNA-loaded DCs|An escalating total dose of BTSC mRNA-loaded DCs (2x10^6, 5x10^6, and 2x10^7 per vaccination) will be evaluated for purpose of establishing a maximum tolerated dose (MTD) and a dose-limiting toxicity (DLT).
45346471|NCT01038583|Drug|100 mg enteric-coated aspirin|100 mg enteric-coated aspirin, taken daily
45346472|NCT01038583|Drug|Placebo|100 mg enteric-coated placebo
45346473|NCT02551107|Device|Measurement of nasal Nitric Oxide level|ECO MEDICS CLD 88 sp Nitric Oxide Analyzer
45346474|NCT02541682|Other|TEMPS-A (Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire)|Participants filled out the TEMPS-A survey at their first visit.
45346475|NCT00818181|Drug|Biological: AL0206st|
45346476|NCT00887848|Other|Lokomat training|15 sessions of Lokomat training within 5 weeks (3 trainings/week)
45346477|NCT01038661|Drug|Docetaxel|"Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-hour IV"
45346478|NCT01038661|Drug|Cisplatin|"Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-3-hour IV"
45346479|NCT01038661|Other|Best supportive care (BSC)|Any treatment including palliative radiotherapy for pain relief-but not chemotherapy - that is considered appropriate by the investigator
45684878|NCT02384668|Dietary Supplement|Placebo|One tablet per day. Placebo tablet identical in appearance to cholecalciferol tablet. Duration and cessation of treatment identical to intervention with cholecalciferol.
46042639|NCT01008618|Drug|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
46042640|NCT01001208|Drug|Methotrexate|Methotrexate tablets over-encapsulated for blinding
46042641|NCT01001208|Drug|Etanercept|1 mL for subcutaneous injection
46042642|NCT01001208|Drug|Placebo|Matching placebo to methotrexate capsules
45475200|NCT01290185|Device|Placement of different catheters for continuous nerve block|Placement different catheters adjacent to the femoral
45475201|NCT05666089|Drug|N-acetyl cysteine|intracanal medication of NAC with concentration 1 gm/ml in the form of a paste
45475202|NCT05666089|Drug|Calcium hydroxide|intracanal medication of calcium hydroxide paste (metapaste)
45475203|NCT04508218|Dietary Supplement|whey protein supplementation powder (Inkospor X-TREME; France)|Protein requirements for burned adults are estimated as 1.5-2.0 g/kg/day. The participants asked to take the calculated serving of whey protein dissolved in 150ml of water two times / day in the morning and in the evening
45475204|NCT04508218|Other|Exercise training program|After healing of the burn (6 weeks after injury), participants in group A and group C started resisted exercise program with a qualified therapist for 1 hour three times/week on nonconsecutive days over 12 weeks. In addition, aerobic exercises were conducted on the treadmill. Peak oxygen consumption was assessed for all patients by using the exercise test on treadmill before participation in aerobic exercises.
46042643|NCT04296708|Other|Exergame Training|An exergame combines exercise and gaming in a holistic approach.
45346480|NCT02355613|Radiation|Radiosurgery with Gamma Knife Perfexion|Gamma Knife Radiosurgery is a very precise form of therapeutic radiology. Even though it is called surgery, a Gamma Knife procedure does not involve actual surgery but it uses 192 isocentric beams of highly-focused gamma rays (60-Co) to treat small to medium size lesions. Minimum beam size is 4 mm. This procedure is frame based.
45346481|NCT02355613|Radiation|Linac-based Radiosurgery with EDGE|EDGE linear accelerator from Varian (Varian, Palo Alto, USA) is a C-arm machine specifically developed for radiosurgery frameless treatment. The characteristics of this linac are a high level of precision and the possibility to include multiple positioning systems for stereotactical treatments, among which Cone Beam CT (CBCT), the Optical Surface Monitoring System (OSMS), and Calypso.
45346482|NCT01038817|Drug|Duraphat|After prophylactic cleaning of the mouth and teeth, application of fluoride varnish according to the manufacturer's recommendations (up to 0.75 ml per application)
45475205|NCT04508218|Other|traditional burn care|ROM exercises, stretching, ADL activities and scar management
45475206|NCT04531839|Behavioral|Evidence-based collaborative quality improvement|Evidence-based collaborative quality improvement interventions including benchmarking, potential better practice list, PDSA implementation and collaborative learning
45475207|NCT01188785|Drug|siG12D LODER|"Phase 0 - subjects diagnosed with an operable adenocarcinoma of the pancreas will have 8 siG12D LODER placed in tumor. The siG12D LODER will be placed in the subject's tumor using an EUS biopsy needle.~Phase I - subjects diagnosed with locally non-operable advanced adenocarcinoma of the pancreas. These subjects will have one of three different siG12D LODERs dose levels placed in tumor - Either 1 siG12D LODER, 2 siG12D LODERs or 8 siG12D LODERs. The siG12D LODER/s will be placed in the subject's tumor using an EUS biopsy needle."
45475208|NCT03732625|Drug|Raltegravir|DTG will be replaced by Raltegravir (RAL) 1200 QD, maintaining the other two drugs that constituted the triple therapy established before the inclusion of the patient in the study.
45475209|NCT03555006|Other|"Dual ultrasound reading local vs remote"|The examination will be interpreted by a department's radiologist and by a remote radiologist in blind of the first interpretation and a posteriori by a third radiologist.
46042644|NCT04296630|Other|Social media message #1|Social media message promoting colorectal cancer screening
46042645|NCT04296630|Other|Social media message #2|A different social media message promoting colorectal cancer screening
46042646|NCT04296630|Other|Social media message #3|A different social media message promoting colorectal cancer screening
46042647|NCT04296630|Other|Tailored social media messages|Tailored social media messages promoting colorectal cancer screening.
46042648|NCT04295460|Drug|Randomize|Randomize to naive-treatment HIV-infected patients to receive dual o triple therapy as initial antiretroviral treatment
45346483|NCT01324219|Behavioral|Staff|Your participation will involve participating in video recordings of nursing care for a participating resident for 2-hour periods on 8 to 10 days. Communication training will be provided to staff in participating nursing homes during paid work hours regardless of their participation in the video recordings. The nursing home you work in may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
45346484|NCT01324219|Behavioral|Resident|Your participation will involve participating in video recordings of nursing care for 2-hour periods on 8 to 10. Communication training will be provided to staff in participating facilities during paid work hours regardless of their participation in the video recordings. Your nursing home may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
45346485|NCT00420511|Drug|Sitagliptin|sitagliptin 100 mg once a day
45346486|NCT00420511|Drug|Placebo|placebo once a day
45346487|NCT00420511|Drug|metformin|metformin 1000 mg twice a day (bid) by mouth (po)
45346488|NCT01038895|Drug|Ramipril|tablet; 10 mg; od; 3 months
45346489|NCT01038895|Drug|Experimental|tablet; 300 mg; od; 3 months
45346490|NCT00420199|Drug|Abatacept|Vials (250 mg/vial), intravenous (IV), 10 mg/kg, monthly infusion , 12 months of treatment
45346491|NCT00420199|Drug|Placebo|Intravenous (IV) bags, IV, 0 mg, monthly infusion, 12 months of treatment
45346492|NCT04598269|Drug|ATI-1777|ATI-1777 topical solution 2.0% w/w
45346493|NCT04598269|Drug|Vehicle|Vehicle topical solution
45684879|NCT02378272|Other|care manager for depression|District nurse (care manager for depression) providing clinical services ( in cooperation with GP) as patient information and education on patient's preferred treatment, development of care plan, assessment of patient's depressive symptoms and regular telephone contacts.
45684880|NCT02377258|Other|Non Interventional|
45684881|NCT02375854|Other|Observation|
45684882|NCT01898923|Drug|ON101 Cream|
46042649|NCT02871102|Procedure|Recruitment Maneuver with PEEP and Tidal Volume Optimization|A staircase recruitment maneuver will be performed on pressure control ventilation followed by a decremental PEEP trial. During the decremental PEEP trial inspiratory tidal volumes will be varied at each step between 3 ml/kg and 10 ml/kg predicted body weight while recording the continuous pressure and flow tracings from the mechanical ventilator. With each PEEP and tidal volume combination, end expiratory and end-inspiratory plateau pressure and stress index will be assessed. At the completion of the decremental PEEP trial, the patient will be returned to ARDSnet-recommended ventilator settings.
46042650|NCT01000974|Biological|GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)|Three doses of 3 different manufacturing lots in primary study at 2, 4 and 6 months of age as intramuscular injection and one dose as booster vaccination.
45346494|NCT01039051|Behavioral|Diet and Lifestyle Intervention in Chinese Postpartum Women|For individual postpartum woman, we will set antepartum participatory training courses, provide specially prepared brochures and supporting VCD, set up a specialized counseling hotline and give individual bedside guidance after birth. For their family members, we will invite every postpartum woman's husband and mother to take part in workshops or seminars, making them know some basic knowledge of postpartum care, and persuading them to promote adoption of the diet and lifestyle we advocated by the postpartum woman. For community environment, we will put up posters about basic knowledge of postpartum care in the community bulletin boards for general population educating and mobilize community leaders and heads from and maternal and child health centers for maximum support.
45346495|NCT00649389|Drug|Olmesartan medoxomil|40mg olmesartan medoxomil
45346496|NCT00649389|Drug|Amlodipine|Amlodipine 10mg
45346497|NCT00649389|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg
45346498|NCT00402103|Drug|Aliskiren|All patients received aliskiren 150 mg for the first two weeks; dose was then force-titrated to aliskiren 300 mg for 52 weeks duration
45346499|NCT00402103|Drug|Amlodipine|All patients received amlodipine 5 mg for the first two weeks; dose was then force-titrated to amlodipine 10 mg for 52 weeks duration
46042651|NCT01000974|Biological|ActHIB™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
46042652|NCT01000974|Biological|Pentacel™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
45346500|NCT00402103|Drug|Hydrochlorothiazide|Optional addition of Hydrochlorothiazide (HCTZ)of 12.5 mg with increase to 25 mg was allowed for patients not adequately controlled.
45475210|NCT03555006|Other|"Dual ultrasound reading local vs local"|The examination will be interpreted by two department's radiologists and a posteriori by a third radiologist.
45475211|NCT03123172|Diagnostic Test|arterial and central venous blood gases|withdrawal of arterial and central venous blood gases to measure Co2 gap
46042653|NCT01000974|Biological|Pediarix™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
46042654|NCT01000974|Biological|Prevnar 13™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
45684883|NCT01898923|Other|Aquacel® Hydrofiber® dressing|
45684884|NCT04251442|Device|OrthoSensor Verasense Technology|IOS is used to send real time information to a monitor within the operating room that assists your surgeon in making decisions about the balance of the ligaments in your knee and the proper insertion of implants.
45684885|NCT04551586|Drug|ACH-0145228: Immediate Release|ACH-0145228 (240 milligrams) will be administered orally on Day 1.
45684886|NCT04551586|Drug|ACH-0145228: Powder-in-capsule|ACH-0145228 (240 milligrams) will be administered orally on Day 1.
45684887|NCT04554004|Diagnostic Test|CCTA, CT-MPI, DSA, FFR|The patients who enrolled the study will undergo coronary CT angiography(CCTA), dynamic CT-MPI, invasive coronary angiography and invasive computation of fractional flow reserve (FFR)
45684888|NCT01924429|Drug|Lisdexamfetamine|Escalating stepped dose titration: 30, 50 or 70mg
45684889|NCT04553848|Behavioral|Augmented Reality|Augmented Reality (AR) systems are computer-based applications that allow an individual to view a simulated environment and dynamically interact within this environment in real-time. Augmented reality activities will be chosen by the therapist based on the primary deficits assessed during baseline testing.
45475212|NCT04694157|Device|cardiac shock wave therapy|Two target segments of left ventricle will be chosen for all participants. In each target segment, 9 sties will be administered with 200 shots at each site. Low-intensity SW (200 impulses/spot; energy flux 0.09 mJ/mm2), will be administered under electrocardiographic R-wave gating. The entire treatment period will last 3 months with 9 sessions. CSWT will be administered in the first week, followed by a 3-week non-treatment interval.
45475213|NCT03636828|Diagnostic Test|ultrasonographic measurement of gastric antral cross-sectional area|Each participant fasted for 10 hours and subjected to a baseline gastric ultrasound and serial sonographic gastric evaluations was performed every hour after 2 hours of the ingestion of a 420 g, 536 Kcal rice-based meal (bibimbap) until the stomach was completely empty.
45840939|NCT00955032|Device|Sham Repetitive Transcranial Magnetic Stimulation|Patients randomized to receive sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
46042655|NCT01000974|Biological|Rotarix™|Two oral doses in primary epoch at 2 and 4 months of age
46042656|NCT01000974|Biological|Engerix™-B|Two or three doses in primary epoch at 2,( 4) and 6 months of age as intramuscular injection
46042657|NCT01000974|Biological|Infanrix™|One dose in the booster epoch at 15-18 months of age as intramuscular injection
45346501|NCT00815217|Procedure|injection of lipoaspirate|Small volume lipoaspiration will be performed. This technique involves harvesting small amounts of fat by making a small incision in the donor site (usually the abdomen) and infiltrating 25-75cc of tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) into the adipose layer with a blunt infiltrator. The Coleman aspiration Cannulae, approximately 2-3 mm in diameter and 15 cm in length attached with a Luer-Lok suction syringe will be used to harvest up to 100 cc of fat. Gently pulling back on the syringe provides a small amount of negative pressure to allow for aspiration into the syringe.For the intervention wound, the adipose tissue will be implanted using the infiltration Cannulae (blunt end, 7 cm- COL-17) or the both approx. 1mm in diameter. The implantation will be in single tunnels radially around each wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
45346502|NCT00815217|Other|control|For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
45346503|NCT00812175|Drug|Sorafenib (Nexavar, BAY43-9006)|Systemic oral therapy according to product information
45346504|NCT00815373|Drug|Dorzolamide+Timolol Maleate0.5%|Cosopt* b. i. d.
45346505|NCT00815373|Drug|Latanoprost+Timolol Maleate0.5%+Lytears|Xalacom* QHS
45475214|NCT03738319|Genetic|Sequencing of miRNA/lncRNA|Next generation sequencing of micro-RNA (miRNA) and long non-coding RNA (lncRNA)
45475215|NCT04503928|Drug|Euphorbia kansui Pill|1 g (10 pills) of Euphorbia kansui Pill taken by mouth, once a day for 7 consecutive days.
45346506|NCT00641667|Drug|Fentanyl|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) to 100 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is as per Investigator's discretion (maximum applied dose is 300 mcg/hr) up to Day 7 and then dose is fixed for next 3 days that is Day 10 (end of treatment period).
45475216|NCT04684875|Device|Radiofrequency Stylus|Low power radiofrequency energy delivered to the posterior nasal nerve area
45840940|NCT00955266|Drug|Calcium Chloride|Calcium chloride 10mg/kg in 50cc NS delivered over 5 minutes
46042658|NCT01193842|Drug|Cyclophosphamide|Given IV
46042659|NCT01193842|Drug|Doxorubicin Hydrochloride|Given IV
46042660|NCT01193842|Drug|Etoposide|Given IV
46042661|NCT01193842|Other|Laboratory Biomarker Analysis|Correlative studies
46042662|NCT01193842|Other|Pharmacological Study|Correlative studies
46042663|NCT01193842|Drug|Prednisone|Given PO
46042664|NCT01193842|Biological|Rituximab|Given IV
46042665|NCT01193842|Drug|Vincristine Sulfate|Given IV
46042666|NCT01193842|Drug|Vorinostat|Given PO
46042667|NCT04295616|Device|Intrapulmonary percussive ventilation (IPV)|"IPV is a well-tolerated method to pump air jets into the lungs via a mouth mask at frequencies of 100-400 pulses per minute.~Each IPV session lasts 15 minutes, whereby the person with MS is firstly administered with a mask for 3 minutes at a high frequency (250 to 400 cycles per minute) and then 12 minutes with a low frequency (75 to 150 cycles per minute). The pressure (1.1 - 1.4 bar) is adjusted so that it is comfortable for every participant, yet there is the maximum possible expansion of the thorax. The sessions are given by speech therapists who are familiar with IPV. The IPV treatment will be provided 5 days a week, during 3 or 4 weeks."
46042668|NCT04295616|Behavioral|Active breathing training|The active breathing exercises are based on the flow-based incentive spirometer (Inspirix). The Inspirix is a device consisting of a tube with a ball. A plastic tube is connected to the device with a mouthpiece in which the person with MS will has to breathe in and out. The device is equipped with a control button to build up the resistance (number of cc / sec). The aim is to train the inspiratory and expiratory volume as well as the inspiratory and expiratory exhalation force. These exercises are offered 5 times a week in groups under the supervision of an experienced speech therapist, during 3 or 4 weeks.
45346507|NCT00704184|Drug|Comparator: Vaniprevir|Vaniprevir 300 mg b.i.d., 600 mg b.i.d., 600 mg q.d., or 800 mg q.d.; duration of treatment: 28 days
45346508|NCT00704184|Drug|Comparator: Pegylated-Interferon (Peg-IFN)|Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks
45475217|NCT04597476|Dietary Supplement|Fucoidan|Fucoidan refers to a class of fucose-enriched sulfated polysaccharides with an average molecular weight of 20,000 Daltons (Da), which can be found in many varieties of edible brown seaweeds and algae . In cell culture studies and animal studies, fucoidan has been shown to possess a range of biological activities, including anti-cancer, anti-inflammatory, and immunoregulatory effects . A recent in vitro study conducted in head and neck squamous cell carcinoma (HNSCC) cell lines (H103, FaDu, and KB) showed that fucoidan could induce cell cycle arrest and possibly apoptosis in a dose-dependent manner, while also enhancing response to cisplatin treatment . In addition, fucoidan has also been shown to inhibit the proliferation of nasopharyngeal carcinoma cells and MC3 human mucoepidermoid carcinoma (MEC) cells .
45475218|NCT04597476|Other|Placebo( Potato starch)|Potato starch 4.4gram
45346509|NCT00704184|Drug|Comparator: Ribavirin|Ribavirin 200 mg tablet b.i.d. (dose based on body weight); duration of treatment: 48 weeks
45346510|NCT00704184|Drug|Comparator: placebo|Matching placebo to vaniprevir; duration of treatment: 28 days
45346511|NCT00641043|Drug|placebo + pioglitazone (30 mg)|placebo + overcapsulated 30 mg tablet, once daily
45346512|NCT00641043|Drug|Linagliptin + pioglitazone (30 mg)|5 mg tablet + overcapsulated 30 mg tablet, once daily
45346513|NCT04062318|Device|Online active TMS|"One single pulse or triple pulse train (3 pulses, 20ms inter-pulse interval) of TMS will be delivered per trial (at least 5 seconds apart) online, or during the tactile detection task, at less than or equal to 80% active motor threshold."
45346514|NCT02551965|Other|Phone nursing follow-up|From the day of geriatric cancer patient's consultation, nurses will identify caregiver and will follow them by phone (caregiver) during 6 months
45346515|NCT02567058|Device|Ultrasound exam|"Ultrasound exam with :~2 successions of 3 measures repeated for 2 visits (day 0 and day 21) for group I~1 succession of 3 measures repeated for 4 visits (day 0, day 14, day 45, day 90)for group II~1 succession of 3 measures for group III"
45346516|NCT02567058|Behavioral|IPAQ questionnaire|IPAQ questionnaire
45346517|NCT00815451|Dietary Supplement|placebo|polyphenol-free dark chocolate 20g to be distributed throughout the day for 4 weeks
45346518|NCT00815451|Dietary Supplement|Acticoa polyphenol-rich dark chocolate|20g to be distributed throughout the day for 4 weeks
45475219|NCT01188863|Drug|300 mg LX4211 (150 mg tablets)|Single oral dose of two 150 mg tablets LX4211
45346519|NCT02552199|Other|gravimetric|
45346520|NCT00812409|Dietary Supplement|Whey protein supplementation with exercise|Whey protein supplementation with resistance and aerobic exercise.
45346521|NCT00812409|Other|Non protein supplementation with exercise (control)|Non protein supplementation with resistance and aerobic exercise.
45475220|NCT01188863|Drug|300 mg LX4211 (50 mg tablets)|Single oral dose of six 50 mg tablets LX4211
45475221|NCT01188863|Drug|300 mg LX4211 (liquid)|Single 30 mL dose of liquid oral solution LX4211 (10 mg/mL)
45596416|NCT03531541|Device|Placebo CJM|Placebo CJM will be performed using an identical position to the active manipulation, however, for only 15 seconds, as proposed by some authors that have used placebo group in their studies. The examiner shall not exert tension in the joint capsule of the segment to ensure the placebo effect. The maneuvers will be carried out by a physiotherapist with more than 5 years of experience in manual therapy. The active or placebo manipulation will be performed on the right or left side according to randomization.
45346522|NCT02567604|Behavioral|Focus Groups|at least three focus groups lasting approximately one hour
45346523|NCT00815529|Device|Acupuncture, Pak-sham needle|25*40mm, from 10 to 15 per each person, with the death from 5 to 20 mm, for from 15 to 20 minutes.
45346524|NCT02551419|Dietary Supplement|ketogenic drink|6 months' supplementation with the ketogenic drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the evening meal.
46042669|NCT04401774|Drug|Nivolumab|Nivolumab will be given every 4 weeks at 480mg flat dose intravenously for one year (total of 13 nivolumab doses).
45346525|NCT02551419|Dietary Supplement|placebo|6 months' supplementation with the placebo drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the
45346526|NCT04063644|Device|Vis Glyc Neo|1 drop in each eye, three times a day.
45475222|NCT03634579|Device|MRI Guided Focal Laser Interstitial Thermal Ablation|"The procedure is done under general anesthesia. Laser fiber placement will be performed by one of two approaches (Trans gluteal or trans rectal) based on the target location within the prostate gland. When the needle position is deemed satisfactory, a 1.5-cm-active tip diode laser fiber will be introduced within an internally cooled catheter through the introducing sheath.~The catheter tip location will be confirmed on Turbo Spin-Echo (TSE) T2-weighted images in the axial and sagittal oblique planes.The introducer sheath will be withdrawn to allow contact of the active laser tip with the lesion. A laser test dose will be done at 9 Watts for about 30 seconds to confirm the site of fiber placement with the subsequent delivery of full dose ablation at 12-27 Watts. Ablation duration is determined based on real time feedback of response using real time temperature and damage estimate maps."
45346527|NCT04063644|Device|Physiological saline solution|1 drop in each eye, three times a day.
45346528|NCT04045275|Behavioral|Calm|"Calm provides daily, 10-minute, guided meditations grounded in mindfulness-based stress reduction (MBSR) and Vipassana meditation. Calm also offers Sleep Stories, developed using techniques from Cognitive Behavioral Therapy and Relaxation Technique. Clam also includes behavioral components to reinforce sustained practice."
45346529|NCT05325138|Other|Interview|Parents of girls aged 9-14yearsold will undergo an interview to determine their knowledge, attitudes and beliefs concerning HPV vaccination
45346530|NCT00812643|Drug|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
45596417|NCT02198027|Drug|Bupivacaine|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of 0.25 % Bupivacaine into renal capsule to skin.
45596418|NCT02198027|Other|Normal saline infiltration|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of normal saline into renal capsule to skin
46042670|NCT01004406|Device|intensive LDL-lowering therapy|The intensive LDL-lowering therapy uses LDL-apheresis in addition to the standard statin therapy. The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks
45840941|NCT00955266|Drug|Placebo|Normal saline, 50cc delivered over 5 minutes
45346531|NCT02567916|Drug|Fresofol|
45346532|NCT02567916|Drug|Propofol|
45346533|NCT00815607|Drug|INXN-1001|Capsules given once daily for 14 days for 3 treatment cycles.
45346534|NCT00815607|Biological|INXN-3001|Intratumoral injection
45346535|NCT04045509|Device|Liquid Jet Esthesiometer Prototype|Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement
45346536|NCT04045509|Device|Tactile Esthesiometer Prototype|A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement
45346537|NCT04045509|Device|Cochet Bonnet esthesiometer|A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
46042671|NCT01004406|Drug|standard statin monotherapy|The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
45346538|NCT02567526|Behavioral|Between-Meal Intervention Group|Non-nursing staff trained as Feeding Assistants were responsible for supplement and snack delivery in the mornings and afternoons between meals supervised by research staff
45346539|NCT00402025|Biological|Talimogene Laherparepvec|Talimogene laherparepvec administered by direct injection into pancreatic tumors using EUS-guided FNI, up to a maximum of 4 mL per treatment.
46042672|NCT04210804|Dietary Supplement|Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA)|200mls Smoothie
46042673|NCT01190644|Drug|ACE 011|35 mg subcutaneous (SC) dose on study Day 1, Day 43, Day 85
46042674|NCT04210570|Device|Memsorb|Memsorb uses a polymeric membrane (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system while maintaining the inhalational anesthetic in the anesthesia circuit
45346540|NCT00812721|Other|Preservative Free Saline|One drop will be instilled into each eye once
45596419|NCT04390113|Biological|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion, visually identical to placebo
45596420|NCT04390113|Biological|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
45596421|NCT02257463|Drug|theophylline, long acting bronchodilators (LABD) or combined LABD and inhaled steroids according to GOLD recommendations|
45596422|NCT02257463|Other|peripheral muscles exercise training|
46042675|NCT04210570|Drug|Chemical granulate absorber|Chemical granulate absorber trap CO2 chemically in granules that are later disposed of when absorption capacity is reached
45346541|NCT00812721|Other|Optive|One drop will be instilled into each eye once
45346542|NCT00812721|Other|Refresh Moderate/Severe|One drop will be instilled into each eye once
45346543|NCT00812721|Other|Systane|One drop will be instilled into each eye once
45346544|NCT00812721|Other|Systane Ultra|One drop will be instilled into each eye once
45346545|NCT00812799|Drug|Oralgen|19.000 BU daily
45346546|NCT00812799|Other|placebo control|placebo control
45346547|NCT00815763|Drug|ginsenoside-Rd|infusion ginsenoside-Rd 20 mg once a day and continued for 14 day
45346548|NCT00815763|Drug|placebo|infusion placebo once a day and continued for 14 day
45346549|NCT00609622|Drug|sunitinib|Sunitinib: 37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2).
45346550|NCT00609622|Drug|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m^2 + leucovorin 400 mg/ m^2 (or 200 mg/ m^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
45346551|NCT00609622|Drug|bevacizumab|Bevacizumab: 5 mg/kg, IV infusion, every 2 weeks.
45346552|NCT00609622|Drug|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m^2 + leucovorin 400 mg/ m^2 (or 200 mg/ m^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
45346553|NCT04045119|Other|Topical Moisturizer|The investigational product is a moisturizing facial cream for skin with imperfections that is applied topically and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at improving skin hydration and characteristics associated acne-prone skin. The moisturizer also contains 0.1% of hemp oil rich in essential fatty acids and antioxidants and 0.5% of cannabidiol with regulatory effect on the skin.
46042676|NCT01189786|Device|CliniMACS CD34 Reagent system|A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.
46042677|NCT01187368|Device|EVAHEART Left Ventricular Assist System (LVAS)|Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
46042678|NCT01187368|Device|HeartMate 3|Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
45346554|NCT00818415|Drug|Naproxen sodium ER (BAYH6689)|Extented release Naproxen sodium (660mg) administered once a day
45346555|NCT00818415|Drug|Commercial Naproxen (Aleve, BAYH6689)|Immediate release Commercial Aleve (220mg) administered in a two ( 440 mg) plus one (220mg) dosing regime, 660 mg daily
46042679|NCT01093612|Procedure|positron emission tomography|PET images performed on a GE Discovery 16 Ste PET-CT scanner
46042680|NCT01093612|Radiation|copper Cu 64-DOTA-trastuzumab|15 mCi of Cu 64-DOTA-trastuzumab, total trastuzumab dose less than 5 mg.
46042681|NCT01093612|Procedure|Biopsy|Correlative Studies
46042682|NCT01093612|Other|Immunohistochemistry staining method|Correlative studies
45346556|NCT04045197|Behavioral|Relaxation Focused Nursing Care|"Relaxation Focused Nursing Care is composed of HypnoBirthing and Transactional Model. Hypnobirthing Philosophy is based on the laws of mind and aims to create positive thoughts and emotions. The Transactional Model defines stress as a special relationship between the person and the environment. Therefore, Relaxation Focused Nursing Care; positive language, positive environment and reducing stressors."
45346557|NCT00699816|Biological|Immuncell-LC|Activated T lymphocyte
45346558|NCT00815841|Drug|METHYLPHENIDATE|15-20mg during one of the two sessions
45382124|NCT05308459|Behavioral|Data-driven health promotion at Vocational Education and Training schools (Data Health VET)|"The intervention consists of the following steps:~A local health profile is conducted among all students~Results are shortly hereafter presented and discussed with all student and staff, and the school decide what health problem they will work with during the next year~A participatory group model process based on a dynamic systems approach is conducted to develop sustainable and system changing activities to address the chosen health problem~The activities are implemented~A new health profile is conducted to a) evaluate the effects of the implemented activities and to b) determine if a new health problem warrant focus and new activities are needed (the process repeats itself)."
46042683|NCT01093612|Other|laboratory biomarker analysis|Correlative studies
46042684|NCT01093612|Genetic|mutation analysis|Correlative studies
45840942|NCT00957684|Drug|eslicarbazepine acetate|once-daily oral tablet
46042685|NCT04554940|Biological|vosoritide|Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
46042686|NCT00620152|Behavioral|1|Low glycemic load diet by telephone counseling
46042687|NCT00620152|Behavioral|2|Low fat diet by telephone counseling
45346559|NCT04044963|Behavioral|Exercise and Prehabilitation|"All participants who are allocated to the exercise group will be asked to complete 4-5 days per week of mixed modality exercise incorporating aerobic, resistance, and flexibility training. The aerobic component can include any modality the patient is capable of doing, including walking, swimming or biking. By the end of the prehabilitation period the target will be 30 minutes of aerobic exercise three times a week at an intensity of 3-5 RPE. The resistance component will include 5-6 exercises using body weight and resistance bands. The target will be 12 repetitions and 3 sets, two times a week. The flexibility component will include 5 exercises that can be completed at the end of each session.~Participants will self-report their participation in the prehabilitation program based on an electronic survey."
45346560|NCT02567760|Dietary Supplement|MP1|Subjects receive MP1 drink at the dose of 400 mg/day after meal for 8 weeks.
45346561|NCT02567760|Other|Placebo|Subjects receive Placebo drink after meal for 8 weeks.
45346562|NCT00813033|Other|patient decision aid for endoscopy|patient decision aid will be administered at the point of decision making
45346563|NCT03897192|Drug|Bevacizumab|Anti-vascular endothelial growth factor (VEGF)
45840943|NCT00957684|Drug|placebo|once daily placebo comparator
46042688|NCT04210648|Device|Mobile app|Mobile app for self-managing emotional dysregulation
46042689|NCT02687308|Procedure|1 Retrograde radical prostatectomy RRP|This open surgical technique described by Patrick Walsh involves prostatic dissection made from prostatic apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture
46042690|NCT02687308|Procedure|2 Anterograde radical prostatectomy RRP2A|This open surgical techniques performing radical retropubic prostatectomy using the same technique of minimally invasive surgery, antegrade way, from bladder neck to the apex, with careful bladder neck dissection and preservation, incremental or not careful nervesparing procedures and urethrovesical anastomosis performed by monofilament running suture, described by the Pasadena consensus for the procedure assisted by robot.
46042691|NCT03900832|Other|Without Heating|Subject will complete walking protocol without any heating procedure
46042692|NCT03900832|Other|Warm Bath|"Subjects will sit in a warm bathtub with water up to their shoulders, while one arm will be out of water for BP and HR measurement. The water temperature and internal temperature (Tcore), BP and HR will be measured throughout the bath.~The water temperature will be controlled between 38-41°C. Subjects will remain in the tub for ≤ 30 minutes. If the HR increases more than 15 -20 bpm, or a significant BP drop occurs (e.g. BP >20 mmHg), the subject will be removed from the bath even if the time is <30 min."
45596423|NCT02257463|Device|inspiratory muscle training|Patients started breathing at a resistance that required generation of 30% of their PImax for one week. The load was then increased incrementally, 5-10%, to reach generation of 60% of their PImax at the end of the first month. Specific IMT was then continued at 60% of their PImax adjusted weekly to the new PImax achieved.
46042693|NCT03900832|Other|Neutral Bath|"Subjects will sit in a warm bathtub with water up to their shoulders, while one arm will be out of water for BP and HR measurement. The water temperature and internal temperature (Tcore), BP and HR will be measured throughout the bath.~The water temperature will be controlled between 35 - 37°C. Subjects will remain in the tub for ≤ 30 minutes."
46042694|NCT03900832|Other|Heating Suit|The mean skin temperature Tsk will be controlled with a water-perfused suit worn by subjects. Whole-body heating will be accomplished by perfusing warm water (~ 45 - 50 °C) through the suit to elevate the Tsk to ≤ 38 °C (100 oF). Warm water is through plastic tubes, and subjects' skin will not directly touch warm water. The heating will be continued until the ∆Tcore reaches ~ 0. 6 - 1.0 °C. This may take approximately 60 - 90 min.
45596424|NCT00162175|Drug|Muraglitazar|
45596425|NCT02198105|Device|Cutting-Balloon-PTA (VascuTrak) and Drug Coated Ballon PTA|"Interventional procedure:~PTA with Cutting-Balloon (60-120 seconds).~PTA with DC-Balloon (60 seconds).~Technical success is defined as~no recoil >30%~no dissection >Type B~no stenting >30% of lesion length."
45596426|NCT02375685|Biological|Gevokizumab|
45346564|NCT00813189|Device|GH treatment|GH treatment will be administered at a weekly dose of 0.46 mg/kg/ week, divided into seven daily subcutaneous injections. Subcutaneous injections should be given slowly, in the thigh. In order to prevent lipoatrophy, the injection site should be varied. The injection should be given at bedtime.
45346565|NCT02551263|Drug|Eribulin|Eribulin 1.4 mg/m2 will be administered intravenously over 2 to 5 minutes on day 1 and 8 of every 21-day cycle, in a real-world setting.
45346566|NCT02567214|Drug|Ultibro®|The intervention in this arm is the Ultibro®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be delivered and the Spiriva will be a placebo. We will measure the exertional dyspnea after 21 days of treatment.
45346567|NCT02567214|Drug|Spiriva®|The intervention in this arm is the Spiriva®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be a placebo and the Spiriva will be delivered. We will measure the exertional dyspnea after 21 days of treatment.
45346568|NCT04044885|Behavioral|Nap|Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
45346569|NCT00888004|Drug|AFQ056|
45346570|NCT00888004|Drug|Placebo|
45346571|NCT00813267|Biological|mesenchymal stem cell infusion|
45346572|NCT00813267|Biological|bone marrow mononuclear cell infusion|
45596427|NCT04371081|Device|Amplatzer Piccolo Occluder|Interventional placement of vascular occluder
45840944|NCT00958308|Other|BIO-K+ CL-1285®|A mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
45346573|NCT00890110|Biological|Autologous renal cell vaccine based on DNP modified cells|Primary or metastatic tumor resected in an Israeli hospital will be used to derive autologous cell lines used for vaccinations following DNP modifications in combination with the regular Sunitinib treatments. Immunological and clinical followup of the patients will be performed
45382125|NCT05306652|Other|Supervised physical activity|patients will have a home-based physical activity prescription, defined on the functional endurance and strength tests and they will be supervised for 3 months. Once monthly they will be examined by the oncologist (visit and questionnaires) and at weeks 4, 6, 8, 10 and 12 at the sport medicine center where the three tests will be repeated. Home-based activity will be monitored daily through a specific application. Endurance improvement is defined as an increase in walking speed; strength improvement is defined as an increase of the number of repetitions
45382126|NCT05306652|Other|Unsupervised physical activity|patients will receive a physical activity counselling, without a real prescription and supervision, and the three test will be repeated once a month for three months at the local sport medicine center and at the oncology center (visit and questionnaires). Counselling will include general informations on physical exercise
45840945|NCT00958308|Other|Placebo|Placebo is devoid of microorganisms.
45840946|NCT00959166|Other|PET scan|PET brain scan
46042695|NCT03900832|Other|Lower limb warm water immersion|Subjects will sit on a chair and put their lower legs and feet in a bucket with warm water. The water level will be just below the knees (depth of approximately 40 cm). The water temperature will be monitored and controlled at ~38 - 42 °C throughout the 30 minutes. BP, HR, Tcore, the skin temperature and skin blood flow (e.g. on a thigh and/or forearm) will be measured before, during and after the lower limbs warm water immersion.
45382127|NCT05306444|Drug|CLN-418|Intravenous (IV) administration
45840947|NCT00961662|Drug|D-Tagatose|powder to be dissolved in water prior to dosage.
46042696|NCT03900832|Other|Gardner walking protocol|The Gardner protocol begins at 2 mph and 0% grade for 2 minutes. The grade increases by 2% every 2 minutes (the speed remains 2 mph) until the subject says they want to stop or 22 minutes maximum. BP and HR will also be measured throughout the protocol.
46042697|NCT00639106|Procedure|Alloderm, Questionnaires|All patients will undergo placement of a temporary tissue expander immediately following mastectomy.Patients will undergo the surgical creation of an expander pocket using implantable Alloderm.
46042698|NCT00639106|Procedure|Without ALLODERM, Questionnaires|A standard, sub-muscular pocket dissection will be performed in the patients assigned to the control group. No Alloderm will be used.
46042699|NCT01182350|Drug|Bevacizumab|
46042700|NCT01182350|Drug|Erlotinib|
46042701|NCT01182350|Drug|Temozolomide|•
45346574|NCT02566824|Behavioral|Cognitive Behavioural & Skills Training|This will be administered in groups of 10 participants in 12 sessions each lasting 1.5 hours. Each session will focus on a new topic- Modules will be introduced via role play illustrating the topic, followed by Q&A. Strategies will be introduced to address the problems illustrated. Adolescents will practice using these strategies via planned activities or games. Obstacles to applying the skills in everyday life will be discussed and a physical reminder will be provided for each skill. A homework activity will be assigned to help participants practice the skill during the week. Each session will begin with homework review. Adolescents will also receive individual telephone coaching twice a week during the 12 weeks, which will taper off during the follow-up phase. Parents will also attend their own support group.
46042702|NCT01182350|Radiation|Radiation|
46042703|NCT02886416|Other|Non interventional study|
46042704|NCT04315844|Device|Ewata balloon guiding|The balloon guide catheter is coaxial cavity and reinforced braided catheter with varying stiffness echelon.The distal end is marked by an impermeable ray, the proximal end has a bifurcated ruhr interface, and the end is embedded with a compliance balloon.The product label indicates the size of the balloon guide catheter and the maximum volume of the balloon.
45382128|NCT05305677|Dietary Supplement|NMN intervention|NMN capsules (total of 600mg/day) for 8 weeks
46042705|NCT05367518|Dietary Supplement|Probiotic Streptococcus salivarius K12 Fast Melt Powder 1 Billion colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable tablet (lozenge) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
45684890|NCT04553848|Behavioral|Treadmill training|The goal of each session will be to increase balance and mobility challenge by increasing speed and minimizing BWS. Appropriate BWS will be chosen at the beginning of each training session. Participants will walk for 1 minute on the treadmill at 30%, 20% and 10% BWS. Maximum walking speed will be determined at each level of BWS and the participant will spend the remainder of the session ambulating with BWS at which they were able to achieve maximum walking speed. Additional BWS will be provided up to 30% of the participant's total body weight if the treating therapist identifies safety concerns or unfavorable gait kinematics. If a safe and kinematically appropriate gait pattern is unable to be achieved at up to 30% BWS, the previously determined walking speed will be reduced to achieve a safe and appropriate walking pattern. Participants will be encouraged not to use upper extremity support while ambulating with BWS.
45346575|NCT02566824|Behavioral|Supportive Group Therapy|This will be administered in groups of 10 participants in 12 sessions each session lasting 1.5 hours. During the initial session group members will be asked to identify a specific goal to address during the program. Each session will review the previous week's events (challenges and positive accomplishments) and psychoeducation on a topic relating to ADHD (topics will be elicited from group members at the outset of each session). Adolescents will also receive a telephone coaching at the same frequency as the CBT+S group participants. These phone calls will deal with issues a given participant had raised in the preceding session, and the approach will emphasize support and unconditional positive regard. Parents will also attend their own support group.
45382129|NCT05305677|Other|Placebo|NMN-free placebo capsules for 8 weeks
45382130|NCT05304949|Other|Lucentis|There is no treatment allocation. Patients administered Lucentis by prescription will be enrolled.
45382131|NCT05304715|Drug|Bezlotoxumab|Single intravenous infusion of bezlotoxumab
45382132|NCT05304715|Drug|Normal saline 0.9% or 5% dextrose water|Single intravenous infusion - Placebo arm
46042706|NCT05367518|Dietary Supplement|Probiotic Streptococcus salivarius K12 Fast Melt Powder 100 Million colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable table (lozenges) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
46042707|NCT01163474|Other|Evaluate video clinic visit prior to Face-to-Face usual care visit|Evaluate video clinic visit prior to Face-to-Face usual care visit
46042708|NCT00603538|Drug|CP-751,871 + carboplatin + paclitaxel|Chemotherapy (carboplatin and paclitaxel) and CP-751,871 (6, 10 or 20mg/kg) will be administered by intravenous infusion every three weeks.
46042709|NCT03854734|Behavioral|Community Event|Formative focus group data was used to design an educational community event to improve information share and vaccine education/knowledge.
45840948|NCT00962598|Drug|Omega 3 Fatty Acids|The study medication will consist of combined EPA/DHA with a ratio of 2:1. Dosage will be titrated based on clinical response and side effects. The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d. Patients will have to remain on a dose for 2 weeks to provide the opportunity to assess clinical response at any one dose. The total duration of the intervention will be 10 weeks.
45346576|NCT02566824|Other|Treatment as Usual - community resources|The treatment as usual group reflects what patients currently receive in the community (mainly medication). Participants will be stabilized on optimal medication (if they choose to be on medication) and referred back to the community for follow-up. Participants are free to seek out any additional interventions that they feel are required. These participants will be evaluated at the same intervals as the two therapy groups. They will receive a follow-up phone call from the study coordinator at two-month intervals in-between evaluation points. If participants indicate during the phone call that they require services, they will be referred to services in the community.
45596428|NCT03534089|Other|Standard infant fomula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula without lactoferrin supplementation.
45840949|NCT00962598|Dietary Supplement|Corn oil|The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment. Placebo (corn oil) and omega-3FA capsules will be identical in color and smell.
45346577|NCT02566824|Drug|Methylphenidate or amphetamine product|Medication is titrated over a 4-week period with stepwise increments each week. Participants, parents and teachers complete ADHD symptom scales at baseline and before each medication visit. They will also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participants remain on this dose for the remainder of the study.
45346578|NCT00813345|Other|light therapy (1500 lux)|light therapy (1500 lux) for 90 minutes
45684891|NCT04553848|Behavioral|Over ground training/standard of care|"Standard of care interventions to address balance and mobility deficits will be chosen from a list of commonly used interventions in outpatient therapy. The goal of each session will be to increase balance and mobility challenge in an over ground condition focusing treatment in the following areas:~Biomechanical Constraints~Stability Limits~Anticipatory Postural Adjustments~Reactive Postural Response~Sensory Orientation~Stability in Gait"
45346579|NCT00813345|Other|standard light (100 LUX)|standard light (100 LUX) for 90 minutes
45346580|NCT00890188|Drug|THALIDOMIDE and UFUR|T: Thalidomide (50): 150 mg/d ((1# tid) U: UFUR(100) 300 mg/d (1# tid) 28 days for one cycle
45346581|NCT05388942|Procedure|Virtual reality hypnosis|VRH offers predefined hypnosis sessions with no need of trained physician or nurse or caregiver mobilization. Consisting of a headset including headphones and a virtual reality screen, VRH allow patients to select a visual and sound environment (e.g.: tropical beach, space, underwater…) into which the hypnotic speech is delivered. That way, the patient's attention is distracted and muscular relaxation is obtained, a major relaxation factor. HRV is simple, quick, and presumably safe.
45346582|NCT05388942|Drug|Nitrous oxide|inhalation of NO usually used to help with ASD reduction but inhaled NO has safety and maintenance issues.
46042710|NCT03854734|Behavioral|Educational Material|Formative focus group data was used to design educational messaging to be electronically distributed to intervention participants
46042711|NCT04545580|Drug|Placebo|Matching placebo for BAY1817080, will be taken twice daily orally as tablet(s)
46042712|NCT04545580|Drug|BAY1817080|BAY1817080 will be taken twice daily orally as tablet(s)
46042713|NCT04185766|Dietary Supplement|Administration of a placebo solution (0.5 ml / kg)|43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (0.5 ml / kg)
46042714|NCT04185766|Dietary Supplement|Administration of a placebo solution (1 ml / kg)|43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (1 ml / kg)
46042715|NCT04185766|Dietary Supplement|Administration of 40% glucose in gel (0.5 ml / Kg)|43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (0.5 ml / Kg)
46042716|NCT04185766|Dietary Supplement|Administration of 40% glucose in gel 1 ml / Kg)|43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (1 ml / Kg).
45346583|NCT04037566|Genetic|XYF19 CAR-T cell|Autologous T cells engineered to specify CD19 transduced with a lentiviral vector and electroporated with CRISPR guide RNA to disrupt expression of endogenous HPK1 administered by IV injection.
45346584|NCT04037566|Drug|Cyclophosphamide|A cytotoxic chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
45346585|NCT04037566|Drug|Fludarabine|A chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
45346586|NCT00699660|Behavioral|CAPS/WHODAS|CAPS/WHODAS structured clinical PTSD interview
46042717|NCT02537938|Drug|NGP 555|
46042718|NCT04033900|Device|Forced air warming devices|"In the treatment group, heating will be started with a pre-surgical forced-air blanket Outpatient Warming Blanket model 11101 Bair Hugger from 3M and a forced-air heating unit Bair Hugger Warming Unit Model 775 from 3M at 38-43º C which will be maintain during the stay in the pre-surgery room until the transfer to the operating room"
46042719|NCT00639184|Other|Early intervention counseling|Bi-monthly home visits by counselor
46042720|NCT00639184|Other|Health education counseling|World Health Education health education counseling program at home visits,twice per month
46042721|NCT02537860|Other|Paravertebral block injections from T12 to L2|Three anesthetic injections are done
46042722|NCT02537860|Other|Placebo at T11 and L3|Two injections that contain saline are performed
46042723|NCT02537860|Other|Paravertebral block injections between T11 and L3|Five anesthetic injections are done
46042724|NCT02537860|Procedure|Herniorrhaphy|Unilateral inguinal hernia repair
46042725|NCT02537860|Drug|Intravenous (IV) fentanyl|Patients will be given 1 μg/kg intravenous (IV) fentanyl as premedication
45346587|NCT00699660|Behavioral|Nonstructured Interview|Usual PTSD clinical PTSD interview, not CAPS or SCID
45346588|NCT00888082|Drug|Goserelin acetate|3.6 mg depot injectable preparation
45346589|NCT00627705|Drug|N-Acetyl Cysteine|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous)."
45346590|NCT00627705|Other|Placebo - sugar pill|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous)."
45596429|NCT03534089|Other|Low level LF infant formula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula supplemented with low level of lactoferrin (38mg/100g).
46042726|NCT02537860|Drug|Bupivacaine|Each patient will receive 75 mg bupivacaine during PVB
46042727|NCT03844750|Procedure|Hepatectomy|Undergo liver resection.
46042728|NCT03844750|Biological|Pembrolizumab|Given IV
46042729|NCT03844750|Drug|Vactosertib|Given orally once a day (QD) for cycle 1, and twice a day (BID) for cycle 2 and beyond
46042730|NCT02687230|Drug|MVT-2163|MVT-2163 is administered intravenously as a PET imaging agent
46042731|NCT02687230|Drug|MVT-5873|MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163
45596430|NCT03534089|Other|High level LF infant formula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula middle supplemented with high level of lactoferrin (76mg/100g).
45346591|NCT04062162|Behavioral|Walking football training|Intervention will involve 3 sessions per week of a structured and supervised walking football program over 16 weeks. Each session will include a warm-up, followed by the practice of specific exercises where specific technical skills (pass, dribble, shot), motor skills (agility, coordination, balance) and physical fitness (cardiorespiratory and musculoskeletal capacity) will be enhanced, ending with a structured game (7x7) of walking football and a cooldown.
45346592|NCT04037488|Diagnostic Test|Inbody 320|Total Skeletal muscle mass (SMM), Skeletal muscle index (SMI), Relative Skeletal muscle mass index (RASM), Fat body mass (FBM), Body mass index (BMI), Body fat percentage, Body water content, Edema Value were calculated by Inbody 320
45596431|NCT02369289|Other|bone mineral density test|
45596432|NCT00160147|Drug|bifeprunox|One week titration with dose adjustments
45596433|NCT00160147|Drug|Placebo|Placebo
45596434|NCT04365387|Drug|Nemolizumab|Nemolizumab will be administered by 2 SC injections as 60-mg loading dose at baseline and a single 30-mg dose at Weeks 4, 8, and 12.
45596435|NCT04365387|Drug|Placebo|Placebo will be administered by 2 SC injections at baseline and a single dose at Weeks 4, 8, and 12.
45684892|NCT01898299|Device|transcranial Direct Current Stimulation (tDCS)|A neurostimulation technique that passes an extremely weak electric current through the brain.
46042732|NCT03797014|Drug|B/F/TAF|Fixed dose combination B/F/TAF (50 mg/ 200 mg/ 25 mg/ tablet) administered orally once daily without regards to food.
46042733|NCT04210102|Diagnostic Test|Lung Ultrasound (LUS)|"Lung Ultrasound : Ultrasound is a medical imaging technique that relies on the use of ultrasound, inaudible sound waves, which allow to visualize lungs."
46042734|NCT04210102|Diagnostic Test|Chest radiography (CR)|The chest X-ray is a medical imaging examination that provides images of the lungs through the X-ray pulse.
46042735|NCT04521946|Drug|Etoposide|Given IV
46042736|NCT04521946|Drug|Fludarabine Phosphate|Given IV
46042737|NCT04521946|Procedure|Hematopoietic Cell Transplantation|Undergo HCT
45346593|NCT05630352|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose|Injection in the muscle
45346594|NCT05630352|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose|Injection in the muscle
45346595|NCT05630352|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose|Injection in the muscle
45346596|NCT05630352|Biological|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 1 microgram dose|Injection in the muscle
45346597|NCT00890422|Biological|FSME vaccination (FSME-Immun)|intra muscular 0.5 ml
45346598|NCT00816075|Drug|distilled water|we plan to administer 200ml of distilled water after TUR of the tumor and block the catheter for 2 hours
45346599|NCT02541370|Biological|anti-CD133-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
45346600|NCT05617014|Radiation|Neuraceq|Amyloid PET imaging with Florbetaben (Neuraceq) injection
45346601|NCT05617014|Radiation|Amyvid|Amyloid PET imaging with Amyvid (Florbetapir) injection
45346602|NCT05617014|Radiation|Tauvid|Tau PET imaging with Tauvid (Flortaucipir) injection
45346603|NCT05617014|Radiation|MK-6240|Tau PET imaging with MK-6240 injection
45346604|NCT05617014|Radiation|NAV4694|Amyloid PET imaging with NAV4694 injection
45346605|NCT05617014|Radiation|PI-2620|Tau PET imaging with PI-2620 injection
45346606|NCT05045820|Procedure|acupuncture|"Acupuncture treatment will both main and supplementary acupoints. Main points include GB30; ST36; LI11- LI4, GB34-SP6; LR3, SP10, DU24, DU20, Yin Tang, Ear Shen Men which are chosen based on the unique clinical features of sickle pain. The remaining individualized acupoints will be selected and manipulated with manual acupuncture with appropriate needling techniques based on the individual Syndrome (reinforce or reduce or Non reinforce or reduce) that is determined by TCM diagnosis. Acupuncture treatment will last 30 minutes per session and will be administered two times per week for 5 weeks, each subject will receive one course of treatment which contains 10 treatment sessions."
45840950|NCT00962754|Procedure|physician no insight in the fluid balance chart|physician had no insight in the fluid balance chart during the first 3 days of admission of the patient when the balance is recorded
46042738|NCT04521946|Biological|Lapine T-Lymphocyte Immune Globulin|Given IV
46042739|NCT04521946|Drug|Melphalan|Given IV
46042740|NCT04521946|Drug|Mycophenolate Mofetil|Given PO or IV
46042741|NCT04521946|Drug|Tacrolimus|Given IV
45346607|NCT05045820|Other|Sham|"Non-Tradition Acupuncture or a Placebo Comparator will be used as sham acupuncture which uses mock laser acupuncture approach. Laser acupuncture device VitaLaser 650 (Lhasa OMS, Weymouth, MA or similar) will be positioned 1-2cm over all of the same acupoints used in verum acupuncture treatment above. No palpation is administered prior to positioning the device and there is no physical contact between device and skin. The laser will not be turned on during the treatment. Sham treatment will also last 30 minutes per session and will be administered two times per week for 5 weeks, each subject will receive one course of sham treatment which contains 10 treatment sessions."
45346608|NCT00610168|Biological|Boostrix TM|Single booster dose of vaccine
45346609|NCT05486286|Device|NCKU-NG system|A live-video system (NCKU-NG system) was developed to assist in the placement of enteral feeding tubes. This system consists of a camera and light source that can be inserted into the commercial NG tube to view live video during feeding tube placement. Manual air insufflation may aid feeding tube placement and improve visualization of anatomic landmarks. After the procedure, an abdominal X-ray is done to confirm the position of the feeding tube.
45346610|NCT00921102|Drug|Bupivacaine|12.5 mg of a 5 mg/ml hyperbaric solution, intrathecally
45596436|NCT03533777|Procedure|Peripheral intravenous catheter placement|The region of the upper extremity in which the IV will be placed will be prepped with chlorhexidine and a proximal elastic tourniquet is applied to the upper arm. A 20 gauge 30 millimeter IV catheter is inserted into an upper extremity vein by an anesthesiologist in either an antegrade or retrograde direction depending on which treatment arm the study subject is randomized to.
45684893|NCT01898299|Device|Sham tDCS|Sham (inactive) tDCS treatment
46042742|NCT04521946|Drug|Thiotepa|Given IV
46042743|NCT02885792|Other|Illness history|Existing psychiatric and somatic diagnosis and treatment. Charlson co-morbidity Index.
46042744|NCT02885792|Other|Measure of social conditions|A self-report questionnaire measuring social isolation, including relations to family and friends.
46042745|NCT02885792|Other|Measure of psychiatric condition|This method measures symptom severity, therapeutic response and general improvement, suicidal ideation, cognitive insight and awareness of illness and need for treatment and the ability to relabel symptoms.
46042746|NCT02885792|Procedure|Cardiovascular measurement|This procedure is used to detect early identification of cardiovascular disease progression.
46042747|NCT01162304|Drug|Extended Release Oxycodone|40 mg tablets one to two every 12 hours, Immediate release 5mg pills 1-2 tablets every 6 hours
45840951|NCT00964548|Drug|Dantrolene|1.25 mg/kg IV once over 60 min
45840952|NCT00964548|Drug|Dantrolene|2.5 mg/kg IV once over 60 min
45840953|NCT00905268|Drug|idebenone|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
45840954|NCT00905268|Drug|Placebo|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
45840955|NCT00965250|Drug|IMC-12|20 mg/kg intravenously once every three weeks
45346611|NCT00921102|Drug|Morphine|200 µg of a 200 µg/ml solution, intrathecally
45596437|NCT03533777|Other|Blood draw|A 20 milliliter(mL) syringe will be connected to the study IV tubing and used to aspirate 20 mL of blood from the study IV catheter. If 20 mL are unable to be aspirated over a 2 minute time frame, a proximal rubber tourniquet will be applied to the upper arm and the blood draw will be reattempted.This will occur twice throughout the study.
45346612|NCT00921102|Drug|Isotonic saline solution|"0.9% NaCl solution~0.1 ml, intrathecally in group Control and IV Atropine~0.1 ml, intravenously in group Control and Intrathecal Atropine"
45346613|NCT00921102|Drug|Atropine|"100 µg of a 1 mg/ml preservative-free solution~intrathecally in group Intrathecal Atropine~intravenously in group IV Atropine"
45596438|NCT03533777|Device|Peripheral intravenous catheter|A 20 gauge 30 millimeter long BD Insyte(TM) Autoguard(TM) angiocatheter will be used for peripheral intravenous catheter placement as described above.
46042748|NCT01162304|Drug|Immediate Release Oxycodone|IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every 4 hours
46042749|NCT04515394|Drug|Tepotinib|Participants received Tepotinib film-coated tablets at a dose of 500 milligrams (mg) orally, once daily (QD) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 [RECIST v1.1]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
45346614|NCT00890500|Drug|Fludarabine|30mg/m2/day IV x 6 days
45346615|NCT00890500|Drug|Melphalan|100 mg/m2/day IV x 1 day
45346616|NCT00890500|Drug|Antithymocyte Globulin|1mg/kg/day x 4 days
45346617|NCT00890500|Drug|Sirolimus|GVHD Prophylaxis: Target range 3-12 ng/ml
45346618|NCT00890500|Drug|Tacrolimus|GVHD Prophylaxis: Target range 5-10 ng/ml
46042750|NCT04515394|Biological|Cetuximab|Participants received weekly intravenous infusions of Cetuximab at a dose of 250 milligrams per square meter (mg/m^2) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 [RECIST v1.1]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
46042751|NCT04206176|Drug|Ticagrelor|Ticagrelor 45mg twice daily per oral administration
45346619|NCT00890578|Procedure|adhesive to suture|surgical closure
46042752|NCT01175018|Drug|Anakinra|Anakinra 100 mg s.c. daily for 14 days
46042753|NCT01175018|Drug|Placebo|0.67 ml of NaCl 0.9% solution given subcutaneously daily for 14 days
46042754|NCT02685514|Device|HIFU Graves|The HIFU treatment technique will be applied to the recruited participants
46042755|NCT04314986|Drug|Cohort 1: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
46042756|NCT04314986|Drug|Cohort 2: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days.
46042757|NCT04314986|Drug|Cohort 3: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
46042758|NCT04314986|Drug|Cohort 4: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
46042759|NCT02685280|Device|Medtronic Restore Advanced 37713|Rechargeable neurostimulators are implanted when the non-rechargeable neurostimulators are end-of-life.
46042760|NCT03754972|Diagnostic Test|Sagittal plane shear index (SPSI)|Report SPSI to surgeon after surgeon records an initial surgical plan, and determine whether the objective spinal stability metric influences a change in the surgical plan.
46042761|NCT01174784|Device|Chronic TOtAl OcclusioN CrossiNg with thE WildCat CatheTer|A Non-Randomized Study of the Avinger Wildcat™ used to Cross Chronic Total Occlusions in the Superficial Femoral and Popliteal Arteries
46042762|NCT02686918|Other|Advanced Practice Nurse consultation|
46042763|NCT04314440|Behavioral|Music therapy|"An accredited music therapist will deliver 15-20 minutes of music therapy every day, 4-5 days in week one and remaining in week two to all MT participants. All participants in music therapy group will get a total of nine sessions. The lullaby twinkle twinkle little star will be sung for ~5 minutes, followed by the same songs played on acoustic guitar for ~5 minutes and another ~5 minutes of the same song sung in voice. This protocol will be followed in all 9 sessions for all infants in the experimental arm. The sound levels will be maintained at 55-65 decibels (dB) using appropriate meters. If MT is interrupted within 10 minutes then a make-up session will be delivered, assuming no discharge. In case of missed sessions and interrupted session infants will receive a maximum of 12 session."
46042764|NCT02686996|Dietary Supplement|carnosine|Carnosine capsules (2g) twice per day for 14 weeks
46042765|NCT02686996|Other|Placebo|Placebo (methylcellulose) capsules for control group identical to intervention capsules and dose
46042766|NCT02687074|Device|HFNC|patients treated with high flow nasal cannula
46042767|NCT02687074|Device|NIV|patients treated with noninvasive ventilation
46042768|NCT01174550|Procedure|Coronary Angiography|Use of standard equipment for usual-care testing
46042769|NCT01174550|Procedure|Stress Echocardiogram|Use of standard equipment for usual-care testing
46042770|NCT01174550|Procedure|Nuclear Stress Test|Use of standard equipment for usual-care testing
45346620|NCT00890734|Drug|CYT003-QbG10|subcutaneous injection
45346621|NCT00890734|Drug|Placebo|subcutaneous injection
45346622|NCT04061772|Drug|Bortezomib|Bortezomib injection
45346623|NCT04061772|Drug|Etoposide|Etoposide injection
46042771|NCT01174550|Procedure|Exercise Electrocardiogram|Use of standard equipment for usual-care testing
46042772|NCT00638326|Drug|clopidogrel|150 mg maintenance dose (2 capsules of 75 mg clopidogrel) for 28 days followed by standard 75 mg clopidogrel for one year
45596439|NCT03533777|Drug|To keep open (TKO) infusion of 0.9% normal saline|After placement of the peripheral intravenous catheter, an infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
45346624|NCT04061772|Drug|Cyclophosphamide|Cyclophosphamide injection
45346625|NCT04061772|Drug|Pharmorubicin|Pharmorubicin injection
45346626|NCT04061772|Drug|Prednisone|Prednisone tablet
45346627|NCT05333874|Drug|Neoadjuvant chemotherapy administered before surgical extraction of a tumor|SignateraTM is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. The Signatera methodology is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual's tumor tissue. This maximizes accuracy for detecting the presence or absence of disease in a blood sample, even at levels down to a single tumor molecule in a tube of blood. Signatera is intended to detect and quantify how much cancer is left in the body, to improve prognosis and help optimize treatment decisions, based on the tissue-informed testing of mutations.
45346628|NCT05333874|Other|Observational|In participants, undetectable ctDNA at fourteen days will be in the observation arm (observation defined as TNBC: No adjuvant chemotherapy. Participants may complete checkpoint inhibitor from neoadjuvant setting; HER2 positive BC: Completed one year of anti-HER2 therapy from the neoadjuvant setting). No investigational drugs will be used. Samples of ctDNA will be collected at time points described in the study arm.
45346629|NCT04061928|Drug|PD-1|2 times PD-1 (240mg) combined with preoperative chemoradiotherapy，then another 2 times PD-1 before operation. 4 times PD-1 combined with postoperative chemotherapy.
45596440|NCT02198261|Drug|5% minoxidil topical foam|5% minoxidil topical foam
46042773|NCT00638326|Drug|clopidogrel plus placebo|75 mg maintenance dose (one capsule of 75 mg clopidogrel and one capsule placebo) for 28 days followed by standard 75 mg clopidogrel for one year
46042774|NCT04187170|Other|Strength physical training|progressive high-load strength training over 6 months, consisting in repeated physical exercises to increase the muscular mass and force by altering concentric and eccentric muscle contractions against high resistance.
46042775|NCT04184830|Device|non-invasive brain stimulation|
46042776|NCT04187560|Drug|LB-102|(N-Methyl amisulpride)
46042777|NCT04314674|Drug|%3 HS bolus|After head fixation %3 HS bolus 3 ml/kg will be administered
46042778|NCT04314674|Drug|%3 HS infusion 20 ml/h|After head fixation %3 HS 20 ml/h infusion will be administered
46042779|NCT04314674|Drug|20% mannitol|After head fixation %20 mannitol 0.6 ml/kg will be administered
45346630|NCT00644787|Drug|Fentanyl 1-day transdermal patch (Titration Phase)|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14.
45840956|NCT00966186|Procedure|Insertion fo ProSeal laryngeal mask airway|Insertion fo ProSeal laryngeal mask airway using each of Standard technique or Rotational technique
45840957|NCT00967044|Drug|Panobinostat|Starting dose of 10 mg by mouth per day, self-administered (by patients), three times per week
45346631|NCT00644787|Drug|Fentanyl 1-day transdermal patch (Double Blind Phase)|Fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
45346632|NCT00644787|Drug|Fentanyl 3-day transdermal patch (Double Blind Phase)|Fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
45346633|NCT00644787|Drug|Placebo|Placebo matching to fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
45346634|NCT00644787|Drug|Placebo|Placebo matching to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
45346635|NCT00699582|Drug|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
45840958|NCT00967044|Drug|Everolimus|Starting dose of 5 mg every day by mouth with 1 cup (8 ounces) of water, in morning after eating a low-fat meal.
46042780|NCT00639262|Drug|Sorafenib|Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)
46042781|NCT00639262|Drug|Temozolomide|For Cohort 2 - Gliomas only.
45346636|NCT00699582|Drug|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
45346637|NCT00699582|Drug|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
45346638|NCT00821301|Drug|Fluphenazine HCl|Fluphenazine HCl will be administered intravenously. To quickly reach and maintain the target bone marrow concentration for 18 hours, the study drug will be administered using 3 bolus injections (0, 6, and 12 hours). Fluphenazine will be dose-escalated according to a modified Fibonacci scheme, terminating in 40% increments. Treatments will be administered on days 1 and 8 of every 21 day cycle.
45346639|NCT05593770|Drug|Fostamatinib|Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
46042782|NCT00639262|Radiation|Radiotherapy|Radiation Therapy (XRT)
45684894|NCT04550650|Other|Training groupe|Using virtual training
45684895|NCT04550650|Other|PNF|PNF technique was used
45684896|NCT04550650|Other|Spinning grp|They only worked with spinning bikes.
45684897|NCT04550650|Other|Balance|Balance development was done
45684898|NCT01886287|Drug|Octreotide LAR|Octreotide LAR as outlined in Treatment Arm.
45684899|NCT04559386|Other|Survey|Questionnaire
45840959|NCT00968838|Procedure|White Blood Cell Transfusion|"4 Transfusions, each taking approximately 1 hour:~Patients <50 years of age receive 4 standard transfusions before they are randomized to receive further radiated or non radiated transfusions.~Patients >50 years of age are randomized to receive either radiated or non radiated transfusions."
45840960|NCT00970320|Other|Pelvic floor muscle training|6 months of daily pelvic floor exercise treatment with regular follow up by specialist physiotherapist.
45840961|NCT00973752|Drug|Prednisone|Orally during Induction, Consolidation 1, CNS, Consolidation 2, and Continuation therapy.
46042783|NCT02886104|Procedure|CRLM resection group|Simultaneous resection of both primary and secondary tumors in synchronous CRLM or resection of metachronous CRLM.
46042784|NCT02886104|Device|CRLM ablation group|Microwave ablation of CRLM with a 2.15-gigahertz(GHz) microwave generator and a 14 gauge diameter transcutaneous antenna within 30 days after resection of primary tumor in synchronous CRLM or ablation of metachronous CRLM.
45346640|NCT05593770|Drug|Placebo|Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
45346641|NCT04645173|Device|CIED envelope|Evaluation of the difference in cohorts for soft tissue healing surrounding the CIED implant and clinical outcomes and complications.
45346642|NCT04062084|Device|Multifunctional Cataract-assisted Retractor|Multifunctional Cataract-assisted retractor operation for cataract with subluxation of lens
46042785|NCT02689102|Device|Probe based optical techniques|During the diagnostic bronchoscopy, optical biopsy of the mucosa and alveolar compartment will be conducted by two different probe based optical techniques (Confocal Laser Endomicroscopy (Mauna Kea technologies) and Optical Coherence Tomography (St Jude Medical)). After the study measurements a biopsy will be obtained in the same area.
45346643|NCT03860727|Diagnostic Test|Welch Allyn IExaminer|Fundus Examination
46042786|NCT02885558|Drug|Efonidipine|8 weeks treatment with either efonidipine
45346644|NCT00640341|Device|PureVision Contact Lens|contact lens for daily wear
45346645|NCT00640341|Device|Acuvue Oasys Contact Lens|contact lens for daily wear
45346646|NCT00640341|Device|O2Optix Contact lens|contact lens for daily wear
45346647|NCT00816153|Other|PVI-guided fluid management|Peroperative comparison of standard care with PVI-guided fluid management (optimization of the PVI value with fluid loading)
45840962|NCT00973752|Drug|Vincristine|Intravenously during Induction, CNS, Consolidation 2 and Continuation Therapy
45840963|NCT00973752|Drug|Doxorubicin|Intravenously during Induction, CNS, and Consolidation 2 therapy
45840964|NCT00973752|Drug|PEG-asparaginase|Intravenously during Induction, Consolidation 1, CNS, and Consolidation 2 therapy
45840965|NCT00973752|Drug|Cytarabine|Intrathecally during Induction and CNS therapy
45840966|NCT00973752|Drug|Methotrexate|Intrathecally during Induction, CNS, and Continuation Therapy
46042787|NCT02885558|Drug|Nifedipine|8 weeks treatment with either nifedipine
46042788|NCT04185688|Other|Functional Reach Test|The Functional Reach Test assesses balance by measuring the limits of stability while the patient reaches forwards as far as possible, having the arms in 90° flexion and without lifting the heels off the floor.
46042789|NCT04446442|Device|tDCS|A current of 1 mA will be administered for 20 minutes of with either anodal or cathodal tDCS administration to the right crus I/II area of the cerebellum.
46042790|NCT01008150|Drug|Paclitaxel|
46042791|NCT01008150|Drug|Trastuzumab|
46042792|NCT01008150|Drug|Neratinib|
46042793|NCT01008150|Drug|Doxorubicin|
46042794|NCT01008150|Drug|Cyclophosphamide|
46042795|NCT02687152|Other|N-hydroxy-nor-L-arginine|
46042796|NCT04186936|Drug|Combination Caplet with Loperamide HCl and Simethicone|Participants will receive combination caplet with loperamide HCl 2 mg and simethicone 125 mg as Test product A per assigned treatment sequence.
46042797|NCT04186936|Drug|Loperamide HCl|Participants will receive loperamide HCl 2 mg tablet-lyophilizate orally as part of Reference product B per assigned treatment sequence.
45346648|NCT02550561|Device|Posterior Tibial Nerve Stimulation|PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots.
45840967|NCT00973752|Drug|Imatinib|Orally during Induction, Consolidation 1, CNS, Consolidation 2 and Continuation Therapy
45346649|NCT00699348|Drug|Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)|Intravenous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 micrograms every 4 weeks for 24 weeks.
45346650|NCT05327634|Other|self-questionnaire|Prospective study on patients aged 75 and over, hospitalised in geriatric short stay or geriatric rehabilitation units
45840968|NCT00973752|Drug|Clofarabine|Intravenously during Consolidation 1 Therapy
45840969|NCT00973752|Drug|6 Mercaptopurine|Orally during CNS, Consolidation 2 and Continuation Therapy
45346651|NCT04062786|Other|Pmsf-PVC gradient measurement|implementation of standard standard hemodynamic monitorin
45840970|NCT00974142|Drug|Cyclosporine|Fifteen patients will receive cyclosporine at an initial dosing of 3.0 mg/kg/day.
45840971|NCT00974142|Drug|Placebo|Fifteen patients will receive will receive placebo.
45840972|NCT00974376|Drug|gabapentin 1200mg/day|gabapentin 1200mg/day for 12 weeks
45840973|NCT00974376|Drug|Placebo|1200mg/day of placebo for 12 weeks
45840974|NCT00974376|Behavioral|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 12 weeks in conjunction with study drug or placebo.
46042798|NCT04186936|Drug|Simethicone|Participants will receive Simethicone 40 mg capsule orally as part of Reference product B per assigned treatment sequence.
45346652|NCT00643851|Drug|Dapagliflozin|Tablets, Oral, Once daily, 24 weeks
45840975|NCT00976248|Drug|RAD001|Taken orally once a day
45840976|NCT00976404|Biological|DNA + HIV-rAd5 vaccine|4 mg subcutaneous injection at weeks 8 (DNA prime), 12 (DNA prime), 16 (DNA prime), and 32 (HIV-rAd5)
45840977|NCT00976404|Drug|ART intensification (raltegravir)|raltegravir 400 mg PO BID for 56 weeks
45840978|NCT00976404|Drug|ART intensification (maraviroc)|maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks
46042799|NCT01007916|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, spherical contact lens having a recommended replacement schedule of monthly.
46042800|NCT01007916|Device|Habitual contact lens|Habitual soft spherical contact lens having a recommended replacement schedule of 2 weeks or monthly.
46042801|NCT02689180|Drug|Placebo|Replacement of furosemide by placebo
46042802|NCT02689180|Drug|Furosemide|Maintenance of furosemide on usual doses
45346653|NCT00643851|Drug|Metformin XR|Tablets, Oral, Once daily, 24 weeks
45346654|NCT05316324|Procedure|Prepectoral Breast Reconstruction with Acellular Dermal Matrix (ADM)|Prepectoral Breast Reconstruction with (ADM)
46042803|NCT01007838|Other|Progressive resistance training programme|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
46042804|NCT01007838|Other|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
45346655|NCT05316324|Procedure|Prepectoral Breast Reconstruction without Acellular Dermal Matrix (ADM)|Prepectoral Breast Reconstruction without ADM
45346656|NCT05575830|Biological|Recombinant Zoster Vaccine|Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60
45346657|NCT00816231|Behavioral|Tobacco|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving tobacco with brief summary at the end of the last session.
45346658|NCT00816231|Other|Alcoholic Beverage|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving and alcohol with brief summary at the end of the last session.
45346659|NCT00816231|Other|Placebo|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving placebo with brief summary at the end of the last session.
45346660|NCT04062864|Device|Pupil size|Measures the diameter of pupil before and after painful stimuli
45346661|NCT00821457|Drug|Juvista|250ng
45346662|NCT00821457|Drug|Placebo|Powder for solution for injection
45346663|NCT00821457|Drug|Juvista|500ng
45346664|NCT03667690|Drug|Rezafungin for Injection|Intravenous antifungal therapy
45346665|NCT03667690|Drug|Caspofungin|Intravenous antifungal therapy
45346666|NCT03667690|Drug|Fluconazole|Oral antifungal therapy
46042805|NCT01007838|Other|Progressive resistance training|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
45346667|NCT03667690|Drug|intravenous placebo|Normal saline
45346668|NCT03667690|Drug|oral placebo|Microcrystalline cellulose
45346669|NCT00821535|Drug|maraviroc (Selzentry, Celsentri)|12 subjects will receive a single dose of 300 mg maraviroc (two 150 mg maraviroc commercial tablets) under fasting conditions.
45684900|NCT04395118|Behavioral|Mailed Outreach|The investigators will randomize elevated LFT patients (~12,000 patients) using a centrally maintained computer-generated list. Patients will be randomly assigned to one of two HCV screening strategies including: visit-based screening as part of usual care (Group 1) or mailed screening invitation outreach and centralized patient navigation (Group 2).
46042806|NCT01007838|Other|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
45684901|NCT04628065|Behavioral|#BabyLetsMove|This intervention will use mobile phones to promote the adoption and maintenance of physical activity, exercise and reduced TV time among overweight or obese, Black, pregnant (<16 weeks) adolescents (15 - 19 years) enrolled in Mississippi's WIC program.
45684902|NCT04393870|Other|Foccusing on Maryam's Flower|Effect of Focusing on Maryam's Flower During the First Phase of the labor
45840979|NCT00977184|Procedure|50 HZ Repetitive TMS|
46042807|NCT02686762|Drug|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.
46042808|NCT02686762|Drug|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.
46042809|NCT02686762|Drug|Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
46042810|NCT02689336|Biological|Erlotinib|
46042811|NCT02689336|Drug|Temozolomide|
46042812|NCT03650764|Drug|Ramucirumab|Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient
46042813|NCT03650764|Drug|Pembrolizumab|Pembrolizumab is commercially available
46042814|NCT03650764|Other|EORTC QLQ-30|-Screening, start of cycle 2, start of cycle 5
46042815|NCT03650764|Other|FACT H&N|-Screening, start of cycle 2, start of cycle 5
46042816|NCT03650764|Procedure|Peripheral blood|-Baseline
46042817|NCT02685592|Drug|5-aminolevulinic acid nanoemulsion|A 1 millimeter thick layer of 5-aminolevulinic acid nanoemulsion light sensitizing gel is applied on the skin and let to absorb 3 hours before illumination.
46042818|NCT04417972|Drug|SHR7280|treatment
46042819|NCT04417972|Drug|Placebo oral tablet|blank control
46042820|NCT01007448|Drug|Bexarotene|Soft gelatin capsules to be taken orally with at least 6 ounces of water or other fluid either with or immediately following the evening meal (a moderate or full meal) or a nutritionally defined liquid food.
46042821|NCT02686684|Drug|Dimethyl fumarate|
46042822|NCT04294056|Drug|Ciprofol|First-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg Second-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg
46042823|NCT04294056|Drug|Propofol|First-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg Second-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg
46042824|NCT02870556|Device|cervical epidural analgesia|
46042825|NCT00628602|Device|BION|"30 patients operated will be randomized into 2 equal groups, a BION Therapy Group (Rx group) and a Control Group (Control group)."
46042826|NCT03538756|Device|Walkasins|Walkasins® consist of two parts for each leg: the Haptic Module (leg unit) and the Receptor Sole (foot pad). The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.
46042827|NCT04204824|Other|Ultrasound and exercise|"The control group's ultrasound will be set at an intensity of 0 w/cm2. The first 3 treatments to the experimental group will be continuous ultrasound with an intensity of 1.0w/cm2 for 7 minutes. The next 6 treatments for the experimental group (2 times a week for 3 weeks) will have pulsed ultrasound at an intensity of 1.0w/cm2 with a 50% (1:1) duty cycle for 10 minutes. All will have a frequency of 3 MHZ.~All participants in each group will be given specific exercises targeting intrinsic and extrinsic muscles of the foot and ankle. Exercises will be performed with a level of thera-band that is challenging to the individual participant in each plane of motion without increased pain for 3 sets of 10 repetitions each and one time each day independently at home during the duration of the treatment protocol (4 weeks) and recorded in an exercise log diary Specific stretches for the plantar fascia and Achilles tendon will be performed 3 times each for 30 second intervals and at home"
46042828|NCT04186702|Procedure|INTRAVITREAL RANIBIZUMAB INJECTION|interventions involving RANIBIZUMAB INJECTION 0.5 mg (0.05 mL of 10 mg/mL solution)
46042829|NCT04187014|Drug|Aminocaproic Acid 1000Mg Tab|Oral administration of a total 6 g of aminocaproic acid to reduce blood loss
46042830|NCT04187014|Drug|Tranexamic acid tablets|Oral administration of 3.9 g of tranexamic acid to reduce blood loss
46042831|NCT02686840|Drug|sublingual misoprostol|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~Paracetamol, eight hourly, will be provided as analgesic or antipyretic.~A specimen bottle to collect the POC if passed out.~Two pairs of disposable gloves.~Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
46042832|NCT02686840|Drug|vaginal misoprostol|"All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic"
46042833|NCT02689024|Drug|Bupivacaine|Local anesthetic: amide group ATC code N01BB01
46042834|NCT02689024|Drug|Acetaminophen|Analgesic drug: Acetanilide derivate with analgetic and antipyretic properties ATC code N02BE01
45840980|NCT00977184|Procedure|Sham rTMS|
45346670|NCT04062006|Drug|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10~6 IU/m2 five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
45475223|NCT01188941|Behavioral|Health System Navigator|Subjects will be enrolled prior to an HIV test. Following TB screening, HIV infected subjects will meet with the health systems navigator who will administer a brief strengths-based interview. During this interview the participant and navigator will identify barriers to HIV and/or TB care and the resources and strengths that will be most helpful in overcoming these barriers. The health system navigator will stay in contact with participants for the next 4 months using phone calls and SMS on a standardized schedule. During the phone contacts the health system navigator will assess where the participant is on the care pathway. If the participant has not completed a step in his/her HIV or TB care, the health system navigator will help the participant draw on strengths identified in the initial interview and overcome any obstacles hindering him/her from accessing care.
45346671|NCT04872582|Drug|PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab|combined
45346672|NCT04061538|Dietary Supplement|zinc sulfate|zinc 20mg tablets
45346673|NCT04061538|Dietary Supplement|Placebo|Sugar pill manufactured to mimic zinc 20mg tablet
45346674|NCT00888316|Procedure|magnetic resonance imaging|"MRI of the liver will be performed within 30 days prior to HSCT (day 0) and can be done during receipt of conditioning regimen chemotherapy and/or radiation therapy. MRI will also be performed in selected patients at 1 year post-HSCT. This MRI will be done within ± 30 days of their 1-year post-transplant followup date.~The R2 MRI is a specific MRI technique and cannot be used for the purpose of general diagnostic imaging. In our study, this modality is being used specifically for the estimation of LIC."
45346675|NCT00888316|Procedure|Serum ferritin|Blood samples will be taken pre-transplant, 3, 6, 9 and 12 months post-transplant
45475224|NCT02730208|Drug|Tezacaftor/Ivacaftor|TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
45475225|NCT02730208|Drug|Ivacaftor|IVA 150 mg tablet.
45475226|NCT02730208|Drug|Placebo|Placebo matched to TEZ/IVA fixed-dose combination tablet.
45475227|NCT02730208|Drug|Placebo|Placebo matched to IVA tablet.
45475228|NCT01291511|Drug|Iloperidone|Iloperidone capsules/tablets will be administered orally using a bid schedule; the strengths used include 1, 2, 4, 6, 8, 10, and 12 mg.
45346676|NCT04351620|Drug|Hydroxychloroquine|Tolerability study of HCQ 1200 mg administered daily in divided doses for a duration of 5-10 days
45346677|NCT00888394|Procedure|chiropody|basic procedure of chiropody in podiatry
45346678|NCT00888394|Procedure|basic orthesis|individual basic orthesis of foot
45346679|NCT00888394|Procedure|advantage orthesis|advantage orthesis of foot with special material and design
45346680|NCT00888394|Procedure|chiropody and advantage orthesis|chiropody and advantage orthesis of foot
45346681|NCT02541760|Drug|Monteleukast|4 ml monteleukast daily for one month
45346682|NCT02541760|Drug|Mometasone|Inhaled mometasone 1 puff in each side of nose for one month
45346683|NCT00888472|Procedure|Leukocytapheresis|5000 ml, the blood volume per body, treated once. Twice at an interval of 6 days.
45346684|NCT00627393|Drug|Standard antimicrobial therapy|Antimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection and should be consistent within a given institution. Participants will undergo the recommended therapy for specific infections for 42 days.
45346685|NCT00627393|Biological|Granulocyte transfusions|Participants will receive one granulocyte transfusion per day until one of the following occurs: recovery from neutropenia, life-threatening toxicity, resolution or improvement of infection, or Day 42 after treatment. Granulocyte content of each transfusion is targeted to be at least 4 x 10^10 per collection (or proportionately less for participants less than 30 kg in weight).
45475229|NCT01291511|Drug|Placebo|Matching placebo capsules will be administered orally duins a bid schedule during the double-blind period.
45475230|NCT03354130|Other|Processed meat dietary intervention|Randomized cross-over dietary intervention with 5 different diets
45346686|NCT00627393|Drug|G-CSF/dexamethasone|Twelve hours before each donation, participants will be injected with G-CSF and will take one dose of dexamethasone by mouth.
45346687|NCT00627393|Device|Apheresis machine|Participants will undergo a procedure using an apheresis machine for granulocyte collection. The procedure will last 3 to 4 hours and will involve the drawing of blood from each arm, the separation of granulocytes from the red cells and plasma in the machine, and the return of the red cells and plasma to the participants.
45346688|NCT04534959|Other|Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)|Post-implementation of targeted normoxemia through oxygen titration for individual patients. Interventions for treatment of hypoxemia will follow usual local practice. Interventions for treatment of hyperoxemia (SpO2 >96% or PaO2 >100 mmHg) will involve down titration of FiO2 (or supplemental oxygen for non-mechanically ventilated patients) within a time frame based on local site preferences-typically in increments of no greater than 0.10 until goal oxygenation in the normoxemia range is achieved (including room air [no supplemental oxygen] for non-mechanically ventilated patients).
45346689|NCT00816309|Device|Acapella Physiotherapy|twice daily- around 20 minutes
45346690|NCT00821691|Drug|Amantadin|Amantadin caps
45346691|NCT00821691|Drug|Placebo|Placebo caps
45346692|NCT00577122|Drug|Medroxyprogesterone progesterone acetate (MPA)|1000 mg po daily
45346693|NCT00577122|Drug|Medroxyprogesterone with Cyclophosphamide + Methotrexate|Medroxyprogesterone Acetate Dose 1000 mg po daily Cyclophosphamide Dose 50 mg po daily Methotrexate Dose 2.5 mg po daily Days 1 and 2 of each week
45346694|NCT00821847|Other|DEXA scan|DEXA scan
45346695|NCT00816387|Procedure|Fallopian tube sperm perfusion|Patients are treated with fallopian tube sperm perfusion
45346696|NCT00816387|Procedure|Intrauterine insemination using standard catheter|Patients are treated with standard intrauterine insemination
46042835|NCT02689024|Drug|Diclofenac|Non-Steroidal Anti-Inflammatory Drug: Acetic acid derivative ATC code M01AB05 Usual dosage is 50 mg t.i.d. orally or 75 mg b.i.d. intramuscularly. In the Netherlands, intravenous administration is not used.
46042836|NCT02689024|Drug|Ibuprofen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE01 Usual dosage is 400 mg t.i.d. or q.i.d. orally.
45346697|NCT05260866|Other|national population-based study|No intervention
45346698|NCT00821925|Procedure|bone densitometry|All patients do a bone densitometry after the inclusion.
46042837|NCT02689024|Drug|Naproxen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE02 Usual dosage is initially 500 mg orally, followed by 250 mg b.i.d. or t.i.d.
45475231|NCT01292213|Procedure|Cough swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
45684903|NCT02707588|Drug|Pembrolizumab|"200mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions)."
45684904|NCT02707588|Drug|Cetuximab|"Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions)."
46042838|NCT02689024|Drug|Dipyrone|Analgesic drug: Pyrazolone derivate with analgetic, antipyretic and antiphlogistic properties ATC N02BB02 Usual dosage is 1000 mg t.i.d. or q.i.d. orally and intravenously
46042839|NCT02689024|Drug|Fentanyl|Opioids: Phenylpiperidine derivative. Short-acting opioid. ATC code N02AB03 Usual dosage is 1 ug/kg intravenously and titrated guided by pain scores and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
46042840|NCT02689024|Drug|Morphine|Opioids: Natural opium alkaloid. Longer-acting opioid. ATC code N02AA01 Usual dosage is 0.1 mg intravenously and titrated guided by pain and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
46042841|NCT02689024|Drug|Levobupivacaine|Local anesthetic: amide group ATC code N01BB10
46042842|NCT02689024|Drug|Ropivacaine|Local anesthetic: amide group ATC code N01BB09
46042843|NCT00638482|Drug|Hydrochlorothiazide|Hydrochlorothiazide
45346699|NCT00816465|Dietary Supplement|Hoodia gordonii|PO administration of 1 Tab Hoodia gordoni extract per day.
45346700|NCT00816465|Other|Placebo|PO Placebo pill
45346701|NCT00822003|Drug|Oral GLP-1|GLP-1 tablet (2mg)
45346702|NCT00822003|Drug|Placebo|Control tablet
45346703|NCT00822081|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
45346704|NCT00822081|Drug|dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination|1 drop BID in each eye
45475232|NCT01292213|Procedure|Oropharyngeal swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
46042844|NCT00639964|Other|blood tests|3 measures during pregnancy and 1 at post partum, 1 measure at time of delivery from fetal cord
46042845|NCT00639964|Other|diet questionnaire|questions about nutrition before and during pregnancy
45346705|NCT00822081|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
45346706|NCT00822081|Drug|dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
45346707|NCT00822159|Device|DensiProbe Hip|DensiProbe (CE marked) is a mechanical probe, which is used intra-operatively to assess mechanical stability of the trabecular bone in the proximal femur. It consists of a drill bit like tool and an electronic system for measuring the peak torque to break-away of trabecular bone in the femoral head. DensiProbe measurements are designed to be integrated in the DHS surgical procedure.
45475233|NCT01292213|Procedure|Nasopharyngeal swabs|Samples will be tested to determine and characterise the bacteria and viruses that may be associated with chronic cough.
45475234|NCT01292213|Procedure|Blood sample|Samples will be tested to determine and characterise the immunological markers that may be associated with chronic cough.
45475235|NCT01292213|Procedure|Bronchoscopy/ bronchoalveolar lavage samples|Samples will be tested to determine and characterise the bacteria, viruses and immunological markers that may be associated with chronic cough.
46042846|NCT00639964|Other|umbilical cord blood collect|collected at the delivery
46042847|NCT00639964|Other|placenta collect|collected at the delivery
46042848|NCT02684968|Procedure|Colorectal surgery|
46042849|NCT04034290|Biological|GamFluVac|The drug is a vaccine that induces high-level immunity against influenza A viruses
46042850|NCT04034290|Other|Placebo|Placebo
46042851|NCT04105894|Device|MSCT of nose and PNs|MSCT of nose and PNs axial, coronal and sagittal cuts without contrast to evaluate the state of the sinuses at the beginning of evaluation and after 2 months duration of medical treatment for GERD
45346708|NCT00696774|Drug|Duloxetine|"Study Period II (Acute Therapy): 60 mg capsules, QD, for 4 weeks.~Study Period III (Optimization): Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more."
45346709|NCT00608842|Drug|Deoxycholic Acid Injection|Administered via intralipomal injection.
45346710|NCT00608842|Drug|Placebo|Matching vehicle placebo administered via intralipomal injection.
45346711|NCT00626925|Drug|topiramate|up to 200mg/day orally (over 12 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
45346712|NCT00626925|Drug|placebo|placebo (12 weeks during which the dosage of study medication is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
45475236|NCT01292213|Other|Data collection|Questionnaire completion.
45475237|NCT03170349|Device|Mitral Valve Repair|Minimal Invasive Transcatheter Mitral Valve Repair
45475238|NCT01292291|Other|biologic sample preservation procedure|
46042852|NCT04105894|Diagnostic Test|Swab from nasal and oral mucous discharge to evaluate presence of HCL and pepsin|Swab from nasal and oral mucous discharge to evaluate presence of HCL and pepsin at the at the beginning of evaluation and after 2 months duration of medical treatment for GERD
46042853|NCT04105894|Drug|medical treatment of GERD t|medical treatment of GERD only for 2 months as described by gastroenterology department
46042854|NCT02688946|Other|Not provided|
46042855|NCT04184596|Other|Discrete Choice Experiment|An online-based Discrete-Choice Experiment (DCE) using a survey for stated treatment preferences and socio-demographics. Furthermore, the neuropathic pain component will be assessed in all patients with the Numeric Pain Rating Scale instrument.
46042856|NCT00638560|Dietary Supplement|Vitamin C, Vitamin E|Vitamin C, 1g po, twice daily Vitamin E, 400 IU po, once daily
46042857|NCT00638560|Dietary Supplement|Antioxidant treatment|no treatment
46042858|NCT04405648|Behavioral|CVS GROUP|the students will respond to CVS-F3 questionnaire to report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors.
46042859|NCT04185064|Device|Game Ready ATX shoulder wrap; Game Ready GRPro 2.1|the Game Ready ATX shoulder wrap that is anatomically engineered for the shoulder joint. The wrap is connected to the Game Ready GRPro 2.1 system enabling the integrated delivery of continuous cold and intermittent pneumatic compression therapy to the shoulder joint and surrounding soft tissues.
46042860|NCT04185064|Other|Standard Care|Participants will undergo post-surgical cryotherapy using the treating surgeons preferred method of cryotherapy, which can include rest, ice, and compression using standard ice packs or bag of ice, a cryocuff, or other such device.
46042861|NCT04303078|Other|Varying levels of harness support during walking|Participants will complete a standard gait and motion analysis at varying levels of harness support and stabilization (low, moderate, and high levels).
45346713|NCT02566746|Device|Chait Trapdoor caecostomie catheter|implantation of the Chait Trapdoor caecostomie catheter
45346714|NCT02566746|Drug|continuation of optimal medical therapy|continuation of treatment with laxative and / or suppositories and / or enemas retrograde At 12 months : implantation of the Chait Trapdoor caecostomie catheter
45346715|NCT00891280|Drug|CX-4945 oral formulation|CX-4945 Capsules, Oral, Dose escalation study, Dose schedule: twice daily or four times daily for 21 consecutive days every 28 days.
45346716|NCT00816543|Drug|DOCETAXEL|50 mg/m² IV as a 1 hour infusion on day 1 for each period of 3 weeks for 3 cycles.
45346717|NCT00816543|Drug|S-1|80mg/m² day 1-14 every 3 weeks for 3 cycles. The curative resection group will receive two oral doses of 40 mg/m²/day for 4 weeks, followed by 2 weeks rest, for 1 year.
45346718|NCT00816543|Drug|OXALIPLATIN|100 mg/m² on day 1 as a two-hour IV infusion for each period of 3 weeks for 3 cycles.
45346719|NCT00819117|Device|Cardiac Resynchronization Therapy implant|Device implant with appropriate leads
45346720|NCT00892684|Dietary Supplement|Omega-3 long chain polyunsaturated fatty acids|2.7g ω-3 LCPUFA i.e., 1.6 g EPA and 1.1 g DHA and 23 mg alfa-tocopherol as an antioxidant
45346721|NCT00892684|Dietary Supplement|Soybean oil (placebo)|2.8 g soybean oil containing 2.5 g linoleic acid and 0.28 g α-linolenic and 36 mg alfa-tocopherol
45346722|NCT00816621|Behavioral|ABC for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the ability of children to regulate their attention, behavior, and physiology and to develop secure, organized attachments to their parents.
45475239|NCT01292291|Other|laboratory biomarker analysis|
45475240|NCT01292291|Other|study of socioeconomic and demographic variables|
45346723|NCT00816621|Behavioral|DEF for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the intellectual and language development of children.
45346724|NCT00698646|Drug|Valsartan + HCTZ|At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.
45346725|NCT00698646|Drug|Valsartan|At week 0 patients received Valsartan(V) 160 mg capsule. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
45346726|NCT00698646|Drug|HCTZ|At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
45684905|NCT02707588|Radiation|Radiotherapy|Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).
45684906|NCT05602480|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL, Intramuscular
45475241|NCT01292291|Procedure|diffusion-weighted magnetic resonance imaging|
45684907|NCT05602480|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL, Intramuscular
45684908|NCT05600296|Drug|Levobupivacaine|Evaluation the postoperative analgesic effects by using ultrasound-guided spermatic cord block (SCB) and IINB in children scheduled for elective open inguinal herniotomy. The study hypothesized that, the combined block with SCB and IINB would result in more effective postoperative analgesia than the use of IINB alone.
45684909|NCT05600296|Procedure|Ilioinguinal/iliohypogastric nerve block (IINB)|Ilioinguinal/iliohypogastric nerve block (IINB)
45475242|NCT01292291|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
45475243|NCT01292291|Procedure|multiparametric magnetic resonance imaging|
45684910|NCT05600296|Procedure|IINB+ Spermatic cord block|IINB+ Spermatic cord block
45684911|NCT05604586|Dietary Supplement|N-acetylcysteine|100 women and men supplementing 1200 mg of N-acetylcysteine daily in three equal doses. Supplementation will last for 7 days.
46042862|NCT02685124|Dietary Supplement|Orange juice|Three days before the start of the study, all participants will restrict their diet avoiding citrus fruits (orange, tangerine, lemon) and its derivatives (washout period), red fruits and vegetables (strawberry, red lettuce, red grape, tomate). The day before the sample collection will be provided a controlled dinner. A fasting for 8 hours will be required before blood and urine collection. All participants will divided into three groups: I (Cara Cara), II (Bahia), III (Isocaloric control drink). They will consume 250 ml of each drink twice daily for 7 consecutive days, with a washout period of 7 days among each intervention.
46042863|NCT00638638|Drug|Abciximab|"Abciximab: 0.25 mg/Kg bolus~Abciximab placebo bolus~Abciximab infusion 10 µg/Kg/min"
46042864|NCT00638638|Drug|Abciximab placebo|"Abciximab placebo Bolus~Abciximab: 0.25 mg/Kg bolus~Abciximab infusion 10 µg/Kg/min"
46042865|NCT02684812|Drug|Tranexamic Acid|Treatment until aneurysm treatment or maximum dosage of 4 gram
45475244|NCT01292291|Procedure|quality-of-life assessment|
46042866|NCT03520114|Device|RP sling placement|A 1.5 cm incision will be made at the mid-urethra through a separate vaginal incision with lateral dissection with Metzembaum scissors. After placement of both trocars, cystoscopy with a 70-degree scope will be performed to assess for bladder and urethral injury. Surgeons will set the tension of the tension-free vaginal tape (TVT) slings so that a spacer can be placed between the sling and the urethra. Sling tensioning will be performed after anterior and apical prolapse is corrected.
45684912|NCT05604586|Dietary Supplement|Placebo|100 women and men supplementing 1200 mg of placebo daily in three equal doses. Supplementation will last for 7 days.
45346727|NCT00891358|Behavioral|Prevention Empowerment Intervention for Young Women|"Using three intervention sites, focus groups will guide the development of the intervention's framework and content areas. An initial list of content areas and potential activities for presentation to the focus groups will be developed by the protocol team by reviewing existing HIV prevention interventions that have been implemented with adolescents and young adults, as well as interventions that have targeted HIV+ populations.~The three focus groups will be convened (1 per selected ATN site) with young women living with HIV to solicit information on their intervention needs."
45346728|NCT02541292|Other|No intervention, observational|
45346729|NCT02565888|Drug|Daclatasvir|
45346730|NCT02565888|Drug|Atazanavir|
45346731|NCT02565888|Drug|Ritonavir|
45346732|NCT02565888|Drug|Cobicistat|
45475245|NCT01292291|Procedure|transperineal prostate biopsy|
45475246|NCT01292291|Procedure|transrectal prostate biopsy|
45475247|NCT01292291|Procedure|ultrasound-guided prostate biopsy|
45475248|NCT03349918|Behavioral|Mobile Health Monitoring|Use of mobile health application to monitor blood pressure and mood.
45475249|NCT04507984|Diagnostic Test|Genetic analysis|After obtaining written consent from patients, DNA is isolated, and genetic analysis of the know familial hypercholesterolemia disease-causing genes (LDLR, APOB, PCSK9) is performed.
46042867|NCT03520114|Device|SIS placement|The sling is introduced through a single anterior vaginal incision of 1.5 cm at the mid-urethra. The sling/needle assembly is advanced behind the ischiopubic rami in a transobturator trajectory toward the obturator space bilaterally.The needle is then removed by simply sliding the fixating tip back out. The other side is then completed in an identical fashion. After the fixation of the two anchors at the 2 and 10 o'clock positions, the patient's bladder is filled with 250 mL of NaCl. Afterward, an intraoperative crede maneuver is performed and the tension adjustment suture is pulled, when necessary, to achieve the desired continence. The mesh will lie in direct apposition to the urethra. The adjustment thread is then cut short and the vaginal incision is closed with an absorbable suture.
45346733|NCT04061616|Behavioral|PASIPD-Fr|Fill-out the PASIPD-Fr self questionaire twice (2 completions at a 2-week interval)
45346734|NCT00609466|Drug|CG5503 IR|75mg IR 4 - 6 hourly Total: 72 hours
45346735|NCT00609466|Drug|Morphine|Morphine 30 mg IR 4 - 6 hourly Total: 72 hours
45346736|NCT00609466|Drug|Placebo|Placebo; 4 - 6 hourly; Total: 72 hours
45346737|NCT00822315|Drug|efavirenz|tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg
45346738|NCT00822315|Drug|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg
45346739|NCT00822315|Drug|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 800 mg
45346740|NCT00608530|Behavioral|Cognitive Behavioral Therapy-Psychologist-Delivered|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a psychologist
45346741|NCT00608530|Behavioral|Supportive Psychotherapy-Psychologist-Delivered|Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was administered by a psychologist
45346742|NCT00608530|Behavioral|Cognitive Behavioral Therapy Nurse-Delivered|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a nurse
45475250|NCT04507984|Diagnostic Test|Lipid levels measurement|Measurements of lipid levels (total cholesterol, LDL-cholesterol, HDL-cholesterol, TG) using standard methods.
45475251|NCT03201900|Drug|E2007|Oral tablet
46042868|NCT04185376|Other|Questionnaire|a self-administered questionnaire for the assessment of pelvic floor disorders, their risk factors and their impact of quality of life during pregnancy and postpartum period which integrates bladder, bowel and sexual function, pelvic organ prolapse, severity, bothersomeness and conditions specific quality of life in women with urinary incontinence (UI) and/or POP. The questionnaire is divided into four main domains (bladder, bowel, pelvic organ prolapse, sexual function) and each question is scored from zero to three. The additive scores are divided by the maximum reachable score and multiplied by ten, giving a value between zero (0 = no symptoms) and ten (10 = maximum symptoms) for each of the domains.
45346743|NCT00608530|Behavioral|Supportive Psychotherapy-Nurse-Delivered|Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian Therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was delivered by a nurse
45346744|NCT00642993|Drug|SCH 497079|100 mg capsule administered orally
45346745|NCT00642993|Drug|Placebo|Placebo capsules matching SCH 497079 administered orally
46042869|NCT04250194|Device|CT-Guided Biopsy|Images will be generated by a CT scanner to accurately insert a needle into the lung nodule allowing a sample to be removed for testing
46042870|NCT04250194|Device|Navigation bronchoscopy|A virtual three-dimensional map of the lung will be generated enabling the physician to perform an anatomically precise biopsy
46042871|NCT04203160|Drug|CPI 613|Given intravenously
45475252|NCT01314729|Device|Fiber-reinforced-composite retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment
45475253|NCT01314729|Device|Composite-wire retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment to prevent treatment relapse
45684913|NCT05604430|Device|731 Series Ventilator|FDA cleared ventilator indicated for use in the management of acute or chronic respiratory failure or during resuscitation.
46042872|NCT04203160|Drug|Gemcitabine|Given intravenously
45475254|NCT03122938|Dietary Supplement|lactoferrin-supplemented formula|Subjects consume lactoferrin-supplemented formula (85mg lactoferrin per 100g) 3 times a day (81g totally).
45684914|NCT05604352|Device|DiaSole|Diabetic ulcer offloading insole
45684915|NCT05604118|Drug|Aspirin|1 week of aspirin supplementation prior to sampling
46042873|NCT04203160|Drug|Cisplatin|Given intravenously
46042874|NCT02686216|Drug|F-18 THK-5351|Totally 24 subjects age 20-90 including 12 healthy cognitively intact subjects and 12 probably AD patients with NINCDS-ADRDA criteria. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
45346746|NCT02541136|Behavioral|Aerobic Exercise|"Each exercise class consisted of a warm-up, an aerobic and a cool-down phase, supervised by a physiotherapist. The warm up and cool down phases consisted of 5-7 minutes of low intensity aerobic exercise, < 40% Heart Rate Reserve (HHR), to allow the cardiopulmonary and musculoskeletal systems to adapt and recover, respectively.~The aerobic component initially consisted of 21 minutes at an intensity of 40-59% HRR and was progressed to 42 minutes at 55-75% HRR by week 8 until programme completion. All participants worked at the same intensity and duration at the various time points throughout the study. Continuous, rhythmic exercise using large muscle groups was prescribed using treadmills, cycle ergometers and other aerobic exercise that increased heart rate to its prescribed level."
45346747|NCT00696696|Drug|Gemcitabine|1000 mg/m^2, intravenous, Days 1, 8, 15 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
45346748|NCT00696696|Drug|Erlotinib|150 mg, taken orally, once a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
45475255|NCT03122938|Dietary Supplement|formula without lactoferrin supplementation|Subjects consume formula without lactoferrin supplementation (<6mg lactoferrin per 100g formula) 3 times a day (81g totally).
45346749|NCT00696696|Drug|Sorafenib|400 mg, taken orally, twice a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
45346750|NCT00822393|Drug|Busulfan|4 x 0.8 mg/kg/d Intravenous Day -4 and -3
45346751|NCT00822393|Drug|Treosulfan|10 g/m2/d Intravenous Day -4, -3, -2
45346752|NCT00892840|Drug|BMS-820836|Oral Solution, Oral, 0.1 mg to 4 mg, Once daily, 14 days
45346753|NCT00892840|Drug|Placebo|Oral Solution, Oral, 0 mg, Once daily, 14 days
45346754|NCT00819195|Drug|Glatiramer acetate|20 mg daily subcutaneous injection. Six-month duration.
45346755|NCT00891514|Behavioral|Aerobic Exercise|Treadmill training- begins at 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 45-60 minutes for 6 months
45346756|NCT00891514|Behavioral|Stretching|Stretching, balance exercises, and components of conventional physical therapy-- begins at 15 minutes and progresses to 45 minutes for 6 months
45475256|NCT01587833|Drug|Benzodiazepine (BZD) use, defined by ATC codes|BZD prescription during the study period between January 1, 2001 and December 31, 2009
45475257|NCT05208723|Behavioral|Stress and emotion management|The handbook materials and lay helper scripts are based on principles of Acceptance and Commitment Therapy (ACT), and aims to enhance psychological flexibility. Psychological flexibility reflects how a person adapts to fluctuating situational demands, reconfigures mental resources, shifts perspective, and balances competing needs. ACT teaches alternative methods to accommodate difficult thoughts and feelings, primarily through mindfulness techniques. At the same time, ACT also focuses on guiding participants to live in ways consistent with their personal values.
45346757|NCT02567682|Drug|GBT440|GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam
45475258|NCT03353974|Device|Video game therapy|Video game therapy will be delivered with a commercial video game console (X-Box 360 Kinect, Microsoft, Inc., Redmond, WA).
45475259|NCT03353974|Device|Balance platform therapy|Balance/rebalancing, postural stability and weight-shifting exercises with and without visual feedback will be administered using a balance platform (Biodex Medical Systems, Inc., Shirley, NY).
45475260|NCT01587911|Other|Whey|Preload containing complete whey protein.
45475261|NCT01587911|Other|Whey-CMP|Preload containing complete whey protein which is missing the CMP/GMP portion of the protein.
45475262|NCT01587911|Other|Control|Preload control matched for energy to the other 5 preloads.
45346758|NCT00892918|Drug|Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3%|Each drug will be given 4 times a day, 1 drop each time to the operated eye, for 21 days.
45346759|NCT04739280|Device|CardioFlux Magnetocardiography|Magnetocardiography
45346760|NCT02551185|Drug|ACY-241|
45346761|NCT00892996|Drug|dexamethasone|Metoclopramide 10 mg and dexamethasone 5 mg intravenous
46042875|NCT02686294|Drug|HL151|Test drug : HL151. 1T, once a day oral administration, for 4 days
45475263|NCT01587911|Other|CMP|Preload containing the CMP (casinomacropeptide) portion cleaved from complete whey protein.
45475264|NCT01587911|Other|MPI|Preload containing whole milk protein.
45475265|NCT01587911|Other|CPI|Preload containing sodium caseinate.
45475266|NCT03800862|Device|CT-FFR and CTP|Those who agree to participate will be scheduled to have the CT-FFR and CTP performed within sixty days of the initial Coronary CTA procedure. A CTA will be performed at rest for FFR. The patient will then take approximately a 30 min break. Regadenoson will then be administered and the dynamic CT procedure will be done for perfusion.
45475267|NCT01572207|Behavioral|Immediate exercise|Subjects in the immediate exercise group will be prescribed a home exercise program during the first meeting and will begin the 12 week training period immediately following the first meeting.
45475268|NCT01572207|Behavioral|Delayed exercise|Subjects in the delayed exercise group will begin the home exercise program 12 weeks following the initial meeting.
46042876|NCT02686294|Drug|TALION tab.|Reference drug : TALION tab. 1T, twice a day oral administration, for 4 days
46042877|NCT02688478|Other|Phthalate|Delivered by inhalation on day 1 of the triad
46042878|NCT02688478|Other|Filtered Air|Delivered by inhalation on day 1 of the triad
46042879|NCT02688478|Other|Allergen|Subject specific allergen is delivered by inhalation on day 1 of the triad
46042880|NCT01004250|Drug|Pemetrexed|500 milligram per square meter (mg/m²) given intravenously on Day 1 of each 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity.
46042881|NCT01004250|Drug|Cisplatin|75 mg/m² given intravenously on Day 1 of 21-day cycle for a maximum of 4 cycles
45346762|NCT00892996|Drug|dexamethasone 5 mg|Ondansetron 8 mg and dexamethasone 5 mg IV
45346763|NCT02567448|Other|Sleep and pulmonary physiologic measurements|Two overnight sleep studies, CT scan of upper airway and chest, pulmonary function test and pharyngeal lavage
45346764|NCT02551341|Procedure|higher PEEP ventilation|
45346765|NCT00891592|Biological|Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells|"Single infusion of Cord Blood Cells AND Single Infusion of ex vivo CD3/CD28 costimulated Umbilical Cord Blood T cells.~Table 6: Dose escalation (Dose level CD3+ cell dose)~1xE5 cells/kg~2xE6 cells/kg~3xE7 cells/kg~4xE8 cells/kg"
45346766|NCT00891592|Other|Observation Arm|Single infusion of Cord Blood Cells
45346767|NCT00822471|Behavioral|Diabetes Self-Management Education|"DSME intervention consisting of two interactive 2-1/2 hour classes taught by a diabetes educator focusing on the ABCs of diabetes and training in how to talk to your doctor."
45684916|NCT05603884|Drug|Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen|"venetoclax combining chidamide and azacitidine (VCA) 28 days per cycle × 2 cycles； 1) chidamide 30mg biw × 2weeks；2) venetoclax 200mg/d × 2 weeks 3) azacitidine 100mg/d d1-7 dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen 28 days per cycle ×2 cycles；~1）dicitabine 25mg d1-3，2）liposome mitoxantrone 20mg d4，3）cytarabine 10mg/m2 Q12h d1-7 4）G-CSF 300ug d-1 until WBC > 20×109/L"
46042882|NCT01004250|Drug|Bevacizumab|7.5 milligram per kilogram (mg/kg) given intravenously on Day 1 of 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity
46042883|NCT02688634|Drug|Amoxicillin|Amoxicillin will be given as: 7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period.
46042884|NCT00639496|Drug|n-acetylcysteine|600 mg x 3, for 12 months
46042885|NCT00639496|Drug|placebo|Placebo
46042886|NCT04186624|Drug|Subacromial-subdeltoid bursa corticosteroid injection|1 ml (7 mg / ml) betamethasone and 4 ml of 0.5% bupivacaine will be given subacromial bursa-subdeltoid space. Injection will be performed ultrasound-guided while the patient is in sitting position with the lateral approach.
46042887|NCT02688400|Drug|Diacerein|
46042888|NCT02688400|Drug|Celecoxib|
46042889|NCT02688400|Drug|Placebo|
46042890|NCT00639574|Drug|Néfopam|"There are two groups :~a group N : néfopam~a group P : placebo All the patients receive, before randomization, 100 mg of ketoprofen (Profenid) on 20 minutes."
45346768|NCT00893230|Dietary Supplement|probiotic L sakei KCTC 10755BP|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
45346769|NCT00893230|Dietary Supplement|microcrystalline cellulose (placebo)|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
45346770|NCT00891670|Drug|cilostazol|100mg twice daily for at least 1 month
45346771|NCT00891670|Drug|clopidogrel|"75mg once daily (triple group arm)~150mg once daily (high maintenance dose group arm)"
45346772|NCT00891670|Drug|aspirin|aspirin 100mg
45346773|NCT00699192|Drug|Amlodipine 5 mg|1 capsule amlodipine 5 mg orally once daily
45475269|NCT04444258|Other|Application of computer aided virtual reality glasses|Experimental I Group: After the Fetal Development Assessment Information Form (FEGBF), a computer-aided and guided virtual reality application prepared by the researchers including the phases of the fetus week by week will be watched and then FEGBF will be applied again by changing the locations of the questions.
45475270|NCT04444258|Other|Teaching fetal development theoretically|Control Group: FEGBF will be applied after 4 hours of theory training. Virtual pregnancy application will not be watched.
45475271|NCT04971005|Drug|Autologous Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation
45475272|NCT04971005|Drug|Ocrelizumab|600 mg every 6 months continuously
46042891|NCT04184752|Diagnostic Test|Urodynamic study|The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position [14]. A 20-minute pad test for each woman was also performed [15, 16]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS [3]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
45475273|NCT04971005|Drug|Alemtuzumab|12 mg/day for 5 consecutive days and again after 365 days for 3 days
45475274|NCT03782532|Drug|Dupilumab SAR231893|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
46042892|NCT02685046|Drug|Imatinib|Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.
46042893|NCT01004172|Drug|carboplatin|
45684917|NCT05603650|Other|Lumineux Oral Essentials rinse|mouthrinse
45684918|NCT05603650|Other|Listerine rinse|mouthrinse
46042894|NCT01004172|Drug|bevacizumab|
46042895|NCT01004172|Drug|herceptin|
46042896|NCT02688244|Procedure|Irrigation|Irrigation of the abdominal cavity with at least 300ml of normal saline using the power suction/irrigator
45475275|NCT03782532|Drug|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
45475276|NCT03782532|Drug|Asthma Controller Therapies (include prednisone/prednisolone)|"Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhalation, oral"
45475277|NCT03782532|Drug|Asthma Reliever Therapies|"Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled"
45475278|NCT04444102|Procedure|Yoga-based stretching|"Different yoga postures (ASANA) were isolated from conventional yoga practice to stretch different muscle groups.~Muscle groups stretched: hip extensor and adductors, hip & plantar flexors, shoulder extensors, shoulder horizontal adductors, shoulder extensors-adductor, wrist flexor, trunk extensors, lateral flexors, and trunk rotators."
45475279|NCT01187069|Behavioral|Training course for practice nurses in autonomy support|An interactive course consisting of 4X4 hours education in autonomy support over a 6 months period. The main-components in the course are 1) communication skills, 2) introduction to patient work-sheets and 3) a quick up-to-date knowledge about treatment recommendations of type 2 diabetes. Furthermore, the nurses in the intervention-practices receive a half an hour support-visit 4-5 months after the end of the course.
45684919|NCT03030274|Device|Occlutech AFR device|Catheter-guided placement of an AFR device following balloon atrial septostomy.
46042897|NCT02688244|Procedure|No irrigation|Suction only, using suction device
46042898|NCT02688322|Drug|Sulbactam|2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate 1 h every 12 h. Blood samples (approximately 5 ml) will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 h after 7th dose of sulbactam
46042899|NCT02870400|Drug|REGN2477|Participants will receive ascending doses of REGN2477
45346774|NCT00699192|Drug|Valsartan 80 mg|1 capsule valsartan 80 mg orally once daily
45346775|NCT00699192|Drug|Valsartan 40 mg|1 capsule valsartan 40 mg orally once daily
45346776|NCT00699192|Drug|Placebo|1 capsule placebo to match valsartan orally once daily
45346777|NCT00891748|Genetic|AdCD40L|Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter
45346778|NCT00921180|Drug|Entecavir and peginterferon alfa-2a|Entecavir (Baraclude) 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
46042900|NCT02870400|Drug|Placebo|Participants will receive matching placebo
46042901|NCT02685904|Biological|ENIA11|
45346779|NCT00921180|Drug|Placebo and peginterferon|Placebo 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
45346780|NCT00891826|Dietary Supplement|Omega-3 fatty acids (EPAX 6015 TG)|The study drug is a food supplement called EPAX 6015 TG. One capsule of EPAX 6015 TG contains 530 mg of EPA (eicosapentaenoic acid) and 150 mg of DHA (docosahexaenoic acid), provided as triglycerides. For the entire study period (12 weeks) patients will receive 4 capsules of EPAX 6015 TG per day.
45596441|NCT02368899|Other|Computerized Alcohol Misuse Intervention|Interventionaire© is a computerized alcohol misuse intervention that includes a normative feedback component unique in its micro-targeting of alcohol use feedback based on participant demographic characteristics (race/ethnicity, gender, and age), drawing population normative data from the National Surveys on Drug Use and Health. This represents a novel use of epidemiological data to inform clinical services.
46042902|NCT02685904|Biological|Placebo|
46042903|NCT00638794|Device|Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)|PCI using any FDA approved drug-eluting stent; Taxus Express2 - Paclitaxel-Eluting Coronary Stent System Cypher Sirolimus-eluting coronary stent Endeavor ABT-578 Eluting Coronary Stent System Xience V Everolimus Eluting Coronary Stent System
46042904|NCT03098290|Procedure|Catheter-based endovascular revascularization|(e.g. PTA-alone, Bare-Metal or Drug-Eluting-Stent, Covered Stent, Atherectomy, Mechanical Thrombectomy, Scoring Ballon, Cutting Ballon)
46042905|NCT03098290|Procedure|Bypass-Surgery|Venous or alloplastic or comparable Bypass
46042906|NCT03098290|Procedure|Endarterectomy|Endarterectomy, Patchplasty
45346781|NCT00891826|Dietary Supplement|Corn oil|The corn oil capsules look exactly the same as the capsules containing omega-3 fatty acids. For the entire study period patients will receive 4 capsules of corn oil per day.
45346782|NCT04060992|Drug|Elagolix 200 MG Oral Tablet [Orilissa]|oral tablet given twice daily
45346783|NCT03624478|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
45346784|NCT04161066|Drug|Psilocybin with facilitated counseling|open-label pilot study
45346785|NCT04061304|Device|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
45346786|NCT04061304|Device|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
45346787|NCT00921336|Drug|KW-2450|Dose escalation may proceed once >= 3 subjects have completed the Day 29 blood sample to evaluate glucose. The safety of each dose level will be established prior to enrollment of subjects in the next dose level. Dose escalation will proceed sequentially with accelerated escalation. Once the criteria for completing the accelerated titration are reached, dose escalation will follow a modified Fibonacci schedule. Up to 6 subjects will be enrolled at each dose level. Enrollment will proceed until the maximum tolerated dose (MTD) has been established or the highest dose level (800 mg/day) has been reached. The Sponsor will enroll up to 12 additional subjects, in an expanded safety cohort.
45346788|NCT04036786|Behavioral|study group|We prepared a preeclampsia education booklet in accordance with the literature,The content of the booklet was guided by the opinion of experts. It was written in easily understandable language and contained attractive and colorful illustrations. This booklet contents were definition and risk factors for the development of preeclampsia, maternal and fetal damages, recommendations for preventing its development (diet, rest, study, exercise, coping with stress techniques), follow-up of symptoms at home (blood pressure, weight and edema follow-up, counting fetal movements), danger signs, drug use, follow up in hospital, risk of developing in subsequent pregnancies, and its results. Pregnant women in the study group were given education and counseling at four times in addition to standard care, using the preeclampsia education booklet, in a special place. The participants' questions were answered, and each received a copy of the booklet.
46042907|NCT04184986|Diagnostic Test|dry blood test|screening test for Fabry disease
45346789|NCT04036786|Behavioral|standard care|standard pregnancy follow up
45346790|NCT05195112|Drug|MT921|Active ingredient
45346791|NCT05195112|Drug|Placebo|Normal Saline
45346792|NCT05190978|Device|Acellular Dermal Matrix|Acellular dermal matrix will surgically implanted around the tissue expanders in patients in the ADM cohort.
45346793|NCT05190978|Procedure|Reconstruction without ADM|Acellular dermal matrix will not be surgically implanted around the tissue expanders in patients in the control cohort.
46042908|NCT00639652|Procedure|3D-histology|The tumor is marked at the 12 o'clock-position. Excision with a safety margin between 2 and 10 mm, depending on tumor size and location. Plastic reconstruction. Removal of the specimen's margins and base as thin layers, using a scalpel. These primarily three-dimensional layers of the specimen's borders are flattened to one level and microscopically screened for tumor cells. 3D-histology is combined with representative vertical sections for histologic diagnosis. Consecutive excisions are performed topographically at the tumor-positive areas and 3D-histology is repeated until tumor-free margins are obtained.
46042909|NCT00639652|Procedure|Shave excision|Tumor removal by shave excision with a safety margin. Healing by secondary intention. Histologic diagnosis of BCC type (nodular, superficial, morpheaform, micronodular, other type, mixed type) or diagnosis of another tumor than BCC. Comment on complete removal (R0 versus R1).
46042910|NCT04186234|Radiation|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 30 to 50 Grays in 5 fractions before liver transplantation
46042911|NCT02685748|Drug|Aspirin|1000 mg pd in two doses
46042912|NCT02685748|Drug|Placebo|two pills twice a day (instead of aspirin and pantoprazole)
46042913|NCT02685748|Drug|Pantoprazole|Pantoprazole 40 mg/pd in two doses, for gastric protection
45684920|NCT04759222|Diagnostic Test|vascular occlusion test|The VOT was performed five times in each patient, before the induction of general anesthesia (baseline, T0), 30 min after the induction of general anesthesia (T1), 30 min after applying CPB (T2), 10 min after injection of protamine (T3), and after sternal closure (T4). Before induction of anesthesia, an NIRS sensor was placed on the thenar eminence and an automated tourniquet was placed around the upper arm. The arterial catheter was placed in the contralateral radial artery and the baseline blood pressure was measured. When the baseline tissue oxygen saturation (StO2) was stabilized, the automatic tourniquet was inflated to 50 mmHg over the patient's baseline systolic blood pressure and maintained for 5 min. After the 5-min ischemic period, the tourniquet rapidly deflated to 0 mmHg. StO2 data were continuously recorded during the VOT procedure.
45346794|NCT00893386|Procedure|LV Lead Extraction|Removal of a LV lead using any tools & techniques.
46042914|NCT04112992|Procedure|Any treatment that is used for a defect of any long bone|Any treatment that is used for a defect of any long bone. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
46042915|NCT04104802|Device|MRI|"All patients included will benefit from both methods of assessing anatomical relationships between the facial nerve and the parotid tumor:~1) New medical imaging technique evaluated: 3 Tesla Parotidic MRI High Resolution with Specific Sequences and Gadolinium Injection 2) Standard Gold: Intraoperative Exam"
46042916|NCT04186312|Behavioral|ACCESS - Accessing Campus Connections & Empowering Student Success|Cognitive-Behavioral Treatment delivered across 2 semesters via group and individual mentoring sessions
46042917|NCT04184440|Dietary Supplement|Cyclocarya paliurus extract|The participants are divided randomly into three groups，one of which are asked to Cyclocarya paliurus extract for three months .
46042918|NCT04184440|Dietary Supplement|Cyclocarya paliurus compounds|The participants are divided randomly into three groups，one of which are asked to take Cyclocarya paliurus compounds for three months .
46042919|NCT04184440|Dietary Supplement|placebo|The participants are divided randomly into three groups，one of which are asked to take placebo for three months .
45346795|NCT04062474|Procedure|Epidural Intervention with TNF-α inhibitor|Epidural administration with TNF-α inhibitor
45346796|NCT02541214|Device|Trial Nasal Mask|
45346797|NCT04671810|Biological|Elizaria®|Elizaria® will be prescribed by the Physician according to the actual SMPC.
45346798|NCT00892138|Behavioral|Mindfulness training|7 week course modeled on MBSR according to Kabat-Zinn
45346799|NCT02567370|Drug|AMG 581|Active drug
45346800|NCT02567370|Drug|Placebo|Placebo
45346801|NCT00893542|Drug|Mycophenolate Mofetil|mycophenolate mofetil 250 mg capsule
45346802|NCT00892216|Device|Acupressure (BioBand)|Band will remain on from 20 minutes before surgery until the end of the hospital stay.
46042920|NCT02685982|Device|Rhythmic Sensory Stimulation|"The stimulation consists of 30 minutes of daily stimulation with specially composed relaxing music tracks embedded with gamma frequency sounds of 30-70 Hz range.~In this study, the stimuli will be delivered with a portable sound device called Sound Oasis Vibroacoustic Therapy System (VTS-1000) unit, which is a low-voltage consumer product that has two built in mid to high frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the Rhythmic Sensory Stimulation with low-frequency sounds, the efficacy of the Sound Oasis VTS-1000 device to deliver the intervention will also be subject to observation."
46042921|NCT04184908|Drug|gel xerostomia|Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
46042922|NCT04184908|Other|gel placebo|Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
45596442|NCT02368899|Other|Attention Control (AC)|These products are designed for entertainment and educational purposes only. No medical claims are made for them and, the participant's interaction with them should be conceptually unrelated to alcohol use behavior.In order to avoid any carryover effect from comparing two active treatments, we have chosen to use a simple attention control condition that is not expected to exert any real intervention effect. In that way, the effect size estimate of the intervention can be readily calculated. No research data will be collected as part of the AC, beyond the amount of time spent on the program.
46042923|NCT00639730|Dietary Supplement|modified Atkins diet|High fat, low carbohydrate diet
45684921|NCT04760080|Other|pre-treatment data|"We will evaluate in all patients pre-treatment data :~Melanoma staging at treatment initiation~Melanoma characteristics at initial diagnosis~Number and location of metastasis~Performans status~Demographic information"
45346803|NCT00892216|Device|Acupressure (BioBand)|Band will remain on from 20 minutes before surgery until the end of the hospital stay. The same band will be placed and turned so the beads face the corresponding point on the dorsal surface of the upper limb area.
46042924|NCT04184674|Other|Pneumotachograph|"Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~The first measurement will be performed 5 minutes after the initial ventilator settings.~Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
46042925|NCT04184674|Other|Esophageal catheter|"Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management~The first measurement will be performed 5 minutes after the initial ventilator settings.~Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
45346804|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 100 mg
45346805|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 50 mg
45346806|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 25 mg, 50mg
45346807|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 25 mg
45346808|NCT00401245|Drug|Placebo|Tapering placebo
45346809|NCT00401245|Drug|desvenlafaxine succinate sustained release|Tapering 50 mg, placebo
45346810|NCT00401245|Drug|desvenlafaxine succinate sustained release|Tapering 50 mg, 25 mg
45346811|NCT00401245|Drug|desvenlafaxine succinate sustained release|Tapering 50 mg QOD
45346812|NCT04661280|Drug|Donepezil|Donepezil 5 mg per day during one month, then 10 mg per day during 5 months.
45346813|NCT04036474|Other|Smoking Prevention Education Program|"The SPEP consisted of three lessons and each lesson took one to two hours to be implemented. SPEP was conducted through direct and indirect method. Direct method was conducted through lectures, question and answer, role play and educational videos. The tools used were video projectors and Power Point presentations. On the other hand, the indirect method was done through distributing of badge buttons and fridge magnets Be Free from Smoking. This method brought a simple message to increase awareness among adolescents to prevent smoking uptake. All instruments and protocols in this intervention were pilot tested to confirm feasibility and cultural appropriateness."
45346814|NCT05278312|Other|Otago Exercise Program|A Home-based Exercise Program to improve strength and balance and prevent falls.
45684922|NCT04760080|Other|during study treatment|"We will evaluate in all patients during study treatment :~Rate of adverse events~Type of adverse events~Radiological response to treatment by CTscans that are routinely performed every three months."
45684923|NCT01885195|Drug|MEK162|MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
45684924|NCT03337594|Drug|Pre-operative MRI with Dotarem|Dotarem® (gadoterate meglumine - Guerbet)
45346815|NCT04036240|Other|Finger feeding|After discharge, subjects will be given HMF supplementation by finger feeding method using finger feeder
45346816|NCT00696384|Drug|Azilsartan medoxomil|"All subjects initiated azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks, force-titrated to 80 mg, tablets, orally, once daily. After Week 8, chlorthalidone, 25 mg, tablets, orally, once daily as needed and other antihypertensive medications as needed to achieve target blood pressure (defined as <140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) and <130/80 mm Hg for participants with diabetes or CKD) for up to 26 weeks.~Study medication could have been up-titrated only after the subject had been at the previous dose level for a minimum of 2 weeks. Study medication could only have been up- or down-titrated by 1 dose level per scheduled or unscheduled visit."
45346817|NCT00696384|Drug|Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.|Azilsartan medoxomil at the final dose received during the open-label phase: (20 mg, 40 mg or 80 mg), tablets, orally, once daily with or without chlorthalidone 25 mg, tablets, orally once daily and other non-ARB antihypertensive medications (if currently taking), for 6 weeks/Week 32.
45346818|NCT00696384|Drug|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily with or without chlorthalidone 25 mg or other non-ARB antihypertensive (if currently taking), tablets, orally, once daily for 6 weeks/Week 32.
45346819|NCT04036162|Behavioral|Cognitive tasks|MagnetoEncephaloGraphy (MEG) records
45346820|NCT01041625|Drug|Apremilast (CC-10004)|Apremilast 20 mg tablet PO administered BID over 12 weeks
45346821|NCT02566356|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
45346822|NCT02566356|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
45346823|NCT00893620|Device|Zenith(R) Connection Endovascular Covered Stent with the Zenith® Branch Endovascular Graft-Iliac Bifurcation and Zenith Flex(R) AAA Endovascular Graft|These devices will be used in patients with an unsuitable distal sealing site for the standard Zenith(R) iliac leg component proximal to the common iliac bifurcation to maintain internal iliac artery patency with endovascular aneurysm repair.
45346824|NCT01039129|Procedure|Endoscopic Cholecystectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus.
45346825|NCT01039129|Procedure|Endoscopic Appendectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus
45346826|NCT01039129|Procedure|Endoscopic Peritoneoscopy|A diagnostic peritoneoscopy with or without biopsy for any indication
45346827|NCT00892450|Drug|Oxybutynin and darifenacin|Participants with overactive bladder will take each medication for 4 weeks.
45346828|NCT01566565|Drug|Theophylline and Bambuterol|Treatment 3: Theophylline, 300 mg plus Bambuterol, 20 mg
45346829|NCT01039363|Drug|Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat|"Salvage reinduction therapy:~Vorinostat 200mg BID po (D1-14) Gemtuzumab ozogamicin 3 mg/m2 once (D1) Idarubicin 12mg/m2 for 2 days (D2-3) Cytarabine 500mg/m2 bid IV for 5 days (D2-6)~Maintenance:~Once achieved CR, then Vorinostat 200mg BID po for 2 weeks, then 1 week's rest (1 cycle) for 11 cycles~Vorinostat should be stopped at least 2 weeks ahead of starting of consolidation therapy.~Gemtuzumab will be omitted in a consolidation schedule.~Allogeneic hematopoietic stem cell transplantation (HSCT) can be performed if HLA-matched sibling or unrelated donor is available. Vorinostat will be stopped 2 weeks prior to starting of conditioning regimen for allogeneic HSCT."
45346830|NCT01039441|Procedure|Intraperitoneal instillation of bupivacaine|A mixture of 50ml solution (20ml of 0.5% bupivacaine + 30ml normal saline) is instilled under the diaphragm.
45684925|NCT03337594|Drug|Pre-operative MRI with MultiHance|MultiHance® (gadobenate dimeglumine - Bracco)
45596443|NCT00147277|Device|Implantable Cardiac Defibrillator|Medtronic Marquis Family ICD, capable of Anti Tachy Pacing (ATP) for Fast Ventricular Tachycardia (FVT) via Ventricular Fibrillation (VF) zone
45596444|NCT02191917|Procedure|Respiratory muscle strength measurements by different techniques.|
46042926|NCT04184674|Other|Transthoracic and / or transesophageal cardiac ultrasound|"The right ventricle systolic function will be assessed thanks to a transthoracic cardiac ultrasound in children, and a transthoracic of a transesophageal cardiac ultrasound in adults :~Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~The first measurement will be performed 5 minutes after the initial ventilator settings.~Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
46042927|NCT04184674|Other|Electrical impedance tomography (EIT) for pediatric patients|For pediatric patients: measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management.
46042928|NCT02684500|Device|Ultrasound|Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) for a aneurysmal subarachnoid hemorrhage using abdominal ultrasound.
45346831|NCT01039441|Procedure|CO2 removal by means of a pulmonary recruitment maneuver|CO2 is removed by means of a pulmonary recruitment maneuver consisting of five manual inflations of the lung with a maximum pressure of 30 cm H2O
45346832|NCT01039441|Procedure|Intraperitoneal instillation of bupivacaine +CO2 removal by means of a pulmonary recruitment maneuver|
45346833|NCT01039441|Other|normal saline|
45346834|NCT01034917|Drug|Etravirine 400 mg dissolved in water every 24 hours|Switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
45346835|NCT01034917|Drug|Continue with the same antiretroviral regimen|Continue with the same antiretroviral regimen
45596445|NCT02198729|Procedure|Endoscopic Submucosal Dissection|
46042929|NCT02685670|Biological|anti-CD19 CAR-T|Ex vivo-expanded autologous T cells modified to express CD19 CAR
46042930|NCT02685670|Drug|Fludarabine|
46042931|NCT02685670|Drug|Cyclophosphamide|
46042932|NCT02684656|Procedure|Hemodialysis|Hemodialysis >/=4h
46042933|NCT02684656|Procedure|Hemodiafiltration|Hemodiafiltration >/=4h, > 20l convection
46042934|NCT00640120|Device|WIM-PC™ device|wheeze detection during dynamic bronchial situations in infants
45346836|NCT01039597|Drug|ORE1001|Oral capsules containing 300 mg of the active, study drug
45684926|NCT03337594|Procedure|Surgery|Cardiac surgery
45346837|NCT01039597|Drug|Placebo|placebo capsules
45684927|NCT03313804|Drug|Immune checkpoint inhibitor|Standard of care immune checkpoint inhibitor
45684928|NCT03313804|Radiation|Radiation Therapy|Stereotactic Body Radiation Therapy OR Fractionated radiation therapy
45840981|NCT00977808|Device|Closed-Loop, Model Predictive Control (MPC)|Subjects used the OmniPod Insulin Management System (Insulet Corp.) and Insulin lispro (Eli Lilly, Indianapolis, IN). MPC algorithm suggested insulin boluses every 15 min, which, if accepted, were programmed into the insulin pump by the attending physician. Otherwise, the admission remained the same as in the open-loop admission (i.e. meals, sleep, etc...).
45684929|NCT04393792|Drug|Povidone-Iodine|0.23% three times daily (tds) for 3 days
45684930|NCT04393792|Drug|Normal saline|0.9% three times daily (tds) for 3 days
45684931|NCT04120714|Device|Active tDCS|active D.C. transcranial stimulation (delivers a low current (1 to 2 mA)) for 10 to 30 minutes, during 5 sessions
45684932|NCT04120714|Device|Placebo tDCS|inactive DC transcranial stimulation (delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation) for 10 to 30 minutes, during 5 sessions
45346838|NCT01041937|Procedure|Cemented Tibia|Total knee arthroplasty with cemented or cemented tibia, and post operative clinical outcome tracking
45840982|NCT00977808|Device|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects used their own insulin pumps and Insulin lispro (Eli Lilly, Indianapolis, IN). Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, sleep, etc...).
45840983|NCT00981474|Drug|blood pressure maintenance based on cerebral blood flow autoregulation measurement|Blood pressure lowered or raised
45840984|NCT00981474|Device|Control group|Institutional standard of care.
46042935|NCT02688010|Behavioral|Noise reduction and cycled light|Reduced noise exposure (sound levels <45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
46042936|NCT00638872|Drug|Polydeoxyribonucleotide|3 times a week perilesional or intramuscular injections
46042937|NCT00638872|Other|0.9% NaCl|same as PDRN
46042938|NCT00638950|Dietary Supplement|n-3 LC-PUFA|Patients received about 40 g fat daily (200 g yoghurt with 3.8% fat, 30 g cheese with about 50% fat in the dry matter, and 20-30 g butter). The milk fat was partially exchanged by special oils. The daily dose of n-3 FA amounted to 2.4 g, consisting of 1.1 g ALA, 0.7 g EPA, 0.1 g DPA, and 0.4 g DHA.
45346839|NCT01041937|Procedure|Cementless Tibia|Assessing the clinical outcomes of the different type of fixation
45346840|NCT00816699|Other|preprint preoperative anesthetic risk information|preprint preoperative anesthetic risk information
45346841|NCT00822549|Drug|intravenous morphine titration|intravenous morphine titration
45346842|NCT00822627|Drug|Influenza Vaccination|0.5 mL Sanofi-Pasteur intramuscular influenza vaccination
45346843|NCT00822627|Behavioral|Education and referral|Patients are given information regarding the inactivated influenza vaccination and a list of community providers who provide influenza vaccination
45346844|NCT00819351|Drug|PEG Asparaginase at six weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (until the patient has received 33 weeks of therapy)
46042939|NCT00638950|Dietary Supplement|Placebo|The placebo products were commercial dairy products with comparable fat contents.
46042940|NCT00639808|Drug|5% dextrose in water|60 ml IV infusion over 30 minutes
45840985|NCT00981630|Biological|Live attenuated Japanese encephalitis virus|0.5 mL,Subcutaneous
45840986|NCT00981630|Biological|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
45840987|NCT00981630|Biological|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
45840988|NCT00981630|Biological|ChimeriVax™ diluent (Placebo)|0.5 mL, Subcutaneous
45840989|NCT00983346|Drug|Bortezomib|"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 8, 15, and 22 of each 42 day cycle.~Patients will undergo nine 42-day cycles. At the end of this (day 378), patients will be assessed for bone remodeling changes. Evaluation for toxicities will be evaluated at the beginning of each cycle."
45346845|NCT00819351|Drug|PEG Asparaginase at two weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (until the patient has received 33 weeks of therapy)
45596446|NCT02198729|Procedure|Endoscopic Mucosal Resection|
45596447|NCT03657745|Device|Combination of 40Hz light and cognitive therapy (ALZLIFE)|Combination of 40Hz light and cognitive therapy delivered by iPad application ALZLIFE
45596448|NCT02091999|Drug|enfortumab vedotin|intravenous (IV) infusion
45596449|NCT03533699|Drug|Propranolol|
45596450|NCT03533699|Drug|Placebo Oral Tablet|oral tablets with no active drug
45596451|NCT00135421|Drug|Pexacerfont|Tablets & Capsules, Oral, 100 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation
46042941|NCT00639808|Drug|TZP-101|1 infusion: IV 2ml/min for 30 minutes for 1 day of either 160, 320 or 600 micrograms/kg
46042942|NCT02687932|Drug|LCZ696|
46042943|NCT02687932|Drug|Valsartan|
46042944|NCT00641602|Drug|Esomeprazole|40mg once daily
46042945|NCT00641602|Drug|Lansoprazole|30mg once daily
46042946|NCT04183972|Procedure|ultrasound examination|the participants will be placed in the supine position, with head turned slightly away from the operating side and arms beside the body. The operator will identify right and left interscalene brachial plexuses by ultrasound equipment (Sonosite EDGE or GE LOGIQ e). Clear images and videos of brachial plexus will be captured and saved.
46042947|NCT03071692|Drug|K-877|0.2mg tablet
46042948|NCT03071692|Drug|Placebo|K-877 matching placebo tablet
46042949|NCT01161524|Drug|Perampanel|2 mg titrated up to 8-12 mg maximum; taken once daily.
46042950|NCT01161524|Drug|Placebo|Matching Placebo taken once daily.
45346846|NCT00636675|Behavioral|Falls QI|"Falls uses the Falls Management Program (AHRQ); it is familiar to nursing homes, uses minimal researcher time, is adaptable, and simulates real word quality improvement practices. Falls is delivered over 3 months. Components include:~In-House Falls Coordinator training on content and falls processes.~Case-based modules about fall prevention and tailored for various team members.~Academic Detailing in which researcher consults with staff regarding challenging residents with falls.~Audit and Feedback. Discussions about comparison of nursing home's current practice on fall-related process and outcome measures, and how it compares with the median and the 90th percentile of peer NHs.~Toolbox: Handbook of useful measures and worksheets."
45596452|NCT00135421|Drug|Escitalopram|Tablets & Capsules, Oral, 20 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
45596453|NCT00135421|Drug|Placebo|Tablets & Capsules, Oral, 0 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
45596454|NCT02200991|Drug|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
46042951|NCT02681224|Other|TR987 Gel with Silon Bandage|Novel healing gel with occlusive dressing
46042952|NCT02681224|Other|TR987 without Silon Bandage|Novel healing gel without occlusive dressing
46042953|NCT02681224|Other|Placebo Gel with Silon Bandage|Placebo gel with occlusive dressing
45596455|NCT02200991|Drug|Sitagliptin|Pharmaceutical form:tablet Route of administration: oral
45596456|NCT02200991|Drug|Insulin glargine HOE901|Pharmaceutical form:solution Route of administration: subcutaneous
45596457|NCT05724823|Other|Virtual Physical Activity Seated Exercises (V-PASE)|The seated exercise program includes a variety of upper and lower limb strengthening, core strengthening, agility (fast arm and leg movements), and flexibility exercises. Participants will be supervised during each session thru videoconferencing by a trained instructor.
46042954|NCT02681224|Other|Placebo Gel without Silon Bandage|Placebo Gel without occlusive dressing
46042955|NCT04182646|Device|Spartz Balloon|The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required
46042956|NCT02683096|Other|Observation|Viable Infants with a failed hearing screen or a diagnosis of SGA who are born at either St. John's Hospital or MMC at ≥ 28 weeks gestation.
46042957|NCT02680990|Behavioral|Band Together|Band Together is a strength training program utilizing resistance bands with progressively increasing resistance, ranging from 3 to 35 pounds. Sessions are to be completed 3 times a week and involve 3 sets of 6 exercises: 1. chair stands, 2. chest press, 3. shoulder press, 4. arm curls, 5. pulls, and 6. calf raises. In addition, Band Together participants will be asked to work up to a walking goal of 10,000 additional steps per week.
46042958|NCT02680990|Other|Exercise Education|Education will consist of counseling by the healthcare provider with supplemental handouts from the American College of Sports Medicine and the National Institute on Aging/ National Institutes of Health.
46042959|NCT04184128|Diagnostic Test|Urodynamic study|The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position [14]. A 20-minute pad test for each woman was also performed [15, 16]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS [3]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
45840990|NCT00985140|Radiation|Total Skin Electron Beam Therapy (TSEBT)|The purpose of the study is to examine the efficacy and safety of total skin electron beam therapy to a dose of 12 Gray (TSEBT 12 Gray) in patients who have mycosis fungoides (MF) staged as IB to IIIB.
46042960|NCT02682940|Device|Vigilant Diabetes Management Application|Subjects will download the Vigilant Diabetes Management Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
46042961|NCT05663944|Drug|Sirolimus 0.5Mg Tab|"Once randomised, participants will receive either sirolimus or placebo daily for 6 months. Participants will start on a dose of 1mg daily (2 x 0.5mg tablets) and will have weekly routine bloods including full blood count, renal function and electrolytes and liver function test along with sirolimus trough levels measured to determine the next dose. The aim will be to achieve a steady state blood trough level of 3-7 ng/ml, which is usually achieved in 3-5 weeks. Placebo will also be started at 2 capsules daily. All participants will undergo weekly blood tests for the first 3-5 weeks and placebo doses will be adjusted randomly to maintain blinding.~All participants will be reviewed by a research clinician at 2, 4 and 6 months."
45346847|NCT00636675|Behavioral|Connect|"Connect, delivered over 12 weeks, helps nursing home staff learn interactions that increase exchange of new information, number and quality of connections among staff, and improve problem-solving about patient care. Protocols:~In-class learning sessions introduce interaction strategies.~Relationship map protocols assist staff to examine existing interaction patterns and agree on goals for improvement. Individuals develop their own relationship maps and use them to practice new horizontal and vertical connections and self-monitoring their own interactions.~Researcher facilitates authentic learning which occurs when learners directly and independently apply concepts. In-house staff volunteers and are facilitated to assume a mentoring role."
45346848|NCT00699998|Drug|Clopidogrel|300 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study
45840991|NCT00986856|Drug|Fucidin® cream|
46042962|NCT05663944|Diagnostic Test|1st MRI scan|If participants opt in for MRI scans, a non-contrast MRI scan will be undertaken at Sir Peter Mansfield Imaging Centre, University of Nottingham at the start of the trial, and at the end, after 6 months of taking trial medication. This is to see whether any radiological features of fibrosis change can be detected to correlate with histological findings.
45346849|NCT00699998|Drug|Prasugrel|30 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight and age), oral, once daily as maintenance dose through end of study
46042963|NCT05663944|Procedure|1st Percutaneous or Endoscopic Ultrasound guided liver biopsy|After informed consent, participants will undertake up to a 4-week screening period to provide baseline data to ensure eligibility. During this period, participants will undergo blood tests, percutaneous or endoscopic ultrasound-guided liver biopsy, unless the participant has undergone a liver biopsy within the past 3 months, in which case the previous liver biopsy sample will be utilised for this study. They will undergo a second liver biopsy at the end of the study, after taking 6 months of the study drug, to look for any histological change in fibrosis progression rate with sirolimus when compared to placebo
46042964|NCT05663944|Drug|Placebo 0.5mg capsule|"Once randomised, participants will receive either sirolimus or placebo daily for 6 months. The placebo is unmatched. Participants will start on a dose of 1mg daily (2 x 0.5mg capsules) and will have weekly routine bloods including full blood count, renal function and electrolytes and liver function test along with sirolimus trough levels, to maintain blinding of the research team members carrying out blood tests. Placebo doses will be adjusted randomly, in a pattern that mirrors the adjustments made to participants on sirolimus.~All participants will be reviewed by a research clinician at 2, 4 and 6 months."
45346850|NCT00699998|Drug|Commercially-available Aspirin|Low-dose aspirin, oral, as prescribed by physician through end of study
45346851|NCT00696072|Drug|Dasatinib|Tablets, Oral, 100 mg once daily, up to 2 years
45346852|NCT00696072|Drug|Letrozole|Tablets, Oral, 2.5 mg, once daily, up to 2 years
45346853|NCT00816855|Drug|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
45346854|NCT00822705|Drug|Placebo tablet|Control arm
45346855|NCT00822783|Drug|Omalizumab|
45684933|NCT04120714|Other|Questionnaires|"visual analogue scale (VAS)~impulsivity scale: Barratt Impulsiveness Scale - version 11 (BIS-11)~Decision-making scales: Iowa Gambling Task (IGT) and Balloon Analogue Risk Task (BART)~Go-No go test~HAM-D scale~SF-12 quality of life scale"
45346856|NCT00822783|Drug|Placebo|
45346857|NCT00816933|Procedure|appendectomy|appendectomy according to the number of trocar
45346858|NCT00634647|Drug|Satraplatin|80 mg/m^2 days 1-5 of every 35 day cycle
45346859|NCT00634647|Drug|prednisone|5 mg twice daily every 35 days
45346860|NCT00576732|Drug|Placebo|Oral solution qd or bid for 6 weeks
45346861|NCT00576732|Drug|Risperidone high dose|Risperidone oral solution 1.25 mg (if <45 kg) or 1.75 mg (if >=45 kg) qd or bid for 6 weeks
45684934|NCT04129762|Other|Diet without NCS|"A standard diet in terms of macronutrients will be calculated.~55% Carbohydrates~20% protein~25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will not contain products with NCS."
45346862|NCT00576732|Drug|Risperidone low dose|Risperidone oral solution 0.125 mg (if <45 kg) or 0.175 mg (if >=45 kg) qd or bid for 6 weeks
45346863|NCT02550639|Other|BIOMARKER- elispot test|ELISPOT TEST
45346864|NCT00822861|Drug|TPI ASM8|4 mg/mL, 1 mg BID for 4 days
45346865|NCT00822861|Drug|TPI ASM8|4 mg/mL, 2 mg BID for 4 days
45684935|NCT04129762|Other|Diet with NCS|"A standard diet in terms of macronutrients will be calculated.~55% Carbohydrates~20% protein~25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will contain products with NCS."
45684936|NCT04129684|Other|Probiotics|subgingival delivery and lozenges
46042965|NCT05663944|Diagnostic Test|Baseline Blood Tests|"During the initial clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~Full blood count~Urea and electrolytes~Liver function tests~Clotting screen~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
46042966|NCT05663944|Diagnostic Test|Baseline Clinical Examination|A thorough medical examination will be undertaken at the first clinical visit (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants are clinical stable. This will also serve as a comparator for future clinical examinations once participants have commenced the study drug.
45684937|NCT03028246|Device|ExAblate 4000 System|Focused ultrasound
45684938|NCT01896895|Drug|IncobulinumtoxinA (Xeomin), 25 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 25 Units per eye.
45684939|NCT01896895|Drug|IncobotulinumtoxinA (Xeomin), 12.5 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 12.5 Units per eye.
45346866|NCT00822861|Drug|TPI ASM8|4 mg/mL, 4 mg BID for 4 days
45346867|NCT00822861|Drug|TPI ASM8|4 mg/mL, 8 mg OD for 4 days
45346868|NCT05180370|Other|Questionnaies|Data entry staff who will be assigned to the centers for 2 weeks will apply a questionnaire consisting of different questions to the patients referred to them by clinicians with the diagnosis of HF (presented in the appendix to this protocol). In addition, Pittsburg Sleep Quality Index will be applied to all cases.
45346869|NCT00817011|Drug|SSRI treated group|Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
45346870|NCT00817011|Drug|non-SSRI treated group|Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
45346871|NCT04061460|Procedure|mechanical plaque control|supra and sub gingival debridment ( plaque control)
45346872|NCT00823017|Other|Patient-preferred music|Music of patients' preference
45346873|NCT00823017|Other|Relaxation Music|Relaxation music compiled from results of first three stages of study
45346874|NCT00823017|Other|Standard Care Environment|Control, no interventions
45346875|NCT00823173|Biological|ESBA105|ESBA105 eye drops (10mg/mL), initially applied in hourly dosing intervals, followed by later dose tapering (prolongation of dosing intervals)
45346876|NCT00819429|Dietary Supplement|Omega-3|1000mg of Omega-3 supplement will be given twice a day for a duration of 6 months. All supplements (including placebo) will be administered as two 500mg softgels twice daily, to be taken during breakfast and during the evening meal.
45346877|NCT00819429|Behavioral|Social Skills Training|1 hourly sessions over 12 weeks duration and 4 booster sessions at 3 weeks intervals. During these 16 sessions, children are taught empathy, pro-social skills, and a variety of positive coping techniques for problem-solving, emotional regulation, conflict resolution, and anger management via the use of practical strategies, materials, activities, role-play and games.
45346878|NCT00819429|Other|Standard Treatment (or TAU in Child Guidance Clinic)|Standard treatment is administered on a monthly basis to the parents of the child participants by the clinicians. Parents will be provided Parent Management Training where they will be taught behaviour and parenting techniques and may be referred to a parent support group. There is clinical pathway for the management of ADHD in our department which will be adhered to (i.e., Clinical Pathway for ADHD).
46042967|NCT05663944|Diagnostic Test|Week 1 - 5 Titration Blood Tests|"Participants will start on a dose of 1mg daily (2 x 0.5mg tablets) and will have weekly bloods:~full blood count,~urea and electrolytes and~liver function tests to check the study drug is not causing any significant organ damage.~Sirolimus trough levels will be measured to determine the next dose. The aim will be to achieve a steady state blood trough level of 3-7 ng/ml, which is usually achieved in 3-5 weeks. Therefore, participants will have a minimum of 3 weeks of blood tests during this period, The need for week 4 and 5 blood tests will be decided by the trial pharmacist who will be monitoring results.~Placebo will also be started at 2 capsules daily. All participants will undergo weekly blood tests for the first 3-5 weeks and placebo doses will be adjusted randomly to maintain blinding."
45346879|NCT00697788|Drug|Dexmedetomidine|Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine [in ug/kg/hr], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.
46042968|NCT05663944|Other|Month 2 Clinical Examination|A thorough medical examination will be undertaken at Month 2 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants remain clinically stable whilst on the study drug. They will also be asked about potential side effects in detail.
45346880|NCT02568878|Drug|Creatine monohydrate|
45346881|NCT00817167|Device|inReach bronchoscopy planning software|inReach planning software creates three-dimensional lung CT reconstruction, enabling rapid virtual endoscopic depiction of the airways that allows to plan bronchoscopy virtually.
45346882|NCT00817167|Device|Standard lung CT viewer|CT viewer, used for standard bronchoscopy
45346883|NCT00400153|Drug|Atrovent Respimat (20 mcg)|
45346884|NCT00400153|Drug|COMBIVENT MDI (36/206 mcg)|
45346885|NCT00400153|Drug|Combivent Respimat (20 mcg/100 mcg)|
45346886|NCT00400153|Drug|Placebo via corresponding inhaler for blinding purposes|
45346887|NCT04062890|Drug|Vigabatrin Pill|Oral Vigabatrin Pill
45346888|NCT04062890|Drug|Placebo oral tablet|Oral Placebo Pill
45684940|NCT01896895|Drug|Placebo|Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
46042969|NCT05663944|Diagnostic Test|Month 2 Blood Tests|"During the Month 2 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~Full blood count~Urea and electrolytes~Liver function tests~Clotting screen~Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
45684941|NCT01896895|Drug|IncobotulinumtoxinA (Xeomin), 35 Units|"IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Open-Label Extension: up to 35 Units per eye."
45346889|NCT02566512|Other|Tracheostomy cuff inflation.|With the tracheostomy cuff inflated, the peak expiratory flow meter will be attached directly to the tracheostomy tube. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times.
45346890|NCT02566512|Other|Tracheostomy cuff deflation|With the tracheostomy cuff deflated, a one-way valve will be attached to the tracheostomy tube. The patient will use a mouthpiece to connect to the peak expiratory flow meter. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times
45346891|NCT00823251|Device|IlluminOss device|The IlluminOss™ Bone Stabilization System is designed to deliver the device to the fracture site via the medullary canal of the bone using percutaneous techniques. Once the device is in place and has spanned the fracture site, the device is expanded and hardened to reduce and stabilize the fracture, to aid in the support and healing of the bone fracture by primary callous formation and remodeling.
45684942|NCT03026764|Procedure|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total hip arthroplasty
45684943|NCT03026764|Procedure|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total hip arthroplasty
45684944|NCT04129606|Diagnostic Test|Computed tomographic cystography|CT cystogram performed after the procedure by the injection of 400mL of 1/4 saline-diluted contrast solution (meglumine ioxitalamate) with low-pressure infusion (60 cm gravity pressure) through the Foley catheter.
45346892|NCT05511818|Dietary Supplement|Rest Study Product Usage|Participants will use their Radicle Rest study product as directed for a period of 4 weeks.
45346893|NCT00817245|Drug|omeprazole, Amoxicillin, metronidazole|we will evaluate the effect of medication(anti h.pylori) on the remission of ICSCR
46042970|NCT05663944|Other|Month 4 Clinical Examination|A thorough medical examination will be undertaken at Month 4 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants remain clinically stable whilst on the study drug. They will also be asked about potential side effects in detail.
46042971|NCT05663944|Diagnostic Test|Month 4 Blood Tests|"During the Month 4 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~Full blood count~Urea and electrolytes~Liver function tests~Clotting screen~Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
46042972|NCT05663944|Other|Month 6 Clinical Examination|A thorough medical examination will be undertaken at Month 6 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants have remained clinically stable whilst on the study drug. At this visit, they will be asked to finish taking the study drug. They will also be asked about potential side effects in detail.
46042973|NCT05663944|Diagnostic Test|Month 6 Blood Tests|"During the Month 6 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~Full blood count~Urea and electrolytes~Liver function tests~Clotting screen~Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
46042974|NCT05663944|Procedure|2nd Percutaneous or Endoscopic Ultrasound guided liver biopsy|All participants will undergo a second liver biopsy at the end of the study, after taking 6 months of the study drug, to look for any histological change in fibrosis progression rate when compared to their first biopsy.
46042975|NCT05663944|Diagnostic Test|1st MRI scan|If participants opt in for MRI scans, a non-contrast MRI scan will be repeated at the end of the trial, after 6 months of taking trial medication. This is to see whether any radiological features of fibrosis change can be detected to correlate with histological findings.
45684945|NCT04129372|Behavioral|New Foods Take Time|New Foods Take Time is a series of 5 classroom lessons focused on increasing children's willingness to try fruits and vegetables.
45684946|NCT02315872|Drug|ACTH|ACTH injections twice weekly for 28 weeks.
45684947|NCT02315872|Drug|Placebo|Placebo injections twice weekly for 28 weeks.
46042976|NCT01000506|Biological|Mepolizumab 750|Mepolizumab 750mg every four weeks by i.v.
46042977|NCT01000506|Biological|Mepolizumab 250|Mepolizumab 250mg every four weeks by i.v.
45346894|NCT02566278|Other|Upper airway collapsibility (Pcrit)|To measure passive Pcrit, patients sleep with a mask over their nose or nose and mouth, and CPAP is applied using a custom made machine that can rapidly change mask pressures in research setting. The idea is that rapid changes in airway pressure produce a clear step change in airflow that will be observed quickly. In contrast, during clinical titrations, the CPAP machines change pressure much more slowly to help promote patient comfort. Passive Pcrit will be measured using both research and clinical equipment in the same patients and the Pcrit result using clinical CPAP titration equipment will be compared to the gold standard: Pcrit measurement done through research equipment that changes CPAP pressure rapidly.
45346895|NCT05457686|Other|kinesio tape|According to this, the proximal part of the band is located close to the lymph node. In our study, as stated in the literature, the proximal part of the tape will be adhered to the fibular head area next to the lymph nodes without applying any stretching. Then 5-10% stretching is applied and the distal part is adhered. 2 separate tapes are applied so that the strips cross each other
45346896|NCT05457686|Other|Sham taping|In the same procedure and time as kinesiotaping, inelastic tape will be used instead of kinesiotape.
45684948|NCT04128826|Other|Resistance Training|Using the cable machine, shoulders will be flexed to 180° for both (PROM & FROM) groups throughout the training; FROM would train with full elbow extension (complete elbow flexion to extension) whereas PROM will train with partial elbow extension from 60° to 110°. A total of 8 sessions, 2 sessions/week for 4 weeks will be carried out by both groups. CON group will not participate in training protocol.
45684949|NCT04128982|Procedure|mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in 2 groups: patient in dorsal decubitus or Rapid Airway Management Positioner.
46042978|NCT01000506|Biological|Mepolizumab 75|Mepolizumab 75mg every four weeks by i.v.
46042979|NCT01000506|Drug|Placebo saline|Placebo saline every four weeks by i.v.
46042980|NCT02682862|Drug|olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg|Inhaler: 2.5 microgram tiotropium (as bromide monohydrate) and 2.5 microgram olodaterol (as hydrochloride) per puff. 2 puffs once daily
46042981|NCT02682862|Drug|olodaterol 2.5 mcg|Inhaler: 2.5 microgram Olodaterol (as hydrochloride) per puff. 2 puffs once daily
46042982|NCT02073838|Drug|Ribavirin|
46042983|NCT02073838|Drug|Vismodegib|
45346897|NCT05457686|Other|Exercise|Routine exercise and physiotherapy program applied after knee arthroplasty surgery will be applied
46042984|NCT02073838|Drug|Decitabine|
45346898|NCT05132634|Other|Hand Massage|Like a massage, the superficial kneading technique which is included in the Swedish massage technique will be applied in a way to create a slight pressure on the patient, and it will be terminated again with the effleurage technique. The procedure was concluded in a way that each massage technique was applied and the massage was for a total of 15-20 minutes.
46042985|NCT00640198|Drug|memantine|Memantine was titrated in 5-mg weekly increments as recommended,from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24)
45346899|NCT03859791|Other|THA|Study participants have received a total hip arthroplasty due to arthritis. We do not make further intervention.
45346900|NCT00823329|Device|cardiac stress testing with an exercise machine|Standardized graded cardiac stress testing with an exercise machine will be performed according to the protocol of the American Heart Association
45346901|NCT02550483|Other|Base diet + high beta-carotene tomato juice|Participants will receive high beta-carotene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
46042986|NCT00640198|Behavioral|constraint-induced language therapy (CIAT)|CIAT is an intensive form of language-action therapy for aphasia performed in a small group setting. In a therapeutic game context, participants had to request objects or cards from each other and understand requests made by others. Feedback of communicative success was regularly given, along with guidance, help and reinforcement. Gesturing replacing verbal language was discouraged although gestures accompanying speech were allowed. Difficulty levels were adjusted to the patients´ communicative abilities by choosing language materials and actions and reinforcement was administered taking into account each patient´s level of performance. Communication rules were introduced by shaping and modelling. Each patient received 30 hours of therapy.
45346902|NCT02550483|Other|Base diet + high lycopene tomato juice|Participants will receive high lycopene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
45684950|NCT04128202|Behavioral|Sunnyside|The Sunnyside intervention is an online intervention (an interactive website with didactic material and interactive tools) targeting skills to manage mood during and after pregnancy. The Sunnyside intervention will consist of 6weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. Each lesson takes approximately 10 minutes to complete.
46042987|NCT00640198|Drug|memantine|Memantine was titrated in 5-mg weekly increments as recommended, from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24).
45346903|NCT02550483|Other|Base diet + placebo beverage|Participants will receive a placebo beverage daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
45346904|NCT04646382|Dietary Supplement|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion).
46042988|NCT00640198|Drug|placebo|Placebo
45346905|NCT04646382|Dietary Supplement|Control|Microcrystalline cellulose
46042989|NCT04296552|Other|Dietary lowFODMAP intervention|Twelve week strict lowFODMAP dietary intervention, involving restricted intake of fermentable carbohydrates (FODMAPs).
45346906|NCT00817323|Procedure|Dietary amino-acid depletion|See detailed description
46042990|NCT02031250|Drug|Cisplatin|Cisplatin 40mg/m2 administered as an IV infusion prior to radiotherapy on day 1 of each week of chemo-irradiation
46042991|NCT02031250|Drug|Carboplatin|Patients considered medically unfit to receive Cisplatin as determined by the prescribing physician, will receive Carboplatin via IV infusion on day 1 of each week of chemo-irradiation
46042992|NCT02031250|Radiation|IMRT (Intensity-Modulated Radiation Therapy)|
46042993|NCT02031250|Radiation|Boost Radiation to Hypoperfused Volumes|
46042994|NCT04293822|Drug|Cetirizine|"The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.~This group will use Cetrizine 1% gel, which will be prepared at the department of Pharmaceutics, Faculty of Pharmacy, Assiut University in the form of Nano-transferosomes (NTF)."
46042995|NCT04293822|Drug|Minoxidil|"The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.~This group will use Minoxidil 5% gel"
45346907|NCT05739188|Biological|Anti-GPRC5D CAR-T cells infusion|"This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells:~Dose level one: 3.0×10^6 /kg±20%; Dose level two:6.0×10^6 /kg±20%; Dose level three:1.0×10^7 /kg±20%."
45684951|NCT04128202|Behavioral|Sunnyside Plus|Sunnyside Plus will build upon the Sunnyside intervention, plus include additional education and support to promote breastfeeding. Breastfeeding education and skills will be provided during the 6weeks of online lessons during pregnancy; each lesson takes approximately 10 minutes to complete. Breastfeeding support will continue through 6 weeks postpartum. This postpartum support will involve weekly online lessons(each taking approximately 10 minutes to complete), text support messages(3 sent during weeks 1 and 2, 2 sent during weeks 3 and 4, 1 sent during weeks 5 and 6), and video support calls with a Lactation Educator (LE)provided on an as-needed basis(exception: at least 1 video call is required during both week 1 postpartum and week 2 postpartum).
46042996|NCT02680600|Drug|Cefepime dosing|Patients will received cefepime administered per standard-of-care as a 30 min intravenous infusion. Dosing will be based on local guidelines (the Sanford guide to antimicrobial therapy 2012-2013) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula to estimate glomerular filtration rate (GFR).
46042997|NCT02680600|Other|Blood sampling|Blood will be sampled immediately prior to dose administration (time = 0 at the start of the 30 min infusion), at 0.5, 1, 3, 5 hours post-start of infusion and just before the subsequent dose. From day two onwards, samples will be taken at the end of the infusion and just before the next dose. For the quantification of cefepime, a validated solid phase extraction-liquid chromatography electrospray-tandem mass spectrometry method will be used.
46042998|NCT02680600|Other|Urine sampling|Timed urine collections were taken during one dosing interval (8 hours in a three times daily regimen) every day.
45684952|NCT04128592|Device|diagnosing noisy breathing in infants and toddlers|breath sampling and nasal mucus sampling to analyze biomarkers and breath sound analysis to diagnose noisy breathing.
45346908|NCT02566434|Dietary Supplement|methionine|4 weeks intervention and 2 to 4 weeks washout in healthy volunteers with free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day.
45346909|NCT00737750|Device|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
45346910|NCT00737750|Device|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
45684953|NCT04128280|Procedure|TUDP|a surgery: transurethral dilation of prostate with a columnar balloon
45684954|NCT04128280|Procedure|TUIB|a surgery: transurethral incision of bladder neck
45684955|NCT04127812|Behavioral|Savor the Flavor|A series of five interactive classroom lessons focused on mindfulness in eating.
45684956|NCT04127890|Dietary Supplement|ELO Water|oxygen-enriched water
45684957|NCT04127890|Dietary Supplement|Placebo drinking water|bottled drinking water
45346911|NCT00737750|Behavioral|Control|Voluntary quadriceps muscle contractions.
46042999|NCT02680600|Other|Determination of renal markers|Creatinine (modified Jaffe method) and urea in serum will be determined using an Architect c16000 analyzer (Abbott, Chicago, IL, USA). Cystatin C will be determined using a particle-enhanced immunonephelometric assay (N Latex Cystatin C, Siemens Healthcare Diagnostics, Marburg, Germany) by use of a BN II nephelometer (Siemens Healthcare Diagnostics). This assay has a calibration traceable to the first certified reference material for cystatin C in human serum (ERM-DA471/IFCC). Kidney injury molecule-1 (KIM-1) in urine and uromodulin in serum will be determined using commercially available ELISA assays: Quantikine ELISA Human TIM-1/KIM-1/HAVCR (R&D Systems, Minneapolis, MN, USA) and Uromodulin ELISA (Euroimmun, Luebeck, Germany), respectively.
45346912|NCT05115474|Diagnostic Test|Magnetic Resonance Imaging|Participants will undergo MRI imaging with and without contrast.
45346913|NCT04608318|Biological|Ibrutinib|Cycles 1 - X: 420 mg daily, d1-28 p.o.
45346914|NCT04608318|Biological|Venetoclax|"Arm VG~Cycle 1: 20 mg (2 tabl. at 10 mg), d22-28 p.o.~Cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28 p.o.~Cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28 p.o.~Arm VI~Cycle 4: 20 mg (2 tabl. at 10 mg), d1-7; 50 mg (1 tabl. at 50 mg), d8-14; 100 mg (1 tabl. at 100 mg), d15-21; 200 mg (2 tabl. at 100 mg), d22-28 p.o.~Cycles 5-15: 400 mg (4 tabl. at 100 mg), d1-28 p.o."
45346915|NCT04608318|Biological|Obinutuzumab|Cycle 1: (100 mg, d1 + 900 mg, d2) or 1000 mg, d1; 1000 mg, d8 + d15 i.v. Cycle 2 - 6: 1000 mg, d1 i.v.
45346916|NCT05733806|Other|chemotherapy, surgery|this is an observational prospective study, therefore no intervention is planned. Patients perform medical and surgical treatment as per standard of case.
45346917|NCT04063358|Drug|Lucentis|Lucentis 0.5 MG Per 0.05 ML Injection
45346918|NCT00921258|Procedure|prostate biopsy|"patient of control group will have :~1 prostate biopsy 3 months after diagnostic biopsy~1 prostate biopsy each year during 2 years~1 prostate biopsy each 2 years during 8 years"
45346919|NCT00631917|Drug|Aliskiren|Aliskiren 300 mg once a day
45346920|NCT00631917|Drug|Ramipril|Ramipril 10 mg once a day
45346921|NCT00631917|Other|Placebo to Ramipril|Placebo capsules to match ramipril.
45346922|NCT00631917|Other|Placebo to Aliskiren|Placebo tablets to match aliskiren.
45346923|NCT04596150|Drug|CX-2009|Intravenous administration of the CX-2009 of 6 mg/kg administered every 3 weeks (Q3W)
45346924|NCT04596150|Drug|CX-072|Intravenous administration of the CX-072 of 1200 mg administered every 3 weeks (Q3W)
45346925|NCT00823407|Drug|MDA|subjects will receive a single oral dose of MDA 98mg/70kg body weight
45684958|NCT04128046|Procedure|PRFM injection|Using a 27-gauge microcannula, a total of 4 mL of PRFM was injected intradermally into the mid-cheek and NLF (2 mL for each site) on one side of the face.
45840992|NCT00987480|Drug|Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.|There are three parts in this transplant study. 1) There will be a pre-transplant - preparation - period to see if patient qualifies for the transplant study. This will be done as an outpatient and lasts 2-4 weeks. Once this is completed, there will be 2) the transplant period itself, during which the patient will be admitted and will be an inpatient. This period usually last for 4-6 weeks. Following that, there will be a 3) post transplant period, during which the patient will be watched carefully and monitored in clinic as an out patient. The post transplant period lasts from three months to one year.
45840993|NCT00987480|Device|CliniMACS device|CD34+ T-cell depleted peripheral blood stem cell transplant
45346926|NCT00823407|Drug|Placebo|Subjects will receive a single oral dose of placebo
45346927|NCT04514523|Other|QBSAfe Toolkit|The QBSAfe toolkit focuses on palliating symptoms, alleviating burden of treatment, facilitating social connections, and optimizing treatment safety.
45346928|NCT00419341|Biological|Human Normal Immunoglobulin for Subcutaneous Administration|
45346929|NCT00694122|Drug|Lantus (glargine)|Described in Arm Description
45346930|NCT00817401|Device|hypothermia|For the systemic hypothermia treatment (TS Med 200, Germany), the infants were nursed under an open unit, covered only by a diaper and a thin linen, loosing heat to the environment and to a cooling mat¬tress which was perfused by circulating liquid at a variable temperature. The rectal temperature was targeted at 33.5 °C (range of 33 to 34 °C) and was meant to be achieved within 60 min. The body temperature was checked every 10 min during induction hypothermia and every hour during the remaining period of cooling. The duration of hypothermia was 72 hrs. Rewarming was started by stopping the cooling system. The infant was meant to reach a 36.5°C rectal temperature in 6 hrs after stopping cooling to prevent rebound hyperthermia.
45346931|NCT03934086|Drug|rimegepant|rimegepant 75 mg
45684959|NCT04128046|Procedure|Saline injection|Using a 27-gauge microcannula, a total of 4 mL of saline was injected intradermally into the mid-cheek and NLF (2 mL for each site) on the contralateral side of the face.
45840994|NCT00987558|Drug|Eslicarbazepine acetate|
45840995|NCT00987558|Drug|Simvastatin|
45346932|NCT02550951|Procedure|lymphangiography|
45684960|NCT04128124|Other|processing signals of airway pressure and airway flow to calculate entropy|processing of previously recorded data from a dedicated software of airway pressure and airway flow in order to calculate entropy
45346933|NCT05417048|Diagnostic Test|Blood Sample|Up to 5mL of blood via venipuncture
45346934|NCT03922620|Drug|Liposomal bupivacaine|Local infiltration of 20cc of Liposomal Bupivacaine infiltrated to the surgical area
45346935|NCT03922620|Drug|Peripheral Nerve Block|Peripheral Nerve Block performed by anesthesia team (blocks will be given by same anesthesia provider utilizing same technique every time in order to reduce variations in delivery of peripheral nerve block).
45346936|NCT03898908|Drug|encorafenib|"Encorafenib 75mg and 50mg (capsules) for a 450mg daily for oral administration during 56 days and after local radiation treatment.~If no progression of disease progression (PD) is reported, treatment will continue until PD, unacceptable toxicity or death."
45346937|NCT03898908|Drug|binimetinib|Binimetinib 15mg (tablets) for a 45mg/12 hours for oral administration during 56 days and after local radiation treatment.
45346938|NCT03898908|Radiation|Whole brain radiation therapy|"The whole brain planning target volume (PTV) will receive 30 Gy in 10 fractions.~Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks."
45346939|NCT03898908|Radiation|Radiosurgery/stereotactic radiosurgery|"Dose selection must be based on previously published Radiation Therapy Oncology Group (RTOG) data, with dose modification left up to the treating physician. The total dose will depend on the size of the metastatic lesion(s) and proximity to critical structures.~Suggested doses are as follow: 1 fraction x 15-25 Gy; 3 fractions x 9-11 Gy; 5 fractions x 6-7 Gy; or 6 fractions x 5-6 Gy.~For GTV > 20 mm hypofractionated stereotactic radiotherapy could be preferred. Treatment will be delivered once daily, alternate-day, 3 fractions per week."
45346940|NCT00419263|Drug|Peramivir 150 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (one injection of peramivir 150 mg and one injection of placebo).
45346941|NCT00419263|Drug|Peramivir 300 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of peramivir 150 mg).
45346942|NCT00419263|Drug|Placebo|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of placebo).
45346943|NCT01034995|Drug|SSR125543|"Pharmaceutical form: capsule~Route of administration: oral"
45346944|NCT01034995|Drug|escitalopram|"Pharmaceutical form: encapsulated tablets~Route of administration: oral"
45346945|NCT01034995|Drug|placebo|"Pharmaceutical form: capsule~Route of administration: oral"
45346946|NCT00921414|Drug|Rituximab|2 months after ASCT maintenance treatment with Rituximab 500mg/m² IV every 2 months during 3 years
45346947|NCT00921414|Other|Watch and wait|No treatment patient follow-up every 2 months during 3 years
45346948|NCT04060914|Drug|Ticagrelor 90mg|Ticagrelor 90 mg plus aspirin for 12 months
45346949|NCT04060914|Drug|Ticagrelor 90mg/60mg|1 month after treatment with ticagrelor 90 mg plus aspirin, followed by treatment with ticagrelor 60 mg plus aspirin for 11 months
45346950|NCT04060914|Drug|Clopidogrel 75mg|Clopidogrel 75mg plus aspirin for 12 months
45346951|NCT03894696|Drug|Direct Acting Antivirals|follow up chronic HCV patients recieving DAAs to detect anxiety and depression
45346952|NCT00399763|Drug|Atomoxetine|Half of participants are randomized to atomoxetine plus individual cognitive behavioral therapy targeting substance use disorder
45840996|NCT00987948|Drug|maraviroc (Selzentry)|dosage varies with other medications being taken; will follow package insert guidelines
46043000|NCT02680600|Other|Population pharmacokinetic modeling|The cefepime concentration versus time data will be fitted using the FOCE-I estimation algorithm in NONMEM® (Version 7.3; GloboMax LLC, Hanover, MD, USA). R® (R foundation for statistical computing, Vienna, Austria) will be used to graphically assess the model's goodness-of-fit and to evaluate the model's predictive capabilities. As a measure of prediction error, the absolute prediction error (APE) will be used. In short, the measured cefepime concentrations for each individual i at time point j were compared against the population predicted cefepime concentrations, i.e. the predictions for each individual without taking into account the between-subject variability (PRED in NONMEM). The distribution of APEs will be summarized by the median and 90% percentile.
46043001|NCT02680600|Other|Covariate screening|Renal function will be assessed by four serum based kidney markers (serum creatinine, cystatin C, urea and uromodulin) and two urinary markers (measured creatinine clearance (CrCl) and KIM-1, both on timed urine collections). Serum creatinine and cystatin C will also be used to calculate the eGFR based on CKD-EPI formulas.
45346953|NCT00399763|Drug|Placebo|Half of participants are randomized to placebo plus individual cognitive behavioral therapy targeting substance use disorder
45684961|NCT04393714|Procedure|Alveolar ridge preservation after extraction|atraumatic extraction followed by graft material insertion
45346954|NCT05324904|Drug|Vitamin D|"- Vitamin D~The aqueous solution of vitamin D3 (cholecalciferol) will be used ampoule 200,000 IU/2 ML,~Using a 27-gauge syringe with the bevel facing upward, a maximum of 0.6 ml (60,000 IU) of vitamin D3 solution will be slowly injected into the base of the largest plantar wart (large warts > 10 mm need multiple injections at different sites)~Treatment sessions will be performed at 3-week intervals for a maximum of 4 sessions"
46043002|NCT02680600|Other|Monte Carlo simulations|Based on the final covariate model, a Monte Carlo-based simulation study will be performed to evaluate the Sanford dose recommendations for ICU patients.
45475280|NCT03854201|Behavioral|Personalized Exercise Counseling (PEC)|At the first counseling appointment, PEC-participants answer the physical activity (PA) questionnaire, perform fitness tests and discuss with their exercise instructor. The target is a personalized short-term PA plan including where and when the PA/exercise takes place and what is the mode. Participants may choose instructed group-exercise sessions provided by the municipal sports/leisure sector or exercising alone as preferred. The exercise instructors utilize the fitness test results and feedback data of the research accelerometers by the UKK Institute to guide the participants. The PEC includes 2 more face-to-face sessions and 4-6 phone calls by the instructors aimed at checking the realization of exercise plans and discussing the outcomes provided by the interactive accelerometer.
45475281|NCT03355768|Drug|Romidepsin|Intravenous administration on a 28 day cycle
46043003|NCT02680678|Other|Colloid Preload|preload infusion
45475282|NCT03355768|Drug|Pralatrexate|Intravenous administration on a 28 day cycle
45475283|NCT04804800|Other|Experimental group 1 : Virtual Reality|Patients benefit from the care recommended by the HAS, the virtual reality program and time for relaxation and body scan.
46043004|NCT02680678|Other|colloid co-load|co-load infusion
46043005|NCT02680678|Other|Crystalloid preload|preload infusion
46043006|NCT02680678|Other|Crystalloid Co-load|co-load infusion
46043007|NCT05663788|Other|E-learning module|"The intervention is a structured e-learning module on a web-based platform (www.trainingopticaldiagnosis.com) that consists of:~10 modules, including theoretical knowledge and multiple exercises.~2 seminars with a tutor (after Module 5 and Module 10)~feedback from the tutor on three cases recorded by the participant.~20-images test before and after the content described above (10 Modules, 2 seminars with tutors and feedback on three cases)~All the Gastroenterologists participating in the study will predict deep submucosal invasion in their routine colonoscopies and will register clinical outcomes during 12 months. The randomisation and intervention will be conducted 6 months after starting to predict deep submucosal invasion and registering clinical outcomes."
46043008|NCT04182724|Drug|Camrelizumab, Apatinib and Nab-paclitaxel|Camrelizumab was administered 200mg iv every 2 weeks, Apatinib was administered 250 mg p.o. qd Nab-paclitaxel was administered 125 mg/m2, 150 mg/m2, 175 mg/m2 or 200 mg/m2, iv. q2w
46043009|NCT02680912|Device|Warm needle acupuncture|There will be 4-6 points used per knee, therefore 8-12 needles per treatment. Two points will be used as the core treatment ST 35 dubi, Ex-LE 5 xiyan. Four other acu-points can also be used from the following: Ahshi painful points local to the knee (locus dolendi), ST 36 zusanli, GB 34 yanglingquan, Sp 9 yinlingquan, ST34 liangqiu, Sp 10 xuehai, GB 33 yangxiguan, LR 7 xiguan, LR 8 ququan, heding Ex-LE 2 In addition to the acupuncture needles the warm needle acupuncture group will receive moxibustion on up to 4 points. Smokeless moxa will be used.
46043010|NCT02680912|Device|Needle acupuncture|The point selection protocol will be exactly the same as the experimental group
45346955|NCT05324904|Drug|acyclovir|"-Acyclovir~Acyclovir vial (Zovirax® vial, 250mg, ) will be diluted with 3.5 ml saline to get approximately 70 mg /ml solution.~After sterilization of the skin, a 27-gauge syringe with the bevel facing upward will be inserted into the base of the largest plantar wart to slowly inject the solution~Treatment sessions will be performed at 2-week intervals for maximum of 5 sessions"
45475284|NCT04804800|Other|Experimental group 2 : Virtual Reality + Multi Sensorial Remediation|Patients benefit from the care recommended by the HAS, the virtual reality program, the multisensory remediation, and also the body scan.
45684962|NCT04127500|Drug|dexmedetomidine|dexmedetomidine
46043011|NCT02682628|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
46043012|NCT04183816|Other|Total cold-water immersion|TCWI group completed a session of 15-minutes in cold water with a temperature of 12°C.
45346956|NCT02085265|Drug|Perindopril|Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
45346957|NCT02085265|Drug|Telmisartan|Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
45346958|NCT00699842|Drug|Lenalidomide|"Dose Level Lenalidomide Schedule~15mg/day for d1-21 out of 28 days~20mg/day for d1-21 out of 28 days~25mg/day for d1-21 out of 28 days"
45346959|NCT01589107|Behavioral|video decision aid|video decision aid
45346960|NCT02567630|Behavioral|Soft Mitt Constraint Therapy for Sensory/Motor Impairment in Cerebral Palsy|The CIMT intervention includes 3 components: (1) placement of a removable soft constraint for ½ each day, with a non-invasive wear monitor (2) demonstration and prescribed home-use of a sensory kit (3) and a reach/grasp tool. The intervention lasts 4 weeks as has been published in older children as well as used in infant trial descriptions.
45346961|NCT03897608|Behavioral|short form 36|"The Short Form (SF)-36 Health Survey was used to measure HRQL. The SF-36 generates a profile of HRQL outcomes by measuring health across eight different dimensions: physical functioning, role limitation because of physical health, social functioning, vitality, bodily pain, mental health, role limitation because of emotional problems and general health. Responses to each question within a dimension are combined to generate a score from 0to100; where100 indicates good health"
45346962|NCT02565498|Radiation|Preoperative intensity modulated radiation therapy|50 Gy delivered in 25 fractions 4-6 weeks prior to surgical excision
45346963|NCT02565498|Radiation|Postoperative intensity modulated radiation therapy|Surgery followed by 50 Gy delivered in 25 fractions within 6 weeks of surgery for patients with negative margins; for patients with positive margins a boost of 16 Gy in 8 fractions will be added.
45346964|NCT00399529|Biological|Allogeneic GM-CSF-secreting breast cancer vaccine|the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 108 cells for each patient and each vaccination cycle) on day 0.
45346965|NCT00399529|Drug|Trastuzumab|Trastuzumab is a humanized monoclonal antibody specific for the extracellular domain of HER-2/neu that is now one component of the standard of care for both early and late stage HER-2/neu-overexpressing breast cancers. It exerts a pleiotropic antitumor effect by multiple mechanisms. The antibody decreases heterodimer formation with other members of the epidermal growth factor receptor (EGFR) family, thereby indirectly inhibiting signaling through the Ras/Raf/mitogen-activated protein kinases (MAPK) and Phosphatidylinositol 3-kinase(PI3K)/protein kinase B (Akt) pathways. It also inhibits tumor neovascularization, and augments apoptosis both in vitro and in vivo. Trastuzumab prevents cleavage of the extracellular domain of HER-2/neu, thus abrogating the constitutive activation of the remaining membrane-associated intracellular domain.
46043013|NCT04183816|Other|Ice massage|Ice cubes massage in a clockwise circular motion on the thigh area (quadriceps) for 15 minutes.
45346966|NCT00399529|Drug|Cyclophosphamide|The doses of Cyclophosphamide are based on previously reported clinical experience as well as our own preclinical data demonstrating augmented vaccine efficacy with CY-modulated vaccination. In particular, 300 mg/m2
45475285|NCT01182701|Behavioral|Cognitive behavioral training|The behavioral training group will be involved six group sessions focusing on cognitive behavioral training for stress and mood management, cognitive restructuring, empowerment, values clarification, problem solving and decision making via a manualized program
45840997|NCT00989586|Biological|milatuzumab|Patient will receive milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive milatuzumab on day 2. Starting in week 2, milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
46043014|NCT04184518|Drug|Cediranib Maleate|Cediranib 20mg, oral, 5 days on and 2 days off until disease progression
46043015|NCT04184518|Drug|Durvalumab|Durvalumab 1500mg, intravenous, every 4 weeks until disease progression
46043016|NCT02680522|Other|Exercise|exercise training with virtual reality in videogame
46043017|NCT01174238|Drug|Axitinib|5mg BID Axitinib Days 1-14 for dual therapy - 5mg BID QD for patients on monotherapy
46043018|NCT01174238|Drug|Carboplatin|Day 1 of each 21 day cycle in combination with paclitaxel if patients are in dual therapy phase
46043019|NCT01174238|Drug|Paclitaxel|Day 1 of each 21 Day cycle in combination with Carboplatin if patients on on dual therapy phase.
45346967|NCT00921050|Drug|levothyroxine sodium|Daily intake (fasting) levothyroxine bimonthly adjusted; to keep TSH between 0.5 to 2.5 mUI/L range. Start with 12.5mcg an investigator other than the caregiver will review the TSH measurements to adjust levothyroxine dose that will contain the coded bottle with the pils given to patient.
45475286|NCT03349840|Drug|Insulin Degludec U100|Patients on any basal insulin including insulin glargine will be randomised and converted to basal degludec insulin
45346968|NCT00921050|Drug|excipient without levothyroxine (placebo)|Daily intake (fasting) a pill. bimonthly adjusted; an investigator other than the caregiver will review the TSH measurements and pretend to adjust dose contained in the coded bottle with the pills given to patient.
45475287|NCT03349840|Drug|Insulin Glargine|Patients on any basal insulin including insulin glargine will be randomised and either glargine will be continued or will beconverted to basal glargine insulin
45346969|NCT05403086|Drug|Psilocybin|Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate.
45346970|NCT05403086|Drug|Ketamine|ketamine hydrochloride injection, for intravenous or intramuscular use, contains ketamine, a nonbarbiturate general anesthetic and has a molecular formula of C13H16ClNO•HCl and a molecular weight of 274.19. The chemical name for ketamine hydrochloride is (±)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride.
45840998|NCT00989586|Biological|veltuzumab|Patient will receive veltuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
45346971|NCT01035307|Genetic|gene expression analysis|
45346972|NCT01035307|Genetic|microarray analysis|
45346973|NCT01035307|Genetic|proteomic profiling|
45346974|NCT01035307|Other|laboratory biomarker analysis|
45346975|NCT02565966|Other|Modified Atkins Diet (MAD)|For those in the MAD intervention group, the dietitian trains the patient and family in the preparation and management of this specialized therapy including sick-day guidelines, meal planning, carbohydrate counting and trouble-shooting. Written and verbal education including, but not limited to: recipes, education materials, sample meal plans and carbohydrate counters are provided to the patient during the initial education session. The caregiver/patient is trained in the outpatient setting and the diet is implemented at home with as much email/phone support from the dietician and ketogenic team as the patient needs to successfully maintain the diet. Medications are all changed over to the lowest carbohydrate forms to eliminate excess carbohydrate intake and all patients are started on vitamin supplements to maintain adequate nutrition.
45346976|NCT01035385|Drug|FOFLOX4|FOLFOX4:Oxaliplatin 85mg/m2 ivgtt d1 2hr calcium leucovorin:200mg/m2 ivgtt d1 d2 2hr fluorouracil:400mg/m2 iv d1 d2 fluorouracil:600mg/m2 civ d1 d2 22hr 2 weeks repeated one cycles
45475288|NCT04786236|Device|"Physiological Control Module for the Medtronic -HVAD Left Ventricular Assist Device"|Software, which sets the device speed according to physiological demand, is activated for the duration of the tests (up to 4 hours). Every patient provides his/her own control, because sequences with active control and with standard pump operation are subsequently performed in randomized order (determined by permutated blocks).
45475289|NCT01187147|Dietary Supplement|green tea extract|Green tea extract capsule, equivalent to 450 ml 2% Green tea containing 540mg EGCG/day
45475290|NCT01182779|Radiation|Carbon ion|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E."
46043020|NCT05663710|Drug|177Lu girentuximab|Given by IV (vein)
46043021|NCT05663710|Drug|Nivolumab|Given by IV (vein)
46043022|NCT05663710|Drug|Cabozantinib|Given by PO
46043023|NCT05663710|Drug|ArabinoFuranosylGuanine [18F]F-AraG|Given by IV (vein)
46043024|NCT04315532|Other|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed for pregnant and non-pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken from all patients baseline and after 8 weeks.
46043025|NCT04315532|Other|Saliva samples|Saliva samples were taken from patients for the evaluation of sex steroid and stress markers baseline and after 8 weeks.
46043026|NCT04315532|Other|GCF samples|GCF samples were taken from patients for the evaluation of stress markers baseline and after 8 weeks.
46043027|NCT02682472|Other|SettleIN - Adjustment to care programme|A programme for care home staff to support new residents with dementia quickly and successfully adjust to life in a care home
46043028|NCT00640900|Behavioral|Usual care|Two individualized weight loss counseling sessions with a dietetics professional, and monthly contacts to maintain communications.
46043029|NCT00640900|Behavioral|Commercial weight loss program|Active weekly participation until weight loss goals are reached, and monthly participation to maintain the weight loss.
46043030|NCT02680444|Behavioral|Self-Administered Mindful-Reappraisal Exercise|Combining the practice of mindful acceptance of negative events combined with a reappraisal of the event by examining its positive aspects.
45346977|NCT00712712|Drug|Acetaminophen|Intravenous administration of paracetamol (4 g / 24h) and patient-controlled analgesia (PCA).
46043031|NCT02680444|Behavioral|Self-Administered Reappraisal-Only Exercise|A reappraisal of daily negative events by examining the positive aspects.
46043032|NCT02680444|Behavioral|Self-Administered Event Recall Exercise|Recall a negative event that took place that day.
45346978|NCT00712712|Drug|Morphine Sulfate|Patient-controlled analgesia (PCA), allowing morphine consumption to be titrated to the patient's needs and thus allowing morphine doses to be adapted to an increase in pain in the patient's post-operative period or a rapid analgesic effect of radiofrequency.
46043033|NCT02928406|Drug|Atezolizumab|Atezolizumab 1200 milligrams (mg) will be administered by intravenous (IV) infusion Q3W.
46043034|NCT01174160|Drug|vernakalant hydrochloride|Patients will receive a 3 mg/kg infusion of vernakalant hydrochloride. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of 2 mg/kg vernakalant hydrochloride will be administered.
45346979|NCT00712712|Other|Questionnaire administration|"Pain notebook will allow the patient to describe the pain specific to the metastasis concerned, containing information on :~The intensity of the minimum, average and maximum pain of the last 24 months. hours as well as the intensity of the pain of the moment according to a scale 11-point digital,~the background morphine analgesic treatment during the last 24 hours,~the morphine analgesic treatment taken during painful attacks,~the possible undesirable effects of morphine treatment.~the morphinic, non-morphinic and co-antalgic treatment is noted, as well as that the total dose of oral morphine or oral morphine equivalent"
45840999|NCT00989586|Procedure|Correlative/Special Studies|To correlate Fcγ receptor polymorphisms with response to treatment with the combination of veltuzumab and milatuzumab. Whole blood will be collected pre-treatment on day 1.
46043035|NCT01174160|Drug|Placebo to vernakalent hydrochloride|Patients will receive an infusion of placebo. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of placebo will be administered.
46043036|NCT04313894|Biological|Wharton Jelly Originated Mesencimal Stem Cell|In this study, the patient who has no systemic disease from Erciyes University, Obstetrics and Gynecology Department will be taken to the cord transport solution which will be medical waste after delivery. Samples for transport bacteriological tests from the transport solution to the laboratory shall be separated. They will be processed in a number of ways. The cells obtained will be administered intraarticularly at a dose of 1 x 100.000.000.
46043037|NCT02683798|Dietary Supplement|Continuous energy restriction|1 x formula food (202-209kcal) meal replacement per day
46043038|NCT02683798|Dietary Supplement|Intermittent energy restriction|4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
46043039|NCT04315454|Drug|Levobupivacaine|A group of patients will receive 20 ml of normal saline into the interfascial plane between rhomboids major &erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side, the other group of patients will receive 20 mg 0.25% Levobupivacaine bilaterally as above 10 mg each side.
45346980|NCT00712712|Procedure|Quality-of-life assessment|Patients' quality of life will be assessed using the quality of life questionnaire EORTC QLQ-C30 at inclusion in the study and at 8 weeks after radiofrequency. ablation.
45346981|NCT00712712|Procedure|Radiofrequency ablation|"Recent technique of thermal destruction of tumors.~This technique consists of inserting an electrode needle into the tumour under X-ray or ultrasound guidance or intraoperatively under laparoscopy for example. This needle carries a current or a light wave depending on the characteristics of the generator to which it is connected (radiofrequency, laser).~Radio frequencies are radiation non-ionising electromagnets. In this context of tissue ablathermia wavelengths ranging from 400kHz to 500kHz."
45475291|NCT01182779|Radiation|Protons|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E."
45346982|NCT00411151|Drug|Sunitinib-Malate|Capsules of 50, 25 or 12,5 mg. Dosage 50 mg, 37.5 mg or 25 mg once daily until progression of disease or untolerable side effects
45346983|NCT00607048|Drug|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 3 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
45475292|NCT03353896|Device|Wear novoTTF-200A|Wear novoTTF-200A device
46043040|NCT02683720|Dietary Supplement|ONS|randomized clinical trial involving different ONS strategies
45346984|NCT00607048|Drug|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 8 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
45346985|NCT00893698|Procedure|bilateral allotransplantation|bilateral allotransplantation of upper limbs
45346986|NCT03592576|Drug|Navitoclax|Tablet, Oral
46043041|NCT02885480|Behavioral|questionnaires|
46043042|NCT02682550|Procedure|blood drawing|blood drawing
45346987|NCT03592576|Drug|Venetoclax|Tablet, Oral
46043043|NCT01161446|Behavioral|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|Participants in this arm will be given access to home HIV self-testing kits with the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use with oral fluids. They will be trained to use this device to test themselves for HIV and be able to request up to one self-testing kit per month throughout follow-up.
46043044|NCT01161446|Device|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|The device is the home HIV self-testing kit that includes the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use on oral fluids. The kit itself is not the focus of this trial. As described in the Behavioral Intervention section, the intervention is having access to home self-testing for HIV.
46043045|NCT02680210|Other|Questionnaires and cognitive measures|
46043046|NCT00641680|Drug|Budesonide|
46043047|NCT00641680|Drug|Fluticasone propionate|
46043048|NCT00641680|Drug|Placebo|
46043049|NCT04183582|Behavioral|Behavioural Activation|"Behavioural Activation is a treatment for depression, the current programme has been adapted to suit the needs of postnatal women Session 1: Getting Started Session 2: Identifying Triggers, Reactions and Avoidance Patterns (TRAPs) Session 3: Turning TRACs in to Triggers, Reactions and Alternative Coping (TRACs) Session 4: Support and Communication Session 5: Being a Good Enough Mum Session 6: Staying Well"
46043050|NCT04033588|Device|Freedom® Total Knee System|To evaluate the survivorship, safety and performance of the Freedom® Total Knee System in the treatment of subjects who in the surgeon's opinion require a primary total knee replacement due to severe knee joint pain and loss of mobility due to osteoarthritis, rheumatoid arthritis or post-traumatic arthritis.
45346988|NCT04035850|Drug|Vortioxetine Tablets|Strength 5-20 mg
45346989|NCT00699608|Drug|GSK1755165; placebo; zopiclone|Subjects receive either 3mg GSK1755165, matching placebo or 7.5mg zopiclone
45346990|NCT00893776|Other|Task Training|Task training is the movement of balls in an individually prescribed fashion using the SaeboFlex orthosis on the affected extremity.
45346991|NCT00895570|Drug|modafinil|During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).
45346992|NCT00895570|Drug|placebo|During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.
45346993|NCT00895648|Drug|Pemetrexed|500 mg/m² iv infusion every 3 weeks for 3 cycles
45346994|NCT00895648|Drug|Cisplatin|75 mg/m² iv infusion every 3 weeks for 3 cycles
45475293|NCT03353896|Procedure|Quality-of-Life Assessment|Ancillary studies
46043051|NCT01174004|Drug|pimavanserin tartrate|pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
46043052|NCT01174004|Drug|placebo|placebo, tablet, once daily by mouth for 6 weeks
46043053|NCT02680288|Drug|Lorcaserin, 10 mg|Oral type 2C serotonergic agonist, low-dose
46043054|NCT02680288|Drug|Lorcaserin, 20 mg|Oral type 2C serotonergic agonist, high-dose
46043055|NCT02680288|Other|Oral Placebo|Oral inert treatment
46043056|NCT02885402|Other|MRI Sodium ( 23Na )|
46043057|NCT04184206|Behavioral|attention training intervention 1|14-day smartphone-based audio-guided attention training program with heavy mindfulness component
45346995|NCT05361512|Device|Tsui test|The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
45346996|NCT05361512|Device|epidural waveform analysis|A pressurized 500ml normal saline bag will be connected to a pressure transducer kit and the transducer will be connected to a portable monitor with the scale set at 0-40 mmHg or to optimum scale. The transducer will be levelled with the heart approximated at the patient's manubrio-sternal angle, with the patient in the sitting position. Sterile tubing will be connected to the epidural needle and attached to transducer. The tubing connection will be filled with saline to ensure proper reflection of the pressure transducer tracing. Test will be considered positive in case of pulsatile waveform is observed in synchrony with heart rate.
46043058|NCT04184206|Behavioral|attention training intervention 2|14-day smartphone-based audio-guided attention training program with moderate mindfulness component
45346997|NCT00893854|Drug|Diclophenac|
45475294|NCT03170271|Drug|Benralizumab (Medi-563)|30mg Benralizumab administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days) In the open label ANDHI IP sub study, all patients will receive benralizumab subcutaneously at Day 168 (Week 24), Day 196 (Week 28), Day 224 (Week 32), Day 280 (Week 40), Day 336 (Week 48), Day 392 (Week 56), Day 448 (Week 64), and Day 504 (Week 72).
45841000|NCT00989586|Procedure|Quantitative T-, B-, and NK cell subsets|Quantitative T-, B-, and NK- cell subsets will be assessed using flow cytometry to quantify the percentage and absolute number of cells expressing CD4, CD8, CD56, CD16, CD19, and CD20 pre-treatment on day 1, after induction (week 5, day 1), and prior to the start of therapy on day 1 week 12, day 1 week 36, and then every 4 months for one year.
45346998|NCT00893854|Drug|Triamcinolone|
45346999|NCT05351294|Other|Questionnaires|"All patients in Arm 2 will be seen and treated by one of three ROs with an interest in participating in this study, who will be trained by the PI to perform these visits reproducibly and with rigor. These will all be regular ROs, who like most ROs administer a mix of curative and PRT in their clinical practice; like most cancer centers, there are no ROs who formally subspecialize in PRT at our institution. Notably, patients in Arm 1 (control arm) will always have standard-of-care RO referral available for consideration of PRT if needed for symptom relief. However, patients in Arm 1 will be seen by other ROs without any specific training for this study. Any courses of PRT administered in either arm are at the discretion of the treating RO in terms of the timing, dose, fractionation, and treatment technique."
45841001|NCT00989586|Procedure|Pharmacokinetics|To assess the pharmacokinetics of veltuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 1 of weeks 1, 2, 4, 12 and 36. One additional sample will be collected each of weeks 5 through 10 (sample may be collected any day during each of these weeks).
46043059|NCT04184206|Behavioral|attention training intervention 3|14-day smartphone-based audio-guided attention training program without mindfulness component
46043060|NCT01173692|Drug|Minocycline|100 mg twice daily (200 mg) by mouth , every day for 7 weeks starting first day of radiation therapy.
46043061|NCT01173692|Drug|Placebo|Twice daily by mouth, every day for 7 weeks starting at first day of radiation therapy.
46043062|NCT00641758|Drug|Pycnogenol|Pycnogenol 100mg twice daily
46043063|NCT00641758|Drug|Placebo|Placebo 100mg twice daily
46043064|NCT00640276|Drug|pitavastatin|Pitavastatin 2mg daily once
46043065|NCT00640276|Behavioral|Lifestyle Modification|conducting mainly exercises and diet
46043066|NCT00640354|Device|Automated external defibrillator|Residents randomized to this group had an automated external defibrillator available for the simulated cardiac arrest. The automated external defibrillator did not actually discharge energy into the simulated patient
46043067|NCT00640354|Device|Manual defibrillator|Residents randomized to this group had a manual defibrillator available for the simulated cardiac arrest. The defibrillator did not actually discharge energy into the simulated patient.
46043068|NCT02680132|Drug|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
46043069|NCT02680132|Drug|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
46043070|NCT02790346|Procedure|arthrodesis talonavicular|
46043071|NCT02790346|Procedure|tendon gestures|
46043072|NCT02683564|Drug|BOW015|monoclonal antibody against TNF-alpha
46043073|NCT02683564|Drug|Remicade|monoclonal antibody against TNF-alpha
46043074|NCT01101035|Drug|Febuxostat|Febuxostat tablets
46043075|NCT01101035|Drug|Allopurinol|Allopurinol tablets
46043076|NCT04306679|Other|Animation clips|The first animation clip focuses on the importance of pain assessment introduce three pain scales (categorical, NPS and faces) followed by explanations on their properties and on the appropriate way to use them.The second movie was aimed to provide an opportunity to implement the new knowledge in case studies
46043077|NCT04306679|Other|Instructions|Routine preoperative preparations, which included a section on pain assessment instructions.
45475295|NCT03170271|Drug|Placebo|Placebo administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
46043078|NCT01100567|Device|Low-magnitude mechanical stimulation platform|Low-magnitude mechanical stimulation platform
45347000|NCT05351294|Combination Product|Early Radiation Oncology Involvement Alongside Standard Oncologic Care|Early Radiation Oncology Involvement Alongside Standard Oncologic Care
45347001|NCT00895726|Drug|APD209|Oral tablets twice per day for 56 days
45347002|NCT00895804|Drug|MDMA|capsule, 1.6 mg/kg body weight, single dose
45475296|NCT03613129|Drug|CT38|Infusion
45347003|NCT00895804|Drug|Pindolol|capsule of 20mg pindolol, single dose 1h before MDMA
45347004|NCT00895882|Drug|vaniprevir (MK7009)|vaniprevir 300 mg soft gel capsules twice daily.
45347005|NCT00895882|Drug|Comparator: vaniprevir (MK7009)|vaniprevir 600 mg soft gel capsules twice daily.
45475297|NCT04504006|Procedure|Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)|Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)
45475298|NCT01187225|Drug|Fibrinogen concentrate|In this arm, children (< 18 year-old)undergoing cardiac surgery with pump will receive fibrinogen concentrate (60 mg/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (< 1g/L) or TEG < 7 mm
45475299|NCT01187225|Drug|Cryoprecipitate|In this arm, children (< 18 year-old)undergoing cardiac surgery with pump will receive cryoprecipiate (10 ml/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (< 1g/L) or TEG < 7 mm
46043079|NCT01160822|Biological|Canakinumab|Intra-articular injection
46043080|NCT01160822|Drug|Placebo to canakinumab|Intra-articular injection
46043081|NCT01160822|Drug|Naproxen|Tablets for oral administration
46043082|NCT01160822|Drug|Placebo to Naproxen|Tablets for oral administration
45347006|NCT00895882|Drug|Comparator: Pegylated Interferon (peg-IFN) alfa-2a|Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly
45347007|NCT00895882|Drug|Comparator: Ribavirin|Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.
45347008|NCT00895882|Drug|Comparator: Placebo to vaniprevir|Placebo to vaniprevir soft gel capsules twice daily.
45347009|NCT03823404|Drug|COR388 capsule|BID (twice daily)
45347010|NCT03823404|Drug|Placebo capsule|BID
45347011|NCT00706706|Drug|Sunitinib Malate (SU011248)|Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
45347012|NCT00894010|Drug|carbamazepine 400mg|
45347013|NCT00894010|Drug|levetiracetam 1000mg|
45347014|NCT00895960|Drug|Dasatinib|Starting dose of 150 mg/day administered by mouth daily on Days 1 to 28 of every 28 day cycle, beginning on the first day of RT.
45347015|NCT00895960|Radiation|RT (Radiotherapy)|As a part of standard of care, receive 60 Gy radiation therapy Monday-Friday for a total of 30 radiation treatments (about 6 weeks).
46043083|NCT01006980|Drug|Vemurafenib|960 mg (as 240 mg tables) orally twice daily
46043084|NCT01006980|Drug|Dacarbazine|1000 mg/m2 intravenously every 3 weeks
46043085|NCT00887926|Biological|IMC-EB10|Cohort 1 will receive IMC-EB10 intravenously for 3 weekly infusions, followed by a 1-week observation period. The starting dose in Cohort 1 will be 5 mg/kg. After all participants in Cohort 1 complete the first cycle of therapy, dose escalation for subsequent cohorts will proceed as follows: Cohort 2 - 10 mg/kg, Cohort 3 - 20 mg/kg, Cohort 4 - 30 mg/kg. Participants who experience a dose-limiting toxicity (DLT) will not receive further IMC-EB10 treatment, but will continue to be followed on the protocol. Participants may continue to receive IMC-EB10 therapy, in the absence of treatment failure, treatment intolerance, or other withdrawal criteria for additional 28-day cycles at the same dose that they initially received. Dosing for Cycle 2 and beyond will be administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle
45347016|NCT00895960|Drug|TMZ (Temozolomide)|75 mg/m^2 capsules daily by mouth for up to a maximum of 7 weeks beginning first day of RT until RT end followed by 4 weeks off then 150 mg/m^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles.
45347017|NCT00410761|Drug|ZD6474 (Vandetanib)|once daily oral tablet
45347018|NCT00894088|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg Tablet
45347019|NCT00737828|Other|Perioperative care pathway guided by CPX results|"AT > 11ml/min/kg no myocardial ischaemia or Ve/VO2 <35 - Level 1 Ward Care~AT > 11ml/min/kg with myocardial ischaemia or Ve/VO2 >35 - Level 2/3 (ITU) Critical Care Unit~AT <11mls/min/kg - Level 2/3 Critical Care Unit~AT <8mls/min/kg - Level 2/3 Critical Care Unit/ consider cancellation or alternative procedure"
45347020|NCT03818178|Dietary Supplement|Intralipid|Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.
45347021|NCT03818178|Dietary Supplement|Palm Oil Emulsion|Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.
45347022|NCT03818178|Other|Saline|All participants will serve as their own controls with a saline infusion study day.
45347023|NCT00896194|Behavioral|Standard Behavioral Treatment|SBT consists of group counseling sessions where participants learn about healthy eating and physical activity. Participants are also given standard calorie goals, fat gram goals, and physical activity goals (minutes).
45347024|NCT00896194|Behavioral|Modified Standard Behavioral Intervention + Self-Efficacy|This group receives identical group intervention sessions. The goals (calories, fat grams, and physical activity minutes) are tailored to the individual's progress. Participants meet regularly with an interventionist for one-on-one lifestyle counseling.
45347025|NCT04063592|Procedure|Residual limb revision|Surgical procedure involving construction of agonist-antagonist myoneural interfaces (AMIs)
45347026|NCT00921128|Drug|Muscimol|
45347027|NCT04035460|Device|Helmet|The helmet encloses the head and neck of the patient, has a rigid ring and is secured by 2 armpit braces. A soft collar adheres to the neck and ensures a sealed connection once the helmet is inflated.
45347028|NCT04035460|Device|High Flow Nasal Oxygen|Large-bore nasal prongs through which oxygen is delivered at high flow rates
45347029|NCT05508776|Drug|LEO 152020|"Film-coated tablet~Route of administration: Orally~50 mg tablets"
45841002|NCT00989586|Procedure|Pharmacokinetics|To assess the pharmacokinetics of milatuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 2 of week 1 and day 1 of weeks 2, 4, 12 and 36. Additional samples will be collected days 3 through 6 of week 1.
46043086|NCT04182178|Other|10 years follow up|Questionnaires
46043087|NCT02679898|Other|Unloaded-Whole Body Vibration (WBVT)|The unloaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
45347030|NCT05508776|Drug|Moxifloxacin|"Tablet (may be film-coated depending on brand)~Route of administration: Orally~400 mg tablet"
45347031|NCT05508776|Drug|Placebo|"Film-coated tablet~Route of administration: Orally~No active ingredient"
45347032|NCT02565342|Procedure|Interscalene brachial plexus block|
46043088|NCT02679898|Other|Loaded-Whole Body Vibration (WBVT)|The loaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Importantly, an external load was applied to a weight vest to account for the necessary weight to perform a specific number of repetitions (progressed from 15-8 repetitions maximum during the 6 weeks). Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
46043089|NCT04296240|Drug|Oxaliplatin and capecitabine|Patients receive 5-Fu and oxaliplatin based neoadjuvant chemotherapy for 3 months
45347033|NCT00896350|Drug|Standard Care Chemoradiation|"External beam radiation to the neck and tumor site of head and neck. Concurrent platinum based chemotherapy. External beam boost at discretion of treating physician."
45347034|NCT02565264|Other|plasma-derived exosomes|Plasma samples from the participants will be filtered through 0.45 μm and 0.20 μm filters. The samples will be filtered through 0.02 μm filter to trap exosomes with the filter. Saline solution will be loaded from the other side of the 0.02 μm filter to obtain exosome rich buffer. The plasma-derived exosomes will be applied to the participants' ulcers daily for 28 days.
45347035|NCT00896428|Drug|Methoxyverapamil (gallopamil)|200 mg/day (1 tablet 100 mg morning and evening) for 12 months.
45347036|NCT00896428|Drug|Placebo.|1 tablet morning and evening for 12 months
45347037|NCT02962050|Procedure|Videofluoroscopic Swallowing Study (VFSS)|Videofluoroscopic swallowing study will be performed to measure oropharyngeal swallowing
45347038|NCT02962050|Device|Voluntary Peak Cough Flow Testing|Voluntary peak cough flow testing will be performed to determine the peak expiratory flow (PEF) and volume of air expelled (FEV1) during voluntary coughing.
45347039|NCT02962050|Device|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
45347040|NCT02962050|Drug|Capsaicin Challenge|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
45347041|NCT02962050|Device|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP) expressed as a percentage of predicted values.
46043090|NCT04296240|Procedure|Total Mesorectal Excision|Patient receive total mesorectal excision after neoadjuvant chemotherapy
46043091|NCT00182728|Procedure|surgery|conventional
46043092|NCT00182728|Procedure|therapy|neoadjuvant
46043093|NCT00182728|Radiation|radiation therapy|intraoperative radiation therapy
46043094|NCT04205058|Dietary Supplement|Standard coffee|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
46043095|NCT04205058|Dietary Supplement|Caffeine-free coffee|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
45347042|NCT02962050|Other|Eating Assessment Tool 10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
45347043|NCT02962050|Other|The Center for Neurologic Study Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
45347044|NCT04486716|Drug|Ofatumumab|Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml)
45347045|NCT00410605|Biological|bevacizumab|Given IV
45347046|NCT00410605|Drug|lenalidomide|Given orally
45347047|NCT00410605|Drug|dexamethasone|Given orally
46043096|NCT04205058|Dietary Supplement|Drinking water|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
46043097|NCT04183738|Drug|NRTIs|"In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined."
45347048|NCT00742638|Drug|Quetiapine fumarate|Investigational product: quetiapine fumarate tablet 25 mg and 200 mg
45347049|NCT00742638|Drug|Sodium valproate|Sodium valproate tablet 200 mg
45347050|NCT00418717|Drug|etanercept|Period A: Weeks 1-4: Etanercept 25mg (25mg vial)bi-weekly (BW); Period B: Weeks 5-12: Etanercept 50mg (50mg vial) weekly (QW)
45347051|NCT01042249|Other|Pelvic Floor Muscle training|12 week training program including home exercises
45347052|NCT00572572|Drug|Aprepitant|Subjects will be randomized to receive aprepitant 125mg PO day 3 then 80mg on days 4-7 on either cycle 1 or cycle 2.
45347053|NCT00572572|Drug|Placebo|Subjects will be randomized to receive placebo on days 3-7 on either cycle 1 or cycle 2.
45347054|NCT00896662|Other|immunologic technique|immunologic technique
45347055|NCT00896662|Other|laboratory biomarker analysis|laboratory biomarker analysis
45347056|NCT00896662|Other|pharmacological study|pharmacological study
45347057|NCT00896740|Genetic|microarray analysis|
45347058|NCT00896740|Procedure|biopsy|
45347059|NCT00896818|Genetic|DNA analysis|
45347060|NCT00896818|Genetic|genetic linkage analysis|
45347061|NCT00896818|Genetic|loss of heterozygosity analysis|
45347062|NCT00896818|Genetic|polymorphism analysis|
45347063|NCT00896818|Other|laboratory biomarker analysis|
45347064|NCT00896818|Other|medical chart review|
45347065|NCT00896818|Other|questionnaire administration|
45347066|NCT00896896|Other|immunologic technique|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
45347067|NCT00896896|Other|laboratory biomarker analysis|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
46043098|NCT04183738|Drug|Darunavir|800mg tablet by mouth once daily for 96 weeks.
46043099|NCT04183738|Drug|Ritonavir|100mg tablet by mouth once daily for 96 weeks.
46043100|NCT04183738|Drug|Dolutegravir|50mg tablet by mouth once daily for 96 weeks.
46043101|NCT02870322|Behavioral|Fruit and Vegetable CSA Prescription|Study Participants will collect and use fruit and vegetable CSA boxes given to them weekly for 10 weeks.
46043102|NCT02870322|Behavioral|Bikeshare Prescription|Study participants will use bikeshare for transportation and physical activity for 10 weeks
45347068|NCT00896974|Other|Laboratory Biomarker Analysis|Correlative studies
45347069|NCT00896974|Other|Pharmacological Study|Correlative studies
45347070|NCT00896974|Drug|Retinoid 9cUAB30|Given orally
45841003|NCT00989586|Procedure|Human Anti-Human Antibodies|To monitor for the development of human anti-veltuzumab antibodies and human anti-milatuzumab antibodies (HAHA) in patients receiving treatment with veltuzumab and milatuzumab. Patients will be monitored for the development of HAHA at the following timepoints: pre-treatment on day 1 of week 1, pre-treatment on day 1 of week 4, pre-treatment on day 1 of week 12, and pre-treatment on day 1 of week 36.
45841004|NCT00989586|Biological|veltuzumab and milatuzumab|Patient will receive veltuzumab and milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab on day 1 and milatuzumab on day 2. Starting in week 2, veltuxumab will be given on day 1 and milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
45347071|NCT00418561|Biological|rhASA - Dose Level 1|Intravenous infusion 25 U/kg as a single dose - hereafter 50 U/kg every other week for 26 weeks
45841005|NCT00990288|Drug|Hemostatic Matrix|FloSeal will be administered following the cementing of all knee components. Prior to release of the tourniquet and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissues by the use of a delivery syringe, Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.
46043103|NCT02682160|Other|use of Protein Assistant|The patient has to complete a dietary record every 2 weeks during 2 months (month 2 and 3 after surgery). The aim is to intake 60g per day. If the aim is not reached, Protein assistant suggests qualitative and/or quantitative solutions.
46043104|NCT04033666|Other|High Flow Nasal cannula|The HFNC will be instituted therapy with high-flow nasal cannula with dosage and cannula calculated according to the child's weight, ranging from 2 l / min to 30 l / min. The therapy will begin with diaphragmatic exercises 3x10 breaths and after high-flow therapy with nasal cannula for 45 minutes, after which will be performed the vital signs evaluations and Peak Flow, HRV, FEV1.
45347072|NCT00418561|Biological|rhASA - Dose Level 2|Intravenous infusion 100 U/kg every other week for 26 weeks
45347073|NCT00418561|Biological|rhASA - Dose Level 3|Intravenous infusion 200 U/kg every other week for 26 weeks
45347074|NCT00897052|Genetic|microarray analysis|Assay RNA obtained from archived formalin fixed paraffin embedded tissue samples
45347075|NCT00897052|Other|laboratory biomarker analysis|The gene expression data will be linked to the clinical information in order to generate profile of recurrence and survival as a biomarker.
45347076|NCT00897130|Drug|Azacytidine|Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted
45347077|NCT00894400|Procedure|catheter ablation|catheter ablation using radiofrequency energy
45347078|NCT00398047|Drug|Azacitadine and Hematopoietic Growth Factors|Combination of Azacitadine and Hematopoietic Growth Factors
45347079|NCT04016584|Behavioral|Diabetes Pueblo|These adults will receive diabetes education, the Diabetes Pueblo Program, and will complete Curriculum (A), Diabetes Fundamentals, and Curriculum (B), Insulin Success.
45347080|NCT00631371|Drug|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
45347081|NCT00631371|Drug|Temsirolimus|Temsirolimus 25 mg IV weekly
45347082|NCT00631371|Drug|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
45347083|NCT00631371|Drug|Interferon-Alfa 9MU|Interferon-Alfa 9MU SC TIW
45347084|NCT00897208|Other|high performance liquid chromatography|
45475300|NCT04664166|Other|Alpena Otago Telehealth Program|"A physical therapist will use video visits to evaluate the participants and provide exercise instructions from Week 1 to Week 4. Each participant will use the Blue Marble Health in Motion app from a mobile tablet to complete the exercise guided by an avatar at their own pace after receiving the exercise instructions from the physical therapist. Participants are encouraged to exercise three days a week and 30 minutes each day using the app for 6 months. The exercise protocol based on the evidence-based Otago program includes warm up, strengthening, and balance exercise.~3.5. Research Study Design and Data Analyses:"
45841006|NCT00991458|Drug|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
46043105|NCT04033666|Other|NIV Noninvasive Ventilation|The Therapy consisted of 3x10 diaphragmatic re-education exercises after a Bipap device was coupled in bipedal mode with parameters Ipap 12 cm H2O and Epap 8 cm H2O, for 45 minutes, according to the patient's tolerance, with Full face facial mask. After therapy evaluated vital signs and measures of Peak Flow, HRV, FEV1.
46043106|NCT02871414|Behavioral|REST - Early Group|Intervention - 7 weeks of sleep skills education provided in group and one-on-one format
46043107|NCT02871414|Behavioral|REST - Late Group|Control for REST - Early Group, then provided group and one-on-one sleep education and sleep skills intervention
45347085|NCT00897208|Other|laboratory biomarker analysis|
45347086|NCT00897208|Other|mass spectrometry|
45347087|NCT00897208|Other|medical chart review|
45347088|NCT00897208|Procedure|evaluation of cancer risk factors|
46043108|NCT00641134|Other|A: Home-Based exercise after Cardiac Rehabilitation|Home-Based exercise program,after CR, with reinforcement sessions
45347089|NCT00409747|Drug|Minocycline|
45347090|NCT04016740|Drug|Ropivacaine|Intraoperative bilateral PIFB block with 20 mL of 0.25% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision
45347091|NCT04016740|Drug|Ketamine|Intraoperative infusion
45347092|NCT04016740|Drug|Remifentanil|Intraoperative infusion
45347093|NCT04016740|Drug|Dexmedetomidine|Intraoperative infusion
45347094|NCT04016740|Drug|Rocuronium|Intraoperative intermittent bolus
45347095|NCT04016740|Drug|Propofol|Intraoperative infusion
45347096|NCT04016740|Drug|Sevoflurane|Intraoperative inhaled as needed
45347097|NCT04016740|Drug|Dexmedetomidine|Post-operative infusion
45347098|NCT04016740|Drug|Propofol|Post-operative infusion
45347099|NCT04016740|Device|EEG monitoring|Perioperative monitoring
45841007|NCT00991458|Drug|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
46043109|NCT02682082|Procedure|Endoscopic ultrasound-guided celiax plexus neurolysis|Endoscopic ultrasound-guided celiax plexus neurolysis
46043110|NCT02682082|Drug|Bupivacaine|Endoscopic ultrasound-guided celiax plexus neurolysis w/wo Bupivacaine
46043111|NCT02870946|Procedure|Simultaneous RRT|The patients in the simultaneous RRT arm will receive RRT when ECMO is commenced. (see Study Description)
45347100|NCT01035541|Device|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measruements
45347101|NCT02540512|Procedure|Auricular Acupuncture|Aiguille Semi-Permanent (ASP) acupuncture needles will be used following the Battlefield Acupuncture Protocol
46043112|NCT02870946|Procedure|Standard care|The patients in the standard care arm will not receive RRT when ECMO is commenced. Only when a patient demonstrates AKI and fulfills any one of the criteria of the conventional RRT indication, RRT would be delivered.
45347102|NCT02540512|Device|Acupuncture|ASP Needles: Small, semi-permanent acupuncture needles that will be used for acupuncture in the ear or taped over the ear for placebo.
46043113|NCT00640432|Drug|Diclofenac|75 mg oral capsule twice daily for 7 days
45347103|NCT02540512|Procedure|Placebo Acupuncture|The ASP needles will be double taped onto the ear for this procedure.
45347104|NCT02540512|Drug|hydrocodone / acetaminophen 5mg/325mg|"Narcotic/NSAID medication used as the standard medical treatment"
45347105|NCT02540512|Drug|Placebo Pill|Pills will be filled with methylcellulose and administered as a placebo for this intervention.
45347106|NCT01039909|Drug|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight size 00 Swedish orange opaque hard gelatin capsules containing placebo are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
45475301|NCT03353818|Behavioral|Golf|A free golf course and free membership for one year in a golf club will be given to participants.
46043114|NCT00640432|Drug|Celecoxib|400 mg oral capsule followed by 200 mg oral capsule with the evening meal (>=4 hours from first dose) on Day 1 then 200 mg oral capsule twice daily for 6 days
45475302|NCT03353818|Behavioral|No intervention|Patients acting as controls will not be restricted in any ways.
45475303|NCT03851939|Combination Product|Transarterial Chemoinfusion (TAI) Combine Toripalimab|Transarterial Chemoinfusion (TAI) Combine Toripalimab
45475304|NCT03355612|Drug|Apatinib|Apatinib: 500 mg, qd, po, last 180 days
45347107|NCT01039909|Drug|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
45347108|NCT00825903|Behavioral|Exercise|Exercise 3 times each week for a total of 12 weeks. Each session is 50 min. in length.
45347109|NCT03742375|Diagnostic Test|HPV genotyping|Quantitative HPV genotyping on anal swab
45475305|NCT03355612|Drug|XELOX|Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
45475306|NCT03235284|Other|Exercises|A program of therapeutic exercises (GC) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The GC treatment program consists of the following protocols: a) protocol 1: 20 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation),10 minutes diagonal exercise scapula (anterior and posterior elevation) and 10 minutes of exercise for trunk extension; b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training
45475307|NCT03235284|Other|Nintendo Wii|"Nintendo Wii program (GW) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The GW treatment program consists of the following protocols: a) protocol 1 games (Boxing and Soccer); b) protocol 2 games (Golf and running). 20 minutes for each game"
45841008|NCT00991458|Drug|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
45475308|NCT03235284|Other|Exercises and Nintendo Wii|In GCW program will be performed 20 minutes GC protocol (1 or 2, used alternately between sessions a week) and 20 minutes GW protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols
45475309|NCT03732547|Drug|PD-1 mAb|Intravenous infusion of PD-1 mAb, 200mg, once a time, every three weeks.
45475310|NCT03732547|Drug|PolyIC|Intramuscular injection of polyIC, 2mg, every other day, for three weeks.
45841009|NCT00993798|Drug|SABER-Bupivacaine Treatment 1a|5.0 ml
45841010|NCT00993798|Drug|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
45841011|NCT00993798|Drug|Bupivacaine HCl Treatment 1c|20.0 ml
45347110|NCT00894478|Procedure|Diffusion Tensor Imaging (DTI)|"MR and DTI: MRI and DTI will be done using 3.0T Philips MR scanner (Philips Medical Systems, Best, The Netherlands) using an eight channel head coil. DTI and axial 3D T1 will be performed on patients and controls.~DTI will be performed using single shot diffusion-weighted echo planar imaging, b=1000s/mm2 and 15 noncollinear directions (TR/TE=10,000/60 ms, slice thickness=2mm, field of view=22cm, matrix=112x112, NEX=2)~Axial 3D T1 (TR/TE=4.9/2.3 ms, slice thickness=1 mm, field of view = 24 cm, matrix=220x220, NEX=1) Patients will have additional sequences (axial and coronal T2, proton density and FLAIR) as part of their clinical scan"
45475311|NCT04503850|Drug|Mirabegron 50 MG|Mirabegron 50 mg daily dose and follow Up of erectile function using international index of erectile function 5 scoring system
45475312|NCT04503850|Drug|Alpha Blockers|Alpha blocker daily and evaluation of erectile function using international index of erectile function 5 scoring system
45475313|NCT03349684|Drug|Acarbose|Uptitrated in the treatment phase from 50 mg per day for 1 week, followed by 100 mg per day for another week, and 150 mg per day for the rest 14 weeks, oral, with the first mouthful of main meal
45841012|NCT00993798|Drug|SABER-Bupivacaine Treatment 2a|7.5 ml
45841013|NCT00993798|Drug|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
46043115|NCT02870244|Biological|Escalating Doses|"Subjects will receive a single infusion of autologous bulk TIL 13831 TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 13831 TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4 + and CD8+ T Cells expressing the TIL 13831 TCR.~Subjects in Cohort 1 will receive 7.5 x 10^6/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 2 will receive 2.5 x 10^7/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 3 will receive 7.5 x 10^7/kg TIL 1383I TCR transduced T cells."
46043116|NCT02679664|Drug|Rosuvastatin|20 mg tablet of rosuvastatin
45347111|NCT00894478|Procedure|Magnetoencephalography|MEG will be performed using a whole-head Omega 151-channel gradiometer system (VSM MedTech, Port Coquitalam, BC, Canada). At least 15 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 625Hz, a bandpass filter of 10 to 70 Hz and a notch filter of 60 Hz.
45347112|NCT00897442|Other|Laboratory Biomarker Analysis|Correlative studies
45347113|NCT04017676|Other|Supervision assissted by measures|In the weeks 10 and 13, about 72 hours after the meeting scheduled for that week, and before the next therapeutic session, there will be a structured training session (based on the recommendations of Krägeloh et al., 2015), based on information in the literature about the various questionnaires
45841014|NCT00993798|Drug|Bupivacaine HCl Treatment 2c|20.0 ml
45841015|NCT00995904|Drug|84ug MAP0020|84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
45841016|NCT00995904|Drug|42ug MAP0020|42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
45475314|NCT03349684|Drug|Metformin|500 mg 3 times daily, oral, with the first mouthful of main meal
45347114|NCT04035772|Other|Wiki101 and WikiTrauma|Wiki101 is a theory-based continuing professional development course to teach healthcare professionals how to use WikiTrauma. WikiTrauma is a wiki containing implementation tools built upon the Google Sites platform.
45347115|NCT00897520|Biological|recombinant interferon alfa|
45347116|NCT00897520|Genetic|proteomic profiling|
45347117|NCT00897520|Other|immunoenzyme technique|
45347118|NCT00897520|Other|laboratory biomarker analysis|
45347119|NCT00894634|Drug|Brompheniramine maleate|
45347120|NCT02540278|Behavioral|Positive Prevention PLUS|PP+ has elven 45 minute lessons: (1) Getting Started, (2) Life Planning, (3) Healthy Relationships, (4) Relationship Violence, (5) Family Planning and Contraceptives, (6) Myths and Stereotypes, (7) HIV Disease and AIDS, (8) Recognizing and Reducing Risk, (9) Peer and Media Pressures, (10) Human Immunodeficiency Virus (HIV)/Sexually Transmitted Disease (STD) Testing and Community Resources, and (11) Steps to Success.
45347121|NCT00630747|Biological|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg once-weekly
45347122|NCT00894712|Other|Sulforaphane-containing broccoli sprout extracts (active agent)|Topical application, prepared with acetone, 280 nml daily, 3 times a week.
45347123|NCT00894712|Device|Vehicle (inactive control)|Subjects will have measurements of skin erythema using a device called a chromometer
45475315|NCT03349684|Drug|Placebo|Acarbose matching placebo, oral
45475316|NCT03856385|Behavioral|Mindful Walking|Weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals.
45475317|NCT03856697|Drug|Abivertinib Maleate Capsules|patients receive the test drug (Abivertinib maleate Capsules) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 3 capsules, and the second dose is 3 capsules. The drugs should be administered with water before or after meals.
45475318|NCT03856697|Drug|Placebo Gefitinib Tablets|patients receive the test drug (Placebo Gefitinib Tablets) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 1 tablet. The drugs should be administered with water before or after meals.
45475319|NCT03856697|Drug|Gefitinib Tablets|patients receive the control drug (Gefitinib Tablets) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 1 tablet. The drugs should be administered with water before or after meals.
45475320|NCT03856697|Drug|Placebo Abivertinib Maleate Capsules|patients receive the control drug (Placebo Abivertinib Maleate Capsules) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 3 capsules, and the second dose is 3 capsules. The drugs should be administered with water before or after meals.
45347124|NCT00897754|Genetic|gene expression analysis|
45347125|NCT00897754|Genetic|protein expression analysis|
45475321|NCT03355378|Procedure|gum chewing|chewing gum orally for 30 minutes
45841017|NCT00995904|Drug|21ug MAP0020|21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
45347126|NCT00897754|Genetic|reverse transcriptase-polymerase chain reaction|
45347127|NCT00897754|Other|immunoenzyme technique|
45347128|NCT00897754|Other|immunohistochemistry staining method|
45347129|NCT00897754|Other|immunologic technique|
45347130|NCT02540902|Device|All-polyethylene tibia (Aesculap AG)|Implantation of an all polyethylene tibial component.
45347131|NCT05278078|Other|psychological support|psychological support will be given to the patients in the experimental group.
45347132|NCT05278078|Other|nutritional education|nutritional education will be given to the patients in the experimental group.
45347133|NCT05278078|Other|psychological support and nutritional education|psychological support and nutritional education will be given to the patients in the experimental group.
45347134|NCT05278078|Other|no intervation|No intervention will be applied to the control group
45347135|NCT00823485|Procedure|fibrinolysis in situ|intraventricular injection of actilyse
45347136|NCT00823485|Procedure|drainage|drainage
45347137|NCT00897832|Other|laboratory biomarker analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), it will be determined if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival.
45347138|NCT02550405|Behavioral|Craving behavioral intervention|The CBI was given once a week for 6 weeks, conducted by four therapists. A pair of therapists was randomly assigned to a CBI+ group. Each session included 5 parts in 2.5-3 hours: warming-up exercise, discussion about the homework from the last session, main structured activity, brief summary, and the homework assignment. There were 6 sessions with each focused on a topic: recognize craving and its relationship with IGD; reduce craving through ameliorating the salience of cues and irrational beliefs, withdrawal symptoms and other negative affects; enhance self-monitoring and control for craving through time management training; relieve fulﬁllment of psychological needs through Internet use and attenuate the relation between craving and gaming behaviors through coping skill training
45347139|NCT00897988|Genetic|gene expression analysis|
45347140|NCT00897988|Genetic|mutation analysis|
45347141|NCT00897988|Genetic|polyacrylamide gel electrophoresis|
45347142|NCT00897988|Genetic|polymerase chain reaction|
45347143|NCT00897988|Genetic|protein expression analysis|
45347144|NCT00897988|Genetic|reverse transcriptase-polymerase chain reaction|
45347145|NCT00897988|Other|flow cytometry|
45347146|NCT00897988|Other|immunoenzyme technique|
45347147|NCT00897988|Other|immunologic technique|
45347148|NCT00897988|Other|laboratory biomarker analysis|
45347149|NCT00897988|Other|pharmacological study|
45347150|NCT00823641|Drug|Infliximab|Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study
45347151|NCT00397891|Drug|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
45841018|NCT00996372|Drug|flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
45684963|NCT04127344|Behavioral|Music Therapy Intervention|Patients randomized to a music therapy intervention will receive an individualised music therapy intervention. The sessions will last 10-20 minutes and they will be done by music therapist and musician.
46043117|NCT02871180|Dietary Supplement|Late night snack|The late night snack was one slice of whole meal rye bread containing approximately 20 g of carbohydrate.
46043118|NCT02871180|Other|No late night snack|Patient consumed no nutrients at late night.
46043119|NCT02679742|Dietary Supplement|β-hydroxymethylbutyrate|β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
46043120|NCT02679742|Dietary Supplement|Placebo|Maltodextrin 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
46043121|NCT04295226|Other|Structured follow-up after stroke.|Stroke-nurse managed follow-up 3 and 12 months after stroke and multidisciplinary rounds resulting in individual treatment plans for stroke-related health problems.
46043122|NCT02679586|Device|Diffusion weighted MRI|
46043123|NCT04295070|Biological|CodaVax-RSV|Codon deoptimized, live-attenuated vaccine against RSV delivered intranasally via dropper
45347152|NCT00397891|Drug|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
45347153|NCT00397891|Drug|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
45347154|NCT00898066|Genetic|cytogenetic analysis|marrow and peripheral blood
45347155|NCT00898066|Genetic|fluorescence in situ hybridization|marrow and peripheral blood
45347156|NCT00823875|Drug|Cilostazol group|Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.
45347157|NCT00823875|Drug|Probucol group|Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
45347158|NCT00823875|Drug|Cilostazol + Probucol group|"Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.~Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner"
45347159|NCT00823875|Drug|control group|routine treatment
46043124|NCT04295070|Biological|Normal saline|Saline (0.9%) administered via dropper
45347160|NCT00898144|Other|Papanicolaou test|
45347161|NCT00898144|Other|laboratory biomarker analysis|
46043125|NCT00641836|Procedure|Transplantation of autologous endothelial progenitor cells|
46043126|NCT02870010|Biological|blood samples (5 ml) will be taken|blood samples (5 ml) will be taken
45347162|NCT01042327|Device|ELISIO dialyzer|3 x week dialysis using ELISIO dialyzer for 12 weeks
45347163|NCT01042327|Device|Fresenius FX100 dialyzer|
45347164|NCT04035928|Device|3D digital scanning for maxillofacial prosthetics|The non-invasive Artec Space Spider 3D scanner will be used to image the indicated areas of the patients head and face. In the case of an intraoral defect, the noninvasive TRIOS intraoral 3D scanner will be used. The study may also use nasometry or nasal endoscopy to measure the amount of airflow through the patient's fistula to help guide the design. The software that will be used will create a 3D image of the prosthesis during the patient's clinic appointment. Once a model of the prosthesis is fully designed and manufactured, the patient will return to clinic for a second appointment which may involve fitting and coloring. A subsequent appointment will involve delivery of a successfully fitted and colored prosthesis that the patient will take home.
45347165|NCT00823953|Drug|Momordica charantia|escalating doses of Momordica charantia administered in the form of capsules for the trial phase of three week.Dose level 1: capsules containing a total of 500 mg of freeze dried powder of Momordica charantia. Dose level 1: capsules containing a total of 1000 mg of freeze dried powder of Momordica charantia. Dose level 3: capsules containing a total of 1500mg of freeze dried powder of Momordica charantia.
45347166|NCT00823953|Other|starch powder|The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
46043127|NCT02870010|Radiation|Chemoembolization|Chemoembolization will take place in the Interventional Radiology room: the syringe, prepared at the pharmacy, will contain microspheres loaded with a defined dose of idarubicin. Then five millilitres of Visipaque® will be added to visualize the injection
45347167|NCT04036084|Diagnostic Test|Cerebral Magnetic resonance imaging (MRI)|Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Inclusion Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Month 1 Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Year 1
45684964|NCT03018730|Biological|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
46043128|NCT02870712|Procedure|Suture of perineum|suture of the tear to obtain hemostasis
45347168|NCT00397189|Drug|Circadin|Prolonged release melatonin 2 mg
45347169|NCT00397189|Drug|placebo circadin|placebo circadin tablets
45347170|NCT00824109|Device|Second Generation Anti-Microbial bifurcated vascular graft (InterGard)|treatment of patients with aorto-iliac occlusion,stenosis, or aneurysm
45347171|NCT00898300|Other|biologic sample preservation procedure|
46043129|NCT02870712|Procedure|hemostatis by digital compression|Digital compression of the tear to obtain hemostasis
46043130|NCT02537782|Device|Cardiac resynchronisation therapy|
46043131|NCT02537782|Other|Echocardiography|
46043132|NCT02537782|Other|Magnetic Resonance Imaging|
46043133|NCT02537782|Other|Positron Emission Tomography|
45347172|NCT00898300|Procedure|biopsy|
45347173|NCT01035619|Drug|moxidectin|Single Dose Moxidectin 4 mg
45475322|NCT03856541|Drug|SHR-A1403|SHR-A1403 is a humanized anti C-Met immunoglobulin G2 (IgG2) monoclonal antibody conjugated with microtubule inhibitor. SHR-A1403 is provided as the lyophilized powder,40 mg/vial.SHR-A1403 was given intravenously per 3 weeks at the day 1.Intravenous infusion over 30 min
45347174|NCT00819819|Dietary Supplement|Gluten|Purified gluten from exaploid wheat introduced per American Academy of Pediatric Recommendations. Three grams from 6-9 months and 5 grams from 9-12 months. The 3-5 grams represents the mean daily intake of gluten during the second half of the first year in infants of different countries.
45347175|NCT00819819|Dietary Supplement|Gluten free diet|Non gluten containing starch added to diet. Three grams from 6-9 months and 5 grams from 9-12 months. After the age of 1 year all children will be allowed age appropriate unrestricted diet.
45347176|NCT04044651|Drug|Lenvatinib|lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily
45347177|NCT04044651|Drug|Nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w
45475323|NCT03353662|Other|Women of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Gamo Gofa between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
45347178|NCT00606034|Drug|U-500 Insulin delivered by Omnipod (disposable insulin pump)|U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs
45347179|NCT00898378|Genetic|gene expression analysis|gene expression analysis
45347180|NCT00898378|Genetic|polymerase chain reaction|polymerase chain reaction
45347181|NCT00898378|Genetic|polymorphism analysis|polymorphism analysis
45347182|NCT00898378|Genetic|protein expression analysis|protein expression analysis
45347183|NCT00898378|Genetic|proteomic profiling|proteomic profiling
45347184|NCT00898378|Other|gas chromatography|gas chromatography
45347185|NCT00898378|Other|laboratory biomarker analysis|laboratory biomarker analysis
45347186|NCT00898378|Other|liquid chromatography|liquid chromatography
45347187|NCT00898378|Other|mass spectrometry|mass spectrometry
45347188|NCT00898378|Other|questionnaire administration|questionnaire administration
46043134|NCT00998400|Behavioral|CBT in combination with WBT and life style modification|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems. The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others. CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
45347189|NCT00819975|Dietary Supplement|Casein|
45347190|NCT00819975|Dietary Supplement|Whey Isolate|
45347191|NCT00819975|Dietary Supplement|Whey Hydrolysate|
45347192|NCT00819975|Dietary Supplement|Alphalact-Albumin|
45347193|NCT00825981|Other|screening coagulation abnormalities|if specific coagulation abnormalities are observed which increase patient's risk of bleeding, appropriate treatment will start
45347194|NCT00898456|Genetic|gene expression analysis|
45347195|NCT00898456|Genetic|molecular genetic technique|
45684965|NCT03017326|Drug|Cisplatin|Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination
46043135|NCT00641212|Drug|Budesonide|
45684966|NCT03017326|Drug|Doxorubicin|Arms C, D and E used in combination
46043136|NCT00641212|Drug|Placebo|
45347196|NCT00898456|Genetic|polymorphism analysis|
45347197|NCT00898456|Genetic|protein expression analysis|
45347198|NCT00898456|Other|diagnostic laboratory biomarker analysis|
45347199|NCT04044417|Procedure|currettage|open flap debridement
45347200|NCT04044417|Drug|curcumin simvastatin paste|Curcumin is the primary active constituent of turmeric. Simvastatin is chemical modification of lovastatin.
45347201|NCT04044417|Drug|EDTA root conditioning|EDTA is an aminopolycarboxylic acid and a colourless, water-soluble solid
45347202|NCT00397033|Drug|Paliperidone ER|6mg/day paliperidone er for 6 weeks
45347203|NCT00397033|Drug|Paliperidone ER|12mg/day paliperidone er for 6 weeks
45347204|NCT00397033|Drug|Placebo|Placebo for 6 weeks
45347205|NCT00820053|Drug|epirubicin and lipiodol|using the technology of Seldinger,The drugs (30 mg epirubicin mixed with 5 ml lipiodol) are given via hepatica propria artery.
45347206|NCT00572728|Procedure|CT|Undergo 18F-FLT PET/CT
45347207|NCT00572728|Drug|18F-FLT|Undergo 18F-FLT PET/CT
45347208|NCT00572728|Procedure|PET|Undergo 18F-FLT PET/CT
45347209|NCT00820131|Procedure|selfgrip mesh|inguinal hernia repair using a selfgrip mesh
45347210|NCT00820131|Procedure|lightweight mesh with suture fixation|inguinal hernia repair using a lightweight mesh with suture fixation
45347211|NCT03857295|Other|No interventions|No intervention
45347212|NCT00699374|Drug|sunitinib malate|sunitinib capsules at starting dose of 37.5 mg PO daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sunitinib dosing interruptions and/or reductions are allowed based on patient tolerability.
45347213|NCT00699374|Drug|sorafenib|sorafenib tablets at starting dose of 400 mg PO twice daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sorafenib dosing interruptions and/or reductions are allowed based on patient tolerability.
45347214|NCT00898534|Device|Bayer DCA2000+ Hemoglobin A1c analyzer|Point-of-care hemoglobin A1c measurement of blood obtained by fingerstick
45684967|NCT03017326|Drug|Carboplatin|Arms C and D used in combination
45684968|NCT03017326|Drug|5Fluorouracil|Arm C used alone
45684969|NCT03017326|Drug|Vincristine|Arms C and D used in combination
45684970|NCT03017326|Drug|Etoposide|Arm D used in combination
45684971|NCT03017326|Drug|Irinotecan|Arm D used in combination
45684972|NCT03017326|Drug|Gemcitabine|Arm F used in combination
45684973|NCT03017326|Drug|Oxaliplatin|Arm F used in combination
46043137|NCT02869776|Behavioral|Questionnaire|Behavioral questionnaires
46043138|NCT02869776|Procedure|Rapid finger stick|HIV and HCV testing through rapid finger stick
46043139|NCT02869776|Procedure|Venipuncture|HIV and HCV testing through venipuncture
46043140|NCT02400190|Other|endocrine therapy alone without radiotherapy|Patients will not receive radiotherapy, which is the current standard for treatment for their type of breast cancer.
46043141|NCT04293900|Other|24-hour dietary recall|Dietary intake assessment conducted by a Registered Dietitian Nutritionist. This assessment will occur prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
45347215|NCT00824187|Drug|EE20/DRSP(YAZ, BAY86-5300)|20 μg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
45347216|NCT00824187|Drug|Placebo|Inert tablet
45347217|NCT00826137|Dietary Supplement|Inulin and fructo-oligosaccharides.|Supplement during antibiotic treatment+14 days.
45475324|NCT03353662|Other|Children of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Gamo Gofa between 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
46043142|NCT04293900|Other|Hand grip strength|Measurement of grip strength using a hand dynamometer. This will test occur prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
45347218|NCT00826137|Dietary Supplement|Placebo|Placebo is base powder of product with no oligosaccharides.
45347219|NCT00606892|Drug|Varenicline|Varenicline (1 mg per day) given for 4 days prior to laboratory session
45347220|NCT00606892|Drug|Placebo|Sugar Pill
45347221|NCT00606892|Drug|IV Nic|IV Nicotine given during the laboratory session following 4 days of exposure to the study medication (varenicline or placebo). This nicotine was given during each laboratory session which followed the 4 days of exposure to either placebo then varenicline or varenicline then placebo.
45347222|NCT00826215|Device|electroacupuncture|Nine sections of 45 minutes electroacupuncture treatment in three weeks
45347223|NCT00826215|Device|Sham laser acupuncture|Sham laser acupuncture
45347224|NCT00826293|Procedure|Stabilization belt|Patients receive true stabilization.
45347225|NCT00826293|Procedure|Stabilization belt|Patients receive sham stabilization.
45347226|NCT04035538|Drug|CKD-320, D012|R: D012 1tablet, QD, PO T: CKD-320 2tablets, QD, PO
45684974|NCT03017326|Drug|Sorafenib|Arm used in combination
46043143|NCT04293900|Other|International Physical Activity Questionnaire|Survey about physical activity over the previous 7 days. This survey will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
45347227|NCT01042483|Device|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
45347228|NCT00894946|Procedure|Lipiodol + IVF|IVF preceded by lipiodol
45347229|NCT00894946|Procedure|IVF|IVF alone
45841019|NCT00996372|Drug|placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
46043144|NCT04293900|Other|Patient-reported outcomes survey|Survey about symptoms and side effects experienced during cancer treatment. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
46043145|NCT04293900|Other|Pittsburgh Sleep Quality Index|Survey about sleep habits and quality over the past month. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
45841020|NCT00997620|Drug|Fluticasone furoate Nasal Spray 110 mcg|Fluticasone fuorate nasal spray 110 mcg 2 sprays each nostril am will be compared to similar appearing placebo given 2 sprays each nostril am. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of fluticasone furoate 110 mcg once daily and continue the evaluations.
46043146|NCT04293900|Other|Functional Assessment of Cancer Treatment - Lymphoma|Survey about quality of life for people with a diagnosis of lymphoma. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
46043147|NCT04293900|Other|urine sample (optional)|Collect three urine samples either in the clinic or at home. This specimen collection will occur prior to starting R-CHOP chemotherapy, after the third round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
46043148|NCT04293900|Other|fecal sample (optional)|Collect a fecal sample either in the clinic or at home. This sample collection will occur prior to starting R-CHOP chemotherapy, after the third round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
45347230|NCT00737906|Procedure|Surgical turbinate reduction procedure|Surgical turbinate reduction using the COBLATION device
45347231|NCT01042561|Dietary Supplement|Vitamin D3|400 IU of vitamin D3 daily. Pts will recieve 1 mL a day with a feeding for 28 days.
45841021|NCT00997620|Drug|Placebo|Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of Placebo once daily and continue the evaluations.
45347232|NCT01042561|Dietary Supplement|vitamin D3 placebo|Placebo designed by research pharmacist. Pts will recieve 1 mL a day with feedings for 28 days.
45347233|NCT00898690|Genetic|cytogenetic analysis|
45347234|NCT00898690|Genetic|gene expression analysis|
46043149|NCT02683486|Device|Intelligent oxygen therapy (an auto-titrating oxygen system)|This device is an auto-titrating oxygen system. The system is programmed to maintain a specific target SpO2 by automatically adjusting the oxygen flow rate. The system can deliver flow rates of 0-5 litres/minute.
45347235|NCT00898690|Genetic|microarray analysis|
45347236|NCT00898690|Genetic|mutation analysis|
45347237|NCT00898690|Genetic|reverse transcriptase-polymerase chain reaction|
45347238|NCT00898690|Other|immunohistochemistry staining method|
45347239|NCT05312996|Other|Heart Rate Variability|Caretaker Heart Rate Variability ECG wrist monitor and chest patch.
45347240|NCT05312996|Other|Galvanic Skin Response (Biopac)|Galvanic Skin Response- measuring autonomic response-via perspiration
46043150|NCT02683486|Device|Long-term oxygen therapy|This is the patients usual long-term oxygen therapy
46043151|NCT04183192|Biological|Mepolizumab|Mepolizumab 3 mg administered SC
46043152|NCT04183192|Biological|Mepolizumab|Mepolizumab 6 mg administered SC
46043153|NCT04183192|Biological|Mepolizumab|Mepolizumab 12 mg administered SC
46043154|NCT04183192|Biological|Mepolizumab|Mepolizumab 24 mg administered SC
46043155|NCT04183192|Biological|Reslizumab|Reslizumab 0.1 mg/kg administered IV
46043156|NCT04183192|Biological|Reslizumab|Reslizumab 0.2 mg/kg administered IV
46043157|NCT04183192|Biological|Reslizumab|Reslizumab 0.4 mg/kg administered IV
45347241|NCT01035775|Procedure|Inspection during insertion|The colonic mucosa will be inspected for lesions during insertion of the instrument, and during withdrawal of the instrument.
45841022|NCT00997932|Drug|Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration|Levonorgestrel-Releasing Intrauterine Contraceptive System, 52 Mg, 5 Year Duration Postpartum placement of LNG-IUS within 10 minutes - 48 hours
46043158|NCT04183192|Biological|Reslizumab|Reslizumab 0.8 mg/kg administered IV
45347242|NCT01035775|Procedure|Inspection during withdrawal|The colonic mucosa will be inspected for lesions only during withdrawal of the instrument from the cecum. The instrument will be inserted to the cecum without deliberate inspection.
46043159|NCT04183192|Biological|Placebo|Placebo (administered either IV or SC)
46043160|NCT02681848|Drug|Varenicline|Smoking cessation medication
45347243|NCT00737984|Procedure|Endometrial sampling|Endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
45347244|NCT04035616|Dietary Supplement|microbial cell preparation [MCP]|active microbial cell preparation
45684975|NCT03014362|Device|Neuronetics NeuroStar XPLOR magnetic stimulator - Active|"Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes.~Treatment Dose: ~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC."
45684976|NCT03014362|Device|Neuronetics NeuroStar XPLOR magnetic stimulator - Sham|Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC.
45684977|NCT04126954|Other|Serum PTH concentrations results|To compare serum PTH concentrations results in patients with primary or secondary hyperPTH resulting from phosphocalcic pathology before and three months after initiation of cinacalcet therapy.
45684978|NCT04126876|Drug|Tilsotolimod|Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
46043161|NCT02681848|Drug|Nicotine replacement therapy|
46043162|NCT00997386|Drug|busulfan, and melphalan, and alemtuzumab|"intravenous busulfan 3.2 mg/kg/dose daily for 2 days, on days -5 and -4 (i.e., 5 and 4 days, respectively, before PBSCT).~intravenous melphalan 100 mg/m2 on day -3.~intravenous alemtuzumab 30 mg/dose for 2 days, on days -2 and -1."
46043163|NCT02394574|Other|Clean Cookstove|Ethanol
46043164|NCT02394574|Other|Traditional Cookstove|Firewood / Kerosene
45347245|NCT04035616|Other|placebo|inactive ingredient
45347246|NCT01035853|Drug|Colistin|Sino-Nasal inhalation, approximately 1 ml / day in each nostril
45347247|NCT05289362|Device|Basket group|Under ERCP, the basket is preferentially used to remove the pancreatic duct stones, and then the balloon is used to evaluate the effect and remove the residual stones.
45347248|NCT05289362|Device|Balloon group|Under ERCP, the balloon is preferentially used to remove the pancreatic duct stones, and then the basket is used to evaluate the effect and remove the residual stones.
45347249|NCT01042639|Behavioral|passive physical activity|extension and flexion range-of-motion exercise against passive resistance of both the upper and lower extremities. Both extension and flexion were performed five times at the wrist, elbow, shoulder, ankle, knee, and hip joints
45347250|NCT04035304|Other|Mindfulness Coach|"Mindfulness Coach provides 4 primary treatment components: 1) psychoeducation about PTSD and Mindfulness (e.g., What is Mindfulness?, Why Practice Mindfulness?, Mindfulness for Veterans, Benefits of Mindfulness for PTSD, Practice Challenges with PTSD, and PTSD Symptoms During Practice), 2) self-monitoring tools for tracking mindfulness practice, 3) 9 audio- guided mindfulness exercises (e.g., Mindful Breathing, Body Scan, Clouds in the Sky, etc.), and 4) reminders to regularly practice mindfulness exercises."
45347251|NCT05274542|Other|high intensity with blood flow restriction|Participants in high intensity with blood flow restriction group (n=12) will be given high-intensity resistance exercise training that restricts blood flow. Open kinetic chain rectus femoris resistance exercise training will be given with free weights, 80% of 1 RM with 8 repetitions, 2 sets and 3 minutes rest between sets. The exercises will be performed in a single session accompanied by a physiotherapist. A blood pressure cuff will be used to restrict blood flow. By applying the cuff to the proximal of the muscle, the blood flow will be restricted with a pressure of 150 mmHg and the muscle will be exercised in this way. After the exercise, the cuff will be removed and evaluations will be made after 2 minutes of rest.
45347252|NCT05274542|Other|high intensity without blood flow restriction group|Participants in high intensity without blood flow restriction group (n=12) will be given high-intensity resistance exercise training. Open kinetic chain rectus femoris resistance exercise training will be given with free weights, 80% of 1 RM with 8 repetitions, 2 sets and 3 minutes rest between sets. The exercises will be performed in a single session accompanied by a physiotherapist. After the exercise, after 2 minutes of rest, evaluations will be made.
45347253|NCT01036243|Dietary Supplement|test formula 1|hydrolyzed formula with probiotics
45347254|NCT01036243|Dietary Supplement|test formula 2|acidified hydrolyzed formula
45347255|NCT01036243|Dietary Supplement|test formula 3|hydrolyzed formula without probiotics
45347256|NCT01036243|Dietary Supplement|reference formula|standard infant formula
45347257|NCT00895024|Behavioral|Phone Interview/Questionnaire|35-minute questionnaire over the phone.
45347258|NCT05268614|Radiation|Radiation therapy|"Participants will receive either 70 gray (Gy), 60 Gy, or 50 Gy of radiation based on the following criteria:~70 Gy: Pretreatment level of plasma circulating free HPV DNA (cfHPV DNA) ≤ 12 copies/mL~60 Gy: Tumor tissue positive for HPV subtype other than 16 OR Pretreatment level of cfHPV DNA 13-99 copies/mL OR Pretreatment level of cfHPV DNA ≥ 100 copies/mL AND <95% decrease in the level cfHPV DNA by the end of week 4 of radiation therapy~50 Gy: Tumor tissue positive for HPV subtype 16, pretreatment level of cfHPV DNA ≥ 100 copies/mL, AND ≥ 95% decrease in the level cfHPV DNA by the end of week 4 of radiation therapy"
45684979|NCT04126876|Drug|Saline (0.9% sodium chloride)|Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
46043165|NCT02870088|Behavioral|Prolonged Sitting|After consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min.
46043166|NCT02870088|Behavioral|Breaking Sitting|After consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min.
46043167|NCT04182256|Device|MS|Magnetic Spiderman (MS) is a novel surgical instrumentIt. It consists of a circular neodymium iron boron magnet packed in a stainless-steel case with a spring and a jagged clamp, which gives it a spider-like appearance.
46043168|NCT02869620|Other|Data collection|
46043169|NCT04182412|Procedure|ARD|surgical reconstruction with laparoscopic technique
46043170|NCT02679820|Device|Copper T intrauterine device|
46043171|NCT02683330|Behavioral|Mindfulness-based intervention (MBI)|MBI consists of 8 sessions and will cover becoming aware of emotions, thoughts and physical sensations, decentering and acceptance. Recordings of the body scan, a sitting meditation and a mindful movement meditation will be provided for daily home practice. Special care will be taken to address safety in the context of PD, and to adapt meditations to the physical limitations of PD.
45841023|NCT00998010|Drug|bortezomib + temozolomide+ radiation therapy|Patients will be treated with Bortezomib at 1.3 mg/m2 IV on days1,4,8,11,29,32,36 and 39 and Temozolomide on 75mg/m2 daily during radiation. External beam fractionated regional radiation will be given on consecutive week days at 200 centigray (cGy) daily doses to a total dose of 6000 cGy.
45841024|NCT00999102|Drug|Metoprolol|Metoprolol 50 mg, Metoprolol 100 mg,
45347259|NCT05268614|Drug|Cisplatin|"All participants will receive 40 mg/m2 of cisplatin intravenously over 60 minutes weekly during radiation therapy.~If cisplatin is not recommended by the treating medical oncologist or is not tolerated, it is permissible to switch to weekly Carboplatin AUC 1.5 and paclitaxel 45 mg/m2."
45347260|NCT01042717|Drug|Plerixafor|Plerixafor administered at 16 hours prior to apheresis
45841025|NCT00999102|Drug|Nebivolol|Nebivolol 5 mg, Nebivolol 10 mg.
45841026|NCT01000662|Radiation|Daily Radiation Therapy|15 daily radiation fractions of 2.7 Gy, Monday to Friday for 3 weeks, to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy). The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed.
45841027|NCT01000662|Radiation|Weekly Radiation Therapy|15 weekly radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed, for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy). The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed.
46043172|NCT00641914|Drug|budesonide|
46043173|NCT00641914|Drug|Placebo|
46043174|NCT02683408|Other|placebo|inactive placebo
46043175|NCT02683408|Dietary Supplement|diosmiplex|diosmiplex is an FDA regulated medical food product
46043176|NCT00640588|Drug|Telbivudine|Arm 1: 600 mg/day, oral telbivudina for 24 weeks
46043177|NCT00640588|Drug|oral adefovir|Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
46043178|NCT05663398|Drug|Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)|Oral, a nonsteroidal anti-inflammatory drug
46043179|NCT05663398|Drug|Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)|Oral, a nonsteroidal anti-inflammatory drug
46043180|NCT02683252|Other|T1 mapping and MR perfusion acquisition|One T1 mapping acquisition with variable flip angles will be performed before contrast injection. One perfusion 3D FSPGR sequence will be acquired after contrast injection
46043181|NCT02681926|Procedure|VISITAG|Paroxysmal atrial Fibrillation (PAF) ablation with contact force technology
46043182|NCT00640666|Behavioral|Exercise Behavior Change|Multidisciplinary
46043183|NCT02679352|Device|SMR Stemless|Total anatomic or reverse shoulder arthroplasty
46043184|NCT00640744|Drug|Atorvastatin|Atorvastatin 80 mg tablet/day for 3 months
46043185|NCT02678026|Device|Cervical pessary|Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early). Early in the pregnancy a round silicone pessary is placed at the opening to the cervix to close it, and then remove late in the pregnancy when the risk of a preterm birth has passed.
45347261|NCT00898768|Procedure|Capsule endoscopy|Capsule endoscopy at baseline and after 2 years
45347262|NCT03655561|Other|Non interventional research|Participants are receiving the standard of care according to Nigerian Center for Disease Control (NCDC) Standard Operating Procedures for Lassa fever case management. This include the administration of intravenous ribavirin for Lassa confirmed cases as well as critically-ill Lassa suspected cases.
46043186|NCT05663008|Procedure|128 electrode electroencephalography (EEG), Bipolar surface electromyography (sEMG), High-density electromyography (HD-EMG)|128 electrode EEG and 8 bipolar EMG or HD-EMG will be noninvasively recorded from electrodes placed in a montage over the scalp and arm muscles while the participant is resting or performing tasks designed to engage specific cortical networks of interest (cognitive, behavioural, motor and sensory)
46043187|NCT02678104|Procedure|Tooth extraction|Tooth removal
46043188|NCT02678104|Drug|Chlorhexidine mouth wash|Chlorhexidine mouth wash
46043189|NCT02678104|Drug|Intra-alveolar application of Manuka Honey|Intra-alveolar application of Manuka Honey directly after extraction.
46043190|NCT04183036|Procedure|Endoclip papillaplasty|Endoclip papilloplasty was performed to repair the Oddi sphincter using sterile repositionable hemostasis clipping device (Micro-tech (Nanjing), Co., Ltd.; stainless-steel). The operator positioned the clip and assessed the clip position and made sure the incision was clipped. Four to five endoclips were positioned in the incision in a zipper way from distal to proximal papillary sphincterotomy
46043191|NCT02681536|Drug|Triptorelin|
46043192|NCT02681536|Drug|Combined oral contraceptive pills|
46043193|NCT02681536|Drug|HMG|
46043194|NCT04183114|Biological|Measles-Rubella vaccine Bio Farma|MR vaccine produced by Bio Frama with 3 consecutive batches
46043195|NCT04183114|Biological|MR Vaccine SII|MR Vaccine produced by SII (Already registered in Indonesia)
46043196|NCT02681692|Device|Magnetic endoscopic imaging system|In the first part,patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system In the second part colonoscopist would be randomized to perform conventional colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
45841028|NCT01000818|Drug|MK0518 (Raltegravir)|400 mg oral tablet of MK0518 once every 12 hours. Period 1 duration is one day, Period 2 duration is one day, Period 3 duration is five days.
46043197|NCT00996996|Biological|Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)|"Dosimetric Dose: 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 mCi (35 mg) of Iodine-131 Anti-B1 Antibody infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush), immediately followed by the patient-specific milliCurie activity (35 mg) of Iodine-131 Anti-B1 Antibody to deliver a total body dose (TBD) of 75 cGy infused over 30 minutes (inclusive of a 10-minute flush). Obese patients were dosed based upon 137% of their calculated lean body mass."
45347263|NCT03516994|Behavioral|Respecting Choices First Steps|Advance Care Planning Approach
45347264|NCT03516994|Behavioral|Five Wishes Form|Advance Care Planning Approach
45347265|NCT03648385|Drug|DHEA tablet|DHEA tablet (50 mg) taken by mouth once a day for 18 weeks.
45475325|NCT03353662|Other|Women of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of West Gojjam between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
45841029|NCT01000818|Drug|famotidine|Single 20 mg famotidine oral tablet taken 2 hours prior to administration of AM dose of MK0518
46043198|NCT04182568|Drug|nab-paclitaxel followed by anthracycline and cyclophosphamide|nab-paclitaxel 260mg/m2 for every 2 weeks followed by anthracycline and cyclophosphamide
46043199|NCT04182568|Drug|Docetaxel followed by anthracycline and cyclophosphamide|Docetaxel 100 mg/m2 for for every 2 weeks followed by anthracycline and cyclophosphamide
46043200|NCT02681380|Other|Relation learning|Seven session are planned. Each will be supervised by a senior, trained to supervised Balint group.
46043201|NCT02681380|Other|Control group|No session will be planned for the participants.
45347266|NCT03648385|Other|Placebo|1 placebo tablet taken by mouth once a day for 18 weeks
45841030|NCT01000818|Drug|omeprazole|20 mg oral tablet of omeprazole, once daily for 5 days
45841031|NCT01001052|Drug|Colcrys™ (colchicine)|0.6 mg taken by mouth on day 1
45347267|NCT03506932|Dietary Supplement|Untreated|Bread made with 20% yellow pea flour that was untreated.
45347268|NCT03506932|Dietary Supplement|Heat treated with 0% moisture|Bread made with 20% yellow pea flour that was heat treated with 0% moisture.
45841032|NCT01001442|Drug|BT062|intravenous administration
45841033|NCT01002456|Other|Level 1: (provide site-specifi information)|provide site-specific information on non-adherence to guideline
46043202|NCT02681068|Other|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation (FMT) for patients with Clostridium difficile associated diarrhea
45475326|NCT03353662|Other|Children of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of West Gojjam between the age of 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
46043203|NCT02870868|Behavioral|Slow breathing|Slow breathing techniques from yoga
46043204|NCT04283682|Behavioral|Early skin-to-skin combined with breast-feeding|Premature infants in the intervention group have access to skin-to-skin once a day for 1 hour at least once no ventilation support needed. During the skin-to-skin period,the breastfeeding is encouraged for about 5-10 minutes. The whole intervention stop until the baby achieve the full oral feeding.
46043205|NCT04033744|Procedure|extraction of mandibular third molar|After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle. An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary
45475327|NCT03353662|Other|Women of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Kamashi between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
45684980|NCT04126564|Behavioral|Inner Engineering Online|Inner Engineering Online (IEO) is a web based intervention administered by the Isha Foundation, a not-for-profit, global, volunteer-based organization.The Inner engineering online program is a holistic tool for promoting well-being that teaches individuals how to mindfully and effectively respond to daily stressors using yogic sciences. The program offers guided meditation and yoga practices to promote harmonizing mind-body-emotion, and energy of the individual while simultaneously promoting mindfulness, joy, and vitality. It includes seven modules of 90 minutes each, discussing meditations & yoga.
45684981|NCT04126564|Behavioral|Reading a book/ journal|Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely.
45475328|NCT03353662|Other|Children of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Kamashi between 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
45841034|NCT01002456|Other|Level 2 (Provide site- and patient-specific information)|provide site-specific information on non-adherence to guideline as well as list of patients with non-adherent prescriptions
45841035|NCT01003080|Device|Aquamantys Device|The Aquamantys is used for hemostasis in patients randomized to receive total knee arthroplasty with the device.
46043206|NCT00628836|Device|BION stimulation|"The study will have two phases, each with a six week duration. During phase 1, the BION group will be implanted with BIONs in the middle deltoid and supraspinatus muscles. The muscles will be stimulated electrically by way of the BION and an external controller for one to two hours per day at 5pps in an on-off duty cycle train. The SE group will begin surface stimulation similar to that of BE group.~Subjects in either group whose initial therapy in phase 1 successfully reduces the amount of shoulder subluxation to 5mm or less will go off stimulation for six weeks, and be reassessed whether subluxation is redeveloping.~If a subject in either group does not respond sufficiently to phase 1 therapy, the participant will move to phase 2 where the shoulder will be stimulated at up to 25 pps either with surface stimulation (SE group) or BION stimulation (BE group) for another six weeks. At the end of phase 2, participants will go off stimulation for six weeks and then be reevaluated."
46043207|NCT02679196|Drug|KA2237|PI3 Kinase p110β/δ inhibitor
46043208|NCT00641368|Behavioral|R4Power Program|In the 10-lesson online R4Power Program, adolescents will learn cognitive skills (link between thoughts, feelings, and behaviors; thinking traps; challenging negative beliefs) and problem-solving skills (assertiveness; relaxation and distraction; overcoming procrastination; decision-making) in order to cope with stressful situations.
46043209|NCT00641368|Other|Waitlist Control|Adolescents in the waitlist control group will complete the R4Power program during the second year of the study.
46043210|NCT00641446|Drug|budesonide|
46043211|NCT00641446|Drug|varicella zoster virus|
45841036|NCT01003080|Other|Standard of care treatment for hemostasis during a total knee arthroplasty.|"The active comparator arm will receive the standard-of-care for hemostasis during total knee arthroplasty. This is achieved with a unipolar Bovie electrocauterization device."
46043212|NCT02677948|Drug|Pacritinib|
46043213|NCT02677948|Drug|Ibrutinib|
46043214|NCT02869854|Behavioral|Mindfulness|Mindfulness course during 8 weeks with 20 minutes mindfulness exercise each day
45841037|NCT01003938|Drug|Topotecan|
45841038|NCT01003938|Drug|Erlotinib|
45841039|NCT01004718|Radiation|Fludeoxyglucose F18|Undergo FDG PET/CT scans
45841040|NCT01004718|Procedure|Computed Tomography|Undergo FDG PET/CT scans
45841041|NCT01004718|Procedure|Positron emission tomography|Undergo FDG PET/CT scans
46043215|NCT02869854|Behavioral|PAP|Physical Activity on Prescription, after 3 months a new prescription
46043216|NCT02679430|Device|Prostate Arterial Embolization|The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms.
45841042|NCT01005576|Drug|Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan|Days -50 to -21: Hydroxyurea 30mg/kg po Day -22: Alemtuzumab 3mg IV Day -21: Alemtuzumab 10mg IV Day -20: Alemtuzumab 15mg IV Day -19: Alemtuzumab 20mg IV Day -8: Fludarabine 30mg/m2 IV Day -7: Fludarabine 30mg/m2 IV Day -6: Fludarabine 30mg/m2 IV Day -5: Fludarabine 30mg/m2 IV Day -4: Fludarabine 30mg/m2 IV Day -4: Thiotepa 8mg/kg IV Day -3: Melphalan 140mg/m2 IV Day 0: Stem cell infusion
45347269|NCT03506932|Dietary Supplement|Heat treated with 10% moisture|Bread made with 20% yellow pea flour that was heat treated with 10% moisture.
45347270|NCT03506932|Dietary Supplement|Wheat|Bread made with 100% wheat
45841043|NCT01005810|Drug|N-Acetylcysteine|1200 mg twice daily for 8 weeks
45841044|NCT01005810|Drug|placebo|2 capsules twice daily for 8 weeks
45841045|NCT01005810|Behavioral|Contingency Management|rewarding biologically verified marijuana abstinence during study visits, with an escalating reward schedule
45684982|NCT04126330|Dietary Supplement|Probiotic, Omega-3, Vitamin D supplement|"The first supplement we would like to assess is named VNP and is composed by Omega-3 Active and vitamin D. It contains a total of 1100 mg fish oils: 640 mg Omega-3 and with 300 mg eicosapentaenoic acid (EPA), 220 mg docosahexaenoic acid (DHA) plus 200 IU Vitamin D per daily dose (2 capsules).~The second supplement we investigate is four-strain probiotics combination based on the commercially available formulation HOWARU® by DuPont; two capsules containing 10 billion CFU total (supplied by Pfizer but manufactured by Danisco, DuPont). The probiotic specific composition, contains equal amounts of each strain per capsule (1.25 x 109 CFU each): Bifidobacterium lactis Bi-07, Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bl-04. One capsule contains 5 billion CFU (Swedish milliards)."
45684983|NCT04126330|Dietary Supplement|Placebo|Placebo generated for probiotic and omega-3/vitamin D supplements
45347271|NCT00738140|Behavioral|Diabetes Prevention Program|12-lesson program which will cover diet, exercise, and behavior modification.
45347272|NCT00625443|Drug|Blinded (placebo)|"Placebo Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
45347273|NCT00625443|Drug|Open Label (Avatrombopag tablets)|"Dose 10 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
46043217|NCT02681146|Other|Multimodal intervention|Educational advice + physiotherapist treatment
45841046|NCT01005888|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
45841047|NCT01005888|Drug|Placebo (saline)|
45841048|NCT01007136|Device|tDCS|1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.
45841049|NCT01007136|Device|Sham tDCS|Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
45347274|NCT00625443|Drug|Blinded (Avatrombopoag tablets)|"Dose: 2.5, 5, 10, or 20 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
45684984|NCT04126720|Dietary Supplement|topical corticosteroids and vitamin E suplements|
45684985|NCT04126720|Drug|Topical corticosteroid and placebo capsules|
45841050|NCT01007526|Other|CCRT followed by VIDL chemotherapy|CCRT followed by VIDL chemotherapy concomitant chemo-radiotherapy followed by VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy with risk-based application of autologous stem cell transplantation
46043218|NCT02679118|Device|Sentire|The device, at predetermined time points, will draw a small amount of gas from the abdomen. Upon obtaining the samples, the machine will analyze the sample for evidence of bowel gas. After each sample, the device will be purged prior to the acquisition of the next gas sample. The results of the analysis of the gas samples will be recorded for future analysis.
46043219|NCT00641524|Procedure|Phlebotomy|Phlebotomy involves the removal of blood (approximately 500mL) each week until body iron levels reach the low-normal level
46043220|NCT02679040|Procedure|Immediate mammary reconstruction|Chemotherapy administration then radiotherapy and then surgery : mastectomy and immediate mammary reconstruction.
46043221|NCT02679040|Drug|Chemotherapy|Chemotherapy treatment
45684986|NCT04126252|Drug|Sildenafil Citrate 50Mg Tab|The Group A received sildenafil citrate 50 mg on demand for a period of max 3 months.
46043222|NCT02679040|Radiation|Radiation therapy|Radiation therapy
46043223|NCT02677636|Drug|MSRD-100|MSRD-100 is a topical gel.
45684987|NCT04126252|Behavioral|Cognitive Behavioral Psychotherapy|The Group B received cognitive behavior psychotherapy for a period of max 3 months.
45684988|NCT04126252|Combination Product|Combined or Integrated Therapy|The Group C received the combined therapeutic approach for a period of max 3 months.
45684989|NCT04126252|Other|Placebo|The Group D received no treatment or placebo for a period of max 3 months.
45684990|NCT04125940|Dietary Supplement|Resync|The product known as Resync contains a blend of nitrate-rich foods including beetroot, red spinach, turmeric, ginger root, and aronia berry extracts. Resync is sold commercially and marketed as an ergogenic aid and/or exercise recovery aid.
45684991|NCT04125940|Dietary Supplement|Resync + Collagen|17g Collagen + 2g Resync + 1g Carbohydrate
45684992|NCT04125940|Other|Placebo|12oz water + food coloring
46043224|NCT02677636|Drug|Vehicle|Vehicle is a topical gel without the active ingredients in MSRD-100
45347275|NCT00898846|Drug|UFT adjuvant chemotherapy|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
45475329|NCT05195229|Device|COVID-19 Aerosol Collection|"Step 1: A nasal and oral swab will be obtained to establish the nasopharyngeal viral load.~Step 2: Study staff will use the CCI and/or UPAS to collect aerosol samples for viral load. Staff will sample the room aerosol for 30 minutes while the participant does not wear a mask, and then if the participant is interested, staff will sample room aerosol while the participant wears different types of masks. If the participant does not tolerate wearing a surgical mask, or if the providers believe this is contraindicated, researchers will forego this portion of the study procedures. If an accompanying family member chooses to stay in the patient room during testing, they will be provided with an N95 respirator."
45475330|NCT03349606|Drug|d-amphetamine|oral d- amphetamine 0.5 mg/kg is used to stimulate dopamine release in the brain
45475331|NCT03349606|Radiation|[C-11]FLB 457|PET radiotracer
45475332|NCT02843451|Drug|Milk Thistle|
45841051|NCT01007994|Drug|New Medication: Enalapril, Isradipine, Propranolol|"Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.~Dosing will be as follows:~ACEI: Enalapril < 40 kg starting dose 2.5 mg titrate to 5 mg > 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine < 40 kg 2.5 mg > 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol <40 kg starting dose 10 mg titrate to 20 mg >40 kg starting dose 20 mg titrate to 40 mg"
46043225|NCT02678962|Device|SN6AD1|Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
46043226|NCT02678962|Device|SBL-3|Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
45347276|NCT00920894|Dietary Supplement|plant stanol ester|the effect of plant stanol esters on plasma lipids
45347277|NCT00824343|Drug|P276-00|For patients to be recruited in amended protocol, P276-00 will be administered to all subjects at a dose of 144 mg/m2/day as i.v infusion in 200 ml of 5% dextrose over 30 minutes from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle. Subjects will receive treatment till progression of disease or till unacceptable toxicity. All subjects will be followed up for survival status till one year of initiation of protocol treatment.
45347278|NCT00895102|Drug|ABT-333 Tablet|See Arm Description for more information.
45347279|NCT00895102|Drug|Placebo|See Arm Description for more information.
45347280|NCT00895102|Drug|ABT-333 Capsule|See arm description for more information
45347281|NCT00820287|Procedure|Biopsy of testicular tumor|testicular biopsies performed through open surgery
45475333|NCT02843451|Drug|Placebo|
45475334|NCT03353506|Biological|LFMT|Lyophilized fecal microbiota transplant
45475335|NCT03353506|Biological|LSFF|Lyophilized sterile fecal filtrate
45841052|NCT01008462|Procedure|Allogeneic Bone Marrow Transplantation|Undergo donor HCT
45841053|NCT01008462|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo donor HCT
45841054|NCT01008462|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
45841055|NCT01008462|Procedure|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-donor tandem HCT
45841056|NCT01008462|Drug|Carmustine|Given IV
46043227|NCT02678962|Device|LS-313 MF30|Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
46043228|NCT02678962|Device|AT LISA tri 839 MP|Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
45347282|NCT04035148|Diagnostic Test|Cardiopulmonary exercise test|we prepared incremental treadmill exercise protocol in which the work rate increased at one-minute intervals.Transthoracic Echocardiography(TTE) : The first step non-invasive method to diagnose PHT.
46043229|NCT02678962|Device|ART|Bilateral cataract surgery with implantation of ART toric multifocal IOLs
45347283|NCT00826371|Drug|ranibizumab 0.5 mg|
45347284|NCT00824499|Other|Complex regional intervention|"Components of the complex intervention:~Introduction of a program coordinator~Introduction of a self-management education program~Bottom up development of a interdisciplinary care protocol~Support program for the intiation of insulin therapy in primary care~Regional audit"
45347285|NCT02540824|Drug|Apatinib single agent arm|For RET-fusion positive advanced NSCLC patients who failed to previous treatment,treat with apatinib, single agent, 750mg once daily, p.o until disease progression
45347286|NCT02540122|Device|Marketed Contact Lens 1|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
45347287|NCT02540122|Device|Marketed Contact Lens 2|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
45347288|NCT02540122|Device|Marketed Contact Lens 3|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
45475336|NCT03854045|Other|Telepsychiatry|Receive telepsychiatry with clinician obtaining initial data and presenting it to the psychiatrist
45475337|NCT03349372|Procedure|Hematopoietic stem cell transplantation|Hematopoietic stem cell transplantation
45475338|NCT01183091|Procedure|Ablation of atrial fibrillation|Ablation of atrial fibrillation
45475339|NCT01292525|Drug|Tacrolimus|"A control group continued conventional therapy, Tacrolimus (Prograf®) (control group) and will be followed in parallel group withdrawal that will stop treatment with Tacrolimus (Prograf®)."
45841057|NCT01008462|Drug|Cyclophosphamide|Given IV
45841058|NCT01008462|Drug|Cytarabine|Given IV
45841059|NCT01008462|Drug|Etoposide|Given IV
45841060|NCT01008462|Drug|Fludarabine Phosphate|Given IV
46043230|NCT02678962|Device|LS-313 MF30T|Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
46043231|NCT05663164|Drug|Vitamin B|vitamin B1 (100mg) will be diluted in 50 ml 0.9% NACL(normal saline) and administered IV every 6 hours for 3 days
45347289|NCT02540122|Device|Marketed Contact Lens 4|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
45347290|NCT02540590|Device|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
45347291|NCT02540590|Device|wound fluid measurement|Wound fluid at the gingival sulcus was volumetrically measured by Periotron 8000 instrument using filter strip
46043232|NCT05663164|Drug|Placebo|Normal saline (0.9% NaCl solution) volume to match all components
46043233|NCT02677558|Other|Transthoracic Echocardiography|Obese term pregnant women and term pregnant women of normal weight are both undergoing transthoracic echocardiography assessment to establish differences in cardiac function in pregnancy caused by obesity.
46043234|NCT00643318|Radiation|CyberKnife Stereotactic Radiosurgery|"Central tumors defined as < 2 cm from carina and < 2 cm from right and left mainstem bronchus and/or < 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus, and the right and left lower lobe bronchus. For central tumors, 4 fractions of 12 Gy will be delivered (12 Gy x 4 fractions = 48 Gy)~Peripheral tumors are defined as being > 2 cms from the carina and > 2 cms from the right and left mainstem bronchus and/or > 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus and the right and left lower lobe bronchus. For peripheral tumors, 3 fractions of 20 Gy will be delivered (20 Gy x 3 fractions = 60 Gy)"
46043235|NCT02537470|Drug|Biphasic Remogliflozin Etabonate|Experimental Drug
45347292|NCT00826527|Drug|Solifenacin PO|Tab 5 mg Daily for 12 Weeks
45347293|NCT00898924|Genetic|molecular diagnostic method|
45347294|NCT00898924|Genetic|mutation analysis|
45347295|NCT02550717|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Low-dose ASA for secondary prevention of cardiovascular events
45347296|NCT02550717|Drug|Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs|Secondary prevention of cardiovascular events
45347297|NCT00820365|Drug|SC12267 (4SC-101)|Peroral administration of SC12267 (4SC-101) in patients with Inflammatory Bowel Disease over 12 weeks.
45347298|NCT00895258|Behavioral|Individual placement and support plus cognitive training (IPS-CT)|One IPS plus one CT session each week for 12 weeks
45841061|NCT01008462|Other|Laboratory Biomarker Analysis|Correlative study
45841062|NCT01008462|Drug|Melphalan|Given IV
45841063|NCT01008462|Drug|Mycophenolate Mofetil|Given PO
45841064|NCT01008462|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo donor HCT
45841065|NCT01008462|Drug|Tacrolimus|Given IV or PO
45841066|NCT01008462|Radiation|Total-Body Irradiation|Undergo TBI
46043236|NCT02537470|Other|Placebo|Placebo Comparator
45475340|NCT01292525|Drug|Placebo|"Patients randomized to the withdrawalgroup will begin the protocol with their usual dose of Tacrolimus (Prograf®) (initial dose). The initial dose of tacrolimus (Prograf®) will be reduced by one third at visit 3 (day 0) and again a third visit 5 (J60). The complete withdrawal Tacrolimus (Prograf®) begins to visit 7 (J120). The withdrawal of Tacrolimus (Prograf®) will be obtained in four months. Monitoring of all patients lasted 17 months in total from the screening visit, which corresponds to 12 months after complete withdrawal of Tacrolimus (Prograf®) for patients in the withdrawal group."
45347299|NCT00895258|Behavioral|Individual placement and support plus enhanced support (IPS-ES)|One IPS plus one ES session each week for 12 weeks
45475341|NCT03355222|Behavioral|Promotion of chicken eggs|Community is provided with chickens and young children are to receive one egg a day; selected mothers will consume eggshell.
45475342|NCT03851861|Other|Mediterranean Diet|"Participants will be instructed to include the following in their diet: a) abundant use of olive oil for cooking and dressing dishes; b) consumption of ≥2 daily servings of vegetables; c) ≥2-3 daily serving of fresh fruits (including natural juices); d) ≥3 weekly servings of legumes; e) ≥3 weekly servings of fish or seafood (at least one serving of fatty fish); f) ≥3 weekly serving of nuts or seeds; g) select white instead of red meats or processed meats (burgers, sausages); h) cook at least twice a week with a tomato herb sauce.~Participants will be instructed to eliminate or limit the consumption of the following foods: cream, butter, margarine, cold meat, paté, duck, carbonated and/or sugared beverages, pastries, industrial bakery products and desserts, French fries or potato chips, and out-of-home pre-cooked cakes and sweets. For usual drinkers, the main source of alcohol should be wine."
45475343|NCT01189019|Drug|ranibizumab|2mg intravitreal injection monthly
45841067|NCT01010568|Drug|Ofatumumab and Bendamustine|Ofatumumab 300-mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 6 cycles Bendamustine 70 mg/m2 IV on days 1 and 2 of each cycle for 6 cycles
45841068|NCT01011816|Biological|BIOSTAT BIOLOGX|One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device
45841069|NCT01011816|Drug|Saline|One injection of up to 4 mL of saline using the Biostat Delivery Device
46043237|NCT02678728|Drug|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion until 12 hrs of aortic cross clamp off
46043238|NCT02678728|Drug|normal saline|IV loading and infusion of same volume of normal saline after induction until 12 hrs of aortic cross clamp off
46043239|NCT04180072|Drug|Atezolizumab|Atezolizumab 1200 mg IV on day 1 every 3 weeks
46043240|NCT04180072|Drug|Bevacizumab|Bevacizumab 15 mg/kg IV on day 1 every 3 weeks
46043241|NCT02678806|Radiation|Postoperative radiotherapy|The radiotherapy group received prophylactic radiotherapy 1 month after operation. All the patients in the experimental group were treated with 6 to 8 MV X-ray, intensity-modulated irradiation (IMRT) technique, which was divided into 4-5 fields, 2Gy/25 times. 5f/W, total dose 50Gy
45347300|NCT02550249|Drug|Nivolumab|Intravenous administration of nivolumab
45347301|NCT00824811|Drug|Cyclosporine Eye Drops (Restasis)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
45347302|NCT00824811|Drug|Lubricant Eye Drops (Refresh Endura™)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
45347303|NCT00824811|Drug|Fluorometholone Eye Drops (FML Forte®)|"Week 1: One drop four times a day to both eyes.~Week 2: One drop three times a day to both eyes.~Week 3: One drop twice a day to both eyes.~Week 4: One drop once a day to both eyes.~Wait at least 10 minutes after Restasis® or Refresh Endura™ instillation to instill FML Forte®."
45347304|NCT00625365|Drug|DEFINITY®|DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert
45347305|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
45347306|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
45475344|NCT01189019|Drug|ranibizumab|2mg monthly x 3 doses, then as needed based on recurrence of activity on OCT
45347307|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
45347308|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
45347309|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
45475345|NCT04515862|Other|Breastfeeding education|The importance of breastfeeding Benefits of breastfeeding for mother and baby Structure of the breast and milk production Breastfeeding techniques and positions Breastfeeding problems and breast care
45475346|NCT01183247|Drug|Rapamycin|Add rapamycin de novo to tacrolimus and MMF
45475347|NCT01183247|Drug|Everolimus|Add everolimus de novo to tacrolimus and MMF
45475348|NCT01183247|Drug|Prednisone|Add prednisone de novo to tacrolimus and MMF
45347310|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
45347311|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
45347312|NCT00824967|Other|Training and valuation of the treating personnel|Training and valuation of the treating personnel
45347313|NCT00820521|Drug|active|
45347314|NCT00820521|Drug|placebo|
45347315|NCT00606580|Drug|WR 279,396 topical cream|WR 279,396 is a topical antibiotic cream containing 15% paromomycin and 0.5% gentamicin that will be applied to each lesion once a day and covered with a sterile gauze and tape dressing.
46043242|NCT02678806|Drug|Postoperative TACE|In the intervention group, TACE was performed in January and March after operation. The femoral artery puncture was performed by Seldinger method, and the cannula was intubated to the hepatic artery by DSA. Then, 50 mg of lobaplatin plus 4 mg of raltitrexed was injected into the vascular artery. The embolic agent was selected as 38.0. % super liquefied iodine solution and / or gelatin sponge particles, the dose is maintained at 5 ~ 20ml. At the end of treatment, a DSA examination again confirmed that the tumor was completely occluded.
46043243|NCT02676076|Drug|CHF 5993 100/6/12.5 µg|
46043244|NCT02676076|Drug|CHF 1535 100/6 µg|
45475349|NCT04515082|Diagnostic Test|Stool-based SDC2 and SFRP2 DNA methylation test|A diagnostic device measuring syndecan 2 (SDC2) and secreted frizzled-related protein 2 (SFRP2) methylation status in stool DNA to detect colorectal cancer
45475350|NCT04515082|Diagnostic Test|FIT|Fecal immunochemical test
46043245|NCT02537626|Device|Erchonia ALS Laser|The Erchonia ALS Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. The total energy delivered to the subject per procedure administration is 22.5 joules.
46043246|NCT02537626|Device|Placebo Laser|The Placebo Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. There is no energy delivered to the subject.
45475351|NCT03853967|Other|Low dose CT scan|low dose CT scan
45841070|NCT01011894|Drug|lenalidomide|Lenalidomide will be administered orally at a starting dose of 2.5mg once daily, days 1-28. Patients will be evaluated prior to treatment and at 4 weeks, 8 weeks, 12 weeks, 16 weeks and at a minimum of 4 weeks thereafter until removal from study. Patients with stable disease or better will continue at their current dose unless they experience toxicity requiring dose reduction. For those patients who have progressive disease on their current dose and have no dose-limiting toxicity, their dose will be increased from 2.5mg, to 5mg, to 10mg, to 15mg, to 20mg one dose level at a time not more frequently than once every 4 weeks. The maximum dose will be 20mg.
45841071|NCT01012362|Drug|Pazopanib|Escalating doses 400-800 mg by mouth once daily beginning day 1 and continuing.
45841072|NCT01012362|Drug|Ixabepilone|Escalating doses 25-32 mg/m2 by intravenous infusion on day 1 of each 21 day cycle
46043247|NCT04181554|Other|Measurement of postural stability|The postural stability will assess by using Biodex balance system.
45841073|NCT01012674|Drug|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
45841074|NCT01012674|Other|TOF MRA|Each subject will undergo a Time Of Flight Magnetic Resonance Angiography (TOF MRA)
46043248|NCT02678650|Drug|volatile anesthetics(isoflurane)|volatile anesthetics wash-in / wash-out operation
46043249|NCT02678650|Drug|propofol intravenous anesthesia|propofol infusion 3-5μg / kg / h
46043250|NCT04180150|Drug|TQ-A3334|TQ-A3334 is a kind of TLR7 receptor agonist.
45347316|NCT00606580|Drug|Paromomycin Alone topical cream|The antibiotic paromomycin 15% in the same topical cream used in arm 1 will be applied to lesions daily and covered with a protective sterile gauze and tape dressing.
45841075|NCT01013844|Behavioral|Skin Self Examination Information and ABCDE Rule|Card with condensed information about skin self examination (SSE) and color illustrations of the ABCDE (asymmetry of shape, border irregularity, color variation, diameter > or equal to 6 mm, and evolution of the lesion) rule. A research assistant gave a skill demonstration using a magnifying lens.
45841076|NCT00986544|Procedure|no drain|drain positioned on the skin
45841077|NCT00986544|Procedure|drain positioned|drain positioned in the subhepatic space
46043251|NCT04180150|Drug|Placebo|Placebo is a treatment which is designed to have no therapeutic value.
45347317|NCT00606580|Drug|Vehicle placebo cream|Applied daily to cutaneous leishmaniasis lesions, primarily ulcerative, and covered with a protective, sterile gauze and tape dressing.
45347318|NCT04543539|Combination Product|IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort|For the treatment of obstructive lesions up to 100 mm in length in the native arteriovenous dialysis fistulae with reference vessel diameters of 4 to 12 mm.
45347319|NCT04543539|Combination Product|IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort|For treatment of stenosis in the AV circuit
46043252|NCT04180150|Drug|Entecavir Tablet|Entecavir (ETV) tablet is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection.
46043253|NCT00643396|Radiation|thoracic radiotherapy|
46043254|NCT02678338|Drug|Hu5F9-G4|
46043255|NCT00642226|Procedure|Grid Laser|ETDRS Grid Laser
46043256|NCT00642226|Procedure|Vitrectomy and 20 mg triamcinolone|Pars plana vitrectomy is followed by an injection of 20 mg purified triamcinolone acetate
46043257|NCT02675608|Biological|Influenza Virus Vaccine|On the first visit, subjects are vaccinated with the 2015-2016 seasonal flu vaccine.
46043258|NCT02678494|Other|Neurofeedback training|
45347320|NCT00826683|Biological|Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures|
46043259|NCT05511610|Procedure|Sevoflurane uptake and supply|"Phase sevo 1)~Moment 1 (M1): from OTI until end-tidal sevoflurane (etSEVO%) exceeds ettSEVO% by 10%. Deliver of sevoflurane to the system (SEVOdel) carried out by completely opening sevoflurane vaporizer (8%).~M2) once etSEVO% surpass ettSEVO% by 10%: turn off sevoflurane vaporizer and observe the progressive fall etSEVO%. When etSEVO% approaches ettSEVO% (0.1-0.2 points above ettSEVO%), the investigators will turn on the sevoflurane vaporizer following the MAAS method to ensure stability in inspired and expired concentrations of sevoflurane.~Phase sevo 2) Objective: to maintain etSEVO% = ettSEVO% ±5% When the etSEVO% increases above the mentioned levels >> reduce SEVOdel by 0.25-0.5%.~When the etSEVO% decreases below the mentioned levels>> increase SEVOdel by 0.25-0.5%."
46043260|NCT05511610|Procedure|Washout phase|The investigators will close the sevoflurane vaporizer and will start the administration of Propofol in intravenous perfusion; the investigators will then open the FGF sequentially at 2>5>10 liters per minute (LPM), until the etSEVO% is <0.2 MAC.
45347321|NCT00899002|Genetic|comparative genomic hybridization|
45347322|NCT00899002|Genetic|molecular genetic technique|
45347323|NCT00899002|Genetic|mutation analysis|
45347324|NCT00899002|Genetic|polymerase chain reaction|Not noted
45347325|NCT00899002|Genetic|proteomic profiling|
45347326|NCT00899002|Other|immunohistochemistry staining method|not noted
45347327|NCT00899002|Other|laboratory biomarker analysis|not noted
45475352|NCT04514146|Other|Water-only fasting|In-patient water-only fasting for at least 10 days followed by at least 5 days of refeeding
45841078|NCT00986544|Procedure|drain not positioned|Drain positioned in the abdominal wall
46043261|NCT05511610|Procedure|Desflurane uptake and supply|"Phase desflu 1)~Moment 1 (M1): from the end of Washout phase until end-tidal desflurane (etDESFLU%) exceeds ettDESFLU% by 10%. Deliver of desflurane to the system (DESFLUdel) carried out by completely opening the desflurane vaporizer (18%).~M2) once etDESFLU% surpass ettDESFLU% by 20%: turn off the desflurane vaporizer and observe the progressive fall etDESFLU%. When etDESFLU% approaches ettDESFLU% (0.8-1.2 points above ettDESFLU%), the investigators will turn on the desflurane vaporizer following the MAAS method to ensure stability in inspired and expired concentrations of desflurane.~Phase desflu 2) Objective: to maintain etDESFLU% = ettDESFLU% ±5% When the etDESFLU% increases above the mentioned levels >> reduce DESFLUdel by 0.25-0.5%.~When the etDESFLU% decreases below the mentioned levels>> increase DESFLUdel by 0.25-0.5%."
46043262|NCT05511610|Procedure|Final phase|"From the end of Phase desflu 2 until the end of the intervention. Maintenance of anesthesia with desflurane following the principles of MAAS Method.~Between 15-20 minutes before the end of the intervention, the investigators will stop the administration of desflurane, registering the time until the reaching etDESFLU% < 0.2 MAC."
46043263|NCT02677402|Other|immersion|
45347328|NCT00899002|Other|mass spectrometry|not noted
45347329|NCT00899002|Other|medical chart review|not noted
45347330|NCT02550327|Drug|Nab-paclitaxel|125 mg/m2
45347331|NCT02550327|Drug|Gemcitabine|1000 mg/m2
45347332|NCT02550327|Drug|Cisplatin|25 mg/m2
45347333|NCT02550327|Drug|Anakinra|100 mg
45347334|NCT00881998|Procedure|Minimally Invasive Total Hip Arthroplasty|
46043264|NCT02677480|Dietary Supplement|Test group, probiotic tablets and gel|Effect of probiotic tablets and gel on acidogenic bacteria
46043265|NCT02677480|Dietary Supplement|Placebo group, placebo tablets and gel|Effect of placebo tablets and gel on acidogenic bacteria
46043266|NCT00996918|Drug|Bapineuzumab 0.5 mg/kg|Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
46043267|NCT00996918|Drug|Bapineuzumab 1.0 m/kg|I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.
46043268|NCT02675530|Drug|ketamine|"For healthy volunteer arm of study, NMDA antagonist ketamine will be administered. 0.23 mg/kg over 1 minute, followed by 0.58 mg/kg/hour for 30 minutes, followed by 0.29 mg/kg/hour for 50 minutes.~No drug administration for patients with schizophrenia"
45347335|NCT00881998|Procedure|Conventional Total Hip Arthroplasty|
45475353|NCT03853889|Procedure|USG guided ONSD measurement preepidural|Measurement of the diameter of the optic nerve sheath preepidural and postepidural anesthesia
45475354|NCT03353428|Biological|LC-CTLs|2 to 4 infusions, once a week, for 1x10^5~4x10^6 CTLs/kg via IV, chest or tumor injection each time
45475355|NCT01183325|Device|Proceed Ventral Patch placement|Placement of a Proceed Ventral Patch for umbilical and small ventral hernias less than 3cm diameter with and without laparoscopic control
45475356|NCT03170193|Drug|AMG 529|Ascending single doses of AMG 529 by subcutaneous (SC) or intravenous (IV) injection
45475357|NCT03170193|Drug|Placebo|Single doses of matching placebo by SC or IV injection
45841079|NCT01014390|Device|WallFlex Biliary RX Fully Covered Stent System|Temporary placement of a biliary stent as a treatment of biliary obstruction resulting from benign bile duct strictures. The stent is fully covered with a silicone polymer to reduce the potential of tissue ingrowth into the stent. The stent is removed after 5 months (±1 month) after stent placement in Post-Liver Transplant patients and after 11 months (±1 month) in Chronic Pancreatitis and Post-Abdominal Surgery patients.
45841080|NCT01015170|Drug|bupropion HCl|150mg BID for up to 8 weeks + counseling
45841081|NCT01015326|Other|Questionnaire|Administered questionnaire
45475358|NCT03349216|Procedure|Intravenous Regional Anesthesia|in this research patients will receive intravenous regional anesthesia as infusion of mini dose (that is 1.5 mg/kg ) lidocaine 0.5% and immediately after procedure their torniquettes (A.T.S. 2000, Zimmer, Inc., Bloomfield, CN) will be deflated (hence named Rapid MiniBier's block). the pain score will be assessed by NRS system before during and after the procedure.
45347336|NCT00825045|Drug|risperidone|Following the baseline clinical and cognitive assessments, risperidone will be initiated at 0.5-1.0 mg/day and subsequently increased by 0.25 - 1.0 mg on a weekly basis with the target of clinical stabilization (i.e. 20 or more % reduction in the total BPRS score) until a maximum dose of 4.0 mg/day is reached. To achieve this, a weekly assessment with BPRS will be performed. Physicians-of-record will be closely liaised with investigators. Dosage modification will be performed following this dosing schedule, however, this can be changed by treating physicians to meet clinical necessity. For example, in case psychotic symptoms are not controlled by this dosing schedule, facilitated dose increment will be allowed.
45475359|NCT03349216|Drug|Systemic Analgesia|in this group the patients will receive ketamine 1-2 mg/kg IV slow ( Bioniche,Ireland Ketamine Hydrochloride 500mg/10cc)and titrated to effect. again here the pain score will be assessed before procedure and after the procedure every 5 minutes until 30 minutes by NRS ( Numerical Rating Score)
45475360|NCT04507750|Drug|Camrelizumab|Carmelizumab: Intravenous infusion of a fixed dose of 200 mg in 30 minutes (not less than 20 minutes, not more than 60 minutes), once every 3 weeks, continuous administration until the disease progresses, the patient If death or intolerable toxicity occurs, medication for up to 1 year; Apatinib mesylate tablets: The initial dose is 250 mg, administered once a day, and continue to be administered. If there is a grade 3 to 4 adverse reaction, it should be administered once every other day.
45475361|NCT03355144|Dietary Supplement|Daily Supplementation with Coffee|"At the beginning of study week 2 (study day 8), two coffee machines (one Nespresso Inissia and one Hamilton Beach 46205 12 Cup Programmable Coffee Maker) will be installed in the resident work rooms at each site.~Subjects will be provided with free coffee beans, milk, cream, sugar and sweetener"
45475362|NCT05173077|Procedure|Identification of specific VOCs in CRC tissue surgery material|Paired tissue samples will be taken during surgery for CRC. Tissue material from the same patient will be obtained from the cancerous tissue as well as from normal resected material without malignant infiltration. Minimum of 100 mg of each tissue per sample will be obtained. To compare the emission of VOCs in the CRC tissue surgery material to the emissions from normal tissue by GC-MS in a reasonable number of cancer cases.
45841082|NCT01015326|Other|Questionnaire|Administered questionnaire
45841083|NCT01016106|Genetic|Buccal Swab|During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT laboratories in Lenexa, Kansas.
45841084|NCT01016652|Device|etafilcon A multifocal contact lens|low-add multifocal contact lens
45841085|NCT01016652|Device|etafilcon A Contact Lens|standard sphere contact lens
45841086|NCT01017042|Drug|colchicine tablets|colchicine 1.2mg initially; then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
45841087|NCT01018056|Drug|D-serine|The dosage schedule will be flexible with a maximum dose for each subject being 30 mg/kg/day. In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of capsules labeled as study drug, but containing either 250 or 500 mg tablets of D-serine or placebo; capsule content to be determined by patient's weight. No changes in dosage will be made during the final week of treatment.
46043269|NCT04179994|Other|Miswak extract-containing toothpaste|Miswak extract-containing toothpaste will be applied to the tooth diagnosed with DH
46043270|NCT04179994|Other|Potassium nitrates-containing toothpaste|Potassium nitrates-containing toothpaste will be applied to the tooth diagnosed with DH
46043271|NCT04179994|Other|Placebo|A toothpaste containing the same ingredients of the test toothpaste except for the active ingredient
45347337|NCT00895336|Biological|Lactobacillus GG|1 capsule taken twice daily for a minimum of 28 days to a maximum of 35 days.
45347338|NCT00899080|Genetic|gene expression analysis|
45347339|NCT00899080|Genetic|reverse transcriptase-polymerase chain reaction|
45347340|NCT00899080|Other|immunoenzyme technique|
46043272|NCT04179916|Diagnostic Test|stimulation in virtual reality|"HTC VIVE pro was used to stimulate patients in virtual reality. The glasses enable high resolution and high fluidity (90Hz) images to be displayed. The display used inside the glasses, OLED class, allows for accurate color replication. Numerous sensors placed in the glasses (such as gyroscope, accelerometer, magnetometer) supported by dedicated processors processing data from the sensors, instantly transfer the movement of the head of the rehabilitated person to virtual reality. Such a set allows to achieve full immersion in the virtual world. Various scenarios will be presented during the stimulation, such as beach, snow landscape, darkened room, rollercoaster ride.~It was planned to submit 3 scenarios with a total stimulation time of up to 20 minutes."
45841088|NCT01018056|Drug|Riluzole|The starting dose of riluzole will be 50 mg for one week; administered as one capsule (50) every morning. Dosage schedules will be flexible. If needed for tic suppression, the dose will be increased weekly by 50 mg and given in BID doses. The maximum dose will be 200 mg/day (administered as 2 capsules BID). In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing placebo capsules. No changes in dosage will be made during the final week of treatment.
45841089|NCT01018056|Drug|Placebo|Placebo tablets will be formulated in look-alike capsules. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing additional placebo capsules.
46043273|NCT02675374|Drug|dexchlorpheniramine (Polaramine®) injection|5 minutes before CPB, patients will receive 10 mg (2 ml) of Polaramine®
46043274|NCT02675374|Drug|Placebo injection|5 minutes before CPB, patients will receive 2 ml of normal saline
46043275|NCT05662930|Behavioral|First arithmetic problem solving|"In a quiet environment, a white paper in A4 format was placed in front of the patient on the table, and the patients were asked to subtract the number 3 from 2907 for 100 seconds.~The researcher was standing in front of the patient and asks to make corrections by giving a warning whenever the patient made a mistake in the calculation."
46043276|NCT05662930|Behavioral|Second arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the first subtraction process, patients were asked to subtract 7 from 6828 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
45347341|NCT00899080|Other|laboratory biomarker analysis|
45347342|NCT00899080|Other|platelet aggregation test|
45347343|NCT02550015|Behavioral|High intensity interval training|Uphill treadmill walking
45347344|NCT02550015|Behavioral|General information|Standard care
45347345|NCT00826761|Dietary Supplement|probiotic|One capsule per meal test (high dose or low dose)
45347346|NCT00826761|Dietary Supplement|placebo|1 capsuel every morning
45347347|NCT03855969|Procedure|Removal of a central venous access device|We are interested in those patients for which a central venous access device was removed.
46043277|NCT05662930|Behavioral|Third arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 13 from 9561 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
46043278|NCT05662930|Behavioral|Fourth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 8 from 5113 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
46043279|NCT05662930|Behavioral|Fifth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 14 from 8318 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
45347348|NCT00820677|Behavioral|DVD/Video|One DVD or Video will be watched by all parents of newborns enrolled into the experimental group.
45347349|NCT00629265|Device|Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)|NMES or Sham NMES will be paired with repeated, effortful swallowing behavior, for 60 swallows, 2 times a day, 6 days a week, for 12 weeks.
45347350|NCT00606502|Drug|Pralatrexate|"Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 230 mg/m2, increased to 270 mg/m2 if patient does not have specific adverse events (AEs) as per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/m2 decrements to 190 mg/m2 per the protocol defined dose modifications.~Protocol amended dose: 190 mg/m2, then 230 mg/m2 if patient does not have specific AEs per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/2 decrements to 150 mg/m2 per the protocol defined dose modifications.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
45347351|NCT00606502|Drug|Erlotinib|"150 mg orally in tablet form~Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met."
45347352|NCT00606502|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of randomization, every 8-10 weeks throughout the study and for at least 30 days after last dose of study treatment."
45475363|NCT05173077|Other|Secondary validation study in general CRC screening settings|"Altogether at least 1000 individuals relatively healthy 40-64 years old population-based collected individuals will get recruited. Breath samples will be collected by asking the study subjects to breath into hybrid breath analyser.~To exclude significant colorectal lesions, laboratory-based FIT testing will be offered to the population cohort group for faecal occult blood in faeces. Serum and plasma samples will also be obtained to have them available if additional testing will be required. Individuals with a FIT test value over the cut-off value (>10 microg/g faeces) will be invited to colonoscopy. The data analysis procedures and classification models will be tested in this general population and cross-checked against FIT and colonoscopy results."
45475364|NCT05173077|Device|Breath sampling for VOC detection|Breath sampling will be performed by using a hybrid sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Strict requirements for subjects will be imposed prior to the breath sampling to standardise the breath sampling and to limit the influence of confounding factors.
45841090|NCT01018134|Drug|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered to affected area once daily for 28 days
46043280|NCT05662930|Behavioral|Sixth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 17 from 9994 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
45347353|NCT00606502|Dietary Supplement|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to randomization, throughout the study and for at least 30 days after last dose of study treatment."
45347354|NCT02549625|Biological|Autologous Bone Marrow-derived Mononuclear Cells|
45347355|NCT00825123|Drug|Ivabradine|Ivabradine 10 mg once
45347356|NCT00825123|Drug|Metoprolol|Metoprolol 50 mg once
45841091|NCT01018134|Drug|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered to affected area twice daily for 28 days
46043281|NCT02678260|Drug|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1.
46043282|NCT02677168|Device|cNEP|continuous negative external pressure
46043283|NCT04181398|Diagnostic Test|Anthropometry|"Actual Height and weight~Calculated BMI from measured weight and height.~Pubertal development (Tanner stage)~Waist circumference~Skin fold measurement (Triceps and Subscapular)~Waist-to-height ratio will be calculated from measured height and waist circumference."
46043284|NCT04181398|Diagnostic Test|Blood pressure|Blood pressure will be measured using an oscillometric, electronic device (Mindray). The blood pressure will be measured 3 times; the first measurement will not be taken into account and the mean of the second and third measurement will be considered as the real blood pressure.
45347357|NCT00825123|Drug|Placebo|Lactose powder
45347358|NCT02540746|Behavioral|ERG Skills Training|Group-based Dialectical Behavior Therapy Skills Training for 12 weeks
45347359|NCT02540746|Behavioral|Motivational Enhancement|Three week Motivational Enhancement group
45347360|NCT02540746|Behavioral|Family Skills Training|12-week group-based family skills training using Family Connections model
45347361|NCT00826839|Drug|Oral contraceptive pill and microdose lupron|Desogestrel/ethinyl estradiol tablets, 0.15 mg/0.03 mg, one tablet by mouth daily for 14 days Leuprolide acetate 40 µg by subcutaneous injection twice a day during ovarian stimulation (approximately 14 days)
45347362|NCT00826839|Drug|E2 patch/antagonist|"Estradiol transdermal system 0.1 mg/day (25 cm2 patch. Patch changed every other day x 3. Final patch left on for about 7 days. Total duration of therapy approximately 14 days.~Gonadotropin-releasing hormone antagonist 0.25 mg subcutaneously every other day for 3 total doses."
45347363|NCT04017988|Dietary Supplement|Ethanol Extracts of Porphyra Tenera(PTE10)|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal, for 8 week
45347364|NCT04017988|Dietary Supplement|Placebo|Placebo for 8 week
45347365|NCT00899158|Other|immunologic technique|
45347366|NCT00899158|Other|laboratory biomarker analysis|
45347367|NCT00899158|Procedure|biopsy|
45347368|NCT00825201|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IP
45347369|NCT00825201|Other|liquid chromatography|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
45347370|NCT00825201|Other|mass spectrometry|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
45347371|NCT00825201|Other|pharmacological study|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
45347372|NCT00825201|Other|laboratory biomarker analysis|Correlative studies
45347373|NCT00901030|Procedure|Blood drawn|Blood samples will be taken once in the preoperative clinic and once again at the end of the surgery in the post anesthetic care unit to do the TEG and PMA tests.
46043285|NCT04181398|Diagnostic Test|Peripheral arterial tonometry|The investigator will measure the pulse wave amplitude by using a finger plethysmograph (peripheral arterial tonometry). The investigator will use the EndoPAT device from Itamar Medical Ltd. At the end of the examination, the participants will be asked to give a VAS-score (Visual Analogue Pain scale).
45347374|NCT00825279|Device|Bare Metal Stent|Stainless steel stent
45347375|NCT00825279|Device|Drug Eluting Stent|stent coated with the biodegradable polymer matrix hemoparin and paclitaxel
45347376|NCT00820833|Other|standard infant formula|standard infant formula given from 3 to 12 months of age, as per standard requirement
45347377|NCT00820833|Other|Test formula|Test formula with different protein and calorie content than standard formula, given from 3 to 12 months of age. As per standard requirement.
45347378|NCT00820911|Drug|cyclosporine (reduced exposure) / everolimus|twice daily
45347379|NCT00820911|Drug|AEB071 300 mg b.i.d. / everolimus|twice daily
45841092|NCT01018134|Drug|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected area once daily for 28 days
46043286|NCT04181398|Other|Questionnaire|General questionnaire on cardiovascular risk factors
46043287|NCT04181398|Diagnostic Test|Blood sample|Blood sample for hs-CRP
45347380|NCT00820911|Drug|AEB071 200 mg b.i.d. / everolimus|twice daily
45347381|NCT00605722|Drug|bevacizumab (Avastin)|5 mg/kg iv on day 1 of each 2 week cycle.
46043288|NCT02677012|Procedure|Autologous Fat Graft|Undergo AFG using the RESOLVE TM technique
46043289|NCT02677012|Procedure|Autologous Fat Graft|Undergo AFG using the Cytori PureGraft TM technique
46043290|NCT02677012|Procedure|Autologous Fat Graft|Undergo AFG using the Coleman technique
45347382|NCT00605722|Drug|erlotinib (Tarceva)|150 mg orally (po) daily.
45347383|NCT00826995|Other|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on melanoma. In the active comparison arm (control arm), the comparison intervention is written patient educational material on melanoma.
45347384|NCT00820989|Biological|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (~5 minutes)
45347385|NCT00882076|Drug|Clofarabine|For Treatment Clofarabine will be administered on Days 2-6 at the dose of 20mg/m2 in Cohort 1, 25mg/m2 in Cohort 2 and 30mg/m2 in Cohort 3 and 4 and 10mg/m2 in Cohort 0 (In the event of excessive DLT in Treatment Cohort 1). For Retreatment Clofarabine will be administered on Days 1-4 at the dose of 20mg/m2 in Cohort 1, 25mg/m2 in Cohort 2 and 30mg/m2 in Cohort 3 and 4 and 10mg/m2 in Cohort 0 (In the event of excessive DLT in Retreatment Cohort 1).
45347386|NCT00882076|Drug|Mitoxantrone|For Treatment Mitoxantrone will be administered on Days 1-3 at the dose of 8mg/m2 in Cohort 1, 2, 3 and on Days 1-5 for Cohort 4 and on Days 1-3 8mg/m2 in Cohort 0 (In the event of excessive DLT in Treatment Cohort 1). For Retreatment Mitoxantrone will be administered on Days 1-2 (2 doses) at the dose of 8mg/m2 in Cohort 1, 2 and 3 and on Days 1-4 (4 doses) at the dose of 8mg/m2 in Cohort 4, and on Days 1-2 (2 doses) at the dose of 8mg/m2 in Cohort 0 (In the event of excessive DLT in Retreatment Cohort 1).
46043291|NCT02677012|Procedure|Reconstructive Surgery|Undergo reconstructive surgery
45841093|NCT01018134|Drug|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected areas twice daily for 28 days
46043292|NCT02677090|Drug|Placebo (including Maltodextrin)|
45475365|NCT05173077|Other|Blood sample collection|Serum, plasma sampling for group description and stratification.
45841094|NCT01018134|Drug|Vehicle once daily|Vehicle topical spray administered to affected areas once daily for 28 days
45841095|NCT01018134|Drug|Vehicle twice daily|Vehicle topical spray administered to affected areas twice daily for 28 days
45841096|NCT01019928|Drug|AZD1386|95 mg, oral solution, single dose
45841097|NCT01019928|Drug|Placebo to AZD1386|Placebo, oral solution, single dose
46043293|NCT02677090|Drug|Dose 1 - Promitor®|
46043294|NCT02677090|Drug|Dose 2 - Promitor®|
46043295|NCT02677090|Drug|Dose 3 - Promitor®|
46043296|NCT04179682|Procedure|40-hour constraint-induced movement therapy|Participants were randomly allocated to 1 of 2 CIMT programs (40 hours): a 2-week 4-hours/day CIMT program and a 4-week 2-hours/day CIMT program. One CIMT program was performed 1 month after a BoNT-A injection, and then the second program was implemented with the next injection.
46043297|NCT04179604|Drug|Levosimendan|Levosimendan SIMDAX 2.5 mg / ml concentrate for solution for infusion. The concentrate is a clear solution, yellow or orange, for dilution before administration. A 5 ml vial contains 12.5 mg of levosimendan. The study drug infusion will start one day before surgery in an Intensive Care Unit with at least 8 hours of administration before surgery. A continuous infusion at 0.1 µg/kg/min will be administered to complete 24h duration.
46043298|NCT04179604|Drug|Placebos|Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.
45347387|NCT00882076|Drug|Etoposide|For Treatment Etoposide will be administered on Days 1-5 at the dose of 100mg/m2 in Cohort 1, 2, 3, 4 and Cohort 0 (in the event of excessive DLT in Treatment Cohort 1). For Retreatment Etoposide will be administered on Days 1-4 at the dose of 100mg/m2 in Cohort 1, 2, 3, 4 and Cohort 0 (in the event of excessive DLT in Retreatment Cohort 1).
45347388|NCT00825435|Procedure|Coronary CT Angiogram|Coronary CT Angiogram
45347389|NCT00901108|Procedure|Trabectome-IOL|"Trabectome removes an arc of trabecular meshwork and inner wall of Schlemm's canal to enhance aqueous outflow through natural drainage pathways.~Trabectome will be done first, followed by cataract surgery because Trabectome requires a clear view through the cornea using a goniolens, and this view may be compromised after cataract surgery."
45347390|NCT00901108|Procedure|Trab-IOL|"Trabeculectomy bypasses the normal aqueous outflow channels of the eye and creates an external filtration pathway (called a filtering bleb) for aqueous to drain and be reabsorbed back into the circulation. Mitomycin C is an agent used during this procedure to decrease scar formation around the new passage.~Cataract surgery will be done first, followed by Trabeculectomy with Mitomycin C."
45347391|NCT00827151|Drug|Estrogen|Estrogen 100 mcg patch twice weekly with 10 days of oral progesterone monthly for 12 months versus no medication
46043299|NCT05277142|Other|oral motor training|they received oral motor training for 40 minutes 3 times/week for twelve successive weeks.
45475366|NCT05173077|Diagnostic Test|Microbiota testing|Faecal samples for microbiota testing.
45475367|NCT05173077|Diagnostic Test|Colonoscopy|Colonoscopy will be used only according to the clinical indications.
45475368|NCT03633331|Drug|Palbociclib|Given PO
45684993|NCT04125862|Diagnostic Test|MRI-based Neuroimaging|During evoked pain fMRI, noxious pressure and heat stimuli will be applied in the two anatomical sites noted above. During fMRI data acquisition, a total of 5 pressure stimulations and 5 heat stimulations will be delivered. Both types of pain stimuli will be applied in a 36/17-sec off/on cycle. The off-condition will correspond to a baseline temperature of 35C and the on condition will match the subject-specific and site-specific 7/10 pressure and heat pain thresholds defined during QST procedures. VAS pain ratings associated with evoked pain stimulation will be collected at the end of each scan. The investigators will also explore the structural properties of the CNS by implementing high-resolution anatomical MRI (gray matter volumes) and diffusion tensor imaging (white matter pathway integrity). All CNS imaging will take approximately 50-60 minutes to complete
45684994|NCT04125862|Diagnostic Test|Non-contrast MRI|Musculoskeletal imaging of the affected lower extremity. Patients will be allowed to watch a movie during data acquisition. The following MRI procedures will be completed in order to identify soft tissue lesions in active or painful regions. Fast spin echo (FSE) T2 fat saturated, T1 weighted MRI, FSE proton density MRI, Short-TI Inversion Recovery (STIR), Diffusion weighted MRI (DW-MRI) and 3D Double Echo Steady State (DESS) will be collected. All musculoskeletal MRI will take approximately 30 minutes to complete.
46043300|NCT05277142|Device|Neuromuscular Electrical Stimulation|They received the same Oral motor training program of Group A for 20 minutes in addition to Neuromuscular Electrical Stimulation (NMES) at intensity ranged from (3-5mA) duration for 20 minutes and frequency of 80 HZ 3 times/week for twelve successive weeks
46043301|NCT02673580|Other|Open Access telePRO|"In open access, contacts to the outpatient clinic are initiated solely by the patient. Contacts may be in the form of a PRO assessment like in standard telePRO, but at a time decided by the patient via the Danish National Health website Sundhed.dk."
46043302|NCT02673580|Other|Standard telePRO|Standard care: fixed interval telePRO follow-up. Patients receive a questionnaire with individually pre-specified intervals.
46043303|NCT02675218|Other|Patients with rheumatoid arthritis|Doppler effect at 3 months after Abatacept treatment initiation.
45347392|NCT00882154|Drug|Cefdinir 300 mg Capsule (Sandoz, Austria)|
45347393|NCT00882154|Drug|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
45347394|NCT00825591|Dietary Supplement|Melatonin|Oral administration before bed. We will test two doses (0.5 or 3.0 mg/m2. 6 week duration.)
45347395|NCT00825591|Dietary Supplement|Placebo Comparator|Oral administration before bed. 6 week duration.
45475369|NCT03633331|Drug|Letrozole|Given PO
45475370|NCT03633331|Drug|Fulvestrant|Given IM
45684995|NCT04125862|Diagnostic Test|18F-FDG-PET/CT|Data will be collected 30 min after the intravenous administration of 18F-FDG with an expected average dose of approximately 200 MBq. CT data will be collected at a low-dose to minimize radiation exposure. Patients will be positioned supine head-first with arms on the side. The investigators project whole body data to be collected, but in some cases, the field of view may be limited to the patient's skull to below the knees. The data acquisition period is expected to last between 15-30 minutes and total radiation dose will be ~3-4 mSv.
46043304|NCT02673502|Dietary Supplement|simple carbohydrate drink|Patients will ingest 400 ml of the simple carbohydrate drink consisting of commercial orange juice without pulp which contains 50 grams fructose/galactose 2 hours before surgery.
46043305|NCT02673502|Dietary Supplement|complex carbohydrate drink|Patients will ingest 400 ml of the complex carbohydrate drink containing 50 grams of maltodextrin powder in water ( orange food color and artificial orange flavor have been added to the drink) 2 hours before surgery
46043306|NCT04179370|Other|N/A - no intervention. Observational study.|N/A - no intervention. Observational study.
45475371|NCT03633331|Other|Questionnaire Administration|Ancillary studies
45475372|NCT03633331|Other|Quality-of-Life Assessment|Ancillary studies
45347396|NCT00899704|Genetic|microarray analysis|
45475373|NCT01292681|Other|Multi-modality imaging|Week -2-0 FDG-PET-CT,1H MRS, DCE-MRI, DWI Week 1 1H MRS, DCE-MRI, DWI, 19F MRS, FDG-PET-CT Week 9 FDG-PET-CT
46043307|NCT00643474|Device|Accu-Chek Aviva Meter|4-point daily glucose monitoring profile 3 times per week
45347397|NCT00899704|Genetic|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
45347398|NCT00899704|Other|diagnostic laboratory biomarker analysis|
45347399|NCT00825669|Drug|TACE|TACE: The chemotherapeutic drugs and 2 to 10 ml lipiodol are given via hepatica propria artery. The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.
45347400|NCT00825669|Procedure|Laser ablation|Laser ablation is given to the PVTT.
46043308|NCT00643474|Device|Accu-Chek Aviva Meter|Frequency and timing of SMBG not specified
46043309|NCT02537704|Behavioral|Group Lifestyle Balance Program|
46043310|NCT02673658|Behavioral|Motor + problem solving|Developmental motor tasks incorporating cognitive concepts such as object permanence
46043311|NCT02673658|Behavioral|body weight support training|Mobility tasks to change positions or move the body with assistance to initiate movement
46043312|NCT04178356|Other|Proprioceptive Neuromuscular Facilitation Training|The Proprioceptive Neuromuscular Facilitation Training will be performed using patterns and techniques in various positions for abdominal and back muscles' facilitation and strengthening. Supine, side-lying, and sitting positions will be used. There will be a rest of about 20 sec between sets. Warm-up for 10 min, main exercises for 25 min, cool-down for 10 min (a total of 45 min), 5 times a week for 4 weeks.
46043313|NCT04178356|Other|Control Group|Ultrasound, TENS, massage, and exercise will be used with each other because in most of the physical therapy clinics these modalities are used together for such problems as a conventional treatment. After massage application, hamstring and paravertebral muscles stretching and also stabilizing exercises will be prescribed, each one for ten times in each session.
45347403|NCT00821067|Dietary Supplement|D-ribose|A 6 gm/day (3 gm/bid) dose of D-ribose in water. Each subject will consume oral D-ribose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
45347404|NCT00821067|Dietary Supplement|Dextrose|A 6 gm/day (3 gm/bid) dose of dextrose in water. Each subject will consume oral dextrose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
45347405|NCT00821145|Procedure|conventional surgery|AAA patients operated using a conventional incision
45347406|NCT00821145|Procedure|laparoscopic AAA resection|laparoscopic AAA resection
45347407|NCT00821145|Procedure|laparoscopic stapler anastomosis|laparoscopic AAA resection, proximal anastomosis performed with a stapler
45347408|NCT00900016|Genetic|protein expression analysis|
45347409|NCT00900016|Genetic|western blotting|
46043314|NCT02675140|Drug|ZENTEL|Children in Group 2 (n=62) received 400 mg single-dose albendazole (helmintic treatment)
46043315|NCT02675140|Drug|ZENTEL and Vitamin A Soft Capsules|Children in Group 3 (n=60) received a 200,000 IU vitamin A capsule combined with 400 mg single-dose albendazole once initially
46043316|NCT00642538|Drug|MKC253 Inhalation Powder|Inhalation Powder, prandial
46043317|NCT00642538|Drug|Technosphere Inhalation Powder|Inhalation Powder, prandial
45475374|NCT01189097|Drug|Dextromethorphan|Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period first and then will be categorized into the opioid free group. The subjects of the opioid using group will be assigned randomly into the following six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo.
45841098|NCT01020006|Drug|PCI-27483|"Part A: Closed to enrollment.Part B: Approximately 20 patients will be randomized to the control arm that will receive a standard regimen of gemcitabine and 20 patients will be randomized to the PCI-27483 arm and treated with both gemcitabine and PCI-27483. PCI-27483 will be administered as subcutaneous (SC) injections, nominally at a dosage of 1.2 mg/kg BID. Patients receiving PCI-27483 with a tumor response or stable disease at 12 weeks will have the option to continue PCI-27483 treatment until disease progression or the investigator considers the study treatment no longer tolerable. Treatment with gemcitabine may continue per standard of care.~All evaluable patients will roll over into Part C at week 16 (Day 113±5). If 2 consecutive INRs at 2 hours postdose are >3.50,a reduced dosage will be calculated."
46043318|NCT00642538|Drug|subcutaneous injection|10µg Exenatide, prandial
45347410|NCT00900016|Other|immunohistochemistry staining method|
45347411|NCT00900016|Other|immunologic technique|
45684996|NCT04125862|Diagnostic Test|18F-NaF-PET/CT|Data will be collected 30 min after the intravenous administration of 18F-NaF with an expected average dose of approximately 200 MBq. CT data will be collected at a low-dose to minimize radiation exposure. Patients will be positioned supine head-first with arms on the side. The investigators project whole body data to be collected, but in some cases, the field of view may be limited to the patient's skull to below the knees. The data acquisition period is expected to last between 15-30 minutes and total radiation dose will be ~3-4 mSv.
45684997|NCT04125628|Behavioral|Exercise with cooling|The exercise training session involved head cooling and neck wraps. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the condition each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed
45347412|NCT00900016|Other|laboratory biomarker analysis|
45347413|NCT00900094|Genetic|fluorescence in situ hybridization|
45347414|NCT00900094|Genetic|polymerase chain reaction|
45347415|NCT00900094|Genetic|protein expression analysis|
45347416|NCT00900094|Other|immunohistochemistry staining method|
45347417|NCT00900094|Other|laboratory biomarker analysis|
45347418|NCT00900094|Other|mass spectrometry|
45347419|NCT00882232|Device|Cross-linked hyaluronan gel|"Single, transperitoneal injection of 9 mL cross-linked hyaluronan gel into anterior perirectal fat under anesthesia. The gel is injected prior to the start of radiotherapy and is absorbed by the body over several months. It increases the seapartion between the prostate and rectum by 1/3 to 2/3 at the start of radiotherapy."
45347420|NCT04038424|Other|Art therapy|Art therapy including coloring, painting and listening to music
45347421|NCT00900172|Biological|bevacizumab|
45347422|NCT00900172|Drug|carboplatin|
45347423|NCT00900172|Drug|paclitaxel|
45347424|NCT00900172|Genetic|gene expression analysis|
45347425|NCT00900172|Genetic|polymerase chain reaction|
45841099|NCT01020006|Drug|Gemcitabine|
45841100|NCT05395962|Drug|Carboplatin|treatment with bleomycin and carboplatin in association with electroporation
45347426|NCT00900172|Genetic|polymorphism analysis|
45347427|NCT00900172|Other|laboratory biomarker analysis|
46043319|NCT00644254|Procedure|Pancreatic resection|PPPD, Whipple, Total pancreatectomy or left pancreatectomy.
46043320|NCT02674906|Drug|ACD-A|use of ACD-A as anticoagulant after blood salvage during cardiac surgery
46043321|NCT02674906|Drug|Heparin|use of heparin as anticoagulant after blood salvage during cardiac surgery
46043322|NCT02674672|Device|VenaTech® (VenaTech Retrievable Filter)|
46043323|NCT02673268|Procedure|Mastectomy|
46043324|NCT02673268|Device|Da Vinci Robot Xi|
46043325|NCT04179214|Other|Thoracic manipulation|Session will be performed twice a week for a three week period if a pop sound occurred then the therapist moved on next procedure ,if not subject will be repositioned and technique will performed again. This procedure will be performed for maximum of two attempts. Approximately 3 minutes of time is required to complete thrust manipulation subjects assigned to thrust manipulation also received general exercise program and manual pressure release technique as the control group. General exercise group involve Stretching exercises for the pectoral muscles and resisted strengthening exercises for the scapular retractors and elevators and the glenohumeral abductors and external rotators were performed three times per week for 3 weeks.
46043326|NCT04179214|Other|conventional pt protocol|This group will receive manual pressure release technique along with general exercises program. General exercise group involve Stretching exercises for the pectoral muscles and resisted strengthening exercises for the scapular retractors and elevators and the glenohumeral abductors and external rotators were performed three times per week for 3 weeks.
46043327|NCT00641290|Device|Vigileo FloTrac Sensor|Comparing the Vigileo FloTrac against the conventional Pulmonary Artery Catheter using the thermodilution method for measurements of cardiac output.
46043328|NCT00643630|Device|Tetrix|Twice daily topical application
45841101|NCT05395962|Drug|Bleomycin|treatment with bleomycin in association with electroporation
46043329|NCT00643630|Device|Tetrix|Twice daily topical application
45684998|NCT04125628|Behavioral|Exercise without cooling|The exercise session performed without cooling. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
45684999|NCT04393480|Other|Robotic therapy|ReoGo™ - Motorika robotic therapy - upper extremity robotic rehabilitation system
45841102|NCT05395728|Other|Deflate the tracheostomy cuff early|The tracheostomy cuff will be early deflated, on beginning the weaning mechanical ventilation
46043330|NCT01160744|Biological|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) once every 3 weeks beginning Day 1, Cycle 1
46043331|NCT01160744|Drug|Pemetrexed|500 milligrams/square meter (mg/m²) on Day 1 of every 21-day cycle
46043332|NCT01160744|Drug|Carboplatin (AUC 6)|Day 1 of every 21-day cycle
46043333|NCT01160744|Drug|Cisplatin|75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle
45841103|NCT05395728|Other|Deflate the tracheostomy cuff after complete weaning mechanical ventilation|The tracheostomy cuff will be deflated onl twenty four hours after complete weaning mechanical ventilation
46043334|NCT01160744|Drug|Gemcitabine|1000 mg/m² on Days 1 and 8 of every 21-day cycle
46043335|NCT01160744|Drug|Carboplatin (AUC 5)|Day 1 of every 21-day cycle
46043336|NCT02677246|Drug|Denosumab|"Denosumab, one sub-cutaneous infusion, given within 2 weeks after engraftment defined as neutrophils > 0,5x10(9)/L and chimerism ≥ 10% of donor origin.~Before starting Denosumab several requirements have to be met: 1) Calcemia and Phosphatemia in the normal ranges, 2) adequate Calcium and Vitamin D intakes according to age.~Biological activity of Denosumab measured by CTX blood level, expected to last for 4 to 6 months after one infusion.~Possibility of subsequent infusions at the same dose level, every 5 to 6 months, for patient remaining on corticotherapy, provided no DLT occurred and provided CTX blood level decreased under the required threshold, after the previous infusions of Denosumab"
45347428|NCT00605566|Drug|Sorafenib|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of > 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
45347429|NCT00605566|Drug|Cyclophosphamide|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of > 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
45347430|NCT00900250|Other|Cytology Specimen Collection Procedure|Correlative studies
46043337|NCT02673112|Behavioral|Subthreshold exercise (STEP) with mobile health coaching|Aerobic exercise program performed below the HR threshold that causes symptoms and administered by an RA using mobile health coaching
46043338|NCT02673112|Behavioral|Light stretching (LS)|Brief daily stretching routine.
45347431|NCT00900328|Other|laboratory biomarker analysis|Correlative Studies
45347432|NCT00882388|Drug|aspirin|aspirin 100 mg qd for 7 days
45347433|NCT00882388|Drug|celecoxib|celecoxib 200 mg bid * 7 days
45347434|NCT00882388|Drug|aspirin + celecoxib|aspirin 100 mg qd + celecoxib 200 mg bid for 7 days
46043339|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group A, one point per ovary.
46043340|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group B, two points per ovary.
46043341|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group c, three points per ovary.
45347435|NCT00882388|Drug|aspirin + clopidogrel|asprin 100 mg qd + clopidogrel 75 mg qd for 7 days
45347436|NCT00882388|Drug|aspirin + clopidogrel + celecoxib|aspirin 100 mg qd + clopidogrel 75 mg qd + celecoxib 200 mg bid
45841104|NCT05395572|Device|Kinesio® Tape|In order to increase the activity of underactive muscles, the tape is applied from origin to insertion with a 15-25% tension. The Kinesio® Tape mechanical muscle correction will be performed with one Y-strip of Kinesio® Tape over the bilateral cervical multifidus and semispinalis cervicis muscles, while also including portions of other cervical extensor muscles (the semispinalis capitis, splenius cervicis, levator scapulae, upper trapezius, longus coli, and splenius capitis).
46043342|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group D, four-five points per ovary.
46043343|NCT04181164|Other|Microindentation|Microindentation is a new technology directly measuring bone strength by a minimal invasive technique.
46043344|NCT04181164|Other|High resolution peripheral quantitative computed tomography (HRpQCT)|HRpQCT scan can assess the cross-sectional geometry of the bone and is an appropriate investigation to evaluate bone quality.
46043345|NCT04181164|Biological|Biochemical analysis of different bone markers.|Measurement of different bone markers by biochemical analysis of blood samples.
46043346|NCT02672800|Behavioral|the Reclaiming Yourself tool|This tool is a behavioural writing intervention, intended to facilitate bereavement for spousal caregivers of persons with dementia
45841105|NCT05394480|Diagnostic Test|Blood pressure (Systolic, Diastolic), Pulse value, O2 saturations were measured.|Salivary cortisol was measured by electrochemiluminescence (ECLIA) method using the Cobas Cortisol ll kit.
46043347|NCT04180774|Biological|Tag-7 gene modified inactivated tumor cells|Patients received GMV once in three weeks subcutaneously in three points in the paravertebral region. One dose consisted of 10 million transfected and inactivated tumor cells. No dose reduction was allowed.
45841106|NCT05394246|Drug|FluoAB|Drug Injection: FluoAB (fluorescent-labeled IgG)
45841107|NCT05394168|Biological|HLX53|The 50 mg, 150 mg, 400 mg, and 800 mg dose groups were administered once every 1 week (QW); the 1600 mg dose group was administered once every 2 weeks (Q2W); and the 2400 mg dose group was administered once every 3 weeks (Q3W).
46043348|NCT02674828|Behavioral|Reinforcement for meeting targeted physical activity goals|Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.
46043349|NCT02674828|Other|Standard of Care|Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it >2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
46043350|NCT01160354|Drug|Plerixafor|Starting at 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before a 1 hour (+/- 30 minutes) IV administration of Clofarabine
45841108|NCT05394090|Diagnostic Test|saliva stimulation|In 50 patients with ischemic stroke, saliva was the option of a neurologopedic massage of choice
45841109|NCT05391048|Drug|IMP4297(20mg)|Single oral dose of IMP4297 administered under fasting conditions 5*20 mg capsules in first intervention period and 10*10 mg capsules in second intervention period (after washout period: at least 7 days)
45475375|NCT01189097|Drug|Dextromethorphan|Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period and then randomly assigned into six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo. If the subjects of the opioid free group suffer from relapses and begin to use heroin, they will receive methadone treatment. The dosage of methadone will be increased or decreased maximal 5 mg each time as necessary.
45475376|NCT02524457|Other|This is an observational study. There are no interventions|
45475377|NCT02518204|Other|BPT|Brain Performance Test (BPT) computerized cognitive assessment battery developed by Lumos Labs, Inc.
45475378|NCT02518204|Other|NP|"Conventional in-person Neuropsychological Assessments (NP)~Subtests from:~HRB: Halstead-Reitan Battery~MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia~WAIS-IV: Weschler Adult Intelligence Scale - IV"
45475379|NCT01187303|Drug|Ofatumumab|300 mg/m2 d1 week 1 1000mg/m2 d1 week 2-8
45841110|NCT05391048|Drug|IMP4297(10mg)|Single oral dose of IMP4297 administered under fasting conditions 10*10 mg capsules in first intervention period and 5*20 mg capsules in second intervention period (after washout period: at least 7 days)
46043351|NCT01160354|Drug|Clofarabine|Fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles).
46043352|NCT00643786|Drug|Oxygène|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
46043353|NCT00643786|Drug|Air Médical|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
46043354|NCT04178512|Drug|Drug:dexamethasone in group Dexamethasone,fentanyl in group Fentanyl,normal saline 0.9%in group Control|prevention of shivering after spinal anesthesia in patients undergoing trans urethral prostatectomy through injection of spinal additives
46043355|NCT02674360|Behavioral|SDM Training|
46043356|NCT04179292|Other|Hand Therapy by Physiotherapist|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~3 days / week with physiotherapist~2 days / week as home program 30 minutes / day 12 repetitions"
45347437|NCT00901420|Procedure|Urodynamics Test|90 Minute videotaped bladder function procedure involving pressure-monitoring catheters in bladder and rectum.
45347438|NCT00901420|Behavioral|Questionnaire|Survey of urinary function and quality-of-life (regarding daily living after surgical treatment for prostate cancer), taking 30 minutes to complete.
45475380|NCT03856151|Device|"HEALTHY BOX Powered heating pad (electronic moxibustion)"|Using heating pad (electronic moxibustion) with insulating materials on low temperatures (56±8℃) in treating patients with intra-dialytic hypotension
45347439|NCT00900406|Genetic|gene expression analysis|blood collection
45347440|NCT00900406|Genetic|microarray analysis|Blood collection
45347441|NCT00900406|Genetic|polymorphism analysis|Blood collection
45475381|NCT02518282|Other|Serum levels of high-sensitivity troponin T|Serum levels of hs-cTn will be measured before surgery, upon arrival at the ICU, as well as every 6 hours for 24 hours, then every 8 hours the following 24 hours and a last blood sample will be taken 72 hours after surgery.
45475382|NCT02518282|Other|Twelve-lead ECGs|Twelve-lead ECGs obtained the day prior to heart valvular surgery, immediately upon arrival at the ICU, and then 24, 48 and 72 hours post-surgery will be reviewed by a cardiologist to evidence signs of MI.
45475383|NCT02518282|Other|Transthoracic echocardiography (TTE)|A TTE will be also performed by a cardiologist after cardiac valvular surgery to determine the ejection fraction of left ventricle and the occurrence of a new regional wall motion abnormality. This TTE will be compared, by the same cardiologist, with a TTE performed before cardiac valvular surgery.
45475384|NCT01187459|Dietary Supplement|Vitamin D|10 ug/day Vitamin D, taken for 6 months.
45475385|NCT01187459|Dietary Supplement|Vitamin D|50 ug/day Vitamin D, taken for 6 months.
45347442|NCT00900406|Genetic|proteomic profiling|Blood collection
45347443|NCT00900406|Other|flow cytometry|Blood collection
45347444|NCT00900406|Other|immunologic technique|Blood collection
45347445|NCT00900406|Other|laboratory biomarker analysis|Blood collection
45347446|NCT00900406|Procedure|biopsy|Blood collection
45347447|NCT00396877|Drug|Clopidogrel (SR25990)|"Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
45347448|NCT00396877|Drug|placebo|"Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
45347449|NCT02540044|Behavioral|ANSWER-2 decision aid|ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
45347450|NCT02540044|Behavioral|Control Group (TAS Consumer Guide)|The Arthritis Society Consumer guide pdf.
45347451|NCT00900484|Other|biologic sample preservation procedure|
45347452|NCT00900484|Other|immunohistochemistry staining method|
45347453|NCT00900484|Other|laboratory biomarker analysis|
45347454|NCT03633253|Other|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages|First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
45685000|NCT04393480|Other|Conventional therapy|Range of Motion (ROM) exercises, muscle strengthening, balance and mobility training, exercises for enhancing activities of daily life, neurophysiological exercises, turnings, bed movements, bridge building, sitting and transfer training, gait training, proprioceptive exercises, balance exercises on the balance board of those affected by the cerebellar system, occupational therapy, cognitive rehabilitation by the relevant psychologist given to those with cognitive impairment
45347455|NCT01040065|Procedure|distal clavicle resection|Presence of tenderness at 2 years after surgery
45347456|NCT00124891|Drug|Double-blind investigational anti-arrhythmic|
45347457|NCT00124891|Drug|GAP-486|
45347458|NCT00882466|Drug|human recombinant erythropoietin|intravenous bolus injection of EPO (50unit/kg)
45347459|NCT00901498|Drug|BMS-708163|Oral, 25 mg Hard Gelatin Capsule, Size #2, 150 mg, Once per period of 3, 7 days between dosings. Will be compared with any 2 comparators.
45347460|NCT00901498|Drug|BMS-708163|Oral, 75 mg Tablet Formulation 1, 150 mg, Once per period of 3, 7 days between dosings
45685001|NCT04393402|Procedure|lung ultrasound (LUS)|Patients with Covid-19 Disease and admitted in critical care unit will be performed a LUS
45685002|NCT03007732|Drug|Pembrolizumab|200 mg IV every 21 days for up to 13 doses (Arms 1 and 2)
45685003|NCT03007732|Drug|SD-101|5 mg will be delivered to the dominant prostatic tumor lesion at time of fiducial marker placement (1-5 weeks prior to Cycle 1, Day 1) and and 1-3 weeks after Cycle 1 Day 1
45685004|NCT03007732|Drug|Leuprolide acetate|22.5 mg will be given intramuscularly (IM). First injection 3 months prior to Cycle 1 Day 1. Intermittent androgen deprivation therapy will be given every 3 months starting Cycle 1, Day 1 for 3 additional doses.
45347461|NCT00901498|Drug|BMS-708163|Oral, 50 mg Hard Gelatin Capsule, Size #0, 150 mg, Once per period of 3, 7 days between dosings
45347462|NCT00901498|Drug|BMS-708163|Oral, 75 mg Soft Gelatin Capsule, 150 mg, Once per period of 3, 7 days between dosings
45347463|NCT00901498|Drug|BMS-708163|Oral, 75 mg Tablet Formulation 2, 150 mg, Once per period of 3, 7 days between dosings
45347464|NCT00628251|Drug|AZD2281|400mg Oral twice daily
45347465|NCT00628251|Drug|Liposomal Doxorubicin|50mg/m2 Monthly Intravenous
45347466|NCT00628251|Drug|AZD2281|200mg oral twice daily
45347467|NCT01036399|Drug|Lenalidomide|Oral Lenalidomide is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
45347468|NCT01040221|Drug|Trichuris Suis Ova|TSO will be administered in vials prepared by Coronado Biosciences. Vials will be diluted with a commercial drink and given to subjects to ingest. Subjects will receive a dose of 2500 ova every two weeks for 12 weeks.
45685005|NCT03007732|Drug|Abiraterone Acetate|1000 mg oral dosage will be given daily for 3 months prior to Cycle 1, Day 1 and daily for 9 months starting Cycle 1, Day 1.
45685006|NCT03007732|Drug|Prednisone|5 mg oral dosage will be given daily for 3 months prior to Cycle 1 Day 1 and daily for 9 months starting Cycle 1, Day 1.
45685007|NCT03007732|Radiation|Stereotactic Body Radiation Therapy|7 Gy x 5 fractions (35 Gy total) 1-2 weeks after fiducial marker placement and simulation over 10-14 days.
45685008|NCT03007420|Drug|Occipital Nerve Block (ONB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive an ONB will receive the block with dexamethasone 2mg (steroid) each site with 3ml 1% lidocaine (local anesthetic), for a total of two sites.
45685009|NCT03007420|Drug|Cervical Medial Branch Block (CMBB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive CMBB will receive the block with dexamethasone 1.5mg (steroid) each site with 2 ml 1% lidocaine (local anesthetic), for a total of three sites on each side.
45685010|NCT04125706|Drug|Minocycline Topical|Minocycline will be delivered locally in the periodontal pocket
45685011|NCT04125706|Drug|Metronidazole Topical Gel|Metronidazole will be delivered locally in the periodontal pocket
45685012|NCT03005782|Drug|REGN3767|
45685013|NCT03005782|Drug|cemiplimab|
45347469|NCT00901654|Biological|ACE527 vaccine|"First cohort: Two doses, each of 3x10^9 cfu of each strain (9x10^9 cfu total per dose) administered on Days 0 and Day 21 (out-patient).~Second cohort: Two doses, each of 3x10^10 cfu of each strain (9x10^10 cfu total per dose) administered on Days 0 and Day 21"
45347470|NCT00901654|Biological|Placebo vaccine|First and second cohort: The placebo vaccine will be administered at Days 0 and Days 21.
45347471|NCT00821223|Procedure|phacoemulsification and SICS|SICS with rigid IOL implantation Phaco with foldable IOL implantation
45347472|NCT00821223|Procedure|manual small incision surgery|
45347473|NCT00821223|Procedure|phacoemulsification|cataract surgery
45685014|NCT04125394|Device|hypertonic Sodium chloride (NaCl 5%) eye drops solution in single-dose|Ophthalmic solution of hypertonic sodium chloride (NaCl 5%) without preservatives in single-dose container
45685015|NCT04125004|Device|Samsung Virtual Reality Headset|Patients will pick a game or feature from the virtual reality headset to use during their procedure
45685016|NCT04125082|Drug|Afrezza Inhalant Product|Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks.
45685017|NCT04125160|Device|Continuous glucose monitoring|Continuous glucose monitoring over 16 days
45685018|NCT04125160|Diagnostic Test|Glycaemic markers|Measurement of HbA1c, glycated albumin and fructosamine.
45347474|NCT00900640|Procedure|ERCP as medically indicated by subjects referring physician|Determine the incidence of adverse reactions to CM administered during ERCP in patients with prior reaction to IV CM administration and/or shellfish allergy.
45347475|NCT00625131|Drug|Nicotine|Delivered through transdermal nicotine patch
45347476|NCT00625131|Behavioral|Cognitive Behavioral Therapy for Smoking Cessation|Manualized protocol for CBT in smoking cessation
45347477|NCT00625131|Drug|Bupropion Sustained Release (SR)|Antidepressant
45347478|NCT00625131|Drug|Placebo patch|Pre-treatment placebo transdermal patch
45685019|NCT04393246|Drug|EDP1815|EDP1815 is an orally administered pharmaceutical preparation of a single strain of Prevotella histicola isolated from the duodenum of a human donor. EDP1815 is currently in phase 2 clinical development and has European and US approval to initiate a multinational psoriasis study.
45685020|NCT04393246|Drug|Dapagliflozin|Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor. Dapagliflozin is licensed for use in the UK for treatment of Type II diabetes. Since this trial is evaluating Dapagliflozin in an unlicensed indication, it is being carried out under a Clinical Trial Authorisation (CTA)
45685021|NCT04393246|Drug|Ambrisentan|Ambrisentan is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and indicated for the treatment of pulmonary arterial hypertension.
45685022|NCT04393246|Other|Standard of care|Regular standard of care for COVID-19 patients
45347479|NCT01036633|Device|Infrared Thermometer|The infrared thermometer will be used to grade the severity of oral mucositis in patients undergoing antineoplastic chemotherapy for multiple myeloma. The photothermal camera will be used to take intraoral digital images of the mouth.
45347480|NCT00900718|Device|Straumann Bone Ceramic|Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
45347481|NCT00900718|Device|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.
45685023|NCT01923181|Drug|semaglutide|Once-daily oral administration as tablets.
45685024|NCT01923181|Drug|semaglutide|Once-weekly,injected s.c./subcutaneously (under the skin) using a pen
45685025|NCT01923181|Drug|oral placebo|Once-daily oral administration as tablets.
46043357|NCT04179292|Other|Hand Therapy as home program|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~3 days / week with physiotherapist~2 days / week as home program 30 minutes / day 12 repetitions"
46043358|NCT01160198|Drug|ferrous ascorbate|100 mg elemental iron
46043359|NCT01160198|Dietary Supplement|ferrous bisglycinate chelate 1 OD|60 mg elemental iron
46043360|NCT01160198|Dietary Supplement|ferrous bisglycinate chelate 2 OD|120 mg elemental iron
46043361|NCT02676934|Device|End tidal control module in Aisys anesthesia workstation|THE USE OF AUTOMATED CONTROL OF END TIDAL SEVOFLURANE CONCENTRATION TO MAINTAIN ANESTHESIA DURING DONOR HEPATECTOMY
45347482|NCT02549547|Behavioral|Group Medical Visits|"Cohorts will participate in a weekly series of 14 Group Medical Visits (GMVs) co-led by a psychiatrist and an exercise professional. Each two-hour Group Medical Visit will be divided into three sections:~Group check in/out; enter patients weekly step count into database; review and outline the day's group program - 20 minutes~Group discussion, regarding selected physical activity topics including psychiatric issues - 50 minutes~Physical activity component - 50 minutes The 'content' or curriculum of the GMVs will support participant Self-Management/Activation. Research has consistently emphasized the role of positive feedback, social support, reinforcement, goal setting, and motivation for improving person's self-perception to uptake physical activity."
45685026|NCT04124224|Other|Unidos|The investigators will collaborate with our community partners to implement and evaluate a Community-Clinical Linkage (CCL) model in which Community Health Workers (CHWs) connect individuals to social determinant and community health services and build sociocultural resilience through CHW-facilitated individual and group support. As a public health practice-based study that incorporates evidence-based strategies, the investigators seek to establish Unidos effectiveness in Arizona counties with the highest percentage of Latinos of Mexican origin (Yuma, Pima, Santa Cruz, and Maricopa). Unidos CHWs, based in local health departments, will use evidence-based strategies to address three elements that are important in addressing chronic disease risk: 1) health promotion resources and programs; 2) individual and group-based social support; and 3) leveraging community resources to address social determinants of health.
45685027|NCT04124302|Drug|Insulin Glulisine|A kind of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
45347483|NCT00923338|Device|Surgisis Biodesign (Vesico-vaginal fistula plug)|Vesico-vaginal fistula plug
45347484|NCT00825747|Device|SeeLens AF intra-ocular lens|the SeeLens AF is an acrylic hydrophilic C shaped haptics intra-ocular lens, designed for implantation in the lenticular capsular bag or the sulcus during cataract surgery.
45685028|NCT04124302|Drug|Insulin Aspart|A kind of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
45685029|NCT04124302|Drug|Insulin Lispro|A kind of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
45347485|NCT01040299|Device|GangTrainer and tDCS|The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
45347486|NCT01040299|Device|control group1|The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
45347487|NCT01040299|Other|Control group2|The control group 2 receive a total of 10 treatments with convectional physiotherapy.
45841111|NCT05387538|Procedure|One-layer Duct-to-mucosa Pancreaticojejunostomy|To create the anterior suturing layers, double needles with a 4/0 or 3/0 Prolene line will be used; one side of the needles will be inserted from the anterior inner side of the pancreatic duct and out through the ventral parenchyma of the pancreatic stump to the anterior surface of the pancreas about 3 cm from the cut edge. The other side of the needles will be started from the inner side of the jejunum lumen, then pushed through the subserosa and seromuscular region, and out from the posterior surface of the bowel but its done after completion of the posterior layer. The posterior suturing layer will be treated in the same manner. An internal pancreatic duct stent will be used
45347488|NCT00901732|Device|Caphosol|Oral Mouth Rinse
45347489|NCT00837291|Drug|CF101|CF101 tablets 1 mg BID
45347490|NCT00837291|Drug|Placebo|Placebo tablets BID
45347491|NCT00882622|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line.
45685030|NCT03004144|Other|FLOAT|
45685031|NCT04123990|Diagnostic Test|Iron status testing|Iron status testing
45685032|NCT04124068|Other|Hydrogen peroxide teeth whitening gel|Hydrogen peroxide teeth whitening gel with concentrations ranging between 6% - 30%
45685033|NCT04124068|Device|GLO Brilliant Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
45685034|NCT04124068|Device|GLO Lit Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
46043362|NCT05277220|Device|Thermal Camera Thermo Malin TC|"Thermo Malin TC thermal camera (also called HIKVISION TP 31B portable thermal camera). Manufacturer of the researched product is HIKVISION.~This thermal camera is equipped with a thermal detector with a resolution of 160 x 120 elements or an infrared resolution of 19,200 pixels.~Thermal sensitivity of the Thermo Malin TC thermal imager is 40 milliKelvin (0.04 °C), with a spatial resolution of 5.48 mrad and a field of view of 37.2 x 50 °. Temperature accuracy at one point varies by +/- 0.5 °C. This thermal imager has four color palettes to highlight the desired elements.~This camera is specially designed for measuring body temperature in a temperature range from +30 to + 45 °C.~As part of the research, the thermal camera will enable the acquisition and recording of thermographic images at three times of study. These images are then transferred to the operating software for the Thermo Malin Series to process, analyze and make changes to elements of thermographic images."
46043363|NCT05351086|Drug|PUR3100|PUR3100 is an inhalation powder containing DHE, an anti-migraine treatment with broad spectrum agonist activity against 5-hydroxytryptamine (5-HT), dopamine, and adrenergic receptors. PUR3100 is provided as 500 µg dose strength capsules. Each capsule contains the drug substance, DHE mesylate, with mannitol, leucine, and sodium chloride as excipients.
45685035|NCT04124068|Device|GLO Science Professional Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
46043364|NCT05351086|Drug|Dihydroergotamine (D.H.E 45)|D.H.E. 45 is ergotamine hydrogenated in the 9, 10 position as the mesylate salt. It is supplied as a clear, colorless solution supplied in sterile ampules for IV, intramuscular, or subcutaneous administration containing (per mL) DHE mesylate, USP 1 mg, ethanol, 94% w/w. 6.2% by volume, glycerin 15% by weight, and water for injection.
45347492|NCT00882622|Procedure|Control/sham procedure|Sham placement of the blood pressure cuff around the upper limb without inflation.
45685036|NCT04411069|Drug|Droperidol|Pacients who had nausea and vomiting induced by chemotherapy will receive three anti emetic drugs: 4mg dexametasone, 4 mg ondansetron and 0,625 mg droperidol
45475386|NCT03354988|Other|Physical exercise group|For the exercise group, systematic physical activity programs consisting of range-of-motion exercises with gentle compression, extension and flexion of all joints of both bilateral upper extremities; including the shoulder, elbow, and wrist and lower extremities; including the hip, knee and ankle, with a total of 12 joints. Each activity was about 10 min a day and was carried out 5 times per week for 4 weeks. This program was started after 1 week of birth. Physical activity continued until discharge from hospital
45475387|NCT03354988|Other|Control group|Other routine care activities such as bathing (every day) and kangaroo care (30 minutes/day), will be done for both the control
45475388|NCT01189175|Drug|BI 113823 + Ketokonazole|5 days ketokonazole with single oral dose of BI 113823 on day 3
45475389|NCT01189175|Drug|BI 113823|single oral dose
45475390|NCT03201003|Biological|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
45475391|NCT03201003|Other|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
46043365|NCT05351086|Other|Matching Placebo for PUR3100|Each capsule of matching placebo is filled with iSPERSE powder comprised of mannitol, leucine, and sodium chloride. The PUR3100 inhalation powder is administered using the supplied RS01 inhalation device (RS01 UHR2, Plastiape S.p.A.).
46043366|NCT05351086|Other|Matching Placebo for D.H.E 45|The matching placebo for D.H.E. 45 is 0.9% sterile saline for injection.
45475392|NCT04503538|Other|Telemedicine visit|Participants will be provided with a Wifi-and cellular enabled electronic tablet. Additionally, participants will receive a kit that contains a thermometer, a blood pressure monitoring cuff, and a pulse oximeter (to measure oxygen saturation level). Participants will attend an educational session to learn how the telemedicine visit works. Caregivers should attend with participants and will be trained to take temperatures, blood pressures, and oxygen saturation levels. Participants will also be asked to complete a test telehealth visit.
45475393|NCT01187537|Procedure|Continuous Femoral Nerve Block|20mls of 0.25% Bupivacaine with 1/400,000 adrenaline (2.5mcg/ml) If catheter localized to < 1.0mA, 0.1mS with patella twitch, start Bupivacaine 0.125% 4ml/hr. If unable to get twitch through catheter in final location or twitch at current ≥ 1.0m/A, start Bupivacaine 0.125% 6ml/hr.
46043367|NCT02885168|Drug|Recombinant Activated Protein C|24 μg/kg/h during 96 hours - intravenous injection
46043368|NCT02885168|Device|Near-infrared spectroscopy (NIRS)|After baseline measurement, cuff is blown up to obtain a muscular saturation at 40% and then deflated. Reactive hyperthermia is measured. It is considered as an index for endothelial function.
46043369|NCT02885168|Drug|Phenylephrine|"Continuous administration of phenylephrine with electric syringe with increasing dosing levels: 0.0; 0.02; 0.05; 0.1; 0.2; 0.5; 0.75; 1.00; 1.50; 3.00; 4.50; 6.00; 9.00 et 12 µg/kg/min. Each level is maintained for 5 minutes. Administration of phenylephrine is stopped progressively with the same schema.~Arterial tension through an invasive approach is measured during the test."
46043370|NCT02885168|Biological|Blood sample|Analysis of inflammation and cellular adhesion markers and free radicals
45475394|NCT03349138|Device|Conventional Therapy|
45475395|NCT03349138|Device|Robotic Glove|
45475396|NCT03349138|Device|Electrical Stimulation|
45475397|NCT03851315|Device|permanent left bundle branch area pacing|Implant the pacing lead in the left bundle branch area instead of traditional RV pacing site(septal or apical). Successful LBBAP was defined as the paced QRS morphology of right bundle branch block pattern in lead V1 and QRS duration (QRSd) less than 130ms.
45475398|NCT03348982|Behavioral|Jogging program|The intervention is a 12-week jogging program consisting of 24 sessions (two sessions per week, 30 min per session).
45475399|NCT05399433|Other|Biopsy and venous blood|"A skin biopsy will be performed under local anesthesia in diabetic and non-diabetic psoriatic patients (25 per group) in the injured area (joint extension) and in the non-injured area more than 2 cm from any lesion in the same area. In patients in the diabetic or non-diabetic control group (25 per group) only one biopsy will be performed.~Peripheral venous blood will be collected in heparin tubes for metabolic parameter analysis and blood CD analysis"
45475400|NCT03856073|Behavioral|Novice|Using the simulate device, the novices in bronchoscopy are going to trained and evaluated the ability of driving bronchoscopy in simulate device and clinical practice.
46043371|NCT05657002|Other|patient A with accurate problem list|A problem list that contains a diagnosis code that is contraindicated with a type of medication (Y). Also, all other relevant diagnoses and medical history for the patient are up-to-date on the problem list, which was defined according to the problem list policy at our institution (i.e. all current active problems and relevant medical history should be documented on the problem list). Additionally, the problem list is included in eight out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. One note includes the problem list with the diagnosis relevant for the question asked.
45475401|NCT03354832|Other|Foetal death|A midwife is in charge to interview the mother during the month following the lost of her infant.
45475402|NCT03354832|Other|New-born death|A midwife is in charge to interview the mother during the month following the lost of her infant.
45475403|NCT03354832|Other|Birth control for foetal death|A midwife is in charge to interview the mother during her hospital stay
45475404|NCT03354832|Other|Birth control for new-born death|A midwife is in charge to interview the mother during her hospital stay
45475405|NCT05115357|Procedure|Pecto-Intercostal Fascial Block|A high-frequency (7-12 Mhz) linear ultrasound transducer will be placed approximately 2 cm lateral to sternal edge in the 4th or 5th intercostal space. A 22-gauge, 50-mm needle will be inserted in-plane under ultrasound guidance. The needle will be advanced through the pectoralis major muscle, and the drug will be deposited in the pecto-intercostal fascial plane located between the pectoralis major muscle and the external intercostal muscles. The separation of the fascial plane and the spread of the drug could be observed on the ultrasound image .The procedure will be repeated on the other side of sternotomy to achieve bilateral blockade.
45475406|NCT05115357|Procedure|Transversus Thoracis Muscle Plane Block|The ultrasound probe will be placed in the longitudinal plane 1 cm lateral to the sterna border. the T4-T5 intercostal space will be identified under US. A parasternal sagittal view of the internal intercostal muscle and the transverses thoracis muscle between the 4th and 5th rib will be visualized above the pleura. A 22-gauge, 50-mm needle will be inserted inplane until the tip of the needle is located in the transversus thoracis muscle plane between the internal intercostal and transversus thoracis muscles . After excluding intravascular and intrapleural placement, local anesthetic will be administered in 5mL aliquots with intermittent aspiration.
45475407|NCT01183715|Drug|PF-05161704 or placebo|PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
45475408|NCT01183715|Drug|PF-05161704 or placebo|PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
45475409|NCT04507672|Drug|Fluid resuscitation|Use the choice of crystalloid for resuscitation during the first 72 hours after enrollment
45475410|NCT01291589|Behavioral|Cognitive-behavioral therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors
45475411|NCT01183793|Radiation|Barium follow-through and MR-enterography|Assessment of the lack of difference between surgical and MR enterography small bowel length measurement with a comparison sample test
45475412|NCT04507516|Other|Water-only Fasting|Water-only fasting for at least 10 days followed by 5 days of refeed.
45475413|NCT03738007|Device|HA IDF II|Treatment with HA IDF II (YVOIRE volume)
45475414|NCT03738007|Device|Perlane|Treatment with Perlane
46043372|NCT05657002|Other|patient B with inaccurate problem list|"A problem list that does not contain the diagnosis code and corresponding details explaining medical history of this diagnosis caused by a type of medication (Y). Additionally, the problem list is included in three out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. The relevant diagnosis is not documented on the problem list and hence is not included in the imported problem list in the notes.~The expert panel provided and anonymized two real-world representative examples of hematology patient records that included inaccurate problem lists and that had many free-text notes. An 'inaccurate problem list' is defined as a problem list where diagnoses are missing resulting in missed trigger medication or order-alerts, where diagnoses are 'active' although they should be closed or removed and/or where the problem list contained duplicated diagnoses."
45347493|NCT02547909|Procedure|probe-based Confocal Laser Endomicroscopy|"Eligible women will be offered to undergo pCLE examination. Conscious sedation will be offered to all patients, who will choose to receive it or not. pCLE will be done using a standard gastroscope, reaching a distance of 25 cm from the anus, to the level of the rectosigmoid angle.~At this point, 2.5 ml fluorescein 10% will be injected. The pCLE probe (GastroFlex-UHD probe, Mauna Kea tech, Paris, France) will be inserted through the endoscope working channel and images will be recorded from areas suspected of harboring an endometriotic tissue."
45347494|NCT02547909|Device|Cellvizio|
45347495|NCT02547909|Drug|fluorescein 10%|
45347496|NCT00882700|Drug|Cefdinir 300 mg Capsule (Sandoz, Austria)|
45347497|NCT00882700|Drug|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
45347498|NCT00408499|Drug|cetuximab|Cetuximab will be administered intravenously weekly at the maximum tolerated dose (determined in Phase I portion of the study) on a 28 day cycle. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
45475415|NCT03855839|Device|Posture shirt|Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle activity, reduce musculoskeletal pain and discomfort.
45347499|NCT00408499|Drug|erlotinib|Erlotinib will be taken by mouth daily on a 28 day cycle. It is in tablet form. The dose will be determined in Phase I portion of the study. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
45347500|NCT00837369|Drug|Regadenoson|400ug IV bolus injection, single dosage
45347501|NCT00900874|Drug|salbutamol|two puffs (100 microgram each of salbutamol) by MDI and spacer
45347502|NCT00900874|Drug|Formoterol|Formoterol 2 puffs (6 µg /puff) by MDI and spacer
45347503|NCT00901810|Device|Electronic Apex Locator|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file.
46043373|NCT05657002|Other|patient A with inaccurate problem list|"A problem list that does not contain the diagnosis code that is contraindicated with the type of medication (Y). Additionally, the problem list is included in eight out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. The relevant diagnosis is not documented on the problem list and hence is not included in the imported problem list in the notes.~The expert panel provided and anonymized two real-world representative examples of hematology patient records that included inaccurate problem lists and that had many free-text notes. An 'inaccurate problem list' is defined as a problem list where diagnoses are missing resulting in missed trigger medication or order-alerts, where diagnoses are 'active' although they should be closed or removed and/or where the problem list contained duplicated diagnoses."
45475416|NCT03855839|Device|Compression shirt|Compression shirts are designed for recreational sport activities and can be bought in any local sports store
46043374|NCT05657002|Other|patient B with accurate problem list|A problem list that contains the diagnosis code and corresponding details explaining medical history of this diagnosis caused by a type of medication (Y). Also, all other relevant diagnoses and medical history for the patient are up-to-date on the problem list, which was defined according to the problem list policy at our institution (i.e. all current active problems and relevant medical history should be documented on the problem list). Additionally, the problem list is included in three out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. One note includes the problem list with the diagnosis and details relevant for the question asked.
46043375|NCT02674282|Procedure|ACL reconstruction|ACL reconstruction with hamstrings autograft.
46043376|NCT02672722|Drug|Definity|During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys
46043377|NCT02672722|Other|Exercise|
46043378|NCT02672722|Other|Kidney Ultrasound|This done before and after exercise with the help of Definity to see changes in kidney blood flow
46043379|NCT00643942|Other|No intervention required|
46043380|NCT02672878|Device|Bioresorbable vascular scaffold|
46043381|NCT01159574|Drug|dexamethasone|40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
46043382|NCT01159574|Drug|clarithromycin|orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
46043383|NCT01159574|Drug|Pomalidomide|orally 4mg daily for days 1-21 of each 28 day cycle
46043384|NCT00910156|Device|Airtraq laryngoscope|Airtraq intubation
46043385|NCT00910156|Device|Glidescope laryngoscope|glidescope intubation
46043386|NCT00910156|Device|Macintosh laryngoscope|Macintosh intubation
46043387|NCT04179058|Other|Follow-up|Clinical data, radiological data and laboratory tests follow-up
46043388|NCT01158950|Drug|Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
46043389|NCT01158950|Other|Placebo|Placebo (200mg) administered at study visit
46043390|NCT02676856|Procedure|hematopoietic stem cell microtransplantation-long-term|Stem cell infusion are administrated once three months for 3 times with the cell count of 3*10^8/kg/once.
46043391|NCT02676856|Procedure|hematopoietic stem cell microtransplantation-short-term|Stem cell infusion are administrated once every 45 days for 3 times with the cell count of 3*10^8/kg/once.
46043392|NCT02676856|Drug|Conditioning for CR group|For the patients in CR group, the conditioning regimen is high-dose Ara-C (3g/m2 q12h d1-3).
46043393|NCT02676856|Drug|Conditioning for Non-CR group|For the patients in Non-CR group, the conditioning regimens include: IAC（IDA 12mg/m2 d1-3，Ara-C 200 mg/m2 d1-7， Cladribine 5mg/m2 d1-5) or HD Ara-C(high-dose Ara-c 3g/m2 q12h d1-3).
45347504|NCT00901810|Device|Dental Radiography|Radiography is used to measure the length of root canal by putting an endodontic file in the canal and taking the radiography to measure the length.
45347505|NCT00830661|Procedure|Ligation of intersphincteric fistula track procedure|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure. This procedure will be performed as per standard operating procedure.
46043394|NCT00910234|Drug|recombinant human erythropoietin (rhEpo)|rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
46043395|NCT00910234|Drug|recombinant human erythropoietin (rhEpo)|rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
46043396|NCT00910234|Drug|Normal saline|normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
46043397|NCT04315220|Other|Corestability training|"Level -1: Mat exercises~Abdominal muscle contraction,bridging,cat stretch,single limb circle and superman.:~Level- 2: Swiss Ball Exercises Abdominal contraction,bridging and squats."
46043398|NCT04315220|Other|No Intervention|No Intervention
46043399|NCT05652322|Drug|Furosemide Pill 150% equivalent iv dose|change from intravenous to oral furosemide
46043400|NCT05652322|Drug|Furosemide Pill 200% equivalent iv dose|change from intravenous to oral furosemide
46043401|NCT05652322|Drug|Furosemide Injection|change from intravenous to oral furosemide
46043402|NCT01172288|Drug|N-Acetylcysteine (NAC)|1 600mg capsule twice a day for 2 weeks and then 2 600mg capsules twice a day for the remaining 10 weeks of the trial.
46043403|NCT01172288|Drug|Placebo|1 600mg Capsule twice a day for two weeks then 2 600mg capsules twice a day for the remaining 10 weeks of the study. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
45347506|NCT00830661|Procedure|anal fistula plug|placement of the porcine anal fistula plug as per the instructions for use in product packaging
45347507|NCT02539810|Device|Renal artery Angioplasty plus stenting.|renal artery stenting
45475417|NCT03353038|Device|3D printed pillbox|The research team interviewed the participant about their habits, routines, preferences, medications, and skills and abilities. Based on the interview, the research team designed and printed a customized 3D printed pillbox.
45347508|NCT02539810|Drug|Anti hypertensive, statin and antiplatelet medication.|Slow release indapamide 1.5 mg/d (or furosemide 40 mg/d if eGFR is < 30 mL/min/1.73m²) + irbesartan 300 mg/d + amlodipine 10 mg/d + aspirin 75 mg/d (or clopidogrel 75 mg/d in case of allergy or gastrointestinal intolerance to aspirin) + atorvastatin 20 mg/d. After randomization, bisoprolol 10 mg/d, prazosin 5 mg/d, and rilmenidine 1 mg/d and spironolactone 12.5 to 25 mg/d, will be sequentially added from months two to five in both groups if home blood pressure remains more than or equal to 135/85 mm Hg.
45347509|NCT04044183|Behavioral|Active Brains 1|Active Brains uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The Active Brains sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal & coping, and growth enhancement). The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a digital monitoring device (i.e., Fitbit) for recording of physical activity.
46043404|NCT02676622|Drug|mobilization of stem cells to prepare for Leukapheresis|"Cyclophosphomide 2 g/m2 x 2 consecutive days.~Filgrastim (G-csf) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapharesis."
46043405|NCT02676622|Other|Leukapheresis- Collection of stem cells|"Placement of an Apheresis Catheter on the day of collection of stem cells.~Leukapheresis will be performed on a continuous flow separator machine to target 3-8 x 106 CD34+ cells/kg body weight."
46043406|NCT02676622|Drug|Preparative regimen 4-6 weeks after Leukapheresis|"Prior to starting medicines, a central venous line will be placed (arm or chest)~Cyclophosphamide iv: 50 mg/kg iv over 2 hours~Mesna iv (uro-protectant): 36 mg/kg iv over 12 hours~r-ATG (Thymoglobulin, Genzyme): 2.5 mg/kg/dose iv over 6 hours on days -3,-2,-1"
45475418|NCT03737929|Procedure|Hybrid ablation|In the hybrid ablation arm, the epicardial surgical ablation procedure will be combined with percutaneous endocardial catheter ablation procedure in a single step procedure (same operative time). During the endocardial approach, the isolation of the pulmonary veins and the posterior box will be checked and completed if necessary. Then additional ablation will be performed for atrial tachycardia or ongoing persisting atrial fibrillation (AF) according the same lesions setup or stepwise protocol than the conventional arm
46043407|NCT02676622|Other|Stem Cell Transplant|"Infusion of the(cryopreserved and thawed)peripheral blood stem cells (PBSC)occurs on Day 0.~Day +5: start Filgrastim (G-csf) subcutaneous injections~Hospitalization in isolation room for 4-5 weeks"
45685037|NCT04123912|Behavioral|Kinesio Taping - Functional Movement Power Training|Subjects assigned to the Kinesio Taping - Functional Movement Power Training (KT-FMPT) group will receive FMPT concurrent with KT. The FMPT protocol was developed by the research team with reference to common physiotherapeutic exercises for children with motor disabilities.9 It comprises 5 functional movement exercises and 6 lower-limb power/resistance training exercises using weights or resistance bands.
45475419|NCT03737929|Procedure|Percutaneous catheter ablation|In the percutaneous catheter ablation arm, the procedure will be performed according to the current guidelines (pulmonary vein isolation, linear ablation and fragmented potentials ablation if needed, with the achievement of sinus rhythm during the procedure being the optimal endpoint. Any atrial tachycardia will be mapped and ablated as well (DC shock performed otherwise).
45475420|NCT03855761|Behavioral|Occupational Therapy|Detailed narrative assessment and person-centered participation in meaningful activities
45475421|NCT03855761|Behavioral|Case management; psychological services|Weekly consultation with case managers to address housing and therapy needs
45685038|NCT04123912|Behavioral|Jogging with placebo taping|Subjects assigned to the control group will receive no FMPT or KT, but participate in a jogging intervention with placebo tape applied on their calf muscles and removed after the intervention.
46043408|NCT02676622|Drug|Low-dose IL-2 administration|"IL-2 Subcutaneous injections will start once ANC is > 500/µL and patient is afebrile (start IL-2 will be approximately day +20)for 6 weeks of treatment.~Once patient or parent has learnt the administration and patient is tolerating it well, then the rest of the treatment can be administered at home after discharge with weekly follow up visits."
46043409|NCT04313816|Other|questionnaire|no intervention at all apart from filling a brief questionnaire
46043410|NCT00644020|Drug|mitomycin, Fluorouracil|All participants will receive 10mg mitomycin and 1g Fluorouracil through the chemoradiative pump which was transplanted during the operation, and this procedure would be executed a day before each research treatment period.
46043411|NCT04178980|Drug|Simvastatin in relapsing remitting multiple sclerosis|Simvastatin use as adjuvant thearapy in relapsing remitting multiple sclerosis
46043412|NCT04179136|Dietary Supplement|lignan capsules contain 300 mg flaxseed (SDG) extract|lignan capsules contain 300 mg flaxseed (SDG) extract
46043413|NCT04179136|Dietary Supplement|Placebo treatment matching intervention|Placebo treatment matching intervention
46043414|NCT02674048|Other|Metvix|
46043415|NCT02674126|Behavioral|Control group|Patients in the control group listened to a blank CD connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
46043416|NCT02674126|Behavioral|Maternal sound group|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
46043417|NCT04178902|Drug|ABBV-467|Intravenous (IV) Infusion
46043418|NCT02672566|Drug|Enoxaparin|Enoxaparin will be delivered to the patients every day at the dose of 4 000 Ui.
46043419|NCT02672566|Other|Usual care|Patients will all benefit from the usual care
46043420|NCT02672488|Drug|Sorafenib|Standard treatment for advanced HCC
46043421|NCT02672488|Drug|Metformin|To evaluate the safety and efficacy of the combined treatment of Metformin and Sorafenib for advanced HCC
46043422|NCT02673892|Other|Patient Oriented Discharge Summary|The PODS provides a written template for providers to engage patients and caregivers when reviewing important discharge instructions on medications, activity and diet restrictions, follow-up appointments and worrisome symptoms warranting emergency care. The PODS also uses plain and simple wording, large fonts, pictograms, and includes white space for patients to take notes and provides the option for translation of major headings into the most common spoken languages. As this will be a pragmatic design, we may make modifications to the process involved in completing the PODS, such as using pre-filled disease-specific information, if system processes and providers involved deem it more usable and feasible.
46043423|NCT00644098|Dietary Supplement|soluble fibre complex and medium chain triglycerides|
45347510|NCT04044183|Behavioral|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback, and interventionist support/feedback. The original HEP was adapted to provide population-specific information on chronic pain and MCI/MRP symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight, and Medical appointments). The HEP program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The HEP is conducted in the same format as Active Brains-Fitbit but are not taught the mind-body, walking, or cognitive-behavioral skills. HEP participants are encouraged to set lifestyle goals instead of quota-based walking goals aided by the Fitbit as in the Active Brains-Fitbit condition."
45347511|NCT00900952|Other|Clinical record review|
45475422|NCT03348826|Drug|Sodium Bicarbonate 8.4% Solution for Injection|3 mL injection into line with up to 2 injections administered
45475423|NCT03348826|Drug|Alteplase Injectable Solution|2 mL injection into line with up to 2 injections administered
45475424|NCT05665777|Drug|Qingyan Lihou Decoction|Chinese medicine granules
45475425|NCT05665777|Other|Placebo|Placebo granules
45475426|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 1 + adjuvant / dose; Day 0 and Day 30
45475427|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 2 + adjuvant / dose; Day 0 and Day 30
45475428|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 3 + adjuvant / dose; Day 0 and Day 30
45475429|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 3 / dose; Day 0 and Day 30
45475430|NCT01290419|Biological|Placebo|Placebo; Day 0 and Day 30
45475431|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 4 / dose; Day 0 and Day 30
45475432|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 4 + adjuvant / dose; Day 0 and Day 30
45475433|NCT04507282|Drug|LMWH|COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level
45475434|NCT03737773|Other|glasses (prismatic lenses)|
45475435|NCT03737773|Other|glasses (neutral)|
46043424|NCT00644098|Dietary Supplement|cellulose and soybean oil|
46043425|NCT02537392|Dietary Supplement|Vitamin B Complex and Folic Acid|Daily oral dose containing 2 mg vitamin B1, 2 mg vitamin B2, 2 mg vitamin B6, 2 μg vitamin B12, 2 mg calcium pantothenate, 15 mg nicotinamide and 0.4 mg folic acid.
46043426|NCT02537392|Dietary Supplement|Iron and Folic Acid|Daily oral dose of 60 mg iron and 0.4 mg folic acid.
45475436|NCT04507048|Other|Active educational intervention|an active educational intervention will be provided in the experimental arm, consisting in the administration of a booklet (passive intervention) + an oral standardized explanation of the booklet given by a trained dermatologist for each center.
45475437|NCT04507048|Other|Passive educational intervention|"Administration of a booklet containing the explanation of 2 clinical rules for early detection of atypical melanocytic lesions: the ABCDE and the ugly duckling rules."
45475438|NCT01183871|Procedure|Monitoring of cerebral oxygenation|The internal jugular vein will be cannulated using ultrasound guidance in a cephalad direction, using the Seldinger J-shaped guidewire and it will be advanced only for 2-3 cm beyond the needle insertion site to avoid vascular injury to the jugular bulb. At which point the catheter is advanced until resistance is met at the jugular bulb, usually about 15 cm. The catheter is then pulled back 0.5-1.0 cm so that the catheter does not continue to abut the roof of the jugular bulb and to minimize the cephalad vascular impact with head movement, thereby reducing the risk of vascular injury. Skull x-ray will be used to confirm placement.
46043427|NCT02537392|Dietary Supplement|Folic Acid|Daily oral dose of 0.4 mg folic acid.
45475439|NCT01060579|Drug|AR-12286 0.5% ophthalmic solution|q.d. PM
45475440|NCT01060579|Drug|AR-12286 0.25% Ophthalmic solution|q.d. PM
45475441|NCT01060579|Drug|Latanoprost ophthalmic solution|q.d. PM
45475442|NCT04443946|Drug|Propofol|5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
45475443|NCT04443946|Drug|1% Sevoflurane|add 1% end-tidal sevoflurane 20 minutes after endotracheal intubation.
45475444|NCT04443946|Drug|1% Sevoflurane continue|1% sevoflurane continued to maintain anesthesia after endotracheal intubation.
45475445|NCT04443946|Drug|Sufentanil|0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase
45475446|NCT04443946|Drug|2% Sevoflurane|2% sevoflurane continued to maintain anesthesia after endotracheal intubation.
45475447|NCT04443946|Drug|Propofol half|2.5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
45475448|NCT01184027|Behavioral|nutrition /swallowing counseling|general nutrition and swalling information
45475449|NCT01184027|Behavioral|G-tube/swallowing intervention|Patient will have active swallowing intervention with an SLP
46043428|NCT05613712|Other|Patients|Description by the patients through the questionnaire of the elements limiting the good ambulatory follow-up
46043429|NCT05613712|Other|Referring physician|Description by the referring physicians through the questionnaire of the elements limiting the applicability of the recommendations issued by the rheumatology department of the CHU Grenoble Alpes
45475450|NCT01184027|Behavioral|nutrition /swallowing intervention|Patient will have active (daily) nutrition and swallowing intervention based on patients individual needs.
45475451|NCT03730129|Drug|Hizentra|Subjects will receive Hizentra 0.4 mg/kg qweekly subcutaneously for 6 months (24 weeks)
45475452|NCT03348592|Dietary Supplement|Oligofructose-enriched inulin (p-inulin)|
46043430|NCT02676700|Behavioral|Pelvic floor muscle training and Kaatsu|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT and Kaatsu training as home training
45347512|NCT00901888|Drug|Apelin infusion|Infusion of up to 10picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
45347513|NCT00901888|Drug|Sodium nitroprusside infusion|Infusion of up to 150-600picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
45347514|NCT04416711|Behavioral|Personalized Feedback|The personalized feedback consists of four components: normative feedback, risk/protective feedback, decisional balance/goal setting, and protective strategy review. Personalized feedback targets include readiness to change, perceptions of risk, and misperceptions of peer attitudes/behaviors.
45475453|NCT03348592|Other|No treatment|Patients do not take a supplement during the first 8 weeks or the last 8 weeks of the study.
45347515|NCT04416711|Behavioral|Cognitive Skills Training|We will address three cognitive targets: focus on affective cues, focus on non-affective cues, and over-perception of sexual interest. The first module targets enhanced focus on women's affective cues and reduced over-perception of sexual interest. We will introduce the role of men's sexual-perception skills in satisfying social and sexual interactions with women, as well as problematic sexual behavior including RSB and SAB. Next, we will instruct participants that affective information is the best-available nonverbal information about how a woman is feeling about a specific man. This instruction will focus on distinguishing four primary dating relevant cues: sexual-interest, friendliness, sadness, and rejection. More detailed focus on each cue will emphasize the increased difficulty of reading these cues with a new partner and under the influence of alcohol and sexual arousal, as well as the importance of checking verbally on assumptions about a woman's current sexual interest.
45347516|NCT04416711|Other|Services As Usual|These participants will receive services as usual
45347517|NCT00908362|Drug|fluticasone|Participants inhale fluticasone (250 µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
45347518|NCT00908362|Drug|fluticasone/salmeterol|Participants inhale fluticasone/salmeterol (250/50µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
46043431|NCT02676700|Behavioral|Pelvic floor muscle training|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT as home training
45347519|NCT00908362|Drug|placebo|Participants inhale placebo twice daily via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
45347520|NCT02549469|Drug|Naproxen Sodium ER (BAY117031), 20% HPMC|1 tablet 660 mg administered orally once daily
45347521|NCT02549469|Drug|Naproxen Sodium ER (BAY117031), 30% HPMC|1 tablet 660 mg administered orally once daily
45475454|NCT03729973|Drug|Ketamine|Patients nebulized ketamine by compressor nebulizing for 15 minutes.
45475455|NCT03729973|Drug|Magnesium Sulfate|Patients nebulized magnesium sulfate 250mg (3ml)plus 2ml normal saline by compressor nebulizing for 15 minutes.
45475456|NCT03729973|Drug|Lidocaine|"In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized lidocaine 5ml by compressor nebulizing for 15 minutes."
45475457|NCT03729973|Drug|Normal saline|"In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized by compressor nebulizing 5ml normal saline for 15 minutes."
45685039|NCT04124146|Radiation|MRI for some patients according functionnal tests results|Depending on the results obtained on the evaluation criteria, additional examinations could be prescribed (imaging) for subjects with an unsatisfactory functional score. There is therefore a potential change in the usual care.
45685040|NCT01896271|Drug|IL-2|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion
45685041|NCT01896271|Radiation|Stereotactic Ablative Body Radiation Therapy|SABR dose varying from 8Gy-20Gy in 1-3 fractions
46043432|NCT02676544|Device|Embosphere microspheres|This is a clinical trial assessing the feasibly and safety of prostate artery embolization (PAE) for benign prostatic hypertrophy (BPH) resulting in severe lower urinary tract symptoms (LUTS) in patients with gland size ≥90 grams who are TURP ineligible or non-operative candidates with Embosphere microspheres.
45685042|NCT03003130|Device|Restylane Defyne|Intradermal injection
45685043|NCT03003130|Device|Restylane|Intradermal injection
45685044|NCT04123600|Device|Origin Stem and Logical Cup|The Origin Stem is a straight, tapered, HA coated cementless femoral stem, and the Logical Cup is a porous coated acetabular cup mated with a cross-linked polyethylene liner. The components are used as part of a total joint replacement prosthesis.
45685045|NCT01884571|Drug|Basiliximab|20 mg, IV (in the vein) on day 1 and 4.
45347522|NCT02549469|Drug|Naproxen Sodium ER (BAY117031), 40% HPMC|1 tablet 660 mg administered orally once daily
45347523|NCT02549469|Drug|Aleve (Naproxen Sodium, BAY117031)|1 tablet 220 mg administered orally three times daily
45347524|NCT00908440|Behavioral|Decision Aid|25 page booklet informing patients about PTSD symptoms and treatment options
45347525|NCT00905866|Other|PAS and SF-36 questionnaires|Patients who agree to participate in this study will be asked to fill out a translated PAS questionnaire and a Taiwan version of SF-36 before and after surgery
45347526|NCT00837525|Procedure|nasal valve implant|Injectable implantation of a biodegradable material for support of the Nasal valve.
46043433|NCT04178278|Diagnostic Test|Shuttle walking test|Patients will be required to walk around a 10-m course marked by cones placed 9 m apart, thus allowing 0.5 m for turning at each end. Walking speed will be regulated by prerecorded signals on a compact disc or MP3 file. Patients will increase walking speed at every minute. patients can stop this study, when they can not maintain their speeds due to dyspnea
45347527|NCT02539576|Drug|ABC/DTG/3TC FDC tablet|"ABC/DTG/3TC FDC will be supplied as purple, biconvex, oval tablets debossed with 572 Trı on one side and plain on the other side. A single dose, with a unit dose strength of 600 mg/50 mg/300 mg will be administered orally."
45347528|NCT00837603|Behavioral|Training|Controlled home ergometer training
45347529|NCT00905944|Other|Endurance exercise|The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.
45347530|NCT00923793|Device|Titanium implant (CranioConstruct™)|One to three weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Titanium implant is ordered.
45347531|NCT00923793|Device|Hydroxylapatite (CustomBone)|Six to eight weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Hydroxylapatite implant is ordered.
45347532|NCT02548533|Device|AFXL|Pretreatment at 2.5 mJ/microbeam and 15% density.
45347533|NCT02548533|Drug|AHES|Topical application on AFXL pretreated skin 15 minutes prior to the treatment.
45347534|NCT02548533|Drug|EMLA cream|Topical application 2 hours prior to the treatment.
45347535|NCT02549391|Drug|KHK7580|Oral administration
45347536|NCT02549391|Drug|KRN1493|Oral administration
45347537|NCT00902122|Drug|rAd-p53 gene|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
45347538|NCT00902122|Procedure|surgery|removal of thyroid tumor
45475458|NCT01189253|Drug|doxorubicin hydrochloride|
46043434|NCT04178278|Diagnostic Test|Exercise stress test|Exercise stress test will be performed with cycle. When patients perform this study, they will gradually increase the velocity. Investigators will measure electrocardiography, vital sign, oxygen saturation, oxygen uptake, minute ventilation and fatigue.
46043435|NCT04178278|Diagnostic Test|6 minutes walking test|When participants perform 6 minutes walking test, patients will walk around the tract during 6 minutes. They can their walking speed according to condition and symptom. Investigators records walking distance, pulse rate, oxygen saturation and Borg scale
46043436|NCT00642928|Drug|Placebo|1 capsule per day during 4 weeks
46043437|NCT00642928|Drug|BF 2.649 5 mg|one BF 2.649 capsule of 5 mg per day during 4 weeks
45347539|NCT00902122|Drug|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
45347540|NCT00902122|Radiation|p53 gene therapy with radioactive iodine|p53 gene therapy with concurrent radioactive iodine pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
45347541|NCT02538172|Other|T-Track® CMV assay|
45347542|NCT00837837|Drug|Chlorpheniramine|
45347543|NCT00908674|Drug|Cyproterone acetate (Androcur)|"The study drug will be administered either as monotherapy or in combination with other interventions (surgical castration or LHRH analogue treatment).~Daily dosage as monotherapy: 200-300 mg cyproterone acetate. Daily dosage following surgical castration: 100-200 mg cyproterone acetate. Daily dosage in combination with an LHRH-analogue: 100-200 mg cyproterone acetate.~Administration period: 12 months."
45347544|NCT00906022|Device|Astron Pulsar Stent|Stenting with Astron Pulsar
45347545|NCT00906022|Device|PTA alone|Balloon angioplasty alone
45347546|NCT00902356|Drug|AMG 167|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
45475459|NCT01189253|Drug|trabectedin|
45475460|NCT01189253|Other|laboratory biomarker analysis|
45475461|NCT01189253|Procedure|quality-of-life assessment|
45475462|NCT04443790|Drug|Leptin Human|
45475463|NCT03166215|Drug|TAK-935|TAK-935 tablets.
45475464|NCT03166215|Drug|Placebo|TAK-935 placebo-matching tablets.
45475465|NCT03851549|Device|New BGMS (US)|New blood glucose monitoring system / In vitro diagnostic device (IVDD)
46043438|NCT00642928|Drug|BF 2.649 10 mg|One BF 2.649 capsule of 10 mg per day during 4 weeks
46043439|NCT00642928|Drug|BF 2.649 20 mg|One BF 2.649 capsule of 20 mg per day during 4 weeks
46043440|NCT00642928|Drug|BF 2.649 40 mg|One BF 2.649 capsule of 40 mg per day during 4 weeks
46043441|NCT02676232|Behavioral|DARWeb|Psychosocial Intervention from the cognitive-behavioral model, including different but related units for parents and children with recurrent abdominal pain.
45475466|NCT04443868|Drug|Nitric Oxide-Releasing Drug|Nasal Spray + Nasal Irrigation
45475467|NCT03851393|Other|Induction of cough with inhaled citric acid|perform artificially induced cough by inhalation of citric acid at various strengths
45475468|NCT03851393|Procedure|Peptest™ analysis of saliva pepsin|collect patient saliva for analysis of pepsin levels
46043442|NCT02673814|Biological|durvalumab|
46043443|NCT02673814|Biological|bavituximab|
46043444|NCT00644176|Drug|azithromycin immediate release (Zithromax)|azithromycin IR 500 mg tablet by mouth for 1 dose
45475469|NCT03851393|Diagnostic Test|Peptest™|The Peptest™ lateral flow device
45475470|NCT04443556|Drug|Tramadol|Before the closure of the thoracotomy, the surgeon will place two catheters through a Tuohy needle into fascial planes for continue the RISS block. First catheter tip will be placed towards the interfascial planes between the rhomboid major and intercostal muscles and the second catheter tip will be placed in subserratus fascial plane. Continue local anesthetics will be injected through the catheters for 48 hours. Also an IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.
45685046|NCT01884571|Drug|Methylprednisolone|125 mg, IV (in the vein) on day 1.
45685047|NCT01884571|Drug|Prednisone|60 mg PO (by mouth) on days 2-7, 40 mg PO days 8-14, 20 mg PO days 15-21, and 10mg PO days 22-28.
45685048|NCT01884571|Drug|Tacrolimus|1-5 mg PO, twice a day (BID) days 2-180.
45685049|NCT01884571|Drug|Mycophenolate mofetil|500 mg PO, BID days 2-7, 500 mg PO each morning and 1000 mg each night, days 8-14, 1000 mg PO BID days 15-180.
45685050|NCT04123678|Device|Deep Ensemble for the Recognition of Malignancy (DERM)|AI-based decision support tool
46043445|NCT00644176|Other|placebo|placebo
46043446|NCT00644176|Drug|azithromycin SR|2.0 g by mouth in the form of liquid for 1 dose
45475471|NCT04443556|Other|IV PCA|An IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.
45475472|NCT05054985|Device|Multi-Branched Thoracoabdominal Stent Graft System|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with multi-branched thoracoabdominal stent graft system .
45685051|NCT04123522|Procedure|anterior approach|anterior approach
45685052|NCT04123522|Procedure|posterior appraoch|posteiror appraoch
45685053|NCT01884337|Drug|Apixaban|
45685054|NCT02996890|Biological|MV-ZIKA|MV-Zika vaccine
45685055|NCT02996890|Other|Placebo|physiological saline
46043447|NCT00644176|Other|placebo|placebo
46043448|NCT02673424|Procedure|FFR-guided stenting|"The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the FFR-guided strategy arm~* Criteria for revascularization: The FFR ≤ 0.80 will be targeted for PCI"
46043449|NCT02673424|Procedure|IVUS-guided stenting|"The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm~* Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or (MLA ≤ 4mm2 AND Plaque burden >70%)"
46043450|NCT02673736|Drug|PLX73086|
46043451|NCT04178200|Drug|Lidocaine 2% Injectable Solution 0.75 ml|0.75 ml of Lidocaine will be added to the anesthetic solution.
46043452|NCT04178200|Drug|Bupivacaine Hcl 0.5% Inj 0.75 ml|0.75 ml of Bupivacaine will be added to the anesthetic solution.
45685056|NCT04123288|Drug|ACT-709478|1 film-coated minitablet contains 2 mg of ACT-709478
45347547|NCT00902356|Drug|Placebo|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
45347548|NCT00621777|Drug|Varenicline|"At each weekly study visit from the baseline visit to study week 11, ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the varenicline condition will receive varenicline at the dose used to attain initial abstinence for 40 weeks."
45475473|NCT01187615|Drug|Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed|In Part A of this trial, regorafenib will be administered in a sequential dosing with a seven day wash out period before the next infusion of pemetrexed and cisplatin. Regorafenib will be administered at a dose of 160 mg qd from Day 2 to Day 14 followed by a 7 days break. Pharmacokinetics of regorafenib will be assessed on Day 14 of Cycle 1 and Day 1 of Cycle 2.
45347549|NCT00621777|Drug|Placebo|"At each weekly study visit from the baseline visit to study week 11,ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the placebo condition will receive placebo pills for 40 weeks."
45475474|NCT01187615|Drug|Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed|In Part B of this trial, regorafenib will be administered continuously from Day 1 to Day 21. Only in Cycle 1, regorafenib dosing will start on Day 2 in order to assess the pharmacokinetics of pemetrexed and cisplatin without concomitant regorafenib dosing. Pharmacokinetics of regorafenib will be assessed on Day 21 of Cycle 1 and on Day 1 of Cycle 2.
45475475|NCT05375097|Other|Erenumab|Patients who met the responder definition of two or more erenumab prescriptions with no evidence of switch to other CGRPi were included in the main analyses
45685057|NCT04123288|Drug|ACT-709478|1 hard capsule contains 10 mg of ACT-709478.
45685058|NCT04392934|Procedure|a conservative physiotherapy protocol|5 minutes of ultrasound (Business Line US 50, Medical Italia, Italy) at a frequency of 1 MHz and intensity of 1.5 watts/cm², 20 minutes of conventional TENS (BTL-5000, UK ) applied to the patients. Then Codman's exercises, shoulder wheel activity, isometric exercises, range of motion exercises, capsular stretching, scapular stabilization exercises, and muscle strengthening exercises were done by patients. After the treatment, cold pack was applied to the shoulder for 10 minutes. The modalities in the treatment program were applied for a total of 20 sessions 5 days per week.
45685059|NCT04123210|Dietary Supplement|Vitamin A supplement|
45685060|NCT04123210|Dietary Supplement|Placebo|
45685061|NCT02994550|Drug|FSH/LH|
45685062|NCT04123132|Other|Kinesiophobia|The presence of kinesiofobia in patients with metabolic syndrome
45685063|NCT01922089|Drug|LCZ696|LCZ696 50 mg/100 mg/200 mg bid
46043453|NCT04178200|Drug|Lidocaine 2% Injectable Solution 1.5 ml|1.5 ml of Lidocaine will be added to the anesthetic solution.
46043454|NCT04178200|Drug|Bupivacaine Hcl 0.5% Inj 1.5 ml|1.5 ml of Bupivacaine will be added to the anesthetic solution.
46043455|NCT00644410|Biological|Mesenchymal stromal cell|Mesenchymal stromal cells 20 - 40 mill.
46043456|NCT00644410|Biological|Saline|12 injection with 0.2 ml saline
46043457|NCT02537158|Drug|Sorafenib|sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).
46043458|NCT02537158|Procedure|TACE|TACE group patients will accept TACE therapy once at a month after resection.
45347550|NCT02538718|Drug|MgSO4|
45347551|NCT02538718|Drug|YTP(Ritodrine)|
45347552|NCT00827229|Device|Labor Monitor|
45347553|NCT02539420|Device|BiPAP treatment|Patients will receive BiPAP (via Respironics V60 or Vision BIPAP device) as part of their treatment for status asthmaticus
45347554|NCT04018599|Drug|40 mg MSB11022|Single dose, as a solution, administered subcutaneously, using an auto-injector.
45685064|NCT04122664|Device|RayOne® Hydrophobic lens 800C|Patients will receive a monofocal, aspheric, hydrophobic acrylic intraocular lens: the RayOne® Hydrophobic lens 800C
45685065|NCT04122664|Device|RayOne® Hydrophilic lens 600C|Patients will receive a monofocal aspheric, hydrophilic acrylic intraocular lens: the RayOne® Hydrophilic lens 600C.
45685066|NCT04122430|Other|Review of Health Information|
45685067|NCT04122586|Drug|Tongxieyaofang(granule)|Take this granule twice a day,one bag for each time,one hour after a meal,for 4 weeks
46043459|NCT04177420|Device|FIR-C mattress|infrared-C irradiation by hot mattress with a powered heating compress
46043460|NCT04177420|Device|FIR-C abdominal pad|infrared-C irradiation by hot abdominal pad with a powered heating compress
46043461|NCT04177420|Device|fake FIR-C mattress|normal mattress with fake controller, custom make for placebo group
46043462|NCT04177420|Device|fake FIR-C abdominal pad|normal abdominal pad with fake controller, custom make for placebo group
45475476|NCT04509934|Other|Connective Tissue Manipulation|The position of the patients during treatment sessions was sitting with the hips and knees at 90° flexion and feet supported, arms relaxed on the thighs, back naked and straight, allowing optimal tension of the connective tissue. The CTM procedure consisted of treating 3 sections in the back. These sections were basic (sacral and lumbar regions), lower thoracic (L1 through T7) and anterior pelvic. All sessions were ended with bilateral long strokes to the iliac crest and subcostal regions. The physiotherapist applied strokes bilaterally by her middle finger of the right or left hand to the defined zones of the mentioned sections in the back. The treatment started from the basic section, and progress to other regions was decided according to the vascular reaction of the connective tissue. Each session lasted for 5 to 20 minutes, depending on the extent of the treated area.
45475477|NCT01189331|Device|CT coronary angiography and computational fluid dynamics|Evaluate coronary blood flow dynamics by CT coronary angiography and computational fluid dynamics
45347555|NCT04018599|Drug|40 mg MSB11022|Single dose, as a solution, administered subcutaneously, using a pre-filled syringe.
45347556|NCT00902512|Drug|Treatment A|Viagra® 100 mg tablet, administered with water single dose
45347557|NCT00902512|Drug|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
45347558|NCT00902512|Drug|Treatment B|Sildenafil 100 mg CT administered with water single dose
45475478|NCT01184105|Drug|Intervention A|A single dose of 60 mg will consist of 6 sprays of the 10 mg strength spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
45347559|NCT00902512|Other|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
45347560|NCT00902512|Drug|Treatment C|Sildenafil 100 mg CT administered without water single dose
45347561|NCT00902512|Other|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
45347562|NCT00830973|Other|Poor Metabolism Status Follow Up Therapy Considerations|If the patient's CYP2D6 metabolism status is 'poor' then specialist pharmacist will discuss drug therapy alternatives to tamoxifen.
45347563|NCT00830973|Other|CYP2D6 Inhibiting Drugs|If the patient after having a CYP2D6 test has any drugs that inhibit tamoxifen metabolism then specialist pharmacist will contact the physician for alternative drug therapies.
45347564|NCT04034914|Other|Questionnaire administration|Ancillary studies
45347565|NCT00827307|Drug|tamoxifen|In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
45347566|NCT00827307|Drug|Goserelin|In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg
45347567|NCT04034602|Other|vibration group|plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 5 minutes.
45347568|NCT04034602|Other|placebo group|the placebo group, both sides will be held in the supine position under the soles of the foot for 5 minutes each so that the device is in contact with the foot without vibration.
45347569|NCT00837915|Drug|Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets|
45347570|NCT00908986|Drug|Rituximab|375mg/m2 q week x 4; repeated in 6 months
45347571|NCT02539264|Other|Smoking|Influence of smoking on parameters derived from overnight PSG
45347572|NCT02539264|Other|Obesity|Influence of obesity on parameters derived from overnight PSG
45347573|NCT02539264|Other|Benzodiazepine use|Influence of benzodiazepine use on parameters derived from overnight PSG
45347574|NCT00827463|Biological|dosage of the NFS and iron|a blood test will be made.
45347575|NCT00909142|Drug|Bonefos (Clodronate, BAY94-8393)|Patients in regular clinical practice receiving Bonefos according to local drug information
45347576|NCT00906256|Drug|AZD7295|Capsules 260mg, 455mg, 650mg (single doses), 650mg q12h, 650mg q8h.
45475479|NCT01184105|Drug|Intervention B|A dose of placebo will consist of 6 sprays of the placebo spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
46043463|NCT02676154|Drug|Fesoterodine|4mg, oral, once daily for 12 weeks; dose adjustments may be permitted.
46043464|NCT02676310|Drug|Bimatoprost|
46043465|NCT04180618|Other|Personal health wallet service for emergency situation|Patients(caregivers) and medical staffs will be provided the personal health wallet service and evaluate the effectiveness and satisfaction for the service.
45475480|NCT02752191|Drug|ferumoxytol|ferumoxytol as an MRI contrast agent infused over several minutes
46043466|NCT04177888|Device|Hot Pack|It is a single-use pack filled with magnesium sulfate and water, which was squeezed between the hands to activate their warming effect. The temperature ranges between 40°C to 50°C, which is safe to use. Thus, it provided a consistent heat therapy for up to 30 minutes. They can be used directly on the skin or covered with gauze to avoid direct skin contact. Applied to the lower back area for 30 minutes, followed by 10 minutes rest between each hot pack application, then it was reapplied for another 30 minutes. This procedure was repeated till delivery.
45347577|NCT00906256|Drug|Placebo|Placebo
46043467|NCT00643084|Procedure|low residue diet/no standard bowel preparation|low residue diet/no standard bowel preparation
45347578|NCT00838071|Drug|Specific intravenous anti-hepatitis B immunoglobulin|Monthly doses of 5000 IU administered intravenously during 6 consecutive months
46043468|NCT00643084|Procedure|standard bowel preparation|standard bowel preparation
46043469|NCT02676388|Procedure|Freeze-dried, Capsulized FMT|
45841112|NCT05387538|Procedure|Two-layer Duct-to-mucosa Pancreaticojejunostomy|The same double needle and 4/0 or 3/0Prolene line will be used. First, the region approximately 1.0 cm from the cutting edge of the pancreatic remnant will be freed; then, the posterior surface of the pancreatic remnant will be sutured to the seromuscular layer of the jejunum using the interrupted suturing method. The jejunum will be brought closer to the stump of the pancreas, and a hole of similar diameter to the main pancreatic duct will be made on the jejunum near the entrance of the main pancreatic duct. The posterior wall of the jejunum near the hole will be sutured to the posterior wall of the pancreatic duct using the interrupted suturing method with Prolene line, and a suitable internal pancreatic duct stent will used . The interior side of the jejunum and pancreas will be sutured using the same method. Then, the anterior surface of the pancreatic remnant and the seromuscular layer of the jejunum will be tightly sutured using the interrupted method.
45347579|NCT02539186|Biological|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve
45347580|NCT02539186|Device|splint|
45347581|NCT04044573|Procedure|Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bolus of i.v. corticosteroid is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Ciprofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
45347582|NCT02538640|Other|High-SDS biscuit|Consumption of the high-SDS product (50g) alone with a glass of water
45347583|NCT02538640|Other|Low-SDS extruded cereals|Consumption of the low-SDS product (42g) alone with a glass of water
45347584|NCT00902824|Biological|ADVAX|Receive 4mg ADVAX at Months 0, 1, and 2 (Biojector), and receive boost of 5x10^7 pfu TBC-M4 (IM)
45475481|NCT02752191|Drug|gadofosveset|gadofosveset as an MRI contrast agent injected over several seconds
45475482|NCT03853577|Other|TMS/EEG|navigated TMS/high-density(hd)-EEG to directly stimulate defined cortical areas and investigate quantitatively the level of consciousness in psilocybin-induced altered brain states
45475483|NCT01290497|Drug|Hyaluronic acid 5 x 2.5 ml|5 intraarticular administration of Adant® 2.5ml with one week interval between administrations (standard treatment)
46043470|NCT02676388|Procedure|Fresh FMT|
46043471|NCT04094974|Device|ANSiscope|Heart rate variability will be assessed using ansiscope before surgery
46043472|NCT04177186|Other|Strength training|Strength training for hamstring and gastrocnemius only, pre and post 12 weeks of intervention
46043473|NCT04177186|Combination Product|Strength training with botulinum toxin|Strength training for hamstring and gastrocnemius with Ultra Sound Imaging method, pre and post 12 weeks of intervention
46043474|NCT04094194|Other|Nordic diet|Healthy dietary pattern that is consumed in Nordic countries
46043475|NCT02672020|Biological|omics identity card|
45347585|NCT00902824|Biological|TBC-M4|Receive 5x10^7 pfu TBC-M4 (IM) at Months 0, 1, and 6.
45347586|NCT00902824|Other|Placebo|"Group A (n=4) will receive the ADVAX placebo (formulation buffer) via Biojector.~Group B (n=4) will receive the TBC-M4 placebo (formulation buffer) via IM."
45475484|NCT01290497|Drug|Hyaluronic acid 1 x 5 ml|1 intraarticular administration of Adant® 5ml
45475485|NCT01290497|Drug|Hyaluronic acid 2 x 5 ml|2 intraarticular administration of Adant® 5ml with a two-week interval between administrations.
45347587|NCT02547519|Drug|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 22.5 mg or placebo for the following 3 months; increasing to daily treatment with 67.5 mg or placebo for the last 6 months of the treatment period.
45347588|NCT02547519|Drug|Placebo|Total of 12 months treatment; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
45347589|NCT02547285|Other|Shoes characteristics|A single parameter of shoe vary for each test (Different insole, heel height, stem length ...)
45475486|NCT03352804|Other|Screening of MDR Bacteriae|questionnaire will be filled by every patient
45475487|NCT03853265|Behavioral|Simulated dental office visit|An immersive first-person point of view (POV) video simulation of the dental office in the three-dimensional environment (using a virtual reality headset) which allows participant to look around the room as they move down the hallways which is to be watched/experienced by the participant as often as possible between the initial visit and the follow up visit
46043476|NCT04096846|Diagnostic Test|laboratory investigation|detection of serum level of methotrexate and serum level of vitamin D
46043477|NCT04092244|Diagnostic Test|CTHRC1 biomarker|its a biomarker detected in the serum of the patients
46043478|NCT04180384|Drug|Oraxol|"Paclitaxel:~5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13- ester with (2R,3S)-N-benzoyl-3-phenylisoserine~HM30181 methanesulfonate monohydrate:~N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide Methanesulfonate monohydrate"
45685068|NCT04122820|Diagnostic Test|Diagnostic of specific learning disabilities or of Developmental Coordination Disorder|Speech therapy assessment, or occupational therapy. In case of pathological disorder, search for a sensory disorder, and therapeutic management. If the pathological disorder persists for more than six months, elimination of a secondary etiology.
46043479|NCT04091776|Radiation|CT scan|"Quantitative CT scan to measure localized osteoporosis and detection of cortices comminution.~Blinded surgeon decision as regard to replace or to fix using DHS or PFN (depending on x-rays data only).~Pathological assessment of osteoporosis in retrieved bone in patients whom hip replacement was decided.~Assessment of fixation failure in fixed fractures if occurred.~Fixation failure is defined as:~5.1. Lag cut through 5.2. Lag cutout 5.3. Z-effect (lag penetration) 5.4. Non-union (within 6 months) 5.5. Loss of reduction with progressive varus deformity 5.6. Femoral fracture 5.7. Intra-operative fracture of lateral wall or anterior cortex"
46043480|NCT02672254|Radiation|Samples with 2 treatments|Study the concomitant effects between chemo- and radiotherapy by means of cellular techniques.
45475488|NCT04509778|Other|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
45841113|NCT05074680|Diagnostic Test|Blood sampling|Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)
45841114|NCT05017584|Drug|Hyperbaric bupivacaine|"The dose for the first subject (A#X) will be 12 mg 0.75% hyperbaric bupivacaine. Two possible outcomes will be recorded: satisfactory or unsatisfactory anesthesia which is determined by occurrence of intraoperative pain and the need for intraoperative analgesia supplementation. Satisfactory analgesia will be defined as a sensory block to the T8 dermatome and the patient shall require no further supplementation for discomfort during her procedure. Unsatisfactory analgesia will be defined as a block not achieving a T8 dermatomal level or when a patient requests additional medication for discomfort at any time during her procedure.~The dose for the next (A#X+1) will be adjusted based on the outcome from previous subjects respectively using up-down sequential allocation method with a biased-coin design. This process will continue in similar fashion with dose adjustments for next subjects to be based on outcome from subjects immediately prior."
45841115|NCT05010096|Drug|Copanlisib|Given IV
45841116|NCT05010096|Drug|Elimusertib|Given PO
45841117|NCT04999332|Drug|leucovorin, oxaliplatin, docetaxel, S-1|Perioperative chemotherapy with LOTS
45841118|NCT04403880|Other|Sample collection|"Optional nasal specimen(s)~Blood collection"
45841119|NCT04147416|Drug|HSK3486 0.1-0.2 /0.3 mg / kg group|Administered with HSK3486 at a loading dose of 0.1-0.2 mg/kg via intravenous pump. Then HSK3486 shall be administered immediately at an initial maintenance dose of 0.3 mg/kg/h respectively.
45347590|NCT04318587|Diagnostic Test|Allosure|Blood is collected from the patient, packaged, and shipped at ambient temperature to CareDx for testing. Donor-derived cell-free DNA is measured via targeted amplification and sequencing of a set of carefully selected and validated SNPs. The AlloSure bioinformatics software calculates the percent dd-cfDNA in the sample tested and applies the QC criteria. The AlloSure results will be compared to the episodes of acute rejection diagnosed by transbronchial biopsy and BOS/CLAD diagnosed by spirometry in the subjects medical records. Transbronchial biopsies and spirometry are standard of care for lung transplant recipients.
45347591|NCT00909454|Dietary Supplement|2000 IU Vitamin D3 daily supplement|2000 IU vitamin D3 supplement to be taken once daily over 4 months
45347592|NCT00909454|Dietary Supplement|400 IU Vitamin D3 supplement|400 IU Vitamin D3 supplement to be taken daily over 4 months
46043481|NCT04177732|Diagnostic Test|Collection of sulcular (crevicular) fluid|Sterile paper strips will be used for collecting crevicular fluid
46043482|NCT04177732|Diagnostic Test|Probing depth|Williams SE manual probe will be used to measure the probing depth
46043483|NCT04177732|Diagnostic Test|Bleeding on probing|Williams SE manual probe will be used to probe the sulcus a oserve the gingival reaction
46043484|NCT04177732|Diagnostic Test|Gingival index|Modified Löe and Silness criteria will be used for evaluating the gingival index score
46043485|NCT04177732|Diagnostic Test|Bone loss rate of alveolar bone|Using modification of criteria described by Schei et al, bone loss rate of alveolar bone will be analyzed on radiographic assessment
45347593|NCT04312737|Device|Self-Collecting Devices|FLOQSwab (Copan) Colli-Pee (Novosanis)
45347594|NCT04312737|Diagnostic Test|In Vitro Diagnostic Assays|Papilloplex (GeneFirst) HPV Oncopredict DNA (Hiantis) HPV Oncopredict RNA (GeneFirst)
45347595|NCT04035070|Combination Product|co-amoxiclav-clindamycin solution|antibiotic-containing solution will be prepared by mixing equal quantities of 1.2gm Co-amoxiclav solution and 600mg Clindamycin solution at a ratio of 1:1 by volume to be used as a root canal irrigating solution
45347596|NCT04035070|Combination Product|MTAD|mixture of 3% doxycycline hyclate, 4.25% citric acid and detergent (Tween 80) to be used as a root canal irrigating solution
45347597|NCT04035070|Combination Product|2.5% sodium hypochlorite|It will be prepared by adding 10mL of sterile distilled water to 10mL of 5.25% sodium hypochlorite solution to be used as a root canal irrigating solution
45347598|NCT00838149|Dietary Supplement|Glutamine|"Glutamine group :~Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
45347599|NCT00838149|Dietary Supplement|Whey protein|"Whey protein group:~Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
45841120|NCT04147416|Drug|Propofol 0.5-1.0/1.5 mg/kg group|Administered with Propofol at a loading dose of 0.5-1.0mg/kg via intravenous pump. Then Propofol shall be administered immediately at an initial maintenance dose of 1.5 mg/kg/h respectively.
46043486|NCT02671942|Drug|Roflumilast|
46043487|NCT02671942|Drug|Placebo|
46043488|NCT00643240|Radiation|yttrium Y 90 anti-CD19 monoclonal antibody BU12|Patients in whom the biodistribution is as expected (unaltered) AND a HAMA response does not develop will receive a single dose of 90Y-BU-12 in a dose escalated manner to establish the maximum tolerated dose (MTD) of 90Y-BU-12 over 60 minutes on Day 0. A single course of BU-12 includes the imaging dose of 111In-BU-12 followed 7-8 days later by the therapy dose of 90YBU- 12.
46043489|NCT00643240|Radiation|111In-BU-12|Patients receive indium-111 BU-12 IV over 60 minutes on day 0
46043490|NCT00644488|Drug|BMS-641988 (AR#2)|Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks
46043491|NCT02675920|Drug|non-ionic monomer iodinated CT contrast media|patients underwent contrast-enhanced CT using aforementioned CT contrast media (non-ionic monomer iodinated CT contrast media)
46043492|NCT02671474|Other|4-dimensional volume-rendered computed tomography|
46043493|NCT02671708|Drug|Idarubicin（IDA）|Idarubicin was administered at 15mg/m2/day on days -12 and -10.
46043494|NCT02671708|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
46043495|NCT02671708|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
46043496|NCT02671630|Other|A community-based computerized cognitive training program|The computer training games included: 1) a phonological loop to train the participants to choose correct song from a list of different songs which can be categorized as people, nature, and musical instrument. The difficulty level progressed from choosing one from two to choosing one from three songs; 2) a visual-spatial sketchpad to train the participants to remember and find the same graphs including vegetable, fruits, daily necessity, and numbers. The difficulty level progressed from finding one pair to three pairs of similar graphs; 3) a central executive system to train the participants to execute dual tasks including conducting dual memory, calculating while listening to music, making phone calls, and matching medication at correct time.
45347600|NCT02548377|Procedure|Remote ischemic preconditioning|
45347601|NCT02548377|Procedure|Sham|
45347602|NCT02538874|Drug|BMS-986171|
45347603|NCT02538874|Other|Placebo|
45475489|NCT01184183|Procedure|Comparing Accuseal Vs. Bovine Pericardial in CEA|"Accuseal patch - The Goretex Company has since designed a new patch, the Accuseal, which is marketed as decreasing the intra-operative time (i.e, having a short hemostasis time) without affecting the perioperative stroke rate.~Bovine Pericardial patch - The Bovine Pericardial patch has been used for nearly two decades, since the late 1990s. However, studies based on retrospective review of data in which patients received the Bovine Pericardial patch, reported the clinical outcomes post-operative stroke, death, time to hemostasis and recurrent restenosis."
46043497|NCT02671552|Drug|Perflutren Protein-Type A Microspheres|Given IV
45347604|NCT00408421|Drug|Duloxetine|
46043498|NCT02671552|Procedure|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
46043499|NCT05277064|Other|Oral FOB|After induction of anesthesia and muscle relaxation, An investigator who has experiences of numerous fiberoptic intubations will measure the optimal preliminary insertion depth of the fiberoptic bronchoscope for oral fiberoptic intubation.
45347605|NCT00408421|Drug|placebo|
45347606|NCT00604786|Drug|omalizumab|Dosing is based on IgE level and weight given every 2 or 4 weeks
45347607|NCT00604786|Drug|placebo|Dosing is based on IgE level and weight given every 2 or 4 weeks
45347608|NCT00902980|Other|Chart Review|Chart review of patients / graft outcome in renal transplant recipients
45347609|NCT04034758|Procedure|Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)|heterologous fecal microbiota transplantation (FMT) by Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)
45347610|NCT04034758|Procedure|placebo capsule|Oral administration of 30 placebo capsule containing edible pigmented starch
45347611|NCT00903136|Other|questionnaire administration|
45347612|NCT00903136|Procedure|comparison of screening methods|
45347613|NCT00903136|Procedure|diagnostic endoscopic procedure|
45347614|NCT00903136|Procedure|esophagogastroduodenoscopy|
45347615|NCT00903136|Procedure|tethered capsule endoscopy|
45347616|NCT01042873|Drug|3 hours intravenous dobutamine|Intravenous dobutamine will be infused during 3 hours. At the first and last 0.5 hors of infusion dose will be increased gradually, while in the middle 2 hours dose will remain constant.
45347617|NCT00906490|Device|Intravenous Blood Glucose monitoring system|Insertion of blood glucose monitoring sensor into peripheral vascular IV line.
46043500|NCT05280340|Drug|Anakinra|Anakinra will be given to enrolled infants starting in the first 24hrs of life for the first 3 weeks of life.
45347618|NCT01042951|Biological|ShanChol Cholera Vaccine|55 adults (18-45 year old) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Toddlers(2-5 years) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Younger children(12-23 months)will be given 2 doses of the bivalent whole-cell cholera vaccine
45347619|NCT01042951|Other|Placebo|55 adults (18-45 year old) will be given 2 doses placebo, 55 Toddlers(2-5 years) will be given 2 doses of placebo, and 55 Younger children(12-23 months)will be given 2 doses of placebo
45347620|NCT01037023|Drug|Topotecan|patients administrated Topotecan according to the prescribing information
46043501|NCT02671006|Other|Basophil patterns|The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
45347621|NCT00604708|Biological|IC51|IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
45347622|NCT00604708|Biological|JE-VAX|JE-VAX, 1mL s.c. injection, 3 vaccinations, days 0, 7 and 28
45347623|NCT00909688|Drug|BLI-489|
46043502|NCT00644566|Other|Shared Care|A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
46043503|NCT04176328|Drug|Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.|Teicoplanin Sandoz administered by inhalation (aerosol).
46043504|NCT04178044|Biological|GB223,7mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:7mg/kg 2 subjects receive placebo.
46043505|NCT04178044|Biological|GB223,21mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:21mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
46043506|NCT04178044|Biological|GB223,63mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:63mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
46043507|NCT04178044|Biological|GB223,119mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:119mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
46043508|NCT04178044|Biological|GB223,140mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:140mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
45347624|NCT00909688|Drug|placebo|
45347625|NCT00903214|Drug|riluzole|100 mg orally twice a day, tablets self-administered, administered from day -14 to day 0 (scheduled surgery and preserve tissue for biormarker analysis)
45347626|NCT00903214|Genetic|polymorphism analysis|Pre-treatment, day -15 but may be done any time after enrollment but before surgery.
45347627|NCT00903214|Procedure|axillary lymph node biopsy|
45347628|NCT00903214|Procedure|digital image analysis|
46043509|NCT04175860|Behavioral|The intervention with the patient (Chronic Patient Care Group and his family.)|"Characterization: through the application of the characterization survey of the dyad (patient-caregiver),~Evaluation of the competence to care at home: Application of the instrument 'competence to care at home, long and short version both the patient and the family caregiver.~Risk assessment: this step is made based on the complexity of the treatment and the results of the evaluation the competence to care at home."
46043510|NCT02671396|Behavioral|Virtual reality based intervention|Virtual reality based balance training
45347629|NCT00903214|Procedure|needle biopsy|
45347630|NCT00903214|Procedure|sentinel lymph node biopsy|
45347631|NCT00903214|Procedure|therapeutic conventional surgery|
45347632|NCT04034836|Drug|Scalp blocks with ropivacaine plus parecoxib|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus 10 mg parecoxib (diluted in 2 mL NS) with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml;An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
45475490|NCT04509466|Drug|Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase|"Drug: Liposomal mitoxantrone hydrochloride (12mg/m2, 16mg/m2, 20mg/m2, 24mg/m2) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle."
45475491|NCT04509466|Drug|Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase|"Drug: Liposomal mitoxantrone hydrochloride (RP2D defined in Part 1) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle."
45754006|NCT05621473|Device|PICC|Tunnel PICC puncture technology is a perfect combination of ultrasound-guided puncture, ECG lead technology, PICC and subcutaneous tunnel. The valve conduction PICC is equipped with an integrated ECG lead Doppler ultrasound machine. Before the catheter is placed, in the yellow area, in the ultrasound mode, evaluate the blood vessel condition, measure the blood flow velocity, and correctly select the puncture site. When the catheter is pushed close to the superior vena cava, the electrocardiograph mode is switched to complete the precise positioning of the catheter according to the principle of ECG positioning technology. A subcutaneous tunnel was prepared in the green area, and the PICC at the puncture site in the yellow area was introduced to the green area and carefully bandaged. Whole-process integrated operation, simple and efficient operation.
46043511|NCT02671396|Behavioral|Conventional intervention|Conventional balance training
46043512|NCT04177342|Drug|Fentanyl|the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group
46043513|NCT04177342|Drug|Oxycodone|the patients use oxycodone and remifentanil as intra-operatively pain control and compare the post-operative pain condition with the fentanyl group
46043514|NCT02671786|Other|MAHAN RUTF & MAHAN Vit-Min mix|MAHAN RUTF dishes are locally prepared by local tribal women and each packet of RUTF provides 500-550 calories & 15-17 gms of proteins.
46043515|NCT00644644|Other|Rapid Response Team (NTX wireless monitoring system)|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
46043516|NCT04016506|Other|nutritional questionnaire|nutritional questionnaire is given to the patient after the injury
46043517|NCT05243524|Other|Maveropepimut-S|SC injection on days 7, 28, then q8w
46043518|NCT05243524|Drug|Cyclophosphamide 50mg|PO BID, one week on, one week off
46043519|NCT02668276|Other|Standard NCCN counseling|
46043520|NCT02668276|Other|Standard NCCN counseling and Oncotype DX results|
46043521|NCT04176094|Other|16h overnight duty|schedule observed by participating ICUs.
46043522|NCT04176094|Other|24h overnight duty|schedule observed by participating ICUs.
45475492|NCT04509466|Drug|Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase|"Drug: Liposomal mitoxantrone hydrochloride (RP2D defined in Part 1) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle."
45475493|NCT03352726|Drug|DBV712 IHRP|DBV712 Solution for Skin Prick Test
45475494|NCT03122626|Behavioral|Together in Movement and Exercise (TIME) Program|The TIME program is an evidence-based, standardized, progressive, licensed exercise program developed by physical therapists at the Toronto Rehabilitation Institute-University Health Network.
45475495|NCT03168711|Drug|Inosine|Subjects on inosine will receive 1-6 capsules a day of 500 mg inosine titrated to target urate levels of 7 - 8 mg/dL.
45475496|NCT03168711|Drug|Placebo|Subjects on placebo will receive 1-6 capsules a day of 500 mg placebo (sugar pill) titrated to target urate levels of 7 - 8 mg/dL.
46043523|NCT04176094|Other|Handover training|Formal handover training for residents in both interventions. ICUs with a pre-existing standardized handover training and process will be asked to continue handover practices throughout the study. In ICUs without a pre-existing standardized handover training and process, ICU education directors will be provided with materials to include in orientation of residents to the ICU and local training to ICU staff physicians at least once per year.
45347633|NCT04034836|Drug|Scalp blocks with ropivacaine and intravenous parecoxib|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) together with 10 mg parecoxib (diluted in 2 mL NS) intravenously. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
45475497|NCT04509856|Behavioral|Teach-back educational method|In the teach-back method, after teaching new information to the patient, the patients were asked to explain that new information in their own words. Then the patients' knowledge and the adequateness of their explanations were determined. The patient should repeat the instructions in their own words. In this way, the healthcare professional can evaluate how the patient understands the information. If the patient repeated the information correctly, the teach-back phase for that information was completed, and progression for new information was resumed. However, if there was a deficiency or error in the information, it was corrected and repeated by the healthcare professional.
45475498|NCT03738215|Drug|Cariprazine|Cariprazine supplied in capsules
45475499|NCT03738215|Drug|Placebo|Placebo supplied in capsules
45475500|NCT03122704|Procedure|GBS screening|Vaginal and anal swabs of patients will be screened for GBS screening
45475501|NCT04523181|Drug|Antroquinonol|double-blind for antroquinonol and Placebo with same out-look and same frequency.
45475502|NCT04523181|Other|Placebo|Capsule without active compound
45475503|NCT04506580|Procedure|DERMABOND™ PRINEO™(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) vs subcuticular nylon suture|DERMABOND™ PRINEO™(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) and subcuticular nylon suture are applied for each knee
45475504|NCT05352321|Drug|Gemcitabine|for induction chemotherapy
45475505|NCT05352321|Drug|Cisplatin|for induction and concurrent chemotherapy
45475506|NCT05352321|Radiation|regular intensity-modulated radiotherapy|in active comparator arm
45475507|NCT05352321|Procedure|surgery|in experimental arm
45475508|NCT05352321|Radiation|Target-reduction intensity-modulated radiotherapy|in experimental arm
45347634|NCT04034836|Drug|Scalp blocks with ropivacaine and intravenous saline|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
45475509|NCT01290575|Drug|Placebo|capsule, Oral, 0.0mg, twice daily, 14 day
46043524|NCT04175158|Biological|GB222|Recombinant humanized antivascular endothelial growth factor monoclonal antibody injection Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is > 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
45347635|NCT02806336|Behavioral|Multi Modal Balance Training|Group balance class, obstacle course, strengthening exercises
45347636|NCT02806336|Behavioral|Weight Loss|Nutritional counseling to achieve 500 kcal standard hypocaloric diet
45347637|NCT00407797|Drug|Pregabalin|150 to 600 mg/day during 21 weeks
45347638|NCT00903292|Drug|erlotinib (Tarceva)|chemotherapy with erlotinib
45347639|NCT00903292|Drug|pemetrexed (Alimta)|Chemotherapy with pemetrexed
45347640|NCT02539030|Procedure|Microfracture|simple microfracture
45347641|NCT02539030|Device|CartiFill|add collagen when doing microfracture
45347642|NCT00906646|Dietary Supplement|Metabolic therapy|Coenzyme Q10 - 100 mg tds Magnesium orotate - 400 mg tds Lipoic acid - 100 mg tds Omega-3 fatty acids - 300 mg (in 1 g fish oils) tds Selenium - 200 µg
45347643|NCT00906646|Dietary Supplement|Placebo|Placebo tablets
45347644|NCT00903604|Drug|AP214|Three 10-minutes infusions of sequential ascending dosages of AP214
45347645|NCT00903604|Drug|Placebo|Three 10-minutes infusions of isotonic saline solution
45347646|NCT00924274|Dietary Supplement|rapeseed oil|rapeseed oil in amounts between 14 and 27 g
45754007|NCT04022174|Behavioral|Moderate dosage training of action Observation and Motor imagery|Motor imagery and action observation of orofacial exercises with moderate dosage
45754008|NCT04022174|Behavioral|Intensive dosage training of action observation and motor imagery|Motor imagery and action observation of the orofacial exercises with intensive dosage
45754009|NCT04022174|Biological|Intensive dosage orofacial exercises|Orofacial exercises with high intensity
45754010|NCT04022174|Behavioral|Moderate dosage orofacial exercises|Orofacial exercises with moderate intensity
46043525|NCT04175158|Biological|Bevacizumab|Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is > 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
46043526|NCT02671318|Drug|Drug conversion to sirolimus|Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.
46043527|NCT02671318|Drug|Maintenance of the current regimen|Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
46043528|NCT02668510|Biological|platelet rich plasma|immediately following shockwave therapy the injection of PRP derived from subjects own blood using Arthex double syringe system will be injected at the origin of the plantar fascia at the calcaneous
46043529|NCT02668510|Drug|Normal saline|placebo injection of normal saline immediately following shockwave therapy
45347647|NCT00924274|Dietary Supplement|sunflower oil|sunflower oil
45347648|NCT00903838|Drug|pardoprunox|1.5 to 12 mg/day
45347649|NCT00903838|Drug|pramipexole|0.75-4.5 mg/day
45475510|NCT01290575|Drug|Placebo|Capsule, Oral, 0.0mg, once daily, 14 day
45475511|NCT01290575|Drug|BMS-820132|Capsule, Oral, 15mg, twice daily, 14 day
45475512|NCT01290575|Drug|BMS-820132|Capsule, Oral, 60mg, twice daily, 14 day
45475513|NCT01290575|Drug|BMS-820132|Capsule, oral, 150mg, twice daily, 14 day
45475514|NCT01290575|Drug|BMS-820132|Capsule, Oral, 300mg, twice daily, 14 day
45347650|NCT00924430|Drug|Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 beta capsule, single dose of 1400 mg SLV337 alpha capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
45347651|NCT00924430|Drug|Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 alpha capsule, single dose of 1400 mg SLV337 beta capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
45347652|NCT03743506|Diagnostic Test|With feedback|To evaluate the displacement of the center of pressure on the disc during the equilibration with feedback.
45347653|NCT03743506|Diagnostic Test|Without feedback|To evaluate the displacement of the center of pressure on the disc during the equilibration without feedback.
45347654|NCT00924586|Drug|ONO-1101|Placebo for one minute IV
45475515|NCT01290575|Drug|BMS-820132|Capsule, Oral, 450mg, twice daily, 14 day
45475516|NCT01290575|Drug|BMS-820132|Capsule, Oral, To be determined (TBD), once daily, 14 day
45475517|NCT01290575|Drug|BMS-820132|Capsule, Oral, 5 mg, twice daily, 14 day
45475518|NCT03352570|Device|COLOVAC|The intervention consists in the placement of the Colovac device, during the colorectal surgery, Once the colorectal anastomosis has been completed as per standard care and the water-thightness of the anastomosis has been verified.
46043530|NCT00644722|Device|MacIntosh Green Lite (metal single use laryngoscope blades)|metal single use laryngoscope blades
46043531|NCT00644722|Device|MacIntosh Green Spec II (metal reusable laryngoscope blades)|metal reusable laryngoscope blades
46043532|NCT02668588|Drug|extended release of octreotide|1 intramuscular injection of extended release of octreotide 30 mg
46043533|NCT02668588|Drug|extended release of placebo|1 intramuscular injection of extended release of placebo
46043534|NCT02668042|Biological|liveness tissue skin|liveness tissue skin safety and effectiveness for the treatment of difficult to heal wounds
45347655|NCT00924586|Drug|ONO-1101|0.125 mg/kg for one minute IV
45347656|NCT00568126|Drug|Maca Root|3g/day of Maca Root for 12 weeks.
45475519|NCT05040087|Other|Intensification of diabetes medication based largely on HbA1c levels|Use of diabetes Rx in controls will be guided largely by HbA1c levels.
45475520|NCT05040087|Other|Intensification of diabetes medication based on glucose levels|Use of diabetes Rx in the intensive Rx groups will be guided by participants' self-monitored blood glucose levels (SMBG), with management aimed to keep glucose levels within the normal range.
45475521|NCT01290653|Other|Dry needling|Deep dry needling until achieving twitch response of the muscle
45475522|NCT01290653|Other|Strain-counterstrain technique|A manual technique to release tension of painful muscles.
45475523|NCT01290653|Other|Placebo manual technique|A placebo technique, consisting of manual contact of the therapist with the patient without any further therapeutic approach
45475524|NCT03348436|Procedure|radiofrequency ablation|
45475525|NCT05031741|Other|Peer Leader Model|Teens will have an opportunity to interact with established peer leaders that are a part of the AccessKCTeen program. These leaders will receive a baseline training of their role, sexual and mental health. They will also receive health education and engage with a peer liason via text messages throughout the study.
45475526|NCT03199911|Drug|Topical Antibiotic Product|Topical antibiotic ointment will be erythromycin or bacitracin. If the patient cannot obtain either (e.g. lack of availability at the pharmacy), bacitracin polymyxin will be prescribed. Allergy to all 3 study drugs means that a patient will be excluded from the study.
46043535|NCT04174690|Device|Force platform|In order to volunteers to be selected for collection a recruitment test will be taken, the volunteer will have to stand on one foot for 5 seconds without additional support. So that the volunteer can go to the balance test on the force platform, he will be dressed with safety equipment (harness), and will also have the attachment of the electrodes.
46043536|NCT02671084|Drug|sevoflurane|compare effect of sevoflurane when administered before PCI
46043537|NCT02671162|Drug|Wheat|3 times a day each time 2 capsules before eating meal for 8 weeks.
46043538|NCT02671162|Drug|Fumaria|3 times a day each time 2 capsules before eating meal for 8 weeks.
45347657|NCT00568126|Drug|Placebo|Placebo provided by research pharmacy daily for 12 weeks.
45347658|NCT00903994|Drug|Ketoprofen Topical Patch 20%|Ketoprofen is a pressure-sensitive adhesive material containing 20% Ketoprofen which is applied to a polyester textile and covered with a foil release liner.for the treatment of mild to moderate acute pain associated with Tendonitis or Bursitis of the shoulder, elbow or knee
45347659|NCT00924742|Drug|Tapimycin (piperacillin 4 g + tazobactam 0.5g)|One intravenous infusion (piperacillin 4 g + tazobactam 0.5 g powder for injection) over 30 minutes/single dosing
45347660|NCT02539498|Device|HR-pQCT|HR-pQCT to evaluate cortical and trabecular bone
45347661|NCT00904228|Other|placement of plastic cap during delivery room stabilization|placement of plastic cap during delivery room stabilization
45347662|NCT00904228|Other|placement of routine cap during delivery room stabilization|
45347663|NCT00924976|Behavioral|Steps for Achieving Financial Empowerment (SAFE)|The SAFE is a brief, 5-component intervention that aims to facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
45475527|NCT03199911|Drug|Topical Non-Antibiotic Ointment|Mineral oil/petrolatum-based artificial tear ointment.
45475528|NCT05511532|Other|Orthopaedic treatment|"Female and male patients aged between 6 and 12 years are included in the study. Initially, the values of dorsiflexion of the tibio-fibular-talar joint and dorsiflexion of the first metatarsophalangeal joint will be measured to rule out hallux rigidus and ankle equinus, respectively.~Those patients who do not present hallux rigidus or equinus ankle, will be included in the study and will have their computerized foot pressures taken."
45475529|NCT03853421|Drug|Sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
45347664|NCT03824860|Behavioral|Yoga|"Participants will attend at least one group class per week (in-person or Zoom) and practice one self-guided yoga video class at home on their own per week, over eight weeks~Participants may choose to attend Flow Yoga and/or Chair Flow Yoga classes. These classes will be videotaped and made available to participants electronically.~Classes consist of:~guided breathing exercises,~upper and lower extremity stretching~structured postures and movements to improve balance and strength"
45475530|NCT03352492|Procedure|Superior laser peripheral iridotomy|Iridotomy placement between 11:00 and 1:00 o'clock
45347665|NCT00407563|Drug|Bevacizumab|Bevacizumab will be given via IV infusion at 10mg/kg given on days 1 and 15 of a 28-day cycle.
45475531|NCT03352492|Procedure|Temporal laser peripheral iridotomy|Iridotomy placement at 3:00 or 9:00 o'clock
45475532|NCT02517814|Dietary Supplement|Vitamin D|
45475533|NCT05349201|Other|KYMRIAH|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma [R/R DLBCL]) or Pediatric and young adult patients (≤25 years of age) with B cell acute lymphoblastic leukemia (ALL) refractory, in relapse post transplant or in second or later relapse
45475534|NCT05349201|Other|YESCARTA|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma [R/R DLBCL])
45475535|NCT04513054|Genetic|Blood collection for genetic analysis|Blood collection for genetic analysis
46043539|NCT04175782|Procedure|Enhanced recovery after surgery (ERAS) protocol|"Preoperative:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative:~Use of short-acting anesthetic agents Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Refraining from the use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results"
46043540|NCT04176796|Other|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = [number of patients surviving after transplant with excellent organ]/[number of patients for whom excellent organ was accepted for transplant] marginal transplant survival = [number of patients surviving after transplant with marginal organ]/[number of patients for whom marginal organ was accepted for transplant]"
45347666|NCT00407563|Drug|Abraxane|Abraxane will be given via IV infusion at 100mg/m²over 30 minutes on days 1, 8, and 15 of a 28-day cycle.
45475536|NCT05303727|Drug|Anti Thymocyte Globulin|2.5 mg/kg/day；2 doses on day -3 and day -2 for matched sibling donor transplantation；3 doses on day -4，-3 and day -2 for unrelated donor transplantation；4 doses on day -5，-4，-3 and day -2 for haploidentical donor transplantation
45475537|NCT05303727|Drug|Fludarabine|30 mg/m2/day for 5 days
45475538|NCT05303727|Drug|Cyclophosphamide injection|60 mg/kg/day for 2 days in cord blood stem cell transplantation
45347667|NCT00906724|Procedure|Aerobic exercise|"A graded exercise stress test (GXT) will be done under cardiologist supervision.~Subjects will undergo three month of supervised aerobic exercise."
45475539|NCT05303727|Drug|Topotecan|2mg/m2/day for 3 days in cord blood stem cell transplantation
45475540|NCT05303727|Drug|Melphalan|70mg/m2/day，for peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation；2 doses on day -3 and day -2 when conditioning regimen containing thiotepa；3 doses on day -4，-3 and day -2 when conditioning regimen not containing thiotepa；
45475541|NCT05303727|Drug|Thiotepa|5 mg/kg/day for 2 days in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation
45475542|NCT05303727|Drug|Busulfan|0.8mg/kg/dose；8 doses in cord blood stem cell transplantation；12 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen containing thiotepa；16 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen not containing thiotepa；
45475543|NCT05303727|Drug|Cyclosporine|2.5~4 mg/kg/dose every 12 hours orally；1.5~2 mg /kg/dose every 12 hours intravenously; trough concentration maintained at 150~250ng/ml
45475544|NCT05303727|Drug|Tacrolimus|0.02~0.03 mg/kg/day as continuous infusion or 12 hour divided doses
45475545|NCT05303727|Drug|Mycophenolate Mofetil|15 mg/kg/dose every 12 hours
45475546|NCT05303727|Drug|Methotrexate|15 mg/m2/dose on d+1 and 10 mg/m2/dose on d+3，d+6 in peripheral stem cell transplantation
45475547|NCT04506658|Device|high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.|"Patient in lithotomy position (supine) with return plate at lumbar level.~Start with high power (within the allowed range) to get a faster hyperthermia and slowly decrease this percentage as the current builds up in the patient's body.~Patients are undergoing high-frequency radio wave electrotherapy 2 times a week (12 procedures at all)."
45475548|NCT04506658|Device|high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.|Doctor uses sham sensor to reduce efficiency to zero.
45475549|NCT05495074|Other|ATP III dietary intervention|The dietary intervention will consist of an approximate decrease of 500 kcal from the calories participants habitually consume, with the following macronutrient distribution 15-20% protein, 50-60% carbohydrates, 25-35% fat. Participants will receive recipes with menus for two weeks.
45475550|NCT05480800|Biological|Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose|3 doses of iNTS-TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose Group in Stage 1 (Europe).
45347668|NCT01037101|Behavioral|In Vivo Exposure Therapy|Three hours of exposure therapy in a high place
45347669|NCT01037101|Behavioral|Virtual Reality Exposure Therapy|Three hours of exposure therapy using a virtual reality system
45347670|NCT01037101|Drug|D-Cycloserine|50 mg of DCS administered 30 minutes before the session
45347671|NCT01037101|Drug|Placebo|50 mg placebo administered 30 minutes before the session
45347672|NCT00904306|Dietary Supplement|Sugar Pill|placebo oral tablet taken once per day
46043541|NCT04176484|Other|Survey|Women age 25 and above who are scheduled for an abdominal procedure and were seen in the General Surgery Clinic will be called and asked to complete a 5-10 minute verbal survey prior to their date of surgery. Some additional information will be gleaned from the medical record during the interview.
46043542|NCT02667964|Other|spiroergometry|Spiroergometry on a bicycle ergometer
45347673|NCT00904306|Dietary Supplement|chromium picolinate|1000 ug/day chromium picolinate for 6 months
45347674|NCT00904306|Dietary Supplement|chromium picolinate|600 ug/day chromium picolinate
45347675|NCT01788553|Other|remission prevalence of generalized anxiety disorder|
45475551|NCT05480800|Biological|Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose|3 doses of iNTS-GMMA low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).
45475552|NCT05480800|Biological|Typhoid conjugate vaccine (TCV) low dose|3 doses of TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).
45347676|NCT00906802|Procedure|R-Y reconstruction|The reconstruction was performed by R-Y anastomosis.
45347677|NCT00567892|Device|rTMS|"Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)"
45347678|NCT00623103|Drug|Rivastigmine capsule|Rivastigmine capsules orally twice a day. Target dose 12 mg/day.
45347679|NCT00623103|Drug|Rivastigmine transdermal patch|Rivastigmine patch once a day in the morning, worn for 24 hours. Target dose 10 cm^2/day delivering 9.5 mg over a 24 hour period.
45347680|NCT01043341|Behavioral|educative folder|folder about HPV infection and vaccines
45347681|NCT01043419|Drug|xenon|Inhalational gas; dose allowed max.70 Vol.% in 30 % oxygen; the duration of the treatment will be to 30 minutes
45347682|NCT01037335|Drug|morphine|Group 1 (control group) was given 10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly. Group 2 (intramuscular morphine) was given 10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly. Group 3 (donor site morphine) was given 5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
46043543|NCT05276986|Other|DOMS protocol|For a maximum repetition of the trunk muscles, two measurements were made with a 45-second rest interval.The values were recorded in Newtons by taking the maximum value of the two repetitions measured. DOMS was formed by eccentric contraction with 80% of this determined value.To generate DOMS in the trunk, participants were seated on the bench with the knees flexed at 90° and the soles of the feet in full contact with the floor, keeping the weight at 80% of the predetermined maximum repetition.The participants were asked to perform trunk extension with eccentric contraction of the trunk in 5 seconds, and trunk flexion with concentric contraction in 3 seconds.Two-minute rests between sets and 45-second rests between repetitions were given.The date and time of the created DOMS were recorded and the measurements were repeated at the 24th and 48th hours.
46043544|NCT00644800|Drug|Ziprasidone|Intramuscular ziprasidone 10 or 20 mg at the investigator's discretion for 1 to 3 days followed by oral ziprasidone capsules 40 to 80 mg twice daily at the investigator's discretion to complete 7 days of treatment
45475553|NCT05480800|Biological|Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) full dose|3 doses of iNTS-TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV full dose_1 Group in Stage 1 (Europe) and to participants in iNTS-TCV full dose_2 Group in Stage 2 (Africa).
46043545|NCT04083586|Other|All investigations; laboratory and radiological, needed for diagnosis|mri brain, ct brain, drug screening
45475554|NCT05480800|Biological|Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) full dose|3 doses of iNTS-GMMA full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses_2 Group in Stage 2 (Africa).
45754011|NCT04108117|Procedure|Robotic nipple sparing mastectomy|Robotic nipple sparing mastectomy means nipple sparing mastectomy performed using robotic surgical systems.
46043546|NCT02670616|Drug|Ibrutinib|560 mg by mouth daily on day 1-21 per each cycle
46043547|NCT02670616|Drug|Rituximab|375 mg/m2 IV, day 1
45347683|NCT00925210|Procedure|Sequential pEBUS - ENB|"Subject will undergo bronchoscopy with peripheral endobronchial ultrasonography to identify the peripheral lung nodule. If the lesion is identified with pEBUS, samples will be collected.~If the lesion is not found by pEBUS, the electromagnetic navigation system will be deployed and directed to the lesion of interest, once again using pEBUS to confirm final location before samples are collected."
45347684|NCT04604821|Behavioral|Enhanced Milieu Teaching|A behavioral language intervention that uses naturally occurring interactions to facilitate young children's language skills.
45347685|NCT04604821|Behavioral|Parent Education|Parents receive information on child developmental milestones.
45754012|NCT04022252|Device|Cheese dental laser|810 nm GaAlAs diode laser device
45754013|NCT04022252|Device|OrthoPulse|850 nm LED (light emitting diode)
46043548|NCT02670616|Drug|Cyclophosphamide|750 mg/m2 IV day 1
46043549|NCT02670616|Drug|Doxorubicin|50 mg/m2 IV day 1
46043550|NCT02670616|Drug|vincristine|1.4 mg/m2 IV on day 1
46043551|NCT02670616|Drug|Prednisolone|100mg per day on day 1-5
46043552|NCT00996840|Drug|SB-681323 Intravenous 3mg|3 mg SB-681323 Intravenous administration infused over 4 hours
45754014|NCT04022252|Other|Placebo|810 nm GaAlAs diode laser device
45754015|NCT03926702|Drug|Radiopharmaceuticals|All subjects will receive radiopharmaceutical for positron-emission tomography (PET) scan.
45754016|NCT00567229|Biological|rituximab|
45754017|NCT00567229|Drug|lenalidomide|
45754018|NCT00567229|Genetic|microarray analysis|
45754019|NCT00567229|Other|flow cytometry|
45754020|NCT00567229|Other|laboratory biomarker analysis|
46043553|NCT00996840|Drug|SB-681323 Intravenous 7.5 mg|7.5 mg SB-681323 Intravenous administration infused over 24 hours
46043554|NCT00996840|Drug|SB-681323 Intravenous 7.5mg|7.5 mg SB-681323 Intravenous administration infused over 4 hours
46043555|NCT00996840|Drug|SB-681323 Intravenous 10mg|10 mg SB-681323 Intravenous administration infused over 24 hours
46043556|NCT00996840|Other|Placebo|Placebo to match intervention
46043557|NCT00645502|Drug|risperidone|
46043558|NCT04174768|Procedure|Bariatric surgery|Bariatric surgery including sleeve gastrectomy and Roux-en-Y gastric bypass
46043559|NCT00644956|Drug|tadalafil|tadalafil 20 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
46043560|NCT00644956|Drug|sildenafil|sildenafil 100 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
45347686|NCT02538952|Device|Xpert device|"Interventions in the Experimental phase of this stepped-wedge trial include: (a) ensuring WHO-recommended TB screening adopted, (b) situating trained TB case finding nurses in the clinics, (c) training clinic personnel in the TB diagnostic algorithms, and (d) activation of the Xpert diagnostic device."
45475555|NCT05480800|Biological|Typhoid conjugate vaccine (TCV) full dose|3 doses of TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses_2 Group in Stage 2 (Africa).
45685069|NCT04121884|Behavioral|Accelerated Resolution Therapy|"The ART protocol first uses the technique of imaginal exposure to elicit physiological reactions associated with patient recall from beginning to end (verbally or non-verbally) of a traumatic/distressing experience. As physiological reactions emerge, the participant is directed to focus their attention on the specific body-centric reactions while laterally performing smooth pursuit eye movements which are achieved by tracking the clinician's hand which oscillates from left-to-right at a short distance from the participant's eyes. Then the participant is directed to imagine a positive way in which they prefer to recall their experience(s), including emphasis on replacing negative images in the brain with positive images. This technique is based on the process of memory reconsolidation, which allows for adding of positive material to the recall of negative, highly emotional past experiences."
45347687|NCT02538952|Other|Intensified TB Case Finding (ICF)|Interventions in the active comparator phase of this stepped wedge trial only include: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; and (c) training health facility personnel in TB diagnostic algorithms. There is no Xpert device activation in this phase. Only the standard of care microscopy algorithm (smear microscopy and chest x-ray) are available during this phase.
45347688|NCT04015492|Biological|Damoctocog-alfa-pegol (BAY94-9027, Jivi)|Single dose, 50 IU/kg BAY94-9027 (IU: international Units)
45347689|NCT04015492|Biological|Rurioctocog alfa pegol (Adynovi)|Single dose, 50 IU/kg Adynovi
45475556|NCT05480800|Biological|GSK's Meningococcal A, C, Y and W-135 conjugate vaccine|1 dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly at Day 1 to participants in the Control_Stage 2 Group in Stage 2 (Africa).
45685070|NCT01884025|Behavioral|Get Moving and Get Well|Walking Class
45685071|NCT01884025|Behavioral|Health and Humor Class|Class about the role of humor in health
45685072|NCT04121494|Biological|ChadOx1 85A - aerosol|Aerosol administration through the Omron MicroAIR NE-U22 nebuliser
46043561|NCT04175002|Drug|utrogestan|oral uterogeston 200mg daily to achieve window of implantation from previous study
45347690|NCT04015570|Biological|High Volume Plasma Exchange|PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity
45347691|NCT04015570|Other|Standard Medical Treatment|Standard Medical Treatment (Albumin+High caloric diet)
45347692|NCT00904462|Drug|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
45347693|NCT00904462|Drug|Placebo patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
45347694|NCT00396565|Drug|ER OROS paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral use. Two tablets once daily for 6 weeks.
45347695|NCT00396565|Drug|Placebo|Form= tablet, route= oral use. Two tablets once daily for 6 weeks.
46043562|NCT04174846|Dietary Supplement|Ready-to-use therapeutic food (RUTF)|SAM children will receive approximately 190 kcal/kg/day of standard RUTF
46043563|NCT04174846|Dietary Supplement|Ready-to-use-supplementary food (RUSF)|SAM children will receive approximately 190 kcal/kg/day of Acha Mum (AM-RUSF)
46043564|NCT02670772|Drug|Stavudine|Stavudine 20mg twice daily for 96 weeks + Placebo 300mg once daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
46043565|NCT02670772|Drug|Tenofovir Disoproxil Fumarate|TDF 300mg once daily + Placebo 20mg twice daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
46043566|NCT02667730|Drug|Acetaminophen|Acetaminophen 500 mg four times daily for 7 days
46043567|NCT02667730|Drug|Naproxen|naproxen 500mg twice daily for 7 days
46043568|NCT02667730|Drug|Celecoxib|celecoxib 100mg twice daily
46043569|NCT02667730|Other|physiotherapy only|physiotherapy only (no drug)
45347696|NCT00396565|Drug|Olanzapine|Type= exact number, unit= mg, number= 2.5, form= tablet, route= oral use. Four tablets once daily for 6 weeks.
45347697|NCT00904540|Drug|Lidoderm®|Patients participated in a 6-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain. Patients were stratified into the following groups at enrollment: acute (<6 weeks) LBP, subacute (6 weeks to <3 months) LBP, short-term chronic (3 months to 12 months, inclusive) LBP, and long-term chronic (>12 months LBP)
45347698|NCT00925366|Other|Imaging Procedure|CT Arthroscopy of the Shoulder - MR Arthroscopy of the Shoulder - MR of the shoulder
45347699|NCT00906880|Drug|Nifurtimox-Eflronithine Combination Treatment (NECT)|co-administration of nifurtimox (10 days, 15 mg/kg/day, p.o. TID) and eflornithine (7 days, 400 mg/kg/day, i.v. BID)
45347700|NCT00925444|Device|FOREseal|a pair of alginate sleeves for linear cutting staplers used in lung surgery
45347701|NCT00925444|Device|Stapling|Stapling alon or associated with sealants
45347702|NCT00904852|Drug|Tandutinib, bevacizumab, and temozolomide|All patients will have completed treatment with concurrent radiation therapy and temozolomide. Patients will be entered into different dosing groups of tandutinib. Patients will receive up to 6 cycles of treatment with oral temozolomide at 150 mg/m2 daily for the first 5 days of a 28 day cycle, oral tandutinib at escalating doses 250, 375, 500, or 625 mg twice daily on days 1 to 28, and intravenous bevacizumab at 10 mg/kg on days 1 and 15 of each cycle
46043570|NCT02667808|Other|Focus Group|Subjects will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.
46043571|NCT02667808|Other|Questionnaire|Participants will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
46043572|NCT02667184|Dietary Supplement|Low FODMAP Oral Nutrition Supplement|
46043573|NCT04294992|Drug|Ondansetron 8mg|Study drugs will be prepared, diluted to a volume of 10 mL using saline 0.9%
46043574|NCT02670460|Device|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left subclavian vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
45347703|NCT00394771|Drug|DR-1031|Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal cycle of 10 mcg EE. The total extended cycle was 91 days and participants were to complete two extended cycles. Active therapy dosage of EE varied by treatment arm.
46043575|NCT00628914|Drug|escitalopram and eszopiclone|escitalopram 10mg tabs QD and eszopiclone 3 mg tabs QD for 8 weeks
46043576|NCT00628914|Drug|Escitalopram, eszopiclone, and placebo|Escitalopram 10mg tabs QD for 8 weeks; Eszopiclone 3mg tabs QD for initial 4 weeks then placebo tabs QD for final 4 weeks
46043577|NCT00628914|Drug|Escitalopram|Escitalopram 10mg tabs QD and placebo tabs QD for 8 weeks
46043578|NCT02670850|Other|Family Caregiver Intervention Program|Family Caregiver Intervention Program included three components: introduction of mild cognitive impairment, maintain and improve cognitive function, and health management.
46043579|NCT02870634|Drug|Cu(II)ATSM|copper-containing synthetic small molecule
46043580|NCT02537236|Dietary Supplement|Omega-3 fatty acids|Omega-3 fatty acid supplementation with fish oil.
46043581|NCT02537236|Behavioral|TLC nutritional intervention|nutritional orientation.
45347704|NCT00394771|Drug|Seasonale®|84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets for two consecutive 91-day cycles.
45685073|NCT04121494|Biological|ChadOx1 85A - IM|Intramuscular administration
46043582|NCT02537236|Dietary Supplement|Omega-3 fatty acid supplementation with fish oil and TLC nutritional intervention.|Omega 3 fatty acid supplementation with fish oil and nutritional counseling of TLC diet.
46043583|NCT04174066|Other|blood sample|blood sample during planned in the follow-up of patients.
46043584|NCT04174066|Other|tissue sample|tissue sample during planned in the follow-up of patients.
46043585|NCT04174066|Other|excreta|urine sample during planned in the follow-up of patients.
45685074|NCT04121416|Drug|Oxycodone 10mg|induction with 0.3mg/kg of oxycodone in general anesthesia
45685075|NCT04121416|Drug|Sufentanil|induction with 0.3 µg/kg of Sufentanil in general anesthesia
45685076|NCT02983864|Behavioral|BASICS|A one session intervention focused on reducing drinking with motivational interviewing
46043586|NCT00645580|Drug|Fluvoxamine|Fluvoxamine 100mg/day PO for 6 weeks.
46043587|NCT02666872|Behavioral|Motivational interviewing|
46043588|NCT02670304|Drug|letrozole|letrozole from the day of oocyte retrieval for 5 days
46043589|NCT02670304|Drug|Aspirin|aspirin from the day of oocyte retrieval for 5 days
46043590|NCT05060458|Other|No intervention|No intervention
46043591|NCT00998946|Drug|Pralatrexate|Pralatrexate injection administered as intravenous (IV) push
45347705|NCT00394771|Drug|Portia®|Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.
45347706|NCT00396409|Drug|Depigoid|Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)
45347707|NCT00396409|Drug|Omalizumab|anti-IgE (Omalizumab) given during the 2006 core study
45347708|NCT00396409|Drug|Placebo|Placebo given during the 2006 core study
45347709|NCT01323829|Other|EMG Guidance of Injection|The use of the EMG guidance is the experimental part of the study. We will perform EMG Needle testing in order to pin-point the best location for the patients Botox injections.
45347710|NCT02924376|Drug|Pemigatinib|Pemigatinibonce a day by mouth for 2 consecutive weeks and 1 week off therapy
45347711|NCT00921492|Device|Low-frequency electro-acupuncture (EA)|2 Hz EA during 30 minutes, twice a week, 14 weeks.
45347712|NCT00921492|Other|Meeting a therapist - attention control|Meeting a therapist, twice a week during 30 minutes in order to control for the increased amount of attention.
45347713|NCT02564328|Genetic|Intravenous stem cell transplantation|Intravenous injection of autologous bone marrow mesenchymal stem cell transplantation
45475557|NCT05480800|Combination Product|GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered intramuscularly at Day 57 to participants in the Control_Stage 2 Group in Stage 2 (Africa).
46043592|NCT00998946|Dietary Supplement|Vitamin B12|1 mg intramuscular (IM) injection
46043593|NCT00998946|Dietary Supplement|Folic Acid|Oral 1 mg tablet
46043594|NCT05146180|Device|Parametric positron emission computed tomography|Patients will undergo parametric positron emission computed tomography in 15 days after the labeled polynuclear scintigraphy
46043595|NCT01158404|Drug|LY900009 - Dose Escalation Phase (Part A)|"2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
45347714|NCT03687762|Behavioral|Cognitive Therapy (CT)|"The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts, recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
45475558|NCT05480800|Combination Product|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly at Day 169 to participants in the Control_Stage 2 Group in Stage 2 (Africa).
45475559|NCT05480800|Drug|Placebo|3 doses of Placebo administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the Placebo_Step 1 and Placebo_Step 2 in Stage 1 (Europe).
45347715|NCT03687762|Behavioral|Mindfulness Meditation (MM)|Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.
45475560|NCT05480800|Other|Saline|3 doses of saline solution administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose, Placebo_Step 1, iNTS-TCV full dose_1, Placebo_Step 2 groups in Stage 1 (Europe) and to participants in iNTS-TCV full dose_2 and Control_Stage 2 groups in Stage 2 (Africa).
45475561|NCT04503525|Other|Nutritional assessment|Nutritional assessment in COVID patients
45475562|NCT05011929|Behavioral|Cognitive behavioral therapy|refer to the arm description
45475563|NCT04502368|Procedure|Fiberoptic Bronchoscopy (FOB)|FOB under full sedation (RASS sedation scale -5) and full paralysis.
45685077|NCT02983864|Behavioral|Integrated BASICS|A one session intervention focused on reducing drinking and sexual behavior while drinking
46043596|NCT01158404|Drug|LY900009 - Dose Confirmation Phase (Part B)|"30 mg LY900009 orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
46043597|NCT02670070|Drug|gemigliptin 50mg, rosuvastatin 20mg|gemigliptin/rosuvastatin 50/20mg
45475564|NCT04502368|Procedure|Bronchoalveolar Lavage (BAL)|BAL under full sedation (RASS sedation scale -5) and full paralysis. Lavage: NaCl 0,9% 50ml x 3 in lung region targetted according to RX/CT scan.
45475565|NCT04502368|Diagnostic Test|Electrical Impedance Tomography (EIT)|Realtime thoracic impedance coupled with ventilation parameters recording.
45475566|NCT04502368|Diagnostic Test|Arterial Blood Gas test (ABG)|Multiples Arterial Blood Gas test (ABG) via arterial catheter.
45475567|NCT04984239|Behavioral|Acceptance and Commitment Therapy for aphasia|The intervention will consist of Acceptance and Commitment Therapy modified to meet the needs of stroke survivors with aphasia, combined with communication strategy training.
45475568|NCT03348358|Behavioral|quiet music|playing quiet music during labor
46043598|NCT00645034|Drug|placebo|placebo by mouth as a single dose
45685078|NCT02983864|Behavioral|Relaxation|A one session intervention focused on increasing relaxation skills
45685079|NCT02983864|Behavioral|Integrated Bystander|A one session intervention focused on reducing sexual assault with a focus on the role of alcohol
45754021|NCT04148846|Drug|Dypirone|Dipyrone 2g, 6 / 6h for 7 days, orally or intravenous
46043599|NCT00645034|Drug|sildenafil|sildenafil 100 mg by mouth as a single dose
46043600|NCT02885090|Procedure|Blood sampling|In children: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml and 2 PAXgene tubes of 2.5 ml (max 0.8-0.9 ml blood/kg) In parents: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml.
46043601|NCT04173832|Drug|Tianqi Pingchan Granule Combined With Amantadine|Tianqi Pingchan Granule and Amantadine are given to patients simultaneously
46043602|NCT04173832|Drug|Placebo Combined With Amantadine|Placebo and Amantadine are given to patients simultaneously
46043603|NCT04173910|Procedure|Ultrasound LPEC/Sellick|We will perform an ultrasound of the carotid artery and then apply a Sellick manoeuvre and a left paratracheal compression of the cervical esophagus respectively.
46043604|NCT00998790|Device|American Medical Systems (AMS) AdVance™ Male Sling System|The AMS AdVance™ Male Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD). The AdVance™ Male Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
46043605|NCT02537002|Drug|PF-05230907|A single intravenous dose of 3 μg/kg
46043606|NCT02537002|Drug|PF-05230907|A single intravenous dose of 5 μg/kg
46043607|NCT02537002|Drug|Placebo|A single intravenous dose of matched placebo
46043608|NCT00645658|Drug|Testim (1% testosterone gel)|Subjects apply contents of gel packet to skin daily.
46043609|NCT01001988|Other|Blood sample|Blood sample for immunogenicity assessment
45347716|NCT03687762|Behavioral|Activation Skills (AS)|Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
45475569|NCT03348358|Behavioral|Rhythmic music|playing rhythmic music during labor
45475570|NCT03348358|Behavioral|control|No music during labor
45475571|NCT04984083|Dietary Supplement|vitamin k|patients will take vitamin k 10 mg/ml once daily orally or IM between four and 96 hours before elective cesarean section
46043610|NCT01001988|Biological|JE-CV administered in Study JEC02|Participants received a single dose of JE-CV at 12 to 18 months of age in Study JEC02. No vaccination was administered in Study JEC05
45475572|NCT03736967|Drug|REGN3500|Administered subcutaneous (SC) every 2 weeks (q2w)
46043611|NCT02667340|Dietary Supplement|Superstarch|0.7 g Superstarch or placebo per kg body mass in two ingestions (before game & at halftime)
45475573|NCT03736967|Drug|Dupilumab|Administered SC q2w
45475574|NCT03736967|Drug|REGN3500 + Dupilumab Combo|Administered SC q2w
46043612|NCT02667340|Other|Placebo|0.7 g glucose per kg body mass in two ingestions (before game & at halftime)
46043613|NCT04293354|Procedure|Serratus Plane Block|Serratus Plane Block was performed
46043614|NCT04293354|Procedure|Control|No block was performed
46043615|NCT02666170|Drug|Alpha-lipoic acid|
46043616|NCT02670148|Procedure|Chiropractic manipulative therapy|We will set an a priori treatment schedule of 8 visits at a frequency of 2 visits per week over a 4 week period. CC participants will receive chiropractic manipulative therapy (CMT). CMT procedures can be broadly divided into two types, thrust and non-thrust. Thrust CMT is a high-velocity low-amplitude procedure characterized by a single, short duration thrust (ranging from 100 to 500 ms) of low amplitude force applied to a target joint that often results in an audible sound, or cavitation. Non-thrust CMT employs low-velocity and often repeated joint movements of varying amplitude. In the event that no CMT treatment is clinically indicated, treatment will not be provided.
46043617|NCT02667262|Other|Algorithm to identify patients experiencing opioid abuse/addiction|
46043618|NCT04077268|Other|GOS-E|Call at 7 days, patients add a brain trauma to know their sequeals
46043619|NCT04919980|Device|Innovalve MR system|Innovalve MR system
45347717|NCT03653832|Drug|Dexmedetomidine|"Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation."
45475575|NCT03736967|Drug|Placebo|Administered SC q2w
46043620|NCT00645736|Other|No intervention|No intervention
45475576|NCT04506502|Device|The ZELTIQ System|The MMS device will be used to perform the treatments.
46043621|NCT02666404|Other|Measurement|We will perform those new measurements and assessments for guidance of fluid resuscitation at 0, 6, 24, 48, and 72 hours after shock diagnosis and concomitant fulfillment of eligibility requirements
46043622|NCT00646126|Drug|Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS)|Standard three day regimen
46043623|NCT00646126|Drug|placebo tablet similar to active drug in shape and size|Dosage similar to active drug(standard three days regimen)
46043624|NCT02670226|Other|Samples|Blood samples, muscle biopsy
46043625|NCT02537080|Drug|Nimodipine group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
46043626|NCT02537080|Drug|Control group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
46043627|NCT02667496|Drug|Sargramostim GZ402664|Pharmaceutical form:solution Route of administration: subcutaneous
46043628|NCT02667496|Drug|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
46043629|NCT02667496|Drug|Florbetapir F18|Pharmaceutical form:solution Route of administration: intravenous
46043630|NCT00645112|Drug|cefdinir (Omnicef)|oral suspension, 7 mg/kg every 12 hours for 5 days
46043631|NCT00645112|Drug|azithromycin|oral suspension 10 mg/kg QD on Day 1 then 5 mg/kg QD on Days 2-5 for a total of 5 days.
46043632|NCT02666482|Behavioral|Stop Smoking SF Web App - baseline|Smoking cessation web app in Spanish and English. Accessible online at no charge.
46043633|NCT02667106|Drug|RX0041-2|Pharmacokinetic study
46043634|NCT02666092|Other|Questionnaire|Questionnaire on domestic exposure to fish, and, for patients with fish allergy, on the characteristics of clinical manifestations)
46043635|NCT02666092|Biological|Detection of anti-Anisakis and anti-fish antibodies|Anti-fish IgE will be detected using ImmunoCAP. Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), immunoelectrophoresis (precipitins) and Western Blot.
46043636|NCT02669524|Drug|LY2409021|
46043637|NCT02669524|Drug|LY2409021 placebo|
46043638|NCT02669524|Procedure|OGTT|
46043639|NCT02669524|Procedure|IIGI|
46043640|NCT02669524|Procedure|Standardised liquid meal|
46043641|NCT04071496|Other|Blood samples|1 dry tube of 5 ml, 3 citrated tubes of 5 ml, 1 tube citrate dextrose acid of 7 ml
46043642|NCT04076566|Device|alfapump system|active implantable device for treatment of malignant ascites
45685080|NCT04121338|Procedure|Celiac ganglion block|The celiac ganglion block will be performed under CT guidance and with the patent under moderate sedation. With the patient prone the back will be prepped and draped sterility. Under CT guidance two 22 gauge needles will be placed with the tips on either side of the celiac artery. This is the location of the celiac ganglia. Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based. Then patient will be observed for 1-2 hours post procedure and then discharged to home
45685081|NCT04121338|Drug|Liposomal bupivacaine|Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based.
46043643|NCT04950712|Procedure|Blood sampling|Blood samples for HSV-2 testing and for HIV test are collected from patients at screening visit (first visit).
45685082|NCT01896193|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
45685083|NCT01896193|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
46043644|NCT04950712|Procedure|Anogenital lesion swab collection|Anogenital lesion swab of all lesions are collected at screening visit (only for newly infected HSV-2 patients) and at first genital HSV-2 recurrence during the study period.
46043645|NCT00996606|Drug|DMARDs|Participants may continue on a stable dose of their current DMARD therapy as prescribed. The choice of DMARD is at the discretion of the treating physician and is not specified by the protocol.
46043646|NCT00996606|Drug|Tocilizumab|Tocilizumab will be given as 8 mg/kg via IV infusion every 4 weeks for a total of 12 infusions. The maximum allowed dose is 800 mg.
46043647|NCT00645814|Drug|placebo for adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
46043648|NCT00645814|Drug|adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
46043649|NCT00645814|Drug|adalimumab|80 mg at Week 0 and 40 mg weekly through Week 11
46043650|NCT02669836|Procedure|Posterior fossa decompression|Planned areas of bone removal from the suboccipital region of the skull and cervical l1 lamina. Then, the constricting epidural band at the level of the foramen magnum is resected.
45347718|NCT03653832|Drug|Clonidine|"Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation."
45347719|NCT03653832|Drug|Propofol|Patients will continue to receive intravenous propofol according to current usual care.
45347720|NCT04060836|Drug|Xyntha|Recombinant Coagulation Factor VIII Injection produced by Pfizer Inc.
45347721|NCT04060836|Drug|Recombinant Coagulation Factor VIII Injection|A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
45475577|NCT04938219|Other|Gloves filled with warm tap water|The intervention in the treatment group will consist of nonsterile gloves, filled with regular tap water at a comfortable warm temperature and sealed with a plastic clip. The temperature of the water will not be measured, the investigators will take a temperature that feels comfortable in their hands
45475578|NCT04506346|Diagnostic Test|difficult tracheal intubation|Grade Ⅲ or Ⅳ according to Cormach-Lehane Grading of laryngoscopic view
46043651|NCT02669836|Procedure|Dural Augmentation|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.
46043652|NCT04174378|Drug|Decapeptyl 0.2mg|IM Decapeptyl o.2 mg was given 2 days before embryo transfer
45475579|NCT04933851|Behavioral|ACT1VATE|ACT1VATE, informed by Acceptance and Commitment Therapy (ACT), will consist of five, 90-minute group-based telemedicine therapy sessions delivered by a Behavioral Health Provider.
46043653|NCT02669446|Device|Medical devices|
46043654|NCT02669446|Device|traditional household remedy|
46043655|NCT00645892|Drug|adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded 40 mg eow through Week 24
46043656|NCT00645892|Drug|placebo for adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded placebo eow through Week 24
46043657|NCT00645190|Drug|Galantamine HBr|
46043658|NCT04293120|Other|Training with weighted ball|Participants will stop or catch a weighted ball
46043659|NCT04174456|Diagnostic Test|FDG PET|baseline and 6-month follow-up FDG PET
46043660|NCT02870166|Other|blood sample|
46043661|NCT02869308|Drug|stannous pyrophosphate|Injection of 1ml Angiocis
45347722|NCT00693420|Drug|Bimatoprost 0.03% sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily.
45347723|NCT00693420|Drug|vehicle sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily
45347724|NCT00742794|Other|Observation|Observation of sting frequency
46043662|NCT02869308|Drug|Technetium-99m|Injection of 900 MBq Technetium-99m, 30 min after Angiocis injection
46043663|NCT02869308|Device|E-CAM Camera|Acquisition of images of angioscintigraphy with E-CAM camera, after injection of Angiocis and Technetium-99m
46043664|NCT02869308|Device|CZT Semiconductor Camera (D-SPECT)|Acquisition of images of angioscintigraphy with D-SPECT camera
46043665|NCT00910390|Other|Slow freezing|Embryos at different developmental stages will be frozen using a solution that contains propanediol and sucrose, individually placed in high security straws, cooled with a programmator and stored in liquid nitrogen.
46043666|NCT00910390|Other|VIT-Irvine|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
46043667|NCT00910390|Other|Vit-Vitrolife|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
45347725|NCT04034524|Drug|GLP-1 receptor agonist|any GLP-1 receptor agonist (other than Saxenda or liraglutide 3.0mg)
45347726|NCT04034524|Drug|Insulin|glargine, detemir, neutral protamine Hagedorn (NPH), degludec
45347727|NCT00925834|Behavioral|Verbal suggestions|Verbal suggestions of a vasodilatory effect on cardiac vessels
45475580|NCT04933851|Behavioral|DSME/S|Diabetes self-management education and support (DSME/S) will be delivered by a Certified Diabetes Care and Education Specialist via one-on-one telemedicine format.
45685084|NCT04121104|Other|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
45685085|NCT04121104|Other|SCS is switched on|Spinal cord stimulator is on
45685086|NCT04120792|Behavioral|Simultaneous exercise and cognitive training|Participants in this arm will engage in a 12-week intervention that combines physical exercise and cognitive tablet-based training. This intervention involves use of an exercise bicycle while engaging in cognitive tasks on a tablet computer three times per week.
46043668|NCT02869698|Procedure|Spectral Dynamic Imaging|
46043669|NCT02869698|Device|Hybride electrode|
46043670|NCT02869698|Device|Macro electrode|
46043671|NCT02665936|Drug|Levobupivacaine|Levobupivacaine will be given epidurally and the duration of analgesia will be calculated
46043672|NCT02665936|Drug|Dexamethasone and levobupivacaine|dexamethasone 4 mg epidurally with levobupivacaine and duration of analgesia is measured
45347728|NCT04034680|Other|TIME|The intervention of the TIME model includes two hours of lectures about dementia and NPS and three hours of training and roleplay in using TIME. The staff of the home care service will receive the TIME manual and access to the TIME website with access to additional educational materials. From each municipality, three staff members called TIME administrators, will receive additional three hours of lectures and roleplay in TIME, and will thereafter have the responsibility for performing the intervention.
45347729|NCT04034680|Other|Education-only intervention|Staff in the home care service in municipalities in the control group will receive thesame two hours lectures about dementia and NPS as the intervention grorp. After the cluster RCT pilot study is ended, municipalities in the control group will receive the same three-hour lessons in the TIME as the intervention group of municipalities.
45347730|NCT00925912|Procedure|spinal block|0.5% bupivacaine 1.5-2 ml injected to subarachnoidal space
46043673|NCT02665936|Drug|Levobupivacaine and Dexamethasone|dexamethasone 8 mg epidurally with levobupivacaine and duration of analgesia is measured
46043674|NCT04292262|Other|Observational|Observational
46043675|NCT02665858|Other|OCT Imaging|
46043676|NCT02869386|Procedure|STEMO|STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure Management (choice of drug at discretion of treating physician), use telemedicine for further expertise as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
46043677|NCT02869386|Procedure|Regular care|A regular ambulance, the comparator intervention, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
46043678|NCT02665780|Procedure|Periodontal debridement|teeth cleaning
46043679|NCT02665780|Other|Cetylpyridium chloride|mouthrinse
46043680|NCT02869464|Other|Imaging-Ultrasound|Abdominal Ultrasound
46043681|NCT02869464|Other|Imaging-MRA|Non-contrast Enhanced Magnetic Resonance Angiogram
46043682|NCT02869464|Genetic|DNA, RNA testing|To test for the co-prevalence of shared genetic markers in afflicted populations.
46043683|NCT00646360|Dietary Supplement|DHA|400 mg/d of docosahexanoic acid (DHA) during pregnancy
46043684|NCT00646360|Dietary Supplement|Placebo|2 tablets daily during pregnancy
46043685|NCT04293510|Procedure|renal biopsy and blood sampling|renal biopsy and blood sampling will be taken from lupus patients for evaluation of Janus-kinase 3
46043686|NCT04174300|Procedure|Manual Therapy|8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N
46043687|NCT00995436|Device|Extraoral anchorage|Extra oral anchorage
46043688|NCT00995436|Device|Miniscrews|Intraoral skeletal anchorage using mini screws
46043689|NCT00995436|Device|Nance|Intraoral dental anchorage by using Nance palatal arch on molars
46043690|NCT04173598|Behavioral|Cognitive Adaptation Training for Caregivers (CAT Famille)|Family CAT manual, with a module each week to be read according to the patient's objectives and a 15-minute webcam feedback by the psychologist.
46043691|NCT04173598|Behavioral|Usual Care|Psycho-education manual, with a weekly reading module and a 15-minute webcam feedback by the psychology student.
46043692|NCT02667028|Procedure|PCI|percutaneous coronary intervention
46043693|NCT04292886|Drug|Tamoxifen and femoston|oral
45347731|NCT00925912|Procedure|Perianal block|0.25% bupivacaine injected at perianal region
45347732|NCT04060602|Behavioral|Personalized Feedback|A report comparing the participant's cannabis use to peer usage, and summarizing problems experienced and risk associated with future use.
45475581|NCT05224089|Drug|Liposomal Bupivicaine/Bupivacaine Admixture|60mL of 0.25% Bupivacaine (150mg)+ 20 mL of 1.3% Exparel (266 mg)+20mL NS=100mL
46043694|NCT04292886|Drug|Vitamin C and femoston|Vitamin C and femoston
46043695|NCT02669134|Other|Device programming|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV"
46043696|NCT04292418|Drug|Tacrolimus capsule , mycophenolic acid|measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test for study group 1 and study group 2
46043697|NCT02666716|Drug|fluconazole|Dose according to summary of product characteristics (SPC) or local protocols
46043698|NCT04292028|Other|Pilates|The Pilates group participated in an 8-week clinical Pilates training program
46043699|NCT04292028|Other|Home exercises|Control group were given a home-based exercise program.
46043700|NCT04064476|Drug|Paliperidone Palmitate|This is a observational study, to see the effect of paliperidone palmitate on schizophrenia patient with violence risk. The intervention is determined by clinical practice in real world setting, only schizophrenia patient with violence risk and treated with Paliperidone Palmitate will be invited to join the observational study.
46043701|NCT02869230|Procedure|ROLL|The ROLL technique (radioguided occult lesion localization) is characterized by the injection of a radiotracer in the center of the lesion
46043702|NCT02869230|Procedure|wire-guided lesion localization|wire-guided lesion localization, including better lesion centricity in relation to margins,decreased marking time, reduced surgery time, and better aesthetic outcomes
46043703|NCT02669290|Other|Guided|LV lead placement will be guided by left ventricular systolic function information from MUGA
46043704|NCT02669290|Other|Non-guided|LV lead placement will be conventional posterolateral placement
46043705|NCT02868840|Behavioral|Tai Chi exercise|exercise twice a week each for one hour
46043706|NCT02868840|Behavioral|symptom management|sending text message weekly to manage symptoms related to stroke
46043707|NCT02669368|Drug|Magnesium Sulfate|Patients in each group receive Magnesium sulfate 30 mg/kg in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
46043708|NCT02669368|Drug|Saline|Patients in each group receive 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
46043709|NCT02669368|Drug|Standard dose Rocuronium|0.6 mg/kg of Rocuronium given with induction of anesthesia
46043710|NCT02669368|Drug|Low dose Rocuronium|0.45 mg/kg of Rocuronium given with induction of anesthesia
46043711|NCT00645268|Drug|sildenafil|In the double-blind phase, patients received sildenafil 50 mg once daily during Week 1 (7 doses), followed by a daily dose of sildenafil 100 mg during the next 3 weeks.
46043712|NCT00645268|Drug|placebo|In the double-blind phase, patients received placebo once daily during Week 1 (7 doses), followed by a daily dose of placebo during the next 3 weeks.
45475582|NCT05224089|Drug|Bupivacaine HCL|80mL 0.25% bupivacaine (200mg) + 300mcg (0.3mL) epinephrine + 5mg (0.5mL) preservative free dexamethasone + 20mL NS= 100mL
45475583|NCT03352258|Radiation|Low dose radiotherapy|10 Gy in 5 fractions of 2 Gy on 5 consecutive days
46043713|NCT00645268|Drug|sildenafil|Eligible subjects then entered an open-label phase during which all subjects received sildenafil 50 mg as needed for sexual activity for the next 2 weeks, which could be titrated to either 25 mg or 100 mg based on the investigator's assessment of efficacy and tolerability, for 10 weeks (12 weeks total).
46043714|NCT00646438|Drug|Strict Glycemic Control for one year post-op CABG|"The CDE and Study Coordinator will also meet with the patient in the hospital to show how the Lifescan One-Touch Ultra II glucometer works and review the study follow-up schedule. Patients will be sent home with the Lifescan One-Touch Ultra II glucometer and a supply of strips.~Post-Discharge Period Patients will meet alternatively with the CDE and study doctor on a specific schedule including every week for the first month, every 2 weeks in the second month, and every month thereafter till the 12th month. During these sessions the BG records will be downloaded from the Lifescan One-Touch Ultra II glucometer and reviewed to see patterns and any areas that could be improved or changed.~For all patients in the study arm, the medications that are being taken and the results of glucose monitoring charts will be reviewed weekly with endocrinologists so that any additional recommendations may be made to improve glucose control."
46043715|NCT02666014|Drug|Sugammadex|Reversal of neuromuscular blockade
46043716|NCT02666014|Drug|Neostigmine|Reversal of neuromuscular blockade
45347733|NCT04060602|Behavioral|Education|Canada's Lower-Risk Cannabis Use Guidelines prepared by the Centre for Addiction and Mental Health which outlines methods to help reduce health risks associated with cannabis use.
46043717|NCT02665702|Drug|NVB|25mg/m2 ，D1，8
46043718|NCT02665702|Drug|DDP|75mg/m2 ，D1 or 25mg/m2 D1-3
45347734|NCT00904930|Device|Wire Composite Splint (Dentaflex 0.45 mm)|Wire-Composite-Splint: Dentaflex 0.45 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow (IvoclarVivadent, Schaadn, Liechtenstein) to the teeth
45347735|NCT00904930|Device|Wire Composite Splint (Denture Strengtheners)|Wire-Composite-Splint: Denture Strengtheners 0.8x1.8 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow to the teeth
45475584|NCT01581203|Drug|Asunaprevir (ASV)|
45475585|NCT01581203|Drug|Daclatasvir (DCV)|
45475586|NCT01581203|Drug|Pegylated-interferon alfa 2a (PegIFN)|
45475587|NCT01581203|Drug|Ribavirin (RBV)|
45475588|NCT04506268|Behavioral|Opt-out Recruitment Email|Behaviorally informed, opt-out framed recruitment email
46043719|NCT02665702|Drug|Endostar|15mg/d，d1-d7 civ
45475589|NCT04506268|Behavioral|Opt-in Recruitment Email|Standard, opt-in framed recruitment email
45475590|NCT03168555|Drug|chenodeoxycholic acid|1250 mg CDCA is given with a study meal
45475591|NCT03352180|Procedure|arthroscopic reapir of subscapularis tendon|arthroscopic reapir of massive rotator cuff tears involving the subscapularis.
45475592|NCT03352180|Procedure|arthroscopic debridement of subscapularis tendon|arthroscopic debridement of massive rotator cuff tears involving the subscapularis.
45475593|NCT03235050|Drug|MEDI0382 low dose|Pharmaceutical form: solution Route of administration: subcutaneous
45475594|NCT03235050|Drug|MEDI0382 mid dose|Pharmaceutical form: solution Route of administration: subcutaneous
46043720|NCT04173676|Drug|Indocyanine Green for Injection|The sentinel lymph nodes were observed by submucosal injection of ICG
46043721|NCT02665156|Procedure|Intracorporeal stapled neobladder using robotic staplers|"Robot assisted radical cystecomy. Separate packages extended pelvic lymph node dissection up to aortic bifurcation. Totally intracorporeal orthotopic ileal neobladder with about 45 cm of ileum according to Vescica Ileal Padovana."
45347736|NCT03545256|Procedure|outpatient surgery for T1-N0 or T2-N0 cancers of the oral cavity or oropharynx with lymph node search|"The surgical procedure associated with the sentinel lymph node technique is carried out in two stages:~- Lymphoscintigraphy at Day-1 : This is the identification of the lymphatic network of the patient by a prior injection of radioactive tracer, nanocolloids labeled with technetium99, around the primary tumor. A planar CT image acquisition is performed to identify the sentinel lymph nodes (Gs(s)) which are then marked on the skin with an indelible marker.~Surgery on D0:~The patient is admitted to the hospital at 7:00 am in outpatient unit. He is reviewed by the anesthetist before the intervention and is transferred to the operating room for the intervention under AG.~The main tumor is operated by mouth."
45347737|NCT00695136|Drug|Donepezil hydrochloride|
45347738|NCT00695136|Behavioral|Increase REM sleep percentage|
45475595|NCT03235050|Drug|MEDI0382 high dose|Pharmaceutical form: solution Route of administration: subcutaneous
45475596|NCT03235050|Drug|Placebo|Pharmaceutical form: solution Route of administration: subcutaneous
45475597|NCT03235050|Drug|Liraglutide|Pharmaceutical form: solution Route of administration: subcutaneous
46043722|NCT04173130|Device|Anuscope with needles|Injection of botulinum toxin into the anal sphincter with the investigational device (anuscope with needles).
46043723|NCT04173286|Procedure|antibiotherapy|< 7 days
46043724|NCT00646750|Drug|Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)|"Day -21: rituximab. 250 mg/m2 iv~Day -14: rituximab. 250 mg/m2 plus Ybritumomab Tiuxetan (Zevalin)(0.4 mCi/kg maximum dose 32 mCi).~Days -6 to -1: BEAM regimen as follows BCNU: 300 mg/m2 over 2 hours, day -6. ARAC: 200 mg/m2/12 hours over 12 hours, days -5 through -2. VP16: 200 mg/m2/day over 2 hours, days -5 through -2. Melphalan: 140 mg/m2/day over 15 minutes, day -1."
46043725|NCT00646516|Drug|budesonide/formoterol (Symbicort)|
46043726|NCT04033198|Procedure|Appendectomy|patients diagnosed as acute appendicitis , appendectomy done
46043727|NCT02665624|Drug|Senna and stewed apricot juice|comparison of bowel cleansing and patient comfort.
46043728|NCT02665624|Drug|Senna alone|comparison of bowel cleansing and patient comfort.
46043729|NCT05258266|Drug|ZX-101A|Q.D., oral dosing
46043730|NCT02668744|Behavioral|Intervention|The intervention consists of building edible gardens at each the eight participating and eligible schools. Educators will be provided to lead 18 gardening, nutrition and cooking lessons throughout the school year intervention to all 3-5th grade students. Nine gardening, nutrition, and cooking classes will be taught to parents every month. Garden Leadership Coalitions (GLCs), made up of parents, teachers and school staff, will be formed and training/resources provided to help with adoption of the program. Training and resources will be provided to the GLCs and teachers in the 2nd year to assist with sustainability.
45475598|NCT01184339|Device|MicroPhage S. aureus/MSSA/MRSA Blood Culture Test|"In vitro diagnostic for the Identification of S. aureus and determination of MSSA or MRSA from a positive blood culture.~Approximately 5 hour rapid test."
45685087|NCT04120792|Behavioral|Exercise training|Participants in this arm will engage in a 12-week exercise intervention that involves use of an exercise bicycle three times per week.
45685088|NCT04120792|Behavioral|Cognitive Training|Participants in this arm will engage in a 12-week intervention that involves cognitive tablet-based training three times per week.
45685089|NCT04120792|Behavioral|Neutral video|Participants in this arm will engage in a 12-week intervention that involves watching neutral videos on a tablet computer three times per week.
45685090|NCT04393012|Other|Provide alternative nurse call and communication device|Evaluate impact of providing access to the nurse call system and a speech generating device.
45475599|NCT03636399|Behavioral|Standard GIST|13 group modules will be administered to outpatients in 12 x 2,5-3 hours sessions. Manualized intervention; In every group session a new topic is presented, discussed and practiced in group exercises. Homework assignments between sessions.
46043731|NCT02668900|Behavioral|Decision Support|The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
45347739|NCT00905008|Procedure|transluminal percutaneous coronary intervention|All interventions were done according to current practice guidelines. The operator was responsible for the decision to choose a specific treatment strategy. Angiographic success was defined as residual stenosis <30% by visual analysis in the presence of TIMI 3 flow grade. The patients were prescribed aspirin plus clopidogrel 75 mg per day, after a loading dose of 300 mg or 600 mg, before or during the index coronary intervention. After procedure, all patients were advised to maintain lifelong use of aspirin. The use of clopidogrel (75 mg per day) was always adapted according to guideline recommendations. Heparin was infused throughout the procedure to maintain an activated clotting time of at least 250 sec. The administration of platelet glycoprotein IIb/IIIa receptor blocker was encouraged, unless in existing contraindications.
45347740|NCT00905008|Device|Drug-Eluting and Bare-Metal stents|Sirolimus-eluting stents (Cypher®), Paclitaxel-eluting stents (Taxus®) Zotarolimus-eluting stents (Endeavor®) and uncoated (bare-metal) stents
45347741|NCT02565420|Other|Normal saline|Patients will be administered normal saline for intraoperative fluid management.
46043732|NCT00910546|Device|visicoil gold marker 0.7 x 20 mm|CT - guided implantation into lung tumors
46043733|NCT00646594|Drug|budesonide/formoterol (Symbicort)|
46043734|NCT00646594|Drug|fluticasone/salmeterol (Advair)|
46043735|NCT00646984|Drug|Standard continuous antiretroviral therapy|
45347742|NCT02565420|Other|Lactated Ringer's solution|Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
45347743|NCT00905086|Other|questionnaire administration|Two weeks before completing planned radiotherapy, patients undergo assessment of stress appraisal and other factors predictive of post-radiotherapy psychosocial adjustment. At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
45347744|NCT00905086|Procedure|cognitive assessment|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
45347745|NCT00905086|Procedure|psychosocial assessment and care|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
45347746|NCT00905086|Procedure|quality-of-life assessment|At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
45347747|NCT00921570|Drug|Amlodipine|calcium channel blocker (Amlodipine 10 mg) during 12 weeks
45841121|NCT04129866|Behavioral|M-IBM|"In this paradigm, an ambiguous word or two-word phrase related to ASCC is followed by a sentence that resolves the word-sentence meaning as threatening or benign. For example, participants are presented with an ambiguous word or two-word phrase for 1 second. On half the trials the combination of the word/phrase and sentence creates a benign meaning (as in the previous example). On the other half of trials this combination creates an anxious-threat meaning Participants are required to judge the relatedness of the word/phrase and the sentence. Participants are given feedback during training such that judging the anxious-threat combinations to be unrelated and the benign combinations as being related would produce a correct response. In contrast, if participants produce an incorrect response they see incorrect."
45347748|NCT00921570|Drug|Valsartan|AII receptor blocker inhibitor (Valsartan 160 mg) during 12 weeks
45347749|NCT00926068|Drug|HO/03/03 10µg|
45841122|NCT04129866|Behavioral|Control-IBM|Placebo IBM where sentences are not related to anxious threat meaning of cue word.
45841123|NCT04098432|Drug|Nivolumab|Nivolumab 3 mg/kg intravenously every two weeks untill disease progression or unacceptable toxicity
45841124|NCT04098432|Radiation|Stereotactic radiotherapy|The prescribed dose will be 32 Gy in four fractions in four weeks (8 Gy per one fraction).
45841125|NCT03984318|Procedure|Blood sample|Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.
46043736|NCT00646984|Drug|CD-4 guided therapy interruption|Stop antiretroviral therapy when CD-4 equal or above 350 and reinitiate when below 350
46043737|NCT00646984|Drug|Viral load driven treatment interruption|Stop antiretroviral therapy when viral load below 30,000 copies/ml and reinitiate when equal or above 30,000 copies/ml
45347750|NCT00926068|Drug|Placebo|
45347751|NCT00905242|Drug|GI medication|Patients on daily dosing were asked to discontinue their GI medication at baseline. Patients on twice daily dosing were asked to reduce GI medication to once a day at baseline and asked to discontinue GI medication at day 30.
45347752|NCT02710890|Drug|Lacosamide|"Pharmaceutical form: solution for infusion~Concentration: 10 mg/ml~Route of Administration: intravenous"
45347753|NCT00742950|Procedure|Nasal 2.8-mm corneal incision|Phacoemulsification through a nasal 2.8-mm incision
45347754|NCT00742950|Procedure|Temporal 2.8-mm corneal incision|Phacoemulsification through a 2.8-mm temporal incision
45347755|NCT00742950|Procedure|Superior 2.8-mm incision|Phacoemulsification through a superior 2.8-mm corneal incision
45347756|NCT05322642|Behavioral|UPA|UP-A is divided into five main treatment modules and three optional modules. The UP-A seek to positively affect how adolescents with anxiety and/ or depression experiences, think about, and respond to a broad range of negative and positive emotions, rather than disorder-specific emotions (e.g., fear, sadness).
45475600|NCT03636399|Behavioral|Intensive GIST|13 group modules will be administered to inpatients during 4 weeks in hospital. Participants is admitted to a hospital unit for cognitive rehabilitation treating patients in acute and/or cronic phase. The participants are given extended leave every weekend to work on homework Assignments between each treatment week.
45841126|NCT03899532|Device|Remote Ischemic Conditioning|Standard manual blood pressure cuff
45841127|NCT03899532|Other|No-Remote Ischemic Conditioning|No-Remote Ischemic Conditioning
46043738|NCT00910468|Procedure|Robot-assisted Laparoscopic myomectomy|Robot-assisted Laparoscopic myomectomy
46043739|NCT04173052|Device|Testis' shocker|The device gives electrical shock ranged (1-5) milliAmpere designed to fit the testis shape for the males.
46043740|NCT04172896|Procedure|Intraperitoneal Uterosacral Ligament Suspension|Vaginal intraperitoneal uterosacral ligament suspension performed by transfixing the ligament, intraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) with three delayed absorbable 0 sutures, performed bilaterally (three sutures per side; six sutures total).
45347757|NCT05322642|Behavioral|Active control condition (Progressive Relaxation Training)|Progressive Relaxation Training (Bernstein and Borkovec) program is divided in ten sessions. Relaxation training often is used in behavior therapy as a means to reduce anxiety, tension, and stress. The goal is to release tension from your muscles, while helping you recognize what that tension feels like.
45347758|NCT00605176|Drug|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
45347759|NCT00605176|Drug|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
45347760|NCT00605176|Drug|Placebo|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
45347761|NCT04060290|Other|Observational study|Observational study of this study, no interventions involved
45347762|NCT00926146|Behavioral|NCMIT|Nurse Case Management Plus Contingency Management and Tracking (NCCMT) Program includes 20 minute case management, delivered by the NCCMT nurse and a separate 45 minute culturally competent specialized education, delivered by the two assigned nurses and research assistants weekly over 8 weeks. Participants of this group will also receive the HBV vaccine subsequently at one month and four months after baseline and incentives for three-weekly urine samples.
45347763|NCT00926146|Behavioral|SCMIT|Standard with Contingency Management and Tracking (SCMT) Program. Participants in the SCMT group will interact three times a week over the four-month intervention period with the research nurse and research assistant and will be offered: 1) a brief HBV/HCV education program; 2) receipt of the vaccine subsequently at one month and four months after baseline; and 3) voucher incentives for three-weekly urine samples. The SCMT participants will not receive the specialized education sessions nor the case management delivered weekly over the first 8 weeks sessions.
46043741|NCT04172896|Procedure|Extraperitoneal Uterosacral Ligament Suspension|Vaginal extraperitoneal uterosacral ligament suspension performed by transfixing the ligament, extraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) using a suture capturing device with two delayed absorbable 0 sutures, performed bilaterally (two sutures per side; four sutures total).
46043742|NCT02665390|Procedure|Percutaneous cryoablation|Percutaneous cryoablation
46043743|NCT04773184|Procedure|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
45347764|NCT00743028|Drug|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation
46043744|NCT04773184|Procedure|Videofluoroscopic Swallowing Study|Videofluoroscopic swallowing study will be performed to measure oropharyngeal swallowing. This is like a moving x-ray of the swallow.
46043745|NCT04773184|Procedure|Voluntary Peak Cough Flow Testing|Voluntary peak cough flow testing will be performed to determine the peak expiratory flow (PEF) and volume of air expelled (FEV1) during voluntary coughing.
46043746|NCT04773184|Procedure|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
46043747|NCT04773184|Procedure|Capsaicin Challenge|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
46043748|NCT04773184|Procedure|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP) expressed as a percentage of predicted values.
45841128|NCT03786042|Behavioral|E-cigarette ad exposure|Participants view a series of e-cigarette TV commercials
45841129|NCT03786042|Other|non e-cigarette TV commercials|Participants view a series of non e-cigarette TV commercials
46043749|NCT04773184|Other|Voicing Tasks|Voicing tasks will be completed to assess vocal ability.
46043750|NCT04172818|Behavioral|quality of life questionnaire|Since 10 years ago, diaries are used in intensive care unit to limit these symptoms after a coma.In analogy, the diary for patients with allogenic hematopoietic stem cell transplantation could be a mean to reduce the psychological adverse impact and long term consequences. The psychological impact of a diary on patients hospitalized for allogenic hematopoetic stem cell transplantation and on their relatives will be evaluated.
46043751|NCT02668978|Device|Hemopatch™ Sealing Hemostat|Hemopatch™ application over lung resection areas
45841130|NCT03767010|Other|Control (no PLM)|Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
45841131|NCT03767010|Other|PLM|PLM Participants will take the PLM on the location of the brachial plexus at the level of the interscalene groove on surface ultrasound images. They will also take a pretest, a post-test and a delayed test at 6 months. Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
46043752|NCT02668978|Procedure|Standard surgical technique|Lung resuturing or restapling
45347765|NCT00743028|Drug|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
45841132|NCT03660072|Other|Non-Interventional|Non-Interventional
45841133|NCT03599544|Behavioral|Robot-Assisted Therapy (RT)|Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks).
45347766|NCT00743028|Drug|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
45841134|NCT03599544|Behavioral|Robot + Active Learning Program(RT-ALPS)|Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks). In addition, participants will receive training in active problem solving, analysis of performance and goal setting focused on home action plan activities to assist with carry-over and generalization to every day activities.
45841135|NCT03554850|Device|Trevo® Retriever|Stent retriever procedure
45841136|NCT03178890|Device|OHMG|Device will be implanted in all enrolled patients.
45347767|NCT00905320|Procedure|Metallic Fasteners and Sutures|Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners and sutures.
45347768|NCT00905320|Procedure|Metallic Fasteners Alone|Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners alone.
45347769|NCT00926224|Device|FibroScan M and XL probes|Each patient undergo two liver stiffness measurements with the FibroScan: once with the M probe and once with the XL probe
45841137|NCT03125148|Device|Enteral stenting|Enteral stent for malignant duodenal obstruction
46043753|NCT00647140|Other|18F-L-DOPA PET|PET performed 30 minutes after IV injection of 4 MBq/kg of 18F-DOPA
46043754|NCT04172428|Diagnostic Test|Functional MRI (fMRI)|fMRI will be done on 3 separate MRI scanners to compare.
46043755|NCT00647218|Drug|Post-operative adjuvant therapy|Adriamycin 60 mg/m2 IV over 20 minutes and Cytoxan 600 mg/m2 IV over 1 hour will be given every three weeks for 4 cycles.
46043756|NCT00647218|Drug|neoadjuvant therapy|Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles
46043757|NCT00647218|Procedure|therapeutic surgical procedure|Modified radical mastectomy or segmental mastectomy plus axillary dissection 6-8 weeks following completion of chemotherapy/Radiotherapy.
46043758|NCT00647218|Radiation|Radiation therapy with concurrent Paclitaxel|Radiation to breast 4680 cGy/26 fractions with concurrent Paclitaxel 30 mg/m2, twice per week
46043759|NCT00647218|Drug|Hormonal Therapy|After completion of postoperative adjuvant Adriamycin and Cytoxan, hormonal therapy should be given at the discretion of the treating physician for all post-menopausal ER and/or PR positive patients. It is also recommended for pre-menopausal patients who are ER and/or PR positive.
46043760|NCT04768114|Behavioral|Genetically-Informed RiskProfile|"Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change.~This is a fully remote trial, with intervention delivered via video conferencing."
46043761|NCT04768114|Other|Brief Cessation Advice|"Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed.~This is a fully remote trial, with brief cessation advice delivered via video conferencing."
46043762|NCT00994890|Drug|Tanezumab 2.5 mg|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
45347770|NCT02538796|Other|TEA + Grober Test + Task 1 + Grober Test|"The Test of Everyday Attention (TEA) measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 1 consists of a stimulus that moves on the screen. The response of the patient is done on the keyboard. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
45347771|NCT02538796|Other|TEA + Grober Test + Task 2 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 2 consists of a stimulus that is fixed on the screen. The response of the patient is done by pushing or pulling a lever. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
45841138|NCT03029364|Behavioral|Study Protocol|"Participants will complete three study protocols 7 - 28 days apart which includes:~3 x main trial days (max. 150 mins) involving body composition analysis, indirect calorimetry, a blood sample, optional muscle and / or adipose tissue biopsies and a maximal cardiorespiratory fitness test.~2 x lifestyle monitoring periods (physical activity and diet) for the prior 7 days before each main trial day.~Maintenance of habitual habits, dietary and physical activity behaviour patterns~We are observing biological / health parameters in a group of individuals who will be assessed under resting and exercising conditions. The current study does not involve an intervention."
45841139|NCT02662062|Drug|Pembrolizumab|200 mg/m2, IV (in the vein) on day 1 every three weeks (Weeks 1, 3, 7, 10, 13, 16 and 19). until progression or unacceptable toxicity develops.
45841140|NCT02662062|Drug|Cisplatin|35 mg/m2, IV (in the vein) every week for six weeks.
45841141|NCT02662062|Radiation|Radiotherapy|2.00Gy once daily for 32 fractions, 5 fractions/week over six weeks and two days (a total of 64Gy).
46043763|NCT00994890|Drug|Tanezumab 5 mg|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
46043764|NCT00994890|Drug|Tanezumab 10 mg|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
46043765|NCT02663830|Drug|Sildenafil & clomiphene citrate|105 Patients will receive 25 mg sildenafil citrate 6hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
46043766|NCT02663830|Drug|clomiphene only|105 Patients will receive clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
46043767|NCT00910702|Device|foldable capsular vitreous body(FCVB)|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB) after PPV
46043768|NCT02665078|Other|Thoracoscopic Ultrasound|We will evaluate the resected specimen using the XLTF-UC180 in the operating room (OR) to determine the localization rate of the targets. Ultrasound measurement and images will be compared to the actual size of the tumor and pathological morphology using HE slides of lung tumor to determine the correlation between those variables. The tumor depth from the lung surface will be also collected to clarify the maximum depth to which the ultrasound can visualize.
45841142|NCT02406222|Drug|Pomalidomide|Chemotherapy
45841143|NCT02406222|Drug|Dexamethasone|Chemotherapy
45841144|NCT02406222|Drug|Cyclophosphamide|Chemotherapy
45841145|NCT02247726|Drug|Saline Placebo (0.5mL injection)|
45841146|NCT02247726|Drug|RSV F vaccine (0.5mL injection)|
46043769|NCT00648544|Drug|Pravastatin|Single-dose 80 mg oral immediate-release tablet
46043770|NCT00648544|Drug|Pravastatin|Single-dose 80 mg oral immediate-release tablets
46043771|NCT00645346|Biological|GBS glycoconjugate vaccine|Study subjects will receive either GBS conjugate vaccine or placebo. Total study size is 65. Study subjects will be followed for a total of 12 months after their last vaccination.
46043772|NCT00645346|Biological|Placebo|Subjects will receive one dose of placebo
46043773|NCT00647374|Other|this is an observational study|
46043774|NCT04175314|Other|Clinical examination of gingival tissues|Measure of the periodontal recession
46043775|NCT00648622|Drug|Carvedilol Tablets 12.5 mg|12.5mg, single dose fed
45347772|NCT02538796|Other|TEA + Grober Test + Implicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are implicit condition to detect an A in the word (yes-no answer)."
45347773|NCT02538796|Other|TEA + Grober Test + Explicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are explicit condition to judge the emotional value of words (positive-negative answer)."
45347774|NCT00905398|Drug|Nilotinib|400mg, Oral, Bid, Daily for three years
46043776|NCT00648622|Drug|Coreg® Tablets 12.5 mg|12.5mg, single dose fed
46043777|NCT00994422|Drug|Ivermectin cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1.
46043778|NCT00994422|Drug|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
46043779|NCT00647452|Behavioral|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
46043780|NCT00648700|Drug|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
46043781|NCT00648700|Drug|Levothroid® Tablets 300 μg|2x300mcg, single dose fasting
45347775|NCT00905710|Procedure|Chromoendoscopy|Chromoendoscopy: spraying of the mucosa of the right colon with indigo-carmine
45475601|NCT03348124|Behavioral|"Children - what does it involve?"|"Thirteen educational lessons based on the conversational material Toolkit will be delivered in the classroom at school, two lessons per theme. The themes consists of: 1) a card game: What i wish 2) Time 3) Money 4) Skills 5) Relations 6) Housing. The material is prepared and same for all schools. This intervention will be given 1-2 lessons per week over a period of 8-14 weeks. During this period the students also care for the RCB simulator during three days and nights, but with a break for day care for the simulator which was between 7 am and 5 pm when the students were in school. All students will practice handling the simulator to be familiar with all types of needs: to rock, change diaper, feed and burp and were taught the skills of head support, techniques to avoid rough handling."
45841147|NCT02242110|Behavioral|ERRT-Bipolar Disorder|The nightmare treatment, called Exposure, Relaxation, and Rescripting Therapy for Bipolar disorder, is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in adults diagnosed with bipolar disorder.
45841148|NCT00475488|Procedure|Coronary artery bypass grafting|Surgery performed due to coronary artery disease.
45347776|NCT00926302|Drug|Levetiracetam (Lotus Pharmaceutical Co.,Ltd.)|Levetiracetam 500mg/tablet Oral once
45347777|NCT00926302|Drug|Keppra (Levetiracetam - USB SA Pharma Sector)|Levetiracetam 500mg/tablet oral once
45347778|NCT00907036|Biological|alemtuzumab|
45841149|NCT00458796|Drug|zoledronic acid|
45841150|NCT00458796|Procedure|quality-of-life assessment|
45841151|NCT01021956|Drug|STAKEL|Open-label,safety and exploratory efficacy study in subjects with active CNV followed for 12 weeks.During first stage(dose escalating stage) subjects assigned to group 1 to 4 will receive a single treatment of VTP at one of three light levels and one of two Drug Light Interval (DLI).Second stage(dose confirmation)will be only initiated at a dose level in which an effect has been seen at week 1 and there is a maximum of one Dose Limiting Toxicity (DLT) out of three subject at week 5.
45841152|NCT01022190|Drug|Etoricoxib (Arcoxia)|Oral intake of 90 mg Etoricoxib (Arcoxia) during 7-days
45841153|NCT01024296|Device|Port Close|Device for applying loop suture to close surgical site
45841154|NCT01024686|Biological|p52-/p36- GAP Vaccine|Administered by five bites from GAP-infected Anopheles mosquito
45347779|NCT00907036|Biological|donor lymphocytes|
45347780|NCT00907036|Drug|cyclosporine|
45347781|NCT00907036|Drug|fludarabine phosphate|
45347782|NCT00907036|Drug|melphalan|
45347783|NCT00907036|Procedure|allogeneic hematopoietic stem cell transplantation|
45347784|NCT02538406|Other|Segmental withdrawal|Interventional group will have at least 3 minutes dedicated to the right side of the colon during segmental withdrawal.
45347785|NCT00905788|Procedure|prevention of embryo expulsion|The prevention of embryo expulsion will be carried out after embryo transfer
45841155|NCT01024686|Biological|p52-p36- GAP Vaccine|Administered by 200 bites from GAP-infected Anopeles mosquito
45685091|NCT04121026|Other|External validation of the PAANTHER TB treatment decision algorithm|"The PAANTHER algorithm will be used for a TB treatment decision by site clinicians in all children enrolled in the study. The PAANTHER algorithm and prediction score was designed as a guiding tool for empirical TB treatment decision in HIV-infected children with presumptive TB. The proposed score includes:~history of contact~suggestive TB symptoms~tachycardia~chest radiography~abdominal ultrasound~Xpert MTB/RIF Ultra. A score of >100 is highly predictive of TB. In children with a score >100, anti-TB treatment will be initiated immediately. In children with a score of <100, TB treatment will not be initiated except in those with severe/life-threatening conditions for whom TB treatment decision could be made at the discretion of the site clinician. TB could be definitely ruled out after further assessment and decision made as to what treatment the children should receive in accordance with existing national protocols, along with clinical follow-up."
45347786|NCT00927238|Device|XL TDR|This will be a lateral approach discectomy and reconstruction with the insertion of the XL TDR device.
45347787|NCT00927238|Other|Lumbar fusion surgery|Lumbar fusion surgery
45347788|NCT00926614|Drug|pioglitazone (Actos)|pioglitazone 30 mg qd for 30 days, then increase to 45 mg
45347789|NCT00926614|Drug|atorvastatin (Lipitor)|atorvastatin 40 mg for 30 days then increase to 80 mg daily
45347790|NCT00694356|Biological|Dalotuzumab|IV infusion
45347791|NCT00926692|Other|Blood draw|Subject will have blood draw.
45347792|NCT00907114|Drug|Ketorolac tromethamine|Presentation 5 mg/ml; Dosage: one drop (0.25 mg) four times a day during one week after panphotocoagulation
45347793|NCT00907114|Drug|Polivynilic alcohol|Presentation: alcohol polivinilico 14 mg/ml; Dosage: one drop (0.7 mg alcohol polivinilico) four times a day during one week after panphotocoagulation
45347794|NCT00692406|Behavioral|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
45347795|NCT00927316|Biological|E. coli 83972|"Active arm: Intravesical inoculation (by urethral catheterization) on three subsequent days with 30 ml E. coli 83972 (100 000 cfu/ml).~Placebo arm: Identical procedure but with saline, 30 ml."
45347796|NCT03889938|Diagnostic Test|Serum and urinary assessment|Assess bioactive lipid mediators in blood and biopyrins in urine
45347797|NCT03415464|Other|Exercise|neuromuscular training
45347798|NCT03384108|Other|5-13C-Glutamine|Intravenous infusion of 5-13C-Glutamine
45347799|NCT03384108|Other|Bone marrow aspiration|Bone marrow aspiration of bone marrow aspirate
45347800|NCT02564094|Drug|Epoetin beta|Participants will receive SC epoetin beta as 30,000 international units (IU) once weekly for 20 weeks.
45685092|NCT01922011|Drug|Daptomycin|IV daptomycin Infusion A in 12 to <18 years old (7 mg/kg); in 7 to < 12 year olds (9 mg/kg); in 24 months to <7 year olds (12 mg/kg); in 12 to <24 month olds (12 mg/kg). Infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.
45841156|NCT01024686|Biological|p52-/p36- GAP Vaccine|Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito
45347801|NCT00745914|Drug|Pioglitazone|oral Pioglitazone 15mg daily for 12 weeks, then 30mg daily for 36 weeks
45347802|NCT00745914|Drug|Placebo comparator|Placebo comparator
45347803|NCT00746070|Other|with the clinical treatment ( ex adrenalectomy or spironolactone|with the clinical observational study
45347804|NCT00746148|Other|Reflexology|10 weekly sessions of 45 minutes each
45347805|NCT00746226|Biological|Lactobacillus acidophilus and Bifidobacterium lactis|Daily 5x10^9 CFU of a combination of L. acidophilus and B. lactis
45475602|NCT01187693|Other|shoe lift|shoe lift for balancing the heights of bilateral pelvis of participants with leg length discrepancy during standing
45347806|NCT00746226|Biological|Placebo|"Microcrystalline cellulose~As capsule which could be opened"
45347807|NCT00396331|Drug|G-CSF plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 7 aphereses or until ≥ 2*10^6 CD34+ cells/kg were collected.
45475603|NCT04933149|Drug|Ketamine Infustion|Intravenous infusion at 0.5 mg/kg/hr from induction to emergence from anesthesia during the subject's brachial plexus reconstruction surgery. In addition, subjects will receive postoperative ketamine infusion of 0.1-0.3 mg/kg/hr for 24 hours titrated to side effects while patients are admitted to the hospital following surgery.
45685093|NCT01922011|Drug|Vancomycin (or equivalent)|IV vancomycin (or equivalent) (Infusions A,B,C,D), 10 to 15 mg/kg, infused over 60 (± 10) minutes q6h (± 1 hour)
45685094|NCT01922011|Drug|Nafcillin (or equivalent)|IV nafcillin (or β-lactam equivalent) (Infusions A,B,C,D) at 100-200 mg/kg/day, in divided doses infused over 60 (± 10) min q6h (± 1 hour)
45685095|NCT04120090|Drug|low dose ruxolitinib|The dose for adult patients(Age>=14 years) is generally 10 mg twice daily. For children(Age<14 years ,weight >=25kg),the dose was generally 5mg twice daily. For children(Age<14 years, weight <25kg), the dose was generally 2.5mg twice daily.
46043782|NCT04172662|Behavioral|Facilitated Music Listening|The patient gets a preparatory session with the music therapist one day before the invasive procedure, where individual assessment is made based on a biopsychosocial approach. Sequences of facilitated Music listening is provided during the pre-, peri and postoperative phase, and a closing dialog performed postoperatively. Patient-preferred music is chosen from a limited set of playlists provided on the app The Music Star.
46043783|NCT00648778|Drug|Loxapine Succinate Capsules 25 mg|25mg, single dose fasting
46043784|NCT00648778|Drug|Loxitane® Capsules 25 mg|25mg, single dose fasting
46043785|NCT00645424|Drug|atorvastatin|Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks
46043786|NCT00645424|Drug|atorvastatin|Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks
46043787|NCT00645424|Drug|atorvastatin|Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks
45841157|NCT01025076|Device|StomaphyX|StomaphyX with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) is a transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
46043788|NCT04172740|Device|Radiesse (calcium hydroxylpatite)|"RADIESSE® injectable implant is a sterile, non-pyrogenic, semi-solid, cohesive implant, whose principle component is synthetic calcium hydroxylapatite (CaHA) suspended in a gel carrier of sterile water for injection, glycerin and sodium carboxymethylcellulose. RADIESSE injectable implant has a CaHA particle size range of 25-45 microns. RADIESSE is available in 1.5cc and 0.8cc pre-filled syringes.~RADIESSE injectable implant is indicated for subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds and it is also intended for restoration and/or correction of the signs of facial fat loss (lipoatrophy)."
46043789|NCT04172350|Other|iCareBreast|The iCareBreast BuddyCare mobile app is an interactive surgery preparation and recovery app for patients. It is a patient-centric care coordination and patient engagement mobile app that supports patients' perioperative journey. The app provides day-to-day information throughout the perioperative journey to patients from 2 weeks before surgery to 2 weeks after the surgery. Meanwhile the healthcare professional can monitor patients' use of the app. That is, the iCareBreast App provides patients with all the information about the surgery-related procedure and treatment via an efficient, user-friendly and interactive timeline. Patients will receive pop-up reminders daily for them to use the app. The objective of this app is to allow each patient to focus on caring for herself as a patient.
46043790|NCT04172350|Other|Routine care|Routine care provided by the hospital includes general information regarding pre-operation preparation and post-operative care (e.g. wound care, pain management and physiotherapy).
45475604|NCT05396638|Behavioral|Contingency Management|Participants will be paid for abstinence at each study visit.
45347808|NCT00927550|Drug|lithium|Patients allocated to lithium will be administered an oral starting dose ranging between 150 and 300 milligrams. Suggested final oral dose will have to achieve plasma levels of 0.4 to 1.0 mmol/L. Clinicians will be free of increasing or decreasing the dose according to clinical status and circumstances. Dose changes will be recorded. Following randomization, treatment is to be taken daily for 1 year unless some clear reason to stop develops. Patients allocated to the lithium arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Any other pharmacological treatment will be allowed.
45347809|NCT00927550|Drug|usual care|Patients allocated to the control arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Patients allocated to the control arm will not be allowed to receive lithium. Any other pharmacological treatment will be allowed.
45347810|NCT00926926|Drug|Oxybutynin Chloride Gel|Once daily for 7 days, followed by single dose of acetaminophen
45347811|NCT00926926|Drug|Placebo Gel|Once daily for 7 days, followed by single dose of acetaminophen
45347812|NCT00396253|Drug|Tenecteplase|2 mL (2 mg) of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter.
45685096|NCT04120090|Drug|high dose ruxolitinib|The dose for adult patients(Age>=14 years) is generally 20mg twice daily. For children(Age<14 years ,weight >=25kg),the dose was generally 10mg twice daily. For children(Age<14 years, weight <25kg), the dose was generally 5mg twice daily
46043791|NCT02664844|Behavioral|Physical activity|
46043792|NCT02665000|Procedure|Structured training programme|Participants will undergo 5-days training sessions
46043793|NCT02663596|Drug|Vancomycin|Patient requiring CRRT and vancomycin that provide consent will be given vancomycin as a continuous infusion by mixing the vancomycin into the CRRT solution(s)
46043794|NCT04171336|Behavioral|Animal-assisted therapy|Six sessions of animal-assisted intervention for children and adolescents, group format. The sessions will focus on psycho-education on pain, mindfulness, defocusing, getting active, and resources. Additionally, the intervention includes two family visits.
46043795|NCT00647530|Biological|panitumumab|
46043796|NCT00647530|Drug|capecitabine|
46043797|NCT00647530|Drug|fluorouracil|
46043798|NCT00647530|Drug|oxaliplatin|
46043799|NCT00647608|Drug|Propranolol Hydrochloride Extended-Release Capsules 160 mg|160mg, single dose fed
46043800|NCT00647608|Drug|Inderal® LA Capsules 160 mg|160mg, single dose fed
46043801|NCT02663440|Radiation|Hypofractionated IMRT|Hypofractionated IMRT
46043802|NCT02663440|Biological|Granulocyte-macrophage Colony-stimulating Factor|Granulocyte-macrophage Colony-stimulating Factor
46043803|NCT02663440|Drug|Temozolomide|Temozolomide
46043804|NCT04171180|Drug|budesonide/formoterol|apply different dosage of budesonide/formoterol in two groups and evaluate the treatment effects.
46043805|NCT02660008|Drug|ZP4207|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c. to hypoglycemic Type 1 diabetic patients
45685097|NCT01883635|Behavioral|Survivor-only progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor only
46043806|NCT02660008|Drug|GlucaGen|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of GlucaGen administered s.c. to hypoglycemic Type 1 diabetic patients
45685098|NCT01883635|Behavioral|Dyadic progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor and caregiver as a dyad
45685099|NCT02983786|Drug|Indocyanine Green|ICG will be injected to derive absolute CBF and calibrate the DCS monitor to yield continuous absolute CBF. During each 12-hour monitoring session, for up to 14 days, the ICG will be injected at baseline(0.2 mg/kg,(4), every four hours (or less if signal is stable).
46043807|NCT02664766|Behavioral|Exercise training program|Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week. Participants will be recording their daily alcohol consumption. Participants will also undergo three trials of acute exercise (before, at the 4th week and at the 8th week of exercise training) in order to investigate whether exercise training can lead to changes in acute responses to exercise. Each trial involves 30 min of exercise on a cycle ergometer at 50-60% HRR.
45347813|NCT00927628|Procedure|Vitrectomy|Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular holes. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were >40-years-of-age.
45347814|NCT00927706|Device|Assistive technology updating and tune up intervention|This intervention includes 4 components: 1) an in-residence assessment of the mobility preferences of the older person and his/her caregiver; 2) a detailed review of forms of assistance, technological and human, that are currently being used; 3) recommendations by an occupational therapist for possible changes in the older person's mobility assistive technology or assistance strategy; and 4) therapist negotiation of an mobility assistive technology updating and tune-up intervention plan with the individual and his or her caregiver.
45685100|NCT04127968|Drug|Vitamin A|Children in intervention group will receive 50,000 IU vitamin A after being randomized.
45685101|NCT04127968|Drug|Oil|Children in control group will receive equal volume of oil.
45347815|NCT00927004|Drug|Etoricoxib (Arcoxia)|60 mg, daily dose, oral delivery, 14 days duration
45347816|NCT00927004|Drug|Sugar pill|Daily dose (1 pill), oral delivery, 14 days
45685102|NCT04125238|Behavioral|Episodic Future Thinking|Participants will generate descriptions of vivid positive future events.
45347817|NCT00604162|Device|PillCam COLON|The PillCam COLON capsule is an ingestible capsule equipped with an endoscope that has two imagers, enabling it to acquire video images from both ends. the device measures 31 by 11 mm and acquires images at a rate of 4 frames per second. Recording and downloading of data are similar those of the data for small-bowel capsule endoscopy.
45685103|NCT04125238|Behavioral|Control Episodic Thinking|Participants will generate descriptions of vivid positive recent past events.
45685104|NCT01921387|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
45685105|NCT01921387|Drug|Carmustine|Given IV
45685106|NCT01921387|Drug|Cytarabine|Given IV
46043808|NCT02664688|Other|Lumbar stabilization exercises|"The home-exercise program included an initial phase, with use of therapeutic heat via a hot pack for 15 minutes at the lumbosacral region, stretching exercises of the thoracolumbar fascia, hip flexors, hamstrings plus the stabilization exercises to encourage stabilizing motor patterns and determine the neutral position of the spine, with the target in control of transversus and internal oblique abdominis, multifidus, pelvic floor muscles, and diaphragmatic breathing control. Progression stages included hot packs, stretching exercises, and lateral, anterior bridges, leg raises in supine position, and arm and leg lifts in quadruped position (bird-dog)"
46043809|NCT02664688|Other|Flexor exercises|The home-exercise program included a hot pack for 15 minutes and flexor exercises routine
46043810|NCT00649168|Drug|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
45685107|NCT01921387|Drug|Etoposide|Given IV
45685108|NCT01921387|Other|Laboratory Biomarker Analysis|Correlative studies
45685109|NCT01921387|Drug|Melphalan|Given IV
45685110|NCT01921387|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSC transplant
45685111|NCT01921387|Radiation|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
45685112|NCT04129996|Drug|camrelizumab in combination with nab-paclitaxel and famitinib|camrelizumab in combination with nab-paclitaxel and famitinib for triple negative breast cancer
46043811|NCT00649168|Drug|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
45475605|NCT03855683|Behavioral|Unified Protocol for The Treatment of Emotional Disorders|Unified Protocol (UP) is is an 8-week intervention designed to specifically benefit individuals who report co-occurring symptoms of anxiety, stress, and mood by providing them with psychoeducation regarding (mal)adaptive emotion regulation, as well as with skills for effectively responding to stress. UP is based on a cognitive-behavioral framework and uses cognitive and behavioral therapy techniques. Each session of UP group therapy is 90 minutes in duration. Sessions themselves generally include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities.
45475606|NCT03853499|Other|No intervention (observational study)|No intervention (observational study)
45347818|NCT00604162|Procedure|Standard colonoscopy|Standard colonoscopy was the standard against which capsule endoscopy was compared,and it was performed after capsule endoscopy (after capsule excretion or at least 10 hours after capsule ingestion, whichever came first), on either the same day as ingestion or the next morning.
46043812|NCT02659774|Behavioral|workshop (Motivational intervention)|Through intensive workshop which includes motivation of quitting enhancement, stress management, smoking triggers, cravings and relapse, to provide smoking cessation intervention
46043813|NCT02659774|Behavioral|Health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking
46043814|NCT02659774|Behavioral|Face to Face counseling|Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
46043815|NCT02659774|Behavioral|Phone counseling|Use motivational interview strategies through telephone counseling to provide smoking cessation intervention
46043816|NCT02659774|Behavioral|SMS|Use motivational interview strategies through telephone messages to provide smoking cessation intervention
46043817|NCT02659774|Behavioral|Booklet|A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting
46043818|NCT02663206|Procedure|peroral endoscopic myotomy|peroral endoscopic myotomy
45347819|NCT02538328|Device|Harmonic scapel|different surgical devices used in the obesity surgery
45347820|NCT02538328|Device|Ligasure|Bipolar vessel sealing system used in obesity surgery
45347821|NCT00396097|Drug|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
45347822|NCT00396097|Drug|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
45347823|NCT00907192|Behavioral|Personal Interview|Interview questions about use of pain drugs and other knowledge and/or attitudes about them. Take about 5-10 minutes to complete.
45475607|NCT03004365|Drug|C16G2 Varnish|Antimicrobial Peptide
45475608|NCT03004365|Drug|Placebo Varnish|Placebo
45685113|NCT03179644|Other|Measurement of oesophageal pressure and pleural pressure|Measurement of oesophageal pressure by a nasogastric tube with an esophageal balloon (also enabling the patient to be fed) and pleural pressure measurement by means of several pleurocath-type catheters (Prodimed Inc, France) which the thoracic surgeon will have previously Positioned at the end of the surgery without any additional skin intrusion
45347824|NCT00907192|Behavioral|Questionnaire|5 short questionnaires about use of pain drugs, attitudes about the pain drugs and their use, and concerns about use of these pain drugs. Take about 10-15 minutes to complete.
45347825|NCT05277610|Diagnostic Test|iron studies|Pulmonary function testing was performed using standardized spirometry for asthmatic patients with iron deficiency anemia and those without iron deficiency anemia
45347826|NCT04014946|Device|ICD implantation|implantation of the Lumax 540 single/dual chamber ICD or successor
45347827|NCT00931450|Drug|exemestane|Given orally
45475609|NCT04502212|Device|Hepatic Ultrasound Insonification|Hepatic ultrasound insonification will be performed after an overnight fast (no food or drinks except for water for at least 10 hours) at approximately the same time on each day for three days.
45475610|NCT01293617|Other|Blackberries|300 g blackberries daily for 5 days
45475611|NCT01293617|Other|Gelatin|300 g gelatin per day for 5 days
45475612|NCT03851471|Drug|Jiu-wei-zhen-xiao Granule|Patients will be treated for 12 weeks, with oral administration of 5g once of Jiu-wei-zhen-xiao Granule,three times a day, based on the conventional treatment for HCC, such as antiviral treatment, supportive treatment or symptomatic treatment.
45685114|NCT04129216|Drug|Tamoxifen Citrate|10mg administered daily. Patients take this drug for 2-6 weeks
46043819|NCT02663206|Procedure|Botulinum toxin injection|endoscopic Botulinum toxin (BTX) injection at lower esophagus
45475613|NCT03352102|Procedure|Electrical stimulation|Neuromuscular electrical stimulation therapy was performed
45685115|NCT04129216|Drug|Letrozole|2.5mg is administered daily. Patients take this drug for 2-6 weeks
45685116|NCT04129216|Drug|Exemestane|25mg is administered daily. Patients take this drug for 2-6 weeks.
45685117|NCT04129216|Diagnostic Test|Blueprint|studies the genomics of the tumor and tumor behavior
46043820|NCT02663284|Drug|Ropivacaine 0.5%|Ropivacaine is used to performed the perineural block
46043821|NCT00647686|Drug|Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay|single application
46043822|NCT00647686|Drug|Fentanyl Transdermal System 25 mcg/h|single application
46043823|NCT04172272|Drug|Systemic multimodal analgesia administered intravenously|"Paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours. Analgesia will start immediately after surgery. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
46043824|NCT04172272|Procedure|Transversus abdominis plane block (TAP block)|"The TAP block will be given postoperatively before waking. It will be given bilaterally in the before mentioned anatomic region (the so-called lateral TAP block) of 0.25% levobupivacin in 40 ml bilaterally. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
46043825|NCT04172272|Other|Combined transversus abdominis plane block (TAP block) with systemic multimodal analgesia administered intravenously|TAP block in addition to systemic, mutimodal analgesia. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
45347828|NCT00931450|Drug|sunitinib malate|Given orally
45347829|NCT00931450|Other|placebo|Given orally
45475614|NCT01189721|Drug|propofol, sevoflurane|"Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min (group1 and 2) group 1 (Active Comparator, sevoflurane)will be infused propofol intraoperatively.~group 2(Experimental, propofol) will be inhaled sevoflurane intraoperatively."
45475615|NCT04503070|Behavioral|Motion capture participant|"Once participants have undergone appropriate calibration processes, they will perform listed swing progressions:~15 dry swings with a wiffle bat at low, medium and high effort~15 dry swings with a weighted bat at low, medium and high effort~15 swings off of a tee at low, medium and high effort~15 swings at an underhand toss at low, medium and high effort~15 swings from a pitching machine at low, medium and high effort"
45475616|NCT03847883|Drug|Intravenous Solution Ateplase|Infusion Low dose 0.6 or 0.75 or 0.9 mg/kg Ateplase injection iv bolus 10% of total dose and infusion 90% of total dose in1 hour , with in 4.5Hr after onset of stroke
45475617|NCT03492216|Behavioral|Incentives for negative EtG test|Economic incentives are given to the study participant contingent on point-of-care (POC) urine ethyl glucuronide (EtG) <300 ng/mL with the amount of the incentive escalating with each subsequent negative EtG test.
45685118|NCT04129216|Diagnostic Test|Mammaprint|studies the genomics of the tumor
45685119|NCT04122274|Behavioral|NCAA education sheet|A fact sheet that includes information about basic signs and symptoms of a concussion as well as steps to take if an individual sustains a concussion and reinforces the need to report the injury.
45685120|NCT04122274|Behavioral|Sham Intervention|An approximately 7-minute video that includes information about basic sports nutrition facts.
46043826|NCT02663050|Other|Kinesio taping|Patients will be taped for four days , ıt will start at the begining of the Dysmenorrhea
45347830|NCT00928330|Drug|GDC-0941|Oral repeating dose
45347831|NCT00928330|Drug|Trastuzumab|Intravenous repeating dose
45347832|NCT00928330|Drug|trastuzumab-MCC-DM1|Intravenous repeating dose
45347833|NCT00928798|Drug|Rapamycin|Application of rapamycin 1 mg/ml oral solution to one predefined skin area on one facial half, twice daily 0,25 ml, during 6 months. The other facial half will be similarly treated with a placebo.
45347834|NCT00928798|Drug|placebo|Application of placebo to one predefined skin area on one facial half, during 6 months. The other facial half will be similarly treated with rapamycin 1 mg/ml oral solution
45685121|NCT04122274|Behavioral|Decision-based interactive concussive education platform|A platform grounded in theoretical frameworks including the socioecological model and theory of planned behavior. It includes a short video to provide an overview of key lessons, a short quiz, and additional resource links that conclude the module.
46043827|NCT02663050|Drug|NSAID's|twice a daily
46043828|NCT00648856|Drug|Sertraline Hydrochloride Tablets 100 mg|100mg, single dose fed
46043829|NCT00648856|Drug|Zoloft® Tablets 100 mg|100mg, single dose fed
46043830|NCT01171976|Drug|Ranibizumab|Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.
45347835|NCT00931840|Drug|EZN-2208, Cetuximab and Irinotecan|"Patients with mutated K RAS tumors will be treated with single-agent EZN-2208 (Arm A). PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL.~Patients with wild-type K-RAS tumors will be randomly assigned in a 2:1 ratio to EZN-2208 + cetuximab (Arm B) or the benchmark of irinotecan + cetuximab (Arm C)."
45347836|NCT04014712|Drug|Tetrahydrobiopterin|Oral, Single dose
45347837|NCT04014712|Drug|Placebo oral tablet|Single dose
45475618|NCT03492216|Behavioral|Incentives for positive IsoScreen test|Economic incentives contingent on POC (IsoScreen) INH urine positive tests with the amount of the incentive escalating with each subsequent positive IsoScreen test.
45475619|NCT03167619|Drug|Olaparib Oral Product|olaparib 300mg twice daily
45347838|NCT00932074|Drug|KP-413 Ointment|Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.
45475620|NCT03167619|Drug|Olaparib Oral Product in combination with Durvalumab|olaparib 300mg twice daily plus intravenous durvalumab every 28 days
45347839|NCT04034368|Drug|Tenofovir Alafenamide (TAF)|Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；
45347840|NCT00907270|Dietary Supplement|Cholecalciferol|Cholecalciferol: 4,000 IU/day and 400 IU/day
45347841|NCT00907348|Drug|LR-CHOP21|"FIRST DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 5 mg/day D1-D14~SECOND DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1;Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 10 mg/day D1-D14~THIRD DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 15 mg/day D1-D14~FOURTH DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 20 mg/day D1-D14 Repeated every 21 days"
45347842|NCT00375505|Drug|Zoledronic acid|
45347843|NCT00375505|Drug|Placebo|Placebo
45347844|NCT00928876|Drug|Anakinra (Kineret)|anakinra 150 mg s/c. daily for four weeks
45347845|NCT00928876|Drug|Placebo|placebo s/c daily for four weeks
45347846|NCT00907504|Drug|CP-751,871|CP-751,871 20mg/kg every 3 weeks
45347847|NCT00907504|Drug|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
45347848|NCT00907504|Drug|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
45347849|NCT00907504|Drug|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
45347850|NCT00907504|Drug|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
45347851|NCT00932230|Other|KinesioTape|An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
45347852|NCT00929032|Radiation|Nanocoll®|To determine reticuloendothelial system (RES) phagocytosis activity and liver phagocytic function respectively we will measure plasma clearance of 99mTc labelled micro-aggregated human albumin without any imaging studies.
45475621|NCT01189799|Behavioral|Motivational therapy|Twelve, 60 minute weekly structured manualized therapy sessions.
45475622|NCT01189799|Other|Dual Recovery Anonymous/Treatment as usual|Twelve 60 minute weekly sessions of peer led 12-step Dual Recovery Anonymous group.
45475623|NCT03578809|Biological|MEDI6012|MEDI6012
45347853|NCT00932308|Dietary Supplement|Western-style diet (WD)|Will comprise of approximately 40% fat, 40% carbohydrates, 20% protein, and 350mg calcium, prepared by the Bionutrition Department using the USDA Nutrient Database.
45347854|NCT00932308|Dietary Supplement|Prudent Diet (PD)|Will contain approximately 20% fat, 60% carbohydrate, 20% protein, and 1100mg calcium; the diets will consist of a 2-day rotating metabolic menu.
45347855|NCT00932386|Drug|Dexmedetomidine Hcl infusion|0.5mcg/kg/hr
45347856|NCT00932386|Drug|normal saline|0.9% normal saline infusing
45347857|NCT00932464|Drug|Neratinib|240-mg oral tablet; single dose under fasted conditions
45347858|NCT00932464|Drug|Neratinib|240-mg oral tablet; single dose with high-fat breakfast
45347859|NCT00932542|Drug|Eutectic mixture|The eutectic mixture of lidocaine + prilocaine + bupivacaine.
45347860|NCT00932542|Drug|placebo|placebo
45347861|NCT00932542|Drug|lidocaine 2,5%; prilocaine 2,5%|lidocaine 2,5%; prilocaine 2,5%
45347862|NCT00907582|Procedure|autologous hematopoietic cell transplantation|"Autologous hematopoietic cell transplantation and condition with the following:~idarubicin 15mg/m2•d day -11 and -10; busulfan 0.8mg/kg•q6h day -6 to -3."
45347863|NCT05277454|Drug|HMPL-653|"Dose-escalation Stage:~Several dose levels will be evaluated for HMPL-653. The participants will receive oral HMPL-653 single-dose evaluation and oral HMPL-653 QD continuously treatment in a therapeutic cycle of 28 days until reaching the criteria for the end of treatment.~Dose-expansion Stage:~The participants will receive HMPL-653 treatment （RP2D）until reaching the criteria for the end of treatment."
45347864|NCT00907660|Behavioral|Weight loss counseling|Monitoring of weight; review of food and physical activity records; counseling to reduce calorie intake by 500-1000 calories per day
45347865|NCT00907660|Dietary Supplement|Portion-Controlled Foods|"Consumption of shakes, meal bars, and prepared entrees for 2 out of 3 meals per day during the 14 weeks of the study. Full dose patients are provided with both meals by the study; half dose patients are provided with one out of two meals by the study."
45347866|NCT00375427|Drug|Zoledronic acid|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
45347867|NCT00929266|Biological|intravenous injection of labeled cRBC|This step will take place within 2 months after stem cell collection. Direct intravenous injection of labeled cRBC in a volume of 1 mL, in a room reserved for the administration of radioactive drugs, situated in the nuclear medicine clinic and adjacent to the preparation laboratory, for regulatory reasons.
45347868|NCT04014634|Drug|Methylprednisolone|Single GON injection with methylprednisolone
45347869|NCT04014634|Other|Placebo|Single GON-injection with NaCl
45347870|NCT01043575|Drug|Rifapentine|During the first 8 weeks of therapy for TB participants > 45 kg will receive rifapentine 600 mg orally given 5 per week and for participants < 45 kg participants will receive 450 mg orally given 5 days per week
45347871|NCT01043575|Drug|Rifampin|During the first 8 weeks of therapy participants will receive rifampin at standard doses (e.g. 600 mg) 5 days per week
45347872|NCT00932776|Device|TBA care device|Tracheal suction maneuvers are performed according to the indications provided by the TBA care device or to clinical parameters whichever occurs first.
45347873|NCT00932776|Device|Control|In this group suction maneuvers are performed according to clinical indications or on a fixed schedule whichever comes first.
45347874|NCT00393913|Device|Continuous Positive Airway Pressure (CPAP)|Positive airway pressure delivered via a nasal mask titrated to a therapeutic level to eliminate all sleep disordered breathing to be used every night for 4-6 weeks.
45475624|NCT03578809|Other|Placebo|Placebo
45475625|NCT01189877|Procedure|Eppendorf hypoximeter|Patients consented to the protocol will proceed to their surgery date without any change in the standard preoperative period. After arriving in the operating room, the patient will undergo intravenous general anesthesia (or spinal/epidural anesthesia) by the anesthesiologist and will receive 40% oxygen. At this time, the principal investigator (along with the assistance of the operating surgeon and a member of the Department of Medical Physics) will use the Eppendorf hypoximeter to gather pO2 measurements. We anticipate that this will add no more than fifteen minutes to the planned procedure. Once the measurements are collected, the anesthesia will be adjusted as appropriate for the surgery and the procedure will continue as usual.
45475626|NCT03438552|Radiation|Stereotactic Body Radiotherapy|This radiotherapy may be administered with the CyberKnife® or a linear accelerator allowing stereotactic radiotherapy.
45475627|NCT03850925|Procedure|Laser therapy|4 consecutive sessions of laser therapy
46043831|NCT00996216|Drug|Eltrombopag|Eltrombopag starting at 25 mg dose and titrated in Part 1 of study to 50, 75, 100 mg. Platelet count must reach sufficient level to allow initiation of antiviral therapy. Eltrombopag dose may be adjusted during antiviral treatment phase of study to maintain platelet count to continue antiviral therapy without adjustment to antiviral dose.
46043832|NCT00996216|Drug|Antiviral therapy|Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.
46043833|NCT00647764|Drug|SNX-5422 Mesylate Hsp90 inhibitor|dose escalated, tablets twice a week; undetermined duration until disease progression
46043834|NCT00647842|Drug|Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay|single application
46043835|NCT00647842|Drug|Fentanyl Transdermal System 25 mcg/h|single application
46043836|NCT02662972|Drug|Botulinum Toxin Type A|
46043837|NCT04291716|Device|Motor Seizure Detection Algorithm (mSDA)|A seizure detection algorithm installed on a propriety mobile application to be used on a commercially available watch with a gyroscope to detect movement.
46043838|NCT02662894|Drug|Valsartan 160mg + Rosuvastatin 20mg|1 tablet, oral, a day
46043839|NCT02662894|Drug|Valsartan 320mg + Rosuvastatin 20mg|1 tablet, oral, a day
46043840|NCT02662894|Drug|Diovan® 160mg + Crestor® 20mg|Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
46043841|NCT02662894|Drug|Diovan® 320mg + Crestor® 20mg|Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
45347875|NCT04437238|Other|KeepWell tool|KeepWell is standalone eHealth application aimed at supporting the self-management of older adults with multimorbidity, and it has the following features: (i) lifestyle advice for any combination of the top 10 chronic conditions affecting older adults); (ii) an avatar health coach that walks users through a health prioritization and goal setting exercise; (iii) a health risk questionnaire (HRQ) covering health (chronic diseases), lifestyle (physical activity, diet, smoking, alcohol, caffeine, bladder health), and social and emotional well-being (social frailty, isolation, loneliness) dimensions; (iv) an evidence-based, customized Action plan; (v) an interactive lifestyle tracker; (vi) journaling; (vii) and a health resources library. A health coach avatar leads users through a health priority and goal setting exercise that allows them to create a customized action plan based on guideline recommendations for lifestyle changes.
45347876|NCT04437238|Other|Control - Usual care|Participants allocated to the control condition will receive care as usual.
46043842|NCT04291794|Drug|Propofol|2mg/kg single bolus
46043843|NCT04291794|Drug|Propofol Injection [Diprivan]|Tritiated Target-Controlled Infusion
46043844|NCT02662660|Drug|Port-sites infiltration:Bupivacaine0.25%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
46043845|NCT02662660|Drug|Epidural analgesia:Levobupivacaine0,125%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
46043846|NCT02662660|Drug|Metamizole and Acetaminophen iv|Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
45347877|NCT01045837|Drug|Prednisolone and Gluten free diet|Gluten free diet and Oral Prednisolone in a dose of 1 mg/ kg will be given for a period of 4 weeks, thereafter Gluten free diet alone will be continued
45347878|NCT01045837|Behavioral|Gluten free diet|Only gluten free diet will be given in this group
45347879|NCT00932854|Procedure|EBUS|Endobronchial ultrasound guided transbronchial needle aspiration will be performed under conscious sedation and as an outpatient procedure. Additional bronchoscopy, transbronchial biopsies and bronchoalveolar lavage will be performed at the investigator's discretion.
46043847|NCT00628992|Other|No specific intervention, standard therapy serving as a control group, passive mobilization of the legs|Muscular rehabilitation of the leg
45347880|NCT00933088|Other|questionnaires|"The study instruments will be given in the following order to the adolescent daughters: 1. Responses to Stress questionnaire; 2. Inventory of Peer and Family Attachment; 3. Youth Self-Report; and, 4. Adolescent data form.~Mothers will be asked to complete data form."
45475628|NCT03198507|Drug|RHB-105|"The intended dose of RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, is equivalent to a total daily dose of:~Rifabutin 150 mg~Amoxicillin 3000 mg~Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind."
46043848|NCT00628992|Other|Electrical stimulation of the thigh|Muscular rehabilitation of the leg
46043849|NCT00628992|Other|Cycloergometer training|Muscular rehabilitation of the leg
46043850|NCT00628992|Other|Electrical stimulation of the thigh and cycloergometer training|Muscular rehabilitation of the leg
46043851|NCT02868606|Other|Physiologic Insulin Therapy|
46043852|NCT02868606|Other|Sliding-Scale Insulin Therapy|
45347881|NCT00567268|Drug|Gabapentin|"GABAPEN Tablets 200mg, GABAPEN Tablets 300mg, GABAPEN Tablets 400mg. GABAPEN is Brand name in Japan.~Dosage, frequency: According to Japanese LPD, Normally, oral gabapentin 600 mg, 3 div., should be given on the first day of administration and an effective dose of 1200mg, 3 div, should be given on day 2. From day 3 on, adults should be maintained on oral gabapentin 1200 mg to 1800 mg, 3 div. Subsequently, the maintenance dose should be suitably adjusted depending on the symptoms (up to a maximum daily dose of 2400 mg).~Duration: According to the protocol of A9451163, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 12 weeks after the first administration."
45347882|NCT00907894|Drug|LDT600 (Telbivudine)|LDT600 (Telbivudine)
45347883|NCT03976648|Drug|GLPG1690|film-coated tablets of GLPG1690 to be administered orally
45475629|NCT03198507|Drug|Active Comparator|"The intended dose of the Active Comparator (250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~Amoxicillin 3000 mg~Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind."
45475630|NCT01184261|Behavioral|behavioral intervention|8 session behavioral intervention.
46043853|NCT02659852|Procedure|side by side|Stenting generally begins with selective guidewire cannulation into the left and right intrahepatic bile ducts. Self-expandable metallic stent(SEMS) deployment is the conventional method and parallel SEMS can be inserted. SEMS deployment can be performed serially or simultaneously.
46043854|NCT02659852|Procedure|stent in stent|After first SEMS deployment, contralateral placement of a second SEMS through the mesh of the first deployed stent was done and it looks like a Y configuration.
46043855|NCT02662738|Dietary Supplement|Natural fruit extract|
46043856|NCT02662738|Other|Placebo|
46043857|NCT02662738|Other|Glucose solution|
45347884|NCT04014556|Device|micropulse laser|"Micropulse session details:~Mainster focal grid contact lens (×1.05 laser magnification) was used to perform laser. The 577-nm yellow laser (OcuLight SLx, Iridex Corp., Mountain View, California, USA) was used. Fixed treatment parameters were used in all cases: 200-μm spot size, 200-ms exposure duration, 400-mW power, and a 5% duty cycle. Confluent applications with no spacing were administered using 5x5 grid pattern over the entire edematous area including the fovea."
45347885|NCT04014556|Drug|Aflibercept|Aflibercept
46043858|NCT00647920|Biological|adalimumab|40 mg adalimumab sc, every other week
46043859|NCT00647920|Biological|placebo|placebo sc, every other week
46043860|NCT02664454|Other|health care organization|"Nurse-led or GP-led Geriatric assessment combined with an educational seminar focused on GA and personalized care-plan as well as a dedicated hotline for general practitioners seeking a geriatric advice~Interactive educational seminar Primary care"
46043861|NCT04172116|Device|Continuous glucose monitoring|see arm/group descriptions
46043862|NCT02662816|Device|Proton magnetic resonance spectroscopy (1H MRS)|
46043863|NCT02662816|Other|a protein rich breakfast at home|
46043864|NCT02662816|Other|a protein rich lunch at the Clinical Investigation Center|
45347886|NCT00929812|Drug|Glucagon hydrochloride (GlucaGen®)|1 mg/1 ml of glucagon hydrochloride intramuscularly
45347887|NCT00929812|Drug|NaCl 0.9%|1 ml NaCl 0.9% intramuscularly
45685122|NCT04120558|Other|Qualitative interviews and focus groups|"Semi-structured interviews will be undertaken with at least 24 and up to as many as 36 through knee and above knee amputees. A topic guide will be used to interview participants about perceived functional ability, body image, adapting post amputation and overall quality of life. A sampling frame will be used to ensure a range of views are sought (e.g. both men and women with through and above knee amputations; and with different mobility levels). Thematic analysis will be used to analyse the data. Focus group discussions will be informed by the findings of the interviews.~The themes that emerge from the semi-structured interviews will be further explored using focus groups and allow for comparison of the experiences between through knee and above knee amputees."
45685123|NCT04120558|Other|Functional mobility tests and questionnaires|"Function in sitting and sit-and-reach will be assessed in non-ambulatory (wheelchair users) individuals. An overall score for each sitting activity will be recorded and the distance reached will be calculated.~Walking, timed-up-and-go, L-test, balance in sitting and standing, seated activities will be assessed in ambulatory (prosthetic using) individuals. The time taken, distance walked, distance reached, and the overall scores for each activity will be compared between the two groups. Fear of falls and confidence levels when performing tasks will be investigated using two questionnaires.~The EQ-5D-5L and SF-36 will be issued to the non-ambulatory and ambulatory participants to complete when attending the testing session.~The Locomotor Capability Index - 5 (LCI-5), Activities-specific Balance Confidence Scale (ABC-UK) and Houghton scale of prosthetic use in people with lower-extremity amputations"
46043865|NCT00830869|Drug|IXAZOMIB|"All participants will receive IXAZOMIB IV injection on Days 1, 4, 8, and 11 of each treatment cycle followed by a rest period of 10 days.~The first stage of the study will be initiated at a starting dose of 0.125 mg/m^2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established."
45347888|NCT00933322|Dietary Supplement|diet enriched with industrial trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with margarine enriched with industrial trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
45347889|NCT00933322|Dietary Supplement|diet enriched with ruminant trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with butter enriched with ruminant trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
45347890|NCT00933322|Dietary Supplement|diet without any trans fatty acids|6 weeks with margarine without any trans fatty acids.
45475631|NCT01189955|Procedure|HS total thyroidectomy|In the HS group, using the new harmonic scalpel device Focus (Ethicon Endo Surgery, Cincinnati, OH, USA) was used for cutting and coagulation . For closure of and division of superior and inferior arteries and veins we set the instrument at a power 2 i.e. more coagulation. And when smaller vessels like capsule veins we set it to the level 5 i.e. more cutting The superior artery and vein was divided close to the gland to avoid damage to superior laryngeal nerve. And control of any bleeding from the bed using the active blade of harmonic. Finally we insert drain.
45475632|NCT01189955|Procedure|conventional total thyroidectomy|A prophylactic antibiotic in the form of a third-generation cephalosporin was administered 2 hours before the operation. The operation was performed with the patient in the supine position under general anesthesia with endotracheal intubation. A Kocher incision, was made at the lower neck crease two finger above suprasternal notch. In the conventional group, mono- and bipolar coagulation, as well as ligatures, were allowed.
45347891|NCT00933400|Procedure|CT Coronary Angiography|CT coronary angiography will be performed without and with contrast in participants randomized to receive imaging as well as traditional care. (For applicable purposes, the decision to perform contrast-enhanced imaging in the presence of a large amount of calcium should be made according to procedures at each individual site.) The imaging test will be considered positive if the participant has a greater than 50% stenosis of the right coronary, left main, left anterior descending, or circumflex arteries or of their branches in contrast-enhanced CT coronary angiography. Results will be communicated to the responsible ED and treating staff immediately upon interpretation; ED staff will determine appropriate course of management. Negative results will result in patient discharge.
45475633|NCT04738344|Device|Percutaneous Coronary Intervention and Stent Implantation|Percutaneous Coronary Intervention and Stent Implantation will be implanted as recommended by guidelines and according to the standard techniques.
45475634|NCT03610165|Device|Acumen HPI-enabled EV1000 screen|Acumen HPI-enabled EV1000 screen.
45347892|NCT00933400|Procedure|Traditional, Standard of Care|Participants randomized to traditional care will be assessed and discharged/treated according to routine standard-of-care procedures in the institution's emergency department.
45347893|NCT00907972|Dietary Supplement|Vitamin D3|Vitamin D3
45347894|NCT00907972|Other|Placebo|Placebo
45347895|NCT03799744|Genetic|VCN-01|Dose level 1: 3.3x10^12 viral particles/patient and Dose level 2: 1x10^13 viral particles/patient
45347896|NCT03799744|Biological|Durvalumab|Dose: 1500 mg Q4W
45475635|NCT03610165|Device|Control|Arterial waveform and pressures
45475636|NCT03850769|Drug|nab-paclitaxel and S-1|Nab-Paclitaxel: 120 mg/m2 d1, 8, S-1: Body surface area < 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 < 1.50 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14;
45475637|NCT04663464|Combination Product|abaloparatide-sMTS|Single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
46043866|NCT02662504|Device|photodynamic therapy (PDT)|"Intra-operative (intrapleural) photodynamic therapy (PDT): briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.~After complete macroscopic resection of the tumour, the thoracic surgeon and his team will set isoprobes (7 at least) in the pleural cavity to monitor by a dosimetry device the correct illumination of the cavity with a visible red light (wavelength of 630 nm; laser source). PDT-related postoperative considerations include light precautions, intensive focus on perioperative nutrition, and a greater than normal fluid requirement in the immediate postoperative period."
45347897|NCT00933478|Device|Clay|Small dime sized piece of clay.
45347898|NCT00933556|Dietary Supplement|VSL#3|6 gms of powder formulation to be given once a day for 4 weeks
45347899|NCT00933556|Dietary Supplement|sugar pill (placebo)|placebo identical to the active product will be given
45347900|NCT00929890|Behavioral|General lifestyle, diet and physical activity counselling|Low-calorie, balanced diet and a general advice on the importance of regular physical activity
45347901|NCT00929890|Behavioral|Exercise training|Subject will receive dietary counselling (low-calorie, balanced diet) and will be enrolled in a supervised, 3 times a week, exercise training program
45347902|NCT04015258|Dietary Supplement|Blueberries|fresh spanish blueberries
45475638|NCT04663464|Combination Product|abaloparatide-SC|Single-dose administration of abaloparatide 80 μg subcutaneous injection to the periumbilical region of the abdomen
45475639|NCT05671601|Diagnostic Test|Automatic picture recognition|A machine that processes photographs automatically taken
45475640|NCT05671601|Diagnostic Test|Manual Assessment Group|Manual recognition of pictures
45475641|NCT03729895|Device|Adjustable Oral Appliance|Adjustable Oral Appliance consist of plastic maxillary occlusal splint，mandible occlusal splint and adjustable connecting rod.It could offer a non-invasive form of treatment but also achieve a good therapeutic effect
45475642|NCT01190033|Device|Neurotome OFF|In this intervention the neurotome will be unconnected.
46043867|NCT02662504|Procedure|thoracic surgery Pleurectomy / extended Decortication|extended P/D is intended to remove any macroscopic tumor including the parietal and visceral pleura when the diaphragm and / or the pericardium was resected
45347903|NCT04015258|Dietary Supplement|Blueberry powder|freeze-dried blueberry powder
45347904|NCT04015258|Dietary Supplement|Blueberry components capsules|encapsulated blueberry components (microcrystalline cellulose powder in actual)
45347905|NCT00933634|Procedure|electrical cardioversion|External cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula); patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
45347906|NCT00933634|Drug|propafenone|Propafenone (2 mg/kg bolus) was administered to obtain pharmacolgic sinus rhythm conversion.
46043868|NCT02662504|Drug|Adjuvant chemotherapy|Chemotherapy should begin up to three months after surgery. It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle every 3 weeks, for up to 6 cycles.
46043869|NCT04061902|Other|Participation with enhanced patient perioperative information|Improved information and dialogue about the care goals in the fast track protocol.
46043870|NCT00648934|Drug|Topiramate Sprinkle Capsules 25 mg|25mg, single dose fed
45841158|NCT01026402|Drug|AZD2014|Dose escalation phase: a single dose taken orally (solution or tablet) of AZD2014 on single dose day 1 (visit 2), followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or Single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal. Expansion phase: twice daily dosing from day 1 until discontinuation or withdrawal or a single dose taken orally of AZD2014 on single dose day 1 (visit 2), followed by a single dose on second single dose day 1 (visit 3) after a washout period (48 hours - 7 days) followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal.
46043871|NCT00648934|Drug|Topamax® Sprinkle Capsules 25 mg|25mg, single dose fed
45841159|NCT01027806|Drug|Montelukast|1 pill per day for 4 months
46043872|NCT04170868|Other|ADHD Psycheducation|The videos will disseminate evidence-based strategies for the management of Attention Deficit Hyperactivity Disorder (ADHD). Each video, roughly two minutes, will both introduce the viewer to a single ADHD management strategy and explain how said strategy can effectively be integrated into their life.
45347907|NCT00933712|Drug|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative for 6 weeks.
45347908|NCT00933790|Drug|ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)|Ethambutol 800 mg for daily, 1200 mg for intermittent therapy, Pyrazinamide 1500 mg for both daily and intermittent, INH 300 mg for daily and 600 mg for intermittent therapy, Rifampicin 450 mg for both daily and intermittent therapy for patients below 60 kg, 600 mg for both daily and intermittent therapy for patients 60 kg and above
45347909|NCT02538250|Dietary Supplement|Nutricomp Drink Plus|Oral nutritional supplementation
45347910|NCT00930124|Procedure|Orthognathic surgery|Patients with moderate maxillary hypoplasia needing an advancement of 4-10mm
45347911|NCT00930124|Procedure|Distraction osteogenesis|
46043873|NCT02659228|Device|EEG recording|EEG recording with anesthetic (DIPRIVAN)
46043874|NCT02659228|Drug|Anesthetics, Intravenous|The participant will receive an intravenous infusion of propofol (DIPRIVAN Injectable Emulsion USP 1%, AstraZeneca).
46043875|NCT00844519|Drug|Maraviroc|For subjects assigned to the maraviroc group, they will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications. For subjects on ritonavir, the dose will be reduced to 150mg by mouth twice daily for 24 weeks.
45347912|NCT00566254|Drug|Zonisamide|8mg/kg per day for approximately 24 weeks.
46043876|NCT00844519|Drug|placebo|For subjects assigned to the placebo group, they will receive a matching placebo pill 300mg to be taken by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications.
46043877|NCT02664376|Other|Sarcopenia detection|"The assessment of sarcopenia is performed according to the recommendations of the EWGSOP (European Working Group on Sarcopenia in Older people). Three measurements are made:~Muscle mass measurement by dual energy X-ray absorptiometry (DEXA).~Walking speed measurement~Hand grip test~A diagnosis of sarcopenia is established if the walking speed is inferior to 0.8 m/sec, the muscular strength is low and the muscular mass is low.~Data regarding the geriatric characteristics of this sarcopenic population will be collected."
46043878|NCT02659462|Other|Cardio Pulmonary Exercise Testing|Cardio Pulmonary Exercise Testing
46043879|NCT00702793|Drug|Varenicline|Varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily through week 12. Administration of twice daily dosing should be at least 8 hours apart.
46043880|NCT04170166|Procedure|Anterolateral subacromial steroid injection|Applying to the anterolateral approach arm, this group will receive their subacromial steroid injection via an anterolateral approach
45841160|NCT01029054|Drug|carfilzomib, lenalidomide plus dexamethasone|"Phase I: Carfilzomib will be administered at the dosage assigned for the subject's cohort as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).~Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.~Dexamethasone 40 mg will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push."
45841161|NCT01029054|Drug|carfilzomib, lenalidomide plus dexamethasone|"Phase II: Carfilzomib will be administered at the Maximum Tolerated Dose (MTD) established in Phase I as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).~Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.~Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push on Days 1, 8, 15, and 22 as follows: Cycles 1-4: 40 mg; Cycles 5-8: 20 mg; and Cycles 9 and higher: 10 mg."
45347913|NCT00566254|Drug|Placebo|
45347914|NCT00930202|Drug|Conivaptan (Vaprisol)|Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
45347915|NCT00933868|Drug|Magnesium Chloride|An infusion of magnesium chloride will be given over 4 to 10 minutes in patients breathing 100% oxygen
45347916|NCT00933868|Drug|Placebo|A saline placebo will be given as an infusion (six infusions over a three week period) in a double blind manner with the active test agent
45841162|NCT01029912|Device|Electrical stimulator|"6-week intervention~15 minutes of therapist-guided stimulated ankle exercise + 30 minutes of physical therapy in the laboratory twice a week.~Self-administered active repetitive ankle dorsiflexion exercise performed twice a day, 6 days a week at home using the device."
45841163|NCT01032330|Device|occlusion treatment|Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.
46043881|NCT04170166|Procedure|Posterior subacromial steroid injection|Applying to the posterior approach arm, this group will receive their subacromial steroid injection via an posterior approach
46043882|NCT01171820|Device|TAXUS® Liberté™|Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
46043883|NCT01171820|Device|XIENCE V® EECSS|Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
46043884|NCT02658916|Drug|BIIB092|Same dose as corresponding CN002003 study panel.
46043885|NCT05518747|Dietary Supplement|Probiotic|In this group participants will receive probiotic supplements twice a day (morning and evening) for a period of 12 weeks.
46043886|NCT05518747|Dietary Supplement|Placebo|In this group participants will receive placebo twice a day (morning and evening) for at period of 12 weeks.
46043887|NCT02662426|Drug|Lingdancao granules|4 packs per time (3g/pack), three times per day
46043888|NCT02662426|Drug|analogous oseltamivir phosphate capsule|1 capsule per time, twice per day
45347917|NCT00908206|Drug|GSK598809|Subjects will receive a single 175 mg oral dose of GSK598809.
45347918|NCT00393523|Biological|Comparator: Modified Process Hepatitis B Vaccine|Single dose 5 µg/0.5ml modified process hepatitis B vaccine
46043889|NCT02662426|Drug|Oseltamivir phosphate capsule|1 capsule per time (75mg), twice per day
46043890|NCT02662426|Drug|analogous Lingdancao granules|4 packs per time, three times per day
46043891|NCT00994110|Drug|Pasireotide (SOM230)|"Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.~Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified."
46043892|NCT00994110|Other|placebo|"Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.~Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified."
45347919|NCT00393523|Biological|Comparator: Comparator: ENGERIX-B|Single dose 10 µg/0.5ml ENGERIX-B
45347920|NCT03993067|Procedure|Hemopatch|Hemopatch is a collagen based sealant is a hemostat agent. We want to investigate his role in the prevention of post operative biliary fistula
45347921|NCT03993067|Procedure|Fribrin glue and Tabotamp|Fibrin glue and Tabotampis the standard treatment
45347922|NCT00393367|Drug|Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg|Patients randomized to budesonide inhalation suspension (BIS) receive 2 nebulized albuterol sulfate (5mg/mL) doses (2mL =10mg for patients over 20kg, 1.5mL =7.5mg for patients 10-20kg) mixed with 8mL (2mg) of BIS(0.5mg/2mL). The albuterol sulfate and BIS mixture is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
45347923|NCT00393367|Drug|Prednisolone, prednisone, or methylprednisolone|All patients are given 2mg/kg of systemic corticosteroids (max 60mg). Patients who can tolerate pills are given oral prednisone, those who cannot are given oral prednisolone, and those who cannot tolerate oral medications are given IV methylprednisolone.
45347924|NCT00393367|Drug|Albuterol, ipratropium bromide|While guardians are approached for possible participation, patients are given a single nebulized dose of albuterol sulfate (5mg/mL) mixed with ipratropium bromide (500mcg/2.5mL). Patients who weigh 10-20kg receive 3.75mg of albuterol. Patients over 20kg receive 5mg of albuterol. All patients receive 500mcg of ipratropium bromide. Albuterol sulfate and ipratropium bromide are delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
45475643|NCT01190033|Procedure|neurolysis|In this procedure the neurotome will be connected
46043893|NCT04315376|Behavioral|Exercise-Diet Intervention|The participants who performed exercise-diet intervention performed an Astrand-rhyming test before and after the exercise program intervention. Participants followed a progressive exercise-program during four months according to initial physical fitness. The main exercises consisted of improving aerobic, speed and resistance performance. During all single sessions, breathlessness and fatigue were measured using 0 to10 Borg scale. A personal trainer certified by American College of Sports Medicine (ACSM) supervised three sessions per week, the other two unsupervised training days the subjects were given the detailed training program to do in house/park. And also, this group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
46043894|NCT04315376|Behavioral|Diet Intervention|This group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
46043895|NCT02662348|Drug|Recombinant Human Interleukin-2|Given SC
46043896|NCT02662348|Drug|HER2Bi-Armed T Cells|Given IV
46043897|NCT02868372|Drug|Povidone iodine|After closure of the anterior wall of the rectus sheath, the subcutaneous tissues of the cesarean section wound will be swabbed with 10% undiluted Povidone iodine without mobbing.
46043898|NCT00629148|Drug|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w Capecitabine 1000mg/m2 D1-D14 q3w
46043899|NCT00629148|Drug|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w. When disease progression or untolerated toxicity occurs, Capecitabine 1000mg/m2 D1-D14 q3w
46043900|NCT02662192|Other|Exercise + health education+ auditory rehabilitation|comparison of 3/4 of an hour balance, resistance and strength training, 1 hour health education, 1 hour auditory rehabilitation
46043901|NCT02662192|Other|auditory rehabilitation alone|10 weeks of one hour per week of group auditory rehabilitation
46043902|NCT00993954|Procedure|Reduction of Radial Head Subluxation|Nurse group will use hyperpronation with extension for first attempt and supination and flexion for second attempt. Physician controls will use either method at their discretion
46043903|NCT02662114|Other|No treatment given|Information will be collected from the medical records (paper/electronic) of each patient at several outpatient clinics to describe the two periods of medical history: before and after the initiation date of Tresiba®. For each patient, data will be collected, to describe a minimum of 6 months to a maximum of 12 months in each period; thus, the study will collect information on 12 to 24 months of medical history for each patient.
46043904|NCT01157234|Drug|Nebivolol|Nebivolol 5 mg once daily, titrated to a maximum total daily dose of 40 mg to achieve a blood pressure of < 140/ 90.
46043905|NCT01157234|Drug|Metoprolol|Metoprolol 25 mg twice daily, titrated to a maximum total daily dose of 400 mg to achieve a blood pressure < 140/90.
46043906|NCT04170712|Other|Tampons|Collection of tampons, blood, cervical swabs, tissue and ascites
46043907|NCT02661802|Other|Oxygen Supplementation|Oxygen delivery was continuous by mask at 40%
46043908|NCT00991302|Behavioral|CAP-IT|Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)
46043909|NCT04170790|Drug|Saxagliptin 5mg|Saxagliptin 5mg oral tablet
46043910|NCT04170790|Drug|Sildenafil 50 mg|Sildenafil 50 mg Oral Tablet
46043911|NCT04219800|Behavioral|Patient-centered counselling and written material|Patient-centered counselling and written material regarding occupational sedentary behaviour, with telephone follow-ups after 1 and 5 weeks.
45347925|NCT00393367|Drug|Ipratropium bromide|500 mcg/2.5mL. All patients receive a final dose of ipratropium bromide after the intervention or placebo. The ipratropium bromide is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM) with an oxygen flow rate of 8L/minute via a tight-fitting face mask.
45347926|NCT00395863|Drug|Multihance|0.5 M at a single injection
45347927|NCT00395863|Drug|Arm 2 - Magnevist|0.5 M Magnevist at a single dose injection
46043912|NCT04219800|Behavioral|mHealth|"Activity tracker armband (Garmin Vivofit); warns of prolonged sitting and counts daily steps.~SMS text messages; reminds of activity breaks.~Mobile video instruction for standing pause gymnastics."
46043913|NCT02661958|Drug|S6G5T-3|once a day topical cream
46043914|NCT02661958|Drug|S6G5T-1|once a day topical cream
46043915|NCT02661958|Drug|S6G5T-5|once a day topical cream
46043916|NCT02661958|Drug|S6G5T-6|once a day topical cream
46043917|NCT02661958|Drug|S6G5T-7|once a day topical cream
46043918|NCT02661958|Drug|S6G5T-8|once a day topical cream
46043919|NCT04291872|Other|Glass -Ionomer Cement with /without Led Light Cure|Teeth were restored as same protocole with non-Heated Group. LED light (GC- D-Light DUO) was used at standard mode 1200 mW/cm2, at 50-60 ºC, for 60 sec.
46043920|NCT04171648|Other|Roasted Peanut Treatment|The subjects will consume 2 ounces or ~48 grams of roasted in shell peanuts a day for two weeks.
46043921|NCT04171648|Other|Boiled Peanut Treatment|The subjects will consume 2 ounces or ~48 grams of boiled peanuts a day for two weeks.
46043922|NCT00995670|Drug|5% dextrose|Glucose is infused to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent ischemia/reperfusion injury.
45685124|NCT04393168|Combination Product|Lymphatic clearance measurement|The indocyanine green in 5% human albumin solution (tracer) (50 μL) will be injected intradermally in both forearms or both lower legs using MicronJet600 microneedles paying attention to the contralateral symmetry of the injections. The signal at the injection sites will be measured over time using a hand-held portable device LymphMeter 1.0 for the total duration of 3 h. In the first hour, the signal will be measured every 15 minutes followed by measurements every half an hour. Immediately after injection (t=0 h), 1.5 h and 3 h after injection the skin area occupied by the tracer will be measured using a standard near-infrared camera, Fluobeam. The dermal reaction at the injection site will be assessed by observations for presence of redness/erythema and measuring its extent according to the needs. The patient will be constantly observed for the signs of allergic reactions, skin irritations or intolerances.
45685125|NCT02983708|Biological|Peripheral blood mononuclear cells (mPBMC)|
45685126|NCT02983708|Drug|G-CSF|
45347928|NCT01045915|Biological|naked DNA coding for protein AMEP|2 injections 1 week interval of 4 increasing doses of plasmid with electrotransfer
45475644|NCT01190111|Biological|Interleukin-7|20 µg/kg/week. 3 administrations, 1 per week (1 cycle) repeated cycles based on a CD4-guided response
45685127|NCT02983708|Drug|Placebo|
46043923|NCT00995670|Drug|Vitamin C|Vitamin C is intended to restore the impairment of the endothelium caused by the dextrose infusion.
46043924|NCT00995670|Drug|Simvastatin|Simvastatin will be ingested to determine the efficacy of a statin to modulate the forearm response to glucose.
46043925|NCT00995670|Drug|Sevoflurane|Sevoflurane will be given to attenuate or prevent the I/R injury during glucose.
45475645|NCT03609619|Drug|AEVI-001|Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily, during the treatment period.
45475646|NCT03609619|Drug|Placebo|Oral doses of Placebo will be administered twice daily, during the treatment period.
45475647|NCT01292993|Drug|400 mg LX4211|400 mg of LX4211 given as a solid oral dose form
45475648|NCT01292993|Drug|1000 mg metformin|1000 mg metformin given as a solid oral dose form
46043926|NCT02661724|Behavioral|TCBR-Pain|The interactive TCBR-Pain uses programmed learning, skill development and behavioral practice to engage persons with burn pain in self-management of pain and related problems. The TCB-Pain program includes 7 lessons addressing key dimensions of pain management for persons with burn injury. Each session is about 20 minutes and focuses on burn injury recovery and life style education. Sessions begin with a brief self-assessment and in later sessions, the participant is given graphical feedback on their progress. The lessons are narrated and include closed captioning, are animated, and include branching to provide personalized content.
45475649|NCT04892355|Device|Root canal irrigation|Devices used during root canal irrigation
45475650|NCT03737617|Drug|Cuvitru 20 % Injectable Solution|Active
45475651|NCT01293773|Device|Taxus Element stent|paclitaxel-eluting stent
45475652|NCT01293773|Device|Integrity Resolute stent|ABT 578-eluting stent
45475653|NCT01293773|Device|Xience Prime stent|Everolimus-eluting stent
45475654|NCT05196477|Drug|Olokizumab|The details of taking olokizumab, including its route of administration, dose and frequency of taking the drug as part of routine clinical practice, will be registered in the electronic case report forms (eCRFs).
45347929|NCT01043731|Procedure|Laparoscopic transvaginal hybrid anterior resection|Transvaginal Hybrid Anterior Resection: three 5mm trocars are placed transabdominally (one trans-umbilical, the other two in the lower abdomen). Identification of the inferior mesenteric vein and artery. Clipping of the vein. Then placement of a 12mm trocar through the posterior fornix of the vagina for stapling of the inferior mesenteric artery. After mobilisation of the colon descendens and the splenic flexure stapling of the proximal rectum through the 12mm trocar placed vaginally. Afterwards the colpotomy is performed and the mobilised left hemi-colon is extracted transvaginally. The proximal colonic resection is performed extracorporeally in the conventional fashion with placement of a purse-string suture and insertion of the circular stapling anvil into the proximal end of the bowel. The bowel is then replaced into the abdominal cavity. The colpotomy is then closed. A circular stapler is inserted transanally and the end-to-end anastomosis is performed.
45347930|NCT00395629|Drug|Deferasirox (ICL670)|
45347931|NCT00392665|Drug|Bevacizumab|Given intravenously on day one of each 3 week cycle
45347932|NCT00392665|Drug|erlotinib|Given orally once a day
45347933|NCT00392665|Drug|Sulindac|Given orally twice a day
45347934|NCT01046071|Procedure|transversus abdominis plane block|UL-guided TAP block with 20 ml of ropivacaine 0,5% bilateral, single dose.
45347935|NCT01046071|Procedure|TAP block placebo|UL-guided TAP block with 20 ml of saline bilaterally, single dose.
45347936|NCT01043809|Behavioral|Procter & Gamble school-based handwashing promotion program|Handwashing promotion lesson and materials targeting first grade students
45475655|NCT05196477|Drug|Standard therapy|Standard treatment (excluding administration of olokizumab, other interleukin (IL) (interleukin-1 and interleukin-17) inhibitors and Janus-kinase inhibitors.
45475656|NCT05671445|Biological|CM326|CM326 injection
45475657|NCT03849833|Dietary Supplement|cholecalciferol, Vitamin D3|Vitamin D3 as dietary supplement
46043927|NCT02658838|Drug|Ticagrelor|Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
46043928|NCT02658838|Drug|full amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
45347937|NCT01043809|Behavioral|expanded school-based handwashing promotion|Procter & Gamble's standard school-based handwashing promotion education and materials targeting first grade students, plus a program enhancement. In China, enhancement consists of a supply of soap for school sinks. In Pakistan, enhancement consists of soap for school sinks, plus enlistment of a peer hygiene champion in each first grade class. In the Philippines, enhancement consists of enlistment of a peer hygiene champion in each first grade class.
46043929|NCT02658838|Drug|half amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
45347938|NCT01043887|Drug|ridaforolimus|single oral dose administration 10 mg ridaforolimus
45347939|NCT01324297|Other|skin test|four patches of 2 x 3cm thin blotting paper will be soaked with an equivalent amount (0.1 mL) of aqueous methyl nicotinate in four different concentrations: 0.1, 0.01, 0.001, 0.0001 M. The four patches will then be applied at the same time to the inner forearm for 60 seconds.
45347940|NCT01043965|Drug|Metformin|Metformin 850mg
45347941|NCT01044043|Procedure|clinical examination and quality of life questionnaire|clinical examination and quality of life questionnaire
45347942|NCT01044121|Other|Mattress Firmness|Current mattress and 6 experimental firmnesses of mattress as defined by a Comfort Support Analysis device.
45347943|NCT00622869|Drug|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
45475658|NCT03849521|Diagnostic Test|MRI|Enhanced carotid calcification presented by UTE MR.
45475659|NCT03167151|Drug|Pembrolizumab|Solution for Infusion (Intravesical and Intravenous) 100mg/ 4ml vial
45475660|NCT01191125|Other|medical food with AN777|Two(220 mL)servings every day for six months
45475661|NCT01191125|Other|oral nutritional formula|Two (220 mL) servings daily for six months
45475662|NCT03660943|Drug|Placebo|Receiving Placebo Injection
46043930|NCT02658838|Drug|No low molecular weight heparin|Patients were treated with no low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
45475663|NCT03660943|Drug|CNTX-4975-05|Receiving CNTX-4975-05 Injection
45475664|NCT03167073|Other|BreastFeeding Friend (BFF)|A novel android app designed to improve breastfeeding rates among low-income women
45475665|NCT03167073|Other|dummy app|A novel android app that looks identical to the intervention app (BFF) but contains limited content.
45475666|NCT04910711|Drug|Dolutegravir|Dolutegravir-based antiretroviral therapy
45475667|NCT04910711|Drug|Levonorgestrel implant|Women initiating the levonorgestrel implant
46043931|NCT04293588|Diagnostic Test|spirometry, FOT, Induced sputum, bloods, nasal brushes, nasal lavage, skin prick, throat swab|At the point of baseline visit, exacerbation and annual visit, the above tests will be performed to allow comparison of a participants profile before and during an exacerbation
46043932|NCT02536534|Other|Correlation assessment|
46043933|NCT00648076|Drug|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fed
46043934|NCT00648076|Drug|Depakote ER® Tablets 500 mg|500mg, single dose fed
46043935|NCT02868294|Device|Fassier-Duval Nail|Implementation of a telescopic system intramedullary
46043936|NCT02869152|Other|Endoscopic injection of 99mTc-sulfur colloid|Radiotracer injection around the rectal tumor for SLN mapping with gamma probe
45475668|NCT04910711|Drug|Depo medroxyprogesterone acetate injection|Women initiating the depo medroxyprogesterone acetate injection
45475669|NCT03731767|Procedure|Distraction thrust manipulation|Distraction thrust manipulation of the talocural joint in supine position
46043937|NCT02869152|Other|Endoscopic injection of ICG|Dye injection around the rectal tumor for SLN mapping with NIR imaging.
46043938|NCT02869152|Other|Endoscopic injection of Spot|Dye injection for tattooing rectal tumor prior to surgical resection.
46043939|NCT02869152|Procedure|Flexible sigmoidoscopy|Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dyes.
46043940|NCT02869152|Procedure|Endoscopic NIR imaging and gamma probe|Endoscopic near infrared (NIR) imaging of ICG and detection of radiotracer with gamma probe after standard removal of rectal neoplasm.
46043941|NCT02869152|Procedure|Dissection of sentinel lymph node(s)|Surgical removal of identified lymph nodes in the rectum.
46043942|NCT00629070|Other|Traditional strength training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise)at 30 degrees/second; 6 sets of 5 maximum-effort concentric actions
46043943|NCT00629070|Other|Velocity-enhanced training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise). Subjects will perform 2 sets of 5 concentric exertions at 30°/second. The following 4 sets of 5 repetitions will be performed at a faster speed, starting at 60° /second. The velocity will be increased weekly in 15° /second increments up to a maximum of 120°/second.
46043944|NCT00649012|Drug|Pioglitazone HCl Tablets 45 mg|45mg, single dose fed
46043945|NCT00649012|Drug|Actos® Tablets 45 mg|45mg, single dose fed
45347944|NCT00622869|Drug|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
45685128|NCT02979496|Dietary Supplement|0 g pomace (control)|16 oz of juice containing 0 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded)
46043946|NCT02869542|Other|Data collection|
46043947|NCT04685590|Drug|Dasatinib + Quercetin|D+Q will be administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
46043948|NCT04685590|Other|Placebo Capsules|Matching placebo capsules following the same administration protocol as the experimental treatment - administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
46043949|NCT04293432|Drug|Drugs, Generic|All drugs having ≥10 TdP cases reported in the FAERS database
45347945|NCT00622869|Drug|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
45347946|NCT00622869|Drug|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
46043950|NCT02661334|Dietary Supplement|Creatine Monohydrate|Creatine monohydrate is a very common supplement used by enthusiasts, athletes, and the general populace
45347947|NCT00622869|Drug|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
45347948|NCT00622869|Drug|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6.
45475670|NCT01191203|Drug|Copper IUD|Copper IUD (CuT360)
46043951|NCT02661334|Dietary Supplement|Rice Flour|rice flour powder matched for color, appearance, taste, and solubility
46043952|NCT04170634|Other|Evaluation of the fracture risk using data from routine qCT (quantitative Computed Tomography) scan and numerical simulation|Assessment of the mechanical tumor bone strength by numerical simulation using qCT routine imagery of proximal femur (applying a monopodal standing load) and vertebrae (applying a uniaxial compression load).
46043953|NCT04274712|Diagnostic Test|INNOGRAFT Heart Suite|Liquid biopsy to identify acute rejection
46043954|NCT04291248|Drug|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
46043955|NCT04291248|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
45475671|NCT01191203|Drug|Depo Medroxyprogesterone acetate|DMPA 150 mg IM q 3 months
45685129|NCT02979496|Dietary Supplement|90 g pomace|16 oz of juice containing 90 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
45475672|NCT03657277|Device|Micropatch|Each micropatch contains 50 tiny projections (800 um in length)
45475673|NCT03197883|Other|Test Product|Restoring lipid balm
45475674|NCT03197883|Other|Cleanser|Moisturizing facial cleanser
45475675|NCT03197883|Other|Sunscreen|SPF (Sun Protection Factor) 50 sunscreen
45685130|NCT02979496|Dietary Supplement|180 g pomace|16 oz of juice containing 180 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
46043956|NCT04170088|Drug|Tranexamic Acid|Tranexamic acid intradermal injections were used for treatment of melasma
46043957|NCT04170088|Drug|0.9% Normal Saline|Normal saline used for comparision of efficacy of tranexamic acid
46043958|NCT02867670|Device|Transcranial Magnetic Stimulation|TMS is a form of non-invasive brain stimulation which uses magnetic pulses to stimulate regions of the brain from outside the head, on the scalp. Specifically, TMS is performed with a copper-and-plastic coil that emits a magnetic field, which can affect brain cells in specific locations. In this study, researchers will also use a form of TMS called theta-burst stimulation (TBS), where TMS pulses are delivered rapidly over time.
46043959|NCT00648154|Drug|Letrozole Tablets 2.5 mg|2.5mg, single dose fed
46043960|NCT00648154|Drug|Femara® Tablets 2.5 mg|2.5mg, single dose fed
46043961|NCT02869074|Genetic|VWF gene analysis|52 exons adjacent intronic regions and promotor of VWF will be analyzed
46043962|NCT02664142|Procedure|BIS Group|BIS monitoring will be used in the BIS Group patients. The BIS value will be known to the anaesthetist, who will be able to act accordingly.
46043963|NCT02664142|Procedure|Non-BIS Group|BIS monitoring will be used in the Non-BIS Group patients. The BIS value will NOT be known to the anaesthetist and will be observed by a trained co-investigator, with subsequent evaluation.
46043964|NCT02664142|Drug|Anaesthetics|Anaesthetics will be administered in both experimental groups, in order to maintain the required general anaesthesia.
45347949|NCT02548065|Other|Balneotherapy|"Bath with mineral water named Debole of Vetriolo at 36°C, 15 minutes for 12 consecutive days in bathtubs"
45347950|NCT02548065|Other|Placebo|Bath with Thermal tap water
45347951|NCT00395083|Behavioral|COPD Self-management Education|The comprehensive self-management intervention incorporates self-management education, development of an action plan, and case management. The intervention is designed using the social cognitive theory with the Precede-Proceed Model which has guided other successful patient education programs.
45347952|NCT00366457|Drug|Bevacizumab|Given intravenously on days 1 and 25 of every 28-day cycle (one every 2 weeks). Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
45475676|NCT03849677|Other|Endothelial function and inflammation|Analysis of endothelial function, oxidative stress
46043965|NCT04291638|Behavioral|Remote Caregiver Training|The remote caregiver training is a 5-hour videoconferencing-based training program that focuses on teaching cognitive behavioral therapy skills to the caregivers of children with selective mutism in a group format across 3 sessions.
46043966|NCT04291638|Behavioral|Remote Intensive Group Behavioral Treatment (IGBT)|The remote IGBT is a 5-day videoconferencing-based treatment program that delivers cognitive behavioral therapy to children and their caregivers in a group format across 2-3 hours per day.
46043967|NCT02664064|Behavioral|Prevent|Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
45347953|NCT00366457|Drug|Erlotinib|Taken orally every day. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
45347954|NCT00366457|Drug|Gemcitabine|Given intravenously on days 1, 8 and 15 of each 28-day cycle. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
45347955|NCT00624819|Biological|GSK1024805A|No vaccination in this trial
45475677|NCT03729661|Behavioral|Nasal High Flow Therapy|Use of Nasal High Flow Therapy during CT and treatment
45475678|NCT03849599|Biological|PRV-300|Treatment
45475679|NCT03849599|Biological|Placebo|Control
46043968|NCT04291482|Behavioral|Choosing Health Intervention|The intervention consists of information materials provided at baseline in a form of eBook or a physical book depending on participants preferences. The book includes the rationale for the intervention, basic information on healthy eating and behaviour change and tables allowing self-monitoring of weight, physical activity and eating (i.e., brief food diary). The book is non-tailored and it has weekly tasks for the participants to complete during 26 weeks (initial 6 months) to support their weight loss. The intervention group will also receive a series of daily text messages and weekly email messages supporting their weight loss and promoting weight loss maintenance. In phase I (month 0-3), the messages and emails will be generic and factual; in the phase II of the intervention, participants will receive text messages and emails tailored to the strongest predictors of outcomes identified in phase I.
46043969|NCT04291482|Behavioral|Choosing Health Control|The control consists of information materials provided at baseline in a form of eBook or a physical book depending on participants preferences. The book includes the rationale for the intervention and basic information on healthy eating and physical activity. The control group will also receive monthly email messages with generic and factual information.
46043970|NCT04169854|Drug|Lidocaine 5% patch|The Lidocaine 5% Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
45347956|NCT00624819|Biological|Prevenar|No vaccination in this trial
45347957|NCT00624819|Biological|Infanrix hexa|No vaccination in this trial
45475680|NCT03731689|Drug|Intrauterine lavage therapy|Intrauterine lavage treatment was performed within 3 to 7 days after the first menstrual period after surgery.
45475681|NCT03731689|Drug|Intrauterine gel-injection therapy|Intrauterine gel-injection treatment was performed within 3 to 7 days after the first menstrual period after surgery.
45475682|NCT03729583|Behavioral|Pulmonary Rehabilitation|A 12 week high intensity PR programme was delivered to both groups. The active group had additional breathing control interventions and exercises
45347958|NCT00624819|Biological|Havrix|No vaccination in this trial
45347959|NCT00624819|Biological|Varilrix|No vaccination in this trial
45347960|NCT01049347|Drug|amitriptyline|150 mg oral, daily, single evening dose, 35 days
45347961|NCT01049347|Drug|paroxetine|40 mg oral, single dose, morning, 35 days
45347962|NCT01046149|Behavioral|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
45347963|NCT01046149|Behavioral|Stress management|Cognitive reconstructive strategies for stress management
45347964|NCT01049425|Drug|Epirubicin|4 cycles, intravenous use, day 1 every three weeks
45347965|NCT01049425|Drug|Cyclophosphamide|4 cycles, intravenous infusion, day 1 every three weeks
45347966|NCT01049425|Drug|Docetaxel|4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy
45347967|NCT01049425|Drug|Cyclophosphamide|6 cycles, intravenous infusion, day 1 every 3 weeks
46043971|NCT04169854|Drug|Placebo patch|The Placebo Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
45347968|NCT01049425|Drug|Docetaxel|6 cycles, intravenous infusion, day one every three weeks
45347969|NCT03832387|Device|Non-invasive mechanical ventilation|
45347970|NCT03832387|Device|Continuous positive airway pressure|
45347971|NCT03832387|Device|Venturi mask|
46043972|NCT02536768|Behavioral|Minimum package of interventions to improve ART adherence|Package of 5 interventions to antiretroviral therapy adherence including fast track initiation counselling, decentralized drug delivery, adherence clubs, fast patient tracing and spaced visits
46043973|NCT02661100|Drug|Pembrolizumab|200mg/kg by IV infusion on Day 1 of each 3 week cycle. Given until disease progression
45347972|NCT03832387|Device|Reservoir mask|
45347973|NCT00838227|Drug|modafinil|Modafinil up to 400 mg daily will be added to a stable antipsychotic regimen
45347974|NCT00827619|Device|Zilver® Flex™ Vascular Stent|Stenting of the Above-the-Knee Femoropopliteal Artery
46043974|NCT02661100|Biological|CDX-1401|1mg given subcutaneously on day 1 of each 3 week cycle. Given for 4 cycles
46043975|NCT02661100|Biological|Poly-ICLC|2mg given subcutaneously on day 1 and 2 of each 3 week cycle. Given for 4 cycles
46043976|NCT00648232|Behavioral|Voluntary brief HIV counseling and testing|Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
46043977|NCT00648232|Behavioral|Voluntary longer, more detailed HIV counseling and testing|Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
46043978|NCT00648232|Behavioral|Enhanced linkage to care|Participants will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area. After leaving the hospital, participants will receive reminder telephone calls 1 week before their scheduled visits at the HIV clinics.
45475683|NCT01191281|Behavioral|Diet/nutrition counsel+food aid|Patients enrolled in the experimental arm will receive dietary and nutritional assistance plus a food aid basket, specifically tailored to meet the nutritional needs of the target population.
46043979|NCT00648232|Behavioral|Routine referral to care|Participants will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services.
46043980|NCT00601354|Behavioral|Emotion regulation group therapy|Emotion regulation guided self-help group therapy involves twelve 2-hour sessions of guided self-help group psychotherapy.
46043981|NCT00601354|Drug|Orlistat/alli program|The orlistat/alli program involves taking 60 mg orlistat three times a day and participating in the alli program, a comprehensive behavioral weight loss program with online access.
46043982|NCT02660866|Drug|Placebo + background APT + SMT|Placebo drug therapy combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
46043983|NCT02660866|Drug|Vorapaxar 2.08 mg/d + background APT + SMT.|Vorapaxar 2.08 mg/d combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
45347975|NCT04043559|Other|MRI scanner|MRI was performed with a 1.5T magnet (Ingenia, Philips, The Netherlands; diffusion-weighted imaging b-values = 0 and 1,000 s/mm2, TR 4,280 ms, and TE 97 ms). In case of technical problems with the 1.5T MRI scanner, a 3T magnet (Skyra, Siemens, Erlangen, Germany) was used. MRI was analyzed by an experienced rater (DR), blinded to clinical data and MRI sequences other than diffusion-weighted imaging.
45475684|NCT01191281|Other|Dietary/nutrition counsel|Patients enrolled in the active comparison arm will receive dietary and nutrition counseling designed to help them meet their nutrition needs, based on foods which are locally available, culturally acceptable and within their budget.
45475685|NCT03729505|Procedure|Pyloric injection of magnesium sulfate and lidocaine mixture|100 mg / 2 ml of magnesium sulphate (Magnesium Sulfate®) is mixed with 5 ml of 2% lidocaine and injected in the pylorus
45347976|NCT04043559|Other|Contrast transoesophageal echocardiography|Contrast transoesophageal echocardiography (including Valsalva manoeuvre)
45347977|NCT00366301|Drug|Insulin glargine injection|Once daily for 14 weeks
45347978|NCT00366301|Drug|metformin|Up to 4 pils per day (2g per day) maximum
45347979|NCT00366301|Drug|Placebo pill|Up to 4 pills per day
46043984|NCT04169932|Biological|CD20 CAR-T|The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD20 CART cells per treatment course. The dose escalation test was designed to evaluate the four dose levels of CD20-CART (1 × 10 ^ 6 cells/kg,2 × 10 ^ 6 cells/kg,4 × 10 ^ 6 cells/kg,8 × 10 ^ 6 cells/kg).
45347980|NCT00831285|Dietary Supplement|food product|food product given at one of six visits
45347981|NCT00838305|Drug|MDMA and citalopram|MDMA 1.5 mg/kg and citalopram 20 mg
45475686|NCT03729505|Procedure|Pyloric injection of saline|5 ml of normal saline is injected in the pylorus
45475687|NCT03234036|Drug|GSK2838232 100 mg tablet|It is a white to slightly colored tablet. It will be supplied as prefilled tablets in bulk for dispensing to subjects at the site according to the treatment code.
45475688|NCT03234036|Drug|GSK2838232 50 mg capsule|It is a pink unmarked capsule. It will be supplied as prefilled capsules in bulk for dispensing to subjects at the site according to the treatment code.
45347982|NCT00838305|Drug|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
45475689|NCT03234036|Drug|Ritonavir 100 mg tablets|It is a white film-coated ovaloid tablets.
45475690|NCT03234036|Drug|Placebo for GSK2838232 tablets|It is a white to slightly colored tablet. The placebo tablets supplied will not be identical to GSK2838232 tablets. It will be administered by site staff via an opaque card or paper tube.
45685131|NCT02979496|Dietary Supplement|Flavored water (control)|16 oz of a flavored, calorie-matched water beverage will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
45347983|NCT00365989|Device|ExAblate Enhanced Sonication|
45347984|NCT00827697|Other|Gen-Probe APTIMA Combo2 (AC2)|Laboratory Test
45347985|NCT00838461|Drug|HSD-016|
45347986|NCT00838461|Drug|placebo|
45347987|NCT01324375|Device|heat pain test (Modular Sensory Analyzer, Somedic AB, Horby, Sweden).|pain during heat test preoperatively
46043985|NCT04169620|Other|aquatic Ai Chi|"The sessions took place in a pool measuring 20 m x 6 m, at a depth of 110 cm. The water temperature was 30oC (with variations of less than 0.5o) and the room temperature was 27.5oC (with variations of less than 1o). The proportions of the pool were ideally suited for collective treatment.~The sessions were designed with a gradual increase in difficulty. Initially, a recreational warm-up activity was performed, followed by 30 minutes dedicated to practicing the Ai Chi Program. At the end of the session there was a calming down activity. The exercises were performed in a specific order, until completion of the 19 possible movements."
45475691|NCT03849365|Drug|TOOKAD VTP|TOOKAD® VTP consists of the combination of a single, 10-minute IV infusion of TOOKAD® at the dose of 3.66 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
45685132|NCT03824080|Drug|Bemcentinib|"Bemcentinib will be self-administered orally (fasted) at a dose mentioned above for a total of at least 4 cycles daily.~Responding patients (defined as at least stable disease) are eligible for up to 5 additional cycles according to the maintenance daily dosing of 2 x 1 capsules of 100 mg for each 28 days cycle (up to 9 cycles in total)."
46043986|NCT04169620|Other|control|These sessions consisted of group sessions of supervised training lasting 45 minutes each. These comprised a 10-minute warm-up that included exercises for gait, trunk mobility and exercises involving the upper and lower limbs. The central part of the sessions consisted of 30-40 minutes of strength training and aerobic exercises, both individual and in groups. Each session was performed with a specific intensity goal, in order to end with a cooling down period, comprising 20 minutes of functional exercises based on activities of daily living, balance exercises, facial muscle exercises, proprioceptive exercises, muscle relaxation and stretching.
46043987|NCT02663986|Behavioral|Organizational Skills Training (OST) Intervention|
45685133|NCT01895335|Drug|Teriflunomide|Pharmaceutical form: film-coated tablet; Route of administration: oral
45685134|NCT02980510|Drug|Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil|
46043988|NCT00853099|Biological|adalimumab|
46043989|NCT00853099|Drug|placebo|
46043990|NCT00648310|Drug|Tolterodine 4 mg|
46043991|NCT00648310|Drug|arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks|
46043992|NCT00702871|Drug|Ranitidine|In arm 1 Ranitidine was given in dose of 50mg i.v. 8 hourly for entire duration of ICU stay.
45347988|NCT00831363|Procedure|minimally invasive total hip arthroplasty|minimally invasive total hip arthroplasty
46043993|NCT00702871|Drug|Sucralfate|In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
46043994|NCT00700453|Behavioral|Control group with no video game play|Subjects will abstain from all video game play during study participation.
46043995|NCT00700453|Behavioral|control 2|Subjects will play 1 week of violent video game play followed by 1 week of no video game play.
46043996|NCT00700453|Behavioral|VG1 group (2 weeks of violent video game play)|Subjects will play a violent video game for 2 weeks of study participation.
46043997|NCT00700453|Behavioral|Cognitive Training|Subjects will play a violent video game for 1 week followed by 1 week of Cognitive Training program.
46043998|NCT00992784|Biological|GSK investigational vaccine 2186877A|Single dose, intramuscular injection
46043999|NCT00992784|Biological|FluarixTM|Single dose, intramuscular injection
46044000|NCT00830167|Drug|Placebo|Dosage: placebo, oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
46044001|NCT00830167|Drug|Pregabalin|Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
46044002|NCT02611531|Behavioral|Video Module Education (VME)|Participants will complete inhaler education on a tablet device
46044003|NCT02611531|Behavioral|Teach-To-Goal (TTG)|Participants will complete intensive in-person inhaler education
46044004|NCT00992394|Drug|etanercept|etanercept 50 mg once weekly as requested.
46044005|NCT00992394|Drug|etanercept|etanercept 25 mg or 50 mg as requested.
45475692|NCT03847805|Other|Scapulothoracic and glenohumeral stabilization exercises|The experimental group followed a program that included three scapulothoracic stabilization exercises and three for glenohumeral stability, while subjects in the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue. Three series, with 10 repetitions of each exercise, with one minute rest between series.
45347989|NCT00831363|Procedure|standard approach total hip arthroplasty|standard Hardinge approach/traditional transgluteal approach
45685135|NCT02980510|Drug|Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan|
45347990|NCT03495505|Device|WiSE-CRT|Intervention will involve placement of the WISE-CRT system which consists of a transmitter, battery and electrode.
45347991|NCT03488953|Procedure|Living donor liver transplantation with two-staged hepatectomy.|Two-stage hepatectomy combined with transplantation of left-lateral lobe from a living donor.
45475693|NCT03847805|Other|Glenohumeral stability exercises|the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue.
45475694|NCT03606109|Drug|Tranexamic Acid (TXA)|One gram of intravenous tranexamic acid (TXA) will be administrated before tourniquet inflation and before closure of the incision, as 1 g has been shown to be a safe amount with minimal side effects
46044006|NCT04291170|Other|QDASH|completing the tasks on the QDASH: open jar, wash wall, carry shopping bag, wash back, cut food, hammer wood
45347992|NCT00622713|Drug|Rivastigmine transdermal patch|The study treatment was delivered as a patch sizes 5 and 10 cm^2 containing respectively 9 and 18 mg of rivastigmine. During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm^2.
45347993|NCT01046227|Biological|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|Serology study before and after Influenza A (2009) monovalent vaccine, inactivated
45347994|NCT04044339|Drug|TD-5202|Study Drug to be administered orally
46044007|NCT04291170|Other|KOOSJR|completing tasks on the KOOSJR: pivot, straighten, go up/down stairs, stand upright, rise from sitting, bend over
46044008|NCT00829933|Drug|DU-176b tablets|DU-176b tablets taken once daily for up to 12 weeks
45347995|NCT04044339|Drug|Placebo|Placebo to be administered orally
45347996|NCT00392197|Drug|Aripiprazole|1 or 2 times a day, p.o., 6 - 24mg a day
45347997|NCT00391807|Drug|Norethindrone acetate/ethinyl estradiol|one tablet per day
45347998|NCT00624585|Drug|Dasatinib|"DOSE ESCALATION OF DASATINIB AFTER 8 WEEKS IF ELIGIBLE~Dose Level and Dose of dasatinib:~Starting dose (1-8 weeks)= 100 mg orally (po) daily~+1 (<8 weeks if no PR and well tolerated) = 150 mg po daily~DOSE MODIFICATION OF DASATINIB~Dose Level and Dose of dasatinib:~Starting dose = 100 mg po daily~-1 = 70 mg po daily~-2 = 50 mg po daily~OR~Dose Level and Dose of dasatinib:~Starting dose = 150 mg po daily~-1 = 120 mg po daily~-2 = 90 mg po daily~-3 = 50 mg po daily"
45347999|NCT01046305|Behavioral|Interview & Questionnaires|30 Minute Interview about what it is like to have CML, followed by symptom questionnaire, quality-of-life questionnaire, and demographic questions taking another 10 minutes for all 3 questionnaires.
45475695|NCT01191359|Biological|oral immunotherapy|orally applied specific immunotherapy
46044009|NCT00829933|Drug|Warfarin potassium tablets|Warfarin potassium tablets taken once daily for up to 12 weeks
46044010|NCT01170962|Drug|BMS-790052|Film coated tablet, Oral, 20 mg, once daily, 24 weeks
46044011|NCT01170962|Drug|BMS-790052|Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks
46044012|NCT01170962|Drug|Placebo|Film coated tablet, Oral, 0mg, Once daily, 24 weeks
46044013|NCT01170962|Drug|peginterferon alfa-2a|Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
46044014|NCT01170962|Drug|ribavirin|Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
46044015|NCT00843193|Drug|INTRAVENOUS GSK679586|GSK679586 will be provided as a clear or colorless to pale yellow liquid with the unit dose strength of 10mg/kg and will be infused over an hour. The infusion will be delivered by a programmable infusion pump
45348000|NCT01046305|Behavioral|Rating Questionnaire|Questionnaire developed in Part 1 to rate the relevance of symptom items, given to 3-5 physicians, 3-5 nurses, 2-4 patients and their family caregivers, taking about 10 minutes.
45348001|NCT01046305|Behavioral|MDASI-CML Questionnaire|Patient questionnaires about CML symptoms over 1 year, completed in person or using Interactive Voice Response (IVR) system every 2 weeks.
45348002|NCT01046383|Dietary Supplement|IMN1207|20 grams of IMN1207 per day for 40 weeks.
45348003|NCT01046383|Dietary Supplement|Casein|20 grams of Casein per day for 40 weeks
45348004|NCT04044261|Procedure|Emotion induction using video|Emotions are induced in the test subjects using videos in Hindi and English. Each subject is shown three video clips for each of the emotions.
45841164|NCT01032954|Drug|Botulinum toxin|"Drug: Botulinum toxin~Indications for eligibility and total doses that will be applied in each part of the face, at visit 1:~Upper face:~Crow's feet wrinkles - 70 units~Glabella - 50 units~Forehead - 40 units~Mid face:~Lower eyelid - 5 units~Nasal wrinkles - 20 units~Malar wrinkles - 10 units~Lower face:~Peri-oral wrinkles - 15 units~Asymmetric smile or gummy smile - 5 units~Cellulitic chin - 20 units~Marionette lines - 25 U According to the patients needs, the doses can vary ±10% in terms of the amount of units that will be injected.~Patients will be allocated in each group and receive the doses described above at visit 1. At visit 2, all the patients will receive a touch-up of a standard dose of 25 U, distributed on the treated areas according patient's needs."
45841165|NCT01033422|Drug|CF101|CF101 1 or 2 mg tablets orally every 12 hours for 16 weeks
45841166|NCT01033422|Drug|Placebo for|Matching placebo tablets orally every 12 hours for 16 weeks
45348005|NCT00838773|Behavioral|YMSM|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
45348006|NCT00838773|Behavioral|YHA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
45475696|NCT01293071|Other|Antibiotic rotation|Rotation of antibiotic classes as specific preferred antibiotic class to be used for empiric treatment of ICU acquired infections.
45475697|NCT01193855|Drug|dutasteride|
45475698|NCT01193855|Drug|gadolinium-chelate|
45475699|NCT01193855|Other|active surveillance|
45475700|NCT01193855|Procedure|diffusion-weighted magnetic resonance imaging|
45475701|NCT01193855|Procedure|functional magnetic resonance imaging|
45475702|NCT01193855|Procedure|prostate biopsy|
45475703|NCT01193855|Procedure|ultrasound imaging|
45348007|NCT00838773|Behavioral|ROMA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
45348008|NCT00838851|Biological|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 20,000 EU Clinical Center Reference Endotoxin (CCRE)
45348009|NCT00831597|Drug|bendamustine|120 mg/m2 IV, Days 1, 2 of Cycles 1-6
45348010|NCT00831597|Drug|rituximab|375 mg/m2 IV, Day 1 of Cycles 1-6
45348011|NCT00622635|Drug|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
45348012|NCT00622635|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
45348013|NCT00622635|Drug|Salmeterol 50 μg|Salmeterol 50 μg was provided in powder filled capsules with a multi-dose dry-powder inhaler (MDDPI).
46044016|NCT00843193|Drug|INTRAVENOUS PLACEBO|Clear or colorless 0.9% sodium chloride saline solution will be infused over an hour. The infusion will be delivered by a programmable infusion pump
46044017|NCT00843193|Drug|FLUTICASONE PROPIONATE|Subjects will be supplied fluticasone propionate at Screening, Run-in and when needed during the study. Subjects will be up-titrated to 1000 μg/day and those who were already taking greater than equal to 1000 μg/day fluticasone propionate or equivalent prior to the study will remain on their pre-study dose.
45348014|NCT00391027|Drug|Insulin Glargine (Lantus®)|Patient will be randomized to Lantus® while remaining on pre-study oral hypoglycemic agents.
45348015|NCT00391027|Drug|Inhaled Human Insulin (Exubera®)|Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.
45348016|NCT00622401|Biological|Dendritic Cell/Tumor Fusion Vaccine|Vaccine is derived from the participants dendritic cells and tumor cells
45348017|NCT00622401|Drug|Interleukin-12|Given subcutaneously at dose of 30ng/kg
45348018|NCT00622401|Drug|Interleukin-12|Given subcutaneously at dose of 100ng/kg
45348019|NCT00827853|Procedure|Conventional angioplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using conventional angioplasty balloon
45841167|NCT05593848|Procedure|Intratissue Percutaneous Electrolysis|Each subject will undergo 3 treatment sessions spaced one week apart. Ultrasound-guided Intratissue Percutaneous Electrolysis in the myofascial trigger points of the infraspinatus muscle
46044018|NCT00829621|Other|75 mmHg suction|Incisional Vacuum Assisted Closure (IVAC) Device, set to 75 mmHg suction throughout the duration of the IVAC use.
45348020|NCT00827853|Procedure|cryoplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using cryoplasty balloon
45348021|NCT04018365|Drug|Empagliflozin Tablets|The administration is oral administration with water before or after breakfast.
45348022|NCT02549235|Other|Ultrasound|Routine 2D/3D ultrasound assessment
45348023|NCT00831831|Behavioral|Safety planning|See detailed description
45348024|NCT00839007|Drug|CD-NP|Infusion of CD-NP at one of up to 6 doses or placebo
45348025|NCT00621621|Device|Freezor® Cardiac Cryoablation Catheter CryoConsole System|cryoablation
45348026|NCT00828087|Drug|Everolimus Eluting Coronary Stent System|Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
46044019|NCT00829621|Other|125 mmHg|Incisional Vacuum Assisted Closure (IVAC) Device, set to 125 mmHg suction throughout the duration of the IVAC use.
46044020|NCT01157078|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
45475704|NCT03771144|Procedure|arthrolysis|Surgery is performed under general anesthesia. The usual duration of this surgery is on average 1h30. This surgery requires an anterior approach and a posterior approach. The patient is placed in lateral decubitus. The arthroscope of 2.7 is introduced by a posterior route. An anterior instrumental track is made from inside out through the rotator interval.
45475705|NCT03849755|Device|PEPPER system|The PEPPER system offers insulin dosing advice that is highly adaptive to the insulin needs of individuals by using Case-Base Reasoning (CBR) approach.
45475706|NCT01294475|Behavioral|Planned Activities Training|Mothers will be provided a parenting intervention, Planned Activities Training (PAT). Some of the mothers will receive the PAT intervention enhanced with a cell phone.
45475707|NCT01193933|Procedure|autologous HSCT|T-cell ALL patients recieve late consolidation with BEAM conditioning and stem cell support
46044021|NCT01157078|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
45475708|NCT03768336|Other|Waitlist control|The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being. Waitlist control receives the adapted 3RP program (3RP-AYA) approximately 2 months after study enrollment.
46044022|NCT00591721|Behavioral|Energy conservation education|The intervention for this study is a group-based educational program delivered by teleconference to 4-6 individuals with MS by a licensed occupational therapist. The program involves 6 weekly sessions. Each session is 1 hour and 15 minutes in duration. Key topics addressed include: importance of rest, positive and effective communication, modification of the environment, using equipment and technology, setting priorities, and activity analysis and modification. Direct instruction, group discussion, and peer support are key elements of the program. Participants receive a manual with application activities that are completed in between sessions.
45475709|NCT03768336|Other|3RP-AYA|The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being.
45475710|NCT01190345|Drug|bevacizumab|Patients receive on day 1 of each cycle : bevacizumab 15 mg/kg (8 injections in total).
46044023|NCT04117399|Other|Pulmonary rehabilitation|The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise group received only aerobic exercise.
45348027|NCT00828087|Device|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)implantation
46044024|NCT01156844|Drug|Indacaterol|Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme.
45348028|NCT00828165|Drug|ARRY-300, MEK inhibitor; oral|single dose, escalating
45348029|NCT00828165|Drug|Placebo|matching placebo
45348030|NCT00839085|Drug|GSE|grape seed extract (100 mg/6h), PO
45348031|NCT00839085|Drug|Vit C (Ascorbic Acid)|Vit C 25 mg/ kg
45348032|NCT02549313|Procedure|position changes of the head|Registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 ° (the order of actions will be determined by drawing lots). The patient will remain 10 minutes in each of these positions.
45348033|NCT00828243|Drug|Nutrient|We administer stable isotopically labeled precursors of surfactant phospholipids ([1-13C1] acetate) and of surfactant protein-B ([5,5,5-2H3] leucine) to infants with neonatal respiratory distress syndrome. Using mass spectrometry, we measure incorporation of stable isotopically labeled precursors in tracheal aspirates and compare surfactant phospholipid and surfactant protein-B turnover.
45475711|NCT01190345|Drug|no bevacizumab|no bevacizumab
45475712|NCT01194011|Behavioral|questionnaire|This research tool was a written questionnaire, did not do invasive or the subjects are exposed to physical danger on the experiment, so now there is no harm in this research and test more than minimal risk.
45475713|NCT02729896|Drug|Atezolizumab [TECENTRIQ]|"Atezolizumab will be administered by intravenous (IV) infusion at a flat dose of 1200 milligram (mg) every 3 weeks (Q3W) on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment.~NOTE: Atezolizumab treatment has been discontinued in all participants currently on study treatment."
45348034|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|10 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
45475714|NCT02729896|Drug|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a flat dose of 1000 mg on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment, and on Day 1 of every other month during maintenance treatment (1 cycle=21 days; infusion rate starts at 50 mg/hour (hr) and increases every 30 min to a maximum of 400 mg/hr).
45475715|NCT02729896|Drug|Polatuzumab Vedotin|Polatuzumab vedotin will be administered by IV infusion. For relapsed or refractory FL either 1.4 mg/kilogram (kg) or 1.8 mg/kg (dose-escalation phase) and at RP2D (dose-expansion phase) on Day 1 of Cycles 1-6 will be given in 21-day cycles during induction treatment. For relapsed or refactory DLBCL, 1.8 mg/kg will be given during run-in phase and either 1.8 mg/kg or 1.4 mg/kg during the expansion phase (1 cycle=21 days; infusion rate starts with 90 min and decreases to 30 min).
45841168|NCT05593848|Procedure|Dry Needling|Each subject will undergo 3 treatment sessions spaced one week apart. Ultrasound-guided dry needling in the myofascial trigger points of the infraspinatus muscle
45841169|NCT05593536|Behavioral|Breastfeeding Education|Biological feeding and classical breastfeeding trainings will be given to pregnant women by a trained nurse.
45841170|NCT05593380|Device|Non-invasive intracranial pressure monitoring|Treatment based on readings from Bioelectrical impedance analysis monitor（intracranial pressure and perturbation index (PI)）.
45841171|NCT05593380|Other|Parenchymal Intracranial pressure monitor|Treatment based on readings from Parenchymal intracranial pressure monitor.
45841172|NCT05593380|Other|Treatment based on clinical and imaging observations|Treatment based on clinical and imaging observations.
45841173|NCT05593224|Device|Intracranial Stent (Tonbridge)|The intracranial stent consists of a self-expanding, laser-carved nickel-titanium stent and its delivery system.
46044025|NCT01156844|Drug|Placebo to Indacaterol|Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.
46044026|NCT00853021|Biological|aldesleukin|SQ Aldesleukin (Days 1-5) Monday through Friday for six weeks followed by a two-week break.
46044027|NCT00853021|Biological|bevacizumab|Bevacizumab will be administered on day -14, then on day 1 and every 2 weeks thereafter (days 1, 15, 29, and 42) in a continuous manner.
46044028|NCT00913237|Drug|Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)|
45348035|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|20 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
45348036|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|30 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
45475716|NCT02729896|Drug|Rituximab|Rituximab will be administered by IV infusion at 375 mg/m˄2 on Day 1 of Cycles 1-6 during induction treatment (1 cycle-21 days; infusion rate starts with 50 mg/hr and increases every 30 min to a maximum of 400 mg/hr).
45348037|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|40 mg od main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
45348038|NCT00839163|Drug|Enoxaparin/Vitamin K-Antagonist|Enoxaparin/Vitamin K-Antagonist main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84). Enoxaparin was to be administered 1mg/kg bid sc for about 5-7 days. It was to be discontinued when INR was within the therapeutic range 2-3 for 2 consecutive days
45348039|NCT02549001|Drug|P-3058 10%|
45348040|NCT02549001|Drug|vehicle of P-3058 10%|
45841174|NCT05593068|Procedure|MRI|Pancreatic MRI
45841175|NCT05592834|Behavioral|positive deviance hearth strategy|"The PD-program is run for 3-months with 2 weeks (12 days) of nutrition education and rehabilitation sessions (NERS) conducted in each month. Each day session includes an half hour education session and a one and half hour peer led cooking session. Caretakers learn how to rehabilitate their malnourished children under the supervision and the support of caregivers who have well-nourished children (positive deviants). Children are nutritionally assessed by trained nutrition assistants or clinician on the 1st day of the NERS sessions and after three months.~During the rehabilitation sessions, caregivers learn how to prepare nutrient-rich meals for their children from locally available food identified during the positive deviance-inquiry, and actively practice good feeding and hygiene practices. Caregivers together prepare food menus based on the PD-inquiry good foods or what they can conveniently access but of equal nutritional value."
45841176|NCT05592834|Behavioral|Parent facilitator trainings|Primary caregivers of children with CP residing in the study setting are trained as parent facilitators by expert physical rehabilitation therapist . Trained parent facilitators then hold fellow caregiver workshops each lasting approximately two hours long and includes between 6-10 caregivers. To ensure quality and consistency of the workshops, the Parent Facilitators follow a detailed manual adapted from the Carer-2-Carer Programme translated into Lusoga, the local language. No expert therapists is involved in the parent facilitator training workshops. Parent facilitator training workshops involve 7 sessions that expose caregivers to understanding CP and how to improve body functioning: session1: what is CP? session2: CP as a way of life, Session 3: Getting my child's body ready to move, Session 4: Eating and drinking a healthy diet, Session 5: communication, Session 6: Play, and Session 7: Central visual impairment.
45841177|NCT05592834|Other|Control|This group will receive neither the PD nor the PFT interventions but care as usual
46044029|NCT00913237|Drug|Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)|
45348041|NCT02549001|Drug|amorolfine 5%|
46044030|NCT05367284|Drug|Testosterone|Testogel 16.2 miligrams/ gram (mg/g) gel
46044031|NCT00843115|Other|donepezil|Routine clinical practice of prescribing donepezil as per the Canadian label. No drug was supplied as part of this study
46044032|NCT01156376|Device|Potassium Oxalate without Fluoride|1.40% Potassium Oxalate Sensitive Mouthwash without fluoride - Rinse with 10ml for 60 seconds, four times daily successively at 1 hour intervals for five days
46044033|NCT01156376|Device|Potassium Oxalate with Fluoride|1.40% Potassium Oxalate Sensitive Mouthwash with fluoride - Rinse with 20ml for 60 seconds, four times daily successively at 1 hour intervals for five days
46044034|NCT01156376|Device|Active Comparator PO-116-A|Rinse with comparator mouthwash 20ml for 30 seconds, four times daily successively at 1 hour intervals for five days
45348042|NCT00621543|Device|IUD insertion [Copper T-380A or Levonorgestrel (intrauterine system) IUS]|When a subject has chosen a method of intra-uterine contraception and has agreed to participate in the study, she will have the intra-uterine device of her choice inserted according to the Food and Druga Administration (FDA) instructions.
45348043|NCT02548221|Device|transthoracic echocardiogram|Thoracentesis was performed on patients with large-volume pleural effusions, and TTE was utilized to access the change of heart and lung function before and after this medical procedure.
45348044|NCT00832143|Behavioral|Referral Card with one-to-one counseling|A Referral Card (Neonatal Well-Being Card) along with one-to-one counseling to mothers within 48 hours of institutional delivery
45348045|NCT00623805|Drug|Bevacizumab|Bevacizumab was supplied as a solution in single-use vials.
45348046|NCT00623805|Drug|Capecitabine|Capecitabine was supplied as film-coated tablets.
45348047|NCT00623805|Drug|Oxaliplatin|Oxaliplatin was supplied as a lyophilized powder in vials.
45348048|NCT02548923|Drug|Dexmedetomidine|comparison to propofol
46044035|NCT00700531|Device|FLC removal HD (Gambro HCO 1100)|FLC removal HD using a extended dialysis schedule on the Gambro HCO 1100
46044036|NCT00700531|Procedure|Standard dialysis on a high flux ployflux dialyser|Standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
46044037|NCT00829387|Behavioral|CBT plus standard pharmaceutical care (CBT/SC)|Ten sessions of individual treatment delivered by a doctoral level psychologist.
45475717|NCT04698174|Procedure|Transepithelial Photorefractive keratectomy (tPRK) without laser polishing|Transepithelial Photorefractive keratectomy (tPRK) with laser ablation of the corneal epithelium and stroma in a single-step procedure using the B+L Teneo 317 Model 2 Excimer Laser.
45475718|NCT04698174|Procedure|Transepithelial Photorefractive keratectomy (tPRK) with laser polishing|Transepithelial Photorefractive keratectomy (tPRK) using the B+L Teneo 317 Model 2 Excimer Laser with end-treatment laser polishing using a fixed thickness of the additional layer of 5 μm.
46044038|NCT00829387|Behavioral|Diabetic Education plus standard pharmaceutical care (ED/SC)|Ten individual sessions of diabetes educations delivered by a doctoral level psychologist under the supervision of a certified diabetes educator.
45685136|NCT03829696|Drug|Mifeprex® (Mifepristone 200 mg)|Participants will receive Mifeprex® (mifepristone 800 mcg) from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period and would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
45685137|NCT03829696|Drug|Misoprostol 800 mcg|Participants will receive misoprostol from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
45685138|NCT03829696|Drug|ella® (ulipristal acetate emergency contraception 30 mg)|Participants will receive one dose of ella (emergency contraception) from a clinician at the same time of receiving mifepristone and misoprostol, in case the participant should have unprotected intercourse or failed contraception and want to prevent unintended pregnancy.
45841178|NCT05592678|Drug|Donepezil|6 months of open label treatment at 10mg PO QD (maximum)
46044039|NCT04313738|Other|Assigned Interventions|Home visit, health education
46044040|NCT00705913|Device|Mitroflow Aortic Pericardial Heart Valve (CarboMedics)|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Pericardial valve as compared to the Edwards Magna valve
46044041|NCT00705913|Device|Carpentier-Edwards Magna Tissue Valve|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Valve as compared to the Edwards Magna valve
46044042|NCT01156142|Drug|doxepin hydrochloride|Oral rinse
46044043|NCT01156142|Other|placebo|Oral rinse
46044044|NCT00842257|Drug|panitumumab|Panitumumab is administered intravenously (IV) by an infusion pump through a peripheral line or indwelling catheter using a 0.2 or 0.22-micron in-line filter infusion set-up over 1 hour 15 minutes. The starting panitumumab dose is 6 mg/kg administered every 14 days for as long as patients are on study without evidence of disease progression or demonstrating intolerance to treatment. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual body weight at each visit. Panitumumab will be diluted in a minimum of 100 mL of pyrogen-free 0.9% sodium chloride solution (normal saline solution, supplied by the site). The maximum concentration of the diluted solution to be infused should not exceed 10 mg/mL.
46044045|NCT00705991|Procedure|ROTEM|
45348049|NCT04043871|Diagnostic Test|Systolic blood pressure|Systolic blood pressure measured by Foot-to-Apex Systolic Interval, conventional oscillometric measurement, and the auscultatory method
45475719|NCT04698174|Procedure|Standard Photorefractive keratectomy (PRK)|Conventional Photorefractive keratectomy (PRK) with alcohol-assisted epithelium ablation. Then the aspheric ablation profile will be performed using the B+L Teneo 317 Model 2 Excimer Laser.
46044046|NCT05603377|Diagnostic Test|functional endoscopic evaluation of swallow|functional endoscopic evaluation of swallow
46044047|NCT00706069|Drug|Vinorelbine oral|Vinorelbine at dose levels of 30mg, 40mg, 50mg, 60mg oral every Monday, Wednesday and Friday
45348050|NCT00832221|Drug|SEROQUEL XR (quetiapine)|repeated dose of oral tablets, 8 times per subject
45348051|NCT00832221|Drug|SEROQUEL IR (quetiapine)|repeated dose of oral tablets, 4 times per subject
45348052|NCT00832221|Drug|radioligand [11C]raclopride|single dose of iv admin, 5 times per subject
45475720|NCT03847727|Drug|BR as Maintenance|Patients of the study group who have achieved at least a partial response after 6 cycles of BR induction will receive additionally 4 cycles of BR every 3 months as maintenance therapy.
45475721|NCT01190423|Behavioral|Family Based Therapy for young adults|Individual and Group Therapy Sessions
46044048|NCT00706069|Drug|Capecitabine|Capecitabine at dose levels of 800 mg/m2, 950mg/m2, 1100mg/m2, 1250mg/m2 per os from day 1 to day 14 every 21 days
46044049|NCT00700609|Behavioral|Attachment Based Family therapy (ABFT)|Attachment-Based Family Therapy (ABFT) is a brief manualized therapy designed exclusively for depressed adolescents and aims at reducing adolescent depression by improving family communication and trust.
45348053|NCT00828399|Dietary Supplement|Glutamine|Oral glutamine 30g/day
45348054|NCT00828399|Dietary Supplement|Whole protein|Oral whole protein 30 g/day
46044050|NCT02884622|Other|nasal epithelial|CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added
45348055|NCT04044027|Behavioral|S.P.A.R.K (Speaking to the Potential, Ability and Resilience inside Kids) Teen Pregnancy Prevention and Mentoring|S.P.A.R.K is a curriculum-based group intervention for youth ages 11-17 living in out-of-home foster care. The curriculum consists of 23 topical lessons made up of a combination of educational and interactive activities on each topic. The curriculum covers four Adult Preparation Subjects (healthy relationships, educational and career success, healthy life skills, adolescent development) as well as mentoring, bully prevention, emotional competency, self-efficacy, communication, conflict resolution, and pregnancy prevention.
45475722|NCT03417960|Device|iTBS|The investigators will treat post-partum depressed subjects with accelerated intermittent theta burst stimulation. iTBS will be delivered via a MagVenture MagPro100 and Cool-B65 coil. The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold. The accelerated paradigm will consist of 10 such sessions separated by 15 minutes, for three treatment days per week. There will be 2 weeks of 10 sessions on each of three days for a total of six treatment days, divided by one treatment-free week between treatment weeks. Treatments will be delivered at the 10-20 EEG coordinate for F3 (approximating the left DLPFC), and will be found using the Beam-F3 method.
45685139|NCT03829696|Diagnostic Test|AccuHome® Pregnancy OTC Test|Participants will receive 6 AccuHome® pregnancy tests, which are midstream urine pregnancy tests and provide results within 3 minutes. Participants may request additional tests to be mailed to them by the study at any time.
45685140|NCT03829774|Device|Primary Relief v 2.0|The test product or device called Primary Relief v 2.0 will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
46044051|NCT02884622|Other|Blood sampling|CF patients with the same procedures as in the usual management of routine care, only the sampling 5ml additional blood will be taken
46044052|NCT04188002|Behavioral|Intervention Physical Activity|4 tailored newsletters focused on improving healthy diet and physical activity delivered at weekly intervals.
46044053|NCT04188002|Other|Usual Care|4 non-tailored newsletters focused on issues relevant to cancer survivors (e.g. returning to work)
46044054|NCT00852475|Dietary Supplement|MUFA MOVE! (Monounsaturated fatty enriched diet)|MUFA MOVE!diet and exercise program
46044055|NCT00852475|Dietary Supplement|PUFA MOVE! (Polyunsaturated fatty acid enriched diet)|PUFA MOVE! diet and exercise program
46044056|NCT01155284|Drug|Sitagliptin and Lansoprazole|"Sitagliptin (dispensed as 50 mg capsules)and Lansoprazole(dispensed as 30 mg capsules) or matching placebo~Subjects age 11-17 years at Visit 2 will take 1 capsule once daily~Subjects age 18-45 years at Visit 2 will take 2 capsules once daily"
46044057|NCT01155284|Drug|Placebo|Sitagliptin 50mg and Lansoprazole 30 mg or matching placebo will be given daily for 12 months. Subjects age 11-17 at visit 2 will take 1 capsule daily; age 18-45 will take 2 capsules daily.
46044058|NCT00852397|Drug|Apixaban|Apixaban 2.5 mg tablet BID for 24 weeks
46044059|NCT00852397|Drug|Apixaban|Apixaban 5.0 mg tablet BID for 24 weeks
46044060|NCT00852397|Other|Placebo|Placebo tablet for 24 weeks
46044061|NCT00841321|Drug|Ginkgo biloba|120 mg orally twice a day for 12 weeks
46044062|NCT00841321|Drug|Placebo|One capsule orally twice a day for 12 weeks
46044063|NCT00986232|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of ProQuad (low, middle, or high dose) at Day 0 and Day 90
46044064|NCT00986232|Biological|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
46044065|NCT00986232|Biological|Comparator: PUVV|A single 0.5 mL subcutaneous injection at Day 0
46044066|NCT00852241|Drug|Restalyne|one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.
45475723|NCT01190501|Device|complier device|"The procedure of use of complier has to follow the recommendations for standardization of subject conditions.~Assessment of arterial distensibility: pulse wave velocity (PWV), aortic stiffness is assessed by PWV which is a classic index of arterial stiffness. A semi-automatic device is used to measure carotid-femoral PWV. The distance covered by the pulse wave is measured on the surface of the body and represented the distance between the 2 recording sites."
46044067|NCT00852241|Drug|Perlane|One syringe of Perlane® (1.0cc) will be used total for both tear trough areas.
46044068|NCT02612233|Drug|Pregabalin or Duloxetine or Placebo|This is a randomized, double blind placebo controlled trial with a head-to-head comparison of duloxetine vs pregabalin vs placebo over-encapsulated to prevent unblinding of treatment arm
46044069|NCT01169636|Drug|Panobinostat|Starting Day -6 of Cycle 1, 20 mg orally on Monday, Wednesday, and Friday during Cycles 1 and 2 (Days -6, -4, and -2 of Cycle 1 and Days 1, 3, 5, 8, 10, and 12 of Cycles 1 and 2); MTD found in Phase 1 used for same schedule in Phase 2.
46044070|NCT01169636|Drug|Ifosfamide|Day 1 of Cycles 1-3, 5 grams/m2 by vein over 24 hours.
46044071|NCT01169636|Drug|Mesna|On Day 1 of Cycles 1-3, 2 grams/m2 by vein over 12 hours.
46044072|NCT01169636|Drug|Carboplatin|On Day 1 of Cycles 1-3, Standard Dose (Target area under curve (AUC) = 5mg/ml/min) by vein over 1 hour.
45475724|NCT04540380|Drug|Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab|Conditioning regimen .Patients will receive Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Thymoglobulin
45596458|NCT01979367|Device|Anodyne|Subjects will be treated with MIRE therapy using the Anodyne® device within 72 hours of previous treatments, and in accordance with the Anodyne® package insert indications for use 30 to 45 minutes professional units on power setting of 8,. In addition, patients will undergo TENS therapy with the use of either the Avazzia® Pro Sport or TENS 3000 (for no less than 30 mins, both on label) in accordance with the indications for use of each TENS device, for a minimum of 15 minutes at the subjective site for pain and each vertebrae nerve base, when impairment is confirmed with the objective Small Pain Fiber (SPF) Nerve Conduction Study (NCS) test performed.
45596459|NCT02201069|Behavioral|health coaching|
46044073|NCT01169636|Drug|Etoposide|On Days 1-3 of Cycles 1-3, 100 mg/m2 by vein over 2 hours.
45841179|NCT05592288|Other|PREDIABE-TR mobile app.|"Module 1: Personal data Containing data on the participant's age, gender, telephone number, email and perception of his/her health (bad, so-so, good, very good).~Module 2: Medical history of the participant In this module, the participants tick the items that apply to themselves or their first-degree relatives by marking the conditions in their medical history that may increase the risk of prediabetes. Additionally, in line with the recommendations of the Turkish Association of Endocrinology and Metabolism, this module contains the Finnish Diabetes Type-2 Risk Score (FINDRISK) which assesses an individual's risk of diabetes.~Module 3: Healthy lifestyle behaviors The sub-sections of the module are devoted to nutrition, height-weight-body mass index (BMI) and physical activity."
46044074|NCT01169636|Drug|Pegfilgrastim|Beginning Day 4 of Cycles 1-3, 6 mg under the skin.
46044075|NCT00706225|Drug|Bazedoxifene and conjugated estrogens|Bazedoxifene 20 mg tablet once daily for 7 days. Conjugated Estrogens 0.625 mg tablet, single doses one week apart.
45475725|NCT04540380|Procedure|Combined bone marrow and kidney transplant|Recipients will receive a conditioning regimen that includes rituximab on study days -7 and -2, fludarabine 10mg/m2/day on days -6 to -3 (4 doses), cyclophosphamide (22.5mg/kg/day) on days -5 and -4, followed by local thymic irradiation (7 Gy) on day -1 and Siplizumabon days -1, 0, and +1. Combined kidney and bone marrow transplant will be performed on study day 0. Methylprednisolone will be started at 250 mg/day on day 0 and tapered to prednisone 20mg by day 10 after which it will be continued until day 20. Prophylaxis will be provided for hemorrhagic cystitis, PCP, fungal infection, CMV, and perioperative infection. All patients who require any blood transfusion will receive only leukocyte-depleted and irradiated blood products for a period of at least 52 weeks following transplantation. The proportion of patients successfully weaned off immunosuppression without chimerism transition syndrome (CTS) will be assessed.
46044076|NCT00703105|Biological|DC vaccination|DC vaccination with 1 x 10(6th) tumor lysate or tumor peptides and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals; (6 weeks)
46044077|NCT00706303|Behavioral|Supported self management training and support|Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Further details of the rubric of the initial training sessions are given in Appendix 1 and will use adapted versions of the Bourbeau self-management and education materials. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.
45348056|NCT00839397|Drug|Paroxetine|"Subjects will take the treatment phase medication once daily after an evening meal. All subjects will be maintained at Dose Level II (20 mg/day) for the first 2 weeks. If a sufficient clinical response (1. Very much improved or 2. Much improved based on the CGI Global Improvement) is achieved, the subject will continue on the same dose level. When the clinical response is not sufficient but the investigational product is well tolerated, the dose will be increased to Dose Level III (30 mg/day) and then to Dose Level IV (40 mg/day) at intervals of at least 2 weeks until a sufficient response is reached. Once a sufficient response is obtained, the treatment will be continued at that dose. The treatment phase will last for a total of 52 weeks. In those patients receiving Dose Level III or IV, dosage reductions to the next lowest level (Dose Level II or III) consequent to an adverse event are permitted.~Dosage adjustment will be made at the discretion of the PI or Sub-PI"
45475726|NCT04506034|Drug|lidocaine patches|for every port entry site from the three in ports of laparoscope, patients received three lidocaine patches 5% (Lidoderm® , Endo Pharmaceuticals, Chadds Ford, PA). Each patch measured 10 cm × 14 cm and contains (700 mg), was divided into two equal parts, six parts applied two of it around one port entry site that marked before sterilization and just before induction of anesthesia. The patches not changed until removed after return of bowel function or on the maximum at fifth postoperative day.
45685141|NCT03829774|Drug|Paracetamol|A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous paracetamol, 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
45348057|NCT04043715|Device|Transcutaneous spinal stimulation|Physical therapy to improve standing and walking
45475727|NCT04506034|Drug|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight >70 kg or 1 mg/min if body weight <70 kg.
45348058|NCT04043715|Device|Epidural spinal stimulation|Physical therapy to improve standing and walking
45348059|NCT00828477|Drug|Xibrom|Xibrom: two times a day for seven days in the first eye.
45685142|NCT02977780|Drug|Temozolomide|Temzolomide capsules
45685143|NCT02977780|Drug|Neratinib|Neratinib tablets
45685144|NCT02977780|Drug|QBS10072S|QBS10072S administered intravenously
45475728|NCT04506034|Drug|IV saline infusion|received i.v. saline infusion.
45475729|NCT01294631|Drug|Canagliflozin 300 mg once daily and HCTZ 25 mg once daily|"Period 1: canagliflozin tablets, oral, 300 mg, once daily on Days 1 to 7 followed 14 days later by Period 2.~Period 2: HCTZ tablets, oral, 25 mg, once daily for Days 1 to 28 followed by canagliflozin tablets, oral, 300 mg, once daily taken with HCTZ tablets, oral 25 mg, once daily on Days 29 to 35.."
45475730|NCT03396822|Drug|Gadoteridol|gadolinium MRI contrast
45348060|NCT00828477|Drug|Nevanac|Nevanac: three times a day for seven days in the second eye.
45348061|NCT00828555|Other|Vaccination Program|Design & implement a program for Ob/Gyns to vaccinate women against human papillomavirus, influenza, & pertussis
45348062|NCT00621309|Drug|Rifampicin|Rifampicin, an antibiotic used to treat TB, is administered at a dose of 300 mg day x 7 days to induce CYP3A5.
45475731|NCT03849209|Device|Stylet slow-pull technique|During endosonographic examination, the pancreatic mass was evaluated with color Doppler to avoid the involvement of vessels. The needle (20 Gauge, EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA) was sharpened by withdrawing the stylet approximately 2 mm, and then was advanced into the lesion: 15 to-and-fro movements within the lesion were performed, with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
46044078|NCT04117009|Drug|Remifentanil 2 MG|Once the participants transferred to operating room, electrocardiography, noninvasive blood pressure, pulse oximetry, and respiratory rate will be recorded. An increase or decrease from the baseline value of 30% in mean arterial pressure will be treated with iv boluses of (5 mg) ephedrine or glyceryl trinitrate (25 micg). All the participants will undergo a baseline transthoracic echocardiographic evaluation to assess the systolic and diastolic function of the left ventricle before the infusion of the study drug. Then the patients will be given oxygen by a face mask at a rate of 5-6 L/min, and Remifentanil infusion will be started using a target controlled infusion pump to reach a target plasma concentration of 2 ng/mL. Once the target concentration is reached, second echocardiographic evaluation to assess the systolic and diastolic function will be performed. Potential side effects of Remifentanil will be monitored.
45348063|NCT00621309|Dietary Supplement|sulforaphane plus rifampicin|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes. Sulforaphane is administered daily for 7 days as a broccoli sprout extract, at a dose rate of 75 mg (~420 umoles)per day for 7 days. Rifampicin is also administered once per day at a dose rate of 300 mg/day for 7 days.
45685145|NCT02974738|Drug|Belzutifan|Belzutifan is a highly selective small molecule that inhibits the function of the HIF-2α transcription factor. As a result, hypoxic signaling in cancer cells is impaired, blocking the transcription of several genes involved in oncogenesis
45685146|NCT02972398|Drug|N-acetylcysteine|Participants of interventional group receive 1000mg N-acetylcysteine twice daily for 12 weeks.
45685147|NCT02972398|Drug|placebo comparator of N-acetylcysteine|Participants of placebo group receive placebo comparator matching with N-acetylcysteine twice daily for 12 weeks.
45685148|NCT02971072|Procedure|Subacromial injection|A subacromial injection consisting up 6 cc 0.5% Marcaine with Epinephrine and 1 cc DepoMedrol will be administered.
46044079|NCT04117009|Diagnostic Test|Echocardiographic evaluation|Transthoracic echocardiographic examination will be performed in the spontaneously breathing patients right before the surgical procedure.
45685149|NCT02971072|Other|Physical Therapy|A standardized six-week exercise protocol supervised by a physical therapist
46044080|NCT04117243|Drug|Misoprostol|patients will be given 400 microgram misoprostol (2 tablets - Cytotec, Pfizer, G.D. Searle LLC) sublingually immediately before starting skin incision (n=115)
45685150|NCT04392778|Biological|MSC Treatment|"Protocol length: 1 week~Doses:~Application: 3 million cells/kg IV-------------------------------------------------0 day~Application: 3 million cells/kg IV ------------------------------------------------3rd day~Application: 3 million cells/kg IV -------------------------------------------------6th day~will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation."
46044081|NCT04117243|Drug|Tranexamic acid|patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes, at least 15 minutes prior to skin incision) (n=115)
46044082|NCT04117243|Drug|Oxytocin|patients will receive an intravenous bolus of 5 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby (n=115)
45685151|NCT04392778|Biological|Saline Control|Saline will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation.
45685152|NCT01617655|Drug|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
45685153|NCT01617655|Drug|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
45685154|NCT01617655|Drug|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
45685155|NCT04758910|Device|High Flow Oxygen Therapy|A 30-minute spontaneous breathing trial using high flow oxygen therapy via tracheostomy.
45685156|NCT04758910|Device|T-piece|A 30-minute spontaneous breathing trial using T-piece via tracheostomy.
45685157|NCT03829072|Other|Cooking Education|cooking Education and adapted physical activity on patients after allo stem cell transplantation
46044083|NCT01169558|Drug|Bevacizumab|5 mg/kg bevacizumab administered intravenously every 2 weeks or 7.5 mg/kg bevacizumab administered intravenously every 3 weeks according to the standard chemotherapy regimen.
46044084|NCT01169558|Drug|Fluoropyrimidine-based Chemotherapy|Fluoropyrimidine-based chemotherapy administered according to standard of care.
46044085|NCT00700687|Drug|PA32540|aspirin/omeprazole
46044086|NCT00700687|Drug|PA32540 and celecoxib|aspirin/omeprazole and celecoxib
46044087|NCT00700687|Drug|aspirin and [NSAID]|aspirin and [NSAID]
46044088|NCT00706459|Device|Magnetic Resonance Imaging|All study subjects will have a 3T MRI examination. The MRI exam will take approximately 90 minutes to complete and will involve the scanning o the spine.
45348064|NCT00621309|Dietary Supplement|sulforaphane alone|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes
45348065|NCT00839553|Procedure|Intrapleural Minocycline application|
45348066|NCT00832611|Device|Arteriovenous Fistula (ROX AC1)|The percutaneous creation of an arteriovenous fistula.
45475732|NCT03849209|Device|Standard suction technique|During endosonographic examination, the pancreatic mass was evaluated with color Doppler to avoid the involvement of vessels. The needle (20 Gauge, EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA) was sharpened by withdrawing the stylet approximately 2 mm, and then was advanced into the lesion: 15 to-and-fro movements within the lesion were performed using a 10-mL suction syringe.
45475733|NCT05342662|Device|Blue light-blocking glasses|Participants will be randomly assigned to wear either blue light-blocking glasses or glasses with clear lenses during the second week of the study. During the third week, participants will be assigned to wear the opposite pair of glasses.
45475734|NCT05342662|Device|Glasses with clear lenses|Non-blue light-blocking glasses
45475735|NCT03847571|Drug|Acetazolamide|Correction of metabolic alkalosis by inhibition of the filtered bicarbonate load reabsorption in the proximal tubules using acetazolamide (AZ)
45475736|NCT01293149|Drug|Ropivacaine|ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
46044089|NCT04314908|Procedure|Apical enlargement|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will be opened. The working length will be measured using apex locator and the 0 point will be based on. After standard irrigation protocol, root canals will be obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
46044090|NCT04314908|Procedure|Apical enlargement + Sonic Activation Assisted Irrigation|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and the 0 point will be based on. After standard irrigation protocol, sonic activation assisted irrigation will be applied to the root canals. Then the teeth were obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
46044091|NCT04314908|Procedure|Non Apical enlargement|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and 1 mm shorter than the 0 point will be based on. After standard irrigation protocol, root canals will be obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
45348067|NCT04018521|Behavioral|PPN|Delivery of Coordinated Specialty Care (CSC) for Y/YA in New York's state program for FEP, called OnTrackNY (OTNY).
45348068|NCT04018521|Behavioral|CSC Usual Care|standard of care provided to youth following first episode of psychosis
45348069|NCT02549079|Other|Blood sample|Blood will be taken from all patients meeting the inclusion criteria.
45348070|NCT00832689|Drug|Irinotecan and Gemcitabine|
45475737|NCT01293149|Drug|Clonidine|clonidine 1 mcg/kg AND ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
45475738|NCT03575065|Drug|BGB-290|Administered orally
45475739|NCT03636672|Procedure|perturbation training|perturbation training during stationary bicycle riding
45475740|NCT03847961|Device|hemoperfusion with cytokine adsorption column (CA330)|Hemoperfusion treatments are performed using a perfusion machine via centrally inserted standard dialysis catheters at a prescribed blood flow rate of 100-300ml/min. In the beginning, lower flow rate is recommended, if there is no discomfort, then gradually increases. Each patient received 2 hemoperfusion treatments within 24 hours with a target duration for each treatment of 120-180 minutes (minimum of 120 minutes). The shorter the interval between the two hemoperfusion is, the better. It is suggested that the second hemoperfusion be performed within 0-5 hours after the first one.
45475741|NCT04454424|Drug|BAY1817080|Study intervention BAY1817080 will be administered orally with tablet(s).
45475742|NCT04454424|Drug|Midazolam|Midazolam will be administered intravenously with dose of 0.1 mg on Day 1.
45475743|NCT02518126|Other|blood sample and tissue sample|After birth and fetal umbilical cord disconnection, a blood sample will be taken from the umbilical cord (cord blood) of IUGR and of AGA fetuses (5cc) for cytokine ELISA testing. Also a small sample of the placenta will be examined in order to assess the level of ACTH protein in IUGR and AGA embryos
45475744|NCT01194167|Drug|Eltrombopag|75 mg per day with possible dose escalation to 150 mg per day and 300 mg per day
45475745|NCT05313802|Drug|LY3502970|Administered orally.
45348071|NCT00567190|Drug|Pertuzumab|Pertuzumab was administered as an intravenous (IV) loading dose of 840 milligrams (mg) q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420 mg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
45348072|NCT00567190|Drug|Placebo|Placebo (matching pertuzumab) was administered intravenously.
45348073|NCT00567190|Drug|Trastuzumab|Trastuzumab was administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 6 mg/kg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
45348074|NCT00567190|Drug|Docetaxel|Docetaxel was administered as an IV dose of 75 milligrams per square meter of body surface area (mg/m^2) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 75 mg/m^2 (up to 100 mg/m^2 as per treating physician discretion) q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. On or prior to Cycle 6, docetaxel was only to be discontinued for progressive disease or unmanageable toxicity. After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician.
45348075|NCT00922389|Procedure|will receive G-CSF and peripheral blood derived mononuclear cells|Multiple intra muscular implantation of mononuclear stem cells derived from peripheral blood after G-CSF (granulocyte colony-stimulating factor)mobilization in either of two individual dose ranges which would be given to equal number of subjects.
45348076|NCT00922389|Drug|G-CSF|5 micrograms/kg/day for 4 days by subcutaneous route
45348077|NCT00922389|Drug|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
45348078|NCT00839631|Drug|EC D-3263 HCl|EC D-3263 HCl, capsules, 50 mg. Oral administration. Dose escalation cohorts (cycle one: single dose on Day 1, daily doses on day 8-28; subsequent cycles: 1 week drug holiday followed by 3 weeks of daily dosing). Expansion Cohort: daily dosing for 28 days followed by a single 7 day drug holiday (Cycle 1), continuing thereafter with daily dosing.
45348079|NCT00691938|Drug|LBH589|
46044092|NCT04314908|Procedure|Non Apical enlargement + Sonic Activation Assisted Irrigation|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and 1 mm shorter than the 0 point will be based on. After standard irrigation protocol, sonic activation assisted irrigation will be applied to the root canals. Then the teeth were obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
45348080|NCT00691938|Drug|Decitabine|
45348081|NCT00365365|Drug|Doxorubicin and cyclophosphamide (AC) + bevacizumab|"For every 3-week cycle~bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~doxorubicin 60 mg/m^2 IV push or infusion followed by cyclophosphamide 600 mg/m^2 IV push or infusion~Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
45475746|NCT03521310|Procedure|Skin-to-skin|Neonates will get Skin-to-skin Contact with parent/caregiver continuously the first 6 hours after birth and as much as possible the first 72 hours after birth.
45475747|NCT03521310|Procedure|Conventional care|Neonates will get Conventional care the first 72 hours after birth
45475748|NCT01293227|Procedure|Surgical treatment of distal radius fractures|Surgical repair of distal radius fracture using either intramedullary locked nail or volar locked plate
45475749|NCT03348046|Drug|Biosimilar Infliximab|A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg
45348082|NCT00365365|Drug|Docetaxel (T) + bevacizumab|"For every 3-week cycle~bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~docetaxel 100 mg/m^2 IV~Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy~Note: The starting dose of docetaxel was reduced to 75 mg/m^2 if toxicity occurred that met the criteria for doxorubicin dose reduction"
45475750|NCT03514134|Behavioral|Virtual Reality Job Interview Training|Students will engage in didactic training related to strategies to perform well during a job interview as well as repeated practice with a virtual hiring manager. Throughout and after completion of the virtual interviews, participants will receive feedback on their performance.
46044093|NCT02884778|Diagnostic Test|Detection of pain after nociceptive stimulus|We will evaluate the changes of the NoL index absolute values after different types of stimulations such as intubation and electrical tetanic stimulation of the forearm (applied with the standard muscle relaxation monitor) in a patient under general anesthesia + epidural anesthesia for abdominal surgery
46044094|NCT00840463|Drug|Ambrisentan|Subjects will be initiated at 2.5 mg per day and increased to 5mg daily in 2 weeks and then 10mg daily if clinically tolerated (edema is controlled and symptoms are stable).
46044095|NCT00840463|Other|Placebo|Sugar pill
45475751|NCT03514134|Behavioral|Services as Usual|Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
45475752|NCT03849287|Drug|CKD-333, formula I|Test drug
45475753|NCT03849287|Drug|CKD-333, formula II|Test drug
45475754|NCT03849287|Drug|CKD-330, D090|Reference Drug
46044096|NCT00706615|Biological|Ad-sig-hMUC-1/ecdCD40L vaccine|
45685158|NCT03829072|Other|adapted physical activity|cooking Education and adapted physical activity on patients after allo stem cell transplantation
45685159|NCT03828916|Other|NuShield|SOC surgery with the addition of NuShield
45685160|NCT02965768|Drug|Naltrexone HCl|4.5 mg Naltrexone HCl, p.o., nocte (standard-dose); 3.0 mg Naltrexone HCl, p.o., nocte (optional-dose);
45685161|NCT01895101|Drug|2 gr tranexamic acid|This group receives pericardial lavage with 2 gr tranexamic diluted in 200 ml normothermic saline solution (NaCl 0.9%).
45685162|NCT01895101|Drug|Saline|This group receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid
45685163|NCT03828682|Drug|Tacrolimus Extended Release Oral Tablet [Envarsus]|Tacrolimus Extended Release Oral Tablet [Envarsus]
45685164|NCT03828682|Drug|Mycophenolate Mofetil|Mycophenolate mofetil capsules or tablets
46044097|NCT01155050|Device|Tele-health Home Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
46044098|NCT01155050|Behavioral|TrestleTree Telephone Coaching|Weekly or bi-weekly phone calls from TrestleTree health coaches with a focus on weight loss.
45348083|NCT00365365|Drug|Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab|"For every 3-week cycle~bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~doxorubicin 50 mg/m^2 IV push or infusion followed by cyclophosphamide 500 mg/m^2 IV push or infusion followed by docetaxel 75 mg/m^2~Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
45685165|NCT03828682|Drug|Mycophenolic Acid Oral Product|mycophenolic acid tablets
45685166|NCT03828682|Drug|Tacrolimus|Twice daily tacrolimus
45685167|NCT03828682|Drug|Methylprednisolone|Methylprednisolone taper
45685168|NCT03828682|Drug|Prednisone|Prednisone taper
45685169|NCT03828682|Drug|Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]|Rabbit Anti-Human T-Lymphocyte Globulin
45685170|NCT03483649|Drug|HLX04|HLX04: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
46044099|NCT01155050|Device|Tele-health Home Monitoring Plus Trestle Telephone Coaching|Daily collection of data through the tele-health home monitor and weekly or bi-weekly phone calls with a Trestletree Health Coach.
46044100|NCT00703183|Drug|ACU-4429|administered as a single dose, orally
45685171|NCT03483649|Drug|US-Avastin®|US Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
45685172|NCT03483649|Drug|EU-Avastin®|EU-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
45685173|NCT03483649|Drug|CN-Avastin®|CN-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
46044101|NCT00703183|Drug|matching placebo|administered as a single dose, orally
46044102|NCT00706693|Dietary Supplement|Ingestion of BD glucose tablets (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with BD glucose tablets by giving 10g of glucose in children 10 and under. Children and teens over 10 will receive 15g of glucose.
45475755|NCT03352024|Other|Relational care|Relational care is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))
46044103|NCT00706693|Dietary Supplement|Ingestion of Skittles (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Skittle by giving 10g of sucrose in children 10 and under. Children and teens over 10 will receive 15g of sucrose.
46044104|NCT00706693|Dietary Supplement|Ingestion of Fruit to Go (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Fruit to Go by giving 10g of fructose in children 10 and under. Children and teens over 10 will receive 15g of fructose.
46044105|NCT02613325|Device|Functional photoacoustic microscopy|-Hybrid imaging technique that detects absorbed diffusive protons ultrasonically through the photoacoustic effect.
46044106|NCT02613325|Procedure|Standard of care surgical excision|
46044107|NCT02613325|Device|Single cell photoacoustic microscopy|
46044108|NCT00700765|Drug|insulin detemir|For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
46044109|NCT02611999|Behavioral|Single median price information|Physicians in this Arm received a single median price in the electronic medical record at the time of ordering in addition to the paper memo.
46044110|NCT02611999|Behavioral|Paired inside/outside price information|Physicians in this Arm received two prices (the inside and outside price) in the electronic medical record at the time of ordering in addition to the paper memo.
46044111|NCT04030897|Behavioral|Parent-Directed Online Single-Session Program|Online, 15-minute self-administered program for parents
46044112|NCT04030897|Behavioral|Youth-Directed Online Single-Session Program|Online, 30 minute self-administered program for youths
46044113|NCT04030897|Behavioral|Information/Psychoeducation/Referral|Usual care at pediatric primary care clinics participating in this study
46044114|NCT04117165|Diagnostic Test|Biotherapy Prescription with SinnoTest® software|The rheumatologist will use the SinnoTest® software to give the best biotherapy to the patient according to the results of the software.
46044115|NCT04117165|Drug|Patient Current Care|The rheumatologist will use the french guidelines of rheumatoid arthritis to choose the more adapted biotherapy treatment to the patient.
45348084|NCT00365365|Drug|Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab|"For every 3-week cycle~bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~docetaxel in 75 mg/m^2 IV followed by carboplatin AUC 6 mg/mL/min IV followed by~trastuzumab 6 mg/kg by IV infusion (For the first cycle 1 only a loading dose of trastuzumab 8 mg/kg IV was infused on Day 2)~Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
45685174|NCT04392388|Biological|Non applicable|to collect data from questionnaires and to collect serological samples
46044116|NCT00828451|Biological|[5,5,5-2H3]leucine (stable isotope labeled leucine)|intravenous infusion of labeled leucine dissolved in 5% glucose water: priming dose of 18 micromoles (1.8 ml)/kg over 5 minutes, then 18 micromoles (1.8 ml)/hr for 6 hours; one infusion total
45475756|NCT03352024|Other|Hypno-analgesia|Hypno-analgesia is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))
45475757|NCT03188718|Device|WatchPAT Intervention|Wearing the device during their clinically indicated sleep study. This is a validation study to the gold-standard polysomnogram.
45475758|NCT05653492|Drug|Sulforaphane|Dosing study one to four 30 mg/d tablets depending on weight
45685175|NCT04612933|Other|Intervention group video consultations|"All appointments, scheduled and non-scheduled are by telemedicine using video to commutate with the health care professionals.~Patients will follow their usual treatment."
45685176|NCT03822208|Biological|AL003|"Single-doses of AL003 in dose-escalating cohorts~Multiple doses of AL003 in a single cohort"
45685177|NCT03822208|Other|Saline Solution|Saline Solution will be administered as a single infusion for each dose escalation cohort in a ratio of 6 active and 2 placebo and as multiple infusions in the single cohort in a ratio of 10 active and 2 placebo
45685178|NCT03822520|Drug|Celecoxib|Celecoxib 400mg capsule
46044117|NCT00839917|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)|Single administration of 0.5 mL subcutaneous injection
45685179|NCT03822520|Drug|Moxifloxacin|Moxifloxacin 400mg tablet
45685180|NCT03822520|Other|Water|Pure water 150ml
45685181|NCT03822364|Drug|009-1|Inhaled apomorphine via Staccato aerosol, Dose 1
45685182|NCT03822364|Drug|active comparator|commercially available apomorphine injector
46044118|NCT00839917|Biological|M-M-R™ II and Varivax™|Single administration of 0.5 mL subcutaneous injection
46044119|NCT00839527|Drug|placebo to match albiglutide|albiglutide matching placebo weekly subcutaneous injection
46044120|NCT00839527|Biological|albiglutide|albiglutide weekly subcutaneous injection
46044121|NCT00839527|Drug|metformin|metformin
46044122|NCT00839527|Drug|glimepiride|glimepiride
46044123|NCT00839527|Drug|pioglitazone|pioglitazone
45348085|NCT00365365|Drug|Bevacizumab and trastuzumab maintenance therapy|"bevacizumab 15 mg/kg was infused IV followed by~trastuzumab 6 mg/kg IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed."
45348086|NCT00365365|Drug|Bevacizumab maintenance therapy|"- bevacizumab 15 mg/kg was infused IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed."
45348087|NCT02564874|Other|Discretionary calorie source|We are assigning participants randomly to either of two different sources of discretionary calories (savory snacks or sugary beverages)
45348088|NCT01046461|Drug|Ramosetron, Aprepitant, Dexamethasone|"Day 1:~Aprepitant 125 mg PO, 1 hour before chemotherapy Ramosetron 0.6 mg IV, 30 min before chemotherapy Dexamethasone 12 mg PO, 30 min before chemotherapy~Day 2 - 3:~Aprepitant 80 mg PO. in the morning Dexamethasone 8 mg PO. in the morning~Day 4 Dexamethasone 8 mg PO. in the morning"
45348089|NCT02375802|Biological|Adipose-derived stromal cells|Adipose-derived stromal cells contain stem cells which have been successful in enhancing wound healing. The product used as the carrier is a fibrin sealant called TISSEEL. Pre-pilot testing was done to verify viability of the stromal cells for up to 72 hours in the fibrin sealant.
46044124|NCT00839527|Drug|placebo to match pioglitazone|pioglitazone matching placebo
45348090|NCT02375802|Drug|Adipose-derived stromal cells|
45685183|NCT03822364|Drug|009-0|Inhaled placebo via Staccato device
46044125|NCT00706771|Drug|Sodium bicarbonate|Sodium bicarbonate: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
46044126|NCT00706771|Drug|Sodium chloride|0.9% sodium chloride: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
45348091|NCT00623727|Biological|rFVIII-FS/pegylated liposomes (BAY79-4980)|35 IU/kg body weight intravenous 1x/week for 52 weeks This arm will be stopped by 30.04.10 the subjects will be offered to change to the active comparator arm
45348092|NCT00623727|Biological|rFVIII-FS/WFI (BAY14-2222)|25 IU/kg body weight intravenous 3x/week for 52 weeks
45348093|NCT00933946|Drug|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 21 consecutive days.
45348094|NCT01046539|Drug|RDC-0313 + Buprenorphine|1 and 4 mg (1 dose for each) + 8 mg
46044127|NCT04031053|Other|Pharmacokinetic study|The blood will be collected at pre-dose and at 1, 3, 4, 5, 6, 8 and 12-hour post dose
46044128|NCT00706927|Drug|latanoprost 0.005% + timolol 0,5% fixed combination|1 drop per day and eye for 6 weeks
46044129|NCT00706927|Drug|brimonidine 0,2% + timolol 0,5% fixed combination|1 drop twice a day per eye for 6 weeks
46044130|NCT00707083|Drug|dexamethasone|Given oral
46044131|NCT00707083|Drug|mercaptopurine|Given orally
46044132|NCT00707083|Drug|methotrexate|Given orally
46044133|NCT00707083|Drug|vincristine sulfate|Given IV
45596460|NCT03531385|Diagnostic Test|Central sensitisation|Central Sensitization Inventory, which is a comprehensive self-report inventory to assess the overlapping symptom dimensions of central sensitisation syndrome will be used to identify participants with central sensitisation.
46044134|NCT05500261|Drug|Dexmedetomidine|intranasal administration of dexmedetomidine
46044135|NCT04116931|Drug|Switch ticagrelor to clopidogrel|Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose（MD）12/24 hours after the last MD of ticagrelor
46044136|NCT00600886|Drug|Pasireotide|Pasireotide LAR - intramuscular (i.m.) depot injection given once every 28 days.
45348095|NCT01046539|Drug|Placebo|0 mg
45348096|NCT04015024|Drug|SKLB1028 150mg bid|150mg oral administration twice a day
45348097|NCT04015024|Drug|SKLB1028 200mg bid|200mg oral administration twice a day
45348098|NCT04015024|Drug|SKLB1028 300mg qd|300mg oral administration once a day
46044137|NCT00600886|Drug|Octreotide|Octreotide LAR - i.m. depot injection given once every 28 days.
46044138|NCT00649324|Drug|Hydrochlorothiazide Tablets 50 mg|50mg, single dose fasting
46044139|NCT00649324|Drug|Hydrochlorothiazide Tablets (50 mg|50mg, single dose fasting
46044140|NCT00648388|Drug|Cilostazol Tablets 100 mg|100mg, single dose fasting
46044141|NCT00648388|Drug|Pletal® Tablets 100 mg|100 single dose fasting
46044142|NCT02658760|Drug|Dexmedetomidine|dexmedetomidine plus placebo
46044143|NCT02658760|Drug|Bupivacaine|dexmedetomidine and Bupivacaine
46044144|NCT02536690|Drug|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
46044145|NCT02536690|Drug|Remifentanil|Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration.
45348099|NCT01044199|Biological|PCEC rabies vaccine given intradermally|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
45348100|NCT01044199|Biological|PCEC rabies vaccine administered intramuscularly|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
45348101|NCT00908284|Behavioral|Exercise Program|Participants will exercise in the study exercise laboratory for 1 hour on 2 nonconsecutive days a week for 12 weeks. The program will consist of a warm-up with flexibility exercises, aerobic conditioning, a muscular circuit, and a cool-down period with flexibility training.
45348102|NCT00908284|Behavioral|Control Group|Participants will attend group sessions once a week for 12 weeks to watch videos, including some exercise videos, and play games that do not require physical activity.
45348103|NCT00828789|Drug|Efavirenz; Tenofovir disoproxil fumarate; Telaprevir|
45475759|NCT05584930|Other|Collection of blood sample|"Visit 1 : At inclusion (day 1 of chemotherapy treatment)~Visit 2 : Onset of aplasia~Visit 3a : day 1 of the 1st febrile aplasia~Visit 3b : day 3 of the 1st febrile episode~Visit 3c : day 8 of the 1st febrile episode~Visit 4a : second febrile episode (after 7 days)~Visit 4b : day 3 of the second febrile episode (after 7 days)"
45348104|NCT00839709|Procedure|blood sampling|peripheral blood draw
45348105|NCT00930358|Drug|MEOPA|anaesthetic gaz inhalation
45841180|NCT05525988|Procedure|Hemi-Hamate Transfer for Proximal Pole Scaphoid Reconstruction|"Surgical Technique:~The participants will be positioned in the supine decubitus on the surgical table with the operated upper limb put on a C-arm (Mobile fluoroscopy device) compatible surgical arm-board. After anesthesia, a pneumatic tourniquet will be placed with a cuff pressure raised to 250 mmHg, then the limb is draped in the regular sterile fashion. Through a dorsal approach to the wrist joint, the proximal pole of scaphoid bone will be assessed before resectioning for confirmation that it cannot be preserved. The hamate bone will be exposed through capsulotomy and the measurements of the resected scaphoid will be transferred. The harvested H-H autograft will be placed and fixed to the distal scaphoid segment. Wound closure is then performed in layers in the usual fashion, and the wound will be covered by a sterile gauze, then a short-arm thumb spica splint will be put on."
45348106|NCT00930358|Drug|general anaesthesia|Anaesthetic intravenous route
46044146|NCT02536690|Drug|Midazolam|Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.03 mg/kg administration 1 min after remifentanil infusion start.
46044147|NCT02660632|Other|Thoracic epidural analgesia (TEA)|Epidural catheter will be inserted at T9-T11. Then, epidural analgesia will be activated with administering bolus of 10 mls 0.25% bupivacaine in conjunction with100 mcg fentanyl to establish a block. This will be followed by an infusion of 0.125% bupivacaine in conjunction with 2 mcg/ ml fentanyl at a rate of 10 mls /hour and then titrated to effect for up to 48 hour postoperative
45348107|NCT00832845|Behavioral|CBSST plus treatment as usual|Patients will receive CBSST in addition to their regular treatment for 36 weeks.
45348108|NCT00832845|Behavioral|Treatment as usual (TAU)|Patients will receive their regular treatment for 36 weeks without CBSST. TAU consists of the standard care that patients receive, including routine visits and contacts with their physicians and clinicians.
45348109|NCT00930436|Drug|sodium bicarbonate|Serum creatinine will be measured on Days 3,7, 30, 90, and 180
45348110|NCT00372775|Drug|Sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen until progression or unacceptable toxicity
45348111|NCT00832923|Behavioral|PEPAC|"The proposed enhancement of the IMPACT DC intervention will consist of three key components: (1) an enhanced IMPACT DC Asthma Clinic visit; (2) short-term case management to increase the rate of primary care follow-up visits in the first month after the IMPACT DC Asthma Clinic visit; and (3) training in an asthma care toolkit to improve communication around asthma care with the child's primary care provider."
45348112|NCT00936676|Drug|rasagiline mesylate|During the Core follow-up study period, subjects will continue to receive 1 mg rasagiline once a day. During the Extended follow-up study period, only subjects who are still on rasagiline at Visit 9 will continue to receive treatment with rasagiline 1 mg per day. Tablets will be supplied by the Sponsor and given according to the label.
45475760|NCT01294943|Device|Tongue cleaner|Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
46044148|NCT02660632|Other|Rectus sheath catheter block|Following insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected through each one. Then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
45596461|NCT03531385|Diagnostic Test|Neuropathic pain|Frequency of neuropatic pain will be investigated using Pain Detect Questionnaire
45475761|NCT04505644|Drug|lidocaine patch|Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
45475762|NCT04505644|Drug|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight >70 kg or 1 mg/min if body weight <70 kg.
46044149|NCT00649090|Drug|exemestane|Exemestane 25 mg oral tablet once daily for a maximum of 3 years
45475763|NCT04505644|Drug|IV saline infusion +Sham patch|received i.v. saline infusion +Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
45475764|NCT03574753|Drug|ABBV-399|ABBV-399 (Process II), 2.7 mg/kg IV over 30 ± 10 minutes, Day 1, Every 21 days
45475765|NCT03850613|Behavioral|E-painting mobile app|The subjects can use the newly developed mobile app to draw their own pictures at the time convenient to them.
45475766|NCT04505800|Dietary Supplement|Tryptophan supplement|"Pure L-tryptophan in capsules (500mg/capsule)~3g tryptophan per day (2 capsules, t.i.d.), at 8AM, 4PM, and 0AM (± 1 hour)"
45475767|NCT04505800|Dietary Supplement|Maltose|Maltose
45475768|NCT03725839|Device|F&P Interface|F&P Interface to be used for OSA therapy
45475769|NCT05200156|Dietary Supplement|Phosphatidyl Choline|conventional management + phosphatidyl choline tablets
46044150|NCT00838903|Biological|albiglutide|albiglutide
46044151|NCT00838903|Drug|sitagliptin|sitagliptin
46044152|NCT00838903|Drug|glimepiride|Glimepiride
46044153|NCT00838903|Drug|metformin|Metformin
46044154|NCT00838903|Biological|placebo albiglutide|placebo to match albiglutide
46044155|NCT00838903|Drug|placebo sitagliptin|placebo to match sitagliptin
46044156|NCT00838903|Drug|placebo glimepiride|placebo to match glimepiride
46044157|NCT02660398|Procedure|Standardized NMBD Management|The intervention phase will introduce a standardized research protocol that spells out NMBD management, including how muscle relaxant should be administered and monitored, and how reversal with neostigmine should be done.
46044158|NCT00648466|Drug|Sumatriptan Succinate Tablets 100 mg|100mg, single dose fasting
46044159|NCT00648466|Drug|Imitrex® Tablets 100 mg|100mg, single dose fasting
46044160|NCT04170322|Device|thin pvc gastric tube|a thin pvc gastric tube of 40 Fr for sleeve is used to guide the surgeon
46044161|NCT04170322|Device|thick silicone gastric tube|a thick silicone gastric tube 40 Fr for sleeve is used to guide the surgeon
46044162|NCT00649402|Drug|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/120mg, single dose fed
46044163|NCT00649402|Drug|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fed
46044164|NCT04477486|Drug|Ibrutinib|Capsule; Oral
46044165|NCT04477486|Drug|Venetoclax|Tablet; Oral
46044166|NCT00649480|Drug|BALSALAZIDE DISODIUM CAPSULES, 750 MG|3x750mg, single dose fed
46044167|NCT00649480|Drug|COLAZAL® Capsules 750 mg|3x750mg, single dose fed
46044168|NCT02656108|Procedure|Ommited controlled cord traction|No controlled cord traction and no fundal pressure. placenta will be allowed to deliver physiologically
45685184|NCT03822364|Drug|009-2|Inhaled apomorphine via Staccato aerosol, Dose 2
46044169|NCT02656108|Procedure|controlled cord traction|active management of third stage of labor in the form of uterine massage with controlled cord traction
46044170|NCT02656342|Drug|D-Cycloserine|Predicted to enhance stabilization of the effects of concentrated exposure treatment
45348113|NCT00839787|Drug|Morphine Sulfate|Morphine Sulfate group: If weight is <50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given
46044171|NCT02656342|Drug|Placebo|Predicted to have no enhancing effect
45348114|NCT01044355|Device|CPAP|6 weeks treatment with fixed CPAP
45348115|NCT01044355|Device|APAP|6 weeks of treatment with auto-titrating positive airway pressure
45348116|NCT01049659|Behavioral|Neuropsychological test|Bayley test (version III) which provides several scales of development. Children are assessed just one time at two year old
46044172|NCT04116385|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
45475770|NCT01293305|Drug|Chondroitin sulfate + Glucosamine sulfate|1 capsule three times daily, preferably in the same period
46044173|NCT02656186|Dietary Supplement|Pre-intervention|First 2-weeks : keeping routine dietary habit
46044174|NCT02656186|Dietary Supplement|Liquid nutritional supplement|Pre-intervention period was followed by an intervention period, during which consumed twice-daily 200 mL cartons of oral liquid nutritional supplementation (total 400 mL daily, containing 16 g protein, 12 g fat and 60 g carbohydrate and providing 400 kcal)
45348117|NCT00936754|Dietary Supplement|Brown seaweed powder|500 mg (in two 250 mg capsules) taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
45348118|NCT00936754|Dietary Supplement|Placebo|Two capsules similar in aspect and weight to active product, taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
45348119|NCT00934258|Drug|rosuvastatin,fenofibrate|Rosuvastatin 10 mg once daily Rosuvastatin 5 mg + SFC fenofibrate 80 mg
45685185|NCT03822364|Drug|009-3|Inhaled apomorphine via Staccato aerosol, Dose 3
45685186|NCT03822364|Drug|009-4|Inhaled apomorphine via Staccato aerosol, Dose 4
45685187|NCT03822364|Drug|009-5|Inhaled apomorphine via Staccato aerosol, Dose 5
45685188|NCT03822130|Drug|Arterial catheter infusion chemotherapy|Arterial catheter infusion chemotherapy
45685189|NCT03822130|Drug|Sodium Bicarbonate|Arterial catheter infusion Sodium Bicarbonate
45685190|NCT03822130|Drug|Systemic Chemotherapy|Systemic Chemotherapy
45685191|NCT03822130|Drug|Oral Chemotherapy|Oral Chemotherapy
46044175|NCT04169464|Drug|Sofosbuvir Oral Product|to investigate the drug effect on renal function and insulin resistance
46044176|NCT02656030|Other|semispinalis cervicis resisted exercise|semispinalis cervicis resisted exercise, 2 time per week, 6 weeks duration
46044177|NCT02656030|Other|cranio-cervical flexion exercise|cranio-cervical flexion exercise, 2 time per week, 6 weeks duration
46044178|NCT02656030|Other|usual care|usual care, 2 time per week, 6 weeks duration
45475771|NCT01293305|Drug|Chondroitin sulfate + Glucosamine sulfate|1 sachet per day of the drug dissolved in a beaker with 200 mL water.
45841181|NCT05517564|Drug|GM-60106|The participants will receive a single oral dose between 2.5 to 100 mg for Part A (SAD), Part B (MAD) once daily for 14 days, and for Part C (MAD) once daily for 28 days.
46044179|NCT00650416|Drug|Carvedilol Tablets 12.5 mg|12.5mg, single dose fasting
46044180|NCT00650416|Drug|Coreg® Tablets 12.5 mg|12.5mg, single dose fasting
45475772|NCT01310257|Other|Questionnaires|Patients will be given questionnaires relevant to their condition to complete. In Study 2 and a sub-study of Study 1, patients will be invited to take part in Quantitative Sensory Testing.
45475773|NCT03347968|Biological|MEDI0382|All participants will receive MEDI0382
45475774|NCT03347968|Drug|Warfarin|All participants will receive Warfarin
45475775|NCT03347968|Drug|Esmolol|All participants will receive Esmolol
45841182|NCT05517564|Other|Placebo|Placebo-to-match GM-60106 capsules
45841183|NCT05489328|Other|Candidate-1|Biological
46044181|NCT00649948|Drug|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
46044182|NCT00649948|Drug|Glucophage XR 500 mg|500mg, single dose fed
45841184|NCT05489328|Other|Candidate-2|Biological
46044183|NCT04254328|Device|Nintendo Wii Fit|Nintendo Wii Fit group will perform including a series of yoga, balance, aerobics and muscle workout exercises by providing visual feedback on the TV screen with the Nintendo wii fit plus game console. Patients will perform these exercises in a room allocated to the thesis supervisor and together with the thesis supervisor physiotherapist. This process takes 40-50 minutes. Before starting test and after test, weight, blood pressure, pulse, respiratory rate, oxygen saturation value will be recorded. Patients will be rested if necessary during exercise.
46044184|NCT04254328|Device|Threshold IMT|Patients in the breathing exercise group will perform deep breathing exercises at home by a small breathing apparatus called as Threshold IMT. It has no unexpected side effects.Patients will do this exercise twice in a day ; morning and evening during 15 minutes. After 4-5 deep breath, patients will take normal breath till feeling relaxed.
45841185|NCT05489328|Other|Candidate-3|Biological
45841186|NCT05489328|Other|Candidate-4|Biological
46044185|NCT04167982|Procedure|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
45348120|NCT00934258|Genetic|CYP2C9, UGT1A1, UGT1A3, OATP2, BCRP|All potential patients will be screened for the eligibility in a screening visit. Those who fill the inclusion criteria at screening will be invited for the registry study into different groups. The follow-up will take place at months 6, 12, 18, and every year thereafter for another 3 years, through clinical visiting, phone follow-up, or records from the NHIB Taiwan. At each clinical visit, vital signs, clinical endpoints, adverse events, concurrent medication information and laboratory specimens will be obtained as complete as possible. With phone or records from NHIB, only clinical endpoints will be recorded. If the primary care physician intends to treat the patient's lipid profile to the target, he/she can add, delete or adjust the LLT by his/her clinical judgement
45596462|NCT03531385|Other|Sleep disturbance|Assessment of sleep disturbance will be assessed by Pittsburgh Sleep Quality Index
45841187|NCT05489328|Other|Candidate-5|Biological
45841188|NCT05489328|Other|Candidate-6|Biological
45841189|NCT05489328|Other|Candidate Control|Biological
45841190|NCT05489328|Biological|13vPnC|13-valent pneumococcal conjugate vaccine
45841191|NCT05489328|Biological|PCV15|15-valent pneumococcal conjugate vaccine
45475776|NCT03848975|Other|Simulation training for ECV|Intervention for the ECV group is a ECV simulation training. The group will have theoretical courses and five simulation sessions with four ECV simulation on a model (i.e., a total of 20 ECV), associated with clinical practice in the delivery room.
45475777|NCT03848975|Other|Simulation training for VE|Intervention for the VE group is a simulation training. The group will have theoretical courses and five simulation sessions with four VE simulation on a model (i.e., a total of 20 VE), associated with clinical practice in the delivery room. The investigators will us Kiwi® Omni Cup Vacuum Delivery System, as this is the vacuum system chosen for clinical practice in our obstetric service.
45596463|NCT03531385|Other|Quality of life|Quality of life will be assessed by the Nottingham Health Profile
46044186|NCT04167982|Drug|Oral conventional-dose isotretinoin|Conventional-dose isotretinoin
46044187|NCT04167982|Drug|Oral low-dose isotretinoin|low-dose isotretinoin
46044188|NCT02651974|Behavioral|Control condition|Patients will be mailed a control invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
46044189|NCT02651974|Behavioral|Cost condition|Patients will be mailed a cost condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
46044190|NCT02651974|Behavioral|Cost/Future condition|Patients will be mailed a cost/future condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
46044191|NCT00649558|Drug|Pioglitazone HCl Tablets 45 mg|45mg, single dose fasting
45596464|NCT02368743|Drug|mesalazine|
46044192|NCT00649558|Drug|Actos® Tablets 45 mg|45mg, single dose fasting
45596465|NCT02201147|Procedure|Cold biopsy polypectomy|removal of eligible polyps using cold biopsy technique until no polyp was visible by narrow-band imaging endoscopy
45596466|NCT02201147|Procedure|Cold snare polypectomy|removal of eligible polyps using cold snare polypectomy technique
46044193|NCT02658604|Other|Home medication review by a pharmacist|Patients will receive a home visit from a pharmacist, including a medication review and the identification and addressing of drug therapy problems through patient education, the provision of pharmacologic and/or non-pharmacologic advice, or the adaptation of therapy or communication of recommendations to prescribers. All activities are within the current scope of practice for pharmacists in Ontario. A detailed assessment of the patient's medication inventory and organization/storage practices will be conducted, followed by a medication cabinet cleanup to help the patient organize their medications and discard any expired or discontinued medications. A list of inappropriate medications found in the home will be documented, detailing the reasons why they are inappropriate and if/how the patient is currently using these medications. With patient consent, inappropriate medications will be removed from the home and returned to the pharmacy for safe disposal.
46044194|NCT02658682|Behavioral|Attention Bias Modification|Computer based Attention Bias Modification
46044195|NCT02658682|Behavioral|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
45348121|NCT00372697|Drug|Octreotide acetate 30 mg suspension|Each vial of study medication contained octreotide acetate 30 mg in a microencapsulated biodegradable polymer, poly (DL-lactide-co-glycolide) (D-(+)glucose), with 17% w/w mannitol in an approximate octreotide:polymer ratio of 1:20. The vehicle contained 0.5% sodium carboxymethylcellulose.
45348122|NCT04014478|Device|Endovascular Denervation|A radiofrequency ablation catheter will be placed in abdominal aorta. At least 6 sites will be ablated with settings of temerature at 60 degree centigrade and time at 120 seconds.
45596467|NCT02201147|Device|Cold snare polypectomy|mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
45596468|NCT02201147|Device|Cold biopsy polypectomy|standard- capacity forceps with narrow band imaging endoscopy
45685192|NCT02923570|Radiation|Photon intensity modulated radiation therapy (IMRT)|Photon intensity modulated radiation therapy (IMRT) to standard dose of 60-66Gy in standard 2 Gy per fraction.
46044196|NCT04169308|Drug|Restylane-L® Filler injection|Restylane-L® Filler injection into the soft tissue of the nose
46044197|NCT02658526|Behavioral|anesthesia - surgery|
46044198|NCT02655718|Other|Patients with ACS|Cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images , T1-weighted images.
46044199|NCT02655718|Device|MRI|
46044200|NCT02651818|Procedure|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
45348123|NCT00934336|Other|Therapeutic and preventive strategies|These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
45348124|NCT00934336|Other|Therapeutic and preventive strategies|These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
45348125|NCT00934414|Drug|Technosphere Insulin Inhalation Powder|30U
45348126|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection at 1400 mg dose level, administered every 2 or 3 months.
45348127|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection at 800 mg/m^2 dose level, administered every 2 or 3 months.
45348128|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection 625 mg/m^2 administered every 2 or 3 months.
45348129|NCT00930514|Drug|Rituximab|Rituximab intravenous infusion 375 milligram per square meter (mg/m^2) administered every 2 or 3 months.
45348130|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection 375 mg/m^2 administered every 2 or 3 months.
45348131|NCT00936988|Drug|cinacalcet|Subjects began open-label treatment with 30 mg cinacalcet twice daily (BID) at the start of the current study. The study consisted of 2 phases planned to total approximately 4¾ years: a 12-week dosetitration phase (visits at weeks 2, 3, 4, 6, 9, and 12) during which 1 possible dose increase of cinacalcet from 30 mg BID to 50 mg BID could occur at week 6, and a maintenance phase (week 12 to 234; visits approximately every 4 weeks until week 24 and approximately every 14 weeks thereafter) during which doses also could be titrated. After July 2004, because of a change in dose strengths, the daily doses used in the study were 30 and 60 mg BID with the option to reduce to 30 mg once daily (QD), if necessary. Ongoing subjects receiving 50 mg BID were switched at that time to 60 mg BID.
46044201|NCT02651896|Radiation|HypoIGRT|"Hypofractionated intensity modulated and image guided radiotherapy 60 Gy in 20 fractions over four weeks for the prostate gland to all groups.~For intermediate and high risk group: seminal vesicle will be included: 48 Gy in 20 fractions over 4 weeks (proximal third to half on physicians description).~Image guidance with cone beam CT will be mandatory before every treatment fraction."
46044202|NCT04438174|Drug|Processed Amniotic Fluid|Injection of 1 ml of processed amniotic fluid per 5 cm2 of wound area
46044203|NCT04438174|Other|Standard of Care Wound Treatment Regimen|ointment-based dressing and non-ointment-based dressings
45348132|NCT00934492|Drug|Cotrimoxazole dispersible tablet|Cotrimoxazole dispersible tablets 120/240mg daily for six consecutive months.
45348133|NCT00934492|Drug|Placebo dispersible tablet|Placebo dispersible tablets 120/240mg daily for six consecutive months.
46044204|NCT02658370|Device|animated home-based exercises (Wii-fit)|
46044205|NCT02658370|Procedure|conventional home-based exercise program|
46044206|NCT00650494|Drug|Valacyclovir Hydrochloride Tablets 1000mg|1000mg, single dose fed
45348134|NCT00934570|Drug|Metformin and standard exercise|Metformin 1500 mg daily for 2 years
45348135|NCT00934570|Drug|Metformin Intensive exercise|Metformin 1500 mg daily for 2 years
45348136|NCT00934570|Behavioral|Placebo Standard exercise|Standard exercise
45348137|NCT00934570|Behavioral|Intensive exercise|Placebo Intensive exercise
45348138|NCT03702634|Behavioral|Spiritual Care Assessment and Intervention (SCAI) framework|The study chaplain will work with the surrogate, using questions in four domains of spiritual care, to assess them and tailor the visit to their specific needs. The study chaplain will then utilize a pre-determined list of spiritual care interventions, and also document observable outcomes that occur at each visit (which are also listed within the SCAI framework).
45348139|NCT00930670|Drug|Rosuvastatin-omeprazole|Rosuvastatin 20 mg for 1 month. Then rosuvastatin 20mg and omeprazole 20mg for 11 months
45348140|NCT00930670|Drug|Rosuvastatin-pantoprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months
45348141|NCT00930670|Drug|Rosuvastatin-esomeprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months
45348142|NCT00930670|Drug|Rosuvastatin-ranitidine|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300mg for 11 months
45348143|NCT00930670|Drug|Atorvastatin-omeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months
45348144|NCT00930670|Drug|Atorvastatin-pantoprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40 mg for 11 months
45348145|NCT00930670|Drug|Atorvastatin-esomeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months
46044207|NCT00650494|Drug|Valtrex® 1000 mg|1000mg, single dose fed
46044208|NCT02655874|Biological|Influenza vaccine|Administered at day 1
46044209|NCT02655874|Biological|Influenza vaccine|Administered at day 180
46044210|NCT02655874|Biological|Tetanus-diphtheria-pertussis vaccine|Administered at day 180
46044211|NCT00828139|Biological|ziv-aflibercept|Given IV
46044212|NCT00828139|Drug|topotecan hydrochloride|Given IV
46044213|NCT02655796|Device|OAK|The OAK device evaluates the fall risk through exercises assessing mobility, equilibrium and postural reaction.
45475778|NCT03731533|Behavioral|WellStart|"Five weekly automated text messages linked to an online article on health and wellness.~Five weekly automated health coach motivational text message to smart phone. Optional back and forth text with their health coach is available.~Daily Option to participate and post comments or questions in online discussion forum moderated by health coaches.~Three group (up to 20 participants) health coach online visits (60 minutes).~Two online group visits with a dietitian in groups of 10-12 participants.~Three one-on-one online visits with a Physician Advisor to review progress, review any changes in medications by the primary medical provider (PCP), review biometrics and lab results, review safety guidelines and symptoms (30 minutes)."
45348146|NCT00930670|Drug|Atorvastatin-ranitidine|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months
45348147|NCT00930748|Device|MR imaging with endorectal coil|MR imaging with endorectal coil
45475779|NCT05179720|Other|puncture stent-assisted transperineal prostate biopsy|Patients in the experimental group used a puncture stent to assist transperineal prostate biopsy
45475780|NCT01191515|Device|Monofocal Intraocular Lenses|Monofocal Intraocular Lenses
46044214|NCT04224688|Drug|Rozanolixizumab|Study participants receive rozanolixizumab by subcutaneous infusion at pre-specified time points.
45475781|NCT03346954|Other|[11C]-Methionine PET/MRI|Implementation [11C]-Methionine PET/MRI performed for each patient in one place (department of nuclear medicine of the Hospices Civils de Lyon). The [11C]-Methionine PET/MRI will be performed after a pituitary MRI and before a transsphenoidal surgery.
45475782|NCT01194557|Device|Rapid diagnostic test|Diagnosis of malaria using rapid diagnostic test
45475783|NCT01194557|Drug|Lumartem|Presumptive treatment of malaria/fever
45348148|NCT00930748|Device|MRI with endo-rectal coil|MRI with endo-rectal coil
45348149|NCT00934804|Device|Galilei dual Scheimpflug analyzer|The Galilei dual Scheimpflug analyzer is a non-invasive, diagnostic system that combines dual rotating Scheimpflug camera measurements and Placido optical system for corneal topography and 3D analysis of the anterior eye segment.
45841192|NCT05479344|Behavioral|A Brief Contextual Behavioural Intervention Based on Strengths, Meaning, Hope and Connection|The intervention strategy combines acceptance and commitment therapy, contextual behavioral science, and positive psychology interventions (strengths, meaning, hope) in the form of a single intervention set (each topic is a single 90-minute intervention, four single intervention combinations).
45348150|NCT00934882|Drug|Regorafenib (BAY73-4506)|Administration of the multi-kinase inhibitor BAY73-4506 (160 mg once daily from Day 4 to Day 10 and from Day 18 to Day 24) as oral treatment in combination with the chemotherapy regimen mFOLFOX6 or FOLFIRI in patients with metastatic Colorectal Cancer
45841193|NCT05467098|Other|Dry Needling|A sterile, disposable, solid filament needle (Seirin Corp., Shizuoka, Japan) will be inserted manually into the MTrP of the infraspinatus muscles. Once the needle has been inserted, the technique described by Hong (1994) will be used. The needle will be pistoned in an up and down motion within the infraspinatus muscle at approximately 1Hz for 10 seconds with the aim of eliciting local twitch responses.
46044215|NCT04224688|Other|Placebo|Study participants receive placebo by subcutaneous infusion at pre-specified time points.
46044216|NCT04222192|Other|Epidural block|Epidural catheter insertions
46044217|NCT04169386|Drug|AK102|AK102 single dose administered subcutaneously
45348151|NCT00937144|Drug|Viagra (Sildenafil)|Viagra treatment to patients with sickle cell anemia.
45348152|NCT00937144|Drug|placebo|
45475784|NCT03729193|Behavioral|Measuring devices and questionnaires|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of athletes. The Expanded Scandinavian Muscle Skeleton Questionnaire (NMQ) and Visible Analogue Scale (VAS) will be used to identify and assess the symptoms of musculoskeletal discomfort as 'pain'. The participant will be evaluated with the algometer for identifying their pain threshold, the sporty trust will be questioned with the Sporty Trust Continuous Inventory, and the Quality of Life will be assessed with the World Health Organization Quality of Life Scale Short Form and Depression will be evaluated with Beck Depression Inventory.
45475785|NCT03346876|Procedure|Nuss surgery|surgical correction for pectus excacatum
45475786|NCT03848897|Other|Metrology of motor behavior|Biomechanical, physiological, psychological and behavioral analyses
45475787|NCT03731455|Device|WISE Cortical Strip|The WISE Cortical Strip is a medical device composed by a strip and by a cable.
45475788|NCT03351946|Procedure|ZEEP|Zero positive end-expiratory pressure (ZEEP) during emergence preoxygenation and awakening.
45475789|NCT03351946|Procedure|PEEP|Positive end-expiratory pressure remains during emergence preoxygenation and awakening and until the study subject is extubated.
45475790|NCT03847259|Diagnostic Test|mechanical posture changes|evaluated by Posture screen mobile, (BackPEI) questionnaire , VISUAL ANALOG SCALE (VAS), Depression Anxiety Stress Scales-21(DASS-21).
46044218|NCT04169386|Drug|Placebo|Placebo single dose administered subcutaneously
46044219|NCT02658214|Drug|paclitaxel + carboplatin|IV infusion
46044220|NCT02658214|Drug|carboplatin + etoposide|IV infusion
46044221|NCT02658214|Drug|gemcitabine + carboplatin|IV infusion
46044222|NCT02658214|Drug|nab-paclitaxel (paclitaxel-albumin) + carboplatin|IV infusion
46044223|NCT02658214|Drug|oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)|IV infusion and bolus administration
46044224|NCT02658214|Biological|durvalumab|IV infusion
46044225|NCT02658214|Biological|tremelimumab|IV infusion
46044226|NCT02658214|Drug|nab-paclitaxel (paclitaxel-albumin) + gemcitabine|IV infusion
46044227|NCT02658214|Drug|cisplatin + 5-fluorouracil (5FU)|IV infusion
45475791|NCT03351868|Genetic|Gene-modified autologous stem cells|Infusion for 5x10^6~1x10^7 per kilogram of body weight of gene-modified cells; or more infusions depending on the circumstances
45475792|NCT01191593|Procedure|Adductor-Canal-Blockade with Ropivacaine|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
45475793|NCT01191593|Procedure|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
45475794|NCT03347890|Drug|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml or Placebo|Patients will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg) or Placebo by pen injector.
45475795|NCT03848819|Device|VitaBreath device|The VitaBreath (Philips, Respironics) is a portable, handheld, battery powered, non-invasive ventilation device, that has been shown by our group to reduce activity-related shortness of breath in patients with COPD. It delivers 18 cmH2O inspiratory and 8 cmH2O expiratory pressures, but can only be used during recovery periods. In our study patients will perform consecutive bouts of exercise alternated by two minute of recovery in order to allow the use of the VitaBreath device during the first minute of each recovery period.
45475796|NCT03347812|Procedure|Endovascular Aortic Repair|Without surgery to expose the lesion directly, minimal invasive treatment for the aortic arch lesion under the guidance of imaging equipment is performed through the blood vessel with a tiny wound of a few centimeters, in our research, including chimney, branch stent-grafts and fenestration techniques.
46044228|NCT04169230|Drug|Citalopram|Single dose administration of citalopram (20mg)
46044229|NCT04169230|Drug|Placebo oral tablet|Single dose administration lactose placebo tablet
46044230|NCT02655952|Drug|Foxy-5|
46044231|NCT02655640|Other|Questionnaires|Questionnaires will be provided to patients
45475797|NCT03347812|Procedure|Total Arch Replacement|A kind of open surgery is performed for the replacement of total aortic arch.
45475798|NCT01190657|Drug|Selbex|50mg/day, 3 times/day, for 14 days
45475799|NCT01190657|Drug|Selbex|50mg/day, 3 times/day, for 56 days
46044232|NCT02658058|Other|Landmark technique|The site of needle insertion will be determined via manual palpation. A line joining the superior aspect of the iliac crests posteriorly (Tuffier's line') will be used as a surface landmark for the L4 vertebral body. The midline will be established by palpation of the tips of the spinous processes, and the site of needle insertion will be marked on the patient's skin. The interspace that appears widest, based on manual palpation, will be chosen for the first attempt. If the first attempt is unsuccessful, further attempts can be made at the same interspace or another interspace.
45685193|NCT02923570|Radiation|Proton beam radiotherapy (PBRT)|Proton beam radiotherapy (PBRT) to standard dose of 60-66Gy in standard 2 Gy per fraction.
45475800|NCT04505488|Behavioral|ASD Screening Parent ENgagement Intervention Program (ASPEN)|The ASPEN intervention is based on naturalistic developmental behavioral intervention strategies to support the development of social communication and play skills and reduce challenging behavior.
45475801|NCT03351790|Other|Questionniare only|A pre-procedure questionnaire will be completed by all participants
46044233|NCT02658058|Other|Ultrasound-guided paramedian technique|The transducer will be applied in the parasagittal plane and the intervertebral levels will be identified by counting upwards from the sacrum (continuous hyperechoic line). The probe will then be angled obliquely to obtain a PSO view. The locations of the interlaminar spaces will be identified by visualizing the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body. The angulation at which the ligamentum flavum-dura mater complex and posterior vertebral body are best visualized will be considered the optimal angle for needle insertion and clearly communicated to the operator. The interlaminar space will be centered on the ultrasound screen and a skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe.
46044234|NCT02658058|Other|Ultrasound-guided midline technique|The transducer will be applied in the parasagittal plane, and after identification of the intervertebral levels, the probe will be rotated 90 degree to obtain the TM view. The transducer is moved in a cephalad-caudad direction between the spinous processes of L2 and L5 vertebra. The probe will be tilted slightly up and down to ensure a sufficient echogenic window at the selected intervertebral space. A skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe. The angle at which the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body are best visualized will be noted
45475802|NCT05584618|Other|Education|education
45475803|NCT04505332|Procedure|arthroplasty|back pain in orthopedists due to working actively and performing arthroplasty every day
45475804|NCT03573505|Drug|BG00011|Administered as specified in the treatment arm.
45475805|NCT03573505|Drug|Placebo|Administered as specified in the treatment arm.
45841194|NCT05412498|Behavioral|BR-30|Battle rope training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
45348153|NCT04014400|Other|Suprathel or Xeroform donor site application|The surgical procedure for recovery of a skin graft will be the same for all patients as follows. Once the patient is taken to the operating room, the selected donor site will be prepared and harvested with a Zimmer Dermatome set at 0.007 to 0.009 thousands of an inch for pediatric patients and 0.12 to 0.14 thousands for adult patients. After the harvesting procedure, the donor site will be covered with Telfa saturated with 1:10,000 epinephrine in normal saline until hemostasis is achieved. The Telfa will be irrigated off the donor site with the epinephrine saline solution. The surgeon will don a new pair of sterile gloves to handle the donor site dressing. The randomized dressing will be applied over the hemostatic donor site with an approximate 1-2cm border. Next, the wound will be dressed with 4x4 cotton gauze pads (fluffs), rolled gauze (Kerlix) and either Coban or BandNet.
45348154|NCT00937222|Dietary Supplement|Peanuts and peanut butter|Peanuts and peanut butter
45841195|NCT05412498|Behavioral|BR-45|Battle rope training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
45348155|NCT00937300|Biological|cyclophosphamide, fludarabine, T-cell infusion, and Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
45348156|NCT00931060|Dietary Supplement|Branched chain amino acids|Branched chain amino acids 0.45g/kg BW. Oral supplement. Administered once on study day
45348157|NCT00937456|Procedure|Laparoscopically-assisted esophagectomy|To compare during the abdominal approach the laparoscopic route to the open route for gastric mobilization. Thoracic approach will be the same between the 2 arms through thoracotomy with extended two field lymphadenectomy
45348158|NCT04014010|Other|Blood pressure|"Systolic Blood Pressure (SBP)~Maximum change from preoperative SBP, in a) absolute change (mmHg), and b) relative change (%)(emergency and elective cases analyzed separately)~Cumulative duration (minutes) >=20% below preoperative SBP~Longest single episode (minutes) below a) 80, b) 90, and c)100 mmHg~Cumulative duration (minutes) below a) 80, b) 90, and c)100 mmHg~Mean Arterial Pressure (MAP)~Maximum change from preoperative MAP, in a) absolute change (mmHg), and b) relative change (%) (emergency and elective cases analyzed separately)~Cumulative duration (minutes) >=20% below preoperative MAP~Longest single episode (minutes) below a) 60, b) 65, c) 70, and d) 80mmHg~Cumulative duration (minutes) below a) 60, b) 65, c) 70, and d) 80mmHg"
45348159|NCT04014010|Other|Heart rate|"Maximum change (beats per minute, BPM) from preoperative heart rate (positive and negative)~Relative change (%) from preoperative heart rate (positive and negative)~Maximum pulse variation (maximum heart rate minus minimum heart rate)~Longest single episode (minutes) a) below 60, and b) above 100BPM~Cumulative duration (minutes) a) below 60, and b) above 100BPM"
46044235|NCT04210024|Other|Diabetes Empowerment Education Program|Individuals identified as Community Health Workers will participate in the Diabetes Empowerment Education Program (DEEP™). DEEP, is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
45348160|NCT04014010|Other|Use of hemodynamic medications (i.e. special medications for blood pressure)|"Vasopressor/inotrope use (yes vs. no): phenylephrine, norepinephrine, epinephrine, vasopressin, dobutamine, or milrinone~Infusion of any vasopressor/inotropes above (yes vs. no) (identified by unit of weight over time)~Phenylephrine/ephedrine bolus (yes vs. no) (identified by unit of weight only)~Vasodilator use (yes vs. no): labetalol, esmolol, nitroglycerin, nitroprusside~Infusion of any vasodilator above (yes vs. no) (identified by unit of weight over time)"
45348161|NCT04014010|Other|Oxygen saturation by pulse oximetry (SpO2)|"Longest single episode (minutes) below a) 88, and b) 90%~Cumulative duration (minutes) below a) 88, and b) 90%"
45348162|NCT04014010|Other|End-tidal Carbon dioxide (EtCO2)|"Longest single episode (minutes) a) below 30, and b) above 45mmHg~Cumulative duration (minutes) a) below 30, and b) above 45mmHg"
45348163|NCT02226276|Radiation|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
45348164|NCT02226276|Procedure|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
45475806|NCT01296425|Device|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
45475807|NCT01293383|Drug|LEO 90105|Ointment
45475808|NCT01296503|Drug|Thalidomide plus dexamethasone|"D+60 after ASCT: randomization in two arms of maintenance: Arm A (dexamethasone alone 40 mg/day for 4 days every 28 days) and Arm B (dexamethasone plus thalidomide 200 mg by mouth daily) for 12 months or until disease progression.~The dose of thalidomide could be reduced if the patient experienced grade 2 or higher adverse events. In this case, thalidomide was discontinued and re-challenged at a lower dose after resolution of the adverse event."
45475809|NCT01296503|Drug|Dexamethasone|dexamethasone alone 40 mg/day for 4 days every 28 days
45348165|NCT02226276|Procedure|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
45348166|NCT02226276|Biological|trastuzumab|Given IV
45348167|NCT02226276|Radiation|copper Cu 64-DOTA-trastuzumab|Given IV
45348168|NCT02226276|Procedure|positron emission tomography|Undergo copper Cu-DOTA-trastuzumab PET
45348169|NCT02226276|Biological|ado-trastuzumab emtansine|Given IV
45348170|NCT02226276|Other|laboratory biomarker analysis|Correlative studies
45475810|NCT01376908|Drug|Kuvan®|Kuvan® (sapropterin dihydrochloride) tablets will be administered orally at the dose of 10 mg/kg/day and will be escalated to 20 mg/kg/day if after 4 weeks a subject's Phe tolerance is not increased by at least 20% versus baseline.
45475811|NCT01376908|Other|Phenylalanine (Phe)-restricted diet|Phe intake will be adjusted every 2 weeks, based on the mean Phe levels of the previous 2 weeks using pre-defined Phe adjustment criteria.
46044236|NCT02655484|Device|"BiPAP® Vision® ventilator（Ventilator, Philips Respironics™ BiPAP® Vision® ）"|See details from arm descriptions.
45348171|NCT03743272|Device|LiverMultiScan|Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.
45348172|NCT00935116|Drug|etoricoxib|"G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.~G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery"
45348173|NCT00931138|Drug|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3
45348174|NCT00931138|Drug|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3
45348175|NCT00931138|Drug|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
45348176|NCT04014088|Device|hCPAP vs fCPAP|The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or facemask CPAP.
45348177|NCT00935194|Drug|oseltamivir|75mg,bid,for 5 days
45348178|NCT00935194|Other|blank|no antiviral therapy
45348179|NCT00935194|Drug|chinese medicinal herbs|200ml,p.o,qid,for 5 days
45348180|NCT00935194|Drug|oseltamivir and chinese medicinal herbs|oseltamivir:75mg,p.o,bid,for 5 days; chinese medicinal herbs:200ml,p.o,qid,for 5 days
45348181|NCT00937534|Drug|Fimasartan|Fimasartan 240mg/day
45348182|NCT00690378|Drug|NXL104/ceftazidime|125mg/500mg TID
45348183|NCT00690378|Drug|Imipenem/Cilastatin|4 x daily
46044237|NCT02651506|Procedure|Electromagnetic Navigation Bronchoscopy|• Participants randomized to the intervention arm will undergo biopsy using the superDimension®InReach™ System. Participants will undergo ENB guided biopsy under general anesthesia or local anesthesia. The procedure will be performed by a thoracic surgeon in the operating room or endoscopy suite. Following electromagnetic mapping, bronchoscopy and biopsy will be performed. Fiducial markings will be placed when necessary.
46044238|NCT02651506|Procedure|Transthoracic Needle Biopsy|• Patients randomized to the control arm (TTNB) will undergo lung biopsy using standard transthoracic needle biopsy technique. The procedure will be performed under local anesthesia with computed tomography guidance by an interventional radiologist. In this procedure, a CT-image is used to locate the area for biopsy. Once identified, the radiologist applies a local anesthetic and inserts an aspiration needle between the ribs, through normal lung tissue, leading into the biopsy area. The sampled lung tissue is then sent for pathological analysis.
45348184|NCT00937612|Radiation|Radiotherapy|postoperative radiotherapy, 60-66 Gy/30-33 fractions, concurrently with triweekly chemotherapy by Cisplatin
45348185|NCT00574275|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle.
45348186|NCT00574275|Drug|Placebo|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle
45348187|NCT00574275|Drug|Gemcitabine|1000 mg/m^2 administered IV over 30 minutes on Days 1, 8, 15, and 22 of Cycle 1 (28 days), and then Days 1, 8, and 15 of subsequent 28-day cycles.
46044239|NCT02655250|Other|Microbiome|
45348188|NCT00931216|Procedure|Integrated ANC, PMTCT, HIV services|Of the 12 study clinics, 6 will be randomized to receive the intervention. At these 6 facilities, health care providers within the ANC department will be trained to also provide HIV/PMTCT care. Women testing positive within ANC clinics at integrated facilities will receive ANC, PMTCT and HIV services within the same visit/same service provider rather than being referred for HIV care and treatment.
45348189|NCT00743418|Device|GPS modem and RFID|The participant will take the GPS kit with him/her everywhere during the whole day for a period of 4 weeks. The GPS tracking kit consists of a GPS receiver with a GSM modem, an RF transmitter contained in a wrist-watch and a monitoring unit located in the home that enables researchers to know whenever the tracked person leaves home. The waterproof RF transmitter will allow researchers to know whether or not research subjects leave home with the GPS device and if they are carrying the device or not at a given moment.
45348190|NCT00935350|Dietary Supplement|PolyGlycopleX (PGX)|2.5 grams of PGX
45348191|NCT00935350|Dietary Supplement|PolyGlycopleX (PGX)|5.0 grams of PGX
45348192|NCT00935350|Dietary Supplement|PolyGlycopleX (PGX)|0 grams of PGX
45348193|NCT00839865|Drug|herb ointment|a kind of ointment made from herb
45348194|NCT02564640|Device|videolaryngoscope|patients intubated by using the videolaryngoscope
45348195|NCT02564640|Device|Macintosh laryngoscope|patients intubated by using the Macintosh laryngoscope
45348196|NCT00839943|Other|ozone, 0.4 ppm|2 hour ozone exposure, 0.40 ppm
45348197|NCT00746382|Drug|Roflumilast cream|Roflumilast cream 0.5% versus Placebo cream
45348198|NCT00746382|Drug|Placebo cream|Placebo cream
45348199|NCT00833001|Device|GYNECARE PROLIFT+M* Pelvic Floor Repair System|Pre-shaped mesh implants made of GYNECARE GYNEMESH M composite mesh, comprised of absorbable polyglecaprone 25 monofilament fiber and nonabsorbable polypropylene monofilament fiber
45348200|NCT04060368|Procedure|Endoscopic Sleeve Gastroplasty (ESG) with OverStitch® system + Lifestyle modifications|Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
45348201|NCT04060368|Procedure|Laparoscopic Sleeve Gastrectomy (LSG) + Lifestyle modifications|Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
45475812|NCT03850457|Other|No intervention|The treatments will be determined by their neonatologists and no additional investigational drugs will be applied to the infants included in this study.
45348202|NCT00828867|Drug|100 mg GSK investigational drug|
45348203|NCT00828867|Drug|200 mg GSK investigational drug|
45348204|NCT00828867|Drug|400 mg GSK investigational drug|
45348205|NCT00828867|Drug|800 mg GSK investigational drug|
45348206|NCT00828867|Drug|2000 mg GSK investigational drug|
45475813|NCT03729037|Other|CPR self-training|
45475814|NCT01295099|Drug|5- fluorouracil|5mg of 5FU injected per 1cm square, at 6 week intervals for 30 weeks = 6 sessions
45348207|NCT00828867|Drug|1500 mg GSK investigational drug|
45348208|NCT00828867|Drug|800mg fed GSK investigational drug|
45348209|NCT00828867|Drug|3000mg GSK investigational drug|
45348210|NCT00828867|Drug|4000mg GSK investigational drug|
45348211|NCT00746460|Behavioral|CVD risk profile|Cardiovascular risk assessment and behavioral counselling
45348212|NCT00567112|Drug|10 mg MK-0941 DFC (fasted)|single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state
45348213|NCT00567112|Drug|10 mg MK-0941 OCT (after meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal
45348214|NCT00567112|Drug|10 mg MK-0941 OCT (before meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast
45348215|NCT00567112|Drug|10 mg MK-0941 OCT (fasted)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state
45348216|NCT01742832|Drug|Vilazodone|A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
45348217|NCT01742832|Drug|Citalopram|For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
45348218|NCT00833079|Drug|Tacrolimus 0.1% manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
45348219|NCT00833079|Drug|Protopic - Tacrolimus 0.1%|Treatment applied as a thin layer to target area twice daily for 14 days
45475815|NCT01295099|Radiation|radiotherapy|after complete excision of keloid they have a single session of radiotherapy
45475816|NCT01295099|Drug|Triamcinolone|TAC 10mg in 1ml injected intralesional
45475817|NCT01310335|Device|whole-body vibration (WBV)|All cases will be trained on a whole-body vibration (WBV) platform (Power Plate) 5 times a week for one week period.
45475818|NCT01426529|Drug|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
45475819|NCT01426529|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
45475820|NCT01426529|Drug|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
45475821|NCT03346798|Behavioral|Food Photography|Participants will engage in food photography on their smart phones while eating
45348220|NCT00833079|Drug|Tacrolimus Vehicle manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
45348221|NCT00935506|Drug|Clopidogrel|Tablets, Oral, 75 mg, Once daily, 8 days
45475822|NCT03346798|Behavioral|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
45475823|NCT03346798|Behavioral|No Phone Use|Participants will not use their smart phones while eating
45475824|NCT03728959|Other|Liquid meal (Nutridrink)|Liquid meal ingested over 1 minute.
45348222|NCT00935506|Drug|Aspirin|Tablets, Oral, 325 mg, Once daily, 8 days
45348223|NCT00833157|Drug|glucosamine sulphate|Subjects are administered glucosamine-sulphate tablets of 500 mg * 3 daily, while they are performing a strength-training program with both legs (*3 weekly) for 12 weeks.
45475825|NCT03728959|Other|GIP|Subcutaneous injected GIP
45841196|NCT05402826|Dietary Supplement|Oral zinc + vitamin E|In the zinc + vitamin E supplementation group, patients will receive a cumulative dose of 120 mg of oral zinc supplementation plus a cumulative dose of 1200 IU of oral vitamin E before surgery. After surgery, from the second day to the end of the hospital stay, patients receive 30 mg of zinc supplement plus 200 units of vitamin E per day.
45841197|NCT05402826|Dietary Supplement|Placebo|Patients in the placebo group will receive placebo pills before and after surgery.
45475826|NCT03728959|Other|GLP-2|Subcutaneous injected GLP-2
45475827|NCT03728959|Other|Placebo (saline)|Subcutaneous injected Placebo (saline)
45841198|NCT05397678|Biological|BCG-Denmark|AJ vaccines, Copenhagen 1331 strain
45841199|NCT05397678|Biological|BCG-Bulgaria|BB-NCIPD Ltd., BCG-SL 222 Sofia strain
45841200|NCT05385042|Dietary Supplement|Sangobion and Thiamine Hydrochloride|"Prophylactic dietary supplements: 1 capsule of Sangobion + separate Thiamine Hydrochloride tablet 100mg per day for 12 weeks.~Then non-anaemic pregnant women will continue with prophylactic nutritional supplements until delivery."
46044240|NCT04201756|Drug|Afatinib|"①Neoadjuvant treatment stage: the enrolled patients take afatinib at a dosage of 40mg per day, 8-16 weeks in total; and receive CT scan re-examination in the 4th/8th/12th post-therapy week.~②Surgical treatment stage: the patients who respond to alfatinib treatment (CR+PR) and the patients who do not respond to alfatinib therapy but could still undergo surgery (SD and PD) will receive radical lung lobectomy+systematic lymph node dissection.~③Adjuvant treatment stage: The CR, PR and SD patients who have been treated surgically will take alfatinib at a dosage of 40mg per day for at least 1 year. The SD and PD patients who could not receive operation and the PD patients who have received operation will be transferred into medical oncology or/and radiation oncology and receive comprehensive therapy (chemotherapy or/and radiotherapy, the regimen is designed by oncologist and radiologist)"
45348224|NCT00833157|Drug|ibuprofen|Subjects are administered 600 mg * 2 daily, while they are performing a strength-training program with both legs (*3 weekly) for 12 weeks
45348225|NCT00833157|Drug|placebo|Subjects are administered placebo tablets, while they are performing a strength-training program (*3 weekly) with both legs for 12 weeks
45348226|NCT00931294|Behavioral|Choir singing|"Choir group participated in various relaxation, breathing and vocal exercises with the choir leader, and received the material To Live with IBS for home studies, weekly for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months."
45475828|NCT03849053|Other|Mézières Therapy for Low back pain|Spinal muscular global stretching
45348227|NCT00931294|Behavioral|Information Group|Meet in groups, studying and discussing on the same materials under the direction of a group leader, weekly, for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months.
45348228|NCT00833235|Other|Artificial Tears|Artificial tears (any brand) may be used to treat dry eye symptoms.
45348229|NCT00935662|Drug|AZD8329|Oral solution, single ascending doses
45348230|NCT00935662|Drug|Placebo|Oral solution, placebo
45348231|NCT04285671|Biological|Necitumumab|Given IV
45348232|NCT04285671|Drug|Osimertinib|Given PO
45348233|NCT04285671|Other|Quality-of-Life Assessment|Ancillary studies
45348234|NCT04285671|Other|Questionnaire Administration|Ancillary studies
45348235|NCT04285671|Biological|Trastuzumab|Given IV
45348236|NCT00931372|Drug|Lixisenatide (AVE0010)|Solution for subcutaneous injection 100 µg/mL
45348237|NCT00931372|Drug|Placebo|Subcutaneous injection
45348238|NCT00829257|Drug|HFA-BDP|HFA-BDP (Qvar) 100ug 2puff b.i.d
45348239|NCT00829257|Drug|Fluticasone|Fluticasone propionate Accuhaler 250ug b.i.d.
45348240|NCT00829257|Drug|Seretide|Fluticasone/Salmeterol (Seretide) 500/50ug, 1 puff b.i.d
46044241|NCT02651350|Drug|Methylprednisolone|Participants will receive methylprednisolone,48mg/d for the 1st week,32mg/d for the 2nd week,24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal.Participants will also receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA) in the first 12 weeks.The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
46044242|NCT02651350|Drug|Standard Treatment|Participants will only receive standard treatment,namely,routine liver protection drugs including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72.
46044243|NCT02658292|Drug|Naftifine hydrochloride foam, 3%|Apply NAFT900 foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
45348241|NCT01618656|Drug|PF-04457845|Study medication will be administered at 4mg by mouth daily for four weeks.
45348242|NCT01618656|Drug|Placebo|Sugar pill
45348243|NCT03978832|Drug|PERSERIS|PERSERIS is an extended-release SC injectable suspension administered once-monthly
45348244|NCT03978832|Drug|Risperidone|Oral risperidone
45348245|NCT00840255|Behavioral|BBTI-MV|Twenty participants will be randomized to BBTI-MV. As previously described, the intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3, and telephone appointments on Weeks 2 and 4. Interventions will be delivered at Western Psychiatric Institutes and Clinic. If possible, (according to space availability), the face-to-face sessions may also be conducted at the VAPHS clinics or at Reserve and Veterans Centers locally and regionally to strengthen our relations with local care and services providers and centers, and to facilitate future collaborative efforts. The duration of the first treatment visit is 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
45348246|NCT00840255|Other|Information Control|Participants will receive two brochures from the American Academy on Sleep Medicine of Sleep Hygiene and on Insomnia. The therapists will read the content of the 2 brochures with participants, and discuss how the information provide relates to individual participants' sleep experiences. No recommendations for altering sleep schedules will be made by the assigned therapist. Participants will be instructed to read these two brochures over the course of the following week, and to consider how the information provided in the brochures related to their own sleep patterns
45348247|NCT00840333|Drug|MP-376 (Levofloxacin solution for Inhalation)|DOSE BASED ON PATIENTS WEIGHT
45596469|NCT02365311|Procedure|transesophageal echocardiography(TEE)|Transesophageal echocardiography examination will be performed TLV in supine and lateral position, 10, 20 and 30 min during OLV in left lateral decubitus position. By using the transesophageal echocardiography, we will evaluate the changes of pulmonary blood flow and cardiac function.
46044244|NCT02658292|Drug|Vehicle|Apply vehicle foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
46044245|NCT02657824|Other|dyspneic patients|measuring mitral valve and septal distance in acute dyspneic patients for estimating left ventricular ejection fraction
46044246|NCT04168996|Behavioral|Individualized discharge planning|Discharge planning is designed to ensure healthcare continuity, avoid preventable poor outcomes among at-risk populations, and promote the safe and timely transfer of patient care. The individualized discharge planning is characterized to take into account the preferences, interests and clinical profile of each patient.
46044247|NCT02655328|Other|blood sample|blood sample
46044248|NCT02655328|Other|urine sample|urine sample
46044249|NCT04169152|Procedure|Cap-assisted endoscopic sclerotherapy|Cap-assisted endoscopic sclerotherapy (CAES) is an innovation technique for having advantages in accurately controlling the injection angle, direction, depth under direct vision of flexible endoscope.
46044250|NCT04168840|Diagnostic Test|Compare clinical test with ultrasound parameters|Compare various clinical test with four ultrasound parameters to predict difficult intubation.
46044251|NCT02655172|Other|cognitive tasks + PANSS+ IQ|Patients will perform different tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield,1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale (Kay et al., 1987) + the experimental task (affordance task with graspable device)
46044252|NCT02655172|Other|cognitive tasks|Healthy volunteers will perform only Edinburgh laterality questionnaire (Oldfield, 1971) + the experimental task (affordance task with graspable device).
45348248|NCT02564172|Device|CMS group|"Conus medullaris stimulation with pentapolar surgical lead includes:~Pentapolar surgical lead implant ((TM)Penta lead from St Judes Medical ANS which is the medical device under study)~Test phase of 10 days according to HAS(Haute Autorité de Santé) recommendation~If test phase positive, the lead is kept and subcutaneous rechargeable generator is implanted.~If test phase negative, the lead is removed.~Optimal medical management : Similarly to patients randomized in active comparator group, patients randomized in experimental group will also be prescribed optimized medical management (treatment for pain relief) under algologist control.~(A decrease of the consumption of pain treatment should be observed if conus medullaris stimulation has a positive effect)."
45348249|NCT02564172|Other|OMM group|"Optimal Medical Management (treatment for pain relief) includes analgesics and/or antidepressant and/or antiepileptics.Usually, drugs for neuropathic pain are prescribed as follows:~at effective dose, and minimal effective dose on the basis of adverse events and contraindications~as alone treatment in first and second line, then combination treatment. All this depends on the patient, on her/his pain, on her/his previous treatment.~Medical treatment prescription will reviewed by algologist at each clinical visit. It is not possible in this indication to establish a standardized treatment.~Non drugs therapies (physiotherapy, psychobehavioral approaches…) will not be forbidden or contra-indicated."
45348250|NCT00840489|Drug|Ribavirin|Ribavirin 1000-1200 mg qd for 24 weeks
45348251|NCT00840489|Drug|Colchicine|Colchicine 0.5 mg bd for 24 weeks
46044253|NCT02657980|Device|Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
46044254|NCT02657980|Device|Sham-Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
46044255|NCT00650572|Drug|ARRY-380, HER2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
46044256|NCT02651038|Drug|Micafungin|Measurement of PK
46044257|NCT00650026|Biological|adalimumab|40 mg adalimumab every other week
46044258|NCT02657902|Procedure|Fractures were treated with a Gamma 3 intramedullary nail|
46044259|NCT02657902|Procedure|Fractures were treated with a Gamma 3 intramedullary nail + U-Blade|
46044260|NCT02536924|Behavioral|Waiting Room Intervention|The waiting room intervention is called RESOLVE (Relaxation SOLving problem and cognitive errors), which is a short film.
46044261|NCT02536924|Behavioral|Treatment as usual.|The patient will receive treatment as usual.
45348252|NCT00743496|Biological|Anti-GD2 antibody|Anti-GD2 antibody
45348253|NCT00937846|Drug|GSK1034702|Single oral 5 mg dose in liquid formulation
45348254|NCT00833391|Drug|open label|This is an open-label, randomized, single-dose, five-period, crossover study. All subjects will receive GSK1838262.
45847570|NCT04945356|Other|upper limb training|The 6-week exercise program will consist of evidence-based exercises covering the breadth and depth of rehabilitation interventions. The therapist will choose the appropriate exercises for each participant's level of function from more than 15,000 exercises implemented within the Physiotec app and developed by rehabilitation experts. Personalized upper limb exercises will be based on the therapist initial assessment of participants, using the TERA+ telerehabilitation platform, and their goals. After each training session, participants will have to rate their perceived level of effort on a Borg scale (/10). The Borg scores will be monitored by the therapist as a precautionary measure to ensure safety and appropriateness of intensity of exercises. Participants will be instructed to train at a target score of around 7/10 (somewhat hard) on the Borg scale.
46044262|NCT02657746|Other|multi-component interventions|The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
45348255|NCT04044105|Other|Pamphlet education|Patients receive an educational intervention explaining proper opioid disposal
45348256|NCT04044105|Other|Pamphlet education + texts|Patients receive an educational intervention and text message explaining proper opioid disposal
45348257|NCT00829335|Procedure|IOUS-GUIDED INTRAHEPATIC VESSEL COMPRESSION|Using the IOUS, the tumor and the level targeted for compression are identified. Than, under the IOUS guidance, the surgeon compresses bilaterally the liver at the targeted position resulting in the compression of the portal pedicle feeding the tumor previously identified. This maneuver is constantly monitored in real-time just using the same microconvex probe, and it is maintained until the surface of the targeted liver area begins to discolor, at that time the first assistant marks the discolored area with the electrocautery, and the compression is released. Once the area is demarcated, liver dissection is started under intermittent Pringle's maneuver.
45685194|NCT04274062|Procedure|Integrated Nursing care of placenta previa|"Phase I :( preparation phase) Phase II: (Implementation phase) includes Preoperative care , intraoperative care and postoperative care by a nurse.~Phase III: (Evaluation phase)"
45685195|NCT03821974|Procedure|wet suction technique|"For the wet suction technique, after removing the stylet, the needle was flushed with 2 mL of saline solution to replace the column of air with saline solution. A 10-mL suction syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle after flushing the needle with saline solution. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion."
46044263|NCT02657668|Behavioral|Emotion Focused Therapy|EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
46044264|NCT04033042|Device|Prototype 0.5|Subjects will perform daily measurements on the IMD (Prototype 0.5) for 41 days.
46044265|NCT02650882|Procedure|Device POWERbreathe|
45685196|NCT03821974|Procedure|dry suction technique|"For the dry suction technique, after locating by EUS, the stylet was removed from the needle before performing FNA. A 10-mL syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle. Suction was applied after the lesion was punctured. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion."
46044266|NCT00838513|Drug|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
46044267|NCT04032886|Other|kinesio tape|This is a taping method used for correction of rounded shoulders.
45348258|NCT00829491|Behavioral|CVD risk reduction program|Participants will be selected through review of the DH administrative databases or by referral from their primary care provider. After completion of the forms, the navigator and client will discuss potential CVD risk reduction activities and programs available through this program for the client to participate in. Potential activities will include self-monitoring using self-help tools,healthy nutrition and exercise activities, community-based exercise programs using the recreation centers in the community, and referral to the Colorado Quitline for smoking cessation activities. Follow-up questionnaires will be completed at 6 and 12 months after enrollment to assess changes in levels of exercise, dietary patterns, and beliefs and attitudes about behavioral change.
45348259|NCT02547051|Other|Food Allergy Testing and Elimination Diet|Food allergy testing and elimination diet
45685197|NCT03821662|Behavioral|OT Diabetes Self-Management Intervention|Occupational therapy chronic disease self-management intervention.
46044268|NCT04032886|Other|exercise|Exercises include basic postural exercises.
45348260|NCT00840567|Procedure|Skin biopsy|
45348261|NCT00840567|Procedure|Blood draw & sample|
45348262|NCT00829569|Dietary Supplement|Intralipid +/- Omegaven|"Intralipid®: the 500 ml 20% Intralipid will be infused during a hyperinsulinemic clamp. Infusion rate will increase from 50 to 100 ml/hour the first 30 min and then continue at 100 ml/hour for the next 210 min, infusion duration 240 min (4 hours) in all.~Intralipid® + Omegaven®: In the 500 ml 20% Intralipid 100 ml will be replaced by 100 ml 10% Omegaven and infused during the hyperinsulinemic clamp as described for Intralipid only. Heparin (0.4 U/kg/min) will be added to both lipid emulsions.~Content of marine n-3 fatty acids in 100 ml Omegaven will be 1.25-2.82 g EPA and 1.44-3.09 g DHA (seasoning variations of n-3 fatty acids in fish oil)."
45348263|NCT02548767|Other|high fructose corn syrup|High fructose corn syrup provided as 15% HFCS/85% water (weight/weight) fruit-flavored beverage
45348264|NCT02548767|Other|aspartame|Aspartame provided as 0.04% aspartame/99.96% water (weight/weight), fruit-flavored beverage
45348265|NCT02548767|Other|Energy-balanced diet|Provided in quantities that equal energy requirement. Formulated such that the overall macronutrient intake; including beverage; equal 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
45348266|NCT02548767|Other|Ad libitum diet|Provided in quantities that exceed energy requirement by approximately 25%. Formulated such that the overall macronutrient intake; including beverage; equals approximately 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
45348267|NCT00840645|Drug|YM178|Oral
45348268|NCT00566722|Biological|adalimumab|Participants received an 80 mg adalimumab loading dose by subcutaneous injection at Baseline (Week 0). From Week 1 to Week 15, participants received 40 mg adalimumab by subcutaneous injection every other week.
45348269|NCT00691704|Drug|Lenalidomide Induction|Induction: Lenalidomide 25 mg daily on Days 1-21 followed by 7 day rest and Dexamethasone 40 mg by mouth (po) daily on Days 1, 8, 15 and 22 every 28 days for 4 cycles.
45596470|NCT00135343|Drug|Atazanvir/ritonavir + efavirenz|Capsules (ATV and RTV) Tablets (EFV), Oral, ATV 300 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
45596471|NCT00135343|Drug|Atazanvir/ritonavir + efavirenz|Capsules (ATV and RTV) Tablets (EFV), Oral ATV 400 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
45596472|NCT02201225|Dietary Supplement|Nutritional supplement with micronutrient|Nutritional supplement powder with micronutrients packed as 27 g individual sachet, administered orally as a single serve
45348270|NCT00691704|Drug|Sequential Maintenance Therapy|"Subjects who achieve >partial response (PR) following induction therapy will receive repeating triplet cycles of alternating low dose therapy until progression, poor tolerance or toxicity. Subjects who complete 24 months of maintenance will be removed from study unless they achieved > stable disease (SD) from maintenance (per discussion with physician):~325 mg aspirin for deep vein thrombosis (DVT) prophylaxis~Cycle 1, 4, 7, etc. - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle~Cycle 2, 5, 8 etc. - Melphalan 6 mg/m2 by mouth (po) daily on Days 1-7~Prednisone 60 mg /m2 po daily on Days 1-7 of a 28-day cycle~Cycle 3, 6, 9, etc. Lenalidomide 10 mg po daily on Days 1-21 of a 28 day cycle."
46044269|NCT02536222|Other|Case investigation of malaria passively detected cases with FT/FDA|Systematic reactive malaria case investigation will be performed in all villages of the six intervention health posts. All malaria cases passively detected in a health post or in the community and confirmed with a positive rapid diagnostic test (RDT) will be considered an index case and will be investigated. A team (field worker and community health worker) will visit the household of the index case and the five closest households (in a 100 meter radius) and will test by RDT all the consenting individuals living in the households. Any households with at least one positive RDT (including the index case) will receive a systematic focal drug administration (FDA) treatment with DHAP through which all members will be treated.
45348271|NCT00833625|Procedure|PET/CT (FDG PET/CT)|PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).
45348272|NCT00833625|Other|Biomarker Testings|Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis.
45348273|NCT00829647|Drug|dasatinib and lenalidomide|dasatinib will be started at 70mg/day po and lenalidomide will be started at 2.5mg/day po
45348274|NCT02564406|Device|LOW FLOW EXTRACORPOREAL CO2 REMOVAL, PROLUNG ESTOR|
45348275|NCT00935896|Procedure|Low tidal volume|twenty patients were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of > 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4).
45348276|NCT00935896|Procedure|Low tidal volume|Immediately after ICU admission, once all inclusion and exclusion criteria were met and consent obtained, twenty patients (16 men, 4 women, median age of 49 yrs) were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of > 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4)
45348277|NCT00935896|Other|low tidal volume|tidal volume of 5-7 ml/kg predicted body weight
45348278|NCT00829725|Device|screws-internal fixation|3-4-screws-internal fixation
45596473|NCT02201225|Dietary Supplement|Nutritional supplement without micronutrient|Nutritional supplement powder without micronutrients packed as 27 g individual sachet, administered orally as a single serve
45596474|NCT02365155|Other|Multicomponent training intervention.|The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including a physical part (endurance, strength, flexibility and balance).
45685198|NCT01894477|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
45685199|NCT01894477|Drug|Fludarabine Phosphate|Intravenously administered Fludarabine Phosphate
45685200|NCT01894477|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
45685201|NCT01894477|Radiation|Total-Body Irradiation|Undergo TBI
45685202|NCT01894477|Drug|Treosulfan|Intravenously administered Treosulfan
45685203|NCT01894477|Other|Laboratory Biomarker Analysis|Correlative Studies
45475829|NCT03728803|Device|Threshold IMT, Philips Respironics, Murrysville, PA, USA|Active inspiratory muscle training (IMT) by the threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cmH20) to be set. When patients inhale through the Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
45348279|NCT00829725|Device|TARGON FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
45348280|NCT00939328|Biological|rituximab|
45348281|NCT00939328|Drug|bendamustine hydrochloride|
45348282|NCT00746538|Device|biliary stent|Metallic stent of plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
45348283|NCT00829881|Drug|Betahistine Hydrochloride|A single betahistine hydrochloride capsule, increasing in dose from 50 mg, to 100 mg, to 200 mg, over 3 weeks
45348284|NCT00829881|Drug|Placebo Capsule|A single placebo capsule
45348285|NCT02563314|Device|Non-invasive mechanical ventilation - Normoxia|Maintenance of an oxygen setting allowing normal oxygen saturation during non-invasive mechanical ventilation (SpO2 targeted 96-98%)
45348286|NCT02563314|Device|Non-invasive mechanical ventilation - Controlled hypoxemia|Maintenance of an oxygen setting allowing mild hypoxemia during non-invasive mechanical ventilation (SpO2 targeted 88-92%)
45348287|NCT00936052|Other|Hyperbaric Oxygen Therapy|in addition to standard radiation and chemotherapy, you will also receive the experimental hyperbaric treatment prior to each radiation treatment (Monday-Friday) during the initial six weeks of treatment. Prior to the first hyperbaric treatment. The hyperbaric treatment lasts approximately thirty minutes. During the hyperbaric treatment, the participant will lie on a stretcher in the hyperbaric chamber and breathe oxygen at greater than normal atmospheric pressure. The investigator will monitor the increased oxygen levels in the tissue by placing a noninvasive electrode on your skin. After each hyperbaric treatment, we will measure your blood sugar by finger-stick to check for hypoglycemia (low blood sugar). If detected, hypoglycemia will be treated by standard medical measures.
45348288|NCT00936130|Procedure|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass surgery
45348289|NCT00936130|Procedure|Laparoscopic gastric banding|Laparoscopic gastric banding surgery
45847571|NCT04918290|Device|Tegaderm Eye Tape|Eye tape to protect the eye from corneal abrasions during surgery.
46044270|NCT00649636|Drug|Fluoxetine Capsules 40 mg|40mg, single dose fasting
46044271|NCT00649636|Drug|Prozac Pulvules 40 mg|40mg, single dose fasting
46044272|NCT04030663|Drug|papaverine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
45348290|NCT00936130|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy surgery
45348291|NCT00936130|Behavioral|Low Calorie Diet|Low Calorie Diet Program
45348292|NCT00829959|Behavioral|Questionnaire|1 - 2 questionnaires, lasting 10-15 minutes.
45348293|NCT04016727|Biological|platelet rich plasma|Platelet rich plasma was prepared using patients own blood. 60 units of PRP was injected on one side of the arch using insulin syringe. Each patient served as his/her own control (the side with PRP injected) and experimental group (the side without PRP injected). Whether the right or left side served as control or experimental was determined by lottery method. Patients were recalled after 4 weeks and the measurements were repeated again between lateral incisors and canines at mid, cervical and incisal of the teeth and their mean was recorded.
45475830|NCT03122392|Device|AMS 800|AMS 800 Artificial Urinary Sphincter
45475831|NCT03847415|Diagnostic Test|ultrasound|to evalute abnormal uterine bleeding in postmenopausal women using 3D(dimensional) ultrasound assessment of endometrial volume .Doppler assessment of endometrium and hysteroscopy and to correlate this finding with pathological finding of endometrial biopsy
45596475|NCT02365155|Other|Nutrition intervention|Both groups will be included in a program of quarterly monitoring receiving nutritional support: nutritional advice plus enteral supplementation should specify.
45685204|NCT03821428|Procedure|Acupuncture|Needling of P6 and CV24 points
45348294|NCT04014244|Drug|Corticosteroid vs. Dextrose|US guided injection of corticosteroid in one hand and 5% glucose in the other will be performed in accordance with randomization. In a syringe both substances will be diluted using 0.9% NaCl to a total injection volume of 6 ml. In-plane ulnar approach will be used to visualize the median nerve at the level of the pisiform bone. A standard 23 gauge needle will be inserted in the carpal tunnel with the needle tip positioned between retinaculum and median nerve.
45847572|NCT04918290|Device|Transpore Eye Tape|Eye tape to protect the eye from corneal abrasions during surgery.
45847573|NCT04902300|Other|Data collection|evaluation of internet addiction
46044273|NCT04030663|Drug|nitroglycerine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
46044274|NCT04030663|Drug|xlyocaine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
46044275|NCT02654938|Drug|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
45348295|NCT04014244|Procedure|Corticosteroid or Dextrose vs. Surgery|Injection will be performed unilaterally, after randomization of sides, by the same examiner as in the first part of the study. In all patients included in the second part of the study surgical release will be performed by the same plastic surgeon. The procedure will be performed under local anesthesia, following the same standard protocol. Both treatments will be performed maximally 2 months after diagnosis, with maximum period between them of 1 week.
46044276|NCT02654938|Drug|Placebo|5% infusion solution of dextrose
46044277|NCT00700921|Drug|Lovastatin|40mg po once daily
45348296|NCT00743808|Other|quality improvement|3-phase quality improvement intervention
46044278|NCT00700921|Drug|Placebo|One capsule, once daily
46044279|NCT00600106|Drug|1/10 NA/EE|Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
45348297|NCT00834015|Other|Outcome of lumbar spinal fusion patients and significance of postoperative exercise therapy: A randomized controlled trial|combined strength and aerobic training group
46044280|NCT00600106|Drug|Placebo|1 mg placebo
45348298|NCT02548611|Drug|Prasugrel|see arm description
45348299|NCT02548611|Drug|Clopidogrel|see arm description
45348300|NCT00937924|Drug|Saline|Saline solution injections
46044281|NCT04168918|Behavioral|Group psychological Intervention|There will be 6 sessions covering 6 topics (Understanding mental disorders, Self-stigma, Social support, Substance use and mental illness, Self-help strategies, Available mental health services). Each session will begin with welcoming, reviewing what was done in the last session and home assignments (where applicable), question-guided discussion, lecture, group sharing and home assignment
46044282|NCT02650726|Dietary Supplement|Anthocyanin|anthocyanin 320 mg daily for 24 weeks
46044283|NCT02650726|Other|Placebo|placebo 320mg daily for 24 weeks
46044284|NCT00850993|Drug|Stannsoporfin|Stannsoporfin administered as a single IM injection
45348301|NCT00937924|Drug|Diphenhydramine|Diphenhydramine injections
45348302|NCT00937924|Drug|Promethazine|Promethazine
45348303|NCT00743886|Biological|Plasma Rich in Growth Factors (PRGF)|injection onto injured area in ligament dose: 3-6mg
45348304|NCT00743886|Drug|saline|injection of 6 cc of saline into injured area
45475832|NCT03728725|Device|Cepheid Gene Xpert MTB/XDR|The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) is an integrated, automated, cartridge-based system for MDR-TB diagnosis that uses the GeneXpert instrument platform. WHO confirmed evidence to support the widespread use of the Xpert MTB/RIF assay in 2010 and the assay has since been widely used in TB programs, but it is only capable of identifying Mycobacterium tuberculosis (Mtb) and detecting RIF resistance. The Xpert MTB/XDR assay will be evaluated for INH and second-line resistance detection, and to recommend its use in diverse clinical settings. The focus of this protocol is the multicentre clinical evaluation.
45475833|NCT03122158|Drug|Escitalopram|Escitalopram treatment will be given to the arms with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
46044285|NCT00850993|Other|Placebo|Placebo (sterile saline solution) administered as a single IM injection
46044286|NCT00850993|Other|PhotoTherapy (as needed)|PT standard care administered as needed, based on bilirubin levels throughout the treatment period
46044287|NCT04168762|Other|Transcranial Ultrasound Magnetic Stimulation|Transcranial Ultrasound Magnetic Stimulation is a paradigm that allows for concurrent and concentric ultrasound stimulation with transcranial magnetic stimulation (TMS).
46044288|NCT02657512|Drug|rivaroxaban|rivaroxaban 40 mg/day (1 day)
46044289|NCT02657512|Drug|rivaroxaban and activated charcoal|rivaroxaban 40 mg/day (1 day) and 50 g of activated charcoal 2 or 5 or 8 hours after rivaroxaban administration (1 day)
46044290|NCT00818779|Drug|Aliskiren|150 - 300 mg once daily for 6 weeks
45348305|NCT00938002|Diagnostic Test|Acceler8 Pheno|
45348306|NCT00830193|Drug|N-acetylcysteine|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo in 100 cc D5W (pre-CT dose) or 2.5 g of NAC or placebo in 50 cc D5W (post-CT doses).
45348307|NCT00830193|Drug|D5W Placebo|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo (D5W) in 100 cc D5W (pre-CT dose) or 2.5 g NAC or placebo in 50 cc D5W (post-CT doses).
46044291|NCT00818779|Drug|Amlodipine|5-10 mg once daily for 6 weeks
45475834|NCT02668653|Drug|Chemotherapy|
45475835|NCT02668653|Drug|Quizartinib|
45685205|NCT03821428|Procedure|Placebo|Application of placebo acupuncture needles to the areas, where the acupoints are situated
45475836|NCT02668653|Drug|Placebo|
45348308|NCT00746772|Drug|Purslane 235mg/day in one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months
45475837|NCT05668481|Behavioral|Transdiagnostic sleep and circadian intervention (TranS-C)|TranS-C is a psychosocial treatment that helps people who have sleep and circadian problems to improve their sleep health.
45475838|NCT03728647|Behavioral|multimedia health education|The program (flat touch computer) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, complications, and experience sharing of insulin injection by a patient group. Technology: steps of insulin injection skills and complete technology demonstration . The program contents were organized using a unit-based piecemeal teaching approach. Participants could adjust their learning pace according to individual situations and could practice injection skills using an injection mold during hospitalization. A diabetes educator has assessed the learning outcome of each participant after intervention. At the day of discharge from hospital, each participant would acquire a copy of the multimedia health education compact disc.
45475839|NCT03728647|Behavioral|regular health education|The traditional education program (a diabetes educator) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, and complications. Technology: steps of insulin injection skills and complete technology demonstration.
45596476|NCT02365155|Other|Cognitive intervention|Both groups will be included in a program of quarterly monitoring receiving cognitive support: detection and treatment of depression and delirium in medical consultation.
45685206|NCT03821350|Other|Information leaflet|The written and visual information form prepared specifically for the patients was aimed to provide detailed information by clearly expressing the procedure, the suggestions that will be needed before and after injection (what to bring next, what circumstances may not be done, the control visit day after the procedure etc.) to be applied on before the injection day.
45685207|NCT03820648|Device|Alexis|The Alexis® (Applied Medical) is a surgical device indicated for use in retracting and protecting an incision during laparoscopic or open surgery. It is intended to allow the surgeon to access through an atraumatic circumferentially 360 degrees retracted wound that provides maximum exposure with minimum incision size. Further, once positioned, the Alexis Wound Retractor is intended to protect against wound contamination.The device will be manufactured in five sizes, extra-small, small, medium, medium-large and large. The Alexis Wound Retractor has been found non-toxic and non-irritant when tested in accordance with ISO 10993, Part 1: Biological Evaluation of Medical Devices. The materials used in the manufacturing of the Alexis Wound Retractor have been tested in accordance with applicable standards and was determined to pass tensile strength, elongation, (ASTM D 412) and Tear Strength (ASTM D 624). Functional performance testing has been completed and has passed the required testing.
45596477|NCT02365155|Other|D-vitamin intervention|Both groups will be included in a program of quarterly monitoring receiving hormonal support: supplementation of vitamin D if required with adjustment for guides.
45685208|NCT03820648|Device|Standard 3M™ Steri-Drape 2|Standard 3M™ Steri-Drape 2 is a standard drape applicated on the skin of the patient before the surgical incision.
45685209|NCT03821194|Other|Gua sha|Scrape the skin around the knee joint
45685210|NCT03821194|Other|hot pack|hot pack
45475840|NCT03122236|Behavioral|Neurorehabilitation of Standard Walking|Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of standard walking will focus on the use of typical steady state walking.
45475841|NCT03122236|Behavioral|Neurorehabilitation of Complex Walking|Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of complex walking will focus on the use of walking tasks that require increased attention and executive functions. The following walking tasks will be used: over obstacles, navigating around obstacles, changing speeds, on soft surfaces (exercise mat), in dim lighting, while conversing with the therapist, up/down ramps and climbing/descending stairs.
46044292|NCT02654548|Other|Sebutape|Women who consent to the study will have a sebutape attached to their and their babies foreheads to measure the levels of androgens.
46044293|NCT02657278|Procedure|Arterial Revascularization surgery or Endovascular procedure|Symptoms limited Cardiopulmonary Exercise Test (CPET) performed before and four weeks after surgical or endovascular correction of peripheral arterial disease
45685211|NCT03820570|Procedure|hernia repair|inguinal hernia repair
45685212|NCT03820414|Biological|CRV 101|(Different formulations)
45685213|NCT03820414|Biological|Placebo|2 doses administered IM in deltoid region of non-dominant arm
46044294|NCT00850759|Device|virtual pedestrian environment|a computer-driven virtual pedestrian environment
46044295|NCT00850759|Device|computer and video|various computer-based and video-based programs such as Otto the Auto and WalkSafe
46044296|NCT00850759|Behavioral|streetside training|one-on-one training by an adult with the child at streetside locations, to teach children street-crossing skills
46044297|NCT02657200|Other|survey|questionnaire assessing the knowlegde, attitude and practices regarding spontaneous abortion
45348309|NCT00746772|Drug|Placebo : one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months .
45348310|NCT00938080|Biological|AG013|Mouth rinse once a day for 14 days
45348311|NCT00938080|Biological|AG013|Mouth rinse three times a day for 14 days
45348312|NCT00938080|Biological|AG013|Mouth rinse six times a day for 14 days
45475842|NCT03122236|Device|Transcranial Direct Current Stimulation (tDCS) dosage A|"tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits."
45685214|NCT03820336|Dietary Supplement|Extra Virgin Olive Oil|Subjects will consume 45 ml (40 g) of EVOO daily for 8 weeks.
46044298|NCT02650492|Device|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherpy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
46044299|NCT00827827|Other|Exercise- Strength Training|3x per week lower-extremity ST lasting approximately 45 minutes to 1 hour.
46044300|NCT00827827|Other|Exercise- Stretching Control|3x per week upper and lower body stretching mixed with active and passive range of motion exercises
46044301|NCT00650728|Procedure|placing gastric tube|
46044302|NCT02654704|Biological|Pneumococcal Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard Pneumococcal Polysaccharide Vaccine (PPSV23) as approved by the FDA.
46044303|NCT02650336|Drug|contrast|a substance used to enhance the contrast of structures or fluids within the body in medical imaging. It is commonly used to enhance the visibility of blood vessels and the gastrointestinal tract
45475843|NCT03122236|Device|Transcranial Direct Current Stimulation (tDCS) dosage B|"tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits."
45475844|NCT03728569|Other|Vanicream Moisturizing Skin Cream|Vanicream Moisturizing Skin Cream daily application
45475845|NCT03728569|Other|Vanicream Cleansing Soap|Vanicream Cleansing Soap daily use
45685215|NCT03820336|Dietary Supplement|Control Oil|Subjects will consume 45 ml (40 g) of a control sunflower seed oil daily for 8 weeks.
46044304|NCT02654626|Drug|KBP-7072|Drug Intervention
46044305|NCT02654626|Other|Placebo|
46044306|NCT00649714|Drug|Zonisamide Capsules 100 mg|100mg, single dose fed
45348313|NCT00938080|Other|Placebo|Mouth rinse once a day for 14 days
45348314|NCT00938080|Other|Placebo|Mouth rinse three times a day for 14 days
45348315|NCT00938080|Other|Placebo|Mouth rinse six times a day for 14 days
45348316|NCT00834327|Drug|aplindore MR tablets or Placebo|aplindore MR tablets administered QD for about 4 weeks
45348317|NCT02563938|Drug|AK001|Given parenterally.
45348318|NCT02563938|Drug|Placebo|
45348319|NCT00938158|Biological|albiglutide|single dose of subcutaneously injected albiglutide
45348320|NCT00840957|Biological|infliximab|chimeric monoclonal antibody to Tumor Necrosis Factor-alpha
45348321|NCT00743964|Drug|Epirubicin|Epirubicin 50 mg/m2 iv on day 1
46044307|NCT00649714|Drug|Zonegran® Capsules 100 mg|100mg, single dose fed
45685216|NCT04391998|Drug|Iron Supplement|oral tablet twice daily after meals
46044308|NCT02654392|Dietary Supplement|corn syrup|This group will receive an iso-energetic corn syrup supplement everyday for 5 weeks
45685217|NCT04391998|Drug|Metronidazole Oral|500 mg oral twice daily
45685218|NCT04391998|Drug|Albendazole|200 mg oral single dose
45348322|NCT00743964|Drug|Cisplatin, capecitabine|Cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Capecitabine 2000 mg/m2 on days 1 to 14.
45348323|NCT00939406|Device|Hyalospine|Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
45348324|NCT00830271|Device|Vicryl plus and Monocryl plus|closure of skin and subcutaneous tissues
45348325|NCT00830271|Device|wound closure with Vicryl and Monocryl|wound closure skin and subcutaneous tissues
45348326|NCT02563236|Other|Parabolic flight|
45348327|NCT00830349|Drug|Risperidone|1 mg Tablet
45685219|NCT03828448|Drug|Ublituximab|- anti-CD 20 monoclonal antibody administered via IV infusion
45685220|NCT03828448|Drug|Umbralisib|- PI3K Delta Inhibitor oral daily dose
45685221|NCT03828604|Behavioral|Stress; Trier Social Stress Task|Standardized acute psychosocial stressor
45685222|NCT03828604|Behavioral|Placebo Trier Social Stress Task|Active control version of the TSST
45685223|NCT03824782|Device|Phototherapy Mask|A standard phototherapy mask (Biliband, Natus, Pleasanton, California, USA) applied over the eyes after instillation of mydriatic drops. The masks will be removed 4 hours after the eye examination, when the pharmacologic effect of the mydriatic agents would have subsided.
45348328|NCT00830349|Drug|Risperidone|1 mg Tablets
45348329|NCT00746850|Procedure|early LC within 72 hours after the diagnosis with H (Harmonic)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with H (Harmonic scalpel)
45348330|NCT00746850|Procedure|early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with MD (Monopolar Diathermy)
45348331|NCT00830427|Drug|PF-00610355|100 mcg, QD, dry powder inhaler
45348332|NCT00830427|Drug|PF - 00610355|600 mcg, QD, dry powder inhaler
45348333|NCT00830427|Other|Placebo|QD, dry powder inhaler
45348334|NCT00830427|Drug|PF - 00610355|300 mcg, QD, dry powder inhaler
45685224|NCT03822598|Behavioral|Teaching Recovery Techniques, TRT|TRT is a , low-threshold, group based, manual driven short term intervention to reduce trauma-related mental health problems. The program is based on principles from trauma-focused cognitive-behavioral therapy
46044309|NCT02654392|Dietary Supplement|Polyunsaturated fatty acid|This groups will receive 4 capsules/70kg body mass (Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, & Pumpkin oils) every day for 5 weeks
46044310|NCT02654158|Drug|Low-dose of Fuganlin Oral Liquid|"less than 1 years old: 5mL each time and three times a day~1~3 years old: 10mL each time and three times a day~4~6 years old: 10mL each time and four times a day~7~12 years old: 10mL each time and five times a day"
46044311|NCT02654158|Drug|High-dose of Fuganlin Oral Liquid|"less than 1 years old: 10mL each time and three times a day~1~3 years old: 20mL each time and three times a day~4~6 years old: 20mL each time and four times a day~7~12 years old: 20mL each time and five times a day"
46044312|NCT02657122|Drug|TD-1473 for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
45348335|NCT02563158|Procedure|non-occlusion technique|Hepatectomy is carried out without hepatic inflow control. (non-occlusion technique)
45348336|NCT00841113|Drug|Abarelix|100 mg by Intramuscular injection on days; 1, 15 and 29 and monthly thereafter
45348337|NCT00841113|Drug|Goserelin plus Bicalutamide|Goserelin - 3.6 mg by monthly subcutaneous injection Biaclutamide 50 mg orally daily for first three months
45348338|NCT00741546|Procedure|Cardiac Surgery|Cardiac Surgery
45348339|NCT00830505|Drug|fluticasone/salmeterol|2 puffs twice a day for 2 weeks
45348340|NCT00830505|Drug|fluticasone|2 puffs twice a day for 2 weeks
45348341|NCT00566020|Drug|BW430C (lamotrigine)|lamotrigine 50mg/day-400mg/day
46044313|NCT02657122|Drug|Placebo for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
46044314|NCT02657122|Drug|TD-1473 for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
46044315|NCT02657122|Drug|Placebo for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
45348342|NCT02563782|Biological|Sub-retinal transplantation of MA09-hRPE cells|transplantation
45348343|NCT02563782|Drug|tacrolimus and mycophenolate mofetil|Immunosuppressive Agents
45348344|NCT02563782|Drug|Placebo tacrolimus and mycophenolate mofetil|placebo
45348345|NCT02563782|Procedure|Sham Surgery|Sham surgery
46044316|NCT04140604|Other|Lactobacillus salivarius AP-32|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
46044317|NCT04140604|Other|Bifidobacterium animalis subsp. lactis CP-9|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
46044318|NCT04140604|Other|Placebo|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
46044319|NCT00600028|Drug|Thalidomide|Thalidomide 50 - 100 mg by mouth daily
46044320|NCT00600028|Drug|Placebo|Placebo 50-100 mg by mouth per day
45348346|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 2.8 milligram per kilogram (mg/kg) will be administered as 1-hour intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) on Day 1, Day 28, Day 42 and Day 56
46044321|NCT02650102|Drug|Risperidone|a kind of antipsychotics
46044322|NCT02650102|Drug|Olanzapine|a kind of antipsychotics
45348347|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 5.5 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 42 and Day 56
45348348|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 11 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
45348349|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
45475846|NCT03736031|Behavioral|Intervention (Promotora)|If the patient is in the intervention group, the promotora will call the patient in order to invite them to a meeting. Meetings will be arranged by the promotora and the patients. A total of 2 group meetings will be required by all participants and 1 family meeting.
45475847|NCT04503304|Other|Exercises|already included in arm/group descriptions.
45348350|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days
45348351|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with ovarian cancer.
45475848|NCT03555565|Drug|Alogliptin and Metformin hydrochloride|Alogliptin and Metformin hydrochloride combination tablets
45475849|NCT01296659|Drug|ridaforolimus|Ridaforolimus administered orally 5 days per week in combination with standard chemotherapy
45596478|NCT02365155|Other|Occupational intervention|The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including occupational support.
46044323|NCT02650102|Drug|Quetiapine|a kind of antipsychotics
46044324|NCT02650102|Drug|Aripiprazole|a kind of antipsychotics
46044325|NCT02650102|Drug|Ziprasidone|a kind of antipsychotics
46044326|NCT02657044|Procedure|EMR|
46044327|NCT02657044|Procedure|ESD|
46044328|NCT00650182|Drug|fentanyl; naltrexone|
46044329|NCT02650180|Device|Soberlink Cellular Device|Alcohol Breath Analyzer
46044330|NCT02653924|Other|silk suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
46044331|NCT02653924|Other|vicryl suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
45348352|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with tumors harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations or pancreatic cancer, or non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck (H&N) cancer that were refractory or resistant to anti-epidermal growth factor receptor (EGFR) therapy
45348353|NCT00741624|Other|Bandage|one application for one week
45348354|NCT00830583|Procedure|blood test|There is only a blood test at the beginning.
45348355|NCT00746928|Other|Chronic Intermittent Hypoxia|Chronic Intermittent Hypoxia mimicking the CIH undergone by patients suffering from Sleep Apnea Syndrome, is applied to Healthy subject during 8 hours a day (nights) for a 14 days period. The cycle of intermittent Hypoxia is 30 drop in SaO2 per hours with a 10% decrease in SaO2.
45348356|NCT00843453|Other|blood collection|blood collection
45348357|NCT00843453|Drug|treatment (cyanocobalamin nasal spray)|cyanocobalamin nasal spray -- 500 mcg q week for eight weeks
46044332|NCT02653924|Other|nylon suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
46044333|NCT02653924|Other|polypropylene suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
46044334|NCT00650884|Device|Ankle Dorsiflexion Dynasplint System|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living.
46044335|NCT00910780|Drug|Aripiprazole|via oral tablets, everyday
46044336|NCT00910780|Drug|Zyprexa|via oral tablets, taken once daily
45348358|NCT00921726|Drug|Zanamivir|Continuous (800 mg in Regimen A, 3600 mg in Regimen C) and intermittent (3600 mg in Regimen D) infusion
45348359|NCT00921726|Drug|Oseltamivir|150 mg oral tablets taken five times over 3 days in Regimens A, B, C, and D
45348360|NCT00938236|Drug|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration
45348361|NCT02546739|Biological|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
46044337|NCT00910780|Drug|Risperdal|via oral tablets, taken once daily
46044338|NCT02649712|Device|biliary stent|Self-expandable biliary nitinol alloys stent
46044339|NCT02656888|Drug|Irlanda-1-Association|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
46044340|NCT02656888|Drug|Placebo|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
45348362|NCT00744198|Procedure|Autologous transobturator tape procedure|A strip of rectus fascia is harvested. Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of the autologous strip by means of reusable needles
45348363|NCT00744198|Procedure|Synthetic transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of synthetic mesh by means of mono-use needles.
45348364|NCT00744198|Procedure|Biological transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of biological mesh by means of mono-use needle
46044341|NCT02656966|Device|Auricular acupuncture|"Five ear acupuncture points: MA-IC, MA-TF1, MA-SC, MA-AT1 and MA-TG will be needled bilaterally in patients, who will wish to receive AA. Indwelling fixed New Pyonex needles (length: 1.5 mm, diameter: 0.22 mm; Seirin Corp., Shizuoka City, Japan) will be used for AA."
46044342|NCT02656810|Drug|Teriparatide|Single subcutaneous injection
46044343|NCT02536612|Other|Lottery|Opportunity for entry in lottery (each time, at months 3 and 6).
46044344|NCT02536612|Other|No Lottery|Transport compensation for study visits at baseline and at months 3 and 6. No chance to win lottery ticket.
46044345|NCT02653846|Procedure|RT-2D-SWE measurement|measurement of liver and spleen stiffness by ultrasound real-time 2D shear wave elastography (SWE™)
45348365|NCT00834951|Radiation|Low dose total body irradiation|Low dose total body irradiation is given 3 weeks after the end of chemo-immunetherapy in the form of 4 daily fractions 0.2 Gy per fraction to be repeated after 2 weeks of rest
45348366|NCT04013776|Dietary Supplement|Phosphate supplemented diet|Participants will be asked to follow a 5 day menu of 750 mg of phosphorus daily along with a daily sodium phosphorus supplement of 500 mg
45348367|NCT00741702|Other|Nurse administered treatment algorithm|Start with Irbesartan 150 mg/d; check BP in 6 wks, if BP >=130/80 mm HF, 300 mg/d irbesartan; check BP at next visit, if BP>= 130/80 mm Hg, add HCTZ 12.5 mg/d; check BP at next visit, if BP>=130/80 mm Hg, add verapamil 180 mg/d; check BP at next visit, if BP>=13/80 mm Hg, increase verapamil to 240 mg/d
45348368|NCT00841347|Behavioral|habitual sleep length period + extended sleep length period|On obese group, realisation of an habitual sleep length period followed by an extended sleep length period
45348369|NCT00841347|Behavioral|extended sleep length period + habitual sleep length period|On obese group, realisation of an extended sleep length period followed by an habitual sleep length period
45348370|NCT00936286|Device|SpiroTiger|Respiratory muscle training with SpiroTiger device, 1 week training initiation and 4 weeks training period with 5 training days per week, training duration 30 min each. Respiratory bag volume set at 50% VC, respiratory frequency starting from 50% MVV. Weekly control trainings.
45348371|NCT00741780|Drug|Placebo|
45348372|NCT00741780|Drug|plerixafor|
45348373|NCT00741780|Drug|granulocyte colony-stimulating factor (G-CSF)|
45348374|NCT00936442|Drug|Anastrozole|(Standard Treatment) 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
45348375|NCT00936442|Other|Educational materials|Reception of educational material on regular basis.
45348376|NCT00744354|Drug|bortezomib|Intravenous Push 1.3 mg/m2 Days 1, 4, 8, and 11
46044346|NCT02653846|Procedure|HVPG measurement|assessment of portal hypertension assessed by hepatic venous pressure gradient measurement
45348377|NCT00744354|Drug|pegylated liposomal doxorubicin hydrochloride|Intravenous infusion, 30mg/m2, Day 4, each cycle
46044347|NCT02649478|Drug|Fluticasone / Salmeterol|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura LOMI inhaler device
46044348|NCT02649478|Drug|Placebo|
46044349|NCT02649478|Drug|Advair Diskus 100/50|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
45596479|NCT02365155|Other|Heart failure follow up.|Both groups will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary medical intervention including and pharmacological treatment of heart failure and comorbidities adjusted according to recent clinical guidelines requirements.
46044350|NCT00650962|Other|cardiopulmonary resuscitation|10 cycles of 30:2 cardiopulmonary resuscitation before rhythm analysis by AED
45348378|NCT00744354|Drug|vorinostat|Oral, 300mg, Days 1, 2, 4, 5, 8, 9, 11, 12, every cycle.
45348379|NCT04043325|Diagnostic Test|Specific antibody-secreting cell (ASC) enzyme-linked immunspot (ELISpot) assay|Clinical samples (nasopharyngeal swabs and max. 5 ml blood) will be collected from patients enroled in the KIDS-STEP study (NCT03474991; children aged 1-10 years) at enrolment (day 1), at day 3, and at day 28.
45348380|NCT00936520|Drug|SAR 1118 0.1%|Daily eye drops (twice daily, ~50 microliter [uL] each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
45348381|NCT00936520|Drug|SAR 1118 1.0%|Daily eye drops (twice daily, ~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
45348382|NCT00936520|Drug|SAR 1118 5.0%|Daily eye drops (twice daily, ~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
45348383|NCT02564562|Drug|[14C] PF-06463922|Single oral dose of 100mg PF-06463922 + [14C] PF-06463922
46044351|NCT00650962|Other|Rhythm analysis|Rhythm analysis as soon as AED is ready
46044352|NCT02653612|Drug|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
45348384|NCT05311566|Combination Product|Camrelizumab plus Concurrent chemoradiotherapy|Participants will be given intravenous administration of Camrelizumab (200mg，every 2 weeks),Cisplatin(40mg/m²，everyweek) and Radiotherapy. After completing 6~8weeks of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until disease progression or unacceptable toxicity.
46044353|NCT04167592|Drug|Benzydamine Hydrochloride 0.15% Oral Rinse|Benzydamine Hydrochloride 0.15% Oral Rinse was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
45348385|NCT00564070|Behavioral|Enhanced treatment as usual plus adherence training|The single-session life-steps treatment targets informational, problem solving, and cognitive-behavioral steps that are geared toward improving medication adherence and diabetes self-management.
45348386|NCT00564070|Behavioral|Enhanced treatment as usual plus CBT-AD|The multiple-session CBT treatment is given after completion of the life-steps session. The CBT sessions focus on treatment of depressive symptoms as well as adherence to diabetes self-care.
45348387|NCT00835029|Drug|Clotrimazole varnish|Each patient will receive 14 syringes (with no needle, equivalent to 50 mg of Clotrimazole in each one) . The varnish will be applied on a dried denture at the inner side by means of a soft brush and left to dry for 60 sec for 14 days.
45348388|NCT00835029|Drug|Clotrimazole troches|The troche group will be asked to dissolve it in the mouth according to the manufacture instructions five times a day after removal of the denture, for 14 days.
45348389|NCT02562768|Drug|LY3154207|Administered orally
45348390|NCT02562768|Drug|Placebo|Administered orally
45348391|NCT00843609|Device|Navigator continuous glucose monitor (Freestyle Navigator®)|Continuous use of the Free Style Navigator for monitoring of glycemia in patients with type 1 diabetes with HbA1c below 7.5 %
45348392|NCT00744510|Other|Reflexology|10 weekly sessions of 45 minutes each
45348393|NCT00835107|Drug|ziprasidone hydrochloride|oral capsules, from 40-80 mg BID, for one month with the option to continue the medication after the study has been completed
45475850|NCT03122080|Device|Electroacupuncture(EA)|"Participants in EA group will receive electroacupuncture treatment. Acupuncture will be applied at Baihui (GV20), Shenting (GV24), Yintang (GV29), bilateral Anmian (EX-HN22), Shenmen (HT7), SanYinjiao (SP6) and Neiguan (PC6). After needle insertion, rotating or lifting-thrusting manipulation will be applied for Deqi sensation. The EA apparatus (CMNS6-1, Jianjian Medical Device CO., LTD, China) will be connected to the needles at GV20 and GV29 for 30 minutes and deliver a continuous wave. The frequency will be set at about 30 Hz and the amplitude will be less than 20V. Participants can regularly take the antidepressants or sedative-hypnotics as before during the intervention. Besides, the investigators will strengthen health education about insomnia and depression for the patients."
45348394|NCT00835107|Drug|placebo|placebo comparator, oral capsules, BID, for one month
45348395|NCT02562846|Other|Psychological testing and biological sample collection|For this study, there will be psychological tests, blood and hair sample collections, and part of the patients will undergo an MRI.
45348396|NCT00843765|Other|acupuncture, massage and basic TCM treatment|"During hospitalization:Patients accept TCM rehabilitation and basic treatment including WM basic treatment and Chinese medicine injection,decoction,herb soak treatment and health education.~After discharge from hospital: In the TCM group,add prescriptions according to two conditions:a. patients using A injection (one Chinese herb injection admitted by SFDA) will take A' capsule (one Chinese herb capsule admitted by SFDA) for 6 months;b.patients using B injection (ditto) will take B' capsule (ditto) for 6 months.Both of them will accept TCM health education.In the WM group, patients are suggested with targeted rehabilitation programs according to different causes."
45475851|NCT03122080|Device|Placebo acupuncture|Participants in the control A group will receive placebo acupuncture treatment with streitberger needles at the same acupoints as the electroacupuncture group. When the tip of the blunt needles touches to the skin, the patient will get a pricking sensation but there is no real needle inserted into the skin. The electroacupuncture apparatus will be set beside the patients, with no connection to the needles. Inform the patients when removing the needles after 30 minutes. Use the dry cotton ball to press the acupoints so that patients can feel the withdrawal of the 'needles'. Same health education and regular administration of antidepressants or sedative-hypnotics will be given to the participants during the intervention.
45475852|NCT03122080|Other|Standard care|Participants in the control B group will keep their standard medical care for the first 8 weeks. Participants will take their regular antidepressants and the sedative-hypnotics during the whole intervention period. Same health education will be conducted as well for the participants. And after waiting for two months, these patients will be treated with the same electroacupuncture treatment as the EA group.
46044354|NCT04167592|Drug|Water|Water was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
46044355|NCT02656732|Biological|amnion chorion allograft membrane|Biologic Amnion chorion allograft membrane derived from placenta of a donor pregnant subject.
46044356|NCT02656732|Procedure|coronally advanced flap with the subepithelial connective tissue graft|coronally advanced flap with the placement of subepithelial connective tissue graft harvested from the palate
46044357|NCT04168294|Drug|Propofol|patients in sedation group will be intravenous injected propofol in bolus
46044358|NCT04168294|Device|endoscopy|endoscopy system
46044359|NCT02653534|Behavioral|Kangaroo Mother Care|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
46044360|NCT02656576|Procedure|Tonsil Biopsy|Biopsies were obtained during endoscopy of Aero-Digestive Tract Superior under general anesthesia.
45348397|NCT00843765|Other|rehabilitation and WM basic treatment|"there two steps:~during hospitalization: patients accept modern rehabilitation and basic treatment of life supporting and medicine using and health education~After discharge: make rehabilitation plans for patients including management of anticoagulant drugs, blood pressure, blood lipid and blood glucose, health education, and some suggestions for resisting alcohol ,smoking and reasonable diet"
45475853|NCT05668403|Drug|B007|Drug: B007 injection Drug: Placebo injection
45475854|NCT05668403|Drug|B007|Drug: B007 injection Drug: Placebo injection
45348398|NCT00843921|Drug|N-carbamylglutamate|100 mg/kg/day or 2.2 g/M2/day in 3-4 divided doses for 3 days
45348399|NCT00690612|Drug|candesartan cilexetil|0.05, 0.2, 0.4 mg/kg, oral solution, single daily dose
45348400|NCT02546505|Other|Front-of-pack nutrition labeling|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods.
45348401|NCT02546505|Other|Consumer information|Information specifically targeting nutritional information and explaining the 5-CNL is presented to the subject (this information will consist in a concept shown to respondents before the shopping session).
45348402|NCT00841503|Other|buckwheat, rice crackers, glucose, sugar substitute|crackers contain equal amounts of available carbohydrates; 50 mls of oral solution for both glucose and Splenda
45475855|NCT05668403|Drug|B007|Drug: B007 injection Drug: Placebo injection
45475856|NCT03725683|Device|Increased caliber balloon|"Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI(ankle-brachial pressure index);Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events."
45475857|NCT03725683|Device|matched caliber balloon|"Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI index;Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events."
45596480|NCT02201303|Drug|Danirixin|Powdered form for in-vitro administration to blood sample
46044361|NCT02656576|Procedure|Smear|The smears are made in consultation a fortnight before performing endoscopic examination. They are carried out after a local anesthetic spray in order to optimize the number of cells collected.
46044362|NCT04167202|Procedure|Hydrogen-rich water|Hydrogen-rich water (one hydrotherapy every 4 hours)
46044363|NCT04167202|Procedure|RICE|RICE protocol
46044364|NCT02649244|Behavioral|The Family Caregiver Training Program|The intervention consisted of a two-hour PowerPoint® presentation throughout three modules (i.e., communication, eating/feeding, and nutrition; transferring and toileting; and dressing, bathing, and grooming). Each module was followed by a hands-on demonstration and practice session, including how to properly position and feed an adult, transfer from a seated position to another seated position, and a case study on modifications and assistance to provide during dressing and grooming.
46044365|NCT02653378|Behavioral|DIET|25% Energy Depletion by Diet only for 3 Days
45348403|NCT00742014|Drug|Sildenafil|One oral dose of Sildenafil (0.5 mg/kg) will be administered nia a nasogastric tube
45348404|NCT00742092|Drug|miglustat|Oral miglustat capsules 200 mg t.i.d. (three times a day) for 7 days and a single 200 mg dose on Day 8
45348405|NCT00742092|Drug|placebo|Oral placebo capsules matching in appearance miglustat capsules given t.i.d. (three times a day) for 7 days and a single dose on Day 8
45348406|NCT00841581|Drug|Ranibizumab|Ranibizumab 0.5 mgs. (0.05 mls.) intravitreally for 6 months then as needed prn for 6 months.
45348407|NCT00742248|Drug|Formoterol|pMDI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
45348408|NCT00742248|Drug|Formoterol|DPI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
45596481|NCT02201303|Other|CXCL1|Escalating concentrations of CXCL1 will be added to whole blood in vitro. A CXCL1/CD11b upregulation concentration response curve will determine the concentration to be used in Part 2.
45475858|NCT04502992|Behavioral|Acceptance and Committment Therapy|Acceptance and Commitment Therapy (ACT) is a mindfulness-based therapy that focuses on enabling individuals to accept what is out of their control, and to commit to valued actions that enrich their lives (Vowles & McCracken, 2008). By emphasizing acceptance instead of avoidance, ACT differs from many other forms of cognitive behavioral therapy. ACT has been shown to be efficacious in terms of clinical outcomes, adherence to treatment, and retention. ACT aims to increase psychological flexibility, and has been associated with improved health outcomes prior randomized controlled clinical trials, including three systematic reviews specific to CP. Psychological flexibility is defined as an individual's ability to recognize and adapt to various demands; shift mindsets or behavioral responses when these strategies compromise personal or social functioning; and maintain balance among important life domains.
45475859|NCT03725605|Combination Product|LTX-315 and TILs|Intratumoural injection of LTX-315 and infusion of TILs
45348409|NCT00742248|Drug|Placebo|Placebo pMDI/DPI 1 dose in the morning and 1 dose in the evening
45348410|NCT04249167|Drug|Atezolizumab|Given IV
45348411|NCT04249167|Procedure|Cryosurgery|Undergo cryoablation of the primary tumor
45348412|NCT04249167|Drug|Nab-paclitaxel|Given IV
45348413|NCT00621153|Drug|Candesartan Cilexetil|Candesartan Cilexetil 16 mg oral
45348414|NCT00621153|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg
45348415|NCT00621153|Drug|Candesartan Cilexetil|Candesartan Cilexetil 32 mg oral
45348416|NCT05447910|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
45348417|NCT05447910|Drug|Letrozole|Given PO
45475860|NCT01194635|Genetic|fluorescence in situ hybridization|
45475861|NCT01194635|Genetic|gene expression analysis|
45348418|NCT02546427|Radiation|Helical TomoTherapy (HT)|
45348419|NCT02546427|Radiation|CyberKnife SBRT|
45348420|NCT02546427|Radiation|Permanent Prostate Implant (PPI)|
45348421|NCT02546427|Radiation|HDR brachytherapy|
45475862|NCT01194635|Genetic|polymerase chain reaction|
46044366|NCT02653378|Behavioral|EX|25% Energy Depletion by Exercise only for 3 Days
45348422|NCT00747084|Procedure|Colonoscopy|The purpose of the study is to conduct an RCT study to determine the effectiveness of loading the sigmoid colon with warm water and warm water irrigation for dealing with colonic spasms in enhancing patient abdominal comfort during unsedated colonoscopy.
45348423|NCT00835419|Drug|P276-00|P276-00 -small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor
45348424|NCT00747162|Device|Measure of muscle oxygenation|The investigators will use an INVOS oxymeter for muscle oxygenation measure.
45348425|NCT00747162|Device|Skin pigmentation determination|The investigators will use a DermaSpectrometer to get a reading from subjects' skin color
45348426|NCT00574119|Drug|spironolactone|spironolactone 50 mg daily for 6 months
45348427|NCT00841737|Other|Psychoeducational group|The intervention group receive weekly a psychoeducational group during 12 weeks run by 2 nurses. The program have a structures contend.
45348428|NCT00841737|Other|Control Group|In the control group the depression is treated as usual with the conventional treatment.
45348429|NCT00705614|Biological|Remicade|The treating physician will determine the treatment regimen and dose of Remicade.
46044367|NCT04168138|Drug|rhTPO|D: Decitabine(15mg/m2) d1-5 G: G-CSF（300ug/d） d0-9(stop using when White Blood Cell (WBC)>20*109/L) T: rhTPO(15000U/d) d3,5,7,9, d11- (Platelet>50*109/L) A: Aclarubicin(10mg/d) d3-6 C: Cytarabine(15mg Q12h) d3-9
46044368|NCT04059562|Combination Product|Combination of Lonsurf® and Irinotecan|"Trifluridine/Tipiracil (Lonsurf®) and Irinotecan~Trifluridine/Tipiracil will be administered at a dose of 25 mg/m2 / dose twice daily on days 1-5 followed by a 9-days recovery period from day 6 trough day 14 of each 14-days treatment cycle.~Irinotecan will be administered at the same time as Trifluridine/Tipiracil (Lonsurf®) on day 1 of each cycle at a dose of 180 mg/m2 / dose."
46044369|NCT02653222|Procedure|Renal sympathicolysis|
45348430|NCT00844155|Drug|Oseltamivir 75 mg|The primary objective of this study is to demonstrate that the pharmacokinetics of oseltamivir, when given enterally to critically ill patients, in the standard treatment dose of 75 mg or double that dose, 150 mg, will yield a plasma concentration - versus - Time Area under the curve (AUC) similar to that observed in adults with influenza treated successfully with a dose of 75 mg, that the disposition characteristics are dose proportionate and are not altered by the concomitant administration of enteral feedings.
45348431|NCT00835653|Procedure|median nerve block|median nerve block performed under echographic guidance
45348432|NCT00835653|Procedure|median nerve block|median nerve block performed under echographic guidance
45348433|NCT00620763|Other|High Meat - High Potential Renal Acid Load (PRAL) diet|Menu high in meat protein
46044370|NCT02653222|Procedure|Ambulatory Blood Pressure Monitoring|1 month before and after surgery the patient will have an ABPM over 24h
45348434|NCT00620763|Other|Low Protein - Low Potential Renal Acid Load (PRAL) diet|Menu low in meat protein
45348435|NCT05669924|Drug|Methylphenidate|0.35 mg/kg methylphenidate will be administered after baseline testing and 45 min-1 hr before post-intervention testing.
45348436|NCT05669924|Drug|Placebo|Placebo for methylphenidate
45348437|NCT00844233|Device|Irinotecan Bead|Irinotecan eluting bead
45348438|NCT00841893|Dietary Supplement|Mustard (dijon)|The specific spice added to a brunch meal
45348439|NCT00841893|Dietary Supplement|Placebo|Placebo added to a brunch meal
45475863|NCT01194635|Genetic|protein analysis|
45475864|NCT01194635|Genetic|protein expression analysis|
45348440|NCT05245682|Drug|Tolinapant|Given PO
45348441|NCT05245682|Radiation|Radiation Therapy|Undergo radiation therapy
45348442|NCT00844311|Drug|rFSH|150 iu/day of rFSH
46044371|NCT02653222|Radiation|Magnetic Resonance Angiography|1 month before and after surgery the patient will have a MRA
46044372|NCT02653222|Biological|Blood test|complete blood count, blood platelets, coagulation profile, irregular agglutinins search
46044373|NCT02656498|Drug|[18F]THK-5351|Imaging for evaluating the accumulation of abnormal tau protein in the brain
45348443|NCT00844311|Drug|human chorionic gonadotropin|50 iu/day of hCG from stimulation day 1
45348444|NCT00844311|Drug|human chorionic gonadotropin|100 iu/day of hCG from stimulation day 1
45348445|NCT00844311|Drug|human chorionic gonadotropin|150 iu/day of hCG from stimulation day 1
45348446|NCT00840801|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive three vaccinations with FSME-IMMUN 0.25ml Junior on days 0, 28 and 360
45348447|NCT00840801|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive two vaccinations with Encepur 0.25ml Children on days 0 and 28 and a third vaccination with FSME-IMMUN 0.25ml Junior on day 360.
45348448|NCT02547597|Drug|Carvedilol|
45348449|NCT02547597|Drug|Atenolol|
45348450|NCT00844389|Device|Near to infrared light retinal stimulation|Patients will be stimulated with 660 nm light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
45348451|NCT00844389|Device|Green light stimulation|Patients will be stimulated with 530 nm LED light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
45348452|NCT02567474|Behavioral|5 A model|self management program based on 5A model
45348453|NCT00835887|Dietary Supplement|low and high dose flavanoids|treatment with flavanoid-rich or flavanoid-low cacao twice daily
45348454|NCT00738218|Other|Multidetector Computed Tomography - 64 detectors|Multidetector computed tomography angiography
45475865|NCT01194635|Other|enzyme-linked immunosorbent assay|
45475866|NCT01194635|Other|immunohistochemistry staining method|
45475867|NCT01194635|Other|laboratory biomarker analysis|
45596482|NCT05724745|Diagnostic Test|1. Standard spirometry|Spirometry is performed in two positions (sitting and supine) and three types of breathing (spontaneous, forced and slow).
46044374|NCT02656654|Other|Whole-body compression|
46044375|NCT02653066|Other|HealtheRx+|Participant receives $5 bill with incentive check and blank consent form
46044376|NCT02653066|Other|HealtheRx++|Participant receives $5 bill when they returned signed PRR consent form.
46044377|NCT00649870|Drug|Valacyclovir Hydrochloride Tablets 1000 mg|1000mg, single dose fed
45348455|NCT00842049|Device|Lumbar Drain (Medtronic lumbar drainage system)|Insertion of lumbar drain to drain cerebrospinal fluid
45348456|NCT00842049|Other|No lumbar drain|No lumbar drain
45348457|NCT05220878|Biological|GNR-069|Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.
45348458|NCT05220878|Biological|Nplate|Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.
45348459|NCT00844467|Biological|serotypes and resistance|screening patients with invasive pneumococci
45348460|NCT00842127|Drug|OROS-methylphenidate (Concerta)|dose: 18mg, 27mg, 36mg, 45mg, 54mg/day, po duration: 8 weeks
45348461|NCT04062500|Other|Mortality and Rehospitalization rate|Mortality and Re-hospitalization of acute decompensated heart failure
45348462|NCT00835965|Drug|Dexamethasone|Dexamethasone 5 mg administered intravenously following endotracheal intubation
45348463|NCT00835965|Drug|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
45348464|NCT00835965|Drug|Placebo Dexamethasone|
45348465|NCT02567786|Procedure|Surgery with CPB|
45348466|NCT02567786|Other|Fresh Frozen Plasma|
45348467|NCT02567786|Other|Plasmalyte|
45348468|NCT00844623|Genetic|TK99UN|escalated dosis from 2x10e10 to 2x10e12 viral particles injected intratumorally
45348469|NCT05667740|Biological|Gamma-PN3|Inactivated whole-cell pneumococcal vaccine
45348470|NCT05667740|Biological|Prevenar-13|Licensed polysaccharide conjugate pneumococcal vaccine
45348471|NCT05667740|Biological|Pneumovax-23|Licensed polysaccharide pneumococcal vaccine
45348472|NCT05667740|Drug|Placebo|Saline
45685225|NCT03792880|Behavioral|Telematic control and self-management program|"During 6 months with CPAP treatment, patients must complete some questionnaires about the presence of refreshing sleep and side effects with the frequency established, using a computing application. Patients can download this application on their own smartphone but, if they prefer, they can be provided with a tablet during the study with this application installed.~A set of variables will be collected using an automatic and wireless transmission from latest generation CPAP to control the CPAP compliance and tolerance. All data will be processed in a platform to generate alarms, which will be controled daily by a researcher, as well as solutions to the problems presented during the monitoring."
46044378|NCT00649870|Drug|Valtrex® Tablets 1000 mg|1000mg, single dose fed
45348473|NCT00842205|Drug|pegylated interferon|peg-IFN alfa 2a 180ug s.c. QW or peg-IFN alfa 2b 1.5 ug/kg s.c. QW
45348474|NCT00842205|Drug|Ribavarin|ribavirin 1000-1200mg p.o. daily 48weeks or ribavirin 100-1200mg p.o. daily 48 weeks
46044379|NCT02536144|Procedure|magnetic-controlled capsule endoscopy system|"A magnetic-controlled capsule endoscopy(MCCE) included camera,magnet,batter and high polymer material shell.~The MCCE would be turned to sleeping mode capturing picture at a rate of 0.5 frame per second after being swallowed.~While reaching cecum, the MCCE would be turned to a working mode capturing picture at a rate of 2 frame per second.~The MCCE would be controlled by the Magnetic-manipulator out of body to finish the motion of e rotation, somersault, Bird's-eye view, worm's eye view from cecum to anus."
45348475|NCT00738296|Drug|ezetimibe (+) simvastatin|Patients will receive the combination of ezetimibe/simvastatin 10/20 mg o.d. with the possibility to increase the dose to 10/40 mg o.d. for 1 year. Tablets
45348476|NCT00738296|Drug|simvastatin|Patients will receive 40mg od. With the possibility to escalate the dose to 80 mg o.d. if therapeutic goals not attained; for 1 year. Tablets
45348477|NCT00738296|Drug|pravastatin|Patients will receive pravastatin 40 mg o.d. with the possibility to add up 10mg of ezetimibe daily if LDL-C goal is not achieved; for 1 year. Tablets
45348478|NCT05216354|Drug|Fruquintinib|Fruquintinib will be administered as a single dose on the morning of Day 1 under fasting conditions
45348479|NCT00836043|Drug|Alemtuzumab (MabCampath)|Intravenous therapy according to product information.
45348480|NCT02567396|Other|Laboratory Biomarker Analysis|Correlative studies
45348481|NCT02567396|Other|Pharmacological Study|Correlative studies
45348482|NCT02567396|Drug|Talazoparib|Given PO
45348483|NCT02547831|Other|Observational approach|Patients will be placed under wait and see approach without any specific treatment
45348484|NCT00738452|Other|high performance liquid chromatography|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
45348485|NCT00738452|Other|pharmacological study|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
45348486|NCT00738452|Procedure|radionuclide imaging|Approximately 1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post infusion.
45348487|NCT00738452|Procedure|single photon emission computed tomography|Approximately 2 days and 3-5 days post infusion
45348488|NCT00738452|Radiation|radiation therapy|3-6 mCi Indium-111 labeled cT84.66(5mg) and dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
45348489|NCT00738452|Radiation|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
45348490|NCT00836121|Procedure|right thoracotomy|complete surgical resection
45348491|NCT05667428|Drug|leuprorelin|From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of leprorelin in each cycle of chemotherapy including the conditioning treatment prior to transplantation.
45348492|NCT05667428|Drug|normal saline|From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of normal saline in each cycle of chemotherapy including the conditioning treatment prior to transplantation.
45348493|NCT00844779|Procedure|Bariatric surgery|Gastric bypass.
45348494|NCT00844779|Procedure|cholecystectomy or benign liver tumor removal|cholecystectomy or benign liver tumor removal
46044380|NCT02536144|Procedure|Colonoscopy|"Bowel preparation should be well done before the examination.~A tube with illumination and camera system would insert into colon from anus.~From the pictures captured by the camera ,the doctor would see the mucous of the colon."
45348495|NCT05664542|Other|ESPB (regional Block)|ESPB is regional block in which we will use 0.2 % ropivacaine and dexmedetomidine
45348496|NCT05664542|Drug|ropivacaine and dexmedetomidine|0.2 % ropivacaine and dexmedetomidine
46044381|NCT04167280|Drug|Ipratropium Metered Dose Inhaler|MDI to deliver 20mcg per puff ipratropium bromide
46044382|NCT04167280|Drug|placebo metered dose inhaler|matched MDI to deliver inactive drug
45685226|NCT03792880|Behavioral|Habitual follow-up in Healthcare System|According to the SEPAR regulation, patients treated with CPAP should be evaluated by the pulmonologist one month after beginning treatment, every 3 months during the first year, every 6 months during the second year and annually from the third year.
46044383|NCT02652910|Drug|CD19.CAR-T cells|Retroviral vector-transduced autologous T cells to express CD19-specific CARs
45348500|NCT00562978|Biological|filgrastim|
45348501|NCT00562978|Drug|cyclophosphamide|
45348502|NCT00562978|Drug|etoposide|
46044384|NCT04167046|Procedure|Erector spinae block|Preoperative erector spinae block.
45685227|NCT03774160|Behavioral|Generacion Actual|See description in arm description.
46044385|NCT02652832|Device|non invasive brain stimulation|non invasive brain stimulation
46044386|NCT02652988|Other|Active-tDCS|Active home-based tDCS applied at home.
46044387|NCT02652988|Other|Sham-tDCS|Sham home-based tDCS applied at home.
46044388|NCT04166968|Device|Anodal transcranial direct current stimulation (A-tDCS)|Anodal tDCS will be performed for 20 minutes over the affected hemisphere with an intensity set to 2 mA
45348503|NCT00562978|Procedure|AHSCT|
45348504|NCT00562978|Radiation|yttrium Y 90 ibritumomab tiuxetan|
45348505|NCT00921206|Biological|VAX102|1 ug i.m. compared to 2 ug s.c.
45348506|NCT00842439|Behavioral|CBI|Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.
45348507|NCT00842439|Dietary Supplement|NUT|Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.
45348508|NCT00940264|Procedure|transvaginal hybrid cholecystectomy|transvaginal hybrid cholecystectomy: using one trans-umbilical 5mm trocar and 2 (one 12mm trocar, one 5-mm trocar)inserted through the posterior colpotomy. Removal of the gallbladder through the transvaginal access.
45348509|NCT04013230|Behavioral|Usual care|Visit doctor and nurse at the clinic.
45348510|NCT04013230|Behavioral|Web-COP|Usual care plus group sessions and a web-based treatment program for 12 weeks for the child and parents.
45348511|NCT00842595|Drug|rituximab|6 courses every 28 days
45348512|NCT00842595|Drug|vinorelbine|6 courses every 28 days
45348513|NCT00842595|Drug|ifosfamide|6 courses every 28 days
45685228|NCT03822286|Other|e-training course|Home care staff received mainly self-study, you can download e-books on your lithography or personal mobile phone reading and learning, with lively animation, sound and video guide home staff Learn the knowledge of demented care. The e-book course sets out the themes of the eight demented care training courses.
45348514|NCT00842595|Drug|Mitoxantrone|6 courses every 28 days
45348515|NCT00842595|Drug|Prednisone|6 courses every 28 days
45348516|NCT04013698|Other|PEEP level 5 cmH2O|PEEP level set for 45 minutes
45348517|NCT04013698|Other|PEEP level 15 cmH2O|PEEP level set for 45 minutes
45348518|NCT00845091|Behavioral|Exercise|moderate-intensity, low-impact, supervised, aerobic exercise
45348519|NCT00845091|Behavioral|Heart Healthy Education|Educational topics related to heart health (e.g., nutrition, smoking, sleep)
45348520|NCT00938626|Biological|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|After completion of induction or salvage chemotherapy, patients receive immunotherapy comprising anti-CD3 x anti-CD20-armed ATC IV weekly for 2 weeks.
45348521|NCT00938626|Procedure|autologous hematopoietic stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
45348522|NCT00938626|Procedure|peripheral blood stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation.
45348523|NCT05193344|Device|A digital care solution for patients with Heart Failure|A digital solution that provides remote symptom monitoring and support of lifestyle-changes by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.
45348524|NCT05193344|Other|Standard of Care for patients with Heart Failure|The best medical therapy including start or optimization of secondary preventive pharmacotherapy, and advise on modifiable risk factors. The participants in the control arm will also receive an information leaflet about relevant lifestyle modifications for HF.
45348525|NCT00842673|Drug|ST101|30 mg; administered once/day
45348526|NCT00842673|Drug|ST101|90 mg; administered once/day
45348527|NCT00842673|Drug|ST101|180 mg; administered once/day
45348528|NCT00842673|Drug|Placebo|placebo to match ST101 tablets
45348529|NCT04013308|Procedure|Iontophoresis with 2% potassium iodide|10 iontophoresis treatments with 2% potassium iodide on the area of thyroid gland; electrodes with tin foil (Amperage:2mA, duration: 30min)
45685229|NCT03822286|Other|Support group|A counseling master mix 8~10 resident staff members, through the counselor to lead the symposium to the case home to implement technical guidance and through the set of social network groups to immediately discuss the care and solutions of dementia cases, and hold once a month in gathering, about 40~60 minutes each time.
46044389|NCT04166968|Device|Cathodal transcranial direct current stimulation (C-tDCS)|Cathodal tDCS will be performed for 20 minutes over the unaffected hemisphere with an intensity set to 2 mA
46044390|NCT04166968|Device|Sham stimulation (sham-tDCS)|placebo stimulation
46044391|NCT04166968|Behavioral|Neuromotor training|conventional neuromotor treatment
46044392|NCT02648854|Drug|CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T|administered CKD-395 0.5/1000mg 1T to oral (fasting condition)
46044393|NCT02648854|Drug|CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T|administered CKD-395 0.5/1000mg 1T to oral (High fat meal fed condition)
45348530|NCT00836199|Biological|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
45348531|NCT00836199|Biological|Placebo vaccine|Placebo vaccine given 6 times over 6 months
45348532|NCT05280262|Diagnostic Test|CogState Test|Computerized cognitive testing which provides a score/measurement of distinct cognitive functions
45348533|NCT04062188|Other|Telephone Interview Form|Telephone Interview Form is an original simple questionnaire developed based on the combination of Barthel Index questionnaire and simplified modified Rankin Scale questionnaire with internal rules.
45348534|NCT04013386|Drug|Aprepitant and Dexamethasone|Aprepitant capsule 80 mg and Dexamethasone 8 mg IVI
45348535|NCT04013386|Drug|Mirtazapine and Dexamethasone|Mirtazapine tablet 30 mg and Dexamethasone 8 mg IVI
45348536|NCT04013386|Drug|Dexamethasone|Dexamethasone 8 mg IVI
45348537|NCT02567084|Device|"CERAMENT™ |BONE VOID FILLER"|Implantation of bi-phasic ceramic bone substitute to provide bone generation and bone remodeling in patients with benign bone tumors.
45475868|NCT05584384|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a non-invasive neuromodulatory method utilizing weak electrical currents to elicit short and long-term central nervous system changes.
45475869|NCT05584384|Device|Sham Transcranial Direct Current Stimulation|The sham was administered using the same tDCS devices as in the active group with a preprogrammed sham protocol of 20 minutes to be virtually indistinguishable from the active stimulation.
45348538|NCT00940420|Drug|Copegus (ribavirin)|800 - 1200 mg po daily for 24 weeks
45348539|NCT00940420|Drug|Copegus (ribavirin)|800 - 1200 mg po daily for 48 weeks
45348540|NCT00940420|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 24 weeks
45348541|NCT00940420|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 48 weeks
45348542|NCT00845169|Procedure|Forearm vascular study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of nitric oxide synthase inhibitors L-NMMA (2-8 µg/min), S-methionyl-L-citrulline (25-200 nmol/min) and 1400W (100-1000 nmol/min) and positive control norepinephrine (60-540 pmol/min)
45348543|NCT00842907|Drug|oral isotretinoin|one 20.0 mg capsule, once a day, every other day, during 24 weeks
45348544|NCT00842907|Drug|Tretinoin|0.05% tretinoin cream applied on face and forearms, once a day, in the night, during 24 weeks
45348545|NCT05181488|Radiation|intraoperative radiotherapy, IORT|A dose of 10 Gy is prescribed to be irradiated at a depth of 5 mm from the surface of the applicator, and the radiation oncologist determines the exact irradiation time. The irradiation time may take 20 to 60 minutes depending on the size of the applicator, and the exact irradiation time is calculated after checking the quality assurance of the radiation generator before treatment every day.
45348546|NCT05180396|Other|Questionnaires|Application of a study based questionnaire described in the protocol
45475870|NCT04313361|Other|No intervention|No drug will be administered as part of this study.
45596483|NCT05724745|Diagnostic Test|2. 3D dynamic lung MRI at UTE in prone and supine positions|Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine before a reversibility test with salbutamol.
45348547|NCT04013074|Procedure|Transjugular Intrahepatic Portosystemic Shunt|Transjugular Intrahepatic Portosystemic Shunt
45348548|NCT04013074|Other|Standard Medical Treatment|Standard Medical Therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
45348549|NCT00620373|Device|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
45348550|NCT00620373|Device|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
45596484|NCT05724745|Drug|3. Reversibility test with salbutamol|Reversibility test with salbutamol administered using a pressurized metered dose bottle and an inhalation chamber at a dosage of 100 μg, 4 times (i.e., 400 μg in total).
45348551|NCT00620373|Drug|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
45348552|NCT02567318|Device|MRI-scan|Magnetic resonance imaging scan of the brain
45348553|NCT03360292|Other|Higher target range|Intervention is using a higher oxygen saturation target range than in routine practice
45348554|NCT00940654|Other|Antipyretic therapy|External cooling;Internal cooling;Non steroid anti inflammatory drugs; Acetaminophen; Steroid
45685230|NCT03822286|Other|traditional classroom teaching course programs|Home care staff received the traditional demented care traditional classroom teaching course and did not accept any e-training and gathering.
45841201|NCT05385042|Dietary Supplement|Sangobion, Thiamine hydrochloride and Vitamin B12|"Treatment dietary supplements: 3 capsules of Sangobion + separate Thiamine Hydrochloride tablet 100mg, Vit B12 100mcg per day for 12 weeks.~If experience a therapeutic increase of 3% Haematocrit within 28 days (responders), they will continue with prophylactic nutritional supplements until delivery.~If no affect in Haematocrit level within 28 days (non-responders; defined by trimester of diagnosis), they will be investigated for their serum ferritin and if this is low (<15ng/mL) intravenous (iv) iron supplement (Venofer®) will be provided. The dose will be calculated for the individual concerned (required iron dose (mg) = (2.4 x (target Hb of 11g/dL (Ht 33%) x pre-pregnancy weight (kg) +1000mg for replenishment of stores). Doses will be administered by slow iv infusion 200 mg per dose (maximum of 3 doses per week).~Following treatment they will continue with prophylactic nutritional supplements."
45841202|NCT05376930|Drug|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
45841203|NCT05306028|Drug|Metformin or insulin treatment|"For patients with new-onset diabetes Fasting blood glucose 7-10 mmol/L, metformin 2 g/day, BID, PO; Fasting blood glucose 10-14 mmol/L, metformin 1 g/day, BID, PO, Novolin 30R Penfil 12 U before breakfast, 8 U; Fasting blood glucose > 14 mmol/L, metformin 1 g/day, BID, PO, Novolin 30R Penfil 16 U before breakfast, 10 U; Adjusting insulin dosage according to the monitor of fasting blood glucose.~For patients with history of diabetes Adjusting metformin or insulin dosage according to the monitor of fasting blood glucose."
45841204|NCT05302596|Drug|Semaglutide Pen Injector|semaglutide (up to 1mg) once weekly injection added to the standard of care weight loss program. Semaglutide dose will be started at 0.25 mg dose during the baseline visit and doubled every 2 weeks up to 1mg dose or up to maximum tolerable dose for total of 16 weeks of intervention
46044394|NCT02649010|Device|Enlite 3 Sensor|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the arm and used with the 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 12 months.
46044395|NCT03978520|Drug|Elsubrutinib|Capsule; Oral
46044396|NCT03978520|Drug|Placebo for Elsubrutinib|Capsule; Oral
46044397|NCT03978520|Drug|Upadacitinib|Tablet; Oral
45348555|NCT00845247|Other|Nurse case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
45348556|NCT05081882|Drug|Kava|Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 28 days.
45596485|NCT05724745|Diagnostic Test|4. 3D dynamic lung MRI at UTE in supine and prone position|Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine after the bronchodilatator's administration.
46044398|NCT03978520|Drug|Placebo for upadacitinib|Tablet; Oral
46044399|NCT02649088|Device|Microscan|It allows to look at sublingual microcirculation
46044400|NCT02649088|Device|NIRS from Hutchinson|It allows to monitor tissue oxygen saturation
46044401|NCT04281160|Device|BeCare Mobile App|The BeCare App is a mobile application that will perform routine assessments of neurological function in individuals with MS and address the most relevant domains that are affected in MS: cognition, afferent visual functioning, motor functioning, fine motor functioning, coordination, gait, and endurance
46044402|NCT02652598|Drug|Tolcapone|
46044403|NCT02648776|Drug|Exposure to sedative-hypnotic drugs|These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.
46044404|NCT02648464|Drug|Hydroxychloroquine|
45348557|NCT05081882|Drug|Placebo|Participants on this arm will take one placebo capsule orally three times daily for 28 days.
45348558|NCT00845325|Behavioral|Group One|They will begin exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work.
45348559|NCT00845325|Behavioral|Control Group Two|The patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
45685231|NCT03820180|Drug|Test Product|2 inhalations of Test and Reference product in each study period
45685232|NCT03820180|Drug|Reference Product|2 inhalations of Test and Reference product in each study period
45685233|NCT01894243|Drug|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
45685234|NCT03822832|Drug|BI 655130|Solution for infusion
46044405|NCT02648464|Drug|Placebo|
46044406|NCT02648542|Other|Compensatory auditory stimulation|Compensating for peripheral hearing loss by adjusting sound levels based on individual audiogram.
45348560|NCT00940732|Other|Destigmatisation and Mental Health Literacy|"Written material delivered over 2 weeks via the Internet, including mythbusters, debunking common myths around anxiety and depression, as well information about a range of celebrities who have identified themselves as having depression or anxiety. Also contains mental health literacy information."
45475871|NCT01190735|Drug|Caffeine alkaloid|"The following intervention will be provided for six consecutive weeks:~Week 1 (100 mg BID), Week 2 (200 mg BID), Week 3 (300 mg BID), Week 4 (400 mg BID), Week 5 and 6(500 mg BID). At the conclusion of the study, patients will decrease their dose by 100 mg BID every other day, until caffeine is stopped. This gradual reduction will be to prevent withdrawal symptoms. If a patient experiences a dose-limiting event, they will be terminated from the study, and will withdraw from the medication in the same manner. If dose-limiting events occur between visits, patients will be encouraged to decrease the caffeine dose back to the previously-tolerated dose until in-person assessment can be performed."
45475872|NCT01296893|Behavioral|Exercise|150 minutes/week of aerobic exercise at 60-70% of heart rate reserve (individualized based on baseline VO2 peak test). The intervention is 24 weeks with an exercise progression to reach the full exercise prescription by week 8. Participants are required to attend two 45 minute supervised sessions per week and complete two additional 30 minute sessions independently at home.
45475873|NCT05097118|Drug|Ketamine Versus Bupivacaine|Drugs Ketamine versus Bupivacaine
45841205|NCT05246202|Behavioral|Alcohol-Anxiety Personalized Feedback Intervention 2.0|AA-PFI 2.0 is a culturally adapted, brief, computer-delivered, personalized feedback intervention to address alcohol misuse in the context of clinical anxiety.
45841206|NCT05246202|Behavioral|Control Personalized Feedback Intervention|C-PFI is a brief, computer-delivered, personalized feedback intervention on exercise and nutrition.
45348561|NCT00940732|Other|Help-seeking list|List of sources for mental health help-seeking delivered over 2 weeks.
45841207|NCT05244798|Drug|Sintilimab|Sintilimab: D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W)
45348562|NCT00940732|Other|Feedback|Written material delivered over 2 weeks via the Internet, including two short self-report measures (Goldberg Anxiety, Goldberg Depression), which will provide feedback to the participant about levels of depression and anxiety.
45348563|NCT02567006|Behavioral|SMS message|SMS messages will be delivered at 6, 4, and 2 days before the next scheduled date of the primary vaccines for the intervention group
45841208|NCT05244798|Radiation|radiotherapy|Radiotherapy: According to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week.
45348564|NCT02567006|Other|Usual care|Health clinic nurse provides regular appointment in the vaccination card with no active reminders
45475874|NCT03847103|Other|Robotic-assisted Therapy with Bilateral Practice|40-minute robotic-assisted therapy with bilateral practice program for wrist and forearm repetitive movement training was performed during each session.
45841209|NCT05244798|Drug|Chemotherapy|Neoadjuvant chemotherapy with TP regimen: albumin-paclitaxel + carboplatin, D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W).
45841210|NCT05193708|Device|Windowed Bonding|A 3D printed tray/guide with open window for the orthodontic brackets
45841211|NCT05193708|Device|Digital Indirect bonding tray|Vacuum formed on a 3d printer cast with brackets
45475875|NCT03847103|Other|Unilateral Task-specific Training|40 -minute unilateral task-specific training using various tasks: picks up beans with spoon, pouring water from one glass to another glass, opening and closing a drawer, drinking from a mug, and wiping the table were chosen for facilitating multitude of upper extremity functions. Three tasks per session were chosen for various specific components of hand-arm function training.
45475876|NCT03847103|Other|Sensorimotor Stimulation Program|10-minute sensorimotor stimulation program with repetitive range of motion exercises of upper extremity, proprioceptive neuromuscular facilitation and Rood approach
45475877|NCT03602053|Biological|ROTAVAC®|0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
45475878|NCT03602053|Biological|ROTAVAC 5D|0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
45475879|NCT03602053|Biological|Rotarix®|1.5 ml of the liquid vaccine will be administered orally twice at 6 and 10 weeks of age.
45841212|NCT05179668|Drug|Dapagliflozin 10 MG|administered orally once daily
45841213|NCT05179668|Drug|Placebo|administered orally once daily
45841214|NCT05163912|Behavioral|Virtual home intervention|Group classes with active videogames and discussions
45348565|NCT00843063|Drug|pantoprazole vs famotidine|pantoprazole 20 mg om and matching placebo nocte vs. famotidine 40 mg om and nocte
45348566|NCT04013464|Drug|Escitalopram|Escitalopram 10-20mg/d
45348567|NCT04043247|Device|TEAS|Bilateral Neiguan and Zusanli acupuncture points, 2/10Hz Dense wave , 6-9mA,30min
45348568|NCT04043247|Device|TEAS without electrical stimulation|Bilateral Neiguan and Zusanli acupuncture points, with no electrical stimulation
45348569|NCT04012918|Drug|Capecitabine plus aromatase inhibitor|Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.
46044407|NCT02648542|Device|transcranial direct current stimulation|Low-current electrical brain stimulation
46044408|NCT02648542|Other|Combined CAS and tDCS|Combined auditory and electrical stimulation
46044409|NCT02648542|Other|Sham stimulation|Sham stimulation
46044410|NCT02652754|Drug|Granexin® gel|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
45475880|NCT03351634|Device|Implantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck|The ACT system is a permanent implant designed for the correction of incontinence in patients.
45475881|NCT01194713|Behavioral|Sleep deprivation|subjects will undergo one night of full sleep deprivation
45475882|NCT05584306|Drug|610 30mg group|610 30mg subcutaneous (SC) Q4W，8 times
45841215|NCT05141214|Behavioral|Virtual Reality Application|In VR application, Chaos Café, patients are immersed into a computer-generated kitchen environment. A humorous robotic chef serves children different food groups. Gameplay is advanced by choosing healthy foods, while eating unhealthy foods does not advance the application.
45841216|NCT05088564|Procedure|Hand-sewn|Doudenojejunal anastomosis by hand-sewn method
45841217|NCT05088564|Procedure|Hemi-double stapling|"Doudenojejunal anastomosis by hemi-double-stapling method EEA25 - Covidien EEA Circular Stapler DST Series 25.0mm x 4.8mm is used for anastomosis"
45841218|NCT05084742|Device|Biodentine™|"Biodentine™ is a bioactive dentin substitute from the  Active Biosilicate Technology®  innovation.~Study participants were treated from 1 year to 5,5 years ago through an endodontic microsurgery using Biodentine™ used in its endodontic indications, i.e., root end-filling, external or internal root resorption repair, root and furcation perforation repair, apexification, and revitalization procedure by means of revascularization."
45841219|NCT05048628|Other|Comparıson|"Only evaluation will be made at 0, 4, 6, and 8 hours after surgery without intervention in the control group.~For other groups; Evaluation will be made at the 0th hour after the operation without application. The application will be made at the 4th, 6th, and 8th hours after the surgery and the resulting pain and hoarseness will be evaluated."
46044411|NCT02652520|Procedure|HEMO2Life® use in organ preservation solution|The surgeon decides whether the local transplant kidney may be part of the study and whether it should be stored in static cold storage or machine perfusion. The transplant kidney will be perfused in situ before procurement with the Belzer UW® cold storage solution furnish by the BridgetoLife company. HEMO2Life® will then be added to preservation solution.
45841220|NCT04959396|Device|IUB SEAD|The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB
45348570|NCT04012918|Drug|A.I.|aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor
45348571|NCT04062578|Behavioral|Physiotherapy program of lumbopelvic stabilization and strengthening of the hip region musculature|The intervention program will begin in August, along with the 2019/2020 season, and will finish at the end of the first round (5-6 months). It will be applied to CD Oliver players in three weekly sessions: preventive force, compensatory force and physiotherapy attention. During this intervention period, the SD Huesca players, control group, continued with their usual training program. They will not implement any physiotherapy program like the designed one for the study.
45475883|NCT05584306|Drug|610 100mg group|610 100mg subcutaneous (SC) Q4W，8 times
45475884|NCT05584306|Drug|610 300mg group|610 300mg subcutaneous (SC) Q4W，8 times
45685235|NCT03822832|Drug|Placebo|Solution for infusion
45685236|NCT04758364|Other|measurement of gait speed|Cross sectional, cohort
45841221|NCT04910724|Other|Energy Deficit|A combination of individualized exercise performed on a cycle ergometer and individualized dietary prescriptions will be used to achieve energy balance or the assigned energy deficits throughout the controlled feeding and testing periods
45841222|NCT04799418|Device|Open Label Extension Study|This study will investigate the safety and efficacy of extended treatments for the management of symptoms related to PD.
46044412|NCT02645110|Device|MC Hand Soap|Washing hand with soap in comparison to hand washing with water alone
46044413|NCT02645110|Device|Tap water|Washing hand with water alone in comparison to hand washing with soap
45348572|NCT05131490|Behavioral|A mobile application intervention developed for gynecological cancer patients receiving chemotherapy|"The mobile application will consist of modules. It is planned to include four education modules and consultancy modules in the application.~Module 1: It will consist of sub-categories with information to be prepared in line with the current literature on gynecological cancer types and treatments applied. There will be information and short videos that will strengthen coping with physical symptoms, especially from chemotherapy.~Module 2: In this area, there will be meditation and relaxation/breathing exercises, information on relaxing complementary therapies, anxiety reduction and stress management techniques videos and audio recordings.~Module 3: Current developments on gynecological cancers will be included.~Module 4: Encouraging recovery stories and videos of cancer survivors will be included.~Module 5: Counseling module. This is the area where patients who cannot find answers in the frequently asked questions section can ask questions to the research team."
45348573|NCT00939718|Dietary Supplement|Vitamin B12|Vitamin B12 injections containing methylcobalamin 1000 mcg given once every six months along with the routine antidepressant treatment.
45841223|NCT04780932|Drug|Macitentan 10mg|Macitentan 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration
45841224|NCT04780932|Drug|Placebo|Placebo 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration
45841225|NCT04780776|Device|UVB treatment|5 weeks of UVB titration to determine individual's UVB sensitivity followed by 16 weeks of UVB exposure intervention
45348574|NCT00843141|Behavioral|cognitive computerized training|cognitive computerized training utilizing executive attention tasks
45348575|NCT00843141|Behavioral|simple cognitive computerized training|simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention
45348576|NCT04062968|Other|Video education|"Prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetic-testing-videos ."
45348577|NCT00938938|Other|Press Guide|The press guide is a 1-page summary of the study findings, written by the investigators.
45348578|NCT00843219|Procedure|PET/CT Scan|PET/CT scan performed with elastic belt around lower chest/upper abdomen to track breathing motion.
45348579|NCT02568098|Drug|IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ|Regimen 1: IVM; Regimen 2: IVM and PQ; Regimen 3: IVM and DHA-PQP; Regimen 4: IVM and DHA-PQP and PQ;
45348580|NCT02568098|Drug|PQ and DHA-PQP and PQ|Regimen 5: PQ; Regimen 7: DHA-PQP and PQ
45348581|NCT02568098|Drug|DHA-PQP|Regimen 6: DHA-PQP
45348582|NCT02732626|Procedure|radiofrequency ablation|
45348583|NCT00836667|Drug|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
45348584|NCT00836667|Drug|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
45841226|NCT04780776|Device|Sham comparator|5+16 weeks of visible light exposure
45348585|NCT03898232|Radiation|Computed Tomography (CT) Scan of the Lumbar Spine|Patients in the cohort who have not received a 12 month post-op CT scan will be asked to enroll in the study and undergo a CT of the lumbar spine.
45841227|NCT04627038|Drug|LY3556050|Given orally
45841228|NCT04627038|Drug|Placebo|Given orally
46044414|NCT02645188|Other|Cueing|Verbal and tactile cueing to enhance gluteus maximus recruitment
45475885|NCT05584306|Other|Placebo 30mg group|placebo subcutaneous (SC) Q4W，8 times
46044415|NCT02645032|Biological|Vi-DT|Manufacturer: SK Chemicals Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
46044416|NCT02645032|Biological|Typhim Vi®|Manufacturer: Sanofi Pasteur Ingredient: Purified Vi-polysaccharide Appearance: colourless liquid Dose: 0.5mL/vial
46044417|NCT02645032|Biological|VAXIGRIP®|"Dose: Single injection, participants 6-35 months of age will receive 0.25 ml (half a dose), participants 36 months of age and older will receive 0.5ml (full dose)~*Participants less than 9 years of age, who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after the last follow-up visit of last participant in their age cohort."
45685237|NCT04613713|Other|Somatocognitive physiotherapy|"The main intervention areas include:~education about the PVD, healthy vulvo-vaginal and sexual behaviors, nature of chronic pain and factors influencing pain intensity~bodily exercises and techniques increasing body awareness, ability to relax and control muscle tension and respiration pattern in different situations~techniques to cope with emotions and thoughts related to bodily experiences and to PVD~structured homework assignments promoting application of the learned techniques in daily situations and gradual exposure of the patient to activities associated with pain.~Participants will be offered maximally 15 treatment sessions. No minimal number of sessions is set. Treatment will be conducted by female physiotherapists experienced in treating long-standing pain conditions."
46044418|NCT02536066|Behavioral|Postprandial physical activity|Adding a minimum of 30 minutes of physical activity starting maximum 30 minutes after the last meal daily
45348586|NCT00940030|Other|mechanical bowel preparation|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. From 16 p. m. to 20 p. m. assumption of Polyethylene Glycol Macrogol 70 mg per 1 liter of water 4 times (1L each hour). A bowel enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
46044419|NCT02644954|Drug|Metformin|Metformin 850 mg twice daily given in the intervention arm to patients of moderate psoriasis
45475886|NCT05584306|Other|Placebo 100mg group|placebo subcutaneous (SC) Q4W，8 times
45475887|NCT05584306|Other|Placebo 300mg group|placebo subcutaneous (SC) Q4W，8 times
45475888|NCT05084937|Other|CeliCAT form|Systematic summary to support transition
46044420|NCT02644954|Drug|Placebo|Placebo drug twice daily given in the intervention arm to patients of moderate psoriasis
46044421|NCT02644954|Drug|Topical Coal tar|Topical coal tar to be applied once daily
46044422|NCT02644954|Drug|Topical calcipotriol|Topical calcipotriol to be applied once daily
46044423|NCT02652286|Device|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy in humans
46044424|NCT00650338|Drug|DE-104 ophthalmic solution, low concentration|Topical ocular application
46044425|NCT00650338|Drug|DE-104 ophthalmic solution, medium concentration|Topical ocular application
46044426|NCT00650338|Drug|DE-104 ophthalmic solution, high concentration|Topical ocular application
46044427|NCT00650338|Drug|Placebo|placebo
46044428|NCT00650338|Drug|0.005% latanoprost|Topical ocular application
46044429|NCT02644720|Procedure|multifocal intraocular lens implantation|In this group, the surgery was performed with cataract extraction and multifocal intraocular lens (IOL) (Tecnis ZMB00). The standard technique in all patients consisted of sutureless phacomulsifacation using the Legacy 2000 Series and Infinity phacoemulsification machine (Alcon Laboratories Inc., Fort Worth, Texas, USA), with clear corneal incisions up to 3.2 mm and 5.0 to 5.5 mm capsulorhexis. Surgery in the fellow eye was performed 1 month later in each patient.
45348587|NCT00940030|Other|enema|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. Dinner: meat broth and fasting starting from midnight. A bowel single enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
45348588|NCT00845559|Drug|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide and will be taught how to administer subcutaneous injections with their exenatide pen and instructed on the following dosing schedule: exenatide - 5 μg twice a day for 7 days, followed by exenatide 10 μg twice a day for the remainder of the four month supply.
45348589|NCT05123612|Behavioral|Fiber|Additional 20 grams of fiber/day.
45685238|NCT04613713|Other|Treatment as usual|The participants will follow the current treatment advice as recommended by the Vulva Clinic at OUH, a tertiary health care center specialized in treatment of vulvar disorders. Advice include guidance about the management of PVD as a condition, use of medication, physiotherapy, sexologist and psychological counseling, usage of internet resources (vulva.no) and others. Participants will be free to pursue treatment options of their choice. The type of treatment, number of treatments and medication usage will be monitored by bi-weekly electronic forms during the whole study period.
45348590|NCT05123612|Behavioral|Fermented Foods|6 servings of fermented foods/day
46044430|NCT02644720|Procedure|monofocal intraocular lens implantation|In the group, the surgery was performed with cataract extraction and monofocal intraocular lens (IOL) (Tecnis ZCB). The surgery technique was same as the multifocal intraocular lens group
46044431|NCT02644720|Drug|Dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery
46044432|NCT02644720|Device|multifocal intraocular lens (IOL) (Tecnis ZMB00)|
45348591|NCT00939016|Other|Lunch meal with 24 hour dietary recall|Each participant will come into the laboratory for a buffet-style lunch meal, where they are instructed to sample each of the foods served. On the next day, a 24 hour dietary recall is performed to test the participants ability to accurately report amounts and types of food consumed. Measures of dietary restraint and social desirability are taken prior to the laboratory meal via phone interview.
45348592|NCT00836823|Drug|Alfuzosin|Alfuzosin 10mg once daily for 12 months
45348593|NCT02567240|Other|Carbon monoxide-bubbled mediums|Islets will be harvested with carbon monoxide bubbled mediums
45685239|NCT03762694|Device|Acupuncture|Electroacupuncture (EA) and Auricular Acupuncture (AA)
46044433|NCT02644720|Device|monofocal intraocular lens (IOL) (Tecnis ZCB)|
45348594|NCT00940810|Procedure|Plasma Disc Decompression/Nucleoplasty|"Subjects assigned to the PDD Group will be scheduled to receive the plasma disc decompression procedure using the Coblation® method.~Similarly to in Conservative Care group, subjects will be followed-up at 2, 8 weeks, 6 and 12 months (calculated from the date of the PDD procedure). The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires."
45475889|NCT01190969|Dietary Supplement|Nutritional Supplement (Ensure Plus)|Subjects will be provided with 2 to 3 serves of Ensure Plus (complete nutritional beverages) and to be taken between meals
46044434|NCT03542266|Drug|CC-486 Administration|CC-486 at 300 mg once daily is to be administered Cycle 1, Day -6 to 0 and Cycles 1 to 5, Day 8 to 21. Antiemetic prophylaxis is recommended before dosing. All efforts should be made to administer CC-486 on all scheduled days of the Cycle 1 priming dosing (7 days, Cycle 1 Day -6 to Cycle 1 Day 0) and the Cycle 1-5 dosing (14 days, Day 8-21). A dose missed earlier in a day can be administered later that day as long as it is taken at least 8 hours before the next scheduled dose. Any missed dose should not be taken beyond the last scheduled day of CC-486 administration for the cycle, but should be returned by the subject for CC 486 accountability. If vomiting occurs after a dose of CC-486 is administrated, that dose should not be made up later that day.
45348595|NCT00940810|Procedure|Conservative Care (physiotherapy)|"Subjects assigned to the Conservative Care Group will be scheduled to receive physical therapy according to standard and customary care locally.~Subjects will be followed-up at 2, 8 weeks, 6 and 12 months . (Calculated from the time of first going through the individual training programme).The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires."
45348596|NCT00843297|Device|Coolgard|invasive Cooling via femoral ICY-catheter
45348597|NCT00843297|Device|ArcticSun|Noninvasive surface-cooling by saline-cooled thermo-vest
45348598|NCT00843297|Other|Conventional treatment|Intensive care-treatment without cooling
45348599|NCT05107778|Drug|ASC42 10mg|ASC42 10mg orally once daily;
45348600|NCT05107778|Drug|ASC42 15mg|ASC42 15mg orally once daily.
45348601|NCT05107778|Drug|ih PEG-IFN α-2a|ih PEG-IFN α-2a 180μg subcutaneous injection once a week.
45348602|NCT05107778|Drug|Entecavir|Entecavir 0.5 mg orally once daily.
45348603|NCT05107778|Drug|Placebo|Placebo orally once daily.
45348604|NCT00372619|Drug|clofarabine|Given IV for 5 days
45348605|NCT00372619|Drug|cytarabine|Given IV
45348606|NCT00372619|Drug|methotrexate|Given intrathecally or IT age based dosage
46044435|NCT03542266|Drug|CHOP Administration|"CHOP is to be administered on Days 1 to 5 of Cycles 1-6. Chemotherapy can be administer within +72h or -24h of Day 1 of each scheduled Cycle. Preparation and infusion rate are according to the package insert and local practice. The doses to be used are:~Cyclophosphamide: 750 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 1 Prednisone: 100 mg PO days 1-5"
46044436|NCT02648386|Procedure|Laparoscopic surgery|Completely resected rectal tumor.
45348607|NCT00372619|Other|laboratory biomarker analysis|
45348608|NCT02546115|Device|tension night splint|this is the use of a commercially available tension night splint device, to be worn by the patient
45348609|NCT02546115|Other|standard practice - a structured rehabilitation programme|this is the standardised structured rehabilitation programme of home exercises given to patients, with supporting literature, and instructions on how to progress the regime themselves
45348610|NCT04477616|Drug|Day 7 regimen|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 7 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC >= 15 x 10^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
45348611|NCT04477616|Drug|Day 3 regimen|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 3 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC >= 15 x 10^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
45348612|NCT00851175|Drug|rosuvastatin|7 day treatment with rosuvastatin 1dd 20mg
45348613|NCT00851175|Drug|caffeine|intra-arterial (brachial artery of non dominant arm) administration of caffeine(90 ug/min/100ml forearm volume)for approximately 60 minutes
45348614|NCT04445792|Other|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
46044437|NCT02648386|Device|NeuroRegen scaffold transplantation|After completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold to the nerve.
45841229|NCT04480008|Behavioral|Resilient Living Program|Participants will be given the journal Resilient Living with Dr. Sood: Building Strength for Difficult Days to use throughout the study. The initial session with one of the investigators will be an introduction and a review of Module 1: Gratitude, and will last 30-60min. Three follow-up sessions will occur approximately every two weeks and the participants should view the videos before those virtual meetings (Session 2 will review Module II: Mindful Presence; Session 3 will review Module III: Kindness; Session 4 will review Module IV: Resilient Mindset). The videos will take approximately 30 minutes each to review and virtual sessions will each take 30-60 minutes.
45841230|NCT04460430|Drug|Neratinib + endocrine therapy|Neratinib plus Fulvestrant, Exemestane or Tamoxifen
45348615|NCT04445792|Other|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
45841231|NCT04316910|Drug|General anesthetic|General anesthesia was induced as follows: 0.3 mg kg-1 intravenous (IV) etomidate, 2 mg IV midazolam, 0.4 μg kg-1 IV sufentanil, and 0.2 mg kg-1 IV cisatracurium. Anesthesia was maintained with an end-tidal concentration of 2-3 vol% sevoflurane and 0.2-0.3 μg kg-1h-1 sufentanil to maintain the bispectral index between 40 and 60.
46044438|NCT02648386|Biological|NeuroRegen scaffold/BMMCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million bone marrow mononuclear cells to the nerve.
45348616|NCT04043013|Device|Mini-Taurus® (Rocky Mountain©) Brackets|
46044439|NCT02648386|Biological|NeuroRegen scaffold/HUC-MSCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million human umbilical cord mesenchymal cells to the nerve.
46044440|NCT02641600|Device|Elastic stockings|Use of elastic stockings to alleviate patient symptoms
45348617|NCT04043013|Device|Smart Clip® SL3 High Torque (3M Unitek©)|
45348618|NCT04043013|Device|Tip-Edge Plus® (TP Orthodontics©)|
45348619|NCT04043013|Device|Victory® (3M Unitek©)|
45348620|NCT00845637|Drug|Eggplant extract|Dry eggplant extract in two 450mg capsules, twice a day (before the main meals) for fourteen days.
45348621|NCT00845637|Drug|Placebo|Placebo in two 450mg capsules, twice a day (before the main meals) for fourteen days.
45475890|NCT03351400|Biological|Stem cells administered to participants|Patients in this arm will receive intracoronary infusion of 1,000,000 autologous c-kit positive cardiac stem cells.
46044441|NCT02641600|Device|Placebo stockings|Placebo stocking with pressure applied to the legs
46044442|NCT02648308|Behavioral|Obesity Management Workshop|Workshop provided to first year medical residents to improve confidence and skill when conducting weight management visits with patients
45348622|NCT03992833|Other|lung cancer screening|"In the first reading, according to the NCCN lung cancer screening guideline, participants with a solid nodule≤ 5 mm in diameter will be referred to undergo follow-up CT 1 year after the baseline. Participants with a solid nodule 6-14 mm will be referred to undergo follow-up thorax CT 3-6 months after the baseline. Participants with a solid nodule ≥ 15 mm will be referred to a multidisciplinary team for clinical investigation.~The simulated management will be based on the volume of lung nodule and volume doubling time from the second reading, lung nodules will be reclassified according to the reference values from the European volume-based lung nodule management protocol. According to the European volume-based protocol, the solid and part-solid lung nodules will be reclassified into three groups: nodules with a volume < 100 mm3 (negative), nodules with a volume of 100-300 mm3 (indeterminate), and nodules with a volume > 300 mm3 (positive)."
45348623|NCT02566226|Drug|Bupivacaine with normal saline|Isobaric bupivacaine 15 mg + normal saline 0.5 cc
45348624|NCT02566226|Drug|Bupivacaine with intrathecal morphine|Isobaric bupivacaine 15 mg + intrathecal morphine 100 mcg
45348625|NCT00837057|Procedure|crrt|early CRRT (35 ml/kg/h)& acute kidney injury or failure or nearly anuria more than 2hr or late conventional dialysis indication
45348626|NCT01046617|Dietary Supplement|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for 21 days
45475891|NCT01194791|Drug|Lenalidomide|Lenalidomide 15 mg by mouth for 21 days followed by 7 days rest during 6 cycles
45685240|NCT01450150|Device|Transcranial Direct Current Stimulation|20-minute daily sessions of 2 mA tDCS for 15 days (Monday to Friday on three consecutive weeks)
45475892|NCT01194791|Drug|Cyclophosphamide|Cyclophosphamide 300 mg/m2, on days 1 and 8 every 4 weeks during 6 cycles
45685241|NCT01450150|Device|Transcranial Direct Current Stimulation|The tDCS stimulator will be turned on for 30 seconds only, after which it will be gradually decreased and then turned off for the remainder of the 20-minute daily sessions for 15 days (Monday to Friday on three consecutive weeks).
45685242|NCT01450228|Drug|KI1001|Prolonged release melatonin 2mg
45475893|NCT01194791|Drug|Dexamethasone|Oral dexamethasone 20 mg/day on days 1-4 and 9-12 given at 4-week intervals during 6 cycles
45348627|NCT00837135|Other|Screening|"A. SCREENING~Consent~Disease Evaluation (CT Scan/MRI; EGC/EUS; Laparoscopy)~Physical Exam, History, Blood Tests~Skin Test (for allergy to saccaromyces cerevisiae) yeast.~Collection of Blood for research~B. CHEMOTHERAPY AND RADIATION (as determined by Doctor)~C. ENROLLMENT INTO ACTIVE PART OF STUDY~Consent~Chemotherapy~GI-4000 Vaccine #1 + Prevnar + Activated T Cells~GI-4000 Vaccine #2~Disease Evaluation (CT Scan/MRI). If disease has spread, subject is taken off study. If disease is stable, subject go on to ARM A or ARM B."
45475894|NCT04831515|Device|Lens A|daily disposable soft contact lens - test lens
45475895|NCT04831515|Device|Lens B|daily disposable soft contact lens - control lens
45348628|NCT00837135|Biological|GI-4000 Vaccine|"Chemotherapy and Radiation~GI-4000 Vaccine #3~GI-4000 Vaccine #4"
45348629|NCT00837135|Biological|GI-4000 Vaccine + Activated T Cells|"Apheresis #2~Chemoradiation~Activated T Cells + GI-4000 Vaccine #3~GI-4000 Vaccine #4"
45475896|NCT03351322|Drug|ENERGI-F701|ENERGI-F701 are applied for treatment of hair loss.
45475897|NCT03351322|Drug|Regaine|Regaine are applied for treatment of hair loss.
45475898|NCT01296971|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
45475899|NCT01296971|Drug|ribavirin [Copegus]|1'000/1'200 mg daily orally, 24 - 72 weeks
46044443|NCT02644876|Drug|Penehyclidine inhalation|Penehyclidine inhalation will be administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
46044444|NCT02644876|Drug|Placebo inhalation|Placebo inhalation will be administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
45475900|NCT01296971|Drug|ribavirin [Copegus]|800 mg daily orally, 16 - 48 weeks
45475901|NCT04697667|Other|Exercise|Supervised exercise program
45475902|NCT04697667|Biological|PRP|Intra-articular PRP injections to knee joint
45475903|NCT03554629|Device|Capnography CO2 cannula sampling Flexiterline (CCSF) designs with supplemental O2|Use of 8 post-market nasal CO2 cannula sampling filterlines; 4 nasal only sampling ports manufactured by Medtronic, Salter, Hudson/Teleflex and FlexiCare) and 4 post-market oral/nasal sampling ports manufactured by Medtronic, Salter, Dispo-Med and Westmed during scripted activity with supplemental O2.
45475904|NCT05049772|Behavioral|Telerehabilitation-based motor imagery training|10 weeks of motor imagery training and stabilization exercises.
45475905|NCT05049772|Behavioral|Stabilization exercises group|10 weeks of stabilization exercises.
46044445|NCT00652600|Drug|Propranolol|ER Capsules, 160 mg, single-dose
46044446|NCT00652600|Drug|Inderal-LA|ER Capsules, 160 mg, single-dose
45348630|NCT00837135|Biological|Surgical Evaluation after Vaccine #4|"SURGICAL EVALUATION (to determine disease status) A. For those who have complete removal of tumor. These subjects will continue to receive Chemotherapy AND GI-4000 Vaccination Monthly during Chemotherapy. Disease evaluation every 3-6 months (CT Scan/MR.~B. For those sucjects who cannot have surgery or who have not had complete removal of tumor. These subjects will continue to have GI-4000 Vaccinations Monthly as long as there is no disease progression. Disease evaluation every 3-6 months (CT Scan/MR."
45475906|NCT03849989|Procedure|Skin biopsy|"Skin biopsy:~Tissue samples will be taken by punch biopsy according to the daily routine of the Department of Dermatology of the Maastricht UMC+.~Steps:~Skin desinfection with chlorhexidine digluconate 1% solution~Local anaesthesia with lidocaine hydrochloride 1%~Biopsy specimens are taken with sterile punch device (disposable biopsy punch delivered by kai medical)~Biopsy specimens are retrieved with sterile pincer and cut with sterile blade~Wound is stitched with a single transcutaneous stich using absorbable suture (vicryl 4.0).~Wound will be treated with R/ fusidic acid ointment 3 to 5 times per day for two weeks~In the first week after laser therapy the wound will be covered by R/ Urgotull non-adhesive gauze, R/ Cutisoft cotton non-sterile gauze and R/ Klinipress exsupad absorbing bandage."
45475907|NCT04691661|Drug|Radotinib HCl 50 mg|Enrolled subject will continue to administer Radotinib 50mg/day, 100mg/day, 150mg/day, 200mg/day, depending on the dose level once daily for 6 months.
45475908|NCT04691661|Drug|Placebo|Placebo
45475909|NCT05046964|Device|Masimo Radical-7 Pulse CO-Oximeter|The Radical-7 Pulse CO-Oximeter uses photospectroscopy to non-invasively measure the total hemoglobin (SpHb) in a patient's blood throughout their C-section.
45685243|NCT01450228|Drug|Placebo KI1001|Placebo KI1001 tablets
45475910|NCT01194947|Device|RCM imaging|RCM imaging will be performed using a commercially-available RCM (Vivascope 1500, Lucid Inc, Rochester, NY, USA) with 830-nm diode laser with emitting power less than 35 milliwatts
45841232|NCT04308330|Drug|Vorinostat|This is a phase I study of the combination of four drugs: vorinostat, vincristine, irinotecan, and temozolomide. This is called a Phase I study because the goal is to find the highest dose of vorinostat that investigators can give safely when it is used together with the chemotherapy drugs vincristine, irinotecan and temozolomide. Investigators are using vorinostat because it seems to work against cancer in test tubes and animals. It may be most effective when it is given with chemotherapy. The combination of these three agents together has never been given to children. Vincristine, irinotecan, and temozolomide are approved and used for the treatment of other types of cancer in adults and children. Vorinostat is approved and used to treat cancer in adults. The combination of these four drugs together is experimental. Investigators do not know if this combination of medicines will work in people. There is a lot that investigators do not yet know about this combination of medicines.
45348631|NCT00562588|Drug|Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg)|
45348632|NCT00562588|Drug|ASA 100 mg qd|
45348633|NCT00851331|Genetic|genome analyzes (genetic defects and pathophysiological mechanisms )|
45348634|NCT04263038|Drug|Rivaroxaban|Anticoagulation
45348635|NCT04263038|Drug|Placebo|Study drug without active agent
45348636|NCT00845715|Other|Early motion|Early referral to physical therapy for range of motion (2 days post)
45348637|NCT00845715|Other|Standard motion|Standard referral to physical therapy for range of motion (4 weeks post)
45348638|NCT02546349|Drug|fluticasone/salmeterol, tiotropium|In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.
45475911|NCT04655001|Behavioral|MORPH|A 12-week movement and caloric restriction intervention meant to reduce pain and body weight.
45596486|NCT02375451|Other|Radioiodine|We will determine if prior radioiodine treatment in childhood impacts salivary function or symptoms. Radioiodine treatment will have been determined by the patient's medical condition and care (NOT assigned by this research study).
45596487|NCT02198339|Drug|BIBN 4096 BS|
45596488|NCT02198339|Drug|Placebo|
46044447|NCT02644642|Other|disconnection technique|Before lung isolation, the ventilator stays switched-off until the carbon dioxide on the capnogram reached to zero. Then, inflate the balloon either on the double lumen tube or on the bronchial blocker.
45348639|NCT00845793|Behavioral|Nutritional guidance|The guidance will be performed using the food tray during the hospitalization and will consist of meeting the nutritionist and receiving brochures along with the meal tray focusing on constituents and elements of the diet. The served meals will consist of elements recommended for patients with T2DM (such as whole grains, low fat dairy products and canola oil).
45348640|NCT00851487|Drug|Amoxicillin|Oral Amoxicillin 15 mg/kg/dose 8 hourly
45348641|NCT00851487|Drug|Placebo|The placebo was similar in colour, consistency and volume as oral amoxicillin
45348642|NCT00622167|Device|Integrated Backscatter IVUS|All subjects have Integrated Backscatter IVUS and Dual Source CT imaging.
45596489|NCT05724667|Other|Flippin' Pain Seminar Series|A chronic pain education campaign
45685244|NCT01450384|Drug|sorafenib tosylate|Given PO
46044448|NCT03201250|Drug|Cabozantinib|"Cabozantinib:~Phase I: Level -1 = 20 mg or Level 0 = 40 mg or Level +1 = 60 mg, PO daily on days 1-28 Phase II: One of phase I dosing levels identified as MTD, PO daily on days 1-28~Carfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16~Dexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)"
45685245|NCT01450384|Drug|pemetrexed disodium|Given IV
45685246|NCT01450384|Other|laboratory biomarker analysis|Correlative studies
45685247|NCT01450384|Procedure|biopsy|Optional correlative studies
45841233|NCT04241796|Device|Multi-Cancer Early Detection Test|Blood collection and multi-cancer early detection testing with return of results.
45348643|NCT00622167|Device|Dual Source Computed Tomography|All subjects have DSCT and IBIVUS imaging
45348644|NCT02547675|Drug|Rociletinib|Rociletinib will be administered to patients orally
45348645|NCT04042857|Device|Next Science Treatment Gel|Next Science Treatment Gel will be applied after nail surface nail-filing and/or debridement.
45348646|NCT04235907|Other|Telerehabilitation|Internet-guided rehabilitation with weekly phone calls from a physical therapist.
45348647|NCT04235907|Other|Standard rehabilitation|Prescription for physical therapy and a printed list of exercises to complete.
45596490|NCT02198807|Drug|Fosmidomycin-Piperaquine|
45596491|NCT03529513|Diagnostic Test|Medibio Depression Diagnostic Aid|The Medibio DDA processes the heart rate and actigraphy data from the third-party devices, characterizes these data in comparison to the benchmark patterns of persons currently experiencing a depressive episode.
45596492|NCT03529513|Diagnostic Test|Mini International Neuropsychiatric Interview|The Mini International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview that was developed as a simple tool to assist clinicians to conduct psychiatric diagnoses according to the DSM-IV and International Statistical Classification of Diseases and Related Health Problems tenth revision (ICD-10) criteria.
45841234|NCT04191876|Other|Wellth - Financial Incentives|Patients who are willing to participate will be offered financial incentives for medication adherence through an app (Wellth) over 10 weeks.
45841235|NCT04104594|Diagnostic Test|Sniffin Stick Test|"The test consists of odorous rods that are presented to the patient's nose. It consists of 3 parts different, with 3 sets of corresponding sticks: an olfactory threshold test, an olfactory discrimination test and an olfactory identification test.~The final score, out of 48, is the sum of the olfactory threshold, discrimination and identification scores. Normal test values are defined as greater than the tenth percentile of the general population, so the test result is compared to reference values on a chart to determine whether the patient is normosmic, hyposmic or anosmic."
45841236|NCT04104594|Other|numerical evaluation scale for olfaction|numerical rating scale from 0 (no smell) to 10 (perfect smell)
46044449|NCT03520504|Radiation|Proton craniospinal irradiation (CSI)|Patients will be enrolled to receive 30Gy (RBE) in 3Gy (RBE) or 25Gy (RBE) in 2.5Gy (RBE) fractions course of proton CSI.
45841237|NCT04104594|Other|numerical evaluation scale for nasal obstruction|numerical rating scale from 0 (no freedom of the nasal passages) to 10 (maximum nasal freedom)
45348648|NCT00562354|Biological|13vPnC|13vPnC for both stratum
45348649|NCT00372385|Drug|Ribavirin|tablet
45348650|NCT00372385|Drug|Pegylated Interferon Alfa 2a|Solution for injection
45348651|NCT00372385|Drug|Placebo|tablet
45348652|NCT00372385|Drug|Telaprevir|tablet
45348653|NCT03830281|Drug|Ultra-Rapid Lispro|Administered SC
45348654|NCT03830281|Drug|Insulin Lispro|Administered SC
45348655|NCT00563368|Drug|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
45348656|NCT00563368|Drug|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
45348657|NCT00563368|Drug|topiramate|topiramate 46 mg, po once daily
45348658|NCT00563368|Drug|topiramate|topiramate 92 mg, po once daily
45685248|NCT01450462|Dietary Supplement|Vitamin D3 (cholecalciferol)|Women in the vitamin D arm take 50,000 international units (IU) of vitamin D3 (cholecalciferol) weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
45841238|NCT04104594|Other|nasal outcome test|"list of symptoms and social/emotional consequences of rhino-sinusitis. 16 questions that the patient must code from no problem to serious problem over the last 15 days"
46044450|NCT04166578|Drug|lignocaine|The group of 62 patients undergoing cataract surgery received Mydrane (Mydrane group) or a combination of 1% solution of lignocaine and 0.025% solution of adrenalin (reference group) as an intraocular anesthetic
46044451|NCT04166578|Procedure|Phacoemulsyfication|Phacoemulsification is a technic of cataract surgery in which the eye's internal lens is emulsified with an ultrasonic handpiece and aspirated from the eye.
46044452|NCT04166578|Procedure|Intraocular lens implantation|An intraocular lens implant is a synthetic, artificial lens placed inside the eye that replaces the focusing power of a natural lens that is surgically removed, usually as part of cataract surgery.
46044453|NCT04166578|Behavioral|Visual Analog Scale for Pain|VAS for Pain is a new tool developed to assess the pain in quantitative terms.
45348659|NCT00563368|Drug|phentermine|phentermine 7.5 mg, po once daily
45348660|NCT00563368|Drug|phentermine|phentermine 15 mg, po once daily
45348661|NCT00563368|Drug|VI-0521|placebo, po once daily
45348662|NCT02535013|Device|Lung ultrasound|Lung ultrasound with appropriate interventions depending on the ultrasound finding
45348663|NCT00390013|Drug|Gabapentin|"300 mg. capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~day 1 you will take 1 capsule for the day~day 2 you will take 1 capsule 2 times for that day~days 3-6 you will take 1 capsule 3 times for those days~days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~days 13-14 you will take 2 capsules 3 times each day~continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~at completion of study treatment you will titrate off study drug over a weeks time."
45348664|NCT00390013|Drug|Placebo oral capsule|"Placebo capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~day 1 you will take 1 capsule for the day~day 2 you will take 1 capsule 2 times for that day~days 3-6 you will take 1 capsule 3 times for those days~days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~days 13-14 you will take 2 capsules 3 times each day~continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~at completion of study treatment you will titrate off study drug over a weeks time."
45348665|NCT00561652|Behavioral|Education & Exercise|Education & Exercise
45348666|NCT00561652|Procedure|Chiropractic treatment (plus Education & Exercise)|Chiropractic treatment (plus Education & Exercise)
45348667|NCT00697346|Drug|Alisertib|Alisertib (MLN8237) PIC or ECT
45348668|NCT00562120|Drug|Placebo|A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs.
45348669|NCT00562120|Drug|Allegra|A single oral dose of Allegra is dosed to subjects in combination with PF-03654746.
45348670|NCT00562120|Drug|Allegra-D|A single oral dose of Allegra-D is dosed to subjects as an active comparator.
45348671|NCT00562120|Drug|PF-03654746|A single oral dose of PF-03654746 is the investigational drug being studied.
45348672|NCT00941044|Device|Neurally adjusted ventilatory assist|application of non-invasive NAVA in healthy volunteers
45348673|NCT00939172|Drug|TTP607|3.3 mg/m^2 given by central venous catheter over 1-4 hours, each day for 5 days in a row, for a 15 day cycle.
45348674|NCT01563016|Dietary Supplement|glucose drink|participants will receive a drink rich in glucose
45348675|NCT00561730|Drug|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
45348676|NCT00697112|Drug|Sirolimus|Non interventional. Sirolimus administered by Principal Investigator per standard practice and labeling.
45348677|NCT00621855|Drug|placebo|matched placebo
45348678|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
45348679|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
45348680|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
45348681|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
45348682|NCT04012762|Device|Whole body vibration training|Intermittent whole-body vibration exposure is a training method providing physical stimulation effect on skeletal muscles by increasing gravitational acceleration on the vibration platform.
45348683|NCT04258280|Behavioral|Education and counseling|Education includes a workbook, counseling includes peer support.
45348684|NCT04258280|Behavioral|Education|Education includes a workbook.
45348685|NCT00940966|Dietary Supplement|standard ADA diet|standard ADA diet
45348686|NCT00940966|Dietary Supplement|energy restricted very-low carbohydrate diet|energy restricted very-low carbohydrate diet
45348687|NCT00940966|Dietary Supplement|low glycemic diet|restricted ketogenic diet
45348688|NCT04230356|Biological|Viral Specific T-cells (VSTs) Scheduled|VSTs will be infused into stem cell transplant recipients on schedule.
45841239|NCT04104594|Biological|dosage of 17 cytokines|dosage of 17 cytokines : G-CSF, GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, MCP-1 (MCAF), MIP-1β,TNF-α
46044454|NCT04166578|Behavioral|Brief Pain Inventory-short form|BPI short form is a tool developed to assess the pain in quantitative terms. The BPI allows patients to rate the severity of the pain and the grade to which their pain interferes with common dimensions of feeling and function.
46044455|NCT04166578|Diagnostic Test|Best corrected visual acuity measurment|Measurement of the best vision correction that can be achieved, such as glasses, as measured on the standard Snellen eye chart. For example, if your uncorrected eyesight is 20/200, but you can see 20/20 with glasses, your BCVA is 20/20.
46044456|NCT04166578|Diagnostic Test|Slit-lamp biomicroscopy|Slit-lamp biomicroscopy allows study of ocular structures and their relationships.
46044457|NCT02647996|Procedure|MRI: functional (resting state) and structural (DTI)|One hour brain MRI recording without active task for the patient, no sedation
45348689|NCT04230356|Biological|Viral Specific T-cells (VSTs) Treatment|VSTs will be infused into stem cell transplant recipients only if viremia is detected.
45348690|NCT00851565|Procedure|Measurement of serum infliximab and anti-infliximab antibodies|"In the intervention group treatment of patients with Crohn's disease with secondary loss of response to infliximab is based on serum infliximab and anti-infliximab Ab levels according to following algorithm:~Low s-infliximab in the presence of anti-infliximab Ab: Adalimumab 80 mg s.c. followed by 40 mg every 2 weeks.~Low s-infliximab without anti-infliximab Ab: Infliximab 10 mg/kg i.v. every 8 weeks.~High s-infliximab without anti-infliximab Ab: Stop infliximab treatment. Review history. Steroids or surgery.~High s-infliximab in the presence of anti-infliximab Ab: Same as number 3."
45348691|NCT00851565|Procedure|Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status|In the control group patients with Crohn's disease with secondary loss of response to infliximab is treated according to current standard of care which is to increase dose of infliximab to 5 mg/kg every 4 weeks without knowledge of serum infliximab levels and anti-infliximab Ab status.
45348692|NCT04222088|Drug|Arthemeter-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to <16kg); 2 tablets (15 to <25kg); 3 tablets (25 to <35kg), 4 tablets for >35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (>13 years old)"
45348693|NCT04222088|Drug|Chloroquine|Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance with national treatment guidelines)
45348694|NCT04222088|Drug|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
46044458|NCT04166734|Drug|Pembrolizumab|"Pembrolizumab will be continued dosed at 200 mg given every 3 weeks~Drug: Pembrolizumab Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks."
46044459|NCT04166734|Radiation|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)
46044460|NCT00653536|Device|NeuroFlo|The device will be inflated for 45 minutes in acute ischemic stroke patients who have failed mechanical recanalization.
46044461|NCT00651352|Drug|4 mg nicotine lozenge|marketed formulation
46044462|NCT00651352|Drug|2 mg nicotine lozenge|marketed formulation
46044463|NCT00651352|Drug|2 mg nicotine prototype|2 mg
46044464|NCT00651352|Drug|4 mg nicotine prototype|4 mg
45348695|NCT00561574|Drug|Esmirtazapine|One tablet daily
45348696|NCT03898076|Device|Flash Glucose Monitoring|Continuous Glucose Monitoring (CGM) values will be downloaded from CGM device for a period of 90 days.
46044465|NCT02641678|Device|Implantation of cardiac monitor|In patients with kryptogenic stroke, a cardiac monitor was implanted to detect atrial fibrillation
46044466|NCT02641444|Procedure|Blood plasma collection|Approximately 3mL of blood will be taken from each subject just prior to the colonoscopy.
46044467|NCT02641444|Procedure|Cervical and Vaginal Biopsy|2 biopsies each will be collected from the vaginal wall and the cervix
46044468|NCT02641444|Procedure|Colonoscopy with Ileal and Rectal Biopsy|10 biopsies each will be collected from the rectum and terminal ileum from each subject during the colonoscopy.
45348697|NCT03898076|Other|A1c|A1c levels will be collected from Hospital EMR prior to CGM data downoad
45841240|NCT03952416|Behavioral|Enhanced Medical Rehabilitation (EMR)|"EMR is a set of behavioral skills that therapists can incorporate into their daily therapy sessions to increase patient engagement and achieve a high intensity of therapy, thereby improving functional and psychosocial outcomes of patients in medical rehabilitation. EMR was built on theories of behavior change, including social cognitive theory and self-regulatory theory, and their applications to patient engagement, such as the Health Action Process Approach and motivational interviewing. It has three foci: (1) a patient-directed, interactive approach stemming from patient-centered goals (Patient as boss); (2) frequent feedback to patients on their efforts and progress (Link activities to personal goals); and (3) increased rehabilitation intensity (Optimize intensity)."
46044469|NCT02644564|Other|Ultrasonography|One doctor does the clinical examination, another does ultrasonography. Both doctors and patient are blinded until results have been registered on written forms. The results are then disclosed to the patient and doctors in order to plan further treatment.
46044470|NCT02648074|Procedure|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen.
45596493|NCT03529513|Diagnostic Test|Hamilton Rating Scale for Depression - 17 Item|The clinician-administered Hamilton Depression Rating Scale (also known as the HAM-D) is the most widely used depression assessment scale . The original version contains 17 items (HDRS17) pertaining to symptoms of depression experienced over the past week. There are numerous versions with varying lengths that include the HDRS21, HDRS24, and HDRS29. This study will utilize the HDRS17 (HAMD-17) version.
45841241|NCT03680508|Drug|TSR-022 and TSR-042|immunotherapy
45348698|NCT03898076|Other|Predictive A1c|Predictive A1c will be calculated based on the first 15 days of CGM data using time in range (TIR), coefficient of variation (CV), mean amplitude of glycemic excursion (MAGE), mean of daily differences (MODD), continuous overall net glycemic action (CONGA). Predictive A1c will be correlated with actual A1c.
45348699|NCT00619827|Drug|300 IR grass pollen allergen extract tablet|300 IR grass pollen allergen extract tablet once daily during four months
45348700|NCT00619827|Drug|Placebo tablet|Placebo tablet once daily during four months
45348701|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
45348702|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
45348703|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
45348704|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
45348705|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
45348706|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
45348707|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
45348708|NCT00848055|Drug|AbGn168 subcutaneous injection|single dose subcutaneous injection
45348709|NCT05545202|Other|Pentaisomaltose|Each subject will receive 1 or 2 bags with cryopreserved cells according to randomization group.
45348710|NCT00687804|Drug|Ranibizumab|0.5 mg ranibizumab administered by intravitreal injection.
45348711|NCT00687804|Procedure|Laser|Laser photocoagulation treatment
45348712|NCT00687804|Procedure|Sham laser|Sham to laser procedure.
45348713|NCT00687804|Drug|Sham to ranibizumab|Sham to ranibizumab administered as an intravitreal injection.
45348714|NCT00848133|Procedure|mini-midvastus surgical approach for total knee arthroplasty|
45348715|NCT00848133|Procedure|mini-subvastus surgical approach for total knee arthroplasty|
45348716|NCT02568020|Drug|keto-amino acids|Ketosteril®( Fresenius Kabi) will be given at a dosage of one tablet/5kg ideal body weight/day, divided into three doses taken during meals.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
45348717|NCT00848445|Device|Guidant Pulsar Max II or Insignia Plus DR|market approved pacemaker. programmed per protocol
45348718|NCT00848445|Device|Atrial pacing preference turned on or off|programing changes in the device
46044471|NCT02648074|Other|Co-culture formation|Eosinophil and linear bronchial smooth muscle cell co-culture formation. Airway smooth muscle cell proliferation, eosinophil adhesion to the bronchial smooth muscle cells, the role of eosinophil integrins in the airway remodelling process is assessed in individual formed co-culture
46044472|NCT00818623|Drug|Degarelix|Degarelix (120 mg (20 mg/mL)) was given as a subcutaneous injection
46044473|NCT00818623|Drug|Degarelix|Degarelix (120 mg (40 mg/mL)) was given as a subcutaneous injection
45475912|NCT01297049|Behavioral|Cognitive behavior therapy (CBT)|All patients will receive standard care (reassurance, education, physiotherapy, and necessary medication). Complementary to this standard care, the participants will be required to closely monitor their blood glucose levels, weight, eating behavior and daily activities, and to relay this information to the nurse specialist trained in treating somatic patients with CBT. The nurse will then suggest appropriate treatment decisions, the patients will receive situational feedback based on the electronic diary during 3 months (daily during 4 weeks intensive treatment and weekly during 2 months as a complement).
45841242|NCT03446664|Device|Microburst Stimulation|Implantable generator with new stimulation feature under study to determine the safety and effectiveness of device stimulation on different seizure types.
45475913|NCT05035030|Drug|Odevixibat|Odevixibat is a small molecule and selective inhibitor of IBAT.
45475914|NCT03846869|Diagnostic Test|major cations|blood sample
45475915|NCT03196791|Drug|Sugammadex Sodium|"INDICATIONS AND USAGE BRIDION® is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. BRIDION (sugammadex) injection is a sterile, clear, colorless to slightly yellow-brown, non-pyrogenic aqueous solution intended for intravenous infusion.~DOSAGE AND ADMINISTRATION BRIDION (sugammadex) injection, for intravenous use, should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents."
45348719|NCT02545881|Other|Magnetic Resonance Imaging (MRI)|MRI of the prostate prior to prostatectomy
45841243|NCT03432078|Other|Hypnotherapy|Non-pharmacological treatment
45841244|NCT03427866|Drug|Ruxolitinib|Ruxolitinib is a medication that blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. The JAK2 pathway is over active in the disease, acute myeloid leukemia.
45348720|NCT02563704|Drug|Artesunate|
45348721|NCT02563704|Drug|Quinine|
45596494|NCT02198417|Drug|Metformin ER|Treatment with metformin ER for 12 weeks
45348722|NCT00848523|Drug|Panobinostat|30 mg, three times a week, patients will continue with treatment until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.
45348723|NCT05604170|Drug|Ganaxolone|GNX will be administered.
45348724|NCT00742404|Drug|bortezomib|
45348725|NCT00742404|Drug|dexamethasone|
45348726|NCT00742404|Drug|pegylated liposomal doxorubicin hydrochloride|
45348727|NCT00742404|Genetic|protein analysis|
45841245|NCT03406338|Procedure|Fasciectomy|Surgical excision of Dupuytren cords causing finger joint contractures. Surgery done under regional or general anesthesia. Additional procedures (such as capsulotomy or skin graft) done if surgeon deemed necessary.
45841246|NCT03406338|Drug|Collagenase Clostridium Histolyticum|Injection of Collagenase into the Dupuytren cord after local anesthesia (nerve block) followed 24-48 hours later by finger manipulation after local anesthesia
45841247|NCT03149562|Drug|plasma transfusions|These critical ill neonates with plasma transfusions
45348728|NCT00742404|Other|immunologic technique|
45348729|NCT05279950|Device|Full-mouth ultrasonic debridement with piezoelectric device (EMS, mini piezon)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
45348730|NCT05279950|Device|Full-mouth ultrasonic debridement with magnetostrictive device (Cavitron Select, Dentsply)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
45348731|NCT00848601|Drug|SGI-1776|Starting dose 100 mg (total daily dose) administer as 50 mg every 12 hours for 14 days of a 21-day cycle, dose escalation in successive cohorts until progression or toxicity develops
45348732|NCT00742482|Drug|HL 10|Freeze dried HL 10
45348733|NCT00939250|Behavioral|Diabetes and depression intervention|Disease self management for diabetes and depression
45348734|NCT00939250|Behavioral|Diabetes intervention|Disease self management for diabetes
45348735|NCT00744666|Drug|Prednisolone 1% topical eye drops|Prednisolone 1% 1gtt qid to the eye requiring IVTA
45348736|NCT04013620|Drug|Belatacept 250 Milligram Intravenous Powder for Solution|"Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15 and 30 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)"
45475916|NCT03347734|Behavioral|Eye exercises group|"20 times hot water, 20 times cold water washing face in the morning and evening.~Palming; 2 hands are rubbed together and warmed up, and the eyes are closed, and 8 digits are drawn with eyes in darkness.~20 blinks~Looking at a clock in a circular shape, from 12 to 6, from 6 to 12, from 3 to 9, from 9 to 3, from 2 to 8, from 8 to 2, oblique from 10 to 4, from 4 to 10, and turning the eyes starting from 12 clockwise and counterclockwise. At the end of the exercises, 2-3 minutes of light massage around the eyes and on sunny days, sunbathing was recommended by closing the eyes for 3-5 minutes and swinging to the left and right."
45475917|NCT03347734|Behavioral|Convergence exercise group|"Close eyes for 15 s,~Focus on a point 1 to 1.5 ft away for 10 s,~Close eyes for 5 s,~Focus on a point 20 ft away for 10 s,~Close eyes for 5 s,~Focus on a point 1 to 1.5 ft away for 10 s,~Blink for 5 s,~Close eyes for 5 s."
45841248|NCT03149562|Drug|non-plasma transfusions|These critical ill neonates without plasma transfusions
45475918|NCT03347734|Behavioral|Oculomotor Exercise Group (OMEG)|"The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes."
45475919|NCT03846011|Other|24-h urine collection|Collecting 24-h urine prior and after stone removal surgery
45841249|NCT03129126|Drug|LP-10|Intravesical tacrolimus
45841250|NCT03031626|Biological|Medical Air vs Oxygen|Medical Air/Oxygen will be given
45841251|NCT01842672|Drug|Clofarabine|Dose Escalation of Clofarabine
45841252|NCT01842672|Drug|Mitoxantrone|
45841253|NCT01531374|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
45841254|NCT01240902|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
45841255|NCT01240902|Device|Surgical Aortic Valve Replacement (SAVR)|Surgical Aortic Valve Replacement (SAVR)
45841256|NCT01034592|Drug|Lenalidomide|2.5 mg/wk up to 5 mg 3x/wk
45841257|NCT01037790|Drug|PD-0332991|Given orally, 125 mg QD on a 21-day
45841258|NCT01038336|Behavioral|Multimedia Hearing Loss Prevention Program|Interactive, multimedia, computer-based HLPP that provides hands-on education and training about hearing loss, tinnitus, hearing protection, and general hearing health care for Veterans.
45348737|NCT02562222|Procedure|anodal tDCS on M1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
46044474|NCT00818623|Drug|Degarelix|Degarelix (160 mg (40 mg/mL)) was given as a subcutaneous injection
45348738|NCT02562222|Procedure|cathodal tDCS on M1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
45348739|NCT02562222|Procedure|anodal tDCS on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
45348740|NCT02562222|Procedure|cathodal tDCS on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
45348741|NCT02562222|Procedure|anodal tDCS on M1 and cathodal on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
45348742|NCT02562222|Procedure|cathodal tDCS on M1 and anodal on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
46044475|NCT00818623|Drug|Degarelix|Degarelix (200 mg (40 mg/mL)) was given as a subcutaneous injection
46044476|NCT00818623|Drug|Degarelix|Degarelix (200 mg (60 mg/mL)) was given as a subcutaneous injection
46044477|NCT00818623|Drug|Degarelix|Degarelix (240 mg (40 mg/mL)) was given as a subcutaneous injection
46044478|NCT00818623|Drug|Degarelix|Degarelix (240 mg (60 mg/mL)) was given as a subcutaneous injection
46044479|NCT00818623|Drug|Degarelix|Degarelix (320 mg (60 mg/mL)) was given as a subcutaneous injection
46044480|NCT02641210|Procedure|Periodontal Treatment|Periodontal Treatment using Gracey curettes and ultrasonic device.
45348743|NCT02562222|Procedure|sham tDCS|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
45348744|NCT04012684|Device|Transcranial magnetic stimulation|For one-session rTMS, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz, 100% resting motor threshold TMS pulses. The inter-train interval is 26 seconds.
45348745|NCT04012684|Device|Sham|For one-session sham stimulation, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz sham pulses. The inter-train interval is 26 seconds.
45348746|NCT05051228|Device|CardioFlux|Magnetocardiography (MCG) is a noninvasive method that measure the magnetic field that arises from the electrical activity of the heart cycle.
45348747|NCT00944788|Other|qi-gong|Physical activity similar to tai-chi
45348748|NCT00749112|Drug|Alemtuzumab, Rituximab|Alemtuzumab 10 mg each 24 hrs subcutaneous for 3 days. Rituximab 100 mg IV every week for 4 weeks.
45348749|NCT00848679|Drug|Epidural lidocaine|Epidural 2% lidocaine, administered in 5mL incremental boluses. Looking at dose-response effect.
45348750|NCT00848679|Drug|Epidural lidocaine 2%|5 x 5ml boluses of either epidural lidocaine 2% or epidural saline
45348751|NCT02567864|Other|Healthy Beat Accupunch exercise program|HBA has three phases and takes 40 minutes to complete.
45348752|NCT02567864|Other|control|participants maintain their daily activities.
45348753|NCT04012606|Drug|TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo|TORIPALIMAB INJECTION(JS001 ) or Placebo combined with chemotherapy, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
46044481|NCT02641210|Drug|Albendazole|All participants took Albendazole 400 mg before the intervention.
46044482|NCT02641366|Device|Electromagnetic tracking|The electromagnetic tracking system will precisely measure the position of a patient's upper extremity in space during routine neurologic examination.
46044483|NCT02641366|Procedure|Tremor kinetics after DBS|We will fit the patient with the electromagnetic sensors and then perform routine outpatient neurologic examinations with their DBS system in both the DBS on and the DBS off settings.
46044484|NCT02641366|Procedure|Tremor kinetics before and after DBS|We will perform two testing sessions: the first session will be performed during a routine preoperative visit, the second session will be performed during a routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
46044485|NCT02644330|Procedure|transthoracic device closure|minimally invasive transthoracic device closure
46044486|NCT02644330|Procedure|surgical repair|surgical repair with cardiopulmonary bypass
45348754|NCT00744744|Other|informational intervention|Patient educational information
45348755|NCT00744744|Other|questionnaire administration|Survey
45348756|NCT00744744|Procedure|management of therapy complications|Survey
45348757|NCT00744744|Procedure|psychosocial assessment and care|Survey
45348758|NCT00744744|Procedure|quality-of-life assessment|Survey
45348759|NCT04043091|Procedure|percutaneous coronary intervention (stenting)|percutaneous stent implantation in coronary artery
45348760|NCT02545959|Drug|Rituximab IT|CSF injection of intrathecal rituximab (20mg)
45348761|NCT02545959|Drug|methylprednisolone IV|blood infusion of methylprednisolone IV (120mg)
45348762|NCT02545959|Drug|Rituximab IV|Blood infusion of rituximab (375mg/m2)
46044487|NCT02644408|Drug|Megestrol（Yining）|Megestrol（Yining）: 160mg/d, po,7 weeks in total, one week before chemoradiotherapy and one week after chemoradiotherapy.
45348763|NCT04012528|Other|ERAS program|ERAS program
45348764|NCT04062110|Device|plaster cast|Closed Reduction of Fracture and Application of Plaster Cast
45348765|NCT00747630|Other|An educational video about Fetal Alcohol Syndrome|A 20 minute video about FAS
45348766|NCT02545647|Device|BRYGB|65 patients undergo a banded RYGB
45348767|NCT00744900|Drug|Pemetrexed, cisplatin|Alimta 500mg/m² IV 10 min infusion and Cisplatin 75mg/m² IV 60 min on day 1. Cycle will be repeated each 21 days.Folic acid orally 400µg should begin 5-7days prior to the first dose of pemetrexed and continuing daily until 3 weeks after the last dose of pemetrexed. Vitamin B12 will be administered as a 1000 mg intramuscular injection, approximately one week before Day 1 of cycle 1 and should repeat approximately every 9 weeks Dexamethasone, 4 mg or equivalent, should be taken orally twice per day on the day before, the day of, and the day after each dose of pemetrexed.WBRT will be administered with high energy photons systematically after cycle 6 or in case of stable disease (SD) after cycle 4 or progressive disease (PD) at any time. The dose will be 3Gy by fraction, 1 fraction per day, for 10 days.
45348768|NCT00727090|Drug|Conivaptan|Conivaptan 20 mg once, followed by conivaptan 20 mg over 24 hours
45348769|NCT00852033|Behavioral|Brief Motivational Intervention (BMI)|Students met with trained interventionists. The initial BMI took place during the fall semester of the freshmen year for approximately 45 minutes. Individualized feedback was used to guide the BMI sessions. The feedback data were gathered through an online survey completed within two weeks of the scheduled appointment to ensure the use of proximal feedback reflecting current drinking. Feedback was tailored so that drinkers received information on their personal drinking patterns, heavy episodic drinking, and alcohol-related consequences, and abstainers received feedback on their perceived barriers for maintaining abstinence, the safety and health benefits of their choice not to drink, and their experience with second-hand effects of alcohol use. In the spring of the freshmen year, students received a BMI 'booster' session. Individualized feedback was created from the original online survey and the 10 month follow-up assessment.
45348770|NCT00852033|Behavioral|Parent Based Intervention plus booster|The PBI is a handbook-based intervention modified from Turrisi and colleagues (2001). It was designed to raise parental awareness of alcohol abuse and consequences among college students and increase parental effort to address this issue with their teen.
45685249|NCT01450462|Dietary Supplement|Placebo|Women in the placebo arm will take their matching supplement weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
45841259|NCT01038336|Behavioral|Hearing Conservation Brochure|Hearing Conservation brochure provides knowledge-based information similar to that of the multimedia HLPP, but in written form.
45841260|NCT01040052|Biological|Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis)|0.5 mL, Intramuscular
46044488|NCT02644408|Radiation|radiotherapy|radiotherapy (radiation): 50Gy in total，2 Gy/d，5d/w.
46044489|NCT02644408|Other|chemotherapy|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total or capecitabine(Aibin) plus Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V. or cisplatin: 75mg/m2 d1，29 5-Fu：750mg/m2CIV24h d1-4，d29-32. The 3 regimens were Randomly distributed to patients.
46044490|NCT05758597|Drug|Remazolam besylate|Remazolam benzoate group was given 0.1-1mg/kg/h, and the target RASS score was maintained.
46044491|NCT05758597|Drug|midazolam|Meanwhile the midazolam group was given 0.05-0.2 mg/kg/h midazolam, and the target RASS score was maintained.
46044492|NCT02644486|Drug|High dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 4.8g/d+Irbesartan 300mg/d
45348771|NCT00852033|Behavioral|Combined brief motivational intervention and parent based intervention plus boosters for both interventions|A combination of Intervention 1 and 2.
45348772|NCT00852033|Other|Assessment only|No intervention, assessment only.
45348773|NCT00944944|Behavioral|limb volume measurements and GCLQ lymphedema symptom assessment questionnaire|Upon obtaining consent, the participants without a history of lower extremity lymphedema will be asked to undergo limb volume measurements to ensure the accuracy of group assignment to the nonlymphedema group. Participants will then be asked to complete the one time GCLQ lymphedema symptom assessment questionnaire. The survey tool and Limb volume (LV) data and feedback from participants about the GCLQ will be collected. We expect the study survey to take approximately 5-10 minutes to complete and 5-10 minutes to collect LV data.
45685250|NCT02643238|Device|BrainPort|This system is a novel, bionic, non-invasive, vision bypass system that conveys environment images from a spectacle-frame-mounted video-camera to the brain via an electro-tactile tongue array. The electro-tactile stimulation delivered by the tongue-array placed on the tongue allows users to interpret the images of objects in their camera's visual field
45685251|NCT01450774|Drug|CHF 1535 50/6µg|fixed combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
45685252|NCT01450774|Drug|beclomethasone dipropionate 50µg + formoterol fumarate 6µg|free combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
45685253|NCT01450852|Behavioral|Strength Training|Each Member of this group completed 12 weeks of progressive, periodized resistance training for 3d/wk.
45685254|NCT01450930|Drug|Hydrocortisone intramuscular first|Hydrocortisone intramuscular first
45348774|NCT00944944|Behavioral|GCLQ lymphedema symptom assessment questionnaire|The gynecologic cancer survivors with lymphedema group will have documented lower extremity lymphedema. Participants will be asked to complete a one time assessment, the Gynecologic Cancer Lymphedema Questionnaire to identify lower extremity lymphedema symptoms in gynecologic cancer survivors. They will also be asked to provide feedback about their satisfaction with and the feasibility of the GCLQ as a brief assessment tool that could be used in the clinical care setting.
45348775|NCT00848835|Device|defibrillation lead (ENDOTAK EZ and RELIANCE)|defibrillation lead
45348776|NCT00950014|Other|Presentation of drug efficacy and side effect data|Data presented in 1 of 5 numeric formats in each arm: percentage only, fixed frequency only, variable frequency, variable combination and fixed combination format.
45348777|NCT00855621|Procedure|Deep brain stimulation of the subthalamic nucleus|Chronic bilateral deep brain stimulation in the nucleus subthalamicus is performed using the most effective of four electrode contacts identified during testing of stimulation settings. Stimulation settings will be variable and adjusted according to the symptoms of each individual patient. Stimulation parameters will be recorded at each individual examination. Dopaminergic and other necessary medication will be given according to the need of each patient.
45348778|NCT00689052|Drug|pramipexole ER|
45348779|NCT00689052|Drug|placebo|
45348780|NCT04012450|Procedure|Epidural anesthesia|Performing an epidural anesthesia
45348781|NCT04012450|Procedure|spina-epidural anesthesia|Performing a spina-epidural anesthesia
45348782|NCT04118595|Behavioral|Educational Video|Educational Video: Development of the original video was funded by the John A. Hartford Foundation and used a systematic approach that included a review of literature and current pain management guidelines and input from emergency physicians, geriatricians, and experts in pharmacology, physical therapy, and risk communication. The video offers information about the pharmacologic management of acute musculoskeletal pain (MSP) and recovery-promoting behaviors. Each video section is followed by a multiple-choice question to promote interaction and reinforce learning. The actress for the 13-minute video is a 56-year-old mixed-race woman who presents herself as a healthcare provider. The video script was developed for a grade level 5.5 and will be shown to the patient within 24 hours of the acute care visit. A link to the video is emailed or texted to the patient.
45841261|NCT01040208|Drug|flibanserin 50 mg to 100 mg qhs|50 to 100mg qhs
45841262|NCT01040208|Drug|flibanserin 100 mg qhs|100mg qhs
45841263|NCT01040208|Drug|placebo 2 tablets qhs|50 mg placebo
46044493|NCT02644486|Drug|Low dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 2.4g/d+Irbesartan 300mg/d
46044494|NCT02644486|Drug|Irbesartan|Irbesartan 300mg/d
45841264|NCT01043094|Drug|Pitavastatin 4mg|Pitavastatin 4mg single dose
45348783|NCT04118595|Behavioral|Telecare|Telecare will be provided via a protocol-guided phone call from a nurse care manager 48-72 hours after discharge from the ED or orthopedic urgent care. The call is designed to support patient decision-making regarding analgesics and behaviors following the content presented in the video. Topics covered in the call will include discussion of goals and priorities the patient has for their pain management, current prescriptions and analgesic use (and adjustments if needed), non-pharmacologic methods of pain management, warnings about potential side effects, current healthcare utilization, and open-ended questions to address additional patient care needs. Conversations will be guided by a shared decision making framework in which the nurse suggests pain management options, discusses their pros and cons, and actively elicits feedback from the patient. The telecare call is designed to last 15 minutes.
45475920|NCT05670899|Procedure|CAD PEEK frame-work|Construction of PEEK framework will be done conventionally by lost wax technique using a vacuum press device. The wax pattern will be invested in a mold using special investment. Then it will be heated and melted to produce a mold into which PEEK will be vacuum pressed. The framework will be fitted on the master cast
45841265|NCT01043562|Diagnostic Test|Defibrillator threshold testing|Measurement of the defibrillation threshold was performed using a modified binary search protocol. This protocol specified three distinct inductions of ventricular fibrillation (VF) for all subjects, with a 3-5 minute observation/waiting period between inductions. The initial shock energy was programmed at 9 joules (J) for all patients, with internal rescue shocks at 31J followed by device-specific maximum deliverable energy. The outcome of the initial induction determined the programmed energies for both the initial and internal rescue shocks for the second induction, and likewise for the third induction. All shocks were biphasic and delivered at manufacturers' default tilt, polarity and duration, and all final programmed shock vectors included an active can. External defibrillation pads were in place for delivery of external rescue shock should the internal shocks fail.
46044495|NCT00652756|Device|Use of ventilator during patient transport (Versamed iVent)|The goal of the transport ventilator is to provide optimal ventilation.
46044496|NCT00652756|Other|Bag-valve ventilation|Use of bag-valve ventilation during patient transport.
46044497|NCT00827359|Drug|Everolimus|Tablet form taken orally once a day
46044498|NCT02641288|Drug|Ropivacaine irrigation|Using a standard irrigation device (no specific device is being used), 300 mg total of ropivacaine in 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
45348784|NCT04118595|Behavioral|Correspondence with Primary Care Provider|Following the telecare conversation, a note will be sent directly to the patient's primary care provider using a secure email or an electronic message that includes: 1) The date, time, location and reason for the index visit; (2) Results of diagnostics studies; (3) Discharge prescriptions/ recommendations; (4) A summary of and link to the video, explaining the emphasis on patient knowledge and SDM; (5) A summary of the telecare conversation; and (6) Encouragement for follow-up. PCPs will be asked to confirm receipt of this message.
45348785|NCT00945022|Device|wetting lips following surgery using anesthesia|The investigator will position the Lipsus device in accordance with the instructions for use
45348786|NCT02565212|Drug|Montelukast,mometazon froat|
45348787|NCT00848913|Other|Rehabilitation with strength training|Basic mobility and exercise therapy following a guideline with 12 specific exercises, progressed individually, and supplemented with progressive knee-extension strength training (10RM) of the fractured limb using ankle weight cuffs, daily during hospital stay.
45475921|NCT05023174|Procedure|Hiatal Hernia Repair with Platelet Rich Plasma|Platelet rich plasma will be injected into the crura of the diaphragm and coating the mesh placed during surgery.
45475922|NCT05023174|Procedure|Hiatal Hernia Repair without Platelet Rich Plasma|Surgery will be performed without the addition of platelet rich plasma injection
45475923|NCT03196635|Device|Patient-Assisted (PA) Breast Compression|The technologist will properly position the breast and apply minimum compression. The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. The technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. This will be done for both standard views CC & MLO.
45475924|NCT03196635|Device|Technologist-Controlled (TC) Breast Compression|TC compression will be conducted per standard of care practices at the site.
45475925|NCT01195181|Drug|peginterferon plus ribavirin|peginterferon alfa-2a at 180ug/week (preempt syringe, sc) or peginterferon alfa-2b at 1,5 ug/kg/week (standard dose) or at 1,0 ug/kg/week (lower dose)(preempt pen, sc) for 24 or 48 week in relation to HCV genotype plus ribavirin (capsules, po) at 15mg/kg/daily combination therapy.
45475926|NCT05065437|Other|Active (Virtual reality and spinal stimulation)|Each session is 25 minutes; 5 minutes of setup, and 20 minutes of simultaneous spinal stimulation at the cervical level and immersive virtual experience/gameplay.
45475927|NCT05388149|Drug|Neratinib|Neratinib administered as 40mg tablets
45475928|NCT05441943|Procedure|Lymphovenous anastomosis|"Pre-operative planning prior to lymphovenous anastomosis using ICG lymphography and ultra high frequency ultrasound for mapping of applicable vessels.~During surgery, mapped vessels are freely dissected and anastomosed."
45475929|NCT05600699|Device|Cardiac pacemaker and Select Secure lead|model 3830, 69cm, Medtronic, Inc., Minneapolis, MN, USA
45475930|NCT05047341|Drug|SHR0302、[14C]SHR0302|8 mg SHR0302/ 80 µCi [14C]SHR0302, once, D1
45475931|NCT03845855|Other|virtual reality|Virtual reality with a game
45475932|NCT03845855|Other|robotic gait|robotic gait therapy
45475933|NCT05043675|Drug|[18F]APN-1607|Subjects will receive one injection of [18F]APN-1607 (0.1~0.15mCi/Kg), a PET radiopharmaceutical selective for fibrillar tau. [18F]APN-1607 injection will be followed by a 10 ml saline flush.
45475934|NCT01196897|Device|WATCHMAN LAA Closure Technology (Gen 4.0)|Implantation of the WATCHMAN device into the left atrial appendage.
45475935|NCT01197053|Biological|Epicutaneous Immunotherapy|100 mcg peanut proteins (active arm) applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
46044499|NCT02641288|Drug|Normal saline irrigation|Using a standard irrigation device (no specific device is being used), 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure.
46044500|NCT04165174|Drug|Terepril monoclonal antibody; Apatinib|Terepril monoclonal antibody,240mg,ivdrip,Q3W Apatinib,250mg,po,QD
45348788|NCT00848913|Other|Rehabilitation without strength training|Basic mobility and exercise therapy without strength training following a guideline with 12 specific exercises, progressed individually.
45348789|NCT00747708|Drug|Granulocyte-colony stimulating factor|5 days subcutaneous injection
45348790|NCT00747708|Procedure|Percutaneous intracoronary injection|Bone marrow derived stem/progenitor cells or placebo infusion is delivered through an over-the-wire balloon catheter into the target coronary vessels using a stop-flow technique.
45348791|NCT00747708|Procedure|Percutaneous intramyocardial injection|Direct intramyocardial injections of bone marrow derived stem/progenitor cells or placebo will be delivered using the electromechanical NOGA mapping and injection system
45348792|NCT05602064|Drug|Ibuprofen|Ibuprofen is a non-steroidal anti-inflammatory drug which acts by reducing the production of cyclo-oxygenases (COX-1 and COX-2)- derived prostanoids in the blood
45348793|NCT05602064|Drug|Paracetamol|Paracetamol is an analgesic that acts peripherally; although its primary site of action is still debatable, it is thought to inhibit prostaglandins in the hypothalamus
46044501|NCT04165174|Radiation|SBRT|6-10Gy/F,5-8F
46044502|NCT02613247|Device|Hylan G-F 20|Intra-articular injection of 6 mL Hylan G-F 20
46044503|NCT02641132|Drug|Mitomycin C 0.02%|Pterygium excision with application of mitomycin C
46044504|NCT02641132|Procedure|Pterygium surgery|Two different procedures- excision of the head and the body and excision of the head only
45348794|NCT05602064|Other|Placebo|A placebo solution will be freshly prepared by an assistant in a manner to match the color and odor of the analgesics
45348795|NCT02565134|Drug|PAC-14028 cream 0.1%|Topical application
46044505|NCT02647840|Behavioral|voice therapy|voice therapy based on Estill Voice Model The study will provide primarily direct intervention, i.e. working directly on the voice with voice exercises based on the Estill model of voice. This will be structured and hierarchical. Participants will work through the content one-to-one with the voice specialist SLT at their level and pace, to suit their specific vocal needs, again reflecting current clinical practice. Participants may need fewer or more than four sessions to gain the required skills. Should patients need more than six session of voice therapy to recover their voice fully, final assessment for the study purposes will be taken at session 6, and voice therapy will continue as required.
45348796|NCT02565134|Drug|PAC-14028 cream 0.3%|Topical application
45475936|NCT01197053|Biological|placebo of peanut|placebo applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
46044506|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)|Single dose administration of E2 + DRSP as a tablet
46044507|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 2 (80458739)|Single dose administration of E2 + DRSP as a tablet
46044508|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 3 (80458755)|Single dose administration of E2 + DRSP as a tablet
46044509|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 4 (80458720)|Single dose administration of E2 + DRSP as a tablet
45348797|NCT02565134|Drug|PAC-14028 cream 1.0%|Topical application
45348798|NCT02565134|Drug|PAC-14028 cream vehicle|Topical application
45475937|NCT03845699|Device|Diagnostic algorithms that detects/predicts hypoventilation|Produce mild and moderate respiratory depression (hypoventilation) using a controlled intravenous infusion of fentanyl while measuring/recording respiratory rate, tidal volume, body activity, and body position.
45475938|NCT05671133|Diagnostic Test|Clinician Decision Support Tool|Clinician Decision Support Tool that provides information about patient's statistical probability of suicide attempt in next 1 month
45475939|NCT03845777|Diagnostic Test|Using Antiseptic solution|Using of iodine including antiseptic solutions. The investigators investigate the urine iodine status of staff before and after the using of antiseptic solution
46044510|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 5 (80458712)|Single dose administration of E2 + DRSP as a tablet
46044511|NCT00653614|Drug|DRSP (ZK 30595) dose 1 (SH T04984F)|Single dose administration of DRSP as a tablet
46044512|NCT00653614|Drug|DRSP (ZK 30595) dose 2 (80458690)|Single dose administration of DRSP as a tablet
46044513|NCT00653614|Drug|Placebo|Placebo administration in each arm
46044514|NCT02647762|Drug|CF101 1 mg|CF101 tablets, 1mg BID for 12 weeks
46044515|NCT02647762|Drug|CF101 2 mg|CF101 tablets, 2 mg BID for 12 weeks
45348799|NCT00747942|Behavioral|Support for Increased Physical Activity|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
45348800|NCT00560950|Biological|pneumococcal 23v polysaccharide vaccine|Duration of Treatment: Single vaccination on Day 1
45348801|NCT02562144|Drug|Xylocaine spray|Cutaneous xylocaine spray before intravenous cannulation.
45348802|NCT02562144|Drug|Placebo|Cutaneous placebo before intravenous cannulation.
45348803|NCT02562300|Drug|Misoprostol|400 micrograms of sublingual misoprostol were given immediately after delivery of the neonate.
45348804|NCT02562300|Drug|Oxytocin|20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h were given immediately after delivery of the neonate.
45348805|NCT00945178|Drug|AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
45348806|NCT00945178|Drug|Placebo for AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
45348807|NCT00945178|Drug|Naproxen|Tablet, single oral dose, 500mg
45348808|NCT00945178|Drug|Placebo for Naproxen|Tablet, single oral dose
45348809|NCT00749346|Device|NovoTTF-100L|TTFields treatment 12h/d for the duration of the study (until progression)concomitant to standard Alimta dosing
45348810|NCT05301478|Device|standard of care insole|standard of care diabetic insole
45348811|NCT05301478|Device|3D Printed Insole - pressure based|3D Printed Insole - pressure based
45348812|NCT05301478|Device|3D Printed Insole - FEA|3D Printed Insole - FEA
45348813|NCT00945412|Device|Micropolysaccharide Hemospheres (Arista)|"MPH is applied as an aerosolized powder which is applied to the bleeding fossa, immediately after suctioning the freshly completed tonsillotomy site to expose the tonsil bed. A separate aerosolizer is used for each patient in order to maximize uniformity per standard dose applied. Each initial dose remains in situ for up to 60 seconds in an attempt to achieve complete hemostasis with a single dose. (Prior data from MPH use has shown that 30-60 seconds is the time typically required for hemostasis for diffuse, non-arterial bleeds.) If there is persistent bleeding after this timeframe, then the bed is irrigated and suctioned and a second equivalent dose is applied.~No pressure pack and no oxymetazoline or other topical vasoconstrictor is applied in either group during these initial hemostatic steps, since they are potential confounders of hemostatic effect."
45348814|NCT00945412|Device|Electrocautery (Monopolar suction cautery)|Monopolar suction electrocautery is used at 20 Watts. Cautery is applied with a light surface touch until bleeding has stopped. In addition, any prominent visible vessels are cauterized.
45348815|NCT00749424|Device|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
45348816|NCT00749424|Device|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
45841266|NCT01043562|Other|Observation of post-shock intrinsic cardiac rhythm|Prior to each of the three ventricular fibrillation inductions performed as part of the binary search protocol, post-shock pacing was re-programmed using a pre-determined, stepwise protocol that progressively decreased the lower rate limit. For the purpose of this protocol, post-shock pacing was considered necessary if 1) ≥7 ventricular-paced beats or 2) asystole >4 seconds was observed in the first 20 seconds after defibrillation, or if the systolic blood pressure demonstrated a >10% decrease from pre-induction baseline at follow-up measurement 1 minute post-defibrillation. Rescue ventricular pacing via the programmer was available for all subjects.
45841267|NCT01043640|Drug|Campath-1H|Administered Days -21, -20 and -19, 0.3 mg/kg subcutaneously (SQ) or intravenously (IV)
45841268|NCT01043640|Drug|Cyclophosphamide|Administered days -10 through -6, 50 mg/kg/day intravenous (IV) over 2 hours - with Mesna continuous infusion or 5 times daily.
45348817|NCT00945568|Drug|Aminoleban EN|benefits of this drug for patients who undergoing liver resection for HCC
45348818|NCT02562690|Other|Thrombin generation assays, TEG and GTT|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
45348819|NCT00950092|Device|Numeris-AF Tethered Coagulation System with VisiTrax|Surgical radiofrequency (RF) epicardial ablation using the nContact Numeris-AF Tethered Coagulation System
45348820|NCT00576758|Drug|obinutuzumab (RO5072759)|1000 mg obinutuzumab intravenous (IV) infusion once a week for 4 weeks.
45348821|NCT00576758|Drug|rituximab|375 mg/m^2 rituximab IV infusion once a week for 4 weeks.
45348822|NCT00923676|Drug|fenofibrate|pill 145 mg, 145 mg/day, for 12 months
45348823|NCT00923676|Drug|Rosuvastatin|pills of 10 mg, 10 mg/day, 12 months
45348824|NCT00923676|Drug|fenofibrate + rosuvastatin|fenofibrate 145 mg/day + rosuvastatin 10 mg/day for 12 months
45348825|NCT00950326|Procedure|Physiotherapy|In intervention group B1, patients with osteoarthritis of the hip or knee will receive specific physiotherapy of the affected hip or knee joint three times a week, but without any disease-specific hydrotherapy. Because of the holistic approach of the clinic, however, these patients will still receive hydrotherapy at sites other than the affected joint, for example, alternate cold and warm affusions of the back or an ascending lumbar affusion.
45475940|NCT03846713|Procedure|non-thermosoftening|By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into normal saline at room temperature.
46044516|NCT02647762|Drug|Placebo|Placebo tablets, 1mg BID for 12 weeks
45348826|NCT00950326|Procedure|Affusion|Patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region (daily). Physiotherapy of other regions, such as the back, is permitted but there will be no specific physiotherapy of the hip or knee joint.
45348827|NCT00950326|Procedure|Affusion/ Physiotherapy|Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
45348828|NCT00745446|Procedure|Forearm Venous Occlusion Plethysmography|Forearm venous occlusion plethysmography with intra-arterial infusion of Acetylcholine (5-20mcg/min), bradykinin (30-300mcg/min), sodium nitroprusside (2-8mcg/min) and Verapamil (2-10 mcg/min) into non-dominant brachial artery
45348829|NCT05425446|Drug|DONQ52|Subcutaneous (SC) injection
45348830|NCT05425446|Drug|Placebo|Subcutaneous (SC) injection
45348831|NCT00921284|Drug|NaCl 9/00|Same volume as in the dexmedetomidine group
45475941|NCT03846713|Procedure|thermosoftening|By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into warm normal saline (40°C).
45348832|NCT00921284|Drug|dexmedetomidine|1 mcg/kg administered in 10 minutes followed by a continuous infusion of 0,5 mcg/kg/hr
45348833|NCT00748020|Procedure|UVB phototherapy|Group 1: every irradiation an increase of 40%, starting with 70% of the minimal erythema dose
45475942|NCT03194217|Drug|BEN-2001|Bavisant dihydrochloride monohydrate for oral use
45475943|NCT03194217|Drug|Placebo|Placebo
45475944|NCT00709618|Drug|Lapatinib, Vinorelbine|Vinorelbine intravenously once weekly for 3 weeks, followed by a rest week in a 4-week cycle) plus lapatinib daily
45475945|NCT01195259|Drug|allocation of treatment with metformin or rosiglitazone|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
45475946|NCT05584228|Drug|Azathioprine + infliximab|Combination therapy using 2-2.5 mg/kg oral azathioprine plus subcutaneous infliximab
45475947|NCT05584228|Procedure|Intestinal resection|Ileocolonic or small bowel resection
45475948|NCT03193047|Drug|bempedoic acid 180mg|Daily bempedoic acid 180mg tablet in addition to monthly PCSK9i (evolocumab) background therapy
45475949|NCT03193047|Other|placebo|Daily matching placebo tablet in addition to monthly PCSK9i (evolocumab) background therapy
45475950|NCT03193047|Drug|evolocumab|Monthly PCSK9i (evolocumab) background therapy
46044517|NCT02647762|Drug|MTX|MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter, for 12 weeks.
46044518|NCT02644252|Drug|Day 1: Cisplatin 75 mg/m2|
46044519|NCT02644252|Drug|Day 1: Vinorelbine 25 mg/m2|
46044520|NCT02644252|Drug|Day 8: Capsule vinorelbine 50 mg/m2|
46044521|NCT02644252|Drug|Day 1: Carboplatin AUC=5|
45348834|NCT00748020|Procedure|UVB phototherapy|Group 2: every irradiation an increase of 20%, starting with 30% of the minimal erythema dose
45348835|NCT00749502|Drug|MK-4827|MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D).
45348836|NCT00560794|Biological|Blinatumomab (MT103)|Administered by continuous intravenous (CIV) over 4 weeks per cycle
45348837|NCT03879330|Device|NIRS monitoring|aSAH patients will be given continuous NIRS and blood pressure monitoring at same time. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained through continuous monitoring of 4 hours. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP.
45348838|NCT00749736|Dietary Supplement|cholecalciferol|"4000 IU of cholecalciferol per day~15 patients will be enrolled in each arm."
45348839|NCT00749736|Dietary Supplement|doxercalciferol|1 mcg of doxercalciferol per day
45348840|NCT00749736|Dietary Supplement|placebo|"placebo for 6 months; with stratification based on stage of CKD by modified MDRD formula.~15 patients will be enrolled in each arm."
45348841|NCT00950404|Drug|Viagra 50 mg tablet|Commercial tablet, 50 mg, single dose administered with water
46044522|NCT02644252|Drug|Day 1: Vinorelbine 30 mg/m2|
46044523|NCT02644252|Drug|Day 8: Capsule vinorelbine 60 mg/m2|
46044524|NCT02644252|Dietary Supplement|Tocotrienol 300 mg x 3 daily until progression|
46044525|NCT02644252|Drug|Placebo 1 capsule x 3 daily until progression|
45348842|NCT00950404|Drug|Formulation B ODT tablet 50 mg|Oral disintegrating tablet (ODT), 50 mg, single dose administered without water
45475951|NCT01197209|Biological|Ad-REIC/Dkk-3|REIC (Reduced Expression in Immortalized Cells) protein is down regulated in a variety of cancer cell lines including prostate tumors. The REIC gene is identical to the Dickkopf-3 (Dkk-3) gene that is a member of the Dickkopf gene family. Ad-REIC/Dkk-3 is designed as a viral vector that delivers a DNA plasmid capable of producing intracellular REIC protein. The expression plasmid includes the full-length human cDNA sequence for REIC. The adenovirus vector is a transport mechanism to infuse the REIC/Dkk-3 plasmid into the cell providing a temporary transfusion of REIC protein.
45475952|NCT03346720|Other|Semi-structured interviews|These interviews will be conducted following an interview guide. Interviews will be conducted in English or Thai at a place convenient and familiar to the interviewee. It is estimated that each interview will last between 45 minutes to an hour.
45685255|NCT01450930|Drug|Hydrocortisone subcutaneously first|Hydrocortisone subcutaneously first
45348843|NCT00950404|Drug|Formulation C ODT tablet 50 mg|ODT, 50 mg, single dose administered without water
46044526|NCT00818389|Drug|Lithium Carbonate|Participants will receive capsules that contain 150 milligrams (mg) lithium carbonate. Participants will be randomized to lithium/riluzole or placebo/riluzole and treated for 52 weeks. Participants originally randomized to placebo who fail (progress) will crossover to lithium for the remainder of the trial.
46044527|NCT00818389|Drug|Riluzole|All participants enrolled in this study will be taking a stable dose of riluzole 50 milligrams (mg) by mouth (PO) twice per day (BID) for at least 30 days prior to screening.
45685256|NCT01451008|Device|Compression anastomotic ring-locking procedure (CARP)|The Compression anastomotic ring-locking procedure (CARP) device is based on a set of rings to make a compression anastomosis between the intestinal ends.
46044528|NCT00818389|Drug|placebo|an inactive substance
45348844|NCT00950404|Drug|Formulation D ODT tablet 50 mg|ODT, 50 mg, single dose, administered without water
45348845|NCT00749814|Dietary Supplement|Melatonin|Melatonin slow release tablets, 2 mg, 1 hour before bedtime for 7 days prior to admission to the hospital and up to 7 days after surgery.
45348846|NCT00749814|Other|Placebo tablets|Placebo
46044529|NCT02640976|Drug|Human menopausal gonadotrophin (HMG)|[Merional® 75 IU ampoules, IBSA institut]
45348847|NCT00950482|Procedure|TA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
45348848|NCT00950482|Other|AA|In Alternative acupuncture (AA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
46044530|NCT02640976|Drug|GnRH antagonist Cetrorelix|[Cetrotide® 0.25 mg syringes, Merck Serono]
46044531|NCT02640976|Drug|Human chorionic gonadotrophin (hCG)|[Choriomon® 5000 IU ampoules, IBSA institut]
45348849|NCT00950482|Other|WC|Waiting Group
45841269|NCT01043640|Drug|Busulfan|Administered every 6 hours: If < or = 12 kg then 1.1 mg/kg/dose intravenous (IV). If > 12 kg then 0.8 mg/kg/dose IV
45841270|NCT01043640|Procedure|Allogeneic stem cell transplantation|Administered > 24 hours after last dose of busulfan.
46044532|NCT04166344|Behavioral|Happyair Ecosystem|"Happyair Ecosystem is a Smart Community for the integral care of patients with chronic or rare respiratory diseases such as Asthma, COPD or Alfa-1.~Our community provides online & offline training and resources in digital health and social care to patients, family, caregivers, healthcare professionals and researchers.~Using our platform, all of our members will be able to connect in order to improve the health and well-being of patients, learn to manage self-care, ensure an active lifestyle, and contribute to the development of current and future research projects."
46044533|NCT04116463|Behavioral|Chronic Disease Self-Management Program (CDSMP)|
45348850|NCT00748176|Procedure|spinal anesthesia|spinal anesthesia with bupivacaine
45348851|NCT02041936|Device|NanoKnife IRE System|
45348852|NCT00941122|Device|Eluted Swab|Comparison of Eluted Swab with AMIES swab for detection of MRSA/VRE
45348853|NCT02565758|Drug|ABBV-085|Administered as an intravenous infusion in 28-day dosing cycles.
45348854|NCT04159922|Other|questionnaire|Bortner self questionnaire: 14 items Cohen PSS Perceived Stress scale: 10 items quality of life scale: 32 items depression scale: 14 items
45475953|NCT03346720|Other|Focus group discussions (FGDs)|These will be conducted following an interview guide. FGDs will be conducted in English or Thai. In addition, a note taker will be present to take notes. FGDs will take place at a place convenient and familiar to the participants. It is estimated that each FGD will last between 1 to 1.5 hours. FGDs will typically consist of homogenous groups e.g. study nurses.
45841271|NCT01043640|Drug|Cyclosporine A|"2.5 mg/kg/dose intravenous (IV_ beginning on day -3. Frequency of daily dosing will be based on the recipient's body weight:~If body weight is ≤ 40 kg dosing will be 3 times daily~If body weight is > 40 kg dosing will be 2 times daily An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2 times the current IV dose (maximum 12.5 mg/kg/day as initial oral dose)."
46044534|NCT04116463|Behavioral|Financial Self-Management Program (FSMP)|
45348855|NCT00941200|Biological|Blood collection|
45348856|NCT00945880|Drug|clemizole hydrochloride|Two 50 mg capsules containing clemizole hydrochloride are to be administered orally twice a day for 28 days for a total daily dose of 200 mg. Followed immediately by standard of care treatment consisting of interferon and ribavirin
46044535|NCT02644018|Drug|Imidazolyl ethanamide pentandioic acid|
46044536|NCT02644018|Drug|placebo|
46044537|NCT02647684|Behavioral|Self-Directed Triple P|10 Week Triple P Self directed workbook
46044538|NCT00850135|Device|The Seven Continuous Glucose Monitoring System|Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
46044539|NCT02647918|Drug|Sotagliflozin|Single dose
46044540|NCT02647918|Drug|Sotagliflozin|2 single doses
45348857|NCT04061174|Other|Shoulder stabilization exercises|When participants are able to do the exercise 15 repetitions without difficulty, the exercise will be advanced by modifying or adding the weight.The exercises include chin tulk exercise, shoulder closed chain weight transfer, prone and iso-abdominal exercises, push-up exercise, lower trapezius muscle strengthening exercise, dead bug exercise, ball rolling on the wall, bench press with dumbbell and internal/external rotation (IR / ER) strengthening exercises
45348858|NCT04061174|Other|Office exercises training|Information will be given in a brochure that includes the appropriate chair height and work table, sitting position, distance between eyes and monitor, and table chair dimensions.approved and standardized office-based stretching and strengthening exercises will be given for workplaces
45348859|NCT00950638|Drug|ARC1905|intravitreal injection
45348860|NCT02565290|Dietary Supplement|Omega 3|Pregnant women should take 2 capsules of omega 3 (1g), 2 times a day, for 21 days.
45348861|NCT02565290|Dietary Supplement|Soy Oil|Pregnant women should take 2 capsules of placebo 3 - soy oil oil (1g), 2 times a day, for 21 days.
45348862|NCT00941278|Drug|PH-10 (0.001% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
45348863|NCT00619359|Drug|Comparator: fosaprepitant dimeglumine|single IV dose of 150 mg of fosaprepitant dimeglumine on Day 1.
45841272|NCT01043640|Drug|Mycophenolate Mofetil|15 mg/kg/dose (max dose of 1gram) IV three times a day beginning on Day -3 at a dose based on body weight: The same dosage is used orally or intravenously. Stop MMF at day +42 or 7 days after engraftment achieved (ANC>500 x 10^6 neutrophils/L x 3 days and chimerism >90%), whichever is later.
45348864|NCT00619359|Drug|Comparator: Aprepitant|Aprepitant 3-day dosing oral regimen (125 mg on Day 1 followed by 80 mg on Days 2 and 3).
45348865|NCT00619359|Drug|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, 8 mg on Day 2, and 8 mg twice a day on Days 3-4.
46044541|NCT02644174|Procedure|Bariatric Surgery|
46044542|NCT03130036|Other|[11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan|A PET scan to measure uptake of acetoacetate and glucose in the brain will be administered to all participants enrolled in the study
45348866|NCT00619359|Drug|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, and 8 mg on Days 2-4.
45348867|NCT00619359|Drug|Ondansetron|single IV dose of 32 mg of ondansetron on Day 1.
45348868|NCT00950716|Behavioral|Patient Peer Support and Empowerment|30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
45348869|NCT00950716|Behavioral|Usual Care|Subjects in Usual CAre will receive standard care with clinicians' usual follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
45475954|NCT05597735|Drug|Tecovirimat|"The experimental intervention is tecovirimat, available as immediate-release capsules containing tecovirimat monohydrate, equivalent to 200 mg of tecovirimat. The route of administration of tecovirimat is oral. Tecovirimat treatment will be initiated as soon as possible after diagnosis.~The international recommended doses will be followed:~25 kg to less than 40 kg: 400 mg (two tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days.~40 kg and above: 600 mg (three tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days."
45685257|NCT02913196|Drug|Apalutamide|"Orally available, small molecule, nonsteroidal potent and selective antagonist of the androgen receptor.~Cohort 1 dose: 120 mg QD Cohort 2 dose: 240 mg QD Cohort 3 dose: 180 mg QD"
45685258|NCT02913196|Drug|Abiraterone acetate|"Abiraterone acetate is the prodrug of the active drug abiraterone. Once absorbed after oral administration, abiraterone acetate is rapidly converted to the active form, abiraterone.~Dose: 1000 mg QD"
45685259|NCT02913196|Drug|Docetaxel|"Taxane cytotoxic chemotherapy with demonstrated survival benefit in those with advanced prostate cancer.~Dose: 75 mg/m2 Q3W"
45685260|NCT02913196|Drug|Prednisone|Dose: 5 mg BID
45685261|NCT01451086|Biological|vaccine made by Beijing Minhai Biotechnology Co., Ltd|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
46044543|NCT02535988|Radiation|Radiation therapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of colorectal cancer.
46044544|NCT02535988|Drug|Thymalfasin|Patients with metastatic lesions of colorectal cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
45841273|NCT01044030|Drug|Xylitol syrup|7.5 mL (5 grams) by mouth three times daily
45841274|NCT01044030|Drug|Placebo|7.5 mL by mouth three times daily
45841275|NCT01044264|Drug|1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Topical Gel
45841276|NCT01044264|Drug|Placebo|Placebo
46044545|NCT02647450|Other|GIANT Completed patient|Patients identified in the GIANT clinic and who fulfill the inclusion criteria will be sent a 9 page questionnaire. Upon receipt the questionnaire will be sent to the patient's GP for validation.
46044546|NCT02640898|Radiation|docetaxel-based chemoradiotherapy|experimental:Patients with Zubrod performance status (PS) of 0-2 received up to 2 21-day cycles of pre- and post-radiation chemotherapy (docetaxel 37.5 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1-3, and a continuous infusion of fluorouracil (FU) 750 mg/m2 on days 1-5), respectively. CCRT between pre- and post-radiation chemotherapy was initiated on day 43 and consisted of 3-dimensional conformal intensity-modulated radiation therapy (45 Gy) plus concurrent docetaxel 20 mg/m2 weekly for 6 weeks;
45841277|NCT01044966|Drug|ITV DepoCyt + Temozolomide|Intrathecal liposomal Ara-C dosing will begin at 50 mg ITV every 2-4 weeks, and de-escalated based on toxicity obtained from the Phase I portion of the trial. Metronomic dosing of temozolomide will be given at 75 mg/m2 for 21 days (continuous oral dosing), followed by 7 days off in a 28 day cycle as a once daily dosing regimen.
45348870|NCT00848991|Drug|Precedex|Subjects randomized to the comparison group will receive a standardized general anesthetic. Anesthesia will be induced with propofol 1.5 ? 2.5 mg/kg, rocuronium 0.6 mg/kg, and sufentanil 0.1 ? 1mcg/kg. Anesthesia will be maintained with an infusion with propofol 25 -200 mcg/kg/min, sufentanil 0.0025 - 0.03 mcg/kg/min, and zemuron as needed. For the Precedex group the drug will be infused at 0.3-0.7 mcg/kg/hr. Blood pressure will be maintained within 10% of baseline prior to opening of the dura, subsequently to be maintained between a systolic of 100 ? 130 mmHg. Hypertension will be managed with standardized amounts of labetalol and nicardipine. Morphine will be titrated as needed to a maximum of 0.05mcg/kg at the conclusion of case. Hemodynamic data and emergence evaluations will be collected in the operating room, pre-induction until the end of anesthesia and discharge from the operating room. There will be no further follow up.
45348871|NCT00848991|Drug|Propofol|evaulation of propofol for emergence from anesthesia
45348872|NCT00941434|Dietary Supplement|RUTF|Children with severe malnutrition will be treated with a daily dose of RUTF till their weight for age z scores no longer fall in severe malnutrition group
45348873|NCT02545725|Other|Questionnaire on Quality of Life|The patients were asked to complete a questionnaire on Quality of Life
45841278|NCT01045122|Drug|Propofol|For propofol, the current study will employ the Marsh parameters, with an initial effect site target concentration of 1.0 mcg/ml, a level likely to produce only mild sedation. Though our patient population is expected to be predominantly obese, a previous pharmacokinetic study has validated that constant infusions utilizing the dosing scheme of mcg-1•kg-1•min will yield similar effect site concentrations.25 The effect site target will be increased in increments approximately every five minutes until the pharmacodynamic targets defined in the study are attained.
45841279|NCT01045122|Drug|Dexmedetomidine|For dexmedetomidine, an intravenous loading dose of 0.5 mcg/kg will be infused over 10 minutes and followed by an infusion starting at 0.5 mcg/kg/hr. This infusion will be titrated up to a maximum of 1.2 mcg/kg/hr.
45841280|NCT01049802|Device|Repetititve transcranial magnetic stimulation|1 Hz rTMS to contralesional hemisphere in patients with stroke
45475955|NCT05597735|Drug|Placebo|The control intervention is a placebo and its route of administration will be identical to the experimental intervention administration to allow treatment arm blinding.
45475956|NCT04970212|Device|BioTraceIO Lite|The BioTraceIO software will analyze the ultrasound images, and provide the physician with an estimated tissue damage map.
45841281|NCT01050582|Drug|Risperidone|As per local prescribing practices
45841282|NCT01050582|Drug|Other atypical antipsychotic drugs|As per local prescribing practices
45841283|NCT01050660|Other|Intravenous fat emulsion|An infusion of intravenous fat will start at 0.5 grams/kg on the first day of life, with increments of 0.5 -1.0 grams/kg every day, until a total dose of 3 grams/kg is reached.
45841284|NCT01050660|Other|Restriction of intravenous fat emulsion to 1 gm/kg/d|Intravenous fat will be started at 0.5 grams/kg on the first day of life and then increase to a dose of 1gram/kg/day the next day. There will be no further increase in the amount of intravenous fat.
45841285|NCT01051440|Drug|Lisdexamfetamine|Start at 20 mg daily. Increased to a maximum of 40 mg daily. Can be decreased in 10 mg increments.
45841286|NCT01051440|Drug|Placebo|Subjects will receive placebo matched to lisdexamfetamine.
45841287|NCT01051518|Device|Medtronic CoreValve System|Transcatheter Aortic Valve
45841288|NCT01051596|Drug|Temozolomide|150mg/m2 Days 1-5 of each 28 day cycle
45348874|NCT00950794|Drug|Salmeterol(SN408D)|Salmeterol(SN408D)：long-acting Beta2-agonist
45348875|NCT00950794|Drug|Hokunalin (tulobuterol) tape|Hokunalin (tulobuterol) tape:long-acting Beta2-agonist
45348876|NCT00852189|Drug|EC0489, Injection|PART A: Dose escalation from a starting dose of 1.0 mg/m2 IV bolus on Monday, Wednesday, and Friday Weeks 1 and 3 of a 4-week cycle to the Maximum Tolerated Dose (MTD)
45348877|NCT00852189|Drug|EC20|20-25 mCi 99mTc-EC20 administered IV bolus 1-2 hours prior to imaging and at end of study for subjects who received 1 cycle or more of EC0489.
45475957|NCT01195337|Behavioral|PA Prescription Plan|Exercise program and instructions.
45475958|NCT01195337|Device|Pedometer|Step monitor for individual PA progress.
45475959|NCT01195337|Behavioral|Newsletters|4 Newsletters with topics based on PA progression phases of adoption and maintenance.
45841289|NCT01051596|Drug|ABT-888|40mg orally BID Days 1-7 of each 28 day cycle
46044547|NCT02640898|Radiation|FU-based chemoradiotherapy|The adjuvant treatment consisted of 425mg/m2 of bolus fluorouracil(5-FU) per day, 20 mg/m2 of leucovorin (LV), per day, for 5 days, followed by 45Gy of radiation with current 5-FU ( 400mg/m2 ) and LV (20mg/m2) as an intravenous bolus on each of of the first four days and the last three days of irradiation. One month after the completion of radiotherapy, two 5-day cycles of 5-FU and FV chemotherapy were given one month apart.
45348878|NCT00852189|Drug|EC0489, Injection|PART B: Once PART A MTD is determined, PART B will begin. Dose escalation from a starting dose of 4.2 mg/m2 IV bolus once weekly in a 4-week cycle to the Maximum Tolerated Dose (MTD).
45475960|NCT04504552|Drug|Avelumab|Subjects will receive treatment with avelumab monotherapy 800 mg as a 60-minute IV infusion on the Day 1 (± 2 days) of a 2-week treatment cycle for 4 administrations.
45475961|NCT01197287|Drug|QAK423A|
45348879|NCT00951028|Behavioral|Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD)|12 therapy sessions delivered over 4 months, using cognitive behavioral strategies to target depressive symptoms and adherence to HIV medications
45475962|NCT01197287|Drug|QAK423A|
45475963|NCT01197287|Drug|QAK423A|
45475964|NCT03351166|Drug|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
45475965|NCT01197365|Other|Infant formula with GOS, beta-palmitate, acidified milk|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae"
45475966|NCT01197365|Other|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients
45475967|NCT05584150|Other|Deep Cleansing Gel|daily use
45475968|NCT03351088|Procedure|DVC ligation|Ligation of the dorsal vascular complex during robot-assisted radical prostatectomy
45475969|NCT03845387|Drug|KDT-3594|oral administration, dose titration
45475970|NCT03845387|Drug|Pramipexole|ER formulation, oral administration, dose titration
45348880|NCT00951028|Behavioral|Life-steps adherence treatment|Single-session adherence treatment that targets informational, problem solving, and cognitive-behavioral steps geared toward improving HIV medication adherence and self-management
45348881|NCT00951028|Behavioral|Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD)|12 therapy sessions delivered over 4 months, providing education and support that target depressive symptoms and adherence to HIV medications.
45348882|NCT00849069|Biological|GSK2231395A|3 doses intramuscular injections
45475971|NCT05584072|Diagnostic Test|Active pedal plantarflexion (APP) test|Active pedal plantarflexion (APP) test
45475972|NCT01197443|Behavioral|Parent-only Group|Parent-only group will include the same skills and techniques to promote weight loss as given to the parent + child group, but the information will be delivered only to the parent. Parent group will be compared to the parent group of the parent + child treatment arm. The focus will be on implementing skills learned to assist the child in weight management. The treatment length is set for 12 weekly meetings and bi-monthly meetings during months 4 and 5. Each group session will be 60-min including weigh-ins. Group meetings focus on behavior change, weight loss, healthy eating and activity for the overweight child and parent.
45841290|NCT01053000|Drug|Tazorac|compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) following topical retinoid pre-treatment with Tazorac vs ALA-PDT with occlusion only (no pretreatment) in subjects with dorsal hand/forearm actinic keratoses, with an incubation time of 60 minutes, using blue light.
46044548|NCT02647606|Procedure|MILS|MILS(Manual in-line stabilization) will be applied during intubation. With MILS, different kinds of laryngoscope will be evaluated in a simulated difficult airway.
46044549|NCT02647606|Device|McGrath videolaryngoscope|McGrath videolaryngoscope will be used for intubation
46044550|NCT02647606|Device|Pentax AWS videolaryngoscope|Pentax AWS videolaryngoscope will be used for intubation
46044551|NCT02647606|Device|Macintosh laryngoscope|Macintosh laryngoscope will be used for intubation
46044552|NCT02535910|Dietary Supplement|vitamin D3|Subjects are asked to consume a breakfast rich in 20 µg vitamin D3
46044553|NCT02535910|Dietary Supplement|25(OH) D3|Subjects are asked to consume a breakfast rich in 20 µg 25(OH)D3
46044554|NCT02535910|Dietary Supplement|Control|Subjects are asked to consume a breakfast without vitamin D
46044555|NCT01154816|Drug|Alisertib|Given orally
46044556|NCT01154816|Other|Laboratory Biomarker Analysis|Correlative studies
46044557|NCT01154816|Other|Pharmacological Study|Correlative studies
45348883|NCT00849069|Biological|TwinrixTM|3 doses intramuscular injections
45348884|NCT00849303|Other|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts within 10 days since stroke onset.
45348885|NCT00849303|Other|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts five weeks after stroke onset.
45841291|NCT05822570|Diagnostic Test|Assessment of Oxygen Dissociation Curve (ODC)|ODC will be assessed at 5 timepoints: T0 after installation of arterial catheter, T1 before clamping of the liver, T2 5-10 min before reperfusion of the liver graft, T3 45 min after reperfusion, T4 1 h after T3 or at end of surgery
45841292|NCT05822557|Other|Bolus Pouch Feed|Following the 7-day baseline period, all patients will enter the 28-day intervention period, where they will receive the intervention feed daily. The feed prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management
45348886|NCT04042545|Drug|PPP001|1 cannabis dosing capsule inhaled 3 times a day with a vaporizer device
45348887|NCT04042545|Drug|Placebo|1 placebo dosing capsule inhaled 3 times a day with a vaporizer device
46044558|NCT03057808|Behavioral|Gestational weight gain intervention|This intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. The intervention will focus on self-monitoring, clear goals (i.e., GWG, caloric intake exercise), and problem solving.
46044559|NCT03057808|Behavioral|Postpartum weight loss intervention|The PPWL intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. (The number of possible telephone sessions will depend on the level of support needed by each participant to meet her weight loss goals). The PPWL intervention will focus on self-monitoring; weight, dietary intake and exercise goals; and problem solving.
45475973|NCT01197443|Behavioral|Parent + Child Group|The treatment for participants in the parent + child group will be administered in two separate groups, one for the parents and one for the child. Treatment will include the same skills and techniques to promote weight loss as given to the parent-only group, but the information will be delivered to both the parent and child. The treatment length, session schedule, treatment content and follow-up assessments are same as the parent-only group.
45841293|NCT05822544|Drug|TLC-6740|TLC-6740
45841294|NCT05822544|Other|Placebo|Placebo-to-match
46044560|NCT00849901|Drug|duloxetine|30-120 mg, PO, QD, for up to 38 weeks
45348888|NCT00951106|Drug|Pyrimethamine/sulfdoxine (Fansidar)|
45348889|NCT00852267|Other|High Carbohydrate, High Saturated Fat Diet|50% Carbohydrate; 12% Protein; 38% Fat (15% Saturated Fat; 15% Monounsaturated Fat)
45348890|NCT00852267|Other|Low Carbohydrate, High Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (15% Saturated Fat; 14% Monounsaturated Fat)
45348891|NCT00852267|Other|Low Carbohydrate, Low Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (8% Saturated Fat; 21% Monounsaturated Fat)
45348892|NCT00372229|Drug|Valganciclovir CMV Prophylaxis|900 mg valganciclovir, taken orally once daily, adjusted to renal function starting within 14 days of transplantation until Day 100 after transplantation.
45841295|NCT05822531|Behavioral|Maternal CVH Intervention|All participants will be enrolled into the intervention arm of this pilot study.
46044561|NCT00849901|Drug|Placebo|Capsules identical in appearance, color, taste and smell to study drug, orally (PO), once daily (QD). Dose: placebo, 6 capsules, QD for 10 weeks
46044562|NCT00849901|Drug|fluoxetine|10-40 milligram (mg), PO, QD, for up to 38 weeks
45348893|NCT00372229|Drug|Valganciclovir (Pre-emptive CMV Therapy)|If plasma polymerase chain reaction (PCR) ≥ 400 CMV copies/millilitre, then 1800 mg valganciclovir per day adjusted to renal function for at least 14 days until the second negative PCR (below 400 copies/ml) followed by secondary prophylaxis for 28 days with 900 mg valganciclovir adjusted to renal function. If CMV disease or no response to valganciclovir treatment after 14 days (not falling viral load), then intravenous (IV) ganciclovir or additional appropriate therapy could have been administered according to the local site's standard, instead of valganciclovir.
45475974|NCT03351010|Behavioral|Mindfulness training program|The mindfulness training program is a self-awareness mindfulness training program by performing the 15-position hand movement series
45348894|NCT00372229|Drug|Ganciclovir|If CMV disease or no response to valganciclovir treatment after 14 days (not falling viral load), then intravenous (IV) ganciclovir or additional appropriate therapy could have been administered according to the local site's standard, instead of valganciclovir.
45348895|NCT05301010|Drug|Faceptor|NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
45348896|NCT05301010|Drug|Herceptin|Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.
45348897|NCT05301010|Drug|Docetaxel|The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.
46044563|NCT04313660|Drug|Anlotinib In Combination With PD-1/L1 Inhibitor|"At the end of chest radiotherapy (c2d1), the simultaneous administration of androtinib hydrochloride capsule and PD-1 / L1 inhibitor was started. L~Arotinib hydrochloride capsule, 12 mg, Po, QD, was taken orally for two weeks, one week, three weeks as a cycle, completed in the first 14 days until the disease progress;~Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.~Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.~The choice of durvalumab / trepril mAb was at the discretion of the researchers."
46044564|NCT02641054|Drug|CVXL-0107|
46044565|NCT02641054|Drug|Placebo|
45348898|NCT00855699|Drug|Acamprosate|Acamprosate 333mg tablets, two tablets three times a day for duration of alcohol detox.
45348899|NCT00855777|Drug|etoricoxib|etoricoxib 120 mg/day for 3 days
45348900|NCT00855777|Drug|ibuprofen|ibuprofen 1,800 mg/day for 3 days
45348901|NCT04012294|Drug|Allopurinol Pill|"Individuals who meet the inclusion criteria and also have morphostructural changes suggestive of MSU crystal deposits in their MSUS will start treatment with allopurinol at a dosage of 150 mg to be taken daily, orally for a month and then to be increased to 300 mg. The rest of the individuals' medication is not to be altered. If a participant presents hypersensitivity to allopurinol, they are to stop the medication and will be excluded from the investigation.~Three months after starting treatment, the participants will have a physical exam, confirm the continuation of the treatment (adjust dosage if needed) and take a blood sample for laboratory tests. Six months after treatment is started, the participants will be reevaluated by MSUS and have another blood sample taken, Once the study is finished, continuing or ending treatment with allopurinol will be decided by the medical judgment of the physician of each participant."
45348902|NCT00849459|Biological|adenovirus-mediated human interleukin-12|"The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC."
45475975|NCT03351010|Device|Cancer pain educational program|A cancer pain education program by using Videos and personalized face-to-face techniques
45475976|NCT01295177|Drug|topic cream insulin|Intervention: Placebo cream versus insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream or insulin cream. The placebo or insulin were used for 8 weeks.
45475977|NCT02918019|Drug|MSTT1041A|MSTT1041A will be administered as subcutaneous injections.
45475978|NCT02918019|Drug|Placebo|Placebo matched with MSTT1041A.
46044566|NCT02641054|Drug|Levodopa|
46044567|NCT02643784|Drug|Rosuvastatin|"Randomized Treatment Period (Day 1 through Day 14): 20 mg once daily for 14 days.~Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
46044568|NCT02643784|Other|Control|"Randomized Treatment Period (Day 1 through Day 14):~No treatment of rosuvastatin for control group. Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
45348903|NCT00852345|Drug|clofazamine|clofazamine 50mg po qday (duration varies according to physician)
45475979|NCT03350932|Behavioral|Sensory imagination about foods|In both groups, children will be presented with pictures of items. In the control group, the pictures will represent landscapes at different seasons. In the experimental group, the pictures will represent a variety of foods. In the experimental group, based on the pictures representing a variety of foods, children will have to perform a food sensory imagination task before choosing the portion size of a food.
45475980|NCT01295333|Drug|the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation|
45348904|NCT00698828|Drug|Placebo comparator|Twice daily subcutaneous injections of placebo for 12 weeks.
45348905|NCT00698828|Drug|SUN11031 20 μg/kg|Twice daily subcutaneous injections of SUN11031 20 μg/kg for 12 weeks.
45348906|NCT00698828|Drug|SUN11031 40 μg/kg|Twice daily subcutaneous injections of SUN11031 40 μg/kg for 12 weeks.
45348907|NCT00619515|Other|questionnaire administration|Patients complete 4 questionnaires at baseline and periodically during study to assess acute and late toxicities and quality of life (e.g., overall health status, patient function, sexual function, and urinary symptoms).
45348908|NCT00619515|Procedure|implanted fiducial-based imaging|Undergo fiducial placement imaging
45348909|NCT00619515|Radiation|stereotactic radiosurgery|Patients undergo fiducial placement using ultrasound. At least 5-10 days later, patients undergo CyberKnife® stereotactic radiosurgery once daily for 5 days.
46044569|NCT04166890|Drug|Articaine / EPINEPHrine Cartridge|The day scheduled for the surgery, vital signs (pulse, blood pressure and oxygen saturation) will be recorded prior the administration of the anesthesia. A volume of 1.8 ml of 4% articaine and epinephrine 1: 100000 solution of either the test product or the reference product will be deposited slowly to proceed to the inferior alveolar nerve block (IANB), according to the table of allocation of treatments in each period. The vital signs will continue to be monitored during the procedure, and once the procedure has been completed. If the volunteer needs more anesthetic, this will be recorded and will be administrated according to the maximum permitted doses (7 mg / kg (up to 500 mg) 5 mg / kg in children 7), and immediately after the administration, the vital signs will be taken again.
45348910|NCT00951184|Behavioral|telephone-based intervention|
45348911|NCT00951184|Other|screening questionnaire administration|
45348912|NCT00951184|Other|study of socioeconomic and demographic variables|
45348913|NCT00951184|Procedure|assessment of therapy complications|
45348914|NCT00951184|Procedure|psychosocial assessment and care|
45348915|NCT03469843|Other|Non intervention|patients without intervention
45348916|NCT00941746|Biological|PG110|Single, slow intravenous infusion
45348917|NCT00941746|Biological|PG110|Single, slow intravenous infusion
45348918|NCT00941746|Biological|PG110|Single, slow intravenous infusion
45348919|NCT00941746|Biological|PG110|Single, slow intravenous infusion
45348920|NCT00941746|Biological|PG110|Single, slow intravenous infusion
45348921|NCT00941746|Biological|PG110|Single, slow intravenous infusion
46044570|NCT02610907|Other|Buffer|The sleeve contains phosphate buffered saline buffer
45348922|NCT00941746|Biological|PG110|Single, slow intravenous infusion
45348923|NCT00941746|Biological|PG110|Single, slow intravenous infusion
45475981|NCT01295333|Drug|The initiation of LT4 as soon as the first biological signs of hypothyroidism.|
45475982|NCT04848454|Drug|Camrelizumab with vinorelbine and cisplatin|Camrelizumab: 200mg iv., every 3 weeks(one cycle), for 1 year(17cycles in total); Vinorelbine: 25mg/m2 day 1, 8 iv. or 60-80 mg/m2 or. day1, 8, every 3 weeks(one cycle), for 6 cycles; Cisplatin: 75mg/m2 (divided into 2 days), every 3 weeks(onr cycle), for 6 cycles.
45348924|NCT00941746|Biological|Placebo|Single, slow intravenous infusion that matches PG110 in appearance
46044571|NCT02610907|Other|Own output|The sleeve contains the subject own ileal effluent
46044572|NCT02610907|Other|simulated output|The sleeve contains simulated output
45348925|NCT00852423|Drug|Dihydroartemisinin-piperaquine|DHA-PQ tablets are green film coated intended for oral use and contain 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively. In this trial the 40/320mg for adults will be used. Developed by Sigma Tau in partnership with Medicines for Malaria Venture.
45348926|NCT00852423|Drug|Artesunate-mefloquine|MQAS will be provided as a fixed-dose ACT. There are 2 strengths (AS25+MQ55mg and AS100+MQ220mg) and dosing regimen is calculated according to 12 mg/kg AS and 24mg/kgMQ total dose over three days. Pregnant women will receive 2 tablets/day for 3 days. It is developed by Farmanguinhos with the Drugs for Neglected Diseases Initiative. To be noted: if the FDCs will not get the WHO pre-qualification before the start of recruitment, the separate AS and MQ will be used
45348927|NCT00852423|Drug|Artesunate-amodiaquine|AQAS, developed by teh DNDi with Sanofi-Aventis and manufactured by Sanofi-Aventis, has been pre-qualified by the WHO in 2008 and is available in several African countries, including those involved in this trial. AQ-AS tablets are round, yellow on one side and white-slightly yellow on the other, with a breaking bar, AS engraved on one side and either 25, 50 or 100 on the other side. Tablets to be used in this trial are those 100mg/270mg AS/AQ, containing 100 mg of artesunate, 352.640 mg of amodiaquine hydrochloride corresponding to 270mg of amodiaquine base.
45348928|NCT00852423|Drug|Artemether-lumefantrine|AL (tablets containing a FDC of 20 mg of artemether and 120 mg of lumefantrine) is manufactured by Novartis and has been extensively used in Africa for the treatment of uncomplicated malaria. AL was registered in Switzerland in 1999, has since received marketing authorisation in several endemic and non-endemic countries and it is WHO pre-qualified.
45348929|NCT02844049|Device|Deep Brain Stimulation|surgical procedure
45348930|NCT00941824|Drug|mycophénolate acid|"Day 0 to Day 7, 720 mg twice daily~Day 8 to Day 30, 540 mg twice daily~Day 30 to Day 90, 360 mg twice daily"
45348931|NCT00849537|Drug|Triamcinolone|Injection of intravitreal Triamcinolone
45348932|NCT03167606|Behavioral|MyPEEPS Mobile|Mobile technology to deliver HIV prevention information specifically developed for at-risk YMSM.
45475983|NCT05530499|Other|Almond supplementation|Daily consumption of 57g of whole almonds
45475984|NCT05530499|Other|Cookie supplementation|Daily consumption of cookie snack calorically equivalent to 57 grams of whole almonds.
46044573|NCT02640820|Drug|Sensitizing DPCP Ointment|Sensitization
46044574|NCT02640820|Drug|Treatment DPCP Ointment|Treatment
46044575|NCT02610985|Device|3-D laparoscopy|3-D laparoscopy
45475985|NCT04842292|Drug|Heparin|Nebulized heparin 25,000 units every 6 hours
46044576|NCT02610985|Device|2-D laparoscopy|2-D laparoscopy
46044577|NCT00652912|Drug|Clonazepam|ODT, 1 mg
46044578|NCT00652912|Drug|Klonopin Wafers|ODT, 1 mg
46044579|NCT02958670|Other|18F-AV-1451 (Tau-PET tracer)|Single i.v. administration of 18F-AV-1451 (Tau-PET tracer) and consecutive Positron-Emission-Tomography-Scan
46044580|NCT01168232|Drug|Ixabepilone|Given IV
45348933|NCT00951262|Behavioral|a life review program|The life review program includes reviewing a life and formalating a life booklet. Reviewing a life consists of three weekly sessions separately addressing illness experience, adulthood life and childhood and adolescence life. Each session lasts about 30 to 60mintues.A booklet with photos documented significant life events will be produced as a gift for the subjects. The edition, photos and contents fo the booklet are determined by the subjects.
45475986|NCT04842292|Drug|Placebo|Sodium chloride 0.9% every 6 hours
45475987|NCT01191905|Drug|high dose CRRT|clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
45475988|NCT01191905|Drug|Conventional dose CRRT|clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
45348934|NCT01049815|Drug|sevelamer hydrochloride|800-3200 mg with each meal
45348935|NCT01049815|Drug|Calcium Carbonate|600 mg with each meal, up to 1800 mg a day
45348936|NCT00849615|Drug|Docetaxel|50mg/m2 qd15
45348937|NCT00849615|Drug|5-Fluorouracil|2600mg/m2 qd15
45348938|NCT00849615|Drug|Oxaliplatin|85mg/m2 qd15
45348939|NCT00849615|Drug|folinic acid|200mg/m2 qd15
45348940|NCT00946036|Drug|Sertraline Hydrochloride|
45348941|NCT00688740|Drug|Docetaxel|intravenous
45348942|NCT00688740|Drug|5-fluorouracil|intravenous
45348943|NCT00688740|Drug|Doxorubicin|intravenous
45475989|NCT01191983|Drug|Methoxy polyethylene glycol-epoetin beta [Mircera]|Starting dose of 1.2 mcg/kg, adjusted according to Hb values, administered by subcutaneous injection Q4W
45475990|NCT03350854|Behavioral|Patient Preference in Treatment Decision Making|The roles are divided into two active roles, a collaborative (or shared) role, and two passive roles in the Patient Preference scale questionnaire. Once the questionnaire is administered, the patient will then proceed to original surgical appointment. The provider is informed of the patient's preferred role and has a discussion with them patient about this in the intervention group, but not in the control group.
45475991|NCT05436561|Drug|MBF-RIC|Reduced intensity conditioning regimen with fludarabine, busulfan and melphalan
45475992|NCT03055988|Drug|Tiotropium|Fixed Dose Combination
45475993|NCT03055988|Drug|Olodaterol|Fixed Dose Combination
45475994|NCT03055988|Drug|Fluticasone propionate|Fixed Dose Combination
45475995|NCT03055988|Drug|Salmeterol|Fixed Dose Combination
45475996|NCT03346642|Drug|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and histocompatibility leukocyte antigen (HLA) expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
45348944|NCT00688740|Drug|Cyclophosphamide|intravenous
45348945|NCT01049893|Drug|Compound AC220|Precomplexed powder in bottle formulation supplied as 135 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
45348946|NCT04088942|Other|High-intensity smoking cessation intervention|"Varenicline for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.~Group-sessions in 6 months:~Preparation phase: 5 sessions Day 1-14: 5 sessions Day 15-30: 5 sessions Day 31-60: 5 sessions Day 61-90: 5 sessions Day 90-180: 5 sessions c) Hotline and scheduled phone consultations:~A hotline is established which the high-intensity group can call.~Weekly calls to all patients in the project for 26 weeks. Call for 5-10 min. If the patient has not had relapse, there will be called week 34 and week 42. If the patient has had relapse, calls continue until relapse-free for 10 weeks, then week 34 and week 42.~d) Buddy-arrangement: i. Patients who have completed the program and have become smoke-free, are matched with new ones in the program. A meeting frequency of approx. every 7-14 days. The first patients are matched with patients from pulmonary medical outpatient clinic who have ceased smoking."
45348947|NCT04088942|Drug|Low-intensity smoking cessation intervention|Varenicline prescribed for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.
45475997|NCT03346642|Drug|GVD chemotherapy|GVD regimen is a chemotherapy regimen consisted by Gemcitabine, Vinorelbine and Doxorubicine. Patients will be administrated with Gemcitabine 0.8 g/m2, Vinorelbine 30mg and Doxorubicin 20mg/m2 intravenously infusion.
45475998|NCT03346642|Drug|SHR-1210|SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
45475999|NCT03636321|Procedure|living donor liver transplantation with internal biliary stent|living donor liver transplantation without internal biliary stent
45476000|NCT01192217|Procedure|Modified thoracoscopic technique|Two-port thoracoscopic technique
45476001|NCT01192217|Procedure|Axillary mini-thoracotomy|Axillary mini-thoracotomy
45476002|NCT02473107|Other|Advanced caries lesions detection (no activity assessment)|The diagnosis strategy will based on detection of only moderate and advanced caries lesions (ICDAS scores 3 to 6). Initial caries lesions will be considered as sound surfaces. Caries activity status will not be evaluated. Clinical decision-making will be proposed for all lesions detected, based on evidence-based protocols.
45685262|NCT01451086|Biological|vaccine made by Chengdu Institute of Biological Products|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
45685263|NCT01451242|Other|no intervention is made|no intervention is made
45348948|NCT02545803|Device|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation
45348949|NCT02534857|Procedure|a shorter exposure of oocyte to spermatozoa|Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours
45348950|NCT00951340|Other|Cognitive behavioral therapy (CBT)|15 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques
45348951|NCT00951340|Behavioral|Emotional processing and interpersonal therapy|15 weekly therapy sessions, the second hour of which will be devoted to interpersonal and emotional processing therapy techniques
45348952|NCT00951340|Behavioral|Listening therapy|15 weekly therapy sessions, the second hour of which will be directed by the participant's questions and discussion
45348953|NCT00748332|Dietary Supplement|Fortimel Extra®|2 bottles (600 kcal, 40 g proteins) per day
45348954|NCT00748332|Dietary Supplement|Fortimel Care®|Fortimel Care® : 2 bottles (660 kcal, 36 g proteins, 2.38 g EPA) per day
45348955|NCT02545569|Device|hearing aid (MD class IIa) - ITE, BTE, RIC|Hearing aid means any wearable instrument or device designed for, offered for the purpose of, or represented as aiding persons with or compensating for, impaired hearing.
45348956|NCT05323058|Drug|tulsi extract|4% topical oral spray
45348957|NCT05323058|Drug|Benzydamine Hydrochloride|0.15% topical oral spray
45348958|NCT02561910|Device|Laparoscopic hernia repair|Preperitoneal mesh implantation because of inguinal hernia disease using the laparoscopic technique
45348959|NCT00552760|Drug|Ramelteon|one 8 mg tablet at bedtime for up to 6 months
45348960|NCT00552760|Drug|Placebo|one tablet at bedtime for up to 6 months
45348961|NCT01046773|Drug|Cholecalciferol|Children less than 35 kg will receive 2,000 IU oral cholecalciferol daily for 6 months.
46044581|NCT01168232|Other|Laboratory Biomarker Analysis|Correlative studies
45348962|NCT01046773|Drug|Cholecalciferol|Children 35 kg or greater will receive 4,000 IU oral cholecalciferol daily for 6 months.
45348963|NCT00745602|Procedure|non-invasive testing|non-invasive tests including Transcranial Doppler ultrasound (TCD), manual cuff blood pressure (BP), beat to beat BP monitoring by a Portapress monitor, and respiratory tidal CO2
45348964|NCT00850005|Biological|Intravenous immunoglobulin|2 g/kg divided over five days
45476003|NCT02473107|Other|All caries lesions detection (+activity assessment)|The diagnosis strategy will based on detection of initial, moderate and advanced caries lesions (ICDAS scores 1 to 6). Caries activity status will be also evaluated. Clinical decision-making will be proposed for all active lesions detected, based on evidence-based protocols. inactive caries lesions will not be treated.
45476004|NCT05583916|Procedure|Same Day Discharge - Video-Assisted Thoracoscopic Surgery (VATS) Lung|All patients will be scheduled to surgery at the start of the day and will be discharged within the same day as the procedure.
45596495|NCT03527953|Other|Tetric EvoCeram Bulkfill|The preparation will be etched with 37% phosphoric acid. It will be then rinsed with an air-water spray and dried, leaving the dentin slightly moist. An etch-and-rinse adhesive, ExciTE F, will be applied and agitated on the prepared surfaces for at least 10 seconds. The adhesive will be air-thinned and light-cured for 20 seconds with an LED curing unit. The sectional matrix will be placed and fixed with wooden wedges. Then the bulk-fill resin composite, TBF, will be placed in bulk in about 4-mm thickness and then will be cured for 20 seconds.
45841296|NCT05822518|Dietary Supplement|Neo-mune powder (otsuka pharmaceutical)|"Preoperative: Neo-mune (otsuka pharmaceutical) powder 60 gm o.d. orally (contains glutamine, arginine and fish oil) for 3 days.~Postoperative: Neo-mune (otsuka pharmaceutical) powder 60 gm o.d. orally (contains glutamine, arginine and fish oil) for 2 weeks starting when the intestinal sounds are audible."
45841297|NCT05822518|Drug|Dipeptiven solution (Fresenius Kabi pharmaceutical)|Dipeptiven (Fresenius Kabi pharmaceutical) solution 50 mg o.d IV ( contains L-ananyl-L-glutamine dipeptide) post operatively for 2 weeks starting from the operation day.
46044582|NCT02647528|Device|Chromogenix Regenlite Transform Treatment|Pulse Dyed Laser - 7mm spot size 3-3.6 J/cm2
46044583|NCT02647528|Device|Chromogenix Regenlite Transform Placebo|Pulse Dyed Laser - 7mm spot size 0 J/cm2
46044584|NCT02640430|Device|standard treatment|20 minutes, twice a day for 10 sessions
46044585|NCT02640430|Device|Free Aspire|20 minutes, twice a day for 10 sessions
46044586|NCT00817531|Drug|Dasatinib|pill form, 100 mg daily
45348965|NCT00850005|Biological|Normal Saline|Same volume as experimental arm
45348966|NCT00941980|Biological|Osteocel Plus|biologic
45348967|NCT04060706|Radiation|Radical Image-Guided Radiotherapy|Questionnaires administered will monitor the clinical toxicity experienced by each patient up to 5 years post radiotherapy
45348968|NCT04012372|Other|ROSA Water|Ad libitum hydration with ROSA oligomineral water
45348969|NCT04012372|Other|Control water|Ad libitum hydration with other waters
45348970|NCT00852501|Other|To perform RT-PCR on the tissue obtained during surgery|The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
45348971|NCT02562534|Device|MRI compatible ElectroCardioGraph|MRI with ECG control for people with healthy heart or heart diseases
45348972|NCT00852579|Drug|Azithromycin|Daily dose 250mg
45348973|NCT00852579|Drug|Placebo|Placebo
45476005|NCT05353751|Behavioral|Kind Minds Program|"The KMP intervention uses an online mindfulness phone based program. During the 9-week program, Community Health Worker (CHW) Kindness Coaches will meet weekly for 30 minutes via Zoom with either a) the caregiver and adolescent (in separate meetings), or b) the adolescent only to review and complete a new session using the online mindfulness program. Participants will be prompted to complete mindfulness activities between sessions by notifications, conducive to their school and work schedules. Weekly content and meditations/activities focus on mindfulness skills of present moment awareness, nonjudgment, compassion, and gratitude."
45476006|NCT04809844|Other|Concurrent chemoradiation|concurrent Paclitaxel and radiation therapy after Adjuvant doxorubicin and Cyclophosphamide chemotherapy for stage ll or lll breast cancer .
45841298|NCT05822453|Drug|Gemcitabine|Gemcitabine (1000 mg/m2) will be administered by IV infusion on Day 1and Day 8 of each 21-day cycle
46044587|NCT00651586|Drug|Gatifloxacin 0.3% ophthalmic solution|Gatifloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
45348974|NCT00942058|Other|Serum and urinary CA9 level|Blood and urinary samples are collected before treatment and at 1, 3, 6, 9 and 12 months.
45841299|NCT05822453|Drug|S1|S1 (60 mg/day if body surface area < 1.25 m2, 80 mg/day if body surface area = 1.25~1.50 m2) will be administered by PO on Day 1 ~ 14 of each 21-day cycle
45841300|NCT05822453|Drug|Tislelizumab|Tislelizumab (200 mg) will be administered by IV infusion on Day 1 of each 21-day cycle
45348975|NCT02562456|Procedure|ART using Fuji IX|Occlusal and occlusoproximal ART restorations in primary molars using the high viscosity GIC Fuji IX will be performed under relative isolation. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked. For occlusoproximal restoration, an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
45348976|NCT02562456|Procedure|Conventional Treatment|Occlusal and occlusoproximal composite resin restorations in primary molars using the Scotchbond Multi-purpose adhesive system and the Filtek Z-350 composite resin wil be performed. Local anesthesia will be used. Absolute isolation will be performed using rubber dam and clamp. Removal of unsupported enamel will be performed using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched using 37% phosphoric acid for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked. an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
45348977|NCT00942136|Drug|GSK1349572|GSK1349572 250 mg suspension as a single dose. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
45476007|NCT05668325|Other|Mini trampoline exercise group|In this study, patients performed a 30-45 minute mini-trampoline exercise program 3 times a week for eight weeks (two months) under the supervision of the investigator.
45476008|NCT05668325|Other|Control group|In this study, patients were visited at home once a week for eight weeks and their feet were checked.
45476009|NCT02912949|Drug|zenocutuzumab (MCLA-128)|full length IgG1 bispecific antibody targeting HER2 and HER3
45476010|NCT03496636|Procedure|Ovarian tissue transplant|Pieces of previously frozen ovarian cortex will be put in the abdomen laparoscopically, or with mini laparotomy
45685264|NCT01451710|Drug|Prednisone or Prednisolone|daily single dose of 1mg/kg (maximum 80mg) or alternate day single dose of 2mg/kg (maximum 120mg),maintained for a minimum period of 6 weeks and maximum period of 12 weeks. After achieving complete remission., corticosteroids should be tapered slowly, 10mg every two weeks tapered to reach 0.15mg/kg/d, then 2.5mg every two to four weeks tapered to reach the minimum dosage 10mg/ alternate day
46044588|NCT00651586|Drug|Ciprofloxacin 0.3% ophthalmic solution|Ciprofloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
46044589|NCT02640508|Drug|Eribulin|Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.
46044590|NCT02640508|Drug|Lenvatinib|Will be taken orally at 20-24 mg daily in each 21 day cycle.
46044591|NCT05312606|Other|Aftoral Oral gel|Patients will use Aftoral® Oral Gel solution for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after gel solution application).
46044592|NCT05312606|Other|Unidea Chlorhexidine digluconate mouthwash 0.20%|Patients will use chlorhexidine mouthwash 0,20% for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after mouthwash application).
46044593|NCT02647372|Procedure|Subthalamic nucleus|Surgery will be performed in 15 patients with DBS target to the subthalamic nucleus
46044594|NCT02647372|Procedure|Globus pallidus|Surgery will be performed in 15 patients with DBS target to the globus pallidus nucleus
46044595|NCT05259566|Behavioral|menthol ban in cigarettes only|menthol ban in cigarettes only, menthol available in e-cigarette
46044596|NCT05259566|Behavioral|total menthol ban|menthol ban in both cigarettes and e-cigarettes
46044597|NCT02643550|Biological|Monalizumab|
46044598|NCT02643550|Biological|Cetuximab|
46044599|NCT02643550|Biological|Anti-PD(L)1|
45685265|NCT01451788|Device|Gelatin matrix with human derived thrombin (Floseal, Baxter)|Floseal will be used to stop cancellous bone bleeding, pedicle channel bleeding or epidural space bleeding by injecting suitable amount of this matrix and irrigating it away after few minutes.
45348978|NCT00942136|Drug|GSK1349572|GSK1349572 50 mg tablets as a single dose on three separate occasions. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
45476011|NCT01250912|Drug|123I-metaiodobenzylguanidine|FDA Approved for use in Cancer patients. This use is Off Label. For the imaging study, an activity of 370 MBq (10 mCi) 123I-mIBG (GE Healthcare) will be administered intravenously, and a 10-minute planar image of the anterior thorax (128_128 matrix) will be acquired beginning 15 minutes after tracer injection.
45348979|NCT00942136|Drug|Placebo|Placebo Suspension as a single dose.
45348980|NCT00942136|Drug|Omeprazole|Omeprazole 40 mg once a day for 5 days. Omeprazole is approved by the FDA currently to reduce stomach acid, treat stomach ulcers, and gastroesophageal reflux disease.
45348981|NCT00748488|Other|Physical therapy aimed to move safely|"Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease solely focused on safety of movement.~Duration program: 2 years Maximum number of sessions: 35 per year Duration sessions: 30 minutes"
45348982|NCT00748488|Other|Physical Therapy aimed to improve Physical Activity|Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease combined with a coaching program aimed to promote the level of physical activity Duration program: 2 years Maximum number of sessions: 35 per year Duration of sessions: 30 minutes
45348983|NCT05300932|Drug|Baricitinib|Orally take Baricitinib 4mg everyday for 48 weeks
45348984|NCT05300932|Drug|Cyclophosphamide|Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d （standard of care）through the 24 weeks double blind period. Subsequently, subject were administered oral Baricitinib 4mg everyday through the 24-48 weeks open label period.
45348985|NCT02545491|Behavioral|Care for Child Development (CCD) program|The Care for Child Development (CCD) Program developed by World Health Organization (WHO) /UNICEF provides recommendations for stimulating child development through play and communication activities.
46044600|NCT00817063|Drug|alitretinoin|Patients receive alitretinoin 30mg one capsule daily for up to 24 weeks
45348986|NCT02545491|Behavioral|Infant and Young Child feeding training by World Vision|Training on breastfeeding benefits, solid introduction and food safety
45476012|NCT05583682|Other|Dental restoration|Restoration of carious mandibular first molar teeth are restored either with nano-filled resin modified glass ionomer or sub-micron resin composite restorative material
45476013|NCT04789304|Drug|BI 1595043|BI 1595043
45476014|NCT04789304|Drug|Placebo|Placebo
45476015|NCT04789304|Drug|Midazolam|Midazolam
45476016|NCT03350776|Behavioral|Care coordination|Care coordination and associated emerging occupations by comparing theoretical expected outcomes to professionals, patients and caregivers representations
46044601|NCT00817063|Drug|Placebo|Patients receive matching placebo for up to 24 weeks
45476017|NCT04780724|Other|Hypoxic gas mixture|Gas mixture of 12% O2 and 88% N2 for five minutes.
45348987|NCT00942214|Drug|Natalizumab|300mg, IV, every 4 weeks
45348988|NCT00850161|Drug|aspart|Meal-time insulin. Administered subcutaneously based on routine clinical therapy.
45348989|NCT00850161|Drug|Nasulin™|100 IU(2 puffs in each nostril)
45476018|NCT04780724|Other|Hypercapnic and hypoxic gas mixture|Gas mixture of 12% O2, 5% CO2, and 88% N2 for five minutes.
45476019|NCT04780724|Other|SpO2 measurement|Two SpO2 measuring devices are active simultaneously during measurement.
45476020|NCT03128866|Procedure|Hemipelvectomy|Undergo hemipelvectomy
45476021|NCT03128866|Drug|Tranexamic Acid|Given IV
45476022|NCT05431101|Procedure|Carpal Tunnel Release|Transection of flexor retinaculum for patients who have carpal tunnel syndrome
45476023|NCT05216276|Procedure|TEP|Laparoscopic totally extra-peritoneal (TEP) inguinal hernia repair
46044602|NCT01167140|Device|Cryo-Touch II|Percutaneous treatment with the device
46044603|NCT02640352|Dietary Supplement|Probi Defendum|
46044604|NCT02640352|Dietary Supplement|Placebo|
46044605|NCT04166188|Procedure|Lumbar erector spinae plane block|Injection of blue solution in the erector spinae plane in L4 ultrasound-guided and posterior dissection of the lumbar region.
46044606|NCT04165876|Device|Primary Motor Cortex Stimulation|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of primary motor cortex (M1) using a ring-cathode configuration
45348990|NCT00951574|Drug|Nadroparin calcium|Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
45348991|NCT00951574|Drug|saline solution (placebo)|Pre-filled syringes of 0.4 ml , 1 subcutaneous injection/day (every 24 hours).
45348992|NCT00686790|Biological|Peginterferon alfa-2b (PegIntron, SCH 54031)|Peginterferon alfa-2b 1.5 mcg/kg/wk subcutaneously (SC) for 52 weeks.
45348993|NCT00850239|Drug|dutogliptin|400 mg
45476024|NCT05216276|Procedure|rTAPP|robotic transabdominal preperitoneal (TAPP) inguinal hernia repair
46044607|NCT04165876|Device|Dorsolateral Prefrontal Cortex Stimulation|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of dorsolateral prefrontal cortex (DLPFC) using a ring-cathode configuration
45476025|NCT03636087|Procedure|Access cavity preparation|High speed handpieces will be used with access burs to open the pulp chamber and get access to the root canal system (As a part of conventional root canal treatment established protocol)
45476026|NCT03636087|Procedure|Working Length Determination|The length of the root canal will be measured using periodical radiographs and Electronic Apex Locators (As a part of conventional root canal treatment established protocol)
45476027|NCT03636087|Procedure|Root canal instrumentation and chemo-mechanical preparation|Rotary files used to properly instrument and prepare canals length and size (As a part of conventional root canal treatment established protocol)
45476028|NCT03636087|Procedure|Root canal obturation|Gutta Percha filling materials will be used to fill the root canal space with root canal sealer (As a part of conventional root canal treatment established protocol)
45841301|NCT05822414|Procedure|Erector spinae plane block|Erector spinae plane block will be injected at the second thoracic vertebral level for patient undergoing rotator cuff repair surgery
46044608|NCT04165876|Device|Multimodal Stimulation (DLPFC+M1)|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.
45348994|NCT00850239|Drug|placebo|
45348995|NCT00946426|Other|Clamp|Insulin sensitivity, Hepatic glucose production, Evaluation of inflammation, Socioeconomic status, Ethnicity and family history
45348996|NCT00942292|Dietary Supplement|Lipidem- fish oil emulsion BBraun UK|
45348997|NCT00942292|Procedure|Digital Contrast MRI scan|
45348998|NCT02563392|Procedure|uterine myomectomy with preventive uterine arteries occlusion|laparoscopic uterine myomectomy with preventive uterine arteries occlusion
45348999|NCT02563392|Procedure|laparoscopic uterine myomectomy without preventive uterine arteries occlusion|laparoscopic uterine myomectomy
45349000|NCT00856089|Drug|Retapamulin|Retapamulin ointment, 1%, apply a thin layer, BID for 5 days
45349001|NCT00942370|Device|non invasive mechanomyographic device based on a 3 axes accelerometer|"This biomedical research consists specifically in the simultaneous acquisition of:~EMG and MMG Signals of rectus abdominis of the abdomen,~Respiratory flow,~An electrocardiogram (ECG).~These acquisitions will be conducted on 16 healthy volunteers according to a standardized protocol, at rest and during voluntary cough and various physical exercises often resulting in urinary leakage in the incontinent person."
45476029|NCT03636087|Procedure|Coronal restoration build up|A Build up material to seal the accessed tooth properly (As a part of conventional root canal treatment established protocol)
45841302|NCT05822401|Behavioral|Blood flow restriction (BFR)|Blood flow restricted training integrated into the daily work tasks for 8 weeks.
45841303|NCT05822401|Behavioral|Usual care (control)|Will continue their work as usual
46044609|NCT04165876|Device|Sham stimulation|Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.
45476030|NCT03636087|Other|Changing gloves before obturation|The treating dentist will change gloves before obturation
45476031|NCT03636087|Other|Disinfecting rubber dam|2.25% Sodium Hypochlorite solution will be used to disinfect the rubber dam surface
45476032|NCT03636087|Other|The use of new instruments at time of obturation|A new instrument's kit will be use at the time of obturation
45476033|NCT03636087|Radiation|Cone Beam Computed Tomography scanning (CBCT)|CBCT will be taken before treatment and one year after completion
45476034|NCT03636087|Radiation|Radiographic imaging using periapical radiographs|Periapical radiographs will be taken before, during and one year after the treatment completion (As a part of conventional root canal treatment established protocol)
45685266|NCT01451866|Other|resistance training|hypertrophic resistance training
45685267|NCT01451866|Other|complex resistance training|complex resistance training with speed, excentric and power-endurance elements
45685268|NCT01451944|Behavioral|education|home asthma case management and education
45685269|NCT01452022|Device|Inductigraft|Synthetic bone graft
45685270|NCT01452100|Drug|prednisone|Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
45841304|NCT01028820|Drug|Aripiprazole|8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
46044610|NCT01166750|Behavioral|CD-ROM|"Treatment Group will continue to follow their treating rheumatologist's recommendations and prescriptions. The program will contain information on the multiple components of pain (the pain puzzle) as a treatment rationale and will then teach children to use cognitive-behavioral techniques for pain management. The information will be presented via visual displays, narration, and interactive menus. Children will be able to navigate through the different lessons at their own pace and will be required to take simple quizzes to assess their learning. Various passwords and homework assignments are embedded within the program to ensure that children are going through the material."
45476035|NCT03733301|Drug|Baricitinib|Administered orally.
45476036|NCT03733301|Drug|Topical corticosteroid|Administered as standard-of-care.
45476037|NCT03733301|Drug|Placebo|Administered orally.
45685271|NCT01452100|Other|placebo|• Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
45685272|NCT02637934|Drug|[18F]FluorThanatrace|
45685273|NCT02637934|Radiation|PET/CT imaging sessions|
46044611|NCT01166750|Behavioral|Wait-list Control Group|Children in the control group will continue to follow recommendations and prescriptions by their treating rheumatologist. After an 8-week wait-list control condition that involves measurement phases identical to those of the Jointstrong Treatment Group but no Jointstrong treatment, the children in the control group will enter the Jointstrong program and will then have the same immediate post-treatment measures that the Treatment Group received. The Control Group will not, however, have the Treatment Group's 12-week follow-up phase.
46044612|NCT02640196|Device|Macintosh|The participants intubated the easy airway simulator with a double lumen tube using the Macintosh laryngoscope followed with intubating the difficult airway simulator
45349002|NCT04041999|Behavioral|Daily Cognition Training Program|"Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.~Specifically we focus on tasks related to taking medication and adherence to treatment. Some examples of tasks are: the management of a medical prescription, expiration of a medication, understanding of the prescriptions made by the doctor, guidelines for taking medication (doses, schedules ...) and indications and contraindications, filling pill boxes, recall of controls doctors, medication control, prospective memory of medical management, etc."
46044613|NCT02640196|Device|GlideScope|The participants intubated the easy airway simulator with a double lumen tube using the GlideScope followed with intubating the difficult airway simulator
46044614|NCT02640196|Device|Airtraq|The participants intubated the easy airway simulator with a double lumen tube using the Airtraq followed with intubating the difficult airway simulator
45349003|NCT00686712|Drug|1- Insulin glargine QHS|Insulin glargine at bedtime (dose titrated to maintain 50% of fasting glucose readings <120 mg/dL)
45349004|NCT00686712|Drug|2 - Insulin glargine QAM|Insulin glargine in AM (dose titrated to maintain 50% of pre-supper glucose readings <120 mg/dL)
45349005|NCT00686712|Drug|3 - NPH insulin QHS|NPH insulin at bedtime (dose titrated to maintain 50% of fasting glucoses <120 mg/dL)
45349006|NCT00852735|Dietary Supplement|Rapeseed Oil (prevention of cardiovascular diseases)|to assess the effect of optimized oil (enriched with micronutriments) on the prevention on cardiovascular diseases
45349007|NCT02545257|Other|Coordinated medication management model|Stage I: a prescription review conducted by community pharmacists Stage II: practical nurse-administered Drug-related Problem Risk Assessment Tool Stage III: Required health care action based on the result of the DRP -Risk Assessment Tool
45349008|NCT00852813|Dietary Supplement|arabinoxylan-oligosaccharides (AXOS)|intake period: 3 weeks, 10 g/day
45349009|NCT00748644|Drug|Rituximab|"rituximab infusion will be performed at J1, J15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
45685274|NCT01452334|Biological|BMS-936559 (Anti PD-L1)|Injection for infusion, Intravenous (IV), 1, 3 or 10 mg/kg, Every 2 weeks, 48-96 weeks depending on response
45685275|NCT01452490|Device|Diode Laser Treatment|Laser treatment once every 6 weeks, for a total of 4 treatment sessions
45685276|NCT01452568|Drug|Aspirin|150mg/daily for three months, starting day after surgery
46044615|NCT02640196|Device|King Vision|The participants intubated the easy airway simulator with a double lumen tube using the King Vision followed with intubating the difficult airway simulator
46044616|NCT04311242|Other|Diet|Ketogenic diet
45841305|NCT05822375|Behavioral|Better Together Physician Coaching|Better Together Physician Coaching Program thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies. BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
46044617|NCT02640274|Behavioral|Nurse-led counselling programme|The intervention is an individual nurse-led counselling programme in addition to usual care. The intervention includes 3 outpatient clinic visits (at weeks 2, 14 and 26) and two telephone calls (at weeks 4 and 16) by a cardiovascular nurse during the first 6 months early discharged. The counselling focuses on cardiac risk reduction behaviour based on guidelines issued by European Society of Cardiology and self-management support.
45349010|NCT00748644|Drug|Azathioprine|"azathioprine (2 mg/kg/d) for 12 months, then progressively tapered until its discontinuation at month 22.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
45685277|NCT01452568|Drug|Warfarin|Warfarin daily dosage to obtain an INR in between 2,0 to 3,0. Started the day after surgery and continued for three months.
45685278|NCT01452646|Other|Risk-adapted, MRD-directed therapy|The general objective of this study is that of setting up a multicentre, risk-adapted study that relies on pre-treatment cytogenetic/genetic features and post-consolidation assessment of MRD to establish the final risk assignment and treatment of younger (≤ 60 years) patients with AML. Aim of this clinical trial is to verify whether the delivery of a post remission therapy whose intensity is risk-driven will improve the outcome in terms of both increased anti-leukemic efficacy and reduced therapy-related toxicity.
46044618|NCT02640274|Other|Usual care|
46044619|NCT04313270|Drug|Evolocumab|12 weeks of treatment with Evolocumab
45349011|NCT04042779|Other|model-based WM training|model-based WM training program: four sessions a week, 45 minutes each; lasting for three weeks
45685279|NCT01452724|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 6 weeks.
45685280|NCT01452724|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 6 weeks.
45685281|NCT01452724|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 6 weeks.
46044620|NCT02640118|Drug|Lixisenatide|single injection of 20 µg lixisenatide subcutaneously
46044621|NCT02640118|Drug|Lixisenatide-Placebo|
45349012|NCT04042779|Other|single-task WM training|single-task WM training program: four sessions a week, 45 minutes each; lasting for three weeks
45349013|NCT04042779|Other|multiple-task WM training|multiple-task WM training program: four sessions a week, 45 minutes each; lasting for three weeks
45349014|NCT04042779|Other|sham intervention|motor training program: four sessions a week, 45 minutes each; lasting for three weeks
45349015|NCT00748722|Device|CT Angiography|Injection of contrast material (iodine)
45349016|NCT00745836|Drug|statin|
46044622|NCT02640118|Other|Standardized liquid meal|standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
45349017|NCT00853203|Behavioral|Interviews|Open-ended Interviews, audiotaped, lasting 30 minutes to 1 hour.
45349018|NCT00853203|Behavioral|Questionnaires|Written survey taking about 1 hour.
45349019|NCT00853203|Other|Electronically Activated Recorder (EAR)|Recording system (a digital tape-recorder and small external microphone) programmed to record for 30 seconds every 12 minutes, repeating over two consecutive days of wearing.
45349020|NCT00853203|Behavioral|Group Meetings|12 Audiotaped Group Meetings over 4 months: 9 weekly meetings, 2 semi-monthly (twice a month) meetings, and a final meeting in month 4. Each meeting will last 1 hour.
45685282|NCT01452724|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 6 weeks.
45685283|NCT02620072|Drug|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 67.5 mg or placebo for the following 9 months of the treatment period. Follow-up will continue for 24 months after the last administration of treatment.
45685284|NCT02620072|Other|Placebo|Total of 12 months intervention period; daily administration of insulin or placebo capsules containing filling substance (microcrystalline cellulose). Follow-up will continue for 24 months after the last administration of treatment.
45685285|NCT01452880|Drug|Remifentanil|Remifentanil is an ultra-short-acting oppioid, which is quickly metabolized by unspecific blood and tissue esterases
45685286|NCT01452880|Drug|Remifentanil|GROUP A (N = 114): patients assigned to this group received Remifentanil at infusion rate of 0.05 mcg / kg / min I.V. ; GROUP B (N = 114): in this group Remifentanil was administered at infusion rate of 0,1 mcg / kg / min I.V. Remifentanil was administered intravenously throughout ESWL procedure.
45685287|NCT01513239|Biological|MK-6072|Single IV infusion of MK-6072 (10 mg/kg of monoclonal antibody to C. difficile Toxin B)
45841306|NCT05822362|Drug|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD improves markers of Alzheimer's progression, cognitive function, sleep, pain, anxiety, oxidative stress, and inflammation.
45349021|NCT00853203|Behavioral|Written Materials|Written educational materials plus community resource information.
45349022|NCT00748800|Behavioral|Affect Management|5 session group intervention that focused on teaching affect management skills and included HIV prevention and sexual health training
45841307|NCT05822362|Other|Placebo|Placebo arm.
45841308|NCT05822349|Behavioral|picograms-enriched label|The intervention care includes usual care (instructions for using each anti-diabetic drug) plus pictograms that show how much medications should be taken at each time of day (morning, noon, evening, and night), how to take them in relation to meals, the purpose of the drug, and the most important non-pharmacologic interventions for diabetic patients (weight loss, exercise, avoiding smoking, blood sugar controlling).
46044623|NCT02643316|Drug|Same day 4 L preparation (Polyethylene Glycol)|Receive 1 gallon (4 L) of Polyethylene Glycol preparation on the morning of the colonoscopy.
45349023|NCT00748800|Behavioral|General Health Promotion|5 session group focused on delivering general health promotion information in didactic format
46044624|NCT02643316|Drug|Split dose 4 L preparation (Polyethylene Glycol)|Receive the split-dose regimen. Will take half (2 L) the preparation the evening before colonoscopy and half (2 L) on the morning of the procedure.
46044625|NCT02647138|Other|white noise|exposure to white noise
45349024|NCT00856167|Drug|TCM|whole system Traditional Chinese Medicine, including acupuncture, herbs, tuina, lifestyle counseling
45349025|NCT00856167|Behavioral|Self-care for TMD|a 5-session 8 hour intervention targeting TMD knowledge, stretching and exercises, stress reduction, lifestyle modification
45349026|NCT00686634|Drug|Sitagliptin|Sitagliptin 100 mg by mouth once daily
45349027|NCT00856401|Drug|PTH1-84 in parent study|daily injection of rhPTH(1-84); 25, 50 75, or 100mcg in parent study. In ADD-ON study, there is no intervention, only testing.
45596496|NCT03527953|Other|Surefil SDR Flowable bulkfill|The preparation will be etched. A two-step etch-and-rinse adhesive, Prime&Bond NT will be applied to all enamel/dentin surfaces, air-dried for 5 seconds, and will be light cured for 10 seconds. After the sectional matrix will be placed, the flowable bulk-fill resin composite, SureFil SDR™ flow (Dentsply Caulk, Milford, DE, USA), will be placed in a 4-mm bulk increment in the dentinal part cured for 20 seconds and will be followed by a covering layer of the nanohybrid resin composite, Ceram.X Mono that will be cured for 20 seconds.
45685288|NCT01513239|Biological|MK-3415A|Single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to C. difficile Toxin A and 10 mg/kg of monoclonal antibody to C. difficile Toxin B)
45685289|NCT01513239|Biological|Placebo|Single IV infusion of normal saline (0.9% sodium chloride)
45685290|NCT01513239|Drug|SOC|SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
45685291|NCT01453114|Behavioral|Cognitive Behavioral Therapy|CBT is administered for 12 sessions over the period of 16 weeks, followed by optional monthly sessions.
46044626|NCT02647216|Behavioral|Mindfulness Based Cognitive Therapy|Weekly MBCT sessions consist of: a) mindfulness practice including breath-focused sitting meditation, body scanning, and mindful stretching; b) review of previous weeks' homework and an overview of the current week's homework; c) barriers to completing the homework. Homework includes: a) practicing the mindfulness exercise reviewed in class using the CDs provided to each participant (guided practice of the relevant exercise); b) maintaining a calendar of pleasant events; c) mindfully engaging in activities of daily living; and d) logging practice efforts in a daily log.
46044627|NCT02647216|Behavioral|Treatment as Usual|Subjects randomized to the Treatment as Usual group will be advised to seek help from their family doctor or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study.
46044628|NCT00653770|Biological|FP85A|Recombinant Fowlpox virus 9 expressing antigen 85A from M. tuberculosis (5 x10^7 pfu)
46044629|NCT00653770|Biological|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis (5 x 10^7 pfu)
45685292|NCT01453192|Drug|Raltegravir|Introduction of Raltegravir 2 days after renal transplantation within an antiretroviral regimen without ritonavir boosted antiprotease
45685293|NCT01453270|Device|NICOM|Assessment of fluid responsiveness will be done using the non-invasive cardiac output monitor (NICOM) and passive leg-raising (PLR) maneuver to target mean arterial pressure of between 65mmHg and 90mmHg; and change in stroke volume index (SVI) less than 10%, prior to administration of fluid boluses.
45685294|NCT01453270|Other|Usual care|Usual care is given at the clinician's discretion in accordance with current best practice. Standard treatment may involve treatment with intravenous fluids, and medications to support the blood pressure and heart.
45685295|NCT01453426|Drug|BG00012 Dose 1|
45685296|NCT01453426|Drug|BG00012 Dose 2|
46044630|NCT00910936|Behavioral|Exercise|12 weeks endurance training, 3 times weekly for 35 minutes
46044631|NCT02640040|Device|llizarov external fixation device|llizarov external fixation device was applied to fix the tibia.
46044632|NCT02640040|Device|intramedullary rod fixation|retrograde intramedullary rod was applied to stabilize the tibia.
46044633|NCT02640040|Procedure|surgery|combined surgery for enrolled patients with CPT: sleeve resection of the pathological soft tissues, retrograde intramedullary rodding, packaged lilac bone autograft,and llizarov external fixation device installation.
46044634|NCT02643160|Other|Functional Trunk Training|The intervention includes neurodevelopment treatment, muscle strengthening and functional activities of trunk region
46044635|NCT04165642|Other|Laser ballon ablation for Pulmonary vein isolation|The patients indicated to AF ablation procedure will be treated with laser balloon ablation without verification of electrical isolation of pulmonary veins using implantable loop recorder and/or Holter monitoring
45685297|NCT01544127|Behavioral|MI-SI+TAU|MI-SI focuses on exploring and resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
45685298|NCT01544127|Behavioral|MI-SI-R+TAU|MI-SI-R focuses on resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
45685299|NCT01544127|Other|TAU Alone|Inpatient treatment includes medication management, case management, meals and a bed, milieu therapy consisting of creative and social activities, and a safety plan. Some families of veterans also received education to create a supportive home environment. As part of Veterans Health Administration (VHA) suicide prevention policy, the care of suicidal patients is also overseen by a local Suicide Prevention Coordinator and case managers.
45685300|NCT01453504|Drug|DHAP|Dexamethasone, Cytarabine, Cisplatin
45685301|NCT01453504|Drug|Everolimus|
46044636|NCT00826267|Drug|lapatinib|lapatinib tablets 1500 mg daily
46044637|NCT00826267|Drug|BIBW 2992|BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
45349028|NCT00560404|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc monthly (starting dose)
45349029|NCT00560404|Drug|Epoetin alfa|As prescribed
45349030|NCT00751920|Procedure|Enhanced MRI Scan|Following the detection of a pulmonary nodule(s) with the unenhanced MRI scan, the subjects will then be injected with the contrast agent, Magnevist, and have a dynamic enhanced MRI scan of the largest pulmonary nodule.
45349031|NCT00850551|Other|Early Intervention|Twice a week home spirometry and symptom assessment
45476038|NCT04767334|Device|Anti-Gravity Treadmill|"Each participant will started with a 5 - 10 minute warm-up on a standard cycle ergometer, manual and therapeutic therapy for upper extremity, and gait training using LBPP. Manual and therapeutic therapy will consist of passive and active ROM, joint mobilization, passive and active stretch, manual resistance exercise, and activities of daily life (ADL). All participants will walk in Alter G one session a day (for 40 min), three days a week, for six weeks. On session one, the Alter G pressure chamber will be set to unload 50% of patient's body weight. On the following sessions, the percentage of unload patient's body weight will be decrease depends on the patient's comfort.~The physical therapist assistance and treadmill speed will be evaluated and altered based on the patient's capacity. The participants can take a rest whenever his/her need during walking. The rest time will be measured and documented."
45685302|NCT01453582|Drug|Total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
45685303|NCT01453582|Drug|total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
45349032|NCT00850629|Behavioral|multimodal lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
45349033|NCT00850629|Behavioral|placebo|no intervention, only follow up
45685304|NCT01512693|Drug|MK-0822|A single oral dose (50 mg tablet) of MK 0822 will be administered on Day 1 after an overnight fast.
46044638|NCT00826267|Drug|trastuzumab|trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly
45349034|NCT00951730|Other|Polysomnography|Polysomnography is the method of choice for the diagnosis of sleep apnea. This test lasts for one night in hospital.
45685305|NCT02588482|Device|high-density electroencephalography|Auditory stimulations during electroencephalography recording
45349035|NCT02546037|Device|FX100 dialyzer|comparison of dialyzers
45349036|NCT02546037|Device|SOLACEA 21H|comparison of dialyzers
45349037|NCT00942526|Drug|Mycostatin oral suspension|peroperative Mycostatin oral suspension ( 0.1MU/cc, 24cc/bt; 5cc qid)for 7 days
45349038|NCT00942526|Other|Water|perioperative gargling with water
45349039|NCT00853281|Other|Hammocks with LLIN|Locally-made hammocks covered with long lasting insecticidal nel (LLIN)
45349040|NCT00853281|Other|Standard vector control measures|Insectice-treated net
45349041|NCT04042389|Behavioral|WhatsApp reminder|"The WhatsApp group received oral health messages once a week for four weeks (totaling 4 messages) as a reminder to practice good oral hygiene~The reminder included an image reminding them to maintain their oral hygiene."
45685306|NCT02588482|Device|Conventional electroencephalography|Auditory stimulations during electroencephalography recording
45685307|NCT01453738|Biological|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
46044639|NCT02639962|Radiation|Cardiac CT|Cardiac CT before the CAG, and follow up after 2 month and 12 month
46044640|NCT00653848|Drug|docetaxel|docetaxel 75 mg/square meter i.v. every third week, six cycles
46044641|NCT00707551|Drug|Ketoconazole|Tablet, administered as repeated doses.
46044642|NCT00707551|Drug|Verapamil|Extended Release tablet, administered as repeated doses.
46044643|NCT00707551|Drug|AZD1305|Extended Release tablet, administered as a single dose.
45349042|NCT04042389|Behavioral|Email reminder|"The Email group received oral health messages once a week for four weeks (totaling 4 messages) as a reminder to practice good oral hygiene~The reminder included an image reminding them to maintain their oral hygiene."
45349043|NCT04042389|Behavioral|Control|No messages sent.
45349044|NCT03967444|Device|Hyaluronic acid|Injectable gel for lip augmentation
45349045|NCT03967444|Device|Hyaluronic acid|Injectable gel. Lip Augmentation and other wrinkles/folds
45349046|NCT00850785|Biological|DRibble vaccine|Docetaxel 75 mg/m2 will be administered in the several days after leukapheresis. Intradermal (ID) vaccine injections of DRibbles made from at least 5 million and up to 20 million cell equivalents per vaccination will begin 14 days after the first docetaxel. Each DRibble vaccine will be followed by the 6-day infusion of GM-CSF via the CADD-MS 3 pump (50 micrograms/24 hrs).
45349047|NCT05300854|Procedure|Standard anesthesia in addition to serratus plane block|a US-guided SPB was performed after induction of general anesthesia with the patient lying supine.
45349048|NCT05300854|Procedure|Standard anesthesia in addition to para-vertebral block|Standard anesthesia in addition to para-vertebral block
45349049|NCT00946504|Drug|Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)|
45349050|NCT00946504|Drug|Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)|
45685308|NCT01453738|Biological|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
45685309|NCT01454908|Device|Oxford Partial Knee|The Oxford partial knee contains tibial and medial components and a mobile meniscal bearing.
45349051|NCT00619983|Drug|donepezil|Group 1: Will receive donepezil 5mg once a day
45349052|NCT00619983|Drug|duloxetine|Group 2: Will receive duloxetine 30 mg twice a day
45685310|NCT04272892|Behavioral|Digital cognitive behavioural therapy for insomnia|6 weeks of cognitive behavioural therapy for insomnia (Sleepio) delivered online
45349053|NCT00619983|Drug|donepezil 2.5 mg and duloxetine 30mg|Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg
45349054|NCT00619983|Drug|placebo|Group 4: Will receive placebo pills
45349055|NCT00619983|Drug|gabapentin|Week 8: all subjects will have open label gabapentin added to their randomized study medication
45349056|NCT00946582|Behavioral|Barkley's parenting management program|It is a parent training group to teach behavior therapy techniques to parents of children with ADHD. The group will contain about 10 parents of children with ADHD. It will be conducted 1.5 hour per session, one session per week, and 11 sessions totally.
45476039|NCT04776278|Behavioral|Brief Alcohol Intervention (BAI)|This session includes a discussion related to harm reduction and the participant's autonomy to make decisions about the information provided in the session; an alcohol use decisional balance exercise; personalized alcohol-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the participant's perception of how much he or she drinks and actual norms, (b) a comparison of the participant's alcohol consumption vs. norms, (c) an estimate of the participant's peak blood alcohol content in the past month, (d) alcohol-related problems experienced, (e) money spent on alcohol, and (f) calories consumed from alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if he or she indicates interest.
45476040|NCT04776278|Behavioral|Substance-free Activity Session (SFAS)|The SFAS session includes : a) discussion of life goals, b) discussion of associations between alcohol and drug use, goals, and substance-free activities; c) a graph depicting the participant's ratings of the relative importance of various aspects of their life and how their actions in the past week have been consistent with these priorities; d) personalized feedback on recent time allocation to activities across life domains, and a discussion of any changes the participant would like to make; e) feedback on symptoms of stress, anxiety and discussion of adaptive coping strategies; f) discussion of enjoyable substance-free activities and hobbies and substance-free recreational activity suggestions tailored to individual's interests and neighborhood; g) a goal setting exercise for specific behavior change plans; h) a Future Thinking Writing Exercise. Participants will receive weekly text-message based booster prompts for four weeks after their SFAS session.
45685311|NCT04272892|Behavioral|Sleep hygiene information|A leaflet detailing advice to improve sleep through changes in sleep hygiene
46044644|NCT02535754|Behavioral|ALIVE|The company assigned to this condition offered employees participation in the ALIVE program. This program was validated in a previous worksite-based randomized controlled trial (RCT). A baseline assessment includes questions asking about: presence of children at home, habits related to cooking and eating out, physical activity preferences, stage of readiness of change, and perceived barriers to achieving heath behavior goals. This information provides the basis for immediate feedback and individually-tailored messages that include goal-setting and tips to achieve these goals, interactive features, and health information. Biweekly messages are sent for a total of 48 weeks. Outcome data were based on all individuals who completed the baseline assessment.
46044645|NCT02535754|Behavioral|CCS BCY|The company assigned to this condition participated in a comprehensive year-long workplace wellness program intervention focusing on nutrition, weight control, and physical activity, led by the CCS BCY. The program was modeled after a previous successful CCS BCY tobacco control worksite program. This program stresses the importance of developing social and environmental supports at the worksite to promote behavior change . Such supports could include food availability (e.g., cafeteria and vending machine selections), the built environment (e.g., availability of bike racks); social environment (e.g., group lunchtime walking clubs), and health communications (e.g., company newsletters). Outcome data were based on all individuals who completed the baseline assessment.
46044646|NCT02535754|Behavioral|ALIVE + CCS BCY|The company assigned to this condition received both the ALIVE and CCS BCY programs. Employees were encouraged to take part in both ALIVE and company initiatives, but participation in these activities was based on individual preference. Outcome data were based on all individuals who completed the baseline assessment.
45349057|NCT00942682|Drug|Sorafenib|Taken orally twice daily
46044647|NCT02642926|Procedure|Monopolar current|Hysteroscopic surgical treatment of menorrhagia by use of monopolar current
46044648|NCT02642926|Procedure|Bipolar current|Hysteroscopic surgical treatment of menorrhagia by use of bipolar current
46044649|NCT00986154|Drug|edoxaban tosylate(DU-176b)|edoxaban tosylate(DU-176b), film-coated tablet for oral use, 30 mg, two tablets (60 mg) once daily, maximum of 12 months treatment
45349058|NCT00942682|Drug|RAD001|Taken orally once daily in the morning
45349059|NCT00853515|Other|Goal-directed fluid resuscitation|Targeted, weight-based fluid resuscitation
45349060|NCT00576420|Biological|FS VH S/D 500 s-apr, 60-seconds polymerization time|FS VH S/D 500 s-apr (FS) is applied to the study suture line. The actual dose of FS VH S/D 500 s-apr depends on the length of the suture line and the intensity of bleeding and is to be decided by the surgeon, but the maximum dose per suture line shall not exceed 4 mL FS VH S/D 500 s apr. After application of FS VH S/D 500 s-apr to the study suture line is completed, the surgeon will wait for 1 minute to allow polymerization of FS VH S/D 500 s-apr.
45349061|NCT00576420|Biological|FS VH S/D 500 s-apr, 120-seconds polymerization time|Treatment will be identical to the FS VH S/D 500 s-apr Group, 60 seconds polymerization time, except that the surgeons will wait 2 minutes to allow polymerization and will then open the cross clamps.
45349062|NCT00576420|Procedure|Manual compression with surgical gauze pads|Treatment of the study suture line with manual compression with surgical gauze pads.
45841309|NCT05822336|Other|Duration of Intramuscular Injections|This study was a single-group crossover clinical trial, where each participant acted as their own control. Two intramuscular injections into the right and left Dorsal Gluteal Region (DRG) were recorded for each participant. One was administered by a nurse, according to the unit's routine, and took 5 seconds to complete. A day after, the same nurse gave the other injection in the opposite DGR, taking 40 seconds to administer. The five-second injections were considered the control group, while the 40 seconds injections were the intervention group. The order of interventions was randomized. The pain level was determined and recorded immediately after each injection.
46044650|NCT00986154|Drug|low molecular weight heparin/unfractionated heparin|"LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily.~Unfractionated heparin - 5,000 IU bolus intravenous administration, 1,300 IU/hour continuous infusion, minimum of 5 days and maximum of about 12 days treatment"
45349063|NCT00951964|Drug|Polyphenon E before Placebo|patients receive polyphenon E during 4 months, then 2 months of wash-out and finally 4 months of placebo
45349064|NCT00951964|Drug|placebo before treatment|patients receive 4 months of placebo, then 2 months of wash out et finally 4 months of treatment
45349065|NCT04144023|Biological|Granulocyte-Macrophage Colony-Stimulating Factor|Given intradermally
46044651|NCT00986154|Drug|warfarin|tablet for oral use; 0.5 mg, 1 mg, 2.5 mg, 5 mg; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; maximum of 12 months treatment
46044652|NCT02611375|Other|transcranial direct current stimulation|High-definition transcranial direct current stimulation is applied over the hand area of the primary motor cortex (M1). Parameters= 2mA for 20 minutes. Functional task practice will be completed concurrently with tDCS and for approximate 40 minutes after the stimulation stops.
46044653|NCT02611375|Other|peripheral nerve somatosensory stimulation|"Electrical stimulation will be applied to the median nerve of the primary hand being trained at parameters that elicit a sensory but not motor response (called peripheral nerve somatosensory stimulation). Stimulation parameters are 100Hz with a 250uS pulse width. Stimulation intensity will vary between 1-10mA per participant. Stimulation will be applied for 1 hour and functional task practice will be completed concurrent with the stimulation."
46044654|NCT02611375|Other|sham transcranial direct current stimulation|During sham transcranial direct current stimulation (tDCS), a sham tDCS device will be used along with functional task practice. The sham tDCS unit will be used for the first 20 minutes of FTP, followed by an additional 40 minutes of FTP.
45349066|NCT04144023|Biological|Multi-epitope HER2 Peptide Vaccine H2NVAC|Given intradermally
45349067|NCT04144023|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
45349068|NCT00942760|Device|3T MRI|The introduction of the 3T scanners provides a potential opportunity to improve the quality of imaging in neuro-oncology.
45349069|NCT00853983|Drug|[14C] AZD0530|Solution, Oral, once
45349070|NCT02545179|Other|web-based daily care training|12 week interactive web based caring training education
45349071|NCT03961204|Other|Data Collection|No study treatment was administered as part of this study
45349072|NCT00749034|Biological|VPM1002|live vaccine
46044655|NCT00653926|Drug|ropivacaine, ketorelac and epinephrine|In Group A, 200 mg ropivicaine, 30 mg ketorelac and 0.5 mg epinephrine (total volume 106 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue After 21 postoperative hours in Group A, 150 mg ropivicaine, 30 mg ketorelac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
46044656|NCT00653926|Drug|saline|In Group P (placebo) no injections were given intaoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
45349073|NCT00749034|Biological|BCG|commercially available live vaccine BCG
45349074|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
45349075|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
45349076|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
45349077|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
46044657|NCT02613091|Drug|Clemastine fumarate|4mg 2x day clemastine fumarate orally.
46044658|NCT02639806|Drug|Sevoflurane|
46044659|NCT02639806|Drug|Lidocaine|
46044660|NCT00653146|Behavioral|Mindfulness-Based Stress Reduction|In the intervention program, a variety of mindfulness meditation techniques will be taught, including the body scan, awareness of breathing, mindful yoga, eating meditation and walking meditation.
45349078|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
45349079|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
45349080|NCT04059510|Procedure|rectovaginal swab|Self taken rectal and vaginal swab
45349081|NCT04059510|Procedure|pregnancy test|Urine pregnancy test
45349082|NCT04059510|Procedure|Menstrual cup|Menstrual cup vaginal fluid collection
45349083|NCT04059510|Procedure|Blood test|Venous blood sample
45349084|NCT04059510|Other|Focus group|Focus group responses will be audio-recorded, transcribed, and analysed by developing a coding framework and identifying emerging themes
45349085|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
45349086|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
45349087|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
45349088|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
45349089|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
45349090|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
45349091|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
45349092|NCT00755742|Other|Lifestyle intervention|"The 3-pronged lifestyle intervention is designed to deliver a period of intensive contact (week 0-12) and less-intensive contact (weeks 12-24):~i) Behavior Modification Counseling: The principles of motivational enhancement and cognitive-behavior therapy (MET/CBT) will be utilized at each visit and telephone contact to provide individually tailored counseling. The goal is to enhance internal motivation and facilitate changes in lifestyle that are adaptable to each participant's usual habits.~ii) Physical activity target: increment in activity of at least 3000 steps/day above the baseline, or total activity of 10,000 steps/day (whichever is greater).~iii) Dietary assessment and nutritional plan: A diet plan designed to both lose weight and improve insulin resistance will be provided."
45349093|NCT00857025|Biological|beta-glucan MM-10-001|Dose escalation with six patients treated at each of the following oral dosages: 2.5, 5.0, 7.5, 10, 15, 20, 30, 40, 50, and 80 mg/day
45349094|NCT00857025|Other|flow cytometry|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and every 4 weeks until the end of study treatment.
45349095|NCT00857025|Other|laboratory biomarker analysis|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and at the end of study treatment.
45685312|NCT04273204|Diagnostic Test|one leg standing test, gross motor function measurement, pedobarographic measurement|OLST:During the OLST,the participants were asked to shoes off,place both hands on their hips and look at a point on the wall at eye level.A recording stopwatch was used to assess their standing duration on one leg while keeping the other leg in 90 degrees of knee flexion.The test was stopped when the contralateral foot touched the ground or when the participant broke 90 degrees of knee flexion.The OLST was repeated three times for each leg.GMFM:To assess standing and walking,running and jumping functions of the UCP group,the D and E dimensions of GMFM were utilized by a certificated physiotherapist.Each item was tested by three trials and the best trial was used.Pedobarography:The participants' plantar pressure was analyzed using pedobarography.For each participant, the pedobarography was calibrated before the assessment.During the pedobarographic analysis, the participants walked barefoot in 90 BPM cadence. Three steps were analyzed for each side.
45685313|NCT01458340|Drug|TD-9855|Once daily
45685314|NCT01458340|Drug|TD-9855|Once daily
45685315|NCT01458340|Drug|Placebo|Once daily
45685316|NCT04847752|Procedure|carotid artery stenting|common treatments for carotid artery stenosis
46044661|NCT00653146|Behavioral|Healthy Lifestyles|In the control condition, information on healthy lifestyles will be presented in a didactic fashion. Session topics include diet and nutrition, physical activity, and healthy behaviors to prevent cardiovascular disease and cancer.
46044662|NCT02642848|Procedure|HTO with microfracture|High tibial osteotomy(HTO) with micro fracture on femoral condyle is an common treatment for the correction of malalignment of the knee treating osteoarthritis. Device: Tomofix
46044663|NCT02642848|Procedure|Transplantation of bone marrow stem cell|Transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone. Bone marrow cell cell 6cc
46044664|NCT02642848|Procedure|Transplantation of adipose derived stem cell|Transplantation of autologous adipose-derived stromal vascular fraction using LipoSculptor collecting from abdominal fat tissue. Adipose derived stem cell from abdominal fat tissue 3cc
46044665|NCT02646904|Drug|Nasal Beclomethasone Dipropionate|Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of nebulized Beclomethasone Dipropionate nasal spray for 21 days.
46044666|NCT02646904|Drug|CERCHIO 10 mg/ml OS|For Children < 12 years old 10 drops die (5 mg die) for 21 days. For Children > 12 years old 20 drops die (10 mg die) for 21 days.
46044667|NCT00848965|Drug|Fluticasone propionate|Corticosteriod, with anti-inflammatory effects
46044668|NCT00848965|Drug|Placebo|Placebo comparator
46044669|NCT02642770|Device|Transesophageal echocardiography|2D LV Speckle tracking strain and 3D LVEF measurements
46044670|NCT00654082|Drug|sildenafil|sildenafil 50 mg tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks; after 2 weeks on treatment, doses could be escalated to 100 mg or reduced to 25 mg
46044671|NCT00654082|Drug|placebo|placebo tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks
46044672|NCT02639416|Dietary Supplement|Polymeric formula|Polymeric formulae are recommended in the management of inflammatory bowel disease in children
46044673|NCT02639416|Dietary Supplement|Elemental formula|Elemental formulae are recommended in cow's milk and other food intolerances in children.
46044674|NCT02639416|Other|Standard management|Standard management with F-100 and/or RUTF
46044675|NCT00654160|Drug|fluorouracil|
46044676|NCT00654160|Drug|irinotecan hydrochloride|
46044677|NCT00654160|Drug|leucovorin calcium|
46044678|NCT00654160|Other|pharmacogenomic studies|
46044679|NCT00654160|Other|pharmacological study|
45349096|NCT00857025|Other|questionnaire administration|Assessment pre-study and week 5, week 9, week 13 and at off study.
45685317|NCT04847752|Procedure|carotid endarterectomy|common treatments for carotid artery stenosis
46044680|NCT02639572|Biological|Siloss® bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing. Randomization was employed.
45349097|NCT00750048|Drug|Naloxone and paracetamol|to check if naloxone induce an inhibiting effect on the analgesic effect of paracetamol in healthy volunteer, using evoked potentials
45349098|NCT00942838|Drug|Cisplatin|PLATINOL®-AQ (cisplatin injection) is a clear, colorless, sterile aqueous solution, each mL containing 1 mg cisplatin and 9 mg Sodium Chloride, USP. HCl and/or Sodium Hydroxide is added to adjust pH of the solution. The active ingredient, cisplatin, is a yellow to orange crystalline powder with the molecular formula PtCl2H6N2, and a molecular weight of 300.1. Cisplatin is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis position. It is soluble in water or saline at 1 mg/mL and in dimethylformamide at 24 mg/mL. It has a melting point of 207°C.
45349099|NCT00942838|Radiation|Whole Abdomen Radiotherapy|Whole abdominal radiotherapy will be delivered with an open-field anterior-posterior/posterior-anterior technique. Radiation will be administered in a dose escalating fashion to determine toxicity. The maximal dose of radiation will be defined as a mean midplane dose to the abdomen of 3,000 Gy through parallel-opposed single ports with a 1-cm margin that will cover the entire abdomen including the diaphragm.
45349100|NCT04041765|Drug|IgM-enriched IVIG|Contains human plasma protein 50mg/ml. With composition of Immunoglobulin M (IgM) 6mg, Immunoglobulin A (IgA) 6mg, Immunoglobulin G (IgG) 38mg (IgG subcl. approx. 63 % IgG1, 26 % IgG2, 4 % IgG3 and 7 % IgG4), Glucose monohydrate, sodium chloride, water for injections
45349101|NCT00752076|Other|cancer cell lines establishment|Detection of epithelial growth factor receptor (EGFR) mutation in malignant pleural effusion of lung cancer patients and cancer cell lines establishment
45349102|NCT02546271|Behavioral|GPS|
45685318|NCT04847752|Drug|Aspirin|the dosage and duration
45685319|NCT04847752|Drug|Clopidogrel|the dosage and duration
45685320|NCT04847752|Drug|Anticoagulant|the dosage and duration
45685321|NCT04847752|Drug|Statin|the dosage and duration
45685322|NCT04847752|Drug|PCSK9 inhibitor|the dosage and duration
45685323|NCT04844554|Other|Active HD-tDCS 3mA|This group will receive HD-tDCS 3mA intensitie. 0 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up to the desired intensity, which was maintained for 20 min.
45685324|NCT04844554|Other|Sham HD-tDCS|This group will receive sham HD-tDCS. The intervention will be applied in 10 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up them turn off.
45349103|NCT04057014|Drug|Amoxicillin|Antibiotic given at different dosages and durations.
45349104|NCT04057014|Procedure|Tooth extraction|Removal of infected tooth on first day of study, this approach does not require an antibiotic drug.
45349105|NCT00946738|Other|Biofeedback|Biofeedback training as behaviour treatment was performed thrice weekly for 4 week.
45349106|NCT00946738|Other|Deep oscillation|Deep oscillation providing a pulsing electromagnetic field was performed thrice weekly for 4 weeks.
45349107|NCT00857103|Behavioral|CHOICE|Use of Choice support system as preparation for patient consultations
45349108|NCT00364351|Drug|Vandetanib|once daily oral tablet
45349109|NCT00364351|Drug|Erlotinib|oral dose
45349110|NCT05279872|Drug|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
45349111|NCT00854139|Drug|Cyclophosphamide, anti-thymocyte globulin|"Cyclophosphamide 60 mg/kg IV on Day -5, -4 Anti-thymocyte globulin 20 mg/kg IV on Day -1, Day +1, +3, +5~Cyclosporine starting on Day -1 at 5 mg/kg daily I.V. and reduced to 3 mg/kg on Day +4, and adjusted to provide a trough whole blood concentration of 250-400 ng/mL. The route of administration will be changed to oral as soon as the patient is able to tolerate oral medications"
45349112|NCT00854139|Procedure|Kidney transplant|On Day 0 the renal transplant is performed according to standard surgical techniques, preferably using an iliac fossa, extraperitoneal approach
45349113|NCT00854139|Radiation|Thymic irradiation|Thymic irradiation 7 Gy on Day -1
45349114|NCT00854139|Procedure|Bone marrow transplant from a related donor|• Donor bone marrow (> 2 x 108 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure at the medical center. A total of 15,000 Units of heparin is mixed with the marrow, which is infused at a rate of 300-500 cc/hr. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed. Protamine, 25 mg, is administered I.V. after completion of the first half of the bone marrow infusion. If a partial thromboplastin time measured after completion of the marrow infusion is > 60 seconds, the protamine treatment shall be repeated
45349115|NCT00755820|Behavioral|Exposure Therapy + D-Cycloserine|Exposure therapy with d-cycloserine medication
45349116|NCT00755820|Behavioral|Exposure Therapy + Placebo|Exposure therapy with placebo medication
45349117|NCT00755820|Behavioral|Supportive Psychotherapy|Supportive psychotherapy
46044681|NCT02639572|Biological|Hydroxyapatitie Bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing.Randomization was employed.
45349118|NCT00952042|Other|Heavy slow resistance training|Heel-raises. 12-6RM. each contraction performed slowly. three times weekly for 12 weeks
45349119|NCT00952042|Other|Eccentric resistance training|Eccentric heel-raises. 3 x 15 reps performed twice daily for 12 wks.
45685325|NCT04841590|Other|Intervention of the experimental group (EG)|Treatment through the use of manual physiotherapy techniques such as mobilization techniques in the spinal column, cranial techniques and visceral mobilization applied by gentle pressure, according to the therapist's diagnostic criteria after performing palpatory and mobility tests.
45685326|NCT04841590|Other|Control Group (CG)|Subjects in the control group (CG) will not receive any treatment
45685327|NCT04841590|Device|Placebo Group (PG)|Subjects belonging to this group will receive the application of off ultrasound applied to the abdominal region for approximately 10 minutes
45685328|NCT04846270|Device|TENA SmartCare Change Indicator|Each participating subject will be provided with TENA SmartCare Change Indicator and incontinence products for the duration of the investigation. Each participating subject will be allocated to the incontinence type(s) that are considered most suitable.
45349120|NCT00752154|Drug|Curcumin (Longvida™)|Curcumin (Longvida™) or matching placebo. They will begin by taking 4 capsules (approximately 2 grams) once a day for 2 weeks and then the dose will be increased to 4 capsules twice a day (4 gram per day) beginning at week 3. Subjects will remain at this dose for an additional 13 weeks for a total 16 weeks. After 16 weeks, the same procedures will be repeated for another 16 weeks
45349121|NCT00854217|Procedure|acute normovolemic hemodilution|
45349122|NCT00943228|Drug|mycophenolate mofetil|High dose 4gms daily
45349123|NCT00755898|Drug|Ingestion of a 200 mg dose of amantadine hydrochloride|Volunteer cancer patients ingest 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper.
45349124|NCT00755898|Drug|Ingestion of a 200 mg dose of amantadine hydrochloride|Healthy subject ingests 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper
45349125|NCT00850941|Behavioral|Questionnaire|Information collection.
45685329|NCT04845568|Behavioral|Virtual Reality Experience|"The virtual reality experience includes psychoeducation content about healthy eating and consideration of future consequences. It includes a game where participants are in a go kart and pick up healthy or unhealthy foods on the road. Participants play in the present and in the future."
45685330|NCT04847206|Drug|3,4-methylenedioxymethamphetamine|A moderate dose of 100 mg MDMA will be administered.
45685331|NCT04847206|Drug|3,4-methylenedioxyamphetamine|A moderate dose of 93.9 mg MDA will be administered.
46044682|NCT02639104|Radiation|Radiography|"Obtaining patients lateral spot cervical spine radiography and will measure;~The segmental angle will be measured from C2-C7 inferior endplates on the lateral radiography~If there is a segmental kyphosis (for example kyphotic angle in C4-5 level), the segmental cobb angle will be measured in the level of the main kyphosis~The segmental cobb angle will be measured between C2-C4 inferior endplates and C4-C7 inferior endplates"
46044683|NCT02639104|Other|Electromyography|"Serratus anterior needle electromyography:~The needle can be inserted into the muscle superficially to the fourth to sixth rib in the medial or posterior axillary line. The usual nerve latency time is between 2.6-4 ms."
46044684|NCT04274556|Other|Post-dialysis recovery group|Before the hemodialysis session, the patients were asked by the investigators how long it took them to recover from a dialysis session, taking the last treatment month into account.
46044685|NCT02642380|Drug|Dexamethasone (4 cycles)|dexamethasone 40mg daily for 4 consecutive days every 14 days for 4 courses
46044686|NCT02642380|Drug|Dexamethasone (1 cycle)|dexamethasone 40mg daily for 4 consecutive days
46044687|NCT02642692|Procedure|Patellar Tendon graft|Acl reconstruction with patellar tendon graft
46044688|NCT02642692|Procedure|Hamstring Graft|Acl reconstruction with hamstring graft
46044689|NCT02642302|Behavioral|HIIT With 60 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 60 seconds rest on VO2Max and aerobic/ anaerobic performance
46044690|NCT02642302|Behavioral|HIIT With120 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 120 seconds rest on VO2Max and aerobic/ anaerobic performance
46044691|NCT02642302|Behavioral|Control|Continuous exercise at 50-55% VO2Max with similar total work of interval training
45476041|NCT04776278|Behavioral|Relaxation Training (RT)|The clinician will begin by establishing the credibility of the session by providing the participant with the rationale that developing relaxation or mindfulness training strategies can reduce stress and enhance wellness. The clinician will then lead the participant through a diaphragmatic breathing exercise, followed by a progressive muscle RT protocol, and then a brief breath-counting (mindfulness) exercise. The session will conclude with a brief discussion of additional stress and anxiety management strategies (e.g., apps to monitor heartrate and breathing). Participants will be asked about their reaction to the techniques and, if interested, encouraged to commit to a specific plan for practicing these techniques.
45685332|NCT04847206|Drug|lysine-3,4-methylenedioxymethamphetamine|A moderate dose of 171.7 mg lysine-MDMA will be administered.
45685333|NCT04847206|Drug|lysine-3,4-methylenedioxyamphetamine|A moderate dose of 165.6 mg lysine-MDA will be administered.
45685334|NCT04847206|Other|Placebo|Placebo (Mannitol)
45349126|NCT00952198|Drug|ARRY-403, glucokinase activator; oral|multiple dose, escalating
45349127|NCT00952198|Drug|Placebo; oral|matching placebo
45349128|NCT00750126|Drug|Fludarabine, Busulfan, Thymoglobulin|"study :~acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post transplantation~the effectiveness of the protocol on tumor response~overall survival"
45685335|NCT04844008|Dietary Supplement|Nanobubble drink|Commercially available sports drink
46044692|NCT01154036|Drug|ezetimibe 10 mg|
46044693|NCT01154036|Drug|atorvastatin|
46044694|NCT01154036|Drug|Comparator: rosuvastatin|
46044695|NCT00816595|Biological|bevacizumab|Given IV
46044696|NCT00816595|Biological|pegfilgrastim|Given subcutaneously
46044697|NCT00816595|Biological|rituximab|Given IV
46044698|NCT00816595|Drug|cyclophosphamide|Given IV
45349129|NCT00851019|Behavioral|DDR|"Ad libitum attendance to engage in Dance Dance Revolution (DDR) Exergaming, for a 3-month period"
45349130|NCT00851019|Behavioral|Treadmill|Ad libitum attendance to engage in treadmill exercise, for a 3-month period
45349131|NCT00946816|Behavioral|Nutritional Intervention|Nutritional Intervention
45349132|NCT00755976|Drug|epirubicin hydrochloride|
45349133|NCT00755976|Drug|sulindac|
45349134|NCT00755976|Other|immunologic technique|
46044699|NCT00816595|Drug|pentostatin|Given IV
46044700|NCT02886026|Device|Bladder tumor resection using diathermia|Conventional bladder tumor resection using diathermia
46044701|NCT02886026|Device|Diode laser (980 nm) tumor destruction|Laser mediated destruction of bladder tumors (LMD-BT)
46044702|NCT00922909|Behavioral|Simon task|Reaction time task
45349135|NCT04012060|Procedure|Limited access aortic valve replacement.|Limited access aortic valve replacement through partial upper hemisternotomy
46044703|NCT05757037|Device|laser acupuncture|a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5W/cm2; pulsed wave; and Bahr frequencies [B1: 599.5Hz, B2: 1199Hz, B3: 2398Hz, B4: 4776Hz, B5: 9552 Hz, B6: 19,104Hz, and B7: 38,208Hz].
46044704|NCT01166438|Drug|Botulinum toxin A (Botox A®)|A single intradetrusor injection of 100U botulinum toxin A in 10 mL plus 0.1 mL of indigo carmine administered during cytoscopy. Between 100 and 200ml of saline is instilled into the bladder prior to injection to allow adequate visualization of the entire bladder urothelium. The treating physician will inject a total of 10.1 mL of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization using disposable needles. Injections will be spread out to equally cover the posterior bladder wall and dome, but spare the bladder trigone and ureteral orifices.
46044705|NCT01166438|Drug|Solifenacin 5mg|Oral Solifenacin 5mg once a day for up to 6 months
46044706|NCT01166438|Drug|Solifenacin 10mg|Oral Solifenacin 10mg once a day for up to 4 months
45349136|NCT04012060|Procedure|Conventional aortic valve replacement|Aortic valve replacement through full median sternotomy
45349137|NCT00752310|Drug|Darunavir|
45349138|NCT00943462|Radiation|External-beam radiation therapy|60 Gy of external beam radiotherapy using a standard technique will be administered in 2-Gy fractions, for a total of 30 fractions
45349139|NCT00943462|Drug|Temozolomide|The chemotherapy will have to be administered in accordance with the protocol used in the CAN-NCIC-CE3 study, which established the current standard for treatment of GBM with the administration of temozolomide as adjuvant therapy at the same time as radiotherapy (clinicaltrials.gov ID NCT00006353).
45349140|NCT02560974|Drug|Capecitabine|Capecitabine will be administered orally at 1000 mg/m^2 BID on Days 1 to 15 of a 3-week cycle, for 8 cycles.
45349141|NCT02560974|Drug|Oxaliplatin|Oxaliplatin will be administered as an IV infusion, 130 mg/m^2 on Day 1 of each 3-week cycle for 8 cycles.
45685336|NCT02868190|Device|Two trabecular micro-bypass stents (iStent inject)|Standalone implantation of two trabecular micro-bypass stents (iStent inject)
45685337|NCT02864914|Drug|Empagliflozin|drug
46044707|NCT01166438|Drug|Trospium chloride|Oral Trospium chloride XR 60mg once a day for up to 2 months
46044708|NCT00707707|Drug|AZD2281|Dose finding study to establish the appropriate dose of AZD2281
46044709|NCT00707707|Drug|Paclitaxel|Intravenous infusion over 1 hour
46044710|NCT02611297|Procedure|Cryoprobe|
46044711|NCT01153958|Drug|Colposeptine|Colposeptine will be administered transvaginally at a dose of 1 capsule every day for 12 consecutive days
46044712|NCT01153958|Drug|Metronidazole|Metronidazole will be administered orally at a dose of 400 mg twice a day for 7 days
46044713|NCT00707785|Dietary Supplement|Vitamin A|50,000 IU of Vitamin A 50,000 IU of vegetable oil
46044714|NCT00599638|Drug|pregabalin|75mg bid titrating to 150mg bid on day 4
46044715|NCT00599638|Drug|pregabalin/PF-00489791|Pregabalin 75mg bid titrating to 150mg bid on day 4; PF-00489791: 4mg od titrating to 10mg od on day 4
46044716|NCT00599638|Drug|Placebo|Placebo
46044717|NCT00654316|Biological|BCG|intradermal injection of 0.1ml BCG over the deltoid muscle
46044718|NCT04165252|Diagnostic Test|Collection of vaginal, neonatal buccal and placental samples|Analysis of microbiome and mycobiota of vaginal, neonatal buccal and placental
46044719|NCT02642146|Drug|Calcium Channel Blockers|
46044720|NCT02642146|Drug|Phosphodiesterase Inhibitors|
46044721|NCT02642146|Drug|Endothelin receptor blocker|
46044722|NCT02642146|Drug|Prostanoids|
46044723|NCT02642146|Drug|Other vasodilator|
46044724|NCT02646514|Device|Radiofrequency ablation with stenting|"Side viewing endoscope or PTCS scope can be used for all procedures. Cholangiogram is performed to confirm the stricture location, length and diameter. And then, RF catheter (ELRA®) is advanced over a guide wire at the level of the biliary stricture and ablation at 7-10 watts for a time period of 60-120s according to the length is conducted.~After performance of RFA, metal stents are inserted to ensure adequate decompression and bile drainage."
46044725|NCT02646514|Device|stenting|Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
46044726|NCT00654394|Drug|Rosuvastatin|
46044727|NCT00911014|Other|Questionnaire|From September 2005 to January 2006, 58 women who underwent surgery for vesicovaginal fistula at the National Hospital Fistula Center in Niamey, Niger were interviewed post-operatively using a questionnaire developed to investigate demographic, social, economic, and cultural factors that may affect formation of fistula. Also included in this questionnaire was evaluation of access to health care as well as patient understanding of counseling regarding their surgery and post-operative instructions, in particular information about future fertility and fistula development.
46044728|NCT00653302|Drug|Lantus (insulin glargine) + Glucophage (Metformin)|
46044729|NCT02638870|Drug|Amitriptyline|This was a prospective, observational study conducted at Samsung Medical Center, Seoul, Korea. Enrolled IBS patients underwent colonoscopy and colonoscopy-related pain score was evaluated. After colonoscopy, all patients received 5 mg amitriptyline once daily at bedtime for the first week and 10 mg for the subsequent 3 weeks. After the intervention period of 4 weeks, the treatment response was determined.
46044730|NCT02641990|Drug|ITCA 650 20/60 mcg/day, ITCA placebo|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days, followed by ITCA osmotic mini pump delivering placebo and Levora® for 28 days
46044731|NCT02641990|Drug|ITCA placebo, ITCA 650 20/60 mcg/day|ITCA osmotic mini pump delivering placebo and Levora® for 28 days, followed by Levora® and ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days
46044732|NCT00653380|Drug|Doxycycline Monohydrate|Capsules, 100 mg, single-dose
45685338|NCT02864914|Drug|DPP-4 inhibitors|drug
46044733|NCT00653380|Drug|Monodox|Capsules, 100 mg, single-dose
46044734|NCT02646592|Drug|Alfentanil|Bolus of alfentanil 10 µg/kg 5 minutes before skin incision
46044735|NCT02646592|Drug|sevoflurane or propofol|
46044736|NCT02646670|Drug|Ranibizumab|- In the first group will be held three applications of intravitreal ranibizumab 0.1 ml, with one application every month and follow up with Optical Coherence Tomography
46044737|NCT02646670|Drug|Aflibercept|- In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml, with one application each month followed by monitoring with Optical Coherence Tomography
46044738|NCT02646670|Drug|Ranibizumab and Aflibercept|- The third group will be held two applications of Ranibizumab 0.1 ml interspersed with one application of Aflibercept 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
46044739|NCT02646670|Drug|Aflibercept and ranibizumab|- In the fourth group will be held two applications of 0.1 ml Aflibercept interspersed with one application of Ranibizumab 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
45349142|NCT00946894|Procedure|Total thyroidectomy|Total thyroidectomy
45685339|NCT04840264|Drug|Docetaxel|25 mg/m2, D1, D8, D15, repeat every 4 weeks.
45349143|NCT00946894|Procedure|Dunhill operation|Unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy
45349144|NCT00946894|Procedure|Bilateral subtotal thyroidectomy|Bilateral subtotal thyroidectomy
45349145|NCT00854451|Drug|omeprazole plus amoxicillin|
45841310|NCT05822323|Other|BTX-A|Vials of 100 U Allergan Botox® (Allergan, Inc., Irvine, California) were diluted with 2 ml of physiological saline and made ready for use. The midline was determined at the mentum region. 5 U of BTX-A was injected into the mental muscle approximately 1 cm away from the chin tip and the midline
45349146|NCT00854451|Drug|omeprazole plus amoxicillin|
45349147|NCT00854451|Drug|omeprazole plus amoxicillin|
45349148|NCT00854451|Drug|omeprazole plus amoxicillin|
45349149|NCT00946972|Drug|JNJ-38431055; Placebo|
45349150|NCT00854529|Drug|Bevacizumab|sub-conjunctival injection of 1.25mg Bevacizumab
45349151|NCT00947050|Other|dynamic physical exercise|dynamic supine bicycle exercise for 6 minutes
45349152|NCT00861237|Drug|Nux vomica (active comparator)|Patients receive Nux vomica in a homeopathic potentiation
45349153|NCT00861237|Drug|Placebo (placebo comparator)|Patients receive Placebo looking similar to active drug
45349154|NCT02544867|Behavioral|Sedentary behavior|Participants were randomized to either reduce their total sitting time or increase sit-to-stand transitions. Information was provided in person, through written materials and by emails and phone calls in both conditions. Both groups received written educational materials on the dangers of excessive sitting and reviewed a generic day to illustrate how many sitting opportunities individuals face each day. During each session, the health educator also discussed the benefits of sitting less or increasing sit-to-stand transitions (depending on study condition) and brainstormed potential barriers to implementing the new behavior as well as strategies to overcome these barriers.
45349155|NCT00952432|Drug|Carbamazepine|Carbamazepine 200mg, 1/2 tablet, TID for 1 month
45685340|NCT04840264|Drug|Oxaliplatin|85 mg/m2, D1, D15, repeat every 4 weeks.
45685341|NCT04840264|Drug|5Fluorouracil|1200 mg/m2, D1, D8, D15, repeat every 4 weeks.
45841311|NCT05822323|Procedure|free gingival graft|The mandibular first incisor was treated with FGG operation due to Miller class III gingival recession and insufficient amount of keratinized gingiva.
45841312|NCT05822310|Procedure|radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerves|Patients are operated under sedation in the operating room. C-arm fluoroscopy device is used for imaging purposes for radiofrequency thermocoagulation process. In order to prevent vascular injury, the needle is advanced under the guidance of ultrasonography. There are target points determined in fluoroscopy for the femoral nerve and the obturatory nerve. Before the thermocoagulation procedure, local anesthetic and steroid are injected into each of the target points.
45841313|NCT05822310|Procedure|intraairticular steroid injection|The patients were placed in the supine position in the operating room. The patient was stained sterile with povidone iodide. The femoral neck was detected under ultrasonography and the joint capsule was entered with a 22G 9 cm spinal needle. Then, 5 cc bupivacaine and 5 mg betamethasone were given and the procedure was terminated.
45349156|NCT00952432|Procedure|Acupuncture|Acupuncture
45349157|NCT00861315|Drug|Nebulized amikacin|Amikacin is nebulized at a dose of 60 mg/Kg (6 first patients of the arm), 80 mg/Kg (6 subsequent patients) or 100 mg/Kg (last 6 patients of the arm)
45349158|NCT00861315|Drug|Intravenous amikacin|20 mg/Kg amikacin are administred intravenousely once a day during three days.
45349159|NCT00861315|Drug|Placebo nebulization|0.9% saline solution is nebulized once a day during three days
46044740|NCT00651976|Drug|letrozole|Take by mouth at a dose of 2.5 mg on days 7-21
46044741|NCT00651976|Other|Blood Collection|Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction
45349160|NCT00861315|Drug|Placebo infusion|0.9% saline is administered intravenousely once a day during three days
45349161|NCT00388297|Drug|Levothyroxine|Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.
45349162|NCT00388297|Drug|Placebo for Levothyroxine|
45349163|NCT00943540|Drug|raltegravir QD|Raltegravir 800mg QD
45685342|NCT04272814|Other|Compression therapy|Compression application
45685343|NCT04272814|Diagnostic Test|initial clinical assessment|Initial clinical assessment (includes history, vascular assessment, limb examination and wound assessment where necessary)
46044742|NCT00651976|Procedure|biopsy/lumpectomy/mastectomy|Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis
45349164|NCT00943540|Drug|atazanavir|atazanavir
45349165|NCT00943540|Drug|lamivudine (or emtricitabine)|lamivudine (or emtricitabine)
45841314|NCT05822310|Procedure|pericapsular nerve group (PENG) block|The patients were placed in the supine position in the operating room. The patient was stained sterile with povidone iodide. The high-frequency linear ultrasonography probe was placed on the anterior superior iliacspina (ASIS). Later, the anterior inferior iliac spine (AIIS) was detected by descending caudally. Afterwards, the probe was brought to the oblique position and AIIS, iliopubikeminence, psoas muscle and tendon were seen. Using a 22G 90-mm Quinckespinal needle, the tendon of the iliopsoas muscle was entered in the lateral-medial direction in the in-plane plane and bone contact was achieved. After negative aspiration, 15 ml of 0.5% bupivacaine were administered by seeing the appropriate drug distribution.
45685344|NCT04841434|Drug|Voraxaze Injectable Product|High-dose Methotrexat Infusion: MTX is given at a dose according to the allocated dose level cohort as a 4-hour IV infusion. HD-MTX cycles (up to 6) should be repeated every 14 days, provided that the patient has recovered (i.e., hematopoietic reconstitution) between cycles. A delay of up to 28 days between cycles is permitted in order to allow patients to recover from the preceding dose of MTX. In patients with a decline of the GFR to <40 mL/min, or in the case of decreased GFR, the decrease is >50% compared with the pretreatment value, treatment will be terminated. At the start of Cycle 3 the dose of MTX can be escalated to the next level if MTX has been well-tolerated according to the criteria described under dose escalation. Voraxaze: 2000 Units in patients weighing ≤100kg and at least 20 Units per kg body weight in patients weighing >100kg is given in each HD-MTX cycle as a slow IV injection at 24 hours (+/- 2 hours) after the start of HD-MTX infusion.
46044743|NCT02638792|Behavioral|Internet-based exposure therapy (I-ET)|"The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book Sluta älta och grubbla med kognitiv beteendeterapi (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images."
46044744|NCT02638792|Behavioral|Internet-based stress management therapy|The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
45349166|NCT00861393|Behavioral|CBT|12 Session CBT group
45349167|NCT00861393|Behavioral|Waitlist CBT|Participants in the waitlist will receive CBT when first group has completed CBT and been tested.
45349168|NCT00943696|Dietary Supplement|Ingestion of white wine vs. tea during and an alco|4 x 50ml glasses of white wine (12% alcohol) or tea will be taken according to a randomization scheme After the meal 1 x 20ml of Kirsch (40% alcohol) or tea will be taken
45349169|NCT00854685|Drug|ART621|3.0mg/kg s.c. - weekly
45349170|NCT00854685|Drug|ART621|3.0mg/kg s.c. - fortnightly
45349171|NCT00854685|Drug|ART621|1.5mg/kg s.c. - weekly
45349172|NCT00854685|Drug|ART621|1.5mg/kg s.c. - fortnightly
45349173|NCT00854685|Drug|Placebo|Placebo s.c. - weekly
45349174|NCT00854685|Drug|Placebo|Placebo s.c. - fortnightly
46044745|NCT02638636|Behavioral|Internet-based exposure therapy|The treatment is a 10 week long cognitive behavior therapy. It is based mainly on the principles of exposure; i.e. the participant is instructed to approach situations they have avoided in order to reduce or avoid pain or other aversive experiences until they feel less discomfort and extended behavior repertoire in presence of pain and aversive inner experiences Other interventions include psychoeducation, mindfulness and acceptance strategies and are employed in order to facilitate exposure.
45685345|NCT04272580|Drug|Control group|No preload was given before spinal anesthesia.
45685346|NCT04272580|Drug|4 ml/kg group.|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
45685347|NCT04272580|Drug|8 ml/kg group.|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
46044746|NCT02646436|Other|HD treatment|Patients with absolute contraindication to the PD method will be treated with HD. HD will be performed after implantation of central venous catheter using Seldinger technique by nephrology team.
46044747|NCT02646436|Other|PD treatment|Patients without absolute contraindication to the PD method will be treated with PD. PD will be performed after implantation of peritoneal catheter using Seldinger technique by nephrology team.
45685348|NCT04272580|Drug|12 ml/kg group.|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
46044748|NCT02638714|Biological|Stem Cells|Intervention: Transplantation of autologous purified stem cells
46044749|NCT00654550|Drug|Nexagon™ or Nexagon™ vehicle|Dose-escalation design in which cohorts of 6 subjects will be studied sequentially.
45685349|NCT04390438|Procedure|Percutaneous Electrolysis|Needle emplacement with a galvanic electrical current
45685350|NCT04390438|Procedure|Dry needling|Needle emplacement without electrical current nor substance
45685351|NCT04843852|Drug|Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]|one 0.5ml intramuscular injection on day 0 and week 4.
46044750|NCT00652054|Drug|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial will proceed to the second stage only if sufficient efficacy is demonstrated in Stage 1.
45685352|NCT04840342|Drug|Eplerenone|Dose escalations of eplerenone 50, 100, or 200mg
45685353|NCT04840342|Drug|Amlodipine|Dose escalations of amlodipine 2.5, 5, or 10mg
45685354|NCT04390516|Device|COViage|The COViage machine learning algorithm is designed to predict mechanical ventilation and mortality within 24 hours after hospital admission.
46044751|NCT04164862|Device|AccuVein AV400 Device Versus Ultrasound-guided Cannulation|Accuvein AV400 device versus Ultrasound guided cannulation
46044752|NCT02646358|Drug|Vepoloxamer|
46044753|NCT02642224|Behavioral|Social Work Case Management|The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
46044754|NCT01166282|Biological|adalimumab|Adalimumab solution for subcutaneous injection.
46044755|NCT01166282|Biological|placebo for adalimumab|Placebo for adalimumab solution for subcutaneous injection.
46044756|NCT02884700|Biological|Real-time PCR testing of lower respiratory tract samples|qPCR and high-throughput DNA sequencing testing of lower respiratory tract samples collected routinely in patients with severe legionellosis
46044757|NCT01153724|Drug|BI 1744|10 mcg solution for oral inhalation
46044758|NCT01153724|Drug|Fluconazole|400 mg capsule
46044759|NCT02884388|Procedure|combined nerve block|Patients in this group were assigned to receive lower lumbar plexus block, sciatic nerve block, and paraspinal nerve L1-2 block.
46044760|NCT02884388|Procedure|general anesthesia|Patients in this group were assigned to receive general anesthesia.
46044761|NCT05246930|Device|Impulse Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
45349175|NCT01864720|Behavioral|Professionally-administered cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. This multimodal approach combines behavioural (i.e., stimulus control therapy, sleep restriction), cognitive (i.e., cognitive restructuring), and educational (i.e., sleep hygiene) strategies that are administered over a 6-week period.
45349176|NCT01864720|Behavioral|Web-based cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). The treatment material will be identical to the video (DVD)-based CBT-I that we previously developed. Patients will complete their daily sleep diary electronically on the website and the content will be interactive. It will include the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.
45685355|NCT02849470|Procedure|Intradermal Injection in hair loss|Comparative Injection of Control (PRP & Acel) in hair loss; 2) Intradermal Injection in hair loss
46044762|NCT02885870|Procedure|Combination of multiparametric MRI and electrophysiology|MRI and electrophysiology will be combined in order to assess the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration will be developed and validated in pathologies that affect differentially white and grey matter: spinal muscular atrophy, X-linked spinal bulbar muscular atrophy and Amyotrophic lateral sclerosis
45685356|NCT02849470|Procedure|Platelet Rich Plasma|Growth factors and cytokines to promote healing and vascular supply
45685357|NCT02849470|Procedure|Adipose Derived Stem/Stromal Cells|Harvesting Adipose Lipoaspirate with Microcannula System
45685358|NCT02849470|Procedure|Stem/Stromal Cellular Isolation (Digestive)|Cell isolation and concentration add back to AD-stem/stromal cells utilizing Centricyte 1000 Protocol
45685359|NCT02849470|Procedure|MatriStem Matrix (ACell) - Current Standard of Care|
45685360|NCT02849470|Procedure|HD-PRP (High Density Platelet Rich Plasma)|
45685361|NCT02849470|Procedure|Emulsified AD-tSVF|
46044763|NCT04314596|Other|Cross Training Course|One day of a supervised, whole body, cross-training course that is meant to produce muscle damage and soreness.
46044764|NCT04314596|Dietary Supplement|Oceanix|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
46044765|NCT02885948|Drug|Naloxone|used to block the effects of opioids, especially in overdose
46044766|NCT02885948|Drug|Placebo|Placebo, ineffective control arm
46044767|NCT01152788|Drug|rIL-21|30 μg/kg IV Daily x 5, weeks 1, 3 and 5 every 8 weeks
46044768|NCT01152788|Drug|Dacarbazine|1000 mg/m2 IV Day 1, every 3 weeks
45349177|NCT00857571|Drug|150 mg Suspension|Single oral dose of 150 mg of PF-02413873 suspension
46044769|NCT01165424|Drug|mometasone furoate|"MFNS 50 μg spray device~3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.~12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning."
46044770|NCT01152554|Drug|TC-5214|Tablet, oral, twice daily for 52 weeks
45349178|NCT00857571|Drug|30 mg Suspension|Single oral dose of 30 mg of PF-02413873 suspension
45349179|NCT00857571|Drug|400 mg Suspension|Single oral dose of 400 mg of PF-02413873 suspension
45349180|NCT00857571|Drug|5 mg Suspension|Single oral dose of 5 mg of PF-02413873 suspension
45349181|NCT00857571|Drug|750 mg Suspension|Single oral dose of 750 mg of PF-02413873 suspension
45349182|NCT00857571|Drug|150 mg Tablet|Single oral dose of 150 mg of PF-02413873 tablets
45349183|NCT00857571|Drug|30 mg Tablet|Single oral dose of 30 mg of PF-02413873 tablets
45685362|NCT02849470|Procedure|Emulsified AD-cSVF|Stem/Stromal Cellular Isolate Added Back to Emulsified AD-tSVF
45841315|NCT05822297|Device|Neuromuscular electrical stimulation|NMES will consist of a 12 week electrical stimulation program, three times a week. Electrical stimulation will be done on the quadriceps muscles of both legs simultaneously. For each leg, one electrode is placed on the proximal side and one on the distal side of the quadriceps muscle. Electrical stimulation sessions will take 30min, at a stimulation frequency of 50Hz, an intensity where we can at least see a visible or palpable contraction with a maximum intensity of 100mA (we will choose the highest intensity that is easily supported by the participant without inducing discomfort) and a pulse width of 400μs. The activation within the activation-rest cycle consists of a 1s ramp-up, 7s full activation and 1s ramp-down, followed by 18s rest. Every 4 weeks the rest period will be diminished with 3s until a total of 9s.
46044771|NCT01152554|Drug|Placebo|Tablet, oral, twice daily for 52 weeks
45349184|NCT00857571|Drug|400 mg Tablet|Single oral dose of 400 mg of PF-02413873 tablets
45349185|NCT00857571|Drug|5 mg Tablet|Single oral dose of 5 mg of PF-02413873 tablets
45685363|NCT05027230|Drug|STSP-0601 for Injection|A multiple-dose design to evaluate the safety,tolerability and efficacy of two doses of STSP-0601 for injection in patients with inhibitory hemophilia
45685364|NCT05027230|Drug|STSP-0601 for Injection|A multiple-dose design to evaluate the safety,tolerability and efficacy of two doses of STSP-0601 for injection in patients with inhibitory hemophilia
45685365|NCT02846974|Device|Pulse oximeter|A pulse oximeter will be used for calibration
45685366|NCT05025358|Drug|LP-118 tablet|Subjects will administered orally with LP-118 tablet at the designated dose once daily, using approximately 240 mL of water during a meal or within 30 minutes after a meal, 28 days per cycle. The treatment will continue until progressive disease, unacceptable toxicity, etc.
45349186|NCT00857571|Drug|750 mg Tablet|Single oral dose of 750 mg of PF-02413873 tablets
45349187|NCT00943774|Other|Physiological maneuvers|These healthy subjects undergo physiological testing, which includes aortic augmentation index, pulse wave velocity, orthostatic stress, baroreflex sensitivity (modified Oxford protocol), mental stress, cold pressor test, isometric handgrip, heart rate variability, 24-hour ambulatory blood pressure monitoring.
45349188|NCT00861627|Biological|REOLYSIN®|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
45349189|NCT00861627|Drug|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
45349190|NCT00861627|Drug|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of 21 day cycle
46044772|NCT00598702|Drug|IV Acetaminophen|Target is 1 to 7 days of therapy with intravenous (IV) Acetaminophen (IV APAP) at a dose of 40 to 75 mg/kg body weight/day administered as an IV infusion (or by syringe pump) over 15 minutes and given every 4 to 6 hours as a scheduled dose
46044773|NCT01148810|Drug|BAF312|
46044774|NCT01148810|Drug|Placebo|
46044775|NCT00624962|Dietary Supplement|nutritional intervention|Nutritional status assessment on enrollment in study, beginning of course 1 and end of study period (week 12 or beginning of Course 5 chemotherapy)
46044776|NCT00624962|Dietary Supplement|therapeutic nutritional supplementation|enteral feedings via a nasogastric tube for 50% or more of the total nutritional support days.
46044777|NCT04313426|Other|Integrative Yoga Therapy|Integrative Yoga Therapy included personalised yoga therapy sessions including their standard care, yoga movements, relaxation, meditation, breathing practices and yoga counselling sessions.
45349191|NCT00943930|Drug|THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC|During each study session participants will be asked to smoke a cigarette. The cigarette may contain marijuana or it may contain placebo (a blank). Participants will also be asked to swallow a capsule 2-hours prior to smoking the cigarette. The capsule could contain placebo (a blank), THC (delta-9 tetrahydrocannabinol, or d-amphetamine.
45349192|NCT00854763|Drug|olmesartan|olmesartan
45476042|NCT04776278|Other|Education Control|This condition will not include any clinical contact other than a brief (2-3 minute) discussion with the research assistant (RA) who completed the assessment session and who will describe the educational handout. This condition is meant to approximate a low-threshold public health-level approach to providing referral information and some of the content included in the BAI+SFAS condition but without any of the personalized information or MI/clinical contact. Thus, participants will receive information on risks associated with alcohol and drug misuse, strategies for reducing use/problems, and strategies for managing stress and setting and follow-through with achievable goals. The handout will also include links to hotlines, websites, and apps related to these domains. This condition will not include booster contact.
45349193|NCT00952666|Device|TRUS-RALRP|During surgery, and part of this research study, the ultrasound probe (TRUS) will be placed in the rectum. Then, using the mechanical support arm to hold and adjust the probe we will take ultrasound images during a portion of the robotic LRP surgery. The ultrasound probe will then be removed, and we will complete the LRP surgery as we usually do. We expect this to add approximately 20 minutes to the regular surgery time; the maximum added time will be 30 minutes.
45841316|NCT05822284|Diagnostic Test|NGS and ctDNA-MRD detection|NGS and ctDNA-MRD detection
45349194|NCT00854841|Drug|Dasatinib and Imatinib|"Dasatinib Dasatinib will be administered orally at a dose of 100 mg QD. During the first month, subjects will be instructed to take dasatinib in the morning.~Imatinib Imatinib will be administered orally at a dose of 600 mg once daily (QD). Each 600 mg dose should be administered with a meal and taken with a large glass of water. If a scheduled dose is missed for more than 12 hours or dosing is interrupted for toxicity or for any other reason, these doses should be omitted."
45841317|NCT05822271|Procedure|Orthognathic Surgery|Type of surgery performed to correct skeletal malocclusions
46044778|NCT02884310|Drug|Remifentanil adapted to SPI|
46044779|NCT02884310|Drug|Remifentanil fixed|
46044780|NCT01151618|Device|Respironics Synchrony ventilator (Non Invasive Ventilation)|Non Invasive Ventilation using forced oscillation technique (FOT)
46044781|NCT01164956|Drug|methylphenidate|
46044782|NCT01164956|Other|Placebo|
46044783|NCT02884232|Procedure|Nasofibroscopy|
46044784|NCT01164722|Other|clinical observation|Patients undergo observation
46044785|NCT01164722|Device|infrared photocoagulation therapy|Anal infrared coagulator ablation
46044786|NCT04314830|Device|Gait training with perturbations|Changes in speed of one of the belt of the split belt treadmill during swing phase
46044787|NCT04314830|Device|Gait training without perturbation|Walking on a treadmill with steady belt speed
46044788|NCT01151540|Drug|Rufinamide|The target dosage is approximately 45 mg/kg/day, taken orally twice a day.
45349195|NCT00944008|Drug|DepoCyte|
45847574|NCT04845282|Dietary Supplement|Graded Protein plus Resistance Training|"Participants will be counseled to consume the specific level of dietary protein plus the protein supplement is MusclePharm Combat 100% Whey. Specific values per week are listed below:~Week 1: 25 g of protein supplement (0.8 g protein/kg body weight) Week 2: 25 g of protein supplement (1.0 g protein/kg body weight) Week 3: 50 g of protein supplement (1.2 g protein/kg body weight) Week 4: 50 g of protein supplement (1.4 g protein/kg body weight) Week 5: 50 g of protein supplement (1.4 g protein/kg body weight) Week 6: 75 g of protein supplement (1.6 g protein/kg body weight) Week 7: 75 g of protein supplement (1.8 g protein/kg body weight) Week 8: 75 g of protein supplement (2.0 g protein/kg body weight) Week 9: 75 g of protein supplement (2.2 g protein/kg body weight) Week 10: 100 g of protein supplement (2.2 g protein/kg body weight)"
45349196|NCT00854919|Drug|atypical antipsychotic drug|For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).
45349197|NCT00854919|Behavioral|exposure response prevention|After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.
45476043|NCT05583214|Drug|Ondansetron 8mg|8mg of Ondansetron IV stat will be given to the group after induction of spinal anesthesia
45476044|NCT05583214|Drug|Dexamethasone 8mg|8mg of Dexamethasone IV stat will be given to the group after induction of spinal anesthesia
45841318|NCT05822258|Other|Walk under 3 conditions (normal, physical tasks, verbal tasks)|"Each patient will have 2 visits :~First visit in the ON state phase, i.e. when their oral treatment allows the maximum improvement of dopamine-responsive parkinsonian symptoms.~A second visit will be scheduled 15 +/- 7 days from the first. Patients will then be assessed in the OFF phase after having stopped taking their antiparkinsonian medications for at least 12 hours before the start of the visit, in order to promote episodes of FOG~For each visit, the patient will be asked to walk at a comfortable speed under the following 3 conditions:~Normal condition without addition of additional physical and verbal tasks~Condition with added physical tasks: The physical task of holding a tray with a plastic cup filled with water~Condition with added verbal tasks: The verbal task of saying as many words as possible starting with a specific letter.~Passing conditions will be randomized. Each condition will be fulfilled a maximum of 5 times. A rest period will be respected"
45841319|NCT05822232|Device|FreeStyle Libre 2 CGM|FreeStyle Libre 2 CGM is FDA-approved and will be used according to FDA-approved labeling
45349198|NCT00861783|Drug|irinotecan and ON 01910.Na|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Irinotecan 180 mg/m2 will initially be administered by IV infusion over 90 minutes q2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labelling."
45841320|NCT05822232|Device|FreeStyle Libre Pro blinded CGM|FreeStyle Libre Pro blinded CGM is FDA-approved and will be used according to FDA-approved labeling
45476045|NCT05583214|Drug|Normal saline|Normal saline will be given IV stat to the group after induction of spinal anesthesia
45841321|NCT05822232|Device|FreeStyle Precision Neo blood glucose meter|FreeStyle Precision Neo blood glucose meter is FDA-approved and will be used according to FDA-approved labeling
45841322|NCT05822206|Behavioral|CBT-TSC|Cognitive Behavioral Therapy for Trauma and Self-Care
46044789|NCT02884466|Behavioral|Multidisciplinary rehabilitation intervention|Both groups will receive examination and medicine adjustment from a rheumatologist, and treatment from physiotherapist, occupational therapist and nursing staff, respectively. The multidisciplinary rehabilitation intervention in both groups will be based on the biopsychosocial model of illness. The inpatient stays of 8-10 hours per day will consist of 1) group tuition, 2) group and individual treatment and 3) unassisted training sessions.
45476046|NCT04502680|Drug|Eribulin Mesylate|Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.
45476047|NCT04768478|Drug|CBD|25mg CBD ODTs (orally disintegrating tablet), with instructions to take CBD tablets t.i.d. (total of 50mg per dose t.i.d.) to be administered with routine post-operative pain management
45476048|NCT04768478|Drug|Placebo|Visually indistinguishable placebo ODTs, with instructions to take two tablets t.i.d., to be administered with routine post-operative pain management
45476049|NCT05578924|Other|" women group "|women aged more than 18 years old
45476050|NCT02871297|Drug|Vortioxetine|Target dose is 10 mg/day, however, the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
45476051|NCT04758104|Radiation|Yttrium90|Intracystic implantation of 90yttrium colloid
45476052|NCT03121924|Procedure|timing for oocyte denudation and Intracytoplasmatic Sperm injection|"Donated oocytes were randomly allocated to two groups concerning the time of cumulus corona removal.~The first group: After oocyte retrieval, cumulus cells were immediately removed and then ICSI was performed; in the second group, the oocyte-cumulus complexes were incubated for 4 hours. Afterwards, the granulosa cells were removedand ICSI was immediately performed."
45476053|NCT03628430|Procedure|lidocaine with epinephrine|Local anesthesia with lidocaine with epinephrine
46044790|NCT02883998|Other|Outpatient Physical Therapy|traditional outpatient physical therapy which occurs at a physical therapy office
45349199|NCT00861783|Drug|oxaliplatin and ON 01910.Na|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Oxaliplatin 85 mg/m2 will initially be administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labeling."
45476054|NCT03628430|Procedure|sodium bicarbonate|sodium bicarbonate as adjuvant to lidocaine with epinephrine in Local anesthesia
45476055|NCT03628430|Procedure|Normal saline|normal saline as adjuvant to lidocaine with epinephrine in Local anesthesia
45476056|NCT03121846|Drug|Apatinib|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
45476057|NCT03628352|Drug|Tricaprilin|Tricaprilin with flavoring agents added
45476058|NCT03122314|Drug|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solutionBristol-Myers Squibb_UK) intravenous (IV) was given 100patients
45685367|NCT05021926|Device|DKL crosslinked sodium hyaluronate 26|is injected into the midface on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of DKL crosslinked sodium hyaluronate 26 will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
45685368|NCT05021926|Device|Juvéderm Voluma™ with lidocaine (Allergan, Inc)|is injected into the midface on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm Voluma™ will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
46044791|NCT02883998|Other|Home Base Physical Therapy|Patients will be provided a packet of exercises via a website which allows access to instructional physical therapy videos specifically designated for UKA patients and equipment to perform the home based physical therapy
45476059|NCT03122314|Drug|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
45476060|NCT03554005|Drug|PEG Interferon Alfa-2b|Participants receive PEG interferon alfa-2b administered by SC injection, in doses ranging from 0.75 mcg/kg OW up to 7.5 mcg/kg OW, for up to 40 weeks of treatment.
45349200|NCT00947128|Drug|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
45349201|NCT00947128|Drug|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
45349202|NCT00947206|Behavioral|LHWO about CRC|2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt
45349203|NCT00947206|Behavioral|Nutrition Education + CRC brochure|Bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
45349204|NCT00857805|Procedure|Transarterial Chemoembolization|Application of carboplatin, doxorubicin in ethiodol into the artery for one or more sessions.
45349205|NCT00857805|Radiation|Proton Beam Radiotherapy|Fifteen consecutive sessions
45476061|NCT03554005|Drug|Acetaminophen|Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.
45476062|NCT01314573|Behavioral|Sprint interval exercise|3 session per week of exercise on a exercise cycle ergometer. Each session involves 30s of maximal exercise followed by 4.5 min of easy cycling at 10W. This is repeated 4 times at each exercise session.
45476063|NCT01314573|Behavioral|Maximal continuous exercise|3 sessions per week of an exercise intervention involving maximal cycling until the participant has completed an amount of work equivalent to a sprint interval training session. This exercise lasts between 3 and 3.5 minutes.
45476064|NCT00709228|Drug|PegIntron|1.5 ug/kg/week
45349206|NCT00947362|Other|Electro-thermo-coagulation|
45349207|NCT00947362|Drug|DAC N-055|moist wound treatment plus 0.05 % pharmaceutical chlorite
45349208|NCT00947362|Drug|saline|physiological saline
45349209|NCT00861861|Drug|Pitavastatin|comparison of two drugs in increasing HDL-C and adiponectin
45349210|NCT00861861|Drug|Atorvastatin|comparison of two drugs in increasing HDL-C and adiponectin
45349211|NCT01529866|Device|New Abutment Connection implant|New abutment connection implant
45349212|NCT01529866|Device|Nanotite Certain Tapered implant|Nanotite certain tapered (standard abutment connection) implant
45476065|NCT00709228|Drug|Rebetol|800-1200 mg/day
45476066|NCT01584557|Drug|Tolvaptan or Samsca|uncoated tablet, 30mg, once per day, for up to 7 days.
45476067|NCT01584557|Drug|placebo or sugar pill|sugar pill
45476068|NCT04806165|Behavioral|Repeated Administration|A discussion with the chatbot, including follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
45685369|NCT05026528|Other|Digital diabetes self management education and support system|Digital diabetes self management and support system
45685370|NCT05024188|Drug|Antibiotics|Ciprofloxacin, 500 mg 2/day & Metronidazole (Flagyl), 500 mg 3/day.
45685371|NCT05024188|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation is the process of transferring stool from a healthy donor to another.
45685372|NCT05024188|Other|Cellules Pills|7 days of cellules placebo pills.
46044792|NCT01163786|Drug|Bortezomib|Each patient will receive 2 cycles of Bortezomib. For each cycle Bortezomib wil be given once a week, 1.3mg/m2 for 4 weeks with 2 weeks between each cycle.
46044793|NCT05367362|Drug|Minocyclin|200 mg intravenous/oral minocycline hydrochloride for a total of 21 days
46044794|NCT00984282|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg will be administered orally, twice daily (approximately every 12 hours).
46044795|NCT00984282|Drug|Placebo|Placebo (2 tablets) will be administered orally, twice daily (approximately every 12 hours).
45349213|NCT00857883|Drug|GSK1521498 or placebo|GSK1521498 is a mu-opioid receptor inverse agonist
45349214|NCT00952900|Behavioral|Biobehavioral|6 sessions of Biobehavioral treatment modalities that include relaxation/biofeedback, stress management, and coping skills techniques.
45349215|NCT00952900|Behavioral|Active Coping/Attention Intervention|6 sessions of didactic educational techniques to expose patients to the causes of TMD, as well as introducing them to traditional treatment modalities for intervening with acute TMD problems.
45349216|NCT02545413|Drug|Probiotic VSL#3|
45349217|NCT02545413|Drug|Placebo|
45476069|NCT04806165|Behavioral|Personalized Recommendation|A discussion with the chatbot, including identifying a personalized recommendation for accessing help for their eating disorder.
45476070|NCT04806165|Behavioral|Motivational Interviewing|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder.
45476071|NCT04806165|Behavioral|Core Modules Only|A discussion with the chatbot, including only the core modules.
45476072|NCT04806165|Behavioral|Motivational Interviewing, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
45476073|NCT04806165|Behavioral|Motivational Interviewing, Repeated Administration|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
45476074|NCT04806165|Behavioral|Motivational Interviewing, Personalized Recommendation|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder and identifying a personalized recommendation for accessing help for their eating disorder.
45476075|NCT04806165|Behavioral|Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including identifying a personalized recommendation for accessing help for their eating disorder and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
45476076|NCT04806165|Behavioral|Psychoeducation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders.
45476077|NCT04806165|Behavioral|Psychoeducation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
45476078|NCT04806165|Behavioral|Psychoeducation, Personalized Recommendation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and identifying a personalized recommendation for accessing help for their eating disorder.
45476079|NCT04806165|Behavioral|Psychoeducation, Motivational Interviewing|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder.
45476080|NCT04806165|Behavioral|Psychoeducation, Motivational Interviewing, Personalized Recommendation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, and identifying a personalized recommendation for accessing help for their eating disorder.
45685373|NCT05024188|Other|Agarose Capsules|Placebo capsules consist a combination of agarose in normal saline/glycerol (the same vehicle as in a FMT capsules)
45685374|NCT05023876|Other|IASTM+respiratory Exercise|Instrument assisted soft tissue mobilization
46044796|NCT01147874|Procedure|lab draws and imaging|1 set of lab draws, imaging consists of radiographic imaging or X-ray, ultrasound and MRI
46044797|NCT04187196|Drug|Propofol|Propofol will be given at an initial dose of 0.8 mg/kg followed by 20 mg every minute after 2 minutes, if adequate sedation is not achieved
46044798|NCT04187196|Drug|Methohexital|Methohexital will be given at an initial dose of 0.5 mg/kg, followed by 10 mg every minute after 2 minutes, if adequate sedation is not achieved
46044799|NCT04292184|Drug|Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25%|The kidney will have 100 mL of 500µM STS added directly to the existing pulsatile perfusion solution at 4°C.
45349218|NCT00944086|Other|Recruitment Manoeuvre|Recruitment Manoeuvre
45349219|NCT00855075|Device|Cerebral State Monitor|A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
45349220|NCT00944164|Behavioral|Healthy eating and physical activity|Parent counseling and coaching regarding healthy eating and physical activity habits for their child
45349221|NCT00944164|Behavioral|Safety and injury prevention|Parent counseling and coaching regarding general personal and household safety
45349222|NCT00686166|Biological|cetuximab|"Chemotherapy cycle 1: Cetuximab, 400 mg/m^2, IV, Day 1; Cetuximab, 250 mg/m^2, IV, Days 8,15,22,29~Chemotherapy+ Radiation Cycle 2: Cetuximab, 250 mg/m^2, IV, Days 50,57,64,71,78"
45349223|NCT00686166|Drug|capecitabine|"Chemotherapy Cycle 1: Capecitabine, 1650 mg/m^2/day, PO, Monday-Friday (Day 1-35)~Chemotherapy+ Radiation Cycle 2: Capecitabine, 1650 mg/m^1, PO, Monday-Friday (Day 50-84)"
45349224|NCT00686166|Drug|oxaliplatin|"Chemotherapy Cycle 1: Oxaliplatin, 50 mg/m^2, IV, Days 1,8,15,22,29~Chemotherapy+ Radiation Cycle 2: Oxaliplatin, 50 mg/m^2, IV, Days 50,57,71,78"
45349225|NCT00686166|Procedure|therapeutic surgical procedure|Surgical resection
45349226|NCT00686166|Radiation|radiation therapy|IMRT (intensity-modulated radiation therapy)
45349227|NCT03963375|Drug|Cladribine|All participants will receive cladribine 10 mg tablets at a cumulative dosage of 3.5 mg/kg divided into 2 treatment courses as per the United States Prescribing Information (USPI) (1.75 mg/kg per treatment course; Year 1 and Year 2 treatment). Patients will be randomized 1:2:2:1 to receive a total of 2 Lumbar Punctures at specific time points during the treatment cycle.
45349228|NCT04280536|Drug|Cohort A|Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
45349229|NCT04280536|Drug|Cohort B|Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
45476081|NCT04806165|Behavioral|Psychoeducation, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
45476082|NCT04806165|Behavioral|Psychoeducation, Motivational Interviewing, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
45476083|NCT04806165|Behavioral|Psychoeducation, Motivational Interviewing, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
45476084|NCT03728491|Device|Simulator|US Mentor simulator, lung module, provided by 3D Healthcare Systems
46044800|NCT01147640|Drug|CXA-101/ tazobactam and metronidazole|CXA-101/tazobactam (1000/500 mg q8h) plus metronidazole (500 mg q8h) administered via IV infusion
46044801|NCT01147640|Drug|meropenem plus saline placebo|meropenem IV infusion (1000 mg q8h) plus a matching saline placebo (q8h) administered via IV infusion
45349230|NCT00944242|Drug|Sertraline|
45349231|NCT00944242|Drug|Sertraline Hydrochloride|
45349232|NCT00363649|Biological|GM-K562 cell vaccine|Given by injection
45349233|NCT00363649|Biological|Interferon alfa|Given by injection
45476085|NCT03728491|Device|Healthy figurants|Medical students or volunteers without any pathology in thorax
45476086|NCT01587599|Behavioral|counseling|The patients grouped to the intervention cohort receive pharmaceutical care by a pharmacist during the study period.
46044802|NCT02867982|Procedure|Subcrestal implant placement|Dental implants placed 2 mm below the alveolar ridge
46044803|NCT02867982|Procedure|Paracrestal implant placement|Dental implants placed flush to the alveolar ridge
46044804|NCT02867982|Drug|prophylactic antibiotics|amoxicillin was used before and after implant surgery for prophylactic reasons
46044805|NCT02867982|Device|dental implant|dental implants (Ankylos® system,Dentsply Implants Manufacturing GmbH, Mannheim, Germany) were surgically placed into the edentulous alveolar ridge
46044806|NCT02867982|Radiation|x-ray examination|radiographies were taken before treatment and at different time point during the follow-up period
46044807|NCT02884154|Device|Echotip ProCoreⓇ HD Ultrasound Biopsy Needle|
45349234|NCT00363649|Biological|Sargramostim|Given by injection
45349235|NCT00855153|Other|VR (Virtual reality)|VR stimulation of combat scenarios utilized as the exposure therapy tool.
45349236|NCT00855153|Drug|D-Cycloserine|50 mg DCS 30 min prior to individual 90 min session with graded VR exposure treatment
45349237|NCT00947440|Drug|ABT-072|See arm description for more information
45349238|NCT02545023|Other|Quality-of-Life Assessment|Complete an in-person one-on-one interview
45349239|NCT02545023|Other|Questionnaire Administration|Complete the demographics questionnaire, SCNS-34, SF-36, and Lifestyle Needs Survey
45349240|NCT00952978|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets(Livzon Pharm Group Inc., China) together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
46044808|NCT01121900|Drug|Trazodone HCl|"Dosage form: Extended-release caplets containing 300 mg trazodone HCl~Dose: 300 mg trazodone HCl extended-release caplets (one caplet) at 23:30 on Day 1 of the test product treatment period following a fasting period of at least 4 hours."
45349241|NCT00952978|Drug|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with two placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
45349242|NCT01046851|Drug|Nopan|Nopan(0.2-1.6 mg/day, starting dose=0.2 mg/day, N=40)
46044809|NCT01121900|Drug|Trazodone HCl|"Dosage form: Immediate-release tablets containing 100 mg trazodone HCl~Dose: 100 mg trazodone HCl immediate-release tablets (one tablet per dosing time) at 23:30 on Day 1, at 07:30 and 15:30 on Day 2 of the reference product treatment period."
45349243|NCT01046851|Drug|Placebo|Placebo in a manner similar to the active comparator
45349244|NCT00861939|Drug|Bupropion HCI 300 mg Extended-Release Tablets EON|
45349245|NCT00861939|Drug|WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline|
45349246|NCT01046929|Dietary Supplement|limonene|oral dosing at 2 gram QD
45349247|NCT00953134|Dietary Supplement|Ferrous fumarate (iron)|60 mg of ferrous fumarate
45349248|NCT00953134|Dietary Supplement|folic acid|400 mcg folic acid
45349249|NCT02544945|Other|3D printed bolus|Using the Cat Scan for treatment planning, a 3D plastic shell can be produced which is shaped exactly to the shape of the patient's chest wall. This shell will act as bolus - the substance that is placed on the skin during chest wall radiotherapy. The bolus allows the right dose of radiotherapy to get to the skin and the underlying chest wall.
45349250|NCT02544945|Other|Standard bolus|A standard 5mm-thick piece of rubber is placed on the patient's chest wall
45349251|NCT00944398|Dietary Supplement|Zinc fortified food|Daily consumption
45349252|NCT00944398|Dietary Supplement|Zinc supplement|Liquid supplement containing zinc sulfate
45349253|NCT00944398|Other|Placebo supplement|Liquid placebo supplement
45349254|NCT00944398|Dietary Supplement|Non-fortified food|Non-fortified complementary food.
45349255|NCT00862017|Dietary Supplement|MSg supplementation|
45349256|NCT00862017|Dietary Supplement|NaCl supplementation|
45349257|NCT00944476|Procedure|Fat-free MRI images utilizing standard magnetization, Questionnaire before the MRI exam|In addition to the traditional MRI exam for clinical use, a fat-free MRI based on standard magnetization transfer magnetic resonance imaging will be acquired. Pts will spend 20 extra minutes and 20 minutes total for volunteers in the MRI scanner. Patients/volunteers will complete the MR Screening Questionnaire before the MRI exam.
45349258|NCT00953368|Procedure|remote ischemic preconditioning|Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis
45349259|NCT00855387|Other|No additional intervention than the intended major surgery in pancreas, liver, colorectal, gastric bypass and small bowel|No additional intervention than the intended major surgery (liver, bile duct, pancreas, colorectal, gastric bypass and small bowel resections) comparing with costs
45349260|NCT00947596|Drug|atropine sulfate|dry powder for inhalation
45476087|NCT04803123|Drug|Copanlisib|Patients must receive at least one dose of copanlisib prior to standard therapy to be evaluable.
46044810|NCT00625040|Other|Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate|"OGTT: The test is performed with 50 g of glucose deluded in 300 ml water~Isoglycemic iv. clamp: Iv. glucose infusion mimicking the glucose response curves from the OGTT~Liquid Meal test: The test is performed with 100g of formula milk deluded in 300 ml. water~Gastric Emptying Rate: Paracetamol absorption test."
46044811|NCT01121666|Drug|Follitropin alfa|150IU per day subcutaneously for a maximum of 16 days
46044812|NCT00984126|Drug|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
45349261|NCT00947596|Drug|atropine sulfate|intramuscular injection
45349262|NCT00865059|Drug|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
45349263|NCT00865059|Drug|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
45349264|NCT00956410|Biological|CAD106|
45349265|NCT00865137|Drug|Tacrolimus, modified release|Oral
45349266|NCT00947674|Device|Cellsorba EX|conduct treatment twice a week for 3 weeks and once a week for 4 weeks, total 10 times
45349267|NCT00862095|Drug|Placebo|Every month for 3 months
45349268|NCT00862095|Drug|Propranolol|target does 80 mg per day for 3 months
45349269|NCT00862095|Drug|Amitriptyline|Target does of 50 mg per day for 3 months
45476088|NCT05215964|Procedure|Renal artery embolization|After catheterization of renal arteries, multiple coils are applied to embolize renal arteries until blood flow stasis
45349270|NCT00862095|Drug|Topiramate|Target dose 100 mg a day for 3 months
45349271|NCT04054128|Drug|Sodium Bicarbonate 7.5% Injection|Sodium bicarbonate solution for catheter lock; 7.5% sodium bicarbonate solution will be used for catheter lock in both catheter lumens, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
45349272|NCT04054128|Drug|Heparin Sodium, 1000 Units/mL Injectable Solution 1|Heparin for catheter lock: 1000 u/mL heparin solution will be used for catheter lock in both catheter lumens as standard treatment, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
45349273|NCT00956566|Behavioral|dietary intervention|dietary counseling, group teaching
45349274|NCT00865215|Drug|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under fasting conditions
45349275|NCT00865215|Drug|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products under fasting conditions
45349276|NCT00684060|Biological|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
45349277|NCT00684060|Biological|Placebo|One time infusion of 30 ml of HSA (5%)
45349278|NCT00865371|Drug|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fed conditions
45349279|NCT00865371|Drug|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
45349280|NCT00865449|Drug|spironolactone|25 mg daily of spironolactone given for 6 months in the peritoneal dialysis patients
45349281|NCT00865449|Drug|Placebo|Placebo, given daily for 6 months to Peritoneal Dialysis Patients
45349282|NCT00865527|Other|Fecal occult blood test|FOBT
45349283|NCT00865527|Procedure|Virtual colonoscopy|computed tomographic colonography
45349284|NCT00865527|Procedure|Optical colonoscopy|optical (conventional / endoscopic) colonoscopy
45349285|NCT00756210|Other|Whole body vibration|Frequence: 35 Hz Amplitude: 'high' (approx. 4 mm)
45685375|NCT05023876|Other|Respiratory Exercise|Respiratory Exercise
45841323|NCT05822206|Behavioral|Life Steps and Sexual Decision-Making|
46044813|NCT00984126|Drug|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
45349286|NCT00858195|Drug|Indomethacin 75mg Extended-Release Capsules, Sandoz|
45349287|NCT00858195|Drug|Indocin 75mg SR Capsules|
45349288|NCT00858351|Behavioral|Thermal Biofeedback Assisted Relaxation|6 sessions, 25 minutes in duration of relaxation and imagery training while temperature of hands and feet are recorded.
45349289|NCT00858351|Behavioral|Discussion with therapist|6 sessions, 25 minutes each, discussing topics with a therapist.
46044814|NCT02867748|Procedure|TVT-Abbrevo|
46044815|NCT02867748|Procedure|Serasis|
46044816|NCT02867514|Device|transcranial Direct Current Stimulation (tDCS)|After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 1 session per day during 10 days (5 days per week during 2 successive weeks). Subjects will be monitored during tDCS for any side effects or adverse events.
46044817|NCT02868060|Drug|Romiplostim|
45349290|NCT03131648|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
45476089|NCT03728413|Biological|RSV A Memphis 37|"Subjects will be inoculated using intra-nasal drops with diluted inoculum at a given dose divided equally between the two nostrils. Dose: Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1ml, 25% sucrose/Dulbecco's Modification of Eagle's Medium. Inoculations using intranasal drops will be done using a 1mL pipette with subjects supine. This will be done slowly with sufficient interval between each inoculation (2-3 minutes) to ensure maximum contact time between with the nasal and pharyngeal mucosa. Subjects will be asked not to swallow during the procedure to ensure maximal pharyngeal contact.~Following inoculation, advice regarding hand hygiene will be given, subjects will be provided with alcohol hand gel and facemasks to reduce spread of virus in the environment."
46044818|NCT04274010|Diagnostic Test|PillCamTM Crohn's capsule|Capsule endoscopy for small and large bowel to assess Crohn's disease activity.
45349291|NCT03131648|Drug|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
45349292|NCT00618813|Other|radiation therapy|Undergo radiation therapy
45476090|NCT04716010|Other|Control|Participants will complete a shopping task in the online grocery store, and the products that contain red meat will not have warning labels or a 30% increase in price.
45476091|NCT04716010|Other|Warning Labels|While completing the shopping task in the online grocery store, the health and environmental warning labels will appear next to the image of every product that contains red meat.
45349293|NCT00618813|Other|therapeutic conventional surgery|Undergo surgery
45349294|NCT00618813|Drug|etoposide|Given IV
45349295|NCT00618813|Drug|ifosfamide|Given IV
45349296|NCT00618813|Drug|doxorubicin hydrochloride|Given IV
45349297|NCT00618813|Drug|cyclophosphamide|Given IV
45349298|NCT00618813|Drug|vincristine sulfate|Given IV
45476092|NCT04716010|Other|Tax|While completing the shopping task in the online grocery store, all products containing red meat will have a 30% increase in price.
45476093|NCT04716010|Other|Combined Warning Labels and Tax|While completing the shopping task in the online grocery store, all products containing red meat will have the health and environmental warning labels appear next to the product image and a 30% increase in price.
45476094|NCT01192373|Other|Metabolic substrate modulation|for high circulation free fatty acids: Heparin (250IE/hour) + intralipid (20%, 62 ml/hour).
45476095|NCT01192373|Other|metabolic substrate modulation|low circulating free acids: hyperinsulinaemic euglycemic clamp (0,8 mUkg/min) with venous blood glucose at 4,5-6,5 mM.
45476096|NCT01310491|Behavioral|Health coaching|Telephone based health coaching supported by tele-monitoring.
46044819|NCT04274010|Diagnostic Test|Magnetic resonance enterography|MRI scan of small bowel to assess small bowel Crohn's disease activity.
46044820|NCT04274010|Procedure|Ileo-colonoscopy|Endoscopic procedure to assess Crohn's disease activity in colon and terminal ileum.
46044821|NCT02868996|Drug|Recombinant human tissue kallikrein|Intravenous DM199
46044822|NCT04290702|Procedure|regional analgesia for labor|three commonly used regional analgesic techniques are used, with local anesthetic ropivacaine, opioid fentanyl, parturient controlled epidural analgesia
46044823|NCT00629226|Biological|cetuximab|Given IV
46044824|NCT00629226|Drug|bortezomib|Given IV
46044825|NCT00629226|Drug|cisplatin|Given IV
45349299|NCT00618813|Drug|topotecan hydrochloride|Given IV
45349300|NCT00618813|Biological|filgrastim|Given SC
45349301|NCT00554788|Procedure|Autologous Bone Marrow Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
45349302|NCT00554788|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
45349303|NCT00554788|Drug|Carboplatin|Given IV
45349304|NCT00554788|Drug|Cisplatin|Given IV
45349305|NCT00554788|Drug|Cyclophosphamide|Given IV
45349306|NCT00554788|Drug|Etoposide|Given IV
45349307|NCT00554788|Biological|Filgrastim|Given SC
45349308|NCT00554788|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
45349309|NCT00554788|Radiation|Radiation Therapy|Undergo radiotherapy
45349310|NCT00554788|Drug|Thiotepa|Given IV
45349311|NCT00554788|Drug|Vincristine Sulfate|Given IV
45349312|NCT00685698|Drug|TG-873870 (Nemonoxacin)|750 mg
45349313|NCT00858429|Drug|capecitabine|1000 mg/m2 twice daily, for 14 consecutive days followed by a 7 day treatment free rest period for cycles 1, 2 and 3.
45349314|NCT00858429|Radiation|yttrium Y 90 glass microspheres|The amount of radioactivity required to deliver the desired dose to the liver is calculated using a formula. The dose depends on the cohort upon which the patient is enrolled. Y90 is administered during Cycle #2 on days 1-7.
45349315|NCT00756366|Other|Positron Emission Tomography|PET imaging at baseline, 1 week and 6-8 weeks. CPAP begins after baseline PET scan.
45349316|NCT00756366|Other|Positron Emission Tomography|PET imaging at Baseline, 1 week and 6-8 weeks. CPAP begins after 6-8 week PET scan.
45476097|NCT05215028|Device|web-application|web application multi-domain familial digital health record PRO The aim is to help for early screening of neurodevelopmental disorders of toddler after birth to 3 years of age and mother's postnatal depression, to improve vaccinations rate of toddlers and to provide advice to parents for child development.
45476098|NCT03725527|Procedure|Rectus Sheath Catheter Block|Sonar guided RSC will be performed using a 16-G, 8-cm TuohyUpon reaching this potential space, after careful aspiration.
45476099|NCT03725527|Procedure|Epidural Catheter Block|Sonar-guided epidurals will be performed with a 17-gauge Tuohy needle and 19 G flex-tip catheter. Using an LOR (loss of resistance) to saline technique, catheters will be inserted 4 cm into the epidural space and a suitable test dose will be administered to exclude intravascular or sub-arachnoid injection.
45476100|NCT05283317|Biological|Mesenchymal stem cells|Standard therapy of sepsis as suggested in the guidelines were given to all patients and additionally MSCs treatment was applied to the patients in the study group.
45841324|NCT05822193|Other|Multiple exposures|Exposures variables (observational study): age, gender, education, comorbidities, vaccination status, severity of the acute episode of COVID-19, treatments used for acute COVID-19.
45841325|NCT05822180|Drug|NANOS1 , argent colloïdal ,|orally, during 5 day
46044826|NCT00629226|Radiation|intensity-modulated radiation therapy|Once daily, 5 days a week, for up to 8 weeks
45349317|NCT00756366|Other|Positron Emission Tomography|PET scan at baseline and 6-8 weeks, no CPAP therapy
45349318|NCT02566928|Drug|2% mupirocin ointment|Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of mupirocin ointment to the anterior nares with a sterile cotton applicator for five days.
45349319|NCT02566928|Other|Chlorhexidine wash|Index patients and consenting household members will daily daily for five days with chlorhexidine wash.
45349320|NCT02566928|Behavioral|Hygiene protocol|Index patients and consenting household members will be given educational materials and instructed to in the use of hand-washing, surface disinfection, and laundering.
45349321|NCT00756522|Other|There is no intervention. Study is observational.|There is no intervention. Study is observational.
45841326|NCT05822167|Other|High Protein Meal at Cold Temperature|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Cold meal will be served at 25 degree C and below."
45841327|NCT05822167|Other|High Protein Meal at Warm Temperarute|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C."
45841328|NCT05822167|Other|High Protein Meal at Hot Temperature|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Meal will be served at hot temperature i.e., 60 degree C and above."
45841329|NCT05822167|Other|High Carbohydrate Meal at Cold Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Cold meal will be served at 25 degree C and below."
45841330|NCT05822167|Other|High Carbohydrate Meal at Warm Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C."
46044827|NCT04291326|Diagnostic Test|Transfontanelle ultrasound|cerebral blood flow measurement using transfontanelle ultrasound
46044828|NCT00979602|Biological|GSK2340274A|One intramuscular injection
46044829|NCT00979602|Biological|GSK2340273A|One intramuscular injection
46044830|NCT02866734|Other|Free screening group|The intervention provide Diabetic Retinopathy screening without charging a fee.
46044831|NCT02866734|Other|Pay screening group ($150)|The intervention is charging HK$150 for the Diabetic Retinopathy screening.
46044832|NCT02866734|Other|Pay screening group ($300)|The intervention is charging HK$300 for the Diabetic Retinopathy screening.
45841331|NCT05822167|Other|High Carbohydrate Meal at Hot Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Meal will be served at hot temperature i.e., 60 degree C and above."
45841332|NCT05822167|Other|High Fat Meal at Cold Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Cold meal will be served at 25 degree C and below.
45841333|NCT05822167|Other|High Fat Meal at Warm Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C.
45841334|NCT05822167|Other|High Fat Meal at Hot Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Meal will be served at hot temperature i.e., 60 degree C and above.
46044833|NCT00629304|Device|placebo|Patients will have face to face visits at 3 and 6 months and no PDA-FIT system. Patients will record glycemia on paper support.
46044834|NCT00629304|Device|VISITS + PDA-FIT system|patients will have face to face visits at 3 and 6 months + PDA-FIT system
45841335|NCT05822141|Dietary Supplement|Fish Oil|For 12 weeks subjects will ingest 6 capsules per day of fish oil (7.8 g/day total omega--3 fatty acids: 3.75 g/day EPA and 1.5 g/day DHA)
45841336|NCT05822141|Dietary Supplement|Placebo|For 12 weeks subjects will ingest 6 capsules per day of olive oil (each capsule contains 990 mg of olive oil)
45841337|NCT05822089|Procedure|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation
46044835|NCT00629304|Device|PDA-FIT System + telephone follow-up|patients will received PDA-FIT system + a telephone follow up (12 phone calls) and a face to face visit at 6 months
46044836|NCT00816361|Drug|MEDI-573|Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.
46044837|NCT05297929|Drug|Irbesartan Tablet|Drug: Irbesartan Oral administration on an empty stomach／fed condition
46044838|NCT00826111|Drug|Eszopiclone|Subjects receive 10 mg escitalopram daily for four weeks and 10 or 20 mg for an additional six weeks. Subjects also receive 3 mg eszopiclone.
45349322|NCT00865605|Drug|Halobetasol Propionate 0.05% Ointment, single exposure|A: Other Subjects received Alpharma/Purepac USHP formulated products
45349323|NCT00865605|Drug|Ultravate® 0.05% ointment, single exposure|Subjects received Bristol-Myers Squibb Company formulated products
45349324|NCT00756756|Drug|G-CSF|after 2 week post MI an d PCI G-CSF was infused for 5 days at dose of 10 microgram/Kg
45349325|NCT00756756|Drug|placebo infusion of normal saline|2 week post MI and PCI normal saline was infused
45349326|NCT02565056|Other|Self help book + telephone support|Self-help book based upon principles of Acceptance and Commitment Therapy
45349327|NCT00865683|Dietary Supplement|DHA Supplements|Participants will receive 800 mg of DHA each day for approximately 3 months (until they give birth).
45349328|NCT00865683|Dietary Supplement|Placebo Supplements|Participants will receive placebo supplements each day for approximately 3 months (until they give birth).
45349329|NCT00953446|Procedure|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging|Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment
45349330|NCT02560818|Other|collection of a blood sample and breast and ovarian tissue|a blood sample and a breast and ovarian tissue sample will be collected in healthy women during their surgery (breast or ovarian surgery according to selection group :A, B or C)
45349331|NCT02560818|Other|use of a previous blood collection for patients|
45349332|NCT03058250|Other|Transesophageal echocardiography|
45685376|NCT04390594|Drug|Nafamostat Mesilate|"Nafamostat mesilate continuous intravenous injection. Daily dose ranging between 0.1 mg/kg/h and 0.2 mg/kg/h, based on the severity and underlying disease of the clinical trial participant.~Administration for 10-14 days based on the severity and underlying disease of the clinical trial participant"
46044839|NCT00826111|Drug|Placebo|Subjects receive 10 mg of escitalopram daily for four weeks followed by 10 or 20 mg for an additional six weeks. Subjects also receive placebo for eszopiclone.
45349333|NCT00956644|Drug|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily in the morning
45349334|NCT00956644|Drug|amlodipine|Pharmaceutical form: 5 and 10 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily in the morning
46044840|NCT05756881|Other|Cosmetic product|Apply on the face twice a day
45349335|NCT00756834|Device|Screening|The MammoDetector™ Pro is a computer-aided software intended to identify and mark regions of interest on standard mammographic views to bring them to the attention of the radiologist after the initial reading has been completed. Thus, the device assists the radiologist in minimizing observational oversights by identifying areas on the original mammogram that may warrant a second review
45349336|NCT03895268|Device|ALiA Analyser|NPS specimens shall be tested with the investigational device
45476101|NCT05670665|Other|Threatened preterm labor|Presence of uterine contractions and cervical shortening between 24+0 and 36+6 weeks of gestation and/or rupture of the membranes between 24+0 and 36+6 weeks of gestation.
45841338|NCT05822050|Drug|Selinexor|XPO1 inhibitor
46044841|NCT00982644|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
46044842|NCT00982644|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
45349337|NCT03895268|Device|Influenza A+B Test Kit|NPS specimens shall be tested with the investigational device
46044843|NCT00815659|Drug|rosuvastatin|medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
45349338|NCT00858663|Radiation|intensity modulated radiation therapy|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
45476102|NCT02606799|Device|CytoSorb cytokine elimination|Hemoperfusion using continuous veno-venous hemofiltration (citrate regional anticoagulation) with CytoSorb cytokine elimination over a period of 48h immediately following admission to the intensive care unit
45476103|NCT05214872|Diagnostic Test|laboratory parameters - complete blood count|"the complete blood count was analyzed using Sysmex K-4500 Automated Hematology Analyzer (by GMI Inc., USA):~hemoglobin (HGB) [g/dl];~red blood count (RBC) [10^12/l];~hematocrit (HCT) [l/l];~white blood cells (WBC) [10^9/l];~platelet count (PLT) [10^9/l]"
45476104|NCT05214872|Other|body mass index (BMI) [kg/m^2] calculation|body mass index (BMI) [kg/m^2] was calculated by dividing a person's weight (post-HD weight in HD group) [kg] by the squared their body height [m]
45841339|NCT05822037|Biological|CT0594CP|Cell injection
45841340|NCT05822024|Behavioral|Promoting Pupils' Physical Literacy Intervention|The physical literacy intervention 3PL is based on activities, games, and modifications of the physical education classes to target and enhance pupils' physical literacy.
46044844|NCT02867904|Drug|Methylprednisolone (40 mg depomedrol, 1ml, injection)|Experimental Drug
46044845|NCT02867904|Drug|Marcaine (4ml 0.5%, injection)|Control
45349339|NCT00858663|Drug|RAD001 (everolimus) + Cisplatin|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
45349340|NCT03894488|Diagnostic Test|FilmArray Gastrointestinal (GI) Panel|The FilmArray GI Panel tests for 22 of the most commonly associated pathogens related to gastroenteritis-all from one patient sample, one easy to use reagent, and results are available in about one hour.
45349341|NCT02544789|Drug|Clofarabine|Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
45349342|NCT04066244|Drug|BLZ945|Investigational drug
45349343|NCT00956722|Drug|Bovine Colostrum Powder|Bovine Colostrum Powder (Biogard)
45349344|NCT00858741|Radiation|single fraction|8 Gy x 1 fraction to 8 Gy total dose in single dose.
45349345|NCT00858741|Radiation|multiple fractions|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
45349346|NCT04985864|Device|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to stroke patients.
45349347|NCT04985864|Device|Treadmill gait training|Lokomat robot training was applied to stroke patients.
45349348|NCT00953602|Other|Genetically modified potato|Genetically modified potato
45349349|NCT00956800|Other|Accu-Chek 360 software|Study group which will receive 3 routine office visits in the same time, and have two visits conducted by computer interaction, using the Accu-Chek 360 software.
45349350|NCT00956800|Other|Normal care|Control group will receive 5 routine office visits in one year
45349351|NCT02565836|Drug|fixed-dose activated prothrombin complex concentrate|"FEIBA VH 500 units IV one time for INR less than 5. FEIBA VH 1000 units IV one time for INR greater than 5.~Check INR after infusion and may repeat dose if INR still elevated"
45476105|NCT05214872|Diagnostic Test|selected parameters of oxidative stress (1)|"Serum concentration of:~advanced glycation ends products (AGE) [µg/mg protein];~3-nitrotyrosine (3-NT) [µmol/mg protein];~advanced oxidation protein products (AOPP) [µmol/mg protein];~carboxymethyle(lysine) (CML) [µg/mg protein]~were determined with the enzyme immunoassay methods (ELISA) using Shanghai Sunred Biological Technology Co kits, China."
45349352|NCT02565836|Drug|variable-dose inactivated prothrombin complex concentrate|"Kcentra 25 units/kg IV one time for INR less than 4. Kcentra 35 units/kg IV one-time for INR 4 to 6. Kcentra 50 units/kg IV one-time for INR greater than 6.~Check INR after infusion and may repeat dose if INR still elevated."
45349353|NCT00865761|Drug|Alprazolam 3 mg Extended Release Tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
45349354|NCT00865761|Drug|XANAX XR® 3 mg tablets, single dose|B: Active comparator Subjects received Pharmacia & Upjohn Company formulated products under fasting conditions
45349355|NCT00953758|Drug|PF-04449913|Escalating doses of PF-04449913 administered as tablets PO QD continuously in 28 day cycles
45685377|NCT02843386|Drug|Adjuvant chemotherapy by Fotemustin|"Fotemustin is given for 6 cycles :~One Induction cycle: Fotemustin 100 mg/m², 1 hour IV infusion, D1D8D15, 5 week rest period, restart on D50.~Five Maintenance cycles: Fotemustin 100 mg/m², 1 hour IV infusion, D1-D21."
45349356|NCT04065776|Radiation|Hippocampal-avoidance proton therapy|Hippocampal-avoidance proton therapy
45349357|NCT00947908|Biological|Hymenoptera venom|Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
45841341|NCT05822011|Procedure|Rhomboid intercostal subserratus plane block|Fascial plane block
45349358|NCT00865839|Drug|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
45476106|NCT05214872|Diagnostic Test|metalloproteinases|"metalloproteinases in the serum [ng/ml]:~metalloproteinase 9 (MMP-9) in the serum was determined by the ELISA method using the Quantikine Human MMP-9 (total) kit, by R&D Systems, Canada;~tissue inhibitor of metalloproteinase 1 (TIMP-1) in the serum - was determined by the ELISA method using the Quantikine Human TIMP-1 kit, manufactured by R&D Systems, Canada;~the MMP-9/TIMP-1 ratio was calculated by the quotient of the MMP-9 and the TIMP-1 concentration."
45685378|NCT02843386|Other|Intensive surveillance|"Intensive surveillance~Total duration: 3 years.~liver functional tests/3 months, - liver MRI or CT-scan/6 months, - whole body CT-scan/12 months."
45349359|NCT00865839|Drug|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
45349360|NCT00549328|Drug|Pazopanib (GW786034)|Pazopanib monotherapy
45349361|NCT00865917|Drug|beta-blocker (Metoprolol)|Metoprolol 95 mg once per day
45349362|NCT00865917|Drug|I(f)-blocker (ivabradine)|ivabradine 7.5 mg once per day
45349363|NCT00865917|Drug|Placebo|matching appearance
45685379|NCT05022082|Other|Chest Physiotherapy- Aspiration- Inhaler drugs group|In the intensive care unit where the study was conducted, the patients who have a respiratory disorder and receive supplemental oxygen therapy with non-invasive mechanical ventilation or an oxygen mask are first administered an inhaler drug therapy placed in the physician's order. It is followed by chest physiotherapy and then oropharyngeal and nasopharyngeal aspiration. However, in practice rendered by the researcher, it is suggested that when chest physiotherapy and aspiration are administered in the first place and then followed by an inhaler drug therapy, it might have a more positive impact on the patient's physiologic parameters.
45685380|NCT05026996|Drug|Pelacarsen|Single subcutaneous injection of pelacarsen
45349364|NCT00696410|Drug|Zinc Acetate|Zinc acetate 50 mg po TID for 10 months. Dose will be titrated to achieve ceruloplasmin levels ~10-12.
45349365|NCT00865995|Procedure|Tracheal Lavage|Tracheal Lavage will be performed on the control population patients and the tracheal fluid obtained from this procedure will be used as the research sample.
45349366|NCT00858897|Other|Cysteine isotope infusion at normoglycemia vs hyperglycemia|L-[3,3-2H2]cysteine
45349367|NCT00858897|Drug|Regular Insulin|Regular insulin, IV, as needed to maintain blood glucose in near-normoglycemic range (80-140 mg/dL) or hyperglycemic range (200-250 mg/mL) during metabolic studies
45476107|NCT05214872|Diagnostic Test|parameters of lipids metabolism in the serum|"total cholesterol (T-C) [mg/dl] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~low-density lipoprotein cholesterol (LDL-C) [mg/dl] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~high-density lipoprotein cholesterol (HDL-C) [mg/dl] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~triglycerides (TG) [mg/dl] - were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~the concentration of low-density lipoprotein (LDL-C) cholesterol - was determined from Friedewalds' equation (LDL-C [mg/dl] = total cholesterol (T-C) [mg/dl]- HDL-C [mg/dl]- TG[mg/dl]/5)."
45349368|NCT00683904|Drug|Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m^2, intravenous (IV) solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 5 mg/min/mL, intravenous IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
45349369|NCT00683904|Drug|Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL|After all participants in Dose Level 1 (ixabepilone, 32 mg/m^2 + carboplatin, 5 mg/min/mL) have been observed for 1 full 21-day cycle, Dose Level 2(ixabepilone, 32 mg/m^2 + carboplatin, 6 mg/min/mL) opened. On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m^2, IV solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 6 mg/min/mL, IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
45349370|NCT00947986|Other|1% Johnson's Baby Shampoo|nasal irrigation 2x a day for 4 weeks
45476108|NCT05214872|Diagnostic Test|parameters of iron metabolism|"iron concentration [mg/dl] - was analyzed with the Cobas Integra 400 plus biochemical analyzer from Roche Diagnostics, USA;~total iron-binding capacity (TIBC) [mg/dl] - was analyzed with the Cobas Integra 400 plus biochemical analyzer from Roche Diagnostics, USA;~the unsaturated iron-binding capacity (UIBC) [mg/dl] was determined by an equation in which iron concentration in plasma is subtracted from TIBC [mg/dl];~ferritin [ng/ml] concentration was determined with the Modular E-170 biochemical analyzer from Roche Diagnostics, USA."
45685381|NCT05026996|Drug|Pelacarsen|Single subcutaneous injection of pelacarsen
45685382|NCT05024422|Drug|Cabergoline|Administration of Cabergoline (one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days)
45685383|NCT05024422|Drug|Pyridoxine|Administration of Pyridoxine (200 mg X 3 per day for a week)
45841342|NCT05822011|Procedure|Erector spinae plane block|Fascial plane block
45349371|NCT00862329|Dietary Supplement|Casein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of casein
45349372|NCT00862329|Dietary Supplement|Milk soluble protein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of milk soluble protein
45685384|NCT05021614|Device|Valveclip® Transcatheter mitral valve repair|Transcatheter mitral valve repair system
45685385|NCT04272502|Drug|CKD-348 F1, CKD-348 F2, CKD-828, D326, D337|Each arm has a different order for taking IP
45685386|NCT04758130|Other|Zamplo Digital Health Platform|This application will be provided to patients and provide them with a method to track various data related to their metabolic disease.
45685387|NCT01890070|Dietary Supplement|Hazelnuts|Italian hazelnuts from Piedmont with Protected Geographical Indication Certification
45685388|NCT01890070|Dietary Supplement|Chocolate|Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
45349373|NCT00862329|Dietary Supplement|Casein and milk soluble proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of a mix of casein and milk soluble protein
45349374|NCT00862329|Dietary Supplement|Soy proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of soy protein
45349375|NCT00956956|Drug|PF-04455242|3, 6, and 23 mg capsules administered orally Q6 hours for 7 days of dosing.
45349376|NCT00956956|Drug|Placebo|Placebo administered orally Q6 hours for 7 days of dosing.
45841343|NCT05822011|Procedure|Thoraccic Epidural analgesia|Neuroaxial block
45847575|NCT04845282|Dietary Supplement|RDA Protein plus Resistance Training|Participants will be counseled to consume the RDA level of protein (0.8g/kg/day) utilizing only dietary protein.
45349377|NCT00866073|Drug|Decitabine 15 mg/m2 i.v.|Decitabine at 15 mg/m2 i.v. x 3 hours, three times daily on three consecutive days
45349378|NCT00957112|Procedure|acupuncture therapy|Patients undergo therapist-acupuncture with or without self-acupuncture
45349379|NCT00957112|Procedure|standard follow-up care|Patients receive standard care
45349380|NCT02544711|Device|Patient specific instrument|The proposed innovation consists in using patient specific instrument (PSI) for tumor resection. It is compounded of a preoperative assistance to plan the surgery and an intraoperative assistance to reproduce the preoperative planning.
45349381|NCT02544711|Procedure|Conventional surgical treatment|The conventional treatment is planned on two-dimensional images (CT and MRI).
45349382|NCT00752466|Drug|Topiramate; flunarizine|
45349383|NCT04982588|Device|Medtronic CoreValve™ Evolut™ PRO System|"The system comprised of the following three components:~CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)~EnVeo™ PRO Delivery Catheter System (DCS)~EnVeo™ PRO Loading System (LS)"
45349384|NCT00957190|Drug|Dorzolamide 20 mg and Timolol 5 mg|Twice daily in the affected eye(s)
45349385|NCT02566850|Device|Ekso|powered lower extremity exoskeleton
45685389|NCT01890070|Dietary Supplement|Red wine|Italian Organic Red Wine
46044846|NCT00825175|Behavioral|Treadmill Training|Parents hold their infants on an infant treadmill for 8 minutes a day, 5 days a week. The treadmill speed is set at 0.2 m/s.
45349386|NCT00866229|Drug|Rosuvastatin|10 mg per day for 12 weeks
45349387|NCT00866229|Drug|Simvastatin|20 mg per day
45349388|NCT04051398|Other|transcutaneous nerve electrostimulation (TENS) of acupuncture points|TENS application session over the acupuncture points: Feishu, Zhongfu, Taiyuan and Dingchuan using a frequency of 200Hz and a pulse time of 80 seconds of sufficient intensity to cause a slight sensation of local numbness without muscle fasciculations. The TENS application time will be 30 minutes.
45349389|NCT00953914|Drug|Pyridostigmine|Pills containing 30 mg of Pyridostigmine will be orally administered 3 times daily for 1 day.
46044847|NCT00825175|Device|Supramalleolar Orthoses|In addition to treadmill training the infants receive Supramalleolar orthoses. They wear the orthoses for 8 hours a day, 5 days a week.
46044848|NCT04290936|Drug|Vemlidy® (Tenofovir Alafenamide; TAF)|Dosage form: Oral Tablets; Dosage: 25mg; Frequency: One tablet with meals, once daily(QD).
45349390|NCT00953914|Drug|Placebo|If subject is randomized to placebo, placebo pills will give 30 mg orally 3 times daily for 2 days
45349391|NCT00858975|Procedure|cryotherapy|Placing 4-6 cryotherapy probes into the renal tumors and conducting two cycles of freezing and thawing
45349392|NCT03891290|Other|Collecting recorded videos of Colonoscopy screening tests of the general population|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
45349393|NCT00756912|Drug|E5564|Three dose levels of Eritoran IV over 14 days for a total of 32, 96, and 224 mg over 14 days.
45349394|NCT00948220|Drug|peginterferon alfa-2a and ribavirin|standard antiviral therapy with peginterferon alfa-2a 180 µg/week and ribavirin 1000-1200 mg/d
45685390|NCT01890070|Dietary Supplement|Olive Oil|Italian Organic Olive Oil
45685391|NCT01890070|Dietary Supplement|Wild mixed greens|Italian organic wild mixed greens
45685392|NCT01890070|Dietary Supplement|Chestnut|Italian Organic Chestnut
45685393|NCT01890070|Other|No Dietary Supplement|Mediterranean Reference Diet, High Fat Diet, Low Carbohydrate or High Protein Diet without an added dietary supplement (hazelnut, chocolate, red wine, wild mixed greens, chestnuts, olive oil)
45685394|NCT02819596|Drug|Savolitinib|
45685395|NCT02819596|Drug|MEDI4736|
45685396|NCT02819596|Drug|Tremelimumab|
45685397|NCT02818894|Drug|Lidocaine|Spinal anesthesia administered prior to participant's THA
46044849|NCT04290936|Drug|Placebo|Dosage form: Oral Tablets; Dosage: N/A; Frequency: One tablet with meals, once daily(QD).
46044850|NCT00707941|Drug|Oseltamivir|"Children ≤12 years: Suspension by Weight (Kg) as follows: Dose X 5 days Volume (ml) < 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows:~1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25"
46044851|NCT00707941|Drug|Placebo|"Children < 12 years, suspension by weight (kg) as follows: Dose X 5 days Volume (ml) < 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows 1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25"
46044852|NCT02866890|Device|Laryngeal Tube Suction|Laryngeal Tube Suction Measurement of leak pressure
45685398|NCT02818894|Drug|Bupivacaine|Spinal anesthesia administered prior to participant's THA
45685399|NCT02818426|Drug|UCPVax|
45685400|NCT01890304|Other|Magnetic Resonance Imaging (MRI)|MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
46044853|NCT04038931|Other|Liver biopsy collection|Liver biopsy collection to Confirm suitability of T1DM, total or partial pancreatectomy patient's liver cells to be used as future personalized cell replacement therapy.
45349395|NCT00756990|Drug|Depot Naltrexone|228mg of injectable naltrexone
45349396|NCT05301244|Other|laughter yoga for nurses|The experimental group was divided into three groups as 17-17-16 people. For four weeks, laughter yoga sessions were held between 20.00 and 21.00, 2 days a week for each group. Laughter yoga sessions were held for the 1st group between 20.00-21.00 on Mondays and Thursdays, for the 2nd group between 20.00-21.00 on Tuesdays and Fridays, and for the 3rd group between 20.00-21.00 on Wednesdays and Sundays. The first sessions lasted 45 minutes, every other session 40 minutes.
45349397|NCT05301244|Other|laughter yoga for nurses-Deep breathing exercises|Deep breathing exercises (5 minutes) Breathing is held for 4-5 seconds after deep inspiration. While the arms are brought to the normal position, exhale slowly and rhythmically. When expressing after deep inspiration, the lips can be pursed as if whistling or exhaled with laughter.
45349398|NCT05301244|Other|laughter yoga for nurses-Warm-up exercises|Warm-up exercises (10 minutes) Rhythm of 1-2, 1-2-3 is added to increase the energy level even more and synchronize the movements of the group. After a few rhythmic clapping movements, another movement is added. Whisking hands left and right. Then an audible rhythm of ho, ho, ha-ha-ha is added to the clapping gesture. Make eye contact with people in the group and smile at them.
45349399|NCT05301244|Other|laughter yoga for nurses-Childish games|"Childish games (10 minutes) Childlike games are used to help laugh without reason just like a child. The group is motivated by visualizing these games in their minds, raising the arms up in the form of a Y letter, and saying very good (applause), very good (applause), hey with palms facing the sky."
45349400|NCT05301244|Other|laughter yoga for nurses-Laughter exercises|Laughter exercises (15 minutes) This section includes a variety of laughter exercises such as greetings, strawberry milk, conductor, bonus, hot soup, lion, aloha, bird, appreciation, laughter lotion, elevator, cream cake, and bursting balloon laughter.
45476109|NCT05214872|Diagnostic Test|selected inflammatory markers|"high-sensitivity C-reactive protein (hsCRP) [mg/l] was measured using DADE Behring, USA and the DADE nephelometer Behring Analyzer II;~neopterin [nmol/l] was determined by using the Neopterin ELISA kit, DRG International, Inc., USA;~interleukin 18 (IL-18) [pg/ml] concentration was determined by Colorimetric Sandwich ELISA, Quantikine Human IL-18 R&D Inc., USA."
45476110|NCT05214872|Device|carotid intima-media thickness (IMT)|"carotid intima-media thickness (IMT) [mm] was measured by The Accuson CV 70 system (Siemens) with a 10 megahertz (Mhz) transducer.~Two longitudinal projections were assessed (anterolateral and posterolateral). The distal 1 cm of the common carotid artery just proximal to the bulb was measured by means of a computer analysis system (Medical Imaging Applications, LLC)."
45349401|NCT04048616|Dietary Supplement|whey protein isolate|one 15-25 gm (based on body weight) protein packet three times a day with each meal
45476111|NCT05214872|Device|non-invasive cardiological examinations|"For non-invasive cardiological examinations, the Portapres device (Finapres Medical Systems (FMS), the Netherlands), the SphygmoCor tonometer (AtCor Medical), the Colin blood pressure monitor (BMP)-7000 (Japan) were used.~Main assessed variables: heart rate (HR) [beats per minute [bpm]]; ejection duration (ED) [millisecons]; peripheral systolic (pSBP) and diastolic blood pressure (pDBP) [mm Hg]; peripheral mean arterial pressure (pMAP) [mm Hg]; peripheral end-systolic pressure (pESP) [mm Hg]; central systolic (cSBP) and diastolic blood pressure (cDBP) [mm Hg]; central mean arterial pressure (cMAP) [mm Hg]; central augmented pressure (cAP) [mmHg]; central mean pressure of diastole (cMPD)[mm Hg]; central mean pressure of systole (cMPS) [mm Hg]; central end-systolic pressure (cESP) [mm Hg]."
45476112|NCT05214872|Device|vessel stiffness assessment|"The following parameters of vessel stiffness were assessed by Pulse Trace 2000 (Micro Medical Ltd., Rochester, Kent, United Kingdom):~reflection index (RI) [in percentages [%]];~vascular stiffness index (SI) [m/s];~peripheral pulse pressure (pPP) [mm Hg];~central puls pressure (cPP) [mm Hg]~peripheral pulse pressure/central pulse pressure (pPP/cPP ratio)."
45685401|NCT01893736|Other|In-hospital professional support|In-hospital professional lactation support will consist of two 30-minute one-to-one hands-on breastfeeding counseling sessions in first 24 hours post-partum and one further 30-minute one-to-one hands-on breastfeeding counseling session on the second day of post-partum hospitalization for a total of three 30-minute sessions. The one-to-one sessions will focus on: (1) education and advice on correct breastfeeding positions and techniques, (2) education and advice on milk supply and how to avoid common breastfeeding problems, and (3) hands-on instruction and assistance with proper breastfeeding positioning and technique, latching on and newborn attachment to the breast, and manual expression of breast milk.
45841344|NCT05821985|Procedure|The study group|The patients within the study group will receive intraarticular TMJ and masseteric Trigger point injection of a solution that contains (0.75 ml. 12.5% Dextrose solution, 0.75 ml. Saline solution, and 1.5 ml. Lidocaine). Each patient will receive three injections at two-week intervals, aided by a 25 gauge needle connected to a 3 ml. plastic syringe.
45841345|NCT05821985|Procedure|The Control group|"The Control group:~Patients in the control group will receive intraarticular TMJ and masseteric Trigger point dry needle insertion without injecting any solution. Each patient will receive three dry needle insertions at two-week intervals, aided by a 25-gauge and 3.8 cm length needle.~i.e., All the patients will be subjected to intraarticular needle insertion. However, only the patients within the study group will be injected with the Dextrose Prolotherapy solution."
45847576|NCT04809324|Procedure|Gross examination of the resection specimen|measurement of the surgical margin by the operating surgeon using sterile scale, margins <7mm will be revised on table
45847577|NCT04809324|Procedure|Frozen section|frozen section evaluation of the specimen by the pathologist
46044854|NCT04290312|Other|Mastiha oil|After overnight fasting, the authorized study staff inserted a plastic cannula in an arm vein of the volunteers in order to minimize discomfort during consecutive blood sampling. A blood sample was collected on time point 0h and then the volunteers consumed 1mL of MO. The dose selection was based on the study of Papada et al. (2017) who administered healthy volunteers with 10g of Mastiha (containing ~10% MO). Afterwards blood samples were collected on time points 0.5h, 1h, 2h, 4h, 6h and 24h after MO intake, and were centrifuged at 3000rpm for 10 minutes at 4◦C for plasma and serum isolation. All samples were stored at -80◦C until further analysis.
45847578|NCT04763226|Drug|BMS-986308|Specified dose on specified days
45847579|NCT04763226|Other|Placebo (for BMS-986308)|Specified dose on specified days
45847580|NCT04763226|Drug|Furosemide|Specified dose on specified days
45847581|NCT04726566|Procedure|Tendon graft|Anatomical surgery for chronic lateral ankle instability under arthroscopy with tendon graft
45476113|NCT05214872|Other|cardiovascular (CV)-related death recording during 2-year follow-up|During a 2-year follow-up from the enrollment to this study, CV-related fatal incidents history has been recorded for each subject separately. The primary endpoint was fatal acute myocardial infarction (AMI) or acute ischemic stroke or any unexpected or sudden death only if autopsy proved CV-related. If there was doubt about the cause of death or there was no contact with the patient during the two years from study enrollment, that patient was excluded and not considered further.
45349402|NCT04048616|Dietary Supplement|potassium bicarbonate (KHCO3)|two 13.5 mmol capsules three times a day with each meal
45349403|NCT04048616|Other|microcrystalline cellulose|identical placebo capsule
45349404|NCT04048616|Other|maltodextrin powder|isocaloric placebo powder
45349405|NCT02561286|Behavioral|BRO HIV Risk Reduction Intervention|BRO HIV Risk Reduction Intervention was designed to strengthen outcome expectancies supporting condom use and other sexual risk reduction strategies and skill and self-efficacy to use condoms and reduce sexual risk behaviors. It consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals. Sessions 1 and 2 included take-home assignments that the participants reviewed at the subsequent session. The delivery of the intervention was tailored to the information that the participants provided during the sessions, including the context in which behaviors occurred and participants' motivation for the behaviors.
45349406|NCT02561286|Behavioral|Health Promotion Intervention|"Health Promotion Intervention was designed to provide a control for Hawthorne effects, reducing the likelihood that the HIV/STI risk-reduction intervention's effects could be attributed to non-specific features, including special attention. It focused on increasing physical activity and fruit-and-vegetable consumption and decreasing fat consumption to reduce the risk of chronic diseases, including heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among African Americans It also consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals."
45349407|NCT00757068|Behavioral|CBT addressing postpartum mood and weight concerns|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. In these treatment sessions, the counselor will address postpartum mood and weight concerns.
45349408|NCT00757068|Behavioral|Supportive Behavioral Therapy|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. A non-specific, supportive condition will be delivered to women who want to remain smoke-free after they give birth.
45349409|NCT00957346|Drug|Mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 400 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
45476114|NCT05214872|Diagnostic Test|glucose (Glu)|glucose (Glu) [mg/dl] was assessed in the serum by a routine technique using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.
45476115|NCT05214872|Diagnostic Test|klotho|klotho [ng/ml] - was analyzed in the serum by Human KL(Klotho) [ng/ml] ELISA Kit, Shanghai Sunred Biological Technology Co kit, China.
45476116|NCT05214872|Diagnostic Test|fibroblast growth factor 23 (FGF-23)|FGF-23 [pg/ml] - was analyzed in rhe serum using Human FGF-23 ELISA Kit, Sigma-Aldrich, USA.
45476117|NCT05214872|Diagnostic Test|parameters of calcium and phosphate metabolism|"total and ionized calcium [mg/dl],~phosphate [mg/dl],~intact parathormone (iPTH) [mg/dl]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
45476118|NCT05214872|Diagnostic Test|liver enzymes activity assessment|"activity of:~alanine transaminase (ALT) [U/l];~aspartate transaminase (AST) [U/l];~alkaline phosphatase (ALP) [U/l]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
46044855|NCT02867826|Device|Cap|Cap-assisted endoscopy
46044856|NCT02867358|Drug|KT07 Capsule|
46044857|NCT02867358|Other|Placebo|
46044858|NCT00824473|Drug|Placebo|Placebo
46044859|NCT00824473|Drug|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 822 mcg
46044860|NCT04291092|Drug|Immunotherapy|Immunotherapy for brain metastasis
46044861|NCT04291092|Radiation|WBRT|local therapy for brain metastasis
46044862|NCT04291092|Drug|Chemotherapy|Chemotherapy for brain metastasis
46044863|NCT04041037|Device|Wound Sheet Matrix 2-Layer and Powder Urinary Bladder Matrix|Porcine-derived extracellular matrix will be used in powder and 2-Layer wound sheet form in masses up to 1000 mg. Each product is intended for a one-time use only.
45349410|NCT00957346|Drug|Placebo+Misoprostol|placebo resembling mifepristone followed 24 hours later by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
45349411|NCT04061096|Diagnostic Test|Evaluation of cold test|Cold test evaluation to describe the sensitivity level of teeth due to induce the hydrodynamic forces in dentine tubules.
45349412|NCT04061096|Diagnostic Test|Evaluation of electrical pulp test|Electrical pulp test evaluation to describe the sensitivity level of teeth due to induce the nerve fibers in pulp tissue.
45349413|NCT04061096|Diagnostic Test|Evaluation of pain during the treatment|Describe the sensitivity level due to induce the hydrodynamic forces during treatment procedure.
45349414|NCT00750984|Procedure|Anterolateral approach|The anterolateral approach is performed with the patient positioned on the side. The blood supply to the femoral neck from the medial circumflex artery is regarded preserved by this surgical method.
45349415|NCT00750984|Procedure|Posterior approach|The posterior approach is performed with the patient positioned on the side. The medial circumflex artery is cut at the lower border of the short external rotators risking a compromised blood supply to the femoral head.
45349416|NCT00750984|Device|ReCap Total Hip Resurfacing|This arm utilizes the anterolateral approach using the ReCap® Total Hip Resurfacing System.
45349417|NCT00750984|Device|ReCap Total Hip Resurfacing|This arm utilizes the posterior approach using the ReCap® Total Hip Resurfacing System.
45349418|NCT00954070|Device|Confocal endomicroscope (Pentax Model EC3870K)|The intervention is an endoscopy procedure using a novel type of endoscope with a powerful confocal microscope attached to its tip. The endoscope (Pentax Model EC3870K) provides both white-light and confocal microscopic imaging.
45349419|NCT00752544|Drug|TMC435350|
45349420|NCT00957502|Device|ENTact™ Septal Stapler|1 year aged septal staples
45349421|NCT00957502|Device|ENTact™ Septal Stapler|18 Month Aged Staples
45349422|NCT00751062|Drug|timolol|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
45349423|NCT00751062|Drug|PhXA41|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
45476119|NCT05214872|Diagnostic Test|total protein and albumin|"total protein (TP) [g/dl];~albumin (ALB) [g/dl]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
46044864|NCT02867436|Other|Gluten-free diet|
46044865|NCT02865486|Dietary Supplement|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 2.
45349424|NCT04031456|Biological|Autologous Platelet Rich Plasma|Autologous PRP intra ovarian infusion
45349425|NCT04031456|Biological|Placebo-Platelet Free Plasma|Autologous PFP intra ovarian infusion
45349426|NCT00948376|Genetic|IFT80 screening|Natural History
45349427|NCT04030052|Drug|Nuwiq (low dose protocol)|After receiving HEMLIBRA® for 1-6 months, rFVIII (NUWIQ®) will be given at low dose (25 ±5 units/kg/dose) every 7-14 days as part of a low dose factor exposure program and for on demand use for acute bleeding episodes/procedures. NUWIQ® will be administered intravenously (IV) via peripheral infusion. If the infant has a central line such as a PICC line or mediport this can be used.
45847582|NCT04726566|Procedure|Suture with biological reinforcement|Anatomical surgery for chronic lateral ankle instability under arthroscopy by suture with biological reinforcement
45349428|NCT04030052|Drug|HEMLIBRA|Four weekly subcutaneous (SQ) injections of HEMLIBRA® loading doses of 3 mg/kg will be given. A total of 12 mg/kg within the first month is allowed for the loading doses. Maintenance dosing will follow, and will either be 1.5 mg/kg/dose weekly, 3 mg/kg/dose biweekly (every 2 weeks), or 6 mg/kg/dose every 4 weeks depending on the recommended dosing.
45476120|NCT05214872|Diagnostic Test|creatinine and urea|"creatinine in the serum [mg/dl] - the assay is based on the reaction of creatinine with sodium picrate as described by Jaffe (Jaffes' colorimetric method) - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~urea [mg/dl] in the serum - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
45847583|NCT04695678|Diagnostic Test|COVID-19 nasal/pharyngeal swab|each study participant receives a nasal/pharyngeal swab
45847584|NCT04636008|Drug|Sintilimab|Sintilimab+Hypofractionated radiotherapy
45847585|NCT04636008|Radiation|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy
46044866|NCT02865486|Dietary Supplement|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 3.
46044867|NCT02865486|Dietary Supplement|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 4.
46044868|NCT02867280|Drug|Sorafenib|red round tablet
45349429|NCT04030052|Drug|Nuwiq (Atlanta protocol)|After completing HEMLIBRA® loading doses, participants will receive intravenous (IV) infusions of NUWIQ® 3 times per week, 100 units/kg the Atlanta protocol. Infusions will be given at least 36 hours from the previous NUWIQ® injection. Participants will continue on the HEMLIBRA® SQ - NUWIQ® IV treatment regimen for up to 12 months of NUWIQ® treatment.
45349430|NCT00752700|Other|Conventional resistance training|Conventional resistance training program (CRT)
45349431|NCT00752700|Other|Whole body vibration resistance training|Whole body vibration resistance training (WBV) on the FITVIBE-platform
45349432|NCT00957736|Genetic|polymorphism analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
45349433|NCT00957736|Other|laboratory biomarker analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
45349434|NCT00751374|Drug|gentamicin|topical gentamicin cream on daily basis
45349435|NCT00751374|Drug|gentamicin cream alternating with mupirocin cream|topical gentamicin cream alternating with mupirocin cream at monthly basis
45349436|NCT02566694|Procedure|Implant|orthopaedic implant
45349437|NCT00954148|Procedure|PET/CT|5 visits with PET/CT as only testing
45349438|NCT00954148|Procedure|NCCN recommendations for solid tumor post treatment|12-14 visits with exams, blood tests, CTs and PET/CT
45349439|NCT03951194|Biological|Autologous Platelet Rich Plasma (PRP) intra ovarian infusion|Autologous PRP intra ovarian infusion
46044869|NCT00815191|Device|a forced-air warming cover|A forced-air warming cover will be placed on the subject prior to surgery, remain on the subject during surgery and removed after surgery.
46044870|NCT00815191|Device|vital HEAT (vH2) Temperature Management System|The vital HEAT (vH2) Temperature Management System will be placed on the subjects arm prior to surgery. remain on the arm during surgery and removed after surgery.
46044871|NCT04290390|Drug|Segesterone Acetate and Ethinyl Estradiol|Contraceptive Vaginal System
46044872|NCT04290390|Drug|Rifampin|CYP3A inducer
45349440|NCT03951194|Other|Placebo: Autologous Platelet Free Plasma (PFP) intra ovarian infusion|Autologous PFP intra ovarian infusion
46044873|NCT04290390|Drug|Itraconazole|CYP3A inhibitor
45349441|NCT00957814|Behavioral|Nutritional education|Systematic nutritional orientation program
45349442|NCT00757224|Behavioral|Guidance|Smoking parents will receive education on the association between parental smoking and respiratory morbidity in the infant. They will also be offered ways to reduce smoke exposure of their infants.
45349445|NCT00954304|Drug|HM30181AK 1mg|HM30181AK 1mg tablet
45349446|NCT00954304|Drug|HM30181AK 5mg|HM30181AK 5mg tablet
45349447|NCT00954304|Drug|HM30181AK 15mg|HM30181AK 15mg tablet
45349448|NCT00954304|Drug|HM30181AK 60mg|HM30181AK 60mg tablet
45349449|NCT00954304|Drug|Loperamide 2mg|Loperamide 2mg capsule
45349450|NCT00752778|Other|pet-scan FDG-F18|
45349451|NCT00363415|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
45349452|NCT00363415|Drug|etoposide|100 mg/m2, intravenous (IV), days 1-3 x 6 cycles
45476121|NCT05214872|Diagnostic Test|selected parameters of oxidative stress (2)|myeloperoxidase (MPO) [ng/ml] in the serum- was determined by the ELISA method using the Quantikine Human MPO test by R&D Systems kit, Canada.
45476122|NCT05214872|Diagnostic Test|selected parameters of oxidative stress (3) sRAGE|soluble receptor for advanced glycation end products (sRAGE) [µg/mg protein] in the serum was tested with enzymatic immunoassay (Quantikine ELISA) using R&D Systems kit, Canada.
45349453|NCT00363415|Drug|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
45349454|NCT00757302|Device|SLN procedure (CarolIReS camera)|"Group I : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²).~Group II : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²)."
45349455|NCT00757380|Procedure|Trypan Blue|Membranepeeling with TB
45349456|NCT00757380|Procedure|Brillant Blue|Membranepeeling and membrana limitans interna peeling with BB
45349457|NCT00957970|Device|Stemless femoral component|Total hip femoral component anatomically designed for a proximal fit without a stem
45349458|NCT00957970|Device|IPS, Depuy cementless femoral stem|Anatomical proximal fitted cementless stemmed femoral component
45349459|NCT00752934|Drug|oral baclofen + placebo|"Group A will be given 13 weeks of oral baclofen followed by a 2-week non-treatment (washout) period, and then 13 weeks of oral placebo.~For participants who with weight under 15 Kg at the time of enrolment, the initial oral baclofen dose will be 2.5 mg daily, increasing weekly over a 7-week period to 10 mg three times a day, and will be continued at that dose for the following 5 weeks.~For those participants who will be over 15 Kg at the time of enrollment, the starting oral baclofen dose will be 5 mg daily, increasing over a 9-week period to 20 mg three times a day, and will be continued for the next 3 weeks at that dose. At the end of each 12-week period, the drug (either baclofen or placebo) will be tapered over 6 days.~Children's carers will given information on possible side effects, and asked to contact one of the researchers if any adverse events occur."
45476123|NCT05214872|Diagnostic Test|selected parameters of oxidative stress (4) MG, CEL, carbamyl protein groups|"methylglyoxal (MG) [µg/mg protein];~carboxyethyle(lysine) (CEL) [µg/mg protein];~carbamyl protein groups [µg/mg protein] were assessed in the serum by competitive enzyme immunoassay (competitive ELISA) using kits from Cell Biolabs Inc, USA."
45476124|NCT05214872|Diagnostic Test|selected electrolytes assessment|"potassium (K) [mmol/l];~sodium (Na) [mmol/l];~magnesium (Mg) [mg/dL]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
45847586|NCT04613154|Dietary Supplement|magnesiumcitrate|Magnesiumcitrate 250 mg, Apoteket AB, Sweden
45349460|NCT00752934|Drug|placebo + oral baclofen|Group B will receive 13 weeks of oral placebo followed by 2-week nontreatment, and then 13 weeks of oral baclofen
45349461|NCT00948532|Biological|biologic, Osteocel Plus|Osteocel® Plus
45847587|NCT04613154|Dietary Supplement|Placebo|Ester-c
45847588|NCT04549428|Drug|Atezolizumab|Intravenous infusion every 21 days, until disease progression, intolerance or loss of clinical benefit.
45476125|NCT05214872|Diagnostic Test|NT-pro-brain natriuretic peptide (NT-proBNP)|NT-proBNP [fmol/ml] - was analyzed in the serum by enzyme immunoassay using the Nt-proBNP kit from Biomedica, Slovakia.
45476126|NCT05214872|Other|estimated glomerular filtration rate (eGFR) calculation|eGFR [ml/min/1.73m^2] - according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 recommendations was calculated based on the Modification of Diet in Renal Disease (MDRD) formula: eGFR = 186 x [creatinine concentration in mg/dl] - 1.154 x [age in years] - 0.203 x [0.724] for the female gender.
45349462|NCT00696020|Drug|BI 1744 CL/tiotropium bromide fixed dose combination|BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
45349463|NCT00696020|Drug|tiotropium bromide|tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
45349464|NCT00696020|Device|Respimat® Inhaler|
45349465|NCT00751608|Drug|APL180|
45349466|NCT00751608|Drug|APL180|
45349467|NCT00751608|Drug|Placebo|
45349468|NCT00958048|Device|non-invasive ventilation|CPAP, BiPAP
45349469|NCT00751686|Procedure|Stool sample|Collection of the stool at least 48 hours after hospitalisation. Stool samples should be obtained preferably within 4 and no later than 10 days after the onset of the GE symptoms.
45349470|NCT00751686|Other|Data collection|Logbook, Health Economic Questionnaire, Telephone call.
45349471|NCT01047085|Procedure|impedance pH measurement|Impedance pH measurement: Impedance-pH is a recently developed technique used to monitor all kinds of reflux (gas, liquid, acides and non-acides), reflux level and the clearance period of the esophagus.
46044874|NCT00708253|Device|Double-balloon procedure (DBE)|Double-balloon procedure (DBE): DBE is performed using the DBE T-type endoscope system (Fujinon Inc, Japan), as described in the literature. The DBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 8.5 mm and a flexible overtube with a length of 145 cm and an outer diameter of 12 mm. Latex balloons are attached to both the endoscope and the overtube. These balloons are inflated and deflated during insertion, as described elsewhere in detail (2,3).
45349472|NCT00576576|Drug|Atorvastatin|Atorvastatin 80 mg a day
45349473|NCT01049971|Device|wound protector|after minilaparotomy, the wound protector is applied
45349474|NCT01049971|Device|no wound protector|use of woven drape instead of wound protector
45349475|NCT04056156|Behavioral|HIV-screening advice|To increase GP's HIV-testing behavior a targeted HIV-testing advice is spread to participants through an electronic mail
45476127|NCT01195571|Biological|cmv vaccine|dose escalation study of 4 towne-toledo chimera vaccines
45476128|NCT01330095|Dietary Supplement|Administration of Bifidobacterium bifidum|Administration of Bifidobacterium bifidum to very low birth weight infants
45476129|NCT01197989|Device|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
45476130|NCT01197989|Device|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
46044875|NCT00708253|Device|Single-balloon procedure (SBE)|Single-balloon procedure (SBE): SBE is performed using the SBE endoscope system (SIF-Q180, Olympus Optical Co., Ltd., Tokyo, Japan). The SBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 9.2 mm and a flexible overtube with a length of 140 cm and an outer diameter of 13.2 mm. One single balloon is attached to the the tip of the overtube. The insertion process follows the method used for DBE, but instead of inflation of the endoscope balloon, the tip of the endoscope is angulated at straightening
45349476|NCT04056156|Behavioral|HIV-testing advice plus group-level training|To increase specific HIV-testing behavior among GPs a targeted HIV-testing advice is spread to participants through an electronic mail and an additional face-to-face group-level training is provided.
45349477|NCT00751764|Drug|Moxidectin|
46044876|NCT04119960|Device|Aided read with InferRead Lung CT.AI|Radiologists read chest CT scans with the aid of InferRead Lung CT.AI
45349478|NCT00757458|Drug|EDTA without re-filling|Target controlled infusion of propofol containing EDTA (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca), without re-filling of syringe.
45476131|NCT03219372|Drug|Pravastatin Pill|statin
45476132|NCT03219372|Drug|Placebo Oral Tablet|placebo
45476133|NCT02427867|Other|Remote ischemic preconditioning|
46044877|NCT00708331|Device|2 HEMA Hydrophilic Acrylic Intraocular Lens|2 HEMA Hydrophilic Acrylic Intraocular Lens implanted into the posterior capsule following cataract surgery for patient life duration.
45349479|NCT00757458|Other|Propofol syringe re-filling with propofol containing EDTA|Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol containing EDTA.
45476134|NCT02427867|Other|no ischemic preconditioning|
45349480|NCT00757458|Other|Target controlled infusion of propofol without EDTA|Target controlled infusion of propofol without EDTA using Marshal´s technic with Alaris® or Fresenius® equipment
45349481|NCT00757458|Other|Re-filling of syringe with propofol without EDTA|Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol not containing EDTA.
45476135|NCT05668247|Other|FOOT BATH|In general, foot bath is a type of relaxation and care performed by putting feet in water. Feet, as the organs carrying the whole body weight are the body parts where fatigue is felt most. In this study, a specially designed foot bath bucket was used in order to apply foot bath for the patients in the experimental group.
45841346|NCT05821946|Other|Web-Based Multi-Source Training on the Prevention of Urinary Tract İnfections|Before discharge, individuals will be given a user name and password to enter the website by the researcher. The first access to the website will be made via the researcher's computer, and the website will be introduced. Individuals will be shown how to access the compatible website on Android and IOS phones and tablets by the researcher. Web-based multi-source training for individuals to prevent urinary tract infections will begin. The researcher will check the use of educational materials by individuals from the administrator's menu. To increase the effectiveness of the training, reminder, motivating, and supportive messages will be sent to the patients twice a week.
45841347|NCT05821933|Drug|RC108|RC108 plus Furmonertinib and/or Toripalimab
45841348|NCT05821920|Device|MUST MINI system|cervical posterior fixation system
45841349|NCT05821894|Other|Observational study|
45841350|NCT05821881|Other|Discontinuation of levothyroxine treatment|Step-wise reduction of levothyroxine treatment guided by thyroid function and symptoms
46044878|NCT04007952|Procedure|Anterior Gastropexy|Two permanent sutures will be introduced into the abdomen and placed along the lesser curvature of the stomach. A suture passer will be used to grasp the ends of the sutures to externalize them at separate fascial punctures. At time of abdominal desufflation, the sutures will be tied and the incision closed per individual surgeon practice.
46044879|NCT05423587|Procedure|Genicular Artery Embolisation|Transarterial catheter directed embolisation of hypervascularity in patients with mild to moderate knee osteoarthritis
46044880|NCT05423587|Procedure|Genicular Artery Injection|Transarterial catheter directed injection of normal (0.9%) saline in patients with mild to moderate knee osteoarthritis
46044881|NCT02866968|Procedure|FLAPS|Surgical procedures will involve 1) excision of pterygium tissue from cornea and conjunctiva, 2) resection of residual Tenon and coagulation to stop any bleeding 3) preparation of a 8x8 mm conjunctiva autograft in the superior bulbar conjunctiva with the femtosecond laser (12 o´clock position) and 4) fixation of the graft with fibrin glue to the resection site.
46044882|NCT04145388|Other|online cancer risk assessment|Electronic surveys to collect family cancer history information.
46044883|NCT04145388|Other|Usual care|Family cancer history captured by provider during a clinical encounter
46044884|NCT04145310|Drug|BOL-DP-o-04 + SCO|sublingual drops
46044885|NCT04145310|Drug|Placebo + SCO|sublingual drops
46044886|NCT04132284|Behavioral|DBT-Based Parenting Intervention|The intervention will consist of 8-10 individual parent sessions, to be completed within one week after the teen completes the IOP program. Sessions will be 1 hour in length and will be offered weekly. Therapists may see parents more than once a week if needed, as long as the total number of sessions does not exceed 10. Sessions will follow the standard agenda used for DBT skills training: 1) mindfulness practice, 2) homework review, 3) teaching of a new skill; 4) practice of the new skill; and 5) assignment of new homework (Linehan, 1993). The intervention will utilize the Middle Path module of the DBT Skills Manual for Adolescents (Rathus & Miller, 2015), which was created by the developers of DBT for adolescents and includes both instructions for therapists and handouts for clients.
45349482|NCT02919098|Behavioral|Bystander, a game-based bystander intervention program|A game-based, high school age-appropriate program delivered by trained facilitators for sexual violence and harassment intervention
45841351|NCT05821868|Device|Dosivent|Dosivent® inhalation chamber is designed to optimize the delivery of inhaled bronchodilators and corticosteroids in the treatment of respiratory diseases
45349483|NCT02919098|Behavioral|Infection City, a game-based program about meningitis|A game-based, high school age-appropriate program delivered by trained facilitators to teach students about meningitis.
45476136|NCT04745403|Drug|mRNA HBV/TCR T-cells|"Study Infusion~The first dose of mRNA HBV-TCR T-cells at dose 1x10e5/kg BW will be infused on Day 0, and subsequently incremental doses on Day 14 and 28, up to the dose of 5-10x10e6/kg BW."
45841352|NCT05821868|Device|Aerochamber Plus Flow Vu|Aerochamber Plus Flow Vu® inhalation chamber is also designed to optimize the delivery of inhaled bronchodilators and corticosteroids in the treatment of respiratory diseases
45841353|NCT05821855|Device|XEN45 Glaucoma Treatment System|Ab interno implantation
45841354|NCT05821855|Procedure|Trabeculectomy|Surgical Intervention
45349484|NCT00923247|Drug|Bortezomib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 & 11 every 28 days in adults
45349485|NCT00923247|Drug|Vandetanib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 & 11 every 28 days in adults
45349486|NCT00757536|Procedure|Encircling Band|ppVE and encircling band
45349487|NCT00757536|Procedure|Endolaser Photocoagulation|ppVE and endolaser photocoagulation
45476137|NCT05339477|Other|Accelerometer measurement|Study personnel will initiate an accelerometer and inform the patient to wear the accelerometer with an elastic belt on their right hip during waking hours for seven consecutive days. Moreover, patients are instructed to register their wear time in an activity diary in paper form. In addition, patients will register their working hours, if relevant. After seven days, patients send back the accelerometer and diary in a pre-paid envelope. The same procedure is repeated at the second follow-up visit at 1 year.
45349488|NCT03890354|Procedure|Hand-Sewn Repair|gastotomy to identify and remove gastric subepithelium tumor and hand sawn repair
45349489|NCT00757614|Genetic|DNA analysis|
45349490|NCT00757614|Genetic|polymorphism analysis|
45349491|NCT00757614|Other|laboratory biomarker analysis|
45841355|NCT05821842|Device|Sonu|Acoustic energy delivery
45349492|NCT00757614|Other|questionnaire administration|
45349493|NCT02866136|Drug|VP16, carboplatin|Systemic treatment : Intravenous injections, 2 cycles (21 days)
45476138|NCT03304080|Drug|Anastrozole|1 mg orally daily, day 1 to day 28
45841356|NCT05821803|Other|Using Insoles|FootBalance %100 Control Orthopedic insoles used for 4 weeks.
45349494|NCT02866136|Drug|Melphalan|intraarterial injections, 3 to 6 cycles (1 month)
45349495|NCT02866136|Drug|VP16, carboplatin, vincristin|Systemic treatment : Intravenous injections, 6 cycles (21 days)
45476139|NCT03304080|Drug|Palbociclib|Dose I: 100 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle (Phase 1 only) Dose II: 125 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle
45841357|NCT05821803|Other|Foot Core Exercises|4 weeks including
46044887|NCT04132284|Behavioral|Treatment as Usual|No parenting intervention provided beyond standard practices in DBT IOP program.
46044888|NCT04290858|Drug|Nitric Oxide|Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted concentration will have a tidal oscillation between 100 and 300 ppm, in order to maintain an average inhaled concentration from 140 to 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or trough a non-rebreathing mask without positive end expiratory pressure, depending on the clinical needs of the patient.
45349496|NCT02866136|Drug|Carboplatin + laser day 1 (chemothermotherapy)|Chemothermotherapy : Intravenous injection by carboplatin and Laser at day 1
45349497|NCT02866136|Device|Laser (local treatment)|
45349498|NCT02866136|Device|cryoapplication (local treatment)|
45349499|NCT02866136|Radiation|I125 radioactive plaques (local treatment)|
45349500|NCT02866136|Drug|intravitreal Melphalan (local treatment)|
45349501|NCT00757692|Drug|Vandetanib|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
45476140|NCT03304080|Drug|Trastuzumab|8 mg/kg IV initial loading dose, followed by 6 mg/kg IV every 21 days
45349502|NCT00757692|Drug|Bicalutamide|Bicalutamide at 50 mg will be administered orally, daily and continuously.
45349503|NCT04041141|Diagnostic Test|CT Scan|An additional cone beam CT will be repeated at midcourse of therapy (3rd week) and during the end of therapy (5th week)
45349504|NCT04041141|Device|Experimental Oral Stent Device|Patients undergoing standard of care planning for head and neck tongue cancer will have a radiation plan of the body imaged via CT scan construction with the experimental oral stent device in place
45476141|NCT03304080|Drug|Pertuzumab|840 mg IV followed by a maintenance dose of 420 mg IV every 21 days
45841358|NCT05821790|Other|Surgical waste and Data collect|Samples required for the study will be obtained from surgical waste of patients who underwent meningioma resection. Data necessary for the study will be collected from the patient's medical records, MRI examinations, and data specific to the characteristics of the surgical waste.
45841359|NCT05821777|Drug|LB101|Part 1: IV infusion of LB101 Q2W (28-day cycle) and Part 2: IV infusion of LB101
45841360|NCT05821751|Dietary Supplement|inulin|"Inulin will be given to enrolled patients according to manufacturer label indications.~ICIs (i.e. nivolumab and pembrolizumab) alone or in combination with chemotherapy, if clinically indicated, and their administration scheduling will be planned as per international and local guidelines."
45841361|NCT05821751|Drug|Pembrolizumab|Pembrolizumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
46044889|NCT04003896|Drug|Abemaciclib|"Participant will take 200 mg capsules or tablets orally twice daily. The participant will be instructed to swallow abemaciclib as a whole tablet and not to chew, crush or split capsules or tablets before swallowing. Participants should not ingest abemaciclib tablets if broken, cracked, or otherwise not intact. Doses should be taken at a approximately the same time every day, twice daily. Capsules or tablets can be taken orally with or without food. If the participant vomits or misses a dose of abemaciclib, the participant will be instructed to take the next dose at its scheduled time.~Participants will also be provided with a diary and instructed to keep a twice daily record of the times they have taken their medications and any other events such as vomiting, diarrhea, etc."
46044890|NCT03986736|Diagnostic Test|Laboratory analysis - upon admission|Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: HMGB-1, sCK, sMb, serum NGAL, and urine NGAL
45349505|NCT02850146|Drug|18F-AV-1451|
45349506|NCT00866385|Drug|AZD8566|Single 6 mg oral solution dose
45841362|NCT05821751|Drug|Nivolumab|Nivolumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
45349507|NCT00866385|Drug|AZD8566 IV carbon labelled|Single 10 mcg intravenous carbon-14 microtracer dose
46044891|NCT03986736|Diagnostic Test|Laboratory analysis - 24 hours after injury|Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: sCK, sMb, serum NGAL, and urine NGAL
45349508|NCT00757770|Biological|Rotarix|Two oral doses.
45841363|NCT05821712|Drug|0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride Mouthwash|mouthwash
46044892|NCT02866656|Other|Conventional conservative treatment|Treatment last for 4 weeks, three times a week,
46044893|NCT02866656|Device|therapeutic ultrasound|Treatment last for 4 weeks, three times a week, stimulation was given 8 minutes every time, location of treatment were lower limb ischemia area and its surrounding tissues；
45349509|NCT00757770|Biological|Placebo|Two oral doses; The placebo consist of all components of the study vaccine i.e. excipients and buffer, but no RV particles.
45841364|NCT05821712|Drug|0.057% sodium fluoride Mouthwash|mouthwash
45841365|NCT05821686|Drug|Proleukin 1.3 MG Injection|All the recruited participants will receive 4 intra-lesional injections of Interleukin-2 with a dose of 250,000 international units (IU) per mm width of tumor to max dose of 10 million IU.
45841366|NCT05821673|Procedure|Argon plasma pre-treated abutment insertion|abutments allocated to the test group were placed in an Argon plasma reactor (Diener Electronic GmbH, Jettingen, Germany) for decontamination and activation. In order to restrict any post-treatment contamination; abutments were inserted immediately after the end of the plasma process. The reactor was set at 75 W of power and -10 MPa of pressure for 12 min.
45841367|NCT05821673|Procedure|abutment insertion|the abutments assigned to the control group were screwed onto the implants without receiving argon plasma pretreatment
45841368|NCT05821660|Other|Five-day hypocaloric and ketogenic programme|Dietary intervention
45841369|NCT05821647|Other|HPI guided treatment advice|Administer hemodynamic altering intervention aimed at either a preload, contractility, or afterload problem to prevent impending hypotension. Treatment options include: administering either fluids, inotropes, vasopressors, positional changes, or a combination.
45841370|NCT05821621|Other|no intervention|observational study : there is no intervention
45349510|NCT04847648|Procedure|Air-polishing|Air-polishing with erythritol powder during non-surgical therapy (at baseline, 5 seconds per surface, and, if necessary, at 3 months).
45349511|NCT04847648|Procedure|Mechanical decontamination|Mechanical instrumentation of implant surfaces during non-surgical therapy (at baseline and, if necesarry at 3 months) including the use of hand instruments and polishing cups aiming at the removal of all soft and hard deposits from the target implant.
45349512|NCT02544555|Procedure|Intentional intraluminal approach|Interventionist performs intentional intraluminal approach to angioplasty. Dedicated 018 and 014 guidewire for Chronic Total Occlusion (CTO) lesion and Chronic Total Occlusion (CTO) devices such as Truepath or Frontrunner can be chosen by interventionist. Methods to confirm successful intraluminal wiring will be selected, as follows; 1) examination for guidewire position in different two angles on fluoroscopy or 2) intravascular ultrasound (IVUS) exam after predilation is performed with an appropriately sized angioplasty balloon. After the guidewire is passed through the lumen of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed, if the case that optimal ballooning response is not obtained.
45349513|NCT02544555|Procedure|Intentional subintimal approach|Interventionist performs Intentional subintimal approach to angioplasty. 035 Terumo guidewires will be used. If 035 Terumo guidewire is not able to re-entry, Re-entry devices such as Offroad or OUTBACK catheter can be used. After the guidewire is passed through the subintimal layer of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed; the case that optimal ballooning response is not obtained should be enrolled. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.
45349514|NCT00753168|Drug|OT-730 ophthalmic solution|one eye drop twice daily
45476142|NCT02422641|Drug|High-dose Methotrexate (8 gm/m2; HD-MTX)|Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
45476143|NCT03628040|Drug|Ropivacaine Injection [Naropin]|Ropivacaine will be injected in the erector spinae plane
45841371|NCT05821582|Other|Stool Collection and Survey Completion|Participants will have 2 scheduled at-home stool self-collections at the time points specified in section 4.0 and complete a questionnaire by telephone contact. The biospecimens collected from participants on this study are stool samples.
45349515|NCT00753168|Drug|timolol maleate ophthalmic solution|one eye drop twice daily
45349516|NCT00753168|Drug|OT-730 placebo|one eye drop twice daily
45349517|NCT02565602|Other|Ca-41(isotope tracer)|Ca-41 is given orally in the form of (Ca-41)Cl3 in citrate-buffered solution. Tracer will be used to determine parameters of calcium metabolism based on tracer excretion data.
45349518|NCT02565602|Other|Sr-84 (isotope tracer)|Sr-84 is given orally in the form of (Sr-84)Cl2 in aqueous solution.Tracer will be used to determine parameters of strontium metabolism based on tracer excretion data.
45349519|NCT02565602|Dietary Supplement|Vitamin D|One tablet daily (400IU per tablet)
45349520|NCT00866463|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
45349521|NCT00866463|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
45349522|NCT00866463|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
45476144|NCT03628040|Drug|Normal saline|Normal saline will be injected in the erector spinae plane
45841372|NCT05821569|Other|Standard approach|Adoption of standard approach (derived by Unicef guidelines) to breastfeed
45841373|NCT05821569|Other|Biological nurturing|Adoption of biological nurturing approach to breastfeed
45841374|NCT05821517|Device|Helmet virtual reality.|"Use of a  virtual reality  (VR) headset of  Pico G2  type with  HypnoVR  software and audio headset  Taotronics BH22  during all the reduction care"
45841375|NCT05821517|Drug|Administration of METHOXYFLURANE|Self administered inhalated methoxyflurane (maximal inhaled dose : 3 mL)
45349523|NCT04051164|Other|Progressive Muscle Relaxation Technique|"PMRT begins by assuming a comfortable position of lying down, sitting or leaning back.~Patient is asked to take a breathe in and intentionally contract muscle and hold muscle and after that release all tension and focus on sensation of relaxation. Each muscle group is tensed for 5-7 seconds and relaxed for 20-30 seconds. PMRT is given twice a day for one week."
45476145|NCT04715763|Drug|Telmisartan Oral Product|Angiotensin Receptor Blocker (ARB) FDA approved for use in hypertension and for cardiovascular risk reduction
45476146|NCT04715763|Drug|Placebo|Gelatin capsules filled with an inactive ingredient
45476147|NCT04487210|Biological|MVC-COV1901|MVC-COV1901 is formulated in the different dosages of Spike (S) protein with CpG 1018 and aluminum content as adjuvant.
45476148|NCT01295411|Device|Magnetic Resonance Imaging|
45476149|NCT01295411|Other|EVALUATION NEUROPSYCHOLOGICAL|
45476150|NCT01330173|Drug|Vismodegib|Given PO
45476151|NCT01330173|Other|Pharmacological Study|Correlative studies
45476152|NCT01330173|Other|Laboratory Biomarker Analysis|Correlative studies
45476153|NCT04603300|Drug|INT301|INT301 is an allergy immunotherapy delivered in the form of a fully functional toothpaste
45476154|NCT04603300|Drug|Placebo|Fully functional toothpaste containing no immunotherapy agents
45476155|NCT05666960|Drug|R-3750|Probiotic
45476156|NCT04440462|Other|Sugar and water solution|2 ml of a water and sugar solution (3 full-teaspoons of granulated sugar dissolved in half glass of water)
45476157|NCT04440462|Other|Sterile water|2 ml of sterile water
45476158|NCT03848741|Behavioral|Non-Exercise Control|Participants will not perform structured exercise and will continue with their normal physical activity for 12-weeks.
46044894|NCT00812929|Drug|Placebo|The current study will include a placebo arm to allow for a valid evaluation of adverse events attributable to GSK2190915 versus those independent of GSK2190915.
46044895|NCT00812929|Drug|GSK2190915|This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.
45476159|NCT03848741|Behavioral|Resistance Exercise Training|Participants will complete a 12-week whole-body progressive resistance exercise training program.
45476160|NCT03848741|Dietary Supplement|Placebo|Participants will be given placebo capsules to consume for 12-weeks.
45476161|NCT03848741|Dietary Supplement|HMB+VitD|Participants will be given HMB+VitD capsules to consume for 12-weeks
45476162|NCT03356626|Device|ULTRACISION Harmonic Scalpel|to use ULTRACISION Harmonic Scalpel when performing gastrectomy
45685402|NCT01893736|Other|Postpartum telephone follow-up support|Postpartum telephone follow-up support will consist of telephone support 72 hours after hospital discharge and weekly for the first 4 weeks, or until weaned. Earlier telephone contacts will focus more on breastfeeding topics. Information will be solicited from the participants about problems or difficulties they are experiencing. Supportive advice will be provided regarding management of breastfeeding problems, and support and encouragement for the continuation of breastfeeding. Later contacts will focus more on advice and encouragement on breastfeeding while resuming daily activities or returning to work, nursing in public places, and expressing and storing breast milk.
45685403|NCT02672644|Device|Emervel Classic|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Classic (moderate NLFs; WSRS = 3/3)
46044896|NCT04034017|Other|no intervention|descriptive study, no intervention
46044897|NCT05326555|Diagnostic Test|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System|Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
46044898|NCT00824161|Drug|TAS-109|"14-day continuous central intravenous infusion at a dose of 2.0 mg/m2/day followed by a 7-day rest period.~Number of cycles: until unacceptable toxicity or disease progression requires discontinuation."
45476163|NCT03356626|Device|Ligasure Maryland|to use Ligasure Maryland when performing gastrectomy
45476164|NCT03356626|Device|Thunderbeat|to use Thunderbeat when performing gastrectomy
46044899|NCT02610829|Dietary Supplement|Gamma tocopherol|3 doses of 1400 mg gamma tocopherol (2 capsules, each is 700mg), at 12 hour intervals
45476165|NCT04540458|Other|3D printed model|Mother or Mother/Father is given 3D printed model of fetus' face
45476166|NCT04540458|Other|Placebo|Mother or Mother/Father is given a picture of 3D ultrasound of fetus
45476167|NCT01295489|Other|Laboratory Biomarker Analysis|Correlative studies
46044900|NCT00979134|Drug|AZD4547|Single dose is followed by washout 5-10 days before multiple dose, and at dose of 80mg twice daily
46044901|NCT00979134|Drug|AZD4547|Patients start at a dose of 80 mg twice daily, with no washout
46044902|NCT00979134|Drug|AZD4547|Single dose is followed by washout 5-10 days before multiple dose
46044903|NCT00824005|Biological|Adult stem cells|Single procedure of intramyocardial electromechanical-guided injection of approximately 100 million bone marrow mononucleated cells (BM-MNCs), administered in 15 different injection sites
45349524|NCT04051164|Other|Conventional treatment|Strengthening exercises of residual limb: After amputation strengthening exercises of residual limb is necessary to prevent shortening of muscles and tightening of joints, moreover it is necessary to make residual limb strong and flexible in order to use a prosthesis. This include Hip abduction, prone hip extension and Prone position. Gait training: This include standing exercises in the parallel bars with or without the prosthesis. Initial walking exercises in which the patient is taught to raise each knee alternately and to try to take weight on his limb as much as possible. Deep Breathing exercise: Deep breathing 10-15 repetitions twice a day.
45476168|NCT04361266|Device|Rotium nanoscaffold|Rotium bioabsorbable nanoscaffold placed between bone-tendon interface of rotator cuff repair construct
45476169|NCT04361266|Procedure|Control arm rotator cuff repair|Standard rotator cuff repair without Rotium
45685404|NCT02672644|Device|Emervel Deep|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Deep (severe NLFs; WSRS = 4/4).
45685405|NCT02668666|Drug|Palbociclib|Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.
45685406|NCT02668666|Drug|Tamoxifen|Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously).
45685407|NCT05586646|Dietary Supplement|alanyl-glutamine|Amino acid solution for parenteral nutrition containing dipeptide alanyl-glutamine
46044904|NCT00824005|Biological|Placebo|Single procedure of intramyocardial electromechanical-guided needle insertions and injection of 5% human serum albumin and saline in 15 different injection sites
46044905|NCT04289844|Other|Elastic-explosive and resistance strength|"The resistance exercises are: running (3 minutes), 2 farmers carrying marching, 3 side to side ankle hops, 4 plyo lunge jump, 5 lateral jump over barrier, 2 monopodalic jump with ball pass, 3 board throw with half court sprint, 4 lateral shuffle mirror, and 5 combo finisher 4x4.~Plyometric exercises are: ankle rotations, knee extension, squat, hip flexion-extension, knee and ankle, ankle mobilizations, squat with rise, pelvis ante / retroversion, global mobilization, stride"
46044906|NCT04289844|Other|Elastic-explosive strength|Plyometric exercises are: ankle rotations, knee extension, squat, hip flexion-extension, knee and ankle, ankle mobilizations, squat with rise, pelvis ante / retroversion, global mobilization, stride
46044907|NCT04104672|Drug|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor.
45349525|NCT03823118|Drug|S1/Anlotinib|Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
45476170|NCT04659746|Device|MejoraCare|mHealth solution to support remote monitoring of symptoms and patient empowerment through education.
45476171|NCT04338828|Drug|Nitric Oxide Gas|Inhaled NO administered at target inspired concentration 140 - 300 ppm for 20-30 minutes
45476172|NCT04338828|Other|Inhaled Supplemental Oxygen|2 L/min oxygen therapy
45476173|NCT01295567|Drug|Dipyridamole|prior to CABG surgery 3 day treatment with dipyridamole 200mg SR twice daily
45476174|NCT01295567|Drug|placebo|prior to CABG surgery 3 day treatment with placebo capsules twice daily
45685408|NCT05586568|Drug|XZP-3621 tablet and itraconazole oral liquid (for Arm1)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1. For period 2,the subjects will take itraconazole from Day11 to Day13，they will take itraconazole in combinaiton with XZP-3621 on Day14，then take itraconazole only, from Day15 to Day27.
46044908|NCT04104672|Drug|Zimberelimab|Zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1.
45349526|NCT00866541|Device|artificial increased resistance (flow proportional pressure support)|respiratory resistance is increased by interpose of an artificial resistance tool in the in- and expiratory airways of the mechanical respirator
45349527|NCT00695864|Drug|Ondansetron and Placebo crossover|
45349528|NCT00684996|Drug|etaracizumab|Given IV
45349529|NCT00684996|Biological|bevacizumab|Given IV
45349530|NCT04841408|Other|Vaginal self-sampling|Vaginal self-sampling performed by the patient at the follow-up visit at 3 weeks and remote follow-up at 9 weeks.
45349531|NCT00751842|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
45349532|NCT00751842|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
45349533|NCT00751842|Drug|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270.
46044909|NCT04104672|Drug|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
45349534|NCT05325008|Drug|Immunosuppression reduction/modification + intravenous immunoglobulin|Participants will receive intravenous immunoglobulin along with immunosuppression reduction/modification.
45349535|NCT05325008|Other|Immunosuppression reduction/modification|Participants will receive immunosuppression reduction/modification.
45349536|NCT00684762|Drug|Cilostazol 100 mg Tablets|Cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours
45349537|NCT00684762|Drug|Cilostazol (Pletal®) 100 mg Tablets|Cilostazol (Pletal® 1 x 100mg tablet) administered after an overnight fast of at least 10 hours.
45349538|NCT00753246|Drug|nimotuzumab|monoclonal antibody
45349539|NCT00695786|Drug|Lenalidomide|Given PO
46044910|NCT04104672|Drug|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
45349540|NCT00695786|Biological|Rituximab|Given IV
45476175|NCT04340752|Drug|Indocyanine Green|ICG is an injectable fluorescent pigment that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision. The ICG will not affect the course of the operative or postoperative period, and will be injected intravenously prior to the actual repair
45685409|NCT05586568|Drug|XZP-3621 tablet and Rifampicin capsules (For Arm 2)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets qd on Day1 . For period 2,the subjects will take Rifampicin from Day11 to Day17，they will take Rifampicin in combinaiton with XZP-3621 on day18，then take Rifampicin only, from Day19 to Day26.
46044911|NCT05756647|Device|Interventional Arm|The MAD arm will consist of participants given a fitted mandibular advancement device that they will wear for the length of the study.
45685410|NCT05586568|Drug|XZP-3621 tablet and esomeprazole tablet (For Arm3)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1 . For period 2,the subjects will take esomeprazole from Day11 to Day 15，they will take esomeprazole in combinaiton with XZP-3621 on Day16.
45685411|NCT01893814|Dietary Supplement|Probiotics|
46044912|NCT05756647|Combination Product|Conservative treatment Arm|Participant will undergo a nightly medicated nasal rinse that will occur for a 4 week period, prior to beginning of the other three conservative therapy interventions. The 4-part combination therapy will take place for 4 weeks total.
46044913|NCT02610673|Device|WiCS-LV System|Implant of left ventricular receiver-electrode and ultrasound transmitter.
46044914|NCT02865564|Dietary Supplement|Lactobacillus reuteri DSM 17938|
46044915|NCT02865564|Dietary Supplement|Placebo|
46044916|NCT02865564|Drug|ampicillin and gentamicin|
45349541|NCT02561676|Other|Education Program Type 1|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
45841376|NCT05821517|Drug|Standard of care|An anticipated analgesia protocol composed of PARACETAMOL 1g +/- OXYNORM 5 mg or 10 mg according to patients weight and pain intensity as evaluated by a simple numeric rating scale is administred prior to the reduction procedure. Inhaled equimolar mixture of oxygen and notrous oxyde (MEOPA) at a 15L/min flux is administered concomitantly to the reduction procedure.
45841377|NCT05821478|Drug|ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy|a 3-week course of ceftriaxone injection + oral metronidazole followed by a 3-week course of oral rifampicin + moxifloxacin +metronidazole followed by a 6-week course of oral rifampicin + moxifloxacin
45841378|NCT05821478|Drug|Lymecyclin and corresponding placebos of the experimental arm|12-week course of oral lymecycline.
46044917|NCT05758051|Procedure|subtrochanteric valgus osteotomy|subtrochanteric valgus osteotomy
45349542|NCT02561676|Other|Education Program Type 2|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
45476176|NCT04656080|Behavioral|CPET exercise testing|"The cardiopulmonary exercise testing (CPET) is done.~EKG testing will be done as part of the CPET test. Allosure testing will be done at baseline and then at 1 hr, 4 hrs, 1 day, 7 days after CPET."
45476177|NCT03474354|Device|chemoembolization|correlation of necrosis with the deposition of beads
46044918|NCT04290468|Device|Dynamic ultrasound|"The ultrasound examination will be carried out blinded to the results of MRI using the Affiniti 70 ultrasound machine by Philips (USA) via a 5-12MHz linear transducer.~MRI was performed on a high field system (1.5 Tesla) magnet units (Philips Acheiva)."
46044919|NCT04130022|Device|Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
46044920|NCT04289610|Device|Transcutaneous pulse radiofrequency therapy|Transcutaneous pulse radiofrequency therapy (TCPRF) is a painless and outpatient physiotherapy modality
46044921|NCT00814879|Drug|Raltegravir|400 mg BID
46044922|NCT00814879|Drug|Atazanavir|300 mg BID
45349543|NCT02560740|Dietary Supplement|PerOx Quench|By 1 week pretreatment of PerOx Quench and following 4 weeks taken to decrease the CIPN incidence.
45476178|NCT03848585|Device|Pilloxa Pillbox|A Pilloxa Pillbox is used for the prescribed immunosuppressants.
45476179|NCT03848585|Other|Non active Pilloxa Pillbox|A Pilloxa Pillbox with reminders disabled and without active mobile application is used for the prescribed immunosuppressants.
45476180|NCT05283239|Other|Follow up|Participants will be followed up at 6th，12th, 18th and 24th months with HPV viral integration/genotyping tests, thinprep cytologic tests (TCT) for cervix and vaginal secretion tests. Colposcopy and biopsy will be conducted for participants if necessary.
45685412|NCT01893814|Dietary Supplement|Control|
45685413|NCT02660320|Device|Dermabrasion|Preparing the graft bed before epidermal cell suspension The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
45685414|NCT02660320|Device|Laser placebo|The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
45685415|NCT02655406|Other|Class 2 compression stockings|
46044923|NCT00814879|Other|Standard treatment regimen|N(t)RTI(s) based backbone plus ritonavir boosted PI
46044924|NCT04289532|Drug|99mTc-RWY|99mTc-RWY were injected into volunteers and patients before the SPECT/CT scans .
46044925|NCT02866422|Other|No Intervention|Observational Study: No intervention
46044926|NCT00708409|Procedure|Cardiac valve surgery|Different autograft implantation techniques.
46044927|NCT03347422|Drug|sutimlimab (BIVV009)|Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
45841379|NCT05821465|Device|HeartWatch|The HeartWatch monitoring device will be worn on the upper left arm for the same duration or up to 48 hours that the standard event recorder or holter monitor is worn. The subject will be provided with a HelpWear smartphone that is paired to the monitor and only used by the participant to tag any events that they may have during the Heartwatch monitoring session.
45841380|NCT05821452|Drug|Camrelizumab|200mgQ3w
45476181|NCT01192529|Dietary Supplement|Supressi. T-Diet plus Range|"Supressi is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patients with neurodegenerative diseases and related malnutrition.~Experimental group patients will receive, 2 packs per day (Tetra brik aseptic)of 200 ml for 6 months."
45841381|NCT05821452|Drug|Paclitaxel|175mg/m2，D1，Q3w
45349544|NCT02560740|Dietary Supplement|PerOx Quench Placebo|By 1 week pretreatment of Placebo and following 4 weeks taken to record the CIPN incidence.
45841382|NCT05821452|Drug|Cisplatin|75mg/m2，D1，Q3w
45349545|NCT03893942|Other|Questionnaires administration|Psychological and quality of life questionnaires
45349546|NCT03893942|Other|Langer Mindfulness Scale (LMS)|The LMS is a 21-item questionnaire, assessing four domains associated with mindful thinking: novelty-seeking, engagement, novelty producing, and flexibility.
45349547|NCT03893942|Other|Mindful Attention Awareness Scale (MAAS)|The MAAS is a 15-item questionnaire, designed to assess a core characteristic of dispositional mindfulness, namely, open or receptive awareness of and attention to what is taking place in the present
45841383|NCT05821452|Radiation|Radiotherapy|41.4Gy, 1.8Gy each time, 5 times a week
45841384|NCT05821426|Device|eTrieve PE Kit|Patients will be treated with the eTrieve PE Kit
45841385|NCT05821400|Other|observational study|observational study
45841386|NCT05821374|Drug|Deucravacitinib|6 mg tablet
45841387|NCT05821361|Drug|HAIC+Cadonilimab+Bevacizumab|Cadonilimab: 10mg/kg, iv,q3w Bevacizumab: 7.5mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
46044928|NCT03347422|Drug|placebo|Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
46044929|NCT00814801|Drug|Placebo|Form= tablet, route= oral use. Corresponding placebo tablets confirmed to be indistinguishable from the galantamine tablets will be administered for 24 weeks.
46044930|NCT00814801|Drug|Galantamine 16 mg/day|Type= exact number, number= 8, 16, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, and 16 mg galantamine daily for the remaining 20 weeks.
46044931|NCT00814801|Drug|Galantamine 24 mg/day|Type= exact number, number= 8, 16, 24, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, then 16 mg galantamine daily for the following 4 weeks, and 24 mg galantamine daily for the remaining 16 weeks.
45841388|NCT05821348|Diagnostic Test|salivary markers|a description of the salivary biochemical profile of GER infants vs. GERD, so that we can develop non-invasive diagnostic strategies and detect personalized therapeutic treatments.
45841389|NCT05821322|Other|Physical activity trial intervention|60 minutes aerobic ergocyle exercice at 60% VO2 Peak
45841390|NCT05821283|Other|exercise program consisting of supervised exercise and physical activity|The Treatment Group (TG) will be included in an exercise program consisting of supervised exercise and physical activity (30 minutes of moderate-intensity walking).
45841391|NCT05821283|Other|exercises program consisting of only supervised exercises.|The Control Group (KG) will be included in the program consisting of only supervised exercises.
45841392|NCT05821270|Other|Ashtanga Vinyasa Yoga Supta|Ashtanga (asta - eight, anga - parts); Vinyasa (freely sequenced practice); Yoga (practice for evolution); Supta (closed eyes)
45841393|NCT05821257|Other|Evaluation of the arm swing during gait|Evaluation of the arm swing during gait: The difference between the maximum flexion and extension of the shoulder is the arm swing amplitude during walking. The arm swing amplitude will be evaluated 2-dimensionally with the help of the Kinovea video player.
45841394|NCT05821257|Other|Functional Tests|To understand the changes in functional mobility, Two Minute Walk Test (2MWT), Timed Up and Go (TUG) and Timed 25Foot Walk Test (T25FW) were conducted.
45841395|NCT05821244|Behavioral|Exercise Timing Groups|Individualized resistance training program, consisting of twice weekly training sessions supervised via telehealth with a cancer exercise trainer.
45841396|NCT05821205|Behavioral|Narrative Persuasion|Narratives will use anonymous testimonials from our prior work combined with open-source pictures. The researchers will ask participants to rate the testimonial message as a measure of engagement.
45841397|NCT05821205|Behavioral|Reciprocity|Researchers will track clicking on the gift card as a measure of engagement
45841398|NCT05821205|Behavioral|Personalized Feedback|Researchers will track clicking on a link and/or opening to review visual data as a source of engagement.
45841399|NCT05821205|Behavioral|Commitment|Providers will receive a commitment message and be asked to reply as a measure of engagement.
45841400|NCT05821192|Drug|Rituximab|375mg/m2 by IV infusion once every 3 weeks
45841401|NCT05821192|Drug|Gemcitabine|1 g/m2 on Days 1 by IV infusion once every 3 weeks
45841402|NCT05821192|Drug|Dexamethasone|40 mg on Days 1 to 4 of each 3-week cycle by IV infusion
45841403|NCT05821192|Drug|Cisplatin|75 mg/m2 on Days 1 by IV infusion once every 3 weeks
45841404|NCT05821192|Drug|PD-1 monoclonal antibody|200mg on Days 2 by IV infusion once every 3 weeks
46044932|NCT00708487|Other|Embryo incubator oxygen concentration|Two concentrations of oxygen are currently used to culture the embryos of infertile patients in commercial human IVF programs - 21% and 5%.
46044933|NCT02638558|Other|written + oral explanation|
45349548|NCT03893942|Other|Cognitive Flexibility Scale (CFS)|The CFS is 12-item self-report test assessing awareness.
46044934|NCT02638558|Other|written explanation|
45841405|NCT05821166|Device|moderate Whole Body Hyperthermia (mWBH)|Patients receiving 3-4 times mWBH
46044935|NCT04164628|Other|Quality of life assessment|Quality of life will be assessed with Nottingham Health Profile
46044936|NCT00823615|Device|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
46044937|NCT00823615|Device|Senofilcon A multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
46044938|NCT00653458|Drug|Ondansetron|ODT, 8 mg, single-dose, fed conditions
45349549|NCT03893942|Other|Life Orientation Test (LOT)|The LOT is a 10-item, self-administered scale assessing generalized expectancies for positive versus negative outcomes.
45349550|NCT03893942|Other|Mini Locus of Control test (MLS)|The MLS is a 6-item questionnaire that includes 3 factors : chance, powerful others, and internality.
45841406|NCT05821153|Drug|Aldesleukin|Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells
45841407|NCT05821140|Procedure|dental treatment for global oral rehabilitation|dental treatment can include conservative, orthodontic, prosthetic or surgical procedures
46044939|NCT00653458|Drug|Zofran|ODT, 8 mg, single-dose, under fed conditions
46044940|NCT05757973|Drug|Talquetamab|Talquetamab will be administered subcutaneously.
45841408|NCT05821140|Other|oral health check up|regular preventive follow-up visit (every 6 months)
45841409|NCT05821127|Behavioral|Virtual Reality Assisted Neurodynamic Exercises and Patient Education with Telerehabilitation Method|A brochure showing the execution of median nerve and tendon gliding exercises and a wrist brace for night use will be provided. In addition, 2 sessions of patient education will be provided with videoconference calls, and with the mobile application to be installed on the phones of the patients as non-immersive virtual reality support, it will be possible to practice median nerve and tendon gliding exercises in the form of 5 repetitions and 6 sets every day with video support for 16 weeks. In this application, the user will use the front camera of phone as a sensor to detect hand movements. A screen on which exercises will be played at the top of the screen and a virtual image of the user's hand in the lower half of the screen will be displayed in the field of view of the camera. Each exercise position will take 5 seconds. Patient education will include neuroscience, etiology, pathophysiology and treatment options of carpal tunnel syndrome, ergonomics and posture education.
46044941|NCT02708836|Procedure|Induction of anesthesia|At the discretion of the primary anesthesiologist. Typically involves the administration of an analgesic agent, hypnotic agent, and neuromuscular blocking agent
46044942|NCT02708836|Device|Placement of LMA [Ambu (R) AuraGain (TM) disposable laryngeal mask]|By standard method. Sizing at the discretion of the primary anesthesiologist.
46044943|NCT02708836|Device|Laryngoscopy and placement of ETT|Via direct or indirect laryngoscopy. Sizing at the discretion of the primary anesthesiologist. Mallinckrodt (TM) Intermediate Hi-Lo cuffed endotracheal tube (Covidien)
46044944|NCT02708836|Procedure|Ventilation via the ETT|Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
45349551|NCT03893942|Other|Hospital Anxiety and Depression Scale (HADS)|The HADS is a 14-items rated on a four-point Likert scale. The questionnaire was designed to screen for the presence and severity of depression (HADS-D) and anxiety (HADS-A) in people with a physical symptomatology
45349552|NCT03893942|Other|Perceived Stress Scale (PSS)|The PSS is 14-item self-report tool commonly used to provide a global measure of perceived stress in daily life.
45349553|NCT04049838|Procedure|postoperative analgesia for lower abdominal surgery in children|compare lateral and posterior approaches of trannsversus abdominis plane block for analgesia after lower abdominal surgery in children
45349554|NCT00753324|Drug|Routine three-drug antiretroviral prophylaxis|Women who are identified as HIV-infected will be offered routine combination antiretroviral prophylaxis starting at 28 weeks gestation (timing consistent with Zambian national guidelines for short-course ZDV). The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and either NVP or lopinavir / ritonavir. In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T). In accordance with the Zambian national guidelines, any patients who are started on NVP will begin with a once daily dose for two weeks before increasing to the regular twice daily schedule
45349555|NCT00757926|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV]|Three oral doses of the vaccine (0.5 ml each) following oral administration of antacid.
45349556|NCT00757926|Other|Placebo|Three oral doses of the placebo (0.5 ml each)following oral administration of antacid.
45349557|NCT02560662|Behavioral|Physical activity|"Preoperative intervention - takes place from randomization until surgery (4 weeks +/-2 w):~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Postoperative intervention - takes place from discharge from the hospital until 4 weeks postoperatively:~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Participants randomized to intervention will receive a visit to a physiotherapist for personally adjusted information regarding the intervention, later followed up with a telephone call."
45349558|NCT02561520|Biological|PRP eye drops|Eye drops 4x a day, patients will start this eye drop first.
45841410|NCT05821127|Behavioral|Neurodynamic Exercises and Patient Education with Traditional Method|A brochure showing the execution of median nerve and tendon gliding exercises and a wrist brace for night use will be provided. Patients will be asked to do the exercises in the form of 5 repetitions and 6 sets every day and to wear the night splint every night for 16 weeks. Each exercise position will take 5 seconds. A brief verbal education will be given to the patients under the same topics as the intervention group, as in the outpatient clinic.
45841411|NCT05821114|Other|Head elevation_H|High flow_Head-elevation
45841412|NCT05821114|Other|Supine_H|High flow_Supine
45841413|NCT05821114|Other|Head elevation_L|Low flow_head elevation
45841414|NCT05821114|Other|Supine_L|Low flow_supine
45841415|NCT05821062|Other|standard Aspirin (ASA) + clopidogrel (CLP) therapy|ASA100mg + CLP 75mg daily
45841416|NCT05821062|Other|standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy|ASA 100 mg + TCG 90mg/b.i.d or PSG10mg daily
45841417|NCT05821062|Other|standard ASA therapy|ASA 100 mg daily
45847589|NCT04498416|Diagnostic Test|Quantitative and qualitative assessments of mental health|Emergency semi-directed interview; Diagnosis Infant and Preschool Assessment (DIPA); Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS); Conners Scale - short version;Weiss functional impairment rating scale - parent (WFIRS); Parenting stress index-short form (PSI-SF); Anxiety Scale
46044945|NCT02708836|Procedure|Removal of the ETT|Either upon emergence of anesthesia after suctioning of the oropharynx and after a positive pressure breath or while deeply anesthetized after release of the pneumoperitoneum in the combined LMA/ETT group.
45841418|NCT05821036|Behavioral|Activitiy Management|"Activity Management training will be applied for 5 weeks, 2 sessions per week, and the 1st and 10th sessions will be pre and post-training evaluation, a total of 10 individual, internet-based sessions.~Week 1:Awareness training and ergonomics training including spine anatomy, correct posture use, ergonomic strategies were planned to increase awareness about FMS. Week 2:Focusing on the challenging activities stated by the individuals, it is aimed to change the behavior by arranging the activity resting cycle in daily life. In addition, the management, adaptation and modification of the activities will be provided within the scope of time management training. Week 3: Joint and energy conservation principles training will be given and it is aimed to create body mechanics and proper posture suitable for activities.Week 4: Relaxation training will be provided as a method of coping with pain.Week 5: Re-evaluation/review of the targets set to reduce pain during activities will be provided."
45841419|NCT05821023|Other|messages|Different messages describing either the benefits of breast cancer screening aimed at supporting continued screening or messages describing the harms of over-screening and making recommendations to stop screening
45841420|NCT05821010|Combination Product|LFMT-capsules|Lyophilized fecal microbiota transplantation capsules
45841421|NCT05820984|Other|SPIRIT checklist plus usual practice|"Peer reviewer will be reminded of the following 10 CONSORT items (including a short description):~Outcomes (12) Sample size (14) Recruitment (15) Allocation implementation (16 c) Blinding (17 a) Data collection methods (18 a) Data collection methods - retention (18 b) Statistical methods (20 a) Population analysed (20 c) Access to data (29)"
45841422|NCT05820984|Other|Usual practice|Peer review as it is usual practice at the journal
45841423|NCT05820958|Other|Shantali massage|"The tactile contact of a mother with the newborn was intensified by means of Shantali massage applied at least 2 times a day, 10 min. Additional, spontaneous sessions were allowed as well. This started on the 3rd day after delivery and lasted until the end of the 12th week after delivery. A total of 169 mandatory sessions should have been provided plus spontaneous sessions, if any.~The order of application:~face and chest; 4 types of movements 10reps each;~upper extremity; 4 types of movements, 10 reps each (left and right separately);~abdomen; 2 types of movements, 10 reps each;~lower extremity; 3 types of movements, 10 reps each (left and right separately);~back; 2 types of movements, 10 reps each;~final integration; 3 types of movements, 10 reps each."
45841424|NCT05820945|Other|Pharmacist-led medication review|Clinical review by a primary care pharmacist of the primary care clinical history and the pharmacological treatment plan. After the review process, a meeting will be held between the pharmacist and the responsible physician in order to present proposals for pharmacotherapeutic optimization.
45841425|NCT05820919|Behavioral|LOCK Sleep Program|The LOCK sleep program is a program that trains NH staff in a NH frontline staff huddling approach. It is derived from evidence supporting strengths-based learning, systematic observation, relationship-based teamwork, and efficiency. Staff learn how to work together as a team to collaboratively problem-solving about resident sleep challenges (e.g., evidence-based sleep promoting best practices and daytime meaningful activity best practices).
45841426|NCT05820919|Other|No intervention (control period/baseline data collection)|Each NH serves as its own control. During the control period, baseline data will be collected.
45841427|NCT05820906|Drug|Cadonilimab+Regorafenib+GC|Cadonilimab:10mg/kg, iv,q3w,D1 Regorafenib: 80mg, po, orally once daily Gemcitabine:1000 mg/m2, iv, Q3W，D1,D8 Cisplatin:25 mg/m2, iv, Q3W, D1,D8
45841428|NCT05820893|Drug|Resistant Potato Starch|MSPrebiotic (MSPrebiotic Inc, Carberry, Manitoba, Canada). MSPrebiotic is an unmodified resistant starch derived from potatoes (Solanar tuberosum). It consists of 20% amylose and 80% amylopectin forming granules the stomach and small intestine are unable to digest allowing for absorption in the colon. MSPrebiotic is consumed by mixing 10g into cold or room temperature foods or beverages; it is not to be heated. Participants will be instructed to take MSPrebiotic 2 or more hours before or after consuming any medications.
45841429|NCT05820880|Drug|Fixed [Per/Ind/Aml]|Fixed Dose combination of Perindopril/Indapamide/Amlodipine
45841430|NCT05820880|Drug|Free [Per/Ind + Aml]|Free dose combination of Perindopril/Indapamide and Amlodipine
45841431|NCT05820867|Procedure|Single-Session Bilateral Mandibular Third Molar Extraction|Participants in this group chose to have both of their lower mandibular third molars extracted during a single appointment. This group will be used to compare the impact of single-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
45841432|NCT05820867|Procedure|Two-Session Bilateral Mandibular Third Molar Extraction|Participants in this group chose to have their lower mandibular third molars extracted during two separate appointments. This group will be used to compare the impact of two-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
45841433|NCT05820854|Other|Self-assess and reporting self-care self-efficacy levels|Patients will have to self-report the self-care self-efficacy levels they experienced in managing the OAC therapy.
45841434|NCT05820789|Other|Family support|Before the extubation procedure, the patient's relatives will be informed, and the patient will be allowed to enter the intensive care unit, and the patient will be able to express that he is with the patient by holding his hand and talking.
45847590|NCT04449432|Behavioral|GROWell (Interactive Obesity Treatment Approach)|Personalized messaging via cell phone to support healthy eating behaviors during pregnancy and through 6 months postpartum
45847591|NCT04449432|Behavioral|Attention Support Control|Personalized messaging via cell phone to support healthy behaviors during pregnancy and through 6 months postpartum
45847592|NCT04350606|Biological|PF-06462700|PF-06462700 is classified as an immunosuppressant/ immunosuppressive agent. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric immunoglobulin G (IgG), from hyperimmune serum of horses that are immunized with human thymus lymphocytes.
46044946|NCT02708836|Procedure|Intubation of the trachea through the LMA|With ETT using fiberoptic bronchoscope guidance.
45349559|NCT02561520|Biological|PPP eye drops|Eye drops 4x a day, patients will start this eye drops after PRP.
45349560|NCT00387127|Drug|Lapatinib oral tablets|Lapatinib is administered orally once daily.
45349561|NCT00387127|Drug|radiotherapy|Radiotherapy is given either as conventional fractionation using Two-dimensional (2D) or conformal techniques, or as Intensity Modulated Radiation Therapy (IMRT). Radiation therapy will be standardised throughout the study. Radiation therapy is given only once daily, with a dose/fraction not exceeding 2.5Gy, to a total dose of 65 Gy (IMRT) or 70 Gy (2D or 3D RT) to the gross site of disease .
45349562|NCT00387127|Drug|cisplatin chemotherapy|Cisplatin is administered intravenously at a dose of 100mg/m2 on days 1, 22 and 43 of radiotherapy (approximately Study Days 8, 29 and 50).
45349563|NCT00683592|Drug|vilazodone|titration to 40 mg tablets qd (once a day) for 8 weeks
45476182|NCT01192529|Dietary Supplement|High Protein. T-Diet plus Range|T-Diet plus High Protein is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patient with related malnutrition and with increased protein requirements.
45476183|NCT02351284|Other|Measurement|Measurement of vitamin D, PTH, and BMD changes in HIV-infected patients
45476184|NCT01195649|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients under daily life treatment according to local drug information
45476185|NCT02226796|Device|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation tool that presents a low current that induces bi-directional polarity-dependent changes in the cortex to facilitate focal, prolonged shifts in cortical excitability at or around the time stimulation is provided. Anodal tDCS (a-tDCS), in which the positively charged electrode is placed over the targeted cortical region, has been shown to increase cortical excitability (upregulation), similar to long-term potentiation (LTP). Combining a-tDCS with behavioral-based approaches has been suggested to enhance the learning process and increase the likelihood of retention.
45476186|NCT03056690|Drug|ASP0819|Oral capsule
45476187|NCT03056690|Drug|Placebo|Oral capsule
45476188|NCT04895267|Device|Low-field thoracic magnetic stimulation (LF-ThMS)|A 30 minutes session of low-field thoracic magnetic stimulation (LF-ThMS) is planned for each participant.
45476189|NCT04500964|Device|TAVR|Trancatheter aortic valve replacement
45476190|NCT03846557|Device|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of the Acurate Neo Transcatheter Heart Valve
45476191|NCT03191799|Drug|Emicizumab|Initial dosing will be 3 mg/kg/week subcutaneously for 4 weeks; Maintenance dosing will follow at 1.5 mg/kg/week subcutaneously for the remainder of the 2-year treatment period
45476192|NCT03845309|Behavioral|Self-Care Behavior|Limitations on liquid and sodium intake will be established in accordance with the NYHA functional classification, and patients will be provided with dietary assessments and nutrition advice according to personal characteristics such as age, physical activity level, and comorbidities. Additionally, suggestions on lifestyle changes were provided by referring to the advice for patients with heart failure from the American Heart Association.
45476193|NCT04647656|Device|Hyperbaric oxygen|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
45476194|NCT04647656|Device|Sham|Each session will include exposure of 90 minutes to 21% at 1.2 ATA during the first five minutes of the session with the noise of circulating air, and then decrease slowly during the next five minutes to 1.03 ATA
45476195|NCT01195727|Drug|Apixaban|
45476196|NCT04639388|Behavioral|neuropsychological testing, questionnaires and experimental tasks|Neuropsychological testing (the Sky Search subtest from the Test of Everyday Attention for Children (TEA-Ch); the Overlapping lines task of Rey; auditory attention of NEPSY II battery); questionnaires completed by the children's legal representatives to assess behavior; experimental tasks evaluating gaze direction and facial expression recognition
45476197|NCT03848507|Drug|albumin 20%|Intravenous administration of 20% albumin during cystectomy
45685416|NCT02649166|Device|Deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, thalamic leads to be implanted in the ventral intermediate nucleus (Vim), and subdural cortical strips. The deep brain stimulation system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for deep brain stimulation. At 6 months, the investigators will determine whether or not the subject is a candidate for closed-loop deep brain stimulation. Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. These subjects will been seen every 6 months for evaluation as part of normal clinical care for deep brain stimulation.
45847593|NCT04340856|Procedure|colon surgery|There are no guidelines to direct surgical therapy in patients with chronic megacolon. Historically, it is the surgeons individual choice to use one of the above mentioned surgical treatments. Therefore, the aim of this study is to analyze the success and downsides of the different surgical approaches.
45349564|NCT00683592|Drug|placebo|placebo
45349565|NCT00695396|Drug|Placebo|Matching volume 2 mLfor 48 weeks
45349566|NCT00695396|Drug|Epoetin alfa|40,000 IU subcutaneously once every week (1 mL dose) for 48 weeks
45349567|NCT00695396|Drug|Placebo|Matching volume 1 mL for 48 weeks
45476198|NCT04958876|Drug|SP-104|oral capsule once daily
45476199|NCT04958876|Drug|Naltrexone immediate release oral capsules|oral capsule once daily
45476200|NCT01195805|Drug|Spironolactone|1 tablet twice a day for 28 days
45476201|NCT01195805|Other|Placebo|1 tablet twice a day for 28 days
45476202|NCT01195805|Drug|Amiloride|1 tablet twice a day for 28 days
45349568|NCT00695396|Drug|Epoetin alfa|80,000 IU subcutaneously once every week (2 mL dose) for 48 weeks
45476203|NCT03627962|Other|gaze-directed oculomotor training|"Device: Tobii PCEye~Protocol: Visual span was calculated by the distance between human-computer and dpi of fonts. Pointer speed was programmed 120pixels (5 degrees)/1sec for image drift of reading.~Dosage: 1) gaze-access required 20 to 10 degrees per fixation to activate text-to-speech (TTS) read-aloud function; about 30 repetitions of saccade and fixation.~2) gaze-directed OMT limited to 10-5 degrees. Chinese characters recognition in multiple choice format, about 60 repetitions.~Target behavior - gaze-directed access by Tobii PCEye: reading from left to right (=horizontal mouse mover); read-aloud function by gaze dwell > 500ms. To enhance purposeful and repetitive eye movement.~Frequency: 2 session/wk x 8 wks~Duration: 30 min/session"
45476204|NCT01192607|Device|Endoscopic treatment during root canal treatment|Endoscopic treatment during root canal treatment
45476205|NCT04899986|Other|Chlorhexidine and Biorepair gel and toothpaste application|Split-mouth application of chlorhexidine gel 1% (quadrants 1 and 4) and Biorepair Periogel (quadrants 2 and 3) after professional dental hygiene. Home oral care will be continued with chlorhexidine 0,12% gel and Biorepair Periogel in the same quadrants, for the following 15 days from the visits, together with the use of Biorepair Parodontogel toothpaste.
45841435|NCT05820776|Other|pulmonary rehabilitation|The intervention is PR delivered via a telemedicine. The intervention is PR delivered via a telemedicine. The program is delivered by the multidisciplinary via a remote application for two sessions per week for ten weeks. Remotely supervised exercise includes: 1) deep breathing reinforcing pursed lip and diaphragmatic breathing; 2) warm up breathing and stretching exercise; 3) a cardiorespiratory aerobic exercise battery; 4) resistance training, and; stretching cool down. There is also an educational component. The secondary (maintenance) program includes ongoing remotely supervised exercise and education once a week for six months (24 sessions). All patients successfully completing the initial PR are offered the maintenance program.
46044947|NCT02708836|Procedure|Ventilation via the LMA|After removal of the ETT. Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
46044948|NCT02708836|Procedure|Emergence from anesthesia|"At the discretion of primary team. Airway device (either ETT or LMA) will be removed when patient is adequately ventilating and able to respond to commands (such as open your eyes or squeeze my hand)."
46044949|NCT00708565|Drug|iloprost|Baseline echo measurements, cardiac output, pulse oximetry will be taken. Subjects will then be given one dose of inhaled iloprost. Post-inhalation, the measurements will be repeated at rest and with exercise.
46044950|NCT02638246|Behavioral|Internet-delivered, Incentive-based intervention + Motivational Interviewing|Blood glucose monitoring was verified by videos uploaded to a secure server. Participants in the experimental group received incentives for adherence whereas participants in the control group received adherence independent of adherence.
46044951|NCT02638246|Behavioral|Internet-delivered, non-contingent incentives + Motivational Interviewing|
45349569|NCT00753402|Biological|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (~5 minutes)
45349570|NCT00753402|Biological|Endotoxin, Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (~5 minutes/Epinephrine 30mcg/kg/min
45349571|NCT05434884|Procedure|occlusal veneer restorations|"occlusal veneer preparation with circumferential chamfer finish line and proximal slot  proposed modified occlusal veneer design for rehabilitation of moderate level of permanent first molars. OrPatients will receive endocrown restorations for rehabilitation of sever level of permanent first molars"
45476206|NCT04899986|Other|Standard oral hygiene|Use of standard toothpastes for home oral hygiene.
45685417|NCT02649166|Device|Closed-loop deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, Vim thalamic leads, and subdural strips. Six months post-surgery, the deep brain stimulation system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for deep brain stimulation. Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention.
45685418|NCT02632708|Drug|AG-120|
45685419|NCT02632708|Drug|AG-221|
45685420|NCT02632708|Drug|cytarabine|
45685421|NCT02632708|Drug|daunorubicin|
45685422|NCT02632708|Drug|idarubicin|
45685423|NCT02632708|Drug|mitoxantrone|
45685424|NCT02632708|Drug|etoposide|
45685425|NCT02624908|Drug|canagliflozin|Subjects randomized to active drug will receive canagliflozin 100 mg . If study drug well tolerated, dose will be increased to 300 mg canagliflozin at Visit 4.
45685426|NCT02624908|Drug|placebo|Subjects randomized to placebo will receive 100 mg placebo pill . If study drug well tolerated, dose will be increased to 300 mg placebo pill at Visit 4.
45685427|NCT02621476|Behavioral|Standardized intervention|Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service
45685428|NCT02621476|Behavioral|Usual care|Usual care
45685429|NCT02616406|Device|GENEactiv|To wear a monitoring device for a period of time prior to surgery and post surgery
45685430|NCT02614534|Drug|MITOMYCIN-C 30 mg|Proactive cytoreductive surgery: Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women) plus HIPEC with Mytomicin C for 60 minutes.
45349572|NCT05434884|Procedure|endocrown restorations|endocrown restorations
45685431|NCT02614534|Procedure|Proactive cytoreductive surgery|Proactive cytoreductive surgery: Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women)
45841436|NCT05820763|Drug|Selinexor|Selinexor is administered by mouth on Days 1, 8, 15, and 22 at a dose of 60 mg during the four cycles of consolidation. Selinexor is then decreased to 40 mg and administered by mouth on Days 1, 8, 15, and 22 for up to 8 cycles of maintenance therapy.
45685432|NCT02608216|Drug|[18F]FLT|[18F]FLT PET/CT scan, imaging tracer
45841437|NCT05820763|Drug|Lenalidomide|"Lenalidomide is administered by mouth daily on Days 1 to 21 at a dose of 10 mg during the first three cycles of consolidation, and then titrated up to 15 mg on Days 1 to 21 for the fourth cycle of consolidation. Lenalidomide 15 mg by mouth daily on Days 1 to 21 can be continued for up to 8 cycles of maintenance therapy.~For patients with baseline renal dysfunction, the starting dose of lenalidomide will be 2.5 mg or 5 mg by mouth daily on Days 1 to 21. Patients may titrate up per physician discretion."
45841438|NCT05820763|Drug|Dexamethasone|Dexamethasone is administered by mouth on Days 1, 8, 15, and 22 at a dose of 20 mg during all four cycles of consolidation only.
45841439|NCT05820750|Device|photodynamic therapy|root canal treatment of primary molars using photodynamic therapy
45841440|NCT05820750|Procedure|pulpectomy with metapex|root canal treatment using standard technique
45841441|NCT05820685|Drug|Standard of care|Participants in this arm will get acetaminophen 1000 mg every six hours, naproxen 500 mg every 12 hours, gabapentin 300 mg every eight hours, and Tramadol 50 mg every six hours as needed for breakthrough pain
45841442|NCT05820685|Drug|Dronabinol|Participants in this arm will get Dronabinol 10 mg in addition to standard of care pain medication as needed for breakthrough pain
45841443|NCT05820672|Other|No intervention|No intervention
45841444|NCT05820659|Behavioral|peer rejection task|Adolescents will be informed that two peers will take turns to choose who they will chat with for different topics. Participants will not be chosen by virtual White peers 75% of the time. In reality, White peers are computerized avatars and whether or not adolescents are chosen by those peers is programmed with E-prime software.
45841445|NCT05820620|Procedure|TAP block|The transversus abdominis plane (TAP) block was introduced as a landmark-guided technique via the triangle of Petit to achieve a field block. It involves the injection of a local anesthetic solution into a plane between the internal oblique muscle and transversus abdominis muscle.
45841446|NCT05820620|Procedure|QLB block|"Quadratus lumborum block is a block of the posterior abdominal wall, interfascial plane block, which is performed exclusively under ultrasound guidance. It was described as a variant of the TAP block."
45841447|NCT05820620|Other|Control Group|Control Group + Patient Control Analgesia (PCA)
45685433|NCT02608216|Device|PET/CT|[18F]FLT PET/CT scan
45685434|NCT02608216|Drug|ribociclib|therapeutic
45685435|NCT02608216|Drug|paclitaxel|therapeutic
46044952|NCT00812461|Drug|Placebo|as-needed use, tablets, orally, 6 months
46044953|NCT00812461|Drug|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
45349573|NCT00758004|Drug|Atorvastatin|A single dose of 80 mg atrovastatin tablet
45349574|NCT00758004|Drug|Atorvastatin pediatric appropriate formulation|A single dose of pediatric appropriate atorvastatin 80 mg formulation
45349575|NCT05388006|Drug|Acalabrutinib|Given PO
45349576|NCT05388006|Biological|Durvalumab|Given IV
45349577|NCT05388006|Drug|Venetoclax|Given PO
45349578|NCT02656706|Drug|Ipilumumab|
45349579|NCT02656706|Drug|Nivolumab|
45349580|NCT00753480|Drug|D4064A|
45349581|NCT00758082|Device|paper support|Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support.
45349582|NCT00758082|Device|PDA-phone + telemonitoring|Patients will received PDA-phone + a telephone follow up + standard visit at 3 months
45685436|NCT02597374|Device|EEG|A 45 mn EEG will be performed in each participants during action and action observation of each hand.
45685437|NCT02591134|Other|Non Nutritive Sweetened Beverages|Non-nutritive sweeteners (NNS) beverages encompass a range of carbonated and still drinks with added artificial sweeteners. Participants will be provided with a list of permitted beverages and are expected to consume at least two portions (330ml) per day.
45685438|NCT02591134|Other|Control|Water beverages provided in 330ml portions to be consumed twice per day over the duration of the trial
45685439|NCT02589106|Device|Anisotropic Textile Braces|The period of the wear trial is 12-18 months in time for each subject. Wear instructions (23 hrs per day) and wash instructions will be provided to the subjects before the wear trial. Evaluation tests based on health in consideration of the use of the anisotropic textile brace (heart and pulmonary function testing and sensory level measurements) will be carried out at the beginning of the wear trial. Clinical, radiography, self-report and follow-up after completion of the study
45841448|NCT05820087|Device|HistoSonics Edison System|Non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.
45841449|NCT05819450|Procedure|Volumetric rejuvenation|Volumetric Rejuvenation with FDA-approved fillers on the skin of the dorsal hands
45841450|NCT05818774|Procedure|Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with parallel lesioning|"Intervention type: RF nerve lesioning at 80-85 degree Celsius for 90 seconds Intervention name: Straight sharp conventional (SIS's technique)~Intervention description:~Technique as described in the SIS Practice Guidelines for parallel lesioning cannulae placement"
46044954|NCT00599326|Drug|Deferasirox|250 mg of deferasirox once daily for 6 months
46044955|NCT02646280|Other|Massage therapy|Massage therapy as a treatment option to induce a relaxation and a reduction of pain and stress in patients affected by chronic low back pain.
46044956|NCT02646280|Other|Neurocognitive rehabilitation|Provided through the association of motor imagery and the words of the physiotherapist with the aim of increasing the effectiveness of massage in reducing pain.
46044957|NCT00978432|Drug|RAD001|10 mg/day for Part 1 of the trial
46044958|NCT00978432|Drug|LBH589|40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial
46044959|NCT00978432|Drug|Doublet (RAD001 and LBH589)|RAD001 7.5 mg by mouth daily and LBH589 15 mg by mouth on Monday/Wednesday/Friday during Part 2.
45349583|NCT04049916|Drug|Pyronaridine Tetraphosphate/Artesunate|Adults: Tablets containing 180 mg pyronaridine-tetraphosphate/60mg artesunate (Pyramax, Shin Poong Pharmaceutical Co.), administered according to weight. Children: Granules containing 60 mg pyronaridine-tetraphosphate/20mg artesunate, administered according to weight.
45841451|NCT05818774|Procedure|Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with end-on lesioning with multitined trident cannulae|"Intervention type: RF nerve lesioning lesioning at 80-850 Celsius for 90 seconds Intervention name: End-on placement of the multitined trident cannulae~Intervention description:~Patient in lateral position, targeting joint position between the inferior C2 and superior C3 facets, the middle of the facet pillars for the third to fifth cervical levels, and the superior part of the sixth and seventh cervical facets."
45841452|NCT05818553|Drug|Part A: 0.5mg/kg/day PRAX-562 for 16 Weeks|Once daily oral or G-tube treatment.
45349584|NCT04049916|Drug|Dihydroartemisinin/Piperaquine|Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau), administered according to weight.
45349585|NCT04049916|Drug|Primaquine Diphosphate|Extemporaneous preparation of 1mg/mL primaquine phosphate solution, from tablets containing 30mg primaquine (A-PQ 30®, ACE pharmaceuticals, NL) dissolved in 30mL water with a non-interacting fruit-flavoured syrup. Solution will be given at 0.25mg/kg.
45349586|NCT00753558|Drug|Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.|"Arm #1: Oral gentamicin & polymyxin E, gentamicin & polymyxin E buccal gel.~Arm #2: Oral placebo solutions, placebo buccal gel."
45349587|NCT02561208|Other|mHealth Intervention Group|Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps specifically devised to increase adherence to triage which will be run on a tablet, and SMS text messages (SMS message) to remind them to attend triage. In addition, Heads of CHWs, chiefs of gynecology services and CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage.
45349588|NCT02559960|Drug|Breviscapine Powder-Injection|Patients will be given Breviscapine Powder-Injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
45476207|NCT01192685|Procedure|Transcranial Magnetic Stimulation (TMS)|TMS will be administered to subjects 5 days a week-typically Monday through Friday, for 6 weeks.
45841453|NCT05818553|Drug|Part A: 0.5mg/kg/day PRAX-562 for 12 Weeks and Matching Placebo for 4 Weeks|Once daily oral or G-tube treatment with PRAX-562 for 12 weeks and matching placebo for 4 weeks.
45841454|NCT05818553|Drug|Part B: 0.5mg/kg/day PRAX-562|Once daily oral or G-tube treatment.
45476208|NCT01192685|Device|near infrared spectroscopy (NIRS)|near infrared spectroscopy (NIRS) will be used to measure the blood flow in the brain
45685440|NCT02291848|Biological|TAA-specific CTLs|"Groups A and B only: Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 5 x 10^6 cells/m2 and Day 14: 5 x 10^6 cells/m2~Dose Level Two:~Day 0: 1 x 10^7 cells/m2 and Day 14: 1 x 10^7 cells/m2~Dose Level Three:~Day 0 2 x 10^7 cells/m2 and Day 14 2 x 10^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
46044960|NCT02646202|Procedure|Sclerotherapy|Injection of varices
46044961|NCT02646202|Procedure|Band ligation|endoscopic banding of varices
45685441|NCT02291848|Biological|TAA-specific CTLs- fixed dose|"Fixed dose of 2 x 10^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
45685442|NCT05586412|Device|vagus nerve stimulation|Vagus stimulation, TENS device with specially designed and shaped surfaces that can be shaped according to the magnifying ear will be performed. The electrodes will be placed in such a way that the tragus is facing the inner and outer world. The wave formula is biphasic asymmetrical, pulses less than 500 microseconds and 10 hertz for 30 minutes. will be custom-made and the amplitude will be set as the sensory threshold.
45685443|NCT02587000|Drug|Ulipristal acetate|
45685444|NCT02587000|Drug|Placebo|
45685445|NCT04757818|Other|0.07% cetylpyridinium chloride (CPC) in mouthwash|A mouthwash and gargles with 15 ml of 0.07% cetylpyridinium chloride (CPC) in mouthwash for 1 minute.
45685446|NCT04757818|Other|Distilled water with the same colorant as the experimental product|A mouthwash and gargles with 15 ml of distilled water for 1 minute
45685447|NCT04758052|Other|Timing of placement|Simultaneous placement of tracheostomy and gastrostomy
45685448|NCT02563678|Drug|Hyperbaric Oxygen|Hyperbaric oxygen therapy
45685449|NCT02563678|Other|Hyperbaric Air/Oxygen|Breathing air inside a hyperbaric chamber, then breathing oxygen inside a hyperbaric chamber
45841455|NCT05818189|Device|Personalized tactile cueing|We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time(synchronized to the gait heel strike), closed-loop tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in closed-loop feedback during daily life for one week.
45841456|NCT05818189|Device|Fixed tactile cueing|We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time, open-loop(fixed rhythm) tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in open-loop feedback during daily life for one week.
46044962|NCT02646202|Procedure|Scleroligation|intra variceal endoscopic sclerotherapy combined with band ligation.
46044963|NCT02638480|Device|KneeMD|KneeMD is a subject-controlled knee rehabilita¬tion device that helps subjects who have undergone total knee replacements or other major knee surger¬ies improve range of motion and stretch in extension.
45349589|NCT00921596|Procedure|cardiac operation with totally endoscopic method|Cardiac operations are performed with three keyholes in the right chest wall. Video images are obtained by digital thoracoscope through one hole. Intracardiac lesions are accessed with surgical instruments and repaired through the other two holes. Cardiopulmonary bypass is set up with femoral cannulations. Moderate system hypothermic is applied for the operation. Cardiac arrest is achieved with ascending aorta clamp and cardioplegia solution delivery through aortic root cannulation. After the intracardiac lesions are repaired, aortic clamp is removed, and the heart is reperfused to restore its spontaneous rhythm. After the patients are rewarmed to normal temperature, CPB is discontinued. Femoral cannulations are removed, and surgical wounds are closed.
45841457|NCT05817526|Drug|BMAC/ collagen|Bone marrow aspirate concentrate loaded on collagen in the peri-implant defect
45841458|NCT05817526|Procedure|Autograft harvesting from chin|Autograft
45841459|NCT05817162|Drug|Ropivacaine injection|Ropivacaine is a local anesthetic that has been synthesized for use in infiltration anesthesia and to produce both peripheral and central block. Unlike one of its analogues, Bupivacaine, Ropivacaine anesthetize the sensory fibers without affecting the without affecting the motor ones. Ropivacaine comes as solution for injection.
45841460|NCT05817162|Procedure|temporomandibular joint arthrocentesis|Temporomandibular arthrocentesis is a minimally invasive surgical procedure, which aims to eliminate the inflammatory mediators from the inside of the TMJ.
45841461|NCT05817162|Drug|PRP injection|Platelet-Rich Plasma (PRP) is an orthobiological adjuvant treatment. PRP has properties to restore intra-articular hyaluronic acid, increases glycosaminoglycan chondrocyte synthesis and balances joint angiogenesis. It is often used as a viscosupplement in TMJ arthrocentesis
45841462|NCT05817162|Drug|Ringer's Lactate solution|Ringers lactate solution is used during arthrocentesis to wash out the joint inflammatory cells and to release the stuck disc phenomenon.
45349590|NCT03625544|Procedure|Instrumented posterolateral spinal fusion|Instrumented posterolateral spinal fusion, with or without an additional interbody device
45841463|NCT05816811|Other|Power-focused resistance training|Participants will undergo 10 weeks of power-focused resistance training.
45841464|NCT05816421|Behavioral|KEEP|The KEEP model focuses on optimizing the role of foster/kin parents as the agents of positive change for children and youth. Parent KEEP groups for children (ages 4-12) and KEEP-Safe groups for teens (ages 13-19) are delivered by two co-group leaders for 16 weeks. Sessions are 90 minutes each week. The same group of 8-10 foster/kin parents attends each week. Each KEEP group follows a manualized curriculum that emphasizes tailoring the content to the unique needs of the parents and youth in the group. The key parenting principles of the model include: (a) reinforce normative and prosocial behavior, (b) incentivize the behavior that parents want to promote, (c) build cooperation, (d) teach new behaviors, (e) use non-harsh effective limit setting, and (f) manage emotions while parenting.
45841465|NCT05816421|Behavioral|Non-Affinity KEEP|Non-Affinity KEEP
45841466|NCT05815628|Diagnostic Test|DISQVER|NGS based infection diagnosis
45841467|NCT05817643|Drug|BMS-984923|Oral capsule
45841468|NCT05814809|Drug|JP-1366 20mg tablet|T : JP-1366 20mg tablet
45841469|NCT05814809|Drug|JP-1366 20mg capsule|R : JP-1366 20mg capsule
45841470|NCT05813223|Drug|Gefapixant|Purinergic (P2X3) Receptor antagonist. Film-coated tablet taken orally.
45841471|NCT05812690|Other|This is a non intervention - observation only study|This is non intervention study
45841472|NCT05811299|Other|Kinesio taping|Total of 8 sessions for 4 weeks 2 sessions in a week.
45841473|NCT05811299|Other|Abominal exercises|Total of 8 sessions for 4 weeks 2 sessions in a week.
45685450|NCT02563678|Other|Normobaric oxygen|Breathing 100% oxygen at normal, atmospheric pressure
45685451|NCT02562430|Drug|Welbutrin XL|12.5% of participants will receive Welbutrin XL in phase 1 of the study.
45685452|NCT02562430|Drug|Placebo|87.5% of subjects will be randomized to placebo in phase 1 of the study.
45685453|NCT02556424|Drug|Dexamethasone|Intravitreal implant at D0
45841474|NCT05810402|Biological|Liquid Biopsy|"30mL blood sample:~1 x 10mL CellSave tube specifically designed for the collection and preservation of CTCs for CellSearch® analysis~1 EDTA tube for PBMCs isolation and circulating immune cells study (5mL),~2 EDTA tubes and 1 dry tube (15mL) for the preparation of the biobank (serum, plasma and cell)."
45685454|NCT02556424|Drug|Triamcinolone|Subconjunctival injection at 4 mm from the limbus at 6 o'clock
45685455|NCT02549638|Genetic|DNA Extraction|We will then extract DNA from tissue sections and blood and use a custom targeted sequencing panel of 23 cancer driver genes with significant mutations in squamous cell carcinoma that we have developed to find the prognostic biomarkers. The DNA will be used in a PCR reaction to generate amplicons for library preparation using Illumina Nextera XT library preparation protocol and targeted sequencing on the Illumina Hiseq sequencer. The reads will be aligned to the HG19 using BWA aligner and variant detection performed with Agilent SureCall and GATK analytic tools.
45841475|NCT05810051|Behavioral|Cardiac rehabilitation|"The patients in this arm will be trained for 1 hour, 2 or 3 times per week for 36 sessions. In addition to the training program, the patients also get access to the cardiovascular educational program.~The training (a 1h session) consists of 60% cardiovascular endurance training and 40% resistance training."
45841476|NCT05809739|Device|STYLAGE Hydro|3 sessions of injections (J0, J14 and J28)
45841477|NCT05809180|Drug|Rituximab|Rituximab 375mg/m2 ivgtt d1;
45841478|NCT05809180|Drug|Orelabrutinib|Orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity;
45841479|NCT05809180|Drug|Pomalidomide|Pomalidomide 4mg d1-7 each cycle. After Phase II of treatment, single agent pomalidomide 4 mg d1-d7 in 21-day cycles for 2 years.
45349591|NCT03625544|Device|MagnetOs™ Granules|8-10cc of MagnetOs™ Granules per spinal level at the randomized allocation side of the spine (left or right)
45349592|NCT03625544|Procedure|Autologous bone graft|8-10cc autologous bone graft per spinal level at the control side of the spine (left or right). This can be a combination of local bone and iliac crest bone, but at least 50% of the volume has to be iliac crest bone graft.
45841480|NCT05809180|Drug|Pro-miniCHOP-like regimen|rituximab 375mg/m2 ivgtt d1; orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity; pomalidomide 4mg d1-7; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
45841481|NCT05809180|Drug|R-miniCHOP-like regimen|rituximab 375mg/m2 ivgtt d1; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
45349593|NCT00575328|Drug|Maca Root|3g/day of Maca Root for 12 weeks.
45685456|NCT02543944|Drug|Gabapentin|N-type calcium channel blocker being examined for its potential efficacy to alleviate opioid withdrawal during buprenorphine-assisted detoxification and transition to depot naltrexone.
45841482|NCT05807854|Procedure|Arthroscopy|The surgeon reattaches the torn tendon to the bone with anchors and sutures.
45685457|NCT02543944|Drug|Buprenorphine|All participants are stabilized on buprenorphine and then undergo a 10 day taper off buprenorphine.
45841483|NCT05807854|Device|Reverse Shoulder Arthroplasty|It consists in replacing the shoulder joint with a total shoulder prosthesis (reverse design).
45841484|NCT05804552|Device|Dorsal genital nerve stimulation|Two types of stimulation electrodes will be used: UCon Patch Electrodes (InnoCon Medical ApS, Denmark) and ValuTrodes/EconoStim Electrodes (5x5 cm, Axelgaard Manufacturing Co. Ltd., United States). The UCon Patch Electrode acts as a cathode and will be placed on the clitoris. The ValuTrode/EconoStim acts as an anode and will be placed on the lower abdomen. The continuous stimulation consists of a train of single pulses provided continuously with a frequency of 20 Hz and a pulse duration of 200 μs. The burst stimulus pattern consists of a train of bursts. The length of the train is 10 s and will consist of 20-30 bursts/s. One burst consists of 5 identical square pulses (monophasic). The inter-pulse interval is 4 ms (time between the onset of 2 consecutive pulses) while a pulse duration of 200 μs will be used.
45841485|NCT05804214|Other|Dairy and plant based infant formula feeding|Parents have already decided to feed their infant with the product (a dairy and plant based infant formula) daily, starting within the first 4 months of life, continuing for at least 2 months
45841486|NCT05802238|Drug|Tranexamic acid (TXA)|1 gram of TXA in 10mg single-dose ampule (100mg/mL) administered 10 minutes prior to surgery
45841487|NCT05802238|Other|Saline|control group will receive 10 mL of normal saline infused intravenously at 1 mL/min.
45841488|NCT05802173|Drug|TDM-105795, 0.0025%|The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
45349594|NCT00575328|Drug|Placebo|Placebo provided by research pharmacy daily for 12 weeks.
45349595|NCT00753792|Drug|methylprednisolone|methylprednisolone 1.000 mg/day intravenous administration during three days
45349596|NCT00753792|Drug|methylprednisolone|methylprednisolone 1.250 mg/day orally administered during three days
45349597|NCT00753792|Drug|Placebo|Placebo of methylprednisolone administered intravenously (Arm 2) or orally (Arm 1)
45349598|NCT05434494|Drug|Remimazolam|"Remimazolam is injected for 30 seconds and the experimental dose will be determined according to the biased coin design up-and-down sequential method.~If loss of consciousness is successful, the dose of the next intravenous dose of the next study subject will be reduced from the previous dose with a probability of 1/19 or the same as the previous dose with a probability of 18/19."
45349599|NCT05434494|Drug|remifantanil|25cc infusion drug will be prepared (labeled as test drug) and infused with TCI mode. The target effect site concentration is 2.0 ng/ml.
45349600|NCT05433792|Device|Myolens CN (Central-Near) soft contact lens|Personal fitting of the Myolens-CN/CF.
45349601|NCT05433792|Device|MiSight® soft contact lens|Control arm device, FDA approved (P180035), and CE marked soft lenses for the management of Myopia in children aged 8-12.
45349602|NCT00753870|Biological|CCRE inhalation|20,000 EU CCRE given as a one-time challenge
45685458|NCT02543944|Drug|Clonidine|All participants who successfully taper off buprenorphine receive Clonidine (0.1 mg) prior to induction onto oral naltrexone.
45685459|NCT02543944|Drug|Naltrexone (oral)|All participants receive increasing doses of oral naltrexone over a 3 day period (day 1: 6.25 and 6.25 mg; day 2: 25 mg; day 3: 50 mg)
45685460|NCT02543944|Drug|Naltrexone (depot)|All participants who tolerate oral naltrexone at 50 mg will receive the naltrexone injection on either the same day as the 50 mg dose or the day after.
45685461|NCT02543944|Drug|Placebo|Microcrystalline cellulose
45685462|NCT02543320|Other|LORETA Neurofeedback Training|Undergo LORETA neurofeedback training
45685463|NCT02543320|Other|Questionnaire Administration|Ancillary studies
45841489|NCT05802173|Drug|TDM-105795, 0.02%|The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
45841490|NCT05802173|Drug|TDM-105795 topical vehicle solution|The assigned placebo will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
45841491|NCT05799807|Procedure|Conservative treatment|Patients with negativ weight-bearing CT will be treated conservative
45841492|NCT05799807|Procedure|Minimally invasive stabilization|Patients with positive weight-bearing CT will be operated by minimally invasive stabilization (eg, isolated homerun screw)
45841493|NCT05796570|Drug|Decitabine|Nucleoside metabolic inhibitor, via IV infusion.
45476209|NCT04866758|Other|Survey|All data gathered will be quantitative in nature. In addition to participant completed surveys, additional demographic, and diagnosis/treatment related information will be collected from the patient's electronic medical record via Health Data Compass. Subsequent data collected as part of the patient's standard psychosocial and cancer related care (i.e., health outcomes, future utilization of UCCC psychosocial services) will also be gathered. This subsequent data collection will not include further participation, but continued access to the patient's medical record. Protected health information collected for this project will include dates (e.g., birth dates, date of diagnosis, date since last treatment, death dates) and participant zip codes. No other identifiable data will be collected. A separate survey emailed to the participant at the end of the study will collect information regarding the participant's completion status of the survey.
45685464|NCT02538484|Drug|Letrozole|Aromatase inhibitor
45841494|NCT05796570|Drug|Filgrastim|Recombinant granulocyte colony-stimulating factor (G-CSF), via subcutaneous injection.
45841495|NCT05791617|Diagnostic Test|cardiac PET/MRI|Patients will undergo cardiac PET/MRI scanning at 30±5 days and at 90±5 days post-stroke.
45685465|NCT02538484|Dietary Supplement|Fish Oil|Omega-3 free fatty acid
45685466|NCT02531308|Drug|Metformin|Metformin upregulates AMPK activity which has been shown to have an anti-proliferative effect on lymphoma cells.
45841496|NCT05791617|Diagnostic Test|Inflammatory markers|Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 30±5 days and at 90±5 days post-stroke
45841497|NCT05791617|Diagnostic Test|Diagnostic Test: NT-proBNP|NT-proBNP is useful both in the diagnosis and prognosis of heart failure and is considered to be a gold standard biomarker in heart failure. Measurement of NT-proBNP on patients' blood samples at 30±5 days and at 90±5 days post-stroke
45841498|NCT05789485|Behavioral|structured treadmill walking|Three doses of AT (i.e., 90, 150, or 300 mins/week) will be tested. All doses will consist of individualized walking delivered up to 7 times per week delivered from TNT initiation until surgery (~32 weeks).
45841499|NCT05789277|Other|Conventional training program|"Conventional training program:~5-10 Repetitions ( 0.5-to 1-min rest);~Vertical jumps~Multiple forward jumps~Running exercises~Sprints alternating with slow jogging"
45841500|NCT05789277|Other|Eccentric hamstring training|Functional training along with specific eccentric hamstrings exercises i.e., prone hamstring curl, exercise ball (or glider) bridge with curl, Nordic hamstring curl, single leg deadlift. The exercise program comprises 3 sets of 15 repetitions once to twice per day for at least 12 weeks.
45841501|NCT05787782|Device|Masimo INVSENSOR00063|Masimo INVSENSOR00063 will be used to measure temperature
45841502|NCT05781438|Behavioral|In-home standing and walking intervention|"Parents/legal guardians will be educated on and provided an activity booklet on intensive standing and walking play activities for their infant in a 9 by 9 foot body-weight support system (BWS). Activities include: squatting play at a couch or table, cruising along and between furniture, walking with a push toy or with one or two hands held, walking without support, and kicking and throwing a soft ball.~For 16 weeks, parents/legal guardians will be encouraged to implement the parent-led, intensive standing and walking intervention using BWS for at least 5 days/week for 30-60 min/day, with weekly telehealth calls and monthly home visits to coach parents in identifying key activities and progressing the program."
45841503|NCT05775523|Drug|No intervention|No intervention
45841504|NCT05768295|Device|Axiom BL X3|collecting data on the use of Axiom BL X3 and patient satisfaction
45685467|NCT02531308|Drug|Rituximab|monoclonal antibody against protein CD20 primarily found on the surface of B-cells
45685468|NCT02531308|Drug|Cyclophosphamide|Interferes with DNA replication
45841505|NCT05755945|Other|eHealth Application|"Custom phone application that integrates data from smart watch. Subjects will complete daily To-Do-Lists where data will be collected on if they had a headache in the past 24 hours, severity of headache, and any analgesics used to treat the headache."
45841506|NCT05752539|Device|CEREC System by Dentsply Sirona|CEREC Tessera blocks achieve exceptional three-way performance through a unique chemistry that incorporates two complementary crystal structures within a glassy zirconia matrix. These two crystals work together to create an unprecedented fusion of strength and beauty in one block while significantly improving overall processing time.
46044964|NCT00629538|Procedure|Therapeutic thoracentesis|Thoracentesis was performed with drainage of 500 ml of pleural fluid first and every 200 ml thereafter until pleural pressure was lower than -20 cm H2O, chest discomfort developed, or no more pleural fluid could be removed.
46044965|NCT04166812|Diagnostic Test|oscillometry|assessment of peripheral airway resistance using oscillometry
46044966|NCT04166812|Diagnostic Test|multiple breath washout testing|assessment of ventilation heterogeneity using multiple breath washout testing
45685469|NCT02531308|Drug|Doxorubicin|anthracycline antitumor antibiotic
45685470|NCT02531308|Drug|Vincristine|Inhibits cell mitosis causing cell death.
45685471|NCT02531308|Drug|Prednisone|a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug. It is used to treat certain inflammatory diseases
45685472|NCT02531308|Drug|pegfilgrastim|stimulates the level of white blood cells (neutrophils).
45685473|NCT02523976|Drug|Dasatinib|Second-generation tyrosine kinase inhibitor
45685474|NCT02523976|Drug|prednisone|
45685475|NCT02523976|Drug|cyclophosphamide|
45841507|NCT05751837|Biological|Lipopolysaccharide|One tumor will be injected with 1 ug LPS (investigational drug) over approximately one minute
45841508|NCT05749848|Drug|[¹⁴C]-LY3372689|Administered orally.
46044967|NCT04166812|Diagnostic Test|spirometry|assessment of lung function using spirometry
45685476|NCT02523976|Drug|daunorubicin|
45685477|NCT02523976|Drug|vincristine|
45841509|NCT05740254|Behavioral|Early Time Restricted Eating|Early Time Restricted Eating 7 AM to 3 PM
45841510|NCT05740254|Behavioral|Late Time Restricted Eating|Late Time Restricted Eating 12 PM to 8 PM
45841511|NCT05738057|Drug|Camrelizumab|200mg on day1 of every 3 weeks, starting on day1 of cycle1
45841512|NCT05738057|Drug|Gemcitabine Injection|1000mg/m2 on day1 & day8 of every 3 weeks, starting on day1 of cycle 1
45841513|NCT05738057|Drug|Cisplatin injection|25mg/m2 on day1 & day8 of every 3 weeks, starting on day1 of cycle 1
45841514|NCT05738057|Drug|Cisplatin-Eluting Beads|used for D-TACE
45841515|NCT05738057|Procedure|D-TACE|TACE with Cisplatin-Eluting Beads (with Cis 30mg). More TACE can be done if clinically necessary.
45685478|NCT02523976|Drug|cytarabine|
45685479|NCT02523976|Drug|mercaptopurine|
45685480|NCT02523976|Drug|methotrexate|
45685481|NCT02523976|Drug|dexamethasone|
45841516|NCT05728970|Diagnostic Test|LumiraDx SARS-CoV-2 Ag Ultra|The LumiraDx SARS-CoV-2 Ag Ultra Test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2 directly from anterior nasal swab samples collected from symptomatic individuals within the first twelve days of symptom onset suspected of COVID-19 by their healthcare provider.
45685482|NCT02523976|Drug|mitoxantrone|
45685483|NCT02523976|Drug|etoposide|
45685484|NCT02523976|Procedure|allogeneic hematopoietic stem cell transplantation|
45685485|NCT02523976|Procedure|autologous hematopoietic stem cell transplantation|
45685486|NCT02514382|Drug|Bortezomib|Given SC or IV
45685487|NCT02514382|Drug|Dexamethasone|Given PO, IV, or IM
45685488|NCT02514382|Other|Laboratory Biomarker Analysis|Correlative studies
45685489|NCT02514382|Other|Pharmacological Study|Correlative studies
45685490|NCT02514382|Biological|Wild-type Reovirus|Given IV
45685491|NCT02507986|Device|Single lead ECG device|The single lead ECG device is a smartphone compatible handheld device that produces a single lead ECG after 30 seconds of measurement. It is non-invasive, electrically safe and easy to use.
45685492|NCT02507986|Device|7-Day Holter monitor.|The Holter is a conventional 7-Day Holter monitor.
45685493|NCT05586334|Biological|Collection of vaginal secretions|In all women included: Vaginal secretion sampling at the time of the obstetrical emergency consultation.
45685494|NCT05586334|Biological|Collection of the placenta and the membranes|In cohort 1, for 30 patients at the Port Royal Maternity Hospital, the placenta and membranes will be collected after delivery
45685495|NCT05586334|Other|Administration of EPDS questionnaire|In cohort 3, the EPDS questionnaire will be administered to all participants after the consultation in the emergency department.
45841517|NCT05728970|Diagnostic Test|LumiraDx SARS-CoV-2 & Flu A/B|The LumiraDx SARS-CoV-2 & Flu A/B test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A and/or Influenza B viral antigens from nasal swab samples.
45841518|NCT05723055|Drug|Axatilimab|Axatilimab (SNDX-6352) is a humanized IgG4 monoclonal antibody (mAb) with high affinity against colony stimulating factor-1 receptor (CSF-1R).
45841519|NCT05723055|Drug|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1)-blocking antibody
45841520|NCT05714098|Behavioral|Gerofit Exercise Program|The tele-Gerofit exercise intervention has training focused on meeting the physical activity guidelines and incorporating cardiovascular, strength, and balance training. Sessions will also include a mindfulness component, warm up, cool-down, and safety checks. Exercises are personalized to each person's functional status. Intensity of exercises will be determined by participants providing a rating of perceived exertion (RPE) on a scale of 0 (easy) to 10 (very hard) throughout the session. Initial exercise sessions will start at low-intensity and will gradually increase the duration and intensity to allow each person to reach recommended exercise levels at their own pace. Exercises are done virtually via Zoom. Each cohort will have 5-8 participants. The exercise program will be optimized after each cohort with modifications based on participant and exercise expert feedback.
45841521|NCT05703347|Behavioral|Fixed sleep goal|Investigators will determine if a fixed guideline-based goal (≥9 hours per night) is more efficacious for increasing sleep duration.
45841522|NCT05703347|Behavioral|Personalized sleep goal|Investigators will determine if a personalized goal (≥9 hours per night, but can be lowered to a personalized level, capped at +30 minutes per night above baseline) is more efficacious for increasing sleep duration.
45841523|NCT05703347|Behavioral|Digital sleep health messaging without virtual study visit|All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. This group will NOT have virtual psychological visits.
46044968|NCT04166812|Diagnostic Test|body plethysmography|assessment of lung function using body plethysmography
46044969|NCT04166812|Diagnostic Test|fractional exhaled nitric oxide|assessment of eosinophilic airway inflammation using fractional exhaled nitric oxide
46044970|NCT04166812|Diagnostic Test|transfer factor|assessment of gas transfer using single breath transfer factor for carbon monoxide
45685496|NCT05586256|Radiation|ultra-hypofractionated whole breast irradiation|"All enrolled patients will be treated with an ultra-ipofractionated whole breast irradiation schedule (26 Gy delivered in 5 consecutive fractions, single dose 5.2 Gy), according to FAST-Forward trial. Whole bresat irradiation should be followed or not by a tumor bed boost (sequential: 7.6 Gy in 2 consecutive fractions, single dose 3.8 Gy or simultaneous intergrated boost: 30 Gy in 5 consecutive fractions, single dose 6 Gy). Either three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) or helicoildal techniques are allowed. Breath control techniques may be used at the discretion of each partecipating centre.~Main exclusion critereria are mastectomy and regional nodal irradiation. Neoadjuvant and/or adjuvant systemic therapies are allowed."
45476210|NCT04709679|Procedure|MicroPulse TransScleral CycloPhotoCoagulation|A laser power of 2000- 2500 mW, a laser duration time of 50 to 80 sec per hemifield and varying da number of sweeps per hemifield 3, 4 or 5 will be randomized between patients
45685497|NCT02505958|Other|high caloric intake|Volunteers will be started on a diet program for 4 ½ days, consisting of 3 meals and 3 snacks over a 24 hour period and containing ~ 6000 Kcal/24 h.
45841524|NCT05703347|Behavioral|Digital sleep health messaging with virtual study visit|All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. The participants will be randomized to additionally receive virtual study visits where doctoral-level psychology trainees will be trained to implement evidence-based behavioral sleep health guidance.
45841525|NCT05703347|Behavioral|Inactive Parent-Directed Loss-Framed Incentive|No parental incentive
45841526|NCT05703347|Behavioral|Active Parent-Directed Loss-Framed Incentive|Parents will receive a financial incentive when their child achieves their sleep goal. The incentive will be loss-framed; parents will receive an endowment of $10 at the start of each intervention week, in a virtual bank account; Investigators will deduct $2 each weeknight the sleep duration goal is not met; the funds remaining in the virtual account will be dispensed each Sunday. The weekly endowment-payment approach allows for fresh starts each week. The incentive will be directed at parents as a method to enhance engagement. Investigators will ask parents at baseline and at the end of each month to rate their perceived support in helping their child to meet their sleep duration goal.
45349603|NCT00575094|Drug|tigecycline|Dosage form: Tigecycline 50 mg for injection (Lyophilized powder in 5 mL vial) Dosage frequency: Tigecycline 100 mg loading followed by 50 mg every 12 hrs (bid) Duration of therapy: 7 to 14 days
45349604|NCT00553696|Drug|Cisplatin|Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
45349605|NCT00553696|Drug|S-1|S-1 80 mg/m2 on days 1-21 of each 28 day cycle
45349606|NCT00553696|Drug|Sunitinib|Sunitinib 25 mg, 37.5 mg and 50 mg daily S-1 80 mg/m2 on days 1-21 of each 28 day cycle Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
45685498|NCT02505958|Other|reduced caloric intake|On days 5 and 6, volunteers will received 3 meals (~333 calories each) totaling ~ 1,000 calories/24 hours.
45685499|NCT02495896|Drug|Cisplatin|Given IV
45685500|NCT02495896|Drug|Docetaxel|Given IV
45349607|NCT05430126|Drug|Protein Kinase Inhibitor|This retrospective pharmacovigilance study will include protein kinase inhibitor and exclude those drugs known to cause hepatotoxicities
45476211|NCT03845231|Biological|Flucelvax(R)|Cohort 1 will receive IM quadrivalent IIV (Flucelvax (R)) at the standard dose of 15 micrograms HA per strain (60 micrograms HA total).
45476212|NCT03845231|Other|Human Challenge virus|A dose of 10^7 50% tissue culture infective dose (TCID50) of human challenge virus will be administered intranasally to all participants using a nasal sprayer.
45476213|NCT04773704|Diagnostic Test|FILMARRAY® Pneumonia Plus Panel technique|FILMARRAY® Pneumonia Plus Panel technique (multiplex PCR) on a respiratory sample
45841527|NCT05703347|Behavioral|Inactive Supportive Feedback|No supportive feedback
46044971|NCT04166812|Diagnostic Test|health status|assessment of health status using validated questionnaires (St. George's Respiratory Questionnaire [SGRQ], COPD Assessment Test [CAT])
46044972|NCT04166812|Diagnostic Test|computed tomography|assessment of lung structure and function using computed tomography (only in patients with clinical indication, Heidelberg site)
46044973|NCT04166812|Diagnostic Test|induced sputum|various biomarkers (subgroup of approximately 75 patients, Großhansdorf site)
46044974|NCT04016155|Device|Abbott FreeStyle Libre|Flash CGMS
46044975|NCT04016155|Device|Patient Own SMBG|Market SMBG
45476214|NCT01791478|Drug|PI3K inhibitor BYL719|Given PO
45476215|NCT01791478|Drug|letrozole|Given PO
46044976|NCT02641756|Other|treatment interruption after in depth sampling under CART|The participants will undergo in depth sampling under CART to characterise the HIV reservoir in different anatomical compartments. Subsequently an experimental viral rebound, by a brief therapy stop, will help us identify the clinically relevant viral reservoir by doing phylogenetic analysis on the rebounding virus and on the virus found in the different compartments under CART.
45349608|NCT05427864|Diagnostic Test|Multiparametric Prostate MRI|Comparison of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer
45476216|NCT01791478|Other|laboratory biomarker analysis|Correlative studies
45476217|NCT01791478|Other|pharmacological studies|Correlative studies
45476218|NCT05126537|Other|no intervention|prospective and observational study with no intervention
45476219|NCT04746560|Device|TEG®6S device with its Platelet mapping® cartridge|Platelet function monitoring using the TEG®6S device with its Platelet mapping® cartridge
45476220|NCT03845153|Drug|Metformin Retard 850 mg|tablet
45476221|NCT03845153|Other|Placebo|placebo tablet
45685501|NCT02495896|Drug|Gemcitabine Hydrochloride|Given IV
45685502|NCT02495896|Other|Laboratory Biomarker Analysis|Correlative studies
45685503|NCT02495896|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
45685504|NCT02495896|Other|Pharmacological Study|Correlative studies
45685505|NCT02495896|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
45841528|NCT05703347|Behavioral|Active Supportive Feedback|Participants will receive a weekly performance summary message each Sunday during the intervention period, with supportive feedback included to motivate children to maintain their good performance in the week ahead, or to try and improve upon a weak or moderate performance in the week ahead. Investigators will ask children will complete an online survey each Sunday to measure how motivated they are to achieve their sleep goal in the week ahead.
45841529|NCT05699408|Drug|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
45841530|NCT05699408|Drug|Insulin Glargine|Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial
45841531|NCT05699031|Device|APP|Patients allocated in the app-group will use the newly developed smartphone app te rehabilitate. 5 exercises are provided daily. Daily questionnaires will monitor exercise performance, VAS pain, household activities. Information modules will be sent at specific times.
45841532|NCT05699031|Other|PHYSICAL THERAPY|Patients allocated in the physio-group will go, twice a week, to a physical therapist of their choice to rehabilitate. The physical therapist will follow the general guidelines provided by the hospital (surgeon).
45476222|NCT04619108|Biological|Thrombosomes®|
45476223|NCT00198718|Drug|Vitamin A (retinyl palmitate)|
45349609|NCT00553540|Device|Back supports|The spinal / back supports are made of polymer shield covered by fabric and foam to be used externally to relieve back pain and offer spinal support. They are to be placed in the chair used in workstation related jobs.
45349610|NCT02559804|Other|survival and late effects|survival and late effects
45476224|NCT05247827|Other|Targeted phantom limb motor execution (exercise)|The targeted phantom motor execution is a specific training program for people with TTA that has been designed to improve the muscles' strength, coordination, and flexibility at the amputated and contralateral intact sides. Such training consists of repeated short-term, short rest interval, and moderate-intensity exercises (Schoenfeld 2010, Krutki, Mrowczynski et al. 2017). Targeted phantom motor execution can improve the body image considering its induced muscular impacts. People with TTA will be trained to follow specific movements of their foot-ankle complexes simultaneously, in order to increase PLA, as well as induce muscular morphologic and brain neuroplastic changes (Moseley and Brugger 2009).
45841533|NCT05689853|Drug|AK119|AK119 is an anti-CD73 monoclonal antibody.
46044977|NCT00975780|Other|Enhanced Oral Care|oral brushing plus oral chlorhexidine plus upright feeding positioning
45349611|NCT03877380|Other|semi-structured interview|Semi-strucured interview to identify the difficulties when first applying for a personalised autonomy allowance by beneficiaries and their relatives
45349612|NCT00958204|Procedure|Light treatment|Light therapy: from a 10,000 lux fluorescent white light box, for 30 minutes per day upon waking in the morning, for 8 weeks.
45349613|NCT00958204|Procedure|Negative ion therapy|Negative ion therapy: from a negative ion generator with an output of 200 trillion ions per second per cubic centimeter, for 30 minutes per day upon waking in the morning, for 8 weeks
45349614|NCT00958204|Drug|Placebo|Placebo Pill: one oral tablet each day, for 8 weeks.
45476225|NCT03951116|Drug|FCN-437|FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
45476226|NCT04500808|Drug|Macitentan Dose 1|Participants will receive Dose 1 of macitentan tablet in Part 1.
45476227|NCT04500808|Drug|Macitentan Dose 2|Participants will receive Dose 2 of macitentan tablet in Part 1.
45476228|NCT04500808|Drug|Macitentan Dose 3|Participants will receive Dose 2 of macitentan tablet in Part 1 and 2.
45685506|NCT02493322|Drug|Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg|1 tablet a day
45685507|NCT02493322|Drug|Olmesartan medoxomil 20mg + Chlortalidone 25mg|1 tablet a day
45685508|NCT02493322|Drug|Olmesartan 20mg + hydrochlorothiazide 12,5mg|1 tablet a day
45685509|NCT01893892|Dietary Supplement|levocarnitine|Given PO
45685510|NCT01893892|Other|placebo|Given PO
45685511|NCT01893892|Other|questionnaire administration|Ancillary studies
45685512|NCT04757974|Drug|Fostemsavir 600 mg|Fostemsavir tablets will be administered via oral route.
45685513|NCT04757974|Drug|Fostemsavir 200 mg|Fostemsavir tablets will be administered via oral route.
45685514|NCT04757506|Drug|Naltrexone|opioid receptor antagonist
45841534|NCT05689853|Drug|AK112|AK112 is a bispecific monoclonal antibody against VEGF and PD-1.
45841535|NCT05689151|Drug|Abrocitinib|Study Drug for Observational Data Collection
45685515|NCT04757506|Drug|Placebo|
45841536|NCT05686083|Dietary Supplement|C6 ketone di-ester|C6 ketone di-ester
46044978|NCT00975780|Other|Usual oral care|Usual oral care and feeding positioning
46044979|NCT00654862|Dietary Supplement|cocoa polyphenols|Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
46044980|NCT00654862|Dietary Supplement|cocoa polyphenols|Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
46044981|NCT02865252|Other|MWM Treatment|
46044982|NCT02865252|Other|MWM Sham|
45349615|NCT00958204|Drug|Fluoxetine|Fluoxetine: 20 mg oral tablet each day, for 8 weeks
45349616|NCT00954460|Drug|velaglucerase alfa|up to 60 U/kg, every other week via intravenous infusion
45841537|NCT05686083|Dietary Supplement|Novel ketone di-ester|Novel ketone di-ester
45841538|NCT05668286|Drug|A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%)|patients in group 1 received an anterior extra-articular steroid injection under USG guidance, patients in group 2 received posterior intra-articular steroid injection under USG guidance. A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%) were injected to all patients.
45841539|NCT05667779|Drug|QRL-101|Up to 9 planned dose levels of QRL-101 in 9 cohorts of 8 participants each, randomized 6:2 (QRL-101: placebo).
45841540|NCT05667779|Other|Placebo|Placebo comparator at all dose levels
45841541|NCT05665465|Drug|Nicotine nasal spray 0.5 mg|Participants will be administered nicotine nasal spray and provide subjective reactions
45349617|NCT00754026|Procedure|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 2cm
45685516|NCT02484820|Device|Silicone pessary|Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
45685517|NCT02477644|Drug|Olaparib|Tablets, per os, 300 mg twice daily;
45349618|NCT00754026|Procedure|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 6cm
45349619|NCT00617409|Drug|Paclitaxel|All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. At any point when a patient develops evidence of progressive disease, the patient will be treated with second-line chemotherapy. Paclitaxel will be given at a dose of 200 mg/m² on day 1 of 21 day cycles.
45349620|NCT00617409|Biological|Drug: Ad.p53-DC vaccines|Patients randomized to Arm B will receive vaccinations on 3 occasions, at 2 week intervals. 1-5x106 p53 positive DCs in 1 ml will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2-3 weeks after vaccine # 3 (first vaccine course). If patients show no sign of disease progression at restaging, then a second leukopheresis will be performed. Patients will then be vaccinated 3 more times (second vaccine course) at 4-week intervals, for a total of 6 possible vaccines. Restaging will occur 2-4 weeks after completing the second vaccine course. Patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
45349621|NCT00617409|Drug|All -trans Retinoic Acid (ATRA)|The patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
45349622|NCT00695318|Drug|Fluocinolone Acetonide|0.2 µg/Day in study eye + Sham in fellow eye
45349623|NCT00695318|Drug|Fluocinolone Acetonide|0.5 µg/Day in study eye +Sham in fellow eye
45349624|NCT00754104|Drug|ABT-869|0.25 mg/kg. daily.
45349625|NCT00754104|Drug|Tarceva|150mg, daily.
45841542|NCT05665465|Drug|Placebo|Participants will be administered placebo nasal spray and provide subjective reactions
45349626|NCT00386425|Drug|Drotrecogin alfa (activated)|intravenous
45349627|NCT05300230|Device|Neuro Zti cochlear implant and Neuro 2 sound processor|"The study will consist in 3 visits:~Visit 1: it will be carried out the first contact and learning the measurement procedure.~Visit 2: it will be evaluated the speech perception and the measurement of the pupil dilatation in silence and noise conditions.~Visit 3: it will be analysed the effect of the change in the cochlear implant programming parameters."
45476229|NCT04500808|Drug|Placebo|Participants will receive matching placebo from Day 1 up to Day 13.
45685518|NCT02477644|Drug|Placebo|Tablets, per os, 300 mg twice daily.
45685519|NCT02472028|Other|blood pressure lowering algorithm|"The treatments used in the enhanced strategy arm are those proposed by national (HAS2013, SFHTA2013) and international (ESH 2013) recommendations, according to their Marketing Authorization and Summary of Product Characteristics : Diuretics, beta-blockers, Angiotensin Converting Enzyme inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blockers Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. All drugs of these classes may be used , no specific drug is tested in this study."
45841543|NCT05664958|Procedure|Erector Spinae Plane (ESP) Block|ESP Block with liposomal bupivacaine and immediate release bupivacaine
45841544|NCT05664958|Drug|bupivacaine liposome injectable suspension|133 mg liposomal bupivacaine per side.
45841545|NCT05664958|Drug|bupivacaine|20 ml bupivacaine 0.25% per side.
45841546|NCT05646628|Behavioral|Qualitative Interviews|Semi-structured Qualitative Interviews
45841547|NCT05645471|Behavioral|Together After Cancer|This is an online couples intervention for Latina breast cancer survivors and their intimate partners.
45841548|NCT05644522|Device|Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH)|The Nomad is a microprocessor-controlled knee-ankle-foot orthosis P-KAFO that incorporates a motor for powered movement assistance and an electronic brake for stance support. The system provides active assistance for knee flexion and extension during the swing phase of gait, reliable stance phase locking at any knee angle, and reliable unlocking without requiring user-generated knee or hip extension torque.
45841549|NCT05643859|Dietary Supplement|Dietary Fiber|Given PO
45841550|NCT05643859|Procedure|Proctoscopy or anoscopy with Biopsy|Undergo proctoscopy or anoscopy
45841551|NCT05643859|Other|Questionnaire Administration|Ancillary studies
45349628|NCT00758238|Other|myBP facilitated e-health self-management|MyOSCAR, a web-based patient-controlled personal health record, provides a mechanism for patients to enter/track health information and can encourage longitudinal patient engagement, better interaction between patients and health care providers, and patient self management. The intervention will provide access via MyOSCAR to a cardiovascular risk profile and BP tracker with sharing to providers enabled. Patients can receive general information about hypertension management; tailored messages related to their modifiable risk factors; and secure messaging with multiple providers. Providers can draw on a 'menu' of links/resources to share with patients. A lifestyle changes planner/checklist and an enhanced medication diary are additional components.
45349629|NCT03529448|Drug|TN-TC11G|"TN-TC11G dose will be gradually increased as follows:~Week 1: TN-TC11G: 0-0-5 mg (THC 5 mg + CBD 5 mg; in the mornings, 90 minutes after breakfast; in the afternoons, 90 minutes after lunch; in the evenings, 90 minutes after dinner).~Week 2: TN-TC11G: 5-0-5 mg Week 3: TN-TC11G: 5-5-5 mg Week 4: TN-TC11G: 5-5-10 mg Week 5: TN-TC11G: 5-5-15 mg Week 6: TN-TC11G: 10-10-15 mg Week 7: TN-TC11G: 10-10-20 mg. Week 8: TN-TC11G: 15-15-30 mg Week 9: TN-TC11G: 20-20-40 mg TN-TC11G will be administered daily at the relevant dose level according to the individual titration performed in the first 9 weeks of treatment. If there is any dose reduction, the reduced dose must be administered."
45349630|NCT03529448|Drug|Temozolomide Oral Product|"During RT, patients will receive Temozolomide (TMZ). All patients will be given TMZ at 75 mg/m2/d concurrently with RT for a maximum of 42 days.~At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles."
45841552|NCT05636059|Other|Therapeutic exercise|32 sessions in total, 2 times a day, 30 min. one session. Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball.
45349631|NCT03529448|Radiation|Radiotherapy|All the patients will receive the Stupp regimen. The radiotherapy (RT) treatment will be administered in fractions of 1.8-2.0 Gy/day delivered 5 days/week to a total dose of 58-60 Gy. Radiotherapy will be delivered to the gross tumor volume with a 2-3 cm margin for the clinical target volume.
45476230|NCT03628274|Device|Magnetic Resonance Imaging (MRI) 7 Tesla|An MRI performed as part of the project
45476231|NCT03628274|Device|Magnetic Resonance Imaging (MRI) 1,5 Tesla|An MRI performed as part of the care
45476232|NCT01192763|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
45476233|NCT01192763|Other|laboratory biomarker analysis|Correlative studies
45476234|NCT01192763|Other|pharmacological study|Correlative studies
45476235|NCT01192763|Procedure|neoadjuvant therapy|
45685520|NCT02472028|Other|usual strategy|The implementation of antihypertensive therapy the current recommendations to reach the blood pressure target in usual care. Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. Combinations of different pharmacological classes can be tested in order to find the most effective and best tolerated combinations.
45841553|NCT05636059|Other|Exercise + cryotherapy|"Exercise program - 16 sessions in total, once a day, 30 min. one session. Cryotherapy - 8 sessions in total, two-three times a week, one session - 2 min. duration, temperature -60 to -140 C degrees.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
45847594|NCT04340856|Drug|Laxatives|There are no guidelines to direct laxative measures in patients with chronic megacolon. Historically, it is the gastroenterologists individual choice to use one of the above mentioned laxative measures. Therefore, the aim of this study is to analyze the success and downsides of the different Laxative measures.
45476236|NCT01192763|Procedure|therapeutic conventional surgery|
45476237|NCT04097210|Diagnostic Test|POC|
45476238|NCT02517892|Procedure|Biopsy|
45476239|NCT04539548|Drug|Dextenza|Dextenza, dexamethasone ophthalmic insert
45476240|NCT04539548|Drug|Prednisolone|Prednisolone, acetate ophthalmic suspension
45476241|NCT02517970|Behavioral|Technology distraction|Infants will be fed with classical music playing in the background for one feeding and with a television show playing for the mother to watch during the other.
45476242|NCT01192841|Other|Physician uniform|Participants were given a clean uniform (scrubs) on the day of the study. They wore this for approximately 8 hours.
45685521|NCT02466334|Drug|Calcitonin-Gene Related Peptide|1,5 µg/min of IV CGRP over 20 mins
45685522|NCT02466334|Drug|Placebo|40 ml of normal saline over 20 mins
45685523|NCT02460874|Drug|Glyburide|1.25mg, twice a day
45685524|NCT02460874|Other|Placebo|1.25mg, twice a day
45685525|NCT02451436|Behavioral|Sleep and Media Use Intervention|
45685526|NCT02451436|Behavioral|Study Skills Control Group|
45685527|NCT02443324|Drug|Ramucirumab|Administered IV
45685528|NCT02443324|Drug|Pembrolizumab|Administered IV
45349632|NCT05352412|Behavioral|Shared Decision Making Aid|Patients will be randomized to the shared decision making aid intervention.
45349633|NCT05352412|Behavioral|Baseline Counseling As usual|Patients will be randomized to the baseline counseling as usual.
45841554|NCT05636059|Other|Exercise + joint mobilization|"Exercise program - 16 sessions in total, once a day, 30 min. one session, two-three times a week.~Joint mobilization - 8 sessions in total, anterior - posterior tibia femoral glide, patella motion, lateral and medial movement.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
45349634|NCT02560428|Behavioral|ESCALATES|The investigators collect and analyze qualitative data to identify the most effective combinations of intervention strategies for various practice types, contexts, and organizational characteristics, and to understand why and how those combinations are effective. The investigators also gather de-identified quantitative data that the R18s collected.
45349635|NCT00859365|Procedure|Real Acupuncture|Real acupuncture treatment in real acupuncture points
45349636|NCT00859365|Procedure|Placebo Acupuncture|empty plastic acupuncture guide-tube located on the patients back in a non visable area and connected to a visible electric stimulator
45349637|NCT00859365|Procedure|No intervention|Patients lay down for a period of 35 minutes without any treatment o intervention
45349638|NCT00948844|Device|Hybrid (3-d accelerometers, and gyroscopes)|A 3 D accelerometer worn on the lower back or leg
45349639|NCT05402592|Dietary Supplement|Carbonhydrate rich drink|It will be prepared by adding 50 g of carbohydrates to 1200 ml of water in total and will be given to the patients the night before the surgery and the morning of the surgery.
45349640|NCT05402592|Other|Water|A total of 1200 ml of water will be given to the patients the night before and the morning of the surgery.
45349641|NCT02544477|Device|High-flow Nasal Cannula Oxygen (HFNCO)|
45349642|NCT02544477|Device|Conventional oxygen treatment|
45349643|NCT00949000|Device|ICD Implantation|Implantation of a commercially available AnalyST or AnalyST Accel ICD
45349644|NCT03993145|Behavioral|Web-based lifestyle intervention|Lifestyle intervention program including educational modules on diet and physical activity with visual and audio. Phone conversation with the clinical dietician at week 1, week 3, week 6, week 12 and month 6 (completion of the study).
45349645|NCT00859599|Device|Monochromatic phototherapy, Biolight®|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
45685529|NCT01893970|Behavioral|SWIFT|Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
45841555|NCT05633459|Drug|QRL-201 - Dose 1|"Drug: Dose 1 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
45841556|NCT05633459|Drug|QRL-201 - Dose 2|"Drug: Dose 2 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)~Diluent: artificial cerebrospinal fluid (aCSF)"
45349646|NCT00859599|Device|Monochromatic phototherapy|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
45349647|NCT05396898|Drug|LCP-tacrolimus|Prophylaxis of transplant rejection in liver and kidney allograft recipients
45349648|NCT05396898|Drug|twice-daily tacrolimus|Prophylaxis of transplant rejection in liver, kidney or heart allograft recipients
45349649|NCT00694304|Drug|Vortioxetine (Lu AA21004)|2.5, 5, or 10 mg/day; tablets; orally
45349650|NCT05352334|Diagnostic Test|self-report Emotional Intelligence test (SSCEIT)|The participants fulfilling the inclusion criteria will be selected from above mentioned different government and private universities. The total number of participants in data collection procedure will be 44. Informed consent will be taken from all the students and self-administered questionnaire will be distributed to students for data collection procedure. The emotional intelligence and physical activity will be measured and collected through Schutte self-report Emotional Intelligence test (SSCEIT) and international physical activity questionnaire. The questionnaires for physical activity will consist of 12 questions and for SSCEIT consist of 33 questions. Emotional intelligence will be measured by schutte self-report emotional intelligence scale and physical activity will be measured by international physical activity questionnaire.
45349651|NCT00371839|Procedure|Audiological Evaluation|Tests of hearing, cognition, and speech perception
45349652|NCT00866853|Drug|TMC435|
45685530|NCT01893970|Behavioral|SWIFT-Acute|acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
45841557|NCT05633459|Drug|QRL-201 - Dose 3|"Drug: Dose 3 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
45349653|NCT05386836|Device|Pulse oximeter validation population|Evaluation of the SpO2 accuracy performance of the Sunrise Sensor 2 placed at the tip of the chin during non-motion conditions over the range of 70-100% by comparison to SaO2 values determined from arterial blood sample specimen analyzed by a CO-oximeter.
45841558|NCT05633459|Drug|QRL-201 - Dose 4|"Drug: Dose 4 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
45349654|NCT00949156|Procedure|Different surgical approach and techniques being used to treat three subtype of CP|According to the presurgical MRI, with the analysis of the morphological characteristic of three subtype of CP, different surgical approach and intrasurgical skills were used to treat tumors with trying to total remove tumor and avoid the hypothalamus injury.
45349655|NCT04685876|Drug|Liposomal bupivacaine|4-quadrant TAP block with liposomal bupivacaine
45841559|NCT05633459|Drug|QRL-201 - Dose 5|"Drug: Dose 5 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
45841560|NCT05633459|Drug|QRL-201 - Dose 6|"Drug: Dose 6 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
46044983|NCT04098276|Behavioral|WeWomen Plus technology based intervention|The WeWomen Plus intervention is a technology based (online, text and phone)culturally tailored intervention designed to reduce the risk of future intimate partner violence or a homicide, improve mental health and increase empowerment of abused immigrant women.
45349656|NCT04685876|Drug|Plain bupivacaine|4-quadrant TAP block with plain bupivacaine
45349657|NCT04685876|Drug|Normal saline|placebo (normal saline).
45349658|NCT02544399|Other|3D CT scan|Measure of bone micro-architecture by 3D micro-tomography
45349659|NCT01044511|Behavioral|Home visits|home visits by specialist nurse 2 times and 1 phonecall
45349660|NCT01044511|Behavioral|standard|hotline
45685531|NCT01894048|Drug|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
45349661|NCT04011904|Other|Cross-over study|Traditional Inuit Diet vs Westernized Diet
45349662|NCT04040517|Diagnostic Test|Evoked potential audiometer|The ASSR [ steady state response] test stimuli are modulated pure tones with insert earphone..
45349663|NCT00682890|Drug|placebo|placebo birth control pill daily
45349664|NCT00682890|Drug|metformin|2000 mg per day for 3 months daily birth control pill
45349665|NCT02565368|Drug|Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg|single oral administration
45349666|NCT02565368|Drug|CKD-395 0.5/1000mg|single oral administration
45685532|NCT02427178|Biological|Hematopoietic Allogeneic Stem Cells|HLA 10/10 matched allogeneic bone marrow cells will be infused into recipient (patient).
45349667|NCT00949390|Behavioral|Questionnaire|Survey given at appointment time, then dropped in specified box anonymously.
45349668|NCT04040595|Procedure|Abdominal fat biopsy|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
45476243|NCT00708916|Drug|CC-10004|20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment
45476244|NCT01196039|Drug|MEMP1972A|Intravenous repeating dose
45476245|NCT01196039|Drug|placebo|Intravenous repeating dose
45685533|NCT02420860|Biological|Elotuzumab|Given IV
45685534|NCT02420860|Drug|Lenalidomide|Given PO
45685535|NCT02420860|Other|Questionnaire Administration|Ancillary studies
45685536|NCT02420314|Drug|Paclitaxel|"Administered intravenously (IV)~Prescribed at 200 mg/m2 (standard dose)~Given once every 21 days (i.e., one cycle)~Up to 4 cycles are administered depending on disease response"
45841561|NCT05633459|Drug|QRL-201 - Dose 7|"Drug: Dose 7 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
45685537|NCT02420314|Drug|Carboplatin|"Administered intravenously (IV)~Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)~Given once every 21 days (i.e., one cycle)~Up to 4 cycles are administered depending on disease response"
45685538|NCT02420314|Drug|Ascorbic Acid|"Administered intravenously (IV)~75g per infusion~Two infusions per week~1 cycle is 3 weeks~given up to 4 cycles~may be given while chemotherapy if delayed due to low counts"
45841562|NCT05633459|Drug|QRL-201- Dose 8|"Drug: Dose 8 of QRL-201 administered via intrathecal injection~Diluent: artificial cerebrospinal fluid (aCSF)~Placebo: consists of the same components as the formulation buffer for QRL-201 administered via intrathecal injection. Calculated volume to match active comparator~Diluent: artificial cerebrospinal fluid (aCSF)"
46044984|NCT02646046|Behavioral|Combi lone-CPR|When study participants meet the arrest victim (simulated), they start chest compression and call for help to EMS at the same time, then continue the chest compression and 2 breath alternatively until the EMS arrival
46044985|NCT02646046|Behavioral|Conventional lone-CPR|When study participants meet the arrest victim (simulated), they first call for help to EMS and then start chest compression and 2 breath alternatively until the EMS arrival
45349669|NCT03992365|Drug|Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)|"The evening before the colonoscopy: Take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 20 tablets.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 12 tablets."
45349670|NCT03992365|Drug|Polyethylene glycol 3350, sodium sulfate anhydrous, sodium bicarbonate, sodium chloride, potassium chloride, aspartame;Bisacodyl|"The day before the colonoscopy: One 5 mg tablet of Dulcolax® will be administered, do not chew or crush the tablet, in the afternoon before the day of colonoscopy. About 4 hours after administration of Dulcolax®, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes."
45476246|NCT02352753|Drug|Denosumab|Subcutaneous (SC) injection.
45349671|NCT04011514|Behavioral|Dedicated stroke nurse care in ED|A specialized SU nursing team partner with ED nursing staff for timely fulfillment of stroke quality care indicators while awationg admission to a dedicated stroke unit
45349672|NCT00921804|Drug|AZD 8529|40mg oral daily capsule administered as a single dose in the morning for 28 days
45349673|NCT00921804|Drug|Risperidone|4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days
45349674|NCT00921804|Drug|Placebo to match AZD8529|Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period
45349675|NCT00921804|Drug|Placebo to match risperidone|Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period
45349676|NCT02534779|Other|Placebo Vaginal Insert|Placebo insert
45349677|NCT00867399|Drug|ABT-126|See arm for details
45349678|NCT00758316|Other|Thoracoscopy and Pleurx|Talc poudrage and tunneled pleural catheter
45349679|NCT00758316|Procedure|Thoracoscopy|Talc poudrage
45349680|NCT00859755|Drug|ARRY-403, glucokinase activator; oral|single dose, escalating
45685539|NCT02418832|Procedure|Sperm cell aspiration and TEFNA|Testicular Fine Needle Aspiration (TEFNA)
45685540|NCT02404012|Dietary Supplement|Oral iron supplementation|Participants will be provided supplementation for 8 weeks
45685541|NCT02403778|Drug|VESANOID|All-trans retinoic acid (ATRA) is a vitamin A derivative that binds the retinoic acid receptor on MDSCs and differentiates immature monocytes into more mature dendritic cells (12). VESANOID is a standard treatment for patients with acute promyelocytic leukemia (APL).
45685542|NCT02403778|Drug|Ipilimumab|Ipilimumab is current standard of care treatment for melanoma.
45685543|NCT01539291|Drug|Idelalisib|Idelalisib tablet(s) administered orally twice daily
45685544|NCT04746040|Drug|Test|2 inhalations of Test and Reference product in each study period
45685545|NCT04746040|Drug|Reference|2 inhalations of Test and Reference product in each study period
45685546|NCT02400814|Drug|Anti-PD-L1 Monoclonal Antibody MPDL3280A|Given IV
45685547|NCT02400814|Radiation|Stereotactic Body Radiation Therapy|Undergo SAR
45685548|NCT02398240|Drug|Brentuximab Vedotin|Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
45349681|NCT00859755|Drug|Placebo; oral|matching placebo
45349682|NCT00754182|Device|Octylcyanoacrylate (Dermabond)|Synthetic glue for surgical use (skin closure)
45476247|NCT01192997|Biological|Menveo|Single dose Menveo (a MenACWY vaccine conjugated to CRM-197).
45476248|NCT01192997|Biological|MenACWY-TT|Single dose MenACWY-TT (MenACWY vaccine conjugated to Tetanus Toxoid, TT)
45685549|NCT02398240|Drug|Doxorubicin|Days: 1 and 15 Dose: 25 mg/m2/dose.
45685550|NCT02398240|Drug|Vincristine|Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).
45685551|NCT02398240|Drug|Rituximab|Days: 2 and 16 Dose: 375 mg/m2/dose.
45685552|NCT02022280|Drug|Lansoprazole|
45685553|NCT02022280|Drug|Placebo|Vitamin pill
45685554|NCT02372734|Other|Pediatric Quality of Life (Peds QL) Survey|The subjects will be administered the Peds QL survey. Children will also have a parental section for parental response. This is NOT an interventional study.
45685555|NCT02364310|Device|Baroreceptor stimulation with Barostim Neo TM|
45685556|NCT02363374|Drug|Induction Chemotherapy arm A|"Patients receive three induction chemotherapy cycles, starting on day 1, 15 and 29, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv~After a break of two weeks, radiotherapy starts combined with:~5-FU: 250 mg/sqm per day, iv, on day 43-57, day 64-77 Oxaliplatin: 50 mg/sqm, day 43, 50, 64, and 71"
45685557|NCT02363374|Radiation|Radiation arm A|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 43 -80
45685558|NCT02363374|Radiation|Radiation arm B|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
45841563|NCT05622500|Procedure|Deep venous stenting|Endovascular reconstruction encompasses balloon venoplasty and venous stenting. A dedicated venous stent will be used, the brand of which the individual interventionist will decide.
45476249|NCT04532294|Drug|BGB DXP593|Administered intravenously (IV) as specified in the treatment arm
45476250|NCT04532294|Drug|Placebo|Placebo to match BGB-DXP593
45476251|NCT04245514|Drug|Durvalumab|Immunotherapy
45476252|NCT04245514|Radiation|Radiotherapy|Immune-modulatory radiotherapy to the primary tumor, with either Cohort A: 20 x 2 Gy weekdaily Cohort B: 5 x 5 Gy weekdaily Cohort C: 3 x 8 Gy q2d
45349683|NCT00754182|Device|Subcuticular reabsorbable suture (Caprosyn)|Every stitch is positioned in the subcuticular tissue by a continuous technique
45349684|NCT00859911|Dietary Supplement|Multiple micronutrients|A tablet on three days a week containing: Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocoblamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
45349685|NCT00954694|Device|NuStep fitness apparatus|The NuStep is a mode of exercise that has recently been used in clinical settings to determine appropriate intensity recommendations and energy expenditures. The NuStep exercise implement provides simultaneous upper and lower body movement while in a seated position. The machine stimulates all major muscle groups while putting minimal strain on joints. Ten resistance settings are offered and the device is fully adjustable to accommodate users of varying sizes (NuStep, 2009).
45841564|NCT05622500|Combination Product|Best medical therapy|Compression stockings encompass a range of therapies used to provide an externally applied graduated-pressure up the length of the limb aiming to improve venous function and decrease lower limb swelling. Compression stockings can be classified by size and grade, i.e. the pressure the stockings applies to the limb. For the purpose of this trial Class II and Class III graduated compression stockings should be used, with the aim of providing Class III if tolerated. Antithrombotic agents include, but are not limited to: warfarin (titrated to international normalised ratio, INR), apixaban, rivaroxaban, aspirin, and clopidogrel.
45349686|NCT00385723|Dietary Supplement|Omega 3 (Fish Oil) Supplementation|1.25 g or 2.496 g daily for 4 months
45349687|NCT00385723|Dietary Supplement|Placebo|matching placebo capsule daily for 4 months
45349688|NCT00698516|Drug|Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)|2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle.
45841565|NCT05620472|Drug|Diagnostic Test: whole body study and SPECT with [99mTc]Tc(CO)3-(HE)3-Ec1|One single intravenous injection of [99mTc]Tc(CO)3-(HE)3-Ec1, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
45841566|NCT05618951|Other|Lower Trapezius Strengthening Exercises|"Lower Trapezius strengthening exercise includes:~Latissimus pull down~Prone V- raise~Modified Prone Cobra"
45841567|NCT05601583|Device|Continuous Glucose Monitor (CGM)|FDA-cleared FreeStyle Libre Glucose Monitoring System manufactured by Abbott. Integrated continuous glucose monitoring system that provides continuous glucose measurements every minute to provide glucose levels, trends and alerts.
45349689|NCT00859989|Behavioral|behavioral dietary intervention|
45349690|NCT00859989|Behavioral|exercise intervention|
45349691|NCT00859989|Behavioral|telephone-based intervention|
45685559|NCT02363374|Drug|Chemotherapy arm B|"chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29.~After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv"
45349692|NCT00859989|Other|counseling intervention|
45476253|NCT03845075|Drug|Tesofensine|During Part 1 subjects will be randomized to treatment with co-administration of 0.5 mg tesofensine/50mg metoprolol (active medication)
45685560|NCT02363374|Procedure|Surgery|Surgery should be performed about 5 (arm B) or 6 (arm A) weeks after the last radiation or chemotherapy, i.e. around day 123
45841568|NCT05592366|Behavioral|Care Partner Hospital Assessment Tool|Complete the adjusted CHAT as well as demographic and caregiving questionnaires during and after loved one's hospitalization.
45349693|NCT00859989|Other|educational intervention|
45349694|NCT00859989|Other|immunoenzyme technique|
45476254|NCT03845075|Drug|Placebo|During Part 1 subjects will be randomized to matching placebo treatment with co-administration of 0.5 mg tesofensine/50mg metoprolol
45476255|NCT02517736|Drug|Sorafenib at a dose of 800 mg / day|
45476256|NCT03727971|Drug|Omalizumab Injection|The treatment is initiated with one injection with weight and serum-immunoglobulin E balanced omalizumab. After omalizumab treatment at ovulation it will again be collected material (blood samples, sputum, secretion of the vagina, secretion of the rectum, secretion of the uterus, microbiota). If no pregnancy has occurred after first IVF cycle, this will be repeated for 3 consecutive IVF cycles in total or until pregnancy has occurred.
45476257|NCT03727971|Drug|NaCl|The treatment is initiated with one injection with placebo. After placebo injection treatment at ovulation it will again be collected material (blood samples, sputum, secretion of the vagina, secretion of the rectum, secretion of the uterus, microbiota). If no pregnancy has occurred after first IVF cycle, this will be repeated for 3 consecutive IVF cycles in total or until pregnancy has occurred.
45476258|NCT03347578|Diagnostic Test|Ultrasonography|Diaphragmatic ultrasound was performed to investigate diaphragmatic function after thoracic surgery
45476259|NCT03844841|Drug|Propofol|At minimum 5 minutes before start of sedation for atrial fibrillation ablation a bolus of fentanyl (20-50 µg) will be administered. Thereafter, sedation is induced via the continuous infusion of propofol using a target-controlled infusion (TCI) pump. The effect-site propofol concentration will be initially set to 1.5 µg/ml, unless the patient is already sedated by fentanyl. Subsequently, an effect-site propofol concentration of 1 µg/ml will be chosen adjusted stepwise (using steps of 0.3 µg/ml) to reach a target score of 2-3 on the MOAA/S scale. In case of pain fentanyl can be administered bolus-wise (10-30 µg) at the cardiologists discretion.
45685561|NCT01538199|Device|Near-infrared radiation via Transcranial LED Therapy|"The subject will lie down comfortably on a exam bed . The sites of application of TLT (left and right forehead) will be inspected for any skin lesions (e.g. laceration or signs of inflammation) which would contraindicate the treatment. The subject will wear protective eyewear in the form of goggles or eye pads.~The staff administering the TLT will be careful not to shine the light in or near the eyes of the subject. The two OLS devices will be secured in position with the use of a Hair Net. The delivery of the TLT is expected to last 20 min total (simultaneous application on the left and right forehead). The subject will be asked to rest for five minutes after the delivery of TLT. The skin at the sites of the application will be inspected again prior to dismissing the subject."
46044986|NCT00814489|Biological|GSK2231395A|Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2. Two different formulations of this vaccine will be tested.
45685562|NCT01538199|Device|Sham device|The sham device does not emit near-infrared radiation.
45841569|NCT05588583|Device|Mepilex Up|"Mepilex Up is a highly conformable dressing that absorbs both low and high viscous exudates, maintains a moist wound environment and minimises the risk of maceration. The dressing has a Safetac® wound contact layer that is a unique adhesive technology. It minimises pain to patients and trauma to wounds and the surrounding skin at dressing removal.~Mepilex Up consists of:~a soft silicone wound contact layer (Safetac)~a flexible absorbent pad of compressed polyurethane foam~an outer polyurethane film which is breathable but waterproof~Dressing material content:~Silicone, polyurethane"
45841570|NCT05581823|Drug|Tavapadon|Oral tablets
45841571|NCT05581823|Drug|Carbamazepine|Extended-release oral tablets
45349695|NCT00859989|Other|laboratory biomarker analysis|
45349696|NCT00859989|Other|questionnaire administration|
45349697|NCT00859989|Other|study of socioeconomic and demographic variables|
45349698|NCT00859989|Procedure|evaluation of cancer risk factors|
45349699|NCT00859989|Procedure|support group therapy|
45349700|NCT00679302|Drug|Trimethoprim-sulfamethoxazole|Participants were randomized to receive placebo or trimethoprim/sulfamethoxazole using a computer randomization program on the initial presentation. The placebo is a Maalox and tonic water combination that resembled the antibiotic in color, texture and taste. The antibiotic dose is a standard trimethoprim/sulfamethoxazole for bacterial infection (10-12mg trimethoprim/kg/day, with a maximum adult dose of 160mg trimethoprim/day, divided into two doses). The concentration of the liquid is 200mg sulfamethoxazole/40mg trimethoprim per 5mL. With a maximum dose of 160mg trimethoprim, this equates to 20mL.
45349701|NCT00679302|Drug|Placebo group|Placebo (Maalox with simethicone and bitter mixture) suspension was dispensed to study participants who were block randomized to receive the placebo.
45841572|NCT05577858|Other|Meat based|Omnivorous diet following dietary guidelines
45841573|NCT05577858|Other|Pulse based|Vegetarian pulse-based diet following dietary guidelines
45349702|NCT04011124|Drug|Fluzoparib|single dose on Day 1 and Day 12
45841574|NCT05568459|Other|Non-Interventional|No study treatment will be administered in this study.
45349703|NCT04011124|Drug|Rifampicin|QD on Day 5-14 for 10 days
45841575|NCT05553951|Behavioral|Controlgroup|The control group and intervention group will receive daily text message reminders twice a week to take their medications and to rinse their nose.
46044987|NCT00814489|Biological|Engerix-B|Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2.
45349704|NCT00862797|Other|pressure measurement during swallowing|measurement of endotracheal tube cuff pressure during swallowing while recovering from anaesthesia
45349705|NCT01047397|Drug|1278863A|25mg, 50mg, 100mg
45685563|NCT01511445|Device|Anterior cervical discectomy and fusion (ACDF) with PEEK Cage|Anterior cervical discectomy and fusion with the use of a PEEK plastic interbody spacer
45685564|NCT01511445|Device|Anterior cervical discectomy and fusion (ACDF) with a Valeo CSC Cage|Anterior cervical discectomy and fusion with a Valeo ceramic cage interbody spacer.
45841576|NCT05553951|Behavioral|Intervention|Patients in the intervention group will receive systematic and structured nursing guidance regarding their adherence, which includes proper use of nasal irrigation once or twice daily, nasal steroid/drops, use of inhaled medications, follow-up of smoking status. The intervention group will receive guidance videos which have been prepared prior to the study and will be standard for the intervention group. Guidance videos will cover the correct use of nasal irrigation, inhalation steroid, and nasal steroid/drops.
45841577|NCT05549180|Drug|BIKTARVY 50Mg-200Mg-25Mg Tablet and Dovato placebo|The patients randomized to experimental arm will be randomized to Biktarvy + Dovato placebo
45841578|NCT05549180|Drug|Dovato 50Mg-300Mg Tablet + Biktarvy placebo|The patients randomized to comparador arm will be randomized to Dovato + Biktarvy placebo
45841579|NCT05540704|Behavioral|iACT|Treatment is based on Acceptance and Commitment Therapy (ACT), a contemporary cognitive behavioral therapy (CBT) that improves human functioning and adaptability by increasing psychological flexibility. Individual therapy sessions are paired with mobile phone delivered interventions.
45841580|NCT05540704|Other|Usual Care|Usual care for problems in Type 1 diabetes management
45841581|NCT05526976|Other|PERISCOPE-care|Patients with planned elective surgery will be asked to complete the PERISCOP3E-Care questionnaire (modified-Althaus & Kalkman, DN4, HADS, Stait-trait, NRS, MPI, EQ-5D-5L) preoperative. One month and three months post op the patients will be contacted to check if they developed persistend postoperative pain and they will also complete questionnaires (DN4, HADS, Stait-trait, NRS, MPI and EQ-5D-5L).
46044988|NCT02610595|Drug|Jianpixiaozhong particles and Wuse Dietotherapy|Jianpixiaozhong particles: Three packs once,bid po; Wuse Dietotherapy: one packs once,bid po
46044989|NCT00708799|Other|Azithromycin on admission - not enrolled in the RCT|One dose of azithromycin prior to inclusion to the RCT
45349706|NCT01047397|Drug|Placebo|matching placebo
45349707|NCT02564822|Procedure|Visual Stimulation|volunteers will be invited to sit in a comfortable chair, in a calm and dark room, at 90 cm of distance from computer screen. It will be asked to fix his right eye visual field on a red point at the center of the screen (the left one will be blindfolded). Visual stimuli will be a black and White grid pattern, alternating at a frequency of 3.1 Hz.
45349708|NCT00862875|Drug|Detemir or Glargine|Initial dose of 10 units of insulin at bedtime. The insulin dose will be increase by 1 unit per day until fasting plasma glucose (FPG) levels are 5.0 mmol/L.
45349709|NCT02566616|Device|Ulnar Nerve Stimulation|1 hour of continued stimulation of the ulnar nerve using a hand held stimulator
45349710|NCT00867477|Procedure|Breathing Test|Exhale into NO breath analyzer for 10 seconds, repeated 3 times (before radiation therapy starts, after completing radiation therapy, and after scheduled PET scan).
45349711|NCT00867477|Behavioral|Respiratory Symptoms Questionnaire|3 page questionnaire about breathing and any symptoms experienced, at each of 2 NO breathing tests.
45685565|NCT01511055|Drug|EC-17|One-time dose of Folate-FITC (EC-17), 0.1mg/kg IV 2-3 hours prior to surgery.
45685566|NCT02362594|Biological|pembrolizumab|Pembrolizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle
45685567|NCT02362594|Drug|placebo|Normal saline solution administered IV on Day 1 of each 21-day cycle
45685568|NCT02362438|Genetic|scAAv9/JeT-GAN|scAAV9/JeT-GAN is a biological gene transfer reagent
45841582|NCT05524454|Device|Novel CBCT Imaging|One or two CBCT images are acquired on the novel CBCT imaging system.
45349712|NCT00867477|Procedure|Pet Scan|Between 40 and 50 days after the end of the radiation therapy. Ten (10) participants will receive a second PET scan within 2-7 days after the first PET scan in order to check reproducibility.
45349713|NCT00867555|Dietary Supplement|Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation|green tea extract TEAVIGO, high in EGCG
45349714|NCT00955006|Biological|VRC-HIVDNA-016-00-VP|Composed of six DNA plasmids in equal concentrations that encode Gag, Pol, and Nef from clade B (strains HXB2, NL4-3, NY5/BRU) and the HIV-1 Env glycoproteins from clade A (strain 92rw020), clade B (strains HXB2/BaL), and clade C (strain 97ZA012). Vaccine will be administered intramuscularly (IM) in the deltoid via needle-free Biojector.
45349715|NCT00955006|Biological|VRCHIVADV014-00-VP|A mixture of 4 recombinant serotype 5 adenoviral replication deficient vectors, each expressing HIV-1 proteins (clade B Gag-Pol fusion, clade A Env, clade B Env, clade C Env). Administered IM via needle and syringe.
45349716|NCT02378246|Dietary Supplement|Iodine|
45476260|NCT03844841|Drug|Dexmedetomidine|At minimum 5 minutes before start of sedation for atrial fibrillation ablation a bolus of fentanyl (20-50 µg) will be administered. Thereafter, sedation is induced with a loading dose of dexmedetomidine (0.8 µg/kg) over 10 minutes. The maintenance dexmedetomidine dose is adjusted to the appropriate sedation criteria for CA (0.4 µg/kg/h) and for a target score of 2-3 on the MOAA/S scale. In case of pain, additional fentanyl can be administered bolus-wise (10-30 µg) at the cardiologists discretion.
45349717|NCT02378246|Dietary Supplement|Placebo|
45349718|NCT02544165|Dietary Supplement|caffeine intake|The subjects of this group should intake 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
45349719|NCT02544165|Other|cigarette smoking|The subjects of this group should smoke one cigarette after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
45349720|NCT02544165|Other|Caffeine intake and Cigarette smoking|The subjects of this group should smoke one cigarette and should consume 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
45349721|NCT00955084|Drug|XL999|XL999 for injection will be supplied as a brown, sterile injectable solution at a concentration of 5 mg/mL
45349722|NCT05343156|Drug|Dexamethasone nanoparticles eye drops|DexNP 15 mg/mL eye drops 3 times a day (every 8 hours) for 12 weeks
45349723|NCT00955162|Drug|Buprenorphine (Subutex)|Sublingual tablet
45349724|NCT00955162|Drug|Buprenorphine/naloxone (Suboxone)|Sublingual tablet
45476261|NCT03197766|Drug|BMN 111|Subcutaneous injection of 15 μg/kg of BMN 111 daily
45476262|NCT03197766|Drug|Placebo|Subcutaneous injection of 15 μg/kg of placebo daily
45476263|NCT03704025|Behavioral|Current guidelines rehabilitation|Exercise training intervention is six months and includes four to five aerobic and two strength training session a week according to American Heart Association guidelines for coronary artery disease patients. All the patients will have a detailed and personalized training diary.
45476264|NCT03704025|Behavioral|Mobile device guided rehabilitation|Exercise training intervention is six months and includes four to five aerobic and two strength training session a week according to American Heart Association guidelines for coronary artery disease patients. Study group will have virtual glasses or mobile device to motivate and control exercise training program.
45685569|NCT02355340|Other|Dual energy x-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
45685570|NCT02355340|Other|Peripheral quantitative computed tomography (pQCT)|Subjects will undergo pQCT assessment of radius and tibia.
45685571|NCT02344186|Drug|Liraglutide|Crossover design - 24 weeks on active drug and 12 weeks daily placebo
45685572|NCT02315716|Procedure|Autologous Stem Cell Transplant (ASCT)|Randomisation to melphalan conditioned autologous stem cell transplant
45685573|NCT02315716|Drug|Consolidation with 4 cycles of CarCyDex|Randomisation to 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone for responding patients following 4 cycles of induction chemotherapy
45685574|NCT04757428|Procedure|Endocrown|Endocrown
45685575|NCT01537887|Drug|LY2484595|Administered orally once daily for 10 days.
45841583|NCT05517707|Device|Nasogastric Tube|Temperature and impedance data will be collected from sensors embedded within the feeding tube wall.
45841584|NCT05513001|Drug|LOU064 (blinded)|LOU064 (blinded) active treatment
45841585|NCT05513001|Drug|Placebo|Placebo
45685576|NCT01537887|Drug|Placebo|Administered orally once daily for 10 days.
45685577|NCT01537887|Drug|Moxifloxacin|Single dose administered orally.
45685578|NCT04757350|Other|Observational research, not applicable|Observational research, not applicable
45685579|NCT02305264|Drug|18F-DPA-714 and 18F-FDG|"Positron emission tomography (PET) imaging following the injection of 2 radiotracers (here considered as the drugs): 1) 18F-DPA-714 ii) 18F-FDG. PET -18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.~18F-FDG , dose 5mci(185MBq), will be injected via an arm intravenous catheter."
45685580|NCT02297698|Biological|NeuVax vaccine|At the time of vaccine administration, a frozen solution of E75 acetate (1.5 mg/mL) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. Patients randomized to this arm will receive vaccinations of nelipepimut-S/GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
45685581|NCT02297698|Drug|Trastuzumab|Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first trastuzumab infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Trastuzumab will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
45841586|NCT05513001|Drug|LOU064 (open label)|LOU064 (open-label) active treatment
45841587|NCT05510297|Device|FitSitt Prototype|FitSitt merges features of a posture chair, exercise machine, and tracking means. It provides seated stepping, postural support, and semi-recline capabilities. A digital interface and app will allow users to set goals and track performance.
45841588|NCT05500599|Drug|Fentanyl Citrate|Intravenous Formulation of Fentanyl Citrate and Midazolam Administered Orally for Premedication
45841589|NCT05498116|Drug|Montelukast|10mg daily
45349725|NCT00742664|Behavioral|Cognitive-behavioral therapy|The manual is informed by behavioral principles and provides a structured, replicable manner of treating OC symptoms in youth with PWS. The treatment is individual in nature, includes a strong family component (i.e., teaching parents to be their child's coach/therapist), and lasts for approximately 12 sessions, held in a twice-weekly format. In addition, the protocol includes several specific components: education about OC symptoms (i.e., etiology, behavioral function, etc.), developing a hierarchy of rituals to target, exposure and response prevention exercises, promoting adaptive familial responses to child behaviors, and relapse prevention and problem solving future situations.
45349726|NCT00742664|Behavioral|Wait-list control|The subject will not receive active treatment during this interval.
45841590|NCT05498116|Other|Placebo|1 capsule daily
45841591|NCT05489978|Behavioral|"Cervical Cancer Stigma Reduction Intervention"|"Change in knowledge:~Cervical cancer burden in Nepal, signs and symptoms, preventive measures available, lifestyle modifications, HPV vaccination, early diagnosis, screening, and treatment.~Change in Stigma~Para-social contact~Video of a person facing cervical cancer what symptoms she got, how she dealt with it, and how she overcame it.~Experiences of a cervical cancer survivor so that women personalize the information by relating it to their own life experiences by changing their attitude and behavior.~Participatory learning techniques~Personal stories: Voluntary self-reflection of any stigma they perceive on cervical cancer or their community perceives cervical cancer.~Group Discussion: Discuss the drivers of stigma, facilitators of sigma, types of stigma prevalent in your community, and consequences of stigma.~Myths vs facts: Negative attitudes, myths, and misconceptions about cervical cancer will be contraindicated by factual information."
45841592|NCT05483686|Behavioral|Shine|This tailored, multifaceted mobile intervention aims to improve HIV-related outcomes and increase gender affirmation among African American transgender women. Potential users will opt-in by texting from their own mobile phone and, once registered, will be enrolled into a program that will be theory-based, targeted, tailored, and personalized. Users will receive three main types of texts: informational, motivational, and skill-building. Finally, the program will include three web-based video components: scripted vignettes, unscripted peer narratives, and educational instruction. By developing an intervention using a technology that is part of the everyday lives of most African Americans, the aim is to reduce HIV disparities. We envision the proposed intervention being used by clinics and community-based organizations that serve transgender women.
45349727|NCT00862953|Dietary Supplement|Normal protein energy-restricted|Normal protein diet energy restricted
45685582|NCT02297698|Drug|GM-CSF|For patients randomized to the GM-CSF alone arm, they will receive inoculations of GM-CSF (250mcg) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first injection will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
45685583|NCT05585944|Diagnostic Test|Genotyping of rs1883832C/T related single-nucleotide polymorphism|Genotyping of rs1883832C/T related single-nucleotide polymorphism by real time pcr
45841593|NCT05483686|Behavioral|Control|A playlist of CDC-developed videos designed to provide information on HIV for transgender women
45841594|NCT05480865|Drug|BBP-398|BBP-398 administered orally
45841595|NCT05480865|Drug|sotorasib|sotorasib administered orally
45841596|NCT05471076|Biological|426c.Mod.Core-C4b 30 mcg|Administered via injection as a split dose into the deltoid muscle (both left and right).
45841597|NCT05471076|Biological|426c.Mod.Core-C4b 100 mcg|Administered via injection as a split dose into the deltoid muscle (both left and right).
45841598|NCT05471076|Biological|426c.Mod.Core-C4b 300 mcg|Administered via injection as a split dose into the deltoid muscle (both left and right).
45841599|NCT05471076|Other|Placebo|Administered via injection as a split dose into the deltoid muscle (both left and right).
45841600|NCT05469178|Drug|Bemcentinib|Bemcentinib capsules will be administered orally.
45841601|NCT05469178|Drug|Pembrolizumab|Pembrolizumab will be administered as an IV infusion as part of CIT every 3 weeks.
45349728|NCT00862953|Dietary Supplement|High protein energy-restricted|High protein diet, with either low or normal carbohydrate content
45476265|NCT04501900|Drug|Clopidogrel|Study subjects diagnosed as stable, unstable ischemic coronary disease or myocardial infarction planning to undergo percutaneous coronary intervention (PCI) and no contradiction to prolonged DAPT are eligible for this trial. All subjects will provide written informed consent to participate. Subjects will be enrolled into the study before or within 24 hours after the index procedure. Subjects will be randomized to either discontinue P2Y12 inhibitor (clopidogrel or ticagrelor) (12 months total) or receive P2Y12 inhibitor for an additional 24 months (36 months total). Aspirin will be maintained in the entire study and can be replaced by cilostazol or indobufen if subjects are intolerant. Dosage of antiplatelet drugs will be according to local standard of practice. Subjects will be treated with XINSORB BRS only.
45349729|NCT00949546|Drug|etanercept|etanercept 50 mg sc twice weekly
45349730|NCT05291364|Drug|Group 1|Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml + 2 μg/kg dexmedetomidine diluted in 0.9% sterile saline (total volume 12 ml) on each side
45476266|NCT03738332|Device|Low-Level Laser|Low-level laser therapy
45476267|NCT04501744|Drug|Cohort 1 of M701|Patients in Cohort 1 will receive 4 escalating doses (2, 5, 10 and 25 μg) of M701 on Days 1, 8, 15 and 22. The maintenance dose during extended treatment period is 25 μg.
45476268|NCT04501744|Drug|Cohort 2 of M701|Patients in Cohort 2 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 25 μg, and the maintenance dose during core treatment period and extended treatment period is 50 μg.
45841602|NCT05469178|Drug|Pemetrexed|Pemetrexed will be administered as an IV infusion as part of CIT every 3 weeks.
45841603|NCT05469178|Drug|Carboplatin|Carboplatin will be administered as an IV infusion as part of CIT every 3 weeks.
45349731|NCT05291364|Drug|Group 2|Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml diluted in 0.9% sterile saline (total volume 12 ml) on each side.
45349732|NCT00742742|Behavioral|healthy life style education|healthy life style education
45349733|NCT00949624|Drug|CP-868,596|Oral tablet 60 mg BID continuous
45685584|NCT01489527|Biological|Gardasil Vaccine|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
45685585|NCT01489527|Other|Placebo|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
45685586|NCT02315170|Device|intraocular injection guide|The device is 35mm long with tapered edges for an easy grip and it aligns with the curvature of the cornea to ensure that needle entry takes place at the optimal distance for injection
45349734|NCT00949624|Drug|Docetaxel|Intravenous 75 mg/m2 every three weeks
45685587|NCT02315170|Device|standard lid speculum|standard wire lid speculum
45685588|NCT01487577|Drug|Mycophenolate mofetil|Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure
45841604|NCT05460169|Device|Renal denervation|The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
46044990|NCT05756491|Other|24 months of inclusion of unaccompanied patients|inclusion for 6 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 24 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
45349735|NCT00949624|Drug|CP-868,596|Oral tablet 100 mg BID continuous
45349736|NCT00949624|Drug|Docetaxel|Intravenous 75 mg/m2 every three weeks
45349737|NCT00949624|Drug|CP-868,596|Oral tablet 100 mg BID continuous
45349738|NCT00949624|Drug|Docetaxel|Intravenous 100 mg/m2 every three weeks
45349739|NCT00949624|Drug|CP-868,596|Oral tablet 60 mg BID continuous
45349740|NCT00949624|Drug|AG-013736|Oral tablet 5 mg BID continuous
45349741|NCT00949624|Drug|Docetaxel|Intravenous 75 mg/m2 every three weeks
45349742|NCT02560272|Biological|Minhai-HIB|0.5ml, intramuscular
45349743|NCT02560272|Biological|Act-HIB®|0.5ml, intramuscular
45349744|NCT04019379|Other|Low Calcium/High Phosphorus Diet|Controlled research diet of low calcium/high phosphorus
45685589|NCT02290366|Radiation|Focal prostate brachytherapy with Cesium-131|
45685590|NCT01928056|Drug|Torrent's Montelukast Sodium Tablets 10 mg|
45685591|NCT05585866|Drug|Anesthesia Agent|The two anesthetic modalities included intravenous propofol anesthesia and sevoflurane gas anesthesia administered according to standard clinical praxis.
45685592|NCT01992952|Drug|AZD5363|Up to 480mg oral tablets twice a day, taken four days on, 3 days off treatment.
45847595|NCT04335240|Other|Premature family music therapy intervention to support parenting, attachment bond and preterm development|We have structured an integrated psychological and music therapeutic protocol that aims to limit or overcome neonatal long-term developmental morbidities, promote parenting and attachment bond in preterm infants.
45847596|NCT04301154|Biological|HIVIS DNA/MVA-CMDR|HIVIS DNA IM by needle-free injection at weeks 0 and 4 followed by intramuscular (IM) needle injection of 1 X 108 IU/mL (1ml) MVA-CMDR at weeks 24 and 36 in the same arm as HIVIS DNA.
46044991|NCT05756491|Other|18 months of inclusion of unaccompanied patients|inclusion for 12 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 18 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
46044992|NCT05756491|Other|12 months of inclusion of unaccompanied patients|inclusion for 18 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 12 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
45349745|NCT04019379|Other|High Calcium/Low Phosphorus Diet|Controlled research diet of high calcium/low phosphorus
45476269|NCT04501744|Drug|Cohort 3 of M701|Patients in Cohort 3 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 50 μg, and the maintenance dose during core treatment period and extended treatment period is 100 μg.
45476270|NCT04501744|Drug|Cohort 4 of M701|Patients in Cohort 4 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 100 μg, and the maintenance dose during core treatment period and extended treatment period is 200 μg.
45476271|NCT04501744|Drug|Cohort 5 of M701|Patients in Cohort 5 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 150 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.
45476272|NCT04501744|Drug|Cohort 6 of M701|Patients in Cohort 6 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 200 μg, and the maintenance dose during core treatment period and extended treatment period is 400 μg.
45476273|NCT04501744|Drug|Cohort 7 of M701|Patients in Cohort 7 will receive a starting doseon Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 250 μg, and the maintenance dose during core treatment period and extended treatment period is 500 μg.
45349746|NCT05351788|Drug|SKB264|SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)
45476274|NCT01196195|Drug|Kaletra dosed once daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = once daily.
45476275|NCT01196195|Drug|kaletra dosed twice daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = twice daily.
45476276|NCT01330329|Behavioral|Standard behavioral treatment|Participants receive a standard behavioral weight loss program similar to that used in other large trials such as Look AHEAD and the Diabetes Prevention Program. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors.
45476277|NCT01330329|Behavioral|SBT + technology system (SBT+FIT)|Participants will receive a standard behavioral weight loss program and will also be asked to use the Body Media FIT system as part of their weight loss intervention. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors. Participants in this group will also wear an armband that measures energy expenditure and they will log their food intake on the internet.
45349747|NCT05351788|Drug|KL-A167|KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)
45349748|NCT05351788|Drug|Carboplatin|Carboplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle（AUC 5)
45476278|NCT03637556|Drug|DST-0509|Novel iron chelator with improved absorption characteristics
45349749|NCT05351788|Drug|Cisplatin|Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (75mg/m²)
45349750|NCT00690482|Drug|AZD1981|Oral tablet, twice daily
45349751|NCT00690482|Drug|Placebo|Placebo Oral tablet, twice daily
45349752|NCT00385255|Biological|Fluarix®|GSK Biologicals' inactivated influenza split virus vaccine.
45476279|NCT03637556|Drug|Jadenu|Commercial iron chelator with standard absorption characteristics
45476280|NCT03637556|Drug|Exjade|Commercial iron chelator with standard absorption characteristics
45476281|NCT04501510|Diagnostic Test|Ultrasonographic examination validation and testing|X-ray imaging as well as the ultrasonographic examination of the fracture and healing process in children will be performed. The validation of an usg will be done.
45476282|NCT01330407|Procedure|cryopreserved skin allografts.|
45476283|NCT01330407|Procedure|Cultured Epidermal Autografts|
45476284|NCT04069910|Other|Quality-of-Life Assessment|Ancillary studies
45476285|NCT04069910|Other|Questionnaire Administration|Ancillary studies
45349753|NCT00385255|Biological|Boostrix®|GSK Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
45349754|NCT04009005|Behavioral|Therapeutic diet and lifestyle|Educational videos, 1 individual support call from RD follwed by monthly support group meetings conducted via an internet based audio/ video conference platform. Patients will be trained on a low lectin modified paleolithic elimination diet; breathing meditation practice, and walking sessions to increase daily moderate to vigorous physiscal activity
45349755|NCT05299996|Procedure|flexible ureterorenoscopy|stone disintegration stricture dilation tumor resection access guidance
45349756|NCT02560506|Device|Elastic assisted treadmill walking|Rubber band pulley system that will assist therapists in advancing limbs while gait training. The device is positioned in front of a treadmill and the stretch of the elastic bands when a legs moves backwards on a treadmill is resists the movement and facilitates limb swing when walking.
45349757|NCT04005339|Drug|Nanoliposomal Irinotecan|Nanoliposomal irinotecan 70 mg/ IV over 90 minutes, every 14 days
45349758|NCT04005339|Drug|Leucovorin|Leucovorin 400 mg/ IV over 30 minutes, every 14 days.
45349759|NCT04005339|Drug|Fluorouracil|Fluorouracil 2,400 mg/m IV over 46 hours.
45349760|NCT00949780|Drug|Chloral Hydrate|
45349761|NCT02560350|Other|no intervention|no intervention
45349762|NCT02544243|Drug|Vinorelbine|
45349763|NCT02544243|Drug|Gemcitabine|
45349764|NCT02544243|Drug|Cisplatin|
45349765|NCT04061408|Radiation|Fractionated stereotactic radiotherapy(FSRT)|3 to 5 fractions and 8Gy per fraction will be used for breast cancer patients with 1-10 brain metastases based on the lesion number and volume.
45349766|NCT04011670|Other|200 mg caffeine tablet|"Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition"
45349767|NCT04011670|Other|Non-active tablet|"Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition"
45476286|NCT04069910|Radiation|Stereotactic Radiosurgery|Undergo SRS/SRT
45685593|NCT01992952|Drug|Placebo|Placebo tablets taken twice a day, 4 days on treatment, 3 days off treatment
45841605|NCT05450484|Drug|Fluorescence endoscopy using durvalumab-680LT|"Tracer administration: The PD-L1-targeted fluorescent tracer durvalumab-680LT will be administered intravenously 2-4 days prior to the endoscopy at the UMCG. Afterwards, patients will be monitored for half an hour by measurements of vital parameters for potential side-effects, such as infusion-related reactions.~Endoscopy procedure: Patients will undergo two endoscopies, before and after neoadjuvant therapy. First, routine high-definition white-light (HD-WL) inspection is used. Quantification of fluorescence using multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy will be performed both in vivo and ex vivo. Subsequently, fluorescence molecular endoscopy (FME) and endoscopic ultrasound (EUS) will be performed. EUS enables single fiber reflectance/single fiber fluorescence (SFR/SFF) spectroscopy measurements via fine needle aspiration (FNA) to gain insight in the drug distribution throughout the tumor. Additionally, biopsies will be obtained."
46044993|NCT05756491|Other|6 months of inclusion of unaccompanied patients|inclusion for 24 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 6 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
45349768|NCT01581073|Drug|Darbepoetin alfa|Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.
45349769|NCT00742820|Drug|Calcium Acetate Oral Solution 667 mg per 5 mL|Drug: Calcium acetate oral solution 667 mg calcium acetate, USP per 5 mL (169 mg of elemental calcium per 5 mL); Dosage: 30 mL of calcium acetate oral solution; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
45349770|NCT00742820|Drug|Calcium Acetate 667 mg GelCaps|Drug: PhosLo GelCaps (calcium acetate) 667 mg (169 mg of elemental calcium per gelcap); Dosage: 6 gelcaps; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses.
45349771|NCT00742820|Dietary Supplement|Calcium Citrate 950 mg Caplets|Drug: Calcium Citrate 950 mg Caplets (200 mg of elemental calcium per caplet); Dosage: 5 caplets; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
45349772|NCT00860145|Procedure|radiosurgery|The stereotaxic frame will be secured to the skull with four pins. Patients will be taken to the MRI unit and receive a stereotaxic MRI. MRI data will be transferred to the Gamma Knife computer. Each patient will receive radiation to the mesial temporal lobe during a single treatment session. The amygdala and anterior 2cm of the hippocampus as well as the immediately adjacent parahippocampal gyrus will be included in the radiosurgical target. Patients will receive 24Gy to the 50% isodose line using an unlimited number of isocenters. The brainstem and optic nerve plus chiasm will receive less than 10 Gy and 8 Gy, respectively. After treatment, the stereotaxic frame will be removed from the patient's head.
45476287|NCT04069910|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
45685594|NCT01992952|Drug|Fulvestrant|2 x 250mg injections, received on Days 1 and 15 of cycle 1, and on day 1 of each subsequent 28 day cycle.
45685595|NCT01928134|Dietary Supplement|Vit K2+ Vit D3+ calcium carbonate (CaCO3)|
45685596|NCT01928134|Dietary Supplement|Vit K2+CaCO3|
45476288|NCT03347500|Other|use of patient-derived biological samples|We will use biological samples that are routinely collected as waste material from patients undergoing prosthetic surgery at IRCCS Istituto Ortopedico Galeazzi. Peripheral blood will be also collected from patients during the pre-surgery visit and during the post-surgery hospitalization coinciding with routine blood sample collection.
45476289|NCT05106257|Behavioral|Self-management education (short)|The self-management education condition is based on the Living Well with COPD program. The program consists of a mailed booklet and structured phone counseling delivered by certified COPD educators. Topics include disease information, breathing retraining, action planning, medication use, energy conservation, and following good health habits. The short condition consists of two calls (30-45 minutes each) to introduce patient education topics and refer to the booklet for further information.
45685597|NCT01894438|Behavioral|Mediterranean lifestyle|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean lifestyle group culinary practices, seasonality, and locality of food products, socialization during meals, rest during the day, as well as the adoption of an active living will be additionally addressed.
45685598|NCT01894438|Behavioral|Mediterranean Diet|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean diet group, all food groups of the Mediterranean diet will be targeted.
45685599|NCT02285140|Drug|Cefazolin|administration as outlined
45685600|NCT02285140|Drug|Vancomycin|administration as outlined
46044994|NCT02610127|Biological|OBIZUR|Treating physician will determine treatment regimen, frequency of laboratory and clinical assessments, according to routine clinical practice.
46044995|NCT00814333|Drug|Thrombin-JMI|5,000 IU, to nasal mucosa via syringe spray applicator
46044996|NCT00814333|Drug|Merocel pack|8 cm pack, inserted within the affected side between the septum and inferior turbinate via bayonet forceps
46044997|NCT01147250|Drug|Lixisenatide (AVE0010)|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast using self-injector pen device (Opticlik®). If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 15 or 10 mcg.
46044998|NCT01147250|Drug|Placebo|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast.
46044999|NCT04205864|Drug|Thrombi-Gel|Thrombin gel Matrix applied on pelvic lymphadenectomy areas after lympadenectomy
45476290|NCT05106257|Behavioral|Ground-based walking training|Participants randomized to this condition will be mailed a pedometer (3DFitBud Simple Step Counter) and instructed on its use to establish baseline steps/ day for 7 days. They will then receive a booklet with instructions to establish a walking program and three brief (10-15 minute), bi-weekly calls from a trained staff member to review step count values and engage in setting personal activity goals over the course of 6 weeks, following established exercise guidelines for individuals with COPD.
45841606|NCT05442203|Device|Zio Patch Monitor|Patch monitor will be applied and worn for a 2-week period at baseline, month 6, and month 12 after assignment to the AF arm.
45476291|NCT05106257|Behavioral|Inhaler training|Participants randomized to this condition will receive two sessions of inhaler technique education using a virtual teach-to-goal (TTG) method in which individuals are observed using their inhaler, provided feedback, and then observed again.
45476292|NCT05106257|Behavioral|Caregiver support|Participants randomized to this condition will identify an informal caregiver who is involved in their healthcare (i.e., spouse, family member, or friend), who will receive a mailed copy of the Respiratory Health Association's COPD Caregiver's Toolkit, a comprehensive informational resource to support the care of the person living with COPD. Caregivers will receive two brief (10-15 minute) check-in calls from a trained staff member. The structured content of these sessions will include providing an overview of toolkit content, identifying goals for sections(s) to review and incorporate into caregiving activities, and addressing any questions.
45476293|NCT05106257|Behavioral|Self-management education (long)|The self-management education condition is based on the Living Well with COPD program. The program consists of a mailed booklet and structured phone counseling delivered by certified COPD educators. Topics include disease information, breathing retraining, action planning, medication use, energy conservation, and following good health habits. The long condition consists of five, weekly calls (30-45 minutes each) following a structured curriculum of patient education topics.
45685601|NCT01928212|Device|Optical coherence tomography|
45685602|NCT01894594|Drug|Sodium Bicarbonate|"Oral sodium bicarbonate tablets administered at a starting dose of 0.6 mEQ/Kg body weight and will be escalated once, at 4 weeks, to 0.9 mEQ/Kg body weight.~Weekly schedule:~0-4 weeks: Serial Measurement at baseline, without therapy 4-8 weeks: *~0.6 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing 8-12 weeks: *~0.9 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing~* to the closest dose of 650 mg (7.74 mEq)~Ideal Body Weight is defined by the following formulas (Devine Calculation):~Ideal Body Weight (men) = 50 + 2.3 (Height (in) - 60) Ideal Body Weight (women) = 45.5 + 2.3 ( Height (in) - 60)"
45685603|NCT01928368|Drug|AMG 282|Single dose either subcutaneously or intravenously on day 1.
45685604|NCT01928368|Drug|AMG 282 Matching Placebo|Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1.
45841607|NCT05442203|Device|Echocardiogram|Ultrasound study of the heart will be completed upon patient consent after assignment to the SHD arm.
46045000|NCT04205864|Procedure|Conventional Pelvic lymphadenectomy|Conventional Pelvic lymphadenectomy
45685605|NCT01970254|Other|Hepatitis B Screening|Undergo 3 HBV screening tests (HbsAg, anti-HBc, and anti-HBs)
45685606|NCT01970254|Other|Survey Administration|Ancillary studies
45841608|NCT05430373|Biological|GT101|Autologous tumor infiltrating lymphocyte injection
46045001|NCT00813943|Drug|Cilengitide (2-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
45841609|NCT05425615|Device|Transcranial Magnetic Stimulation|Deymed DuoMag XT-35 rTMS
46045002|NCT00813943|Drug|cilengitide (5-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously 5-times weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
45349773|NCT00860145|Procedure|temporal lobectomy|The temporal lobectomy will be performed under general anesthesia. The superior temporal gyrus will be resected to a minimal degree (typically between 1 and 2cm) and the middle and inferior temporal gyri will be resected to approximately 3cm.The minimum amount of lateral temporal cortex required to perform an aggressive resection of medial temporal structures will be performed. The temporal portion of the amygdala and the anterior two to three cm of the hippocampus will be resected. In addition, nearby entorhinal cortex will be removed.
45841610|NCT05412446|Drug|ADAPT6-SPECT|Diagnostic SPECT for HER2 expression in primary tumour and metastatic lymph nodes
45841611|NCT05408377|Other|MA group|We will select Ashi points (the most obvious local pain over the breast), Tanzhong(CV17), bilateral Wuyi (ST15), Rugen (ST18), Tianzong(SI11), Geshu (BL17), Ganshu(BL18), Hegu(LI4), Sanyinjiao (SP6) and Taichong (LR3)in this trial.After insertion, all needles will be manually manipulated (equal manipulations of twirling, lifting, and thrusting)to achieve De qi sensation.
45841612|NCT05408377|Other|SA group|The SA group will use a special needle in which the tip is blunt and the pedestal is opaque. There is an adhesive pad below the base to ensure that the whole pedestal can adhere to the points. Participants will receive superficial touch at bilateral sham GV8(Jinsuo), sham GV7(Zhongshu), sham GV6(Jizhong), sham GV5(Xuanshu), sham GV4(Mingmen), sham BL37(Yinmen), and sham BL57(Chengshan), the needles will touch the skin and not be inserted into the skin, then lift and twist each point evenly for 3 times, make the subject feel the similar sensation of deqi.
45349774|NCT00754728|Device|JACTAX DES|Drug Eluting Stent
45349775|NCT05301166|Behavioral|Technology Based Motivation Education Program|Technology-Based Motivation Education Program consists of web-based education, motivation program and individual motivation interviews. This program will be prepared according to the Health Belief Model (HBM). It will be applied for 4 months. Participants will take a pre-test before starting the program and a post-test at the end of the program. Individual motivation interviews will be 6 sessions in total. A website will be prepared for the Technology Based Motivation Education Program. This website consists of two parts, a web-based education and motivation program for obesity. The motivation program will enable the participant to follow the program and receive motivational messages.
45349776|NCT05301166|Other|Web Based Education|Students in the control group will participate in web-based educations on obesity prepared only according to the Health Belief Model in the Technology-Based Motivation Education Program. Individual interviews supporting web-based education will be held with the control group once a month.
45349777|NCT00742898|Other|Non-targeted opt-out rapid HIV screening|Experimental Arm: Integrated non-targeted opt-out rapid HIV screening Active Comparator Arm: Integrated diagnostic rapid HIV testing
45349778|NCT04040283|Procedure|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a technique in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
45349779|NCT05435430|Other|PERSPECTIVE, MULTICENTRIC and observational|we will enroll women with 25-45ys old and previously SARS-COV2 infection. first outcome to be investigate the impact of SARS-COV2 infection on female reproductive health and the main clinical-laboratory parameters (FSH, LH, AMH) relating to women with procreative research, in a path of medically procreation assisted programm and on any quantitative variations, duration and periodicity of the menstrual cycle after Covid infection compared to the pre-infection period.
45685607|NCT04756882|Drug|AbobotulinumtoxinA 500 UNT|"Anaerobic fermentation of the bacterium Clostridium botulinum produces botulinum toxin. A range of different C. Botulinum strains have been recognized; eight immunologically different serotypes (type A-H) are created and consist of botulinum neurotoxin complexed with a number of related proteins.~Neurotoxin type A preparations are the most widely used for therapeutic application. There are currently three leading botulinum neurotoxin type A (BoNT/A) products on the market in the Western Hemisphere: onabotulinumtoxinA (ONA; Botox/Vistabel, Allergan Inc., Irvine, CA, USA), abobotulinum toxin A (ABO; Dysport/Ipsen Limited, Slough Berkshire, UK), and incobotulinum toxin A (INCO; Xeomin/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany). In nature, BoNT-A is synthesized as macromolecular protein complexes"
45685608|NCT04756492|Drug|sandimmun|follow up for treatment response
46045003|NCT00813943|Drug|Temozolomide|Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] will be administered intravenously once daily from Week 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
45349780|NCT01324843|Drug|EMLA Cream|
46045004|NCT00813943|Radiation|Radiotherapy|Radiation therapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Week 1 to 6, total dose 60 Gy.
45349781|NCT01324843|Drug|Aveeno Daily Moist|
46045005|NCT05403931|Device|Low level laser therapy|Omega XP is the particular device producing low level laser therapy and has been in use for therapeutic purposes to treat different musculoskeletal conditions.
45349782|NCT01324843|Device|Derma Vax|
45349783|NCT01324843|Procedure|Intradermal Electroporation|
45685609|NCT02271256|Device|Functional Intimate Apparel|The design of functional intimate apparel will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining with the application of 3-point pressure system, d) axial rotation or coupled motion by using uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure.
46045006|NCT04037371|Other|Cold exposure|Participants were tested for white fat thermogenic activity against their environmental temperature exposure
46045007|NCT00821509|Behavioral|Hand washing|Instructions for proper coughing and sneezing, and for reduced hand shaking, frequent hand washing in office and at home
45349784|NCT01324843|Procedure|Visual Analogue Scale|
46045008|NCT00821509|Behavioral|Disinfectant rubbing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
45349785|NCT01324843|Procedure|Present Pain Intensity|
45349786|NCT01324843|Procedure|McGill Pain Questionnaire|
45349787|NCT01324843|Procedure|Skin Assessment|
45685610|NCT02269150|Biological|fecal microbiota transplantation (FMT)|
46045009|NCT00821431|Device|Compression Device|"Subjects randomized to the compression device regime were instructed to wear the compression device for all wakings hours for 12 weeks. The device was applied at the following pressures:~Foot 40 mmHg, ankle 40 mmHg, mid-calf 30 mmHg, upper cuff 20 mmHg.~Subjects were instructed to wear the Intermittent Pneumatic Compression for 2 hours per day."
46045010|NCT00821431|Device|Profore|Subjects randomised to the 4-layer compression bandage regime, Profore, were to wear the bandage system for 24 hours a day and bandage applications/dressing changes were to be performed by a trained health care professional. Four different sizes of Profore were available and size selection was based on measurement of the ankle circumference of the subject on the index leg. Profore was to be used according to the instructions provided by the manufacturer described in their package insert.
45349788|NCT02566460|Other|Resuscitation|First, either crystalloid or colloid could be given to achieve a CVP of 8 to 12 mm Hg. Second, if the mean arterial pressure (MAP) was less than 65 mm Hg, norepinephrine was administrated to maintain MAP ≥65 mm Hg. If the mean arterial pressure was higher than 90 mm Hg, vasodilators were given until it was 90 mm Hg or below. Finally, SCVO2 or lactate clearance will be checked to determine red blood cells transfused or not to achieve a haematocrit of at least 30%. If ScvO2 or lactate clearance remains unmet target value, dobutamine could be used in the treatment.
45349789|NCT00863031|Behavioral|problem-solving therapy|Three sessions of problem-solving therapy at week 1, 3 and 5.
45349790|NCT00863031|Behavioral|Video-viewing|Three sessions of viewing health educational videos.
45349791|NCT00949936|Device|CAdisc™-L (Total Disc Replacement)|
45349792|NCT00742976|Drug|Insulin Detemir; Insulin Insulatard|Dosage is individual but fixed in study period (if possible). Detemir is given once daily, Insulatard is given twice daily.
45349793|NCT00742976|Drug|Insulin Detemir, Insulin Insulatard|Fixed doses in study period (if possible). Insulin Detemir once daily, Insulin Insulatard twice daily.
45349794|NCT00571662|Drug|Pentostatin|4 mg/m^2 intravenous(IV)once a day(QD)x3days (days -10, -9, -8)
45349795|NCT00571662|Radiation|Total-body irradiation (TBI)|TBI will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. TBI will be given on day -1.
46045011|NCT05389345|Behavioral|Transcranial direct current stimulation|Participants will receive bilateral prefrontal anodal stimulation with cathode placed on the back of the upper neck. Transcranial direct current stimulation (tDCS) will be delivered by a research assistant under the supervision of a psychiatrist.
45349796|NCT00571662|Drug|Cyclosporine A (CsA)|CsA will be given at 2.0 mg/kg intravenous (IV) Q 12hrs on days -1,0,and+1 (total 6 doses) then converted to oral at 2 mg/kg by mouth (PO) twice a day (BID) until day+80, then tapered 10% per week over approximately 3 months if no GVHD for related donor transplants. For unrelated CsA will be given at same dose and schedule until day+100 then tapered by 10% per week if no GVHD
45349797|NCT00571662|Drug|Mycophenolate Mofetil (MMF)|MMF 15 mg/kg by mouth twice a day (PO BID) will be given from day 0-27 then stopped without tapering for related donor transplants. For unrelated donor transplants MMF will be given at same dose until day+40 then tapered over 2months. in absence of GVHD. Doses will be rounded to nearest 250 mg.
45685611|NCT02269150|Other|No fecal microbiota transplantation (FMT), routine management|
45685612|NCT01894126|Behavioral|Two-way SMS Dialogue|
45685613|NCT01894126|Behavioral|One-way SMS Messaging|
45685614|NCT02267512|Drug|ATG-F|Intravenous (IV)
45349798|NCT00571662|Drug|G-CSF|10 mcg/kg/day subcutaneously for at least 4 consecutive days.
45349799|NCT04040985|Procedure|Total Knee Arthroplasty using Legion Total Knee System|Primary Total Knee Arthroscopy using Legion Total Knee System
45349800|NCT00955240|Biological|cetuximab|
45349801|NCT00955240|Drug|cisplatin|
45349802|NCT00955240|Drug|fluorouracil|
45685615|NCT02266420|Procedure|Blood samples of 10 mL|Blood samples of 10 mL will be collected at initial visit; serum samples will then be stored at the end of the study (-80°C) and may be used for the purpose of further scientific research.
45349803|NCT00955240|Other|laboratory biomarker analysis|
45349804|NCT00955240|Radiation|radiation therapy|
45349805|NCT02566382|Procedure|arthroscopy arthrodesis of the shoulder|The shoulder surgery will be realized under arthroscopy only
45349806|NCT03387085|Drug|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
45349807|NCT03387085|Biological|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
45349808|NCT03387085|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
45841613|NCT05404412|Procedure|Epidural Steroid Injection|This intervention is applied mostly for cervical or lumbar radiculopathy. The intervention was carried out under sterile conditions with the C-arm fluoroscopy guidance. It is performed via spinal needle and the needle is inserted into the epidural space, then a combined local anesthetic and glucocorticoids are delivered to the epidural space.
45349809|NCT03387085|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
45349810|NCT03387085|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
45349811|NCT03387085|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
45685616|NCT01928602|Behavioral|TherAppy Language App|Language TherAppy combines the receptive exercises of Comprehension TherAppy and Reading TherAppy with the expressive training of Naming TherAppy and Writing TherAppy. The app uses the same core functional vocabulary (nouns, verbs, & adjectives) and over 700 clear pictures. Each app tracks data, sends professional e-mailed reports, and has built-in levels, cues, and options.
45349812|NCT03387085|Biological|GI-6207|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
45685617|NCT01928602|Behavioral|Mind-Games|A mind-game app is said to improve brain functioning at any age. The chosen app will give feedback such as score history, and progress reports. Tasks will focus on attention, memory spatial awareness and executive function.
45685618|NCT01536951|Drug|LY3009104|administered orally
45685619|NCT01536951|Drug|Placebo|Administered orally
45685620|NCT01536951|Drug|moxifloxacin|Administered orally
45685621|NCT02259322|Behavioral|Standard-of-Care|Standard-of-Care with bariatric team. Participants will be encouraged to continue their care with their bariatric team.
45685622|NCT02259322|Behavioral|Behavioral Weight Loss Treatment|Biweekly individual guided self-help sessions for 3 months
45685623|NCT02259322|Behavioral|Cognitive Behavioral Therapy|Biweekly individual guided self-help sessions for 3 months
45685624|NCT01536795|Drug|WR279,396 with Tegaderm Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing
45349813|NCT03387085|Biological|GI-6301|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
45349814|NCT03387085|Biological|haNK for Infusion|NK-92 [CD16.158V, ER IL-2]
45349815|NCT03387085|Biological|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
45349816|NCT03387085|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
45349817|NCT03387085|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
45349818|NCT03387085|Drug|Cisplatin|cis-diamminedichloroplatinum(II)
45349819|NCT03387085|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
45349820|NCT03387085|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
45349821|NCT03387085|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
45349822|NCT03387085|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
45349823|NCT03387085|Procedure|SBRT|Stereotactic Body Radiation Therapy
45685625|NCT01536795|Drug|WR 279,396 with Gauze and Tape Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days
45685626|NCT04767633|Drug|split dose vs standard dose of sodium pico sulfate plus magnesium sulfate in children for bowel cleansing|The preparations will be dispensed by a nurse who carefully explained how the products should be taken, emphasising the importance of complete intake of the solution to ensure a safe and effective procedure. Moreover, each patient will be provided with dietary instructions: low residue diet for 3 days before colonoscopy. During and after bowel preparation, solid food will not be allowed. Clear liquid could be taken until 2 hours before the procedure. All colonoscopy will be performed between 11:00 and 15:00 by two endoscopists.
45841614|NCT05402293|Diagnostic Test|Blood samples to measure lidocaine levels|Blood sampling is the only intervention Plasma samples will then be analyzed for lidocaine concentration
45841615|NCT05398484|Drug|Psilocybin 25 mgs|One capsule containing 25mg of psilocybin will be administered with water orally. The appearance of psilocybin is Size 2 HPMC opaque.
45841616|NCT05398484|Drug|Niacin 100mg|One capsule contains 100mg of niacin will be administered with water orally. The appearance of the active placebo is Size 2 HPMC opaque.
45349824|NCT03844893|Procedure|Mini bal|Mini-BAL is a minimally invasive technique frequently used in the investigator's local intensive care units (ICUs) to obtain alveolar fluid samples from mechanically ventilated patients. This is typically done for microbial analysis.
45841617|NCT05398484|Behavioral|Psychotherapy|The manualized psychotherapy platform will consist of 6 hours of preparatory psychotherapy (prior to the single medication session) and 8 hours of integration psychotherapy following the dosing session.
45841618|NCT05389982|Other|mHealth (GetWell)|GetWell Loop utilizes an interactive health care application to allow patients to more actively participate in their care. We plan to work with GetWell to develop a custom build plan for kidney stone formers to achieve key aspects of stone prevention and provide patient education. This care plan will be developed using native capabilities within GetWell Loop.
45841619|NCT05389982|Other|Standard Care|Office based pathway
45349825|NCT05261100|Other|Core stability exercises|"Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercises will be performed along with core stability exercises.."
45841620|NCT05388786|Behavioral|Delphi Questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in ILND for penile cancer, vulvar cancer, and melanoma.~The Delphi questionnaire will be administered via Welphi.com. In the first survey, panel members will outline the ILND complications and adverse events definition and classification with a series of 5-point Likert scale assessments and options for free-text responses relating to the surgeon's perception.~The experts will fill out the online questionnaire. For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed."
45349826|NCT05261100|Other|Conventional Physical Therapy|"Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercise perform."
45841621|NCT05388058|Drug|Cannabidiol|Applied topically
45349827|NCT00867867|Drug|Ferrous fumarate|9.3 mg once per day, 6 days per week, for 9 months
45349828|NCT00867867|Drug|Ferric pyrophosphate|9.3 mg once per day, 6 days per week, for 9 months
45349829|NCT00867867|Drug|Placebo|9.3 mg once per day, 6 days per week, for 9 months
45685627|NCT01894750|Behavioral|group-based skill building self-care program|
45685628|NCT01894828|Dietary Supplement|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily for 14 days before surgery
45841622|NCT05388058|Drug|Placebo Administration|Applied topically
45841623|NCT05388058|Other|Quality-of-Life Assessment|Ancillary studies
45349830|NCT00955318|Drug|KW-6500|Subcutaneous injection of 1to 6 mg of KW-6500 for the OFF state
45349831|NCT01044667|Behavioral|GI and Quality of Life Assessment|
45349832|NCT01766492|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy for prostate
45349833|NCT00860223|Drug|Digoxin|
45349834|NCT00860223|Drug|Neratinib|HKI-272
45349835|NCT05223504|Device|Continuously monitoring|Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge. Monitoring will last for a maximum of eight days.
45841624|NCT05388058|Other|Questionnaire Administration|Ancillary studies
45841625|NCT05387733|Drug|10 mg CBL-514 per injection|"The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (2 mL each); total of 10 mg CBL-514.~Lipoma diameter of >2.0cm and ≤3.5cm - 2 injections (2 mL each); total of 20 mg CBL-514.~Lipoma diameter of >3.5cm and ≤5.0cm - 3 injections (2 mL each); total of 30 mg CBL-514.~Lipoma diameter of >5.0cm and ≤6.0cm - 5 injections (2 mL each); total of 50 mg CBL-514."
45349836|NCT01044823|Other|3D and thermal imaging|subjects will be imaged before and after receiving DMARD therapy
45349837|NCT02564276|Procedure|Sentinel lymph node biopsy|
45349838|NCT00860301|Other|Acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse is alone with the infant for five minutes. Infants in the acupuncture group get acupuncture. One needle is inserted 1-3 mm in the point LI4 on one of the infants hands for one to three seconds and then withdrawn.
45685629|NCT05585554|Radiation|MRIdian|Stereotactic MRI-guided On-table Adaptive Radiation Therapy delivered on MRIdian linac
45685630|NCT05583760|Procedure|Experimental: Osteopathic manipulation TUG for scaphoid bone|The sequence of execution of the scaphoid TUG technique shall be applied as follows. Patient in the supine position. The inner hand of the intervener makes contact with the pisiform through the hypothenar eminence and ulnar border of the hand over the scaphoid tubercle, the outer hand reinforces the contact. The thumbs are directed to the sole of the patient's foot. The parameters are sought by bringing the sole of the foot into eversion, thus bringing the scaphoid into internal rotation (the direction of correction). In order to reduce the slack, the operator drops his body weight backwards while increasing the internal rotation parameter of the scaphoid. The manipulation is performed by associating a rapid traction movement with an increase of the correction parameter towards the internal rotation of the scaphoid.
45685631|NCT05583760|Procedure|Sham group: Sham osteopathic manipulation TUG for scaphoid bone|The intervention will be performed in the same way as the intervention group, without actually performing the TUG manipulation on the scaphoid bone, only placing it in tension.
45685632|NCT01928914|Drug|Tafenoquine 300mg|Single dose of Tafenoquine give on Day 3 only
45349839|NCT01047631|Behavioral|Functional circuit training and lifestyle counseling|"Tests are performed at the beginning, and repeated after 12 and 24 weeks:~Measure general fitness levels such as walking, strength and balance.~Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~Blood and urine tests and a heart ultrasound.~Questionnaires & activity measures.~Group assignment for 12 weeks:~-Exercise classes & activity guidance: Twice-weekly class that focuses on exercises that are similar to daily activities, such as walking and carrying objects. Obtain customized information and education to help you exercise and follow a low salt diet.~Follow-up:~-Monthly phone calls during the 12 week follow up period."
45349840|NCT01047631|Behavioral|Health education and independent walking|"Tests are performed at the beginning, and repeated after 12 and 24 weeks.~Measure general fitness levels such as walking, strength and balance.~Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~Blood and urine tests and a heart ultrasound.~Questionnaires & activity measures.~Group assignment for 12 weeks:~-Health education and walking: Weekly health education classes covering general topics related to heart failure, like medications, diet and exercise. Receive a pedometer for an at-home walking program.~Follow-up:~-No follow up support"
45349841|NCT05216796|Behavioral|Diet Intervention|Meal will be prepared and delivered by SNAP Kitchen, which has 7 locations in Austin and offers 20+ options for low-carbohydrate and low-calorie meals, each meal available in different sizes varying in energy intake. Meals will be entered into the Nutrition Data System for Research (NDS-R) software to confirm low-calorie profile. Meals will be delivered to participants' homes twice a week.
45349842|NCT04018287|Other|HR-pQCT scans, BMD measurements, bone specific circulating microRNAs (miRNAs)|"HR-pQCT scans (XtremeCT, SCANCO Medical, Brütisellen, Switzerland) will be performed in all patients with HPP and all CTRL at the ultradistal radius and the distal tibia, using the manufacturer's standard protocol.~Volumetric bone Mineral density (vBMD) will be carried out. The peripheral trabecular density adjacent to the cortex and the central medullary trabecular density will be automatically evaluated. Bone microstructure including trabecular bone volume fraction, trabecular number, trabecular thickness inhomogeneity of the network, cortical thickness and cortical porosity will be analyzed.~Measurements will be carried out by two well-trained physicians and performed with the latest available software (software version 6.0). Daily crosscalibrations with standardized control phantoms (Moehrendorf, Germany) will be conducted for validation."
45349843|NCT00698204|Drug|celecoxib|Subject was asked to take celecoxib each day that radiation therapy was given.
45685633|NCT01928914|Drug|Tafenoquine 600mg|Single dose of Tafenoquine given on Day 3 only
45685634|NCT01928914|Drug|Tafenoquine 1200mg|400mg Dose of Tafenoquine given on each of the three consecutive dosing days
45685635|NCT01928914|Drug|moxifloxacin|moxifloxacine given on Day 3 only
45685636|NCT01928914|Drug|Placebo for Tafenoquine|Placebo given on all three days to all groups except for group 5 on Day 3
45685637|NCT01928914|Drug|Placebo for moxifloxaxin|Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3
45685638|NCT02249104|Drug|Adapalene/benzoyl peroxide gel, 0.1%/2.5%|Topical AV therapy
45841626|NCT05387733|Drug|15 mg CBL-514 per injection|"The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (3 mL each); total of 15 mg CBL-514.~Lipoma diameter of >2.0cm and ≤3.5cm - 2 injections (3 mL each); total of 30 mg CBL-514.~Lipoma diameter of >3.5cm and ≤5.0cm - 3 injections (3 mL each); total of 45 mg CBL-514.~Lipoma diameter of >5.0cm and ≤6.0cm - 5 injections (3 mL each); total of 75 mg CBL-514."
45841627|NCT05386615|Device|Body System - Functional|MR-Guided Focused Ultrasound
45841628|NCT05374655|Other|Preoperative blood glucose control|Patients included in this group, under the guidance of endocrinologists, develop hypoglycemic strategies for patients, follow up and guide patients to take medication, review HbA1c levels after 6 weeks, perform surgical treatment if they meet preoperative HbA1c<7.5%, continue hypoglycemic therapy if still above standards, and administer drugs according to the corresponding type of heart disease during this period.
45685639|NCT02249104|Other|Cetaphil Acne Regimen|Cleanse, Moisturize, and Protect
45685640|NCT01928992|Device|3D|subjects that underwent 3D mammography
45685641|NCT01928992|Device|2D|those subjects that underwent 2D mammography
45841629|NCT05372757|Procedure|Partial Heart Transplantation|The donor heart will be recovered and the new heart valve will be removed from this heart by the clinical team. The child will be scheduled for an emergent operation once the donor heart valve is deemed acceptable. The child will have general anesthesia during surgery. This is a state of unconsciousness, which is carefully controlled by the anesthesiologist with a mixture of very potent drugs, to prevent or lessen pain. The child will have a partial heart transplant using the donated heart valve to replace the dysfunctional heart valve. Expected hospital stay will range from weeks to months. The medical care after surgery is performed by the child's clinical team. This type of re-operation could similarly be required after a standard heart valve replacement.
45349844|NCT00698204|Drug|placebo|Subject was asked to take placebo each day that radiation therapy was given.
45349845|NCT02560194|Procedure|Flexible Sigmoidoscopy|Examination of the rectal and distal colon by means of a flexible endoscope
45349846|NCT02560194|Other|Fecal occult blood test|Test for hemoglobin in faeces
45476294|NCT04641351|Drug|Zilretta Injectable Product or Placebo|The purpose of this intervention is to determine the use of extended release steroid knee injection (Zilretta) at the end of the surgery and its effects on your knee pain.In this study Zilretta will be injected intra-operatively for your arthroscopic partial meniscectomy (APM) surgery.Participants will have MRIs x-rays, and provide a sample of the synovial fluid from both knees at the beginning of surgery. This fluid is drained at the beginning of surgery and then usually discarded. Three samples each of blood and urine will be collected over the study period from each participant and sample of joint (synovial tissue) taken. Participants will be asked to answer questions about knee pain.
45476295|NCT03759314|Other|Observation|to use a simple screening tool to find out the risk of falling, the nutritional status and the level of cognitive functioning activity
45349847|NCT00549718|Drug|Lurasidone HCl|Once daily
45349848|NCT00863187|Biological|rituximab|b cell depletion
45349849|NCT00754884|Drug|salmon calcitonin|daily intranasal 200 U.I. salmon calcitonin for periods of 14 days at a time
45349850|NCT00754884|Drug|intranasal saline solution plus glycerol|daily intranasal (one shot) saline solution plus glycerol for a period of 14 days
46045012|NCT05389345|Behavioral|Executive function training|The Executive Training (ET) aspect of the study will be completed by all participants. ET sessions consist of 50% of the session practicing computerized cognitive training exercises, and 50% of the session developing cognitive strategies to use in the computerized exercises. Participants are encouraged to complete 40 minutes of computerized training per day, and complete strategy worksheets, on the unit or in the library at Ontario Shores between sessions. ET will be delivered virtually and group sessions will be conducted using the online platform Zoom. For any group sessions, a PHIPA and PIPEDA compliant license will be used. This means that participants will not be able to record their screen using Zoom or a third-party program. Dr. Best will also go through some rules during the first group Zoom session regarding the use of third-party equipment and the importance of confidentiality.
45349851|NCT00743210|Drug|L-citrulline|Oral L-citrulline, 3 grams once per day for 3 weeks.
45349852|NCT00743210|Drug|Placebo|Placebo, 3 grams once per day for 3 weeks.
45349853|NCT00371761|Biological|Pegylated interferon alfa-2b (PegIntron)|Powder for injection in vials ( 100, and 120 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
45685642|NCT01894204|Other|HTPPE|No drug and no placebo were used in this study. Some exams must be performed (DLCO - evaluation of the dyspnoea and pulmonary scintigraphy), and in function of the result of the pulmonary scintigraphy, the medical care of the patient will be different : negative pulmonary scintigraphy, stop of the explorations and taken care usual of the patients; positive pulmonary scintigraphy,realisation of a cardiac echography to estimate the presence or not of a not very probable, possible or likely HTP. The indication of the right cardiac catheterization is then put on the combination of the results of the cardiac echography and the evaluation of the dyspnoea.
45685643|NCT01929538|Procedure|ERCP|endoscopic retrograde cholangiopancreatography
45685644|NCT01929538|Device|covered self-expanding biliary metal stent, 12mm in diameter|
45349854|NCT00371761|Drug|Adefovir dipivoxil (adefovir)|10 mg adefovir dipivoxil (equivalent to 5.4.5 mg adefovir) tablets, oral, dose of 1 tablet per day for up to 48 weeks
45349855|NCT05435274|Drug|HS-10376|HS-10376 will be administered orally once daily in a continuous regimen
45349856|NCT03888794|Device|Magnetic Resonance Imaging|Magnetic Resonance Imaging on pregnant women after 18 weeks of pregnancy with US diagnosis of congenital CNS fetal abnormality.
45476296|NCT04500730|Drug|Shaoyao Gancao Decoction Jiawei|"Study herb will be prescribed for 28 consecutive days. Study follow up will be offered every 7 days till 56th day after enrolment.~Daily leg cramps log will be filled in by each individual everyday from day 0 to day 56."
45476297|NCT03346330|Drug|TRK-750|TRK-750 capsule
45476298|NCT03346330|Drug|Placebo|Placebo capsule
45476299|NCT01193387|Drug|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
45476300|NCT01193387|Drug|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
45476301|NCT05560594|Device|Coloplast SpeediCath CH12 standard male intermittent catheter|Drainage of the bladder through the urethra when using the SpeediCath standard male intermittent catheter.
45685645|NCT01929538|Device|covered self-expanding biliary metal stent, 10mm in diameter|
45685646|NCT04389736|Behavioral|Sitting|Participants sat in a chair with back, arms and legs supported.
45685647|NCT04389736|Behavioral|Standing|Participants were asked to stand with arms supported and feet spaced approximately 15 cm apart. If needed, adjustment of standing posture was allowed during standing trial to prevent orthostatic hypotension.
45349857|NCT05351398|Drug|PDO group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. And they are treated with individualized neoadjuvant therapy under the guidance of a patient-derived organoid (PDO)-based drug sensitivity assay.
45349858|NCT05351398|Drug|Traditional group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.
45349859|NCT00860613|Other|medical nutrition therapy program|the dietary guidelines were based on the Nutrition Practice guidelines for gestational diabetes developed by the American Dietetic Association. Dietary strategies were based on carbohydrate counting and/or restriction of high glycemic index foods. Even carbohydrate distribution throughout the day was emphasized.
45349860|NCT00754962|Drug|protriptyline|10 mg tablet
45349861|NCT02564666|Other|telephone counseling|regular telephone counseling for compliance and advese event
45349862|NCT00868023|Drug|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
45349863|NCT00868023|Drug|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
45349864|NCT00868023|Drug|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg)
45349865|NCT00868023|Drug|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg
45349866|NCT00868023|Drug|Placebo|Placebo
45349867|NCT05300386|Drug|Escitalopram|We use Escitalopram 5~10 mg for two groups to observe the impact of sleep apnea on the treatment of generalized anxiety disorder
45349868|NCT01050127|Drug|ABT-436|See Arm Description for details.
45349869|NCT01050127|Drug|Placebo|See Arm Description for details.
45349870|NCT00955396|Drug|GSK1014802|Tablets
45476302|NCT04479332|Procedure|Tracheal intubation and cardiopulmonary resuscitation|Critical patients at the emergency room who require tracheal intubation and/or cardiopulmonary resuscitation will be sequentially allocated to either the resuscitation area or negative pressure isolation room for treatment by the designated medical staff wearing personal protective equipment.
45476303|NCT01196273|Other|Comprehensive non invasive cardiovascular examination|"The examination includes:~Anamnesis incl. admission form~Physical examination~Documentation of the medical therapy (incl. HAART)~Electrocardiogram~Transthoracic echocardiography~Exercise electrocardiogram~6 minute walk test~Blood collection~Questionnaire to quality of life and health economics"
45476304|NCT03346174|Other|AAD|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of AAD . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
46045013|NCT01134614|Biological|Ipilimumab|Given IV
45349871|NCT00955396|Drug|Placebo|Tablets
45685648|NCT04389736|Behavioral|Self-selected maximal intensity of neuromuscular electrical stimulation|Small electrodes placed (5*5 cm) on the lower limb of both legs. The instruction for NMES intensity was that the maximal intensity participants were be able to withstand for 2 hours whilst imagining sitting at home watching TV without feeling discomfort.
45349872|NCT00863499|Drug|Short Acting Methylphenidate|Dosage: 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly. Daily dosage above 60 mg is not recommended.
46045014|NCT01134614|Biological|Sargramostim|Given SC
46045015|NCT04037293|Diagnostic Test|CIMT and baPWV measurement|All patients will receive carotid intima media thickness (CIMT) and brachial-ankle pulse wave velocity (baPWV) measurement at baseline and 5-year follow-up.
46045016|NCT03982368|Drug|rhNGF 20 μg/ml|one drop of rhNGF 20 μg/ml will be instilled in both eyes three times daily (every 6-8 hours)
45349873|NCT00863499|Drug|Long Acting Methylphenidate|Dosage: 9 to 20 mg once daily in the morning (with or without food) with gradual increments of 9 to 20 mg weekly. Daily dosage above 60 mg is not recommended.
46045017|NCT03982368|Drug|rhNGF 20 μg/ml + vehicle|"one drop of rhNGF 20 μg/ml will be instilled in both eyes two times daily plus one drop (40 μL) of vehicle will be instilled in both eyes once daily (every 6-8 hours).~rhNGF will be instilled in the morning and in the evening while the vehicle will be instilled in the afternoon."
45349874|NCT04061642|Device|Clinical Decision Aid|The Clinical Decision Aid is a predictive model that takes as input individual patient characteristics, called 'features', which are inputted by the physician or by patient self-report, and outputs a list of all possible treatments, with each treatment associated with a predicted efficacy (likelihood to achieve response and likelihood to achieve remission, each expressed as a percentage). The treatments, which may include any approved treatment for depression, will be ordered by efficacy and presented to the physician. Lifestyle interventions, such as exercise or mindfulness, which have an evidence base, but do not require formal regulatory approval, will also be outputted. The system will additionally produce a side effect profile for each pharmacological treatment recommended, including known side effects, modified by a prediction about which side effects may be more likely for a given individual based on their individual characteristics.
45349875|NCT03992053|Other|sacroiliac joint injection|Image-guided sacroiliac joint injection under fluoroscopy or CT guidance and the success of intraarticular access was demonstrated by inter-articular contrast spread (the standard of care, not part of study intervention).
46045018|NCT03982368|Other|Vehicle|one drop of vehicle will be instilled in both eyes three times daily (every 6-8 hours)
46045019|NCT00813865|Drug|afegostat tartrate|
46045020|NCT05756335|Behavioral|(Un)predictable and (un)attended stimuli|Subjects will complete four task conditions in each scan session: (1) Visual Unpredictable, (2) Visual Predictable, (3) Auditory Unpredictable, and (4) Auditory Predictable. In visual and auditory conditions subjects attend to visual or auditory stimuli and ignore the other domain, pressing a button when they detect an infrequently occurring stimulus inversion in the target domain. In unpredictable and predictable conditions, the attended domain either presents random (unpredictable) stimuli, or the same face or word stimuli repeated (predictable).
46045021|NCT04311164|Other|Questionnaire-based survey|The online questionnaire-based survey is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions, rating scales and validated questionnaire scales to measure general and diabetes/insulin pump-specific behavior, psychological concepts and preferences.
45349876|NCT00755118|Drug|Oxaliplatin|Oxaliplatin (I.V) 85mg/m2 on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
45349877|NCT00755118|Drug|5-Fluorouracil|5-Fluorouracil (I.V) 1750mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
45349878|NCT00755118|Drug|Leucovorin|Leucovorin (I.V) 500mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
45476305|NCT03346174|Other|BAAD|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of BAAD . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
45476306|NCT04467554|Device|T-chair|Participants will receive 15 sessions of intervention, four weeks in total with a duration of one hour for each session. The focus of the intervention will be trunk rehabilitation.
45841630|NCT05366699|Procedure|axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA)|lymphatic reconstruction where the cut lymphatic vessels are reconstructed by anastamosing to the veins
45841631|NCT05366699|Procedure|Axillary lymphadenetomy alone|oncologic axillary lymphadenectomy
45476307|NCT01198223|Drug|garlic , nystatin|mouthwash
45476308|NCT03346564|Behavioral|Ritual training program|Ritual training program including education and demonstration
45476309|NCT03346564|Behavioral|Routine care|
46045022|NCT04311164|Other|No intervention given.|No intervention was given.
46045023|NCT02883296|Other|Pelvis Magnetic resonance imaging|
46045024|NCT05379127|Other|Patient-empowered follow up|"The patient-empowered follow-up protocol consists of patient-reported outcome measures (PROMs), self-assessment tools and clinical assessment including physical examination. Radiographs will only be taken when progression of the scoliosis (curve progression) or postoperative complications are suspected based on test results and based on the criteria of so called 'sense of alarm'.~Note: Sense of alarm ('niet pluis') is based on any deterioration on the above-mentioned PROMs, self-assessment tool, and clinician-based measurement instruments, which is a signal for the treating physician to consider when a radiograph is appropriate. Sense of alarm is described as any other concern by the orthopaedic surgeon, parent or child which warrants a radiograph. For both the Bunnell Scoliometer (clinical assessment tool) and the Scolioscoop (patient self-assessment tool) a threshold of ≥4° is used."
45476310|NCT03346486|Other|Control diet|Regular diet
45476311|NCT03346486|Other|Intervention diet|Brainfood dietary regime planned to be optimal for metabolism and cognitive function; having focus on regular meal frequency (breakfast, lunch and afternoon snack) and well-balanced light lunch at work according to the so-called plate model and optimized recipes- will be provided.
45685649|NCT04395040|Other|Semi-structured interview|Semi-structured interview
45685650|NCT01929070|Drug|HCP1007|
45685651|NCT01929070|Drug|Omarco and Crestor|
45685652|NCT01536561|Biological|Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)|131-I anti-B1 is the product of 131-I labeling of the anti-CD20 murine monoclonal antibody and the anti-B1 antibody itself is an intact IgG2a murine monoclonal antibody which has specificity far the CD20 antigen on human B cells. Anti-B1 is a clear, colorless liquid. 131-I labeling of the anti-B1 antibody will be carried out by iodogen technique. Trace labeling of the antibody will involve the labeling of approximately 1 to 3 mg of antibody with 5 mCi of 131-I.
45685653|NCT02243020|Device|Vagus Nerve Stimulation (VNS)|
45685654|NCT01929148|Procedure|Prophylactic bilateral salpingectomy|Salpingectomy will be performed by coagulation and section of the tube, beginning from the very distal fimbrial end, carefully preserving the ovarian vascularization, and proceeding toward the uterine cornu
45685655|NCT01929148|Procedure|Laparoscopic myomectomy without PBS|Standard laparoscopic myomectomy without salpingectomy
45685656|NCT02236312|Drug|Botulinum Toxin Type A|
45685657|NCT02236312|Drug|Placebo|
45685658|NCT01916278|Device|Emervel Lips Lidocaine|
45349879|NCT00755118|Drug|Bevacizumab|Bevacizumab (I.V) 10mg/Kg on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
45349880|NCT00755118|Drug|Irinotecan|Irinotecan (I.V) 110mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
45685659|NCT01916278|Device|Juvéderma Volbella with Lidocaine|
45685660|NCT03084640|Drug|CMP-001|CMP-001 will be administered SC as per the dose and schedule specified in the respective arms.
45841632|NCT05351502|Drug|Nitric Oxide 25,000 ppm|Intratumoral injection of 25,000 gNO
45841633|NCT05351502|Drug|Nitric Oxide 50,000 ppm|Intratumoral injection of 50000 gNO
45841634|NCT05351502|Drug|Nitric Oxide 100,000 ppm|Intratumoral injection of 100,000 gNO
45841635|NCT05351502|Drug|Nitric Oxide selected dose|Intratumoral injection of selected does on gNO
45841636|NCT05336084|Behavioral|Ultradian sleep/wake protocol|120-minute schedule, consisting of 80 minutes awake followed by a 40 minute sleep opportunity for 36 hours
45841637|NCT05334979|Other|Kidney stones Normal controls Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic|"Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic~Subjects in both arms will be asked to partake in the same activities, as follows: The day before presenting to the research clinic subjects will collect urine at home. Subjects will will come in to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. We will give them a special liquid that contains oxalate, and they will receive a specially prepared breakfast that is low in oxalate and citrate. After this, we will collect urine and blood throughout the day. While at the clinic, subjects will also receive specially prepared snacks."
45841638|NCT05327296|Drug|Isoflurane|Inhaled isoflurane administered by Sedaconda ACD-S
45841639|NCT05327296|Drug|Propofol|Intravenous infusion of propofol
45349881|NCT00755118|Drug|Cetuximab|Cetuximab (I.V) 500mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
45349882|NCT00755352|Drug|pravastatin tablets and Welchol tablets|pravastatin tablets, 1 tablet/day for 6 weeks; Welchol Tablets, 6 tablets/day for 6 weeks
45349883|NCT00755352|Drug|pravastatin tablets and Welchol placebo tablets|pravastatin tablets, 1 tablet/day; Welchol placebo tablets, 6 tablets/day
45349884|NCT00549640|Drug|Methylphenidate|54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
45349885|NCT00549640|Drug|Placebo|non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
45349886|NCT00868335|Device|Activ C disc prosthesis|cervical disc prosthesis
45349887|NCT00868335|Procedure|Anterior cervical discectomy|Removal of protruding cervical disc through an anterior approach
45349888|NCT03963960|Device|Hemodialysis with low dialysate flow|Hemodialysis with low dialysate flow
45349889|NCT03963960|Device|Conventional triweekly high-flow hemodialysis|Conventional triweekly high-flow hemodialysis
45349890|NCT00860691|Procedure|Therapeutic conventional colorectal surgery|Patients with colorectal cancer undergo open laparotomy and colorectal resection
45349891|NCT00860691|Procedure|Therapeutic laparoscopic colorectal surgery|Patients with colorectal cancer undergo laparoscopic colorectal resection
45476312|NCT01196351|Other|Dietary Supplement: water with noncalorie sweetener|
45476313|NCT01196351|Other|Activity: With noncalorie sweetener or glucose|
45476314|NCT05559424|Diagnostic Test|OCT|OCT will be used to assess results after intervention
45596497|NCT03527953|Other|everX fiber-reinforced resin|The enamel will be etched with 37% phosphoric acid for 10 seconds, then will be rinsed, and dried with an air/water syringe for at least 5 seconds. Self-etch adhesive, G-aenial Bond (GC Co., Tokyo, Japan), will be applied to all enamel/dentin surfaces and gently air thinned and then will be light cured for 10 seconds. After the matrix will be placed and wedged, mesial or distal walls will be built with 1-2-mm layers of G-aenial Posterior resin composite. The fiber-reinforced composite, everX Posterior, will be placed into the cavity in approximately 4-mm thickness. The last 2 mm of the cavity will be restored using the G-aenial Posterior composite as an overlay layer. Each increment will be light cured for 20 seconds using an LED unit.
45841640|NCT05317026|Procedure|Vertebroplasty|"SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume.~The vertebroplasty will be performed according to the usual procedure at the center in the angiography suite under local anesthesia and conscious sedation~Introduction of a vertebral needle, under biplanar fluoroscopic guidance, polymethylmethacrylate (PMMA) cement injection.~Cone-beam volume-CT at the end of the procedure, with the angiography table and c-arm, to evaluate the cement distribution and detect any leak.~Decubitus position for 2 hours following procedure, then hospital discharge on the same day."
45596498|NCT02201459|Drug|Nilotinib (Tasigna ®), capsules of 150 mg|Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months
45685661|NCT03084640|Drug|Pembrolizumab|Pembrolizumab will be administered as per the schedule specified in the respective arms.
45349892|NCT00860691|Other|Peripheral blood sampling and performing: ELISA test of sFas, sFasL, IL - 17 and Bursttest|Informed consent will be obtained.Blood samples will be obtained at one time point. .Samples will be processed to serum, using a refrigerated centrifuge, then stored at -80C until analysis. Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube.Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fas MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R&D Systems Inc, Minneapolis, USA). Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R&D Systems Inc, Minneapolis, USA).Respiratory burst neutrophil production will be determined quantitatively by flow cytometry using a commercial kit Bursttest Kit (Cat. No: 10-0200; ORPEGEN Pharma, Germany)
45349893|NCT04444804|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Dosage at the discretion of the treating physician
45349894|NCT04444804|Drug|LMWH and Phenprocoumon|Dosage at the discretion of the treating physician
45349895|NCT05226741|Device|Head protection device|The participants are fitted with a form of head protection over the craniectomy and provide feedback on design, use, and comfort
45841641|NCT05317026|Procedure|Stereotactic Body Radiation Therapy only|SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume
45349896|NCT04010890|Behavioral|Culturally adapted CBT|Culturally adapted CBT for South Asian Canadians
45841642|NCT05317000|Drug|Combination 5-azacytidine and nivolumab|The primary objective of the study is to determine whether exposure to the demethylating agent 5-azacytidine will sensitize HPV-associated oropharynx cancer to nivolumab by induction of interferon response, neoantigen expression, and augmentation of lymphocyte infiltration of the tumor microenvironment.
45841643|NCT05317000|Drug|5-azacytidine|Chemotherapy is the use of drugs to destroy cancer cells. It usually works by keeping the cancer cells from growing, dividing, and making more cells. Because cancer cells usually grow and divide faster than normal cells, chemotherapy has more of an effect on cancer cells. 5-azacytidine works by slowing down the growth of cancer cells. 5-azacytidine has been demonstrated to improve the cell's ability to make some proteins which signal to the immune system.
45349897|NCT00921882|Procedure|Oral glucose tolerance test|Subjects will have the Oral glucose tolerance test 48 hours post-partum and the same test 8 weeks post-partum.
45841644|NCT05317000|Drug|Nivolumab|"Immunotherapy is a type of treatment that uses your body's own immune system to help fight cancer. Specifically, Nivolumab belongs to a class of anti-cancer drugs known as immune checkpoint inhibitors. Cancer cells are able to turn off the immune system by increasing the production of a protein called PD-1. Nivolumab can block PD-1 and may be able to re-activate the immune response to kill head and neck cancer cells."
45841645|NCT05292755|Drug|Carboxymethylcellulose (CMC) Artificial Tears|A pack of 21 vials of artificial tears containing carboxymethylcellulose 0.5% will be given to subjects in the treatment group.
45685662|NCT03084640|Drug|CMP-001|CMP-001 will be administered IT as per the dose and schedule specified in the respective arms.
45685663|NCT01536405|Biological|MMRV (AMP)|Measles, mumps, rubella, and VZV vaccine made with an alternative manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
45685664|NCT01536405|Biological|MMRV (2006 process)|Measles, mumps, rubella, and VZV vaccine made with the 2006 manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
45685665|NCT01892410|Other|Cetaphil Restoraderm Skin Restoring Body Wash|Diluted (10%) 0.2ml or 0.2g of Cetaphil on semi-occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
45685666|NCT04409691|Drug|prednison and Sirolimus|If the intravenous prednisolone 4 mg / kg / d (one time in the morning and one time in the evening, 2mg / kg body weight each time) is effective, it will be gradually reduced to 2mg / kg / D (one time in the morning and one time in the evening, 1mg / kg body weight each time), gradually converted to oral prednisone of equal dose, and the hormone will be removed within 4-6 weeks. At the same time, the dosage of sirolimus oral liquid is 0.8 mg / m2 twice a day, with an interval of 12 hours, maintaining the blood concentration of 8-15 ng / ml. if there is no intolerable side effect, the treatment will last for 6 months
45685667|NCT04409691|Drug|prednison|Prednison is taken at a dose of 4mg/kg/d. If the hormone treatment is effective, it will be gradually reduced to 2mg / kg / d (one time in the morning and one time in the evening, 1 mg / kg body weight each time), and repeated after 2 months of continuous treatment and 1 month of drug withdrawal.
45841646|NCT05292755|Drug|Preservative-free, CMC-free Artificial Tears (control)|A pack of 21 vials of artificial tears containing 0.4% polyethylene glycol 400 and 0.3% propylene glycol will be given to subjects in the control group.
46045025|NCT05379127|Other|Standard follow-up|Routine radiographs are taken at each follow up visit during standard care (to detect possible curve progression or rule out postoperative complications).
46045026|NCT01147172|Device|Elevess|Injectable gel, 0.5mL or 1.0mL material supplied in a 1.0mL pre-filled sterile glass syringe with two 30 gauge needles
46045027|NCT05377723|Device|Neodyne Device|See Arm Description: Neodyne Device
45476315|NCT05005988|Behavioral|Actions for Empowered Maternal Neonatal Care|"The intervention includes three 30-minute face-to-face sessions:~Session 1. Recognizing prematurity and the NICU environment: includes definitions of prematurity, characteristics of premature infants, equipment and dynamics of NICU care. Mothers are encouraged to identify their own and contextual resources that can help empower them.~Session 2. Identifying the care of a premature baby: aspects related to the kangaroo method, feeding, thermoregulation, among others, are presented. Knowledge is presented as an empowerment resource.~Session 3: Preparation for the return home. Aspects related to the discharge process and transition to home are described. Includes information on the transition home, warning signs, emergency situations, physical burden, and recognition of sources of personal and professional support.~Session on admission to the out-of-hospital kangaroo program: presents the dynamics of the kangaroo program, as well as the goals in the new care setting."
45349898|NCT00863577|Drug|Oral bemiparin|Bemiparin tablets and bemiparin tablets into hard gelatine capsules
45349899|NCT05351320|Drug|WX-0593 Tablets|WX-0593 60 mg, tablets, orally, once daily for 7 days, followed by WX-0593 180 mg, tablets, orally, once daily
45349900|NCT05351320|Drug|chemotherapy|Platinum-based chemotherapy
45841647|NCT05289752|Procedure|dental implants in the mandible|placement of two interforaminal dental implants in the canine region in the mandible
45349901|NCT05351320|Radiation|Thoracic Radiation Therapy（TRT）|Five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy
45476316|NCT01193465|Device|Datex Ohmeda excel anesthesia machine|maintain one of following fresh gas flow, 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Datex Ohmeda excel anesthesia machine after draping complete
45476317|NCT01193465|Device|Datex Ohmeda Avance anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Datex Ohmeda Avance anesthesia machine after draping complete
45476318|NCT01193465|Device|Drager Cato anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Drager Cato anesthesia work-station after draping complete
45841648|NCT05289752|Device|locator attachment and overdenture|placement of locator attachment and insertion of mandibular overdenture
45841649|NCT05283395|Drug|Rocklatan® (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%|Enrolled subjects will be instructed to self-instill 1 drop of Rocklatan® (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% in each eye daily in the evening
45841650|NCT05277532|Behavioral|High intensity interval training (HIIT)|HIIT performed either in the morning or in the afternoon
45841651|NCT05275205|Drug|UBX1325 injection 50 μL|Patients randomized to the UBX1325 arm will receive UBX1325 on Day 1, Weeks 4, 24, and 28
45841652|NCT05275205|Drug|EYLEA® (aflibercept) Injection 2 mg (0.05mL)|Patients randomized to the active-control aflibercept arm will receive aflibercept per label every 8 weeks starting from day 1 until Week 40. In addition, these patients will receive UBX1325 on Week 24 and Week 32; and a sham procedure at Week 4 and Week 28.
45841653|NCT05274451|Biological|LYL797|LYL797 is an autologous, genetically (Gen-R™) and epigenetically (Epi-R™) reprogrammed ROR1-targeted chimeric antigen receptor (CAR) T-cell therapy
45841654|NCT05270863|Drug|BRIMOCHOL™ PF|A single drop in each eye at a visit.
45841655|NCT05270863|Drug|Carbachol PF|A single drop in each eye at a visit.
45841656|NCT05270863|Drug|Brimonidine tartrate|A single drop in each eye at a visit.
45349902|NCT00868413|Drug|ABT-263|ABT-263 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
45349903|NCT00868413|Drug|FCR|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle; Fludarabine will be given by intravenous infusion for 3 days out of each 28 day cycle; and Cyclophosphamide will be given by intravenous infusion for 3 days out of each 28 day cycle
45349904|NCT00868413|Drug|BR|Rituximab will be given by intravenous infusion for 2 days out of each 28 day cycle and Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle
45349905|NCT05351008|Other|Cognitive physical therapy|Cognitive therapy techniques, TENS, ultrasound, massage
45841657|NCT05269511|Drug|Chinese herbal medicine is in the form of granules (9 g/sachet), which is comprised of ten medicinal herbs.|Oral administration, twice per day.
45841658|NCT05264857|Behavioral|Thyroid Nodule Management Education|Participants will receive information about thyroid nodules and their management
45841659|NCT05261711|Drug|AB1|This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 4 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 16mg, and 32mg. Each dose will be taken orally, once daily, for 8 weeks
45841660|NCT05256654|Drug|LY3561774|Administered SC
45841661|NCT05256654|Drug|Placebo|Administered SC
45841662|NCT05251298|Other|"Coordination through the online platform JamesAKTIV"|"Coordination of the treatment through the online platform JamesAKTIV that allows neurologists and therapists to select specialised therapies for the predominant symptoms of the patients and communicate easily about problems during the treatment"
45841663|NCT05240612|Biological|MT-3921|Solution for infusion; Intravenous (IV)
45841664|NCT05240612|Biological|Placebo|Solution for infusion; Intravenous (IV)
45841665|NCT05237219|Procedure|Passive heating|Patients will perform baths in 38°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
45349906|NCT05351008|Other|Physical therapy|TENS, ultrasound, massage, exercise
45841666|NCT05237219|Procedure|Thermoneutral|Patients will perform baths in 30-32°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
45841667|NCT05237141|Drug|Etonogestrel implant|Implant insertion in second menstrual cycle prior to ovulation
45841668|NCT05232409|Biological|Zeaxanthin|The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.
45841669|NCT05232409|Combination Product|Zeaxanthin Plus Pembrolizumab|"The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.~The dose of pembrolizumab will be administered at a fixed dose of 400 milligrams intravenous every 6 weeks which is an FDA approved dosing schedule to treat cancer patients with pembrolizumab."
45349907|NCT00860769|Behavioral|ASHA LIFE|6-session education groups discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills
45349908|NCT00860769|Behavioral|USUAL Care|3 session educational group focusing on HIV prevention, anti-retroviral therapy and parenting
45476319|NCT01193465|Device|Drager Primus anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Drager Primus anesthesia work-station after draping complete
45476320|NCT03347344|Drug|Riluzole|50 mg will be administered (per os) twice a day
45349909|NCT04010500|Device|no mouthguard|Control (not using mouthguard)
45841670|NCT05226078|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive behavioral treatment of insomnia
45349910|NCT04010500|Device|'boil and bite' mouthguard|KHZ058 Bicolor Mouth Guard (Shenzhen Kanghao Industrial Co. Ltd, China) will be immersed in a bowl of hot water (about 80 °C). After 50 seconds, the softened sheet will be fitted on the maxillary arch of the participant. The participant will then bite down to ensure the mouthguard stay firmly on the maxilla. After that, the mouthguard will be removed and immersed in cold water to retain its shape.
45349911|NCT04010500|Device|custom-fitted mouthguard|The custom-fitted mouthguards will be constructed using the dual laminated technique with two layers of ethylene vinyl acetate (EVA) thermoplastic sheets (Dentsply International Raintree Essix, Court East Sarasota, USA).
45349912|NCT04040829|Behavioral|Cognitive remediation therapy (CR)|Cognitive remediation therapy is a behavioral intervention that aims to improve cognition. This intervention has the goal to produce long-term improvements in cognition as well as to generalize these improvements in daily functioning.
45349913|NCT04040829|Behavioral|Supported education (SE)|Supported education (SE) is a behavioral intervention that aims to help people return to school and/or succeed in school. SE offers a wide range of services that are personalized to the needs of each patients.
45349914|NCT04040829|Other|Treatment as usual (TAU)|Treatment as usual (TAU) consists of medication and routine contact with the clinical team.
45349915|NCT03897348|Drug|Placebo|Oral medication
45349916|NCT03897348|Drug|Lacosamide 100 mg|Oral medication
45349917|NCT03897348|Drug|Lacosamide 200 mg|Oral medication
45685668|NCT01887808|Other|Cetaphil DermaControl Oil Control Moisturizer SPF 30|
45685669|NCT04096989|Other|Traditional Chinese medicine regimen-based lifestyle mobile health APP|The Experimental group receives TCM regimen-based lifestyle mobile health application intervention.
45476321|NCT03347344|Drug|Placebo|50 mg will be administered (per os) twice a day
45476322|NCT01193543|Dietary Supplement|calanus oil|1 gram twice daily
45476323|NCT01193543|Dietary Supplement|olive oil|1 gram twice daily
45685670|NCT04096989|Other|Lifestyle mobile health APP|Sham comparator group receives mobile health application, but there is no traditional Chinese medicine information.
45841671|NCT05218369|Drug|IL6 Antagonist|Patients will receive IL-6 antagonist therapy at the consultant's discretion.
45841672|NCT05213741|Device|Autonomous navigation of a magnetic colonoscope|The proposed magnetic-assisted colonoscope system consists of an megnetic field nevigator, magnetic-assisted colonoscope, and image receiving decoder. All participants will receive the magnetic-assisted colonoscopic examination by using this proposed magnetic-assisted colonoscope system
45476324|NCT04220866|Drug|Ulevostinag|IT injection
45476325|NCT04220866|Biological|Pembrolizumab|IV infusion
45476326|NCT03173456|Drug|oxycodone/APAP|Oxycodone/acetaminophen 5 mg-325 mg oral tablet
45476327|NCT03173456|Drug|hydrocodone/APAP|Hydrocodone/Acetaminophen 5 Mg-300 Mg oral tablet
45476328|NCT03173456|Drug|codeine/APAP|Codeine/acetaminophen 30 mg-300mg oral tablet
45476329|NCT03173456|Drug|400 ibuprofen/APAP|ibuprofen/acetaminophen 400 mg-1000mg oral tablet
45476330|NCT03173456|Drug|800 ibuprofen/APAP|ibuprofen/acetaminophen 800 mg-1000 mg oral tablet
45476331|NCT03846245|Other|No intervention|No intervention
45476332|NCT01193621|Drug|haloperidol, PET|"Biodistribution study Intravenous 18F haloperidol(10 mCi) Dose injection two times before whole body PET scan~D2-receptor occupancy study Group Doses No. of subjects 1 0.5 mg 4 2 1 mg 4 3 3 mg 4~above doses will be administrated orally every 24 hours for 7 days."
45685671|NCT02223208|Drug|Ro-CHOEP-21 (PHASE I)|"Romidepsin (dose escalation) Starting dose: 12mg/ms iv day +1 and +8~Dose modification according to toxicity:~14mg/ms day +1 and +8~10mg/ms day +1 and +8~8mg/ms day +1 and +8~CHOEP-21~Doxorubicin 50 mg/ms iv day +1 or +2,~Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2~Cyclophosphamide 750 mg/ms iv day +1 or +2~Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR:Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --> AUTO-SCT, PR --> ALLO-SCT)"
45349918|NCT04010734|Procedure|Peroral Cholangioscopy and Endoscopic retrograde cholangiopancreatography|"The peroral cholangioscopy (DSOC), one of a newer method of endocanal exploration via ERCP- commonly known as the SpyGlass - helps to provide the visual diagnostics of the strictures based on morphological and vascular patterns and to provide directed intraductal biopsy (SpyBite) from the lesions. The combination of both should increase the diagnostic yield in the evaluation of indeterminate biliary stricture by DSOC.~ERCP is the most widely used diagnostic procedure in patients with biliary obstruction. It enables to identify the biliary stricture, to determinate its location and help providing tissue sampling from the stricture for cytological evaluation. Different methods were used to take samples from the site of the stenosis. Brushing and endocanal forceps biopsies were the most used techniques. The samples from these two techniques will be additionaly examinated using Fluorescence in Situ Hybridization (FISH)."
45841673|NCT05202119|Device|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) a non-invasive brain stimulation technique where a weak direct current (2 mA) is applied on the scalp through electrodes. The current modulates the underlying neural activity. The sessions are 30 minutes, 3-5 time a week.
45349919|NCT04010578|Dietary Supplement|MK-7 and vitamin D3|Patients will receive 400 micro-grams of Menaquinone-7 and 80 micro-grams of vitamin D3 per day.
45349920|NCT04010578|Other|Placebo|Patients will receive a placebo each day.
45841674|NCT05202119|Device|Sham Transcranial direct current stimulation|To blind the participants of the stimulation, a standardized sham protocol is used where the current ramped up and then down breifly in the beginning and end of each session to simulate active stimulation.
45685672|NCT02223208|Drug|Ro-CHOEP-21 (PHASE II)|"Ro-CHOEP-21 x 3 cycles~Romidepsin dose according to phase I iv day +1 and +8~Doxorubicin 50 mg/ms iv day +1 or +2,~Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2,~Cyclophosphamide 750 mg/ms iv day +1 or +2~Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --> AUTO-SCT, PR --> ALLO-SCT)"
45685673|NCT02219776|Drug|Benzoyl Peroxide solution Plus Chlorhexidine Scrub|Subjects will be provided instructions on how to use and apply the chlorhexidine using a scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient application
45841675|NCT05163795|Procedure|Lateral locking plate|Plating of the distal femur fracture with lateral locking plate.
45841676|NCT05162586|Drug|Enpatoran low dose|Participants will receive film-coated tablets of Enpatoran at a low dose orally, twice daily (BID) up to 24 weeks.
46045028|NCT02610517|Behavioral|Provider Training|All providers will receive an online survey about alcohol pharmacotherapy, and an on-site training on alcohol pharmacotherapy will be offered at UAB and UW. The training will cover the most commonly prescribed alcohol pharmacotherapy. Some medications (ex: Zofran) have been used clinically for alcohol pharmacotherapy but have not yet received FDA approval for this indication. Research has shown these medications are beneficial as alcohol pharmacotherapy and are more frequently used by doctors due to the more favorable side effects. Providers in this study will use their clinical judgment in prescribing alcohol medications per their normal standard of care and using any new information gained from the alcohol pharmacotherapy training.
45685674|NCT02219776|Other|Standard of Care - Chlorhexidine Scrub only|Subjects will be given instructions on how to apply the Chlorhexidine using a scrub brush
45841677|NCT05162586|Drug|Enpatoran medium dose|Participants will receive film-coated tablets of Enpatoran at a medium dose, orally, BID up to 24 weeks.
45841678|NCT05162586|Drug|Enpatoran high dose|Participants will receive film-coated tablets of Enpatoran at a high dose, orally, BID up to 24 weeks.
45841679|NCT05162586|Drug|Placebo|Participants will receive placebo matched to Enpatoran up to 24 weeks.
45841680|NCT05142332|Other|Covid-19 vaccine education materials|videos and flyers containing Covid-19 vaccine educational information
45841681|NCT05137301|Device|X-ray bone age instrument|Bone age films were taken by X-ray bone age instrument
45349921|NCT00868491|Drug|docetaxel, cisplatin, 5-fluorouracil|docetaxel 75 mg/m2 I.V. day 1, cisplatin 75 mg/m2 I.V. day 1, 5-fluorouracil 750 mg/m2 I.V. continuous infusion days 1-5 repeated every 21 days for 4 cycles
45841682|NCT05137262|Other|Abiraterone acetate|Given by IV
45841683|NCT05137262|Drug|Durvalumab|Given by IV
45841684|NCT05137262|Drug|Methotrexate|Given by IV
45841685|NCT05137262|Drug|Vinblastine|Given by IV
45841686|NCT05137262|Drug|Doxorubicin Hydrochloride|Given by IV
45349922|NCT00868491|Radiation|radiotherapy|Three-dimensional conformal radiotherapy planning and delivery (35x2 Gy/day over 7 weeks - weeks 14 - 20 of the study protocol
45685675|NCT04756960|Drug|CHF6001|4 inhalations of CHF6001 800µg/20mg NEXThaler® DPI (total dose of 3200µg) co-administered with an intravenous microdose (18.5µg (18.5kBq)) of [14C]-labelled CHF6001
45685676|NCT04757038|Device|Intradiscal injection|The injection will be administered at V1 baseline (day 0). Any physical activity (e.g. jogging, tennis, weightlifting, prolonged upright position) in the 48 hours following the injection should be avoided.
45685677|NCT01487265|Drug|BKM120 and Erlotinib|BKM120 and Erlotinib will be given once daily. Erlotinib 100 mg PO will be administered. During Cycle 1-Week 1 all patients will receive 80 mg PO daily BKM120. After the first week of Cycle 1, the dose of BKM120 will escalate to 100 mg PO daily and treatment will continue as long as there are no unexpected or prohibitive toxicities, or disease progression.
45841687|NCT05137262|Drug|Cisplatin|Given by IV
45349923|NCT00868491|Drug|cetuximab, cisplatin|"cetuximab 400 mg/m2 I.V. week 13, cetuximab 250 mg/m2 I.V. weeks 14-20~cisplatin 30 mg/m2 I.V. weeks 14-20 (concomitantly with radiothrapy)"
45349924|NCT00955630|Drug|ranibizumab|3 monthly injections of ranibizumab followed by prn injections for the remainder of the study
45349925|NCT00955630|Drug|ranibizumab|prn injections of ranibizumab throughout the study
45349926|NCT00868569|Procedure|TACE + folfox 4|"tace: oxaliplatin 100mg + fudr 1g + mmc 10mg + iodine 2ml~folfox4"
45349927|NCT00868569|Procedure|TAC + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4"
45841688|NCT05137015|Other|Injury prevention program|"The execution of the program takes 10-15 minutes. The program will be performed in the training sessions, after the usual warm-up.~The program is based on scientific evidence that has previously shown good efficacy on injury prevention in football. The exercise categories address 7 aspects:~Balance~Core stability~Hamstring eccentrics~Glute activation~Plyometrics~Running~Games The games are included with the aim to increase the attractiveness of the program.~Each category contains 2 exercises and the coach is free to decide which one to choose in every training session. All exercises are organized in five or six levels with increasing difficulty (physically and cognitively)."
45685678|NCT01516606|Drug|clarithromycin, oral, high dose|2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
45841689|NCT05130398|Biological|rVSVΔG-ZEBOV-GP, V920|The experimental vaccine is the rVSVΔG-ZEBOV-GP, an Ebola vaccine.
45841690|NCT05130398|Dietary Supplement|Fibre and equilibrate breakfast and lunch|Participants receive fibres and caloric equilibrate diet during breakfast and lunch every day for 21 consecutive days.
45841691|NCT05130398|Diagnostic Test|Active detection and treatment of pathogens|Monthly diagnostic and treatment of childhood infections Active detection and treatment of pathogens.
45841692|NCT05130398|Combination Product|Fibre and equilibrate breakfast and lunch plus Active detection and treatment of pathogens|Participants receive fibres and caloric equilibrate diet during breakfast and lunch every day for 21 consecutive days and diagnostic and treatment of childhood infections Active detection and treatment of pathogens every month for 12 months
45841693|NCT05130398|Biological|Chikenpox or Varicella vaccine (VARILRIX)|The active comparator vaccine, a Varicella vaccine (VARILRIX®)
45841694|NCT05130398|Other|Placebo|About 30 children do not receive diet, nor active pathogen detection
45841695|NCT05124691|Combination Product|Albendazole and Ivermectin fixed dose coformulation|400 mg Albendazole - 9 mg Ivermectin OR 400 mg Albendazole - 18 mg Ivermectin
45841696|NCT05124691|Drug|Albendazole|Albendazole 400mg single dose
45841697|NCT05124080|Drug|Deucravacitinib|All participants will receive 6 mg of Deucravacitinib daily.
45841698|NCT05114837|Drug|allogeneic CAR19 regulatory T cells (CAR19-tTreg)|A single dose administration of CAR19-tTreg
45841699|NCT05114837|Drug|Fludarabine|Fludarabine 30 mg/m^2 is administered as an intravenous (IV) infusion per institutional guidelines once a day on 4 consecutive days (Day -5, Day -4, Day -3 and Day -2)
45596499|NCT02201459|Drug|Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®)|"Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months and~Pegylated interferon alfa 2a subcutaneously once a week (auto-injection syringes of 135 and 90 micrograms) at 30 micrograms/week the first month alone (= priming procedure), then at 30 micrograms/2weeks the first month of combination to nilotinib and then at 45 micrograms/week thereafter until month 24 after nilotinib initiation."
45596500|NCT02365389|Drug|MTZ vaginal gel|MTZ vaginal gel once daily for 5 days
45685679|NCT04389970|Behavioral|Time Restricted Feeding|Participants will eat all food within an 8 hour window each day. They will only consume water or black coffee during the remaining 16 hours.
45685680|NCT01485627|Behavioral|Communication training and coaching|Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
45685681|NCT02209636|Drug|Lanthanum carbonate|Non-calcium containing phosphorus binder
45841700|NCT05114837|Drug|Cyclophosphamide|Cyclophosphamide 500 mg/m^2 is administered as an IV infusion per institutional guidelines once a day on 2 consecutive days (Day -5, and Day -4)
45685682|NCT02209636|Drug|placebo|Table identical to lanthanum carbonate but with no active ingredient
45685683|NCT02209636|Drug|Ascorbic Acid|Intravenous administration during measurement of flow mediated dilation.
45685684|NCT02209636|Drug|Nitroglycerin|Drug that is administered under the tongue that relaxes blood vessels. To be administered during measurement of flow mediated dilation.
45685685|NCT02209636|Procedure|Flow-mediated dilation measurement|Measurement of the blood flow in the brachial artery, an artery in the upper arm, using ultrasound.
45841701|NCT05107336|Drug|AZD2693|Participants will receive subcutaneous injection of AZD2693, once per month.
45349928|NCT00863733|Drug|DMXAA|Administered as a 20 minute IV infusion, once every three weeks at doses ranging from 6 mg/m2 to 4900 mg/m2
45685686|NCT02209636|Procedure|Aortic pulse-wave velocity|Measurement of the stiffness of the arteries using a transcutaneous tonometer, a small device placed over the skin over the carotid, brachial, radial and femoral arteries.
45685687|NCT02209636|Procedure|Endothelial cell collection|Collection of endothelial cells from vein in arm. A flexible wire is inserted through an IV into a forearm vein to collect endothelial cells for further study. This is performed at the baseline visit and and the final study visit.
45685688|NCT02250352|Other|cytology specimen collection procedure|Correlative studies
45841702|NCT05107336|Drug|Placebo|Participants will receive subcutaneous injection of placebo (volume matching to AZD2693 injection [0.9% saline solution]), once per month.
45841703|NCT05102656|Other|Best Practice|Physician conversations occur in-person
45349929|NCT00549562|Drug|Paliperidone ER|Starting dose is 3 mg per day. Can be titrated up to a maximum dose of 9 mg per day.
45841704|NCT05102656|Procedure|Discussion|Physician conversations occur via video call
45841705|NCT05102656|Other|Questionnaire Administration|Ancillary studies
45349930|NCT00860925|Drug|active clonidine|Prior to surgery (goal 2-4 hours) patients will ingest 1 tablet of clonidine (0.2 mg) and will have a transdermal clonidine patch (0.2 mg/day) applied. The patch will be removed at 72 hours after surgery.
45349931|NCT00860925|Drug|active ASA|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA tablets (81 mg per tablet). After the first dose, patients will ingest 1 tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take ASA orally will receive it rectally.
45349932|NCT00860925|Drug|Clonidine Placebo|Prior to surgery (goal 2-4 hours) patients will take oral clonidine placebo and will have a transdermal placebo patch applied. The patch will be removed at 72 hours after surgery.
45349933|NCT00860925|Drug|ASA Placebo|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA placebo tablets. After the first dose, patients will ingest 1 placebo tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take placebo orally will receive it rectally.
45349934|NCT00681564|Procedure|One-Stage Full-Mouth Disinfection|"Scaling and root planing, four quadrants in one session~Tongue brushing with a 1% chlorhexidine gel (1 minute)~Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes)~Subgingival chlorhexidine (1%) irrigation in all pockets~Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention~Basic oral hygiene instructions~Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)"
45349935|NCT00681564|Procedure|Periodontal care|"Basic oral hygiene instructions~Supragingival plaque removal"
45349936|NCT05350930|Other|Assessment of patient satisfaction regarding tele-consultation|Questionnaire completed following the teleconsultation, if applicable.
45349937|NCT05350930|Other|Literacy questionnaire|Questionnaire completed during hospitalization for the first chemotherapy cycle
45349938|NCT05350930|Other|Collection of socio-demographic characteristics|Questionnaire completed during patient hospitalization for the first chemotherapy cycle
45349939|NCT05350930|Other|Assessment of patient knowledge on chemotherapy side effects and support medications|Questionnaire completed during patient hospitalization for the first, second and sixth cycle of chemotherapy
45841706|NCT05097274|Other|MRI pelvis or CT imaging under clinical management for Pr Ca|Individuals to undergo a clinical MRI or CT scan of Pelvis and the study reviews the images.
45841707|NCT05097274|Other|Whole body bone scan imaging|bone scan of the whole body (under clinical diagnosis).
45841708|NCT05097274|Other|PET-CT imaging|Pt will undergo a PET-CT for their clinical treatment and we will review the images of this scan.
45841709|NCT05064553|Device|Study CT/MRI Imaging|Subjects with negative ultrasound will be sent for a study CT/MRI.
45685689|NCT01515904|Behavioral|STOMP Clinic|"A new interdisciplinary clinic (STOMP) was created to provide care for children and adolescents with severe 'complex' obesity. As part of the program, a subset of adolescents undergo bariatric surgery. The core elements include an interdisciplinary team, frequent visits, individualized care plans for medically-complex adolescents) and building on other aspects, such as increased psychosocial intervention; involvement of a key worker (nurse practitioner) to support families; provision of continuity of care with other health providers in all settings, community services and schools; a more diverse patient population; and group support sessions."
45685690|NCT02203240|Other|Cocoa|
45841710|NCT05064553|Device|Standard of Care CT/MRI Imaging|Subjects with positive ultrasound are anticipated to have standard of care imaging follow-up as well as other procedures as needed.
46045029|NCT02610517|Behavioral|Patient Intervention|Eligible participants will be screened using the Audit and Mini instruments that are routinely asked during regular clinic visits. Once a participant consents, they will be shown 2 computerized brief interventions (CBIs) - one after enrollment (visit 1) and one 3-6 months after enrollment (visit 2). Participants will interact with the touch-screen computer via Peedy the Parrot, a three dimensional animated character. The intervention emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. At the end of both visits, patients will complete a patient satisfaction survey with questions related to ease of use of CBI and satisfaction with program content. Providers will have the opportunity to prescribe pharmacotherapy at visit 1 and 2.
45349940|NCT05350930|Other|Assessment of patient satisfaction on pharmaceutical follow-up|Questionnaire completed during patient hospitalization for the sixth chemotherapy cycle
45685691|NCT02203240|Other|Placebo|
45685692|NCT01508325|Drug|Bisoprolol|Subjects will receive bisoprolol fumarate (Concor®) at a dose of 5 milligram (mg) once daily orally as sustained release (SR) tablets for a period of 4 weeks. The dose of bisoprolol will be escalated to 7.5 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 10 mg orally once daily for the next 4 weeks (Weeks 8 to 12), if clinic systolic blood pressure (SBP) was greater than or equal to (>=) 140 millimeters of mercury (mmHg) and/or diastolic blood pressure (DBP) was >=90 mmHg measured every 4 weeks.
45685693|NCT01508325|Drug|Metoprolol|Subjects will receive metoprolol succinate (Betaloc SR) at a dose of 47.5 mg once daily orally as SR tablets for a period of 4 weeks. The dose of metoprolol will be escalated to 71.25 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 95 mg orally once daily for the next 4 weeks (Weeks 8 to 12) if clinic SBP was >=140 mmHg and/or DBP was >=90 mmHg measured every 4 weeks.
45685694|NCT01514344|Drug|intralesional rituximab|10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months
45685695|NCT01514344|Biological|supplemental autologous serum|patients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum
45841711|NCT05064553|Diagnostic Test|Oncoguard™ Liver Test|Subjects will have a blood sample collected for the Oncoguard™ Liver Test.
45841712|NCT05036785|Other|Timing of suture removal|Patients will either be randomized to have their sutures removed at 7 or 10 days post skin surgery
45841713|NCT05035082|Drug|semaglutide|Oral administration The doctor will give a prescription for the medicine and tell how to take it.
45349941|NCT05350852|Biological|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
45349942|NCT00955786|Drug|CX-3543|Escalating doses of CX-3543 administered intravenously daily for 5 consecutive days every 21 days.
45841714|NCT05035082|Drug|oral glucose-lowering medications (commercially available)|Oral administration The doctor will give a prescription for the medicine and tell how to take it.
45349943|NCT04237012|Drug|Dextenza 0.4Mg Intracanalicular Insert|all patients will receive Intracanalicular dexamethasone, 0.4mg insert lower punctum and able to use over the counter artificial tears PRN at patient discretion
45349944|NCT04237012|Other|Over the counter Artificial tears|over the counter artificial tears PRN at patient discretion
45349945|NCT00863889|Drug|Depomedrol injection|1 cc of Depomedrol 80
45349946|NCT00863889|Drug|Lidocaine, Marcaine|4 cc of each local anesthetic
45349947|NCT05299450|Dietary Supplement|Beet It shots|In addition to the procedures for the control group, women will be supplied with 84 Beet-It shots which they will be asked to take every morning with breakfast for 12 weeks. Women below 60kg will be advised to take a proportion of the 'shot' in order to comply with European Commission Accepted Daily Intake for nitrate, the active ingredient, of 0-5mg/kg. https://www.beet-it.com/product/beet-it-sport-shot/
45349948|NCT05299450|Behavioral|Exercise|In addition to the procedures for the control group, women will be supplied with gym membership for 12 weeks, 2 initial personal training sessions to design a personal exercise program followed by monthly personal training sessions.
45596501|NCT02365389|Drug|Conventional MTZ vaginal gel|Conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days
45349949|NCT05299450|Other|Control group|Women will be supplied with a wearable device to measure physical activity, weighing scales and a home blood pressure monitor. They will be asked to record minutes of physical activity, exercise undertaken, resting blood pressure, resting heart rate and weight daily for 12 weeks.
45349950|NCT00861003|Device|Medication Event Monitoring System (MEMS)|MEMS is a medication vial cap that electronically records the date and time of bottle opening.
45349951|NCT01563250|Device|Point of Care testing|"The investigators will implement 6 months of randomized testing periods, 2 weeks each. During this 2 week block, cardiac biomarkers will be tested at the bedside in the ED using the Triage Cardiac Panel that will test for CK-MB, Myoglobin, and Troponin I.~Each blood sample that is take for point of care testing will be saved. The plasma from the saved sample will be frozen and the sample will be sent to an off-site testing center for high sensitivity troponin testing.~All patients will be followed at the 30-day mark and those patients who are discharged home from the ED will be followed within 48 hours as well."
45349952|NCT00677352|Drug|sertraline|dosage : 25mg , 50mg , placebo; dosage form : tablet; frequency : once daily after dinner; duration : 14 weeks
45349953|NCT00677352|Drug|Paroxetine|dosage : 10mg, placebo; dosage form : capsule; frequency : once daily after dinner; duration : 14 weeks
45349954|NCT00861081|Behavioral|Care Management|Over a period of one year, subjects will participate in two regular stroke clinics, three group clinics, obtain self-management tools, and will receive a series of four scheduled telephone calls by nurse practitioners to review information delivered during the group clinics and help with care coordination. Usual care will also be available.
45349955|NCT00861081|Behavioral|Written Materials|Educational materials about stroke that will be distributed during the group clinic session will be mailed to these subjects. These materials have been developed by the American Heart Association. Usual care will also be available.
46045030|NCT05154032|Other|Traditional Float-REST Therapy|Traditional Float-REST therapy uses sensory deprivation tanks that consist of a very large warm water enclosure with a high concentration of Epsom salt to create a completely buoyant environment. This, along with a combination of temperature that is kept equal to skin temperature (94 degrees), allows the participant to eliminate the gravitational effects on the body, and along with lack of sound and low to no light (depending on comfort) allows the brain and body to completely relax for augmented physical and mental recovery. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions three times a week for 3 weeks.
45349956|NCT04010110|Diagnostic Test|visual field testing (10-2), spectral domain ocular coherence tomography and Fundus auto-fluorescence|The diagnosis of toxic retinopathy was based on the positivity of at least two objective tests to confirm the subjective findings. The presence or absence of toxicity was recorded.
45349957|NCT00864045|Drug|Sertindole|Sertindole flexible doses per os, 12, 16 or 20mg/day according to response and tolerability, initially up-titrated from 4mg/day to target dose 16mg/day within the first 16 days
45349958|NCT00864045|Drug|Olanzapine|Olanzapine flexible doses per os, 10, 15 or 20mg/day according to response and tolerability, initially up-titrated from 10mg/day to target dose 15mg/day within the first 16 days
45349959|NCT00755508|Drug|Ramelteon and gabapentin|Ramelteon 4 mg, tablets, orally, once daily and gabapentin 400 mg, capsules, orally, once daily for up to one week.
45349960|NCT00755508|Drug|Ramelteon and gabapentin|Ramelteon 8 mg, tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
45349961|NCT00755508|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
45596502|NCT02201537|Device|renal echography|"Renal biopsy will be performed at 3 and 12 months.~The functional imaging examinations will be held as follows:~Step 1: the conventional Doppler ultrasound Step 2: ultrasound elastography Step 3: CEUS"
45349962|NCT00755508|Drug|Gabapentin|Ramelteon placebo-matching tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
45476333|NCT04501198|Device|moxibustion combined with characteristic lifestyle intervention of traditional chinese medicine|"The moxibustion acupoints will be selected as①zhongwan, guanyuan, shenque, and zusanli;②pishu,shenshu. Acupoints group①will be selected on Monday, Wednesday, and Friday, Acupoints group②will be selected on Tuesday, Thursday, Saturday.Moxibustion treatment will be applied once every day, 6 times per week, for 8 consecutive weeks.~Xiusheng decoction, traditional exercises, and modern lifestyle intervention will be combined as the characteristic lifestyle intervention method of TCM to help participants establish healthy living habits. The Xiusheng Decoction should be taken twice a day. Traditional exercises will be taken for 35~40 minutes everyday, 7 times a week. The intervention of Xiusheng Decoction and traditional exercises will be conducted for 8 weeks. All patients will be instructed to follow a good living habits which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks."
45685696|NCT01506856|Drug|Paclitaxel(intravenous) + Carboplatin(intravenous)|Paclitaxel(intravenous) + Carboplatin(intravenous) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IV infusion, Day1 A total of 6 to 8 cycles will be repeated.
45685697|NCT01506856|Drug|Paclitaxel(intravenous) + Carboplatin(intraperitoneal)|Paclitaxel(intravenous) + Carboplatin(intraperitoneal) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IP injection, Day1 A total of 6 to 8 cycles will be repeated.
45685698|NCT01508169|Device|Foot orthosis (Orthotics Unit of the Clinical Hospital of UNICAMP)|Custom foot orthoses made of ethylene-vinyl acetate (EVA) with medial arch supports and metatarsal pads (supporting the diaphysis of the second to fourth metatarsals) that were manufactured by the Orthotics and Prostheses Unit of the Clinical Hospital of UNICAMP.
45685699|NCT01536171|Other|running with normal running shoes and barefoot|shod condition: normal running shoes barefoot condition: running with no shoewear
45841715|NCT05029271|Device|InPen with Guardian 4 System|Subjects will receive the InPen™ and InPen™ Diabetes Management App combined with the Guardian™ 4 system.
45349963|NCT00755508|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
45349964|NCT02544087|Drug|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
45349965|NCT02544087|Drug|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
45349966|NCT02544087|Drug|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
45349967|NCT03680352|Drug|cefepime/AAI101|Fixed dose combination of cefepime and AAI101
45685700|NCT02196376|Other|History|the physician / PI will conduct a history that may include: demographics Framingham risk factors metabolic diseases inflammatory diseases autoimmune disorders review of medications date of last menstrual period (females) family history of autonomic disorders Onset of postural orthostatic tachycardia syndrome
45685701|NCT02196376|Other|Physical|"the physical exam will include: height weight orthostatic vitals (heart rate and blood pressure), supine and standing for up to 10 minutes.~Beighton Criteria for Join Hypermobility Syndrome Dependent acrocyanosis"
45349968|NCT00955942|Dietary Supplement|flaxseed|Given orally
45349969|NCT00955942|Other|placebo|Given orally
45349970|NCT00864201|Drug|bosentan|bosentan 62mg bid x 4 weeks, followed by bosentan 125mg bid x 20 weeks
45349971|NCT00864279|Drug|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fast conditions
45349972|NCT00864279|Drug|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fast conditions
45349973|NCT02559648|Drug|Denosumab|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
45349974|NCT02559648|Drug|Placebo|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
45349975|NCT05299372|Other|Telemonitoring via Careportal®|The question sets and overnight oximetry results will be monitored and screened by a call centre commissioned by the Liverpool Clinical Commissioning Group (LCCG). The call centre will screen the weekly data and contact clinicians where appropriate (i.e. NIV team, MND specialist nurse, or patient's GP). PVI data will be examined by NIV physiotherapists, where required, following the contact from LCCG to ensure the maximum benefits of NIV to patients.
45349976|NCT00870285|Radiation|UVB 311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
45349977|NCT00755586|Procedure|Mononuclear cell injection: 4 * 10e8 cells|350 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 4 * 10e8 cells in the m. biceps brachii.
45841716|NCT05024097|Drug|Etrumadenant (AB928)|Patients will receive a radiation therapy dose of 25Gy in 5 fractions in combination with etrumadenant 150 mg orally, once daily as part of a continuous dose regimen.
45349978|NCT00755586|Procedure|Mononuclear cell injection: 8 * 10e8 cells|650 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 8 * 10e8 cells in the m. biceps brachii.
45841717|NCT05024097|Radiation|Radiation therapy|Patients will receive a radiation therapy dose of 25Gy in 5fx
45349979|NCT00755586|Procedure|No mononuclear cell injection|Patients will receive a muscle tendon transposition surgery without bone marrow aspiration or mononuclear cell injection.
45476334|NCT04501198|Device|Moxibustion combined with lifestyle intervention.|"The moxibustion acupoints will be selected as①zhongwan, guanyuan, shenque, and zusanli;②pishu,shenshu. Acupoints group①will be selected on Monday, Wednesday, and Friday, Acupoints group②will be selected on Tuesday, Thursday, Saturday.Moxibustion treatment will be applied once every day, 6 times per week, for 8 consecutive weeks.~All patients will be instructed to follow a good living habits including diet and exercise intervention which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks."
45476335|NCT04501198|Device|lifestyle intervention|All patients will be instructed to follow a good living habits including diet and exercise intervention which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
45476336|NCT02668874|Device|Isolite System|
45476337|NCT02668874|Other|Cotton Roll Technique|
45476338|NCT05211479|Behavioral|educational intervention|"In the light of up-to-date information, Type I Diabetes Education Guide was created. With this guide, both face-to-face and tele-nursing training will be provided. Both working groups will receive training before starting research. The intervention group will continue their weekly training throughout the study."
45476339|NCT02517424|Drug|High THC/Low CBD Cannabis|Dried cannabis
45476340|NCT02517424|Drug|High THC/High CBD Cannabis|Dried cannabis
45476341|NCT02517424|Drug|Low THC/Low CBD Cannabis|Dried cannabis
45476342|NCT03846323|Other|Visiting policies: 24 hours a day, 7 days a week|
45476343|NCT03846323|Other|Restriction of visiting policies < 6 hours|
45476344|NCT01567904|Drug|Semuloparin sodium|"Solution for injection in single dose vials (10 mg/mL and 20 mg/mL)~Subcutaneous injection"
45349980|NCT05350462|Behavioral|Community pilot L-PZQ distribution - intervention is NOT part of this observational study|Data collection will occur at two main time points of the ADOPT-community intervention project: before (baseline assessment) and during/after the community pilot L-PZQ distribution, in order to inform the design and process of the implementation, including that of advocacy and mobilisation, of Levo-Praziquantel delivery to PSAC.
45476345|NCT02517346|Other|Standard follow-up|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
45476346|NCT02517346|Other|Telemonitoring|Follow up by telemonitoring system during 3 months
45476347|NCT01196507|Drug|Carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol or with a maximum of 12.5 BD.
45685702|NCT02196376|Other|blood draw|"blood will be drawn for: antibodies regulating cardiovascular function inflammatory markers~no more than 15 ml (1 TBSP) will be drawn."
45841718|NCT05024097|Drug|FOLFOX regimen|After completing the radiation therapy, patients will receive FOLFOX regimen for 9 cycles in combination with etrumadenant and zimberelimab. All patients will be offered adjuvant zimberelimab for up to one year.
45476348|NCT01196507|Drug|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 4 BD.
45596503|NCT04441411|Device|NEMOST system|Minimal invasive double rod posterior Non-Fusion Scoliosis Surgery
45596504|NCT02201615|Other|Perineal massage in childbirth|
45685703|NCT02196376|Behavioral|Questionnaires|"The questionnaires will be completed directly online (web-based interface) using a personalized link that will be provided to the subjects after they give their informed consent. These will be created in a REDCap-Survey environment, with the data collected and stored on a password-protected, HIPAA-compliant, secure computer server.~The following questionnaires will be conducted:~RAND-36 Health Thermometer Chalder Fatigue Scale Daily diary of Fatigue Symptoms - Fibromyalgia Pain Detect Questionnaire Orthostatic Grading Scale COMPASS-31"
45685704|NCT01536093|Other|oropharyngeal administration of own mother's colostrum|application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
45841719|NCT05024097|Drug|Zimberelimab (AB122)|After completing the radiation therapy, patients will receive FOLFOX regimen for 9 cycles in combination with etrumadenant and zimberelimab. All patients will be offered adjuvant zimberelimab for up to one year.
45476349|NCT02340884|Behavioral|Promoting Resilience In Stress Management (PRISM)|"The brief format of the PRISM intervention involves 4, 50-minute, one-on-one sessions approximately 2 weeks apart, plus a 5th parent-inclusive session 2-4 weeks following session #4. These are complimented with age-specific handouts describing the skills and opportunities to practice them, as well as weekly (text- or email based) check-ins from study staff and in-person booster sessions once monthly. Specifically, the intervention incorporates four primary skills: 1) stress management/mindfulness; 2) goal-setting; 3) cognitive restructuring; and, 4) meaning-making/benefit finding."
45349981|NCT00864357|Drug|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under non-fasting conditions
45349982|NCT00864357|Drug|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under non-fasting conditions
45349983|NCT02559492|Drug|Itacitinib|Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
45349984|NCT02559492|Drug|Epacadostat|Epacadostat tablets will be administered orally, twice daily.
45349985|NCT02559492|Drug|Itacitinib|Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
45349986|NCT02559492|Drug|INCB050465|INCB050465 tablets will be administered orally once daily.
45685705|NCT01536093|Other|oropharyngeal administration of sterile water|application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
45349987|NCT00864435|Drug|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fasting conditions
45349988|NCT00864435|Drug|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fasting conditions
45349989|NCT00755664|Dietary Supplement|Low-dose complex B-vitamins|The complex B vitamins supplement has been made as capsule and packaging 31 capsules in 1 bottle with a pre-determined code number on its cover. The main content contains either vitamin C 50mg alone or combination with folate 0.4 mg, vitamin B6 2mg, vitamin B12 10μg and vitamin C 50 mg. Two kinds of the supplements could not be discriminated by appearance, smell, taste, size and package.volunteers in either arms are required to take 1 capsule per day and last for 48 weeks.
45349990|NCT00956098|Drug|oltipraz|60mg bid 90mg qd
45349991|NCT00956098|Drug|placebo|
45349992|NCT00864591|Procedure|SPECT Imaging|Myocardial SPECT imaging will be performed 10-12 minutes after the stress injection of Tl-201, at 4 hours, and at 18-24 hours in patients with non-reversible or partially reversible defect on 4-hour imaging. Images will be obtained with a rotating single- or dual-head gamma camera equipped with low-energy high resolution collimators. Energy windows of 20% and 10% will be centered on the 70 KeV and 167 KeV peaks of Tl-201, respectively. Thirty images will be obtained (40 seconds each for the stress and 4-hour redistribution imaging, and 60 seconds each for the 18-24-hour imaging) over 180° extending from the 45° right anterior oblique to the 45° left posterior oblique projections.Localization of the disease in the left anterior descending artery (LAD), left circumflex (Cx) and right coronary artery (RCA) will be performed using a quantitative analysis software.
45476350|NCT03347266|Drug|VVZ-149 injections|•VVZ-149 injection
45476351|NCT03347266|Drug|Placebo|water for injection
45349993|NCT00864591|Procedure|Stress Adenosine CMR|"CMR will be performed using a 3-T scanner and a dedicated eight-element cardiac phased-array coil Cine CMR will be performed using steady state free precession in the short-axis, two chamber, three chamber and four-chamber, 8 mm thick, separated by 0-mm gaps.~Adenosine perfusion CMR: Adenosine will be administered intravenously at 140 µg/kg/min over 6 min. Four minutes into the infusion (or earlier if angina is provoked), a bolus (0.1 mmol/kg at 5 ml/s) of Gadolinium DTPA will be administered. Patients will be instructed to hold their breath. Stress perfusion images will be acquired in the short axis plane (parameters and planning will be similar for stress and rest perfusion evaluation). The patients will be monitored by vector ECG, noninvasive sphygmomanometry, pulse oximetry and capnography."
45349994|NCT05350384|Drug|Methylprednisolone|1 g. of methylprednisolone in saline solution 250 cc once a day for 5 days, and one eye drops of Diclofenac per eye 3 times a day for 30 days
45349995|NCT00870441|Drug|ASP2151|Oral
45476352|NCT04987970|Drug|CKD-386(2)|QD, PO
45476353|NCT04987970|Drug|D013, D326, D337|QD, PO
45476354|NCT02517190|Other|Parabolic flight|
46045031|NCT00913861|Behavioral|hypnosis|Hypnosis: induction of hypnosis by visual fixation and recollection of a pleasant memory, suggestion of relaxation, of self-control and post-hypnotic suggestion for bowel relaxation.
46045032|NCT00913861|Drug|standard sedation|Standard sedation: fentanyl 2x0,5 microg/kg at beginning of procedure and propofol PCS: 20mg bolus than 10mg/bolus, lock-out = 0.
46045033|NCT00913861|Behavioral|Structured attention|Structured attention: verbal and nonverbal communication; attentive listening; provision of the perception of control; encouragement; use of emotionally neutral descriptors, focus on a sensations.
46045034|NCT04030273|Diagnostic Test|Diagnostic hysteroscopy|"Diagnostic hysteroscopy performed in outpatient setting, using no touch vaginoscopy technique with a 2.9 mm 30-degree rigid hysteroscope with a single inflow sheet using normal saline as distention media."
45349996|NCT00870441|Drug|Valacyclovir|Oral
45476355|NCT02517190|Other|neuro-endocrine measurements|psychic stress tests, stress hormones: prolactin, cortisol, endo-cannabinoids
45685706|NCT02191930|Drug|B-CAP|
45685707|NCT02191930|Drug|Brentuximab Vedotin|
45685708|NCT01872208|Biological|HAV implantation|Patients will be implanted with a Human Acellular Vessel (HAV) as an above-knee femoro-popliteal bypass graft using standard vascular surgical techniques.
45685709|NCT01536015|Drug|Rotigotine|"Strength and Form: 4 - 8 mg patches, one patch applied every 24 hours~Dosage and Frequency: One patch every 24 hours~Duration: 10 weeks"
45349997|NCT00870441|Drug|Placebo|Oral
45349998|NCT04786704|Diagnostic Test|Stool-based SDC2 DNA methylation test|A diagnostic device measuring syndecan 2(SDC2) methylation status in stool DNA to detect colorectal cancer
45349999|NCT04786704|Diagnostic Test|quantitative Fecal immunochemical test|A diagnostic device using immunoturbidimetric methods to measure fecal hemoglobin concentration
45350000|NCT04079452|Drug|Doravirine|Doravirine 100 mg tablet
45476356|NCT02517190|Other|immunological measurements|blood cell counts, B2 integrins, cytokines, C-reactive protein
45476357|NCT02517190|Other|cellular energy metabolism measurements|purines, lactate
45841720|NCT05014087|Drug|Intravenous digoxin|"Loading dose: the total loading dose of digoxin will be determined using the Loading nomogram. The FDA-recommended total IV digoxin loading dose range is 8 to 12 mcg/kg. The lowest recommended dose of 8 mcg/kg was used in constructing the digoxin Loading nomogram that will be used in this trial.~Maintenance dose: the maintenance dose will be started approximately 24 hours after initiation of digoxin loading. The post-loading digoxin trough will be reviewed prior to starting maintenance dosing.~Subjects on P-gp inhibitors or spironolactone, will have an additional digoxin level performed 12-hours after any dose adjustment. Once digoxin levels are stable, 24-hour blood draws will be performed."
45841721|NCT05012878|Behavioral|Cardiac rehabilitation - high intensity interval training (HIIT)|During cardiac rehabilitation (12-weeks, 3 sessions/week), exercise training will comprise of 4x4-min high intensity aerobic intervals at a rating of perceived exertion 15-17 (hard to very hard), interspersed by a 3-min active recovery at a rating of perceived exertion 11-13 (fairly light to somewhat hard). Warm-up (4-min) and cool-down (3-min) at a light intensity.
46045035|NCT00709189|Drug|Norgestimate/Ehinyl Estradiol; Folic acid.|
46045036|NCT02866188|Device|Check pulse with Smart watch on 3 parts of patient's body surface|Check pulse with smart watch on wrist, carotid artery, and eye of patients in shock or cardiac arrest state.
45350001|NCT04079452|Drug|Descovy|Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
45350002|NCT00864669|Drug|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
45350003|NCT00864669|Drug|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
45350004|NCT00760890|Dietary Supplement|Fer-In-Sol (ferrous sulfate)|7.5 mg/day in the form of 0.3 ml once each day
45350005|NCT00760890|Dietary Supplement|Iron fortified cereal|1 jar each day of one of three wet pack cereals manufactured by the Gerber Company: Each jar provided 7 mg of ferrous sulfate.
45350006|NCT00864747|Drug|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under non-fasting conditions
45350007|NCT00864747|Drug|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products non-under fasting conditions
45350008|NCT05279716|Drug|Eybelis ophthalmic solution 0.002%|Ophthalmic eye drop
46045037|NCT00709267|Drug|Folic acid|
45350009|NCT04619628|Biological|COVI-VAC|intranasal, live attenuated vaccine against SARS-CoV-2
45350010|NCT04619628|Other|Placebo|normal saline
45350011|NCT02543853|Other|direct trocar entry|direct trocar entry to provide pneumoperitoneum
45350012|NCT02543853|Other|veres needle entry|veres needle entry to provide pneumoperitoneum
45350013|NCT02543931|Drug|Meriva|Meriva is an enhanced-bioavailability, curcuminoid-enriched turmeric dietary supplement that is sold over the counter in the United States and other countries.
45350014|NCT02543931|Drug|placebo|Placebo capsules containing inert ingredients
45350015|NCT04604652|Drug|HTD1801 (BUDCA)|HTD1801 (BUDCA) 250 mg tablets. Dose 1000 mg twice daily with food for 12 weeks.
45476358|NCT05180201|Dietary Supplement|Synbiotic|Lactiplantibacillus plantarum ATCC 202195 with fructooligosaccharide
45476359|NCT05180201|Dietary Supplement|Probiotic|Lactiplantibacillus plantarum ATCC 202195
45476360|NCT05180201|Other|Placebo|Maltodextrin
45476361|NCT03627650|Procedure|lipofilling/ fat grafting|liposuction, processing/ cleaning of fat tissue; reinjection with sharp needle transcutaneous
45350016|NCT05350228|Diagnostic Test|CNN based model|It is an automatic detector model based on convolution neural network created by computer science expert
45476362|NCT03627650|Procedure|placebo injection|
45476363|NCT03143660|Behavioral|Coaching|The eight weekly 30-minute Fitline calls provide personalized behavioral counseling and coaching to guide parents in improving their child's weight-related behaviors through targeted lifestyle changes recommended by the AAP for Stage 1, Prevention Plus. Calls are scheduled at a time convenient for the parent, including nights and weekends, with one nutritionist assigned to a family for consistency.
45476364|NCT03143660|Behavioral|Materials|The workbook contains tips and practical strategies for implementing the AAP-recommended behavior changes discussed in the counseling sessions to support families in making lifestyle changes.
46045038|NCT01120964|Drug|Intravenous L-Citrulline|
46045039|NCT01120964|Drug|Placebo of Intravenous L-Citrulline|Placebo of intravenous L-Citrulline given at the same prescribed times as L-Citrullne Drug
46045040|NCT02865408|Dietary Supplement|Peptamen 1.5% via enteral|Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard enteral Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d.
45350017|NCT00870519|Drug|I-123-MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
45350018|NCT00870519|Drug|123-I MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
45350019|NCT02559102|Drug|Dexmedetomidine sedation|Patients receive dexmedetomidine sedation
45350020|NCT02559102|Drug|General sevoflurane anaesthesia|Patients receive general sevoflurane anaesthesia with endotracheal intubation
45350021|NCT02559102|Procedure|Caudal anaesthesia|single shot caudal anaesthesia
45350022|NCT02559102|Procedure|Inguinal hernia surgery|Infant inguinal hernia repair.
45350023|NCT05348668|Drug|Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors|Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors
45350024|NCT05309044|Behavioral|Planetary Health Diet Group|This group includes a diet proportional to the EAT-Lancet reference diet (2500 kcal), with a caloric intake of 1200 to 1800 kcal, in addition to a behavioral change protocol during the time of the study (4 months).
45350025|NCT05309044|Other|Low-fat diet group|This group includes a low-fat, low-calorie diet (1200-1800 kcal), in addition to a behavioral change protocol
45350026|NCT05309044|Other|Waiting list group|This group will only receive digital information with recommendations on healthy eating. When the study has finished, this group will receive a behavioral change protocol with a low-fat, low-calorie diet.
45350027|NCT00864825|Drug|Allopurinol|Allopurinol 1 capsule 300 mg, or placebo, bid (twice a day) for 42 days.
45841722|NCT05012878|Behavioral|Cardiac rehabilitation - moderate intensity continuous training (MICT)|During cardiac rehabilitation (12-weeks, 3 sessions/week), exercise training will comprise of 34-min of continuous aerobic exercise at a rating of perceived exertion 11-13 (fairly light to somewhat hard). Warm-up (3-min) and cool-down (3-min) at a light intensity.
45350028|NCT00870597|Procedure|Multifocal IOL implantation + Vitrectomy|25-gauge transconjuntival sutureless vitrectomy (TSV)
45350029|NCT00870597|Procedure|Multifocal IOL implantation - Vitrectomy|Multifocal IOL implantation without transconjunctival vitrectomy
45350030|NCT00956176|Drug|Cidofovir|Single dose of 5 mg/kg administered in 100 ml of normal saline solution through a foley catheter to bladder. The catheter will be clamped for 2 hours to keep the drug in bladder.
45350031|NCT00864981|Drug|Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.|
45350032|NCT00864981|Drug|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline|
45350033|NCT00371683|Drug|Enoxaparin + Placebo|Syringes + tablets, Subcutaneous + Oral, 30mg, twice daily, 12 day treatment period
45350034|NCT00371683|Drug|Apixaban + Placebo|Tablet + Syringes, Oral + subcutaneous, 2.5 mg, twice daily, 12 day treatment period
45350035|NCT05286580|Behavioral|Morbidity and mortality conference toolkit|"Standardized slide deck~Code of conduct~Conference planning checklist~Case documentation form"
45476365|NCT02517112|Other|Parabolic flight|
45476366|NCT02517112|Other|Cardiovascular parameters measurements|with Ballistocardiography (BCG), electric cardiography (ECG), impedance cardiography (ICG) and echocardiography
45476367|NCT02517112|Device|3D-BCG sensor|
45476368|NCT05670509|Drug|administration of Nasal midazolam in home group as a rescue medication for seizure control.|Children from home group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing
45476369|NCT05670509|Drug|administration of Buccal midazolam in home group as a rescue medication for seizure control.|Children from home group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
45350036|NCT00876057|Procedure|Total abdominal hysterectomy|Total abdominal hysterectomy
45350037|NCT00876057|Procedure|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy
45350038|NCT05276128|Dietary Supplement|lipids|Investigations of dose-response effects of 3 different doses of an bioactive plant based lipid consumed at breakfast, after overnight fasting. Total amounts of lipids in each test portion are 15g, and the lower doses are supplemented with a control lipid to sum upp to 15 g total lipids. A control product with15g control lipids and without active lipids is also included. The lipids are supplemented to a white wheat bread, corresponding to 50 g available starch. A White wheat bread portion without lipid supplementation is included as a well studied reference product.
45350039|NCT05226273|Other|no intervention|no intervention
45685710|NCT01536015|Drug|Placebo|"Frequency: One patch applied every 24 hours~Duration: 10 weeks"
45685711|NCT01865110|Drug|R-CHOP|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 8 cycles
45685712|NCT01865110|Drug|R-CHOP / R-HAD|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) administered in 3 week cycles for 3 cycles R-HAD (rituximab, cytarabine, dexamethasone) administered in 3 week cycles for 4 cycles alternating
45685713|NCT01865110|Drug|Rituximab|Rituximab SC 1400 mg every 8 weeks for 24 months
45685714|NCT01865110|Drug|Lenalidomide|Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months
45350040|NCT00956332|Biological|MultiGeneAngio|Low-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
45350041|NCT00956332|Biological|MultiGeneAngio|Intermediate-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
45350042|NCT00870753|Behavioral|Yoga|90 min hatha yoga 2 times per week for 12 weeks.
45350043|NCT03825718|Biological|GC007F|GC007F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive GC007F as one dose. The dosage ranges from 6×10^4 to 2×10^6 CAR+T/Kg.
45350044|NCT00876135|Drug|Ventolin|Ventolin or Placebo will be given before the 4 field tests (2 with ventolin in prevention and 2 with placebo in prevention) and 2 eucapnic voluntary hyperpnoea tests (one preceded by Ventolin and one preceded by Placebo).
45841723|NCT05012878|Behavioral|Cardiac rehabilitation - control|Participants will receive exercise advice in line with usual hospital discharge procedures. This involves exercise physiologists providing verbal and written information on achieving the national physical activity guidelines (150min/week of moderate intensity exercise) 60 and range of movement exercises for surgical patients with sternotomy. However, no structured or supervised exercise training program or other contact with participants will be provided after hospital discharge, to reflect the usual care process for patients that decline cardiac rehabilitation.
45350046|NCT05214742|Other|Diagnostic Test|Molecular diagnosis carried out in the context of care
45476370|NCT05670509|Drug|administration of intramuscular midazolam in homegroup as a rescue medication for seizure control.|Children from home group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh
45350047|NCT00870831|Other|OGTT (Oral Glucose Tolerance Test)|Subjects would consume 75grams of sugar (Dextrose, 10 oz) and blood samples taken at specified time points to measure glucose, insulin and C-peptide
45841724|NCT05012878|Behavioral|Cardiac rehabilitation - observational|During cardiac rehabilitation (12-weeks), program frequency and exercise training protocol will align with clinical care decisions and/or patient choice rather than random assignment.
45476371|NCT05670509|Drug|administration of Nasal midazolam in ER group as a rescue medication for seizure control.|Children from the ER group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing
45350048|NCT03588286|Procedure|Electrophysiology study (EPS)|EPS will be performed in all patients in the intervention arm with programmed ventricular stimulation with a drive train of 8 beats at 400 ms with up to 4 extrastimuli and stimulation from the right ventricular apex with current delivered at twice pacing threshold. The end point for stimulation will be sustained monomorphic ventricular tachycardia (VT) lasting > 10 seconds. If sustained monomorphic VT with cycle length (CL) ≥200ms is induced by ≤4 extra stimuli the EPS result will be considered positive for inducible VT.30 Ventricular fibrillation or flutter with CL<200ms will be considered a negative result. The Programmed Ventricular Stimulation (PVS) induction will be repeated a second time if the initial induction was negative for VT.
45350049|NCT03588286|Other|Standard Care|The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).
45476372|NCT05670509|Drug|administration of Buccal midazolam in ER group as a rescue medication for seizure control.|Children from ER group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
45476373|NCT05670509|Drug|administration of intramuscular midazolam in ER group as a rescue medication for seizure control.|Children from ER group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh
45476374|NCT04959422|Other|Active scheduling|Active scheduling, tracking and rescheduling, if necessary.
45596505|NCT04441177|Device|PlayStation®VR training|Participants in the study group receive conventional rehabilitation therapy over 50 minutes on weekdays and 7 sessions (flexible schedule in different day) of PlayStation®VR of 20 minutes each in the main 16-day study period.
45596506|NCT02201693|Dietary Supplement|MODULEN IBD|2 week ON / 6 weeks OFF treatment every 8 weeks covering at least 100% of daily caloric requirement (approx. 2-2.5L/day).
45685715|NCT04725825|Other|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
45685716|NCT04725825|Other|Sham needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
45596507|NCT02201693|Dietary Supplement|MODULEN IBD|25% of daily caloric requirements, approx. 500mL/day
45685717|NCT03028077|Dietary Supplement|GS-3K8|GS-3K8 (ultrafiltered red ginseng extract) 1 g/day
45685718|NCT03028077|Dietary Supplement|GINst15|GINst15 (hydrolyzed ginseng extract) 1 g/day
45841725|NCT05007093|Drug|Anlotinib hydrochloride|If intolerance occurs, the dose can be downregulated
45841726|NCT05005793|Drug|Sodium bicarbonate|Oral sodium bicarbonate at 0.5 mEq/kg-lean body weight/day
45841727|NCT05005793|Drug|Placebo|Placebo at 0.5 mEq/kg-lean body weight/day
45841728|NCT04982640|Behavioral|Iyengar yoga|60 minute group-classes of Iyengar yoga delivered twice weekly for 12 weeks
45350050|NCT03588286|Procedure|Cardiac Magnetic Resonance (CMR)|CMR will be performed on either a 1.5-T or 3-T scanner. Gadolinium contrast (Gd-BOPTA, MultihanceTM) will be administered for quantification myocardial perfusion imaging with subsequent late gadolinium enhanced imaging after a total dose of 0.1mmol/kg. Exclusion criteria specific for CMR will include pregnancy, renal insufficiency defined as glomerular filtration rate (GFR) <30 mL/min, contraindication to MRI (including non-MRI compatible pacemaker/ICD or metal implants, non-MR safe prosthetic heart valves), claustrophobia which cannot be controlled via standard methods (benzodiazepines and/or sedative antihistamine administration) and prior allergic reaction to gadolinium-based contrast agent.
45841729|NCT04982640|Behavioral|Standard Exercise|60 minutes, twice weekly for 12 weeks, group-based walking program
45350051|NCT00876291|Dietary Supplement|Lactobacillus GG (probiotic )|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
45350052|NCT00876291|Dietary Supplement|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
45841730|NCT04982640|Behavioral|Nutrition Counseling|One, 30-minute session with registered dietitian
45841731|NCT04970134|Other|Immunohistochemistry (IHC)|VENTANA pan-TRK technique (EPR17341) Assay, with Optiview DAB-detection kit and Optiview amplification kit. Using FFPE slices
45350053|NCT03563482|Diagnostic Test|PET scan|Tumor biopsy at baseline; PET scan performed after 8 weeks of treatment
45350054|NCT00870909|Procedure|active tDCS|Intensity 2 mA during 20 minutes, 2 times per day
45350055|NCT00870909|Procedure|sham tDCS|sham condition as delivered by the stimulator
45350056|NCT04039815|Drug|Ascorbic acid-Vitamin B1-Hydrocortisone|intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), plus Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days
46045041|NCT02865408|Dietary Supplement|Prosol 20% IV to 1.75g/kg/day|Patients in group 2 will receive Peptamen 1.5% but in addition, will receive sufficient intravenous amino acid supplements (Prosol 20%) to achieve an effective fixed dose of 1.75 g/kg/day.
45350057|NCT04039815|Drug|Placebo|patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
45350058|NCT00876525|Device|Freedom SOLO|The Freedom SOLO heart valve prosthesis is a stentless bioprosthesis manufactured with bovine pericardium.
45350059|NCT00870987|Biological|DNA vaccine prime|2 mg total dose (1 mg per construct in a volume of 1 mL)
45350060|NCT00870987|Biological|adenovirus type 5 vaccine boost|2 x 1010 particle units (pu) (1 x 1010 pu per each of 2 constructs including CSP and AMA1 respectively)
45476375|NCT03964246|Behavioral|Compassion Meditation (CM) intervention|"Thee CBCT-Vet includes 10 90-minute sessions that will be led by certified CBCT therapist with significant experience in administering CBCT-Vet. Sessions 1 - 4 assist participants in basic mindfulness breathing practices; sessions 4 - 8 focus on personal analysis of factors underlying difficulties with compassion for self or others; the final two sessions (9 and 10) review content and assist with relapse prevention. Session by session topics are: (1) Introduction and learning breathing meditation, (2) Focused attention, (3) Creating space, (4) Mindful awareness, (5) Re-engaging with heroic spirit, (6) Seeing ourselves in others, (7) Appreciation and gratitude, (8) Empathy and engaged compassion, (9) Putting it all together, and (10) Putting it all together 2."
45685719|NCT03028077|Dietary Supplement|Placebo|Placebo 1 g/day
45685720|NCT01863940|Device|Wound Catheter|Wound catheter placement in split thickness skin graft donor site on the thigh with continuous infusion of procaine 0.5% at 4-5cc/hr for 48 hours.
45685721|NCT01484691|Drug|Budesonide|Inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
45685722|NCT01464034|Drug|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
45685723|NCT01464034|Drug|Pomalidomide|PO daily on Days 1-21, every 28 Days
45685724|NCT01464034|Drug|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
45841732|NCT04970134|Other|Fluorescence In-Situ Hybridization (FISH)|FISH using FFPE slices for genes: Neurotrophic tyrosin kinase 1 (NTRK1), Neurotrophic tyrosin kinase 3 (NTRK3) and rearranged during transfection (RET)
45841733|NCT04970134|Other|Oncomine Focus Assay Platform with 52 genes|Oncomine Focus Assay Platform with 52 genes (35 Hotspot genes, 19 Copy number variants and 23 Gene fusions). Using FFPE slices
46045042|NCT02865408|Dietary Supplement|Prosol 20% IV to 2.5g/kg/day|Patients in this group will receive intravenous amino acids, Prosol 20% in addition to standard enteral Peptamen 1.5% to achieve an effective protein intake of 2.5 g/kg/d.
46045043|NCT05757739|Procedure|Tenex|In the Tenex procedure, the surgeon inserts a special needle into the damaged portion of the tendon under ultrasound guidance. Ultrasonic energy vibrates the damaged tissue and it can be suctioned out. This procedure is done with local anesthesia in surgeon's office.
46045044|NCT05757661|Other|Focal Vibration|"A single 30-minute focal vibration procedure will be performed on both quadriceps with the V-Plus Wintecare® machine.~Three channels will be used on the muscle bellies of the rectus anterior, vastus internus and vastus externus. The positioning of the vibration heads will be done with straps designed by the manufacturer to keep the vibration focus stable on the muscle belly.~The configuration of the vibration program will be in an automatic mode of 10 seconds of vibration and 3 seconds of rest to avoid the coupling of the mechanoreceptors. The frequency used will be between 60 Hz to 150 Hz with a power of 80%."
45350061|NCT03951766|Behavioral|Smiling Instead of Smoking (SiS) App Version 2|The investigators have developed a smartphone app that acts as a behavioral, in-the-pocket coach and uses positive psychology exercises to enhance quitting success. It is anonymous, portable, and provides just-in-time support, an important feature for smokers who smoke under specific conditions and circumstances. To support treatment, investigators use a positive psychology approach. The smartphone app administers positive psychology exercises to enhance and/or maintain positive affect, which is hypothesized to stimulate nondaily smokers to enact healthier alternatives to smoking by broadening their thought-action repertoire, increasing confidence, and decreasing craving and defensiveness about smoking-related health information.
45350062|NCT00871065|Drug|Sildenafil citrate|20 mg tablet orally every 8 hours until Day 14 post-hemorrhage
45350063|NCT00876603|Procedure|ACDF|Anterior cervical decompression and fusion
45350064|NCT00876603|Procedure|Cervical laminoplasty|Cervical laminoplasty
45350065|NCT00371137|Drug|Xyrem®|two doses
45350066|NCT00371137|Drug|Placebo|Oral Solution
45350069|NCT01050283|Procedure|Comparator: [18F]-FDG PET/CT and Volumetric CT|Patients will receive gemcitabine-based therapy as prescribed by their treating physician. FDG-PET/CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy. Volumetric CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy.
45350070|NCT00961870|Procedure|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups.
45350071|NCT05175417|Other|MRI|3 tesla (T) MRI to provide higher resolution and quality brain images.
45350072|NCT01047787|Other|Polysomnography|examination for sleep disorders
45350073|NCT00871299|Behavioral|Mindfulness Based Cognitive Therapy|"Mindfulness-Based Cognitive Therapy (MBCT) is a group treatment that integrates mindfulness meditation training with some CBT concepts and was specifically developed as a relapse prevention intervention for MDD. The program teaches skills that allow patients to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns, as a way to reduce future risk of relapse and recurrence of depression."
45476376|NCT03964246|Other|Heathy Aging Psychoeducation|The investigators will develop and test a 10-week psychoeducational group focused on topics in healthy aging to examine its feasibility as a control condition for a subsequent VA Merit-supported randomized controlled trial. This will include multiple resources for community education regarding healthy aging, including a library of videotaped community-focused talks, such as increasing happiness, mental resilience and health, nutrition, and physical activity. These resources will be incorporated into 90-minute sessions wherein the key information from talks is shown to participants, with a follow-up discussion and review period led by the group facilitator. In the context of the present feasibility study, the investigators anticipate modifying and refining the content and format of the group in response to participant feedback.
45350074|NCT00871299|Behavioral|Health Enhancement Program and medication management|The Health Enhancement Program (HEP)was developed at the University of Wisconsin, Madison and is modeled after traditional activity and nutrition programs used in weight management- cardiac rehab and diabetes prevention programs. The program is designed to increase overall health and well-being by focusing on four health domains that impact health and are interventions regularly practiced at integrative medicine. These include: (I) Music Therapy (2) Nutrition (3) physical activity including, walking and stretching and (4) Functional movement.
45476377|NCT05282771|Drug|Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
45476378|NCT05282771|Drug|Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
45841734|NCT04966351|Behavioral|Time-restricted feeding|Each subject will participate in both conditions (CM and CM+TRF)--one in which food is allowed during the nighttime period and one in which food will be restricted to the daytime only. Food intake will be matched across conditions and designed to keep participants weight stable.
45476379|NCT05282771|Drug|Placebo|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
45476380|NCT03954652|Genetic|WGS-Diagnostic|Blood sampling, shot clinical characterization, WGS-based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA-seq.
45476381|NCT03848117|Other|Cyriax approach i.e. DTF massage and Mill's manipulation|Each patient in group I i.e. Cyriax group was given 20-minute session. Each session started in sitting position and initially deep transverse friction massage was done at lateral compartment of the elbow joint and immediately after that mill's manipulation at elbow joint with flexion at wrist joint in pronated arm position. This session was repeated three times a week for one month (Total 12 sessions/ one month).
45685725|NCT01860898|Other|Skin Biopsy|Biopsy samples will be taken as a 2mm x 2cm excision of a wedge of skin at the edge of the incision during your surgery at the Mayo Clinic Rochester. Such excisions are frequently done as part of routine skin closure for optimal skin cosmesis following the surgical procedure.
45841735|NCT04966351|Behavioral|Circadian Misalignment|Healthy lean subjects will undergo circadian misalignment induced using a simulated night shift-work protocol in both conditions of the study. Each condition will last approximately 6 days.
45841736|NCT04955678|Drug|Calcium, hydrolysed divinylbenzene-Me 2-fluoro-2-propenoate-1, 7-octadiene polymer sorbitol complexes|ZG-801 is powder for suspension. In Run-in period, ZG-801 is taken once a day for 4 or 5 weeks. In Double-blind period, ZG-801 is taken once a day for 4 weeks.
45841737|NCT04955678|Drug|Placebo|Placebo is powder for suspension. In Double-blind period, Placebo is taken once a day for 4 weeks.
45841738|NCT05175547|Drug|Clevidipine|Blood pressure management with Clevidipine
45841739|NCT04948866|Behavioral|ADRD-PC Program|Included in arm/group descriptions
45841740|NCT04924166|Drug|Placebo|Inactive dose of capsules that appear identical to active dose
45841741|NCT04924166|Drug|Hydrocortisone|Hydrocortisone 180 mg in capsule form
45841742|NCT04921787|Other|Low Intensity|Training and education only, a low-intensity strategy inclusive of an HBOT manual, one-time live training on how to use the HBOT manual, and 7 video conference presentations.
45350075|NCT02534545|Device|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
45476382|NCT03848117|Other|Mulligan approach i.e. Taping and MWM|Each patient in group II i.e. Mulligan group was given 30 to 45-minute session. Each session started in sitting position and it included mobilization with movement which was given in such a way that initially lateral glide at elbow joint was performed and after holding it, I asked the patient to make a fist and open the fist. In this way, I repeated this procedure 36 times and after 12 repetitions, a short rest period was given. Taping was applied after mobilization around the elbow joint over extensor carpi radialis muscles. This session was repeated three times a week for one month (Total 12 sessions/ one month).
45476383|NCT02512978|Drug|Levothyroxine|Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
45350076|NCT02534545|Device|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
45350077|NCT00962026|Drug|Rilonacept|Rilonacept given subcutaneously, dose per package labeling, once weekly.
45350078|NCT03753789|Device|Microwave Ablation|NEUWAVE microwave ablation of soft tissue liver lesions will be performed percutaneously by an interventional radiologist while the patient is under general anesthesia or deep conscious sedation.
45476384|NCT05487833|Biological|insulin|5% glucose in 0.9% NaCl with 4 IU of short acting insulin per 500 ml added, infused at a rate determined by the treating physician, treatment duration: 18 hours
45476385|NCT05487833|Other|standard treatment|infusion of a balanced solution, infused at a rate determined by the treating physician, treatment duration: 18 hours
45476386|NCT03197376|Biological|Pneumosil|10-Valent Pneumococcal Conjugate Vaccine
45476387|NCT03197376|Biological|Synflorix|Pneumococcal conjugate vaccine (Non-Typeable Haemophilus influenzae (NTHi) protein D, diphtheria or tetanus toxoid conjugates) adsorbed
46045045|NCT05757661|Other|Sham Group|The same procedure of the intervention group will be performed but without the focal vibration head contacting the skin (sham). A sufficient space will be left between the head and the headgear so that the vibration does not touch the skin.
45476388|NCT01295957|Behavioral|reminiscence therapy|24 bi-weekly sessions of reminiscence therapy, lasting one hour each one, over a period of 12 weeks. The latter refers to the use of images, sentences or memorabilia which help to focus on specific segments of the life history of an individual, and stimulates the emergence of affect-laden personal recalls, which are later verbalized in the context of guided conversations12. The term story life is intended to highlight samples of meaningful events of the subject's life rather than a historically structured biography13. Three main variables contributed to reminiscing: individuality, evaluation and structure.
45685726|NCT01458730|Drug|Immunochemotherapy|Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Iphosphamide, Vincristin, Vindesin, Temozolomide, Depocyte
45841743|NCT04921787|Other|High Intensity|Practice facilitation, a high-intensity strategy inclusive of low-intensity training, plus practice facilitation that is based in part on a program planning model. This study is a hybrid implementation effectiveness design, testing an implementation strategy while observing and gathering information on the clinical intervention's impact on relevant outcomes.
46045046|NCT02865330|Other|Registry|National Registry of patients with prostate cancer as monitored through active surveillance, with the intention of testing the hypothesis that cancer-specific mortality in very low-risk and low-risk patients is less than 5% at 15 years.
46045047|NCT02611219|Other|General Health Module-Baseline Adolescent-Self Report (13-18 years)|"38 question questionnaire~Answers range from 1=all of the time to 5=none of the time"
45350079|NCT00876681|Procedure|Popliteal catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: Popliteal-sciatic catheter placed via ultrasound-guidance or placed via electrical stimulation. All patients will be given 40ml of 1.5% mepivicaine prior to surgery and then given a pain pump after surgery containing 0.2% ropivacaine. The patients pain scores will be assessed just prior to surgery and the day following surgery. The time of catheter placement and numbness the patient is experiencing in their foot and toes is also assessed and recorded by research staff.
45350080|NCT05299840|Diagnostic Test|Oncogramme results available|in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
45350081|NCT05299840|Diagnostic Test|Oncogramme results unavailable|in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
45350082|NCT03991897|Dietary Supplement|Ketogenic diet|Ketocal, a nutritionally complete ready-to-drink liquid, is foreseen to ensure adequate amounts of vitamins and minerals will be used. After 24 weeks a Modified Atkins diet will be started.
45350083|NCT03991897|Dietary Supplement|Isocaloric diet|Patients will follow an isocaloric diet
45350084|NCT00616239|Drug|20-30% Salicylic Acid peels to the right side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the right side of the face.
45350085|NCT00616239|Drug|20-30% Salicylic Acid peels to the left side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the left side of the face
45350086|NCT03234166|Other|Non interventional study|Only data will be taken of patient's file.
45350087|NCT01045213|Other|Integrated Care|Study looking at the efficacy of a combination of Guideline-based COPD education, self-management training, remote telemonitoring and enhanced communication with a coordinator.
45350088|NCT00876759|Radiation|whole brain radiotherapy|WBRT in 10 fractions to a total dose of 30Gy
45350089|NCT00876759|Radiation|whole brain radiotherapy with simultaneous boost|Total dose: 10 fractions: whole brain total dose: 30Gy, metastases: total dose 50Gy
45350090|NCT01045291|Device|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Market approved InSync Sentry™ model 7298, dual chamber Implantable Cardioverter Defibrillator (ICD) with Cardiac Resynchronization Therapy (CRT) including sequential biventricular pacing and OptiVol® fluid monitoring or market approved InSync Maximo™ model 7304 dual chamber ICD with CRT including sequential biventricular pacing.
45476389|NCT01295957|Behavioral|comparison group|The control group was administered counseling and informal social contacts in bi-weekly sessions of one hour, common subjects addressed by comparison group were social security incomes, diets, family visits.
45685727|NCT01535235|Drug|Lisinopril|Lisinopril 20mg QD x 24 weeks
45841744|NCT04919681|Other|Stretch exercises|The intervention comprises of six weeks daily bi-lateral static stretching of the knee flexors. Stretches are performed seated on the ground. The participant sits upright on the floor with one leg straight. The sole of the other foot should be placed on the inside of the outstretched leg. The participant leans slightly forward, trying to touch their toes while maintaining full knee extension. Stretching is performed to the point of discomfort, and each stretch is held for 30-seconds for three repetitions.
45841745|NCT04908371|Procedure|Selective Trunk Block|"It is one type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 20ml) injected at the trunks of the brachial plexus in order to produce the anesthesia of the whole upper extremity of the patients scheduled for upper limb surgery. SeTB will be performed as a two-injection technique. One at the side of the neck (interscalene groove) of the affected upper limb, injections will be made near the superior trunk (5mL) and follow by redirection of the needle under ultrasound guidance to inject the LA to middle trunk (5mL). Then the second skin puncture will be made near the upper part mid-collar bone (supraclavicular fossa) to inject the LA to the inferior trunk (10mL)."
46045048|NCT02611219|Other|General Health Module-Follow Up Adolescent-Self Report (13-18 years)|"38 question questionnaire about child~Answers range from 1=all of the time to 5=none of the time"
46045049|NCT02611219|Other|General Health Module-Baseline Parent Report-Adolescent (13-18 years)|"38 question questionnaire about child~49 question questionnaire about parent~Answers range from 1-all of the time to 5=none of the time"
46045050|NCT02611219|Other|General Health Module-Follow Up Parent Report-Adolescent (13-18 years)|"38 question questionnaire about child~49 question questionnaire about parent~Answers range from 1-all of the time to 5=none of the time"
45350091|NCT05167539|Procedure|Aortic valve surgery|mechanical aortic valve replacement versus ross procedure and stentless bioprothesis
45350092|NCT01047943|Drug|Topical application of STA-21 ointment for treatment of psoriasis|
45350093|NCT00547534|Drug|bortezomib|1.3 mg/m^2 on days 1, 4, 8, 11
45350094|NCT00547534|Drug|bendamustine|90 mg/m^2 days 1 and 4
45476390|NCT01295957|Other|control|advise and informal counseling
45476391|NCT01196585|Procedure|CT-Guided pleural needle biopsy with Abrams' needle|Patients will be randomized into two groups: Group A: CT-guided Abrams' needle biopsy.
45350095|NCT00547534|Drug|rituximab|375 mg/m^2 day 1
45350096|NCT00871455|Drug|Baclofen|Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
45350097|NCT00962182|Drug|STAN1|3-4 capsules/day at meals
45350098|NCT00962182|Drug|Placebo enzyme|3-4 capsules/day at meals
45350099|NCT00962182|Drug|STAN1+gluten|3-4 capsules/day at meals plus 500 mg gluten b.i.d
45350100|NCT00871533|Drug|IFNα2b|IV injection at 20 million IU/m2. IFNα2b IV injection will be performed every day between day -14 and day -9 (5 infusions) and also every day between day -7 and day -2 (5 infusions) for a total of 10 infusions.
45350101|NCT00871533|Drug|IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary, at 10 million IU/m2. IFNα2b Injection will be performed every other day between day -14 and day -9 (3 injections) and also every other day between day -7 and day -2 (3 injections) for a total of 6 injections.
45350102|NCT00871533|Drug|PEG- IFNα2b|SC injection at 6mcg/kg will be performed systemically (at site that is not regional): first injection at day -14, second injection at day -7, for a total of 2 injections.
45476392|NCT01196585|Procedure|Ultrasonography guided cutting pleural needle biopsy|Patients will be randomized into two groups: Group B: Ultrasonography guided cutting-needle biopsy.
45476393|NCT01193699|Drug|PEG-P-INF alpha-2b (P1101)|µg (starting with 50 µg), subcutaneously, 2-weekly administration
45685728|NCT01535235|Drug|Placebo|Placebo QD x24wks
45685729|NCT02985723|Device|AT LISA tri toric 939MP|
45685730|NCT04748211|Procedure|Infraclavicular Block|USI and neurostimulator guided infraclavicular block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
45685731|NCT04748211|Procedure|Interscalen Block|USI and neurostimulator guided interscalen block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
45350103|NCT00871533|Drug|PEG- IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary at 3ug/kg: first injection at day -14, second injection at day -7, for a total of 2 injections.
45476394|NCT03600805|Drug|Sarilumab SAR153191|Pharmaceutical form: solution for injection Route of administration: subcutaneous
45350104|NCT05157022|Device|ESWT|Extracorporeal Shock-wave Therapy
45350105|NCT00962260|Drug|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks at the dose level equal to each patient's previous imiglucerase dose before reduction or discontinuation due to shortage
45350106|NCT00877149|Drug|telbivudine/LDT600|
45841746|NCT04908371|Procedure|Interscalene-Supraclavicular Brachial Plexus Block (IS-SC BPB)|"It is another type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 30ml) injected at the interscalene groove and supraclavicular fossa, so two-injection technique will be adopted. The first skin puncture will be near the side of the neck (interscalene groove) of the affected upper limb (15mL) and then the second skin puncture will also be made near the upper mid-collar bone (supraclavicular fossa) to inject 15mL of LA."
45350107|NCT00877227|Drug|5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv)|Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns.
45476395|NCT03600805|Drug|Sarilumab matching placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
45476396|NCT03600805|Drug|Prednisone|Pharmaceutical form: tablets or capsules Route of administration: oral administration
45476397|NCT03600805|Drug|Prednisone matching placebo|Pharmaceutical form: capsules Route of administration: oral administration
45476398|NCT01196663|Device|Intraoperative temperature measurement by TMS thermometer|Measurements will be taken from the patient's body using a biocompatible patch that will transfer data to the receiving unit. The patch will be sterilized before each surgery.
45476399|NCT01196663|Device|Esophageal or urinary bladder temperature measurement|Standard temperature measurement as is being measured from patients during surgery today
45476400|NCT05473247|Behavioral|Ring-Fit Adventure Group|Participants will be asked to play the exergame software, Ring-Fit Adventure, and attend weekly virtual health coaching sessions.
45841747|NCT04893551|Biological|Tilvestamab|Tilvestamab will be administered as IV infusion.
45350108|NCT05149846|Procedure|Pre-conditioning|Pre-conditioning by three consecutive 60 seconds balloon inflations, spaced 120 seconds apart followed by 10 minutes rest prior to PCI
45350109|NCT00871767|Drug|AZD5672|40 mg tablet (Test formulation)
45350110|NCT00871767|Drug|AZD5672|40 mg tablet (Reference formulation)
45350111|NCT00871767|Drug|AZD5672|100 mg tablet (Test formulation)
45350112|NCT00871767|Drug|AZD5672|100 mg (2 x 50 mg tablet (Reference Formulation)
45350113|NCT05279248|Biological|HPV+MMR（0d），HPV（6m）|Simultaneously administrated with MMR vaccine and HPV 16/18 bivalent vaccine at first. And six months later, administrated with the second dose of HPV 16/18 bivalent vaccine.
45350114|NCT05279248|Biological|HPV（0d），HPV（6m），MMR（7m）|Administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (0,6 months).And at the 7th month , administrated with MMR vaccine.
45350115|NCT05279248|Biological|MMR（0d），HPV（1m），HPV（7m）|Administrated with MMR vaccine at first day. And administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (1,7 months).
45350116|NCT00384397|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
45350117|NCT00384397|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
45476401|NCT01198379|Drug|aspirin|aspirin 100 mg qd for 3 years
45476402|NCT01198379|Drug|Placebo|
45476403|NCT02729740|Device|Penumbra Smart Coil|
45476404|NCT02729740|Device|Penumbra Coil 400TM (PC400), Penumbra Occlusion DeviceTM(POD)|Other Penumbra Coils available as standard of care
45476405|NCT05283005|Procedure|Grafting of the alveolar cleft|alveolar cleft grafting using either the conventional technique or the double cortex technique
45476406|NCT05433857|Drug|Lacteol forte capsules|probiotic Lacteol Forte® capsules (5 billion heat-killed Lactobacillus LB, corresponding to lactobacillus delbruekii and lactobacillus fermentum) Two capsules are To be taken once daily
45476407|NCT03848039|Biological|Gardasil-9|administration by intramuscular injection of the 9-valent HPV vaccine according to a 3-dose vaccination schedule (0, 2, 6 months).
45841748|NCT04893512|Drug|Orally Suspension of CoV2-OGEN1|CoV2-OGEN1 will be supplied as a 10mL oral suspension in a plastic bottle containing 50-200 mcg of formulated drug
45841749|NCT04870645|Procedure|Advanced Magnetic Resonance Imaging|Undergo advanced MRI
45350118|NCT00384397|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
45841750|NCT04870645|Procedure|Conventional Magnetic Resonance Imaging|Undergo conventional MRI
45841751|NCT04870645|Drug|Gadolinium-Chelate|Contrast agent
45841752|NCT04870645|Drug|Iopamidol|Contrast agent
45841753|NCT04863313|Dietary Supplement|Probiotic|Experimental group will consume one probiotic capsule every day during 12 weeks at breakfast.
45350119|NCT00877305|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to 200 mmHg (at least a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line).
45350120|NCT00877305|Other|Control|Sham intervention with four 5-min cycles of inflation of the blood pressure cuff at 20 mmHg and 5 min deflation without any upper leg ischaemia.
45350121|NCT04039659|Device|Negative-pressure wound therapy (PICO)|After the selection of patients and the signing of the consent, patients will be randomized and the device will be placed to those who belong to the PICO group in the operating room.
45685732|NCT04095429|Behavioral|Expect Respect|Expect Respect is a 24 session curriculum designed to support middle school students to increase skills in emotion regulation, relationship skills, communication, and positive bystander intervention behaviors.
45841754|NCT04863313|Dietary Supplement|Placebo|Placebo group will consume one placebo capsule every day during 12 weeks at breakfast.
45841755|NCT04838379|Drug|Dexmedetomidine|Ninety patients were randomized to receive ultrasound-guided RSB&tap block After the induction of anesthesia and patient stabilization, the abdomen was sterilized and draped. Then, under complete aseptic conditions, ultrasound-guided Bilateral Rectus Sheath Block & tap block was performed
45841756|NCT04830878|Drug|Methotrexate|Systemic and intraoperative intravitreal injection of methotrexate
45841757|NCT04815889|Behavioral|PRIMUS parent training Group|"The parents offered a PRIMUS Group-based parent support program for 5 half days. This parenting education for preschool children with developmental problems but without the requirement of diagnosis Hellström (2019) has been designed and tested in other parts of the country but not scientifically validated, which can be done in this study. The teachers will be offered a teacher group for half a day together with the parents.~For those families who need more intervention the PLUSS toddler team (from the specialist Healthcare) is established.~The PLUSS toddler team makes a management plan as referral to Habilitation Center, Child and Adolescent Psychiatry, Speech Therapist, or interventions eg:~Support in the child's everyday environment home / preschool~Targeted Parent Groups: toilet, sleep, food, everyday structure, handle behavioural problems~Web courses"
45841758|NCT04812366|Drug|Apalutamide 60mg Tab|4 tablets by mouth once a day for 24 weeks
45841759|NCT04812366|Drug|Abiraterone Acetate 250mg|4 tablets by mouth on an empty stomach once a day for 16 weeks
45841760|NCT04812366|Drug|Prednisone 5mg Tab|1 tablet by mouth once daily while taking abiraterone acetate
45841761|NCT04812366|Drug|Docetaxel|Infusion every 3 weeks for 6 cycles (each cycle has 3 weeks)
45841762|NCT04812366|Drug|Niraparib 100mg Oral Capsule|3 capsules by mouth once daily for 16 weeks
45841763|NCT04812366|Drug|Atezolizumab|1200mg infusion every 3 weeks for 6 cycles
45841764|NCT04811716|Drug|Pozelimab|Administered Sub-cutaneous (SC) per protocol
45841765|NCT04811716|Drug|Cemdisiran|Administered SC per protocol
45841766|NCT04800107|Biological|Curcumin-phosphatidylcholine|500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl
46045051|NCT02611219|Other|General Health Module-Baseline Parent Report-School Age (5-12 years)|"34 question questionnaire about child~49 question questionnaire about parent~Answers range from 1-all of the time to 5=none of the time"
46045052|NCT02611219|Other|General Health Module-Follow Up Parent Report-School Age (5-12 years)|"34 question questionnaire about child~49 question questionnaire about parent~Answers range from 1-all of the time to 5=none of the time"
45350122|NCT03796767|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
45350123|NCT03796767|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45350124|NCT03796767|Procedure|Metastasectomy|Undergo salvage oligometastasectomy
45350125|NCT03796767|Other|Quality-of-Life Assessment|Ancillary studies
45350126|NCT03796767|Other|Questionnaire Administration|Ancillary studies
45350127|NCT03796767|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45350128|NCT02715388|Device|GlasScope Surgical Microscope|3D visualization of the poterior chamber for silicon oil removal
45350129|NCT05119894|Drug|Brexpiprazole LAI: Dose 1|Cohort 1: Single Dose Intramuscular Injection: Brexpiprazole LAI Dose 1
45685733|NCT04095429|Behavioral|Enhanced Usual Care|Participants will be connected via a warm referral to available individual behavioral health supports and resources in their community that can support them.
45685734|NCT02168686|Genetic|ADVM-043|Gene transfer vector administration
45685735|NCT04756336|Drug|LTX-109 gel, 3% w/w|The drug is applied to affected lesions according to treatment regimen
45685736|NCT01456390|Device|iStent and iStent supra|Implantation of two iStent devices and one iStent supra device
45841767|NCT04800107|Biological|Placebo capsule|Placebo capsule
45841768|NCT04796051|Device|Neck orthosis - with posterior cervical weight|The posterior cervical weight orthosis is made of a well-padded adjustable Velcro attached to the end with a two-kilogram weight attached with two durable straps. The device is firmly anchored around the curvature of the jaw and attached with Velcro to the apex of the skull.
45841769|NCT04796051|Other|Deep cervical flexors exercise|The participant will lay down in crook lying position, participant's head relaxed on the flat surface. Each participant will passively tuck in his/her chin without activation of superficial cervical muscles. Participants of this group will do 15 repetitions x 3 sets of deep neck flexor exercises every day of the week.
45841770|NCT04786782|Diagnostic Test|PPG-detecting software|Virtual PPG (vPPG) of patients in experimental group is calculated based on anatomical and hemodynamic information of portal system collected by ultrasound and CT tests.
45841771|NCT04786782|Diagnostic Test|LSM and PLT count|Patients whose LSM >15kPa, or PLT count < 150*10^9 should be screened with upper GI endoscopy
45841772|NCT04786574|Drug|Tolvaptan (OPC-41061)|Tolvaptan suspension will be administered orally or via nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. Treatment duration is 2 years.
46045053|NCT02611219|Other|Demographic Data Form|-16 questions about demographics such as household income, race, and gender
46045054|NCT02611219|Other|SCT Daily Activity Log|"Uses Fitbit Flex~Log that lists time in 15 minute increments and allows for checking when out of bed and describing the activity that occurred while out of bed"
45841773|NCT04783857|Drug|Progesterone 200 MG Oral Capsule|Progesterone, 200mg, once daily, oral tablet/capsule
45841774|NCT04783857|Other|Placebo Oral Tablet|Placebo oral tablet, once per day
45841775|NCT04783168|Other|Best Practice|Receive usual care
45841776|NCT04783168|Other|Health Promotion and Education|Install and use Fitbit app
45841777|NCT04783168|Other|Medical Device Usage and Evaluation|Use Fitbit to monitor step count
45350130|NCT05119894|Drug|Brexpiprazole LAI: Dose 2|Cohort 2: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 2
45350131|NCT05119894|Drug|Brexpiprazole LAI: Dose 3|Cohort 3: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 3
45350132|NCT05119894|Drug|Brexpiprazole LAI: Dose 4|Cohort 4: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 4
45350133|NCT00877539|Drug|PF-03526299|Inhaled, two doses 4 hours apart
45685737|NCT02157532|Procedure|mechanical thrombectomy|Mechanical thrombectomy using any already approved stent-retriever device
45841778|NCT04783168|Other|Quality-of-Life Assessment|Ancillary studies
45841779|NCT04783168|Other|Questionnaire Administration|Ancillary studies
45841780|NCT04769986|Behavioral|Mobile Mindfulness-Relapse Prevention (mMBRP)|Mindfulness Coach 2.0 is a mobile application designed by the VA's National Center for PTSD. The app provides: (a) psychoeducational topics related to mindfulness; (b) audio-guided mindfulness exercises; (c) self-assessment using the Five Facet Mindfulness Questionnaire (d) a journal to track mindfulness practice sessions; (e) goal setting and tracking; (f) personal, customizable reminders; and (g) immediate access to support and crisis resources. We will enhance Mindfulness Coach with MBRP content by adding information about the triangle of awareness to understand connections among thoughts, sensations, and emotions, and specific meditations of sober breathing space and urge surfing to deal with cravings. We will add additional MBRP-specific modules. Participants will be asked to complete the intervention during 8 weeks, with two to three modules per week. After a beta test with 20 veterans, feedback will be used to refine the app for the national randomized clinical trial (RCT).
46045055|NCT02611219|Other|The Functional Independence Measure for Children|"18-item, 7-level ordinal scale instrument that measures a child's consistent performance in essential daily functional skills. Three main domains (selfcare, mobility, and cognition) are assessed by interviewing or by observing a child's performance of a task to criterion standards~Categorized into 2 main functional streams: Dependent (ie, requires helper: scores 1-5) and Independent (ie, requires no helper: scores 6-7). Scores 1 (total assistance) and 2 (maximal assistance) belongs to the Complete Dependence category. Scores 3 (moderate assistance), 4 (minimal contact assistance), and 5 (supervision or set-up) belongs to the Modified Dependence category. Scores 6 (modified independence) and 7 (complete independence) belongs to the Independent category."
45350134|NCT00877539|Drug|Placebo|Inhaled, two doses 4 hours apart
45350135|NCT00877539|Drug|Fluticasone propionate|Inhaled
45350136|NCT04039737|Drug|Qingpeng Ointment|Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
45476408|NCT03848039|Drug|Placebo|administration by intramuscular injection of the placebo according to vaccination schedule of the 9-valent HPV vaccine (0, 2, 6 months)
45476409|NCT01296269|Drug|Oxytocin|one-time intranasal administration, 24 International Units, 5 puffs for each nostril
45476410|NCT01296269|Drug|Arginine Vasopressin|one-time intranasal administration, 20 International Units, 5 puffs in each nostril
45685738|NCT02157532|Drug|Best standard treatment|Intravenous r-tPA infusion or any other medical management option
45685739|NCT02317744|Drug|Naltrexone and bupropion combination|
45685740|NCT02317744|Other|Pill Placebo|
45841781|NCT04769986|Behavioral|Exercise/healthy eating mobile app|Participants in the control condition will be asked to download an exercise/healthy eating mobile app and use it for 8 weeks. Similar to Mindfulness Coach, the app will have specialized self-management guides that follow a guide-per-week format, educational videos that teach diet and exercise strategies, and a diary to track diet and exercise progress.
45841782|NCT04761159|Drug|Ketamine|Different mixture of ketamin-propofol will apply for anesthesia induction.
45350137|NCT00872157|Drug|BMTP-11|Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
45350138|NCT00872235|Drug|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets|
45350139|NCT00877617|Behavioral|QOL Questionnaire|Mailed survey.
45476411|NCT01296269|Drug|placebo|contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient, one time intranasal administration, 5 puffs in each nostril
45476412|NCT05595772|Drug|Drug: Growth Factors (CGF)|Application of biological membrane of Concentrated growth factor (CGF) over bone grafting and implant
45841783|NCT04747626|Device|B-SAFER|Simplified hybrid frozen elephant trunk repair will be performed by utilizing B-SAFER technique which involves a physician modified endovascular stentgraft to treat the proximal aorta in subjects with aortic disease involving multiple segments.
45841784|NCT04723641|Other|functional training exercises|progressive resistive functional strength training from plantigrade foot position conducted for one hour, 3 days/week. The therapist will replace the conventional physical therapy with the progressive resistive functional strength training, when this is consistent with the objectives of the strength training.
45841785|NCT04716296|Drug|Ketamine|Ketamine will be given for the second stage of the DBS surgery.
45841786|NCT04716296|Drug|Saline|Saline will be given for the second stage of the DBS surgery.
45841787|NCT04704141|Drug|Hormone replacement therapy|A hormone replacement regimen using any medication of a number of standard treatment options
45841788|NCT04682041|Dietary Supplement|Bovine Plasma-Derived Immunoglobulin Concentrate|EnteraGam® 10.0 g, containing 5.0 g of serum-derived bovine immunoglobulin/protein isolate (SBI) BID (every 12 hours) for 2 weeks.
45841789|NCT04682041|Other|Standard of care|Standard of care PSMAR protocol for COVID-19 patients.
45841790|NCT04675931|Drug|KAE609|"Two doses of Intravenous Cipargamin will be evaluated in the initial phase of the study (Cohorts 1-2).~These doses will cover a wider exposure range and facilitate the selection of an appropriate dose for later Cohorts 3-5."
45841791|NCT04675931|Drug|IV Artesunate|Parenteral artesunate is the WHO recommended first line treatment for severe malaria. Hence IV artesunate is used as comparator. Also, this will be used as rescue medication for participants where IV KAE609 is not working.
45350140|NCT00877695|Behavioral|Entre Culturas: Navigating Culture, Identity, and HIV Risk|A pilot test of a culturally and developmentally tailored MEI to reduce risky sex (unprotected anal sex and multiple partners) among young Hispanic men who have sex with men (YHMSM) to be delivered face-to-face (FtF) and through the Internet using a real-time implementation approach. A tailored MEI for two delivery modalities, and a health education control (HEALTH) comparable in time and number of sessions. We will test the MEI's acceptability and feasibility, obtain effect size estimates of the intervention's strength to reduce risky sex, and determine if it is ready for efficacy testing.
45350141|NCT00872391|Radiation|Hypofractionated linear accelerator radiotherapy|10 fractions of stereotactic linear accelerator radiotherapy with 6 Gy per fraction at the 80% isodose for the planning target volume.
45685741|NCT02150902|Procedure|Wide area circumferential catheter ablation|All subjects in the control arm of the trial will undergo wide area circumferential catheter ablation (WACA; lesions delivered 1-2 cm away from the pulmonary vein ostium) around all four pulmonary veins to the endpoint of electrical isolation (demonstrated by entry and exit block using differential pacing). Catheter ablation will be performed using contact force (CF) and electroanatomical mapping system guidance (average CF >10g, FTI > 500 g-sec and minimum ablation duration >10 sec). Dormant pulmonary vein conduction will be tested using adenosine, after completion of the lesion set, and additional lesions will be delivered to eliminate dormant PV conduction.
45350142|NCT00872469|Drug|Tranexamic acid|1-2 grams by intravenous injection
45350143|NCT00872469|Drug|Placebo [Saline]|Matched to active comparator
45350144|NCT00872547|Device|DePuy ASR™ Hip System|Resurfacing system
45841792|NCT04675931|Drug|Coartem|Oral Standard of Care
45841793|NCT04669678|Drug|Etonogestrel (ETG) implant|Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm. The most widely available implant in South Africa is currently Implanon®/Nexplanon®/Implanon NXT®, containing etonogestrel (ETG, 3-keto desogestrel). Implanon® consists of a single rod of ethylene vinyl acetate and contains 68 mg of ETG; it is manufactured by Merck and is approved for 3 years.
45350145|NCT00872547|Device|DePuy ASR™ XL Head / ASR™ Acetabular Cup System|Large Metal-on-Metal Total Hip Replacement
45841794|NCT04669678|Drug|Intramuscular depo-medroxyprogesterone acetate (IM DMPA)|DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide, and the most commonly used method of reversible injectable contraception in sub-Saharan Africa.
45841795|NCT04669678|Drug|Sub-cutaneous medroxyprogesterone acetate (SC MPA)|SC MPA or Sayana® Press is a single-dose container with 104 mg medroxyprogesterone acetate (MPA) in 0.65 mL suspension for injection. Sayana® Press is indicated for medium-long term female contraception.
45841796|NCT04669678|Device|Non-hormonal intrauterine device (IUD)|The NOVA T-380 non-hormonal IUD consists of a T-shaped polyethylene frame wound with copper wire, along with two monofilament threads to aid in removal of the IUD. IUDs may be left in place for up to 5 years.
45841797|NCT04652661|Drug|Dexmedetomidine|30 children will be sedated with 2 μg/kg intranasal DEX.
45841798|NCT04652661|Drug|Midazolam|30 children will be sedated with 0.3 mg/kg intranasal midazolam.
45841799|NCT04650451|Biological|chimeric antigen receptor (CAR) T cell therapy|HER2-targeted dual-switch CAR-T cells
45841800|NCT04640480|Drug|SNB-101|SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting
45841801|NCT04637165|Other|This is a non-interventional study|This is a non-interventional study
45841802|NCT04625465|Behavioral|CBT Text Messaging|Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order, with content equally distributed across the four content areas (i.e., psychoeducation regarding effects of stress, distress tolerance, emotion regulation, alcohol reduction).
45841803|NCT04625465|Behavioral|Attention Control Text Messaging|Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order. All texts will be supportive messages which express empathy and unconditional positive regard and provide support for dealing with stressors. These messages will be nondirective and will not include any CBT skill suggestions.
45841804|NCT04623931|Other|Quality-of-Life Assessment|Ancillary studies
45841805|NCT04623931|Other|Questionnaire Administration|Ancillary studies
45841806|NCT04623931|Radiation|Radiation Therapy|Undergo radiation therapy
45841807|NCT04623931|Drug|Temozolomide|Given PO
45350146|NCT05225883|Genetic|GWAS|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
45350147|NCT00878007|Drug|Intermittent screening and treatment for malaria|All children will be screened for malaria using rapid diagnostic tests (RDTs) once a term (thrice yearly). Children (with or without clinical malaria symptoms) found to be RDT-positive will be treated with artemether-lumefantrine according to national guidelines. Screening and treatment will be administered by district public health staff once a school term, observed by the evaluation research team.
45350148|NCT00878007|Behavioral|Teacher training on literacy instruction|Education intervention designed to improved early grade literacy instruction, focusing on phonological awareness & vocabulary and relationship between letters and sounds in a systematic and explicit fashion. Specific interventions will include training on (i) how to monitor students' progress in large classes (ii) developing and using instructional materials for reading (iii) lesson planning for explicit teaching of letter-sound relationships (iv) instructional techniques for large classes.
45350149|NCT00878007|Other|IST plus literacy instruction programme|Schools will receive both IST and the literacy instruction programme
45350150|NCT00872625|Drug|cyclophosphamide|
45350151|NCT00872625|Drug|docetaxel|
45350152|NCT00872625|Drug|epirubicin hydrochloride|
45350153|NCT00872625|Drug|fluorouracil|
45350154|NCT00872625|Procedure|neoadjuvant therapy|
45841808|NCT04611542|Behavioral|Fathering In Recovery|Fathering In Recovery (FIR) will be designed to address the unique needs of fathers in treatment for opioid misuse. FIR integrates evidence-based parenting interventions that have well-documented positive outcomes on children, parents, and families, with innovative web-based mobile technology to maximize accessibility, fidelity, and consistency of intervention and support.
45841809|NCT04609878|Drug|BGF MDI 320/28.8/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
45841810|NCT04609878|Drug|BGF MDI 320/14.4/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
45841811|NCT04609878|Drug|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler
45841812|NCT04609878|Drug|BFF pMDI 320/9 μg|Budesonide/formoterol fumarate pressurized metered dose inhaler
45841813|NCT04607330|Other|High protein liquid|After a 1-day baseline period to establish patients' acceptability, gastrointestinal tolerance, compliance, dietary intake while also capturing information related to user experience, risk of malnutrition, physical function, dietary intake, anthropometry and safety with their currently prescribed nutritional regimen, each patient will receive the high protein liquid daily for 28 days where the same measures will be replicated. The amount of the high protein liquid prescribed will always be completed by the patients' managing dietitian.
45841814|NCT04600323|Drug|Sodium Bicarbonate Tablets|Participants will be given sodium bicarbonate at 0.5 mEq/kg-LBW/day for 12 months
45841815|NCT04600323|Drug|Placebo|Participants will be given placebo at 0.5 mEq/kg-LBW/day for 12 months
45841816|NCT04590781|Biological|XmAb18087|Monoclonal bispecific antibody
45841817|NCT04590781|Drug|XmAb18087 ± Pembrolizumab|XmAb18087 ± Pembrolizumab
45841818|NCT04573751|Drug|Standard therapy|Standard therapy as follows: adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
45841819|NCT04573751|Drug|Epinephrine|Standard therapy plus epinephrine as follows: epinephrine, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
46045056|NCT02611219|Other|Manual Muscle Testing|"-Isometric muscle strength is tested in specific positions, usually with the muscle at an optimal working length. Using a break test, the test giver overpowers the muscle being tested to determine the muscle grade."
45350155|NCT00872625|Procedure|therapeutic conventional surgery|
45350156|NCT00872625|Radiation|hypofractionated radiation therapy|
45350157|NCT00872625|Radiation|image-guided radiation therapy|
45350158|NCT00872625|Radiation|radiation therapy|
45350159|NCT00872625|Radiation|stereotactic radiosurgery|
45350160|NCT00878085|Device|Robot Therapy Device|3x a week for 4 weeks
45350161|NCT00878085|Behavioral|Occupational Therapy|3x a week for 4 weeks
45350162|NCT00878241|Device|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
45350163|NCT00878319|Procedure|Open reduction and internal fixation (ORIF)|Antero-latero or posterior surgical approach using dynamic compression plate
45350164|NCT00878319|Other|Non-surgical|Sugartong splint followed by transition to functional co-aptation brace
45350165|NCT00872781|Drug|fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets|
45350166|NCT00384085|Drug|Insulin Glulisine|Subcutaneous injection up to 1 injection per day
45841820|NCT04573751|Drug|Verapamil|Standard therapy plus verapamil as follows: verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
45841821|NCT04573751|Drug|Epinephrine + verapamil|Standard therapy plus epinephrine + verapamil as follows: epinephrine, verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
45841822|NCT04545437|Other|Admission to ICU|Exposure is admission to an Intensive Care Unit
45841823|NCT04539704|Device|magnet and sham|In same subject some areas will have magnet and others will have sham
46045057|NCT02611219|Other|3-Minute Step Test|"Using an aerobic step, the participant walks up and down for a given amount of time with the heart rate being checked before and after~Using the difference in heart rate and a shortness of breath scale, this test is able to give an estimate of aerobic tolerance"
46045058|NCT02611219|Other|HSCT Module-Follow Up Adolescent-Self Report (13-18 years)|"7 question questionnaire about child~Answers range from 1=all of the time to 5=none of the time"
45350167|NCT00384085|Drug|Insulin Glargine|Subcutaneous injection once-a-day
45350168|NCT00384085|Drug|Premixed Insulin|Subcutaneous injection twice-a-day.
45350169|NCT00384085|Drug|Insulin Glulisine|Subcutaneous injection up to 3 injections per day.
46045059|NCT02611219|Other|HSCT Module-Follow Child-Self Report (5-12 years)|"10 question questionnaire about child~Answers range from 1=all of the time to 5=none of the time"
45350170|NCT00878397|Device|School-based delivery of long lasting insecticide nets|Free distribution of long lasting insecticide nets to school children and their younger siblings
45350171|NCT00872859|Procedure|Implantation of Dermal Matrix substitute|Dermal Matrix implanted in post mastectomy pts at time of mastectomy.
45350172|NCT04039581|Other|Kinesio Taping|Kinesio Taping
45350173|NCT04039581|Other|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS
45350174|NCT00361231|Drug|Bevacizumab|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
45350175|NCT00361231|Drug|Gemcitabine|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
45350176|NCT00361231|Drug|Oxaliplatin|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
45350177|NCT01050361|Procedure|Transthoracic Echocardiogram (TTE)/Transesophageal Echocardiogram (TEE)|Duration lasts the entire operation.
45350178|NCT01048021|Procedure|Supraclavicular Block|"Baseline values of forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and peak expiratory flow rates (PEFR) will be measured in both the sitting and supine position. Ultrasound-guided supraclavicular brachial plexus blocks will be performed in the supine position with a Pajunk 22g block needle and nerve stimulator. The patients will receive local anesthetic injection with 15 mL of 0.75% Bupivicaine. A maximum of 3 cc of 5% Dextrose will be utilized as contrast to confirm needle tip placement and fluid spread prior to injection of the local anesthetic.~At 60 minutes post-injection, FEV1, FVC, and PEFR measurements will be taken in the sitting and supine position."
45350179|NCT01050439|Procedure|UDAlloSCT|unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT)
45841824|NCT04536701|Behavioral|Mood Monitoring and Behavioral Recommendation System|The purpose of this project is to develop a monitoring, modeling, and interactive recommendation solution (for caregivers) for in-home dementia patient care that focuses on caregiver-patient relationships. This includes monitoring for mood and stress and analyzing the significance of monitoring those attributes to dementia patient care and subsequent behavior dynamics between the patient and caregiver. In addition, novel and adaptive behavioral suggestions will be provided to family caregivers via text messages on project Smart phones at the right moments aimed to help improve familial interactions related to caregiving, which over time should ameliorate the stressful effects of the patient's illness and reduce strain on caregivers.
45350180|NCT01050439|Other|Therapy|Full Intensity Therapy (myeloablative) (TBI + Thiotepa + Cyc) OR Reduced Intensity Therapy (Fludarabine, Busulfan, and Alemutuzumab (FBA))
45350181|NCT00676650|Drug|Prednisone|5 mg BID, oral
45350182|NCT00676650|Drug|sunitinib|37.5 mg/day, oral, administered on a continuous daily dosing regimen
45350183|NCT00676650|Drug|Placebo|37.5 mg/day, oral, administered on a continuous daily dosing regimen
45476413|NCT05595772|Drug|Drug: Growth Factors (PRGF)|Application of biological membrane of Plasma rich in growth factors combined with Xenogeneic bone grafting material around immediate implant
45476414|NCT05595772|Procedure|Surgery: Dental Implant surgery|Immediate implant following extraction
45476415|NCT05595772|Procedure|Tooth extraction|A Traumatic tooth extraction
45476416|NCT05595772|Procedure|Xenogenic bone grafting|Application of bovine bone grafting over area of dehiscence around immediate implant
45350184|NCT00676650|Drug|Prednisone|5 mg BID, oral
46045060|NCT02611219|Other|HSCT Module-Follow Up Parent Report-adolescent (13-18 years)|"7 question questionnaire about child~49 question questionnaire about parent~Answers range from 1=all of the time to 5=none of the time"
46045061|NCT02611219|Other|HSCT Module-Follow Up Parent Report-School Age (5-12 years)|"7 question questionnaire about child~49 question questionnaire about parent~Answers range from 1=all of the time to 5=none of the time"
45350185|NCT01045369|Drug|Kaletra and Intelence Tablets|Kaletra 400 mg twice a day and Intelence Tablets 200mg twice a day.
45350186|NCT00573183|Behavioral|STAGE-12|The STAGE-12 intervention will consist of a combination of five group and three individual sessions. The five group sessions will be taken from the Project MATCH Twelve Step Facilitation manual as modified for use with drug abusers and adapted for delivery in a group format. The group sessions will be augmented by three individual sessions derived from the introductory and termination sessions from the TSF manual and incorporating elements of the brief intensive 12-step referral procedure.
45350187|NCT00573183|Behavioral|Treatment as Usual|
45350188|NCT00615459|Drug|Indacaterol|Indacaterol 150 μg or 300 μg, delivered via SDDPI
45350189|NCT00615459|Drug|Tiotropium|Tiotropium 18 μg once daily delivered via inhalation device
45350190|NCT00615459|Drug|Placebo|Placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium manufacturer's proprietary inhalation device (HandiHaler®)
45350191|NCT03524430|Procedure|Core needle biopsy|"1st core needle biopsy for RDA (2 specimens): Time Point: 35 +/-4 days after initiation of chemotherapy.~If no change is made to the therapy, a second biopsy (2 specimens) will be performed at 55 +/- 5 days after therapy initiation.~If there is a change of drugs, the second biopsy (2 specimens) will be performed at ~2-3 weeks after initiation of new drugs; Timing by type of drug schedule 3-weekly: at 16 days +/- 2 days, Bi-weekly: at day of 2nd dose preferably before drug admin., Weekly: at day of 4th dose preferably before drug admin."
45350192|NCT04048902|Device|Pilates and Shortwave placebo|Pilates exercises and application of the device without produce thermal effects
45350193|NCT04048902|Device|Pilates and Shortwave active|Pilates exercises and application of the device producing thermal effects
45476417|NCT03844451|Drug|Liposomal Bupivacaine|At the conclusion of the procedure, liposomal bupivacaine will be administered as a V2 nerve block.
45476418|NCT03844451|Drug|Bupivacaine and Epinephrine|At the start of the procedure, 0.5% bupivacaine and 1:200,000 epinephrine as a surgical field block.
45476419|NCT03346096|Drug|Thiotepa|fixed dose 5mg/kg on days -7-6
45476420|NCT01198457|Drug|Clodronate (Bonefos, BAY94-8393)|Random group of patients in oncology clinic
45476421|NCT02516956|Other|Breakfast consumption|Participants will consume the assigned breakfast each morning for 7 days. Participants will express a hedonic rating of the breakfast through 7-point Likert Scales before (overview) and after breakfast consumption.
45476422|NCT02516956|Other|Blood tests|On the third day, participants will be involved in blood tests. Blood will be taken at baseline (fasting), and up to 4 hours after consuming the breakfast. Participants will complete serial visual analog rating scales of hunger and fullness before (fasting) and every 30 minutes up to 4 hours after breakfast consumption.
45476423|NCT02516956|Other|Food choices and energy intakes assessments|Following the last blood sample, participants will be given the opportunity to consume food ad libitum from a buffet lunch. Double weighing of food will be set up to evaluate food choices and energy intake of lunch. During the test week, participants will record all foods and beverage on a 7-day food dairy.
45841825|NCT04528836|Drug|BBP-398 (Formerly known as IACS-15509)|oral capsules
45350194|NCT03839511|Procedure|Hyperinsulinemic-hypoglycemic clamp|Subjects will arrive at the inpatient unit in the morning after at least a 10 hour overnight fast. Upon arrival to PBRC, participants will be admitted to the inpatient unit. Following measurement of weight, vitals, and pregnancy test (women only), the 4-hour hypoglycemic clamp procedure (30 minute baseline, 120 minute insulin infusion, and 90 minute recovery) will be performed. Upon completion of the clamp procedure, participants will be provided lunch (Standard American Diet). Following lunch, the CGM sensor will be removed and pending a stable blood glucose level in the normal range, the participant will be discharged from the inpatient unit. This completes the study.
45350195|NCT03876366|Other|online survey|Part 1: online survey (quantitative) with questions on basic socio-demographic data, medical data and family characteristics (e.g. age, ethnicity, education) and information about FP.
45350196|NCT03876366|Other|focus group meeting|Part 2: At the end of the online survey, participants are invited to attend one of the consecutively performed focus groups conducted according to standardized focus group methodology and moderated by a clinical psychologist and a specialist in reproductive medicine.
45350197|NCT00383149|Drug|Ixabepilone|Intravenous Infusion (IV), 32 mg/m^2 every 21 days.
45350198|NCT00383149|Drug|Cetuximab|Initial dose of 400 mg/m^2 intravenous (IV) over 2 hours) followed by a weekly lower dose of 250 mg/m^2 IV over 1 hour.
45350199|NCT03366012|Device|Cytosponge|The Cytosponge consists of a 3cm diameter, polyester, medical grade spherical sponge on a string, compressed within a gelatin capsule. The capsule is swallowed while the patient or the research specialist holds onto the string. After 3-5 minutes the gelatin capsule dissolves allowing the spherical sponge to expand. The sponge is then retrieved by gently pulling on the string, thus collecting cells along the passageway through the entire length of the esophagus. The sample is then put into a preservative to be processed for immunohistochemical testing for trefoil factor 3 (TFF3) to determine diagnosis of Barrett's esophagus.
45350200|NCT03364296|Other|Blood Samples|Blood sample retrieved for biological assessment and biobanking
45476424|NCT02516956|Other|Attention tests|On the fourth day, 4 hours after the breakfast consumption and avoid other foods, participants will be involved in attentional test (Mackworth Clock Test for sustained attention and Stroop Test for selective attention).
45476425|NCT02516956|Other|fRMI tests|On the fifth day, 4 hours after the breakfast consumption and avoid other foods, participants will focus on a set of photographs (stimuli will be randomly choose from three categories of pictures including food, nonfood, and blurred baseline images) during an fMRI brain scan procedure to scan brain activation responses
45841826|NCT04526834|Drug|CD30.CAR-T|"Bendamustine and Fludarabine (3 days)~Dose level 1: 2 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 2: 4 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 3: 6 x 108 cell/m2 CD30.CAR-T (Day 0)"
45841827|NCT04522622|Drug|Teriparatide|20 micrograms
46045062|NCT02611141|Procedure|Retromolar laryngoscopy and scoring of the visualisation of the vocal cords according to Cormack & Lehane|"To facilitate the insertion of the straight blade laryngoscope (Miller #4) the head of the patient will be turned to the left side. The blade will be inserted and then pushed laterally rightwards until the retromolar space will be finally reached. Thereafter the epiglottis will be lifted up in order to achieve the best direct view to the vocal cords and scored according to Cormack & Lehane .~This score will be assessed at least 2 minutes after muscle relaxation:~Once without a backward, upward, rightwards pressure maneuver (=BURB) and immediately thereafter (i.e. 5-10 seconds later):~If 100% visualization of the vocal cords is not possible a BURP maneuver will be performed and the scored again.~Intubation will then be performed by the conventional method using a Macintosh blade #3. In the case that intubation with the conventional method is not successful the retromolar technique will be used."
45350201|NCT00878631|Drug|hypertonic saline mixed with dextran|a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 is given within 4 hours from the time of the accident
45350202|NCT00878631|Drug|Normal Saline|250 ccs of normal saline infused within 4 hours of the accident
45841828|NCT04522622|Diagnostic Test|DXA,VFA, X-ray, HR-pQCT, 18-F NAF PET/CT|All participants undergo DXA and VFA or X-ray scans 3 times during the study. Some participants (those connected to Herlev) are offered 18F NAF PET/CT scans at baseline and after 18 months and some participants (those connected to Odense University Hospital and Aalborg University Hospital) are offered HR-pQCT scans at baseline and after 18 months. The 18F-NAF PET/CT and HR-pQCT are optional, so it is not a must to have these procedures done to participate in the study.
46045063|NCT01146860|Drug|BNO 1016|sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
45350203|NCT00921960|Other|Intervention Care|Intervention Care is defined as a collaborative cardiovascular management between primary care and specialist hospital based services. This will involve natriuretic peptide guided evaluation of LVD and follow-up as appropriate - for example including echocardiographic assessment of left ventricular systolic dysfunction and appropriate pharmacotherapy.
46045064|NCT01146860|Drug|Placebo|sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration 15 days
45350204|NCT00878787|Device|Transcranial magnetic stimulation|
45350205|NCT00382993|Drug|Placebo|Matching placebo tablet
45350206|NCT00382993|Drug|Combination Product (sumatriptan succinate/naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in second layer.
45350207|NCT04585464|Drug|EDG-5506|EDG-5506 is administered orally as a single dose or once daily
45350208|NCT04585464|Drug|Placebo|Placebo is administered orally as a single dose or once daily
45350209|NCT00873405|Procedure|Silastic® ring sleeve gastrectomy|SRSG group: ligation of the vessels of the greater curvature of the body and fundus of stomach; resection of the fundus and part of the body of stomach using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the remaining stomach; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
45350210|NCT00873405|Procedure|Silastic® ring gastric bypass|SRGB group: creation of a small, proximal gastric pouch using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the gastric pouch; creation of an intestinal loop of 150 cm and a biliopancreatic loop of 40 cm; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
45350211|NCT04049682|Behavioral|Delayed School Start Time|Francis Parker High School implemented 45-minute later school start time.
45350212|NCT00760968|Drug|TAK-783 and methotrexate|TAK-783 100 mg, tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
45841829|NCT04522622|Procedure|Bone biopsy|All participants are invited to undergo a bone biopsy after 18 months, but it is not a must to have the procedure done to participate in the study.
45841830|NCT04522622|Diagnostic Test|Cardiac tests|All participants are invited to undergo 24-hour blood pressure measurements and pulse wave measurements at baseline and after 18 months, but it is not a must to have these procedures done to participate in the study.
45841831|NCT04522622|Other|Blood and urine samples and physical examination|All participants must undergo a physical examination and deliver blood and urine samples in order to participate in the study.
45841832|NCT04511962|Other|Tele-Pulmonary rehabilitation|The tele-rehabilitation programme will be delivered via an NHSX / NHS Digital approved commercial video conferencing application. It will comprise an initial assessment followed by 12 bespoke classes delivered by video link over a 6 week period. Participants will be advised to undertake exercises on 5 days each week.
45841833|NCT04483102|Device|Declined liver in Normothermic Machine Perfusion (NMP)|The discarded livers rejected by all other centers and meeting pre-NMP eligibility criteria will receive NMP using the OrganOx® metra device. The NMP-treated liver that meets the viability criteria will be transplanted to patients who are eligible and consented to the study.
46045065|NCT00591565|Drug|Acamprosate|acamprosate 333mg tab, 3 by mouth 3 times a day
45350213|NCT00760968|Drug|Methotrexate|TAK-783 placebo-matching tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
45350214|NCT00369967|Drug|NuvaRing|Initiation of NuvaRing for contraception
46045066|NCT01146782|Device|Attune Sleep Apnea System|Console and mouthpiece sleep apnea system
46045067|NCT00978120|Biological|H1N1 vaccine high dose|30 mcg of unadjuvanted Novartis H1N1 vaccine delivered as two, 15 micrograms (mcg), intramuscular injections. Each 30 mcg dose is administered 21 days apart.
46045068|NCT00978120|Biological|H1N1 vaccine low dose|15 mcg of unadjuvanted Novartis H1N1 vaccine delivered in two intramuscular injections 21 days apart
46045069|NCT04288986|Behavioral|Keep Achieving|The 8-week group based activity programme will consist of 8 sessions each lasting 50 minutes.
45350215|NCT00878865|Drug|Alprazolam|1 mg tablet one oral dose
45350216|NCT00878865|Drug|Alprazolam|1 mg tablet
45350217|NCT00873483|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|0.55 mg ethinyl estradiol & 2.1 mg gestodene, 21 days for 3 cycles
45350218|NCT01050517|Drug|albendazole + ivermectin + praziquantel|albendazole (400 mg one dose) + ivermectin 200 microgram/kg body weight) + praziquantel (40 mg/kg)
45350219|NCT01050517|Drug|albendazole + ivermectin + (1 week later) praziquantel|albendazole (400 mg one dose) + ivermectin (200 microgram/kg body weight) + (1 week later) praziquantel (40 mg/kg)
45476426|NCT03386214|Drug|Pevonedistat|The amount of pevonedistat to be administered will be based on body surface area (BSA). BSA will be calculated using a standard formula on Cycle 1 Day 1, and on Day 1 of subsequent cycles if the patient experiences a > 5% change in body weight from the weight used for the most recent BSA calculation.
45350220|NCT02534467|Drug|Montelukast|daily dose according to age for 8 weeks out of 16 weeks of assessment
45350221|NCT01050595|Drug|Methylnaltrexone Bromide|The experimental group will receive the recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg. If creatinine clearance <30 will decrease dose by 50%. This will be given after 72 hours of no bowel movement. Bowel management protocol will be instituted four hours afterward with the methylnaltrexone being given every other day.
45350222|NCT01050595|Drug|Placebo-Normal Saline|Control group will be given an equal amount of normal saline in an identically appearing vial every other day until a bowel movement occurs. A bowel management protocol will also be started.
45350223|NCT00616629|Drug|AZD1305|Intravenous infusion
45350224|NCT03991975|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor.
45841834|NCT04483102|Procedure|Standard cold preservation of liver|"The study will have three comparison groups - one local comparison group and two comparison groups from the national UNOS data.~Comparison group 1 will be patients who received a standard liver transplantation and follow-up care at the Washington University/ Barnes Jewish Hospital (n=50). Patients will be matched by a 5-year age category, sex, MELD score, donor liver graft type (e.g., DCD, DBD), donor age (5-year category), and donor sex. Washington University/ Barnes Jewish Hospital maintains a liver transplantation database that prospectively collects pre- and post-transplantation patient data.~Comparison group 2 will be patients who received DBD liver transplantation in the OPTN/UNOS database (n=100). Patients will be matched by age, sex, MELD score, donor age, and donor sex.~Comparison group 3 will be patients who received DCD liver transplantation in the OPTN/UNOS database (n=100). Patients will be matched by age, sex, MELD score, donor age, and donor sex."
45350225|NCT03991975|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
45350226|NCT04039269|Other|Preoperative video information|
45350227|NCT02534311|Drug|Tocilizumab|Tocilizumab will be administered at 162 mg SC injection for 48 weeks.
45476427|NCT03386214|Drug|Ruxolitinib|-Standard of care outside of protocol
45841835|NCT04474483|Drug|Melatonin|Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.
45841836|NCT04474483|Other|Placebo (Methylcellulose) capsule|Placebo capsules will be prepared with opaque gelatin capsules, filled using methylcellulose and over-encapsulated to appear identical to interventional drug. Placebo capsules will be given orally in the same regimen as intervention (three times daily for 14 days). Capsules will be prepared by the research pharmacist and will be mailed to study subjects directly by courier. Placebo capsules will be stored at room temperature.
45841837|NCT04432207|Biological|IMU-201 (administered as PD1-Vaxx) - Regimen 1|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 64 and thereafter every 63 days until discontinuation from study.
45350228|NCT00873561|Drug|NBI-6024|0.1, 0.5 or 1 mg NBI-6024 First 3 doses every 2 weeks. Remaining doses given monthly. Total duration of dosing 24 months. Placebo controlled.
45350229|NCT04039425|Procedure|Hair cut|Use only head hair. Cut samples of hair from back of head (see illustration). Cut hair as close to the scalp as possible. As each piece of hair is cut from the head, save only 3.7 square inches of hair closest to the scalp. According to the Doctors Data Lab, this amount is about enough hair to fill a tablespoon. Cut off and discard the rest. Place the saved hair on the scale. Keep cutting and adding hair to the scale until it tips. Hair collection will be about the weight of one to two paper clips (about 3800 strands). Remove the hair on the scale and put it in the plastic bag. Label the plastic bag with the patient's unique random identification and the date collected. Put the hair into the plastic bag, seal, and send to The Doctor's Data Lab.
45350230|NCT02534389|Dietary Supplement|omega-3 fish oil|2,4g of EPA + DHA
45350231|NCT00878943|Drug|Sildenafil citrate|20 mg tablet to be taken thrice daily for 1 year
45350232|NCT00873639|Drug|insulin aspart|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
45350233|NCT00873639|Drug|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
45350234|NCT00879021|Drug|Lyrica|study participants will start will be on 150mg of Pregabalin or placebo capsules by mouth , twice a day.They will be on drug approx. 49 weeks and followed for another 49 weeks after stopping the medication.
45476428|NCT03386214|Procedure|Peripheral blood draw|"Baseline or Cycle 1 Day 1 (prior to study treatment administration)~Cycle 2 Day 1 (prior to study treatment administration)~Cycle 4 Day 1 (prior to study treatment administration)~End of treatment"
45350235|NCT00879021|Drug|matching placebo|150 mg by mouth ,twice a day for 49 weeks
45350236|NCT00879099|Drug|Paroxetine|Paroxetine 20 mg once a day during two treatment periods. One treatment period lasts for 3 days.
45350237|NCT00879099|Drug|Placebo|Gelatine capsule once a day during two treatment periods. One treatment period lasts for 3 days.
45476429|NCT03386214|Procedure|Skin biopsy|A skin punch biopsy specimen will be collected at the baseline visit. One 6 mm punch biopsy of normal skin will be performed using standard techniques and local anesthesia.
45841838|NCT04432207|Biological|IMU-201 (administered as PD1-Vaxx) - Regimen 2|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every subsequent 63 days until discontinuation from study.
45476430|NCT01198535|Biological|Cetuximab|Given IV
45476431|NCT01198535|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
45476432|NCT01198535|Other|Laboratory Biomarker Analysis|Correlative studies
45841839|NCT04432207|Biological|IMU-201 (administered as PD1-Vaxx) - Regimen 3|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every 56 or 63 days until discontinuation from study.
45841840|NCT04432207|Drug|Atezolizumab|Atezolizumab will be administered every 2 weeks (Q2W) starting Day 15 until discontinuation from study.
45841841|NCT04432207|Drug|Standard of care chemotherapy|Chemotherapy to be administered according to the prescribing information.
45841842|NCT04425447|Drug|Tumescent local anesthesia|"Surgical disinfection of the area will be performed, skin inﬁltration with 2 mL of 1% lidocaine will be done, and wetting fluid will be used (1000 ml normal saline, 20 ml lidocaine 2%, and 1 mg epinephrine).~Infiltration will be initiated with a 25-gauge needle. The 25-gauge needles cause little discomfort and provide enough local anesthesia to allow painless, more complete infiltration using a 20-gauge spinal needle. After the glandular nipple tissue is made somewhat tumescent, a larger (20-gauge) spinal needle can be more easily passed through the otherwise dense and resistant tissue."
46045070|NCT04289064|Device|Taking a fundus image|The participant only needs to take a fundus image as usual.
46045071|NCT03971760|Other|Suction drain removal|Removal of negative pressure suction drain left in place to drain the surgical space after a neck surgery
46045072|NCT00978042|Device|Juvéderm® VOLUMA XC|Treating Investigator determines the appropriate volume of VOLUMA XC to be injected up to a maximum total of 12 mL for initial and touch-up treatment. One repeat treatment with up to 12 mL may be performed at the Subject's option after study completion.
45350238|NCT00879099|Drug|timolol maleate|Oftan Timolol 0,5 % eye drop. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
45476433|NCT01198535|Other|Pharmacological Study|Correlative studies
45476434|NCT02516878|Procedure|Acupuncture|"Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.~Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated."
46045073|NCT01133678|Drug|Everolimus|Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel (175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Everolimus 5 mg PO daily. Following induction patients received [paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
46045074|NCT01133678|Drug|Placebo|Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel(175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Placebo PO daily. Following induction patients received [paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
45350239|NCT00879099|Drug|timolol maleate|Timosan 0,1 % eye gel. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
45476435|NCT01198613|Biological|ToleroMune Ragweed|Intradermal injection 1 x8 administrations 2 weeks apart
45350240|NCT00369655|Biological|ziv-aflibercept|
45350241|NCT00615069|Device|31 mm GORE EXCLUDER® AAA Endoprosthesis|GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)
45476436|NCT01198613|Biological|Placebo|Intradermal injection, 1x8 administrations 2 weeks apart
45841843|NCT04425447|Drug|Thoracic paravertebral block|The paravertebral block (PVB) will be performed in the sitting position. Surgical disinfection of the thoracic paravertebral area will be done. A linear high-frequency transducer will be used. The scanning process (longitudinal out-of-plane technique) will be started at 5 to 10 cm lateral to the spinous process to identify the rounded ribs and parietal pleura underneath. The transducer is then moved progressively more medially until transverse processes are identiﬁed as more squared structure and deeper to the ribs. Once the transverse processes will be identiﬁed, skin inﬁltration with 2 mL of 1% lidocaine will be done. A 100-mm, 22 G needle will be inserted out of the plane to contact the transverse process and then walk off the transverse process 1 to 1.5 cm deeper searching for loss of resistance to inject 20 mL (5mL lidocaine 2% and 15 mL bupivacaine 0.25%) at each level of T4.
46045075|NCT03693040|Device|Digital Health Feedback System|This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their PrEP medication. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their PrEP medication.
45476437|NCT02516644|Behavioral|Virtual Reality|12 sessions of 1 hour (30 min of virtual reality and 30 min of aerobic exercise with treadmill training): three times a week over four weeks
45476438|NCT02516644|Behavioral|Conventional Therapy|12 sessions of 1 hour of conventional physiotherapy: three times a week over four weeks
45350242|NCT01050751|Drug|Lersivirine|Oral Lersivirine 750 mg (1 x 750 mg) single dose
45350243|NCT01050751|Drug|Lersivirine|Oral Lersivirine 750 mg (3 x 250 mg) single dose
45350244|NCT00879177|Drug|Varenicline|Varenicline: 1 tab 0.5mg once a day for 3 days; 1 tab 0.5mg twice a day for 4 days; followed by 1 tab 1mg twice a day for 11 weeks.
45350245|NCT00879177|Behavioral|behavioral therapy|confirmed negative smoking status at different time points
45476439|NCT05081219|Drug|Insulin (Humulin® R U-100)|Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.
45476440|NCT05081219|Drug|Empagliflozin 10 MG|Participants will be assigned to receive Empagliflozin 10 mg capsules to be taken by mouth once daily.
45476441|NCT05081219|Device|Aptar Pharma CPS Intranasal Delivery Device|Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.
45476442|NCT05081219|Drug|Placebo (Insulin Diluent)|Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.
45476443|NCT05081219|Drug|Placebo (Capsules)|Participants will be assigned to receive placebo capsules (Empagliflozin 10 mg) to be taken by mouth once daily.
45476444|NCT03909334|Drug|Osimertinib|Osimertinib 80 mg orally on Day 1
45476445|NCT03909334|Drug|Ramucirumab|Ramucirumab 10 mg/kg intravenously (IV) over 60 minutes for first infusion and if tolerated subsequent infusions may be over 30 minutes
45350246|NCT01050829|Drug|Gadobutrol (Gadovist, BAY86-4875)|Single administration at a dose of 0.1 mmol/kg
45350247|NCT01050829|Drug|Gadopentetate Dimeglumine (Magnevist, BAY86-4882)|Single administration at a dose of 0.1 mmol/kg
45847597|NCT04301154|Biological|HIVIS DNA + Cervarix and MVA-CMDR|Cervarix IM by needle injection followed by 1500 micrograms (0.5ml) per injection of HIVIS DNA IM by a needle-free injection device in the skin above (proximal to) the Cervarix injection (within 1.5 cm). They will receive 1 X 108 IU/mL (1ml) MVA-CMDR IM by needle injection at weeks 24 and 36 in the same arm as HIVIS DNA. They will also receive 0.5 ml Cervarix at the time of the first MVACMDR injection in the opposite arm from the MVA injection at week 24.
45847598|NCT04301154|Biological|Cervarix|Cervarix by IM needle injection at weeks 0, 4 and 24.
45847599|NCT04239846|Drug|AC-701 Topical Gel 0.3%|AC-701 Topical Gel 0.3%, BID
45847600|NCT04239846|Other|Placebo Gel|Placebo Gel, BID
46045076|NCT02638324|Procedure|Renal nervous denervation|The heart failure patients will undergo renal nervous denervation if they have not properly responded to medication and biventricular pacing therapy.
45350248|NCT00873717|Other|Dentary|cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed).
45476446|NCT05670977|Dietary Supplement|Study product plus collagen supplement|The participants in this arm will use the assigned product for 2 months, 5g one time, once a day.
45476447|NCT05670977|Dietary Supplement|Study product without collagen supplement|The participants in this arm will use the assigned product for 2 months, 5g one time, once a day.
45476448|NCT03896620|Device|Preoperative RT|Radiation delivered before surgery.
45476449|NCT03896620|Device|Postoperative RT|Radiation delivered after surgery.
45476450|NCT03896620|Drug|Chemotherapy|Physician's choice of chemotherapy.
45476451|NCT03896620|Other|Surgery|Surgical excision of tumor.
45476452|NCT05427539|Device|TEST LENS|AO1DfA manufactured with PG hydration
45476453|NCT05427539|Device|CONTROL LENS|AO1DfA manufactured with IPA hydration
45476454|NCT03860038|Drug|TJ202 and Dexamethasone|one dose of TJ202 16 mg/kg or an adjusted dose will be administered on Day 1 and Day 4 of Week 1, then every week from Week 2 to Week 12, then every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter, until the subjects experience an onset of endpoint events like intolerance or PD. DEX 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.
45350249|NCT00873717|Other|Nutrition|control of the administration of dietary prescriptions, incitement to eat.
45841844|NCT04425447|Drug|Thoracic interfascial plane block|"Total LA injected was 80 mL (10 mL lidocaine 2% and 70 mL bupivacaine 0.25%) The linear probe will be placed below the outer third of the clavicle to detect anatomical landmarks, such as the serratus anterior muscle (SAM), external intercostal muscle (EIM), pectoralis muscles, thoracoacromial artery, and second rib. A test bolus of 1-2 ml of LA will be injected; upon confirmation of diffusion of the test dose between the external intercostal muscles and the SAM, a total of 20 ml of LA will be injected. The needle will be then carefully moved in the direction of the third and fourth ribs while confirming the expansion of the fascial plane.~In the performance of the pecto-intercostal fascial plane block (PIFB), a probe will be placed parallel to the long axis of the sternum at a distance greater than 2 cm from the attachment of the second rib and sternum to identify the pectoralis muscles, EIM, and second rib. A"
45841845|NCT04399837|Drug|Spesolimab|Solution for injection
45476455|NCT04499404|Other|Breastfeeding related information delivered by WeChat|Participants in the intervention group will be asked to follow our WeChat public account immoderately after randomization. They will receive breastfeeding related messages three times a week from WeChat, including preparation for breastfeeding after birth and the health benefits of breastfeeding, from baseline until childbirth. After childbirth, intervention group mothers will continue to receive information, which is mainly about breastfeeding, once a week for 6 months. WeChat will send push notifications to remind mothers about the importance of exclusive breastfeeding, build confidence and motivate them to continue exclusive breastfeeding.
45841846|NCT04399837|Drug|Placebo|Solution for injection
45841847|NCT04373707|Drug|Enoxaparin|"For example (Enoxaparin):~4000IU twice a day in patients <50kg~5000IU twice a day in patients 50-70kg~6000IU twice a day in patients 70-100kg~7000IU twice a day in patients above 100kg"
45350250|NCT00873717|Other|Dentary + Nutrition|"trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.~associated with control of the administration of dietary prescriptions, incitement to eat."
45685742|NCT02150902|Procedure|Augmented- wide area circumferential ablation procedure|Subjects in this group will have WACA performed as described for WACA. Following completion of the WACA procedure a second set of circumferential ablation lesions will be delivered around the first set of ablation lesions. The ablation catheter tip will be positioned at each of the ablation lesions along the first WACA line and then moved away (from the PV ostia) until healthy, non ablated tissue is recorded from the catheter tip. Energy will be delivered using CF and FTI data as described previously. Once the first WACA ablation line has been completely duplicated the procedure will be deemed complete. In case PV isolation is not achieved after the first WACA lesion set repeat electrophysiologic testing will be performed to determine whether the augmented-WACA procedure was successful in achieving PV isolation.
45841848|NCT04373707|Drug|Enoxaparin|For example (Enoxaparin): From 4000IU once a day in patients admitted in medical ward to 4000IU twice a day in patients admitted in the ICU. In patients with severe renal insufficiency (GFR=15-30 mL/min/1.73m²), LMWH doses will be reduced by 50%.
45841849|NCT04345718|Drug|Extended Release Buprenorphine|XR-BUP administration prior to hospital discharge will increase engagement in OUD care on the 34th day following hospital discharge more than is currently afforded by ACS TAU approaches (e.g., methadone, SL-BUP, and naltrexone).
45841850|NCT04345718|Drug|Treatment as Usual|Community standard medication for opioid use disorder (e.g., methadone, sublingual buprenorphine, naltrexone) initiated prior to hospital discharge.
45841851|NCT04338581|Biological|AMG 714|anti-IL-15 monoclonal antibody (Anti-IL-15 MAB)
45841852|NCT04338581|Biological|Placebo|Placebo for AMG 714
45841853|NCT04338581|Procedure|nbUVB phototherapy|Participants will undergo narrow band ultraviolet B (nbUVB) phototherapy if their total body Vitiligo Area Scoring Index (T-VASI) does not improve by ≥ 25% at Week 24 compared to Week 0. Phototherapy will be administered in accordance with the Vitiligo Working Group expert recommendations.
45841854|NCT04332068|Drug|Oral ivermectin|Ivermectin (Iver P®) 3 mg tablets are round, white, and scored on one side. Ivermentin 3mg tablets will be crushed and mixed thoroughly in 10mL of water.
45350251|NCT00676338|Drug|exenatide once weekly|subcutaneous injection, 2mg, once weekly plus placebo oral once daily
45350252|NCT00676338|Drug|metformin|oral, 1000-2500mg, daily plus placebo once weekly subcutaneous injection
45476456|NCT04499404|Other|Non-breastfeeding related information delivered by WeChat|Participants in the control group will be asked to follow our WeChat public account immoderately after randomization. They will receive messages mainly on topics of healthy lifestyle and nutrition during pregnancy, from baseline until childbirth. After childbirth, they will continue to receive information on other topics of interest to mothers, such as immunization, safety, infant growth, and etc., until 6 months postpartum.
45841855|NCT04332068|Drug|Permethrin Cream|permethrin cream 5% (Pioletal® Plus) is a white coloured lotion with a homogenous appearance and an odour of fennel and lavender.
45841856|NCT04332068|Other|Placebo tablet|placebo tablets are round, white, scored on one side. There are no active substances in the placebo tablets.
45841857|NCT04332068|Other|Placebo cream|A placebo cream is a white coloured lotion with a homogenous appearance and an odour of fennel and lavender but lacking the permethrin agent.
45841858|NCT04323787|Other|observational|No Intervention
45841859|NCT04323449|Device|Compare two control methods for a wheelchair-mounted robotic manipulator|Participants will pay one visit to the lab where they will be asked to complete a set of manipulation tasks using a wheelchair-mounted robotic manipulator using the new custom vision-guided control and default joystick or switch control. The sequence of the two control methods will be counterbalanced.
45841860|NCT04298541|Drug|Ga-68- DOTATATE|"The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery."
45841861|NCT04298541|Drug|Ga-68-DOTATOC|"The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery."
46045077|NCT00652132|Drug|cisplatin|
46045078|NCT00652132|Drug|sodium thiosulfate|
46045079|NCT02645890|Drug|CKD-397|Arm A:Tamsulosin/ Tadalafil Fixed dose combination
46045080|NCT02645890|Drug|TD+TM|Arm B: Tamsulosin/ Tadalafil Coadministration
45350253|NCT00676338|Drug|sitagliptin|oral, 100 mg, daily plus placebo once weekly subcutaneous injection
45350254|NCT00676338|Drug|pioglitazone|oral, 30-45mg, daily plus placebo once weekly subcutaneous injection
45350255|NCT02534623|Procedure|Spinal anesthesia|
45350256|NCT02534623|Procedure|General anesthesia|
45350257|NCT02534623|Drug|bupivacaine|
45685743|NCT01810588|Device|CliniMACS® CD34 Reagent System|The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
45685744|NCT01810588|Drug|Fludarabine|Administer 30 mg/m2 /day intravenously x 5 days (Day -7 to Day -3) of a total dose of 150 mg/m2. Fludarabine will be dosed according to actual body weight.
45685745|NCT01810588|Drug|Melphalan|Administer 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis
45685746|NCT01810588|Drug|anti-thymocyte globulin (rabbit)|Administer 1.5 mg/kg/day intravenously x 3 days, total 4.5 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
45350258|NCT02534623|Drug|fentanyl|
45350259|NCT02534623|Drug|propofol|
45350260|NCT02534623|Drug|sevoflurane|
45350261|NCT00873795|Drug|aripiprazole , sertraline|In this ten weeks,double-blind,placebo-control,randomized,fixed dose study, study,subjects were randomly assigned to treatment with aripiprazole 2.5mg/day plus sertraline 50mg/day or sertraline 50mg/day plus placebo.
45350262|NCT00879489|Biological|Dendritic Cell Vaccination|Autologous dendritic cells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally.
45685747|NCT01810588|Drug|Rituximab|Administer one dose of 375 mg/m2 prior to or upon admission for all patients not previously exposed to rituximab or who have not received rituximab in the six months prior to transplant.
46045081|NCT04164784|Behavioral|therapeutic monitoring|According to the glucose lever recorded by FreeStyle Libre H (Flash Continuous Glucose Monitoring System) ,the investigators give the intervention group instructions to adjust their diet and lifestyle to abtain a good glucose control.
45350263|NCT00382291|Drug|Regular Titration|Sertraline will be administered in standard dosing. Treatment with sertraline will last 18 weeks.
45350264|NCT00382291|Drug|Placebo|The placebo will be administered in the same manner as sertraline. Treatment with placebo will last 18 weeks.
45350265|NCT00382291|Drug|Slow Titration|Sertraline will be administered in slow titration. Treatment with sertraline will last 18 weeks.
45350266|NCT00873951|Other|Intestinal and metabolic exploration|Subjects are studied for 8h following the ingestion of a standard meal containing 15% of energy as protein. Intestinal, blood and urine are collected at regular intervals.
45841862|NCT04272736|Dietary Supplement|Low calorie protein substitute|The evaluated dietary supplement is a lower calorie amino acid based liquid protein substitute designed for patients with PKU.
45841863|NCT04261673|Procedure|Decompressive Craniectomy|A large bone flap must be raised. The evacuation of epidural hematoma is depended on surgeon's preference. The bone flap should not be replaced at the end of the operation. DC has an advantage in controlling brain swelling, but patient is necessary to have another operation of cranioplasty to reconstruct the skull in the future.
45841864|NCT04261673|Procedure|Craniotomy|A large bone flap must be raised. The evacuation of epidural hematoma is depended on surgeon's preference. However, the bone flap must be replaced and fixed with fixation system (plates and screws). The patient will not need an additional operation to rebuild the skull in the future. But undisciplinable brain swelling and increased intracranial pressure may happen in some patients, and additional decompressive craniectomy is recommended in these cases.
45841865|NCT04249037|Drug|bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)|A 30 day supply of Bictegravir 50mg/Emtricitabine 200mg/Tenofovir Alafenamide 25mg will be provided to the rapid start arm.
45841866|NCT04249037|Drug|Standard initiation of antiretroviral therapy (ART)|Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.
45841867|NCT04248868|Device|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
45841868|NCT04248868|Drug|r-tPA|Pulse spray and infusion
45350267|NCT00873951|Dietary Supplement|15N-labelled intact casein|standard mixed meal containing 15% of energy as 15N-labelled intact casein
45350268|NCT00873951|Dietary Supplement|15N-labelled hydrolyzed casein|standard mixed meal containing 15% of energy as 15N-labelled hydrolyzed casein
45350269|NCT00873951|Dietary Supplement|mixture of AA|standard mixed meal containing 15% of energy as a mixture of AA mimicking the composition of casein but devoid in serine
45476457|NCT03844685|Drug|Promensil|1 tablet (80 mg) /day of MCE-11 (Promensil) taken orally for 24 months
45841869|NCT04246138|Procedure|alignment types|types of alignment mechanical versus kinematic of TKA to be studied
45841870|NCT04217993|Drug|Jaktinib hydrochloride tablets|Jaktinib hydrochloride tablets 100mg twice dose group，Jaktinib hydrochloride tablets 150mg qd dose group, Jaktinib hydrochloride tablets 200mg qd dose group and Jaktinib hydrochloride tablets 100mg qd dose group
46045082|NCT00655174|Drug|fluvoxamine|Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
45350270|NCT00874107|Biological|Imprime PGG® Injection|4 mg/kg, i.v. over 2 hr, weekly until progression or discontinuation
45476458|NCT03844685|Drug|Placebo Oral Tablet|Placebo tablet (80 mg) (without active principle) given once a day for 24 months
45476459|NCT02942966|Device|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
45476460|NCT04151069|Other|Procedure A|Up-dosing nut drink at home
45476461|NCT04151069|Other|Procedure B|Up-dosing nut drink at the hospital
45841871|NCT04211831|Drug|URO-902|intradetrusor injection
45841872|NCT04211831|Drug|Placebo|intradetrusor injection
45841873|NCT04208529|Biological|CTX001|CTX001 infusion.
45841874|NCT04205656|Biological|Leukocyte-Poor Platelet Rich Plasma (LP-PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the vein.
46045083|NCT00655174|Drug|sertraline|Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
46045084|NCT00655174|Drug|Placebo|Patients in this study arm will receive capsules that appear identical to those of the two study drugs but will contain no active ingredient.
46045085|NCT04166422|Other|Cardiac rehabilitation program|Aerobic treatment plus strength exercises
46045086|NCT04166422|Other|Experimental intervention|Aerobic treatment plus strengh exercises plus virtual reality
45841875|NCT04205656|Biological|Bone Marrow Concentrate (BMC)|Participants will have a knee injected with BMC stem cells harvested from the iliac crest
45841876|NCT04205656|Other|Control group (Placebo)|Participants will undergo ACLR surgery with no injection into their knee.
45476462|NCT04151069|Other|Control group|Strict avoidance of tree nut consumption
45841877|NCT04203381|Device|GnRH Agonist|Forty participants who are transgender and who have been prescribed a gonadotropin-releasing hormone (GnRH) agonist by their physician will undergo magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), dual-energy x-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT) scans at baseline, at 12 months and at 24 months after initiation of the GnRH agonist therapy. This longitudinal observational study of two cohorts seeks to identify significant changes in bone marrow adiposity and bone density over 24 months. The same assessments will be obtained in 40 healthy control subjects matched for age, race/ethnicity and body mass index, all factors that are known to influence skeletal outcomes. The evaluations of bone marrow adiposity will be correlated with bone density measurements and the assessments of mood (validated anxiety and depression scales) and health-related quality of life, before and after pubertal blockade.
46045087|NCT00655018|Dietary Supplement|Vitamin treatment (alpha tocopherol plus ascorbic acid)|alpha tocopherol 600 IU/d plus ascorbic acid 500 mg/d and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
45476463|NCT03844763|Drug|Avelumab|Avelumab: 10 mg/kg every 2 weeks, untill PD or major toxicity
45476464|NCT03844763|Drug|CTX|CTX: 50 mg Daily untill PD or major toxicity
46045088|NCT00655018|Dietary Supplement|Placebo|placebo and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
46045089|NCT02635750|Drug|BI 409306|
45476465|NCT03844763|Radiation|RT|RT: 8 Gy single shot day 8
45685748|NCT01810588|Radiation|Total Body Irradiation|Patients at high risk of CNS relapse (e.g. ALL or Burkitt's lymphoma) or patients at high risk for graft rejection (i.e., donor-specific HLA antibodies, patients with severe aplastic anemia, or hemoglobinopathies) may receive 2 doses of TBI as part of the conditioning.
45685749|NCT01810588|Drug|Mycophenolate Mofetil|Will be started on Day -2 and given at a dose of 1000 mg every 8 hours until Day 28. Mycophenolae Mofetil can be given orally or intravenously. Infection, toxicity, very low patient weight (<50 kilograms) may prompt earlier discontinuation or adjustment of doses.
46045090|NCT02635750|Drug|Donepezil low dose|
45476466|NCT02516566|Other|PEEP|Mechanical ventilation with PEEP 8 cmH2O
45476467|NCT05018039|Other|Collaborarive Care Model|"Collaborative care involves three professionals: a physical health care provider (physiotherapist or occupational therapist), a mental health care provider and a case manager. The case manager will work closely with the patient to identify the mental health support necessary. This may involve appointments with a psychologist or psychiatrist as part of their musculoskeletal treatment.~The case manager will define a treatment plan and organise appointments with the patients and monitor their progress using validated questionnaires, adjusting their mental or physical care support when required. This professional will also monitor patients' attendance and support managing their appointments and routinely update the clinical team on patient progress, and relaying information back to the clinical team. This model of care will work in parallel to the regular musculoskeletal appointments (usual care)."
45476468|NCT03121300|Other|CT Scan|Quantitative lung SPECT-CT
46045091|NCT02635750|Drug|Donepezil high dose|
46045092|NCT04164706|Device|HumiGard device|HumiGard is a CE marked device that delivers warmed humidified CO2 during laparoscopic surgery
46045093|NCT04164706|Other|Standard care (with sham HumiGard device)|Standard methods of keeping the patient warm whilst in theatre, including warmed IV fluids, warming blankets/forced air warming devices.
46045094|NCT04164238|Drug|Toripalimab|Toripalimab Injection
45476469|NCT03121300|Other|Lung CT|CT lung ventilation
45476470|NCT03121300|Other|MRI|DCE MRI
46045095|NCT04164238|Drug|Paclitaxel|Paclitaxel Injection
46045096|NCT04164238|Drug|Carboplatin|Carboplatin Injection
46045097|NCT04164238|Drug|Cisplatin|Cisplatin injection
45350271|NCT00874107|Biological|Bevacizumab|15 mg/kg, i.v., over 90 minutes, on Day 1 only of each 3-week treatment cycle
45350272|NCT00874107|Drug|Paclitaxel|200 mg/m2, i.v. over 3 hr, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles.
45685750|NCT01810588|Drug|Tacrolimus|Administered 0.03/mg/kg/day intravenous continious infusion (CI) over 24 hours from 4pm Day -2 until engraftment or when subject is able to take orally, then tacrolimus approximately 0.09 mg/kg orally in 2 divided doses. Tacrolimus should be given at full dose to maintain levels of 5-15 ng/mL through Day 180, tapered by 20% every week thereafter. Infection, toxicity or other clinical circumstances may prompt earlier discontinuation or adjustment of doses. In the presence of Graft versus Host Disease, a clinical decision by the attending physician will determine if tacrolimus can be tapered or should be continued. Oral tacrolimus can be used when intravenous access for CI tacrolimus is unavailable.
45350273|NCT00874107|Drug|Carboplatin|AUC of 6 mg./mL · min based on the Calvert formula; i.v. over 30 min, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
45350274|NCT00761358|Drug|Z-338|Oral
45350275|NCT00761358|Drug|Placebo|Oral
45350276|NCT05213637|Biological|Expanded Activated Lymphocytes (EAL)|12~20 doses of EAL (1×10^9~2×10^10 cells per dose) will be infused into patients.
45685751|NCT02144584|Drug|Memantine XR|The active drug will be encapsulated by the University of Utah Research Pharmacy to maintain blinding.
45841878|NCT04193371|Other|Active acupuncture|The rationale of the active acupuncture protocol is based on Western Medical Acupuncture theories and follows CONSORT and STRICTA protocols. All patients received acupuncture treatment for 30 minutes three times a week, with a maximum of 48 acupuncture treatments.
45350277|NCT05213637|Procedure|transarterial chemoembolization (TACE)|After angiography, fluorouracil will be injected into the proper hepatic artery or the segment of liver where the original lesion is located, and then microcatheter will be introduced into the segment of liver artery where the incision margin is located, and iodized oil injection and epirubicin will be mixed and embolized.
45847601|NCT04233060|Drug|CS3005|CS3005 will be orally administrated twice daily (BID) until PD, unacceptable toxicity, withdrawal of informed consent, or until maximum treatment duration per protocol (2 years)
45350278|NCT03992989|Device|Phonak Bolero M90-M|The Phonak Bolero M90-M is a Behind-the-Ear Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss
45685752|NCT02144584|Drug|Placebo (for memantine)|Placebo to be capsuled to look identical to active drug (memantine)
45685753|NCT05577442|Drug|Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy|Trastuzumab (8-6mg/3weekly)，Pyrotinib（320mg/day）Dalpiciclib（125mg/day，With three weeks separated by one week）
45350279|NCT03992989|Device|Roger Select|The Roger Select is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
45350280|NCT00879723|Dietary Supplement|Vitamin and Mineral supplementation|"IV - 2x per day given 2 - 12 hours apart. A.M. solution - Infuvite multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. solution - Cuperic Chloride 9mg (provides Copper 3.36mg) and Vitamin C 500mg. Each fluid solution will run for 4 hours.~Enteral (oral) 2 x per day given 2 - 12 hours apart. A.M. dose - multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. dose - Copper 4mg and Vitamin C 500mg."
45350281|NCT00874341|Other|Fruit and vegetable intervention|Dose-response effect of fruit and vegetable intake (1-2 vs 4 vs 7 portions per day for 12 weeks)
45350282|NCT00874419|Drug|erlotinib|erlotinib 150 mg oral, once a day
45350283|NCT00874419|Drug|gemcitabine/carboplatin|gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
45350284|NCT00547378|Device|InterStim|
45350285|NCT00547378|Drug|Standard Medical Therapy|Oxybutynin 2.5mg, 5mg Oxybutynin extended release 5 mg, 10mg, 15mg Oxybutynin transdermal 3.9mg Solifenacin 5mg, 10mg Tolterodine 1mg, 2mg Tolterodine extended release 2mg, 4mg Trospium 20mg Darifenacin extended release 7.5mg, 15mg fesoterodine Fumarate 4mg, 8mg
46045098|NCT04164238|Drug|5-fu|5-fu injection
46045099|NCT04164160|Other|integrated-care-model benefiting group|Patients will be called for the ﬁrst interview of the study by the healthcare professional. Their data will be automatically entered in the Salut + Social app, they will be asked to respond to the study questionnaires (ad hoc questionnaire for sociodemographic data, EuroQol-5D, Zarit questionnaire and Morisky-Green test) and will take part in the future actions to be planned for them. Patients will receive an appointment to attend their PCC at 6, 9, and 12 months after their incorporation into the program. In those follow-up, the same questionnaires will be provided together with the IEXPAC questionnaire, which evaluates the experience of the chronic patient with the new care model.
45350286|NCT00381043|Drug|Acamprosate (Campral)|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
45350287|NCT02534701|Device|ERIC® and SOFIA™|a self-expanding clot retrieval system
45350288|NCT00962338|Behavioral|Information|Information on short convalescence (1 day). Example: Operated today and getting started with normal activities again tomorrow.
45350289|NCT01050985|Drug|Temsirolimus and capecitabine|temsirolimus in escalating doses starting at 15-mg IV on days 1 and 8 of a 14 day cycle capecitabine in escalating doses starting at 1000 mg/m2 by mouth twice a day on days 1-7 of a 14-day cycle
45350290|NCT04010656|Procedure|PVR-based self-catheterization|Home self-catheterization based on standard of care
45476471|NCT03121300|Other|Walk Test|6 minute hall walk test
45476472|NCT03121300|Other|SGRQ|St. George Respiratory Questionnaire
45476473|NCT03121300|Other|Biological Sample Collection|Blood Draw
45476474|NCT03121300|Other|Toxicity|Toxicity Evaluation
45476475|NCT03121300|Other|Cardiac Assessment|Cardiac MRI Scan
45350291|NCT00962416|Device|Biolimus eluted from an erodable stent coating (Biomatrix)|The Biolimus-eluting stent (Biomatrix) has a corrugated ring design available in six and nine cell models and is laser cut from 316L VM stainless steel hypotube. The nominal dosage of Biolimus A9 goes from 133 to 442 microgram. The producer of the drug is Nippoon Kayaku Co., Ltd Takasaki Plant, 239, Iwahanamachi, Takasaki-shi, Gumma 370-1028 Japan. The biodegradable polymer is polylactic acid, which has become one of the most commonly used biodegradable polymers. Polylactic acid, its co-polymers, and mixtures have been evaluated in the preclinical, and clinical studies, revealing a favorable biocompatability profile. The polymer has been demonstrated to be safe when used as implant of drug release-control polymer for both animals and humans.
45350292|NCT00962416|Device|bare-metal stent (Gazelle)|A bare-metal stent of identical design without surface application of polymer and drug.
45350293|NCT00614991|Drug|Raltegravir|400mg BID
45350294|NCT00614991|Drug|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
45350295|NCT00614991|Drug|Ritonavir|100 mg BID or QD
45350296|NCT00962494|Behavioral|Cancer: Thriving and Surviving Online Workshop|
45350297|NCT04010032|Device|Programmed intermittent epidural bolus|bolus administration of 0.15 ml of ropivacaine 0.15 ml / kg into epidural space every hour(intermittent bolus injection) using PCA device
45350298|NCT04010032|Device|Continuous epidural infusion|Continuous infusion of 0.15% ropivacaine 0.15 ml / kg / h into the epidural space using PCA device using PCA device
45476476|NCT02512822|Procedure|Noninvasive Radiofrequency TruSculpt|Heating subcutaneous fat up to 45℃ continuously at least 3 minutes without surface damage and induces adipocytes apoptosis.
45476477|NCT02516722|Device|Therapeutic Intra-Vascular UltraSound (TIVUS™) System|"The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.~Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation."
45476478|NCT05016947|Drug|Venetoclax|Tablet, taken by mouth
45476479|NCT05016947|Drug|Dexamethasone|Taken orally
45476480|NCT05016947|Drug|Inotuzumab Ozogamicin|Intravenous infusion
45685754|NCT01895764|Drug|Adalimumab|adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26
45476481|NCT03606616|Procedure|no further ALND arm|Patients meeting the Z0011 inclusion criteria to receive no additional ALND
45350299|NCT00360529|Drug|flibanserin|flibanserin placebo versus 50 mg qhs versus 100 mg qhs
45350300|NCT04858971|Other|Perception of information source|Participants will see the same health advice, with no source or one of three other sources indicated
45350301|NCT02247388|Behavioral|Computerized Alcohol Screening|iPad based automated alcohol screening
45476482|NCT01198847|Behavioral|Dietary, physical activity and sleeping|"The intervention in the present study will be delivered through sessions aiming at developing healthy lifestyle habits regarding physical activity, food intake and regular sleeping habits for parents and children. These sessions will be performed face to face by trained health care workers and carried out in the welfare centres with the parent/s. Children will not be approached directly in the present study. All families will meet with their coach/facilitator during at least 12 times (including start and final evaluation meeting) until the children reach 6 years of age (such as school age). However extra effort (as boosting sessions) will be made if growth records show an increased BMI (weight induced meetings). The parents are also encouraged to keep contact with their coach either by phone or e-mail as often as they feel needed.~The Low intensity arm will only receive written information and no direct face to face support"
45476483|NCT02512666|Device|AM4113-N5UT Dino-Lite|
45476484|NCT01198925|Drug|piperacillin continuous infusion|piperacillin continuous infusion
45476485|NCT01198925|Drug|piperacillin extended infusion|piperacillin extended infusion
45476486|NCT04501354|Drug|Mesenchymal Stem Cell|Mesenchymal Stem Cell + NaCl 0,9% 2ml
45350302|NCT02247388|Behavioral|Brief Negotiated Interview|iPad based automated brief negotiated interview (BNI)
45350303|NCT00874575|Dietary Supplement|Placebo|
45350304|NCT00874575|Dietary Supplement|Vitamin D|
45350305|NCT00874575|Dietary Supplement|Beta-hydroxy-Beta-methylbutyrate|
45350306|NCT00874575|Drug|Beta-hydroxy-Beta-methylbutyrate and Vitamin D|
45350307|NCT02009800|Biological|Quadrivalent HPV vaccine|One dose of Gardasil administered in the intervention group
45476487|NCT03844139|Device|Feeding pump and glycerin syringe|The continuous group use feeding pump and the intermittent group use syringe to give dysphagia patients after stroke prescribed nutrition through nasogastric tube.
45476488|NCT03579862|Other|Blood Draw|
45476489|NCT05670041|Behavioral|Intensified follow-up|Early, intensified follow-up after discharge from TAVI-procedure.
45476490|NCT03346408|Behavioral|Questionnaire|patient (self-questionnaire) and algologist physician (questionnaire)
45685755|NCT01895764|Drug|Methotrexate|methotrexate, subcutaneous injection, 10mg per week, week -2 until week 26
45685756|NCT04756102|Other|Observation of their fetomaternal outcome|observe the fetal outcome and maternal outcome
45685757|NCT01895140|Device|Renal denervation device|
46045100|NCT02645734|Drug|bevacizumab|1.25 mg of bevacizumab is injected
46045101|NCT02645734|Drug|ziv-aflibercept 1.25 mg|1.25 mg of ziv-aflibercept is injected
46045102|NCT02645734|Drug|ziv-aflibercept 2.5mg|2.5 mg of ziv-aflibercept is injected
46045103|NCT02635594|Dietary Supplement|L-Carnitine|1000mg of L-Carnitine provided as 1475mg Carnipure® tartrate
46045104|NCT02635594|Other|Placebo|1000mg cellulose + 475mg L-tartaric acid
46045105|NCT02635906|Other|2 hours|BED REST FOR TWO HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
46045106|NCT02635906|Other|4 hours|BED REST FOR FOUR HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
46045107|NCT00652210|Other|Multiphoton microscopy|Use of multiphoton microscopy to diagnose cancer
45350308|NCT05205213|Other|Surgical Technique (lateral retromuscular preperitoneal)|Open abdominal wall repair through the previous lateral incision for L3-L4 Incisional hernias
45350309|NCT03083808|Drug|Pembrolizumab|"Pembrolizumab 200mg IV every 21 days~+~Physician's choice chemotherapy with one of the following every 21 days:~Docetaxel 75mg/m2 IV~Pemetrexed 500mg/m2 IV (non-squamous only)~Gemcitabine 1000mg/m2 IV on days 1 and 8"
45350310|NCT05205057|Other|Saliva|Unstimulated whole saliva is collected
45350311|NCT00874653|Drug|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for intrauterine treatment of menorrhagia
45350312|NCT00369577|Drug|Inhaled Placebo|Inhaled Placebo, single dose
45350313|NCT00369577|Drug|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, single dose
45350314|NCT00369577|Drug|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, single dose
45350315|NCT02559336|Other|Integrated palliative oncology care|Integrated palliative care and oncology care for advanced cancer patients who have an unplanned admission to hospital
45350316|NCT00879957|Drug|heparin|Heparin will be added to PICC infusions at a dose of 0.5 units heparin per milliliter of intravenous fluid/parenteral nutrition.
45350317|NCT00879957|Drug|No heparin|In the no heparin group, the subjects will not receive heparin as an additive to their PICC infusions.
45685758|NCT02138734|Biological|BCG+N-803|"BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG+N-803 for 3 consecutive weeks at 3, 6, 12, & 18 months.~An additional 6 week re-induction of BCG+N-803 for patients with eligible disease at 3 months in phase IIb is included."
45841879|NCT04193371|Other|Sham acupuncture|In the sham acupuncture protocol, 2 needles were inserted superficially to a depth of less than 5 mm, 1 in each shoulder and 1 in each upper arm at nonacupuncture and non-meridian points, and then, 4 needles were attached to electrodes and the stimulator was turned on to mimic the active acupuncture but with zero intensity, no electrical stimulation. They also received the treatment for 30 minutes three times a week and a maximum of 48 treatments.
45847602|NCT04040790|Device|Scleral contact lens without a passive artificial iris|Participants wear a scleral contact lens without a passive artificial iris (Design A) on the dominant eye to perform the baseline visual performance assessment
45350318|NCT04400214|Behavioral|Food Allergy Superheroes Training (FAST) Program|The primary aim of the FAST intervention is to 1) increase the young child's understanding of food allergies (FA) and 2) promote-adherence to FA safety guidelines through active skills training. We will achieve this aim through the use of educational materials (session 1) and a developmentally-tailored skills training intervention (session 2-5). Core components embedded within each skill straining session include instructions, modeling, rehearsal, and reinforcement/corrective feedback. The young child and their parent/caregiver will be present for the entirety of all sessions; however, all intervention materials (i.e., educational content, skills training components) are designed with the young child as the primary focal point of interest. All children will be rewarded with a small toy (<$5 value) at the end of each successfully completed session.
45350319|NCT04400214|Other|Food Allergy Knowledge Intervention|"The primary aim of the FAK intervention is to increase the young child's understanding of FAs including prevalence, symptoms, and management strategies among other topics. We will achieve this aim through the use of educational materials targeting knowledge acquisition through a variety of didactic materials made freely available through the Food Allergy Research Education (FARE) website (www.foodallergy.org). More specifically, we will employ information embedded within the Food Allergy 101 segment of the FARE website. The young child and their parent/caregiver will be present for the entirety of all sessions; however, all intervention materials are designed with the young child as the primary focal point of interest. All children will be rewarded with a small toy (<$5 value) at the end of each successfully completed session. All FAK sessions will occur within the child's home and will include informational handouts relevant to the day's session."
45350320|NCT00874809|Device|CGMS with an insulin pump using rapid acting insulin|To determine basal changes subject will wear a CGMS with an insulin pump infusing rapid acting insulin
45685759|NCT02138734|Biological|BCG|"BCG will be administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG for 3 consecutive weeks at 3, 6, 12, & 18 months.~An additional 6 week re-induction of BCG for patients with eligible disease at 3 months in phase IIb is included."
45476491|NCT04500496|Drug|INH|3 tablet of INH inserted by the patient 12 hours before the scheduled office hysteroscopy
45350321|NCT02534155|Device|MitraClip®|one or more (if needed) MitraClip® devices are placed on the leaflets of the mitral valve during catheterisation in a catheter laboratory
45350322|NCT02534155|Procedure|Mitral valve Surgery|Repair or replace mitral valve
45350323|NCT04376268|Drug|Chlorhexidine mouthwash|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
45476492|NCT04500496|Drug|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
45476493|NCT01199627|Drug|A|"Group A: 1st dose 15mg/kg of TXA (tranexamic acid) in 100ml saline 0.9% after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
45476494|NCT01199627|Drug|B|"Group B: 1st dose: 10mg/kg of TXA(tranexamic acid) in 100ml 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes of 10mg/kg of TXA in 100ml saline 0.9% at three hours after the first administration."
45476495|NCT01199627|Drug|C|"Group C: 1st dose: intravenous infusion over 10 minutes in 100ml of 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
45476496|NCT02512744|Procedure|Decannulation protocol.|Comparison of two different decannulation protocols: one protocol based on capping trial tolerance to decide when to decannulate vs. protocol based on suctioning frequency of respiratory secretions to decide when to decannulate (criteria: ≤2 aspirations every 8 h along 24 consecutive hours).
45476497|NCT02512744|Device|High flow conditioned oxygen therapy|High flow conditioned oxygen therapy will be applied during all study period through tracheal cannula in the experimental arm (suctioning frequency based protocol) and during periods out of capping trials in the control arm (capping trials based protocol).
45476498|NCT03146507|Radiation|Ultrasound|ultrasound assessment of gestational age, amniotic fluid index, and fetal weight
45476499|NCT03146507|Radiation|Doppler ultrasound|Umbilical artery and Middle cerebral artery Doppler blood flow assesment
45476500|NCT03146507|Radiation|Fetal echocardiography|The cardiac output (ratio between right side cardiac outputs to left side cardiac output) was calculated
45476501|NCT02512588|Drug|BTD-001|
45476502|NCT02512588|Drug|Placebo|
45476503|NCT01566617|Other|Standard care and Pharmaceutical care|Pharmaceutical care is the direct interaction between the pharmacist and the drug's users in order to improve the therapeutic compliance among outpatients and promote adequate pharmacotherapeutic follow-up.
45476504|NCT01566617|Other|Standard care|These patients will only receive standard care, with out follow-up by the pharmacist
45476505|NCT02516254|Dietary Supplement|fortified bread|50 g of fortified bread + placebo daily
45476506|NCT02516254|Dietary Supplement|supplement|vitamin D supplement+ plain bread
45476507|NCT02516254|Dietary Supplement|placebo|plain bread+placebo
45476508|NCT02516176|Behavioral|treadmill training|Paretic leg step training while standing on a treadmill sideways and responding to treadmill being turned on suddenly.
45476509|NCT04810169|Device|Smart inhaler|"Automatic record (number of actuations and their timing) of the use of the emergency treatment through the smart inhaler~Questionnaire sent to the parents at each use of the smart inhaler to get information regarding the reason of use and the efficacy of the treatment given"
45476510|NCT01199081|Drug|Dronedarone|"Pharmaceutical form: tablet~Route of administration: oral (together with meal)~Dose regimen: 400 mg twice daily"
45476511|NCT02512354|Other|Sample of a fragment of fetal tissue|
45476512|NCT02512354|Other|Parent's blood samples|
45476513|NCT02516020|Drug|Global|Embryos are cultured in single step culture from day 1 to day 5
45476514|NCT02516020|Drug|Origio|Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast)
45476515|NCT03841955|Device|PICC with high pressure tolerance|Subjects signed informed consent, meet the inclusion criteria and did not meet the exclusion criteria, and were randomly admitted to the experimental group and given the intervention.
45476516|NCT03841955|Device|rontine central venous catheter|Subjects signed informed consent, meet the inclusion criteria and did not meet the exclusion criteria, and were randomly admitted to the control group and given the intervention.
45841880|NCT04193371|Other|Lifestyle management|"All women will receive lifestyle management before randomization after baseline measurements. The lifestyle management assisted by a PCOS lifestyle management system (Invention patent, ZL 2015 1 0500978.9).~All participants will get a step-counter for daily use and physical exercise diary for daily reporting of exercise: number of steps, type of activity, intensity and time (minutes). Once a week each participant receive a SMS in which they report the activity during the week."
45841881|NCT04190550|Drug|Cytarabine|Given IV
45350324|NCT04376268|Procedure|Chlorhexidine mouthwash with boric acid (0.1%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
45841882|NCT04190550|Drug|Idarubicin Hydrochloride|Given IV
45841883|NCT04190550|Drug|Navtemadlin|Given PO
45841884|NCT04169074|Drug|Abemaciclib|Treatment will consist of a single neoadjuvant cycle of 10-21 days (+7 days). Abemaciclib will be administered from days 1-21 in both arms. Abemaciclib may be continued for an additional 7 days, or up to 28 days, for delays in planned surgery.
45476517|NCT04500886|Drug|PEG-rhG-CSF|PEG-rhG-CSF is a sustained-duration form of rhG-CSF, a recombinant methionyl form of human granulocyte colony-stimulating factor (G-CSF), similar to rhG-CSF, PEG-rhG-CSF increases the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils, resulting in dose-dependent increases in neutrophils.
45350325|NCT04376268|Procedure|Chlorhexidine mouthwash with boric acid (0.5%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
45476518|NCT04500886|Drug|rhG-CSF|rhG-CSF can increase the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils.
45476519|NCT04989335|Drug|Bisantrene|Combined escalated dose chemotherapy
45476520|NCT04989335|Drug|Fludarabine|Combined escalated dose chemotherapy
45476521|NCT04989335|Drug|Clofarabine|Combined escalated dose chemotherapy
45476522|NCT03346018|Diagnostic Test|Analysis of aqueous humor and plasma samples|"The collected samples will be analyzed as follow:~Determination of the concentration of various cytokines, chemokines and groeth factors in aqueous humor and in the plasma.~Analysis of the mononuclear cells ( T helper lymphocytes CD3+ and CD4+, T cytotoxic lymphocytes CD3+ CD8+, B lymphocytes CD19+, Natural killer lymphocytes CD56+ and CD3- and monocytes CD14+) present in the aqueous humor by cytofluorimetry.~Evaluation of the presence of anti-human HSP70 antibodies in plasma samples by Western blot immunoprecipitation assays.~Whenever possible (adequate number of cells), in vitro stimulation of mononuclear cells presence in aqueous humor with epitopes from tuberculosis mycobacterium antigens and the analysis of cytokines production in the supernatants."
45841885|NCT04158739|Drug|Cytarabine|Given IT
45841886|NCT04158739|Biological|Flotetuzumab|Given IV
45841887|NCT04148105|Drug|Cilostazol 100 MG|The addition of 100 mg cilostazol, twice daily for 14 days, to the standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
45841888|NCT04148105|Other|Placebo|The standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
45841889|NCT04139122|Drug|SJP-0132|SJP-0132 is administered as an eye drop
45841890|NCT04139122|Drug|Placebo|Placebo is administered as an eye drop
45841891|NCT04121676|Drug|AGEN2373|An Anti-CD137 Monoclonal Antibody
45841892|NCT04121676|Drug|Botensilimab|Anti-CTLA-4 Monoclonal Antibody
45841893|NCT04101565|Behavioral|Text4Father|Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of age.
45841894|NCT04092530|Behavioral|LINCC intervention - enable co-schedule feature|Clinics will offer postpartum contraception appointments earlier and the opportunity to co-schedule these appointments with their infant's next well-baby visit
45841895|NCT04067518|Biological|SHP674|SHP674: powder for solution for injection, IV (administered by 1 to 2 hours of drip infusion), dose determination : if BSA ≥0.6 m^2: 2500 IU/m^2 every 14 days if BSA <0.6 m^2: 82.5 IU/kg every 14 days
45841896|NCT04033419|Drug|Memantine|"memantine dose~Week 1: 5 mg dose once daily~Week 2: 5 mg dose twice daily~Week 3: 5 mg each morning/10 mg each evening~Week 4 through the end of Chemotherapy: 10 mg dose twice daily~Total duration: 12 - 26 weeks (depending on chemotherapy regimen)"
45841897|NCT04026607|Dietary Supplement|Protein Supplementation|Participants will continue to ingest the standardized diet; however, supplements will be consumed twice daily (25g per serving x 2 servings/day or 50g supplemental protein/day)
45841898|NCT04019197|Drug|Semaglutide Injectable Product|semaglutide subcutaneous injection
45841899|NCT04019197|Drug|Placebo|placebo injection
46045108|NCT01133522|Biological|Evolocumab|Administered by subcutaneous injection
45841900|NCT04014283|Dietary Supplement|Selenium supplementation or placebo treatment|Patients from this group will receive selenium supplement to achieve optimal selenium level
46045109|NCT01133522|Biological|Placebo|Administered by subcutaneous injection
46045110|NCT04164394|Other|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
46045111|NCT04164394|Dietary Supplement|I31 Probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
46045112|NCT01133288|Device|Yulex gloves|Study participants will be asked to wear Yulex gloves for routine bowel and bladder care (~30 minutes per day) over a 3 month period.
45841901|NCT04014283|Other|Diet modification|Patients from this group will have modified diet over the course of the study. Diet modification is aimed to lower selenium concentration in blood.
45841902|NCT04014283|Other|Selenium supplementation or placebo treatment and diet modification|In this group patients will receive supplement, placebo or diet modification. The goal is to raise selenium concentration in blood
45841903|NCT04013542|Biological|Ipilimumab|Given IV
45841904|NCT04013542|Biological|Nivolumab|Given IV
45841905|NCT04013542|Radiation|Radiation Therapy|Undergo radiation therapy
45841906|NCT04009681|Drug|THOR-707|Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration
45841907|NCT04009681|Drug|Checkpoint inhibitor|Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration
45841908|NCT04009681|Drug|anti-EGFR antibody|Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration
46045113|NCT00682318|Drug|Fish Oil|"Part 1.1: Dose of 9.3 g/day EPA plus 7.5 g/day DHA;~Part 2a (run-in phase): Dose of 1 time 2 capsules per day of Lovaza (total of 1.7 g/d ω-3 PUFA consisting of 930 mg/day EPA and 750 mg/day DHA) for 29±1 days;~Part 2a (study arm): Dose of 3 times 4 capsules per day of Lovaza (total of 10.1 g/d ω-3 PUFA consisting of 5580 mg/day EPA and 4500 mg/day DHA) for 29±1 days"
46045114|NCT00682318|Dietary Supplement|Safflower Oil|Part 2a: (Study Arm): Omega-6 polyunsaturated fatty acids 3 times 4 capsules per day (total of 10.2 g/d ω-6 PUFA) for 29±1 days
46045115|NCT00682318|Dietary Supplement|Ethanol|"Part 1 & Part 1.1:~Dose of 0.9 g/kg body weight 98% alcohol solution~Part 2a:~Doses of 0.4 and 0.9 g/kg body weight 98% alcohol solution and a control placebo drinking solution~Part 2b, Part 3:~Doses of 0.4, 0.6 and 0.9 g/kg body weight 98% alcohol solution"
45841909|NCT04000529|Drug|TNO155|Capsule
45841910|NCT04000529|Drug|Spartalizumab|Concentrate for solution for infusion
45841911|NCT04000529|Drug|Ribociclib|Capsule and tablet
45841912|NCT03990610|Procedure|Mammoplasty|Undergo standard of care breast reconstructive surgery
45841913|NCT03990610|Procedure|Vascularized Lymph Node Transfer|Undergo vascularized lymph node transfer
45841914|NCT04257578|Drug|Acalabrutinib|Given PO
45841915|NCT04257578|Biological|Axicabtagene Ciloleucel|Given IV
45841916|NCT03970746|Biological|PDC*lung01|PDC*lung01 includes, in similar proportion, seven active agents, made of irradiated human plasmacytoid dendritic cells (PDC) loaded separately with a distinct synthetic peptide encoded by a lung tumor antigen, namely NY-ESO-1, MAGE-A3, MAGEA4, Multi-MAGE (an epitope common to several MAGE-A antigens), SURVIVN, MUC1 or a peptide derived from the Melan-A antigen.
45841917|NCT03970746|Drug|Keytruda Injectable Product|The intention and decision to prescribe the anti-PD-1 monotherapy as SoC (TPS≥50%) must have been made by the investigator before and regardless of the patient's participation in the study.
45841918|NCT03970746|Drug|Alimta Injectable Product|For patients with non-squamous NSCLC included in Cohorts A1 and A2, maintenance by pemetrexed (IV every 3 weeks) can be administered according to SoC.
45841919|NCT03959098|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
45847603|NCT04040790|Device|Scleral contact lens with a passive artificial iris with low contrast (<1:5)|Participants wear a scleral contact lens with a low contrast (<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment
46045116|NCT00682318|Dietary Supplement|Omega-3 polyunsaturated fatty acids|"Part 2b:~Alimentary diet delivering ≈ 500 mg/day EPA/DHA,or Alimentary diet delivering ≈ 900-1000 mg/day EPA/DHA, or Alimentary diet delivering ≈ 1500-1800 mg/day EPA/DHA;~Part 3:~Alimentary diet delivering EPA/DHA in a quantity to be determined by Part 2b."
46045117|NCT00682318|Dietary Supplement|Omega-6 polyunsaturated fatty acid|"Part 2b:~Control omega-6 fatty acid alimentary diet (<130 mg/day EPA/DHA)"
45350326|NCT04376268|Procedure|Chlorhexidine mouthwash with boric acid (1%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
45350327|NCT04376268|Procedure|Chlorhexidine mouthwash with boric acid (1.5%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
46045118|NCT02881892|Other|Measure plasma and dialysate level of IL-6, procalcitonin and VEGF|correlation between plasma levels, dialysate appearance rate of VEGF, inflammatory cytokines (IL- 6, procalcitonin) and PSTR, dialysis adequacy in CAPD patients.
45350328|NCT04376268|Procedure|Chlorhexidine mouthwash with boric acid (2%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
45685760|NCT01894360|Drug|Belimumab 200 mg/mL|Clear to opalescent, colorless to pale yellow sterile solution sterile solution for SC injection in a single-use liquid formulation of Belimumab 200 mg/mL will be supplied in 1mL long glass prefilled syringe or autoinjector device.
45685761|NCT01483599|Drug|CNTO 1959 (5 mg)|Subcutaneous (SC) injections
45685762|NCT01483599|Drug|CNTO 1959 (15 mg)|SC injections
45685763|NCT01483599|Drug|CNTO 1959 (50 mg)|SC injections
45685764|NCT01483599|Drug|CNTO 1959 (100 mg)|SC injections
45685765|NCT01483599|Drug|CNTO 1959 (200 mg)|SC injections
45841920|NCT03959098|Procedure|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving highvelocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
46045119|NCT02635516|Device|Near-Infrared Phototherapy|"The In Light Wellness Systems Near-Infrared Phototherapy Device (manufactured by In Light Wellness Systems, Inc.) contains alternating rows of 402 red (640 nm) and infrared (880 nm) light-emitting diodes embedded in 2 neoprene pads. One pad circles the skull, providing 720 Joules/min, and the other pad covers the top of the head, providing 360 joules/min. For each treatment session, the A setting on the 3-port controller is utilized, which runs approximately 6.7 min of 73 Hz, 587 Hz, and 1175 Hz in an automated sequential manner. No other interventions were utilized."
45847604|NCT04040790|Device|Scleral contact lens with a passive artificial iris with high contrast (>1:5)|Participants wear a scleral contact lens with a low contrast (<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment
46045120|NCT00655252|Drug|Everolimus|
45685766|NCT01483599|Drug|Adalimumab|SC injections
45685767|NCT01483599|Drug|Placebo|SC injections
45841921|NCT03959098|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom saline:bee venom ratio, 10,000:1) filtered for allergens will usually be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, hinchang medical co., Korea).
45476523|NCT04800029|Other|Telehealth in preventing suicide (TIPS)|The TIPS synchronous telehealth protocol will consist of (a) two-way televideo evaluation with enhanced suicide risk components, performed by a Masters-level evaluator from Community HealthLink, and (b) telephone consultation and, in some cases, televideo evaluation by a psychiatrist for patients the evaluator judges should be admitted. The primary evaluation will gather data form the ED providers, patient, and any other collateral sources available. The core of the evaluation itself will consist of Community HealthLink's existing standard adult emergency mental health evaluation, which is a semi-structured evaluation focused primarily on informing a disposition decision on whether to admit the patient to a psychiatric unit. The evaluators will use this same evaluation to guide the telehealth evaluation.
45476524|NCT04800029|Other|Modified ED-SAFE|"Half of the ED discharged patients with suicide risk will be invited to receive post-discharge telephone counseling originally developed during the Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE) study. The participant will receive three coaching/counseling calls, clustered within three months of the index visit, with some flexibility to continue beyond that if desired. These coaching calls will still follow the original structure and content from ED-SAFE, with modifications guided by study investigators."
45476525|NCT04800029|Other|Treatment as Usual (TAU)|No study related intervention, just monitoring of current practices used to provide suicide-related care in the non-intervention EDs.
45476526|NCT03345940|Drug|Fingolimod|Fingolimod is a currently approved oral DMT for the treatment of relapsing remitting MS. It modulates sphingosine-1 phosphate receptors.
45841922|NCT03959098|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be dministered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
45476527|NCT03345940|Drug|Dimethyl Fumarate|Dimethyl Fumarate is a currently approved oral DMT for the treatment of relapsing remitting MS. The mode of action comprises immunomodulatory effects and an activation of nuclear (erythroid-derived 2) related factor mediated antioxidative response pathways leading to additional cytoprotective effects.
45841923|NCT03959098|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
45841924|NCT03959098|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
45841925|NCT03959098|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
45841926|NCT03959098|Procedure|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
45841927|NCT03958006|Device|Cochlear implant|Tumor resection with cochlear implant
45841928|NCT03912233|Drug|VX-121|Tablets for oral administration.
45841929|NCT03912233|Drug|TEZ|TEZ tablet for oral administration.
46045121|NCT02645578|Device|Right median nerve stimulation|Right median nerve electrical stimulation (RMNS) is administered via a pair of lubricated one-inch square rubber surface electrodes pasted on the volar aspect of the right distal forearm over the median nerve. An electrical neuromuscular stimulator supplied trains of asymmetric biphasic pluses at an amplitude of 20 milliamps with a pulse width of 300 microseconds at 40 Hz for 20 sec/min. The RMNS treatment continues 8 hours per day for two weeks.
46045122|NCT04058626|Diagnostic Test|Transcutaneous pressure of oxygen (TcPO2)|Measurements will be taken from the dorsum of the foot using an automated machine equipped with Clark electrodes.
45350329|NCT04376268|Procedure|Chlorhexidine mouthwash with boric acid (2.5%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
45841930|NCT03912233|Drug|VX-561|Tablets for oral administration.
45841931|NCT03912233|Drug|TEZ/IVA|Fixed-dose combination tablets for oral administration.
45841932|NCT03912233|Drug|IVA|Tablets for oral administration.
45841933|NCT03912233|Drug|Placebo|Placebos matched to VX-121, TEZ, and VX-561 for oral administration.
45841934|NCT03895489|Device|Journey II|Smith and Nephew Richards (SNR) Journey II Knee prosthesis
45841935|NCT03895489|Device|Stryker|Stryker Triathlon Total Knee prosthesis
45841936|NCT03895489|Device|Zimmer|Zimmer Persona® The Personalized Knee prosthesis
45350330|NCT04376268|Procedure|Boric acid mouthwash (2%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
45350331|NCT00880035|Device|MP3 music program listening|3 days with two 1 hour periods of headset music listening (1 day on, 1 day wash-out, 1 day off)
45350332|NCT00761436|Biological|Spheramine (BAY86-5280)|Stereotactic Intrastriatal Implantation
45350333|NCT00880113|Procedure|Non-contrast CT, CT-perfusion and CT-angiography|Included patients will undergo one additional combined CT-scan (NCCT, CTP and CTA) on day 3 (+/- 2 days).
45350334|NCT00880347|Device|Blood sampling|Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)
45350335|NCT00874965|Device|Electrostimulation|50Hz; 0.4 ms; 30 min; 5 times / week
45841937|NCT03888105|Drug|Odronextamab|Administered by intravenous (IV) infusion
45350336|NCT00874965|Device|Sham stimulation|30 min; 5 times / week
45350337|NCT00875199|Behavioral|contingency management|Prize-based contingency management for weight loss
45350338|NCT00875199|Behavioral|weight loss manual-guided individual therapy sessions|once weekly counseling session with research staff
45350339|NCT00875355|Drug|temozolomide|Given orally
45350340|NCT00875355|Radiation|radiation therapy|Patients undergo radiotherapy
45350341|NCT00678288|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously
45350342|NCT00678288|Drug|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously. IFN alpha-2a 3MIU FIW s.c., from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
45350343|NCT04772859|Behavioral|Online Lifestyle Intervention|"The intervention will be based on the Planet Nutrition program. This program was previously designed by the present research group and has a handbook that includes nutrition topics, framed by different behavior change strategies. The nutrition education and physical activity sessions will be offered 3 days a week, in the same 1-hour class: 30 minutes for each.~Nutrition education: presentations based on the Planet Nutrition program, a dedicated website, and the Zoom application, will be used to deliver the intervention. The website will be used to upload the nutrition materials and the recorded sessions. Participants will work on self-monitoring of different health behaviors.~Physical activity: The classes will be delivered by the Physical Activity team through the Zoom application. A website will be used to upload the recorded sessions.~Parents participation. The same website and a private Facebook group will be used to upload nutrition information once a week."
45350344|NCT04772859|Other|Control Group|They will receive one digital brochure with general information on a healthy diet, at the beginning of the program.
45350345|NCT00880659|Behavioral|Soap|Promotion of handwashing with soap
45841938|NCT03879668|Device|eIPOS|Electronic version of IPOS
45350346|NCT04038879|Diagnostic Test|MRI|MRI of the heart
45841939|NCT03847194|Behavioral|Promoting Resilience in Stress Management (PRISM)|PRISM was developed based on stress and coping theory to be a brief, disease non-specific, skills-based intervention targeting adolescent resilience resources. PRISM teaches 4 pillars of resilience including stress management, goal setting, cognitive restructuring and benefit-finding in a one-on-one training program consisting of two, 45-60 minute sessions and supported by 6-months of booster sessions and a fully developed digital app for practice and tracking. A family session follows the individual sessions and was designed for the adolescent to communicate to his/her caregiver(s) the skills learned, and how the caregiver(s) could best support ongoing practice.
45841940|NCT03842865|Biological|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms (TGFβ-1 and TGFβ-2).
45841941|NCT03834870|Behavioral|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
45841942|NCT03834519|Biological|Pembrolizumab|IV infusion
45841943|NCT03834519|Drug|Olaparib|Oral tablets
45350347|NCT00880815|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo ASCT
45350348|NCT00880815|Biological|Anti-Thymocyte Globulin|Given IV
45350349|NCT00880815|Drug|Bendamustine|Given IV
45350350|NCT00880815|Biological|Filgrastim|Given IV
45350351|NCT00880815|Drug|Fludarabine|Given IV
45350352|NCT00880815|Drug|Methotrexate|Given IV
45350353|NCT00880815|Biological|Rituximab|Given IV
45350354|NCT00880815|Drug|Tacrolimus|Given IV and PO
45476528|NCT05670353|Drug|Cannabis Derivatives|CBD 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks
45476529|NCT05670353|Drug|Placebo|Placebo 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks
45841944|NCT03834519|Drug|Abiraterone acetate|Oral tablets
45841945|NCT03834519|Drug|Prednisone|Oral tablets
45350355|NCT00369343|Drug|Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)|DVS-SR 50-200mg, daily (QD), tablet form, treatment period up to 34 weeks
45350356|NCT00369343|Drug|Placebo|Placebo, daily (QD), tablet form, treatment period up to 8 weeks
45476530|NCT05670353|Drug|Hormonal Contraceptive Agents|All participants will be given hormonal contraceptive.
45350357|NCT00880971|Radiation|Postoperative 3D-CRT or IMRT|Postoperative radiotherapy using 3D-CRT or IMRT techniques, 2 Gy per fraction, total 25 fractions (50Gy) over 5 weeks.
45350358|NCT03992599|Procedure|Laparoscopic modified complete mesocolic excision|First, complete kocherization may be required to clear possible tumor spread if the tumor is infiltrating or adhering to the duodenum or perinephric fat tissue. Second, if the tumor is locally advanced, the entire prerenal soft tissue behind Gerota's fascia may need to be cleared, especially for tumors growing toward the posterior. The third difference of mCME with the conventional CME involves the tailored resection of the mesocolon and ileal mesentery according to tumor location. After identifying the root of the middle colic artery, the site of the vascular ligation depends on the location of the tumor. When the tumor is located in the cecum and ascending colon, only the right branch of the middle colic artery is ligated. If the tumor was present in these latter sites, the root of the middle colic artery is ligated.
45350359|NCT00881049|Drug|Imatinib (Gleevec)|Imatinib will be given for enrolled patients to investigate efficacy and safety
45350360|NCT00881127|Drug|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)|
45350361|NCT00881127|Drug|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
45350362|NCT00369265|Drug|Lansoprazole|Lansoprazole 30mg twice daily
45350363|NCT00369265|Dietary Supplement|Sugar pill|placebo twice daily
45350364|NCT00875745|Drug|Sorafenib-Vorinostat|Patients will be entered in successive cohorts. The first cohort will receive Sorafenib at 400 mg bid (800 mg daily) and Vorinostat at 100 mg bid (200 mg daily).
45841946|NCT03834519|Drug|Enzalutamide|Oral tablets or oral capsules
45350365|NCT00368875|Drug|vorinostat|Given orally
45476531|NCT02512120|Device|volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied VCV by Zeus®(Dräger, Germany).~- Tidal volume : 8ml/kg(ieal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
45476532|NCT02512120|Device|autoflow-volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied autoflow- VCV by Zeus®(Dräger, Germany).~- Tidal volume : 8ml/kg(ideal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
45841947|NCT03834519|Drug|Prednisolone|Oral tablets
45476533|NCT01202201|Other|Database analysis|Review and collect data from database (electronic admission database or any other applicable database of the hospital)
45841948|NCT03812302|Diagnostic Test|68-Ga HA-DOTATATE PET/CT|See arm description.
45841949|NCT03810105|Drug|Olaparib|Olaparib 300mg twice daily (600mg total daily dose)
46045123|NCT04058626|Diagnostic Test|Toe Brachial Pressure Index (TBPI)|TBPI will be measured using the photoplethysmography (PPG) method, employing an infrared sensor placed on the hallux and index finger.
46045124|NCT04058626|Diagnostic Test|Podiatry Ankle Duplex scan (PAD-scan)|Podiatry ankle duplex scan (PAD-scan) involves using an ultrasound machine to visualise the anterior and posterior tibial arteries at the ankle.
45841950|NCT03810105|Drug|Durvalumab|Durvalumab 1500mg IV monthly
45841951|NCT03781817|Drug|Intravenous Ketamine|Subject randomized to IV Ketamine arm will receive IN Normal Saline at induction. After 8 minutes subjects will receive IV Ketamine (10 mg/mL) at a dose of 1.5 mg/kg. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
45350366|NCT00368875|Drug|paclitaxel|Given IV
45350367|NCT00368875|Biological|bevacizumab|Given IV
45350368|NCT00614055|Drug|insulin degludec/insulin aspart|Formulation 1: Treat-to-target dose titration scheme, injection s.c., once daily
45350369|NCT00614055|Drug|insulin degludec/insulin aspart|Formulation 2: Treat-to-target dose titration scheme, injection s.c., once daily
45350370|NCT00614055|Drug|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
45350371|NCT00614055|Drug|metformin|Tablets, 1500-2000 mg/day
46045125|NCT04058626|Diagnostic Test|Duplex Assist|Continuous Doppler device which gives visual display of arterial spectral waveform at the ankle.
45841952|NCT03781817|Drug|Intranasal Ketamine|Subject randomized to IN Ketamine arm will receive IN Ketamine (100 mg/mL) at a dose of 9 mg/kg at induction. After 8 minutes subjects will receive IV Normal Saline. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
45841953|NCT03757091|Device|Laryngoscopy|Undergo video laryngoscopy
45841954|NCT03757091|Procedure|Tracheal Intubation|Undergo flexible scope intubation
45841955|NCT03732352|Other|Fludeoxyglucose F-18|Given IV
45841956|NCT03732352|Drug|Osimertinib|Given PO
46045126|NCT04058626|Diagnostic Test|Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the DPA and PTA.
46045127|NCT00883090|Biological|FXIII Concentrate (Human)|Subjects will receive approximately 40 U/kg of FXIII every 28 days for 3 doses administered as a bolus intravenous (IV) injection at approximately 250 U/minute.
45350372|NCT01051141|Behavioral|Computer-delivered Brief Intervention (CBI)|"The multimedia, interactive CBI condition will be delivered using touch-screen tablet computers with audio delivered via headphones. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
45350373|NCT01051141|Behavioral|Intervener-delivered Brief Intervention (IBI)|"The IBI condition will be delivered by a master's-level clinician with the aid of graphics. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
45350374|NCT01051141|Behavioral|Adapted Motivational Enhancement Therapy (AMET)|The AMET session will have a similar general outline (~45 minutes) to the BI in the ED, including a review of participants' goals and values, alcohol use and consequences, decisional balance exercises, and change plan.
45350375|NCT04040127|Biological|Cord blood stem cells|Umbilical cords are collected from eligible donors at the time of delivery and transported to the processing facility on ice (2-8℃) in Dulbecco's Modified Eagle Media (DMEM). Cords are processed immediately under aseptic conditions and MSCs are collected for culture. Culture is maintained this way until the target number of cells has been reached, at which point passaged cells are suspended in Stem Cellbanker (Amsbio, Cambridge, MA) and frozen at -80℃.
45350376|NCT04040127|Other|Saline solution|saline solution used to rinse the canal.
45350377|NCT04039971|Procedure|ACL Reconstruction|Surgical techniques
45350378|NCT00613821|Drug|Lidocaine|5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
45350379|NCT00613821|Drug|Lidocaine|Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
45476534|NCT03345862|Behavioral|non-pharmacological multicomponent|Following the proposal of Nicholson & Shellman, (2013) collected in its CARELINK program, an intervention is proposed that includes: 6 sessions at home [30-60 minutes] for 16 weeks (1 fortnightly session) and 5 telephone sessions [20 min.] That will be intercalated (in the 16 weeks) depending on the particular characteristics of each person. The first visit, aimed at defining objectives and creating a relationship of trust for future visits.
45350380|NCT04038723|Behavioral|High-intensity interval training|Cardiac patients have completed 36 times of exercise training with the exercise frequency of 2-3 times per week. Subjects performed five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak after the warm-up period. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak.
45350381|NCT00882765|Dietary Supplement|genistein|Given orally
45350382|NCT04543695|Combination Product|Concurrent Chemoradiotherapy|"Radiotherapy:~50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d"
45350383|NCT04543695|Drug|XELOX|"Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles.~6 courses，3 weeks per course"
45350384|NCT04543695|Drug|mFOLFOX|Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 9 cycles.
45350385|NCT04543695|Procedure|TME|Total mesorectal excision
45476535|NCT01199159|Drug|Misoprostol|400mcg misoprostol given sublingually 30 minutes before total abdominal hysterectomy
45350386|NCT00548548|Drug|Bevacizumab|Intravenous bevacizumab 7.5 mg/kg once every 3 weeks, given until disease progression or unmanageable toxicity.
45476536|NCT01199159|Drug|Vitamin B 6|20mg vitamin B6 given sublingually 30 minutes before total abdominal hysterectomy
45350387|NCT00548548|Drug|Capecitabine|Oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, given until disease progression or unmanageable toxicity.
45350388|NCT00548548|Drug|Cisplatin|Cisplatin 80 mg/m˄2 as a 2 hr intravenous infusion with hyper-hydration and pre-medication (steroids and anti-emetics), given every 3 weeks for a maximum of 6 cycles or until disease progression or unmanageable toxicity.
45350389|NCT00548548|Drug|Placebo|Intravenous placebo every 3 weeks, given until disease progression or unmanageable toxicity.
45476537|NCT05669963|Drug|lactoferrin|"study grop receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotin).~And another group not reciving lactoferrin.(control group) During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month."
45476538|NCT02507440|Drug|Lidocaine|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
45476539|NCT02507440|Drug|Placebo|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
45350390|NCT00548548|Drug|5-fluorouracil|For participants with difficulty swallowing, malabsorption, or other conditions that could affect intake of oral capecitabine medication, 5-fluorouracil was administered instead, at a dose of 800 mg/m˄2/day as a continuous intravenous infusion over 5 days (days 1 to 5 of each cycle), every 3 weeks.
45841957|NCT03732352|Procedure|Positron Emission Tomography|Undergo fludeoxyglucose F-18 PET scan
45350391|NCT00613509|Biological|ALVAC(2) Melanoma multi-antigen therapeutic vaccine|0.5 mL, 2 cycles
45350392|NCT00613509|Biological|Intron A, Interferon alpha -2b|0.5 mL, 5 times per week for 4 weeks
45350393|NCT00881439|Drug|Aliskiren|Oral, 300 mg, once daily, 6 months
45350394|NCT00881439|Drug|Placebo|Matching Placebo once daily, 6 months
45350395|NCT00881517|Drug|HCMV-specific hyperimmune globulin (Cytotect®)|100U (2.0ml)/Kg i.v. every 4 weeks up to 38 weeks' gestation or HCMV-positive amniocentesis or pregnancy termination.
45350396|NCT00881517|Drug|Isotonic solution of sodium chloride (placebo)|2.0ml/Kg i.v. every 4 weeks until 38 weeks'gestation or HCMV-positive amniocentesis or pregnancy termination
45350397|NCT00881595|Drug|Chemoradiotherapy Temozolomide|Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks.Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
45350398|NCT00881595|Radiation|Proton therapy|50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
45350399|NCT00881595|Procedure|Proton Chemoradiotherapy followed by surgery|Proton Chemoradiotherapy followed by surgery. Resection of tumor at 4-6 weeks post-treatment.
45841958|NCT03729648|Behavioral|Expressive Arts Therapy|The intervention brings together the strengths of different art modalities, such as visual art, music, movement, dance, drama and writing to assist reflect and response in individuals to their personal issues. Such variety of art forms multiplies the avenues by which a person in therapy may seek meaning, clarity, insight and healing.
45476540|NCT02507440|Drug|Propofol|All patients will receive intravenous propofol as anesthesia for EGD
45841959|NCT03707938|Drug|Brigatinib|Given PO
45841960|NCT03707938|Procedure|Local Consolidation Therapy|Undergo local consolidative therapy
45350400|NCT00883155|Drug|Bupropion HCl 100 mg Tablets (Invamed Inc.)|
45350401|NCT00883155|Drug|Wellbutrin 100 mg Tablets (Glaxo Wellcome)|
45350402|NCT01505062|Drug|SAR421869|"Formulation: Sterile suspension for intraocular injection, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection"
45350403|NCT00881673|Drug|AL38583 Ophthalmic Solution|Topical ophthalmic
45350404|NCT00881673|Drug|Maxidex|Topical ophthalmic
45350405|NCT00881673|Drug|Vehicle|AL38583 Vehicle
45350406|NCT00881829|Device|Pulse Oximeter, Blood Pressure, Respiratory Rate, Respiratory Gasses, Temperature|Measurement of physiological parameters.
45350407|NCT01293448|Device|Cryoballoon Ablation|"Device: CryoBalloon Ablation System(TM) C2 Therapeutics Inc. received FDA market clearance for the CryoBalloon Ablation System on September 29, 2010. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications. (K101825)"
45476541|NCT04962659|Behavioral|Mindfulness-Based Music and Songwriting|The Mindfulness-Based Music and Songwriting (MBMS) program involves up to 8 weekly sessions (~1 hour each) delivered via telehealth. During sessions, the participant works with a therapist (e.g., board-certified music therapist) to learn and apply mindfulness practices via music-based meditations and mindful songwriting. Supported by the therapist, participants write two songs during the program.
45841961|NCT03706690|Drug|Durvalumab|Durvalumab 1500 mg every 4 weeks [q4w] intravenously [iv] until clinical progression/ deterioration or confirmed radiological progression.
45841962|NCT03706690|Other|Placebo|Matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression
45841963|NCT03689868|Behavioral|Virtual Reality|Virtual Reality headset with calming scenery
45841964|NCT03644342|Drug|Nirapaib|(see treatment regimen and method of treatment assignment)
45841965|NCT03636451|Drug|40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block|Women undergoing D&C in the first trimester for either surgical abortion or miscarriage management will receive 40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
45841966|NCT03636451|Drug|20cc 1% lidocaine with 2 units of vasopressin paracervical block|Women undergoing D&C in the first trimester for either surgical abortion or miscarriage management will be randomly assigned to receive 20cc 1% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
45841967|NCT03628677|Drug|Domvanalimab|Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT
45350408|NCT04638465|Procedure|Transoral robotic surgery|Transoral resection with neck dissection
45350409|NCT04638465|Drug|Cisplatin - Dose Level 1|6 Cycles of 40 mg/m2
45350410|NCT04638465|Drug|Cisplatin - Dose Level 2|7 Cycles of 40 mg/m2
45476542|NCT02507362|Radiation|adjusted corneal collagen cross-linking|UV-A irradiation for 7 minutes
45476543|NCT02507362|Radiation|accelerated corneal collagen cross-linking|UV-A irradiation for 10 minutes
45350411|NCT04638465|Radiation|Dose Level 1|60 Gy/6 weeks - 2 Gy/fraction, 5 fractions/week
45350412|NCT04638465|Radiation|Dose Level 2|70 Gy/7 weeks - 2 Gy/fraction, 5 fractions/week
45350413|NCT00961714|Device|OsseoFix Spinal Fracture Reduction System|All enrolled into the study will be receiving the OsseoFix if meet inclusion / exclusion criteria.
45350414|NCT00881907|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
45476544|NCT02507362|Drug|riboflavin 0.1% combined with dextran 20 %|after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation
45476545|NCT02507362|Procedure|epithelial debridement|corneal epithelium will be removed by a cottons swab
45841968|NCT03628677|Drug|Zimberelimab|Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
45476546|NCT04958369|Device|Ultrasound-guided axillary venous access|Venous access is obtained through ultrasound-guided axillary vein puncture and Seldinger technique.
45476547|NCT04958369|Device|Cephalic venous access|Venous access is obtained through cephalic vein cut-down.
45476548|NCT03196284|Drug|Concizumab|A loading dose of 0.5 mg/kg will be given as the first dose, followed by 0.15 mg/kg (with potential stepwise dose escalation to 0.25 mg/kg) administered daily s.c. (subcutaneously, under the skin). Treatment duration is 24 weeks in the main trial, and up to 52 weeks in the extension phase
45350415|NCT00881907|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
45476549|NCT03196284|Drug|Eptacog alfa|A single dose of 90 μg/kg eptacog alfa one week after dosing with concizumab. On-demand treatment during bleeding episodes in both treatment arms
45350416|NCT00881907|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
45841969|NCT03576989|Dietary Supplement|EPA+DHA|EPA+DHA are the n-3 polyunsaturated fatty acids contained in fish oil
45476550|NCT05640830|Drug|trastuzumab, bevacizumab with paclitaxel (triple combination)|Trastuzumab 4 mg/kg Day 1, 15 Bevacizumab 5 mg/kg Day 1, 15 Paclitaxel 80 mg/m2 Day 1, 8, 15 every 4 weeks
45476551|NCT02512198|Behavioral|Prescription Data Feedback to GP Practices|GP practices will be randomly assigned to receive reports on one of the two topics. They will get these three times at six-monthly intervals. Within the feedback, alongside the patient-level analysis, there will be action-orientated messages to guide the GP practice.
45476552|NCT05638412|Behavioral|JASPER|JASPER is a therapist and caregiver-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes caregivers as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
45476553|NCT05638412|Behavioral|Psychoeducational Curriculum|The psychoeducational modules will include written information about child development, communication and social interaction skills, behavioral principles for managing challenging behavior and strategies for teaching new skills. No direct caregiver-child mediated coaching will be provided. The material provided will be similar to what a pediatrician or developmental specialist may review as a part of routine care.
45476554|NCT04938947|Device|Blood Flow Restriction Cuffs|This intervention consists of inflatable cuffs that are designed to partially occlude veinous blood return from the lower extremities during resistance training.
45841970|NCT03576989|Other|placebo|placebo contains mineral oil
45841971|NCT03546062|Other|patients treated by HTx|From removed and frozen hearts, authors will conduct a tissue and molecular analysis of possible mechanisms T2DM linked.
45841972|NCT03539952|Drug|Penicillamine (D1-W12)|Penicillamine during baseline period (D1-W12)
45841973|NCT03539952|Drug|TETA 4HCL (W12-60)|TETA 4HCL during post randomisation and 1st extension period (W12-W60)
45841974|NCT03539952|Drug|Penicillamine (W12-W60)|Penicillamine during rondomisation and 1st extension period period (W12-W60)
45841975|NCT03539952|Drug|TETA 4HCL (60-<W108)|TETA 4HCL during 2nd extension period (W60-<W108)
45841976|NCT03504163|Drug|Pembrolizumab (MK-3475)|Pembrolizumab (MK-3475) will be administered as a 400 mg intravenous (IV) infusion at 6- week intervals for 9 doses over a 48-week.
45841977|NCT03504163|Drug|Bacillus Calmette-Guérin (BCG)|Intravesical BCG will be administrated once per week over a 6-week period as induction therapy, followed by maintenance BCG consistent with standard clinical practice
45350417|NCT04487925|Drug|A single Gonadotropin-Releasing Hormone (GnRH) antagonist corifollitropin alfa (CFA) stimulation|CFA will be administered in combination with Follitropin beta.
45350418|NCT04487925|Drug|Up to three modified natural cycles with Follitropin beta.|Follitropin beta in a low dose will be given.
45350419|NCT00547300|Drug|Metoprolol ER|Metoprolol ER once daily, oral administration
45350420|NCT00547300|Drug|Nebivolol|Nebivolol once daily, oral administration
45350421|NCT04386759|Other|Cohort|None. Only implementation of a cohort with data collection via individual self-questionnaires and administrative services for contextual data.
45350422|NCT00958516|Drug|LEO 29102 cream|LEO 29102 cream in different doses and the cream vehicle
45350423|NCT00881985|Device|continuous positive airway pressure|Use CPAP whenever sleep
45350424|NCT00962572|Behavioral|Patient management|"Aggressive patient management will be implemented by a corps of patient manager volunteers backed by a transportation, nutrition, and social services network. The social services professionals will work with the volunteers to establish the support needed for each patient. The volunteer managers will in turn constantly monitor that such support is addressing the patient's ability to be treated. Access to sponsored housing will be coordinated. Nutritional support will be coordinated by the Dietary department and will consist of counseling, and supplements when necessary. Provision of supplemental feeding for housed patients will be arranged."
45350425|NCT00612807|Behavioral|Weekly marital therapy|Weekly marital therapy for 6 months.
45350426|NCT00612807|Drug|As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.|"Study doctor may prescribe antidepressant medication for the treatment of depression. Medications will be prescribed according to empirically supported guidelines outlined in the Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED Approach; Steffens, 2002).~SSRIs (daily dose of at least 20 mg for citalopram, 20 mg for fluoxetine, 100 mg for sertraline, 20 mg for paroxetine)~SNRIs (e.g., venlafaxine)~Bupropion SR (achieve dose of at least 150 mg BID)~Mirtazapine~Tricyclic antidepressants (nortriptyline with drug levels 80-120 ng/dl)~Lithium augmentation~MAOI (daily dose of at least 30 mg tranylcypromine or 45 mg of phenelzine)"
45350427|NCT00962806|Behavioral|Exercise|8 weeks of intensive exercise, 60-90 minutes 3 days each week
45476555|NCT04938947|Other|Low-Intensity Resistance Training|This intervention consists of performing low-intensity bilateral (both legs at the same time) leg extensions using 30% of a participants 1 repetition maximum (the maximum weight an individual can complete 1 repetition with, but not 2) to volitional failure.
45476556|NCT04938947|Other|High-Intensity Resistance Training|This intervention consists of performing high-intensity bilateral (both legs at the same time) leg extensions using 80% of a participants 1 repetition maximum (the maximum weight an individual can complete 1 repetition with, but not 2) to volitional failure.
45476557|NCT02507284|Drug|SRX246|
45685768|NCT05376358|Device|MoodRing App|"Adolescents and parents in the MR arm will receive instructions to download the MR app and AWARE app, customize the app, utilize an app-based self-guided onboarding, and review questions with the research team. The MR app provides the adolescent and their parent a notification to view a weekly report predicting their mood score (i.e. depression severity level similar to the Patient health questionnaire-9). The MR app will provide a library of coping strategies for adolescents and opportunities to self-track their mood.~Clinicians in the MR Arm will get access to a MR portal online. They will be able to view patients they are a provider for. The clinician will receive in-person and/or video-based training to use the portal."
45685769|NCT05376358|Other|Usual Care|Adolescents and parents in the usual care arm will receive instructions to download the AWARE app. This app will only track data and will not be interactive. Otherwise they will receive care as per routine by their healthcare provider team.
45841978|NCT03479697|Device|HIRREM|Technology
45841979|NCT03479697|Other|Continued Current Care|Continue their current clinical care.
45841980|NCT03471078|Drug|Avatrombopag|Oral avatrombopag tablet
45841981|NCT03471078|Drug|Placebo Oral Tablet|Placebo comparator tablet
45350428|NCT00962806|Behavioral|Lifestyle counseling|Baseline and final visit dietary and activity advice and weekly healthy lifestyle messages
45350429|NCT05299684|Other|EVALUATION|The level of addiction was assessed with the Smartphone Addiction Scale Short Form (SAS-SF). The posture of participants was evaluated by New York Posture Rating Chart (NYPRC), mostly usage smartphone posture, forward head and myofascial trigger points were questioned according to Simon and Travel criteria. Mann-Whitney U test Pearson's chi-squared test were used for analyzing the data.
45350430|NCT04038801|Procedure|Quadrant-wise scaling and root planning (Q-SRP)|Quadrant-wise scaling and root planing were performed by assortment of manuel periodontal curettes over four visits at 1-weekly intervals.
45350431|NCT04038801|Procedure|Full-mouth ultrasonic debridement (FMUD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts in two visits of the same day.
45476558|NCT02507284|Drug|Placebo|
45476559|NCT03636594|Other|Dance|The dance program consisted of one-hour dance classes delivered twice a week for 8 weeks. The classes featured different dance types (such as partnered and non-partnered) and genres (such as salsa, ballroom and jazz) with increasing complexity.
45476560|NCT04500262|Device|Open-tip pulsed needle biopsy (NeoNavia Biopsy System)|Ultrasound-guided biopsy using 14G open-tip pulsed biopsy needle
45476561|NCT04500262|Device|Core needle biopsy (CNB)|Ultrasound-guided biopsy using standard of care core needle biopsy
45685770|NCT01407562|Drug|Pazopanib|Starting dose is 400 given on Days 2-5, 9-12, and 16-26 of each 28 day cycle
45685771|NCT01407562|Drug|Paclitaxel|Starting dose is 60 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle
45841982|NCT03459807|Drug|Anti-Hypertensive medications|Use of standard Anti-Hypertensive medications
45350432|NCT04038801|Procedure|Full-mouth disinfection (FMD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts and an intensive regime of chlorhexidine in two visits of the same day.
45350433|NCT00962962|Behavioral|Aerobic Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,000 calories per week equaling approximately 10 miles per week OR 2.5-3.5 hours per week
45350434|NCT00962962|Behavioral|Aerobic Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 4-6 hours per week
45350435|NCT00962962|Behavioral|Aerobic Exercise|Aerobic exercise at 75% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 2-3 hours per week
45350436|NCT00962962|Behavioral|Exercise and Diet|"Exercise - 150 minutes per week (30 minutes / 5 days per week) of aerobic exercise at 50% peak oxygen use/consumption equaling approximately 10 miles per week~Diet - The Clinical Lifestyle Intervention sessions will provide training on needed skills (e.g., calorie counting, portion size estimation) as well as motivation and support in a group counseling setting designed to achieve a weight loss goal of 5 to 7% of baseline body weight."
46045128|NCT04162288|Other|Online Training - Shared Decision Making in Prenatal Screening|TThe intervention consisted of an online self-study training program lasting 3 hours which aims to engage SDM in a prenatal screening context. The training was divided into four main modules: 1)SDM, 2)DS prenatal screening, 3)Decision aid and 4)Communication between healthcare professionals and patients. In each module, the targeted learning objectives and the work to be carried out (e.g. readings to be made, video to be viewed, evaluation to be carried out, etc.) are presented. Various teaching methods and medias are used during this training: videos, interviews, narrated capsule, readings, links to scientific articles and complementary websites. Videos are done with experts on SDM, ethics of prenatal testing. A simulation in the end is done to put participants in context of an actual consultation with a pregnant woman and her partner. This training was designed to adapt to the learning pace of the user, is hosted on University Laval platform and needs an identification code to enter.
45350437|NCT00882063|Drug|P276-00|Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.Starting dose level of P276-00 is 50 mg/m2/day to be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min from day 1 to day 5 every 21 days. This constitutes one cycle of P276-00. Six such cycles will be administered to subjects.
45350438|NCT00958672|Other|Endoscopic capsule|Endoscopic capsule
45350439|NCT00958750|Drug|minoxidil|the investigators compared two different formulations and concentrations of minoxidil in this study
45350440|NCT00882141|Behavioral|Diet modification|Weight loss sessions are held by a registered dietitian for 1 hour once a week for 6-9 months; recommended caloric intake to elicit a weight loss of approximately 0.2-0.4 kg per week
45350441|NCT00882141|Behavioral|Aerobic exercise|Treadmills and other aerobic exercise equipment 3 times a week for 6-9 months, beginning at low levels of VO2max and progressing in duration and intensity to more than 75% VO2max for 45 minutes
45350442|NCT04902274|Other|Transcranial Direct Current Stimulation|The Halo Sport (Halo Neuroscience, San Francisco, CA) is a commercial off-the-shelf tDCS device that delivers a 2.2 mA current to the motor cortex through three elastomer foam scalp pads with a 24 sq. cm surface area (see https://www.haloneuro.com/). The tDCS is controlled through the Halo Sport App where the therapist and patient are blind to an actual or sham treatment. Patients in the tDCS group will complete a 20-minute tDCS session while performing the warm-up.
45350443|NCT04902274|Other|Sham Transcranial Direct Current Stimulation|The Halo Sport (Halo Neuroscience, San Francisco, CA) is a commercial off-the-shelf tDCS device that delivers a 2.2 mA current to the motor cortex through three elastomer foam scalp pads with a 24 sq. cm surface area (see https://www.haloneuro.com/). The tDCS is controlled through the Halo Sport App where the therapist and patient are blind to an actual or sham treatment. Patients in the sham tDCS group will complete a 20-minute sham-tDCS session while performing the warm-up, but the app will discontinue the treatment after 30 seconds.
45350444|NCT04902274|Other|Physical Therapy|After the tDCS session is complete, the patient will complete treatment consistent with the standard of care for rehabilitation of acute ankle inversion sprain. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes. Patients will also perform a standardized home exercise program that reinforces the in-clinic treatment.
45476562|NCT03730961|Drug|BMS-986231|Intravenous administration
45476563|NCT03730961|Drug|Furosemide|Intravenous administration
45476564|NCT03730961|Drug|Placebo|Intravenous administration
45476565|NCT01078454|Drug|melphalan|Given PO
45476566|NCT01078454|Drug|dexamethasone|Given PO
45476567|NCT01078454|Drug|bortezomib|Given IV
45476568|NCT02968602|Drug|Minocycline|Minocycline capsules taken twice daily for two weeks.
45476569|NCT02968602|Other|Placebo|Placebo capsules taken twice daily for two weeks.
45476570|NCT03345004|Biological|Diamyd|Alhydrogel®-formulated recombinant human glutamic acid decarboxylase (rhGAD65)
45476571|NCT03345004|Dietary Supplement|Vitamin D|Oil suspension of Vitamin D
45476572|NCT03345004|Biological|Placebo for Diamyd|Alhydrogel® only
45476573|NCT03345004|Dietary Supplement|Placebo for Vitamin D|Placebo oil suspension for Vitamin D
45476574|NCT03552757|Drug|Semaglutide 1.0 mg|Subcutaneous (s.c.) injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
45350445|NCT00958906|Drug|Infliximab (intravitreal, 2.0mg/0.05ml)|One injection of intravitreal infliximab (2.0mg/0.05ml).
45476575|NCT03552757|Drug|Semaglutide 2.4 mg|Subcutaneous injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
45476576|NCT03552757|Drug|Placebo I (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 2.4 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
45685772|NCT01407562|Drug|Carboplatin|Starting dose of carboplatin that corresponds to an AUC of 2, IV on days 1, 8, and 15 of each 28 day cycle
45841983|NCT03459807|Procedure|Dry Weight Adjustment|The participant's target post-dialysis dry weight is adjusted
45841984|NCT03454035|Drug|Ulixertinib|Ulixertinib 300mg, orally, twice a day concomitantly with palbociclib
45841985|NCT03454035|Drug|Palbociclib|Drug: Palbociclib 125mg, orally, once a day concomitantly with ulixertinib
45841986|NCT03355365|Biological|Intrathecal MSC-NP injection|MSC-NPs represent a neural subpopulation of MSCs from bone marrow with reduced pluripotency and minimized risk of ectopic differentiation, thus are likely to be more suitable for CNS delivery. Importantly, characterization of MSC-NPs demonstrated their immunoregulatory and trophic properties, and MSC-NPs derived from MS and non-MS patients alike were therapeutically viable.
45841987|NCT03355365|Other|Intrathecal saline injection|Placebo
45841988|NCT03332550|Procedure|Laparoscopic lavage|Operation with laparoscopic lavage for perforated diverticulitis Hinchey 3
45841989|NCT03332550|Procedure|Colon resection|Operation with colon resection for perforated diverticulitis Hinchey 4
45841990|NCT03295227|Biological|Pembrolizumab|Given IV
45841991|NCT03278691|Drug|Saline|1 ml saline IV Q6H
45841992|NCT03278691|Drug|Ketorolac|15 mg (15 mg/ml) IV Q6H
45841993|NCT03253991|Device|MRgFUS treatment|ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects
45841994|NCT03243513|Other|Retrospective Chart Review|There is no intervention in this research. This research project is a retrospective chart review.
45841995|NCT03218384|Drug|Ferric Carboxymaltose|Intravenous Ferric Carboxymaltose 750 mg mixed under sterile conditions in 100 ml of normal saline for final concentration of 7.5 mg/ml and administered via volumetric infusion pump over 15 minutes.
46045129|NCT04162288|Other|Online Training - Online Training on Prenatal Screening|The control intervention consisted of an online self-study training program lasting 3 hours which aims to provides knowledge for prenatal screening. The training has four main modules: 1)Context and history of prenatal screening(new), 2)DS prenatal screening(existing), 3)Consent in prenatal screening(new) and 4)Communication between healthcare professionals and patients(existing). In each module, the targeted learning objectives and the work to be carried out are presented. Various teaching methods and medias are used during this training: videos, interviews, narrated capsule, readings, links to scientific articles and complementary websites. Videos are done with experts on SDM, ethics of prenatal testing. For the 2 new modules, narrated capsules and reports have replaced videos of experts. There is no simulation at the end. This training was designed to adapt to the learning pace of the user, is hosted on University Laval platform and needs an identification code to enter.
46045130|NCT02645656|Drug|Curcumin Arm|Curcumin gel will be applied in sites with Oral Submucous Fibrosis at designated time intervals
46045131|NCT04163848|Other|Pollution|CO2 equivalent productions related to anesthetic gases use during general anesthesia for laparoscopic surgery
45685773|NCT01406548|Drug|BPS804 20mg/Kg|
45685774|NCT01406548|Drug|Placebo to 20mg/Kg BPS804|
45685775|NCT01798810|Procedure|Supplemental Perioperative Oxygen|Patients receiving perioperative oxygen will receive 80% FiO2 during surgery.
45685776|NCT01393522|Drug|Milnacipran|titration schedule starting with 12.5mg per day increasing to 50mg twice a day, starting with day 1 to day 90 and then taper down as appropriate for dose.
45685777|NCT01393522|Drug|Placebo|Placebo dosing schedule was Day 1-2, 1 tablet daily, Day 3-6 BID, Day 7-14 BID, Day 15 an on through day 90 BID and taper down
45685778|NCT02086786|Drug|Risperidone ISM|"Four doses of 75 mg of Risperidone ISM as intramuscular (IM) injection into the deltoid muscle at 28-day intervals.~Four doses of 75 mg of Risperidone ISM as intramuscular injections into the gluteal muscle at 28-day intervals."
45685779|NCT02120482|Device|Combined apheresis|Semiselective immunoadsorption combined with membrane filtration
45685780|NCT02318992|Biological|Fecal Microbiota|Fecal Microbiota will be delivered via colonoscopy.
45685781|NCT02118922|Procedure|Brillouin imaging|
45685782|NCT01787500|Biological|Cetuximab|Given IV
45685783|NCT01787500|Drug|Irinotecan Hydrochloride|Given IV
45685784|NCT01787500|Other|Laboratory Biomarker Analysis|Correlative studies
45685785|NCT01787500|Other|Pharmacological Study|Correlative studies
45685786|NCT01787500|Drug|Vemurafenib|Given PO
45841996|NCT03218384|Drug|Placebo|100 ml of normal saline solution, and administered via volumetric infusion pump over 15 minutes.
45841997|NCT03218384|Device|31P MRS/MRI|Each participant will perform the same rhythmic plantar extension exercise protocol twice, for sequential acquisition of magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI) measurements. For the exercise protocol, the participant will lay supine on the scanning table with the right leg inside the volume coil. The exercise consists of repeated plantar flexion movements using resistance bands at a frequency of one repetition per second for 1-2 minutes. Data are collected continuously for 2 minutes before the exercise (baseline), during exercise, and 5 minutes after the exercise for the MRS and MRI experiments.
45685787|NCT01782352|Drug|Omega-3 fatty acids (fish oil)|
45685788|NCT01782352|Dietary Supplement|Vitamin D3|
45685789|NCT01782352|Dietary Supplement|Vitamin D3 placebo|
45685790|NCT01782352|Dietary Supplement|Fish oil placebo|
45350446|NCT00882219|Device|Xience V®|Placement of a Xience V® stent within a restenosed bare metal stent.
45350447|NCT04318665|Diagnostic Test|CT Perfusion|Severe Traumatic Brain Injury patients will be undergoing CT perfusion test
45350448|NCT00959062|Drug|clonidine|5 mcg/kg (maximum 200 mcg) enterally every 6 hours
45350449|NCT00959062|Drug|placebo|Preparation visually identical to clonidine.
46045132|NCT01132820|Drug|Cediranib Maleate|Given PO
45350450|NCT04296981|Other|video-based patient information|explanatory video (8 minutes) concerning communication, stroke issues and stages of the continuum of care
45350451|NCT04009564|Dietary Supplement|Date coffee|45 g of date seeds coffee in 280 ml of water
45350452|NCT04009564|Dietary Supplement|Normal coffee|6 g of normal coffee in 280ml of water
46045133|NCT01132820|Other|Laboratory Biomarker Analysis|Correlative studies
45350453|NCT04009564|Dietary Supplement|Placebo|water, food colouring and coffee flavouring
45350454|NCT04038411|Drug|PD-1 Antibody, chidamide, lenalidomide and etoposide|PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
45350455|NCT04009642|Other|Surely observational based on disease state|Metabolism in T2DM vs non diabetic
45350456|NCT00882297|Procedure|Echoguided vein puncture|Puncture with echographic visualization of vein in transversal and longitudinal way.
45350457|NCT04155424|Drug|Eculizumab|Following a weight-based weekly dose of eculizumab during an induction phase, participants will receive weight-based doses of eculizumab every 2 weeks during the Primary Treatment Period and Extension Treatment Period.
45350458|NCT00883467|Procedure|preconditioning|3 times of five minutes ischemia, produced by cuff inflation to a suprasystolic pressure positioned on the thigh
45350459|NCT00883467|Procedure|no preconditioning|no preconditioning
45350460|NCT00963118|Dietary Supplement|plant based nutrition bar|Nutrition bars made from Angelica keiskei (5g), glycine max (5g), Angelica keiskei (2.5g) + Glycine max (2.5g) or rice powder (12g) will be supplemented twice/day for 4 wks.
45350461|NCT00882375|Drug|Nicotine|Nicotine administered using novel NRT user instructions
46045134|NCT04163770|Device|caliberation of pacemaker|evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold
46045135|NCT04163770|Device|caliberation of pacemaker|evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold
46045136|NCT04162444|Diagnostic Test|Physical examination|A physical examination is a routine screening procedure used to investigate a patient's symptoms or complaints. It consists of a series of questions regarding patient medical history followed by an examination of the symptoms to determine the correct diagnosis and treatment plan.
46045137|NCT04162444|Diagnostic Test|The Ross Classification for Heart Failure in Children|The assessment is performed by pediatric cardiologist according to the classic Ross scale. One of the 4 classes of chronic heart failure is registered.
45847605|NCT04040790|Drug|Tropicamide and phenylephrine|Participants receive pupil dilation eye drops on the dominant eye, after baseline measurement and before wearing the scleral contact lenses (Designs A, B and C)
46045138|NCT04162444|Diagnostic Test|The Aristotle score|Surgical risks will be assessed by the ARISTOTLE score developed specially for the task. The calculation will be performed online, available from http://www.aristotleinstitute.org.
46045139|NCT04162444|Other|Assessment of administered specific therapy|"The data will be registered as groups of administered medicines:~Antiplatelet agents~Loop diuretics~Potassium-sparing diuretics~Angiotensin-converting enzyme inhibitors"
45350462|NCT00882375|Drug|Placebo|Placebo administered using novel NRT user instructions
45350463|NCT00963196|Dietary Supplement|Omega-3 fatty acid|2400mg daily of fish oil containing 1440mg combined EPA and DHA for 12 weeks
45350464|NCT00963196|Drug|Bovine gelatin capsules|Bovine gelatin capsules that appear similar to active drug acting as placebo.
45350465|NCT00882453|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Intravenous therapy according to product information
45350466|NCT04860778|Dietary Supplement|BDNF Essentials|Participants will take two capsules, twice daily with water for 84 days.
45350467|NCT00883545|Other|Woman endoscopist|This group will receive an invitation to schedule a screening colonoscopy with a woman endoscopist.
45350468|NCT00883545|Other|Usual care|This group will receive an invitation to schedule a screening colonoscopy with any available endoscopist.
45350469|NCT04812340|Other|High intensity circuit training|6 series with 3 minutes rest between the series. each series will consist of 30 seconds each of burpees, skipping, lunges, 1- legged squat, leg levers, and push-ups with 30 seconds rest in between. the volume of exercise will be increased progressively over a period of 8 weeks.
45350470|NCT04812340|Other|Low intensity interval training|4 series with 3 minutes rest in between. each series will consist of 10 minutes of jogging and 5 minutes walking with 30 seconds recovery in between. the volume of exercise will be increased progressively over a period of 8 weeks.
45350471|NCT00882531|Drug|isotretinoin|0.25 mg/kg, 1 per day, 4 month of treatment
45350472|NCT00882531|Drug|placebo|
45350473|NCT00923403|Dietary Supplement|plant sterol enriched soymilk|plant sterol enriched soymilk
45350474|NCT00923403|Dietary Supplement|control dairy milk|control dairy milk
45350475|NCT00963274|Drug|Bortezomib|Starting dose: 1.3 mg/sq m
45350476|NCT00963274|Drug|Romidepsin|Starting dose: 8 mg/sq m
45350477|NCT00882609|Device|Bone Scan: F18-Fluoride PET/CT or TC-MDP|Each patient will be randomized into one of two groups with one group receiving Sodium Fluoride F18 Injection and the other receiving the control agent, 99mTc-MDPSodium Fluoride F18 Injection Dosing and Administration. The dose will be tailored for the specific patient for whom the dose was ordered. The dose of Sodium Fluoride F18 Injection administered will range from 5-10 mCi/patient.Each patient randomized to the control group will be administered 99mTc-MDP as a single intravenous bolus dose. The administered radioactivity will be determined based on the sites routine clinical practice for conventional bone imaging.
45350478|NCT05272618|Diagnostic Test|Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)|Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)
45350479|NCT00883623|Drug|Lenalidomide|Up to 6 cycles of oral L-Mel-Dex, every 28 days Revlimid® 10 mg daily for 21 days, (add on therapy), Melphalan 0.15 mg/kg/day day 1-4, Dexamethasone 20 mg day 1-4
45350480|NCT00959218|Drug|Dronabinol|oral solution, daily dose up to 15 mg, treatment up to 2.5 years
45350481|NCT00959218|Drug|Placebo|oral solution
45350482|NCT04009954|Other|Fecal and blood samples collection for analysis|"Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs)."
45685791|NCT04389814|Diagnostic Test|Biochemical markers|Multiple biomarkers of myocaridial ishemia will be obtained serially to calculate thier time of their release according to their release kinetics
45350483|NCT00678210|Drug|CP-690,550|tablets, 2 mg BID for 12 weeks
45350484|NCT00678210|Drug|CP-690,550|tablets, 5 mg BID for 12 weeks
45350485|NCT00678210|Drug|CP-690,550|tablets, 15 mg BID for 12 weeks
45350486|NCT00678210|Drug|Placebo|tablets, BID for 12 weeks
45685792|NCT01776736|Device|Posture Correction Girdle|Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
45685793|NCT02108158|Drug|Azzalure|
45685794|NCT01774630|Drug|Nilotinib|300 mg/twice a day
45685795|NCT01895920|Other|Blood sample|
45841998|NCT03190317|Other|HIV-infected Veterans who use MHV|The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
45350487|NCT00959296|Device|Various|Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
45350488|NCT00611715|Drug|erlotinib hydrochloride|OSI-774 150 mg/day
45350489|NCT00611715|Drug|letrozole|Letrozole 2.5 mg/day
45350490|NCT00611715|Genetic|fluorescence in situ hybridization|To determine HER2 gene amplification or excess copies of the HER2 gene
45350491|NCT00611715|Other|immunohistochemistry staining method|to measure the epidermal growth factor receptors (EGFR)
45350492|NCT00611715|Other|laboratory biomarker analysis|To determine if specific biomarkers exhibit a longer time to tumor progression after treatment with the study drugs
45350493|NCT04722718|Drug|Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin|Sintilimab:200mg,ivgtt,d1,21days/cycle;Apatinib:250mg po,d1-14days,21days/cycle;Albumin-Bound Paclitaxel(Nab-Paclitaxel):125mg/m2,ivgtt,d1,d8,21days/cycle;Carboplatin:AUC=1.5,ivgtt,d1,d8, 21days/cycle.Monitoring of blood routine, biochemical and urine routine, electrocardiogram, and record the patient's drug-related adverse reactions every cycle,according to the curative effect of patients, compliance and tolerance, neoadjuvant therapy 6 cycles,every 2 cycles to evaluate curative effect (ultrasonic, breast X-ray CT, bone scan, brain, lungs, assessment and breast MRI imaging).
45350494|NCT04649710|Biological|BMS-986036|Specified dose on specified days
45350495|NCT04649710|Other|Placebo|Specified dose on specified days
45350496|NCT00885573|Device|Measurement of pharyngeal sensitivity (SENSITEST)|Measurement of pharyngeal sensitivity using the SENSITEST the morning following the nocturnal polysomnographic recording to diagnose sleep disordered breathing.
45350497|NCT00761670|Drug|amisulpride and risperidone|amisulpride tablet 400-800 mg/day risperidone tablet 4-8 mg/day
45350498|NCT00963664|Drug|lovastatin|lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals
45350499|NCT00963664|Drug|interferon alfa-2b|interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly
45350500|NCT00677820|Biological|Trivalent influenza virus vaccine|Trivalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 ml of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10:7 FFU (fluorescent focus units) of each of three cold-adapted, attenuated, 6:2 reassortant influenza strains A/South Dakota/6/07 (H1N1), A/Uruguay/716/07 (H3N2), and B/Florida/4/2006.
45350501|NCT00677820|Biological|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 ml of sucrose-phosphate buffer.
45350502|NCT05267236|Other|Intervention #1: Treatment Group Receiving On-Demand TYRO Services|Treatment group participants receive TYRO Couples curriculum in an on-demand format that is delivered in five 2-hour weekly sessions for a total of 10 hours.
45350503|NCT05267236|Other|Intervention #2: Control Group Receiving In-Person TYRO Services|Control group participants receive TYRO Couples curriculum in a live format (virtual or in-person) that is delivered in five 2-hour weekly sessions for a total of 10 hours.
45350504|NCT00611559|Biological|Infanrix™ penta|Subjects received a booster dose
45350505|NCT00611559|Biological|Infanrix™ hexa|Subjects received a booster dose
45350506|NCT00963742|Device|Lenstec Softec HD IOL implantation|surgical removal of cataract and implantation of Softec HD PCIOL
45350507|NCT00963898|Device|Target controlled infusion(TCI), Bispectral index(BIS)|Using TCI and BIS or not
46045140|NCT04162444|Diagnostic Test|Multispiral computed tomography/3D echocardiography|"All patients enrolled in the study should be routinely examined with multispiral computed tomography (MS-CT) or 3D-echo before surgery and 3 years later. As a result, a 3D aortic root reconstruction will be made to assess its size and anatomy and subsequently build a 3D soft model for surgery imitation.~At the study onset, we plan to perform MS-CT, then 3D-echo. If the correlation resulting from 3D-echo and the actual sizes will be high, the isolated 3D-echo will be preferred in the future.~If none of the methods is available, the patients will not be enrolled in the study.~The following data will be registered for further analysis:~Perimeter of the aortic valve~Diameter of the aortic valve at sinuses level~Height of the aortic sinuses~Morphology of the aortic valve"
45350508|NCT00761904|Behavioral|Free Generic Samples (hydrochlorothiazide, simvastatin)|Free samples of generic hydrochlorothiazide (12.5 mg tabs) and simvastatin (20 mg tabs)
45350509|NCT00963976|Drug|labetalol/hydralazine/enalapril|Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
45350510|NCT04238520|Behavioral|Functionally Tailored Oral Care Intervention|Participants receive a 4-week, hands-on, functionally-tailored intervention. The intervention will address topics including tooth brushing, denture care, inter-dental care, tongue care, and dry mouth care. There will be four sessions in total, with each intervention session lasting approximately 45 minutes.
45350511|NCT04238520|Behavioral|Control Intervention|Participants will receive a home-based, un-tailored oral care training. The training includes a tooth brushing and dental care demonstration, and information about oral diseases and dry mouth. This training will be 15 minutes in duration. Participants will have the opportunity to participate in the functionally tailored intervention following the end of this study.
45350512|NCT00964054|Other|Public Health Dose of Exercise (PHD)|17.5 kcal per kilogram per week
45350513|NCT00964054|Other|Low Dose Exercise (LD)|7.0 kcal per kilogram per week
45350514|NCT02559258|Drug|0.1 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1, infused over 30 minutes
45685796|NCT01895218|Drug|Iron isomaltoside 1000|A single dose of 1200 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9 % sodium chloride and given over approximately 15 min.
45685797|NCT01895218|Other|Standard medical Care|Standard medical Care is most often to recommend women with PPH to continue oral iron supplementation as recommended during pregnancy or to advise the subject to take 100 mg oral iron 1-2 times a day
45350515|NCT02559258|Drug|0.3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
45685798|NCT02100904|Procedure|Radiofrequency ablation of fibroids|
45685799|NCT02100904|Procedure|Myomectomy of fibroids|
45350516|NCT02559258|Drug|1.0 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
45350517|NCT02559258|Drug|3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 60 minutes
45476577|NCT03552757|Drug|Placebo II (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 1.0 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
45685800|NCT01895998|Drug|Albuterol|This medication will be used as routine part of pulmonary function testing to assess for airway hyperreactivity. This is routinely done in a clinical capacity for pediatric patients with various pulmonary disease processes.
45350518|NCT02559258|Drug|10 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 120 minutes
45350519|NCT00964132|Drug|NRX194204|Once Daily, Oral
45350520|NCT02558868|Drug|Irinotecan|
45350521|NCT02558868|Drug|Oxaliplatin|
45350522|NCT00611247|Drug|Temozolomide|"Priming, Group 2 only, 100 mg/m2/day temozolomide.~Induction (both arms) 200 mg/m2/day temozolomide"
45350523|NCT04038177|Behavioral|Superset strength training|Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by superset strength training two days per week for 12-weeks. Superset 1 are bench-press and seated rows, and superset 2 are leg-press and lateral pulldown. Each superset is performed three times.
45350524|NCT04038177|Behavioral|Traditional strength training|Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by strength training two days per week for 12-weeks. Each exercise is performed for three sets with rest intervals between each set.
45350525|NCT00885651|Drug|Metoprolole (Selo-Zok ®)|Tablets, 200 mg, once a day, 10 days
45685801|NCT02095288|Procedure|Blood draw|This is a single blood donation, no drugs or devices administered
45847606|NCT04027998|Diagnostic Test|strain and applied pressure measurement|Measurement of median nerve strain and applied pressure at proximal carpal tunnel level
45350526|NCT00885651|Drug|Placebo|
45350527|NCT00885729|Procedure|stem cells|Stem cells or chondrocytes under a commercial available membrane
45350528|NCT00885729|Procedure|Chondrocytes|Implantation of chondrocytes
45350529|NCT00885729|Other|Rehabilitation program|Strength exercises, neuromuscular exercises
46045141|NCT04162444|Diagnostic Test|Transthoracic and transesophageal echocardiography|"Transthoracic echocardiography is carried out at baseline, at discharge and then annually. It is performed in order to assess the contractile function of the heart and hemodynamic characteristics of the aortic valve and its autopericardium graft.~Transesophageal echocardiography is carried out directly after the withdrawal of the artificial circulation when performing augmentation of the aortic valve with autopericardium in order to asses hemodynamic characteristics of the aortic neo-valve."
45350530|NCT00883935|Drug|GSK1349572|GSK1349572 30 mg once a day for 5 days in Period 1 and 14 days in Period 2
45350531|NCT00883935|Drug|Atazanavir 300 mg|Atazanavir 300 mg once per day for 14 days in Period 2
45350532|NCT00883935|Drug|Atazanavir 400 mg|Atazanavir 400 mg once a day for 14 days in Period 2
45350533|NCT00883935|Drug|Ritonavir|Ritonavir 100 mg once a day for 14 days in Period 2
45350534|NCT00675948|Drug|Sativex|"Containing delta-9-tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml; both as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours."
46045142|NCT04162444|Diagnostic Test|12-lead electrocardiogram|"Registering 12-lead electrocardiogram (ECG) is used as a tool for assessment of the regularity of the heart rhythm as well as screening and predictive tool for assessment of fibrosis and hypertrophy processes in the myocardium. The following data will be registered:~Heart rate~Sinus rhythm (yes/no)~Positive R wave in leads V5-6~Angle α less than 0~Presence/absence of abnormal Q wave~Presence/absence of ST-segment depression in precordial leads"
45350535|NCT00675948|Drug|GW-2000-02|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
46045143|NCT00655330|Drug|Valsartan|Valsartan (160mg/day)
46045144|NCT00655330|Drug|Placebo|Placebo
46045145|NCT00655330|Drug|Probucol|Probucol (750mg/day)
45350536|NCT02659878|Procedure|bleeding, intraventricular and/ or intracerebral hemorrhage.|Patient's age, sex, comorbidities, medications, the exact time point of bleeding, the circumstances of bleeding neurological and cardiological status are recorded, laboratory tests, Transcranial Color Doppler (TCCD), echocardiography and chest X-ray examinations are carried out within 24 hours after the patient is being admitted to the ICU.
45350537|NCT04037787|Procedure|ERAS protocol|In colorectal cancer surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting with administration of oral carbohydrates before surgery, use of intestinal preparation for selected cases only (rectal surgery), the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, preference for minimally invasive surgery, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.
45350538|NCT02529696|Device|Accelerometer|Measures patient movement
45350539|NCT00885885|Drug|Panitumumab+FOLFOX-4|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFOX 4 chemotherapy will be administered on day 1 of each 14-day treatment cycle:~Oxaliplatin 85mg/m2 as a 120 minute infusion on day 1 of each cycle~Folinic acid 200mg/m2 as a 120 minute infusion on days 1 and 2~A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on days 1 and 2~5-FU at 600mg/m2 as a continuous infusion of 22 hour infusion on days 1 and 2"
45350540|NCT00885885|Drug|Panitumumab+FOLFIRI|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFIRI chemotherapy will be administered on day 1 of each 14-day treatment cycle:~Irinotecan 180 mg/m2 will be administered over 90 minutes ± 15 minutes on day 1 of each cycle~Folinic acid 400 mg/m2 will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing~A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on day 1~5-FU at 2400 mg/m2 continuous intravenous infusion over 46-hour ± 2-hour on day 1 of each cycle."
45350541|NCT04077762|Procedure|Radial Access|Radial Access
45350542|NCT04077762|Procedure|State-of-the-art femoral access with 18 gauge needle|State-of-the-art femoral access with 18 gauge needle
45476578|NCT03042156|Radiation|Palliative Radiation Therapy|
46045146|NCT00353470|Behavioral|Cognitive behavioral therapy|CBT for panic disorder will include 19 to 24 sessions over 12 weeks.
45350543|NCT04077762|Procedure|State-of-the-art femoral access with 21 gauge needle|State-of-the-art femoral access with 21 gauge needle. For patients randomized to micropuncture (21G) the micropuncture wire must be advanced under fluoroscopy to avoid inadvertent wiring of side-branches.
45350544|NCT00610935|Drug|Peramivir|To evaluate the efficacy of peramivir administered intramuscularly compared to placebo on the time to alleviation of clinical symptoms in adult subjects with uncomplicated acute influenza.
45350545|NCT00610935|Drug|Placebo|Single intramuscular injection
45350546|NCT00761982|Procedure|Infusion on autologous CD34+ stem cells into middle cerebral artery|Intraarterial infusion of autologous bone marrow stem cells into middle cerebral artery of acute stroke patients
45350547|NCT04049448|Drug|ABX464|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks).
45350548|NCT02303028|Drug|Topotecan and Pazopanib|Low-dose metronomic Topotecan and Pazopanib will be escalated as per the dose escalation schema.
46045147|NCT00353470|Behavioral|Applied relaxation training (ART)|ART with exposure protocol will include 19 to 24 sessions over 12 weeks.
46045148|NCT00353470|Behavioral|Panic focused psychodynamic psychotherapy (PFPP)|PFPP will include 19 to 24 sessions over 12 weeks.
45350551|NCT02287818|Drug|Placebo|Placebo twice daily from Day 1 to Week 12
45350552|NCT02287818|Drug|AC-201|AC-201 CR tablet 100 mg twice daily from Day 1 to Week 12
45350553|NCT02287818|Drug|Febuxostat|Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration <6 mg/dL
45350554|NCT02542449|Dietary Supplement|Globes®|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months Globes® and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
45350555|NCT02542449|Dietary Supplement|Placebo|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months placebo and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
45350556|NCT00762060|Device|ON-Q Silver soaker System|Continuous infusion of local anesthetic to surgical site
45350557|NCT00762060|Drug|Patient controlled analgesia|IV opioids delivered via PCA
46045149|NCT00655408|Drug|elemental iron|Iron supplementation.
46045150|NCT04163536|Drug|Methylprednisolone|In the experimental group, methylprednisolone will be administered intravenously for 5 days at a dose of 1 mg/kg/day. Methylprednisolone will be provided for reconstitution and dilution in 50 ml of NaCl 0.9% solution and administered over 15 minutes, once a day.
45350558|NCT00884169|Drug|M518101|Proper quantity twice a day
45350559|NCT00884169|Drug|placebo|Proper quantity twice a day
45350560|NCT00886041|Procedure|laparoscopy|subjected to laparoscopy
45350561|NCT00886041|Other|ovarian stimulation|ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
45350562|NCT05278923|Device|SALAD simulation device|An airway CPR manikin was modified to simulate regurgitation during CPR . A manual pump was fixed on the bottom of the torso to simulate the stomach. A clear vinyl tube was connected the manikin's oesophagus and the outflow port of the pump. A water container outside the manikin was filled with simulated gastric content and connected to the inflow port of the pump through another vinyl tube. The manikin's left main bronchus was occluded using a red cap provided by the manufacturer. The lung was simulated by an anaesthesia breathing bag placed outside the manikin and connected to the manikin's right main bronchus via a breathing circuit. A compression pad was attached to the bottom of the manikin's compression plate. During chest compression, the compression pad squeezed the pump to regurgitate gastric contents into the oropharynx
45476579|NCT03730103|Other|Same day discharge|Patients will be discharged home from the hospital on the day of her surgery.
45476580|NCT03034356|Drug|Levetiracetam|Anticonvulsant drug
45476581|NCT03034356|Drug|Placebo|Placebo
46045151|NCT04163536|Drug|Placebos|in the control group, placebo will be administered intravenously for 5 days. Placebo will be identical (color and aspect) to experimental substance, will be provide as a 50 mL of NaCl 0.9% solution and administered intravenously over 15 minutes, once a day.
46045152|NCT02637544|Other|acupuncture|classical acupuncture therapy
46045153|NCT02645500|Behavioral|Holistic health training and physical exercise messages|The physical activity message arm includes a training workshop in relation to holistic health, and daily physical activity messages.
46045154|NCT02645500|Behavioral|Holistic Health Training with healthy diet messages|The healthy diet message arm includes a training workshop in relation to holistic health, and daily healthy diet messages.
46045155|NCT00652288|Drug|Insulin analogs (Lispro and Aspart)|Insulin bolus given through insulin pump
46045156|NCT00652288|Drug|Insulin analogs (Aspart and Detemir)|Drugs given separately
46045157|NCT00652288|Drug|Insulin analogs (Aspart and Detemir)|Drugs given in the same injection
45350563|NCT00610857|Drug|Anti-CTLA4 monoclonal antibody and HDI|"One course of therapy consists of three cycles (1 cycle=28days). Anti-CTLA4 monoclonal antibody (15 mg/kg i.v.) will be given during the first cycle only. HDI will be given all three cycles - cycle 1: 20 MU/m2 i.v. on days 0, 1, 2, 3, 4 a week (MTWRF) for 4 weeks; cycle 2: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks; and cycle 3: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks.~Response assessment will be carried out at day 56 and day 84. Every patient will receive 3 cycles regardless of response status after the first 2 cycles. However, a patient may be taken off therapy in the event of clinical progression at the discretion of the treating physician.~Patients without evidence for disease progression after 3 cycles may be offered additional cycles two weeks after completion of the third cycle. Therapy will continue for a maximum of 12 months."
45350564|NCT00672984|Drug|immediate release guanfacine hydrochloride|Subjects will receive 2x2mg immediate-release guanfacine on day 1. Subjects will receive 4x2mg immediate-release guanfacine on day 6.
45350565|NCT00672984|Drug|moxifloxacin|Subjects will receive 400mg of moxifloxacin on day 1. Subjects will receive 400mg of moxifloxacin on day 6.
45350566|NCT00672984|Drug|Placebo|Subjects will receive placebo on Day 1. Subjects will receive placebo on Day 6.
45350567|NCT02543697|Radiation|Adrenal venous sampling|We go trough the femoral vein with a catheter up to the adrenal vein first on the left side, then on the right side. We take blood samples and analyze cortisol, metanefrin/ normetanefrin, aldosterone both from the adrenal veins and from the peripher vein. Then we use criteria from the Majo clinic to identify if the overproduction of cortisol is uni- or bilateral.
46045158|NCT00652288|Drug|Insulin analogs (Lispro and Glargine)|Drugs given separately
46045159|NCT00652288|Drug|Insulin analogs (Lispro and Glargine)|Drugs given in single injection
45350568|NCT00762138|Device|AutoloGel System|"The AutoloGel™ System may be used for chronic or surgically-debrided wounds up to twice a week for eight (8) weeks. The treating health care practitioner may elect to continue the treatment up to twelve (12) weeks. The AutoloGel™ System should be used in conjunction with standard of care procedures for comprehensive wound management , such as:~Removal of necrotic or infected tissue Off-loading Compression therapy for venous stasis ulcers Establishment of adequate blood circulation Maintenance of a moist wound environment Management of wound infection Wound cleansing Nutritional support, including blood glucose control for subjects with diabetic ulcers Bowel and bladder care for subjects with pressure ulcers at risk for contamination Management of underlying disease"
45476582|NCT03345706|Procedure|Selective cerebral hypothermia|Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Cooling will be initiated and targeted to reach ipsilateral nasal temperature of 27±2°C for 12 hours, followed by controlled rewarming.
46045160|NCT03598894|Other|Ambulatory blood pressure measurements|Blood pressure will be assessed with ambulatory blood pressure measurements over the course of a day to discern day/night differences
46045161|NCT04162132|Device|Smartphone app|Study procedures related to the DynamiCare Rewards intervention were conducted via smartphone. Research visits included collection of urine samples and medical exams. Participants assigned to the DynamiCare Rewards group received: 1) the app on their smartphone, 2) drug testing devices when indicated (pocket-sized breathalyzer), and a reloadable debit card for receiving the financial incentives (the PEX debit card). Global Positioning System (GPS) tracking was used to track whether patients had attended their scheduled appointments but was not used at any other times. All information was uploaded from the app onto the DynamiCare Analytics website, which treatment providers could view. The information reported was: attendance status of appointments, the status of all alcohol and drug testing, and incentives earned. Each patient's intervention period (period of time when they used the app) lasted four months from the date of their enrollment.
46045162|NCT00911092|Procedure|Blood sampling|Before any study treatment, 14 days after radiotherapy, 15 weeks after radiotherapy
46045163|NCT00911092|Radiation|Radiation|Week 1 to week 5-6 1.8-2 Gys/fraction, 5 days a week for a total of 5 to 6 weeks
46045164|NCT00911092|Drug|Chemotherapy (Fluorouracil and Cisplatin)|"At weeks 1, 5, 8 and 11~Day 1 to day 4: Fluorouracil 1 gr/m²/day~Day 1 or 2: Cisplatin 75 mg/m²"
46045165|NCT02637622|Other|Best-Worst Scaling (Case 2)|Respondents receive questions asking them to choose the best and worst features of a hypothetical medication.
46045166|NCT02637622|Other|Discrete Choice Experiment|Respondents receive questions asking them to choose the medication they prefer between a pair of hypothetical medications.
46045167|NCT00655720|Other|infant formula|"hydrolyzed infant formula without probiotics~hydrolyzed infant formula with probiotics~hydrolyzed infant formula with probiotics"
46045168|NCT02635360|Drug|Pembrolizumab|200 mg of study drug is given through intravenous (IV) administration once every 21 days for 3 months.
45350569|NCT02543775|Procedure|Preoperative and intraoperative SLN Mapping|"Patients will undergo preoperative SLN mapping, which includes an injection of a radiocolloid and lymphosinctogram and SPECT/CT. Patients will also receive an intraoperative injection of blue dye. A handheld probe will be utilized to detect radiolabelled or hot nodes and direct visualization will identify blue nodes which will be labelled Sentinel Nodes and sent to pathology for intraoperative frozen section."
45350570|NCT00758472|Device|ReCap Total Hip Resurfacing|ReCap Total Hip Resurfacing
45350571|NCT00886275|Drug|Dexmedetomidine|The loading dose of dexmedetomidine is 0.5 mcg/kg over 10 minutes as needed. Then, continuous infusion of 0.2-0.7 mcg/kg/h dexmedetomidine is used to maintain RASS between 0 to -3.
45350572|NCT00886275|Drug|Midazolam|The loading dose of midazolam is 0.05 mg/kg over 10 minutes as needed. Then, continuous infusion of 20-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
45350573|NCT00886275|Drug|Dexmedetomidine, Midazolam|The loading doses are dexmedetomidine 0.25 mcg/kg and 0.025 mg/kg of midazolam over 10 minutes. Then, continuous infusion of 0.1-0.7 mcg/kg/h dexmedetomidine and 10-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
45350574|NCT02543619|Other|Injection technique|One group received Gow-Gates technique and the other group received Infra Alveolar Nerve Block technique for their failed first one anesthesia
45476583|NCT03345706|Procedure|Regular hypothermia|Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Subjects will receive systemic hypothermia via ECMO at 33.5±0.5°C (33-34°C) for 48 hours at the same time.
45350575|NCT00886353|Biological|APN01|APN01, a physiological formulation of recombinant human Angiotensin Converting Enzyme 2 administrated i.v.
45350576|NCT00886353|Other|Placebo|Physiological saline administrated i.v.
46045169|NCT02635360|Radiation|Brachytherapy|Radiation is done for standard clinical care purposes.
45350577|NCT02543463|Device|Trident X3 Insert with Navigation system|
45350578|NCT02543463|Device|Trident X3 Insert with conventional instrumentation|
45350579|NCT04037709|Procedure|scaling and root planing (SRP) + PDT placebo|Patientes will receive periodontal treatment (scaling and root planing - SRP) with universal curettes and ultrasound depending on their needs. The SRP will be done in one session. The PDT placebo wil be done using an agent with the same vehicle as that of the methylene blue to mimic irrigation with the photosensitizer; the laser will be switched off at the time of application.
45350580|NCT04037709|Procedure|scaling and root planing (SRP) + PDT|patients will receive the same scaling and root planing treatment that placebo group.However the PDT will be done using methylene blue 0.005% .The red laser diode (λ = 660 nm) will be applied with an output power of 100mW . The laser head will be positioned in direct contact with the pseudo periodontal pockets.
45350581|NCT04017897|Drug|The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab)|Subjects with treatment naïve, surgically unresectable metastatic melanoma stages IIIB to IVM1c will be treated with combination of anti-PD1 (pembrolizumab or nivolumab) and radiotherapy.
45350582|NCT02543541|Behavioral|Structured palliative care|Supportive care for the patient and caregiver will be provided by the outpatient palliative care team which includes clinicians with specialized palliative care training, social workers, spiritual care specialists and mental health clinical nurse specialist.
45350583|NCT02543541|Behavioral|Standard supportive care|Supportive care for the patient and caregiver will be provided by the treating oncologist.
45350584|NCT02542137|Radiation|Radiotherapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of small cell lung cancer.
45350585|NCT02542137|Drug|Thymalfasin|Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
45476584|NCT03003468|Drug|Imprime PGG|Arm A: Phase Ib Cohort 1: 2mg/kg IV; Arm A: Phase Ib Cohort 2: 4mg/kg IV
45847607|NCT03854058|Diagnostic Test|magnetic phrenic nerve stimulation|cervical and cortical stimulation of N. Vagus
46045170|NCT02635360|Drug|Cisplatin|40 mg of chemotherapy drug will be given weekly for 5-6 weeks.
45847608|NCT03707184|Procedure|Computed Tomography|Undergo PET/CT scan
45847609|NCT03707184|Drug|Fluciclovine F18|Given IV
46045171|NCT02635282|Drug|intranasal ketamine|
46045172|NCT02635282|Drug|intranasal fentanyl|
46045173|NCT02635282|Drug|intranasal midazolam|
46045174|NCT02635438|Drug|Unique Pharmaceutical Laboratories, India|Clotrimazole troche/ lozenges, 10 mg 5 times a day for 14 consecutive days
45476585|NCT03003468|Drug|MK-3475|200mg IV
46045175|NCT02635438|Drug|Roxane Laboratories Inc., USA|Clotrimazole Troche/ Lozenges USP, 10 mg 5 times a day for 14 consecutive days
46045176|NCT00655798|Dietary Supplement|Placebo|plain yogurt and capsules containing cellulose
45350586|NCT00886431|Other|embryo vitrification|Ultra rapid cooling of embryos by immersion in liquid nitrogen. The formation of potentially damaging ice crystals is prevented by briefly incubating the embryos in high concentrations of a mix of cryoprotectants.
45476586|NCT03003468|Drug|Imprime PGG|Arm B: Phase II treatment: administered at the maximum safe dose of 2mg or 4 mg as established in the Phase Ib cohort study.
45350587|NCT00886509|Biological|pegfilgrastim|s.c. administration of pegylated G-CSF over 6 months
45350588|NCT00886509|Other|Placebo|Placebo control Arm 1: Collateral promotion; PCI after 6 months
45350589|NCT00886665|Drug|placebo|placebo, 4 g, powder, oral, 3 times a day
45350590|NCT00886665|Drug|JWHGWT|JWHGWT, 4 g, powder, oral, 3 times a day
45476587|NCT03587532|Diagnostic Test|Indocyanine green angiography|ICGA will be performed twice during standard esophagectomy: 30 minutes after the stomach graft creation and immediately before the esophagogastric anastomosis. stock dose of 25 mg ICG (Pulsion Medical Systems, Germany) will be diluted to 5 mg/mL with sterile water. An IV bolus of 0.5 mg/kg of ICG will be injected via a central venous catheter. Video data will be obtained with a charge-coupled device (CCD) camera fitted with a light-emitting diode emitting at a wavelength of 760mm (Visera® elite II, Olympus medical system corp, Tokyo, Japan). Images will be recorded starting immediately prior to injection until 3 minutes afterwards.
45476588|NCT03587532|Diagnostic Test|Hemodynamic evaluation|Advanced continuous hemodynamic monitoring during surgery will be performed using a PiCCO® (Pulse index Continuous Cardiac Output, Pulsion Medical Systems, Germany) catheter.
45476589|NCT03587532|Diagnostic Test|Biological and pathological markers of ischemia|"Systemic and local capillary lactate on blood samples~Mitochondrial Respiratory activity analyses on biopsies at 3 region of interest (ROI)~Pathological analyses of the biopsies at 3 ROI"
45350591|NCT02543385|Drug|S Ketamine|S+ketamine will be given in group I only in the doses of 0.25mg/kg (iv bolus) before induction along with midazolam and 0. 25 mg/kg (iv bolus) 20 minutes prior to extubation
45350592|NCT00886977|Drug|YAM80|Oral administration, 2 to 6 mg, once a day.
45476590|NCT02511808|Behavioral|Brief Advice|Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
45476591|NCT02511808|Behavioral|Motivational Interviewing|Motivational Interviewing will consist of standard techniques, such as developing discrepancy, enhancing motivation, and developing a change plan, that have been adapted to treatment for problem drinkers.
45476592|NCT02511808|Behavioral|Behavioral Self-Control Training|Behavioral Self-Control Training will consist of Cognitive Behavioral Therapy adapted to problem drinkers, whose core components include a functional analysis, skills training, daily self-monitoring, homework, and graded exposures and mastery of high risk situations.
45685802|NCT02086708|Device|Shear Wave sonoelastography|Shear Wave Sonoelastography as a ultrasound technique to measure liver fibrosis is performed on patients scheduled for non-focal liver biopsy. Results are compared with pathological score of fibrosis from liver biopsy.
45685803|NCT02065882|Biological|BT524 (fibrinogen concentrate from human plasma)|single intravenous infusion
45685804|NCT01507545|Drug|MORAb-004|MORAb-004 8mg per kg IV once a week
45685805|NCT01507545|Drug|Placebo|Placebo - normal saline IV once a week
45685806|NCT01507545|Other|Best supportive care|Best supportive care to improve quality of life
45841999|NCT03190317|Other|HIV-infected Veterans who do not use MHV|The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is not used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
45842000|NCT03190317|Other|Providers and staff of HIV-infected veteran|The investigators will interview providers and staff to understand why they think Veterans at their health system use or do not use the MHV portal for self management. The investigators will create and test an intervention based on information learned that will encourage use of MHV among Veterans and providers/staff.
45350593|NCT00884481|Other|Natalizumab|Participants treated with Tysabri
45350594|NCT02543307|Procedure|Nurse-led Patient Pathways|The NPP include a comprehensive needs and goal assessment. Patients appreciated written information provided at an early stage of their hospital stay that helped to prepare them for discharge. The NPP continue with pre- and post-operative patient care, and conclude with a newly implemented follow-up phone call after hospital discharge. Nursing interventions were presented in a checklist format, based on scientific and clinical evidence. The NPP were developed with regard to patient and family centered goals and objectives and were explicitly emphasized in the NPP. NPP guided the nursing care plan. Nurses act as advocates for patients' interests. Therefore NPPs represent a means to formalize these nursing activities and contribute to transparency in relation to other health professionals.
45350595|NCT02543151|Procedure|SpyGlass (direct visualization system) choledochoscopy|SpyGlass (direct visualization system) choledochoscopy procedure will be performed pre and post biliary complication treatment
45350596|NCT02543229|Drug|OPT-302|OPT-302 will be administered by intravitreal injection once every month for 3 months
45350597|NCT02543229|Drug|Lucentis™|Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months
45350598|NCT02543073|Biological|MSCs|MSCs will be given at a median dose of 1×10^6 cells/kg once weekly for 4 weeks as one cycle treatment.
45350599|NCT02543073|Drug|AZM|AZM will be given （0.25g qd）for 4 weeks as one cycle treatment.
45350600|NCT02543073|Drug|Glucocorticoid|Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.
45350601|NCT02542995|Other|QI interventions|Intervention categories: communication improvement, chronic disease QI projects (for patients), workflow redesign
45350602|NCT00887055|Device|CRT device|
45350603|NCT04037553|Other|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
45685807|NCT04409535|Other|WHOQOL-BREF survey|Participants will be surveyed and interviewed about their perceptions regarding COVID-19 health emergency
45350604|NCT04037553|Other|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
45350605|NCT04037553|Other|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
46045177|NCT00655798|Dietary Supplement|Plain Yogurt + mix of anti-oxidants capsules|plain yogurt and capsules containing mix of anti-oxidants
45350606|NCT00884559|Other|instruction|Debriefing
45350607|NCT00546364|Drug|Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 40 mg/m^2, administered as a 3-hour intravenous (IV) infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
45350608|NCT00546364|Drug|Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 32 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
45350609|NCT00546364|Drug|Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2|Docetaxel 75 mg/m^2 administered as a 1-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
45350610|NCT00887211|Device|stent|ProStent rapamycin-eluting stent system manufactured by Tianjian Medical Technology (Suzhou) Co., Ltd.
45350611|NCT00887211|Device|stent|Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.
45350612|NCT00887367|Drug|GSK598809|Two 175 mg doses of GSK598809 will be given.
45350613|NCT00887367|Other|Ethanol|A constant ethanol level of 0.6 g·L-1 for five hours will be given to the subjects intravenously. This level shows significant CNS effects, without causing too many inadvertent events. Furthermore this level is considered safe as it is just above the legal driving limit in the Netherlands (i.e. 0.5 g·L-1) and these levels are routinely achieved during social drinking. Moreover, this level leaves enough room for CNS-impairment without compromising safety, in case of a (supra-) addictive drug-alcohol interaction.
46045178|NCT00655798|Dietary Supplement|Yogurt containing Lactobacillus helveticus|Yogurt containing the probiotic Lactobacillus helveticus
46045179|NCT00655798|Dietary Supplement|Yogurt containing Bifidobacterium animalis ssp.|Yogurt containing the probiotic Bifidobacterium animalis ssp.
46045180|NCT02635048|Procedure|Mini Percutaneous Nephrolithotomy|patients undergo PNCL with 18Fr nephrostomy tract
45350614|NCT00887445|Drug|SLV341|5 - 1000mg once daily
46045181|NCT02635048|Procedure|Percutaneous Nephrolithotomy|patients undergo PNCL with 24Fr nephrostomy tract
45350615|NCT00887445|Drug|placebo|
45350616|NCT00964210|Drug|Licensed quadrivalent HPV vaccine, Gardasil|The dose of the four valent (4v) HPV vaccine is 0.5ml administered by intramuscular (IM)injection. The recommended schedule is 0, 2 and 6 months.
45350617|NCT00964288|Drug|GSK1014802 low dose|oral tablet
45350618|NCT00964288|Drug|Lidocaine|positive control
45350619|NCT00964288|Drug|GSK1014802 high dose|oral tablet
45350620|NCT00964288|Drug|Placebo|To match GSK drug and positive control
45476593|NCT02506972|Other|Classic Quaker Quick Oats|Various doses of oats without or with sugar
45476594|NCT02506972|Other|Cream of Rice Cereal|Various doses of cereal without sugar
45476595|NCT03727841|Drug|Marizomib|0.8mg/m(2) intravenous (IV) on days 1, 8, and 15 of each 28-day cycle, 24 cycles total.
45685808|NCT01482819|Device|galyfilcon A|contact lenses worn bilaterally for 8-12 hours
45685809|NCT01482819|Device|galyfilcon A plus|contact lenses worn bilaterally for 8-12 hours
45685810|NCT01482819|Device|lotrafilcon A|contact lenses worn bilaterally for 8-12 hours
45685811|NCT01482819|Device|polymacon|contact lenses worn bilaterally for 8-12 hours
45685812|NCT01482819|Other|spectacles|habitual spectacles owned by subject, non-specific manufacturer
45685813|NCT01534533|Dietary Supplement|Placebo|one gelatine capsule containing starch per day, for 12 months
45685814|NCT01534533|Dietary Supplement|Lutein group|one gelatine capsule containing 20mg lutein per day, for 12 months
46045182|NCT00652522|Device|ICD/CRT implant|Implantation of a ICD/ CRT device if not yet implanted
46045183|NCT00652522|Procedure|AF ablation|Atrial Fibrillation ablation by pulmonary vein isolation
46045184|NCT00652522|Other|Best Medical Treatment|Best medical treatment according to current guidelines for Management of Patients with Atrial Fibrillation and for Management of Chronic Heart Failure.
45350621|NCT00964522|Other|Nurse education and care program|Random allocation of the patients in two arms according to the nursing cares. The arm A is the one of standard education and care. They consist of receiving programmed oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle of treatment. Also, the patients will be able to ask for information to the nurses when they need it. Arm B is the one of experimental education and care. They consist of receiving oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle. In addition, the patients assigned to arm B will receive programmed education and care about the chemotherapy by a Oncology nurse before the beginning of the treatment and in each cycle, in a specific nurse consultation.
45350622|NCT00964600|Procedure|TAP blockade|15 cc Bupivacaine 0.25% ,injected bilaterally in the TAP blockade arm
45350623|NCT00964756|Genetic|Ad5.SSTR/TK.RGD|Group 1 Day 1-3 IP 1 x 10 9th vp/d Group 2 Day 1-3 IP 5 x 10 10th vp/d Group 3 Day 1-3 IP 1 x 10 12th vp/d
45350624|NCT00964756|Drug|Ganciclovir (GCV)|GVC Day 5-18 IV 5 mg/kg BID all groups
45350625|NCT00964834|Drug|Doxycycline and Valortim|Days 1-5 100mg IV Doxycycline BID over 60 minutes. Day 6 20mg/kg Valortim IV over 60 minutes.
45350626|NCT00964834|Drug|Placebo Antibiotic and Valortim|Days 1-5 20mg/kg IV Normal Saline BID over 60 minutes. Day 6 20mg/kg IV Valortim over 60 minutes.
45350627|NCT00964834|Drug|Placebo Antibiotic and Placebo Valortim|Days 1-5 200mL IV Normal Saline for Placebo Antibiotic BID over 60 minutes. Day 6 20mg/kg IV Normal Saline for Placebo Valortim over 60 minutes.
45350628|NCT00612105|Drug|Retigabine|150mg/day up to 900mg/day
45350629|NCT00612105|Drug|Placebo|daily
45476596|NCT03345628|Drug|Sedatives|sedated group received sedative drugs to tolerated intubation and ventilation
45476597|NCT03552523|Device|Bionic Pancreas|During this arm the subject will ONLY use our bionic pancreas device with an insulin only configuration using a rapid-acting insulin analog. Subjects will wear a continuous glucose monitoring device (the Dexcom G5) as part of the bionic pancreas, and use the study provided glucose meter.
45476598|NCT03552523|Other|Usual Care|Subject will wear a continuous glucose monitoring device (the Dexcom G5) and use the study provided glucose meter.. Subject will not change their prescribed home insulin therapy regimen during this arm whether that be an insulin pump or multiple daily injections.
45476599|NCT03345550|Drug|Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules.|Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA & 100 mg EPA) or placebo capsules.
45476600|NCT03345550|Drug|Placebo - Cap|Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA & 100 mg EPA) or placebo capsules (olive oil capsules that look identical to the intervention DHA+EPA).
45476601|NCT03728101|Drug|Simvastatin, Dabigatran Etexilate|The subjects receive dabigatran etexilate with and without simvastatin administration
45476602|NCT03186378|Combination Product|VP-102 with applicator|Subjects will receive treatment to their molluscum contagiosum with VP-102.
45476603|NCT02511964|Behavioral|Interval Training at 1% Incline|Six Sessions of Running at 1% incline
45476604|NCT02511964|Behavioral|Interval Training at 10% Incline|Six Sessions of Running at 10% incline
45476605|NCT03844217|Drug|Macimorelin 0.5mg/kg body weight|oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin
45476606|NCT03844217|Drug|Macimorelin 0.75mg/kg body weight|oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight Macimorelin
45476607|NCT04170972|Other|Acute exercise|One hour of acute one-legged knee-extensor exercise followed by 3 hours recovery and 2 hours insulin (1.5 mU/min/kg) stimulation.
45476608|NCT02515864|Drug|FYU-981|
45350630|NCT04017741|Drug|Combined Depo-Medrone and Lidocaine|"Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle, the IMPs are injected at a 90 degrees angle till the bony endpoint is obtained. A combination of 2 mls of 2% lidocaine and 80mg methylprednisolone will be administered.~Patients who no longer receive any benefit will be crossed over to the placebo arm."
45350631|NCT04017741|Drug|Sodium Chloride 0.9% Inj|Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle the 4mls of normal saline (0.9%) are injected at a 90 degrees angle till the bony endpoint is obtained. Patients who no longer receive any benefit will be crossed over to the active arm.
45476609|NCT02515864|Drug|Placebo|
45476610|NCT02515864|Drug|Moxifloxacin|
45476611|NCT02515864|Drug|Moxifloxacin Placebo|
45685815|NCT01534533|Dietary Supplement|Combination group|one gelatine capsule containing 20mg lutein and 20 mg lycopene per day, for 12 months
45685816|NCT01534533|Dietary Supplement|Normal lutein control group|subjects without early atherosclerosis, treated with one gelatine capsule containing 20mg lutein per day, for 12 months
45685817|NCT02986035|Other|ECA cream|
45685818|NCT02061358|Drug|UV-4B 3 mg|Oral solution, single dose
45842001|NCT03155997|Drug|Abemaciclib|Administered orally.
45842002|NCT03155997|Drug|Standard Adjuvant Endocrine Therapy|Administered according to label instructions.
45685819|NCT02061358|Drug|UV-4B 10 mg|Oral solution, single dose
45685820|NCT02061358|Drug|UV-4B 30 mg|Oral solution, single dose
45350632|NCT00546052|Drug|losartan potassium (+) hydrochlorothiazide|All patients received Losartan 50mg at Visit 2 titrated to Losartan 100mg (if target BP not achieved) titrated to Losartan 100mg + HCTZ 12.5mg (if necessary) up to Losartan 100mg + HCTZ 25mg. Duration of treatment was one year.
45350633|NCT00887601|Drug|MK3134|Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.
45350634|NCT00887601|Drug|Comparator: Placebo|Placebo capsules only in one of the four treatment periods.
45350635|NCT00887601|Drug|Donepezil|Single dose 5 mg donepezil capsules in two of the four treatment periods.
45350636|NCT00887601|Drug|MK3134|Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods
45842003|NCT03105336|Biological|axicabtagene ciloleucel|A single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered intravenously.
46045185|NCT02645344|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
45350637|NCT02542839|Device|NeuroStar TMS therapy|Application of repetitious transcranial magnetic stimulation (TMS) pulses using NeuroStar device to a specific brain target at predefined stimulation parameters.
45350638|NCT02542839|Device|Sham NeuroStar TMS therapy|Same procedure as real rTMS without stimulating the cerebral cortex.
45350639|NCT02542839|Other|Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)|All participants will receive a clinical assessment of dystonia severity by using the TWSTRS test.
45685821|NCT02061358|Drug|UV-4B 90 mg|Oral solution, single dose
45842004|NCT03105336|Drug|Cyclophosphamide|Administered intravenously
46045186|NCT02645344|Behavioral|Sensory Cueing (SC)|
46045187|NCT02645344|Behavioral|Conventional Rehabilitation|
46045188|NCT02637700|Drug|Intravenous Immunoglobulin|Comparison between intravenous immunoglobulin and placebo (saline 0.9%).
46045189|NCT02637700|Drug|Placebo|Comparison between placebo (saline 0.9%) and intravenous immunoglobulin.
45350640|NCT02542839|Other|Craniocervical Dystonia Questionnaire (CDQ-24)|All participants will fill out the Craniocervical Dystonia Questionnaire (CDQ-24) quality of life questionnaire.
45350641|NCT02542839|Other|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
45350642|NCT02542839|Procedure|Botulinum toxin injections|All participants will receive Botulinum toxin(BoNT) injections as part of their standard of care
45350643|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.025 mg, single dose, one dose
45350644|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.1 mg, single dose, one dose
45350645|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.25 mg, single dose, one dose
45350646|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
45842005|NCT03105336|Drug|Fludarabine|Administered intravenously
45842006|NCT03100747|Procedure|Bilamellar 3 mm|Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 3 mm from the eyelid margin
45842007|NCT03100747|Procedure|Bilamellar 5 mm|Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 5 mm from the eyelid margin
45842008|NCT03100747|Procedure|Trabut 3 mm|Trichiasis surgery using Trabut procedure with incision 3 mm from the eyelid margin
45350647|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 1 mg, single dose, one dose
45350648|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 2 mg, single dose, one dose
45685822|NCT02061358|Drug|UV-4B 180 mg|Oral solution, single dose
46045190|NCT02637466|Drug|Vortioxetine|
46045191|NCT02637388|Dietary Supplement|Oatwell28 Oatwell Original Powder|
46045192|NCT02637388|Dietary Supplement|Control Breakfast|Isocaloric breakfast without added beta-glucans
46045193|NCT02634892|Device|PRO-TECT|Patient will be placed on ROHO SOFFLEX2 mattress with has been modified with gel cushions in the sacral region for heal dissipation by standard closed system cooling pad
46045194|NCT02634970|Drug|Ranibizumab|0.5 mg, intravitreal injection
46045195|NCT00885352|Drug|Sitagliptin|Sitagliptin 100 mg tablet orally once daily for 26 weeks.
45350649|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
45350650|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 5 mg, single dose, one dose
45350651|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 8 mg, single dose, one dose
45350652|NCT00964912|Drug|Placebo|Oral Solution, Oral, 0 mg, single dose, one dose
45350653|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
45350654|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
45350655|NCT00887757|Drug|ABT-263|"150mg of ABT-263 is taken orally once daily on Days 1-3 and Days 8-10 out of each 21 day cycle.~325 mg of ABT-263 is taken orally once daily on days 1-3, 8-10, 15-17 out of each 28 day cycle.~This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study."
45350656|NCT00887757|Drug|gemcitabine|Gemcitabine 1000 mg/m2 will be given by intravenous infusion on Day 1 and Day 8 of each 21 day cycle. Gemcitabine 1000 mg/m2 will be given by intravenous infusion on days 1, 8 and 15 of each 28 day cycle.
45350657|NCT00965068|Other|Cholesterol|
45350658|NCT02542527|Procedure|Fluid filled breast pump|breast milk pumping with a fluid filled breast pump
45350659|NCT00965224|Biological|dendritic cell vaccination (active specific immunotherapy)|
45685823|NCT02061358|Drug|UV-4B 360 mg|Oral solution, single dose
45685824|NCT02061358|Drug|UV-4B 720 mg|Oral solution, single dose
45685825|NCT02061358|Drug|UV-4B 1000 mg|Oral solution, single dose
45685826|NCT02061358|Drug|Placebo|Oral solution, single dose
45685827|NCT01758796|Procedure|Non-operative treatment|Below-the-knee cast for six weeks.
45685828|NCT01758796|Procedure|Surgery|Open reduction and internal fixation with 1/3 semi-tubular plate and screws.
46045196|NCT00885352|Drug|Comparator: Placebo|Placebo to sitagliptin 100 mg tablet orally once daily for 26 weeks.
46045197|NCT00885352|Drug|Pioglitazone|Participants taking 30 mg or more pioglitazone oral tablet(s) daily at screening in combination with metformin will enter a 4-week dose-stable period followed by a 2-week single-blind run-in and a 26-week treatment period. Participants taking 4 mg or more rosiglitazone oral tablet(s) daily at screening in combination with metformin were to be switched to a corresponding dose of pioglitazone prior to starting a 4-week dose-stable period. Participants who are taking less than 30 mg/day or no pioglitazone at screening will be titrated to a stable dose of at least 30 mg pioglitazone once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with pioglitazone will be up to 42 weeks.
45350660|NCT00887835|Device|PERPOS™ PLS|To stabilize the spine as an aid to fusion through bilateral immobilization of the facet joints.
45350661|NCT04392921|Drug|Amiodarone|"Patients will undergo one of the two regimens of amiodarone, based on their ability to tolerate po (per os) intake in the post-operative period:~• All patient will receive 1050mg of amiodarone in 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~If unable to tolerate po intake: daily infusion of 1050mg in 100mL of 5% dextrose for postoperative days 1 to 5 or until the day of discharge (whichever occurs first)."
45476612|NCT00687596|Drug|TAC-101|Participants were randomized to TAC 101 received TAC 101 20 mg (administered as 2 10 mg formulated tablets) PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) for 14 days followed by a 7 day recovery period. This cycle was repeated every 21 days.
45476613|NCT00687596|Drug|Placebo|Participants randomized to placebo received 2 placebo tablets (identical in appearance to the TAC 101 tablets) administered PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) in a regimen identical to that for TAC 101.
45476614|NCT02507206|Drug|DAR 0-100A|15 mg DAR 0100A is dissolved in 150 cc NS administered over 30 minutes intravenously.
45350662|NCT04392921|Drug|Placebo|"Patients will undergo one of the two schedules or intravenous infusion, based on their ability to tolerate po intake in the post-operative period:~All patients will receive 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~o If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~Esophagectomy patient will receive 100mL of 5% dextrose at the time of anesthesia induction at a rate of what would be 0.73mg/min or 43.75mg/h if it contained 1050mg of amiodarone, followed by daily infusion of 100mL of 5% dextrose for 4 days or until the day of discharge (whichever occurs first)."
45350663|NCT00959530|Procedure|lingualized occlusion|occlusal surface arranged by lingualized occlusion
45476615|NCT02507206|Drug|Placebo|15 mg DAR placebo is dissolved in 150 cc NS administered over 30 minutes intravenously.
45476616|NCT03844373|Dietary Supplement|STOCKHOLM|STOCKHOLM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision.
45476617|NCT02892409|Drug|Clarithromycin|Clarithromycin tablets
45476618|NCT02892409|Drug|Amoxicillin|Amoxicillin capsules
45350664|NCT00959530|Procedure|Full Bilaterally Balanced Articulation|occlusal surface arranged by Full Bilaterally Balanced Articulation
45476619|NCT02892409|Drug|Tripotassium bismuth dicitrate|Tripotassium bismuth dicitrate tablets
45476620|NCT02892409|Drug|Lansoprazole|Lansoprazole capsules
45476621|NCT02892409|Drug|TAK-438|TAK-438 tablets
45476622|NCT03219216|Drug|Glecaprevir/Pibrentasvir|Film-coated tablet
45476623|NCT05668169|Other|Family-centered support program for caregivers of stroke survivors|Once participants joined the family-centered support group, participants received 90-minute interventions, including an introduction to stroke and rehabilitation education, problem-solving skills training, and long-term care information. Investigators also invited participants to join the instant messaging application-based 24-h peer-support group for caregivers. On the second and fourth days after receiving the interventions, the researcher visited the participants to review and practice the content provided on the first day; each session was 30 to 40 minutes long. The researcher contacted the participants one week after participants joined the study to discuss their care difficulties or experiences and did so three times biweekly thereafter via the instant messaging application.
45476624|NCT02507128|Drug|liraglutide|Liraglutide were taken 30 min before PCI.
45476625|NCT02507128|Drug|placebo|Placebo were taken 30 min before PCI.
45476626|NCT03731377|Drug|Crystalloid Solutions|Mini-fluid challenge with crystalloid 250 ml will be given to patients first. After observation of hemodynamic parameters, further fluid challenge will be given for response observation.
45476627|NCT02507050|Drug|Ivabradine|To start Ivabradine 6 weeks prior to PCI.
45476628|NCT03844529|Device|Sunmax FULLSGEN with Lidocaine|Subject who voluntarily sign the informed consent form (day -14~1) will be randomly assigned to investigational or control group and have intradermal allergy test. After the injection treatment by randomly choosing the device, every subject would have 6 follow-up visits.
45476629|NCT03728023|Drug|AZD4205|SAD: 5mg, 20mg, 50mg, 100mg and 150mg MAD: low, medium and high dose once daily X14 days
45847610|NCT03707184|Procedure|Positron Emission Tomography|Undergo PET/CT scan
45350665|NCT00959608|Behavioral|Think Health! program|Brief 10-15 minute counseling with Primary Care Provider for weight management, Participant binder with eating, physical activity and stress management educational materials, adapted from the Diabetes Prevention Program (DPP)(Knowler et al, 2002; DPP Research Group, 2002), physical activity resource guide, and telephonic health related messages (year 2).
45350666|NCT00959608|Behavioral|Basic Plus program|15 minute counseling sessions with lifestyle coach, in addition to the Basic Think Health! program intervention.
45350667|NCT00673920|Drug|Methotrexate|Oral or parenteral repeating dose
46045198|NCT00885352|Drug|Metformin|Participants taking 1500 mg or more metformin oral tablet(s) and at least 30 mg pioglitazone or 4 mg rosiglitazone daily at screening will enter a 4-week dose-stable period followed by a 2-week single-blind placebo run-in, and a 26-week treatment period. Participants who are taking less than 1500 mg/day metformin at screening will be titrated to a stable dose of at least 1500 mg metformin once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with metformin will be up to 42 weeks.
45350668|NCT00673920|Drug|Ocrelizumab|"Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).~Ocrelizumab was administered in combination with Methotrexate."
45350669|NCT00673920|Drug|Placebo|Intravenous repeating dose
45350670|NCT00959686|Drug|Bendamustine|Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
45350671|NCT00379795|Drug|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year)
45350672|NCT04588948|Drug|Intravitreal Aflibercept|Two arms (non-vitrectomized, and vitrectomized) are included in the study to evaluate the effect of vitrectomy on the intraocular and systemic pharmacokinetics of intravitreal aflibercept injection
45350673|NCT00758628|Drug|Bromefenac|Bromfenac BID 3 months
45476630|NCT03728023|Drug|Placebo|Single dose in SAD and once daily for 14 days
45476631|NCT03344926|Behavioral|ACTsmart|"Participant receive ACT treatment via a smart phone application, including psychologist support via a message function within the application.~Treatment content is divided into four modules:~education about pain behaviors, exposure and acceptance and commitment therapy~education about pain physiology~exercises on changing behaviors, acceptance, mindfulness, defusion and exposure~value based exposure in the participant's daily life"
45476632|NCT02878044|Other|Thyroid Decision Aid|The Thyroid Decision Aid is a tool designed to help clinicians and patients discuss treatment options for thyroid nodules.
45476633|NCT01199315|Drug|AZD1446|oral capsule, Moderate Release
45685829|NCT01746160|Drug|C1 Implant|Patients treated with dental implants.
45350674|NCT00758628|Drug|Blink|Blink BID for 3 months
45350675|NCT00959998|Other|Self-administered Acupressure|
45350676|NCT01048411|Drug|Naja-comp.|homeopathic remedy
45685830|NCT01895296|Drug|Pasireotide|somatostatin analogue pasireotide
45350677|NCT01048411|Drug|Placebo|s.c. injection of NaCl-solution three times a week
45350678|NCT00765024|Drug|Ivermectin|single dose of 200 mcg/kg
45350679|NCT00765024|Drug|ivermectin|two single dose of 200mcg/kg in 2 weeks
45350680|NCT00765024|Drug|Albendazole|Albendazole 7 days
45350681|NCT01743391|Procedure|Office-hysteroscopy with biopsy|
45350682|NCT05279638|Diagnostic Test|serum ATG5|This kit is used to assay the Autophagy protein 5(ATG5) in the sample of human's serum, blood plasma, and other related tissue Liquid
45350683|NCT02557932|Drug|Standard triple therapy|Lansoprazole 30mg, 2 times a day + Clarithromycin 500mg, 2 times a day + Amoxicillin 1000mg, 2 times a day for 7 days
45350684|NCT02557932|Drug|Bismuth quadruple therapy|Lansoprazole 30mg, 2 times a day + Bismuth 300mg, 4 times a day + Tetracycline 500mg, 4 times a day + Metronidazole 500mg, 3 times a day for 10 days
45350685|NCT00965614|Other|MCG|Cardiac Arrhythmia,Heart Disease
45350686|NCT00762684|Drug|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
45685831|NCT01895296|Drug|Placebo|placebo s.c.
45685832|NCT04272190|Other|clinical routine treatments|The cohort stratified by four factors: preoperative treatment (not received, neoadjuvant chemotherapy, preoperative radiotherapy); surgical approach (laparoscopic, abdominal, vaginal, robotic); hysterectomy types (type A, type B, type C1, type C2), primary treatment (Radical hysterectomy + pelvic lymph node dissectionp; radiochemotherapy)
46045199|NCT00885352|Drug|Glipizide|Participants not meeting specific glycemic controls during the 26-week treatment period will use glipizide oral tablets as rescue therapy. In countries where glipizide is not available, participants will receive a sulfonylurea marketed in that country.
46045200|NCT02637310|Drug|N02RS1 1200mg|1200mg/day, Three times a day orally, 2 tablets once, 7 days
45350687|NCT00762684|Drug|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
45350688|NCT00960232|Drug|Cholecalciferol|40.000 IU cholecalciferol per week for 6 months
45350689|NCT00960232|Drug|placebo|placebo
45350690|NCT00765180|Device|TRE vs. NBI|TRE NBI
45350691|NCT04577014|Drug|Retifanlimab|"Phase I:~Dose Level 1 - 375 mg (flat dose) Dose Level 0 - 210 mg (flat dose) Dose Level -1 - 375 mg (flat dose) Dose Level -2 - 375 mg (flat dose)~Phase II: 375 mg (flat dose)"
45350692|NCT04577014|Drug|Gemcitabine|"Phase I:~Dose Level 1 - 900 mg/m2 Dose Level 0 - 900 mg/m2 Dose Level -1 - 750 mg/m2 Dose Level -2 - 675 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab ) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),"
45350693|NCT04577014|Drug|Docetaxel|"Phase I:~Dose Level 1 - 75 mg/m2 Dose Level 0 - 75 mg/m2 Dose Level -1 - 60 mg/m2 Dose Level -2 - 50 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),"
45350694|NCT05282550|Drug|Trazodone|50mg of trazodone administered for 4 weeks.
45350695|NCT05282550|Drug|Placebo|Placebo administered for 4 weeks.
45350696|NCT00960310|Drug|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
45350697|NCT00960310|Drug|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
45476634|NCT01199315|Drug|Placebo|oral capsule
45476635|NCT03727945|Other|abdominopelvic exercise and posture|n=21 women received supervised abdominopelvic exercise with previous postural correction. During 12 sessions a specialized physiotherapist supervised to realization of progressive abdominopelvic exercises, previous explain postural correction pelvis, cervical and dorsal zone.
45476636|NCT03727945|Other|abdominopelvic exercise|n=21 women received supervised abdominopelvic exercise. During 12 sessions a specialized physiotherapist supervised to realization of progressive abdominopelvic exercises.
46045201|NCT02637310|Drug|Placebo|1200mg/day, Three times a day orally, 2 tablets once, 7 days
45350698|NCT00610155|Drug|Placebo|BID
45476637|NCT02506582|Dietary Supplement|jerusalem artichoke and fermented soybeans powder mixture|40 g jerusalem artichoke and fermented soybean powder mixture
45476638|NCT02506582|Dietary Supplement|placebo|40 g powdered rice flour
45350699|NCT00610155|Drug|Pregabalin|Dose 75 mg titrated to 150 mg, bid
45350700|NCT00610155|Drug|Tramadol SR|Dose 50mg titrated to 200 mg, bid
45350701|NCT00960466|Behavioral|Distress Thermometer and Problems List|When using the distress thermometer and problem list (DT&PL), the nurse or radiographer asks the patient to indicate distress over the past week on a visual analogue scale from 0 (no distress) to 10 (high distress). Next, from a list of 42 items, patients identify practical, family, emotional, spiritual or physical problems that have caused distress. The completion of the DT&PL should be a collaborative exercise with patients able to review what is written on the assessment sheet. Potential solutions will be discussed which may involve the following: i) concerns that can be resolved immediately (e.g. providing information, prescribing an analgesic); ii) concerns that require patient actions (e.g. participating in support groups); iii) concerns that require a referral (e.g. mental health specialist, social or pastoral care). The meeting will end with a summary plan of action.
45350702|NCT00960466|Behavioral|Usual psychosocial support|If patients express concerns about psychosocial issues, then clinic staff will discuss these issues, offer advice or make a referral as they see fit. However, no formal time will be set aside to monitor patient distress using the DT, elicit problems using the PL or develop a plan of action based on these tools. Because of the nature of the intervention, both the patient and the therapist will be aware of treatment assignment.
45476639|NCT02292758|Biological|Bevacizumab|Given IV
45476640|NCT02292758|Biological|Cetuximab|Given IV
45842009|NCT03093909|Drug|Gemcitabine|Nebulized dose of aerosol GCB twice a week continuously (escalating treatment dose schema, starting at 0.75 mg/kg to 3.0 mg/kg). Participants receive a pre-determined volume of nebulized solution, according to the dose level and weight of the participant, with each aerosol GCB administration. One cycle is 4 weeks in duration.
46045202|NCT00655954|Procedure|Induced sputum|Used Ultrasonic nebuliser
45350703|NCT00758940|Device|Acrysof ReSTOR multifocal IOL|Implanted into the study eye following cataract extraction surgery
45350704|NCT00759018|Biological|remestemcel-L|Patients will be treated with Prochymal® twice per week at a dose of 2 x 10^6 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
45350705|NCT00965770|Device|Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
45350706|NCT02541825|Device|the stent of diameter of 7mm|108 patients use the stent of diameter of 7mm in TIPS
45350707|NCT02541825|Device|the stent of diameter of 8mm|108 patients use the stent of diameter of 8mm in TIPS
46045203|NCT00656032|Other|paricalcitol|1 to 20 micrograms administered via IV; every other day, 3 days per week, for 8 weeks
45476641|NCT02292758|Drug|Irinotecan|Given IV
45476642|NCT02292758|Other|Laboratory Biomarker Analysis|Correlative studies
45476643|NCT02292758|Other|Placebo|Given IV
45476644|NCT04154904|Other|Exercise|Subjects will be randomized to complete either aerobic, high intensity interval training, or resistance exercise videos twice weekly at home.
45476645|NCT04721249|Dietary Supplement|D-serine|Patients will receive four 500mg capsules of D-serine each day over a course of six weeks (two after breakfast and two after dinner).
45842010|NCT03070223|Drug|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food
46045204|NCT00656032|Other|cinacalcet|0 to 180 mg administered orally every day for either 8 weeks or 16 weeks
46045205|NCT02637154|Behavioral|Motivational Interviewing|Motivational Interviewing method
46045206|NCT02637154|Behavioral|Standard Education|Standard Education material will be used
46045207|NCT00656734|Biological|MDX 1411|MDX-1411 (fully human monoclonal antibody) administered as an i.v. infusion for up to 5 doses per cycle, with a maximum of 17 cycles total
45350709|NCT00884871|Procedure|LapBand|Prospective observation study of 100 obese women undergoing laparoscopic gastric banding to determine impact of weight loss on pelvic floor disorders
45350710|NCT00765414|Biological|Myozyme|30 mg/kg qow f and 40 mg/kg qow
45350711|NCT00960544|Drug|Capecitabine|Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
45350712|NCT00888147|Dietary Supplement|Fiber containing tube feeding formula|This group will be prescribed adequate calories, protein and fluid using a formula that contains fiber.
45350713|NCT04049136|Diagnostic Test|NT-proBNP|Measure levels of NT-proBNP in healthy pregnancy women across BMI categories.
45350714|NCT04554160|Device|Loop recorder implantation|A loop recorder is implanted in the start of the study after informed consent is signed and enables continuous cardiac monitoring.
45350715|NCT04037631|Diagnostic Test|Diagnostic device|Diagnostic test
45350716|NCT00762840|Device|the Apexum Protocol|using the apexum kit for minimally invasive removal of periapical lesion tissue.
45350717|NCT00762840|Procedure|Conventional endodontic procedure|Standard root canal treatment
45350718|NCT00888225|Procedure|Eccentric exercise|Eccentric exercise treatment performed at home with three sets of 15 repetitions daily
45350719|NCT00888225|Procedure|Concentric exercise|Concentric exercise treatment at home with three sets of 15 repetitions daily
45350720|NCT00765492|Drug|AZD8529|oral
45350721|NCT00765492|Drug|Placebo|oral
45350722|NCT00960700|Device|Visual Acuity|Assessment of visual acuity
45350723|NCT00960700|Device|Contrast sensitivity|Assessment of contrast sensitivity
45350724|NCT00960700|Device|Reading Speed|Assessment of reading speed
45350725|NCT00960700|Procedure|Eye Health|Examination of eye health through use of a slitlamp/ photography. Assessment of Intraocular Pressure.
45350726|NCT02541747|Behavioral|massage|massage
45350727|NCT04488952|Device|nerve block combined with general anesthesia|Patients in this group receive nerve block combined with general anesthesia.
45350728|NCT04488952|Device|spinal anesthesia|Patients in this group receive spinal anesthesia.
45350729|NCT04037475|Device|photodynamic therapy herpes labialis|Patients will receive Photodynamic Therapy (PDT), irradiations will be performed with the Laser Duo® red laser diode (MMOptics, São Carlos, SP, Brazil) with a wavelength of 660 nm, with a power of 100 mW, the energy density of 300 J / cm², with energy of 3 J in the center of the lesion for 30 seconds. The laser will be positioned in direct contact with the lesion, perpendicular, applied centrally to each isolated lesion that presents with fixed energy per point of 3J. Wash in abundance with saline solution until the removal of the photosensitizer is complete. All treatment proposed in group 1 (simulation of PDT + delivery of aciclovir cream) in each patient will be concluded in a single session. Treatment for group 2 (PDT + placebo cream) will also be completed in a single session. All possible adverse effects will be noted and qualified during the treatment protocol and maintenance period (3/3 months) using the questionnaire developed for this protocol.
45350730|NCT00888303|Drug|Dexamethasone|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
45350731|NCT00888303|Drug|saline solution|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
45350732|NCT00888303|Procedure|Thyroidectomy, total or partial|Surgical standard intervention
45350733|NCT00967642|Drug|Intravenous Insulin|continuous intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
45350734|NCT02541591|Other|Neuroprotective goal directed hemodynamic optimization|
45350735|NCT02541591|Other|MAP > 65mmHg|MAP > 65mmHg
46045208|NCT00885118|Drug|Placebo (middle dose)|Placebo tablets once a day
45350736|NCT00961012|Procedure|The Big Squeeze|Trunk release as per MSIP protocol. Standing at the foot of the bed, facing the subject, Experimenter A grasps both ends of the flat sheet to pull the trunk forward and away from the mattress surface. As the trunk release procedure is performed, Experimenter A checks to verify that the laser beam shines through to the opposite wall to confirm that the shoulders have cleared the mattress.
45350737|NCT00674700|Drug|300 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
45350738|NCT00674700|Drug|500 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
45842011|NCT03070223|Drug|Placebos|One tablet taken once daily, orally with or without food
45350739|NCT00674700|Drug|Placebo tablet|One sublingual tablet daily for one year
46045209|NCT00885118|Drug|Placebo|Placebo tablets once a day
46045210|NCT00885118|Drug|BI 10773|BI 10773 middle dose tablets once a day
46045211|NCT00885118|Drug|BI 10773|BI 10773 high dose tablets once a day
46045212|NCT00885118|Drug|BI 10773|BI 10773 middle dose tablets once a day
46045213|NCT00885118|Drug|Placebo (high dose)|Placebo tablets once a day
46045214|NCT00885118|Drug|BI 10773|BI 10773 low dose tablets once a day
46045215|NCT00885118|Drug|Placebo (low dose)|Placebo tablets once a day
46045216|NCT00656812|Drug|Rituximab|375 mg/m2 on day 1 of a 21-day treatment cycle
46045217|NCT00656812|Drug|2-CdA|0.1 mg/kg s.c. on days 1 - 4 of a 21-day treatment cycle
45350740|NCT00888537|Other|AMI Choice Decision Aid|The decision aid describes the risk of dying in the first six months following a heart attack without and with taking a bundle of medications to help the heart heal.
45350741|NCT00888537|Other|Usual Care|Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
45350742|NCT02542371|Other|Arterial Imaging|
45350743|NCT00762918|Dietary Supplement|cholecalciferol|cholecalciferol 5000 IU capsule by mouth daily for 3 months
46045218|NCT00656110|Drug|equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml|Bilateral 3rd/4th common digital nerve injections with neuroma treatment mixture given weekly for 3 weeks
46045219|NCT00656110|Drug|Normal saline - 1ml|Bilateral 3rd/4th common digital nerve injections with normal saline given weekly for 3 weeks
45350744|NCT00546910|Drug|Atomoxetine|A one-week atomoxetine treatment period with the 0.5 mg/kg per day lead-in dose will be succeeded by a 7 week period at the target dose of 1.2 mg/kg per day. 3 capsules of study medication have to be taken once daily in the morning, with or without food.
46045220|NCT04163692|Other|Progressive relaxation exercises|"Following intructions have been performed by patients:~Punch your hands and contract your forearm~Punch your hands, push your elbow towards the seat~Bend your elbows~Push your shoulders back~Press your knee down and pull your toes towards you~Pull your knees towards you and push your feet down~Tighten your hips~Push your head back~Lift your eyebrows~Make wrinkles on your nose~Tighten your teeth~Push your chin down~Close your eyes and think of good things."
46045221|NCT00656188|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5mg or 10mg or 20mg taken orally on demand 1 hour prior to sexual intercourse
45350745|NCT00546910|Drug|Placebo|3 capsules of placebo have to be taken once daily in the morning, with or without food.
45350746|NCT00763074|Behavioral|Standard life style modification for type 2 diabetes|"Two session of education for exercise and diet.~----------- Exercise: 30min/day x 4/week Diet: ideal body weight x 30~35kcal/day"
45350747|NCT00763074|Behavioral|Diet restriction|"Education for diet and exercise every 2 weeks~----------- Dietary calorie restriction: reduce their usual intake by -500kcal/day"
45350748|NCT00763074|Behavioral|Exercise|"Education for diet and exercise every 2 weeks~----------- Exercise: more than 60min/day of exercise with moderate activity level twice per day"
45350749|NCT00763074|Behavioral|Diet and exercise|"Education for diet and exercise every 2 weeks~----------- Exercise education like as exercise group and diet education like as diet group"
45350750|NCT02541513|Drug|paliparidone|All patients will begin receiving oral paliperidone 3 mg daily for three days, beginning on Day 5 of the inpatient phase. All patients will receive an injection of Paliperidone 150 mg injection on Day 8 of the inpatient phase. Patients will receive monthly 150 mg injection for the next 3 months.
46045222|NCT00656188|Drug|Placebo|Matching placebo
45350751|NCT00888693|Drug|ABT-288|See Arm Description for details.
45350752|NCT00888693|Drug|Placebo|See Arm Description for details.
45350753|NCT02558712|Other|Technology-based Eye Care Services (TECS) Protocol|Extensive History will be taken. Distance auto-refraction measurements will be made on both eyes. Eye pressure using the iCare tonometer and central corneal thickness (CCT) using the corneal pachymeter will be taken for each eye. Participants will have fundus photos taken following the standard VA diabetic teleretinal protocol. Then participants will have OCT Macula and Nerve performed. After protocol complete, then patients will see an ophthalmologist for standard eye exam.
45350754|NCT05278767|Other|E-Mobile Education and Counselling|The patients in the experimental group received e-mobile training and consultancy services with the mobile application developed specifically for bariatric surgery that started before the operation and lasted for 3 months.
45350755|NCT00961168|Other|Volume Control Ventilation|Mechanical ventilation at a constant tidal volume of 6 mL/kg.
45350756|NCT00961168|Other|Pressure Control Ventilation|Mechanical ventilation at a constant airway pressure of 25-30 cm H2O
45350757|NCT00885183|Procedure|Acupuncture therapy|12 acupuncture treatment sessions for a period of 16 weeks
45685833|NCT04389502|Device|CaPtyVa app|The apps stores all the current local Clinical practice guidelines information related to CRC screening and surveillance and through its decision algorithms assist physicians in the screening process. In the screening function, CaPtyVa helps the physicians to classify patient´s according to their individual CRC risk and to determine how and when to start with screening tests. In the surveillance, function the app assist the physician in determining when to repeat the next colonoscopy according to guideline recommendation
45685834|NCT04389502|Other|Control group|current physician knowledge on local current CRC screening and surveillance guidelines
46045223|NCT00880906|Procedure|Esophageal dilation|The esophagus is stretched during the upper endoscopy using Maloney dilators or balloon dilatation.
45350758|NCT00763152|Other|Observation of transponder stability|Observation of transponder stability and placement in the prostatic bed following radical prostatectomy
45350759|NCT00759720|Drug|TAK-559 and glyburide|TAK-559 16 mg, tablets, orally, once daily and glyburide stable dose orally, once daily for up to 26 weeks.
45350760|NCT00759720|Drug|TAK-559 and glyburide|TAK-559 32 mg, tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
45350761|NCT00759720|Drug|Glyburide|TAK-559 placebo-matching tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
45476646|NCT04721249|Dietary Supplement|Placebo|Patients in the placebo group will receive four placebo capsules each day (two after breakfast and two after dinner). The placebo capsules will contain Mannotol / Mannitol-Silica (99.5/0.5, respectively) and will be indistinguishable from D-serine by matching colour, shape, size and packaging.
45685835|NCT01895374|Procedure|laser treatments|
45685836|NCT01895374|Other|amniotic membrane application|
45685837|NCT01895374|Device|hydrocolloid application|
45685838|NCT02056756|Drug|Carfilzomib|
45685839|NCT01299532|Device|Macrolane VRF30|Device: Macrolane VRF30 (stabilized hyaluronic acid of non-animal origin) Treatment: Initial injection of a maximum of 120 ml/breast. Re-injection of a maximum of 120 ml/breast in a subgroup of subjects.
45476647|NCT02511652|Device|Ambu AuraGain evaluation|Evaluation of clinical performance in terms of Insertion, ventilation, position and complications
45476648|NCT02511652|Device|LMA Supreme evaluation|Evaluation of clinical performance in terms of Insertion, ventilation, position and complications
45476649|NCT02511652|Procedure|Laparoscopic surgery|Gynecologic laparoscopic surgery in the trendelemburg position
45476650|NCT03727867|Drug|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor|Oral EGFR TKI begins on day 1 and continues until disease progresses.
45842012|NCT03044158|Device|GeneXpert I|Onsite molecular testing with GeneXpert I as a replacement for microscopy
45350762|NCT04037319|Diagnostic Test|24 Hour Holter Monitor|24 hour holter monitor to be performed pre-operatively, and at day 30 and 90 post-operatively.
45842013|NCT03044158|Behavioral|Process re-design|Research and Uganda NTLP staff will engage health center staff in a discussion of how to re-organize clinical, laboratory and pharmacy services to enable same-day TB diagnosis and treatment.
46045224|NCT00880906|Drug|Steroid and Proton Pump Inhibitor Therapy|
46045225|NCT04160182|Behavioral|Energy Conservation Work Simplification Education|"The intervention will last approximately 45 minutes, and will be provided once/week for 6 weeks. The intervention is delivered live using web-cameras (e.g., Microsoft Zoom).~Registered and licensed occupational therapists will deliver the intervention. At beginning of the intervention, the participant and interventionist prioritize the 5 most critical fatigue-related problems that they would like to solve during the intervention. Each week, the interventionist will guide the participant through a workbook to provide knowledge and examples on how to apply the knowledge to everyday fatigue-related problems. The workbook contains: (a) information regarding fatigue in breast cancer survivors, (b) knowledge regarding fatigue management strategies, and (c) worksheets to develop skills to recognize and solve fatigue-related problems. Participants will retain the workbook after study completion."
45350763|NCT00888069|Drug|CTAP101 Capsules|Single dose oral administration
45350764|NCT00888069|Drug|CTAP101 Injection|single IV injection
45350765|NCT00763230|Device|Transcranial direct current stimulation|tDCS will be given every weekday. For each session, tDCS will be given continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash as described in the safety section above). For sham stimulation, the current will be left on for another 30s, then gradually reduced to zero over another 30 seconds, so that the initial tingling sensation experienced by subjects will be identical for the two groups. The stimulator will be placed behind the subject's head so any adjustments to the current by the operator are not evident. This sham procedure resulted in successful blinding in our pilot study.
45350766|NCT00379639|Drug|Romidepsin|7, 10 or 12 mg/m^2 via intravenous infusion over 4 hours on either Days 1, 8 and 15 or Days 1 and 15 of each 28-day cycle.
45350767|NCT00379639|Drug|Gemcitabine|800 or 1000 mg/m^2 via intravenous infusion over 30 minutes on either Days 1,8 and 15 or Days 1 and 15 of each 28 day cycle.
45476651|NCT03727867|Device|Stereotactic Body Radiation Therapy|Participants were given Stereotactic Body Radiation Therapy in a dose of 60 Gy/8 fraction for the central tumor or 50 Gy/5 fraction for the peripheral lung cancer, respectively.
45476652|NCT03843983|Device|Lipiflow® application|"Lipiflow® will be applicated in both lids of each eye during 12 minutes once. Firstly, a drop of anesthetic will be instilled in each eye. Then, while the participant stays with his eyes closed, a one-used applicator will be placed covering the subject's lid. The instrument applies heat and pressure in the lid during 12 minutes. Time frame: between 2 and 7 days after visit 1.~Then, there will be 3 follow-up visits in 3, 6 and 12 months after treatment."
45350768|NCT03948334|Drug|ZPL389 30mg|30mg of ZPL389; once daily
45476653|NCT02832648|Dietary Supplement|selenase (selenium)|Selenase (Biosyn, Germany) Sodium selenite pentahydrate
45476654|NCT02506738|Device|Intervention using mHealth|Patients in the intervention used at home a mobile system to monitor their clinical and health status.
45476655|NCT03727711|Other|TPTNS|We will be comparing hospital treatment to TPTNS at home
45476656|NCT03195660|Device|ASV Therapy|AirCurve 10 ASV device set up in AutoSet mode
45476657|NCT04497532|Other|Diet as suited for gestational diabetes mellitus|Diet that consists of complex carbohydrates, and a regimen that includes 6 meals per day, as tailored gor gestational diabetes.
45476658|NCT04497766|Drug|Nebulized Magnesium sulfate|MgSO4 100mg in 20 ml normal saline will be given via ultrasonic nebulizer over 10 minutes,and PAS score will be assessed at 30,60,120,240,360 minutes
45476659|NCT04497766|Drug|Intravenous magnesium sulphate|pts age 2 to 12 years will receive intravenous magnesium sulphate 50 mg/kg over half hour
45842014|NCT03044158|Other|Performance Feedback|Feedback of TB diagnostic evaluation quality indicators to health center staff
45842015|NCT02948569|Drug|3-V Bioscience-2640|Subjects will take a singly daily dose of 3-V Bioscience-26400 before bedtime or 22:30, whichever comes first, for 10 days.
45842016|NCT02929108|Behavioral|Facebook|Participants will be enrolled in a Secret Facebook group for social support and education
45842017|NCT02929108|Behavioral|ACCESS|"Intervention will have two components.~Participants will be enrolled in a Secret Facebook group for social support and education~Participants will use web conferencing technology to participate in their interdisciplinary team meeting"
45842018|NCT02880631|Device|BAROSTIM NEO™ System|
45350769|NCT03948334|Drug|ZPL389 50mg|50mg of ZPL389; once daily
45476660|NCT03841721|Drug|Linezolid oral tablet 300 mg/day for 5 day|Linezolid oral tablet 300 mg/day for 5 day and blood sample were obtained by direct venipuncture at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hour after drug administration in day 5
45476661|NCT03194490|Other|combined intervention group|The combined intervention group received the cervical passive mobilization, stretching, and home program (Stretching and ROM exercise).Stretching, cervical passive mobilization, and range of motion: The manual therapy was conducted by a physical therapist who has licensed from the California Board of Physical Therapy. The cervical passive mobilization were selected by the physical therapist based on the participant's condition. Stretching techniques were performed in the combined intervention group for 30 seconds and repeated 3 times twice a week in the following order on the following muscles: anterior, middle and posterior scalene, upper fibers of trapezius, pectoralis minor and interspinous muscles .AROM Exercise were performed 10 repetitions 3-4 times daily. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral.
45350770|NCT03948334|Drug|TCS and/or TCI|Topical corticosteroids (TCS) and /or topical calcineurin inhibitors (TCI) were used concomitantly or intermittently based on disease severity.
45476662|NCT03194490|Other|The standard intervention|"The standard intervention group will receive cervical mobilization and home program (ROM exercises).~Cervical mobilization and range of motion: The manual therapy was conducted by a physical therapist who has experience in manual therapy and is licensed from the California Board of Physical Therapy. The manual therapy intervention will consist of Passive Accessory Intervertebral Movements (PAIVMs). The nature of PAIVMs techniques was selected by the physical therapist based on the participant's condition.~Active Cervical Range of Motion Exercises (ACROM) were performed 10 repetitions 3-4 times daily. Subjects were advised to maintain their usual activity within the limits of pain. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral ."
45685840|NCT01276600|Drug|Emtricitabine/tenofovir|200mg of emtricitabine 300mg of tenofovir
45685841|NCT02040376|Drug|Metformin|Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
45350771|NCT00609765|Drug|Avastin|Every 28 Days: Avastin 5mg/kg iv days 1 and 15
45350772|NCT00609765|Drug|Fluorouracil|Every 28 Days: Fluorouracil 400mg/m^2 iv bolus daily days 1-5
45842019|NCT02880618|Device|Barostim Neo™ System|
45350773|NCT00609765|Drug|Doxorubicin|Every 28 Days: Doxorubicin 40mg/m^2 iv bolus day 1
45350774|NCT00609765|Drug|Streptozocin|Every 28 Days: Streptozocin 400mg/m2 iv bolus daily days 1-5
45350775|NCT00609765|Drug|Dexamethasone|Premedication: Dexamethasone 20mg intravenously days 1-5
45350776|NCT00609765|Drug|Ondansetron|Premedication: Ondansetron 16mg intravenously days 1-5
45350777|NCT00763308|Behavioral|Web-based Heart Healthy Program|The Heart Healthy program will be developed during the course of the study based on goals set by researchers and based on feedback from focus groups. The goals of the program are to educate users in the fundamentals of heart health and risk factors for heart disease and to provide a system for starting and sustaining lifestyle changes that reduce risk of heart disease.
45350778|NCT01051219|Drug|Losartan|50 milligrams to be taken orally, daily
45350779|NCT00885417|Drug|Cravit-based sequential therapy|Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
45350780|NCT00766272|Device|Lokomat|Body-weight will be supported using a harness, which suspends the subject above a motorized treadmill (Lokomat, Hocoma, Zurich, Switzerland). The system also incorporates a robot-driven gait orthotic, called the Lokomat, which will be secured to the subject's lower extremity and pelvis using adjustable cuffs and pads. The Lokomat uses computer-controlled motors to drive the hips and knees toward more normative kinematic patterns for gait.
45842020|NCT02876042|Device|BAROSTIM NEO™ System|Implantation of the BAROSTIM NEO™ System
45350781|NCT00961246|Behavioral|general health information|participants received general health information
45350782|NCT00961246|Behavioral|individually-tailored intervention|participants received individually-tailored intervention
45350783|NCT05288712|Other|Training protocol with the device cervical for treatment (CDAT)|Training protocol with the cervical device for treatment (CDAT)
45350784|NCT05288712|Other|Conventional training protocol|Conventional training protocol
45382133|NCT05301959|Device|low intensity percutaneous musculoskeletal electrolysis|An acupuncture needle (0.30mm X 25mm) will be introduced into the device's strut. With the equipment on and with a base intensity of 120µA, the acupuncture needle is introduced in a proximal-distal and postero-anterior direction, in the area of the Achilles tendon body. The position of the needle will be checked with ultrasound and once the point to be treated is reached, the working intensity will be increased up to 600 µA. The emission will be maintained until the participant reports a pain of 60/100 in VAS. At that moment, the emission will be paused completely until the participant reports a sensation of at least 20/100 in VAS. After this period the emission will be continued at 600 µA. This cycle will continue until the emission lasts for more than 120 sec, continuously. At this point, the needle will be repositioned to repeat the emission protocol a maximum of 3 times in total.
45842021|NCT02726763|Device|Transcranial Direct Current Stimulation (tDCS)|
46045226|NCT04160026|Drug|Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine|Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
45476663|NCT03841643|Device|patient-specific implant|solid titanium implant that functions as a guiding template for harvesting, and as an implant for reconstruction of the cranial defect
45476664|NCT03841643|Device|cement|norian cement for reconstruction of the cranial defect
45842022|NCT02726763|Behavioral|Questionnaires|
45476665|NCT02515786|Other|oxygen humidification|humidification for oxygen delivered by nasal catheter
45476666|NCT03843827|Device|Laryngeal Mask Airway|The aim of this study is to compare between cLMA and I gel regarding insertion success rate, the time of insertion, leaking pressure, assessment of position by fiber optic, hemodynamic, Spo2 for each device during insertion and maintenance of general anaesthesia and postoperative complications in obese patients
45476667|NCT03843827|Device|I gel Airway|I gel is a new type of laryngeal mask and doesn't have an inflatable cuff. Because of its thermoplastic elastomer structure, it exactly adapts to the supraglottic tissue by binding with body temperature, thus minimising air leakage
45476668|NCT04500184|Other|cardiac rehabilitation|rehabilitation performed by professional trainers
45685842|NCT02040376|Drug|Placebo|Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
45842023|NCT02705846|Other|Observation of treatment outcomes via Questionnaire|
46045227|NCT04160026|Drug|Monthly intermittent preventive treatment with sulfadoxine-pyrimethamine|Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
46045228|NCT04160026|Drug|Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine with targeted information transfer|Feasibility study to assess adherence to guidelines among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
45685843|NCT04756180|Drug|Omega-3-acid ethyl ester or Placebo|Omega-3-acid ethyl ester 2 gm/day for first 4 week followed by 4gm/day for 8 week
45685844|NCT04745806|Device|ActiGraft|Whole blood clot (WBC) gel
45685845|NCT04755868|Drug|Talazoparib|The Arm A (Experimental arm) Maintenance therapy with talazoparib (1mg once daily) (once daily 1.0 mg oral administration), 103patients
45685846|NCT04755868|Drug|Placebo|The Arm B (Control arm) Maintenance therapy with placebo (once daily 1.0 mg oral administration), 103patients
45842024|NCT02661295|Drug|Ferric Citrate|Study participants will receive ferric citrate at a starting dose of 2 tablets with each meal if serum phosphorus levels are ≥ 6.0 mg/dL calcium levels are in the normal range, Tsat ≥ 20 and < 50% and ferritin ≥ 200 and < 500 ng/ml after a 2 week wash out period.
45842025|NCT02657265|Device|SpineJack system|Spine fracture management for traumatic vertebral compression fracture
45842026|NCT02657265|Device|Conservative management|Surgical corset according to measurement's impression, rigid corset with sternal support
45842027|NCT02653716|Behavioral|New Orleans Intervention Method|An attachment based assessment, then a tailored intervention aimed at maximising the chances of the maltreated child being returned to the birth family
45842028|NCT02653716|Behavioral|Case Management|A social work assessment of family functioning that makes future recommendations regarding the future placement of a maltreated child.
45476669|NCT01203683|Behavioral|Active computer-based training|8 sessions across 4 weeks.
45350785|NCT01048489|Behavioral|Health education in the high school|"(12- 13 years old): 1.Questionnaire and measuring of carbon monoxide in air. 2.Role Games.3.Build a machine that simulates a cigarette.~(13-14 years old):1.Questionnaire and measuring of carbon monoxide in air.2. Workshop dealing with current television series broadcast in Spain in which tobacco is constantly present.3.Workshop dedicated to make young people and their families stop smoking.A competition is performed between all the schools in order to reward the bookmark with the best motto asking any close person to stop smoking or thanking them for having quit.~(14-15 years old):1.Questionnaire and measuring of carbon monoxide in air. 2. Workshop to go into depth about tobacco effects,by searching in the internet, aiming for the creation of an anti-tobacco pressure group in social networks such like Facebook.3.Workshop to create an advertising campaign to encourage non-consumption by mobile messages,use of internet..coinciding with the international day without tobacco."
45350786|NCT00961324|Drug|insulin degludec|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
45350787|NCT00961324|Drug|insulin glargine|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
45350788|NCT00766350|Drug|amitriptyline|initial dose 10 mg/day, target dose: 25 mg/day, maximum dose: 75 mg/day, dosage form: tablets, duration: 16 weeks
45350789|NCT00766350|Drug|quetiapine|initial dose: 50 mg/day, target dose: 100 mg/day, maximum dose: 300 mg/day, dosage form:extended release tablets , duration: 16 weeks
45350790|NCT00889161|Drug|Curcumin|Initial dosage of 500mg twice a day for 3 weeks. Using the forced dose titration design, dose will be titrated up to 1g twice a day at Week 3 for a total of three weeks and then titrated again to 2g twice a day at Week 6 for three weeks.
45350791|NCT03992755|Drug|LIQ861 Inhaled Treprostinil|LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
45350792|NCT01563328|Drug|DTG|50 mg q24h
45350793|NCT01563328|Drug|BCV|800 mg q8h
45350794|NCT01563328|Drug|TVR|750 mg q8h
45350795|NCT00889239|Other|lithia-disilicate-based crown|all-ceramic crown
45476670|NCT01203683|Behavioral|Inert computer training|8 sessions across 4 weeks.
45350796|NCT00760032|Drug|Ciprofloxacin|Ciprofloxacin oral, 500 mg capsules, one capsule per day during four weeks.
45350797|NCT00760032|Drug|Placebo|Placebo capsules, one capsule per day during four weeks.
45350798|NCT00961480|Drug|sitagliptin phosphate (+) metformin hydrochloride|place holder - do not post
45350799|NCT00961480|Drug|Comparator: metformin 500mg|A single dose of metformin 500 mg tablet
45350800|NCT00961480|Drug|Comparator: sitagliptin|A single dose of 50 mg sitagliptin tablet
45350801|NCT00961480|Drug|Comparator: FMI sitagliptin / metformin 50 mg/500 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
45350802|NCT00961480|Drug|Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
45350803|NCT00961480|Drug|Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
45476671|NCT04073238|Device|Low-level Red-light Therapy|In addition to wearing single vision spectacle lens with power for correcting distance refraction, low-level red-light therapy is performed twice per school day at home with an interval of at least 4 hours, each treatment lasting 3 minutes.
45476672|NCT04500340|Behavioral|Group CBT for test anxiety|The cognitive-behavioral therapy protocol developed by Flaxman, Bond & Keogh (2004) will be used as the intervention protocol. This protocol consists of 10 Sessions which are provided twice a week (each group will have 10 students).
45685847|NCT04772638|Behavioral|PLAY|This intervention focuses on promoting physical activity in preschoolers and the adults (parents and teachers) in their lives. It consists of 1) Teacher training 2) Activity trackers for children, teachers and parents and 3) text messaging with content and individualized goal setting.
45350804|NCT00961480|Drug|Comparator: metformin 1000 mg|A single dose of metformin 1000 mg tablet
45350805|NCT00961480|Drug|Comparator: metformin 850 mg|A single dose of metformin 850 mg tablet
45350806|NCT00760110|Device|blood pressure measurements based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes, the 400 patients were classified as with or without hypertension based on HBP and CBP measurements at baseline
45350807|NCT00608829|Device|GORE TAG® Thoracic Endoprosthesis|Implant
45350808|NCT04462393|Other|Admission to ICU for COVID-19|All patients admitted to Swedish ICUs with COVID-19 between 6 Mar - 6 May 2020
45350809|NCT04049370|Other|No intervention|"Assessment of the actual state prior to implementation of the SOP as clinical decision tool into the electronic database of the chest pain unit."
45350810|NCT00961558|Procedure|Varicocelectomy|Varicocelectomy
45476673|NCT05282303|Procedure|CABG operation|Efficacy of regional analgesia techniques in coronary artery bypass operations
45685848|NCT04772638|Other|Wait list control|not an active intervention
45350811|NCT00889317|Device|fmri (functional magnetic resonance imaging)|functional image acquisition (75mn) anatomical image acquisition (15mn)
45350812|NCT00763464|Procedure|stress-echocardiography|stress-echocardiography will be performed once using Adenosin (140 µg/kg/min over 6 Minutes) and a contrast agent (SonoVue)
45350813|NCT00763464|Procedure|stress-MRI|stress-MRI will be performed once using Adenosin (140 µg/kg/min over 6 Minutes)and a contrast agent (Gadovist)
45350815|NCT00973492|Other|functional insulinotherapy class|"The functional insulinotherapy class lasts for 4 days. It is taught by 2 nurses, 2 dieticians and 2 physicians to 6 to 10 patients.~On day 1, patients describe their difficulties with diabetes. Fast-acting insulin scales are elaborated from preprandial and postprandial blood glucose levels. At dinner, patients start a 24-hour glucose-fasting period to evaluate their need for basal insulin. Meals contain virtually no carbohydrates. Correcting doses of insulin are administered if preprandial glycemia is over 1.50 g/l or postprandial glycemia is over 2 g/l. Blood glucose levels must stay within normal values during the whole 24-hour period.~Carbohydrate management is taught during meals and every afternoon through workshops about dietetics. Patients also learn how to deal with hypoglycaemia, hyperglycaemia and physical activity.~A one-day follow-up takes place 3 months later."
45685849|NCT05567926|Dietary Supplement|Beetroot juice concentrate (140 ml)|A beetroot juice concentrate (140 ml) will be administered to participants in experimental conditions.
45685850|NCT05567926|Dietary Supplement|Blackcurrant juice (placebo)|140 ml of blackcurrant juice with added appropriate amount of sugar to equalize the carbohydrate value and lemon juice fort the taste.
45350816|NCT00760188|Device|Cementless Oxford Partial Knee|Cementless Oxford Partial Knee Replacement
45350817|NCT00973570|Behavioral|TABADO program|The intervention takes place in 3 stages: (i) a general information session on tobacco consumption is delivered to all teenagers, both smokers and nonsmokers. (ii) For smokers wishing to join the program, this session is followed by individualized consultations with a team of tobacco addiction physicians. (iii) The volunteers then benefit from a small group approach, consisting of discussion sessions to share experiences, strengthen motivation, and prevent relapse. There will be 4 sessions in total, comprising individual counseling and work in groups spread over 3 months (taking into account the availability of the trainees because of their alternate-week training schedule).
45685851|NCT05560204|Device|Combined Pulsed-field Ablation (PFA) + Left Atrial Appendage Occlusion (LAAO)|"Pulsed-field ablation (PFA) is a non-thermal ablation technology that uses high amplitude pulsed electrical fields to ablate tissues through the mechanism of irreversible electroporation~Percutaneous LAA Occlusion (LAAO) has been emerged as an alternative to oral anticoagulants for stroke prophylaxis in patients who refused or contraindicated to OAC"
45350818|NCT00892593|Device|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
45350819|NCT00892593|Device|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
45350820|NCT00766662|Drug|Sulfadoxine pyrimethamine|
45685852|NCT02027896|Other|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
45685853|NCT05228314|Biological|Candidate vaccine, SCB-2020S|a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19
45685854|NCT05228314|Biological|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
45685855|NCT05228314|Other|Squalene based adjuvant|Squalene based adjuvant
45842029|NCT02621489|Drug|Bydureon|2 mg Once Weekly
45842030|NCT02621489|Drug|Humulin kwickpen|Humulin kwickpen 10U QD at bedtime
45350821|NCT00965926|Drug|YM178|oral
45350822|NCT00889395|Behavioral|MISC training for primary caregivers|Caregivers of children in the intervention arm will undergo a year long training in MISC
45350823|NCT02557776|Genetic|Germline genetic testing of BRCA1 and BRCA2|
45350824|NCT00966004|Drug|YM178|oral
45685856|NCT05228314|Other|CpG/alum adjuvant|CpG/alum adjuvant
45685857|NCT01659658|Drug|IXAZOMIB|IXAZOMIB capsules
45685858|NCT01659658|Drug|Dexamethasone|Dexamethasone tablets
45685859|NCT01659658|Drug|Melphalan|Melphalan tablets
45842031|NCT02621489|Drug|Metformin|Metformin 1g BID
45842032|NCT02596880|Drug|Sofosbuvir|400 mg, included in a combination pill (Sovodak) with 60 mg daclatasvir
45842033|NCT02596880|Drug|Daclatasvir|60 mg, included in a combination pill (Sovodak) with 400 mg sofosbuvir
45842034|NCT02596880|Drug|Ribavirin|1000 mg/day if <75 kg, 1200 mg/day for >75 kg. Divided into two daily doses
45842035|NCT02553525|Procedure|Therapeutic Stimulation Patterns|During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to suppress oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
45350825|NCT00966004|Drug|Placebo|oral
45350826|NCT00966004|Drug|tolterodine|oral
45350827|NCT00892671|Other|Simulation|simulation of airway management and vascular access
45350828|NCT04048590|Other|Skilled Nursing Facility at Home|We plan to deploy an innovative and tailored set of rehabilitation services delivered in a patient's home that would allow for discharge from the hospital directly to home, despite the need for more intensive rehabilitative care not currently found in the home setting. We plan to combine a high-touch and high-tech approach that combines novel uses of personnel practicing at the very top of their license with novel uses of technology.
45350829|NCT00966082|Procedure|endoscopic band ligation|Perform EBL until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
45350830|NCT00966082|Procedure|endoscopic band ligation+Propranolol|Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min
45350831|NCT00766740|Device|thrombectomy devices|mechanical or manual devices able to remove thrombus from the coronary arteries.
45842036|NCT02553525|Procedure|Symptogenic Stimulation Patterns|During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to exacerbate oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
45350832|NCT00766740|Device|angioplasty|percutaneous coronary angioplasty with use of balloon catheters and bare metal stents or drug eluting stents.
45350833|NCT00892749|Drug|ASP1585|oral
45350834|NCT00763542|Behavioral|CBT for SUD|CBT for SUD focuses on patient-motivation, self-control strategies and relapse-prevention.
45476674|NCT02515708|Device|Normothermic Liver perfusion Device|The liver grafts will be preserved at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase.
45476675|NCT03184038|Procedure|Cognitive Assessment|Undergo assessment of neurocognitive function
45476676|NCT03184038|Radiation|Stereotactic Radiosurgery|Undergo SRS
45476677|NCT03184038|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45685860|NCT01659658|Drug|Cyclophosphamide|Cyclophosphamide tablets
45685861|NCT01659658|Drug|Thalidomide|Thalidomide capsules
45842037|NCT02527434|Biological|Tremelimumab monotherapy|IV infusion
45842038|NCT02527434|Biological|MEDI4736 monotherapy|IV infusion
45350835|NCT00763542|Behavioral|Structured writing therapy for PTSD|Patients progress through three stages, in which instructions for writing and feedback by therapists are successively aimed at achieving trauma processing, cognitive restructuring and social sharing of a traumatic event.
45350836|NCT00889629|Drug|Doxercalciferol|Active group receives doxercalciferol (Hectorol) 1mcg
45350837|NCT00889629|Drug|placebo|Group 2 receives placebo (dummy bottle with pills resembling doxercalciferol)
45350838|NCT00889629|Drug|25-OH Vitamin D3|All groups received cholecalciferol
45350839|NCT00966160|Drug|Lopinavir/Ritonavir plus Lamivudine/Zidovudine|400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
45350840|NCT00966160|Drug|Efavirenz plus Lamivudine/Zidovudine|600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
45476678|NCT03184038|Other|Quality-of-Life Assessment|Ancillary studies
45476679|NCT02515552|Behavioral|The Fibromyalgia Wellness Project|Web-based symptom and behavior self-monitoring program with automated feedback derived from the user's personal data. A personal informatics approach is used involving proprietary within-subject statistical analysis procedures to determine user feedback that provides behavioral guidance based on statistically significant change in symptom levels associated with specific user behavior and self-management strategies.
45685862|NCT01659658|Drug|Lenalidomide|Lenalidomide capsules
45842039|NCT02527434|Biological|MEDI4736 + tremelimumab combination therapy|IV infusion
45350841|NCT00766818|Drug|Kaletra|Kaletra 400/100mg BID, then increase at 30weeks to 500/125mg BID
45350842|NCT04009252|Behavioral|3D Model Education|A 3D model of the patients ankle fracture will be printed and used as a teaching tool to discuss long-term outcomes and potential complications.
45476680|NCT03164057|Drug|Azacitidine|Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.
45476681|NCT03164057|Drug|Decitabine|Administered intravenously (IV) over approximately one hour.
45476682|NCT03164057|Drug|Cytarabine|Given IV or intrathecally (IT).
45476683|NCT03164057|Drug|Daunorubicin|Given IV.
45476684|NCT03164057|Drug|Etoposide|Given IV.
45476685|NCT03164057|Combination Product|ITMHA|Given IT.
45476686|NCT03164057|Drug|Idarubicin|Given IV.
45476687|NCT03164057|Drug|Fludarabine|Given IV over approximately 30 minutes.
45476688|NCT03164057|Drug|Mitoxantrone|Given IV.
45476689|NCT03164057|Drug|Erwinia asparaginase|Given IV or intramuscularly (IM).
45476690|NCT03164057|Drug|Sorafenib|Given PO.
45350843|NCT04036383|Other|vestibular exercise training|The home exercise program consists of vestibulookular reflex stimulating exercises, lower extremity somatosensory system training, static and dynamic balance exercises
45350844|NCT04036383|Other|Balance training with computerized balance system|Thanks to the receivers under the Neurocom balance master platform, the data of the center of gravity is transferred to the system and visual feedback is provided. Qualitative information reflects progression during static and dynamic postural exercises of the patient. To correct the load distribution, it is necessary to move the cursor to the specified targets in the exercises. The degree of difficulty of training can be increased by increasing the distance between the targets, reducing the time required to reach the targets, changing foot positions or adding upper extremity activity.
45685863|NCT01896076|Other|ultrasound evaluation of caudal space|"After induction of general anesthesia, the patients were placed in the lateral position. The ultrasound evaluation include transverse and longitudinal view.~First, investigators place the transducer at the sacral cornua to obtain a transverse view.~In the transverse view, the distance between two cornua and the depth of caudal space at the sacral hiatus were measured. In the longitudinal view, the distance from the skin to the sacrococcygeal membrane and the optimal angles and the safety distance for needle insertion depending on the points of insertions were measured. From the end of dura sac to the sacral hiatus were regarded as safety distance for the needle insertion during caudal block."
45350845|NCT04036383|Other|square step exercises|Elderly individuals in the square step exercise group will perform step exercises on 2.5x1.0 m thin cushions divided into 40 equal parts. Square step exercises include exercises that include anterior, posterior, lateral and diagonal directions of increasing difficulty. The order of the training program is at four different levels and is organized according to small, basic, regular and advanced levels.
45350846|NCT02558556|Device|Laparoscopic Fluorescence Imaging System (Karl Storz)|The Laparoscopic Fluorescence Imaging System (incl. laparoscope, light source, light cable) will supply the needs for near-infrared fluorescence imaging with ICG. The hypothesis is that this device will help in visualizing the anatomical structures such as the common bile duct, which are hard to visualize in white light due to the surrounding tissues.
46045229|NCT02636920|Other|Therapeutic Education to the Patient (TEP)|"Educational Diagnosis, asking what patient has, what he knows, what he is doing, what he would like to do.~Therapeutic Contract, to define objectives to reach at the end of educational path, integrating new knowledges and replacing wrong cognitive-behavior models with new schemes.~Educational Therapeutic Intervention, with individual or group methodologies (Role Playing, Brain Storming) and a disease diary in which patients could describe symptoms, therapies, behaviors and benefits.~Assessing of the knowledges acquired by patients."
45350847|NCT02558556|Other|Indocyanine Green|Indocyanine Green will be injected intravenously as a contrast agent for the use of the Laparoscopic Fluorescence Imaging System.
45350848|NCT00966316|Drug|aspirin，chinese herbs；|aspirin 300mg/100mg,qd,chinese herbs, one dose ，qd
45350849|NCT00889785|Behavioral|Comprehensive intervention (disease management program)|The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.
45350850|NCT00889785|Behavioral|Usual Care|Will receive usual care and monthly phone calls as an active control.
45350851|NCT04049292|Other|Better and safer return to sport (BEAST)|The RTS assessment includes a Lachman test, modified stroke test, side hop test, triple hop test, and quadriceps muscle power test. The sport-specific progression plans have 6 participation levels in practice and 6 participation levels in match play. A minimum of 2 weeks and 4 training sessions without pain or effusion must be completed before the athlete progresses to the next level. Criteria for full, unrestricted participation in practice: (1)at least 9 months from ACLR, (2)modified stroke test grade 0, (3)completed previous levels in the sport-specific progression plan, (4)negative Lachman test, (5)side hop test limb symmetry at least 90%, (6)triple hop test limb symmetry at least 90%, (7)quadriceps power symmetry at least 90%. The strength training and knee control exercise protocols each have 3-4 different exercises of 3-4 sets that are performed 3 days per week.
45685864|NCT01252888|Device|iStents|Implantation of two iStents through a small temporal clear corneal incision
45685865|NCT01642342|Other|laboratory biomarker analysis|Correlative studies
45350852|NCT04049292|Other|Usual care|Usual care is determined by the treating health care professional
45685866|NCT01642342|Other|pharmacological study|Correlative studies
45685867|NCT01642342|Biological|recombinant albumin fusion protein sEphB4-HSA|Given IV
46045230|NCT02634736|Device|Exergame plus usual treatment|An individualised [i.e. frequency and duration will be set according to each participant's baseline levels] Exergame programme incorporated into participant's normal routines plus usual falls prevention treatment (prescribed by the physiotherapists).
45350853|NCT00892827|Drug|Rituximab (Mabthera) , FFP (Fresh Frozen Plasma)|Rituximab (375 mg/m2) with FFP will be given every two weeks
45476691|NCT03164057|Drug|G-CSF|Given IV.
45476692|NCT03164057|Drug|Dexrazoxane|Given IV immediately before idarubicin administration.
45842040|NCT02522520|Behavioral|Pedometer intervention|12 weeks physical activity intervention (supervised/non-supervised)
45842041|NCT02522520|Behavioral|Pedometer + hospital based intervention|12 weeks physical activity intervention (supervised/non-supervised)
45842042|NCT02522520|Device|Omron Walking Style pro. 20|
45842043|NCT02512718|Drug|Omegaven|Comparison of FOLE vs. SOLE
45842044|NCT02512718|Drug|Soybean oil lipid emulsion|Comparison of FOLE vs. SOLE
45350854|NCT00766896|Drug|Aspirin (platelet sensitive versus platelet hyperreactivity)|"The dose of aspirin to be prescribed in this study will be 300 mg orally or by nasogastric tube once a day (assisted therapy), with first dose tomography soon after admission if the patient has no indication of thrombolytic therapy. After the acute phase, patients will receive aspirin at a dose of 200 mg/day. Aspirin will be administered in a simple preparation (no buffer, no extended release)."
45350855|NCT00889941|Procedure|LASIK|laser-assisted in situ keratomileusis
45350856|NCT00766974|Device|Anti-embolism Knee High Stocking|Anti-embolism Knee High Compression Stocking
45350857|NCT00766974|Device|20-30 Knee High Compression Stocking|20-30 mmHg Knee High COmpression Stocking
45350858|NCT00890019|Biological|AdCh63 ME-TRAP|"A:Intradermal injection 1x10^8 vp at day 0~A:Intradermal injection 1x10^9 vp at day 0~A:Intradermal injection 1x10^10 vp at day 0~A:Intradermal injection 5x10^10 vp at day 0~5:Intramuscular injection 1x10^10 vp at day 0~6A:Intramuscular injection 5x10^10 vp at day 0~7A: Intramuscular injection 2x10^11 vp at day 0"
45350859|NCT00890019|Biological|AdCh63 ME-TRAP; MVA ME-TRAP|"B: AdCh63 ME-TRAP intradermally at dose of 1x10^8 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~B: AdCh63 ME-TRAP intradermally at dose of 1x10^9 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~B: AdCh63 ME-TRAP intradermally at dose of 1x10^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~B: AdCh63 ME-TRAP intradermally at dose of 5x10^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~6B: AdCh63 ME-TRAP intramuscularly at dose of 5x10^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~7B and 7C: AdCh63 ME-TRAP intramuscularly at dose of 2x10^11 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)"
45350860|NCT00973726|Other|Glucose test|Subjects ingest an oral glucose tolerance test.
45350861|NCT00763620|Device|catheter for mini bronchoalveolar lavage|For each patient included an endotracheal aspiration and a mini bronchoalveolar lavage will be performed. After local anaesthesia, a suction catheter will be introduced in trachea by nasotracheal way. An endotracheal aspirate will be performed. Then, the mini bronchoalveolar lavage will be performed with the specific catheter introduced through the suction catheter. Expectorated sputum will also be ordered. This procedure will be performed once at the admission patient in intensive care unit.
45350862|NCT00973804|Drug|EPOCH-F/R|
46045231|NCT04159870|Drug|Rifaximin|Rifaximin pills 400 mg x 3/day
45350863|NCT00973804|Drug|FLAG|
45350864|NCT00973804|Drug|Transplant Preparative Regimen (Flu/Cy/Mes)|
45842045|NCT02474368|Radiation|Intensity Modulated Radiation Therapy (IMRT)|
45350865|NCT00973804|Drug|GVHD Prophylaxis (tacrolimus and sirolimus)|
45350866|NCT00973804|Procedure|Double Cord Blood Transplantation|
45685868|NCT01639690|Genetic|Autologous CD34+ cells transduced with TNS9.3.55|Patients will receive Filgrastim followed by apheresis of peripheral blood stem cells. CD34+ cells will be purified and transduced ex vivo. Transduced cells will be frozen in several aliquots whenever possible while vector copy number determination and biosafety testing are performed. Patients will be treated in the outpatient and/or inpatient units, and receive intravenous busulfan (8mg/kg) as non-myeloablative conditioning. Patients will be administered 2-12 x 10^6 transduced CD34+ cells per kg in 1 or several infusions. A back-up of 2 x 10^6 untransduced CD34+ cells per kg will be preserved for every patient.
45685869|NCT00580996|Other|water high dose|water 16 oz PO x 1
45350867|NCT04018131|Drug|Cimetidine|Antihistamine 2 antagonist
45350868|NCT04018131|Drug|Placebos|Placebo drug
45685870|NCT00580996|Other|water tiny dose|water 1 oz PO x 1
45842046|NCT02474368|Drug|Cisplatin|
45842047|NCT02474368|Radiation|Stereotactic Body Radiotherapy (SBRT)|
45842048|NCT02439775|Device|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
46045232|NCT04159870|Drug|Norfloxacin|Norlfloxacin 400 mg 1 pill/day
46045233|NCT02634658|Other|Muscle Ultrasound|Ultrasound will be performed using a linear-array transducer with standardized gain and varying depth based on the amount of overlying soft tissue and muscle size. The subjects will be examined in the supine position with extended limbs and relaxed muscles. We will perform bilateral scans of the biceps, anterior forearm, and anterior thigh at standardized sites. For muscle echogenicity measurements, we will scan the same muscles at the same points.
45350869|NCT00767052|Drug|AZD1236|75mg once daily or 75mg twice daily will be administered in multiple dose part.
45350870|NCT00767052|Drug|Placebo|Placebo tablet matching to the active in multiple dose part.
45350871|NCT00767052|Drug|AZD1236|75mg single dose will be administered in relative bioavailability part.
45350872|NCT00767052|Drug|AZD1236|75mg oral suspension single dose will be administered in relative bioavailability part.
45350873|NCT00973882|Drug|Carboplatin|Carboplatin AUC4 on day 1 repeated every 3 weeks for a maximum of 6 cycles
45842049|NCT02439775|Procedure|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
45350874|NCT00973882|Drug|Etoposide|Etoposide 100 mg/m2 on day 1, day 2 and day 3 repeated every 3 weeks for a maximum of 6 cycles
45350875|NCT02558322|Other|Primary medical care|All study participants receive primary care as usual in the respective region
45350876|NCT03666819|Device|Carbon Dioxide Fractional Laser|Undergo CO2RE laser therapy
45350877|NCT03666819|Other|Questionnaire Administration|Ancillary studies
45350878|NCT05278455|Behavioral|Lifestyle Medicine|A smartphone-delivered application with a series of lifestyle medicine components, including lifestyle psychoeducational, physical activity, dietary recommendations, stress management, sleep management, and motivation and goal-setting techniques.
45350879|NCT02558088|Drug|Salmeterol|
45350880|NCT05279482|Other|observation for outcome of methylprednisolone dose|no intervention as it is retrospective study for outcome
45350881|NCT00890175|Drug|Inhaled loxapine @ 0 & 10 h|10 mg, 2 doses, 10 hours apart
45350882|NCT00890175|Drug|Inhaled placebo @ 2 & 10 hours|placebo, 2 doses, 10 hours apart
45685871|NCT04755556|Other|home based intensive bimanual training|Home Based Intensive Bimanual Training with Routine Physical Therapy bimanual training includes. functional activities play with ball, make a dough, make beads, make blocks .Routine Physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.
45685872|NCT04755556|Other|Routine Physical Therapy|Routine physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.
45842050|NCT02439749|Device|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
45842051|NCT02439749|Procedure|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
45842052|NCT02412748|Behavioral|BBTF Intervention|The Building Bridges to Fatherhood (BBTF) intervention consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
45842053|NCT02412748|Behavioral|Financial Literacy Program|The Financial Literacy Program (FLP) attention control condition consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
45842054|NCT02320435|Drug|Pertuzumab|In general, patients will continue to receive 420 milligrams (mg) of pertuzumab administered as an intravenous infusion every 3 weeks following the guidance of the Parent protocol.
45842055|NCT02320435|Drug|Trastuzumab|If trastuzumab intravenous infusions were given in combination with pertuzumab as part of the Parent study, patients will continue to receive treatment at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
45842056|NCT02320435|Drug|Other Combination Anti-Cancer Therapies|If other anti-cancer therapies were given in combination with pertuzumab as part of the Parent study, patients will receive all treatments at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
45842057|NCT02305095|Drug|FDC I/H|All subjects in both groups will be initiated on drug, FDC I/H with dose titrated up to target doses based on clinical guidelines
45842058|NCT02272946|Drug|Canakinumab|150mg Canakinumab received subcutaneously
45842059|NCT02272946|Drug|Placebo|150mg Placebo received subcutaneously
46045234|NCT02634658|Other|Nerve Conduction Study|Nerve Conduction Studies will be performed using a Nicolet EDX using standard procedures. Repetitive stimulation of the median motor nerve are performed in all subjects. Bilateral sural, radial and median sensory nerves will be analyzed. We will only perform surface, not subdermal sensory recordings. The bilateral peroneal, tibial and median motor responses will be recorded over extensor digitorum brevis, abductor hallucis brevis, and abductor pollicis brevis muscles. The peroneal motor nerve will be stimulated at the fibular head and lateral popliteal fossa, recording from the tibialis anterior muscle. The compound motor action potential (CMAP) responses will be elicited from standard distal and proximal sites.
45842060|NCT02115698|Procedure|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 52 weeks.
45350883|NCT00966472|Drug|Erlotinib + Rosuvastatin|Patients will receive Erlotinib 150mg po daily. They will also receive Rosuvastatin at escalating dose levels starting at 1mg/kg po daily for 3 weeks, followed by a 1-week rest period. Patients may continue to receive rosuvastatin and erlotinib in the absence of disease progression or unacceptable toxicity.
45350884|NCT00767208|Other|oral glucose load|oral ingestion of 13C labeled glucose
45476693|NCT03164057|Biological|Stem Cell Transplant|The transplant protocol will depend on the patient's donor and transplant physician's preference.
45685873|NCT01245712|Radiation|Accelerated Partial Breast Irradiation|Undergo APBI delivered with proton radiation
45685874|NCT01245712|Radiation|Proton Beam Radiation Therapy|Undergo APBI delivered with proton radiation
45685875|NCT01245712|Other|Quality-of-Life Assessment|Ancillary studies
45350885|NCT00892983|Behavioral|FAB|Standard well child care plus 7 extra parent contacts for augmented education and support around breast feeding, food and activity with 1 before birth and then at 1-2 weeks, and 3, 4, 7, 9, 13, and 18 months post-partum.
45350886|NCT00892983|Behavioral|Sleep|"Standard well child care plus 2 extra contacts focussed on Sleep with 1 before birth (anticipatory guidance), and sleep problem prevention at 3 weeks. A sleep problem intervention starting at 6 months was possible for those indicating their child had a sleep problem at 6 months of age. Main prevention advice focussed on placing baby to sleep awake, maximising night-day differences and use of sleep place in parents bedroom for first 6 months. Intervention after 6 months uses preferentially a technique called parental presence, and if this does not fit family a technique called camping out and finally, if neither of the first two fit family, controlled crying."
45350887|NCT00760422|Device|NIR|Thermometer
45350888|NCT00890253|Drug|Basiliximab (Simulect)|20 mg basiliximab (Simulect) iv on day 0 and 4 after OLT
45350889|NCT00890253|Drug|Myfortic|1080 mg q12 EC-MPS (Myfortic) po starting within 24h after OLT
45350890|NCT00890253|Drug|everolimus|1 mg q12 everolimus (Certican) po starting on 10th post-operative day
45350891|NCT00890253|Drug|Prednisolone|Prednisolone 1mg per kg body weight starting within 24 hours after transplantation. Then q24 but with reduction by 5 mg every 48 hours until maintenance dose of 7.5 mg
45350892|NCT00760500|Other|Nasopharyngeal Swab|Nasopharyngeal Swab
45350893|NCT00545818|Device|OsseoSpeed™ length 6 mm|OsseoSpeed™ dental implant, length: 6 mm
45350894|NCT00545818|Device|OsseoSpeed™ length 11 mm|OsseoSpeed™ dental implant, length: 11 mm
45350895|NCT00674154|Drug|Cholecalciferol|2800 IE daily in 52 weeks
45350896|NCT00974038|Behavioral|psychotherapy|1) cognitive-behavioral therapy or 2) supportive psychotherapy
45350897|NCT00967954|Drug|antiandrogen therapy|
45350898|NCT00967954|Drug|releasing hormone agonist therapy|
45350899|NCT00967954|Genetic|DNA analysis|
45842061|NCT02115698|Procedure|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 52 weeks.
45350900|NCT00967954|Genetic|RNA analysis|
45476694|NCT03164057|Drug|Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn|May be used in the event of an Erwinia asparaginase shortage. Given intramuscularly (IM).
45476695|NCT03620526|Drug|Iloprost|Investigators performed cardiac catheterization as previously described. Hemodynamic values were recorded for the ﬁrst exercise phase (before any drug administration) and after return to steady state baseline hemodynamic values, and the second exercise phase (after drug administration). Subjects were randomized 1:1 to inhalation of placebo (normal saline solution) or iloprost (50 mg/kg/min) (Bayer Pharmaceuticals, Scottsdale, Ari-zona) for 5 min. The iloprost/placebo inhalation were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of inhalation content. After finishing inhalation process for 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 6 min, identical to the study's ﬁrst phase.
45842062|NCT02115698|Dietary Supplement|Protein Whey|Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
45842063|NCT02115698|Dietary Supplement|Protein Collagen|Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.
45350901|NCT00967954|Genetic|comparative genomic hybridization|
45350902|NCT00967954|Genetic|gene expression analysis|
45350903|NCT00967954|Other|laboratory biomarker analysis|
45350904|NCT00967954|Procedure|diffusion-weighted magnetic resonance imaging|
45350905|NCT00967954|Procedure|magnetic resonance spectroscopic imaging|
45350906|NCT04048980|Behavioral|CARExDEM|CARExDEM is an educational program addressed to nurses working in traumatology units and looking after patients with dementia. This intervention pretends to provide strategies to nurses for cognitive impairment management in acute hospital settings, to raise awareness about personalized care in dementia and to improve continuity of care in acute situations in PwD. Training sessions will be held to inform and train nurses about care of PwD and their caregivers by the research team in each hospital.
45350907|NCT00974116|Behavioral|MEND Childhood Obesity Program|The number of children who are obese in the UK is steadily increasing with both short and long term consequences for health. The aim of this study is to determine whether the MEND Programme (a new national initiative for the treatment of childhood obesity) is a successful and sustainable treatment for childhood obesity and obesity related health problems.
45350908|NCT00974116|Behavioral|Control Group|No intervention
45842064|NCT02115698|Dietary Supplement|Carbohydrate|Two daily 30 g carbohydrate supplementations for 52 weeks.
45350909|NCT00767286|Drug|flutamide|
45350910|NCT00767286|Drug|goserelin acetate|
45350911|NCT00767286|Radiation|low-LET cobalt-60 gamma ray therapy|
45350912|NCT00767286|Radiation|low-LET photon therapy|
45476696|NCT03620526|Drug|Placebo|Investigators performed cardiac catheterization as previously described. Hemodynamic values were recorded for the ﬁrst exercise phase (before any drug administration) and after return to steady state baseline hemodynamic values, and the second exercise phase (after drug administration). Subjects were randomized 1:1 to inhalation of placebo (normal saline solution) or iloprost (50 mg/kg/min) (Bayer Pharmaceuticals, Scottsdale, Ari-zona) for 5 min. The iloprost/placebo inhalation were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of inhalation content. After finishing inhalation process for 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 6 min, identical to the study's ﬁrst phase.
45476697|NCT04499560|Dietary Supplement|Supplement Drink|Superfoods based nutritional supplement
45476698|NCT02850588|Procedure|Transcarotid artery revascularization|Direct implantation of a stent into the carotid artery via a surgical incision in the neck combined with blood flow reversal in the carotid artery during stent placement
45476699|NCT02850588|Procedure|Carotid endarterectomy|Removal of carotid atherosclerotic plaque (endarterectomy) via a surgical incision in the neck
45476700|NCT04535076|Procedure|Transcatheter Aortic Valve Implantation|Transcatheter Aortic Valve Implantation
45476701|NCT04535076|Procedure|Surgical Aortic Valve Replacement|Surgical Aortic Valve Replacement
45842065|NCT02040714|Procedure|Osteotomy + Long Term Non-Weight Bearing|Surgical procedure that improves femoral head containment, plus a post-operative protocol that requires patient to maintain non-weight bearing for 6 months.
45842066|NCT02040714|Procedure|Osteotomy + Short Term Non-Weight Bearing|Surgical procedure that improves femoral head containment, plus a post-operative protocol that allows early return to function after 6 weeks of non-weight bearing.
45842067|NCT02040714|Procedure|Nonoperative Observation|Group will not undergo any surgical or invasive procedures during course of treatment.
45842068|NCT02040714|Procedure|Multiple Epiphyseal Drilling|Multiple epiphyseal drilling is a procedure that creates small holes in the femoral head growth plate to increase blood flow into the femoral head.
45842069|NCT01995344|Drug|Cyclophosphamide|
45350913|NCT00966628|Drug|Hypertonic sodium lactate|Hypertonic sodium lactate 5 ml/kg BW administered within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study solution infused again at same dose. After recovery from shock state, patients receive maintenance dose at 1 mL/kgBW/hour for 12 hours. After 12 hr. infusion with study fluid, patients receive RL infusion as per standard protocol of DSS management at site.In case of repeated shock within 12 hours, study drugs can be infused again. If patient still not recovered from shock state, the patients will be given HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
45350914|NCT00966628|Drug|Ringer's lactate|Ringer lactate infused at dose 20 mL/kgBW within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study fluid infused again at same dose. After recovery from shock, patient received maintenance dose of RL. In case of repeated shock, patients received HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
45350915|NCT00968110|Drug|omalizumab|Dosing table established for omalizumab
45350916|NCT00608517|Biological|anti-thymocyte globulin|Given IV
45350917|NCT00608517|Drug|cyclophosphamide|Given IV
45350918|NCT00608517|Drug|fludarabine phosphate|Given IV
45350919|NCT00608517|Drug|methylprednisolone|Given IV
45350920|NCT00608517|Radiation|total-body irradiation|Given daily for 1-4 days
45842070|NCT01995344|Drug|Fludarabine|
45842071|NCT01995344|Genetic|Tumour Infiltrating Lymphocytes|
45842072|NCT01995344|Drug|Interleukin-2|
45842073|NCT01923662|Device|IST-16 (16-Channel implanted stimulator-telemeter|Surgical implantation of IST-16 stimulator and electrodes to stimulate paralyzed muscles. Subjects will receive exercise and physical therapy with the implanted device. Functional training and laboratory assessments of clinical and technical performance will be conducted.
45842074|NCT01845688|Drug|Losartan Tablets & QingReMoShen Granule|
45842075|NCT01845688|Drug|Losartan Tablets & Placebo Granule|
45350921|NCT00966706|Drug|capecitabine|Given systemically
45350922|NCT00966706|Drug|cisplatin|Given systemically
45350923|NCT00966706|Drug|docetaxel|Given systemically
45350924|NCT00966706|Drug|epirubicin hydrochloride|Given systemically
45350925|NCT00966706|Drug|gemcitabine hydrochloride|Given systemically
45350926|NCT00763776|Device|clamp crushing technique|Liver transection during hepatectomy by clamp crushing technique
45350927|NCT00763776|Device|ultrasonic dissector|Liver transection during hepatectomy by the ultrasonic dissector
45350928|NCT00966784|Other|Dietary Fibers|
45350929|NCT00893061|Drug|anastrozole|Given orally
45350930|NCT00893061|Drug|exemestane|Given orally
45350931|NCT00893061|Drug|letrozole|Given orally
45350932|NCT00893061|Drug|tamoxifen citrate|Given orally
45350933|NCT00763932|Biological|Myozyme|10 mg/kg or 20 mg/kg qw OR 20 mg/kg or 40 mg/kg qow
45350934|NCT00966862|Other|Other: Dietary Fibers|
45350935|NCT00890331|Behavioral|TeamWork CS Sessions|The intervention focuses on an authoritative parenting approach that emphasizes continued parental involvement in daily disease care. Dyadic coping skills of communication, problem solving, conflict resolution, along with attitude and behavior change are highlighted. Families meet with a study interventionist in conjunction with four consecutive medical appointments.
45350936|NCT00890331|Behavioral|Diabetes Education|Diabetes Education The education comparison group meets with an educational interventionist in conjunction with four consecutive medical appointments. This group focuses on diabetes educational and resource support for parents and their youth with type 1 diabetes.
45476702|NCT04532346|Drug|Hydroxychloroquine|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug. hydroxychloroquine has been reported to improve the clinical status of chILD cases wtih genetic causes. The exact mechanism of action of hydroxychloroquine is unknown. In additon to having anti-inflammatory properties, hydroxychloroquine has been shown to affect intracellular processing of surfactant protein.
45476703|NCT02987153|Radiation|Kypho-IORT|The radiation source is inserted into the lesion and switched on for a few minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and clinical applications of this device have been well studied.
45476704|NCT03217968|Device|Cefaly® Abortive Program device|The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS).
45476705|NCT03843749|Drug|Pyrotinib|Pyrotinib in Combination With Trastuzumab
45476706|NCT01199783|Drug|Daptomycin|Infusion (6 mg/kg/bodyweight) once daily
45476707|NCT01199783|Drug|Vancomycin|vancomycin once daily (effective blood-plasma concentration of 15 mg/L)
45476708|NCT02710968|Device|11540KE and Balt Goldbal 2 balloon|Fetoscopic tracheal occlusion will be performed using above devices and reversed after 4-5 weeks.
45476709|NCT03841877|Procedure|endodontic treatment|The operator will remove the pulp inside the tooth, clean, disinfect and shaping the root canals and seal the space with endodontic sealer.
46045235|NCT02634658|Other|Electromyography|EMG studies will be performed using standard precautions. Insertional activity, spontaneous activity, motor unit potential (MUP) morphology and recruitment/activation pattern will be recorded from some combination of the deltoid, triceps, biceps, first dorsal interosseous, abductor pollicis brevis, iliopsoas, vastus medialis, and tibialis anterior muscles. The specific muscles studied for each patient will vary according to the patient's level of consciousness and ability to activate the muscles either voluntarily or during spontaneous limb movement. If possible, we will try to examine 3 unilateral upper extremity and 3 unilateral lower extremity muscles. If a patient is not able to volitionally participate in EMG testing (by contracting their muscles on command), we will analyze insertional/spontaneous activity and potentially morphology/recruitment (e.g. stroking the sole of the foot to stimulate contraction of the tibialis anterior).
46045236|NCT00657514|Drug|Ranolazine|500mg tablet po bid up to 1000mg (2 500mg tablets) po bid
46045237|NCT00657514|Drug|Placebo|1 tablet po bid up to 2 tablets po bid if tolerated
46045238|NCT04159792|Other|no intervention|No intervention
45350937|NCT00974194|Procedure|Single Trocar CCK|CCK using Triport
45350938|NCT00974194|Procedure|Standard CCK|CCK using three or four ports
45350939|NCT00974272|Drug|Exenatide|Single subcutaneous injection (10 μg)
45350940|NCT00974272|Other|Normal Saline|Single subcutaneous injection
45350941|NCT02558478|Genetic|blood sampling|
45350942|NCT00974428|Dietary Supplement|Wobenzym® N|4 tablets TID, 6 weeks
45350943|NCT00974428|Dietary Supplement|Placebo|4 tablets TID
45350944|NCT00760734|Drug|Low pressure hyperbaric oxygen therapy|HBOT at 1.5 ATA/60 minutes twice/day, five days/week for 40 or 80 treatments
45476710|NCT04697927|Other|Questionnaires|The epidemiologic questionnaires used in this study are a composite of validated questions from multiple sources. Many of the questions are an expansion of the MSK General Medical Health clinical questionnaire. Validated questions capturing demographics, employment, risk behaviors, family history, as well as, specific research domains including psychosocial, food security, and financial toxicity have already been utilized in other MSK minimal risk studies. The COVID-19 symptom and history tracker questions were largely drawn from the COronavirus Pandemic Epidemiology (COPE) consortium study.
45476711|NCT03192306|Drug|Merlin|glycolic acid/ethanol solution
45476712|NCT03192306|Drug|Ethanol|Ethanol solution
45476713|NCT04066829|Behavioral|Default setting intervention|The new default settings will be implemented only for patients in the experimental arm.
45476714|NCT01203995|Behavioral|Nutrition information|Brief nutrition education with take home reference materials and portion size tools
46045239|NCT04159948|Dietary Supplement|Carbohydrate drink|"This is a commercially available pre-op carbohydrate drink used in enhanced recovery programmes."
45350945|NCT00760734|Drug|Low pressure hyperbaric oxygen therapy|HBOT: 1.5 ATA/60 minutes twice/day, 5 days/week for 40 or 80 treatments
45350946|NCT00974506|Other|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine care therapy by general practitioner
45350947|NCT00974506|Other|Routine care therapy|Routine care therapy by general practitioner
45350948|NCT00764010|Dietary Supplement|No dietary counseling and omega-3 capsules|Omega-3 2.4 g/day
45350949|NCT00764010|Dietary Supplement|Omega-3 capsules and dietary counseling|Omega-3 2.4 g/day and Mediterranean-like diet
45350950|NCT00764010|Dietary Supplement|Dietary counseling, placebo capsules for omega-3|Mediterranean-like diet
45350951|NCT00968188|Behavioral|Keep It Up!|Online HIV Intervention Prevention Website tailored to Young Men that Have Sex with Men. Website is tailored to be more engaging, includes videos and games.
45350952|NCT00968188|Behavioral|Information only|Medically fact based HIV information delivered online.
45350953|NCT00974584|Drug|GDC-0941|The GDC-0941 at a starting dose of 60 milligrams (mg) will be administered once daily orally for 14 consecutive days (Days 1 to 14) in 3-week cycles except for the first cycle that has Day 1 of single-agent GDC-0941 preceding Day 2 with combination chemotherapy.\n\n\n\n\n\n
45350954|NCT00974584|Drug|bevacizumab|Bevacizumab 15 milligrams per kilograms (mg/kg) intravenously (IV) on Day 1 of every 3-week cycle.
45476715|NCT01203995|Behavioral|Nutrition education and exercise training|Twice per week nutrition education and exercise class held either in-clinic or through vide-conference.
45350955|NCT00974584|Drug|carboplatin|Carboplation IV on Day 1 of every 3-week cycle, at a dose to achieve an area under concentration time curve of 6 milligrams per milliliter*minute (mg/mL*min).\n
45350956|NCT00974584|Drug|cisplatin|Cisplatin 75 milligrams per square meter (mg/m^2) IV on Day 1 of every 3-week cycle.\n
45350957|NCT00974584|Drug|paclitaxel|Paclitaxel 200 mg/m^2 IV on Day 1 of every 3-week cycle.\n\n
45350958|NCT00974584|Drug|pemetrexed|Pemetrexed 500 mg/m^2 IV on Day 1 of every 3-week cycle.
45350959|NCT00608205|Drug|cisplatin|Given IV
45350960|NCT00608205|Drug|fluorouracil|Given IV
46045240|NCT04160104|Other|Questionnaire|Patients were asked to complete a questionnaire before colonoscopy. Bowel preparation was subsequently assessed by single endoscopist in each center using Boston bowel preparation quality score (BBPS). Both univariate and multivariate logistic regression models were used to identify high-risk factors associated with IBP and a predicting model with the bowel preparation score (BPS) was developed in the training cohort.
45476716|NCT03216954|Drug|Alcohol|During each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.
45476717|NCT03216954|Drug|Placebos|Subjects will receive placebo capsules
45476718|NCT03216954|Drug|N-acetyl cysteine|Subjects will receive n-acetyl cysteine capsules
45476719|NCT01200017|Biological|CD34+ enriched, T Cell Depleted donor stem cell product|stem cell transplant
45476720|NCT04497922|Device|e-ink screen|A virtual display screen developed by e-ink that displays patient status, basic demographics, care team information, pending tests and anticipated disposition
45476721|NCT04497922|Behavioral|Treatment as usual|Treatment as usual in the emergency department with communication of testing results, imaging and disposition by the primary clinical emergency department team.
45350961|NCT00608205|Radiation|radiation therapy|Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks
45350962|NCT00968266|Behavioral|Patient-centered group intervention|"Session 1: Group discussion about the personal barriers for medication adherence. Supervisor: Pharmacist. Duration: 90 minutes. Goal: After this session the patient is aware of the benefits and barriers of adherence. The individual barriers to adherence (concerns and practical problems) and necessity beliefs about medication are identified and discussed.~Session 2: Group based education on benefits of medication and discussing personal concerns about medication, practical barriers and beliefs about the necessity of medication. Supervisor: Pharmacist and rheumatologist. Duration: 90 minutes. Goal: Improving realistic beliefs about medication, stimulating an equal relationship between patient and health professional and motivating patients to be adherent."
45476722|NCT03978702|Other|Blood sampling|20 mL will be collected at each time point (day-1,day 0, day 1, day 3, day 7, 1 year after pancreatectomy)
45476723|NCT03841487|Device|Aspiration thrombectomy|In the aspiration thrombectomy group, aspiration thrombectomy was performed for patients with ST elevation myocardial infarction who underwent primary percutaneous coronary intervention (PCI). In the PCI alone group, the STEMI patient received conventional primary PCI without aspiration thrombectomy during the procedure.
45476724|NCT05669807|Drug|Camrelizumab|200mg d1, the first day, every 14 days as a cycle
45476725|NCT05669807|Drug|Albumin-Bound Paclitaxel|100 mg/m2, the 1st, 8th and 15th days, every 28 days as a cycle
45685876|NCT01621906|Device|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
45476726|NCT05669807|Drug|Irinotecan|180 mg/m2, the first day, every 14 days as a cycle
45476727|NCT03599089|Drug|CA-008|single-dose wound infiltration prior to surgical incision closure
45476728|NCT03599089|Drug|Placebo|single-dose wound infiltration prior to surgical incision closure
45842076|NCT01844726|Drug|GLYX-13|Single injection (5 mg/kg) of GLYX-13, an NMDAR partial agonist
45842077|NCT01844726|Drug|Placebo|Single injection of placebo (saline)
46045241|NCT04160104|Other|Questionnair|Patients were asked to complete a questionnaire before colonoscopy. The predicting modle established by the training cohort will be used to assessing the preparation of validation cohort. The result will compared with endoscopists assessment of preparation.
45842078|NCT01827098|Procedure|Endodontic Regeneration|Blood clot formation is induced in the root canal after disinfection. Collagen material is placed over the clot. The canal access is sealed with white MTA and glass ionomer restoration. Permanent restoration is placed 3 months later on top of the MTA.
45847611|NCT03556800|Drug|Estrogel|"Each subject will receive the following IMPs in accordance with the randomisation code:~Test IMP: a single-dose of 0.5g, 0.75g and 1.25g VML-0203 cream~Reference IMP: a single-dose of 1.25g EstroGel"
46045242|NCT04163146|Diagnostic Test|Measurements of PEF and FEV1|Measurements of PEF and FEV1 at home, twice a day (07:00 - 09:00 and 19:00 - 21:00) and for a period of 3 months, using portable spirometers connected to smartphone
45350963|NCT00974662|Drug|WST11|WST11-mediated VTP will consists of the combination of a single IV administration of WST11 at doses of 5, 7.5 & 10 mg/kg, using 753 nm laser light at a fixed power of 250 mW/cm and escalating fixed energy dose (200 Joules/cm and 300 Joules/cm) locally delivered to the obstructing tumor through an optical fiber placed, during endoscopy, in the endoscope operating channel with visual control, possibly video-transmission assisted. The fiber illuminating diffusion length is fixed (2 cm).
45350964|NCT00974740|Drug|Atorvastatin|atorvastatin 40 mg (tablet for oral intake) once daily in the evening for 4 weeks, thereafter 80 mg for the remaining treatment period (total treatment period 18 months)
45476729|NCT03599089|Drug|Ketorolac|30mg IV administered intraoperatively
45842079|NCT01679132|Device|BAROSTIM NEO System and Medical Management|"Experimental: Device and Medical Management~Subjects have been implanted with the BAROSTIM NEO System and receive optimal medical management, including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics; Thiazide Diuretics; Potassium-sparing Diuretics; Aldosterone receptor blockers; Beta-blockers; Beta-blockers with intrinsic sympathomimetic activity; Combined alpha- and beta-blockers; ACE inhibitors; Angiotensin II antagonists; Calcium channel blockers- non-Dihydropyridines; Calcium channel blockers- Dihydropyridines; Alpha1-blockers; Central alpha2-agonists and other centrally acting drugs; Direct vasodilators."
45842080|NCT01624220|Radiation|Spinal SBRT (Standard Dose)|Group 1 and 2: Standard doses of radiation therapy to the normal esophagus while treating the tumor. Up to 2 groups of 10 participants enrolled.
45842081|NCT01624220|Radiation|Spinal SBRT (Higher Dose)|Group 3 and 4: Higher dose of radiation to esophagus than group before it, if no intolerable side effects were seen. 2 groups of 10 participants enrolled in the second part of study. Only participants who will receive a single spinal SBRT treatment are eligible for second part of study.
45842082|NCT01624220|Procedure|Gold Seed Implantation|4 gold seeds implanted into bones of spine: 2 gold seeds above and 2 gold seeds below the area of tumor to be treated.
45842083|NCT01624220|Behavioral|Questionnaires|Completion of questionnaire before radiation treatment starts, and 1 time a week for the next 4 weeks. It should take about 10 minutes to complete.
45350965|NCT00974740|Drug|atorvastatin matching placebo|atorvastatin matching placebo tablets once daily in the evening, corresponding to 40 mg atorvastatin for the first 4 weeks (run-in period), and corresponding to 80 mg atorvastatin thereafter (total treatment period 18 months)
45350966|NCT00967096|Drug|Rifaximin|Rifaximin for Bone marrow transplant patients
45350967|NCT04037163|Diagnostic Test|Fractional flow reserve, Coronary CT angiography|Coronary CT angiography was performed as part of routine clinical practice for patients with suspected coronary artery disease and the decision to perform coronary CT angiography before invasive angiography was at the judgment of the physicians in charge.
45685877|NCT01621906|Device|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
45685878|NCT01220752|Radiation|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
45685879|NCT01615510|Drug|Tapentadol immediate release|100 mg, single administration
45685880|NCT01615510|Drug|placebo|placebo, single administration
45685881|NCT00530062|Drug|Albuterol-HFA-MDI|Inhalation Aerosols, 90 mcg, 1 dose per treatment period
45842084|NCT01591291|Drug|Ondansetron + Brief Behavioral Enhancement Treatment|Ondansetron 4ug/kg twice daily
45842085|NCT01591291|Drug|Placebo + Brief Behavioral Enhancement Treatment|Placebo twice daily
45842086|NCT01471834|Device|BAROSTIM NEO System|
45842087|NCT01471834|Drug|Medical Management|
45842088|NCT01154920|Drug|Paclitaxel|135 mg/m^2 weekly, Weeks 1 - 6
45842089|NCT01154920|Drug|Carboplatin|AUC of 2 weekly, Weeks 1 - 6
45842090|NCT01154920|Drug|Cetuximab|"PCC Arm: 400 mg/m^2 by vein over about 1-2 hours on Day 1; 250 mg/m^2 weeks 2 - 6.~C-TPF Arm: 250 mg/m2 weeks 2, 4, 5, 7 and 8."
45350968|NCT05227300|Drug|Onset Sodium Bicarbonate Inj., 8.4%, USP Neutralizing Additive Solution|Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic
45685882|NCT00530062|Drug|Albuterol-HFA-BAI|Inhalation Aerosol (Breath-Actuated), 90 mcg, 1 dose per treatment period.
45685883|NCT04283656|Drug|Doravirine/Lamivudine/Tenofovir|100mg/300mg/300mg orally for one dose, daily
45685884|NCT04283656|Drug|Spironolactone 100mg|200mg orally for two doses, twice-daily
45685885|NCT04283656|Drug|Estradiol 2mg|4mg orally for two doses, twice-daily
45685886|NCT04283656|Other|Placebo|Placebo for one dose, daily
45685887|NCT01209364|Device|Durolane is a device, methylprednisolone in a drug|single intraarticular injection
46045243|NCT00656266|Drug|mycophenolate mofetil|immunosuppresion medication called mycophenolate mofetil, also known as MMF or CellCept
46045244|NCT00656266|Other|placebo medication|medication that looks like mycophenolate mofetil
46045245|NCT00882310|Drug|Gemcitabine|Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
46045246|NCT00882310|Drug|Docetaxel|Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
46045247|NCT00882310|Drug|Capecitabine|Day 1-14: capecitabine at 1000 mg/m2/day divided into 2 doses given two times a day (BID) by mouth (PO) Maximum dose 2000mg/day divided into BID dosing
45350969|NCT05227300|Drug|2% lidocaine with 1:100,000 epinephrine|Septodont's standard formulation of 2% lidocaine with epinephrine
46045248|NCT00656344|Other|Cognitive behavioral treatment enhanced by virtual reality|A cognitive behavioral protocol with cognitive and behavioral techniques will be used to treat symptoms. The exposure part of the treatment will be enhanced with the use of a virtual environment.
45476730|NCT03599089|Drug|Acetaminophen|1000mg IV administered intraoperatively
45476731|NCT03599089|Drug|Oxycodone|5mg PO prn post-surgery
46045249|NCT00884650|Drug|oral analgesic|per clinical standard of care
46045250|NCT00884650|Drug|intravenous analgesic per pump|per clinical standard of care
45350970|NCT00890487|Other|hyaluronic acid pill|pill, 220 mg, once a day, three months
45350971|NCT02541357|Behavioral|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice"
45685888|NCT05090722|Device|PureWick System|The PureWick system consists of the external catheter, collection tubing, and collection canister with lid. It operates via a power cord that is plugged into the device outlet and the A/C power outlet.
45685889|NCT05080192|Drug|Fenofibrate|145 mg/d of Tricor (administered as part of the parent FERMIN trial) for 10 days, or renal corrected dose equivalent (depending on renal function)
45685890|NCT05080192|Drug|Placebo|Matching placebo (once/day) for 10 days
45685891|NCT01192048|Other|Blood Sample Collection|Blood sample collection for direct sequencing, microarray, single nucleotide polymorphism, whole-genome array comparative genomic hybridization DNA analyses, and/or whole exome or genome sequencing.
45685892|NCT00479128|Drug|Bortezomib|Starting dose: 0.8 mg/m^2 IV Over 3-5 Seconds
45685893|NCT00479128|Drug|Gemcitabine|Starting dose: 225 mg/m^2 IV Up to 90 Minutes
45685894|NCT00479128|Drug|Doxorubicin|Starting dose: 12.5 mg/m^2 IV Over 15-30 minutes
45842091|NCT01154920|Drug|Docetaxel|75 mg/m^2 by vein over 1 hour on Day 1 of each 21 day cycle for 3 cycles of induction therapy
46045251|NCT02636842|Drug|Aripiprazole Lauroxil|Intramuscular (IM) injection, single dose
45350972|NCT02541357|Behavioral|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
45350973|NCT00890565|Drug|granisetron|Treatment A: Sancuso® patch (3.1mg/24 hours) on Day 1 and IV placebo (0.9% saline) on Day 3 Treatment B: Granisetron IV 10 mcg/kg over 30 seconds on Day 1 and placebo patch on Day 3 Treatment C: Placebo patch on Day 1 and IV placebo on Day 3 Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3
45350974|NCT00890643|Drug|prazosin hydrochloride|prazosin 1-20 mg/day in divided doses
45350975|NCT00890643|Drug|placebo|placebo
45350976|NCT00893217|Drug|Betaseron (Interferon beta-1b, BAY86-5046)|250 mcg
46045252|NCT04163380|Behavioral|Resistance Training|Participants will exercise at the mid-point of each menstrual cycle phase (EFP- day 4, LFP- day 11, ELP- day 18 and LLP- day 25 for a 28 day menstrual cycle). Training will consist of a warm up. Intensity will be set at 70% of 1RM, and the circuit training will include 7 strength exercises: leg press, rows, back squat, weighted crunches, deadlifts, bench press, and weighted squat jumps. The participant will perform 3 sets f 10 repetitions with 30 seconds of rest
45350977|NCT00893217|Drug|Betaseron (Interferon beta-1b, BAY86-5046)|500 mcg
45350978|NCT00767598|Drug|phosphodiesterase type 5 inhibitor|single oral administration of 20mg vardenafil
45350979|NCT00767598|Drug|phosphodiesterase type 5 inhibitor|single oral administration of 100mg sildenafil
45476732|NCT03599089|Drug|Bupivacaine Hydrochloride|0.5% infiltration pre-surgery
45476733|NCT01200173|Other|1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
45476734|NCT01200173|Other|2-Non fermented dairy product (control)|
45476735|NCT03192150|Drug|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
45476736|NCT03192150|Other|Vehicle|Vehicle twice daily for 16 days
45476737|NCT01204073|Drug|TAK-441|"TAK-441 will be administered as an oral tablet as follows:~Patients enrolled in the dose escalation cohorts will receive:~A single-dose administration on Day 1, followed by a 1-week washout period during which pharmacokinetics is assessed~Continuous daily dosing on Days 8 through 28 in Cycle 1~In subsequent cycles, continuous daily dosing over 21 days, repeated continuously~Patients enrolled in the expansion cohorts will receive continuous daily dosing on Days 1 through 21 of each 21-day cycle"
45685895|NCT00474370|Drug|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
45842092|NCT01154920|Drug|Cisplatin|100 mg/m^2 by vein over 1-3 hours on Day 1 of each 21 day cycle for 3 cycles of induction therapy
45842093|NCT01154920|Drug|Fluorouracil|700 mg/m^2 continuous infusion Days 1-4 on Day 1 of each 21 day cycle for 3 cycles of induction therapy
45842094|NCT01154920|Radiation|Radiotherapy (RT)|Radiation about 2-4 weeks after induction therapy, Monday through Friday for about 7 weeks, or as recommended by the treating radiologist.
45842095|NCT01154920|Other|Chemotherapy|PCC group receives 6 and C-TPF group receives 3 chemotherapy treatment cycles. If receiving radiation + chemotherapy, weekly Cisplatin 40 mg/m^2 by vein over 1-3 hours or Carboplatin AUC 2 by vein over 1 hour beginning 2 to 3 weeks after conclusion of induction program.
45842096|NCT01093300|Device|Paclitaxel-eluting balloon catheter|
45350980|NCT00767598|Drug|phosphodiesterase type 5 inhibitor|single oral administration of 200mg udenafil
45685896|NCT00474370|Drug|Placebo|One tablet of placebo once daily.
45685897|NCT00472966|Drug|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels|Apply cream once daily at night. Subjects will be asked to discontinue use of Fluocinolone acetonide/hydroquinone/tretinoin Cream 2 days prior to the peel and restart 2 days after the peel; Glycolic Acid Peels - In office treatment at weeks 2, 4, 6, 8 and 10
45685898|NCT01896154|Dietary Supplement|NPS|Comparison of multiple dietary non-digestible polysaccharides
45685899|NCT01579552|Behavioral|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
45842097|NCT01093300|Device|Everolimus-eluting stent|
45842098|NCT00852124|Biological|VSL#3|VSL#3 2 times daily
45842099|NCT00852124|Biological|VSL#3 or placebo|1 packet 2 x daily of placebo
45842100|NCT01053078|Drug|Naltrexone|1 month treatment; Naltrexone 25mg once daily for 5 days, then 50 mg once daily for 23 days
45842101|NCT01053078|Other|Placebo|1 month treatment; placebo tablet once daily for 28 days
45842102|NCT01053156|Drug|minocycline hydrochloride|Minocycline hydrochloride dosed orally once a day for 3 months.
46045253|NCT04163302|Biological|CD19-PD1-CART Cell|This study was a single-center, open-label, single-arm, non-randomized clinical trial, which has 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patients in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, the investigators select the safest dose and recruit more patients for CART test to explore its effectiveness.
46045254|NCT02535598|Behavioral|Normal presentation|All the material will be presented as plain text.
46045255|NCT02535598|Behavioral|Enhanced presentation|The material of the intervention is designed to be as appealing as possible with clear organization, animated presentations, ample illustrations, etc.
45350981|NCT00670800|Drug|Metformin|Following the baseline studies, PCOS affected women will be initiated on metformin at a dose of 500 mg orally after breakfast and the dose will be increased the following week to 500 mg twice daily (BID), adding a dose after lunch. On the third week, the dose will be increased to 500 mg three times daily (TID), adding a 500 mg tablet after supper. All subjects will be monitored for possible side effects such as nausea, vomiting, diarrhea, anorexia, and abdominal discomfort. These side effects tend to be mild, dose-related and improve with continued use of metformin. Hypoglycemia is rare and tends to occur in the setting of alcohol abuse or prolonged starvation. Malabsorption of vitamin B12 and folate occurs with long-term treatment, although it usually does not lead to anemia.
45350982|NCT00764166|Drug|Docetaxel + hormonal treatment (LH-RH agonist)|"Docetaxel will be administered:~To D1 of every cycle in the dose of 70 mg/m²,~Perfusion IV of 60 minutes diluted in 250 ml with physiological serum or with serum glucoside from a peripheral or central vein, Every 3 weeks during 6 cycles (except when unacceptable tolerance).~Triptorelin was given by injection for 4 times every 3 months Bicalutamide was given at the same time with LH-RH agonist for 3 weeks ; taken orally"
45476738|NCT03838523|Other|Open Label Placebo|See group description
45476739|NCT03597529|Drug|Melatonin|melatonin
45476740|NCT01204151|Behavioral|discrete-trial training|
45842103|NCT01053156|Drug|Placebo|Placebo will be given daily for 3 months.
45842104|NCT01053312|Drug|[18F] Flutemetamol|All subjects will receive an intravenous (IV) dose of [18F]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of [18F]flutemetamol will be 185 megabecquerels (MBq).
45842105|NCT01054404|Drug|Furosemide|Furosemide 0.3 mg/kg
45842106|NCT01054404|Drug|Placebo|Placebo (up to 5mL)
45842107|NCT01055184|Biological|2009 H1N1 Virus Vaccine|Single 0.2 mL dose of live monovalent vaccine, delivered through nasal spray
45842108|NCT01056198|Drug|Santyl|2 mm Santyl applied once daily.
45842109|NCT01056198|Procedure|Control|Daily gauze and optional sharp debridement
45842110|NCT01058070|Device|Torax Medical, Inc. LINX Reflux Management System|Implantable device, Magnetic Esophageal Sphincter
45842111|NCT01060020|Drug|Sildenafil|Single oral dose of 40mg or 80mg of Sildenafil
45685900|NCT01579552|Behavioral|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
45685901|NCT01573780|Drug|Smac mimetic TL32711|Given IV
45685902|NCT01573780|Drug|gemcitabine hydrochloride|Given IV
45685903|NCT01573780|Other|laboratory biomarker analysis|Correlative studies
45685904|NCT01573780|Other|pharmacological study|Correlative studies
45685905|NCT01573780|Procedure|biopsy|Optional correlative studies
45685906|NCT01186276|Dietary Supplement|Fiber|Dietary fiber supplements to be consumed daily for 6 weeks.
45685907|NCT01186276|Dietary Supplement|Corn starch|Corn starch to be consumed daily for 6 weeks. This will serve as the control/placebo arm.
45842112|NCT01060098|Drug|anti-TNF therapy (etanercept or adalimumab)|Biological DMARD
45842113|NCT01061034|Drug|aspirin and omeprazole|aspirin 100 mg, once daily aspirin 100 mg and omeprazole 20 mg both once daily.
45842114|NCT01064076|Device|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the SQ-RX pulse generator (Model 1010), the Q-TRAK subcutaneous electrode (Model 3010), the Q-TECH programmer (Model 2020), and Q-GUIDE electrode insertion tools (Models 4010 and 4020).
45842115|NCT01065480|Behavioral|Live teleconference supervision|Participants receive live teleconference supervision during a session with a client on their use of Motivational Interviewing (MI) in the session. MI is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence. Compared with nondirective counselling, it is more focused and goal-directed. The examination and resolution of ambivalence is its central purpose, and the counselor is intentionally directive in pursuing this goal.
45842116|NCT01065480|Behavioral|Taped Review Supervision|Participants audio record a session with a client and receive supervision after the session on their use of Motivational Interviewing during the session.
45842117|NCT01065558|Drug|Ecopipam|Tablets, once daily, for two weeks up to 200 mg/day
45847612|NCT03551886|Behavioral|Advanced Emotion App|The app is designed to help TAY better recognize their emotions using enhanced features
46045256|NCT02535598|Behavioral|Normal support|Participants receive semi-standardized support once a week and there will be no formal training or competence.
46045257|NCT02535598|Behavioral|Enhanced support|Participants are offered daily support through the internet from trained therapists.
46045258|NCT04159636|Other|Carbohydrate beverage|The participants in this group are allowed to drink carbohydrate until 2 hours before surgery
46045259|NCT02634502|Procedure|radiofrequency ablation|
46045260|NCT02634502|Drug|S-1|
46045261|NCT04161820|Behavioral|The effect of education and telephone follow ups based on the Chronic Care Model on self-management, quality of life and patient satisfaction in patients with ischemic stroke|The effect of education and telephone follow ups based on the Chronic Care Model on self-management, quality of life and patient satisfaction in patients with ischemic stroke Self-management, quality of life and patient satisfaction were assessed by scales at the first interview and 3 months later. Metabolic variables of the patients were obtained from the patient clinical information system at the first interview and 3 months later.
45350983|NCT00764166|Drug|Hormonal treatment (LH-RH agonist)|Triptorelin was given by injection for 4 times every 3 months. Bicalutamide given at the same time with LH-RH agonist for 3 weeks ; taken orally.
45350984|NCT00770406|Drug|botulinum toxin type A|100 or 200 units intravesically
46045262|NCT04161976|Drug|LY900027|LY900027 administered to participants with T1DM using CSII.
46045263|NCT04161976|Drug|Insulin Lispro|Insulin lispro administered to participants with T1DM using CSII.
45350985|NCT02557542|Other|One Stop Vein Clinic|Same day diagnosis and treatment
45350986|NCT02557542|Device|Radiofrequency ablation|Venous ablation
45350987|NCT02557542|Device|Endovenous laser ablation|Venous ablation
45350988|NCT02557542|Drug|Foam sclerotherapy (Polidocanol or Sodium Tetradecyl Sulphate)|Venous ablation
46045264|NCT04159558|Device|Mobile application|Experimental group will use a mobile application to help them in their self-care
46045265|NCT04163068|Other|Interview|The interview will last approximately 45 minutes, will be audio-recorded, transcribed, and analysed
46045266|NCT02634424|Device|MyPKFiT|Adjustment of the treatment dose using a decision support software according to the PK values
46045267|NCT00656422|Drug|insulin Levemir|The participant will receive an insulin dose of insulin Levemir at dinner subcutaneously according to a dosing algorithm.
45842118|NCT01065714|Drug|Hydrogel vehicle|Each morning and evening, gently wash the target area with warm water and gently pat dry with soft towel. Once dry place a small amount of Hydrogel vehicle onto the tip of your finger. Place a dab of the Hydrogel vehicle on either the left or right side of the body as instructed. (Do not use Hydrogel vehicle and Eucerin lotion on the same side of the body.)
45842119|NCT01065714|Drug|Eucerin Lotion|Each morning and evening, gently wash the area with warm water and pat dry with a soft towel. Once dry, place a small amount of Eucerin lotion to the target area on either the left or right side of the body as instructed. (Do not use Eucerin and Hydrogel vehicle on the same side of the body.)
45842120|NCT01066026|Procedure|hyaluronic acid with metallic cannula or standard needle.|"The sides of injection were randomized and both the subject and the evaluator were blind to it. The injections were performed according through two different devices:~In one of the sides, the hyaluronic acid (Restylane®) was injected in its conventional pharmaceutical presentation, with a standard needle which is part of the product's kit;~In the other side, the hyaluronic acid (Restylane®) was injected through a metallic cannula, which replaced the needle of the product's kit.~Local analgesia was provided for both applications: topical analgesics 4% Lidocaine, for the application with the standard needle, and nerve block (Lidocaine 2%), where the application was performed with the metallic cannula."
46045268|NCT00656422|Drug|insulin Lantus|The participant will receive an insulin dose of the insulin Lantus at dinner subcutaneously according to a dosing algorithm.
46045269|NCT00881608|Drug|Placebo|Placebo, 1 capsule daily for five days
45685908|NCT01141426|Behavioral|Intensive Short-term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.
45842121|NCT01066026|Drug|Hyaluronic acid injected with the new tool.|hyaluronic acid with metallic cannula.
45847613|NCT03551886|Behavioral|Basic Emotion App|The app is designed to help TAY better recognize their emotions using basic features
46045270|NCT00881608|Drug|Proellex|Proellex, one 3, 6, 12 or 25 mg capsule daily for five days
46045271|NCT04162912|Behavioral|Motivational Interviewing tailored Advance Care Planning|The trained interventionist who is experienced in MI techniques will explore their illness experiences, emotions and beliefs about their health conditions and future care in an empathetic manner and explore their ambivalence for ACP behaviours.
45685909|NCT01141426|Behavioral|Secondary Care Treatment as Usual|At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
45685910|NCT01895530|Dietary Supplement|Saccharomyces boulardii|The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
45685911|NCT01547260|Drug|Gemzar|Gemcitabine (Gemzar®), 1000 mg/m2 in 0.9% sodium chloride will be administered as intravenous infusion over 30 minutes, weekly for 3 weeks then rest for 1 week (days 1, 8, 15 of each 28-day cycle).
45842122|NCT01072032|Device|Anklebot (Ankle Robot)|Impedance controlled ankle robot provides assistance as needed for participants to perform ankle movements while playing a video game, is used to assist stroke patients to enhance motor recovery
45842123|NCT01072188|Device|Arginine/Calcium Carbonate|One time treatment
45842124|NCT01072188|Device|Nupro - Fluoride Free|Brush twice daily
45842125|NCT01072656|Device|Deep Brain Stimulation for Thalamic Pain Syndrome|Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V). In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six. In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group. In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.
45350989|NCT00767754|Drug|Paxil CR|12 week treatment of Paxil(20-40mg)
45350990|NCT00607893|Device|Continuous Positive Airway Pressure (CPAP)|Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.
45350991|NCT00607893|Device|Sham CPAP|Participants will use the lower pressure CPAP every night for 8 weeks.
45476741|NCT03991091|Drug|discontinuation of oxytocin administration|Discontinuation of oxytocin administration at the beginning of the active phase of the 1st stage of labor, i.e. oxytocin infusion will be stopped beyond a cervical dilatation of 6cm. In the experimental group, oxytocin can be re-started, if necessary, after 2 hours of arrest of labor.
45842126|NCT01076244|Procedure|Minimally Invasive Lumbar Decompression|This minimally invasive procedure is performed under fluoroscopic image guidance through a dorsal approach to the spine. The patient is given local anesthesia and a sedative but needs to be responsive to the surgeon's questions for neurological monitoring. Under image guidance, the mild tools are inserted and positioned on the posterior spinal lamina, to the left or right of the spinous process. The tools are used to cut and remove tissue and bone from the posterior side of the lumbar spine to create a space inside the spine that can help decompress some of the spinal nerves.
45842127|NCT01083654|Behavioral|Standard Treatment Counseling|Standard Treatment Counseling will be based on recommendations in the 2008 U.S. Public Health Service Guideline (Treating Use and Dependence) including topics on preparing to quit, nicotine addiction, coping with stressors and challenging situations, coping with withdrawal symptoms, seeking support, and relapse prevention. Counseling will be delivered in an accessible, personalized manner by Ms. Fossum (an enrolled member of the Menominee Tribe) but no American Indian culturally-appropriate treatment elements will be incorporated into the counseling. In other words, the counseling in the Standard Treatment will be similar to the kind of evidence-based counseling offered to other smokers regardless of race or ethnicity.
45350992|NCT00571038|Behavioral|Peer Led|Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
45476742|NCT03991091|Drug|continuation of oxytocin administration|continuation of oxytocin administration
45842128|NCT01083654|Behavioral|Culturally-Tailored Treatment|The Culturally-Tailored Treatment consists of the Standard Treatment Counseling plus culturally-appropriate treatment elements including: discussion of the long history of sacred/traditional use of tobacco (honoring and respecting native traditions) and how it differs from use of commercial tobacco use (harming health); custom booklet on smoking and smoking cessation tailored for Menominee and other American Indian smokers; and participants will be encouraged to make their own traditional tobacco pouch (symbol of long life)
46045272|NCT02636764|Other|exercise|exercises designed with the objective of strengthening the musculature: flexor and extensor of the knee; extensor, abductor, lateral rotator of the hip.
45476743|NCT03906240|Behavioral|Moral Elevation intervention|The intervention will be administered twice per week for 8 sessions total. The intervention will include two types of moral elevation exercises related to witnessing virtuous behavior and subsequently setting session goals aimed to facilitate social engagement.
45476744|NCT01202357|Behavioral|Community Case Management|Community case management for psychosis by designated key-worker according to specified protocol
45476745|NCT05420454|Drug|Docetaxel|75 mg/m2, d1, q3w,6 cycles
45476746|NCT05420454|Drug|Carboplatin|AUC 6, d1, q3w ,6 cycles
45476747|NCT05420454|Drug|Trastuzumab|starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w ,6 cycles
45476748|NCT05420454|Drug|Pertuzumab|starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w,6 cycles
45476749|NCT05420454|Drug|Nab paclitaxel|220 mg/m2, d1, q3w,6 cycles
46045273|NCT02636764|Device|interferential current|The basic principle of Interferential Therapy (IFT) is to utilise the significant physiological effects of low frequency (<250pps) electrical stimulation of nerves without the associated painful and somewhat unpleasant side effects sometimes associated with low frequency stimulation
45476750|NCT05420454|Drug|Epirubicin|90 mg/m2,d1, q3w × 4 cycles,followed by docetaxel
45476751|NCT05420454|Drug|Cyclophosphamide|600 mg/m2, d1, q3w ,4 cycles,followed by docetaxel
46045274|NCT02636764|Device|short-wave diathermy|Is a modality that produces deep heating via conversion of electromagnetic energy to thermal energy
45476752|NCT05420454|Drug|Docetaxel|100 mg/m2, d1, q3w × 4 cycles
45476753|NCT05420454|Drug|Epirubicin|90 mg/m2,d1, q2w × 4 cycles,followed by nab-paclitaxel
45350993|NCT00571038|Behavioral|Seminar|Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
45350994|NCT00764244|Procedure|Vitrectomy|Vitrectomy
45350995|NCT00764244|Drug|Intravitreal triamcinolone injections|Intravitreal triamcinolone injections
45350996|NCT00764244|Procedure|Laser photocoagulation|Laser photocoagulation
45476754|NCT05420454|Drug|Cyclophosphamide|600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
45476755|NCT05420454|Drug|Nab paclitaxel|125 mg/m2, d1,8,15, q3w× 4 cycles
45476756|NCT02961959|Procedure|Surgery|Arthrodesis of SI-joints, Physiotherapy
45476757|NCT02961959|Other|Non-surgery|Physiotherapy
45476758|NCT03180528|Drug|Remetinostat|Applied topically under bandage occlusion
45476759|NCT04667507|Drug|Dexamethasone Ophthalmic implant|Dexamethasone ophthalmic insert 0.4 mg for intracanalicular use
45476760|NCT03843905|Other|no intervention|The aim of this translational research project is to study the impact of these new prognostic tools on surgical and oncologic results in a prospective cohort of patients who underwent CRC surgery at the Digestive Surgery Department of the University Hospital of Clermont-Ferrand (France)
45476761|NCT03597295|Drug|Retifanlimab|Retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).
45350997|NCT00770640|Drug|Pioglitazone and insulin|Pioglitazone 30 mg, tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
45350998|NCT00770640|Drug|Insulin|Pioglitazone placebo-matching tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
45350999|NCT00764400|Behavioral|Word Retrieval Treatments for Aphasia|Speech therapy sessions take place 4 times per week for up to 90 minutes per session. Following a phase of baseline pre-testing, two phases of speech therapy will take place lasting up to 20 sessions per phase. Post-testing will take place immediately upon completion of the treatment phases and again at 1 month post study completion.
45351000|NCT00770718|Drug|Recombinant Activated Factor VII (rFVIIa)|Five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is >1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given.
45351001|NCT00770718|Drug|Prothrombin Complex Concentrate|5 patients will receive PCC based on ideal body weight. Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size. Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.). INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total. The INR will also be checked 24 hours post-administration. If at any time, the INR is >1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. A maximum total of 60 iu/kg can be administered.
45351002|NCT00770718|Biological|Fresh Frozen Plasma|Five patients will receive transfusions of FFP to normalize INR. If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently. If the initial INR is >4, then 4 units of FFP will be administered (Round 1). The INR will be checked after each round of FFP infusion completed. Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion. If the INR should ever return to >1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
45351003|NCT00770796|Drug|Atorvastatin|80 mg die
45351004|NCT00770796|Drug|Placebo|
45476762|NCT03180138|Behavioral|Reminders alone|Automated reminders (text and /or voice in local language) for upcoming vaccination visit(s) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
45476763|NCT03180138|Behavioral|Compliance-linked incentives|Automated compliance-linked incentives (as cell-phone minutes) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
45476764|NCT04652921|Dietary Supplement|Creatine-guanidinoacetic acid|A dietary supplement provided as powder dissolved in a glass of water
45476765|NCT04652921|Other|Inulin|A dietary supplement provided as powder dissolved in a glass of water
45476766|NCT01314612|Behavioral|Cognitive-Behavioral Insomnia and Nightmare Group|Group based cognitive-behavioral therapy meeting weekly for 90 minutes over the course of 9 weeks. Utilizes stimulus control, sleep scheduling, and progressive muscle relaxation to address symptoms of insomnia. Imagery rehearsal and rescripting are used to address nightmare symptoms.
45685912|NCT01547260|Drug|Revlimid|Lenalidomide capsules will be taken orally in the morning each day on days 1-21 of each 28-day cycle. Phase I; Three subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day, respectively. Phase II; Lenalidomide at dose determined in Phase I, will be administered orally once daily for 21 days followed by 7 days rest.
45685913|NCT02317042|Device|Juno|Juno device set to ST mode with participant's current therapy settings.
45685914|NCT02317042|Device|Juno|Juno device set to AutoEPAP iVAPS mode.
45685915|NCT02317042|Device|Juno|Juno device set to Fixed EPAP iVAPS mode.
45685916|NCT04205266|Drug|Ferumoxytol|IV iron infusion
46045275|NCT02636764|Device|Low level laser therapy|Laser treatment in which the energy output is low enough so that the temperature of the treated tissue does not rise above 98.6°F (36.5° C) or normal body temperature.
45685917|NCT04205266|Drug|Ferrous Sulfate|oral iron therapy
45685918|NCT01896388|Drug|Ifenprodil Tartrate|
45685919|NCT01896388|Drug|Placebo|
45685920|NCT01125436|Dietary Supplement|Cholecalciferol|50,000 units of oral vitamin D3(cholecalciferol) weekly plus 800 calcium daily
45685921|NCT01125436|Dietary Supplement|Cholecalciferol|Weekly placebo plus 800 calcium alone
45842129|NCT01083732|Drug|dabigatran etexilate|Experimental dose chosen based on age and weight
45842130|NCT01084278|Drug|Colchicine|Colchicine tablets
45842131|NCT01085760|Drug|Vancomycin|Comparison of different doses of drug
46045276|NCT02636764|Device|Ultrasound therapy|Ultrasound (US) is a form of mechanical energy, not electrical energy and therefore strictly speaking, not really electrotherapy at all but does fall into the Electro Physical Agents grouping.
45351005|NCT00767988|Dietary Supplement|Urex-cap-5 (2x10^9 cfu each of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1)|Capsules once daily at approximately the same time each day for 6 months.
45351006|NCT00767988|Other|Placebo|Capsule once daily at approximately the same time each day for 6 months.
45351007|NCT00545740|Drug|SPD476 (1.2g)|1.2g SPD476 once daily (QD) orally
45351008|NCT00545740|Drug|SPD476 (2.4 g)|2.4g SPD476 QD orally
45685922|NCT01113658|Device|SNaP Wound Care System|"The intervention is negative pressure wound therapy (NPWT) with the Spiracur SNaP Wound Care system for the treatment of a variety of acute and chronic wounds including pressure ulcers, trauma wounds, diabetic foot ulcers, venous stasis ulcers, and skin grafts.~The Spiracur SNaP Wound Care system weighs less than 4 ounces, does not utilize an electric pump (device has no electrically powered parts), is fully disposable after use, and is designed for particularly small chronic wounds that require advanced wound care management. It delivers NPWT at a constant pressure level over several days without any required adjustments by the patient or clinician."
45685923|NCT04755322|Drug|Hydroxychloroquine|Hydroxychloroquine 400 mg at start of pregnancy
45685924|NCT04755322|Drug|Folic acid|5 mg
45685925|NCT04755322|Drug|Low-dose aspirin|75 mg
45842132|NCT01085760|Drug|Vancomycin|Comparison of different doses of drug
45842133|NCT01085760|Drug|Metronidazole|Comparison of different doses of drug
45842134|NCT01085760|Drug|Metronidazole|Comparison of different doses of drug
45842135|NCT01085760|Drug|Vancomycin|Comparison of different drug doses
45842136|NCT01086228|Device|XIENCE V / PROMUS stent|Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.
45842137|NCT01086852|Biological|FACTOR X|"Presurgery loading dose- The FX level of 70%-90% should be achieved.This will be calculated based on the patients weight on day of surgery and the required rise. Initial dose should not exceed 60IU/kg.~Post surgery- FX trough levels of 50% should be achieved.~Intravenous infusion of factor X is given at a suggested rate of 10mL/min but not exceeding more than 20mL/min."
45476767|NCT01200251|Drug|Bimatoprost eyelash gel|Bimatoprost 0.03% solution was compounded into a gel - patients used on eyelash margin once daily placing gel with a fingertip or Q-tip for 6 months
45476768|NCT03597139|Drug|Voclosporin Ophthalmic Solution|Investigational Drug
45842138|NCT01088646|Device|PillCam® Express Capsule Endoscopy Delivery System|"The PillCam® Express Capsule Endoscopy Delivery System is comprised of three parts: a catheter, a syringe and the capsule holder. The catheter is passed through the accessory channel of a standard endoscope and the capsule holder is snapped on to the distal end of the device. The endoscope is used to guide the Capsule Endoscopy Delivery System to the proximal duodenum. The capsule is then released pneumatically, using an air-filled syringe attached to the proximal end of the catheter.~Once the capsule is deployed, the endoscope is withdrawn and the capsule holder is cut off at the distal part of the device with scissors. The catheter is then retracted and discarded.~The PillCam® Express Capsule Endoscopy Delivery System is single-use, disposable and latex-free."
45351009|NCT00545740|Drug|SPD476 (4.8 g)|4.8g SPD476 QD orally
45351010|NCT00545740|Drug|Placebo|QD orally
45685926|NCT04755322|Drug|Placebo|oral tablets
45685927|NCT04755478|Procedure|Thoracotomy|Participants will undergo lobectomy via open thoracotomy at the discretion of the surgical team.
46045277|NCT00657670|Device|Ready-made spectacles|Ready-made spectacles will be dispensed to correct refractive error. Ready-made spectacles are spectacles which are available from an existing inventory. This is different to prescription spectacles which are usually made to order. They have the same spherical power for the right and left eyes and do not include a correction for astigmatism. The limited inventory for this trial includes +1.00 to +4.00 in 0.50 steps, +5.00, +6.00 and +8.00, -1.00 to -6.00 in 0.50 steps, -7.00, -8.00, -9.00 and -10.00. The appropriate spectacles are selected based on the spherical equivalent refractive error. If there is a difference between the two eyes the lower correction is selected.
45351011|NCT05208190|Drug|Clozapine|treatment will occur naturalistically, as per standard clinical guidelines
45351012|NCT05208190|Drug|treatment as usual|naturalistic treatment with any other antipsychotic medication except clozapine
45351013|NCT00609609|Procedure|Photopheresis|8-9 photopheresis treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60. After day 60, your doctor will decide whether ECP is worth continuing, and the frequency of treatments.
45685928|NCT04755478|Procedure|VATS|Participants will undergo lobectomy via VATS at the discretion of the surgical team.
45351014|NCT00609609|Drug|Methylprednisolone|2 mg/kg daily with a taper to no less than 1 mg/kg/day by day 14, followed by a tapering schedule according to the suggested guidelines.
45351015|NCT00968422|Drug|ABT-384|3 escalating doses will be administered daily for 21 days
45351016|NCT00968422|Drug|Matching placebo to ABT-384|Doses will be administered daily for 21 days
45351017|NCT00673452|Drug|duloxetine hydrochloride|60-120 mg, oral, every day, 12 weeks (acute blinded phase followed by a 12 week blinded continuation phase).
45351018|NCT00673452|Drug|placebo|oral, daily, 12 weeks (acute blinded phase followed by 12 weeks of blinded duloxetine treatment)
45351019|NCT00890799|Device|Shanghai pmVSD occluder|Ventricular Septal Defects Occluders with sizes from 4mm to 20mm.
45842139|NCT01090752|Drug|Pioglitazone|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
45351020|NCT00890799|Procedure|surgery|Patient in this group received open surgical repair of pmVSD.
46045278|NCT00657670|Device|Spectacles|Spectacles will be prescribed to correct refractive error. These spectacles will be custom-prescribed based on the sphero-cylindrical refractive correction. The spectacles used in this arm will be custom made for each participant based on their refraction and can be made in a full range of spherical powers and astigmatic corrections for up to 2.00 dioptres of cylinder.
46045279|NCT02632630|Drug|Amino Acids w/Electrolytes in Dextrose|Patients will receive peripheral parenteral nutrition to a maximum of 2L/day (with a minimum rate of 45mL/hour and a maximum rate of 85mL/hour) of pre-packaged Peri-OLIMEL 2.5% E. The PPN will be administered in place of their maintenance crystalloid solution, and will be adjusted or stopped as clinically indicated by the attending medical team., for up to 5 days of hospitalization or until discharge, whichever is sooner.
45351021|NCT00967174|Drug|Nicotine Patch|25 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days.
45351022|NCT00967174|Drug|Placebo Patch|Placebo Patch applied on the lower back, according to treatment sequence, daily for 21 days.
45351023|NCT00967174|Drug|SLS Comparator Patch|0.1% (w/v) SLS patch applied on the lower back, according to treatment sequence, daily for 21 days.
45351024|NCT00890877|Drug|OC000459 or placebo|Pills, active and/or placebo given twice daily for 17 weeks
45351025|NCT00967252|Drug|Atorvastatin|Atorvastatin 10 mg daily or equivalent dose in another statin
45351026|NCT00967252|Drug|Atorvastatin|Atorvastatin 20 mg daily or equivalent dose in another statin
45351027|NCT00967252|Drug|Atorvastatin|Atorvastatin 40 mg daily or equivalent dose in another statin
45351028|NCT00967252|Drug|Atorvastatin|Atorvastatin 80 mg daily or equivalent dose in another statin
45351029|NCT00967252|Other|Control|No statin being taken
45351030|NCT00890955|Drug|Amrubicin|"Dose Level -1: 20mg/m2~Dose Level 1: 25mg/m2~Dose Level 2: 30mg/m2~Dose Level 3: 35mg/m2~Dose Level 4: 40mg/m2~Amrubicin will be given as a slow IV push or infusion over approximately 5 minutes once daily for 3 consecutive days starting on day 1 of each 21 day cycle."
45351031|NCT00890955|Drug|Cyclophosphamide|Cyclophosphamide will be given at a fixed dose as 500mg/m2 IV infusion over 30-60 minutes on day 1 of each 21 day cycle (following amrubicin).
45842140|NCT01090752|Drug|Metformin|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
46045280|NCT02632630|Dietary Supplement|Ensure product|Patients will receive one package of Ensure two times daily in hospital. At discharge, patients randomized to receive Ensure will be provided with 28 packages of Ensure with instructions to attempt to consume 1 package per day.
46045281|NCT02632630|Drug|Crystalloid solutions|Standard care intravenous maintenance fluid administration for up to 5 days of hospitalization or until discharge, whichever is sooner.
45351032|NCT00974896|Drug|AMG 479|AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
45351033|NCT04008550|Procedure|Right Heart Catheterization|A right heart catheterization will be done in patients with PAH before TAVI (3 months after TAVI)
45351034|NCT00893295|Other|informational intervention|
45351035|NCT00893295|Other|medical chart review|
45351036|NCT00893295|Other|screening questionnaire administration|
45351037|NCT00893295|Other|study of socioeconomic and demographic variables|
45351038|NCT00893295|Procedure|barium enema injection|
45351039|NCT00893295|Procedure|colon imaging study|
45351040|NCT00893295|Procedure|screening colonoscopy|
45351041|NCT00893295|Procedure|sigmoidoscopy|
45351042|NCT00975052|Drug|sitagliptin phosphate|100 mg sitagliptin daily for two days in one out of four treatment periods
45351043|NCT00975052|Drug|Comparator: metformin|500 mg twice daily on Day 1 and 1000 mg once daily on Day 2 in one of four treatment periods.
45351044|NCT00975052|Drug|Comparator: sitagliptin and metformin|100 mg sitagliptin once daily and 500 mg metformin twice daily on Day 1 and 100 mg sitagliptin once daily and 1000 mg metformin once daily on Day 2 in one of four treatment periods.
45351045|NCT00975052|Drug|Comparator: placebo|Placebo only on Days 1 and 2 in one of four treatment periods.
45351046|NCT00891033|Drug|Bortezomib (Velcade)|During the study Bortezomib will be administered intravenously as a 3-5 second bolus IV injection, at a dose of 1.0 mg/m2 on days 1, 4, 8, and 11 of each 21-day treatment cycle.
46045282|NCT02632630|Dietary Supplement|Oral nutritional supplementation|Standard of care oral nutritional supplementation is determined by the clinician. A dietitian may also be involved.
45351047|NCT00891033|Drug|Panobinostat|During the study, panobinostat IV will be administered intravenously as once daily on (day 1 and 8 of the 21 day cycle 2 and beyond). Patients enrolled on first group will receive 5 mg/m2 panobinostat IV, second group 10 mg/m2 panobinostat IV, third group 15 mg/m2 panobinostat IV and the fourth group 20 mg/m2 panobinostat IV. Each infusion of panobinostat will be administered over 30 minutes.
45351048|NCT00770952|Drug|Pioglitazone and Glimepiride|"Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 2 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 4 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 45 mg, tablets, orally, once daily and Glimepiride 4 mg, orally, once daily for up to 20 weeks."
45351049|NCT00770952|Drug|Glimepiride|"Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 4 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 5 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 6 mg, tablets, orally once daily for up to 20 weeks."
45351050|NCT00891111|Behavioral|Direct Payment|$25 gift card given upon completion of Health Risk Assessment
45351051|NCT00891111|Behavioral|Regret Lottery|Entered into a lottery upon completion of Health Risk Assessment
45351052|NCT00764556|Drug|Insulin|Intravenous insulin (actrapid) Subcutaneous insulin (aspart, glargine, detemir)
45351053|NCT00968578|Drug|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
45351054|NCT00968578|Drug|Placebo|Saline iv pre-operatively in equivalent volume (placebo)
45351055|NCT00893373|Drug|sorafenib|Standard AML chemotherapy plus sorafenib 400 mg BID
45351056|NCT00893373|Drug|placebo|Standard AML chemotherapy plus placebo
45351057|NCT00891267|Drug|Olmesartan medoxomil tablets low dose|Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
45351058|NCT00891267|Drug|Olmesartan medoxomil tablets high dose|Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
45351059|NCT00891267|Drug|Amlodipine|Amlodipine tablets taken once daily for 6 weeks
45351060|NCT04036617|Drug|NaQuinate|SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150mg
45351061|NCT04036617|Drug|Placebo|SAD cohorts will receive 1 dose of placebo between 10-150 mg. MAD cohorts will receive 7 days dosing of placebo between 70-150mg
45351062|NCT00891345|Biological|ALECSAT|Autologous activated CTL and NK-cells injected as a single intravenous injection.
45476769|NCT03597139|Drug|Restasis®|Comparator
45476770|NCT04639583|Device|Near-infrared spectroscopy (NIRS) utilization|The NIRS devise will be applied so that cerebral regional oxygen saturation (cRSO2) can be measured.
45476771|NCT01202435|Drug|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for four days.
45476772|NCT01202435|Drug|Pregabalin immediate release, 25 mg|25 mg immediate release capsules administered three times daily for four days
45685929|NCT04755400|Other|isotonic saline 9%|1 Liter of Isotonic saline administered I.V.
45351063|NCT02541279|Procedure|Physiotherapy exercises guideline|Exercises controlled by a physiotherapist.
45351064|NCT00545584|Drug|sitagliptin phosphate|sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks
45351065|NCT00545584|Behavioral|Comparator: Diet|Diet
45351066|NCT00545584|Behavioral|Comparator: Physical Activity|Physical Activity
45351067|NCT00378703|Biological|Bevacizumab|Given IV
45351068|NCT00378703|Other|Laboratory Biomarker Analysis|Correlative studies
45476773|NCT03179202|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT PNS System is a device which delivers mild electrical stimulation to the muscles in the low back. The System includes up to four small wires (called Leads) that are placed through the skin into the muscles in the low back. The wires attach to device(s) worn on the body that deliver stimulation (called Stimulators). The PNS System was approved by the FDA for up to 60 days of use for the management of acute and chronic pain, including back pain."
46045283|NCT02634034|Drug|A: NK-104-CR 8 mg|NK-104-CR 8 mg (Controlled Release single 8-mg tablet)
46045284|NCT02634034|Drug|B: Pitavastatin IR 4 mg|Pitavastatin IR 4 mg (Immediate Release single 4-mg tablet)
46045285|NCT02634034|Drug|C: Pitavastatin IR 8 mg|Pitavastatin IR 8 mg (Immediate Release two 4-mg tablets)
46045286|NCT00657748|Drug|Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)|Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study
45351069|NCT00378703|Other|Pharmacological Study|Correlative studies
45351070|NCT00378703|Drug|Sorafenib Tosylate|Given PO
45842141|NCT01093014|Behavioral|Low-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, using either a lab-based system or a portable system for up to 1 year.
45351071|NCT00378703|Drug|Temsirolimus|Given IV
45351072|NCT00893451|Drug|cholecalciferol (TillVal-D)|In a randomized, two-way cross-over design participants will take vitamin D3 or placebo twice daily during treatment periods of 10 weeks separated by a washout period of 6 weeks.
45351073|NCT00893451|Drug|Placebo|Placebo orally twice daily
45351074|NCT00893529|Dietary Supplement|lemonade with sugar|250 milliliters of lemonade with sugar daily for 18 months
45351075|NCT00893529|Dietary Supplement|lemonade low in sugar|250 milliliters of lemonade low in sugar daily for 18 months
45351076|NCT00967408|Drug|Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
46045287|NCT02636686|Drug|Drisapersen|Subjects will receive 6 mg/kg of drisapersen by subcutaneous injection once weekly. If subjects have experienced an intolerable injection site reaction(s), in consultation with the investigator, the subject may be allowed intermittent injections (8 weeks on/4 weeks off) or weekly intravenous infusions of 3 or 6 mg/kg
45351077|NCT00967408|Drug|Placebo|Rehabilitative treatment + oral inactive placebo for 6 months
45351078|NCT00967408|Other|Rehabilitative treatment|Rehabilitative treatment
46045288|NCT04162990|Behavioral|Lifestyle remodeling Intervention|Participants will be received 2 phases of intervention of lifestyle remodeling, 3 months for each phase, which contained cognitive stimulating activities and physical activities.
46045289|NCT04162990|Behavioral|Does Comparator: regular treatment|Participants in this group would be treated as usual, which contained the healthy education.
46045290|NCT02634190|Other|Thinprep® LBC|liquid based cytology
46045291|NCT02634190|Other|APTIMA® HPV Assay|in vitro diagnostic test
46045292|NCT02634190|Other|HR HC2® HPV DNA|in vitro diagnostic test
45842142|NCT01093014|Behavioral|High-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke summated, high-force contractions, using either a lab-based system or a portable system for up to 1 year.
45351079|NCT00891423|Drug|Meropenem short infusion|
45351080|NCT00891423|Drug|Meropenem extended infusion|
45847614|NCT04741620|Other|Capsaicin 10microM (TRPV1 natural agonist)|10 mL Capsaicin 10microM solution 3 times per day (before each meal) during 14 consecutive days.
45351081|NCT04035382|Procedure|Labor induction|The study intervention is labor induction from 39 0/7 to 39 6/7 weeks. The individual labor induction process will be at the discretion of the physician or midwife managing the subject's care. Methods of induction that may be used include misoprostol, intracervical Foley catheter, oxytocin, and/or amniotomy. Participating clinicians will be encouraged to use only one course of cervical ripening followed by oxytocin infusion and amniotomy.
45351082|NCT00891501|Procedure|Bone Marrow Aspiration|Autologous bone marrow is aspirated from the iliac crest (hip bone) of the patient using a 21-gauge bone marrow aspiration needle under complete aseptic conditions and proper anaesthesia
45351083|NCT00891501|Procedure|Bone marrow mesenchymal stem cell implantation|The culture expanded mesenchymal stem cell pellet will be implanted into the osteochondral knee defect via open surgery or arthroscopically under complete sterile aseptic conditions and proper anaesthesia. The defect will be covered with an autologous periosteal flap from the proximal tibia and then sealed with human fibrin glue to seal the defect and retain the cell pellet in place
45351084|NCT00967564|Other|epidemiologic study|QoL assessment
45351085|NCT02541045|Drug|metadoxine|metadoxine 500mg tablets: 1 Tablet by mouth twice in day during 6 months
45351086|NCT02541045|Other|placebo|placebo tablets: 1 Tablet by mouth twice in day during 6 months
45351087|NCT05131282|Diagnostic Test|Blood test of PE risk|A blood test is applied to women at the 1st or early 2nd trimester to evaluate risk of developing PE
45351088|NCT00968656|Radiation|PET/CT|Patients receive F-18-ISO-1 i.v. and undergo PET/CT imaging at 2-3 time points following the injection.
45351089|NCT00968656|Other|Laboratory Testing|Blood and urine samples for laboratory analysis and radioactive counts will be obtained during the imaging sessions
45476774|NCT03843671|Drug|Hyperbaric oxygen|Hyperbaric oxygen therapy
46045293|NCT02634190|Other|Colposcopy|Colposcopy
46045294|NCT04161586|Drug|Prilocaine Hydrochloride|Spinal Prilocaine for Ambulatory Surgery
46045295|NCT02636452|Other|cardiopulmonary exercise test|
46045296|NCT02636218|Drug|Ketamine|500 ml of ketamine (0.2 mg/ml) infused at 5 ug/kg/min for 4 hours.
46045297|NCT02636218|Drug|0.9% NaCl|500 ml of 0.9% NaCl infused at 5 ug/kg/min for 4 hours.
46045298|NCT01088399|Drug|Somatropin (rDNA origin)|Dose, frequency and duration are at discretion of attending physician, and determined on an individual basis.
46045299|NCT04161508|Drug|Sugammadex Injection|injection of sugammadex for the reversal of neuromuscular blockade at the end of the surgery
46045300|NCT04161508|Drug|Neostigmine Injection|injection of neostigmine for the reversal of neuromuscular blockade at the end of the surgery
46045301|NCT00598078|Drug|Sodium Oxybate|Dose 1
46045302|NCT00598078|Drug|Sodium Oxybate|Dose 2
46045303|NCT00598078|Other|Placebo|Dose 3
46045304|NCT02636296|Other|Pilates|The Pilates program was conducted twice weekly, 60 minutes/session, for twelve consecutive weeks by a certified Pilates Instructor.
46045305|NCT02636296|Other|Control|The control group did not receive the Pilates training program and were instructed to maintain their currently activities during the twelve-week follow-up period.
45351090|NCT00968656|Other|Safety Testing|ECG tracings, and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during, and after the imaging sessions.
45351091|NCT00968656|Other|Immunohistochemistry staining|If available tissue from a biopsy or surgery will be tested cellular proliferation markers such as Ki67 and sigma 2 receptors
45351092|NCT00968656|Drug|F-18-ISO|Patients receive F-18-ISO-1 i.v.
45351093|NCT04036149|Device|Intraocular lens|Implantation as part of cataract surgery
45351094|NCT00975442|Other|Eccentric training|A home training program of eccentric training of the wrist extensors to be carried out daily with 3 sets of 15 repetitions. All subjects were instructed to use the forearm band (Epi Forsa 4061, Rehband, Sweden)
45351095|NCT00975442|Device|Forearm band|All subjects were instructed to use the forearm band during all daily activities.
45351096|NCT00975442|Device|Forearm band|All patients were instructed to use a forearm band during all daily activities.
45351097|NCT00891579|Drug|Pemetrexed (Alimta)|treatment of single pemetrexed with vitamin supplement until discontinued conditions are met
45351098|NCT00891579|Drug|Gefitinib (IRESSA)|treatment of Gefitinib will be applied until discontinued conditions are met
45351099|NCT00968734|Dietary Supplement|colecalciferol|50.000UI single oral dose
45476775|NCT03843671|Device|Hyperbaric chamber|Hyperbaric chamber
45476776|NCT05406102|Drug|Remimazolam|Patients received an initial dose of 0.1mg/kg of remimazolam (add to 0.05 mg/kg top-ups doses to a total of up to five times within 15minutes).
45476777|NCT05406102|Drug|Propofol group|Patients received an initial dose of 1.5mg/kg of propofol(add to 0.5 mg/kg top-ups doses to a total of up to five times within 15minutes).
45476778|NCT01200563|Device|MIST Therapy|Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
45476779|NCT01200563|Device|Vacuum Assisted Closure|Controlled negative pressure (vacuum) delivering negative (sub-atmospheric) pressure to the wound site applied by a tubing which decompresses a foam dressing, continuously or intermittently depending on wound type.
45476780|NCT01200563|Device|MIST Therapy and Negative Pressure Wound Therapy|MIST Therapy will be provided 3 times per week, NPWT will be provided according to the manufacturer's recommended guidelines.
46045306|NCT00656500|Behavioral|Standard brief advice|Brief general assistance with smoking cessation
45476781|NCT02821182|Radiation|stereotactic body radiotherapy|"In patients with metastatic melanoma, anti-PD-1 treatment will be combined with stereotactic body radiotherapy (SBRT).~A total dose of 24 Gy SBRT will be delivered in 3 fractions to one measurable lesion and fractions will be separated >48h and <96h."
45476782|NCT01204229|Behavioral|Motivational and Cognitive Intervention for Drinkers (MCID)|Integrate social anxiety/ depression and drinking intervention
45476783|NCT01204229|Behavioral|Brief Motivational Intervention (BMI)|Integrate drinking intervention
45476784|NCT03725215|Behavioral|Split-Belt Treadmill Training|One session of 6 x 5 min with 1 min intervals.
45476785|NCT01204307|Drug|Docetaxel/cisplatin|The treatment schedule comprises a maximum of six 3-week treatment cycles consisting of weekly docetaxel (30 mg/m2) and cisplatin (37.5 mg/m2) for 2 consecutive weeks followed by a 1-week treatment-free period. The patients will be assessed after each cycle and a final assessment will be done after three and six cycles.
45476786|NCT01204307|Drug|Pemetrexed/cisplatin|The patients are given pemetrexed (500 mg/m2 as a 10-min intravenous infusion) and cisplatin (75 mg/m2) on day 1 every 21 days. Dexamethasone (4 mg) is administered twice daily on the day before, the day of, and the day after each dose of pemetrexed. Oral folic acid supplementation (1000 mg) is administered daily, beginning approximately 2 weeks prior to the first dose of pemetrexed and continues until 3 weeks after treatment discontinuation. A 1000 mg vitamin B12 injection is administered intramuscularly approximately 1-2 weeks before the first dose of pemetrexed and is repeated approximately every 9 weeks until 3 weeks after therapy discontinuation.
45476787|NCT03725137|Other|Analysis of T-lymphocytes|Analysis of T-lymphocytes regarding the development of cognitive function after stroke
45476788|NCT01204385|Procedure|Sample collection|Middle ear fluid and urine
45842143|NCT01093014|Behavioral|Sequential low-force and high-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, followed by: 1) a 1-month washout period, then; 2) electrical stimulation to evoke summated, high-force contractions.
46045307|NCT00656500|Behavioral|Quitline intervention|Brief intervention designed specifically to encourage quitline utilization
46045308|NCT00883558|Drug|Insulin Lispro|
46045309|NCT00883558|Drug|regular human insulin|
46045310|NCT00883558|Drug|recombinant human hyaluronidase PH20|
46045311|NCT00883558|Drug|Insulin glargine|
45351100|NCT03620643|Drug|Crizotinib Oral Capsule [Xalkori]|Crizotinib 250 mg Crizotinib 200mg
45351101|NCT03620643|Drug|Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]|Fulvestrant (Faslodex or generic) is supplied as two 5-mL clear neutral glass (Type 1) barrels, each containing 250mg/5mL of fulvestrant solution for intramuscular injection and fitted with a tamper evident closure.
45351102|NCT04008316|Drug|Colchicine|colchicine 1mg/day
46045312|NCT04162834|Drug|Papaverine|Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.
46045313|NCT04162834|Drug|Normal saline|Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
46045314|NCT00656578|Drug|4975|Single dose, solution
45351103|NCT00893607|Drug|NRL001|10mg NRL001 was administered as a slow release suppository
45351104|NCT00969046|Drug|EPO906 (patupilone)|
45351105|NCT05011708|Device|I-DROP MGD|I-DROP MGD are eye drop produced by I-MED PHARMA for the management of moderate to severe Dry Eye Disease.
45842144|NCT01093794|Drug|Co-administration of 50 mg sitagliptin and 500 mg metformin|Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.
45351106|NCT05011708|Device|Thealoz Duo|I-DROP MGD are eye drop produced by Laboratoires Thea for the management of Dry Eye Disease.
45351107|NCT00893685|Device|Wireless monitors for disease specific clinical parameters.|Homes of participants will be equipped with wireless monitors for blood pressure, blood oxygen, blood glucose, peak expiratory flow, electrocardiogram, body weight. All vital parameters are monitored on a continuous, at least daily basis and obtained values are transmitted to a monitoring centre. Abnormal values are classified for their health risk and health alarms and/or intervention of health professionals is triggered.
45351108|NCT05008354|Drug|Pyridoxine|Pyridoxine tablet 40mg once daily
45351109|NCT05008354|Drug|Placebo|Placebo tablet once daily
45351110|NCT00975754|Drug|Pulmicort pMDI HFA|Inhalation aerosol, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
45351111|NCT00975754|Drug|Budesonide pMDI HFA|Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations
45351112|NCT00975754|Drug|Pulmicort Repulses|Suspension for nebulisation, 0.5 mg/mL. Each subject receive a single dose from 100 inhalations
45351113|NCT00975754|Drug|Pulmicort Turbohaler|Inhaled powder, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
45842145|NCT01093794|Drug|sitagliptin/metformin 50 mg/500 mg tablet|Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
45842146|NCT01093794|Drug|Co-administration of 50 mg sitagliptin and 850 mg metformin|Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.
45842147|NCT01093794|Drug|sitagliptin/metformin 50 mg/850 mg tablet|Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
45842148|NCT01094106|Drug|Ropivacaine 0,75%|Postoperative wound infusion 2 ml/ h/ 48h
45842149|NCT01094106|Drug|NaCl 0,9%|Postoperative wound infusion 2 ml/h/48h
45842150|NCT01094574|Drug|Alfentanil|An infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump.
45351114|NCT01045681|Drug|Bendamustine, Velcade and Dexamethasone|Bendamustine : 70 mg/m2 iv on D1 and 8, for each cycle Velcade : 1.3 mg/m2 iv on D1, 8, 15 and 22, for each cycle Dexamethasone : 20 mg/day po on D1, 8, 15 and 22, given prior to Bendamustine and Velcade
45842151|NCT01094574|Drug|Propranolol|An infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump.
45842152|NCT01094574|Drug|Placebo|An infusion of normal saline was administered over 3 hours using a programmable infusion pump to mimic the 2 drug arms,
45351115|NCT00868647|Procedure|Radiofrequency ablation (RFA)|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
45476789|NCT03727555|Genetic|Intracerebral LV gene therapy|Intracerebral LV gene therapy to deliver high levels lenvirus which carry normal ABCD1 gene at 1-2×10^9 multiplicity of infection/ml per site in multiple sites.
45476790|NCT01567241|Other|clinical hypnosis or relaxation music|25 minute tape recording
45842153|NCT01095510|Biological|CINRYZE|
45842154|NCT01096290|Drug|lubiprostone|24mcg BID, capsule, oral 30days
45842155|NCT01096290|Drug|Matched placebo|Twice daily for 30days, oral
45842156|NCT01096680|Drug|SPD489 20 mg|Single oral dose of 20 mg
45842157|NCT01096680|Drug|SPD489 50 mg|Single oral dose of 50 mg
45842158|NCT01096680|Drug|SPD489 70 mg|Single oral dose of 70 mg
45842159|NCT01096680|Drug|Armodafinil|Single oral dose of 250 mg
45351116|NCT00868725|Other|no intervention, observation only|Oral cavity will be imaged by a thermal camera.
45476791|NCT05223296|Device|Compare between two procedure for II-IV degree pile excision|LigaSure or diathermy excision of III-IV degree pile?
45476792|NCT03920111|Biological|IMOJEV|live attenuated Japanese encephalitis (JE) vaccine IMOJEV®
45476793|NCT00708214|Drug|BIBW 2992|BIBW 2992 at high and medium dosages
45476794|NCT00708214|Drug|BIBW 2992|BIBW 2992 at high and medium dosages
45476795|NCT00708214|Drug|Letrozole|Letrozole at standard dosage
45476796|NCT00708214|Drug|Letrozole|Letrozole at standard dosage
45476797|NCT04906694|Biological|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
45842160|NCT01096680|Drug|Placebo|Single oral dose
46045315|NCT00656578|Drug|Placebo|Single dose, solution
46045316|NCT04159168|Behavioral|Facial Affect Sensitivity Training (FAST)|The FAST intervention program represents a novel computerized intervention for high-risk youth that strategically targets implicated facial affect sensitivity deficits directly via a computerized real-time automated feedback and incentive system to remediate callous-unemotional tendencies associated with behavioral dysfunction.
45842161|NCT01096992|Drug|Bendamustine|"Phase 1: Starting Dose of 20 mg/m2 IV on Days 1,2,3 (after fludarabine)~Phase 2: 30 mg/m2 by vein (fixed) on Days 1,2,3 (after fludarabine)"
46045317|NCT04159168|Behavioral|Implicit Gaze Training task (Active control condition)|"This computerized task was developed to target implicit training of eye gaze but not facial emotion recognition per se via real-time feedback and incentives. On each trial, a fixation cross is followed by an emotional face with eyes directed either left, straight ahead, or right (balanced across expressions), followed by a response key. The child's task is to say which direction the eyes are looking (e.g., 1 or left). Stimuli are black and white standardized photographs of men and women models from the Ekman Pictures of Facial Affect each displaying the 3 gaze directions for 6 emotion expressions."
46045318|NCT00657904|Drug|Bicalutamide|150mg daily
45351117|NCT00975910|Drug|lidocaine|Lidocaine arm: lidocaine (2%) as an intravenous bolus (1.5 mg/kg) during induction followed by an intravenous infusion (2 mg. kg(-1).h(-1)) after induction until at the end of surgery
45351118|NCT00975910|Drug|saline|Saline arm: infused at the same rate as lidocaine
45351119|NCT01048567|Other|Lactobacillus acidophilus/rhamnosus|2 capsules (at least 2 billion cells per capsule) three times daily for duration of antibiotic therapy
45351120|NCT01048567|Other|Placebo|2 capsules three times daily for entire duration of antibiotic therapy.
45351121|NCT00969202|Radiation|Stereotactic Radiosurgery using the Novalis Tx|Five treatments given every other day.
46045319|NCT00657904|Drug|Placebo|once daily
46045320|NCT04161196|Procedure|tonsil pillars suturing|The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.
45351122|NCT01051375|Behavioral|Psychoeducational Workshop and telephone support|The intervention involves completion of a single workshop (delivered by a psychiatrist and adolescent health physician), provision of psycho educational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list.
45842162|NCT01096992|Drug|Fludarabine|Course 1: 20 mg/m2 intravenous (IV) on Days 2,3,4 Courses 2-6: 20 mg/m2 IV, Days 1,2,3
46045321|NCT04161196|Procedure|tonsillectomy without tonsil pillars suturing|tonsillectomy without The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.
45842163|NCT01096992|Drug|Rituximab|Course 1: 375 mg/m2 IV, Day 4 (after fludarabine) Courses 2-6: 500 mg/m2 IV, Day 1
45842164|NCT01097304|Drug|Ursodiol|Given PO
45842165|NCT01097304|Other|Laboratory Biomarker Analysis|Correlative studies
45351123|NCT03617913|Drug|Avelumab|Given IV
45351124|NCT03617913|Drug|Cisplatin|Given IV
45351125|NCT03617913|Drug|Fluorouracil|Given IV
45351126|NCT03617913|Drug|Mitomycin|Given IV
45351127|NCT03617913|Other|Quality-of-Life Assessment|Ancillary studies
45351128|NCT03617913|Radiation|Radiation Therapy|Undergo RT
45351129|NCT05073328|Other|COVID-19 required hospitalisation|Patients who contracted a COVID19 required hospitalisation
45842166|NCT01097460|Drug|MM-111 + Herceptin|For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV
45842167|NCT01098006|Other|Blood withdrawal|A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.
45351130|NCT00975988|Drug|TYKERB® tablets|Patients administrated TYKERB® tablets according to the prescribing information
45351131|NCT03570333|Diagnostic Test|progenitor potential of Gingival Mesenchymal cells|tissues collected from the molar and premolar sites will be sent to the lab for cell culturing. once in the lab, the tissues will be already separated and labeled (molar) and ( premolar) and then treated to extract the cells from them. then, these cells will be tested for their capacity to form different kinds of cells and tissues ( bone, cartilage, fibers for periodontal ligaments). After this test, results will be collected for how many cells were collected from each tissue sample.
45476798|NCT04906694|Drug|Placebo|Diluent solution
45842168|NCT01098318|Dietary Supplement|Herbal extract|340-1,360 mg daily
45842169|NCT01098318|Drug|Sertraline|50-200 mg daily
45842170|NCT01098318|Other|Lactose monohydrate|1-4 capsules daily
46045322|NCT00880750|Drug|Lanthanum carbonate Granule Formulation|3x's per day for 3 days, 1 dose in the am for day 4. (A single dose equals 1000mg of lanthanum carbonate granule formulation. Dose is administered immediately after each meal.)
46045323|NCT00880750|Drug|Lanthanum carbonate Chewable Tablets (Fosrenol)|3x's per day for 3 days, 1 dose on day 4. (A single dose equals a 1000mg tablet of lanthanum carbonate. Dose is administered immediately after each meal.)
46045324|NCT02636374|Behavioral|Guided Imagery|A fifteen minute recording of gentle music together with soft talking to guide relaxation.
46045325|NCT02535676|Device|Transcranial Direct Current Stimulation|The device will produce a direct current of 2 mA from one electrode to the other. In active stimulation, the device will be turned on for 20 min and in sham stimulation the device will be turned in 2 mA for one minute and will be automatically turned off the remaining 19 minutes. The sham or active mode is chosen by a numeric code.
45351132|NCT00976066|Drug|Part A Assessing GSK1521498|"Each participant will receive up to three [11C]carfentanil PET scans and up to two doses of GSK1521498 in total. The doses used will span the expected receptor occupancy range providing these were well tolerated in the first-time in human study.~Each subject will receive baseline [11C]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively), followed by two treatment sessions (Treatment Sessions 1 and 2). Treatment session 1 and 2 are followed by PET scans and an fMRI scan (session 1 only). Sessions will be separated by at least 12 days. PET scans will be timed to coincide with peak brain occupancy. fMRI will begin approximately 30-60 minutes after completion of the PET scan."
45476799|NCT05669495|Device|ANNE Vital Sign System|The ANNE Vital Sign System is a wireless remote monitoring system consisting of two flexible, soft, and skin-mounted electronic devices for use by researchers and healthcare professionals for continuous collection of physiological data in home and professional healthcare settings. The ANNE Vital Sign System integrates simultaneous synchronized ambulatory measurement of electrocardiography, photoplethysmography with derived pulse oximetry, pulse arrival time with derived beat-to-beat blood pressure, triaxial accelerometry, respiratory rate, and temperature, which would enable accurate measurement of sleep apnea. Indeed, in compelling in-laboratory preliminary data, we show the capacity for the ANNE Vital Sign System to detect and characterize sleep apnea in older patients. The ANNE Vital Sign System is non-invasive, flexible, easy to use, comfortable, and skin safe.
45351133|NCT00976066|Drug|Part B Assessing GSK1521498|"The purpose of Part B is to establish the timecourse of receptor occupancy of GSK1521498. Each participant in Part B will receive up to three [11C]carfentanil PET scans and one single oral dose of GSK1521498 expected to provide 50-75% receptor occupancy (selected with reference to data from Part A).~Each Part B subject will receive baseline [11C]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of GSK1521498 followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2)."
45351134|NCT00976066|Drug|Part C Assessing Naltrexone|A range of doses of naltrexone will be tested in up to 12 participants in an adaptive design. Each Part C participant will receive up to three [11C]carfentanil PET scans and a single oral dose of naltrexone. No dose of naltrexone will exceed 50 mg, the dose usually used therapeutically in the treatment of opiate and alcohol dependence. Each Part C subject will receive baseline [11C]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of naltrexone followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2).
45351135|NCT03557619|Drug|Venetoclax|tablet; oral
45351136|NCT03557619|Drug|ethinyl estradiol/levonorgestrel|tablet; oral
45476800|NCT01568216|Drug|AMG 747|Three dose levels once-daily oral administration
45476801|NCT01568216|Drug|Placebo|Once-daily oral administration
45476802|NCT02749955|Behavioral|PS-PrEP Intervention Group|This group will involve working with a PS-PrEP social worker to learn about PrEP. The PS-PrEP social worker will help subjects develop a care plan based on the subject's decision about whether or not to use PrEP. This may include referrals for PrEP, other services, and/or HIV testing. Personal contact will continue by way of phone calls, and messages in between visits.
45685930|NCT04755400|Dietary Supplement|Potassium nitrate|24 mmol of Potassium nitrate is the active comparator substance, that is ingested every morning for 4 days before and on the examination day.
45685931|NCT04755400|Dietary Supplement|Potassium chloride|24 mmol of Potassium nitrate is the placebo substance, that is ingested every morning for 4 days before and on the examination day.
45685932|NCT04777942|Procedure|neo-TACE-HAIC+Surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
45685933|NCT04777942|Procedure|Surgery alone|hepatic resection remove the liver tumors
45685934|NCT00436540|Drug|Clobetasol Propionate 0.05% Spray|Apply to affected areas twice daily
45685935|NCT00436540|Drug|Clobetasol Propionate 0.05% Foam|Apply to affected areas twice daily
45842171|NCT01100112|Drug|Budesonide|One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.
45842172|NCT01100268|Drug|Methylphenidate ER|Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
45842173|NCT01101750|Biological|Quadrivalent HPV for types 6, 11, 16 and 18|"Per standard of care, Gardasil 0.5ml IM injection on day one, month 2, and month 6.~Serum samples on day one, month 3 and month 7."
45842174|NCT01102218|Drug|Erythropoietin|Standard of Care
45842175|NCT01102218|Drug|Erythropoietin|Standard of Care
45842176|NCT01102218|Drug|Pentoxifylline|400 mg qd po for 6 months
46045326|NCT02633878|Drug|Chinese Herbal Medicine plus Progesterone Capsules|"New Shoutai Pill Granules plus Micronized Progesterone Capsules"
46045327|NCT02633878|Drug|Chinese Herbal Medicine Placebo plus Progesterone Capsules Placebo|"New Shoutai Pill Granules Placebo plus Micronized Progesterone Capsules Placebo"
45476803|NCT02749955|Behavioral|PrEPLine Control Group|This group follows routine department of public health care as a Linkage to Care Specialist from the PrEPLine provides subjects with PrEP education and the ability to schedule an initial PrEP appointment. In addition to this care, subjects will be referred for additional testing for STIs/HIV and subjects will be given information about programs available to prevent HIV infection, which include PrEP.
45476804|NCT04894214|Diagnostic Test|Arterial blood gas (ABG)|Arterial blood gasses will be drawn during baseline PCV, and every 15 minutes during FCV and VCV respectively. pO2 (mmHg), pCO2 (mmHg) and pH will be recorded.
45476805|NCT04894214|Other|Recording of hemodynamic monitoring|Hemodynamic parameters (invasive arterial blood pressure (mmHg) and heart rate (beats per minute)) will be recorded every 5 minutes.
45476806|NCT04894214|Other|Recording of respiratory monitoring|Tidal volume (ml), respiratory rate (breaths per minute), minute volume (l/min), dynamic compliance (ml/cmH2O), resistance (cmH2O/l/min), plateau pressure (cmH2O), mean airway pressure (cmH2O), positive end-expiratory pressure (cmH2O), peak inspiratory pressure (cmH2O) and fraction of inspired oxygen will be recorded every 5 minutes.
45476807|NCT02506894|Drug|Magnesium Sulfate|magnesium sulfate will be given for 24 hours
45476808|NCT02506894|Other|0.9% sodium chloride solution|normal saline will be given as intravenous drip over 24 hours
45476809|NCT03909737|Drug|Azithromycin to pregnant women|Azithromycin to pregnant women at antenatal care visits and during delivery
45476810|NCT03909737|Drug|Azithromycin to infants|Azithromycin to infants at 6 and 14 week EPI visits
45476811|NCT03909737|Other|Placebo to pregnant women|Placebo to pregnant women at antenatal care visits and during delivery
45476812|NCT03909737|Other|Placebo to infants|Placebo to infants at 6 and 14 week EPI visits
45476813|NCT03909737|Other|No intervention to pregnant women|No intervention to pregnant women
45476814|NCT04891250|Drug|Ivermectin|Treatment of SARS Cov-2 patients with Ivermectin
45476815|NCT04891250|Other|Prophylaxis|Treatment of high risk population with Ivermectin as prophylaxis
45351137|NCT00976144|Drug|GSK573719|GSK573719 is a long-acting, inhaled, muscarinic receptor antagonist or anticholinergic bronchodilator. GW642444 is a potent and selective long-acting beta-2 agonist. Both are in development for once daily monotherapies for the treatment of COPD. In this study, their effects are investigated following individual and concurrent administration.
45476816|NCT03570697|Drug|Evolocumab|Participants will receive evolocumab (AMG 145) subcutaneous monthly.
45476817|NCT03570697|Drug|Placebo|Participants will receive matching placebo subcutaneous monthly.
45476818|NCT03570697|Drug|Statin therapy|"high-intensity statin treatment with atorvastatin ≥ 40 mg daily or equivalent as background therapy~Investigators will up-titrate statin therapy to the maximally tolerated dose, in accordance with local guidelines, prior to randomization."
45476819|NCT03878381|Combination Product|Skin Care Cream|The skin care regimen we will be testing includes ingredients such Hyaluronic acid 1%, Vitamin E Acetate, Vitamin A Acetate, Co-enzyme Q 10, L-Arginine, L-glutamine, Phytonadione, Argireline Peptide solution, GABA, Vitamin C, glycolic acid, and Fenugreek.
46045328|NCT02633878|Drug|Chinese Herbal Medicine plus Progesterone Capsules Placebo|"New Shoutai Pill Granules plus Micronized Progesterone Capsules Placebo"
45476820|NCT03878381|Drug|Placebo|The placebo will be a formula with no active ingredients
45842177|NCT01102764|Behavioral|Telemedicine|Prolonged Exposure (PE) therapy provided at patients house via telemedicine
45842178|NCT01102764|Behavioral|In Person|PE therapy delivered in person at the VAMC
45842179|NCT01103934|Drug|Vitamin D3|4000 IU once daily
45351138|NCT04008472|Other|Telemedecine|Initiation of tele-medical consultation with the resident, a caregiver for the nursing home, the referring physician and geriatrician téléexpert. After a overall geriatric assessment in nursing homes by UPSAV the first teleconsultation is organized within 10 days. Subsequent visits are scheduled every 3 months for 12 months. Spontaneous visits can be requested at the initiative of the referring physician.
45351139|NCT00969592|Drug|insulin glulisine, insulin aspart|single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during second euglycemic glucose clamp
45476821|NCT02511574|Drug|natural progesterone|
45476822|NCT02511574|Device|cervical pessary|
45842180|NCT01103934|Drug|Placebo|Placebo taken once daily
45842181|NCT01103934|Drug|Fluticasone Propionate|200 mcg daily, intranasal
45842182|NCT01104090|Device|C-MAC direct laryngoscopy|Patients will be intubated using C-MAC with direct laryngoscopy.
46045329|NCT02633878|Drug|Chinese Herbal Medicine Placebo plus Micronized Progesterone|"New Shoutai Pill Granules Placebo plus Micronized Progesterone Capsules"
45685936|NCT00425230|Drug|Duloxetine|
45685937|NCT00410956|Biological|bevacizumab|
45685938|NCT00410956|Drug|dexamethasone|
45685939|NCT00410956|Drug|floxuridine|
45685940|NCT00410956|Genetic|protein expression analysis|
45685941|NCT00410956|Other|flow cytometry|
46045330|NCT02877797|Device|Cap|cap assisted esophagogastroduodenoscopy
46045331|NCT00597766|Drug|Lidocaine|One-time Screening/Eligibility Neer's Test: 5 cc of 2% lidocaine
46045332|NCT00597766|Drug|Triamcinolone + Lidocaine|Low Dose -- One-time injection of 20 mg triamcinolone: 1.5 cc of normal saline, 0.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
46045333|NCT00597766|Drug|Triamcinolone + Lidocaine|Standard Dose -- One-time injection of 40 mg triamcinolone: 1 cc of normal saline, 1 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
45476823|NCT02506504|Device|Inspiratory help then sham ventilation|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
45476824|NCT02506504|Device|Sham ventilation then Inspiratory help|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
45842183|NCT01104090|Device|C-MAC Indirect laryngoscopy|Patients will be intubated using C-MAC with indirect laryngoscopy.
45842184|NCT01104402|Device|Home lung function and symptom monitoring|subjects in the intervention arm will measure spirometry and CF symptoms with the use of a handheld device.
45842185|NCT01105650|Drug|Fludarabine|Administered intravenously, 25 mg/m^2, days -6 through -2 (5 days).
45351140|NCT00969592|Drug|insulin aspart, insulin glulisine|single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during second euglycemic glucose clamp
46045334|NCT00597766|Drug|Triamcinolone + Lidocaine|High Dose -- One-time injection of 60 mg triamcinolone: 0.5 cc of normal saline, 1.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
46045335|NCT02877563|Other|Contrast ultrasound perfusion imaging of the limb|Contrast enhanced ultrasound imaging at rest and during contractile exercise will be performed prior to revascularization and 3-4 weeks after revascularization.
46045336|NCT04159090|Diagnostic Test|F18-PSMA|Patients with moderate or high risk of prostate cancer
45351141|NCT00368641|Drug|Extraneal|Periotneal Dialysis
45351142|NCT00976222|Drug|intravitreal injection with ranibizumab|0.5 mg in 0.05 ml, monthly, 12 months
45351143|NCT00979888|Other|educational intervention|
45351144|NCT00979888|Other|informational intervention|
45351145|NCT00979888|Other|psychosocial support for caregiver|
45351146|NCT00979888|Other|questionnaire administration|
45351147|NCT00979888|Procedure|dyspnea management|
45351148|NCT00979888|Procedure|management of therapy complications|
45351149|NCT00976300|Drug|Cyclosporine A|Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months. The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
45351150|NCT00976300|Drug|Cyclophosphamide|Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals). The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
45476825|NCT01200641|Drug|Melatonin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
45476826|NCT01200641|Drug|Gabapentin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
45842186|NCT01105650|Drug|Cyclophosphamide|Administered intravenously, 60 mg/kg, days -5 and -4.
45842187|NCT01105650|Drug|Cyclosporine|Administered intravenously, CsA 1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14
45842188|NCT01105650|Biological|Natural killer cells|Administered by infusion over less than 1 hour, no more than 8.0 x 10^7 cells/kg will be given.
45842189|NCT01105650|Drug|IL-2|Will be given subcutaneously at 9 million units 3 times a week for a total of 6 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 5 million units/m^2 3 times per week for 6 doses).
45842190|NCT01105650|Drug|Methylprednisolone|Administered intravenously (IV) 10 mg/kg Days -2 to +4 and 1 mg/kg Days +5 to +9
45842191|NCT01105650|Drug|Methylprednisolone|Administered intravenously (IV) 1 mg/kg Days -2 to +9
45685942|NCT00410956|Other|immunoenzyme technique|
46045337|NCT04161274|Procedure|Traditional method: Electrosurgery|"The patient will be prepared before this technique by removing all metal objects in his possession. The area should be disinfected with a local antiseptic, leaving the area aseptic. Afterwards, perilesional infiltrated local anaesthesia (subcutaneous or intradermal) will be applied. Once the area has been anaesthetised, excision is made with scissors cutting through the most proximal part of the skin tag pendulum and the lesion is coagulated with the handle or knife of the electrocoagulator (previously regulated with the intensity in coagulation mode). The resulting abrasion will form an eschar that will be disinfected with povidone-iodine, and a protective dressing of sterile occlusive gauze bandage will be placed.~Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or sunlight."
46045338|NCT04161274|Procedure|Traditional method: Cryotherapy|The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. for a few minutes the tip of an Adson forceps will be introduced in a container with liquid nitrogen until freezing. It will then be applied to the most proximal part of the skin tag pendulum until it is observed that the frostbite has reached the base of the lesion and the surface becomes whitish, with a halo of 1-3 mm. When this happens, it will be excise above the frost part in the pendulum. After application, it is disinfected with povidone- iodine and covered with a protective dressing of sterile occlusive gauze plaster. It will then form an eschar. Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or sunlight.
46045339|NCT04161274|Procedure|Traditional method: Silver nitrate|"The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. Excision will be made with scissors of the skin tag cutting through the most proximal part of the skin tag pendulum, then cauterized with the tip of the silver nitrate rod, trying not to apply in the perilesional zone.~The resulting abrasion will form an eschar that will be disinfected with povidone-iodine, and a protective dressing of sterile occlusive gauze bandage will be placed.~Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or solar rays."
45351151|NCT00976378|Drug|NOX-A12|single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg
45351152|NCT00976378|Drug|NOX-A12|single IV dose, at efficacious dose level
45351153|NCT00976534|Drug|AZD1386|90 mg, capsules, oral, during 3 weeks
45351154|NCT00976534|Drug|Placebo|capsules, oral, during 3 weeks
45685943|NCT00410956|Other|immunohistochemistry staining method|
45685944|NCT00410956|Other|immunologic technique|
45685945|NCT00410956|Other|laboratory biomarker analysis|
45351155|NCT00979966|Drug|Temsirolimus|25 mg intravenously, once weekly infusion
45351156|NCT00979966|Drug|Sunitinib|50 mg oral once daily for 4 weeks, followed by 2 weeks rest.
46045340|NCT04161274|Procedure|Moist healing environment method|The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. Excision will be made with scissors of the skin tag by cutting through the most proximal part of the pendulum of the skin tag, later it will be disinfected with chlorhexidine and thin hydrocolloid dressing will be placed. Indications to the patient: the project participant will be told not to touch the dressing until the next control after 3 days with the research team. In case of incidents with the dressing (fall of the dressing), the patient will be given a replacement dressing for this purpose and be able to restore it immediately. It is recommended not to expose the area to the solar rays
45351157|NCT00969826|Drug|GCPGC, Neulasta, Placebo|A single subcutaneous administration of GCPGC 30 μg/kg, GCPGC 100 μg/kg, GCPGC 300 μg/kg, placebo or Neulasta 100 μg/kg
45476827|NCT01200641|Drug|placebo|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
45476828|NCT03731143|Procedure|insertion of self retaining bicanalicular stent|"The pigtail probe was passed through the canalicular system from the normal punctum to the occluded aspect. When the tip of the pigtail probe was positioned near the occluded punctal area, the surgeon pushed the area to be tented with the pigtail probe. After they advanced the pigtail probe back and forth several times until they could locate the correct position of the occluded punctum, the authors incised the tented area with a scalpel No. 11 to make a new punctal opening.~To ensure punctal and canalicular patency, syringing was repeated through the perforated punctum. To prevent re-occlusion of punctal opening, a self retaining bicanalicular tube (FCI®; Paris, France) was inserted through the normal and perforated puncti"
45476829|NCT01856270|Drug|Amitriptyline|Participants with headache will be enrolled within the first 12 weeks after injury and will be randomly assigned to 2 groups (see Table 1 for summary of protocol). Group 1 will be assessed within 3 months of injury (baseline, Day 0) (when they will receive their initial ramp-up dosage containers; see Table 2 for dosing), Day 30 and Day 60 (to monitor compliance and distribute study drug), and for final outcome on Day 90. Group 2 will be assessed within 3 months of injury (baseline, Day 0) but will not receive medication until their Day 30 visit. Those in group 2 who report headache at Day 30 will receive their initial dosage container and will then be reassessed at Day 60 (to monitor compliance and distribute study drug) and Day 90 (final outcome).
45351158|NCT04007926|Behavioral|Aerobic exercise programme|Participants will start with 3 x 20 minute exercise sessions in the first week, building up to 5 x 60 minutes of exercise by weeks 9-12 of the intervention, at an intensity of 65-80% of predicted maximum heart rate.
45351159|NCT04007926|Behavioral|Resistance exercise programme|Participants will undertake two supervised sessions per week. The exercises performed during each session will consist of leg press, calf press, leg extension, leg curl, chest press, shoulder press, lateral pull down and seated row. Exercises will be performed at 60-80% 1RM. In weeks 1-2 participants will perform, during each session, a single set of 5-10 repetitions of each exercise (tiring but comfortably achievable) to ensure they are comfortable with the exercises and are performing these in the correct form. In weeks 3-4 participants will perform, during each session, two sets of each exercise to voluntary muscular failure - defined as not being able to perform single another repetition. In weeks 5-12 this will progress to 3 sets of each exercise to voluntary muscular failure, in each session.
45351160|NCT00969904|Drug|N-acetylcysteine|600 mg TID for 12 weeks
45351161|NCT00969904|Drug|placebo|placebo tablet TID for 12 weeks
45476830|NCT02506270|Device|Airseal Trocar|28 patients are treated with the AirSeal insufflation and trocar system
45351162|NCT00976612|Drug|Nilotinib|Nilotinib 400mg bid daily
45476831|NCT02506270|Device|conventional trocar|28 patients are treated with a conventional insufflation and trocar system
45476832|NCT03727321|Combination Product|Fecal Microbial Transplant|Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.
46045341|NCT00657982|Drug|RAD001|10mg BID
45351163|NCT00976690|Drug|Azathioprine OR Mesalazine|Azathioprine : 2mg/kg/day Mesalazine : 4g/day
45351164|NCT00976768|Drug|oxaliplatin, 5-fluorouracil|Oxaliplatin 85 mg/㎡ IV, day 1 over 2 hours 5-FU 400 mg/㎡ IV bolus day 1 followed by 5-fluorouracil(FU) 2,400 mg/㎡ and leucovorin (LV) 100 mg/㎡ IV continuous over 46 hours (every 2 weeks)
45351165|NCT00608985|Drug|almorexant|2 100 mg almorexant tablets and 1 placebo matching over-encapsulated zolpidem
45351166|NCT00608985|Drug|almorexant|1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem
45351167|NCT00608985|Drug|Placebo|2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem
45351168|NCT00608985|Drug|zolpidem|2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated
45842192|NCT01105650|Drug|Interleukin-2|Will be given subcutaneously at million units 3 times a week for a total of 3 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 3 million units/m^2 3 times per week for 6 doses).
45842193|NCT01106040|Drug|Lymphoseek|The total volume of Lymphoseek injection will be between 0.1 - 1.0 mL.
45842194|NCT01110252|Drug|Stem cells stimulation|Subcutaneous injection of 5mcg/kg of G-CSF 3 days before the procedure.
45842195|NCT01110252|Procedure|stem cells collection|pullout of 200ml of bone marrow through the puncture of the iliac crest
45685946|NCT00410956|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
45842196|NCT01110252|Genetic|stem cells infusion|slow infusion through the brachial vein of 30ml of bone marrow mononuclear cells diluted in albuminous saline.
45685947|NCT04778098|Other|Received SMS reminder|telenursing
45685948|NCT04777786|Other|Physical Therapy|Individualized physical therapy treatments will be provided based on impairments identified during assessments. Treatment may include but is not limited to the following: passive, assisted and active ROM, manual therapy, soft tissue massage, myofascial release, therapeutic activities and exercise and patient education. Treatment duration and frequency will be specific to each patient, providing personalized care. This type of intervention is considered a pragmatic approach, which will allow for generalization of the results due to the similarity with clinical practice.71 Pilot data indicates women will receive physical therapy intervention 1-2x/week for 3-6 weeks beginning ~4 weeks after surgery (x̄=10 visits).
45685949|NCT03800524|Drug|Tauroursodeoxycholic Acid|"Tauroursodeoxycholic acid (TUDCA) 250 mg capsules~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~Mode of administration: orally~Duration: 18 months"
45685950|NCT03800524|Drug|Placebo|"Placebo 250 mg capsules~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~Mode of administration: orally~Duration: 18 months"
45685951|NCT03793738|Procedure|Anterior component separation|
45685952|NCT03793738|Procedure|Posterior component separation|
45685953|NCT03783052|Device|SmartPill in fasted state|SmartPill administration in fasted state
45842197|NCT01110876|Drug|Vorinostat|"Phase I Starting Dose: 200 mg twice daily by mouth on Days 1-7, 15-21 of each 28 day cycle.~Phase II Dose: MTD from Phase I."
45351169|NCT00969982|Drug|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
45351170|NCT00969982|Drug|misoprostol+placebo|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
45842198|NCT01110876|Drug|Erlotinib|"Phase I Starting Dose: 200 mg by mouth daily on Days 1-21 of 28 day cycle. For patients on enzyme inducing anticonvulsants (EIACs), starting dose of 400 mg.~Phase II Dose: MTD from Phase I."
45351171|NCT00976846|Device|Dialyzer Baxter Xenium XPH 210|High-Flux dialyzer
45842199|NCT01110876|Drug|Temozolomide|125 mg/m2 by mouth daily on days 1-7, 15-21 of each 28 day cycle.
45351172|NCT00976924|Device|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
45842200|NCT01112358|Drug|r-FSH|r-FSH will be administered as specified in the arm description.
45842201|NCT01112358|Drug|r-hLH|r-hLH will be administered as specified in the arm description.
45476833|NCT03727321|Dietary Supplement|Fiber|A combination of soluble corn fiber (PROMITOR®: Tate&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), and Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS) for a total of 6 weeks (men 33g/day; women 27g/day)
45476834|NCT03727321|Dietary Supplement|Cellulose|Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
45685954|NCT03783052|Device|SmartPill in fed state|SmartPill administration in fed state
45685955|NCT03783052|Other|Aspiration|Aspiration of gastrointestinal samples in fasted and fed state
45842202|NCT01112358|Drug|Analogous GnRH antagonist|Analogous GnRH antagonist will be administered as specified in the arm description.
45842203|NCT01112358|Drug|r-hCG|r-hCG will be administered as specified in the arm description.
45842204|NCT01112358|Drug|Progesterone|Progesterone will be administered as specified in the arm description.
45842205|NCT01112670|Drug|Sitagliptin|sitagliptin 100 mg x 1 dose
45842206|NCT01112670|Drug|atorvastatin|atorvastatin 40 mg x 5 doses
45351173|NCT00970060|Behavioral|Exercise|Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
45351174|NCT02540967|Drug|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|Gadovist dosage following summary of product characteristics
45685956|NCT03783052|Other|Gastric emptying scintigraphy|Gastric emptying scintigraphy in fed state
45685957|NCT04634578|Drug|Bevacizumab|"All participants will receive a single intravitreal injection of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.~Eyes meeting eligibility criteria will receive a single dose of 0.063 mg or 0.25mg bevacizumab provided by the pharmacy at the investigator's institution."
45842207|NCT01114620|Biological|Arepanrix™|Intramuscular administration, one dose
45842208|NCT01115556|Drug|Ranibizumab|2.0 mg
45842209|NCT01115556|Drug|Ranibizumab|0.5 mg
45842210|NCT01116024|Device|ATS 3f Enable Aortic Bioprosthesis Model 6000|Replacement Aortic Heart Valve
45842211|NCT01116102|Drug|Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution|Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution
45847615|NCT04741620|Other|Piperine 150microM (TRPV1 & TRPA1 natural agonist)|10 mL Piperine 150microM solution 3 times per day (before each meal) during 14 consecutive days.
45476835|NCT02511340|Drug|Flumatinib mesylate tablet 600 mg qd|Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients
45476836|NCT04543253|Other|MUSE biofeedback|biofeedback through a headband
45842212|NCT01118988|Behavioral|Mentorship|Subjects in this condition receive 10 sessions over 8 weeks (2 sessions for the first 2 weeks, 1 session per week for the remaining 6 weeks) with a mentor presenting information on pain self-management and coping techniques, as well as discussing concerns and feelings with the subject receiving the intervention. Information is presented on slides via internet connected home computer. Mentor-mentee interaction is conducted via telephone on a conference call line with a doctoral level psychologist monitoring call for safety of all parties.
45351175|NCT00970138|Drug|apatinib tablet|"A850: apatinib 850 mg qd p.o. plus placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~B425: apatinib 425 mg bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~Cpla: placebo bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent"
45842213|NCT01119222|Drug|Gabapentin|Capsule, single 1200mg dose
45842214|NCT01119222|Drug|Diphenhydramine|Tablet, single 50mg dose
45842215|NCT01119222|Drug|Morphine|IV, single 10mg dose
45842216|NCT01119222|Drug|Placebo|Placebo formulations (Capsule, tablet, IV to match the active treatments and to be administered in a double-dummy fashion).
45842217|NCT01119456|Biological|IMC-RON8|"5 milligrams per kilogram (mg/kg) intravenously (IV)~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 1"
45842218|NCT01119456|Biological|IMC-RON8|"10 mg/kg IV~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 2"
45842219|NCT01119456|Biological|IMC-RON8|"15 mg/kg IV~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 3"
45842220|NCT01119456|Biological|IMC-RON8|"15 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 4"
45842221|NCT01119456|Biological|IMC-RON8|"20 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 5"
45842222|NCT01119456|Biological|IMC-RON8|"25 or 30 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 6"
45842223|NCT01119456|Biological|IMC-RON8|"30, 35, or 40 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 7"
45842224|NCT01119456|Biological|IMC-RON8|"20 or 25 mg/kg IV~Once every week for each 4-week treatment cycle, for a total of four doses per cycle.~Cohort 8"
45842225|NCT01120236|Drug|Bicalutamide|Given PO
45842226|NCT01120236|Biological|Cixutumumab|Given IV
45842227|NCT01120236|Drug|Goserelin Acetate|Given SC
46045342|NCT04159246|Device|Optical coherence tomography angiography|"Recent Optical coherence tomography angiography OCT-A will be performed to all patients before Treatment Administration.~Examination will be performed using Optovue AngioVue® Optovue, Inc., Fremont, CA, which uses split-spectrum amplitude-decorrelation angiography algorithm, which minimizes motion noise. This system also allows quantitative analysis, since it provides numerical data about flow area and flow density maps.~The patient will be examined before and after finishing the treatment course"
46045343|NCT04159246|Drug|Sofosbuvir (Sovaldi)|Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C , here it's used with Daclatasvir for 3 months
45351176|NCT00892125|Drug|paliperidone ER; Carbamazepine|
45476837|NCT02506348|Drug|Diclofenac|
45476838|NCT02506348|Drug|Nepafenac|
45476839|NCT05223140|Behavioral|Birth within 7 minutes of rumping|Birth within 7 minutes of rumping (+3 station), within 5 minutes of birth of pelvis, within 3 minutes of birth of umbilicus
45476840|NCT05223140|Behavioral|Premature cord clamping|Umbilical cord clamping <1 minute following birth
45476841|NCT02511262|Device|illumigene® Mycoplasma Direct, illumipro-10|DNA amplification assay
45476842|NCT03569371|Drug|INCB054707|INCB054707 administered once daily orally with water without regard to food for 8 weeks.
45476843|NCT02506426|Procedure|Endoscopic sinus surgery + Septoplasty|Opening of the paranasal sinuses along with correcting the nasal septum
45476844|NCT02506426|Procedure|Septoplasty alone|Straightening of the nasal septum without opening the paranasal sinuses
45842228|NCT01120236|Other|Laboratory Biomarker Analysis|Correlative studies
45842229|NCT01120236|Drug|Leuprolide Acetate|Given IM
45842230|NCT01120236|Other|Pharmacological Study|Correlative studies
45847616|NCT04741620|Other|Cinnamaldehyde 756,6microM + zinc 70microM (TRPA1 natural agonist)|10 mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times per day (before each meal) during 14 consecutive days.
45847617|NCT04741620|Other|Citric acid 457,5microM (pH=3,5) (ASIC3 natural agonist)|10 mL Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
45847618|NCT04741620|Other|Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) (TRPV1 & ASIC3 natural agonists)|10 mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
46045344|NCT02636140|Other|Light|A brief, 1 minute exposure to light of varying color and intensity. The combination of color and intensity will be the same in all participants, but the order in which they are received is randomized.
45847619|NCT04741620|Other|Placebo (Methyl benzoate, Propyl benzoate, Propylenglycol)|10 mL placebo solution 3 times per day (before each meal) during 14 consecutive days.
46045345|NCT02633722|Behavioral|Lifestyle intervention B|Time limiting feeding from 8-5pm (TRFb)
46045346|NCT02633722|Behavioral|Lifestyle Intervention D|Time limiting feeding (12-9pm)
46045347|NCT02633566|Device|Plantar orthoses|
46045348|NCT02633410|Procedure|Femoral tunnel creation|Arthroscopic surgery approach used to create tunnel in femur into which graft is positioned
45476845|NCT03841019|Device|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of MST in four weeks (three sessions per week)
45476846|NCT03841019|Device|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of ECT in four weeks (three sessions per week)
45847620|NCT03034902|Device|Combined EEG and fNIRS|The EEG+NIRS recordings will be obtained via an extended EEG cap that is applied to the subject's head. Changes in neuronal activity and hemodynamics will be measured. The EEG component is the microEEG by BioSignal Group, UA. The fNIRS component is the NIRScout 24x32, NIRx Medizintechnik GmbH, Germany
45351177|NCT00977002|Other|Positive Pressure Noninvasive ventilation|Patients randomized to this group are submitted to positive pressure noninvasive ventilation for 12 hours or more. Children younger than one year use nasal prong and older than one year use nasal or facial mask. A blood gas is collected in the moment of intubation and one hour after.
45351178|NCT00977002|Other|Inhalatory O2|Patients randomized to this group are submitted to inhalatory O2 using mask or nasal catheter. A blood gas is collected in the moment of intubation and one hour after.
45351179|NCT00869037|Drug|Periarticular Injection|A 20 ml bolus of saline will be given through the sham femoral nerve block catheter. Periarticular infiltration solution containing 400 mg Ropivicaine, 30 mg Ketorolac, 5 mg Epidural Grade Morphine, and 0.6 ml of 1:1000 Epinephrine will be made up to a volume of 100 ml with saline. Intra-op, 20 ml will be injected into the posterior capsule; 40 ml in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 40 ml in the skin and subcutaneous tissues. The sham catheter will be connected to a saline infusion running at 15 ml/hr until the morning of post-operative day 2.
45476847|NCT02515396|Drug|MMI-0100|
45351180|NCT00869037|Drug|CFNB + Posterior Capsular Injection|A 20 ml bolus of 0.2% Ropivacaine will be given via a femoral nerve catheter. Periarticular infiltration will be performed intra-op. 20 ml of 1% Ropivacaine in the posterior capsule; 20 ml of normal saline in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 20 ml of normal saline for the skin and subcutaneous tissues. Postoperatively, the femoral catheter will be infused with 0.15% Ropivacaine running at 15 ml/hour until the morning of post-operative day 2
45476848|NCT02515396|Drug|Placebo|
45351181|NCT00980356|Drug|Vildagliptin|Patients receive once daily 50 mg Vildagliptin
45351182|NCT00869115|Drug|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
45351183|NCT00869115|Drug|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
45351184|NCT00869115|Drug|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
45351185|NCT00869115|Drug|Istaroxime|Placebo continuous i.v. infusion for 24 hours
45351186|NCT00368251|Other|Placebo|"Pharmaceutical Form: Tablet~Concentration: 2.5 mg, 25 mg and 50 mg~Route of Administration: Oral use"
45351187|NCT00368251|Drug|BRV 2.5 mg|"Pharmaceutical Form: Tablet~Concentration: 2.5 mg~Route of Administration: Oral use"
45351188|NCT00368251|Drug|BRV 25 mg|"Pharmaceutical Form: Tablet~Concentration: 25 mg~Route of Administration: Oral use"
45476849|NCT03731065|Dietary Supplement|Fructose-maltodextrin|Fructose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
45476850|NCT03731065|Dietary Supplement|Fructose-maltodextrin hydrogel|Fructose plus maltodextrin in a ratio of 1:1.4, encapsulated in an alginate-pectin hydrogel diluted in water to produce a 16% carbohydrate solution.
45476851|NCT03731065|Dietary Supplement|Glucose-maltodextrin|Glucose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
45476852|NCT01200719|Device|transcranial alternating current stimulation (tACS)|Patients in the tACS group received a total of 15 sessions of brain stimulation. The sessions were conducted on weekdays (from Monday to Friday) for three consecutive weeks. Each session lasted 30 minutes. The alternating current stimulations were generated by a CVFT-MG201 machine. Stimulations were delivered by two U-shaped electrodes (approximately 7 cm2) fixed on the patient's left and right mastoid regions (anode or cathode varied depending on polarity of the alternating current). The frequencies (supra-slow waves: < 1 Hz; theta to gamma), levels of intensities (0 to 3mA), and density function (follows a bell-shaped curve; mean intensity ~ 2.1mA) of the current were delivered according to the manufacturer's pre-set random protocol.
45476853|NCT01318070|Drug|Alogliptin and pioglitazone|Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
45476854|NCT01318070|Drug|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
45476855|NCT01318070|Drug|Pioglitazone|Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
45476856|NCT03345316|Drug|FFI-1010|Intravenous single dosing
45476857|NCT01202513|Drug|Bimatoprost 0.03% topical ophthalmic solution|
45476858|NCT03345238|Procedure|Deep Dry Needling|Deep Dry Needling in the upper trapezious muscle is an invasive technique of Physical Therapy.
45476859|NCT03730909|Drug|Sodium Lactate|IV infusion
45476860|NCT03730909|Drug|Sodium chloride|IV infusion
45476861|NCT04497688|Drug|PEG-rhG-CSF|Patients received a single dose of PEG-rhG-CSF per cycle. The chemotherapy regimen must meet the interval between two chemotherapy sessions at least 12 days.
45476862|NCT03835715|Drug|Vortioxetine|Flexible doses (10-20 mg) of vortioxetine; 10 mg during the first week which may be increased up to 20 mg week 2-8
45476863|NCT03727165|Other|Continuous enteral nutrition infusion|Enteral nutrition administration in continuous infusion during 24 hours per day
45476864|NCT03727165|Other|Cyclic enteral nutrition infusion|Enteral nutrition administration in continuous infusion during 16 hours per day
45476865|NCT02510716|Behavioral|SGR|
45476866|NCT02510716|Behavioral|Support message only|
46045349|NCT02633254|Device|Magnetic Resonance guided High Intensity Focused Ultrasound|Targeted vessel ablation of type 3 uterine fibroids with magnetic resonance guided high intensity focused ultrasound
46045350|NCT04160962|Procedure|lappg|Laparoscopic gastrectomy for pylorus preservation
46045351|NCT03960996|Procedure|dacryocystorinostomy|Dacryocystorinostomy is a surgical procedure indicated in patients with lacrimal duct obstruction.
46045352|NCT04290156|Other|joint visits|The intervention is the implementation of joint transition visits with the participation of both the pediatric and the adult gastroenterologist. One-year intervention period was chosen. In total, there are four joint visits every third months for the adolescents aged 17-18. Each joint visit lasts for at least for 20 minutes, although in case of complex medical history, there is no restriction with respect to the length of the visit. Joint transition visits 1, 2 and 3 (V1-3) are led by the pediatric gastroenterologist, and visit 4 (V4) is led by the adult gastroenterologist.
45351189|NCT00368251|Drug|BRV 50 mg|"Pharmaceutical Form: Tablet~Concentration: 50 mg~Route of Administration: Oral use"
45351190|NCT00893841|Drug|quetiapine (Seroquel) XR|tablets and caplets, take with liquid before bedtime
45351191|NCT00893841|Drug|quetiapine (Seroquel) XR|tablets, take with liquid before bedtime
45351192|NCT00893841|Drug|placebo|placebo
45351193|NCT00893841|Drug|pramipexole dihydrochloride|tablets and caplets, take with liquid before bedtime
45351194|NCT02541123|Other|Blood draw|Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7. Control group only undergoes 2 blood draws 4 hours apart on Day 1.
45351195|NCT00980512|Behavioral|Parent Training|16 weeks of parent training led by trained group facilitator
45351196|NCT02534077|Drug|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
45351197|NCT02534077|Drug|Omegaven|Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 2 years.
45351198|NCT02534077|Drug|Omegaven|If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
45476867|NCT03727087|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
45476868|NCT04877366|Dietary Supplement|Dietary Supplement: Sprinkled Format REDUCOSE.|2 G powder sprinkle containing 250 mg REDUCOSE (mulberry leaf extract - 250 mg - 5% DNJ) + fiber, vitamin D, and chromium picolinate
45476869|NCT04877366|Other|Reference control|A placebo matching to the test product will be used as control
45685958|NCT04778254|Other|PEEK attachment retained obturator|attachment retained obturator for management of hemi maxillectomy
45351199|NCT00977158|Procedure|Throat Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the throat and processed for bacterial cultures and for bacterial DNA extraction.
45351200|NCT00977236|Device|Orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error and over-specs for a period of two years
45351201|NCT00977236|Device|Single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
45351202|NCT00378079|Other|Counseling Only|Counseling only in prison, with passive referral to drug abuse treatment upon release
45351203|NCT00378079|Drug|Counseling + Transfer|Counseling only in prison, with opportunity to enter methadone maintenance upon release
45351204|NCT00378079|Drug|Counseling + Methadone|Counseling and methadone maintenance in prison, with opportunity to continue that treatment upon release
45351205|NCT00970450|Drug|Paracetamol|Paracetamol 1 g i.v. once
45351206|NCT00970450|Drug|Tropisetron|Tropisetron 5 mg i.v. once
45351207|NCT00970450|Drug|Placebo|Saline
45351208|NCT00970528|Drug|Acarbose (Glucobay, BAYG5421)|uptitrated 100mg three times a day with insulin glargine alone or in combination with metformin
45685959|NCT04778254|Other|metalic attachment retained obturator|attachment retained obturator for management of hemi maxillectomy
45685960|NCT04778254|Other|conventional obturator|clasp retained obturator for management of hemi maxillectomy
45351209|NCT00970528|Drug|Voglibose (Basen)|uptitrated 0.3mg three times a day with insulin glargine alone or in combination with metformin
45351210|NCT00977392|Behavioral|compliance monitoring|
45351211|NCT00977392|Other|cervical Papanicolaou test|
45351212|NCT00977392|Other|educational intervention|
45476870|NCT04877366|Other|Active comparator|Acarbose 100 mg tablet (provided in open-label format)
45476871|NCT01202669|Other|No intervention planned, observational study only.|No intervention planned, observational study only.
45685961|NCT01066858|Drug|Tenofovir disoproxil fumarate (TDF)|Some participants will receive varying doses of TDF during pregnancy or breastfeeding as part of the larger study (IMPAACT 1077 PROMISE).
45685962|NCT04777552|Other|diazepam (or equivalence if other benzodiazepine)|
45685963|NCT04777318|Other|Conventional physiotherapy|A total of 12 sessions of conventional physiotherapy program for 4 weeks will be applied 3 days a week. The conventional physiotherapy program will include 20 min hotpack , 10 min ultrasound, 20 min conventional (Transcutaneous electrical nerve stimulation) TENS application.
45847621|NCT02952846|Other|Algorithm for tapering og analgosedation|Algorithm for tapering og analgosedation
45476872|NCT02505802|Drug|BoNT-A injection|In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu).
45351213|NCT00977392|Other|screening questionnaire administration|
45351214|NCT00977392|Other|survey administration|
45351215|NCT00977392|Procedure|colposcopy|
45351216|NCT03936244|Device|Transurethral Resection of the Prostate (TURP)|Randomized allocation to M-TURP or PK-TURP
45351217|NCT04009486|Device|Whole Body Vibration|"Subjects will undergo whole body vibration (standing on a power plate device 3 times a week, for 30 minute sessions, for 6 weeks)"
45351218|NCT05279404|Other|electroacupuncture|Electroacupuncture at Neiguan and Jianshi acupoint
45351219|NCT05191576|Other|Children's sleep habits questionnaire (CSHQ)|"Children's Sleep Habits Questionnaire is a validated tool to screen sleep behavior in young children's assessment of pediatric sleep problems.~DSM-V Level II Sleep Disturbance- Child Report. is retrospective, 8-item self-report used to assess the pure domain of sleep disturbances in children and adolescents age of 11-17 years in the past seven days.Higher scores indicate more severe sleep disorders. High scores on a particular domain might indicate significant and problematic areas for the child that may warrant further assessment.~DSM -V Sleep Disturbance -Adult Report. is used to assess the pure domain of sleep disturbances in adults for the past seven days.~SDQ).is used to screen emotional and behavioral problems in children.~SDQ is used to screen emotional and behavioral problems in children."
45351220|NCT00970762|Drug|Rocuronium 0.6 mg/kg intubating dose|Rocuronium 0.6 mg/kg intubating dose
45351221|NCT00970762|Drug|Rocuronium 0.9 mg/kg intubating dose|0.9 mg/kg intubating dose of rocuronium
45351222|NCT00970762|Drug|Rocuronium 0.1 mg/kg maintenance dose|Rocuronium 0.1 mg/kg maintenance dose following the intubating dose.
45351223|NCT00970762|Drug|Rocuronium 0.15 mg/kg maintenance dose|Rocuronium 0.15 mg/kg maintenance dose following the intubating dose
45476873|NCT03627884|Drug|Sodium Bicarbonate Catheter Lock Solution|Using Sodium Bicarbonate Catheter Lock Solution
45476874|NCT03627884|Drug|Normal Saline Catheter Lock Solution|Using Sodium Bicarbonate Catheter Lock Solution
45476875|NCT03835559|Procedure|Cyanoacrylate closure|After successful access of target vein and insertion of guidewire under any type of anesthesia, the procedure of cyanoacrylate closure is performed. A 5 French introducer and catheter is advanced and positioned 5.0 cm caudal to the junction with proximal saphenous vein compression by the ultrasound probe, two injections of approximately 0.10 mL glue are given 1 cm apart, followed by a 3min period of compression, and then repeat injections and 30sec ultrasound probe and hand compression sequences until the entire length of the target vein is treated. The catheter is removed.
45847622|NCT01785420|Drug|Trastuzumab|A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.
46045353|NCT00657124|Dietary Supplement|Aminolevan EN|The present study used carbohydrate and BCAA-enriched soft-powder nutrient-mixture for preoperative supplementation. Supplementation with Aminolevan EN (100 g per day) started at two weeks prior to the surgery under the careful monitoring of compliance.
46045354|NCT00657124|Dietary Supplement|Placebo|placebo
46045355|NCT00658294|Other|Stop treatment|
46045356|NCT02866500|Behavioral|Quality of life survey/ dental statement|Assessment of oral state and patients quality of life before radiotherapy and along treatment for oral cancer
46045357|NCT04080024|Drug|SN132D|Novel manganese-based macromolecular MRI contrast agent
46045358|NCT00979992|Other|Laboratory Biomarker Analysis|Correlative studies
46045359|NCT00979992|Drug|Sunitinib Malate|Given PO
45351224|NCT00970762|Drug|Rocuronium 0.2 mg/kg maintenance|Rocuronium 0.2 mg/kg maintenance dose following the intubating dose
45351225|NCT00970762|Drug|Vecuronium 0.1 mg/kg intubating dose|Vecuronium 0.1 mg/kg intubating dose
45351226|NCT00970762|Drug|Vecuronium 0.025 mg/kg maintenance dose|Vecuronium 0.025 mg/kg maintenance dose following the intubating dose
45351227|NCT00980824|Behavioral|Cognitive behavioural therapy|Six sessions brief CBT.
45351228|NCT00980824|Other|Standard treatment|Referral to NHS services appropriate to patient's needs
45351229|NCT00977626|Drug|Part 1 - AZD2423 or Placebo|AZD2423 Oral Solution, multiple dosing during 10-14 days or Placebo Oral Solution, multiple dosing during 10-14 days
45351230|NCT00977626|Drug|Part 2 - AZD2423|AZD2423 Oral solution, multiple dosing
45351231|NCT00977626|Drug|Part 3 - AZD2423|AZD2423 Oral solution, single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
45351232|NCT00970840|Dietary Supplement|LNS-20gM or LNS-P&L|Participants consumed a test meal (45 g or 50 g) consisting of LNS-20gM or LNS-P&L mixed with fermented maize porridge, after which they were provided with the respective LNS supplements for use at home daily for 14 d
45351233|NCT00978172|Drug|artesunate and mefloquine|artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, orally
45351234|NCT00970918|Procedure|Measurement of the Carotid Intima Media thickness|one time, radiological procedure on both sides of the neck
45351235|NCT00970918|Biological|Blood sample testing for hs-CRP|one time, blood sample taking
45351236|NCT03923530|Drug|Eplerenone|Eplerenone 50 mg daily
45351237|NCT00608907|Drug|bortezomib|1.3 mg/m^3 on days 1, 4, 8, 11 over a 21-day treatment cycle
45685964|NCT04777318|Other|Conventional physiotherapy and Muscle Energy Technique|In addition to conventional therapy, the muscle energy technique will be applied to the individuals in the second group at the same frequency. Muscle energy technique will be applied to the upper trapezius, sternocleidomastoideus , scalene (anterior-medius-posterior) and levator scapula muscles. According to the MET post-isometric relaxation method, each muscle will be applied as one set (each set includes three repetitions). The patient will be asked to perform a 7-second isometric contraction corresponding to 20% of the maximum isometric contraction force in the area where the limitation is felt. After the application, the patient will be asked to breathe and relax. The stretching will be kept beyond the resistance barrier for 30 seconds and then the technique will be repeated by taking the neck back to the barrier point.
45351238|NCT00608907|Drug|bortezomib, rifampicin|bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3
45351239|NCT00608907|Drug|bortezomib, dexamethasone|bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3
45351240|NCT00970996|Drug|Temozolomide|250 mg/m^2 by mouth on days 1, 2, and 3 of each 21-day cycle.
45842231|NCT01120704|Drug|Short Term Combination Nicotine Replacement Therapy (patch + gum)|"IF participant smokes >10 cigs/day AND is randomized to a 8 week condition: they will be asked to take one 21 mg patch/day for 4 weeks, THEN one 14 mg patch/day for 2 weeks, THEN one patch 7mg/day for 2 weeks.Participants will also be asked to use 4-mg gum every 1-2 hours (9 pieces maximum per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment.~IF participant smokes 5-10 cigs/day AND is randomized to the 8 week medication condition: they will be asked to take one 14 mg patch/day for 4 weeks, THEN one 7 mg patch/day for 4 weeks. Participants will also be asked to use 2-mg gum every 1-2 hours (9 pieces max per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment."
45351241|NCT00970996|Drug|Abraxane|100 mg/m^2 given in a short intravenous infusion 1 hour after completion of Temozolomide and a 2nd dose of 70 mg/m^2 given on day 5 of each 21-day cycle.
45351242|NCT00970996|Drug|Cisplatin|20 mg/m^2 intravenously on days 1, 2, 3, and 4 delivered immediately after Abraxane of each 21-day cycle.
45847623|NCT01785420|Drug|Placebo|A 90 minute intravenous infusion of saline as placebo
45847624|NCT00800514|Drug|amantadine|amantadine twice daily
45351243|NCT00970996|Biological|Interleukin-2|9 MIU/m^2 in a continuous intravenous infusion over 24 hours on days 1, 2, 3, and 4 (total of 96 hours) beginning after completion of Cisplatin of each 21-day cycle.
45351244|NCT00970996|Biological|Interferon alpha 2b|5 MIU/m^2 in subcutaneous injection on days 1, 2, 3, 4, and 5 of each 21-day cycle.
45351245|NCT00869193|Dietary Supplement|Grape seed extract|Subjects will daily consume one capsule with grape seed extract for 8 weeks.
45351246|NCT00869193|Dietary Supplement|Microcrystalline cellulose (placebo)|Subjects will daily consume one capsule with microcrystalline cellulose for 8 weeks.
45351247|NCT04009018|Other|Perioperative Satisfaction Scale in Regional Anesthesia|This study is methodological research. Perioperative Satisfaction Scale in Regional Anesthesia will be used to collect data.
45351248|NCT00869271|Procedure|tac + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again."
45351249|NCT00869271|Procedure|Folfox4|"folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle"
45351250|NCT00971074|Drug|Hylan G-F 20|6 ml intra-articular injection given once. The injection takes approximately 15 seconds.
45351251|NCT00971074|Other|Sham Injection|A needle will be inserted through the knee capsule but no medication will be injected.
45351252|NCT00971152|Drug|menotropins for injection|comparison of different dosages
45847625|NCT00800514|Drug|amantadine|amantadine 100 mg twice daily
45847626|NCT02780622|Drug|Oseltamivir|Oseltamivir 75 mg orally, twice daily for 4 days and once on Day 5.
45847627|NCT02780622|Drug|Warfarin|Warfarin once daily, at a dose determined through titration by participants' usual hematologist.
45351253|NCT00971152|Drug|urofollitropin for injection|comparison of different dosages
45351254|NCT00893919|Drug|mycophenolate mofetil|mycophenolate mofetil 250 mg capsule
45351255|NCT00981136|Procedure|Single Incision Laparoscopic Appendectomy|A single incision through the umbilicus to remove the appendix
45847628|NCT02781480|Biological|AAV RPE65|Comparison of different dosages of AAV RPE65
45847629|NCT02783820|Drug|MMV390048 40 mg|
45847630|NCT02783820|Drug|Placebo to match MMV390048 40 mg|
45847631|NCT02783820|Drug|MMV390048 80 mg|
45847632|NCT02783820|Drug|Placebo to match MMV390048 80 mg|
45351256|NCT00981136|Procedure|3 port laparoscopic appendectomy|Standard 3 port laparoscopic appendectomy with intracorporeal stapling
45351257|NCT05278689|Other|No intervention|No intervention
45351258|NCT00377611|Biological|Fluarix™|
45351259|NCT00978328|Drug|oxycodone immediate release (OXYRX)|Characteristics of pts. receiving prescription medications containing OXYRX
45847633|NCT02783820|Drug|MMV390048 120 mg|
46045360|NCT01079741|Biological|NY-ESO-1 protein; Poly-ICLC; Montanide|"Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen (100µg) and Montanide (1.1mL) will be held constant.~Phase II: The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B)."
45351260|NCT00869427|Drug|vitamin C|vitamin C 1g bid for 1 year
45476876|NCT03835559|Procedure|Surgical stripping|All types of anesthesia (general, spinal, regional block, or local anesthesia) can be used. The surgical stripping is performed with a proper incision in the groin, with division and ligation of the saphenous vein and division of all tributaries. The saphenous vein is then removed using a stripper.
45685965|NCT04777318|Other|Conventional physiotherapy and Cervical Mobilization Techniques|Cervical mobilization techniques will be applied to the individuals in the third group in addition to conventional physiotherapy at the same frequency. In the first few sessions, bridging and manual traction techniques will be applied in 3-5 repetitions. In the next sessions, in addition to these techniques, rotation with 3-5 repetitions of manual traction, anteroposterior sliding with traction and cervical lateral shift techniques will be applied. Vertebrobasilar Insufficiency Test will be applied to all participants to determine the appropriateness of cervical mobilization. Before mobilization, a deep friction massage will be applied on painful spasmic nuchal muscles for 3-4 minutes in order to increase blood circulation and relax tense tissues.
45685966|NCT01506609|Drug|Placebo|
46045361|NCT04289220|Biological|Anti-CD19 CAR-T Cells Injection|Dosage form：injection Dosage:1-2.5x10^6 cells/kg, 100ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes, Frequency: total one time
46045362|NCT02877641|Dietary Supplement|Cholecalciferol|Given PO
45351261|NCT00971230|Drug|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
45351262|NCT00971230|Drug|Placebo|Placebo
46045363|NCT02877641|Other|Laboratory Biomarker Analysis|Correlative studies
45351263|NCT00892359|Drug|Anidulafungin|treatment for 3 days, 200 mg intravenously on the first treatment day and 100 mg on the 2 following treatment days each.
46045364|NCT02877641|Dietary Supplement|Multivitamin|Given PO
45351264|NCT00892515|Behavioral|exercise intervention|
45351265|NCT00892515|Other|counseling intervention|
45351266|NCT00892515|Other|gas chromatography|
45476877|NCT02505646|Other|Observational study. No special intervention will be made|Data will be recorded in a context of fluid load in a context of circulatory failure. Stroke volume will be monitored, before, after an abdominal compression and after a fluid load.
45351267|NCT00892515|Other|immunoenzyme technique|
45351268|NCT00892515|Other|immunologic technique|
45351269|NCT00892515|Other|laboratory biomarker analysis|
45351270|NCT00892515|Other|mass spectrometry|
45351271|NCT00892515|Other|physiologic testing|
45351272|NCT00892515|Other|questionnaire administration|
45351273|NCT00892515|Other|survey administration|
45351274|NCT00892515|Procedure|dual x-ray absorptometry|
45351275|NCT00892515|Procedure|magnetic resonance imaging|
45351276|NCT00892515|Procedure|study of high risk factors|
45351277|NCT00978484|Behavioral|Virtual Reality Exposure Therapy - Dynamic|10 weeks of Virtual Reality Exposure using full, immersive VR
45351278|NCT00978484|Behavioral|Augmented Exposure Therapy|Exposure Therapy augmented with a still computer image
45476878|NCT05222282|Other|Sexual Health|Prevention of sexual dysfunction
45476879|NCT02895295|Behavioral|Expert Recommendation|Decision support tool that provides personalized information on the financial implications of enrolling in different plans and expert recommendations of particular plans.
45685967|NCT01506609|Drug|Veliparib|
45685968|NCT01506609|Drug|Carboplatin|
45685969|NCT01506609|Drug|Temozolomide|
45685970|NCT01506609|Drug|Paclitaxel|
45847634|NCT02783820|Drug|Placebo to match MMV390048 120 mg|
45847635|NCT02783898|Device|AliveCor Heart Monitor|Smart phone based ECG event recorder
45847636|NCT02784444|Drug|MSDC-0602K|MSDC-0602K capsules
45847637|NCT02784444|Drug|Placebo|Placebo capsules
45847638|NCT02787564|Behavioral|Intervention Group|The intervention consists of providing free fruits and vegetables of the participants' liking for a period of 4 weeks. Each week, a total of 2 portions of either fruits and/or vegetables per day will be provided.
46045365|NCT02877641|Other|Placebo|Given PO
46045366|NCT02877641|Other|Questionnaire Administration|Ancillary studies
46045367|NCT01079663|Drug|Chlorhexidine 2.5 mg|
46045368|NCT01079663|Drug|Placebo chip|
46045369|NCT04071990|Behavioral|FB-CBGT|CBGT for OCD patients, with Involvement of family members (partner, parent, sibling, ...)
45685971|NCT04777162|Drug|Tislelizumab|For included participants, tislelizumab would be administrated 200mg q3w iv.
45685972|NCT04777162|Drug|Anlotinib|Patients will be administrated with Anlotinib 12mg p.o. d1-d14 q3w.
45351279|NCT01051531|Drug|Paliperidone palmitate|One intramuscular (IM) injection of paliperidone palmitate 150 mg equivalent (eq.) on Day 1, 100 mg eq. on Day 8, and 75 mg eq. on Day 38. Thereafter, one IM injection of paliperidone palmitate 50, 75, 100, or 150 mg eq. once monthly. Doses may be adjusted every 30 days per the clinician's judgment within the dose range of 50 to 150 mg eq.
45351280|NCT00971308|Drug|BMS-824393|Capsule, Oral, 50mg, Once Daily, 3 days
46045370|NCT04071990|Behavioral|CBGT|CBGT for OCD patients, without involvement of family members
45351281|NCT00971308|Drug|BMS-824393|Capsule, Oral, 100mg, Once Daily, 3 days
45351282|NCT00971308|Drug|BMS-824393|Capsule, Oral, 10mg, Once Daily, 3 days
45351283|NCT00971308|Drug|BMS-824393|Capsule. Oral, 1mg, Once Daily, 3 days
45685973|NCT02087956|Behavioral|Navigation|The navigator provides up to 4 months outreach and support to implement the personal care plan. Patients determine the preferred frequency and type of contact with the navigator. . At the end of the four months, the patient and navigator will review the personal care plan, and the navigator will work with the patient as to how she can continue progress through accessing other supports and resources as needed.
46045371|NCT02867046|Drug|S1 transforaminal epidural steroid(dexamethasone) injection|"medial approach group (n=85): check intravascular injection while performing S1 transforaminal epidural steroid(dexamethasone) injection in medial side of S1 foramen under fluoroscopy~lateral approach group (n=85): same as medial approach group except using lateral side of S1 foramen"
46045372|NCT02865174|Drug|Topical tranexamic acid|Intraarticular application of tranexamic acid 3g in 100 ml normal saline into knee joint after closure of the joint capsule
46045373|NCT02865174|Drug|Floseal®|Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
46045374|NCT02865174|Drug|Enoxaparin|Enoxaparin will be administrated sc 40mg each day postoperatively as venous thromboembolism prophylaxis in the duration of hospital stay
46045375|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
46045376|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
46045377|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
45351284|NCT00971308|Drug|BMS-824393|Capsule, Oral, Flexible, ≤100mg, Once Daily, 3 days
45382134|NCT05301959|Device|Sham application|A modification will be made in a second equipment, closing the circuit with a 10kΩ resistor inside the equipment, in the output strand chip. Allowing the simulation of emission without emitting current to the participant and without being able to appreciate any type of alteration in the handling of the equipment, by the operators. Therefore, the same steps will be followed as in the experimental group.
45382135|NCT05301959|Other|Silbernagel protocol|The Silbernagel et al. protocol comprises several heel raising exercises with concentric and eccentric movements, performed on two legs and one leg. It is composed of 3 sets of 15 repetitions and that during the exercises allows pain to be present, but not being disabling. The exercises will be performed only once a day. The progression will be made by changing from standing exercises to monopodal support, moving from concentric-eccentric to purely eccentric loading, adding weight in a backpack (in steps of 5 kg when pain does not exceed 5 in the pain monitoring model) and finally using fast rebound exercises and plyometric exercises.
45382137|NCT05297305|Device|Tornier Ascend Flex stem|Reverse Total Shoulder Arthroplasty using onlay component (tray placed at top of humerus)
45382138|NCT05297305|Device|Tornier Perform Stem Reverse+|Reverse Total Shoulder Arthroplasty using inlay component (tray placed in humerus)
45351285|NCT00869583|Behavioral|Physical Activity Program|Participants will receive counseling from a community health educator that will focus on the importance of increasing physical activity. Participants will be encouraged to engage in moderate physical activity (3.0 to 6.0 metabolic equivalents [METS]) for 30 minutes on 5 or more days per week. Participants will be encouraged to start their physical activity program slowly and to gradually increase both frequency and intensity to meet the study goal (e.g., beginning with three sessions per week for 15 minutes and building up to five sessions per week for 30 minutes by Week 12). They will receive educational materials and telephone calls or visits from health educators on a monthly basis for 6 months.
46045378|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
45351286|NCT02533843|Procedure|radiofrequency catheter ablation|Radiofrequency catheter ablation of atrial fibrillation with or without being guided by FIRMap (using RhythmView™ Workstation from TOPERA)
45351287|NCT00971386|Behavioral|Slow breathing|The subjects will be given instructions in slow breathing at a rate of 6 to 10 breaths per minute and asked to practice it for some time. Hemodynamic measurements would be repeated before, during and after the trial of slow breathing. A Noninvasive Cardiac Output Monitor will be used. It uses a technology called impedance to measure cardiac output and other hemodynamic parameters by the passage of electric currents through the thorax. This device uses four electrode stickers applied to the thorax and the neck.
45351288|NCT00894075|Biological|ENB-0040|1mg/kg subcutaneous injection thrice weekly for 6 months
45351289|NCT00971464|Behavioral|eccentric viewing (EV) training|Eccentric viewing training for 6 weeks, minimum two 10 minutes per day.
46045379|NCT02633176|Drug|Cetuximab|400 mg/m^2 intravenously on day 1,then 250 mg/m^2 intravenously every week of each 21 day cycle for 6 cycles of induction chemotherapy.250 mg/m^2 intravenously every week concurrent with radiotherapy.
45351290|NCT00971464|Device|Closed circuit television (CCTV)|A CCTV is an electro-optical device mainly used for reading.
45476880|NCT02895295|Behavioral|Individual Analysis|Decision support tool that provides personalized information on the financial implications of enrolling in different plans.
45476881|NCT02895295|Behavioral|Usual Care|Study subjects randomized to the control arm will receive information on how to download their prescription drug information from their electronic medical record and provided with a list of resources available in the community to help them choose a prescription drug plan.
45476882|NCT02505724|Behavioral|conventional training|After completing the initial assessment, faculty randomized to the conventional training group received a link to a web-based instructional video. In addition, they were given a laparoscopic box trainer, laparoscopic instruments and sutures that they could use to practice with at their leisure.
45476883|NCT02505724|Behavioral|peer-coaching|Faculty randomized to the peer-coaching group received ½ hour of peer-coaching after completing the initial assessment on the simulator. Each faculty member sutured on the box trainer while being observed by his or her peer-coach. All study participants had the same peer-coach.After the coaching session, study participants received a link to the web-based video as well as the box trainer and supplies to independently practice laparoscopic suturing. Similar to individuals in the control group, no specific guidance regarding the amount of independent practice was given.
46045380|NCT02633176|Drug|Cisplatin|75mg/m^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.30 mg/m^2 intravenously every week concurrent with radiotherapy.
45476884|NCT03843281|Drug|Paracetamol|s. above
45476885|NCT03843281|Drug|Placebo|s. above
45476886|NCT03843281|Drug|Morphine|s. above
45476887|NCT02515240|Biological|PPV23|23 valent pneumococcal polysaccharide vaccine in Healthy adults.
46045381|NCT02633176|Drug|Docetaxel|75mg/m^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.
46045382|NCT02633176|Drug|Capecitabine|1000mg/m^2 orally twice a day, days 1 to 14 of each 21 day cycle for at least 2 years or until progression following concurrent chemoradiation.
46045383|NCT02633176|Radiation|Radiotherapy|60-66 Gy if complete response or 66-70 Gy if partial response following induction chemotherapy.
46045384|NCT04156984|Drug|Golimumab Prefilled Syringe|See arm description
46045385|NCT04157140|Drug|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
46045386|NCT04157140|Device|TACE+RFA|TACE first, followed by RFA within day7（+/-3days）
45476888|NCT03727009|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
46045387|NCT04158778|Drug|MDMA|Two sessions of MDMA-assisted psychotherapy will take place (session 3 & 7) within the 10 week course of psychotherapy. An initial dose of 125mg MDMA will be followed by an optional dose of 62.5mg 2 hours later.
46045388|NCT04158778|Other|Psychotherapy|Two sessions of MDMA-assisted psychotherapy will take place (session 3 & 7) within the 10 week course of psychotherapy.
45842232|NCT01120704|Drug|Long Term Combination Nicotine Replacement Therapy (patch + gum)|"IF the participant smokes >10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 21 mg patch per day for 22 weeks, THEN one 14 mg patch per day for 2 weeks, THEN one patch 7 mg patch per day for 2 weeks. Participants will also be asked to use one piece of one 4-mg- gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment.~IF the participant smokes 5-10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 14 mg patch per day for 22 weeks, THEN one patch 7 mg patch per day for 4 weeks. Participants will also be asked to use one piece of 2-mg gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment."
45476889|NCT03843515|Drug|Nivolumab|Neoadjuvant nivolumab flat dose 400mg
45476890|NCT02515318|Other|Physiotherapy program|The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes, and included: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
46045389|NCT01132664|Drug|BKM120|Buparlisib (BKM120) is the investigational drug. Burparlisib was supplied as 10 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area. Buparlisib capsules were packaged in high density polyethylene bottles with a plastic child resistant closure.
45685974|NCT02087956|Behavioral|Enhanced Screening and Referral|Patients assigned to ESR will be provided with a print-out of their Promote-W comprehensive health screening results. More specifically, they will receive a list of concerns they endorsed plus a resource list of locations where they can obtain assistance with those issues, which are largely free.
45685975|NCT03027219|Drug|Alprostadil|Vasodilator for anastomosis-site of free flap
45685976|NCT04776772|Dietary Supplement|Synbiotic complement|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic)."
46045390|NCT01132664|Drug|Trastuzumab|Trastuzumab was used in this study according to the local regulations in each participating country. A loading dose (4 mg/kg) of trastuzumab was administered (if required as assessed by the principal Investigator based on the timing of the last trastuzumab dose prior to enrollment) on Day -7 over 90 minutes, followed by weekly intravenous infusion of 2 mg/kg maintenance doses from Day 1 of Cycle 1 (over 30 minutes if the previous infusion was well tolerated).
46045391|NCT01132664|Drug|Capecitabine|1000 mg/m2 twice a day from day 1 to Day 14 of a 21-day cycle.
45842233|NCT01120704|Behavioral|Intensive Maintenance Counseling|Participants randomized to this condition will receive eight 15-minute phone counseling sessions at Weeks 3, 4, 6, 8, 10, 14, 18 & 22. The counseling will encourage continued practice of coping skills, and avoidance of danger situations. Another emphasis will be the continued provision of social support as a means of enhancing motivation. Participants who have relapsed will receive counseling aimed at motivating and planning renewed quit attempts. Other aims are enhancing motivation, especially competence self-appraisals, providing intratreatment support, and encouraging pleasurable activities.
45842234|NCT01120704|Behavioral|Cognitive Medication Adherence Counseling (CAM)|Participants randomized to this condition will be given a brief (10 minute) session of CAM treatment at both Visits 1 and 2. CAM will include information on NRT such as the following: NRT reduces withdrawal and urges; sustained use reduces the likelihood of relapse; willpower and medication make a good combination; NRT will help a lapsing smoker reachieve abstinence. The tailored counseling component of the CAM intervention is based on brief evaluation of the smoker's beliefs, concerns, and possible misconceptions about smoking cessation medications.
45842235|NCT01120704|Behavioral|Electronic Medication Monitoring Device (the Helping Hand) + Feedback|If randomized to this condition, the case manager will give patients a computer-generated feedback sheet showing the patient's medication self-administration since the last visit. The case manager will provide problem-solving counseling regarding barriers to medication use. This problem-solving counseling intervention will be given in brief in-person sessions (three in-person sessions for those in the 8 week medication condition and five in-person sessions for those in the 26 week medication condition). Medication monitoring counseling will also occur via phone (two 10-minute sessions for those in the 8 week medication condition and four 10-minute sessions for those in the 26 week medication condition).
45842236|NCT01120704|Behavioral|Automated Adherence Prompting Phone Calls|"Participants in this condition will receive fully automated prompts with messages designed to encourage participants to take their medication.~Adherence prompting calls will occur two times in the first week of the quit attempt, and then once a week in weeks 2, 3, 4, 5, and 7. Those in the 26-Week medication condition who are assigned to the active adherence prompting calls intervention, will receive one prompting call a week during Weeks 11, 15, 19 & 23."
45842237|NCT01121250|Behavioral|Telephone Discussion Groups|Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).
46045392|NCT00591409|Drug|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex (0.5 to 4 mg/kg) IV was administered."
46045393|NCT00591409|Drug|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of placebo IV was administered"
45685977|NCT04776772|Dietary Supplement|Placebo|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (placebo)."
45351291|NCT03992911|Drug|Simmtecan, 5-FU and l-LV|Simmtecan was administered intravenously at 80 mg per square meter on day1 with LV 400 mg per square meter administered as a 2-hour infusion, and 5-FU 2400 mg per square meter as a 46-hour infusion on day1 every 2 weeks in one course.
45685978|NCT01506453|Drug|gabapentin|Participants randomized to the active treatment arm will receive gabapentin 20mg/kg/day PO divided into 3 doses and rounded to the nearest 100 mg for capsules and 10 mg for liquid preparation.
45685979|NCT01506453|Drug|placebo|Participants randomized to the placebo treatment arm will receive look-alike capsules or liquid in a respective capsule size or liquid measure equivalent to the active treatment arm, but which contain no active treatment.
45685980|NCT00218686|Behavioral|psychoeducational|psychoeducational
45685981|NCT00218686|Behavioral|control|VTC
45685982|NCT04389580|Drug|Drug: Isotretinoin plus Tamoxifen|"20 mg PO (by mouth) twice daily for 14 days~13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days starting after three days of taking tamoxifen"
45351292|NCT03992911|Drug|Toripalimab|Toripalimab was administered intravenously at 240 mg on day 1 every 2 weeks in one course.
45476891|NCT02515318|Drug|Medical standard treatment|"The standard medical treatment consists on:~Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones."
46045394|NCT05756179|Drug|Diosmin and Hesperidin Combination|Diosmin 450 mg and Hesperidin 50 mg Combination
46045395|NCT02610361|Drug|BGB-283|"In the dose escalation part(phase 1a): the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In dose expansion phase(Phase 1b): Patients will be assigned to different groups based on their tumor types"
45685983|NCT04389580|Drug|Aerosolized Isotretinoin plus Tamoxifen|"20 mg PO (by mouth) twice daily for 14 days~Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days starting after three days of taking tamoxifen"
46045396|NCT05756101|Device|Research on the application of novel restraint devices in postoperative patient safety management in cardiac surgery|According to the individual characteristics of ICU patients and the needs of patients, a new type of restraint device was innovatively made and the effectiveness and safety of the new restraint device were studied, which provided clinical reference and theoretical basis for standardizing postoperative patient restraint.
45351293|NCT03992911|Drug|Etoposide, Cisplatin|Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 with Cisplatin at 80 mg per square meter on day 1 every 3 weeks in one course.
45351294|NCT03992911|Drug|Etoposide, Carboplatin|Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 and Carboplatin with AUC 5mg/mL/min on day 1 every 3 weeks in one course.
45351295|NCT00895479|Procedure|Graft placement surgery plus Trinam therapy|"Trinam arm: graft placement surgery plus 1ml perivascular administration of Trinam vector.~Control arm: graft placement surgery"
45351296|NCT01324765|Behavioral|TARGET|12-session group therapy twice weekly 6 weeks
46045397|NCT00709345|Behavioral|Cognitive behavioral sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on promoting healthy behaviors, dieting, and exercise.
46045398|NCT00709345|Behavioral|Time-matched attention control sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on improving communications, developing healthy techniques for coping with stress, and resolving conflicts.
46045399|NCT01078805|Drug|FORTEO|prescribed in accordance with usual clinical practice for up to 24 months
45351297|NCT01324765|Behavioral|SGT|12 sessions supportive group therapy twice weekly 6 weeks
45351298|NCT02541201|Dietary Supplement|Plant sterols-enriched low-fat milk|The study product is a dried partly skimmed milk powder with no more than 12% milk fat (11.4g total fat/100g product) containing unesterified, unhydrogenated plant sterols.
45351299|NCT02541201|Dietary Supplement|Low-fat milk|The placebo product is a dried partly skimmed milk powder.
45351300|NCT00545272|Drug|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
45351301|NCT00545272|Drug|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
45351302|NCT00545272|Drug|placebo to indacaterol|Placebo TWISTHALER® device
45685984|NCT01482429|Other|Multidisciplinary weaning-ventilator protocol|We implemented a multidisciplinary protocol for weaning from mechanical ventilation.This consist of a daily screening for readiness, performing a spontaneous breathing test, evaluation of signs of intolerance and decision on extubation.
45476892|NCT03776201|Other|Balance Training|We expect that a balance training intervention that utilizes an external focus of attention will lead to the adoption of balance strategies that are protective against falls. The mechanism for this behavioral change will be identified using a Dynamical Systems Theory framework (i.e., entropy) to quantify postural sway characteristics before, during and after the training. We will determine whether the balance intervention utilizing an external focus of attention will lead to positive benefits through the three specific aims.
45476893|NCT00245960|Drug|etanercept|
45476894|NCT00245960|Drug|etanercept|
45476895|NCT00245960|Drug|Placebo|
45476896|NCT04443322|Drug|Durvalumab Injection|Anti-PD-L1 Monoclonal Antibody
45476897|NCT04443322|Drug|Lenvatinib 4 MG|Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β etc.
45476898|NCT01202825|Drug|TMC647055|One single dose as oral solution, doses from 100 mg up to a maximum of 3000 mg increasing in sessions I through VI.
45476899|NCT01202825|Drug|Placebo|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
45476900|NCT01202825|Drug|TMC647055|Oral solution given in session XIII, treatment arm 1 during 10 days at a dose of 1000 mg every 12 hours.
45476901|NCT01202825|Drug|TMC647055|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
45476902|NCT01202825|Drug|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
45476903|NCT01202825|Drug|TMC435|Oral capsule given in session XIII, in treatment arm 1 during 10 days and in treatment arm 2 during 6 days at a dose of 150 mg once daily.
45476904|NCT01202825|Drug|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
45476905|NCT01202825|Drug|TMC647055|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
45476906|NCT01202825|Drug|Placebo|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
46045400|NCT00626249|Drug|Technosphere Inhalation Powder|Technosphere Inhalation Powder
46045401|NCT02876939|Other|kinesiology tape around the hip, knee and ankle joints|We will also demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
46045402|NCT02876939|Other|No kinesiology tape around the hip, knee and ankle joints|Investigators will demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
46045403|NCT00820027|Drug|Etoricoxib 90 mg|One 90 mg tablet once daily
46045404|NCT00820027|Drug|Etoricoxib 120 mg|Two 60 mg tablets once daily
46045405|NCT00820027|Drug|Ibuprofen 600 mg|One tablet three times daily
46045406|NCT00820027|Drug|Matching Placebo for Etoricoxib 120 mg|Two tablets once daily
45351303|NCT00545272|Drug|placebo to formoterol|Placebo AEROLIZER® device
45351304|NCT00545272|Drug|short acting β2-agonist|100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
45351305|NCT00869739|Behavioral|telephone-based intervention|
45351306|NCT00869739|Other|educational intervention|
45351307|NCT00869739|Other|partner-assisted coping skills training|
45351308|NCT00869739|Other|questionnaire administration|
45351309|NCT00869739|Procedure|psychosocial assessment and care|
45351310|NCT00869739|Procedure|quality-of-life assessment|
45351311|NCT00377455|Drug|Bosentan|62.5 mg by mouth (PO) twice daily (Bid) for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
45351312|NCT00377455|Drug|Placebo|62.5 mg PO Bid for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
45351313|NCT00895557|Drug|chantix|.5 mg once a day 1 to 3, .5 mg twice a day on days 4 to 7, 1 mg from day 8 to end of treatment
45351314|NCT01051609|Other|History and Physical Exam|The physical exam includes vital signs and ECOG performance status.
45351315|NCT01051609|Other|Grip Strength Measurement|A hand grip strength test will be used to measure and compare baseline and post-AI treatment forearm muscle strength in each hand.
45476907|NCT01202825|Drug|TMC647055|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
45476908|NCT02515162|Procedure|Fischer Cone Biopsy Excisor|Electrosurgical excision method using a triangular electrode to remove the abnormal cervical Transformation zone
45476909|NCT02515162|Procedure|Loop Excision Procedure|Electrosurgical excision method using a circular electrode to remove the abnormal cervical Transformation zone
45476910|NCT03843203|Device|Transcranial Direct Current Stimulation - tDCS|- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
45476911|NCT02510872|Other|18F-FDG PET combined with CT with iodinated contrast injection|
45476912|NCT02510872|Other|18F-FDG PET combined with CT without injection|
45476913|NCT05222204|Drug|intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel|intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel in patients with pancreatic cancer with peritoneal metastasis
46045407|NCT00820027|Drug|Matching Placebo for Etoricoxib 90 mg|One tablet once daily
46045408|NCT00820027|Drug|Matching Placebo for Ibuprofen|One tablet three times daily
45351316|NCT01051609|Behavioral|Surveys|Self-administered surveys including Health Assessment Questionnaire Disability Index, CES-D, FACIT-F, PSQI, GAD7, number of minutes of morning stiffness, and questions pertaining to vasomotor symptoms will be used in this study to assess for presence, severity, characteristics, and associations of AI-associated musculoskeletal symptoms.
46045409|NCT00820027|Drug|Morphine|As needed via patient-controlled analgesia (PCA) device or as a bolus intravenous injection
45351317|NCT01051609|Other|Blood Collection|A set of blood markers will be assayed at baseline, 6 months, and 12 months.
45351318|NCT01051609|Procedure|Ultrasound of Hand/Wrist|An inflammatory arthritis ultrasound scoring method similar to the RAMRIS scoring system used in rheumatoid arthritis, will evaluate joints in the most affected hand and wrist at 6 months.
45351319|NCT00869895|Drug|E7050|Oral dosing starting at 100 mg once daily. After the MTD of once daily dosing has been determined, subsequent cohorts will be treated with a divided dosing schedule either twice or three times daily. The starting dose for this schedule will be an appropriate level below the MTD for once daily dosing.
45351320|NCT00978640|Other|fast and exercise|fasting 36 h and exercise 1 h 50% VO2max
45351321|NCT00978640|Other|exercise|exercise 1 h 50% VO2max
45351322|NCT02533687|Procedure|Bipolar TURP-1|Bipolar transurethral resection of prostate (TURP)
45351323|NCT02533687|Procedure|Bipolar TURP-2|Bipolar TURP
45351324|NCT02533687|Procedure|Monopolar TURP|Monopolar TURP
45351325|NCT00869973|Drug|Aprepitant|Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3
45351326|NCT00869973|Drug|dexamethasone|dexamethasone 4 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on day 3
45351327|NCT03553095|Procedure|Periodontal Surgery|Samples will be collected from patient in need of periodontal therapy (surgical procedures i.e. gum surgery, tooth extraction and or dental implant surgery). As standard during this procedures remnant tissue is otherwise discarded.
45351328|NCT01048645|Drug|ATRA|Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
45351329|NCT01048645|Other|PLACEBO|Patients were randomized to receive or placebo (P/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
45351330|NCT04008784|Drug|Crisaborole 2% Topical Application Ointment [EUCRISA]|Ointment
45351331|NCT04008784|Drug|Triamcinolone Acetonide 0.1% Ointment|Topical Corticosteroid
45351332|NCT03544905|Drug|CYH33 for tablet|1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)
45351333|NCT04008394|Genetic|Anti-CD30 CAR T cells|Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.
45351334|NCT00895635|Behavioral|Treadmill Exercise Training|60-minute sessions of supervised treadmill exercise training three times a week for 12 weeks
46045410|NCT00820027|Drug|Oxycodone|5 mg as needed
46045411|NCT02877407|Procedure|patient who undergo laparoscopic/robotic-assisted hysteropexy|
45351335|NCT00895635|Behavioral|Arm Ergometry Exercise Training|60-minute sessions of supervised aerobic arm exercise training using an arm ergometer three times a week for 12 weeks
45351336|NCT00895635|Behavioral|Usual Care|Usual care for PAD
45351337|NCT01051687|Drug|Botulinum toxin A|"Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.~For each patient with focal vitiligo, one vitiliginous patch - or two patches from different sites- will be treated. The other patches from the contra lateral site will be left untreated and used as control at the follow-up visit. For each patient with segmental vitiligo, half of the lesion will treated. The other half will be left untreated and used as a control at the follow-up visit."
45351338|NCT00978718|Dietary Supplement|high-selenium baker's yeast|Given orally
45351339|NCT00978718|Dietary Supplement|selenium|Given orally
45351340|NCT00978718|Other|placebo|Given orally
45351341|NCT00894153|Drug|chemotherapy plus p53|chemotherapy plus p53
45351342|NCT00894153|Drug|chemotherapy|chemotherapy
45351343|NCT00894153|Radiation|radiotherapy|radiotherapy
45351344|NCT01048801|Device|Rapid diagnostic test|Use of rapid daignostic tests for diagnosis of malaria
46045412|NCT02877407|Procedure|patient who undergo vaginal hysterectomy|
46045413|NCT02876549|Drug|Chloroquine|10 mg/kg on day 0 & 1 and 5mg/kg on day 2, (Afghanistan NMLCP guidelines)
46045414|NCT02876549|Drug|Primaquine 0.25 mg/kg/day|0.25 mg/kg/day for 14 days
46045415|NCT02876549|Drug|Primaquine 0.75 mg/kg weekly|0.75 mg/kg weekly for eight weeks
45842238|NCT01121250|Behavioral|Education sessions|Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
45842239|NCT01122030|Drug|Naldemedine|Tablets or solution for oral administration
45842240|NCT01122030|Drug|Placebo|Tablets or solution for oral administration
45842241|NCT01122108|Drug|Cholestyramine|Cholestyramine 12 grams, one time dose
45842242|NCT01122108|Drug|Colesevelam HCl|Colesevelam HCl, 4 grams, one time dose
45351345|NCT01048801|Other|presumptive malaria treatment|Treatment of malariabased on clinical diagnosis without use of diagnostic test
45842243|NCT01123512|Device|Vertebral augmentation|Vertebral augmentation for one or two osteoporotic vertebral compression fractures
45842244|NCT01124370|Device|remedē (TM) system|Implantation of the remedē (TM) system, including implantable pulse generator, stimulation lead, and (optional) sensing lead. Nightly provision of unilateral transvenous phrenic nerve therapy during sleep periods.
45842245|NCT05307042|Diagnostic Test|Deamino Arginine Vasopressin (dDAVP)|After voiding, 40 μg 1-desamino-8-D arginine vasopressin (dDAVP) will be administered intranasally. Throughout the day, urine volume and maximal renal concentrating ability will be determined by measuring osmolality in urine collected at 4 and 6 hours after administration of dDAVP. In addition, water intake, body weight, blood pressure and heart rate will be determined at baseline and 6 hours after administration of dDAVP.
46045416|NCT02876627|Behavioral|Exercise training|twelve-week aerobic exercise training program consisted of three sessions per week, each session lasting 30 to 60 minutes 50 to 75 percent of their maximum heart rate reserve
45351346|NCT00971542|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen & adjuvant, or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups.
45351347|NCT00895713|Drug|intramuscular hepatitis B virus immune globulin|Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months
46045417|NCT00913549|Drug|Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)|
46045418|NCT00913549|Drug|Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)|
46045419|NCT01076153|Drug|Clarithromycin (Klacid® MR)|Klacid MR 500mg (clarithromycin)
46045420|NCT01076075|Drug|Sitagliptin phosphate|Phase A (Weeks 0-24): Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): Sitagliptin 100 mg once a day for 30 weeks
45351348|NCT01051765|Drug|irinotecan/cisplatin|irinotecan 130mg/m2 d1 cisplatin 30mg/m2, d1,d2 every 3 weeks
45351349|NCT00978796|Drug|Sitagliptin|Sitagliptin 100mg tablet taken orally once daily for 4 weeks and then switch over to sugar pill taken daily for 4 weeks
46045421|NCT01076075|Drug|Comparator: placebo to pioglitazone|Phase B (Weeks 24-54): placebo to pioglitazone 30 mg once a day for 30 weeks
46045422|NCT01076075|Drug|Comparator: placebo to Sitagliptin|Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): placebo to Sitagliptin once a day for 30 weeks
46045423|NCT01076075|Drug|Comparator: pioglitazone|Phase B (Weeks 24-54): pioglitazone 30 mg once a day for 30 weeks
45351350|NCT00978796|Drug|Sugar Pill|Sugar pill taken daily for 4 weeks and then switched over to active comparator of sitagliptin 100mg tablet taken daily for 4 weeks
45476914|NCT02515006|Other|Homeopathy Medicine|Homeopathy, or homeopathic medicine, is a holistic system of treatment. Individualized homeopathy remedy was based on the most characteristic and clear mental symptoms. Secondly, general symptoms were taken into account.C-potencies were provided and manufactured according to the Homeopathic Pharmacopoeia and Hahnemann's methodology. Each individualized homeopathic remedy were be prescribed in C-potencies
45685985|NCT03856437|Behavioral|HPV vaccination messages|Digital multimedia messages consisting of text and imagery conveying the benefits of being vaccinated against HPV, the costs of not being vaccinated against HPV, or neither benefits or costs but simply a call for action.
45685986|NCT04409067|Diagnostic Test|electromyography|Surface electromyography (sEMG) was used as an additional non-invasive tool for assessing patients with TMD.The electromyographical (EMG) potentials of the temporalis and masseter muscles were measured with a DAB-Bluetooth Instrument (Zebris Medical GmbH, Germany) at rest and during maximum voluntary clenching (MVC).
45685987|NCT00199108|Drug|Depocyt|
45685988|NCT00199108|Drug|Dexamethasone|
45685989|NCT04776538|Biological|Stem cells|Each participant will be double-blindly randomized to receive either adipose-derived allogeneic stem cells or placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
45685990|NCT04776538|Biological|Placebo|Each participant will be double-blindly randomized to receive either adipose-derived allogeneic stem cells or placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
45685991|NCT01504971|Other|symptom questionaire|GerdQ questionaire
45685992|NCT01504971|Procedure|pH monitoring|24-hour pH monitoring
45351351|NCT00894231|Drug|levocetirizine (Xyzal)|5mg po QD
45351352|NCT00894231|Drug|placebo|sugar tablet
45351353|NCT00870207|Behavioral|Tu Salud Si Cuenta Worksite Intervention|The intervention will consist of providing TSSC newsletters to employees of the worksite. Additionally, informational sessions about physical activity and healthful food choice (consistent with the TSSC messages) during work hours will be implemented. Social support groups for the behavior changes will be established thru colleague networks. Individualized behavior change plans will be designed for enrolled participants. Additionally, environmental changes including a well equipped exercise facility on site and access to healthful foods in vending machines and work groups providing fruit and vegetable access in kitchen area will be implemented.
45351354|NCT05030974|Biological|mRNA-1273|SARS-CoV-2 vaccination
45351355|NCT05030974|Biological|Ad26.COV2.S vaccine|SARS-CoV-2 vaccination
45351356|NCT00377299|Drug|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects. Citicoline or placebo (identical in appearance) add-on therapy was given beginning at one tablet (500mg/day) with an increase to two tablets (1000 mg/day) at week 2, three tablets (1500 mg/day) at week 4 and four tablets (2000 mg/day) at week 6. Doses were decreased, if needed, due to side effects.
45351357|NCT00377299|Drug|Placebo|Placebo matching active medication in all other physical aspects
45351358|NCT00981604|Procedure|SILS|Single Incision Laparoscopic Cholecystectomy
45351359|NCT00981604|Procedure|Standard Laparoscopic Cholecystectomy|4 port technique
45351360|NCT03472365|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
45476915|NCT02558465|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Treatment parameters following the summary of product characteristics and the physician's decision
46045424|NCT01076075|Drug|Glimepiride or gliclazide|Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of glimepiride or gliclazide; Phase B (Weeks 24-54): stable dose, as prescribed by investigator, of glimepiride or gliclazide
46045425|NCT01076075|Drug|Metformin|"Phase A (Weeks 0-24): stable dose, as prescribed~by investigator, of metformin; Phase B (Weeks 24-~54): stable dose, as prescribed by investigator, of~metformin"
45351361|NCT03472365|Drug|Capecitabine|1000 mg/m^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
45351362|NCT03472365|Drug|Oxaliplatin|130 mg/m^2 administered IV Q3W on Day 1 of each 3-week cycle.
45685993|NCT01504971|Procedure|Tri-modal imaging endoscopy|To investigate WLI,NBI and AFI
46045426|NCT01076075|Drug|Pioglitazone rescue therapy|Phase A (Weeks 0-24): participants not meeting specific glycemic goals will receive pioglitazone (open label) at a dose determined by the investigator. These participants will not initiate Phase B (Weeks 24-54) double blind pioglitazone.
46045427|NCT01075763|Drug|Interferon beta-1a|Interferon (IFN) beta-1a [Rebif® 22 microgram (mcg), three times per week (tiw)] administered subcutaneously (sc)
46045428|NCT01075763|Drug|Placebo|The inactive substance (placebo) looks the same as Interferon beta-1a (Rebif®), and is given the same way
46045429|NCT00881530|Drug|BI 10773|BI 10773 high dose once daily
46045430|NCT00881530|Drug|Metformin|open label comparator
45351363|NCT03472365|Drug|Apatinib|375 mg administered as continuous oral once daily (QD) of each 3-week cycle.
45351364|NCT03200977|Other|Non-Interventional|Non-Interventional
45351365|NCT00971776|Device|AB Portable Driver System|Evaluate the safety and performance of the AB Portable Driver System in home environment.
45351366|NCT00978952|Device|Large Diameter Advanta™ V12 Covered Stent|Stent placement
45351367|NCT00896259|Other|home based exercise and education program|Individual assessment with physiotherapist with educational information, exercise instruction and prescription provided. Instructed to perform home exercises and walking for 12 weeks. Will be individually tailored to participants, bi-monthly phone calls will be used to monitor and facilitate exercise and walking progression .
45351368|NCT00971854|Procedure|Alteration of deep brain stimulator settings|From 130Hz to 60Hz pallidal stimulation
45351369|NCT00894621|Drug|Norepinephrine|Solution administration contend titrated norepinephrine in doses of 0,1 to 0,4 mc/kg/min. Initiated solution 24 hours after beginning mechanical ventilation. Use of the solution during 72 hours.
45351370|NCT00894621|Drug|Placebo|
45351371|NCT04036227|Drug|GS-248|GS-248 oral solution
45351372|NCT04036227|Drug|Placebo|Placebo oral solution with the same composition to match active drug
46045431|NCT00881530|Drug|BI 10773|BI 10773 low dose once daily
46045432|NCT00881530|Drug|Sitagliptin|open label comparator
46045433|NCT01075685|Behavioral|interactive online programme to reduce alcohol consumption|"The programme includes several steps:~personalized feedback on alcohol consumption and related risks~reviewing motivations and fears regarding drinking reduction~analyse of drinking habits~reduction goal setting~follow-up tools (alcohol diary, craving scales, well-being scales)~a final screen allowing participants to monitor their progress through graphs and automatically adapted comments."
46045434|NCT01075685|Behavioral|Minimum information|"This intervention includes:~information about hazardous drinking~an alcohol diary"
46045435|NCT01075217|Drug|iopamidol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
45476916|NCT02515084|Device|PET|A FDG PET scan and a diffusion-weighted Magnetic Resonance Imaging will be performed to compare the efficacy to diagnose relapse in thyroid carcinoma
45351373|NCT00901095|Behavioral|Lifestyle intervention|Participants will attend a 15 weekly class sessions during the first 4 months. Classes will be co-lead by a dietician and exercise specialist and will involve a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by action-planning and goal-setting. During the next 2 months, participants will meet with a dietician on an individual basis for a private weigh-in, personal discussion and problem solving, review of self-monitoring records, and action-planning. The last 6 months will consist of applying and maintaining what has been learned in previous class sessions. Self-monitoring records, questions and problems will be discussed with interventions at least once every 2 months or more frequently if needed.
45351374|NCT00979108|Other|Physical therapy rehabilitation|Mechanical cervical traction will be applied at a moderate force and adjusted based on symptom relief. In addition, subjects will be trained in cervical and postural exercises.
45476917|NCT02515084|Device|MRI imaging|
46045436|NCT01075217|Drug|iodixanol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
46045437|NCT02632474|Drug|Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)|The first 2 weeks, TDF (300 mg) + 3-TC (300 mg) + EFV (400 mg); week 3, TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg ); week 4, TDF (150 mg) + 3-TC (300 mg) + EFV (400 mg).From week5, if the HIV viral load decreased as expected or no rebound, use TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg) until study complete; if the viral load increases, switch to the standard treatment regimen: TDF (300 mg) + 3-TC (300 mg) + EFV (600 mg).
46045438|NCT04156750|Drug|LY3556050|Administered orally.
46045439|NCT04156750|Drug|Placebo|Administered orally.
46045440|NCT04156750|Drug|Iohexol|Administered IV.
46045441|NCT04156750|Drug|Metformin|Administered orally.
45351375|NCT00979108|Other|Physical therapy rehabilitation|Subjects will be instructed in use of an over-the-door traction unit utilizing weights up to 20 pounds in sitting. In addition, subjects will be trained in neck and postural exercises.
45351376|NCT00979108|Other|Physical therapy rehabilitation|Subjects will be instructed in neck and postural exercises.
45351377|NCT00376675|Drug|methylphenidate hydrochloride|Given orally
46045442|NCT02877173|Drug|Alprostadil Liposomes for Injection|3 doses of Alprostadil Liposomes for Injection are 20ug/q.d,40ug/q.d,60ug/q.d.All groups will be continuous administration for 3 weeks.
46045443|NCT02877173|Drug|Alprostadil Injection|Alprostadil Injection(the positive control group):10ug/q.d,continuous administration for 3 weeks.
46045444|NCT00658450|Behavioral|Cognitive rehabilitation training|"A computerised cognitive training package where children will be required to complete several cognitive tasks. The aim is to strengthen the different cognitive processes during these tasks which in turn may lead to improve cognitive processes.~Children will complete these tasks in 16 session for 8 weeks."
45351378|NCT00376675|Other|placebo|Given orally
45476918|NCT03834467|Other|Arm 1 - Elevation Stimulus Video|Subjects will watch a video that has been shown in previous studies to elicit an elevation response. This video shows a news story about a man saving the life of another man who falls onto the subway tracks.
45476919|NCT03834467|Other|Arm 2 - Control Stimulus Video|Subjects will watch a nature video.
45476920|NCT03840785|Other|Argentine tango|"Argentine tango sessions will consist of:~Body perception and body control: sitting, standing then moving around four axes : space, time, energy, gravity.~Awareness of oneself, of other and music: listening, communication, touch, empathy, kinesthesia, letting go, feeling"
45476921|NCT04825184|Behavioral|Body image chatbot|See arm/group description.
45476922|NCT02729194|Drug|Pazopanib|
45476923|NCT02729194|Other|Low Fat Diet|Registered subjects will take pazopanib by mouth with a low-fat meal (containing less than 400 calories and less than 10% fat or 10 grams per meal.
45685994|NCT01504971|Drug|rabeprazole|10mg, bid, p.o.
46045445|NCT04305743|Drug|OnabotulinumtoxinA 100 UNT|Intradetrusor onabotulinumtoxin A is administered cystoscopically with 100 unit dose given as either 5 or 20 injections in a single procedure based on the arm the participant is randomized into.
46045446|NCT00661180|Drug|Nexavar (Sorafenib, BAY43-9006)|Patients will receive Bay 43-9006 400 mg po twice daily in a continuous, uninterrupted schedule. Treatment will continue until there is objective evidence of disease progression, or until evidence of toxicities that are unacceptable and thought to be related to study drug, which requires discontinuation of drug, or due to withdrawn patient consent.
45842246|NCT05306730|Device|ECHOcardiography, Point-of-Care UZ|Emergent echocardiography is reproducible method providing clinically significant information during primary survey of acute cardiovascular diseases. Possible benefit is the risk stratification of acute non-stemi coronary syndromes and differentiation from other serious conditions, such as pulmonary embolism or aortic dissection. The aim of interest is to consider riscs and benefits of the ultrasound of heart done by non-cardiologist after standardized course.
45842247|NCT05306184|Procedure|Electroconvulsive therapy (ECT)|ECT
45842248|NCT05291442|Other|To integrate Family System Care and Theme Care Action Module|"First, understand the care needs of patients and caregivers, and apply The Specific Thematic Nursing Care Action Modules (STNC-AM) platform for education and training.~The Specific Thematic Nursing Care Action Modules (STNC-AM) platform that we present here is an educational program that integrates education and coaching. STNC-AM has six key aspects: stroke prevention, management of emotions, management of fatigue, physical activity, caregiver training, and integrative resources. Each scope contains detailed care guidance."
46045447|NCT02632942|Procedure|HAQ criteria|"Obliteration of accessory vein which satisfy the HAQ criteria as below:~60% or greater diameter of the main AVF~50% diameter of AVF with at least one more av>40% in diameter.~50% in diameter and divides into branches of same size.~av likely to interfere with cannulation on physical examination.~>30% in diameter and associated with stenosis at site of origin."
45842249|NCT05289960|Other|lung ultrasound|Lung ultrasound score was done at the end of SBT using curved array ultrasound probe 2-5 MHz, Siemens X300, Korea
45842250|NCT05288478|Combination Product|Dentoxol mouthrinse dosages|Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between.
46045448|NCT02632942|Procedure|Current Recommendation|Obliteration of accessory vein which satisfy current recommendations defined as the diameter greater than 25% of the AVF diameter.
46045449|NCT04032574|Combination Product|Herbal Medicinal Product|
46045450|NCT04032574|Other|Placebo|
45476924|NCT05218616|Drug|Aviga, capsules 50 mg / Sutent®, capsules 50 mg|Aviga is manufactured by JLLC NATIVITA, Republic of Belarus. Each capsule contains 50 mg of Sunitinib / Sutent® is manufactured by Pfizer Italia S.R.L., Italia. Each capsule contains 50 mg of Sunitinib.
45476925|NCT05218616|Drug|Sutent®, capsules 50 mg / Aviga, capsules 50 mg|Sutent® is manufactured by Pfizer Italia S.R.L., Italia. Each capsule contains 50 mg of Sunitinib / Aviga is manufactured by JLLC NATIVITA, Republic of Belarus. Each capsule contains 50 mg of Sunitinib
45351379|NCT02539875|Behavioral|AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices|Use AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices interventions to achieve smoking abstinence
45351380|NCT00979186|Device|NOTES GEN 1 Toolbox|Articulating Hook Knife, Articulating Snare, Articulating Needle Knife Articulating Graspers, Articulating Biopsy Forceps, Steerable Flex Trocar with Rotary Access Needle, Flexible Bipolar Hemostasis Forceps, Flexible Maryland Dissector, and Tissue Apposition System.
45476926|NCT02505880|Other|Local anesthetic + Hypnosis|Modified state of consciousness allowing to be at the same time here and somewhere else. The individual is going to dive into his imagination to extract of an uncomfortable situation. And local anesthetic (solution of Xylocaine with adrenaline 1 % dabbed in 20 % of bicarbonate of sodium 4,2 %, maximal dose of 0,5ml / kg)
45476927|NCT02505880|Drug|General anesthesia|Sufentanil intravenous (0.1 in 0.2 µg / kg) and propofol (5 in 10 mg / kg on 3 mn) administration
45351381|NCT04017663|Other|Application of questionnaires|Application of questionnaires to identify characteristics and main barriers of patients
45351382|NCT00979264|Behavioral|Intensive quality improvement tools|Personalized performance improvement interventions, including premier site data reports, personalized feedback/teleconferences, comprehensive toolkits, and focused webinars; in addition to other general QI tools typically available through participation in Get With the Guidelines Heart Failure.
45351383|NCT02539719|Drug|SC-003|
45476928|NCT03840629|Other|No study intervention.|
45842251|NCT05115942|Drug|Hydronidone capsules|After randomization, the experimental group received hydronidone capsules three times a day, 3 capsules each time, for 52 weeks.
45842252|NCT05115942|Drug|The placebo capsules|After randomization, The control group received three placebo capsules three times a day. 3 capsules each time, for 52 weeks.
45476929|NCT05218304|Biological|Blood sample|A questionnaire, physical measurements (height, weight, perimeter abdominal and blood pressure) for all arm will be done, approximately 5400 people carried out by investigators. Only 1800 will undergo blood samples carried out by nurses
45476930|NCT02505490|Other|Television|The purpose is to determine whether television impacts liking of food.
45476931|NCT02505490|Other|No Television|The purpose is to determine whether the lack of television impacts liking of food.
45842253|NCT04974138|Drug|Amlodipine besylate tablets|The amlodipine used in this study is a listed product. All drugs used in the Randomized Treatment Period of this study will be packed into bottles with the same outer appearance and corresponding labels of the clinical trial (100 tablets/bottle).
45842254|NCT04974138|Drug|Amlodipine besylate and folic acid tablets|The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020. All drugs used in the Randomized Treatment Period of this study will be packed into bottles with the same outer appearance and corresponding labels of the clinical trial (100 tablets/bottle).
45842255|NCT04973982|Drug|Envarsus|3 month treatment, given once daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
45842256|NCT04973982|Drug|Adoport|3 month treatment, given twice daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
45842257|NCT04973514|Procedure|Cardiac surgery in grown-up congenital heart disease patients|Analysis of patient blood management, influence on 30 day and 6 month outcome
45842258|NCT04733664|Device|VFI using the FAST PV Technology|The bolus IV administered visible fluorescent injectate (VFI) agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
45842259|NCT04503720|Device|CLoWI|Patients will receive a continuous wound infusion with ropivacaine and normal saline in the PCA pump.
45842260|NCT04503720|Device|PCA|Patients will receive a continuous wound infusion with normal saline and morphine in the PCA pump.
45351384|NCT02539719|Drug|SC-003 in combination with ABBV-181|
45351385|NCT04007614|Other|Questionnaire|Fardellone questionnaire (evaluation of calcium intake) Tolerance of treatment
45351386|NCT05178628|Drug|Innohep|Patients will receive Tinzaparin sodium 20.000 Anti-Xa IU/ml in prefilled syringes. Administered at 175 Anti-Xa IU/Kgr of body weight, subcutaneously, once daily
45351387|NCT05178628|Drug|Chemotherapy: Gemcitabine + Nab-Paclitaxel|All patients will receive chemotherapy per clinical practice
45351388|NCT00896571|Drug|Ethinylestradiol/Gestogene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
45351389|NCT00896727|Genetic|gene expression analysis|
45351390|NCT00896727|Genetic|protein expression analysis|
46045451|NCT04032496|Behavioral|Contemplative-Based Intervention for People Living with SLE|Intervention sessions will follow a 6-week format consisting of weekly in-person sessions as well as guided homework to encourage practice at home. Some mindfulness practices that will be included are meditation, group exercise (yoga), group discussions, and deep breathing. Both participants diagnosed with SLE as well as caregivers will participate in the intervention sessions. 5 sessions will be approximately 2 hours long, while the final session will be approximately 4 hours long. Each intervention group will include approximately 4 participants with SLE and 4 caregivers.
46045452|NCT04032496|Behavioral|Health Enhancement Program (HEP)|The HEP was designed to create an active control for mindfulness-based stress reduction (MBSR) interventions. The structure of this intervention will mirror that of the other arm of this study, but will lack the mindfulness component. The HEP includes topics such as physical activity, functional movement, music therapy, and nutrition education.
45476932|NCT03215706|Biological|Ipilimumab|Specified dose on specified day
45351391|NCT00896727|Other|fluorescent antibody technique|
46045453|NCT02876471|Other|CPAP|OSA complicated with hypertension：In order to avoid the effects of drugs on this study, we calculated the time to stop based on the half-life of patients taking oral drugs and last time administration time. The subject who withdrawal time was less than three days was enrolled in our study. These patients were hospitalized and close monitoring of blood pressure, for blood pressure three times greater than 180/110mmHg or appearing dizziness, headache and other clinical syndrome, we give a timely clinical intervention and get rid of our study. Screening of 40 newly diagnosed patients with hypertension and subjects with poor blood control,the investigators would give one-night CPAP
45351392|NCT00896727|Other|laboratory biomarker analysis|
45351393|NCT00981838|Drug|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after reconstitution in normal saline to a concentration of 1 mg/ml given though a 0.22 micron in line filter. The initial infusion rate will be 1 ml/kg/h and will be progressively increased up to 4 ml/kg/h according to drug tolerability. Pre-medication with steroids and/or antihistaminic agents will be done according to per-center's practice.Rituximab administration will be repeated in those patients > 5 B cells/mm3 in the peripheral blood on the day after first Rituximab administration.
45351394|NCT03931330|Device|Percutaneous neurostimulation|Percutaneous neurostimulation using NSS-2 Bridge device
45351395|NCT00901329|Device|NexGen Gender Fixed Bearing Knee prosthesis|new female prosthesis
45351396|NCT00901329|Device|NexGen LPS-Flex Fixed Bearing Knee prosthesis|standard knee prosthesis
45842261|NCT04487964|Dietary Supplement|Licorice extract|"LICORICE CAPSULES; 250 mg standardized extract (25% Glycyrrhizin - 62.5 mg) For 10 days, with measuring blood pressure daily.~Dose:~One capsule, twice daily, before meals. Boswellia serrata Gum Resin; B. serrate contains volatile oils (5-15%), pure resin (55-66%), and mucus (12-23%). The resin contains terpenoids, phenolic compounds, flavonoids, and phenylpropanoids. More than 12 different Boswellic acids have been identified, the amounts of 11-keto-β-boswellic acid KBA is 3-4.7% and acetyl-11-keto-β-boswellic acid(AKBA) is 2.2-2.9%, Dose: 2 gm, 4 times daily For 15 days, Boswellia Gum Resin is administered by chewing for a half-hour"
46045454|NCT04032340|Other|dog presence|This project seeks to assess positive impacts of companion dog presence in elderly living at home ; to assess loneliness and isolement between eldlery with a companion dog and without, at home
45351397|NCT01048957|Behavioral|Real Time Feedback Training|
45351398|NCT01051999|Dietary Supplement|Glutamine|Oral glutamine powder
45351399|NCT01051999|Dietary Supplement|L-alanine|L-alanine oral powder
45351400|NCT00894777|Other|Clinical record review|
45351401|NCT00981994|Behavioral|Decision Support for ARI Management|Use of history and physical examination findings to estimate probability of pneumonia in patients with acute respiratory infections and thereby guide treatment decisions
45351402|NCT01049113|Drug|ON 013105|2-hour intravenous infusion once a week. Starting dose is 17 mg. Maximum dose will be 1525 mg.
45351403|NCT04017585|Dietary Supplement|diet containing gluten|gluten will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to placebo for another 7 days
45351404|NCT04017585|Dietary Supplement|Diet containing placebo|Placebo will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to gluten for another 7 days
45351405|NCT02533765|Drug|Olaparib|Olaparib dispensed to patients at the dose of 300 mg twice daily (BID) continuously until the patient completes the study, withdraws from the study or closure of the study.
45382145|NCT05294341|Drug|Norethindrone Acetate 5 MG|As specified in arm design
45382146|NCT05294341|Drug|Norethindrone 0.35 MG|As specified in arm design
45382147|NCT05293964|Drug|SIM0270|SIM0270 is an oral, selective estrogen receptor degrader (SERD)
45382148|NCT05293964|Drug|Palbociclib|palbociclib is a selective inhibitor of cyclin D-cyclin-dependent kinase (CDK) 4/6
45382149|NCT05293964|Drug|everolimus|Everolimus is an inhibitor of mTOR (mammalian target of rapamycin)
45476933|NCT03215706|Biological|Nivolumab|Specified dose on specified day
45842262|NCT04482972|Procedure|DCB|Angioplasty with DCB is an angioplasty technique which allows drug delivery to the coronary artery without stent implantation.
45351406|NCT00979342|Device|Hysteroscopic Morcellator|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade.When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
46045455|NCT04032262|Diagnostic Test|Gastrointestinal and Parkinson's Disease|Subjects with Parkinson's disease will come for visits that will contain questionnaires about their PD, their bowel movements, and do further tests using anal rectal probes to understand further their constipation, and other tests to gather data on their digestion.
46045456|NCT01078571|Biological|adalimumab (HUMIRA®)|The primary objective of the study is to evaluate the safety and tolerability of adalimumab (HUMIRA®) treatment, administered both in monotherapy and combined therapy, in rheumatoid arthritis (RA) patients under usual practice conditions.
46045457|NCT04160728|Other|Work/ rest scenario|For every hour of work, the participants were asked to take 3-10 minutes break in the shade.
46045458|NCT04160728|Other|Hydration scenario|Participants were asked to consume at least 750ml of water or ice-slushies for every hour of work
45685995|NCT04776616|Device|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day
45685996|NCT04776616|Device|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day
45842263|NCT04482972|Procedure|DES|Angioplasty with DES is an angioplasty technique which permits drug delivery to the coronary artery and permanent implantation of a stent.
45382150|NCT05293743|Device|Foot abduction bracing for clubfoot with novel dynamic bar|After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares the standard straight bar in a foot abduction brace to our novel dynamic bar. This group uses the novel bar.
45382151|NCT05293743|Device|Foot abduction bracing for clubfoot with standard straight bar|After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares the standard straight bar in a foot abduction brace to our novel dynamic bar. This group uses the standard bar.
45382152|NCT05292521|Other|Best Practice|Receive usual care
45382153|NCT05292521|Other|Informational Intervention|Receive QOL fact sheet
45382154|NCT05292521|Other|Questionnaire Administration|Ancillary studies
45842264|NCT04461600|Drug|AL101|AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
45842265|NCT04342182|Biological|Convalescent plasma|"Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products"
45842266|NCT04237974|Device|computed tomography pulmonary angiography|The radiological severity of pulmonary embolism will be assessed by using the computed tomography pulmonary arterial obstruction index (CT-PAOI)
45842267|NCT04187352|Drug|CS1001+ Fluorouracil+Cisplatin|"CS1001 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle."
45842268|NCT04187352|Drug|Placebo+ Fluorouracil+Cisplatin|"Placebo 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle."
45382155|NCT05292144|Device|Xperience Pro|Patients in whom treatment with (Xperience Pro) has been attempted
45382156|NCT05290207|Diagnostic Test|The hyperinsulinaemic hypoglycaemic clamp|Glucose will be clamped at 5.0 mmol/L for approximately 30 minutes, and then be lowered to 3.0 mmol/L for 30 minutes
45382157|NCT05286255|Biological|Allogeneic Mesenchymal Stromal Cells|Intravenous MSCs 1.2-1.5 x 10^6 cells/kg on Days 1 and 3 after study enrollment
45382158|NCT05281731|Device|Sonobiopsy|Ultrasound combined with microbubbles to facilitate sampling of biomarkers from brain tumors via blood-based liquid biopsy
45382159|NCT05281731|Procedure|Research blood|No more than 10 minutes prior to ultrasound sonication, 10 minutes after ultrasound sonication, 30 minutes after ultrasound sonication (optional at the discretion of the PI), and 60 minutes after ultrasound sonication (optional at the discretion of the PI)
45842269|NCT04142892|Drug|Onapristone|50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD) during 3 weeks (+/-3 days)
45842270|NCT04125498|Other|Osteopathic treatment|Manual treatment that aims to release myofascial tensions
46045459|NCT04160728|Other|Clothing scenario|Participants were asked to wear different types of clothing during the work shift i.e. ventilated garments, white breathable coveralls, clothing with water submerged parts
46045460|NCT04160728|Other|"E-carts scenario"|"Participants that were involved in manual labor by carrying heavy weights were provided with e-carts (automated carrying vehicles)"
45842271|NCT04125498|Other|Placebo treatment|Similar to OMT without pressure
45842272|NCT04125498|Other|Self-massage|Women will be instructed to perform self-massage at home once a day for 5 minutes.
46045461|NCT04160728|Other|Business as usual scenario|No interference with the usual work day of the participants
46045462|NCT04160728|Other|Sham evaluation|Participants were monitored during a usual day of work shift while sham measurements were recorded in order for them to get familiarized with the study environment
46045463|NCT04017364|Device|PCB PTCA|Predilatation of coronary de-novo stenosis followed by a PCB
46045464|NCT04017364|Device|SCB PTCA|Predilatation of coronary de-novo stenosis followed by a SCB
46045465|NCT02877329|Behavioral|Internet-delivered ACT|Therapist-guided Internet-delivered ACT (acceptance and commitment therapy) for 8 weeks
45685997|NCT01479777|Device|FES Stepping (RT600 from Restorative Therapies, INC.)|You will be transferred to the RT600 device and secured in a support harness. We will place your legs onto the RT600 device and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs, buttock, stomach, and back. The pads will be connected to a stimulator box through a wire. We will then start the stepping motor and stimulate your muscles with electric current. This will cause your legs to step. You will do this for 1 hour.
45382160|NCT05281731|Genetic|Cancer Personalized Profiling|Cancer Personalized Profiling by deep Sequencing will be used to compare the frequency of tumor-specific variants in the blood before and after sonobiopsy.
45685998|NCT00954226|Drug|Erlotinib Hydrochloride|Given PO
45685999|NCT00954226|Other|Laboratory Biomarker Analysis|Correlative studies
45686000|NCT03027063|Behavioral|10,000 steps|Participants will be asked to achieve 10,000 steps daily and to participate in 30 minutes of continuous exercise of their choosing. They will also receive text messages during the week and weekly motivational call
45686001|NCT03027063|Behavioral|Usual Care|Participants will receive the ACC/AHA exercise guidelines
45382161|NCT05281731|Device|Definity®|Being used off-label in this trial
45382162|NCT05281471|Biological|olvimulogene nanivacirepvec|Olvi-Vec is an engineered oncolytic vaccinia virus
45382163|NCT05281471|Drug|Platinum chemotherapy: carboplatin (preferred) or cisplatin|Administered according to local practice
45476934|NCT03215706|Drug|Carboplatin|Specified dose on specified day
45686002|NCT04776304|Behavioral|Art Therapy|"This is a pilot study in which every participant receives the art therapy intervention arm. There are no waitlist or control arms. Art therapy is one promising intervention that helps service members (SMs) develop a visual voice, using imagery, symbolism, and metaphor to externalize emotions and experiences that they may not be able to express in words. The standardized, integrative mental health and human services approach of the art therapy program at the NICoE utilizes a mask-making directive to explore thoughts, feelings, and experiences of combat and self-understanding. This process is especially relevant to SMs with PTS symptoms who often remember their trauma as an incoherent, fragmented memory that is often predominantly sensory in nature. NICoE researchers have provided preliminary evidence suggesting associations between recurring art themes represented within the masks and individual BH symptoms."
45686003|NCT04753918|Drug|Porfimer sodium|Photofrin 2mg/kg was iv injected 48-50 hours before light illumination.
45842273|NCT04017702|Device|Expiron respirator|Respiratory volume monitor (RVM) (ExSpiron, is a non-invasive FDA approved device that monitors minute ventilation (MV) and provides an early indication of respiratory status in non-intubated patients. The system consists of a lightweight monitor, a patient cable, and a disposable electrode PadSet, which detects changes in breathing.
45842274|NCT03848286|Drug|KL-A167 Injection|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
46045466|NCT04160416|Drug|Capecitabine-Oxaliplatin-Irinotecan Combination|CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; CET: 500 mg/sq.m (d.i.v.) D1; Administered every 2 weeks.
45686004|NCT04753918|Drug|Ethiodized oil|In hybrid operation room setting, a navigational bronchoscope guide sheath was inserted to the proximal end of the tumor region. About 5 ml Lipiodol was infused to full cover whole the tumor.
45686005|NCT04753918|Procedure|Novel light delivery methods of photodynamic therapy|Using high-refraction index contrast medium: lipiodol as a light diffusor to enhance the range of photodynamic therapy
45842275|NCT03829098|Other|Intervantions for anastomotic leakage after esophagectomy|nil by mouth regime; antibiotic treatment according to local protocols; NG tube placement (with/without suction); NG tube repositioning (with/without suction); tube placement though anastomotic defect; endoVAC/endoSponge placement; stent placement (stent type if applicable); endoscopic clipping; nasoduodenal/nasojejunal feeding tube placement; radiologic drainage (thoracic cavity, mediastinum); bedside surgical chest tube placement; reoperation; reoperation approach; reoperation procedure (drainage only, suturing of the leak; resection of the leak and re-anastomosis; repair of anastomosis with muscle flap; disconnection and cervical esophagostomy; surgical jejunal feeding tube).
46045467|NCT02876237|Other|geriatric assessment and quality of life|"Included patient must have a geriatric assessment before radiotherapy and 6 months later. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities .~Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later."
45686006|NCT04753918|Device|Fiber optic|A cylindrical laser fiber was then inserted through the guide sheath to the tumor region then illuminate light to complete the photodynamic therapy.
45686007|NCT04161664|Drug|Paclitaxel and Carboplatin|6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
45686008|NCT00936832|Drug|FOLFIRI regimen|
45686009|NCT00936832|Drug|fluorouracil|
46045468|NCT02876237|Radiation|Radiotherapy|standard radiotherapy
46045469|NCT00661336|Drug|buthionine sulfoximine|
46045470|NCT00661336|Drug|melphalan|
46045471|NCT00661336|Genetic|microarray analysis|
46045472|NCT00661336|Other|high performance liquid chromatography|
46045473|NCT00661336|Other|laboratory biomarker analysis|
46045474|NCT00661336|Other|pharmacological study|
46045475|NCT00661336|Procedure|biopsy|
45842276|NCT03795168|Device|Transcranial vibrating system|The transcranial vibrating system (TCVS) will be worn by participants performing vestibular physical therapy (PT) exercises. The TCVS vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises. The TCVS will be set at an optimal vibration frequency as determined in a previous study.
45842277|NCT03795168|Device|Transcranial vibrating system sham|A transcranial vibrating system (TCVS) sham set at an irrelevant vibrating frequency will be worn by participants performing vestibular physical therapy (PT) exercises in arm 2. The TCVS sham vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS sham will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises.
45842278|NCT03792360|Drug|SVF (Stromal Vascular Fraction)|The stromal vascular fraction (SVF), isolated when fresh lipoaspirates are enzymatically digested with a collagenase, contains a heterogeneous cellular and extracellular milieu. SVF is an aqueous fraction, consisting of endothelial cells and their precursors, macrophages, smooth muscle cells, lymphocytes, pericytes, pre-adipocytes and actual AMSCs.
45686010|NCT00936832|Drug|irinotecan hydrochloride|
45686011|NCT00936832|Drug|leucovorin calcium|
45842279|NCT03749928|Device|OstiSense biosensor - active|The activated biofeedback back night guard will be used to reduce sleep bruxism
45842280|NCT03749928|Device|OstiSensor biosensor - not activated|A not-activated night guard will be used as control device
45842281|NCT03697356|Drug|Lenalidomide, Bortezomib, Rituximab, Dexamethasone|"step 1; R-VRD induction : rituximab, bortezomib, lenalidomide, and dexamethasone induction~Rituximab 375 mg/m2 intravenous on day 1~Bortezomib 1.3mg/m2 subcutaneous on day 1, 8, 15~Lenalidomide 15mg p.o on day 1-21~Dexamethasone 20 mg/m2 intravenous or p.o on day 1-4~Step 2 ; Maintenance Beginning 8 weeks after completion of induction therapy, patients receive lenalidomide 10mg once day 1-21 for 4 weeks. Treatment repeats every 1 months for 24 months."
45842282|NCT03616782|Drug|Ixazomib|Ixazomib 3mg on day 1, 8, 15 q 4 weeks for 24 months or until progression
45842283|NCT03555552|Device|Anticoagulation and Thrombosis Point of Care Test(AT-POCT)|Capillary action automatically draws blood into the channel containing printed assay reagents which solubilize upon contact with blood and react with analytes of interest.
45842284|NCT03555552|Device|Duke Central Automated Laboratory (DCAL)|DCAL measurement of INR will occur by an ACL TOP 750 Analyzer (IL Inc.), and LDH by standard enzymatic activity assay will be run on the automated Beckman DxC800.
45842285|NCT03336372|Drug|Picato|Picato 0.05% or 0.015% topical gel applied nightly for 3 consecutive nights
45842286|NCT03099798|Other|Questionnaires|"All patients will complete a number of questionnaires at different time points.~SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ~1 week, 1 month, 3, 6 and 12 months after treatment"
45842287|NCT03099798|Diagnostic Test|MRI abdomen|Patients who were treated with splenic artery embolization will also undergo an MRI one month and one year after treatment.
45842288|NCT02410512|Drug|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody|Atezolizumab will be administered intravenously.
45842289|NCT02410512|Drug|MOXR0916, a humanized agonist anti-OX40 monoclonal antibody|MOXR0916 will be administered intravenously.
45842290|NCT02364492|Drug|MAG-TN3 + AS15|
45842291|NCT02323464|Procedure|Open surgery for colorectal cancer|
45842292|NCT02323464|Procedure|Laparoscopic or robotic surgery|
45842293|NCT02176434|Procedure|Kidney and hematopoietic stem cell transplantation|Kidney transplantation (day 0) Induction therapy (s. above) Hematopoietic stem cell transplantation (s. above)
45842294|NCT02176434|Biological|hematopoietic stem cell|
46045476|NCT04158700|Drug|LY3200882|LY3200882 administered orally
46045477|NCT04158700|Drug|Pembrolizumab|Pembrolizumab administered IV
46045478|NCT02876003|Drug|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
46045479|NCT04306289|Device|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive technique of neuronal modulation that has been used in different neurological conditions, neuropathic pain.
46045480|NCT00657202|Drug|Ranibizumab|Given as an injection into three cutaneous neurofibromas on day 1 of the study treatment.
46045481|NCT00626483|Biological|RNA-loaded dendritic cell vaccine|Only one dose of DCs (2 x 10^7) is being assessed.
46045482|NCT00626483|Drug|basiliximab|Basiliximab 20 mg and 40 mg is being assessed depending on dose-cohort enrollment.
45686012|NCT00936832|Drug|sunitinib malate|
45686013|NCT00936832|Other|laboratory biomarker analysis|
45686014|NCT00936832|Other|pharmacogenomic studies|
45686015|NCT00936832|Other|pharmacological study|
45686016|NCT04753606|Drug|Obicetrapib|tablets
45686017|NCT04755946|Drug|Roflumilast|adding one tablet of roflumilast 500 mcg to the standard ACEI (captopril) for diabetic nephropathy management
45686018|NCT04755946|Drug|Placebo|Placebo
45686019|NCT01896466|Device|Cranial Nerve Non-Invasive Neuromodulation|Portable device delivers electrical stimulation to cranial nerves V and VII via an electrode array placed on the anterior surface of the tongue. Stimulation is combined with rehabilitation exercises targeting walking and balance.
46045483|NCT02632864|Radiation|Proton arm|Proton beam therapy
46045484|NCT00626717|Procedure|Riboflavin/UVA crosslinking|Removal of epithelium. Riboflavin eye drops. UVA exposure.
46045485|NCT00626717|Procedure|Sham treatment|Fluorescein eye drops. Exposure with blue light
45842295|NCT00849888|Biological|Serum Free Thymus Transplantation with Immunosuppression|Cyclosporine pre-transplant (trough 180-220ng/ml) until naive T cells develop. Subjects >4,000/cumm T cells, pre-transplant methylprednisolone or prednisolone 1-2mg/kg/day. All subjects pre-transplant days -5,-4,-3: 3 doses 2mg/kg rabbit anti-thymocyte globulin. Thymus tissue (unrelated donor), donor, & donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects, FBS cultured thymus is transplanted in 1 leg & serum free (SF) in other. After first 2 subjects >10% naïve T cells, 3rd receives only SF thymus. After 3rd subject >10%naive T cells, 4th subject transplanted. Thymus dose 4-18 grams/m2 body surface area. Thymus biopsy 8-12 weeks post-transplant. Skin biopsy at time of transplant & thymus biopsy. Followed by immune evaluations.
45842296|NCT00849888|Other|Serum Free Thymus Transplantation without immunosuppression|Thymus tissue (unrelated donor), donor, & donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects: FBS cultured thymus transplanted in 1 leg & serum free cultured thymus in other leg. After first 2 subjects have thymopoiesis in serum-free biopsy, >10% naïve T cells, 3rd subject receives only serum free cultured thymus. After 3rd subject >10% naive T cells, 4th subject receives transplant of only serum free cultured thymus. Dose 4-18grams/m2 body surface area. At time of transplant, skin biopsy. Allograft biopsy & skin biopsy done 8 to 12 weeks post-transplant. (Graft biopsy not done if subject medically unstable.) Post-transplant, subjects followed by immune evaluations, using blood samples, for two years.
46045486|NCT00661414|Biological|ASONEP (sonepcizumab/LT1009)|"ASONEP [sonepcizumab/LT1009] is supplied as a colorless,particulate-free, pH 6.5, sterile solution containing approximately 10 mg/mL or 20 mg/mL of drug.~The candidate drug is intended for single intravenous (iv) use administered over 90 minutes on a weekly basis."
46045487|NCT04776941|Behavioral|Behavioral Intervention|Read positive messages
45351407|NCT04035993|Other|Controlled hypoglycaemic state while driving with a driving simulator|"Patients will arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants will drive on a designated circuit using a driving simulator. Initially, euglycaemic state (5.0-8.0 mmol/L) will be kept stable and then blood glucose will be declined progressively targeting at a level between 2.0-2.5mmol/L by administering an insulin bolus. Glucose will be kept stable at the hypoglycaemic level for 30 minutes. Thereafter, it will be raised again and kept stable for another 30 minutes at an euglycaemic level between 5.0-8.0mmol/L. During the procedure, we will analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression, will be recorded by a smart-watch, a CGM device, an eye-tracker and an onboard camera, respectively.~Participants will be blinded to the glucose values during the procedure. They will have to rate their symptoms and their performance on a 0-6 scale every 15 minutes."
46045488|NCT04776941|Behavioral|Behavioral Intervention|Write about positive experiences
46045489|NCT04776941|Behavioral|Behavioral Intervention|Write about neutral topics
46045490|NCT04776941|Behavioral|Behavioral Intervention|Read neutral messages
46045491|NCT04776941|Other|Quality-of-Life Assessment|Ancillary studies
46045492|NCT04776941|Other|Questionnaire Administration|Complete questionnaires
46045493|NCT04160572|Behavioral|Morning sleep schedule|sleep right after night shifts
46045494|NCT04160572|Behavioral|Evening sleep schedule|sleep before night shifts
45351408|NCT00367237|Drug|Infliximab + methotrexate (IFX + MTX)|Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks. Methotrexate dose can be increased to 20 mg/week at week 6.
45351409|NCT00367237|Drug|Methotrexate (MTX)|Oral methotrexate 15 mg/week for 15 weeks. Dose can be increased to 20 mg/week at Week 6.
45351410|NCT04006912|Procedure|phacoemulsification and Toric intraocular lens implantation|A clear corneal incision is made in a different position
45351411|NCT02540889|Behavioral|Auditory comprehension therapy.|100 hours of Auditory comprehension therapy embedded within a computer game.
45351412|NCT00894855|Behavioral|education about sun protection|This comprehensive education program included a visit with a health educator, on the education van, who gave education about sun safety.
45351413|NCT00894855|Behavioral|biometric feedback|Participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
45686020|NCT01896466|Behavioral|Sham Cranial Nerve Non-Invasive Neuromodulation|Subjects participate in gait and balance rehabilitation exercises while using a device set to sub-threshold levels.
45686021|NCT01479621|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 12.5, 25, 50 or 100 mcg of Fp one inhalation twice a day for a total daily dose of 25, 50, 100 or 200 mcg. Study drug was administered in the morning and in the evening"
45476935|NCT03215706|Drug|Paclitaxel|Specified dose on specified day
45476936|NCT03215706|Drug|Pemetrexed|Specified dose on specified day
45476937|NCT03215706|Drug|Cisplatin|Specified dose on specified day
45476938|NCT03840863|Dietary Supplement|Commercially-Available Energy Drink|Participant will consume 2 cans of an energy drink (16 oz./can) per day. One in the morning and one in the afternoon.
45476939|NCT02510950|Biological|Personalized peptide vaccine|
45476940|NCT02510950|Drug|Poly-ICLC|
45351414|NCT00894855|Other|dermatologist skin exam|Full body skin exam.
45686022|NCT01479621|Drug|Flovent Diskus|Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 100 mcg was used twice a day, once in the morning and evening, for a total daily dose of 200 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
46045495|NCT04156204|Other|Medication Event Monitoring System (MEMS)|AYA kidney recipients will receive a Medication Event Monitoring System (MEMS) via medication bottle and cap system
46045496|NCT04156204|Drug|Once-Daily Tacrolimus extended release|AYA kidney recipients will receive once daily tacrolimus XR 1-10mg daily
46045497|NCT04305821|Other|Dosage of S100β protein|Dosage of S100β protein
46045498|NCT02631694|Drug|Propranolol|Intake of propranolol pill (40 milligram)
46045499|NCT02631694|Drug|Placebo|Intake of placebo pill (40 milligram)
46045500|NCT02631694|Other|Carbon dioxide|Inhalation of 35% carbon dioxide
45351415|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 5ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
45351416|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 50ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
45351417|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 250ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
45351418|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 1000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
45351419|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 25ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
45351420|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 125ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
45351421|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 500ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
45476941|NCT02510950|Drug|Temozolomide|
45476942|NCT05670197|Other|No intervention. Participants will take part in a qualitative interview|No intervention. Participants will take part in a one-off, audio-recorded qualitative interview, lasting up to 60 minutes. The interviewer will ask about participants' views on complex digital remote monitoring.
45476943|NCT04499872|Other|Advance Care Plan with Trajectory Touchpoint Technique|Advance Care Plan with Trajectory Touchpoint Technique
45476944|NCT03840473|Behavioral|MET|The patient was in a supine position with the cervical spine in the opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were in a lengthened position.19 The moderate isometric contraction (approximately 75% of maximal) of the upper trapezius muscles was elicited for a period of 5 seconds followed by 3 seconds of relaxation while reaching the new barrier. The technique was repeated four times in each session.
46045501|NCT02631694|Other|Compressed air|Inhalation of air
46045502|NCT04306133|Procedure|PENG block|After performing spinal anesthesia, PENG block with 20 mL of 0.375 % Ropivacaine will be executed as described by Giron-Arongo et al with a low frequency curvilinear probe. A 22G 80 mm needle (Stimuplex Ultra 360, Braun ) will be used.
45476945|NCT03840473|Behavioral|ICT|The patient lying in the supine position with the cervical spine in opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were kept in a lengthened position.18,22 The physiotherapist applied gradually increasing pressure to the MTrPs until the subject perceived the first noticeable pain. At that moment, the pressure was maintained until the discomfort and/or pain eased by around 50% as perceived by the patient, at which time the pressure was increased until the discomfort appeared again. This process was maintained for 90 seconds.
45476946|NCT03840473|Behavioral|Conventional Intervention|Hot packs (75°C) for 20 minutes and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions). Active stretching exercises were done by all the participants under the supervision of the physical therapist. This approach was standardized for all participants.
45476947|NCT05221814|Diagnostic Test|gross pathologic photo based deep learning model|Whether apply gross pathologic photo based deep learning model to predict pathologic subtype
45476948|NCT02514928|Procedure|resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy|Resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy. Regional lymph nodes includes group 5,6,8a,8p,9,12a,12b,12c,12p,13,14a,14b,14c,16,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
45686023|NCT01479621|Drug|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
45686024|NCT01479621|Drug|Placebo MDPI|Placebo multidose dry powder inhaler in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
45842297|NCT00255138|Drug|Atomoxetine|
45842298|NCT01125774|Drug|Telcagepant|Telcagepant 140 mg film coated tablet for oral administration
45842299|NCT01125774|Drug|Placebo|Placebo to match telcagepant 140 mg film coated tablet for oral administration
45842300|NCT01128192|Drug|pasireotide|Pasireotide 600 μg (batch number Y050DE) or 900 μg bid (batch number Y1270908) for subcutaneous injection. Placebo (batch number Y069HC) for subcutaneous injection.
45842301|NCT01128270|Drug|Dichloroacetate environmental dose|On day 6 they receive Dichloroacetate 2.5 ug/kg orally times 1 and have pharmacokinetics.
45351422|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 2000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
45351423|NCT00984646|Drug|Placebo|Intradermal Placebo, 100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
45842302|NCT01128270|Drug|Chloral Hydrate environmental dose|Study subjects are given 1.5 ug/kg of Chloral Hydrate for 5 nights and pharmacokinetics are done on night 1 and 5.
45842303|NCT01128270|Drug|Dichloroacetate therapeutic dose|Subjects receive 25 mg/kg DCA on Day 6. Pharmacokinetics are done on nights 1 and nights 5.
45351424|NCT03991585|Behavioral|Musical Contour Regulation Facilitation (MCRF)|MCRF involves 20-minute music therapy sessions comprised of seven interconnected components. Each session follows the same contour of neutral, low, and high arousal experiences facilitated through music.
45842304|NCT01128270|Drug|Chloral Hydrate therapeutic dose|Subject is given 25 mg/kg of Chloral Hydrate for five nights.
45842305|NCT01128426|Other|No Intervention|No Intervention
45842306|NCT01128972|Drug|Sodium fluoride|Test fluoride toothpaste and test fluoride mouth rinse
45842307|NCT01128972|Drug|Sodium monoflurophosphate|United Kingdom marketed fluoride toothpaste
45842308|NCT01128972|Drug|Sterile water|Sterile water rinse
46045503|NCT04306133|Procedure|Wound Infiltration|At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.375 % Ropivacaine.
46045504|NCT04305587|Drug|PF-07081532|Investigational Drug once daily for up to 42 days; multiple ascending dose design.
46045505|NCT04305587|Other|Placebo|Placebo once daily for up to 42 days.
46045506|NCT04305587|Drug|Clopidogrel|Part B may include a drug-drug interaction study using open-label clopidogrel. Clopidrogrel may be given as two single doses of 75 mg administered on day -2 and day 41.
46045507|NCT00658840|Drug|Capecitabine (Xeloda®)|Capecitabine is administered orally at a dose of 800 mg/m2 twice daily (total daily dose 1600mg/ m2) continuous regimen regimen during RT (5 days of treatment followed by a 2 day rest: Saturday and Sunday). Capecitabine is given approximately 12 hours apart and taken orally with water within 30 minutes after ingestion of food (breakfast or dinner).
46045508|NCT00658840|Radiation|Localization, simulation and immobilization|"Radiation dose and planning~Total dose 55.8Gy, 28 fractions, 6-7 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to emcompass GTV with a margin of 1-1.5cm.~Dose prescription : 90% isodose volume of prescribed dose encompassed PTV~The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the liver, duodenum, stomach, the kidneys, spinal cord, etc., was calculated."
45351425|NCT00901407|Drug|lamotrigine|lamotrigine augmentation 25 to 100 mg tablets, 25 to 200 mg bid,10 weeks
45351426|NCT00901407|Drug|placebo|placebo: 1-2 tablets bid; 10 weeks
45351427|NCT00901407|Drug|paroxetine|open label paroxetine 10 to 50 mg, at bedtime for 18 weeks (8 weeks prior to randomization and 10 weeks after)
45351428|NCT01052155|Other|Urine Drug Testing|LC/MS/MS Laboratory Evaluation
45842309|NCT01129206|Drug|pralatrexate|IVP(intravenous push)over 3-5 minutes on day 1 at a dose of 120 mg/m2.
45842310|NCT01129206|Drug|docetaxel|Given Intravenous Piggyback (IVPB)as one-hour infusion at a dose of 3 mg/m2 on day 1 of a cycle. cycle defined as 14 days.
45842311|NCT01129206|Radiation|fludeoxyglucose F 18|Correlative studies
45842312|NCT01129206|Procedure|positron emission tomography|Correlative studies
45842313|NCT01129440|Device|Fluoride Varnish|Topical application of 0.25mL of fluoride varnish on each dental arch (upper and lower) at baseline and every 6 months.
46045509|NCT00665782|Other|laboratory biomarker analysis|
46045510|NCT00665782|Other|questionnaire administration|
46045511|NCT00665782|Other|study of socioeconomic and demographic variables|
46045512|NCT00665782|Procedure|assessment of therapy complications|
46045513|NCT00665782|Procedure|psychosocial assessment and care|
46045514|NCT00665782|Procedure|therapeutic conventional surgery|
46045515|NCT04305353|Other|Diary (blank journal) plus PTSD psycho-education|A blank journal where a prospective account of a patient's ICU course (everyday events) can be documented by family members and healthcare providers
46045516|NCT04305353|Other|PTSD psycho-education alone|"We administered a pamphlet to patients with information regarding PTSD symptoms, potential psychiatric complications after discharge, and available mental health resources.~References for our education include the following which are included in our references section: Jensen 2015, Jones 2010, Knowles 2009, Parker 2015, Wintermann 2015."
46045517|NCT00658918|Drug|Ciclesonide nasal|safety of Ciclesonide (200µg, 100µg, 25µg)
45351429|NCT01563562|Drug|Bardoxolone Methyl|Oral, Single dose
45351430|NCT00896883|Device|Middle Turbinate Implant|Middle Turbinate Implant placement at time of surgery and follow ups.
45351431|NCT00984724|Behavioral|Standard Treatment (ST)|Mailing of packet of materials including a letter referring smokers to the Texas Quitline, nicotine replacement therapy when participants are ready to quit and standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months).
45351432|NCT00984724|Behavioral|Telephone Counseling|"MAPS-6: 6 MAPS proactive telephone counseling sessions delivered over a 2-year period~MAPS-12: 12 MAPS proactive telephone counseling sessions over a 2-year period"
45351433|NCT00984724|Behavioral|Quitline|Letter referring participants to a Quitline providing quit smoking services.
45351434|NCT00984724|Behavioral|Nicotine Replacement Therapy (NRT)|300 pieces of nicotine gum issued at baseline visit.
46045518|NCT00658918|Drug|Placebo|placebo
46045519|NCT02876081|Drug|Afatinib|to evaluate the efficacy of afatinib, an EGFR TKI, on lung adenocarcinomas, EGFR wild-type, bearing the NTS/NTSR1 complex with a high level of expression
46045520|NCT02631616|Drug|Somatostatin|Monthly injections of Somatostatin
46045521|NCT02876783|Other|Observational - No intervention|
46045522|NCT00661648|Device|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
45351435|NCT04035915|Procedure|Limited driving pressure|Keep driving pressure <15 cmH2O
45351436|NCT04035915|Procedure|Conventional mechanical ventilation strategies|Keep tidalvolume </= 8
45686025|NCT00918892|Genetic|gene expression analysis|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
45686026|NCT00918892|Other|immunohistochemistry staining method|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
45351437|NCT00972400|Genetic|protein analysis|
45351438|NCT00972400|Other|laboratory biomarker analysis|
45351439|NCT00972400|Other|mass spectrometry|
45351440|NCT00972400|Other|questionnaire administration|
45351441|NCT00972400|Procedure|assessment of therapy complications|
45351442|NCT00972400|Procedure|cognitive assessment|
45351443|NCT00972400|Procedure|quality-of-life assessment|
46045523|NCT04306055|Other|Questionnaire with precaution information|Ever blood donors in this group would receive a questionnaire which includes some information about how donors can donate safely and how blood center will protect the blood donors during the epidemic of COVID-19.
45351444|NCT00896961|Drug|EF5|
45351445|NCT00896961|Other|diagnostic laboratory biomarker analysis|
45351446|NCT00896961|Other|pharmacological study|
45351447|NCT00984802|Drug|CMX-2043|Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.
45351448|NCT00984802|Drug|Placebo control|Vehicle solution for IV administration single dose.
45351449|NCT00901563|Drug|Rotigaptide|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
45351450|NCT00901563|Other|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min) or Acetylcholine (5, 10 , 20 micromol/min) . Venous blood sampling via cannula in antecubital fossa.
46045524|NCT04306055|Other|Experimental: Questionnaire without precaution information|Ever blood donors in this group would receive a questionnaire which dose not include the information above.
46045525|NCT04156282|Procedure|knot burial technique|surgical suturing intervention
46045526|NCT04156282|Procedure|classical closure|surgical suturing intervention
46045527|NCT00977106|Drug|tocilizumab [RoActemra/Actemra]|single iv infusion 8 mg/kg
46045528|NCT00977106|Drug|placebo|single iv infusion
46045529|NCT00977106|Drug|tocilizumab [RoActemra/Actemra]|iv infusion 8mg/kg every 4 weeks for 11 months
46045530|NCT00665860|Dietary Supplement|Placebo|Three pills per day for two years
46045531|NCT00665860|Dietary Supplement|Soy isoflavones|Three pills that delivered 80 mg of aglycone isoflavones per day for two years
46045532|NCT00665860|Dietary Supplement|Soy isoflavones|Three pills that delivered 120 mg aglycone isoflavones per day for two years
45842314|NCT01129440|Device|Glass Ionomer Sealant|"Fluoroaluminosilicate glass powder and polyacrylic acid liquid are mixed together in a capsule to form the glass ionomer sealant material.~After toothbrushing and conditioning dental surfaces with 20% polyacrylic acid for 10 seconds, pink-colored fluoride releasing glass ionomer dispensed from a capsule is applied to the occlusal (biting) surface of the molar."
45842315|NCT01130844|Drug|MMX Mesalamine|30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
45351451|NCT00901641|Device|CogniFit Personal Coach®|The program provides individually tailored cognitive training based on the results of a baseline evaluation (the Neuropsychological Examination - CogniFit Personal Coach®).7 The program assigns scores to 17 cognitive abilities that are subsequently trained by means of 21 different tasks.
45842316|NCT01130844|Drug|MMX Mesalamine|60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
45351452|NCT00972556|Drug|Gray Mineral Trioxide Aggregate (GMTA)|Once hemorrhage from the pulp chamber is under control using direct pressure of a sterile cotton pellet, pulp stumps are covered with a MTA paste, obtained by mixing 0.2g GMTA powder with sterile water in a powder to liquid ratio of 3:1 in weight. The GMTA will be then immediately covered with a zinc-oxide eugenol base (IRM) material.
45351453|NCT00972556|Drug|Diluted (20%) Formocresol (DFC)|After the pulp hemostasis is achieved with direct pressure of a sterile cotton pellet, a sterile cotton pellet dampened with 20% DFC will be placed in contact with the pulp for 5 minutes, followed by the immediate placement of a zinc-oxide eugenol base (IRM) material.
46045533|NCT00661882|Other|medical chart review|"Medical information, called protected health information (PHI), which includes demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history will be accessed from the subject's medical record."
45351454|NCT00897039|Other|flow cytometry|
45351455|NCT00897039|Other|immunohistochemistry staining method|
45351456|NCT00984880|Drug|AZD3043|Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)
45686027|NCT00918892|Other|laboratory biomarker analysis|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
45686028|NCT04776226|Drug|Citalopram|Antidepressant use in patients with depression
45686029|NCT02319304|Drug|FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}|see arm description
45686030|NCT02319304|Radiation|Low dose fractionated radiation therapy (LDFRT)|see arm description
45686031|NCT00910312|Device|Ice-Sense|Ice-Sense Cryoprobe
45351457|NCT02540499|Radiation|DIBH VMAT|Radiotherapy delivered in deep inspiration breath-hold with volumetric modulated arc therapy technique.
45842317|NCT01130844|Drug|MMX Mesalamine|100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
45351458|NCT00972634|Other|computer-assisted intervention|symptom assessment
45351459|NCT00972634|Other|questionnaire administration|Symptom assessment
45351460|NCT00972634|Procedure|assessment of therapy complications|Symptom assessment
45351461|NCT00972634|Procedure|quality-of-life assessment|Symptom assessment
45351462|NCT00901719|Drug|Apelin|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial apelin infusions at 0.3, 1.0 and 3.0 nanomol/ml.
45351463|NCT00901719|Drug|Acetylcholine|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 5, 10 and 20 microg/min
45351464|NCT00901719|Drug|Sodium nitroprusside|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 1, 2 and 4 microg/min
45686032|NCT00899782|Other|cytology specimen collection procedure|correlative studies
45686033|NCT00885664|Drug|Truvada (tenofovir/emtricitabine)|Tenofovir/emtricitabine fixed dose combination once daily
45686034|NCT00885664|Drug|Kaletra (lopinavir/ritonavir)|Lopinavir/ritonavir 400/100 mg twice daily
45686035|NCT04775992|Other|gabapentoids|Preemptive analgesia
45842318|NCT01134198|Drug|Mifepristone|Mifepristone 600mg, 3x/wk for 4 weeks
45842319|NCT01134198|Drug|placebo|placebo
45842320|NCT01134276|Procedure|biliary drainage|biliary drainage via PTBD or ERBD/ENBD
45842321|NCT01134900|Other|Pharmacy Dashboard Review and Intervention|Clinical pharmacist reviews patients on dashboard and makes intervention with providing team when necessary.
45842322|NCT01135368|Drug|Lansoprazole|Lansoprazole capsules
45842323|NCT01136226|Drug|Eligard (TM)|Eligard (TM) 22.5 mg administered at baseline and Month 3
45842324|NCT01137006|Biological|IMC-20D7S (Cohort 1A)|"5 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants, then enrollment into Cohort 2A."
45842325|NCT01137006|Biological|IMC-20D7S (Cohort 2A)|"10 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2A, then enrollment into Cohort 3A."
45351465|NCT00901719|Drug|Systemic apelin infusion|Following plethysmography patients will receive systemic infusion of (Pry)Apelin-13 (30, 100 and 300 nmol/min) for 5 mins cardiac output, blood pressure, heart rate and systemic vascular resistance will be measured at 5-min intervals.
45686036|NCT04775758|Behavioral|Self-evaluating questionnaires|Patients are asked to describe their disease (gathering of anamnesis) and to categorize their symptoms according to their strength. Furthermore, patients complete self-evaluating questionnaires: Visual analog scale, Hospital anxiety and depression scale, Pittsburgh sleep quality index, Big five personality traits questionnaire.
45842326|NCT01137006|Biological|IMC-20D7S (Cohort 3A)|"20 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 3A, then enrollment into Cohort 4A."
45351466|NCT00972712|Drug|Bortezomib and Tipifarnib|"Dose level -1: Bortezomib (0.7 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 1: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 2: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (200 mg po BID)~Dose level 3: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 4: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (400 mg po BID)~Schema B~Dose level 1: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 2: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (400 mg po BID)"
45351467|NCT00984958|Device|Bulkamid|injection of Bulkamid in the urethra
45351468|NCT00984958|Device|Bulkamid expectation|expectance
45351469|NCT00897273|Genetic|comparative genomic hybridization|
45351470|NCT00897273|Genetic|gene expression analysis|
45842327|NCT01137006|Biological|IMC-20D7S (Cohort 4A)|"30 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle."
46045534|NCT00661882|Other|questionnaire administration|Provide or complete personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, age of death) will be recorded. This information will be collected by whichever method they prefer; completing the questionnaires on hardcopy (to then be entered into the PCCR by a data manager) or by logging on to the PCCR website to complete the questionnaires by obtaining a user id and password to enter their information directly into the PCCR. Study participants who are in the EDRN project are required to complete the questionnaires on hardcopy (to then be entered into the PCCR by a data manager).
45686037|NCT04775758|Behavioral|iMotions analysis platform|While patients' anamnesis and questionnaire indexes are being gathered, iMotions software will gather facial expression analysis, galvanic skin response and heart rate data which will be compared with self-evaluating questionnaires.
45686038|NCT04775602|Drug|18F-PSMA|18F-PSMA will be injected intravenously at a dosage of 200-250 megabecquerel (MBq) prior to perform Image acquisition (Topogram, CT, PET)
45842328|NCT01137006|Biological|IMC-20D7S (Cohort 1B)|"10 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants in Cohort 1B, then enrollment into Cohort 2B."
45842329|NCT01137006|Biological|IMC-20D7S (Cohort 2B)|"20 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2B, then enrollment into Cohort 3B."
45842330|NCT01137006|Biological|IMC-20D7S (Cohort 3B)|"30 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle."
45842331|NCT01137396|Drug|Modafinil|Modafinil 400mg PO QDaily following up-titration for ~8weeks
45842332|NCT01137396|Behavioral|Cognitive Behavioral Therapy|Once weekly cognitive behavioral therapy for cocaine dependence
45842333|NCT01138098|Biological|Engerix™-B|Intramuscular, single dose
45351471|NCT00897273|Other|study of socioeconomic and demographic variables|
45351472|NCT00897273|Procedure|evaluation of cancer risk factors|
45351473|NCT00897273|Procedure|study of high risk factors|
45351474|NCT04007302|Other|measurement of bilateral activity of the prefrontal cortex by a NIRS system (near infrared spectroscopy)|measurement of the cerebral oxygenation response by the use of the Near Infrared Spectroscopy (NIRS) method
45351475|NCT04007302|Other|completion of questionnaires|igroup presence questionnaire (IPQ), Dallas Pain Questionnaire (DRAD), Fear-Avoidance Beliefs (FABQ) and Quebec Back Lumbago Scale
45351476|NCT04007302|Other|completion of questionnaires for pain|analogical visual and numerical scale and Borg scale
45382164|NCT05281471|Drug|Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin|Administered according to local practice
46045535|NCT00661882|Other|study of socioeconomic and demographic variables|Share the information they provided with the PCCR research collaborators. This national group has formed the PCCR and is dedicated to pooling their efforts against pancreatic cancer.
46045536|NCT00661882|Procedure|biopsy|Release a portion of pancreatic tissue, tumor tissue and/or metastatic pancreatic cancer tissue and/or paraffin embedded tissue that has already been collected and saved from their previous surgery or biopsy for storage in the UNMC Solid Tumor Bank for future studies done here or at collaborating institutions. All studies will be proposed in future IRB submissions.
45686039|NCT04784104|Drug|Bupivacaine HCl 0.5% Injectable Solution|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
45686040|NCT04784104|Drug|Prilocaine HCl 2% Injectable solution|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
45686041|NCT04784104|Drug|Adrenaline amp. 0.5 mg|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
45686042|NCT04784104|Procedure|Ultrasound guided supraclavicular block with coronal oblique method|The blocks will be performed by an experienced anesthesiologist with a USG guidence.
45686043|NCT04784104|Procedure|Ultrasound guided lateral sagittal infraclavicular block|The blocks will be performed by an experienced anesthesiologist with USG guidence.
45686044|NCT00880594|Drug|Desipramine|"Desipramine 25 mg/day administered in the evening. Dosing may be increased dependent upon side-effects and clinical response to a maximum of 100 mg/day. Absent significant side-effects, all patients are increased at the one week visit to 50 mg/day at bedtime if they have not achieved a report of Adequate relief. Thereafter, up to week 4, the daily desipramine dose may be increased weekly by 25 mg up to the 100 mg/d maximum."
45686045|NCT04783870|Drug|Dapagliflozin|Dapagliflozin 10 mg PO QD
45686046|NCT04783870|Drug|Placebo|Placebo
45686047|NCT00878254|Biological|G-CSF|Granulocyte-colony stimulating factor (G-CSF) 480 mcg subcutaneously (SQ) starting on Day 13 of Cycles 1 and 3; and Day 7 of Cycles 2 and 4, per study protocol.
45351477|NCT00901797|Procedure|Arthroscopic Bankart repair|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
45382165|NCT05281471|Drug|Bevacizumab (or biosimilar)|Administered according to local practice
45842334|NCT01139190|Drug|PL3100|Oral administration
45842335|NCT01139190|Drug|Naproxen|Oral administration
46045537|NCT00659074|Drug|Ondansetron|ODT, single-dose, fasting
46045538|NCT00659074|Drug|Zofran|ODT, single-dose, fasting
46045539|NCT02632318|Device|Light|30 minutes of dawn simulation
46045540|NCT00665938|Other|Infant formula|"Arm 1. extensively hydrolyzed infant formula without probiotics (Nutramigen LIPIL)~Arm 2. partially hydrolyzed infant formula with probiotics~Arm 3. extensively hydrolyzed infant formula with probiotics"
46045541|NCT01077713|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
46045542|NCT01077713|Drug|cisplatin|60mg/m2 on day 1 of each 3 week cycle
46045543|NCT01077713|Drug|gemcitabine|1200mg/m2 on days 1-8 of each 3 week cycle
46045544|NCT01077713|Drug|gemcitabine|1000mg/m2 on days 1-8 of each 3 week cycle
46045545|NCT04290234|Other|fMRI assessment of cognitive and reactive fear|An fMRI paradigm will be used to probe how childhood maltreatment may modulate the defensive survival circuitry that facilitates escape decisions when subjects encounter fast- or slow-attacking threats.
45382166|NCT05278624|Drug|Roflumilast Cream|Topical Cream
45382167|NCT05275010|Drug|Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC)|A single dose of PH FDC SC (600 mg pertuzumab/600 mg trastuzumab) will be administered by a healthcare professional subcutaneously (SC) into the anterior thigh, using either a handheld syringe with hypodermic needle (Arm 1) or the on-body delivery system (Arm 2).
45382168|NCT05275010|Device|Handheld Syringe with Hypodermic Needle|A single 10-mL dose of PH FDC SC will be administered as a subcutaneous (SC) injection using a handheld manual syringe.
45382169|NCT05275010|Device|On-Body Delivery System|A single 10-mL dose of PH FDC SC will be administered as a subcutaneous (SC) injection using the on-body delivery system.
45476949|NCT02514928|Procedure|standard pancreatoduodenectomy|Standard pancreatoduodenectomy with regional lymph nodes includes group 5,6,8a,12b,12c,13,14a,14b,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
45686048|NCT00878254|Drug|Rituximab|Rituximab 375 mg/m^2 intravenously (IV) on Day 1 for 4 Cycles, per study protocol. For study participants achieving complete remission, during maintenance therapy every 6 months for up to three years, per study protocol.
45842336|NCT01139814|Device|Amigo catheter robot|The Amigo Catheter System is intended to facilitate manipulation, positioning and control of a Diagnostic Catheter.
45842337|NCT01140360|Drug|Gleevec|Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA > 1.8 m2 or 55 mg/m2 twice daily for patients with BSA < 1.8 m2. For patients with a BSA > 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA < 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
46045546|NCT00666016|Drug|TRO19622|TRO19622 500 mg once a day before noon meal during 6 weeks
46045547|NCT00813709|Drug|RNF|Single dose of RNF will be administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
46045548|NCT00813709|Drug|RNF|Single dose of RNF will be administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
46045549|NCT00813709|Drug|RNF|Participants who were initially randomized in Study 27025 (REFLEX) to the placebo treatment group will be switched to single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
46045550|NCT00813709|Drug|Placebo|Single dose matching placebo will be administered subcutaneously twice weekly. Placebo is supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 milliliter (mL).
46045551|NCT04160884|Procedure|Indocyanine Green Injection through Peripheral Vein|After ligation of the segmental pulmonary artery supplying the targeted segment, indocyanine is injected intravenously at a specific concentration intraoperatively.
46045552|NCT02866266|Other|Retrospective database review|
46045553|NCT02865876|Procedure|Accelerated Corneal Cross-linking|All participants in this group receiving conventional therapy (moxifloxacin 0,5% for bacterial keratitis or natamycin for mycotic keratitis) plus accelerated cross-linking (Avedro Inc., Waltham, USA) under topical anesthesia using 0.1% riboflavin (Vibex, Avedro Inc, Waltham, USA) for 10 minutes and irradiation 30 mW/cm2 during 3 minutes.
46045554|NCT04158622|Procedure|PnR + laser/cryotherapy|Pneumatic retinopexy plus laser/cryotherapy
46045555|NCT04158622|Procedure|PPV + laser/cryotherapy|Pars plana vitrectomy plus laser/cryotherapy
46045556|NCT02866110|Behavioral|Neurofeedback|The Blood Oxygenation Level Dependent (BOLD) signal from the amygdala, recorded with functional magnetic resonance imaging, is utilized as a feedback signal to patients.
45351478|NCT00901797|Procedure|ABR+ARIC|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Through additional anterior superior portal a suture is passed inferior and adjacent to the SSP and through the superior portion of the Sub Scapularis tendon while the arm in 30 degree of external rotation. Tightening the suture on top of the capsule underneath the deltoid. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
45351479|NCT02539641|Radiation|Gastric emptying scintigraphy|Scintigraphy is performed to evaluate gastric emptying after eating a pancake labeled by 20 megabecquerel (MBq) Technetium-99m-Albumin (TC-99m-LyoMAA)
45351480|NCT02539641|Other|Determination of gut hormones|Gut hormone levels will be determined after eating a standard meal in the RYGB and SG groups.
45351481|NCT00544882|Drug|DR-1021|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus seven 10 μg EE tablets.
45351482|NCT00544882|Drug|Mircette®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
45686049|NCT00878254|Drug|Cyclophosphamide|Cyclophosphamide 800 mg/m^2 IV on Day 1 and 200 mg/m^2 IV on Days 2 through 5 of Cycles 1 and 3, per study protocol.
45686050|NCT00878254|Drug|Cytarabine|Cytarabine 2 grams/m^2 IV on Days 1 and 2 of Cycles 2 and 4, per study protocol.
45686051|NCT00878254|Drug|Doxorubicin|Doxorubicin 45 mg/m^2 IV bolus Day 1 of Cycles 1 and 3, per study protocol.
45686052|NCT00878254|Drug|Etoposide|Etoposide 60 mg/m^2 IV on Days 1 through 5 of Cycles 2 and 4, per study protocol.
46045557|NCT02866110|Device|MRI|Echo-planar Imaging of brain BOLD signal
46045558|NCT01077323|Drug|exenatide|subcutaneous injection, dosing according to normal clinical practice
45842338|NCT01141374|Other|auriculotherapy by needles|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
45842339|NCT01141374|Other|auriculotherapy by seeds|We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
45842340|NCT01141608|Other|Vigorous Intensity High Dose Exercise|Participants randomized to the exercise condition will begin with supervised exercise sessions 3 times per week during the 12-week acute phase of the study. Supervised sessions will be conducted as one-on-one (i.e., individual) sessions. Vigorous intensity high dose exercise will be prescribed at a dose of 12 kcal/kg/week (KKW), with intensity ranging from 70-85% maximal heart rate.
45842341|NCT01141608|Other|Health Education Intervention|Participants randomized to the health education condition will also begin with visits 3 times per week during the 12-week acute phase. The health education sessions will be conducted as one-on-one (i.e., individual) sessions. Health education sessions will consist of information on health-related topics distributed via methods such as didactics, audio and video materials, and written materials.
45842342|NCT01142310|Drug|Lamotrigine|Lamotrigine will be initiated at 25 mg/day and upwardly titrated to a dose of 400 mg/day over 10 weeks.
45842343|NCT01142310|Drug|Placebo|
46045559|NCT01077323|Drug|Other antidiabetic therapies|Includes metformin, thiazolidinediones, insulins, sulfonylureas, non-sulfonylurea secretagogues, sitagliptin, and alpha-glucosidase inhibitors; In all cases, dosing according to normal clinical practice
46045560|NCT01077323|Other|No diabetes therapy|Subjects not diagnosed with diabetes
45351483|NCT00544882|Drug|Kariva®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
46045561|NCT00662116|Drug|alagebrium|200 mg (two 100 mg tablets) two times daily for 24 weeks
45351484|NCT04035603|Drug|D-Cycloserine|50 mg d-cycloserine given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
46045562|NCT00662116|Drug|placebo|placebo tablets - two tablets taken twice daily
45382170|NCT05274269|Drug|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablets for oral administration.
45686053|NCT00878254|Drug|Ifosfamide|Ifosfamide 1.5 grams/m^2 IV on Days 1 through 5 of Cycles 2 and 4, per study protocol.
45686054|NCT00878254|Drug|Leucovorin|Leucovorin: 100 mg/m^2 IV beginning 36 (+/-4) hours after start of Methotrexate infusion, and then 10 mg/m^2 at 6 hour (+/- 30 min) intervals until Methotrexate level is < 0.1 µmol/L during Cycles 1 and 3 per study protocol.
45686055|NCT00878254|Drug|Mesna|Mesna 360 mg/m^2 IV on Days 1 through 5 of Cycles 2 and 4, per study protocol.
45382171|NCT05274269|Drug|IVA|Tablet for oral administration.
45686056|NCT00878254|Drug|Methotrexate|Methotrexate 1,200 mg/m^2 in 250 mL D5W IV over 1 hour, followed by Methotrexate 3,000 mg/m^2 in 1,000 mL D5W by continuous infusion over 23 (+/-2) hours on Day 10 of Cycles 1 and 3, per study protocol.
45686057|NCT00878254|Drug|Vincristine|Vincristine 1.5 mg/m^2 IV push (maximum of 2 mg) on Days 1 and 8 of Cycles 1 and 3, per study protocol.
45686058|NCT01896310|Device|probe-based confocal laser endomicroscopy|all patients will receive pCLE examination
45686059|NCT04783636|Drug|leuprorelin acetate 3.75mg|PT105, PT105R
45686060|NCT04784026|Other|Gait assessment (single)|The single walk will be evaluated with a 10-meter walking test and a G-Walk portable device.
45842344|NCT01143636|Device|Transcranial Direct Current Stimulation|Chronic pain subjects will be randomized to receive either active or sham stimulation for the duration of the trial. The subject will receive 10 consecutive sessions at an intensity of 2mA with each session lasting 20 minutes. If the subject receives active stimulation the current will be applied for the full 20 minutes, while in the sham group current will only be applied for 30 seconds. In the healthy cohort, subjects will receive one session of active stimulation and one session of sham stimulation. The parameters will be the same as the pain subjects, at an intensity of 2mA for 20 minutes.
45476950|NCT05221736|Procedure|Ultrasound-Guided Ethanol Sclerotherapy (UGES)|Comparison between Ultrasound-Guided Ethanol Sclerotherapy (UGES) & surgical excision in management of warthin tumor of parotid gland.
45686061|NCT04784026|Other|Dual task gait assessment (motor+motor)|The dual task gait, 10-meter walking test and a motor (carrying a full water glass) will be combined with the task and evaluated with the G-Walk portable device.
46045563|NCT03870438|Drug|Lamivudine Oral Solution|In the intervention arm, HIV-1 negative children with HIV-1 positive mothers who have an HIV-1 viral load ≥ 1000 copies/ml will receive lamivudine syrup orally (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight <8 kg; and 50 mg twice a day if weight >8 kg). The intervention will last a maximum of 10 months (until the baby is 12 months old or until the confirmed end of breastfeeding). Breastfeeding will be considered to be ceased if the mother confirms she is no longer breastfeeding for 2 consecutive monthly visits
46045564|NCT05758831|Drug|Perfusion of treatment Rituximab|Perfusion of treatment (Mabthera®, Truxima®, Rixathon®, Ruxience®)
46045565|NCT05758831|Drug|Perfusion of treatment Ocrelizumab|Perfusion of treatment (Ocrevus®)
46045566|NCT04287894|Drug|Durvalumab|The IP will be given to the patient as long as there is a clinical benefit, in invertigator's judgment. Per day, 1500 mg
45686062|NCT04784026|Other|Dual tak gait assessment (motor+cognitive)|The dual task gait will be combined with a 10-meter walking test and a cognitive (1-back test) task and evaluated with the G-Walk portable device.
45686063|NCT00820846|Biological|pGA2/JS7 DNA vaccine|1 mL of pGA2/JS7 DNA vaccine
45686064|NCT00820846|Biological|Placebo|1 mL of sodium chloride for injection
45686065|NCT00820846|Biological|MVA/HIV62 vaccine|1 mL of recombinant modified vaccinia Ankara/HIV clade B gag-pol-env (MVA/HIV62)
45686066|NCT03371368|Procedure|Roux-en-Y Gastric Bypass (RYGBP)|This is a standard RYGBP procedure that would be performed clinically and is not research-specific.
45686067|NCT03371368|Procedure|Sleeve Gastrectomy (SG)|This is a standard SG procedure that would be performed clinically and is not research-specific.
45686068|NCT03371368|Behavioral|Very Low Calorie Diet (VLCD)|Weight loss with calorie restricted liquid diet. Subjects will be placed on a 800 kcal/day diet with a meal replacement (Optifast) provided by the investigator for 12 weeks. Then, transitioning to a higher calorie diet intake up to a year. Subjects will be closely monitored by study dietitian
45686069|NCT03364348|Drug|Utomilumab|Given IV
45686070|NCT03364348|Drug|Trastuzumab|Given IV
45686071|NCT03364348|Drug|Ado-Trastuzumab Emtansine|Given IV
45686072|NCT04775290|Behavioral|Yoga lessons|2 weekly yoga classes during the 5 weeks of radiotherapy
45842345|NCT01143792|Behavioral|Community Reinforcement Approach (CRA) + HIV prevention|12 sessions of the CRA and 2 sessions of HIV prevention.
46045567|NCT04287894|Drug|Tremelimumab|Per day 75mg
46045568|NCT04287894|Drug|Pemetrexed|500 mg/m2 on day 1 every 3 weeks for 2 cycles
46045569|NCT04287894|Drug|Cisplatin|6 mg / m2 on day 1 every 3 weeks for 2 cycles
46045570|NCT04287894|Radiation|chemo radiotherapy|Once-daily fraction, 2 Gy per fraction. Total dose is 60 Gy.
45351485|NCT04035603|Drug|Placebo oral tablet|matching 50 mg identical placebo given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
45382172|NCT05274269|Other|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration.
45382173|NCT05274269|Other|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
45686073|NCT04782622|Drug|Apatinib+Camrelizumab|Apatinib 250mg po qd+Camrelizumab 200mg ivdrip q14d
45686074|NCT04775212|Drug|Desﬂurane|compare effects of inhaled anaesthetic desflurane and sevoflurane on liver functions.
45686075|NCT04775212|Drug|Sevoflurane|Sevoflurane
45686076|NCT03355066|Drug|SM08502|SM08502 tablets to be administered orally.
45686077|NCT04774900|Procedure|Administration of oxygen|Administration of high-flow oxygen via face mask to a high fidelity mannequin.
45686078|NCT04774900|Procedure|Administration of drug in a nebulizer|Administration of bronchodilator via nebulizer mask to a high fidelity mannequin.
46045571|NCT04287894|Procedure|Resection|After CIT-CRT
45476951|NCT03665909|Other|Remote activity monitoring system|The home-based sensor technology of eNeighbor relies on multiple, non-invasive and safe remote monitors (up to 6 sensors) that can alert family caregivers and/or health professionals to potentially negative situations that lead to adverse outcomes (e.g., wandering, falls, incomplete activity of daily living tasks). The technology platform of eNeighbor relies on wireless infrastructure that allows for remote monitoring via alerts that are communicated to the family caregiver's or nurse care manager's personal computers or handheld devices. The Alerts that are generated from the sensors detected abnormal motion or activity are sent to the family caregiver as well as a nurse care manager that monitors the real-time information generated by the eNeighbor sensors.
46045572|NCT04287582|Other|Electromyographic device|An 8-channel surface EMG system (DELSYS Trigno Wireless System) will be used to measure signals from muscles during stair climbing activity by surface electromyography measurements.Surface EMG measurements will be carried out during stair climbing activity without any intervention in the body. Surface EMG electrodes will be placed bilaterally in the vastus lateralis, biceps femoris, tibialis anterior and gastrocnemius medialis muscles.
46045573|NCT02863848|Dietary Supplement|OraftiR inulin-type fructans|
46045574|NCT02863848|Dietary Supplement|Placebo|maltodextrin
45842346|NCT01143792|Behavioral|Case Management + HIV Prevention|12 sessions of case management and 2 sessions of HIV prevention.
45842347|NCT01143792|Behavioral|Motivational Enhancement Therapy (MET) + HIV prevention|2 sessions of MET and 2 sessions of HIV prevention.
46045575|NCT04287426|Drug|Rocuronium 0.6 mg/kg|Rocuronium 0.6 mg/kg is compared to patients with 2 µg/kg remifentanil
45351486|NCT04035603|Behavioral|Open Phase CBT that preceeds the randomization phase|Four sessions of weekly individual cognitive-behavior therapy (CBT: a form of psychotherapy that treats problems by helping people modify thoughts, behaviors, and emotions; in this case, for the goal of smoking cessation). Session topics include educational (e.g., health risks of smoking, effectiveness of different treatment approaches), motivational enhancement (e.g., identifying personally relevant benefits of quitting, and costs of continuing to smoke), and cognitive-behavioral elements (e.g., identifying smoking triggers, developing coping strategies for these triggers, planning for high risk situations, relapse prevention).
45351487|NCT04035603|Drug|Open phase smoking cessation pharmacotherapy that proceeds the randomization phase|Initiating 2 weeks prior to quit date and continuing for 8 weeks after quit date, choice of one of three pharmacological smoking cessation aids: Nicotine Replacement Therapy (nicotine patch), Varenicline, or Bupropion.
45476952|NCT02510560|Drug|NTRA-2112|
45686079|NCT04774900|Procedure|Securing intravenous line|Securing an intravenous line at the forearm of high fidelity mannequin.
45686080|NCT04774900|Procedure|Administration of IV drug|Administration of bronchodilator via IV line to a high fidelity mannequin.
45686081|NCT04774900|Procedure|Needle decompression of tension pneumothorax|Needle decompression of tension pneumothorax on a high fidelity mannequin.
45686082|NCT04774978|Device|TTE|Transthoracic echocardiography
45686083|NCT04774822|Procedure|Color Fundus Photography|Stereoscopic Fundus photography
45686084|NCT04774822|Drug|Mydriatics Agent|Eye dilating agent
45686085|NCT04774822|Procedure|Optical Coherence Tomography (OCT)|Optical Tomographic imaging of retina
45686086|NCT04782934|Device|The YANG SENSOR is an active implantable device, for Real Time Continuous Glucose, Lactate and Ketone Measurement|The YANG SENSOR is an active implantable device, that is intended to be implanted in the subcutaneous abdominal tissue, approximately 10mm below the skin. The SENSOR is battery powered. The battery is wirelessly recharged through the skin by the YANGEXD, using a charging coil ('Donut') applied to the skin with an adhesive patch at the level of the SENSOR. The 'Donut' also receives data from the sensor.
45686087|NCT04782388|Drug|Alprazolam|Study participants will receive Staccato alprazolam at prespecified time-point.
45686088|NCT04782388|Other|Placebo|Study participants will receive Staccato placebo at prespecified time-point.
45686089|NCT04782076|Drug|Dabigatran|Administered orally.
45686090|NCT04782076|Drug|Selpercatinib|Administered orally.
46045576|NCT04287426|Drug|Remifentanil 2 µg/kg|Rocuronium 0.6 mg/kg is compared to patients with 2 µg/kg remifentanil
46045577|NCT05757505|Device|Intracranial Stent (Tonbridge)|Endovascular treatment with Intracranial Stent (Tonbridge).
46045578|NCT05757505|Device|Wingspan Stent System (Stryker Neurovascular)|Endovascular treatment with Wingspan Stent System (Stryker Neurovascular).
45351488|NCT00606801|Drug|Galantamine|Galantamine 8 mg/day
45351489|NCT00606801|Drug|placebo|sugar pill
45476953|NCT02510560|Drug|Placebo|
45476954|NCT05361252|Procedure|SVV-guided fluid management|fluid will be guided by value of stroke volume variation
45476955|NCT05651594|Procedure|Biopsy|Undergo tissue collection
46045579|NCT04287504|Diagnostic Test|SavvyCheck Vaginal Yeast Test|Point-of-care test for the detection of vaginal candidosis
46045580|NCT04287504|Diagnostic Test|OSOM BVBLUE Test|Point-of-care test for the detection of bacterial vaginosis
45351490|NCT00972790|Procedure|Bilateral Scalp Nerve Blocks|Scalp nerve blocks will be performed bilaterally at the end of the surgery under general anaesthesia and before removal of the head holder. Patients will receive scalp nerve blocks with a total of 20 ml of 0.5% bupivacaine + epinephrine 1:200,000 or 20 ml of saline + epinephrine 1:200,000. Solution volume is as follows: 2ml each bilaterally for supraorbital and supratrochlear nerves; 3 ml for the auriculotemporal nerves; 2 ml for the postauricular branches of the greater auricular nerves and for the greater, lesser, and third occipital nerves 3 ml of solution will be infiltrated along the superior nuchal line, approximately halfway between the occipital protuberance and the mastoid process.
45842348|NCT01143870|Other|"Diabetes Report Card"|"Enrolled participants will receive an individualized diabetes report card which depicts their current level of diabetes control in one of three ways--hemoglobin A1C, face, or letter grade."
45842349|NCT01144026|Biological|TUTI-16 (0.2mg)|Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
45842350|NCT01144026|Biological|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
45842351|NCT01144338|Drug|Exenatide Once Weekly|Subcutaneous injection, 2 mg, administered once weekly.
45842352|NCT01144338|Drug|Placebo|Subcutaneous injection, matching volume of placebo, administered once weekly.
45842353|NCT01144494|Drug|Brimonidine|One drop of brimonidine in each eye three times a day for six weeks.
45842354|NCT01144494|Drug|Artificial tears|Lubricating drops added three times a day for six weeks
45351491|NCT04007458|Behavioral|Letter|MaineGeneral Radiology will generate a reminder letter about their need for an annual low dose CT scan to the subjects in this arm.
45351492|NCT04007458|Behavioral|Community Health Worker Phone Call|Patients will receive a phone call from community health worker, offering to help them overcome barriers to repeat annual screening and offering to help them schedule their screening.
45351493|NCT00897351|Genetic|mutation analysis|
45351494|NCT00897351|Genetic|polymorphism analysis|
45842355|NCT01146600|Drug|Clarithromycin followed by placebo|Clarithromycin 500 mg po bid for two weeks, then one week with no medication, then matched placebo po bid for two weeks.
46045581|NCT04047576|Drug|Sirolimus|The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects.For experimental group, if a patient is assessed as treatment failure (TS), the patient should be withdrawn from the study and receive rescue treatment. Whereas, a patient would be transferred to the control group if he/ she cann't stand the side effects of sirolimus but not serious adverse event (SAE).
46045582|NCT04047576|Drug|Corticosteroid|The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects. For active comparator group, if a patient is assessed as treatment failure (TF), the patient should be withdrawn from the study and receive rescue treatment.
45351495|NCT00897351|Genetic|protein expression analysis|
45351496|NCT00897351|Other|immunohistochemistry staining method|
45351497|NCT00897351|Other|laboratory biomarker analysis|
45351498|NCT04008862|Behavioral|Partnership-based nursing practice|Provided by clinical nurse specialists (n=2) and specialized nurses (n=3): i) Partnership-based theoretical nursing practice framework: Family involvement, living with symptoms and access to healthcare -primary goal of enhancement of the health experience. Key question: What are your main concerns about the health of the person with the lung disease? Followed by conversations: a) Existence of lung disease and symptoms that the patient has. b) Nature of disease, its management, quitting smoking, use of inhaler medications, utilization of health care, negative feelings and issues. Skills and motivation to undertake activities to maintain and improve well-being, skills in communication with family, relatives and health professionals. ii) Empirical knowledge about the nature of COPD, symptom management and palliative care and the GOLD clinical guidelines. iii) Patients are seen over an undefined time period in the out-patient clinic or at home depending on needs and capabilities.
45351499|NCT00901875|Drug|Buprenorphine + naloxone (Suboxone)|Sublingual tablets
45351500|NCT00901875|Drug|Buprenorphine + naloxone (Suboxone)|
45476956|NCT05651594|Procedure|Biospecimen Collection|Undergo collection of blood samples
45476957|NCT05651594|Procedure|Computed Tomography|Undergo CT scans
45476958|NCT05651594|Drug|Fluorouracil|Given IV
45476959|NCT05651594|Drug|Leucovorin|Given IV
45476960|NCT05651594|Drug|Oxaliplatin|Given IV
45686091|NCT04782310|Drug|Pregabalin|Pregabalin 75mg two hour preoperatively, 12 hours postoperative and will continue for one week twice per day.
45686092|NCT04782310|Drug|Duloxetine|Duloxetine 30mg two hour preoperatively …will be continued for one week once per day after breakfast .
45686093|NCT04781998|Drug|liraglutide 3 mg (Saxenda®) once-daily|Liraglutide 3 mg (Saxenda®) 6 mg/ml, 3 ml pre-filled pen-injector. The injection is administered subcutaneously. The initial daily dose will be 0.6 mg liraglutide (Saxenda®) for one week. If tolerated patients increase the dose by +0.6 mg each week until the full maintenance of 3 mg is reached (week 1: 0.6 mg, week 2: 1.2 mg, week 3: 1.8 mg, week 4: 2.4 mg, week 5-26: 3.0 mg. If necessary, a longer titration period is accepted). If the lowest tolerated dose is less than 1.8 mg of liraglutide (Saxenda®) once-daily after 12 weeks from inclusion, the patient will be excluded from the study.
45686094|NCT04781764|Procedure|surgery|surgery
45686095|NCT04774432|Other|GM-CSF group|GM-CSF added to CAPA and maturation medium
45686096|NCT04774432|Other|Control group|GM-CSF will not be added to CAPA and maturation medium
45476961|NCT05651594|Biological|Pembrolizumab|Given IV
45476962|NCT05651594|Drug|Propranolol Hydrochloride|Given PO
45476963|NCT05651594|Other|Questionnaire Administration|Perceived Stress Scale
45476964|NCT01204619|Behavioral|Intensive training group|an extra structured patient centric training program on PD technique and diet according to the developed training curriculum
45842356|NCT01146600|Drug|Placebo then Clarithromycin|Matched placebo po bid for two weeks, then one week with no intervention, then clarithromycin 500 mg po bid for two weeks
45476965|NCT03636750|Drug|HB002.1T|HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy
45476966|NCT01982357|Device|Laser Speckle Imaging and Diffuse Optical Spectroscopy|Laser Speckle Imaging and Diffuse Optical Spectroscopy
45476967|NCT02510404|Biological|mCTLs|The investigators have elected to limit this phase I study to PIDD patients with active viral infections unable to be controlled with standard pharmacotherapy, who are therefore likely to benefit from mCTLs treatment. This trial will be performed as dose-escalation study. Patients will be evaluated for matched lines from a bank of third-party mCTLs, derived from CMV seropositive donors. These lines will have been used clinically in prior clinical trials, with safety demonstrated in the post-HSCT setting.
45476968|NCT01314456|Device|NaviGo|Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
45476969|NCT05218226|Drug|Avatrombopag|The subjects will initiate treatment with 60 mg/d Avatrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 60 mg daily. Subjects whose platelet count ≤100×109/L，the Avatrombopag dose will maintain. If platelet count >100×109/L for 2 weeks, the subjects need to reduce the dose of Avatrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Avatrombopag to 20mg once every other day or lower frequency during the treatment period, Avatrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Avatrombopag if the platelet is greater than 50×109/L.
45842357|NCT01146834|Drug|bortezomib (Velcade)|1.3 mg/m2 IVP on days 1, 4, 8 and 11
45842358|NCT01146834|Drug|cyclophosphamide|2.0 g/m2 (day 4 for Arm A and day 1 for Arm C)
45476970|NCT05282537|Behavioral|In person academic activities|All participants will perform academic activities in person from March to December, 2022
45476971|NCT02514850|Drug|Biochaperone Combo|Injection of BioChaperone Combo
45842359|NCT01146834|Drug|G-CSF|given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C and start on Day 1 for Arm D)
45842360|NCT01146834|Drug|Plerixafor|plerixafor is given on day 4, approximately 11 hours prior to stem cell collection attempt on Day 5, plerixafor daily until stem cell collection is complete (Arm D), start on Day 12, approximately 11 hours prior to stem cell collection attempt and plerixafor daily until collection if complete (Arm E)
45842361|NCT01147302|Biological|Placebo|
45842362|NCT01147302|Biological|C1 Esterase Inhibitor (Human)|
45476972|NCT02514850|Drug|Humalog Mix25|Injection of Humalog Mix25
45842363|NCT01147380|Biological|Liver NK cell inoculation|Liver transplant recipients will receive once liver NK cell inoculation several days after liver transplantation.
45842364|NCT01149876|Other|Nu Skin Product|Thin layer of Nu Skin product applied to face.
45842365|NCT01149876|Other|Cosmetic instrument|Cosmetic instrument with topical Nu Skin product. Thin layer of Nu Skin product applied to face followed by galvanic, used for 3 minutes.
45476973|NCT02514850|Drug|Humalog|Injection of Humalog
45476974|NCT02514850|Drug|Lantus|Injection of Lantus
45476975|NCT02514850|Drug|Placebo|Injection of saline 0.9% solution
45476976|NCT05217992|Other|Genetic assessment (hemophilia testing)|Determination of carrier ship of hemophilia with molecular tests
45476977|NCT04454411|Drug|Brixadi|Extended release injectable Buprenorphine
45476978|NCT04454411|Drug|Vivitrol|Extended release injectable Naltrexone
45476979|NCT03178266|Device|Knee Arthroplasty|Standard Knee Arthroplasty will be performed on study subjects. The closure method will be studied at 3 weeks and 6 weeks and patients will be asked about satisfaction with the closure method assigned.
45842366|NCT01149876|Drug|Tretinoin cream 0.05|Thin layer of tretinoin applied to face.
45842367|NCT01149876|Other|CeraVe moisturizer|Thin layer of CeraVe applied to face.
45842368|NCT01150500|Device|MDT-4107 Zotarolimus-Eluting Coronary Stent|
45842369|NCT01151046|Drug|MM-121|MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week
45842370|NCT01151046|Drug|Placebo|Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day
45842371|NCT01151046|Drug|Exemestane|Exemestane (25 mg) administered orally once per day
45842372|NCT01151436|Device|hyaluronic acid dermal fillers|1 injection per indication and 1 touch-up injection if necessary
45842373|NCT01152294|Behavioral|DVD & Booklet called: Managing Menopause|DVD and booklet that provides information about treatment choices for menopause symptoms. Complete title: Managing Menopause: Choosing treatments for menopause symptoms
45842374|NCT01153620|Drug|Lavasept 0.04%|"Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Lavasept® 0.04% 50 ml 50ml or as much needed to completely saturate the compress.~Treatment Duration 60 minutes"
46045583|NCT00976950|Drug|Tipranavir|
46045584|NCT00976950|Drug|ritonavir|low-dose
46045585|NCT04290078|Device|Kaia Back Pain Study App|Kaia Back Pain is an integrated solution for self-management of low-back pain that digitizes multidisciplinary rehabilitation into a smartphone application.
46045586|NCT04290078|Other|Usual Care|Participants in the control arm will be provided with online links to educational materials about home exercises and pain management and asked to continue their usual care. On-line resources will include links to Web MD, the National Library of Medicine (Medline), and OnHealth
45351501|NCT00972868|Device|A unidirectional face mask (Modified 'Respironics PerformaTrak' Mask)|The regular face mask will be replaced with the study mask and patients will receive NPPV via the study mask for 30 min. The study mask insures a unidirectional breathing pattern, in through the nose and out through the mouth or in through the mouth and out through the nose. The sequence of these two breathing patterns with opposite flow direction will be chosen randomly. Each will be applied for 30 min with data collected during and at the end of the period.
45476980|NCT03837197|Device|Kidney-Hypothermic oxygenated|"Kidney perfusion will be performed through the renal artery at 25-30 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (20 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 2 hours for kidneys."
45476981|NCT03837197|Device|Liver-Hypothermic oxygenated|"Liver perfusion will be performed through the portal vein at a 5 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 1 hour for livers."
45476982|NCT05553028|Procedure|Computerised tomography|Screws placement will be evaluated for each patient by a CT scan on D1 post-intervention. The evaluation of the placement of the screws (reading of the CT images) will be carried out by 2 radiologists independent of the surgical team, blinded to the technique used for the placement of the screws (robot-assisted/conventional surgery). In case of disagreement between the 2 evaluators, a 3rd evaluator will be requested.
45686097|NCT04774588|Other|VSI streamer and Microsoft Hololens 2 classed as a Class III device by Health Canada.|1.1 Description of VSI streamer device and software The VSI Streamer is a box that can be connected to ultrasound, endoscope, microscope, laparoscope and other devices via HDMI connection. The view of the imaging devices, which is conventionally displayed on a monitor, is transmitted wirelessly and in real time to the Mixed Reality HoloLens 2 (Microsoft Inc.) and appears as a virtual monitor that can be flexibly moved and positioned in space. Since this is Mixed Reality, the real environment remains visible. If required, several virtual monitors can be streamed into the Mixed Reality glasses at the same time
45842375|NCT01153620|Other|Ringer's Solution|"Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Ringers' solution 50ml or as much needed to completely saturate the compress. Treatment Duration 60 minutes"
46045587|NCT00629382|Device|Polymyxin B immobilized fiber column|Hemoperfusion with PMX will be performed in ICU. The 1st PMX treatment (day 0) will be carried out for 2 hours and ideally within 24 hours but not later than 48 hours after diagnosis of severe sepsis. The second PMX treatment has to be performed 24 to 48 hours after the end of the first PMX treatment, ideally after 24 hours. Hemoperfusion therapy will be performed in addition to conventional medical therapy in the ICU.
46045588|NCT00629382|Other|Conventional medical therapy in the ICU|Including, but not limited to: antibiotic therapy, nutrition, administration of gamma-globulins, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, corrective measures for metabolic abnormalities, renal replacement therapy when appropriate.
46045589|NCT02865954|Device|iball (mhealth application)|mhealth application and associated device to support activation of the pelvic floor muscles.
45842376|NCT01154322|Device|Pixi pediatric mask|The study mask is designed for use with PAP therapy to treat OSA in pediatric patients aged 2-7 years. The study mask is designed to be used in the hospital and the home environment. The study subject will use the device for up to 30 days while participating in the study.
45842377|NCT01154634|Drug|AZD2516, 5 mg|Capsule, oral
46045590|NCT04288440|Procedure|Surgery|Removal of epiretinal membrane and ILM
45842378|NCT01154634|Drug|AZD2516, 16 mg|Capsule, oral
45842379|NCT01154634|Drug|AZD2516, 40 mg|Capsule, oral
45842380|NCT01154634|Drug|Placebo|Capsule, oral
46045591|NCT04288440|Device|Vitrectomy machine|Pars plana vitrectomy
46045592|NCT02866032|Drug|MOB015B|
46045593|NCT02866032|Drug|Ciclopirox 80 mg/g|
46045594|NCT00976716|Drug|Celecoxib|"Day 1~The first dose: Celecoxib 400mg~The second dose: Celecoxib 200mg during a period between 6 hours post-first dose and before bed~Days 2 to 8 (Study drug should be taken until the dose scheduled after breakfast on the day of Day 8)~- Celecoxib 200mg twice daily"
46045595|NCT00819247|Drug|Degarelix|Given as a subcutaneous injection.
46045596|NCT03842982|Drug|HIPEC|"HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40°C for 90 minutes, along with an IV perfusion of sodium thiosulfate.~Administration of the dose should be according the following schedule:~50% of the dose at start of perfusion, 25% of the dose after 30 minutes from start of the perfusion and 25% of the dose after 60 minutes from start of the perfusion.~The procedure takes 120 minutes with a 90-minute perfusion period. The IV perfusion of sodium thiosulfate is for renal protection. At the start of HIPEC procedure, 9 g/m2 in 200 ml of distilled water will be administered by IV over 15 to 30 minutes. It will be then followed by 12 g/m2 in 1 liter (1L) distilled water in a continuous IV for 6 hours."
46045597|NCT05757349|Behavioral|Face-down position time 1-day|Postoperative face-down position of subjects wearing the novel positioning sensor device for 1-day.
45351502|NCT00897429|Procedure|laboratory biomarker analysis|Correlative studies
45351503|NCT00982306|Behavioral|Brief intervention|20 minute one to one counseling session
45351504|NCT00985036|Procedure|Blood test|an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test
45842381|NCT01155180|Drug|Leptin|Hormone - daily self injections for 6 months
45842382|NCT01155180|Drug|Placebo|Placebo
45842383|NCT01155336|Drug|Lovaza®|Lovaza® is prescription grade EPA+DHA fish oil supplement.
45842384|NCT01155336|Drug|The placebo contained 1 gram of corn oil in each capsule.|Placebo Pill
45842385|NCT01161420|Device|Inspire Upper Airway Stimulation System|Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
45842386|NCT01163214|Drug|Nerve Block|Regional anesthetic nerve block using an indwelling femoral nerve catheter and a single shot sciatic nerve block using 0.5% ropivacaine.
45842387|NCT01163214|Drug|Periarticular Injection|Periarticular local injection into the periarticular soft tissues at the time of knee replacement using a combination of ropivacaine, epinephrine, ketorolac, and morphine sulphate. Subjects in this arm received the injection combination based on three subject weight categories.
45842388|NCT01163604|Drug|Argatroban|Intravenous Infusion, 20mg/day for 2 days before and 3 days after stenting, (10mg/3h, twice a day), with accompanied aspirin and clopidogrel treatment
45842389|NCT01163604|Drug|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
45842390|NCT01163760|Device|etafilcon A|daily disposable contact lens
45842391|NCT01163760|Device|ocufilcon D|daily disposable contact lens
45842392|NCT01167504|Other|Saliva sample collection|Collection of either whole mouth saliva or parotid saliva. Whole mouth saliva is collected through stimulation by inert gum. Parotid saliva is collected by using a Lashley cup placed over the parotid duct and stimulated by a fruit sweet.
46045598|NCT05757349|Behavioral|Face-down position time 3-day|Postoperative face-down position of subjects wearing the novel positioning sensor device for 3-day.
45686098|NCT04774510|Other|Diagnostic Test: optimized C-Arm Cone Beam Computed Tomography|Optimized C-ARM CBCT using new geometry and a novel software can rapidly and accurately detected brain abnormalities and hemorrhagic complications for critical patients with acute stroke. This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the neuro angiography suite (NAS).
45686099|NCT04774276|Other|cardiac rehabilitation protocol without occupational therapist|cardiac rehabilitation protocol without occupational therapist will be performed (usual practice before January 2021).
45686100|NCT04774276|Other|cardiac rehabilitation protocol with occupational therapist|"This intervention (occupational therapist) have been added since 2021 for all patients who need a cardiac rehabilitation protocol.~Occupational therapy is scheduled with sessions 3 times a week for 1 month."
45686101|NCT04774042|Dietary Supplement|Infloran probiotic|Infloran
45842393|NCT01168674|Drug|ziprasidone|Ziprasidone will be administered as a pill. The once-daily total daily dose will be 80-160 mg/d of ziprasidone. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
46045599|NCT00973674|Drug|Premarin IV|One time dose of Premarin IV
45686102|NCT04774042|Dietary Supplement|HAC probiotic|HAc probiotic
45686103|NCT04774042|Dietary Supplement|Infloran placebo|Infloran placebo
45686104|NCT04774042|Dietary Supplement|HAC placebo|HAC placebo
46045600|NCT00973674|Drug|Placebo|One time dose of Placebo
46045601|NCT00819091|Drug|BI 1356|5mg orally (po) tablet qd
46045602|NCT00819091|Drug|Placebo|Placebo matching BI 1356 5mg one tablet daily
46045603|NCT04288596|Other|Participants undergoing ACHD intervention|Participants will receive standard of care for their ACHD intervention.
46045604|NCT02864784|Drug|Amorphous calcium carbonate|Subjects in this arm of the study will receive standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab) as well as AMOR-1 tablets, containing 200 mg elemental calcium per tablet, individually titrated up to the maximum level which does not induce grade 2 hypercalcemia.
46045605|NCT02864784|Other|Placebo|
46045606|NCT04287270|Other|Assesment|Evaluations which explained in the arms section will be made as described.
46045607|NCT04287114|Behavioral|Acute exercise|Acute exercise with different exercise intensities
45686105|NCT03300544|Drug|Capecitabine|Given PO
45842394|NCT01168674|Drug|Sugar pill|The once-daily total daily dose will be 80-160 mg/d of the sugar pill. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
46045608|NCT04286724|Behavioral|"Brief behavioural procedure including a computerized visuospatial task (computer game Tetris)"|"Brief behavioural procedure including a computerized visuospatial task (the computer game Tetris) preceded by a reactivation of the traumatic memory of childbirth"
45842395|NCT01168908|Drug|Sildenafil|20mg tablet three times daily
45842396|NCT01168986|Other|Pulstar Multiple Impulse Therapy|Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.
45842397|NCT01168986|Other|Exercise|Participants perform an exercise to strengthen the deep neck flexors
46045609|NCT00973362|Device|APTIMA HPV Assay|"The APTIMA HPV Assay is an in vitro nucleic acid amplification test (NAAT) that qualitatively detects human papillomavirus (HPV) E6/E7 messenger RNA (mRNA) from 14 HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are associated with cervical cancer (high-risk types). The assay cannot determine the specific high-risk HPV type(s) present and does not cross-react with 5 HPV types that are considered non-oncogenic (not associated with cervical cancer; types 6, 11, 42, 43, and 44)."
46045610|NCT00973362|Device|FDA-Approved HPV DNA Test|A FDA-Approved HPV DNA Test is used as the comparator assay.
45351505|NCT00972946|Biological|Administration of autologous Endorem-labelled mononuclear cells intravenously|single dose
45351506|NCT00972946|Drug|Administration of Endorem|single dose, intravenous
45351507|NCT00973180|Other|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
45351508|NCT00606177|Drug|Aripiprazole|oral, 24mg(4 tablets)/day
46045611|NCT00629694|Procedure|adenoidectomy, myringotomy, tubes insertion|adenoidectomy, myringotomy and tubes insertion (A-T)against adenoidectomy and myringotomy alone (A-M)
45351509|NCT00606177|Drug|placebo|oral, 0mg(4tablets)/day
45351510|NCT00985270|Drug|Rifampicin|
45351511|NCT00985270|Drug|Placebo|
45351512|NCT00359281|Drug|atorvastatin|Atrovastatin 20 mg and AEGR-733 10 mg or 60 mg
45351513|NCT00359281|Drug|simvastatin|Simvastatin 20 mg and AEGR-733 10 mg or 60 mg
45351514|NCT00359281|Drug|ezetimibe|Ezetimibe 10 mg and AEGR-733 10 mg
45351515|NCT00359281|Drug|fenofibrate|Micronized Fenofibrate 145 mg and AEGR-733 10 mg
45351516|NCT00359281|Drug|dextromethorphan|Dextromethorphan 30 mg and AEGR-733 10 mg
45351517|NCT00359281|Drug|Extended Release Niacin|1000 mg ER niacin and AEGR-733 10 mg
45686106|NCT03300544|Drug|Fluorouracil|Given IV
45686107|NCT03300544|Drug|Leucovorin|Given IV
45686108|NCT03300544|Drug|Oxaliplatin|Given IV
45686109|NCT03300544|Radiation|Radiation Therapy|Undergo chemoradiation
45686110|NCT03300544|Biological|Talimogene Laherparepvec|Given intralesionally
45686111|NCT00698854|Device|Vanguard™ Complete Knee System|Primary Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)
45686112|NCT00698854|Device|Vanguard™ Patient-Specific Femur|Primary Total Knee System used with Signature technique to provide a patient-specific femur
45842398|NCT01169064|Device|Silver-containing surgical dressing|Dressing placed over surgical incision and remain for 3-5 days
45842399|NCT01169064|Device|Cloth adhesive dressing|Cloth adhesive dressing placed over surgical incision and remains for 3-5 days
45842400|NCT01170390|Drug|All participants (Aviane)|20 mcg EE/0.1 mg LNG cyclically
45842401|NCT01170390|Drug|Portia|30 mcg EE/0.15 mg LNG cyclically
46045612|NCT00629694|Procedure|A-M|adenoidectomy and myringotomy alone
46045613|NCT05225454|Other||
45476983|NCT05221268|Other|Level walking exercise|treadmill exercise with 0 inclination
46045614|NCT04289766|Other|Conventional Treatment|These individuals will receive the conventional intervention including the routine rehabilitation therapy like active and passive ROMs, stretching, strengthening of upper limb, balance improvement exercises. Time duration is of 40 minute 3 times per week.
46045615|NCT04289766|Other|Focal Muscle Vibration (120Hz)|These individuals will receive conventional therapy along with Focal Muscle Vibration applied to the hyper toned muscles (Bicep Brachialis and Extensor Carpi Radialis). Evaluation at baseline and after the end session (Total 24 session). i.e. 3 sessions/week for 8 weeks.
45476984|NCT05221268|Other|Downhill exercise|treadmill exercise with -20 inclination
45476985|NCT04450511|Device|Magnetic stimulation -Armchair type (MS)|MS was applied two days a week, 20 minutes a day, a total of 12 sessions for 6 weeks.
45476986|NCT04450511|Other|Bladder Training (BT)|Bladder Training (BT)
45476987|NCT02505568|Drug|Infliximab|Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 for the induction phase. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion every 8 weeks up to week 32 in the maintenance phase.
45476988|NCT03627572|Other|No intervention|Not applicable (no intervention)
45842402|NCT01170390|Drug|Aviane|20 mcg EE/0.1 mg LNG continuously dosed
45842403|NCT01170546|Other|plate-loaded kneeling leg curl with internal rotation|The participant was instructed to point toes toward medial side as knee flexing. This is an open-kinetic chain (OKC) exercise and medial hamstring was emphasized.
45842404|NCT01170546|Other|plate-loaded squat press|The subject was instructed to position his back properly against the backrest on a machine, with the feet slightly apart. He was instructed to place his feet higher on the foot plate and draw his two knees as close as possible while the knees flexed so that medial hamstring would supposedly bear more tension in the course of knee flexion. This is a closed-kinetic chain (CKC) exercise and was expected to strengthen the quadriceps and hamstring with medial hamstring emphasized.
45842405|NCT01170546|Other|plate-loaded kneeling leg curl|An open-kinetic chain (OKC) exercise was intended to strengthen the hamstring muscle without lateralization emphasized.
45476989|NCT05356728|Drug|Thealoz Duo (combination of trehalose and hyaluronate) eye drop and Hyabak (hyaluronate) eye drop|One of the eyes will be assigned to use Thealoz Duo while the other with Hyabak by using randomisation table
45686113|NCT03249844|Drug|Methylprednisolone + prednisolone|"The experimental intervention consists of 5 consecutive days Methylprednisolone at a daily single intravenous dose of 20 mg/kg body-weight (max 1 g/day) followed by a 4-week course of tapering Prednisolone given at a daily single oral dose in the morning:~week 1 and 2, oral Prednisolone 1 mg/kg/day (max 40 mg/day), ,~week 3 and 4, oral Prednisolone 0,5 mg/kg/day (max 20 mg/day),"
45686114|NCT04755166|Procedure|Lateral ridge augmentation|
45686115|NCT00684580|Other|Data Collection|Continuing review of outcomes and late toxicities
45686116|NCT04755010|Device|Linq II implantable cardiac monitor|Implantation of Linq II implantable cardiac monitor
45686117|NCT04781608|Behavioral|English: In It Together (IIT)|Digital intervention program that consists of 4 modules, to be completed 1 week apart. The modules consist of psychoeducation, as well as acceptance and commitment therapy-inspired activities.
46045616|NCT04289766|Other|Focal Muscle Vibration (60Hz)|These individuals will receive conventional therapy along with Focal Muscle Vibration applied to the hyper toned muscles (Bicep Brachialis and Extensor Carpi Radialis). Evaluation at baseline and after the end session (Total 24 session). i.e. 3 sessions/week for 8 weeks.
45476990|NCT02514694|Drug|LEO32731|
45476991|NCT02514694|Other|Placebo|
45476992|NCT05344482|Other|Secukinumab|Included all the patients treated with secukinumab
45476993|NCT05217836|Diagnostic Test|ferritin; iron; transferrin; transferrin saturation; hemoglobin in reticulocyte; hepcidin|All patients will have the following laboratory parameters determined: ferritin, iron, transferrin, transferrin saturation, hemoglobin in reticulocyte, hepcidin. Patients with hemoglobin in reticulocyte below reference range will receive parenteral iron.
45686118|NCT00637624|Drug|N-Acetylcysteine|N-Acetylcysteine intravenously once every 3 weeks 40 mg/kg
45842406|NCT01134510|Drug|C1 Esterase Inhibitor|C1 Esterase Inhibitor 20 units/kg twice weekly x 4 weeks
45842407|NCT01134510|Drug|Placebos|NS (comparable volume as intervention) twice weekly x 4wks
45842408|NCT01171794|Drug|Ibuprofen|3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)
45842409|NCT01171794|Drug|Placebo|identical number of visually identical tasteless pills as ibuprofen arm
45842410|NCT01172184|Procedure|Cardiac catheterization|Before surgical intervention for severe mitral regurgitation, cardiac catheterization will be performed and left ventricular filling pressure will be assessed. Simultaneously, echocardiography, including left atrial distensibility, will be performed.
45842411|NCT01172418|Drug|Alemtuzumab|Alemtuzumab used as part of combined Induction.
45842412|NCT01172418|Drug|Daclizumab|Daclizumab used as part of combined induction.
45842413|NCT01172418|Drug|Thymoglobulin|Thymoglobulin used as part of combined induction.
45842414|NCT01175148|Drug|Atorvastatin calcium (Lipitor)|40 mg PO daily
45842415|NCT01175226|Drug|BTA798|BTA798 twice daily
45351518|NCT00982384|Other|Disease management|Disease management by COPD nurses, including active follow-up and coordination of care in addition to best care according to clinical guidelines for COPD patients
45842416|NCT01175226|Drug|Placebo|Placebo twice daily
45351519|NCT00982384|Other|Best care|Comprehensive care for COPD patients recommended in clinical guidelines
45351520|NCT00982462|Dietary Supplement|Docosahexaenoic acid (DHA) and arachidonic acid (ARA)|Micro-encapsulated powder containing the long-chain polyunsaturated fatty acids, DHA to ARA in a 1:1 ratio. Two foil-packets containing active intervention (200mg DHA+200mg ARA) or placebo (400 mg corn oil) per day added to a selection of recommended foods.
45842417|NCT01175850|Device|Drug-Coated Balloon (DCB)|balloon dilatation and provisional stenting with IN.PACT DCB
45842418|NCT01175850|Device|PTA Balloon: Balloon Angioplasty|balloon dilatation and provisional stenting with standard non-coated PTA balloon
45842419|NCT01177098|Drug|bimatoprost /timolol formulation A fixed combination ophthalmic solution|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
45842420|NCT01177098|Drug|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
45842421|NCT01177956|Biological|Cetuximab|"The initial dose of cetuximab will be 400 milligram per square meter (mg/m^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m^2 as an IV infusion over 60 minutes.~Chemotherapy will be continued for up to a maximum of six 3-week cycles in the absence of progressive disease (PD) or unacceptable toxicity. All subjects will receive cetuximab treatment until the occurrence of PD or unacceptable toxicity to cetuximab."
45842422|NCT01177956|Drug|Cisplatin|Subjects will receive 75 mg/m^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle.
45842423|NCT01177956|Drug|5-Fluorouracil|Subjects will receive 750 mg/m^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 5 of each 3-week treatment cycle.
45842424|NCT01178268|Device|XIENCE V EECSS|Patients who will receive this stent.
45842425|NCT01178268|Device|CYPHER SELECT PLUS SECSS|Patients who will receive this stent.
45842426|NCT01179984|Device|Bard® LifeStent® Vascular Stent System|Stent Implantation
45351521|NCT00982462|Dietary Supplement|Corn oil placebo|Micro-encapsulated powder containing corn oil as the placebo.
45686119|NCT00637624|Drug|Placebo|Placebo once every 3 weeks intravenous saline fluid
45686120|NCT04754620|Other|real time online video visit|Participants have received an online visit by a smartphone application
45686121|NCT04773964|Drug|MET642|MET642 active treatment
45686122|NCT04773964|Drug|Placebo|Placebo comparator
45686123|NCT01479465|Biological|Simtuzumab|SIM administered via intravenous infusion over 30 minutes
45686124|NCT01479465|Drug|Placebo to match SIM|Placebo to match SIM administered via intravenous infusion over 30 minutes
45686125|NCT01479465|Drug|Leucovorin|l-Leucovorin 200 mg/m^2 or dl-leucovorin 400 mg/m^2 administered via intravenous infusion over 2 hours
45476994|NCT02514616|Procedure|Laparoscopic IPG and lead implant procedure|EST placement
45686126|NCT01479465|Drug|Irinotecan|Irinotecan 180 mg/m^2 administered via intravenous infusion over 90 minutes
45686127|NCT01479465|Drug|Fluorouracil|Fluorouracil 400 mg/m^2 administered via intravenous bolus and 2400 mg/m^2 via intravenous infusion over 46 hours
45842427|NCT01181076|Dietary Supplement|Individualized Nutrition|The patients who are able to achieve oral nutrition requirement will receive a therapeutic diet using regular foods, which is lactose-reduced and energy-enriched. The naso-jejunal tube will be inserted during the first five days after transplantation. EN will be given when oral intake discontinue. EN with an additional PN will be given if the estimated requirements by the enteral route is lower than reference values.
45842428|NCT01182480|Behavioral|Patient Relationship Management (PRM) Program|"Patients will be contacted through SMS text messaging under the following circumstances:~7 days, 2 days, and 1 day before scheduled appointments. Messages will contain the date, time, and location where the appointment is scheduled. Patients will be prompted to respond with 'YES' if they are able to keep their appointment, and 'NO' if they need to reschedule. An acknowledgement of receipt will be sent in response to all patient-initiated messages.~3 days per week to request that patients respond with fasting blood sugar measurements. An acknowledgement of receipt will be sent in response to all patient-initiated messages."
45842429|NCT01183650|Drug|Tadalafil|5 mg, administered orally, daily for 10 days
45842430|NCT01183728|Other|Autologous bone marrow mesenchymal stem cells (MSV)|Bone marrow collection from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by articular injection.
45842431|NCT01184898|Drug|Sirolimus|Sirolimus, by mouth, will be given as a 12mg loading dose followed by 8 daily doses of 4mg/day.
45842432|NCT01184898|Drug|Mitoxantrone|Mitoxantrone 8mg/m2/day IV
45842433|NCT01184898|Drug|Etoposide|100 mg/m2/day IV
45686128|NCT02428192|Biological|Ipilimumab|Given IV
45686129|NCT02428192|Other|Laboratory Biomarker Analysis|Correlative studies
45686130|NCT02428192|Biological|Nivolumab|Given IV
45842434|NCT01184898|Drug|Cytarabine|1000mg/m2/day IV every 24 hours for 5 days
45842435|NCT01188876|Drug|carboplatin|Given intravenously on Day 1 of each 28-day cycle
46045617|NCT04044768|Genetic|afamitresgene autoleucel (previously ADP-A2M4)|Single infusion of autologous genetically modified afamitresgene autoleucel (previously ADP-A2M4) Dose: 1.0 x109 to 10x109 transduced by a single intravenous infusion
46045618|NCT00819013|Biological|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 1, Intramuscular
46045619|NCT00819013|Biological|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 2, Intramuscular
46045620|NCT00819013|Biological|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM FLU-A low dose, Intramuscular
46045621|NCT00819013|Biological|Saline placebo|0.5 mL, Intramuscular
46045622|NCT00976560|Drug|GW856553|Wet Granulated, film coated white, 9mm round, biconvex, plain faced tablets, containing 7.5 mg of GW856553
46045623|NCT00976560|Other|Placebo|Film coated white, 9mm round, biconvex, plain faced tablets obtained by direct compression.
46045624|NCT02610049|Behavioral|Cognitive Processing therapy|8 sessions of standard CPT from CPT manual developed by Dr. S Resick, Monson & Chard (11/2010)
45351522|NCT03992287|Dietary Supplement|Hydrolysed Red Ginseng Extract|10 ml/day, 2.4g/day for 12 weeks
45686131|NCT04773574|Device|Corneal topography, Optical coherence tomography (OCT) and Optical coherence tomography angiography (OCTA)|"Ocular investigations were performed in each trimesters and at 6 weeks after childbirth.~st trimester : gestational age 8-12 weeks~nd trimester : gestational age 24-28 weeks~rd trimester : gestational age 34-38 weeks"
45686132|NCT04773496|Diagnostic Test|instrumental description of the subject's center of gravity (COG) sway|qualitative and quantitative analysis of the balance function through the description of the center of gravity (COG) sway
45686133|NCT04773886|Drug|Mineral trioxide aggregate|Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent
45686134|NCT04773886|Drug|Biodentine|Vital Pulpotomy will be done using Biodentine as pulp capping agent
45686135|NCT04773886|Biological|Platelet rich fibrin|"10 ml of blood was drawn from the peripheral vein in the selected patients with the help of sterilized disposable syringe and blood was collected in the pre-sterilized borosilicate glass test tube, without any addition of anticoagulant and was immediately centrifuged at 3000 rpm for 15 minutes in a centrifuge unit.~The product obtained after centrifugation consisted of three layers:~Acellular platelet plasma- top most layer~Platelet rich fibrin -middle layer~Red blood corpuscles- bottom layer PRF was then separated from the red blood corpuscles base with the help of sterile tweezers and scissors and squeezed with the help of sterile gauze piece"
45686136|NCT04781686|Drug|Camrelizumab|Camrelizumab (200mg) will be given i.v. on day 1 of each 3-week cycle
46045625|NCT02610049|Behavioral|Art + CPT|8 sessions of individual therapy of mixes techniques Art + CPT 8 sessions of standard CPT (same 8 as in control group) from manual developed by Dr.s Resick, Monson & Chard (11/2010)
45351523|NCT03992287|Dietary Supplement|Placebo|Placebo for 12 weeks
45351524|NCT02540343|Other|questionnaires|fill out all questionnaires twice
45842436|NCT01188876|Drug|pralatrexate|Given intravenously on Day 1 and Day 15 of each 28-day cycle.
45351525|NCT00973258|Dietary Supplement|Nutritional Intervention|Each subject in the nutritional intervention group is provided with a commercial liquid formula (Fortisip Multi Fibre, Nutricia), which should be taken every evening for a period of 24 weeks. Subjects are also given one capsule of iron and folate supplement (Sangobion, Merck; consisting of 1 mg folate and 29mg iron), one capsule of Vitamin B6 and vitamin B12 supplement (Neuroforte; consisting of 200mcg B12 and 200mg vit B6) and one tablet of Caltrate with Vitamin D (consisting of 200 IU vitamin D and 600 mg of calcium) for a duration of 24 weeks.
45351526|NCT00973258|Other|Physical Exercise|The exercise intervention group comprises a combination of 2 types of exercise: resistance exercise and in-balance exercise. Key components in both programs are balance and strength, because these are the most prominent domains that should be addressed in at risk frail elderly. The first program is administered in the first 6-week, and then followed by the second program for the next 6-week of intervention period. Both exercise programmes are tailored to the functional needs of the participants, maintaining a moderate intensity that focuses on long-term sustainability and enjoyment.
45476995|NCT02514616|Device|Active Electric Stimulation Therapy|Device programming by the technician to deliver the EST system active (Treatment group) or no stimulation (Control group) for the following 12 weeks, at the 2 weeks visit.
45351527|NCT00973258|Other|Cognitive Training|"The proposed cognitive training intervention program comprises:~Reasoning training focusing on inductive reasoning, the ability to solve problems that follow a serial pattern and manifest in executive functioning.~Memory training focusing on verbal episodic memory, which deals with acquisition and retrieval of information acquired in a particular place at a particular time.~Speed training focusing on visual search and the ability to identify and locate visual information quickly in a divided attention format, with and without distractors."
45351528|NCT00973258|Other|Combined|Nutritional Intervention + Physical Exercise + Cognitive Training
45351529|NCT00973258|Other|Placebo|Participants will receive their usual diet and placeboes.
45476996|NCT02514616|Device|Delayed Electric Stimulation Therapy|Device programming by the technician to deliver the EST system no stimulation for the following 12 weeks at the 2 weeks visit. Active Electric Stimulation Therapy will be programmed at the 14 weeks visit.
45476997|NCT03842735|Other|exercise and rehabilitation counselling|The intervention consists in a standardized physical exercise (PE) and rehabilitation counselling indications (RCI). PE is done 5 days/week (2 days in autonomy by the patient with parents support and 3 days supervised). Each session lasts 30 minutes and this is supervised by one therapist for all patients. Patients are enrolled in an EP composed by three different types of exercises, each carried out for 10 minutes per session: muscle strength exercises for upper and lower extremities preceded by warming up, aerobic exercises and stretching. The kind of exercise is differentiated by age range (children, 5-12 years and adolescents, 13-18 years).
45351530|NCT00902031|Drug|Docusate Sodium, Sennoside|"Docusate sodium: given in capsule form (100 mg/capsule), at a dosage of 200 mg, taken twice daily for 10 days.~Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days."
45686137|NCT04781686|Drug|Apatinib Mesylate|Apatinib (250mg) will be administered orally once a day .
45686138|NCT04781686|Drug|S1|S1 (BSA<1.25 40mg, BSA >=1.25-<1.5 50mg, BSA >=1.5 60mg) will be administered orally twice daily on days 1-7 of each 3-week cycle
46045626|NCT02610049|Behavioral|CPT + Art Therapy|Subjects to complete 8 sessions of standard Cognitive Processing Therapy from manual developed by Dr. S. Resick, Monson & Chard (1/2010) CPT + Art Therapy of mixed individual techniques
45686139|NCT04781686|Drug|Docetaxel injection|Docetaxel (75mg/m2 IV.drop) will be administered on day 1 of each 3-week cycle, for six cycles.
45686140|NCT04781920|Other|datas collection|data collection in history medical : operative report, clinical examination, questionnaires, imaging, isokinetic tests
45686141|NCT02390284|Drug|Latanoprost|Lower intraocular pressure (IOP) by increasing outflow of fluid from the eye.
45686142|NCT02390284|Drug|Bimatoprost|Lower intraocular pressure by increasing outflow of fluid from the eye.
46045627|NCT04868461|Dietary Supplement|Unheated Whey Protein (UWP) beverage|The preload is made from whey protein powder. The energy load of the preload is 119.7 kcal and has banana flavor and sweetener.
45351531|NCT00902031|Drug|Sennoside + Placebo|"Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.~Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days"
45351532|NCT03991039|Radiation|Gamma knife|Microvascular decompression
45351533|NCT00897663|Genetic|gene expression analysis|
45351534|NCT00897663|Genetic|microarray analysis|
45351535|NCT00897663|Genetic|protein expression analysis|
45351536|NCT00897663|Other|diagnostic laboratory biomarker analysis|
45686143|NCT02390284|Drug|Travoprost|Lower intraocular pressure by increasing outflow of fluid from the eye.
45686144|NCT02390284|Drug|Timolol|Lower intraocular pressure by decreasing production of fluid
45686145|NCT02390284|Drug|Dorzolamide|Lowers intraocular pressure by decreasing intraocular fluid production
45351537|NCT00897663|Other|immunohistochemistry staining method|
45476998|NCT03842735|Behavioral|rehabilitation counselling|RCI, which have to be followed daily, consist in some practical advice was given on how to adopt an active lifestyle during the recovery (e.g., getting up to go to the bathroom, getting up to move to the window to talk with visitors, sit on chair to have school lessons).
45686146|NCT02390284|Drug|Brinzolamide|Lowers intraocular pressure by decreasing intraocular fluid production
45686147|NCT02390284|Drug|Acetazolamide|Lowers intraocular pressure by decreasing intraocular fluid production
46045628|NCT04868461|Dietary Supplement|Heated Whey Protein (HWP) beverage|The preload is made from whey protein powder of 95% and it is heated for a certain amount of time. The energy load of the preload is 119.7 kcal and has banana flavor and sweetener.
46045629|NCT04868461|Dietary Supplement|Casein (Cas) beverage|The preload is made from casein powder. The energy load of the preload is 105 kcal and has banana flavor and sweetener.
46045630|NCT04868461|Dietary Supplement|Water|The preload is water acting as a control and contain the same banana flavor and sweetener to match the other three intervention - protein beverages.
45351538|NCT00985348|Drug|Levetiracetam (Keppra)|"Test Drug :~Levetiracetam dry syrup~Reference Drug :~500 mg oral tablets of Levetiracetam. Frequency: Single Dose"
45476999|NCT03833843|Diagnostic Test|imaging|ECG, Echocardiography and cardiac magnetic resonance imaging
45477000|NCT05220644|Procedure|Protocols for the management of end-of-life symptoms|Application of the care protocol and data collection
45477001|NCT02510482|Other|No intervention|
45477002|NCT05220566|Behavioral|Reserved Therapeutic Space|The main objective of the 'Reserved Therapeutic Space' intervention is to enhance the therapeutic bond of trust, to enable the agreement of objectives and interventions in a shared manner in relation to their recovery process in the unit. The intervention is carried out through individual meetings between the nurse and the patient in a comfortable and intimate space, where there are no interruptions and which is also chosen by the person who is hospitalized. The content of the spaces must be constructed individually according to the patients' concerns at each moment of the process.
45477003|NCT02505178|Other|Problem Solving Therapy|PST is a minimally invasive treatment. The five sessions of CM implemented PST will involve psychotherapy also known as talk therapy between the CM's and study participants in a group setting. Psychogeriatric interdisciplinary staff (CM's) i.e. psychiatric nurses, social workers who have been previously trained in PST will function in the roles of facilitator, cofacilitator and scribe. The roles can be shared amongst the professionals to build capacity in each role or maintained over time if so desired. Sessions will be approximately one-and-a-half to two hours in length and conducted at the Cherry Hill Mall library in London.
45477004|NCT05217524|Device|Galaxy BIA watch|Digital multifunction watch
45842437|NCT01188876|Drug|Folic Acid|Given orally on a daily basis starting 7 days before the first dose of pralatrexate and continuing until 30 days after the last dose of pralatrexate.
45842438|NCT01188876|Drug|Vitamin B12 Injection|Given vitamin B12 injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks after the first dose of pralatrexate.
45842439|NCT01189110|Device|Auriculotherapy using TENS unit Stim Flex 400A|Although the mechanism of action of auriculotherapy is not well understood, the dominant scientific theory for how traditional acupuncture procedures works has suggested possible neurophysiologic and neurochemical pathways that may explain its effectiveness for treating specific disorders
46045631|NCT02865642|Drug|Serotonin Uptake Inhibitors|
45351539|NCT03990961|Drug|Pembrolizumab|Subjects will receive pembrolizumab treatment at a dose of 200mg IV every 3 weeks for a duration of 2 years (35 cycles).
46045632|NCT02865642|Drug|Placebo|
46045633|NCT03774888|Procedure|Connective tissue graft at time of bone graft|following the placement of the bone graft and the membrane, a CTG will be harvested and sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
46045634|NCT03774888|Procedure|Acellular Demal Matrix at time of bone graft|following the placement of the bone graft and the membrane, an ADM will be sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
46045635|NCT03774888|Procedure|No soft tissue grafting at time of bone graft|Following the placement of the bone graft and the membrane, the flaps passively sutured on top on the bone. No soft tissue graft will be added.
45351540|NCT00973336|Drug|Calcium and vitamin D|1000mg calcium per day 800 IE vitamin D per day
45351541|NCT00902109|Device|Perimetry|different perimetric devices, different perimetric grids: Octopus: New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) HFA: 30-2, Sita (Swedish Interactive Thresholding Algorithm) full threshold
45351542|NCT00902109|Device|Confocal Scanning Laser Tomography|HRT examinations for the clinical evaluation of the optic disc.
45351543|NCT00902109|Device|Optical Coherence Tomography (OCT)|imaging of the retinal nerve fiber layer
45477005|NCT02510248|Drug|AL-704|JNJ-54257099 (also known as ALS-022704 or AL-704) is a hepatitis C virus (HCV) nonstructural (NS)5B inhibitor, belonging to the nucleoside / nucleotide inhibitor class, and is being developed as an orally administered anti-HCV therapeutic.
45477006|NCT02510248|Drug|Placebo|Placebo to match AL-704
45477007|NCT03833453|Behavioral|EMDR|EMDR is a PTSD treatment that specifically addresses troubling memories of and the personal meaning of the traumatic event and consists of 12 to 18 sessions in a maximum of 6 months.
45477008|NCT03833453|Behavioral|DBT|DBT is a treatment for personality disorders (PD) focused on emotion regulation. It takes at least one group-session per week, and one individual coaching session every two weeks, for the duration of one year.
45686148|NCT02390284|Drug|Methazolamide|Lowers intraocular pressure by decreasing intraocular fluid production
45686149|NCT05605132|Other|Proprioceptive Training Exercise|"oculomotor exercises will be applied to the participants three times a week for four weeks.~oculomotor exercises:~head relocation~gaze stability~eye follow~saccadic eye movement~head and eye coordination"
45842440|NCT01192542|Device|galyfilcon A prototype lens|Prototype silicone hydrogel contact lens
45842441|NCT01192542|Device|enfilcon A lens|Marketed silicone hydrogel contact lens
45842442|NCT01193010|Procedure|Computer-Assisted Surgical Planning|Using a CT reconstructing of affected distal radius and the normal contralateral limb, surgical guides for the osteotomy will be created to assist with surgical planning.
45842443|NCT01193010|Procedure|distal radius osteotomy|In this control group, the planning and surgical execution of the distal radius osteotomy will be performed as usual, without computer-assisted planning of the osteotomy.
45351544|NCT03991273|Other|Y-M2M©|The Y-M2M© group will receive classes that will be delivered onsite at a YMCA facility. Movement-to-Music (M2M©) is an instructor-guided exercise program that is coupled with music to enhance strength, cardiorespiratory capacity, range of motion, and balance.
45351545|NCT03991273|Other|B-M2M©|The B-M2M© group will receive the same onsite M2M© classes as the Y-M2M© group, but they will also be provided with the option of performing home-based M2M© that will be delivered via videoconferencing.
45477009|NCT03886064|Other|Multi-behavioral intervention|The interventional group will then meet regularly under the aegis of the trainer to work on modifying each person's risk factors. The one-hour sessions will be scheduled every two weeks for two months and then every month for two months and then every three months until the end of the study (13 sessions). These sessions will be behavior change sessions, focused on goal setting, action planning, and problem solving. Trainers will facilitate these sessions and use motivational interviewing techniques
45477010|NCT02514538|Drug|Non- effervescent Paracetamol kern|1g
45477011|NCT02514538|Drug|Effervescent paracetamol termalgin|1 g
45842444|NCT01193868|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
46045636|NCT05157919|Behavioral|ICU-Care|The mobile app intervention, ICU-CARE, will consist of 3 separate education modules, each approximately 5-7 minutes in length: (Module #1) ICU orientation, (Module #2) Symptom Assessment, (Module #3) Symptom Management
46045637|NCT04204590|Other|Deprescribing algorithm|For this study an implicit, evidence-supported and patient-centred algorithm has been developed. The outcome of the algorithm is an advice to the doctor to deprescribe or not deprescribe the statin and/or PPI.
45351546|NCT00973414|Drug|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after CSEA in cesarean section
45477012|NCT05219786|Behavioral|Appendicitis Decision Support Tool|Viewing of a decision support tool.
46045638|NCT02609425|Device|Stratafix PGA Suture|Subject leak Stricture rates post procedure
46045639|NCT03762564|Drug|Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15
46045640|NCT03762564|Drug|Paclitaxel|Paclitaxel 80 mg/m2 on day 1, 8, 15
46045641|NCT00975156|Other|Physical Therapy|Conventional physical therapy
45477013|NCT05219786|Behavioral|Control Infographic|Viewing of a standardized infographic
45351547|NCT00973414|Drug|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after CSEA in cesarean section
45477014|NCT05281913|Other|Psychoeducational Game|Psychoeducational Game
45477015|NCT02510170|Other|no intervention|
45842445|NCT01193868|Other|laboratory biomarker analysis|Correlative studies
45842446|NCT01193868|Other|pharmacological study|Correlative studies
45842447|NCT01195116|Drug|Dexmedetomidine|1 mcg/kg/hour
45842448|NCT01195116|Drug|Normal Saline|1mcg/kg/hr
45842449|NCT01196442|Other|electrical stimulation pain therapy|Electrical stimulation pain therapy for 45 minutes on Day 1, then 30 minutes Days 2-10
46045642|NCT00975156|Device|Lokomat|Robotic-assisted walking device
45842450|NCT01196442|Other|questionnaire administration|Brief Pain Inventory questionnaire administration at baseline, weekly, then monthly for 3 months
45842451|NCT01197612|Drug|pulmicort|applied to nasal packing after surgery
45842452|NCT01198158|Biological|Bevacizumab|Given IV
45351548|NCT00902187|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
45477016|NCT05202392|Other|Myofascial release with isometric exercises|Patients in group A will receive 40 minutes of combined therapy treatment session including myofascial release of muscles with trigger point release and 5 isometric exercises of neck at alternative 3 days/week for 4 weeks.
45842453|NCT01198158|Drug|Everolimus|Given PO
45842454|NCT01198158|Other|Laboratory Biomarker Analysis|Correlative studies
45477017|NCT05202392|Other|Myofascial release with scapular stabilization exercise|Patients in group B will get 40 minutes of myofascial therapy same as the first group combined with scapular stabilization exercise in 5 different positions and this treatment session will be at alternative 3 days/week for 4 weeks.
45477018|NCT04499794|Drug|ALK inhibitor|ALK inhibitor treatment on ALK fusion positive NSCLC patients
45842455|NCT01198158|Other|Pharmacological Study|Correlative studies
45477019|NCT01566851|Other|Cardiovascular check-up|Cardiovascular check-up once a year in patients with rheumatoid arthritis
45842456|NCT01199952|Behavioral|Treatment group: receives counseling phone call intervention|Subjects in the treatment arm will receive a phone call from a health educator to assist with contraception, 3 to 4 weeks after enrollment.
46045643|NCT02610205|Other|caring touch|The caring touch was adjusted to suit each participant and lasted for 20-60 minutes, once a week, for a maximum of eight treatment sessions altogether. The tactile massage, a soft tissue massage, without applying direct pressure or stretching to the muscles. The massage can be described as slow, gentle, structured, circulating movements with the palm of the therapist's hand, during which natural oil, or oil with the fragrance of lavender, was applied. The healing touch was based on an established procedure, during which the therapist applied a light pressure to the feet, ankles, knees, hips, stomach, heart area, arms, throat, forehead and scalp. The participant was fully dressed during the healing touch, as the therapist used her/his hand in different positions on the participant's body.
46045644|NCT04204746|Other|We will observe and evaluate the temperature and moisture in the respiratory circuit by a thermo-hygrometer.|
45351549|NCT00902187|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
45351550|NCT01052233|Procedure|Arthroscopic partial meniscectomy|Arthroscopic partial meniscectomy of the degenerative tear of medial meniscus
45477020|NCT03840395|Device|Pharyngeal Electrical Stimulation (PES)|The Phagenyx® system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation to the oropharynx. The Phagenyx® devices are CE labelled (2012) and will be used in accordance with their intended use label.
45351551|NCT01052233|Procedure|Arthroscopy (diagnostic)|Diagnostic arthroscopy of the knee
45351552|NCT00902343|Procedure|nomogram-based selection for acute normovolemic hemodilution|Will use the nomogram to determine whether or not the patient needs ANH during surgery. The nomogram assigns a point value to certain pre-op factors to determine whether or not the patient will need an ANH. Preoperative factors that will be used are platelet count, planned amount of liver to be removed, hemoglobin level, if the surgeon needs to operate on any organ outside of the liver to remove the tumor, and the patients health overall.
45477021|NCT05707052|Other|Neck-Trunk Stabilization Exercises and conventional physical therapy|Neck-Trunk Stabilization Exercises along with conventional physical therapy in which stretching, strengthening, ROMs positioning and electrical stimulation are included.
45477022|NCT05707052|Other|Bobath Therapy and conventional physical therapy|Bobath based exercises along with conventional physical therapy in which stretching, strengthening, ROMs positioning and electrical stimulation are included.
45477023|NCT02514460|Device|plaque excision system|
45477024|NCT02514460|Device|Stent|
45842457|NCT01200030|Behavioral|electrical stimulation with exercises|electrical stimulation with exercises
45842458|NCT01200030|Behavioral|placebo stimulation with exercises|placebo stimulation with exercises
45842459|NCT01200498|Drug|SB939|Starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
45842460|NCT01203774|Drug|Glargine insulin|20-180 units per day
45842461|NCT01205568|Device|Transcatheter Cutting Balloon therapy|
45842462|NCT01205568|Procedure|High Pressure Balloon Angioplasty|
45842463|NCT01205646|Drug|zoledronate therapy|Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration. Intravenous (through a vein in the arm) infusion every four weeks. Dose will be determined by kidney function.
45842464|NCT01205646|Device|PET Scan|2 scans [about 1-2 weeks apart] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility.A third PET scan will be obtained within 1-2 weeks after Zometa administration.
45842465|NCT01206660|Drug|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
45842466|NCT01206660|Drug|placebo|Placebo administered to affected area twice a day for 28 days
45842467|NCT01206738|Behavioral|Persuasive communication|The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
45842468|NCT01206738|Behavioral|Action plan|This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
45842469|NCT01206738|Behavioral|General intervention|No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
45842470|NCT01207752|Drug|Systane Balance|Artificial tear emulsion drop
45842471|NCT01207752|Drug|Optive Lubricant Eye Drops|Artificial tear eye drop
46045645|NCT00629616|Drug|anastrozole|1 mg/day for either 4 months or 6 months depending on the clinical evaluation
46045646|NCT00629616|Drug|fulvestrant|500mg at day 1, day 15 and day 29 500mg every 28 days for either 4 months or 6 months depending on the clinical evaluation
45477025|NCT01567007|Behavioral|individual counseling|Consisting of three sessions within a maximum period of 3 months. We conducted a counseling, aimed at increasing physical activity, aiming to raise at least 2000 steps over the first week of monitoring. Furthermore, we discuss the importance of physical activity, such as overcoming barriers to physical activity and targets agreed between the parties. The pedometer is given along with a diary to record the number of steps and returned in the last session.
45477026|NCT01567007|Behavioral|group counseling|The counseling was conducted in groups (10-12 individuals) for 6 sessions at weekly intervals, and two sessions with fortnightly. Each session lasts 60 minutes. The advice is aimed at behavioral changes using the following approaches: advantages and disadvantages of behavior change, how to overcome barriers to physical activity, self-monitoring of physical activity by using the pedometer and setting goals (number of steps / day) in the short term and what to do in case of relapse (not accomplish what was represented) besides livings practices. As the GII and the goal is to raise at least 2000 steps daily on average, with the main focus physical activity in leisure time and transport
45477027|NCT01567007|Behavioral|aerobic training|The fitness program is held two times per week with individuals and groups with three sessions lasts for 40 minutes performed on a treadmill.
45477028|NCT05706896|Procedure|Intravitreal injection of CB-PRP|The procedure consists in a trans-scleral puncture to access the vitreous cavity, with subsequent injection of CB-PRP
46045647|NCT02609971|Other|Vibration at 50 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
46045648|NCT04269096|Other|Protocol Compliance|Compliance with the Prisma Health-Upstate Laparoscopic Cholecystectomy Perioperative Protocol
46045649|NCT04268940|Diagnostic Test|Thromboelastography|Thromboelastography (TEG 6s, global hemostasis cartridge) will be performed before ECMO insertion and at different time-points during the course of ECMO. In parallel a full coagulation work-up (aPTT, prothrombin time [PT], anti-Xa, activated clotting time[ACT], platelets count, d-dimers, von Willebrand panel and fibrinogen) will be measured simultaneously with each TEG.
46045650|NCT04832737|Behavioral|ADDapt Ability Framework|12 week individual therapeutic coaching intervention
45351553|NCT00902343|Procedure|standard selection for ANH based on a planned resection of 3 or more segments|Will use the planned amount of liver to be removed to determine whether or not the patient needs an ANH during surgery.
45477033|NCT05281445|Behavioral|Tic suppression task|Tic Suppression Task (TST, administered to Tourette syndrome participants only): At the beginning of the task, the child participant will be seated alone in front of a computer monitor with a countdown timer visible on the screen. For the first 10 minutes (baseline condition) they will be asked to tic freely and not to try to suppress their tics. For the second 10 minutes children will be asked to suppress their tics and will receive points for successful suppression. Participants will then be asked to sit alone in the room and tic freely for an additional 10-minutes.
45477034|NCT05706818|Other|Validity and reliability study|Validity and reliability assessment of the Community Integration Questionnaire-revised
45477035|NCT03343912|Drug|Estriol 0.400 mg/day and Trimegestone 0.06 mg/day|Vaginal ring with a nominal delivery rate of 0.400 mg/d estriol (E3) and 0.06 mg/d trimegestone (TMG), vaginal application
45477036|NCT03343912|Drug|Estriol 0.300 mg/day and Trimegestone 0.12 mg/day|Vaginal ring with a nominal delivery rate of 0.300 mg/d estriol (E3) and 0.12 mg/d trimegestone (TMG), vaginal application
45477037|NCT03343912|Drug|Estriol 0.200 mg/day and Trimegestone 0.18 mg/day|Vaginal ring with a nominal delivery rate of 0.200 mg/d estriol (E3) and 0.18 mg/d trimegestone (TMG), vaginal application
45351554|NCT01052311|Drug|Tredaptive (1 g extended release niacin+ 20 mg laropiprant)|Laropiprant (LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) once daily for the first 30 days. from day 31 to 90 it will be 2 g of extended-release niacin and 20 mg laropiprant once daily.
45351555|NCT01052311|Drug|Placebo|Placebo tablets once daily
45477038|NCT03833219|Behavioral|Weekly feedback|Send push notification reporting user's handheld phone use while driving compared to distribution for driver cohort (age, geographic area) each week.
45477039|NCT03833219|Behavioral|End of intervention period incentive|Notify participant about potential incentive at the end of the intervention period, but do not provide weekly feedback about performance.
45842472|NCT01207908|Drug|IGF-1|IGF-1 will be administered once daily by subcutaneous injection every morning with breakfast. Duration 6 months.
45842473|NCT01208220|Device|Negative Pressure Wound Therapy|NPWT changed 3 times weekly
45842474|NCT01208220|Biological|Collagenase Ointment|Apply TIW
45842475|NCT01208922|Drug|Rifamycin SV-MMX®|2 Rifamycin SV-MMX® 200 mg tablets and 1 placebo to ciprofloxacin capsule, b.i.d.
45842476|NCT01208922|Drug|Ciprofloxacin|1 ciprofloxacin 500 mg capsule and 2 placebos to Rifamycin SV-MMX® 200 mg tablets, b.i.d.
45842477|NCT01209702|Biological|tocilizumab|Administered intravenously (iv) every 4 weeks
45842478|NCT01209702|Drug|Placebo|Placebo to tocilizumab administered intravenously every 4 weeks
45842479|NCT01210170|Drug|placebo|placebo inhalation before albuterol.
45842480|NCT01210170|Drug|mometasone 400 mcg|mometasone inhalation before albuterol.
45842481|NCT01210170|Drug|mometasone 200 mcg|200ug mometasone before albuterol.
45842482|NCT01210560|Drug|Tolvaptan MR|20 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
45842483|NCT01210560|Drug|Tolvaptan MR|20 mg Tolvaptan MR capsule(morning and afternoon); Placebo capsules/tablets (morning and afternoon) for 7 days
45842484|NCT01210560|Drug|Tolvaptan MR|60 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
45686150|NCT05605132|Other|Tactile Acuity Training|Participants will be requested to lie face down. Five points will be marked in the painful areas on the right and left sides of the neck. The distance between the points will equal the two-point discrimination value. A photograph of the neck will be taken. The patient will not see his/her own neck during the application but see the photograph of his/her neck. The points will be touched lightly with two different stimuli (a pen with a 2 mm diameter and a mushroom probe with an 11 mm diameter). Participants will be asked about the location and type of the stimuli. The interstimulus interval will be 15 seconds. If more than 90% of correct answers are obtained, the distance between the points will be reduced by 10%. The training will be performed in three separate blocks, a total of 72 stimuli (block duration = 6 minutes, rest time between blocks = 3 minutes, number of stimuli applied in each block = 24 stimuli). The treatment time will be 24 minutes.
46045651|NCT02864628|Biological|MVA-BN-RSV|MVA-mBN294B
45686151|NCT05605132|Other|Control Group|The participants will be evaluated two times at 4-week intervals. No intervention will be applied during the time frame.
45351556|NCT01052311|Drug|Tredaptive|Tredaptive 1 g [Laropiprant 20 mg(LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) and 1 g of extended-release niacin]from day 1 to 30 once daily. From day 31 to 90, the same but 2 g instead of 1 g of extended-release niacin.
45351557|NCT00988078|Drug|Placebo|Capsule (without biologic action) administered three times a day for six months
45351558|NCT00988078|Drug|Metformin|Metformin 500mg three times a day for six months
45351559|NCT00895089|Drug|Moxifloxacin (Avelox)|moxifloxacin 400 mg IV qd for 14 days, followed by moxifloxacin 400 mg po qd for another 1 week
45351560|NCT00895089|Drug|ceftriaxone|ceftriaxone 2 gm IV q 12 h for 14 days, followed by cephalexin 1 gm PO q 6 h for 1 week
45351561|NCT00982540|Drug|caspofungin as preemptive antifungal therapy|70 mg day 1 followed by 50 mg/day IV
45351562|NCT00897741|Genetic|microarray analysis|
45686152|NCT04780906|Other|Wrist taping|Wrist taping as used as standard in CrossFit practice
45351563|NCT00897741|Other|laboratory biomarker analysis|
45351564|NCT04674358|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
45351565|NCT04674358|Drug|Vehicle Opthalmic Solution|Vehicle Ophthalmic Solution administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
45351566|NCT00897819|Genetic|DNA methylation analysis|
45842485|NCT01210560|Drug|Tolvaptan IR|90 mg Tolvaptan IR tablet(morning); 30 mg Tolvaptan IR tablet (afternoon); Placebo capsules (morning and afternoon) for 7 days
45351567|NCT00897819|Genetic|loss of heterozygosity analysis|
46045652|NCT02864628|Other|Placebo|Tris Buffered Saline
46045653|NCT05297461|Other|Medication review|Community pharmacy benchmarking guideline Pharmaceutical Services Division provides guidelines for medication review in community pharmacy settings in Malaysia
45351568|NCT00897819|Genetic|microsatellite instability analysis|
45351569|NCT00897819|Other|laboratory biomarker analysis|
45351570|NCT00366535|Drug|Placebo|4 tabs b.i.d.
45351571|NCT00366535|Drug|Neurotropin|4 tabs b.i.d.
45351572|NCT00982618|Drug|Lidocaine|1% Lidocaine 1mg/kg/hr IV drip x 48hr
45351573|NCT00982618|Procedure|Epidural Block|0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
45351574|NCT00982618|Drug|PCA Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
45477040|NCT03833219|Behavioral|Loss-framed weekly incentive|Send push notification reporting user's handheld phone use while driving compared to distribution for driver cohort (age, geographic area) each week. Pay participant weekly according to where they fall on the distribution each week.
45477041|NCT02509858|Drug|thyroxine|treatment with 50μg of thyroxine once daily for two months.
46045654|NCT00810043|Device|Kyphon® Curette|The Kyphon® Curette is intended to scrape and score bone in the spine. It may be used as an adjunctive device with Kyphon's family of standard access and fracture reduction instruments designed to treat compression fracture during balloon kyphoplasty procedures
45686153|NCT03996460|Drug|Placebo|"Fifteen (15) patients in group 1 will receive the sachet of matching placebo ( equivalent to a capsule of placebosugar pill) orally daily for 12 weeks (90 days) without food."
45842486|NCT01210560|Drug|Tolvaptan MR|120 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
45351575|NCT00895167|Dietary Supplement|curcumin|one oral dose of 12 caplets = 12 g curcumin
45686154|NCT03996460|Drug|192 mg powder of K0706|Fifteen (15) patients in group 2 will receive the sachet of 192 mg powder of K0706 ( equivalent to 96 mg capsule of K0706) orally for 12 weeks (90 days) without food.
45842487|NCT01210716|Device|Therapeutic plasma exchange|Patients are randomized to either Therapeutic plasma exchange procedures on AMICUS or Spectra first. The second procedure (based on time interval determined by physician) will be completed on the other instrument.
45842488|NCT01211106|Behavioral|Prolonged Exposure|Although almost every form of psychotherapy has been advocated for PTSD, all evidence-based psychotherapies for PTSD are CBT programs that include variants of exposure therapy (Prolonged Exposure), cognitive therapy (CT), stress inoculation training (SIT), eye movement desensitization and reprocessing (EMDR), or combinations of these procedures. Exposure therapy involves helping PTSD sufferers to gradually confront distressing trauma-related memories and reminders to facilitate successful emotional processing of the trauma memory and reduction of associated distress. Most exposure therapy programs include both imaginable confrontation with the traumatic memories and in vivo exposure to trauma reminders.
45842489|NCT01211106|Behavioral|Motivational Enhancement Therapy|Motivational Interviewing (MI) is defined as a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. MI is characterized by its spirit, which is defined as collaboration with the client, evocation of the client's own perceptions, goals, and values, and respect for the client's autonomy.
45842490|NCT01211340|Behavioral|ACTIVE|Assessing Caregivers for Team Intervention via Video Encounters: this intervention uses video technology to bridge geographic distance to empower hospice caregivers to participate in plan of care meetings for their patient
45842491|NCT01211730|Drug|Insulin|Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.
45842492|NCT01212900|Drug|Statins, HMG CoA|Statin therapy
45842493|NCT01215240|Device|Peritoneal dialysis|Prophylactic peritoneal dialysis
45842494|NCT01215318|Device|modified vaginal tampon|modified vaginal tampons versus unmodified vaginal tampons, comparing the urinary contamination
45842495|NCT01215786|Drug|AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)|One drop of AGN-207281 ophthalmic solutions (0.1% on Days 1-7 and 0.3% on Days 8-14) instilled to both eyes in the morning followed by one drop of AGN-207281 vehicle ophthalmic solution (placebo) instilled to both eyes in the evening for 13 days.
45842496|NCT01215786|Drug|timolol ophthalmic solution 0.5%|One drop of timolol ophthalmic solution 0.5% instilled to both eyes, in the morning for 14 days, and in the evening for 13 days
45842497|NCT01215786|Drug|AGN-207281 vehicle ophthalmic solution (Placebo)|One drop of AGN-207281 vehicle ophthalmic solution instilled to both eyes, in the morning for 14 days and in the evening for 13 days.
45842498|NCT01216410|Drug|Metoclopramide|Prophylactic Metoclopramide 10 mg given before spinal together with prophylactic phenylephrine infusion
45842499|NCT01216410|Drug|Phenylephrine infusion|Prophylactic phenylephrine infusion after spinal and placebo antiemetics
46045655|NCT04807933|Behavioral|Heart rate variability Biofeedback [HRV-BFB]|BFB consists of a physiological recording used as a visual physiological feedback that can teach us how to control our physiology, which is naturally unconscious and uncontrollable. The BFB focused on the heart rate variability (HRV-BFB) could regulate the autonomic nervous system (vagal tone and sympathetic-parasympathetic balance) and the emotional state. The HRV BFB has received several clinical and experimental confirmations as a physiological remediation method. It is an innovative and non-pharmacological therapy frequently used to relieve stress.
46045656|NCT05156203|Drug|T-1301 Capsules|T-1301 Capsules, 10 and 50 mg, are opaque hard gelatin capsules for oral administration.
46045657|NCT01120184|Drug|docetaxel|75 mg/m2 or 100 mg/m2 intravenously every 3 weeks for a minimum of 6 cycles.
46045658|NCT01120184|Drug|paclitaxel|80 mg/m2 intravenously weekly for a minimum of 18 weeks
45842500|NCT01216410|Drug|Combination Group|Metoclopramide and ondansetron prophylaxis with phenylephrine infusion
45842501|NCT01218048|Drug|Cetuximab|Pre-Surgery: IV, 400 mg/m2 day 1 then 250 mg/m2 alone days 8 and 15; Post-surgery: IV, 250 mg/m2 weekly concurrent with RT
45842502|NCT01218048|Procedure|Surgery|Surgery for tumor
45842503|NCT01218048|Radiation|Post-surgical radiation|Radiation (2 Gy/d) to min of 60 Gy + max of 66 Gy post-surgery
45842504|NCT01218048|Drug|Cisplatin or carboplatin|Cisplatin 30 mg/m2 or carboplatin AUC 1.5-2/week weekly, Concurrent with radiotherapy
45351576|NCT00988234|Procedure|SGPP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position
45351577|NCT00988234|Procedure|SGTPP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position
45351578|NCT00988234|Procedure|SGLP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position
45351579|NCT00988234|Procedure|SGTLP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
45686155|NCT03996460|Drug|384 mg powder of K0706|Fifteen (15) patients in group 3 will receive the 384 mg powder of K0706 (equivalent to 192 capsule of K0706) orally daily for 12 weeks (90 days) without food.
45686156|NCT04780594|Procedure|The study evaluates all surgical patients operated, both elective scheduled and emergent cases|Administrative database was automatically collected. That included demographic, clinical antecedents, surgical team and surgical procedure, primary and secondary diagnoses and principal and secondary surgical procedures. A case-mix grouping system administrative automatic recorded based on the ICD-10-AM International Classification of Diseases. According to the Diagnoses-related Groups (DRG's). the Severity of Illness Index assigns to each patient an overall severity score (from 1 to 4) and mortality risk score (from 1 to 4)
45686157|NCT04780750|Drug|Docetaxel|Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\m2) and cisplatin (80mg\m2 every 3 weeks)
45686158|NCT04780672|Drug|Molixan|The investigational drug in this study is Molixan in the dosage form of 30 mg/ml solution for intravenous and intramuscular injection. Against the background of standard therapy: Molixan® at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
45842505|NCT01218672|Device|Photoselective Vaporization of the Prostate|"GreenLight XPS laser console GreenLight XPS consists of a 532 nm laser console capable of achieving power outputs between 20W and 180W. Laser technology is used to vaporize tissue for debulking prostatic hyperplasia and improvement of lower urinary tract symptoms. The 532 nm wavelength is in the visible spectrum as green light and is strongly absorbed by oxyhemoglobin.~GreenLight XPS will be used in conjunction with the MoXy™ fiber. The fiber features a side firing mechanism delivering up to180W of 532 nm light to vaporize and coagulate the prostate tissue. The fiber is guided to the treatment site by the continuous flow cystoscope, consisting of an inner and outer sheath set, 30ْ forward oblique telescope and visual obturator."
45842506|NCT01218672|Device|Transurethral Resection of the Prostate|Monopolar and bipolar loop TURP Systems The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system that carry the CE mark may be used for the study.
45842507|NCT01218984|Drug|Medisorb naltrexone 75 mg|Single administration via intramuscular (IM) injection.
45842508|NCT01218984|Drug|Medisorb naltrexone 150 mg|Single administration via IM injection.
45842509|NCT01218984|Drug|Medisorb naltrexone 300 mg|Single administration via IM injection.
45842510|NCT01218984|Drug|Hydromorphone (10 mg/mL)|Increasing doses of 0, 3, 4.5, and 6 mg were administered at baseline (pre-study drug administration). After study drug administration, additional hydromorphone challenge sessions consisting of administering 0, 3, 4.5, and 6 mg were administered at 1-hr intervals at each of the postdose evaluation visits. In addition, at a randomly selected evaluation visit, subjects received four 0 mg (placebo) doses at 1-hour intervals.
46045659|NCT01120184|Drug|pertuzumab|840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
46045660|NCT01120184|Drug|pertuzumab-placebo|840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
45351580|NCT00902421|Drug|Selective serotonin reuptake inhibitors|escitalopram 10mg once daily for 3 months
45351581|NCT00902421|Drug|Antimuscarinics|Antimuscarinics for 3 months
45351582|NCT00985660|Drug|Nisoldipine Extended-release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
46045661|NCT01120184|Drug|trastuzumab [Herceptin]|trastuzumab [Herceptin] doses when administered with docetaxel: 8 mg/kg intravenously on cycle 1 followed by 6 mg/kg every 3 weeks in subsequent cycles or trastuzumab (Herceptin) doses when administered with paclitaxel: 4 mg/kg intravenously on day 1 of cycle 1 followed by 2 mg/kg weekly starting on day 8 of cycle 1.
45351583|NCT00985660|Drug|Sular® Extended Release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
45351584|NCT00350545|Drug|Rituximab|375 mg/m2;IV infusion once weekly for four doses (days 1,8,15,22); option for second 4-week course at week 9
45351585|NCT00350545|Drug|Prednisone|1 mg/kg; po per day with taper
46045662|NCT01120184|Drug|trastuzumab emtansine|3.6 mg/kg intravenously every 3 weeks
46045663|NCT01120028|Drug|Alemtuzumab|Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart
45351586|NCT00350545|Drug|Cyclosporine A|trough 200-300 or lower; po
45351587|NCT00350545|Drug|tacrolimus|trough 5-10 or lower; po
45351588|NCT04006054|Drug|Dexmedetomidine|When the patients who suffered traumatic brain injury are in NICU，Dexmedetomidine is given for sedation about 5 days .
45351589|NCT04006054|Drug|Midazolam|When the patients who suffered traumatic brain injury are in NICU，Midazolam is given for sedation about 5 days .
45351590|NCT00897975|Dietary Supplement|red yeast rice|600 mg 3 capsules bid
45351591|NCT00897975|Drug|phytosterol|phytosterol 450 mg 2 tabs bid with food
45351592|NCT00897975|Behavioral|therapeutic lifestyle program|TLC - 12 weeks
45351593|NCT00897975|Drug|placebo|placebo
45351594|NCT00985816|Dietary Supplement|Lactobacillus Reuteri|L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day
45351595|NCT00985816|Dietary Supplement|Placebo|Placebo
45351596|NCT01052389|Drug|Aripiprazole|Patients allocated to aripiprazole will be prescribed daily oral dose of drug, based on individual response and side-effects. Suggested starting dose will be 10 mg/day and dose range will be 10-30 mg/day.
46045664|NCT01120028|Drug|Basiliximab|20 mg intravenously, two doses 96 hours apart
45477042|NCT02509858|Drug|Placebo|treatment with 50μg of placebo, once daily, for two months.
45477043|NCT02509858|Other|A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)|
45477044|NCT05706662|Procedure|inguinal hernia repair with mesh|inguinal hernia repair with mesh
45477045|NCT01201187|Drug|YY-162|YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication
45477046|NCT01201187|Drug|Placebo|Placebo 1T/twice a day(bid) for 8weeks, po medication
45477047|NCT05706584|Other|control grup (skills lab.) and experimental group (mateverse skill lab.)|The universe of the study consists of students (N: 190) who took a pediatric nursing course in the 3rd year of the Teaching Department at Istanbul Medipol University. The sample of the study will consist of the students who took the 3rd year child health and diseases nursing course in the nursing department, accepted the study, and met the study criteria. It will try to reach the universe where the sample selection of the research will not be made. With the simple randomization method, students will be assigned to the experimental and control groups. Even the last digit of the student number will be randomized to the experimental group and odd ones will be randomized to the control group
45477048|NCT03842579|Other|Resistance training|Supervised progressive explosive type heavy-resistance training two times per week
45477049|NCT03842579|Other|High-protein diet|Daily supplementation with milk-based protein-rich products
45477050|NCT03842579|Other|Recommendations|Provided with the official national recommendations on nutrition
45477051|NCT05217290|Behavioral|transtheoretical model|The Transtheoretic Model is a conscious behavior change model and argues that behavior change is a process and that the attempts made in accordance with the change stage of the individual facilitate the change, otherwise resistance to behavior change is developed.
45842511|NCT01218984|Drug|Naloxone Challenge and Oral Naltrexone Tolerability Testing|Administered according to the instructions provided by the respective manufacturer. Testing occurred at least 7 days after the baseline hydromorphone challenge and prior to study drug administration.
45842512|NCT01220466|Device|STAR S4IR LASIK with iDesign Aberrometer|CustomVue LASIK targeted for emmetropia
46045665|NCT01120028|Drug|Sirolimus|Sirolimus: target trough levels 6-12 ng/mL for first 6-months after maintenance therapy randomization, then 5-10 ng/mL
45477052|NCT02505256|Other|No intervention|
45477053|NCT03551951|Diagnostic Test|Test for circulating tumor cells, DNA alterations|
45477054|NCT02510092|Device|Percutaneous coronary intervention with new generation fully resorbable scaffold|
45477055|NCT02505100|Other|Touching relaxant|
45477056|NCT02505100|Other|Hypnoses|
45477057|NCT05669417|Drug|Magnesium sulfate|Based on serum levels, bolus and or continuous administration is provided as dictated by study protocol.
45477058|NCT02513992|Procedure|intra-arterial injection of tracer|intra-arterial ictal injection of perfusion tracer
45477059|NCT02513992|Drug|99m-Technetium Ethyl Cysteinate Dimer|administration of perfusion tracer 99m Tc-ECD during epileptic seizure
45477060|NCT02513992|Device|intra-arterial catheter|placement of intra-arterial catheter via femoral artery
45477061|NCT02513992|Device|pressure injector|the injection of the perfusion tracer will be delivered with a pressure injector
45477062|NCT03832673|Drug|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks (for 3 cycles)
45686159|NCT04780672|Drug|Placebo|Placebo will be used as a comparator drug and will be an analogue of the investigational drug without active substance. Against the background of standard therapy: Placebo at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
45686160|NCT04780984|Drug|Tiotropium bromide inhalation solution|Tiotropium bromide inhalation solution
45842513|NCT01222260|Drug|Bendamustine|"Patients will start bendamustine at dose level 0 and according to CrCl on day 1 and 2 of each cycle:~CrCl ≥ 60 mL/min: 100 mg/m2 IV on day 1 and 2 of each cycle~CrCl 59 - 30 mL/min: 90 mg/m2 IV on day 1 and 2 of each cycle~Available to qualifying subjects is the option to dose escalate to dose level (+)1:~120 mg/m2 (if CrCl ≥ 60 mL/min at the time of inclusion into the study)~100 mg/m2 (if CrCl 59-30 mL/min at the time of inclusion into the study)"
45842514|NCT01222260|Drug|Dexamethasone|40 mg orally on days 1, 8, 15, 22 of each cycle
46045666|NCT01120028|Drug|Tacrolimus|Tacrolimus: target trough levels 5-7 ng/mL after maintenance therapy randomization.
46045667|NCT00878800|Drug|PXD101|Administered in combination with doxorubicin (BelDox)
46045668|NCT00878800|Drug|Doxorubicin|Administered in combination with PXD101 (BelDox)
46045669|NCT00662272|Biological|Fluzone vaccine with JVRS-100 adjuvant|One vaccination on Day 0 with Fluzone vaccine at 22.5µg mixed with JVRS-100 adjuvant at one of four dose levels (7.5µg, 25µg, 75µg, 225µg) given by IM injection in the upper deltoid.
45351597|NCT01052389|Drug|Olanzapine|Patients allocated to olanzapine will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden. Suggested starting dose will be 5 mg/day and dose range will be 10-20 mg/day.
45351598|NCT01052389|Drug|Haloperidol|"Patients allocated to haloperidol FGA arm will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden.~Suggested starting dose will be 1-3 mg/day and dose range 3-10 mg/day (chlorpromazine equivalents: suggested starting dose 50-100 mg/day; dose range 150-300 mg/day)."
45351599|NCT02539485|Other|heating precondition|The streamlined liner of the pharynx airway (SLIPA) was heated 2 hours before use.
45351600|NCT01052467|Drug|Xamiol® Gel|Once daily application for about 4 weeks
45477063|NCT03832673|Drug|Epacadostat|Epacadostat 300 mg (BID) orally continuously every 28 days (for 3 cycles)
45686161|NCT04780984|Drug|Placebo|Placebo comparator
45686162|NCT04773340|Behavioral|Dialectical Behavior Therapy|Behaviorally-focused intervention for individuals with personality disorder and a history of significant behavioral problems.
46045670|NCT00662272|Biological|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 22.5µg given by IM injection in the upper deltoid.
46045671|NCT00662272|Biological|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 45µg given by IM injection in the upper deltoid.
45351601|NCT05277987|Drug|HEC-016(0.5×10^6 CAR-T Cells)|The initial dose is set to 0.5 × 10^6 car-t cells / kg, and 3 ~ 6 subjects are expected to be included in the dose group. DLT was observed within 28 days after cell infusion.
45351602|NCT05277987|Drug|HEC-016(0.5×10^6.5 CAR-T Cells)|The Second dose is set 0.5 × 10^6.5 car-t cells / kg, and 3 ~ 6 subjects are expected to be included in the dose group.
46045672|NCT00662350|Device|The Wallterm™ System|The Wallterm™ System is intended to ablate prostatic glandular and stromal tissue to relieve moderate to severe symptoms of outflow obstruction secondary to benign prostatic hyperplasia (BPH).
45477064|NCT04499716|Procedure|IPACK|25 milliliters of ropivacaine 0.3% will be injected between popliteal artery and femur.
45477065|NCT04499716|Procedure|Femoral triangle block|25 milliliters of ropivacaine 0.3% will be injected on the lateral side of the femoral artery at the distal part of the femoral triangle.
46045673|NCT00662428|Other|Symptom based discharge management|Depressive symptoms of patients are weekly assessed by Beck Depression Inventory (BDI II). Patients are discharged when BDI-score is under 20 points. Patients are treated in the same hospital for two more weeks as outpatients before being referred to outpatient care (general practitioner or specialist).
45477066|NCT04499716|Procedure|Obturator nerve block|20 milliliters of ropivacaine 0.3% will be injected between the adductor magnus and adductor brevis muscles and between the adductor brevis muscle the pectineus.
45477067|NCT04499716|Procedure|Femoral nerve block|20 milliliters of ropivacaine 0.3% will be injected in supine position under the fascia iliaca lateral to the femoral artery.
45477068|NCT04499716|Procedure|Sciatic nerve block|25 milliliters of ropivacaine 0.3% will be injected in prone position in the subgluteal space by lateral approach.
45686163|NCT02090374|Other|Poly ICLC|Dose escalation: 10ug, 100ug, 500ug Highest dose: 1000ug
45686164|NCT02090374|Other|Poly I:C|Single dose: 500ug
46045674|NCT00662428|Other|Treatment as usual|Treatment as usual is the usual stationary depression treatment which consists of a combination of several psychopharmacological and psychotherapeutical treatments. Duration of treatment is varying widely.
45351603|NCT05277987|Drug|HEC-016(0.5×10^7 CAR-T Cells)|The Third dose is set 0.5 × 10^7 car-t cells / kg, and 3 ~ 6 subjects are expected to be included in the dose group.
45686165|NCT02090374|Other|R848|High dose: 10ug Low dose: 1-2ug
45686166|NCT02090374|Other|Timothy Grass Pollen|Dose: 5000 SQ-U/100µl
45686167|NCT02090374|Other|Vitamin D|4000U orally
45686168|NCT02090374|Other|Tuberculin|Tuberculin PPD
45351604|NCT00895323|Other|enzyme-linked immunosorbent assay|
45351605|NCT00895323|Other|pharmacological study|
45351606|NCT00895323|Procedure|whole-body scintigraphy|
46045675|NCT04158856|Drug|Pyrotinib|400mg po every day
46045676|NCT04158856|Drug|Trastuzumab|Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days
45351607|NCT00895323|Radiation|iodine I 131-labeled anti-CEA/anti-HSG bispecific monoclonal antibody TF2|
45351608|NCT00898053|Other|laboratory biomarker analysis|Correlative studies
45351609|NCT00349921|Drug|clonidine|Clonidine-a drug commonly used to treat high blood pressure-has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain.
45477069|NCT04499716|Procedure|Lateral femoral cutaneous nerve block|5 milliliters of ropivacaine 0.3% will be injected laterally to the sartorius muscle.
45477070|NCT03832283|Diagnostic Test|CAD-MDD/CAT-DI screening via MyChart|Patients will receive invitations via MyChart to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (<50=normal, 50 to 65=mild, 66 to 75=moderate, and >75=severe).
45477071|NCT03832283|Diagnostic Test|CAD-MDD/CAT-DI screening during clinic visit|During routine in-clinic visits, medical assistants or providers will ask patients to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (<50=normal, 50 to 65=mild, 66 to 75=moderate, and >75=severe).
45477072|NCT03832283|Other|CAT-DI monitoring via MyChart|Patients with active MDD will receive invitations via MyChart to complete the CAT-DI to assess MDD severity and remission. A normal CAT-DI score (<50) will indicate that a patient's MDD is in remission.
45686169|NCT04772716|Procedure|operation|The intervention was not decided by the investigator but studied following emergency or elective surgeries undergoing in the system
45686170|NCT04772794|Other|fraction of inspired oxygen|after induction of general anaesthesia, different fraction of inspired oxygen will be given to patient according to their group allocation
45686171|NCT04773028|Other|matrix metalloproteinase enzymes 2 and 9|concentration of matrix metalloproteinase 2 and 9 enzymes
45686172|NCT04772872|Other|Assessment by Brazelton neonatal behavior for group A,Band C|"Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~Apgar score will be represented by the variance of degree of scores.~Birth weight will be measured in grams."
45686173|NCT02222740|Drug|10 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
46045677|NCT00659308|Procedure|amniotic membrane transplantation|patients are submitted to amniotic membrane transplantation
45477073|NCT03832283|Other|PHQ-9 monitoring during clinic visits|During routine in-clinic visits, medical assistants or providers will ask patients to complete the PHQ-9 to assess MDD severity and remission. A PHQ-9 score < 5 will indicate that a patient's MDD is in remission.
45842515|NCT01222494|Behavioral|Behavioral Weight Loss|This intervention is a family-based, behavioral weight loss program that has been employed in studies with overweight and obese children, as well as with children who have diabetes. For the proposed study, the program has been modified to fit the needs of disruptive and behaviorally disturbed youth and their families. The modified program includes 16 weeks of weekly visits with a study interventionist, and supplemental phone contacts as needed. Phone contacts will only replace in-person visits if absolutely necessary to achieve the visit.
45686174|NCT02222740|Drug|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
45686175|NCT04752982|Behavioral|c-SIGHT intervention|The c-SIGHT active intervention involves grasping, lifting and balancing wooden rods using the unaffected hand. C-SIGHT uses a training mat, three wooden rods of different lengths, a laptop (to run the computer program) and a small motion tracking sensor which records the user's session length and trials completed. The participant's existing television is used to present the program (connected to the laptop).
45686176|NCT04752982|Behavioral|c-SIGHT attentional control|The c-SIGHT attentional control exercises involves grasping and lifting wooden rods from one end using the unaffected hand. Identical to the intervention group, the c-SIGHT attentional control version uses a training mat, three wooden rods of different lengths, a laptop (to run the computer program) and a small motion tracking sensor which records the user's session length and trials completed. The participant's existing television is used to present the program (connected to the laptop).
45351610|NCT00349921|Drug|adenosine|Adenosine-a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms-has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.
45686177|NCT04780360|Procedure|Cayanoacrylate tissue adhesives|Cyanoacrylates are a family of strong fast-acting adhesives with industrial, medical, and household uses. They are various esters of cyanoacrylic acid. The acryl groups in the resin rapidly polymerize in the presence of water to form long, strong chains
45686178|NCT04780360|Procedure|Silk suture|Non Absorbalble suture materiel used to fixed the edges of the incision in place until healing
45351611|NCT00349921|Drug|placebo|inactive substance
46045678|NCT00659308|Procedure|anterior stromal puncture|the other group is submitted to anterior stromal puncture
46045679|NCT01119950|Drug|NVA237 12.5 µg once daily|NVA237 12.5 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
46045680|NCT01119950|Drug|NVA237 25.0 µg once daily|NVA237 25.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
46045681|NCT01119950|Drug|NVA237 12.5 µg twice daily|NVA237 12.5 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
46045682|NCT01119950|Drug|NVA237 50.0 µg once daily|NVA237 50.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
46045683|NCT01119950|Drug|NVA237 25.0 µg twice daily|NVA237 25.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
45351612|NCT00349921|Drug|placebo|inactive substance
45351613|NCT00902655|Drug|Desmopressin|Desmopressin 0.1,0.2 or 0.4 mg once daily for 3-weeks of dose titration phase and 4-weeks of treatment phase
45351614|NCT01052623|Drug|Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate|1 mg Estradiol valerate with for two days before GH-testing pre pubertal girls older than 8 years and pre pubertal boys older than 10 years. L-Arginin-Hydrochloride in the vein (0.5 g/kg KG maximum dose 30g) over 30 minutes. Clonidine orally (0,075 mg/m2 BSA). Somatropin-NutropinAq subcutaneum,a single one shot (dose 0.03 mg/KG, daily, over five days).
45351615|NCT00902733|Other|medical chart review|
45351616|NCT00902733|Other|questionnaire administration|
45351617|NCT00902733|Procedure|fatigue assessment and management|
45351618|NCT00902733|Procedure|psychosocial assessment and care|
45351619|NCT00902733|Procedure|quality-of-life assessment|
46045684|NCT01119950|Drug|NVA237 100.0 µg once daily|NVA237 100.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
45351620|NCT01058785|Biological|Lucanix|Monthly intradermal injections of four irradiated allogeneic TGF-beta2 antisense gene modified NSCLC cell lines. Patients are randomized to receive either 12,500,000, 25,000,000 or 50,000,000 cells per injection for up to 16 injections.
45351621|NCT00898209|Genetic|protein expression analysis|Blood and exhaled breath condensate will be collected.
45351622|NCT00898209|Genetic|proteomic profiling|Blood and exhaled breath condensate will be collected.
45351623|NCT00898209|Other|biologic sample preservation procedure|Blood and exhaled breath condensate will be collected.
45351624|NCT00898209|Other|laboratory biomarker analysis|Blood and exhaled breath condensate will be collected.
45351625|NCT00898209|Other|matrix-asst laser desorption/ionization time flight mass spectrometry|Blood and exhaled breath condensate will be collected.
45351626|NCT00898209|Other|questionnaire administration|Questionnaire will be completed.
45477074|NCT04499638|Device|Peripheral vascular catheters|Carry time of common peripheral vascular devices in clinical practice and the reason for his withdrawal
46045685|NCT01119950|Drug|NVA237 50.0 µg twice daily|NVA237 50.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
46045686|NCT01119950|Drug|Placebo to NVA237 once daily|Placebo to NVA237 via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
45351627|NCT01325077|Other|model of health care service|Conventional model(C): Nurses give fixed-dose analgesic according to surgeons' prescription Study model(S): Nurses give initial-dose analgesic according to surgeons' prescription. In case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.
45477075|NCT03548935|Drug|Semaglutide|Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks. Dose escalation of semaglutide will take place as follows: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 68.
45477076|NCT03548935|Drug|Placebo (semaglutide)|Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks.
45477077|NCT04499014|Device|ultrasound|5 days a week, a total of 10 sessions
45477078|NCT03832205|Device|Capaciflector monitoring|Non-invasive capaciflector monitoring of respiratory rate and heart rate.
45477079|NCT02513758|Other|sample|Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
45477080|NCT01485497|Device|3D endoscopic Fourier Domain OCT|Evaluation of Obstructive Sleep Apnea
45686179|NCT04780438|Drug|Dapagliflozin|Patients rendomized in this arm will receive dapagliflozin at a target dose of 10mg once daily.
45351628|NCT00902811|Drug|AM(FDC)|Artesunate-mefloquine fixed dose combination (artesunate 25mg/mefloquine hydrochloride 55mg, or artesunate 100mg/mefloquine hydrochloride 220mg), according to age-group.
45842516|NCT01222494|Behavioral|Diet and Exercise Education|Participants assigned to this arm will receive monthly medically validated, individualized diet and exercise education by a trained research professional.
45351629|NCT00902811|Drug|AM(LT)|Artesunate (Arsumax®, Sanofi) 50 mg tabs given at 4 mg/Kg/day on day 0, day 1 and day 2 (total 12 mg/Kg) PLUS Mefloquine 250 mg base tabs given at 25 mg/Kg on day 0. Treatment is given in three equally divided daily doses to the nearest quarter tablet.
45351630|NCT00902811|Drug|AL|Coartem®: artemether 20 mg - lumefantrine 120 mg co-formulated tabs (Coartem®, Novartis) given as six twice-daily doses over three days, according to weight-groups. The second dose should be taken 6 to 10 hours after the first dose, given at inclusion. Patients will be advised to take some fatty food (or encouraged to give breast feeding) before each dose is taken. Fatty food or milk will not be provided by the researchers.
45477081|NCT02504944|Drug|Propranolol 0.2% eye drops|Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, four times daily (every 6 hours). Propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP) Cooperative Group.
45686180|NCT04780438|Drug|Placebo|Patients rendomized in this arm will receive placebo.
45686181|NCT04780126|Other|Sarcopenia diagnosis|History, physical, laboratory and ultrasound parameters to diagnose sarcopenia
45686182|NCT04779892|Drug|Infliximab|100mg/vial
45686183|NCT02844868|Device|Active tDCS|During the first 20 min of training program, patient will have active tCDS : the patient received a 2 mA anodal tDCS over the lower limb ipsilesional motor area. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
45842517|NCT01222572|Radiation|Stereotactic boost|
45842518|NCT01222572|Radiation|Conventional RT|
45842519|NCT01222572|Drug|Etoposide|
45842520|NCT01222572|Drug|Cisplatin|
46045687|NCT02882828|Drug|switched from Prograf® to Envarsus®|
46045688|NCT02882126|Drug|Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump.
46045689|NCT01145222|Drug|A. CNS 7056|Initial low dose plus supplemental doses as necessary.
46045690|NCT01145222|Drug|B. CNS 7056|Initial intermediate dose plus supplemental doses as necessary.
45477082|NCT01201499|Drug|Intrathecal morphine|a single dose of intrathecal morphine (ITM, 4 µcg/kg, or ~0.1-0.3 mg morphine before induction of general anesthesia, followed by postoperative patient-controlled morphine analgesia (IV-PCA) for postoperative pain.
45477083|NCT01201499|Drug|Continuous IV remifentanil|a continuous infusion of IV remifentanil supported by a single bolus of IV morphine, 0.2 mg/kg at the end of surgery, followed by IV-PCA morphine.
45477084|NCT02504632|Other|test|"Peripheral venous citrated blood will be collected just before and 10-15 min after the implantation of the valve. Samples will be obtained after starting the infusion of contrast media. In peripheral venous blood before 24 h and after the procedure and at hospital discharge, 4-6 days when the usual transient thrombocytopenia after TAVI has recovered.~The results will be used to analyse the kinetics of haematological changes in peripheral blood following aortic valve replacement.~Platelet activation will be monitored by flow cytometry to assess the expression of specific membrane markers and the phosphorylation of signalling proteins, as well as the formation of platelet/monocyte aggregates."
45477085|NCT02504632|Other|control group|In this group, only one sample (2 tubes filled with 4.5 ml, i.e. 9ml) will be obtained in venous peripheral blood to establish reference values in age-matched, aspirin-treated, atherosclerotic population.
45477086|NCT03473639|Drug|Entinostat|In metastatic breast cancer patients, entinostat will be taken orally starting at 3 mg per week and will increase to 5 mg per week in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.
45842521|NCT01222884|Drug|Monofer|Iron isomaltoside 1000 (Monofer®) administered as 500 mg intravenous single bolus injection over approximately 2 minutes
45842522|NCT01222884|Drug|Iron sucrose|Iron sucrose is administered undiluted in doses of 100mg at baseline, 200mg at week 2 and 200 mg at week 4 as fractionated IV bolus injections according to local Summary of Product Characteristics
46045691|NCT01145222|Drug|C. CNS 7056|Initial high dose plus supplemental doses as necessary.
46045692|NCT01145222|Drug|D. Midazolam|Initial standardized dose plus supplemental doses as necessary.
45351631|NCT00902811|Drug|DP|40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/ Piperaquine 160 mg tablets),. Treatment is given according to age groups. In the age group <6yrs of age, a subdivision according to weight is made
45351632|NCT00902811|Drug|AA(FDC)|Artesunate-amodiaquine fixed dose combination (FDC) (Artesunate Amodiaquine Winthrop® Sanofi Aventis); Artesunate 25mg/amodiaquine 67.5mg; Artesunate 50mg/amodiaquine 135mg ; Artesunate 100mg/amodiaquine 270mg
45351633|NCT04035681|Behavioral|Problem-Solving Therapy|Problem-Solving Therapy is a brief psychosocial intervention for management of depressive symptoms. Participants will have six, one-hour sessions with an interventionist to learn a structured approach to problem-solving.
45351634|NCT04035681|Other|Stroke-Related Health Education|The stroke-related health education program will teach participants about various topics related to stroke. Participants will have six, one-hour sessions with an interventionist to learn about different topics related to stroke.
45477087|NCT03473639|Drug|Capecitabine|In metastatic breast cancer patients, capecitabine will be taken by mouth starting at 800 mg/m2 twice a day for 14 days per cycle and increase to 1000 mg/m2 (for 14 days per cycle) in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.
45351635|NCT02539173|Other|Ultrasound scan|"Non-invasive and non-irradiating. The diaphragmatic thickening in recovery is measured before and after the completion of the anesthetic block using the ultrasound system, the ultrasound probe and of an aqueous gel by trans-thoracic approach.~It measures the thickness on deep inspiration and expiration in supine position. Each measurement is repeated twice. This measurement series lasts 4 minutes, is repeated 15 minutes after completion of the engine block when a block is found and contralateral. The total measurement time is about 12 minutes."
45351636|NCT00898287|Drug|P276-00|Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/ m 2/day x 5 q 3 weeks Level 2 - 140 mg/ m2/day x 5 q 3 weeks Level 3 - 185 mg/ m2 /day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.
45477088|NCT02504710|Device|Kinematic Real Time Feedback|
45477089|NCT02504710|Other|Traditional systems of manual therapy teaching|
45477090|NCT03547687|Device|Electrical Stimulation Treatment|"An Intelect Neuromuscular Electrical Stimulator (NMES) (Chattanooga Group) device will be used to provide the stimulation. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 5 seconds on, 15 seconds off Ramp up and down time: 2 seconds each"
45842523|NCT01223352|Drug|bosentan|32 mg quadrisected dispersible tablet. The dosage of bosentan (2 mg/Kg) was adjusted according to the patient's body weight at initiation of the study treatment. Dosage readjustment was permitted after 12 weeks of treatment.
45842524|NCT01224210|Drug|Ambrisentan|Ambrisentan once-daily in the morning with or without food. The adult dose selected for this study will be 5 mg for the first 4 weeks. After the initial 4 weeks the dose will be increased to 10mg (available doses are 5, and 10 mg) based on tolerance safety. Subjects will remain on 10mg until they complete the study. Dose adjustments may be made based on side effects.
45842525|NCT01224444|Other|standard polypectomy snare|Electrocautery snare resection of sessile colonic polyps
46045693|NCT01145066|Drug|borage/echium oil combination|borage/echium oil combination containing 0.85g/day SDA and 1.7g/day GLA
46045694|NCT01145066|Dietary Supplement|fish oil|1.6g/day EPA and 1.08g/day DHA
46045695|NCT01145066|Dietary Supplement|corn oil|contains 4.5 g/day linoleic acid
46045696|NCT02883920|Other|Allergy and respiratory functional tests|
45351637|NCT00898287|Drug|Gemcitabine|Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m 2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity.
45351638|NCT02539251|Behavioral|Arabic ASQ -3|Administration of a developmental questionnaire in Arabic (A-ASQ-3) and validation using BSID-III as a gold standard
45351639|NCT04034823|Biological|KN035|KN035 5 mg/kg s.c. Q3W
45351640|NCT04034823|Biological|Trastuzumab|8 mg/kg IV loading followed by 6 mg/kg Q3W IV
45351641|NCT04034823|Drug|Docetaxel|100 mg/m2 Q3W IV
45842526|NCT01224678|Dietary Supplement|vitamin D|Given orally
46045697|NCT01132118|Drug|Hydroxychloroquine|Hydroxychloroquine comes in 200 mg tablets and is taken orally. The dose provided will be based upon a calculation of 6.5 mg/kg (subject's weight), which is the dose range commonly used to treat rheumatoid arthritis and lupus. Dosages will be rounded to the nearest 100 mg.
46045698|NCT00637442|Drug|Reminyl retard|retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg
46045699|NCT00972816|Biological|MF59-eH1N1|MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).
46045700|NCT02882048|Procedure|NADA Protocol|NADA Protocol is a standardized acupuncture technique in which five designated points in the ear are needled.
45477091|NCT03547687|Device|Neuromuscular Electrical Stimulation Treatment|"If a muscle contraction is not produced with the Intelect NMES portable device, the Vectra Neo Clinical Therapy System (Chattanooga Group) device will be used instead. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 10 seconds on, 30 seconds off Ramp up and down time: 2 seconds each"
45477092|NCT03840317|Biological|Autologous CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells
45351642|NCT00902889|Procedure|Stimulation|6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation GPE (upper cranial two contacts)
45477093|NCT02509780|Other|Vichy|Volunteers will be asked during 3 days to take their usual intake of fluids. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 1 pm. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 7 am and 7 pm. Ph and density measurement of urine will be made three times a day, at 7 am, 2 pm and 8 pm.
45477094|NCT03121690|Drug|Prednisone|prednisone 40 mg/day for 7 days
45477095|NCT03121690|Drug|placebo|5ml saline / day for 7 days
45477096|NCT01483703|Device|Laser Speckle Imaging|Laser Speckle Imaging of Critical Care Neonates
45477097|NCT03730831|Behavioral|Narrative Exposure Therapy|8-10 sessions: 1 lifeline session, 6-10 sessions narrative exposure, 1-2 sessions of future-oriented counselling
46045701|NCT02882048|Other|Medication management|Standard of care medication management defined by an opioid weaning protocol with specific, symptomatic medication regimens.
45351643|NCT00902889|Procedure|Stimulation|6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
45351644|NCT00895401|Dietary Supplement|Nepro with Carb Steady|Nepro with Carb Steady is a commercially available renal specific oral nutritional supplement designed to meet the nutrient needs of dialysis patients. The supplement is 8 oz and provides 425 kcal and 19 grams of protein.
45686184|NCT02844868|Device|Sham tDCS|During the first 20 min of training program, patient will have sham tCDS : the patient received a 2 mA anodal tDCS (only during the first and the last 30 seconds of the stimulation) and then, patient will have sham tDCS. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
45686185|NCT04771780|Drug|KHK7791|oral administration
45686186|NCT04389268|Diagnostic Test|Visual Event-Related Potentials|Auditory P300-evoked brain potential: an eventrelated potential of cognitive neurophysiological significance. It represents the brain response to certain sensory/cognitive stimuli by paying attention to the different stimulus among the stereotypical ones (the auditory oddball paradigm). It measures mainly the decision-making process (Polich and Kok, 1995).
45686187|NCT04771702|Device|Edmon|Exhaled air will be analyzed for propofol
45686188|NCT04771546|Device|Colpofix|Intravaginal gel with carboxymtheyl beta-glucan and polycabophil. Posology: 1 application / day x 20 days, rest 10. Repeat 20 x 3 cycles
45842527|NCT01224678|Other|placebo|Given orally
45842528|NCT01225068|Drug|Milnacipran|Total of 100 mg (50 mg twice a day) for 6 weeks. Option to increase to 200 mg (100 mg twice a day) after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
45842529|NCT01225068|Drug|Placebo|2 matching pills per day for 6 weeks. Option to increase dose after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
46045702|NCT05207306|Procedure|Type of interfascial plane block|"In the M-TAPA group, after finding the right 10th costal cartilage using ultrasound guidance, a anesthesiologist inject 0.375% ropivacaine 15ml into the lower aspect of the chondrium. Perform left M-TAPA in the same way.~In the subcostal TAPB group, a anesthesiologist inject 0.375% ropivacaine 15ml into end of right rectus abdominis muscle using ultrasound guidance. Perform left subcostal TAPB in the same way."
46045703|NCT00969618|Drug|Atomoxetine|40-120 milligrams/day (mg/day) taken by mouth, once a day for 48 weeks
46045704|NCT02864472|Procedure|PDT|PDT and ranibizumab
46045705|NCT02864472|Drug|Ranibizumab|Ranibizumab
46045706|NCT02864472|Drug|ranibizumab PRN|ranibizumab PRN
46045707|NCT00969540|Device|Active Mattress Cover|Active Mattress Cover
46045708|NCT00969540|Device|Placebo Mattress Cover|Placebo Mattress Cover
45351645|NCT00895401|Other|Standard of Care|Standard of Care for malnourished maintenance hemodialysis patients
45351646|NCT00606021|Drug|pemetrexed|500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles
45351647|NCT00606021|Drug|Best Supportive Care|Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
45477098|NCT03840551|Other|Biomechanical analysis with inertial sensors (XSENS) and motion capture (BTS)|The kinematics of lower limbs, trunk and upper limbs will be calculated both with inertial sensors (XSENS) and motion capture marker-based system (BTS ). Inertial sensors and markers will be placed on the subjects clothes and on the skin (totally non-invasive) to identify body segments. Then subjects will perform their motor tasks normally. Lately, through the data post-processing, the kinematics evaluated with both the systems will be used to describe how well the task is performed in terms of ACL prevention, through derived biomechanical parameters.
45477099|NCT03724591|Procedure|a high ligation of IMA|total mesorectal excision (TME) for rectal cancer by a high ligation of IMA without preservation of left colic artery
45477100|NCT03724591|Procedure|a low ligation of IMA|total mesorectal excision (TME) for rectal cancer by a low ligation of IMA with preservation of left colic artery
45477101|NCT03831269|Drug|Azithromycin|Patients will be randomly distributed and start taking azithromycin according to the known dose /kg/day for repeated cycles till improvement or reaching the end of study
46045709|NCT00975000|Drug|Cinacalcet|Possible sequential doses are 30, 60, 90, 120, and 180 mg.
45477102|NCT03831269|Other|nbUVB|The patients will be randomly distributed to start nbUVB sessions and clinical improvement will be compared to that of Azithromycin
45477103|NCT02513836|Other|Pre-education intervention|All study participants will be tested with a questionnaire (POEM; Patient Opioids Education Measurement) on their opioid knowledge during 1st visit at the pain clinic.
45477104|NCT02513836|Other|Post-education intervention|All study participants will be educated on opioids via an education sheet, pamphlet and video from the Institute for Safe Medication Practices (ISMP) Canada. The questionnaire (POEM) will be tested again after this education on opioid knowledge on the same day.
45686189|NCT03080896|Device|King Vision video-laryngoscope with #3 disposable blade and endotracheal tube stylet|intubation using King Vision video-laryngoscope with #3 disposable blade with stylet convert to intubation with video-laryngoscope and fiber-optic bronchoscope bronchoscope (aScope III) for failure to intubate after three attempts
45686190|NCT03080896|Device|fiberoptic bronchoscope aScope III|Intubation using the videolaryngoscope/fiberoptic bronchoscope (aScope III)
45686191|NCT04389424|Drug|Tamoxifen|Use of tamoxifen for breast cancer recurrence prevention
45686192|NCT04389424|Drug|Exemestane|Use of exemestane for breast cancer recurrence prevention
45686193|NCT04389424|Drug|Anastrozole|Use of anastrozole for breast cancer recurrence prevention
45686194|NCT04389424|Diagnostic Test|Basal|Initial diagnosis of breast cacner by biopsy or mastectomy
45686195|NCT04389424|Diagnostic Test|Recurrence|Breast cancer recurrence under endocrine therapy
45686196|NCT04389346|Procedure|Periapical surgery using autologous platelet aggregate|PRF will be placed over the denuded root surface, following apicoectomy and before flap repositioning
45686197|NCT04389346|Procedure|Periapical surgery without autologous platelet aggregate|Flap will be repositioned following apicoectomy directly without placing any platelet aggregate
45686198|NCT04771390|Drug|Selitrectinib (BAY2731954) Adult tablet|Tablet, oral administration
46045710|NCT00975000|Drug|Placebo|Administered orally following the same dosing regimen as the experimental arm.
45686199|NCT04771390|Drug|Selitrectinib (BAY2731954) Pediatric tablet|Tablet, oral administration
45686200|NCT04771390|Drug|Selitrectinib (BAY2731954) Oral solution|Oral solution after reconstitution
45686201|NCT04771390|Drug|Selitrectinib (BAY2731954) Oral suspension|Oral suspension after reconstitution
46045711|NCT04286802|Device|Salt-meter|Salt-meter, developed by Faculty of Engineering at Mahidol University, is a device to measure sodium chloride content in the food and reflects to user with number and symbols for easy-understanding.
46045712|NCT04286802|Behavioral|Education|Program dietary education by certified dietician who did not know the patients arm allocation.
46045713|NCT02863614|Drug|Ibuprofen 600 mg|
46045714|NCT02863614|Drug|Lorazepam 1 mg|
46045715|NCT02863614|Drug|Placebo|
46045716|NCT04288908|Other|Cyberball experimental task|Cyberball is an experimental task in which participants have to pass a ball to two virtual players during 60 passes in total
45477105|NCT02513680|Device|Infrared Laser + Amber LED|This group will make the application on the machine program that uses laser and led together to photorejuvenation . Laser is applied for 30 seconds and soon after begins the LED by 2:30 minutes in each region to apply.
45842530|NCT01225926|Device|Toric T3 - T9|Commercially available, acrylic, multifocal IOL intended to provide visual correction over the lifetime of the cataract patient
45477106|NCT02513680|Device|Amber LED|This group will make the application on the machine program that uses LED photorejuvenation only 3 minutes of time for each area to be applied.
45842531|NCT01225926|Device|IQ SN60WF|Commercially available, acrylic, monofocal IOL intended to provide visual correction over the lifetime of the cataract patient
45842532|NCT01226706|Drug|Botulinum Toxins, Type A|Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
45842533|NCT01226706|Drug|Placebos|Placebos injected into the detrusor at Day 1, followed by injection of botulinum toxin Type A 100U after 24 weeks has elapsed from previous treatment, if requested/qualified.
45477107|NCT03831035|Other|Genetic analyse by whole exome sequencing|Exome sequencing requires analytic, bio informatic and interpretation steps.
45477108|NCT03547531|Other|Natural Tooth Brushing Method|Natural tooth brushing method is the method that is naturally used by the people with horizontal, rotary, or simple up and down motions and any position of the brush without any instruction of particular tooth brushing method.
45477109|NCT03547531|Other|Modified Circular Tooth Brushing Method|Modified Circular tooth brushing method is a combination of small circular motion of brushing with the position of the brush slightly reach underneath the gingival that are applied for each jaw in all facial surfaces and posterior lingual of tooth arches.
45686202|NCT04771468|Device|MOSTCAREup Monitoring|The patients will be equipped with mini-invasive hemodynamic monitoring (the MOSTACAREup system). The MOSTCAREup obtains the hemodynamic data from either the same arterial femoral line used by the neuro-radiologist to perform the treatment or from a dedicated radial artery, as decided by the attending anesthetist to monitor and optimize arterial pressure (the decision to use the arterial line is at discretion of the attending anesthetist for clinical reasons and does not delay the procedure, which starts using always the femoral access).
45842534|NCT01231230|Drug|fluticasone|220- mcg once
46045717|NCT00974922|Drug|Aliskiren|150 mg once daily for 2 weeks, then titrated to 300 mg once daily for 4 weeks
45686203|NCT04771468|Device|Ecocardiography|Echocardiography will be performed 1) soon after the end of the treatment (whenever possible, avoiding delays, before od during the treatment in the angiography room); 2) at day 1 after the procedure; 3) at day 3 after the procedure.
45686204|NCT05570578|Device|HD-tDCS|The anode electrode will be placed over Broca's area, 4 cathode electrodes will be placed at about 2 cm distance each from the anode in 4 directions.
45686205|NCT04779502|Other|oregawash|mouthwash containing oregano essential oil
45686206|NCT04779502|Other|corsodyl|0.2% chlorhexidine mouthwash
45686207|NCT04779502|Other|placebo|distilled water
45686208|NCT05480956|Behavioral|SIRI Checklist|A standardized checklist of clinical items to review by the attending hospitalist with participants.
45842535|NCT01231230|Drug|placebo inhalation|placebo inhalation once
45842536|NCT01231230|Drug|Salmeterol|50 mcg salmeterol once
45842537|NCT01231230|Drug|fluticasone/salmeterol|inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol
45842538|NCT01232946|Drug|liraglutide|1.8mg subcutaneous qd for 3 months
45842539|NCT01232946|Drug|insulin detemir|5units subcutaneous bid titrated to fasting glucose of <130mg/dL for 3 months
45842540|NCT01232946|Drug|liraglutide plus insulin detemir|liraglutide 1.8mg subq qd plus insulin detemir 5units bid titrated to fasting blood glucose <130mg/dL for 3 months.
45842541|NCT01233726|Dietary Supplement|T-Diet plus Diabet IR|Group 1 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
46045718|NCT00974922|Dietary Supplement|Cholecalciferol|3000 I.U. once daily for 6 weeks
46045719|NCT00974922|Dietary Supplement|Placebo|Placebo for two weeks
46045720|NCT04288518|Diagnostic Test|SPECT with 99mTc-1-thio-D-glucose|One single intravenous injection of 99mTc-1-thio-D-glucose, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
45351648|NCT00337675|Drug|montelukast sodium|Montelukast 4 mg (or 5 mg, depending on age of patient) qd + episode driven supplemental Pbo qd for 12 days for a 52-wk treatment period.
45351649|NCT00337675|Drug|Comparator: Placebo (unspecified)|Placebo (Pbo) qd + episode driven supplemental Pbo for 12 days for a 52-wk treatment period.
45477110|NCT02513602|Procedure|Dental implant insertion|Dental implant insertion will be carry out in the mandible of the patients enrolled, through a surgical template in order to repeat the same position of the simulating implant insertion. After a trephine bur passage, the final two or three twist-drills will be used to realize the implant socket. After implant positioning, a cover screw will be tightened and the mucosa sutured above.
45477111|NCT01333553|Device|Image-guided remove Port Wine Stain|Image-guided surgery remove Port Wine Stain
45351650|NCT00337675|Drug|montelukast sodium|Pbo qd + episode driven supplemental Montelukast 4 mg (or 5 mg, depending on age of patient) qd for 12 days for a 52-wk treatment period.
45351651|NCT00898521|Drug|DGD|"DGD is a mixture of lyophilized enzymes derived from purified Bromelain from pineapple stem.~Two grams or 5 grams of Debrase powder are dissolved in 20 grams or 50 grams of Gel Vehicle to obtain DGD. DGD is applied to the burn wound at a dose of 2g Debrase/20g Gel per 100 cm2 of skin or 5g Debrase/50g Gel per 250 cm2 for a duration of four hours. In an average human adult, 100 cm2 represents approximately 1% of Total Body Surface Area (TBSA).~Please note that for individuals of exceptional size (e.g. children), it is important to calculate the dosage based on the 100 cm2 measurement.~The Debrase powder and the Gel Vehicle are to be mixed at the patient bedside for a maximum of 15 min prior to use.~DGD should not be applied to more than 15% TBSA in one session. If the wound area to be treated is more than 15% TBSA, DGD should be applied in two or more separate sessions.~DGD should not be applied more than twice to the same burn wound area."
45351652|NCT03985579|Other|Kinesiology taping application|Application of elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability from athletic injuries and a variety of other physical disorders
45351653|NCT00902967|Drug|Atorvastatin|Atorvastatin 10 mg, once a day dosing at night after meals
45351654|NCT00902967|Drug|Placebo|Placebo tablets of similar shape size and color given once a day at night time after meals
45351655|NCT01324921|Other|No breakfast/beverage only|12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
45351656|NCT01324921|Other|Breakfast|1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
45477112|NCT02504476|Drug|AMG 581|Active drug
45477113|NCT02504476|Drug|Placebo|Placebo
45351657|NCT01324921|Other|10004RF|1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
45351658|NCT00898599|Dietary Supplement|Prebiotic|Inulin type fructooligosaccharides
45351659|NCT00898599|Dietary Supplement|Placebo|Maltodextrin as placebo
45477114|NCT02504476|Drug|Midazolam|Interaction
45686209|NCT05480956|Behavioral|Enhanced Peer Recovery Coach|Participants will receive the addiction medicine standard of care plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.
45842542|NCT01233726|Dietary Supplement|ISOSOURCE PROTEIN FIBRE|Group 2 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
45477115|NCT04313855|Diagnostic Test|SMS in the early detection of postoperative neuropathic pain|"7 days after the intervention, the patient receives a standardized questionnaire by SMS, to determine whether the patient has pain at the operating site and whether this pain has the characteristics of neuropathic pain. After replying to the SMS, the patient will be contacted by phone to assess: the intensity of pain at the operating site using a numerical scale and the existence of neuropathic pain. Depending on the responses received by SMS and/or phone, a consultation appointment with an anesthesiologist specializing in pain may be offered within a maximum of 2 weeks.~Ninety days after your surgery, the patient receives the same standardized questionnaire by SMS. The patient will be contacted by telephone, in order to assess the intensity of pain at the operating site and the existence of neuropathic pain using. If the patient has post-operative pain, a consultation appointment with an anesthesiologist specializing in pain will be offered to him within a maximum of 2 weeks."
45842543|NCT01233726|Dietary Supplement|GLUCERNA SELECT|Group 3 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
45842544|NCT01235910|Drug|Aliskiren|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
45842545|NCT01236300|Device|Cellvizio needle-based Confocal Laser Endomicroscopy (nCLE) system|
45351660|NCT01055665|Other|cognitive behavior therapy|6 cognitive behavior therapy groups
45351661|NCT00903045|Drug|Propiverine hydrochloride|Propiverine hydrochloride 20mg twice a day
45351662|NCT00903045|Drug|Placebo|Identical placebo twice a day
45351663|NCT02539095|Device|CartiZol|The product, CartiZol, which contains absorbable collagen, is applied on the cartilage defect to stimulate the neovasculization and cell penetration and to assist the natural wound healing process. It supplements the defective or damaged cartilage. Place the needle on the tip of the syringe and inject the product into the articular cavity.
45351664|NCT02539095|Device|Normal saline|"Supplementation of fluid and electrolytes (sodium or chlorine deficiency)~Diluent for injection solution Place the needle on the tip of the syringe and inject the product into the articular cavity."
45477116|NCT02504398|Other|Fast injection speed by immunizer|
45477117|NCT02504398|Other|Slow injection speed by immunizer|
45477118|NCT03842501|Dietary Supplement|Release Supplement|Calorie reduced diet plus Release supplement
45477119|NCT03842501|Dietary Supplement|Placebo|Calorie reduced diet plus Placebo
45351665|NCT00337285|Drug|Vyvanse (lisdexamfetamine dimesylate), NRP104|NRP104 capsule once-a-day orally beginning at 30mg/day and titrated by 20 mg per day at weekly intervals up to a maximum daily dose of 70 mg
45351666|NCT03991117|Behavioral|resistance exercise|unilateral knee extensions until fatigue with varying load and speeds of contraction
45351667|NCT04035525|Dietary Supplement|MaxSimil® fish oil + CoQ10|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
46045721|NCT04287972|Procedure|DPC|The anterior fat pad is dissected until the left crura is visible, pars flaccida is open and the right crura exposed. Phreno-oesophageal ligament is sectioned starting from the right crura. Posterior and anterior vagal nerve are recognized before the oesophageal dissection. An intra-abdominal oesophagus lengths of 2 or 3 cm is obtained in order to reduce tension. Left and right crura are sutured with 2 or 3 non absorbable 2-0 stitches; an additional anterior stitch is posed if necessary to calibrate hiatus size without oesophageal deviation.
45477120|NCT02509390|Procedure|Blood samples|Investigators analyze hematological parameters with blood sampled daily in severe trauma patients
45477121|NCT01205009|Drug|Ovitrelle|One dose of Ovitrelle 250 mcg
45477122|NCT02504242|Device|Inject BMP|
45477123|NCT02504242|Procedure|Locally Harvested Bone|
45842546|NCT01236378|Drug|Sirolimus|Sirolimus, 1 mg, white, triangular tablets, daily dose, dosages of any of these medications must be stable for at least 2 weeks prior to screening and continue with no change until completion of the last PK sample collection.
45351668|NCT04035525|Dietary Supplement|Rice bran oil + CoQ10|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
45351669|NCT04035525|Dietary Supplement|CoQ10 as powder form|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
45351670|NCT04035057|Other|Behaviorally Enhanced Training|Therapists in the Behaviorally Enhanced Training will receive the same didactic instruction as those in the Standard Didactic Training arm during the first full day of training. In the second half-day training, those in the Behaviorally Enhanced Training arm will focus on behavioral strategies (i.e., exposure to exposure) that provide direct experience with the process of treatment delivery.
45351671|NCT04035057|Other|Standard Didactic Training|Therapists in the Standard Didactic Training arm will complete training as usual, consisting of PowerPoint and video training tasks instructing the delivery of exposure therapy for anxious youth.
45351672|NCT04034979|Behavioral|decision aid|One hour online training about shared-decision making about goals-of-care and best practices regarding goals-of-care discussions and decision-making. One hour debriefing in presence.
45351673|NCT00905853|Procedure|Catheter Ablation|Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
45351674|NCT00905853|Drug|Escalated Antiarrhythmic Therapy|"Patients who have 'failed' antiarrhythmic therapy (except amiodarone) will be prescribed: Amiodarone 400 mg twice daily for 2 weeks, followed by 400 mg/day for 4 weeks, followed by 200 mg/day thereafter.~Patients who 'failed' amiodarone (less than 300mg/day) will be prescribed: Amiodarone 400 mg three times a day for 2 weeks, followed by 400 mg/day for 1 week and 300 mg/day thereafter.~Patients who 'failed' amiodarone (greater or equal to 300mg/day) will be prescribed: Amiodarone at the current dose with the addition of mexiletine 400 to 800 mg/day"
46045722|NCT04287972|Procedure|LSG|After omental section close to gastric insertion, gastric stapling is realised with triple line endo stapler (normally 5 or 6 re-loads). The gastrectomy begins 5-6 cm from the pylorus; gastric fundus is totally resected keeping a distance of 5-10 mm from oesophagus. Any bleeding on staple line is controlled with surgical clips or coagulator.
45842547|NCT01236768|Drug|AG200-15|"Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week patch free period."
45842548|NCT01236768|Drug|Levora|One tablet of Levora will be taken each day for a 28 day cycle.
45351675|NCT00905931|Drug|Lycopene|30 mg oral, daily, for 21 days
45351676|NCT00905931|Drug|placebo|starch
45351677|NCT02540187|Other|blood specimen|
45351678|NCT04035291|Other|exercise|exercises,play therapy models and positioning, handling and holding principles for babies, daily routins
45477124|NCT01297205|Biological|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|Dose A - 10 million cells per kg Dose B - 20 million cells per kg Single intratracheal administration
45477125|NCT02513524|Procedure|Direct Observed Therapy test|There is one group only, all of whom will undergo direct observed therapy testing
45477126|NCT03830489|Drug|polyethylene glycol|The experimental arm will take 4 L polyethylene glycol solution (PEG) in split dose plus bisacodyl and 3 days of fiber-free diet
45477127|NCT03830489|Drug|polyethylene glycol plus ascorbic acid|The control arm will take 2 L polyethylene glycol solution (PEG) plus ascorbic acid in split dose plus 1 day of fiber-free diet
45842549|NCT01237080|Device|GlideScope|The GlideScope is an anatomically shaped, rigid, fibreoptic videolaryngoscope.
45842550|NCT01237080|Device|Fastrach|The Fastrach is an intubation laryngeal mask.
45842551|NCT01238640|Drug|Code STD|"2 mg Single-dose of experimental nicotine product coded STD"
46045723|NCT00972504|Drug|GSK835726 10mg|GSK835726 10mg tablet
45686210|NCT05480956|Behavioral|SIRI Checklist + Enhanced Peer Recovery Coach|A standardized checklist of clinical items to review by the attending hospitalist with participants. Participants will receive the addiction medicine standard of care plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.
45686211|NCT05411380|Drug|Tucidinostat|20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)
45842552|NCT01238640|Drug|Code STE|"2 mg Single-dose of experimental nicotine product coded STE"
45842553|NCT01238640|Drug|Nicorette Microtab|A comparative 2 mg Single-dose of marketed tablet
45842554|NCT01240122|Device|Biotrue MPS|Multi-purpose contact lens care solution
45842555|NCT01240122|Device|Investigational MPS|Multi-purpose contact lens care solution
45842556|NCT01241916|Device|Static-Progressive Splint|Static progressive splinting is a well-established adjunct for restoring elbow motion. Such splints apply a static stress relaxation force to the elbow tissues, which is sequentially increased, as motion is achieved.
45842557|NCT01241916|Device|Dynamic Splint|Dynamic splints are a popular alternative, and apply a constant prolonged force to the tissues as additional motion is achieved.
45842558|NCT01243320|Drug|10ppm Oral Silver Particle|Silver nanoparticles at 10ppm
45842559|NCT01243320|Drug|32ppm Oral Silver Particle|Silver nanoparticles at 32ppm
45842560|NCT01245270|Dietary Supplement|Bilberry capsule first, then control cap|"Male subjects aged >40 and <70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
45842561|NCT01245270|Dietary Supplement|Control capsule first then bilberry cap|"Male subjects aged >40 and <70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
45842562|NCT01245972|Procedure|PDL Treatment|Pulsed-dye laser (PDL) treatment at one of two settings.
45842563|NCT01246050|Other|HF training|These are CBOC Providers who received HF Training as the active intervention. HF training includes didactic lectures, case discussions and interactive symposia, course materials including teaching material, textbooks, copies of HF clinical guidelines and patient education material for distribution, participation in HF Clinics and Inpatient Heart Failure Rounds. Providers were given access to clinical pharmacist services Including medication and disease teaching, adjustment and uptitration. There was quarterly analysis of patient compliance including individualized confidential, non-punitive feedback to providers from a set of prespecified core HF performance measures.
45842564|NCT01246050|Other|No HF training|These are control providers drawn from the same CBOCs who have not received HF training, access to clinical pharmacist medication titration services or performance feedback
45842565|NCT01247064|Drug|Nebulized 3% saline|4 mL of nebulized 3% saline once
45842566|NCT01247064|Drug|Nebulized 0.9% Normal Saline|4 mL of 0.9% nebulized normal saline once
45842567|NCT01247220|Drug|Ranibizumab|Intravitreal Ranibizumab 0.5 mg
45842568|NCT01247220|Procedure|Peripheral Laser|Angiography-directed peripheral laser
45842569|NCT01247298|Combination Product|Stereotactic Body Radiation Therapy (SBRT)|This investigational study will evaluate the combination of TACE along with high dose SBRT. TACE has been used extensively in the palliative treatment of hepatocellular carcinoma (HCC). It will be performed by the Interventional Radiologist prior to radiation therapy.
46045724|NCT00972504|Drug|GSK1004723 1000mcg|GSK1004723 1000mcg nasal spray solution
46045725|NCT00972504|Drug|Cetirizine 10mg|Cetirizine 10mg active comparator
46045726|NCT00972504|Drug|placebo|placebo to match actives
46045727|NCT00969228|Biological|Rotarix ™|Two oral doses
46045728|NCT00969228|Biological|Placebo|Two oral doses
46045729|NCT00969150|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER (flexible dose) Study drug is to be given orally, in capsule form, once daily, for 8 weeks.
46045730|NCT00969150|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
46045731|NCT04286022|Other|Speed Loss 20% Strength Training|Strength training based on the control of speed loss in execution.
46045732|NCT04286022|Other|Reduced Rest Time Strength Training|Strength training based on a protocol that includes reduced rest times between sets.
46045733|NCT03925194|Drug|Anakinra|Application of Anakinra once daily for 28 days
46045734|NCT00974220|Drug|fentanyl|single dose, 50 mcg of nebulized fentanyl citrate
46045735|NCT00974220|Drug|normal saline (placebo)|single dose, 0.9% saline solution
46045736|NCT03904758|Diagnostic Test|Pepsin in saliva test|The presence of pepsin in the saliva will be tested in both groups of patients.
46045737|NCT02863536|Device|Polybactum®|3 cycles treatment one per month.. Duration of one cycle: 1 week; administration for each cycle: 1 ovule at Day 1, 1 ovule at Day 4; 1 ovule at Day 7.In the two following cycles, the same treatment will be repeated immediately after the end of the first and second menstrual bleeding.
45351679|NCT00898833|Other|laboratory biomarker analysis|
45351680|NCT04035135|Drug|ANX005|investigational drug
45351681|NCT04035135|Drug|Intravenous immunoglobulin|investigational drug
45351682|NCT04035213|Behavioral|Behavior of Sleep Course|The current study will evaluate whether a semester-long course focused on sleep improves college students' sleep patterns over one semester compared to students completing a similar-level course in the same department (Psychology) at the same university.
45477128|NCT02509468|Drug|Sirolimus|"each patient will be followed during a 12-month-period~each patient will start by an observational period and end being treated by sirolimus~at a random date (between month 4 and month 8), each patient will switch from the observational period to the sirolimus period"
45477129|NCT03344614|Drug|raltitrexed combined with apatinib|raltitrexed, 3 mg/㎡, ivgtt, d1, apatinib 500 mg, QD po, d1-21, Every 3 weeks for 1 cycles
45351683|NCT00898911|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
45477130|NCT01205087|Drug|OKT3|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up of 9 patients will be treated at each dosage level, and up to additional 9 patients will receive placebo.
45477131|NCT02513368|Device|augmentation procedure with Bio-Oss® and Bio-Gide®|soft tissue management using GBR procedure
45477132|NCT02513368|Procedure|augmentation procedure with connective tissue graft|soft tissue management using the bilaminar technique
45477133|NCT01205243|Drug|ZIAGEN®|Basically there is no treatment allocation. Subjects who would be administrated ZIAGEN® at their physician's discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
46045738|NCT00971178|Drug|local dexmedetomidine|Preoperative normal saline infusion and 1mcg/kg dexmedetomidine infiltrated locally to wound at the end of operation.
45351684|NCT04034745|Drug|telotristat ethyl|250 mg tablets of Xermelo (telotristat ethyl) is administered orally 3x daily in combination with somatostatin analogs (SSAs) for approximately 84 days as per standard of care
45351685|NCT00903279|Drug|Placebo|Placebo will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
45351686|NCT00903279|Drug|Altabax (retapamulin)|Retapamulin 1% ointment will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
45351687|NCT00903435|Other|Quantitative Sensory Testing and Stimulus|No therapeutic intervention will be given. Quantitative Sensory Testing, thermal/mechanical/ischemic stimulus will be performed.
45477134|NCT02504164|Drug|midazolam 0.02mg/kg|
45477135|NCT02504164|Drug|No premedication|No premedication before sedation for endoscopic submucosal dissection
45477136|NCT02509234|Drug|Combined chemotherapy with trabectedin followed by irinotecan|"Day 1:~Trabectedin 1,1 - 1,5 mg/m²/day i.v.~Day 3-5 and 10-12:~Irinotecan 30- 90 mg/m²/day p.o. or i.v."
45477137|NCT01203215|Behavioral|2 print based physical activity interventions|physical activity promotion
45477138|NCT02504086|Behavioral|Online Support|3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals
45477139|NCT01205321|Drug|Bombesin (68Ga) labeled (BAY86-7548)|Cancer patients, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, PET/CT
46045739|NCT00971178|Drug|Peripheral normal saline|Same volume of normal saline as dexmedetomidine is infiltrated and IV infusion.
46045740|NCT00971178|Drug|IV dexmedetomidine|IV dexmedetomidine 1mcg/kg peroperative and normal saline infiltrated to wound at the end of operation
46045741|NCT04288284|Procedure|Curative resection of colorectal cancer|
45351688|NCT02540109|Device|HD-tDCS (Soterix Medical, Active)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
45477140|NCT01205321|Drug|Bombesin (68Ga) labeled (BAY86-7548)|Healthy volunteers, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY86-7548 in blood
45477141|NCT02504008|Drug|AXS-02 (oral zoledronate)|Once weekly for 6 weeks
45477142|NCT02504008|Drug|Placebo|Once weekly for 6 weeks
45477143|NCT01203293|Behavioral|Cognitive behavior based therapy|15-20 individual psychotherapy sessions
45477144|NCT01203293|Behavioral|Treatment as usual|Treatment as usual is an active comparator group in which patients are provided referrals to specialty mental health care services or can use any primary or specialty care services available to them in usual care.
45351689|NCT02540109|Device|HD-tDCS (Soterix Medical, Sham)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
45351690|NCT02539017|Drug|Chemo|Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles
45351691|NCT02539017|Biological|Immunotherapy|Immunotherapy with double dendritic cell (DC)and cytokine-induced killer (CIK) cell
45351692|NCT04034667|Other|No intervention|No intervention
45351693|NCT00605865|Drug|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501090, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 16 weeks after the first administration."
45477145|NCT01297361|Other|Blood Sample|Blood sampling for diagnosis of vitamins deficiencies
45477146|NCT03566485|Drug|Atezolizumab|Given by IV
45477147|NCT03566485|Drug|Cobimetinib|Given by mouth
45477148|NCT03566485|Drug|Idasanutlin|Given by mouth
45477149|NCT02503930|Device|Active tDCS|In this group subjects will receive 20 min of treatment.
45351694|NCT00899145|Other|Laboratory Biomarker Analysis|Correlative studies
45477150|NCT02503930|Device|Sham tDCS|In this group subjects will receive 20 min of sham stimulation.
45477151|NCT05281367|Procedure|Breast milk odor group|The researcher applied the breast milk that dripped on the pad for 3 minutes before the heel stick for 36 premature newborns in the breast milk odor group. About three cc breast milk dripped onto a sterile pad and placed at a distance of 10 cm from the nose of the newborn. It continued until 3 minutes after the invasive procedure. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
45686212|NCT05411380|Drug|Capecitabine|500mg orally three times a day (continuously)
45686213|NCT05411380|Drug|Endocrine Therapy|Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily or fulvestrant 500 mg each time, intramuscularly, injected on the 1st day and 15th day of the 1st cycle, and on the 1st day for subsequent cycle( 4 weeks for one cycle)
45686214|NCT04779580|Procedure|Lateral Cutaneous Nerve Of The Thigh Nerve Block Using Local Anaesthetic|Currently accepted aseptic conditions will be met. The lateral cutaneous nerve of the thigh will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.
45686215|NCT04779580|Procedure|Subcostal Nerve Block Using Local Anaesthetic|Currently accepted aseptic conditions will be met. The subcostal nerve will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.
46045742|NCT03670602|Behavioral|Episodic Future Thinking|Participants will practice using these cues when making decisions about health choices. Participants will implement EFT while using The Traffic Light Diet, The Traffic Light Activity Program, and a variety of behavioral techniques including stimulus control, self-monitoring, goal setting, problem solving, resetting rewarding mechanisms by reducing need for immediate gratification, finding behavioral substitutes for highly reinforcing food.
45351695|NCT00922467|Drug|NaCl 9/00|Same volume as in the esmolol group
45842570|NCT01249872|Drug|GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
46045743|NCT03670602|Behavioral|Daily Check in|Participants will be asked to access the electronic app at the same rate as the experimental group (e.g. daily). Participants will receive behavioral weight loss treatment including The Traffic Light Diet, The Traffic Light Activity Program, and a variety of behavioral techniques including stimulus control, self-monitoring, goal setting, problem solving, and finding behavioral substitutes for highly reinforcing food.
46045744|NCT00968526|Biological|GSK investigational vaccine GSK2340272A|One or two intramuscular injections in the deltoid region of the non-dominant or the dominant arm.
46045745|NCT03664674|Drug|OTO-104|Single intratympanic injection of 12 mg dexamethasone
46045746|NCT03664674|Drug|Placebo|Single intratympanic injection of placebo
45351696|NCT00922467|Drug|Esmolol|1 mg/kg administrated over 10 minutes followed by an infusion of 0,2 mg/kg/hr during all the anesthetic period
45351697|NCT00903747|Drug|prucalopride|2-10 mg prucalopride
45351698|NCT00903747|Drug|moxifloxacin|400 mg moxifloxacin (Group 2a)
45351699|NCT00903747|Drug|placebo|placebo (Group 2b)
45351700|NCT02538627|Drug|MM-151|MM-151
45351701|NCT02538627|Drug|MM-121|MM-121
45351702|NCT02538627|Drug|MM-141|MM-141
45351703|NCT02538627|Drug|trametinib|trametininb
45686216|NCT04771312|Behavioral|Mobile app information-only intervention|Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants can respond to daily questions in a diary. Participants can also use a locator tool to find where PrEP can be found near them.
45686217|NCT04771312|Behavioral|Mobile app social support network intervention|Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants are shown an online chatting tool where they can discuss with each other and answer daily questions. Participants can also use a locator tool to find where PrEP can be found near them.
45842571|NCT01249872|Drug|GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE|Patients receive intraoperatively(45 min before the estimated end of the surgery)an epidural bolus dose of 1mg of morphine.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
46045747|NCT00967668|Behavioral|Small change approach to improve physical activity and diet|"The Aspire to Lifelong Health (ASPIRE) initial treatment program draws on the strengths of traditional lifestyle change and non-dieting weight loss approaches. ASPIRE incorporates CBT elements, problem-solving therapy, and the small change approach from behavioral choice therapy. For the first week in the program, participants use a food diary to track caloric intake and a pedometer to log their daily physical activity (step counts). Baseline information provides a starting point for participants and their Lifestyle Coach to set one small, but potentially permanent, change in daily food choices and physical activity to promote a caloric deficit. Small changes are cumulative over the weeks and the participant makes their own goals within the context of their own lifestyle."
45842572|NCT01249872|Drug|GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intraoperatively (45 min before the estimated end of the surgery) a bolus dose 2 mg of morphine, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
45842573|NCT01249872|Drug|GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
46045748|NCT00967668|Behavioral|MOVE! Usual Care|The MOVE! program offers a stepped-care framework of increasingly intensive treatment. A combination of Level 1 (self-management support) and Level 2 (group sessions and/or individual specialty consultation) will be offered to participants as part of usual care.
46045749|NCT00970944|Drug|Amantadine Hydrochloride|184 patients who remain in VS or MCS 4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine (200 - 400 mg/day) followed by a 2-week washout period. The Disability Rating Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised (CRS-R) serving as a supplementary measure.
46045750|NCT00970944|Drug|Placebo|Placebo administered twice daily.
46045751|NCT05780723|Drug|Treatment group: Rectal instillation of QHQYP|QHQYP is decocted in water, with a dose of 100ml each time, and rectal drip before going to bed, once a night, for 8 weeks.
46045752|NCT05780723|Drug|Control group: Mesalazine enema treatment|Mesalazine enema, 4g/tube, 1 tube each time, enema before bed, once a night, a total of 8 weeks of continuous treatment.
45351704|NCT00899457|Genetic|proteomic profiling|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
45351705|NCT00899457|Other|biologic sample preservation procedure|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
45351706|NCT00899457|Other|laboratory biomarker analysis|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
45351707|NCT00899457|Procedure|bronchoscopy|Collection of breath condensate.
45351708|NCT00906321|Behavioral|Web-Based Decision Support|
45351709|NCT00903825|Procedure|Ultrasound guided injection of femoral local anesthetic (lidocaine)|Injection of lidocaine (< 10 mls of lidocaine, 1%w/v) before femoral artery puncture with free-hand duplex ultrasound guidance.
45351710|NCT00903825|Procedure|Injection of femoral local anesthetic (lidocaine) with manual palpation|Injection of lidocaine before femoral artery catheterization with manual palpation.
45351711|NCT00899535|Genetic|DNA analysis|
45351712|NCT00899535|Genetic|RNA analysis|
45351713|NCT00899535|Genetic|microarray analysis|
45351714|NCT00899535|Genetic|mutation analysis|
45351715|NCT00899535|Genetic|polymorphism analysis|
45351716|NCT00903981|Drug|Avanafil|2 tablets(Avanafil 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
46045753|NCT05780697|Procedure|Surgery of Drainage of septic hip arthritis|Surgery for septic hip arthritis by anterior or lateral approach and inspection of femoral head
46045754|NCT05780671|Other|oxygen|inhaled oxygen 10L/min with face mask for 1 hour
45477152|NCT05281367|Procedure|Facilitated tucking group|The Facilitated tucking position was given to 36 premature newborns in the Facilitated tucking group, from 3 minutes before to 3 minutes after the heel stick procedure. Premature newborns were kept in the facilitated tucking position by the investigator using the incubator windows without opening the incubator cover to prevent heat loss of the newborn. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
45686218|NCT05403658|Behavioral|Family Navigation|FN will be delivered by navigators who will provide support and services that complement obesity management care provided by multidisciplinary teams at the study clinical sites. With advanced training in motivational interviewing and patient- / family-centered care, navigators will access a bundle of logistical and relational strategies to help families derive the greatest possible benefit from their care, which will include working to reduce barriers to care, improve access, and optimize treatment outcomes related to obesity management that is part of their Usual Care. Navigators will provide various resources/supports to study participants including, but not limited to, offering communication via text message, flexible navigator appointments, parking/transit passes, community-based resources, and liaising with members of the multidisciplinary clinical teams at each site.
45686219|NCT05403658|Behavioral|Usual Care|Usual Care is delivered similarly across the 2 clinical sites. Obesity management is offered by multidisciplinary teams that include clinicians with advanced expertise in pediatrics, nutrition, mental health, physical activity/exercise, and behavior change. Interventions are tailored to families' readiness, capabilities, and motivation to make healthy lifestyle and behavioral changes.
45686220|NCT04770688|Drug|Osimertinib|Osimertinib, 80mg, QD, p.o.
46045755|NCT05780606|Other|Exposed to UV|Two healthy volunteers will be exposed to UV or visible light in the forearm region. Suction bubbles, and skin biopsies will be performed in test areas, suction bubbles for transcriptome, biopsies for immunohistochemistry
46045756|NCT05780528|Other|mulligan mobilization|The patients will receive mobilization with movement technique of lateral glide. the patients will be in supine subject and pronate forearm, during the application of the lateral glide by the physiotherapist, each patient was asked to perform the closure of the fist (provocative but painless gesture in the execution of the technique) for 3 sets of 10 repetitions.
46045757|NCT05780528|Other|instrumented assisted soft tissue mobilization|the participant will receive instrumented assisted soft tissue mobilization. The participant's elbow will rest on a table. A lubricant (Vaseline) will be applied to the skin around the elbow prior to treatment and the blade will be cleaned with an alcohol pad. First, the blade will be used to find the exact areas of restriction in the common extensor origin. Then the M2T blade will be used in the treatment planes 1, 2, and 3, to apply slow strokes along the muscle, without causing any discomfort or pain, from the muscle origin to its insertion (sweeping technique)
46045758|NCT05780528|Other|conventional treatment|the patients will receive conventional treatment in the form of Ultrasound therapy, conventional transcutaneous electrical nerve stimulation (TENS) - hot pack - stretching and strengthening exercises and wrist rest splints
45686221|NCT04770688|Drug|Anlotinib|"(Phase Ib) Anlotinib, from 8mg to10mg to 12mg, QD, p.o. from day 1 to 14 of a 21-day cycle.~(Phase IIa)Anlotinib, given at RP2D dose QD, p.o. from day 1 to 14 of a 21-day cycle."
45686222|NCT05399758|Device|NOL monitor|NOL monitor data will be acquired, as well as clinical assessment of pain and fentanyl dosage.
46045759|NCT05780515|Biological|ANX009|ANX009 will be administered per schedule specified in the arm description.
45686223|NCT05390476|Drug|Capecitabine|500mg orally three times a day (continuously)
45842574|NCT01249872|Drug|GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 1mg of morphine, epidurally.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
46045760|NCT05780502|Behavioral|Passive Dynamic Brace|Patient receiving the Passive Dynamic Brace
46045761|NCT05780489|Diagnostic Test|Determination of progesterone and oestradiol|Blood and saliva samples will be taken for determination of progesterone and oestradiol hormones.
45351717|NCT00903981|Drug|Avanafil|2 Tablets(Avanafil 200mg tablet + Placebo 100mg tablet), 30 minutes before sexual intercourse
45351718|NCT00903981|Drug|Placebo|2 Tablets(Placebo 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
45351719|NCT00899613|Other|laboratory biomarker analysis|
45351720|NCT00899613|Procedure|study of high risk factors|
45686224|NCT05390476|Drug|Tucidinostat|20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)
45351721|NCT00899691|Genetic|protein expression analysis|
45477153|NCT05281367|Procedure|Non-nutritive sucking group|36 premature newborns who were in the non-nutritive sucking group were given a silicone pacifier suitable for the week of the baby's mouth from 3 minutes before to 3 minutes after the heel stick. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
45477154|NCT05281367|Procedure|Control group|"The control group will consist of 36 premature newborns who are routinely applied in the clinic. In the clinic where the research was conducted, no attempt is made to reduce pain during heel stick. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study.~Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP)."
45686225|NCT04770298|Other|Halliwick Concept|Halliwick Concept: Water intervention Bobath Concept: Neurodevelopmental Treatment
45686226|NCT05379088|Behavioral|Phone/zoom calls|Participants will complete weekly follow-up phone/zoom calls with a member of the research team. The phone/zoom calls will typically last 30-60 minutes. Participants will discuss barriers to activity and goals for upcoming weeks.
45351722|NCT00899769|Genetic|protein expression analysis|
45351723|NCT00899769|Genetic|proteomic profiling|
45842575|NCT01249872|Drug|GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive an epidural bolus dose of 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
45842576|NCT01250184|Other|Physical therapy|Twelve sessions (3 per week)
45686227|NCT01503021|Drug|SFP|Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
45842577|NCT01250184|Drug|Lidocaine injection|blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
45842578|NCT01250184|Other|Lidocaine injection + physical therapy|blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
45842579|NCT01250730|Drug|PF-02341066|Cohort 1: a 150 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 1 x 100 mg IRT.
45842580|NCT01250730|Drug|PF-02341066|Cohort 2: a 250 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 2 x 100 mg IRTs.
45842581|NCT01250730|Drug|PF-02341066|Cohort 3: a 400 mg single dose of PF-02341066 administered as 4 x 100 mg IRTs.
45842582|NCT01251042|Device|Sangvia|The Sangvia® Blood Salvage System used to collect blood intra-operatively.
45686228|NCT01503021|Other|Placebo|Dialysis with standard liquid bicarbonate concentrate without iron
45842583|NCT01251588|Biological|autologous cultured chondrocytes on porcine collagen membrane|Implantation received in the previous MACI00206 study
45842584|NCT01251588|Procedure|Microfracture|Arthroscopic Microfracture treatment received in the previous MACI00206 study
45842585|NCT01251978|Drug|Ranibizumab 2 mg|intravitreal injections of ranibizumab once a month, times 3.
45842586|NCT01251978|Drug|0.5 mg Ranibizumab|6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.
45842587|NCT01253148|Device|TheraSphere® Yttrium-90 (Y-90) Microspheres|Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver.
46045762|NCT05780476|Behavioral|Psychoeducation|6 sessions of 2 hours over 6 weeks
45351724|NCT00899769|Other|immunoenzyme technique|
45351725|NCT00899769|Other|laboratory biomarker analysis|
45351726|NCT00899769|Other|liquid chromatography|
45351727|NCT00899769|Other|mass spectrometry|
45351728|NCT00904059|Drug|BMS-650032|Capsules, Oral, 600 mg, Q12h, Days 1-7
45351729|NCT00904059|Drug|BMS-790052|Capsules, Oral, 60 mg, Q24h, Days 1-7
45351730|NCT00904059|Drug|BMS-650032|Capsules, Oral, 200 mg, Q12h, Days 8-21
45351731|NCT00904059|Drug|BMS-790052|Capsules, Oral, 30 mg, Q24h, Days 8-21
45351732|NCT00348673|Drug|UK-453,061|Placebo BID, Placebo QD, UK-453,061 10 mg BID, 30 mg BID, 100 mg BID or 500 mg QD for 7 days
45351733|NCT00348673|Drug|UK-453,061|Placebo BID, Placebo QD, UK-453,061 100 mg QD, 500 mg BID or 750 mg QD for 7 days
45351734|NCT00904137|Procedure|Cast|
45351735|NCT00904137|Procedure|Splint|
45351736|NCT00904137|Procedure|Tape|
45351737|NCT00906477|Procedure|Modified CI therapy|10 treatment days 3 hours a day: Shaping exercises 2 hours. Task practice 0,5 hours. Behavioral therapy (Transfer package) 0,5 hour. Encouragement to wear a restraining mitt on the least affected arm for all safe activities.
45477155|NCT02513290|Drug|Bilastine|
45477156|NCT02513290|Drug|Loratadine|
45686229|NCT04779034|Other|Measurement of heart rate variability|Heart rate variation will be evaluated with the Polar RS800CX model heart rate monitor
45686230|NCT04778956|Drug|Toripalimab|Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); Toripalimab should be completed for 2 cycles at 1-2 weeks before surgery, and continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
45477157|NCT01297439|Procedure|suctioning of fetal nose and mouth during delivery|"Normal delivery without pushing maneuver: either an expectative attitude or a suctioning of fetal nose and mouth during delivery, since the crowning of the head (appearance of the fetal scalp at the introitus between pushes)."
45477158|NCT01297439|Procedure|Pushing maneuver|"The pushing maneuver is performed gently on the fetal head since the crowning of the head (appearance of the fetal scalp at the introitus between pushes), during one uterine contraction, aiming to facilitate the anterior shoulder to slip off behind the symphysis pubis, reducing thus the risk of shoulder dystocia."
45351738|NCT03987607|Device|neuromuscular blockade monitoring|Neuromuscular blockade monitoring via two different types of monitoring devices
45351739|NCT00900003|Genetic|protein analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), we will determine if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival. The markers targeted are proteins secreted by cancer cells and/or cancer associated cells.
45351740|NCT00900003|Other|laboratory biomarker analysis|A method of extracting and identifying secreted cytokines and growth factors from tissues of the quantity of typical biopsy tissues has been developed.The purpose of this study is to determine if this method of biomarker discovery can now be applied to pancreatic cancer population.
45351741|NCT00906555|Procedure|modification of hemodialysis parameters on dialysis machine|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
45351742|NCT00337207|Biological|bevacizumab|Bevacizumab 15 mg/kg every 3 weeks over 30 to 90 minutes. One cycle = 3 weeks. Treatment continues until progressive disease or unacceptable toxicity.
45477159|NCT03839927|Other|Validity and reliability of Life-Space Assesment|Life-Space Assesment and SF-36 surveys will be applied. The reliability and validity of the results will be analyzed.
45351743|NCT01052857|Procedure|acupuncture|acupuncture application
45477160|NCT02508844|Dietary Supplement|Vivomixx®|probiotics intake (four capsules of Vivomixx®; total of 450 billion CFU/day) from gestational age 14-20 until delivery
45477161|NCT02508844|Dietary Supplement|Placebo|Four capsules/day from gestational age 14-20 until delivery. The placebo capsule contains microcrytalline cellulose, magnesium stearate and silicon dioxide.
45477162|NCT05669651|Other|Fecal Microbiota Transplantation|Fecal microbiota transplantation (FMT) refers to the transplantation of functional flora from healthy people's feces into patients' intestines to rebuild new intestinal flora and achieve the treatment of intestinal and parenteral diseases. In this study, 100 patients with recurrent hepatic encephalopathy were randomly divided into 1:1 groups to receive FMT with different amounts of bacteria, observe the therapeutic effect and adverse reactions of hepatic encephalopathy, and evaluate the effectiveness and safety of the two groups of patients. At the same time, the blood and stool samples of patients with recurrent hepatic encephalopathy before and after FMT were collected clinically, the composition of bile acid and other metabolites in stool and serum samples was analyzed, and the effective core flora was identified to clarify the mechanism of intestinal bacteria transplantation for the treatment of recurrent hepatic encephalopathy.
45477163|NCT02501200|Drug|CKD-391|Investigational product is prescribed to all of randomized subjects for two times.
45477164|NCT02501200|Drug|Atrovastatin and Ezetimibe combination therapy|Investigational products are prescribed to all of radomized subjects for two times.
45686231|NCT04778956|Procedure|salvage surgery|Endoscopic nasopharyngectomy is used for recurrent nasopharyngeal tumor and selective neck dissection for recurrent regional lymph node.
45842588|NCT01253460|Drug|Cyclophosphamide|250 mg/m2 by vein (IV) over 30 minutes, 2 hours following the dose of Sapacitabine on days 1, 2, and 3 of each 28 day course.
45842589|NCT01253460|Drug|Rituximab|375 mg/m2 by vein over 6 - 8 hours on day 3 of course 1 after cyclophosphamide, then at 500 mg/m2 on day 1, after cyclophosphamide for subsequent courses. Each course is 28 days.
45842590|NCT01253460|Drug|Sapacitabine|350 mg flat dose by mouth in the morning of days 1,2, and 3 of each 28 day course.
45842591|NCT01254396|Drug|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
45351744|NCT01055743|Procedure|Radical resection|Radical resection of hepatocellular carcinoma
45351745|NCT01055743|Drug|Fluorouracil Implants|Implanted during the surgical treatment
45351746|NCT00604695|Drug|Tenecteplase|Intracoronary injection of IV tenecteplase.
45351747|NCT00604695|Drug|Sterile Saline|Intracoronary injection of IV sterile saline
45351748|NCT01055821|Drug|pegylated interferon and ribavirin|48 weeks
45351749|NCT01055821|Biological|TG4040 + SOC|6 injections
45351750|NCT01055821|Biological|TG4040 + SOC|13 injections
45351751|NCT00900081|Other|immunohistochemistry staining method|
45351752|NCT00900081|Other|laboratory biomarker analysis|
45351753|NCT00900081|Other|medical chart review|
45477165|NCT01205477|Drug|EXPERIMENTAL|Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
45477166|NCT01205477|Drug|PLACEBO|Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
45477167|NCT02501278|Biological|INO-3112 vaccine|"INO-3112 i.e. the combination of VGX-3100 and INO-9012, specifically:~VGX-3100 (HPV16 and HPV18 E6-E7 DNA vaccine) will be administered at 3 mg per plasmid (6 mg total DNA)~INO-9012 (IL-12 DNA plasmid) will be administered at 1 mg per dose will be administered using the CELLECTRA® electoporation device"
45351754|NCT03990727|Diagnostic Test|Retina Analysis-mosaic|Fundus retina pattern study
45351755|NCT03990727|Diagnostic Test|Autofluorescence|Fundus reflectance-functionality
45351756|NCT03990727|Diagnostic Test|OCT- 1 micra|Fine tomography fundus retina
45477168|NCT02501278|Radiation|Radiotherapy (Extrernal beam radiotherapy + brachytherapy)|"The whole pelvis will be irradiated with 45 - 50.4 Gy in 25-28 fractions in fractions of 1.8 Gy over 5 weeks daily.~Those patients with pelvis positive and/or para-aortic positive lymph nodes should be treated with an elective dose to the para-aortic area of 45 Gy in fractions of 1.6-1.8 Gy in 25-28 fractions.~Pelvic and para-aortic nodes known to contain gross/macroscopically visible disease and heavily involved parametria or tumor areas that may lie beyond the high-dose range of brachytherapy should be treated with additional small volume boost of EBRT to a total dose of 60-65 Gy using a combination of either sequential and/or concomitant boost. Fractions of 1.8-2 Gy can be used in the sequential boost."
45477169|NCT02501278|Drug|Cisplatin chemotherapy|Cisplatin chemotherapy will be administered i.v. at a dose of 40 mg/m2 (total 5 cycles during week 1-5) weekly in concomitance with RT with the total dose not to exceed 70 mg per week.
45686232|NCT04778800|Drug|almonertinib|Patients was given a standard dose of 110mg/day of almonertinib, orally, and the first efficacy evaluation was carried out 4 weeks later. If the patient's lungs and/or other parts of the disease (PD) progress, then leave the group to receive other treatment; if the patient's lungs If the brain and other parts are stable or relieved and the brain has not progressed, continue the original dose treatment, and evaluate the effect every 8 weeks. Until the patient's lungs and/or other parts progress (PD), then leave the group to receive other treatment; if If the patient's lungs and other parts are stable or relieved and the brain is progressing, the dose of almonertinib can be increased to 165mg/day, orally ± radiotherapy (the investigator's decision), and then the efficacy will be evaluated every 8 weeks until the patient's lungs and/ Or there is progress (PD) in other parts, then the group will receive other treatment.
45351757|NCT03990727|Procedure|Genotype analysis|Molecular target retina dystrophy analysis
45351758|NCT02540031|Drug|"Additional oral preparation (3L of PEG+Asc, Coolprep®)"|"The interventional or experimental arm will receive 1l of additional PEG+Asc, Coolprep® on the day of colonoscopy~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
45842592|NCT01254396|Drug|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
46045763|NCT05780476|Behavioral|Psychoeducation + virtual reality|6 sessions of 2 hours over 6 weeks. Virtual reality experience will be carry out in the last 30 minutes of each meeting. Virtual reality consists of 360-degree videos depicting everyday situations and allowing the caregivers to feel the specific symptoms of dementia (e.g., disorientation, agnosia, apraxia and memory loss).
45351759|NCT02540031|Drug|"Standard oral preparation (2L of PEG+Asc, Coolprep®)"|"The control arm will receive currently used oral preparation (2l of PEG+Asc, Coolprep®) for colonoscopy~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
46045764|NCT05780411|Other|questionnaire|The symptom related checklist questionnaire, Quality of life questionnaire, Coping strategies questionnaire, Distress thermometer
45351760|NCT03985423|Drug|Emapalumab-Lzsg|Emapalumab administered intravenously at the initial dose of 6 mg/kg, and continued at the dose of 3 mg/kg every 3 days until Study Day 15, and twice-a-week afterwards
45351761|NCT00904293|Other|Genotype-guided dose determination|Patients in both arms will be treated with warfarin. Those in the experimental group will have initial doses determined using an algorithm (from www.warfarindosing.org) incorporating genetic and clinical factors. Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
45351762|NCT00904293|Other|Non-genotype guided warfarin dosing|Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
45351763|NCT00900549|Device|CRT on|12 months
45351764|NCT00900549|Device|CRT off|12-month
45351765|NCT00904449|Drug|Oxymorphone ER|10mg, 20mg, and 40mg PO
45351766|NCT00904527|Behavioral|relaxation (Schultz)|Patients have relaxation consultations during 2 months
45351767|NCT00348595|Drug|Revlimid|one 5 mg/day capsule or one 25 mg/day capsule with matched placebo capsule day 1-21 (28 day cycle)
45351768|NCT02538939|Drug|Sodium thiosulfate|
45842593|NCT01254552|Drug|iobitridol|Xenetix 350 was administered at a dose up to 180 ml, according to the patient's body weight measured on the day of administration.
45351769|NCT00904605|Drug|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h
45686233|NCT04778800|Drug|LM-first line treatment|Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
46045765|NCT05780385|Device|nasotracheal intubation|patients requiring tracheal intubation receive nasotracheal intubation
45686234|NCT04778800|Drug|LM-second line treatment|Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
45686235|NCT01531725|Device|Percutaneous coronary intervention|Percutaneous coronary intervention
45842594|NCT01254552|Drug|gadoterate meglumine|Dotarem was administered at a dose of 0.1 mmol/kg body weight (0.2 ml/kg body weight)
45842595|NCT01256034|Dietary Supplement|Oral IMPACT|oral supplementation for 5 days (1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
45842596|NCT01244724|Drug|Lexapro|Escitalopram will begin at 10mg. a day. Visits will occur biweekly for 12 weeks. Subjects with minimal or no response and minimal or no side effects after 4 weeks will have the dose increased to 20mg. a day. The maximum dose of escitalopram will not exceed the FDA-approved maximum dose of 20 mg per day.
45842597|NCT01256424|Drug|HAL 5% with illumination|Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation
45842598|NCT01256424|Drug|HAL 1% with illumination|Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation
45842599|NCT01256424|Drug|HAL 0.2% with illumination|Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation
45842600|NCT01256424|Drug|Placebo ointment without illumination|Treatment with a singe dose of 2g placebo ointment, no photoactivation
45842601|NCT01257750|Drug|Pazopanib (5mg/ml)|Topical pazopanib, 4 times per day for 3 weeks
45351770|NCT00904605|Drug|Celecoxib|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
45351771|NCT00904761|Other|exercise training|The exercise group took supervised aerobic training twice per week at hospital and thrice per week at home for eight weeks at the intensity of 60-70% VO2peak
45351772|NCT00337129|Drug|eribulin mesylate|1.4 mg/m2 by IV bolus on Days 1 and 8 of an every 21-day cycle.
45351773|NCT00905073|Drug|cyclosporin and methotrexate|cyclosporin 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for one year and methotrexate 5 mg/kg/day for one year. After 6 weeks, cyclosporin doses will adjusted to maintain blood cyclo levels to 100-200 ng/ml.
45351774|NCT02538705|Drug|Neovasculgen|
45351775|NCT00905229|Drug|Phytonadione|2.5 mg po
45351776|NCT00905229|Drug|Phytonadione|0.5 mg IV
45351777|NCT01052935|Biological|Group B streptococcus (GBS) vaccine|"No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P1 study."
45842602|NCT01258374|Drug|Raltegravir|Raltegravir, 400 mg bid
45842603|NCT01258374|Drug|Darunavir|Darunavir, 800 mg QD + ritonavir 100 mg QD
45842604|NCT01260324|Other|No intervention given in this observational study|No intervention given in this observational study
45842605|NCT01260324|Other|No intervention given in this observational study|No intervention given in this observational study
45842606|NCT01262118|Drug|CP-690,550 (tasocitinib)|CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis
45842607|NCT01263132|Drug|F0434|F0434 will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2).
46045766|NCT05780385|Device|orotracheal intubation|patients requiring tracheal intubation receive orotracheal intubation
45477170|NCT03176238|Drug|everolimus|one 10 mg tablet or two 5 mg tablets of everolimus were administered orally once daily on a continuous dosing schedule starting on Day 1
45477171|NCT03176238|Drug|exemestane|25 mg tablet was administered orally once daily on a continuous dosing schedule starting on Day 1
45477172|NCT04495660|Device|Near InfraRed Spectroscopy (fNIRS)|Functional neuroimaging examination by fNIRS at each follow-up visit for all children of both cohorts: this non-invasive imaging technique involves the installation of a cap carrying electrodes to collect brain activity on the surface of the scalp , during stimulation. It is very insensitive to movement and therefore represents a method particularly suitable for its use in children. In addition, this technique is compatible with the cochlear implant. It will be used during 6 tasks adapted to each cohort
45351778|NCT00605085|Biological|Japanese Encephalitis purified inactivated vaccine (IC51)|IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
45351779|NCT00605085|Biological|Placebo|Placebo: Phosphate-buffered saline (PBS) solution containing 0.1% aluminum hydroxide as an adjuvant, 0.5 mL, i.m. injection, 2 injections, days 0 and 28
45351780|NCT00905463|Procedure|Lung transplantation|Lung transplantation
45351781|NCT00905541|Drug|simvastatin|40 mg/day
45351782|NCT00905541|Drug|simvastatin|80 mg simvastatin acute-on-chronic
45351783|NCT00348283|Biological|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab 40 mg eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
45351784|NCT00348283|Biological|placebo|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
45351785|NCT00348283|Biological|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab or placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8. In the Open-Label arm, interventions were either adalimumab 40 mg SC eow or adalimumab 40 mg SC weekly. There was no placebo intervention post Week 52.
45477173|NCT04495660|Behavioral|Passive perceptual stimulation|Passive perceptual stimulation: For this passive task the child is on his parents' lap in front of a screen. He will see images, hear everyday noises and watch small videos. Duration 8-10 minutes.
45477174|NCT04495660|Behavioral|Task A not B|Task A not B: the child will play with an adult who will hide an object under a cloth several times. The child will have to find the hidden object. Duration 10 minutes maximum
45477175|NCT04495660|Behavioral|VSWMT task|VSWMT task: the child will be on the parents' lap in front of a screen and will watch a monkey hiding bananas in the trees several times. Duration of 10 minutes maximum.
45477176|NCT04495660|Behavioral|Perceptual Go-No-Go|Perceptual Go-No-Go: This perceptual task consists in the discrimination of images (faces) and sounds (words) through 3 conditions (auditory, visual and visuo-auditory) presented independently of each other and lasts 15 to 20 minutes in total. It is presented by means of a computer
45477177|NCT04495660|Behavioral|Verbal memory task|Verbal memory task :the child will be presented with 5 lists of 5 words which he will have to restore after a predefined delay of a few seconds. Its duration does not exceed 10 minutes.
45477178|NCT04495660|Behavioral|The sensory room|The sensory room: the child will sit in the middle of a carpet and play with the adult. He will hear everyday noises and see light effects. Duration 8-10 minutes
45477179|NCT03565315|Biological|VRC-HIVMAB095-00-AB (10E8VLS)|10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.
45477180|NCT03565315|Biological|VRC-HIVMAB075-00-AB (VRC07-523LS)|VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
45842608|NCT01263132|Drug|Gabapentin|Gabapentin will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2)
45842609|NCT01264614|Behavioral|Strengthening exercise|3 months of 3-5 times per week of low-intensity exercises using a chair and small weights
46045767|NCT05780372|Radiation|Intensity Modulated Radiation Therapy|All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
46045768|NCT05780372|Drug|Chemotherapy|Chemotherapy will be arranged by the physician-in-charge according to the NCCN guideline, patient's stage and physical condition.
45351786|NCT00905697|Procedure|Living donor lung transplantation|Living donor lung transplantation
45351787|NCT03987295|Drug|AL001|60 mg/kg of AL001 every 4 weeks
45351788|NCT01055899|Biological|REGN88|Single SC Dose
45477181|NCT03840161|Device|non-invasive tissue glucose prediction|Generation of non-invasive and invasive glucose readings for comparison with a standard laboratory reference glucose determination method (YSI glucose analyzer)
45477182|NCT01205555|Device|urine LH testing|"The study group will start urine LH (LHu) testing according to the mean diameter of the leading follicle on ultrasound as per :~13mm or less - Repeat ultrasound scan in 1-2 days 14-17mm - start urine LH testing the evening of the day of the scan 18mm or greater - do one LHu test in the afternoon of the day of the scan before HCG administration Once the patient has commenced LHu testing she will perform 2 tests per day. The tests will be performed at 7am and 7pm. LHu testing will continue until the time of HCG administration or positive uLH.If the LHu result is positive either in the morning or afternoon, the insemination will be the next morning without the administration of exogenous HCG.~If the patient has an inconclusive LHu result, a blood LH test will be taken. If the LH blood test is negative (<8 IU\L) she will continue testing LHu. If the LH blood test is positive (≥ 8 IU\L) the insemination will be the next day."
45842610|NCT01267422|Drug|rAAV2-ND4|injection
45477183|NCT01957332|Procedure|Molecular imaging|On the day of FES-injection&scan or the day after FES-injection, 89Zr-trastuzumab (~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.
45842611|NCT01267656|Device|Lubricating and Rewetting Drops|Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
45477184|NCT01957332|Procedure|Molecular imaging|All patients receive 18F-FES (~200MBq) injection followed by a FES-PET.
45477185|NCT03840083|Behavioral|Sleep|Participants will sleep (either a mid-day nap or normal overnight sleep)
45477186|NCT02509000|Other|air purifier|filtration units randomly allocated to active- and sham-mode in 20 recruited households for four weeks
45477187|NCT02501122|Other|Pediatric Health Information System (PHIS), Partners for Kids (PFK) and Nationwide Children's Hospital Perioperative Database|Utilizing these databases to assess standards for quality of care measures in adenotonsillectomy patients.
45477188|NCT01205633|Procedure|venous angioplasty|catheter venous angioplasty via femoral vein approach
45686236|NCT05369806|Behavioral|Interactive two-way SMS dialogue|This study uses Mobile WACh, a human-computer hybrid system that enables two-way SMS communication and patient tracking, to provide consistent support to women and their infants during the peripartum period and 6 weeks into the baby's life. Women will receive automated SMS messages targeting the appropriate peripartum period and will have the capability to respond and spontaneously message a nurse based at the clinic. During pregnancy, automated SMS will be delivered weekly. Two weeks prior to the participant's estimated due date (EDD), daily messaging will begin, and will continue for two weeks after delivery is ascertained. Thereafter, SMS will be delivered every other day. Women who experience pregnancy or infant loss will be enrolled into an infant loss track. The NLP model will be applied to incoming participant messages. Those flagged as urgent by the model will be flagged within the SMS system, allowing study nurses to triage and appropriately respond to those messages.
45842612|NCT01267656|Device|AMO Blink Contacts Lubricant Eye Drops|Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
45842613|NCT01269372|Device|PillCam Colon 2|"Each subject will be required to follow a bowel preparation regimen and will undergo Capsule Endoscopy (CE).~Following capsule ingestion and depending on capsule progression through the digestive tract subjects will be required to take an additional volume of laxatives in order to enhance capsule propulsion and maintain adequate cleansing of the colon."
46045769|NCT05780359|Device|Drug eluting stent|Sirolimus drug-eluting self-expanding stent available from 20mm to 250mm in length, 3.5mm to 7.5mm in diameter of superficial femoral and proximal popliteal arteries (SFA/PPA) cases for inhibiting in-stent restenosis and improve long-term outcome.
46045770|NCT05780359|Device|drug coating balloon|A proprietary lipophilic coating technology that uses magnesium sterate as excipient, facilitates paclitaxel transfer to the vessel wall, enhances drug delivery, and brings minimal downstream effect. Available from 20mm to 300 mm in length, 3mm to 12 mm in diameter, fits every SFA cases, reduces radiation exposure time.
46045771|NCT05780320|Other|Prophylactic amiodarone and posterior pericardiotomy|"Patients after the implementation of the protocol receive postoperative prophylactic amiodarone and a posterior pericardiotomy.~The amiodarone regimen consists of amiodarone 1mg/min x 10 hours (600 mg total) via central line upon arrival to the intensive care unit followed by 400 mg PO BID on postoperative days 1 and 2 followed by 200 mg PO BID on postoperative days 3 and 4 or until discharge, whichever occurs first.~The posterior pericardiotomy occurs during the cardiac procedure."
45351789|NCT01055899|Biological|REGN88|Single SC Dose
45351790|NCT01055899|Biological|REGN88|Single SC Dose
45351791|NCT00336895|Drug|Myfortic|Myfortic 360mg or 720 mg BID for 90 days.
45351792|NCT01059019|Dietary Supplement|Omega-3 Fatty Acid Supplements|Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients, while another 20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day. Patients will be asking to follow up postoperatively after 2 days, 4 days, 1 week, 3 months and 6 months
45477189|NCT01923636|Other|detection of CMV|Clinical, radiological and laboratory (virological and immunological) standardized reports
45351793|NCT00336583|Drug|Oxaliplatin|Oxaliplatin, 130 mg per square meter, on day 1
45351794|NCT00336505|Drug|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
45351795|NCT00336505|Drug|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
45351796|NCT00357877|Drug|10% w/v chlorhexidine acetate coating FDA IND #45466|Dental coating topically applied by dental professional supragingivally to the full dentition
45351797|NCT00357877|Other|Placebo|
45842614|NCT01269372|Device|Colonoscopy|The colonoscopy procedure will be scheduled approximately 4-6 weeks after the CE procedure, and the colonoscopy bowel preparation will be the same as the bowel preparation for CE.
45351798|NCT03990337|Device|Ultrasound|Ultrasonography of cricoid cartilage.
45351799|NCT03987529|Other|sevoflurane|volatile anesthetic
45477190|NCT03565237|Biological|RIXUBIS: On-Demand|RIXUBIS used under standard clinical practice in India: On-Demand treatment.
45351800|NCT03987529|Other|propofol|intravenous anesthetic
45477191|NCT03565237|Biological|RIXUBIS: Prophylaxis|RIXUBIS used under standard clinical practice in India: Prophylaxis treatment.
45477192|NCT05307432|Behavioral|SPI+ Delivered by ED Staff|ED staff will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
45477193|NCT05307432|Behavioral|SPI+ Delivered by SPCC Clinicians|The Suicide Prevention Consultation Center (SPCC) will be located external to the Emergency Department (ED). ED staff will be able to refer patients at risk for suicide to the SPCC. Licensed and credentialed mental health clinicians will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) via telehealth to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
45842615|NCT01270542|Drug|Avastin (bevacizumab)|single 0.05 mL intravitreal injection of bevacizumab 1.25 mg
45477194|NCT01205711|Drug|FOLFIRI regimen|
45842616|NCT01270542|Other|Sham injection|Subject's eyes will be anesthetized but no injection will be performed.
45477195|NCT01205711|Drug|fluorouracil|
45477196|NCT01205711|Drug|irinotecan hydrochloride|
45477197|NCT01205711|Drug|leucovorin calcium|
45477198|NCT01205711|Drug|zibotentan|
45477199|NCT01205711|Other|laboratory biomarker analysis|
45477200|NCT01205711|Other|pharmacogenomic studies|
45842617|NCT01271244|Drug|Escitalopram|10-20mg daily for 12 weeks
46045772|NCT05780294|Drug|5-fu|5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.
46045773|NCT05780294|Drug|Lobaplatin|30mg/m2, used on the 1st and 28th day of each cycle.
46045774|NCT05780294|Drug|Placebo|2 tablets/dose 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, 3 tablets/dose 3 times daily during chemotherapy, and continued to be given orally 2 tablets/dose 3 times daily for 4 weeks after the end of chemotherapy.
45351801|NCT03990259|Other|Running the CSP Mountain Race|The runners completed a 107,6 km mountain race
45351802|NCT00335959|Drug|capecitabine|850 mg/m2/dose PO q 12 hours Days 1-14 and 22-35. 650 mg/m2/dose PO q 12 hours Days 43-77.
45351803|NCT00335959|Drug|oxaliplatin|130 mg/m2 by 2-hour infusion Days 1 and 22
45351804|NCT00335959|Procedure|conventional surgery|Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy
45351805|NCT00335959|Radiation|radiation therapy|Beginning Day 43, patients will be treated 5 days/week at 180 cGy/day times 25 fractions to a total dose of 4,500 cGy.
45351806|NCT01056133|Other|Omega-3 capsules-Fish Oil|Patients will take 2 capsules (1.0 g each) of n-3 PUFA (0.82/0.44 g of EPA/DHA) daily x 12 months. Since n-3 PUFA supplementation can be a potential treatment for NASH and since BMI will be< 30 kg/m2 for all subjects, patients will be told to keep their lifestyle, diet and medication stable (unless medically necessary) for the study duration in order to minimize environmental effect on gene expression.
45351807|NCT01059097|Procedure|Pancreaticoduodenectomy|
45351808|NCT01053091|Behavioral|exercise|The trained subjects will be trained on a bicycle ergometer at about 60-70%of heart rate reserve for 35-55 minutes (that will include 10-min warm-up, 15-35-min main exercise, and 10-min cool-down) per day, 3 days per week for 12 weeks
45351809|NCT03987061|Device|MOTIV BVS|MOTIVS BVS in below-the-knee artery disease
45477201|NCT02508922|Dietary Supplement|Vitamin D3|2,000iu vitamin D drops will be taken daily for 20 weeks
45477202|NCT02508922|Dietary Supplement|Placebo|Matching placebo drops will be taken daily for 20 weeks
45477203|NCT02894437|Other|qualitative interviews|semi-structured interviews as a conceptual frame work
45477204|NCT01860456|Drug|Imatinib/Nilotinib|Imatinib: 400 mg/day oral - Nilotinib: 600-800 mg/day oral
45477205|NCT03730675|Procedure|Portal irradiation stent placement|The irradiation portal vein stent was designed as two separate parts that consisted of an outer seeds-loaded-stent and an inner self-expandable metallic stent
45477206|NCT03730675|Procedure|TACE|TACE is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply.
45477207|NCT03730675|Drug|Sorafenib|Sorafenib is a kinase inhibitor drug approved for the treatment of advanced hepatocellular carcinoma.
45842618|NCT01271868|Biological|IB1001|
45842619|NCT01271946|Device|Diagnostic catheterization procedure|Intervention includes diagnostic catheterization procedure involving access through a 5F or 6F introducer in the femoral artery.
45842620|NCT01272882|Device|Electrical Impedance Tomography monitoring|Chest belt with 16 electrodes connected to the EIT device
45842621|NCT01272960|Device|Post-Placenta Mirena Insertion|Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta
46045775|NCT05780294|Drug|leucogen|40 mg/dose was used 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, and 60 mg/dose was used 3 times daily during chemotherapy, and 40 mg/dose was continued orally 3 times daily for 4 weeks after the end of chemotherapy.
46045776|NCT05780255|Device|VV-ECMO|veno-venous extracorporeal membrane oxygenation
45686237|NCT05324332|Drug|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
45686238|NCT05324332|Drug|68Ga-PSMA-11|Intravenous injection of 68Ga-PSMA-11 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-PSMA-11 will be used to image lesions of prostate cancer by PET/CT.
45686239|NCT04778878|Device|Mediracer® NCS|A point-of-care, hand-held nerve conduction device
45686240|NCT04769908|Drug|Systemic Chemotherapy|Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
45686241|NCT04769908|Drug|Lenvatinib|Lenvatinib, 8mg or 12mg, po, QD
45842622|NCT01272960|Device|Interval Insertion|Insertion of Mirena 4-8 weeks post partum after vaginal delivery
45842623|NCT01273896|Drug|STA-9090|All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.
45842624|NCT01274520|Device|The Medtronic Portable Bypass System (PBS®)|Will be used for machine perfusion of liver grafts.
45842625|NCT01275300|Drug|Aspirin|
45842626|NCT01275300|Drug|Placebo|
45842627|NCT01275300|Drug|Niacin|
45842628|NCT01276314|Drug|anti- TNF-a|25mg BIW, SC
46045777|NCT05780242|Behavioral|Self-questionnaire Eating Attitudes|self-diagnostic and quantitative questionnaire of 40 questions evaluating the behavior, severity and evolution of anorexia nervosa
45351810|NCT01053169|Biological|Beriplex® P/N|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
45351811|NCT01053169|Biological|Fresh Frozen Plasma (FFP) and Beriplex® P/N|FFP is administered before Beriplex® P/N. Each treatment is given as an intravenous infusion, with the dosage of each calculated on an individual patient basis.
45351812|NCT01053169|Other|Fresh Frozen Plasma|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
45686242|NCT04769908|Drug|Sintilimab|Sintilimab, IV, 200mg, q3w
45686243|NCT05324254|Device|Weighted blanket|A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
45686244|NCT01478373|Drug|Dovitinib (TKI258)|Oral Dovitinib (TKI258) as a gelatin capsule of 100 mg strength and dosed on a flat scale of 500 mg on a 5 days on /2 days off dosing schedule.
45686245|NCT04778488|Device|Near-Infrared-Spectroscopy (NIRS)|Placement of 2 NIRS optodes on the patients' forehead, measurement of NIRS during cardiac arrest and up to 72h post return of spontaneous circulation
45686246|NCT02951338|Behavioral|PROPEL program|The PROPEL program involves both group aerobic exercise and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
45842629|NCT01276314|Drug|Prednisolone|1-1.5 mg / kg / day
45842630|NCT01276860|Device|Psychomotor Vigilance Testing|The purpose of this study is to examine the use of psychomotor vigilance testing (PVT) as a tool in the diagnosis and prediction of pediatric obstructive sleep apnea. PVT simply involves responding to a light by pressing a button on a small handheld device. It is a simple measure of reaction time.
45351813|NCT01059253|Other|AdvanStep training program - Turtle Pop|Balance / mobility exercise program using the AdvanStep in a virtual reality context
45842631|NCT01280058|Drug|Carboplatin|Given IV
45842632|NCT01280058|Other|Laboratory Biomarker Analysis|Correlative studies
45842633|NCT01280058|Drug|Paclitaxel|Given IV
45842634|NCT01280058|Biological|Wild-type Reovirus|Given IV
45842635|NCT01280604|Drug|Fenofibrate 54mg|Subjects will receive fenofibrate 54mg daily.
45842636|NCT01282242|Drug|IV rt-PA|open-label
46045778|NCT05780242|Behavioral|Situational Anxiety and Trait Anxiety|"assess anxiety as a personality trait (feelings of apprehension, tension, nervousness and worry that the subject usually feels), and anxiety as a ' emotional state linked to a particular situation"
46045779|NCT05780242|Behavioral|Beck Depression Inventory (BDI) scale|a diagnostic self-questionnaire allowing a quantitative estimation of the intensity of depressive symptoms in adults and adolescents
46045780|NCT05780242|Behavioral|• Post-traumatic Check List Scale|questionnaire includes 20 items, each question is to be rated between 1 and 5 depending on the intensity and frequency of symptoms during the previous month.
45842637|NCT01283022|Drug|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
45842638|NCT01285050|Drug|Antiretroviral therapy (ART)|Peginterferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications. Peginterferon is used to produce a measurement but the intervention is the HIV medications which are specified as raltegravir, emtricitabline, and tenofovir disoproxil fumerate.
45351814|NCT01059331|Drug|Pregabalin|150 mg x 2 daily for 2 days
45351815|NCT01059331|Drug|Sugar pill|1 tablet x 2 daily, for 2 days
45351816|NCT03985345|Device|intravaginal device (probe) EMY|Free use of EMY and its mobile application for 10 minutes during 5 different days per week.
45351817|NCT01059409|Procedure|Meniscal Allograft|Meniscal Allograft
45351818|NCT01059487|Other|Traditional Chinese Medicine|Traditional Chinese Medicine includes acupuncture, herbal, tuina and other accessory techniques
45477208|NCT04495738|Other|Control Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
45477209|NCT04495738|Other|Control Toddler Drink|16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
45842639|NCT01285050|Drug|raltegravir|raltegravir is an HIV medication given 400 mg twice daily by mouth
45842640|NCT01285050|Drug|Emtricitabine and tenofovir disoproxil fumarate|Emtricitabine and tenofovir disoproxil fumarate are HIV medications, combination pill, once per day by mouth
45842641|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
45477210|NCT04495738|Other|Experimental Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
45477211|NCT04495738|Other|Experimental Toddler Drink|16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
45477212|NCT04495738|Other|Supplemental Formula for HM Group|Ad libitum formula given up to 12 months of age if HM is supplemented
45477213|NCT04495738|Other|Toddler Drink for HM group|16 fl oz per day if weaned from HM feedings
45477214|NCT01297673|Procedure|video-urodynamic examination|Assessment of bladder function during video urodynamic determine of incidence degree and localization of vesico ureteral reflux based on the result of video urodynamics
45477215|NCT01765140|Drug|3,4-diaminopyridine|Treatment use of 3,4-DAP for patients with congenital myasthenic syndrome (CMS)
45477216|NCT03726853|Drug|CKD-497 200mg|CKD-497 200mg
45842642|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
45477217|NCT03726853|Drug|CKD-497 300mg|CKD-497 300mg
45842643|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
45842644|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
45842645|NCT01286454|Drug|fesoterodine|single dose of tablet
45842646|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
45842647|NCT01287078|Drug|Cyclosporine Inhalation Solution|sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
45842648|NCT01290978|Drug|ChloraPrep|The application sites (subjects' backs) will be prepped with ChloraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
45842649|NCT01290978|Drug|DuraPrep|The application sites (subjects' backs) will be prepped with DuraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
45842650|NCT01291056|Other|Placebo|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
45351819|NCT01059721|Procedure|Medialising insertion of patella tendon|surgical treatment of medialising tibial tuberosity
45351820|NCT03985111|Device|Central Venous Catheter|Insertion of a central venous catheter insertion pre-operatively (electively)
45477218|NCT03726853|Drug|CKD-497 placebo|Placebo of CKD-497
45351821|NCT03742063|Drug|first-line chemotherapy|patients who routinely received neoadjuvant chemotherapy according to Peking University People's Hospital chemo-protocols (PKUPH-OS and PKUPH-ES)
45351822|NCT03741985|Behavioral|The handgrip exercise|The control group was given routine dialysis treatment and daily handgrip exercise .Patients are asked to squeeze a rubber ring 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
45477219|NCT03726853|Drug|Comparator|Comparator
45477220|NCT03726853|Drug|Comparator placebo|Comparator placebo
45477221|NCT01205867|Drug|AZD8848|Nasal spray solution, intranasal, single ascending doses, 1.4 - 60 μg
45477222|NCT05219214|Other|Chinese medicine|There are no restrictions on TCM therapy, including Chinese herbal medicine, Chinese patent medicine, external treatment, acupuncture and moxibustion, etc
45477223|NCT03343288|Device|Silver doped hydroxyapatite coated implants|In this study, CE marked, domestic manufactured standard orthopedic implants will be used in 30 patients after silver ceramic coating with electrospray method. These patients will be tasted for the evaluation of liver and kidney functions and blood and urine silver levels in addition to routine tests such as full blood, complete biochemistry, C-reactive protein, erythrocyte sedimentation rate required in the normal diagnosis and treatment processes, and will be monitored for at least 12 months.
45842651|NCT01291056|Drug|Clomiphene|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
45842652|NCT01292304|Drug|Tolvaptan|Oral administration once daily Dosage will range from 15 mg to 30 mg
45842653|NCT01292538|Device|Erchonia GLS|532 nm green diode low level laser light device
45351823|NCT03741985|Behavioral|The dumbbell exercise|The experimental group was given routine dialysis treatment and daily dumbbell exercise .Patients are asked to hold 6-pound dumbbells to exercise 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
45842654|NCT01292538|Device|Placebo laser|Sham light output with no therapeutic benefit
45842655|NCT01293396|Drug|Insulin Aspart|Patients received insulin aspart before breakfast and before lunch.
45351824|NCT01059955|Drug|Dexamethasone Phosphate Ophthalmic Solution (EGP-437)|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only).
45351825|NCT01059955|Drug|Dexamethasone phosphate ophthalmic solution|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only)
45351826|NCT01060033|Device|MR Spectroscopy|
45351827|NCT01060033|Device|Fat-Saturation and Diffusion-Weighted Imaging|
45351828|NCT01060033|Device|Dynamic Contrast Enhancement MRI (MR-DCE)|
45351829|NCT01060033|Device|Diffusion Tensor Imaging (DTI)|
45351830|NCT01060189|Drug|Ulinastatin|
45351831|NCT01060189|Drug|Tranexamic Acid|
45351832|NCT01060189|Drug|Saline Solution|
45351833|NCT03984877|Diagnostic Test|Diagnosis of amyloidosis|Scintigraphy and protein electrophoresis
45351834|NCT01060267|Drug|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
45842656|NCT01293396|Drug|Insulin Aspart 30|Patients received biphasic insulin aspart 30 before breakfast and before lunch.
45351835|NCT01060267|Drug|Placebo|patients in placebo group 50ml of normal saline over 10 minutes, 1/2 hour before endoscopy.
45351836|NCT01060423|Drug|Cetuximab|Starting dose of 400mg/m2, followed by weekly 250mg/m2
45842657|NCT01293396|Drug|Insulin Aspart 70|Patients received biphasic insulin aspart 70 before breakfast and before lunch.
45842658|NCT01294098|Drug|Marcaine|0.75 cc/kg of 1/4% Marcaine
45842659|NCT01295112|Drug|Active bevacizumab and Sham dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Sham dexamethasone intravitreal implant: blunt needling of the sclera with no penetration of the globe
45351837|NCT01060423|Drug|Irinotecan|Irinotecan 180 mg/m² to be administered every two weeks
45351838|NCT01060423|Device|Irinotecan eluting BEADS|A minimum of two treatments per lobe (four bi-weekly sessions in the event of bilobar disease) at week 0 and 4 with up to 4ml (100-300µm DC Bead loaded with up to 200mg irinotecan) will be scheduled (i.e. for bilobar disease right lobe: week 0, left lobe: week 2, right lobe: week 4 and left lobe: week 6: following toxicity and extending interval if toxicity seen).
45351839|NCT03984721|Diagnostic Test|Amyloidosis typing using mass spectrometry-based proteomics|Amyloidosis typing using nanoLC-MS/MS method
45351840|NCT01060501|Drug|Folinic Acid, interferon-alpha|5-FU, 450 mg/m² i.v. for 60 min, weekly for 52 weeks postoperatively Folinic acid, 200 mg/m² i.v. 10 min, weekly for 52 weeks postoperatively 6x10 (high6) I.U. as subcutaneous self injection 3x weekly. Training of self injection was initiated on day 28 (duration until week 52)
45351841|NCT00670488|Drug|MK-2206|MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.
45351842|NCT00671658|Drug|Rituximab|375 mg/m2 by vein
45351843|NCT00671658|Drug|Cyclophosphamide (CTX)|300 mg/m2 by vein
45351844|NCT00671658|Drug|Doxorubicin|50 mg/m2 by vein
45477224|NCT01345682|Drug|Afatinib|Once daily
45477225|NCT01345682|Drug|Methotrexate|Weekly
45842660|NCT01295112|Drug|Active bevacizumab and Active dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Dexamethasone intravitreal implant: 0.7 mg, single dose
45351845|NCT00671658|Drug|Vincristine|2 mg by vein
45351846|NCT00671658|Drug|Dexamethasone|40 mg by vein or by mouth (P.O.)
45351847|NCT00671658|Drug|Methotrexate (MTX)|"12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7~200 mg/m2 by vein followed by 800 mg/m2 for Courses 2,4,6,8"
45351848|NCT00671658|Drug|Cytarabine|"100 mg intrathecal for Courses 1,3,5,7~3 gm/m2 by vein for Courses 2,4,6,8"
45351849|NCT00671658|Drug|G-CSF|10 ug/kg subcutaneous injection
45351850|NCT00671658|Drug|Mesna|600 mg/m2 a day by vein
45351851|NCT00671658|Drug|Pegylated asparaginase|2000 International units/m2 by vein
45842661|NCT01296360|Biological|IXIARO|0.25 ml i.m. (milliliter, intramuscular)
45842662|NCT01296360|Biological|IXIARO|0.5 ml i.m. (milliliter, intramuscular)
45842663|NCT01298544|Procedure|Blood draw|One 5mL blood draw for immunogenicity at least 3 years post completion of clinical study 0887X-101518.
45351852|NCT00671658|Drug|Pegfilgrastim|6 mg (flat dose) within 72 hrs after completion of chemotherapy
45351853|NCT00671658|Drug|Solumedrol|40 mg by vein for Courses 2,4,6,8
45842664|NCT01299090|Device|Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator|two treatments spaced 30 days apart
45842665|NCT01301742|Drug|BI 10773|1 tablet single dose BI 10773 in the morning
45842666|NCT01301742|Drug|Gemfibrozil|Gemfibrozil 600 mg bid for 5 days
45842667|NCT01301742|Drug|BI 10773|1 tablet single dose BI 10773 in the morning
45351854|NCT00768378|Device|Training with the BrainPort balance device|Subjects are randomly assigned to one of two groups, the perceived stimulation group or the subliminal stimulation group. Some of these devices provide a stimulus that you can feel. Others provide a stimulus that is below conscious awareness. We are conducting this study to determine if one type of stimulation is more effective than the other.
45477226|NCT05295264|Other|Moderate exercise program|"Exercise program All sessions will begin with a warm-up of 7-8 minutes composed of mild movements and joint mobility of upper and lower limbs exercises. Then a central part of 35-40 minutes, four types of activities will be included (aerobic work, muscle strengthening, coordination/balance tasks, pelvic floor exercises), finally a section of flexibility, relaxation, and final talk (comments and sharing) will be performed (12-15 minutes).~Healthy lifestyle advise This intervention consists of providing guidelines and videos with advice on healthy habits throughout the pregnancy process. This type of content will be related to daily physical activity, food recommendations, and fundamental exercises to perform during pregnancy."
45477227|NCT03343210|Diagnostic Test|quality of life and pain measurement .|comparison of quality of life measurement in residents with cancer and in cancer-free residents, by a geriatric consultations'nurse
45351855|NCT00764712|Drug|insulin|Insulin was was administered according to each protocol rules/suggestions into a central venous line as a continuous infusion (Bath and eMPC protocols) or as a combination of a continuous infusion and boluses (Matias protocol). A standard concentration of 50 IU of insulin in 50 ml of 0.9% NaCl was used. In all patients, infusion of 10% glucose solution was initiated upon admission to ICU with glucose dose of 2.5 g/kg of ideal body weight (height in centimetres minus 100) per hour and lasted for 18 hours, when normal oral food intake was started. In ventilated patients, the glucose infusion lasted for 48 hours, and then standard enteral nutrition was initiated.
45351856|NCT00768456|Drug|Ropivacaine 0.5 %|Local Infiltration with Ropivacaine 0.5 %
45351857|NCT00768456|Drug|Isotonic NaCl|Local Infiltration with NaCl
45477228|NCT03839849|Procedure|: i-PRF|The description of this intervention has been already given before
45477229|NCT03839849|Procedure|saline|The description of this intervention has been already given before
45351858|NCT02557464|Behavioral|An eye tracking experiment|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
45351859|NCT02557464|Behavioral|A neuropsychological evaluation|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
45842668|NCT01303068|Device|13C urea breath test Kit|20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas
45842669|NCT01303224|Drug|Ibodutant|Oral tablet, low dose, once daily, for 8 weeks
45842670|NCT01303224|Drug|Ibodutant|Oral tablet, intermediate dose, once daily, for 8 weeks
45842671|NCT01303224|Drug|Ibodutant|Oral tablet, high dose, once daily, for 8 weeks
45842672|NCT01303224|Drug|Placebo|Oral tablet, (identical in appearance and weight to Ibodutant tablets), once daily, for 8 weeks
45842673|NCT01304082|Drug|Lidocaine|1 ml subcutaneous injection of 0.9% lidocaine, given once
45842674|NCT01304082|Drug|normal saline|1 ml subcutaneous injection 0.9% sodium chloride, given once
45842675|NCT01304082|Drug|alkalinized lidocaine|1 ml subcutaneous injection of 0.9% lidocaine and 0.84% sodium bicarbonate
45351860|NCT00542386|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
45351861|NCT00542386|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
45351862|NCT00768612|Drug|SCA-136 50mg/day|
45842676|NCT01304238|Drug|lepirudin|lepirudin
45842677|NCT01304238|Drug|danaparoid|danaparoid
45842678|NCT01304238|Drug|argatroban|argatroban
45842679|NCT01304238|Drug|fondaparinux|fondaparinux
45842680|NCT01305252|Drug|treprostinil inhalations|Treprostinil inhalation QID starting at 3 breaths per inhalation & gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
45842681|NCT01305252|Drug|tadalafil|tadalafil 20mg QD PO increasing to 40mg QD as tolerated
45842682|NCT01307748|Other|aroma|Comparison of known stress reducing aroma to placebo aromas without stress-reducing effects
45351863|NCT00768612|Drug|SCA-136 150 mg/day|
45351864|NCT00768612|Drug|SCA-136 300mg/day|
45351865|NCT00768612|Drug|Risperidone 4mg/day|
45477230|NCT02503696|Device|Stool Collection Kit|Stool Collection Kit.
45477231|NCT03562117|Drug|Gepotidacin|It is an immediate-release tablet (1500 mg (2 x 750 mg), containing gepotidacin (free base) an inactive formulation excipients.
45477232|NCT04497064|Other|survey|survey asking questions regarding breakfast habits and composition, sports nutrition knowledge and exercise habits
45477233|NCT01314924|Dietary Supplement|Dark chocolate|70% cocoa
45477234|NCT02503462|Drug|Darunavir|darunavir 800 mg once daily will be first given together with ritonavir 100 mg once daily for one month (period 1) and then darunavir 800 mg once daily will be given together with cobicistat 150 mg once daily for one month (period 2). Afterwards, all patients will be switched back to darunavir/ritonavir (800/100 mg once daily).
45477235|NCT02503462|Drug|ritonavir|ritonavir 100 mg once daily will be used to boost darunavir 800 mg once daily (period 1).
45477236|NCT02503462|Drug|cobicistat|cobicistat 150 mg once daily will be used to boost darunavir 800 mg once daily (period 2).
45477237|NCT05217212|Radiation|Radiochemotherapy|Primary radiotherapy of the primary tumor and nodal basin with curative intent with or without concomitant chemotherapy with cisplatin, carboplatin, or cetuximab weekly.
45351866|NCT00604383|Drug|ruboxistaurin|32-mg tablet, orally, daily, up to 42 months
45842683|NCT01308060|Drug|Botulinum Toxin Type A|During part A, Azzalure will be administered at Baseline 60 Speywood units at canthal lines and compared with placebo.
45842684|NCT01308060|Other|Placebo|
45477238|NCT05706428|Device|NHFOV|The neonate patients with respiratory distress will have nasal high frequency ventilation as an initial mode of respiratory support.
45477239|NCT05706428|Device|NCPAP|The neonate patients with respiratory distress will have nasal continuous positive airway pressure as an initial mode of respiratory support.
45477240|NCT03561883|Drug|IW-3718|oral tablet
45477241|NCT03561883|Drug|placebo|oral tablet
45686247|NCT02951338|Other|Group aerobic exercise|"Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.~Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites."
45351867|NCT00604383|Drug|placebo|1 tablet, orally, daily, up to 42 months
45477242|NCT03561883|Drug|Standard-dose PPIs QD|background therapy
45686248|NCT01502709|Device|Caloric Vestibular Neurostimulation|1 treatments of caloric vestibular neurostimulation for 7.5 minutes in the right ear
45686249|NCT01502709|Device|placebo|Matching placebo device
45842685|NCT01308294|Biological|2 vaccine injections in 1 limb|Participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide. The content of each syringe is injected s.c. in the same limb at about 5 cm distance from each other.
45842686|NCT01308294|Biological|2 vaccine injections in distinct limbs|Participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide.The content of each syringe is injected s.c. in different limbs.
45842687|NCT01308294|Biological|"2 vaccine injections in distinct limbs"|
45842688|NCT01308840|Drug|Panitumumab|Day 1 and 15 = 6 mg/kg IV
45842689|NCT01308840|Drug|oxaliplatin|Days 1 and 15 = 85mg/m2 IV
45842690|NCT01308840|Drug|gemcitabine|Days 1 and 15 = 1000 mg/m2 IV
45842691|NCT01310400|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Days 0 and 28"
45351868|NCT00771108|Behavioral|exercise|For 16 weeks subjects will exercise from 30-60 minutes five times a week.
45351869|NCT04048200|Drug|Fentanyl|Anesthesia will be induced by fentanyl, propofol, and rocuronium with maintenance of anesthesia using sevoflurane.
45351870|NCT04048200|Drug|Dexmedetomidine Ketamine|No opioid will be used in induction of anesthesia. A combination of dexmedetomidine and ketamine will be infused. Sevoflurane will be used for maintenance of anesthesia.
45351871|NCT00985894|Other|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via store and forward teledermatology.
45351872|NCT00985894|Other|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
45477243|NCT04495426|Other|Non-interventional study|There are no treatments to stop or even slow down the progression of this disease although there are treatments that temporarily improve the symptoms, such as anti-seizure medications.
45477244|NCT05217056|Other|measurements|All of the infants with high risk of cerebral palsy will be assessed from birth to 12 months age with the assessments of Prechtl's General movements (GMs) until 20 weeks of age. Also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) will be performed at the 3rd, 6th, and 12th months for the cognitive development.
45477245|NCT02503306|Drug|AVANAFIL|Pharmaceutical form:tablets Route of administration: oral
45477246|NCT02503306|Drug|placebo|Pharmaceutical form:tablets Route of administration: oral
45477247|NCT02508766|Procedure|Plantar stimulation|The manipulation was performed with the subject in the supine position. The intervention lasted ten minutes and consisted of four stages: 5 glide pressures focused on each interdigital space, that lasted 10 seconds in duration, 5 compression-decompression of each metatarsophalangeal joint, 5 glide pressures applied for 5 seconds each, on the region of metatarsal heads, 5 static pressures applied for 10 seconds each, focused on four points of the sole.
45686250|NCT03843268|Device|AMPS Gondola|Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS); the treatment requires less than 2 minutes.
45686251|NCT03843268|Device|Sham Gondola|The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger
45842692|NCT01310400|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~15 µg HA antigen of A/Brisbane/59/2007 (H1N1)-like virus~15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
45842693|NCT01310400|Biological|Agrippal|"Agrippal influenza vaccine~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
45842694|NCT01311102|Drug|Lidocaine|1.33 cc 2% liquid lidocaine
45842695|NCT01311102|Drug|Normal Saline|1.33cc normal saline
45842696|NCT01312038|Drug|Simethicone|single 125 mg chewable tablet
45842697|NCT01312038|Drug|Placebo|chewable calcium tablet
45842698|NCT01312272|Drug|Oxytocin|Oxytocin 40 units/ml nasal spray: use 5 sprays per nostril (40 IU total) one time
45842699|NCT01312272|Drug|Inactive placebo nasal spray|A placebo nasal spray will be prepared identically to the oxytocin nasal spray except lacking oxytocin. Its ingredients are mannitol, glycerin, and preserved water. It will be administered at 5 sprays to each nostril, one time.
45842700|NCT01312818|Drug|Bortezomib|1.3 mg/m^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1, 4, 8 and 11.
45842701|NCT01312818|Drug|Vorinostat|180 mg/m^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14
45842702|NCT01312818|Drug|Dexamethasone|6 mg/m^2 by mouth (PO) divided twice a day (BID) on days 4-15.
46045781|NCT05780229|Procedure|Conservative treatment|The rehabilitation is based on restoring the balance of the shoulder joint. Aiming to diminish pain and restore function, pain control and inflammation are addressed during the firsts 3-6 weeks. Before week 3, pendulum movements are allowed to initiate mobilization of the shoulder joint. Aiming to gain (almost) complete shoulder joint mobility, a passive and active mobility exercise program is carried out. Lastly, the focus is on muscle reinforcement, performing a series of active exercises with weights or bands to exercise different muscles of the shoulder or the shoulder girdle.
46045782|NCT05780229|Procedure|Arthroscopic Decompression Surgery|Arthroscopic decompression surgery of the rotator cuff tear consists of cleaning the subacromial space. The procedures that are sometimes performed to diminish pain may include, removing the inflamed bursa, releasing the long head of the biceps (if injured), or lightly burring the acromion bone under which the tendons slide.
45842703|NCT01312818|Drug|Methotrexate|Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)
45477248|NCT05706350|Biological|Influenza vaccine|Single dose of the Influenza vaccine Participants have to wait until they are invited to receive the vaccine by the general practitioner; this study does not interfere with national planning of the vaccine
45477249|NCT05706350|Dietary Supplement|Plant stanol soft chews (2g per day)|Participants have to consume 4 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 2g daily
45477250|NCT05706350|Dietary Supplement|Plant stanol soft chews (3g per day)|Participants have to consume 6 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 3g daily
45477251|NCT05706350|Dietary Supplement|Plant stanol soft chews (4g per day)|Participants have to consume 8 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 4g daily
45842704|NCT01312818|Drug|Imatinib mesylate|"For Ph+ acute lymphoblastic leukemia (ALL) patients only:~Imatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for >18 years on Days 1-16."
45842705|NCT01313520|Drug|Infliximab|3 mg/kg of Infliximab at Weeks 0, 2, 6, 14 via intravenous infusion
45842706|NCT01313520|Drug|Placebo|250 mL of 0.9% sodium chloride at Weeks 0, 2, 6, 14 via intravenous infusion
45842707|NCT01313910|Dietary Supplement|Immunolin®|Immunolin® 500 mg capsules to be taken 5 capsules twice daily for eight weeks
45477252|NCT05706350|Dietary Supplement|Control soft chews|Participants have to consume 6 control soft chews per day that does not contain plant stanols
45477253|NCT03343678|Drug|Venetoclax|Venetoclax given alone and then in combination with BI 836826
45477254|NCT03343678|Drug|BI 836826|Venetoclax given in combination with BI 836826
45842708|NCT01315002|Drug|Transdermal nicotine patch|7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)
45842709|NCT01315002|Drug|Placebo patch|Placebo patch
45842710|NCT01315158|Drug|Propofol Alone|"Recommended Propofol doses before considering crossover:~Induction: 2-2.5 mg/kg~Maintenance: 0.1-0.2 mg/kg/min"
45842711|NCT01315158|Drug|Propofol+Benzo/Opioids|"Recommended Versed:~a. Prior to intubation~patient is < 50 kg = 1 mg Versed~patient is 50-75 kg = 1.5 mg Versed~patient is > 75 kg = 2 mg Versed~Recommended Fentanyl~Prior to intubation = 0.5 ug/kg~Total procedural dose = 1 ug/kg"
45842712|NCT01317030|Device|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed with Bausch + Lomb Sensitive Eyes Saline. The lenses will then be placed into Biotrue multi-purpose solution and soaked for at least 10 hours but no more than 24 hours prior to lens insertion into one eye.
45842713|NCT01317030|Device|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed each side with Bausch + Lomb Sensitive Eyes Saline just prior to lens insertion into fellow eye.
45842714|NCT01317030|Other|Non-Contact Lens Wear|No intervention
45842715|NCT01318278|Drug|Dopamine|dopamine at low/medium/and high dose (5, 10, 15, and 20 mcg/kg/min) given IV as a continuous infusion, titrated up for efficacy
45842716|NCT01318278|Drug|Arginine Vasopressin|vasopressin at low/medium/and high dose (0.01, 0.02, 0.03, or 0.04 units/kg/hr) given IV as a continuous infusion, titrated up for efficacy
45842717|NCT01318356|Behavioral|Cognitive behavioral therapy|CBT will consist of a protocolized intervention of 12 sessions during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).
45842718|NCT01318356|Drug|Doxycycline|Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.
45477255|NCT03724279|Device|ByCross Atherectomy and Thrombectomy|"After assessment of the lesion by angiography the ByCross is advanced over a 0.035 guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the intervention is to achieved more than 70% opening."
45477256|NCT02500966|Device|DUDA device|Insertion DUDA device
45477257|NCT02500966|Procedure|LEEP|Loop Electrosurgical Excision Procedure
45477258|NCT05216822|Drug|Racecadotril|racecadotril (dose of 1.5 mg/kg/day, an oral single daily dose for three days
45842719|NCT01318356|Drug|Placebo|Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)
45842720|NCT01322022|Behavioral|ParentTraining|5 sessions of individual parent training
45842721|NCT01322022|Other|Parent Education|Parent Education to control for time and attention
45842722|NCT01324128|Drug|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
45842723|NCT01324128|Drug|Sevelamer carbonate|Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day)
45842724|NCT01324128|Drug|PA21-1 (1.25 g tablet containing 250 mg iron)|Low dose comparator (1.25 g/day)
45842725|NCT01324518|Drug|ORM-12741|60mg twice a day
45842726|NCT01324518|Drug|ORM-12741|200mg twice a day
45842727|NCT01324518|Drug|Placebo for ORM-12741|Placebo twice a day
45842728|NCT01326780|Drug|1.2% JNJ 10229570-AAA|1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks
45842729|NCT01326780|Drug|2.4% JNJ 10229570-AAA|2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks
45842730|NCT01326780|Drug|3.6% JNJ 10229570-AAA|3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks
45842731|NCT01326780|Other|Vehicle control|Color matched cream vehicle, applied once daily to the face for 12 weeks
45842732|NCT01328184|Drug|levonorgestrel|multiple doses
45842733|NCT01328184|Drug|levonorgestrel|multiple doses
45842734|NCT01328184|Drug|Ethinylestradiol|multiple doses
45842735|NCT01328184|Drug|Microgynon + BI 10773|multiple doses BI 10773
45842736|NCT01328184|Drug|Ethinylestradiol|multiple doses
45842737|NCT01328964|Drug|Fluticasone propionate|fluticasone propionate 44 mcg
45842738|NCT01328964|Drug|Budesonide|budesonide
45842739|NCT01328964|Drug|Montelukast|montelukast
45842740|NCT01329198|Device|NeuroPace RNS® System Deep Brain Stimulator|Utilizes a signal that the device detects and will respond to with an electrical pre-defined pulse if the signal is encountered.
45842741|NCT01330134|Drug|lidocaine|2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection
45842742|NCT01330134|Drug|lidocaine|1% lidocaine subcutaneous injection alone
45842743|NCT01330290|Drug|Neupro®|Neupro patches were prescribed by the treating physician according to the Summary of the Product Characteristics. Patients with idiopathic Parkinson's Disease (iPD) were treated for at least 1 month with a combination of Levodopa (L-DOPA) or other oral iPD medication and Neupro by the time the questionnaire was completed.
45842744|NCT01331304|Drug|Lithium|600-900mg per day over 6 months
45842745|NCT01331304|Drug|Quetiapine|100-800mg a day over 6 months
45842746|NCT01331694|Drug|fluticasone/salmeterol combination (FSC) 250/50mcg|patients initiating treatment with fluticasone/salmeterol combination (FSC) 250/50mcg
45842747|NCT01331694|Drug|tiotropium|patients initiating treatment with tiotropium
45842748|NCT01331694|Drug|ipratropium bromide alone or in fixed dose combination with albuterol|patients initiating treatment with ipratropium/albuterol
45351873|NCT04034589|Drug|Pyrotinib combined with fulvestrant|Pyrotinib 400 mg once daily; Fulvestrant 500 mg administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days
45351874|NCT04048434|Device|Cytosorb|extracorporeal cytokine adsorption
45842749|NCT01333098|Drug|Mifepristone|300mg per day, by mouth, for 21-28 days
45842750|NCT01333488|Device|Arctic Sun|Core Body Temperature will be lowered using an Arctic Sun device to 34C. Bladder probe will monitor core temperature.
45842751|NCT01333488|Drug|Magnesium Sulfate|IVI drug levels of Magnesium Sulfate targeted to plasma levels of magnesium of 2.5-3.5 mEq/Liter.(1.25-1.75mmol/L; or 3.04 - 4.26mg/dL)for 72 hours.
45842752|NCT01335204|Drug|Cabazitaxel plus bavituximab|Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle, and bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
45842753|NCT01335750|Other|Multipurpose Solution #1|B&L Renu Fresh Multipurpose Solution
45842754|NCT01335750|Other|Multipurpose Solution #2|Optifree Replenish Multipurpose Solution
45842755|NCT01335750|Other|Mutlipurpose Solution #3|Ciba ClearCare Multipurpose Solution
45842756|NCT01335750|Other|Multipurpose Solution #4|Saline Solution
45842757|NCT01336296|Drug|mycophenolic acid|Comparing mycophenolic acid 720mg orally twice daily starting 2 weeks prior to transplant to mycophenolic acid 720mg orally twice daily starting day of transplant.
45842758|NCT01337076|Device|cochlear implant|Cochlear implant surgery
45842759|NCT01337700|Drug|Milnacipran|Patients will receive a titrated dose of milnacipran increasing to a maximum of 100mg a day over the 12 week study period. Dosing will be based on a fixed schedule that will be monitored using a side effect profile.
45842760|NCT01337700|Drug|Placebo|Subjects will be given placebo tablets at dosing corresponding to the fixed schedule between 12.5mg and 100mg.
46045783|NCT05780229|Procedure|Reverse Prosthesis|The reverse prosthesis consists of shoulder articular joint replacement. The humeral head is sectioned, and, on the scapular side, a metal tray is placed, which is fixed with screws, and a metal half-sphere fixed to the metal tray. On the humeral side, a metal stem with a concave plastic component is placed to articulate with the metal half-sphere, allowing shoulder mobility without the need of rotator cuff muscles.
46045784|NCT05780229|Drug|Pain-Relief Medication|In the reverse prosthesis procedure and arthroscopic decompression surgery, the pain-relief medication plan is a standard regimen for all patients, which can be modified as needed. This plan is based on 50mg of dexketoprofeno, 1g of paracetamol, and 100mg of tramadol.
45842761|NCT01339260|Drug|Netupitant and Palonosetron|
45842762|NCT01339260|Drug|Palonosetron|
45842763|NCT01339260|Drug|Dexamethasone|
45842764|NCT01340586|Drug|Apixaban|Tablets, Oral, 5 mg, Once, 4 days
45842765|NCT01340586|Drug|Apixaban|Tablets, Oral, 5 mg, Twice, 15 days
45842766|NCT01341912|Biological|Human-cl rhFVIII|Human-cl rhFVIII is administered intravenously on demand for bleeding episodes and prophylactically in case of surgery. The dosage depends on the severity of the bleeding episodes and the surgery.
45842767|NCT01342458|Other|Flexible footwear|The patients of the Intervention Group (IG) will be use over 6 month a flexible and non-heeled footwear (Moleca; Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a women's flexible flat walking shoe, without heels, with an anti-slip rubber sole, 5-mm thin, with a 3 mm internal wedge of ethylene vinyl acetate, made out of dubbed canvas. It had a mean weight of 172 ± 19.6 g, ranging from 142 to 193 g depending upon the size.
45842768|NCT01342770|Other|Laboratory Biomarker Analysis|Correlative studies
45842769|NCT01342770|Drug|Pioglitazone Hydrochloride|Given PO
45842770|NCT01342770|Other|Quality-of-Life Assessment|Ancillary studies
45842771|NCT01343004|Drug|Placebo|Placebo 0 mcg subcutaneous daily
45842772|NCT01343004|Drug|BA058 80 mcg|BA058 80 mcg subcutaneous daily
45842773|NCT01343004|Drug|teriparatide|teriparatide 20 mcg subcutaneous daily
45842774|NCT01343160|Device|GORE® VIABIL® Biliary Endoprosthesis|Deployment of GORE® VIABIL® Biliary Endoprosthesis to the area of stricture
45351875|NCT00988312|Biological|autologous idiotype-protein pulsed dendritic cells|Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks
45351876|NCT00906867|Other|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
45351877|NCT00906867|Procedure|Rhino-laryngoscopy|Topical anesthesia (Xylocain Pump spray) followed by transnasal fiberoptic laryngoscopy with a flexible fiberoptic laryngoscope.
45686252|NCT02931058|Other|Two knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
45686253|NCT02931058|Other|Four knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
45686254|NCT02931058|Other|Six knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
45686255|NCT01477749|Biological|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
45842775|NCT01347060|Drug|fluticasone propionate/salmeterol xinafoate combination|Fluticasone propionate/salmeterol xinafoate combination for asthma, all doses (100mcg/50mcg, 250 mcg/50mcg and 500 mcg/50mcg)
45842776|NCT01347060|Drug|inhaled corticosteroids|Inhaled corticosteroids: beclomethasone dipropionte, mometasone, fluticasone propionate, budesonide, and flunisolide
45842777|NCT01351740|Drug|atazanavir|switch to unboosted atazanavir 400 mg daily
45842778|NCT01351740|Drug|atazanavir/ritonavir|Continue current regimen of atazanavir 300 mg/ ritonavir 100 mg daily
46045785|NCT05780229|Device|Reverse Prosthesis Device|In the reverse prosthesis procedure, a Delta III reverse shoulder prosthesis is applied. The original design was developed by Grammont in 1980's, and has 2 components: 1) a metal tray fixed with screws, and a metal half-sphere fixed to the metal tray, and 2) a concave polyethylene component.
46045786|NCT05780190|Device|New artificial liver CABA system (BS330+CA280) +PE|The new artificial liver CABA system (BS330+CA280) combioned plasma exchange in the treatment of end-stage liver disease with inflammatory status
45351878|NCT00768690|Drug|ABT-333|Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.
45351879|NCT00768690|Drug|ketoconazole|Tablet, see arms for intervention description
46045787|NCT05780164|Other|Research readiness tool|Online/paper based tool containing information about lung cancer clinical trials
46045788|NCT05780151|Other|Methodological intervention|All three arms will receive the same clinical intervention but will differ in their level of decentralisation, the methodological intervention.
46045789|NCT05780151|Drug|Toujeo|All participants in the study will receive Toujeo® (insulin glargine 300 U/mL). During the treatment period, Toujeo® injection will be administered once daily at the same time as the participant's previous basal insulin was injected, for participant previously treated with once daily injection. In case of previous insulin treatment administered twice a day, the time of injection of Toujeo® will have to be agreed between the physician and the participant before first administration.
46045790|NCT05780138|Behavioral|Parents Taking Action|Educational intervention designed to provide caregivers of children with autism information about autism, and strategies to advocate and support their child's development.
45351880|NCT00768690|Drug|placebo|Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.
45351881|NCT04006990|Behavioral|Provision of recliner chairs and encouragement to get out of bed|Provision of recliner chairs and encouragement to get out of bed
45351882|NCT02538549|Behavioral|ACE4|Activity Challenge 4 is a single player card game that is based on principles of behavioral activation. The game was used with crisis and transitional case management clients, with positive feedback.
45351883|NCT00982774|Biological|LEISH-F2 + MPL-SE vaccine|LEISH-F2 protein (10 ug) + MPL-SE (25ug) Three injections, 14 days apart
45351884|NCT00775008|Behavioral|electronic health information|Participants will receive weight loss information via 1 of 2 different mediums.
45842779|NCT01352286|Genetic|Autologous Genetically modified T cells|"Patients will undergo myeloma restaging at days +42, +100, 6 months, 9 months and 1 year post infusion. At this point, in accordance with FDA Guidelines, all patients will enter long term follow up (LTFU) and be followed biannually for monitoring for gene transfer delayed adverse events until year 5 post infusion. From year 5, all patients will require annual LTFU visits for monitoring for delayed adverse events until year 15 after receiving the genetically modified T cells.~Patients whose disease progresses prior to year 1 will enter LTFU at time of progression; however these patients will be seen quarterly from progression until year 1 post infusion and then follow the LTFU schedule mentioned above."
45842780|NCT01352442|Device|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
45842781|NCT01352598|Radiation|stereotactic body radiotherapy|Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
45842782|NCT01257438|Device|Fluency Plus Endovascular Stent Graft|Treatment of in-stent restenosis
45842783|NCT01257438|Device|Percutaneous Transluminal Angioplasty only|Treatment of in-stent restenosis
45351885|NCT00985972|Behavioral|Physical Activity and Nutrition Education|School-based interventions involving Physical Activity or/and Nutrition Education.
45351886|NCT02539953|Device|Ambulatory blood pressure monitoring|Patients with dizziness on taking rivaroxaban will have ambulatory blood pressure monitoring to assess haemodynamic effects indirectly
45351887|NCT00768768|Other|Electrokinetic Transungual System (ETS) - Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 3 mA-min as 0.3 mA for 10 min"
45351888|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.5 mA for 12 min"
45351889|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.3 mA for 20 min"
45351890|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 10 mA-min as 0.5 mA for 20 min"
45351891|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 15 mA-min as 0.5 mA for 30 min"
45477259|NCT05706272|Other|Comprehensive geriatric assessment (CGA)|The intervention includes a holistic comprehensive geriatric assessment using the PASTEL assessment tool that includes medical, psychiatric, functional and social aspects. Physical tests will include function, risk of falling, hand muscle strength, Timed up and Go (TUG), chair-stand test, blood pressure, saturation and BMI. A proactive person centered care plan will be established based on identified needs and the patients own priorities. A nurse will coordinate the care in the elderly team at the intervention practice with access to rehabilitation staff such as physiotherapist and occupational therapist. Follow-ups at the primary care practices will be carried out in accordance with the study plan. To strengthen care coordination, contact will be taken with other health care providers before the follow-ups.
45477260|NCT05706272|Other|Care as usual|The control group will receive care as usual at the matched control primary care centers
45351892|NCT00988390|Behavioral|Cognitive-behavioral, small-group format sessions|The intervention was delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions).
45351893|NCT00775086|Drug|norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.|
45351894|NCT00908427|Procedure|photoselective vaporization prostatectomy (PVP)|PVP using 80 W KTP laser with a Greenlight system (GreenLight PVTM, Laserscope®, San Jose, CA)
45351895|NCT00908427|Procedure|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
45351896|NCT00988468|Procedure|Manual Therapy|Grade 1 and 2 oscillatory manual mobilization of the tibiofemoral joint at various ranges of motion.
45842784|NCT01353144|Drug|aspirin|aspirin, 100 mg, qd x 8 weeks
46045791|NCT05780112|Other|breathing exercise|"Place one hand on your chest and the other on your stomach.~Slowly take a deep breath through the nose.~During inhalation, your hand on your stomach should rise upwards as the air fills the lungs. If it is under your hand on the chest, there should not be much movement.~Hold your breath and stretch your muscles in a second or two.~Take air through your nose with your mouth closed and exhale slowly through your mouth by pursing your lips like a whistle.~Set the time you use when exhaling air to be twice the time you use when exhaling.~As you exhale, focus on the inward movement of your abdominal hand."
46045792|NCT05780099|Other|Inpatient or Outpatient visit|Patients will be seen and treated at the clinics like in the usual care
46045793|NCT05780086|Drug|30% icodextrin and 10% dextrose|Dwell time of 24 hours using a 500 ml sodium-free peritoneal dialysis solution based on 30% icodextrin and 10% dextrose
45351897|NCT00988468|Behavioral|Therapeutic Exercise|Subjects will perform 5 minutes of lower extremity cycle ergometer with minimal resistance followed by 10 minutes of resistance exercise to the quadriceps at 3 tibiofemoral positions (0 degrees, 30 degrees and 60 degrees of knee flexion).
45842785|NCT01355484|Drug|GTx-024|subjects will be randomized to receive GTx-024 for the full duration of the trial.
45351898|NCT00988468|Behavioral|Video Observation|Subjects will watch a 15 minute video on a health topic unrelated to knee osteoarthritis.
45477261|NCT02508688|Procedure|thoracoscopic diaphragmatic repair|patients with refractory hepatic hydrothorax (> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair
45477262|NCT04495036|Other|data collection (21-items-patient descriptive survey)|"Dermatology patients are asked to complete a 21-items-survey while waiting for the doctor's consultation. Following variables will be addressed:~Demographic data of telemedicine users and non-users~Subjective disease perception of the dermatology patients~Use of internet, telemedicine and telemedicine insurance model~Patients´ willingness for additional features of telemedicine~Advantages and disadvantages telemedicine and face-to-face consultation~Suitable fields of dermatology for telemedicine from the patient's perspective~Recommended structure of telemedical services by users and non-users"
45477263|NCT04495036|Other|data collection (23-items-physician descriptive survey)|"To obtain the view of Swiss dermatologists, other physicians and medical staff on telemedicine a 23-items-survey will be completed. Following variables will be addressed:~Objective disease perception of the treating dermatologist (regarding the urgency of the patient's medical examination, the functional impairment and cosmetic burden due to patient's disease, the impairment of life quality due to patient's disease and the estimation of the course of the patient's disease)~Suitable fields of dermatology for telemedicine from the physician's and medical staff's perspective"
45842786|NCT01355484|Drug|placebo|subject will receive placebo for the duration of the trial
45842787|NCT01355796|Drug|Xylitol|Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks
45842788|NCT01355796|Drug|Hypertonic saline|4 ml of 7 % saline aerosolized twice a day for 2 weeks
45842789|NCT01356498|Biological|pegloticase|8 mg intravenous infusion
45842790|NCT01357356|Drug|SER120 (750 ng/day)|
46045794|NCT05780073|Drug|Dasatinib 70 mg|Commercially available tablets containing 50 and 20 mg of dasatinib will be used. The tablets will be re-capsulated to keep the study blind
46045795|NCT05780073|Other|Placebo|Maltodextrin capsules with identical size and appearance (shape, size, colour and flavour) as the dasatinib-containing capsules.
45842791|NCT01357356|Drug|SER120 (1000 ng/day)|SER120 (1000 ng/day)
45842792|NCT01357356|Drug|SER120 (1500 ng/day)|
45842793|NCT01357356|Drug|Placebo|
45842794|NCT01357512|Device|magnetic resonance imaging, Siemens|Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device
46045796|NCT05780034|Drug|AC676|AC676 will be given orally (PO) on a 28-day cycle.
46045797|NCT05780021|Behavioral|Motivational Support Program Emotiv|A motivational support program including a motivational and self-assessment remote application in the form of a Smartphone application for chronic low back pain patients after multidisciplinary functional rehabilitation.
45351899|NCT02557854|Drug|Doxorubicin HCl liposomal injection|50mg IV every 4 weeks
45351900|NCT02557854|Device|Philips Sonalleve MR-HIFU Hyperthermia|Hyperthermia to 42C for 30 minutes every 4 weeks
45351901|NCT00908505|Procedure|physiotherapy|physiotherapy either by biphasic cuirass ventilator or physiotherapist
45842795|NCT01362192|Device|532 nm KTP Excel V Laser, manufactured by Cutera, Inc.|"The 532 nm KTP Excel V laser treatment parameters to be used in this study are as follows:~Spot Size: 5 mm~Fluence: 13-15 J/cm2~Pulse Duration: 40 ms~Epidermal contact-cooling: 5° Celsius"
45686256|NCT05606458|Behavioral|İntervention Group|Before the procedure, the baby was started to be breastfed (1st stimulus). The mother supported her baby's back and bottom with one hand. He started to touch by positioning the thumb of the other hand to prevent the baby's nose from being blocked, and the other fingers of the same hand to touch the baby's face (2nd stimulus). The mother started to talk to her baby with a gentle tone of voice, sometimes using sentences (lullaby, song, etc.) that she wanted to increase the volume of her voice (3rd stimulus). The mother was in the baby's sight (4th stimulus). Clothes were removed as much as possible for the smell of the mother's skin (5th stimulus). The baby's foot in the mother's arms was warmed in the nurse's hand for a minute. The area was determined, and the baby's heel was wiped with 70% alcohol. It was expected to dry. Heel piercing was performed while the stimuli continued. Heel blood was taken. When the evaluation period is complete, the process is over.
46045798|NCT05780008|Behavioral|Eat My ABCs|"The Eat My ABCs curriculum incorporates senses into learning (hear, see, smell, taste) and includes two sessions/week: 1) healthy eating learning; and 2) mindful food taste-testing activities to expose children to the one fruit, one vegetable, and relevant food items made from the one fruit and one vegetable to teach children the creative ways to make fruit/vegetable healthy and tasty.~Child Letter to Parents. Every week, each child will create one letter, using stickers, regarding the one fruit and one vegetable presented in the program that he/she tasted or wanted to try at home.~Program Cookbook. The investigators have developed a targeted program cookbook for low-income families. The program cookbook contains all budget-friendly recipes for healthy breakfasts, family meals, quick-fixes, kid-friendly snacks, and occasional sweets. In addition, the cookbook contains creative ways of making fruit/vegetable healthy, tasty, and kid-friendly at home."
45686257|NCT05297734|Other|Receive technology-based supportive cancer care|All participants will receive an electronic health record message or email with standardized information provided regarding advance care planning and symptom management.
45842796|NCT01362894|Device|nelfilcon A contact lens|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear.
45351902|NCT00988546|Other|Computer based template for exam documentation|exam documentation performed using computer based template
45351903|NCT00988546|Other|Dictation for exam documentation|exam documentation performed using dictation, the standard practice
45351904|NCT02557386|Drug|Levobupivacaine 5 mL|Levobupivacaine 0.25% 5 mL in adductor canal nerve block
45351905|NCT02557386|Drug|Levobupivacaine 10 mL|Levobupivacaine 0.25% 10 mL in adductor canal nerve block
45351906|NCT02557386|Drug|Levobupivacaine 15 mL|Levobupivacaine 0.25% 15 mL in adductor canal nerve block
45351907|NCT02557386|Drug|Levobupivacaine 20 mL|Levobupivacaine 0.25% 20 mL in adductor canal nerve block
45351908|NCT02557386|Drug|Levobupivacaine 25 mL|Levobupivacaine 0.25% 25 mL in adductor canal nerve block
45351909|NCT02557386|Drug|Levobupivacaine 30 mL|Levobupivacaine 0.25% 30 mL in adductor canal nerve block
45351910|NCT00986050|Drug|Abciximab|Abciximab bolus 0,25mg/kg, 10-60 minutes before PCI. Infusion 0,125ug/kg/min for 12 hours after PCI.
45351911|NCT00986050|Device|bare metal stent prokinetic, chrono, skylor or bluemedical|bare metal stent in culprit artery in acute myocardial infarction
45351912|NCT00986050|Device|drug eluting stent (sirolimus eluting) - CYPHER stent|stent implantation in culprit artery in acute myocardial infarction
45842797|NCT01362894|Device|etafilcon A contact lens|Commercially marketed, etafilcon A, toric, soft contact lens for daily disposable wear.
45842798|NCT01363050|Drug|Ketorolac tromethamine|Subjects received intranasal ketorolac tromethamine (30 mg) three times daily (t.i.d.) for three days (seven doses in total). Doses were administered every eight hours.
46045799|NCT05779995|Drug|XW001|Inhalation solution
46045800|NCT05779995|Drug|Placebo|Inhalation solution with matched volume
45351913|NCT00986128|Drug|topiramate|100 mg tablet twice daily for 3 weeks
45842799|NCT01363128|Drug|Cyclophosphamide|Given IV
45351914|NCT00986128|Drug|topiramate|One 100 mg and one 200 mg tablet twice daily for 3 weeks
45351915|NCT00771342|Drug|Nitric Oxide|1% gaseous nitric oxide, delivered for 40 minutes daily for 3 consecutive days
45842800|NCT01363128|Drug|Cytarabine|Given IV
45842801|NCT01363128|Drug|Dexamethasone|Given IV or PO
45842802|NCT01363128|Drug|Doxorubicin Hydrochloride|Given IV
45842803|NCT01363128|Other|Laboratory Biomarker Analysis|Correlative studies
45351916|NCT00771342|Drug|Nitrogen|Nitrogen gas, delivered topically for 40 minutes daily for 3 consecutive days
45686258|NCT05297734|Behavioral|Receive redesigned team-based supportive cancer care|Lay Health Workers will meet with 1:1 with participants over 12 months to discuss advance care planning, surrogate decision-makers, advance directives and physician orders for life sustaining treatment.
45842804|NCT01363128|Drug|Methotrexate|Given IV
46045801|NCT05779982|Procedure|Sentinel lymph node biopsy followed by axillary lymph node dissection|This is a retrospective study to determine the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant systemic therapy (NAST) according to response to NAST and breast cancer subtypes. All patients received SLNB followed by axillary lymph node dissection after NAST.
46045802|NCT05779969|Other|Chest CT scan|Comparison of structural damage to the manubriosternal joint (MST) between a population of patients with radiographic axSpA and a control population free of chronic inflammatory rheumatism on chest CT.
45686259|NCT04094259|Behavioral|Questionnaire.|patients will respond to a specific questionnaire regarding the use of alternative medicine
45686260|NCT05606380|Drug|HLX60|HLX60(anti-GARP Monoclonal Antibody）have 5 dose cohorts: 0.5, 2, 5, 15, 25mg/kg, intravenous infusion, every 3 weeks.
46045803|NCT05779930|Biological|CD19 specific Chimeric Antigen Receptor T Cell|Infusion of CD19 CAR-T Cells manufactured on-site using the CliniMACS Prodigy
45351917|NCT00775164|Drug|pioglitazone|15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
45351918|NCT00775164|Drug|Metformin|Metformin XR; 1000 mg once daily
45351919|NCT00988624|Drug|Dimebon IR Tablet|Pharmacokinetics of a single oral dose of 10 mg dimebon immediate release tablet will be assessed on Day 1 - 3.
45351920|NCT00988624|Drug|Dimebon MR1|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR1, will be assessed on Day 1 - 3.
45351921|NCT00988624|Drug|Dimebon MR2|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR2, will be assessed on Day 1 - 3.
45351922|NCT00988624|Drug|Dimebon MR3|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR3, will be assessed on Day 1 - 3.
45351923|NCT00988624|Drug|Dimebon MR4|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR4, will be assessed on Day 1 - 3.
45351924|NCT00771420|Drug|CAM-3001|A single patient shall be dosed with a dose of 0.01mg/kg of CAM-3001 followed no sooner than 24 hours later by a second patient at a dose of 0.03mg/kg.
45351925|NCT00771420|Drug|CAM-3001|Dosed at 0.1mg/kg.
45351926|NCT00771420|Drug|CAM-3001|Dosed at 0.3mg/kg
45351927|NCT00771420|Drug|CAM-3001|Dosed at 1.0 mg/kg.
45351928|NCT00771420|Drug|CAM-3001|Dosed at 3.0 mg/kg.
45686261|NCT00054028|Drug|suramin|Given IV
45686262|NCT00054028|Drug|paclitaxel|Given IV
45686263|NCT00054028|Other|pharmacological study|Correlative studies
45842805|NCT01363128|Biological|Ofatumumab|Given IV
45842806|NCT01363128|Drug|Vincristine Sulfate|Given IV
45842807|NCT01365624|Drug|Ketorolac tromethamine|Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)
45842808|NCT01367262|Drug|LY2886721|Administered orally
46045804|NCT05779917|Biological|CAR-T cells|Transfer CAR-T cells into patients for anti-ancer therapy.
45842809|NCT01369758|Device|MyoSure Tissue Removal System|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade. When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
45842810|NCT01371786|Drug|ciclesonide nasal aerosol|A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister
45842811|NCT01371786|Drug|mometasone Aqueous (AQ) nasal spray|A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle
45842812|NCT01373580|Device|The Raindrop Near Vision Inlay|The Raindrop Near Vision Inlay is implanted in the cornea for treatment of presbyopia
45351929|NCT00771420|Drug|CAM-3001|Dosed at 10 mg/kg.
45686264|NCT04753060|Procedure|Waxing|Donor sites of patients skin grafts are waxed prior to surgery for donor harvesting.
45686265|NCT02795104|Behavioral|Educational Intervention via brochure|"Educational Intervention via brochure:~In this arm of the educational intervention the participant receives brochures"
45842813|NCT01374438|Drug|MSDC-0160|MSDC-0160 150 mg capsules given once daily for 90 days
46045805|NCT05779891|Other|Mulligan Traction Straight Leg Raise Technique|The individuals in the Group A will be receive hot pack at lower back for 10 minutes followed by ultrasound at 1.5w/cm2 for 10 minutes. The treatment will be preceded by Mulligan straight leg raise technique . Three repetitions of Mulligan's Traction Straight Leg Raise will be done with 7 seconds hold and 5 seconds relax time. The total treatment protocol will be 30 minutes.
46045806|NCT05779891|Other|Slump Stretching|The individuals in the Group B will be receive hot pack at lower back for 10 minutes followed by ultrasound at 1.5w/cm2 for 10 minutes. The treatment will be preceded by Slump Stretching technique. Five repetitions of Slump stretching technique will be done with 30 seconds hold and 5 seconds relax time. The total treatment protocol will be 30 minutes
46045807|NCT05779878|Other|Post Isometric Relaxation|Post-isometric relaxation (PIR) is a soft tissue stretching technique used by many health care professionals to lengthen both acute and chronic short muscles.
45351930|NCT00771420|Other|Placebo|Active: Placebo 5:1 for arms 2-6
45351931|NCT00983008|Behavioral|Protected time and Dedicated time|On Sunday through Thursday nights medical intensive care unit interns will have a 5 hour protected period from 2 to 7 am. During this time they will relinquish their pager and cell phone to the Night Float PGY2 or PGY3 who is already responsible for the ICU patients. The four hours between 2 and 6 am are entirely protected. 6 AM to 7 AM is dedicated time during which the interns will be expected to start pre-rounding on the ICU patients and to begin progress notes for the remaining members of the ICU team but still have no pager, cell phone, or cross coverage duties. On Friday and Saturday nights there will be no protected time but these interns will have 42 consecutive hours off following their extended shifts.
45351932|NCT04767256|Drug|Dexamethasone and dexmedetomidine|General anesthesia was induced with sufentanil 0.5-0.8 ug/kg, propofol 1.5-2.0 mg/kg, and rocuronium 0.5-1.0 mg/kg. Intravenous dexamethasone 10 mg was injected and a 50-ml syringe containing dexmedetomidine 1 ug/kg in 0.9% saline was infused after induction of general anaesthesia over a 30-min period. Anesthesia was maintained by remifentanil and sevoflurane to keep the Narcotrend index reading between 40 and 60.
45351933|NCT04767256|Drug|Dexmedetomidine|Intravenous dexmedetomidine 1 ug/kg was infused after induction of general anaesthesia over a 30-min period.
45686266|NCT02795104|Behavioral|Educational Intervention via DVD|Educational Intervention via DVD: In this arm of the educational intervention the participant receive a tailored interactive DVD to watch
45686267|NCT02795104|Behavioral|Educational Intervention-DVD & Telephone Based Navigation|Educational Intervention via Telephone-Based Navigation: In this arm of the educational intervention the participant receives a tailored interactive DVD to watch and telephone calls from a patient navigator
45686268|NCT05274334|Other|Assessment of de novo lipogenesis non-invasively in exhaled breath|"Healthy participants have a good nights sleep whereas they don't eat during the night and until measurements.~They come to the lab and make first baseline exhalation sets. An exhalation set consists of 6 exhalations in Mass Spectrometer positive mode and the same in negative mode. One exhalation set takes around 7minutes from start to finish.~Participants consume a single oral dose of dose of 70% 2H2O at 2 g/kg body-water.~Participants execute several exhalation sets over time.~Participants consume 300g of 'Excellence Joghurt Nature gezuckert.~Participants execute several exhalation sets over time.~After around 4.5hours with regular exhalation sets taking place, the trial is concluded."
45686269|NCT00058240|Drug|alvocidib|Given IV
45686270|NCT05606146|Device|IUB SEAD|The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB
45842814|NCT01374438|Drug|Placebo|Placebo capsules given once daily for 90 days
45842815|NCT01377636|Drug|Isoproterenol|patients will receive isoproterenol, have a BIS monitoring device and a modified isolated forearm test (no neuromuscular blockade).
45842816|NCT01378416|Drug|Decitabine (Dacogen)|Intravenous injection; total dose-per-cycle was 135 mg/m^2 of decitabine.
45842817|NCT01379664|Drug|Isoflurane|Isoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
45842818|NCT01379664|Drug|Sevoflurane|Sevoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
45842819|NCT01380366|Drug|Somatropin|Patients are given somatropin (growth hormone) for their short bowel syndrome for 28 days at a dose of 0.1 mg/kg subcutaneously daily to a maximum of 8 mg daily.
46045808|NCT05779878|Other|Myofascial arm pull technique|Myofascial therapy is described as the promotion of psychophysiological, neurological and structural adaptive capability as multiplexed via the myofascial system. Fascia covers all body structures, particularly muscles and their constituent myofibrils
45351934|NCT04767256|Other|Ultrasound-guided lumbar erector spinae plane block|The probe was installed in the sagittal axis in the midline at the L3 vertebral level. The spinous processes were ﬁrst visualized, after which the probe was lateralized, and the transverse processes and the erector spinae muscle were visualized approximately 3 cm laterally to the midline. The needle was advanced between the transverse process and the deep fascia of the erector spinae muscle from the caudal to the cranial using in-plane technique. The location of the needle was confirmed with 2mL saline solution, after which 20 mL of 0.4% ropivacaine was administered.
45351935|NCT04767256|Other|PCIA|Intravenous PCA included 0.9% saline with sufentanil and was programmed to run at 2ml with a 1-ml bolus dose and a 10-min lockout time. The patients with VAS more than 4 despite using intravenous PCA were treated with rescue analgesics comprising intravenous parecoxib.
45351936|NCT00771498|Drug|Lopinavir|ARV treatment: 2 NRTIs + lopinavir/r 800mg / 200 mg (4 tablets of Kaletra) every 12 hours, daily and orally Antituberculosis treatment: rifampin (600 mg/daily) + isoniazide (400 mg/daily) for 6 months, both in fasting condition + pirazinamide (2000 mg) for the first two months
45351937|NCT00986206|Diagnostic Test|Biomarker LPA and HE4|Non Interventional Trial
45351938|NCT00986284|Drug|gefitinib|Patients with EGFR mutation in exon 19 or 21 will be administrated with gefitinib as neoadjuvant therapy. Then evaluated for response and then operation for operable patients.
45477264|NCT05706194|Diagnostic Test|Early neurological prognostication with biomarkers, EEG and CT|Biomarker samples collected at 12, 24, 48 and 72 h after randomisation, CT and EEG performed as early as possible after 24 h post randomisation in patients still unconscious (defined as not awake and able to follow verbal commands)
45477265|NCT02503072|Behavioral|Small lottery prizes based on adherence|Clients coming for clinic visits have their MEMS data extracted, and if they show 95% adherence or higher are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
45477266|NCT02503072|Behavioral|Small lottery prizes based on timely clinic visits|Clients coming for clinic visits have their patient booklet checked to confirm that they came on their scheduled day; if so, they are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
45477267|NCT03627338|Diagnostic Test|questionaire, interview|questionaire, interview
45477268|NCT04498936|Drug|Sofosbuvir and Ledipasvir|Evaluate the efficacy of Sofosbuvir/Ledipasvir in treatment of COVID-19
45477269|NCT04498936|Drug|Nitazoxanide|Evaluate the efficacy of Nitazoxanide in treatment of COVID-19
45842820|NCT01380366|Procedure|Seven Day Food Diary|Subjects are asked to fill out a seven day food diary the week prior to their inpatient appointment, prior to receiving rHGH treatment for their short bowel syndrome. Subjects will be asked to repeat the use of a food diary after completing the administration of the growth hormone.
46045809|NCT05779800|Device|Flowble resin composite stent|Flowble resin composite is a filling material used in operative dentistry and characterized by being flow and easily adapting the surfaces.
46045810|NCT05779800|Device|periodontal pack|Non eugenol containing dressing supplied in two tubes
46045811|NCT05779787|Procedure|TAVR Aligned|Investigate the feasibility of coronary re-engagement after commissural alignment technique in terms of success rate (%) and procedure complexity taking into account radiations, time and contrast used.
45477270|NCT02502994|Drug|GEN0101|
45351939|NCT00768846|Device|Endeavor Resolute Stent|Zotarolimus-eluting Endeavor Resolute Stent
45351940|NCT00768846|Device|Xience V Stent|Everolimus-eluting Xience V Stent
45351941|NCT00988702|Behavioral|Dan Tian Breathing|Dan Tian Breathing for one month
45351942|NCT00988702|Behavioral|Progressive muscle training|Progressive muscle training for one month
45477271|NCT03627260|Behavioral|Fill up a handful of sunscreen and spread it all over your body. Sunscreen, Actinica|"Volunteers were asked to follow the rule of thumb: Fill up a handful of sunscreen and spread it all over your body."
45477272|NCT02503150|Biological|APDC + Chemotherapy|Patients in Arm APDC+Chemotherapy receive maximum 12 cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1,and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours).On day 8 of cycle1-3 and 7-9, patients also receive APDC vaccine infusion in 100ml saline. After 12 cycles, patients in Arm APDC+chemotherapy will receive 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks) plus APDC therapy (once every 3 months). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
46045812|NCT05779787|Procedure|TAVR Random|TAVR Random Feasibility comparison of coronary re-engagement between the randomly implanted Navitor valve (unaligned) and the others implanted with the commissural alignment technique in terms of success rate (%) and complexity of the procedure, taking into account radiation, time and contrast used
45842821|NCT01380366|Procedure|Blood Tests (standard of care)|Blood tests are taken (standard of care) to evaluate the potential hepato-protective effects of improving intestinal barrier function on those receiving human growth hormone for short bowel syndrome. Per clinical protocol to test liver function i.e. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline phosphatase (ALP), Gamma-glutamyl transpeptidase (GGT), Total Bilirubin). A complete blood count (CBC) with platelets (PLTS) and white-count differential (WBC with diff) is performed to check for anemia and infection. These tests will be taken at baseline (before fasting) and repeated again on the 28th day (last dose) of the growth hormone. Blood is also taken at clinical visit over the next two years (approximately every two months).
45842822|NCT01380366|Other|Fasting|Eight hour overnight fast prior to being given sucralose, mannitol, lactulose, and sucrose. This is done at baseline (day one) and repeated again after the last dose of growth hormone and prior to sugar permeability urine tests.
45842823|NCT01380366|Other|Sugar Permeability Test|Subject will be given 4 capsules of sucralose (250mg per capsule), 2.0 grams of mannitol, 7.5 grams of lactulose, and 40 grams of sucrose in 150 mL of water. This will be given on the second day of the study after an 8-hour overnight fast and repeated within 72 hours of the last dose of growth hormone.
45842824|NCT01380366|Other|Urine Collection|Urine will be collected for the following five hours after subject has been given combination of sucralose, mannitol, lactulose, and sucrose to complete the intestinal sugar permeability test looking at urine ratio of lactulose to mannitol (L/M ratio). Tests include urinalysis (UA) and a blood urea nitrogen (BUN)/creatinine (Cr).
45842825|NCT01383720|Device|Lotus Valve System|The Lotus Valve System includes the Lotus Valve, a bovine tissue tri-leaflet bioprosthetic aortic valve, and the Lotus Delivery Catheter for guidance and placement.
45842826|NCT01386528|Drug|nonacog beta pegol|The patients will receive nonacog beta pegol at screening just prior to and during surgical intervention, administered intravenously (into the vein).
45842827|NCT01387464|Drug|ISV-303|0.075% bromfenac in DuraSite dosed QD
45842828|NCT01387464|Drug|Bromday™|0.09% bromfenac dosed QD
45842829|NCT01388946|Drug|Ropivacaine 0.75|
45842830|NCT01388946|Drug|Normal saline|
45842831|NCT01390818|Drug|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) single dose capsule was administered at dose of 15 milligram (mg), 30 mg, 60 mg, 90 mg orally in successive 21-day cycles.Dose escalation was proceeded until Maximum Tolerated Dose (MTD) was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohorts enrolled subjects with Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Melanoma, and Colorectal Cancer.
46045813|NCT05779748|Other|Single bout of exercise|isometric wall squat at a knee joint angle of 100 degrees. Instruct participant to place their back against the wall with feet positioned parallel and spaced shoulder-width apart. Lower themselves down until they reached a knee joint angle of 100 degrees. Measure knee joint angle by placing a goniometer on the lateral epicondyle of the knee, in line with the femur whilst the anchor arm was in line with the lateral malleolus.
46045814|NCT05779722|Device|Vapor barrier|Vapor barrier
46045815|NCT05779683|Device|Caretaker Device placement|placement of the device on the postoperative cardiac surgery patient that has a pulmonary artery catheter for comparison readings
46045816|NCT05779618|Other|no intervention|observational study, all data collected are binary
46045817|NCT05779566|Diagnostic Test|bone densitometry|bone densitometry every 6 month
46045818|NCT05779553|Diagnostic Test|Tumor Endothelial Marker 1 ( TEM1 ) by ELISA kits|measurement of serum TEM1 in CRC patients, its relation to staging and comparing the diagnostic performance of serum TEM1 with serum CEA and CA19-9 for diagnosis of CRC. and Early detection of CRC patient
46045819|NCT05779540|Device|Safeback SBX|The intervention consists in the test of the active device.
46045820|NCT05779540|Device|Sham device|The intervention consists in a similar device to that emits same noise but does not deliver airflow.
45351943|NCT00988780|Drug|maraviroc|"Maraviroc 600mg po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops."
45477273|NCT02503150|Drug|Chemotherapy|Patients in Arm Chemotherapy receive maximum 12cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1, and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours). After 12 cycles, patients in Arm chemotherapy will receive only 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
45477274|NCT05706038|Drug|Adalimumab|"Adalimumab is a fully human, high-affinity, recombinant anti-tumor necrosis factor (TNF) alpha monoclonal antibody used to treat rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn disease, ulcerative colitis, etc.~Adalimumab is a fully human, high-affinity, recombinant immunoglobulin G (IgG) anti-TNF alpha monoclonal antibody. It is a molecule comprising 1330 amino acids and has a molecular weight of approximately 148 kDa.[4] It inhibits the binding of TNF alpha (both soluble and membrane-bound) to its receptor. Specifically, it inhibits TNF alpha's interaction with p55 (TNFR1) and p75 (TNFR2) cell surface TNF receptors, which in turn interferes with cytokine-driven inflammatory processes. It is identical in structure and function to the naturally occurring human IgG1 and thus has high selectivity for TNF alpha and has low immunogenic potential."
45351944|NCT00988780|Drug|Placebo|"Placebo tablets po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops."
45351945|NCT00775242|Drug|Estradiol and Progesterone|Injectable suspension of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Administered on a monthly basis during a six-month period.
45351946|NCT00775242|Drug|Estradiol and Progesterone|Injectable suspension of three different formulations of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Each will be applied on a monthly basis during a six-month period
45477275|NCT02500810|Drug|monosialoganglioside|40mg in the vein on day 1 - day 8 of each 21 days cycle. Number of Cycles: 2 cycles.
45686271|NCT05606068|Device|Paxman Limb Cryocompression System (PLCS)|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Cryocompression will be applied during every cycle of chemotherapy for a duration of up to 4 hours. All chemotherapy patients will receive 30 minutes pre-infusion cooling and 30 minutes post-infusion cooling. Cryocompression for each cycle will not exceed 4 hours. Chemotherapy and concomitant limb cryocompression are performed for 12 cycles and may be continued further in consultation with the PI. Overall, limb cryocompression will be administered for no longer than four hours."
45686272|NCT05605990|Device|Innovative tourniquet (Acusense Nonpneumatic tourniquet)|To use this innovative tourniquet before collecting blood samples, and setting IV catheter. We also use this innovative tourniquet to occlude the flow of blood.
45686273|NCT01502631|Drug|SUN13837 injection|SUN13837 injection, injection 1 x daily for 28 doses
45686274|NCT01502631|Drug|Placebo|Matching placebo, volume equivalent to injection 1 x daily for 28 doses
45842832|NCT01390818|Drug|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) capsule was administered orally at a dose of 30 mg, 50 mg, 70 mg and 90 mg in successive 21-day cycles. Dose escalation was proceeded until MTD was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohort enrolled subjects with Breast Cancer, NSCLC, Melanoma, and Colorectal Cancer.
45842833|NCT01390818|Drug|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) capsule was administered twice daily orally at a dose of 60 mg and 45 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of MSC1936369B (pimasertib) was combined with a lower dose of SAR245409 (PI3K and mTOR inhibitor).
46045821|NCT05779527|Behavioral|Mindful Parenting Programme|Online Mindful Parenting Programme with group support sessions
46045822|NCT05779514|Drug|Mirabegron|Health Volunteers ：Mirabegron p.o. 28 days 100mg qd./ Tumor patients ：Mirabegron p.o. 28 days 100 mg qd or 200 mg qd.
46045823|NCT05779488|Dietary Supplement|maca|2.25 g of Maca extract, twice per day for 12 weeks
46045824|NCT05779488|Dietary Supplement|placebo|2.25 g of starch, twice per day for 12 weeks
46045825|NCT05779462|Other|Dynamic MRI Sequence|Addition of a Dynamic MRI Sequence during the MRI examination performed in routine care
45842834|NCT01390818|Drug|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) was administered twice daily orally at a dose of 30 mg and 50 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of SAR245409 (PI3K and mTOR inhibitor) was combined with a lower dose of MSC1936369B (pimasertib).
45842835|NCT01391286|Drug|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
45842836|NCT01391286|Drug|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
45842837|NCT01391364|Device|SofLens in investigational solution|SofLens in investigational solution, worn on a daily disposable basis for 7 days.
45842838|NCT01391364|Device|SofLens in currently marketed solution|SofLens packaged in currently marketed solution, worn on a daily disposable basis for 7 days.
45842839|NCT01393392|Behavioral|Intensive, tailored intervention|Eight, 45 minute counseling sessions, tailored to the individual and based on the Information-Motivation-Behavioral Skills model of behavior change. Incorporates motivational interviewing, education, cognitive-behavioral skills training. 12 week course of nicotine replacement patches provided. Nicotine lozenges also provided.
45842840|NCT01393392|Behavioral|NJ Quitline Referral|Participants will receive a facilitated referral to the NJ Quitline (i.e. fax to quit).
45842841|NCT01393704|Drug|Vasopressin|Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.
45842842|NCT01395966|Drug|DF289|Ear drops
45842843|NCT01395966|Drug|DF277|Ear drops
45842844|NCT01395966|Drug|DF289 plus DF277|Ear drops
45842845|NCT01396044|Other|Electronic checklist|Electronic checklist for process of care issues implemented in our institution. Training on a regular basis of the electronic checklist arm to use the electronic checklist. Process of care issues on the electronic checklist include several that are under investigation: antibiotics and mechanical ventilation.
45842846|NCT01396044|Other|Verbal prompting|Prompting by study investigators of physicians on the verbal prompting arm. Prompting will include questions related to antibiotic utilization and mechanical ventilation weaning.
45842847|NCT01399008|Drug|Arhalofenate|Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks
45351947|NCT00986518|Biological|Adaptive autologous cell immunotherapy|each patient will undergo a blood cytapheresis to collect circulating lymphocytes. Ex-vivo cell sorting procedure will deplete patient's collected lymphocytes from regulatory T cells. Autologous Treg-depleted lymphocytes will be administered to the patient following a 5-day reduced intensity chemo-therapeutic conditioning.
46045826|NCT05779449|Dietary Supplement|Prebiotics and Probiotics supplementation|"From the 1st day to the 15th day (included) patients with MS in the Pre-Pro group will receive daily:~1 capsule of Probactiol Duo, Metagenics (6 billions of Saccharomyces boulardii and 8,5 billions of probiotics including Bifidobacterium lactis Bi-07®, Bifidobacterium lactis Bl-04, Lacticaseibacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM®)~packet of Probactiol Stips, Metagenics (4 g inulin enriched with oligofructose)~From the16th day to the 365th day (included) patients with MS in the Pre-Pro group will receive daily:~capsules of Probactiol HMO Combi, Metagenics (7,5 billions of Lactobacillus acidophilus NCFM®, 7,5 billions of Bifidobacterium lactis Bi-07®, 2,5 ug Vitamine D3, 320 ug Vitamine A, 100 mg Threonine, 250 mg 2'-Fucosyllactose)."
45842848|NCT01399008|Drug|Allopurinol|Allopurinol 300 mg as active comparator
45842849|NCT01399008|Drug|Colchicine|0.6 mg colchicine daily as flare prophylaxis
45842850|NCT01399008|Drug|Placebo|Placebo
45842851|NCT01399866|Drug|D-cycloserine|2 single weekly doses, 50 mg capsule
45842852|NCT01399866|Drug|Placebo|
46045827|NCT05779449|Dietary Supplement|Placebo supplementation|1-year supplementation with two placebo capsules/day containing starch, the probiotic bacteria carrier.
46045828|NCT05779449|Procedure|peripheral blood withdrawal|40 ml of blood for the isolation of Peripheral Blood Cells (PBMCs) and T cells.
46045829|NCT05779449|Procedure|Transcranial Magnetic Stimulation (TMS)|Intermittent theta burst stimulation (iTBS) protocol
46045830|NCT05779423|Drug|Ipilimumab|Monoclonal antibody administered through intravenous infusion
46045831|NCT05779423|Drug|Nivolumab|Monoclonal antibody administered through intravenous infusion
46045832|NCT05779423|Procedure|Cryoablation|Procedure of freezing a tumor performed via CT-guidance by interventional radiologist.
46045833|NCT05779410|Dietary Supplement|Vitamin D|Participants received 5,000 IU of vitamin D orally twice daily for 4 weeks
45842853|NCT01401582|Other|Implementation of Dementia Care Manager|"Home-visits of trained Dementia Care Manager (DCM) at least monthly for 6 months. The DCM will, in close cooperation with the general practitioner, establish and include a subsidiary support system for subjects and their caregivers."
45842854|NCT01402050|Drug|CERVIDIL (Dinoprostone)|INDUCTION OF LABOR
45842855|NCT01402050|Device|FOLEY BALLOON|INDUCTION OF LABOR
45842856|NCT01402128|Dietary Supplement|Barley beta-glucan(3.0g)|Barley beta-glucan(3.0g/day) for 12 weeks
45842857|NCT01402128|Dietary Supplement|Placebo|Placebo for 12 weeks
45842858|NCT01403376|Drug|teriflunomide|"Film-coated tablet~Oral administration"
45842859|NCT01403376|Drug|Interferon-β-1|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
45842860|NCT01403376|Biological|Influenza vaccine|"Inactivated, split-virion influenza vaccine 2011-2012~One administration by intramuscular or intradermal route as per product specification"
45842861|NCT01404078|Drug|Single Dose Polycap|Low strength polycap contains Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin
45842862|NCT01404078|Drug|Double dose Polycap|2 Capsules of low strength polycap with 30mEq of Potassium
45842863|NCT01404936|Drug|Interferon-2A|4 (x106 IU/m^2) subcutaneously on days 1-4.
46045834|NCT05779410|Dietary Supplement|Medium-chain triglycerides|Participants received the same amount of placebo matching vitamin D orally twice daily for 4 weeks
46045835|NCT05779384|Other|It was an observational study|data collected concerning the incidence of exacerbations
46045836|NCT05779371|Behavioral|Integrated-based Laughing Qigong Program|The protocol of the Integrated-based Laughing Qigong Program (IB-LQP) combined laughter intervention and mental health promotion courses. It was a two-hour community activity held twice a week for six weeks. The content was 50-60 minutes of a laughter practice program and 50 minutes of mental health lectures, separated by a 10-minute break.
46045837|NCT05779358|Other|Expectancy and gluten|Effect of expectancy to receive gluten and/or actual gluten intake
45477276|NCT03546907|Drug|SAR440340|Pharmaceutical form: Solution for injection; Route of administration: SC
46045838|NCT05779345|Procedure|surgery|short implant placement
46045839|NCT05779332|Other|survey application|Children's OHRQoL was measured by the Child Perceptions Questionnaire (CPQ8-10). Oral examination of children were conducted for presence and severity of MIH, dental caries experience and oral hygiene status.
45842864|NCT01404936|Drug|Adriamycin|25 mg/m^2 by vein on day 4.
45842865|NCT01404936|Drug|Bleomycin|10 mg/m^2 by vein on day 4.
45842866|NCT01404936|Drug|Velban|6 mg/m^2 by vein on day 4.
46045840|NCT05779319|Device|non contact measurement with the IOL Master 700|postoerpative we will perform non contact measurement with the IOL Master 700
45351948|NCT00769158|Drug|Topiramate and Naltrexone|Topiramate 200 mg and Naltrexone 50 mg
45351949|NCT00769158|Other|Placebo|Placebo Comparator
45477277|NCT03546907|Drug|Placebo|Pharmaceutical form: Solution for injection; Route of administration: SC
45477278|NCT03546907|Drug|Any Inhaled Corticosteroids as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: Inhaled
45477279|NCT03546907|Drug|Any Long Acting Beta Agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
45842867|NCT01404936|Drug|Dacarbazine|375 mg/m^2 by vein on day 4.
45842868|NCT01405794|Drug|32ppm Silver Particle|Oral silver dose of 32ppm
45842869|NCT01405794|Drug|Placebo|Sterile Water No Silver
45842870|NCT01408992|Procedure|Audiometry|Standard hearing test performed by audiologists
45842871|NCT01408992|Other|Thai-Five Minute Hearing Test|All subjects will be interviewed with Thai-Five Minute Hearing Test
45842872|NCT01410084|Dietary Supplement|Vitamin D3|100,000 IU vitamin D3 once monthly for 5 months
45842873|NCT01410084|Dietary Supplement|Vitamin E|400 IU vitamin E once monthly for 5 months
45842874|NCT01410552|Device|PARADYM DR model 8550; PARADYM CRT model 8750; PARADYM RF DR model 9550; PARADYM RF CRT model 9750; PARADYM RF CRT SonR model 9770|PARADYM ICD and CRT-d with PARAD+ algorithm available
45842875|NCT01411488|Device|Fecal management system|rectal tubes/fecal management systems: we compared products to determine if there is a difference in the incidence of anal erosions
45842876|NCT01413516|Behavioral|Smoking cessation counseling|Counseling sessions provided by a trained smoking counselor
45842877|NCT01413516|Drug|Placebo|Sugar pill without any active medication
45842878|NCT01413516|Drug|Varenicline|Varenicline (an approved medication for smoking cessation)
45842879|NCT01413750|Drug|Paclitaxel|Given IV
45842880|NCT01413750|Drug|Carboplatin|Given IV
45842881|NCT01413750|Drug|Vorinostat|Given PO
46045841|NCT05779280|Other|THDA + Acetyl Zingerone Topical Product|A skin care product with Acetyl Zingerone (Synoxyl® AZ) and THDA (VitaSynol® C) used twice daily
46045842|NCT05779280|Other|THDA|A skin care product with THDA (VitaSynol® C) used twice daily
46045843|NCT05779254|Drug|Neomycin Sulfate|Postoperative day-1 Oral Antibiotic Prophylaxis + patients get po. 3x1000mg Neomycin sulfate and 3x500 mg Metronidazole
46045844|NCT05779228|Behavioral|Mode Switching Training|Wear of colored lenses for 1 hr, 5 times per day, for 5 days
45351950|NCT00983086|Drug|Flavanones of orange juice|The main objective of this study is to evaluate, in healthy volunteers with young children (50 and 65) and slightly overweight according to their usual diet, the effects of single dose (in postprandial period) and made repeated orange juice or orange flavanones purified on vascular function. The selection criteria for age and weight should, within a healthy population to select individuals who exhibit cardiovascular risk factors, and thus for which it should be a priori easier to identify a beneficial effect of dietary factors on the parameters associated with cardiovascular risk.
45351951|NCT00775320|Procedure|FLT-PET scan|Imaging test
45351952|NCT00983164|Dietary Supplement|Antioxidant Supplementation|antioxidant supplementation (vitamin E 800 mg, C 500 mg and zinc 40 mg) for 24 weeks
45351953|NCT00769236|Other|Blood sampling and biopsy|Biopsy and blood : Research for various antibodies
45351954|NCT00769236|Other|Biopsy and blood sampling|Biopsy and blood : research for various antibodies
45351955|NCT00769236|Other|Biopsy and blood sampling|Blood and biopsy : research for various antibodies
45351956|NCT00988936|Drug|[F-18]RGD-K5|Approximately forty (40) patients with non-squamous non-small cell lung cancer, metastatic breast cancer, metastatic colon or rectum cancer will receive chemotherapy plus Avastin® and will be imaged under PET/CT with [F-18]RGD-K5
45842882|NCT01413750|Other|Placebo|Given PO
45351957|NCT00333775|Drug|Docetaxel|Docetaxel was supplied in 2 vials, 1 containing docetaxel and 1 containing a solvent, for intravenous infusion.
45351958|NCT00333775|Drug|Placebo to bevacizumab|Placebo to bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
45351959|NCT00333775|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
45351960|NCT00771732|Device|light therapy|6 minute light therapy
45351961|NCT00771732|Device|light therapy|combination of wavelengths
45351962|NCT03860428|Drug|Ibuprofen|In the medical treatment arm the in-tention is to close the ductus arteriosus.
45351963|NCT03860428|Drug|Paracetamol|In the medical treatment arm the in-tention is to close the ductus arteriosus.
45842883|NCT01413750|Other|Laboratory Biomarker Analysis|Correlative studies
45842884|NCT01415232|Device|Sonosite S-Nerve® US system (SonoSite, Bothell,WA)|Ultrasound to measure depth to the epidural space in morbidly obese parturients
46045845|NCT05779215|Other|Visit at D90|Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access.
45351964|NCT03860428|Other|Expectant Management|Expectative PDA management is character-ized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
45351965|NCT02557074|Drug|IL2|IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses
45351966|NCT02557074|Drug|placebo|NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
45351967|NCT03808870|Drug|NBM-BMX softgel capsules|Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
45842885|NCT01415934|Other|discontinue statins|patients will be randomized to either continue taking statins or discontinue.
45842886|NCT01417026|Drug|Intranasal Oxytocin (Trade name: Syntocinon)|This is a double-blind placebo-controlled trial of intranasal oxytocin in children and adolescents with ASD. Subjects will be randomized to 24 IU intranasal oxytocin or placebo for a 5 day period with concomitant game play of computer games, which are designed to enhance face perception skills. Measures of social function and cognition will be administered before and after the intervention period.
46045846|NCT05779189|Behavioral|Game-based virtual reality (Game)|Besides reading the health education flier, they also need to trained with the game-based virtual reality in Biodex Medical Systems, which is a machine, includes 4 games: Catch Game, boating, Ball Maze, and Word Search. And all of the games are balance control games. The games were implemented in person for 30 minutes one time, total is 16 times (once to twice day a week).
45351968|NCT00771888|Drug|lanreotide|lanreotide
45351969|NCT00989170|Behavioral|Family Program for the Prevention of Weight Gain|The Family Workbook is a step-by-step instruction guide for families to use throughout the 6-month period, detailing healthy lifestyle. All handouts, instructions, activities, and a timeline of the program are laid out for families in this workbook.
45351970|NCT00989170|Behavioral|Control Group|This group will not be provided the workbook and it is hypothesized those in the control group will gain excess weight.
45351971|NCT00771966|Procedure|Standard therapy|Standard therapy
45351972|NCT00771966|Procedure|Maximization of cardiac stroke volume with fluid infusion|Maximization of cardiac stroke volume with fluid infusion
46045847|NCT05779189|Behavioral|Conventional health education|The health education flier was made refer to medical institutions, e.g., hospitals or clinics, the video of balance exercise was collected from the internet. Participants were assigned to read the health education flier, and follow suit the video of balance exercise at home of their free will.
46045848|NCT05779176|Procedure|Therapeutic hypothermia|The study intervention is therapeutic hypothermia. After intubation, patients assigned to therapeutic hypothermia will receive central venous catheterization through right jugular vein or femoral vein depending on the cooling application and the unique needs, a flexible catheter will be inserted and iced saline was circulated through the multiple balloons of the catheter in a closed-loop design to induce therapeutic hypothermia. This system also has a hydrophilic coating with heparin and a triple-lumen central venous catheter to satisfy the need of fluid or drug infusion, blood draw and central venous pressure monitoring. After central venous catheterization, patients assigned to TH will receive intravascular temperature management to achieve the target temperature of 34-35 °C.
45351973|NCT00605475|Drug|Canakinumab|Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
45351974|NCT00605475|Drug|Placebo|Placebo to Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
45351975|NCT00605475|Drug|Metformin|Participants continued on their stable daily dose of metformin throughout the study
45351976|NCT00986596|Dietary Supplement|vitamin D3|4000 IU once daily by mouth for 4 months
45351977|NCT00986596|Dietary Supplement|Placebo|microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)
45351978|NCT00772044|Device|Provent Professional Sleep Apnea Therapy Device|Application of active device (Provent)
45351979|NCT00772044|Device|Sham Device|Sham device will be applied
45477280|NCT03546907|Drug|Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
45477281|NCT03546907|Drug|Any short-acting β agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: inhaled
45477282|NCT02500888|Radiation|Radiosurgery|Only one radiation session of about 180 Gy in bilateral internal capsule.
45477283|NCT05126264|Drug|Ibuprofen 400 mg|morning and afternoon
45477284|NCT05126264|Drug|Ibuprofen 400 mg|morning, afternoon and night
46045849|NCT05779150|Other|CeraVe® Moisturising Cream|CeraVe® Moisturising Cream contains 3 kinds of skin-native ceramides, which can protect the skin against external stimuli, strengthen the damaged skin barrier, fill the intercellular lipids to deeply trap water, relieve dry skin, and increase skin hydration.
45477285|NCT02508298|Procedure|HVPG|HVPG will be performed by placing a placing a 7F venous catheter into a supra-hepatic vein and then advancing a 5F balloon-tipped catheter into the right hepatic vein. Wedged hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP) will be measured by connection to an external transducer and polygraph (PowerLab, ADInstruments Inc., Colorado Springs, CO). After inflating the balloon catheter, adequacy of the occlusion will be established by injection of a small amount of radiologic contrast medium. Hepatic Venous Pressure gradient (HVPG) will be calculated as the difference between WHVP and FHVP.
45477286|NCT02508298|Drug|Indocyanine Green Retention test|As decribed in arm descriptions
45477287|NCT02508298|Device|Liver stiffness measurement|As decribed in arm descriptions; perfromed by ARFI
45477288|NCT02508298|Device|Spleen stiffness measurement|As decribed in arm descriptions; performed by ARFI
45477289|NCT03730597|Device|reverse shoulder arthroplasty|prosthesis implantation
45477290|NCT02500654|Device|Emdogain®|Surgery and Emdogain®
45842887|NCT01420146|Drug|Zr89-trastuzumab|trastuzumab labelled with zirconium 89 for PET/CT
45842888|NCT01420848|Other|Auriculotherapy|Auriculotherapy stimulates points to achieve better emotional balance, mental and physiological.
45842889|NCT01420848|Other|Placebo Group|They were evaluated at the baseline,twelve sessions and 15-day follow-up and received 12 sessions through the Fist and Outer ear points.
46045850|NCT05779150|Other|Standard Cream|placebo cream
46045851|NCT05779098|Procedure|Extensive hepatectomy|Extensive hepatectomy
45477291|NCT02500654|Device|Surgery alone|Surgery alone
46045852|NCT05779085|Other|Dermocosmetic|Use of daily cleanser to treat facial acne
46045853|NCT05779072|Device|Single Vision Soft Contact Lens|Subjects refit to Single Vision Soft Contact Lens for 1 year
45477292|NCT01318382|Device|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
45477293|NCT04495114|Other|40g carbohydrate load (Apple juice)|A 40g carbohydrate drink will be administered to subjects with non-insulin dependent type 2 diabetes 3 hours prior to their operation. This is standard practice in subjects without diabetes.
45477294|NCT03001817|Drug|K-877|
45477295|NCT03001817|Drug|Fenofibrate|
45477296|NCT03001817|Drug|Placebo (for K-877)|
45477297|NCT03001817|Drug|Placebo (for Fenofibrate)|
45477298|NCT03726697|Other|Tahneek|A single dose of soft date containing glucose equivalent to 200mg/kg at 1 h after birth will be massaged into the buccal mucosa of the palate and cheek from right to left side, until the date paste is fully absorbed
45477299|NCT02508376|Other|AP10-602|AP10-602 contains GLA formulated with liposomes and an additional immunological adjuvant. The ID93 (10 mcg) + AP10-602 (5 mcg) arm will receive intervention on days 1, 29 and 57. The ID93 (10 mcg) + AP10-602 (10 mcg) arm will receive intervention on days 1, 29 and 57.
45477300|NCT02508376|Biological|GLA-SE|Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE). The ID93 (10 mcg) + GLA-SE (5 mcg) arm will receive intervention on days 1, 29 and 57
45477301|NCT02508376|Biological|ID93|ID93 is a fusion polyprotein comprising four Mtb antigens (Rv2608, Rv3619, Rv3620, Rv1813). All arms will receive 10 mcg ID93 IM on days 1, 29 and 57
45477302|NCT03560869|Other|Normal hydration|see description in 'arms'
45477303|NCT03560869|Other|Dehydration|see description in 'arms'
45477304|NCT04498624|Procedure|inverted flap|full thickness macular hole surgery
46045854|NCT05779059|Drug|De-escalation to ticagrelor 60 mg at day 30|Change of P2Y12 receptor antagonist regimen to ticagrelor 60 mg bid at day 30.
46045855|NCT05779059|Drug|De-escalation to prasugrel 5 mg at day 30|Change of P2Y12 receptor antagonist regimen to prasugrel 5 mg qd at day 30.
46045856|NCT05779059|Drug|Switch to ticagrelor 60 mg at day 45|Switch to ticagrelor 60 mg bid at day 45.
46045857|NCT05779059|Drug|Switch to prasugrel 5 mg at day 45|Switch to prasugrel 5 mg qd at day 45.
45842890|NCT01421472|Drug|MM-121|MM-121 IV at 40 mg/mg loading dose on Cycle 1, Week 1 followed by 20 mg/mg weekly for all subsequent doses
45842891|NCT01421472|Drug|Paclitaxel|Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
45842892|NCT01428336|Procedure|1 ug ACTH stimulation test|1 ug cortrosyn dose
45842893|NCT01428336|Procedure|250 ug ACTH stimulation test|ACTH stimulation test will be done using 250 ug cortrosyn dose
45842894|NCT01428336|Procedure|25 ug Cortrosyn stimulation test|ACTH stimulation test using a 25 ug cortrosyn dose
45477305|NCT04498624|Procedure|peeling internal limiting membrane (ILM)|full thickness macular hole surgery
45842895|NCT01428336|Procedure|Insulin tolerance test|subjects will undergo an insulin tolerance test
45842896|NCT01429272|Drug|Minocycline|100 mg po bid for 6 weeks
45842897|NCT01429272|Drug|Aspirin|81 mg po bid for 6 weeks
45842898|NCT01429272|Drug|placebo|placebo for minocycline and/or aspirin
45842899|NCT01429350|Drug|intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|0.9mg/kg to a maximum of 90mg
45842900|NCT01429350|Device|Penumbra System|The Penumbra System is an aspiration based mechanical thrombectomy device
45842901|NCT01431300|Drug|gadofosveset|Intravenous administration of the specified dosage of gadolinium contrast agent
45842902|NCT01431846|Behavioral|Intervention|Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
46045858|NCT05779046|Other|HIT 1:1|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:1 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternating with low intensity 50-55% of maximum heart rate for 1 minute).
46045859|NCT05779046|Other|HIT 1:2|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:2 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternate with low intensity 50-55% of maximum heart rate for 2 minutes).
45477306|NCT02502682|Drug|Sage 2% Chlorhexidine Gluconate Cloth Patient Preoperative Skin Preparation|Daily bathing.
45842903|NCT01432236|Drug|Pregabalin|Pregabalin 300 or 450 mg/day dosed BID ( twice a day) for 14 weeks; 150 mg/day starting dose
45842904|NCT01432236|Drug|placebo|placebo capsules twice a day for 14 weeks
45842905|NCT01434030|Behavioral|Focus Group|Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
45842906|NCT01434186|Drug|Placebo matching with Saxagliptin|Tablet, Oral, 0.0 mg, Daily, Day 1 through week 52
45842907|NCT01434186|Drug|Metformin IR|Tablet, Oral, 1000 mg -2000 mg, Daily , Day 1 through week 52
45842908|NCT01434186|Drug|Metformin XR|Tablet, Oral, 1000 mg -2000 mg, Daily, Day 1 through week 52
45842909|NCT01434186|Drug|Saxagliptin|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
46045860|NCT05778994|Device|INTORUS|Exercise protocol with intorus
46045861|NCT05778981|Diagnostic Test|FMD - Troponin measurement|Echographic FMD evaluation. Pre and post-operative troponin measurements.
46045862|NCT05778968|Procedure|low etco2|Etco2 levels will be adjusted at levels ranging between 25 mm Hg and 30 mm Hg
46045863|NCT05778968|Procedure|normal etco2|Etco2 levels will be adjusted at levels ranging between 31 mm Hg and 40 mm Hg
46045864|NCT05778968|Procedure|high etco2|Etco2 levels will be adjusted at levels ranging between 41 mm Hg and 45 mm Hg
46045865|NCT05778955|Genetic|detection and monitoring of cirulating tumor DNA|detection and monitoring of cirulating tumor DNA in pediatric soft tissue sarcoma
45477307|NCT03590743|Drug|Apixaban|Active anticoagulation with apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily to complete a total of 3 months treatment.
45477308|NCT03590743|Other|Placebo|apixaban matching placebo 2 tablets twice daily for 7 days followed by one tablet twice daily to complete a total of 3 months.
45477309|NCT03053102|Drug|Danicopan|Danicopan was administered as multiple oral doses over a period of at least 28 days.
45477310|NCT03726619|Behavioral|e-CHEC-uP|One time online-based education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
45477311|NCT03726619|Behavioral|CHEC-uP|One time face-to-face education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
45477312|NCT05705960|Other|Chestnut|Daily consumption of roasted chestnut (150g) for 14 days
45477313|NCT03343600|Drug|Imatinib|Imatinib 100 mg/tablet, 2 tablets daily
45477314|NCT03343600|Drug|Placebo|Placebos 2 tablets daily
46045866|NCT05778929|Diagnostic Test|Radiomics Model|"A total of 694 consecutive eligible patients with first episode of acute pancreatitis that recommended for iopromide 370 mgI/ml enhanced pancreatic CT scan within 14 days after onset of symptoms (the sample size ratio of training set: test set: validation set is 5:2:3) will be sequentially enrolled at 10 sites (This study is observational in nature. The routine enhanced pancreatic CT protocol at all selected sites is similar or equivalent to that used in the PI site in the study).~Relevant clinical information of the enrolled subjects is collected. Radiomics features are extracted from the selected regions of interest on pancreatic CT images and classified. The subjects are followed up for 12 months and divided into recurrent group and non-recurrent group according to the first recurrence status."
46045867|NCT05778916|Procedure|5 year follow up on patients operated for hallux valgus deformity|Clinical and radiological control of patients operated for hallux valgus deformity between 2016-2018.
45686280|NCT03027999|Other|tight nursing follow-up|"In addition to the usual follow-up by their rheumatologist tight nursing follow-up patients will benefit of~a training session to self-assess their RA: Self-assessment of the number of painful and swollen joints, of pain and disease activity (global assessment by the patient) (self-DAS). During this session, a scheduled dosage of ESR and CRP levels will be given to the patient.~A monthly call by a nurse who inquires about the results of the patient's self-assessment. As soon as she suspects a relapse of RA, she plans a consultation to confirm or not the relapse. For this purpose, she calculates the DAS28 taking into account the results of the biological test, the articular count and the disease activity. Clinical relapse is documented by a DAS28-CRP > 2.7"
45686281|NCT03027921|Other|elastography|
45842910|NCT01434342|Drug|Nicotine Replacement Patch|Study participants will receive a baseline assessment after they consent to participate and before randomization. The intervention period will last 12 weeks (approximately 1 week for the in-office intervention and 12 weeks for all components of the Quitline intervention- telephone counseling and habitrol patches). Follow-up assessments will be administered at 3, 6, 12, & 24 weeks after the date of the in-person intervention (for Quitline Intervention group) or the provision of the physician letter (for the Usual Care Plus group).
45842911|NCT01435512|Behavioral|PTSD-Focused CBT for Partner Violence|PTSD-Focused CBT (PFCBT) will consist of 12 2-hour weekly sessions,led by two project therapists. In each session, group members will discuss materials and do assignments to practice skills.
45842912|NCT01435824|Drug|Human milk-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of breast milk to have 100mL of a 50mg/mL suspension.
45842913|NCT01435824|Drug|Water-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of water to have 100mL of a 50mg/mL suspension.
45842914|NCT01436526|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 2*5 mg tablet in first intervention period and 1*10 mg tablet in second intervention period (after washout period)
45842915|NCT01436526|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 1*10 mg tablet in first intervention period and 2*5 mg tablet in second intervention period (after washout period)
45842916|NCT01437852|Biological|StrataGraft Skin Tissue|
45842917|NCT01438008|Drug|24% sucrose po solution|"CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of a 24% sucrose solution. The maximum amount of the study solution will be administered according to the infant's gestational age and according to the hospital's Sucrose policy. The total amount of the study solution will be divided into a maximum of 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure."
45842918|NCT01438008|Drug|Placebo po|"CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (almost identical in color, consistency and odor placebo to the sucrose solution in identical packaging) The total amount of the study solution will be divided into 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure"
46045868|NCT05778643|Behavioral|TaKeTiNa music therapy|TaKeTiNa music therapy uses a group to perform music together. Each member of the group is needed for the synchronization of the whole group. The group actively makes Music with hands, feet, and the voice. At the same time, the therapist frequently introduces new elements into the process and challenges the group in this playful manner. Through this, patients consistently report an increase in mindful awareness and an alleviation of many depressive symptoms, although these effects have not been shown in controlled studies yet.
46045869|NCT05778422|Drug|Suprascapular nerve block with bipuvacaine|Suprascapular nerve block with Bipuvacaine: a 50mm 22G needle (Stimuplex, BBraun) was introduced up to the suprascapular fossa, guided by ultrasound, and the location was confirmed by motor stimulation with contraction of the supraspinatus and infraspinatus muscles. Next, 5 ml of 0.25% bupivacaine with adrenaline was injected.
46045870|NCT05778422|Procedure|Pulsed radiofrequency|After confirming the location, the needle mandrel was removed and the radiofrequency cannula was introduced through the needle, 2ml of 1% lidocaine without epinephrine was injected, followed by application of pulsed radiofrequency for 180sec at 42°C by radiofrequency (radiofrequency generator system BMS-50N, Bramsys).
45686282|NCT05262946|Behavioral|sensorimotor training based on Feldenkrais method|8 weeks of balance and sensorimotor training twice a week
45686283|NCT05262946|Behavioral|foot care education|Recommendations for preventing foot ulcers
45686284|NCT05262946|Combination Product|usual care|drugs and diet usual care
45686285|NCT03026907|Drug|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
45686286|NCT03026907|Drug|Azathioprine|Oral azathioprine tablets twice daily in a dose of 1.5 or 2.5mg/kg/day, depending on the thiopurine methyltransferase (TPMT) activity.
45686287|NCT00060424|Drug|Cyclosporine|Given PO
45686288|NCT00060424|Drug|Fludarabine Phosphate|Given IV
45686289|NCT00060424|Procedure|Hematopoietic Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
45686290|NCT00060424|Other|Laboratory Biomarker Analysis|Correlative studies
45842919|NCT01438710|Drug|Prograf|Oral Prograf or generic tacrolimus doses will be taken b,i,d, consistently in 2 divided doses, once in the morning and once in the evening, to maintain trough level in the range of 3 to 12 ng/mL. Target trough level for the subject will be determined per clinical practice.
45477315|NCT05705882|Other|Malnutrition|For the diagnosis of malnutrition, the investigators adopted the Global Leadership Initiative on Malnutrition (GLIM) scheme based on three phenotypic criteria (non-volitional weight loss, low body mass index, and reduced muscle mass) and two etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least one phenotypic criterion and one etiologic criterion should be present in patients with nutritional risk.
45686291|NCT00060424|Drug|Mycophenolate Mofetil|Given PO
45686292|NCT00060424|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
45351980|NCT00333619|Behavioral|Nonpharmacological sleep intervention|The intervention combines: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies
45351981|NCT00333619|Behavioral|Active control|Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
45351982|NCT00986752|Device|Stenting (Smart Stent)|Nitinol stent
45842920|NCT01438710|Drug|LCP-Tacro|LCP-Tacro will be administered orally q.d. in the morning based on a conversion factor from Prograf or generic tacrolimus to LCP-Tacro of 0.7 for non-African American subjects and 0.85 for African American subjects to maintain target trough level of 3 to 12 ng/mL.
45351983|NCT00986752|Device|Stenting after PEB (Smart Stent, Invatec)|Stenting (nitinol stent) after dilation with Paclitaxel-eluting balloon (PEB).
45351984|NCT00986752|Procedure|Atherectomy (SilverHawk device)|Atherectomy
45351985|NCT00772122|Drug|G-CSF|daily sub-cutaneous administration of the recombinant G-CSF, at a dosage of 1 microgram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
45351986|NCT00772122|Drug|saline solution|daily sub-cutaneous administration of saline solution 0.2ml from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.
45351987|NCT04006678|Procedure|computer guided sandwich osteotomy|segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla. Either using surgical guides (Computer guide segmental sandwich osteotomy technique) for study group and conventional segmental sandwich osteotomy technique for control group.
46045871|NCT05777161|Behavioral|Parent Coached Exposure Therapy - Individualized|Subject and parent begin by working with a therapist to create an individualized fear hierarchy consisting of situations and stimuli that produce anxiety for the child, gradually progressing from less anxiety to more anxiety.
45351988|NCT00769470|Biological|trastuzumab|Given IV
45351989|NCT00769470|Drug|carboplatin|Given IV
45351990|NCT00769470|Drug|docetaxel|Given IV
45351991|NCT00769470|Drug|lapatinib ditosylate|Given orally
45686293|NCT00060424|Radiation|Total-Body Irradiation|Undergo TBI
46045872|NCT05777161|Behavioral|Cognitive Behavior Therapy|Subjects will work with a therapist using anxiety management strategies to address thoughts, feelings, and behaviors.
46045873|NCT05777161|Behavioral|Parent Coached Exposure Therapy - Group (removed from study)|Subjects and parents will work in a group setting to receive exposure therapy consisting of situations and stimuli that produce anxiety for the child, gradually progressing from less anxiety to more anxiety.
46045874|NCT05777070|Behavioral|Bimanual Cup Stacking Training|Children practices bimanual cup stacking, 15 trials/day for 5 consecutive days
45351992|NCT04854382|Behavioral|Tailored information|Tailored information about coronavirus for patients with chronic kidney disease by information videos followed by a teach back procedure
45351993|NCT00605319|Drug|Toviaz (Fesoterodine)|4mg to 8mg by mouth once daily
45686294|NCT03026751|Procedure|Bone Marrow Aspirate|Bone marrow aspirate
45686295|NCT05253040|Other|KEEP Intervention|Educational intervention
45686296|NCT05253040|Other|control|booklet from Parkinson's UK
45686297|NCT05215522|Device|The BCI-FES Intervention|To evaluate whether the participant can effectively control FES using the developed remote BCI system. Thus, participants will receive a three-week BCI-FES intervention at their home, including three sessions of intervention per week. Each session will last around 60 minutes, including 10 minutes of preparation, 40 minutes of intervention and 10 minutes interview on the user's experience with the device and any experienced side effects, if any.
45351994|NCT04006834|Other|No intervention involved|No intervention involved
45351995|NCT00922038|Behavioral|Cash reward|Enrollees testing negative for treatable sexually transmitted infections will receive cash rewards.
45351996|NCT00983320|Drug|quetiapine|flexible dosage (50 to 300 mg)
45351997|NCT00983320|Drug|placebo|placebo
45351998|NCT00908661|Device|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh
45351999|NCT00989248|Other|Aerobic and anaerobic capacity use aquatic exercises|Improve aerobic capacity use aquatic exercises in patients with Congestive Heart Failure
45352000|NCT00983398|Drug|Carboplatin|Given IA
45352001|NCT00983398|Drug|Mannitol|Given IA
45352002|NCT00983398|Drug|Melphalan|Given IA
45477316|NCT02502760|Behavioral|Physical Exercise Program|Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
45477317|NCT02502760|Dietary Supplement|Whey Protein Isolate Powder|"Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Powder (Immunocal) is provided.~Immunocal1.5g/kg PO (by mouth) per day separated in 2 daily doses"
45477318|NCT02502760|Behavioral|Relaxation Techniques|Relaxation techniques consisting of breathing exercises and using a relaxation CD.
45477319|NCT05085938|Procedure|gonadal vein embolization|"GVE was performed under local anesthesia with 5.0-10.0 mL of 0.5% lidocaine solution with a patient under intravenous sedation. For the left GV embolization, the transfemoral approach was used, while for the right or both GV embolization, the transjugular approach was used. The 5F multipurpose angiographic catheters (Cordis; USA), standard 'moving core' J .035 guidewire, and an angled hydrophilic guidewire (Radiofocus; Terumo Corp., Japan) were used. For the GV occlusion, the pushable 0.035 standard stainless steel coils (Gianturco; William Cook, Bjæverskov, Denmark) and 0.035 coils made of Inconel with interwoven long collagen fibrils (MReye; Cook Medical Inc., Bloomington, USA) were used. The diameter of coils was 8-12 mm, and the length was 10-20 cm."
45477320|NCT02502604|Behavioral|Goal Management Training|Goal management training sessions will be 2 hours in length and focus on learning skills that will assist in planning, carrying out, and monitoring goal-directed behaviours.
45477321|NCT05152706|Other|Aerobic training|Cycling at the aerobic intensity
45477322|NCT05152706|Other|Photobiomodulation|Photons therapy
45477323|NCT04498702|Drug|APL-1202 treatment|A modified 3+3 design was employed: The dose was started at 300 mg and increased to 450 mg, 600 mg and 750 mg if there was no dose-limiting toxicity (DLT) in 3 subjects after 4-week consecutive administration of APL-1202. When the dose-escalation study was in progress, the doses for any newly enrolled subjects would be the starting dose or the highest dose confirmed with no DLT by the dose-escalation cohort at the time of enrollment. When the MTD or the 750 mg daily dose was attained as a safe dose, the dose for all subjects in the study or subsequently enrolled subjects would be MTD or 750 mg/day.
45686298|NCT00062764|Drug|Actos (Pioglitazone)|Pts receive drug in a dose of 15 mg daily for at least 1 year; the dose is escalated to 30 mg daily if serum ALT levels do not fall to normal by the 1 year pt; if pts have a biochemical response, drug is continued for 3 years,
45842921|NCT01442844|Device|Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile dressing that will be placed on the surgical wound.
45842922|NCT01443546|Drug|HCG|hCG Trigger
45842923|NCT01443546|Drug|Lupron Trigger|leuprolide acetate 2 mg SQ
45842924|NCT01443546|Drug|Dual Trigger|a combination of the two drugs in low dosage (leuprolide acetate 2 mg and hCG 1500 IU).
45842925|NCT01444716|Biological|Ofatumumab|Given IV
45842926|NCT01445028|Drug|Isotretinoin|Isotretinoin 20mg daily for 12 weeks
45842927|NCT01447914|Drug|Tivantinib|Given at a dose of 360 mg oral (PO) twice daily continuously for each day of every 4-week treatment cycle, which will be taken as three tablets of 120 mg each.
46045875|NCT05776355|Biological|NKG2D CAR-NK|Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion
46045876|NCT05776095|Procedure|Cataract surgery|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
46045877|NCT05776095|Device|Eyedeal® Model PX65AS1 IOL|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
46045878|NCT05775328|Other|Intense pulsed light|Already described in the arm/group description
45352003|NCT00983398|Other|Quality-of-Life Assessment|Ancillary studies
45352004|NCT00983398|Other|Questionnaire Administration|Ancillary studies
45352005|NCT00983398|Drug|Sodium Thiosulfate|Given IV
45352006|NCT00333229|Drug|Zoledronic Acid|4 mg zoledronic acid in 5 mL concentrate solution. Plastic vials.
45352007|NCT00333229|Drug|Placebo|Matching Placebo
45352008|NCT00769548|Drug|flutamide|Drug used for TAS.
45352009|NCT00769548|Drug|goserelin acetate|Drug used for TAS.
45352010|NCT00769548|Radiation|low-LET photon therapy|radiation therapy
45352011|NCT05277675|Drug|Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab|Immune checkpoint inhibitor (tislelizumab/sintilimab) combined with anti-angiogenic drugs (lenvatinib/bevacizumab) used as neoadjuvant therapy
45842928|NCT01447914|Other|Diagnostic laboratory biomarker analysis|Correlative studies
45842929|NCT01447914|Other|Questionnaire administration|Ancillary studies
45352012|NCT05277675|Procedure|RFA|RFA will be performed in a percutaneous way guided contrast enhanced ultrasound.
45352013|NCT00769626|Other|Usual Care|Patients in the usual care group will receive advice and education to remain active and anticipate a favorable prognosis. Patients will also receive medication from the primary care provider consistent with current evidence-based guidelines(acetaminophen or non-steroidal anti-inflammatories). Consistent with current practice guidelines, patients will be instructed to return to the primary care provider if they are not satisfied with their progress after 4 weeks.
45352014|NCT00769626|Other|Early Treatment|Patients in the early treatment group will receive the usual care intervention (advice and education, and medication consistent with current evidence-based guidelines). Patients will also be referred to physical therapy for 4 sessions over a 3-week period. A standardized protocol will be used in physical therapy including spinal manipulation and trunk strengthening exercises. Patients will be instructed to return to the primary care provider if they are not satisfied with their progress after completion of the 4 sessions.
45352015|NCT03984409|Dietary Supplement|Kroger low calorie orange juice beverage|Kroger low calorie orange juice beverage will be consumed for 7 days followed by a 24 hour urine collection with Litholink to see if urine alkalization similar to potassium citrate can be achieved
45352016|NCT00900939|Behavioral|Low-fat, vegan diet|Participants in the intervention group will be asked to follow a low-fat, vegan diet for the full 16 weeks of the study. They will also be guided to favor foods with a low glycemic index. The diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products, added oils, and added sugars will be excluded.
45842930|NCT01447914|Procedure|Quality-of-life assessment|Ancillary studies
45352017|NCT00900939|Behavioral|Control|Participants assigned to the control group will be instructed to follow their usual diets for the full 16 weeks of the study.
45352018|NCT00775554|Other|ultrasound guided hematoma block|pt. will receive ultrasound guided hematoma block
45352019|NCT00775554|Other|ultrasound guided hematoma block|ultrasound will be used to guide hematoma blocks
45352020|NCT04005820|Other|Radiologic Centralized Review|The patient's imaging will be examined in one of the examination centers
45477324|NCT03589885|Drug|Placebo 2 mL auto-injector|"All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48"
45842931|NCT01449240|Other|No treatment|
45842932|NCT01449864|Radiation|Proton therapy|The goal of radiation therapy is to deposit the majority of the radiation dose to the target while minimizing the dose to the surrounding normal tissues.
45842933|NCT01452126|Drug|Ropivacaine concentration|Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block
45842934|NCT01456494|Other|Brief Intervention|A brief educational strategy that employs verbal and written instructions, without demonstration or repeated rounds of instruction, to teach patients how to use their inhalers.
45842935|NCT01456494|Other|Teach-to-Goal Education|Teach-to-goal (TTG) is a method of patient instruction that employs repeated rounds of teaching (demonstration, verbal, written instructions) and assessments (teach-back) of patient comprehension.
45842936|NCT01457196|Diagnostic Test|Tumor Genetic Sequencing|This study will look at genetic material from a sample of the subjects tumor, look at certain changes in the genetic material, and see if these changes are related to the subjects cancer.
46045879|NCT05775081|Other|Regenerative endodontic procedues|Treating non-vital immature permanent teeth with either treated dentine matrix paste or platelet rich fibrin
45352021|NCT04005820|Other|Tissue sample (tumor, sung, urine)|all the samples will be made during the patients care
45352022|NCT02538159|Device|CVC|The inclusion of any CVC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. In the case of CVC, the subclavian vein of choice will be followed by the femoral and jugular. Seldinger technique with direct radiation control in the operating room is used.
45352023|NCT02538159|Device|PICC|The inclusion of any PICC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. PICC vein of choice is the basilica vein with help of Ecography in the interventional radiology room.
45352024|NCT00983554|Drug|Anastrazole|Arimidex 1mg daily
45352025|NCT00983554|Drug|Testosterone|Testim 10g daily
45842937|NCT01457430|Drug|Icatibant|30 mg subcutaneous dose of Icatibant
46045880|NCT05774860|Other|No intervention|No intervention
46045881|NCT05774847|Other|No intervention|No intervention
46045882|NCT05774834|Other|No intervention|No intervention
46045883|NCT05774743|Other|Consent with Visual Aid|Participants who receive the study intervention will receive the standard anesthesia consent procedure with the addition of the visual aid. The visual aid is a poster with pictorial representations of the information that is verbally communicated to participants during the standard consent process.
45352026|NCT00983554|Drug|Dutasteride|Avodart 2.5mg daily
45352027|NCT00983554|Drug|GnRH antagonist|Acyline 300 µg/kg subcutaneous injections every 2 weeks
45686299|NCT00063232|Drug|Metformin|After complete medical evaluation and liver biopsy, patients who qualified for therapy were started on metformin in an initial dose of 500 mg once daily. After 2 weeks, the dose was increased to 500 mg twice daily and after 4 weeks to the full dose of 1000 mg twice daily. Subsequent dose reductions were carried out based on tolerance, with particular attention to gastrointestinal upset and abdominal bloating. Patients were seen in the out-patient clinic, had a brief medical history and examination and routine blood tests at 2 and 4 weeks after enrolment and every 4 weeks thereafter. The oral and intravenous glucose tolerance tests were repeated after 40 and 44 weeks respectively and liver biopsy and imaging tests at 48 weeks. Metformin was discontinued after 48 weeks in patients without diabetes on the pre-treatment evaluation.
45686300|NCT00063622|Drug|Pioglitazone|30 mg daily
45842938|NCT01458288|Drug|TG-0054|3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)
45842939|NCT01458990|Drug|Omeprazole|20mg PO BID for 20 days
45842940|NCT01460940|Drug|panobinostat|Administered orally Monday, Wednesday, Friday of every week for 4 weeks. A cycle is define as 28 days.
45842941|NCT01460940|Drug|lenalidomide|Lenalidomide will be administered orally daily on days 1-21. Lenalidomide will not be given on days 22-28. A cycle is define as 28 days.
46045884|NCT05774366|Drug|Remimazolam|General anesthesia was induced with 12 mg/kg/hr of intravenous remimazolam. When loss of consciousness was achieved, the infusion rate of remimazolam was reduced to 1mg/kg/hr for maintenance. At the end of surgery, 0.2 mg of flumazenil is administered.
45842942|NCT01462812|Drug|Sumatriptan|Sumatriptan 20mg
46045885|NCT05774366|Drug|Desflurane|Desflurane (1 minimum alveolar concentration (MAC) of end-tidal desflurane concentration) is used for the maintenance of general anesthesia. Induction of general anesthesia is achieved with 1-2 mg/kg of intravenous propofol bolus.
45842943|NCT01462812|Drug|Placebo|Matching placebo
45842944|NCT01463202|Drug|Depot medroxyprogesterone acetate|Postpartum administration of DMPA (prior to hospital discharge)
46045886|NCT05774080|Other|Observational|Observational
46045887|NCT05774067|Drug|Saline|patient received normal saline 4ml/kg/hr with deflation of tourniquet
46045888|NCT05774067|Drug|Norepinephrine|patient received noradrenaline infusion at rate 0.1 mcg/kg/min. with deflation of tourniquet
45352028|NCT00908739|Genetic|gene expression analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
45352029|NCT00908739|Other|immunohistochemistry staining method|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
45352030|NCT00908739|Other|laboratory biomarker analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
45352031|NCT04741516|Drug|Foquest|The drug being evaluated in this study is controlled release methylphenidate HCl control (Foquest®). Foquest® is a novel formulation of MPH developed by Purdue Pharma (Canada) and is approved in Canada for the treatment of ADHD in patients six years of age and older. Foquest® is the first methylphenidate product approved in Canada with an onset of action within one hour and a duration of action up to and including 16 hours (Wigal et al.2016). Foquest® is an ADHD treatment option for patients who require a rapid onset of action and extended duration of action
45352032|NCT05004987|Drug|Escitalopram Oxalate|The daily dose of ESC/PBO will be 10 mg for the first 2 weeks, then increase to 20 mg as tolerated, with an option to reduce back to 10 mg if necessary.
45352033|NCT05004987|Drug|Placebo|Daily dose of placebo will mimic that of ESC.
45352034|NCT05712694|Drug|ADI PEG20|Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
45686301|NCT00063622|Dietary Supplement|Vitamin E|800 IU daily
45686302|NCT00063622|Drug|Matching placebo|Daily
45842945|NCT01463202|Drug|Depot medroxyprogesterone acetate|Delayed administration of DMPA (4-6 weeks postpartum)
45842946|NCT01463358|Device|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDD60 is supposed to prevent events of syncope, presyncope of cardioinhibitory origin and symptom associated to av block
45842947|NCT01463358|Device|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDDI30 is supposed to act as a safety backup upfront to episodes of syncope, presyncope or AV block, but not supposed to reduce symptoms.
45842948|NCT01467882|Drug|Triptorelin|Powder and solution for solution for injection
45842949|NCT01468350|Drug|dalfampridine-ER 10mg|
45842950|NCT01468350|Other|Placebo|
45842951|NCT01468584|Drug|MP-424 (generic name:Telaprevir)|750mg q8h for 12 weeks
45842952|NCT01468584|Drug|Ribavirin|400 - 1000 mg/day based on body weight for 24 weeks
46045889|NCT05774067|Drug|glypressin|patient receive glypressin infusion at rate 2 mcg/kg/hr.
46045890|NCT05774041|Device|SIS System|FDA-cleared software that enhances standard clinical images for the visualization of structures in the basal ganglia area of the brain which are commonly targeted for DBS lead placement.
46045891|NCT05772403|Diagnostic Test|CEUS|CEUS for atypical liver nodules
46045892|NCT05772338|Drug|BNP105 (25 + 25 + 15)|BNP105 oral suspension, 25 mg + 25 mg + 15 mg, oral. Up to six applications per day.
45842953|NCT01468584|Drug|Peginterferon alfa-2b|1.5mcg/kg/week for 24 weeks
45842954|NCT01468974|Device|ESPRIT BVS|Subjects receiving ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries
45842955|NCT01471626|Device|polysomnograph Dream and Sleep Box|Portable polysomnograph will be placed at home around 7:00PM. The Sleep Box (wireless monitoring device) will be left near the patient, to allow real-time GPRS transmission of recorded sleep parameters to the sleep lab.
45842956|NCT01472718|Device|coronary thrombectomy|coronary thrombectomy with either Angiojet device (rhelytic thrombectomy) or Export device (manual aspiration)
45842957|NCT01472718|Device|standard primary PCI (with stenting, as required)|standard primary PCI (usually with stenting) for STEMI, without use of thrombectomy or distal protection devices
45842958|NCT01472874|Drug|Once a day Trientine|Trientine at a dosage of ~15 mg/kg rounded upwards to the nearest 250 or 300 mg in a single daily dosage. The entire daily dosage will be taken at once in the AM an hour before any meal. Duration of the study is 1 year.
45842959|NCT01474122|Drug|Macitentan 3 mg|Macitentan 3-mg tablet once daily
45352035|NCT05712694|Other|Placebo|Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
45352036|NCT00908817|Drug|triamcinolone acetonide|paste applied over tracheal tube for lubrication
45352037|NCT00908817|Drug|chlorhexidine gluconate|jelly applied over tracheal tube for lubrication
45686303|NCT05605912|Other|Control|Participants perform five one-hour conventional training sessions at the Sint Maartenskliniek in which they perform functional exercises. After the conventional training program, the control group will receive a recommendation for physical activity at home for six weeks.
45686304|NCT05605912|Device|Myosuit|Participants perform five one-hour Myosuit training sessions at the Sint Maartenskliniek in which they perform functional exercises and learn to don, doff and use the device for standing, walking, climbing the stairs and sit-to-stand transitions. After the clinical Myosuit training program, participants receive the Myosuit at their disposal at home and a recommendation for physical activity at home for six weeks.
45842960|NCT01474122|Drug|Macitentan 10 mg|Macitentan 10-mg tablet once daily
45842961|NCT01474122|Drug|Placebo|Placebo tablet matching macitentan tablet, once daily
45842962|NCT01474200|Device|Isolated veno-venous ultrafiltration (AQ)|Aquapheresis treatment (isolated veno-venous ultrafiltration) using the Aquadex FlexFlow System during index hospitalization until the patient's signs and symptoms of fluid overload have improved to the satisfaction of the treating physician. Ultrafiltration rates, duration and frequency of treatment are dependent on the amount of patient fluid excess and on the rate of fluid movement from the interstitial spaces into the vascular compartment during Aquapheresis (Plasma Refill Rate, or PRR)
45842963|NCT01474200|Drug|IV Loop Diuretics (LD)|"IV Loop Diuretics treatment using only FDA approved IV loop diuretics indicated for the treatment of patients with fluid overload. This includes furosemide or other IV loop diuretics administered at equivalent doses to furosemide. Patients will receive either a twice daily IV bolus or continuous IV LD infusions according to the high dose protocol of theDiuretic strategies in patients wth acute decompensated heart failure (DOSE) trial."
45842964|NCT01474590|Drug|Epiduo/Tactuo|topical to the face, once daily in the evening
45842965|NCT01474590|Other|vehicle gel|topical to the face, once daily in the evening
45842966|NCT01474590|Drug|doxycycline 200mg|oral, 2 capsules once daily in the morning with aglass of water and with food
45842967|NCT01474590|Drug|Isotretinoin|oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.
45842968|NCT01477320|Drug|Pantoprazole 40 mg IV daily and tube feed.|"Patients randomized to the control group active Comparator will receive tube feed plus an Pantoprazole 40 mg IV daily."
45842969|NCT01477320|Other|Placebo and tube feed|"Patients randomized to Placebo group placebo Comparator will receive tube feed plus an Placebo."
45842970|NCT01477710|Procedure|Hold mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
45842971|NCT01477710|Procedure|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
45842972|NCT01477710|Procedure|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
45352038|NCT04005898|Device|Near-infrared fluorescence cholangiography|Real-Time Fluorescence Imaging (VISERA ELITE II Imaging System). These device is used to identify anatomy, using infrared light that causes the indocianine green to fluoresce.
45686305|NCT05605756|Drug|OnabotulinumtoxinA 145 UNT [Botox]|"Botulinum A toxin injection: Will follow the FDA-approved guideline of the treatment of chronic migraine. The following modifications are planned: (a) Total units 145 instead of 155. (b) Number of injection sites 29 instead of 31. (c) the 6 injection sites in the trapezius muscle will be eliminated as they are irrelevant to our attempt to reduce seizure events. Instead, 4 injections will be made subcutaneously along the superior sagittal suture (see figures below), where no muscles exist and thus no muscle weakness is likely. This dose (145 Units) is well below the FDA-approved guideline on safety for adolescents and adults (no more than 10 Units/Kg or a total of 340 Units).~Botox injections will take place in the BIDMC Headache Clinic which is a part of the Arnold Pain center at 1 Brookline Place. Injections will be administered by Dr. Sait Ashina, the Director of the Headache Clinic."
45842973|NCT01478256|Drug|Erythromycin|Topical erythromycin ointment twice a day
45842974|NCT01478256|Drug|Besifloxocin|Topical Besifloxocin twice a day
45842975|NCT01479270|Drug|TAP Block|Bilateral transversus abdominal plane injection under ultrasound guidance, done at conclusion of hysterectomy procedure, prior to emergence from general anesthesia
45842976|NCT01479348|Drug|[F-18]-5-FLUORO-2'-DEOXYCYTIDINE|18FdCyd radiotracer
45842977|NCT01479348|Drug|Tetrahydrouridine intravenous (IV)|Total dose of THU = 350 mg/m^2, IV
45842978|NCT01479348|Drug|Tetrahydrouridine (oral)|Total dose of THU is 3000 mg, oral
45842979|NCT01479348|Diagnostic Test|Positron emission tomography (PET)/Computed tomography (CT)|One prior CT and 3 sequential whole body PET
45842980|NCT01479426|Dietary Supplement|EFLA400|EFLA400(960mg/day)for 12 weeks
45842981|NCT01479426|Dietary Supplement|Placebo|Placebo(960mg/day) for 12 weeks
45842982|NCT01483560|Drug|Metformin|3 years treatment duration
45842983|NCT01483560|Drug|Placebo|3 years duration
45842984|NCT01484340|Drug|Nicotine|"The nicotine patch be given in three phases:~2 weeks of patches at enrollment~6 weeks of patches at two-week follow-up visit~2 weeks of patches at two-month follow-up visit~This schedule will cover the entire 10-week course of therapy as per label instructions: 6 weeks at 21mg; 2 weeks at 14mg; and 2 weeks at 7mg."
45842985|NCT01484340|Behavioral|Intensive Counseling|"The advice to quit smoking message will follow NCI's 5A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.~Visit schedule:~Baseline~2-week follow-up (Quit Day)~1-month follow-up~2-month follow-up~3-month follow-up~6-month follow-up~Participants abstinent at 6-month follow-up will be next seen at 12-month follow-up.~Participants still smoking at 6-month follow-up will be offered group-assigned intervention again."
45842986|NCT01484652|Drug|COV795|2 tablets taken every 12 hours
45842987|NCT01484652|Drug|Placebo|2 tablets taken every 12 hours
45842988|NCT01485588|Drug|hI-con1™ 60µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
45842989|NCT01485588|Drug|hI-con1™ 150µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
45842990|NCT01485588|Drug|hI-con1™ 300µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
45352039|NCT00332839|Drug|Everolimus|Participants, switching from the CsA based treatment, initially received everolimus 1.5 mg/day and then from day 7, 3 mg/day, and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml). Participants, switching from the tacrolimus based treatment, initially received 3 mg/day and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml).
45352040|NCT00332839|Drug|Cyclosporin A (CsA)|The dose was based on the participants' blood level of C0h (80-150 ng/ml).
45352041|NCT00332839|Drug|Tacrolimus|The dose was based on the participants' blood level of C0h (5-10 ng/ml).
45352042|NCT00332839|Drug|Enteric Coated - Mycophenolate Sodium (EC-MPS)|The dose was ≥ 720 mg/day.
45352043|NCT00332839|Drug|Corticosteroids|Corticosteroids were given according to local standard and/or the Investigators' discretion.
45352044|NCT00983632|Procedure|Selective vagus nerve stimulation|"Stimulus will be combination of quasi-trapezoidal cathodic and rectangular anodic current pulses. Precisely, the resulting current, biphasic and charge balanced combination will be composed of a quasi-trapezoidal cathodic phase with a square leading edge with different intensity ic , a plateau tc of 300 μs, and exponentially decaying phase texp of 500 μs, followed by a wide rectangular anodic phase ta of allow current magnitude ia. Anodic phase ia will be one-tenth of the magnitude in the cathodic phase. However, the width of the anodic phase ta will be dependent upon the charge injected in the cathodic phase: the greater the charge, the wider the anodic phase.~For details see detailed study description"
45352045|NCT00983632|Device|selective vagus nerve stimulation|electrical vagus stimulation
45352046|NCT00927147|Radiation|BNCT|Boronophenylalanine infusion followed by neutron irradiation
45352047|NCT00927147|Drug|cetuximab|cetuximab infusion 250 to 400 mg/kg intravenously, 1 to 3 infusions
45352048|NCT05712616|Drug|Strontium Ranelate|Dual mode of action, anabolic and anti-resorptive
45352049|NCT05712616|Drug|Lacto-N-Hexaose|Placebo look alike drug
45352050|NCT00927225|Drug|ropivacaine 0.2%, 50 mL|
45352051|NCT00927225|Drug|normal saline|
45352052|NCT00357097|Drug|Ropinirole|
45352053|NCT00983710|Behavioral|PC-PEP - Prostate Cancer Patient Education Program|Men in the intervention group will receive a new patient education intervention to help them manage side-effects related to treatment for localized prostate cancer. The intervention will be delivered by phone and by mail and is targeted to me with low health literacy. The intervention consists of written materials, audio materials, and telephone-based problem-solving education.
45352054|NCT00983710|Behavioral|Usual care|Booklet on coping with localized prostate cancer
45352055|NCT00927303|Device|Cirrus-Spectralis|512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter
45352056|NCT00927303|Device|Spectralis-Cirrus|retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter
45352057|NCT00983788|Drug|Bezafibrate|3 x 200 mg/ day
45352058|NCT00983788|Other|Placebo|Placebo
45686306|NCT05185726|Behavioral|Lidcombe Program|"The LP consists of Stage 1 and Stage 2. Stage 1 aims at reducing the stuttering of the PCWS to (near) zero levels of stuttering. During stage 1, parents learn to provide verbal contingencies during daily, 10-minute practice sessions with their PCWS.~During Stage 1, treatment sessions are scheduled weekly. When the child has typical scores of 0 and 1 on the SR-scale with more 0s than 1s per week for three consecutive weeks, and the stuttering is rated as 0 or 1 during the treatment session, the child can proceed to stage 2.~The maintenance phase starts when the stuttering is reduced to (near) zero stuttering and parents are able to implement the practice sessions when it is necessary (when stuttering relapses). Treatment sessions to monitor if achieved goals are maintained are scheduled with an interval of 2, 2, 4, 4, 8, 8 and 16 weeks."
45842991|NCT01488318|Drug|Cetuximab|Cetuximab 250 mg/m2 IV weekly after loading dose 400 mg/m2 on cycle 1, day 1
45842992|NCT01488318|Drug|Dasatinib|Dasatinib 150 mg po
45842993|NCT01488708|Drug|LY2127399|120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
46045893|NCT05772338|Other|Placebo|Placebo. Up to six applications per day.
45352059|NCT00983866|Behavioral|Tailored Telephone Counseling|The intervention is comprised of a letter introducing patients to the idea of participating in a clinical trial as a possible treatment option, followed by a telephone call by a nurse educator who describes the clinical trials process and answers any questions patients may have. The nurse educators will use a tailored counseling protocol that will enable them to conduct an assessment of patients' understanding about and interest in clinical trials and tailor messages according to patient health literacy and language. The protocol will consist of both proactive and reactive counseling. The nurse educator will have a general list of topics to cover but will tailor the discussion and information provided to individual patients' questions and desire for particular types of information.
45352060|NCT00983944|Biological|bleomycin sulfate|Given IV
45352061|NCT00983944|Biological|rituximab|Given IV
45352062|NCT00983944|Drug|EPOCH regimen|Given IV or orally
45352063|NCT00983944|Drug|cyclophosphamide|Given IV or orally
45352064|NCT00983944|Drug|doxorubicin hydrochloride|Given IV or orally
45352065|NCT00983944|Drug|etoposide|Given IV or orally
45352066|NCT00983944|Drug|prednisone|Given IV or orally
46045894|NCT05772299|Radiation|Er:Yag laser|Submucosal debridement is performed with Er:Yag laser using a P-400 tip under rinsing water.
46045895|NCT05772299|Device|EMS ultrasound|Submucosal debridement is performed with piezoelectric ultrasound (EMS) with a PEEK (plastic coated) tip under rinsing water.
46045896|NCT05772000|Diagnostic Test|cerebrospinal fluids exams|cerebrospinal fluids will be examined by conventional cytology and flow cytometry
46045897|NCT05771948|Device|AqueousJoint|AqueousJoint is a new intra-articular (IA) injectable joint lubricant for patients suffering from joint pain developed by Liposphere LTD. AqueousJoint is a liposomal boundary lubricant which coats the cartilage surface and protects it from further damage and degradation.
45352067|NCT00983944|Drug|vincristine sulfate|Given IV or orally
45352068|NCT00927459|Drug|PRO-040201|Single dose IV infusion
45477325|NCT03589885|Drug|Placebo 1 mL prefilled syringe|"All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48"
45477326|NCT03589885|Drug|Secukinumab 2 mL auto-injector|2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15 , 16 and 4-weekly thereafter until week 48
45686307|NCT05185726|Behavioral|Mini-KIDS|Mini-KIDS for 4-6-year old PCWS consists of four stages: Stage 1 = desensitization, Stage 2 = identification, Stage 3 = modification and Stage 4 = generalization. The program for 2-4-year old child does not include stage 2. SLT and parent(s) are the speech model for the child. They add normal disfluencies and pseudo-stuttering to their speech at first to make sure the child dares to stutter and the child as well as the parent(s) are desensitized for it. Later on in treatment and if necessary, child learn to recognise and alter their stuttering moments. The maintenance phase starts when the child and parent(s) achieved the goals of Stage 4. Usually the stuttering is reduced to (near) zero stuttering. Treatment sessions to monitor if achieved goals are maintained are scheduled with an interval of 2, 2, 4, 4, 8, 8 and 16 weeks.
45842994|NCT01488708|Drug|Placebo|Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.
45842995|NCT01490892|Drug|3D HI and SHI of UCA|Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
45842996|NCT01491984|Device|Laryngoscopy order: 1) MAC, 2) Levitan|Laryngoscopy with MAC, then Levitan
46045898|NCT05771649|Behavioral|Mindfulness-based intervention|A mindfulness instructor will guide focused attention meditations that will last from 15 to 30 minutes. Participants will be instructed at the beginning of the intervention and will have audio files to guide the exercises during their practice.
46045899|NCT05771649|Behavioral|Physical exercise|An instructor will guide to running with mental association strategies that will last from 15 to 30 minutes. Participants will be instructed at the beginning of the intervention and will have audio files to guide the exercises during their practice.
46045900|NCT05769842|Drug|propofol|Propofol was mainly used in the intervention group during anesthesia extubation. Propofol was given a small amount of times about 1~2mg/kg before extubation when the patient recovered spontaneously.
46045901|NCT05769842|Drug|normal saline|Same dose as propofol.
46045902|NCT05768217|Behavioral|Community Resiliency Collective Efficacy Intervention (CRCEI)|The Community Resiliency Collective Efficacy Intervention (CRCEI) will involve community members in dialogue on thriving, community leadership, and organizing for social change. Participants in the intervention condition will be asked to participate in 2 sessions of discussions about community thriving and a 7-week training program on the following topics: Building on the Strengths of Your Community, Collective Efficacy and its Effects on Violence Prevention & Community Mental Health, Non-threatening Peaceful Intervention Principles and Strategies: Part One, Non-threatening Peaceful Intervention Principles and Strategies: Part Two, Safety and Roles of Police and Community in Intervening, Active/Effective listening and non-violent communication skills, and Community Resources and Indirect Intervention.
45352069|NCT00927459|Drug|Placebo|placebo
45352070|NCT00356863|Behavioral|Increasing awareness to cardiac rehabilitation programs|Increasing awareness to cardiac rehabilitation programs: Before coronary artery bypass grafting (CABG) surgery patients received a face-to-face explanation on their right to participate in cardiac rehabilitation programs (CRPs) under the Israeli Basket of Health Services; they were also provided with a brochure on the benefits of CRP participation and the availability of CRPs throughout the country.
45352071|NCT00927537|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Kinzal according to local drug information.
45352072|NCT00927537|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide|Patients under daily life treatment receiving Kinzalplus according to local drug information.
45352073|NCT00987064|Device|Temperature controlled Laminar Airflow (Protexo)|The intervention is designed to reduce the allergen load in the patients breathing zone by vertically displacing the allergens, originating from the bed and the ambient room environment, with a temperature controlled laminar airflow (TLA) during night sleep. The airflow is filtered through a high efficiency particulate air filter(HEPA), slightly cooled and ''showered'' over the subject. Due to the higher density, the cooled air descends slowly, and displaces the allergens from the breathing zone.
45352074|NCT00987064|Device|Placebo TLA|TLA treatment with disabled filtration function
45352075|NCT02538003|Drug|LCB01-0371 Tablet 800 mg(R)|Reference: taken drug before meal
45352076|NCT02538003|Drug|LCB01-0371 Tablet 800 mg(T)|Test: taken drug after meal
45352077|NCT03760744|Procedure|CDT with Negative Pressure|Complete decongestive therapy (physical therapy conservative intervention of compression, manual lymphatic drainage, skin care and exercises) in conjunction with manual intervention of graded negative pressure application for lymphatic stimulation/ tissue clearance
45352078|NCT03760744|Procedure|CDT alone|Complete decongestive therapy (physical therapy conservative intervention of compression, manual lymphatic drainage, skin care and exercises) for lymphatic stimulation/ tissue clearance
45352079|NCT00909129|Drug|pegylated interferon-alpha (Pegasys)|Pegylated interferon-alpha 2a 180 micrograms s.c. weekly
45477327|NCT03589885|Drug|Secukinumab 1 mL prefilled syringe|2 x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
45477328|NCT03121222|Drug|N-acetylcysteine|The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom). The participants were instructed to receive the capsules every twelve hours in order to achieve high concentration of N-acetylcysteine throughout the 24 h. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for N-acetylcysteine.
45477329|NCT03121222|Drug|Lactose|The placebo group received orally two lactose tablets per day. The participants were instructed to receive the capsules every twelve hours. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for placebo.
45477330|NCT05074394|Biological|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody that is a neutralizing antibody to SARS-CoV-2
45352080|NCT00909129|Drug|ribavirin (COPEGUS)|ribavirin bid 800-1200 mg depending on HCV genotype and body weight
45477331|NCT05074394|Drug|Placebo|Diluent solution
45352081|NCT01053325|Drug|Cotrimoxazole prophylaxis|Daily prophylaxis with cotrimoxazole
45477332|NCT05059964|Other|Circuit Training program|"The 4 weeks Circuit Training program, it will be of 3 times per week. Each CT workout includes 6 stations per circuit Training. Before the training period, all participants underwent an exercise familiarization session to ensure proper execution of technique.~The 6 stations will be included as 40 lb. carry for 100 ft., 3-min stair climb, 45 s plank pose, 20 lb. carry with a fast walk for 100 ft., right and left single leg stands for as long as balance was maintained, and a 15 lb. carry up and down 30 stairs"
45477333|NCT05059964|Other|Continuous aerobic exercise Group|Continuous aerobic exercise Frequency 3 time per week Intensity 50% of Heart rate reserve Type continuous aerobic exercise Time 40 minutes
45477334|NCT03120988|Biological|Lavage with Platelet Poor Plasma (PPP)|Lavage of 50cc PPP
46045903|NCT05768217|Behavioral|Health Education Sessions|Comparison neighborhoods will receive health education sessions across a variety of community-identified health topics as a control intervention. (9 sessions)
46045904|NCT05767190|Behavioral|Motivational interviewing|During the intervention, the trained-nurse will provide a motivational interviewing-based intervention consisting of one session divided into two parts: educational (the concepts of sleep apnea and the symptoms, and the CPAP treatment will be focused on) and training activity (using MI not directly advocate for behavioral change (i.e., use CPAP as prescribed), but asks key questions to help the patient explore conflicting feelings about the change, weighs the positive consequences and negatives of this change, and allows the patient to realize the discrepancy between current risk behavior (i.e. not using CPAP as directed) and the patient's self-identified goals. The intervention will be tailored on the patient's stage of change based on Prochaska and DiClemente transtheoretical model (1982), in fact, the nurse will use MI not only at the beginning of therapy but also in every contact with the patient throughout the treatment (subsequent follow-up visits, phone calls, etc.).
46045905|NCT05766917|Behavioral|peer education group|Patients in this group will receive the routine hospital care, in addition to the proposed peer education by trained peer
46045906|NCT05764122|Drug|BIIB131|Administered as specified in the treatment arm.
46045907|NCT05764122|Drug|Placebo|Administered as specified in the treatment arm.
45352082|NCT01053325|Drug|SP IPT|Intermittent preventive treatment with sulphadoxine-pyrimethamine
45352083|NCT04733404|Device|Dragonfly Transcatheter Mitral Valve Repair System|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
45477335|NCT03639493|Drug|Exforge® tab 10/160mg, Crestor® tab 20mg|Co-administration of Amlodipine 10mg/ Valsartan 160mg(combination drug) and Rosuvastatin 20mg
45477336|NCT03639493|Drug|CJ-30060 10/160/20mg|Fixed-dose combination drug containing Amlodipine 10mg and Valsartan 160mg and Rosuvastatin 20mg
45352084|NCT05277363|Other|None (Observational study)|No investigational intervention, marketed product, or placebo will be administered to study participants in this study.
45352085|NCT03990181|Dietary Supplement|meal matrix & NPPS|Test meal consumed with the natural polyphenol supplement
45352086|NCT03990181|Dietary Supplement|meal matrix & CS|Test meal consumed with the control supplement
45477337|NCT05705804|Drug|Pitavastatin|Pitavastatin 4 mg will be given.
45477338|NCT05705804|Drug|Pitavastatin plus Ezetemibe|Pitvastatin 4 mg plus ezetemibe 10 mg will be given.
45352087|NCT03990181|Dietary Supplement|no-matrix & NPPS|Test drink consumed with the natural polyphenol supplement
45352088|NCT03990181|Dietary Supplement|no-matrix & CS|Test drink consumed with the control supplement
45352089|NCT05712148|Biological|Stem cell implantation|Suprachoridal mesenchymal spheroidal stem cell implantation
45352090|NCT00909207|Behavioral|Interview|Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
45352091|NCT01053403|Drug|3,4-methylenedioxymethamphetamine or Placebo|1.5mg/kg MDMA or matched Placebo administered during 2 inpatients stays. There are 2 dosing sessions and all subjects will receive MDMA at least one time.
45477339|NCT05705804|Drug|Atorvastatin|Atorvastatin 40 mg will be given.
46045908|NCT05760664|Other|Group Experimental/Fascial Fitness|Participants will receive twelve treatment sessions, twice a week, for six weeks, lasting 30 minutes per session. The interventions will be applied by a physiotherapist with previous experience and training in the proposed protocols.
45352092|NCT00987142|Drug|CX501|Cultured chimeric skin
46045909|NCT05760664|Other|Group Sham/Static stretching exercise|Participants will receive twelve treatment sessions, twice a week, for six weeks, lasting 30 minutes per session. The interventions will be applied by a physiotherapist with previous experience and training in the proposed protocols.
45352093|NCT00987142|Device|Occlusive non adherent dressing|Application of an occlusive non adherent dressing in the skin donor site
45477340|NCT03120910|Device|Pulse CO-Oximeter Sensor|Investigational Pulse Oximeter Sensor will measure hemoglobin (SpHb), pulse rate (PR), perfusion index (PI), pleth variability index (PVI), oxygen reserve index (ORI), etc.
45477341|NCT03724045|Dietary Supplement|Back Side of the Moon|"The procedures are: several measurements will be performed, including some which are not part of the Standard Operating Procedure, hence causing it to be considered interventional.~Follow-up during consultation on pneumology until max. 6 months post-admission on the ICU."
45477342|NCT05150678|Procedure|removal of ceserean section scar|we will remove the previous scar in group A
46045910|NCT05760664|Other|Control Group/Placebo|The placebo intervention will be performed using ultrasound turned off in the thoracolumbar region for 15 minutes followed by rest for 15 minutes for 6 weeks, twice a week. Participants will be evaluated on the first day, fourth week and sixth week of intervention.
45477343|NCT05150678|Procedure|non removal of cesearean section scar|we will open in the previous cesearean scar in group B
45352094|NCT00927615|Drug|abciximab|0.25 mg/kg body weight (intracoronary)
45477344|NCT03344302|Drug|Oxytocin|intravenous infusion of oxytocin 30 units over 5 minutes diluted into 500 mL of normal 0.9% sodium chloride
45477345|NCT05136638|Behavioral|dCBTi|The dCBTi adopts a multi-module approach, consisted of 6 weekly modules including psychoeducational on sleep, insomnia, sleep hygiene, sleep restriction and prescription, stimulus control, relaxation and worry time, cognitive restructuring, and relapse prevention. In each module, participants will watch short videos to learn strategies to improve their sleep.
45842997|NCT01491984|Device|Laryngoscopy order: 1) Levitan, 2) MAC|Laryngoscopy with Levitan, then MAC
45352095|NCT00927615|Drug|abciximab|0.25 mg/kg body weight (intravenous)
45352096|NCT03990103|Drug|S1|80-120 mg/day, PO, D1-14, every 21 days
45352097|NCT03990103|Drug|Paclitaxel|20 mg/m2/day, IP, D1-3; 50 mg/m2, IV, D1; 70 mg/m2, IV, D8; every 21 days
45352098|NCT03990103|Drug|Bevacizumab|200 mg, IP, D1, every 21 days
45352099|NCT03990103|Drug|Oxaliplatin|130 mg/m2, IV, D1, every 21 days
45352100|NCT00927693|Other|Coronary Artery Calcium (CAC) Scan|A coronary artery calcium (CAC) scan is performed during the baseline clinic visit. The results including the actual images from the scan are viewed by the subject during the risk factor consultation with the nurse practitioner. Results are available for the subjects' physicians upon request.
45352101|NCT00987220|Drug|Placebo|Oral
45842998|NCT01495572|Drug|Fludarabine|25 mg/m^2 IV (in the vein) for 5 days (day -5 to -1)
45842999|NCT01495572|Drug|Cyclophosphamide|60 mg/kg IV (in the vein) for days -7 and -6
46045911|NCT05759689|Dietary Supplement|Dietary Supplement: Resource Energy|Carbohydrate Supplement
46045912|NCT05759689|Dietary Supplement|Dietary Supplement: Calogen|Polyunsaturated liquid fat supplement
45352102|NCT00987220|Drug|donepezil (Aricept)|5mg oral
45477346|NCT05136638|Behavioral|Virtual coaching|A virtual coach will be added to the app functionality. It will be in the form of a text-based forced-choice conversation bot. It will initiate conversations with the users to check their understanding of treatment materials and guide them to come up with specific action plans to implement the treatment strategies.
45477347|NCT05136638|Behavioral|Non-therapist coaching|A research intern will answer questions and address concerns raised by the participant at the end of modules 1, 3, and 6 by phone. The contact time will be within 30 minutes on each occasion.
45477348|NCT05136638|Behavioral|Therapist coaching|A clinical psychology trainee will provide therapeutic support to enhance the use and adherence to CBTi treatment strategies at the end of modules 1, 3, and 6 by phone. The contact time will be within 30 minutes on each occasion.
45843000|NCT01495572|Drug|Aldesleukin|Only given to patients assigned to high dose (HD) Arm - 720,000 IU/kg intravenous (IV) over 15 minutes, every 8 hrs (+/- 1 hr) for up to 5 days (max 15 doses).-6
46045913|NCT05759663|Procedure|MIRRAD|Repair of the diastasis with MIRRAD technique
46045914|NCT05759663|Procedure|Plication of the entire diastasis arm|Plication of the entire diastasis
45843001|NCT01495572|Drug|MART-1 Reactive CD8+ PBL|Intravenous (IV) over 30 minutes on day 0
45843002|NCT01496352|Drug|DFA-02|Modified release product containing gentamicin and vancomycin for application at the conclusion of surgery after closure of the fascia and prior to skin closure
45843003|NCT01496352|Drug|Placebo|DFA-02 placebo
45843004|NCT01497756|Device|CAPP use|Any abdominal pelvic pressure
45843005|NCT01499862|Device|Tibion Bionic Leg|A programmable, carbon-fiber robotic leg orthosis (Tibion Bionic Leg, Tibion Corporation, Sunnyvale, CA) was used during therapy to actively supplement concentric and eccentric quadriceps function on the participant's impaired side. The device uses internal sensors at the foot and knee joint to detect intention of movement and, once a variable force threshold is passed, the devices provides appropriate assistive and resistive adjustments.
45843006|NCT01504854|Drug|Resveratrol|The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).
46045915|NCT05756270|Diagnostic Test|pCASL|Brain 3 Tesla MRI with pCASL sequence
46045916|NCT05755997|Drug|Cerebrolysin|40 ml Cerebrolysin and 60 ml 0.9% NaCl per day for 4 days every month for 1 year
46045917|NCT05755997|Drug|0.9 % NaCl|100 ml 0.9% NaCl per day for 4 days every month for 1 year
46045918|NCT05755841|Other|Outpatient management of preterm prelabor rupture of membranes|"Patients who will be managed as outpatients will be discharged after 48 hours of hospitalization with the following management:~Twice weekly fetal cardiotocography.~Complete blood count once a week.~A weekly clinical and ultrasound examination."
46045919|NCT05755841|Other|Inpatient management of preterm prelabor rupture of membranes|In the Inpatient Care Policy group, the same protocol as outpatient group will be applied, but the patient will not be discharged until delivery.
46045920|NCT05750862|Procedure|Marking of the intended axis of IOL-Implantation manually with an ink and marking device on the surface of the eye|The marking of the intended implantation axis of the interocular lens will be marked in all patients with topography guided in the corneal stroma with laser and in addition manually with a caliper and ink on the corneal surface
46045921|NCT05739929|Drug|Colchicine 0.5 MG Oral Tablet|0.5 mg colchicine tablets twice daily.
46045922|NCT05739929|Drug|Placebo|Placebo tablets twice daily
46045923|NCT05735587|Other|Freeze-dried Blueberry Powder|Participants will be asked to consume 48 grams of freeze-dried blueberry powder (~ equivalent to 2 cups of fresh blueberries) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
45352103|NCT01581151|Drug|Dexamethasone intravitreal implant|Patients will receive a Dexamethasone implant and ranibizumab, as needed. A comparison will be made between ranibizumab and Dexamethasone implant with rescue ranibizumab.
45352104|NCT01581151|Drug|Monthly Ranibizumab|30 days between treatments
45352105|NCT00909285|Device|TMS stimulation|TMS stimulation and cognitive training
45352106|NCT00909285|Device|Sham comparator|Sham comparator
45352107|NCT00909285|Behavioral|Cognitive training|TMS stimulation and cognitive training
45352108|NCT01053481|Dietary Supplement|vitamin D|Vitamin D supplement
45352109|NCT01053481|Behavioral|exercise program (rebounding on a trampoline)|40 days at 30 min/d
45843007|NCT01504854|Drug|Placebo|The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.
45477349|NCT05136638|Behavioral|Sleep Hygiene and Self-Monitoring Control|An app with self-monitoring function and videos and written materials about sleep hygiene will be provided.
45477350|NCT02502292|Behavioral|Fotonovela|"Comparing fotonovela brochure to traditional brochure, as a template communicative behaviors embedded in a picture story where the older people could use before and during primary care consultations with their GP. Relevant communicative behaviors will include 'asking questions', 'expressing lack of or misunderstanding', 'expressing uncertainty', 'expressing preferences and needs' and other relevant communicative behaviors which are based on communication theory / literature and on the output of the focus group discussions.~The researchers will randomly assigned the participants into four groups as described earlier. Mainly to identify the outcomes of the comparison between fotonovela and traditional brochure in both traditional hard-copy and in tablet."
45477351|NCT03545503|Drug|Etomidate|Etomidate will be administered as the sedative for RSI on even days
45477352|NCT03545503|Drug|Ketamine|Ketamine will be administered as the sedative for RSI on odd days
45477353|NCT01297829|Drug|Intravenous Ibuprofen|800 mg IV ibuprofen 30 minutes preoperatively
45477354|NCT01297829|Other|IV Placebo|IV normal saline
45686308|NCT05185726|Behavioral|Social Cognitive Behavioural Therapy|"A parent training is organised for parents with children who stutters who receive SCBT.~The parent training exists of 10 one-hour group evening sessions for parents to discuss and offer education topics about what stuttering is, how stuttering looks like, ...~The program is delivered in 5 phases and each phase takes as long as is necessary for the PCWS (variable): (1) conditioning speaking activities, (2) cognitive training focused on emotions, (3) cognitive training focused on cognitions, (4) emotional training and (5) skill training.~The maintenance phase starts when the child and parent(s) achieved the goals of the 5 phases. During the maintenance sessions, the SLT asks the parent(s) to report about the child and observes the speech of the child."
45686309|NCT00153166|Drug|atorvastatin and pioglitazone|atorvastatin 80 mg orally once daily (to reduce inflammation) and pioglitazone 30 mg orally once daily (to improve insulin sensitivity)
45686310|NCT00153166|Drug|atorvastatin/placebo|atorvastatin 80 mg orally once daily and matching placebo orally twice daily
45843008|NCT01505166|Biological|Vigil™ Vaccine|Patients will receive 1 x 10^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
46045924|NCT05735587|Other|Placebo Powder|Participants will be asked to consume 48 grams of a nutritionally matched placebo powder (that does not contain fiber or anthocyanins) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
45477355|NCT05685992|Other|no intervention|no intervention
45686311|NCT00153166|Drug|pioglitazone/placebo|pioglitazone 30 mg orally once daily and matching placebo orally once daily
46045925|NCT05734547|Behavioral|Stepping Together for Children after Trauma (ST-CT)|ST-CT is Step One of Stepped Care CBT for Children after Trauma (previously called Stepped Care Trauma-focused Cognitive Behavioral Therapy; Salloum et al., 2014). It consists of five components: psychoeducation, stabilization, trauma narrative, in-vivo exposures and consolidation. The parent and child have 11 at-home-meetings and complete tasks in a workbook, Stepping Together (from the Preschool PTSD Treatment by Michael Scheeringa et al), over 6-9 weeks. In addition, there are weekly calls and five sessions with the therapist. Children who meet responder-criteria (i.e., no more than four symptoms of PTSS) continue to a 6-week maintenance phase, after which treatment is complete if the child still meets responder criteria. For those who do not meet responder-criteria, or are not able to complete the workbook, the responsibility for the treatment is transferred from the municipal service level to the corresponding child and adolescent mental health service (BUP).
46045926|NCT05734547|Behavioral|Usual care|Therapists in the control group will provide the treatment they usually provide, and develop a treatment plan in collaboration with the parents. This may consist of individual sessions with the child, parent sessions, group treatment, meetings with the school and other collaborating services, or referral to the second line mental health centres (BUP).
46045927|NCT05734508|Biological|MVA-BN vaccine|A live vaccine produced from the Modified Vaccinia Ankara-Bavarian Nordic strain (MVA-BN), an attenuated and non-replicating orthopox virus
46045928|NCT05732675|Behavioral|"Vina-STEAM (Skills to Empower Affirmative Men)"|The investigators propose and pilot test a community-based, peer-driven minority stress as well as HIV-stigma reduction program in small group of GBM in Ho Chi Minh City, Viet Nam.
46045929|NCT05732610|Diagnostic Test|MGC Health COVID-19 & Flu A+B Home Multi Test|self-collected direct anterior nares swab samples
46045930|NCT05732610|Diagnostic Test|MGC Health COVID-19 & Flu A+B Home Multi Test (2 to 13 y/o)|adult lay user collected anterior nares swab sample
46045931|NCT05726994|Biological|exhaled breath collection|Fasting children will be asked to breathe normally through a mouthpiece for the collection and analysis of exhaled breath.
45352110|NCT05712070|Behavioral|App-guided lifestyle modification|Smart watch and smartphone application-based life style modification for 12 weeks
45686312|NCT00153166|Drug|placebo/placebo|placebo orally three times daily
45686313|NCT00156910|Biological|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
45686314|NCT00156910|Other|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
45686315|NCT02188108|Other|Wisconsin Stone-QOL survey|Patients will complete a health-related quality of life survey at multiple time points at enrollment and at multiple time points thereafter.
45686316|NCT01475721|Drug|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
45686317|NCT01475721|Drug|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
45686318|NCT01475721|Drug|ADVAIR 500/50mcg|fluticasone propionate/salmeterol combination (500/50mcg) twice daily (AM and PM) for 6 months
45352111|NCT05712070|Behavioral|A book-based self-education of lifestyle modification|A take-home book-based self-education for lifestyle modification
45352112|NCT00927771|Drug|azelaic acid gel|azelaic acid 15% gel twice a day for 6 months
45477356|NCT04496440|Other|Contracture Correction Therapy|Non-drug and non-surgical treatment of contracted knee capsules
45477357|NCT03829943|Diagnostic Test|Vitamin D|Blood will be drawn for Vitamin D level
45352113|NCT00927771|Drug|hydroquinone cream|hydroquinone 4% cream twice a day for 6 months
45352114|NCT01053559|Drug|certolizumab pegol|400mg subcutaneous injections at week 0, week 2, week 4, then every 4 weeks thereafter
45352115|NCT00987298|Device|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
45686319|NCT01475721|Drug|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
45686320|NCT01475721|Drug|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
45686321|NCT01475721|Drug|FLOVENT 500mcg|fluticasone propionate (500mcg) twice daily (AM and PM) for 6 months
45352116|NCT00909441|Procedure|Sentinel Lymph Node Biopsy|Sentinel node biopsy is a technique in which a radioactive isotope is injected in the breast, with or without blue dye. These substances will then migrate and concentrate in the first nodes in the axilla that drain the breast: The sentinel nodes. These nodes (usually one to four nodes) are then evaluated for the presence of cancer cells.
45352117|NCT00984100|Procedure|NOTES Transvaginal Cholecystectomy|An operation to remove the gallbladder, but instead of removing it via an incision in the abdominal wall, will be removed using an endoscope inserted through an opening in the posterior vagina (which then enters the abdominal cavity).
45352118|NCT01053637|Drug|hydrocodone/acetaminophen|0.17 mg/kg hydrocodone component to max of 10 mg. If dose is vomited within 5 minutes, second dose may be administered.
45352119|NCT01053637|Drug|Sugar water|An equal volume of sugar water will be dispensed, as for the weight based 0.17 mg/kg hydrocodone solution given for the study drug
45352120|NCT00928005|Behavioral|Weight loss diet|The weight loss diet will follow the American Diabetes Association guidelines and be nutritionally balanced with a reduced saturated fat content.
45352121|NCT00928005|Behavioral|Weight loss diet plus exercise|The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training.
45686322|NCT00065806|Drug|Atorvastatin|Participants weighing more 50 kg will receive 10 mg of atorvastatin po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
45686323|NCT00065806|Drug|Placebo atorvastatin|Participants weighing more 50 kg will receive 10 mg of placebo po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
45686324|NCT02091466|Device|pre-warming|warming patients 30 minutes prior to anesthesia
45686325|NCT01530087|Device|CASTLE barrier|Prototype barrier to be used in place of current two piece device
45686326|NCT00068770|Radiation|radiation therapy|Radiation is standard treatment 6000cGy in 30 fractions. Patients will receive celecoxib 400 mg bid during RT treatment
45686327|NCT00068770|Drug|Celecoxib|Celecoxib will begin 1 week prior to RT at 400mg bid orally. One day 1 only 1 dose will be administered. Starting on day 2 and throughout treatment until progression, 2 doses will be administered at least 12 hours apart. Celecoxib will continue throughout the 6 week course of RT.
45686328|NCT01475487|Procedure|Utrasound guided cricothyrotomy|Utrasound guided cricothyrotomy
45686329|NCT04102527|Other|Questionnaires|"Patients have to complete the study questionnaires every 2 months :~Digestive Functional Score of Neurological Patients~Bowel Function Index~Severity score for constipation~Bristol Scale~Constipation assessment scale~Estimate scale of risk of constipation"
45686330|NCT01475331|Drug|Ethanol|Cysts will be lavaged for 3-5 minutes with 80% EtOH
45477358|NCT03545113|Procedure|Upper arm arteriovenous graft surgery|Creation of arteriovenous graft vascular access for hemodialysis
45477359|NCT03545113|Procedure|Upper arm arteriovenous fistula surgery|Creation of arteriovenous fistula vascular access for hemodialysis
45477360|NCT02508142|Drug|Hyoscine-N-Butylbromide|"Study Drug: 20 mg/2 mL Hyoscine-N-Butylbromide in 98 mL normal saline (totally 100 mL) ıntravenous form of Hyoscine-N-Butylbromide in normal saline is in the same appearance with placebo Study drug: 100 mL normal saline (placebo) (totally 100 mL)~Drug: Fentanyl 1 mcg/kg as rescue analgesia at 30th minute"
45686331|NCT01475331|Drug|Normal Saline|Cysts will be lavaged for 3-5 minutes with normal saline
45686332|NCT01475331|Drug|Chemotherapy|Following lavage with either 80% ethanol (control group) or normal saline (study group), cysts will be injected with a cocktail of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
45686333|NCT01500213|Drug|Rolapitant|200 mg PO
45686334|NCT01500213|Drug|Granisetron|10 mcg/kg IV
45686335|NCT01500213|Drug|Dexamethasone|20 mg PO and 8 mg PO
45686336|NCT01500213|Drug|Placebo|(4 X 0 mg capsules) o mg PO
45686337|NCT00069160|Drug|docetaxel|Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.
45686338|NCT00069160|Drug|tariquidar|Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.
45686339|NCT00069160|Other|99mTc-sestamibi imaging|Bolus injection of 29 mCi of 99mTc-sestamibi intravenously for each imaging study.
45686340|NCT00071890|Drug|Interleukin 2|Three cycles of IL-2 (6 MUI bid during 5 days = one cycle)
45686341|NCT00071890|Drug|HAART|HAART from week 0 to week 24
45686342|NCT00071890|Drug|Treatment interruption|HAART is interrupted from week 24 in both arms
45477361|NCT05662124|Other|Remote monitoring|"Patients will download the patientMpower app and be provided with a spirometer (Spirobank Smart, MIR) and oximeter (Nonin) to record their spirometry and pulse oximetry which will upload to the application via Bluetooth for clinical review.~Patients will be asked to upload measurements three times per week."
46045932|NCT05726994|Other|Data collection|Clinical data will be collected in order to seek correlations with the exhaled breath profile.
45352122|NCT00928161|Drug|Dexlansoprazole|Dissolving tablet taken by mouth (60 mg tablet), once a day. Take dose first thing in morning on empty stomach, then nothing but water for 30-45 minutes afterwards.
45352123|NCT00909519|Drug|naproxcinod|naproxcinod 750 mg bid
45352124|NCT00909519|Drug|Naproxen|Naproxen 500 mg bid
45352125|NCT00909519|Drug|placebo|placebo
46045933|NCT05725902|Drug|Etavopivat|The study intervention is etavopivat (400 mg), administered orally and once daily (QD)
45352126|NCT00909519|Drug|furosemide|furosemide
45352127|NCT00928239|Procedure|laparoscopic sacropexy with mid vaginal attachment|"supracervical hysterectomy for uterine prolapse~exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~dissection up to ventrolateral part of the levator ani muscle~Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~Two separate meshes, Gynemesh® (Johnson&Johnson) a polypropylene mesh, for anterior and posterior compartment~suturing of posterior mesh caudally to levator ani muscle and proximally 4cm from the apex of the vagina or cervical stump~placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2"
45352128|NCT00928239|Procedure|laparoscopic sacropexy with caudal vaginal attachment|"supracervical hysterectomy for uterine prolapse~exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~dissection up to ventrolateral part of the levator ani muscle~Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~Two separate meshes, Gynemesh® (Johnson&Johnson) a polypropylene mesh, for anterior and posterior compartment~suturing of posterior mesh caudally to the levator ani muscle and proximally at caudal part of the vagina or cervical stump~placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2"
45352129|NCT00928317|Drug|ART621|3.0mg/kg s.c.
45352130|NCT00928317|Drug|ART621|1.5mg/kg s.c.
45352131|NCT00928317|Drug|ART621|0.75mg/kg s.c.
45352132|NCT00928317|Drug|Placebo|Placebo s.c.
45352133|NCT05014815|Drug|Ociperlimab|Ociperlimab intravenous injection
45352134|NCT05014815|Drug|Tislelizumab|Tislelizumab intravenous injection
45477362|NCT02508220|Drug|Syntocinon|Oxytocin nasal spray
45477363|NCT02508220|Drug|Placebo|distilled water in nasal spray
45686343|NCT01475253|Drug|Lidocaine Releasing Intravesical System - LiRIS®|Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
45686344|NCT01475253|Other|LiRIS Placebo|LiRIS Placebo contains inactive substance only; LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
45686345|NCT01475253|Procedure|Sham Cystoscopy Procedure|Cystoscopy procedure only; no investigational product is inserted/removed from the bladder.
46045934|NCT05721196|Behavioral|Culturally adapted Psychoeducation (CaPE)|This intervention consisted of 12 psychoeducation sessions, one session per week, that would be administered on an individual patient basis and to be added to treatment as usual. Each session lasted for approximately 1 h, beginning with a 20-30 min presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for relapse). The content is a reduced and modified version of the Barcelona Psychoeducation Program for bipolar disorders.
46045935|NCT05721196|Drug|Treatment as Usual (TaU)|This group of patients will receive routine treatment, which in Nigeria means attending the outpatient clinic and taking prescribed medication.
46045936|NCT05720143|Procedure|Osseodensification|Procedure: the osteotomy will make by Piezo and bone splitting will do by osseodensification bur. After that Immediate implantation will be done.
46045937|NCT05720143|Procedure|Magnetic mallet|Procedure: the horizontal and vertical osteotomy will do by Piezo and bone splitting will make by chisels of magnetic mallet. Immediate implantation will be done after splitting.
45352135|NCT05014815|Drug|histology-based chemotherapy|Administered intravenously
45352136|NCT05014815|Drug|Placebo|Administered as an intravenous injection
45352137|NCT00355615|Drug|Rosuvastatin|oral
45352138|NCT00355615|Drug|Placebo|oral
45477364|NCT01297907|Other|Methacholine Challenge Test|Methacholine challenge test to evaluate airway hyperreactivity
45477365|NCT01297907|Other|Fractional Exhaled NO (FENO)|Fractional Exhaled NO to evaluate eosinophilic inflammation
45477366|NCT01297907|Other|Blood Test|Blood Tests (Eosinophil Count)
45477367|NCT01297907|Other|PCDAI|Clinical Evaluation for Pediatric Crohn's Disease Activity Index (PCDAI)
45477368|NCT02508064|Drug|BMS-663068|BMS-663068
45477369|NCT05705570|Drug|Cyclophosphamide|Cyclophosphamide 60mg/Kg on day -6
45477370|NCT05705570|Drug|Fludarabine|Fludarabine 25mg/m^2 IV on days -5 to -3
45686346|NCT00072514|Drug|gemcitabine hydrochloride|Given IV
45686347|NCT00072514|Drug|carboplatin|Given IV
45686348|NCT00072514|Drug|dexamethasone|Given PO
45843009|NCT01505166|Drug|Placebo|Patients will receive 1 x 10^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
45843010|NCT01508052|Device|sequential compression device|applying sequential compression device during the surgery
45477371|NCT05705570|Biological|"Chimeric antigen receptor T cells to be implemented in a 3 + 3 design on day 0"|"Level -1 (1 x 105 cells/kg)~Level 1 [Starting dose] (5 x 105 cells/kg)~Level 2 (1 x 106 cells/kg)~Level 3 (2 x 106 cells/kg)"
45477372|NCT01206023|Other|NA-NOSE artificial olfactory system|NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
45686349|NCT00072514|Biological|rituximab|Given IV in CD20-POSITIVE LYMPHOMAS cases
45686350|NCT00074308|Drug|imatinib mesylate|Given orally
45843011|NCT01508052|Device|elastic stockings|applying elastic stockings during the surgery
45352139|NCT00907179|Drug|LBH 589|"LBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and PD studies will be performed (week -1).~Dose level: 1 LBH589: 10 mg Pemetrexed: 500 mg/m2~Dose level: 2 LBH589: 15 mg Pemetrexed: 500 mg/m2~Dose level: 3 LBH589: 20 mg Pemetrexed: 500 mg/m2~Dose level: 4 LBH589: 30 mg Pemetrexed: 500 mg/m2"
45352140|NCT00907179|Drug|Pemetrexed|Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given.
45352141|NCT00347269|Behavioral|Cognitive-behavioral therapy|Participants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.
45843012|NCT01508832|Drug|Lidocaine Digital Nerve Block|Lidocaine 1% Digital Nerve Block (2 cc
45843013|NCT01508832|Drug|Bupivacaine Digital Block|Bupivacaine 0.25% Digital Block (2 cc)
45843014|NCT01509612|Drug|Additive classical homeopathy|Homeopathic remedies every 2 to 3 months
45843015|NCT01509612|Drug|Homeopathic Placebo globules|Homeopathic placebo globules every 2 to 3 months
45352142|NCT00347269|Drug|Psychotropic medication optimization|For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.
45352143|NCT00347269|Behavioral|Treatment as Usual|Participants in the control group will receive standard treatment from their PCP.
45352144|NCT00928473|Behavioral|A family-centered, multidisciplinary obesity treatment program|The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
45352145|NCT01053793|Other|Glycemic response to different varieties of potatoes|the glycemic response top 50g available carbohydrates from 4 potato varieties will be compared to a 50g glucose standard
45477373|NCT02502448|Procedure|Acute normovolemic hemodilution (ANH)|applying acute normovolemic hemodilution (ANH) by using HES 130/0.4 of 5 ml/kg before the initiation of cardiopulmonary bypass
45477374|NCT02502448|Drug|hydroxyethyl starch (HES 130/0.6)|
45843016|NCT01510704|Drug|APD421|IV
45843017|NCT01510704|Drug|Placebo|IV
45843018|NCT01511016|Drug|"Human recombinant leptin (metreleptin)"|Metreleptin was administered at a dose of 0.02 mg / kg body weight for two months, followed by a dose of 0.04 mg / kg for two more months.
45686351|NCT00074308|Biological|bevacizumab|Given IV
45686352|NCT00074308|Other|pharmacological study|Correlative studies
45686353|NCT00074308|Other|laboratory biomarker analysis|Correlative studies
45686354|NCT00159250|Drug|AVI-4658 (PMO)|morpholino antisense oligonucleotide
45686355|NCT00165958|Procedure|Excisional surgery of epidermal cyst|Traditional extirpation of cyst en toto
45686356|NCT00165958|Procedure|Punch incision of epidermal cyst|removal of cyst first with incisional effort with a punch biopsy tool
45686357|NCT01898026|Dietary Supplement|Bread|Samples of white bread, with or without the addition of PGX fibre blend
45686358|NCT01898026|Dietary Supplement|Mashed Potatoes|samples of mashed potatoes, with or without the addition of soluble fibre blend
45686359|NCT01898026|Dietary Supplement|Muffins|Samples of muffins, with or without the addition of PGX fibre blend
45843019|NCT01511016|Drug|Placebo|Placebo was administered at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg / kg for two more months.
45843020|NCT01511640|Drug|Pregabalin|pregabalin 2x daily for duration of study
45843021|NCT01511640|Drug|Placebo|placebo 2x daily for duration of study
45843022|NCT01513122|Drug|Lopinavir / ritonavir|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily
45843023|NCT01513122|Drug|2-3N(t)RTI|
45843024|NCT01513122|Drug|raltegravir|raltegravir 400mg 1 tablet twice daily.
45477375|NCT05684120|Behavioral|Mood Lifters for Undergraduates|Participants will need to attend 14 hour-long virtual weekly meetings on Zoom that focus on helpful mental health strategies and skills. Participants will be encourage to practice what they learn at home in order to improve their mood or mental wellness.
45352146|NCT04034433|Procedure|Handgrip exercise program|Handgrip exercise with a rubber ball 4 weeks before the surgery until 4 weeks after the surgery 20 contractions per minute for a total of 20 minutes each day.
45352147|NCT01056211|Procedure|laser treatment|Starlux 300 Lux 1540nm Fractional laser hand piece
45843025|NCT01513902|Drug|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing <40 kg. Oral tablets will be used for children weighing ≥40 kg. Children aged 12 to less than 18 years who are unable to swallow tablets will have the option of taking oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
45352148|NCT01056211|Procedure|treatment without laser|Starlux 300 Lux 1540nm Fractional laser hand piece
45352149|NCT01056211|Procedure|laser treatment|Starlux 300 Lux 1540nm Fractional laser hand piece
45352150|NCT00924105|Drug|CYT013-IL1bQb|s.c. injection
45352151|NCT00924105|Drug|Placebo|s.c. injection
45352152|NCT00544648|Drug|carboplatin|(AUC 2) through a vein over 30 minutes following nab-paclitaxel, once per week x 7 weeks
45352153|NCT00544648|Drug|nab-paclitaxel|Phase I: beginning at 40 mg/m2 through a vein over 30 minutes once per week x 7 weeks Phase II: Maximum tolerated dose through a vein over 30 minutes once per week x 7 weeks
45352154|NCT00544648|Radiation|Radiation therapy|3D conformal radiotherapy or Intensity-Modulated Radiation Therapy (IMRT), 2.0 Gy per day x 5 days per week for 33 days during Weeks 1-7 ; Total Dose = 66 Gy
45352155|NCT00924183|Other|Treatment-as-usual|
45352156|NCT00346333|Drug|Lutein|12mg/d
45843026|NCT01513902|Drug|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing <40 kg. Oral tablets will be used for children weighing ≥40 kg. Children less than 12 years of age with a body weight of ≥40 kg will have the option of taking oral solution or tablets. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
45352157|NCT00346333|Dietary Supplement|Cornstarch control|Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
45352158|NCT00924261|Other|Hip Stretch|Hip flexor stretch daily for 3 min x 10 weeks
45686360|NCT01898026|Dietary Supplement|Hot Breakfast Cereal|Samples of hot breakfast cereal without the addition of soluble fibre blend
45686361|NCT02501980|Biological|Biomarker testing and Ultrasonography|
45352159|NCT00924261|Other|Shoulder Stretch|Shoulder Adduction stretch - 3 minutes, daily, for 10 weeks
45352160|NCT00928551|Drug|vabicaserin|
45352161|NCT01053871|Drug|propofol|conscious sedation using propofol
45352162|NCT01053871|Drug|midazolam with fentanyl|conscious sedation using midazolam with fentanyl
45686362|NCT00166036|Drug|Atorvastatin|12 Weeks of Oral Atorvastatin 10 mg therapy.
45352163|NCT00984178|Other|Granulocite Colony Stimulating Factor treatment (G-CSF)|G-CSF will be administered at a dose of 10 mcg/kg/day. The administration begins at the first 24 hours post-reperfusion, remaining for 5 days
45352164|NCT00984178|Other|Bone marrow mononuclear cells|Bone marrow mononuclear cells will be isolated with a Ficoll technique from 50 cc of bone marrow aspiration
45352165|NCT04034277|Other|Lee Silverman Voice Therapy|LSVT LOUD® comprises maximum effort non-speech and speech drills. The non-speech drills include the production of 15 sustained 'ah' phonation at high volume and pitch glides (5 repetitions moving from modal pitch to high pitch and 15 repetitions moving from modal pitch and going down on production of sustained 'ah'). The speech drills utilize a hierarchy of speech tasks moving from single words through phrases and onto conversational speech to generalize
45686363|NCT00166036|Drug|Pravastatin|12 Weeks of Oral Pravastatin 80 mg therapy.
45686364|NCT01500135|Drug|TachoSil®|TachoSil® is a sterile, ready-to-use, absorbable patch for intra-operative topical application. It consists of an equine collagen patch coated with fibrin glue components: human fibrinogen and human thrombin.
45686365|NCT01500135|Drug|Surgicel® Original|Surgicel® Original is an absorbable hemostat (oxidized regenerated cellulose)
45843027|NCT01513902|Drug|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Children with a body weight ≥30 kg will have the option of taking oral solution or tablets, and children weighing <30 kg will be dosed with the oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-6 1 1; 7-9 1.5 1.5; 10-12 2 2; 21-15 2.5 2.5; 16-19 3 3; 20-22 3.5 3.5; 23-26 4 4; 27-29 4.5 4.5; ≥30 5 5
45686366|NCT00167206|Procedure|Hematopoietic Stem Cell Transplant|Bone marrow failure may be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
45686367|NCT00167206|Procedure|Thymic Shielding During Radiation|protecting the thymus during total body radiation (450 cGy administered)
45686368|NCT00167206|Procedure|Total Body Irradiation|Six days before the stem cells are given (day -6), subjects will receive total body irradiation with thymic shielding. Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
45686369|NCT00167206|Drug|Cyclophosphamide, Fludarabine|Day -5 through Day -2, subjects will receive a chemotherapy regimen of Fludarabine, Cyclophosphamide via central line
45843028|NCT01514292|Device|Continuous Glucose Monitoring of glucose levels (Dexcom)|Manipulation of glucose levels during multiple clinic days. Achieved through diet, exercise and insulin regimen defined in protocol.Evaluation of CGM performance characteristics in reference to a laboratory standard.
45843029|NCT01515072|Other|RIPC (Remote Ischemic Preconditioning)|Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet. The intervention will consist of tourniquet inflation on the mid-thigh for 5 minutes, followed by a deflation period of 5 minutes for a total of 4 cycles. The intervention will take place at two time points: First, after determination of brain death and consent for organ donation and again upon incision for organ recovery. The second intervention will occur in a manner identical to the first intervention but in the opposite limb.
45352166|NCT04034277|Other|Conventional Treatment|"speech rehabilitation protocol comprehend:~Respiratory and phonatory exercises: exercises to increase diaphragmatic and respiratory functions, exercises to increase expiration time using natural expiration or sibilant, exercise to increase phonation time by pronouncing the vocal /a/, exercise to reduce oral stiffness.~Articulation and prosody exercises: repetition or reading lists of possibly long and complex words that start with or contain consonants groups. Read aloud texts, sentences or words, making sure to articulate and pronounce the words well without diminishing or increasing the rhythm of speech, with the correct punctuation and intonation. If necessary, ask patients to hyperarticulate, accelerate or slow down, or exaggerate intonation."
45352167|NCT01053949|Drug|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
45686370|NCT01475097|Drug|Iodixanol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
45686371|NCT01475097|Drug|Iopamidol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
45686372|NCT04779190|Device|Low-level laser therapy|Gallium-aluminum-arsenide diode laser device
45686373|NCT04779190|Device|Therapeutic ultrasound|Therapeutic pulsed ultrasound with a frequency of 1 MHz
45686374|NCT04779190|Other|Home-based exercise|Home-based exercises 3 days a week; each exercise comprises one set with 5 repetitions over 4 weeks.
45686375|NCT01529385|Device|mild compression diabetic sock|A diabetic sock that provides mild compression (18-25mm Hg) is to be worn everyday for four weeks
45686376|NCT01529385|Device|Standard diabetic sock|A diabetic sock that is not designed to provide compression is to be worn everyday for four weeks
45686377|NCT01474551|Drug|vemurafenib|All patients would be treated with vemurafenib given orally at 960 mg twice a day, which was the phase III dose. One cycle is 4 weeks long.
45686378|NCT02094586|Biological|PXVX0200 Lot A|Lot P700-1CA03
45686379|NCT02094586|Biological|PXVX0200 Lot B|Lot P700-3CA03
45686380|NCT02094586|Biological|PXVX0200 Lot C|Lot P700-6BA03
45843030|NCT01515540|Drug|lidocaine|5% lidoderm patch
45843031|NCT01515540|Drug|placebo|placebo
45352168|NCT01053949|Drug|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
45352169|NCT00928629|Procedure|Ankle-brachial index (ABI) Screening Test|Patients will undergo an ABI measurement
45352170|NCT04005508|Diagnostic Test|Overnight sleep study|The patients will undergo an overnight sleep study using Watch-PAT sleep study device
45352171|NCT00987376|Device|Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy|C11 Choline, C11 Acetate PET and MRI
45352172|NCT00924339|Dietary Supplement|soy protein diet|Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
45352173|NCT00924339|Dietary Supplement|rapeseed oil|Control-Group (n = 15): Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
45352174|NCT00987454|Drug|Epoetin Alfa|40,000 IU given as subcutaneous injection weekly up to 3 doses
45352175|NCT00987454|Drug|Sodium Chloride 0.9%|1 m/L given as subcutaneous injection weekly up to 3 doses
45352176|NCT03986983|Device|Shockwave therapy|Shockwave therapy protocol - The shockwave therapy protocol was performed in the prone position. The application was radial shockwave with 3,5bar, 15Hz of frequency and 3000 impulses.
45352177|NCT03986983|Other|Aerobic exercise|Aerobic exercise protocol - 30 minutes of aerobic moderate-intensity exercise (40% of reserve heart rate) using Karvonen´s formula, performed on a step.
45352178|NCT00924417|Behavioral|Routine Care|Parent given placebo intervention that entails brief information about what is routine care for intravenous line placement in the emergency department
45352179|NCT00924417|Behavioral|Distraction|"Parent given brief information about the cognitive behavioral technique known as distraction. Parent and child then given 3 distraction toys/tools to assist with peripheral intravenous line placement."
45352180|NCT04015245|Drug|Stronger Neo-Minophagen C|intravenous injection after TACE
45352181|NCT03983785|Other|Pilates|In pilates group: Pilates training twice a week for 6 weeks.
45352182|NCT03983785|Other|Elastic taping|Elastic taping group: Elastic taping application after the pilates training twice a week for 6 weeks Wait List
45352183|NCT00924495|Device|transcranial magnetic stimulation|rTMS therapy daily for two weeks, five times per week each lasting for half an hour
45352184|NCT04005664|Drug|Phenylephrine|Prophylactic phenylephrine infusion as part of fluid coload
45686381|NCT02094586|Biological|Placebo|Placebo
45352185|NCT00928785|Biological|REPEVAX|1 dose of 0.5 mL at Day 0
45352186|NCT00928785|Biological|Monovalent Tetanus vaccine|1 dose of 0.5 mL at Day 0
45352187|NCT00330967|Drug|20% Intralipid|lipid infusion
45352188|NCT00928863|Other|implementation aids|testing a taylor made strategy for implementation NVOG guideline and MOET instruction in 3 hospitals
45352189|NCT03983629|Other|Collection of data and genetic analysis|Data collected are: History of disease, medical history, family medical history, biological results, Imaging results, disease progression Genetic analysis will be performed with whole genome and whole exome sequencing
45352190|NCT00987610|Device|Percutaneous coronary intervention (PCI)|PCI for chronic total occlusion is performed using either arm of guidewire
45352191|NCT00924573|Drug|Metformin|oral administration
45352192|NCT00924573|Drug|placebo|oral administration
45352193|NCT00924573|Drug|Glimepiride (HOE490)|oral administration
45352194|NCT01054027|Drug|1% phenylephrine and 0.2% cyclopentolate|given as drops, prior to eye exam
45686382|NCT02985645|Procedure|maxillary sinus augmentation with CGF|Graftless maxillary sinus augmentation surgery with CGF application utilizing DIVA system
45686383|NCT02985645|Device|"dynamic implant valve approach - DIVA system"|The DIVA system will be used to apply the CGF to the maxillary sinus.
45686384|NCT01500057|Device|Greenlight XPS Laser|Treatment of BPH with Greenlight XPS laser
45352195|NCT00928941|Behavioral|cognitive training|A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units/hours.
45352196|NCT00928941|Behavioral|video game|An active control condition (computer game without increasing difficulty) will be implemented for at least 3-4 hours a week for 40 hours.
45352197|NCT01054105|Drug|Iloprost|Iloprost inhalation, 2.5 - 5mcg, 6 times per day
45352198|NCT00987688|Other|Hypothermia|exposure: Early and sustained hypothermia. Hypothermia will initially be induced by infusion of up to 2L ice cold saline. Following a safety assessment the patient will be rapidly cooled to 33C using surface temperature control equipment. They will be maintained at 33C for 72 hours. Rewarming will occur at a rate of 1C/4hrs and will be titrated to intracranial pressure (ICP) control and BP.
45686385|NCT01500057|Device|BiVAP Saline Vaporization of the prostate|treatment of BPH with BiVAP Saline Vaporization
45686386|NCT02094664|Device|Heated and humidified oxygen|
45686387|NCT01499667|Drug|Fingolimod|Fingolimod 0.5 mg capsules for oral administration once daily
45352199|NCT05277597|Diagnostic Test|The exercise 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.|Participants in the group ET+S (n=8) exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.Blood and stool samples were collected before and after the 4-week training program.
45352200|NCT05277597|Diagnostic Test|The same exercise training program without the sauna treatments|The control group (ET, n=7) engaged in the same exercise training program without the sauna treatments. Blood and stool samples were collected before and after the 4-week training program.
45352201|NCT00907413|Procedure|ERCP and Photodynamic Therapy|Photodynamic Therapy is a new therapeutic approach that specifically targets neoplastic cells. This therapy has been used in other tumors as a local treatment and involves the intravenous administration of a photosensitizing agent followed by activation of the agent by illumination with non-thermal light of a specific wavelength, resulting in cell death from direct cytotoxicity and ischemic necrosis. Cytotoxicity is directly proportional to tissue oxygenation.
45352202|NCT00907413|Procedure|ERCP only|Endoscopic retrograde cholangiopancreatography and stenting.
45352203|NCT00330343|Drug|naloxone|continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour
45352204|NCT00987766|Drug|erlotinib hydrochloride|Taken daily by mouth for 6 days every other week.
45477376|NCT03839615|Procedure|guided bone regenerations|"intra oral procedures.~Flap will be done.~In the study group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks.~In the control group: : bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral and packed at the defected area then covered by a titanium reinforced polytetraflouroethelene membrane which will be stabilized by tacks.~The site will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
45352205|NCT00987766|Drug|gemcitabine hydrochloride|Given through a vein in the arm 1 time every other week.
45477377|NCT02502370|Drug|observation alone|
45477378|NCT02502370|Drug|LV5FU2|
45477379|NCT02502370|Drug|FOLFOX|
45352206|NCT00987766|Drug|oxaliplatin|Given through a vein in the arm 1 time every other week.
45477380|NCT03829709|Other|Rehabilitation|The first training session each week will be held at the LAERF under the direct supervision of the investigator and the other two home-based training sessions under the supervisor's distance supervision. They will receive the Threshold® IMT linear loading device, and guidelines for handling, posture and asepsis. The initial training load for each participant will be adjusted to 25% of PiMáx. Participants will be trained and instructed to do the exercise program on their own at home. Once a week, during the return to the laboratory the researcher will determine the new values for load (1st week 25%, 2nd week 35%, 3rd week 40%, 4th week 45%, 5th week 50%).
45477381|NCT02502136|Procedure|carbon dioxide insufflation during endoscopy|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
45352207|NCT00987766|Other|laboratory biomarker analysis|Blood and tissue collection.
45352208|NCT00984412|Procedure|Allogeneic hematopoietic stem-cell-transplantation|2 allogeneic BMTs 6 weeks apart
45352209|NCT04005430|Drug|Episcleral Dexamethasone|Sequestered Transscleral, Controlled-Release Dexamethasone
45477382|NCT02502136|Procedure|Room air insufflation during endoscopy (Placebo)|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
45477383|NCT05670236|Drug|Lidocaine Hydrochloride|10 mL of 1% lidocaine hydrochloride for each intraarticular knee injection
45477384|NCT01206179|Biological|cell injection|Injection of mesenchymal cells in fractured zone
45352210|NCT00330187|Drug|Bupropion SR|Bupropion SR, with goal dose 300 mg/day, for 6 weeks of active treatment
45352211|NCT00330187|Behavioral|Contingency Management|Contingency Management provided at twice-weekly visits during the 6-week active treatment. Escalating schedule, with resets, reinforcing smoking abstinence.
45352212|NCT00330187|Other|Placebo|Placebo, matched in appearance to Bupropion SR, for 6 weeks of treatment
45352213|NCT00987844|Drug|Prucalopride|1 mg tablets, free dosing regiment with max. of 4 tablets o.d., treatment duration: up to 24 months
45352214|NCT01056445|Procedure|valsalva maneuver|valsalva maneuver after carotid stenting
45477385|NCT03214380|Drug|LY900014|Administered SC
45477386|NCT03214380|Drug|Insulin Lispro|Administered SC
45477387|NCT03214380|Drug|Insulin Glargine|Administered SC
45477388|NCT03214380|Drug|Insulin Degludec|Administered SC
45352215|NCT01056445|Procedure|valsalva maneuver|valsalva maneuver after carotid stenting
45352216|NCT04006132|Device|Fitting of Ponto 3 SuperPower|Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting two bone-anchored sound processors (Ponto 3 SuperPower) to patients that are already bilaterally implanted with abutments.
45477389|NCT03214380|Drug|Metformin|Administered orally.
45477390|NCT03214380|Drug|SGLT2 inhibitor|Administered orally.
45477391|NCT03344224|Diagnostic Test|laboratory test|laboratory test
45477392|NCT05669612|Dietary Supplement|Dairy based protein|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
45477393|NCT05669612|Dietary Supplement|Mixed protein|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
45352217|NCT03986905|Drug|Scopolamine Nasal Gel|All subjects will receive both a patch and nasal gel: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, or placebo nasal gel + TDS patch.
45352218|NCT03986905|Other|Placebo|placebo nasal gel + placebo patch
45352219|NCT05711602|Other|Pilates|raining based on a basic level Pilates exercise program will be as follows: A duration of weeks with a frequency of 2 sessions a week and with a duration of 55 minutes each. The exercises to be performed will be divided into three distinct phases: warm-up, lasting 15 minutes; Main part with a duration of 30 minutes and the return to calm, based mostly on stretching and with a duration of 10 minutes. The repetitions of the exercises will be between 5 and 10 according to the difficulty.
45352220|NCT04713280|Procedure|Maxillary posterior dento-alveolar intrusion|Mini-screw supported maxillary or bi-maxillary posterior dento-alveolar intrusion
45477394|NCT05669612|Dietary Supplement|Plant-based protein 1|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
45352221|NCT00987922|Device|Hypothermia|Hypothermia to core temperature of 35C for 12 hours, rewarming rate 0.2C until the patient reaches 36.8C
45352222|NCT03595774|Dietary Supplement|Beet root juice|Beet root juice
45477395|NCT05669612|Dietary Supplement|Plant-based protein 2|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
45477396|NCT02502058|Device|Densah Bur™ , osseodensification|Densah™ bur (Versah Osseodensification Company™) is used to prepare dental implant sites, in human subjects, by compacting (osseodensification ) bone vs. removing bone to create the opening in the jaw bone into which the dental implant is then placed. This osseodensification process results in increased bone-ridge width, increased compact bone in the outer wall of the prepared sites, and; it is believed, increases implant stability.
45477397|NCT03819179|Other|Burt's Bees Serum|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol.
45477398|NCT03819179|Other|Burt's Bees Serum with Biulin|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, PreBIULIN FOS (GOVA).
45477399|NCT03819179|Other|Burt's Bees Serum with Bonicell|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, Bonicel (Ganaden).
45477400|NCT03819179|Other|Burt's Bees Serum with Berenew Complex|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, BeRenew CLR Complex (CLR).
45477401|NCT03819179|Other|Burt's Bees Serum with Ecoskin|This is a commercially available over-the-counter product. Ingredients: Caprylic/Capric Triglyceride, Dimer Dilinoleyl Dimer Dilionoleatem, Silica, Citronellyl Methylcrotonate, Tocopheryl Acetate, Xymenynic Acid, Alpha-glucan Oligosaccharide, Fragrance, Slareolide, Polymnia sonshifolia root juice, Helianthus annuus (sunflower) seed oil, Maltodextrin, Tocopherol, Beta-sitosterol, Lactobacillus, Squalene.
45477402|NCT04498234|Procedure|ultrasound guided erector spinae plane block with bupivacaine 0.25% And ultrasound guided Paraveretebral block with bupivacaine 0.25 %|One groupvwill receive 0.25% bupivacaine (20 ml ) into interfascial plane below erector spinae muscle at level of T4 and the other group willreceive (0.3 ml /kg ) 0.25% bubivicaine divided equially at each level of T2 , T4 and T6 at thoracic paravertebral space .
45477403|NCT01206257|Drug|Iopromide (Ultravist, BAY86-4877)|Intravenous/intraarterial digital subtraction angiography (DSA); Generally doses of up to 1.5 g iodine per kg body weight are well tolerated.
45477404|NCT03343444|Drug|12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)|Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 12 weeks
45477405|NCT03343444|Drug|8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)|Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 8 weeks
45477406|NCT03819023|Diagnostic Test|Respilife monitor|Respilife monitor
45477407|NCT04498390|Drug|LY3493269|Administered orally.
45686388|NCT01499667|Drug|Placebo|Matching placebo in capsules for oral administration once daily.
45686389|NCT00168298|Drug|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
45686390|NCT00168298|Drug|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
45686391|NCT00168298|Other|Sham Injection|Sham injection on Day 0.
45686392|NCT01474317|Device|G3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.
45352223|NCT04914286|Drug|GFH018|Subjects are planned to be dosed in oral GFH018 tablets twice daily for a continuous 14 days in a 28 days cycle (7days on 7days off may be tested based on available data from phase I dose escalation study of single agent). the starting dose of GFH018 will be derived from the maximum safe dose explored in rom phase I dose escalation study of single agent.
45477408|NCT04498390|Drug|Placebo|Administered orally.
45477409|NCT03819101|Drug|Acetylsalicylic acid|100mg
45477410|NCT03819101|Drug|Atorvastatin|80 mg
45843032|NCT01515696|Drug|Gastrografin|Patients will receive 3ml Gastrografin + 6ml sterile water/kg as a single dose via a nasogastric tube during the first 24 hours of life.
45843033|NCT01515696|Drug|Sterile water|Patients will receive 9ml/kg sterile water as a single dose via a nasogastric tube during the first 24 hours of life.
45477411|NCT05705102|Other|Coronary intervention|Coronary intervention will be done immediately in patients with OMI (even STEMI criteria are negative), instead of waiting for <24h.
45686393|NCT00075088|Device|Electrocardiogram (ECG) Intervention|"Pre-hospital electrocardiographic (ECG) monitoring with special software to detect myocardial ischemia and to automatically transmit an ECG to the destination hospital emergency department with a voice alarm announcing Incoming ECG from the field and print out in the ED."
45686394|NCT00075088|Other|Routine Clinical Practice|ECG in the ED as part of routine clinical practice.
45843034|NCT01516632|Behavioral|SMS USA|Intervention participants receive text messages daily pre-and post-quit. Everyone receives messages 14 days prior to the Quit day, and through the day after Quit. Then, participants are 'pathed' to particular messages based upon their self-reported smoking status at Day 2 and Day 7 post quit, respectively. Those who are successful at quitting receive messages aimed at relapse prevention whereas those who have slipped receive messages aimed at getting the person to recommit to quitting and trying again.
45843035|NCT01518270|Other|No treatment|No treatment will be provided
45843036|NCT01519284|Drug|BIA 9-1067 5 mg|BIA 9-1067 OPC, Opicapone 5 mg
45843037|NCT01519284|Drug|Entacapone|Entacapone 200 mg
45843038|NCT01519284|Drug|Placebo|placebo (four times a day)
45352224|NCT04914286|Drug|Toripalimab|Subjects are planned to be dosed at 3 mg/kg Toripalimab as an intravenous infusion once every 2 weeks.
45477412|NCT02501746|Other|Usual Clinical Care|Non-hypertensive diabetic individuals will not be pharmacologically treated for BP reduction; those with BP 120-139/80-89 will be advised on lifestyle changes to reduce BP as recommended by the 2013 Standards of Medical Care in Diabetes. Care will be provided to each individual at the rural health facility by a rural clinician mentored by the CDM Program, including regular monthly consultation, vital signs, physical examination, and prescriptions. CHWs will assist with linkage and retention of patients to the care program, and provide health education. The 12-month follow-up BP will be measured in the rural health facility, in order to mimic real-world practice. If the patient does not present to the rural health facility for the 12-month visit, the local CHW will trace the patient at home and will check the 12-month BP at that time, again consistent with real-world conditions.
45352225|NCT04864444|Drug|Dihydroartemisinin-piperaquine|DHA-PPQ will be given over the course of three consecutive days using 160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets. DHA-PPQ will be administered via age-based dosing. All three doses will be directly observed and given orally with water and without food.
45477413|NCT02501746|Other|Group Medical Visits|"The CHW will facilitate a group discussion about a self-care or health education topic chosen by the group while the rural clinician reviews the BP, sugar, and adherence data to determine a clinical recommendation as per the CDM clinical algorithm. which is communicated to each individual patient privately by the rural clinician in a five-minute breakout time. The rural clinician will not change the regimen for non adherence but instead will use the breakout time to assess barriers to adherence and try to help the patient identify solutions to those barriers.The breakout time can also be used to perform a physical examination or other assessments as clinically required. After all patients have had individual consultations with the rural clinician, the entire group re-convenes for a closing session, which consists of a question-and-answer period and determination of the next session's self-care or health education topic."
45477414|NCT02501746|Other|Microfinance Groups|The rural clinician and the CHW will organize a meeting with AMPATH's Safety Net Program representatives, who will introduce the concept of microfinance groups, the potential benefits, and encourage the formation of new groups to meet monthly. The microfinance groups need to incorporate an element of self-selection and self-formation, so that individuals have the freedom to choose with whom they will create a group. The groups are therefore formed voluntarily, and usually along geographical boundaries, which facilitates participation, retention, and meeting logistics.
45352226|NCT04864444|Drug|Primaquine|Primaquine will be given once with the first dose of DHA-PPQ. Primaquine will be administered in an aqueous solution according to age-based dosing guidelines.
45477415|NCT05704010|Device|Video capsule endoscopy|Video capsule endoscopy every 2 years
45477416|NCT02507674|Device|ultrasound|
45477417|NCT05199324|Drug|Oral fluoroquinolones (most commonly, ciprofloxacin) or oral trimethoprim-sulfamethoxazole|Clinically stable / non-critically ill inpatients with uncomplicated Gram-negative bacteraemia randomised to the intervention arm will be switched early to oral antibiotics (within 72 hours from index blood culture collection)
45477418|NCT05199324|Drug|Standard of care intravenous antibiotics (e.g. ceftriaxone, cefazolin)|Clinically stable / non-critically ill inpatients with uncomplicated Gram-negative bacteraemia randomised to the standard arm will continue to receive an active intravenous antibiotic therapy for at least another 48 hours post-randomisation before clinical re-assessment and decision making by the treating doctor
45477419|NCT03818867|Procedure|Insertion of cervical cerclage|insertion of a stitch around the neck of the womb in order to provide extra support.
45477420|NCT03343366|Drug|Metronidazole|Systemic AAT would contain Metronidazole (MET) 400 mg x 3 for 10 days
45477421|NCT03343366|Procedure|Scaling Root Planing|SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth.
45477422|NCT03343366|Behavioral|Oral Hygiene Instructions|OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.
45477423|NCT05044416|Device|VieScope|intubation with VieScope laryngoscope
45477424|NCT05044416|Device|Videolaryngoscopy|intubation with videolaryngoscope
45477425|NCT05622773|Other|Mat use application|In the research, repeated measurements will be made by using mats and foot baths in a single group and the data will be recorded.
45477426|NCT02507518|Procedure|PET scan imaging|a PET scan will be done 2 weeks before the start of maintenance therapy and another 16 days after to predict the earlier response to treatment
45477427|NCT01298297|Drug|Buprenorphine|0.4 mg, SL (sublingual) Buprenorphine PLUS 5 ml Placebo IV (in the vein)
45477428|NCT01298297|Drug|Morphine|Placebo SL PLUS 5 ml Morphine sulfate (1mg/ml) IV
45477429|NCT04498312|Other|Extracorporeal shock wave|The participant was placed into supine lying position then the head of the shock wave was applied on the anterior or posterior aspect of the thigh which was scanned with 2000 shots for both horizontal direction and vertical direction. The period of each session was 15 minutes, 2 times/week for 4 weeks
45477430|NCT01300715|Procedure|lumbar medial branch radiofrequency neurotomy|the classic tunnel vision technique versus the alternative technique
45843039|NCT01519284|Drug|levodopa/carbidopa|standard release levodopa/carbidopa 100/25 mg (single-dose)
45843040|NCT01519284|Drug|BIA 9-1067 15 mg|BIA 9-1067 OPC, Opicapone 15 mg
45352227|NCT03914950|Diagnostic Test|PET/CT results with TOF/without TOF|"Diagnostic CT of the abdomen or upper abdomen with parenteral contrast medium (Visipaque=Iodixanol) if creatinine, GFR, and TSH levels are within the normal range and oral (water) contrast medium within TOF-18F-FDG PET/CT. In the case of elevated creatine or decreased GFR or TSH levels a diagnostic CT of the abdomen or upper abdomen without contrast medium is performed.~Biopsy or FNA or operation of the pancreas."
45352228|NCT00329797|Dietary Supplement|Calcium|A single dose of 500 mg of elemental calcium orally each day for 3 years.
45843041|NCT01519284|Drug|BIA 9-1067 30 mg|BIA 9-1067 OPC, Opicapone 30 mg
45352229|NCT00329797|Dietary Supplement|Zoledronic acid|Patients receive IV over 15 minutes once every 6 months for 3 years. The goal dose of zoledronic acid is 4 mg, but the selection of dose is determined based on calculated creatinine clearance at baseline.
45352230|NCT00329797|Radiation|radiation therapy|Patients must receive external beam irradiation, brachytherapy (HDR or LDR), or a combination of external beam irradiation and brachytherapy at the discretion of the treating physician. Dose/duration also will be at the discretion of the treating physician; however, dose will not exceed 45 Gy to 100% of the proximal femur, and no proximal femur will receive ≥ 60 Gy.
45352231|NCT00329797|Drug|LHRH|LHRH therapy must take place for a minimum of one year. Choice of LHRH agonist, dose, and duration are at the discretion of the treating physician.
45352232|NCT00329797|Dietary Supplement|Vitamin D|400 IU (10μg), orally each day for 3 years.
45352233|NCT00541450|Drug|Comparator: sitagliptin phosphate (sitagliptin)|sitagliptin 100 mg tablet q.d. orally for a 12-wk treatment period
45352234|NCT00541450|Drug|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/metformin HCl (Sita/Met) 50/500 mg b.i.d. orally and then 50/1000 mg b.i.d. orally for a 28-wk treatment period
45352235|NCT00541450|Drug|Comparator: pioglitazone|pioglitazone 15 mg tablet q.d. orally for 6 weeks, followed by 30 mg q.d orally for 6 weeks, followed by 45 mg q.d. orally, up to 40 weeks.
45352236|NCT00541450|Drug|Matching placebo to pioglitazone|"matching placebo to pioglitazone tablet q.d. orally, for a 40-wk treatment period.~Participants were administered matching placebo the 15 mg pioglitazone q.d. orally for 6 weeks, followed by matching placebo to 30 mg pioglitazone q.d orally for 6 weeks, followed by matching placebo to 45 mg pioglitazone q.d. orally, up to 40 weeks."
45352237|NCT00541450|Drug|Matching placebo to sitagliptin|matching placebo to sitagliptin q.d., orally for a 12-wk treatment period.
45352238|NCT00541450|Drug|Matching Placebo to Sita/Met FDC|matching placebo to Sita/Met FDC - 50/500 mg b.i.d. for 4 weeks and then 50/1000 mg b.i.d. orally for a 28-wk treatment period (Week 12 to Week 40).
45352239|NCT03989635|Drug|QAW039|QAW039 450mg
45352240|NCT03986827|Behavioral|Cool Kids Anxiety Program - Social Enhanced|Specific G-CBT intervention for adolescents with social anxiety disorder
45843042|NCT01520454|Drug|Saline|IV saline at 0.83 mL/kg/hr for six hours
45843043|NCT01520454|Drug|Intralipid|Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
45352241|NCT03986827|Behavioral|Cool Kids Anxiety Program|Generic G-CBT intervention for adolescents with anxiety disorders
45352242|NCT01054261|Drug|avanafil|200 mg avanafil tablet QD
45352243|NCT01056679|Drug|Doxorubicine|50mg/m2 day 1 + 15
45352244|NCT01056679|Drug|DTIC|375mg/m2 day 1 + 15
45843044|NCT01520454|Dietary Supplement|Water|Water by mouth
45843045|NCT01520454|Dietary Supplement|oral fat|Soybean oil by mouth at 1.25 g/kg x 2 doses
45843046|NCT01520454|Drug|Heparin|Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours
45352245|NCT01056679|Drug|Lenalidomide|day 1 - 21
45352246|NCT01056679|Drug|Vinblastine|6mg/m2 day 1 + 15
45352247|NCT03989791|Dietary Supplement|absolute diet|Patients in absolute diet group were fasted from any food with intravenous infusion of 5% glucose and sodium chloride instead in the first 24 hours. Then, the patients will be given soup for the next 24 hours if there was no delayed complication or discomfort during the fasting. Finally, they will gradually transit from soup to normal diet such as porridge, noodles and rice in the third 24 hours.
45352248|NCT03989791|Dietary Supplement|normal diet|Patients in normal diet group were directly given normal diet such as porridge, noodles and rice as usual after polypectomy. Meanwhile, all the patients in two groups were given PPI for 3 days intravenously and restricted from vigorous exercise for 14 days.
45352249|NCT00355147|Behavioral|Physician stroke guideline adherence|Provided clinicians with Secondary Stroke Prevention Guidelines/Posted near workstations for Discharge Planning and Provided Clinicians with Seminar on Motivational Interviewing and Goal Setting to Modify Patient Health Behaviors
45352250|NCT00355147|Behavioral|Stroke Self Management|Provided Post Stroke Guidelines on Secondary Prevention to Clinicians Preparing Discharge Plans; Provided Secondary Stroke Self-Management and Stroke Peer Support to Veteran Patients with Stroke/TIA
45352251|NCT00355147|Other|Attention Control Group|Received Phone Calls from Staff to Control for Attention
45843047|NCT01520532|Other|Magnetic Resonance Imaging (MRI)|MRI's will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at the Pre-Discharge will undergo an MRI at the 1 month follow-up visit.
45352252|NCT05711368|Behavioral|Distress tolerance training|It consisted of seven sessions. A 90-minute session will be conducted twice a week for four weeks. The first introductory session will be concerned with helping the student learn how to engage in distress tolerance training and define goals of distress tolerance. At the end of the 1st session, a written plan for every session (time, duration and setting) will be scheduled individually with each student.The next six training sessions will cover three core skills which comprised three sets: Crisis Survival Skills, the skills of Reality Acceptance; and the Skills When the Crisis Is Addiction. The distress tolerance training methods will include individualized interactions, demonstration, and rehearsal, psychoeducation, practice exercises and homework assignments. Follow up between sessions will done using telephone calling and messaging in order to encourage performance homework assignments, and provide help and support when needed particularly at the time of stress. .
45352253|NCT04769362|Drug|Discontinuation of β-blocker|Discontinuation of β-blocker after at least 1 year of β-blocker therapy after acute myocardial infarction
45352254|NCT03983551|Drug|Dipeptidyl Peptidase 4 Inhibitor|Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily
45352255|NCT03983551|Drug|Sulfonylurea|Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily
45477431|NCT02674464|Behavioral|Provider Audit-Feedback, Stratified by Race and Ethnicity|Transparent and timely access to and review of clinical performance data are among the key elements of successful improvement activities. The RICH LIFE Project provides the health systems with the logic to build practice and provider level hypertension (HTN) dashboards, support in building the dashboard, and education in utilizing the dashboard. The practice dashboard provides a display of the percentage of patients achieving BP control, defined as <140/90 mm Hg for the overall practice, while the provider dashboard provides a display of the percentage of patients achieving BP control for each provider's patient panel. Both the practice and provider Dashboards stratify hypertension performance data by race (White, non-Hispanic; Black, non-Hispanic; and All Hispanic) to help practice administration and clinicians evaluate differences between races and ethnicities in BP control rates. New reports are generated at least quarterly and will display data from the previous 3 months.
45477432|NCT02674464|Behavioral|Blood Pressure Measurement Standardization|"All adult medicine staff at participating study practices receive standardized, evidence-based, best practices BP measurement training. Aspects of the training include proper patient preparation and positioning, how use of an automated BP measurement device, and executing a screen and confirm protocol when measuring patients' blood pressures."
45352256|NCT05709574|Drug|Tadalafil 20 MG|Tadalafil 20 mg tablets will be taken daily for 2 weeks alone and then for 8 weeks in combination with neoadjuvant chemotherapy in the window between gastric/GEJ adenocarcinoma diagnosis and interventional surgery.
45352257|NCT04767100|Device|Social telepresence robot|Use of a social telepresence robot at home, during three months with the aim of reducing the feeling of loneliness and social isolation among the elderly.
45352258|NCT05706142|Other|Motor Imagery Education|"Within the scope of motor imagery training, a presentation will be made to the students of pediatric rehabilitation lecture in the intervention group about what motor imagery is. PETTLEP model will be used for imagery training. In this model, imagery training will be prepared in accordance with our purpose, taking into account the physical, environmental, time, task, learning, emotion and personal subheadings. In the training sessions, relaxation exercises will be given for 5 minutes first. After the relaxation exercises, special colic massage imagery training will be given to newborns for 10 minutes. The massage will also be shown as practically at class."
45686395|NCT00076258|Behavioral|SSRI + LD|Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
45843048|NCT01520688|Drug|Fluticasone, Budesonide, Beclomethasone|Fluticasone 100 mcg bid Budesonide 180 mcg bid Beclomethasone 80 mcg bid
45843049|NCT01520688|Drug|Fluticasone, Beclomethasone, Budesonide|Fluticasone 100mcg BID Beclomethasone 80 mcg BID Budesonide 180 mcg BID
45843050|NCT01520688|Drug|Budesonide, Fluticasone, Beclomethasone|Budesonide180 mcg BID Fluticasone 100 mcg Beclomethasone 80 mcg BID
45843051|NCT01520688|Drug|Budesonide, Beclomethasone, Fluticasone|Budesonide 180 mcg BID Beclomethasone 80mcg BID Fluticasone 100mcg BID
45843052|NCT01520688|Drug|Beclomethasone, Fluticasone, Budesonide|Beclomethasone 80 mcg BID Fluticasone 100mcg BID Budesonide 180 mcg BID
45843053|NCT01520688|Drug|Beclomethasone, Budesonide, Fluticasone|Beclomethasone 80mcg BID Budesonide 180 mcg BID Fluticasone 100mcg BID
45352260|NCT04740034|Drug|AMG 340|AMG 340 is a bispecific antibody targeting prostate-specific membrane antigen (PSMA) on tumor cells and CD3 on T-cells
45352261|NCT04732936|Device|Temporary Peripheral Nerve Stimulator|Temporary Peripheral Nerve Stimulator to deliver 1-hr of electrical stimulation to injured nerves.
45352262|NCT05546242|Drug|Cabotegravir/Rilpivirine|injectable long-acting cabotegravir 600mg + long-acting rilpivirine 900mg administered every 2 months
45352263|NCT05546242|Drug|Antiretroviral|Oral antiretroviral therapy in the form of 2NRTIs + dolutegravir 50mg administered daily
45352264|NCT04004494|Other|3D reconstruction|3-dimensional computed tomography reconstruction guided VATS segmentectomy
45352265|NCT05705908|Other|Hot Foot Bath 1|"Hot foot bath device has a built-in heater (max. 44°C),~Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water)."
45352266|NCT05705908|Other|Hot Foot Bath 2|"Hot foot bath device has a built-in heater (max. 44°C),~Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water).~3 drops of lavender essential oil were dripped in the water"
45352267|NCT05690464|Dietary Supplement|magnesium glycinate supplement|magnesium glycinate (480 mg/day)
45352268|NCT05690464|Dietary Supplement|placebo|placebo
45352269|NCT04268914|Device|Oculus Go VR|The Oculus Go is a standalone headset with built-in speakers that runs independently of a smartphone. Via the Oculus Go, participants will engage with BearBlast (developed by AppliedVR). Throughout the world, plush moles play the role of antagonist, standing in for the nuisance and distraction of pain. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. The VR HMD runs independently of a smartphone and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image.
45352270|NCT04268914|Device|Mira Prism VR|The Mira Prism is a portable, augmented reality (AR) HMD powered by iPhone. When paired with the iPhone, the Mira Prism goggles can superimpose computer-generated images on the user's view of the real world. Unlike the full immersion of VR, AR allows users to view the outside world while interacting with digital content. In this study, the patient will interact with Magic Mallet (developed by Miney Moe) until falling asleep during the anesthesia induction process. Magic Mallet is a distraction game designed for pain management and communication during procedures. The game automatically adjusts cognitive load for optimal effect for users. Study team iPhones specifically loaded with Magic Mallet, and without cellular capability, will be used with the Mira Prism.
45843054|NCT01521546|Drug|eplerenone|25mg tablet, once daily by mouth for 12 months
45352271|NCT04697212|Behavioral|Healthcare team- + patient-directed intervention|"Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities, and will also complete a patient prompt list that elicits strategies that they prefer the healthcare team to use during their visit."
45352272|NCT04697212|Behavioral|Healthcare team-directed intervention|Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities.
45352273|NCT04690504|Other|dim light melatonin onset (DLMO)|A series of saliva samples will be collected and assayed for melatonin so that the timing of melatonin secretion onset can be determined.
45352274|NCT00540124|Drug|Tadalafil|5 mg once a day
45352275|NCT00540124|Drug|Placebo|once a day
45352276|NCT00540124|Drug|Tamsulosin|0.2 mg once a day
45352277|NCT00540046|Device|Copper T 380A IUD|Copper T 380A IUD will be placed at the 2-4 week post-operative visit.
45352278|NCT05525572|Device|Shockwave Therapy (SWT)|"Shockwave Therapy (SWT):~720 shocks will be administered administered in every session to each treated region (left and right corpora cavernosa and crura). Each session will last approximately 20 minutes. A total of 3600 shocks will be administered over 5 weekly sessions."
45352279|NCT05525572|Drug|Autologous Platelet-Rich Plasma (PRP)|"Autologous Platelet Rich Plasma (PRP):~5 mL PRP will be administered via intra-cavernous penile injection with a 30 ± 7 day treatment interval."
45352280|NCT05677126|Drug|Tralement|Tralement with Manganese
45352281|NCT05677126|Drug|Fixed-dose trace element combination product of zinc, copper, and selenious acid|Tralement without Manganese
45352282|NCT04613830|Drug|Bupivacaine Hydrochloride|The patient will be placed in a sitting position under complete aseptic condition and a cover sheath will be used for the ultrasound probe with an appropriate amount of lubricating gel applied on the probe, a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the L3 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. then injecte bupivacaine hydrochloride
45352283|NCT04613830|Drug|Tramadol hydrochloride|Patients in group Tramadol will intravenously administrate dose of 1 mg/kg/8hr tramal to be increased upon patient needs up to 2mg/kg/6hr as rescue analgesic
45352284|NCT04599166|Behavioral|Who Would You Choose: Serious Fun|"Who Would You Choose: Serious Fun is a conversation activity that prompts players (using scenarios and metaphors) to choose a spokesperson whose qualities are best suited to the role. At the end of the activity, players identify a real-life spokesperson based on the qualities considered during gameplay."
45352285|NCT04573660|Device|Coronary and peripheral stents|The participants in the Coronary and peripheral stents arm will receive Coronary and peripheral stents
45352286|NCT04573660|Device|Pacing catheters|The participants in the Pacing catheters arm will receive Pacing catheters
45352287|NCT04573660|Device|Vascular plugs|The participants in the Vascular plugs arm will receive Vascular plugs
45352288|NCT04573660|Device|Measurement and imaging (FFR and OCT)|The participants in the Measurement and imaging (FFR and OCT) arm will receive Measurement and imaging (FFR and OCT)
45352289|NCT04573660|Device|Peripheral dilatation catheters|The participants in the Peripheral dilatation catheters will receive Peripheral dilatation catheters
45352290|NCT04573660|Device|Coronary dilatation catheters|The participants in the Coronary dilatation catheters will receive Coronary dilatation catheters
45352291|NCT04573660|Device|Coronary and peripheral guidewires|The participants in the Coronary and peripheral guidewires will receive Coronary and peripheral guidewires
45352292|NCT04573660|Device|Vessel closure/compression devices|The participants in the Vessel closure/compression devices will receive Vessel closure/compression devices
45843055|NCT01521546|Drug|placebo|one tablet by mouth daily for 12 months
45843056|NCT01521780|Procedure|MRI|Participants undergo volumetric & diffusion weighted (DW) MRI. Participants are scanned twice, with an intervening fifteen minute walk between the scans.
45843057|NCT01521780|Procedure|Pathology|Participants who are undergoing surgical resection of HCC per their standard of care treatment, will submit tumor samples for biomarker analysis.
45352293|NCT04573660|Device|Vascular access introducers|The participants in the Vascular access introducers arm will receive Vascular access introducers
45352294|NCT05676892|Procedure|Laparoscopic cholecystectomy|"Method of operation~Surgery was started under general anesthesia~A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~The trocar was removed, and the skin was sutured"
45352295|NCT00689936|Drug|Lenalidomide and low-dose dexamethasone|"Lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg 20mg, or 25 mg capsules, given either days 1-21 of each 28 day cycles or given every other day for 21 days until documentation of PD.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle up to disease progression"
45843058|NCT01521780|Procedure|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml. During Visit 3, blood samples totaling 22 ml, are collected at least 6-18 hours post-resection, and every other day up to a week until discharge. At follow up Visit 4, 5.5 ml of blood is collected.
45686396|NCT00076258|Behavioral|SSRI + PHD|Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
45843059|NCT01521780|Procedure|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml, and follow up Visit 4 - 5.5 ml.
45843060|NCT01523496|Drug|Vitamin D control dose|18,000 IU per month
45843061|NCT01523496|Drug|Vitamin D supplementation-|60,000 IU per month(medium dose) or 120,000 IU/month(high dose)
45843062|NCT01523808|Drug|GRASPA|Each patient will receive one administration of GRASPA . A stepwise increase of 4 single doses of GRASPA will be administered to cohorts of 3 patients per dose
45686397|NCT00078286|Drug|Sertraline|Dosage ranging from 50 mg to 200 mg once a day
45843063|NCT01523964|Other|Testing with EIM|
45843064|NCT01526538|Drug|d-cycloserine|50 mg d-cycloserine
45686398|NCT00078286|Drug|Placebo|Dosage ranging from 50 mg to 200 mg once a day
45686399|NCT00078754|Drug|Fluoxetine|Fluoxetine capsules by mouth, up to 60 mg daily
45686400|NCT00078754|Drug|Divalproex|Divalproex ER capsules by mouth, up to 3000 mg daily
45843065|NCT01526538|Drug|sugar pill|placebo
45843066|NCT01527162|Device|SAFO worn|Child wears their prescribed SAFO for 14 days by random assignment
45843067|NCT01527162|Other|SAFO not worn|Child does not wear their prescirbed SAFO for 14 days by random assignment
45843068|NCT01528332|Device|Pain Relief Patch|The Pain Relief Patch is a non CE-marked device that is worn on the painful area of the back, where it shines light (453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm²). It will be used 5 times over 14 days for 30 minutes each time.
45843069|NCT01528332|Device|Control PRP device|The Control PRP device is also a non CE-marked device. It is similar in appearance to the active Pain Relief Patch, except that it shines light of a different wavelength(531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm²) for just 5 seconds before it turns off. Participants in the control arm will be treated with the control PRP device 5 times over 14 days for 30 minutes each time.
46045938|NCT05720143|Procedure|Piezo-surgery|Procedure: the horizontal and vertical osteotomy will do by Piezo and bone splitting will make by inserts of piezosurgery and bone expander. Finally, immediate implantation will be placed.
45686401|NCT00078754|Drug|Placebo|Placebo capsules by mouth, up to 8 capsules daily
45686402|NCT00080470|Device|bion|battery powered microstimulator
45686403|NCT00081328|Drug|Metformin|capsule, 1000 mg bid
46045939|NCT05716139|Procedure|Natural Cycle|The participant will be administered a S/C injection of 5000IU hCG to assist ovulation and timing of the embryo transfer, when the dominant follicle reaches ≥ 18mm and serum LH < 20 IU/L, the administration of hCG will be in the evening, and the embryo transfer will be scheduled seven days later (window of ± two days). The participant will begin transvaginal progesterone administration 2x400mg/day (Utrogestan®) from the day after the trigger until ten weeks of gestation
45352296|NCT00689936|Drug|Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles|"lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg, 20 mg or 25 mg capsules given on days 1-21 of each 28 day cycle or every other day for 21 days for 18 cycles.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle for 18 cycles"
45352297|NCT00689936|Drug|Melphalan, Prednisone and Thalidomide|Melphalan - oral, 2mg tablets dosed at either 0.25mg/kg, 0.125 mg/kg, 0.20mg/kg or 0.10mg/kg on days 1-4 of each 42 day cycle up to 12 cycles Prednisone - oral, 5mg, 10mg, 20 mg and 50 mg tablets dosed at 2mg/kg daily days 1-4 of each 42 day cycle for up to 12 cycles Thalidomide - oral, 50mg, 100mg and 200 mg capsules dosed at either 100mg or 200 mg daily on days 1-41 of each 42 day cycle for up to 12 cycles
45352298|NCT04238728|Device|Silverlon|silver nylon dressing will be applied daily
45352299|NCT04528576|Device|Dragonfly mitral valve repair system|With transesophageal echocardiographic guidance,implanting clip using Dragonfly mitral valve repair system
45352300|NCT05661682|Drug|Tralement|Tralement with Manganese Sulfate
45352301|NCT05661682|Drug|Fixed-dose trace element combination product of zinc, copper, and selenious acid|Tralement without Manganese Sulfate
45686404|NCT00081328|Drug|Rosiglitazone|capsule, 4 mg bid
45686405|NCT00081328|Behavioral|Lifestyle Program|a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study
45686406|NCT04756570|Other|Control|Individuals in this group will be randomly recruited from hospitalized stroke volunteers. Since these individuals receive routine rehabilitation 5 days a week, they will be evaluated at the beginning and end of 18 sessions over a total period of 6 weeks. Conventional physiotherapy will include normal joint movements, muscle strengthening exercises, balance and mobility exercises, and exercises to improve daily life activity.
45686407|NCT04756570|Other|Robotic Group 1|Individuals in this group will receive one session of robotic rehabilitation in addition to conventional therapy each week
45686408|NCT04756570|Other|Robotic Group 2|Individuals in this group will receive two sessions of robotic rehabilitation in addition to conventional therapy each week
45686409|NCT00082342|Device|Phoressor II (IOMED)|sham stimulation
45686410|NCT00082342|Device|Phoressor II (IOMED)|real tDCS stimulation
45686411|NCT01499355|Biological|BIIB023|
46045940|NCT05716139|Procedure|Artificial Cycle|Estrogen priming with oral estradiol valerate 6mg/day (2mg every 8 hours) starting from cycle D1-D5 after a first TVU. TVU will be performed 10-15 days after beginning estradiol until ET ≥ 7mm, maximum until 28 days. Patients will begin progesterone injection 100mg/day until blastocyst transfer. Frozen embryo transfer will be performed on day 6 +/- 2 days of progesterone administration. After embryo transfer, a supplementation with 2x400mg/day (Utrogestan®) intra vaginal will be administrated. Patients will continue Estradiol 2 mg thrice daily until 6 weeks of gestation; then dose tapering will be done to 2 mg twice daily until 9 wks of gestation. From 9th wk the estrogen dose will be tapered further to 2 mg once daily for 10 days before stopping.
46045941|NCT05715684|Other|Exercise Training|Virtually supervised exercise training for four weeks prior to cystectomy
46045942|NCT05715684|Dietary Supplement|Nutritional Intervention|Patients scheduled to undergo cystectomy will receive liquid Ensure supplemental shakes for 2 weeks prior to surgery and liquid Ensure supplemental shakes for 1 week postoperatively
45352302|NCT05279170|Other|MAVEPPIC: MAsk VEntilation with Paratracheal Pressure In Children|"Pressure will be applied with two fingers in the area located between the trachea and the sternal head of the sternocleidomastoid muscle on the left side to compress the cervical esophagus.~The force applied (after measuring the equivalent force applied on a precision scale) will be about 10 - 15 N. This force will be adapted according to the child's body weight : 10 N below 20 kgs and 15 N between 20 kgs and 40 kgs"
46045943|NCT05712265|Drug|Miricorilant|Miricorilant 6 x 100 mg coated tablets
45352303|NCT01563718|Drug|naltrexone for extended release injectable suspension|VIVITROL (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, at a dose of 4cc (380mg of naltrexone base), administered by intramuscular injection to the buttocks (alternating sides monthly) for six months.
45686412|NCT01499355|Biological|Placebo|
45686413|NCT01499355|Drug|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
45686414|NCT01499355|Drug|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
45686415|NCT00083122|Drug|cisplatin|Given IV
45686416|NCT00083122|Drug|alvocidib|Given IV
45686417|NCT00083122|Drug|cisplatin/flavopiridol|Given IV
46045944|NCT05712265|Drug|Fluvoxamine|Fluvoxamine 50 mg tablet
46045945|NCT05712187|Drug|ALTO-100|ALTO-100 tablet BID
46045946|NCT05712187|Drug|Placebo|Placebo tablet BID
46045947|NCT05709808|Other|Kinesio-taping|kinesiotape is a method of taping used to improve support and increase proprioceptive awareness of the joint, while the exercise program was designed to improve postural stability and balance
46045948|NCT05709808|Other|exercises|A standard proprioceptive training program will be implemented three times a week. The training includes both static and dynamic balance on Wobble board with the eyes open while the last stage will be repeated with the eyes closed.
46045949|NCT05709808|Other|mixed kinesiotape plus exercises|kinesiotape is a method of taping used to improve support and increase proprioceptive awareness of the joint, while the exercise program was designed to improve postural stability and balance. A standard proprioceptive training program will be implemented three times a week. The training includes both static and dynamic balance on Wobble board with the eyes open while the last stage will be repeated with the eyes closed.
46045950|NCT05697497|Behavioral|Daily exercise intervention|Participants will complete four exercises each day, The first two weeks they will be instructed to complete as many repetitions as possible, each day, for 15 seconds and progressing to 30 seconds per exercise after the first two weeks. Participants are asked to increase their goal repetitions by 1 or 2 from their previous best each week. For all exercises with modifications, we will encourage participants to move to the next most difficult modification once they can do 15 repetitions of that exercise.
46045951|NCT05690295|Other|Prolonged resistance-type exercise training|All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
45352308|NCT05485714|Other|Reviewing records retrospectively of patients undergoing screening endoscopy|Reviewing records retrospectively of patients undergoing screening endoscopy to assess Baveno VI, expanded Baveno VI, Platelet count/spleen diameter and other non-invasive predictors of esophageal varices or varices needing treatment
45352309|NCT05473234|Drug|Azithromycin|Children enrolled in the trial and randomized to receive azithromycin will receive a single dose of azithromycin at 20 mg/kg up to the maximum adult dose of 1g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.
45352310|NCT05473234|Drug|Amoxicillin|Children enrolled in the trial and randomized to receive amoxicillin will receive a 5-day course of amoxicillin to be given in twice-daily doses of 15 mg/kg per the Nigeria guidelines for severe acute malnutrition. The first dose will be administered at the time of enrollment, and the remaining doses will be administered by the caregiver at home. Enrolled children will also receive RUTF.
45352311|NCT04500418|Drug|Cenicriviroc (CVC)|Treatment with Cenicriviroc tablets of 150mg. (450g/300g on day 1 and 300mg/d on days 2-28).
45352312|NCT04500418|Drug|Placebo|Optically identical pills without CVC.
45352313|NCT05473156|Drug|AP203|"Eight dose levels ranging from 0.00064 to 20 mg/kg will be evaluated to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) or the recommended phase 2 dose(s) (RP2D[s]).~Participants will be administered by intravenous (IV) infusion, every week (Q1W [± 1days]) for the first 3 weeks (from the first to the fourth dose), then administered every 2 weeks (Q2W [± 3 days]) for all the following doses."
45352314|NCT05473156|Drug|AP203|The dose-expansion phase will be conducted following completion of dose escalation for AP203. Participants will receive AP203 by IV infusion, administered Q1W (± 1 days) for the first 3 weeks (from the first to the fourth dose), then administered Q2W (± 3 days) for all the following doses, at the RP2D for each expansion cohort.
45352315|NCT04005196|Diagnostic Test|EEG|Data recording will continue up until a maximum of 120 hours after emergence from sedation or at CVICU discharge. This study period is informed by baseline data from our institution where the median duration of delirium following emergence from coma was 2 days, allowing sufficient time to capture transitions from coma to wakefulness with and without delirium. EEG recordings will be divided in to epochs corresponding to coma, wakefulness, and delirium if present.
45352316|NCT00671034|Drug|Calaspargase Pegol-mknl|Given IV
45352317|NCT00671034|Drug|Cyclophosphamide|Given IV
45352318|NCT00671034|Drug|Cytarabine|Given IV, IT, PO, or SC
45352319|NCT00671034|Drug|Daunorubicin Hydrochloride|Given IV
45686418|NCT01474239|Drug|bevacizumab [Avastin]|10 mg/kg every 2 weeks intravenously until disease progression or unacceptable toxicity
45686419|NCT01474239|Drug|fotemustine|75 mg/m2 intravenously on days 1, 8 and 15 followed by, after a 5 weeks interval, 100 mg/m2 on day 1 of a 3-weeks cycle. Until disease progression or unacceptable toxicity
45686420|NCT03026829|Device|CART sound therapy|"The study consists of two parts:~Phase 1: laboratory evaluation of CART sound acceptability~Phase 2: take home evaluation of CART sound therapy including baseline without CART"
45686421|NCT01473381|Drug|Vilazodone|Vilazodone was supplied as film-coated tablets.
45686422|NCT01473381|Drug|Placebo to citalopram|Placebo to citalopram was supplied as a capsule.
45686423|NCT01473381|Drug|Placebo to vilazodone|Placebo to vilazodone was supplied as film-coated tablets.
45352320|NCT00671034|Drug|Dexamethasone|Given PO or IV
45352321|NCT00671034|Drug|Doxorubicin Hydrochloride|Given IV
45686424|NCT01473381|Drug|Citalopram|Citalopram was supplied as encapsulated tablets.
45352322|NCT00671034|Other|Laboratory Biomarker Analysis|Correlative studies
45352323|NCT00671034|Drug|Mercaptopurine|Given PO
45352324|NCT00671034|Drug|Methotrexate|Given IV, IT, or PO
45352325|NCT00671034|Drug|Pegaspargase|Given IV
45352326|NCT00671034|Other|Pharmacological Study|Correlative studies
45352327|NCT00671034|Drug|Prednisone|Given IV or PO
45352328|NCT00671034|Radiation|Radiation Therapy|Some patients undergo RT
45352329|NCT00671034|Drug|Thioguanine|Given PO
45352330|NCT00671034|Drug|Vincristine Sulfate|Given IV
45843070|NCT01528878|Radiation|Stereotactic Radiosurgery using the CyberKnife System.|"Radiation: Stereotactic Radiosurgery using the CyberKnife System. The CyberKnife system has been cleared by the U.S. Food and Drug Administration (FDA) to treat lesions, tumors and conditions, anywhere in the body when radiation treatment is indicated. To address movement of target lesion during the respiratory cycle, the Synchrony™ option will be used.~The Synchrony option precisely tracks tumors in or near the target organ as they move, enabling the highly focused beams of radiation to destroy the tumors with minimal injury to adjacent normal tissue. The Synchrony option records the breathing movements of a patient's chest and combines that information with sequential x-ray pictures of tiny markers inserted inside or in the proximity of the tumor to enable precise delivery of radiation during any point in the respiration cycle. The CyberKnife system with the Synchrony option enables reduced normal tissue exposure by using smaller treatment margins and increased accuracy."
46045952|NCT05684653|Drug|Orelabrutinib Tablets|50 mg, single oral dose
46045953|NCT05683860|Drug|WVE-004|WVE-004 is a stereopure antisense oligonucleotide. It is administered via intrathecal injection
45686425|NCT00168454|Biological|botulinum toxin Type A|botulinum toxin Type A injected into detrusor on Day 1
45686426|NCT00168454|Drug|Placebo|Placebo (normal saline) injected into detrusor on Day 1
45686427|NCT00175006|Other|Measurement of Tophi to validate procedure|Intra- and Inter-rater Reproducibility measurements of the area (in mm2) of each tophus nodule.
45686428|NCT04737772|Behavioral|Behavioral: Quitline treatment as usual|TAU is state quitline treatment that may include coaching sessions, text messaging and access to the web-based program plus cessation medications and unlimited calls to the QL for support between sessions.
45686429|NCT04737772|Behavioral|QL Marijuana Check-Up intervention (QL-MJCU)|QL Marijuana Check-Up intervention (QL-MJCU) was developed for non-treatment seeking MJ users and is based on Motivational Enhancement Therapy. Includes TAU (see standard quitline arm) with a trained coach plus a MJ assessment and Personalized Feedback Report (PFR).
45686430|NCT01499277|Drug|Ceftaroline fosamil|IV ceftaroline 600mg every 8 hours
45686431|NCT01499277|Drug|Vancomycin|IV vancomycin 15mg/kg every 12 hours
45686432|NCT01499277|Drug|Aztreonam|IV aztreonam 1 g every 8 hours
45843071|NCT01529502|Procedure|Red blood Cells auto-transfusion|Withdrawal from 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 3 days storage time. The same 14 subjects will be included in every arm of the study.
45843072|NCT01529502|Procedure|Red blood Cells auto-transfusion|Withdrawal from the same 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 40 days storage time.
45843073|NCT01529502|Drug|Inhaled Nitric Oxide (iNO) administration|Subjects will breath iNO (80ppm) for 10 minutes before, during and for one hour after the autologous old-blood transfusion.
46045954|NCT05677386|Diagnostic Test|Primary preventive treatment guided by CTCA|Computed tomography coronary angiography (CTCA)
46045955|NCT05677386|Other|Cardiovascular risk Score|Systematic COronary Risk Evaluation 2 model for cardiovascular risk prediction
45686433|NCT00176800|Drug|Tetrathiomolybdate (TM)|Tetrathiomolybdate: 20mg p.o. per day with largest meal. This will be started 4-6 weeks post-op, and continued x 2 years or until progression of disease is documented.
45843074|NCT01532700|Drug|Ofatumumab with GSK2110183|"GSK2110183 125mg OD continuously~Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses"
45843075|NCT01533948|Drug|axitinib|Given PO
45843076|NCT01533948|Other|laboratory biomarker analysis|Correlative studies
45843077|NCT01534416|Drug|Bupivacaine|Subjects are injected paracervically with 10 ml of 0.5% bupivacaine with 1:200000 units epinephrine prior to surgical incision.
46045956|NCT05661825|Other|phase II cardiac rehabilitation|Phase II cardiac rehabilitation was provided in the the department of physical medicine and rehabilitation in Wan Fang Hospital. The programs are two times a week, one session for 30 minutes (30 sessions in total). The training programs are focused on aerobic training with bicycles. The training intensity is calculated with 40% to 80% oxygen consumption reserve from the result of cardiopulmonary exercise test. In case of safety, heart rate, blood pressure, EKG and rate of perceived exertion will be monitored during training.
46045957|NCT05659654|Drug|Ursodeoxycholic acid|250 mg/capsule, 2 capsules per day, for 4 weeks
45843078|NCT01534416|Drug|Normal Saline|Subjects are injected paracervically with 10 ml of normal saline prior to surgical incision.
46045958|NCT05654376|Behavioral|Art therapy|"Participant's creativity is stimulated by visual arts materials and various art therapy techniques, in relation to 6 topics: self-care, stress management, flourishing caregiving, challenging caregiving, loss and grief, and sense of professional meaning.~The strategy consists of stimulating an observant and symbolic gaze, facilitating visual expression, promoting communication about what it has been expressed, and gather learning from the multidimensional impact of the creative art process (sensations, emotions, cognitions and spiritual experiences)."
46045959|NCT05653856|Drug|64Cu-PSMA I&T|Radiolabeled Receptor-Targeted Diagnostic Product
46045960|NCT05649683|Biological|Evaluation of cytokine production|The patient will have samples at initiation of treatment (J0), after treatments 1 and 2 (S6), after the first radiological assessment at S11 and/or the progression of the disease and/or occurrence of a grade 3-4 adverse event
46045961|NCT05648045|Behavioral|Behaviour intervention targeted for Lifestyle modification|An intervention to strengthen resilience that controls self-efficacy, self-esteem and optimism.
45352331|NCT04483648|Other|Exercise|Home exercises were performed three times in a week for six weeks. Home exercises included range of motion exercises, coordination exercises and strengthening exercises. Repeats and durations of the exercises increased every week to provide progression.
45352332|NCT04432792|Other|Questionnaire|Study survey participants will be administered 3 online surveys.
45352333|NCT00743522|Device|ICD/ CRT-D|Cardiac device
45352334|NCT05623462|Device|The C-Mill virtual reality treadmill|The C-Mill treadmill is an innovative device used for the training of impaired gait and balance. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications.The instrument is supplied with a safety frame, body weight support, treadmill force plates, treadmill belt, adjustable handrails, cameras, user operating system, interactive visual screen and augmented reality projection.
45352335|NCT05623462|Other|Conventional Physical Therapy Program|"The Conventional Physical Therapy Program includes the following:~- Indoor open environment gait training exercises (over-ground gait training exercises.). (using obstacles, cones, stepper, balance board , and uneven surfaces) (either between or outside the parallel bar)"
45352336|NCT00743600|Other|ultrasound of painful shoulder|Patients who have a shoulder that is painful or has limited movement who were referred to Radiology will have an ultrasound exam of their shoulder.
45352337|NCT00743600|Other|ultrasound|Healthy volunteers who do not have pain or limited movement will have an ultrasound exam of their shoulder.
45686434|NCT00176800|Procedure|Radiation|Radiation treatments will be administered twice per day with each dose separated by more than 6 hours, on Days 1-5, 8-12 and 15-19.
45686435|NCT00176800|Procedure|Surgery|The persons's esophagus will be surgically removed (esophagectomy) on approximately Day #50.
45686436|NCT00176878|Procedure|Stem cell transplant|Stem cell transplant on Day 0 - healthy marrow from an unrelated individual. A minimum of 1.0 x 10^9/kg nucleated cells/kg ideal body weight will be collected with a goal of 2.0 x 10^9/kg.
45686437|NCT00176878|Drug|Fludarabine monophosphate|fludarabine 175 mg/m^2 (total) on Days -6 through -3.
46045962|NCT05641454|Dietary Supplement|ElevATP supplement|ElevATP supplement containing apple and ancient peat extract
46045963|NCT05641454|Dietary Supplement|Placebo|Maltodextrin placebo
45477433|NCT02674464|Behavioral|System Level Leadership Intervention|"This System-Level Leadership intervention aims to create a learning network through an inter-organizational approach to promote health equity and reduce CVD disparities. Elements of the system-level leadership intervention, then, include: 1) an introductory session during the kick-off event (baseline); 2) a quarterly 1 hour content call with a presentation on leading for equity and discussion among system-level leaders, community organization leaders, and interested practice champions in the CC/Stepped care arm conducted via conference call/webinar; and 3) monthly coaching calls for the system and practice level leaders, CMs, and CHWs in the CC/stepped care arm to discuss the interventions, while they are actively engaged in the intervention phase."
46045964|NCT05638113|Procedure|Pleural injection of autologous blood|120 ml autologous blood will be drawn from simple venous puncture and immediately injected through the drain into the pleural cavity followed by flushing with 50ml of saline.
46045965|NCT05637060|Drug|Test Drug|One single dose of Vaptor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
46045966|NCT05637060|Drug|Reference Drug|One single dose of Crestor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
45477434|NCT02674464|Behavioral|Collaborative Care Team Intervention|The collaborative care intervention creates a collaborative care team that, at a minimum, consists of PCP, nurse, or social worker care manager, and community health worker. The collaborative care team develops the medical management plan in partnership with patients; 2) uses care coordination to maximize interaction of the patients' PCPs with other care providers addressing medication management, patient self-management, and psychosocial support on a regular, consistent basis; and 3) determines patient access to CHW support and subspecialty consultations.
45686438|NCT00176878|Procedure|Total lymphoid irradiation|Dose 500 cGy radiation therapy to specific areas of the body
45843079|NCT01535664|Other|Withdrawal of dalfampridine-ER 10mg|"Withdrawal of dalfampridine-ER 10mg (7 days on study drug followed by withdrawal period of 10 days, followed by on study drug until study completion)~On drug Day-7 (visit 1) through Day 1 (visit 2)~Off drug Day 5±2 days (visit 3) through Day 11±2 days (visit 4)~On drug Day 15±2 days (visit 5)"
46045967|NCT05636293|Drug|Ritlecitinib|200mg Ritlecitinib
46045968|NCT05636293|Drug|Placebo|Placebo
46045969|NCT05636293|Other|Gluten|10g of gluten
46045970|NCT05635604|Drug|Eptinezumab|Eptinezumab or ALD403 is a humanized anti-calcitonin gene-related peptide IgG1 monoclonal antibody that binds to calcitonin gene-related peptide (CGRP). It selectively binds human CGRP ligand to prevent activation of the CGRP receptor and blocks its binding to the receptor for the prevention of migraine.
45477435|NCT02674464|Behavioral|Community Health Worker Referral|"As a stepped up component of the Collaborative Care Team Intervention for patients needing support in overcoming a variety of social determinants"
45686439|NCT00176878|Drug|Busulfan|Busulfan 8 mg/kg (total) on Days - 8 and -7 (orally or through the catheter),
45686440|NCT00176878|Biological|anti-thymocyte globulin|anti-thymocyte globulin (ATG) 15 mg/kg on days -2 and -1 via catheter
45686441|NCT01898182|Other|Kinetin, N6-furfuryladenine, 0.1%|
46045971|NCT05635604|Drug|PACAP-38|PACAP-38 is a naturally occurring peptide diffusely expressed throughout the body. The Danish Headache Center has used infusion of PACAP-38 for several years and the first time in 2007 where infusion of PACAP-38 triggered headaches and migraines in migraine patients.
46045972|NCT05622851|Device|Restylane Contour|Hyaluronic Acid dermal filler
45686442|NCT02338336|Drug|Nowarta110|Nowarta110 contains fig extract as the main drug substance, and colloidal silver is used as a medium for penetration of fig extract into the wart lesion. Liquid for topical administration.
46045973|NCT05622851|Device|Juvederm Voluma|Hyaluronic Acid dermal filler
45477436|NCT02674464|Behavioral|Specialist Care Consultation|"As a stepped up component of the Collaborative Care Team Intervention for patients with complex medical conditions and/or patients that may not typically have access to specialist care"
45477437|NCT05525338|Drug|Alectinib|In case of an alectinib plasmaconcentration Cmin <435 ng/mL, determined by TDM, and manageable toxicity, the alectinib dose will be increased with 150mg BID up to a maximum of 900mg BID. In case of unacceptable toxicity (i.e. unbearable or persistent grade 2 toxicity and grade 3/4 toxicity), the alectinib dose can be reduced by 150mg BID.
45477438|NCT04302467|Procedure|fluid therapy during operation|ERAS protocol of lobectomy will implemented to all the participants during perioperation,two groups of participants will be given different intraoperative fluid therapy strategy.
45477439|NCT03818945|Drug|shofu PRG barrier coat|Trilaminar structure which forms a type of stable glass ionomer allowing ion release and recharge, while protecting the glass core from the damaging effects of moisture, greatly improving long-term durability.(Na, BO3, Al, SiO3, F,Sr)
45352338|NCT04425070|Combination Product|ICE [ifosfamide+carboplatin+etoposide]|"• Combined with ICE chemotherapy regimen:~Ifosfamide: 5 g/m2, continuous intravenous (iv) infusion (mesna 5 g/m2 synchronously iv infusion for rescue), on Day 2;~Carboplatin: with concentration-area under time curve (AUC)=5 (highest concentration to 800 mg), iv infusion, on Day 2;~Etoposide l00 mg/m2, iv infusion, on Days 1-3;~ATG-010 60 mg/once, oral, on Days 4 and 11. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW)."
45352339|NCT04425070|Combination Product|GEMOX [gemcitabine+oxaliplatin]|"• Combined with GEMOX chemotherapy regimen:~Gemcitabine 1000 mg/m2, iv infusion, on Days 1 and 8;~Oxaliplatin 130 mg/m2, iv infusion, on Day 1;~ATG-010 60 mg/once, oral, on Days 2 and 9. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW)."
45352340|NCT04425070|Combination Product|Tislelizumab|Tislelizumab will be administered intravenously at a fixed dose of 2 0 0 mg every 3 weeks on Day 1 of each cycle
45352341|NCT04607954|Biological|Durvalumab|Given IV
45352342|NCT04607954|Drug|Lurbinectedin|Given IV
45686443|NCT02338336|Drug|Placebo|Matching placebo liquid for topic administration.
45352343|NCT00743678|Drug|FOLFOX6/cetuximab|Neoadjuvant FOLFOX6/cetuximab
45352344|NCT04421014|Dietary Supplement|Ketone Ester drink|The main ingredient of the Ketone Ester drink [(R)-3-hydroxybutyl (R)-3-hydroxybutyrate)] is regulated as GRAS (Generally Recognized as Safe) substance by the FDA (https://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&amp;id=515). The Ketone Ester compound is already being sold in the market as a ketogenic supplement and is especially popular among athletes, such as cyclists (sold by the official website of the company TdeltaS(R) Global (https://www.deltagketones.com/products/g-ketone-performance). The dose and formulation (25 g of KE contained in 59 ml of a drink), daily scheme (3 times daily) and total duration (28 days) are identical to a previous safety human study. The Ketone Ester drink provided by DeltaG will be repackaged by the NIA Pharmacist into new bottles identical to the ones that will be used for the placebo to ensure the blinding of participants and researchers to the drink.
45352345|NCT04421014|Dietary Supplement|Placebo: isocaloric dextrose drink|The main content of the Placebo will be an aqueous solution containing approximately 35 g of dextrose, a fruity flavor powder and stevia. We will also add Denatonium Benzoate (Bittrex) to match the bitterness of the Ketone Ester drink. The placebo will be prepared and dispensed by the NIA Pharmacist.
45352346|NCT00743756|Dietary Supplement|home-delivered meals|3 diabetic meals per day, 7 days per week for 12 months
45352347|NCT00743756|Dietary Supplement|home-delivered meals|diabetic meals 3 times per day, 7 days a week for six months
45352348|NCT00743756|Behavioral|diabetes education for 12 months|subjects in this group received diabetes education for 12 months
45352349|NCT05604508|Other|Many posters with prices|No poster number or price restrictions
45352350|NCT05604508|Other|Many posters, no prices|No poster number restrictions, but price restrictions
45352351|NCT05604508|Other|Fewer posters, no price restrictions|Poster number restrictions, but no price restrictions
45352352|NCT04409080|Drug|REGN7257|Single dose will be administered by intravenous IV infusion
45352353|NCT00772278|Procedure|carotid artery stenting|carotid artery angiography, angioplasty and stenting
45352354|NCT00772278|Procedure|carotid endarterectomy|open surgery including endarterectomy
45352355|NCT02679508|Drug|Vonoprazan|Vonoprazan fumarate 10 mg or 20 mg capsules
46045974|NCT05620784|Drug|Furosemide|20mg of IV furosemide injection during the morcellation phase of HoLEP
46045975|NCT05619419|Behavioral|Mindfulness-enhanced positive affect induction|Participants will receive brief psychoeducation about biopsychosocial pain management and practice with the MPAI via guided audio recording. They will then listen to the audio recording a final time before beginning the cold pressor test for experimental pain induction. They will be instructed to continue using the MPAI to manage pain during the cold pressor test.
45352356|NCT02679508|Drug|Lansoprazole|Lansoprazole 15 mg or 30 mg capsules
45352357|NCT00775632|Drug|Alemtuzumab|A new GVHD prevention strategy will be tested against established GVHD prophylaxis in patients undergoing matched sibling donor transplant using peripheral blood stem cells.
45352358|NCT00775632|Drug|mycophenolate or cyclosporine and methotrexate|One of the two GVHD prophylaxis used at PMH-either cyclosporine and mycophenolate or cyclosporine and methotrexate
45477440|NCT03818945|Drug|Sodium fluoride varnish|5% sodium fluoride [22,600 ppm F-]
45477441|NCT02501824|Other|anthroposophic therapeutic speech|anthroposophic therapeutic speech
45477442|NCT05281289|Other|kinesio-tape|KT is comprised of a polymer elastic strand warped by 100% cotton fibers and designed to allow a longitudinal stretch of 55-60% of its resting length.
45477443|NCT05281289|Other|stretching exercise|15 seconds of passive stretching exercise for calf muscle followed by 30 seconds of rest
45477444|NCT05281289|Other|instructions about dealing with calf cramps|instructions about dealing with calf cramps by self low sustained stretch of calf muscle
45477445|NCT02631798|Dietary Supplement|Food grade dye mucosal staining|mucosal staining with food grade dye
45352359|NCT04047654|Drug|Non vitamin K oral anticoagulants|Non vitamin K oral anticoagulants are apixaban, dabigatran, rivaroxaban, and edoxaban
45352360|NCT04404478|Behavioral|B-SWELL: Midlife Black Women's Stress Reduction Wellness Program|Stress reduction and culturally tailored information on healthy lifestyle behaviors will be used to increase healthy lifestyle behaviors according to the AHA's Life's Simple 7. Focus of intervention on per support, goal setting, stress reduction, and culturally relevant information.
45352361|NCT04404478|Behavioral|WE: Wellness program for Midlife Black Women|Culturally tailored information will be provided about healthy lifestyle behaviors will be used to increase healthy lifestyle behaviors according to the AHA's Life's Simple 7. Focus of intervention on peer support and culturally relevant content.
45352362|NCT00772356|Device|Accu-Chek Spirit Insulin Pump|
45352363|NCT00772356|Device|Comparator insulin pump|
45352364|NCT00769782|Procedure|therapeutic conventional surgery|All patients undergo suegery to achieve macroscopic complete resection within 28 days after enrollment (including enrollment day). As long as tumor free margin is ensured, all resection margin distances and all surgical procedure are accepted. Surgical treatment in this study excludes the following, radiofrequency ablation (RFA) without resection of liver only or microwave coagulation therapy (MCT) only; for RFA or MCT is used as additional treatment under judgment of primary physician for new liver tumor which comfirmed during surgery in different parts of liver except portion scheduled for resection, RFA and MCT are included. After histological curative resection, patients are observed without treatment until comfirming recurrence. Patients with incomplete tumor removal are withdrawn from protcol treatment and receive imatinib treatment, 400 mg/day orally. For reccurrence is comfirmed, patients receive imatinib treatment, 400 mg/day orally.
45352365|NCT04360096|Drug|ZYESAMI™ (aviptadil acetate)|Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer
45352366|NCT04360096|Drug|Placebo|Normal Saline Inhalation
45352367|NCT04360096|Device|Nebulized administration of ZYESAMI™ or Placebo|Use of 510(k) cleared mesh nebulizer to deliver investigational product
45352368|NCT04048356|Drug|Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.|Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
45477446|NCT03344068|Radiation|Radiotherapy|Intensity Modulated Radiation Therapy, Dose: GTVnx 6810cGy/30Fr, GTVnd 6400-6600cGy/30Fr, CTV1 6000cGy, CTV2 5400cGy.
46045976|NCT05619419|Behavioral|Breathing Meditation|Participants will receive brief psychoeducation about biopsychosocial pain management and practice with the BM via guided audio recording. They will then listen to the audio recording a final time before beginning the cold pressor test for experimental pain induction. They will be instructed to continue using the BM to manage pain during the cold pressor test.
45352369|NCT04005040|Procedure|Mobile X-ray|Evaluating the effect of mobile x-ray compared to x-ray at the Hospital
46045977|NCT05617859|Drug|Lenvatinib mesylate capsule|Lenvatinib mesylate capsule, 8mg (body weight ≤60kg) or 12mg (body weight >60kg), orally, once daily. Take the medicine about half an hour after meals (the time of taking the medicine should be the same as possible every day) and take it with warm water.
46045978|NCT05616494|Drug|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
46045979|NCT05614609|Drug|Lidocaine topical|Comparing lidocaine spray and muscle relaxing medication
45352370|NCT04048044|Device|Exposure to GHz electromagnetic energy (RejuvaMatrix)|75 decibels of 54 to 78 GHz daily for 60 minutes
45352371|NCT00775710|Device|Nocturnal non-invasive ventilation|Prolongation of non-invasive ventilation during 3 nights.
45352372|NCT04047888|Other|Nutrition-based education on infant feeding and practices as well as Non nutrition-based educational message|60 minute educational message at each visit
45477447|NCT03344068|Drug|Chemotherapy|Nedaplatin 80mg/m2 d1+5-fluouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.
45352373|NCT04047888|Other|Non nutrition-based educational message|No nutrition-based education on infant feeding and practices
45352374|NCT04004650|Procedure|Gluteal turnover flap|Link to procedure: https://www.youtube.com/watch?v=u7_vH2_1ZZc
45352375|NCT03730792|Behavioral|SHIFT Onboard Intervention|A 12-month onboarding process and social challenge supported with goal setting, computer-based training, self-monitoring, and group motivational interviewing.
45352376|NCT04394182|Radiation|Ultra-Low-dose radiotherapy|The total dose to be administered was 0.8 Gy in an only single session including both whole-lungs extended 1cm isometric in all directions.
45352377|NCT04394182|Device|ventilatory support with oxygen therapy|Oxygen Therapy: Nasal Cannula (NC); Ventimask (VMK) or VMK with reservoir
45352378|NCT04394182|Drug|Lopinavir/ritonavir|100/400 mg/12h; 7-10 days
45352379|NCT04394182|Drug|Hydroxychloroquine|200 mg/12h
45352380|NCT04394182|Drug|Azithromycin|500 mg/24h, 3 days
45477448|NCT03344068|Dietary Supplement|Nutren® Optimum|Nutren® Optimum, 7 scoops each time, three times a day, at begin of radiotherapy
45477449|NCT01330056|Procedure|FOPS|"Functional organ preservation (FOPS) as a first-line treatment modality~Postoperative RT or CRT may be included for the patients of this group."
45477450|NCT01330056|Radiation|CRT|"Concurrent chemoradiotherapy as a first-line treatment modality~Salvage surgery may be applied for the patients with persistent or recurrent cancers after RT or CRT"
45477451|NCT01206335|Drug|OHR/AVR118|OHR/AVR118 given subcutaneously at 4mL per day
45352381|NCT04394182|Drug|Piperacillin/tazobactam|4 g / 0.5 g administered every 6-8 hours through a vein (directly into the bloodstream), for 5-14 days. Adjustment to kidney function
45352382|NCT04394182|Drug|Low molecular weight heparin|prophylactic doses
45352383|NCT04394182|Drug|Corticosteroid injection|250mg x 3 boluses
45352384|NCT04394182|Drug|Tocilizumab|600mg single dose
46045980|NCT05605093|Drug|Shionogi Protease Inhibitor (S-217622)|S-217622 is an oral anti-SARS-CoV2 PI that does not require ritonavir co-administration The dose is 375/125 (375 mg on Day 0, followed by 125 mg daily on Days 1-4).
45352385|NCT05386576|Drug|Venetoclax|"During Induction I, for patients on Dose Level 1, venetoclax will be administered at a dose of 100mg on day 5, 200mg on day 6 and 400mg on days 7-28. For patients on Dose Level 01, venetoclax will be administered at a dose of 100mg on day 5 and 200mg on days 6-28.~During Induction II, venetoclax will be administered at either 400mg daily (Dose Level 1) or 200mg daily (Dose Level -1) from days 1-14 and 29-42."
45352386|NCT05376124|Other|original therapy|Patients on ETV 0.5mg/ day or TDF 300mg/ day or TAF 25mg/ day continued the original regimen (ETV 1.0mg/ day or TDF 300mg/ day or TAF 25mg/ day), Oral treatment lasted 48 weeks ②Patients who received TDF 300mg/ day plus ETV 0.5mg/ day on initial treatment continued with the original regimen (TDF 300mg/ day plus ETV 0.5mg/ day) and oral therapy for 48 weeks ③Patients who received TAF 25mg/ day plus ETV 0.5mg/ day as initial treatment continued the original regimen (TAF 25mg/ day plus ETV 0.5mg/ day) for 48 weeks of oral therapy
45352387|NCT05376124|Other|rescue therapy|TDF 300mg/ day +ETV 1.0mg/ day or TAF 25mg/ day +ETV 1.0mg/ day, oral treatment for 48 weeks.
45352388|NCT04244890|Device|Uninterrupted CPAP for the first hours of life|Directly at birth the infant will be supported with PPV with PEEP as needed, followed by nasal CPAP. Support will be provided with a single device for up to four hours.
45352389|NCT04223206|Dietary Supplement|NATURLENS|Oral administration of dietary supplement (26 g/day) to dissolve in 100 or 150 mL of water
45352390|NCT04146922|Other|Step down to oral antimicrobial therapy|Step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.
45477452|NCT04300751|Drug|Alcohol|Active alcohol or placebo, administered orally
45686444|NCT04672174|Diagnostic Test|Questionnaire: DemTect|Questionnaire is handed out to subjects
45686445|NCT01499199|Drug|Dolutegravir|50mg Once Daily
45686446|NCT01499043|Drug|PLX3397|Capsules administered twice daily, continuous dosing. Subjects will take PLX3397 at 1000 mg/day.
45843080|NCT01535976|Drug|Placebo|"Placebo Comparator: Placebo~.9 normal saline infusion"
45843081|NCT01535976|Drug|Ketamine|Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case
45843082|NCT01536366|Drug|BIA 9-1067|25 mg BIA 9-1067 (single-dose)
45843083|NCT01536366|Drug|Repaglinide|0.5 mg repaglinide (single-dose)
45843084|NCT01537302|Device|CTO crossing in femoropopliteal arteries CONNECT II|CTO crossing in femoropopliteal arteries using the Ocelot System
45843085|NCT01537926|Drug|N-acetylcysteine|NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.
45843086|NCT01537926|Drug|Placebo|sugar pill manufactured to minic NAC 600mg capsule
46045981|NCT05605093|Drug|placebo|Placebo is an oral tablet administered once (3 tabs) on Day 0 and once (1 tab) daily on days 1-4, 5-day course.
46045982|NCT05603052|Biological|EuCorVac-19|COVID-19 vaccine
46045983|NCT05603052|Biological|ChAdOx1|COVID-19 vaccine
46045984|NCT05601050|Other|There is no intervention|There is no intervention
46045985|NCT05599217|Other|Dietary and nutritional questionnaire|Nutrition assessment, nutrient intake, dietary inflammatory index, and frailty status will be examined using questionnaires.
46045986|NCT05599217|Other|Neurological function, cognitive function, and life quality assessment|Neurological function, cognitive function, and life quality will be examined using Glasgow Coma Scale, Modified Rankin Scale, Markwalder Grade Scale, Mini-mental state examination, and EuroQol five dimensions questionnaire.
46045987|NCT05599217|Other|Peripheral blood test|Collect peripheral blood samples from patients.
46045988|NCT05599217|Other|Metabonomic test|Collect urine and stool samples from patients.
45352391|NCT04146922|Other|IV antimicrobial therapy|No step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.
45352392|NCT03472768|Diagnostic Test|Plasma Haptoglobin Concentration|N/A, comparison of haptoglobin concentration between groups
45352393|NCT05325580|Drug|Magnesium sulfate|"magnesium group 1g paracetamol + 20 min infusion of 2 g magnesium in 150 ml of saline serum and Placebo Group~1g paracetamol + 20 min infusion of 150 ml of saline serum"
45352394|NCT04179448|Procedure|SAMRI|Side Access Mucosal Releasing Incision (SAMRI) will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
45477453|NCT04300751|Drug|Opioid Agonist|Active opioid agonist or placebo, administered orally
45477454|NCT02562612|Drug|SM-88|Daily SM-88 in multiple ascending doses over 6 months
45686447|NCT00087022|Biological|girentuximab|Given IV
45686448|NCT00087022|Other|placebo|Given IV
45686449|NCT00179998|Drug|Recombinant Human DNase (Pulmozyme)|2.5 mg in 3 ml diluent delivered by nebulization given daily for 6 months with 3 ml diluent placebo delivered by nebulization given daily for 6 months
46045989|NCT05599217|Other|Hematoma test|Collect hematoma fluid, dura mater, and hematoma outer membrane samples from patients.
46045990|NCT05598957|Diagnostic Test|Vitamin D Binding protein|Vitamin D-free and bioavailable metabolites were calculated by using Bikle and Vermeulen methods with using albumin, 25-OH vitamin D, vitamin D binding protein (ELİSA kit) levels
45843087|NCT01538862|Drug|Granulocyte Colony Stimulating Factor (GCSF)|G-CSF 10mcg/kg/d SQ for 7 days
45352395|NCT04179448|Procedure|STA|Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
45352396|NCT04144348|Biological|mRNA-1653|Sterile liquid for injection
45477455|NCT02501356|Dietary Supplement|ISOThrive Supplement|Consumption of ISOThrive supplements for 3 months
45477456|NCT02501356|Dietary Supplement|Placebo Supplement|Consumption of Placebo supplement (Magnesium stearate or methylcellulose) for 3 months
45352397|NCT04144348|Biological|Placebo|Sterile liquid for injection
45477457|NCT03636516|Device|SWL|extracorporeal shockwave lithotripsy apply
45477458|NCT05622695|Device|catheterization|Swan-Ganz catheterization (also called right heart catheterization or pulmonary artery catheterization) is the passing of a thin tube (catheter) into the right side of the heart and the arteries leading to the lungs. It is done to monitor the heart's function and blood flow and pressures in and around the heart.
45843088|NCT01540266|Procedure|Information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
46045991|NCT05597137|Dietary Supplement|Zinc Gluconate|Each participant should receive a high-magnesium diet for weeks 1-2 and take magnesium supplements for weeks 3-4.
46045992|NCT05586230|Drug|Pretomanid|Administered orally based on participant's weight
45352398|NCT04126408|Device|gammaCore|The intervention consists of a transcutaneous non-invasive stimulation of the cervical branch of the vagus nerve (nVNS) using gammaCore, an FDA approved device for the treatment of migraine and cluster headache. This will be compared to the sham device, which is the same device which will not provide stimulation to the nerve. Stimulation frequency will be identical to the frequency used in previous nVNS studies for the treatment of migraine headache.
45352399|NCT00539734|Drug|ranibizumab|A single dose of 0.5 mg ranibizumab injected intravitreally.
45352400|NCT03907072|Drug|WVE-210201 (suvodirsen)|WVE-210201 is a stereopure antisense oligonucleotide (ASO)
45352401|NCT03907072|Drug|Placebo|Buffered saline solution
45352402|NCT04004338|Drug|Kyprolis|Patients receiving kyprolis (carfilzomib)
45843089|NCT01540266|Procedure|no information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
45843090|NCT01541358|Radiation|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
45843091|NCT01541358|Procedure|positron emission tomography/computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
45843092|NCT01542372|Drug|Medication augmentation|
45843093|NCT01542372|Behavioral|CBT|
45352403|NCT04092010|Behavioral|Problem-solving education (PSE)|PSE will be offered to mothers with low baseline depressive symptoms (the first, preventive step of the SCI). PSE participants will have their symptoms assessed at each session and will convert to Engagement Sessions if they meet pre-specified 'step up' criteria.
45352404|NCT04092010|Behavioral|Engagement sessions|Engagement sessions will be offered to mothers with greater depressive symptoms to link them to formal mental health services (the second, referral step of the SCI)
45352405|NCT04092010|Behavioral|Usual care|Normal services provided children and their mothers in Head Start
45843094|NCT01542684|Drug|Azacytidine|Starting dose: 40 mg/m^2 intravenously (IV) or subcutaneously (SQ) daily for 4 days.
45477459|NCT03343990|Procedure|Interlocking multi-twisted wires in sternal closure|One of many ways in cloure of sternal give more stabilization. At least 6 wires have to be passed. The wirs should run around the sternum in the intercostals spaces except in the manubrium where it has to be passed through the bone . Adjacent wires on the surgeon's side are wrapped around each other. The wires on the surgeon's side are then pulled towards the assistant so that the sternum is re-approximated. Alternatively the surgeon can also pull the wires at the assistant's side towards himself or herself approximating the sternum. Adjacent wires on the assistant's side are then wrapped around each other. The wrapped wires on both sides are then wrapped around each other The wrapped wires are then twisted around with a twister, closing the sternum tightly and the ends of the are burried
45352406|NCT04209322|Procedure|pulsed Radiofrequency|Non-surgical treatment of lumbar disc herniation causing sciatica using pulsed radiofrequency (10 minutes) directed to the interested dorsal root ganglia (percutaneous technique); after radiofrequency application, using the same needle, steroid was administered (as per the control arm). The procedure was guided by CT imaging
45352407|NCT04209322|Procedure|Transforaminal Epidural Steroid Injection|Percutaneous injection of steroid in the nerve root foramen. The procedure was guided by CT imaging
45352408|NCT04004572|Drug|LEAP regimen|Patients will be given LEAP regimen every 3 weeks for 8 cycles.
45352409|NCT04050436|Drug|Cemiplimab|Cemiplimab administered intravenously
45352410|NCT04050436|Biological|RP1|RP1 administered intratumorally
45352411|NCT04045912|Other|AGYW-Friendly Services|"Drug shops will offer a loyalty program (the Queen Club) through which AGYW can earn mystery prizes and discreetly request free SRH products. Drug shops will also have an SRH product display and a tablet with SRH videos for interested customers, and drug shop employees will receive training on contraceptive counseling for AGYW."
45352412|NCT04045912|Other|HIVST|Drug shops will provide HIVST kits to AGYW for free. Employees will receive training on HIVST and will institute an HIV care referral plan for customers who require linkage to confirmatory testing or treatment.
45352413|NCT01093976|Drug|Dronabinol|2.5mg-15mg by mouth once a day for twelve-weeks
45352414|NCT04597346|Device|Bronchoscopic Transparenchymal Nodule Access|Bronchoscopic Transparenchymal Nodule Access (BTPNA) is locating the lesion in the lung tissue guided by the bronchoscope navigation system (LungPro) in the natural lumen (bronchus), and automatically calculates the best point of entry (POE) and the best route to avoid blood vessels. An opening is made from the POE under the endoscope, and is extended with a balloon dilator. Combined with X-ray fluoroscopy, a sheath with a blunt-tip core is used in the lung parenchyma to reach the lesion site, and then biopsy diagnosis or treatment.
45352415|NCT00329719|Procedure|Conventional Surgery|Undergo surgery
45352416|NCT00329719|Other|Laboratory Biomarker Analysis|Correlative studies
45352417|NCT00329719|Drug|Sorafenib Tosylate|Given PO
45843095|NCT01542684|Drug|GM-CSF|250 mcg/m^2 IV or SQ one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.
45843096|NCT01543074|Dietary Supplement|BSE placebo|2 pills = 0 micromoles of Sulforaphane/day
46045993|NCT05586230|Drug|Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB|Non-study prescribed OBR will vary according to local, national and/or international guidelines for treatment of children with MDR-TB. Administered in addition to single dose of Pa.
46045994|NCT05583162|Behavioral|Healthy Sport Project|2 interactive information lectures (given per class of 30 pupils), and 4 interactive workshops (given to sex-homogenous groups of 10 pupils). One per week, a total of 6 weeks with intervention.
46045995|NCT05581056|Drug|CFTR modulators|Introduction of CFTR modulators by pneumologists for pneumologic issues
45352418|NCT00329719|Drug|Temsirolimus|Given IV
45352419|NCT04008628|Drug|Nitrous Oxide|Inhalation of a 50%/50% nitrous oxide/oxygen mixture (Kalinox®)
45352420|NCT04004806|Device|Hill Rom tracking device|Location tracking devices from Hill Rom company.
45477460|NCT03343990|Procedure|Eight Figure techniqe in sternal closure|The figure-eight closure is described as faster, simpler, and more reliable than its trans-sternal counterpart; with only oblique forces sutures are less likely to loosen or fracture the sternum. The advantage of figure-eight closure is that it allows oblique and horizontal angle of shearing forces instead of direct perpendicular forces. Thus these wires are less likely to loosen or fracture
45477461|NCT03842423|Procedure|Brachial Plexus Anaesthesia|Regional anaesthesia for treatment of upper extremity injuries.
45843097|NCT01543074|Dietary Supplement|Garlic oil|1 pill = 30 mg garlic oil/day
45843098|NCT01543074|Drug|BSE|2 pills = 200 micromoles of Sulforaphane/day
45843099|NCT01543074|Dietary Supplement|Garlic Oil Placebo|1 pill = 0 mg garlic oil/day
45843100|NCT01544088|Behavioral|Group Cognitive Behavioral Treatment (GCBT)|GCBT is a 14 week intervention that includes components of exposure (imaginal and in vivo), cognitive restructuring, and relapse prevention.
45352421|NCT00743834|Drug|Luvox CR|In light of the Luvox-CR dosing procedure of Hollander et al (2003) (50 mg increments weekly) and the available dose capsules of Luvox-CR (100 mg and 150 mg), the Luvox-CR dose will be increased over the first 6 weeks of treatment as tolerated in 50 mg to 100-mg increments every week, as tolerated and clinically indicated, to a bedtime dose between 100 and 300 mg/day. The dose will then be held constant for the duration of the study
46045996|NCT05580575|Device|Daily disposable toric soft contact lens|Daily disposable toric soft contact lens
45477462|NCT03172026|Drug|Maraviroc 300 mg|FDA approved chemokine receptor (CCR5) inhibitor. Maraviroc will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
45686450|NCT00179998|Drug|Placebos|2.5 ml sterile solution (8.77 mg/ml sodium chloride, 0.15 mg/ml calcium chloride, pH 7.0 +/- 2.0) delivered daily by nebulization for 6 months, either preceding or following 6 months of Pulmozyme depending on randomization of the subject
45686451|NCT00181168|Drug|Euthyroid Group|Euthyroid Group: Received rhTSH to prepare for radioiodine therapy.
45352422|NCT00743834|Behavioral|Behavioral Therapy|The web-based CBT (CT STEPS) includes an introductory session explaining the treatment, with videotapes of OCD patients who used an earlier version, along with 9 subsequent treatment modules. The CBT will include weekly email feedback from a psychologist in response to questions asked about the CBT by the subjects assigned to this treatment arm.
45686452|NCT02151526|Drug|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product was administered by intravenous (IV) infusion.
45843101|NCT01544088|Behavioral|Present Centered Group Treatment|The active comparison treatment is a 14 week treatment that focuses on here and now problems, especially problem solving skills concerning ongoing stressors.
45843102|NCT01544166|Drug|Gadobutrol (Gadavist, BAY86-4875)|Single intravenous bolus injection of gadobutrol 0.1 mmol/kg BW in term newborns to infants <2 years of age.
46045997|NCT05580575|Device|Monthly replacement toric daily wear soft contact lens|Monthly replacement toric daily wear soft contact lens
46045998|NCT05576753|Procedure|Hernia repair|Robot assisted laparoscopic preperitoneal repair (vTAPP: ventral transabdominal preperitoneal hernia repair) of a midline ventral hernia
45686453|NCT00089752|Device|Continuous Positive Airway Pressure (CPAP) Treatment|CPAP device used at night
45686454|NCT00089752|Device|Sham CPAP device - CPAP device with pressure delivered <1 cm H20|Sham CPAP device used at night
45352423|NCT00743912|Drug|rifaximin|550 mg TID
45843103|NCT01545336|Drug|Anastrozole|1 mg tablet to be taken 1 time daily
45843104|NCT01545336|Drug|Placebo|1 mg tablet to be taken 1 time daily
45843105|NCT01546194|Other|Phone call explaining the research project|A phone call on the day before surgery will be provided to subjects explaining the nature of the clinical trial
46045999|NCT05576649|Other|Task difficulty adaptation according to Arvaneh et al. (2019)|The task difficulty in the P300 speller training will be adapted according to Arvaneh et al. (2019).
46046000|NCT05576649|Other|Random task difficulty|The task difficulty in the P300 speller training is chosen randomly.
46046001|NCT05576649|Other|Task difficulty adaptation according to iterative learning controller|The task difficulty in the P300 speller is determined by an iterative learning controller.
46046002|NCT05573997|Diagnostic Test|Investigation of clinical profile, laboratory and novel echocardiographic imaging biomarkers|Complete and comprehensive medical interview will be conducted in each eligible patient. In addition, patient's laboratory data will be recorded on admission and pre-discharge. Each patient will undergo a full echocardiographic examination with a specific protocol upon admission and pre-discharge. This will include among others 2-dimensional speckle-tracking analysis of all cardiac chambers, and non-invasive calculation of myocardial work indices of the left and right ventricle.
46046003|NCT05572879|Biological|EuCorVac-19|COVID-19 vaccine
46046004|NCT05572879|Biological|ChAdOx1|COVID-19 vaccine
45352424|NCT02563886|Other|Electrically Assisted Movement Therapy|Electrically Assisted Movement Therapy (EAMT) is an extension of conventional Constraint-Induced Movement Therapy (CIMT) for moderately-to-severely paralyzed patients. During EAMT, patients use a movement controller with the healthy hand, controlling movements generated through neuromuscular electrical stimulation of the paralyzed arm and hand. During each session three types of exercises can be performed: mobilization, games, and training for activities of daily living, all three involving proper shaping of exercise difficulty at therapist discretion. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks.
45352425|NCT02563886|Other|Usual and customary care|Usual and customary care ranges from no treatment to varying amounts of orthotics, home-based and clinic-based occupational therapy, or physiotherapy, but always excludes CIMT and EAMT. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks, whenever possible, to match EAMT amount of therapy.
45352426|NCT05306080|Drug|Tadekinig alfa (IL-18BP)|"Tadekinig alfa will be administered via subcutaneous injection. The site of subcutaneous injection should be rotated to avoid injection site reactions; e.g. the outside of the thighs, arms, and the various quadrants of the anterior abdominal wall.~Injection #1/Day 1:~o Loading dose of 4 mg/kg; Maximum dose of 350 mg.~Repeat Injection(s): 2 mg/kg/injection; Maximum dose of 160 mg/injection. Missed doses will not be made up.~Injection #2/Day 3: Approximately 48 hours (+/- 5 hours) after receipt of the 1st injection.~Injection #3/Day 5: Approximately 48 hours (+/- 5 hours) after receipt of the 2nd injection.~Continued Dosing (Optional): Approximately q48-72 hours; If the subject is responsive to initial therapy, but has ongoing symptoms of CRS/CRHLS."
45686455|NCT00090844|Drug|triptorelin|3.75 mg TRELSTAR DEPOT (triptorelin) administered monthly as single intramuscular injection
45686456|NCT01897012|Drug|Alisertib|Given PO
45352427|NCT04060472|Drug|albumin-bound paclitaxel + oxaliplatin|Using albumin-bound paclitaxel (125 mg/m2, d1, 8, 15, ivgtt) + oxaliplatin (80 mg/m2, d1, 8, ivgtt) with or without other chemotherapeutic drugs, 28 days /cycle, until the disease progresses or patients can not tolerate toxicity. The investigators decide the follow-up treatment plan.
45352428|NCT02563730|Procedure|Lung biopsy|transbronchial lung biopsy. First kryobiopsy, second open biopsy
45352429|NCT00329641|Drug|carboplatin|Given IV
45352430|NCT00329641|Drug|paclitaxel|Given IV
45352431|NCT00329641|Drug|sorafenib tosylate|Given orally
45352432|NCT02566070|Other|Continuous Gastric Feeding|
46046005|NCT05571813|Drug|CKD-341|A single dose of 1tablets under fasting condition
46046006|NCT05568667|Behavioral|Low risk|"remote support in physical activity and nutrition via digital media~monthly collective physical activity sessions~logbook"
45352433|NCT02566070|Other|Bolus Gastric Feeding|
45352434|NCT02533219|Drug|18 F-DOPA|Subjects will undergo PET imaging with [18F]-DOPA. All PET imaging will be performed after administration of a single dose (0.08 - 0.16 mCurie/kg) of [18F]-DOPA. PET imaging can be performed on either Philips Ingenuity TF PET/MRI or PET/CT.
45686457|NCT01897012|Other|Laboratory Biomarker Analysis|Correlative studies
45686458|NCT01897012|Drug|Romidepsin|Given IV
46046007|NCT05568667|Behavioral|Moderate risk|"remote support in physical activity and nutrition via digital media~monthly collective physical activity sessions~one collective health education session~logbook"
46046008|NCT05568667|Behavioral|High risk|"remote support in physical activity and nutrition via digital media~monthly collective physical activity sessions~one collective health education session~3 individual sessions of motivational coaching~connected watch~logbook"
46046009|NCT05567068|Drug|Atorvastatin 80mg|Atrovastatin is one of the most effective drugs used to reduce intracellular cholesterol synthesis. it exerts numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement and immunomodulation independent of its basic lipid-lowering properties
45352435|NCT03366220|Drug|Plasma|Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.
45352436|NCT03366220|Drug|Balanced crystalloids|Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
45352437|NCT00743990|Other|Ointment containing camphor, eucalyptus oil, and menthol|One time use
45352438|NCT00743990|Other|Petroleum jelly|One time use
45352439|NCT00329407|Drug|Topiramate (Topamax)|Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM & 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM & 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM & 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
45352440|NCT04595006|Other|Cold Stimulation (CS)|Subject wear cooling vest to stay cool
45352441|NCT04595006|Other|Browning Nutraceutical (BN)|Subject will consume 2000mg of curcumin a naturally-occurring polyphenol antioxidant that is found in turmeric ginger rhizome root
45352442|NCT04595006|Other|Cold Stimulation and Browning Nutraceutical (CSBN)|Subject wear a cooling vest and consume 2000mg of curcumin
45352443|NCT04004728|Procedure|1064 Nd:YAG laser|1064 laser - 135J 25ms spot 3mm GLicose - 75% - 3 ml
45352444|NCT01056757|Drug|Ribavirin|1000 mg bid, po, q28days
45352445|NCT00744068|Behavioral|Continuing Care Telephone Support|Counselor-provided telephone support as strategies to promote patient aftercare attendance and sustained abstinence from stimulant use. To this end, we will develop and compare the efficacy of four low-cost telephone support protocols for patients who have completed the intensive phase of a structured, outpatient stimulant abuse treatment program.
45352446|NCT05288452|Behavioral|Digital Health Coaching|The digital health coaching intervention program involves an evidence-based curriculum and one-on-one support to promote positive health behaviors and patient self-management of diabetes.
45352447|NCT05288452|Dietary Supplement|Food Box Delivery|The food box intervention component will consist of biweekly food boxes delivered directly to participants over the course of 6 months. The food boxes will contain shelf-stable groceries that adhere to ADA nutritional guidelines for individuals with T2DM.
45477463|NCT03172026|Behavioral|Rehabilitation therapy|"All participants will have routine outpatient or home health physical and occupational therapy after inpatient discharge as prescribed by their physicians.~Each group will be contacted weekly by phone to help maintain interest in the trial, count the number of usual care physical and occupational therapy completed, assure use of the assigned medication, ask about possible adverse reactions, and to encourage them to be active. The coordinator will obtain this information and provide the feedback using a standard script and checklist. A unique aspect of this trial is a telerehabilitation component that aims to give feedback to all participants to practice with the affected arm and walk daily."
45352448|NCT05288452|Behavioral|Remote Patient Monitoring (RPM)|The RPM team will instruct the participants to monitor blood glucose levels 4 times daily. Glucose levels will be monitored 8 a.m. to 5 p.m.Monday to Friday. Data summaries will be reviewed bi-monthly with RNs and pharmacists. Participants will be provided with a glucometer, test strips, and mobile divide to record their blood glucose levels.
45477464|NCT03172026|Drug|Placebo 300 mg|Matched placebo will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
45477465|NCT01201577|Dietary Supplement|Bifidobacterium longum BB536|2 capsules od
45477466|NCT01201577|Dietary Supplement|Active hexose correlated compound (AHCC)|One capsule tds
45686459|NCT01498887|Drug|Fingolimod (FTY720)|Hard gelatin capsules containing 0.5 mg of fingolimod.
45352449|NCT05288452|Behavioral|Core Intervention: Diabetes Self-Management Education and Support (DSMES) Program|DSMES program is certified by the American Diabetes Association (ADA) and provided by an ADA-certified diabetes educator. DSMES includes 4-6 hours of interactive group classes covering topics related to diabetes management.
45352450|NCT01056835|Drug|prostaglandin I2 analogue|
45352451|NCT03989323|Other|Estimation of the incidence of the irAE|Assessment of the incidence of the irAE in patients treated with immunotherapy at the Hospices Civils de Lyon (irAE of all grades and from all organs) and creation of a biological collection of blood, plasma, serum and PBMCs from patients before treatment, under treatment and at the onset of irAEs.
45352452|NCT03986515|Drug|apatinib plus SHR-1210|apatinib 250mg qd, 3-5 days later SHR-1210 200mg q3w
45352453|NCT03989479|Behavioral|Brushing demonstration using T shaped toothbrush|Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
45352454|NCT03989479|Behavioral|Brushing demonstration using conventional toothbrush|Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
46046010|NCT05567068|Drug|Mesalamine|Mesalamine
46046011|NCT05565001|Drug|Levcromakalim|Intravenous administration of levcromakalim or placebo over 20 minutes. After 3 hours from the administration of levcromakalim or placebo, participants will receive intravenous infusion of sumatriptan over 10 minutes.
45352455|NCT01056991|Other|warming mattress|comparison of under patient warming mattress to forced air warming blankets in preventing peri-operative hypothermia
45352456|NCT01056991|Other|warming blanket|
45352457|NCT00328783|Device|Active Breathing Coordinator (ABC)|The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.
45352458|NCT00328783|Radiation|Radiation Therapy|
45352459|NCT00567489|Drug|Physioneal|Physioneal 40 or Physioneal 35
45352460|NCT00567489|Drug|Dianeal|Dianeal 1.5% Dextrose (1.30% glucose), 2.5% Dextrose (2.27% glucose), 4.5% Dextrose (3.86% glucose)
45352461|NCT00567489|Drug|Extraneal|7.5% Icodextrin
45352462|NCT00567489|Drug|Nutrineal|Amino Acids 1.1%
46046012|NCT05561062|Drug|Atorvastatin 80mg|Atorvastatin is one of the most effective drugs used to reduce intracellular cholesterol synthesis. it exerts numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement, and immunomodulation independent of its basic lipid-lowering properties
45352463|NCT00669942|Biological|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
45352464|NCT00669942|Drug|Placebo|Placebo to AIN457
45352465|NCT00929019|Biological|autologous dendritic cells electroporated with mRNA|Autologous mature monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
45352466|NCT00907491|Device|pulmonary sounds analyzer|Cough counting device based on the WIM Technology
45352467|NCT00929097|Other|Implementation aids|"Patients and clinicians have access to a website with information on familial colorectal cancer risk; a risk assessment tool and decision aids~Clinicians receive the guidelines and a risk communication tool, as well as education"
45352468|NCT00929097|Other|Control|Dissemination of guidelines
45352469|NCT00769938|Device|PCI (percutaneous coronary intervention)|only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment
45352470|NCT00907569|Radiation|Hypofractionated Chest Radiotherapy|Hypofractionated chest radiotherapy regimen of 58 Gy delivered in 25 fractions in 5 weeks.
45352471|NCT02538393|Drug|Sorafenib (BAY43-9006) Film-coated tablet|Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state in Treatment A
45352472|NCT02538393|Drug|Sorafenib (BAY43-9006) Oral suspension|Treatment C: Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state in the second intervention period; Treatment B: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state in the third intervention period; Treatment D: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) in the fourth intervention period.
45352473|NCT00770016|Drug|Levothyroxin|Dosage regulation will follow the local recommendations of treatment
45352474|NCT00924963|Device|J-Tip jet injector|0.2ml 1%buffered lidocaine delivered by jet injector
45352475|NCT00924963|Device|Jet injection saline|0.2ml saline delivered via J-Tip jet injection
45352476|NCT00924963|Drug|lidocaine cream|4% lidocaine cream applied for 30 minutes to the skin
45352477|NCT00770094|Device|Excimer Lasers|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment AMO/VISX CustomVue™ wavefront guided Excimer Laser System
45352478|NCT00770094|Device|Excimer Laser for the LASIK procedure|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System
45352479|NCT00770094|Device|Excimer Laser for LASIK|WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment Bausch and Lomb Planoscan™ Excimer Laser System
45352480|NCT00925041|Device|Vedera KXS|one treatment with the Vedera KXS
45352481|NCT00775788|Procedure|Autologous Fat Grafting to Breasts|Fat injection of Fat to breasts
45352482|NCT00929175|Device|active CPAP|auto-PAP with pressure between 6 and 12 cm H2O or sham CPAP will be administered to randomized patients
45686460|NCT01498653|Drug|GW685698/GW642444|ICS/LABA
45686461|NCT01498653|Drug|CCI18781|ICS
46046013|NCT05551819|Dietary Supplement|MDF then RUTF/RUSF|Children randomized to feeding order 1: children will be provided MDF for the first two weeks then crossover to consume RUTF/RUSF for a second two weeks.
46046014|NCT05551819|Dietary Supplement|RUTF/RUSF then MDF|Children randomized to feeding order 2: children will be provided RUTF/RUSF for the first two weeks then crossover to consume MDF for a second two weeks.
45352483|NCT00929175|Device|sham-CPAP|The sham-CPAP was the same equipment used for active CPAP (Respironics Remstar-Auto, Murraysville, PA) fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al. The differences between the two were undetectable except for the pressure generated in the facial mask in the sham-CPAP that was no greater than 1cm H2O.
45352484|NCT00929409|Drug|Ferric carboxymaltose|Intravenous infusion of Ferric carboxymaltose in a dose calculated to meet the individual patient's requirements following the Ganzoni formula
45352485|NCT00929409|Drug|Ferrous sulfate tablets|Standard tablets containing 100 mg ferrous sulfate, 1 tablet two times daily
45352486|NCT00772512|Drug|PF-04802540|5 mg capsule, single dose
45352487|NCT00772512|Drug|PF-04802540|15 mg capsule, single dose
45352488|NCT00772512|Drug|Placebo|Placebo capsule, single dose
45352489|NCT00925197|Other|INR self-testing program|
45352490|NCT00775866|Procedure|MRI-Guided Biopsy|Technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table.
45352491|NCT00669864|Drug|biphasic insulin aspart 30|Subcutaneous (under the skin) injection, twice daily
45352492|NCT00669864|Drug|metformin|Tablets, 1000 - 2000 mg daily
45352493|NCT00770172|Biological|filgrastim|Given subcutaneously
45352494|NCT02557620|Drug|semaglutide|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
45352495|NCT02557620|Drug|placebo|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
45352496|NCT00776022|Drug|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions
45352497|NCT00772824|Dietary Supplement|Glutamine|2g/kg body weight twice daily in divided doses for 5 days
45352498|NCT00772824|Dietary Supplement|IV Glutamine|50 ml of 20% glutamine IV before chemotherapy
45352499|NCT03875040|Behavioral|kinesiophobia|patients who have a high-level or low-level kinesiophobia have been evaluated.
45352500|NCT04047732|Biological|KB105|KB105, a replication-incompetent, non-integrating HSV-1 vector expressing human transglutaminase 1 (TGM1) formulated as a topical gel
45352501|NCT00772902|Drug|Truvada + Kaletra|Truvada (emtricitabine 200 mg/tenofovir DF 300 mg)once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
45352502|NCT00772902|Drug|Kivexa + Kaletra|Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
45352503|NCT02557152|Device|GentleWave System Treatment|
45352504|NCT00779220|Drug|placebo|Intravenous repeating dose
45352505|NCT00779220|Drug|methotrexate|Oral repeating dose
45352506|NCT00779220|Drug|ocrelizumabu 50mg|Intravenous repeating dose (50mg)
45352507|NCT00779220|Drug|ocrelizumabu 200mg|Intravenous repeating dose (200mg)
45352508|NCT00779220|Drug|ocrelizumab 500mg|Intravenous repeating dose (500mg)
45352509|NCT00776256|Dietary Supplement|beta-glucan and fructooligosaccharide|1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
45352510|NCT00779376|Drug|Zidovudine 300mg tablets|
45352511|NCT00779454|Drug|Gemcitabine, Oxaliplatin, Capecitabine,|Gemcitabin: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7
45352512|NCT00779454|Drug|Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine|Gemcitabine: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7 Panitumumab: 6 mg/kg day 1
45352513|NCT00772980|Drug|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.
45352514|NCT00772980|Drug|Placebo|Double-blind treatment period of 17 weeks placebo, 12 weeks follow-up.
45352515|NCT00773058|Drug|hydrocortisone|hydrocortisone 100mg q8h
45352516|NCT00773058|Drug|placebo|normal saline 100ml q8h
45352517|NCT00776334|Drug|Fosinopril 40mg Tablets|
45352518|NCT00779610|Procedure|Vibration with flexion|Vibration with forearm flexion (active contraction)
45352519|NCT00779610|Procedure|Vibration without flexion|Vibration without forearm flexion (passive)
45352520|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Ewing's Sarcoma/PNET~10 milligrams per kilogram (mg/kg) intravenous (IV) infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
45352521|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Rhabdomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
45352522|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Leiomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
45352523|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Adipocytic sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
45352524|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Synovial sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
45843106|NCT01548690|Drug|Ornithine Phenylacetate|"Up to 36 patients will be enrolled into 2 groups [~18 with minimal renal dysfunction (Cohort 1) & ~18 w/ comprised renal function (Cohort 2)] and receive OCR-002 infusion for at least 72 hrs. OCR-002 will be administered in the vein and pharmacokinetics (pk) assessed for all subjects who receive the infusion.~The first 24 enrolled subjects received OCR-002 at 3 ascending dose levels (DLs 1-3) with a maximum target infusion rate equivalent to 10g/24h.~The remaining 12 patients (~6 Cohort 1 & ~6 Cohort 2) will be enrolled and receive identical quantities of OCR-002 at 20g/24hr continuously for 5 days (Dose Level 4)."
45843107|NCT01551030|Drug|Buparlisib|Buparlisib will be administered at a dose of 100 mg orally once daily (two 50 mg capsules) continuously. Intra-patient dose reduction may be required depending on the type and severity of the individual toxicity encountered. Re-staging imaging studies will be performed after every two cycles of treatment (one cycle = 4 weeks). Patients may continue on study as long as they are tolerating therapy and are free of disease progression.
45843108|NCT01551186|Dietary Supplement|Lactobacillus rhamnosus GG|1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
45843109|NCT01551264|Device|Foot Abduction Brace (FAB)|After clubfoot correction, the participants will wear the FAB 23 hours/day for 3 months and then wean to naps and nighttime (8-12 hours/day) for either 2 or 4 years depending on which arm they are in.
45843110|NCT01551888|Drug|Aclidinium/formoterol 400/12μg|Aclidinium/formoterol 400/12μg fixed dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
45843111|NCT01551888|Drug|Formoterol|Formoterol 12 μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
45843112|NCT01553058|Drug|Adalimumab (Humira)|Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.
45843113|NCT01553058|Drug|Placebo Injection|Placebo injection will be given according to the same dose and schedule as the active comparator.
45843114|NCT01553058|Other|NB-UVB phototherapy|Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.
45843115|NCT01553292|Device|ECALMIST|Labelled catheter at level of the lips (6 cm plus weight) will inserted through the vocal cords under direct vision using a standard laryngoscope without premedication while maintaining CPAP. 5 ml/kg surfactant syringe will be connected to the catheter hub and 0.25-0.5 ml was administered; then the syringe will be disconnected from the catheter to observe the surfactant moving up and down or coming back as indication of accurate intubation of the trachea. The surfactant the slowly administer by boluses of 0.25-0.5 ml over 20-30 seconds with 10 seconds apart. At the end of the procedure, the operator flushed the catheter with 0.5 ml of air before removing the catheter while maintaining CPAP
45843116|NCT01553292|Device|ECALMIST|Vascular catheter of 1.6 French size of 133 mm length 16 gauge used to deliver the BLES; a large volume surfactant while maintain CPAP
45843117|NCT01556100|Drug|18F-DTBZ AV-133|A total 40 PD subjects will be included in this study. PD subjects between 20 and 80 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, and blood test.
45843118|NCT01556724|Drug|0.1% or 0.2% ropivacaine nerve blocks|Either 0.1% or 0.2% ropivacaine will be infused at 7 mL/hr through lumbar plexus nerve block catheter based upon randomization, and can then receive a 6 ml bolus of either 0.1% or 0.2% ropivacaine. Additional pain relief will be available by nurse administered boluses of additional local anesthetic (from their randomized infusion) with a maximum dose of an extra 3 ml per bolus and limited to one bolus per hour. This bolus of their randomized local anesthetic will remain available until the nerve catheters are removed. Nerve block infusion rates may be increased to 9 ml/h for patients with increased pain without increased motor blockade as determined by the acute interventional perioperative pain service (AIPPS) or decreased to 5 ml/h for patients with increased motor blockade or weakness from the peripheral nerve block as determined by the AIPPS .All continuous lumbar plexus catheters will be removed on post operative day (POD) 2.
45352525|NCT00667992|Drug|Budesonide HFA|standard daily inhaled dose
45352526|NCT00667992|Drug|Budesonide CFC|standard daily inhaled dose
45477467|NCT01201577|Dietary Supplement|Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC)|One capsule tds (prebiotic) and two capsules od (probiotic)
45477468|NCT01201577|Dietary Supplement|Corn starch placebo capsule|One capsule tds and two capsules od
45352527|NCT02556294|Behavioral|Self-acceptance based intervention|The intervention will consist of HIV/STI counseling and testing as well as individual counseling sessions and group sessions. The primary focus of the group sessions are to help foster self-acceptance by the support from the group, as well as learn skills to reduce distress and HIV risk. The primary purpose of the individual sessions is to help develop and implement an individualized plan for HIV risk reduction, and, as needed and available, linkage to other services.
45352528|NCT02556294|Behavioral|HIV/STI counseling and testing|The counseling component is standard of care in India and will focus on HIV/STI risk and how to minimize risk. This is followed by biological testing for HIV and STIs.
45352529|NCT00779688|Device|Probe-based confocal laser endomicroscopy|ERCP with or without cholangiopancreatoscopy will be performed by the endoscopist as clinically indicated. If findings at ERCP and/or prior imaging studies and/or clinical assessment suggest possible malignancy and/or an indeterminate biliary or pancreatic pathology Cellvizio probe-based endomicroscopy will be performed during ERCP.
45352530|NCT00776490|Drug|Glimepiride 1mg Tablets|
45352531|NCT00779844|Procedure|bariatric coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a close-loop system with the Bispectral Index as the single input for the controller
45352532|NCT00779844|Procedure|supra-umbilical coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a closed-loop system with the Bispectral Index as the single input for the controller
45352533|NCT00773214|Behavioral|Exercise|12-week supervised exercise programme (5 times /week at 75% maximal Heart Rate)
45843119|NCT01557894|Other|iSOFIE|Cognitive - Behavioral: Internet-administrated CBT for social phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
45843120|NCT01558128|Drug|Amiodarone|Bolus given 150mg IV, then IV drip 1mg per hour infused for 6 hours, 0.5mg per hour infused for 18 hours.
45352534|NCT00776568|Procedure|Extra-corporeal shockwave|Low intensity shock waves are applied as 300 shocks per visit for 09 visits. The treatment visit is carried at week 1, 5 and 9.
45352535|NCT00776568|Drug|Anti-hypertensive drugs|ACE inhibitors, Ca channel blockers, Beta blockers, Diuretics, Cholesterol lowering agents and/or other drugs used alone or in combination, as prescribed.
45352536|NCT00779922|Drug|lenalidomide|
45352537|NCT00776646|Drug|hydrochlorothiazide 50 mg tablet|
45352538|NCT00780078|Procedure|extubation|extubation failure in patients intubated orotracheally
45352539|NCT00773448|Device|Comprehensive computed tomography of the abdomen/pelvis|Virtual colonoscopy and gastroscopy, a biphasic enhanced CT for hepatoma and renal cell carcinoma, parenchymal pancreatogram with minimum intensity projection (MinIP) reformation for pancreatic carcinoma, and finally uniphasic enhanced CT of distended bladder for bladder and ovarian carcinomas.
45477469|NCT01201577|Drug|Azithromycin|250mg od
45477470|NCT02496520|Biological|dendritic cells|vaccines with dendritic cells pulsed with tumor lysate
45843121|NCT01558128|Procedure|Cardioversion|Cardioversion done if atrial fibrillation continues following 24 hour infusion of amiodarone. Cardioversion done following hospital protocol.
45477471|NCT02496520|Procedure|Surgery as needed by the patient´s tumor and stage|
45477472|NCT02496520|Drug|Chemotherapy as needed by the patient´s tumor and stage|
45477473|NCT02496520|Radiation|Radiation therapy as needed by the patient´s tumor and stage|
45352540|NCT00773448|Other|Limited Malignancy Screening|"1) A complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin, LDH); 4) renal function test (creatinine); 5) chest X-ray (if not performed in the past year)~In women, a pap smear/pelvic examination (if > 18 and < 70 years old and not performed during the past year),a mammogram (> 50 years old) will be performed if not conducted in last year. Similarly for men, prostate examination +/- PSA testing (>40 years old) will be performed if not conducted in the past year."
45352541|NCT00776724|Drug|Taxotere , Epirubicin|Taxotere 70 mg/m2 1hr iv infusion / Epirubicin 90 mg/m2 (TE) iv infusion on day 1.
45352542|NCT00776724|Drug|E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP|"Tau+ topo II+ ERCC1+ : Epi 45mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II+ ERCC1- : Epi 45mg/m2 iv/ Cis 35mg/m2 24 hrs iv infusion day 1 and 8.~Tau+ topo II- ERCC1+ : Vin 25mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II- ERCC1- : Cis 35mg/m2 24 hrs infusion / Vin 25mg/m2 iv day 1 and 8.~Tau- topo II+ ERCC1+ : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II+ ERCC1- : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II- ERCC1+ : Tax 35mg/m2 1hr infusion / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau- topo II- ERCC1- : Tax 35mg/m2 1hr infusion / Cis 35mg/m2 24 hrs infusion day 1 and 8."
45686462|NCT01498575|Behavioral|Teen driving plan|Web-based intervention designed to facilitate parent supervised practice driving with novice teen driver.
45686463|NCT01498185|Drug|Dapagliflozin|Tablets, Oral, 1 mg, Once daily, 14 days
46046015|NCT05550402|Drug|Salbutamol|Visit 1, After predosed spirometry is done, the patients will be received 4 puffs of salbutamol. 30 minutes later, if they meet the criteria of fixed airway obstruction based on ATS criteria, then they will continue to undergo serial spirometry at 1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of ipratropium and do spirometry at 4.5 and 5 hours.
45843122|NCT01559064|Device|Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)|All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.
45843123|NCT01559922|Drug|Normal Saline|Administration of up to 2 study treatments administered 6 weeks apart
45843124|NCT01559922|Device|Artefill|Administration of up to 2 study treatments administered 6 weeks apart
45686464|NCT01498185|Drug|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, Once daily, 14 days
45686465|NCT01528605|Dietary Supplement|placebo|Placebo, one gelatine capsule containing starch per day, for 96 weeks
45686466|NCT01528605|Dietary Supplement|low lutein|one gelatine capsule containing 10mg lutein per day, for 96 weeks
45686467|NCT01528605|Dietary Supplement|high lutein|one gelatine capsule containing 20mg lutein per day, for 96 weeks
45686468|NCT01528605|Dietary Supplement|lutein plus zeaxanthin|one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks
45843125|NCT01560624|Drug|Treprostinil Diolamine|Active
46046016|NCT05550402|Drug|Ipratropium Bromide|Visit 2, After predosed spirometry is done, the patients will be received 4 puffs of ipratropium they will continue to undergo serial spirometry at 30 minutes,1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours.
45843126|NCT01560624|Drug|Placebo|Placebo
45352543|NCT00773526|Drug|RO5126766|Administered orally daily for 28 days, at escalating doses (with a starting dose of 0.1mg) (Part 1). Optimal biological dose or maximum tolerated dose administered orally, daily (Part 2).
45352544|NCT00776802|Drug|GCS-100|GCS-100 80 mg/m2 IV (in the vein) on Study Days 1, 2, 3, 4, and 5 of a 21-day course. Three or up to six patients will be enrolled in each cohort until the maximum tolerated dose is reached. The dose levels: 1) 80 mg/m2; 2) 120 mg/m2; 3) 160 mg/m2
45352545|NCT00776802|Drug|Etoposide; Dexamethasone|Etoposide 100 mg/m2 on Study Days 3, 4 and 5; Dexamethasone 10 mg/m2 on Study Days 1, 2, 3, 4 and 5.
45352546|NCT00780312|Other|physiotherapy|50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse. Furthermore they receive in all 6-7 sessions of physiotherapy treatment for a 5-6 weeks period with sessions of approximately 45 minutes. 2 months after having completed radiotherapy treatment they receive a final physiotherapy treatment. The treatment consists of instruction in active and passive exercises for mouth opening, stretching exercises for the neck and shoulder region, tongue exercises, mimic exercises, self administered lymph drainage and softening of fibrotic tissue.
45352547|NCT00776880|Other|ASA scale|ASA scale evaluation before operation
45352548|NCT00776880|Other|PPS scale|PPS scale evaluation before operation
45477474|NCT03058770|Other|Sensorimotor retraining|Subjects will receive education regarding sensation and sensory retraining; practice in detection and localization of touch and in discrimination of hardness, texture and temperature in sitting and standing with vision obscured; proprioception training; and practice of these sensations in functional activities.
45352549|NCT00780390|Other|Autonomic Function Assessment|
45352550|NCT00780468|Behavioral|Existing diet plan|
45477475|NCT03058770|Other|Relaxation technique|Subjects will perform guided relaxation by using the Jacobson technique.
45477476|NCT01298609|Device|Occipital Stimulation|Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system
45352551|NCT00780468|Behavioral|New diet plan|
45352552|NCT00773682|Other|local mud-pack therapy and balneotherapy|Patients will be treated with local mud-pack application on the hands for 20 minutes and thermal-mineral bath once a day for 15 days.
45352553|NCT00773760|Other|SNP genotyping|Coded blood specimens will be transported to the Department of Gene Technology TTÜ and genotyping analysis will be performed. Lymphocytes will be isolated from blood specimens using Ficol-Paq gradients, and genomic DNA isolated using a salting-out procedure. Variants of the MOR gene and other genes of interests will be performed by DNA sequence analysis of PCR-amplified DNA, using primers located in flanking intron sequence. All methods proposed are currently in operation in the respective facilities.
45352554|NCT00773916|Drug|Methylphenidate|Dose increments according to clinical evaluation, starting with 0,3 mg/kg of weight/day
45352555|NCT00773994|Other|Normal Velopharyngeal Mechansim|The amount of radiation exposure that you will receive from this procedure is about 0.3 rem to the head and neck, with minimal exposure of the other body areas.
45352556|NCT00774072|Drug|Tobramycin (Gernebcin®)|1 ml / day in each nostril
45352557|NCT00774150|Behavioral|Cognitive Behavioral Therapy|16 sessions of CBT
45352558|NCT00774150|Behavioral|Client Centered Therapy|16 sessions of CCT
45352559|NCT02556996|Biological|ETEC/rCTB vaccine|Cocktail of five whole-cell, formalin-inactivated ETEC strains (total of 10^11 formalin-killed bacteria per dose) plus recombinant cholera toxin B-subunit (rCTB) (1 mg)
45477477|NCT04496050|Drug|Prostaglandin E1|The same drug will be used. In this study the same patients will be evaluated after the same dose of medication.
45477478|NCT01300793|Drug|Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide|Rituximab, 375 mg/m2, IV on day 1 Etoposide, 100 mg/m2, IV on days 2 to 4 Carboplatin, AUC 5 (using the Calvert Formula), IV on day 3 Ifosfamide, 5 g/m2 with Mesna 5 g/m2, CIV over 24 hours beginning D. 3 Bortezomib,1.0mg/m2 starting cohort. Based upon a satisfactory safety profile, additional pts. will be enrolled into the 1.3, 1.5 and 1.7mg/m2 cohorts given IVP over 3 sec. d. 1, 4, 8 & 11 q. 28 days.
45477479|NCT03342040|Procedure|Laparoscopic ventral hernia repair with TAP block|Transverse abdominis plane block is given under ultrasound guidance during laparoscopic ventral hernia surgery
45477480|NCT03342040|Procedure|Laparoscopic ventral hernia repair without TAP block|No block administered during Laparoscopic ventral hernia surgery
45477481|NCT02495974|Drug|enzalutamide|oral
45477482|NCT01206413|Dietary Supplement|Low glycemic index diet|
45352560|NCT02556996|Other|Placebo|Heat-killed, nonpathogenic E. coli K-12 bacteria (total of 10^11 heat-killed bacteria per dose)
45352561|NCT00774228|Device|I-ZIP Ocular Bandage|
45352562|NCT00774228|Device|Oasis 24 Hour Soft Shield Collagen Corneal Shield|
45352563|NCT00780624|Device|NIPPV|Ventilator is Bird VIP.
45352564|NCT00780624|Device|NIPPV|Ventilator(Bird VIP) is used for NIPPV device. Non-invasive NIPPV is used in the NIPPV group instead of nCPAP in the control group.
45352565|NCT00780624|Device|NIPPV|Ventilator (Bird VIP, USA) is used for provide of NIPPV in the NIPPV group instead of nCPAP in the control group. The duration of NIPPV is according to the baby's respiratory condition.
45352566|NCT04047498|Device|Alternating DBS|Constant DBS will be changed to DBS that is up- and downmodulated alternating between the left and right stimulation side.
45352567|NCT00780702|Drug|Airipiprazole|Participants receive aripiprazole (orally, up to 15 mg/day) plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
45352568|NCT00780702|Drug|Placebo|Participants receive identical capsules containing no active medication plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
45477483|NCT01206413|Dietary Supplement|High glycemic index diet|
45477484|NCT01206413|Other|Home-based exercise intervention|
45352569|NCT00780780|Drug|Triamcinolone + Nepafenac|Triamcinolone intravitreal injection 0,1 ml (4mg) Nepafenac 1 drop, tid, during 6 months
45477485|NCT01206413|Other|Non-exercisers|
45477486|NCT03818633|Device|Elastic abdominal binder|Each woman in the intervention group is fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder is placed snuggly tight (keeping in mind patient's comfort) on top of the hospital gown with the incision positioned at the middle part of the binder. The patients are encouraged to wear binders at all time. However, periods of break from wearing the binder are allowed at their convenience.
45477487|NCT03818789|Behavioral|Mindfulness and acceptance training|A breathing mediation, body scan, talking about acceptance, and presence activity are used. All are low-impact and expected to cause no distress
45477488|NCT03818789|Behavioral|Study skills video|A YouTube video describing study skills and suggested habits is used as a control condition.
45477489|NCT03337048|Device|SpeediCath|SpeediCath is a standard intermittent catheter that is on the market.
46046017|NCT05550402|Drug|Salbutamol plus Ipratropium Bromide|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm). Then, the patients requested to be administered 4 puffs of ipratropium and 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours (Salbutamol plus ipratropium arm)
45352570|NCT00780780|Drug|triamcinolone intravitreal injection|triamcinolone intravitreal injection
45352571|NCT00780858|Drug|Ganirelix|Ganirelix 0.25mg s.c every 24 h starting stimulation day 6
45352572|NCT00780936|Procedure|femoral nerve block|
45352573|NCT00776958|Other|Questionnaire|Information Collection for Entry into Multicenter Registry: Survey 5-10 minutes. Participation lasts as long as patient agrees to continue having study information collected
45352574|NCT00774384|Biological|NZ MenB OMV vaccine (NZ98/254)|3 doses by intramuscular injection
45352575|NCT00777114|Drug|bortezomib, tositumomab|"0.30mg/m2 bortezomib and 50cGy 131I-tositumomab,~0.30 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~0.60 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~0.90 mg/m2 bortezomib and 75 cGy 131I-tositumomab, and~1.2 mg/m2 bortezomib and 75 cGy 131I-tositumomab."
45352576|NCT00669396|Drug|Copper T380 IUD|Copper T380 IUD
45352577|NCT00669396|Drug|levonorgestrel|1.5 mg
45352578|NCT00774462|Drug|Rituximab|Rituximab 1000 mg intravenous, 2 times, 2 weeks apart and 1000 mg 6 months after the last injection
45477490|NCT03120364|Biological|NBP608|Preparation of Oka/SK strain of live, attenuated zoster virus
45477491|NCT03120364|Biological|Zostavax|Preparation of Oka/Merck strain of live, attenuated zoster virus
45477492|NCT01298843|Drug|Ceftaroline fosamil|Single dose of 15 mg/kg (up to 600 mg) by intravenous infusion
45477493|NCT03336970|Other|EDTA|
46046018|NCT05550402|Other|Placebo|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm).
46046019|NCT05547165|Device|Percutaneous Patent Ductus Arteriosus Closure (PPC)|Infants in this group will undergo catheter-based PPC closure ≤48 hours following randomization and within 7-days of qualifying ECHO. All participants assigned to PPC will receive the Amplatzer Piccolo™ Occluder which will be implanted within the duct (intraductal placement). The Piccolo™ occluder is approved by the US FDA for this purpose.
45352579|NCT00777192|Behavioral|Questionnaires|20 Minute Questionnaires beginning Visit 1, to measure pain/other symptoms, mood, and quality of life
45352580|NCT00669318|Biological|alemtuzumab|
45352581|NCT00669318|Biological|rituximab|
45352582|NCT00669318|Drug|pentostatin|
45477494|NCT03336970|Other|NaOCl|
45477495|NCT03336970|Other|CHX|
45477496|NCT03336970|Other|Calcium hydroxide|
45686469|NCT01528605|Dietary Supplement|high zeaxanthin|one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks
45352583|NCT00669318|Drug|sargramostim|
45352584|NCT00781092|Other|Systane Ultra|Ophthalmic Solution, 1 gtt, three times daily to both eyes for 1 month post operative
45352585|NCT00781092|Other|Bausch and Lomb Sensitive Eyes|Ophthalmic Solution, 1 gtt, three times a day in both eyes for 1 month after LASIK
45352586|NCT00781170|Procedure|allogeneic hematopoietic SCT|
45352587|NCT00774540|Drug|1 Ketorolac intraarticular|Ketorolac intraarticular 5 mg
45352588|NCT00774540|Drug|Placebo|Saline
45352589|NCT00777270|Procedure|repair of episiotomy or second degree tears|continuous suture technique with continuous non-locking suture in the vagina, perineum and subcutaneous tissue.
45352590|NCT00777270|Procedure|repair of episiotomy or second degree tears|interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture
45352591|NCT00774618|Device|Resection with or without plate fixation|Some enrolled subjects will undergo rib fracture surgery at OHSU. Devices used in the repair of rib fracture non-union could include RibLoc® or BioBridge ™. RibLoc® is a U-shaped permanent device that secures to the rib with screws locking from the front to the back of the metal plate (through the rib). BioBridge ™ is a resorbable, non-permanent device that stabilizes the ribs. Both devices are designed to stabilize the rib fracture non-union and promote healing of the non-union rib. For some patients, it may be determined that resection of the rib fracture non-union without an implanted device is the most appropriate treatment. The goal of surgical intervention is to improve the pain and disability associated with rib fracture non-union in appropriate patients.
45352592|NCT00669240|Drug|Varenicline|According to the approved Summary of Product Characteristics (SmPC), patients will be required to orally take 0.5 mg once daily for the first 3 days and titrate up to 0.5 mg twice daily for days 4 - 7. From day 8 to the end of treatment patients should take 1 mg twice daily. Patients who cannot tolerate adverse effects of Champix may have the dose lowered temporarily or permanently to 0.5 mg twice daily. Patients should be treated for 12 weeks. Treatment should start 1 - 2 weeks prior to quitting smoking.
45352593|NCT00669162|Drug|Docetaxel|20mg/m2 IV weekly for 7 weeks
45352594|NCT00669162|Radiation|Radiation Therapy|66.0 Gy delivered in 33 daily fractions at 2.0 Gy/fx
45352595|NCT00669162|Drug|Casodex and Zoladex (or Lupron)|Casodex 50 mg po daily for 6 months, and Zoladex 10.8 mg sc q 3 mos x 2 (or Lupron 22.5 mg im q 3 mos x 2)
45352596|NCT00774696|Drug|clarithromycin 500mg tablets|
45843127|NCT01561716|Device|Wii Fit|This is a randomized, crossover study to evaluate the energy expenditure associated with Wii Fit games. After the baseline resting energy expenditure assessment, each participant complete the following physical activities on separate days in a random order, (1) 30-minute Wii Fit Aerobics Free Run, (2) 3 bouts of Wii Fit Aerobics (Advanced Step, Super Hula Hoop, and Rhythm Boxing in a random order) each lasting 10 minutes, and (3) 30-minute treadmill running/walking.
45843128|NCT01562886|Drug|Rilpivirine|Rilpivirine 26mg
45352597|NCT00774774|Device|control|"Non sterile surgical mask,high filtration AEROKYN,type 2 with eardrop"
45352598|NCT00774774|Device|Face mask|"Non sterile surgical mask, high filtration AEROKYN, type 2 with eardrop Masks will be worn at home by the patient over a period of 5 days following inclusion, whenever a member of the household will attend the same room or in other confined space (eg car), and changed after 3 hours of consecutive use or sooner if they are tor~Masks will not be worn:~during the night,~when the patient is alone in the room. Moreover, for all households, an incentive in nocturnal isolation of index-patient will be recommended"
45352599|NCT02556060|Drug|Lamotrigine|Starting from 25 mg/day in the first week, then titrated up to 200 mg/day for 12 weeks
45352600|NCT02556060|Drug|Placebo|Same dosing schedule as study drug
45352601|NCT00400946|Drug|asparaginase|
45352602|NCT00400946|Drug|cyclophosphamide|
45352603|NCT00400946|Drug|cytarabine|
45352604|NCT00400946|Drug|dexamethasone|
45352605|NCT00400946|Drug|dexrazoxane hydrochloride|
45352606|NCT00400946|Drug|doxorubicin hydrochloride|
45352607|NCT00400946|Drug|etoposide|Given IV
45352608|NCT00400946|Drug|leucovorin calcium|
45352609|NCT00400946|Drug|mercaptopurine|Given orally
45352610|NCT00400946|Drug|methotrexate|
45352611|NCT00400946|Drug|methylprednisolone|
45352612|NCT00400946|Drug|pegaspargase|Given IV
45352613|NCT00400946|Drug|prednisolone|
45352614|NCT00400946|Drug|therapeutic hydrocortisone|
45352615|NCT00400946|Drug|vincristine sulfate|
45352616|NCT00400946|Radiation|radiation therapy|
45352617|NCT00354770|Drug|Placebo|daily
45352618|NCT00354770|Drug|N-Acetyl Cysteine|600mg capsules in varying doses for 12 weeks.
45352619|NCT00741494|Device|PICSI dish|Sperm are added to the PICSI dish. Only those that bind to the hyaluronan microdots are selected for ICSI
45352620|NCT00744146|Biological|Protexia|Single 50 mg IM dose
45352621|NCT00744146|Biological|Protexia|Single 100 mg dose
45352622|NCT00744146|Biological|Protexia|Two 250 mg doses, IM, one at Day 1 and one at Day 72
45352623|NCT00744146|Biological|Protexia|Single 500 mg dose, IM
45352624|NCT00744146|Biological|Protexia|Single 750 mg dose, IM
45843129|NCT01563198|Behavioral|Comfort Talk®|Personnel of MRI units will be trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This will entail 16 hrs class room work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
46046020|NCT05547165|Combination Product|Responsive Management Intervention|"Interventional PDA-closure, including PPC or surgical ligation and post-randomization pharmacologic (NSAID or acetaminophen) (enteral or intravenous) PDA treatment, are not allowed unless secondary treatment thresholds (see below) are met. Healthcare decisions for Responsive Management will be made at the discretion of the treatment team, while the infant is carefully monitored for any decline in status that may be attributed to the presence of PDA, in which case, Secondary Intervention (described below) may be considered.~Despite widespread acceptance of responsive PDA management, no consensus definition exists. The following Responsive Management interventions are permitted but not required per clinician discretion: 1) fluid restriction between 120-140 mL/kg/day; 2) diuretics (per local practice); 3) increases in positive end-expiratory pressure (PEEP)."
46046021|NCT05547165|Diagnostic Test|Echocardiogram, cardiac|"An echocardiogram, also known as ECHO, is an ultrasound image of the heart. Echocardiography is a common test used for the diagnosis and management of cardiac diseases or conditions."
45352625|NCT00744224|Drug|Placebo|Single dose of placebo with saline infusion
45352626|NCT00744224|Drug|Prednisolone|Single dose of 80 mg prednisolone with saline infusion
45352627|NCT00744224|Drug|Prednisolone and Exenatide|Prednisolone 80 mg single dose Exenatide infusion 20 mg/min
45352628|NCT00744302|Drug|physiological (1.25 mmol/L ) calcium dialysate|Using the physiological calcium dialysate (1.25 mmol/L calcium dialysate)for Stable haemodialysis treatment for more than 3 months, undergoing 2 to 3 times haemodialysis a week for 4 to 5 hours per session
45352629|NCT00666588|Drug|idarubicin|Given IV
45352630|NCT00666588|Drug|cytarabine|Given IV or IT
45352631|NCT00666588|Drug|bortezomib|Given IV
45843130|NCT01564914|Drug|TRC105|10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
45843131|NCT01564914|Drug|Bevacizumab|IV
45352632|NCT00666588|Drug|etoposide|Given IV
45352633|NCT00666588|Other|laboratory biomarker analysis|Correlative studies
45352634|NCT00689390|Biological|Boceprevir|In previous treatment studies, boceprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
45352635|NCT00689390|Biological|Narlaprevir|In previous treatment studies, narlaprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
45843132|NCT01565538|Drug|Erlotinib|150 mg Given orally
45843133|NCT01565538|Drug|Pemetrexed|500mg/m2 Given IV
46046022|NCT05544214|Drug|CKD-371|PO
46046023|NCT05543512|Device|Algorithm to diagnose food allergens|An algorithm to diagnose food allergens that will drive diet intervention assignment for those in the active arm. Subjects randomized to this group will receive a diet assignment based on results of the algorithm.
46046024|NCT05543512|Other|Sham diet|Sham diet developed via selecting a random number of foods from a random list of the potential eliminated foods.
45352636|NCT00689390|Biological|Peginterferon alfa-2b|In previous treatment studies, peginterferon alfa-2b was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
45352637|NCT00689390|Drug|Ribavirin|In previous treatment studies, ribavirin was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
45352638|NCT00689390|Other|Blood/Plasma Collection|Blood samples were collected at all visits during the LTFU for blood chemistry and hematology. Plasma samples were collected at all visits as appropriate from participants who were sustained responders at the end of FU in the previous treatment protocol for HCV-RNA PCR and HCV sequence analysis.
45352639|NCT00781248|Device|NG Shield|A device to reduce pain/discomfort related to nasogastric tube usage
45352640|NCT00567879|Drug|Panobinostat|Participants received escalating doses of panobinostat until the maximum tolerated dose (MTD) was reached. The starting dose of panobinostat i.v. was 10mg/m^2 at days 1 and 8 during a 21-day treatment cycle. The oral panobinostat starting dose was 20 mg twice weekly.
45352641|NCT00567879|Drug|Trastuzumab|Fixed doses of trastuzumab were given in parallel with panobinostat. Trastuzumab i.v. was given weekly according to the instruction in the package insert.
45352642|NCT00781404|Drug|Adenosine|Single dose of adenosine. Solution for infusion of 0.45 mg/mL. Enteral use.
45352643|NCT00777504|Drug|usage oral angiogenesis inhibitor|see under 'study arms'
45352644|NCT00777504|Drug|stop oral angiogenesis inhibitor|see under 'study arms'
45352645|NCT00781482|Drug|eszopiclone, zolpidem, placebo|In random order, each subject will receive one study drug per visit over three visits. Visits will occur about 1 week apart. Each subject will eventually receive eszopiclone 3 mg., zolpidem 10 mg., and a placebo. PET scans will be done 1-2 hours after each dose.
45352646|NCT00925275|Drug|I-131-CLR1404|Single intravenous injection of 10 millicuries of I-131-CLR1404 given on Day 0
45352647|NCT00907725|Other|serum BhCG follow-up|Subjects in this arm will receive medical abortion follow-up using BhCG blood draw
46046025|NCT05542355|Drug|EXL01|Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
46046026|NCT05542355|Drug|Placebo|Oral EXL01 matching placebo once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
45352648|NCT00907725|Other|ultrasonographic follow-up|Subjects in this arm will receive medical abortion follow-up by ultrasound
45352649|NCT00603915|Drug|Gemcitabine|1000mg/m^2 intravenous (IV) day 1 and day 8
45352650|NCT00603915|Drug|Carboplatin/Cisplatin|Area under curve (AUC)=5 (Carboplatin) or 70mg/m^2 (Cisplatin) intravenous (IV) day 1
45352651|NCT00603915|Drug|erlotinib|150mg daily (post GC therapy)
45352652|NCT00929487|Device|Contact lens multi-purpose solution|Lens care solutions CE-marked for intended use. A fresh pair of contact lenses was soaked overnight in the test contact lens solution and a pre-cycled lens case prior to study visit, then worn for two hours on the day of the study visit. Up to four solutions were evaluated in randomized order with the same brand of contact lenses, and a minimum of 12 hours of no lens wear separated each wear period.
45352653|NCT00929487|Other|Saline/blister pack solution|A fresh pair of contact lenses was soaked overnight in saline prior to study visit or was inserted directly from the blister pack, then worn for two hours on the day of the study visit.
45352654|NCT00929487|Device|Contact lenses|CE-marked silicone hydrogel contact lenses soaked overnight for at least 10 hours prior to the study visit, then worn for two hours on the day of the study visit. A fresh pair of the same brand of contact lenses was used for each overnight soak (ie, 4 solutions plus saline/blister pack solution), and a minimum of 12 hours separated each wear period.
45352655|NCT00603837|Device|NeoWrap|This is a polyethylene wrap that will be placed around the ELGAN from the neck down to prevent heat loss.
45352656|NCT00603837|Device|InfaTherm|A gel blanket containing a sodium acetate-based medium that, when activated, becomes exothermic and provides heat.
45352657|NCT00925431|Behavioral|Lifestyle Modification|16 hours of motivational, lifestyle management session, 8 hours nutritional education.
45352658|NCT00925431|Behavioral|Supportive education|16 hours general fibromyalgia education, 8 hours of nutritional education
45352659|NCT04015089|Dietary Supplement|Partially hydrolyzed formula (pHF)|Infant formula with partially hydrolyzed protein
45352660|NCT04015089|Dietary Supplement|Standard formula (SF)|Infant formula with intact protein
45352661|NCT00925509|Procedure|Therapeutic assessment -Radio-surgical guidance.|"The first steps of the procedure include the production of a radiosurgical guide and the preparation of a mask in order to allow precise, non invasive repositioning of the guide.~Secondarily, the patient undergoes a CT-scan with the mask on and the radiosurgical guide in place. This provisional scan is used for preimplantation evaluation and drilling of the guide hole.~Under general anaesthesia, the mask is placed on the patient and the guide is fixed to the mask. A hole is drilled with a burr in the mandible through the hole in the guide. Implants are placed and the guide and mask are removed.~A second, post-implantation CT-scan is planned 3 months after implantation. Comparison of pre- and post-implantation CT-scans allows to evaluate the precision of the placement."
45352662|NCT00925665|Device|Glidescope|Patients are to be intubated using the Glidescope technique
45352663|NCT00925665|Device|Macintosh laryngoscope|Patients are to be intubated using direct laryngoscopy with a Macintosh laryngoscope
45352664|NCT00925743|Drug|cabazitaxel (XRP6258)|"administered by IV infusion~in addition to cisplatin treatment"
45352665|NCT00925821|Procedure|allogeneic stem cell transplant versus second autologous transplantation|Transplantation of stem cells from a MRD or MUD, respectively after dose-reduced conditioning versus autologous stem cell graft after preparation with melphalan 200 mg/m²
45352666|NCT00925821|Drug|RAD|After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.
45352667|NCT00925977|Drug|insulin Glargine + Insulin Apidra|12 wees treatment with Insulin Glargine + Insulin Apidra
45352668|NCT00925977|Drug|Insulin NPH + Insulin Apidra: Active Comparator|Insulin NPH + Insulin Apidra: Active Comparator
45352669|NCT00926055|Drug|Ezetrol (Ezetimibe)|Ezetrol - 10 mg once daily for 3 months
45352670|NCT00926055|Drug|Vytorin (Ezetimibe + Simvastatin)|Vytorin - 10/20 mg once daily for 3 months
45352671|NCT04015635|Other|None involved|NO intervention
46046027|NCT05542355|Other|SoC corticosteroid - Induction Period|Oral prednisone 40 mg or budesonide 9 mg once daily for 3 to 7 weeks, as assigned by the investigator
46046028|NCT05542355|Other|SoC corticosteroid - Tapering|"Same product as the Induction Period.~Oral prednisone: 30 mg for 1 week, 25 mg for 1 week, 20 mg for 1 week, 15 mg for 1 week, 10 mg for 1 week, 5 mg for 1 week and stop.~OR~Oral budesonide: 6 mg for 3 weeks, 3 mg for 3 weeks, stop."
45477497|NCT01567319|Biological|Skin Prick Test|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
45477498|NCT01567319|Biological|Skin Prick Test - Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source,together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
45352672|NCT00926133|Other|OGTT|Oral glucose tolerance test (diagnostic procedure) eary after an acute STEMI and at three months follow-up.
45352673|NCT00907959|Drug|BZL101|Oral BZL101 20 grams/day (10 grams BID).
45352674|NCT00667602|Biological|MenACWY-CRM197 (two doses)|Two 0.5mL doses of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
45352675|NCT00667602|Biological|MenC|One 0.5mL dose of MenC vaccine was administered by intramuscular injection.
45477499|NCT01567319|Biological|Skin Prick Test - No Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
45352676|NCT00667602|Biological|PCV7|One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.
45352677|NCT00667602|Biological|DTPa-IPV-HepB-Hib|One 0.5mL dose of Combined Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-IPV-HepB-Hib) vaccine was administered by intramuscular injection.
45352678|NCT00667602|Biological|MenACWY-CRM197 (one dose)|One 0.5mL dose of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
45477500|NCT03829163|Device|Hydraulic Adjustable Walker|The HAW is a based on a conventional walker but has innovative telescoping legs with a leg adjustment assembly that includes at least one valve and at least one tube that delivers hydraulic fluid into the legs and allows a user to control the length of each leg. The legs of the walker are hydraulically adjustable, so that the front legs may be shortened and the back legs extended, or two side legs shortened and the two opposing side legs extended, so as to allow the walker to be securely placed on two different steps. This allows the user to be able to stand on a stair without worrying about sharing the same stair with the device. It also ensures that the height of the walker continues to be the right height for the user to minimize loss of balance.
45477501|NCT03829163|Device|Conventional Walker|A walker consists primarily of a metal frame with four legs which are stabilized by crossbars. These walker frames come in a variety of shapes and sizes; many consist primarily of two inverted U-shaped leg modules connected by crossbars. Regardless of the shape or form of the leg modules, each walker frame forms a 3-sided box with an opening in which the user may stand.
46046029|NCT05541458|Other|Food as medicine|"Encourage participants to make dietary changes by increasing consumption of nutritious foods, particularly fruits and vegetables.~Reduce food insecurity by making it easier for participants to access nutritious foods to ensure they are eating a balanced diet.~Increase nutrition literacy.~Improve health-related outcomes of participants by decreasing chronic health conditions by decreasing health metrics using food as medicine."
45477502|NCT01343888|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
45352679|NCT04034199|Drug|Denosumab|Denosumab is a human monoclonal antibody against receptor activator of nuclear factor kappa-B ligand (RANKL) and its use is associated with a reduced risk of vertebral, non-vertebral and hip fracture in post-menopausal women. RANKL plays a crucial role in the pathogenesis of glucocorticoid-induced osteoporosis (GIOP). Its production is increased by GC, resulting in stimulated osteoprotegerin ligand production and increased bone resorption. Recent randomized controlled trial from Saag et al have shown that denosumab is more efficacious than risedronate in the improvement of BMD in GIOP patients. Denosumab has been confirmed efficacious in GIOP patients but its efficacy in high-risk osteopenia patients are not well studied. It is given subcutaneously at 60mg every 6 months.
45352680|NCT04034199|Drug|Zoledronic Acid|Zoledronic acid belongs to bisphosphonates and is licensed for the treatment of GIOP and 2 RCTs found zoledronic acid has superior efficacy in improvement in BMD at lumbar spine or femoral neck at 12 months when compared to risedronate. It is given intravenously every year at a dosage of 5mg.
45352681|NCT02538237|Drug|placebo|the mouthwash(ibuprofen 2% or placebo) Subgingival Irrigation of mouthwash with an insulin syringe 0.5 ml were rinsed.
45352682|NCT02538237|Drug|Ibuprofen 2% mouthwash|
45477503|NCT01343888|Drug|BI 201335|BI 201335 once daily high dose
46046030|NCT05541159|Drug|TNO155|Single oral dose of TNO155 on Day 1
46046031|NCT05538689|Drug|Myfembree Oral Product|The study drug Myfembree will be taken orally with water, once daily, at approximately the same time, with or without food. Each tablet of Myfembree contains Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5 mg.
45352683|NCT00691028|Drug|TA-650 3 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
45352684|NCT00691028|Drug|TA-650 6 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6 weeks. Then 6 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
45477504|NCT01343888|Drug|BI 201335|BI 201335 once daily low dose
46046032|NCT05535374|Device|Feetme Connected Soles|Walk for 10 meters (and 30meters): - By wearing the European Community (EC) labelled connected soles in patient's shoes, triggered by smartphonecollection of data by smartphone - By being filmed by a camera camera mounted on a tripod (excluding the face) for steps counting (2 observers). If there is a technical problem during the walk test, this one can be performed 1 time again 1 hour after initial test.This is expected to happen very rarely.
46046033|NCT05532631|Procedure|Percutaneous coronary intervention|The studied intervention will be percutaneous coronary angioplasty with drug eluting stent implantation. Percutaneous coronary intervention may be performed during one single procedure or during staged procedures. The decision will be left at the investigator choice. PCI will be performed using drug eluting stent exclusively. The techniques for bifurcation lesions and chronic total occlusion angioplasty will be left at the operator choice. The choice of the drug eluting stent used will be left at the operator's choice. Anti-platelet therapy will be given to all patients randomized to PCI. The choice of the anti-thrombotic regiment and its duration will be left at the investigator choice (after assessment of initial presentation, bleeding and ischemic risks) but will have to comply with the European Society of Cardiology guidelines.
45352685|NCT00691028|Drug|TA-650 10 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
45352686|NCT05277441|Diagnostic Test|Novel severity grading system of unexpected events in pediatric surgery|Classification of unexpected events according to the Clavien-Madadi classification for pediatric surgical patients and simultaneously the non-modified Clavien-Dindo classification in more than 10.000 patients who have been treated at a single center from 2017 to 2022.
45352687|NCT05280327|Other|Virtual Reality Application|The pregnant women in the experimental group were played by the researcher during the active and transitional phases of labor with virtual reality glasses, which were designed for research and included methods used to cope with labor pain
45352688|NCT00929721|Procedure|Blood draw|culture for Streptococcus pneumoniae Frequency-1
45352689|NCT00929721|Procedure|Chest X-ray|image of the lungs to assess changes consistent with pneumonia Frequency-1
45352690|NCT00929721|Procedure|urine specimen|assay for the presence of Streptococcus pneumoniae Binax and UAD
45477505|NCT01343888|Drug|Placebo|
45477506|NCT03336892|Behavioral|Mental Health Care Coordination|Enhanced usual care with written mental health resources and system navigation information in addition to individualized mental health care coordination by a dedicated specially trained mental health care coordinator.
45477507|NCT03829085|Other|EARLY ORAL REFEEDING|the oral refeeding will be started after admission. Patients will receive a low fat solid diet with more and less 1500 calories, 35 g fat day
45477508|NCT02495740|Behavioral|Commuting to work|Commuting by an electric assisted bike to work for a period of 4 weeks at least 3 times per week
45477509|NCT04185389|Other|HPV and cytology co-testing (via Liquid based collection device)|Liquid-based cytology co-testing is a procedure in which that a cervical sample is taken, and can be co-tested for HPV and standard cytology at the same time. It is collected in the same way that a traditional Pap is collected
45477510|NCT03336814|Drug|Terlipressin|Administration of terlipressine
45686470|NCT01528605|Dietary Supplement|zeaxanthin plus lutein|one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks
45686471|NCT01528215|Device|OsseoSpeed EV|OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
45686472|NCT01528215|Device|OsseoSpeed TX|OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
45686473|NCT01527357|Biological|Fibrocaps|Human fibrinogen and thrombin powder, for topical administration.
45686474|NCT01527357|Biological|Gelatin sponge|Absorbable gelatin sponge for topical administration.
45352691|NCT00929721|Procedure|Nasopharyngeal swab|culture for Streptococcus pneumoniae Frequency-1
45352692|NCT00929721|Procedure|sputum|culture for Streptococcus pneumoniae Frequency-1
45352693|NCT04533230|Behavioral|Educational intervention with prescription feedback|Educational intervention and targeted feedback on prescription of benzodiazepines and benzodiazepine-like hypnotics
45477511|NCT03336814|Other|Placebo|Administration of placebo
45477512|NCT03818555|Other|Sebacia Microparticles Treatment|Sebacia Microparticles procedure involving microparticles and 1064 nm laser. Three treatment procedures over a two-week period.
45477513|NCT02495584|Dietary Supplement|Fortified milk (10µg vitamin D3)|
45477514|NCT02495584|Dietary Supplement|Unfortified milk (placebo)|
45477515|NCT02495584|Dietary Supplement|10µg vitamin D3 supplement|
45477516|NCT02495584|Dietary Supplement|Placebo supplement|
45352694|NCT04533230|Behavioral|Information on treatment guidelines|Written information on treatment guidelines.
45352695|NCT00908193|Device|Laparoscopic DA VINCI Robot Assisted coelioscopy|Patients with abdominal wall hernia will be treated by robot-assisted coelioscopy for the poses of abdominal plate
45352696|NCT00908193|Procedure|conventional coelioscopy|Patients with abdominal wall hernia will be treated by conventional coelioscopy for the poses of abdominal plate
45352697|NCT03885050|Other|Ross score|modified score used for evaluation of heart failure in children, as a diagnostic tool for severity of heart failure
45352698|NCT00781638|Device|Adacolumn®|The medical device Adacolumn® (CE-Mark Certificate G1 07 01 366 76013) is an adsorptive type extracorporeal apheresis column. It has been shown to effectively improve clinical and endoscopic signs and symptoms in UC in adults by removing granulocytes and monocytes and by changing the Cytokine production.
45352699|NCT00781716|Device|Drug eluting coronary stent system|Cypher Sirolimus-Eluting Coronary Stent System vs Endeavor Zotarolimus-Eluting Coronary Stent System
45352700|NCT05461586|Device|Refractive Technique (MR #1)|Fogging method that employs fogging lens to ensure there is sufficient visual defocus to induce blur.
45352701|NCT05461586|Device|Refractive Technique (MR #2)|Duochrome method that employs the chromatic aberration of the eye, with the shorter wavelengths (green) focused in front of the longer (red) wavelengths
45352702|NCT00690794|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
45477517|NCT03828851|Other|Domiciliary care - Activities of Daily Living|Home-based ADL training.
45477518|NCT03336736|Diagnostic Test|Exercise|"The study design will be a prospective cross-sectional observational project, with no intervention.~Data on a participant's physical activity levels, physical fitness and quality of life will be collected using physical testing and questionnaires."
45477519|NCT05623904|Procedure|Carotid Revascularization|Carotid Artery Stenting/Carotid Endarterectomy
45477520|NCT05623904|Drug|Medical Treatment|"Aspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was adjusted according to blood lipids levels. Best medical treatment also includes risk factor control: good lifestyle, smoking cessation, weight control, regular exercise, SBP < 140 mmHg, HDL < 70 mg/dl (1.8mmol/L), and glycemic control. Patients with poor control of risk factors were dynamically adjusted during follow-up.~In addition, patients undergoing CAS received dual antiplatelet therapy for at least 3 to 5 days before surgery, and patients undergoing CEA also received a preoperative oral antiplatelet drug (aspirin 100mg/ day, or clopidogrel 75mg/ day) for at least 3 days after enrollment."
45477521|NCT03589807|Biological|A/H7N9|Monovalent split 2017 A/H7N9 Inictivated Influenza Virus vaccine containing the HA and NA from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).
45477522|NCT03589807|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
45477523|NCT03589807|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent split 2013 A/H7N9 Inavtivated Influenza Virus vaccine containing the HA and NA from avian influenza A/Shanghai/2/2013 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).
45352703|NCT00690794|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.
45352704|NCT00741650|Behavioral|Information and Peer advisor|Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.
45352705|NCT00741650|Behavioral|Information, peer advisor and fast referral|"Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.~In addition, the peer advisor can refer employees who do not improve to a two day educational program that also includes a medical exam and individual counselling.~In addition,"
45477524|NCT03589807|Other|Phosphate Buffered Saline (PBS) diluent|Diluent for Influenza Virus Vaccine.
45686475|NCT00093964|Drug|Cilengitide 500 mg|Subjects will receive 1-hour intravenous infusion of 500 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
45686476|NCT00093964|Drug|Cilengitide 2000 mg|Subjects will receive 1-hour intravenous infusion of 2000 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
45352706|NCT00666276|Drug|linezolid (Zyvox)|"Zyvox Tablets 600mg, Zyvox Injection 600mg Dosage, Frequency: According to Japanese Package Insert, In adults, administer usually 600mg of linezolid twice daily (q 12 hours) for a total daily dose of 1200 mg.~Duration: According to the protocol of A5951142, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 8 weeks after the first administration."
45352707|NCT00567255|Drug|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
45352708|NCT00567255|Drug|Placebo|
45352709|NCT00567255|Behavioral|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
45843134|NCT01565616|Drug|Conditioning Regimen with Bone Marrow Transplant|"The bone marrow transplant regimen is below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~Day -8 BU 3.2 mg/ kg/dose IV~Day -7 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV~Day -6 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 0.5mg/kg IV~Day -5 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 1.0mg/kg IV~Day -4 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -3 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -2 ATG 1.5mg/kg IV~Day -1 Rest~Day 0 Stem cell infusion~Graft Versus Host Disease (GVHD) Regimen~Day -3 Calcineurin Inhibitor (Cyclosporine or Tacrolimus) therapeutic doses through day 180, then taper~Day 0 Stem cell infusion~Day +1 Methotrexate 7.5 mg/m2 IV~Day +3 Methotrexate 7.5 mg/m2 IV~Day +6 Methotrexate 7.5 mg/m2 IV~Day+11 Methotrexate 7.5 mg/m2 IV"
45843135|NCT01566084|Drug|Slow sodium tablets|The normal salt condition is maintained with 2300 mg / day in the form of slowly released salt (NaCl) tablets.
45843136|NCT01566084|Other|placebo|Placebo tablets are administered to maintain the low sodium condition.
45843137|NCT01566162|Drug|Lurasidone|Lurasidone 40-80 mg taken orally taken once daily
45843138|NCT01566630|Drug|Placebo|Placebo to RLX030 as intravenous infusion for 72 hours
45352710|NCT00744458|Other|Treatment contract|Patients signs in for a agreement - to respect a regular follow-up at the health facility.
45352711|NCT00744458|Other|Tracing and recall at home by a community worker|The local health committee sends out a member to trace the patient and to motivate him to take up again regular treatment visits.
45352712|NCT00744458|Other|Incentive|Incentive by giving free treatment after a 4-month regular follow-up
45352713|NCT00781794|Drug|NSA-789 at 2 different doses|
45352714|NCT00746174|Drug|Rosiglitazone|Rosiglitazone 8mg PO daily for 16 weeks
45352715|NCT00746174|Drug|Placebo|Placebo 1 tablet PO daily for 16 weeks
45352716|NCT00784446|Drug|Oxaliplatin, Capecitabine, Bevacizumab, Imatinib|"Dose level I:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 100 mg/m2 Capecitabine days 1-14 bid: 800 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22.~Dose level II:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 130 mg/m2 Capecitabine days 1-14 bid: 1000 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22."
45352717|NCT00744536|Drug|Lenalidomide and melphalan|Lenalidomide (Revlimid) 10 mg po daily for 21d/28 Melphalan (Melphalan) 2 mg po daily for 21d/28
45686477|NCT01526889|Drug|LFG316|LFG316 administered intravitreally (IVT)
45686478|NCT01526889|Drug|Conventional Therapy|Conventional Therapy administered in accordance with its prescribing info.
45686479|NCT00181714|Drug|methylphenidate HCl (Concerta)|OROS MPH will be openly prescribed to a maximum of 1.5 mg/kg/day (maximum 126 mg/day). Doses will be titrated according to clinical assessment of efficacy and tolerability.
45686480|NCT04643626|Device|artificial intelligence dietary android mobile application|subjects use artificial intelligence dietary mobile application to monitor dietary intake
45843139|NCT01566630|Drug|RLX030|RLX030 1 mg/mL vials
45352718|NCT05028972|Other|Personal Amplifier|The intervention group will receive personal amplifiers (PockeTalkers) while they receive care in the ED
45352719|NCT05028972|Other|No Personal Amplifier|The control group will not receive personal amplifiers while they receive care in the ED
45352720|NCT00744614|Procedure|Capnography|A technique for monitoring the concentration or partial pressure of CO2 levels in respiratory gases
45352721|NCT00929799|Drug|recombinant human Growth Hormone (Genotropin® )|Once daily by subcutaneous injection using a Genotropin pen in the abdomen at 22:00 h. Maximal GH dose of 0.003 mg/kg/day.
45686481|NCT01472835|Drug|Midazolam|Used for anxiolysis
45686482|NCT01472835|Drug|Fentanyl|Used for analgesia and as a sedative
45686483|NCT00185692|Procedure|non-myeloablative hematopoietic cell transplantation|TLI and ATG infusion of the donor graft Post-transplant immunosuppression with cyclosporine and mycophenolate mofetil.
45352722|NCT00777738|Drug|BORTEZOMIB|"Bortezomib (Velcade(R)): 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days for 2 cycles (IV route, push).~For responding patients : up to 6 cycles~For non responding patient : Adjunction of dexamethasone (HD DXM) : 20 mg Days 1,D2, D 4,D 5, D8, D9 and D 11,D12 every 21 days"
45352723|NCT00744770|Drug|TMC278|
45352724|NCT00926523|Other|Blood Gas|Subject will have both venous and arterial blood draws to assess for the bloods content of MIF
45352725|NCT00926523|Other|Pulmonary Exercise Test|Subject will ride exercise bike to assess their pulmonary function level.
45352726|NCT00926523|Other|Spirometry|To assess subjects lung function
45686484|NCT00185692|Drug|Anti-Thymocyte Globulin|1.5 mg/kg QD x 5, IV. Dosage will be based on body weight. Purified, sterile IgG fraction of immune serum of rabbits immumixied with human thymus lymphocyte. This drug acts to modify the number and function of lymphocytes.
45843140|NCT01567020|Other|Diagnostic|All participants will be evaluated with a battery of behavioral and electrophysiological measures to assess central auditory processing abilities.
45843141|NCT01569126|Drug|LY110140|Administered orally as capsules
45843142|NCT01569126|Drug|Placebo|Administered orally as capsules in the placebo arm and to maintain the blind in the 20 mg LY110140 (MD) arm
45843143|NCT01569828|Drug|LCZ696A|
45843144|NCT01569828|Drug|LCZ696A|once daily administration of 400 mg LCZ696 for 5 days
45843145|NCT01573260|Other|Argentinean Tango classes|Tango participants will attend an 1-hour Argentinean Tango classes twice a week during 12 weeks, with experienced professional tango instructors.
45352727|NCT00926523|Other|Breath Condensate Collector|Subject with use breathing apparatus to allow researchers to collect breath condensate to assess level of MIF in breathe condensate.
45352728|NCT00781872|Biological|Injection of autologous bone marrow derived mesenchymal stem cells|60 million cells intrathecally (approximately 1 million cells per Kg of body weight) and 20 million cells intravenously
45352729|NCT00741728|Other|Spider flash EKG, echocardiography tracking, step test|cardiac rhythm recorded during health check up, echocardiography tracking of the right common carotid, step test during 2 minutes
45352730|NCT00784680|Drug|Anastrozole|1mg, orally, once daily
45352731|NCT00784680|Drug|Tamoxifen|20mg, orally, once daily
45352732|NCT00908271|Drug|Dapagliflozin|Tablet and IV solution, Oral and IV, 10 mg po and 100 µg IV, Single oral dose followed by a single IV dose (IV dose administered at 1h after oral dose), 1 day
45352733|NCT02556840|Other|insulin therapy|
45352734|NCT00741806|Biological|GHB04L1|single dose intranasal administration of GHB04L1
45498232|NCT03680118|Device|autogenous rings with GBR and autogenous graft with ti-mesh|"Autogenous Onlay ring block harvested from either mandibular ramus or chin will be placed over the defected site and fixed using titanium screws (1.6mm diameter) and then GBR using autogenous particulate will be placed around and over the blocks and covered with a resorbable bilayer collagen membrane (Bio-Gide®, Geistlich, USA)~Autogenous bone graft will be placed on the defected site and covered by a titanium mesh which will be fixed by titanium screws.~Flap advancement will be acquired by releasing the mylohyoid muscle attachment from the lingual flap and periosteal releasing incision for the buccal flap to provide tension free closure.~The flap will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using horizontal mattress and interrupted 4/0 polypropylene sutures."
45686485|NCT00185692|Drug|Cyclosporine|6.25 mg/kg BID, PO.Mechanism of action is inhibition of T-cell activation by binding to a cytoplasmic protein (cyclophillin).
45686486|NCT00185692|Drug|Mycophenolate Mofetil|15 mg/kg Q 8 hours, PO. Inhibtis the enzme inosine monophsophate dehydrogenase (MPDII) noncompetitively which blocks the de nobo synthesis of guanosine required for DNA synthesis and has an effect on T and B cells.
45686487|NCT00185692|Drug|G-CSF|16 mg/kg, SQ Growth factor used to make bone marrow produce more blood cells
45843146|NCT01573260|Other|Simple pamphlet about the exercise in PD|Controls will follow their usual schedule of pharmacological treatment; will be provided by simple pamphlet about the exercise in PD, and will otherwise to go about their lives as usual.
45843147|NCT01573572|Drug|pegaptanib sodium injection|0.3mg of Macugen in a single-use, prefilled glass syringe given every 6 weeks for 48 weeks
45843148|NCT01575522|Other|Laboratory Biomarker Analysis|Correlative studies
46046034|NCT05532631|Procedure|Coronary artery bypass grafting|Coronary artery bypass grafting technique will be total arterial revascularization unless internal mammary grafts are unavailable or have inadequate flow. All patients will be treated with anti-thrombotic therapy according to the European Society of Cardiology guidelines
45352735|NCT00741806|Other|Placebo|SPGN buffer
45352736|NCT00929877|Drug|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
45352737|NCT00929877|Drug|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
45352738|NCT00929877|Drug|Placebo|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
45352739|NCT00741884|Drug|Varenicline Controlled Release 1.2 mg|Varenicline CR tablet 1.2 mg BID for 7 weeks
45686488|NCT00185692|Drug|Solumedrol|1.0 mg/kg IV 2 hours prior to ATG Used to treat severe inflamation
45352740|NCT00741884|Drug|Varenicline Controlled Release 1.8 mg|Varenicline CR tablet 1.8 mg BID for 7 weeks
45352741|NCT00741884|Drug|Varenicline Controlled Release 2.4 mg|Varenicline CR tablet 2.4 mg BID for 7 weeks
45843149|NCT01575522|Drug|Tivantinib|Given PO
46046035|NCT05524064|Radiation|FLASH Radiotherapy|A dose of 8 Gy delivered in a single fraction will be prescribed to the PTV, delivered with FLASH Radiotherapy (>40 Gy/s).
46046036|NCT05519293|Drug|H002|Small molecule, Capsule
45352742|NCT00741884|Drug|Varenicline Immediate Release 1 mg|Varenicline IR tablet 1 mg BID for 7 weeks
45352743|NCT00741884|Drug|Placebo|Placebo BID for 7 weeks
45352744|NCT00777816|Drug|XOMA 052|A single dose of study drug on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
45352745|NCT00777816|Drug|Placebo|A single dose of placebo on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
45686489|NCT00185692|Drug|Acetaminophen|650 mg PO, 30 minutes prior to infusion Pain reliever
46046037|NCT05503095|Genetic|Genetic analysis for PCSK9 polymorphisms|Determination of PCSK9 gene polymorphism and serum PCSK9 concentration
46046038|NCT05499455|Device|Positional Sleep Belt|Rematee Positional Sleep Belt
45352746|NCT00931437|Dietary Supplement|vitamin K-rich dairy product|several forms of vitamin K: phylloquinone, menaquinone-7,-8,-9,and -10.
45352747|NCT00741962|Dietary Supplement|VR-3 Herbal Blend|This is a liquid blend of various reputed adaptogenic herbs. The dosage will be 2ml of liquid per day.
45352748|NCT00741962|Dietary Supplement|Placebo|The placebo will be a similar tasting liquid as VR-3 Herbal blend. The dosage will be 2ml of liquid per day.
46046039|NCT05499455|Device|Control|Control Device
46046040|NCT05490030|Drug|TNO155|Single oral dose of TNO155 on Day 1
45352749|NCT00782028|Other|Centering parenting/Group well child care|Intervention families will receive well child care in a group format for the first 12 month of the child's life.
45352750|NCT00782028|Other|Standard Care|
45352751|NCT04014621|Device|SPG stimulation|The BrainsGate Ischemic Stroke System (ISS) consists of an implantable neurostimulator designed to deliver electrical stimulation to the sphenopalatine ganglion (SPG) and/or nerves within the greater palatine canal and pterygopalatine fossa.
45352752|NCT00742040|Drug|Captopril|A rapid 3-day up-titration protocol
45477525|NCT05619107|Device|Transauricular nerve stimulation|The first allocated intervention will be undertaken for 30 minutes. The electrode placement and stimulation parameters are described in the arm/group section. After the 30-minute intervention, day 1 of the protocol will be complete. The investigator will remain present in the room with the participant to ensure compliance and adherence to the protocol. The allocated intervention will then be repeated by the participant at a similar time of day for 7 consecutive days. The investigator will arrange video-calls with the participant whilst off-site to ensure ongoing compliance and adherence to the protocol. On the seventh day, participants return to the clinical research facility to take the final first allocated intervention. A 14-day rest period will follow. Then the participants will perform the same 7-day protocol for the opposite intervention to their first treatment allocation.
45352753|NCT00742040|Drug|Captopril|A slower 9-day up-titration protocol
46046041|NCT05481541|Other|written education|"Other names:~Written/E-Mobile training The study was conducted as a three-group randomized controlled trial to examine the effect of written/mobile education on the quality of life and sleep of patients undergoing transurethral resection of the prostate. Written education was applied to the first group and mobile education was applied to the second group. Group 3 formed the control group."
46046042|NCT05481320|Behavioral|REACH VN Phone Intervention|4-6 intervention sessions delivered via phone over the course of 1-3 months.
46046043|NCT05481320|Behavioral|Enhanced Control|A single phone session providing education about dementia.
45477526|NCT02495818|Procedure|Lidocaine|Suprascapular Nerve Block Guided by Ultrasound with 5ml lidocaine at 2%.
45477527|NCT02495818|Procedure|Saline solution|Suprascapular Nerve Block Guided by Ultrasound with 5ml saline solution
45477528|NCT02495818|Other|Homemade exercises|Codman and Hughston exercises.
45477529|NCT05614856|Device|EVAR off-label use|Normally a femoral access was used, although a brachial approach can be useful for crossing total occlusions. For TASC B and C lesions, predilatation of the iliac lesions is advisable, while for TASC D it is mandatory. In case of total aortic occlusions, the procedure demands that recanalization of the distal aorta occurs as close as possible to the bifurcation.. The key technique is to recanalize from one common iliac artery into the opposing snaring the wire to create a femoral-femoral crossover. The femoral-femoral wire is then replaced with a MPA catheter; the SurePass wire attached to the contralateral limb is then passed through the catheter. The sheath can be placed within 5 cm of the aortic bifurcation, and the AFX can be delivered through the common iliac and aortic occlusion. Predilatation were performed with bilateral 6-8 mm x 150 mm balloons and or progressive dilatators.
45477530|NCT01201733|Other|Traditional Thai massage|The participants will receive a thirty minutes session of traditional Thai massage onto the scapular region
45477531|NCT01201733|Other|Ultrasound therapy and hot pack|
45843150|NCT01575756|Biological|Octafibrin|Octafibrin was supplied as a powder for reconstitution with water for injection.
45843151|NCT01575756|Biological|Haemocomplettan® P or RiaSTAPTM|Commercially available Haemocomplettan® P or RiaSTAPTM (same product with different names in different markets) were supplied as powders for reconstitution with water for injection.
45843152|NCT01575912|Other|experimental pain tests|
45843153|NCT01577238|Drug|1% SPL7013 Gel|Vaginal gel, daily for 7 days
45843154|NCT01577238|Drug|Placebo|Vaginal gel, daily for 7 days
46046044|NCT05475990|Drug|Hydroxyethyl starch|10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
45352754|NCT00777894|Radiation|3-dimensional conformal radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~(3 patients) 27 x 2 Gy = 54 Gy~(3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~(3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
45352755|NCT00777894|Radiation|intensity-modulated radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~(3 patients) 27 x 2 Gy = 54 Gy~(3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~(3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
45352756|NCT00777894|Radiation|stereotactic body radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~(3 patients) 27 x 2 Gy = 54 Gy~(3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~(3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
45352757|NCT00926757|Drug|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of chemotherapy to 3 months after completing chemotherapy
45352758|NCT00926757|Drug|Therapeutic entecavir|Entecavir 0.5cm daily since hepatitis flare and HBV reactivation, till hepatitis remission
45352759|NCT00746408|Other|Expert system guided tailored information|The prototype is realised by a web-based information system. The HTML web-interface guides the user through the search process by querying the information demand. This is done by an integrated expert system. The expert system uses a rule based inference to determine an internal diagnosis. Based on this internal diagnosis the system searches quality labeled websites and presents relevant information to the user.
45352760|NCT00782106|Biological|Recombinant human hyaluronidase + immune globulin intravenous|Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered
45352761|NCT00782106|Biological|Recombinant human hyaluronidase + immune globulin intravenous|"IV infusion of IGIV, 10% to determine pharmacokinetics~Intervention as in Arm 1: Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered"
45352762|NCT00929955|Drug|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
45352763|NCT00929955|Drug|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
45352764|NCT00929955|Drug|Placebo|Placebo added to TAU
45352765|NCT00742118|Procedure|Colic biopsies|colic biopsies and analysis
45352766|NCT00784914|Drug|temsirolimus|Receive temsirolimus IV
45352767|NCT00784914|Other|pharmacological study|Plasma levels of temsirolimus and sirolimus will be evaluated in serial blood samples.
46046045|NCT05475990|Drug|Crystalloid|10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
45352768|NCT00784914|Other|cytokine levels|Dialysate samples are collected at regular intervals during the 96 hours following placement of the catheter to measure changes in levels of cytokines, chemokines and growth factors
45352769|NCT04060238|Diagnostic Test|Anomaloscope (colour vision test)|"The Heidelberg Multi Colour (HMC) Anolmaloscope (Oculus Inc., Dutenhofen/FRG) is used to differentiate between normal controls (normal trichromatopsia) and test subjects with protanopia (inherited red colour blindness)"
46046046|NCT05473871|Behavioral|Faith in Action|"Interpersonal level: Group exercise classes offered 6 days/week (walking, cardio dance, strength training), Kickoff event~Individual level: Motivational Interviewing calls every 6 months, Health handouts on 14 topics distributed at PA classes"
46046047|NCT05473871|Behavioral|Faith in Action+|Standard Faith in Action Intervention plus: 1) Health Behavior Change Workshop for FBO leaders; 2) Targeted Messaging; and 3) Empowerment Training for Promotoras
45477532|NCT02495662|Drug|PEG-liposomal prednisolone sodium phosphate|Liposomal prednisolone
45477533|NCT02495662|Drug|Placebo|0.9% normal saline
45686490|NCT00185692|Drug|Diphenydramine|50 mg IV, 30 minutes prior to infusion Used to relieve allergy symptoms
45686491|NCT00185692|Drug|Hydrocortisone|100 mg IV, 1 hour prior to infusion Used to relieve itching, redness and swelling of the skin
45686492|NCT01526733|Drug|Sham Injection|
45352770|NCT00784992|Procedure|Endonasal dacryocystorhinostomy|"The standard dacryocystorhinostomy operation performed in this centre uses silicone tubes to stent open the newly created ostium between the lacrimal sac and the nasal cavity. However many surgeons in other departments / countries around the world perform the surgery without tubes. No large well-conducted RCT has been published comparing success rates / complication rates for the two techniques. For this study the control group is the arm which receives tubes (our standard procedure) and the 'interventional' group is the arm not receiving tubes.~Details of the operative technique for endonasal DCR with tubes can be found in the following reference: Dolman PJ. Comparison of external dacryocystorhinostomy with nonlaser endonasal dacryocystorhinostomy. Ophthalmology. 2003 Jan;110(1):78-84. The group that will not receive tubes will undergo the same procedure except that the insertion of tubes will be omitted."
45352771|NCT00745004|Drug|Ondansetron|Over-encapsulated 4mg ondansetron tablets. Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days. For 5 weeks.
45352772|NCT00745004|Drug|Placebo|Capsule matching over-encapsulated experimental drug. 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days. For 5 weeks.
45352773|NCT00745160|Other|blood sample and questionnaire|After giving informed consent, all patients will be asked to complete questionnaire and will be asked to provide a blood sample for DNA analysis. The questionnaire will consist of a detailed smoking questionnaire, based on the most recent Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System Survey Questionnaire.
45352774|NCT05450978|Drug|Lamotrigine|Anti-seizure concentrations
45352775|NCT05450978|Drug|Levetiracetam|Anti-seizure concentrations
45352776|NCT04060550|Biological|Xolair|This is in vitro mechanistic study. No drug will be given in vivo to patients.
45352777|NCT00921674|Drug|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
45352778|NCT00667446|Drug|Leuprolide Acetate 3 Month Depot|
45352779|NCT00742430|Procedure|PCI|percutaneous coronary intervention in stable coronary artery disease
45352780|NCT03873168|Device|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in gynecological, urological, vascular, ENT and head and neck surgeries.
45352781|NCT00688844|Drug|KuvanTM Therapy|BH4 treatment was prescribed by each participant's medical provider, not an intervention that was assigned as part of the current study.
45352782|NCT02555670|Other|BIA|Bioelectrical impedance analysis was performed within 4 days after a CT-scan was made
45352783|NCT00777972|Drug|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
46046048|NCT05473871|Behavioral|Faith in Action++|Enhanced Condition plus: 1) Foster community collaborations and 2) Provide maintenance support
46046049|NCT05464225|Device|COSD|The exercise protocol will include using the tongue to compress the COSD against the hard palate, or against the tongue depressor for 30 repetitions, 3 times per day, on 3 days of the 7-day week. For the first week, the participants who are in the COSD group will be issued a COSD bulb that corresponds to no less than 60% of their baseline maximum strength. After week 1, they will switch to a COSD bulb that corresponds to no less than 80% of their maximum tongue strength for the remaining 7 weeks.
45352784|NCT00745238|Other|withdrawal of non-invasive ventilation|Four weeks withdrawal of non-invasive ventilation
45352785|NCT00782262|Dietary Supplement|KicStart™|KicStart™ is a nutritionally complete, but lower energy formulated liquid meal. Two sachets of KicStart™ (one for breakfast and one for lunch) provides 450 cal of energy per day, 0.8 grams per kilogram ideal body weight of high quality protein, and the recommended daily allowances (RDI) of minerals, vitamins, trace elements, omega 3 and 6 essential fatty acids. The Kicstart is supplemented with some salads, carbohydrate free vegetables and a small piece of meat fish or chicken each day in order to achieve a total energy intake of approximately 850 kcals/day.
45352786|NCT00778050|Drug|Amoxicillin 600mg|
45686493|NCT01526733|Drug|Recombinant human hyaluronidase PH20|
46046050|NCT05464225|Device|SOC|The exercise protocol will include using the tongue to compress the COSD against the hard palate, or against the tongue depressor for 30 repetitions, 3 times per day, on 3 days of the 7-day week. For the tongue depressor group, they will be given 8 tongue depressors, which are disposable, for the duration of the study.
45352787|NCT00746486|Drug|budesonide|One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
45352788|NCT00746486|Drug|budesonide placebo|One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
45352789|NCT00785148|Drug|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)|
45352790|NCT00745550|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
45686494|NCT01526733|Drug|Insulin aspart|
45686495|NCT01526733|Drug|Insulin lispro|
45686496|NCT00094900|Drug|IL-1 Trap|
45686497|NCT00096460|Drug|Cyclophosphamide and Rituximab|Prior to undergoing HSCT, all patients will receive Cyclophosphamide 4 gm/m2 with Rituximab 375 mg/m2 x 2 doses and G-CSF support.
45686498|NCT00096460|Drug|Filgrastim|Autologous HSCT patients will receive 10 mcg/kg/day and allogeneic HSCT patients will receive 5 mcg/kg/day subcutaneous (SQ) or intravenous (IV) starting 2 days after the initiation of Cyclophosphamide.
45843155|NCT01577706|Drug|Alprazolam|Alprazolam, gel-capsule, 1mg, single-dose, 1-day
45843156|NCT01577706|Drug|Dextroamphetamine|Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
45843157|NCT01577706|Other|Placebo|Placebo, gel-capsule, single-dose, 1-day
45352791|NCT00778128|Drug|CP-4126|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose. Step 2: Oral CP-4126 day 1 and 15 + IV Gemcitabine 1000 mg/m2 day 8 in a 4 week schedule until complete response or disease worsening / progression
45352792|NCT00778128|Drug|Gemcitabine|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose Step 2: Oral CP-4126 day 8 and 15 + IV Gemcitabine 1000 mg/m2 day 1 in a 4 week schedule until complete response or disease worsening / progression
45352793|NCT00778284|Drug|Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets|
45352794|NCT02563418|Device|Eye-tracking|
45352795|NCT00749060|Other|conventional treatment|with our without brace
45352796|NCT00749060|Procedure|kyphoplasty with balloons|Balloon Kyphoplasty which consists of placing through a percutaneous posterior approach under radiological guidance, into the fractured vertebra a balloon which is inflated with fluid and creates a cavity. This may restore part of the vertebral height loss due to the fracture. In addition, after balloon deflation, polymethylmetacrylate cement is injected with low pressure into the created cavity.
45352797|NCT00749060|Procedure|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
45352798|NCT00749138|Drug|tamoxifen|giving drug tamoxifen
45352799|NCT05001906|Behavioral|Exercise group|The exercise program comprises static and dynamic breathing exercises, muscle stretching exercises and muscle strength exercises, exercises to strengthen the abdominal wall muscles, exercises to strengthen the thigh muscles - quadriceps femoris (lat. musculus quadriceps femoris), to strengthen gluteal muscles, exercises to increase pelvic mobility, exercise to improve circulation, as well as pelvic floor muscle training with relaxation techniques.
45477534|NCT03827915|Device|Double sequential external defibrillation|DSED is the process of using two defibrillators near simultaneously at their highest allowed energy setting and aims to treat refractory atrial fibrillation. The first set of pads is placed in the traditional anterolateral position and the second set can be either placed adjacent to the first set (antero-lateral) or in the antero-posterior position. Shocks are then delivered simultaneously or near simultaneously
45352800|NCT02563340|Other|BM-MSCs|BM-MSCs are from third-party healthy donors, and have no HLA alleles similar to renal allograft donors or reacting to positive anti-HLA antibodies in recipients.
45352801|NCT02563340|Other|Desensitization therapy (PP, IVIG, rituximab or Bortezomib)|At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition.
45352802|NCT00782652|Drug|inhaled nitric oxide|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
45477535|NCT05702060|Procedure|Radial Artery Puncture Method for Coronary Angiography and Intervention|Radial Artery Puncture Method for Coronary Angiography and Intervention
45477536|NCT02496052|Procedure|dried biological amnion graft|Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane
45352803|NCT00782652|Drug|nitrogen gas|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
45686499|NCT00096460|Radiation|Chemotherapy or Radiation therapy|"Chemotherapy - BCNU 15 mg/kg IV x 1 dose to be administered over 2 hours on Day -6 pre-HSCT. VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4.~Radiation - administered at a rate of < 20 cGy/min in one of the following doses; 120 cGy/fraction are administered at no less than 4-hour intervals three times/day or 2 times/day for a total of 10 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5), or doses of 150 cGy/fraction twice daily for a total of 8 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5). VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4 pre-HSCT.~Cyclophosphamide 100 mg/kg IV x 1 dose to be administered over 2 hours on Day -2 pre-HSCT. G-CSF 5 mcg/kg SQ or IV to start on Day +5 post-HSCT and continue until ANC > 500/mm3 x 3 days."
45686500|NCT00096460|Drug|Non-myeloablative Conditioning regimen|Fludarabine 30 mg/m2 IV x 3 doses total to be administered daily over 30 minutes on Days -6, -5 and -4 pre-HSCT. Cyclophosphamide 750 mg/m IV x 3 doses total to be administered daily over 1 hour on Days -6, -5 and -4 pre-HSCT. Administer cyclophosphamide approximately 4 hours after start of fludarabine infusion. Rituximab 375 mg/m2 IV x 4 doses total to be administered on Days -13 and -6 pre HSCT and Days +1 and +8 post HSCT.
45686501|NCT00096460|Procedure|Allogeneic transplant|Infusion of G-CSF mobilized allogeneic hematopoietic stem cells
45686502|NCT00096460|Procedure|Autologous transplant|Infusion of G-CSF mobilized autologous hematopoietic stem cells
46046051|NCT05456373|Device|ClearEdge device|ClearEdge tissue imaging device uses a new technology to detect tissue abnormalities at the surgical margins of a surgically excised breast tissue specimen. Adding the use of the imaging device has the potential to assist the surgeon in identifying DCIS or invasive cancer involved margins of the excised specimen.
45843158|NCT01580592|Drug|Omalizumab|150mg, s.c., every 4 weeks
45843159|NCT01580592|Drug|Omalizumab|300mg, s.c., every 4 weeks
45477537|NCT02496052|Device|Foley balloon|Device: Foley balloon Uterine application of Foley balloon
45352804|NCT00746642|Device|Mellitor device for glucose measurement|"Glucose measurement using Mellitor device"
46046052|NCT05452447|Device|Transfluthrin|Passive emanator with formulated transfluthrin
45352805|NCT02562092|Behavioral|Reducing Risk Behavior|A small survey will be conducted to identify risk factors and assess demographics. Participants will receive psychological support and counseling on reducing risk behavior for one year.
45477538|NCT02496052|Drug|estradiol valerate tablets+dydrogesterone Tablets|oral estradiol valerate tablets+dydrogesterone Tablets
45477539|NCT01206569|Drug|Long-acting tacrolimus (Advagraf, Astellas Pharma)|Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.
45477540|NCT04494334|Procedure|Bronchoscopy for Probable Idiopathic Pulmonary Fibrosis and Sarcoidosis|Blood samples and Nasosorption sampling
46046053|NCT05452447|Device|Placebo|Passive emanator with formulated inert ingredients
45843160|NCT01580592|Drug|Placebo|Placebo, s.c., every 4 weeks
45843161|NCT01580904|Behavioral|Intervention: Pharmaceutical Care|Patients will be followed by the pharmacist by the Pharmaceutical Care Practice
45352806|NCT02562092|Behavioral|Support and Guidance|A small survey will be conducted to identify risk factors and assess demographics. Participants with a positive HIV test will receive standard HIV care, support, and guidance from a psychologist and case manager including an assessment of basic needs (food, clothing, shelter), and counseling on risk taking behaviors for one year.
45352807|NCT00745706|Device|Implantable Loop Recorder (ILR)|Insertion of ILR 3 months prior to clinical ablation procedure to collect data on actual Atrial Fibrillation episodes and correlation with patient symptoms through patient diary entry. Then patient undergoes their previously indicated clinical ablation procedure and is then followed up with ILR insitu for 30 months post-ablation for the same as mentioned above.
45352808|NCT00785382|Drug|Placebo|Lactulose Placebo
45352809|NCT00785382|Drug|Pregabalin 150 mg|150 mg Q12H x 2 doses
45352810|NCT00745784|Behavioral|in-person or telephone interview|Participants will be administered one battery of questionnaires that should take 50- 55 minutes, which may be broken down into two or more segments if necessary. They may choose to have these questionnaires administered to them in person at the hospital, in person at their home, or via telephone by a trained master's level research assistant.
45352811|NCT00745862|Behavioral|questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided|This pilot study will measure illness related distress in female patients undergoing surgical treatment of cutaneous melanoma within two years of diagnosis and treatment. Areas of particular focus will be survival anxiety, family functioning/childbearing concerns, and aesthetic impact of surgery. Patients will complete a one time only set of quality of life assessments these questionnaires will take 30-45 minutes to complete.
45843162|NCT01583868|Device|B&L RD2135-01 lens C|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
46046054|NCT05449119|Biological|Fecal and blood sampling and collection of nutritional, cognitive and sensorimotor data|at T0, T3 months, T6 months, T9 months and T12 months
46046055|NCT05449119|Other|Body Mass Index (BMI)|Calculation of BMI with height measurement by heel-knee distance measurement at T0, T3 months, T6 months, T9 months and T12 months
46046056|NCT05449119|Other|24-hour food and beverage record|at T0, T3 months, T6 months, T9 months and T12 months
46046057|NCT05449119|Other|Mini Nutritional assessment (MNA)|at T0, T3 months, T6 months, T9 months and T12 months
46046058|NCT05449119|Other|Measurement of muscle mass by bioelectrical impedance analysis|at T0, T3 months, T6 months, T9 months and T12 months
46046059|NCT05449119|Other|Measurement of sensorimotor functions|at T0, T3 months, T6 months, T9 months and T12 months
46046060|NCT05449119|Other|Measurement of cognitive functions|at T0, T3 months, T6 months, T9 months and T12 months
45352812|NCT00667368|Drug|Metronidazole|Bi-monthly testing and treatment for BV with Metronidazole if BV is detected; 500mg twice daily for 7 days.
45352813|NCT00785460|Drug|Benfotiamine|
45352814|NCT00778518|Drug|ARX201|Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.
46046061|NCT05444946|Drug|Prednisone tablet and Itraconazole|Oral prednisolone 0.5 mg/Kg body weight tapered over 4 months and oral itraconazole (400 mg/day). The dose of itraconazole will be adjusted according to therapeutic drug monitoring to achieve a serum trough level of 0.5 microgram/mL. traconazole will be given for 12 months
45352815|NCT00778518|Drug|ARX201|Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.
45843163|NCT01583868|Device|B&L RD2135-01 lens D|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
46046062|NCT05444946|Drug|Oral itraconazole|Oral itraconazole (400 mg/day). The dose of itraconazole will be adjusted according to therapeutic drug monitoring to achieve a serum trough level of 0.5 microgram/mL. Itraconazole will be given for 12 months
46046063|NCT05415072|Drug|DYP688|Single agent DYP688
46046064|NCT05409157|Drug|BMS-986166|Specified dose on specified days
46046065|NCT05409157|Drug|Bisacodyl|Specified dose on specified days
45352816|NCT00778518|Drug|ARX201|Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.
45352817|NCT05264844|Other|Masking tape|IV catheters will be fixed with masking tape
45352818|NCT00785616|Other|MEMS cap monitoring|Electronic monitoring of medication adherence using MEMS caps
45352819|NCT00785616|Other|MEMS cap monitoring|Adherence to antiretroviral medications will be measured using electronic bottle caps (MEMS caps) that record the time signature of each bottle opening.
45352820|NCT00785616|Other|MEMS cap monitoring|Adherence to antiretroviral medications will be measured using electronic bottle caps (MEMS caps) that record the time/date signature of each bottle opening.
45352821|NCT00567567|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
45352822|NCT00567567|Drug|Carboplatin|Given IV
45352823|NCT00567567|Drug|Cisplatin|Given IV
45352824|NCT00567567|Drug|Cyclophosphamide|Given IV
45352825|NCT00567567|Drug|Doxorubicin Hydrochloride|Given IV
45352826|NCT00567567|Drug|Etoposide|Given IV
45352827|NCT00567567|Radiation|External Beam Radiation Therapy|Undergo EBRT
45352828|NCT00567567|Biological|Filgrastim|Given IV or SC
45352829|NCT00567567|Drug|Isotretinoin|Given orally
45352830|NCT00567567|Other|Laboratory Biomarker Analysis|Correlative studies
45352831|NCT00567567|Drug|Melphalan|Given IV
45352832|NCT00567567|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
45352833|NCT00567567|Other|Pharmacological Study|Correlative studies
46046066|NCT05407519|Drug|Tislelizumab + Sitravatinib|Drug: Tislelizumab Tislelizumab 200mg IV q3w Other Names: BGB-A317, Immunotherapy, Anti-PD-1 antibody Drug: Sitravatinib Sitravatinib 100mg PO qd Other Name: tyrosine kinase inhibitor, TKI
46046067|NCT05405738|Procedure|2 flap palatoplasty technique|cleft palate repair by 2 flap palatoplasty technique
45352834|NCT00567567|Drug|Thiotepa|Given IV
45352835|NCT00567567|Drug|Topotecan Hydrochloride|Given IV
45352836|NCT00567567|Drug|Vincristine Sulfate Liposome|Given IV
45352837|NCT00666198|Drug|SILDENAFIL|"Revatio® Tablets 20 mg Dosage, Frequency: According to Japanese LPD, For oral use, the adult dose is 20 mg three times a day.~Duration: According to the protocol of A1481263, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 3 years after the first administration."
46046068|NCT05405738|Other|normal group|control normal group
46046069|NCT05405738|Procedure|Furlow with buccinator technique|cleft palate repair by Furlow with buccinator technique
46046070|NCT05404841|Dietary Supplement|CoffeeBerry Supplement|A Coffeeberry supplement containing 200mg Caffeine and 14mg polyphenols, manufactured by FutureCeuticals Inc.,
45352838|NCT00778596|Drug|Prednisolone|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
45352839|NCT00778596|Drug|Placebo priming|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
45352840|NCT00785694|Drug|hexaminolevulinate|Instillation of 50mL of 8mM Hexvix into the bladder through a catheter.
45352841|NCT00778674|Drug|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
45352842|NCT00778752|Drug|Revlimid (Lenalidomide)|"3 pat. will be enrolled on dose level 0. If no DLTs are observed during cycles 1+2 dose will be escalated to the next higher level in the 3 patients. If 1 of 3 pat. experiences DLT at the current dose, then up to 3 more pat. will be accrued at the same level. If none of these 3 additional pat. experience DLT dose will be escalated in subsequent patients. If 1 of these 3 patients experiences DLT, the next lower level will be declared to be MTD and the study will be filled up with patients at this dose level up to 25 pat. overall.~If 2 or more of 3 pat. or 3 or more of 6 pat. in the same cohort encounter DLT, the MTD has been exceeded and the previous lower dose level will be declared as MTD and the study will be filled up with patients at this level up to 25 pat. overall.~If DLT is observed in level 0, the next dose level will be -1 for the following cohort of 3 patients. If level 2 is well tolerated without DLT, this level will be claimed as recommended dose for further trials."
45352843|NCT00926835|Drug|paroxetine|6 weeks, 20-50mg/day
45352844|NCT00926835|Drug|Escitalopram|10-20mg/day for 6 weeks
45352845|NCT00926835|Drug|Venlafaxine XR|Venlafaxine 75-225mg/day for 6 weeks
45352846|NCT00926835|Drug|Paroxetine+Bupropion|paroxetine 20-50mg/day + bupropion 150-400mg/day for 6 weeks
45352847|NCT00926835|Drug|Paroxetine+Lamotrigine|Paroxetine 20-50mg/day + lamotrigine 100-400mg/day for 6 weeks
45352848|NCT00926835|Drug|Paroxetine+Lithium|Paroxetine 20-50mg/day + lithium 0.5-1.2 mEq/L
45352849|NCT00926835|Drug|Escitalopram+Mirtazapine|escitalopram 10-20mg/day + mirtazapine 15-45mg/day for 6 weeks
45352850|NCT00926835|Drug|Escitalopram+Aripiprazole|escitalopram 10-20mg/day + aripiprazole 5-15mg/day for 6 weeks
45352851|NCT00926835|Drug|Paroxetine + Venlafaxine XR|Paroxetine 20-50mg/day + Venlafaxine 75-225mg/day for 6 weeks
45352852|NCT00930033|Procedure|Nephrectomy|Current surgery
46046071|NCT05404841|Dietary Supplement|Placebo|Placebo
46046072|NCT05399056|Behavioral|Telephonic Peer Coaching|Telephonic Peer Coaching from an individual with lived experience with COPD and Pulmonary Rehabilitation trained in motivational interviewing
45352853|NCT00930033|Other|Sunitinib alone|Sunitinib alone without nephrectomy
45352854|NCT02719977|Drug|CX5461|
45477541|NCT03544333|Device|transcranial magnetic stimulation|We will assess safety and efficacy of the following protocol: 1Hz of rTMS over the Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al., 1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.
45352855|NCT00931593|Device|Esophageal high resolution manometry associated or not with manometry with perfused Dentsleeve probe (as determined by randomization)|"Visit V0 (day 0 - 2 to 14 days):~Subject selection~Obtaining of written informed consent~Visit V1 (day 0):~Fasting subject~Randomization to determine the examination order~Esophageal high resolution manometry (Sierra Scientific Instruments, California CA) associated or not with manometry with perfused Dentsleeve probe (as determined by randomisation): 3-hour recording (1 hour fasting, ingestion of a 600-kcal liquid meal in 10 minutes, 2 hours post prandial)~Visit V2 (day 0 + 1 day): Phone contact~Visit V3 (day 0 + 2 to 7 days):~Same as V1~Visit V4 (V3 + 1 day): Phone contact and end of the study"
45352856|NCT00664560|Drug|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
45352857|NCT00664560|Drug|celebrex|200 mg celecoxib qd
45352858|NCT00664560|Drug|Placebo|sugar pill bid
45352859|NCT00664560|Drug|Rescue Antacid|Antacid Tablets
45352860|NCT00566709|Procedure|Red blood cells transfusion|Patients will be transfused (one to one red blood cells unit transfusion)
45477542|NCT01206647|Drug|Metformin and Saxagliptin|Metformin 500mg/daily titrated to 2000mg/d in 4 Weeks (continued for 20 weeks) Saxagliptin 5 mg daily over complete trial
45686503|NCT00096460|Drug|Rituximab maintenance therapy|"Patients must have sufficiently recovered from autologous HSCT in order to receive rituximab maintenance therapy as specified below:~Dose #1: Day +42 post-autologous HSCT Dose #2: Day +49 post-autologous HSCT Dose #3: Day +56 post-autologous HSCT Dose #4: Day +63 post-autologous HSCT"
45352861|NCT00785850|Drug|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower|
45352862|NCT00931671|Other|Exercise training|aerobic exercise training
45352863|NCT00931749|Device|Low intensity pulsed ultrasound therapy|1 MHz, Spatial Average Intensity of 0.2 W /cm2, pulsed duty cycle 20%, 9.5 minutes, Therapeutic dose= 112.5 J/cm2. Fixed application on the medial side of the knee joint. Three sessions per week, during 2 months ( 24 sessions)
45352864|NCT00931749|Device|Sham Low intensity pulsed ultrasound therapy|The Ultrasound device will not have the transducer´s crystal, so no ultrasonic energy will be provided.
45352865|NCT00783042|Drug|Rosuvastatin|40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).
45352866|NCT00783042|Drug|Placebo|Tablet, oral, once daily for 1 month (double blind)
45352867|NCT02556528|Behavioral|Health Coaching|
45352868|NCT00688688|Drug|Mirabegron|Tablets
45352869|NCT00688688|Drug|Tolterodine|Extended release capsules
45352870|NCT00688688|Drug|Placebo to Mirabegron|Matching mirabegron placebo tablets.
45352871|NCT00688688|Drug|Placebo to Tolterodine|Matching tolterodine placebo capsules.
45352872|NCT00926991|Other|No intervention|No intervention; observation only
45352873|NCT00930189|Drug|intravitreal injection of ranibizumab|
45352874|NCT00930189|Drug|intravitreal injection of triamcinolone|
45352875|NCT00930189|Procedure|photodynamic therapy|
45352876|NCT00936819|Biological|Plasma-Lyte A and 25% Autologous Plasma|Single dose of 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
45477543|NCT02495506|Other|Cold stored platelets|Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.
45477544|NCT02495506|Other|Room temperature platelets|Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.
45686504|NCT00096460|Drug|GVHD Prophylaxis|Tacrolimus 0.09 mg/kg/day PO, based on body weight formulas will start on Day -2 and continue until Day +90 post-HSCT. Tacrolimus (or cyclosporine, if applicable) will be given orally in a twice-daily divided dose. Methotrexate 5 mg/m2 Intravenous Pyelogram (IVP) will be administered on Days +1, +3 and +6 post-HSCT.
45686505|NCT00006178|Drug|Sirolimus|
45686506|NCT00006178|Drug|Thymoglobulin|
45686507|NCT00097708|Drug|experimental anti-anxiety drug|
45686508|NCT00098956|Drug|topotecan hydrochloride|Given IV
45352877|NCT00936819|Biological|Autologous EPCs|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
45352878|NCT00936819|Biological|Autologous EPCs Transfected with human eNOS|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
45352879|NCT00937053|Other|Transfusion level 120 g/dL|Patients whose hemoglobin falls below 120 g/dL will be transfused with red cells within 24 hours.
45352880|NCT00937053|Other|Transfusion level 70 g/dL|Patients whose hemoglobin falls below 70 g/dL will be transfused with red cells within 24 hours
45352881|NCT00937053|Other|Platelet transfusion|Patients whose platelets fall below 10 x 10*9 will be transfused with platelets
45352882|NCT04013997|Device|EksoGT|The intervention group received a minimum of 15 hours of standard of care, including physical and occupational therapy, for acute inpatient rehabilitation per week. After enrolling into the study, participants received locomotor training with the exoskeleton as part of their acute inpatient rehabilitation using the Ekso. Standing and walking with the Ekso started as soon as the clinical team determined it was safe for participants to begin standing, and continued until the participant was discharged from inpatient rehabilitation.
45352883|NCT00931827|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Patients under daily life treatment receiving Mirena according to local drug information.
45352884|NCT00931827|Drug|Implanon (Etonogestrel)|Patients under daily life treatment receiving Implanon according to local drug information.
45352885|NCT00664326|Drug|Regorafenib (Stivarga, BAY73-4506)|Patients will be treated with BAY73-4506 160 mg po qd for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Patients will continue treatment with BAY73-4506 until disease progression, intolerable toxicity, or patient refusal to continue with the study or investigator decision to remove the patient from study.
45352886|NCT04015323|Device|Interferential current|An electrotherapy current with different carrier frequencies
45352887|NCT00778908|Radiation|Late-course accelerated hyperfractionated IMRT|"IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease~IMRT delivery scheduling: (1) Six-week treatment: PTV1=60Gy/30fractions, PTV2=57Gy/30fractions,PTV3=54Gy/30fractions.(2) Concomitant boost to PTV1 as a second daily treatment for the last 10 treatments of the Six-week treatment: PTV1=12Gy/10fractions.(3) PTV3 will be treated with conventional radiotherapy technique separately."
45352888|NCT00778908|Drug|Concomitant cisplatin chemotherapy|cisplatin:40mg/m2 weekly infusion for 6 weeks
45352889|NCT00778908|Radiation|Conventionally fractionated IMRT|IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease IMRT delivery scheduling: (1) Seven-week treatment: PTV1=70Gy/35fractions, PTV2=63Gy/35fractions,PTV3=55.8Gy/31fractions.(2) PTV3 will be treated with conventional radiotherapy technique separately.
45352890|NCT00931905|Drug|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.The drugs were administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
45477545|NCT05599256|Drug|Ruxolitinib|"Model-predicted high-risk patients: weight ≤ 25 kg, ruxolitinib, 2.5mg bid po until at least day 60 post-transplant and terminated after day 100; weight > 25 kg, ruxolitinib, 5mg bid po until at least day 60 post-transplant and terminated after day 100. If 'azoles' are taken concomitantly, ruxolitinib will start at half dose. If the patient tolerates ruxolitinib, the dose can be increased to 10mg bid po.~Model-predicted low risk: regular aGVHD prophylactic regimens."
45477546|NCT03336580|Drug|PRX004|"PRX004 (0.1, 0.3, 1, 3, 10, and 30 mg/kg) IV every 28 days~PRX004 IV every 28 days at RP2D(s)~PRX004 IV every 28 days at RP2D(s)"
45477547|NCT03726541|Other|physiotherapy|Physiotherapy program includes breathing exercises, incisive spirometer study, grade ambulation. Oxygen saturation, heart rate and blood pressure values will be recorded before and after the session. Changes in the follow-up parameters will be discussed.
45477548|NCT03814655|Procedure|Full digital workflow|Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be full digital.
45686509|NCT00098956|Drug|7-hydroxystaurosporine|Given IV
45686510|NCT01472757|Drug|VR506|VR506 inhalation powder delivered via a new dry powder inhaler
45686511|NCT01472757|Drug|Placebo|Placebo delivered via a new dry powder inhaler
45686512|NCT02197156|Drug|10 mg HC-ER|Single dose
45686513|NCT02197156|Drug|20 mg HC-ER|Single dose
45686514|NCT02197156|Drug|30 mg HC-ER|Single dose
45686515|NCT02197156|Drug|40 mg HC-ER|Single dose
45686516|NCT02197156|Drug|10 mg HC / 325 mg APAP|Single dose
45686517|NCT02197156|Drug|Matching Placebo|Single dose
45352891|NCT00931905|Other|Hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol. It was administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
45686518|NCT00187720|Drug|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
45843164|NCT01583868|Device|PureVision2|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
45843165|NCT01583868|Device|Air Optix Aqua|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
45843166|NCT01588158|Drug|Acetaminophen|325 mg
45843167|NCT01588158|Drug|Vicodin|Vicodin 5/325 mg
45843168|NCT01588236|Drug|high dose KYG0395|3 KYG0395 capsules tid (morning, midday, and evening)
45843169|NCT01588236|Drug|lower dose KYG0395|3 KYG0395 capsules 2 times a day (bid) (morning and evening) plus 3 capsules of placebo (midday)
45843170|NCT01588236|Drug|Placebo|3 capsules of placebo tid (morning, midday, and evening)
45843171|NCT01588470|Drug|pioglitazone|45 mg per day for 6 months
45843172|NCT01589484|Device|SWL - Compact Delta Dornier Med Tech|All patients will be submitted to a noncontrast computed tomography before to SWL. Patients will be submitted to SWL under the following conditions: outpatient, general anesthesia, 3000 impulses, rate of 90/min, discharged from hospital in the same day with alpha-blocker (doxazosin) during 30 days.
45843173|NCT01590264|Device|Bimodal rTMS|"High frequency (10 Hz) at 110% of the motor threshold TMS delivered over the left dorsolateral prefrontal cortex, subsequently, a low frequency TMS (1 Hz) at 110% motor threshold will be delivered over 31 minutes over the TPJ area, according to the protocol below.~DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000~TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000"
45843174|NCT01591044|Drug|Placebo|1 puff bid or 2 puffs bid
46046073|NCT05399056|Behavioral|Storytelling|Video narratives of an individual with lived experience with COPD and Pulmonary Rehabilitation describing their journey through Pulmonary Rehabilitation
45686519|NCT01472289|Other|Autologous Bone Marrow Mononuclear cells (BMMNCs)|Multiple intramuscular injections of concentrated bone marrow derived mononuclear cells (0.5 cc/injection) into the ischemic muscle of the affected limb.
45686520|NCT00006244|Drug|melphalan|Given IV
45686521|NCT00006244|Biological|recombinant interferon alfa|Given SC
45352892|NCT02561468|Drug|Nefopam|
45352893|NCT02561468|Drug|Saline|
45352894|NCT02555748|Drug|Pazopanib|
45352895|NCT02555748|Drug|Sunitinib|
45352896|NCT04014933|Diagnostic Test|LASER SPECKLE FLOWGRAPHY|Non-invasive, real-time imaging and measurement of ocular blood flow of the optic disc and peripapillary region
45686522|NCT00006244|Biological|aldesleukin|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
45686523|NCT00006244|Procedure|in vitro-treated peripheral blood stem cell transplantation|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
45843175|NCT01591044|Drug|R940343 1mg|R343 1mg, 1 puff bid
45843176|NCT01591044|Drug|R940343 2mg|R343 2mg, 2 puffs bid
45843177|NCT01591746|Drug|Botulinum Toxin Type A|
45843178|NCT01591746|Drug|Placebo|5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A
45843179|NCT01597128|Device|Flex HD|Flex HD mesh for hernia repair
45843180|NCT01597128|Device|Strattice|Strattice mesh for hernia repair
45843181|NCT05566860|Procedure|Positional Therapy|After the a forementioned sleep endoscopy, if the patient has postural sleep apnea, he was treated with positional therapy for three months.
45843182|NCT05566860|Procedure|Intraoral Negative Pressure Therapy|If the patient is effective with intraoral negative pressure therapy (iNAP), this therapy was used for three months.
45843183|NCT05566860|Procedure|Oral Appliances|If the patient is effective with oral appliances use, it was used be for three months.
45477549|NCT03814655|Procedure|Partially digital workflow|Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be partially digital.
45477550|NCT03341884|Drug|Ipatasertib|A single oral dose of 100 mg ipatasertib will be administered.
45686524|NCT00187876|Procedure|ACL reconstruction control|The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
45352897|NCT00751946|Behavioral|Trauma Adaptive Recovery Group Education and Therapy|"Trauma Affect Regulation: Guidelines for Education and Therapy (TARGET; Ford & Russo, 2006) is a manualized gender-specific treatment for PTSD. The 12-session individual therapy version in the present study is being adapted for adolescent girls based on a parallel version for young mothers and a group version that has been field tested with more than 20 adolescent girls.~TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences. The skills are designed in a sequence mirroring the three phases of complex traumatic stress disorder treatment (Ford, Courtois, Van der Hart, Nijenhuis & Steele, 2005), summarized by an acronym FREEDOM. TARGET also uses creative arts activities: personalized lifelines via collage, drawing, poetry, and writing."
45352898|NCT00751946|Behavioral|Enhanced Treatment As Usual|Enhanced Treatment as Usual (ETAU) is a 12-session supportive therapy adapted from the Present Centered Therapy co-developed by the first author (McDonagh-Coyle, Friedman, McHugo, Ford, Mueser, & Sengupta, 2005). In ETAU therapists invite the participant to talk about goals or problems that are important to her. The therapist's focus is on providing the core conditions of client centered psychotherapy (nonjudgmental acceptance, empathy, interpersonal warmth) and engaging the participant in a strengths-based solution-focused reflection on how she is successful (or has been in the past) in managing stressors, handling problems, achieving personal goals, and developing healthy relationships with peers, family, and other community members.
45352899|NCT02555592|Procedure|Primary surgical resection with sequential adjuvant therapy|First, surgery resection of the affected lung with mediastinal lymph node dissection, including sub- and para-aortic lymph node, will be performed. If malignant tumor involvement only in the sub- or para-aortic lymph nodes is identified, adjuvant chemotherapy will be initiated within 8 weeks after surgery. After completion of adjuvant chemotherapy, post-operative radiotherapy will be initiated within 2~4 weeks after adjuvant chemotherapy.
45352900|NCT04059614|Procedure|HFNC; COT|"HFNC: high-flow nasal cannula therapy COT: conventional oxygen therapy"
45352901|NCT00930345|Drug|Sunitinib (SUTENT)|"Sunitinib, SUTENT, 50 mg daily p.o., on schedule 4/2, for 2 cycles. Two weeks of rest prior to surgery (week 11 and 12).~Radical nephrectomy at the end of week 12. Sunitinib 50 mg/d, schedule 4/2, reintroduced 2 weeks after surgery (week 14, may be postponed by one or two weeks if wound healing delay or surgical complications). Treatment until disease progression, unacceptable toxicity or consent withdrawal. Dose reduction depending on the type and severity of toxicity.~At the end of the treatment period patients will be treated at the discretion of the Investigator."
45352902|NCT00786006|Drug|FOLFIRI.3|FOLFIRI.3: Irinotecan 70 mg/m2 (over 60 min) on D1, LV 400 mg/m2 (over 2h) D1, 5-FU 2000 mg/m2 (over 46 hours) from D1, then irinotecan 70 mg/m2(over 60 min) at the end of the 5-FU infusion
45352903|NCT00786006|Drug|FOLFOX|FOLFOX: oxaliplatin 85 mg/m2 (over 120 min) on D1, LV 400 mg/m2 (over 2hour) on D1, 5-FU 400 mg/m2 IVP on D1, 5-FU 2,000 mg/m2 (over 46 hours)
45352904|NCT02562326|Drug|BioChaperone insulin lispro|Injection immediately before the start of the individualised standard meal
45352905|NCT02562326|Drug|Humalog®|Injection immediately before the start of the individualised standard meal
45352906|NCT00930501|Biological|blood tests|time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy
45352907|NCT00783120|Other|Repetitive transcranial magnetic stimulation|10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold); in total 15.000 stimuli.
46046074|NCT05398107|Behavioral|Experimental: Building Emotion Awareness and Mental Health (BEAM)|The BEAM Program is based on best-practices in telehealth and science-based program design aimed at promoting maternal mental health and supportive parenting. The BEAM Program app is hosted on the University of Manitoba secure servers and is designed/managed by Tactica Interactive. The weekly group telehealth sessions will be led by clinical coaches (a mental health professional or Doctoral-Level Clinical Psychology Student) and will use the secure videoconferencing platform Zoom (Healthcare license). Parent coaches will be mothers who have recently participated in a prior iteration of the BEAM program. Parent coaches will engage with participants on the community peer support forum and will also attend weekly telehealth sessions. The therapeutic aims of the BEAM program are to improve symptoms of anxiety and depression as well as parenting skills, and will emphasize self-compassion, effective communication practices, and social support networks.
46046075|NCT05398107|Behavioral|Control: MoodMission|"MoodMission will be used as our Standard of Care control group. MoodMission is an app based on CBT principles which creates tailored missions for mothers. These missions are based on self-reported mood and are aimed to improve mental health symptoms."
45352908|NCT00783120|Other|Sham repetitive transcranial magnetic stimulation|placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session; in total 15.000 stimuli
45352909|NCT00746720|Drug|Etoricoxib 60 mg|film coated tablet 60 mg (orally), 120 mg (= 2 tablets a 60 mg) once daily, on day one post surgery
45352910|NCT00746720|Drug|Placebo for Etoricoxib 60 mg|film coated tablet (orally), two tablets once daily, on day one post surgery
45352911|NCT00746720|Drug|Etoricoxib 60 mg|film coated tablet (orally), 120 mg (= 2 tablets a 60 mg) once daily, two hours before and 24 hours after surgery
45352912|NCT00746720|Drug|Placebo for Etoricoxib 60 mg|film coated tablet (orally), 2 tablets once daily, two hours before and 24 hours after surgery
45352913|NCT00783276|Drug|SYN115|100 mg single dose
45352914|NCT00783276|Drug|PLACEBO|PLACEBO
45352915|NCT00932061|Other|Traditional Acupuncture|"Fibromyalgia subjects will be randomized to receive 9 acupuncture treatments over the course of four weeks.~Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria."
45352916|NCT00932061|Other|Sham Treatment|"Fibromyalgia subjects will be randomized to receive 9 sham treatments over the course of four weeks.~Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria."
45352917|NCT02562170|Device|TiLoop Bra|
45352918|NCT02562170|Device|Protexa|
45352919|NCT03538197|Other|clinical and biological correlates|"To measure the rate of suicidal re attempt (SR) in a population of young adults aged 18 to 25 years.~To identify sociodemographic, clinical and biological characteristics of a population of suicidal young people, in an attempt to highlight potential risk factors"
45352920|NCT00686972|Drug|GLP-1|5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
45352921|NCT00937287|Other|There is no intervention in this study.|No intervention is provided in this study as it is exploratory.
45352922|NCT00665652|Drug|Lenalidomide|Subjects will receive lenalidomide 25 mg per day for days 1-21 followed by 7 days rest (28-day cycle) for 12 cycles.
45352923|NCT00937365|Behavioral|Exercise|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
45352924|NCT00937365|Procedure|Spinal Manipulation|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
45352925|NCT00937365|Procedure|Neuroemotional Technique (NET)|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
45352926|NCT00783588|Biological|ISF35|Subjects participating in this study will receive up to two doses of 1x10^8, 3x10^8, or 1x10^9 autologous Ad-ISF35-transduced CLL B cells, depending on the dose they received in the previous Phase I trial.
45352927|NCT02561390|Procedure|Skin prick test|skin prick test to American cockroach, dog, cat, dust mite and mold allergen extracts are performed
45352928|NCT02561390|Other|specific IgE measurement|measure specific IgE of American cockroach, dog, cat, dust mite and mold
45352929|NCT00937443|Other|Physical Fitness|Does intensity of aerobic walking exercise modify cardiac reparative factors
45352930|NCT00937443|Biological|Walking Exercise Group|Walking Group will increase intensity, duration, and steps of walking per week.
45352931|NCT00752024|Device|YL-1 type of intracranial hematoma puncture needle|"YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward."
45352932|NCT00752024|Drug|dehydrating agent, haemostatic|In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
45352933|NCT04046952|Device|Statseal with TR Band|Patients will have a Statseal Advance RAD (SS) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SS disc with the center of the balloon (the green dot) over the center of the SS disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 40 minutes (60 minutes after procedure), the TR band will be completely deflated.
46046076|NCT05397457|Device|low-level light therapy|"Device: Hair Boom 69~All participants within the experimental group will undergo low-level light therapy sessions 3 times a week for the total duration of 4 weeks starting at their last CT administration.~If the participants can not cooperate to receive the therapy 3 times a week due to personal reasons, we will recommend that they undergo 2 courses of the therapy per week at least and finish the 12 courses of the intervention in 6 weeks."
46046077|NCT05395741|Drug|Regorafenib|Patients will receive regorafenib orally at doses adjusted for age, body surface area and pharmacokinetics. Treatment with regorafenib will be continued for up to 1 year or until disease progression, patient death, unacceptable toxicity, or study closure. Pharmacokinetics and safety profile of the investigational product (IP) will be determined throughout the course therapy. In the event of progression or relapse, patients in the control group will have the option to receive the IP along with the standard treatment of the next line.
45477551|NCT05358899|Device|accelerated theta burst stimulation|cTBS was administered at 80% of each participant's M1 area in a burst-firing pattern (3 pulses at 50 Hz) with a repetition frequency of 5 Hz (200 ms intervals). During each session, participants received 1800 pulses (120 s).
45686525|NCT00187876|Procedure|ACL Biocleanse, surgical|The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
45686526|NCT01525875|Drug|Magnesium Oxide|"Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).~Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening)."
45686527|NCT01525875|Drug|Placebo|1000 mg (one 500 mg capsule two times daily) of placebo.
45686528|NCT01898260|Device|Ultrafilcon B contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
45686529|NCT01898260|Device|Stenfilcon A contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
45686530|NCT04409379|Diagnostic Test|Relative telomere length|Relative telomere length in peripheral blood cell
45352934|NCT04046952|Device|TR band only|Patients will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 60 minutes following the procedure for all patients (regardless of diagnostic or PCI procedure), after which full deflation attempts will commence.
45352935|NCT00937599|Dietary Supplement|Brazil Nut|During 16 weeks the adolescents consumed 3-5 nuts/day
46046078|NCT05386355|Behavioral|COVID-19 Vaccine Uptake App|A mHealth mobile application (app) that will provide educational and logistical information about the COVID-19 vaccination for children. The target audience will be parents of unvaccinated children.
45352936|NCT00937677|Drug|Tysabri|"Infusion of TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour at month 0 and 12 and 24 months. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP.~Use of filtration devices during administration has not been evaluated. Other medications should not be injected into infusion set side ports or mixed with TYSABRI®.~TYSABRI® concentrate is supplied as 300 mg natalizumab in a sterile, single-use vial free of preservatives. Each package contains a single-use vial."
45352937|NCT00786162|Other|Internet-enabled automated self-management program|An internet platform to display blood pressure readings and provide subjects with automated messages and educational information about hypertension management.
45352938|NCT00786162|Other|BP cuff at workplace|Provided BP cuff for communal use at the worksite
45352939|NCT00778986|Device|heart failure remote patient monitoring system|remote monitoring of weight, blood pressure, ECG, and symptoms
45352940|NCT00786240|Drug|Fesoterodine|Single dose of 4 mg tablet in formulation D under fasted conditions (Reference)
45352941|NCT00786240|Drug|Fesoterodine|Single dose of 4 mg tablet in formulation E(1) under fasted conditions (Test)
45352942|NCT04498923|Drug|Bupivacaine, dexamethasone, epinephrine|Bupivacaine 75 mg, dexamethasone 4 mg, epinephrine 0,18 mg
45352943|NCT00779064|Drug|Rivaroxaban (BAY59-7939)|10mg BID, Semi-sequential, dose escalation.
45352944|NCT00779064|Drug|Rivaroxaban (BAY59-7939)|20mg BID, Semi-sequential, dose escalation.
45352945|NCT04046874|Drug|Usual Care|Pain Medication, imaging, referrals to other health services, other health care appointments
46046079|NCT05386355|Other|General Health App|A mobile application (app) that will provide general pediatric health and infection prevention and mitigation strategies.
46046080|NCT05380856|Device|Turning ON the neuromodulator|IPG on
45352946|NCT04046874|Other|SPLIT Stratified Model of Care|Physiotherapy targeted treatment system of increasing complexity for each subgroup (low, medium or high) of risk of chronicity. Includes patient education, manual therapy and exercise
45352947|NCT00932217|Drug|filgrastim|subcutaneous filgrastim administration
45352948|NCT00932217|Drug|lenograstim|subcutaneous lenograstim administration
45352949|NCT00786318|Drug|ziprasidone|ziprasidone 20mg IM
45352950|NCT00786318|Drug|Standard therapy|Haldol 5mg/ Ativan 2mg IM
45352951|NCT00783666|Drug|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
45352952|NCT00566631|Drug|Paliperidone|Paliperidone ER tablet in flexible daily dose of 3, 6, 9 or 12 milligram (mg) as per Investigators' discretion will be given once daily orally for 6 weeks in the core treatment phase and no longer than 12 months in the extension phase after the completion of core treatment phase.
46046081|NCT05380856|Device|Turning OFF the neuromodulator|IPG OFF
46046082|NCT05369065|Combination Product|Ablation Treatment|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
45352953|NCT00932295|Other|OB|10 puffs from the participants own brand brand of cigarette (lit; 30 second inter puff interval)
45352954|NCT00932295|Other|Sham smoking|10 puffs from the participants own brand brand of cigarette (NOT lit; 30 second inter puff interval)
45352955|NCT00932295|Other|CROWN SEVEN|"10 puffs from a so-called electronic cigarette named CROWN SEVEN (16 mg cartridge; 30 second inter puff interval)"
45352956|NCT00932295|Other|NJOY|"10 puffs from a so-called electronic cigarette named NJOY(16 mg cartridge; 30 second inter puff interval)"
45352957|NCT04014699|Procedure|modified 2.2mm microincision|enlarging the internal incision about 0.4mm for conventional 2.2mm coaxial microincision phacoemulsification
45352958|NCT04014699|Procedure|conventional 2.2mm microincision|conventional 2.2mm coaxial microincision phacoemulsification
45352959|NCT00937911|Drug|YM150|oral
45686531|NCT04409613|Other|Education and counseling|All patients or their caregivers will receive twenty minutes educational sessions for the first three visits according to patient ability to understand. At subsequent visits along the study duration, we will briefly review our educational material to refresh the patient's information. This will include: The objectives of treatment, disease progression process, risk factors, common symptoms of bleeding/thrombotic events and how to deal with this. Lifestyle modifications, including smoking cessation, blood pressure and diabetes control. Drug information: drug action, dose, indication, possible side effects, how to deal with the side effects, actions to take when missing the dose, storage conditions and when and how to administer. Possible interactions including drug-drug and drug-food interactions. Target INR and INR monitoring
45686532|NCT01525641|Drug|Mirapex LA|Pramipexole Hydrochloride Hydrate
46046083|NCT05369065|Diagnostic Test|Arterial Angiography Only|Arterial Angiography Only without Intervention
46046084|NCT05369065|Combination Product|Single Arm non-Randomized Ablation Treatment|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
46046085|NCT05355311|Drug|Acetyl-l-carnitine|Acetyl-L-carnitine is an endogenous precursor of acetylcholine and metabolic intermediate that facilitates the transport of acetyl groups across the mitochondrial membrane and shows promise for treating alcohol use disorder and depression.
46046086|NCT05355311|Drug|Placebo|Matching placebo (sugar pill)
46046087|NCT05354232|Device|2 mA transcranial direct current stimulation (tDCS)|tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the 2mA condition, the investigators will assist the administration of a 2mA current stimulation from the device.
45352960|NCT00937989|Other|educational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
45352961|NCT00937989|Other|informational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
45352962|NCT00937989|Other|medical chart review|Baseline, 3, 6 and 9 months after starting the study
45352963|NCT00937989|Other|questionnaire administration|Baseline, 3, 6 and 9 months after starting the study
46046088|NCT05354232|Device|1 mA transcranial direct current stimulation (tDCS)|tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the 1mA condition, the investigators will assist the administration of a 1mA current stimulation from the device.
46046089|NCT05354232|Device|Sham transcranial direct current stimulation (tDCS)|tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the sham condition, the investigators will assist the administration of a sham stimulation from the device.
46046090|NCT05354219|Other|Imaging|Imaging with 3 iris cameras
45352964|NCT00937989|Other|study of socioeconomic and demographic variables|Baseline, 3, 6 and 9 months after starting the study
45352965|NCT00937989|Procedure|quality-of-life assessment|Baseline, 3, 6 and 9 months after starting the study
45382174|NCT05271240|Drug|Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation|Subjects who are assigned to the IA BV+TMZ/RT group (Treatment Group), in addition to your standard of care cancer treatment, you will have a dose of bevacizumab delivered directly to your brain through superselective intra-cranial intra-arterial catheterization of the arteries that supply blood to your brain tumor along with the start of the initial 42 day oral temozolomide treatment. IA BV will be repeated every three months for a total of 3 infusions.
45382175|NCT05271240|Drug|Temozolomide and Radiation Alone|Subjects who are assigned to the TMZ/RT alone group (Control Group) you will receive standard of care cancer treatment that involves a daily oral dose of temozolomide for 42 days with radiation to the tumor followed by 28 days of rest and then repeated maintenance treatment cycles of daily oral temozolomide 5 days on and 23 days off.
45382176|NCT05269459|Drug|Cannabidiol (CBD) as Nantheia ATL5|Gel caps containing 100mg of Nantheia ATL5. Subjects will take 4 capsules twice daily.
45382177|NCT05269459|Drug|Placebo|Matching gel caps containing no active drug. Subjects will take 4 capsules twice daily.
45382178|NCT05268042|Other|Moderately carbohydrate-restricted diet|For this study, the investigators will use the low glycemic, moderately carbohydrate-restricted diet that the investigators have previously shown is associated with depletion of hepatic lipid content, and improvement in insulin resistance in adolescents with NAFLD. This diet has a macronutrient composition of approximately 25% energy from carbohydrate, 20% energy from protein, and 55% energy from fat. No food group is excluded in this diet prescription; however, the diet emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary. Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included.
45382179|NCT05268042|Other|Fat-restricted diet|The fat-restricted, control diet will consist of approximately 60% carbohydrate, 20% protein, 20% fat. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide <2300 mg/day sodium. Saturated fat will be limited to 10% of total fat intake, and all dairy products will be fat-free (or low fat).
45382180|NCT05264883|Drug|Venetoclax-Decitabine/Azacitidine-Aclarubicin Association|Treatment with Venetoclax+Decitabine/Azacitidine+Aclarubicin
45382181|NCT05264883|Drug|Venetoclax-Decitabine/Azacitidine Association|Treatment with Venetoclax+Decitabine/Azacitidine
45382182|NCT05263453|Drug|HL-085|HL-085 capsule 12mg administered orally twice daily in a 21-day treatment cycle
45382183|NCT05263453|Drug|Vemurafenib|Vemurafenib tablet 720mg administered orally twice daily in a 21-day treatment cycle
45477552|NCT05358899|Device|Sham stimulation|Similar process with the accelerated theta burst stimulation with the coil 90 degrees tilted to the surface of the scalp, which could produce identical sound and vibration while avoiding real magnetic stimulation.
45352966|NCT00938067|Behavioral|Staying Connected|The overarching goal of the Staying Connected intervention is to establish a compassionate and culturally sensitive treatment trajectory that diminishes posttraumatic suffering by reducing symptomatic distress, improving functional recovery, and reducing the risk of injury recurrence. This trajectory begins with surgical treatment and extends through outpatient care and community rehabilitation. The collaborative care intervention fundamentally restructures the delivery of mental health care within trauma care systems by bringing together providers currently working independently to form an interdisciplinary mental health team. Team members work together and in a liaison capacity with other trauma center providers and community practitioners in order to bridge care across service delivery sectors.
45352967|NCT00938223|Biological|4-peptide and 12-peptide melanoma vaccines|"Each vaccination will be administered over a 6-week period (days 1, 8, 15, 29, 36, 43). Patients will be randomized into one of two groups, Group A or Group B.~Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a tetanus helper peptide.~Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.~All vaccines will contain GM-CSF-in-adjuvant and will be administered intradermally and subcutaneously. Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 identical vaccinations in a distal site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods and will be referred to as the sentinel immunized node (SIN)."
45352968|NCT04014777|Biological|NGM621|NGM621 Dose 1
45352969|NCT04014777|Biological|NGM621|NGM621 Dose 2
45352970|NCT04014777|Biological|NGM621|NGM621 Dose 3
45352971|NCT04014777|Biological|NGM621|NGM621 Dose 4
45352972|NCT00930891|Drug|Standard Chemotherapy (PCDE or PE)|"PCDE: cisPlatin 75 mg/m² D2 ; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles"
45352973|NCT00930891|Drug|Experimental Treatment (PCDE or PE + bevacizumab)|"PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression"
45477553|NCT02495194|Behavioral|Horticultural Therapy|The Horticultural Therapy intervention consists of 1 hour sessions weekly for first 3 months, followed by monthly session for the next 3 months. They will be taught on the basic gardening techniques such as sowing, weeding and fertilization during the hands-on sessions. They will also be taken on walks to the various parks to enjoy the therapeutic effect of the park greenery
45477554|NCT03827837|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
45477555|NCT03827837|Drug|Famitinib|a small-molecule multikinase inhibitor
45477556|NCT03560245|Drug|Bryostatin|The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
45477557|NCT03560245|Other|Placebo|The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the experimental drug
45477558|NCT03336424|Diagnostic Test|Non-invasive investigations|Ultrasound, blood tests, urine analysis and culture, uroflowmetry
45477559|NCT03336424|Diagnostic Test|Invasive investigations|Cystomanometry, pressure flow study, EMG
45477560|NCT04857788|Other|Pandah Application smartphone only|Patients will have an application on their smartphone to help them do their homework
45686533|NCT03026985|Other|Observational cohort|Ultrasound assessment of quadriceps, muscle strength testing, highest mobility level
45686534|NCT00006400|Drug|Hydroxyurea|Participants will receive hydroxyurea.
45686535|NCT00006400|Drug|Placebo|Participants will receive placebo.
45686536|NCT01496469|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks
45686537|NCT01496469|Drug|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
45686538|NCT04633096|Behavioral|tailored feedback of depression screening results|The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The information is tailored to the participant's individual symptom profile, illness perceptions and preferences.
45352974|NCT00930891|Drug|Prerandomization Chemotherapy (PCDE or PE)|"PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 2 cycles~PE: cisplatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 2 cycles"
45352975|NCT00938301|Drug|PF-04455242|Powder-in Capsule (EP-PIC), will be used to administer doses from 0.5 mg up to and including 56 mg of a single rising dose over 3 treatment periods receiving two doses of PF-04455242 and one dose of placebo. A one-week (minimum) washout will separate each treatment period.
45352976|NCT00938301|Drug|Placebo|PIC matching in appearance to PF-04455242 will be used to administer placebo.
45352977|NCT00938379|Drug|20% deet insect repellent|skin-applied repellent lotion
45352978|NCT00938379|Drug|placebo control|Identical base formulation of lotion but without any deet active
45352979|NCT00938535|Behavioral|Obesity Prevention|This arm includes an action plan, tailored print materials, telephone support calls, interactive self-monitoring, and a 12-month YMCA membership for the participant.
45352980|NCT00661830|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 body surface i.v. first cycle at day 1, 8, 15, 22, 29, 36, 43. Next cycles at day 1, 8, 15.
45352981|NCT00661830|Drug|Placebo|Placebo
45352982|NCT00661830|Drug|Sorafenib|Sorafenib 400 mg bid orally continuously
45352983|NCT00932529|Drug|Olanzapine|Olanzapine tablets 2.5mg - 20 mg per day once daily, or at the treating clinicians discretion
45352984|NCT00932529|Drug|Quetiapine|Tablets, 25 mg-800 mg given twice daily, or at the treating clinicians discretion.
45477561|NCT03818243|Behavioral|Diary (for reporting all impulse control disorders especially compulsive eating disorders)|During 7 days, at home, patients must report in their diary all their impulse control disorders especially their compulsive eating disorders. They will detailed each food intake and drink intake and the time.
45477562|NCT02495272|Drug|Oxytocin|Oxytocin 10IU Administered intramuscularly.
46046091|NCT05327062|Device|CRT implantation guided by XSpline, a non-invasive electrical and venous anatomy assessment|"The following information and data will be obtained from the routine clinical work up of the patients: Patient demographics, cardiovascular medical history, and clinical examination; 12-lead ECG; Standard echocardiography; Computed tomography angiography for visualization of atria, ventricle, and coronary sinus.~Imaging data will be transferred to the cloud-based web-platform using a dedicated software provided by study sponsor. Data processing includes evaluating the quality of the data and calculation of various anatomical and electrical parameters, and identification of the target zone as a point in the target vein closest to the latest activation zone.~LV-lead location is based on the information provided by the dedicated software followed by visual X-ray based verification of anatomically suitable/most desirable position.~The patient will undergo CRT device implantation according to local protocols."
45686539|NCT04633096|Behavioral|standardized feedback of depression screening results|The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
45686540|NCT00189436|Drug|Nebulized Budesonide|Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
45686541|NCT00189436|Drug|Usual care (albuterol with or without oral steroid)|Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)
45352985|NCT00932529|Drug|Risperidone|Tablets, 1mg-6mg per day, once or twice daily, or at the treating clinicians discretion.
45352986|NCT00932529|Drug|Ziprasidone|Tablets, 20mg - 160 mg twice daily, or at the treating clinicians discretion
45352987|NCT00783744|Drug|Insulin Glargine|In the morning to target FBG ≤ 100 mg/dl
45352988|NCT00783744|Drug|Glimepiride|Glimepiride 3 or 4 mg
45352989|NCT00783744|Drug|Metformin|At least 850 mg od
45352990|NCT00783744|Drug|Insulin monotherapy with premixed insulin NPH 30/70|Given before breakfast and before dinner, target of pre-prandial BG ≤ 100 mg/dl
45352991|NCT00932607|Drug|sublingual immunotherapy|"Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily. Or 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Route of administration: Sublingual application. Drops (for SUBLIVAC Birch) or puffs (for Staloral Birch) are to be held underneath the tongue and then will be swallowed.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
45352992|NCT00783822|Other|RGCT|rapid genetic counseling and testing
45352993|NCT00932685|Drug|Midazolam|Midazolam 0.5mg/kg
45352994|NCT00932685|Device|Game Boy|Children given video game as a distraction in preop holding and were permitted to continue playing the game in OR during induction
45352995|NCT05000346|Drug|Drug, inhalation|Solution administered by inhalation
45352996|NCT00931125|Drug|ranibizumab and vitrectomy|ranibizumab 10mg/ml intravitreal injection, 0,05 ml
45352997|NCT00931125|Procedure|vitrectomy without preoperative ranibizumab|sham intravitreal injection before vitrectomy surgery
45352998|NCT00789984|Device|noncontact specular microscopy|
45352999|NCT00932763|Drug|Amlodipine besylate|10 mg tablets (Torrent Pharmaceuticals, India)
45686542|NCT04091607|Other|Music Therapy|Subject will listen to Music using provided ear buds or headphones.
45477563|NCT05565482|Behavioral|Work Chat: An Interactive Virtual Workday|Study participants will receive Standard Transition Services plus Work Chat will be a simulation training using virtual characters to role-play conversations. It will contain conversations with a coworker, a customer, and a supervisor within a workplace setting.
45477564|NCT03814811|Diagnostic Test|Circulating Osteocalcin-positive (cOC) cells|Quantitative measurement of osteocalcin-positive cells in the peripheral blood mononuclear cells by flow cytometry
45353000|NCT00932763|Drug|Norvasc|10 mg dose (Pfizer, USA)
45353001|NCT00786396|Behavioral|Directly administered antiretroviral therapy|Daily observation of subjects taking their HIV medications
45353002|NCT04014543|Other|gastronomy|"to study the quality of life of caregivers and children with generic questionnaires (13-16), validated and used in other pathologies and chronic diseases of the child.~This will allow reproducibility and comparisons to other populations, general or other chronic diseases (acute leukemias ...) This is to conduct a pilot study, preliminary to the construction of a larger study, longitudinal with several evaluation times."
45353003|NCT00783900|Other|metoprolol, biatrial pacing|Prevention, atrial fibrillation, cardiac surgery, biatrial pacing, metoprolol
45353004|NCT00932841|Other|Placebo|One packet PO daily x 8 weeks.
45353005|NCT00932841|Drug|VSL#3 900 billion bacteria|One packet PO daily, x 8 weeks
45353006|NCT00932841|Drug|VSL#3 90 billion bacteria|One packet PO daily, x 8 weeks.
45353007|NCT00783978|Other|whole blood sample|2 ml of whole blood for children 5 ml of whole blood for parents that will be used only if 1 mutation is found in children
45353008|NCT00938613|Drug|Budesonide|nasal spray, one spray per nostril at time 0
45353009|NCT00938613|Drug|Placebo|nasal spray, one spray per nostril at time 0
45353010|NCT00938613|Drug|Budesonide|nasal spray, one spray per nostril at time 0
45353011|NCT00786552|Drug|pemetrexed + paclitaxel|Pemetrexed 500 mg/m² i.v. over 10 minutes on day 8 Paclitaxel 90 mg/m² i.v. over 60 minutes on day1 and 8
45353012|NCT00938691|Procedure|Intradermal Suture|
45353013|NCT00938691|Procedure|Intradermal Suture|
45477565|NCT03336346|Drug|dolutegravir|HIV integrase strand transfer inhibitor used in combination ART
45477566|NCT03336346|Device|ENG implant|Reversible contraception implant
45477567|NCT03336346|Drug|Efavirenz|non-nucleoside reverse transcriptase inhibitor used in combination ART
45477568|NCT03841292|Drug|Varenicline|Varenicline (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet) twice daily for the remainder of 12 weeks. Dose adjustments due to adverse events will be allowed (i.e. decrease to 0.5 mg twice daily).
45477569|NCT03841292|Device|Active tDCS|Active 2mA tDCS (Nuraleve, Canada) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session
45477570|NCT03841292|Device|Sham tDCS|Shame tDCS (Nuraleve, Canada) (30 seconds of 2mA and 19.5 minutes of 0 mA) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session.
45477571|NCT05659199|Device|extracorporeal shockwave|Patients will be treated with extracorporeal shockwave therapy (ESWT) with bladder lithotomy position, twice a week for 4 weeks, 3,000 individually with a maximum total energy flow density of 0.25 mJ/mm2, rate 3Hz each time. Extracorporeal shockwave (RUIDI.SWT001, Shenzhen, China) can provide a kind of physical spark wave energy, that will be delivered by the probe. The water sac probe will be moved slowly over the groin, perineum and crura of the penis.
46046092|NCT05323266|Device|Nasal Continuous Positive Airway Pressure (nCPAP)|The two main interventions in this study were Nasal continuous positive airway pressure (nCPAP) and high-flow nasal cannula (HFNC) in patients with acute stroke. Nasal continuous positive airway pressure (nCPAP) is a way of ventilation completed in a non-invasive ventilator. In this study, the nasal mask is mainly used to replace the traditional oral and nasal mask.
45353014|NCT04046640|Device|Infrared thermal imaging|"Infrared thermal imaging will be adopted to assess the heat transport characteristics of meridian phenomenon for participants in the two groups.~Experimental device: a NEC InfRec R450 infrared thermal imaging camera~Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. The height and angle of the infrared thermal imaging camera is adjusted so that the measurement sites of the participant's arm is located in the center of the camera screen. The infrared thermal imaging and acupoint temperature will be recorded for 5 minutes.~Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
45353015|NCT00938769|Other|Self-Efficacy Training for Caregivers|"The Enhanced Caregiver Training intervention will be delivered to informal caregivers of cancer patients before hospital discharge who are randomly selected to receive this intervention. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress.~2-hour in-person instruction of home care issues for caregivers of patients with cancer."
45477572|NCT05659199|Behavioral|myofascial release|pressure was applied at 1 kg/cm2 (within the patient's tolerable range depending on the individual) to the points where patients had a VAS pain score of 4 or more during palpation. Intermittent pressure will be applied for 180-210s at the tenderness until the muscle relaxed.
45353016|NCT00938769|Other|Comparison Conditions for Caregivers|"Subjects randomly selected to participate in the attention control training will receive an informational session about cancer and resources for caregiving.~2-hour counseling session for cancer caregivers to locate community support resources"
45353017|NCT04047186|Drug|Nivolumab Injection|Nivolumab 3mg/kg on day-28 and day-14 prior to planned surgical resection
45353018|NCT00931203|Drug|Celecoxib|Celecoxib (400 mg/d) will be continued from day 1 to 65
45353019|NCT00784056|Drug|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)
45353020|NCT00540592|Biological|GlaxoSmithKline Biologicals' influenza vaccine GSK576389A|Single dose, Intramuscular injection, 8 different formulations were tested (one per group)
45353021|NCT00540592|Biological|Fluarix|Single dose, Intramuscular injection
45353022|NCT03970395|Other|Osteopathic manipulative therapy (OMTh)|The Osteopathic Manipulative Therapy includes evaluation and treatment. The evaluation considers the pelvic girdle and lower limb, thorax abdominal area, pectoral girdle and upper limbs, cervical and upper thoracic area, cranial vault, cranial base and viscero cranium. The treatment is based on balanced ligamentous tension technique, myofascial release, visceral manipulation, and balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 minutes of evaluation and 30 minutes of treatment.
45353023|NCT03970395|Other|Light Touch Therapy (LTT)|The LTT is consistent with the OMT during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body, moving the hands every few seconds, and by flattening and softening the surface of the hands to minimize focal areas of force.
45353024|NCT03970395|Other|Repositioning therapy|"It consists of strategies that guide the parents to position the baby back to sleep, by alternating head position, the use of tummy time while supervised, and the infants must spend minimal time in car seats or other devices that promote supine positions. In active counter-positioning the parents are suggested to place some toys on the side of the head where neck rotation is limited while, when using the changing table, to alternate the end of the table at which the infant's head is placed."
45353025|NCT00790140|Dietary Supplement|Prosure|This is an enteral tube feed with 125 kcals & 6.65g protein per 100mls. It contains Fat, Carbohydrate, and vitamins and minerals and is enriched with 2.2g Eicosapentaenoic Acid per 500mls of feed. Patients on this trial who are randomized to Prosure will receive the product orally for 5 days prior to surgery and for 21 days post surgery vis a feeding jejunostomy tube
46046093|NCT05323266|Device|High-Flow Nasal Cannula (HFNC)|The high-flow nasal cannula (HFNC), as another oxygen therapy, is also used as an intervention in this study to study the effect of early prognosis in patients with acute ischemic stroke.
45353026|NCT00790140|Dietary Supplement|Ensure Plus|This is a standard enteral tube feed with 150 kcals & 6.3 g protein per 100mls as well as carbohydrate, fat and vitamins and minerals. It does not have any active immunonutrients. Patients randomized to this arm will receive the product for 5 days pre op and 21 days post surgery via a feeding jejunostomy tube
45353027|NCT00565773|Drug|Belatacept|Belatacept will be given within 24 hours of transplantation via a peripheral intravenous catheter at a dose of 10mg/kg (actual body weight) infused over 30 mins. The dose will be repeated on study days 4 (post op day 3) and 8 (post op day 7), then every 2 weeks for 5 additional doses. Thereafter, belatacept will be given once every 4 weeks (+/- 3 days) at 10mg/kg through 6 months then at 5mg/kg indefinitely.
45353028|NCT00565773|Drug|Sirolimus|Sirolimus will be started on postoperative day 1 at a dose of 2 mg per day orally. Doses will be adjusted to maintain 24-hour trough levels of 8-10ng/ml until the drug is weaned. Toxicity attributable to sirolimus (e.g., mouth ulcers, arthralgias) will prompt dose reduction to address clinical concerns in this regard. If sirolimus trough levels need to be reduced below 4ng/ml to control drug side effects, the patient will be considered intolerant to the drug and will be changed to other medications.
45477573|NCT02495350|Other|Questionarie|"Parturients will be asked to fill out a labor satisfaction questionnaire detailing initial desire for epidural analgesia, final desire for epidural analgesia, adequacy of pain relief during labor and satisfaction with laborOn the third day postoperatively the parturients will be called and assessed for mood and signs of postpartum depression using Edinborough Postnatal Depression scale validated into Hebrew (10) , and we will assess whether or not they are breastfeeding.~At 6 weeks we will follow-up to assess breastfeeding duration ,and postpartum depression using the Edinborough Postnatal Depression scale.~Our comparison will include average pain scores, breast feeding success, and postpartum depression assessment."
45498233|NCT01783041|Drug|L-carnitine|Infants will receive L-carnitine 50 micromoles/kg/day, divided into three doses, intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
46046094|NCT05318703|Behavioral|tai ji quan|cognitively enhanced tai ji quan exercise
46046095|NCT05318703|Behavioral|Stretching|Stretching exercise
46046096|NCT05311033|Other|Exacyl|Healthy males with at risk of post-inflammatory hyperpigmentation have a skin samples for evaluate the activity of tranexamic acid.
46046097|NCT05310708|Diagnostic Test|Polysomnography|Measuring and recording multiple physiological parameters from a patient which are used by clinicians to make a decision on the diagnosis of sleep.
46046098|NCT05303025|Other|Survey|Survey to acquire baseline demographic information as well as information regarding professional experience, working environment and attitudes towards artificial intelligence.
46046099|NCT05303025|Other|Semi-structured group discussion|Semi-structured group discussion.
45353029|NCT00565773|Drug|Alemtuzumab|All participants will receive a single dose of 30 mgs of alemtuzumab on the day of transplantation.
45353030|NCT00932919|Behavioral|Thought field therapy|5 sessions with Thought field therapy
45353031|NCT00932919|Behavioral|Cognitive therapy|12 sessions of Cognitive therapy
45353032|NCT00932919|Behavioral|Wait list|3 months waiting, then randomized to either thought field therapy or cognitive therapy
45353033|NCT00932997|Behavioral|telephone-based intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
45353034|NCT00932997|Other|counseling intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
45353035|NCT00932997|Other|educational intervention|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
45353036|NCT00932997|Other|questionnaire administration|Baseline and 9 months after enrollment and intervention
45353037|NCT00932997|Procedure|psychosocial assessment and care|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
45353038|NCT00932997|Procedure|quality-of-life assessment|Baseline and 9 months after enrollment and intervention
45353039|NCT00570492|Drug|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray 110mg QD
45353040|NCT00570492|Drug|Placebo nasal spray|Placebo nasal spray
45353041|NCT00931281|Drug|ABT-450|capsules, QD or BID, 14 days, ascending doses
45477574|NCT04805996|Behavioral|Diabetes remission using total diet replacement and eHealth contact with the healthcare provider|Participants will replace usual foods with the commercially available total diet replacement Modifast (Impolin AB), which is delivered to them during the study period without any cost. Participants will be supplied with a scale, a finger-stick blood glucose meter and a blood pressure monitor and will be advised to measure body weight, fasting blood glucose and blood pressure every morning. The results are registered in the mobile phone application Telia Health Monitoring (Telia Sweden AB) and are wirelessly transmitted to the study team.
46046100|NCT05293392|Behavioral|Culturally-Tailored COVID-19 Vaccine Uptake Intervention|This is a multi-component intervention to increase COVID-19 vaccine uptake among youth that was co-created with community partners and refined with qualitative feedback from Black and Latino youth and parents. The intervention consists of culturally-tailored educational materials to increase awareness about the COVID-19 vaccine, culturally-sensitive communication strategies employed by pediatric primary care providers and community health workers, and strategies to facilitate and standardize access to the COVID-19 vaccine in the primary care clinic.
46046101|NCT05293392|Behavioral|Standard Care|Standard care includes routine offer of the COVID-19 vaccine and counseling about the COVID-19 vaccine by pediatric primary care providers.
45353042|NCT00931281|Drug|ritonavir|capsules, QD or BID, 14 days, ascending doses
45353043|NCT00931281|Drug|Placebo for ABT-450|capsule, QD or BID, 14 days
45477575|NCT05665231|Other|A - Bone defect (clinical variables)|At T0, the edentulous space to be rehabilitated will be characterized in terms of the morphometric level of the existing defect in the vestibular cortical, according to the classification by Caplanis N. in EDS-1 or EDS-2.
45353044|NCT00931281|Drug|Placebo for ritonavir|capsule, QD or BID, 14 days
45353045|NCT04204330|Device|CardioQvark cardiac monitor and software, single-lead ECG|"Registration certificate for the medical device No. РЗН 2019/8124 dated February 15, 2019.~Product form: phone case.~Way of applying:~Download the CardioQVARK mobile application; create a profile.~Fill out the questionnaire:~age;~date of birth;~sex;~weight;~height;~blood type;~eye color;~hair color;~occupation;~town;~alcohol consumption;~tobacco use;~overeating;~insufficient sleep;~hypertension;~type 2 diabetes;~pacemaker;~the 10th revision of the International Classification of Diseases (ICD-10) code;~medicines.~Place index fingers on sensors that are on the case's backside and record 1-lead ECG of up to 3 minutes duration.~Recorded parameters:~time parameters of the ECG intervals (RR, P, PR, QRS, QT, QTc);~abnormal rhythms;~heart rate variability;~additional function - blood pressure and blood sugar diary. All recorded and calculated parameters are passed to the server."
45353046|NCT00933075|Drug|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 5 weeks (treatment period).
45353047|NCT03958630|Drug|11C-ER176|PET biomarker for inflammation
45686543|NCT01471353|Drug|Sorafenib Plus Capecitabine (SorCape)|Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days
45686544|NCT01525407|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
45353048|NCT03958630|Drug|11C-PIB|PET biomarker for amyloid
45353049|NCT04014855|Drug|Iron Supplement|in iron deficiency anemia
45353050|NCT00933153|Dietary Supplement|Ensure Plus|Ensure plus supplement with meals
45353051|NCT00933153|Dietary Supplement|Meals on Wheels|Two Meals on Wheels twice daily
45353052|NCT00571922|Drug|Acamprosate|2 gr/day (333 mg, TID)
45353053|NCT00571922|Drug|placebo|matching placebo
45353054|NCT00786630|Behavioral|Strengths-based case management|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline.
45477576|NCT05665231|Other|B- Bacterial plaque index (O'Leary index)(clinical variables)|At time T-1 and T4, the investigator will analyse the existing plaque on teeth adjacent to the surgical site using a dichotomous score (0 = no visible plaque at the soft tissue margin, 1 = visible plaque at the soft tissue margin). The result will be present in percentage (0% (better)-100%(worse)) and will describe the change between T-1 and T4, and compare the results between implants type.
45477577|NCT05665231|Other|C- Probing depth|At Time T-1 and T4, the investigators will analyse the probing depth of the teeth adjacent to the site to be treated at 6 points: mesiobuccal, vestibular, distobuccal, mesiopalatal, palatine, distopalatal. The recordings will be carried out with a CP 15 UNC, Hu-Friedy® Chicago, IL, EUA manual probe.The result will be present in millimeters. The change between T-1 and T4 is also going to be analysed and compare implants results.
45477578|NCT05665231|Other|D- Bleeding on probing|At time T-1 and T4, the investigators will analyse the bleeding on probing of the teeth adjacent to the site to be treated at 6 points: mesiobuccal, vestibular, distobuccal, mesiopalatal, palatine, distopalatal. The recordings of bleeding on probing will be carried out with a CP 15 UNC, Hu-Friedy® Chicago, IL, EUA manual probe.The result will be present in percentage (0% (better)-100%(worse)) and will describe the change between T-1 and T4 and compare between implants type.
45477579|NCT05665231|Other|E- Gingival phenotype|At time T-1, the identification of the gingival phenotype is performed by clinical inspection with a periodontal probe. The gingival phenotype will be classified as thin, moderate or thick. The investigators will compare implant results.
45477580|NCT05665231|Other|F- Implant insertion torque (Clinical variables)|Recording of implant insertion torque, in Ncm during placement in T1, and compare implants results.
45477581|NCT05665231|Other|G- Implant stabilization quotient (ISQ) (clinical variables)|Determination of the implant stability coefficient at the time of implant placement (T1) and in the 2nd surgical phase (T3) using the Osstell® device (minimum 1; maximum 100; high stability when ≥70) and analysis of the change between T1 and T3 and different implants results.
45477582|NCT05665231|Other|Morphometric results (Direct measurements - millimeter)|"Compare Direct measurements (millimeters) at the different times intervention with periodontal probe or gauge and analyse the change between times and compare implant results.~In T-1, T2 and T3c and T4 the investigators will evaluate interdental distance; BPD, cortical bone, papilla and volume, corresponding of measurements: a,b,c and r.~In T0, the investigators will evaluate interdental distance; BPD, cortical, bone and global volume corresponding to measurements: a, b, c, d, e, q, r, s, t, and u).~In T1 e T3, the investigators will evaluate interdental distance; BPD, cortical, bone and global volume, implant parameter corresponding to measurements: a, b, d, e, f, g, h, I, j, k, l, m, n, p, q, r and ISQ value."
45477583|NCT05665231|Other|Morphometric results (plaster models measurements - millimeter)|"Preparation of plaster models at times T-1 and T4 and the following measurements (millimeter) will be evaluated with the use of periodontal probe or gauge and will analyse the change between T-1 and T4 and compare implants results:~interdental distance~bucco-palatal distance (BPD)~presence of papilla~r. global volume."
45477584|NCT05665231|Other|Imaging Results (X-ray) (millimeter)|"The investigator will measure (millimeters, using the imaging software virtual ruler) the results of digital X-ray at times T-1, T1,T4 and analyse the variation and compare implants results. The measurements are:~a. interdental distance; i. implant - cemento-enamel junction (CEJ) of adject teeth distance; l. distance from the implant position depth to the buccal bone crest; n. implant diameter; o. implant length."
45498234|NCT01783041|Drug|5% Dextrose|Infants will receive 5% dextrose (placebo) three times a day (volume equivalent to the experimental drug) intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of enteral placebo (5% Dextrose) will be given to the study patients.
45498235|NCT01569321|Device|MRI|
45686545|NCT01525407|Drug|Atorvastatin Calcium|Given PO
45686546|NCT01525407|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
45686547|NCT01471197|Biological|Ipilimumab|Intravenous (IV) solution, IV, 10mg/kg, Once every 3 weeks for 4 doses, then once every 12 weeks during Treatment Phase, 90 minute infusion
45498236|NCT01569321|Device|PET-CT scan|
45843184|NCT05566860|Procedure|Surgery|If the interventions mentioned above are ineffective, or the patient does not want to try the above treatments, surgery is required. The surgical patients were divided into three groups according to their body weight. One group was overweight patients (BMI>32) who were treated with upper airway surgery and/or bariatric surgery, and/or postoperative diet education; the other group was overweight people with a BMI between 27 and 32, upper airway surgery and/or bariatric surgery, and/or postoperative diet education will be done; if the weight is normal with the BMI is less than 27, or those patients who are overweight but are not willing receive above mentioned weight loss treatment, upper airway surgery will be done.
45843185|NCT05566860|Procedure|Tongue Muscle Strength Training|If the tongue strength of the aforementioned patient is insufficient, it is recommended that the patient need to do tongue muscle strength training at the same time for three months. If the ambient temperature and humidity have an impact, we will recommend patients to control the ambient temperature and humidity and use the ECG patch to track the changes before and after three months.
45843186|NCT05566470|Diagnostic Test|Assessment of Central Neuromuscular Dysfunction, Shoulder Physical Functionality and Psychological Factors|Each of the 2 groups will be evaluated in terms of functional level and psychological factors; American Shoulder and Elbow Surgeons evaluation form (ASES), Connor-Davidson Psychological Resilience Scale (CDPRS) and the Depression, Anxiety, Stress-21 Scale (DASS-21) will be used to evaluate these factors. Furthermore, the corticospinal excitability of the deltoid muscle will be assessed with Transcranial Magnetic Stimulation (TMS). Both deltoid muscles of the patient will be evaluated by saving motor evoked potentials signals that respond to TMS, and motor excitability will be compared between the affected arm and the unaffected arm. In addition, the control group will also be assessed in terms of functional level and psychological factors with TMS, ASES, DASS-21 and CPDRS.
45843187|NCT05566314|Dietary Supplement|Amunizer|12 oz. herbal, probiotic and antioxidant herbal beverage
45843188|NCT05566314|Other|Placebo|12 oz. flavored beverage
45843189|NCT05566236|Behavioral|board game|A board game was designed based on situated learning theory and the results of relevant studies. This board game contains a summary, answer booklet, and multiple card game tasks including situations of interpersonal interaction. The participants must discuss, share personal experiences, and find the answer together.
45843190|NCT05566080|Procedure|Carotid endarterectomy|Patients who have a significant carotid stenosis and who undergo surgical carotid endarterectomy
45843191|NCT05566002|Diagnostic Test|Right heart catheterization|RHC is commonly used essential test to make gold-standard diagnosis of PH with mPAP >20 mmHg. All multimodal data from patients eligible for inclusion would be randomly assigned to development datasets (70% of the study population) to train the artificial intelligence models for the detection of PH, which would be validated and tested by other datasets (30% of the study population).
45843192|NCT05565924|Other|Group- A (100% weight-bearing; n=14), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (100% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)."
45843193|NCT05565924|Other|Group- B (70% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (70% weight-bearing) plus medications plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)"
45843194|NCT05565924|Other|Group- C (50% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (50% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)"
45686548|NCT01471197|Biological|Pemetrexed|IV solution, IV, 500 mg/m2, Once every 3 weeks during Treatment Phase, 10 minute infusion.
45686549|NCT04408989|Drug|MB02-SP|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
45843195|NCT05565924|Other|Group- D (30% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (30% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)."
45843196|NCT05565924|Other|Group- E; Control group|"Control: No aerobic exercise training on the antigravity treadmill, but only medications (Biguanide alone or Sulfonylureas plus Biguanide combination) throughout the study."
45686550|NCT04408989|Drug|MB02-DM|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
45686551|NCT04408989|Drug|US licenced Avastin®|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
45686552|NCT00011986|Drug|Paclitaxel|Given IV
45686553|NCT00011986|Drug|Carboplatin|Given IV
45686554|NCT00011986|Drug|Gemcitabine Hydrochloride|Given IV
45686555|NCT00011986|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|
45686556|NCT00011986|Drug|Topotecan Hydrochloride|Given IV
45686557|NCT00011986|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45353055|NCT00786630|Behavioral|Case management plus facilitated treatment alliance|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline. They will also receive a facilitated treatment alliance, which consists of meetings with methadone counselors to aid in treatment entry.
45353056|NCT00933231|Drug|tacrolimus|Standard dose, Oral
45353057|NCT00933231|Drug|tacrolimus|Low dose, Oral
45353058|NCT00933231|Biological|Simulect|IV
45353059|NCT00933231|Drug|Cellcept|Oral
45353060|NCT00933231|Drug|Corticosteroids|IV and Oral
45353061|NCT00933231|Drug|Ramipril|Oral
45353062|NCT00933231|Drug|Irbesartan|Oral
45353063|NCT00746876|Device|Unipolar hip hemiarthroplasty|Unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
45353064|NCT00746876|Device|Bipolar hip hemiarthroplasty|Bipolar hip hemiarthroplasty for the treatment of femoral neck fractures
45686558|NCT01898416|Drug|5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.|"60 mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia.~Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In case of positive margins a second operation and 5-ALA administration or irradiation will be given."
45353065|NCT00790374|Drug|BN83495 (Cohort 1)|20 mg daily BN83495 for 28 days
45353066|NCT00790374|Drug|BN83495 (Cohort 2)|40 mg daily BN83495 for 28 days
45353067|NCT00790374|Drug|BN83495 (Cohort 3)|60 mg daily BN83495 for 28 days
45353068|NCT04054466|Behavioral|Nursing Counseling in the change of Alcohol Consumption Behavior in patients receiving HAART|"It is a health intervention, performed by the nurse with the purpose of providing support or support to the patient's health care. The main objective of counseling is to improve adherence to treatment in patients who receive HAART but also consume alcoholic beverages.~The components of the differentiated counseling according to the levels of consumption are consolidated according to the recommendations given by the World Health Organization (WHO) after the application of the AUDIT:~Social consumption (sometime in life, in the last year or in the last month) = mainly education about consumer risks, its application will be bi-monthly."
45353069|NCT04054466|Behavioral|Habitual Counseling|Regular counseling provided to patients receiving HAART, based on education and guidance to comply with antiretroviral treatment
45353070|NCT03489525|Biological|Dose Escalation, MEDI2228, ADC (antibody drug conjugate)|Single agent MEDI2228 will be administered to adult subjects with R/R MM. The study aims to evaluate up to 9 planned, sequentially ascending main dose levels
45353071|NCT03489525|Biological|Dose Expansion, MEDI2228, ADC (antibody drug conjugate)|Adult subjects with R/R MM with measurable disease will be enrolled in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase.
45353072|NCT00784212|Drug|BGG492|
45686559|NCT01524783|Drug|Everolimus|Participants were treated with everolimus 10 mg (two 5 mg tablets) once daily orally taken
45353073|NCT00784212|Drug|BGG492|
45353074|NCT00784212|Drug|Placebo|
45353075|NCT00752180|Biological|Wosulin R|Total dose per subject will be 0.3 IU/Kg given Subcutaneously.
45686560|NCT01524783|Drug|Placebo|Participants were treated with two tablets of matching placebo once daily orally taken.
45353076|NCT00752180|Biological|Actrapid|Total dose per subject will be 0.3 IU/kg given Subcutaneously.
45686561|NCT01524783|Other|Best suportive care (BSC)|Best supportive care includes all care provided to participants deemed necessary by the treating physician, such as but not restricted to anti-diarrheals and analgesics. The optimal care of the patient is based on the treating physician's best medical judgment.
45686562|NCT01494987|Drug|Ranolazine|Ranolazine tablet(s) administered orally
45686563|NCT01494987|Drug|Placebo|Placebo to match ranolazine for the duration of the study
45686564|NCT01494987|Drug|Glimepiride|Glimepiride tablets (2 mg or 4 mg) administered orally once daily with the morning dose of study drug or placebo. The target dosing regimen for glimepiride is 4 mg once daily.
45686565|NCT01494987|Behavioral|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
45686566|NCT01494987|Behavioral|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
45686567|NCT04409769|Other|Description of use of ceftaroline and ceftobiprole|Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. Description of condition of use of thoses antibiotics in PJI and BJI
45843197|NCT05565690|Device|MRS|It is a tool used to determine the molecular structure of compounds or to detect the compound presence , it provides metabolic information from living brain
45843198|NCT05565300|Other|Cycling exercise|30 minutes of cycling (90 rpm).
45843199|NCT05565300|Other|Cognitive tasks|30 minutes of cognitive tasks based on the different domains of the Mini Mental Scale.
45353077|NCT00784290|Drug|Orantinib (TSU-68)|200 or 400 mg bid day 1～day 28 cycle until progression or unacceptable toxicity develops
45353078|NCT00752336|Behavioral|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day
45353079|NCT00752414|Drug|MP-376 (Levofloxacin solution for Inhalation)|Daily for 5 days
45353080|NCT00752414|Drug|Placebo|same frequency as MP-376
45353081|NCT00790530|Behavioral|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition
45353082|NCT00790530|Other|Usual Care|Usual Care
45498237|NCT01569321|Device|PEM scan with ClearPemSonic|
45353083|NCT03396562|Other|Assessments of Development and Growth|Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, and 5 or 6 years.
46046102|NCT05292703|Other|Participatory activity based on art and olfactory stimulation|practicing art in a group under supervision, involving the participants directly in the creative process, allowing them to become co-authors. Participants will meet once a week for 4 weeks for a 2-hour workshop at the Institut Claude Pompidou in Nice in a dedicated space, A different theme will be offered each week. Each workshop will be led by the same artist who will propose creative activities to be carried out by the participants and each session will result in a creation that the participant will take away, bringing into play artistic skills and olfactory identification capacities.
45353084|NCT04059224|Drug|Trametinib|Trametinib 2 mg once a day by mouth.
45353085|NCT04059224|Drug|Dabrafenib|Dabrafenib 50 mg twice a day by mouth. Dabrafenib can be uptitrated to 150 mg twice a day in case of dose-limiting trametinib-associated skin toxicity.
45353086|NCT02554266|Device|Lutonix 014 Drug Coated Balloon PTA Catheter|Drug Coated Balloon PTA Catheter for Treatment of Below-the-Knee (BTK) Arteries
45353087|NCT00786942|Procedure|high tibial osteotomy|addition of bone graft to fill the osteotomy gap
45353088|NCT00786942|Procedure|higi tibial osteotomy|the gap of the tibia is unfilled
45353089|NCT02193958|Drug|FF-10501-01|FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
45353090|NCT00686894|Procedure|PDUS|PDUS scored for each enthesitis every 2 weeks for 24 weeks.
45353091|NCT00686894|Drug|Infliximab|"5 mg/kg~IV~Frequency : weeks 0,2,6"
45353092|NCT00328627|Drug|Alogliptin|Alogliptin tablets.
45477585|NCT05665231|Other|Imaging Results (CBCT)(millimeter)|"The investigator will measure (millimeters, using the imaging software virtual ruler) the results of CBCT at times T-1 and T4, analyse the variation and compare implants results. The measurements are:~interdental distance;~bucco-palatal distance (BPD);~d. buccal cortical distance; e. palatal cortical distance; f. mesial cortical distance; g. distal cortical distance; h. jumping distance; j. buccal cortical wall-implant distance; k. jumping distance space depth; l. distance from the implant position depth to the buccal bone crest; m. distance from the buccal cortex to the center of the implant; n. implant diameter; o. Implant length; q. global bone volume; r. global volume; s. alveolus buccal-palatal distance; t. alveolus mesial-distal distance; u. alveolus depth."
45498238|NCT01381809|Drug|Group 2: Placebo|form= solution for injection, route= subcutaneous use, weekly injections for 24 to 48 weeks
45686568|NCT01470417|Drug|Chemotherapy|Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
45686569|NCT01470417|Drug|Chemotherapy + ChemoRadiotherapy|Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
45353093|NCT00328627|Drug|Alogliptin placebo|Alogliptin placebo-matching tablets.
45353094|NCT00328627|Drug|Pioglitazone|Pioglitazone tablets.
45353095|NCT00328627|Drug|Pioglitazone placebo|Pioglitazone placebo-matching tablets.
45353096|NCT03374956|Drug|Phentermine-Topiramate|Extended Release at dose of 7.5/46 mg oral daily
45353097|NCT03374956|Drug|Liraglutide|dose of 3 mg subcutaneous daily
45353098|NCT03374956|Drug|Naltrexone/bupropion|Oral naltrexone extended-release/bupropion extended-release at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)
45353099|NCT03374956|Drug|Phentermine|15-37.5 mg oral daily
45353100|NCT02562248|Other|Automated screening for pediatric anxiety|families receiving care at the intervention clinics with concern for disruptive behaviors will be administered the SCARED tool for anxiety in addition to the Vanderbilt tool for ADHD
45353101|NCT02562248|Other|Usual Care|families receiving care at the control clinics with concern for disruptive behaviors will be administered the Vanderbilt tool for ADHD only
45353102|NCT03977727|Drug|Fiasp®|Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
45353103|NCT03977727|Drug|Novolog®|Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
45353104|NCT03977727|Device|670G hybrid closed loop continuous subcutaneous insulin infusion system|CSII
45353105|NCT02563184|Biological|Fluzone|
45353106|NCT03882034|Drug|Pegvisomant|A fixed dose of pegvisomant 10-mg started on Day 1 of intervention and continued daily afterwards, will be administered subcutaneously according to manufacturer's recommendations. Adjustment of the dose will occur as per protocol.
45353107|NCT00663858|Drug|Cetrorelix 78+78|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + 78 mg combining Week 26 (52 mg) and Week 28 (26 mg)
45353108|NCT00663858|Drug|Cetrorelix 78 + Placebo|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + Placebo on Week 26 and Week 28
45353109|NCT00663858|Other|Placebo|Placebo on Week 0, Week 2, Week 26 and Week 28
45353110|NCT00749372|Other|T2* Cardiac and Liver MRI|Patients will undergo an MRI of the heart and liver.
45353111|NCT04060004|Other|Dry needling|Dry needling is a technique used by physiotherapists.
45477586|NCT05665231|Other|Photographic results PES/WES index|The investigator will analyse the intraoral photographs to describe the Pes/Wes index, in time T-1 (initial) and T4 (final), and compare the PES/WES results between implants.The score will range on 0-10, the best score is ≥8.
45477587|NCT02495428|Procedure|Kinesio Tape Method|
45477588|NCT05701514|Procedure|Elective surgical resection of CPAM between 6 and 9 months of age|Surgical resection of the CPAM between 6 and 9 months of age
45477589|NCT03726463|Procedure|Kidney transplantation|Bilateral nephrectomy of polycystic kidneys are routinely performed during kidney transplantation in ADPKD patients
45477590|NCT03814577|Diagnostic Test|Total Antioxidant Status|Total Antioxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.
45477591|NCT03814577|Diagnostic Test|Total Oxidant Status|Total Oxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.
45477592|NCT03814577|Device|Bispectral Index|Bispectral Index is a method for depth of anesthesia and assessment of sedation. The values of bispectral index decreases with the deepening of anesthesia. The values of 40-60 characterize the appropriate depth of anesthesia.
45477593|NCT03814577|Other|Invasive arterial monitorization|Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
45477594|NCT03730363|Drug|Pentamidine|Pentamidine will be administered as an IV infusion on treatment day 1-3 of a 21-day cycle 3 cycles using 2, 3, and 4 mg/kg dose escalation schedules. Non-investigational agents will be administered as follows: Ifosfamide 5000 mg/m2, Carboplatin 5 area under curve (AUC), and Etoposide 100 mg/mg2.
46046103|NCT05292703|Other|practicing art virtually in conjunction with olfactory identification|"For the remote group, , they will receive the connection link to the internet application and an individual connection code.~The intervention is a participative activity based on art and olfactory stimulation which consists of practicing art virtually in conjunction with olfactory identification by following a dedicated program developed in partnership with the same artist involved in the workshops in presence, so that the virtual activities are very similar to those of the face-to-face workshop.~The artistic workshops will take place according to 4 themes with a different theme per week. Each workshop end with an original artistic creation received by email, bringing into play artistic skills and olfactory identification capacities. Each participant will connect once a week at their convenience during 4 weeks."
45353112|NCT04060004|Other|Sham dry needling|Sham dry needling is a technique used by physiotherapists to compare the effects of dry needling.
45353113|NCT04060004|Other|Electrotherapy + therapeutic exercise|Standard care of neck pain.
45477595|NCT02493166|Other|dual task cost (cognitive-motor interference)|comparing single versus dual task performance (on both motor and cognitive task)
45477596|NCT01206725|Other|Exercise|"Moderate Intensity Exercise Group (ME). Exercise equivalent to the current exercise guidelines. In total 210 minutes per week of continuous moderate intensity (70% HRmax) exercise. Home based training.~Aerobic interval training (AIT). Exercise equivalent to the current guidelines achieved through high-intensity interval training.The exercise starts with warming-up for 10-min at 70% of HRmax before performing 4x4min intervals at 90-95% of HRmax, with 3-min active recovery at 70% of HRmax between each interval, and a 5-min cool-down period, giving a total of 40-min."
45686570|NCT01524627|Drug|Varenicline|Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
45686571|NCT01524627|Drug|Placebo|Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
45686572|NCT01469637|Drug|sulfamethoxazole + MMX placebo|800 mg sulfamethoxazole/160 mg trimethoprim twice daily (BID) + MMX Mesalazine/mesalamine placebo once daily (QD) orally for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + single does of MMX Mesalazine/mesalamine placebo orally on Day 4.
45686573|NCT01469637|Drug|Sulfamethoxazole + MMX Mesalazine/mesalamine|800 mg sulfamethoxazole/160 mg trimethoprim BID + 4.8 g MMX Mesalazine/mesalamine QD for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + a single dose of 4.8 g MMX Mesalazine/mesalamine on Day 4
45353114|NCT05223400|Drug|Clindamycin Injection|it is a clindamycin use evaluation study
46046104|NCT05292378|Other|2500 ppm Carbon Dioxide|2.5 hour exposure to 2500 ppm carbon dioxide
45353115|NCT00790608|Drug|Nitric Oxide|Gaseous nitric oxide (1%), delivered for 30 minutes per day for 3 consecutive days
45353116|NCT02562014|Other|Glucose|75g glucose
45353117|NCT02562014|Other|Inulin|75g glucose plus 24g inulin
45353118|NCT02562014|Other|Resistant Starch|75g glucose plus 28.2g resistant starch
45353119|NCT00787098|Other|ETM protocol|ETM is 4 levels. Level 1, each receives repositioning from lateral to supine positions at even hours, totaling 60 minutes of activity/positioning over 24 hours. If tolerated, two periods of 20 minutes of supine position with a reverse trendelenberg position of 15-20 degrees will be used to promote orthostasis. Level 2 is turning every 2 hours, positioning in reverse trendelenberg at 15-25 degrees as tolerated, active resistance with ICU staff for 20 minutes daily for a total of 60-80 minutes of activity/positioning daily. At Level 3, 2 times 20 minutes of a sitting are added to active ROM and inbed turning (estimated 80-100 total minutes of activity daily). Sitting is in bed or with non-weightbearing assisted transfer to chair with backrest elevation at 75-90 degrees and legs in a dependent position. Level 3 interventions; minimal weight-bearing. Level 4, weight-bearing transfer to chair and ambulation are added to inbed turning.
45353120|NCT00749450|Drug|capecitabine|Given orally
45353121|NCT00749450|Drug|fluorouracil|Given IV
45353122|NCT00749450|Drug|oxaliplatin|Given IV
45353123|NCT00795444|Drug|maraviroc|Maraviroc (INN), 300 mg tablets. A dose of 300 mg will be administered every 12 hours.
45353124|NCT00790686|Procedure|Insertion of Memokath 051|Patients usually treated with double J stents will be included. The double J stent will be replaced by a MEMOKATH 051 stent under general anesthesia during a cystoscopy.
45353125|NCT02561936|Drug|Rilpivirine Oral Tablet|Rilpivirine formulated as 25 mg oral tablet.
45353126|NCT02561936|Drug|Rilpivirine formulation G007|Rilpivirine G007 formulation as 10*2.5 mg tablets.
45353127|NCT02561936|Drug|Rilpivirine formulation G009-01|Rilpivirine G009-01 formulation as 10*2.5 mg tablets.
45353128|NCT02561936|Drug|Rilpivirine formulation G002|Rilpivirine G002 formulation as 10 g of 2.5 milligram per gram (mg/gm) granules.
45353129|NCT02561936|Dietary Supplement|Standardized Breakfast|It will consist of (or its equivalent) 4 slices of bread, 2 slices of ham and/or cheese, butter, fruit preserve and 1 or 2 cups (up to 480 milliliter [mL]) of decaffeinated coffee or decaffeinated tea with milk and/or sugar, if desired (containing approximately fat: 21 gram (gm), carbohydrates: 67 gm, proteins: 19 gm; calories 533 kilocalorie (kcal) [189 kcal from fat, 268 kcal from carbohydrates, and 76 kcal from proteins]).
45353130|NCT00790764|Biological|MESENDO|For the cell product, proper aliquots of each cell type will be taken to fulfill the doses established for this protocol. The two aliquots will be mixed and resuspended to a final volume of 3 ml in the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin.
45353131|NCT00790764|Other|placebo|For placebo, 3 ml of the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin will be transferred to a 5 ml syringe
45353132|NCT00752492|Other|Isocapnic Hyperpnoea|IH is a method of increasing alveolar ventilation (Va) while preventing the unwanted hypocapnia by addition of CO2 to the inhaled mixture.
45353133|NCT02554968|Other|Questionnaires|
45353134|NCT00752648|Drug|TMC435350|
46046105|NCT05292378|Other|600 ppm Carbon Dioxide|2.5 hour exposure to 600 ppm carbon dioxide
45353135|NCT00790920|Drug|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 - 2 minutes on 1st day
45353136|NCT00790920|Drug|Placebo|IV, single bolus over 1 - 2 minutes on 1st day
45353137|NCT02563262|Other|body angles measurements during weightlessness|
45353138|NCT04053218|Combination Product|Exercise plus omega-3 supplement|Supervised aerobic exercise and omega-3 supplement
45353139|NCT04053218|Dietary Supplement|Placebo|Olive oil placebo
45353140|NCT00659880|Other|BioCleanse Meniscus|Subjects will undergo routine meniscal allograft transplant surgery.
45353141|NCT00752882|Drug|ceftazidime|
45353142|NCT01060735|Dietary Supplement|Vitamin D|Vitamin D 2000iu/ day from the 27 week of pregnancy up to delivery
45353143|NCT00747032|Drug|NYC 0462 Ointment|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
45353144|NCT00747032|Drug|Placebo|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
45353145|NCT02555358|Drug|docetaxel,0xaliplatin,capecitabine|docetaxel 60mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14; oxaliplatin 130mg/m2， ivgtt，2h，d1;q21d
45353146|NCT02555358|Drug|oxaliplatin,capecitabine|oxaliplatin 130mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14;q21d
45686574|NCT04409223|Drug|Famitinib capsules|Oral KIT/PDGFRA kinase inhibitor
45353147|NCT01057303|Genetic|RNA analysis|
45353148|NCT01057303|Genetic|gene expression analysis|
45353149|NCT01057303|Genetic|reverse transcriptase-polymerase chain reaction|
45353150|NCT01057303|Other|laboratory biomarker analysis|
45353151|NCT00683774|Drug|diazoxide|100mg orally three times per day for 10 days
45353152|NCT03741907|Procedure|FAUCS|extraperitoneal cesarean with a paramedian left section
45353153|NCT03741907|Procedure|MLC|Gold standard
45353154|NCT00787410|Drug|ZD1839|250mg tablet, once daily, orally administered
45353155|NCT02555124|Drug|JNJ-42847922, 5 mg|Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 on Day 1, fasted condition.
45353156|NCT02555124|Drug|JNJ-42847922, 20 mg|Participants will receive single oral dose of 20 mg of JNJ-42847922 on Day 1, fasted condition.
45353157|NCT02555124|Drug|JNJ-42847922, 40 mg|Participants will receive single oral dose of 40 mg of JNJ-42847922 on Day 1, fasted condition.
45353158|NCT02555124|Drug|Placebo|Participants will receive placebo on Day 1, fasted condition in Cohort A, Cohort B and Cohort C.
45353159|NCT03989557|Drug|Aspirin and clopidogrel/Ticagrelor|The modification of aspirin and clopidogrel/ticagrelor maintenance doses based on a biomarker assays.
45353160|NCT03989557|Device|Light transmittance aggregometry|point-of-care method to assess platelet function by light transmittance aggregometry.
45353161|NCT03989557|Drug|Aspirin and clopidogrel/Ticagrelor|maintenance dose of aspirin, clopidogrel and ticagrelor.
45353162|NCT00787488|Device|Hyperthermia|Every 3 weeks
45498239|NCT01381809|Drug|Group 1: Epoetin alfa|type = range, unit= IU/Kg, number= 337.5 to 1050 IU/Kg, form= solution for injection, route= subcutaneous use, weekly injections (max 40,000 IU per week for first 8 weeks of treatment, max 80,000 IU per week later) using pre-filled 1mL 40,000 IU syringes for 24 to 48 weeks
45686575|NCT04409223|Drug|Sunitinib Capsules|Oral receptor tyrosine kinase (RTK) inhibitor
46046106|NCT05286736|Diagnostic Test|Neuroimaging|This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI) and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function.
46046107|NCT05286736|Diagnostic Test|Quantitative assessments|Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function
46046108|NCT05284110|Behavioral|Physical activity|Multiple bouts of 3-min brisk walking, every 30 min, for 4 hours.
46046109|NCT05283265|Behavioral|Sentence Type|Subjects read different types of sentences (object-relative, subject -relative and control sentences) to observe how that sentence affects their intracranially recorded neural activity.
45353163|NCT01054495|Drug|Acupuncture|"The acupuncture needles are inserted in PC 6 bilaterally at the acupuncture point Pericardium 6 (PC6) on each forearm (fig 2). According to the cun measurement system of Traditional Chinese Medicine (TCM), the points are located on the palmar surface of anterior forearm at a distance equivalent to the combined width of the women's middle three fingers, proximal to the most prominent wrist crease, and between the tendons of palmaris longus and flexor carpi radialis. We try to keep the depth of the needling to approximately 1,5 cm. At insertion of the acupuncture needle, DeQi is obtained and the needle is then left without any further manipulation/ stimulation (even method) in situ for 15 minutes."
45353164|NCT01054495|Device|Sham acupuncture|A sham acupuncture needle is placed at PC 6 bilaterally and the tactile stimuli of the skin during the procedure should be obtained. The sham acupuncture needle is then left at site for 15 minutes without any further manipulation/stimulation.
45353165|NCT01054495|Device|Laser acupuncture|A laser is placed in a stand, pointing at PC 6 bilaterally, and left at site for 15 minutes without any further manipulation/stimulation.
45353166|NCT00790998|Drug|Moxidectin|Single dose of moxidectin 2 mg oral tablet x 4
45353167|NCT00790998|Drug|Ivermectin|Single dose of ivermectin 3 mg oral tablet x 2, 3 or 4
45353168|NCT01057459|Other|laboratory biomarker analysis|Correlative studies
45353169|NCT02555046|Procedure|Local Anesthesia|Use of unspecified local anaesthesia (fx lidocain or bupivacaine)
45353170|NCT00787878|Drug|somatropin|SGA previously treated with Norditropin®
45847639|NCT02788188|Biological|SAB-301|SAB-301 is a purified human immune globulin G (hIgG) polyclonal antibody designed to specifically bind to the MERS-CoV spike (S) protein, a component of the virion membrane that is responsible for binding of the virus to the host cell. The hIgG is purified from the plasma of immunized transchromosomic (Tc) bovines that were immunized with a recombinant spike protein produced in insect cells. SAB-301 is purified hIgG in a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
45353171|NCT00787878|Drug|No treatment given|Untreated SGA
45353172|NCT00787878|Drug|No treatment given|AGA (Average gestational age)
45353173|NCT00787956|Behavioral|Internet Chronic Disease Self-Management Program (ICDSMP)|
45498240|NCT03679806|Other|Halliwick|The exercise program was progressed by increasing the speed and the range of motion of the movements. Patients were asked not to accelerate the exercise and to focus on their alignment. Mental adjustment, sagittal rotation, transverse rotation, and combined rotation controls, balances in stillness steps of the Halliwick concept were included.
45686576|NCT04748367|Device|Virtual Reality Headset|Virtual Reality Headset running SILVER software
45686577|NCT00012298|Biological|rituximab|Given IV
45686578|NCT00012298|Biological|yttrium Y 90 ibritumomab tiuxetan|Given IV
46046110|NCT05283265|Other|Direct brain stimulation|On some trials the investigators will apply intracranial electrical current through the electrodes implanted in the participants and observe the effect this has on their behavior (which picture they choose at the end of the trial) and the effect this has on their neural activity that the investigators record simultaneously through-out the experiment.
46046111|NCT05281562|Drug|Lovaza|Daily dose of 1.68grams omega-3 fatty acids, 2 Lovaza pills per day.
46046112|NCT05281562|Drug|L-Arginine Powder|Daily dose of 4.5 grams L-Arginine, powder form.
46046113|NCT05281562|Drug|Vitamin C|Daily dose of 500 mg Vitamin C, powder form.
46046114|NCT05276596|Drug|Ephedrine|The control group will be taken care of according to the protocols in force. The first anesthetic post-induction hypotension will be managed by intravenous injection of ephedrine (dilution: 3 mg / ml) at a dose of 6 mg (i.e. 2 ml). Any subsequent hypotension will be treated with ephedrine until injection of a total dose of 30 mg. Thereafter, if a new arterial hypotension occurs, we will pass to the administration of noradrenaline in intravenous injection using an electric syringe pump, at the dilution of 0.016 mg / ml, posology adapted to the objectives. blood pressure.
46046115|NCT05276596|Drug|Norepinephrine|Immediately use of norepinephrine by intravenous injection using an electric syringe pump, at a dilution of 0.016 mg / ml, at the time of anesthetic induction and without waiting the 1st possible arterial hypotension. Noradrenaline will be started at a dose of 0.48 mg / h and then adapted according to the blood pressure objectives.
45353174|NCT00354679|Biological|bevacizumab|
45353175|NCT00354679|Drug|cisplatin|
45353176|NCT00354679|Drug|irinotecan hydrochloride|
45353177|NCT00354679|Genetic|proteomic profiling|
45353178|NCT00354679|Other|diagnostic laboratory biomarker analysis|
45353179|NCT00354679|Other|mass spectrometry|
45353180|NCT00354679|Procedure|adjuvant therapy|
45353181|NCT00354679|Procedure|neoadjuvant therapy|
45353182|NCT00354679|Procedure|therapeutic conventional surgery|
45353183|NCT00354679|Radiation|radiation therapy|
45353184|NCT00683696|Device|Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)|All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.
45353185|NCT00345631|Other|Manual Compression|Manual compression
45353186|NCT00345631|Device|Vascular Closure Device|Investigational vascular closure device
45353187|NCT00540514|Drug|Albumin-bound paclitaxel|Administered by intravenous infusion.
45686579|NCT00012298|Biological|indium In 111 ibritumomab tiuxetan|Given IV
45353188|NCT00540514|Drug|Paclitaxel|Administered by intravenous infusion.
45686580|NCT00012298|Biological|oprelvekin|Given subcutaneously
45686581|NCT00012298|Biological|filgrastim|Given subcutaneously
45353189|NCT00540514|Drug|Carboplatin|Administered by intravenous infusion. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate [GFR] + 25). For the purposes of this protocol, the GFR is considered to be equivalent to creatinine clearance (calculated by the method of Cockcroft and Gault, 1976).
45686582|NCT00193258|Drug|Bevacizumab|10mg/kg IV infusion every 2 weeks
45686583|NCT00193258|Drug|Erlotinib|150 mg po daily
45686584|NCT00193258|Drug|Imatinib|400-600mg daily
45686585|NCT00029536|Biological|Progesterone Lozenges|200mg Progesterone Lozenges
45686586|NCT00029536|Other|Matched Placebo Lozenges|Matched Placebo Lozenges
45353190|NCT00663702|Drug|Abatacept|Subcutaneous injection, 125 mg/mL, once weekly, 48 months
45353191|NCT03986281|Other|Omron Wearable Device|Omron wearable device compared to arterial line readings
45353192|NCT03986281|Other|Standard Arterial Line|Omron wearable device compared to arterial line readings
45353193|NCT02022592|Drug|Lormetazepam|
45353194|NCT02022592|Drug|Midazolam|
45353195|NCT03990025|Diagnostic Test|Linked Color Imaging|Linked Color Imaging (LCI) is a form of image enhanced endoscopy that uses a laser endoscopic system that acquires images by simultaneously using narrow-band wavelength light and white light in an appropriate balance. This enhances slight color differences in the red region of the mucosa.
45353196|NCT03990025|Diagnostic Test|White Light Imaging|White Light Imaging (WLI) uses conventional white light that encompasses all bandwidths of light to illuminate areas of interest to obtain endoscopic images.
45353197|NCT00683618|Drug|Rosuvastatin|Capsule/Tablet, oral, qd, 6 or 12 weeks
45353198|NCT00683618|Drug|Atorvastatin|Capsule/Tablet, 10mg, oral, qd, 6 weeks
45353199|NCT01057537|Drug|polypill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg."
45477597|NCT03726307|Biological|DCreg: 0.5 million cells/kg+SOC|"DCreg 0.5 (±0.1) million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
46046116|NCT05274971|Other|Active dietary management and aerobic exercise training.|Active dietary management and aerobic exercise training.
46046117|NCT05273931|Other|Lifestyle intervention|Documents explaining the strategies to achieve and maintain recommended behaviours as part of a healthier lifestyle
45353200|NCT01057537|Drug|Usual cardiovascular medications|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
46046118|NCT05272644|Behavioral|surface electromyographic biofeedback assisted pelvic floor muscle training|participants will be doing surface electromyographic biofeedback assisted pelvic floor muscle training for 2 months
45498241|NCT03679806|Other|Aquatic Plyometric Exercises|The APE programme was progressed by increasing speed and the range of motion of the movements. Patients were carefully informed not to deform the exercise just to emulate the speed. The three phases of each exercise; eccentric (or loading) phase, the amortization phase, and the concentric (or unloading) phase explained thoroughly at the beginning of every exercise.
46046119|NCT05272644|Behavioral|surface electromyographic biofeedback and electrical stimulation|participants will be doing surface electromyographic biofeedback and electrical stimulation assisted pelvic floor muscle training for 2 months
46046120|NCT05269706|Drug|Cannabidiol|Cannabidiol 200 mg
46046121|NCT05269706|Drug|Cannabidiol|Cannabidiol 400 mg
46046122|NCT05269706|Drug|Epidiolex|Epidiolex 400 mg
46046123|NCT05269706|Drug|Cannabidiol|Cannabidiol 400 mg
46046124|NCT05268887|Device|GENUS device (Active Settings)|Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 30-60 minutes
46046125|NCT05268887|Device|GENUS device (Sham settings)|Participants in the control group will use the GENUS devices configured to the sham settings for 30-60 minutes
46046126|NCT05245396|Drug|Ref (TF2)|Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.
46046127|NCT05245396|Drug|Evobrutinib MR-T1|Participants will receive single oral dose of MR-T1 on Day 1 in treatment period 1, 2, and 3 of Part A.
46046128|NCT05245396|Drug|Evobrutinib MR-T2|Participants will receive single oral dose of MR-T2 on Day 1 in treatment period 1, 2, and 3 of Part A.
45843200|NCT05564988|Other|Preconditionning|"Remote ischemic conditioning will be induced using a Tourniquet cuff applied to the patient's non-dominant arm. The device used will be an Ulrich Kariba machine. A strip of absorbent cotton will be applied to the arm and the tension cuff will be placed over it in a standard way. The systolic pressure and the application time will be set manually.~Ischemia will be obtained after inflating the cuff to a pressure of 200 mmHg (or a pressure at least 50 mmHg above the patient's systolic pressure). After a five-minute period, the cuff will be deflated and the arm allowed to reperfuse for five minutes. These maneuvers will be repeated until 3 cycles of ischemia- reperfusion have been completed once a day. Patients will experiment with this procedure for at least 5 days."
45843201|NCT05564832|Drug|Pilocarpine 1.25% Eye drop|One millimeter of pilocarpine eye drop (Bakhtarbiochemistry Company, Iran) contains pilocarpine hydrochloride 1.25% (12.5 mg) as an active ingredient, equivalent to 1.06% (10.6 mg) pilocarpine free-base. The medication preservative is 0.0075% benzalkonium chloride. Inactive ingredients in the ophthalmic are boric acid, sodium citrate dihydrate, sodium chloride, purified water. Another pilocarpine eye drop was Vuity® (1.25% pilocarpine; Allergan company) contains the active intergradients of pilocarpine hydrochloride 1.25% (12.5 mg/mL), equivalent to 1.06% (10.6 mg/mL) pilocarpine free-base and the preservative agents was 0.0075% benzalkonium chloride.
45843202|NCT05564676|Dietary Supplement|flaxseed oil and pomegranate dry extract|The flaxseed oil were yellow capsules with 1.0 g each and the pomegranate dry extract capsules were green with 0.6 g each.
45843203|NCT05564676|Dietary Supplement|sunflower oil and microcrystalline cellulose|The sunflower oil were yellow capsules with 1.0 g each and the microcrystalline cellulose capsules were green with 0.6 g each.
45843204|NCT05564442|Drug|20% benzocaine gel|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
45843205|NCT05564442|Device|Transcutaneous electric nerve stimuli|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
45843206|NCT05564442|Drug|Emla gel|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
45843207|NCT05564442|Other|Ice application|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
45843208|NCT05532774|Device|AI defocusing frame glasses|AI defocusing frame glasses have the function of eye behavior management, which can delay the progression of myopia through scientific management of eye behavior including outdoor light exposure (≥2 hours/day), duration of continuous close eye use (30 seconds rest every 30 minutes) and close eye distance (one punch, one foot and one inch), etc.
45843209|NCT05521074|Device|Active tDCS|The investigators will use commercially available tDCS equipment (Neuroelectrics©, Barcelona, Spain). The cathode will be placed over the pre-SMA using the 10-20 EEG system and the anode will be on the right deltoid.
45843210|NCT05521074|Device|Sham tDCS|The investigators will use commercially available tDCS equipment (Neuroelectrics©, Barcelona, Spain). The cathode will be placed over the pre-SMA using the 10-20 EEG system and the anode will be on the right deltoid. tDCS will not be active in this condition.
45843211|NCT05493540|Drug|Ibuprofen oral suspension|"The medical treatment group will receive oral Ibuprofen with conservative therapy in the form of fluid restriction, Positive End Expiratory Pressure (PEEP), and/or diuretics~An additional course of Ibuprofen may be offered if there is:~Moderate/Severe PDA on Echocardiography~Prolonged ventilation or Increased ventilatory setting~Prolonged use of inotropes or vasopressors or escalating dose~Another form of treatment may be offered if the patient developed side effects from Ibuprofen"
46046129|NCT05245396|Drug|Evobrutinib MR-T3|Participants will receive single oral dose of MR-T3 on Day 1 in treatment period 1, 2, and 3 of Part A.
45498242|NCT03679728|Behavioral|First trimester|Analysis of sensorimotor outcomes
45498243|NCT03679728|Behavioral|Second trimester|Analysis of sensorimotor outcomes
45686587|NCT00193492|Drug|Bevacizumab|
45686588|NCT00193492|Drug|Rituximab|
45686589|NCT00194116|Drug|Divalproex Sodium ER|Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
45847640|NCT02788188|Other|Normal (9%) Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
45847641|NCT02791308|Drug|Pimecrolimus Cream 1% (Valeant)|
45847642|NCT02791308|Drug|Vehicle cream|
45847643|NCT02791308|Drug|Pimecrolimus Cream, 1%|
45847644|NCT02796144|Drug|Lorcaserin|Max dose of 10 mg BID
46046130|NCT05245396|Drug|Evobrutinib MR-T4|Participants will receive single oral dose of MR-T4 on Day 1 in treatment period 1, 2, and 3 of Part A.
46046131|NCT05245396|Drug|Evobrutinib MUPS-C1|Participants will receive single oral dose of MUPS-C1 on Day 1 in treatment period 1, 2, and 3 of Part B.
46046132|NCT05245396|Drug|Evobrutinib MUPS-C2|Participants will receive single oral dose of MUPS-C2 on Day 1 in treatment period 1, 2, and 3 of Part B.
46046133|NCT05245396|Drug|Evobrutinib MUPS-C3|Participants will receive single oral dose of MUPS-C3 on Day 1 in treatment period 1, 2, and 3 of Part C.
46046134|NCT05245396|Drug|Evobrutinib MUPS-C4|Participants will receive single oral dose of MUPS-C4 on Day 1 in treatment period 1, 2, and 3 of Part C.
46046135|NCT05245396|Drug|Evobrutinib MR-T adapated|Participants will receive single oral dose of MR-T adapted on Day 1 in treatment period 1, 2, and 3 of Part D.
46046136|NCT05241262|Drug|N-Acetylcysteine|1800, 3600 or 5400 mg NAC per day (divided into 3 daily doses) depending on dose toxicity plan
45477598|NCT03726307|Biological|DCreg: 1.2 million cells/kg+SOC|"DCreg 1.2 (±02) million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
45477599|NCT03726307|Biological|DCreg:2.5 to 5.0 million cells/kg+SOC|"DCreg 2.5 to 5.0 million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
45477600|NCT01206803|Drug|Ovarian stimulation in a GnRH-antagonist protocol|Long-acting FSH 150µg & daily recombinant FSH 200 IU, GnRH-antagonist 0.25mg, 5,000-10,000 IU urinary hCG, triptorelin 0.2mg, vaginal progesterone
45477601|NCT00707434|Device|Guardian® blood-sugar monitoring device|The device has a small catheter that will be inserted subcutaneous tissue of the subject's abdomen or thigh set to continuously monitor glucose throughout the ICU stay for up to 15 days.
45477602|NCT03818009|Other|Assessment document|The anesthesiologist will evaluate through his sheet women's cognitive functions.
45477603|NCT03054428|Drug|Dupilumab|Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.
45477604|NCT03054428|Drug|Placebo|Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.
45353207|NCT00795678|Drug|capecitabine|Capecitabine is an oral prodrug of 5 deoxy-5-fluorouridine (5DFRU) that is converted to 5-fluorouracil (5-FU). 5-FU is metabolized to 5-fluoro-2-deoxyuridine monophosphate (fDUMP) and 5-fluorouridine triphosphage (FUTP) which cause cell injury. Capecitabine is supplied in 150 mg (light peach colored) and 500 mg tablets (film coated)and will be administered pre-operatively.
45477605|NCT03335956|Drug|CORT125281, 40mg, fasted|CORT125281 is supplied as capsules for oral dosing
45477606|NCT03335956|Drug|Prednisone 25mg, fasted|"Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered"
45477607|NCT03335956|Drug|Placebo oral capsule, fasted|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered"
45477608|NCT03335956|Drug|Pioglitazone 15mg Tablet|"Probe Substrate, Dose and Route of Administration:~15 Mg tablet, orally administered"
45353208|NCT00795678|Drug|cyclophosphamide|Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites that cross-link tumor cell DNA. Cyclophosphamide is supplied in 100 mg, 200 mg, 500 mg and 1 gram and 2 gram vials as a white powder. The drug should be reconstituted with Sterile Water for Injection, USP, and may be diluted in either normal saline or D5W. Cyclophosphamide will be mixed in 250 mL of D5W and infused over 30 minutes prior to surgery.
45353209|NCT00795678|Drug|doxorubicin hydrochloride|Doxorubicin is an anthracycline anticancer agent which mediates tumoricidal effects by intercalating into double-stranded DNA and producing structural changes that disrupt DNA and RNA synthesis. Doxorubicin is supplied in 10, 20, and 50 mg single use vials, and 150 mg multidose vials as a red-orange, lyophilized power which has a storage stability of a least two years. The dose will be given 60mg/m2 over 15 minutes of time pre-operatively.
45477609|NCT03335956|Drug|Placebo oral capsule, fed|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered"
45477610|NCT03335956|Drug|Prednisone 25mg, fed|"Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered"
45477611|NCT03335956|Drug|CORT125281, 120mg, fasted|CORT125281 is supplied as capsules for oral dosing
45477612|NCT03335956|Drug|CORT125281, 360mg, fasted|CORT125281 is supplied as capsules for oral dosing
45847645|NCT02796144|Drug|Metformin|Max dose of 1,000 mg BID
45477613|NCT03335956|Drug|CORT125281, 720mg, fasted|CORT125281 is supplied as capsules for oral dosing
45477614|NCT03335956|Drug|CORT125281, 360mg, fed|CORT125281 is supplied as capsules for oral dosing
45686590|NCT00194116|Drug|Placebo|. Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
45353210|NCT00795678|Drug|gemcitabine hydrochloride|Gemcitabine is a fluorinated deoxynucleoside prodrug which disrupts DNA synthesis and induces apoptosis in a broad number of human tumors, including breast cancer. Gemcitabine is supplied as a lyophilized powder in sterile vials containing 200 mg of 1000 mg (1 gram) of gemcitabine as the hydrochloride salt (expressed as the free base) mannitol and sodium acetate. Dosage will be 1250mg/m2, IV pre-operatively over 30 minutes.
45353211|NCT00795678|Drug|lapatinib ditosylate|: Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets with one side of the tablet plain and other side of the tablet embossed with FG HLS. Lapatinib may also be supplied as oval, biconvex, tan tablets, with no markings. Lapatinib will be administered for at least 3 days pre-operatively at 1250mg.
45686591|NCT02096458|Drug|Dexlansoprazole|Dexlansoprazole delayed-release orally disintegrating tablets
45353212|NCT00795678|Drug|paclitaxel|Paclitaxel will be given as an intravenous infusion (80mg/m2) the morning of surgery as specified in the protocol, diluted in 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection. Paclitaxel will be administered via an infusion control device (pump) using non-PVC tubing and connectors, such as the IV administration sets (polyethylene or polyolefin) which are used to infuse parenteral nitroglycerin.
45353213|NCT00795678|Drug|vinorelbine ditartrate|Vinorelbine (Navelbine®) is a unique semi-synthetic vinca alkaloid 3', 4-didehydro-4' deoxy-C'-norvincaleukoblastine (ditartrate) (IUPAC). The pyogen free, sterile parenteral dosage form is supplied in 10 mg/1 ml ampules/vials and 50 mg/5 ml vials. It will be administered at a dosage of 25mg/m2 IV over 10-30 minutes pre-operatively.
45382184|NCT05261633|Device|Diffusion Weighted Magnetic Resonance Imaging|Diffusion-weighted (DW)-MRI has a unique ability to probe tissue microstructure without the need for ionizing radiation or intravenous contrast agents. DW-MRI of the abdomen is utilized in detection, staging, and treatment surveillance of malignancies, and has shown great promise in various other applications, including for the assessment of fibrosis in the liver, pancreas, kidneys, and other organs.
45382185|NCT05259917|Drug|Placebo|Placebo to KVD900 Tablet
45382186|NCT05259917|Drug|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
45382187|NCT05259917|Drug|KVD900 300 mg|KVD900 Tablet 300 mg (1 x 300 mg)
45382188|NCT05257629|Combination Product|Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling)|Varenicline and nicotine e-cigarettes plus counseling
45382189|NCT05257629|Other|Varenicline Plus Counseling|Varenicline plus counseling
45382190|NCT05257343|Dietary Supplement|Liquid Placebo Supplementation|8-weeks of supplementing with a visually identical liquid placebo supplement.
45382191|NCT05257343|Dietary Supplement|Liquid Iron Supplement (Blood Builder ®)|8-weeks of supplementing with a liquid iron supplement (Blood Builder ®)
45382192|NCT05253469|Procedure|Cryopreserved Aortic Homograft|CAH is used for aortic root reconstruction and for repair of mitro-aortic curtain (emicommando procedure) and it is inserted as miniroot . In cases of PVE the infected prosthesis is removed with aggressive debridement of all infected and necrotic tissue. (7)The coronary ostia are prepared for reconstruction of aortic root. In complex valve endocarditis involving aortic and mitral valve a double homograft may be used.Mitro-aortic endocarditis intervalvular fibrosa is largely involved.The abscess cavity is precisely bounded and debrided. and a double homograft is used for the reconstruction (commando procedure
45382193|NCT05253469|Procedure|Stented/Non stented xenograft|The insertion of stented/non stented xenograft may be performed using separate or continuos stich with or without teflon pledget. Biological valves may be implated alone or combined with polyester or pericardial patch when reconstruction of annulus is required. In cases of aggressive lesions requiring root and /or intervalvular fibrosa reconstruction the choice of prosthetic bioroot using bioprosthetic valve is considered acceptable alternatives to CAH although it should be guided by the surgeon's experience
45382194|NCT05253469|Procedure|Mechanical prostheses|The insertion of conventional mechanical valves may be performed using separate or continuos stich with or without teflon pledget. Mechanical prostheses may be implated alone or combined with polyester or pericardial patch when reconstruction of annulus is required. In cases of aggressive lesions requiring root and /or intervalvular fibrosa reconstruction the choice of prosthetic valved conduit with a mechanical valve is considered acceptable alternatives to CAH although it should be guided by the surgeon's experience
45382195|NCT05250037|Procedure|Home spirometry|Undergo spirometry measurements
45382196|NCT05250037|Procedure|Biospecimen Collection|Undergo nasal and/or oral swabs, and blood collection
45382197|NCT05250037|Other|Questionnaire Administration|Complete questionnaires
45382198|NCT05249400|Procedure|Off-site assistance|The trainer supervised the trainee's cannulation operation outside the procedure room through a high-definition screen displaying the endoscopic and fluoroscopic view. The trainer was allowed to provide unlimited verbal instructions to the trainee by an intercom.
45686592|NCT02096692|Device|Patients with a ProMRI ICD System|Tachycardia Fast Heart Beat
45353214|NCT00795678|Drug|Trastuzumab|Trastuzumab is a monoclonal immunoglobulin G1 kappa antibody which acts as a mediator of antibody-dependent cellular cytotoxicity (ADCC) agent through its high affinity, high specificity binding to extracellular domain of HER2 Receptor. Trastuzumab is supplied as a lyophilized, sterile powder containing 440 mg trastuzumab per vial under vacuum. Each carton contains one vial of 440 mg trastuzumab and one 30 ml vial of bacteriostatic water for injection, USP, 1.1% benzyl alcohol. This will be given the morning of surgery at 2mg/m2 IV over 90 minutes.
45353215|NCT00753038|Biological|REOLYSIN®|3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
45353216|NCT00753038|Drug|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
45353217|NCT00753038|Drug|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
45847646|NCT02796144|Drug|Placebo|Matching placebos will be administered for each drug.
45353218|NCT00753116|Device|Renal Denervation with a catheter-based procedure|Disruption of the renal nerves with a catheter-based procedure
45353219|NCT00795756|Drug|liposome-encapsulated cytarabine (DepoCyte)|DepoCyte 50 mg injected intrathecally x6-8 (6: B-lineage, 8: T-lineage) during induction/consolidation phases
45353220|NCT00795756|Drug|Triple intrathecal therapy (TIT)|Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy
45353221|NCT04058522|Other|Rotator cuff rehabilitation classes|
45353222|NCT04058522|Other|Individual Physiotherapy|
45353223|NCT04058522|Drug|Triamcinolone Injection|Subacromial Injection 40mg/1ml
45353224|NCT04004026|Other|Assesment|3-m backwards walk test, timed up and go test, 12-item MS Walking Scale, 2-min walk test, timed 25-foot walk test, 4-square step test.
45353225|NCT00795834|Dietary Supplement|High polyphenol beverage|"Antioxidant capacity umol TE/L(ORAC): 19987 Polyphenolic Content(mcg/ml): 1445 Vitamin C (mg/100ml): 35.35 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
45353226|NCT00795834|Dietary Supplement|Placebo Beverage|"Antioxidant capacity umol TE/L(ORAC): negligible Polyphenolic Content(mcg/ml): negligible Vitamin C (mg/100ml): 0.00 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
45353227|NCT02022514|Other|Mononuclear cells from autologous bone marrow|Mononuclear bone marrow cells autologous intracoronary
45353228|NCT02022514|Drug|Conventional medical treatment|
45353229|NCT00791232|Drug|extended-release (ER) OROS paliperidone|
45353230|NCT00749840|Behavioral|Questionnaire|Questionnaire taking 60-90 minutes.
45353231|NCT01563952|Device|Non-IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
45353232|NCT01563952|Device|IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
45353233|NCT01563952|Device|Non-IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
45353234|NCT01563952|Device|IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
45353235|NCT00795912|Drug|Atorvastatin|atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
45353236|NCT02562794|Behavioral|Family Strengthening Intervention-Refugees|This study aims to design a preventive intervention for at-risk refugee children and families. The intervention is focused on strengthening core family resources and promoting resilience and healthy parent-child interactions.
45353237|NCT05360134|Drug|Carica Papaya Leaf Extract|Carica Papaya Leaf Extract 1100 mg X TDS started at least 3 days preoperatively and continued on post operative day 3 to day 7
45686593|NCT02096692|Other|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine
45686594|NCT00194896|Drug|rosiglitazone|Tablet taken orally at a dosage of 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved. Study drug was taken up to 3 years.
45847647|NCT02796300|Device|Bioflo Dialysis Catheter|The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
45847648|NCT02796300|Device|Palindrome Dialysis Catheter|The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
45353238|NCT05360134|Other|Placebo|Placebo will be given in a similar manner
45353239|NCT00788034|Drug|Lu AA21004|5 or 10 mg/day
45353240|NCT00788034|Drug|Placebo|Once daily
45382199|NCT05245669|Biological|ENZ215|healthy volunteers receive ENZ215 (60mg) once
45353241|NCT04058444|Combination Product|ERAS protocol|No routine bowel preparation Antibiotics prophylaxis PONV (Postoperative Nausea and Vomiting) prophylaxis Spinal anesthesia Post- Cesarean analgesia (Acetaminophen 1g IV q6h, Tramadol 50mg IV q6h, Quadratus lumborum Block Oral pain relief medication Pain scores every day (VAS) Hospital length of stay Patient satisfaction
45353242|NCT05208814|Drug|TPN171H single dose|10 mg TPN171H taken once
45353243|NCT04004884|Drug|Ulipristal Acetate|Assess the variations of liver blood test parameters during UPA treatment for symptomatic uterine fibroids
45353244|NCT00688064|Drug|Adapalene BPO Gel associated with Doxycyline Hyclate|Adapalene BPO Gel: Topical to the face, once daily in the evening Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
45353245|NCT00688064|Drug|Vehicle Gel associated with Doxycycline Hyclate|Vehicle Gel: Topical to the face, once daily in the evening; Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
45353246|NCT00788112|Drug|vorinostat|
45353247|NCT00788112|Genetic|protein expression analysis|
45353248|NCT00788112|Other|immunohistochemistry staining method|
45353249|NCT00788112|Other|laboratory biomarker analysis|
45353250|NCT00788112|Procedure|neoadjuvant therapy|
45353251|NCT00788112|Procedure|therapeutic conventional surgery|
45353252|NCT03112174|Drug|Ibrutinib|Administered orally once daily
45353253|NCT03112174|Drug|Venetoclax|Administered orally once daily
45353254|NCT03112174|Drug|Placebo Oral tablet to match Venetoclax|Administered orally once daily
45353255|NCT04058600|Behavioral|Virtual Reality Software|Patients will be exposed to a virtual reality software that simulates the hospital environment, from admission to the operating room and the recovery room.
45353256|NCT00788190|Procedure|Distal Radius Fracture Reduction|Surgical Intervention to Reduce Distal Radius Fracture
45353257|NCT00788190|Other|Conservative Management|Conservative management of Distal Radius Fractures
45353258|NCT00749918|Dietary Supplement|Cholecalciferol (vitamin D3)|Oral capsules of cholecalciferol, 5000 IU/ capsule, two capsules daily for one month.
45353259|NCT00791310|Drug|Flucis|FDG injected i.v
45353260|NCT04058132|Drug|Sildenafil Citrate 50Mg Tab|sildenafil citrate (Viagra®, Pfizer. Inc., NY, NY). Sildenafil citrate is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1Hpyrazolo[4,3-d]pyrimidin-5-yl)-4- ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate. Sildenafil citrate is a white to off-white crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7. For this study, we will use 50 mg tablets for the single dose studies.
45353261|NCT04058132|Device|functional Near-infrared Spectroscopy (fNIRS)|Functional Near-Infrared Spectroscopy (fNIRS): Functional near-infrared spectroscopy (fNIRS) a noninvasive technique that can measure cerebrovascular reactivity (CVR) will be used to measure regional cerebral blood flow and cerebrovascular reactivity in the brain. The device (fNRIS100, fNIR Device LLC), uses laser emission diodes (730nm and 850nm)which in a headband that is worn on the front of the scalp and forehead. Surrounding detectors a few centimeters away detect the light as it scatters through the underlying tissues. The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes. fNIRS will be performed twice at each study visit, once before and once about 45 minutes after single dose administration of sildenafil 50 mg.
45353262|NCT04058132|Other|Carbon Dioxide (CO2) 5%|"Carbon Dioxide (CO2) 5% mixed with room air. Both the fNIRS procedure and one Magnetic Resonance Imaging (MRI) session at visits that include imaging will be done with a hypercapnia challenge for comparison.~CO2 (hypercapnia) challenge is similar to holding one's breath. Participant will wear a nose clip and a mouth breathing apparatus while in the MRI scanner or sitting in a chair during the fNIRS procedure.~During the 7-minute hypercapnia procedure, participants will breathe room air and then switch to room air mixed with 5% CO2, from one to the other for one minute each."
45353263|NCT04058132|Other|Neuropsychological Assessments|TBI Neuropsychological Assessments: Study participants will be administered a set of Neuropsychological Tests designed by the NINDS Common Data Elements (CDEs) initiative for TBI, in order to provide a comprehensive and broad assessment of deficits commonly found after TBI. We anticipate that the neuropsychological battery will require approximately 1 hour to complete. The measures (pencil and paper exercises, questionnaires, and interview by the examiner) to be administered are: Glasgow Outcome Scale-Extended (GOS-E). Learning trials portion of the California Verbal Learning Test (CVLT-II): The Trail Making Tests A and B (TMT): Subsets of the Wechsler Adult Intelligence Scale (WAIS-IV) (Digit Symbol and Symbol Search): Behavioral Symptoms Inventory-18: Satisfaction with Life Scale (SWLS): Word Reading subtest of Wide Range Achievement Test (WRAT)-4: Rivermead Post-Concussion Symptom Questionnaire.
46046137|NCT05224011|Device|Boppli Infant Blood Pressure Monitor|The intervention is a medical device for the non-invasive measurement of blood pressure in infants
46046138|NCT05218785|Drug|Botox|75 U in medial gastrocbemius head. x 3
46046139|NCT05203159|Other|Ocean sound|The experimental group will listen to ocean sound, starting at the 1st minute before the ROP examination and ending at the 5th minute after the ROP examination.
46046140|NCT05203159|Other|Routine|No sound will be played before, during and after the ROP examination.
46046141|NCT05189860|Device|C-MIC system|This study aims to follow up patients already treated with a C-MIC System over a period of 2 years following the initial treatment with the device, to assess the long term results.
45353264|NCT04058132|Drug|Gadolinium contrast infusion|Gadolinium contrast infusion: Brain MRI with gadolinium contrast: Dynamic contrast-enhanced (DCE) MRI with intravenous gadolinium-based contrast agents (GBCAs) to measure their transfer rate between intravascular and extravascular compartments as a marker of blood-brain barrier (BBB) permeability. For the DCE sequence, the participant is injected with the contrast agent through a heplock/iv in the scanner and the sequence takes about 15 min. Half-life of gadolinium is about 1 ½ hours and 90-98% clearance from the body in 24 hours in people with normal kidney function.
45353265|NCT04058132|Procedure|Blood sample collection for research purposes|Serum and plasma (5 ml each) will be collected at at each study visit 10 m or 2 tsp. per visit or up to 40 ml or 8 tsp. over the 180 day course of the study). Samples will be collected by study personnel.
45353266|NCT04058132|Other|Structural brain Magnetic Resonance Imaging (MRI|"Structural brain Magnetic Resonance Imaging (MRI): The scanner used is a 3.0 Tesla MR (Model 750, General Electric Healthcare), which is equipped with a high-performance gradient subsystem and a 32-channel head coil (General Electric Healthcare). These scans involve lying still in a scanner for several minutes at a time which is tube shaped, using magnetism to take images of the brain. There is no radiation in MRI. The participants will have up to 3 research brain MRIs. Healthy controls will have 1 MRI session.~Common TBI MRI techniques will be performed. Block-design BOLD fMRI during which there will be a 7 minute hypercapnia challenge will be done to assess brain blood flow and measure cerebral vascular reactivity (CVR)."
46046142|NCT05189821|Procedure|Radiofrequency Ablation|Ultrasound guided radiofrequency ablation
45353267|NCT03050476|Drug|bRESCAP|intravenous application before, during, and for 24, 48, or 96 hours after heart surgery
45353268|NCT03050476|Drug|placebo|intravenous application before, during, and for 24, 48, or 96 hours after heart surgery
45477615|NCT03335956|Drug|CORT125281, 360mg|CORT125281 is supplied as capsules for oral dosing twice, 12 hours apart, fasted (morning) and after evening meal
45477616|NCT03335956|Drug|CORT125281, 120mg|CORT125281 is supplied as capsules for oral dosing once daily
45477617|NCT03335956|Drug|CORT125281, 180mg|CORT125281 is supplied as capsules for oral dosing twice daily
45477618|NCT03335956|Drug|CORT125281, 240mg|CORT125281 is supplied as capsules for oral dosing twice daily
45477619|NCT03335956|Drug|CORT125281, 360mg|CORT125281 is supplied as capsules for oral dosing once daily
45477620|NCT03335956|Drug|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal"
45477621|NCT03335956|Drug|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, twice daily"
45477622|NCT03335956|Drug|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, once daily"
46046143|NCT05189808|Procedure|Radiofrequency Ablation|Ultrasound guided radiofrequency ablation
45477623|NCT03817931|Drug|Anticholinergic|Tablet taken once daily.
45477624|NCT03817931|Drug|Beta-3 Agonists, Adrenergic|Tablet taken once daily.
45477625|NCT03817931|Diagnostic Test|Functional magnetic resonance imaging (fMRI)|All subjects have fMRI at baseline and again after 30 days
45477626|NCT03817931|Diagnostic Test|Rey Auditory Verbal Learning Test (RAVLT)|All subjects have RAVLT at baseline and again after 30 days. RAVLT evaluates: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information, and differences between learning and retrieval.
45498244|NCT03679572|Procedure|Robot assisted partial nephrectomy super-selective clamping|The device used to performe the surgery is a Da Vinci robot. After injection of infracyanine, the super-selective clamping is possible. The surgery is performed using a specific clamping of the tumor arteries. Super-selective ischemia is checked using near infrared fluorescence.
45498245|NCT03679572|Procedure|Robot assisted partial nephrectomy with renal artery clamping|Partial nephrectomy is performed with the conventional method in wich a renal artery clamping is done.
46046144|NCT05189314|Procedure|Thyroidectomy|Surgical Resection of thyroid nodules
46046145|NCT05189314|Procedure|Radiofrequency Ablation|Radiofrequency Ablation of thyroid nodules
46046146|NCT05188677|Biological|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
46046147|NCT05188677|Biological|Comirnaty Vaccine|intramuscular injection
46046148|NCT05188677|Biological|Vaxzevria Vaccine|intramuscular injection
46046149|NCT05188677|Biological|CoronaVac Vaccine|intramuscular injection
46046150|NCT05178849|Other|Hypnosis|Hypnosis
46046151|NCT05178849|Drug|Local anesthetic|For the local anesthesic, the doctor uses in both arms of the study a 20 ml vial of lidocaine hydrochloride without adrenaline for injection dosed at 2%.
46046152|NCT05166265|Device|Active transcutaneous bone conduction hearing system|The Sentio system consists of the Sentio 1 sound processor (SP) and Sentio Ti implant with fixation band and screws.
46046153|NCT05161936|Drug|Lumasiran|Lumasiran will be administered by SC injection.
46046154|NCT05161936|Drug|Placebo|Placebo will be administered by SC injection.
45686595|NCT00194896|Drug|glyburide|Tablet taken orally, initially 2.5 mg in the morning or dose subject received prior to starting the study. Dosage was increased by 2.5 mg in the evening up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control. Study drug was taken up to 3 years.
46046155|NCT05158023|Drug|Placebo|Sterile solution for subcutaneous injection
46046156|NCT05158023|Biological|ASLAN004|Sterile solution for subcutaneous injection
46046157|NCT05158023|Biological|ASLAN004|Sterile solution for subcutaneous injection
45353269|NCT00791544|Drug|AVE1642|intravenous infusion
45353270|NCT00791544|Drug|sorafenib|oral intake
45353271|NCT00791544|Drug|erlotinib|oral intake
46046158|NCT05158023|Biological|ASLAN004|Sterile solution for subcutaneous injection
46046159|NCT05158023|Biological|ASLAN004|Sterile solution for subcutaneous injection
46046160|NCT05143424|Drug|Morphine Sulfate|Morphine sulfate 30 mg tablets as a single dose twice
46046161|NCT05137067|Dietary Supplement|Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)|Chemotherapeutic side effect elimination without adversely effecting the Chemotherapeutic agent drug.
46046162|NCT05137067|Drug|Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo|Placebo
46046163|NCT05137067|Drug|Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).|Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
45353272|NCT05178784|Device|External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation|Relivion®DP is a device by Neurolief that delivers external, combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS), which is proposed as a novel treatment approach for MDD. The Relivion®DP device is designed for at-home self-administration by patients; it is comprised of a headset that holds electrodes, and it is worn externally on a person's head. When activated, the device delivers mild electrical stimulation pulses which can be managed by the user. The stimulation is intended to reduce MDD symptoms.
45382200|NCT05245669|Biological|EU Sourced Prolia|healthy volunteers receive Denosumab (60mg) once
45382201|NCT05245669|Biological|US Sourced Prolia|healthy volunteers receive Denosumab (60mg) once
45382202|NCT05243316|Procedure|Clamping|There will be a randomized selection of patients who will have a clamping of the chest tube 6 hours prior to chest tube removal.
45382203|NCT05243316|Procedure|Non Clampling|There will be a randomized selection of patients who wont have chest tube clamping 6 hours prior to chest tube removal.
45382204|NCT05233332|Drug|HL-085|12mg BID HL-085
45382205|NCT05233332|Drug|Vemurafenib|720mg BID Vemurafenib
45353273|NCT00753350|Device|Sensate™ anchored gastric device|Delivery/anchoring of the Sensate™ device in the stomach. Withdrawal of the Sensate™ device and its anchoring components after 8 weeks.
45353274|NCT05171686|Drug|Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)|The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed
45353275|NCT00753428|Other|Community-based Survey|"Questionnaires will be used to record detailed information regarding demographic and socioeconomic characteristics, maternal medical history, recent obstetrical history (including access to preventive services for mother-to-child HIV transmission), and infant medical history. Infant deaths will also be recorded as part of the survey. In cases where either the mother or infant has died, we will perform verbal autopsy interviews (Appendix 5) with surviving family members to determine cause of death and gather information regarding HIV infection and/or exposure.~Heel/finger pricks will be taken so as to perform dried blood spot cards, and test for HIV in children and adults."
45353276|NCT00990028|Drug|Rosuvastatin|20 mg oral, for 10 days
45353277|NCT00990028|Drug|Placebo|20 mg vehicle
45353278|NCT04052906|Other|Training|Planned Inhaler Medication Trainning
45353279|NCT05361226|Other|Accuracy measurement|"Three months following the implant placement, patients were called back to the implant clinic to record the actual implant position with the digital impression technique. Full mouth scans were done by using the intraoral scanner (Trios 3, 3Shape, Copenhagen, Denmark). The surface scans were then exported as an STL file and were imported to coDiagnostiX software. The Treatment evaluation tool function tool was used to measure the accuracy of the implant placement which measured the amount of deviation of the placed implant from the planned position. The outcomes were generated into three main parameters."
45353280|NCT00663234|Drug|Atorvastatin|10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.
45353281|NCT00683384|Drug|Etanercept (Enbrel)|
45353282|NCT00753662|Device|1Hz TMS with H2 coil|1Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
45686596|NCT00197392|Device|Bactiseal TM EVD|Standard of care implantation of external ventricular drainage catheter
45847649|NCT02796924|Device|MagStim Rapid2 Transcranial Magnetic Simulation|A non-invasive method of brain stimulation
45847650|NCT02798952|Biological|Engerix-B Kinder|Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 14-15 years of age.
45353283|NCT00753662|Device|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
45353284|NCT00753662|Device|SHAM TMS with H2 coil|SHAM TMS with H2 coil to prefrontal and parieto-temporal cortex
45353285|NCT04003714|Device|Repetitive Transcranial Magnetic Stimulation|Patients in r-TMS group received 5 Hz of r-TMS. R-TMS applied with MagVenture device (MagPro X100, Denmark, 2009) and figure eight coil (MMC 140 parabolic, MagVenture).
45353286|NCT04003714|Device|Sham Repetitive transcranial Magnetic Stimulation|Control group received sham r-TMS.
45353287|NCT02561312|Other|Rapid manual partial exchange transfusion|The first four participants will receive peripheral red blood cells via rapid manual partial exchange transfusions every month for 6 months. There is a pre-study washout for 3 months then there is a 3 month test period (data collection) before the participant is transferred to ST treatment.
45353288|NCT02561312|Other|Simple Transfusion|The second group of four participants will receive peripheral red blood cells via simple transfusion every month for 6 months. There is a pre-study washout period for 3 months then there is a 3 month test period (data collection) before the participant is transferred to RMPET treatment.
45353289|NCT05361148|Other|no interventions will be used|This is a cohort study with no interventions.
45353290|NCT00788346|Behavioral|Computerized alerts|Computerized Clinical Decision Support to clinician at the time of prescribing
45498246|NCT03677466|Drug|Pharmaco-invasive strategy|"Patient with primary STEMI will received standard doses of fibrinolytics with following PCI.~After reperfusion strategies will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images. and Global Longitudinal Strain measured with echocardiography."
45686597|NCT00197392|Device|Standard EVD Catheter|Standard of care EVD system other than Bactiseal.
45686598|NCT04348474|Drug|Hydroxychloroquine Sulfate|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D7) for 7 days.
45686599|NCT04348474|Drug|Azithromycin Tablets|All patients included in the study will receive AZT 500 mg per day for 5 days.
45686600|NCT04318834|Other|Tumour and germline molecular profiling|Tumour whole genome sequencing, germline whole genome sequencing, tumour whole transcriptome sequencing
45353291|NCT00788346|Behavioral|Alerts Plus Detailing|Computerized Clinical Decision Support to clinician at the time of prescribing PLUS one group academic detailing session
45686601|NCT04272268|Device|Nasal High flow Oxygen|If the patient is successfully extubated within 4 hours following surgery and meets the post surgery inclusion/exclusion criteria, Nasal high flow oxygen will be administered continuously using a humidifier machine for 5 days. Breathing circuits and nasal cannulae will be connected to the machine to deliver oxygen at 20L/min to the patient.
45843212|NCT05493540|Drug|Placebo|"Placebo Group will receive Oral Placebo and Conservative therapy in the form of fluid restriction, PEEP, and/or diuretics~An Open-label option might be offered if there are concerns by attending physicians over the poor patient condition that might be attributed to persistent PDA:~Prolonged Ventilation or Escalating Ventilatory Setting~Prolonged Use Of Inotropes or Vasopressors or escalation of Doses~Rescue therapy in the form of a course of oral ibuprofen may be offered:~After 5 days of recruitment~Moderate/Severe PDA on Echocardiography~Prolonged ventilation or Increased ventilatory setting~Prolonged use of inotropes or vasopressors or escalating dose - Another form of treatment may be offered if the patient developed side effects from Ibuprofen"
45843213|NCT05427240|Other|Pre-Test Intervention|Secure and accessible by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
45843214|NCT05427240|Other|Standard of Care|Standard of Care with a Genetic Counselor by Remote Services
45843215|NCT05427240|Other|Post-Test Intervention|Secure and accessible by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
45843216|NCT05214924|Biological|Injectable platelet-rich fibrin|Intra-articular injection of injectable platelet-rich fibrin into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
45843217|NCT05214924|Biological|Platelet-rich plasma|Intra-articular injection of platelet-rich plasma into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
45843218|NCT05672940|Behavioral|Aerobic plus resistance training|Aerobic plus resistance training
45843219|NCT05672940|Behavioral|Stretching plus breathing training|Stretching plus breathing training
45843220|NCT05672784|Procedure|genicular nerve block plus standard analgesia|In supine position with a pillow under the popliteal fossa, a 12 MHz linear transducer (XarioTM SSA-660A, Toshiba Medical Systems Corporation, Otawara, Japan) will be placed parallel to the shaft of long bones of the legs. The target points will be next to superior lateral, superior medial, and inferior medial genicular arteries to block the superior lateral, superior medial, and inferior medial branches of genicular nerve. Identification will be done using color Doppler near the periosteal areas (the junctions of the epicondyle and the shafts of the femur and tibia, accordingly). The needle will be inserted in the plane of the ultrasound probe in the long-axis view. After confirming the placement of the needle-tip next to the genicular arteries, a 2.5 mL of bupivacaine (5%) will be injected at each target points.
46046164|NCT05134779|Procedure|Live Biobank|Tumor tissue will be collected from consented patients at sequential inflection points in the disease course: at the time of initial diagnosis, at the time of surgery and during recurrence or metastasis. In addition to this, 40ml of research bloods will also be collected at these key inflection points.
45353292|NCT00753740|Drug|IT-101 (12mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive a blinded infusion of IT-101 (12mg/m2/dose) every other week until disease progression.
45353293|NCT00753740|Drug|IT-101 (15mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of IT-101 (15mg/m2) every other week until disease progression.
45498247|NCT03677466|Procedure|Primary PCI|After primary PCI patients will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images and Global Longitudinal Strain measured with echocardiography.
45686602|NCT04290364|Other|Palliative care|The patients in the prospective part of the study are seen on home-visits and offered standard palliative care within three weeks of diagnosis.
46046165|NCT05132283|Device|3D Slicer|Navigational device used during surgery to locate abnormal lymph nodes.
46046166|NCT05132283|Device|Monaco|Navigational device used during surgery to locate abnormal lymph nodes.
46046167|NCT05127837|Behavioral|CBTpro|CBTpro is a novel spoken language technology tool to support high-quality skills training in CBT for psychosis.
46046168|NCT05126238|Drug|Lithium Carbonate|In preoperative period patients will take 300 mg of lithium carbonate on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will take 300mg of lithium carbonate 2 hours before surgery.
45353294|NCT00753740|Drug|5% Dextrose (Placebo)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of placebo every other week until disease progression.
45353295|NCT00796380|Drug|Xingnaojing|injection
46046169|NCT05126238|Drug|Placebo|In preoperative period patients will take placebo on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will placebo 2 hours before surgery.
45353296|NCT00326911|Biological|cetuximab|I.V. infusion of 400 mg/m2 (over 120 minutes) on day 1 of cycle 1
45353297|NCT00326911|Biological|bevacizumab|10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks.
45353298|NCT00326911|Drug|gemcitabine|1000 mg/m2 administered intravenously at 10 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks.
45353299|NCT00326911|Biological|cetuximab|I.V.infusions of 250 mg/m2 (over 60 minutes) weekly
45686603|NCT04290286|Other|i2TransHealth|i2TransHealth: online intervention for TGD people
45686604|NCT00107536|Drug|lapatinib ditosylate|
45686605|NCT00107536|Other|laboratory biomarker analysis|Correlative studies
45686606|NCT04389190|Other|Fluoroscopy settings for image acquisition|X-ray radiation is routinely used for imaging in coronary cath labs. Intervention involves lowering patient and operators X-ray exposure by employing various setting on the fluoroscopy machine.
45498248|NCT03196297|Drug|Concizumab|0.15 mg/kg (with potential stepwise dose administration to 0.25 mg/kg) administered daily s.c (subcutaneously, under the skin). Treatment duration is 24 weeks in the main phase, and 52 weeks in the extension phase
45498249|NCT03196297|Drug|Turoctocog alfa|Breakthrough bleeding episodes will be treated by the patients at home with turoctocog alfa at the discretion of the study doctor, who will also choose dose levels
45353300|NCT00990262|Radiation|Cardiac Computed Tomography|"Localization of the heart position in a projectional topographic scan of the chest.~Determination of contrast agent transit time: 10 ml contrast agent.~CT coronary angiography: CT scan in spiral acquisition mode with 330 ms rotation time, 32 x 0.6 mm collimation, a pitch of 2.8 mm/rotation, tube voltage of 120 kVp, and maximum tube current of 850 mA. 80 ml of contrast agent, followed by 40 ml saline solution will be injected at a rate of 4 ml/s. The mean breath hold duration for this acquisition is approximately 13 seconds."
45353301|NCT00791622|Drug|Paliperidone ER|
45353302|NCT00747110|Drug|budesonide|3x 3mg budesonide capsules once daily
45353303|NCT00747110|Drug|mesalazine|3x 1000mg mesalazine onc daily
45353304|NCT05359900|Other|Pain neuroscience education|Pain neuroscience education lecture
45353305|NCT05359900|Other|Red Flag Education|Red Flag education lecture
45353306|NCT00796458|Drug|docetaxel|Given IV
45353307|NCT00796458|Drug|releasing hormone agonist therapy|Patients receive luteinizing hormone-releasing hormone analogue therapy until disease progression.
45353308|NCT00753818|Other|DHA and ARA|various levels of DHA and ARA
45353309|NCT00753818|Other|Control|
45353310|NCT05359744|Diagnostic Test|Performance testing|Performance testing on a bicycle ergometer.
45353311|NCT00747188|Behavioral|PBL|
45353312|NCT04046016|Drug|Paclitaxel|Liporaxel and microdose 18F-Liporaxel administration study was conducted in two breast cancer patients. Therapeutic dose of Liporaxel was 200 mg/m2 and 18F-Liporaxel was 0.98-2.9 μg (185-555 MBq).
45353313|NCT01057615|Dietary Supplement|Fish Oil|10 fish oil (3.2g EPA + 2.0g DHA) capsules per day for 3 weeks
45353314|NCT01057615|Dietary Supplement|Ascorbic Acid|2 pharmaceutical grade ascorbic acid (1500mg) capsules per day for 3 weeks
45353315|NCT01057615|Dietary Supplement|Fish Oil Placebo|10 placebo fish oil (soy bean oil) capsules per day for 3 weeks
45686607|NCT00108550|Drug|gabapentin|Gabapentin 300m on Day 1, with daily or weekly increase to 3600 mg (maximum) by mouth by Week 5 of the 12-week trial
45353316|NCT01057615|Dietary Supplement|Ascorbic Acid Placebo|2 placebo ascorbic acid (sucrose) capsules per day for 3 weeks
45353317|NCT04046718|Device|electro-acupuncture stimulation|stimulation of acupoints of the liver meridian of lv3 lv14
45353318|NCT02561858|Other|acid load test|
45353319|NCT05124418|Diagnostic Test|palatal masticatory mucosa thickness measurement|Measure the thickness of palatal masticatory mucosa by a dynamic navigation system (Navident®, ClaroNav Inc., Toronto, Canada) and periodontal probe piercing.
45353320|NCT00788424|Drug|AS101 Cream|4% AS101 Cream or Placebo cream, twice a day for 12 weeks
45353321|NCT00747422|Device|Ulthera™ System|ultrasound treatment
45353322|NCT04003870|Device|CASO|Customized arch support orthoses (CASO)
45353323|NCT04003870|Device|HL|Orthotic Heel Lift (HL)
45353324|NCT00796536|Behavioral|Group cognitive behavioral therapy|Each CBT session will last for 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
45353325|NCT00796536|Behavioral|Pain education|Patients will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
45382206|NCT05232084|Drug|Bupivacaine + Fentanyl|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
45686608|NCT00108550|Drug|Inert placebo|Inactive placebo capsule, one capsule on Day 1 with daily or weekly increase to 9 capsules daily by Week 5 of the 12-week trial
45353326|NCT04057274|Other|Exercise assessment|The moderate-intensity aerobic interval exercise will be performed on a cycle ergometer under the supervision of trained staff in an exercise science laboratory. Participants will perform a 5 to 10-minute warm-up that begins by pedalling against a light resistance (60 W) and progressively increases in resistance until a target heart rate of 50-60% heart rate reserve is achieved. Participants will then complete 6 x 5-minute bouts at 60% heart rate reserve whilst maintaining a cadence of 60 rev·min-1, separated by 2.5-minutes of pedalling against light resistance (60 W). The session will finish with a cool-down at light resistance (60 W) lasting 10-minutes.
45353327|NCT02686060|Device|0.2 micron positively charged PALL Corporation filters and 1.2 micro IV in-line filters used for lipid administration|
45353328|NCT00791856|Drug|testosterone|28 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
45353329|NCT00791856|Drug|testosterone|14 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
46046170|NCT05123313|Behavioral|Deprescribing intervention|"The intervention is comprised of a minimum of three consultations with a general practitioner (GP), where adjustment of the patient's medication is made according to the patient's preference, goals and needs~Consultation 1: Patient and GP discuss how the patient feels about their medical treatment, and the GP provides the patient with written material for the patient to prepare prior to the next consultation.~Consultation 2: A clinical pharmacist have beforehand examined the patient's medication list and provided suggestions to the GP on which drugs can be deprescribed. The patient and GP discuss the patient's preferences and initiate deprescribing initiatives aligned with the patient's priorities.~Consultation 3: Patient and GP follow up on the changes initiated and initiate new deprescribing initiatives if such can be identified. If needed, subsequent consultations (Consultation X) are planned until the patient and GP consider the patient's medical treatment optimal."
45353330|NCT02561780|Behavioral|Curriculum|A mental health educational resource delivered in the classroom by trained educators
45353331|NCT02561780|Behavioral|eLearning Follow-up|An online mental health education module that students access individually
45353332|NCT00796692|Drug|Nadroparin|LMWH is given with a weight adjusted dose of 86 international anti-factor Xa units of nadroparin (Fraxiparine) per kilogram of body weight(86 anti-factor Xa IU/kg) subcutaneously every 12 hours,which will be used at least 5-7 days.
45353333|NCT00796692|Drug|Unfractionated heparin(UFH)|UFH is received with an initial bolus dose of 80 IU per kilogram, followed by a continuous intravenous infusion at an initial rate of 18 IU per kilogram per hour. The dose is subsequently adjusted so that the activated partial thromboplastin time (APTT) would be 1.5 to 2.5 times the control value in normal subjects. The tests are performed 4 hours after the start of treatment, whenever a sub-therapeutic APTT had been measured after a dose adjustment, and otherwise daily.UFH will be used at least 5-7 days.
45353334|NCT00540436|Drug|GSK1325760A|Primary evaluation period: 5 mg/day, po, 12 weeks. Dose adjustment period: 2.5 mg, 5 mg or 10 mg/day, po, 12 weeks.
45353335|NCT00754286|Other|Aromatherapy Scented Wand|"The aromatherapy used in this will be Quease Ease™, manufactured by Soothing Scents, Inc. Quease Ease is a blend of lavender, spearmint, ginger, and peppermint soaked into a pad placed within a wand dispenser that emits a fragrance when placed within a few inches of the nares. Participants will be given aromatherapy wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the aromatherapy treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety."
45382207|NCT05231980|Dietary Supplement|Alpha lipoic acid (ALA)|ALA is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect.
45382208|NCT05231980|Drug|Pentoxifylline (PTX)|Pentoxifylline is a methylxanthine derivative which acts as a vasodilator by increasing blood flow to tissues, inhibits inflammatory responses, and reduces blood viscosity by impeding platelet aggregation
45382209|NCT05231980|Drug|Clomiphene Citrate|is a medication used to treat infertility in women who do not ovulate
45382210|NCT05231122|Biological|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Given IV
45382211|NCT05231122|Biological|Bevacizumab|Given IV
45382212|NCT05231122|Biological|Pembrolizumab|Given IV
45382213|NCT05231122|Other|Quality-of-Life Assessment|Ancillary studies
45382214|NCT05231122|Other|Questionnaire Administration|Ancillary studies
45382215|NCT05229783|Procedure|Electronic chromoendoscopy|Inspection of the Barrett's esophagus using the electronic chromoendoscopy modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions.
45353336|NCT00754286|Other|Placebo wand|Placebo wands will look identical to the scented wands but will not contain a scent. Participants will be given the placebo wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the placebo treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety.
45353337|NCT00796770|Biological|Dendritic Cell Vaccine|"Biological/Vaccine: Experimental: Dendritic Cell Vaccine Patients will receive 4 doses of the vaccine at weeks 0, 4, 8 and 12. The vaccine will be injected subcutaneously, in 3 separate injection sites in the upper and lower extremities.~At week 24, patients will have HAART treatment interrupted. The HAART treatment will be resumed at week 48 or earlier at any time point if one of the following occur:~two consecutive measurements of CD4+ T cell count below 350x10e6 cells/L and/or 25% of total lymphocytes within at least a 2 weeks~an opportunistic infection~a CDC class C-defining event (defined in appendix 2)~a serious non-AIDS defining event.~Patients will have follow-up visits on weeks: 22, 24, 25, 26, 27, 28, 32, 36, 40, 44, and 48."
45353338|NCT00788580|Drug|pazopanib hydrochloride|
45353339|NCT00788580|Drug|temsirolimus|
45353340|NCT00788580|Procedure|immunoenzyme technique|
45353341|NCT00788580|Procedure|laboratory biomarker analysis|
45353342|NCT00788580|Procedure|pharmacological study|
45353343|NCT00788658|Behavioral|Diet modifications|Diet consultation
45353344|NCT00788658|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy
45353345|NCT03878498|Other|therapeutic management|therapeutic management of anal fistula in Crohn Disease
46046171|NCT05118828|Behavioral|Guided internet-based cognitive behavioural therapy|AS-iCBT offers guided CBT intervention for anxiety and depression, each consisting of 6 modules. It is recommended for clients to complete 1 module weekly. The structure and content of the programme modules follow evidence-based CBT principles, and comprises cognitive and behavioural components such as self-monitoring, gradual stimulus control, exposure, behavioural activation, and cognitive restructuring. It is recommended that therapist support is provided weekly during short sessions that focus on progress monitoring and feedback on completed work. Support sessions should last 15-20 minutes and are preferably delivered by phone or video conference.
45353346|NCT00792012|Radiation|Hypofractionated Intensity-Modulated Radiation Therapy|All patients will receive one fraction of radiation therapy a day, 5 days a week, Monday through Friday. Radiation fraction size and number of fractions depend on dose fraction level the patient is assigned to.
45353347|NCT00792012|Drug|Temozolomide|Temozolomide will be administered orally, once a day starting on the first day of radiation, for 28 consecutive days during radiation, and after radiation for those patients completing radiation in less than 28 days.
45353348|NCT00990418|Drug|Separated (Two Part) E-TRANS (fentanyl HCl) System; Integrated E-TRANS (fentanyl HCl) System|
45353349|NCT02562950|Drug|GLPG1837 500 mg|Each subject will receive multiple oral daily doses of GLPG1837 (250 mg b.i.d. for 11 days) from Days 2 to 12.
45353350|NCT02562950|Drug|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12).
46046172|NCT05118828|Behavioral|Treatment as usual in Prompt Mental Health Care (TAU-PMHC)|TAU-PMHC includes both low-intensity (guided self-help, group-based psychoeducation) and high-intensity CBT (F2F-CBT). The TAU-PMHC condition basically represents how PMHC services currently operates (i.e. a pragmatic stepped care model) and provides therapists with more flexibility to accommodate client needs and preferences.
45353351|NCT02562950|Drug|GLPG1837 1000 mg|Each subject will receive multiple oral doses of GLPG1837 (500 mg b.i.d. for 11 days) from Days 2 to 12.
45353352|NCT02599948|Other|no intervention|
45353353|NCT00788814|Behavioral|Pathways|Strength-based curriculum addressing depression in women with with physical disabilities
45353354|NCT00796848|Device|Navigator Continuous Glucose Monitor|
45353355|NCT00754754|Procedure|Brain Retraction Monitoring Sensor|This is a sensor incorporated into a brain retractor blade to monitor electrical activity and pressure applied to the brain during retraction required for the selected skull base operations.
45353356|NCT00792090|Other|Fermented milk|Formula used for non breastfed children or in complement of breastfeeding
45353357|NCT00792090|Other|Standard milk|Formula used for non breastfed children or in complement of breastfeeding
45353358|NCT00792168|Drug|venlafaxine (Effexor)|venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
45353359|NCT00792168|Other|placebo|venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
45353360|NCT02554188|Biological|Seasonal influenza (flu) vaccine|"Seasonal influenza (flu) vaccine~Fluzone Quadrivalent Vaccine (Sanofi Pasteur), for participants ages 50 - 64 years old~Fluzone High-Dose (Sanofi Pasteur), for participants ages 65 years and older"
45353361|NCT02554188|Other|Diet|A 5-day low calorie fasting-mimicking diet
45353362|NCT00687440|Drug|Pegylated Liposomal Doxorubicin|"Stage 1: 25 subjects will be treated with Caelyx IV 30 mg/m^2 on day 1, every 3 weeks~Stage 2: 45 new patients will be treated at the recommended dose level (defined in the first step) on day 1, every 3 weeks."
45353363|NCT00687440|Drug|Docetaxel|Stage 1 and Stage 2: Docetaxel 60 mg/m2 IV as 1-hour infusion, on day 1, every 3 weeks.
45353364|NCT00687440|Drug|Trastuzumab|Stage 1 and Stage 2: 4 mg/kg IV 90-minute infusion loading dose. Then 2 mg/kg IV weekly during 6 cycles (18 weeks).
45477627|NCT02494960|Behavioral|The brief smoking cessation AWARD model|"Ask whether or not the patient currently smokes~Warn the patients that at least one out of two smokers will be killed by smoking. Recent research shows that two out of three smokers will be killed by smoking. The 10-20-second script could be like 'I warn you that smoking can kill you by many serious diseases and that your chance to be killed prematurely by smoking is about 50% to 67%.~Advice the patients to quit now or as soon as possible because quitting can reduce the excess risks substantially.~Refer the patients to a smoking cessation clinic or call telephone quitlines (if available) as soon as possible, emphasizing that smoking cessation counsellors are caring and helpful.~Do it again: Repeat the intervention among smokers who fail to quit or relapse, and encourage them to try to quit again."
46046173|NCT05117502|Device|intermittent Theta Burst Stimulation|intermittent Theta Burst Stimulation (iTBS) is a type of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered by the MagVenture MagPROX100 with MagOption Stimulator and MagPro Cool Coil B65 A/P. The MagPro Cool Coil B65 A/P can be switched from active to placebo.
45353365|NCT02554734|Drug|levodopa, carbidopa, ODM-104|
45353366|NCT02554734|Drug|levodopa, carbidopa, entacapone|
45353367|NCT00990496|Drug|Fludarabine|30 mg/m2
45353368|NCT00990496|Drug|Cyclophosphamide|600 mg/m2
45353369|NCT00990496|Biological|CMV Specific Cytotoxic T Lymphocytes (CTL)|CTL Infusion (3 - 5 x 10E6 cells/kg)
45353370|NCT00754910|Drug|porfimer sodium|Given IV
45686609|NCT00109876|Procedure|Computed Tomography-Guided Optical Sensor-Guided Radiofrequency Ablation|Undergo RFA
46046174|NCT05117502|Device|Placebo intermittent Theta Burst Stimulation|The placebo coil magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active iTBS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e. clicking) nearly identical to that of the active coil.
46046175|NCT05116852|Other|Survey|All study participants will be asked to complete two surveys relevant to their personal experience either losing a loved one to opioid-related death, supporting a loved on in recovery for Opioid Use Disorder, or both.
45353371|NCT00754910|Procedure|bronchoscopy|Patients undergo bronchoscopy
45353372|NCT00755066|Drug|Fluticasone propionate|200 µg intranasal, 4 weeks, od.
45353373|NCT00755066|Drug|Placebo|Placebo intranasal spray
45353374|NCT00990574|Device|Wiley Spinal Catheter|The WSCG (wiley spinal catheter group) will have a Wiley spinal catheter placed, but it will not be dosed until the patient is in the supine position with left uterine displacement. Participants will receive the medication (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) in sequential doses.
45353375|NCT00990574|Device|Spinal Anesthesia Group (SAG)|"The SAG (spinal anesthesia group) will have their drugs (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) dosed intrathecally as a single shot while still in the sitting position."
45353376|NCT00659490|Drug|AZD1940|800ug oral administration
45353377|NCT00659490|Drug|Naproxen|500mg oral administration
45353378|NCT00659490|Drug|Placebo|Placebo given pre-surgery
45353379|NCT00792246|Drug|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
45353380|NCT00792246|Drug|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
45353381|NCT00539500|Drug|Carboplatin|Carboplatin by vein over 24 hours for 4 days, dosing as determined at day 1.
45353382|NCT00539500|Drug|Etoposide|300 mg/m^2 by vein over 24 hours for 4 days
45353383|NCT00539500|Drug|Melphalan|70 mg/m^2 Intravenous Bolus for 3 Days
45353384|NCT00539500|Procedure|Stem Cell Infusion|Stem Cell Infusion (approximately 5x10^8 TNC cells/kg CD133+ selected) on Day 0.
46046176|NCT05112705|Diagnostic Test|Proximal lower limb ultrasound|Twice weekly proximal lower limb ultrasound
46046177|NCT05108649|Other|Nicotine Messaging|After completing a 7-day baseline period, participants will be randomized to a 28-day experimental period and will view nicotine corrective messaging at each in-person session or delayed control messaging at the final study session.
46046178|NCT05108649|Other|Cigarette Condition|After completing a 7-day period of smoking own brand cigarettes, participants will be randomized to a 28-day experimental period and will receive reduced nicotine content (RNC) cigarettes or normal nicotine content (NNC) cigarettes.
46046179|NCT05105399|Procedure|Serratus plane block (continuous or single-shot)|Patients assigned to the interventional arms will receive either continuous serratus plane block or single-shot serratus plane block
46046180|NCT05104515|Biological|OVM-200|"The first part (Phase 1a) comprises a first-in-human (FIH) multiple-dose, sequential-cohort 3+3 design to establish a dose of OVM-200 that is safe and tolerable, and that elicits an immune response in humans.~This dose will be taken forward into the second part (Phase 1b) of the study. Phase 1b will further assess the safety and tolerability of the selected dose and investigate the immune and tumour response in 3 expansion cohorts of additional patients with NSCLC, ovarian cancer, and prostate cancer."
46046181|NCT05100888|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|Theta-burst stimulation
46046182|NCT05097391|Behavioral|Warm-up (5 minutes)|Participants will benefit from passive stretches of hamstrings, calf muscles including a range of motion (ROM) exercise to the lower limbs as mat exercises.
45353385|NCT00539500|Device|ClinicMACS|Device used to process the blood and separate the CD 133+ cells needed for transplantation
45353386|NCT00662532|Drug|Minocycline HCl|1mg microspheres for professional subgingival administration into periodontal pockets two times throughout the duration of the trial
45353387|NCT05070988|Other|Semi-structured interview|Semi-structured interview with the investigating doctor of the study lasting 30 minutes to an hour
45353388|NCT00686036|Drug|vandetanib|300 mg orally, once daily for up to 18 months
45353389|NCT00686036|Drug|Placebo|
45353390|NCT00788970|Behavioral|Acupressure adjuvant therapy|Acupressure provided in 40-minute sessions, twice a week for 4 weeks. For placebo acupressure, different meridian points will be used.
45353391|NCT00792324|Drug|Etravirine|Four 100mg tablets daily for 12-24 weeks
45353392|NCT00792324|Drug|Efavirenz|One 600mg tablet daily
45353393|NCT00747734|Drug|MNRP1685A|Escalating intravenous dose
45353394|NCT00990808|Drug|anacetrapib|[Intervention Name: MK0859] MK0859 100 mg tablet once daily for 8 weeks.
45477628|NCT02494960|Behavioral|Placebo intervention|Advice the smokers to eat vegetables, and engage in regular physical activities, and offer the smokers a card which contains information about the benefits of eating vegetables and a pictorial information leaflet which shows the recommended amount of vegetables and fruits an adult should eat a day
45477629|NCT01206881|Drug|pegylated liposomal doxorubicin|35 mg/m2, IV, day 1 every 21 days, 4 cycles
45477630|NCT02494804|Drug|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
45353395|NCT00990808|Drug|Comparator: atorvastatin|Atorvastatin 20 mg tablet once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
45353396|NCT00990808|Drug|Comparator: placebo to MK0859|Placebo to MK0859 once daily for 4 weeks.
45353397|NCT00990808|Drug|Comparator: placebo to atorvastatin|Placebo to atorvastatin once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
45477631|NCT02494804|Biological|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
45477632|NCT01299155|Device|ReSTOR +3|Bilateral implantation of an Alcon AcrySof ReSTOR +3 Intraocular Lens (IOL) Model SN6AD1 following cataract extraction.
45353398|NCT00750230|Dietary Supplement|NEM|see Treatment Arm
45353399|NCT00797082|Device|MRI|MRI = Myocardial Perfusion Stress
45353400|NCT00797082|Device|MPS|MPS = Myocardial Perfusion Scintigraphy
45353401|NCT00755144|Device|LCS Knee|Cementless total knee arthroplasty with LCS Knee
45353402|NCT00755144|Device|ROCC Knee|Cementless total knee arthroplasty with ROCC Knee
45686610|NCT02093962|Drug|TH-302 combination with pemetrexed|"400 mg/m2 of TH-302 will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after TH-302 administration."
45686611|NCT02093962|Drug|Matched placebo in combination with pemetrexed|"Matched placebo will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after placebo administration."
46046183|NCT05097391|Behavioral|Conventional physiotherapy exercise (15 minutes)|The conventional treatments will be active-assisted and free active exercises to the lower limbs on the mat for five (5) minutes. This will be followed by strength training such as sit-to-stand exercises for five (5) minutes and squatting exercises for five (5) minutes prior to the over-ground training.
45353403|NCT00797160|Drug|propofol|2mg/Kg IV in bolus before tracheal intubation
45477633|NCT01299155|Device|LENTIS MPlus|Bilateral implantation of a LENTIS MPlus Intraocular Lens (IOL) following cataract extraction.
45353404|NCT00682448|Drug|Metformin|Drug: Metformin 500 mg po daily titrated up to but no greater than 2000 mg based upon fasting blood glucose during study visits over six months.
45353405|NCT00682448|Drug|Placebo|Drug: Placebo. Subjects will remain on placebo for 6 months.
45353406|NCT00797238|Other||No intervention in this study
45353407|NCT04003792|Drug|oxaliplatin|intra-arterial oxaliplatin administration
45353408|NCT04003792|Drug|FOLFIRI Protocol|systemic FOLFIRI chemotherapy
45353409|NCT04003792|Drug|Bevacizumab|systemic bevacuzimab therapy
45353410|NCT00747890|Procedure|Modified tonsillectomy|"Tonsillectomy~Uvulectomy~Soft palatal resection~Lifestyle counselling by physician: General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance"
45353411|NCT00747890|Other|Lifestyle counselling by physician|General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance.
45353412|NCT00789048|Other|radiograph|One radiograph with the patient lying on his contralateral side
45686612|NCT02094118|Biological|Point-of-care washed red blood cell transfusion.|
45353413|NCT00990886|Drug|Placebo|Once daily for 12 weeks
45353414|NCT00990886|Drug|Oxybutynin chloride|15 mg once daily for 12 weeks
45686613|NCT02094118|Biological|Standard of care red blood cell transfusion.|
45686614|NCT01897636|Procedure|EUS-guided fine-needle injection of DCs vaccinations|
46046184|NCT05097391|Behavioral|Over-ground training with lower limb loading (15-25 minutes)|"Participants will perform the over-ground training exercise with an external 1.5kg load on the paretic lower limb placed 2cm above the ankle joint. Before commencing the over-ground training, all the participants will observe a pre-exercise rest period of about two (2) minutes during which their heart rate and blood pressure measurements will be recorded.~The over-ground training will involve the patients walking within a demarcated path. Each participant will be instructed to stand and walk 15meters to and fro for five (5) minutes after which they will be asked to stop and rest for two (2) minutes. The over ground training exercise will be repeated 3 times in the first 2 weeks of the training (15 minutes); 4 times in weeks 3-4 of the training (20 minutes); and 5 times in weeks 5-8 of the training (25 minutes)."
46046185|NCT05087108|Device|OsciPulse system|The OsciPulse system is an intermittent pneumatic limb compression system. The OsciPulse sleeves that are applied to the top portion of the user's calves and are periodically inflated with rapid bursts of compressed air to create frequent pulses of venous return.
46046186|NCT05087108|Device|Reference Therapy 1|The Venaflow Elite is a sequential compression device that uses compressed air to inflate sleeves worn on the calf of the user to stimulate venous return. The Venaflow system sleeves cover the entire calf region of the user and contain two bladders that are inflated sequentially to induce venous return.
46046187|NCT05087108|Device|Refence Therapy 2|The Kendall SCD device is a sequential compression device that uses compressed air to inflate sleeves worn on the calf of the user to stimulate venous return. The Kendall SCD sleeves cover the entire calf region of the user and contain three bladders that are inflated sequentially to induce venous return.
45353415|NCT00755300|Procedure|Measurement of total thrombolic load|A video recording of the right atrium using TE echo will be used to quantitate the total thromboembolic load
45353416|NCT00789126|Drug|VX-509|
45353417|NCT00755378|Drug|AZD8529|Oral
45353418|NCT00755378|Drug|Placebo|Oral
45353419|NCT02207062|Drug|Ibrutinib|Given PO
45686615|NCT00200902|Drug|Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
45353420|NCT02207062|Other|Laboratory Biomarker Analysis|Correlative studies
45353421|NCT00789204|Other|Global Postural Re-education|The treatment in Global Postural Re-education is a global approach that seeks to identify the biomechanical cause of the problem also in other parts of the body and involves actively the patient in the postural change. Using principles like causality, globality and individuality, the treatment consists of the use for one hour of progressive active stretching posture for specific muscular chain that are shortened. Every posture is maintained for 20 minutes with controlled breathing and the use of manual traction
45353422|NCT00789204|Other|Standard Exercise Training|The exercise programme included passive lumbar flexion, pelvic tilt, strengthening of flexor muscles, strengthening of extensor muscles, spine mobilization and stretching exercises.
45353423|NCT01899976|Device|X-Suit NIR Covered Biliary Stent|
45498250|NCT03677310|Drug|3% Sodium Chloride|3% sodium chloride will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
45498251|NCT03677310|Drug|Normal Saline|Normal Saline will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
45498252|NCT03447132|Drug|Fulvestrant 500mg|All patients in all arms will receive Fulvestrant 500mg
45498253|NCT03447132|Drug|Palbociclib 125mg|Dose reduction to 100 mg and 75 mg
46046188|NCT05081401|Other|This is a non-intervention observational study.|No applicable intervention. This is a secondary data analysis observational study.
45477634|NCT02494726|Other|Thromboelastography|TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine. Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm. K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening. These are measured in minutes. Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP. Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line. Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function. G is the measure of the clot firmness; measured by a formula (G=(5000*MA)/(100-MA) in dynes/cm2). LY30 is a measure of clot lysis at 30 minutes after MA is reached.
45477635|NCT01301105|Behavioral|Mindfulness Based Stress Reduction (MBSR)|8 week class in stress reduction through instruction in mindfulness related techniques.
45477636|NCT01301105|Behavioral|Health Enhancement Program (HEP)|8-week intervention designed to be structurally equivalent to MBSR but without a mindfulness component. Consists of nutrition, functional movement, physical activity, and music therapy.
45477637|NCT01299233|Device|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the peripapillar nerve fiber layer with different settings of ART
45477638|NCT03341650|Behavioral|High Pasta|Participants received a personalised diet program considering their food preferences and eating behaviour, based on the Italian guidelines for a healthy and Mediterranean diet and were encouraged to maintain their habitual consumption of pasta (at least 5 times/week). To encourage participants to prepare healthy meals by using high-quality ingredients, participants were provided with a recipe book and dietary guidelines and recommendations.
45477639|NCT03341650|Behavioral|Low Pasta|Participants received a personalised diet program considering their food preferences and eating behaviour, based on the Italian guidelines for a healthy and Mediterranean diet and were encouraged to maintain their habitual consumption of pasta (no more than 3 times/week). To encourage participants to prepare healthy meals by using high-quality ingredients, participants were provided with a recipe book and dietary guidelines and recommendations.
45477640|NCT03558997|Drug|Dupilumab|Dupilumab was administered SC in a single-use, pre-filled glass syringe
45477641|NCT03558997|Drug|Timothy Grass SCIT|Timothy grass extract was administered SC.
45477642|NCT03558997|Drug|Placebo matching dupilumab|Placebo matching dupilumab was prepared in the same formulation without the addition of protein
46046189|NCT05075252|Procedure|laparoscopic lavage|This study aims to investigate the impact of laparoscopic lavage on the incidence of postoperative abscesses stratifying patients on the grade of appendicitis and peritoneal contamination.
45477643|NCT03558997|Drug|Placebo matching SCIT|Placebo matching SCIT was prepared in the same formulation (SCIT diluent) without the addition of Timothy grass extract
45477644|NCT03814421|Drug|intermittent (40mg as a bolus injection daily for 72hours)|Current guidelines recommend an intravenous bolus dose of a proton pump inhibitor(PPI) followed by continuous PPI infusion after endoscopic therapy in patients with high-risk bleeding peptic ulcers. However, recent many studies suggests intermittent low dose PPI infusion might have equal efficacy at preventing peptic ulcer hemorrhage recurrence. So, the present investigator assumed that intermittent administration of proton pump inhibitor will not be different from administration of continuous proton pump inhibitor for the prevention of rebleeding in patients with peptic ulcer bleeding. Also, intermittent proton pump inhibitor administration in patients with high risk of rebleeding (Rockall score 6 points or more) will not be different from prevention of rebleeding compared with continuous proton pump inhibitor administration.
45477645|NCT02493244|Other|Cliradex|Cliradex is simply water and 4-Terpineol, a natural organic compound found Melaleuca alternifolia. The other ingredients in Cliradex are in less than 1% of the formulation and are Glycerin, Polysorbate 20, Polysorbate 80, Carbomer, Triethanolamine.
45477646|NCT03814343|Drug|amphotericin B in 30% DMSO|amphotericin B in 30% DMSO was given to patients in active comparators group for continuous 12 weeks.
45477647|NCT03814343|Drug|30% DMSO|30% DMSO was given to patients in placebo comparators group for continuous 12 weeks.
45477648|NCT03341572|Other|5,10 and 15cmH2O positive end expiratory pressure|every patients undergo 5,10 and 15cmH2O positive end expiratory pressure,and observe the central venous pressure of the mentioned points
45477649|NCT04603274|Procedure|8 sessions of electroacupuncture to the upper limb with carpal tunnel syndrome|All participants will accept 8 sessions of electroacupuncture, 2 days a week for 1 month by experienced physicians. Acupuncture sterile disposable needles 0,25x 0,25 mm will be inserted for 20 minutes at specific acupuncture points to all patients. Electrical stimulation will be applied at specific acupuncture points for 20 minutes.
45477650|NCT03817541|Device|Edmon (reg), BBraun|exhaled propofol will be compared With plasma propofol values
45477651|NCT03341494|Drug|Thalidomide|Gefitinib 250mg Thalidomide 200 MG
45477652|NCT03814265|Behavioral|Laughter yoga|440/5000 Laughter yoga; It is an exercise program that combines breathing techniques with unconditional laughter. During the sessions, laughter is simulated by hand clapping and warm-up exercises and by eye contact with other members in the group and by playing childish games with group members. Most of the time this simulation turns into genuine and contagious laughter. Laughter yoga is based on the argument that the brain cannot distinguish between real and unreal laugh.
45477653|NCT03341416|Device|deep brain stimulation on stimulation - active|bilateral deep brain stimulation reaching the dentate nucleus turned ON - phase active
46046190|NCT05073432|Other|Experimental|Usability of the Discussion Prioritization Tool (DPT) by completing Geriatric Assessment and Conjoint Analysis
46046191|NCT05070780|Device|Robot-assisted examination|evaluation of muscle tone with Robot-assisted perturbation
46046192|NCT05063461|Device|Tetanic stimulation|For each participant, record the first concentration that ANI≥50 after the tetanic stimuli, as the sufficient concentration.
45477654|NCT03341416|Device|deep brain stimulation off stimulation - sham|bilateral deep brain stimulation reaching the dentate nucleus turned OFF - phase sham
45843221|NCT05672784|Procedure|genicular nerve block plus infiltration Between Popliteal Artery and Capsule of Posterior Knee plus standard analgesia|IPACK block will be performed in supine position with flexion of the knee in 45o. low frequency transducer at a depth of 3.5-4 cm will be placed transversely over the medial aspect of the knee, 2-3 cm above the patella, with sliding the transducer proximally and distally to identify the distal part of the shaft of the femur and the popliteal artery ( If the two femoral condyles appear first, proximal sliding of the probe until the humps of the femoral condyles disappeared and the flat metaphysis appeared). Advance the needle in plane toward the space between the popliteal artery and the femur then 15 ml of bupivacaine 0.5% will be injected plus genicular nerve block
45843222|NCT05672784|Drug|standard analgesia (paracetamol and meloxicam)|(paracetamol 1 gm thrice daily and meloxicam (15 mg) every 24).
45843223|NCT05672706|Procedure|CFR and IMR group|Participants will undergo repeat intracoronary adenosine administration during CFR and IMR measurement
45843224|NCT05672472|Drug|Sivelestat sodium|Continuous infusion of sivelestat sodium for 5 days
45843225|NCT05672394|Procedure|Continuous Serratus anterior plane block|in lateral position a linear transducer (10-12MHz, M-Turbo) will be used, The 5th rib is identified in the mid-axillary line. The following muscles are overlying the rib latissimusdorsi ,teres major, and serratus muscle.The needle (22G, 50-mm Tuohy needle) is introduced in-plane targeting the plane superficial to serratus muscle. local anesthetic is injected then a catheter is threaded and . Ultrasound-guided SAPB was done using a serratus anterior catheter Group DL (n=20) received a bolus of 30 mL of 0.25% bupivacaine followed by a continuous infusion of 0.125% bupivacaine at a rate of 7-12 ml/hr according to patient response upon ICU arrival after the stabilization of the clinical status. The infusion was continued until the end of the 1st 24 hours postoperatively .
45843226|NCT05672394|Procedure|Thoracic Epidural|A thoracic epidural catheter was done to the patient while sitting. Tuohy needles are used. Epidural space can be identified by loss of resistance. Injection begins with a negative aspiration and a test dose (3 ccs of 1.5% lidocaine with 1:200,000 epinephrine) .A Continuous epidural technique through the placement of a catheter 3-5 cm beyond the needle is applied. Injection in 5ml increments of 0.25% bupivacaine is used until the block of the required segments achieved ( 10 to 15ml). sensory testing is via pinprick and cold test to detect sympathetic block . Throughout the technique hourly injection of 5 ml 0.25% bupivacaine for maintenance.
45843227|NCT05672394|Drug|Bupivacaine|bupivacaine
45843228|NCT05672394|Drug|lidocaine with epinephrine|3 ccs of 1.5% lidocaine with 1:200,000 epinephrine
45843229|NCT05672160|Diagnostic Test|CT evaluated sarcopenia|At L3 level of CT scan we will measure the area and density of muscles and fat tissue. We devided the patients to sarcopenia and non-sarcopenia groups according to these values.
46046193|NCT05063461|Procedure|Skin incision|Infuse the sufficient concentration for at least 5min of the steady-state period, then surgical stimulus is applied. The surgical stimulus is defined as the first skin incision to establish pneumoperitoneum.
46046194|NCT05057507|Diagnostic Test|Atrial cardiac magnetic resonance imaging|To include assessment of atrial size, shape, function, fibrosis and fat
46046195|NCT05057507|Diagnostic Test|Atrial electro-anatomic mapping|To include assessment of atrial voltage and local activation time
45843230|NCT05672004|Other|PUMP-fit strategy (implementation toolbox)|"Healthcare professionals will receive the ProMuscle training from one of the researchers during a one-hour online meeting (during the control period).~Healthcare professionals will be informed about the platform and toolbox. Healthcare professionals receive a personal log-in for the online platform. Healthcare professionals receive a questionnaire about their readiness for implementation. The results of this questionnaire are directly visible on the platform Within the separate environment of the online platform, healthcare professionals can access their implementation toolbox. The toolbox is tailored to their personal context based on the results of the 'Readinesstool'."
46046196|NCT05057507|Other|Atrial fibrillation symptom questionnaire|To include assessment of atrial fibrillation symptoms and quality of life
46046197|NCT05057507|Diagnostic Test|Patch-based 2 week ambulatory monitor|To assess atrial fibrillation burden post-ablation
46046198|NCT05046444|Diagnostic Test|Next Generation Sequencing|NON-Interventional Observation only study comparing sequencing-only approaches to classical diagnostic methods
46046199|NCT05045534|Drug|Comparison of TB-840 treatment with Placebo|Single dose or Multiple Dose of TB-840 treatment
45477655|NCT03827135|Other|Traditional physical therapy|"Cervical isometrics 10 repetitions×1 set, 4 days/week and targeted muscle strechings (trapezius, scalenes and sternocleidomastoid) 10 repetitions×1 set, 4 days/week.~Total of 4 sessions were given each consisting of 40 mins."
45353424|NCT00797394|Dietary Supplement|Combination of 2007RD01 and saw palmetto lipidic extract|Oral administration of one capsule containing a combination of 250 mg of 2007RD01 (a natural extract) and 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
45353425|NCT00797394|Dietary Supplement|Saw palmetto lipidic extract|Oral administration of one capsule of 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
45353426|NCT00792480|Behavioral|Dietary and lifestyle counseling|"The intervention group will undergo a complete history and physical with attention to prepregnancy weight, current weight, height, and BMI. At the initial visit, they will meet with a registered dietician to receive a standardized counseling session, including information on pregnancy-specific dietary and lifestyle choices. The patient will be instructed to engage in moderate intensity exercise at least 3 times per week and preferably 5 times per week. They will also receive information on the appropriate weight gain during pregnancy using the IOM guidelines. Each subject will meet with the dietician only at the time of enrollment.~At each routine obstetric appointment, the participant's weight will be measured and charted on an IOM Gestational Weight Gain Grid in front of the participant. The healthcare provider will inform the participant if her weight gain was at the appropriate level and counsel her accordingly regarding increasing or decreasing her intake and exercise."
45353427|NCT00681824|Biological|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|Application of a thin layer of FS VH S/D 500 s-apr to the entire length of the suture loop and the adjacent area to at least 5 mm away from the suture line, including all suture holes. After application, the product is to be allowed to polymerize for 3 minutes.
45353428|NCT00681824|Procedure|Standard of care|Standard care: defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen-based dura substitute.
45477656|NCT03827135|Other|Cyriax manipulation|"Experimental group was given cyriax manipulation protocol along with the cervical isometrics and muscle strechings.~Traction with rotation was not given in cases of bilateral arm pain. cervical isometrics 10 repetitions×1 set, 4 days/week and targeted muscle strechings (trapezius, scalenes and sternocleidomastoid) 10 repetitions×1 set, 4 days/week.~Total of 4 sessions were given each consisting of 40 mins."
45477657|NCT03723733|Behavioral|screen high and low triat subjects|use a range of questionniares to screen screen high and low triat subjects (eg. Autism, Anxiety, Depression traits and social network size)
45477658|NCT02492932|Device|Ultrasonography|Ultrasonography evaluation of the internal jugular vein.
45477659|NCT03586609|Drug|Azacitidine|Given SC or IV
46046200|NCT05039424|Procedure|Endoscopic per-oral pyloromyotomy (POP)|Per-oral pyloromyotomy (POP), alternatively knows as gastric per-oral endoscopic myotomy (G-POEM), accomplishes longitudinal division of the pylorus using an endoscope. This procedure involves utilizing endoscopic electrosurgical knife to make an incision in the gastric mucosa and develop a submucosal tunnel to visualize the pyloric ring. The pyloric ring is divided longitudinally, and the mucosotomy incision is sealed with endoscopic clips.
46046201|NCT05039424|Procedure|Diagnostic esophagogastroduodenoscopy (EGD) without pyloric disruption|While under general anesthesia, a standard gastroscope is introduced and a diagnostic upper endoscopy is performed. The operator talks through the procedure steps as if completing POP. The gastroscope is withdrawn and the patient is extubated.
45477660|NCT03586609|Drug|Cladribine|Given IV
45477661|NCT03586609|Drug|Cytarabine|Given SC
46046202|NCT05032131|Biological|ADSVF|Group 1 and 2 : Escalating dose of ADSVF injection (5 millions of cells, 10 millions of cells and 20 millions of cells).
46046203|NCT05028621|Diagnostic Test|Genetic testing|Genetic testing of blood or tissue sample and limited medical information sent to an outside company. Database will link genome sequence data with human trait information, including cancer and other diseases, to be sent to participant's physician.
45353429|NCT00797472|Drug|R-mabHD|An intravenous infusion containing R-mabHD 375mg/m2 will be administered over a period of 3 to 8 hours every week for eight weeks in a row.
45353430|NCT00797472|Drug|ABVD|A combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) will be given intravenously over a period of 3 hours every other week for 12 treatments.
45353431|NCT00991042|Other|blood collect|Five milliliters of venous blood was drawn in the morning from subjects and immediately centrifuged.
45477662|NCT03586609|Drug|Venetoclax|Given PO
45477663|NCT01207037|Procedure|blood samples and scintigraphy|at 3 months, 6 months, 12 months, 18 months and 24 months will allow a clinical evaluation and an additional sampling of blood of 5 mL at each visit Scintigraphy at 6 months and 18 months
45477664|NCT03817619|Drug|Zepatier whole tablet|Single-dose ELB/GZR as a whole tablet in a fasted state.
45477665|NCT03817619|Drug|Zepatier crushed tablet|Single-dose crushed ELB/GZR in a fasted state.
45477666|NCT05480774|Drug|KRG hard capsule|Each subject was given orally 2 KRG hard capsules/day for 12 weeks
45477667|NCT05480774|Drug|Placebo hard capsule|Each subject was given orally 2 placebo hard capsules/day for 12 weeks
45477668|NCT03335410|Other|Non- interventional|Non- interventional
45498254|NCT03447132|Drug|Goserelin 3.6 MG|Only for pre or peri menopausal patient
45353432|NCT00789282|Other|multidisciplinary approach|Provides an integrated, proactive approach to the management of patients with chronic diseases (ie: diabetes and sequelae) Wagner Model- care encompassed in 3 overlapping galaxies: wider community; the health care system; and the provider organization. There are 6 essential elements: community resources and policies; health care organization; patient self-management support; delivery system design; decision support; and clinical information systems.
45353433|NCT00789282|Other|multifactorial approach - for enhanced care group|optimized medical management support for development of enhanced patient self management skills organized proactive follow-up chronic disease management teams
45353434|NCT00789282|Other|reflects current patterns of care|"Continue under the care of their family physician and specialists with referral to diabetic assessment and treatment centers at the discretion of the patient and physician.~Normal manner of care: could attend diabetic self education classes and consultations regarding management of diabetes. Or, participate in other patient self management program of their choice."
45353435|NCT00681668|Drug|Quetiapine|150-800 mg, oral, twice a day (bid)
45353436|NCT00792558|Drug|BMS-817378|Capsule, Oral, Dose escalation to a MTD from a starting dose of 25 mg, once daily, until disease progression/subject discontinuation
45353437|NCT00539188|Drug|N-Acetylcysteine|3000 mg PO (1200 mg AM, 1800 mg PM), 6 weeks
45353438|NCT00539188|Drug|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 6 weeks
45353439|NCT00681590|Dietary Supplement|cholecalciferol (vitamin D)|400 IU daily (low dose)
45353440|NCT00681590|Dietary Supplement|cholecalciferol (vitamin D)|2000 IU daily (high dose)
45353441|NCT04980456|Device|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
45353442|NCT04980456|Device|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
45353443|NCT04980456|Device|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
45353444|NCT05359432|Drug|Empagliflozin|Receiving allocated drug dosage as per clinical needs
45353445|NCT05359432|Drug|Vildagliptin|Receiving allocated drug dosage as per clinical needs
45353446|NCT00755456|Drug|PD solution containing glucose|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 120 days.
45686616|NCT00200902|Other|Placebo|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
45686617|NCT00200902|Behavioral|Interpersonal Clinical Interaction (ICI)|Interaction with and assessment by clinical research personnel on a fixed schedule, with the pharmacotherapeutic alliance assessed both by research personnel and subjects.
45686618|NCT00201448|Biological|Hepatitis A Vaccine|Single dose give IM
45686619|NCT00201448|Biological|Towne CMV Vaccine|Single dose given subcutaneously
46046204|NCT05028309|Other|Mechanical unloading of the Thorax using an external cuirass|External cuirass (i.e., a plastic shell over the thorax) will be used to mechanically unload the chest wall. The cuirass has different operating modes. It can generate a constant negative pressure over the chest wall (e.g., -20cmH2O) or it can be triggered off mouth flow so it can generate a negative pressure on the chest wall during inspiration (e.g., -21cmH2O) and a positive pressure during expiration (e.g., +7cmH2O).
46046205|NCT05026619|Other|Information about age-related fertility|"The following information is provided:~Age and fertility IVF success rates and side effects"
46046206|NCT05026619|Other|Information about policy initiatives|"The following information is provided:~Assisted reproductive technology treatment subsidies Other fertility-related policies"
46046207|NCT05026619|Other|Information about diabetes|"The following information is provided:~Diabetes risk factors and treatment Diabetes-related policies"
46046208|NCT05023070|Drug|Cannabidiol|Cannabidiol 200 mg
46046209|NCT05023070|Drug|Cannabidiol|Cannabidiol 400 mg
46046210|NCT05023070|Drug|Cannabidiol|Epidiolex 400 mg
45353447|NCT00755456|Drug|PD solution containing glucose and L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 120 days.
45498255|NCT03447132|Drug|Placebos|Placebo
45353448|NCT00991120|Device|Chronicle Implantable Hemodynamic Monitor (IHM) System, Chronicle Implantable Cardioverter Defibrillator (ICD)|Surgical implantation of chronic ambulatory hemodynamic monitoring device and intracardiac lead
45353449|NCT00755534|Drug|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
45686620|NCT00201760|Drug|Gemcitabine|1000 mg/m2 IV over 30 minutes on Days 1 and 8.
45686621|NCT00201760|Drug|Trastuzumab|2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.
45353450|NCT00755534|Drug|Capecitabine|Capecitabine (p.o) 2000 mg/m2 (1000 mg/m2 x 2) on day 1-7 every 2 weeks until progression
45353451|NCT00755534|Drug|Cetuximab|Cetuximab(IV) 500 mg/m2 on day 1 every two weeks until progression
45353452|NCT00755534|Drug|Oxaliplatin|Oxaliplatin (I.V) 85 mg/m2 on day 1 every two weeks until progression
45353453|NCT00326599|Drug|carboplatin|Given IV
45353454|NCT00326599|Drug|cediranib maleate|Given orally
45353455|NCT00326599|Drug|gemcitabine hydrochloride|Given IV
45353456|NCT00797550|Biological|Bone Repair Cells (BRCs)|BRCs will be administered during spine fusion surgery
45353457|NCT00797550|Procedure|Autologous bone graft|
45353458|NCT05004688|Biological|Biological/Vaccine: Bacillus Calmette-Guerin (BCG)|Two Bacillus Calmette-Guérin (Japan BCG) vaccine injections spaced four week apart. Each injection will have 0.36-3.9 x 10^6 colony forming units (CFU) reconstituted in 0.1 mL saline.
45353459|NCT00797628|Behavioral|Decide2Quit|Patient intervention website that includes 1) interactive calculators to assess readiness to quit, symptoms and quit plan, 2) motivational content, and 3) links to other high quality information.
45686622|NCT00201760|Drug|Cisplatin|30 mg/m2 IV on Day 1 and Day 8.
45686623|NCT00201838|Drug|Gemcitabine|The starting dose will be 1000mg/m2 IV, weekly x 7 with a one week rest followed by weekly x 3 with one week rest for the remainder of treatment.
45353460|NCT00797628|Behavioral|Smoking Coach|"Control Patients will be referred by paper prescription to the control- Smoking Coach website."
45353461|NCT00750386|Drug|Paclitaxel|175 mg/m2, I.V, every 2 weeks
45353462|NCT00750386|Drug|Carboplatin|Carboplatin AUC, I.V, 5 every 2 weeks
45353463|NCT04972266|Device|AcumenTM Hypotension Prediction Index software|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
45353464|NCT00539032|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
45353465|NCT00539032|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
45353466|NCT00797706|Drug|CHRONSEAL|Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions
45353467|NCT00685802|Drug|Cilostazol 50 mg Tablets|Cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours
45686624|NCT00201838|Drug|Etanercept|Etanercept will be self administered subcutaneously by patients with injections 11 prepared by the investigational pharmacy, beginning 7 days prior to the first dose of gemcitabine and continued twice weekly for the duration of the study.
45686625|NCT00040846|Biological|alemtuzumab|Given IV
45686626|NCT00040846|Drug|fludarabine phosphate|Given IV
45686627|NCT00040846|Radiation|total-body irradiation|Undergo TBI
45686628|NCT00040846|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
46046211|NCT05023070|Drug|Cannabidiol|Cannabidiol 400 mg
46046212|NCT05009771|Drug|Intravenous patient-control analgesia|At the two trial sites, IV-PCA is commonly used with morphine. The device is installed after delivery and removed within 3 days.
45353468|NCT00685802|Drug|Cilostazol (Pletal®) 50 mg Tablets|Cilostazol (Pletal® Tablets, 2 x 50mg) administered after an overnight fast of at least 10 hours.
45353469|NCT00991198|Drug|Topical oxygen|0.5% concentration of Topical oxygen
45353470|NCT00991198|Drug|Topical oxygen|0.25% concentration topical oxygen
45353471|NCT00991198|Drug|placebo|no O2
45353472|NCT01054651|Drug|Artesunate+Sulfamethoxypyrazine/pyrimethamine|
45353473|NCT01054651|Drug|Praziquantel|
45353474|NCT00792714|Drug|Mannitol|400mg twice daily for 7 days
45353475|NCT04961554|Other|loco-regional anesthesia|demonstrate that the mouth opening (measured in millimeters) of a patient treated for mandibular surgery with a very limited opening (defined by a threshold less than 20mm, not allowing the passage of a video laryngoscope blade per route buccal) is more important after locoregional anesthesia of the V3 than before anesthesia.
45353476|NCT04059692|Other|Cervical manipulation intervention|Cervical manipulative technique
45353477|NCT04059692|Other|Placebo intervention|Sham intervention
45353478|NCT00789594|Behavioral|laboratory monitoring alerts|laboratory monitoring alerts
45353479|NCT00789594|Behavioral|Result management module|Result management module
45353480|NCT00354601|Drug|capecitabine|oral capecitabine twice daily on days 1-21
45353481|NCT00354601|Drug|docetaxel|docetaxel IV over 30 minutes on days 1, 8, and 15
45477669|NCT03725995|Drug|Midazolam|Patients received 0.5 mg/kg midazolam, with a maximum dose of 10 mg, Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
46046213|NCT05009771|Drug|Dinalbuphine sebacate|Dinalbuphine sebacate is a prodrug of nalbuphine. With oil-based formulation, the active ingredient releases slowly and the effect lasts longer than nalbuphine. After delivery, a single 150 mg dose of dinalbuphine sebacate is administered intramuscularly.
46046214|NCT05003713|Drug|CORT125236|CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration
46046215|NCT05003713|Drug|Placebo matching CORT125236|Placebo matching CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration
46046216|NCT05003713|Drug|Prednisone|Prednisone tablet 25 mg (20 mg + 5 mg tablets) for oral administration
46046217|NCT04990128|Combination Product|Aspire Needle + Emcyte PureBMC|The Aspire Needle will be utilized to extract the bone marrow and the Emcyte PureBMC will be used to concentrate bone marrow aspirate. The final concentrate will be injected into the hip.
45353482|NCT05360914|Other|Hospital at Home (HaH) treatment|The intervention is a new pathway of providing acut treatment for elderly acute ill patients in their own home. If the patient is randomized to the intervention group, the municipalities acute teams start the treatment. The acute team can take venous blood tests, ECG and bladder scan at home. The acute team handles the treatment at home and follows the patient closely. During the treatment course, the acute team and the ED specialist discuss the treatment process either over the phone or virtually on an iPad, where the patient is also involved. If the specialist would like to see the patient for assessment or send the patient for an X-ray, the specialist informs the acute team that the patient must go to a short check-up in the ED. Here, the specialist examines the patient himself and assesses whether the patient can continue to be treated at home, or whether the patient must be admitted to the hospital due to deterioration of the condition.
45353483|NCT05360914|Other|Standard hospital admission|The active comparator is the standard hospital admission for elderly acute ill patients.
45353484|NCT00792792|Device|Modulated Imaging|Modulated Imaging Spectroscopy
45353485|NCT01563640|Other|permethrin insecticide|commercial permethrin insecticide impregnation of clothing before transmission season
45353486|NCT01563640|Other|washing|normal washing of school uniforms, without permethrin insecticide impregnation
45477670|NCT03725995|Drug|Lidocaine-Midazolam|Patients received a puff of lidocaine 2% in each nostril, after 60 seconds, they received 0.5 mg/kg midazolam, with a maximum dose of 10 mg. , Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
45686629|NCT00040846|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
45686630|NCT00040846|Drug|mycophenolate mofetil|Given PO
46046218|NCT04990128|Drug|Triamcinolone|40 mg (1 mL) triamcinolone and 4 cc of lidocaine 1% that will be injected into the hip.
45686631|NCT00040846|Drug|cyclosporine|Given IV or PO
45686632|NCT00041938|Drug|aspirin|325 mg per day
45686633|NCT00041938|Drug|Warfarin|INR 2.5-3.0; target INR 2.75
45686634|NCT00202930|Drug|anti-CD20 (Rituximab)|4 weekly doses of IV rituxan at 375 mg/m2 on days 1, 8, 15 and 22
45686635|NCT00044044|Drug|Lurasidone 20 mg|Lurasidone 20mg/day tablets
45686636|NCT00044044|Drug|Lurasidone 40mg|Lurasidone 40mg/day tablets
46046219|NCT04981119|Other|Apheresis|Apheresis procedure performed for collection of PBMCs.
46046220|NCT04981119|Diagnostic Test|Next Generation Sequencing (NGS)|NGS on tumor tissue and a matched normal sample for loss of heterozygosity in tumor tissue and tumor tissue markers.
46046221|NCT04981119|Diagnostic Test|Long Range NGS HLA typing|Long range NGS on whole blood to determine germline HLA type.
46046222|NCT04980794|Behavioral|Parent-child intervention|Families (two adult caregivers, child between 4 and 17) receive four interactive, asynchronous psychoeducation modules to review on their own paired with weekly contact with a communication coach and two live sessions with a communication coach to discuss psychoeducation, receive feedback on their interactions, and practice a communication technique.
46046223|NCT04980794|Behavioral|Self-study Intervention|Families (two adult caregivers) receive information in a newsletter format to review on their own, paired with weekly contact from a communication coach to answer questions and direct their attention toward specific topics in the newsletter.
45686637|NCT00044044|Drug|Lurasidone 80 mg|Lurasidone 80mg/day - 2 40mg tablets
45686638|NCT00044044|Drug|Haloperidol 10mg|Haloperidol 10mg/day tablets
45353487|NCT00792870|Behavioral|Evaluation of the Shape Up RI Campaign|The SURI Standard group will receive all of the Shape-Up RI program materials plus an organized directory of useful websites related to healthy eating, exercise, and weight control. The SURI enhanced group will receive the standard Shape-Up RI program materials plus access to 12 behavioral weight loss lessons.
45686639|NCT00044044|Drug|Placebo|Matching Placebo to Lurasdione and Haloperidol
45353488|NCT00750620|Drug|YM178|oral
45353489|NCT03827473|Drug|Abiraterone Acetate|Given PO
45353490|NCT03827473|Drug|Antiandrogen Therapy|Given per standard of care
45353491|NCT03827473|Drug|Docetaxel|Given IV
45353492|NCT03827473|Drug|Prednisone|Given PO
45353493|NCT03827473|Other|Quality-of-Life Assessment|Ancillary studies
45353494|NCT03827473|Other|Questionnaire Administration|Ancillary studies
45353495|NCT00800592|Drug|sildenafil|10 mg sildenafil bolus
45353496|NCT00755690|Behavioral|High/ Low Phosphate diet|Low phosphate diet (750mg/day).
46046224|NCT04980781|Behavioral|Physical exercise and dietary therapy (PED-t)|Behavioral therapy: Physical exercise and dietary therapy (PED-t) is a treatment of bulimia nervosa and binge eating disorder, relying on guided, progressive resistance exercise therapy and dietary therapy (dietary education and group discussions) following a designed therapy manual.
46046225|NCT04980781|Procedure|Implementation program for PED-t in ERC|Participating in a training program for therapists in PED-t; to increase knowledge of eating disorders and to be able to implement and run the PED-t. Training program consists of a therapy manual, digital lectures, and 3 work shops.
45353497|NCT00755690|Behavioral|High/ Low Phosphate diet|Low phosphate diet (750mg/day) with the addition of the phosphate binder aluminum hydroxide (500mg three times per day).
45353498|NCT00755690|Behavioral|High/ Low Phosphate diet|III. High phosphate diet (2000mg /day).
45353499|NCT00991354|Biological|PENNVAX-B|DNA vaccine encoding the Gag, Pol, and Env proteins of HIV
45353500|NCT00991354|Biological|IL-12 DNA plasmids|Adjuvant for HIV vaccines
45353501|NCT00800670|Biological|Ad5Ag85A|Single intra-muscular administration of 10^8 pfu of recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
45353502|NCT00800670|Biological|Ad5Ag85A|Single intra-muscular administration of 10^9 recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
45353503|NCT00755768|Behavioral|additional review by dietician|
45686640|NCT00112918|Biological|Bevacizumab|Administered as an intravenous infusion over 30 - 90 minutes.
45686641|NCT00112918|Drug|Capecitabine|Film-coated tablets
45686642|NCT00112918|Drug|5-Fluorouracil (5-FU)|Administered as either a bolus injection or continuous intravenous infusion over 22 hours.
45353504|NCT05360836|Other|Conservative treatment via telerehabilitation|"Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, massage application for 5 minutes, passive, active assistive normal range of motion. Ice application. After 4 weeks strenghtening exercise. The treatment time 8 weeks."
45353505|NCT05360836|Other|Conservative treatmen + motor imagery|"Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, 5-minute massage, passive, active auxiliary normal range of motion. Ice application. Strengthening exercise after 4 weeks. The duration of treatment is 8 weeks. This group applies motor images for a maximum of 5 minutes. They will implement functionality-based motor images."
45353506|NCT00797784|Drug|etanercept(Enbrel®)|etanercept(Enbrel®) 50mgs subcutaneous (SC) injections twice weekly for 20 weeks
45353507|NCT03983395|Biological|ISB 1302 250 ng/kg|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 250 ng/kg
45353508|NCT03983395|Biological|ISB 1302 325 ng/kg|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 325 ng/kg
45353509|NCT03983395|Biological|ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 425 ng/kg on D8, D15, D22
45353510|NCT03983395|Biological|ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, D15, D22
45477671|NCT03725995|Drug|Placebo|Patients received saline 9% (placebo), 0.5 mg/kg, with a maximum dose of 10 mg, Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
45686643|NCT00112918|Drug|Leucovorin calcium|Administered as a 200 mg/m^2 infusion over 2 hours.
45686644|NCT00112918|Drug|Oxaliplatin|Administered as an intravenous infusion over 2 hours.
45686645|NCT00046228|Drug|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
45353511|NCT03983395|Biological|ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 700 ng/kg on D15, D22
45353512|NCT03983395|Biological|ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 900 ng/kg on D15, D22
45353513|NCT03983395|Biological|ISB 1302 escalating doses,1200 ng/kg D15,22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 700 ng/kg on D8, and 1200 ng/kg on D15, D22
45353514|NCT03983395|Biological|ISB 1302 at the MTD and/or RP2D dose|ISB 1302 at the MTD and/or RP2D dose in separate groups in the Q1W and/or the Q2W dose regimen.
45353515|NCT00747968|Drug|Byetta, Exenatide|Drug: Exenatide or placebo Dosage form: Infusion Dosage: Exenatide (Eli Lilly/Amylin Pharmaceuticals) 0.066 pmol*kg-1*min-1 Duration: 5 hours Frequency: Drug given once, placebo given once
45353516|NCT00793026|Drug|Dermacyd Breeze Pocket BR (Lactic Acid)|Dermacyd Breeze Pocket BR (Lactic Acid) during 21 consecutive days
45353517|NCT00755924|Dietary Supplement|Vinegar|Apple cider vinegar 2 TBlsp/day
45353518|NCT00755924|Other|Placebo|Water placebo colored with balsamic vinegar
45353519|NCT00797940|Drug|IL-4PE|Subjects will receive intratumoral infusion of PRX321 administered via convection-enhanced delivery (CED) at a concentration of 1.5 μg/mL and a total volume of 60 mL over 2 to 7 days.
45353520|NCT00800748|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a was administered at a dose of 180 mcg SC weekly for 48 weeks to participants with genotype 1, 4, 5, 6 and to participants with HIV co-infection, or for 24 weeks to participants with genotype 2 and 3.
45477672|NCT01299311|Behavioral|NEAT|4 days of everyday activities, including 4 hours of walking, 8 hours of sitting, 2 hours of standing, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
45353521|NCT00800748|Drug|Ribavirin|Ribavirin was administered at a dose of 1000-1200 mg PO daily for 48 weeks to participants with genotype 1, 4, 5, 6 or 800 mg PO daily for 24 weeks to participants with genotype 2 and 3.
45686646|NCT00046228|Drug|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
45686647|NCT00046228|Drug|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
46046226|NCT04961645|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|"TMS is a safe and noninvasive method for affecting brain function relying on the properties of electromagnetic induction. Action potentials are triggered in neurons, along with a subsequent period of deactivation. Normal ongoing brain activity is disrupted providing a way for investigators to produce a transient and reversible period of brain disruption.~Participants will be seated comfortably in a chair and asked to complete either a simple computer-based task or a simple behavioral task that will require them to walk around in a small room. During or just before each of these tasks, participants will receive rTMS. In rTMS, a small plastic coil is placed next to the participant's head. The coil will be placed over the relevant brain region identified during the participant's fMRI scan. The coil will then generate a magnetic pulse, and stimulation will occur. The entire visit will last about one and a half hours."
46046227|NCT04955002|Other|No intervention|No intervention
46046228|NCT04953780|Drug|Calaspargase pegol-mknl|Calaspargase pegol-mknl
46046229|NCT04945369|Other|clinical and biological measurements and questionnaires|"Blood and urinary samples collection for evaluation of insulin resistance and of renal function analysis.~Assessment of body composition by BOP-POD and by impedancemetry. Assessment of pulse wave by popmetre. Questionnaires for analysis of eating behaviour and of neuropsychological development."
45353522|NCT05426174|Biological|mRNA NA vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
45353523|NCT05426174|Biological|High Dose Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
45353524|NCT00345397|Device|Percutaneous endoscopic colostomy (PEC) tube|PEC placement for antegrade enemas uses commercially available PEG tubes
45686648|NCT00046228|Drug|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
45686649|NCT00046228|Drug|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
45477673|NCT01299311|Behavioral|Exercise|4 days of activity program, including 1 hour biking (exercise), 13 hours of sitting, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
45477674|NCT03341260|Drug|Diclofenac Potassium 50mg Tab.|A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
45477675|NCT03341260|Drug|Placebo|A placebo will be taken one hour before initiation of endodontic treatment.
45477676|NCT03052400|Drug|Mifepristone 600 mg daily|Glucocorticoid receptor antagonist
45477677|NCT03052400|Drug|Placebo|Matching placebo
45353525|NCT00793260|Behavioral|Enhanced Support|"The Enhanced-Support Group program used lower risk thresholds for targeted outreach of individuals with chronic illness and for those likely to face discrete surgical interventions. Individuals at high financial risk but without one of the five chronic conditions were included in the Enhanced-Support Group.~The Enhanced-Support Group received up to five initial reach attempts while the Usual-Support Group received up to three attempts.~The Enhanced-Support Group used a 'tight loop' management structure including detailed, timely coach level feedback reports on efficiency and effectiveness."
45353526|NCT00793260|Behavioral|Usual-Support|Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
45477678|NCT01301261|Drug|sugammadex|Sugammadex 2 mg/kg when a two count of train of four appears
45353527|NCT00756080|Drug|citrulline|0.06 G/kg three times/day during 7 days
45353528|NCT00756080|Drug|placebo|placebo (equimolar mixture of 6 non essential amino acids: alanine, aspartate, glycine, histidine, proline, serine) 0,006 g/kg 3 times/day during 7 days
45353529|NCT00798252|Drug|Capecitabine|Tablets, Oral, Dose escalation to a MTD from a starting dose of 850 mg/m², twice a day (BID) x 14d per cycle, until disease progression
45477679|NCT01301261|Drug|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg are given when a posttetanic count 1-3 appears
45353530|NCT00798252|Drug|Doxorubicin|IV, Dose escalation to a MTD from a starting dose of 40 mg/m², Q3wks, until disease progression
45477680|NCT01301261|Drug|Sugammadex 16mg/kg|Sugammadex 16 mg/kg three minutes after the injection of cis-atracurium
45477681|NCT03723577|Device|Fibrillar collagen powder dressing|A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.
45477682|NCT03341182|Procedure|Fluoroscopically Guided Lumbar Transforaminal Epidural Injections|Lay the subject down on the stomach and hold the pillow on the stomach. The skin of the injection area is sterilized by aseptic method and covered with aseptic pouch. After confirming the level of he vertebrae around the C-arm and aligning the anteroposterior view of the endplate of the vertebral body, rotate the C-arm 20~30 degrees diagonally in the direction to be performed. After confirming the best Scotty dog view, confirm the final target point at 6 o'clock directly below the pedicle. At this position, the skin point is marked on the skin. And then both groups proceed in parallel with the beam direction of the transducer with the tunnel view technique until the needle reaches the back of the vertebral body at the level of the spinal nerve roots. At this time group A uses a mirror and group B dose not. The final reach of the target point (ideal depth) is confirmed through the anterior and posterior views and lateral views.
45477683|NCT03341182|Procedure|conventional manner|A portable mirror is located at the side of surgical table and used in this procedure.
45477684|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
45477685|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 12 days. Last dose given 8 hrs before allergen challenge
45477686|NCT01299467|Drug|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
46046230|NCT04943484|Procedure|imaging fluorescence NIR/ICG|"Preoperative upper GI endoscopy (UGE) UGE with submucosal injection of 2ml of ICG 0.125mg/ml solution to four peritumoral sites 15-20 hours before surgery Surgery D2 Distal gastrectomy with dissection of 1, 3, 4sb, 4sd, 5, 6, 7, 8a, 9, 11p, 12a lymph node stations (LNS) D2 Total gastrectomy with dissection of 1, 2, 3, 4sa, 4sb, 4d, 5, 6, 7, 8a, 9, 11p, 11d, 12a LNS Intraoperative NIR/ICG technology, change of surgical conduct (CSC) A visualization of the operative field (OF) with NIR/ICG technology is performed at the beginning of surgery and before to dissect each LNS. Subsequently, surgery is performed with the naked eye.~At the end, a visualization of the OF is performed using NIR/ICG technology to verify whether residual lymph nodes in each D2 nodal station exist. CSC is defined as the occurring of the following situation: in case of persistence of nodal fluorescence in D2 nodal stations, the completion of the dissection of the residual nodal fluorescent structures."
45477687|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
45477688|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 12 days. Last dose given 8hrs before allergen challenge
45686650|NCT00046228|Drug|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
45686651|NCT00205504|Drug|Ortho Tri Cyclen|Ortho Tri Cyclen, one tablet daily, for 6 cycles
45686652|NCT00205660|Other|Stayers|Participants remain on their current antipsychotic.
45686653|NCT00205660|Other|Switchers|Subjects are randomized to switch to aripiprazole from their current antipsychotic.
45477689|NCT01299467|Drug|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
45477690|NCT03730285|Device|Telemedicine|Installation of videotelephone with broadband in patient's home
45686654|NCT00113230|Drug|Avastin (Bevacizumab, RHUMAB VEGF)|Starting Dose 5 mg/kg intravenously on day one of radiotherapy, given every 2 weeks +/- 2 days for a total of 3 doses.
45686655|NCT00113230|Drug|Capecitabine|900 mg/m^2 by mouth twice a day during days of radiation for all five weeks of therapy.
45477691|NCT03335176|Behavioral|Endurance ad Resistance Training Exercise|Patients received a 6-week tele-supervised rehabilitation with 3 exercise sessions per week
45353531|NCT00798252|Drug|Ixabepilone|IV, Dose Escalation to a MTD from a starting dose of 32 mg/m², Q3wks, until disease progression
45353532|NCT00798252|Drug|Docetaxel|IV, Dose escalation to an MTD from a starting dose of 60 mg/m², Q3wks, Until disease progression
45353533|NCT00798252|Drug|Paclitaxel|IV, Dose escalation to an MTD from a starting dose of Paclitaxel 135 mg/m², Q3wks, Until disease progression
45843231|NCT05672004|Other|Implementation as usual|"First, healthcare professionals will receive the ProMuscle training from one of the researchers during a one-hour online meeting.~At the end of the training healthcare professionals are informed about the mandatory conditions to implement ProMuscle (champion, material, approval of management).~Healthcare professionals receive a questionnaire about their readiness for implementation. The results of this questionnaire are directly visible. Results contain a graph of possible barriers for implementation in their practice.~Hereafter they will be instructed to start with implementation as usual."
45353534|NCT00798252|Drug|Brivanib alaninate|Tablets, Oral, Dose escalation to a MTD from a starting dose of 400 mg, daily (QD), until disease progression
45353535|NCT00748046|Drug|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight.
45353536|NCT00326209|Drug|Encapsulated Mesalamine Granules (eMG)|eMG capsules will be administered per dose and schedule specified in the arm.
45353537|NCT00537940|Drug|Pregabalin|150, 300, 450 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
45353538|NCT00537940|Drug|Gabapentin|300, 600, 1200, 2000 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
45353539|NCT00661362|Drug|Saxagliptin|Oral tablet, once daily for 24 weeks
45353540|NCT00661362|Drug|Placebo|oral tablet, once daily for 24 weeks
45353541|NCT00661362|Drug|Metformin|oral tablet, once daily for 24 weeks
45353542|NCT00991432|Device|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS concurrent with space maintenance devices for soft tissue management on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments approximately 6 months after surgery. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
45353543|NCT00748202|Drug|C1-Esterase Inhibitor|1000 I.E.
45353544|NCT00325897|Drug|Macrolide Antibiotic (Azithromycin)|Azithromycin (daily capsule, 250 mg for 12 months)
45353545|NCT00325897|Drug|Placebo|Placebo taken on a daily basis
45353546|NCT00800826|Drug|dexmedetomidine|
45353547|NCT04926142|Device|Implantation of Holter device|Implantation of a Holter device (Reveal Linq, Medtronic) for telemonitoring of cardiac rhythm
45353548|NCT04926142|Procedure|Percutaneous PFO closure|Patients will undergo percutaneous closure of patent foramen ovale
45353549|NCT00756392|Procedure|3T MR Spectroscopy|A Magnetic Resonance Spectroscopy (MRS)study of a patient's prostate will be conducted with the 3 Tesla Philips Intera Nuclear Magnetic Resonance (NMR) scanner before and after filling the rectum with barium. Scan duration from Preparation to Completion will be approximately 30 minutes. The spectra will be acquired without and with the presence of Barium solution to compare to see if the latter is advantageous.
45353550|NCT03989089|Drug|Pembrolizumab|"The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda® development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumour type.~All participants who off study treatment with stable disease (SD) or better may be eligible for up to an additional 17 cycles (approximately 1 year) of pembrolizumab treatment if they progress after stopping study treatment from the initial treatment phase. This retreatment is termed the Second Course Phase of this study and is only available if the study remains open and the participant met certain criteria as stated in the protocol."
45843232|NCT05607342|Drug|Osanetant|To evaluate the effect of Osanetant on the testosterone levels.
45843233|NCT05597904|Genetic|Genetic predisposition|Assessment of genetic predisposition to various celiac disease phenotypes. No intervention.
46046231|NCT04939545|Drug|Ropivacain|"Intercostal continuous loco-regional ropivacaine (2 mg/ml) administration over an elastomeric pump through a surgically placed intercostal catheter (ICC) for a maximum of 72h.~As concomitant treatments a standardized anesthesia protocol including intravenous continuous application of propofol and remifentanil is used. Additionally, i.v. metamizol at a dose of 1 g will be administered at the end of surgery as a standard, if not contraindicated.~In a standardized postoperative pain protocol the use of basic oral medication is documented as part of the postoperative follow-up and consists of:~ibuprofen 3 x 400 mg p. o. for 3 days, metamizol 4 x 1 g p. o. for 3 days; if ibuprofen and/or metamizol contraindicated then paracetamol p. o. 3 x 1g for 3 days will be administered; morphine 10 mg p. o. 6 times daily will be given on a patient demand basis."
45353551|NCT00756626|Behavioral|Bottle Weaning Intervention|WIC Nutritionist will deliver bottle weaning intervention education with participants in intervention group at 12 month baseline and at 15, 18, 21, and 24 month follow-up as needed
45353552|NCT00793338|Drug|Sildenafil|Sildenafil 20mg three times a day for 3 months.
45353553|NCT05406856|Radiation|External beam radiation therapy: IMRT/VMAT|EBRT is given to a total dose of 45 Gy in 25 daily fractions of 1.8 Gy in 5 weeks. Involved nodes are boosted using a simultaneous integrated boost (SIB) to reach a total EBRT plus brachytherapy dose of 60 Gy EQD2 to provide high nodal control.
45353554|NCT05406856|Radiation|External beam radiation therapy: IMPT|EBRT is given to a total dose of 45 Gy in 25 daily fractions of 1.8 Gy in 5 weeks. Involved nodes are boosted using a simultaneous integrated boost (SIB) to reach a total EBRT plus brachytherapy dose of 60 Gy EQD2 to provide high nodal control.
45353555|NCT05406856|Drug|Cisplatin|The standard chemotherapy regimen is weekly cisplatin (40 mg/m2) for 5 weeks.
45353556|NCT05406856|Radiation|Brachytherapy|Brachytherapy is performed using a high-dose rate (HDR) after loading system to deliver a boost to any residual tumor and the cervix. Brachytherapy dose is (21-) 28 Gy in fractions of 7 Gy specified at 100% isodose around the high-risk CTV, according to the EMBRACE-II prescription protocol. The aim is to reach an equivalent dose in 2 Gy fractions including EBRT (EQD2_D90) of the high-risk CTV between 90-95 Gy, using MRI-guided adaptive brachytherapy.
45353557|NCT00756704|Behavioral|Smoking cessation guideline implementation|"a tutorial on brief cessation counseling for ED nurses and physicians~use of an ED algorithm that includes recommended tobacco counseling items~fax referral of motivated smokers to Quitline Iowa for proactive telephone counseling plus free nicotine replacement therapy~group feedback to ED staff"
45353558|NCT00798408|Dietary Supplement|Fluid Supplement|The fluid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation*1.5 activity factor, volume, and amount and type of macronutrients
45353559|NCT00798408|Dietary Supplement|Solid Supplement|The solid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation*1.5 activity factor, volume, and amount and type of macronutrients
45353560|NCT00344773|Drug|Gefitinib|250mg tablet oral tablet once daily
45353561|NCT02561546|Drug|p53 gene therapy|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
45353562|NCT02561546|Drug|Trans-catheter embolization|Trans-catheter embolization alone
45353563|NCT00991588|Procedure|PCL, posterolateral reconstruction|The operative procedures involve either a single- or double-strand PCL graft which is usually harvested from the patient's knee. In cases of multiple ligament procedures, allograft tissues may be used which are obtained from tissue banks certified by the American Associate of Tissue Banks and that have passed FDA inspection. The posterolateral structures, including the fibular collateral ligament (FCL), are reconstructed with one or two grafts, depending upon the severity of damage encountered at surgery.
45353564|NCT02554344|Drug|Curcumin|Patients will receive 500mg of curcumin administered orally, twice a day for 12 weeks.
45353565|NCT00750854|Dietary Supplement|NEM Formulation X|see Treatment Arms
45353566|NCT00750854|Dietary Supplement|NEM Formulation Y|see Treatment Arms
45382216|NCT05229783|Procedure|White light endoscopy with Seattle protocol|Inspection of the Barrett's esophagus using the white light modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions, and then systemic quadrantic biopsies every 2 centimeters from the esogastric junction to the top of the Barett's esophagus (Seattle protocol)
45382217|NCT05224622|Diagnostic Test|VOX|Breath exhalation into the mouthpiece of the VOX breath diagnostic device.
45477692|NCT03341104|Drug|Bupivacaine liposome|Replace bupivacaine with bupivacaine liposome
45477693|NCT03538951|Drug|10% VDA-1102|200 mg twice-daily for 12 weeks
45477694|NCT03538951|Drug|20% VDA-1102|200 mg once-daily for 12 weeks
45477695|NCT03335098|Drug|Bortezomib|Six 4-week cycles
45477696|NCT03341026|Other|Metronom CGM device|Patient receives three Metronom CGM devices on day 1. On day 1, 4, 7 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
45477697|NCT03341026|Other|Metronom CGM device|Patient receives three Metronom CGM devices on day 1. On day 1, 7, 10 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
45353567|NCT01054963|Behavioral|peer mentor training|A quasi-experimental, before and after study design is proposed to obtain data for planning and implementing a larger-scale study. A training workshop for individuals with IA to become peer mentors will increase peer mentors' confidence and skills to provide one-on-one support to individuals with EIA. Using a combination of lectures, experiential learning and question/answer sessions, peer mentors will learn and practice informational, emotional, appraisal support techniques and skills (communication skills, problem-solving strategies, use of decision tools). Training will be conducted face-to-face, in small-group format by research team and others (2 sessions approx. 5 hours each), in a private meeting room at SHSC. Peer mentors will then provide support to individuals newly diagnosed with IA for 12 weeks (once per week) by telephone and /or face-to-face. Peer mentors will receive ongoing support from the research team (telephone, meetings).
45353568|NCT02554422|Device|PalpEar|Palpation of the middle-ear ossicles using the PalpEar device, to measure mobility of the ossicle chain
45353569|NCT01055041|Drug|inhaled budesonide and formeterol plus oral montelukast|1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening
45353570|NCT01055041|Drug|inhaled budesonide and formeterol plus oral doxophylline|1st two weeks -run in period, all participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet doxophylline sustained release(400 mg/day)orally in the morning
45353571|NCT01055041|Drug|Doubling the dose of inhaled budesonide and formeterol|1st two weeks -run in period, all groups participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
45353572|NCT02561624|Behavioral|Behaviour change communication via text message|
45353573|NCT01060813|Dietary Supplement|Leucine supplements|leucine supplements
45353574|NCT00793416|Device|Shunt flow detection|Shunt flow detection based upon ShuntCheck results compared to radionuclide test results
45353575|NCT00748280|Procedure|One-visit root canal therapy|Teeth were isolated, caries was removed and access cavities were prepared. Canal preparation was conducted using step-back technique. The working lengths were determined and confirmed by radiographs. The minimum size file for preparing the working length was size ISO #25 K-file to within 0.5-2 mm of the radiographic apex of the root. During hand instrumentation, canals were frequently irrigated with adequate amount of sterile normal saline solution. The root canals were filled with multiple gutta-percha cones and sealer using lateral condensation technique. Placing a cotton pellet in the pulp chamber, the access cavity was temporarily filled. The treatments of all samples were performed one-visit.
45353576|NCT00748280|Procedure|pulpotomy|Pulpotomy was performed with a large round bur in a high-speed handpiece with copious irrigation; removing inflamed pulp tissue to stump level. Hemostasis was achieved by irrigation of the cavity with sterile normal saline and application of small pieces of sterile cotton pellets. The blood clot-free pulpal wound was covered with approximately 2 mm layer of endodontic bio-materials, a sterile wet cotton pellet was then placed over the MTA/CEM cement and the cavity sealed with Cavit.
45353577|NCT00798642|Behavioral|Hypnotherapy|8 weeks of gut-directed hypnotherapy
45353578|NCT00798642|Behavioral|Standard care|8 weeks of standard of care
45353579|NCT00798642|Behavioral|Mind Body Therapy|8 weeks of mind-body therapy
45353580|NCT00325819|Drug|Acetaminophen|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
46046232|NCT04939545|Drug|NaCl 0.9%|"Intercostal continuous loco-regional placebo solution (NaCl 0,9%) administration over an elastomeric pump through a surgically placed intercostal catheter (ICC) for a maximum of 72h. As concomitant treatments a standardized anesthesia protocol including intravenous continuous application of propofol and remifentanil is used. Additionally, i.v. metamizol at a dose of 1 g will be administered at the end of surgery as a standard, if not contraindicated.~In a standardized postoperative pain protocol the use of basic oral medication is documented as part of the postoperative follow-up and consists of:~ibuprofen 3 x 400 mg p. o. for 3 days, metamizol 4 x 1 g p. o. for 3 days; if ibuprofen and/or metamizol contraindicated then paracetamol p. o. 3 x 1g for 3 days will be administered; morphine 10 mg p. o. 6 times daily will be given on a patient demand basis."
46046233|NCT04931836|Behavioral|Physical Activity Intervention|Three walking sessions/week for a total of 8 weeks (24 total sessions) - Walking sessions will either take place on new commercial treadmills in the Epidemiology Clinical Research Center or remotely at or around a participant's home. Regardless of the walking location, walking sessions will be 30 min in duration during intervention weeks 1 through 4 and a minimum of 45 min each during intervention weeks 5 through 8.
46046234|NCT04923646|Other|Primer|Mailed postcard notifying Veteran of upcoming FIT kit for annual CRC screening.
46046235|NCT04907383|Other|quality of life|QoL assessment
46046236|NCT04907370|Drug|PD-1 blocking antibody|"IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~IMRT phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of IMRT or CCRT and continue every 3 weeks for 3 cycles till the end of IMRT.~Adjuvant PD-1 blocking antibody: every 3 weeks × 11 cycles; 240 mg, day 1"
46046237|NCT04907370|Drug|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
46046238|NCT04907370|Drug|Cisplatin (80mg/m2)|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
45353581|NCT00325819|Other|placebo|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
45353582|NCT00801216|Drug|High-dose sequential chemotherapy and autologous transplant|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 & 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
45353583|NCT00756782|Drug|TAC-101|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
45353584|NCT00756782|Drug|Placebo|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
45353585|NCT00748358|Drug|sunitinib|37.5 mg orally once daily, continuously, for 6 cycles of 6 consecutive weeks.Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individual safety and tolerability.
45353586|NCT00751088|Procedure|MiniArc positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. MiniArc will be placed by means of curved single use needle. Incision closure."
45477698|NCT03723499|Other|Medical data collection|Medical data collection by medical record will be collected: demographics data, medical history, clinical symptoms, smoking, type of endoscopic method, complete treatment or not, type of surgeries if yes, anatomopathology of the injury and recurrence if yes
46046239|NCT04907370|Drug|Cisplatin (100mg/m2)|Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
46046240|NCT04907370|Radiation|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
45353587|NCT00751088|Procedure|TVT secur system positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. TVT Secur System will be placed by means of two curved, stainless steel, single use introducers. Incision closure."
45353588|NCT00751088|Procedure|Ajust positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. Ajust will be placed by means of a safe hook geometry introducer. Incision closure."
45498256|NCT03622879|Behavioral|MT|A customised angle-adjustable frame with a mirror board (60 × 90 cm) will be used. All subjects are instructed to perform hip flexion/abduction, knee flexion/extension and ankle dorsiflexion/plantarflexion on the intact-limb during a 15 minutes period.
46046241|NCT04906746|Drug|Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.|There will be intra-patient dose escalation of ruxolitinib in every patient enrolled on study.
46046242|NCT04903054|Biological|Lulizumab|Lulizumab is a pegylated, humanized monovalent domain antibody construct that is specific for human cluster of differentiation CD28.
46046243|NCT04903054|Drug|Tacrolimus|Standard of Care: Renal transplant rejection prophylaxis.
46046244|NCT04903054|Biological|Thymoglobulin®|Standard of Care: Renal transplant rejection prophylaxis.
46046245|NCT04903054|Drug|Methylprednisolone|Standard of Care: Renal transplant rejection prophylaxis.
46046246|NCT04903054|Drug|Mycophenolate Mofetil|Standard of Care: Renal transplant rejection prophylaxis.
46046247|NCT04903054|Drug|Prednisone|Standard of Care: Renal transplant rejection prophylaxis.
46046248|NCT04901702|Drug|Onivyde|Given intravenous on Days 1 and 8
46046249|NCT04901702|Drug|Talazoparib|Given orally twice on Day 1 (daily maximum is 1000mcg/day), then daily on Days 2-6
46046250|NCT04901702|Drug|Temozolomide|Given once a day on Days 1-5.
46046251|NCT04897321|Drug|Fludarabine|Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis. Intravenous
46046252|NCT04897321|Drug|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA. Intravenous
45686656|NCT00113230|Radiation|Radiation Therapy|45 Gy in 25 fractions to the pelvis followed by 5.4 Gy as a boost dose to the primary tumor with margin, for a total dose of 50.4 Gy over 28 treatment days.
45843234|NCT05572242|Procedure|Premolar extraction and socked preservation with L-PRF|"Partially edentulous patients in need of a single-tooth extraction in the premolar region[ (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with elevators and then carefully extracted with forceps without raising a flap.~L-PRF group will use 2-5 PRF clots, depending on the size of the socket, which will be inserted and compressed with a large plunger until they reach the alveolar crest. The site will thereafter be covered with L-PRF membranes. Then, crossed horizontal mattress suture will be placed followed by single interrupted sutures for stabilization. No efforts will be undertaken to obtain primary wound closure. The grafted socket will be left to heal for 4 months.~After 4 months of socket preservation, a dental implant will be inserted into the socket. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration."
45843235|NCT05572242|Procedure|Premolar extraction and socked preservation with Xenogenic bone and collagen membrane.|"Partially edentulous patients in need of a single-tooth extraction in the premolar region (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with straight and angled elevators and then carefully extracted with forceps without raising a flap.~In the control group, the socket will be grafted with xenogeneic bone substitute material (up to the palatal/lingual bone crest) and covered with a collagen matrix. Single interrupted sutures will be placed to stabilize the collagen matrix. Sutures will be removed at 7-10 days. The grafted socket will then be left to heal for a period of 4 months.~The xenogenic material will be Bio-Oss Collagen® and collagen matrix Bio-Gide® .~After 4 months of socket preservation, a dental implant will be placed. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration."
45843236|NCT05464992|Other|Additional CEST sequences during PET/MRI exam|CE-Marked Advanced Technology Software Modules (ATSM) for Magnetic Resonance Imaging from General Electric Healthcare
45843237|NCT05407818|Drug|JNJ-63733657|JNJ-63733657 will be administered as an IV infusion.
45843238|NCT05392296|Other|Power ball|experimental group getting the power ball training with conventional treatment.
45843239|NCT05392296|Other|isometric hand grip strengthening exercises|conventional treatment (isometric hand grip training exercises)
45843240|NCT05326464|Drug|Tofacitinib 10mg|10 mg given orally twice daily until evidence of progression, intolerance of treatment, withdrawal of consent, or death.
45686657|NCT00049036|Biological|rituximab|Given IV
45686658|NCT00049036|Drug|etoposide|Given IV
45843241|NCT05274828|Device|H7-Coil Deep TMS for CUD|The Study group will receive dTMS treatment three times a day for ten days.
45686659|NCT00049036|Drug|doxorubicin hydrochloride|Given IV
45843242|NCT05194956|Procedure|Intraoral scan|An intraoral scan is multiple images taken using an intraoral scanning device which results in a digital mould being taken of the participants mouth and bite. It works by systematically placing the scanner tip over the teeth and gums, whilst it constructs an image on screen.
45843243|NCT05194956|Procedure|Alginate impressions|Alginate impressions are the conventional method of creating dental moulds for orthodontic records. A plastic tray is filled with an alginate material, which is placed into the mouth to take a mould of the teeth. This requires two moulds for both top and bottom arches. In addition, the participant would also bite into a warm piece of wax to record their bite.
45498257|NCT03622879|Device|TENS|TENS will be delivered to the common peroneal nerve of the paretic leg. The stimulation frequency will be 100Hz and with an intensity just below the motor threshold.
45686660|NCT00049036|Drug|vincristine sulfate|Given IV
45686661|NCT00049036|Drug|prednisone|Given orally
45686662|NCT00049036|Drug|cyclophosphamide|Given IV
45686663|NCT00049036|Other|laboratory biomarker analysis|Correlative studies
45686664|NCT00212446|Device|Electrical Intervention (EI)|Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
45686665|NCT00049504|Drug|cyclophosphamide|Given IV
45686666|NCT00049504|Drug|fludarabine phosphate|Given IV
45686667|NCT00049504|Drug|tacrolimus|Given IV or orally
46046253|NCT04897321|Drug|MESNA|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide
46046254|NCT04897321|Drug|B7-H3 CAR T cells|The study participant will receive B7-H3-CAR T cells by vein, through either an IV or a central line.
46046255|NCT04894747|Dietary Supplement|Bolus ingestion of protein|Ingestion of 25g of protein
46046256|NCT04892147|Behavioral|Mobility-Oriented Behavioral Activation|12-weeks of mobility-oriented behavioral activation group
46046257|NCT04890249|Device|Investigational IOL Model C1V000|IOL replaces the natural lens removed during cataract surgery.
46046258|NCT04890249|Device|Investigational IOL Model C2V000|IOL replaces the natural lens removed during cataract surgery.
46046259|NCT04890249|Device|Control IOL Model ICB00|IOL replaces the natural lens removed during cataract surgery.
45353589|NCT00751088|Procedure|Tension free vaginal ttape|Patient placed in lithotomic position. 15 mm vaginal incision below urethral meatus. Dissection of the paraurethral space on each side of the incision and of the bladder from the inferior edge of the pubis. Transversal 10 mm skin incisions at level of superior pubic margin. Top-down or bottom-up approach passage of the needles and sling. Adjustment of sling tension. Closure of vaginal and skin incisions.
45353590|NCT00748436|Drug|betahistine dihydrochloride|(24mg tablet Betahistine + placebo tablet) BID per os 12 weeks
45353591|NCT00748436|Drug|betahistine dihydrochloride|(24mg tablet Betahistine + 24mg tablet Betahistine) BID per os 12 weeks
45353592|NCT00748436|Drug|placebo|(placebo tablet + placebo tablet) BID per os 12 weeks
45477699|NCT03725917|Other|Physiotherapy protocol|The intervention will consist of a physiotherapy protocol twice a week for twelve weeks. The protocol will be done in three phases, constituting each month, a phase of the protocol. The first two phases will include therapeutic exercise of progressive difficulty and manual therapy, while the last phase will include only one week of manual therapy and therapeutic exercise, the last three weeks being composed only of therapeutic exercise
45477700|NCT03120598|Behavioral|ATTC strategy|Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
45686668|NCT00049504|Drug|mycophenolate mofetil|Given orally
46046260|NCT04881838|Drug|P regimen|Dexamethasone 5 mg/m2 Days 1 and 2; 10mg/m2 Day 3 to 5; Cyclophosphamide 200 mg/m2 Days 1 and 2 Intrathecal therapy Day 1
45353593|NCT00751244|Behavioral|Trauma Affect Regulation: Guide for Education and Therapy|"Trauma Affect Regulation: Guide for Education and Therapy (TARGET; Ford & Russo, 2006) is a manualized gender-specific treatment for PTSD. TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences, summarized by a mnemonic (FREEDOM), e.g., Focusing (F), Recognizing current triggers. TARGET also involves creative arts activities, i.e., personalized lifelines via collage, drawing, poetry, and writing that may include traumatic experiences but emphasize life story narrative reconstruction with no exposure therapy."
45477701|NCT03120598|Behavioral|ISF strategy|Implementation & Sustainment Facilitation (ISF) strategy: An organization-focused strategy that includes 7 discrete strategies (e.g., use of an implementation advisor, organize implementation team meetings, conduct cyclical small tests of change).
45477702|NCT03817385|Device|repetitive TMS|rTMS x 10 times
45477703|NCT03817385|Device|robotic GT|robotic gait training for 20 times
45477704|NCT03639571|Drug|Ibuprofen 200 mg TEPI Medicated Plaster|Ibuprofen 200 mg TEPI Medicated Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
45477705|NCT03639571|Other|Placebo TEPI Plaster|Placebo TEPI Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
45477706|NCT03814031|Other|NO internvention|NO internvention
45686669|NCT00049504|Genetic|polymerase chain reaction|Correlative studies
45686670|NCT00049504|Genetic|fluorescence in situ hybridization|Correlative studies
45686671|NCT00049504|Genetic|polymorphism analysis|Correlative studies
45686672|NCT00049504|Genetic|gene expression analysis|Correlative studies
46046261|NCT04881838|Drug|Course A1 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
45686673|NCT00049504|Radiation|total-body irradiation|Undergo total-body irradiation
45686674|NCT00049504|Procedure|allogeneic bone marrow transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
45686675|NCT00049504|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
45686676|NCT00050986|Drug|Temozolomide|Starting Dose Level: 100 mg/m^2 taken by mouth once daily for 7 days, followed by 7 days rest and another 7-day dosing period and 7-day rest period.
45686677|NCT00050986|Drug|R115777|Starting Dose Level: 400 mg taken by mouth for 7 consecutive days every other week on alternating weeks (days 8-14 and 22-28) every 4 weeks.
46046262|NCT04881838|Drug|Course B1 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
46046263|NCT04881838|Drug|Course A2 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
45353594|NCT00751244|Behavioral|Present Centered Therapy (PCT) - psychotherapy|"Present Centered Therapy (PCT) is a 12-session supportive therapy adapted a 14-session version co-developed by the first author (McDonagh-Coyle et al., 2005). Psychoeducation is provided about the link between traumatic events, PTSD symptoms, and problems in relationships, and social problem solving skills are taught to address the traumagenic dynamics of betrayal, stigma, powerlessness, and sexualization (Finkelhor, 1987). PCT focuses on addressing current problems rather than trauma memory-based exposure therapy, and uses a distinctive mnemonic to organize the skill set. PCT has clients keep a journal of relational stressors and responses as between-session homework."
45353595|NCT00751244|Other|"No-treatment waitlist group"|After a 90 day wait-list period, participants were invited to choose one of the treatment approaches (PCT or TARGET) and engage in 12 sessions of therapy.
45353596|NCT00751322|Other|RBC transfusion of 5 days or less storage age|RBC transfusion of 5 days or less storage age
45353597|NCT00751322|Other|RBC transfusion of conventional storage age|RBC transfusion of conventional storage age
45477707|NCT03052322|Drug|MSB11022|Participants received MSB11022 (modified buffer and stabilizer) subcutaneously at dose of 40 milligram (mg) every other week from Day 1 up to Week 48.
45353598|NCT00756860|Drug|AMG 223|2 g AMG 223 (4 x 500 mg capsules ) TID on Days 1 through 7
45353599|NCT00756860|Drug|Renagel® (sevelamer hydrochloride)|2g Renagel® (2 x 800 mg capsules + 1 x 400 mg capsule) TID on Days 1 through 7
45353600|NCT00757016|Drug|Triamcinolone|1 ml triamcinolone 20mg/ml will be given once to the insertion of the sacrospinous ligament bilaterally.
45353601|NCT00757016|Drug|Saline solution|Saline solution
45353602|NCT00687362|Biological|Infliximab|Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.
45353603|NCT00757250|Drug|Angiotensin 1-7|Once daily subcutaneous injection of 50, 100, 200 or 300 mcg/kg/day
45477708|NCT03052322|Drug|EU-Humira|Participants received EU-Humira subcutaneously at dose of 40 mg every other week from Day 1 up to Week 48.
45477709|NCT03722173|Drug|Itraconazole|Oral solution
45477710|NCT03722173|Drug|BI 894416|Tablet
45477711|NCT05465512|Other|response to neoadjuvant chemotherapy|Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).
45477712|NCT05655455|Behavioral|walking group: 1.group|In the study, walking attempt will be applied (2 x40 min/week and 6 weeks in total) to the 1st intervention group (n:15) in a gym. It will be given by a specialist in public health nursing. (first researcher)
45686678|NCT00214786|Biological|Islet cell transplantation|Allogenic islet transplantation
45686679|NCT00118144|Drug|bortezomib|Given IV
45686680|NCT00118378|Drug|Modafinil|50 mg per day, increasing to 200 mg per day as clinically indicated
45686681|NCT00118378|Drug|Placebo|50 mg per day, increasing to 200 mg per day as clinically indicated
45353604|NCT00751478|Drug|ALO-01|ALO-01 capsules
45353605|NCT00751478|Drug|MSIR|immediate release morphine sulfate
45353606|NCT00751478|Drug|Placebo|Placebo
45353607|NCT00751556|Drug|Naproxen Sodium 660mg|Extended release Naproxen Sodium (660mg) administered once a day
45353608|NCT00751556|Drug|Commercial Aleve 220 mg|Immediate release commercial Aleve (220 mg) administered in a 2 (440 mg) plus one (220 mg) dosing schedule, 660 mg total
45353609|NCT00748592|Drug|Placebo|Subjects in this arm will be administered 3 capsules of placebo 30 minutes before bedtime for two consecutive nights in the sleep lab.
45353610|NCT00748592|Drug|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 5 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
45353611|NCT00748592|Drug|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 15 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
45353612|NCT00748592|Drug|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 30 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
45353613|NCT00748670|Device|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
45353614|NCT00757640|Procedure|cholecystectomy|prophylactic cholecystectomy during standard gastric surgery for cancer
45353615|NCT00325195|Other|placebo|placebo by intravenous infusion every 2 weeks
45353616|NCT00325195|Biological|pegloticase|8 mg pegloticase by intravenous infusion
45353617|NCT02562560|Behavioral|Neuropsychological tests|
45353618|NCT02562560|Device|Cerebral imaging (MRI, PET-FDG)|
45353619|NCT03976401|Drug|EFX|Administered by subcutaneous injection
45353620|NCT03976401|Drug|Placebo|Administered by subcutaneous injection
45353621|NCT00757718|Device|CPAP|One half of the subjects will be randomly assigned to wear continuous a positive airway pressure device on the second night of the study. Portable polysomnography will be repeated for this night and morning bloodwork for inflammatory markers will be repeated.
45353622|NCT00757718|Device|Oral Appliance|Half of the subjects will be assigned to wear an oral appliance and nasal strip on the second night of the study. Repeat portable polysomnography will be performed and morning bloodwork will again be drawn for inflammatory markers.
45477713|NCT05655455|Behavioral|dance and movement therapy group: 2.group|In the study, dance and movement therapy will be applied (2 x40 min/week and 6 weeks in total) to the 2nd intervention group (n:15) in a gym. It will be given by a specialist in psychiatric nursing.
45477714|NCT03340948|Behavioral|Mindfulness Based Stress Reduction (MBSR)|An 8-week course in mindfulness meditation, yoga training and weekly group support in the form of weekly 2,5 hour meetings at the hospital.
45477715|NCT02493010|Device|Arousal-based biofeedback system|
45477716|NCT03521791|Drug|PRO-155|"PRO-155 (Zebesten ofteno®) Active agent: bromfenac 0.90 mg / mL, dropper bottle of low density polyethylene for multidose administration in the form of an ophthalmic solution of 5 mL (milliliters). Sanitary registry in Mexico: 108M2014~Sodium hyaluronate 0.4% [Lagricel ofteno®] 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac"
45353623|NCT00748748|Biological|Culturelle|10^10 Lactobacillus rhamnosus GG per capsule
45353624|NCT02532907|Procedure|Liver Biopsy|patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point. The liver biopsy is performed using standard protocol with ultrasound guidance.
45353625|NCT00751712|Device|Cerebral oximeter sensor|The INVOS Cerebral Oximeter utilizes two electrodes to monitor cerebral oxygenation. The recommended placement of these electrodes is on the forehead to monitor the frontal cortex. In this study, one electrode will be placed in the normal position on the forehead, and the other will be placed at the base of the skull. The stickers will be placed on the patient at the beginning of surgery and removed at the end. The maximum amount of time that they will be on the patient's skin is approximately six hours. Application of the stickers and the data they provide will not alter the provider's treatment plan. This procedure will be used for all enrolled patients, whether they are enrolled in Part I or Part II.
45353626|NCT00938847|Device|PCI|Stent implantation after acute myocardial infarction
45353627|NCT02562638|Other|Non-fasting|Clear fluids up to 1hour pre-procedure and fasting for solids for up to 4 hours
45353628|NCT04013607|Dietary Supplement|fructo- and galacto-oligosaccharides|A NDC drink rich in fructo- and galacto-oligosaccharides
45353629|NCT04875156|Other|measurement of range of motion and strength|measurement of range of motion (goniometer) and strength (dynamometer) of the metacarpophalangeal joint of the thumb
45353630|NCT00685334|Drug|Olanzapine|Participants will take olanzapine daily for 12 weeks.
45353631|NCT00685334|Drug|Aripiprazole|Participants will take aripiprazole daily for 12 weeks.
45353632|NCT00325039|Procedure|retropubic mid-urethral sling (TVT)|This trial is a comparison of two types of mid-urethral slings. The retropubic mid-urethral mesh sling is used for treatment of stress incontinence; this procedure was less invasive than the fascial sling procedures that were reference standards at the start of the study. Specifically, a synthetic tape is passed transvaginally at the midurethral level through the retropubic space.
45477717|NCT03521791|Other|Placebo|"The placebo is constituted by agents, additives and vehicles, of the formulation PRO-155 without pharmacological activity. It is dispensed in dropper bottle of low density polyethylene for multi-dose administration in the form of ophthalmic solution of 5 mL~Sodium hyaluronate 0.4% (Lagricel ofteno®) 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac"
45477718|NCT01207193|Biological|cell injection|injection of mesenchymal cells to bone cyst defect
45477719|NCT05127434|Drug|Placebo|0.9% sodium chloride (normal saline) injection
45477720|NCT05127434|Drug|mRNA-1345|Sterile liquid for injection
45477721|NCT02492698|Dietary Supplement|Probiotic group|The 2 g of probiotic powder contained 0.1 g of Lactobacillus curvatus HY7601, 0.1 g of Lactobacillus plantarum KY1032, 1.24 g of crystalline cellulose, 0.5 g of lactose, and 0.06 g of blueberry-flavoring agent.
45477722|NCT02492698|Dietary Supplement|Placebo group|The 2 g of placebo powder contained 1.34 g of crystalline cellulose, 0.6 g of lactose, and 0.06 g of blueberry-flavoring agent.
45477723|NCT03817697|Other|Questionnaire|The socio-demographic characteristics of patients, their current and past drug use as well as their knowledge of hepatitis B and vaccination, will be collected via a questionnaire, conducted by the service's addictologists at the beginning of the consultation.
45498258|NCT03622879|Behavioral|Lower-limb task-oriented training|The lower-limb task-oriented training comprises 6 exercises, namely stepping up and down, heel lift a dorsiflexed position, partial squatting, kicking a ball with alternate legs, gait re-education and transition training. Each exercise last for 10 minutes
45353633|NCT00325039|Procedure|transobturator mid-urethral sling (TVT-O and the Monarc)|This trial is a comparison of two types of mid-urethral slings. The transobturator mid-urethral sling is used for treatment of stress incontinence; this procedure was developed to minimize the potential for bladder and bowel injuries associated with the retropubic sling, since the sling is passed through the obturator canal, avoiding the pelvic organs in the retropubic space.
45353634|NCT00801294|Drug|BIBF 1120 and BIBW 2992|
45353635|NCT04013919|Drug|Multiple Daily Injections of Insulin|Basal/ Bolus insulin injections
45353636|NCT04013919|Drug|Single insulin injections|Basal insulin injections only
45477724|NCT03335020|Device|Shear Wave Elastography|The subject will be asked to lay on a hospital bed for ultrasound imaging of the arteries. The subject will have an automatic blood pressure cuff put on to measure blood pressure. The subject will also have a three-lead ECG taken during the experiment. The artery will be visualized using ultrasound imaging, and the depth of the arterial wall will be noted. The focal depth on the device will be set to measure shear wave propagation in the walls of the artery. Measurements will be made at multiple locations along the artery's length and at different phases of the cardiac cycle determined by ECG gating. Either or both the Verasonics or GE Logiq systems will be used for measurements. Measurements made with these systems use acoustic output within the FDA regulatory limits of diagnostic imaging.
45477725|NCT03335020|Device|Pulse Wave Imaging|Researchers will use the Verasonics device to acquire data for measurement of wave velocity in the tissue of interest (arterial walls and surrounding tissue) due to the pressure pulse from ejection of blood by the heart into the systemic circulation. Using ECG gating we can regulate the timing of the individual acquisitions. In each acquisition, high frame rate ultrasound imaging is used to acquire data to measure the motion of the propagating waves. Multiple measurements on different heartbeats are made with varying delays to obtain measurements throughout the heart cycle assuming at that the behavior during consecutive heartbeats is similar. Multiple measurements will be made in a given artery and multiple locations in the arterial wall.
45477726|NCT03335020|Drug|Contrast-Enhanced Ultrasound|Will be done using Lumason (Bracco Diagnostics, Inc) administered intravenously via slow hand infusion. Real-time contrast-enhanced carotid cine-loop (longitudinal and short axis) images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the determined artery will be acquired and digitally stored for off line analysis. Up to two vials will be used for a study.
45353637|NCT00938925|Procedure|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
45353638|NCT00938925|Procedure|Nail lacquer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
45477727|NCT03335020|Other|Strain Imaging|Measurements will be performed offline on the workstation using Echo PAC software (GE Healthcare Inc., Princeton, NJ). The media-adventitia interface of the arterial wall will be manually traced from a still frame image. The circumferential and radial strain curves will be automatically obtained. Measurements of the peak radial and circumferential strain, strain rate will be obtained. If arterial plaque is identified: A region of interest will be placed at the plaque in 3 different regions: 2 shoulder regions and the fibrous cap top, the measurement results of the peak longitudinal, radial and circumferential strain, strain rate will be acquired by the software.
45477728|NCT03335020|Device|3-D Volume Ultrasound|When generating a 3D volume the ultrasound data can be collected in 4 common ways. Freehand, which involves tilting the probe and capturing a series of ultrasound images and recording the transducer orientation for each slice. Mechanically, where the internal linear probe tilt is handled by a motor inside the probe. Using an endoprobe, which generates the volume by inserting a probe and then removing the transducer in a controlled manner. The fourth technology is the matrix array transducer that uses beam steering to sample points throughout a pyramid shaped volume
45353639|NCT04864548|Biological|SARS-CoV-2 virus|The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
45353640|NCT03743181|Other|pharmaceutical care services|detection of drug therapy problems and investigation of the impact of clinical pharmacist interventions on the patient clinical outcome and quality of life
45353641|NCT04045938|Other|Low Glycemic Index or Glycemic Load|Dietary pattern focused on low glycemic index foods or on a low glycemic load
45353642|NCT00344461|Drug|Nevirapine, FTC, and Tenofovir|One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.
45686682|NCT00217438|Drug|melphalan|Given IV
45353643|NCT00939081|Behavioral|Adaptive step recommendation|Participants in this group receive 3 education sessions: at baseline, at 3 months and at 6 months. The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.
45353644|NCT00939081|Behavioral|10,000 step/day recommendation|Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
45353645|NCT00685178|Drug|topiramate|"topiramate powder 0mg - 150 mg with lactate in blind capsules. Two capsules dispensed daily. One capsule ingested under supervision at the methadone window. One capsule to be ingested at home at bedtime. Participant is expected to return the empty blister pack on the following day.~capsules are administered from week 4 through 25 of the trial"
45353646|NCT00685178|Behavioral|Contingency Reinforcement|monetary reward for self-reported cocaine abstinence confirmed by urine toxicology results
45353647|NCT00685178|Drug|placebo + NonCR|participant receives placebo capsules and monetary reinforcers by chance, irrespective of cocaine use or abstinence
45353648|NCT00537394|Drug|Enfuvirtide|90mg subcutaneously twice daily
45353649|NCT00537394|Drug|Raltegravir|400 mg twice daily
45353650|NCT00537394|Drug|Darunavir|Two 300-mg tablets twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
45353651|NCT00537394|Drug|Tipranavir|Two 250-mg capsules twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
45353652|NCT00537394|Drug|Etravirine|Two 100-mg tablets twice daily
45353653|NCT00537394|Drug|Maraviroc|Dosage dependent on regimen in which maraviroc is included
45353654|NCT00793494|Other|Probaclac|Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™)
45353655|NCT00793494|Other|Placebo|Placebo composition matodextrin, gelatin, ascorbic acid, soya
45353656|NCT03187977|Behavioral|Cognitive training|Cogmed is a computer-based cognitive training program that consists of rotating exercises that train attention and working memory. The exercises are presented in a child-friendly, game-like format. The program is completed at home for 15-45 minutes each weekday for 5-9 weeks.
45353657|NCT03986359|Device|low energy extracorporeal shockwave therapy|Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
45353658|NCT02554110|Device|Stimulator active device|This is a stimulator active device that delivers peripheral nerve stimulation in conjunction with pulse oximetry information.
45353659|NCT02554110|Device|Stimulator sham Device|This is an stimulator sham device that is not providing peripheral nerve stimulation.
45353660|NCT00933309|Drug|Exemestane|25 mg tablets orally once a day
45353661|NCT00933309|Drug|Avandamet|Beginning dose 2 mg rosiglitazone with 500 mg metformin hydrochloride (2mg/500 mg) tablets taken orally once a day
45353662|NCT00352885|Drug|Escitalopram|Participants will begin medication approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 10 mg per day. If 10 mg is well tolerated by the participant, the dosage will be increased to 20 mg per day. The dosage for the remainder of the study will be 20 mg per day.
45353663|NCT00352885|Drug|Placebo|Participants will begin the placebo approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 1 pill per day, if 1 pill is well tolerated by the participant the dosage will be increased to 2 pills per day. Two pills per day will be the dosage for the reminder of the study.
45353664|NCT00352885|Drug|IL-2|IL-2 is a 12-week treatment regimen with intravenous (IV) IL-2. There will be one cycle every 3 weeks for a total of four cycles. One cycle is 720,000 units/kg every 8 hours for 5 days.
45353665|NCT00933387|Drug|Cetuximab,Paclitaxel,Cisplatin|Cetuximab 500 mg/m2 iv infusion (120 min for the 1st infusion, 90 min for the 2nd , and 60 min for the subsequent) Paclitaxel 120 mg/m2 3-hour iv infusion Cisplatin 50 mg/m2 2-hour iv infusion
45353666|NCT00660660|Drug|Esomeprazole|Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
45353667|NCT00660660|Drug|Placebo|once daily
45353668|NCT02560766|Drug|HORIZANT 300 mg|HORIZANT 300 mg once daily
45353669|NCT02560766|Drug|HORIZANT 600 mg|HORIZANT 600 mg once daily
45353670|NCT02560766|Drug|Placebo|Placebo once daily
45353671|NCT00933465|Drug|Imodium (Loperamide Hydrochloride) syrup|"syrup (orally), max dose per day; 16x 5ml spoonfuls (80ml) Titrated from low dose to clinically relevant dose as described by the patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most."
45477729|NCT01207271|Behavioral|Cognitive Therapy|16 sessions of cognitive therapy administered weekly by a community mental health therapist
45477730|NCT01207271|Behavioral|Supportive-Expressive Psychodynamic Therapy|16 sessions of supportive-expressive psychodynamic therapy administered weekly by a community mental health therapist
45477731|NCT03340870|Drug|Sonazoid™|Single Dose of Sonazoid™ lipid-stabilised aqueous suspension of perfluorobutane (PFB) gas microbubbles.
45477732|NCT03521635|Drug|Pramipexole SR|Tablets
45477733|NCT03521635|Drug|Pramipexole IR|Tablets
45477734|NCT03813953|Procedure|Liver resection|Resection of diseased liver
45477735|NCT03340792|Device|Ambulation training utilizing an exoskeleton robot|Participants undergo 40 hours of ambulation training utilizing an exosksleton robot within 3 months.
45477736|NCT03813797|Device|Airseal®|Medical device set to the mode Airseal®, pressure adjustment between 5 and 7 mmHg
45686683|NCT00217438|Drug|amifostine trihydrate|Given IV
46046264|NCT04881838|Drug|Course B2 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
45477737|NCT03813797|Device|Standard Insufflation|"Medical device set to the mode Standard Insufflation, pressure adjustment between 12 and 15 mmHg"
45477738|NCT03120754|Procedure|Place the peritoneal drainage|In the experimental group, the abdominal drainage was not placed
45477739|NCT03120754|Procedure|No peritoneal drainage|Intraoperative placement of peritoneal drainage as control group.
46046265|NCT04881838|Drug|Course A3 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
46046266|NCT04881838|Drug|Course B3 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
45353672|NCT00933465|Drug|Imodium (Loperamide hydrochloride) tablets|"tablets (orally) max dose per day; in chronic diarrhea, 8 capsules (16 mg) titrated from low dose to clinically relevant dose as described by patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most"
45353673|NCT00757874|Drug|Tacrolimus cream|0.5 g per day at bed time for 3 months or less.
45353674|NCT00757874|Drug|Clobetasol cream|0.5 gram each day at bed time during 3 months or less.
45353675|NCT00933621|Procedure|Autologous bone marrow intracoronary infusion|Percutaneous intracoronary mononuclear bone marrow cell infusion
45353676|NCT04050254|Device|Real tDCS|Real tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days.tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
45353677|NCT04050254|Device|Sham tDCS|Sham current (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days. Sham tDCS will be applied for the same time than real tDCS.
46046267|NCT04881838|Drug|Maintenance therapy|Vinorelbine 25 mg/m2 IV, weekly for 3 consecutive weeks followed by 1-week rest. Totally 80 cycles.
45353678|NCT04050254|Device|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening for five sessions on alternate days. The program will include exercises and will last 30-45 minutes.
45353679|NCT00933699|Drug|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
45353680|NCT00344305|Biological|Trivalent influenza virus vaccine live, intranasal|A single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 FFU of three influenza virus strains.
45353681|NCT00933777|Drug|Combination of sorafenib and everolimus|Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg
45353682|NCT00757952|Other|Fourier transform ion cyclotron resonance mass spectrometry|
45353683|NCT00757952|Other|chromatography|
46046268|NCT04879225|Behavioral|Tobacco e-liquids|Marketplace includes tobacco flavored e-liquids
45353684|NCT00757952|Other|diagnostic laboratory biomarker analysis|
45353685|NCT00757952|Other|questionnaire administration|
45353686|NCT01564030|Other|Empty|overnight fast
45353687|NCT01564030|Other|Fluid|250mL apple juice
45353688|NCT01564030|Other|Solid|breakfast
45353689|NCT00801450|Drug|Triamcinolone acetonide|4 mg
45353690|NCT00801450|Drug|Triamcinolone acetonide|40 mg
45353691|NCT05434988|Procedure|appendectomy|Open or Laparoscopic appendectomy procedure is typically performed under general anaesthesia. in the laparoscopic approach, the main principle is the triangulation of instrument ports to visualize and expose the appendix clearly. The first trocar (10 mm) for the optical device is introduced peri-umbilically, followed by two 5 mm trocars, one in the right lower quadrant just above the pubis (to grasp the appendix) and the other in the left iliac fossa (for the (right-handed) surgeon's right hand), assuming the appendix is in its normal anatomic position. The locations of the 5 mm trocars can be changed based on the anatomic position of the appendix as determined before to surgery (for example a subhepatic appendix could lead to placing the trocars as for cholecystectomy)
45353692|NCT00989326|Other|Home Monitoring|Both patient groups are followed for 18 months and will be followed with Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
45353693|NCT00933855|Behavioral|Questionnaires and training workshop|"We will recruit a minimum of 1 and maximum of 12 patients for each workshop.~The workshop will follow the approximate time table below:~10 minutes: Sign-in, welcome and introductions 25 minutes: Didactic session, videos and discussion 10 minutes: Group discussion 15 minutes: Closing plenary and final assessment"
45353694|NCT02554578|Other|Multidisciplinary follow-up programme supported by mHealth|"The follow-up programme integrates an online health platform (app and web) to monitor patients remotely, into the multidisciplinary team workflow, in order to improve heart transplant management.~Patients will use the mobile application designed to help them to manage their health issues and facilitate communication with the transplant team.~Data recorded manually by the patient using the mHealth application include pharmacotherapeutic information (medication adherence, barriers to adherence, side effects, interactions, etc.), clinical symptoms and other relevant clinical information (blood pressure, cardiac frequency, exercise, glucose level, diet, mood, etc.).~mHealth will be used by the transplant team as a complementary way of deliver patient care. Analysis of the data collected by the multidisciplinary team may help to prioritise and provide personalized pharmacotherapeutic and medical interventions to patients and their families."
45498259|NCT04133623|Drug|Ketorolac|Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.
45686684|NCT00217438|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
45353695|NCT03988777|Device|Preoperative localisation technique|Impalpable breast lesions are preoperatively localised, either with hooked-wire (retrospective study) or Magseed (prospective study)
45353696|NCT00660816|Drug|erlotinib hydrochloride|Given orally once daily on days 2-19.
45353697|NCT00660816|Drug|pemetrexed disodium|Given IV over 10 minutes on day 1
45686685|NCT00217438|Genetic|fluorescence in situ hybridization|Correlative study
46046269|NCT04879225|Behavioral|Menthol and Tobacco e-liquids|Marketplace includes menthol and tobacco flavored e-liquids
46046270|NCT04879225|Behavioral|Mint, Menthol and Tobacco e-liquids|Marketplace includes mint, menthol and tobacco flavored e-liquids
46046271|NCT04879225|Behavioral|All e-liquid flavors|Marketplace includes fruit, dessert, mint, menthol and tobacco flavored e-liquids
45353698|NCT00660816|Drug|docetaxel|IV over 60 minutes on day 1.
45353699|NCT00991666|Procedure|blood flow measurement|Fundus pulsation amplitude measurement Pulsatile ocular blood flow measurement
45353700|NCT00801528|Drug|Ropivacaine, Diclofenac, Water for injection|Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.
45353701|NCT01060891|Drug|colimycin|
45353702|NCT04003402|Drug|ASP8062|oral
45353703|NCT04003402|Drug|Alcohol|oral
45353704|NCT04003402|Drug|ASP8062 Placebo|oral
45353705|NCT04003402|Drug|Alcohol Placebo|oral
45353706|NCT04045860|Procedure|Complete Decongestive Therapy|A combination of manual lymph drainage , compression bandaging, physical exercise and a skin care regimen
45353707|NCT04045860|Other|Observation|Standard of care is currently observation
45477740|NCT03723421|Other|Rapid Injection Group Without Aspiration|After filling in the personal information form, the tetanus vaccine was administered by using rapid injection without aspiration technique (the injector was held at 90 degrees, it was pricked into tissue rapidly, and the drug was given in 1-2 seconds without performing aspiration). (the injector was held at 90 degrees, it was pricked into tissue rapidly, and the drug was given in 1-2 seconds without performing aspiration). 2 days after the vaccination, the researcher got in contact with the students in the intervention and the control groups in order to ask whether a local side effect developed in the vaccination site or not.
45353708|NCT00576056|Drug|Sorafenib|Oral sorafenib (400 mg BID) will start the next day after the first TACE treatment until unacceptable toxicity occurs, or until study termination.
45353709|NCT00576056|Drug|TACE|TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin.
45353710|NCT00798798|Device|Externally Implantable Tissue Expansion Device|Will Apply Externally Implantable Tissue Expansion Device for 2 Days
45353711|NCT05360602|Dietary Supplement|Alpha Lipoic Acid plus the standard care for post-PCI MI|Intravenous and oral administration of Alpha Lipoic Acid 600 mg plus the standard care for post-PCI MI which will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
45353712|NCT05360602|Drug|The standard care for post-PCI MI|will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
45353713|NCT00793728|Procedure|Sleeve gastrectomy|Perform a gastrectomy guided by a 38F catheter and parallel to the small curvature of the stomach
45353714|NCT00991744|Drug|Liposomal cytarabine|Intrathecal liposomal cytarabine combined with intrathecal prednisolone and oral dexamethasone during maintenance treatment for high-risk ALL
45353715|NCT00991744|Drug|Intrathecal triple|Intrathecal methotrexate (8-12 mg), cytarabine (20 - 30 mg) and prednisolone sodium succinate (12,5 - 20 mg) 6 times during maintenance treatment in high-risk ALL protocol
45353716|NCT00575510|Behavioral|Intervention|Multiple component intervention based in the unified theory of behavior
45353717|NCT00575510|Behavioral|Active control|Partial intervention (full intervention minus cultural-specific component)
45353718|NCT00798876|Dietary Supplement|Fish Oil|Subjects will be asked to take 10 grams of fish oil per day for 4 weeks.
45477741|NCT03723421|Other|Control|After filling in the personal information form, the tetanus vaccine was made in accordance with the standard injection technique included in the application (the injector was held at 90 degrees, it was pricked into tissue, and the drug was given in 5-10 seconds after performing aspiration). 2 days after the vaccination, the researcher got in contact with the students in the intervention and the control groups in order to ask whether a local side effect developed in the vaccination site or not.
45477742|NCT03817073|Device|Iowa Oral Performance Instrument (IOPI)|Using biofeedback to attain repetitions of 80% of baseline MIP.
45477743|NCT03170544|Drug|MK-1092, 4.0 nmol/kg|MK-1092, 4.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
45353719|NCT00798876|Dietary Supplement|Vitamin E supplement|Subjects will be asked to take 800 International Units per day of Vitamin E for 4 weeks.
45353720|NCT00798876|Dietary Supplement|Western Diet|Subjects will be provided with a standard western diet, food and beverages, to consume during their 4 week participation in this study.
45353721|NCT00798876|Dietary Supplement|Low-Fat Diet|Subjects will be provided with a low-fat diet (food and beverages) for their 4 week participation in this study.
45353722|NCT00798876|Other|Medical Examination|Subjects will have a routine medical exam.
45353723|NCT00798876|Other|Dietary Interview|Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.
45353724|NCT00798876|Other|Blood Draw|40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.
45353725|NCT00798876|Procedure|Radical Prostatectomy|Subjects will undergo a radical prostatectomy as part of their standard of care.
45353726|NCT00989404|Drug|Zanamivir|Rotahaler placebo 10mg BID 5 days
45353727|NCT00989404|Drug|Zanamivir|Rotahaler Zanamivir 10mg BID 5 days
45353728|NCT00989404|Drug|Zanamivir|Diskhaler Zanamivir 10mg BID 5 days
45353729|NCT00758030|Drug|Paliperidone ER OROS|
45353730|NCT02636439|Behavioral|dietary, aerobic and resistance training|hypocaloric diet individual exercise prescription for aerobic training individual exercise prescription for resistance training.
45353731|NCT02636439|Behavioral|dietary, and aerobic exercise|hypocaloric diet individual prescription for aerobic training.
45353732|NCT00343915|Biological|Engerix™-B (thiomersal-free) 20µg|In the primary study: 2 deep intramuscular injections (Months 0, & 6)
45353733|NCT00343915|Biological|10 μg Engerix™-B (preservative-free)|In the primary study: 3 deep intramuscular injections (months 0, 1 & 6)
45353734|NCT00343915|Biological|placebo|In the primary study: 1 deep intramuscular injection (month 1)
45353735|NCT00751868|Drug|Ixabepilone|Ixabepilone is administered as 3-hour intravenous infusion (iv) at the dose of 40 mg/mq, every 14 days for 4 cycles (with G-CSF support), sequentially to Fluorouracil 600 mg/mq as intravenous (iv) infusion, Epirubicin 90 mg/mq as intravenous (iv) bolus and Cyclophosphamide 600 mg/mq as intravenous (iv) infusion every 14 days for 4 cycles (with G-CSF support)
45353736|NCT00991822|Drug|Dorzolamide 2%|
45353737|NCT00991822|Drug|Timolol 0.5%|
45353738|NCT00798954|Device|Sirolimus-eluting coronary stent (Cypher)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
45353739|NCT00798954|Device|Paclitaxel-eluting stent (TAXUS)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
45353740|NCT02560064|Procedure|Laparotomy|Small bowel length will measure in laparotomy, regardless of indication.
45353741|NCT00989482|Behavioral|Computer kiosk Education|computerized patient education; guidelines for physicians
46046272|NCT04875234|Device|Clear-K Low Vision Aid Treatment|A Clear-K Low Vision Aid Device is used to produce small corneal shape and refraction changes in order to redirect light onto functional areas of the retina.
45353742|NCT04348981|Device|Wearable fitness tracking device|Patients having a wearable fitness tracking device will be monitored for their level of activity after surgery. Declines in activity level will prompt a phone call from the surgical provider.
45353743|NCT00934011|Other|C-reactive protein guided antibiotic therapy|plasma CRP measurement to guide the duration of antibiotic therapy
45353744|NCT00934011|Other|Procalcitonin guided antibiotic therapy|plasma PCT measurement to guide the duration of antibiotic therapy
45353745|NCT02554032|Procedure|Axillary artery cannulation|The right axillary artery will be exposed via an infraclavicular incision and a Dacron graft sewn to it in an end to side fashion after 5000 units of IV heparin. Following median sternotomy and full systemic heparinization, CPB will be initiated and the patient cooled. The base of the innominate artery will be clamped, and antegrade cerebral perfusion will be provided via the axillary artery. Following completion of the distal open aortic anastomosis, the clamp on the innominate artery will be removed, CPB via the aorta will be resumed and the patient will be rewarmed. After completion of surgery and weaning from CPB, the axillary artery graft will then be removed, the artery repaired and the skin will be closed.
45353746|NCT02554032|Procedure|Innominate artery cannulation|After median sternotomy, systemic heparinization, cannulation of the ascending aorta and right atrium, CPB and systemic cooling will be initiated. The ascending aorta, proximal arch and the base of the innominate artery will be mobilized. Purse-string sutures are placed on the anterior wall of the proximal innominate artery and a pediatric venous cannula inserted using a J wire and sequential dilatation. Circulatory arrest with ACP is provided by clamping the base of the innominate artery and connecting the afferent limb of the CPB circuit to the innominate cannula. Once the distal aortic anastomosis is completed, ACP is discontinued, and full CPB via the aortic graft is resumed. Rewarming and the remaining surgery are then completed.
45353747|NCT04040504|Device|ERCP procedure with Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)|ERCP procedure using Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC) and any necessary accessories.
45353748|NCT04040504|Device|ERCP procedure with Pentax ED-34i10T Duodenoscope|ERCP procedure using Pentax ED-34i10T Duodenoscope with any necessary accessories.
45353749|NCT01055119|Dietary Supplement|Omega-3 fatty acids|duration: 4 month
45353750|NCT00934167|Biological|heparin sodium - Hipolabor|5.000 UI/0,25mL
45353751|NCT00934167|Biological|Heparin sodium - APP|5.000 USP/mL
45353752|NCT00801606|Drug|Zinc|Zinc 20 mg/day
45353753|NCT00801606|Drug|Micronutrient without zinc|Multimineral 2 RDA
45353754|NCT00801606|Drug|Micronutrient with zinc|Multimineral 2 RDA and zinc 20 mg per day
45353755|NCT00801606|Drug|Placebo|Placebo
45353756|NCT05408806|Other|Exercise Interventions|Rehabilitation methods and exercise practices to improve postural control in children with cerebral palsy. In addition to neurodevelopmental treatment, one group is treated with virtual reality games and the other group is treated with a hippotherapy simulator.
45477744|NCT03170544|Drug|MK-1092, 8.0 nmol/kg|MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
45353757|NCT00934245|Biological|Inactivated Trivalent Influenza Vaccine|Vaccine administration will occur twice, one month apart, in the first year of participation in the study. This will occur as TIV vaccine becomes available in India, in the early autumn. Subsequent years will provide one immunization. Due to the inclusion of the pandemic 2009 influenza A H1N1 virus in the 2010-2011 northern hemisphere vaccine formulation and recommendations that children should receive 2 doses of this vaccine this study will administer 2 doses of vaccine in the second year of the study.
45353758|NCT00934245|Biological|Inactivated polio vaccine (IPV)|Vaccine administration will occur twice, one month apart, in the first year of participation in the study to parallel administration of TIV (experimental intervention). Subsequent years will provide one immunization except 2011 schedule modified to accommodate changes in TIV schedule as per above..
45353759|NCT05394532|Other|Education|Common Education
45353760|NCT02560688|Drug|DS-1040b|20 mg single 12-hour intravenous infusion
45353761|NCT02560688|Drug|Clopidogrel|Clopidogrel (Plavix) administered orally 300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5
45353762|NCT00939549|Drug|Cyclophosphamide/Glatiramer acetate|Cyclophosphamide 50 mg/kg IV each day for four consecutive days. Glatiramer acetate 20 mg SC daily for 1 year.
45353763|NCT00799032|Device|PCI|coronary stent implantation
45477745|NCT03170544|Drug|MK-1092, 16 nmol/kg|MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
45477746|NCT03170544|Drug|MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
45686686|NCT00217438|Procedure|bone marrow ablation with stem cell support|Undergo transplant
45353764|NCT00758186|Procedure|Emergency endoscopic colonic stenting|Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction. Patients who had successful stenting were discharged and re-admitted for elective surgery. Patients in whom stenting was unsuccessful underwent emergency surgery. The choice of surgery performed was up to the individual consultant colorectal surgeon.
46046273|NCT04874051|Device|Experimental Group|The experimental treatment will be provided by means of the OAK system. This device consists of 1 cabinet with 2 independent balance boards, 2 monitors (one for the physiotherapist and one for the patient) and 3 wireless IMUs (one for the left lower limb, one for the right lower limb and one for the trunk). The 2 balance boards provide body weight transfer exercises, while the wireless motion sensors provide one leg stance exercises or trunk exercises in a virtual environment.
45353765|NCT00758186|Procedure|Emergency surgery|Patients underwent emergency surgery for acute left-sided malignant colonic obstruction. The choice of surgery performed was up to the individual consultant colorectal surgeon. Surgery included primary resection with or without defunctioning stoma and palliative diverting stoma only.
45353766|NCT00989560|Procedure|endoscopy|patients receive best treatment and care with an additional endoscopy
45353767|NCT00934323|Drug|Amaryl M SR 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group
45353768|NCT00934323|Drug|Amaryl M SR 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 2 for RT sequential group
45353769|NCT00793962|Radiation|hypofractionation radiotherapy|radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region
45353770|NCT00793962|Radiation|conventional fractionation radiotherapy|50Gy/25/f/5w
45353771|NCT00575666|Drug|Insulin or Placebo|intranasal, 40IU, 4 times daily
45353772|NCT05378230|Dietary Supplement|Probiotic preparation of three Lactobacillus plantarum strains (CECT 7527, CECT 7528, CECT 7529)|"All subjects were submitted to 4 weeks intervention consisting on a dose-dependent regime of Lactobacillus plantarum AB-B (strains CECT 7527, CECT 7528, CECT 7529; AB-LIFE). Before starting the intervention period, all subjects were submitted to a 2-weeks run-in period. During the wash-in and intervention-periods, participants were instructed to maintain their habitual dietary habits and to continue their normal pattern of physical activity throughout the study period.~Treatments during the intervention period were: Week 1: 1 capsule/day taken during breakfast; Week 2: 2 capsules / day at- breakfast; Week 3: 2 capsules at breakfast and 1 at dinner; Week 4: 2capsules at breakfast and 2 capsules at dinner. Each capsule contains 1.2x10^9 cfu (colony forming units) in a 1: 1: 1 ratio of the three strains."
45353773|NCT00934479|Drug|Lubiprostone|Following the initial stool and breath collections and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, (that is, chronic constipation (CC) versus constipation due to irritable bowel syndrome (C-IBS), the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.
45353774|NCT00658632|Drug|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
45353775|NCT00658632|Drug|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
45353776|NCT05408650|Other|Aromatherapy Massage|"The PI will dilute pure lavender essential oil (Lavandula angustifolia) with almond oil at a dilution rate of 2.5% and apply it to the hands and feet of the patient.~The massage technique including effleurage, petrissage, friction and lymphatic drainage on hands and feet will be adapted from Salvo, (2015) and Youssef and Hassan, (2017).~The massage will be applied to the patient's hands and feet while the patient in semi-fowler's position."
45353777|NCT00677534|Drug|Cholecalciferol|50,000 Units PO Twice weekly for 8 weeks
45353778|NCT05408494|Behavioral|Gamified behavioral weight loss treatment|12-month mHealth fully-gamified version of the same program, comprised of a behavior change program with digital reinforcers for attainment of streaks and milestones, and an integrated neurotraining video game
45353779|NCT05408494|Behavioral|mHealth behavioral weight loss treatment|a 12-month mHealth weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets, physical activity and a control (sham) non-game neurotraining
45353780|NCT00940173|Device|DIABECELL(R)|10,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
45353781|NCT00940173|Device|DIABECELL(R)|15,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
45353782|NCT00940173|Device|DIABECELL(R)|20,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
45353783|NCT00940173|Device|DIABECELL(R)|5,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
45353784|NCT02559284|Other|A postoperative care after ethmoid sinus surgery|"A comparison of two products used for nasal cavity cleansing, at the rate of 4 washes/day (240mL per wash), as local postoperative care following endoscopic sinus surgery. This surgery, known as an ethmoidectomy, aims to improve sinus ventilation, treat the chronically infected area, and remove polyps that cause nasal obstruction.~Detailed information concerning the purpose of nasal irrigation, as well as how to use and clean the device, will be given to patients upon inclusion.~The nasal washing procedure will be as follow:~Washing both nostrils using 180mL of solution distributed equally on each side to remove crusting and clotting~Gentle blowing of the nose~Rinsing both nostrils with the remaining 60mL of solution distributed equally on each side (no nose-blowing)."
45353785|NCT00801762|Device|Fibered confocal microscope|
45477747|NCT03170544|Drug|MK-1092, 64 nmol/kg|MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
46046274|NCT04874051|Other|Control Group|The Control Group will perform conventional balance exercises similar to the exercises provided with the OAK system.
46046275|NCT04873245|Behavioral|Intensive Behavioral Program|Participants randomized to this group will receive intensive behavioral therapy.
46046276|NCT04873245|Drug|Semaglutide and Behavioral Program|Participants randomized to this group will receive semaglutide and behavioral therapy.
46046277|NCT04863014|Drug|evinacumab|Intravenous infusion every 4 weeks (Q4W)
45477748|NCT03170544|Drug|Glargine 3.0 nmol/kg|Glargine 3.0 nmol/kg, SC, as a single dose
45477749|NCT03170544|Drug|Lispro 1.2 nmol/kg|Lispro (Humalog®), 1.2 nmol/kg, IV infusion SC over 3 hours as a single dose starting ~12 hours after MK-1092 administration.
46046278|NCT04863014|Other|Placebo|Intravenous infusion Q4W
46046279|NCT04862156|Device|Normothermic Machine Perfusion (NMP)|Storage and transportation of the donated liver using the OrganOx metra device.
45353786|NCT00989716|Drug|Transdermal glyceryl trinitrate patch|5mg per day
45353787|NCT00989716|Drug|Pre-stroke antihypertensives|Continue or stop pre-stroke anti-hypertensives
45353788|NCT00660348|Drug|morphine sulfate|This is morphine given in the traditional methods.
45353789|NCT00660348|Device|Medtronic intrathecal pump|This pump will be inserted into the research subject and then the pump will deliver morphine.
45353790|NCT05408416|Procedure|preoperative group and intraoperative group|ranibizumab injection (0.5mg/0.05ml) 3-5 days before vitrectomy or ranibizumab injection (0.5mg/0.05ml) at the end of vitrectomy
45353791|NCT00940251|Drug|Mersina|capsule, 3g/day, 3 months
45353792|NCT03891602|Behavioral|Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale)|Perceived Smoking-Related Stigma will be measured using the 5-item Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale). The response scale is 1 = strongly disagree, to 4 = strongly agree, and scores range from 5 to 25 (high stigma). Cronbach's alphas were 0.75 to 0.89 in prior studies.
45353793|NCT03891602|Behavioral|Patient Trust in the Medical|"Medical Mistrust will be measured using the 5-item Patient Trust in the Medical Profession Scale.80 The five-point Likert responses measure the extent to which patients perceive their clinician to be honest, caring more about convenience, thorough and careful, and trusted. The range of scores is 5 to 25 (higher mistrust). Reliability and validity have been well established with a Cronbachs alpha of 0.84."
45353794|NCT03891602|Behavioral|Decision Conflict Scale - Lung Cancer Screening|"The DCS is a 16-item Likert-response item scale that has been modified for the lung cancer screening and smoking cessation contexts. The DCS was developed by OConnor,74-75 and validated in many health decisions including breast cancer screening with Cronbachs alphas ranging from 0.78 to 0.81. 74-75 Despite its name, the DCS measures more than decision conflict to encompass personal perceptions of perceived decision-making quality such as feeling the choice is informed, values based, and likely to be implemented as well as expressing satisfaction with the decision. 74-75 The DCS is comprised of items with response options ranging from 1 (strongly disagree) to 5 (strongly agree). The items are summed to total scale score with lower scores reflective of higher decision conflict and higher scores reflective of lower decision conflict."
45353795|NCT03891602|Behavioral|Shared Decision Making Questionnaire - Patient|"Shared Decision Making Process will be measured from the patient perspective using the 9-item Shared Decision Making Questionnaire (SDM-Q-9),77 which has been validated with a Cronbachs alpha of 0.94."
45353796|NCT03891602|Behavioral|Stage of Readiness for Smoking Cessation - Contemplation Ladder|Among current smokers
45353797|NCT03891602|Behavioral|Primary Care Clinicians' Lung Cancer Screening Survey|Includes items to assess attitudes, barriers, and knowledge of lung cancer screening guidelines.
45353798|NCT04013373|Device|SOZO Bioimpedance Spectroscopy Device|Bioimpedance spectroscopy measurements for assessment of fluid status
45353799|NCT03734198|Drug|Ibrutinib|Ibrutinib will be given at the fixed dose of 420 mg daily for the duration of treatment.
45843244|NCT04997616|Dietary Supplement|Happy Lane Hemp Extract/CBD soft gels (25 mg/capsule)|Half of the study participants (5 women and 5 men) will be taking one gel capsule per day (25 mg/day dose), while the other half (5 women and 5 men) will be taking 2 gel capsules per day (50 mg/day dose). Study participants will be taking gel capsules for 10 consecutive days. At the end of this 10-day regimen, study participant will return to the TRI where blood specimen (up to 15 mL) will be collected within 2 to 6 hours after the last dose. Major plant cannabinoids and cannabinoid metabolites in each blood specimen will be determined using liquid chromatography-mass spectrometry.
45353800|NCT03734198|Drug|Daratumumab|Daratumumab will be started 28 days after beginning of ibrutinib and will be administered at the standard dose of 16 mg/kg (divided over two days for the first infusion), then 16 mg/kg for the following infusions, weekly for 2 months, then every other week for 4 months and then once a month until progression or intolerance.
45353801|NCT00660192|Drug|Botox|subjects randomized to receive Botox with have a series of injections of onobotulinumtoxinA totalling 200 to 300 units. Botox is prepared b adding 1cc of preservative free saline in 100 unit vial. Final dose is determined by bod and neck size.
45353802|NCT00660192|Other|Placebo|subjects randomized to receive Placebo will have a series of injections of saline solution totalling 2cc's to 3cc's injected into the scalp in a halo pattern; and into affected neck muscles.
45353803|NCT01564108|Drug|Ranibizumab|Series of intravitreal injections of Ranibizumab
45353804|NCT00801918|Drug|Denileukin Diftitox|Denileukin Diftitox: 18 mcg/kg/day: days 1-5 in cycles 1,2,3,4
46046280|NCT04846413|Other|Speech task|Speech task which consists of a sustained emission of the vowel /e/.
45353805|NCT00801918|Drug|Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide|Denileukin Diftitox: 18 mcg/kg/day days 1-2 in cycles 5 and 6 Ifosfamide: 3000mg/m²/IV/d X 3 days + Mesna 3000 mg/m2/d X 3 days Carboplatin: 635mg/m2/d X 1 day Etoposide: 100mg/m2/d X 3 days
45353806|NCT03704948|Behavioral|Listening Visits via zoom|6 sessions, approximately one hour in length, delivered by a nurse who uses empathic listening and problem solving.
45477750|NCT03170544|Drug|Placebo to glargine|Placebo to glargine, SC, as a single dose
46046281|NCT04843059|Other|The resident memory T-cell infiltrate in perilesional vitiligo skin|"The 3 groups will receive a combination of narrowband UVB (Nb-UVB) 3 times a week and oral mini pulses of systemic steroids (5 mg of d medrol 16mg twice a week) for 24 weeks.~Three visits will be done (inclusion, Week 12 and 24) A skin biopsy will be done on lesional and peri-lesional area at baseline. Another skin biopsy will be taken after 24 weeks but only in perilesional area. A blood sample for assessing the circulating memory T cells and for checking the tolerance will be performed at baseline, then at W12 and W24."
46046282|NCT04840797|Device|HeartStart HS1|Automated External Defibrillator
46046283|NCT04839289|Device|Receiver-in-canal hearing instrument; Manufacturer A|Commercially available receiver-in-canal hearing instrument from manufacturer A
46046284|NCT04839289|Device|Receiver-in-canal hearing instrument; Manufacturer B|Commercially available receiver-in-canal hearing instrument from manufacturer B
46046285|NCT04834557|Drug|Placebo|Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
46046286|NCT04834557|Drug|Digoxin 0.25 mg|All subjects will receive digoxin administered at 0.25 mg every other day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
46046287|NCT04834557|Drug|Ursodeoxycholic acid (UDCA) 500 mg|All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
46046288|NCT04825093|Dietary Supplement|Vitamin D supplementation in pregnant women|Intervention group will be administered 1,000 UI of vitamin D and a control group will be administered 400 UI of vitamin D. Participants will take the supplementation from the enrollment to delivery.
46046289|NCT04820478|Dietary Supplement|Beta Hydroxybutyrate Ester (KetoneAid KE4)|see arm/group description
46046290|NCT04820478|Dietary Supplement|Placebo|see arm/group description
46046291|NCT04797039|Procedure|MR guided cryoablation|MR guided cryoablation of focal biopsy proven prostate cancer
46046292|NCT04793152|Drug|Vancomycin|Administration as outlined
45353807|NCT00799188|Drug|Everolimus|50% reduction of calcineurin inhibitors daily dose followed by further decrease or withdrawal. Everolimus will be introduced and tapered to a trough level of 6 to 10 microg/l.
45353808|NCT00799344|Device|Catania Stent|coronary stent implantation
45353809|NCT00571688|Drug|Risperdal (risperidone) Consta|Risperdal Consta (TM) will be administered every 2 weeks by deep intramuscular (IM) gluteal injection, by a trained health care professional. Injections will alternate between the two buttocks. The initial dose will be 25 mg IM every 2 weeks. A minimum dose of 25 mg. every 2 weeks will be maintained. At the clinician's discretion, the dose may be advanced to 37.5 mg. or 50 mg. In addition, the dose will be raised to 37.5 mg. or 50 mg. if the following conditions remain: (1) Young Mania Rating Scale (YMRS) score > 12; or (2) Evidence of impending relapse; and no dose limiting side effect. If the 25 mg. dose is not tolerated, the dose can be held temporarily; however, attempts will be made to achieve and maintain the dose at 25 mg. (or higher) until the end of the study period.
45353810|NCT00571688|Drug|Treatment as usual|Treatment was provided in this arm based solely on the choice of the treatment provider and participant. Treatment providers were not part of the study staff and were completely free to make treatment choices except that they were not allowed to select a long-acting injectible.
45353811|NCT00989794|Device|GelrinC|Applied once during surgery
45353812|NCT00794274|Drug|CC-100004|After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis.
45353813|NCT00989872|Drug|EDP-322|
45353814|NCT02560610|Drug|OC000459|
45353815|NCT02560610|Drug|Placebo|
45353816|NCT00799500|Other|Screening|Weekly vaginal pH
45353817|NCT05590546|Other|No intervention|No intervention, only performing cross-sectional analysis of pooled data collected in previous studies
45353818|NCT02560532|Drug|Clazosentan|Concentrated solution for intravenous injection
45353819|NCT00799656|Drug|ataciguat (HMR1766)|oral administration 200mg once daily for 28 days
45353820|NCT00799656|Drug|placebo|oral administration once daily for 28 days
45353821|NCT05408182|Procedure|Robotic colorectal resection with ERAS (or eRCS) perioperative care|All patients will undergo robotic colorectal resections using the Da Vinci xi system. All common colorectal procedures will be included: right/left colectomy, sigmoid colectomy, anterior resection with PME/TME/TaTME. Patient will undergo an enhanced recovery pathway perioperatively ensuring prompt recovery and early discharge. Most ERAS guidelines will be followed including preoperative nutrition, behavioral training, avoidance of drains, NG tubes, catheters, opioids, patient based volume repletion, wound local anesthetic infiltration, early mobilization, early postoperative feeding, spirometry and physiotherapy.
45353822|NCT04050020|Biological|Platelet-Rich Plasma (PRP)|All subjects of this group will receive 2 sessions of PRP penile injection with 30 +/- 3 day treatment interval, 10 ml of PRP will be injected at each session.
45477751|NCT03170544|Drug|Placebo to MK-1092|Placebo to MK-1092, SC, as a single dose
46046293|NCT04787978|Other|Physical Activity and Education Intervention|"The intervention involves peer teams, health coaches and community health workers [CHW]. Each participant will be assigned to a CHW and grouped into a team of 10-20 participants based on participant proximity to a Columbus Recreation and Parks Center. Each team will be assigned 4 health coaches, 2 medical students, 1 undergraduate student and 1 nursing student from OSU Health Sciences Colleges.~The lifestyle intervention is 24 weeks consisting of 1 hour and 15 minutes of in person training time per week. The training time consists of 45 minutes of physical activity and 30 minutes of educational content was informed by evidence-based strategies and stakeholder feedback.~Health coaches will implement the curriculum based on the Diabetes Prevention Program and the American Heart Association Check, Change, Control Program and develop team-based SMART (specific, measurable, achievable, relevant, and time-bound) wellness goals."
45353823|NCT04050020|Biological|Normal saline injection|All subjects of this group will receive 2 sessions of normal saline penile injection with 30 +/- 3 day treatment interval for all subjects, 10 ml of normal saline will be injected at each session.
45353824|NCT05408104|Drug|tolvaptan|LVAD recipients with post-operative hyponatremia (Na < 135 mEq/L). Subjects took tolvaptan 15 mg daily as part of their standard care.
45353825|NCT00802152|Other|Home monitoring|The subject will take their blood pressure or glucose measurements 1-4 times per day, depending on patient condition. They will upload these measurements using the device to a secure website at least every other day. Data will be reviewed at least 2 times per week Monday through Friday by the clinic nursing staff. Data indicating problems, e.g., critical out of range values, will be communicated to the patient's primary care physician after review by the nurse. The physician will then determine what is needed for follow up action based on the patient's condition and data (e.g., telephone call to patient home, scheduling a clinic appointment, etc).
45353826|NCT04837716|Biological|Bevacizumab|Given IV
45353827|NCT04837716|Drug|Carboplatin|Given IV
45353828|NCT04837716|Drug|Ensartinib|Given PO
45353829|NCT04837716|Drug|Pemetrexed|Given IV
45353830|NCT00343291|Biological|Cetuximab|Administered intravenously
45353831|NCT00343291|Biological|Bevacizumab|Administered intravenously
45353832|NCT00343291|Drug|Paclitaxel|Administered intravenously
45353833|NCT00343291|Drug|Carboplatin|Administered intravenously
45353834|NCT05360212|Procedure|Anatomy-based fitting (ABF)|MAESTRO 9 can display the tonotopic frequency of each individual electrode channel imported from OTOPLAN to further support fitting based on these measures. The audiologist can set a frequency-band distribution that is more closely aligned to the tonotopic frequency distribution as imported from OTOPLAN.
45353835|NCT05360212|Procedure|Standard Fitting|These group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9.
45353836|NCT05360212|Procedure|Standard fitting+ ABF|Patients of this group are both fitting using the standard frequency-band distribution and the anatomy-based frequency distribution in MAESTRO 9. So, subjects will have both study maps on their audio processor throughout the whole study. They will have to change weekly between both fittings: standard fitting and anatomy-based fitting. Here, the performance with anatomy-based fitting is assessed by comparing performance with standard fitting and anatomy-based fitting.
45353837|NCT00799734|Drug|EXD|Interventions: Intake of prepacked Chinese herbal medicine therapy (EXD), one sachet of granules (15g extracted granules) twice a day and placebo therapy of 15g granules with similar colour and taste.
45353838|NCT05407870|Drug|Etomidate Injection|"Proofol and etomidate are drugs used for sedation and have the same white color.~Gastric endoscopic submucosal dissection is performed using propofol in the control group and etomidate in the experimental group.~Efficacy and safety of sedatives were confirmed using propofol and etomidate."
45353839|NCT05407870|Drug|Propofol Injection|"Proofol and etomidate are drugs used for sedation and have the same white color.~Gastric endoscopic submucosal dissection is performed using propofol in the control group and etomidate in the experimental group.~Efficacy and safety of sedatives were confirmed using propofol and etomidate."
45353840|NCT03988231|Drug|Receipt of enoxaparin|Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
45477752|NCT03170544|Other|Dextrose|20% solution for continuous infusion for the duration of the glucose clamp as needed to maintain blood sugar at pre-clamp target levels.
46046294|NCT04773483|Dietary Supplement|Quorn Foods products|180 g mycoprotein (wet weight; corresponding to 45 g dry weight) per day (equates to approx. 215 g Quorn Foods products, depending on the product)
45477753|NCT03170544|Biological|Insulin|Participants will receive insulin IV, as needed, prior to dosing and clamp initiation and after dosing.
45477754|NCT05259371|Drug|Pulse Electrical Stimulation (Device: Nu Eyne M02)|Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
45477755|NCT03582943|Behavioral|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 7 visits, occurring on consecutive weekdays.
46046295|NCT04773483|Dietary Supplement|Meat/fish products|Standard meat/fish products matched to Quorn group for protein intake
46046296|NCT04770493|Drug|Lamotrigine|Participants will be randomized to lamotrigine (25 mg/day to 200 mg/day in two divided doses) for 9 weeks. A comparator group will receive placebo (sugar pills).
46046297|NCT04770493|Drug|Placebo|Matching placebo (sugar pill)
45353841|NCT03988231|Drug|Placebo|Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
45353842|NCT03988465|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
45353843|NCT03742219|Behavioral|Lifestyle Modification|"Community awareness: a) individuals will be made aware of their own chronic lifestyle diseases and risk factors b) communities will be made aware of their aggregated data concerning chronic lifestyle related diseases and risk factors.~Education for individuals and communities on the meaning of the lifestyle diseases and risk factors. a) individual and small group sessions explaining diseases and lifestyle measures that are helpful, b) community level education to tentatively include i) shopping guides and recipes, ii) urban gardening projects, iii) puppet shows and other community presentations, iv) literature and posters."
45477756|NCT03582943|Behavioral|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 7 visits, occurring on consecutive weekdays.
45477757|NCT03582943|Behavioral|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. This is a motor learning task. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
45477758|NCT03813563|Drug|RL|lactated Ringer's
45477759|NCT03813563|Drug|PLA|PlasmaLyte
45353844|NCT00658788|Drug|clobetasol propionate spray 0.05%|clobetasol propionate spray, 0.05%, applied topically twice daily
45353845|NCT00658788|Drug|calcitriol ointment|calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily
45353846|NCT05407402|Behavioral|laughter yoga practice|To reduce the pain and increase the comfort of individuals diagnosed with migraine with these planned interventions.
45353847|NCT05407402|Behavioral|watching funny videos|To reduce the pain and increase the comfort of individuals diagnosed with migraine with these planned interventions.
45353848|NCT01060969|Drug|Tadalafil and acetazolamide|Experimental arm: Tadalafil 20 mg daily + acetazolamide 125 mg BID beginning above 3000 m altitude.
45353849|NCT01060969|Drug|Acetazolamide|Active comparator arm (control): acetazolamide 125 mg BID beginning above 3000 m altitude
45353850|NCT05407246|Drug|Hemay005|Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;
45353851|NCT01061047|Drug|Ertapeneme|
45353852|NCT00799890|Drug|Sunphenon EGCG|200-800mg (1-4 capsules)
45477760|NCT03334786|Drug|FLX-787-ODT|Oral Disintegrating Tablet
45477761|NCT02494414|Other|Long-term follow-up|Vital and neurological follow-up
45477762|NCT03813641|Drug|Raltitrexed|Experimental: Oxaliplatin + Raltitrexed + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Raltitrexed (3mg/m2, intravenous drip for 15 minutes, d1)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
45477763|NCT03813641|Drug|Capecitabine|Other: Oxaliplatin + Capecitabine + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
45843245|NCT04965246|Behavioral|Physical Activity|The physical activity program will focus on increasing physical activity, starting with a target of 100 minutes per week. The session durations will build over time to 150 minutes per week. Participants will be instructed to walk, or engage in other forms of light-intensity physical activity to achieve these goals. Participants will be instructed on the use of the ratings of perceived exertion scale (6-20). As the participants' health and fitness status improves, frequency, intensity, and session duration will be modified accordingly during weekly support calls. As participants will enter the study engaging in varying levels of physical activity, goals will be responsive to the most recent week's achieved minutes.
46046298|NCT04763993|Procedure|Roux-en-Y-Gastric bypass, Sleeve gastrectomy|RYGBP consists in creating a small gastric pouch along the little curvature of the stomach, followed by the section of the small bowel. The restoration of the gastro-intestinal tract is achieved by performing a gastro-jejunal and a jejuno-jejunal anastomosis, giving this procedure the characteristic aspect of a Y. Also, for RYGBP the laparoscopic approach requires the placement of 5 trocars in the upper part of the abdomen.
45477764|NCT02494492|Other|intravitreous administration of regulator T-cells|The 3 levels of Tregs doses will be respectively 0.4, 1.2 and 3.6 million.
45477765|NCT02492464|Dietary Supplement|Red yeast rice|1 capsule to be taken before to sleep, each day, for 6 months
45843246|NCT04965246|Other|Usual Care|Participants in the usual care group will receive no intervention
45843247|NCT04887792|Drug|Acetazolamide|ACZ 250 mg/day in gelatin capsules will be administered initially and increased over 7-10 days to 2g/day.
45843248|NCT04887792|Drug|Placebo|Identical gelatin capsules will be prepared by filling with inert excipients.
45843249|NCT04771416|Biological|PBKR03|Single dose of PBKR03, via intra cisterna magna
46046299|NCT04763993|Procedure|SG|SG consists in removing the fundus and the body of the stomach, along the greater curvature. To perform it with a laparoscopic approach, we create the pneumoperitoneum with Veress needle and place 5 trocars in the upper part of the abdomen. The first step is the dissection of the greater curvature of the stomach, that starts at 6 centimetres from pylorus and it's conducted up to the angle of His, freeing the fundus and exposing the left pillar. A 38 Fr bougie is placed inside the stomach to calibrate its section. After it is carried out, the specimen is removed from the greater trocar site.
45353853|NCT00799890|Drug|Placebo|1-4 capsules
45477766|NCT02492464|Dietary Supplement|Placebo|
45477767|NCT05210478|Device|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a non-invasive imaging test which uses light waves to take cross-section pictures of the retina.
45477768|NCT05255159|Diagnostic Test|18F-DOPA with furosemide|Diagnostic 18F-DOPA PET/CT scan
45477769|NCT03532009|Drug|Sodium Zirconium Cyclosilicate|Oral use for approximately 3 months
45477770|NCT03532009|Drug|Placebo|Oral use for approximately 3 months
45353854|NCT01057771|Behavioral|Meditation|Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
45353855|NCT01057771|Behavioral|Exercise|Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
45353856|NCT00799968|Drug|Urokinase|UK,bolus 4 400 U/kg followed by intravenous 2 200 U/kg•h for 12 hours
45353857|NCT00799968|Drug|Urokinase|UK,20 000U/kg continuously intravenous infusion for 2 hours
45353858|NCT01061125|Other|TTM and Holter monitor|Standard of care visits recordings reviewed during clinical visits
45353859|NCT01055275|Device|Implantation with a Cook Iliac Branch Graft|Treatment of an aortic, aorto-iliac or iliac aneurysm with a CE-marked Cook Iliac Branch Graft.
45353860|NCT05590312|Other|general anesthesia|All patients will undergo general anesthesia. Group D will receive fresh gas flow of 1 l/min and Group Y will receive fresh gas flow of 4 l/min.
45477771|NCT05465434|Drug|Zinc Supplement|Zinc sulphate 50 mg
45353861|NCT00800046|Device|AccuCinch® Ventriculoplasty System|Mitral valve repair due to functional disease
45477772|NCT05207046|Other|Mechanical Ventilation|Patients will be assessed and measurements will be taken during controlled ventilation (most likely <72 hours of ICU admission), during partially assisted ventilation, and until spontaneous unassisted breathing is reached.
45353862|NCT04002544|Drug|NTG patch|A half-NTG patch (dose calculated at 5-12.5 mcg/kg/hr) will be applied to patients at the site of radial pulsation one hour before induction of anesthesia. The NTG patch will be applied to the right upper in half of the patients and will be applied to the left upper limb in the other half
45353863|NCT04002544|Other|gauze cover|A gauze will be applied near the radial artery pulsation to ensure blinding
45353864|NCT04829214|Drug|OTO-313|Single intratympanic injection
45353865|NCT04829214|Drug|Placebo|Single intratympanic injection
45353866|NCT00802230|Drug|Terbutaline Infusion|
45353867|NCT04650256|Other|Complementary and alternative medicine (CAM)|CAM will be applied topically on the chest wall once during the day (or immediately after radiotherapy) and once at night daily.
45477773|NCT05251727|Drug|thrombomodulin alfa|Weight based dose of reconstituted treatment
46046300|NCT04761432|Device|neoGuard|NeoGuard is a wireless wearable vital signs monitor that continuously measures temperature, pulse rate, respiratory rate and oxygen saturation.
46046301|NCT04753788|Diagnostic Test|PCR|qPCR for T.pallidum
45477774|NCT05251727|Drug|Placebo|Weight based dose of reconstituted treatment
45477775|NCT03340558|Biological|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.
45353868|NCT00802308|Drug|Morphine sulphate|Extended release tablet combined with alcohol or water
45353869|NCT00562965|Drug|inotuzumab ozogamicin|IV administration, 1.8mg/m² on day 2 of each cycle every 28 days, for up to 8 cycles.
45353870|NCT00562965|Drug|rituximab|IV administration, 375 mg/m² on day 1 of each cycle every 28 days, for up to 8 cycles.
45353871|NCT00562965|Drug|rituximab|intravenous rituximab at a dose of 375 mg/m2 on day 1
45353872|NCT00562965|Drug|cyclophosphamide|intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1
45353873|NCT00562965|Drug|vincristine|intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1
45477776|NCT03340558|Drug|Cobimetinib|MEK inhibitor
45477777|NCT04905108|Drug|Riboflavin|Administration of riboflavin one drop every 2 minutes during UVA exposure
45477778|NCT04905108|Drug|Riboflavin|Administration of riboflavin one drop every 10 minutes during UVA exposure
45477779|NCT04443166|Combination Product|A platelet-rich plasma (PRP)+ hyaluronic acid (HA) program|a combination of intra-articular knee injection with platelet-rich plasma (PRP) and hyaluronic acid (HA)
45477780|NCT04509570|Procedure|Biopsy|5~20mg/ml, intralesional injection every 1 month. Number of cycles: until the lesions are clinically cleared
45477781|NCT01560221|Behavioral|Therapeutic Workplace|Participants can access stipend supported academic and job skills training for adults and/or receive wages or wage subsides for actual employment. Access to training and employment is contingent upon meeting therapeutic targets. Potential targets include, but are not limited to, drug abstinence and medication adherence.
45498260|NCT04133623|Drug|Ibuprofen|Administration of ibuprofen 10 mg/kg up to 600 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ketorolac.
46046302|NCT04753788|Diagnostic Test|LAMP|LAMP assay for T.pallidum
45353874|NCT00562965|Drug|prednisone/prednisolone|oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5
45353875|NCT00562965|Drug|mitoxantrone|mitoxantrone 10 mg/m2 intravenous on day 2
45353876|NCT00562965|Drug|fludarabine|fludarabine 25 mg/m2 intravenous on days 2 through 4
45353877|NCT00562965|Drug|dexamethasone|oral dexamethasone 20 mg/day on days 1-5
45353878|NCT05358496|Diagnostic Test|Data collection|Clinical data collection
45353879|NCT05407090|Dietary Supplement|probiotic supplementation|Participants enrolled in the probiotic group will receive probiotics for 12 weeks before surgery.
45353880|NCT05407090|Dietary Supplement|placebo|Participants enrolled in the placebo group will receive a placebo instead of probiotics.
45353881|NCT00802620|Procedure|Conjunctival autograft versus conjunctival autograft treatment for recurrent pterygia|Amniotic membrane Conjunctival autograft Conjunctival autograft Recurrent pterygia
45353882|NCT05406934|Biological|Infliximab|obseravation with investigation
45353883|NCT00800124|Procedure|cemented Landos prosthesis vs. uncemented Landos prosthesis|randomization between the cemented and non-cemented prosthesis.
45353884|NCT00940329|Drug|Roflumilast|Treatment A (500 μg/d roflumilast from day 2 to day 18 and 48 μg/d formoterol from day 12 to day 18)
45353885|NCT00940329|Drug|Roflumilast|Treatment B (48 μg/d formoterol from day 2 to day 18 and 500 μg/d roflumilast from day 9 to day 18)
45477782|NCT01560221|Drug|Methadone|Methadone in liquid form, with the dosage determined by physician on an individual basis. Anticipated dose range 30mg to 100mg daily. Methadone is administered daily at a methadone clinic for as long as enrollment in the methadone clinic is maintained.
45477783|NCT01560221|Drug|Buprenorphine|Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) are approved for the treatment of opiate dependence. Subutex and Suboxone treat opiate addiction by preventing symptoms of withdrawal from heroin and other opiates.
45477784|NCT03334474|Other||no intervention
45477785|NCT03813329|Dietary Supplement|Modified Sodium Bicarbonate|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate
45477786|NCT03813329|Dietary Supplement|Acute Sodium Bicarbonate|3 progressively larger doses of calcium carbonate followed by one acute dose of sodium bicarbonate (300 mg/kg)
45477787|NCT03813329|Dietary Supplement|Calcium carbonate (placebo)|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of calcium carbonate
45477788|NCT03723343|Drug|GP+IMRT|Gemcitabine 1000 mg/m2 intravenously, d1&d8 +Cisplatin 80 mg/m2 intravenously, d1 21~28 days/cycle, 4 patients with oligometastasis, 6 cycles with multiple metastases
45477789|NCT03723343|Drug|TPF+IMRT|Docetaxel: 75mg/m2 intravenous drip, d1+Cisplatin75mg/m2 intravenous drip, d1~d5+5-fluorouracil 750mg/m2/d intravenous drip, d1~d521~28 days/cycle, patients with oligometastasis take 4 cycles, moreTransfer patients for 6 cycles
46046303|NCT04745117|Behavioral|READHY - questionnaire|The READHY tool consists of 70 questions divided into three sections, one with a focus on eHealth literacy, one on self-management and one on the social context. The READHY consists of the eHealth Literacy Questionnaire (eHLQ) that includes seven scales, supplemented with four scales from the Health Education Impact Questionnaire (heiQ) and two scales from the Health Literacy Questionnaire (HLQ). The READHY tool has been validated. Each question presented to the participant as a statement and scored on a 4-point rating, from 1=strongly disagree to 4=strongly agree. The overall score of each scale was calculated as the mean score of the 4-6 items (i.e., statements) that constitute the scale (2).
45477790|NCT03340480|Drug|NVP-1402|Oral
46046304|NCT04741464|Drug|Tinzaparin|"Tinzaparin 20 000 anti-Xa IU/mL dispensed in graduated syringes of 0.5 mL, 0.7 mL and 0.9 mL at the dose of 175IU/Kg/d.~Strategy: Tinzaparin 175 UI/Kg/d for 21 days After this time the physician will continue the treatment of his choice to treat DVT."
45353886|NCT00794898|Biological|Infliximab (Remicade)|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6. All patients will continue to receive the same dose of MTX they were receiving at entry throughout the subsequent treatment period.
45477791|NCT03639415|Drug|Increasing the Controlled-Release Oxycodone dose frequency|Keep the daily dose while increase the dose frequency of Controlled-Release Oxycodone so that reduce the single dose
45477792|NCT03334240|Drug|CLS003|CLS003
45353887|NCT00934557|Drug|ATG Fresenius|
45353888|NCT00934557|Drug|ATG Fresenius|
45353889|NCT00934557|Drug|ATG Fresenius|
45353890|NCT00934557|Drug|ATG Fresenius|
45477793|NCT03334240|Drug|Vehicle|Vehicle
45477794|NCT03813485|Other|Dry Needling in upper trapezius|"The following criteria are required for a patient to have latent TrPs: the presence of a palpable taut band in the upper trapezius muscle, the presence of a hypersensitive spot in the taut band, a palpable or visible local twitch on snapping palpation, and a no familiar reproduction of referred pain elicited by palpation of the sensitive spot.~Dry needling is performed with solid filiform needles (0.30x30 mm), these needles are sterile and separately packaged. Needles are not reused and are immediately deposited in a needle container after usage. Patients receive dry needling in latent myofascial trigger point (LTRs) in upper trapezius. The needle is penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
45477795|NCT03813485|Other|Dry Needling in lower trapezius|"The following criteria are required for a patient to have latent TrPs: the presence of a palpable taut band in the lower trapezius muscle, the presence of a hypersensitive spot in the taut band, a palpable or visible local twitch on snapping palpation, and a no familiar reproduction of referred pain elicited by palpation of the sensitive spot.~Dry needling is performed with solid filiform needles (0.30x 30 mm), these needles are sterile and separately packaged. Needles are not reused and are immediately deposited in a needle container after usage. Patients receive dry needling in latent myofascial trigger point (LTRs) in lower trapezius. The needle is penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
45353891|NCT00934557|Drug|ATG Fresenius|
45477796|NCT03340402|Radiation|Accelerated Partial Breast Irradiation|Proton radiation
46046305|NCT04740892|Other|Wash IP|Parent participant will bathe the child participant with the investigational wash at least 3 times per week, but no more than once daily, for 4 weeks.
46046306|NCT04740892|Other|Cream IP|Parent participant will apply the investigational cream on their child participant twice daily for 4 weeks.
45353892|NCT00934557|Drug|ATG Fresenius|
45353893|NCT00934557|Drug|ATG Fresenius|
45353894|NCT00934557|Drug|ATG Fresenius|
45353895|NCT05357092|Device|Appliance. Orthodontic appliance to carry out dentoalveolar movement|"A digital 3D model obtained with a 3D scanner: (T1,baseline), (T2, aprox 8 weeks), and at the end of othopedic treatment previous to primary lip surgery (T3, aprox 16 weeks).~Once a week, clinical check."
45353896|NCT00800280|Drug|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally
45353897|NCT00800280|Drug|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally on Day 2.
45353898|NCT00800280|Drug|cimetidine|600 mg q 6 hours cimetidine immediate release formulation administered orally on Days 1 through 5.
45477797|NCT03340402|Device|AlignRT|AlignRTTM uses infrared imaging to capture the 3D data of the patient's position to ensure accuracy of treatment delivery
45686687|NCT04480450|Drug|Rituximab|Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a mouse human chimeric monoclonal antibody against CD20. Administration leads to between 90 and 100% peripheral B cell depletion via complement dependent cytotoxicity.
45843250|NCT04594200|Behavioral|Audit and Feedback (A&F)|"In this protocol, we propose comparing 2 intervention design elements in a multifactorial design. Specifically, we will evaluate:~i) an emphasis on antibiotic-associated harms in comparison to messages that focus on lack of benefit; ii) simple versus adjusted peer comparators to represent a target for the prescribing quality indicators~We will also investigate the effects of the inclusion of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing"
45843251|NCT04518228|Drug|Bictegravir (BIC)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
45843252|NCT04518228|Drug|Tenofovir alafenamide (TAF)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
45843253|NCT04518228|Drug|Cabotegravir (CAB)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
45843254|NCT04518228|Drug|Dolutegravir (DTG)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
45843255|NCT04518228|Drug|Atazanavir/ritonavir (ATV/r)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
45843256|NCT04518228|Drug|Darunavir/ritonavir (DRV/r)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
45843257|NCT04518228|Drug|Lopinavir/ritonavir (LPV/r)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
45843258|NCT04518228|Drug|Cobicistat|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
45843259|NCT04518228|Drug|Ritonavir|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
45843260|NCT04518228|Drug|First-Line TB Treatment|"Participants will be receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), or moxifloxacin (MFX).~Drugs will be administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants."
45843261|NCT04518228|Drug|Second-Line TB Treatment|"Participants will be receiving second-line TB treatment with at least one of the following second-line TB treatment drugs:~Levofloxacin (LFX) 750mg - 1000mg q.d.~Clofazimine (CFZ) 100mg q.d.~Linezolid (LZD) 300mg - 600mg q.d.~Bedaquiline (BDQ) 200mg three times per week (t.i.w.)~Delamanid (DLM) 100mg b.i.d.~Moxifloxacin (MFX) 400mg or 800mg q.d., and at least one other second-line TB treatment drug under study~Drugs will be administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants."
45686688|NCT00217594|Drug|Alemtuzumab (Campath)|
45686689|NCT00118534|Behavioral|Integrated Care for Smoking Cessation in PTSD patients|Smoking cessation therapy is integrated with PTSD therapy.
45686690|NCT00118534|Behavioral|Standard of Care|Patients interested in quitting smoking are referred to a separate smoking cessation clinic, per standard of care.
46046307|NCT04727047|Device|neuromuscular electrical stimulation|All subjects will receive standard rehabilitation for Achilles tendon repair. In addition, neuromuscular electrical stimulation will be applied to the calf muscles of the injured leg. The stimulation volume, the electrode placement and the intensity of the stimulation will be selected based on the mechanical strength of healing Achilles tendon. The intervention will be applied for 6 weeks after repair.
45686691|NCT00052078|Drug|Sertraline (SRT)|Participants were treated with sertraline.
46046308|NCT04715893|Device|Ostomy belt|Stealth ostomy belt continuous for eight weeks
45477798|NCT03721939|Device|FLEX Scoring Catheter|Vessel preparation with the FLEX Scoring Catheter® with a 30° rotation between each passage is performed, followed by a DEB angioplasty.
45686692|NCT00052078|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants received CBT.
45686693|NCT00052078|Drug|Placebo|Participants were treated with a placebo pill.
45686694|NCT05820646|Other|Boswellia Sacra|"Boswellia Sacra used as an intracanal medicament for 3 days~Boswellia Sacra used as an intracanal medicament for 7 days"
45353899|NCT04014153|Procedure|Iodinated contrast media|Percutaneous coronary intervention with iodinated contest media
45353900|NCT04996576|Procedure|infrazygomatic approach sphinopalatine ganglion block|"A lateral fluoroscopic view of the face will be obtained with the C-arm by superimposing the mandibular rami on top of each other spinal needle with a slightly bent tip is inserted with lateral fluoroscopic guidance. superiorly and medially toward the sphinopalatine fossa.~(AP) view intermittently obtained to check the depth 0.2 mL of contrast material will be injected to rule out intravascular spread and confirm spread of the dye within the sphinopalatine fossa .Local anesthetic, such as 2 mL of 1% lidocaine will be slowly injected"
45353901|NCT04996576|Procedure|intranasal injection approach of sphinopalatine ganglion block|method 2 ml Lidocaine with Epinephrine 1/200000 will be injected posterior to meatus of middle concha to block terminal nerve branches of sphinopalatine ganglia
45353902|NCT00800358|Drug|Paricalitol|oral paricalcitol variable daily dosing based on intact PTH level for 6 months
45353903|NCT00800358|Drug|Calcitriol|oral calcitriol variable daily dosing based on intact PTH level for 6 months
45353904|NCT00934713|Drug|montelukast|montelukast 4mg once per day for 8 weeks period
45353905|NCT05358262|Device|Airvo|Fisher & Paykel's AIRVO 2 is a humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases to spontaneously breathing patients through a variety of interfaces including nasal cannula. Flow can be delivered from 2 to 60 LPM
45353906|NCT00802698|Device|Transcorneal electric stimulation|central artery occlusion
45686695|NCT05820633|Radiation|Report and compare changes in a non-inferiority analysis of the International Prostate Symptom Score (I-PSS)|Assess early and late genito-urinary (GU) toxicities induced assessed via the International Prostate Symptom Score (I-PSS) in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
45686696|NCT05820633|Radiation|"Report and compare changes in a non-inferiority analysis of the expanded prostate cancer index composite (EPIC-26):"|Assess early and late genito-urinary (GU) and gastro-intestinal (GI) toxicities induced and quality of life assessed via expanded prostate cancer index composite (EPIC-26) in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
46046309|NCT04698564|Drug|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) [ 13C]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize [13C]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and [13C]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as [1- 13C]pyruvate, [2- 13C]pyruvate and [1,2- 13C]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body [Koletzko et al., 1997]."
45353907|NCT00802698|Device|Transcorneal stimulation|new waveform
45353908|NCT00802698|Device|transcorneal electric stimulation|Novel waveform central artery occlusion
45353909|NCT00935025|Drug|AZD1305|single and multiple oral doses, extended-release capsule
45353910|NCT00935025|Drug|Placebo|single and multiple oral doses, capsule
46046310|NCT04685265|Drug|anle138b|capsule containing excipient and anle138b
46046311|NCT04685265|Drug|Placebo|matching placebo capsule containing excipient
46046312|NCT04666584|Device|ScoreFlex balloon|Pre-dilatation with a ScoreFlex balloon
45353911|NCT00802776|Procedure|Femtosecond laser assisted keratoplasty|
45353912|NCT00802776|Procedure|PKP|
45353913|NCT00939861|Procedure|laparoscopy|colorectal resection
45353914|NCT00939861|Procedure|laparotomy|colorectal resection
45353915|NCT00802932|Device|Non-contrast Computed Tomography (CT) Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy, and during weeks 2, 4, 6.
45353916|NCT00802932|Device|Non-contrast CT Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy and on Day 5.
45353917|NCT00935103|Behavioral|Psychoeducation|
45353918|NCT01057849|Drug|risperidone|3-6 mg per day
45353919|NCT01057849|Drug|olanzapine|5-20 mg per day
45353920|NCT01057849|Drug|Aripiprazole|10-30 mg per day
45353921|NCT00940407|Device|Photobiomodulation (Gentlewaves, Warp 10)|Two separate light emitting devices that are already approved for other indications are used. Treatment will consist of 18 treatments lasting approximately two minutes per treatment.
45353922|NCT00794976|Drug|Dexamethasone Iontophoretic Patch (low dose)|
45353923|NCT00794976|Drug|Dexamethasone Iontophoretic Patch (high dose)|
45353924|NCT00794976|Drug|Dexamethasone Passive Patch|
45353925|NCT00794976|Drug|Placebo Patch|
45353926|NCT00939939|Drug|sitagliptin|sitagliptin 100 mg/d for 10 weeks
45353927|NCT00939939|Drug|glimepiride|glimepiride 1 mg/d for 10 weeks
45353928|NCT00537082|Drug|FTY720|Administered orally once daily for 6 months
46046313|NCT04666584|Device|Device: standard non-compliant balloon|Pre-dilatation with a standard non-compliant balloon
45353929|NCT00537082|Drug|Placebo|Administered orally once daily for 6 months
45353930|NCT03828487|Device|Masimo O3 Neonatal Sensors|Regional Oximetry sensor for Neonates
45353931|NCT03828487|Device|510(k) cleared sensor|Cleared Regional Oximetry sensor for Neonates
45353932|NCT00795054|Other|Household financial data collection|Baseline financial survey pre-transplant, financial diary post-transplant every two weeks for 3 months, and financial questionnaire via phone survey at 6, 12, 18 and 24 months post-transplant.
45353933|NCT04012983|Diagnostic Test|gingival crevicular fluid level|gingival crevicular fluid collection
45353934|NCT00805662|Drug|oxytocin, placebo|intranasal oxytocin during intrauterine insemination
45353935|NCT03988153|Combination Product|Probiotic Milk Formula|Drink 200 mL of PMF for 10 weeks and followed by 2 weeks of follow up period for monitor any adverse effect
45353936|NCT04014309|Other|Supportive and survivorship care program|Provision of routine systematic screening using distress thermometer and problem list with accompanying supportive care nurse service.
45353937|NCT04014309|Other|Usual care|Usual care
45353938|NCT04978012|Drug|Fluzoparib and Camrelizumab|Maintenance therapy of Fluzoparib and Camrelizumab, until disease progression or intolerable adverse effect.
45353939|NCT00803088|Device|The Alair System|Treatment of airways with the Alair System
45353940|NCT01061203|Drug|Grazax|Treatment with 75.000 SQ-T once daily
45353941|NCT01061203|Drug|Placebo|Tablet with no active grass component.
45353942|NCT00803166|Drug|Halobetasol Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of three days
45477799|NCT01299623|Behavioral|Comparison of evidential versus non-evidential education on women's breast cancer prevention behaviors|Participants will be randomized to either the evidential or non-evidential group. Both groups will receive primarily the same information, except one group will receive information that is more tailored to African American women, while participants in the other group will receive general information about breast cancer prevention.
45477800|NCT03334162|Behavioral|Sensorimotor training|"Supervised training sessions will last for about 20 to 30 minutes in total, including a child-specific warm-up and cool-down. The children will be asked to maintain balance in a previously acquired short-foot-position, knees slightly flexed (30°), without shoes. Training will consist of 5 playful balance exercises, chosen from a standardized pool of exercises according to the child's age, with increasing difficulty (5 degrees of difficulty - e.g. by reducing the base of support, or dual task exercises - per exercise depending on the age group) in order to allow for individual, optimal progression. Each of the 5 exercises will contain of 5 repetitions for 10sec. allowing for a 20sec. rest in between each set and a 1min rest between each exercise in order to avoid neural fatigue. Children will be given a training manual and diary to train at home after the study. Guardians will be instructed in order to be able to assist their children"
45477801|NCT02916953|Device|AGN1 Femoral Local Osteo-Enhancement Procedure|A procedure that is intended to increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck. Local treatment of the proximal femur with AGN1 is intended to be adjunctive to appropriate systemic therapy and overall osteoporosis management as directed by the patient's treating physicians.
45353943|NCT00803166|Drug|Halobetasol Propionate 0.05% Cream-Test product 1|Small amount applied and evaluated over the course of three days
45353944|NCT00803166|Drug|Halobetasol Propionate 0.05% Cream-Test Product 2|Small amount applied and evaluated over the course of three days
45353945|NCT04578574|Other|Bodily Illusions (BI) Procedure|Each sessions will consists of two types of illusions that are 15 min each, the rubber hand illusion (RHI) and the walking illusion (WI) that involve both arms and legs.
45353946|NCT04578574|Device|Transcranial direct electrical stimulation (tDCS)|Each sessions will consists of electrical current delivered from a battery-driven, constant current stimulator using saline-soaked surface sponge electrodes. One electrode will be placed on your scalp on the right side and the other electrode over the left eye on your forehead. A weak current will be applied for 30 min at the same time as the BI.
45353947|NCT04578574|Other|Sham Transcranial Direct Electrical Stimulation (tDCS)|Each session of the Sham tDCS will be applied for 30 min at the same time as the BI.
45353948|NCT00935181|Behavioral|respiratory muscle stretching|stretching exercises for respiratory muscles like diaphragm, pectoral, dorsalis etc
45353949|NCT00324961|Drug|adefovir dipivoxil tablets|adefovir dipivoxil once daily 10 mg orally
45353950|NCT04855422|Diagnostic Test|Allosure|AlloSure Analysis For the AlloSure test, 10-20 mL of blood will be obtained in Streck Cell-Free DNA BCT tubes and shipped to CareDx, Inc. (Brisbane, CA) at ambient temperature in insulated packaging to minimize temperature fluctuation. The AlloSure test will be performed at the CareDx CLIA/CAP-accredited clinical laboratory. Samples will be tested, and results provided within 3 days of blood draw
45353951|NCT04855422|Diagnostic Test|AlloMap|AlloMap Kidney is intended to aid in the identification of SPK transplant recipients who have a low probability of rejection at the time in testing in conjunction with standard clinical assessment. For the AlloMap-Kidney test, approximately two tubes of blood will be obtained in PAXgene Blood RNA tubes and shipped to CareDx, Inc. (Brisbane, CA), where it will be tested.
45353952|NCT04002232|Device|CPP-ACP-NaF varnish|calcium phosphate containing fluoride releasing varnish to prevent caries
45353953|NCT04013451|Behavioral|Acts of kindness|Both intervention and control groups will receive an email with access to a relaxation and stress management booklet from Western University's (UWO) Wellness Education Centre (http://studentexperience.uwo.ca/docs/RelaxationAndStressManagement.pdf). In addition, the intervention group will be asked to (1) complete and log/submit a minimum of three deliberate acts of kindness per day for one month, and (2) join the study-dedicated online site to connect with, support, and share experiences and ideas with each other around acts of kindness.
46046314|NCT04663555|Drug|Dexamethasone|Patients in the intervention group after randomization will receive dexamethasone 20 mg intravenously once daily on day 1-5, followed by dexamethasone 10 mg intravenously once daily on day 6-10. If successful extubation occurs before day 10, treatment with dexamethasone is withdrawn.
45686697|NCT05820633|Radiation|Report and compare changes in a non-inferiority analysis of the Sexual Health Inventory for Men (SHIM)|Assess early and late sexual health in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
46046315|NCT04662632|Combination Product|VT-X7 Treatment System|Seven-day local antibiotic irrigation (alternating tobramycin sulfate and vancomycin HCl) via the VT-X7 Knee or Hip Spacer.
46046316|NCT04662632|Drug|SOC|Forty-two days (minimum) systemic antibiotic administration adjuvant to two-stage exchange arthroplasty with temporary antibiotic-impregnated cement spacer per SOC. Antibiotics will be selected by treatment provider and administered in accordance with national and local treatment guidelines.
45353954|NCT05357014|Diagnostic Test|echocardiography|evaluation of cardiac function hn children on regular heamodialysis by echocardiography
45353955|NCT04846140|Device|transcranial electrical stimulation (tES)|Transcranial electrical stimulation (tES) is a form of neuromodulation that uses constant, low direct current delivered via the electrodes on the skull. Three types of tES will be applied in this study, include a-tDCS, tACS, and tRNS. Additionally, sham stimulation will be applied as a placebo-controlled intervention.
45353956|NCT00935337|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
45353957|NCT00935337|Behavioral|Sleep Hygiene|treatment as usual
45353958|NCT00809250|Biological|GM-K562/leukemia cell vaccine|Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
45353959|NCT00935415|Drug|Montelukast|Montelukast 5 mg
45353960|NCT00935415|Drug|Placebo|capsules of matching placebo
45353961|NCT00935571|Drug|propofol, remifentanil, sevoflurane|Propofol: using target controlled infusion (TCI); 1-3ug/ml remifentanil: using TCI by 5-20 ng/ml sevoflurane: 2-3volume% (1-2 MAC)
45353962|NCT00324649|Drug|Truvada|Truvada once daily with continuation of the current NNRTI or PI at randomization.
45477802|NCT02492542|Device|PHENIX USB 8.|Electrical stimulation program: frequency: 1/4/Hertz (HZ), pulse width: 270/230/270 μs, time: 30min. Electrode piece: 50*50mm sticky electrode plate. Position: an electrode piece is placed in the S3, and an electrode piece is placed in the bladder region.Current intensity adjusted according to the patient's tolerance, the maximum current intensity of the pain was not appropriate, generally not more than 100milliampere(mA).Devices PHENIX USB 8.
45477803|NCT03334084|Drug|ARGX-113|intravenous or subcutaneous administration
45477804|NCT05623787|Diagnostic Test|Whole-body diffusion-weighted magnetic resonance imaging|See arm description.
45477805|NCT03340324|Biological|V-Endo|V-Endo is a tableted immunotherapeutic derived from hydrolyzed, heat-inactivated, pooled blood from women with endometriosis
45686698|NCT05820633|Radiation|Report and compare changes in a non-inferiority analysis of the toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE)|Assess early and late toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE) in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
45353963|NCT00324649|Drug|Zidovudine/lamivudine|Continuation of the zidovudine + lamivudine containing regimen plus the current NNRTI or PI at randomization.
45353964|NCT03743259|Drug|LuminoMark inj. 0.1mL|Injection LuminoMark inj. (Conc. for fluorescence) 0.1mL once in this study.
45353965|NCT03743259|Drug|LuminoMark inj. 0.2mL|Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
45353966|NCT03743259|Drug|Charcotrace Inj.|Injection Charcotrace Inj. about 0.3~1mL once in this study.
45353967|NCT04045782|Drug|single arm|switch from originator (Humira) to biosimilar (Imraldi)
45353968|NCT02553720|Other|exercise in water|The patients will be instructed to perform walking or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
45353969|NCT02553720|Other|aquatic activity plus conventional management|walking in water or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
45353970|NCT00935727|Other|Elastographic imaging|ultrasound imaging using a specialized computer that processes the data for tissue hardness
45353971|NCT00803478|Procedure|LASIK|
45353972|NCT03983239|Drug|Fedratinib|Fedratinib
45353973|NCT03983239|Drug|Rifampin|Rifampin
45353974|NCT03983239|Drug|Efavirenz|Efavirenz
45353975|NCT00935805|Drug|Metformin|850 mg TID
45477806|NCT03520387|Procedure|Lumbar medial branch nerve radiofrequency ablation (LRFA)|Radiofrequency ablation of the dorsal rami of the lumbar spinal nerves, using electrode placement parallel to the medial branches, 18G electrodes or larger, and 2 lesions per nerve.
45353976|NCT00935805|Drug|Glybenclamide|10 mg BID
45353977|NCT00935805|Drug|NPH insulin|Variable SC dose
45353978|NCT00935805|Drug|Hydrochlorothiazide|25 mg QD introduced as initial therapy for hypertension
45353979|NCT00935805|Drug|Propranolol|40 mg BID
45353980|NCT00935805|Drug|Captopril|50 mg TID
45353981|NCT00935805|Drug|Amlodipine|10 mg QD
45353982|NCT03986125|Behavioral|Emotional Awareness & Expression Therapy|emotion-focused
45477807|NCT03520387|Procedure|Simulated LRFA with targeted steroid injections|Performed in an identical fashion to the experimental arm (LRFA), except for medial branch lesioning, which will not be done in simulated LRFA, and 2) the simulated LRFA control group will receive an injection of triamcinolone acetonide at each site where a radiofrequency lesion would normally be applied.
45477808|NCT03520387|Behavioral|AcTIVE-CBT|AcTIVE-CBT involves a standardized CBT protocol for pain, delivered via a video telehealth interface. AcTIVE-CBT also incorporates use of an activity tracker to provide objective feedback on activity levels, which can inform participants' and providers' impressions of goals and progress.
45477809|NCT03520387|Behavioral|TBSCE|TBSCE control is a focused program of CBT involving an initial 60-minute telephone education session by a psychologist; the provision of printed educational materials on chronic pain self-management, and a workbook for CBT self-management; and structured, written plans for weekly practice, reading and homework using the workbook.
45477810|NCT02492386|Device|Bioabsorbable everolimus-eluting stent deployment|Bioabsorbable everolimus-eluting stent deployment
45686699|NCT05820633|Radiation|Report and compare the biochemical disease free survival (bDFS)|Assess the 5 and 10 years biochemical disease-free survival (bDFS) in the UHF group and compare them for non-inferiority to those of the control group.
45686700|NCT05820633|Radiation|Report and compare the disease free survival (DFS)|Assess the 5 and 10 years disease-free survival (DFS) in the UHF group and compare them for non-inferiority to those of the control group.
45686701|NCT05820633|Radiation|Report and compare the metastase free survival (MFS)|Assess the 5 and 10 years metastasis-free survival (MFS) in the UHF group and compare them for non-inferiority to those of the control group.
45686702|NCT05820633|Radiation|Report and compare the overall survival (OS)|Assess the 5 and 10 years overall survival (OS) in the UHF group and compare them for non-inferiority to those of the control group.
45686703|NCT05820607|Biological|Microbiome, metabolome, transcriptome, genome|Fecal genome, serum metabolome, leukocyte transcriptome, gastric mucosa genome
45843262|NCT04518228|Drug|Doravirine (DOR)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
46046317|NCT04662632|Procedure|Two-stage exchange arthroplasty|Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis, followed by systemic administration of postoperative antibiotics for 42 days (inclusive) to 90 days (inclusive).
46046318|NCT04662320|Device|Checkpoint BEST System|"Single use medical device, consisting of electric stimulator and intraoperative lead. Therapy consists of single, 10 minute dose delivered proximal to site of decompression/repair.~Other Name: Checkpoint BEST System"
46046319|NCT04637763|Genetic|CB-010|CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.
46046320|NCT04637763|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
46046321|NCT04637763|Drug|Fludarabine|Chemotherapy for lymphodepletion
46046322|NCT04630262|Device|ATTUNE Cementless CR Fixed Bearing|Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and CR or (Medial Stabilized) MS Tibial Insert.
46046323|NCT04630262|Device|ATTUNE Cementless PS Fixed Bearing|Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and PS Tibial Insert.
45353983|NCT03986125|Behavioral|Mindfulness Meditation Training|meditation training and practice
45353984|NCT00935961|Drug|RAD001 + docetaxel + cisplatin|Patients will receive daily RAD001 (everolimus, per dose escalation scheme) plus concurrent docetaxel (75 mg/m2 intravenously every 3 weeks) + cisplatin (75 mg/m2 intravenously every 3 weeks). Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle. Patients will be followed for toxicity for 30 days after the last dose of RAD001. Patients should undergo re-staging imaging studies within 2 - 6 weeks after the final treatment with cisplatin/docetaxel. After the completion of induction chemotherapy and the 30-day observation period after treatment, patients are removed from the study.
45353985|NCT00656370|Drug|recombinant human hyaluronidase|150 Units in 1mL
45353986|NCT01055431|Other|Control bread|Control bread
45353987|NCT01055431|Other|Teff Bread|Teff bread
45353988|NCT00936039|Behavioral|unloading|2 weeks of unloading of a single leg
46046324|NCT04616417|Procedure|Investigational Oocyte Cryopreservation|Transvaginal oocyte retrieval under ultrasound guidance
45353989|NCT00803556|Drug|Alvespimycin|Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT
45353990|NCT00803556|Drug|Trastuzumab|Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT
45353991|NCT00803556|Drug|Paclitaxel|Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT
45353992|NCT00936195|Drug|Efavirenz-Tenofovir-Emtricitabine|Atripla (R) : Efavirenz 600 mg - Tenofovir 300 mg - Emtricitabine 200 mg; Dosage : 1 pill/day
45353993|NCT00936195|Drug|Zidovudine-Lamivudine-Lopinavir/Ritonavir|"Combivir (R) : Zidovudine 300 mg - Lamivudine 150 mg Dosage : 1 pill twice a day~Kaletra (R) or Aluvia (R) : Lopinavir 200 mg / Ritonavir 50 mg Dosage : 2 or 3 pills twice a day"
45353994|NCT02552550|Procedure|Ability to swallow, speak and quality of life|This study will not change the patient's treatment. This will just be an evaluation, before any treatment, his ability to swallow, speak, then his quality of life, as in normal practice, after 3, 6 and 12 months after treatment.
45353995|NCT00680186|Drug|Warfarin|PRN (to maintain a target INR of 2.0-3.0)
45686704|NCT05820594|Biological|Intradermal BCG (bacillus calmette-guerin) vaccine AJV|Participants will receive a one off dose of BCG (bacillus calmette-guerin) Vaccine AJV which contains the Danish Strain of Mycobacterium bovis BCG at a dose of 6 - 24 x 105 CFU (three times the standard dose). This will be injected intradermally into the upper deltoid region.
45353996|NCT00680186|Drug|Dabigatran etexilate|150mg bid
45353997|NCT00936429|Biological|DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)|3 doses of DEN1-80E vaccine administered as 0.5 ml intramuscularly in deltoid.
46046325|NCT04600544|Other|Non-interventional|Translational, observational study
45353998|NCT00936429|Biological|Placebo for DEN1-80E|3 doses of placebo vaccine administered as 0.5 ml intramuscularly in deltoid.
45353999|NCT00656292|Drug|Simvastatin|40 mg po/nasogastric tube (NG) every day for 6 days
45354000|NCT00656292|Drug|Placebo|1 pill po/NG every day x 6 days
45477811|NCT05623709|Device|Positive airway pressure with continuous positive airway pressure or noninvasive ventilation|CPAP or NIV prescribed by the treating respirologist for long-term use at home
45477812|NCT03340168|Other|Bisphenol-S|Oral and dermal exposure in volunteers
45477813|NCT03170232|Drug|Danirixin 35 mg tablets|Danirixin 35 mg (as hydrobromide hemihydrate salt) is a white film coated oval shaped tablet. It will be provided in a labeled high-density polyethylene (HDPE) bottle with desiccant.
45686705|NCT05820568|Behavioral|ICBT-IU|Internet delivered Cognitive Behavior Therapy for Generalized Anxiety Disorder based on the Intolerance of uncertainty model of worry
45686706|NCT05820542|Other|miller laryngoscope|The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
45686707|NCT05820542|Other|McGrath MAC videolaryngoscope|The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
45354001|NCT00936507|Other|Energy Density/Portion Size|
45354002|NCT00352417|Drug|VIA-2291|100 mg, oral dosing, 1 time daily for 12 weeks
45354003|NCT00352417|Drug|Placebo|oral dosing, 1 time daily for 12 weeks
45354004|NCT00944541|Drug|maraviroc|maraviroc 150 mg or 300 mg or 600 mg twice a day for 24 weeks
45686708|NCT05820529|Procedure|adenotonsillectomy|removal of adenoid,tonsil in one session
45686709|NCT05820529|Procedure|adenoidectomy|removal of adenoid
45686710|NCT05820529|Procedure|tonsillectomy|removal of tonsil
45686711|NCT05820516|Device|TricValve implantation|TricValve implantation
45686712|NCT05820503|Procedure|Ultrasound-guided lower abdominis rectus sheath block|Under ultrasound guidance, the probe was transversely placed at the lateral level of the umbilicus . Using the in-plane technique, the needle was advanced until the posterior aspect of the rectus muscle was penetrated. No blood and no gas were drawn back; furthermore, a small volume of saline was initially injected to ensure that the needle tip was correctly positioned. When the needle was located between the posterior rectus muscle and posterior sheath, 5ml of 0.25% ropivacaine was injected bilaterally
45354005|NCT00809640|Behavioral|Education (Back Comic-Book)|Through the Back Comic-Book the schoolchildren are taught prevention methods for low back pain.
45477814|NCT03170232|Drug|Placebo|Placebo is a white film coated oval shaped tablet. It will be provided in a labeled HDPE bottle with desiccant.
45354006|NCT01055509|Behavioral|Cognitive Adaptation Training|All patients receive treatment as usual. Additionally, patients in the intervention arm receives training concerning solving concrete problems related to the patient's daily life using tools such as schedules, schemes and signs. Additional the patient can receive SMS messages or instructions for the use of schedules in cell-phones to prompt for activities. The intervention is conducted in the patients homes every 14th day in a period of six months.
45354007|NCT00944619|Device|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
45354008|NCT00944619|Device|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
45354009|NCT00805896|Drug|Songyou|4g/pack
45354010|NCT00805896|Drug|placebo|4g/pack
45354011|NCT00323869|Drug|Bevacizumab|Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody
45354012|NCT00323869|Drug|Gemcitabine|Nucleoside analog
45354013|NCT00323869|Drug|Carboplatin|Alkylating agent
45354014|NCT05434832|Behavioral|Virtual Reality|Distraction method
45354015|NCT05434832|Behavioral|Local cold-vibration|Distraction method
45354016|NCT01057927|Drug|OC000459|OC000459 capsules 2x100mg BID for 28 days
45477815|NCT03170232|Device|Metered dose inhaler (MDI) sensor device|MDI sensor devices will be fitted onto rescue medication MDI devices to electronically record rescue medication usage.
45686713|NCT05820503|Procedure|Local anesthesia infiltration|Local anesthesia drugs were injected into the peri-umbilicus cord
45354017|NCT01057927|Drug|Placebo|Placebo capsules to match OC000459 100mg capsules, 2 tablets BID
45354018|NCT02559986|Other|telephone interview|telephone interview about their care received during the first year of life and associated events
45354019|NCT01058083|Drug|BMS-770767|Active, Oral, 15 mg, Daily, 28 days
45354020|NCT01058083|Drug|BMS-770767|Active, Oral, 50 mg, Daily, 28 days
45354021|NCT01058083|Drug|BMS-770767|Active, Oral, 150 mg, Daily, 28 days
45354022|NCT01058083|Drug|BMS-770767|Active, Oral, 50 mg BID, Daily, 28 days
45354023|NCT01058083|Drug|Placebo|Placebo, Oral, 0 mg, daily, 28 days
45354024|NCT05434676|Device|Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System M5 & S4|To assess the safety and effectiveness of IVL treatment used in combination with DCB to treat moderate and severely calcified femoropopliteal arteries
45354025|NCT00323557|Drug|Sargramostim (GM-CSF)|Starting with 3 doses of 250 micrograms subcutaneously, either pre or post vaccine. For pre vaccine, GM-CSF on days -7 (+ 1 day) and -3 (+ 1 day), in the week prior to vaccination for pre-vaccination immune priming; 3rd dose on the day of vaccination (day 0); and for post-vaccine GM-CSF given simultaneously on day of vaccination (day 0) and 2 more doses Day +3 and Day +7 after pneumococcal vaccine.
45354026|NCT00323557|Biological|Pneumococcal Vaccine|Subcutaneously on Day 0
45354027|NCT02559050|Other|Customized 3D-printed nasal stent|Silicone stent with unconventional shape, 3D-printed based on patient's computed topographical images, to exactly fit newly made nasal cavity.
45354028|NCT00558363|Drug|Avodart|0.5 mg administered orally once daily
45354029|NCT00558363|Other|placebo|Patients will be randomized at Visit 2 in 1:1 ratio to receive either 0.5 mg dutasteride or placebo
45354030|NCT00323479|Drug|Anastrozole|1mg/Day oral
45354031|NCT00352105|Drug|cisplatin|20mg/m2/d IV continuous infusion x4 days
45354032|NCT00352105|Drug|fluorouracil|1000mg.m2/d IV continuous x 4 days
45354033|NCT00352105|Drug|Iressa|250mg/PO qd x 2 years
45354034|NCT00352105|Radiation|hyperfractionated radiation therapy|120cGy bid
45354035|NCT00944775|Behavioral|Exercise training|10-month exercise training program during hemodialysis sessions
45354036|NCT03988075|Other|Acetaminophen and hydrocodone based pain control|Patients receive acetaminophen 650mg every 4 for pain level 1-3, hydrocodone/acetaminophen 5/325mg every 4 for pain level 4-6, or hydrocodone/acetaminophen 10/650mg every 4 for pain level 7-10 on as needed basis.
45354037|NCT03988075|Other|Acetaminophen and ibuprofen based pain control|Patients receive standing dose of acetaminophen 650mg every 8 hours and ibuprofen 800mg every 8 hours with alternating ibuprofen and acetaminophen every 4 hours.
45354038|NCT00944853|Dietary Supplement|Liquid zinc syrup|Liquid zinc syrup containing 5 mg zinc as zinc sulfate
45686714|NCT05820438|Device|Electromyography|"Disposable bipolar surface electrodes will be used.~The patient's skin will be clean with cotton gauze soaked in alcohol before electrodes placement to reduce skin impedance. The operator will palpate the muscle belly while the patient clenches his teeth and will position surface electrodes in parallel to the muscular fibres.Doing so the position of the electrodes results as follows:~Masseters electrodes will be fixed parallel to the exocanthion-gonion line and with the upper pole of the electrode under the tragus-labial commissural line. Temporalis electrodes will be positioned along the anterior margin of the muscle (corresponding to the frontoparietal suture). Suprahyoid muscles electrodes will be placed in the submental area nearly 1 cm posterior to the mental symphysis, paramedian to the midline and lightly diverging. A reference electrode will be applied to the forehead of the patient."
45354039|NCT00944853|Dietary Supplement|Zinc tablet|Dispersible zinc tablet containing 5 mg zinc
45354040|NCT00944853|Dietary Supplement|Liquid placebo supplement|Liquid placebo supplement containing 0 mg zinc
45354041|NCT03987997|Device|Early association of electrical muscle stimulation with cyclo-ergometer|Early electrical muscle stimulation in patients usually mobilized with cyclo-ergometer in ICU.
45354042|NCT03985891|Drug|Anti-PD-1 Monoclonal Antibody JS001|Anti-PD-1 monoclonal antibody combined with chemotherapy in patients with locally advanced colon cancer (perioperative treatment)
45354043|NCT03985891|Drug|Chemotherapy|Folfox
45354044|NCT00350779|Drug|sitagliptin|Sitagliptin 100mg tablet each day for 54 weeks. All subjects will be given placebo to sitagliptin for a 2 week period.
45354045|NCT00350779|Drug|Comparator: Placebo|Placebo to sitagliptin 100mg tablet each day for 54 weeks.
45354046|NCT00350779|Drug|rosiglitazone|Subjects taking 4mg or greater rosiglitazone at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 4mg/day or no rosiglitazone at screening will be titrated to a stable dose of at least 4mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
45477816|NCT03170232|Drug|Rescue medication|Subjects may continue to use rescue medication(s) via their usual route. Allowed medications are: short acting beta agonists (SABA) (e.g., albuterol/salbutamol); short acting muscarinic antagonists (SAMA) (e.g., ipratropium); short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb, Combivent)
45354047|NCT00350779|Drug|metformin|Subjects taking 1500mg or greater metformin at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 1500mg/day or no metformin at screening will be titrated to a stable dose of at least 1500mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
45354048|NCT00350779|Drug|glipizide|Subjects not meeting specific glycemic controls during the 54-week treatment period will use glipizide as rescue therapy. Glipizide will be titrated in 5mg doses up to a maximum 40mg each day. (In Canada, the rescue therapy will be a sulfonylurea agent marketed in that country.)
45354049|NCT00350623|Biological|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
45354050|NCT00350623|Biological|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
45354051|NCT00350623|Biological|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
45477817|NCT01299701|Drug|ASA404|(5,6-dimethylxanthenone-4-acetic acid) DMXAA or DXAA
45354052|NCT00656136|Drug|placebo|Patients receive placebo once daily
45354053|NCT00656136|Drug|BIBW 2992|Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
45354054|NCT00676520|Device|XIENCE V® Everolimus Eluting Coronary Stent|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
45354055|NCT00652938|Biological|HPV Vaccine (GSK580299) Cervarix TM|IM administration
45354056|NCT00652938|Biological|Engerix B|IM administration
45686715|NCT05820412|Other|Intensive interdisciplinary therapy|Intensive interdisciplinary therapy includes an intense burst of physical, occupational, and/or speech therapy with high intensity and frequency in a duration (e.g. 3-6 hours/day, 3-5 days/week for 4 weeks)
45843263|NCT04493658|Diagnostic Test|Questionnaires|Cognitive ability questionnaires, dry eye symptom questionnaires (Ocular Surface Disease Index, Impact of Dry Eye in Everyday Life, Visual Function Questionnaire-25, Eye Dryness Visual Analog Scale, Visual Fatigue Visual Analog Scale, Visual Tasking Questionnaire, Short Form Survey-36, Profile of Fatigue and Discomfort, European League Against Rheumatism Sjögren's Syndrome Patient Reported Index) will be completed by the subjects
45843264|NCT04493658|Diagnostic Test|Tear fluid sampling|Using microcapillary tubes, 1 microliter of tear fluid will be collected in both eyes of each subject.
46046326|NCT04581369|Other|Care Coordinator Intervention for Direct Intervention Group|"The First Visit: The care coordinator will conduct a visit within 72 hours of hospital discharge to assess the patient's physical, cognitive, and psychological status, and will complete a needs assessment for both the patient and family caregiver. These measures will be used to guide the use of care protocols and development of the individualized care plan. The care plan will be developed with an emphasis on coordinating services with the patient's providers.~The Second Visit: During the second visit, the coordinator will review the individualized care plan with both the patient and the family caregiver and will make revisions to the plan based on assessment outcomes.~The 6-month Interaction Period: Approximately every 2 weeks, the coordinator will meet with the participant to revisit the care plan and to facilitate care.~At the end of 6 months, all patients will be transitioned to receive full care by their primary care and specialty physicians."
45477818|NCT03340090|Device|Medical Device Hemopatch-PEG-coated collagen patch|Two pieces of PEG-coated collagen patch Hemopatch will be applied in one patient. One piece to improve hemostasis in the bed of LIMA harvesting and second piece of Hemopatch will be placed beneath the sternum.
45477819|NCT03333850|Device|Visual feedback of physical activity|A monitor (tablet) will display the level of physical activity during hospitalisation. The monitor will be placed at the bedside (table).
45477820|NCT03333850|Device|No feedback of physical activity|There will be no visual feedback of the physical activity (no monitor placed at the bedside (table)).
45477821|NCT03333850|Device|Measurement of physical activity|A pair of accelerometers placed on the chest and on the thigh will measure the physical activity level during hospitalisation. The measurement is made continuously and stored on a secure web-server.
45477822|NCT03721861|Device|Intra-operative neural cuff stimulation|A feasibility study consists of placing 2 electrodes around the radial or medial nerves intraoperatively. The movements caused by the electrical stimulation of these nerves are observed.
45686716|NCT05820399|Dietary Supplement|Organic Guayusa Extract|Supplementation: Participants will supplement daily with organic guayusa extract, which is a caffeinated Amazonian 'super-leaf' belonging to the holly species that contains a very unique blend of polyphenol antioxidants and caffeine (~20% caffeine, 30% chlorogenic acids, 5% catechins) during 6 weeks of high intensity exercise training. Investigators and participants will be blinded to condition.
45686717|NCT05820399|Dietary Supplement|Placebo|Participants will supplement daily with placebo (maltodextrin). Investigators and participants will be blinded to condition.
45843265|NCT04493658|Diagnostic Test|Impression Cytology|Under topical anesthesia, impression cytology sampling will be performed in the temporal bulbar conjunctiva of both eyes of each subject.
45354057|NCT05434520|Procedure|Preoperative biliary drainage (ERC og PTC-aided)|Placement of biliary stent (plastic, covered SEMS, uncovered SEMS) endoscopic by ERC or placement of plastic catheter by PTC
45354058|NCT02559908|Device|Hyaluronic Acid Injectable Gel|Hyaluronic Acid Injectable Gel (VYC-25L) injection into the chin and/or jaw areas (up to 4.0 mLs).
45686718|NCT05820386|Procedure|Skin-to-skin Contact (SSC)|For the Skin-to-skin Contact (SSC) transfer, the bare-chested father will seat in a wheelchair. Newborns who will wear only a diaper and a cotton cap or noninvasive ventilation headgear will be placed in the kangaroo position against the father's chest to ensure direct contact with the father's skin. Preterm infants with gestational age less than 33 weeks will be wrapped with their father using plastic bags plus warmed cotton towels. More gestationally mature infants will be wrapped with only warmed cotton wraps. The newborn's heart rate, oxygen saturation and skin temperature will be monitored throughout the procedure.
45843266|NCT04421352|Drug|CS1001|"low-dose radiation+CS1001 1200mg Q3W. In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~Dose A: 3Gy/1f; Dose B: 9Gy/3f; Dose C: 15Gy/5f;~In the dose expansion part, more SCLC patients will be assigned."
45843267|NCT04356612|Other|Chart Review|This is a retrospective chart review to determine the etiologies contributing to prolonged PACU discharge at a major Orthopedic Ambulatory Surgical Center.
45843268|NCT04270188|Other|evolution of patient symptoms|evolution of symptoms on the PGI-I scale (score 1, 2, or 3) 2 months after surgery
45843269|NCT03861468|Other|Care pathway|Screening for OSA using a combination of bicarbonate assay and STOP-BANG questionnaire and further management by a pneumologist as necessary
45843270|NCT03729258|Drug|Infex 400 MR|Infex (cefpodoxime) 400mg once a day (QD) for 10 days
45843271|NCT03729258|Drug|Infex 200 IR|Infex (cefpodoxime) 200mg twice a day (BID) for 10 days
45843272|NCT03593772|Behavioral|Mission Reconnect|This four-year randomized controlled trial with one intervention arm and one wait-list control arm will utilize mixed methods to evaluate the effectiveness and perceived value of the MR program in relation to physical and psychological symptoms, global health, and social outcomes.
45354059|NCT00805974|Biological|Biological examinations (blood and urinary).|
45354060|NCT00322621|Drug|Duloxetine|
45354061|NCT02558972|Drug|Northera (Droxidopa)|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
45843273|NCT03355170|Combination Product|Lansoprazole/Domperidone|Experimental
45843274|NCT03355170|Drug|Lansoprazole|Active comparator
45843275|NCT03180840|Biological|Pegunigalsidase alfa|Pegunigalsidase alfa 2 mg/kg every 4 weeks
45843276|NCT03009240|Drug|Decitabine|Given IV
45354062|NCT02558972|Drug|Placebo|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
45843277|NCT03009240|Other|Laboratory Biomarker Analysis|Correlative studies
45843278|NCT03009240|Drug|Pevonedistat|Given IV
45843279|NCT03009240|Other|Pharmacological Study|Correlative studies
45843280|NCT02819778|Procedure|usual care|
45477823|NCT01299779|Drug|PEG-SD|"PEG-SD~Bisacodyl: two 5-mg tablets at 3 pm day prior~1L sports drink* (labeled #1) with PEG-3350 119 gram bottle (labeled #1) at 6 pm night prior~1L SD* (labeled #2) with PEG-3350 119 gram bottle (labeled #2) starting 4 hrs prior to colonoscopy~Same flavor, non-red Gatorade® for all patients."
45477824|NCT01299779|Drug|PEG-ELS|"1L + 500 cc clear liquids at 6 pm night prior~1L + 500 cc clear liquids starting 4 hours prior to colonoscopy"
45843281|NCT02819778|Procedure|S100B|
46046327|NCT04581369|Other|Care Coordinator Intervention for Standard of Care Group|For participants randomized to this arm, a consultation with the care team will be arranged prior to hospital discharge. Outcome measures will be obtained by blinded research staff from all enrolled subjects at baseline, 3 months, and 6 months. This is the extent of interventions received for participants in this arm.
46046328|NCT04581369|Other|Caregiver Intervention|Caregivers of the participants will be assessed for caregiver burden at 3 time points.
45843282|NCT02760498|Drug|cemiplimab|
45843283|NCT02538666|Biological|Nivolumab|
45843284|NCT02538666|Biological|Ipilimumab|
45843285|NCT02538666|Other|Placebo|
45843286|NCT02438358|Drug|LUM015|
45843287|NCT02438358|Device|LUM 2.6 Imaging Device|
45843288|NCT02407236|Drug|Placebo IV|Placebo will be administered as intravenous infusion.
45843289|NCT02407236|Drug|Placebo SC|Placebo will be administered Subcutaneously.
45354063|NCT02558972|Drug|Northera (Droxidopa)|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP>140mmHg or diastolic BP>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
45477825|NCT02492620|Drug|Ferric Citrate|Auryxia (ferric citrate) is a non calcium based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis
45477826|NCT02426034|Drug|ApatinibTablets|Apatinib Tablets, recommended dose of 850mg
46046329|NCT04569136|Other|Education|The education session including education about mastitis, feeding techniques, lifestyle changes, thermal/cryo therapy and demonstration of breast self-massage will take approximately 20 minutes.
46046330|NCT04569136|Other|Therapeutic ultrasound|Participants will be treated with 5 minutes of therapeutic ultrasound (pulsed mode) at a frequency of 1 Mega Hertz, a duty cycle of 20%, a pulse intensity of 1.8 Watt/centimetre squared. The ultrasound probe will be moved at a speed of about 4 centimetre/second. The intensity and duration will be adjusted if the patient complains of discomfort. The ultrasound transducer head will massage over the tender point on the breast.
45477827|NCT03813251|Device|ForConti Contix Fecal Incontinence Management System (FIMS)|Use the device for up to 12 hours per use for 4 weeks
45477828|NCT03519919|Device|somofilcon A multifocal lens|contact lens
45477829|NCT03340012|Device|GTR + radiation-sterilize allogenic bone graft|Guided tissue regeneration of intrabony defects with collagen membrane (Bio-Gide® Perio, Geistlich Biomaterials) and radiation-sterilized allogenic bone graft from the Central Tissue Bank in Warsaw
45477830|NCT03340012|Device|GTR + xenogenic graft|Guided tissue regeneration of intrabony defects with collagen membrane (Bio-Gide® Perio, Geistlich Biomaterials) and xenogenic graft (Bio-Oss®, Geistlich Biomaterials)
45477831|NCT01301417|Device|ColonRing™|Creation of a circular Compression Anastomosis
45477832|NCT03812939|Drug|Octreotide|Patients will receive 6-12 monthly injections every 28 (+/- 3) days.
45477833|NCT03333772|Behavioral|REAL-T Intervention|Individualized lifestyle intervention conducted via internet-based videoconferencing and incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants will have approximately 6-10 sessions lasting about one hour each, over a 3-month period.
45477834|NCT03813173|Procedure|lymph node dissection|The patient was operated under general anesthesia with cervical hyper extension. The affected side or bilateral glandular lobes were resected routinely, which was confirmed as PTC by frozen section. Then one or both central lymph node dissection were separately packed and sent for examination. Scope of lymph node dissection in central carotid region: hyoid bone at the upper border, anonymous artery at the lower border, bilateral common carotid artery at the inner edge, shallow from the superficial layer of deep cervical fascia, deep to the deep layer of deep cervical fascia (anterior fascia). The right recurrent laryngeal nerve (RLN) passes through the central area of the right neck and should be specially protected.
45477835|NCT03339856|Device|Selective retina therapy|"The selective retina therapy (SRT) is a laser treatment to the retina using the R:GEN device (Lutronic, Goyang-si, South Korea).~Laser energy began at 80 µJ and was increased in 5-10 µJ intervals until the optimal energy delivery was confirmed by the RFD system. Following confirmation, the optimal laser energy was applied to fluorescein leakages. If the energy was indeed optimal at leakage points, laser shots were administered around the leakages. If the energy was not optimal at the leakage points, laser energy was again increased in 5-10 µJ increments until optimal energy delivery."
45477836|NCT03333694|Drug|Cutaneous Cream application|Cutaneous Cream application twice daily with experimental (CLL442)
45477837|NCT03333694|Drug|Placebo Cutaneous Cream application|Cutaneous Cream application twice daily with placebo
45477838|NCT05623631|Other|Survey|Surveys were distributed using REDCap, and participants were asked to complete these within 5 weeks of receiving the invitation.
45477839|NCT03333538|Biological|GamEvac-Lyo (component A)|Biological: GamEvac-Lyo (vaccine) vaccination, single administration, component A
45477840|NCT03333538|Other|Placebo|Placebo vaccination
45477841|NCT03333538|Biological|GamEvac-Lyo (component B)|Biological: GamEvac-Lyo (vaccine) vaccination, single administration, component B
46046331|NCT04569136|Other|Sham ultrasound|Participants will receive 5 minutes of 'sham' ultrasound at 0 Watt/centimetre squared intensity from a physical therapist.
45686719|NCT05820386|Procedure|Incubator|In the incubator group, infants will be transferred after resuscitation in an incubator with air temperature set to 36°C. The newborn will be laid on his/her back in a polyethylene bag with a cap. The newborn's heart rate, oxygen saturation and skin temperature will be monitored throughout the procedure.
46046332|NCT04569136|Other|Breast massage|Breast massage includes general and focused massage. Participants will lie in supine position. The breast massage will be applied according to the Vodder method to the affected breast.
45354064|NCT02558972|Drug|Placebo|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP>140mmHg or diastolic BP>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
45354065|NCT00809718|Drug|Raltegravir and rifapentine|"Period 1- Raltegravir 400 mg q12h by mouth for 4 days~Period 2- Rifapentine 900 mg taken by mouth once per week for 3 doses and raltegravir 400 mg q12h by mouth for 4 days~Period 3- Rifapentine 600 mg taken by mouth once daily for 5 of 7 days per week for 10 doses and raltegravir 400 mg q12h by mouth for 4 days"
45354066|NCT05427266|Other|Tap Block - Bupivacaine|The medicinal product for both groups is the same - Bupivacaine. The mode of administration is what this study is reviewing: Control group (Standard port site infiltration) and Study Group - Laparoscopic Transversus Abdominis Plane Block (LTap Block)
46046333|NCT04569136|Other|Usual obstetric care|Usual obstetric care may include verbal advice/printed patient information regarding mastitis and breastfeeding from the medical or nursing staff.
46046334|NCT04565288|Drug|Atomoxetine|Participants randomized to receive the study medication, atomoxetine (brand name: Straterra) for 6-weeks (40 mg/day for 3 days then 80 mg/day thereafter). A comparator group will receive placebo (sugar pills).
45354067|NCT04793334|Procedure|sleeve gastectomy|routine sleeve gastrectomy
45354068|NCT00575042|Drug|Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)|160 mg per day for 1 year
45354069|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
45354070|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
45354071|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
45843290|NCT02407236|Drug|Ustekinumab IV|Ustekinumab will be administered as intravenous infusion at Week 0 or Week 8 in Induction Study.
46046335|NCT04565288|Drug|Placebo|Matching placebo (sugar pill)
46046336|NCT04560361|Other|Electroacupuncture treatment|Continue the electroacupuncture treatment as described above for 30 minutes.
46046337|NCT04560361|Other|Sham electroacupuncture treatment|Continue the sham electroacupuncture treatment as described above for 30 minutes.
46046338|NCT04544865|Device|Staple Line Reinforcement|ENDOPATH ECHELON Staple Line Reinforcement is used for reinforcement of staple lines during lung resection and bariatric surgical procedures, according to instructions for use.
45354072|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
45354073|NCT00676208|Behavioral|Shared Medical Appointments|Participated in shared appointments for patients as part of interprofessional team providing care for diabetes
45354074|NCT02533297|Other|Providing clinical skills conditions|
45354075|NCT00656058|Drug|Singulair (Montelukast Sodium)|Singulair (Montelukast Sodium):5-10 mg (weight based dosing) by mouth (PO) hour of sleep (HS)
45354076|NCT03871764|Diagnostic Test|blood sample , doppler of uterine vessel and placenta|blood sample for factor V and doppler examination of uterine arteries , placenta pathology post partum
45354077|NCT00537316|Biological|Infliximab (IFX)|IFX intravenous (IV) infusion dosed at 5mg/kg of body weight
45354078|NCT00537316|Drug|Azathioprine (AZA)|AZA 50 mg tablet dosed at 2.5 mg/kg of body weight orally every day
45843291|NCT02407236|Drug|Ustekinumab SC|Ustekinumab will be administered as subcutaneously.
45843292|NCT02318472|Device|VACOped orthosis|Weight-bearing orthosis with adjustable range of motion of the ankle
45354079|NCT00537316|Drug|Placebo to Azathioprine|Placebo to AZA tablet orally every day
46046339|NCT04527926|Behavioral|STEPuP Intervention|"Project STEPup has 4 components designed to address barriers to MAT and EBP adoption: 1) a hub and spoke remotely-supported provider education and training program, 2) addiction teleconsultation support, 3) case management and telepsychiatry support, and 4) a partnership with health system administrators and payers to address administrative and reimbursement related needs."
45354080|NCT00537316|Drug|Placebo infusion|Placebo to IFX intravenous (IV) infusion
45354081|NCT00803868|Drug|varenicline|up to 1mg po bid for 9 weeks
45354082|NCT00803868|Drug|placebo|placebo matching study drug up to 1mg po bid
45354083|NCT03827395|Biological|HEV 239|Hepatitis E vaccine against HEV genotypes 1 and 4. The HEV 239 vaccine is a 26 kDa recombinant polypeptide corresponding to amino acid residues 368-606 of the capsid protein of a genotype 1 HEV strain. The vaccine is expressed in Escherichia coli (E. coli) and vaccine doses contain 30 µg of the purified antigen in 0.5 mL buffered saline adsorbed to 0.8 mg aluminium hydroxide.
45354084|NCT03827395|Other|Placebo|0.9% Sodium Chloride Injection, USP (Normal Saline) is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection (WFI). Each mL contains sodium chloride 9 mg and may contain HCl or NaOH for pH adjustment (pH 5.3 [4.5 - 7.0]).
45354085|NCT04504708|Drug|ZX-101A|Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle
45354086|NCT00655980|Drug|Vitamin B12 and folic acid|1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion
45354087|NCT00655980|Drug|Nitrous oxide and placebo|
45354088|NCT00655980|Other|standard of care|
45354089|NCT00679172|Biological|Dose of 5.0 x 10^9 CFU (Cohort 1)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
45354090|NCT00679172|Biological|Dose of 7.5 x 10^9 CFU (Cohort 2)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
45354091|NCT00679172|Biological|Dose of 1.1 x 10^10 CFU (Cohort 3)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
45354092|NCT00679172|Biological|Dose of of 1.7 x 10^10 CFU (Cohort 4)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
45354093|NCT00679172|Other|Placebo (Cohorts 1-4 pooled)|Excipients only, single dose, oral administration
45477842|NCT03333538|Biological|GamEvac-Lyo|Biological: GamEvac-Lyo (vaccine) vaccination, therapeutic scheme: the sequential introduction of components A and b with an interval of 21 days
45686720|NCT05820373|Behavioral|Yoga therapy|Women being allocated to the intervention group will attend a 12-week, bi-weekly, specially designed yoga therapy course. In each yoga class, participants will be taught to perform a standardized yoga sequence including postures and breathing exercise. Each class lasts 60 minutes. A DVD demonstrating the yoga sequence will be given to each participant to prompt daily home practice.
45686721|NCT05820373|Behavioral|Active control group|Women being allocated to the active control group will attend a 12-week, weekly, relaxation course. In each relaxation class, participants will be taught to learn mediation and guided relaxation, called Shavasana. Participants will be asked to lie on their back, with legs apart and their eyes closed. During the practice, participants learn how to relax the body and breath normally. Each session lasts 60 minutes.
45686722|NCT05820373|Behavioral|Passive control group|The passtive control intervention will be the standard post-operative exercises which are currently introduced to women following surgery, for all women allocated to the control group. A DVD demonstrating the post-operative exercise will be given to participants to practice at home daily.
46046340|NCT04527926|Behavioral|Usual Care|Standard of Care
46046341|NCT04519580|Diagnostic Test|PET/CT|FDG-PET/CT at baseline, week 8 and week 10.
46046342|NCT04511130|Drug|MT-401|MT-401 (zedenoleucel) is an allogeneic multi-tumor-associated antigen (MultiTAA)-specific T cell product manufactured under Good Manufacturing Practice (GMP) using donor-derived T cells obtained from apheresis.
46046343|NCT04501861|Drug|Norepinephrine|Hemodynamic effect of norepinephrine on the pulmonary circulation in cardiac surgery patients
46046344|NCT04501861|Drug|Vasopressin|Hemodynamic effect of vasopressin on the pulmonary circulation in cardiac surgery patients
46046345|NCT04501393|Other|Clear liquid intake|Clear oral fluid including water, pulp-free juice and tea or coffee without milk
45354094|NCT01063621|Drug|KW-6500|Subcutaneous injection of 1 to 6 mg for the OFF state during 52 weeks
45354095|NCT02533141|Device|Dynamic Vessel Analyzer (DVA)|Measurement of flicker induced vasodilatation, retinal vessel diameters and oxygen saturation
45354096|NCT02533141|Device|Laser Doppler Velocimetry (LDV)|Measurement of red blood cell velocity in retinal vessels
45354097|NCT02533141|Drug|Simvastatin|Simvastatin Ranbaxy (Basics GmbH, Leverkusen, Germany) Dosage: 40 mg per day for 4 weeks, ingested in the morning Route of administration: peroral
45354098|NCT02533141|Other|Placebo|Placebo, once daily for 4 weeks
46046346|NCT04496024|Drug|ofloxacin|ofloxacin treatment in patients with bone and joint infections
45354099|NCT00809796|Drug|pentamidine|one dose of 4 mg/kg to two dose of 4 mg/kg with possibility of escalated to two dose of 6 mg/kg with or without standard chemotherapy.
45843293|NCT02318472|Device|Plaster cast|Lower limb plaster cast
45843294|NCT01893138|Other|Placebo|Placebo control is the vehicle solution used for the study product.
45843295|NCT01893138|Biological|Iltamiocel|AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intraurethral injection of 150 x 10^6 cells.
45843296|NCT00221598|Procedure|Haemodialysis with different dialysate temperatures|Haemodialysis with different dialysate temperatures is used.
45843297|NCT05120076|Drug|Dexamethasone 4 Mg/mL Injectable Solution|s. arm/group description
45843298|NCT05120076|Drug|NaCl 0.9%|s. arm/group description
45354100|NCT05589454|Drug|Atorvastatin Calcium tablets 80mg|Atorvastatin calcium tablets 4 pills (80 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
45354101|NCT05589454|Drug|Atorvastatin Calcium tablets 20mg|Atorvastatin calcium tablets 1 pill (20 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
45477843|NCT05602571|Other|ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught a home exercise program including stretching and eccentric strengthening exercises by an experienced physiotherapist. The eccentric exercises consisted of the following: three sets of 10 repetitions for wrist and elbow ﬂexion; two sets of 10 repetitions for wrist extension strengthening, starting with 50% of maximum strength and density and increasing the resistance each week; and ﬁnally, two sets of 10 repetitions for the wrist ﬂexor and extensor muscle groups comprising 20s of stretching and 10s of relaxing using the unaﬀected hand. Exercise program will be done twice a day for 3 months."
45477844|NCT05602571|Procedure|PRP+ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught aforementioned home exercise program. Exercise program will be done twice a day for 3 months.~Procedure:~10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged. Approximately 3 cc of the PRP obtained will be applied to the tendinosis area under USG guidance. All injections will be performed with long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe)."
45686723|NCT05820347|Device|Artificial Intelligence Estimation of Muscle Pressure during Mechanical Ventilation|Estimation of inspiratory muscle pressure by an artificial intelligence algorithm integrated in the mechanical ventilator (FlexiMag, Magnamed, Brazil).
45354102|NCT01063699|Procedure|Laparoscopic Kasai operation|the Kasai procedure (hepatoportoenterostomy) is performed laparoscopically, thus not in open surgery.
45354103|NCT00803946|Drug|Ibuprofen Tablets, 800 mg|
45354104|NCT00676130|Drug|trimethoprim-sulfamethoxazole|"Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): trimethoprim-sulfamethoxazole 40/200 mg four times daily~20-24 kg (42-53 lbs): trimethoprim-sulfamethoxazole 60/300 mg four times daily~25-29 kg (53-64 lbs): trimethoprim-sulfamethoxazole 72/360 mg four times daily~29-60 kg (64-132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60 kg (132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60-80 kg (132-176 lbs): trimethoprim-sulfamethoxazole 160/800 mg three times daily~> 80 kg (176 lbs): trimethoprim-sulfamethoxazole 160/800 mg four times daily"
45354105|NCT00676130|Drug|Cephalexin|"Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): Cephalexin 300 mg four times daily~20-24 kg (42-53 lbs): Cephalexin 400 mg four times daily~25-29 kg (53-64 lbs): Cephalexin 500 mg four times daily~29-60 kg (64-132 lbs): Cephalexin 500 mg four times daily~60-80 kg (132-176 lbs): Cephalexin 1000 mg three times daily~> 80 kg (176 lbs): Cephalexin 1000 mg four times daily"
45354106|NCT04874818|Diagnostic Test|[89Zr]Df-IAB22M2C PET/CT scan|PET imaging procedure
45354107|NCT02553408|Device|FreeStyle Precision Neo-Meter|Participants will receive a free glucose meter (Neo) and test strips from their care providers with education and instructions on how to use the meter to monitor their glucose level. Three months after the start of using the meter, participants will be interviewed on their experiences, likes and dislikes about the meter.
45354108|NCT03742882|Drug|CC-90001|CC-90001
45686724|NCT05820308|Behavioral|Companion Dog Walking|Participants will be asked to walk their dog three times per week, for a minimum of 30 minutes each day of walking, over an 8-week period.
45686725|NCT05820308|Behavioral|Attention Control Group|Participants will be asked to read educational materials on dog health once per week, over an 8-week period.
45686726|NCT05820282|Behavioral|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing delivery of behaviour change interventions
45686727|NCT05820282|Other|Control condition|Participants are asked to identify situations and solutions and place a tick next to each one they think would be useful to them. Therefore, participants in the control condition are not asked to form implementation intentions.
45686728|NCT05820269|Behavioral|parents-child psychotherapy|filling out questionnaires during psychotherapy consultations
46046347|NCT04496024|Other|questionnaire|questionnaire of ofloxacine side effects will be completed by the clinician at Day 3, Day 21 and Day 42
46046348|NCT04496024|Biological|Ofloxacin Serum concentration|Serum concentration of ofloxacin will be measured at Day 3 (Cmin and Cmax), Day 21 and Day 42 (Cmin).
46046349|NCT04488419|Drug|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
46046350|NCT04488419|Drug|Placebo|Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
46046351|NCT04487171|Other|Questionnaire|The mothers were administrated three questionnaires, (i) the Edinburgh Postnatal Depression Scale (EPDS), (ii) the State-Trait Anxiety Inventory (STAI-YA), and (iii) the Mother-to-Infant Bonding Scale (MIBS) in two stages, on days 2-3 after delivery and during a phone call between days 25-35.
46046352|NCT04482114|Radiation|ULD CT|All the examinations are part of the routine care. Addition of the ULD CT protocol does not require injection of contrast agent and does not extend the duration of the examination.
46046353|NCT04450732|Drug|GQ1001|anti-HER2 antibody drug conjugate
45686729|NCT05820256|Dietary Supplement|Milk Protein Isolate (MPI)|Study participants will consume two smoothies per day containing a milk protein isolate (MPI) for 31 days.
45686730|NCT05820256|Dietary Supplement|Soy Protein Isolate (SPI)|Study participants will consume two smoothies per day containing a soy protein isolate (SPI) for 31 days.
45686731|NCT05820243|Other|Moderate Intensity Aerobic Exercise|Participants will complete 1 hour of exercise on a cycle ergometer at the power output that elicits 60% of their peak rate of oxygen consumption (V02peak).
45354109|NCT04317820|Behavioral|Deep Brain Reorienting (DBR)|Trauma processing through DBR involves bringing up a traumatic memory and encouraging the client to focus on tensions arising in the muscles of the shoulders, neck, head and face (i.e., those involved in orienting toward a threatening person/event). The rationale is as follows: Physiologically, orienting to a stimulus, whether external or in the mind's eye, comes before any affective response to it. Here, it is hypothesized that there is activity in certain midbrain structures , i.e.,Superior Colliculi (SC) and Periaqueductal Gray (PAG). The deep layers of the SC bring on a brief (orienting) tension in the neck as well as preparing for eye movements, which is later followed by the processing of raw affect in the PAG. In session, if we can attend to this tension - even if we have to backtrack from the emotion that follows - we can establish an anchor in the body that precedes the affect and is hypothesized to protect against emotional overwhelm.
45354110|NCT00804024|Device|ClearWay™ RX Local Therapeutic Infusion Catheter|The ClearWay™ RX Local Therapeutic Infusion Catheter is a micro-porous PTFE balloon catheter designed for the localized infusion of various diagnostic and therapeutic agents into the coronary and peripheral vasculature.
45354111|NCT00809874|Dietary Supplement|Casein|
45354112|NCT00809874|Dietary Supplement|Whey Isolate|
45354113|NCT00809874|Dietary Supplement|Whey Hydrolysate|
45354114|NCT00809874|Dietary Supplement|Alphalact-Albumin|
45354115|NCT00809952|Procedure|recombinant FSH|
45354116|NCT00676052|Drug|GSK233705 12.5mcg|Once daily via dry powder inhaler
45354117|NCT00676052|Drug|GSK233705 25mcg|once daily via dry powder inhaler
45354118|NCT00676052|Drug|GSK233705 50mcg|Once daily via dry powder inhaler
45354119|NCT00676052|Drug|GSK233705 100mcg|Once daily via dry powder inhaler
45477845|NCT05602571|Procedure|Sham PRP+ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught aforementioned home exercise program. Exercise program will be done twice a day for 3 months.~Procedure:~In Sham-PRP group,10 ml of venous blood will be taken and after the same waiting time 3 cc of 0.9% saline will be injected to the tendinosis area under USG guidance. All injections will be performed with long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe)."
45477846|NCT03339700|Drug|Gemcitabine|4800mg/m2, intravenous (IV), divided 4 days, 1200mg/m2/day, during days -5 to -2
45477847|NCT03339700|Drug|Busulfan|12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7 to -4.
45686732|NCT05820191|Drug|Amyvid, Intravenous Solution|Amyvid 370MBq (10mCi) absorbed dose 7mSv of will be introduced intravenously and 30-50 minutes after the PET images will be acquired.
45686733|NCT05820165|Radiation|high-resolution 3D-T1|Subjects undergo a high-resolution 3D-T1 imaging to obtain structural images
45686734|NCT05820165|Radiation|diffusion tensor imaging (DTI)|Subjects undergo a DTI imaging to obtain images of white matter lesions
45686735|NCT05820165|Radiation|resting-state functional magnetic resonance imaging (rs-fMRI)|Subjects undergo rs-fMRI to investigate the differences in intra-regional brain activity and inter-regional functional connectivity
45686736|NCT05820165|Radiation|arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI)|Subjects undergo arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI) to clarify the difference of cerebral blood flow (CBF) perfusion in certain regions
46046354|NCT04442399|Behavioral|Family Connections|Ten intervention sessions were covered, ranging form understanding HIV and to handling stigma and discrimination.
46046355|NCT04440813|Behavioral|Education and Training by Clinicians|Training in the use of PPE and education about the risks of blood exposure.
45354120|NCT00676052|Drug|GSK233705 200mcg|Once daily via dry powder inhaler
46046356|NCT04440813|Behavioral|Training and Education from Traditional Healers and Clinicians|Training in the use of PPE and education about the risks of blood exposure.
46046357|NCT04425473|Drug|Esketamine|Esketamine will be administrated intravenously when suturing incision, with total dose of 0.2mg/kg and continuous infusion for 40 minutes.
46046358|NCT04425473|Drug|Normal saline|Equivalent amount of normal saline will be administrated intravenously suturing incision.
45354121|NCT00676052|Drug|Placebo|Once daily via dry powder imhaler
45354122|NCT03011372|Drug|Pemigatinib|"Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.~Participants will receive either the intermittent dose (as written) or continuous dosing."
45354123|NCT05436158|Other|Implant placement in the safe angle position in the anterior maxilla|After assessing the CBCT of patients, the immediate implants will be assessed if they were placed in the safe zone. the safe zone is described as; that there is an angle between the intersection of the incisal long axis perpendicular to the palate or the occlusal plane, and the long axis of the root. When this relation is shifted more palatal, where the incisal plane line will be at the cingulum position or slightly palatal to it, it is named the safe angle position. The more palatal relocation to the cingulum is performed according to the availability of palatal bone, the occlusion with the opposing dentition, the type of the restoration (screw vs cemented).
45354124|NCT05436002|Device|With Cross-linked Hyaluronic Acid|Without Cross-linked Hyaluronic Acid
45354125|NCT02560376|Drug|68Ga-NOTA-exendin-4|68Ga-NOTA-exendin-4 were injected into the patients before the PET/CT scans
45354126|NCT05435690|Device|Computer-assisted arthroplasty|Computer-assisted arthroplasty
46046359|NCT04394468|Device|PlasmaJet|Data will be collected during two contact moments, in particular during her admission for surgical laparoscopy, and during her postoperative check-up. Both of these are standard of care. No additional questionnaires will be taken. During the admission the postoperative pain scoreswill be monitored and collected. The duration of her stay in the hospital will also be recorded. During the postoperative check-up, which takes usually place six weeks after the surgery, complications will registered.
45354127|NCT00535288|Drug|Esmirtazapine|Four different doses (2.25, 4.5, 9.0, and 18 mg) encapsulated esmirtazapine tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
45354128|NCT00535288|Drug|Placebo|Encapsulated placebo tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
45354129|NCT00921830|Drug|ibuprofen|Each subject will receive single doses of (i) ibuprofen 50 mg suppository (ii) ibuprofen 200 mg suppository and (iii) ibuprofen 200 mg tablet in 3 separate dosing periods. Doses will be administered after an overnight fast.
45354130|NCT05435534|Other|ActiveFLS intervention|"A comprehensive geriatric assessment with a multicomponent physical exercise program guideline based on ActiveHip+ for 3 months. In the subsequent revisions, exercise guidelines from the Vivifrail program will be given~A protocolized nutritional intervention will be carried out. In case of oral nutritional supplementation, supplements enriched in β-hydroxy-β-methylbutyrate (HMB) will be selected~Osteoporosis treatments according to national guideline~A review and adaptation of the treatment will be carried out according to the STOPP (Screening Tool of Older Persons' Prescriptions) and START (Screening Tool to Alert to Right Treatment) criteria~An approach will be made to the patient's mood and fear of falling. In case of depression, both pharmacological and non-pharmacological approaches will be assessed~Screening for cognitive impairment will be performed. In the event of evidence of memory problems, a recommendations for cognitive stimulation will be delivered"
45354131|NCT05435534|Other|Usual care group|Participants randomly assigned to the usual care group will receive normal outpatient care, including physical rehabilitation when needed.
45354132|NCT02560220|Biological|Mitomycin C-induced peripheral blood mononuclear cells (MICs)|MICs are given intravenously 2 or 7 days before kidney transplantation from a living donor
45354133|NCT05356078|Drug|Antidepressant|"Delirium event reported in the World Health Organization global database in subjects aged over 65 years taking antidepressants, comparative analysis by antidepressant class"
45354134|NCT05435456|Other|Exercise|Strengthening and Relaxation Exercises
46046360|NCT04387071|Biological|Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949|Given IT
46046361|NCT04387071|Drug|VLP-encapsulated TLR9 Agonist CMP-001|Given SC and IT
45354135|NCT04836832|Drug|Acalabrutinib|Given PO
45354136|NCT04836832|Drug|Duvelisib|Given PO
45354137|NCT02917928|Dietary Supplement|carnosine|Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks
45686737|NCT05820165|Radiation|susceptibility-weighted images (SWIs)|Subjects undergo susceptibility-weighted images (SWIs) to segment the vein network
45843299|NCT05094804|Drug|OR2805|IgG1 monoclonal antibody that binds specifically to the CD163 protein.
45843300|NCT05094804|Drug|Cemiplimab|IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
45843301|NCT05094804|Drug|Docetaxel|An antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.
46046362|NCT04385017|Other|COVID-19 patients|It will consist in the collection of 2 additional tubes at their blood draw. For DNA analysis, informed consent will be collected in writing
46046363|NCT04377490|Other|venous ultrasound|Venous ultrasound will be performed on patients once a week, every week from the day of admission in Amiens Hospital until the day of patient discharge
46046364|NCT04377490|Biological|blood sample|blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in Amiens Hospital until the day of patient discharge
46046365|NCT04374708|Diagnostic Test|fMRI|fMRI: body morph test and neurocognitive testing
46046366|NCT04367805|Diagnostic Test|nasopharyngeal Covid 19 RT-PCR|nasopharyngeal Covid 19 RT-PCR
45477848|NCT03339700|Drug|Cyclophosphamide|80mg/kg, intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 and -2.
45477849|NCT03339700|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
45843302|NCT05079204|Other|Intra oral scan|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study and/or among similar interventions Intervention consists in an 3D intra oral representation of the oral cavity.
45843303|NCT05079204|Other|No intervention|No intervention
45843304|NCT05030844|Behavioral|IMB model based Diabetes Education and Motivational Interviewing|"IMB model-based interventions were applied to the intervention group for 3 month. For the information component of the IMB model, diabetes education consisting of four sessions was given in groups of five in the first two weeks. Each patient was given a Diabetes Management Education Booklet prepared by the researchers. For the motivation component of the IMB model, total 5 sessions 30-minute motivational interview was made with individual Whatsapp calls once every two weeks starting from the third week."
46046367|NCT04366752|Other|venous ultrasound|Venous ultrasound will be performed on patients once a week, every week from the day of admission in ICU until the day of patient discharge
46046368|NCT04366752|Other|blood sample|blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in ICU until the day of patient discharge
46046369|NCT04350502|Procedure|chest tube drainage|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g*3 by day) and clavulanic acid (200mg*3 by day).
45477850|NCT05623553|Device|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
45354138|NCT02917928|Drug|Placebo|Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
45354139|NCT03904420|Other|Clinical Education and Treatment Model|Patients will have self directed equipment education and standardized programming approaches
45354140|NCT03904420|Other|Traditional Model|Standard clinical practice and education
45477851|NCT03813095|Drug|APH-1501|The investigational drug product APH-1501 is CBD encapsulated in biodegradable polymer nanospheres, is a lyophilized powder intended for oral administration.
45477852|NCT03813095|Drug|Placebo|The placebo is a sterile pyrogen free lyophilized powder identical in appearance to the experimental drug product.
45477853|NCT03333460|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
45686738|NCT05820152|Drug|NFS-02 Injection|The starting dose is 1.5×108 vg, 0.05 mL eye/dose. If drug-related dose-limiting toxicity (DLT) events are observed in < 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be escalated to 5.0×108 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in < 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the 5.0×108 vg, 0.05 mL eye/dose, the dose can be escalated to 1.5×109 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in ≥ 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be de-escalated to 5.0×107 vg, 0.05 mL eye/dose after the approval by SRC.
45686739|NCT05820126|Biological|Cold-stored platelet concentrate|Patients will be transfused a unit of pooled, pathogen reduced platelets that have been stored for >24 hours at 1-6˚C
46046370|NCT04350502|Biological|antibiotic concentration in pleural fluid|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g*3 by day) and clavulanic acid (200mg*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
45847651|NCT02800356|Procedure|Subthreshold 577 nm yellow wavelength laser photo-coagulator|"Subthreshold photocoagulation is a method in which the burn spots (treated areas) cannot be seen with biomicroscopy, on color fundus photograph, on Optical Coherence Tomography or Fluorescein Angiography when the subthreshold level is adequately set. Subthreshold photocoagulation can be considered to be truly minimally invasive or non-damaging photocoagulation. A term sometimes used is photo-thermal stimulation since the Retinal Pigment Epithelium (RPE) layer is heated and stimulated, but not destroyed.~The threshold level output power is set to obtain barely visible burn at approximately 200 mW to 250 mW using the titration mode, and irradiation is conducted after switching over to Endpoint Management."
45847652|NCT02801370|Drug|12 mg ciprofloxacin|Single administration of OTO-201
45354141|NCT05222438|Drug|loncastuximab tesirine|loncastuximab tesirine for maintenance therapy between day 30 and 60 following autoSCT and will receive a total of 6 months of therapy (8 cycles).
45354142|NCT05358184|Device|High frequency Percussive ventilation|High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz
45354143|NCT02783300|Drug|GSK3326595|GSK3326595 will be administered with and without food, in tablet and capsule formulation.
45354144|NCT02783300|Drug|Pembrolizumab|Pembrolizumab will be administered.
45354145|NCT02781272|Procedure|Pelvic imaging|Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
45354146|NCT02781272|Procedure|Blood draw|Within 30 days prior to, or on the day of the pelvic mass evaluation procedure, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
45354147|NCT02781272|Procedure|Imaging guided biopsy, surgical biopsy or surgical excision|Imaging guided biopsy, surgical biopsy or surgical excision for evaluation of the pelvic mass will be performed by a qualified individual. Tissue samples will be sent to the local pathology department for histological examination in accordance with standard institutional practices. Results of the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
45477854|NCT01301495|Device|HANAROSTENT TM covered Esophageal Stent|HANAROSTENT covered Esophageal Stent for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and or extrinsic malignant tumors only and occlusion of concurrent esophageal fistula
45354148|NCT04293484|Device|Anodal bilateral motor cortex and cathodal spinal tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
45354149|NCT04293484|Device|Sham bilateral motor cortex and sham spinal tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
45354150|NCT04273594|Device|FemBloc|Treatment with FemBloc for women who desire permanent birth control (female sterilization)
45354151|NCT05355922|Other|Electrical electrostimulation of the quadriceps muscle|Exercises associated with electrical electrostimulation of the quadriceps muscle of patients with knee osteoarthritis
45354152|NCT05355922|Other|Electrical electrostimulation of the quadriceps muscle (placebo)|Exercises associated with electrical electrostimulation (placebo) of the quadriceps muscle of patients with knee osteoarthritis
45354153|NCT00675506|Drug|Growth hormone releasing hormone (GHRH) 1-44|2-mg sub-cutaneous injections once daily for 12 months
45354154|NCT00675506|Drug|Placebo|2-mg sub-cutaneous injections once daily for 12 months
45354156|NCT02558660|Behavioral|Education|Educational intervention about an existing SNAP healthy food incentive program
45354157|NCT02558660|Behavioral|voucher|$10 voucher to spend on produce at farmers markets
45354158|NCT04001920|Other|Training program|12-week, 18-session training program. To offer a complete training program aimed at improving function it was divided : the first 6 weeks were dedicated to strength-training (2 sets of 6 repetitions at 80% of 1-RM), whereas the following weeks focused on endurance-training (1 set of 25 repetitions at 40% of 1-RM).
45354159|NCT05435378|Drug|Vitamin B3 100 MG Oral Tablet|After the non surgical treatment and the oral hygiene instructions The systemically administered vitamin B3 capsules will then given to the patients under the previously mentioned dosage.
45354160|NCT05435378|Drug|vitamin B9|After the non surgical treatment and the oral hygiene instructions the systemically administered vitamin B9 capsules will then given to the patients under the previously mentioned dosage.
45354161|NCT05435378|Drug|Placebo|After the non surgical treatment and the oral hygiene instructions The systemically administered placebo capsules will then given to the patients under the previously mentioned dosage.
45354162|NCT05435378|Procedure|full mouth non surgical periodontal treatment|full mouth scaling and debridement will be done by the primary investigator using ultrasonic scaler and periodontal curettes. After the non surgical treatment patients will be given oral hygiene instructions where they will be instructed to brush twice daily and shown how to brush using the horizontal scraping technique they will also be instructed to use the dental floss and shown how to use it.
45354163|NCT04002622|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
45354164|NCT05435300|Other|PET Scan|Participants will undergo two PET scans throughout the study.
45354165|NCT04003324|Behavioral|Op is Top - using feedback from the Activator to reduce sedentary behavior in older adults|Participants will receive a self-monitoring tool (i.e. the Activator) aimed at the reduction of sedentary behavior. Participants will be able to use the self-monitoring tool for four weeks. Apart from that, participants will receive general sedentary behavior information and an explanation on how to use the self-monitoring tool.
45686740|NCT05820113|Device|Deep learning based reconstruction of T2-TSE sequence|A newly developed deep-learning based reconstruction of a primarily low-resolved T2-TSE sequence is included in the imaging protocol for evaluation of prostate cancer.
45686741|NCT05820074|Diagnostic Test|Neural Activity Recording|Neural Activity is measured using EEG in all groups. Additionally, in Parkinson's patients, local-field-potentials from deep brain stimulation electrodes are recorded.
45686742|NCT05820074|Diagnostic Test|Movement Parameter Recording|Gait-related movement parameters are non-invasively recorded using motion capture, accelerometers and electromyography.
45477855|NCT03339622|Combination Product|PPP001|1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)
45477856|NCT03339622|Combination Product|placebo|1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
45477857|NCT05661149|Device|Hybrid closed loop insulin delivery systems|Tandem Control-IQ ; DBLG1 system ; MiniMed 780G system
45477858|NCT03333304|Diagnostic Test|Procalcitonin measurement|Discontinuation of antimicrobials according to Procalcitonin Kinetics
45477859|NCT01299857|Drug|Rituximab|375mg/m2
45847653|NCT02801370|Drug|Sham Control|Simulated, single adminstration
45354166|NCT02560454|Behavioral|Cogmed|"Cogmed training working memory (unifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~Cogmed working memory training CogMed RM® (RoboMemo,Cognitive Medical Systems AB, Stockholm) version for children will be used in this program. Twelve exercises target verbal and visio-spatial working memory. Difficulty is adjusted depending on participant performance's"
45354167|NCT02560454|Behavioral|Presco|"Presco drive of several cognitive functions (multifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~The program PRESCO® (Program in Cognitive Stimulation and rehabilitation ) comprises 40 exercises targeting: verbal and visio spatial working memory, attention capacities, reasoning, executive functioning , language and mental imagery. Only exercises targeting verbal, visual spatial working memory, and attentional capacities altered in ADHD are used in this present study. Difficulty is adjusted depending on the participant performances."
45354168|NCT05589220|Other|Music Intervention|Music therapy carried out with MUSIC CARE©
45354169|NCT05589220|Drug|Nicotine replacement|NRT: Nicotine Patch, Nicotine Gum
45354170|NCT03895840|Drug|Zilretta|Zilretta (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee osteoarthritis.
45477860|NCT05465356|Other|Questionnaire|Questionnaires completed as part of routine care - this is an observational study
45686743|NCT05820074|Other|Neuromodulation|Neural signals are recorded with the electrodes of the deep brain stimulation device. Parkinson's patients are asked to modulate their neural activity by observing the streamed neural activity and applying mental strategies.
46046371|NCT04350502|Drug|Amoxicillin + clavulanic acid|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g*3 by day) and clavulanic acid (200mg*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
46046372|NCT04347291|Behavioral|FAMS 2.0|FAMS components include monthly phone coaching following a semi-structured protocol plus daily automated text message support to the patient participant and less frequent automated text messages to their support person, if enrolled.
45477861|NCT05465356|Other|Semi-structured interview|Semi-structured interview to review factors involved in patients engaging or not-engaging with the digital tools
45477862|NCT03816371|Other|Head-of-bed elevation|Respiratory pattern including respiratory rate, peripheral oxygen saturation and dyspnea, and drainage including amount of drainage and hematoma formation of all patients were evaluated at 1st, 2nd, 3rd, and 4th hours after positions.
45477863|NCT02500420|Other|Diagnosis examens|"Cardiac MRI: is usually recommended in the diagnosis or in the follow-up of the disease. The MRI will respect the standard protocol: cineMRI sequences, perfusion sequences, LGE sequences at 10 minutes after gadolinium injection. The investigators will realize some additional sequences: T1 mapping before and after gadolinium injection to study the diffuse fibrosis and stress perfusion sequences after injection of a vasodilatator (Persantine°).~Exercice stress echocardiography: is realized almost systematically in all the diagnosis of HCM and it's very informative. The investigators will research left ventricular dysfunction: in particular segmentary hypokinesia and anomalies of deformation parameters (2D Strain) and the development of a dynamic left ventricular outflow obstruction or a mitral regurgitation at exercice."
45686744|NCT05820061|Diagnostic Test|upper endoscopy|data will be collected from the enoscopy archive files in Department of Tropical Medicine and Gastroenterology,Sohag University Hospital
45686745|NCT05820048|Drug|Lansoprazole 15 mg|"Short-term treatment of active duodenal ulcer~Short-term treatment of active benign gastric ulcers~Thin heat of Helicobacter pylori to prevent recurrence of duodenal ulcer~Maintain duodenal ulcer after treatmentLaw~Treatment of nonsteroidal anti-inflammatory analgesics-induced gastric ulcers~Reducing the risk of developing nonsteroidal anti-inflammatory analgesic-induced gastric ulcers~Short-term treatment of gastroesophageal reflux disease~Short-term treatment of erosive reflux esophagitis~Post-treatment maintenance therapy for erosive reflux esophagitis~Pathological hyperdivision, including Zolinger Ellison syndrome"
45686746|NCT05820009|Device|GORE® VIABIL® Biliary Endoprosthesis|Endoscopic treatment of benign biliary stricture secondary to Chronic Pancreatitis with the GORE® VIABIL® Biliary Endoprosthesis.
45686747|NCT05820009|Device|GORE® VIABIL® Short Wire Biliary Endoprosthesis|Endoscopic treatment of benign biliary stricture secondary to Chronic Pancreatitis with GORE® VIABIL® Short Wire Biliary Endoprosthesis
46046373|NCT04347291|Behavioral|Print Materials|Quality print materials about diabetes management provided upon enrollment and in quarterly study newsletters.
46046374|NCT04336995|Diagnostic Test|contrast echocardiography|giving echocardiographic contrast and taking echocardiographic images before and after exercise
46046375|NCT04307381|Drug|Donidalorsen|Donidalorsen administered SC
46046376|NCT04300920|Drug|N-acetyl cysteine|600 mg N-acetylcysteine (NAC) oral tablets three times daily for 24 months.
46046377|NCT04300920|Drug|Placebo|Matching oral placebo tablet three times daily for 24 months.
46046378|NCT04287075|Procedure|Surgical Management of Neuroma|Surgical procedures targeted to treat the source of a participant's chronic, neuropathic pain
46046379|NCT04286568|Behavioral|WOW Intervention|Health education and coaching, health care navigation,
46046380|NCT04285515|Drug|Lumateperone|Lumateperone 42mg oral capsule
46046381|NCT04285515|Drug|Placebos|Placebo oral capsule
45686748|NCT05819996|Behavioral|Environmental educational campaign|Educational campaign will be conducted to promote participation in indoor air testing.
45686749|NCT05819983|Drug|Ivermectin Tablets|Ivermectin 200µg/kg BW
45354171|NCT00310375|Drug|Ezogabine: USAN Retigabine (International Nonproprietary Name)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patient receives between 600 and 1200 mg of retigabine per day. The duration will be until the trial concludes or the patient leaves the trial.
45354172|NCT01061281|Device|Tecnis MF IOL|20 patients enrolled with the Tecnis MF IOL.
45354173|NCT01061281|Device|Crystalens AO IOL|20 patients enrolled with the Crystalens AO
45354174|NCT02532985|Other|Negative Control|No added fiber beverage
45354175|NCT02532985|Other|Positive Fiber Control|positive control fiber supplemented beverage provided over 4 servings
45354176|NCT02532985|Other|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
45354177|NCT02532985|Other|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
45354178|NCT02532985|Other|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
45354179|NCT00309907|Biological|etanercept|Given IV and subcutaneously
45354180|NCT00309907|Drug|methylprednisolone|Given IV and orally
45354181|NCT01063777|Other|A 12 week exercise therapy program and patient education.|"The exercise protocol includes exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults.Patients will be required to exercise for 60 minutes, three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) will be registered by the physical therapists.~All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time."
45354182|NCT01063777|Other|Patient education|All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time.
45354183|NCT00655824|Drug|ofatumumab|1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
45354184|NCT03985969|Drug|elafibranor|Elafibranor 120mg is a coated tablet for oral administration
45477864|NCT03822923|Other|Experimental group|Neurodynamics with conventional treatment. Intervention will be applied for 6 weeks (10 reps per set, 1 set per day, 3 days per week) for 30 minutes
45686750|NCT05819983|Drug|Permethrin Cream|Permethrin cream 5%
45686751|NCT05819970|Drug|Allium Sativum Oil|Allium sativum oil will be used as non-vital pulpotomy medicament
45686752|NCT05819970|Drug|Turmeric Gel|Turmeric gel will be used as non-vital pulpotomy medicament
46046382|NCT04280627|Other|Sample Collection|This study will involve the collection of oral swabs, saliva, urine and faeces samples, blood and skin scrapings from patients before and after kidney and pancreas transplantation at day 0, day 1, week 1 and at 3, 6 and 12 months post-transplant.
46046383|NCT04270734|Procedure|EEG|Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Resolution Electroencephalography will be performed
45354185|NCT03985969|Drug|CHRONO-INDOCID|CHRONO-INDOCID 75mg is a capsule for bis in die (bid) oral administration
45354186|NCT01061437|Drug|PACx14|Standard 14 day, 3 drug regimen: lansoprazole, amoxicillin, clarithromycin (PACx14)
45354187|NCT01061437|Drug|PACMx5|Concomitant therapy - 5 day, 4 drug regimen: lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5)
45354188|NCT01061437|Drug|PAx5/PCMx5|Sequential Therapy - 10 day, 4-drug regimen: lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5)
45354189|NCT00575588|Drug|Metformin|open-label metformin
45354190|NCT00575588|Drug|Sulphonylurea|Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)
45354191|NCT00575588|Drug|Saxagliptin|Saxagliptin 5 mg tablets
45354192|NCT01058317|Drug|Propranolol|Propranolol 2mg/kg divided twice daily
45477865|NCT03822923|Other|Control group|Conventional treatment
45477866|NCT02494024|Drug|Single dose C2N-8E12|C2N-8E12 is a humanized recombinant anti-human tau antibody.
45477867|NCT02494024|Drug|Single dose placebo|Subjects will be block randomized to receive a single dose of C2N-8E12 or placebo in two blocks of 4 subjects (3:1, C2N-8E12:placebo) per cohort.
45477868|NCT03478969|Device|Accu-Chek® Solo micropump system|Medical device for subcutaneous delivery of insulin in a personalized way.
45477869|NCT03478969|Device|mylife™ OmniPod® Insulin Management System|A patch pump system delivering insulin.
45686754|NCT05819905|Diagnostic Test|PET/CT|Pre treatment staging 18F-FDG PET/CT
46046384|NCT04270734|Procedure|NIRS|Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Density Near Infrared Spectroscopy will be performed
45354193|NCT02553096|Device|ACCESS|The ACCESS system consists of a smartphone, a pulse-oximeter, a spirometer and a forehead thermometer. Questions concerning changes in symptoms, physical limitations and emotions are answered by touch screen on the smartphone, complemented by measurements of the pulse-oximeter, spirometer and thermometer. Based on this information, the system calculates the current risk of an exacerbation and, when applicable, the participant will receive personalized instructions about which actions to take in order to manage the exacerbation. Participants are instructed to use ACCESS in case of symptom worsening.
45354194|NCT00810030|Drug|Ferric carboxymaltose|Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® (10 to 20 ml) must be diluted only in sterile 0.9% sodium chloride (max 250 ml) FERINJECT® will be administered via i.v. drip infusion. Minimum administration time 15 minutes Dosage: 500 mg, 1000 mg, 1500 mg, according to patients' Hb and body weight
45354195|NCT00810030|Drug|Iron Sucrose|"VENOFER® will be administered via i.v. drip infusion, diluted only in sterile 0.9% sodium chloride solution as follows:~• 10 mL Venofer® (200 mg iron) in maximum 200 mL sterile 0.9% sodium chloride solution in at least 30 minutes.~The first 25 mL of solution should be infused as a test dose over a period of 15 minutes. If no adverse reactions occur, use infusion rate no more than 50 mL in 15 minutes.~The individual iron deficit will be calculated using the modified formula of Ganzoni.~If the patient's body mass index is >25, a normalised weight will be used for the calculation of iron deficit. Normalised weight = 25 x height [m] x height [m].~The calculated cumulative VENOFER® dose is to be rounded up or down to the nearest 200 mg.~Patients will receive one 200 mg VENOFER® infusion, twice a week, up to 11 times (max dosage 2200 mg), depending on their calculated iron deficit."
45354196|NCT00804102|Device|Transcorneal Electrical Stimulation|Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.
45354197|NCT00804102|Device|DTL-electrode attached without energy|DTL-electrode attached to patient eye receives no energy from neurostimulator. Treatment times remain the same as used for each treatment arm.
45354198|NCT00804180|Behavioral|Self-Injection Anxiety Counseling|This 5-session group intervention involves: psychoeducation; physiological treatment of anxiety though the instruction and practice of relaxation techniques; cognitive restructuring for anxiety-reduction; practice physiological and cognitive treatments through in vivo injection procedures; and problem solving strategies to generalize treatment gains.
45354199|NCT00675428|Drug|BG00002 (natalizumab)|
45354200|NCT05405426|Other|Red blood cell transfusion|The intervention is a strategy for when red blood cell transfusion will be administered (see description of Arms). However, volume of RBC transfused in the two arms is not specified by this study. Red blood cell transfusion strategy for ECMO weaning and decannulation is not specified by this study. Red blood cell transfusion after ECMO decannulation is not specified by this study.
45354201|NCT04049396|Other|Berberine|24 Patient consumed 6,25 g/day Berberine for 6 weeks
45354202|NCT00760916|Drug|UT-15C 1 mg|UT-15C 1 mg
45354203|NCT00760916|Drug|UT-15C 0.25 mg|UT-15C 0.25 mg
45354204|NCT00760916|Drug|UT-15C 5 mg|UT-15C 5 mg
45354205|NCT00760916|Drug|Placebo|Placebo
45354206|NCT05166200|Other|Experimental Formula|Diabetes-specific study formula
45354207|NCT05166200|Other|Test Meal|Instant oatmeal
45354208|NCT00761228|Drug|Apomorphine|Patients will receive an ascending dosing schedule of continuous subcutaneous apomorphine to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
45354209|NCT00761228|Drug|Placebo|Patients will receive a continues subcutaneous infusion of saline solution.
45354210|NCT05008718|Other|38% SDF group|Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
45354211|NCT05008718|Other|5% NaF group|Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
45354212|NCT00921908|Other|2 mBq radioactive technetium diluted in 20 mL saline|
45354213|NCT02558738|Device|ear spray|
45354214|NCT00758732|Drug|Docetaxel|Docetaxel at the dose of 75mg/m2 over a 60 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
45354215|NCT00758732|Drug|Carboplatin|Carboplatin 5 AUC over a 90 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
45354216|NCT00758732|Drug|Docetaxel|Docetaxel at the dose of 40mg/m2 over a 60 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
45354217|NCT00758732|Drug|Liposomal doxorubicin|Liposomal doxorubicin at the dose of 20 mg/m2 over a 90 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
45354218|NCT00761384|Drug|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
45354219|NCT00758888|Procedure|Orthopedic Blocking|Place the blocks under the pelvis for 2 minutes
45354220|NCT00758888|Procedure|Trochanter Belt|Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.
46046385|NCT04270136|Procedure|total mastectomy|breast cancer non conserving surgery
46046386|NCT04262232|Behavioral|Adapted Ca-HELP for Geriatric Cancer Patients|Intervention group: This intervention will be informed by social-cognitive theory10-13 and modeled after the tailored education and coaching intervention (TEC) used for Ca-HELP previously and consists of six components: (1) Assessment of current knowledge, attitudes, and preferences; (2) clarification and correction of misconceptions about cancer pain control; (3) teaching of relevant concepts (education about cancer pain control); (4) planning (identifying goals of care, creating achievable goals of care, and creating strategies to communicate goals of care to providers and family members); (5) rehearsal of communication strategies using role play exercises; and (6) portrayal of learned skills (patient applies skills in visit with healthcare provider).
46046387|NCT04254250|Diagnostic Test|Preoperative risk estimation of disc herniation recurrence|Risk estimation of disc herniation recurrence will be evaluated preoperatively, depend on the risk significance each patient will be assigned to one of two groups - with high risk and low risk. Then each patient will undergo conventional one-level microdiscectomy.
45477870|NCT03478969|Other|Multiple Daily Injections (MDI) therapy|Injecting insulin as per participant's need.
45477871|NCT03812783|Procedure|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
45477872|NCT03812783|Drug|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
45354221|NCT00758888|Other|Blocking Sham|Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
45354222|NCT02559674|Biological|Gemcitabine|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of gemcitabine given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
45354223|NCT02559674|Biological|Nab-paclitaxel|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of nab-paclitaxel given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
45354224|NCT02559674|Biological|ALT-803|Subcutaneous Injection; Patients will receive two 4-week cycles consisting of ALT-803 given on Day 2, 9, 16, 30, 37, and 44. Eligible patients may receive up to 10 additional treatment cycles.
45354225|NCT00761540|Drug|liraglutide|Liraglutide for s.c. injection once daily: dose step 1 (9 subjects)
45354226|NCT00761540|Drug|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1 (3 subjects)
45354227|NCT00761540|Drug|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose step 2 (9 subjects)
45354228|NCT00761540|Drug|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose step 2 (3 subjects)
45354229|NCT00761540|Drug|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (9 subjects)
45354230|NCT00761540|Drug|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (3 subjects)
45477873|NCT03812783|Drug|Sorafenib|administration of Sorafenib
45477874|NCT03812783|Procedure|Hepatic arterial infusion chemotherapy|administration of Irinotecan, Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
45477875|NCT03812783|Drug|FOLFIRINOX|Irinotecan, Oxaliplatin , fluorouracil, and leucovorin
45354231|NCT04913636|Device|Treatment Gel|In the evening subjects will perform their regular denture cleaning routine. They will be instructed to sleep without dentures. Subjects will rinse out their mouth with water (if subjects brush their oral mucosa with brush, they will be allowed to continue doing so) and apply the gel to their mucosa where they normally wear upper or lower denture.
45354232|NCT04913636|Other|Sham Control|Subjects will perform their regular denture cleaning routine.
45354233|NCT00761696|Drug|IPI-926|Oral daily dosing
45354234|NCT00759122|Drug|venlafaxine (Effexor)|Matching capsules containing venlafaxine 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
45477876|NCT02500498|Drug|Nulojix|
45477877|NCT03812861|Other|CAMDS bundle|Cognitive aids for the assessment and management of deteriorating surgical patients (CAMDS). This bundle contains instructions for doctors and nursing staff to assess, manage and escalate care of deteriorating surgical patients. These management instructions will be derived from best practices that are linked with improved mortality and morbidity in surgical patients.
45354235|NCT00759122|Drug|placebo|Matching capsules containing placebo 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
45354236|NCT00759200|Drug|alb-interferon alfa 2b|900 mcg every 4 weeks
45354237|NCT00759200|Drug|alb-interferon alfa 2b|1200 mcg every 4 weeks
45354238|NCT00759200|Drug|alb-interferon alfa 2b|1500 mcg every 4 weeks
45354239|NCT00759200|Drug|alb-interferon alfa 2b|1800 mcg every 4 weeks
45354240|NCT00759200|Drug|peg-interferon|Peg-interferon alfa 2a: 180 mcg 1x per wk.
45477878|NCT02500342|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
45477879|NCT02500342|Drug|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
45477880|NCT02500264|Device|TENS|
45354241|NCT00557505|Drug|PF-03732010|IV infusion. Escalating dose levels, starting at 0.5 mg/kg to Maximum Tolerated Dose. Cycle length of 4 weeks for first cycle, and 2 weekly for subsequently cycles was originally explored, yet based on emerging PK data the Cycle 1 duration is 2 weeks and then weekly. Number of Cycles: Until Progression or unacceptable toxicity develops.
45354242|NCT02558816|Drug|Ibrutinib + GA101 +GDC-0199|Step A : 9 patients receive the combination of Ibrutinib + GA101 Step B : 24 patients receive the combination of Ibrutinib + GA101 + GDC-0199 Step C : 15 untreated patients receive the combination of Ibrutinib + GA101 + GDC-0199
45354243|NCT00759278|Procedure|ultrasound evaluation in pregnancy|Subjects enrolled will have a series of ultrasound evaluations to assess parameters in the study. Ultrasound is a non-invasive technique for creating images that does not use radiation and is routine in obstetrical practice
46046388|NCT04253392|Device|LINX Reflux Management System|"The LINX Reflux Management System consists of a series of titanium beads each with a magnetic core connected with independent titanium wires to form an annular shape when implanted. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak lower esophageal sphincter (LES) closed. During swallowing, the magnetic beads slide away from each other on the independent titanium wire links to allow esophageal distention as the bolus passes by."
45354244|NCT01299753|Drug|placebo|identically packed placebo
45354245|NCT01299753|Drug|propranolol|20-40 mg q6-8h
45354246|NCT02559440|Drug|mometasone furoate|50μg, 1 puff in each nostril every evening
45354247|NCT02559440|Drug|Placebo|1 puff in each nostril every evening
45354248|NCT02559440|Drug|Oxymetazoline + Placebo|1 puff of Oxymetazoline +1 puff of Placebo in each nostril every evening
45354249|NCT02559440|Drug|Placebo + placebo|1 puff of placebo +1 puff of Placebo in each nostril every evening
45354250|NCT02559440|Drug|mometasone furoate + Placebo|1 puff of mometasone furoate +1 puff of Placebo in each nostril every evening
45354251|NCT02559440|Drug|mometasone furoate + Oxymetazoline|1 puff of mometasone furoate +1 puff of Oxymetazoline in each nostril every evening
45354252|NCT01190943|Other|Laboratory Biomarker Analysis|Correlative studies
45477881|NCT05644223|Drug|edaravone dexborneol|intravenous edaravone dexborneol 37.5mg twice daily
45477882|NCT02500108|Drug|Domperidone|"Current exposure to domperidone will be defined as a prescription dispensed within 30 days before the index date.~Recent exposure to domperidone will be defined as a prescription dispensed between 31 and 90 days before the index date (without a dispensing during the 30 days period preceding index date).~Past exposure to domperidone will be defined as a prescription dispensed between 91 and 365 days before the index date (without prescription in the 90 days period prior index date)."
45354253|NCT00944931|Device|DC Brain Polarization|
45354254|NCT04861220|Behavioral|Physical exercise|"The prescription will be divided into 3 phases:~Warm-up: with the object of removing the body from rest and preparing it to start the activity, it consists of exercises for upper and lower limbs, 1 minute each.~Physical exercise: Object of physical conditioning, it consists or aerobic training with walking and muscle activation through concentric contraction of the rectus abdominis in supine position, sit and get up from a chair and resistance exercises for upper members. The patient must perform 2 sets of 12 repetitions for each exercise with a 1-minute interval between the sessions.~Stretching and relaxing: Streching the arms above the head, stretching the legs and stretching the trunk to the left and right side will be oriented. Each stretching exercise should be done for 20 seconds. The relaxation should be performed in a sitting position, eyes closed, calm and silent place, soft breathing, for 5 minutes."
45354255|NCT00202761|Behavioral|PIH|Intensified training
45477883|NCT03816215|Behavioral|Volunteer experience|Participants will be assigned to a meaningful volunteer experience from a menu of local options (e.g., volunteering at an animal shelter or in a library) for 30 hours.
45354256|NCT04012281|Device|Percutaneous coronary intervention|PCI was performed using 2nd generation DES
45354257|NCT00674570|Drug|Hydrocortisone|25 mg/oral one hour prior to extinction task
45354258|NCT00674570|Drug|D-Cycloserine|50 mg/oral one hour prior to extinction task
45354259|NCT00674570|Drug|Placebo|One hour prior to extinction task
45354260|NCT00940563|Drug|Imatinib|
45354261|NCT00759512|Other|Therapeutic Touch|
45354262|NCT00940641|Drug|AZD7325|IV Dose
45354263|NCT00940641|Drug|AZD7325|oral dose
45354264|NCT00761852|Drug|Ruboxistaurin|32 mg daily for 2 weeks
46046389|NCT04252768|Drug|Eftilagimod Alpha|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 30 mg efti subcutaneously on Day 1 and 15 in a 28-day (4-week) cycle. Efti will always be given after paclitaxel. The maintenance phase comprises 6 visits with 4 weekly intervals; during each such visit 30 mg efti is given subcutaneosuly as monotherapy.
45686755|NCT05819879|Procedure|peri capsular nerve group block|The block will be administered under ultrasound guidance with low frequency curvilinear probe. The probe will be placed parallel to the inguinal crease, at the level of anterior superior iliac spine. The scanning will be done with gradual caudad movement of the probe. After the anterior inferior iliac spine (AIIS) become visible, the probe will be turned slightly medial until the hyperechoic continuous shadow of superior pubic ramus become visible. The psoas muscle with prominent tendon will be identified just above the pubic ramus. The target is the plane between these two structures. Aligning the pubic ramus in the center of the image and targeting the pubic ramus just medial to the AIIS, a standard 25G Quincke needle will be introduced and 20 mL 0.125% bupivacaine with 4 mg dexamethasone was administered using ultrasound-guided out-of-plane technique.
45843305|NCT05029206|Procedure|Autologous hematopoietic stem cell transplantation|"The therapeutic intervention of AHSCT consists of four parts: the mobilization of hematopoietic stem cells (HSC), the harvest of HSC, the ablation (conditioning) of the immune system and the reinfusion of autologous HSCs.~In Sweden, the mobilization of HSCs has been made by a combination of cyclophosphamide (2 g/m2) and granulocyte-colony-stimulating factor.~A minimum of 2 × 10^6 CD34+ cells/kg is harvested and cryopreserved. No in vitro manipulation is done to the stem cells.~Two conditioning regimens have been used in Sweden for ablation. The BEAM-ATG protocol include carmustine (BCNU) 300 mg/m2, etoposide 800 mg/m2, cytarabine arabinoside (ARA-C) 800 mg/m2 and melphalan 140 mg/m2 + rATG or hATG. The Cy-ATG protocol include cyclophosphamide 200 mg/kg + rATG/hATG with 1000 mg Metylprednisolone given day -5 to -1.~After a minimum of 24 hours after the last administration of chemotherapy have passed, the reinfusion of autologous CD34+ cells is performed."
45843306|NCT05025462|Dietary Supplement|Supplement dose 15g/d|Supplementation with 15g/day of SPF or Comparator
45843307|NCT05025462|Dietary Supplement|Supplement dose 7.5g/d|Supplementation with 7.5g/d of SPF ou comparator
45843308|NCT04946916|Diagnostic Test|blood sample taken|Comparaison of Neurofilament light chain serum concentration between the arms
45843309|NCT04934826|Dietary Supplement|Hydrolyzed Proteins|Patients in experimental arm will receive a test meal based on marked hydrolyzed proteins
45843310|NCT04934826|Dietary Supplement|Intact proteins|Patients in active comparator arm will receive a meal based on intact marked proteins.
46046390|NCT04252768|Drug|Paclitaxel|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 80 mg/m2 paclitaxel intravenously on Day 1, 8 and 15.
46046391|NCT04250857|Device|HeartStart FRX|Automated External Defibrillator
46046392|NCT04248491|Device|BTL Emsella chair|Subjects will sit on the device. The RNC will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased with every treatment until the subject reaches 100%.
46046393|NCT04246944|Procedure|harvesting induced membrane|The induced membrane will be harvested during the second step of the bone reconstruction.
46046394|NCT04233073|Drug|andexanet alfa|Andexanet is a recombinant version of human FXa
46046395|NCT04222010|Drug|loco-regional anesthesia serratus plane bloc (Ropivacaine 2 mg/mL, 40 mL) and paravertebral placebo bloc (saline, 20 mL)|Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia
46046396|NCT04222010|Drug|Loco-regional anesthesia : paravertebral bloc (Ropivacaine 4 mg/mL, 20 mL) and serratus plane placebo bloc (saline, 40 mL)|Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia.
46046397|NCT04222010|Drug|Loco-regional anesthesia : serratus plane bloc (Ropivacaine 1,3 mg/mL, 40 mL) and paravertebral bloc (Ropivacaine 1,3 mg/mL, 20 mL)|Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia.
46046398|NCT04221763|Device|His-bundle pacing.|Cardiac resynchronisation therapy can be achieved using biventricular pacing involving placement of three leads into the right atrium, right ventricle and coronary sinus (epicardial left ventricle). Alternatively the third lead may be placed at the bundle of His or left ventricular septum to pace the left bundle directly.
46046399|NCT04203550|Procedure|Intraoperative irrigation|Operation with irrigation
46046400|NCT04203550|Procedure|No irrigation|Operation without irrigation
46046401|NCT04200651|Drug|Dexamethasone Ophthalmic Insert|DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.
46046402|NCT04200651|Drug|Prednisolone Acetate 1% Oph Susp|Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.
45354265|NCT00761852|Drug|Placebo|1 tab po QD for 2 weeks
45686756|NCT05819879|Procedure|scaitico femoral block|. After draping the left inguinal region, the femoral nerve will be identified lateral to the femoral artery using a 5- to 13-MHz linear phased array transducer ). Under ultrasound guidance, a 25G Quincke needle will be introduced toward the femoral nerve parallel to the ultrasound beam, and 20 mL of a local anesthetic mixture 20 mL 0.125% bupivacaine with 4 mg dexamethasone will be injected. The trajectory of the needle was adjusted to achieve even distribution of the local anesthetics around the femoral nerve. Then, the patient will be placed in the right lateral position with the left hip and knee joints flexed by 30° to 50°. Following the identification of the left sciatic nerve located in the intermuscular plane of the gluteus maximus and medius muscles between the ipsilateral ischial tuberosity and greater trochanter using a convex phased array transducer 20 mL 0.125% bupivacaine with 4 mg dexamethasone will be placed near the sciatic nerve through the 22-ga Tuohy needle
46046403|NCT04186585|Drug|BP-C2|Oral daily intake
46046404|NCT04183803|Procedure|anatomic anterior cruciate ligament (ACL) reconstruction|The reconstruction will be performed with hamstring tendon graft or patellar tendon graft. The femoral and tibial tunnels placement will be guided by the Rosa robot (Zimmer®).
45354266|NCT00940719|Dietary Supplement|vitamin D3|Oil-based solution, 1 dose of 500 microgram each day, during 3 months.
45354267|NCT04795232|Other|COD45|Participants will perform 2 sets of 10 sprints. The total distance for each sprint will be 27.6 meters and will include two changes of direction of 45 degrees. The recovery time will be 16 seconds between sprints and 2.20 minutes between sets
45354268|NCT04795232|Other|COD90|Participants will perform 2 sets of 10 sprints. The total distance for each sprint will be 21.2 meters and will include two changes of direction of 90 degrees. The recovery time will be 16 seconds between sprints and 2.20 minutes between sets
45354269|NCT00940797|Drug|DMMET-01|60 days: 30 days; dose 1050.6 mg per day (before dinner)+ 30 days; dose 1050.6 mg twice a day 30 more days (before breakfast ando before dinner)
45354270|NCT00940797|Drug|Placebo|60 days: 30 days placebo once a day (before dinner) + 30 days twice a day (before breakfast and before dinner)
46046405|NCT04169646|Other|Multi-component intervention|Participants' workstation ergonomics will be assessed using an observation-based ergonomics assessment checklist for office-workers adapted to Swiss guidelines. Based on the initial assessment, best practice ergonomics will be applied individually using existing infrastructure. Participants will attend health promotion information group workshops for approximately one hour per week for 12 weeks. it. Participants will receive an individual progressive exercise programme aimed at conditioning the muscles of the neck and shoulder girdle. The exercises will be performed in groups (maximum of ten per group) at the workplace in a dedicated room, for approximately one hour (3x20 minutes) per week; once per week supervised by a physiotherapist, a human movement scientist, or a health scientist, and twice per week individually. Workshop session attendance will be recorded as an indication of adherence to health promotion. Adherence to neck exercises will be recorded with the Physitrack® app.
46046406|NCT04169646|Other|Control|No intervention takes place during the control phase.
45354271|NCT00759590|Procedure|CT scan and Pressure volume curve|CT scan
45354272|NCT04012905|Drug|Corticosteroids for Systemic Use|"Corticosteroids tapering over 28 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,5 mg/kg S6 = 0,4 mg/kg S8 = 0,3 mg/kg S10 = 0,25 mg/kg S12 = 0,2 mg/kg S14 = 0,15 mg/kg S16 = 0,15 mg/kg S20 = 0,1 mg/kg S24 = 0,05 mg/kg S28 = 0 mg/kg~Corticosteroids tapering over 52 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,6 mg/kg S6 = 0,5 mg/kg S8 = 0,4 mg/kg S10 = 0,3 mg/kg S12 = 0,25 mg/kg S14 = 0,2 mg/kg S16 = 0,175 mg/kg S20 = 0,15 mg/kg S24 = 0,125 mg/kg S28 = 0,01 mg/kg S32 to S52: - 1mg per month"
45354273|NCT02559518|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
45354274|NCT02559518|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
45354275|NCT02559518|Device|tDCS|Sham ctDCS will be applied using the same electrodes placement and parameter settings of cathodal ctDCS. However, stimulation will last only 30 seconds but volunteers will be with electrodes montage for 20 minutes.
45477884|NCT02500186|Drug|Luseogliflozin|Study patients orally receive luseogliflozin 2.5 mg s.i.d. before breakfast for 7 days from the 8th day of starting the study meal to the 14th day.
45477885|NCT02500186|Other|Meal containing different carbohydrate ratio and GI value|High GI meal containing 55% carbohydrate Low GI meal containing 55% carbohydrate High GI meal containing 40% carbohydrate
45477886|NCT05635643|Drug|SRF114|SRF114
45477887|NCT02500030|Procedure|Glossopharyngeal Breathing|Glossopharyngeal Breathing is a type of lung recruitment technique where the patients take a multiple inssuflations with their glossopharyngeal muscle.
45477888|NCT02500030|Procedure|Air Stacking|Air Stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.
45686757|NCT05819814|Genetic|Polygenic risk-based detection of subclinical coronary atherosclerosis|Disclosure of a high polygenic risk result followed by screening for subclinical coronary atherosclerosis using coronary computed tomography angiography.
45686758|NCT05819736|Other|Monitoring|Monitoring
45686759|NCT05819723|Other|CAM score|"The CAM scores assess the presence of delirium rapidly and accurately and also differentiates delirium from other cognitive impairment with a sensitivity of 94-100% and specificity of 90-95%.~It is an algorithm that consists of four features:~(i) Acute and fluctuating variation in mental status, (ii) Inattention, (iii) Incoherent or disorganized thinking, and (iv) Altered level of consciousness. CAM scores indicate delirium if the first two features are present and either the third or fourth feature is present."
45686760|NCT05819697|Other|FIRE Trial/Track Your Happiness notifications|"All participants will receive notifications to their smart phones 3 times a day for 12 weeks. They will be asked questions related to burning mouth, to exercise as well as non-clinical Track Your Happiness questions, e.g., Are you interacting with anyone right now? How do you feel right now?"
45354276|NCT02559518|Device|rTMS|High frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 10Hz, 110% RMT, 33 trains, 50 stimuli per train, intertrain interval of 25 seconds, 1650 stimuli.
45354277|NCT02559518|Device|rTMS|Low frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 1Hz, 110% RMT, 1000 stimuli (1 train).
45354278|NCT02559518|Device|rTMS|Sham c-rTMS will be performed with low frequency protocol using two coils. The first one - connected to the stimulator (Rapid², Magstim, UK) - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left cerebellar hemisphere.
45354279|NCT02559518|Device|pp-TMS assessment|SICI and ICF will be evaluated through pp-TMS. Subthreshold conditioning stimuli (80% of RMT) and suprathreshold test stimuli (120% of RMT) will be delivered at 2 milliseconds ISI, in order to determine SICI. ICF will be evaluated by MEP average at an ISI of 10 milliseconds. Ten stimuli will be applied at each condition (unconditioned pulse and pairs of stimuli with ISI of 2 and 10 milliseconds). Stimuli order delivery will be pseudo-randomized and SICI and ICF will be expressed as conditioned stimulus percentage regarding an unconditioned stimulus.
45354280|NCT04012515|Device|Electrode Pads|Participants wear six electrode pads in total; three different types of pad, worn in the same positions on both sides of the face. The pads on the left-hand side of the face are replaced daily, and those on the right-hand side are replaced every other day. The pads do not administer a medical treatment or perform any other active function. The purpose of the intervention is to determine which combination of pad and replacement regime maximises the tolerability of wear over a 30-day period.
45354281|NCT00759746|Behavioral|SFM+ Low Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet less often than families that receive the Social Facilitation Maintenance (SFM) - High Dose intervention, giving them more opportunities to practice new skills between clinic visits.
45354282|NCT00759746|Behavioral|Weight Maintenance Education|The Weight Maintenance Education intervention will help participants in parent and child groups to learn more about healthy eating and physical activity in a group setting. Participants will also learn about exercise and exercise safety, hydration during exercise, and stress management. Parent and child groups will combine for particular on-site and off-site activities, such as cooking demonstrations, grocery store tours, gym tours, and dance lessons.
45477889|NCT05623475|Behavioral|OSCEs|Scenario-based education intervention, including objective structured clinical examinations (OSCEs)
45477890|NCT05623475|Behavioral|Lecture|Face-to-face Education using Delirium Care Flip Chart
45477891|NCT05623475|Behavioral|E-learning|Including 7 parts of delirium care video
45477892|NCT02499874|Drug|Efavirenz|oral Efavirenz 400mg
46046407|NCT04165694|Procedure|Single Anastomosis Duodenal Ileal Bypass (SADI)|The purpose of the research is to study additional weight loss and resolution of comorbidities in patients who undergo revision of their sleeve gastrectomy to a Single Anastomosis Duodenal Ileal bypass (SADI). The sleeve gastrectomy which you have already undergone is now the most common bariatric procedure performed. This operation was part of a 2-stage operation known a Duodenal Switch (DS) which was a sleeve gastrectomy followed by a long bypass of the intestine that involved 2 connections. This operation has many complications such as vitamin deficiencies and potential malnutrition. The SADI procedure is a version of the DS that bypasses less of the intestine and one less connection of the small bowel.
45477893|NCT02499874|Drug|tenofovir /emtricitabine|tenofovir 245 mg/emtricitabine 200mg
45477894|NCT02499874|Drug|tenofovir/lamivudine|tenofovir 245mg/lamivudine 300mg
45477895|NCT02499874|Drug|lamivudine/zidovudine|lamivudine 300mg/zidovudine 600mg
45477896|NCT05093777|Other|Program Intensified Habilitation|The program is based on a holistic and family-centered concept, which acknowledges parents as experts on their child's abilities and needs. The program involves both parents and local professionals, and includes goal setting and goal-directed treatment targeted to the needs of the individual child. The program lasts for about one year and contains three in-patient group sessions over 2 weeks. In between the children are receiving individualized home training programs at home and in pre-school/kindergarten. The children train on a daily basis, both during the inpatient sessions and in the home setting.
45477897|NCT05093777|Other|Habilitation as usual|"When the participants are not joining the study year containing the intervention program, they will be offered habilitation services as usual administered by the primary health care services in the local community."
45686761|NCT05819645|Behavioral|Fluid intake not as per standard guidlines|The participant will be randomized into two arms. After the randomization one arm will get the per os fluid intake before the standard time frame.
45686762|NCT05819632|Other|curcumin gel 2%|curcumin gel 2%
45686763|NCT05819606|Other|Immunohistochemistry (IHC) analysis|Setting of the percentage amount of PSMA expression on the primary tumor cell surface on post-surgical samples by the Immunohistochemistry method (IHC)
45686764|NCT05819567|Device|Newly Developed Ankle Brace|The ankle brace is made of gripping tissue and includes two straps and one latex wedge. The purpose of this brace is to lift up the plantar arch.
45686765|NCT05819554|Procedure|Trans-sphenoidal surgery|Surgical removal of pituitary tumor by trans-sphenoidal approach
45686766|NCT05819541|Drug|Montelukast Oral Granules|Oral montelukast granules at weight-based doses between 2 mg/kg and 3 mg/kg to a maximum of 180 mg.
45686767|NCT05819541|Drug|Albuterol|Inhaled albuterol by metered-dose inhaler (MDI) or nebulizer
46046408|NCT04159571|Device|Real TBS to the vmPFC|This will be delivered with the Magventure Magpro system; active sham coil (double blinded)
46046409|NCT04159571|Device|Sham cTBS to the vmPFC|The MagVenture MagPro system has an integrated active sham that uses two surface electrodes placed on the skin beneath the coil.
45686768|NCT05819541|Drug|Corticosteroid|Oral or parenteral corticosteroid (e.g., dexamethasone, methylprednisolone)
45354283|NCT00759746|Behavioral|SFM+ High Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet more often than families that receive the Social Facilitation Maintenance (SFM) - Low Dose intervention, allowing for more in-depth discussion and practice of key skills and concepts related to creating a social environment that supports a healthy lifestyle. These participants will receive more feedback and reinforcement from fellow group members, family interventionists, and group leaders for practicing their new behaviors.
45354284|NCT00940953|Drug|Budesonide + Azelastine|nasal spray, one spray per nostril at time 0 plus one spray Placebo
45354285|NCT00940953|Drug|Budesonide + Azelastine|nasal spray, one spray of each per nostril at time 0
45354286|NCT00940953|Drug|Placebo|nasal spray, one spray per nostril from each of 2 bottles at time 0
45686769|NCT05819489|Diagnostic Test|Dynamic Vision Testing|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
45354287|NCT00759824|Drug|Adriamycin, cyclophosphamide, vindesine, valproic acid|Adriamycin 45 mg/m² day 1 IV Cyclophosphamide 1 g/m² day 1 IV Vindesine 3 mg/m² day 1 IV Valproic acid 20-30 mg/kg/day from day -7 until the end of treatment, orally
45354288|NCT04012593|Behavioral|Diary|
45354289|NCT04049240|Device|Device: low-flow nasal oxygenation (LFNO) 18<BMI<30 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
45354290|NCT04049240|Device|Device: low-flow nasal oxygenation (LFNO) 30≤BMI<35 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
45354291|NCT04049240|Device|Device: low-flow nasal oxygenation (LFNO) BMI≥35 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
45354292|NCT04049240|Device|Device: High-flow nasal oxygenation (HFNO) 18<BMI<30 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
45354293|NCT04049240|Device|Device: High-flow nasal oxygenation (HFNO) 30≤BMI<35 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
45354294|NCT04049240|Device|Device: High-flow nasal oxygenation (HFNO) BMI≥35 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
45354295|NCT00760058|Device|AcrySof® IQ IOL|Replacement of natural crystalline lens in cataract surgery
46046410|NCT04159571|Device|Real TBS to the dlPFC|This will be delivered with the Magventure Magpro system; active sham coil (double blinded).
46046411|NCT04159571|Device|Sham TBS to the dlPFC|The MagVenture MagPro system has an integrated active sham that uses two surface electrodes placed on the skin beneath the coil.
45354296|NCT00760058|Device|Tecnis® Aspheric intraocular lens|Replacement of natural crystalline lens in cataract surgery
45354297|NCT00760058|Device|Akreos® MI60 intraocular lens|Replacement of natural crystalline lens in cataract surgery
45354298|NCT00762242|Procedure|blood sampling and brachial artery ultrasound|"Intravenous blood sampling will be performed before and 15 seconds, 30 seconds, 1,2,5,10,and 30 minutes following an ischemic stimulus (inflation of a blood pressure cuff to suprasystolic pressure for 5 minutes)~Brachial artery ultrasound imaging will be performed before and 1 minute after a 5 minute ischemic stimulus, to assess endothelium-dependent vasodilation of the brachial artery.~Following completion of blood sampling, an additional resting image of the brachial artery will be obtained. Sub-lingual nitroglycerin will be administered, and the artery will be imaged again after 3 minutes, to assess endothelium-independent vasodilation."
45354299|NCT02558426|Procedure|Venous Surgery|Patients with Varicose Veins will undergo to venous surgery procedure. Samples obtained from patients undergoing surgical removal of varicose veins will be collected and immediately preserved at -80°. Briefly, the venous tissueswill be excised, homogenized with a motor-driven homogenizer and total RNA will be isolated using the Trizol reagent (Invitrogen, Milan, Italy), according to the manufacturer's instructions. The expression of ERα, ERβ and GPER will be quantified by real-time PCR using the Step OneTM sequence detection system (Applied Biosystems Inc., Milan, Italy), following the manufacturer's instructions
45354300|NCT00561951|Drug|fesoterodine fumarate|8mg tablets OD for 12 weeks
46046412|NCT04156386|Dietary Supplement|Recovery animal (20g whey) protein supplement|Animal protein supplement consumed post exercise to aid recovery of muscle function following strenuous exercise.
45354301|NCT00561951|Drug|Placebo|Corresponding placebo tablets OD for 12 weeks
45354302|NCT00561951|Drug|fesoterodine fumarate|4mg tablets OD for 12 weeks
46046413|NCT04156386|Dietary Supplement|Recover vegan (26g pea) protein supplement|Vegan protein supplement consumed post exercise to aid recovery of muscle function following strenuous exercise.
46046414|NCT04156386|Dietary Supplement|Placebo (32g maltodextrin)|Placebo consumed post exercise to aid recovery of muscle function following strenuous exercise.
46046415|NCT04150900|Drug|Bavituximab|Bavituximab is a chimeric (human/mouse) monoclonal antibody (mAb) derived from murine mAb 3G4 that targets phosphatidylserine (PS) after binding to β2-glycoprotein 1 (β2-GP1).
46046416|NCT04150900|Drug|Pembrolizumab|Pembrolizumab is a highly selective humanized mAb designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
46046417|NCT04133701|Behavioral|Time-Restricted Feeding|After baseline measurements have been completed, participants will enroll in a time-restricted feeding intervention. Participants will be asked to restrict the time in which they eat each day to 10 hours, fasting for the remaining 14 hours. Participants will also be asked to finish their last meal of the day at least 2 hours prior to bedtime.
46046418|NCT04120116|Drug|FX-322 (One Dose)|Patients will receive one dose of FX-322.
46046419|NCT04120116|Drug|FX-322 (Two Doses)|Patients will receive two doses of FX-322.
46046420|NCT04120116|Drug|FX-322 (Four Doses)|Patients will receive four doses of FX-322.
46046421|NCT04120116|Drug|Placebo|Patients will receive Placebo.
46046422|NCT04116736|Device|ACUVUE® OASYS with Transitions™|JJVC Marketed Contact Lens
45354303|NCT02558348|Drug|AL3818|Administered orally
45354304|NCT00762398|Device|Masimo hemoglobin-meter|Placing a probe on the finger
45354305|NCT00762398|Biological|drawing blood sample|drawing a blood sample less that 0.5 mL each time, for around 10-12 times along the surgery (depends on surgical time)
45354306|NCT00760136|Procedure|Computed Tomography|CT imaging of bilateral knee
45354307|NCT04552886|Biological|TH-1 Dendritic Cell Immunotherapy|Adult patients with histopathologically diagnosed glioblastoma will be eligible for this novel, personalized dendritic cell vaccine after completing standard of care chemoradiation.
45354308|NCT00762632|Drug|NILOTINIB|400 mg Nilotinib bid (total daily dose 800 mg) should be continued 25 weeks
45354309|NCT00762632|Drug|EVEROLIMUS|Everolimus at 2,5 mg/day should be continued 25 weeks.
45354310|NCT00322387|Drug|G-CSF and plerixafor|G-CSF and plerixafor were administered as described in the treatment arms.
45354311|NCT00561015|Drug|Telaprevir|Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.
45354312|NCT00561015|Drug|Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)|Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 & PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
45354313|NCT00561015|Drug|Placebo|Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks.
45354314|NCT00945087|Other|Bacteriophage preparation|Bacteriophage lysates or purified phage formulations containing phages lytic for Staphylococcus, Enterococcus, Pseudomonas, Escherichia, Klebsiella, Proteus, Citrobacter, Acinetobacter, Serratia, Morganella, Shigella, Salmonella, Enterobacter, Stenotrophomonas, or Burkholderia strains isolated from a patient used for oral, rectal and/or topical application.
45354315|NCT00560937|Drug|Pregnenolone|Pregnenolone 50 mg twice a day (BID) x 2 weeks, Pregnenolone 150 mg BID x 2 weeks, Pregnenolone 250 mg BID x 4 weeks
45354316|NCT00560937|Drug|Placebo|Placebo (similar to active comparator) 50 mg BID x 2 weeks, Placebo (similar to active comparator) 150 mg BID x 2 weeks, Placebo (similar to active comparator) 250 mg BID x 4 weeks
45354317|NCT00945165|Behavioral|Exercise intervention|various exercise characteristics
45354318|NCT00945165|Behavioral|No exercise|No exercise control period
45686770|NCT05819476|Procedure|OLP-injection|Open-label placebo injections without any active ingredient (5 ml 0.9% saline). All participants will be informed that the administered injections are placebo infusions.
45843311|NCT04873596|Drug|Nebulized dexmedetomidine|parturient will receive nebulized 3ug/kg dexmedetomidine.
45843312|NCT04873596|Drug|Nebulized midazolam|parturient will receive nebulized 0.2 mg/kg midazolam.
45354319|NCT04012437|Device|Sphincter Control Training (SCT)|The SCT + device consists of 8 different exercises and an educational session into a app using a masturbation electronic aid device
46046423|NCT04116736|Device|Silicone Hydrogel Contact Lens|Any reusable spherical silicone hydrogel brand that is approved and marketed in the country conducting the study.
46046424|NCT04115553|Diagnostic Test|MRI examination|Subjects will be placed in supine position. The systematic use of a headset will reduce the noise inherent to the machine. Standard MRI examination using a 32-channel head coil consists of angiographic, morphological and phase-contrast 2D flow sequences. The flow planes are set perpendicularly to the structure axis (blood or CSF regions). The velocity measured in the pixels inside the region of interest allow the calculation of a mean flow rate as well as the volume displaced during a cardiac cycle.
45354320|NCT04012437|Behavioral|Sphincter Control Training (SCT)|The SCT consists of 4 different exercises and an educational session into a app using a masturbation electronic aid device
45354321|NCT00945399|Procedure|CARTIPATCH® procedure|Cartilage is harvested and treated for chondrocytes isolation and culture. After multiplication, the chondrocytes are transferred into a biomaterial support and surgically implanted.
45354322|NCT00945399|Procedure|Microfracture|Tiny fractures are created at the cartilage surface to stimulate cartilage growth.
45843313|NCT04868760|Drug|Ipilimumab|Drug: Ipilimumab 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
45843314|NCT04868760|Drug|IBI310|Drug: IBI310 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
45843315|NCT04865952|Procedure|periodontal surgery + 24 hr buccal attached gingiva (G) biopsy|Periodontal surgery will be performed and 24 hr after the surgical procedure a 2mm punch biopsy will be harvested at the level of the buccal attache gingiva (G).
45354323|NCT00941187|Other|diffusion NO/CO method|pulmonary capillary blood volume (Vc), measured by the double diffusion NO/CO method: this method is to inhale during a deep inspiration with a mixture of helium (8-10%), CO (2000 ppm) and NO (20-40 ppm), the O2 (21%)
45354324|NCT04012359|Diagnostic Test|Lung ultrasound|Non-invasive external ultrasonography of the chest wall
45354325|NCT04012359|Diagnostic Test|Chest radiography|Chest radiography to search for visible pleural edge, synonym with persistent pneumothorax
45354326|NCT04012359|Diagnostic Test|Pulmonary function tests|Pulmonary function evaluation as part of routine care for emphysematous patients
46046425|NCT04115553|Diagnostic Test|ECG|A cardiac synchronization system using peripheral ECG allows the synchronization with the subject's heart rate.
46046426|NCT04111107|Drug|Investigational Agent|Treatment will be administered on an inpatient or outpatient basis based on the type of medication selected. The investigatory will administer the drug as directed in the FDA approved label.
45354327|NCT04012359|Other|Clinical examination|Standard clinical examination performed by investigating physician
45354328|NCT04012047|Drug|Levcromakalim|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
45354329|NCT04012047|Drug|Saline|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
45354330|NCT00941265|Drug|levodopa and benserazide|Daily Monday to Friday CAT with Daily Monday to Friday levodopa 100 mg with benserazide 25 mg , in the morning 1 h after breakfast, during 2 weeks .
45354331|NCT00941265|Drug|placebo|Daily CAT Monday to Friday with daily placebo Monday to Friday , in the morning 1 h after breakfast, taken 5 out of 7 days during the 2 weeks of one of the two treatment periods.
45843316|NCT04865952|Other|HA application|HA will be applied at the end of the surgical procedure, at the level of the vertical released incisions (VRIs) and over VRIs
45354332|NCT00941343|Drug|Alfuzosin (XATRAL® - SL770499)|One tablet of XATRAL® 10mg OD once a day at the end of an evening meal. The tablets had to be swallowed whole without being chewed or crushed
45354333|NCT00561795|Drug|pazopanib (GW786034)|800 mg orally once a day for 6 cycles
45354334|NCT00561795|Drug|carboplatin|IV over one hour every 3 weeks of 6 cycles
45354335|NCT00561795|Drug|paclitaxel|IV 175 mg/m^2 given over 3 hours on day one of a 21 day cycle for six cycles
45354336|NCT00652626|Drug|azacitidine|
45354337|NCT00941421|Device|oesophagal videocapsule and oeso-gastro-duodenal fiberoptic endoscopy|each patient receive one OVC and one OGDFE the same day
45354338|NCT00560703|Drug|COL-101 (doxycycline, USP) capsules|40mg, once per day for 84 days
45354339|NCT00560703|Drug|placebo|sugar capsule
45354340|NCT00308737|Drug|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
45354341|NCT00308737|Drug|Usual Care|Subjects will receive antidiabetes treatment at the discretion of their physicians
45354342|NCT04711902|Drug|Secukinumab (AIN457)|Biological
45843317|NCT04803708|Biological|TP-102|One mL of IP solution will be applied topically per cm3 of target ulcer. The titer of each bacteriophage in TP 102 is 1x10^9 plaque forming units per milliliter (PFU/mL).
45354343|NCT04711902|Other|Secukinumab Placebo|Matching placebo
45354344|NCT00941499|Drug|HAI Oxaliplatin|140 mg/m^2 by HAI (hepatic arterial infusion)over 2 hours on Day 1 of each 21 day cycle
45354345|NCT00941499|Drug|5-FU|900-1750 mg/m^2 HAI infusion over 24 hours on Days 1 - 2 of each 21 day cycle.
45354346|NCT00941499|Drug|Bevacizumab|10 mg/Kg by vein on Day 1 of 21 day cycle.
45354347|NCT00941499|Drug|Cetuximab|Loading dose of 250-500mg/m^2 and Maintenance dose of 125-250 mg/m^2 by vein on Day 1 of 21 day cycle.
45354348|NCT00941499|Drug|Leucovorin|200 mg/m^2 by vein on Days 1 and 2 of each 21 day cycle.
45843318|NCT04651452|Behavioral|Value Affirmation|Participants will complete writing tasks regarding their personal values.
45843319|NCT04651452|Behavioral|Reflective Journaling|Participants will complete writing tasks regarding their least important values and discuss why they may be important to others. They will also describe aspects of daily life.
45354349|NCT00941499|Drug|5-FU|300-400 mg/m^2 bolus + 600-1000 mg/m^2 infusion over 22 hours on Days 1-2 of each cycle.
45354350|NCT00941499|Drug|Bevacizumab|7.5 - 15 mg/Kg by vein on Day 1 of 21 day cycle.
46046427|NCT04111107|Other|Supportive Care Regimens|Supportive care regimens will vary depending on the type of drug that will be administered at the treating investigator's discretion.
46046428|NCT04111107|Diagnostic Test|Next Gen Sequencing Report|1) Next Gen Sequencing report obtained as Standard of Care within the past 12 months of enrollment date will be used. If more than one report exists in this time period, the most recent report will be used.
45354351|NCT04752384|Drug|Buprenorphine|Transdermal buprenorphine will be started at 5 mcg/hr once a week. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 20 mcg/hr once a week.
45354352|NCT04752384|Drug|Tramadol|Oral tramadol will be started at 50 mg/day. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 400 mg/day.
45354353|NCT04752384|Device|Oral Mucositis (OM) Pain App|"Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed. Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.~Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels."
45354354|NCT04743804|Biological|Ravulizumab|Body weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
45354355|NCT04743804|Other|Placebo|Matching placebo
45354356|NCT04743804|Other|Best Supportive Care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
45477898|NCT04495192|Genetic|Genetic analysis of different single nucleotide polymorphisms on ApoE, BDNF and DRD2 genes assessment|Genomic DNA will be obtained from EDTA-whole venous blood sample by Automated Systems QiaCube (Qiagen). The genetic analysis of 5 different single nucleotide polymorphisms on ApoE, BDNF and DRD2 genes will be performed by HRM analyses and direct sequencing on Automatic Genetic Analyzer. All the aliquots will be amplified by a real-time PCR. The genetic polymorphism data will be compared to sex- and age-matched control of the DNA banking of the neurogenetic Laboratory of Florence Hospital.
45477899|NCT03816059|Diagnostic Test|Respiratory virus testing|All patients will be tested for respiratory viruses
45686771|NCT05819476|Other|Scripted Evidence-based treatment rationale|As a second component the intervention will consist of an evidence-based treatment rationale, which will be delivered to patients receiving the intervention prior to the OLP-injections, explaining placebo analgesia in pain in general and specifically in OLP. In the context of OLP treatments this rationale is important in order to create a mental state of positive expectations.
45843320|NCT04566978|Drug|89Zr-DFO-REGN3767|89Zr-DFO-REGN3767 is comprised of the anti-LAG-3 antibody, REGN3767 labeled with the positron-emitter zirconium-89 (89Zr) through the chelator-linker DFO. REGN3767 is an investigational monoclonal antibody that target LAG-3 receptors.
46046429|NCT04103762|Procedure|laparoscopic cholecystectomy|laparoscopic cholecystectomy
46046430|NCT04103762|Diagnostic Test|systematic intraoperative cholangiography|systematic intraoperative cholangiography in both groups (use of Indocyanine Green in ICG group and Iomeron in the CPO group)
45354357|NCT00941577|Drug|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
45354358|NCT00941577|Drug|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
45354359|NCT00945789|Drug|Human recombinant erythropoietin|Epo dse is 2500 IU/kg subcutaneous daily for 5 days.
45354360|NCT00945789|Procedure|EEG and Brain MRI|EEG to be done twice in hte first 48 hours and at 2-3 weeks. MRI to be done at 3 weeks of age.
45477900|NCT04495270|Diagnostic Test|"Analysis of treatment outcomes of teeth with apical periodontitis based on cone-beam computed tomography and estimated by means of Periapical and Endodontic Status Scale"|Patients were examined by cone-beam computed tomography at baseline and in 24 months after endodontic treatment. Treatment outcome was evaluated using estimates of periapical radiolucencies in size, relation with anatomical structures and location.
46046431|NCT04099706|Procedure|Autologous Fat Grafting / Fat Transplant|See arm descriptions.
46046432|NCT04084171|Device|Tandem t:slim X2 with Control-IQ Technology + Dexcom G6|Subjects will use the Tandem t:slim X2 with Control- IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor [CGM].
46046433|NCT04080414|Behavioral|Home-based high-intensity interval training|Participants will be instructed to complete four, high-intensity interval training workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
45354361|NCT00945789|Biological|Nitric oxide measurement in the blood|Concentration of nitric oxide is measured in the blood at enrollment. For the 2 groups with asphyxia, measurement to be repeated in 2 weeks.
45354362|NCT04737096|Drug|DAOIB|The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
45354363|NCT04737096|Drug|Placebo|placebo
45354364|NCT04737096|Device|tDCS|tDCS
45354365|NCT00941811|Drug|Imiquimod|Local Imiquimod three times weekly for 16 weeks
45477901|NCT03815903|Drug|Induction chemotherapy|3 cycles, each 21 days, of Cisplatin 80mg/m2 plus Paclitaxel 175mg/m2
45354366|NCT04725006|Device|Spinal cord stimulation system|These systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain. Stimulation will be applied to the system using an external stimulator to see if sensations can be evoked in the participant's limb/foot.
45354367|NCT02553018|Drug|Methotrexate|
45477902|NCT03815903|Combination Product|Chemoradiotherapy|Radiotherapy 70Gy convencional fractionation concomitant to 3 cycles, each 21 days, of Cisplatin 100mg/m2
45354368|NCT00950079|Drug|Sodium bicarbonate|3 mL/kg for 1 hour immediately before contrast injection , 1mg/kg/hr during procedure and 6 hours after procedure
45477903|NCT02499796|Device|Hygrovent Gold|
45686772|NCT05819476|Other|Experimental model of acute pain|Experimental model of acute pain (simulating wound pain: this installation will apply monophasic, rectangular electrical pulses of 0.5ms duration with alternating polarity at 2 Hz frequency. The current will be increased to target a pain rating of 6 of 10 on the NRS (0 = no pain, 10 = worst imaginable pain). Three further adjustments in current will be made every 5 minutes for the next 15 minutes to compensate for habituation. This final current will be kept constant until the end of the particular experiment).
45354369|NCT00950079|Drug|saline|0.9% normal saline with 1 mL/kg/hr infusion 12 hours before procedure and 12 hours after procedure
45354370|NCT00941967|Drug|gemcitabine hydrochloride|Given IV
45354371|NCT00941967|Drug|oxaliplatin|Given IV
45354372|NCT00941967|Drug|sorafenib tosylate|Given orally.
45354373|NCT00655746|Drug|Dasatinib + Omeprazole|Tablet/Capsule, Oral, (Dasatinib 100 mg)/(Omeprazole 40 mg), once daily, 7 days
45354374|NCT00338455|Drug|Natrecor (nesiritide)+Standard Care+dobutamine or milrinone|3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min
45354375|NCT00338455|Drug|Placebo+Standard Care+dobutamine or milrinone|28-day continuous infusion, no bolus
45354376|NCT00950157|Other|Presentation of information on approval based on a surrogate outcome and levels of caution|"Presentation of information that one drug is approved on a surrogate outcome only while another drug has clinical outcomes. Participants are randomized to 1 of 3 caution (e.g. open question) statements: no open question statement, non-directive open question statement or directive open question statement."
45354377|NCT00806208|Drug|MEDI-507|0.012 mg/kg MEDI 507 and Methylprednisolone
45354378|NCT00806208|Drug|MEDI-507|0.04 mg/kg MEDI 507 and Methylprednisolone
45354379|NCT00806208|Drug|MEDI-507|0.12 mg/kg MEDI 507 and Methylprednisolone
45354380|NCT00806208|Drug|MEDI-507|0.4 mg/kg MEDI 507 and Methylprednisolone
45354381|NCT00806208|Other|Placebo|Placebo IV (alternative) study days 0, 3,6, and 9
45354382|NCT00942045|Biological|Biologic - Osteocel Plus|Osteocel Plus
45354383|NCT05301309|Behavioral|breastfeeding consultation|Integrative early breastfeeding support and intervention programs: breastfeeding for prematurity brochure, group education class, weekly interview, one-by-one breastfeeding consultation and online peer group support.
45354384|NCT00651924|Behavioral|IVR-based Cognitive-behavior therapy|Standard cognitive-behavior therapy for chronic pain management using Interactive Voice Response (IVR) compatible materials and handouts
45354385|NCT00804258|Drug|intraperitoneal chemotherapy|
45354386|NCT00804258|Other|educational intervention|
45477904|NCT02499796|Device|Heated and moisture exchanger (HME)|
46046434|NCT04080414|Behavioral|Home-based moderate-intensity continuous exercise|Participants will be instructed to complete five, moderate-intensity continuous exercise workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
46046435|NCT04075318|Biological|UB-312|A synthetic peptide-based vaccine
45354387|NCT00804258|Other|medical chart review|
45354388|NCT00804258|Other|questionnaire administration|
45354389|NCT00804258|Procedure|assessment of therapy complications|
45354390|NCT00804258|Procedure|end-of-life treatment/management|
45354391|NCT00804258|Procedure|psychosocial assessment and care|
45354392|NCT00804258|Procedure|quality-of-life assessment|
46046436|NCT04075318|Biological|Placebo|Matching placebo
45354393|NCT00950313|Other|Self Assessment|Self assessment used to determine current risk of diabetes and likelihood of requiring further testing
45477905|NCT02499796|Device|Heated humidifier (HH)|
45477906|NCT03822299|Dietary Supplement|healthy feces microbiota|Suspension of healthy feces microbiota in sterile saline solution
45477907|NCT03333226|Procedure|Axillary Reverse Mapping (ARM)|ARM lymph node preservation versus removal
45477908|NCT03822221|Other|MVIC and NMES with hip at 85º and knee at 20º|With hip joint at 85º (seated) and knee at 20º (SK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
46046437|NCT04060589|Other|Tissue donation|Biopsies will be performed as part of standard of care, additional cores will be performed for research. Access to standard of care prostate biopsy tissue will also be requested after standard of care reporting is complete.
46046438|NCT04060589|Other|Blood Donation|Phlebotomy will be performed prior to tissue collection following trust standard operating procedures or drawn when cannula already in situ in preparation for the prostate biopsy.
46046439|NCT04060589|Other|Urine Donation|Urine will be collected prior to prostate biopsy
45354394|NCT00950313|Other|Electronic risk score|Patients current risk of diabetes is determined by a electronic risk algorithm. They are then invited to attend fof further testing.
45354395|NCT00678392|Drug|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg twice daily [BID] with continuous dosing
45354396|NCT00678392|Drug|Sorafenib|sorafenib will be given at a dose of 400 mg twice daily [BID] with continuous dosing
45354397|NCT00950391|Drug|Tacrolimus|Tacrolimus 3 mg/day taken twice daily to maintain blood level of 3-6 ng/ml for duration of 1 year or less
45354398|NCT00804336|Drug|SOM230|Given subcutaneously twice a day for four weeks then given intramuscularly once every four weeks thereafter
45354399|NCT00804336|Drug|RAD001|Given orally once a day
45354400|NCT00942201|Drug|Dexamethasone|Single loading dose in ED 0.6 mg/kg, rounded to nearest 2 mg,use 4 mg tabs max dose 16 mg.
45354401|NCT00942201|Drug|Dexamethasone|Firstdose in ED 0.6 mg/kg, rounded to nearest 2 mg, use 4 mg tabs max dose 16 mg; a prescription for second dose as above to be taken on day 3 after discharge
45354402|NCT00804414|Drug|SBG|Solution for topical use
45354403|NCT00804414|Drug|Placebo Comparator|Solutin for topical use
45477909|NCT03822221|Other|MVIC and NMES with hip at 85º and knee at 60º|With hip joint at 85º (seated) and knee at 60º (SK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
45477910|NCT03822221|Other|MVIC and NMES with hip at 0º and knee at 20º|With hip joint at 0º (lying) and knee at 20º (LK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
45477911|NCT03822221|Other|MVIC and NMES with hip at 0º and knee at 60º|With hip joint at 0º (lying down) and knee at 60º (LK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
45477912|NCT03333148|Drug|Nestle IMPACT Immunonutrition|Along with standard of care nutritional therapy patients (n=146) will be asked to consume 3 cartons/day for 14 days of Nestle IMPACT Advanced Recovery Immunonutrition.
45477913|NCT03333148|Other|Arm B- Standard of Care|No intervention standard of care nutrition (n=146).
45477914|NCT02492308|Procedure|SVF-MSC induction|"Procedure: infusion of autologous SVF derived MSC to the recipients of living-relative kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD"
46046440|NCT04060589|Other|Healthcare data linkage|Men will consent to healthcare data linkage via national databases.
46046441|NCT04055428|Drug|Sacubitril, Valsartan 97-103 mg Oral Tablet|The subject will be randomized, in a double-blind manner to sacubitril/valsartan 97/103 mg twice daily for a period of 12 weeks.
46046442|NCT04055428|Drug|Valsartan 160 mg|The subject will be randomized, in a double-blind manner to valsartan 160 mg twice daily for a period of 12 weeks.
46046443|NCT04055428|Other|Intravenous Glucose Tolerance Test|An assessment of the insulin sensitivity will be done using the IVGTT, at baseline and after 12 weeks of pharmacological interventions.
46046444|NCT04055428|Dietary Supplement|Standardized Meals|Participants will consume the standardized study mixed meal for the assessment of postprandial GLP-1 response to the meal.
46046445|NCT04055428|Other|Exercise capacity VO2 maximum determination|Each participant's maximal oxygen capacity will be determined using modified Bruce treadmill protocol.
45354404|NCT00942435|Drug|YM150|oral
45354405|NCT00942435|Procedure|mechanical prophylaxis|The investigator will determine the method of mechanical prophylaxis
45354406|NCT05301075|Drug|Rhomboid Intercostal and Sub-Serratus block|Rhomboid Intercostal and Sub-Serratus block under ultrasound guidance
45354407|NCT00950547|Device|CARDIOPAT|Cell Saver System at bedside for ICU stay
45354408|NCT00950547|Device|Traditional Chest Drains|Chest drains as usual with no possibility to reinfuse lost blood
45354409|NCT00946179|Biological|Influenza virus (split virion, inactivated) vaccine|0.5 mL, Intramuscular
45354410|NCT00946257|Drug|Otelixizumab|A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.
45354411|NCT00950625|Drug|lignocaine|200 mg of intraperitoneal lignocaine will be given once during surgery
45354412|NCT00950625|Drug|bupevacaine|100 mg of bupevacaine will be given once during laparoscopic cholecystectomy
45354413|NCT04461158|Behavioral|Patient Navigator Services|The navigator services most commonly provided include facilitation and coordination of care, practical support, including transportation and financial assistance, appointment scheduling and reminders, education and psychosocial support
45354414|NCT00942513|Other|trt 1|Fructose - 14 g; Lactose - 10 g; Sucrose - 16 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
45354415|NCT00942513|Other|trt 2|Fructose - 30 g; Lactose - 10 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
45354416|NCT00942513|Other|trt 3|Fructose - 24 g; Lactose - 8 g; Sucrose - 8 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
45354417|NCT00942513|Other|trt 4|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
45354418|NCT00942513|Other|trt 5|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
45354419|NCT00942513|Other|trt 6|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
45354420|NCT00942513|Other|trt 7|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
45354421|NCT04049318|Other|Education+ exercise (delivered digitally)|The intervention consisted of a digital, structured and individualized treatment program for people with hip or knee OA (Joint Academy®; www.jointacademy.com). The program consists of neuromuscular exercises appropriately adjusted to each patient in regard to degrees of complexity and difficulty, continuous access to and dialogue with a physiotherapist through a chat function, and/or telephone , and information in the form of text or video lessons (with quizzes on the material after each episode) on subjects related to OA, OA symptoms and its management.
45354422|NCT04049630|Drug|LEV 1 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
45354423|NCT04049630|Drug|LEV 1,5 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
45354424|NCT04049630|Drug|LEV 2,5 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
45354425|NCT04049630|Drug|Placebo|5 tablets of placebo will be administrated to the participants.
45354426|NCT00942591|Drug|Interferon beta 1b|
45354427|NCT00942591|Drug|Atorvastatin|
45354428|NCT02559362|Behavioral|Survey|
45354429|NCT00950781|Procedure|ACTH|During the ACTH test an IV will be placed in subjects arms, 25mL of blood will be drawn at -30 minutes and 6mL of blood will be drawn at -15 minutes and 0 minutes respectively. Following, 0.25mg of ACTH will be injected intravenous over 60 seconds, and a final 12mL of blood will be drawn 60 minutes later. That is, a total of 50mL of blood will be drawn to test serum blood hormone levels from the subjects during the ACTH (Hormone) Stimulation Test.
45354430|NCT00946335|Drug|veliparib|Given PO
45354431|NCT00946335|Drug|temozolomide|Given PO
45354432|NCT00946335|Other|pharmacological study|Correlative studies
45354433|NCT00946335|Other|laboratory biomarker analysis|Correlative studies
45354434|NCT00760370|Drug|Zoledronic Acid|4 mg intravenous (iv), one treatment
45354435|NCT00762944|Device|Biomet TMJ Replacement System|Total replacement of the temporomandibular joint with a Biomet TMJ Replacement System
45354436|NCT00763022|Drug|TAK-559|TAK-559 16 mg, tablets, orally, once daily for up to 26 weeks.
45354437|NCT00763022|Drug|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
45354438|NCT00763022|Drug|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
45354439|NCT00760448|Drug|insulin detemir|
45354440|NCT00760448|Drug|insulin NPH|
45354441|NCT04392284|Behavioral|Diet Counseling|"Delivery of nutrition counseling intervention to improve diet quality. Suggested energy intake will be prescribed with the intent to maintain energy balance and current body weight. A total of 16 nutrition counseling sessions lasting ~30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of nutrition counseling through the end of the study, meeting with the dietitian every other week. Starting at week 9, those identified as non-responding participants will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin."
45477915|NCT02492308|Drug|Basiliximab induction|The control group will be inducted with Basiliximab before living-relative kidney transplantation and on POD 4
45477916|NCT03820895|Diagnostic Test|Blood test|Serum 25-hydroxyvitamin D 25(OH) D levels were measured for Vitamin D status, by electrochemiluminescence immunoassay (Roche, USA). Cobb's angle measurement was done by measuring the major spinal curve and was taken from the upper end vertebra to the lower end vertebra through an x-ray for all the patients included in the study.
45354442|NCT04392284|Behavioral|Exercise Counseling|"Delivery of exercise counseling intervention to increase engagement in physical activity. The exercise specialist will counsel participants to progressively increase their weekly physical activity. Weight loss is not a primary goal of these exercise counseling sessions. A total of 16 exercise counseling sessions lasting ~30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of exercise counseling through the end of the study, meeting with the exercise specialist every other week. Starting at week 9, those identified as non-responders will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin."
45354443|NCT00760604|Procedure|Esophagectomy|Comparison of en-bloc vs. non-en bloc esophagectomy
45843321|NCT04566978|Diagnostic Test|PET/CT|"A PET/CT scan extending from top of skull to feet will be performed to determine the biodistribution.~Part A patients will be imaged at three time points post-injection to allow for selection of optimal imaging time and dosimetry determination. For these patients, top of skull to feet scans will be acquired:~Within one to four hours following injection of tracer on Day 1~24-72 hours post-injection (Day 2-4)~20-168 hours post-injection (once during days 5-7)"
45354444|NCT00763178|Drug|Duloxetine|"Dosage given according to the following schedule:~Week 1: 30mg QD, Week 2: 60mg QD, Week 3: 60mg QD, Week 4-6: Flexible dosing according to clinical situation, dose range between 60-120mg QD, Weeks 7 + 8: fixed dose"
45354445|NCT04391348|Radiation|PET-TDM with 18F-FDG + PET-TDM with 18F-fluorocholine|Experimental procedure combining PET-TDM with 18F-FDG and PET-TDM with 18F-Fluorocholine
45354446|NCT00760682|Procedure|Hyperbaric oxygen|30 preoperative and 10 postoperative HBO sessions 90 minutes each. Sequestrectomy is performed after 30 sessions.
45354447|NCT04351178|Behavioral|Mobile phone supported and team based rehabilitation|Participants in the intervention group will receive an 8-week mobile phone supported and team based rehabilitation intervention (F@ce 2.0).The participants will be introduced to a problem-solving strategy intended to facilitate the learning and problem-solving process to be used during the intervention. The strategy will provide a structure for healthcare professionals delivering the intervention. Three goals in daily activities will be formulated that the person wants and needs to do within the home environment. Each activity will be practiced together with the healthcare professionals and significant others. The significant others will be informed about the participant's goals and the planned strategies for reaching the goals. The participants will practice the activities in their home environment supported by mobile phone calls and text messages. In addition they will be given information about stroke.
45354448|NCT04351178|Behavioral|Rehabilitation as usual|Control group participants will receive rehabilitation as usual and in addition information about stroke.
45354449|NCT00308581|Biological|Certolizumab pegol|400mg Certolizumab Pegol, Q4W, administered 4-weekly
45354450|NCT00308581|Biological|Certolizumab pegol|400mg Certolizumab Pegol, Q2W, administered 2-weekly
45354451|NCT00308581|Other|Placebo|placebo administered 4-weekly in Active 1
46046446|NCT04052126|Other|Individualized physical activity program|"Participants who agreed to participate in the study will participate in an individualized 6-month physical activity (PA) program, consisting of 3 periods: initiation (1st month), transition (2nd-3rd months) and autonomy (4th-6th months). It is based on 4 PA modalities:~The supervised PA session in a sterile room or at home once a week during the initiation and transition phases (20-45 min, low-to-moderate intensity, walking, muscle strengthening, balance and flexibility exercises).~The unsupervised PA session in a sterile room or at home once a week during the transition phase and twice a week during the autonomy phase (same as supervised session).~Follow-up by telephone once a month during the autonomy phase (30 min, support to PA).~Continuously wearing an activity tracker throughout the entire program (promotion of walking).~Activities are planned over a period of 6 months to achieve an intervention that meets the key principles of progression, specificity and empowerment."
45354452|NCT00678080|Drug|Metformin|Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily
45843322|NCT04508166|Drug|Dexmedetomidine|Volunteers receive a single dose of dexmedetomidine sublingually at scheduled bedrest in the sleep laboratory
45843323|NCT04508166|Drug|Gamma-Hydroxybutyrate|Volunteers receive a single oral dose of gamma-hydroxybutyrate at scheduled bedrest in the sleep laboratory
45843324|NCT04508166|Drug|Placebo|Volunteers receive an oral (saline) or sublingual (orodispersible tablet) at scheduled bedrest in the sleep laboratory
46046447|NCT04050644|Drug|Preservative Free drop treatment|Patients will use the preservative-free dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
46046448|NCT04050644|Drug|Preserved drop treatment|Patients will use the preserved dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
45354453|NCT00678080|Drug|Insulin (NPH and Regular)|Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day
45843325|NCT04508166|Behavioral|Experimental Model Trauma Film|Each volunteer views experimental model trauma film before scheduled bedrest in the sleep laboratory. This video is ca. 15 minutes in duration and is composed of short (a few seconds to a few minutes) individual and unrelated scenes of violent death and injury of varying description. Six versions of the film without re-occurring scenes will be presented in balanced order across drug order conditions.
45843326|NCT04444440|Drug|Ciprofloxacin|Fluoroquinolone antibiotic.
45843327|NCT04444440|Other|Placebo Pill|Placebo Pill
45843328|NCT04420026|Radiation|Interact Active Tracker|Interact Active Tracker, allowing the automation of the fusion between a CBCT and ultrasound imaging
45843329|NCT04342260|Other|Active Monitoring|The participants randomized to active symptom monitoring will have alerts sent to their clinicians when their PRO symptom scores exceed baseline postoperative scores (when discharge day scores are available) by 2 points or more, or when 'severe' or 'very severe' symptoms are reported.
45843330|NCT04342260|Other|Passive Monitoring|Participants randomized to the passive PRO monitoring arm will complete the same PROs as participants in the active monitoring arm, but will not have alerts sent to their clinician.
45843331|NCT04309500|Behavioral|Personalized DAT Risk Disclosure Protocol|Individual participants and their co-participants will receive information about the participant's DAT risk based on their clinical history, structural magnetic resonance imaging, apolipoprotein-E (APO-E) genotype, and amyloid and tau burden on positron emission tomography (PET) scanning. This session will include consent, psychoeducation, re-consent, personal risk feedback, action suggestions, participant/caregiver resources, and a written summary of results. Risk assessment and safety planning will be applied if needed.
45843332|NCT04279236|Other|Abbreviated Profile Hearing Aid Benefit (APHAB)|An intervention in this study which is outside the routine clinical practice of the clinics is the APHAB questionnaire that will be completed by the subjects on 2 occasions.
45843333|NCT04279236|Other|Glasgow Benefit Inventory (GBI)|An intervention in this study which is outside the routine clinical practice of the clinics is the GBI questionnaire that will be completed by the subjects on 2 occasions.
45354454|NCT00658320|Drug|Everolimus|0.75 mg twice daily, trough level adjusting between 3 and 8 ng/ml.
45354455|NCT00658320|Drug|Mycophenolate mofetil (MMF)|The initial dose of 2 gm/day Mycophenolate mofetil was started within 24-36 hours from reperfusion after transplantation. MMF was administered daily for 12 months in the core study and 12 months in the extension study.
45354456|NCT00658320|Drug|Basiliximab|Patients received first dose of basiliximab (20 mg) 2 hours prior to transplantation and 20 mg at Day 4 or according to local practice
45843334|NCT04279236|Other|Additional follow-up visit|There is an additional follow-up visit after surgery (compared to the routine clinical practice of the surgeons/clinics).
45843335|NCT04265196|Other|cognitive behavioral group therapy|A unique protocol that includes cognitive-behavioral psychological therapy with emphasis on coping with pain
45843336|NCT04265196|Other|Mindfulness-based group therapy|Unique protocol that includes mindfulness-based psychological therapy with emphasis on coping with pain
45354457|NCT00658320|Drug|Cyclosporine A|The cyclosporine was initiated either pre-transplant or within 24 hours after transplantation following local regime. Standard dose of cyclosporine was administered with MMF. The Reduced dose of cyclosporine was administered with everolimus.
45843337|NCT04175964|Behavioral|ketogenic diet|The ketogenic diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
45843338|NCT04175964|Combination Product|caloric diet with Metformin|The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet with Metformin for 8 weeks.
45354458|NCT00658320|Drug|Corticosteroid|Corticosteroid was administered according to local practice during the trial but at a dose not less than 5mg per day for 12 months of the study
45354459|NCT02558192|Dietary Supplement|Lactobacillus Rhamnosus GG|1 vials q12 for 15 days
45354460|NCT02558192|Dietary Supplement|PLACEBO|1 vials q12 for 15 days
45354461|NCT04137614|Procedure|Drug coated balloon (DCB)|Drug coated balloon (DCB）is a new type of PTA, which could improve the re-stenosis rate significantly.
45354462|NCT04137614|Procedure|Digital substraction angiography (DSA)|DSA was used to evaluated the stenosis of renal artery
45354463|NCT02553252|Other|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants in the SKY group will undergo a 12-week training course in Sudarshan Kriya Yoga (SKY) conducted by certified instructors from the Art of Living Foundation.
45354464|NCT02558270|Drug|Dapagliflozin|
45354465|NCT02558270|Drug|Placebo|
45354466|NCT00804492|Behavioral|Multifaceted intervention|consulted, educated, referred or receive an exercise training for their fitness, strength and balance
45354467|NCT00763568|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
45354468|NCT00763568|Biological|Peginterferon alfa-2a|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
45354469|NCT04049006|Other|complex treatment|The complex treatment will be based on health education, aerobic physical exercise and cognitive-behavioral therapy, during 12 weeks in sessions of 2 hours/week. The sessions will be conducted in the primary health care by trained professionals.
45354470|NCT00806754|Drug|Ciclesonide nasal spray + placebo Azelastine|Ciclesonide nasal spray 50 mcg + Placebo Azelastine
45843339|NCT04175964|Behavioral|caloric diet|The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
45847654|NCT02803164|Device|Wound Vacuum-assisted dressing|The NPWT system (V.A.C. Therapy System, KCI USA Inc.) consisted of a medical-grade non-adherent polyvinyl alcohol white foam applied directly to the infected surface, followed by an open-pore reticulated polyurethane black foam cut to fit the wound and covered by a transparent air-tight adhesive drape. A suction cup with tubing was placed over a small slit on the drape and connected to a suction machine (V.A.C. ULTA Therapy Unit).
45686773|NCT05819437|Other|Balneotherapy program|"Whirlpool bath, bath with immersion showers, poultice application and underwater massage.~The baths were performed in an individual tub in ten-minute sessions. The temperature was set specifically for each patient, on average from 34 to 38°C. These were baths with jets and air diffusion.~The mud was applied as a poultice to the 2 knees and if necessary (duration of application: 10 minutes).~The massages were carried out by qualified physiotherapists under an affusion ramp of thermal water at 38°C for 10 minutes.~The water used is a mixed sulphated Natural Mineral Water, collected by drilling the capuchins at a depth of 975 m. The temperature of the water at the outlet of the borehole is 41.8°C and is lowered to 35°C."
45843340|NCT03968172|Behavioral|EBBC programme|"Web-based behavioural lifestyle intervention that provides patients with coordinated information based on their existing health beliefs, interests, etc. In the programme, techniques and exercises will be taught in sequentially active interactive learning units (simulated dialogues) and followed-up with email and SMS reminders in the second study year. The following topics will be focused on:~Diagnosis and disease progression~Support in disease processing~Techniques for coping with stress and depressive symptoms as well as developing positive emotions~Optimisation of dietary behaviour~Optimisation of physical activity behaviour~Sleep hygiene and methods for dealing with insomnia.~The programme will accompany each patient with information material and e-mail reminders over a period of 12 months with initial 2-3 weekly tasks, later only weekly reminders and inputs every 2 weeks. All in all, the intervention programme will consist of 16 modules."
45354471|NCT00806754|Drug|Ciclesonide nasal spray + Azelastine|Ciclesonide nasal spray 50 mcg + Azelastine 137 mcg
45354472|NCT00760760|Drug|reesterified long-chain n-3 polyunsaturated fatty acids (EPA, DHA)|4g daily, 8 weeks
45354473|NCT00760760|Drug|control|equivalent amount of fat as butter
45354474|NCT00764816|Other|grain (soy) protein diet|The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
45354475|NCT00764816|Other|casein (meat) protein diet|The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
45354476|NCT00810654|Dietary Supplement|Aspergillus niger prolyl endoprotease|160 PPU daily for 2 weeks
45354477|NCT00810654|Dietary Supplement|Placebo|Placebo
45354478|NCT00764894|Device|Foundation Knee|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis who received a primary Foundation Knee replacement and is willing to participate in the study.
45477917|NCT01300169|Behavioral|The Collaborative Assessment and Management of Suicidality|"Intensive outpatient, suicide-focused, psychotherapy designed to target and treat the drivers of suicidal ideation and behaviors."
45477918|NCT01300169|Behavioral|Enhanced Care as Usual|This is just standard outpatient mental health care that is routinely provided in the study site outpatient clinic
45477919|NCT05865470|Drug|Cannabis|smoked cannabis
45847655|NCT02803164|Other|Control group|Retrospective review of subjects medical records with open chest wounds who were treated with the traditional treatment techniques.
45354479|NCT00804726|Device|Akreos MI Five-O|Small incision cataract surgery with phacoemulsification cataract extraction and Akreos MI Five-O IOL surgical implantation
45354480|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
45354481|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
45354482|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
45847656|NCT02806908|Drug|JZP-110|
45354483|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
45354484|NCT00322153|Drug|memantine ER|28mg(7mg capsules) once daily and oral administration for 24 weeks.
45354485|NCT00322153|Drug|Placebo|Matching placebo oral administration once daily.
45477920|NCT05865470|Drug|Dronabinol|Oral delta-9-THC
45477921|NCT05865470|Drug|Smoked Placebo|Placebo Cannabis
45477922|NCT05865470|Drug|Oral Placebo|Oral Placebo
45477923|NCT05865444|Behavioral|Values alignment wise intervention|"The intervention includes: (1) reading materials, such as recent journalistic works that expose the deceptive and manipulative marketing practices of food companies and the harmful effects of these practices on society, with particular emphasis on harm to young children and the economically disadvantaged. Stories from other young people will also be included in order to contribute to the perception of widespread outrage and to suggest how that outrage can be channeled into taking a stand against the injustice perpetrated by food companies by eating less unhealthy or healthier food; (2) writing exercises, such as a story with a brief statement of what the participants would tell a younger child about the ads; and (3) an interactive activity, called Make It Real in which they are shown pictures of food ads and allowed to write and draw about them, making whatever changes (e.g., crossing out and substituting words) they feel necessary to make the ad real (i.e., no longer misleading)."
45354486|NCT00806910|Drug|Conivaptan|IV Vaprisol initially at 20 mg IV injection over 30 minutes, followed by a 20 mg IV infusion over the next 24 hours (i.e. 20 mg bolus, 20 mg continuous infusion approximately 24 hrs).
45354487|NCT00806910|Other|Placebo|Placebo (will be given at the same rate of Vaprisol given in the treatment arm)
45354488|NCT00807066|Drug|Gefitinib|Gefitinib 250 mg/day
45354489|NCT00807066|Drug|Platinum|Platinum based chemotherapy with cycles every 21 days
45354490|NCT01058551|Device|Implantable Loop Recorder Insertion|Implantable Loop Recorder Insertion. The device will be explanted after reaching outcome (First AF detected) or at 36 months
45354491|NCT00804960|Drug|Letrozole|1) Letrozole 5 mg starting on cycle day 2, which will be continued until the day of trigger. Recombinant FSH at doses 100-225 units, as determined by BMI, AFC, age, and ovarian reserve markers will be added on cycle day 4. The dose will be adjusted based on the response. An antagonist will be administered once the lead follicle reaches 14-mm in diameter or when estradiol level reaches 250 pg/mL. Oocyte maturation will be triggered by 20 iu of leuprolide acetate.
45354492|NCT00804960|Drug|Std IVF Protocol|2) Long protocol with luteal phase GnRHa suppression with gonadotropin dose at 200-450 IU. Oocyte maturation will be triggered by 250 micg of ovidrel.
45354493|NCT00805116|Dietary Supplement|Whale blubber oil|15 ml/day for 4 months, divided on dosage morning and evening, orally.
45354494|NCT00805116|Dietary Supplement|Cod liver oil|15 ml/day for 4 months, divided on dosage morning and evening, taken orally
45354495|NCT03985735|Drug|General anesthesia|For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation. Additional cisatracurium （0.05 mg/kg）and fentanyl (30-50 μg at the end of surgery) were used as needed, in accordance with the clinical requirements.
45477924|NCT05865444|Behavioral|Educational traditional intervention|The educational intervention includes information on nutrition and physical exercise. It includes reading and writing exercises.
45477925|NCT05865431|Drug|Zinc Oxide and Avobenzone|Zinc Oxide is applied to one area of the forearm, Avobenzone is applied to another area of the forearm.
45498261|NCT03623724|Behavioral|blended Cognitive-behavioral Therapy|The protocol includes ten face-to-face cognitive-behavioral sessions combined with nine online sessions based on Moodbuster self-help treatment, delivered over a period of 16 weeks. The Moodbuster includes 7 modules (introduction, psychoeducation, behavioral activation, cognitive restructuring, problem solving, exercise and relapse prevention), a calendar and the possibility of sending and receiving messages to and from therapist, respectively. The mobile phone application will be used to support the therapeutic sessions and register the ecological momentary assessments concerning mood, sleep quality, anxiety and other emotional states that will be collected in a daily basis before, during and after the treatment.
45847657|NCT02806908|Drug|Placebo|
45847658|NCT02813070|Drug|[18F] Flutemetamol|PET brain imaging and Magnetic resonance brain imaging
45354496|NCT00807222|Drug|lisdexamfetamine dimesylate|Subjects will receive Vyvanse 30, 50, or 70 mg per day or placebo capsules orally for up to (a maximum of) seven (7) weeks.
45354497|NCT00657618|Drug|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
45354498|NCT02553564|Other|Checklist driven clinical encounter after hospital discharge|"Within 96 hours of hospital discharge an Nurse Practitioner will perform a checklist guided assessment to preventing rehospitalizations. The assessment consists of the following:~The participants's hospital course will be reviewed and their clinical recovery and stability assessed.~Determination of the participants's estimated dry weight (EDW).~The participants's post discharge medications will be checked, compared to the prehospitalization medication, and discrepancies will be reviewed and corrected.~Blood tests will be ordered for the participants's first return dialysis treatment if medically appropriate after clinical assessment.~Write new dialysis orders.~Dialysis Access- review access and determine any changes required in treatment"
45354499|NCT00657540|Drug|Analatro|30 mL of lyophilized antivenom, reconstituted in 50 mL saline infused over 10 minutes, up to 2 doses
45354500|NCT00657540|Drug|Saline|50 mL of saline infused over 10 minutes
45354501|NCT00672620|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
45354502|NCT00672620|Drug|Duloxetine|Duloxetine capsules
45354503|NCT00672620|Drug|Placebo|Placebo-matching capsules
45354504|NCT00805272|Other|QTF-TB Gold and T-SPOT TB|evaluation of the theoric therapeutic impact of the use of IGRAS for diagnosis of LTBI in HIV-infected patients
45847659|NCT02815644|Drug|empagliflozin/linagliptin FDC|empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
45354505|NCT00764972|Drug|Sorafenib and Vinorelbine|"vinorelbine, administered as a brief infusion twice every three weeks (on day 1 and 8 of 21-day cycles);~sorafenib, that you will take orally every day, at the dosage that your study doctor will prescribe."
45354506|NCT04042532|Device|Theta-burst stimulation (TBS)|We will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, we will give two sessions of iTBS separated by 15 min.
45354507|NCT00765050|Biological|CD133+ cells transplant|intramuscular administration of CD133+ cells that have been mobilized from peripheral blood.
45354508|NCT00673790|Drug|Nebivolol with concomitant losartan or lisinopril|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
45354509|NCT00673790|Drug|HCTZ with concomitant losartan or lisinopril|Encapsulated Hydrochlorothiazide 12.5 mg or 25 mg total daily dosage, oral administration with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
45477926|NCT05865418|Other|Loaded high intensity training|Participants will be familiarized to all the exercises. All exercises will have 3 sets, and the participants will be asked to perform as many repetitions as they can in 30s for each set. They will have 30 seconds to rest between sets (if they want more rest, we can let them more time but not exceed 60 seconds to limit the total amount of time for completing the exercise protocol) and 90 seconds to rest between exercises. Training sessions will occur twice per week with at least 24 hours between sessions. From the week 3rd of the intervention, the participants will perform the exercises with an adjustable weight vest with 5% of their body weight. In the middle intervention (post week 6 of the intervention which will be week 9 of the study), adolescents will be reevaluated for all the measures tested at the baseline. Weight vest will increase to 10% of their body weight for the last 4 weeks of the intervention.
45477927|NCT05865418|Other|High intensity circuit training (HICT)|Participants will be familiarized to all the exercises. All exercises will have 3 sets, and the participants will be asked to perform as many repetitions as they can in 30s for each set. They will have 30 seconds to rest between sets (if they want more rest, we can let them more time but not exceed 60 seconds to limit the total amount of time for completing the exercise protocol) and 90 seconds to rest between exercises. Training sessions will occur twice per week with at least 24 hours between sessions.
46046449|NCT04048239|Procedure|cochlear implantation|cochlear implantation is a system developed to restore hearing in people with profound sensorineural hearing loss, whose classical hearing aids are ineffective. Surgery is necessary to insert the internal part into the cochlea and requires milling the mastoid to access the round window. This approach is technically difficult, and is performed under a microscope by an experienced surgeon.
46046450|NCT04048239|Other|computerized tomography (CT) scan|computerized tomography (CT) scan of the facial nerve
46046451|NCT04048239|Other|electromyograph|electromyographic verification of the facial nerve
46046452|NCT04047706|Biological|IDO1 Inhibitor BMS-986205|Given PO
46046453|NCT04047706|Biological|Nivolumab|Given IV
46046454|NCT04047706|Radiation|Radiation Therapy|Undergo radiation therapy
46046455|NCT04047706|Drug|Temozolomide|Given PO
45354510|NCT00673790|Drug|Placebo with concomitant losartan or lisinopril|Placebo with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
45354511|NCT00763646|Drug|Taxotere, Cisplatin, and 5-FU|Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total), 1 - 2 weeks, Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total)
45354512|NCT00763880|Drug|Lidocaine|2% Lidocaine (no epinephrine) in the dose of 2.5 mg/kg to a maximum of 10mL will be instilled once into the fracture site in the form of a hematoma block.
45354513|NCT00763880|Drug|Saline|Volume of normal saline equivalent to providing 2.5mg/kg of 2% lidocaine, to a maximum of 10mL.
45354514|NCT00765440|Dietary Supplement|therapeutic nutritional supplementation|Given orally
45354515|NCT00765440|Other|placebo|Given orally
45354516|NCT00657150|Drug|Enoxaparin|40 mg once daily
45354517|NCT00657150|Drug|Dabigatran etexilate|220 mg once daily
45354518|NCT00770354|Drug|AS1402|A complete treatment cycle spans 28 days. Patients randomised to AS1402 will receive a 1-hour infusion of 9 mg/kg on day 1, 8, 15 and 22 of each cycle. Patients will receive letrozole (2.5 mg daily tablet).
45354519|NCT00770354|Drug|Letrozole|Daily 2.5 mg oral letrozole tablet
45354520|NCT02553486|Other|quality of life evaluation|
45354521|NCT00670748|Biological|Anti-NY ESO-1 T-cell receptor PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T-cell receptor (TCR) peripheral blood lymphocytes (PBL) and high dose aldesleukin. On day 0,cells (1x10e8 to 1x10e11)will be infused intravenously on the Patient Care Unit over 20-30 minutes.
45354522|NCT00670748|Drug|aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days(maximum of 15 doses)
45354523|NCT00670748|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
45354524|NCT00670748|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
45354525|NCT00670748|Biological|ALVAC NY ESO-1 vaccine|Approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10e7 cell culture infectious dose 50 (CCID50) (with a range of approximately 10e6.4 to 10e7.9 / mL) of the ESO-1 ALVAC virus S.C. in each extremity (total of 4 x 10e7 CCID50/2 mL.
45354526|NCT00646776|Drug|Rifabutin|Capsule, Oral, 150 mg, once daily, 11 Days
45354527|NCT00646776|Drug|Rifabutin + Atazanavir + Ritonavir|"Capsules, Oral, 18 Days~Rifabutin (150 mg, 2x/wk)~Atazanavir (300 mg, once daily)~Ritonavir (100 mg, once daily)"
45354528|NCT00765596|Other|Liquid diet for 3 days|The control group were given a 3 -day liquid diet similar to the RYGB post-op diet
45354529|NCT04048928|Behavioral|maximal strength training|The training group (TG) performed MST training carried out as free-barbell squats twice a week over five weeks.
45354530|NCT02558114|Drug|Ribavirin|
45354531|NCT00770666|Drug|Nicotine patch, nicotine inhaler, bupropion|Patch - 21 mg - taper as able Inhaler - as needed Bupropion SR 150 mg daily
45354532|NCT00770666|Drug|Nicotine patch|21 mg daily for 6 weeks followed by 14 mg for 2 weeks and then 7 mg for 2 weeks
45354533|NCT00764036|Drug|artesunate|add-on therapy with daily single oral doses of 100, 150 or 200 mg of artesunate
45354534|NCT00764114|Drug|antibiotic|6 or 12 weeks
45354535|NCT00811200|Drug|ranibizumab|three initial monthly intra vitreal injections with 0.5 mg ranibizumab
45354536|NCT00811200|Drug|triamcinolone acetonide|at baseline one intra vitreal injection with 4.0 mg triamcinolone acetonide
45354537|NCT00811200|Other|sham|at baseline one sham-injection
45354538|NCT00764192|Procedure|blood sample|blood sample before and after a single HD
45354539|NCT00764192|Procedure|Flow-mediated dilation (FMD) before and after a single HD|measuring of the flow-mediated dilation using high-resolution ultrasound
45354540|NCT00811356|Drug|GSK932121; Rosiglitazone; Rosuvastatin|GSK932121 is the study drug that will be tested in all parts of this study as described above. Rosiglitazone and rosuvastatin will only be tested in the drug-drug interaction substudy.
45354541|NCT00765908|Device|Angioplasty balloon|90 second balloon inflation x 2
45354542|NCT00765908|Device|Angioplasty balloon|30 seconds or less balloon inflations x 2
45354543|NCT00765986|Other|18F-FAZA|Radioactive dose of 110-600 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) of RT, then 4 weeks, 90 days and 12 months post-RT and upon logo-regional progression or recurrence.
46046456|NCT04042493|Behavioral|Connect for Health|The program includes (1) electronic health record (EHR)-based clinical decision support tools to guide pediatric providers in child weight management; (2) clinician and medical staff training in obesity management best practices, (3) family educational materials focused on evidence-based behavioral targets; and (4) social- and community-informed text messages for parents to support behavior change.
45843341|NCT03968172|Behavioral|Control group programme|"Web-based information platform with optimized standard care compiled from information material of the German Multiple Sclerosis Society (DMSG). Information will be provided in sequentially activated modules over a period of 12 months, covering the following topics:~Disease progression~Invisible symptoms of multiple sclerosis~Symptomatic therapy~Immunotherapy decision support~Coping strategies~Autonomy~Fatigue~Quality of life~Physical activity~Nutritional behaviour~In addition, a reminder system with neutral e-mail reminders will be used to promote the use of the programme."
46046457|NCT04041089|Behavioral|Recognition of objects|"Name of shapes / colors / images / objects~Classification of shapes / colors / images / objects"
46046458|NCT04041089|Behavioral|Location of objects|"Search for frequent/rarse targets among distractors sharing one or more characteristics with the target~Hit/catch a stationary/mobile target as quickly as possible"
46046459|NCT04041089|Behavioral|Manipulation of objects|"Storage of shapes/objects~Use of everyday objects (pen, cutlery, etc.)"
45354544|NCT00765986|Other|18F-Fluorodeoxyglucose (18F-FDG)|Radioactive dose of 100-710 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) RT, then 4 weeks, 90 days, and 12 months post-RT, and upon loco-regional progression or recurrence.
45354545|NCT00766064|Drug|Paliperidone|"Paliperidone will be gradually increased to a final dose between 3 - 6 mg/day according to the following schedule:~Weeks 1 - 3: 3 mg daily, Weeks 4 - 5: flexible dosing according clinical situation, dose range between 3 mg - 6 mg daily*, Week 6: fixed dose,~*Criteria to increase the dose from 3 mg to 6 mg daily are 1] absence of any side effects, 2] patients not showing a sufficient response to 3 mg paliperidone can be increased to 6 mg daily. Response is defined as change in depression and anxiety ratings of at least 30% compared to baseline."
45477928|NCT05865405|Behavioral|MS CATCH|Participants will respond to a set of surveys every month to increase communication on mood with their clinician.
45498262|NCT03623724|Other|Treatment-As-Usual|The protocol consists in routine care that patients receive when they are diagnosed with major depression in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked (e.g., medication). The psychiatrist of our team will monitor possible medicine intake (stabilized throughout the trial).
45686774|NCT05819411|Behavioral|Project iSTRIVE|This intervention includes 6 face-to-face therapy sessions with a trained clinician to develop skills to counter internalized stigma and shame as barriers to HIV self-care. Both the intervention group and the active control group will also receive a mobile app-based iDOT intervention.
45686775|NCT05819411|Behavioral|incentivized Directly Observed Therapy (iDOT)|Both the intervention group and the active control group will receive a mobile app-based iDOT intervention.
45843342|NCT03845712|Drug|MT1621|deoxythymidine/deoxythymidine substrate enhancement therapy
45843343|NCT03701568|Drug|dC/dT|Collection of retrospective data from TK2 patients previously treated with dC/dT
45843344|NCT03678402|Device|PUP™ sock|The Palarum Fall Prevention System that includes the PUP™ (Patient is Up) System, is made upon of seven tangible elements: an inpatient room Android tablet (IRT), a nurse station Android monitor (HUC), a local server (PLS), a cloud server (PCS), a Bluetooth Low Energy beacon(s), an Android smart watch, and an e-textile sock connected sensor transmitter (PUP™ sock). The PUP™ sock monitors and transmits pressure, force, acceleration and motion data.
45843345|NCT03626532|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|"The MBSR program is a mind-body approach developed by Kabat-Zinn to reduce pain and stress through mindfulness meditation. MBSR is a form of mental training characterized by the self-regulation of attention and focal orientation to present moment experiences. Mindfulness practice is thought to effectively promote emotional and cognitive control. Mindfulness includes directing awareness away from thoughts, emotions and sensations towards some specific anchor to the present, such as the breath. Participants will engage in various practices including breath awareness, body scans, mindful listening, etc."
45843346|NCT03626532|Behavioral|Lifestyle Education (LifeEd)|This group will engage in light stretching exercises at each session. They will also be provided with information drawn from the scientific literature on topics related to healthy aging, including physical activity, sedentary behavior, nutrition, hydration, stress, sleep, and cognitively stimulating activities. Group discussion will be incorporated throughout.
45843347|NCT03624270|Drug|Oral arsenic Trioxide, ATRA and ascorbic acid|Oral arsenic trioxide-based frontline induction, consolidation and maintenance will be provided to patients with newly diagnosed acute promyelocytic leukemia.
45843348|NCT03588468|Other|Electrophysiological biomarkers|Motor and sensory nerve conduction study will be performed on median, ulnar, tibialis, peroneal and sural nerves.
45843349|NCT03588468|Other|MRI biomarkers|T1, T2, STIR and magnetisation transfer ratio (MTR) will be performed unilaterally on the thigh and the leg.
45843350|NCT03567096|Device|BiV pacing with MPP and SyncAV|This cohort will receive Bi-Ventricular Pacing (left ventricle and right ventricle pacing) with MultiPoint Pacing of the left ventricle (two stimulation sites) and the SyncAV algorithm active.
46046460|NCT04034251|Drug|Paclitaxel|Paclitaxel (IP and IV), Day 1 of each 3-week cycle: Paclitaxel IP - Intraperitoneal paclitaxel (60 mg/m2) will be diluted in 500 mL of 0.9% NS, to be infused as rapidly as tolerated once per 3-week cycle on Day 1. Paclitaxel IV - Intravenous paclitaxel (80 mg/m2) will be administered concomitantly over 3 hours, diluted in 100 to 250 ml of 0.9% NS once per 3-week cycle on Day 1.
46046461|NCT04034251|Drug|Capecitabine|Day 1-15 of each 3-week cycle: oral capecitabine (825 mg/m2) to be taken twice a day starting the evening of Day 1 of each cycle until the morning of Day 15, followed by a 7-day rest period during each 3-week cycle.
45686776|NCT05819372|Procedure|Zygomaticomaxillary fracture repair|"A cone beam CT (CBCT) scan of the patient will be used to create a 3D scanned image of zygomaticomaxillary complex fracture (ZMC)~3D images will be introduced to finite element (FA) software to evaluate Stresses (MPa), Micromotion (microns), and Life time (cycle) For each model and determine which point of fixation is the best~After application this point of fixation on the patient~Finite element analysis will be done again to verify the previous results"
45686777|NCT05819359|Drug|BIA 28-6156 10 mg|BIA 28-6156 10 mg, once daily, oral administration.
45686778|NCT05819359|Drug|BIA 28-6156 60 mg|BIA 28-6156 60 mg, once daily, oral administration.
45686779|NCT05819359|Drug|Placebo|Placebo, once daily, oral administration.
45686780|NCT05819333|Other|Exercise Program + Respiratory Strength Training|Strength, Flexibility, Cardiovascular exercise + respiratory strength training
45686781|NCT05819333|Other|Exercise Program + Respiratory Relaxation Training|Strength, Flexibility, Cardiovascular exercise + respiratory relaxation training
45843351|NCT03567096|Device|LV only pacing with MPP and SyncAV|This cohort will receive left ventricular only pacing (no right ventricle pacing) with MultiPoint Pacing of the left ventricle (two stimulation sites) and the SyncAV algorithm active.
45843352|NCT03498066|Drug|Beta-blockers withdrawal|withdrawal of all type of betablockers
45843353|NCT03498066|Drug|Continuation of the Betablockers (βB) treatment|Use Betablockers treatment
45354546|NCT00770744|Drug|Zicronapine|5-7mg/day; orally, encapsulated tablets, once daily
45354547|NCT00770744|Drug|Olanzapine|10-15mg/day; orally, encapsulated tablets, once daily
45354548|NCT00770822|Device|HIFU (Sonablate® 500)|High Intensity Focused Ultrasound
45354549|NCT00770822|Device|Brachytherapy|Standard of care
45354550|NCT00764348|Other|no treatment|
45354551|NCT00655668|Drug|Lenalidomide|Lenalidomide capsules, 25 mg daily for 21 days in each 28 day cycle
45686782|NCT05819307|Device|OCT/FLIM|OCT/FLIM imaging of the retina
45354552|NCT04047992|Device|Indego™ Exoskeleton|The Indego® is a powered exoskeleton that can be used as a mode of therapy in an institutional setting. Proper walking in this device requires the user to manipulate their center of gravity and balance by postural trunk excursions in order for the legs to take steps.
45354553|NCT00770900|Drug|montelukast sodium|"Asthmatic children and teenagers took montelukast daily for 12 weeks.~Children aged 2-5 years took 4mg tablet of montelukast~Children aged 6-15 years took 5mg tablet of montelukast~Children >15 years took 10mg tablet of montelukast"
45477929|NCT05865392|Behavioral|Move physical activity support program|The Move program includes four intervention components: 1) 3, 60-minute group-based classes, 2) 3, 45-minute individualized support sessions, 3) access to an online fitness membership, and 4) weekly mental guided imagery sessions. Participants will be asked to build up their physical activity levels up to 150 minutes/week. They will receive an online fitness center membership during this entire 12-week program.
45477930|NCT05865340|Behavioral|oral health + MED diet|oral health + MED diet education
45354554|NCT00770900|Drug|Comparator: placebo comparator|Asthmatic children and teenagers took Placebo tablet daily for 12 weeks.
45477931|NCT05865340|Behavioral|oral health|oral health education
45477932|NCT05865340|Behavioral|MED diet|MED diet education
45477933|NCT05865327|Procedure|Cryoneurolysis|Cryoneurolysis will be performed on the intercostal nerve associated with each fractured rib using a handheld cryoneurolysis machine (Iovera). Cryoneurolysis will consist of two 103 second cycles (includes cooling, ice ball formation and warming time) per rib fracture level. Ultrasound guidance will be used to identify appropriate rib fracture levels and to target the device tip in real time. All participants will also receive standard multimodal analgesia and ESP catheter infusion.
45843354|NCT03455088|Behavioral|Dialectical Behavioral Group Therapy|DBT is based on the model for the development of emotion regulation, designed for teaching how to regulate their adaptive emotions and behaviors cased by mood disorders , so it is valid for BN patient.
45843355|NCT03455088|Drug|Drug: fluoxetine|Antidepressant fluoxetine can reduce binge eating and purging behaviors in BN patients in a short time.
46046462|NCT04034251|Device|BardPort Titanium Implanted Port with Peritoneal Catheter|After peritoneal chemo infusion port is placed (Days 1-3, as dictated by clinical status), patients will begin intraperitoneal paclitaxel and intravenous paclitaxel (Day 1) followed by oral capecitabine on the evening of Day 1 to the morning of Day 15.
45843356|NCT03355560|Drug|Nivolumab|Nivolumab 480 mg IV infusion
45354555|NCT00766220|Drug|SIR-spheres Agent Administration|SIR-Spheres, resin microspheres containing pure Beta emitter Yttrium-90, given through femoral catheter over 10 minutes.
45354556|NCT00766220|Drug|Cetuximab|"400 mg/m2 by vein over 2 hours once a week.~Cetuximab infusions will be continued weekly at a dose of 250 mg/m2 unless toxicity necessitates interruptions."
45354557|NCT00766220|Drug|Irinotecan|350 mg/m2 (or 300 mg/m2 in patients who are greater or equal to 70 years of age, or have an ECOG PS of 2 or have had prior pelvic and/or abdominal irradiation), by vein over 90 minutes, every three weeks.
45354558|NCT00807300|Radiation|CT-guided brachytherapy|catheter placed into the tumor by CT-guidance, radiation with iridium 192
45354559|NCT00807300|Procedure|transarterial chemoembolization|application of doxorubicin and cisplatin in lipiodol into the tumor-feeding artery
46046463|NCT04029623|Other|Partnered Rhythmic Rehabilitation (PRR)|Partnered Rhythmic Rehabilitation (PRR) is moderate intensity, cognitively-engaging social dance that targets postural control systems. PRR involves learning complex stepping patterns and fosters tactile communication of motor goals between partners, enhancing social interaction's effect on cognition. Class sizes will consist of 10 or fewer pairs of participants with pAD and partners to maximize safety. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Classes include practicing previously-learned steps, a 20-minute standing warm-up, and partnering and rhythmic enhancement exercises.
46046464|NCT04029623|Other|Group walking (WALK)|WALK sessions consist of 10 minutes of warm-up, and evaluation/tips for practicing safe walking form mechanics (i.e., head up, shoulders relaxed, abdominals engaged, heel strike, roll and toe off; keep natural stride length, and speed up cadence if increased speed is desired), 55 minutes of walking with breaks, and 20 minutes of balance and stretching. WALK will take place in small groups with research assistants and trained family members and/or caregivers to control for social effects/contact of intervention. Participants of similar walking abilities will be 'buddied' with research assistants and trained physical therapy students who will act as group backmarkers, although participants will lead the pace. WALK participants will keep walking logs documenting their progress. WALK is expected to expend 3 metabolic equivalents (METs), like that of PRR.
45354560|NCT00813540|Behavioral|Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 times per week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 110% of the power output obtained at V02peak. Resistance training will be completed twice per week and will include exercises for all major muscle groups. The training will progress from 60% to 80% of 1RM over the course of the intervention.
45354561|NCT00813540|Other|Usual Care|Usual Care
45354562|NCT00770978|Drug|ceftobiprole q12h|Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
45354563|NCT00770978|Drug|ceftobiprole q8h|Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
45354564|NCT02557724|Procedure|blood samples|liver transplant patients will have (5) 3cc blood samples drawn at specific time points.
45354565|NCT02557724|Procedure|blood samples|liver resection patients will have (3) 3cc. blood samples drawn at specific time points
45354566|NCT00766298|Behavioral|Exercise|16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR
45354567|NCT00766298|Behavioral|Weight Loss|The reduction of kcal/day through implementation of low fat diet
45354568|NCT00766298|Behavioral|Exercise and weight loss|"Exercise: 16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR.~Weight Loss: Reduction of kcal/day through implementation of a low fat diet."
45354569|NCT00569166|Behavioral|Paced breathing (15 min once daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
46046465|NCT04024150|Biological|Blood test|Single blood sample of 2 ml at birth on the occasion of blood sampling routine checkup
46046466|NCT04020432|Behavioral|questionary|"A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.~Women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally."
45354570|NCT00569166|Behavioral|Paced breathing (15 min twice daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
45686783|NCT05819281|Dietary Supplement|Probiotic blend|(Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium lactis, Bifidobacterium bifidum e Lactobacillus rhamnosus - Final concentration: 1 x 1010 CFU/day).
45686784|NCT05819281|Dietary Supplement|PLACEBO|Maltodextrin
45686785|NCT05819255|Other|Non-Interventional|"This prospective, non-interventional clinical study will enroll patients with metastatic melanoma, who have been selected by their oncologist to receive standard of care dual-agent immunotherapy and monitored for treatment response using SOC FDG PET/CTs.~The primary objective of this clinical study is to investigate intent to change treatment decisions after the addition of treatment response information from the TRAQinform Immuno technology."
45686786|NCT05819242|Diagnostic Test|Angulus|Smartphone app
45843357|NCT03342534|Device|DC-stimulator (Neuroconn, Germany)|A current of 2 mA will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.
45843358|NCT03081390|Other|Mixed meal tolerance testing|An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours.
46046467|NCT04020159|Other|Patient Registry|No intervention/treatment
46046468|NCT03999359|Other|Home-based Metacognitive Therapy|Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
45354571|NCT00569166|Behavioral|Paced breathing (10 min once daily, 14 breaths/min)|Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
45354572|NCT00764426|Drug|red wine, beer, ethanol|Alcoholic beverages equivalent to 30g of alcohol per day for men and 20g/d for women for 3 weeks
45354573|NCT00764426|Drug|de-alcoholised red wine, de-alcoholised beer, water|de-alcoholised red wine, de-alcoholised beer, water
45354574|NCT02558036|Other|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned the neutral Head and Neck Position
45686787|NCT05819229|Drug|Oral antibiotic therapy|"Empirical choice: amoxicillin-clavulanic acid 50 mg/kg/day divided into three doses.~If the sensitivity pattern is available, another oral antibiotic, preferably smaller-spectrum, can be used instead.~Total duration of antibiotic therapy will be 10 days."
45354575|NCT02558036|Other|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
45686788|NCT05819216|Device|Treadmill|Gait training on treadmill training
45686789|NCT05819203|Device|Healsea Babykids|7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
45354576|NCT02558036|Other|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in the neutral Head and Neck Position
45354577|NCT02558036|Other|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
45354578|NCT00807378|Other|LUMBAR PUNCTURE|LUMBAR PUNCTURE FFOR CSF COLLECTION
45686790|NCT05819203|Device|Placebo|7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
45686791|NCT05819190|Device|Healsea Rescue*|Subjects will be administered with Healsea Rescue* by spraying 2 puffs in each nostril 2 times per day during 7 days.
45843359|NCT03081390|Other|Skin conductance & cold pressor test|Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal.
46046469|NCT03998397|Biological|blood alcohol concentration withdrawal|The blood alcohol concentration is systematically performed in all intoxicated patients admitted in Emergency Department
46046470|NCT03993301|Other|Probiotic A formula|Feeding baby two meals a day with Infant formula with probiotics (10^8 colony-forming unit per day) at least.
46046471|NCT03993301|Other|Probiotic B formula|Feeding baby two meals a day with Infant formula with probiotics (10^8 colony-forming unit per day) at least.
46046472|NCT03993301|Other|Regular formula|Feeding baby two meals a day with regular formula at least.
45354579|NCT04048772|Behavioral|CALM IVF|The intervention will be three 1-1.5 hour interactive sessions that are scheduled throughout the participant's first in vitro fertilization cycle. These sessions will provide additional time for discussion about treatment with providers, learning opportunities on topics of interest to fertility patients, and stress reduction techniques.
45354580|NCT04048772|Other|Standard of Care|Patients will receive the standard of care IVF treatment at the University of Iowa.
45354581|NCT00764582|Drug|1.5% levofloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 1: 30 minutes prior to surgery~Group 2: 1 hour prior to surgery~Group 3: 2 hours prior to surgery~Group 4: 4 hours prior to surgery"
46046473|NCT03987373|Other|non-interventional|This study is a non-interventional, observational study. After completing 12-month treatment from DACAB trial, investigators would not make any interventions or impact on subjects' therapeutic strategy.
45354582|NCT00764582|Drug|0.5% moxifloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 5: 30 minutes prior to surgery~Group 6: 1 hour prior to surgery~Group 7: 2 hours prior to surgery~Group 8: 4 hours prior to surgery"
45354583|NCT00766454|Genetic|DNA analysis|
45354584|NCT00766454|Genetic|mutation analysis|
45354585|NCT00766454|Genetic|polymorphism analysis|
45354586|NCT00766454|Other|laboratory biomarker analysis|
45354587|NCT00766454|Other|medical chart review|
45354588|NCT00766454|Other|questionnaire administration|
45354589|NCT00766454|Procedure|evaluation of cancer risk factors|
45354590|NCT00813618|Drug|MEDI-507|0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9
45354591|NCT00813618|Drug|MEDI-507|0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9
45686792|NCT05819190|Device|Placebo|Subjects will be administered with isotonic saline nasal spray indistinguishable from the Healsea Rescue* by spraying 2 puffs in each nostril 2 times per day during 7 days.
45686793|NCT05819177|Other|Rehabilitation program|This group of patients underwent standard rehabilitation programs set by national guidelines.
45686794|NCT05819164|Device|Masimo oximeter|During this period, the Masimo oximeter Radical 7 was used for SpO2 reading
45686795|NCT05819164|Device|Nellcor oximeter|During this period, the Nellcor oximeter N-600 was used for SpO2 reading
45686796|NCT05819164|Device|Nonin oximeter|During this period, the Nonin oximeter was used for SpO2 reading
45686797|NCT05819151|Diagnostic Test|HbA1c Test|HbA1c Test is required. No other interventions. The researchers will only take photos of the subjects' tongues, and ask them to fulfil a questionnaire.
45686798|NCT05819138|Drug|Semaglutide Pen Injector|Semaglutide injection
45686799|NCT05819138|Drug|Placebo|Semaglutide placebo injection
45354592|NCT00813618|Drug|MEDI-507|0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9
45354593|NCT00771212|Other|Observational pain control study|Observational pain control study
45354594|NCT00811668|Device|CPAP before SOMNOVentCR|4 weeks CPAP treatment, 1 week wash out period, 4 weeks SOMNOventCR treatment
45354595|NCT00811668|Device|SOMNOventCR before CPAP|4 weeks SOMNOventCR treatment, 1 week wash out period, 4 weeks CPAP treatment
45686800|NCT05819099|Diagnostic Test|An Intelligent Endoscopic Diagnosis System Developed and Verified Based on Deep Learning|This study will compare the established AI model with the diagnostic results of endoscopists to evaluate the clinical auxiliary value of the model for endoscopists.
45354596|NCT02557802|Biological|Fluenz Tetra|Intranasal spray, 0.2 ml dose
45354597|NCT02557802|Biological|Fluarix Tetra|Intramuscular injection, 0.5 ml dose
45354598|NCT04048226|Drug|Placebos|The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
45354599|NCT04048226|Drug|Dexmedetomidine +Ketamine|The patients in this group will be connected to the syringe pump that contain mixture of dexmedetomidine and ketamine with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery. The solution will contain 2 ug dexmedetomidine/ml and 1 mg ketamine/ml.
45354600|NCT00811746|Drug|Rozerem (Ramelteon)|8 mg taken orally 30 minutes before a split-night PSG
45354601|NCT00811746|Drug|Lunesta (Eszopiclone)|3 mg taken orally 30 minutes before the start of a split-night PSG
45354602|NCT00811746|Other|Historical Controls|Chart review matched for demographics and comorbidities of the study drug groups.
45354603|NCT00766766|Behavioral|Health Risk and Behavioral Skills Coaching Sessions|Health Risk and Behavioral Skills Coaching Sessions
45354604|NCT00766766|Behavioral|Telephone Coaching Sessions|Telephone Coaching Sessions
45354605|NCT00766766|Behavioral|Physician Feedback Letter|Physician Feedback Letter
45354606|NCT04048070|Drug|Flurbiprofen Axetil|One kind of NSAIDs, 200mg for 48 hours after surgery.
45354607|NCT04048070|Drug|Sufentanil|One kind of opioid drugs, 1.5μg/kg, and recorded the drug consumption after surgery
45354608|NCT04048070|Behavioral|Extended perioperative counseling|The extended perioperative counseling contained additional information, including surgery procedures, importance of medicine treatment and medical help to relieve depression and anxiety about disease during peri-operation period.
45354609|NCT04048070|Behavioral|Shorter fasting food and water time before surgery|The patients in ERAS group were required to fast food for 6 to 8 hours and provided 12.6% maltodextrin carbohydrate supplement beverage for 2 hours before surgery
46046474|NCT03976505|Other|reading a table format prescription on a touch screen|Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
46046475|NCT03976505|Other|reading a textual format prescription on a touch screen|Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
45354610|NCT04048070|Behavioral|Conventional perioperative counseling|THe conventional perioperative counseling included the risk of surgery and prognosis of disease and other things patients need to know.
45354611|NCT04048070|Behavioral|Regular fasting food and water time before surgery|The stricter control of preoperative fasting requirements, prohibiting solids and liquids from previous midnight to operation time.
45354612|NCT00655356|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of 3 mm post auricular skin punch biopsies.~Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
45354613|NCT00655356|Biological|Placebo|"Collection of 3 mm post auricular skin punch biopsies.~Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
45354614|NCT00571064|Drug|Donepezil HCl|One 5 mg tablet per day (for the first 6 weeks) with a full glass of water. For the last 6 weeks, one 10mg tablet per day with a full glass of water.
45354615|NCT00811824|Behavioral|Physical activity and dietary change|6 months of combined resistance training and aerobic exercise (5 times per week x 30 minutes) plus 6-week nutrition counseling class
45354616|NCT04045626|Procedure|corneal cross-linking|Riboflavin is instilled over cornea followed by Ultraviolet-A irradiation
45354617|NCT04045392|Behavioral|Mediterranean diet|Two meals (breakfast and dinner) a day, five times a week, are delivered to participants' homes without charge. The meals are prepared, under the supervision of an expert nutritionist, by a chef trained on the principles of the Mediterranean diet.
45354618|NCT00811980|Drug|Linezolid or Vancomycin|Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.
45354619|NCT00766844|Device|spinal cord stimulation|electrode is inserted into cervical epidural space for continuous spinal cord stimulation
45354620|NCT03895372|Drug|PF-06826647 or Placebo|Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period
45354621|NCT03895372|Drug|PF-06826647|Delivered orally (tablet) once daily (QD) for 24 weeks during the Extension Period
45354622|NCT02551926|Behavioral|mobile text messages|
45354623|NCT02551926|Behavioral|virtual community|
45354624|NCT02551926|Behavioral|brochures|
45354625|NCT02551926|Other|Usual care|
45354626|NCT02551926|Device|mobile phone|
46046476|NCT03976505|Other|filling a virtual pillbox displayed on the screen as prescribed in the prescription|filling a virtual pillbox displayed on the screen as prescribed in the prescription
45354627|NCT00775034|Drug|Tisseel®|Mesh repair for open incisional hernia repair with fibrin sealant
45354628|NCT00775034|Procedure|Drainage|Mesh repair for open incisional hernia repair with drainage
45354629|NCT00813696|Drug|gemcitabine|1000 mg/m2 IV weekly for 7 weeks. Starting at week 9, gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks
45354630|NCT00813696|Drug|cisplatin|25 mg/m2 IV on days 1, 8, and 15 every 4 weeks
45354631|NCT02557880|Behavioral|Sleep Application Diary|Tool used to document sleep hygiene.
45354632|NCT02557880|Behavioral|Treatment As Usual|Sleep hygiene counseling
45686801|NCT05819086|Behavioral|Rate Emotional Response|Participants will view their assigned video package, and will be asked to rate their emotional response to the message
45354633|NCT00771290|Procedure|Air insufflation with standard endoscopy unit, CO2 insufflation for colonoscopy (special CO2 insufflation unit)|comparison of Air insufflation to CO2 insufflation during intraoperative endoscopy
45686802|NCT05819086|Behavioral|Rate Impact of Message|Participants will view their assigned video package, and will be asked to rate the impact of the presented messages on motivation to quit smoking.
45686803|NCT05819060|Drug|Fuzuloparib Combination with Bevacizumab|For the first 6 patients, if DLT≤33.3%, Fuzuloparib 150mg/bid will be used for follow-up research; if DLT>33.3%, Fuzuloparib will be used for follow-up research at 100mg/bid; Bevacizumab 7.5mg/kg, d1, Q3W.
45843360|NCT03081390|Other|Flow-mediated dilation testing|At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques.
46046477|NCT03976505|Other|eye-tracker|In the touch-screen condition an eye-tracker is used to record eye fixations and scanpaths in real time.
46046478|NCT03976505|Other|cognitive tests and questionary|Once the 2nd pillbox filling is finished a battery of cognitive tests and questionnaires is administered to participants to identify Pd subtypes of impaired performances.
45354634|NCT00813774|Biological|Certolizumab pegol|Lyophilized certolizumab pegol vial of 200mg for reconstitution of a solution with 1 mL water for injection, single dose of 400 mg given as two subcutaneous injections of 200mg
45354635|NCT00813774|Biological|Certolizumab pegol|Certolizumab pegol liquid formulation 200 mg/mL in 1 mL vial single dose of 400 mg given as two subcutaneous injections of 200mg
45354636|NCT00813774|Biological|Certolizumab pegol|200 mg/1 mL liquid certolizumab pegol solution in a pre-filled syringe, single dose of 400 mg given as two subcutaneous injections of 200mg
45354637|NCT02557490|Drug|oxaliplatin and raltitrexed|"TACE methods: use of epirubicin 20-40mg emulsifier lipiodol embolization target vessel, with gelatin sponge particles or PVA particles or microspheres embolization supplement.~Hepatic arterial chemotherapy: Bi embolization catheter in the hepatic artery or left hepatic artery branch within the right, chemotherapy, for the experimental group (A group): OXA 130mg / m2 artery 0-4 hours pumped Raltitrexed 3mg/m2 4-5 hours pumped into the arteries; the control group (group B)"
45354638|NCT00775112|Device|pillow|use of pillow for lumbar punctures
45354639|NCT00813852|Behavioral|exercise training, IMT|Each exercise session includes graded treadmill walking and resisted exercises. The graded treadmill walking exercise begins with a 5 minute warm-up period with the intensity of about 40% of maximal oxygen consumption (VO2max) follows by a 30 minutes training phase. The training intensity is set at about 70%-85% of VO2max and ends with a 5-minute cool-down period with the intensity of about 40% of VO2max. The resisted exercise program includes 20 minutes of weight training with rest after the first 5 minutes.
45477934|NCT05865327|Procedure|Sham Cryoneurolysis|Participants in the control group will receive sham CN (i.e., application of device without skin puncture or activation of unit) to maintain participant blinding. All participants will also receive standard multimodal analgesia and ESP catheter infusion.
45686804|NCT05819034|Other|Scoliosis-Specific Exercise Program|"Adolescents in the control group will receive a scoliosis-specific exercise program which will be prescribed to control the progression of the scoliotic curve. This exercise program will include frontal plane active or passive correction exercises for scoliotic posture. The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.~The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour."
45843361|NCT02481336|Other|Questionnaires|EORTC CIPN20 and EQ-5D-3L
45843362|NCT02481336|Procedure|Peripheral nervous system examination|nerve conduction velocity (NCV), quantitative sensory test (QST), and nerve excitability test (NET)
45843363|NCT02481336|Genetic|Whole Genome Sequence|Genetic Test : 10 mL blood will be collected in Blood Sample Collection
45354640|NCT02551848|Drug|Botulinum toxin type A|
45354641|NCT00807534|Drug|ipratropium bromide|ipratropium bromide nebulization
45354642|NCT00807534|Drug|placebo|placebo nebulization
45354643|NCT00807534|Behavioral|constant rate step test|nebulization of 500ug
45354644|NCT00807534|Behavioral|constant rate shuttle walk test|nebulization of 500ug
45354645|NCT00812058|Drug|RG2417|1g bid dose escalates to 2g bid for weeks 2-8.
45354646|NCT00812058|Drug|Placebo|Similarly sized placebo pills to be taken in the same fashion as the RG2417 tablets.
45354647|NCT05589142|Behavioral|Time Restricted Eating|Eating calories only during a specific feeding window.
45477935|NCT05865314|Other|Optimisation of nutrition therapy coupled with early mobilisation|"Optimisation of nutrition therapy coupled with early mobilisation with:~Optimisation of nutrition therapy during ICU stay~Optimisation of physiotherapy during ICU stay~Better communication and closer collaboration between physiotherapy and nutrition teams.~Optimisation of continuity of the care."
45477936|NCT05865314|Other|Standard care|Patients will receive nutritional therapy and mobilisation according to local standard procedures.
46046479|NCT03969459|Biological|breast milk collection|3 samples of 20 ml of breast milk will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
45354648|NCT05589064|Behavioral|Experimental: Dietetic counseling|Patients will receive dietary counselling to increase caloric and nutrient intake, stabilize glycemia, and optimize hydration.
45354649|NCT05589064|Dietary Supplement|Active Comparator: Omega-3, vitamin D3 and creatine monohydrate|Patients will be prescribed dietary supplements which will be taken daily for 8 weeks, as per the supplement protocol.
45354650|NCT05589064|Behavioral|Other : Physiotherapy treatment|Patients will receive weekly physiotherapy treatment.
45354651|NCT00807690|Drug|Tacrolimus ointment|Tacrolimus ointment 0.1%every night for at least 3 months, half body side
45354652|NCT00813930|Behavioral|INTERxVENT lifestyle modification program|It is a lifestyle behavior modification program which helps Type 2 diabetics manage diabetes better and reduce cardiovascular risk factors. The program involves up to 12 telephone mentor/coaching sessions with a certified health professional.
45354653|NCT05355844|Drug|Benzoyl peroxide|Benzoyl peroxide application in the incision area before surgery
45354654|NCT00814008|Drug|Insulin|Insulin Dosage form : intravenous infusion, infusion period 60 minutes Dosage: continuous dose of 0.5 mU/kg/min infused intravenously over 60 min; Insulin Lilly, Huminsulin, Lilly, Fegersheim, France
45354655|NCT00814008|Drug|Glucose|"Glucose:~Dosage form : intravenous infusion, infusion period 60 minutes per dose level Dosage: at a rate to maintain blood glucose level at 100mg ; 20mg/100ml Glucose"
45354656|NCT04197700|Other|Target MAP Management|Target MAP Management
45354657|NCT00814086|Drug|Paclitaxel|Given IV or intraperitoneally
45354658|NCT00814086|Drug|Cisplatin|Given intraperitoneally
45354659|NCT04114786|Device|3D-printed mask|After patient is enrolled to the study, patients will have CT Sim. MR Sim (used to create 3D printed mask for intervention arm only) CT sim repeat (for intervention arm only) before start of radiation Patients will be asked to fill out a questionnaire after each CT Scan, and during the first and last week of radiation treatment
45354660|NCT04114786|Device|Thermoplastic mask|Patients will undergo standard of care simulation, planning and treatment with conventional workflow using thermoplastic mask.They will complete the tolerability questionnaire after CT-sim, and towards the end of the first and last week of treatment.
45354661|NCT00669110|Drug|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|"tablet~subjects randomly assigned to 10-200 mg/day by age group~6 month treatment period(~182 days)"
45354662|NCT04604860|Behavioral|Fitness intervention|Patients will follow exercise plans designed to promote physical activity (exercise and behavioral coaching).
45354663|NCT00654732|Drug|Bleomycin|Given IV
45686805|NCT05819034|Other|Soft orthoses with external strapping.|Adolescents in the experimental group will receive a scoliosis-specific exercises program which will be prescribed to control the progression of the scoliotic curve in addition to wearing the soft orthoses with external strapping. The wearing schedule of the soft orthosis with the external strapping for every participant in this group will be 12 hours daily for 12 successive weeks.
46046480|NCT03969459|Biological|meconium collection|3 samples of 20 ml of meconium milk will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
46046481|NCT03969459|Biological|newborn feces collection|3 samples of 20 ml of newborn feces will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
45354664|NCT00654732|Drug|Dacarbazine|Given IV
45354665|NCT00654732|Drug|Doxorubicin Hydrochloride|Given IV
46046482|NCT03969459|Other|questionary of pesticide exposure of the mother|maternal questionary of pesticide exposure of the mother
46046483|NCT03967249|Drug|IONIS GHR-LRx|Participants will receive IONIS GHR-LRx by subcutaneous injection.
45354666|NCT00654732|Biological|Rituximab|Given IV
45354667|NCT00654732|Drug|Vinblastine|Given IV
45686806|NCT05818995|Drug|angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker|Drug types: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blockers Treatment prescription: medication alone or in combination Dose used: <standard dose, standard dose, >standard dose Frequency of administration: once a day, twice a day, three times a day.
45354668|NCT04553068|Drug|EVO100|EVO100 vaginal gel
45354669|NCT04553068|Drug|Placebo|Placebo vaginal gel
45354670|NCT00771368|Drug|Nitric Oxide|1 % Gaseous Nitric Oxide, delivered for 30 minutes daily for 3 consecutive days
45354671|NCT00767156|Other|Omega7 Sea Buckthorn Oil Cream|The subjects use Omega7 Sea Buckthorn Oil Cream on the face, twice per day
45354672|NCT00767156|Other|Base cream|The subjects use the base cream on the face, twice per day
45354673|NCT00767156|Dietary Supplement|SBA24 Sea Buckthorn Oil Capsule|The subjects take SBA24 sea Buckthorn Oil Capsules, 2 x 2 capsules (2.0 g oil) per day and use topically Omega7 Sea Buckthorn Oil Cream, twice per day.
45354674|NCT00767156|Dietary Supplement|SBA24 Sea Buckthorn Oil Capsule|Teh subjects took SBA24 Sea Buckthorn Oil Capsule, 2 x 2 capsules (2 g oil) per day and use topically the base cream, twice per day
45354675|NCT05358028|Other|Hand Arm Bimanual Intensive Technique including Lower Extremity (HABIT-IL)|"HABIT-ILE along with the conventional Bobath treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities.~Functional task as maintaining ADL:~i.Eating with spoon while standing ii. Combing hair while standing. iii. Counting cards while standing and putting them in box. Standing and walking I. standing with support of upper extremity II. walking with the help walkers III. walking on parallel bar playing activities: I. playing with cards while standings II. taking toys out of box and putting them in other box while standing III. grasping a fixed rod by hand and trying to maintain balance on physio stability ball"
45477937|NCT05865301|Other|Questionnaire for patients receiving therapy|Questionnaires will be given (at baseline, 1, 3, 6, and 12 months post CAR infusion) including baseline demographics, individual/family and neighborhood socioeconomic data, measures of household material hardship (housing and transportation insecurity, household energy and food insecurity), barriers to care at the CAR T cell institution, as well as patient reported outcomes following Kymriah infusion.
45354676|NCT05358028|Other|Hand Arm bimanual intensive Technique (HABIT)|"HAIBT along with the conventional Bobath treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities HAIBT along with the conventional Bobth treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities~Playing activities on table:~I. building towers with Lego blocks, II. Holding book by one hand and turning pages , III. Playing games with cards, IV. Drawing random impressions on paper, V. taking toys out of one box and placing them in other box one by one~Activities of daily living :~I. eating with spoon from bowel II. combing hair while sitting, III. opening of bottle cap for drinking water Age appropriate video games while sitting will be provided according to the ease of children"
45354677|NCT00771524|Drug|Ceftobiprole|Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
46046484|NCT03967249|Drug|Somatostatin Receptor Ligand (SRL)|Participants will receive Somatostatin Receptor Ligand (lanreotide, octreotide) once monthly.
46046485|NCT03940963|Device|AxoGuard® Nerve Cap|Entubulation of the nerve stump into the AxoGuard® Nerve Cap following surgical excision of symptomatic neuroma
45354678|NCT00649428|Biological|Autologous Human Fibroblast (azficel-T)|"Collection of 3 mm post auricular skin punch biopsies.~Three injection treatments administered 5 ± 1 weeks apart on each side of the face."
45354679|NCT00649428|Biological|Placebo|"Collection of 3 mm post auricular skin punch biopsies.~Three injection visits administered 5 ± 1 weeks apart on each side of the face."
45354680|NCT05588050|Device|smart phone application and AutoCAD software|to assess the validity and reliability of smart phone application and AutoCAD software in assessing knee joint position sense in patients with patellofemoral pain syndrome
45354681|NCT00767234|Procedure|Observation|Standard of Care
45354682|NCT04090762|Behavioral|Conditional cash transfer|Pregnant women receive cash payments conditioned on their use of prenatal services and use of a health facility for child birth.
45354683|NCT04090762|Behavioral|Risk information provision|Pregnant women who exhibit characteristics associated with a greater risk of a poor birth outcome - these will be identified from the medical and epidemiological literature - will be informed that they possess these characteristics.
45354684|NCT00767390|Device|ACL Patch|Observe and characterize the changes in relative conductivity between the six ACL patches over period of six hours. Investigation only involves passive data collection on pressure impact and adhesiveness properties of ACL patches.
45354685|NCT02552082|Device|Scorpio NRG posterior stabilized (PS)|
45354686|NCT04000438|Drug|DF01|The subject receives sc injections of tafoxiparin solution once daily for up to 7 days until labor induction or spontaneous onset of labor. Induction is done according to clinical practice; 1st balloon, 2nd PGE1
45354687|NCT04000438|Drug|PL1|The subject receives sc injections once daily of placebo solution for up to 7 days until labor induction or spontaneous onset of labor. Induction is done according to clinical practice; 1st balloon, 2nd PGE1
45354688|NCT00771680|Drug|insulin detemir|Start dose and frequency at the discretion of the physician following clinical practice
45354689|NCT00771680|Drug|biphasic insulin aspart 30|Start dose and frequency at the discretion of the physician following clinical practice
45354690|NCT00771680|Drug|insulin aspart|Start dose and frequency at the discretion of the physician following clinical practice
45354691|NCT02552784|Behavioral|data assessment of the state of health and quality of life of patients and their families|Study medical determinants, socioeconomic, behavioral, environmental of health, school and professional integration, and short- and medium-term quality of life of all patients residing in France for which the diagnosis of hereditary diseases metabolism with specific diet (MHMRS) was performed during their childhood.
45354692|NCT04003558|Other|No interventions|As this is a patient registry, there are no interventions.
45354693|NCT00767468|Drug|sorafenib tosylate|Sorafenib 400mg BID until disease progression or patient withdrawal.
45847660|NCT02816346|Biological|Shigella sonnei 53G|"Investigational Product: Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.~Dose: 500-1500 cfu (doses were to be increased or lowered based on results of preceding cohorts)"
45354694|NCT05074914|Procedure|oesophagectomy|removal of oesophagus
45354695|NCT05583604|Drug|secukinumab|The recommended dose is 300 mg of secukinumab by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4, followed by a maintenance dose of 300 mg every 2 weeks. Each 300 mg dose is given as one subcutaneous injection of 300 mg or as two subcutaneous injections of 150 mg.
45354696|NCT00812136|Behavioral|Using Parent Mentors to Improve Asthma Care for Urban Minority Children|
45354697|NCT00669032|Device|Hyaluronic acid|3 cycles of 5 hyaluronic acid injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
45354698|NCT00669032|Other|Placebo|3 cycles of 5 saline solution injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
45354699|NCT04001998|Drug|BLD-2660|Randomized to active product
45354700|NCT04045236|Other|Registry|Data collection
45477938|NCT05865288|Drug|Oxytocin nasal spray|Intranasal OT will be performed using a spray containing 24IU (12IU administered to each nostril), sorbitol, benzyl, alcohol glycerol, distilled water. Dosage and administration method was determined by standard OT studies instructions and guidelines. The substance will be prepared immediately after randomization by an external preparation and delivered and stored until administration under required conditions. The nasal spray will be self administered, with the nursing staff supervising for proper administration of substance, after training and guiding the patient, and for supervision of side effects.
45847661|NCT02820324|Drug|Oliceridine|
46046486|NCT03940963|Procedure|Standard Neurectomy|Surgical excision of symptomatic neuroma
46046487|NCT03937102|Procedure|cardiac output measure with TTE|All patients included will be simultaneously monitored with transthoracic echocardiography (TTE) and the Physioflow® thoracic electrical bioimpedance device. Cardiac output is measured by the Physioflow® Thoracic Bioimpedance Device and TTE before and after passive leg raising maneuver (PLR)
45354701|NCT04490200|Device|VESTA respirator|The protocol will be composed by the use of the VESTA respirator for 21 days (approximately 8 consecutive shifts lasting 6 to 12 hours, followed by approximately 36 hours of rest). Each participant will receive a total of approximately 8 respirators, with instructions for a maximum usage time of 6 hours. Therefore, participants will receive 1 respirator to be used in each shift of 6 hours, and 2 respirators in shifts of 12 hours. All participants will receive a booklet with guidelines and training in the use and proper handling of the respirator. All respirators will be sterilized and packaged in the laboratory, to ensure that they are not contaminated before use by the participants. The intervention will not change the participants' routine, considering that they already follow instructions for the use of protective personal equipment (PPE) and the proposed intervention will follow all local regulations and guidelines for the use and conservation of PPE and semi facial respirators.
45477939|NCT05865249|Other|Spirometry decision support software (ArtiQ.Spiro)|ArtiQ.Spiro is a decision support software that combines two sub-components - one focussing on quality assessment (ArtiQ.QC), and one on spirometry interpretation (ArtiQ.PFT). It is intended to be used as an adjunct to spirometry to assist with the grading of spirometry quality and the interpretation of spirometry by providing the probability of six disease / or no disease categories.
45477940|NCT05865236|Procedure|Infra-red lamp therapy + Kegal Exercises|The infrared the infrared lamp will be placed at distance of 45 cm away from the perineum with the heat emitted with 220 volts used for 10-15 minutes IRR is beneficial for promoting wound healing, tissue repair, and skin rejuvenation.
45477941|NCT05865236|Procedure|Dry air heat group + Kegal Exercises|Woman should lie on the bed without panties or the sanitary Pad. Place towels under buttocks to absorb any vaginal discharge. She should lie on her back with the knees bent and feet flat. Let the vagina dry by holding a hair dryer 10 to 12 inches away from episiotomy. The dry heat will gives a soothing effect on the wound
45477942|NCT05865223|Other|Mckenzie exercise program|MacKenzie extension exercise program for cervical spine
45477943|NCT05865223|Other|Conventional Physical therapy|hot pack for 15 minutes will be given followed by joint mobilization,and home exercise program.
45477944|NCT05865210|Other|Kegel Exercise|Kegel exercises (also called pelvic floor exercises) will be used to strengthen the pelvic floor muscles it will involve repeatedly contracting and relaxing the muscles that form part of the pelvic floor.
45477945|NCT05865210|Other|Myofascial release technique|Myofasical release will include deep pressure for 10-15 seconds to release the trigger points and also gentle, light soft tissue massage on the vaginal muscles and surrounding areas.
45477946|NCT05865197|Other|Data collection|Data collection of clinically relevant signals using home-based sensor system
46046488|NCT03937102|Procedure|cardiac output measure with Physioflow® thoracic electrical bioimpedance|All patients included will be simultaneously monitored with transthoracic echocardiography (TTE) and the Physioflow® thoracic electrical bioimpedance device. Cardiac output is measured by the Physioflow® Thoracic Bioimpedance Device and TTE before and after passive leg raising maneuver (PLR)
45477947|NCT05865184|Other|Data collection|Data collection of clinically relevant signals using home-based sensor system
45477948|NCT05865158|Other|Home-based exercises|Home-based exercises proposed through the CardioSafe+ platform, guided by therapists specialized in cardiovascular disorders, who will try to adapt the sessions to each participant.
45477949|NCT05865145|Device|Electronic Bicycle Ergometer|Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be adjusted for High or Low interval intensity training.
45477950|NCT05865132|Drug|Palbociclib|120mg/125mg po qd on day 1 to 21, every 28 days
45477951|NCT05865132|Drug|Afatinib|30mg/40mg po qd on day 1 to 28, every 28 days
45477952|NCT05865119|Device|OPTIMUS covered stent|The procedure involves placement of a long and large balloon-expandable covered stent in the superior vena cava that tunnels the abnormal pulmonary venous return to the left atrium.
45843364|NCT01597440|Drug|N-carbamylglutamate|"Active NCG & Standard of Care Chemical Composition: N-carbamyl-L-glutamic acid (NCG) The daily dose will be 100 mg/kg/ day. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube (standard of care will prevail when choosing the mode of drug administration).~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.~This drug will be administered for 7 days after admission or until discharge (whichever is sooner)."
46046489|NCT03937050|Behavioral|Intervention|"Three film-based components:~Professional development of doctors and nurses to improve screening and management of GDM. Modules will cover knowledge and relevant clinical guidelines, skills for glucose monitoring and managing medication, specialist obstetric care, and lifestyle counselling. The films will be screened at professional development meetings.~Awareness-raising among pregnant women and family members regarding GDM and the importance of healthy lifestyles during pregnancy. The film will be culturally tailored and will be screened in waiting areas of antenatal clinics/electronic versions of the films will be made available for viewing on mobile devices.~Structured diabetes self-management programme for women with GDM to empower them with the necessary knowledge, skills, and confidence to manage GDM successfully. The programme will incorporate behavioural counselling and educational reinforcement. Films will be screened at group sessions/viewed on mobile devices."
46046490|NCT03935139|Biological|glucose measurement|Glucose values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
45354702|NCT04490200|Device|Conventional N95 respirator|The protocol will be composed by the use of the N95 respirator for 21 days (approximately 8 consecutive shifts lasting 6 to 12 hours, followed by approximately 36 hours of rest). Each participant will receive a total of approximately 8 respirators, with instructions for a maximum usage time of 6 hours. Therefore, participants will receive 1 respirator to be used in each shift of 6 hours, and 2 respirators in shifts of 12 hours. All participants will receive a booklet with guidelines and training in the use and proper handling of the respirator. All respirators will be sterilized and packaged in the laboratory, to ensure that they are not contaminated before use by the participants. The intervention will not change the participants' routine, considering that they already follow instructions for the use of protective personal equipment (PPE) and the proposed intervention will follow all local regulations and guidelines for the use and conservation of PPE and semi facial respirators.
45354703|NCT04045314|Other|Topical moisturizer|The investigational product is an intensive emollient cream that is applied topically on the skin and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at soothing and conditioning the skin as well as improving hydration. The moisturizer also contains 1% hemp oil rich in essential fatty acids and antioxidants as well as 0.5% of CBD with regulatory and conditioning effect on the skin
45686807|NCT05818982|Drug|Afatinib|Afatinib will be administered orally at 40 mg per day (qd) in each 6-week cycle.
45686808|NCT05818982|Drug|Irinotecan|Irinotecan, intravenous drip, 140-180mg/㎡, D1, Q14D
45686809|NCT05818969|Behavioral|Hypnosis Therapy|Pre-recorded hypnosis therapy audio recording with accompanying visual of a calming ocean scene to be played at least once daily for 7 days preoperatively.
45686810|NCT05818917|Drug|FHND5071|"The proposed starting dose is 40 mg FHND5071 once daily (QD) orally (PO). For the purposes of this study treatment cycles will be 28 days or 4 weeks.~FHND5071 will be administered orally in the morning following a fast of approximately 10 hours before dosing on PK collection days. Subjects will continue to fast for approximately 4 hours after the administration of FHND5071. On non-PK days the subjects will fast approximately 2 hours before FHND5071 and continue to fast for approximately 2 hours afterwards.~Other dosing regimens may be considered based on the analysis of emerging PK, progressive disease, and/or safety data."
45843365|NCT01597440|Other|Standard of Care|Standard of Care
45843366|NCT01598064|Dietary Supplement|GK#10|GK#10, 1 pack tid
45843367|NCT01598064|Drug|Placebo|Placebo 1 pack tid po
45843368|NCT01598922|Behavioral|Internet Cognitive Behavioral Therapy|8 weeks of online treatment program
45843369|NCT01600170|Drug|Atorvastatin (generic Lipitor)|Atorvastatin is an FDA approved prescription drug which is frequently used to lower cholesterol levels.It is available in the form of tablets ranging in dose from 10-80mg.
46046491|NCT03935139|Biological|lactacte measurement|Lactate values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
46046492|NCT03935139|Biological|pyruvate measurement|pyruvate values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
46046493|NCT03935139|Biological|glycerol measurement|glycerol values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
45354704|NCT00775424|Biological|PENNVAX-B|PENNVAX-B is a cocktail of three expression plasmids. The plasmids include the genes which encode a synthetic HIV-1 envelope protein (pEY2E1-B), Gag (gagCAM02), and Pol (pK2C1). Each plasmid is manufactured to a concentration of 4.0 mg/mL and is formulated with bupivacaine (0.25%) as a facilitating agent for DNA uptake. All plasmids (2.0 mg each gag, pol, env) are premixed by the manufacturer in the same vial.
45354705|NCT00775424|Biological|GENEVAX IL-12-4532|GENEVAX IL-12-4532 This molecular adjuvant plasmid contains nucleotide sequences necessary for expression of the human IL-12 protein. IL-12 DNA is formulated at a concentration of 2.0 mg/mL with bupivacaine (0.25%).
45686811|NCT05818904|Other|Physical Therapy|All arthrosis participants will be treated as the traditional methods using physical therapy.
45686812|NCT05818826|Drug|normal saline solution|Prepare 100 ml of normal saline solution, packed out in the same format, dose, and administration of the drug were exactly the same as in the conventional cessation group.
45843370|NCT01600170|Drug|placebo|A substance containing no medication and prescribed or given to reinforce a patient's expectation to get well.
45843371|NCT01600482|Device|CELT ACD|The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous intervention procedure using a 6F procedural sheath.
45843372|NCT01600638|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
45843373|NCT01600950|Drug|LY2963016|Single 0.3 U/kg dose administered subcutaneously
45843374|NCT01600950|Drug|Lantus|Single 0.3 U/kg dose administered subcutaneously
45843375|NCT01603056|Biological|Pangramin SLIT HDM mix.|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
45843376|NCT01603056|Biological|Placebo|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
45843377|NCT01604772|Drug|Akt Inhibitor MK2206|Given PO
45843378|NCT01604772|Other|Laboratory Biomarker Analysis|Correlative studies
46046494|NCT03935139|Procedure|Bone free flap monitoring|Bone free flaps will be monitored with a microdialysis catheter directly positioned in bone tissue.
46046495|NCT03934632|Other|Postabsorptive|Saline will be infused to mimic postabsorptive circulating amino acid concentrations
46046496|NCT03934632|Other|Postprandial|An amino acid infusate will be administered to mimic postprandial circulating amino acid concentrations
46046497|NCT03934632|Procedure|Immobilisation|One leg will undergo 2 days immobilisation prior to the test day
46046498|NCT03927079|Biological|measure of intra-alveolar antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
46046499|NCT03927079|Procedure|broncho-alveolar lavage (BAL)|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
46046500|NCT03927079|Biological|blood test to measure plasmatic antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic
46046501|NCT03926403|Other|"State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire)"|"Patients will be given, a State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire) that will be collected on the same day. Each patient's initial anxiety score will be calculated so as to select only patients who are at least lightly anxious about their management (score ≥ 36)."
46046502|NCT03926403|Procedure|hypnosis techniques|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from experimental management based on hypnosis techniques.
46046503|NCT03926403|Procedure|local anaesthesia|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from conventional management (local anaesthesia).
45847662|NCT02820324|Drug|Placebo|
45847663|NCT02820324|Drug|Morphine|
45686813|NCT05818826|Drug|Hydrocortisone and normal saline solution|Prepare hydrocortisone with normal saline solution 100 ml starts dose at least 200 mg/day according to doctor's order after patient meets the criteria of refractory septic shock then continues conventional cessation of hydrocortisone according to doctor's order after required dose of vasopressor less than 0.1 mcg/kg/min.
45843379|NCT01605942|Drug|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
46046504|NCT03919188|Procedure|air temperature control (ATC)|Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): second parameter : air temperature control (ATC)
45477953|NCT05865119|Procedure|Surgical correction of a SVD|Under cardiopulmonary bypass and open heart surgery, surgical correction of SVD either using single patch, double patch or Warden techniques
45477954|NCT05865106|Device|Smartphone-based speech therapy|Participants will be instructed to use the speech therapy app for 1 hour per day (5 days for 1 week) over a 4-week period.
45477955|NCT05865106|Other|Traditional speech therapy|Participants will receive treatment maintaining the same frequency as the intervention group.
45477956|NCT05865067|Other|Yoga Therapy|The intervention sessions will consist of 12 yoga therapy sessions, each one approximately 30 to 45 minutes long, it will be given once a week (on Saturdays) in a room in the building of the School of Health Professions in the Campus of Medical Sciences from the University of Puerto Rico.
45477957|NCT05865067|Other|Exercise|The wait-list control group will be motivated to exercise at home (except for Yoga).
45477958|NCT05865054|Diagnostic Test|Magnetic Resonance Imaging (MRI)|Combined orbital and cranial vessel wall MRI
45477959|NCT05865015|Other||
45477960|NCT05865002|Drug|AUR107|Once daily
45477961|NCT05864989|Procedure|Non-incised papila surgical approach only|Reconstructive periodontal surgery
45477962|NCT05864989|Procedure|Non-incised papila surgical approach with connective tissue grafting|Reconstructive periodontal surgery
45686814|NCT05818813|Device|Renal denervation|Renal denervation (ReCor Medical)
45686815|NCT05818800|Device|digital solution|randomised controlled trial where patients with hypertension will be randomised either to one of the two digital solutions
45686816|NCT05818800|Other|Standard Care|randomised controlled trial where patients with hypertension will be randomised r to standard care
45686817|NCT05818748|Device|virtual reality|virtual reality distraction
45686818|NCT05818670|Drug|Tamsulosin|long term follow up
45686819|NCT05818670|Drug|Tadalafil|long term follow up
46046505|NCT03919188|Procedure|skin servocontrol (SSC)|Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): Third parameter : skin servocontrol (SSC).
46046506|NCT03919162|Drug|PQ912|PQ912 150 mg tablets
46046507|NCT03919162|Other|Placebo|Placebo tablets to mimic PQ912 150 mg tablets
45354706|NCT00775424|Biological|PLACEBO|PLACEBO
45354707|NCT00775424|Biological|IL-15 adjuvant|pIL15EAM is a plasmid that encodes human IL-15 and has been optimized to express 87 fold higher than native IL-15 DNA and 5.7 fold higher than an earlier generation optimized IL-15 DNA construct. This plasmid is formulated at a concentration of 4.0 mg/mL with bupivacaine (0.25%).
45686820|NCT05818657|Biological|levels of CKD markers, Oral health status, apical periodontitis|To observe levels of CKD markers :Levels of serum keratinise ,urea, eGFR, and assessment of Oral health status, apical periodontitis
45354708|NCT04652622|Device|Mindful Garden|Mindful Garden is an interactive digital behavior modification platform utilizing inbuilt sensors and screen based delivery system. The platform delivers calming visual output of real nature video layered with hyper-real animations of growing and receding flowers and butterflies in flight in a volume directly responsive to measured patient activity. Patient movement and vocalization are the surrogate markers for agitation and using proprietary algorithms drive onscreen content.
45354709|NCT00814242|Procedure|surgical resection|radical resection performed in patinets with HCC.
45498263|NCT03736213|Behavioral|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. I
45354710|NCT00814242|Procedure|percutaneous radiationfrequency ablation|CT or Ultrasound-guided percutaneous radiofrequency ablation performed in patinets with HCC
45354711|NCT00775502|Drug|BIW-8962|Intravenous administration of liquid dosage form. Doses 0.03, 0.10, 0.30, 1.0, 3.0, and 10 mg/kg. Frequency is once every two weeks. Duration is 6 months
45354712|NCT05582668|Procedure|Bariatric surgery|Bariatric surgery
45686821|NCT05818657|Biological|systemic inflammatory marker, Oral health status, apical periodontitis|estimation of hs-CRP levels, and assessment of Oral health status, apical periodontitis
45354713|NCT00775580|Drug|Atenolol 100mg Tablets|
45354714|NCT00767546|Drug|Botulinum toxin|60- 100 units Local injection to the rash area
45354715|NCT00654498|Drug|Pramipexole|
45354716|NCT00654498|Drug|Placebo|
45354717|NCT00771992|Procedure|Bronchoscopy|Bronchoscopy with segmental allergen challenge
45354718|NCT00670046|Drug|valproic acid|given orally
45354719|NCT00670046|Other|standard of care follow-up|participant follow the standard of care for patient with metastatic prostate cancer
45354720|NCT00814398|Procedure|Double Embryo Transfer (DET)|Two embryos are transferred during an IVF treatment
45354721|NCT00814398|Procedure|Single Embryo Transfer (SET)|A single embryo is transferred during an IVF treatment
45354722|NCT02557334|Dietary Supplement|Low Dose Strawberry Powder|40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder
45354723|NCT02557334|Dietary Supplement|High Dose Strawberry Powder|40 g freeze dried strawberry powder
45354724|NCT02557334|Dietary Supplement|Placebo Powder|40 g color and taste matched placebo powder
45354725|NCT00560391|Drug|Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg|Participants received dasatinib, 70 mg once daily (QD), for 28 days plus lenalidomide, 15 mg QD, for 21 days plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
45354726|NCT00560391|Drug|Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received dasatinib, 70 mg QD, for 28 days plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
45354727|NCT00560391|Drug|Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
45354728|NCT00560391|Drug|Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
45686822|NCT05818605|Behavioral|Moderate Intensity Exercise Program|Subjects randomized to the EXER arm will undergo 24 weeks of Moderate Intensity Exercise Training (MIET). Patients will be signed up for 60-minute exercise sessions, 3 times a week
45686823|NCT05818592|Other|Self-Pulse Monitoring|Participants will manually monitor pulse for irregularities.
45843380|NCT01605942|Drug|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
45354729|NCT00560391|Drug|Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received dasatinib, 140 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22. Cohort includes 4 participants who received treatment during the dose-finding phase and 13 participants who received treatment in the dose-expansion phase.
45354730|NCT00767780|Device|APOS biomechanical gait system|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
45354731|NCT00775736|Drug|biphasic insulin aspart 30|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
45354732|NCT00775736|Drug|biphasic insulin aspart 50|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
45354733|NCT00775736|Drug|biphasic insulin aspart 70|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
45354734|NCT04047914|Device|pdt Photodynamic therapy|"Application of 0.01% methylene blue with enough sterile swab to cover the inner nostril extension with a 1 minute pre-irradiation time~• Irradiations will be performed with a red laser diode (wavelength = 660 nm), 240 seconds and 4-point nostril application"
45354735|NCT00942669|Device|SleepStrip OTC(TM)|self contained SAS screening device
45843381|NCT01607112|Biological|Fluarix/Influsplit SSW 2012-2013|1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
45354736|NCT01058629|Device|SynergEyes A2 Hybrid Contact Lens|SynergEyes A2 is a hybrid contact lens cleared by the US Food and Drug Administration (FDA) for daily wear correction of up to +20.00 and -20.00 in eyes with astigmatism up to 6.00D and for presbyopia.
45354737|NCT00537238|Drug|pregabalin|300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
45354738|NCT00537238|Drug|levetiracetam|1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
45354739|NCT00772226|Device|music pillow|according to randomisation patients will receive with/without music.
45354740|NCT00772226|Device|pillow without music|According to randomisation patients will receive a pillow with/without music
45354741|NCT00946413|Behavioral|CBT plus parent education|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution. The issues taught and discussed included an introduction to adolescent depression and suicide, their etiology, symptoms, treatment, and prognosis, as well as stress management. A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
45477963|NCT05864963|Procedure|Medial tab-type fasciocutaneous flap|"The flap can be taken in different ways depending on the defect. Once the base of the flap is identified, the posterior edge of the tibia is taken as reference; marking of the tab is performed considering that the posterior incision is located 5 cm from the posterior edge of the tibia, and the anterior incision is located longitudinally of the medial region of the tibial diaphysis, the length of the incision depends on the base of the flap and the defect's size.~The posterior incision is made first in the skin, subcutaneous cellular tissue until the fascia is identified; the subfascial flap is dissected to avoid injuring perforators, dissection is completed up to the anterior edge of the flap, if needed direct cutaneous perforators are ligated; once the subfascial plane has been identified and dissected, the tab is completed in its proximal or distal part according to the previous surgical planning. Later, the tab is rotated to the anterior region of the tibia to cover the defect."
45477964|NCT05864937|Other|infertily evaluation|All couples had undergone a standard infertility evaluation, which included medical history, physical examination, and assessment of tubal patency by either hysterosalpingography or laparoscopy and hormonal analysis on cycle day 3. A transvaginal ultrasound scan was performed on the second day of the cycle. On the same day, ovarian stimulation was carried out with recombinant FSH follitropin);rFSH;Gonal-F,MerckSerono,France,orfollitropin ; Puregon, MSD, France), urinary FSH (urofollitropin, Fostimon, France),orhMG(menotropin,Menopur,France)atastarting dose of 75 IU/day from the second day of the cycle.
45354742|NCT00946413|Behavioral|CBT alone|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution.A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
45354743|NCT03982771|Drug|Bortezomib|-Bortezomib: 1.3mg/m2 subcutaneous injection on Day 1,8,15,22 every month for 9 months; And maintained with 1.3mg/m2 subcutaneous injection every two weeks from Month 9 to 21;
46046508|NCT03907657|Drug|Perflutren lipid microsphere|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
45477965|NCT05864924|Biological|Cohort A: 3.0x10^6 CAR-T cells/kg|Intravenous infusion
45843382|NCT01607658|Drug|Placebo|placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
45843383|NCT01607658|Drug|Low dose TBS-2|Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
45843384|NCT01607658|Drug|Medium dose TBS-2|Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
45843385|NCT01607658|Drug|High dose TBS-2|High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
45354744|NCT03982771|Drug|Cyclophosphamide|-Cyclophosphamide: (oral) 300mg/m2 on Day 1, 8, 15, 22 every month for 9 months;
45354745|NCT03982771|Drug|Dexamethason|Dexamethasone: (oral) 40mg on Day 1,8,15,22 every month for 9 months; and maintained with 20mg (oral) every two weeks from Month 9 to 21.
45354746|NCT00775814|Drug|Candesartan and Hydrochlorothiazide|Candesartan 8 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for 2 weeks; increased to Candesartan 16 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
45354747|NCT00775814|Drug|Hydrochlorothiazide (HCT)|Candesartan placebo-matching tablets and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
45354748|NCT03966885|Behavioral|Brief Intervention|The BI used in the trial combines motivational interviewing skills with cognitive behavioral therapy elements in order to assist clients with self identified substance misuse to begin to consider changing their rates of drinking and drug use. The intervention lasts 30 to 40 minutes and consists of 5 components including: 1) screening 2) identification and information on the impacts of substance misuse 3) talking about change and goal setting 4) understanding the primary reason for drinking 5) skill building with practice and 6) referral for services.
45354749|NCT03966885|Behavioral|Common Elements Treatment Approach (CETA)|The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems, and for alcohol and substance misuse. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
45354750|NCT04048148|Device|Novel designed myopia control spectacle lenses|A novel designed myopia control spectacle lenses (test lenses) will be given to both arms to wear for 12 months.
45843386|NCT01608672|Biological|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
45843387|NCT01610154|Drug|Sitagliptin|Sitagliptin 100 mg QD for 12 weeks
46046509|NCT03907657|Drug|Sulfur hexafluoride lipid microspheres|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Lumason will be used as a secondary contrast agent only if Definity(perflutren) is unavailable.This drug will be administered using the dosing range and administration type within the Lumason prescribing information. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
46046510|NCT03897777|Behavioral|Exercise Training effect on Hypertension and Gut Dysbiosis|the proposed research will: 1) Characterize gut microbial community structure in AA with hypertension in two important compartments that make up the overall gut bacteria in the colon (fecal and colon mucosa); 2) Quantify the relationship between aerobic exercise training and gut bacteria to identify SCFA microbes that adapt to exercise and benefit BP.
45354751|NCT00772460|Device|Patient Warming with conductive / convective warming|Warming device set to maximum (43 °C)
45354752|NCT03965403|Device|Arm motor function retraining with BURT|Intervention will be focused on patients impairments to assess the feasibility of the BURT device to carry-on long interventions
45354753|NCT00775892|Device|SeriACL Device ACL Reconstruction|Long-term Bioresorbable ACL Scaffold
45354754|NCT00775970|Behavioral|walking activity|
45843388|NCT01611948|Drug|Aprepitant|125mg/day for 8 weeks
45354755|NCT00942747|Drug|temsirolimus|Weekly infusion of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a maximum of 12 months in the case of continuing response to treatment
45477966|NCT05864924|Biological|Cohort B: 9.0x10^6CAR-T cells/kg|Intravenous infusion
46046511|NCT03894566|Other|No intervention - birth cohort study|There are no interventions because it is a birth cohort study
45843389|NCT01611948|Drug|Placebo|125mg/d placebo pill for 8 weeks
45843390|NCT01611948|Behavioral|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
45843391|NCT01612494|Drug|Hypertonic Saline|intravenous formulation of 3% hypertonic saline in a bolus dose of 10ml/kg over one hour
45843392|NCT01612494|Other|Normal Saline|intravenous formulation of normal saline in a bolus dose of 10ml/kg over one hour
46046512|NCT03884101|Drug|Lenvatinib|Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
46046513|NCT03884101|Biological|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
46046514|NCT03884101|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 IV infusion given on Day 1 of each cycle.
46046515|NCT03884101|Drug|Carboplatin|Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
45354756|NCT03863470|Behavioral|Early mobilization intervention|The intervention consists of 3 components: 1) A simplified mobilization goal (using the Surgical Optimal Mobility Score) will be defined during daily morning ward rounds and displayed on the doors of patients' rooms; 2) a facilitator will communicate to the care team regarding mobility goals; 3) clinicians will receive feedback on patient's mobility as mobility scores will be made available electronically on the ICU board - a dashboard for monitoring patient care in the ICU
45477967|NCT05864924|Biological|Cohort C:1.5x10^7 CAR-T cells /kg|Intravenous infusion
45843393|NCT01612884|Drug|Prasugrel|Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
45843394|NCT01612884|Drug|Clopidogrel|Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder
45843395|NCT01614210|Drug|Tamoxifen|All patients will take tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery.
45843396|NCT01614210|Procedure|Breast cancer surgery|Breast cancer surgery
45843397|NCT01616082|Behavioral|Low Calorie Diet (LCD)|A Diet History Questionnaire was completed and subjects had dietary counseling and were provided shakes. The low calorie diet began, to continued for a period of 8 weeks.
45354757|NCT00946491|Drug|Haloperidol 10 mg Tablets (Cord Laboratories)|
45843398|NCT01616082|Drug|Phentermine|"Individuals not on track to achieve their target weight by four weeks received the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects were given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.~Protection Against Risk:~Prior to administering any phentermine, a history and physical including EKG will be conducted (at the screening visit) and will be used to determine whether the participant is clear to receive the medication.~Participants will see the study doctor or nurse practitioner at every study visit after the drug is initiated."
45843399|NCT01616160|Drug|mometasone furoate|2 sprays/nostril BID
45686824|NCT05818579|Other|Virtual reality experience|The VR experience is launched on the participants using all-in-one VR head-mount devices. Tablet computers are used to optimize the settings by the intervention facilitators. Each session lasts for approximately one hour with 10 minutes spent on the briefing, 20 minutes spent on the VR experience, and 30 minutes spent on the post-VR group discussion. There are two sessions per week. The whole course lasts for six weeks and there are a total of 12 sessions.
45686825|NCT05818540|Device|Eclipse novel CPAP mask|Participants will wear the mask for 6 hours a night for 60 days.
45477968|NCT05864911|Device|the Gastric Bypass Stent System|The Gastric Bypass Stent System is a newly designed endoscopic duodenal-jejunal bypass liner for the treatment of obesity by Hangzhou Tangji Medical Technology Co., Ltd.. It consists of three main parts: a 60-cm polyethylene sleeve fixed into the duodenal bulb by anchors with barbs, a delivery system and a retrieval system. Compared to the Endobarrier, it has several technical adjustments. First, it improved sleeve materials to provide better barrier properties and reduce the breeding of bacteria resulting in hepatic abscess. Second, the barbs on the anchoring system have been modified to reduce duodenal injury. Third, the delivery and retrieval system have been optimized to eliminate the need of fluoroscopic guidance during implantation and explantation.
45477969|NCT05864885|Drug|Minoxidil|Topical formulation applied once a day.
45686826|NCT05818540|Device|ResMed P-10 mask|Participants will wear the mask for 6 hours a night for 60 days.
45686827|NCT05818527|Device|Acceledent vibrating device|used to accelerated the movement of teeth during orthodontic treatment
45686828|NCT05817552|Diagnostic Test|Geomagic Control X|3D Surface matching and compare
45686829|NCT05817422|Biological|cAd3-Marburg vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP) from the Angola strain.
45686830|NCT05817422|Other|Placebo|0.9% NaCl solution for injection.
45686831|NCT05817383|Other|Freeze-dried Blueberry Powder|Participants will be asked to consume 48 grams of freeze-dried blueberry powder (~ equivalent to 2 cups of fresh blueberries) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
45686832|NCT05817383|Other|Placebo Powder|Participants will be asked to consume 48 grams of a nutritionally matched placebo powder (that does not contain fiber or anthocyanins) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
45354758|NCT00946491|Drug|Haldol 10 mg Tablets (McNeil Pharmaceuticals)|
45354759|NCT00776126|Device|Digital Breast Tomosynthesis Exam|Digital Breast Tomosynthesis Exam consisting of single view (MLO) of each breast will be performed.
45354760|NCT03336190|Behavioral|avatar-based training|Interaction with an avatar-based module to practice skills learned during the toolkit training
45354761|NCT00776204|Device|JACTAX Drug eluting stent|Jactax stent placed in coronary artery
45354762|NCT00776204|Device|JACTAX LD drug eluting stent|JACTAX LD stent placed in coronary artery
45686833|NCT05816915|Behavioral|Cognitive behavioral therapy|Subjects will receive professional lifestyle intervention conducted by STOB organization. Using CBT and the so-called third wave of CBT, especially mindfulness, the patients will be guided by certified experts to increase motivation and to change eating and exercise habits, which will be mapped before and after the intervention.
45843400|NCT01618422|Other|Directly Observed Therapy (DOTS) plus|The regimen used to treat MDR-TB comprises 5 to 6 drugs to which the organism is or likely to be susceptible for the initial 6 months, and then 3 to 4 drugs subsequently. In addition, TB cases with rifampicin resistance but not amounting to MDR-TB are also at risk of unfavourable treatment outcomes. The availability of pretreatment susceptibility test results will provide a guide in selection of drugs in treating such cases.
46046516|NCT03877458|Other|L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088|Taking 1 mix probiotics capsule at bed time everyday for three months.
46046517|NCT03877458|Other|L. reuteri GL-104|Taking 1 probiotic capsule at bed time everyday for three months.
46046518|NCT03877458|Other|Placebo|Taking 1 placebo capsule at bed time everyday for three months.
46046519|NCT03876678|Other|Lactobacillus Salivarius|Taking 1 probiotic capsule two times everyday for 7 days.
46046520|NCT03876678|Other|Bifidobacterium Animalis subspecies Lactis|Taking 1 probiotic capsule two times everyday for 7 days.
46046521|NCT03876678|Other|Placebo|Taking 1 placebo capsule two times everyday for 7 days.
46046522|NCT03871621|Drug|Diabetes Medicines|Anti-diabetic medications except SGLT2 inhibitors
46046523|NCT03871621|Drug|Dapagliflozin|Dapagliflozin tablet (10 mg)
45354763|NCT00776204|Device|Taxus Libertè|Taxus Libertè stent placed in coronary artery
45686834|NCT05816681|Drug|DWJ1230|Daewoong Pharmaceutical
45843401|NCT01618422|Other|Directly Observed Therapy (DOTS)|The DOTS strategy (current strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
45354764|NCT04011969|Diagnostic Test|Score assessment|Asia Pacific Colorectal Screening (APCS) is a validated tool to predict the risk of colorectal cancer in asymptomatic Asian population. The scoring system comprises of three categories: low risk (score 0-1), moderate risk (score 2-3) and high risk (score 4-7). Patients with moderate and high risk will undergo further examinations.
45477970|NCT05864872|Procedure|axillary brachial plexus block|conventional group, 3 to 6 mL of bupivacaine was infiltrated blindly subcutaneously at the same level of the axilla in the anteroposterior direction prior ultrasound group:1 and 2 mL of bupivacaine was injected around each visible nerve branch (Intercostobrachial and Medial Brachial Cutaneous ); if the nerve branches were not visible, 5 mL of the local anesthetic was injected in the subcutaneous area located above the brachial fascia, with a posterior direction, toward the latissimus dorsi muscle.
46046524|NCT03867188|Drug|Liposomal Bupivacaine|A 25 gauge or larger bore needle will be used to inject the liposomal bupivacaine at the site of operation following the prescription guidelines provided by Exparel®. The maximum dose allowable for this study is 266mg or 20 mL as indicated in the FDA package insert.
45477971|NCT05864859|Other|Simulation|In the simulation session, while 2 participants (1 midwife, 1 pregnant) performed the roles in accordance with the clinical scenario, the performance was recorded in the control room. A Wearable Pregnancy Simulator was worn by the student performing the pregnant role. During the simulation, the participants were able to interact with the facilitators when they had questions. The application time did not exceed 10 minutes.
45477972|NCT05864794|Diagnostic Test|MRI|MRI scan of the brain
45477973|NCT05864781|Behavioral|Jigsaw Technique|Jigsaw technique is one of the cooperative learning methods. A topic planned to be learned in the lesson is divided into sections and these sections are distributed to the students in the main group. Students who are responsible for the same sections in the groups combine to form expert groups and specialize by working on the subject. They then return to their main group to share their knowledge and make a presentation on the topic.
45477974|NCT05864768|Dietary Supplement|Vegan/vegetarian diet|"At baseline, following the compilation of a periodontal chart in which pocket probing depth (PPD) and FMPS and FMBS were recorded, patients with pathological probing depths >3mm associated with periodontitis were excluded. Healthy patients underwent a prophylaxis session and oral hygiene instructions with brushing and flossing. A mouthwash based on chlorhexifdine 0.20% to be used twice a day was prescribed.~At 15 days from the baseline (T0) the periodontal chart was compiled again and the parameters relating to PD, FMP, FMBS and the Eastman Interdental Bleeding Index (EIBI) were collected. Patients with FMBS and FMPS values >20% were excluded.~From time T0 all patients were asked to suspend the interdental hygiene maneuvers by interrupting the use of dental floss and abandoning the use of mouthwash. All patients were recalled weekly, for a total of 4 times (T1, T2, T3, T4) in which parameters related to FMBS, FMPS and EIBI were recorded."
45477975|NCT05864768|Dietary Supplement|Omnivorous diet|"At baseline, following the compilation of a periodontal chart in which pocket probing depth (PPD) and FMPS and FMBS were recorded, patients with pathological probing depths >3mm associated with periodontitis were excluded. Healthy patients underwent a prophylaxis session and oral hygiene instructions with brushing and flossing. A mouthwash based on chlorhexifdine 0.20% to be used twice a day was prescribed.~At 15 days from the baseline (T0) the periodontal chart was compiled again and the parameters relating to PD, FMP, FMBS and the Eastman Interdental Bleeding Index (EIBI) were collected. Patients with FMBS and FMPS values >20% were excluded.~From time T0 all patients were asked to suspend the interdental hygiene maneuvers by interrupting the use of dental floss and abandoning the use of mouthwash. All patients were recalled weekly, for a total of 4 times (T1, T2, T3, T4) in which parameters related to FMBS, FMPS and EIBI were recorded."
45477976|NCT05864742|Drug|Ibrutinib|560 mg daily continuously
45477977|NCT05864742|Drug|Venetoclax|Oral daily. Dose escalation every 7 days (if no TLS) 20mg, 50mg, 100mg, 200mg and 400mg
45686835|NCT05816681|Drug|DWB2001|Daewoong Bio
46046525|NCT03856879|Behavioral|Proactive E-consult|E-consult recommendations and orders will be developed by a panel of pulmonologists and will address a range of care elements for patients with COPD.
46046526|NCT03833141|Other|Survey Administration|Patient Reported Outcomes (PROs) of health, quality of life, and economic outcomes during routine clinical practice.
45354765|NCT04011969|Diagnostic Test|Blood sampling|"Blood samples will be taken before colonoscopy procedure to evaluate the level of serum CEA by ELISA method and to evaluate the presence of NF-ҡB by immunohistochemical method.~Carcinoembryonic antigen (CEA) is a well-known marker for colorectal cancer. A pre-treatment serum CEA level of ≥ 5 ng/mL is associated with poor prognosis in colorectal cancer patients.~NF-ҡB is a chronic inflammation marker found in colorectal cancer patients."
45354766|NCT04011969|Diagnostic Test|Fecal sampling|"Fecal samples will be taken before colonoscopy procedure to be tested for FIT and to evaluate the gut microbiome.~Fecal immunochemical test (FIT) is a recommended screening method for colorectal cancer. Detection of hemoglobin over a certain level in fecal samples indicated a positive FIT. Patients with positive FIT will undergo further examinations.~Gut microbiome examination will be conducted with next generation sequencing (NGS) method."
45843402|NCT01619982|Drug|Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride|Cefazolin 25 mg/kg/dose administered intravenously over 5 minutes within 60 minutes of surgical incision and then re-dosed (25 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery and Vancomycin 15 mg/kg (max 1.5 gram/dose) will be administered intravenously over 1-2 hours (after completion of cefazolin infusion) For patients younger than 1 month of age, a one-time repeat dose of 15 mg/kg can be given intraoperatively 12 hours after the beginning of the first vancomycin dose if the procedure is > 12 hours in duration. For patients equal to or older than 1 month, a one-time repeat dose of 15 mg/kg (max 1.5 grams) will be given intra-operatively 8 hours after the beginning of the first vancomycin dose if the procedure is > 8 hours in duration.
45354767|NCT05355610|Drug|Gentamicin|Intratympanic gentamicin and dexamethasone administered in two doses one week apart
45354768|NCT05355610|Drug|Dexamethasone|Intratympanic gentamicin and dexamethasone administered in two doses one week apart
45354769|NCT00552669|Drug|Oral sirolimus|Oral sirolimus given orally during 14 days plus bare metal stent implantation was compared with DES.Oral sirolimus was given as bolus of 10 mg started day before intervention followed by 3mg per day during 13 days after PCI. 180 mg of Diltiazem was added during oral administration of sirolimus .
45354770|NCT00552669|Device|Drug Eluting stent|Any Drug eluting stent
45354771|NCT02557568|Other|Staphylococcus aureus carriage|Staphylococcus aureus carriage is measured in the nose. Nasal samples were taken by the nursing staff of the ward using nylon flocked swab. Prior taking the sample, swabs were wetted using an additional tube containing a sponge impregnated with normal saline solution.
45354772|NCT00768170|Drug|MK0633|MK0633 (50 mg) Oral, single dose
45354773|NCT00943059|Drug|Acipimox|A capsula is given with 250mg Acipimox, 3dd; 1 after each meal. This will be done during 14 days.
45354774|NCT00943059|Drug|Cellulosum Mycrocryst|Capsule with cellulosum powder; this has to be taken 3 dd; 1 after each meal during 14 days.
45354775|NCT00943137|Drug|5-Fluorouracil|"Chemotherapy will be one of the following:~de Gramont: folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~FOLFIRI: Irinotecan 180mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~Modified FOLFOX-6: Oxaliplatin 85mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2."
45354776|NCT05547568|Procedure|Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy|
45354777|NCT00772616|Drug|Remifentanil|closed-loop administration using bispectral index as the single input for the controller.
45354778|NCT00772616|Drug|Sufentanil|dosage according to usual criteria
46046527|NCT03811743|Behavioral|Brenner FIT|Brenner FIT pediatric weight management program enrollment. an interdisciplinary, family-based pediatric weight management clinic based upon the Familial Approach to Treatment of Childhood Obesity. Patients are referred by a physician for obesity or overweight with a weight-related comorbidity. Treatment teams are comprised of a pediatrician, counselor, dietitian, and physical activity specialist, with others (e.g., social workers, physical therapists) as needed. The entire family is encouraged to attend all aspects of the treatment program, although only one attending caregiver is required.
45477978|NCT05864742|Drug|Navitoclax|Oral daily. Dose-escalation every 14 days (if plt >75x10^9/L) 50mg, 100mg, 150mg, and 200mg (target dose)
45477979|NCT05864742|Drug|Rituximab|375mg/m2, intravenous. To be given on day 1 of weeks 1, 2, 3, 4 of C1 and day 1 of C2-C8
45477980|NCT05864729|Diagnostic Test|Coronary angiography with physiological lesion assessment by fractional flow reserve (FFR) and contrast fractional flow reserve (cFFR).|Hemodynamic invasive study employing FFR (after intracoronary adenosine administration) and cFFR (after intracoronary lopamidol contrast media administration) measurements of hyperemic intravascular pressure.
45477981|NCT05864716|Biological|Colonscopic probiotics spray|20g of multi-strain probiotics powder via colonoscopic spray. The probiotic used in this study is SynPro-15G, which has 15 probiotics, including Bacillus coagulans BC1031, Bifidobacterium bifidum BB14, Bifidobacterium breve BR18, Bifidobacterium animalis subsp. lactis BAL06, Bifidobacterium longum (B. longum) BL986, Lactobacillus acidophilus LA1063, Lactobacillus casei LC122, Lactobacillus delbrueckii subsp. lactis LDL114, Lactobacillus fermentum LF26, Lactobacillus helveticus LH43, Lactobacillus paracasei LPC12, Lactobacillus plantarum LP198, Lactobacillus reuteri LR21, Lactobacillus rhamnosus LRH10, and Streptococcus thermophilus ST37 at a concentration of 2x1010 CFU/g (Synbiotech Corp., Kaohsiung, Taiwan). SynPro-15G is made either as a vial of powder (2x1011 CFU /vial) for colonoscopic spray or as a capsule (2x1010 CFU/capsule) for oral intake.
45477982|NCT05864677|Drug|Cerebrolysin|Patients, who will be randomized to group CER, will receive Cerebrolysin at the dose of 50 mL before surgery, followed by 50 mL on the morning of days 1,2,3, and 4.
45477983|NCT05864664|Procedure|Wide awake local anaesthesia no tourniquet technique|"Patient awake with no form of sedation or analgesia~A mixture of lidocaine, adrenaline, normal saline, bicarbonate is used to get 40-50ml solution~Injection is performed around incision site - superficial to deep including periosteum~Incision is performed in the normal fashion~Plate and screws are removed and incision is closed"
45354779|NCT05488678|Drug|VNRX-7145|single oral dose
45354780|NCT05488678|Drug|Ceftibuten|single oral dose
45354781|NCT00768326|Drug|Zicronapine|"Study Part A:~3mg; orally, film-coated tablets, once daily, 8 weeks"
45354782|NCT00768326|Drug|Zicronapine|"Study Part B:~5mg; orally, film-coated tablets, once daily, 8 weeks"
45477984|NCT05864612|Behavioral|Screening Questionnaires|Standard care screening questionnaires on anxiety and depression
45354783|NCT00768326|Drug|Zicronapine|"Study Part C:~7mg; orally, film-coated tablets, once daily, 8 weeks"
45354784|NCT00768326|Drug|Zicronapine|"Study Part D:~2 x 5mg; orally, film-coated tablets, once daily, 8 weeks"
45477985|NCT05864586|Behavioral|Vaping study EC A|Vaping two puffs using the study EC device
45686836|NCT05816512|Drug|Gold Nano particle from Pelargonium Graveolens Mouthwash|Gold Nano particle from Pelargonium Graveolens Mouthwash will be applied by using 15ml of it for one minute, two times daily for three weeks and then follow up after three weeks the clinical parameters as ( plaque index, gingival index and calculus index ) and microbiological aspect will be assessed .
45354785|NCT00768326|Drug|Zicronapine|"Study Part E:~2 x 7mg; orally, film-coated tablets, once daily, 8 weeks"
45354786|NCT00768326|Drug|Placebo|"Study Part A, B, C, D and E:~Placebo; orally, film-coated tablets, once daily, 8 weeks"
45354787|NCT00951717|Behavioral|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
45686837|NCT05816512|Drug|Chlorhexidine gluconate mouthwash .|Chlorhexidine gluconate mouthwash will be applied by using 15ml of it for one minute, two times daily for three weeks and then follow up after three weeks the clinical parameters as ( plaque index, gingival index and calculus index ) and microbiological aspect will be assessed .
45686838|NCT05816499|Drug|Cadonilimab|Given IV, 10mg/kg Q3W
45686839|NCT05816499|Drug|Anlotinib|oral，6mg/8mg/10mg qd 2W/3W
45686840|NCT05816499|Drug|Docetaxel|Given IV, 60-75mg/m2 Q3W
46046528|NCT03811743|Behavioral|By Design|Weight loss program for adults/caregivers of those enrolled in Brenner FIT. Participants in the By Design condition (adult caregivers) will be prescribed the Essentials lifestyle intervention which includes tailored dietary and physical activity goals designed to achieve 1-2 lbs./week of weight loss, provided by a multidisciplinary team of medical providers, dietitians, behaviorists, and exercise specialists. A daily calorie restriction of 500 kcal/day is prescribed based on estimates of total energy expenditure (TEE) obtained from a measured resting metabolic rate (RMR) prior to enrollment.
46046529|NCT03811743|Behavioral|Coordination|"This component adds four additional strategies: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. This innovative approach will seek to employ components of motivation and communication theories to increase self-monitoring, positive communication, problem solving, and social support to increase healthy physical activity and eating behaviors to increase the effectiveness of the weight loss programs beyond gains observed in matched controls.~Essentials (adults), with four additional components: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment"
45354788|NCT05406700|Drug|Niraparib|Oral, daily, dosage per protocol,4 Weeks
45354789|NCT05406700|Drug|Resection/Treatment with Niraparib|"The participants in both arms will resume/start on treatment with niraparib 2 -4 weeks after surgery.~Treatment can be held for an additional 28 days to allow for recovery from surgery, at the investigator's discretion. Participants will continue treatment for up to 12 total cycles of treatment or until tumor progression, unacceptable toxicity or withdrawal of consent."
45354790|NCT00768404|Drug|Topirmate and Phentermine|A single oral dose of the combination product VI-0521 (15 mg phentermine and 92 mg topiramate) will be administered with 240 mL of water at hour 0.
45354791|NCT05406622|Device|MOTIV Sirolimus-Eluting Bioresorbable Scaffold|Participants will receive the MOTIV device
45354792|NCT05406622|Device|Percutaneous Transluminal Angioplasty (PTA) Device|Participants will receive PTA treatment
45354793|NCT00776282|Drug|loratadine 10 mg orally disintegrating|
45354794|NCT00943293|Drug|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3.
45354795|NCT00943293|Drug|Melphalan|Melphalan 140 mg/m2 IV on day -2.
45354796|NCT00943293|Drug|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
45354797|NCT05385718|Other|Magnetic Resonance Imaging|Participants are required to undergo a non-invasive magnetic resonance imaging (MRI) scan approximately 30 minutes in length.
45354798|NCT00776360|Drug|oxytocin|80mIE/min as continuous infusion for 70 minutes
45354799|NCT00776360|Drug|oxytocin|80 mU/ min of oxytocin infusion for 70 min along with measuring the gastric emptying by ventricle scintigraphy
45354800|NCT00946725|Drug|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)|
45686841|NCT05816486|Diagnostic Test|Immunobiogram|This is not an interventional study. However the assay being tested on the blood samples of all enrolled participants is the Immunobiogram (IMBG). IMBG is an in vitro diagnostic immunoassay which can obtain dose-response curves that describe the inhibitory effect of each immunosuppressant on immune response cells (immunologically stimulated PBMCs) in kidney transplant patients.
45686842|NCT05816434|Behavioral|Sleep extension|>1 hour additional time in bed per night for 1 week.
45354801|NCT00946725|Drug|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)|
45354802|NCT03041740|Drug|Perfluorooctyl Bromide|Subjects in the PFOB group will receive PFOB partial liquid ventilation instilled via side port of endotracheal tube (2.5 mL/kg/day) across 10 treatment days.
45354803|NCT00772694|Drug|sorafenib|tablets 200mg, 400mg bid continuously in 4-week cycles
45354804|NCT00951873|Drug|activated recombinant human factor VII, long acting|Single injection of long acting activated recombinant human factor VII subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
45686843|NCT05816369|Other|Taste session of five ONS flavors|Patients will taste a small sample (30 mL) of five ONS flavors and report their taste experiences by completing questionnaires of each flavor during the taste session. Participants will also complete a malnutrition risk screening (MST), a three-day food diary, questionnaires of self-reported taste and smell changes (TSS), and quality of life (RAND-36).
45686844|NCT05818930|Diagnostic Test|REMI|Diagnostic monitoring
45843403|NCT01619982|Drug|Cefazolin 30 mg/kg body weight|"Intervention: Drug: Cefazolin pre-operative prophylaxis~Other Names:~Cefazolin: Brand Names Ancef, Kefzol~Cefazolin 30 mg/kg/dose administered intravenously over 10 minutes within 60 minutes of surgical incision and then re-dosed (30 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery."
45354805|NCT00951873|Drug|placebo|Single injection of long acting activated recombinant human factor VII placebo subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
45843404|NCT01620216|Other|Antitumor Drug Screening Assay|Undergo pre clinical kinase inhibitor activity screening
45843405|NCT01620216|Drug|Dasatinib|Given PO
45843406|NCT01620216|Drug|Idelalisib|Given PO
45354806|NCT00951873|Drug|activated recombinant human factor VII, long acting|Single dose of 0,1 mg/kg long acting activated recombinant human factor VII injected intravenously (into a vein).
45354807|NCT05366140|Other|Prospective follow-up of patients who have received instrumented lumbar arthrodesis supplemented the Implanet Jazz System(TM)|To assess the clinical outcomes of patients receiving standard of care Implanet Jazz System(TM) at the time of their instrumented lumbar arthrodesis.
45354808|NCT00776438|Biological|Inactivated, split-virion, influenza vaccine|0.1 mL, Intradermal
45354809|NCT00776438|Biological|Inactivated, split-virion, influenza vaccine|0.5 mL, Intramuscular
45354810|NCT00776438|Biological|Inactivated, split-virion influenza vaccine|0.1 mL, Intradermal
45354811|NCT00776438|Biological|Inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
45354812|NCT00943371|Drug|MK6349|Panel A: MK6349 in single doses beginning at 16 mg and rising to 90 mg in up to four treatment periods Panel B: MK6349 in single doses beginning at 90 mg and rising to 160 mg in up to four treatment periods Panel C: MK6349 in divided doses beginning at 20 mg q.a.c. (before each meal) and rising to 50 mg q.a.c. in up to four treatment periods
45686845|NCT05816343|Drug|Orlistat|Orlistat is an inhibitor of gastric and pancreatic lipases and can reduce dietary fat absorption by 30%. Orlistat at a dose of 2 capsules (each containing 60 mg of active drug) three times a day with each meal (a total dose of 360 mg daily).
45686846|NCT05816343|Drug|Placebo|Placebo at a dose of 2 capsules (each containing 60 mg placebo) three times a day with each meal (a total dose of 360 mg daily).
45843407|NCT01620216|Other|Laboratory Biomarker Analysis|Correlative studies
45843408|NCT01620216|Drug|Pacritinib|Given PO
45843409|NCT01620216|Other|Pharmacological Study|Correlative studies
45686847|NCT05816317|Behavioral|Single-Session Mechanism-Focused Intervention (SSMFI)|A brief intervention for patients hospitalized for suicide risk that directly targets hopelessness and perceptions of social relatedness.
45686848|NCT05816317|Behavioral|Distress Tolerance Skills Review|Treatment as usual at the inpatient setting for this study.
45843410|NCT01620216|Drug|Ponatinib|Given PO
45843411|NCT01620216|Drug|Ponatinib Hydrochloride|Given PO
45843412|NCT01620216|Drug|Ruxolitinib|Given PO
45843413|NCT01620216|Drug|Sorafenib|Given PO
45843414|NCT01620216|Drug|Sorafenib Tosylate|Given PO
45843415|NCT01620216|Drug|Sunitinib|Given PO
45843416|NCT01620216|Drug|Sunitinib Malate|Given PO
45843417|NCT01621230|Drug|Epidural Bupivacaine plus fentanyl|The subjects will receive 0.125% bupivacaine with fentanyl 2 mcg/mL at a rate of 10 mL/hr.
45843418|NCT01621230|Drug|Epidural fentanyl|The subjects will receive epidural fentanyl 10 mcg/mL with the rate of 10mL/hr.
45843419|NCT01621776|Drug|Apidra|Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
45843420|NCT01621776|Drug|Humalog|Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
45843421|NCT01621776|Drug|Novolog|Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
45843422|NCT01622010|Behavioral|Allied Health Education Class Option|An Allied Health Education Class is provided as part of standard care on an optional basis. It involves a one time attendance at a 90 minute class which provides basic education from a multidisciplinary team.
45354813|NCT00943371|Drug|Comparator: Placebo to MK6349|Panel A: Placebo to MK6349 in single doses in up to four treatment periods Panel B: Placebo to MK6349 in single doses in up to four treatment periods Panel C: MK6349 in divided doses q.a.c. (before each meal) in up to four treatment periods
45354814|NCT05352646|Drug|Autologous memory lymphocyte Injection (NewishT), low-dose group|Recruited participants in low-dose group will receive autologous memory lymphocyte (NewishT) intravenous infusion every 4 weeks, a total of 2 times.
45354815|NCT05352646|Drug|Autologous memory lymphocyte Injection (NewishT), high-dose group|Recruited participants in high-dose group will receive autologous memory lymphocyte (NewishT) intravenous infusion every 2 weeks, a total of 4 times.
45354816|NCT00552513|Procedure|Early Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) as soon as possible (and within 24 hours of randomisation).
45354817|NCT00552513|Procedure|Delayed Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) any time after 36 hours after randomisation.
45354818|NCT00946803|Behavioral|Patient-Controlled Cognitive-Behavioral Intervention|Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player to be used at least once per day or more frequently, as needed for pain, fatigue, and sleep disturbance.
45354819|NCT00943449|Drug|4SC-201|oral administration
45686849|NCT05816291|Dietary Supplement|Time to Exhaustion at velocity at VO2max|During a familiarization trial prior to supplementation and before and after each supplementation period at the beginning of each study visit, participants will complete a standardized warm-up consisting of walking on a treadmill for 5 minutes, a series of whole-body dynamic movements (high knees, butt kicks, walking lunges, straight-leg marching, etc.), and a self-prescribed period of jogging on the treadmill for no more than ten minutes. The speed on the treadmill will then be set at the velocity upon which 100% VO2Peak was achieved. Participants will be instructed to run at this velocity for as long as they can. No feedback in terms of duration, pacing, etc. will be provided, and participants will be provided verbal encouragement to run for as long as possible.
45686850|NCT05816265|Drug|IV Iron Infusion Group|Subjects will receive IV Iron Infusion. Dosage of iron will be at discretion of physicians
45354820|NCT00943449|Drug|Sorafenib|oral administration
45354821|NCT00952029|Biological|bevacizumab|
45354822|NCT00952029|Drug|FOLFIRI regimen|
45354823|NCT00952029|Drug|fluorouracil|
45354824|NCT00952029|Drug|irinotecan hydrochloride|
45686851|NCT05816239|Procedure|Dual Energy CT|Patient will receive Dual Energy CT
45686852|NCT05816226|Drug|Hydrocortisone 2.5%|Applied four times daily to TMJ with arthralgia
45354825|NCT00952029|Drug|leucovorin calcium|
45843423|NCT01622010|Other|Physiotherapy treatment intervention on referral|The option exists for referral to physiotherapy, according to standard protocol, for assessment and individual exercise prescription.
46046530|NCT03808337|Radiation|Stereotactic Body Radiotherapy/SBRT|Radiation to each metastatic site should be delivered to a minimum dose of 30 Gy in 5 fractions (BED of 48 Gy10). The exact dose of radiotherapy will be determined by the treating radiation oncologist. Preferred regimens for lung metastases include 50 Gy in five fractions, 48 Gy in four fractions, or 54 Gy in three fractions, although lower doses may be employed to respect dose limits to critical structures such as the esophagus. Recommended SBRT dosing for other sites includes 27 to 30 Gy in three fractions or 24 Gy in one fraction for bone metastases.
45354826|NCT00560313|Biological|Men ACWY CRM|A single dose of a 0.5 mL injectable solution
45354827|NCT00560313|Biological|4CMenB|All subjects received the study vaccine following a 0,2,6 vaccination schedule. Pre-filled syringe, administered by intramuscular injection into the deltoid area of the non dominant arm.
45354828|NCT00667862|Drug|Panobinostat|
45354829|NCT00952107|Device|FLARE imaging system|Testing of operation of imaging system
45354830|NCT00952185|Other|cytology specimen collection procedure|
45354831|NCT00952185|Other|fluorescent antibody technique|
45354832|NCT00952185|Procedure|assessment of therapy complications|
45354833|NCT00776516|Drug|mirabegron|oral
45686853|NCT05816226|Drug|Diclofenac 1% topical|Applied four times daily to TMJ with arthralgia
45354834|NCT00776516|Drug|rifampin|oral
45354835|NCT00946959|Procedure|Cardiac surgery|A study-certified cardiothoracic surgeon must deem a patient, who otherwise fulfills all inclusion and exclusion criteria for any cardiac surgery (conventional, off-pump cardiac surgery). The procedure must be performed as soon as possible.
45354836|NCT00768638|Drug|Atorvastatin|Atorvastatin 10mg 1co id (10mg active) Placebo 40mg 1co id (40mg inactive)
45354837|NCT00768638|Drug|Atorvastatin|Atorvastatin 40mg 1co id (40mg active) Placebo 10mg 1co id (10mg inactive)
45354838|NCT00952263|Biological|MBL-HCV1|Single infusion of MBL-HCV1 at escalating doses as determined by cohort assignment: Cohort 1 @ 1 mg/kg, Cohort 2 @ 3 mg/kg, Cohort 3 @ 10 mg/kg, Cohort 4 @ 30 mg/kg, Cohort 5 @ 50 mg/kg.
45354839|NCT02557958|Drug|Azithromycin|We hypothesize that in patients with COPD, treatment with azithromycin will show reduced inflammatory markers, transcription factors changes, and lung function changes consistent with reduced inflammation.
45354840|NCT02557958|Drug|Placebo|We hypothesize that in patients with COPD, treatment with placebo will show NO change in inflammatory markers, transcription factor changes and lung function from baseline.
45354841|NCT00776672|Drug|Fosinopril 40mg Tablets|
45354842|NCT00535132|Drug|Oral Risperidone|4 or 6 mg MG once daily for 0-2 weeks
45354843|NCT00535132|Drug|Paliperidone ER|6, 9 or 12 MG once daily for 4-6 weeks
45354844|NCT00570908|Drug|sunitinib|Sutent
45354845|NCT00570908|Drug|capecitabine|concurrently
45354846|NCT00570908|Radiation|WBRT|Whole Brain Radiotherapy 30 Gy in 10 fractions
45354847|NCT00773084|Drug|Aliskiren plus spironolactone vs. Lisinopril plus spironolactone|Subjects will be in the study for a total of 8 weeks. Subjects with stable diastolic HF on current ACEI therapy will be randomized into two treatment groups. The study group will receive Aliskiren plus spironolactone and the control group will receive Lisinopril plus spironolactone. These 2 groups will be further divided according to ethnicity: Mexican Americans and non-Hispanic whites. Sixty patients will be recruited, 30 per treatment group. Subjects will have a 2 week wash-out period. At the end of this period, blood will be collected and subjects will be asked to take the assigned medication once daily for 6 weeks. Subjects will be asked to return every 2 weeks at which time blood pressure, serum potassium and creatinine levels will be assessed. Their medications will be titrated depending on clinical tolerance and symptom control. At the end of 6 weeks of treatment blood markers will be drawn and differences will be analyzed.
45354848|NCT00321919|Drug|epoetin beta [NeoRecormon]|Participants in the early treatment group immediately started epoetin beta treatment to reach a target Hb level of 13-15 g/dL at the end of the correction phase.
45354849|NCT00321919|Drug|epoetin beta [NeoRecormon]|Participants in the late treatment Group started epoetin beta treatment once a decline in Hb level to <10.5 g/dL had occurred.
45354850|NCT00781391|Drug|warfarin tablets|Warfarin tablets plus Edoxaban placebo tablets each taken once daily for 24 months
45686854|NCT05816213|Device|Portable low-field MRI|"Three FDA-approved low-field (LF) portable MRI commercialized by Hyperfine Research Inc. (www.hyperfine.io) will be employed. Patients will undergo LF-MRI in the CT suite during the downtime of preparation which usually occurs after urgent imaging in the CT suite (mean time, as calculated basing on the current door to imaging time: ~20-25 minutes), thus not delaying the conventional diagnostic processes and treatment administration. LF-MRI will be also repeated by the study staff at predefined time-points: 24 h, 72 h, at the discharge and 4 weeks after the event.~A prespecified acquisition of Fast-Spin Echo (Fast-SE) essential stroke sequences will be performed, starting with diffusion weighted imaging (DWI) + apparent diffusion coefficient (ADC) mapping and fluid attenuated inversion recovery (FLAIR)."
46046531|NCT03808337|Drug|Systemic Therapy/Standard of Care|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist. For patients randomized to receive SBRT, systemic therapy can be continued during SBRT at the discretion and concensus of treating physicians (medical oncologist and radiation oncologist). If the treating physicians recommend discontinuing systemic therapy during SBRT, general guidelines for stopping and reinitiating systemic regimen are as follows: Hormonal therapies and immunotherapy can be continued during SBRT. Consideration can be given to holding cytotoxic chemotherapy beginning 3 to 7 days prior to the initiation of SBRT until 3 to 7 days after the completion of SBRT. Similarly, consideration can be given to holding biologic agents during SBRT and for 0 to 3 days before and after.
45843424|NCT01622010|Device|Keeping the Beat with Physiotherapy: Heart Failure edition|Educational DVD covering the basics of physiotherapy education for the patient with heart failure.
45354851|NCT00781391|Drug|Edoxaban tablets (high dose regimen-60mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
45354852|NCT00781391|Drug|Edoxaban tablets (low dose regimen-30mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
45354853|NCT00781391|Drug|placebo warfarin|placebo warfarin
45354854|NCT00781391|Drug|placebo edoxaban|placebo edoxaban
45354855|NCT00776750|Biological|trivalent split influenza vaccine|standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection
45354856|NCT00534976|Drug|Comparator: montelukast sodium|"Patients 4-5 years: 4 mg Montelukast chewable tablet daily~Patients 6-14 years: 5 mg chewable tablet daily"
45354857|NCT00534976|Drug|Comparator: Comparator: placebo (unspecified)|"Patients 4-5 years: 4 mg Pbo chewable tablet daily~Patients 6-14 years: 5 mg Pbo chewable tablet daily"
45354858|NCT00768794|Dietary Supplement|Acidophilus|"Use of Acidophilus in the first part of the study, two participants will begin radiation therapy. When signs and symptoms of thrush are noted, such as smooth, creamy, white/yellow coating and/or patches on the tongue and inside of their mouth that are painful, subjects will begin taking acidophilus capsules twice each day until the last day of radiation therapy.~The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region."
45354859|NCT00768794|Dietary Supplement|Acidolphilus|The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region.
45477986|NCT05864586|Behavioral|Vaping study EC B|Vaping two puffs using the study EC device
45354860|NCT00773162|Drug|Seroquel|seroquel XR- oral extended release tablets, 50mg - 300mg, 16 weeks
45354861|NCT00773162|Drug|Sugar Pill|Sugar pill to match seroquel
45354862|NCT00768950|Procedure|Capsule endoscopy examination|Examination of the small bowel with endoscopic videocapsule
45354863|NCT00768950|Procedure|Colonoscopy|Endoscopic examination of the large bowel and terminal ileum
45354864|NCT00769028|Drug|Hyperimmune caprine serum|Subcutaneous injection of serum, 1ml twice weekly for 6 months
45354865|NCT00769028|Drug|Albumin|Subcutaneous injection of albumin, 1ml twice weekly for 6 months
45354866|NCT00321763|Biological|Candidate Influenza Vaccine GSK1247446A - 3 different formulations|Single dose, Intramuscular injection
45477987|NCT05864586|Behavioral|Vaping study EC C|Vaping two puffs using the study EC device
45477988|NCT05864586|Behavioral|Vaping study EC D|Vaping two puffs using the study EC device
45477989|NCT05864586|Behavioral|Vaping study EC E|Vaping two puffs using the study EC device
45843425|NCT01624350|Device|Permacol collagen paste|Collagen paste intended to reinforce soft tissue where filling is required such as to repair fistulas, including anal and rectal fistulas.
45354867|NCT00321763|Biological|Fluarix TM|Single dose, Intramuscular injection
45354868|NCT02822716|Procedure|IRE treatment|The treatment procedure is carried out percutaneously under ultrasound or CT guidance, or using laparoscopic or laparotomy approach when the lesion is close to hollow viscera or abdominal wall, with the patient under general anaesthesia. Insulated needle electrodes, will be placed in the treatment areas under ultrasound or CT guidance. The tumor lesion is identified, measured, and located by ultrasound or CT. Electrical current is administered in pulses with electrocardiographic synchronization to reduce the risk of cardiac arrhythmia.
45354869|NCT02822716|Device|Ultrasound|
45354870|NCT00776828|Drug|cilostazol|Pletaal (Otsuka Pharm.) 100mg bid for six months
45477990|NCT05864586|Behavioral|Vaping study EC F|Vaping two puffs using the study EC device
45477991|NCT05864586|Behavioral|Vaping study EC G|Vaping two puffs using the study EC device
45477992|NCT05864586|Behavioral|Vaping study EC H|Vaping two puffs using the study EC device
45477993|NCT05864586|Behavioral|Vaping study EC I|Vaping two puffs using the study EC device
45477994|NCT05864586|Behavioral|Vaping study EC J|Vaping two puffs using the study EC device
45477995|NCT05864573|Biological|ZGGS15|ZGGS15 for dose escalations are set as 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg, intravenous infusion, once every 3 weeks.
45477996|NCT05864560|Device|Ankura™ AAA Stent Graft System; Ankura™ Cuff Stent Graft System; Ankura™ AUI Stent Graft System|Patients will be implanted with Ankura™ AAA, Cuff or AUI Stent Graft System in accordance with the Instructions for Use (IFU).
45477997|NCT05864521|Dietary Supplement|Active Beetroot Juice Supplement (aBRJ)|aBRJ will consist of 70ml concentrated beetroot juice with 6.45-7.26mmol inorganic nitrate (range for inter-batch variability) taken orally.
45843426|NCT01624740|Device|Low Rate Stimulation|Stimulation was given at a rate of 2 Hz.
45843427|NCT01624740|Device|High Rate Stimulation|Stimulation was given at a rate of 1200 Hz.
45843428|NCT01627002|Biological|PA401|Part A of Study: Subcutaneous, 0.1mg to 50mg, single ascending doses Part B of Study: Subcutaneous, up to 17.1mg, single dose
45843429|NCT01627002|Other|Placebo|Subcutaneous
45354871|NCT04002466|Other|Risk factors for anemia|Diet, iron, vitamin B12, folate, inflammation, soil transmitted helminth infection, malaria, other morbidities and other health/nutrition/sociodemographic factors
45354872|NCT00776906|Device|Advance® 18PTX® Balloon Catheter|
45354873|NCT00776906|Device|Advance® 18LP Balloon Catheter|
45354874|NCT00773240|Drug|Grazax|1 tablet, 75,000 SQ-T, daily during the trial period
45354875|NCT00773240|Drug|placebo|1 placebo tablet, matching the active treatment, daily during the trial period
46046532|NCT03805451|Behavioral|Life Steps for PrEP for Youth|Life-Steps is a modular adherence intervention based on principles of cognitive-behavioral therapy (CBT), that allows for recipients of the intervention to focus on the greatest challenges that they perceive in maintaining optimal adherence to pre-exposure prophylaxis.
46046533|NCT03796884|Drug|Linaclotide|Given PO
46046534|NCT03796884|Other|Placebo|Given PO
46046535|NCT03773146|Other|1X Airtime Incentive|An incentive given in the form of airtime
46046536|NCT03773146|Other|Lottery Airtime Incentive|An incentive given in the form of airtime
45477998|NCT05864521|Dietary Supplement|Placebo Beetroot Juice Supplement (pBRJ)|pBRJ will consist of 70ml concentrated beetroot juice and will be chemically devoid of inorganic nitrate taken orally.
45354876|NCT01063933|Drug|Peramivir|Peramivir is a liquid for parenteral administration. Cohort I: Peramivir, 10 mg/kg intravenously (IV) every day (QD) (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort II: Peramivir 12 mg/kg IV QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort III: Peramivir 16 mg/kg QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Proposed doses for subjects in Cohorts IV, V, VI, and VII are 18, 18, 14 and 12 mg/kg, respectively, IV, QD for 5 days or until hospital discharge, whichever comes first. IV peramivir will be administered over 60 minutes.
45354877|NCT02556866|Drug|rituximab|Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
45354878|NCT02556866|Drug|Prednisone|
45354879|NCT02556866|Drug|Placebo|
45477999|NCT05864508|Drug|Oxytocin nasal spray|intranasal oxytocin treatment once a day during 6 weeks
45478000|NCT05864482|Other|Psychosocial nursing intervention|The sessions were planned to be at least 45 minutes in a time suitable for the groups, with the bed curtains drawn if possible. Session 1: The purpose of this session; Brief CIS information will be provided. Session 2: The session starts with mood control of individuals. It is discussed whether they have experienced an event that occupies their minds and is likely to affect their illness. Session 3: It starts with mood control of individuals. They are asked if there is anything from the places where the guests are. Cognitive reviews are reviewed. It aims to describe recent stressful observations, negative automatic outcome descriptions, and evaluation of such experiences. 4.Session: The session starts with the mood control of the patient. It is discussed whether the patient has experienced an event that occupies his mind. Continuous analysis of negative thoughts and review of cognitive techniques and coping mechanisms are provided.
45478001|NCT05864443|Procedure|Severe complications following emergency surgery|The respondents are limited to surgeons who had previously experienced severe complications following emergency surgery as chief surgeons.
45354880|NCT01064011|Procedure|Rt-PA thrombolysis|patients will be administered a total of six doses of rt-PA (each 1 mg/ml) through the external ventricular drain every eight hours.
45354881|NCT01064011|Procedure|endoscopic hematoma evacuation|In the operating room under general anesthesia, the external ventricular drain will be removed and the burr hole enlarged to allow for entry of the endoscope. The neuroscope will be introduced through the burr hole down the prior external ventricular drain tract into the ipsilateral ventricle. utilizing a standard technique combining gentle aspiration, continuous irrigation, and grasping forceps,the intraventricular hematoma will be evacuated. After the evacuation the endoscope will be removed and an external ventricular drain will be reattached to a closed system and permitted to drain post-operatively.
45354882|NCT00769106|Biological|cytokine-induced killer cell (CIK) treatment|cytokine-induced killer cell treatment every two weeks, for 4 cycles
45354883|NCT01064089|Drug|HSP990|
45354884|NCT00773318|Procedure|SPECT/CT guided LM/SL|Detection, localization, and removal of sentinel lymph node (s) from prostate cancer guided by an integrated SPECT/low-dose multislice CT
45354885|NCT03946306|Drug|5,25% NaOCl with syringe needle irrigation alone|In group 1 (control group), a final irrigation will be made with 1.5 ml of NaOCl per canal, during 30 seconds in an up-and-down motion, with the needle 1 mm short of the working length, without binding. After this, a 30 seconds pause will be done. This step will be repeated once again.
46046537|NCT03758508|Device|High Flow Oxygen nasal cannula|High Flow Oxygen nasal cannula
45686855|NCT05816200|Device|Low-Level Light Therapy|Punctual applications of infrared laser (L2) (power of 100mW, 808 nm, 6 joules of energy/60 seconds) in the affected region, keeping one centimeter of distance between the points, until the entire area of the complaint was irradiated. being held one session per week, totaling eight weeks of treatment at the end of the study.
45686856|NCT05816200|Device|Transcutaneous Electric Nerve Stimulation|Using a device at a frequency of 50 Hertz with intensity modulated according to the patient's comfort ranging from 1 - 4 (pulse amplitude) with a duration of 25 minutes per session, with one session per week, totaling eight weeks of treatment at the end of the study. The device's self-adhesive electrodes were fixed on the participant's face, following the path of the trigeminal nerve branch on the side affected by pain and/or burning.
45686857|NCT05816161|Diagnostic Test|Integrated Neuromuscular Inhibition Technique|Exercises
45354886|NCT03946306|Device|EDDY|In group 2, a final irrigation will be made with 1.5 ml of NaOCl per canal and the irrigant will be activated using EDDY tips, 1 mm short of the working length without binding. The activation will be performed during 30 seconds, followed by a 30 seconds pause, and the cycle will be repeated once again, according to manufacture instructions.
45354887|NCT05184452|Drug|PGDM1400LS (5mg/kg, IV)|5 mg/kg to be administered via IV infusion
45354888|NCT05184452|Drug|PGDM1400LS (20mg/kg, IV)|20 mg/kg to be administered via IV infusion
45354889|NCT05184452|Drug|PGDM1400LS (20mg/kg, SC)|20 mg/kg to be administered via SC infusion
45354890|NCT05184452|Drug|PGDM1400LS (40mg/kg, IV)|40 mg/kg to be administered via IV infusion
45686858|NCT05816161|Diagnostic Test|Myofascial Release|Exercises
46046538|NCT03758508|Device|Noninvasive ventilation|In this arm, participants receive noninvasive ventilation through an interface (such as full face mask or oro-nasal mask) alternated with continuous high flow oxygen though humidified nasal cannula
46046539|NCT03753074|Drug|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg, Tablet, Oral, Daily
45354891|NCT05184452|Drug|PGDM1400LS (40mg/kg, SC)|40 mg/kg to be administered via SC infusion
45478002|NCT05864430|Other|Face-to-face Training Group|The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.
45478003|NCT05864430|Other|DataMatrix supported Face-to-face training group|Students will follow the lesson with the QR code given simultaneously with the training given during the education process. The training will be held in such a way that the students will be given the opportunity to ask questions and will end with 10 minutes of time to be given to the questions of the students.
45478004|NCT05864430|Other|Online training group|The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.
45478005|NCT05864417|Other|Sunscreen Color tone 2.0|Participants will topically apply sunscreen color tone 2.0.
45478006|NCT05864417|Other|Sunscreen Color tone 3.0|Participants will topically apply sunscreen color tone 3.0.
45478007|NCT05864365|Drug|ATH434|ATH434 taken by mouth two times per day
45354892|NCT05184452|Drug|PGDM1400LS (1.4g, IV)|1.4gram to be administered via IV infusion
45478008|NCT05864339|Behavioral|A designed empathy intervention|Students watch 4 smokers' videos, read the textual materials, fill out the HEMs and discuss a quit counseling plan for an assigned smoker using the 5As counseling skilll.
45478009|NCT05864339|Behavioral|Smoking cessation counseling tutorial|Students watch 4 smokers' videos, read the textual materials, and discuss a quit counseling plan for an assigned smoker using the 5As counseling skill.
45478010|NCT05864313|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|10 Hz rTMS for 5 seconds over the frontal eye fields with 25 second intertrain interval for 10 trains (500 pulses) at 90% of the resting motor threshold,
45478011|NCT05864313|Behavioral|Gait training|Subjects will practice stepping on virtual targets with real-time feedback of their foot position displayed on a screen while walking on a treadmill.
45478012|NCT05864313|Behavioral|Gaze training|Subjects will perform gaze stabilization and gaze shifting exercise via a virtual reality headset.
45478013|NCT05864313|Device|Sham rTMS|Sham rTMS stimulation will produce discharge noise and vibration without stimulating the cerebral cortex.
45478014|NCT05864300|Behavioral|Neurocheck frequency|Randomized to hourly or every-other-hour examinations
45498264|NCT03736213|Behavioral|Ultrasound biofeedback|In ultrasound biofeedback, the elements of traditional articulatory treatment are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
45686859|NCT05816148|Other|Questionnaire survey|On leisure physical activity, barriers to physical activity and quality of life.
45354893|NCT05184452|Drug|PGDM1400LS (1.4g, SC)|1.4gram to be administered via SC infusion
45686860|NCT05816122|Device|MSCopilot® mobile application|MSCopilot® includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to fatigue and Multiple Sclerosis quality of life
45843430|NCT01628016|Behavioral|a word dot-probe task for training procedure|In the word dot-probe task for training procedure of attention bias modification, 90% of the targets appeared at the neutral word position and 10% at the sad word position.In the placebo condition, the targets appeared with equal probability in the sad (50%) and neutral (50%) word positions.All participants in ABM and placebo conditions received eight 12-min training sessions over a 2-week period.During each session, participants completed 216 word dot-probe trials.
46046540|NCT03752411|Other|Research Bottle|The purpose of the study is to test a research prescription bottle that will monitor the physical environment inside the bottle.
46046541|NCT03752411|Other|Regular prescription Bottle|This will test if the research bottle changes behavior relative to the research bottle
46046542|NCT03745040|Drug|Liposomal bupivacaine|20ml bupivacaine liposome injectable suspension 1.3% (266mg) + 50ml 0.25% Bupivacaine (150mg) + 70ml preservative-free 0.9% neutral saline
46046543|NCT03740737|Drug|Follitropin delta|"FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 12 µg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 µg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 µg, and the maximum daily dose was 24 µg.~Subjects could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed."
45354894|NCT05184452|Drug|VRC07-523LS (20mg/kg, IV)|VRC07-523LS 20mg/kg administered via IV infusion
45354895|NCT05184452|Drug|VRC07-523LS (20mg/kg, SC)|VRC07-523LS 20mg/kg administered via SC infusion
45354896|NCT05184452|Drug|VRC07-523LS (1.4g, IV)|VRC07-523LS 1.4g administered via IV infusion
45354897|NCT05184452|Drug|VRC07-523LS (1.4g, SC)|VRC07-523LS 1.4g administered via SC infusion
45354898|NCT05184452|Drug|VRC07-523LS (40mg/kg, IV)|VRC07-523LS 40mg/kg administered via IV infusion
45354899|NCT05184452|Drug|PGT121.414.LS (20mg/kg, IV)|PGT121.414.LS 20mg/kg administered via IV infusion
45354900|NCT05184452|Drug|PGT121.414.LS (20mg/kg, SC)|PGT121.414.LS 20mg/kg administered via SC infusion
45354901|NCT05184452|Drug|PGT121.414.LS (1.4g, IV)|PGT121.414.LS 1.4g administered via IV infusion
45354902|NCT05184452|Drug|PGT121.414.LS (1.4g, SC)|PGT121.414.LS 1.4g administered via SC infusion
45354903|NCT05184452|Drug|PGT121.414.LS (40mg/kg, IV)|PGT121.414.LS 40mg/kg administered via IV infusion
46046544|NCT03740737|Other|Placebo|Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049. Subjects could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed.
46046545|NCT03704532|Procedure|Operative treatment|Open surgical repair of tendon rupture
45354904|NCT05356624|Other|Mulligan Mobilization|It is technique in which passive mobilization is applied by therapist to improve the normal position and by holding the passive glide active movement in restricted direction of motion to reduce pain or improve range of motion or function. A total of 3 sets of 10 repetition three times a week on alternate days for 6 week
45478015|NCT05864287|Behavioral|Bodies in motion intervention program|Intervention groups will be offered separately to male- and female-identifying athletes; each group will consist of six to eight athletes and multiple groups may be run each academic term. Facilitators will use the gender-specific programs in their delivery. Intervention athletes will receive a participant workbook as well as be invited to join a BIM-specific, private social media platform that will allow them to share, connect, and support each other through out their involvement in the program. As part of our mixed-methods design, we will also conduct qualitative interviews to explore the student athletes' experiences of the BIM program. Following intervention, we will invite 12-16 male and 12-16 female identifying athletes who completed the BIM program to participate in the structured interviews. Interviews will be semi-structured and are expected to last 60-90 minutes
45478016|NCT05864274|Behavioral|Cognitive training application|Patients will participate with a cognitive training application and undergo neurocognitive testing during and after chemotherapy.
45478017|NCT05864261|Drug|JT1801 60ug|JT1801, 60ug, IV injection
45478018|NCT05864261|Drug|NESP 60ug|NESP, 60ug, IV injection
45354905|NCT05356624|Other|Soft Tissue Mobilization|in this technique for joint the passive glides are applied, for CMC joint mobilization patient hand is rest on table. The therapist grasp trapezium with one hand and 1st metacarpal between index and thumb of other hand to apply glide. A total of 3 sets of 10 repetition three times a week on alternate days for 6 weeks.
45354906|NCT00308113|Drug|Prednisone|Prednisone 0/75 mg/kg/day.
45478019|NCT05864248|Device|Supira System|The Supira System is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
45478020|NCT05864235|Behavioral|Control|Each week for 6-weeks, control group participants will receive the following weekly text message assessments (without receiving any feedback or support): (1) Thursdays (3pm): weekend plans to drink and desire to get drunk; (2) Sundays (12pm): most drinks consumed on any weekend day and peer pressure to drink.
45478021|NCT05864235|Behavioral|Goal Support (GS)|Each week for 6-weeks, GS group participants will receive prompts and tailored feedback and support focused on weekly drinking limit goal commitment & confidence assessments and subsequently receive tailored feedback on goal success to either bolster future goal striving or reframe goal failure.
45478022|NCT05864235|Behavioral|Coaching for Context-specific Peer Support (CCPS)|Each week for 6-weeks, CCPS group participants will receive weekly motivation and strategies to enlist peer support during drinking episodes.
46046546|NCT03704532|Procedure|Nonoperative treatment|Nonoperative treatment with lower leg orthosis and functional rehabilitation
45478023|NCT05864222|Other|Aromatherapy|Elequil Aroma-Tabs are available on all clinical nursing units for staff. Instructions will be provided to participants to place the aroma tab on the back of their badge every workday for the entire duration of their shift. They will wear their badge in whatever position is most comfortable to them for the duration of the study (6 months).
45478024|NCT05864209|Other|Phthalate- and Bisphenol-free Baby Products|3-month supply. Products include wipes and diaper cream.
45478025|NCT05864209|Other|Cloth Diapers|Subscription to cloth diaper service.
45478026|NCT05864209|Other|Conventional Disposable Diapers|3-month supply.
45354907|NCT00308113|Dietary Supplement|Coenzyme Q10|serum levels of greater or equal to 2.5 micrograms/mL.
45354908|NCT03903640|Device|Optune|-Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS.
45354909|NCT03903640|Biological|Nivolumab|-Standard of care
45354910|NCT03903640|Biological|Ipilimumab|-Standard of care
45478027|NCT05864209|Other|Conventional Baby Products|Products include wipes and diaper cream.
45478028|NCT05864196|Radiation|Two-Fraction Stereotactic Body Radiation Therapy (SBRT)|Two-fraction SBRT with an MRI directed, dominant intraprostatic lesion, simultaneous integrated boost (SIB) based on genomic classification in the treatment of localized prostate cancer.
45478029|NCT05864183|Diagnostic Test|HbA1c|HbA1c will be measured for all patients to minimize the risk of developing diabetes or its complications .
45354911|NCT05157386|Other|Braining|Core components of Braining: Personnel-led training sessions, motivating contact with psychiatric staff, measurement and evaluation before and after the training period; usually 12 weeks. PE is added on to treatment as usual (TAU). The training sessions are moderate to intense aerobic group training, 30-45 minutes. Each training session is preceded by a short (5-10 minutes) individual meeting with staff including assessment of daily form, motivational work, and the opportunity to ask questions. The target frequency for participation is preferably at least three training sessions/week during a 12 week period. The training period for each patient begins with an informative and motivating group or individual lecture or and an individual introductory meeting with staff including psychiatric and somatic examination, self-assessment scales for symptoms and quality of life, and blood samples. The training period ends with a meeting with staff with follow-up on the parameters.
45354912|NCT03982849|Drug|Hydroquinone 4% Cream|Hydroquinone is tyrosinase inhibitor and thus inhibits melanogenesis.
45354913|NCT03982849|Drug|silymarin 0.7% cream|Silymarin is a plant derived flavonoid, extracted from fruits and seeds of milk thistle.
45354914|NCT05154344|Drug|Capmatinib|Available through expanded access
45478030|NCT05864183|Diagnostic Test|lipid profile|lipid profile will be measured for all patients to minimize the risk of developing diabetes or its complications .
45478031|NCT05864183|Diagnostic Test|CBC|CBC will be measured for all patients to minimize the risk of developing diabetes or its complications
45354915|NCT05357872|Device|deep anesthesia depth|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
45354916|NCT05357872|Device|light anesthesia depth|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
45478032|NCT05864183|Diagnostic Test|Alb/cr ratio|Alb/cr will be measured for all patients to minimize the risk of developing diabetes or its complications
45478033|NCT05864183|Diagnostic Test|serum creatinine .|serum creatinine will be measured for all patients to minimize the risk of developing diabetes or its complications
45478034|NCT05864183|Diagnostic Test|CRP|CRP will be measured for all patients to minimize the risk of developing diabetes or its complications
45478035|NCT05864183|Diagnostic Test|urine analysis|urine analysis will be measured for all patients to minimize the risk of developing diabetes or its complications
45478036|NCT05864183|Diagnostic Test|ECG|ECG will be done for all patients to minimize the risk of developing diabetes or its complications
46046547|NCT03696082|Behavioral|Aerobic Activity|Moderate-intensity exercise aerobic exercise that involves participating in activities similar to brisk walking that increase heart rate and breathing rate, with activity progressing to 150 minutes per week. Activities other than brisk walking, such as dance, aerobics, swimming, cycling or other activities that increase heart rate and breathing rate to a moderate intensity that can be sustained for at least 10 minutes will also be encouraged. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
46046548|NCT03696082|Behavioral|Resistance Training|Resistance exercise that involves participating in activities similar to lifting weights that cause the participant to work specific muscles of your body, with activity progressing to 150 minutes per week. This can involve using weight training machines, elastic tubes that create resistance, or weights such a dumbbells. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
45478037|NCT05864183|Diagnostic Test|fundus examination|fundus examination will be done for all patients to minimize the risk of developing diabetes or its complications
45478038|NCT05864170|Biological|β-globin restored autologous hematopoietic stem cells|β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q
45478039|NCT05864157|Other|Gait training without rhythmic auditory cues|Gait training on treadmill and overground without any rhythmic auditory cues
45478040|NCT05864157|Other|TRAC|Metronome set to 85% on treadmill and 115% when walking overground
45478041|NCT05864157|Other|dTRAC|Metronome set around 85% on treadmill and around 115% when walking overground
45478042|NCT05864131|Behavioral|Lying|After the urethral catheter is inserted, the participant lies on an examination table lined with paper towels and diapers.
45354917|NCT03983005|Procedure|EUS-B-FNA|Endoscopic ultrasound with bronchoscope fine needle aspiration (EUS-B-FNA) is an endoscopic technique based on a trans-esophageal needle aspiration performed by an interventional pulmonologist with the echo-bronchoscope
45354918|NCT01061593|Dietary Supplement|Immunoxel|1 lozenge once per day
45354919|NCT01061593|Other|Placebo|1 lozenge once per day
45354920|NCT00769262|Other|Conservative weaning|Infants will not be weaned from the isolette until their feeds are at full calorie goal (120 kcal/kg/day) and at least half of feeds are taken orally.
45354921|NCT00769262|Other|Aggressive Weaning|Infants will be weaned from the isolette based solely on their temperature without regard to feed status (current standard of care in our NICU)
45478043|NCT05864131|Behavioral|Holding|Holding is performed as a non-pharmacological intervention to relieve pain in children during cystometry. After the urethral catheter is inserted, the participant's parent sits in the chair, placing a paper towel and diaper on their lap. The researcher lifts the participant by the shoulder and puts them on their parent's lap, and the parent holds the participant in their arms.
45354922|NCT03979261|Diagnostic Test|evolution of sex ratio according to age|Histological study of the collected valves to study the differences according to the sex of the inflammatory reaction and the cellular type found.
45354923|NCT00777218|Drug|propranolol|standard pediatric doses, based on body weight
45843431|NCT01628718|Behavioral|Adaptive Disclosure (AD)|Adaptive Disclosure (AD) is an eight-session fully manualized and piloted intervention designed specifically for Marines with PTSD stemming from a variety of traumatic deployment experiences. The approach combines imaginal exposure to activate trauma-related emotions and beliefs and cognitive and experiential techniques to modify maladaptive interpretations of the implication of various combat and operational experiences that contribute to symptoms and dysfunction.
45478044|NCT05864118|Diagnostic Test|Respiratory pathogen panel PCR test|Respiratory pathogen panel PCR test and COVID-19 antibody test.
45478045|NCT05864118|Diagnostic Test|COVID-19 antibody test|COVID-19 antibody test
45478046|NCT05864092|Other|Virtual Reality Goggles|We will offer patients virtual reality goggles with guided meditation software in addition to standard medical therapy (NSAID and opioid).
45478047|NCT05864053|Drug|Ketamine|Ketamine will be administered over a 45-minute period.
45478048|NCT05864053|Drug|(2R,6R)-hydroxynorketamine|(2R,6R)-Hydroxynorketamine hydrochloride will be administered over a 45-minute period.
45843432|NCT01628718|Behavioral|Cognitive Processing Therapy, cognitive version only (CPT-C)|"Cognitive Processing Therapy (CPT) is a 12-session manualized therapy for posttraumatic stress disorder. The theory behind CPT conceptualizes PTSD as a disorder of non-recovery in which erroneous beliefs about the causes and consequences of traumatic events produce strong negative emotions and prevent accurate processing of the trauma memory and natural emotions emanating from the event. A significant contributor to the interruption of natural recovery process is the ongoing use of avoidance as a coping strategy. CPT incorporates trauma-specific cognitive techniques to help individuals with PTSD more accurately appraise these stuck points and progress toward recovery."
45843433|NCT01630200|Drug|Roflumilast|Roflumilast coated tablet, 500µg oral application, once daily in the morning
45843434|NCT01630200|Drug|Placebo|Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning
45843435|NCT01631682|Drug|Propranolol|40mg single pill
45478049|NCT05864053|Drug|Saline|Saline will be administered over a 45-minute period.
45354924|NCT00777218|Drug|zonisamide|standard pediatric dosages, based on body weight
45354925|NCT00777218|Drug|topiramate|standard pediatric dosages, based on body weight
45354926|NCT05357716|Device|HeartWatch|The HeartWatch arm band provides continuous, high-quality single lead electrocardiograph (ECG) data in a variety of environments. The ECG data is transmitted via Bluetooth and stored on the user's smartphone. It is then uploaded to the cloud for subsequent analysis using either a commercial ECG software package or a customized software package from HelpWear.
45354927|NCT05357716|Device|Event Recorder|A standard 1 or 2-lead Sirona Event Recorder will be used to collect high-resolution data. Subjects will be asked to wear the clinical monitor for at least 48 hours and no longer than 84 hours. ECG signals will be continuously collected as long as the skin patches are attached to the skin and the recorder is properly connected to the wires.
45354928|NCT05357716|Device|Holter Monitor|A standard 5-lead SEER Holter will be used to collect 3-channels of high-resolution data. Subjects will be asked to wear the clinical, conventional monitor for at least 36 hours and no longer than 60 hours. During this time ECG signals will be continuously collected.
45478050|NCT05864027|Behavioral|Peer-led Oral Health Recovery Group|"The interactive Oral Health Recovery group will be centered around the tailored materials previously developed, with topics such as it's never too late to make a change, oral health and whole health, taking care of your teeth, and going to the dentist."
45478051|NCT05864027|Behavioral|Educational Video about Oral Health|The video comparison will be pulled from Toothflix 2.0 Patient Education DVD Series, which are patient education videos developed by the American Dental Association.
45478052|NCT05864014|Drug|Hetrombopag|Hetrombopag
45478053|NCT05864014|Drug|Hetrombopag plus Placebo|Hetrombopag plus Placebo
45478054|NCT05864014|Drug|Placebo|Placebo
45478055|NCT05864001|Behavioral|STAR-C mobile app|Digital coaching intervention for healthy lifestyle
45478056|NCT05863988|Other|Functional Electrical Stimulation|The group A will receive functional electrical stimulation 30-45 min session 5 days per week for 8 weeks.
45843436|NCT01631682|Behavioral|Reactivation|subject is re-exposed to CS+R on day 2 (code for CS that is both paired with shock and reactivated on day 2)
45843437|NCT01631682|Drug|Mifepristone|1800mg, 9 tablets
45843438|NCT01631682|Drug|Intranasal oxytocin|32 IU, 8 self-administered intranasal sprays, 4 in each nostril
45478057|NCT05863988|Other|Upper Limb Loading Exercises|The group B will receive Upper Limb Loading Exercises 30-45 min session 5 days per week for 8 weeks.
45478058|NCT05863975|Drug|Human interferon alpha 2b vaginal Effervescent capsules|①Interferon group: human interferon alpha 2b vaginal effervescent capsule vaginal medication. ② Promestriene group: promestriene cream vaginal medication. ③Interferon + promestriene combination group: two drugs were given in combination.
45478059|NCT05863962|Other|walking and Stretching|Stretching exercise will be given for 6 weeks (3 sessions per week). 15 minutes of moderate walking with stretching exercises 5 times a week with Warm up and Cool down. Videos will be provided to participants to follow at home. Participants will be provided forms for home to fill after every session completed and frequency of each exercise
45354929|NCT04047758|Drug|Palbociclib + Letrozole|(1) Palbociclib (trade name: Ibrance®; Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; imported drug license No. H20180040): 125 mg/capsule, 1 capsule by mouth once a day, for 21 successive days, followed by 7 days off treatment [3 weeks on (days 1-21) and 1 week off (days 22-28)], repeated every 28 days. (2) Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
45354930|NCT04047758|Drug|Letrozole|Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
45354931|NCT00922064|Procedure|ECT|ECT series consisting of 6 to 14 ECTs
45354932|NCT05355064|Drug|Trehalose|Enrolled subjects will daily take 4 g of trehalose in oral administration for 24 weeks.
45354933|NCT00307801|Drug|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|1 pill per day taken orally over 7 cycles of 28 pills per cycle
45354934|NCT00307801|Drug|Placebo|1 pill per day taken orally over 7 cycles of 28 pills per cycle
45354935|NCT00671060|Drug|Misoprostol|200 mcg buccal misoprostol administered every 6 hours for up to 48 hours until fetus is delivered.
45354936|NCT00671060|Drug|Misoprostol|100 mcg buccal misoprostol administered every 6 hours for upto 48 hours
45354937|NCT05354986|Other|Toothpaste with hexametaphosphate, tripolyphosphate and polyvinylpyrrolidone (PVP)|"Subgingival instrumentation will be performed in two sessions, with a maximum interval of one week, with hand and automatic devices, under local anaesthesia. Full-mouth dental polishing (air-polishing) will be performed immediately after the second session, to eliminate any dental staining.~Experimental anti-staining toothpaste formulation (Dentaid, Barcelona, Spain) includes hexametaphosphate, tripolyphosphate and polyvinylpyrrolidone (PVP), within its ingredients. Participants will use the test or control toothpaste three times daily with a manual toothbrush followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse."
45354938|NCT05354986|Other|Toothpaste without hexametaphosphate, tripolyphosphate and polyvinylpyrrolidone (PVP)|"Subgingival instrumentation will be performed in two sessions, with a maximum interval of one week, with hand and automatic devices, under local anaesthesia. Full-mouth dental polishing (air-polishing) will be performed immediately after the second session, to eliminate any dental staining.~Experimental anti-staining toothpaste formulation without tripolyphosphate and polyvinylpyrrolidone (PVP), within its ingredients. Participants will use the test or control toothpaste three times daily with a manual toothbrush followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse."
45354939|NCT00769418|Drug|odanacatib|"Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: odanacatib tablets 2.5 mg qd for 14 days.~Panel B: odanacatib tablets 5 mg qd for 14 days.~Panel C: odanacatib tablets 10 mg qd for 14 days.~Panel D: odanacatib tablets 25 mg qd for 14 days.~Panel E: odanacatib tablets 0.5 mg qd for 21 days.~Panel F: odanacatib tablets 2.5 mg qd for 21 days.~Panel G: odanacatib tablets 10 mg qd for 21 days."
45354940|NCT00769418|Drug|Comparator: Placebo|"Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: placebo to odanacatib tablets 2.5 mg qd for 14 days.~Panel B: placebo to odanacatib tablets 5 mg qd for 14 days.~Panel C: placebo to odanacatib tablets 10 mg qd for 14 days.~Panel D: placebo to odanacatib tablets 25 mg qd for 14 days.~Panel E: placebo to odanacatib tablets 0.5 mg qd for 21 days.~Panel F: placebo to odanacatib tablets 2.5 mg qd for 21 days.~Panel G: placebo to odanacatib tablets 10 mg qd for 21 days."
45354941|NCT05257252|Behavioral|"Persons With Disability Friendly Nursing Education Program"|Persons With Disability Friendly Nursing Education Program developed based on the Story Theory, 2 weeks program
45354942|NCT00773552|Drug|solifenacin succinate|5mg PO Qday x 90 days
45478060|NCT05863962|Other|walking and Jacobsons relaxation technique|Jacobson's Relaxation Technique will be given for 6 weeks. 15 minutes of moderate walking with Jacobson's Relaxation Technique. Videos will be provided to participants to follow at home. Participants will be provided forms for home to fill after every session completed. Participants will also bring their Pedometer
45478061|NCT05863949|Dietary Supplement|vitamin D +/- calcium|vitamin D 1000iU daily +/- calcium 500mg BID daily
45478062|NCT05863949|Other|Placebo|placebo pill x3 daily
45478063|NCT05863936|Drug|Methylprednisolone Injectable Suspension|Methylprednisolone pulse therapy, total dose from 1500mg to 3000mg.
45354943|NCT00773552|Drug|placebo|1 tab PO Qday x 90 days
45478064|NCT05863936|Drug|Belimumab Injection|Belimumab at a dose of 10mg per kilogram at weeks 2, 4, and 6, and every 4 weeks for 24 weeks.
45478065|NCT05863936|Drug|Immunosuppressive Agents|"Mycophenolate Mofetil, oral, 1.0-1.5g per day;~Tacrolimus, oral, 2-4mg per day."
45478066|NCT05863923|Behavioral|mHealth Messaging to Motivate Quitline use and Quitting among Persons Living With HIV (PLWH) in Vietnam (M2Q2-HIV)|Participants in the intervention group will be exposed to the texting intervention through a series of culturally tailored assessments and motivational text messages from the text messaging system sent throughout the 6 months of duration of the study.
45843439|NCT01633398|Genetic|Saliva Genetic testing|To compare the genetic variants between the two phenotypes of reduced versus preserved ejection fraction (HFrEF versus HFpEF)
45843440|NCT01634256|Dietary Supplement|Placebo|Placebo(3.0g/day)
45843441|NCT01634256|Dietary Supplement|Fermented turmeric|Fermented turmeric(3.0g/day)
45843442|NCT01635504|Biological|Botulinum toxin A|Botulinum toxin A 50 units per side of the posterior cheek enlargement, injected into the masseter muscle and parotid gland (10 units into 5 points of the posterior cheek enlargement per side, giving a total of 100 units per patient)
45354944|NCT04002700|Drug|Haloperidol|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of haloperidol. No drug will be administered as part of this study.
45354945|NCT04002700|Drug|Typical Antipsychotics|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of typical antipsychotics which includes Haloperidol, Loxapine, Thioridazine, Molindone, Thiothixene, Fluphenazine, Trifluoperazine, Perphenazine, Chlorpromazine. No drug will be administered as part of this study.
45478067|NCT05863923|Behavioral|M2Q2-HIV Comparison|Participants in the comparison group will be exposed to a brief set of five texts with facts about smoking risks and assessment messages that are not culturally tailored from the text messaging system.
45843443|NCT01636206|Drug|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: ~1 year
45354946|NCT04002700|Drug|Atypical Antipsychotics|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of atypical antipsychotics which includes Aripriprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Paliperidone, Ziprasidone, Risperidone, Quetiapine, Olanzapine. No drug will be administered as part of this study.
45354947|NCT00769496|Drug|BAY 77-1931|Lanthanum Carbonate (BAY 77-1931)
45354948|NCT05354908|Other|scientific and academic productivity|Number and quartile of scientific products generated by the group
45354949|NCT04098653|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
45354950|NCT04098653|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
45478068|NCT05863910|Drug|Medical Cannabis|Any cannabis product that is available to participants through the Medical Cannabis Access Program is eligible to be included in this study.
45478069|NCT05863897|Behavioral|e-COGRAT (a blended eHealth intervention)|The blended eHealth intervention for fatigue complaints after ABI, e-COGRAT, is a cognitive behaviorial intervention. It consists of 12 weekly sessions, including 6 individual online sessions, 2 face-to-face group sessions and 4 online group sessions, in 4 groups of 4 patients.
45478070|NCT05863884|Behavioral|Impact of Community Health Worker Home Deployment on COVID-19 Vaccine Confidence and Uptake|CHWs will conduct home visits to provide diabetes and COVID-19 health education based on the participant's needs, interests, and clinical health assessment results. All adults in the household will be invited to participate in the health education discussions. At each visit, the CHW will use diabetes management and COVID-19 educational materials to facilitate and inform discussions. CHWs will also make available at-home COVID-19 testing kits with instructions for the patient and their household family members. The discussion of COVID-19 beliefs, perceptions, and related behaviors will be raised during a later visit, i.e., after rapport and trust has been established and if it has not been raised by the participants during the earlier visits. In addition, CHWs will help schedule vaccination and healthcare appointments upon participant's interest.
45478071|NCT05863871|Drug|Linperlisib|80 mg, qd
45478072|NCT05863858|Drug|Sequential Regimen: Levofloxacin 500 mg BID, Amoxicillin 1 gm BID, omeprazole 20 mg BID for first five days followed by Levofloxacin 500 mgBID, Tinidazole 500 mg BID, Omeprazole 20 mg BID|The eradication rate of H. Pylori with levofloxacin-based sequential therapy
45843444|NCT01636206|Drug|Placebo|Dosage Form: Ophthalmic Solution Dosage: placebo Frequency: BID Duration: ~1 year
45843445|NCT01636284|Biological|JX-594 recombinant vaccina GM-CSF|Enrolled patients will receive 5 weekly IV infusions on Days 1, 8, 15, 22, and 29. After Day 43, if their disease has improved or remained stable and they have not started other cancer therapy, they may be able to continue to receive JX-594 via IV infusion every three weeks. This treatment extension may continue until radiologic progressive disease, initiation of other cancer therapy, or patient withdrawal.
45478073|NCT05863858|Drug|Triple Regimen: Moxifloxacin 400mg OD, Amoxicillin 1 gm BID, Omeprazole 20mgBID|The eradication rate of H. Pylori with moxifloxacin-based triple therapy
45478074|NCT05863845|Drug|Venetoclax|100mg day -10, 200mg day -9, 400mg day -8, 800mg day -7 to -1, Given PO
45843446|NCT01638468|Device|AngioJet Ultra PE Thrombectomy System|Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System
45478075|NCT05863845|Drug|Carmustine|300mg/m2 day -7, Given IV
45478076|NCT05863845|Drug|Cytarabine|100mg/m2/d, day -6 to day -3, Given IV
45843447|NCT01639872|Drug|Clozapine|Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day
45478077|NCT05863845|Drug|Etoposide|200mg/m2/d, day -6 to day -3, Given IV
45478078|NCT05863845|Drug|Melphalan|140mg/m2, day -2, Given IV
45478079|NCT05863845|Procedure|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
45843448|NCT01639872|Drug|Risperidone|Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day
45843449|NCT01640340|Drug|aprepitant|Given by mouth
45843450|NCT01640340|Drug|palonosetron hydrochloride|Given IV(intervenous infusion)
45843451|NCT01640340|Drug|ondansetron|Given PO
45478080|NCT05863832|Drug|Ciprodiazole|Ciprofolxacin 500 mg / Metronidazole 500 mg
45478081|NCT05863832|Drug|Ciprofloxacin Tablets & Metronidazole tablets|Ciprofolxacin 500 mg + Metronidazole 500 mg
45843452|NCT01640340|Drug|dexamethasone|Given PO
45843453|NCT01641042|Biological|Meningococcal vaccine GSK134612|2 doses of the vaccine administered intramuscularly in the anterolateral thigh muscle of the non-dominant leg for subjects aged 12 months to 2 years and in the deltoid of the non-dominant arm for older subjects.
45843454|NCT01641120|Drug|Avonex|Intramuscular injection administered using 25 gauge or 30 gauge needle
45843455|NCT01642056|Drug|EPI-743|This medication is used to treat disorders of energy metabolism such as mitochondrial diseases. It does not correct the inherited disorder of energy metabolism or mitochondrial diseases. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
45843456|NCT01642056|Drug|Placebo|
45354951|NCT04098653|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
45354952|NCT00769574|Other|Biological analysis of biomarkers|Biological analysis of biomarkers
45354953|NCT00769574|Other|Biological analysis of biomarkers|Biological analysis of biomarkers
45354954|NCT04002154|Device|Papilocare vaginal gel|Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
45354955|NCT00777374|Drug|Patch|epicutaneous application of allergen patch
45354956|NCT00777374|Drug|Placebo patch|epicutanoeus application of a placebo patch
45354957|NCT05297123|Drug|All-trans retinoic acid|All-trans retinoic acid (ATRA) 20mg 3 times a day for 8 weeks.
45354958|NCT05297123|Drug|Arsenic Trioxide|ATO 0.15mg/kg/d for 8 weeks (If the total daily amount is greater than 10mg, only 10mg/d can be given)
45478082|NCT05863806|Other|Mulligan Mobilzation|"Participants were instructed that MWM, including shoulder movement, must be pain-free and should be immediately stopped if any pain is experienced during the treatment.~The single session of MWM technique was last around 20 minutes, in 3 sets of 10 repetitions with a rest interval of 30 seconds between each sets."
45478083|NCT05863806|Other|Trasverse Friction Massage|"Deep friction massage was given to rotator cuff tendon with the tip of index finger, which is reinforced by middle finger.~It was given in transverse direction for 10 - 12 minutes. Transverse friction massage was Given twice a week with the gap of days for the first 3 week and then the repetition is increased to 3 to 4 times a week for the rest of duration."
45686861|NCT05816109|Diagnostic Test|superficial cervical block|After anesthesia and surgical procedures, bilateral superficial cervical plexus block will be applied to the lower border of the sternocleidomastoid muscle, accompanied by ultrasonography. After cleaning the area with povidone iodine before the block, the sternocleidomastoid muscle and carotid artery and other vascular structures are determined using a linear ultrasound probe. Local anesthetic will be administered between the lower border of the sternocleidomastoid muscle and the upper border of the prevertebral fascia with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection method with saline before local anesthesia is given. After the location of the needle is confirmed, 2 ml of saline will be injected, followed by 10 ml of 0.5% bupivacaine. The deep cervical fascia of the superficial lamina will appear to open.
45686862|NCT05816109|Diagnostic Test|without superficial cervical block|patients who underwent anterior cervical surgery and did not undergo superficial cervical block
45354959|NCT05297123|Drug|Realgar-Indigo naturalis formula|60 mg/kg/d for 8 weeks
45354960|NCT00654420|Drug|Dalotuzumab|Dalotuzumab 20 mg/mL in sterile solution. Intravenous (IV) infusion over 60 minutes at 5 mg/kg, administered weekly at dosage according to treatment group.
45354961|NCT00654420|Drug|Erlotinib|Open-label erlotinib administrated orally (tablets) by mouth (PO) at 150 mg daily.
45686863|NCT05816096|Combination Product|Hall technique|The child will be placed to them SSC on one of their HSPM affected teeth. Pain during treatment will be assessed using the FLACC scale and satisfaction the child and parent will be evaluated using likert scale after the treatment immediately and after one month and evaluate the success restoration adapted from Innes et al. after 3_6_9_12 month.
45686864|NCT05816096|Combination Product|ART|The child will be restored to them one of their HSPM affected teeth by GIC. Pain during treatment will be assessed using the FLACC scale and satisfaction the child and parent will be evaluated using likert scale after the treatment immediately and after one month and evaluate the success restoration adapted from Innes et al. after 3_6_9_12 month.
45686865|NCT05816083|Behavioral|Virtual Reality Tool|Virtual Reality Tool for At-Risk Trauma-Exposed Young People
45686866|NCT05816070|Drug|IVIEW-1201|Four times per day for day 1-2 and three times per day for day 3-7
45686867|NCT05816070|Drug|Ofloxacin Eye Drops|Four times per day for day 1-2 and three times per day for day 3-7
45354962|NCT00773630|Drug|Cilostazol|100 mg Cilostazol
45354963|NCT03683836|Diagnostic Test|No intervention|No intervention
45354964|NCT05356312|Biological|Vaccination|Personalized neoantigen vaccination
45498265|NCT03192475|Behavioral|GLB plus phone contacts|GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The active treatment group also receives 8 additional group phone conference calls for social support and problem solving.
45354965|NCT05353114|Other|3D feet scan (smart-fitting by Podiapp - Podartis s.r.l Unipersonale-Crocceta del Montello (TV), Italy).|The 3D foot scan becomes a movile app that recommends a specific size and model of therapeutic footwear according to the measurements
45354966|NCT04016922|Other|Oral ferrous fumerate for Group A, Parenteral iron sucrose for Group B, Compatible blood transfusion for Group C|"Consent, history. US: fetal heart activity, placental site, fetal biometry, AFI, anomalies, Doppler: umbilical artery, MCA, fetal renal artery, C\U ratio.~* Maternal Hb,US at time of first visit, 10 days later after initiation of treatment, at EDD .~As part of routine medical care of these patients, they are managed as:~A: give oral iron in the form of ferrous fumerate with the possible side effects. if Hb returns to normal, continue iron for 3 mon.~B: admit to receive IV iron sucrose according to product literature allergic reaction may happen; antiallergic measures. C: give blood transfusion in the form of packed RBC. allergic and pyrogenic reaction and infection may occur. At delivery will be subjected to: examination, investigations, US."
45843457|NCT01643382|Drug|Insulin|Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL
45354967|NCT03646474|Drug|tranexamic Acid infusion|The tranexamic Acid group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision.
45354968|NCT03646474|Drug|saline infusion|In the placebogroup, patients will receive a placebo of 100 mL 0.9% normal saline.
45354969|NCT00808002|Drug|Raltegravir|Raltegravir 400 mg every 12 hours
45354970|NCT00808002|Drug|Maraviroc|Maraviroc 300 mg every 12 hours
45354971|NCT00808002|Drug|Tenofovir/Emtricitabine|Tenofovir/Emtricitabine 300/200 mg every 24 hours
45354972|NCT00307489|Drug|tenofovir DF|300 mg tablet, once daily (QD)
45478084|NCT05863793|Other|Acupuncture|The obligatory acupoints include Zhongwan (CV12), bilateral Weiwanxiashu (EX-B3), bilateral Ganshu (BL18), bilateral Pishu (BL20), bilateral Shenshu (BL23), bilateral Zusanli (ST36), bilateral Yanglingquan (GB34), bilateral Sanyinjiao (SP6), bilateral Taixi (KI3), and Bafeng (EX-LE10). Additional acupoints Baxie (EX-UE9) will be added when patients' symptoms appear not only in the lower limbs but also in the upper limbs. After skin disinfection, disposable, stainless steel acupuncture needles will be inserted into the skin of acupoint (approximately 10-20 mm depth), and then manipulations of twirling, lifting, and thrusting will be performed on all needles for at least 10 s to reach De qi (a compositional sensation including soreness, numbness, distention, and heaviness), which is believed to be an essential component for acupuncture efficacy. Needles will be retained in these acupoints for 20 min.
45843458|NCT01643382|Drug|Insulin, Asp(B28)-|Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.
45843459|NCT01643616|Drug|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
45354973|NCT00307489|Drug|emtricitabine /tenofovir DF|emtricitabine 200 mg/tenofovir DF 300 mg once daily (combination tablet)
45354974|NCT04001764|Procedure|The radial artery cannulation over 2 cm of the wrist|The radial artery catheterization performed as short axis out-of-plane with USG over 2 cm of the wrist.
45354975|NCT04001764|Procedure|The radial artery cannulation in the distal 3/4 area of the forearm|The radial artery catheterization will be performed in the distal 3/4 area of the forearm with ultrasound-guided short axis out of plane intervention.
45354976|NCT04001764|Procedure|The radial artery cannulation in the distal 1/2 area of the forearm|The radial artery catheterization will be performed in the distal 1/2 area of the forearm with ultrasound-guided short axis out of plane intervention.
45354977|NCT00812292|Drug|TMC278|
45354978|NCT04003168|Drug|Human BCMA targeted T Cells Injection|Autologous genetically modified anti-BCMA CAR transduced T cells
45354979|NCT00812370|Drug|Bivalirudin|The initial bolus dose will be 0.125 mg/kg followed immediately by a continuous infusion of 0.125 mg/kg/hour.
45354980|NCT05284786|Device|nerve ultrasonography|Ultrasonography of different nerves was performed using a high frequency 18 MHz probe (esaote Ultrasound systems). Each nerve was scanned in axial plane, and the cross-sectional area (CSA) was measured at standardized anatomical points, in brief: median nerve in upper arm, elbow, forearm; ulnar nerve in upper arm and forearm; tibial nerve in popliteal and ankle; peroneal nerve in popliteal fossa, sural nerve in the calf and the vagus nerve.
45354981|NCT00645840|Drug|Anakinra|Patients will receive daily anakinra therapy for 28 days
45354982|NCT05259124|Device|positional perfusion index variation|positional perfusion index variation to predict spinal anesthesia-induced hypotension in elderly patients
45354983|NCT00773708|Drug|raltegravir|intensify their therapy with Raltegravir(RAL):1 Protease inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL or 1 non-nucleoside reverse transcriptase inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL
45686868|NCT05816057|Biological|semaglutide injection|The subject will receive either a dose semaglutide once weekly (subcutaneous (s.c.) injection). The initial dose of 0.25 mg is s.c. once weekly, and the dose is increased to 0.5 mg after 4 weeks of administration, and the dose is increased to 1 mg after 4 weeks of 0.5 mg administration, and the dose is continued at a stable dose of 1 mg for 24 weeks.Treatment duration 32 weeks.
45686869|NCT05816031|Dietary Supplement|Ketogenic diet|Ketogenic diet administrated to obese patients planned for right laparoscopic adrenalectomy
45843460|NCT01643616|Drug|Prilocaine 1%|20ml Prilocaine 1% for distal sciatic nerve block (30ml Prilocaine 1% in outpatients)
45354984|NCT00307333|Device|HeRO heart rate characteristics monitor|24 hour continuous HRC monitoring with display
45354985|NCT00762359|Drug|Lansoprazole|Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.
45354986|NCT00762359|Drug|Gefarnate|Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.
45354987|NCT04003090|Drug|Citicoline|After treatment with a solution containing citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride patients underwent a 23G standard 3-port pars plana vitrectomy. The vitreous sample was taken at the beginning of the surgery and then analyzed.
45354988|NCT00777530|Drug|Bosutinib (SKI-606)|
45354989|NCT00814476|Other|Medtronic CareLink therapy management system|At the first segment, the usage of the CareLink system will be accompanied by the diabetic team, through at least monthly contact via the internet initiated by the diabetic team. In the second phase of the study,during the following 4 months, there will be regular home use of the CareLink system, without support initiated by the diabetic team
45354990|NCT00814476|Other|regular home use and Medtronic CareLink Therapy Management|At the first 4 months patients will continue at their regular treatment and contacts initiated by the study team via internet/electronic mail will be made once a month. At the second segment of the study patients there will be home use of the CareLink System until the end of the study. No further contact will be initiated by the study team.
45354991|NCT04002856|Device|Profhilo®|Profhilo® (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2.25 ml non-pyrogenic pre-filled syringe, containing 2 ml of 3.2% hyaluronic acid for intradermal use (32 mg H-HA + 32 mg L-HA dissolved in 2 ml of saline buffered sodium chloride
45478085|NCT05863793|Other|Sham Acupuncture|Patients in the SA group will receive sham acupuncture. The procedure and duration of treatment in the SA group will be identical in the MA group except the needles are blunt tip and there will be no skin penetration and needle manipulation for De qi.
45686870|NCT05815979|Behavioral|virtual reality|Presentation of the virtual reality glasses and an information meeting will be held for all students in the experimental group, and the working procedure of the virtual reality glasses will be introduced. Afterwards, students will monitor the practice skill at least once using virtual reality glasses. After the completed follow-up, the students will be asked to practice their nasogastric tube application skill on a simple simulation mannequin/model with low reality in the laboratory environment.
45354992|NCT01061749|Biological|Cixutumumab|Given IV
45354993|NCT01061749|Other|Laboratory Biomarker Analysis|Correlative studies
45354994|NCT01061749|Other|Pharmacological Study|Correlative studies
45354995|NCT01061749|Drug|Selumetinib|Given PO
45843461|NCT01643616|Drug|Ropivacaine 0.75%|10ml Ropivacaine 0.75% for distal sciatic nerve block (not in outpatients)
45843462|NCT01643616|Drug|Prilocaine 1%|10ml Prilocaine 1% for saphenous nerve block
45843463|NCT01643616|Device|ultrasound guidance|In group US the sciatic nerve localization and needle guidance is realized using ultrasound.
45354996|NCT02551614|Procedure|Lipopolysaccharide challenge|Lipopolysaccharide solution inhaled using a dosimeter.
45354997|NCT02551614|Procedure|Saline challenge|0.9% sodium chloride solution inhaled using dosimeter.
45354998|NCT02551614|Procedure|Labelled neutrophils and Imaging assessment|Injection of labelled neutrophils and imaging assessments
45354999|NCT05350306|Device|Chincup|Patients will receive an individual fabricated bonded bite block and occipital chincup. A 400-500g/side retroactive force will be applied in the direction of the condyles. Patients or panthers will be instructed to wear the appliance /14-16/ hours a day.
45843464|NCT01643616|Device|nerve stimulation technique|In the group NS sciatic nerve localization and needle guidance is realized using nerve stimulation technique. However, ultrasound is used observing (Observer) the procedure, but blinded for the physician (Anesthetist) performing the block.
45843465|NCT01644240|Drug|TD-8954|Intravenous infusion
46046549|NCT03696082|Behavioral|Yoga|Yoga involves a series of movements and poses that are performed in a specific sequence that are adapted to your ability, with activity progressing to 150 minutes per week. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
46046550|NCT03696082|Behavioral|Health Education|This involves the participant receiving information regarding aspects of health that are important for older adults, and also physical activity in the form of light stretching activities and movements. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
45355000|NCT05350306|Other|Control group|The changes in condyle-mandibular volumes and superficial areas and relative positions of the condyles and glenoid fossa will be calculated after 16 months of observation.
45355001|NCT03978949|Drug|Bacillus Licheniformis|Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
45355002|NCT03978949|Drug|Placebo|Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
45478086|NCT05863780|Other|Carpal bone mobilization|"Carpal bone mobilization 5 repetition/1 set lasted for 15 secs followed by 10 secs of rest- 3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
45843466|NCT01644240|Drug|Placebo - saline|Intravenous infusion
45843467|NCT01644396|Biological|Adalimumab|
45843468|NCT01645098|Drug|Ketamine|1 mg/kg IV, additional doses of 0.5 mg/kg as needed
45843469|NCT01645098|Drug|Dexmedetomidine|0.5 mcg/kg/hr IV
45843470|NCT01646346|Radiation|4D Conformal Image-Guided Partial Breast RT|External beam partial breast radiation to target a portion of the breast twice a day for 5 days.
45355003|NCT05356234|Behavioral|Treatment Intervention: Responsible Parenting, Relationships, and Employment Services|The Intervention group will be assigned a Case Manager and placed in the next available On My Shoulders (OMS) curriculum that offers strategies to help individuals develop a strong and healthy self in the service of making current and/or future relationships of all forms (parent-child, romantic, family, work) successful and satisfying. This curriculum is intended to equip men (and, where applicable, women) with the skills they need to build and nurture healthy relationships. This curriculum should help participants improve family functioning. Additionally, Transforming Impossible into Possible (TIP) financial literacy curriculum will be utilized to help participants increase job retention for those currently employed, improve wages through additional educational and training opportunities, and learn skills to better manage family finances. This curriculum should help participants increase economic stability and mobility.
45355004|NCT00769964|Drug|VA111913 TS / placebo|
45355005|NCT03327922|Device|Vicryl absorbable suture|Vicryl absorbable suture is a synthetic sterile surgical suture made up of a copolymer
45355006|NCT01066117|Other|PeeRelease gel absorbent pad|A larger gel containing pad was developed, suitable to absorb up to half a liter liquid, it eliminates odors and enables the users to wear ordinary clothes
45355007|NCT00770042|Drug|Ritonavir|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8)
45355008|NCT00770042|Drug|Ketoconazole|Ketoconazole 400 mg qd for 5 days (Days 2-6)
45355009|NCT00770042|Drug|Erythomycin|Erythromycin 500 mg every 12 hours for 5 days (Days 2-6)
45355010|NCT00770042|Drug|Avanafil|Avanafil 50 mg on Days 1 and 8
46046551|NCT03686345|Drug|Midostaurin|Midostaurin associated with standard chemotherapy in patients with core-binding factor leukemia
46046552|NCT03681327|Other|Sensory stimulation during sleep|Sensory stimulation during sleep
46046553|NCT03675711|Device|Midline|Patient will receive a Midline catheter within 48h after disappearance of indication for CVC
45355011|NCT00770042|Drug|Avanafil|Avanafil 50 mg on Days 1 and 6
45355012|NCT00770042|Drug|Avanafil|Avanafil 200mg Days 1 and 6
45355013|NCT03321370|Diagnostic Test|Continuous electrocorticography post severe traumatic brain injury requiring neurosurgical intervention|Continuous electrocorticography via subdural electrode strips for 1 to 3 weeks in the neuro intensive care unit following traumatic brain injury
45355014|NCT03982615|Device|Laser-Lok abutment|"Each subject will receive two dental implants. One implant will receive (by randomization) a laser-etched (Laser-Lok) abutment."
45355015|NCT03982615|Device|Standard healing abutment|Each subject will receive two dental implants. One implant will receive (by randomization) receive a standard healing abutment (not laser-etched).
45355016|NCT00777686|Procedure|MRI/MRS Scan|MRI/MRS brain scan with intravenous contrast prior to chemotherapy, then repeated every 8 weeks.
45355017|NCT00654186|Drug|Revlimid|25mg daily on days 1 - 21 followed by 7 days of rest repeated every 28 days
45355018|NCT03275818|Drug|nab paclitaxel|Subjects in the DT cohort will receive a maximum of three cycles. Subjects in the DSRCT and ES cohort will receive unlimited cycles until disease progression, the subject begins a new anticancer treatment, withdrawal of parent/guardian/subject consent/assent, parent/guardian/subject refusal, physician decision, toxicity that cannot be managed by dose delay or dose reduction alone or the study ends for any reason
45355019|NCT03979105|Drug|Ketamine|Drug: Ketamine Side effects associated with ketamine infusion to treat acute pain, were reviewed after 48 hours of exposure and frequency of tachycardia, hypertension, hallucinations, delirium and nightmares were registrated for comparison
45355020|NCT00773942|Behavioral|Basic medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
45355021|NCT00773942|Behavioral|Enhanced medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and chart information.
45355022|NCT01061905|Behavioral|Calorie information|Posting of Calorie information for sugar-sweetened and zero-calorie beverages
45355023|NCT01061905|Behavioral|Exercise Equivalent only|Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
45355024|NCT01061905|Behavioral|Calorie & Exercise equivalent information|Posting of both calorie and exercise equivalents information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
45355025|NCT00814554|Behavioral|Educational strategy|1.Educational strategy. The strategy is to implement health promotion actions aiming at developing personal skills to adopt healthy behaviors in the field of nutrition and physical activity in conformity with up-to-date recommendations and references. Each adolescent will be provided with about 50 education hours distributed in individual and collective activities in school (15 hours), interventions during courses (20 hours), and outdoors activities (15 hours).
45478087|NCT05863780|Other|Flexor retinaculum stretch|"Flexor retinaculum stretch 5 repetitions/ 1 set held for 60 secs at a time,-3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
46046554|NCT03675711|Device|PVC|Patient will receive a standard PVC within 48h after disappearance of indication for CVC
46046555|NCT03674619|Procedure|Anterior discectomy|Anterior discectomy will be performed and a microscope is used. After separation of the platysma muscle the pre-vertebral space is reached by an approach medial to the sternocleido-mastoid muscle and the carotid artery and lateral to the trachea and oesophagus. Then the disc is incided and the corpora are distracted to perform discectomy. Usually the posterior ligament is cut and the spinal root is decompressed and if necessary the arthritic rims are removed. An inter-vertebral fusion device is inserted, two levels are allowed in the spondylosis study.
46046556|NCT03674619|Behavioral|Conservative treatment|Patients will first attend an experienced specialist in physical medicine and rehabilitation who will answer concerns and questions and if necessary repeat the information given before inclusion. The aim of the brief intervention is to promote better understanding and coping of the condition. The intervention will include supervision by a physiotherapist (6 sessions altogether) and provide advice on how to handle secondary neck muscle pain and dysfunction, reduce eventual fear avoidance, and advice to stay active.
46046557|NCT03673371|Other|Questionnaire|This is a questionnaire developed by DoD and VA researchers specifically for this study.
45478088|NCT05863780|Other|Carpal bone mobilization and flexor retinaculum stretch|"Carpal bone mobilization 5 repetition/1 set lasted for 15 secs followed by 10 secs of rest.3 sessions on alternate days per week for 04 weeks.~Flexor retinaculum stretch 5 repetitions/ 1 set held for 60 secs at a time-3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
45478089|NCT05863767|Other|Baduanjin sequential therapy|Baduanjin sequential therapy consists of eight different movements including the preparatory phase till final movement (gathering the energy). The session will account for 30 minutes twice a day for four weeks.
46046558|NCT03671967|Drug|Piperacillin/tazobactam|4.5 grams QID
46046559|NCT03671967|Drug|Meropenem|1 gram TID
46046560|NCT03657810|Drug|CL-108 5 mg|hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg
46046561|NCT03657810|Drug|Norco|hydrocodone 5 mg/APAP 325 mg
46046562|NCT03657810|Drug|Placebo|Placebo matching CL-108
45355026|NCT00814554|Behavioral|Screening strategy|2. Screening strategy. Screening includes measurement of BMI and plotting the growing chart with adolescents, measurement of eating troubles. Screening will be performed by the school medical and nurse team. At risk subjects will be defined according to precise criteria and will be referred to the GP and to obesity networks developed by Health Insurance system where they are provided with specific activities with dieticians, physical activity teachers and psychologists. Subjects with psychological difficulties will be referred for psychological care.
45355027|NCT00814554|Other|Environmental strategy|3. Environmental strategy. The strategy is to develop in schools favorable and supportive environments for healthy behaviors targeting the collective catering and physical activity offer and the establishment policy. Especially actions aim at increase fruits and vegetables availability, water consumption, physical activity inside the schools.
45355028|NCT00761969|Other|Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice|Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice.
45355029|NCT00774020|Drug|Zoledronic acid|5mg, i.v. single dose
45355030|NCT04100447|Drug|Tranexamic Acid|A total of 700 mL of study drug should be completely consumed orally 2-12 hours prior to surgery as a split dose; 350 mL 6-12 hours prior to surgery and the remaining 350 mL 2-6 hours prior to surgery.
45355031|NCT03274804|Biological|Pembrolizumab|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22)
45355032|NCT03274804|Drug|Maraviroc|Maraviroc will be administered perorally on day 1 to 21 of each cycle (d1-21; qd22)
45355033|NCT05493449|Combination Product|UHT Milk|In this group of participants, UHT milk, 180 mL was provided and results were compared with control and flavored milk group
45355034|NCT05493449|Combination Product|Flavored Milk|In this group of participants, flavored milk, 180 mL was provided and results were compared with control and UHT group
45355035|NCT00774098|Drug|dextrose 10% (D10W ®) infusion|Started at 8pm the day before surgery until the procedure begins
45355036|NCT00774098|Drug|hyperinsulinemic normoglycemic clamp|Started as the procedure begins, decreased at the end of the procedure and continued until 16 hours postoperatively
45843471|NCT01647438|Behavioral|Lifestyle Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 6 to 8 participants who will attend 6 weekly, 90 minute group education sessions at Metropolitan Asian Family Services. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management. Participants will receive telephone support after each session and up to 12 weeks after they have completed the classes to help reinforce learning objectives.
45355037|NCT00774098|Dietary Supplement|high calorie diet 35 kcal/kg|High Calorie meals start the day before the surgery and are given 5 hours apart. The last meal is given at 7 pm the day before surgery
45355038|NCT00774098|Drug|Intravenous normal saline (NS 0.9)|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
45355039|NCT00761891|Other|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
45355040|NCT00777842|Device|GTX™ Drug Eluting Coronary Stent System|Drug eluting stent
45355041|NCT04002076|Behavioral|Robot-assisted hand combined with occupational therapy|Robot-assisted hand group contains 15 minutes of grasp and release motion, 15 minutes of visual feedback training and 30 minutes traditions occupational therapy. Traditional occupational therapy includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
45355042|NCT04002076|Behavioral|Traditional occupational therapy|Occupational therapy contains 60 minutes of traditional occupational therapy, which includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
45355043|NCT00774332|Drug|CODOX-M|Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine
45355044|NCT00321685|Biological|Bevacizumab|Given IV
45355045|NCT00321685|Drug|Capecitabine|Given PO
45355046|NCT00321685|Drug|Fluorouracil|Given IV
45355047|NCT00321685|Drug|Leucovorin Calcium|Given IV
45355048|NCT00321685|Drug|Oxaliplatin|Given IV
45355049|NCT00321685|Radiation|Radiation Therapy|Undergo radiotherapy
45355050|NCT00321685|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
45843472|NCT01647438|Other|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
45843473|NCT01648452|Biological|NT-501 CNTF-releasing implant|20 ng/day released into the eye
45843474|NCT01648530|Other|No Treatment|No Treatment
45843475|NCT01648920|Device|NIOX MINO® Instrument (09-1100)|The NIOX MINO® Instrument (09-1100) is a 10 second test based on exhaled breath measured at a 50 ml/second flow rate.
45843476|NCT01650324|Drug|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
45843477|NCT01650324|Drug|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
45843478|NCT01650402|Other|Anti-hypertensive therapy to SBP 130 mm Hg|Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 130 mm Hg
45843479|NCT01650402|Other|Anti-hypertensive therapy to SBP 145 mm Hg|Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 145 mm Hg
45843480|NCT01651104|Biological|Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)|A single 0.5 mL dose of study vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm.
45843481|NCT01651806|Drug|Tranexamic Acid standard dose|Uniform 1 gram dosing
45843482|NCT01651806|Drug|Females Tranexamic Acid weighted dose|Weighted dose--20mg/kg of the drug will be given
45843483|NCT01651806|Drug|Females receiving a uniform dose of TA|Patients will receive a uniform 1 gm dose of tranexamic acid prior to tourniquet release during a primary TKA.
45478090|NCT05863767|Other|Conventional Therapy|Neck stretches Arm circles Triceps stretch Calf stretch Forward step up Strengthening exercises Every exercise 5 repetitions three times a day
45478091|NCT05863754|Device|Networked Neuroprosthesis Device|The Networked Neuroprosthesis Device is an implantable, configurable neuromodulation platform that provides functional movement by the coordinated activation of peripheral neural pathways activating innervated paralyzed muscles, and sensing of physiological signals.
45843484|NCT01651806|Drug|Males Weighted Dose TA|Weighted dose--20mg/kg of the drug will be given
45843485|NCT01652040|Device|Resistance Training and Testosterone Patches|We are going to activate the knee extensor muscle group to lift ankle weights over 16 weeks and we are going to provide Tp to improve anabolic profile.
45843486|NCT01652040|Drug|Testosterone Patches|The investigators will provide Tp patches for 16 weeks for patients with Spinal Cord Injury.
45843487|NCT01652976|Drug|Dasatinib|Dasatinib 150mg PO daily on days 1-14 of each 14 day cycle
46046563|NCT03640026|Drug|Tacrolimus|Tacrolimus will be initiated at 0.1 mg/kg/day in two separate 12-hour oral doses (capsules) for 14 days.
45478092|NCT05863728|Procedure|Piezosurgery assisted group|apicectomy will be done using the Piezosurgery device
45843488|NCT01652976|Drug|mFOLFOX6|mFOLFOX6 (oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV, 5-Fluorouracil bolus 400mg/m2 IV, and 5-Fluorouracil 2400mg/m2 IV) on day 1 of each 14 day cycle
45843489|NCT01653288|Behavioral|Coping Coach|Coping Coach is a self-guided web-based intervention that utilizes an interactive, developmentally appropriate, game-like format, to provide practical information and teach children adaptive coping strategies. Children are primary users of the intervention, with parent supervision. Modules (20-30 minutes each) can be repeated to solidify skills / learning. The feelings module targets recognition of emotions after potentially traumatic experiences. The appraisals module targets the connection of helpful or unhelpful thoughts to feelings and behavior. The avoidance module targets reducing reliance on avoidance as a (maladaptive) coping response. Promoting social support is folded throughout the intervention. Information will be provided to parents about how to access additional resources and when to get additional professional help.
45843490|NCT01654068|Radiation|Conformal High Dose Intensity Modulated Radiation Therapy|Conformal High Dose Intensity Modulated Radiation Therapy 14-16Gy single fraction dosing using 6MV photons
45843491|NCT01656252|Drug|Phase I- Cytarabine & Eltrombopag|"Cycle 1= Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Eltrombopag (Open-Label) by mouth daily until platelet recovery or for 35 consecutive days, whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.~One cycle of consolidation therapy with high-dose cytarabine and eltrombopag will be received on study. Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
45843492|NCT01656252|Drug|Phase II- Sequence A|"Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 1st cycle of high-dose consolidation chemotherapy and placebo by mouth daily with 2nd cycle.~Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.~Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
46046564|NCT03638297|Drug|PD-1 antibody + cox inhibitor|"BAT1306 100mg /pembrolizumab 200mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks~Contraindication to aspirin :~Allergic or intolerance to aspirin; With peptic ulcers; With hemophilia or other bleeding tendencies; Have the gentic disease glucose-6 phosphate dehydrogenase deficiency."
46046565|NCT03618849|Device|tDCS|Real and sham tDCS/Mozart piano sonata (K.448)
45478093|NCT05863728|Procedure|Trephine Bur assisted group|apicectomy will be done using the trephine burs
45478094|NCT05863715|Behavioral|Visual Search Cue Type|Participants receive a target color cue (positive), a distractor color cue (negative), or a neutral non-informative cue prior to visual search.
45355051|NCT00777998|Procedure|Auto-Allo Tandem SCT and maintenance therapy with Thalidomide/ DLI|"*Multiple myeloma~-> Induction Therapy (max. 8 cycles)~-> Registration of patient, stem cell mobilization, start of donor search~-> Melphalan (200mg/qm) plus autologous PBSCT~-> 2 months later: Melphalan plus allogeneic PBSCT~-> day 120 after allogeneic PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)~-> day 180 after allogeneic PBSCT (if CsA discontinued): First DLI (1 x 10^6 (MRD) or 5 x 10^5 (MUD) CD3+ cells per kg BW)~-> day 250 after allogeneic PBSCT: second DLI (if no signs of GvHD: dose escalation by 0,5 Log)~-> Day 320 after allogeneic PBSCT: Third DLI (if no signs of GvHD: dose escalation by 0,5 Log)~-> Further DLI depending on MRD-measurement"
45355052|NCT00777998|Procedure|auto-auto Tandem stem cell transplantation and maintenance therapy with Thalidomide|"*Multiple myeloma~-> Induction Therapy (max. 8 cycles)~-> Registration of patient, stem cell mobilization, start of donor search~-> Melphalan (200mg/qm) plus autologous PBSCT~-> if no donor available (max 4 weeks after autologous PBSCT) or if patients declines allogeneic PBSCT): 2 months: Melphalan (200mg/qm) plus autologous PBSCT~-> day 120 after autologous PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)"
45355053|NCT05348200|Drug|Monad 1|Single therapy cream containing Lidocaine. Lidocaine is a topical anesthetic.
45355054|NCT05348200|Drug|Monad 2|Single therapy cream containing Halobetasol Propionate (low-strength). HPB is a topical corticosteroid.
45355055|NCT05348200|Drug|Monad 3|Single therapy cream containing Halobetasol Propionate (high strength).
45355056|NCT05348200|Drug|Combination - CITI-002 (low dose)|Combination cream containing Lidocaine and HBP (low)
45355057|NCT05348200|Drug|Combination - CITI-002 (high dose)|Combination cream containing Lidocaine and HBP (high)
45686871|NCT05815966|Behavioral|The effect of emotion recognition and empathy focused education program|"Emotion recognition and empathy-oriented education program is a group-based, interactive program that includes techniques such as vision development, brainstorming, painting and drawing, recital, role-playing, gamification and information notes, which requires the active participation of children. Within the program; There are trainings aimed at establishing bilateral relations, gaining in-group commitment, expressing emotions comfortably, feeling that they are not alone, and learning new resources that will make them feel good when they feel bad.~The aims of education; children,"
45355058|NCT00778076|Device|Hyaluronic acid|3 consecutive injections, each one week apart, of 20mg/2ml Hyaluronic acid.
45355059|NCT00778076|Device|Placebo (Saline injection)|3 consecutive injections, each one week apart, of 20mg/2ml of Placebo.
45355060|NCT05196412|Device|PulseOn Arrhythmia Monitor device|Wearing of the wrist device for a period of two weeks
45355061|NCT00779090|Procedure|Alveolar recruitment manoeuvre|Increase airway pressure during pressure controlled ventilation up to peak-airway pressure of 40 cmH20 and PEEP of 15 cmH20.
45355062|NCT04002778|Diagnostic Test|Fine needle aspiration|
45355063|NCT04002778|Diagnostic Test|Rapid on-site evaluation|
45355064|NCT02557022|Other|GI and/or GL|Randomized controlled trials of equal or more than 12 weeks duration looking at the GI and/or GL of diet as a whole and providing data on body weight
45355065|NCT01564342|Procedure|wound irrigation with study fluid|wounds were either irrigated with sterile normal saline or tap water.
45478096|NCT05863689|Diagnostic Test|Spectralis SD-OCT|Optical Coherence Tomography
45478097|NCT05863676|Procedure|Oophorectomy|Ovary will be removed for fertility preservation.
45355066|NCT00779480|Drug|KW-2449|KW-2449 50 mg capsules administered 3 or 4 times per day for 21-day cycles up to 6 cycles
45355067|NCT03902392|Dietary Supplement|NaturOx Group (A)|Comparison between dietary supplement and placebo
45355068|NCT03902392|Other|Placebo Group (B)|Comparison between dietary supplement and placebo
45355069|NCT00306787|Drug|Famciclovir|Famciclovir 500 mg tablet
45355070|NCT00306787|Drug|Valacyclovir|Valacyclovir 500 mg capsule
45355071|NCT00306787|Drug|Placebo matching famciclovir|Famciclovir placebo, matching in size, color and forms of famciclovir tablet.
45355072|NCT00306787|Drug|Placebo matching valacyclovir|Valacyclovir placebo, matching in size, color and forms of valacyclovir capsule.
45355073|NCT00778232|Drug|Gabapentin tablets 800 mg|
45355074|NCT01564264|Procedure|Sentinel Lymph Node Biopsy|Sentinel node biopsy after injections of 0.4 mci of Technetium 99 in the cervix and 4 mL of Patent Blue into the myometrium followed by standard retroperitoneal lymph node dissection
45355075|NCT00774488|Other|Glucose dependent insulinotropic polypeptide (GIP)|GIP-Infusions for 4 h in a postprandial concentration
45355076|NCT01066195|Drug|iressa|iressa 250mg per day every day
45355077|NCT01066195|Drug|alimta|alimta 500mg/m2 every 3 weeks
45355078|NCT03147742|Drug|Ruxolitinib|Ruxolitinib starting dose level 10 mg orally, twice daily (BID).
45355079|NCT00774644|Drug|Clarithromycin 500mg|
45355080|NCT03979027|Dietary Supplement|Breakfast: ready-to-eat-cereal and milk|
45478098|NCT05863676|Diagnostic Test|Infectious Disease Testing|Infectious Disease Testing will be done on participants.
45478099|NCT05863663|Other|questionnaire|cross sectional questionnaire
45686872|NCT05815953|Device|Polarstem|Stem used in total hip replacement. Manufacturer: Smith & Nephew Orthopaedics AG, Baar, Switzerland.
45686873|NCT05815953|Device|Corail|Stem used in total hip replacement. Manufacturer: De Puy Int Ltd, Leeds, UK.
45686874|NCT05815940|Behavioral|Mobile Application|a mobile application was developed that can be used by children with urinary incontinence and their parents.
45686875|NCT05815927|Drug|Pembrolizumab|Pembrolizumab: 400mg Q6W up to 2 years (i.e 17 cycles).
45355081|NCT00778388|Biological|IC43|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
45355082|NCT00778388|Drug|Placebo|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
45355083|NCT05123092|Other|Ultrasound guided lumbar erectae spinae block|One group by using ultrasound for making erectae spinae block
45355084|NCT05123092|Other|Intrathecal Morphine injection|Injecting intrathecal morphine
45478100|NCT05863650|Device|Digital based simulation|Algorithms will be created for various musculoskeletal diseases and these algorithms will be controlled by taking the opinions of physiotherapists and physicians who are experts in their fields. After the algorithms are created, a website with patient scenarios containing these algorithms will be established with the support of a software company. In addition to the website, a database will be created and the applications made on the site will be recorded. In this way, the data of users using the website will be collected.
45478101|NCT05863650|Other|Face to face education|In the face-to-face education group, two case analyzes will be applied by the students together with the educators themselves in the classroom environment, with the educational content prepared in parallel with the patient scenarios in the simulation-based education group.
45478102|NCT05863624|Procedure|Lichtenstein hernioplasty vs TEP hernioplasty|surgical procedures in inguinal hernia
45478103|NCT05863611|Other|arms|During the research, a questionnaire form (age, gender, educational status, etc.) in which your demographic information will be recorded for evaluation purposes and a consent form for participation in the study will be filled. Standardized Mini Mental Test will be applied. Then fragility will be evaluated with the Fried Fragility Index. Fall assessment will be assessed with the Fall Risk Self-Assessment Scale. Balance assessment will be made with the Tinetti Balance and Gait Assessment.
45478104|NCT05863585|Drug|BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum)|100µg
45478105|NCT05863572|Other|Primary care health worker training|Training primary care workers to detect and treat psychosis.
45478106|NCT05863572|Other|Community Health Workers Training|training community health workers in detection and referral
46046566|NCT03616834|Drug|Tomivosertib (eFT-508)|Tomivosertib (eFT-508) is a novel, small-molecule investigational drug being developed by eFFECTOR Therapeutics, as an antitumor therapy that acts by selectively inhibiting mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase (MNK)1 and MNK 2.
46046567|NCT03601949|Device|SInergy Cooled Radiofrequency|ablation of low back pain
46046568|NCT03601949|Other|Medical Management|physical therapy, medications, lifestyle changes
46046569|NCT03601702|Device|Mechanical thrombectomy with EmboTrap ® II Device|Endovascular treatment with mechanical thrombectomy using EmboTrap ® II Device (Neuravi)
46046570|NCT03596801|Biological|RSV 6120/∆NS1|Delivered as nose drops
46046571|NCT03596801|Biological|RSV 6120/F1/G2/∆NS1|Delivered as nose drops
46046572|NCT03596801|Biological|Placebo|Delivered as nose drops
46046573|NCT03594344|Procedure|Hyperbaric oxygen therapy|Breathing 100% oxygen for 30+30+30 min at 2,4 ATA. in a multiplace hyperbaric chamber. Total of 30 sessions
45355085|NCT05356156|Procedure|Closure of the mesenteric defects|The surgically created mesenteric defects will be closed after radical gastrectomy with D1+/D2 lymph node dissection.
45355086|NCT05356156|Procedure|Non-closure of the mesenteric defects|The surgically created mesenteric defects will not be closed after radical gastrectomy with D1+/D2 lymph node dissection.
45355087|NCT04001530|Drug|Half Normal Saline 0.45% Infusion Solution Bag|Randomization to half normal saline
45355088|NCT04001530|Drug|Normal Saline 0.9% Infusion Solution Bag|Randomization to normal saline
46046574|NCT03565029|Drug|XELOX|Capecitabine and Oxaliplatin (4x cycles)
45355089|NCT05344846|Other|Guided imagery|The individuals in this group will be provided with guided imagery application. Guided imagery will be applied to the participants in the hospital environment 6-10 hours after the cesarean section. Afterwards, guided imagery application will be requested every day for two weeks.
45355090|NCT05282056|Diagnostic Test|CAD analysis|CAD shows the radiologist automatically delineated areas of potential COVID-19 affection, together with an overall lung affection percentage.
45355091|NCT05278936|Other|The cataract surgery and the anterior vitrectomy|Surgical
45355092|NCT00991900|Device|Measurement of oxygen saturation of retinal vessels with optical reflectometer|5 repeated measurements on both study days
45355093|NCT00769067|Drug|Erlotinib|Continuous oral dosing at 150 mg daily.
45355094|NCT00769067|Drug|PF-00299804|Continuous oral dosing at 45mg daily
45355095|NCT00321373|Biological|Candidate Influenza Vaccine GSK1247446A - 2 different formulations|Single dose, Intramuscular injection
45686876|NCT05815927|Radiation|stereotattic ablation radiotherapy (SABR)|Total dose and number of fractions will depend on the site of the disease. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments have to be completed within 10 working days.
45355096|NCT00321373|Biological|FluarixTM|Single dose, Intramuscular injection
45686877|NCT05815914|Other|app|The app will include a nutritional education programme through the APP throughout the study. At 2, 4, 6 and 8 months data will be collected through a telematics questionnaire
45355097|NCT02826928|Biological|blood sample withdrawn|
45355098|NCT04001608|Drug|Seraprevir|Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12
45355099|NCT04001608|Drug|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12
45686878|NCT05815914|Other|control group|Routine nutritional and dietary recommendations will be given.
45686879|NCT05815901|Drug|Epaminurad 6 mg|Epaminurad 6 mg tablet
46046575|NCT03565029|Radiation|Radiotherapy|Pelvic radiotherapy
45355100|NCT00667394|Biological|Bevacizumab|Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
45355101|NCT00667394|Drug|MLN-518 (Tandutinib)|Tandutinib 500 mg by mouth daily dose twice a day.
45355102|NCT00667394|Procedure|Quality-of-life assessment|Forty-five one-sentence questionnaire to assess health related quality of life in patients with brain cancer.
45355103|NCT04103021|Device|Port-A-Cath|Totally implanted central venous access device
45355104|NCT05357326|Drug|Atropine Sulfate 0.01% Eye Drop|use one drop into subconjunctiva
45355105|NCT05357326|Device|Orthokeratology|wear orthokeratology at night while sleeping
45355106|NCT05357326|Drug|Atropine Sulfate 0.04% Eye Drop|use one drop into subconjunctiva
46046576|NCT03562494|Biological|VY-AADC02|Adeno-associated viral vector serotype 2 encoding human aromatic L-amino acid decarboxylase (AAV2- hAADC) infusion into the brain
46046577|NCT03562494|Other|Sham (Placebo) Surgery|Bilateral partial burr/twist holes without dura penetration
45355107|NCT00778466|Drug|metformin hydrochloride 1000 mg tablets|
46046578|NCT03555396|Behavioral|SMART Couples 2|The intervention will consist of 4 sessions with activities designed to strengthen communication and support within the couple to improve adherence to antiretroviral therapy and increase linkage to drug treatment services. The activities are based on cognitive-behavioral therapy. Participants' adherence will be monitored continuously through electronic monitoring devices and surveys completed at baseline and follow-up periods.
46046579|NCT03555396|Behavioral|Standard of Care|Standard of Care consists of an appointment with an AIDS Center nurse at baseline and two months later. Under current Standard of Care in Almaty, no behavioral intervention is provided. Participants obtain prescription refills and give blood for viral load and CD4 tests once every 6 months.
45355108|NCT05055778|Behavioral|SmokefreeTXT|"The program is identical to the publicly available program available through the National Cancer Institute Smokefree.gov Initiative but has been set up to be delivered through a research account. The program will send 3-5 messages a day over 7 weeks, with one week to prepare for a quit attempt and 6 weeks of cessation support messages. Participants can get real time support for cravings, mood, and slips by texting keywords to the program. They keywords are CRAVE, MOOD, and SLIP. Participants can also re-set their quit date by texting NEW. The program asks questions each week to ask about smoking status and about mood and cravings."
45355109|NCT00761735|Biological|Peginterferon alfa-2b|In the previous treatment protocol (P02538 Part 1), peginterferon alfa-2b was administered at a dose of 60 μg/m^2 by subcutaneous injection weekly for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
45355110|NCT00761735|Drug|Ribavirin|In the previous treatment protocol (P02538 Part 1), ribavirin was administered at a dose of 15 mg/kg/day orally in two divided doses for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
45355111|NCT00569946|Drug|AG-013736|"AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID.~Number of cycles: until progression or unacceptable toxicity develops."
45355112|NCT00778544|Drug|amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension|
45355113|NCT04001374|Drug|Ticagrelor|90mg tablet bid for 12 months
45355114|NCT04001374|Drug|ASA|enteric coated aspirin 81mg-100mg daily p.o. for 12 months
45355115|NCT02602067|Combination Product|131I-Tenatumomab|I131anti-Tenascin monoclonal antibody administered to be targeted on neoplasms expressing Tenascin-C
45686880|NCT05815901|Drug|Epaminurad 9 mg|Epaminurad 9 mg tablet
45355116|NCT02556320|Drug|anti-epileptic drug|Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
45355117|NCT02556320|Biological|Blood sampling|Blood sampling is done for Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
45355118|NCT05330494|Other|transcutaneous electrical acupoint stimulation(TEAS)|transcutaneous electrical acupoint stimulation (TEAS), the modern therapies derived from traditional acupuncture, which could activate nerve endings or fibers and generate action potentials.s. TEAS uses self-adhesive electrodes placed on the surface of acupoints, instead of needles for electrical stimulation.The resulting stimulation signals, which are transmitted to the spinal cord and brain, stimulate the central nervous system to generate specific chemical mediators to induce relevant physiological effects.
45686881|NCT05815901|Drug|Febuxostat 40 mg|Febuxostat 40 mg tablet
45355119|NCT03869658|Behavioral|COCO application|All participants will complete a screening survey to determine their eligibility for the study, if eligible and willing to participate, he or she will sign an informed consent form. Once participants are enrolled in the study, a demographics questionnaire will be completed along with 5 days of food tracking on the COCO application. Between days 3 and 7, participants will complete two 24-hr diet recall, one a day, and a patient satisfaction questionnaire.
45355120|NCT05265910|Drug|olopatadine hydrochloride ophthalmic solution 0.7%|Pataday® Once Daily Relief Extra Strength (eyedrop)
45478107|NCT05863572|Other|Home visits|home visits conducted by people with lived experience of psychosis
45478108|NCT05863559|Behavioral|Super Chef: Family Fun in the Kitchen!|Two-phase intervention: in the online phase, a professional chef will demonstrate cooking strategies to help families modify existing recipes to be consistent with the Mediterranean Dietary pattern. Effective food parenting practices will also be integrated into the intervention. The intervention is guided by theory - Family Systems, Social Cognitive, and Self Determination - and gamification techniques. At the end of the online phase, dyads will set a goal to use the cooking strategy and make a plan to facilitate goal attainment. In the home phase, the dyad will work together to use the plan to meet the goal. Dyads can also participate in bonus activities. Prior to viewing the next session, dyads will report whether the goal was attained and any bonus activities completed. Collectively, this will determine level of Super Chef status the family achieves at the end of the program (Session 4).
45478109|NCT05863546|Device|therapeutic ultrasound|US treatment sessions will be performed for 6 min per session , once a day, three days a week, for a total of 4 weeks.
45686882|NCT05815901|Drug|Febuxostat 80 mg|Febuxostat 80 mg tablet
45843493|NCT01656252|Drug|Phase II- Sequence B|"Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Placebo by mouth daily with 1st cycle of high-dose consolidation therapy and Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 2nd cycle.~Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.~Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
45478110|NCT05863520|Behavioral|Zones of Regulation|ZOR is rooted in CBT principles and uses a metacognitive framework to increase awareness of feelings and to build regulation, prosocial skills, and overall wellness.
46046580|NCT03544736|Drug|Nivolumab|Experimental: Nivolumab
46046581|NCT03544736|Radiation|Radiotherapy|Radiotherapy
45478111|NCT05863520|Behavioral|Facing Your Fears - School Based|FYF-SB is a CBT program for managing anxiety in autistic youth.
45478112|NCT05863507|Dietary Supplement|Grape powder supplementation|The participants will be willing to consume the grape powder dissolve in water daily for 6 weeks
45686883|NCT05815901|Drug|Epaminurad 6 mg placebo|Placebo tablet
46046582|NCT03544736|Drug|Chemotherapy|Chemotherapy
46046583|NCT03544736|Procedure|Surgery|Surgery
45355121|NCT05265910|Drug|loratadine 10 mg|Claritin® Tablets 24-Hour (tablet)
45355122|NCT05265910|Drug|Tears Naturale|Tears Naturale® II (eyedrop)
45355123|NCT05265910|Drug|Placebo|Placebo tablet (tablet)
45686884|NCT05815901|Drug|Epaminurad 9 mg placebo|Placebo tablet
45686885|NCT05815901|Drug|Febuxostat 40 mg placebo|Placebo tablet
45686886|NCT05815901|Drug|Febuxostat 80 mg placebo|Placebo tablet
45686887|NCT05815888|Diagnostic Test|Lung Ultrasound Score|"one hemithorax is consisted of 6 scanning zones. Each of them are evaluated via ultrasonography in terms of presence of vertical B lines (<4 B lines: 1 point; >3 B lines or thick B lines: 2 points; marked disturbance in pleural line: 3 points). Higher scores reflect worse outcomes such as atelectasis and consolidation, and totally 12 zones are evaluated.~Three different time points are defined for LUS:~T1: 5 minutes after orotracheal intubation T2: At the end of surgery, before extubation T3: 30 minutes after extubation, in postanesthesia care unit.~DeltaT= T2LUS-T1LUS~Blood gas analysis will be evaluated hourly throughout the surgery"
45843494|NCT01660230|Biological|3K3A-APC, diluted in 0.9% sodium chloride in water|
45843495|NCT01660230|Drug|0.9% NaCl in water|
45843496|NCT01660698|Dietary Supplement|Maltodextrin|maltodextrin powder
46046584|NCT03534518|Other|BWS overground training|BWS will be provided with the goal to impose the maximal lower extremity weight bearing load without excessive knee flexion during stance phase and/ or toe dragging during the swing phase. The walking tasks will be roughly divided into different domains like skilled walking, balance, dual tasking, walking speed, walking endurance.
45686888|NCT05815875|Combination Product|STEADI Program|The investigators will conduct STEADI Algorithm for Falls Prevention educational sessions for healthcare providers in the neurosurgery unit, including doctors, nurses, physical therapists, and pharmacists. All healthcare providers in the neurosurgery unit will be invited to attend the educational sessions. Their participation will be voluntary and no obligations will be made, though. Healthcare providers will be invited to attend one 2-hour educational session. In each session, The investigators will have between 8-10 healthcare providers. The educational sessions will be delivered in the classroom available in the neurosurgery unit to facilitate the healthcare providers' access. PowerPoint presentations, videos, quizzes, case studies, and in-class discussions will be used to deliver learning content during the educational sessions. Healthcare providers will then be asked to apply the STEADI interventions on a group of patients.
45843497|NCT01660698|Dietary Supplement|Probiotic|probiotic blended in maltodextrin powder
45843498|NCT01661088|Drug|FOLFIRINOX|"Starting dose levels as following:~Oxaliplatin 85mg/m2 intravenously over 120 minutes on day 1. Irinotecan 180mg/m2 intravenously over 90 minutes on day 1. NOTE: patients homozygous for the UGT1A1 (TA)7 promoter allele will be treated at an initial lower dose 140mg/m2 (please see Section 6.3.a) Leucovorin 400mg/m2 intravenously over 90 minutes on day 1. 5FU 400mg/m2 as bolus intravenous injection following leucovorin on day 1. 5FU 2,400mg/m2 infused intravenously as a continuous infusion over 46 hours following the bolus 5FU, beginning on day 1."
45843499|NCT01661088|Radiation|Intensity-modulated radiotherapy (IMRT)|50.0Gy in 2.0Gy per fraction
45843500|NCT01661088|Procedure|Surgical Exploration|Patients without metastatic disease will be offered surgical exploration.
45843501|NCT01661712|Device|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation (one night of electrical current titrated according to skin sensation)
45843502|NCT01661712|Device|Sham stimulation|Sham stimulation for one night (no electrical stimulation)
45843503|NCT01661946|Drug|Bevacizumab|Bevacizumab is an off-label but cheaper treatment for diabetic macular edema.
45843504|NCT01661946|Drug|Ranibizumab|Ranibizumab is a vascular endothelial growth factor inhibitor designed for ocular use
45843505|NCT01662882|Drug|florbetapir (18F)|IV injection, 370 MBq(10mCi), single dose
45843506|NCT01662960|Behavioral|Mirror therapy|A home-based therapy involving mirrored visual feedback
45843507|NCT01662960|Behavioral|Divider therapy|A home-based therapy involving removed visual feedback.
45843508|NCT01663272|Drug|CABOZANTINIB|Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.
45843509|NCT01663272|Drug|gemcitabine|Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.
45843510|NCT01667250|Device|GammaCore Active Device|
45843511|NCT01667250|Device|GammaCore Sham Device|
45843512|NCT01667406|Drug|Kisspeptin 1.6nmol/kg|single kisspeptin dose 1.6 nmol/kg subcutaneously
45478113|NCT05863507|Dietary Supplement|Placebo|The participants will be willing to consume the placebo powder, similar to the grape powder, dissolve in water daily for 6 weeks
46046585|NCT03534518|Other|BWS treadmill training|Training will be conducted on a standard treadmill with an overhead BWS system that can provide active BWS. Participants are allowed to hold the rails but weight bearing is not allowed. BWS will be provided with the goal to impose the maximal lower extremity weight bearing load without excessive knee flexion during stance phase and/ or toe dragging during the swing phase. Main walking tasks will be endurance (walking long distances at preferred speed) and speed (walking at maximal possible speed).
46046586|NCT03533010|Dietary Supplement|Ca500mg|subjects receive a daily dose of 500mg elemental calcium
46046587|NCT03533010|Dietary Supplement|VitD800IU|subjects receive a daily dose of 800IU VitD3
46046588|NCT03533010|Other|Placebo|subjects receive placebo tablet
45498266|NCT03192475|Behavioral|GLB plus newsletter contacts|GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The placebo comparator includes 4 additional newsletters only.
45843513|NCT01667406|Drug|Kisspeptin 3.2nmol/kg|single kisspeptin dose 3.2 nmol/kg subcutaneously
45843514|NCT01667406|Drug|Kisspeptin 6.4nmol/kg|single kisspeptin dose 6.4 nmol/kg subcutaneously
45843515|NCT01667406|Drug|Kisspeptin 9.6nmol/kg|single kisspeptin dose 9.6 nmol/kg subcutaneously
45843516|NCT01667406|Drug|Kisspeptin 12.8nmol/kg|single kisspeptin dose 12.8 nmol/kg subcutaneously
45843517|NCT01667406|Drug|Kisspeptin 9.6 nmol/kg double|kisspeptin dose 9.6 nmol/kg given twice 10hrs apart subcutaneously
45843518|NCT01667406|Drug|Kisspeptin 9.6 nmol/kg + saline|kisspeptin dose 9.6 nmol/kg subcutaneously and saline subcutaneously, 10hrs apart
45843519|NCT01667796|Dietary Supplement|Vitamin D3|
45843520|NCT01668030|Drug|Enzymatic agent|Enzymatic agent
45843521|NCT01668030|Drug|Bacitracin|
45843522|NCT01669434|Drug|ACEI continuation|These chronic medications will be taken without interruption preoperatively.
45843523|NCT01669434|Drug|ACEI omission|Although taken chronically by patients in this intervention, the final preoperative dose of these medications will be omitted, whether it was scheduled for the morning of surgery or the day prior.
45843524|NCT01670760|Device|Zero-heat-flux thermometry|The zero-heat-flux thermometer will be placed on the subject's lateral forehead for the duration of the surgery to measure deep tissue temperature.
45843525|NCT01673022|Drug|IC Green|IC Green
45843526|NCT01673256|Device|SJM Confirm ICM|
45843527|NCT01673568|Device|ETO garments|patients wearing abdominal binder for 7 days postoperatively
45843528|NCT01673802|Drug|CT scan|Gadoxetate (Eovist) enhanced dual energy CT
45843529|NCT01675830|Device|Heat Retention Head Wrap|Applied to infant's heads during the rewarming phase of CBP surgery
45843530|NCT01676298|Device|Spartan FRX CYP2C19 Test System|
45843531|NCT01676532|Other|Students attending SBHC|School based health clinic. This is a cohort study as such there is only one group of children who used the SBHC
45843532|NCT01677312|Procedure|Pancreatic Biopsy|A FNA needle will be used to biopsy the pancreatic mass. The rates of diagnostic accuracy (%) will be assessed. Diagnostic accuracy is defined as the proportion of patients in whom a definitive diagnosis can be obtained within a predetermined number of FNA passes.
45355124|NCT02601521|Behavioral|Internal tobacco coach|"The internal coaching program will provide cognitive-behavioral counseling and medication adherence support for smokers who are ready to quit in the next 3 months It consists of:~Telephone counseling by the Tobacco Coach (8 calls over 12 weeks). supplemented by automated phone calls using interactive voice response. At each IVR contact, smokers can request a call back from the Tobacco Coach. Smokers who are not quit after 3 months can restart into the 12-week counseling program.~The Tobacco Coach will assist smokers in choosing pharmacotherapy and in obtaining a prescription from the smoker's physician.~Support and monitoring for 12 months using automated phone calls. If relapse occurs, the smoker will have the option to return to the active 12-week program."
45355125|NCT02601521|Behavioral|External tobacco coach|Referral to Massachusetts Smokers Helpline (telephone quitline operated by the Massachusetts Tobacco Control Program) for proactive telephone counseling.
45355126|NCT00814866|Drug|Adalimumab|Adalimumab 40 mg sub-cutaneously every two weeks
45355127|NCT00991978|Other|89Zr-bevacizumab PET|PET-scan with 89Zr-bevacizumab
45355128|NCT05328076|Drug|Indocyanine green|Indocyanine green is used to perform intraoperative angiography.
46046589|NCT03529383|Device|Connected device|Women will receive a connected wristband (https://www.carefitness.com/) and a subscription to a smartphone application and website (http://disco.biomouv.com/). They will have to participate in a 6-month personalized non-supervised exercise program consisting of 3 weekly sessions of 20 min to 1-hr of moderate-to-vigorous physical activity (≥3 METs): 2 sessions of brisk walking and 1 session of muscle strengthening. Women should wear the wristband daily to track their number of steps (automatic Bluetooth synchronization to the application). Duration and intensity of sessions and target number of daily steps will progressively increase (+15% up to 10,000 steps) to place the patients in a progression dynamic. Women will receive phone-based follow-up at 1 week, 2 months, and 4 months.
45355129|NCT05328076|Device|SPY Portable Handheld Imaging (SPY-PHI)|The device is used to perform intraoperative angiography.
45355130|NCT00645528|Other|Insulin Education Class|Participation in an Insulin Education Class at week 0 and week 2
45355131|NCT04001140|Behavioral|Enhancement of emotion regulation skills|Regarding the intervention, 7 sessions will be carried out. The main purpose is to help adolescents to enhance their emotion regulation, with the ultimate goal to decrease their risk of developing addictions and other psychopathology.
45355132|NCT00812448|Dietary Supplement|tea catechin extracts|catechins are composed of tea catechin extracts available in grren tea supplements
45355133|NCT05326672|Drug|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 8 weeks after enrolment.
45355134|NCT05326672|Drug|Placebo|Placebo, applied twice daily for 8 weeks after enrolment.
45355135|NCT00295633|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (6 months ST, 12 months LT)
45355136|NCT00295633|Drug|Saxagliptin|Tablets, Oral, 5 mg, once daily (6 months ST, 12 months LT)
45355137|NCT00295633|Drug|Placebo|Tablets, Oral, 0 mg, Once daily (6 months ST, 12 months LT)
45686889|NCT05815875|Other|Routine care|The control group participants will receive routine care. Routine care involves only assessing for falls using Morse Falls Scale (MFS). MFS assesses a patient's fall risk upon admission, following a change in status, and at discharge or transfer to a new setting.
45355138|NCT00295633|Drug|pioglitazone|Tablets, Oral, 30 mg or 45 mg, once daily (6 months ST, 12 months LT)
45355139|NCT00295633|Drug|rosiglitazone|Tablets, Oral, 4 mg, once daily or 8 mg, either as once or twice daily (6 months ST, 12 months LT)
45686890|NCT05815862|Drug|AL2846 capsule|AL2846 is a multi-target tyrosine kinase inhibitor.
45686891|NCT05815849|Dietary Supplement|Olive oil|0.5 cc/30 ml of olive oil (a brand easily available in the markets) was added to the milk at each feeding of the infants in the intervention group
45686892|NCT05815823|Other|robotic exercise therapy|Functional exercise programs such as collecting rain in a glass, grating vegetables, goalkeeper, cleaning the stove, watering flowers, wiping windows, catching fish, and exploring landscapes were applied by robotic games to the patients
45686893|NCT05815823|Other|conventional therapy|streching, range of motion, strengthening, balance and walking exercise
45355140|NCT00295633|Drug|metformin|Tablets, Oral, 500-2500 mg, as needed (12 months LT)
45355141|NCT00812526|Procedure|Suction cup application|
45355142|NCT00812526|Procedure|Squatting|
45355143|NCT02368444|Behavioral|Cognitive Behavioral Therapy and Yoga|Group Cognitive Behavioral Therapy Treatment and Yoga Program
45355144|NCT05068596|Other|expermintal|progressive resistive functional strength training in the plantigrade foot position plus designed physical therapy program
45355145|NCT05068596|Other|CONTROL|Designed physical therapy program
45355146|NCT00570674|Drug|Abraxane|
45843533|NCT01677312|Procedure|Histological Samples|The proportion of patients (%) in whom a histological tissue can be obtained when performing a biopsy of the pancreas using a specific needle will be assessed.
45355147|NCT00570674|Drug|Erbitux|
45355148|NCT00570674|Drug|Carboplatin|
45355149|NCT00570674|Radiation|Intensity Modulated Radiation Therapy|
45498267|NCT03442374|Other|Exercise|The exercise protocol consists of 1 set of 20 repetitions (range 15-25 reps) at a rate of 5 seconds/repetitions with a starting weight of 60-80% of their computerized strength score. Patients will be instructed to target an exertion level of 7/10 on the Borg Rate of Perceived Exertion (RPE) scale within their available passive ROM range into flexion-extension
45498268|NCT03683862|Other|orthodontic appliance|Orthodontic device for retention in the upper arch, after the end of orthodontic treatment
45478114|NCT05863494|Device|Transcranial Direct Current Stimulation (tDCS)|TDCS is a non-invasive brain stimulation that uses electrical currents to stimulate specific areas of the brain. A constant, low-intensity current passes through two to four electrodes, which can be placed on various locations on the head, to modulate neuronal activity. tDCS can administer anodal and cathodal stimulation to excite (depolarization) or inhibit (hyperpolarization) neuronal activity, respectively. Using low-amplitude direct currents applied via scalp electrodes to alter cortical excitability is not a novel concept. This non-pharmacological approach has held promise for decades as a way to treat a plethora of neurological and psychiatric disorders. Although tDCS is not currently FDA-approved it is considered a non-significant-risk therapy with no record of serious adverse effects.
45478115|NCT05863494|Device|Transcranial Direct Current Stimulation (tDCS) sham|"TDCS is a non-invasive brain stimulation that uses electrical currents to stimulate specific areas of the brain. A constant, low-intensity current passes through two to four electrodes, which can be placed on various locations on the head, to modulate neuronal activity. tDCS can administer anodal and cathodal stimulation to excite (depolarization) or inhibit (hyperpolarization) neuronal activity, respectively. Using low-amplitude direct currents applied via scalp electrodes to alter cortical excitability is not a novel concept. This non-pharmacological approach has held promise for decades as a way to treat a plethora of neurological and psychiatric disorders.~The sham group will receive 1 minute from 0.0mA to no more than 0.5mA at the initiation of the treatment after which the current will be turned off. This is to maintain a blind trial. 0.5mA is negligible current, but mimics treatment with an initial small tingle."
45355150|NCT00808314|Drug|Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 0.56 mg/kg of dipyridamole will be infused over 4 minutes. Three minutes after the completion of the infusion, approximately 60 mCi of Rb-82 will be infused. Peak stress images will be acquired with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan will be acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
45355151|NCT00808314|Drug|Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 400 umg of Lexiscan(TM) will be injected, and then approximately 60 mCi of Rb-82 waill be infused. Peak stress images will be acquired in list mode with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan willbe acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
45355152|NCT04992052|Device|Bone wax|The surgeons will apply the bone wax to the exposed cancellous bone after the implant has been cemented in place in patients randomized to the treatment arm.
45478116|NCT05863481|Procedure|Laparoscopic cerclage placement|The surgical method of the laparoscopic cerclage procedure at Aarhus University Hospital previous described in a paper by Riiskjaer et al (DOI: 10.1111/aogs.12001)
45478117|NCT05863468|Device|ArchSinus implantation|Unilateral or bilateral in-office middle turbinate medialization and subsequent ArchSinus implantation
45478118|NCT05863455|Drug|mild sedation and analgesia|Intravenous injection of 0.1ug/kg sufentanil and 0.03mg/kg midazolam for sedation and analgesia before radial artery cannulation
45478119|NCT05863455|Drug|control|ntravenous injection of an equivalent volume of saline before radial artery cannulation.
45478120|NCT05863442|Drug|Soliris 300 MG in 30 ML Injection|Active Comparator
45478121|NCT05863442|Drug|TUR03 300 MG in 30 ML Injection|Investigational medicinal Product, eculizumab - Turgut
45478122|NCT05863429|Biological|Taking biological samples (blood) and keeping records with phone calls|Within the scope of the study, no intervention will be made to the participants. According to the vaccination program implemented in Turkey, subjects who apply to the study centers for TURKOVAC vaccine will be invited to the study.
45478123|NCT05863416|Drug|Dexmedetomidine infusion|Intraoperative dexmedetomidine infusion
45478124|NCT05863403|Diagnostic Test|Neuromuscular Training|Neuromuscular Training on Balance and Fall in Geriatric Population With Fall Risk
45478125|NCT05863403|Diagnostic Test|Traditional Exercise|Traditional Exercise on Balance and Fall in Geriatric Population With Fall Risk
45478126|NCT05863390|Behavioral|McKenzie exercise|routine simple McKenzie exercise
45478127|NCT05863390|Diagnostic Test|Trochanteric belt|Trochanteric belt with conventional physical therapy
45478128|NCT05863364|Drug|Low-dose of Rifaximin|The patients in group B were given rifaximin with the dose of 600mg/d (600mg, qd) for 24 weeks
45478129|NCT05863364|Drug|Conventional dose of Rifaximin|the patients in group C were delivered 1200mg/d (600mg, bid) for 24 weeks
45478130|NCT05863351|Procedure|Computed Tomography|Undergo CT
45478131|NCT05863351|Procedure|Magnetic Resonance Imaging|Undergo MRI
45843534|NCT01678794|Drug|Candesartan|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
45355153|NCT00812682|Drug|Symbicort|
45355154|NCT00768989|Drug|Atazanavir|Capsules, Oral, 300 mg, twice daily, 96 weeks
45355155|NCT00768989|Drug|Raltegravir|Tablet, Oral, 400 mg, twice daily, 96 weeks
45355156|NCT00768989|Drug|Atazanavir|Capsules, Oral, 300 mg, once daily, 96 weeks
45355157|NCT00768989|Drug|Ritonavir|Capsules, Oral, 100 mg, once daily, 96 weeks
45355158|NCT00768989|Drug|Tenofovir/Emtricitabine|Tablet, Oral, 300-mg Tenofovir/200-mg Emtricitabine, once daily, 96 weeks
45355159|NCT04991038|Device|DAISe Device|Thrombectomy using the DAISE device
45355160|NCT04991038|Device|Trevo or Solitaire|Thrombectomy using TREVO or Solitaire device
45355161|NCT00779714|Drug|DTIC (dacarbazine)|1000 mg/m2, d1 every 21 days
45355162|NCT00779714|Drug|paclitaxel + cisplatin|paclitaxel 200 mg/m2 cisplatin 50 mg/m2 d1 every 21 days
45355163|NCT00779714|Drug|treosulfan + cytarabine|treosulfan 2500 mg/m2, d2 cytarabine 100 mg/m2, d1-3 every 21 days
45478132|NCT05863351|Other|Questionnaire Administration|Ancillary studies
45478133|NCT05863351|Procedure|Stereotactic Ablative Radiotherapy|Undergo SAbR
45478134|NCT05863351|Procedure|Systemic Therapy|Given standard of care systemic therapy
45498269|NCT03623490|Other|managment of oral therapy|Initial consultation with a trio oncologist / pharmacist / nurse
45498270|NCT03425838|Drug|CDK 4/6 inhibitor|Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
45498271|NCT03425838|Drug|Non-Steroidal Aromatase Inhibitor|Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
46046590|NCT03529383|Behavioral|Therapeutic education|"Women will be invited to participate in the 6-month therapeutic patient education program Mieux manger, mieux bouger (Eat better, move better) elaborated at the Léon Bérard cancer center. The program consists in four sessions:~a 1-hour individual session of educational diagnosis to assess their needs and establish a contract of objectives,~two educational sessions of 1h30 each using tools, in group of 10 patients maximum to improve their daily practice of physical activity,~a 1-hour individual session of educational assessment to evaluate whether their objectives were reached."
46046591|NCT03528031|Other|Intervention Daily Avocado|Participants follow their usual diet and lifestyle but also are provided with 1 avocado to consume per day for 6 months.
46046592|NCT03495440|Behavioral|Center Sessions|Program to support relationships and communication between parents and typically developing adolescent siblings of individuals with intellectual and/or developmental disabilities.
46046593|NCT03495440|Behavioral|At-home|Self-study resources paired with regular contact with study personnel.
45355164|NCT00812760|Drug|levodopa|1 tablet of 200 mg levodopa plus 50 mg benserazide
45355165|NCT00814944|Drug|Sirolimus|Subconjunctival injection of 440 micrograms sirolimus in each eye.
45355166|NCT00814944|Drug|Sirolimus|Subconjunctival injection of 220 micrograms sirolimus in each eye.
45355167|NCT00814944|Drug|Sirolimus|Subconjunctival injection of 880 micrograms sirolimus in each eye.
45355168|NCT00814944|Drug|Sirolimus|Subconjunctival injection of placebo in each eye.
45355169|NCT05308498|Diagnostic Test|ESView software with proscan|Each reviewer will review random video and record all lesions/findings with the ESView software with ProScan.
45355170|NCT05308498|Diagnostic Test|Rapid software with SBI|Each reviewer will review random video and record all lesions/findings with the PillCam Rapid software with SBI.
45355171|NCT00779792|Drug|clobetasol|0.5 mg Clobetasol propionate (0.5 mg/g) ointment applied twice daily for 10 consecutive days
45355172|NCT00779792|Drug|triamcinolone acetonide|0.5 mg ointment twice daily for 10 consecutive days
45355173|NCT00779792|Drug|tacrolimus|0.5 mg tacrolimus ointment(0.1%) twice daily for 10 consecutive days
45355174|NCT00779792|Drug|glycerol|0.5 mg glycerol ointment (20%) twice daily for 10 consecutive days
45355175|NCT00779792|Drug|vehicle ointment (paraffin oil/soft white paraffin)|0.5 mg vehicle ointment twice daily for 10 consecutive days
45355176|NCT00992134|Drug|Rituximab, Bendamustine, Cytarabine|"Rituximab IV 375 mg/m2 on day 1. Bendamustine IV 70 mg/m2 over a 30-60 minute infusion on day 1 and 2. Cytarabine IV 800 mg/m2, over a 2-hour infusion, 2 hours after Bendamustine, on Day 1, 2, and 3.~Four to six cycles. Recycle every 28 days."
45355177|NCT02551536|Drug|Montelukast|
45355178|NCT02551536|Drug|Fexofenadine|group B received FDC tablet of montelukast 10mg and fexofenadine 120 mg O.D
45355179|NCT02551536|Drug|Levocetrizine|group A recieved FDC tablet of montelukast 10 mg and levocetrizine 5mg O.D
45355180|NCT02556164|Procedure|Electroacupuncture|Acupuncture is an alternative medicine methodology that treats patient by various techniques including inserting small, thin needles at specific points of body. Electroacupuncture (EA), like the name implies, combines classical acupuncture and low electric current running through the needles, which are often used to enhance a treatment.
45355181|NCT02556164|Other|Body-worn sensor technology|Three-dimensional acceleration and angular velocity of shanks, thighs and the trunk were measured using wearable sensors each included a triaxial accelerometer and a triaxial gyroscope (LEGSys™ and BalanSens™ - BioSensics, Boston, MA)
45355182|NCT00815022|Drug|bupivacaine/fentanyl/morphine|Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
45355183|NCT00774722|Drug|Metronidazole|10% ointment, three times daily for 14 days
45355184|NCT00808392|Biological|Haemophilus influenzae type b vaccine|3 doses one month apart of Monovalent conjugated vaccine against Haemophilus influenzae type b vaccine
45355185|NCT00808392|Biological|Commercial Haemophilus influenzae type b vaccine|3 doses one month apart of Haemophilus influenzae type b vaccine.
45355186|NCT04045548|Drug|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
45355187|NCT04045548|Drug|Placebo|one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
45355188|NCT02262988|Procedure|Total knee replacement|Total knee replacement (TKA)
45355189|NCT02556944|Device|Phacoemulsification with multifocal intraocular lens|Phacoemulsification and implantation of a multifocal intraocular lens (IOL) with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally. They're called mix and matched patients.
45355190|NCT00808548|Other|counseling, emotional support|
45355191|NCT00808548|Other|emotional support|emotional support during the interview
45355192|NCT00808548|Other|emotional support|emotional supporting during the interview
45355193|NCT04920136|Procedure|Strip Free gingival graft (SGG) + Acellular Dermal Matrix graft (ADM)|A horizontal incision is then placed at the middle of residual KT. Two vertical releasing incisions are followed to allow for apical displacement of the flap. The flap will be then elevated with a split-thickness flap beyond the mucogingival junction where it is sutured at this apical position using a mattress (5-0, monocryl) suture. The recipient site should ideally retain intact periosteum that is firmly attached to bone with no loose fibers, no irregularities and no perforations.
45355194|NCT04920136|Procedure|Free Gingival graft|Two vertical incisions are made, and a partial thickness flap are designed to provide a firm and immobile periosteal bed. The raised partial thickness flap will be excised. Muscle and unattached connective tissue fibers are thoroughly scraped with a scalpel to prevent graft mobility. Autogenous FGG was harvested with #15C scalpel blade from hard palate at the same side randomly selected to receive the FGG. Donor area was sutured with 5-0 gut sutures. FGG, is placed and stabilized with simple interrupted 5-0 vicryl sutures at recipient site coronal border and horizontal or periosteal anchorage sutures over the graft.
45478135|NCT05863338|Behavioral|NURSING FOLLOW-UP BY PHONE|The training was carried out in the form of individual training and as a single session.The training,which lasted about 30 minutes,was carried out in the training room of the polyclinic with the support of Barco vision.In the training session,lecture,question-answer methods were used and at the end of the training session,a booklet containing the training content was given to the patients.The researcher phoned the patients once a week for 24 weeks,conveyed how they were doing,whether there was anything they wanted to ask or learn,and provided counseling to the patients in line with their needs.The next week's plan was also determined in the phone calls made in the following weeks.Patient follow-ups as stated were continued for 24 weeks.At the 12th and 24th weeks of the telephone nursing follow-up, the patients filled out the scales again.
45843535|NCT01678794|Drug|Placebo|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
45843536|NCT01679028|Drug|T89 Group A|150mg single dose on day 1
46046594|NCT03490838|Drug|177Lu-PSMA-R2|radio-ligand therapy
46046595|NCT03463954|Device|Novilase Laser ablation|Image-guided, percutaneous laser ablation of breast tumors
46046596|NCT03462004|Biological|HPIV3/ΔHNF/EbovZ GP vaccine|Administered intranasally
46046597|NCT03462004|Biological|Placebo|Administered intranasally
45355195|NCT00780104|Drug|Rapamycin, Mitoxantrone, Etoposide, Cytarabine|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
45355196|NCT00780104|Drug|Rapamycin + MEC|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
45355197|NCT00815100|Drug|Ivabradine|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
45355198|NCT00815100|Drug|Placebo|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
45355199|NCT00992212|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple sites; appr. 160 subjects exposed to the annual vaccine registration will be invited to take part into this study. In addition, a total of 224 healthy subjects not yet exposed to the seasonal influenza vaccines will be enrolled.
45355200|NCT04047680|Drug|Sofosbuvir / Velpatasvir Oral Tablet|Sofosbuvir/velpatasvir for 12 weeks
45355201|NCT04047680|Drug|Sofosbuvir and Ledipasvir|Sofosbuvir and ledipasvir for 12 weeks
45478136|NCT05863325|Drug|HB1801|HB1801 will be administered by intravenous (IV) injections on the first day of each cycle.
45355202|NCT04047680|Drug|Sofosbuvir Tablets|Sofosbuvir plus ribavirin (RBV) or daclatasvir (DCV) for 12 weeks
45355203|NCT04047680|Drug|Ombitasvir/paritaprevir/ritonavir|Ombitasvir/paritaprevir/ritonavir for 12 weeks
45355204|NCT04047680|Drug|Elbasvir / Grazoprevir Oral Tablet|Elbasvir/grazoprevir for 12 weeks
45355205|NCT04047680|Drug|Glecaprevir and Pibrentasvir|Glecaprevir/pibrentasvir for 12 weeks
45478137|NCT05863325|Drug|Taxotere|Taxotere will be administered by intravenous (IV) injections on the first day of each cycle.
45498272|NCT03425838|Drug|Fulvestrant|Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
45498273|NCT03189745|Biological|MenACWY-TT|Single dose of MenACWY-TT given 10 years after first vaccine with either MenACWY-TT or Mencevax ACWY
45498274|NCT03188263|Other|Bright Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance is 230 μW/m2 and lux is 500 lux.
45686894|NCT05815810|Other|Attuned: A mobile application|Subjects will undergo voice and communication modification therapy via the Attuned application. This consists of an 11 week program consisting of different modules to learn how to modify voice (e.g., pitch, intonation, resonance). At the end of each module, participants will be given exercises to practice what they learned.
45355206|NCT00815178|Behavioral|Inspiratory muscle training|For Inspiratory muscle training (IMT)patients carried out the IMT on a daily basis for eight weeks, with duration of 30 minutes and intensity corresponding to 30% of resting PImax, with a linear pressure resistance device (Threshold®). Weekly maximum inspiratory pressure (PImax) evaluations and workload adjustments were performed. Inspiratory load was adjusted on a weekly basis to maintain 30% of the subject's PImax. Training sessions were carried out at home for both groups and supervised once a week at the hospital.
45355207|NCT00815178|Behavioral|Inpiratory muscle training placebo|Inspiratory muscle training was carried out on the same basis as in the intervention group but with no inspiratory load.
45355208|NCT00774878|Drug|AVE1642|AVE1642 is administered intravenously at the dose of 8 mg/kg.
45686895|NCT05815810|Other|In-Person Voice Modification Therapy|Subjects will undergo standard of care in-person voice modification therapy at Ithaca College.
45686896|NCT05815797|Drug|SDD formula|SDD formula consists of 23 herbal medicines
45686897|NCT05815797|Drug|Placebo|Placebo
45686898|NCT05815784|Drug|Atropine|0.05% atropine. One drop per eye per day for 2 years.
45686899|NCT05815784|Device|MiSight contact lenses|Daily wear for 2 years.
45355209|NCT00774878|Drug|Fulvestrant|Fulvestrant is administered as a slow intramuscular injection (just before the AVE1642 infusion when given in combination).
45686900|NCT05815771|Procedure|Micro fragmented adipose tissue mixed with bone marrow stem cells|mixture of stem cells
45686901|NCT05815771|Procedure|Bone Marrow stem cells aspirate|stem cells
45686902|NCT05815745|Device|Pacemaker - Physiological pacing|The approach for physiological pacing will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.
45686903|NCT05815745|Device|Pacemaker - Right Ventricular pacing|Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice).
46046598|NCT03456336|Other|Active Treatment|Infants assigned to the active treatment group will receive indomethacin or ibuprofen per their local site usual care dosing and schedule if the infant has a sPDA. The choice of indomethacin or ibuprofen will be left to the center, however, infants may only receive one or the other. If the infant receives both, it will be considered a protocol violation.
46046599|NCT03456336|Other|Expectant Management|Infants assigned to the expectant management group will receive indomethacin or ibuprofen if cardiopulmonary compromise occurs.
46046600|NCT03453112|Drug|Foster 100/6mg NEXThaler|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler
46046601|NCT03453112|Drug|Foster 100/6mg pMDI|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as pMDI with HFA_134a propellant
45686904|NCT05815732|Other|Physical exercise|Personalized exercise program, with defined modalities, intensity, duration, frequency and progression of the exercise.
45355210|NCT04917172|Diagnostic Test|postoperative acute pancreatitis evaluation|Surgical resection and reconstruction will be carried out according to the Institutional standards. After the surgical procedure, serum pancreatic amylase and lipase activity will be systematically measured two hours after surgery on postoperative day (POD) 0 and every day at 7 a.m. until POD 5 according to our institutional policy. At our institution, the upper limit of normal for serum pancreatic amylase is 52 U/L and for serum lipase is 60 U/L. Postoperative protocols included the routine measurement of inflammatory markers (white blood cell [WBC] count and C-Reactive Protein [CRP]). A urine trypsinogen strip test will be done on POD 1. A trypsinogen-2 concentration of more than 50 µg/l is considered a positive test. As routine clinical practice, a post-operative imaging will be scheduled to check for potential surgical morbidity. Abdominal magnetic resonance imaging (MRI) will be assessed on POD 3.
45355211|NCT00815256|Procedure|Collagen Cross Linking with Riboflavin and UVA light|The patients randomized and allocated to this group are submitted to the treatment with riboflavin and ultraviolet -A light, if they do not match any of the exclusion criterion. The treatment is done as follows:after topical anesthesia, the epithelial tissue was removed in a 8.0mm diameter area of the central cornea, the 0,1% riboflavin solution were applied every 2 min, for 30 min followed by cornea irradiation with UVA light with a wavelength of 370 nm and an irradiance of 3 mW/cm2. During the irradiation, drops of the riboflavin solution were continuously applied onto the cornea every 5 min. After the procedure, a therapeutic contact lens and antibiotic eye ointment are applied onto the cornea for a week. We see the patient in the next day.
45355212|NCT00774956|Procedure|Exercise training program|A 6 week shoulder exercise training program
45355213|NCT00774956|Procedure|Exercise training program|A 6 week shoulder exercise training program
45355214|NCT00815334|Procedure|Endoscopic subureteric injection|Endoscopic subureteric injection for the treatment of vesicoureteral reflux using variable materials (polydimethylsiloxane, collagen, and dextranomer/hyaluronic acid copolymer)
45478138|NCT05863312|Procedure|Pars plana vitrectomy|Pars plana vitrectomy will be performed in a standard fashion starting with central vitrectomy, then by localizing retinal breaks, and marking them with endodiathermy. Perfluorocarbon will be used to displace subretinal fluid which will be aspirated at its exit from the retinal break as much as possible and maximal vitreous base shaving will be performed in all cases. This will be followed by an air-fluid exchange. Use of cryotherapy to solidify the retina intraoperatively and use of internal limiting membrane peeling of the posterior pole will be at the discretion of the surgeon. In all cases, laser photocoagulation around retinal breaks, holes, areas of lattice degeneration, and posterior to sclerotomy sites will be done and then a 360° laser retinopexy will be performed at the surgeon's discretion and consisted of three rows of medium-white burns anterior to the level of the vortex vein, towards and beyond the equator.
45478139|NCT05863312|Procedure|Pars plana vitrectomy with scleral buckle|In cases with SB, after 360° peritomy and dissection in 4 quadrants, a 41-circling band with 3082 sleeves (Labtician Ophthalmics, Oakville, ON Canada) will be used in all cases and fixed to the sclera at approximatively 11.5 mm from the limbus (or 5.5 from the insertion of rectus muscles) using partial thickness scleral tunnel or mattress sutures with 5.0 prolene or nylon performed in 4 quadrants depending on the surgeon preferences. Pars plana vitrectomy will then be performed as in the PPV only group.
45478140|NCT05863312|Other|Sulfur hexafluoride gas tamponade|At the end of the surgery, the eye is filled with sulfur hexafluoride gas tamponade.
45478141|NCT05863312|Other|Perfluoropropane gas|At the end of the surgery, the eye is filled with perfluoropropane gas tamponade.
45686905|NCT05815719|Drug|Corifollitropin Alfa|150 micrograms per dose
45355215|NCT00778778|Drug|cefprozil 500mg tablets|
45355216|NCT00815412|Behavioral|Counseling in use of health care|
45355217|NCT00815412|Behavioral|Counseling in diet, exercise|
45355218|NCT00815412|Other|Control|
45355219|NCT00305773|Drug|vorinostat|Given orally once daily
45355220|NCT00305773|Drug|vorinostat|Given orally three times daily
45355221|NCT00778856|Procedure|Hand transplantation|allotransplantation of deceased donor composite tissue (hand and forearm)
45355222|NCT02552004|Device|pCLE|Histological examination by pCLE technique preceding the frozen section
45355223|NCT02552004|Drug|IV fluorescein administration|IV Fluorescein (fluorescent contrast agent) administration
45478142|NCT05863273|Drug|Apremilast|Dosage of Apremilast（Otezla®） from 10mg qd, titrate to recommended dosage of 30 mg BID，recommended by specification.
45478143|NCT05863260|Drug|Treatment Group|Treatment Group
45686906|NCT05815719|Drug|Follitropin Alfa|Variable dose.
45686907|NCT05815719|Drug|Follitropin Alfa Biosimilar|Variable dose.
45686908|NCT05815719|Drug|Urinary Human follicle stimulating hormone|Variable dose.
45686909|NCT05815706|Device|MEDELA Supplemental nursing system|The experimental group participants were fed based on the MEDELA Supplemental Nursing System, which consists of a syringe/container and a feeding catheter. One end of the feeding probe is in the syringe/container, while the other is fixed to the mother's nipple through a plaster. MEDELA SNS is a sterile product with an adjustable breast milk flow system and neck strap. It is bisphenol A (BPA) free. All its parts are in direct contact with breast milk. This system allows the baby to both suck and feed (MEDELA Supplemental Nursing System, 2018).
45843537|NCT01679028|Drug|Placebo Group A|150mg single dose
45843538|NCT01679028|Drug|Placebo Group B|300mg single dose
46046602|NCT03449511|Other|Ginger aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
46046603|NCT03449511|Other|Orange aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
46046604|NCT03449511|Other|Lavender aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
46046605|NCT03449511|Other|Jojoba aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
46046606|NCT03409198|Drug|Ipilimumab|Ipilimumab blocks CTLA-4 and may deplete regulatory T cells
45843539|NCT01679028|Drug|T89 Group B|300mg single dose
45355224|NCT00780182|Drug|CMX001|CMX001 tablet fasted, CMX001 tablet fed, CMX001 solution fasted
45355225|NCT00812994|Drug|Escitalopram|SSRI antidepressant
45478144|NCT05863221|Drug|ZYNRELEF 200Mg-6Mg Extended-Release Solution|ZYNRELEF® is an extended-release, fixed-ratio combination product that contains bupivacaine (a local anesthetic as the free base) and low-dose meloxicam (an NSAID) incorporated in a bioerodible polymer (termed Biochronomer®).
45478145|NCT05862766|Drug|Isatuximab|The dose will consist of isatuximab 10 mg/kg actual body weight given weekly for the first 4 weeks, followed by 10 mg/kg biweekly for an additional 4 doses. Isatuximab is a clear, colorless to slightly yellow solution. It is supplied as 100 mg/5 mL or 500 mg/25 mL single-dose vials.
45478146|NCT05862766|Procedure|bone marrow biopsy|Bone marrow biopsy at the time of lung transplantation and at approximately 1 month following completion of therapy. Initial bone marrow biopsy to be performed during the lung transplant operation and to be collected from the sternum by the operating surgeon. Follow-up bone marrow biopsy to be completed by credentialed hematologist during a regularly scheduled follow-up bronchoscopy with standard procedural anesthesia sedation.
45843540|NCT01679028|Drug|Placebo Group C|225mg bid
45843541|NCT01679028|Drug|T89 Group C|225mg bid
45843542|NCT01680666|Procedure|central line placement|central line placement
45843543|NCT01680666|Device|Ultrasound|Ultrasound guided central venous access
45843544|NCT01680900|Drug|vilazodone|capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved.
45843545|NCT01680900|Drug|placebo capsules|placebo capsules matched to drug capsules.
45843546|NCT01682538|Drug|Nitisinone, capsule|
45843547|NCT01682538|Drug|Nitisinone, suspension|
46046607|NCT03409198|Drug|Nivolumab|Nivolumab blocks PD-1 and thereby enhances the effector phase of the immune reaction, by enabling T cells to kill tumor cells and engage effectively with other PD-L1 expressing targets.
45478147|NCT05862272|Drug|Relugolix Combination Tablet|A fixed-dose combination tablet containing relugolix 40 mg, estradiol (E2) 1 mg, and norethindrone acetate (NETA) 0.5 mg.
45843548|NCT01684020|Biological|ARTISS human fibrin sealant|
45843549|NCT01684410|Biological|Alpha-1 HC 100 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 100 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
45843550|NCT01684410|Biological|Placebo|Phosphate Buffer Saline with Polysorbate (placebo) composed of the same elements listed for Alpha-1 HC, minus the 50 mg/mL of Alpha-1 HC. Placebo inhaled once daily for 21 days for a total of 21 inhaled treatments.
45843551|NCT01684410|Biological|Alpha-1 HC 200 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 200 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
45843552|NCT01684566|Device|episil(R)|episil® is a lipid-based liquid that spreads onto mucosal surfaces and transforms into a protective, strongly bioadhesive FluidCrystal® film after intraoral administration.
45843553|NCT01684566|Other|Oral hygiene procedures|Oral hygiene by using toothbrush, toothpaste, lip balm and dental floss (if available)
45843554|NCT01686750|Behavioral|Integrated care centers|
45843555|NCT01688310|Procedure|Gomco Clamp with Tissue Adhesive|"According to WHO (2011), the Gomco clamp has …an impeccable safety record. In the USA, where it is estimated that well over 1 million neonates are circumcised each year, the Gomco clamp has become the leading instrument used to perform non-ritual male circumcision. Tissue adhesive is widely used in multiple areas of medicine; specifically, multiple observational studies and RCTs have shown cyanoacrylate tissue adhesives to be superior to suture closure in VMMC."
45843556|NCT01688310|Procedure|Open surgical circumcision|The World Health Organization, in its Manual for Male Circumcision under Local Anaesthesia, describes three open surgical techniques (forceps assisted, dorsal slit and sleeve technique), all three of which involve (a) exposure of subcutaneous tissues and (b) suturing for hemostasis and for skin closure.
45843557|NCT01688856|Device|Electrical Stimulator|"The 12-week treatment period consists of two components:~Therapist-guided task practice performed 70 minutes twice a week in the research laboratory. If Arm+Hand CCFES or Hand CCFES, the stimulator is used during task practice.~Self-administered muscle stimulation exercise performed 10 sessions per week at home using the device. If Arm+Hand CCFES or Hand CCFES, each session is 46 minutes. If Arm+Hand Cyclic NMES, each session is 60 minutes."
45843558|NCT01689324|Biological|(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis|0.5 mL, Intramuscular
46046608|NCT03409198|Drug|Pegylated liposomal doxorubicin|Chemotherapy
45355226|NCT00812994|Drug|Placebo|
45355227|NCT00780260|Behavioral|strengths-based case management|5 session individual strengths-based case management; peer-involvement v. no peer involvement
45355228|NCT00784394|Drug|diindolylmethane|Given PO
45355229|NCT00784394|Other|placebo|Given PO
45355230|NCT00784394|Other|pharmacological study|Correlative studies
45355231|NCT00784394|Other|laboratory biomarker analysis|Correlative studies
45355232|NCT00784394|Other|quality-of-life assessment|Ancillary studies
45355233|NCT00778934|Other|Intimate Health Gel|Intimate Health Gel
46046609|NCT03409198|Drug|Cyclophosphamide|Chemotherapy
46046610|NCT03385980|Other|Proteomic analysis|Proteomic analysis of tissues collected from all sites of disease, guided by either imaging performed prior to the patient's death or post-mortem findings. Peripheral blood mononuclear cells (PBMC) will be collected with the purpose of identifying somatic changes occurring specifically in the tumor cells and not in normal DNA of the same patient.
45355234|NCT04047524|Other|Monitoring using a FitBit|Each participant will receive a Fitbit. The Prehabilitaiton Group will receive a Fitbit Charge 2 and they will be able to review their progress on this and be required to increase their exercise activity and input information and data about the exercise they have completed each day during their participation in the study. The Control group will receive a Fitbit Flex and will not be required to review any of their activity or input any data and will be encouraged to continue with their daily activity rates i.e. not to change.
46046611|NCT03382548|Drug|Reducing Antibiotics treatment duration|Antibiotics should be stopped from day 3 to 7 if respiratory cultures are negative and the patients fulfill a set of stringent clinical criteria signifying cardiopulmonary stability for 48 hours. If the respiratory cultures are positive, patients who fulfill the same set of clinical criteria should have their antibiotics stopped from day 5 to 7.
46046612|NCT03382548|Drug|Standard Antibiotics treatment duration|Participants in the control (long duration) arm will receive standard care, which is antibiotic treatment for at least 8 days with the exact duration decided by the primary physician.
45355235|NCT02556398|Behavioral|Sugar Sleuth|"Educational module and use of smart phone app (Sugar Sleuth)"
45355236|NCT00305695|Other|Laboratory Biomarker Analysis|Correlative studies
45355237|NCT00305695|Drug|Zoledronic Acid|Given IV
45355238|NCT00784472|Drug|oxycodone|intravenous according to patients weight, pn.
45355239|NCT00784472|Drug|morphine|intravenous administration according to patients weight, pn.
45355240|NCT00779012|Biological|Infliximab|Remicade 5 mg/kg, given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks (maximum 9 infusions).
45355241|NCT00784706|Other|EP|Participants were asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
45355242|NCT00784706|Other|CIT|The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log.
45355243|NCT00784706|Other|conventional therapy|Traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
45843559|NCT01692756|Drug|Kenalog or placebo|
45355244|NCT00647556|Drug|adapalene gel, 0.3%|applied topically once daily in the evening
45355245|NCT00647556|Drug|tretinoin 0.05% emollient cream|applied topically once daily in the evening
45355246|NCT03978559|Drug|caspofungin|caspofungin 70mg ivdrip the first day, then 50mg ivdrip qd for 21days
45843560|NCT01692756|Drug|Kenalog then Placebo|
45355247|NCT03978559|Drug|TMP/SMZ(trimethoprim/sulfisoxazole)|TMP:15mg/kg/d for 21 days +SMZ:75mg/kg/d for 21days
45843561|NCT01692756|Drug|Kenalog|
45843562|NCT01692756|Drug|Placebo|
45843563|NCT01695330|Drug|Subcutaneous bortezomib|Bortezomib will be administered SC at a dose of 1.0 mg/m2. Doses are to be administered on days 1, 4, 8, and 11 of a 28-day cycle. All other drugs used in combination with the SC bortezomib as well as their doses and schedules will be at the discretion of the Principal Investigator.
45843564|NCT01698528|Device|Tablet Computer|
45355248|NCT03978559|Drug|Methylprednisolone|40mg ivdrip q12h for 5 days , then 40mg ivdrip qd for 5 days , 20mg for 11 days
45355249|NCT03981133|Behavioral|offer a pacifier|offer a pacifier to normal newborn infants the first days of life
45355250|NCT03981133|Behavioral|no pacifier|not to offer a pacifier at 15 days of life
45355251|NCT00813072|Drug|PEP02|"120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
45355252|NCT00813072|Drug|irinotecan|300 mg/m2, IV infusion on day 1 of each 21 day as a treatment cycle. Number of Cycles: until progression or unacceptable toxicity develops.
45355253|NCT00813072|Drug|docetaxel|"75 mg/m2, IV infusion for 60 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
45355254|NCT03980821|Drug|AZD4635|AZD4635 taken orally
45355255|NCT00813228|Drug|Sitagliptin (Januvia)|
45355256|NCT00320593|Device|Progressive Addition Lenses (PALs)|Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition
45355257|NCT00320593|Device|Single Vision Lenses (SVLs)|Single vision lenses
45355258|NCT00813306|Drug|AZD2066|13 mg oral solution, 1 single dose
45355259|NCT00813306|Drug|Placebo|Oral solution, 1 single dose
45355260|NCT00813306|Drug|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
45355261|NCT00813306|Drug|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
45843565|NCT01698684|Drug|Placebo|One dose 15 minutes before attempting intercourse
45843566|NCT01698684|Drug|Avanafil 100 mg|One dose 15 minutes before attempting intercourse
45355262|NCT00813306|Drug|Placebo|Oral solution, 1 single dose
45355263|NCT00813384|Drug|AMG 208|AMG 208 is a small molecule inhibitor of c-Met which is a well-characterized receptor tyrosine kinase expressed on the surface of epithelial cells. C-Met receptor signaling has been shown to play a key role in the survival of cancer cells. AMG 208 inhibits both ligand-dependent and ligand-independent c-Met cellular growth regulation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival.
45355264|NCT01061983|Device|Medtronic Activa Deep Brain Stimulation|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
45355265|NCT00808626|Drug|99mTc-rBitistatin|Intravenous administration of a single dose (10 mCi, 0.1 ug/kg body weight) of 99mTc-rBitistatin, followed by collection of scintigraphic (planar and SPECT) images at 1 hour and 2-4 hours.
45355266|NCT04017078|Other|diagnosis of carotid artery calcification on digital panoramic radiograph|Suspected carotid arty calcifications findings were defined as one or more radiopaque mass adjacent to the cervical vertebrae at or below the intervertebral space between C3 and C4 on the DPR.
45355267|NCT00808704|Drug|recombinant human erythropoietin|r-hu-EPO were administered either 300 U/kg or 500 U/kg, subcutaneously the first time and then intravenously every other day for 2 weeks.
45355268|NCT00817518|Drug|RO4987655|Administered po daily for 28 days, at escalating doses, with a starting dose of 1mg (Part 1) maximum tolerated dose administered po daily until disease progression(Part 2)
45355269|NCT00817518|Drug|RO4987655|Administered po daily for 28 days, at escalating doses , with a starting dose of 1mg (Part 1). Optimal biological dose administered po daily until disease progression (Part 2)
45355270|NCT00320515|Drug|pemetrexed|"Phase 1 - dose escalating: 600 mg/m2 level 1, 700 mg/m2 level 2, 800 mg/m2 level 3, 900 mg/m2 level 4, intravenous (IV), every 21 days, until disease progression~Phase 2 - 700 mg/m2, intravenous (IV), every 21 days, until disease progression"
45355271|NCT00320515|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days, until disease progression
45355272|NCT02551458|Other|Systematic surgery|
45355273|NCT02551458|Other|Surveillance and rescue surgery in cases of resectable loco-regional recurrence|
45355274|NCT01066273|Device|P-Stim|The P-Stim is a battery-powered, transcutaneous electrical stimulator that delivers 1 per second bipolar 1 millisecond pulses to three points on the auricle. The device connects via three fine insulated stainless steel wires to three needles (each 0.4 mm diameter, 2 mm long) that have been applied to three different points on the auricle. The device is powered by three zinc air batteries, each with a voltage of 1.4 V. The device is on for 180 minutes, then off for 180 minutes, for a maximum period of up to 96 hours. The battery and electronics are contained in a 6 mm by 2.5 mm pack that has one adhesive surface which is applied to the skin behind the ear. The adhesive is conductive and acts as the return for the device. The battery pack is secured with tape.
45355275|NCT00808782|Device|Deep rTMS|Repetitive transcranial magnetic stimulation targeting the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks.
45355276|NCT00808782|Device|Sham rTMS|Sham (non-active) repetitive transcranial magnetic stimulation over the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks
45355277|NCT02550834|Other|Wheelchair indoors curling training|8x 90 minutes of training and playing indoors curling in 4 weeks
45355278|NCT00662012|Drug|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days for less responsive; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
45355279|NCT00808860|Dietary Supplement|GP group|Gliclazide MR 30mg once a day, orally Gynostemma pentaphyllum tea 3 grams twice daily, orally
45355280|NCT00808860|Dietary Supplement|Placebo group|Gliclazide MR 30mg once a day, orally Placebo tea 3 grams twice daily, orally
45478148|NCT05862233|Drug|MIL62|An intravenous (IV) infusion of 1000 mg of MIL62 will be administered at Week 1，Week 3.If the treatment is effective, MIL62 will continue be administered at W25，W27
45478149|NCT05862233|Drug|Cyclosporine|Participants will receive Cyclosporine at a starting oral dose 3.5 mg/kg/d in 2 divided doses, try to give every 12 hours.The dose was adjusted according to the blood concentration of cyclosporine monitored every 2 weeks±3 days until the target blood concentration of 125~175 ng/ mL was reached.If the treatment is effective,cyclosporine would be reduced by about 1/2 of the original dose each month, and discontinued after 2 months.
45478150|NCT05861024|Other|Bladder Augmentation|Bladder Augmentation using bowel loop (ileal or sigmoid loop)
45478151|NCT05860998|Diagnostic Test|Presence of Toxoplasma gondii IgG Antibodies|Testing for the presence of Toxoplasma gondii IgG Antibodies in participants blood.
45478152|NCT05860504|Diagnostic Test|Echocardiography|All patients in the study will be examined with echocardiography
45478153|NCT05860504|Diagnostic Test|Cardiac magnetic resonance imaging|Sub-group of patients with left ventricular systolic dysfunction will be examined with cMRI
45478154|NCT05860504|Diagnostic Test|Coronary CT|Sub-group of patients with left ventricular systolic dysfunction will be examined with CCT
45478155|NCT05860452|Other|ropivacaine|single shot bilateral TAP block
45478156|NCT05860452|Other|normal saline|single shot bilateral TAP block
45478157|NCT05860387|Diagnostic Test|Next generation improvement of early invasive aspergillosis|Next generation improvement of early invasive aspergillosis test is intended to determine the suitability of new potential biomarkers of aspergillosis.
45498275|NCT03188263|Other|Dim Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance in this dimmed is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
45498276|NCT03188185|Drug|ALKS 5461|Samidorphan + buprenorphine, administered sublingually
45498277|NCT03188185|Drug|ALKS 5461 Placebo|Placebo tablet, administered sublingually
45498278|NCT03679182|Drug|Olanzapine|Olanzapine 5 mg Tab at 0, 12, 24, and 36 hours
45843567|NCT01698684|Drug|Avanafil 200 mg|One dose 15 minutes before attempting intercourse
45355281|NCT04045002|Other|'MyPinkMom' educational intervention|"The intervention will be carried out for 2 weeks. There will be three sessions of 'MyPinkMom' that will be delivered to respondents per week. In each session, a respective 'MyPinkMom' video with audio explanation will be delivered to respondents in intervention group through WhatsApp application. It will be delivered every alternate day per week and each video will take about 3 minutes duration. Each session has its own objective and different content.~Each of the respondent in the intervention group will be given 'MyPinkMom' diary in which they are required to document time of iron tablet intake daily as well as time of reading of 'MyPinkMom' material in each session. At the end of the intervention, a meeting with all the respondents from the intervention group will be held for question and answer session."
45355282|NCT00815568|Drug|fludarabine phosphate, busulfan|Fludarabine ( 30mg/m2, iv, D-7~D-2) Busulfan (3.2mg/kg, iv, D-6~D-3) Total body irradiation (200cGy/day, D-2,-1)
45355283|NCT00815646|Drug|Sildenafil|After measurement of the effect of cold water on cardiac output and pulmonary artery and wedge pressures, a single dose of sildenafil (50 mg) will be given orally, followed by similar hemodynamic measurements.
45355284|NCT01066351|Drug|beta erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
45355285|NCT01066351|Drug|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
45355286|NCT00817752|Dietary Supplement|Ashwagandha|Participants consume 3mL of Ashwagandha for 5 days. Blood work/immune cells (CD4 T-cells, CD8 T-cells, B-cells, NK cells, macrophages, IL-1, IL-6 and TNF-alpha) and psychological assessments (POMS and STAI Self-Evaluation) given at specified time intervals.
45355287|NCT03980353|Other|Questionnaires|The questionnaires have two parts: a general part and a second part focused on the integration in community of the type 1 diabetes children with specific questions about blood glucose, mealtimes, sporting activities and school trips.
45355288|NCT00808938|Device|MST|Magnetic Seizure Therapy
46046613|NCT03377816|Behavioral|Art Therapy|In a group setting participants will be encouraged to engage in art making for increased emotional awareness, expression, and acceptance. The role of the art therapist is to encourage a non-judgmental and exploratory approach to artmaking in which the process is emphasized over product. The art therapist obtains these goals by creating an atmosphere that is calm and by remaining tuned in to the verbalizations and body language of participants. If needed she can provide individual attention that is geared toward neutralizing concerns regarding performance during the art making.
45355289|NCT02532361|Device|Hysteroscopic device placement including Essure (ESS305, BAY1454032)|Essure is a permanent, minimally invasive, non-hormonal implantable device used for contraception and Adiana sterilization method is a combination of controlled thermal damage to the lining of the fallopian tube followed by insertion of a non-absorbable biocompatible silicone elastomer matrix within the tubal lumen
45478158|NCT05859425|Device|Real-time rehabilitative ultrasound imaging (RUSI)|Τhe ultrasound equipment used was B-K Μedical Mini Focus 1402 equipped with high frequency linear probe (8670, 5-12MHz) using standard musculoskeletal settings and the software: V 1.01.01.137. Ultrasound gel (AQUASONIC® 100, Parker Inc., Orange, NJ) was used as coupling agent. TrA imaging was initially performed with participants in crook lying, with the US head positioned along the lateral abdominal wall with reference points at the lower point of the rib cage (last rib) and the anterior superior iliac spine, on the right side of the person, midway between these two points. The US head was moved until tester (investigator) had the best possible visualization of the lateral abdominal muscles (external oblique, internal oblique and TrA). During the execution of the exercises, the participants could watch the ultrasound screen along with the therapist's guidance, thus receiving information (US-visual feedback) of their TrA activation
45478159|NCT05859425|Other|Tactile feedback (control intervention)|Palpatory-guided (manual) feedback for TrA activation
45478160|NCT05858385|Other|Routine oral care|During the radiotherapy period, all patients received pain management, diet consultation and appropriate dental preventive management every week by radiologists, dietitian and dentists, and all patients completed treatment unrelated to the severity of mucositis.
45478161|NCT05856500|Dietary Supplement|basic nutrition|An adequate supply of energy and protein in diet, oral nutrition supplement or tube feeding enteral nutrition supplement when diet is deficient.
46046614|NCT03377816|Behavioral|Sham Art Therapy|In a group setting participants will engage in Mandala coloring
46046615|NCT03377205|Device|Compression screws and neutralization plate|Open reduction and internal fixation with screws and plate
46046616|NCT03377205|Device|Acumed Fibular Rod System|intramedullary nailing of fibula
46046617|NCT03374631|Device|active anodal tDCS|active anodal tDCS with behavioral tasks and self-report measures to assess paranoid ideation
45355290|NCT02532361|Procedure|Tubal ligation|Tubal ligation or tubectomy is a surgical procedure for sterilization in which a woman's fallopian tubes are clamped and blocked, or severed and sealed, either method of which prevents eggs from reaching the uterus for implantation
45355291|NCT00809016|Radiation|3-dimensional conformal radiation therapy|
45355292|NCT00809016|Radiation|fludeoxyglucose F 18|
46046618|NCT03374631|Device|sham tDCS|sham tDCS with behavioral tasks and self-report measures to assess paranoid ideation
46046619|NCT03371485|Biological|AST-VAC2|Allogeneic dendritic cell vaccine.
45355293|NCT00809016|Radiation|intensity-modulated radiation therapy|
45355294|NCT03980431|Diagnostic Test|FBY PET Examination|A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later.
45355295|NCT00817830|Drug|lodenafil carbonate|Patients will do a cardiopulmonary exercise test after placebo administration. Seven days later, a new cardiopulmonary test should be done using lodenafil carbonate, 80mg, orally.
45478162|NCT05856500|Dietary Supplement|oral supplement of creatine and curcumin|Creatine and curcumin are orally added other than basic nutrition treatment.
45355296|NCT00815724|Behavioral|Distributed Asthma Learning Initiative (DALI) distance learning program|Participants will take part in two Webinar teleconferences, have access to an interactive Web site, and receive a CD-ROM of study materials and a toolkit.
45355297|NCT02552862|Drug|Vivomixx®|Vivomixx® is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) and lactobacilli (L. paracasei DSM 24733, L. acidophilus DSM 24735, L. delbrueckii subsp bulgaricus DSM 24734, L. plantarum DSM 24730). The active agent will be supplied as a 4.4g sachet at a dose of 450 billion live bacteria per sachet with maltose and silicon dioxide as excipients.
45355298|NCT02552862|Drug|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
45355299|NCT00661778|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
45355300|NCT00661778|Drug|Cisplatin|Bevacizumab was supplied as a sterile liquid in glass vials.
45355301|NCT00661778|Drug|Docetaxel|Bevacizumab was supplied as a sterile liquid in glass vials.
45355302|NCT04045080|Device|AMADEO|"AMADEO® is an end-effector system enables intensive training with frequently repeated gripping movements. It offers the possibility to select from between passive, assistive and active modes using exercise of finger strength, finger movement, movement control and a selective activation of the fingers.~Moreover, even without muscular strength, active work can be done using EMG-based training. The Continuous Passive Motion (CPM Plus) therapy facilitates the implementation of automatic movement sequences even when the patient is unable to complete the entire range of motion on their own. It may be used in all phases of finger-hand rehabilitation and can be adapted to the needs of every patient.~In patients with PD, it will be useful in improving bradykinesia and potentially distal hypostenia."
45355303|NCT04045080|Other|Training|training
45478163|NCT05853133|Other|Erector Spinae Plane Block|Group E (ESP block), before the operation, the ESP block will be applied to the patients in the prone position under sedation by same anesthesiologist. ESP block will be applied bilaterally, 20 ml of %0.25 bupivacaine between the erector spinae muscle and transverse process at the 11th thoracic level. All patients will be equipped with an IV tramadol patient-controlled analgesia (PCA) device. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life.
45355304|NCT04045080|Other|OT Training|training
45478164|NCT05853133|Other|Wound Infiltration|Group W, at the end of the operation,wound infiltration will be administered under general anesthesia in supine position by same surgeon. Subfascial and subcutaneous wound infiltration is performed (20 ml of 0.25% bupivacaine each). All patients will be equipped with an IV tramadol patient-controlled analgesia (PCA) device. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life.
45478165|NCT05852457|Device|DAT Clip|All patients scheduled to undergo endoscopic procedures as medically indicated will be considered for the study. Data will be prospectively recorded according to the data collection form. The use of the DAT clip will be performed as medically indicated and consistent with the indications for endoscopic clipping (e.g., management of bleeding, treatment of fistulas, perforations, tissue approximation). The investigators on this project will also oversee the medical care of all patients that will participate in the study. Therefore, follow-up will be carried out as medically indicated and no clinical visits will be needed specifically for the purpose of this study.
46046620|NCT03370341|Device|active anodal tDCS|active anodal tDCS with behavioral tasks to assess IA
45686911|NCT05815667|Behavioral|Individualised Active Communication Education (I-ACE)|The swedish I-ACE consists of five modules with different themes, all with sections of information alternated with reflective tasks. The participants are assigned one module each week and provided with weekly feedback from a health care professional on their work, before being assigned the next module.
45843568|NCT01699542|Device|WallFlex Esophageal RX Fully Covered Stent|Temporary placement of the WallFlex Esophageal RX Fully Covered Stent for treatment of refractory anastomotic esophageal strictures. The stent will be removed after 8 weeks (plus or minus 7 days) indwell
45843569|NCT01699542|Device|Esophageal Bougie Dilator Per Investigator preference|Commercially available Esophageal Bougie Dilator Per Investigator preference
45843570|NCT01699698|Other|Tumor markers|Duodenal juice are collected using endoscope and cannula. Tumor markers of collected samples are analyzed. The marker concentration is applied to statistical analysis.
45843571|NCT01701024|Drug|ACYC|ACYC active, topically applied to the face for 12 weeks
45843572|NCT01701024|Drug|ACYC vehicle|ACYC vehicle (placebo), topically applied to the face for 12 weeks
46046621|NCT03370341|Device|sham tDCS|sham tDCS with behavioral tasks to assess IA
46046622|NCT03360695|Other|Proactive Psychiatry Consultation (PPC)|Proactive Psychiatry Consultation and Case Management aims to improve communication among the patient, oncology team, and mental health clinicians, and increase engagement of family and community caregivers, which may help patients to receive the cancer care they need.
45355305|NCT00789932|Behavioral|cognitive behavioral therapy|32 weeks of CBT, 1.5 hours weekly.
45355306|NCT00789932|Behavioral|Usual community care|16 weeks of community care, 16 weeks of CBT, 1.5 hours/week.
45355307|NCT04047212|Diagnostic Test|biopsy for oral cancer|surgical biopsy is to be taken for diagnosis of oral cancer or premalignant lesions
45355308|NCT04047212|Diagnostic Test|periodontal examination|Periodontal clinical examination to all by periodontal charting
45355309|NCT00319735|Procedure|Radiation Therapy|External beam radiation therapy, beginning on day 1, 4500 cGy to esophagus with boost of 540 cGy at 180 cGy per fraction for 6 weeks
45355310|NCT00319735|Procedure|Surgery|Surgical resection of primary tumor and adjacent mediastinal and/or celiac lymph nodes by a transthoracic approach after satisfactory hematologic and functional recovery within 8 weeks of completion of radiation therapy
45355311|NCT00319735|Procedure|Tissue Sample|For patients who give their consent, fresh frozen tissue will be obtained per EUS at baseline, per EUS 2 weeks after the initiation of chemotherapy, and at the time of surgery for pathology submission
45355312|NCT02556242|Other|Targeted indoor residual spraying|IRS is carried out in neighbourhoods of cases
45355313|NCT02556242|Other|Generalised Indoor residual spraying|IRS is carried out as normally practiced
45355314|NCT01062139|Drug|Xarlin (Levocetirizine)|Combination therapy compared to mono therapy
45478166|NCT05850806|Device|The KmAsthma self-management smart phone app intervention|KmAsthma is a free app which enables users to track their symptoms, access their action plan, learn about asthma and set goals to make change
45843573|NCT01701102|Procedure|Mepivacaine (24 mg) plus fentanyl|Mepivacaine (24 mg) and fentanyl (10 µg)
45478167|NCT05850520|Drug|Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose|Intravitreally (IVT) injection.
45843574|NCT01701102|Procedure|Mepivacaine (27 mg) plus fentanyl|Mepivacaine (27 mg) and fentanyl (10 µg)
45843575|NCT01701102|Procedure|Mepivacaine (30 mg) plus fentanyl|Mepivacaine (30 mg) and fentanyl (10 µg)
45843576|NCT01701102|Procedure|Mepivacaine|Mepivacaine 37.5 mg
45843577|NCT01701414|Drug|Femoral nerve block: 25 mL of 0.5% bupivacaine|25ml of 0.5% bupivacaine will be injected along the nerve sheath. The nerve block will be administered by one of the physician co- investigators all of whom are emergency physicians and all of whom have been trained in the use of ultrasound and ultrasound guided nerve blocks.
45843578|NCT01701414|Drug|Placebo: 3cc of 0.9% Normal Saline|1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% NS subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice
45355315|NCT01062139|Drug|Cosalin (Petasites hybridus CO2 extract)|Combination therapy compared to mono therapy
45355316|NCT00780650|Drug|Atomoxetine|80 mg oral dose, once per day for 6 weeks
45355317|NCT00780650|Drug|Placebo|80 mg dose once per day for 6 weeks
45355318|NCT00653328|Drug|atrasentan hydrochloride|Atrasentan 10 mg orally everyday continuously beginning on Day 1.
45355319|NCT00653328|Drug|doxil|50 mg/m2 intravenously every 28 days
45355320|NCT01664182|Biological|Bevacizumab|Given IV
45355321|NCT01664182|Drug|Pazopanib Hydrochloride|Given PO
45355322|NCT01664182|Drug|Sorafenib Tosylate|Given PO
45355323|NCT01664182|Drug|Sunitinib Malate|Given PO
45355324|NCT01664182|Biological|Trebananib|Given IV
45355325|NCT00780728|Drug|Sildenafil|
45355326|NCT00809172|Drug|Ciclosporin|5 mg/kg/day per os during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
45355327|NCT00809172|Drug|Methotrexate|15 mg/week per os in one tablet during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
45355328|NCT05032196|Drug|WVE-003|WVE-003 is a stereopure antisense oligonucleotide (ASO)
45355329|NCT02552940|Drug|Tocilizumab|Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
45355330|NCT00780806|Biological|meningococcal B rLP2086 vaccine candidate|vaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months
45355331|NCT00780806|Procedure|Blood draw|Blood draw
45355332|NCT02551380|Drug|FOLINORAL|Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
45355333|NCT02551380|Other|Placebo|Placebo 5mg twice a day (10 mg per day) during 12 weeks
45355334|NCT00815880|Device|C-Pulse™ (Implantable Counterpulsation Therapy)|Implantation and activation of counterpulsation therapy for the full duration of the study period. The device may be turned off briefly for personal hygiene, etc.
45355335|NCT00784862|Drug|Anastrozole|1mg, orally, once daily
45355336|NCT00784862|Drug|Tamoxifen|20mg, orally, once daily
45478168|NCT05850520|Drug|Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg|Intravitreally (IVT) injection.
45478169|NCT05850520|Drug|Sham|Sham procedure will be given on visits when an active injection is not planned.
45355337|NCT02556476|Procedure|mechanical ventilation|ventilator support for the patients presenting with acute respiratory failure
45355338|NCT02556476|Procedure|neuromuscular blockade|paralysis of the skeletal muscles in order to optimize mechanical ventilation, especially during ARDS
45355339|NCT02556476|Procedure|renal replacement therapy|the procedures used to treat acute kidney injury
45686912|NCT05815654|Device|Warm Palace Analgesic Point Sticker|The Warm Palace Analgesic Point Sticker is developed by Changchun University of Traditional Chinese Medicine
46046623|NCT03360695|Other|Enhanced Usual Care (EUC)|At enrollment, study staff will inform the treating oncologist of the psychiatric diagnosis and will inform the oncologist, patient, and caregiver of available psychosocial services.
46046624|NCT03329170|Behavioral|educational intervention using motivational interviewing|A dental hygienist will offer the families verbal and written information regarding oral health and its importance in children with CHD at the cardiac ward, when child is <12 months. At 6, 12 and 18 months of age, oral health behaviour is assessed via internet, the parents of the child will be sent written information regarding oral health, a tooth brush and a 1000ppm Fluoride tooth paste, after which the dental hygienist will call the parents of the child, to provide additional counselling regarding oral health and its importance in children with CHD. The counselling will be done by motivational interviewing. The themes discussed will be the parents' concerns regarding main points in the written information from the cardiac ward: oral home care, eating habits and dental contact.
45843579|NCT01703598|Device|Deep Brain Stimulation|Placement of Deep Brain Stimulation electrodes
45686913|NCT05815641|Dietary Supplement|food (breakfast)|The breakfast composition is 56 kcal% carbohydrates, 12 kcal% protein and 34 kcal% lipids and comprises yogurt, cereals and almonds
45686914|NCT05815615|Device|Plasmapheresis|Plasma donation at different frequencies
45843580|NCT01703598|Procedure|DBS surgery|Placement of DBS electrodes
45843581|NCT01706952|Drug|Cocaine|Pledgets soaked in 4% cocaine hydrochloride solution were placed intranasally (one side).
45843582|NCT01706952|Drug|Adrenaline|Pledgets soaked in 1/1000 adrenaline solution were placed intranasally (one side).
45843583|NCT01707108|Device|Dental Implant (MIS Technologies)|MIS Technologies Ltd. C1 Dental implants
45843584|NCT01707420|Drug|Gabapentin|The active comparator, Gabapentin, is a structural analog of g-aminobutyric acid which has anticonvulsant properties. This study is a prospective randomized double-blinded trial examining the effectiveness of a single dose of liquid Gabapentin given 60 minutes prior to surgery for pain management in pediatric tonsillectomy/adenoidectomy pediatric patients.
45843585|NCT01707420|Drug|liquid placebo|Subjects randomized to the liquid placebo will receive an identical appearing liquid placebo of 0.4mL/kg.
45843586|NCT01707654|Device|Nerve flap|Based on the Teoh et al.'s technique, we combined the nerve graft into the bipedicled heterodigital arterialized island flap and used this composite flap tissue for reconstructing complicated infected wound in the finger.
45843587|NCT01708122|Drug|Fentanyl|100 mcg in 1 mL intranasal spray
45843588|NCT01708122|Drug|saline|Sodium Chloride 0.9% intranasal spray
45843589|NCT01708278|Drug|Quercetin|"COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take one of the following for 1 week~Quercetin 500 mg/350 mg of vitamin C and 10 mg niacin~Quercetin 1000 mg/350 mg of vitamin C and 10 mg niacin~Quercetin 2000 mg/350 mg of vitamin C and 10 mg niacin"
45843590|NCT01708278|Other|Placebo - sugar chew|COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take placebo (sugar chew containing 350 mg of vitamin C and 10 mg niacin)
46046625|NCT03326245|Drug|Oral Methylphenidate followed by IV placebo|Oral MP (60 mg) will be given 30 minutes prior to bolus [11C]raclopride injection followed by iv placebo (PL) given 30 minutes post bolus injection of [11C]raclopride.
45843591|NCT01708590|Drug|210 mg brodalumab|210 mg brodalumab administered subcutaneous (SC)
45843592|NCT01708590|Drug|140 mg brodalumab|140 mg brodalumab administered subcutaneous (SC)
45843593|NCT01708590|Drug|placebo|Placebo administered subcutaneous (SC)
45355340|NCT02556476|Procedure|non-invasive ventilation|Procedure used for ventilation support in patients with congestive heart failure, pulmonary edema, COPD and some other conditions.
45355341|NCT00642642|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of 3 mm post auricular skin punch biopsies.~Administration of 3 study treatments administered 14 ± 7 days apart."
45355342|NCT00642642|Biological|Placebo|"Collection of 3 mm post auricular skin punch biopsies.~Administration of 3 study treatments administered 14 ± 7 days apart."
45355343|NCT00780884|Device|acupuncture|16 sessions of acupuncture treatment, twice a week.
45355344|NCT00818064|Drug|anti-IL-20|Single s.c. injection (per dose cohort)
45355345|NCT00818064|Drug|placebo|Single s.c. injection (per dose cohort)
45355346|NCT00784940|Drug|Anastrozole|1mg, orally, once daily
45686915|NCT05815589|Other|screw retained prosthesis group|hybrid prosthesis screwed on four mandibular intra-foraminal implants
45686916|NCT05815576|Behavioral|Intrinsic foot muscle fatigue|"Electrostimulation will be delivered through electrodes placed on the abductor hallucis (NOT invasive).~The investigators plan 4 sets of 4 minutes of repeated contractions (electrostimulation + voluntary contraction)."
45355347|NCT00784940|Drug|Tamoxifen|20mg, orally, once daily
45478170|NCT05850520|Diagnostic Test|Fluorescein|Fluorescein 100 mg/mL solution for injection is a dye that makes the retinal vessels visible during FA examinations, and as such, it will be used as an auxiliary medicinal product (AxMP) in this periodic ophthalmic examination. This medicine is for diagnostic use only. It is not used to treat any condition.
45478171|NCT05849779|Drug|Inhaled sedation with sevoflurane|"In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP)."
45478172|NCT05849779|Drug|Intravenous sedation (current practice)|"In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP)."
45686917|NCT05815550|Drug|PPI|Use of PPI defined as PPI mentioned in the safety report
45686918|NCT05815524|Other|Physical activity training|training on treadmill
45686919|NCT05815511|Dietary Supplement|Probiotic mixture|Oral capsule consumption once a day for 12 weeks
46046626|NCT03326245|Drug|Oral placebo followed by IV Methylphenidate|Oral PL will be given 30 minutes prior to bolus [11C]raclopride injection followed by iv MP (0.25 mg/kg) given 30 minutes post bolus injection of [11C]raclopride.
45686920|NCT05815511|Dietary Supplement|Placebo|Oral capsule consumption once a day for 12 weeks
45686921|NCT05815472|Device|Fitbit charge|Internet of Things Technologies Device
45686922|NCT05815433|Other|Donor Human Milk - Nutritional Replacement|All DHM in North America is pasteurized and provided through certified milk banks regulated by the Human Milk Banking Association of North America. DHM for this study will be obtained from the NorthernStar Mothers Milk Bank (NMMB). The milk is pasteurized and rigorously tested according to Human Milk Banking of North America guidelines. In Canada, DHM is categorized as food or nutritional therapy and the milk bank is monitored and certified by the Canadian Food Inspection Agency. The product used for this study will be the same product that is provided to other hospital units (mainly the neonatal intensive care units) in Alberta and around Canada. The product will not be modified or tampered with in any way.
46046627|NCT03326245|Drug|Oral Placebo followed by IV Placebo|Oral PL will be given 30 minutes prior to bolus [11C]raclopride injection followed by iv PL given 30 minutes post bolus injection of [11C]raclopride.
46046628|NCT03321656|Drug|Tacrolimus|0.1-0.2 mg/kg/day orally divided into two doses every 12 hours orally
46046629|NCT03321656|Drug|Envarsus XR|0.07-0.14 mg/kg/day every morning orally
46046630|NCT03299335|Other|Blood collection|assay of CPK and anti-cN-1A antibodies
46046631|NCT03294148|Other|Open-Label Placebo Treatment for Chronic Back Pain|Subcutaneous injection of 1ml medical grade saline into the lower back.
46046632|NCT03294148|Behavioral|Psychotherapy Treatment for Chronic Back Pain|Twice weekly 50 minute psychotherapy sessions for 4 weeks, plus an initial medical history session
45355348|NCT00790166|Device|CPAP + ThermoSmart™ humidity|an absolute humidity (AH) of 28 mg/l +/- 2mg/l
45355349|NCT00790166|Device|CPAP + Conventional humidity|an absolute humidity (AH) of 18 mg/l +/- 2 mg/l
45355350|NCT00790166|Device|CPAP + No added humidity|ambient humidity
45355351|NCT02552706|Dietary Supplement|probiotics|Administration of mixture probiotics 500mg by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
45355352|NCT02552706|Dietary Supplement|glucose solution|Administration of 1 mL of a 5% glucose solution by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
45355353|NCT00790244|Drug|doxorubicin , ifosfamide|doxorubicin 60mg/m2+ifosfamide 6g/m2 every third week
45355354|NCT00790244|Drug|doxorubicin, ifosfamide|Doxorubicin and Ifosfamide given every three weeks, totally 6 courses.
45686923|NCT05815420|Device|Non invasive ventilation|Treatment by non invasive ventilation
45686924|NCT05815407|Other|No intervention|No intervention
45355355|NCT00790244|Drug|doxorubicin, ifosfamide|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and four.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
45355356|NCT00790244|Drug|doxorubicin, ifosfamide|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
45355357|NCT00818142|Behavioral|ED/DM Support Group|The ED/DM Recovery Group focuses on assisting individuals with diabetes and an eating disorder - specifically the struggle of withholding insulin. The group utilizes strategies and tools that have been taught in other EDI programs, and also builds on the strengths of a group. The group is a means for learning and support as the individuals continue a regular schedule of school, work, and/or family life.
45355358|NCT00815958|Procedure|Reaming with Synthes RIA (Reamer-Irrigator-Aspirator)|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the RIA group (Arm A), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines up until femoral reaming. These patients will receive reaming with RIA. The remainder of the surgery will also be done according to the standard of care. TEE and TCD data will be recorded throughout the surgery.
45355359|NCT00815958|Procedure|Reaming with conventional reamer|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the control group (Arm B), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines. These patients will receive reaming with the conventional method/reamer. TEE and TCD data will be recorded throughout the surgery.
45355360|NCT00785018|Drug|C1-esterase inhibitor|C1-esterase inhibitor 100 U/kg infusion over 30 minutes.
45355361|NCT00785018|Drug|Endotoxin administration|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
45355362|NCT00821340|Genetic|rAAV2-hRPE65|Uniocular subretinal injections; relative doses: Cohort 1 - basic (lowest) viral dose; Cohort 2 - higher (1.5 times basic) viral dose; Cohort 3 - patients 8-17 years of age will receive basic viral dose; patients 18 years of age and over will receive higher dose;
45355363|NCT00790322|Drug|SBG|Soluble beta-1,3/1,6-glucan is a solution for oral use
45355364|NCT00790322|Other|Placebo|Solution for oral use
45355365|NCT00534352|Drug|TMC125; darunavir; ritonavir|TMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
45355366|NCT00642174|Drug|prasugrel|Oral prasugrel 60-mg loading dose, followed by 6-9 days of oral prasugrel 10-mg/day tablet maintenance dose.
45355367|NCT00642174|Drug|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6-9 days of oral clopidogrel 150-mg/day tablet maintenance dose.
45355368|NCT04001296|Behavioral|21 day Brush Day and Night school programme|Children participating in the 21 day Brush Day and Night school programme are provided with toothpaste and a toothbrush each and enjoy brushing instruction, supervised brushing, and the singing of songs to facilitate learn the importance of brushing day and night, and stickers and calendars to track progress. A celebration is held at the end of the programme with certificates and rewards. The programme is supported by colourful and attractive materials with bespoke cartoon characters. Parents are provided with educational leaflets.
45355369|NCT00992290|Biological|Lactobacillus GG|1 capsule of lactobacillus GG BID compared to placebo BID
45355370|NCT00992290|Biological|Placebo|1 capsule of lactobacillus GG BID compared to placebo BID
45355371|NCT02550444|Drug|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
45355372|NCT02550444|Drug|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
45355373|NCT02550444|Drug|Placebo|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
45478173|NCT05847517|Drug|Metoprolol Injection|"A dilution of 15 mg Metoprolol tartrate in 100 ml saline shall be performed and infused for 10 minutes. No dose reduction or increase is allowed. Systolic blood pressure and heart rate shall be measured 3 and 6 minutes after starting the infusion.~In case of a consistent drop in systolic blood pressure or heart rate, the infusion shall be stopped and the infusion noted."
45478174|NCT05847517|Drug|saline 0.9%|"A dilution of 0.9% sodium chloride in 100 ml saline shall be performed and infused for 10 minutes. No dose reduction or increase is allowed. Systolic blood pressure and heart rate shall be measured 3 and 6 minutes after starting the infusion.~In case of a consistent drop in systolic blood pressure below 110 mmHg or heart rate below 60 bpm, the infusion shall be stopped and the infusion noted."
45686925|NCT05815394|Drug|177Lu-labeled NY108|Patients will receive a tracer (40-60ug) dose of 177Lu(28.5-31.5mCi) labelled NY108.
45686926|NCT05815381|Other|Questionnaires, quantitative sensory testing, blood sampling, skin biopsies, functional magnetic resonance imaging, magnetic resonance spectroscopy|se arm/group descriptions
45355374|NCT00665366|Drug|Aripiprazole|5-, 10-, or 15-mg oral tablets in titrated doses for 12 weeks
45355375|NCT00665366|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
45355376|NCT00665366|Drug|Lithium|Participant's ongoing dose
45355377|NCT00665366|Drug|Valproate|Participant's ongoing dose
45355378|NCT00992368|Procedure|reduction mammaplasty|patients submitted to reduction mammaplasty
45355379|NCT01141738|Behavioral|Caregiver Problem-Solving Intervention|Subjects will meet for two counseling sessions while their family member is hospitalized and will receive the treatment manual, which contains the content for the 10 sessions, work sheets, and handouts. The standardized content will be complemented by tailoring to the specific concerns and problems of CGs which are influenced by culture and developmental life stage as well as the stroke and other environmental and personal factors. Problems specific to stroke caregiving are emphasized. After the stroke survivor has been discharged, the counselor will contact the CG weekly by phone for 5 weeks and then bi-weekly for the next three sessions (a total of 10 sessions) at times convenient for the CG.
45686927|NCT05815368|Device|REMO|REMO training will consist of sEMG-biofeedback exercises provided by REMO device. The training will be provided 1 hour a day, for 5 days/week, for totally 3 weeks.
45355380|NCT01141738|Behavioral|Wait List Control|Subjects in the WLC condition will receive usual patient and family education. If these subjects are noted to be distressed when assessment measures are administered or during conversation, the research assistant (RA) will inform the PI or Co-PI, who will follow-up. To aid retention, a counselor who is naïve to the CPSI will call the WLC subjects in the second and fifth months post-discharge to check contact information and ask how they are doing. Access to individual or group therapy through community resources during this study will be monitored during routine data collection. Following the T3 assessment, the WLC subjects will be offered a minimal intervention (receipt of the Adapting to Stress booklet 100 and five 30 minute telephone sessions).
45478175|NCT05840250|Other|Continuous Glucose Monitoring and Education Support|Participants will be provided with a device to monitor their blood glucose (Abbott Free Style Libre2 Flash CGM system) along with educational materials to better understand and manage their diabetes and other supporting services. Pre and post intervention surveys will be implemented. Participants will be closely monitored for 3 months and then followed up for 3 more months for a total of 6-month participation.
45478176|NCT05837923|Dietary Supplement|Relief Active Study Product 1.1 Usage|Participants will use their Radicle Relief Active Study Product 1.1 as directed for a period of 6 weeks.
45478177|NCT05837923|Dietary Supplement|Relief Active Study Product 1.2 Usage|Participants will use their Radicle Relief Active Study Product 1.2 as directed for a period of 6 weeks.
45478178|NCT05837923|Dietary Supplement|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
45478179|NCT05837182|Procedure|augmented fixation techniques|augmented fixation techniques like percutaneous transsarcal screws fixation, tension band plating, INFIX technique, triangular fixation and cement augmentation techniques
45478180|NCT05837104|Drug|Magnesium vitamin B6|Magnesium citrate (100mg) and Pyridoxine hydrochloride (10mg) in tablet form, taken three times daily for four weeks.
45478181|NCT05837104|Drug|Placebo|Placebo tablet, three times daily for four weeks.
45478182|NCT05833334|Behavioral|Public health infographic (AIM 3)|Standard public health infographic about home air radon testing, plus information about requesting a free home air radon test kit
45478183|NCT05833334|Behavioral|Online health promotion intervention tailored by smoking status (AIM 3)|Online health promotion intervention with messaging about home air radon testing tailored by the participant's stated smoking status, plus information about requesting a free home air radon test kit
45478184|NCT05833334|Behavioral|Online health promotion intervention tailored by smoking status, plus reminder messages (AIM 3)|Online health promotion intervention with messaging about home air radon testing tailored by the participant's stated smoking status, plus information about requesting a free home air radon test kit, plus reminder messages about home air radon testing sent over two months
45478185|NCT05833334|Behavioral|Focus group with educational overview (AIM 1)|90-minute online focus group discussion about home air radon testing, plus an educational overview about home air radon testing using a standard public health infographic
45686928|NCT05815368|Other|Task-Oriented Training|Task-Oriented training will consist of task-specific functional exercises. The training will be provided 1 hour a day, for 5 days/week, for totally 3 weeks.
45686929|NCT05815355|Dietary Supplement|exclusive enteral nutrition treatment group|
45843594|NCT05711238|Other|Robotic rehabilitation|In robot-assisted therapy, the therapist selects different programs with personalized environments to train patients to strengthen limb muscles that have previously had difficulty with movements or are relatively weak. Active (individual finger movement, memory, motility, apple tree, target board, recycling bins, balloons, firefighter), auxiliary, and passive (cpm, cpm plus) treatment options are available in the system.
46046633|NCT03277638|Drug|Pembrolizumab at 7 days prior|Pembrolizumab injections 7 days before surgery
45355381|NCT00775684|Drug|Exenatide|Exenatide (Byetta®)-5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
45498279|NCT03679104|Procedure|Closure of mucosotomy using endoscopic clips|Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done using endoscopic clips. These are used in endoscopy to mechanically close two mucosal surfaces without the need for surgery and suturing. In this study, the following endoclips may be used: Resolution 360™ Clip (Boston Scientific), QuickClip Pro™(Olympus) or Instinct™ Endoscopic Hemoclip (Cook Medical).
46046634|NCT03277638|Drug|Pembrolizumab at 14 days post|Pembrolizumab injections 14 days after surgery
46046635|NCT03277638|Drug|Pembrolizumab at 35 days post|Pembrolizumab injections 35 days after surgery
46046636|NCT03277638|Procedure|Laser Interstitial Thermotherapy|surgical procedure to heat hard to reach tumors with a laser beam
45355382|NCT00775684|Drug|Sitagliptin|Sitagliptin (Januvia®)100 mg by mouth every morning
45355383|NCT00775684|Drug|Glimepiride|Glimepiride (Amaryl®)-0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose < 110mg/dl
46046637|NCT03269032|Other|American Diet|"According to National Health and Nutritional Examination Survey (NHANES) data, the nutritional composition of the baseline typical American diet is 50%Carbohydrates, 15% Protein, 35% Fat, >11% Saturated Fatty Acids, <12% Monounsaturated Fatty Acids, and >8% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period."
46046638|NCT03269032|Other|Mediterranean-style Diet|"The nutritional composition of the baseline typical Mediterranean-style diet is 46% Carbohydrates/Alcohol (red wine will be included in the Mediterranean diet only), 17% Protein, 32% Fat, <7% Saturated Fatty Acids, >18% Monounsaturated Fatty Acids and <5% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period."
45355384|NCT04001218|Drug|Injection of hypertonic saline|Painful condition: Participants will be injected in a neck muscle with 0.5ml of hypertonic saline (5.8%)
45355385|NCT04001218|Drug|Injection of Isotonic saline|Control condition: Participants will be injected in a neck muscle with 0.5ml isotonic saline (0.9%)
45355386|NCT02556008|Drug|cannabidiol (CBD)|Treatment will begin with 2 mg/kg/day given in two divided doses. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.
45355387|NCT00992524|Drug|Misoprostol|Oral solution dose will be 20mcg/hour (misoprostol) or 10ml/hour (placebo) in the first six hours with an increase of 20mcg/hour (10ml/hour) of misoprostol or placebo each six hours if labour does not start, until the maximum dose of 80mcg/hour or 40ml/hour in the first 24 hours.
45355388|NCT00992524|Drug|Misoprostol|Vaginal tablets will have 25mcg of misoprostol or placebo.
45355389|NCT00785096|Other|Questionnaire|Questionnaire, complications, grading severity, visual analog scale
45478186|NCT05828615|Other|Group A|"Close your eyes and exhale through your left nostril fully and slowly, once you have exhaled completely, release your right nostril and place your ring finger on the left nostril.~Breathe in deeply and slowly from the right side. Make sure your breath is smooth and continuous. Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9)."
45478187|NCT05828615|Other|Group B|"The position of the woman should be relaxed and comfortable e.g., crock lying, sitting, standing position. Place one hand on chest and other on stomach and close eyes to relax and focus on breathing. Slowly breathe in through nose with your closed mouth.Breathe out through your nose and try to use as small effort as possible and make your breaths slow, relaxed and smooth.~Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9)."
45355390|NCT00998842|Device|Recom Model 100|Battery Operated, Ambulatory, Digital Wireless ECG Monitor System
45355391|NCT00998842|Device|GE 5000 ECG Monitor System|Wired ECG system
45355392|NCT00781040|Other|Severe sepsis vs. non-severe sepsis|To compare these two groups
45355393|NCT00995254|Behavioral|SHI counseling|The SHI will be delivered in three different individualized counseling sessions: the initial in person counseling (30-45 minutes), at 1 week in person or telephone counseling (15-30 minutes) and at 1 month in person counseling (15-30 minutes). During the initial counseling, CHWs will emphasize the health hazards of SHS exposure towards young children and its possible illness outcomes. Then subjects will be asked to assess the SHS exposure of children in the household (e.g., estimating the number of hours for SHS exposure on the child per week or day) and the source of SHS. The concept of smoking hygiene and non-smoking household policy will be discussed and any potential barriers ascertained. Furthermore, the CHWs will use the transtheoretical model of Prochaska to assess the stage of readiness of the household member to change smoking behavior existing in the household. Individuals who wish to quit smoking will receive a brief advice on quitting smoking.
45355394|NCT00785174|Device|continuous positive airway pressure|respiratory assistance using face mask and positive expiratory pressure apllied by a Boussignac valve
45355395|NCT00785174|Device|noninvasive pressure support ventilation|noninvasive pressure support ventilation can provide inspiratory pressure support and expiratory positive pressure
45355396|NCT00785174|Device|noninvasive pressure support ventilation|noninvasive pressure support ventilation provides an inspiratory aid and positive expiratory pressure using ventilator through face mask
45355397|NCT00992680|Device|ROX Anastomotic Coupler System (ACS)|The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein)
45355398|NCT00642018|Drug|docetaxel|Docetaxel 75 milligrams per square meter (mg/m²) intravenously on Day 1 of a 21-day cycle. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
45355399|NCT00642018|Drug|LY2181308 sodium|LY2181308 sodium (referred to as LY2181308 throughout this record) administered weekly plus docetaxel 75 mg/m² intravenously administered every 21 days. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
45355400|NCT00642018|Drug|Prednisone|Prednisone 5 mg given orally twice daily continuously while receiving docetaxel therapy
45478188|NCT05828303|Drug|TPX-0005|Oral TPX-0005 capsules
45478189|NCT05828303|Drug|Metformin Hydrochloride|oral solution
45478190|NCT05828303|Drug|Digoxin|oral tablet
45478191|NCT05828303|Drug|Rosuvastatin Calcium|oral tablet
46046639|NCT03236987|Drug|Clarithromycin 1000 MG|The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Clarithromycin, Ethambutol and Rifampicin.
46046640|NCT03236987|Drug|Azithromycin 250 mg|The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Azithromycin, Ethambutol and Rifampicin.
46046641|NCT03236987|Drug|Rifampicin|The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
46046642|NCT03236987|Drug|Ethambutol|The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
45355401|NCT00532948|Drug|capecitabine [Xeloda]|500mg/m2 po bid (starting dose)
45355402|NCT00998920|Drug|S-equol|oral, BID, 14 days
45355403|NCT00998920|Drug|Placebo|oral, BID, 14 days
45355404|NCT00998998|Behavioral|Home stimulation|Weekly visit of one hour to the home over the course of one year to foster the mother-child relationship.
45355405|NCT00998998|Behavioral|Surveillance|Weekly visits to the home over the course of one year to record iron intake, feeding, and health information.
45355406|NCT00998998|Dietary Supplement|Iron|Six-month-old infants treated orally for 1 y with 15 mg elemental Fe/d as ferrous sulfate. Twelve-month old infants treated orally for a minimum of 6 months with 30 mg elemental Fe/d.
45355407|NCT00992758|Biological|Iodine-131 Anti-B1 Antibody|"Dosimetric Dose: 450 mg unlabeled Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody of which 1-2 mg has been labeled with 5 mCi of Iodine-131 infused over 20 minutes.~Therapeutic Dose: 7-14 days after dosimetric dose, 450 mg Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody labeled with the subject-specific dose of Iodine-131 to deliver the desired total body radiation, infused over 20 minutes The dose escalation will be initiated at 45 cGy and will be increased in 10 cGy increments until the maximum tolerated dose (MTD) is reached."
45355408|NCT00641706|Drug|vorinostat|Given orally
45355409|NCT00641706|Procedure|therapeutic conventional surgery|Patient undergoes surgery
45355410|NCT00641706|Drug|bortezomib|Given IV
45478193|NCT05826535|Drug|IMPT-314|CAR T-cell therapy
45478194|NCT05823571|Drug|Itacitinib|A standard 3+3 design will be used to evaluate the safety of itacitinib plus different immunosuppression regimens. This study has four predefined Regimens that will be explored in the optimal Regimen-finding phase and are listed in Table 2 of the protocol. Itacitinib will be given in conjunction with each of four different regimens for immunosuppression. Regimen 1 is the current standard for our BMT patients, with a duration of MMF from day 5-35. Regimen 2 will decrease the duration of MMF from 35 to day 25. Regimen 3 will decrease the duration of MMF from 35 to day 15. Regimen 4 will eliminate MMF altogether. We will start with Regimen 1, which combines itacitinib with the current standard of immunosuppression. Progression through cohorts (Regimens) will be based on a standard 3+3 design to find the optimal regimen.
45478195|NCT05821907|Behavioral|data collection group|The scale development process generally consists of three stages as item production, theoretical analysis and psychometric analysis. The researcher provides theoretical support to the item pool during item production. In the theoretical analysis stage, the content validity of the new scale is evaluated and the first item pool is ensured to reflect the desired structure. In the final stage of the psychometric analysis, the researcher evaluates whether the new scale establishes validity and reliability.
45478196|NCT05821309|Drug|PEG 3350|The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes
45686930|NCT05815329|Other|cognitive training|After the multidimensional evaluation at T0, the participants will be randomly allocated into an experimental group and a wait list control group. Specifically, cognitive training will be offered to half of the outpatients included in this research by means of technological devices (Neurotablet). A neuropsychologist will supervise the cognitive training offline (about 30 minutes per 5 days, 8 weeks) and through a face-to-face 1 hour-session each week per each outpatient.
45686931|NCT05815316|Drug|18F-PSMA-1007|(3S, 10S, 14S)-1-[4-[[(2S)-4-carboxy-3-[(2S)-4-carboxy-2-(6-[18F]fluoropyridin-3- amido)butanamido]butanamido]methyl]phenyl]-3- [(naphtalen-2-yl)methyl]-1,4,12-trioxo-2,5,11,13-tetraazahexadecane- 10,14,16-tricarboxilyc acid
45686932|NCT05815303|Drug|Cadonilimab|10mg/kg iv on day 1, every 21 day
46046643|NCT03187366|Other|Bottom-up intervention|Some interventions are bottom-up, where we manipulate the resources of snails and some are top-down, where we manipulate the predators of snails.
46046644|NCT03181282|Behavioral|Physical Therapy|Postural stability exercises will follow a framework targeting quiet stance, anticipatory and reactive postural adjustments, and dynamic postural control. Gait exercises will include treadmill walking and practice with dual-task gait. A home exercise program (HEP), to be completed twice weekly, will be provided on each participant's initial visit with the physical therapist following STN-DBS surgery. The HEP will include the following exercises: trunk rotation, standing hip flexion, standing hip abduction, standing plantarflexion, and standing squat.
45355411|NCT00995332|Drug|Cytarabine, all-trans retinoic acid, valproic acid|ATRA: 22.5 mg/m2 twice daily for 2 weeks every third month Valproic acid: continuous therapy, dosage guided by serum levels Cytarabine: 10 mg/m2 once daily for up to 10 days every third month
45355412|NCT00992914|Procedure|Sympathetic nerve block with 1% lidocaine 1-2 ml|Stellate Ganglion Injection
45355413|NCT00992914|Procedure|Superficial subcutaneous injection|Superficial subcutaneous injection with saline
45355414|NCT00999232|Drug|Erythromycin|Subjects receive 4x250mg erythromycin i.v. daily after intubation of a self-propelled feeding tube
46046645|NCT03149380|Behavioral|Web-based education|The investigators will utilize interactive lessons and activities to educate about Alzheimer's disease prevention, treatment and caregiving, with focus on evidence-based lifestyle and nutritional recommendations that have been associated with delaying cognitive decline.
45355415|NCT00999232|Drug|Placebo|Subjects receive 4x placebo i.v. daily after intubation of a self-propelled feeding tube
46046646|NCT03129282|Other|Home-based Metacognitive Therapy (Home-MCT)|Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
45355416|NCT00993070|Drug|Capsaicin|0.025% topical capsaicin applied 4 times per day for 8 weeks
45355417|NCT00993070|Drug|placebo|vehicle gel, applied 4 times per day for 8 weeks
45355418|NCT00993304|Drug|liraglutide|In the first 3-week period, the treatment will be one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg liraglutide. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of 3 weeks' treatment with placebo. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
45355419|NCT00993304|Drug|placebo|In the first 3-week period, the treatment will be with placebo. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg of liraglutide. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
45355420|NCT05189002|Drug|Dimolegin 40 mg|Dimolegin - DD217 - 40 mg
45355421|NCT05189002|Drug|Dimolegin 60 mg|Dimolegin - DD217 - 60 mg
45355422|NCT05189002|Drug|Fragmin|Fragmin 5000 IU in 0.2 ML Prefilled Syringe
45478197|NCT05821309|Drug|PEG-3350 with electrolytes|The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes
45478198|NCT05821309|Drug|Glycerin|Glycerin will be given to patients based on standard of care, at the discretion of the pediatric gastroenterology and pediatric surgery teams. Glycerin administration will not be randomized. For secondary analysis, the microbiomes of those who have and have not received glycerin will be compared.
45478199|NCT05818865|Device|CLG|"The development of an innovative device (CLG) consisting of an aqueous gel based on hyaluronic acid and commercially available (Belotero) able to be loaded and to release chemokine CXCL12 recreating a kind of fake niche able to attract immune cells- and CTCs-CXCR4+. The added value is the ability to attract and trap cells capable of leaking out and potentially with a higher metastatic capacity."
45843595|NCT05711238|Other|Conventional rehabilitation|Conventional therapy group In the pediatric rehabilitation of the children's hands on the affected side, an exercise program consisting of 40 minutes of hand finger joint range of motion exercises (passive, active assistive), strengthening exercises, and coarse and fine dexterity exercises was planned, accompanied by a physiotherapist experienced for at least 5 years.
45843596|NCT05711004|Behavioral|Education via SMS|Participants in the experimental group will receive three messages per week in the morning (9-10 am) for three months. The investigators will call them every month to ensure that the SMS is delivered.
45355423|NCT00644358|Drug|vilazodone|titration to 40 milligrams (mg) every day (qd) for 1 year
45355424|NCT01564498|Other|vegetable|200-300 g raw carrots or 300-500 g cooked potatoes
45355425|NCT00993538|Procedure|Blood sampling|
45355426|NCT00993538|Procedure|Bone marrow aspiration|
45355427|NCT00821418|Device|PulseHaler treatment|treatment is for two weeks, 3 times per day
45355428|NCT00821418|Device|CPAP treatment (through a deactivated version of PulsHaler)|treatment is for two weeks, 3 times per day
45355429|NCT00993694|Drug|chemotherapy|
45355430|NCT00993694|Drug|dapsone|
45355431|NCT00993694|Other|medical chart review|
45355432|NCT00993694|Procedure|assessment of therapy complications|
45355433|NCT04000828|Device|Placement of Sensimed Triggerfish|Sensimed Triggerfish is placed on the corneal surface
45355434|NCT00640926|Drug|Radezolid|300 mg/day, orally for 7-10 days
45355435|NCT00640926|Drug|Radezolid|450 mg/day orally for 7-10 days
45355436|NCT00640926|Drug|Radezolid|900 mg/day orally for 7-10 days
45355437|NCT03892564|Drug|MC2-01 Cream, irradiation|One application of MC2-01 Cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
45355438|NCT03892564|Drug|MC2-01 Cream, no irradiation|One application of MC2-01 Cream. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
45355439|NCT03892564|Drug|MC2-01 vehicle, irradiation|One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
45355440|NCT03892564|Drug|MC2-01 vehicle, no irradiation|One application of MC2-01 vehicle. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
45355441|NCT03892564|Drug|Control, irradiation|Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
45355442|NCT00821496|Drug|ethinyl estradiol, norethindrone, VI-0521|Oral contraceptive
45355443|NCT00999622|Other|laboratory biomarker analysis|
45355444|NCT00999622|Other|questionnaire administration|
45355445|NCT00818220|Procedure|delayed umbilical cord clamping|at birth, the clamping of the umbilical cord will be delayed 30 to 45 seconds while the child is held lower than the placenta. At the end of the time, the cord is milked once and the cord is clamped. If the obstetrician feels he cannot delay the cord clamping, then the cord can be milked 2 to 3 times.
45355446|NCT00818220|Other|Immediate cord clamping|The umbilical cord is cut within 10 seconds after birth
45355447|NCT03891862|Drug|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
46046647|NCT03127059|Other|Breathing Exercises|"Key points in the intervention are~Reduction (or normalising) of the respiration rate; use of rhythmic, nasal inspiration, diaphragmatic breathing; reduction of depth of breath, longer expiration; breath-holding at functional residual capacity.~Relaxation, especially the neck, jaw, tongue, and shoulders. Emphasizing the impact of gravity to the body.~Inclusion of the breathing modification into walking and other physical activities.~Daily home exercise of BrEX."
46046648|NCT03127059|Other|Usual care|Participants will receive only short information given initially at recruitment. No instruction or booklet will be distributed in the Usual care-Group.
46046649|NCT03122366|Diagnostic Test|Detection of single nucleotide polymorphisms (SNP)|Asp299Gly SNP in the third exon of the TLR4 gene will be detected in blood
45355448|NCT03891862|Drug|Placebo oral capsule|non-active dosage form
45355449|NCT00640614|Biological|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Polyvinylpyrrolidone (PVP; excipient 1) Hydrocortisone-17-butyrate, 0.020 mg/cm2 in PVP Hydroxypropylcellulose (HPC; excipient 2) MDBGN, 0.0055 mg/cm2 in PVP Bacitracin, 0.60 mg/cm2 in HPC Gold sodium thiosulfate, 0.075 mg/cm2 in HPC Parthenolide, 0.0030 mg/cm2 in PVP Disperse Blue 106, 0.050 mg/cm2 in PVP Bronopol, 0.25 mg/cm2 in PVP~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
45355450|NCT02550912|Drug|Vitamin D3|vitamin D drops for paediatrics
45355451|NCT02550912|Other|Placebo|glucose syrup with same taste and color to vitamin D3 drops
45355452|NCT00999700|Drug|docetaxel - cisplatin - 5-fluorouracil|docetaxel 75 mg/sqm day1 cisplatin 75 mg/sqm day1 5-fluorouracil 750 mg/sqm/d c.i. day1 to day4 q21
45355453|NCT00999700|Radiation|radiotherapy|"Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated."
45355454|NCT00999700|Drug|cetuximab|400 mg/sqm at the 1st infusion - before starting RT 250 mg/sqm weekly - concurrent with RT up to the last week of treatment
45355455|NCT00999700|Drug|cisplatin|Cisplatin, 100 mg/sqm every 3 weeks, three times, concurrent with RT, starting from day 1 of treatment.
45355456|NCT00999700|Radiation|radiotherapy|"Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated."
45355457|NCT00818298|Drug|ziprazidone|Up to and including the time of the third PET scan, subjects will be titrated to 60 mg BID of ziprazidone. Thereafter they will receive 20-80 mg BID of ziprazidone, according to clinical effectiveness and side effects.
45355458|NCT00821574|Drug|Fluvastatin|Fluvastatin: daily 80 mg, oral
45355459|NCT00821574|Drug|Valsartan|Valsartan: daily 160 mg, oral
45478200|NCT05818761|Device|virtual reality|wearing virtual reality glasses
45478201|NCT05818761|Behavioral|stress ball|squeezing the stress ball during the attempt
45478202|NCT05818150|Device|EmboSphere Microspheres|Embolic Agent: Embosphere Microspheres
45355460|NCT00821574|Drug|Hydrochlorothiazide|Hydrochlorothiazide: daily 12.5mg, oral
45355461|NCT00995800|Drug|Fluticasone propionate / Formoterol fumarate|2 dose strength vs. placebo
45355462|NCT00818376|Other|Dental prophylaxis|Two randomized quadrants will be cleaned with a prophylaxis to disrupt dental biofilm presence.
45355463|NCT00993850|Behavioral|Cognitive behavioral therapy for insomnia|Attending 6-10 treatment sessions in one of our interview rooms. The sessions will be offered on a weekly basis. Each session takes approximately 50 minutes.
45355464|NCT00993850|Other|Bipolar education|Psychoeducation
45478203|NCT05818150|Drug|Corticosteroid injection|Corticosteroid injection
45686933|NCT05815303|Drug|Oxaliplatin|130mg/m2 iv on day 1, every 21 day
45686934|NCT05815303|Drug|Capecitabine|1000mg/m2 po bid on day 1 to 14, every 21 day
45686935|NCT05815290|Drug|Cadonilimab|Cadonilimab 10mg/kg iv on day 1 for every 21 days with a total of 8 cycles
45355465|NCT00816192|Procedure|Long-term electrical isolation of pulmonary veins|All AAD except amiodarone will be stopped five half-lives before the procedure. Our ablation protocol will require 3 catheters. A quadripolar stearable mapping catheter was inserted into the coronary sinus, a decapolar circular mapping catheter was placed at the antrum of the PV after transeptal puncture to help for electrical disconnection of all four PV with the randomized ablation catheter. After transseptal access, an intravenous bolus of heparin was administered and repeated 3 to 4 hours later. Atrial burst will then be used to induce AF. With the ablation catheter positioned proximal to Lasso catheter on the atrial aspect of PV ostium, isolation will be performed.
45355466|NCT00999778|Behavioral|Caregiver-Mediated Intervention|1 (two- 1/2 jour sessions weekly) hour of intervention per week for 10 weeks in which parents and their child meet with the interventionist together using the caregiver as a means to facilitate change in their child's development
45355467|NCT00999778|Behavioral|Caregiver-Education Intervention|The caregiver meets 1 time (1 hour each session) a week for 10 weeks with an interventionist - caregiver will receive information on child development and have the opportunity to ask questions and discuss the information vis-a-vis their own child
45355468|NCT00821652|Drug|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod|Part I: a cohort of 3 patients to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical resiquimod 1000 mg of the 0.2% gel on days 1, and 3. If no DLT observed, we will proceed to cohort 2 with Resiquimod dosing on days 1,3 and 5. If DLT is found in the second cohort, the trial will proceed to Part II; with the limited dosing for days 1 and 3 only, as used in the first cohort. If no DLT is found in second cohort, the trial will proceed to Part II with Resiquimod dosing for days1, 3 and 5.
45355469|NCT00821652|Drug|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo|Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I. The cycles will be repeated every 3 weeks for a total of 4 cycles (on Study week 1, 4, 7 and 10). All procedures may occur within + 3 days of the planned date.
45478204|NCT05817825|Behavioral|Smart IOP Intervention|Smart IOP is a remotely delivered IOP program in operation since 2016, allowing patients to complete addiction treatment entirely online. The original program, consisting of 72 video modules across 8 different topics, will be adapted and tailored to hospitalized patients with serious infections from injection drug use. Participants will watch video content asynchronously, and will be required to correctly answer knowledge questions to proceed to the next module. The whole treatment program will require approximately 4 weeks to complete. Participants are also asked to answer questions about how to apply the knowledge to their own personal circumstances. The answers to these are reviewed by the peer recovery coach during weekly encounters. Videos can be viewed at a time that is most convenient to the participants. T
45686936|NCT05815264|Biological|23-valent pneumococcal polysaccharide vaccine|This vaccine（0.5ml） is produced by Ab&b Biotechnology Co., Ltd.JS. Subjects will receive one dose of 23-valent pneumococcal polysaccharide vaccine administered by intramuscular injection.
45355470|NCT00761657|Drug|Roxadustat|Capsule
45478205|NCT05817825|Behavioral|Peer Recovery Coach|Peer recovery coach, an individual in sustained recovery (>5 years) and certified to be a coach, will meet weekly with the participant to review progress, answer questions about the videos, review answers to questions, and encourage continuation of treatment after discharge. These meetings will occur in-person or remotely.
45686937|NCT05815264|Biological|pneumococcal vaccine polyvalent|This vaccine（0.5ml） is produced by Merck Sharp & Dohme Corp. Subjects will receive one dose of pneumococcal vaccine polyvalent administered by intramuscular injection.
45843597|NCT05710926|Behavioral|Evolutionary Systems Therapy for Schizotypy|A novel therapy for schizotypal traits integrating evolutionary psychopathology, compassion focused therapy, and metacognitively oriented psychotherapy.
45686938|NCT05815199|Other|E-cigarette (EC)|Fixed dose. Participants are to use the EC as replacement for smoking combustible cigarettes. Participants will vape the EC.
45686939|NCT05815199|Other|Nicotine Replacement Therapy (NRT)|Includes nicotine patches, lozenges and gum. NRT use recommendations will follow the guidelines of the product, e.g. one patch per day.
45686940|NCT05815199|Behavioral|Harm-Reduction Counseling|At baseline, after randomization, participants will receive their first telehealth session (20~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Up to five additional sessions will be delivered, 15~20 minutes each.
45686941|NCT05815199|Behavioral|Ecological Momentary Intervention (EMI) Text Messaging|EMI can be defined as delivering tailored interventions via electronic messages (i.e., regular text messages) that include personalized feedback based on real-time assessment responses and other contextual factors. EMI will take place throughout the intervention period.
45686942|NCT05815186|Drug|Sotorasib|Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles
45355471|NCT00761657|Drug|Placebo|Capsule
45478206|NCT05816941|Procedure|Conventional Periodontal Treatment (Complete Oral Disinfection)|"Oral hygiene instructions followed by complete oral disinfection (removal of hard and soft deposits, scaling and root planing, mouth rinse with 0.2% chlorhexidine twice in one minute, pocket rinse with 0.2% chlorhexidine three times in ten minutes). Ultrasonic (Piezoled, KaVo) and hand instruments (Gracey curettes, Hu-Friedy, USA) were used for this purpose.~For the next 14 days, all patients were asked to rinse their oral cavities twice daily with 0.12% chlorhexidine."
45478207|NCT05816941|Procedure|Adjunctive Photodynamic Therapy|"Photodynamic Therapy as adjunctive treatment in pockets with PPD ≥ 5 mm. For this purpose, a Fotona XD -2 diode laser (Fotona, Ljubljana, Slovenia) with a wavelength of 810 nm, a power of 250 mW and the photosensitizing agent indocyanine green at a concentration of 1 mg/ml was used. First, the area to be irradiated was isolated, and the photosensitizing agent was applied to the periodontal pocket. After 60 seconds, the supragingival excess of the photosensitizing agent was removed by gentle rinsing with a saline solution. This was followed by irradiation for ten seconds on each side.~For the next 14 days, all patients were asked to rinse their oral cavities twice daily with 0.12% chlorhexidine."
45478208|NCT05811039|Device|Remo-Wax® Oil|Remo-Wax® Oil (abbreviated RWO; GMDN (Global Medical Device Nomenclature) code 46259, Earwax softening oil), is a CE-marked, non-sterile fluid mixture, used for prevention of impacted earwax. Remo-Wax® Oil also moisturizes the skin in the ear canal and reduces itching and irritation caused by the ear canal dryness
45478209|NCT05801705|Drug|Aromatase inhibitor|Aromatase inhibitor includes Arimidex, Aromasin, Femara.
45478210|NCT05801705|Procedure|ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist)|Gonadotropin-releasing hormone agonist includes Buserelin, Goserelin, Leuprorelin, Nafarelin, Triptorelin
45355472|NCT00816270|Procedure|Bilateral Upper eyelid blepharoplasty|Bilateral upper lid blepharoplasty was performed on each patient by the same experimented surgeon using a standard technique. One side (right or left upper eyelid) was randomly chosen for experimental closure with liquid bandage and the opposite eyelid served as the control being used a 6/0 nylon continuous sutures.
45478211|NCT05801705|Drug|Tamoxifen|tamoxifen,10mg, bid
45478212|NCT05801705|Drug|toremifene|toremifene, 60 mg, qd
45478213|NCT05798624|Diagnostic Test|Ultrasound between 6+0 and 6+7 weeks of pregnancy - With Isthmocele|"Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior)~Size of isthmocele:~Depth of isthmocele~Width of isthmocele~Circumference of isthmocele~Distance between isthmocele and outer cervical os (measured with the trace line) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac Measurements of the isthmocele size / circumference / distance between isthmocele / CS and outer cervical os"
45478214|NCT05798624|Diagnostic Test|Ultrasound between 6+0 and 6+7 weeks of pregnancy - Without Isthmocele|Location of implantation of the GS amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac
45478215|NCT05798624|Diagnostic Test|Ultrasound between 6+0 and 6+7 weeks of pregnancy|"Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites (A: fundal, B: anterior, C: posterior)~Size of gestational sac"
45498280|NCT03679104|Procedure|Closure of mucosotomy using OverStitch™ suturing device|Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done by OverStitch™ (Apollo Endosurgery Inc., Austin, Texas, USA), which is a suturing device that enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope.
45498281|NCT03623568|Drug|glecaprevir/pibrentasvir tablets|12 weeks of treatment with Mavyret
46046650|NCT03114644|Other|Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.|Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.
46046651|NCT03094637|Drug|Azacitidine|Given IV
46046652|NCT03094637|Biological|Pembrolizumab|Given IV
46046653|NCT03057834|Behavioral|Pelvic floor muscle exercise|Standardized pelvic floor muscle exercise regimen
46046654|NCT03055507|Drug|Ibuprofen 400 mg|Addition of ibuprofen to standard pain regimen.
46046655|NCT03055507|Drug|Acetaminophen 650 mg|Standard analgesic provided post-operatively to patients undergoing sinus surgery
46046656|NCT03055507|Drug|OxyCODONE 5 Mg Oral Tablet|Standard PRN medication offered post-operatively for breakthrough pain
45355473|NCT00999856|Device|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
45355474|NCT00999856|Device|GOMIS and Photometer|An improved insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
45355475|NCT00999856|Device|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer version 2 will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
45355476|NCT00999856|Device|GOMIS and Photometer|After comparing Photometer Version 1 and Version 2 the better one of them will be used for measurements in Cohort 4. A new insert will be implanted under the conjunctiva.
45355477|NCT00999856|Device|GOMIS and Photometer|The insert version with the best results will be implanted. The photometer that was used in Cohort 4 will be taken again for fluorescence measurements.
45355478|NCT00319501|Drug|Placebo|Intramuscular autoinjector; administered at onset of an episode
45355479|NCT00319501|Drug|Vanquix Auto-Injector (Diazepam Injection)|Intramuscular autoinjector: 5, 10, 15, or 20 mg (based on participant's age and weight); administered at the onset of an episode
45355480|NCT00994006|Dietary Supplement|Magnesium oxide|520 mg of elemental magnesium q.d.
45355481|NCT00994006|Dietary Supplement|Magnesium citrate|Magnesium citrate , 98.6 mg of elemental magnesium t.i.d.
45355482|NCT00818610|Drug|Beta lactam (amoxicillin / clav. acid OR cefuroxime)|1.2 g 4x/d OR 1.5 g 3x/d IV
45686943|NCT05815186|Drug|Ladarixin|Ladarixin administered twice-daily at the recommended phase II dose (RP2D) (determined in the phase I portion of this trial) over 21-day treatment cycles.
45686944|NCT05815147|Dietary Supplement|Fortified Powdered Beverage|Participants will be asked to take the fortified powdered beverage everyday for 6 weeks.
46046657|NCT03038256|Drug|concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME|"concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.~XELOX:~Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks~Surgery Procedure:~Total Mesorectal Excision"
46046658|NCT03038256|Drug|concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX|"concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.~XELOX:~Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks~Surgery Procedure:~Total Mesorectal Excision"
46046659|NCT03009981|Drug|Apalutamide|Take apalutamide 240 mg (four 60 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.
45498282|NCT03186781|Biological|VRC-FLUNPF081-00-VP (HA-F A/Sing)|VRC-FLUNPF081-00-VP (HA-F A/Sing) is an investigational influenza HA ferritin vaccine.
45686945|NCT05815134|Biological|blood sample|10ml of blood will be sampled from patients before undergoing IVF treatment, the cell free DNA will be extracted and then quantified by a real time PCR. Another 10ml sample will be drawn the day of oocyte puncture for a new quantification of cell free DNA in plasma and cell free DNA will also be dose in follicular fluid of patients
45686946|NCT05815121|Other|Acupressing|Acupuncture with placement of 4 vaccaria seeds covered with stickers on the ears and 2 on the wrists.
45686947|NCT05815121|Other|Control|with stickers only on the points, and the points should not be massaged.
45355483|NCT00818610|Drug|Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)|1.2 g 4x/d OR 1.5 g 3x/d IV AND 0.5 g 2x/d IV/PO
45355484|NCT01000012|Device|Becker 50 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
45498283|NCT03186781|Biological|VRC-FLUDNA082-00-VP (DNA A/Sing)|VRC-FLUDNA082-00-VP (DNA A/Sing) is an investigational influenza plasmid DNA vaccine.
45686948|NCT05815108|Other|NO INTERVENTION|NO INTERVENTION
45686949|NCT05815095|Other|PREAUT grid|Patient with abnormal results in this evaluation would be referred to a specialized center early for advice and treatment if necessary
45686950|NCT05815082|Procedure|Colorectal cancer resection combined with liver metastasis resection.|The preferred surgical approach is resection of the corresponding colon segment with regional lymph node dissection. If conditions permit, synchronous resection of the primary lesion and liver metastases of colorectal cancer can be performed to achieve curative resection.
45686951|NCT05815082|Drug|FOLFOX chemotherapy regimen|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
45843598|NCT05710926|Behavioral|Cognitive Behavioral Therapy|An adaptation of Cognitive Behavioral Therapy for those diagnosed with personaloty disorders.
45355485|NCT01000012|Device|Becker 25 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
45355486|NCT02551302|Device|Solera™ Medtronic|The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF). Solera™ Medtronic
45355487|NCT02551302|Device|CD HORIZON BalanC™ Medtronic|"The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed with the following devices:~CD HORIZON BalanC™ Medtronic"
45355488|NCT00995878|Procedure|Focused ultrasound (MRgFUS)|MRgFUS treatment will take place in a MRI machine and powerful ultrasound waves go through the abdominal wall to destroy the fibroid or fibroids. No incision is made during this treatment and light sedation is required. There are certain fibroids that may not be treated with this technique and there is no treatment of normal uterine tissue.ough the abdominal wall to destroy the fibroid.
45355489|NCT00995878|Procedure|Uterine artery embolization (UAE)|UAE treatment takes place on a regular x-ray machine. A small incision is made where the leg meets the trunk and a small tube is used to use very small pellets to block off the blood supply to the entire uterus. Sedation is used. Most fibroids are treated with this technique and normal uterine tissue is also affected.
45355490|NCT00761579|Drug|Paliperidone|Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
45355491|NCT00994084|Behavioral|Healthy Kids-Houston program|Children receive 90 minutes of after-school structured physical activities and 30 minutes of nutrition and behavior lessons twice a week during three 6-week sessions at the community centers. The 6-week sessions take place once in the fall, once in early spring and once in late spring.
45355492|NCT00994084|Behavioral|Control|Children do not receive the Healthy Kids-Houston behavior modification program but will participate in the regular after-school enrichment programs offered by the community centers.
45355493|NCT04100525|Behavioral|Neuropsychological testing intervention plus follow up|Neuropsychological testing for women experiencing significant fatigue, mood, or cognitive symptoms. Feedback type and case management services varied depending on randomized group.
45355494|NCT01000168|Other|Treadmill therapy and conventional walking therapy.|"The experimental group received 30 sessions of treadmill therapy with body weight support for a time period of 10 weeks.~The conventional group received traditional walking therapy for the same time period."
45355495|NCT01000246|Biological|influenza virus vaccine (influvac or vaxigrip)|one i.m. dose of 0.5 mL
45355496|NCT00627042|Biological|Ramucirumab (IMC-1121B)|Participants will receive ramucirumab (IMC-1121B) at 8 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
45355497|NCT00319111|Drug|bosentan|"Oral bosentan~Initial dose: 62.5 mg twice a day (b.i.d.) for 4 weeks for all patients~Maintenance dose: 125 mg b.i.d. (62.5 mg b.i.d. if weight < 40 kg)"
46046660|NCT03009981|Drug|LHRH Analogue|"Patients will receive a LHRH analogue therapy of either Degarelix OR Leuprolide with bicalutamide.~Degarelix:~Patients will receive subcutaneous injections every 28 days (+/- 3 days). Patients will receive a loading dose of 240 mg (two 120 mg injections) on C1D1, followed by maintenance dose of 80 mg on Day 1 of subsequent cycles.~Leuprolide:~Patients treated with leuprolide will receive a 7.5 mg IM injection on C1D1. Patients in arm A ONLY will take this in combination with bicalutamide 50 mg orally once daily starting on C1D1 and continuing for 28 days through completion of cycle 1. Starting on C2D1, patients will continue on one of the following two treatments at investigator discretion:~Leuprolide 7.5 mg IM injection on Day 1 of subsequent cycles without concurrent bicalutamide.~OR:~Leuprolide 22.5 mg IM injection at the following visits without concurrent bicalutamide: C2D1, C5D1, C8D1, and C11D1."
46046661|NCT03009981|Drug|Abiraterone Acetate|Take abiraterone acetate 1000 mg (four 250 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.
45355498|NCT00994396|Dietary Supplement|Placebo|Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos.
45478216|NCT05797727|Device|LifeChamps Platform HCP|Healthcare professionals that will participate in the study will be introduced will have access to the LifeChamps Dashboard, which will display the data monitored from the patients, thus potentially facilitating patients' follow-up between clinical consultations. The LC Dashboard will provide pseudonymised information regarding the patients' physical activity and PROMs for the purpose of the pilot feasibility trial. They will not be able to view real time processed information, such as risk of frailty, QoL, risk of dependency and psychological condition, from the LIFECHAMPS analytics engine. They will be shown the anonymised outputs of the engine per patient and asked their opinions on the usability, acceptability and on whether such information would have helped better manage their patients' supportive care.
45686952|NCT05815069|Diagnostic Test|[18F]AlF-NOTA-pentixather PET/CT|The radiotracer 18F-AlF-NOTA-pentixather PET/CT (dose 4.81 MBq/Kg body weight) was injected intravenously according to the patient's body weight. The whole-body PET/CT examination from the top of the skull to the root of the thigh was performed using a PET/CT examination instrument (Siemens Biograph mCT Flow) 50-60 minutes after the injection of radiopharmaceuticals. Flow Motion flow scanning technology with a matrix of 128x128 and a layer thickness of 3 mm was used. all PET images were iteratively reconstructed. Patients who have undergone surgery routinely undergo pathological examination.
45686953|NCT05815056|Device|Sedakit (R) using hypnosis induced by the virtual reality device|we use the virtual reality device and no medication during the surgery
46046662|NCT03009981|Drug|Prednisone|Take two prednisone 5 mg tablets daily, starting on C1D1 and continuing throughout the 52-week treatment period. Following completion of treatment period, patients will taper off prednisone per institutional guidelines. Suggested tapering plan: prednisone 5 mg daily for 7 days, then 2.5 mg daily for 7 days before discontinuing.
46046663|NCT02996253|Procedure|FHL transfer|endoscopic transfer og flexor hallucis longus
45355499|NCT00994396|Dietary Supplement|Vitamin D 3 cholecalciferol|4000 IU (2 soft gels at 2000 IU each) vitamin D3 per day for 6 months.
45355500|NCT00818688|Procedure|compression ultrasonography at 3 months|A three-month follow-up prospective study was performed in the subgroup of patients with symptomatic ST but without deep-vein thrombosis on compression ultrasonography or documented symptomatic pulmonary embolism at inclusion, a group defined as patients with 'isolated ST'.
45478217|NCT05797727|Device|LifeChamps Platform|Participants will be asked to provide 5 endpoints (PROMS) and will be provided with the study equipment, i.e., a mobile app, smartwatch, smart scale, location home sensor, a smart plug, and a micro-computer, with which they will need to interact with the devices for three months. Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors will be passively collecting information about their everyday living during these three months. At the end of the 3 month period, the participants will return the devices and will be asked to provide the 5 endpoints and their opinions regarding the usability and acceptability of the platform using structured questionnaires
46046664|NCT02932280|Drug|Neratinib|Neratinib will be administered orally, or through existing gastrostomy feeding tube, once a day with food, preferably in the morning, continuously for 28-day cycles, with no rest between cycles. Dose will be scaled by body surface area (BSA).
45355501|NCT03978013|Other|Pomegranate juice|Pomegranate juice
45355502|NCT03978013|Other|Apple juice|Apple juice
45355503|NCT00821808|Device|Compression Device|"The compression device will be worn for 8 hours each day on one leg. The device will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:~Immediately following device application~1 hour~4 hours~8 hours"
45355504|NCT00821808|Device|Profore®|"Profore® will be worn for 8 hours each day on opposite leg. Profore® will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:~Immediately following device application~1 hour~4 hours~8 hours"
45355505|NCT04000984|Behavioral|Mindfulness Based Training (MBT) Program|Participants in the MBT program will meet weekly for 8 weeks. Each session will last one-and-a-half hours. Mindfulness, defined as caring moment-to-moment awareness, will be cultivated through the teaching and formal practice of sitting and walking meditation, body scan, and mindful movement (e.g. yoga). Participants will also be taught how to practice mindfulness informally when eating, engaging in pleasurable activities and through interactions with others. Participants will be encouraged to practice approximately 30 minutes a day, and will be provided handouts as well as guided audio recordings of formal practices taught in session to aid their practice at home.
45355506|NCT04000984|Behavioral|Cognitive Rehabilitation Training|Participants in the CRT program will meet weekly for 8 weeks. Each session will last one-and-a-half hours. The 8 week-program will consist of the following components: (i) identifying and working on at least one personal rehabilitation goal related to everyday life that is associated with cognitive difficulties; (ii) reviewing and building on the use of practical memory strategies, and or introducing and teaching the use of a new strategy or memory aid; (iii) introducing techniques for learning new information and associations, identifying the preferred strategy, and encouraging the application of this strategy in daily life; (iv) providing practice in maintaining attention and concentration; and (v) exploring current ways of coping with stress and anxiety as well as providing relaxation techniques to help aid with coping (Clare, 2007). Participants will be provided with instructional hand-outs as well as logs to record, monitor and evaluate their progress.
45355507|NCT00816426|Drug|Rifampicin|Rifampicin or rifampin (RIF) is a semi-synthetic compound derived from Amycolatopsis rifamycinica. It is mostly used in combination to treat TB, while other disease indications include brucellosis, leprosy, legionnaire's disease and problematic drug-resistant staphylococcal infections. RIF inhibits DNA-dependent RNA polymerase in bacterial cells by binding its beta-subunit, thus preventing transcription to RNA. Its MIC against replicating TB bacilli is 0.1 g/ml and its minimum bactericidal activity (MBC) is 0.5 g/mL. It is one of the rare anti-TB drugs with some activity against nonreplicating cells.
45478218|NCT05791344|Device|ECG monitoring|Intra-procedural ECG changes during TAVR
45686954|NCT05815056|Drug|drug intervention|using sufentanyl 5mg intravenously during the surgery
46046665|NCT02870738|Procedure|Pelvic Floor Physical Therapy|Internal and/or external myofascial release of the pelvic floor muscles
46046666|NCT02870738|Drug|Bladder Instillations|A solution of heparin sulphate 40,000 IU (4 cc of 10,000 units/cc), lidocaine 2% 16 ml, Sodium bicarbonate 8.4% 4 ml and Kenalog 40 mg (1cc) to reach a total fluid volume of 25 ml will be instilled into the bladder with a urinary catheter
46046667|NCT02811653|Device|Brain MRI|
46046668|NCT02811653|Other|neuropsychological evaluation|
46046669|NCT02811653|Biological|Blood|
45355508|NCT00816426|Drug|Isoniazid|Isoniazid (INH) is a first-line antituberculous medication discovered in 1952 and used in the prevention (alone) and treatment (in combination) of tuberculosis. Isoniazid is a prodrug and must be activated by a bacterial catalase to inhibit the synthesis of mycolic acids in the mycobacterial cell wall. Consequently, INH is bactericidal to rapidly-dividing mycobacteria, with an MIC of 0.05 g/ml and an MBC of 1 g/ml, but is inactive if the mycobacterium is nonreplicating or slow-growing.
45355509|NCT00816426|Drug|Pyrazinamide|Pyrazinamide (PZA) is a synthetic derivative of nicotinamide requiring ctivation by the mycobacterial enzyme pyrazinamidase, only active under acidic conditions which are thought to be found within the phagolysosomal compartment of macrophages. The conversion product, pyrazinoic acid, inhibits fatty acid synthetase I, required by the bacterium to synthesize fatty acids, though this has been disputed. It has an MIC of 6 g/ml and is not cidal under in vitro conditions. Overall, its mechanism of action and reasons for good sterilizing activity in vivo are poorly understood. It is part of the 4-drug combination recommended by the WHO to treat drugsensitive tuberculosis and is also included in most econd-line regimens.
46046670|NCT02795533|Behavioral|Clinical follow-up|"All included patients will have a clinical follow-up consisting of:~A medical examination~Quality of life questionnaires~Neuropsychological test~All instruments have been translated into Norwegian and validated and tested in clinical practice."
46046671|NCT02789982|Drug|β-adrenergic blocker propranolol|
45355510|NCT00816426|Drug|Kanamycin|Kanamycin (KM) is an aminoglycoside antibiotic belonging to the same class of drugs as Streptomycin, one of the first drugs used to treat TB in the 50 s. It kills sensitive bacteria by binding to the 30S ribosomal subunit and interfering with protein synthesis. Its MIC and MBC against MTB are 2 and 6 g/mL, respectively, with a remarkably low MBC/MIC ratio. However, KM is only used to treat serious bacterial infections due to severe renal toxicity and ototoxicity. No interaction with the metabolism of other drugs has been reported. The drug is approved by the Korean Ministry of Food and Drug Safety (MFDS) but not the US FDA for use against pulmonary TB.
45355511|NCT00816426|Drug|Moxifloxacin|Moxifloxacin (MXF) is a synthetic fluoroquinolone antibiotic. It inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, which are essential enzymes playing a crucial role in the replication and repair of bacterial DNA. Its MIC, MBC and intracellular activity against MTB are 0.5, 2 and 1 g/mL, respectively, with again a low MBC/MIC ratio.
45355512|NCT00996190|Drug|Phenylephrine|phenylephrine 120 micrograms/mL, administered either by continuous infusion or by intermittent bolus dose
45355513|NCT03860064|Other|Non intervention|Non
45686955|NCT05815043|Behavioral|Low-sodium intake|Participants will consume less than or equal to 720 milligrams of sodium per day for 3 days.
45355514|NCT00996268|Drug|GSK2212836|Treatment A - GSK2212836 test formulation 1, Treatment B - GSK2212836 test formulation 2, or Treatment C -GSK2212836 marketed formulation.
45355515|NCT00996268|Drug|GSK2212836|Treatment D - low dose of GSK2212836 test formulation, Treatment E - medium dose of GSK2212836 test formulation, Treatment F - high dose of GSK2212836 test formulation, Treatment G - GSK2212836 marketed formulation, or Placebo.
45355516|NCT00816504|Drug|Galactose|Oral galactose, 0.2 g/kg/dose twice daily for 28 days
45478219|NCT05785104|Other|Myofascial release|Is Facilitation of mechanical and neurological adaptive capacity as integrated through the Myofascial system
45478220|NCT05785104|Other|Muscle energy technique|Is manual therapy procedure that involves alternating periods of resisted muscle contraction and assisted stretching
45478221|NCT05780216|Drug|DMT + harmine|The intervention used in this study is a combination of the two main ingredients of ayahuasca, DMT (N,N-dimethyltryptamine) and harmine in purified form.
46046672|NCT02789982|Behavioral|Treatment as usual|
45686956|NCT05815043|Dietary Supplement|High-sodium intake|Participants will supplement their existing diets with 10 salt tablets daily for 3 days.
46046673|NCT02746718|Other|Blood sample|A blood sample for CPK dosage and pompe disease test
46046674|NCT02738645|Other|pneumonia|
46046675|NCT02714465|Other|hyperbaric oxygen therapy|hyperbaric oxygen therapy
46046676|NCT02701829|Other|CONTROL- Usual & Customary Health Fair Follow-up|participating drivers may fall into 1 of 2 categories- Regular follow-up, or Urgent Follow-up.
46046677|NCT02701829|Other|Health Fair + TECH [Text Messaging + Home Blood Pressure Monitoring]|all participating drivers receives standard Health Fair services initially falling into 1 of 2 categories-Regular Follow-up or Urgent Follow-up. Additionally all participating drivers will receive Home Blood Pressure Monitors and have the mobile health text messaging intervention.
46046678|NCT02701829|Other|Heal th Fair + TECH [Text Messaging + Home Blood Pressure Monitoring] + Social Network Support (SNS)|all participating drivers receives standard Health Fair services initially falling into 1 of 2 categories-Regular Follow-up or Urgent Follow-up. Additionally all participating drivers will receive Home Blood Pressure Monitors for daily BP self-monitoring and text messaging, and they will receive the social network support intervention including an SNS guide for each SNS.
46046679|NCT02673281|Other|Walnut shake|walnut shake will be administered for 5 days as a morning snack instead of a typical breakfast
46046680|NCT02673281|Other|Placebo shake|placebo shake will be administered for 5 days as a morning snack instead of a typical breakfast
45355517|NCT01000402|Drug|Psychopharmacotherapy|Lithium (according to response, serum levels, and tolerance) 150-1500mg Valproate (according to response, serum levels, and tolerance) 125-2000mg Risperidone (according to response, and tolerance)0.5-6mg Olanzapine(according to response, and tolerance)2.5-20mg Ziprasidone(according to response, and tolerance)40-160mg Topiramate (according to response, and tolerance)25-300mg Quetiapine (according to response, and tolerance)25-500mg Aripiprazole (according to response, and tolerance)5-20mg Lamotrigine (according to response, and tolerance)25-200mg Fluoxetine (according to response, and tolerance) 1-40mg Sertraline (according to response, and tolerance)25-200mg Methylphenidate (according to weight, response, and tolerance)0.3 -0.7mg/kg/day
45355518|NCT00640224|Drug|rosiglitazone|4 mg daily for 6 months
45355519|NCT00640224|Drug|drospirenone/ethinyl estradiol|1 tab (3mg/30mcg) daily for 6 months
45355520|NCT01000558|Other|biologic sample preservation procedure|
45478222|NCT05780216|Drug|Placebo|The placebo consists of pharmaceutically inactive ingredients and additional flavors, and is organoleptically hardly distinguishable from the verum.
45478223|NCT05778617|Drug|Ambroxol Hydrochloride (420mg)|Oral tablet
45478224|NCT05778617|Drug|Placebo|Oral tablet
45355521|NCT02550990|Behavioral|Cognitive training|
45355522|NCT02550990|Behavioral|Aerobic exercise training|
45355523|NCT02550990|Behavioral|Sequential combination of aerobic exercise and cognitive training|
45355524|NCT03742804|Biological|Intratumoral G100|G100 agent is a potent Toll-like receptor (TLR)4 agonist. G100 is composed of glucopyranosyl lipid A (GLA) formulated in a stable emulsion (SE). GLA is a fully synthetic TLR4 agonist that is a potent stimulator of innate immune responses.
45355525|NCT00822042|Other|Samples and procedures|"Scanner, histomorphometry : at the inclusion and M3 visits~whole blood samples, cytoponction : at the inclusion and M3 visits"
45355526|NCT01000714|Drug|Psirelax|
45478225|NCT05774886|Combination Product|Implantable Microdevice (IMD)|"Small, implantable device with 30 reservoirs for drug and drug combinations.~Placement of 2 microdevices into tumor will be performed via needle, percutaneously, and guided by interventional radiologic techniques.~Drugs include all or a subset of the following: Doxorubicin, Paclitaxel, Carboplatin, Eribulin, Pembrolizumab, Atezolizumab, Tazemetostat, Panobinostat, Olaparib, Capecitabine, Sacituzumab govitecan, Abemaciclib, Venetoclax, Doxorubicin + cyclophosphamide (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin (combination), Carboplatin + paclitaxel (combination), Doxorubicin + cyclophosphamide + pembrolizumab (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin + Pembrolizumab (combination), Paclitaxel + atezolizumab (combination), Paclitaxel + pembrolizumab (combination), Carboplatin + gemcitabine + pembrolizumab (combination), Carboplatin + paclitaxel + pembrolizumab (combination), Trastuzumab deruxtecan"
46046681|NCT02667886|Drug|X4P-001|Continuous, oral, once-daily dosing
45478226|NCT05769647|Device|Virtual Reality Glasses|3 minutes after the individual starts watching the video, the IV catheter insertion attempt will be performed while continuing to watch the video.
45478227|NCT05769647|Device|Stress Ball|Patients will be given a ball and instructed to tighten and loosen with their free hand during IVC placement. The patient will continue to squeeze the ball throughout the IV catheter insertion attempt.
45478228|NCT05766592|Behavioral|LGBTQ-affirmative CBT|16-session LGBTQ-affirmative psychotherapy using cognitive behavioral techniques
45355527|NCT00822198|Device|plantar vibration|Subjects in the experimental component of the trial will be provided with a Juvent 1000-CS device in their home or workplace. The device will be placed in a convenient location where the device does not represent a trip hazard, and yet is readily accessible for use. The subjects will be instructed to use the device whenever it is convenient to do so, either by standing on the device, or by sitting with their feet on the device. Downloads of usage data will be obtained intermittently. Period interviews with the subjects will be conducted to ensure that the device is operating and that no problems are encountered with device usage.
45355528|NCT01000792|Drug|Levocetirizine|The study drug is Xyzal® 5 mg (API: levocetirizine dihydrochloride). 28 film tablets will be dispensed. Oral intake should be performed once daily (administration in the evening).
46046682|NCT02667886|Drug|axitinib|Continuous, oral, twice-daily dosing
45355529|NCT01000792|Drug|Levocetirizine|Levocetirizine
45355530|NCT02550756|Drug|CTNX-4975|
45355531|NCT01000870|Drug|MNI-513-01|Subjects will be administered a single IV injection of IMP with a total activity amounting to 300MBq (8.1 mCi) +/- 20% of MNI-513 followed by PET imaging.
45355532|NCT01000948|Drug|ZD4054|ZD4054 10 mg given orally, once daily in tablet form to all patients in two years or until investigator consider the drug for useless.
45355533|NCT01001026|Biological|Arepanrix|Adults: One dose Arepanrix vaccine given IM (0.5 mL)
46046683|NCT02637245|Other|No intervention|No intervention
46046684|NCT02623972|Drug|Eribulin|administered IV for 4 cycles
46046685|NCT02623972|Drug|Adriamycin|administered IV with cyclophosphamide for 4 cycles
46046686|NCT02623972|Drug|Cyclophosphamide|administered IV with adriamycin for 4 cycles
46046687|NCT02614066|Biological|brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered intravenously.
46046688|NCT02614066|Drug|Cyclophosphamide|Administered intravenously.
46046689|NCT02614066|Drug|Fludarabine|Administered intravenously.
46046690|NCT02587195|Drug|Teriflunomide|
45355534|NCT01001026|Biological|Arepanrix|Children: Two doses of Arepanrix vaccine given IM (0.25 mL) three weeks apart
45355535|NCT01001182|Other|non interventional|non interventional
45355536|NCT01001260|Drug|No ASA|Alternative antiplatelet therapy instead of aspirin
45355537|NCT01001260|Drug|Low dose ASA|Low dose aspirin (81mg) prior to PTCA
45355538|NCT01001260|Drug|325 mg ASA|high dose of aspirin prior to PTCA
45355539|NCT00996424|Drug|Acetylcysteine|Inhalation with N-Acetylcysteine
45355540|NCT00996424|Drug|normal saline|Inhalation with normal saline solution
45355541|NCT00994474|Procedure|Fractional carbon dioxide laser treatment|With the CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA), patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %. We employed 'pin-point bleeding' and serosanguinous exudate as a clinical end point. The pulse duration was 10 msec.
45355542|NCT00994474|Procedure|Fractional Er:YAG laser treatment|The Er:YAG laser (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany) was used in 4 passes with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses); the pulse duration was 400 μsec.
45355543|NCT05220280|Drug|Imatinib|Oral imatinib 400 mg tablet once a day for 14 days.
45355544|NCT05220280|Drug|Infliximab|Infliximab is administered as a single IV infusion with the proposed dosing schedule of 5 mg/kg body weight.
45355545|NCT00318643|Drug|Mitomycin C|intravesical administration
46046691|NCT02582008|Drug|Bupropion Hydrochloride|Given PO
45355546|NCT00318643|Drug|Chemophase|intravesical administration
45355547|NCT00996814|Behavioral|Proactive Ethics Intervention|The ethicist will: 1) meet with the patient or surrogate to assess the case and the decision-making capacity of the patient; 2) make an ethical diagnosis, framing the issues in easily understood ethical terms with the involved parties; 3) recommend the next steps, including measures to improve communication. The ethicist will help to articulate consensus or disagreement and either facilitate implementing the consensus or facilitate ways to address and resolve disagreements; 4) document the consultation in the patient's medical record, identifying the ethical issues identified, the steps taken to address those issues, the options and ethical rationales considered, the outcome and the future plan; 5) follow-up to provide ongoing support and record a follow up progress note in the chart; and 6) participate in evaluation.
45355548|NCT01001650|Biological|Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)|"Group 1: 4 doses of 7,500 PfSPZ/immunization,~Group 2: 4 doses of 30,000 PfSPZ/immunization,~Group 3: 4 doses of 135,000 PfSPZ/immunization, and~Group 4: 4 or 6 doses of 135,000 PfSPZ/immunization.~If > 80% protective efficacy is not achieved in Groups 1, 2, or 3, volunteers in Group 4 will receive a fifth and sixth dose."
45478229|NCT05766592|Behavioral|ABFT-SGM|16-session attachment-based family therapy for sexual and gender minority young adults and their nonaccepting parents
46046692|NCT02582008|Other|Laboratory Biomarker Analysis|Correlative studies
46046693|NCT02582008|Drug|Nicotine Replacement|Given NRT
46046694|NCT02582008|Other|Quality-of-Life Assessment|Ancillary studies
46046695|NCT02582008|Other|Questionnaire Administration|Ancillary studies
46046696|NCT02582008|Drug|Varenicline|Given PO
45355549|NCT01001728|Radiation|Imaging investigations (with radiation)|
45355550|NCT00318565|Device|RF energy delivery for treatment of Typical Atrial flutter|Navistar ThermoCool catheter
46046697|NCT02544074|Behavioral|neuropsychological testing|standard neuropsychological testing including brief standardized assessments
45355551|NCT00994552|Other|Pressure support ventilation|Pressure support ventilation
45355552|NCT00994552|Other|Pressure control ventilation|Pressure control ventilation
45355553|NCT01001884|Other|caregiver psychoeducational consultation program (CPCP)|6-session caregiver psychoeducational consultation program (CPCP)
45355554|NCT03983083|Behavioral|Physical activity|Access to website created to teach cancer survivors to live more active lives, with monthly email reminders/website updates. Intervention participants will also receive exercise bands for at-home resistance training.
45355555|NCT01325389|Dietary Supplement|Myo-Mel|
45355556|NCT01325389|Dietary Supplement|Placebo|
45355557|NCT00994708|Drug|esomeprazole|
45355558|NCT01064557|Drug|all-trans retinoic acid (ATRA)|
45355559|NCT01001962|Drug|empagliflozin|ACTIVE TREATMENT FOR DIABETES
45355560|NCT01001962|Drug|Metformin|ACTIVE TREATMENT FOR DIABETES
45355561|NCT01002040|Biological|Arepanrix|Group A receives one dose of Arepanrix
46046698|NCT02544074|Behavioral|eSAGE testing|Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
45355562|NCT01002040|Biological|Arepanrix|Group B receives 2 doses of Arepanrix 3 weeks apart
45355563|NCT03978169|Diagnostic Test|pleuropulmonary ultrasound|three pleuro-pulmonary ultrasound scans will be performed, preoperatively on the day of surgery, post-operatively in the recovery room and the day after surgery
45478230|NCT05766345|Biological|BCG-Vaccine SSI [Statens Serum Institut]) Danish strain 1331|Nothing to add
45478231|NCT05766345|Biological|Placebo|Nothing to add
45478232|NCT05765344|Biological|Bulevirtide|Administered via subcutaneous injections.
46046699|NCT02502799|Behavioral|Brief Early Intervention|Adolescents receive 5 individual sessions designed to strengthen the following skills: problem-solving, resisting peer pressure, and coping with emotions. Parents join portions of 3 sessions.
46046700|NCT02502799|Behavioral|Parent Training with Adolescent Cognitive Behavioral Therapy|Participants receive 12 family sessions with individual adolescent, parent, and joint adolescent and parent time. Includes additional parent training in behavioral modification, adolescent and parent contracting, and adolescent decision-making skills.
46046701|NCT02502799|Drug|Methylphenidate|Adolescents will receive methylphenidate.
46046702|NCT02456246|Procedure|FLT-PET|Positron emission tomography scan using the 18f-FLT (3'deoxy-3'-fluorothymidine) tracer
45355564|NCT00304915|Behavioral|Collaborative Care Interventions|Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.
45355565|NCT05206786|Other|Conventional preventive work out|Female players in the control group will carry out a conventional preventive work that is organised in 3 training days per week. First training session includes preventive strength and proprioception exercises. Junior and senior teams (above 16 years old) will also do plyometrics exercises. In the second training session, players will do preventive strength exercises with an increased load compared to the previous session and proprioception exercises. Junior and senior players will also do anaerobic work. In the third session, players will perform reaction speed exercises.
45355566|NCT05206786|Other|Gluteus maximus strengthening specific program|"Female players will carry out a gluteus maximus strengthening work out in addition to the control group programme. Of the following four exercises, the first and the third ones will be done on the first training session and the second and the fourth exercises will be done on the second one. Dosage will be 2 sets of 10 repetitions for each leg.~Clam Shell: Lateral decubitus with the knees and hips bend, the working leg placed on top of the other. Separate this knee while feet stay in contact.~Unilateral gluteal bridge: Supine decubitus with one foot flat on the floor and bent knee. This leg pushes the ground with the foot until the pelvis is lifted while the other leg remains straight.~Quadruped hip extension with knee extension : Quadruped on forearms. Straighten the hip by bringing the whole leg up and back with knee extension.~Quadruped hip extension with bent knee: Performed as the previous one, but during this one, the knee of the working leg is bent at 90º."
45355567|NCT03980197|Other|Active surveillance and preemptive isolation|Active surveillance test and preemptive isolation is performed. If MDRO is isolated in surveillance test, contact precaution is needed.
45355568|NCT03980197|Other|Control|No active surveillance and preemptive isolation. If clinical isolates are positive for MDRGNB, start contact precaution
45355569|NCT00997048|Procedure|Laying open|Laying open Antibiotics Dalacin 300 mg tablets or iv infusion 600 mg
45355570|NCT00997048|Procedure|Sinus excision|Sinus excision Antibiotics Dalacin tablets 300 mg or iv infusion 600 mg
45355571|NCT02532829|Other|blood sample analysis|Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.
45355572|NCT01002196|Behavioral|Stimulus fading procedures|"Core elements : 1.Behavior techniques (BT's) are used to gradually master the anxiety (stimulus fading and reward).~2. Children are first met at home where they feel most safe, and the BT's are first conducted at home in cooperation with the parents.~3.The same interventions are then continued in the environment where the problem primarily exist (kindergarten / school) not at the clinic.~4.Defocused communication- and interaction is a general treatment principle (e.g. avoid looking directly at the child, sit beside not opposite to the child, no direct questioning, and communication is based upon a motivating activity, not about the child).~5.Frequent and short interventions. 6.Information to parents and teachers on how to communicate with children with SM"
45355573|NCT01002196|Behavioral|Guidance on defocused communication|Guidance and supervision to teachers working with the children with SM. Frequency: Twice during three months
45355574|NCT01066429|Drug|Dexamethasone and dose-dense immunochemoterapy|Administration every 14 days of the EDOCH-R scheme.
45355575|NCT01002274|Drug|MCS-2|2 soft-gel capsules Qd for 40 weeks
45355576|NCT03978247|Diagnostic Test|NASHMIR|An additional blood sample will be taken upstream of the surgical procedure and a liver biopsy will be performed in all included patients. The two results obtained by the spectroscopic test and by means of the biopsy will then be compared to determine the diagnostic performance of the developped test (NASHMIR test).
45355577|NCT05200390|Device|Continuous glucose monitor|FreeStyle Libre 2 system
45355578|NCT00994786|Drug|pregabalin|pregabalin starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin will be 600 mg/day.
45355579|NCT00994786|Drug|Placebo|Placebo starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin/placebo will be 600 mg/day.
45478233|NCT05764564|Diagnostic Test|Positive or negative pressure|Positive or negative pressure is applied via a closed chamber.
45478234|NCT05756153|Drug|GFH925|GFH925 tablets administered orally daily.
45478235|NCT05756153|Drug|Cetuximab|Cetuximab administered intravenously Q2W.
45478236|NCT05752552|Drug|DO-2|Deuterated MET kinase inhibitor
45355580|NCT01002430|Biological|VEGF-D gene transfer|Gene transfer will be performed by using endocardial injection system (NOGATM) and an escalating dose of 1x109, 1x1010 and 1x1011 vpu of AdVEGF-D will be injected into 10 sites of the myocardium (0.2 ml per site).
45478237|NCT05749679|Other|training and audit|"An evaluation of the practices with clinical audit before and after the management will be carried out.Every 3 months for 2 years, the investigating physicians of the intervention group will report for these patients the modifications or cessation of treatment, modification or implementation of interventions such as physical activity or implementation of nutritional modifications. Physician investigators will be asked to report any occurrence of adverse events to their regional pharmacovigilance centers.10 possible actions to be deployed :~Hygienic and dietary measures~Physical activity~Smoking cessation~Avoidance of nephrotoxic substances~Treatment of hypertension~Proteinuria reduction~Oral antidiabetics; choice~Optimal HBA1c~Statin~Compliance"
45355581|NCT01002508|Biological|Influenza vaccine|One dose of influenza vaccine
45355582|NCT00994864|Drug|FOLFOX|One cycle of standard FOLFOX pre-operatively followed by 11 cycles of standard adjuvant FOLFOX chemotherapy.
45355583|NCT01002586|Other|Wii-Fit intervention|Half hour daily, five days a week, for 8 weeks
45355584|NCT01002586|Other|Walking exercise program|walking exercise program
45478238|NCT05749679|Other|Routine care|"Physicians in the control group will receive training on the study procedures. An evaluation of practices with a clinical audit before and after the treatments will be carried out. Every 3 months for 2 years, the investigating physicians in the control group will report for these patients the modifications or cessation of treatment, the modification or implementation of interventions such as physical activity or the implementation of modifications in terms of nutrition. The investigating physicians will be asked to report any occurrence of adverse events to their regional pharmacovigilance centers. Physician investigators in the control group will continue their care as usual."
45355585|NCT01002664|Drug|MCS-2|30 mg/day (two 15 mg capsules) Qd for 12 weeks
45355586|NCT01002664|Drug|Placebo|2 soft-gel placebo capsules Qd for 12 weeks
45355587|NCT00997282|Drug|OPC-262 2.5 mg|orally administered once daily for 24 weeks
45355588|NCT00997282|Drug|OPC-262 5 mg|orally administered once daily for 24 weeks
45355589|NCT00997282|Drug|Placebo|orally administered once daily for 24 weeks
45355590|NCT00997360|Drug|PKI-179|
45355591|NCT00994942|Drug|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 30 mg (10 mg / 5 mL) oral solution, morphine sulfate injection 10 mg (1 mg / mL)
45478239|NCT05743777|Drug|Pembrolizumab|400 mg IV q6 weekly for a maximum of 18 cycles
45478240|NCT05743777|Drug|MET-4|Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily
45478241|NCT05743777|Drug|Placebo|Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily
45686957|NCT05815030|Other|video informational/educational intervention|Videos relating to PrEP use, its benefits, side effects, and other information. The educational/round-table video will highlight individuals from diverse backgrounds and identities who will share their experiences using PrEP, including perceived benefits and effectiveness, experienced barriers to PrEP uptake, their reasons for using PrEP, and their own self-efficacy. The control group's (generic / standard video) materials will be focused on PrEP uptake without a kink identity perspective. The treatment group's materials, however, will include videos that feature kink-identified individuals who discuss PrEP uptake through a kink perspective.
45478242|NCT05743283|Device|SynEx Wound Cleanser|SynEx is a concentrated form of SynePure®, an FDA 510(k) cleared aqueous, osmotically balanced wound cleanser containing patented chitosan derivatives. The ingredients are USP purified water, chitosan arginine (a patented chitosan derivative), sorbitol powder, and betaine. SynEx cleanser is packaged in a collapsible plastic pouch for reconstitution in water before debriding and cleansing a wound.
45478243|NCT05743283|Other|Saline|The saline solution is composed of water and salt. It is packaged in a collapsible plastic pouch.
45355592|NCT00995098|Dietary Supplement|early enteral nutrition|Enteral nutrition will be administered within 24 hours of admission through naso-jejunal tube and continue for 7 days after admission. Naso-jejunal tube will be set up by endoscopy. X-ray will be used to place the distal end of the feeding tube and EN would not start until the distal end of the feeding tube has been placed at the remote end of Treitz ligament. Standard enteral nutrition liquid regimen (Nutrison Fibre) will be used. Patients are targeted to receive calories for 25 kcal/kg/day and nitrogen for 0.2g/kg/day.
45355593|NCT00995098|Dietary Supplement|Parenteral nutrition|PN administration will start within 12 hours of admission and continue for 7 days after admission. Patients will receive calories for 25 kcal/kg and nitrogen for 0.2g/kg. Twenty percent of the calories will be provided by fat emulsion (LCT/MCT) and the remaining will be provided by dextrose. Nitrogen will be provided by balanced amino acids injection (Novamin). All PN components will be compounded into 3-liters bags under sterile conditions. Nutrition regimen will be administered through subclavian central venous catheter.
45355594|NCT01003912|Biological|ALD-601|ALD-601 is manufactured by Aldagen from the 20% compartment of the selected umbilical cord blood unit within 24 hrs of planned injection. A dose of ALD-601 that delivers 1 x 105 - 2 x 106 cells/kg of estimated fetal weight at day - 1 is suspended in 300 microliters of dialysis media.
45355595|NCT01002898|Drug|lopinavir/ritonavir soft gel capsule|Ritonavir-boosted lopinavir in soft gel formulation at 400/100 mg and lamivudine at 150 mg were given twice daily.
45355596|NCT01003054|Drug|Busulfan|130 mg/m^2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -7 to -4)
45355597|NCT01003054|Drug|Cyclophosphamide|60 mg/kg in 500 ml of normal saline over 4 hours on each of 2 consecutive days (day -3, -2)
45355598|NCT01003054|Drug|Imatinib Mesylate|Starting dose 100 mg/day (mg/d), escalated to maximal dose of 400 mg/d as tolerated, after day 28 when Absolute neutrophil count (ANC) is >1500/mcl and platelets >50,000 /mcl, may be titrated to maintain ANC >1.0 and platelets >50,000 /mcl.
45355599|NCT01003054|Procedure|Autologous Stem Cell Transplantation|Stem Cell Infusion: Unpurged hematopoietic stem cells administered intravenously on day 0.
45355600|NCT01003132|Other|Acceptance and Commitment Therapy|Up to 10 sessions of a psychological therapy called Acceptance and Commitment Therapy
45355601|NCT01004068|Other|SET-diet plus clomiphene|Two months of structured exercise program plus hypocaloric diet followed by 150 mg daily of clomiphene citrate
45478244|NCT05729347|Behavioral|Virtual Reality headset with calming scenery|Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
45478245|NCT05727215|Biological|SARS-CoV-2 subunit protein recombinant vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
45478246|NCT05726331|Other|Chiropractic Care|Chiropractic care will be delivered by community-based chiropractors that meet pre-set qualifications. Chiropractic treatment protocol will be multimodal and will follow predefined standard operating procedures including the following 6 components: 1) Posture correction and spinal stabilization exercises; 2) Soft tissue release techniques; 3) Manual spinal manipulation; 4) Condition-specific education; 5) Myofascial strengthening and motor control training; 6) Ergonomic and lifestyle modifications/advice. Subjects randomized to chiropractic treatment groups will receive up to 10 chiropractic sessions over 16 weeks.
45478247|NCT05726331|Other|Tai Chi|Tai Chi (TC) will be delivered by community based Tai Chi schools that meet pre-set qualifications. TC programs will emphasize core principles including biomechanically efficient alignment, relaxed integrated movements, deep breathing, and heightened body awareness. Subjects randomized to TC treatment group will attend at least one TC class per week for 16 weeks.
45478248|NCT05726331|Other|Enhanced Usual Care|Enhanced Usual Care will include educational materials about neck pain provided by the study, in addition to usual medical care for CNNP. Usual care for CNNP generally includes medications (non-narcotic analgesics, NSAIDs, muscle relaxants), interventional pain management (e.g., steroid injections), and self-care exercises (all of which will be monitored and recorded in all three study arms).
45478249|NCT05725811|Other|Dynamic foam rolling|The foam roller will be in contact with the muscle being tested and the patient will exert a load until they feel a slight pain. In this way, the patient performs a self-massage in the direction of the muscle fibers.
45686958|NCT05815017|Device|Yoomi Physical Therapy Software|Physical Therapy software via a computer/monitor will be set up for the patient. It will begin with a tutorial video for different exercises in the form of games and then ask patients to perform in sequence with prompting and motion tracking. Exercises include Frontal Bicep Curls, Arm Crosses, Press Ups, Arm Rotations, and Basketball Shots.
46046703|NCT02427269|Other|Specimen Collection|"1 10mL red tube and 1 8.5mL yellow tube for serum, plasma, and buffy collection~Up to 10 research-specific biopsies obtained from the esophagus during the routine care EGD.~Four biopsies will be taken from the midpoint of the current BE (or midpoint of previous BE if the patient has already received ablation for previous BE),~Two biopsies from normal squamous epithelium, and~One biopsy from each area of esophageal nodularity seen during the procedure~Pathology slides from routine care biopsies taken during the enrollment procedure, as well as retrospective pathology slides from routine care biopsies taken prior to enrollment on the study.~Up to 4 cytology brushes during the procedure."
45355602|NCT01004068|Drug|Clomiphene citrate|Clomiphene citrate at 150 mg daily for one cycle
45355603|NCT01004068|Behavioral|Structured exercise program plus hypocaloric diet|SET plus diet
45355604|NCT03687970|Other|Brief Pain Inventory|-A self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning. The patient is asked to rate their worst, least, average, and current pain intensity (4 items which generate the PAIN SEVERITY score), list current treatments and their perceived effectiveness, and rate the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life (7 items which generate the PAIN INTERFERENCE score) on a 10 point scale.
45355605|NCT03687970|Other|Hospital Anxiety and Depression Scale|"14 item scale with even of the items relating to anxiety and seven relating to depression~Each item on the questionnaire is scored from 0-3 and this means that a patient can score between 0 and 21 for either anxiety or depression"
45355606|NCT03687970|Other|Neuropathic Pain Symptom Inventory|-The NPSI questionnaire utilized in this study includes eight parameters (i.e., burning pain, squeezing pain, pressure pain, electric shock pain, stabbing pain, tingling pain, pins and needles pain and allodynia [pain provoked by light touch]). Each of the parameters includes recall of the past 24 hours
45355607|NCT03687970|Procedure|Diode Laser fiber type Selective Stimulator|"-Each patient will have an A and C fiber stimulation. Stimulation will be performed on the dorsum of the foot using stimulation previously published parameters to elicit burning pain, which is from activation of C-fibers and pinprick pain from A-fibers"
45355608|NCT03687970|Procedure|Quantitative sensory testing|"Quantitative sensory testing will be performed on the dorsal mid-foot and the ipsilateral shoulder will serve as control area~Cold and warm detection thresholds, cold and heat pain thresholds, mechanical detection thresholds, and wind-up ratio"
45355609|NCT03687970|Procedure|Conditioned pain modulation efficiency|-Immersion of a hand up to the wrist to a thermostat-controlled water bath maintained at 12 degrees Celsius, and the application of a heat stimulus on the contralateral forearm.
45355610|NCT03687970|Other|Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS)|"-The subjects are asked to rate the intensity of their current pain on a 0-10 scale - 0 denoting no pain and 10 denoting worst imaginable pain."
45355611|NCT01004224|Drug|BGJ398|
45355612|NCT01003366|Device|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing down
45355613|NCT01003366|Device|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing up
45478250|NCT05725395|Behavioral|Virtual Reality|During in-patient care participants will be randomized to receive or not receive the educational virtual reality intervention on the first day. After two days, participants will receive a total of 10 minutes interventional in the morning (between 8am to 12pm) every day until their in-patient care concludes.
45478251|NCT05725395|Behavioral|Standard of Care|For case control, participants will service as their self control and be randomized to receive no virtual reality intervention on either the first day or the second day of in-patient care.
45478252|NCT05717907|Device|suction catheter|a suction catheter will be first inserted through the ETT so that about 10 cm of the catheter was protruding from the distal end of the tube. The tip of the catheter is then inserted through the selected nostril until it passes to the pharynx. If resistance is felt to the passage of catheter, the other nostril will be tried. The nostril with less resistance to the catheter passage will be chosen for the completion of the procedure. The Endotracheal tube is then advance over the catheter through the nasal passage while holding the catheter proximal to the tube to prevent its advancement with the tube. After the tube tip reach to the pharynx, the suction catheter is withdrawn and tracheal intubation will be completed.
45478253|NCT05715125|Drug|Dose A VTX958|Dose A VTX958
46046704|NCT02420431|Behavioral|Metacognitive Therapy|Metacognitive therapy (MCT) helps clients to identify episodes of worry and rumination in response to negative thoughts and bring these responses under control. This process is facilitated by exercises that enhance the flexibility of attention control, challenge unhelpful beliefs about thinking and enable new relationships with thoughts
46046705|NCT02420431|Behavioral|Cardiac Rehabilitation (treatment as usual)|Stress management, relaxation training, exercise and dietary advice.
45355614|NCT00530920|Drug|tipranavir|
45478254|NCT05715125|Drug|Dose B VTX958|Dose B VTX958
46046706|NCT02400359|Drug|Lorcaserin HCl|Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.
45478255|NCT05715125|Drug|Placebo|Placebo
46046707|NCT02400359|Drug|Placebo|This is a placebo oral pill that is a visual replica of the Lorcaserin medication but with no active ingredients.
45478256|NCT05713669|Behavioral|Encounter visit with Patients|Participants in this encounter group will be asked to complete a pre and post-intervention survey, participate in a meeting with a former ICU patient at a post-ICU clinic, and undergo an in-person interview within fourteen days following the encounter.
45478257|NCT05713669|Behavioral|Non-encounter surveys|Surveys will be completed pre and post patient follow-up.
45478258|NCT05705687|Drug|BEP Protocol|anticancer therapy
46046708|NCT02290769|Device|Short guide wire rapid exchange|Use of short guide wire rapid exchange to guide the cannulation during primary ERCP
46046709|NCT02290769|Device|Long guide wire|Use of long wire to guide the cannulation during primary ERCP
45355615|NCT00530920|Drug|ritonavir|
45355616|NCT01004302|Procedure|ventral capsular/ventral striatal gamma capsulotomy|Comparison of active radiosurgical with sham radiosurgeries
45355617|NCT01003444|Procedure|Muscle biopsy|Collection of muscle biopsies of the vastus lateralis will be performed by a consulting specialist. The first muscle biopsy (Day 1, 2 hour) will be obtained from the vastus lateralis muscle of the non-dominant leg. The second biopsy (Day 1, 4 hour) will be obtained from the same vastus lateralis muscle on the same leg approximately 10 centimeters from the first muscle biopsy site.
45355618|NCT01004380|Drug|Farletuzumab, Carboplatin, and PLD|All subjects will receive approximately 6 cycles with carboplatin (AUC5-6) i.v. and PLD (30 mg/m2) i.v. on Day 1 of every 4-week Combination treatment cycle. In addition, subjects will also receive weekly farletuzumab at 2.5 mg/kg administered i.v. Following completion of the Combination treatment period (carboplatin/PLD/farletuzumab therapy),maintenance treatment with single agent farletuzumab will be administered once Q3W at 7.5 mg/kg until disease progression as defined by GCIG CA-125 (i.e., CA-125 is less than or equal to 2 × (ULN) documented on 2 occasions) or modified RECIST v.1.0 using CT or MRI.
45355619|NCT01003522|Other|Arterial puncture|Patients will undergo arterial blood gas sampling from the radial artery. This will be done by experienced doctors who are highly skilled in this procedure.
45355620|NCT01003522|Other|Venepuncture|Blood samples for baseline biochemistry, full blood count, and clotting screen will be taken. In patients additionally providing optional consent blood will be taken for laboratory based basic science research into lung cancer carcinogenesis and pharmacogenetics. Blood will be taken by qualified and experienced nurses, doctors and phlebotomists.
45478259|NCT05705687|Drug|Dose-dense regimen|T-BEP-Oxaliplatin followed by Cisplatin - Ifosfamide - Paclitaxel
45478260|NCT05705687|Procedure|Early tumor resection or HD-CT|TIP protocol + early surgery or high-dose chemotherapy if surgery not feasible or metastatic disease
45355621|NCT01003522|Procedure|General anaesthetic|Patients randomised into the stenting arm will undergo rigid bronchoscopy under general anaesthetic.
45355622|NCT01003522|Procedure|Inpatient stays|Patients randomised into the stenting arm will be admitted overnight for the procedure
45355623|NCT01003522|Other|Walking test|All patients will be asked to complete a 6 minute walking test at baseline and on day 15. Patients randomised into the stent arm (Arm A) will complete a further 6 minute walking test at 24 hours post-stent
45355624|NCT01003522|Other|Spirometry & flow volume loop assessment|All patients will undergo spirometry and flow volume loop assessments at baseline and on day 15.
45355625|NCT01003522|Other|Biopsy material|For patients randomised to stenting and giving additional voluntary consent, 2 pairs of biopsies of tumour tissue, and 1 pair of biopsies of normal airways tissue will be taken for basic scientific research into lung cancer carcinogenesis, and pharmacogenetics.
45355626|NCT01004458|Behavioral|Cognitive behavioral therapy|The treatment, adopted to reduce hostility and stress behavior, was given during group sessions once a week during six months with two follow-up occasions during the next six months
45355627|NCT01004458|Other|Waiting list|The group served as referents during the trial and received no intervention other than measurements at the same points in time as the intervention group
45355628|NCT01003600|Behavioral|Questionnaire|The questionnaire will be administered by telephone and will take approximately 20-30 minutes. The questionnaire will elicit survivor responses along five domains: knowledge about diagnosis and treatment, knowledge about ongoing risks and recommended testing, history of health care utilization since the end of treatment, preferences for relevant information about these topics, and employment after the end of cancer treatment.
45355629|NCT01004536|Device|silicone gel|twice daily application onto designated half of cesarean section wound for 12 weeks
45355630|NCT01004536|Other|no treatment|left untreated during the study period
45355631|NCT01003678|Drug|Clofarabine|"Dose Escalation Schedule - Level 1: 1 mg daily x 5 days (orally) followed by 23 days off drug.~Levels 2, 3, 4 and 5 are: 3, 5, 10 and 15 mg daily x 5 days followed by 23 days off drug."
45478261|NCT05704478|Drug|Vericiguat|soluble guanylate cyclase stimulator
45478262|NCT05701007|Drug|abiraterone|mCRPC
45478263|NCT05701007|Drug|enzalutamide|mCRPC
45478264|NCT05701007|Drug|docetaxel|mCRPC
45478265|NCT05701007|Drug|apalutamide|mCRPC
45355632|NCT01003756|Other|Preoperative neuromuscular exercise|A neuromuscular exercise programme delivered 8-10 weeks preoperatively. The programme is developed in Lund, Sweden. A journal of this study is under peer-review
45478266|NCT05701007|Drug|cabazitaxel|mCRPC
45478267|NCT05701007|Drug|Radium-223|mCRPC
45355633|NCT04000204|Device|HYAJOINT Plus|60 mg / 3 ml cross-linked hyaluronan, SciVision Biotech Inc.
45355634|NCT04000204|Device|Durolane|60 mg / 3 ml cross-linked hyaluronan, Bioventus LLC.
45478268|NCT05701007|Drug|Lutetium-177|mCRPC
45478269|NCT05701007|Drug|degarelix|mCSPC
45355635|NCT01003834|Behavioral|Computerized brief intervention|Intervention based on Motivational Interviewing technique
45355636|NCT01003834|Behavioral|Computerized health screening|Behavioral intervention
45355637|NCT01003834|Behavioral|Computerized assessment|Behavioral intervention
45355638|NCT01003834|Behavioral|Therapist-delivered motivational intervention|Behavioral intervention
45355639|NCT01004692|Device|Occlusal splints|The splint will be a hard acrylic-resin stabilization appliance to wear in the upper jaw. The OSS does not come in contact with the gums of the patient and does not act as an orthodontic device. The OSS will be used only for the three nights in a row, of the ambulatory-PSG recording with the OSS in situ.
45478270|NCT05701007|Drug|goserelin|mCSPC
45478271|NCT05701007|Drug|leuprorelin|mCSPC
45478272|NCT05701007|Drug|triptorelin|mCSPC
45478273|NCT05691803|Behavioral|Exercise intervention|"The 6 month intervention consists of usual care (PaP) plus an initial 12 weeks of instructor led exercise (described below) followed by a 12 week period in where the participant will have to conduct their physical activity on their own.~Exercise intervention:~Participants are invited to a 12 week exercise intervention at a private fitness center after they have received their PaP. The exercise, including a variety of aerobic and resistance training, is performed in a group setting starting with one session per week for the first three weeks and then two sessions per week for week 4-12. A follow-up session is also included after 12 weeks in where a physiotherapist contact the participant and discuss how they will adhere to their Physical activity on prescription."
45478274|NCT05688852|Drug|VTX958|Dose A VTX958
45478275|NCT05688852|Drug|VTX958|Dose B VTX958
45478276|NCT05688852|Drug|VTX958 Placebo|Placebo
45478277|NCT05688475|Drug|CC-122|Specified dose on specified days
45478278|NCT05688475|Drug|Dexamethasone|Specified dose on specified days
45355640|NCT04000126|Device|Pupil reflex dilation measurement (PRD)|Pupillary Reflex Dilation (PRD) measured for 60 s during orotracheal intubation using a video pupillometer
45355641|NCT04000126|Device|PPI (Pupillary Pain Index)|Pupillary Reflex Dilation (PRD) measured using a video pupillometer 5 min after orotracheal intubation
45355642|NCT04000126|Drug|lidocaine|1.5 mg/kg lidocaine/ 100ml 0,9% NaCl iv 10min before intubation
46046710|NCT02269761|Device|Nuvis Diagnostic Ultrasound System|Ultrasound of the chest
45355643|NCT04000126|Drug|Placebo|100ml 0,9% NaCl iv 10min before intubation
45355644|NCT04000126|Device|Bispectral Index (BIS)|Bispectral Index will be monitored to assess the depth of anaesthesia
45355645|NCT04000126|Device|HR|HR in beats/min will be measured by the electrocardiogram monitor
45478279|NCT05682625|Other|No intervention|No intervention
45355646|NCT04000126|Device|BP|BP will be measured automatically by an occluding upper arm cuff
45355647|NCT01004926|Device|Echelon foot|One Echelon foot for each subject, for a period of a month.
45355648|NCT01008826|Dietary Supplement|broccoli sprouts extract|Glucoraphanin-rich broccoli sprouts extract: 800 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice Sulforaphane-rich broccoli sprouts extract: 150 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice
45355649|NCT01005004|Biological|HuCNS-SC cells|intracerebral transplantation
45355650|NCT01005082|Behavioral|Low salt diet|
45355651|NCT01005082|Behavioral|Water therapy alone|
45478280|NCT05678959|Drug|Ligelizumab 120 mg|1 injection of 1.0 mL ligelizumab and 1 injection of 1.0 mL placebo
45478281|NCT05678959|Drug|Ligelizumab 240 mg|2 injections of 1.0 mL ligelizumab
45478282|NCT05676203|Drug|Standard ADT (androgen deprivation therapy)|as prescribed by the treating physician.
45478283|NCT05676203|Drug|Standard Darolutamide|2x600 mg/d as prescribed by the treating physician
45355652|NCT01008982|Drug|LimphoStat-B|subjects will receive 10 mg/kg belimumab, in solution for infusion, monthly
45478284|NCT05676203|Drug|Docetaxel|Docetaxel
45686959|NCT05815004|Drug|Gene therapy|AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase)
46046711|NCT02196818|Device|Mpact Acetabular Shell|Total Hip Replacement
45355653|NCT03999736|Device|transcranial direct current stimulation using a Soterix mini-CT device|TDCS is used to non-invasively stimulate the brain through the application of electrical currents to a small region of the scalp using a battery-powered stimulator (Soterix Medical 2018) with rubber electrodes and conductive material (saline-soaked sponges). Both electrodes are attached to the scalp with a band. The stimulation points will be located using the 10-20 system of electroencephalogram (EEG) electrode location (localization carried out using a bespoke head strap). The electrode size of the stimulator used in this study is large (25 cm2) and the current strength used is low (2 mA) resulting in very low current density (0.08 mA/cm2). This protocol applies no more than 30 minutes of stimulation in a single session, which is typical for experimental studies (Brunoni et al. 2015; Loo et al. 2017). TDCS is an investigational device and has proceeded with a non-significant risk designation in many past trials and not required an investigational device exemption from the FDA.
45355654|NCT01005160|Drug|Metformin|CKD-501 0.5mg, metformin 1000mg
45355655|NCT01005160|Drug|CKD-501|CKD-501 0.5mg, metformin 1000mg
45478285|NCT05675540|Device|Macusense Assessment Software|Macusense is software designed to assess change in status and response of patients eyes undergoing intravitreal treatment for macular conditions. The output of the Macusense software will be compared with the decision of the treating clinician.
46046712|NCT02175186|Drug|ALBIS|
46046713|NCT02175186|Drug|Placebo|
46046714|NCT02135133|Drug|Idelalisib|150 mg BID Oral Daily
46046715|NCT02135133|Drug|Ofatumumab|Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8).
46046716|NCT02086448|Device|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevents apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
46046717|NCT02086448|Device|sham-CPAP|
46046718|NCT02086448|Other|Sleep hygiene|Information about sleep apnea and healthy sleep. Information about local sleep resources
46046719|NCT02052583|Procedure|therapeutic hypothermia at 32 ° C|
46046720|NCT02052583|Procedure|therapeutic hypothermia at 34 ° C|
46046721|NCT01993836|Drug|Total intravenous anesthesia with propofol|
45355656|NCT03878758|Device|BD Nano™ PRO|Insulin Pen needle
45355657|NCT03878758|Device|33G Artsana Insupen Extr3me|Insulin Pen Needle
45355658|NCT03878758|Device|34G Artsana Insupen Extr3me|Insulin Pen Needle
45355659|NCT03878758|Device|Simple Diagnostics Comfort EZ™|Insulin Pen Needle
45355660|NCT03878602|Procedure|Delayed umbilical cord clamping|Umbilical cord will be clamped after 1 min after the birth of the newborn
45355661|NCT03878602|Procedure|Immediate umbilical cord clamping|Umbilical cord will be clamped immediately after the birth of the newborn
45478286|NCT05673928|Drug|Trastuzumab emtansine|Given by IV (vein)
45478287|NCT05673928|Drug|Tucatinib|Given by PO
45478288|NCT05663502|Procedure|Biospecimen Collection|Undergo blood and/or tumor tissue sample collection
45478289|NCT05659537|Drug|Dulaglutide|Administered SC
46046722|NCT01993836|Drug|General anesthesia with isoflurane|
46046723|NCT01988285|Other|Specimen Collection|Blood collection, possible saliva collection, possible urine collection, and biopsy collection
46046724|NCT01988285|Other|Questionnaires|Subjects will complete a questionnaire utilizing validated symptom-specific instruments (Mayo Dysphagia Scale; GERD-HRQL Scale). The questionnaire will also record patient demographics, medical history, and current and past medication use
45478290|NCT05651945|Other|Cardiac rehabilitation program|The cardiac rehabilitation program is an outpatient exercise intervention consisting of 36 sessions (30-50 minutes) of a progressive exercise program. Participants are closely monitored throughout the sessions using a telemetry monitor and are supervised by a team of cardiac rehabilitation nurses and exercise physiologists. In addition to the exercise program, participants will receive educational sessions for cardiovascular disease (CVD) risk factors including: 1) Diet/Nutrition, 2) Smoking cessation, 3) Physical activity, 4) Medication management/adherence and 5) Behavior change. As a part of the program, based on the initial assessment results, patients are referred to a rehabilitation psychologist or a dietician for consultation and evaluation if needed. In addition, participants will also receive their standard of care therapies as prescribed by their treating physicians.
45478291|NCT05642663|Device|Stapler|Stapling performed with ALTUS Powered Stapler
45355662|NCT05230810|Drug|Alpelisib|Orally twice a day
45478292|NCT05640765|Other|Best Practice|Receive standard of care services
45478293|NCT05640765|Other|Educational Intervention|Receive additional educational and supportive material
45478294|NCT05640765|Other|Health Promotion and Education|Participate in BeWell360-CG Care Model sessions
45478295|NCT05640765|Other|Questionnaire Administration|Ancillary studies
45478296|NCT05638516|Behavioral|Vira mobile app intervention|The Vira app is installed on the participant's phone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also so prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Users will be asked to use Vira for 12 weeks.
45478297|NCT05638516|Behavioral|Vira mobile app intervention + coaching|"The Vira app can also be supported by a health coach. The health coach interacts with the user (via an instant messaging platform) and who also schedules just-in-time reminders (i.e., nudges) to arrive in the user's phone at scheduled times to support their behavior change plan. The Vira Health Coach Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the coach's workflow."
45478298|NCT05634837|Behavioral|Decision Support System counseling|Decision Support System counseling to improve diet and lifestyle in pregnancy
45478299|NCT05634837|Behavioral|Standard nutritional counseling|Counseling to improve diet and lifestyle in pregnancy
45686960|NCT05815004|Drug|Enzyme Replacement Agent|A hydrolytic lysosomal glucocerebrosidase-specific enzyme
46046725|NCT01962818|Other|HFOV combined with sigh breaths|"It is planned only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh"
46046726|NCT01828190|Other|Hyperbaric oxygen|HBOT will be given for 40 sessions of 2 atmospheres for 90 minutes each session, 5 times a week (2 months). TNF alpha blocker therapy will remain the treatment received before recruitment.
45355663|NCT05230810|Drug|Tucatinib|Orally once a day
45355664|NCT05230810|Drug|Fulvestrant|"500 mg intramuscularly into the buttocks slowly~*Fulvestrant will be administered only in patients with HR+/HER2+ metastatic breast cancer"
45355665|NCT01005238|Drug|Lamivudine|
45355666|NCT01005238|Drug|Telbivudine|
45355667|NCT01009216|Drug|ABT-384|Doses will be administered daily for 5 days.
45355668|NCT01005394|Device|Navigated TMS examination|diagnostic examination using a single pulse TMS paradigm to evaluate corticospinal motor tract integrity and its evolution after stroke
45355669|NCT05224414|Behavioral|Cognitive bias modification for interpretation bias|Sessions of scenario-based CBM-I training for OCD will be administered, based on the widely-used paradigm of ambiguous scenario training developed by Mathews and Mackintosh (2000), in which participants are presented with scenarios that are ambiguous in whether or not they are threatening. Participants will complete a computer task consisting of a series of written scenarios designed to improve interpretation and attributional biases; these scenarios conclude with word fragments, which participants must fill in to resolve the ambiguity.
45355670|NCT05224414|Behavioral|Psychoeducation|Sessions of psychoeducation will be administered, which will describe symptoms of anxiety, the nature of biased thinking in anxiety, and summarize common psychosocial as well as pharmacological treatments for anxiety. The sessions will provide relevant information but will not provide training in changing thinking styles.
45355671|NCT05087290|Other|Cases|"All performed at baseline, 12 months and 18 months Medical and drug history Anthropometric tests Electrocardiogram Brachial flow mediated dilatation 6 minute walk test Blood sampling Urine sampling 24-hr Ambulatory Blood Pressure Monitor Questionnaires~Optional:~Stool sampling,24-hr Urine collection, Home Blood Pressure Monitor"
45355672|NCT05087290|Other|Controls|"All performed at baseline, 12 months and 18 months Medical and drug history Anthropometric tests Electrocardiogram Brachial flow mediated dilatation 6 minute walk test Blood sampling Urine sampling 24-hr Ambulatory Blood Pressure Monitor Questionnaires~Optional:~Stool sampling,24-hr Urine collection, Home Blood Pressure Monitor"
45355673|NCT01005472|Drug|sunitinib malate|
45355674|NCT01005472|Drug|temozolomide|
45478300|NCT05634720|Drug|HA Chemotherapy|On Day 1 of the treatment period, patients will undergo standard-of-care diagnostic laparoscopy to confirm the absence of metastatic disease not seen on staging imaging, as well as tissue acquisition (blood and liver biopsies) for pre-specified correlative scientific studies. On Day 2 (±1 day), patients will receive the interventional treatment, which is neoadjuvant HA chemotherapy. On Day 14 (±5 business days), patients will undergo standard-of-care resection of their primary tumor, as well as tissue acquisition (blood, liver biopsies, primary tumor, regional lymph nodes) for pre-specified correlative scientific studies.
45686961|NCT05814978|Other|Experimental Scapular Therapeutic Exercise Group|"All subjects will perform a program of scapular therapeutic exercises including: neuromuscular control/strength - scapular therapeutic exercises that leads to, at least, moderate muscular activity levels; and stretching exercises.~The intervention period will be of 8 weeks, considering in-person and/or home sessions."
45686962|NCT05814965|Procedure|endodontic treatment in the form of root canal treatment|Patients will receive endodontic treatment, and inflammatory markers will be assessed
45355675|NCT03742726|Device|Smart Matrix scaffold|Smart Matrix dermal replacement scaffold
45355676|NCT01005550|Drug|6 mg of ropivacaine|6 mg of ropivacaine are used for the spinal anaesthesia
45355677|NCT01005550|Drug|8 mg of ropivacaine|8 mg of ropivacaine are used for the spinal anaesthesia
45355678|NCT01005550|Drug|10 mg of ropivacaine|10 mg of ropivacaine for the spinal anaesthesia
45686963|NCT05814965|Procedure|endodontic treatment|Patients will receive endodontic treatment in the form of root canal treatment, and inflammatory markers will be assessed along with metabolic markers assessment
46046727|NCT01818739|Procedure|sentinel lymph node detection|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
45355679|NCT01005550|Drug|12 mg of ropivacaine|12 mg of ropivacaine for the spinal anaesthesia
45355680|NCT03999580|Drug|vitamin D3|"3000 or 4000 UI/ day:~Weight at inclusion < 40 kg : 1 ml per day of the selected concentration at induction and 1ml per day of the selected concentration at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration at induction and 1 ml per day of the selected concentration at maintenance~600 UI/ day:~Weight at inclusion < 40 kg :1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance"
45355681|NCT00768755|Drug|axitinib|5mg BID po up to max 10mg BID po
45355682|NCT00768755|Drug|axitinib|5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy
45355683|NCT00768755|Drug|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
45355684|NCT00768755|Drug|axitinib|5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy
45355685|NCT00768755|Drug|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
45355686|NCT05734222|Procedure|A new method of repair of the abdominal wall of mid-lateral postoperative ventral hernias|"It is planned to study potential sources of bleeding and hematoma formation during SRM plastic surgery. On this basis, recommendations on the technique of the operation will be formulated.~It is supposed to find a way to preserve intercostal neurovascular bundles when performing SRM repair. This should improve the quality of abdominal wall reconstruction by preserving neurovascular bundles of muscles and reducing neuroalgic pain syndrome.~It is proposed to develop a method for combining retromuscular and subaponeurotic spaces in the treatment of mid-lateral hernias~It is planned to substantiate the effectiveness and expediency of the application of the developed surgical techniques based on the analysis of the immediate and long-term results of treatment."
45355687|NCT01005628|Drug|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
45355688|NCT00530842|Drug|Tiotropium plus Salmeterol|
45355689|NCT00530842|Drug|Fluticasone/Salmeterol|
45355690|NCT01005784|Drug|Cetrorelix (Cetrotide)|flexible antagonist administration according to specified criteria
45355691|NCT01005784|Drug|Cetrorelix (Cetrotide)|fixed antagonist administration on day 6 of ovarian stimulation
45686964|NCT05814965|Diagnostic Test|assessment of inflammatory marker|assessment of inflammatory markers
45686965|NCT05814965|Diagnostic Test|inflammatory markers will be assessed along with metabolic markers assessment|inflammatory markers will be assessed along with metabolic markers assessment
45686966|NCT05814952|Genetic|LX103 Injection|Qualified subjects will receive a single unilateral intravitreal injection of LX103 at Day 0 in the trial.
45686967|NCT05814939|Drug|VC005 tablets|VC005 groups repeat administration for 12 weeks
45686968|NCT05814939|Drug|Tofacitinib Citrate Tablets|Tofacitinib Citrate groups repeat administration for 12 weeks
46046728|NCT01818739|Drug|indocyanine green solution|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
46046729|NCT01818739|Drug|isosulfan blue|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
45355692|NCT05734144|Procedure|The intraoperative ERCP has been performed immediately before LC|combination approach has been used to improve patient compliance and shorten hospital stays. The intraoperative ERCP has been performed immediately before Laparoscopic Cholecystectomy
45355693|NCT05734144|Procedure|POES followed by LC|Treatment in two stages, which combines a preoperative ES followed by LC (sequential treatment).
45355694|NCT05154136|Drug|Etrumadenant|Capsule
45355695|NCT05154136|Drug|Itraconazole|Capsule
45355696|NCT01005862|Biological|PF-04360365|10 mg/kg, single dose administered intravenously
45355697|NCT01005862|Drug|Placebo|Placebo
45355698|NCT01005940|Device|Mandibular advancement device|Mandibular advancement device made to subject specific specifications
45355699|NCT05733988|Procedure|Bailout edge to edge|Edge to edge repair is the suture of the mitral valve leaflets in the regurgitant spot. It can be used as a bailout procedure when the first attempt of mitral valve repair with other surgical techniques is not satisfactory at intraoperative echo control. In this case, a second run of cardiopulmonary bypass is carried out, the heart is reopened and an edge-to-edge is performed.
45355700|NCT01006096|Drug|erlotinib|100mg tablet, once daily for 16 weeks
45355701|NCT01006096|Other|placebo tablet|placebo tablet (lactose), once daily for 16 weeks
45355702|NCT01006174|Other|Soybean Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of soybean oil that is added to a salad.
45355703|NCT01006174|Other|Canola Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of canola oil that is added to a salad.
45355704|NCT01006174|Other|Butter|Depending on the experimental group assigned, each subject which will be given one of three different amounts of butter that is added to a salad.
45355705|NCT05733442|Other|Treatment as usual (TAU)|TAU entails medication to support patients' recovery (i.e., the partial opioid agonist, buprenorophine + naloxone/ Suboxone gel films), in-person case management and behavioral health intervention (i.e., in-person group and individual counseling), and referrals to other health care and behavioral health services.
45355706|NCT05733442|Other|CHaRRM-CN|The CHaRRM-CN intervention includes changes and additions to TAU to make MAT more culturally aligned (i.e., offering regular community-based, cultural programming; offering culturally aligned healing groups in the MAT program, such as Talking Circles and beading group) as well as lower barrier and incentivized (i.e., offering medication and behavioral health appointments via in-person, videoconference or telephone; offering harm-reduction groups in addition to abstinence-based groups; providing mailed and in-person pick-up options for buprenorphine prescriptions; conducting weekly chart reviews to ensure prescriptions and basic needs are continuously met; bimonthly, automated text outreach; contingency management supporting attendance at in-person or telehealth appointments).
45686969|NCT05814939|Drug|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 12 weeks
45686970|NCT05814926|Drug|GP681|GP681, tablet, oral
45686971|NCT05814900|Device|Two photon microscopy imaging|Excised tissues will be imaged with two photon microscopy
45355707|NCT05733364|Dietary Supplement|Capsules with B vitamins & taurine|Administered orally in a span of 28 days between mealtimes
45355708|NCT05733364|Other|Microcrystalline cellulose placebo|Administered orally in a span of 28 days between mealtimes
45355709|NCT01006408|Procedure|Low Level Laser|Low Level Laser twice a week for 8 weeks
45355710|NCT01006408|Procedure|Placebo followed by Low Level Laser|Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
45355711|NCT01006486|Other|Anticoagulation clinic|Patients randomized to this arm will be cared at an anticoagulation clinic, with educational measures and standardized procedures related to the use of coumarins.
45355712|NCT01006486|Other|Standard anticoagulation care|Patients randomized to this arm will be cared by their physician, with standard care. No standardized protocol of the use of coumarins will be established.
45686972|NCT05814887|Device|ReLink|Medical device
45686973|NCT05814874|Dietary Supplement|selenium supplement|Selenium supplement containing 55 µg of sodium selenate
45686974|NCT05814874|Dietary Supplement|Brazil nut|Brazil nut butter; consumption corresponds to a selenium intake of 55 µg/d
45686975|NCT05814874|Other|Placebo|Placebo pill
45686976|NCT05814861|Diagnostic Test|culture and PCR|"Stool samples will be cultured inTwo media :~A-Locke egg serum medium (LE) B- Jones' medium Then Molecular identification of Blastocystis hominis using polymerase chain reaction (PCR)."
46046730|NCT01818739|Procedure|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
46046731|NCT01793623|Other|atrial tissue|retrieval of discarded atrial tissue
45355713|NCT01006564|Other|Imaging Investigations (not radiation)|Pre-hormone therapy MRI scans will be performed as an adjunct to the patients' staging MRI scan; post hormone MRI will be done wholly for research purposes.
46046732|NCT01717586|Drug|Pravastatin|Comparison of different drug dosages. Women will be instructed to take a pravastatin pill everyday starting the day of randomization and ending the day of delivery. The women will be divided into three cohorts. Each cohort will receive one of the following doses of pills: 10mg or 20mg or 40mg.
46046733|NCT01717586|Drug|Placebo|Women will be instructed to take a placebo pill daily beginning the day of randomization and ending the day of delivery.
46046734|NCT01714349|Procedure|Nerve Transfer|A nerve transfer procedure will be individualized to each patient's functional deficit.
45355714|NCT01006564|Other|Other|Insertion of gold seeds into prostate for image registration.
45355715|NCT01006720|Drug|Sugammadex|"Single intravenous injection of either:~Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)"
45355716|NCT01006720|Drug|Neostigmine|Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)
45478301|NCT05629039|Behavioral|Volitional Help Sheets|The volitional help sheet is an intervention which provides an opportunity for people to actively plan their behavioural changes by using a list of situations and solutions. The list of situations are critical situations which provoke unwanted behaviour, and the solutions are the responses to overcome the situations which urge the unexpected behaviour. In the context of smoking behaviour, the list of situations is the situations that will provoke cigarette uptake and the list of solutions is the appropriate responses to reduce or stop the urge to smoke.
45355717|NCT01006720|Drug|Saline|Saline 0.9% (Saline)
45355718|NCT04000048|Genetic|sequencing of the complete exome|Once the pathological diagnosis is confirmed (WHO 2016), a tumor fragment will be selected and frozen for each lobe. DNA extraction will be performed for each fragment. The samples (4 different DNAs per GDBG corresponding to the DNA extracted from each of the 3 lobes and the blood DNA) will be sent to the Montpellier Genomix platform for sequencing of the complete exome.
45355719|NCT05733052|Other|Polyester suture|A No2 polyester suture will be used for tying special anatomical structures fr telieving the symptom. of stress urinary incontinence
45478302|NCT05618561|Diagnostic Test|EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test|Subjects have two swabs taken for analysis, one (combined or nasopharyngeal) with the kit under investigation and the other (by standard of care) for analysis with PCRl.
45478303|NCT05615779|Other|Placebo Comparator: Randomized pectin diet|UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in pectin
45355720|NCT05136352|Procedure|adductor canal block|loco-regional anesthesia using adductor canal block
45355721|NCT05136352|Procedure|iPACK block|loco-regional anesthesia using infiltration between the popliteal artery and the capsule of the posterior knee
45355722|NCT05732974|Other|Resected non small cell lung cancer|plasma sample, tissue sample and computed tomography scan images
45355723|NCT01006798|Other|Placebo|enteric coated capsule containing no vaccine virus
45355724|NCT01006798|Biological|Ad4-H5-Vtn|a live, replication-competent, recombinant Ad4 virus expressing the HA of H5N1 influenza (A/Vietnam/1194/2004) in an enteric capsule for oral administration
45355725|NCT01006798|Biological|Sanofi Pasteur Influenza Virus Vaccine, H5N1|Single administration of a heterologous boost given to volunteers 3 to 15 months following their last vaccination with Ad4-H5-Vtn or placebo.
45355726|NCT01006876|Drug|Coumadin|Continuous oral Coumadin therapy through the catheter ablation procedure
45478304|NCT05615779|Other|Randomized B-fructan diet|UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan
45478305|NCT05615779|Other|Personalized pectin diet|UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in pectin based on personal host (biopsy) and microbe (stool) response at baseline
45478306|NCT05615779|Other|Personalized B-fructan diet|UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan based on personal host (biopsy) and microbe (stool) response at baseline
45478307|NCT05615220|Drug|Ecopipam Hydrochloride|Selective dopamine D1 and D5 receptor antagonist
45478308|NCT05610891|Drug|CLR 131|CLR 131 will be administered IV (intravenously) at a fixed dose based on patients BSA
45478309|NCT05603169|Other|High intensity resistance Exercise Training|The resistance training will consist of five resistance exercises (thrice a week on non-consecutive days): squat, leg press, knee extension, lunges, and abdominal crunches. Every participant will be assessed pre and post intervention for hormonal change, BMI/anthropometric measures, fasting glucose and quality of life.The plan will be followed for 12 weeks
45478310|NCT05603169|Other|High intensity aerobic Exercise Training|The training protocol will begin with a 5-minute warm-up and will end with a 5-minute cool down, during which the HR will be 60-75% of the HRmax. At least 90 min of exercise per week for obese PCOS patients, with treadmill walking that may include whole-body movement involving more than 2/3 of the muscles, the exercise intensity will be high intensity
45478311|NCT05602363|Drug|AS-1763|oral tablet, twice daily
45478312|NCT05602363|Drug|AS-1763|oral tablet, twice daily
46046735|NCT01639586|Behavioral|respite platform|Impact of the respite platform patient care on health profit
46046736|NCT01639586|Behavioral|Day care|Impact of the day care on health profit of patient
46046737|NCT01639586|Behavioral|No access to a respite structure|Control group without access to a respite structure
46046738|NCT01620541|Procedure|Ankle Arthrodesis|All surgeons will employ a well-established technique of rigid internal fixation. In this technique, the joint is prepared by removing cartilage from the surfaces, the bones are positioned as desired, and screws and/or a plate are attached to compress the bones together and prevent motion. This technique obviates the need for a cast or external support. Patients are allowed to walk with weight bearing aids immediately. Radiographs are performed at 6 weeks to determine weight bearing status. Weight is allowed on the limb in increments over the 6 to 12 weeks after surgery.
45355727|NCT01006876|Drug|Coumadin|Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.
45355728|NCT01006876|Drug|Coumadin|Oral tablets, daily dose, till the therapeutic INR of 2-3 is achieved
45355729|NCT05043220|Device|PPG and PROM|description will follow
45355730|NCT01006954|Drug|Microdose GnRh|Microflare protocol in poor responders for IVF/ICSI
45355731|NCT01006954|Drug|Flare up|Flare up protocol in poor responders for IVF/ICSI
45355732|NCT05732818|Device|PerQdisc Nucleus Replacement System|Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
45355733|NCT01007188|Other|1.5PD almonds|average American diet plus 1.5 oz per day almonds
45355734|NCT01007188|Other|3.0PD almonds|average American diet plus 3.0 oz per day almonds
45355735|NCT01007188|Other|Base (without almonds)|average American diet without almonds
45355736|NCT05035576|Drug|OPN-019|400 mg OPN-019, 2 sprays per nostril (one dose)
45355737|NCT03882424|Biological|TRS003|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
45355738|NCT03882424|Biological|China-approved Bevacizumab|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
45355739|NCT03882424|Biological|US-licensed Avastin|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
45355740|NCT05732662|Radiation|SBRT|24-50Gy/8-12.5Gy/3-4f
45355741|NCT05732662|Drug|Cadonilimab|10 mg/kg,q3w
45355742|NCT03879772|Drug|Mometasone furoate nasal spray|intranasal administration
45355743|NCT03879772|Drug|Beclomethasone dipropionate nasal spray|intranasal administration
46046739|NCT01620541|Procedure|Ankle Arthroplasty|Protocols are similar among participating centers. Each surgeon uses an anterior surgical approach between the tibialis anterior tendon and the toe extensor group, splints the ankles for 2 weeks, and restricts weight bearing for the first 6 weeks. Radiographs are performed at 6 weeks to determine weight bearing status. The study involves only FDA approved implants with which the surgeon has established experience.
45355744|NCT03879772|Drug|Placebo nasal spray|intranasal administration
45355745|NCT03879772|Drug|Chlorpheniramine maleate syrup|oral administration
45686977|NCT05814835|Drug|2-4 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2-4 mCi 68Ga/64Cu-FAPI-XT117 injection.
45686978|NCT05814835|Drug|4-6 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4-6 mCi 68Ga/64Cu-FAPI-XT117 injection.
46046740|NCT01523977|Drug|Everolimus|Orally, daily days 1-32 per assigned dose level
45355746|NCT01007266|Behavioral|Assignment of a Lay Patient Partner|
45355747|NCT05027620|Other|Motor-cognitive exercise therapy in the home|"Participants engage in a progressive 10-week exercise program targeted at improving motor and cognitive function. Motor exercises target functional strength, gait and physical activity level. Training sessions occur 3 times weekly and supported by a digital application which has been adapted for people with Parkinson's disease. Weeks 1-2 focus solely on motor exercises. Dual-task (Motor-cognitive) exercises are introduced at week 3 and progressed until week 10. Participants are also encouraged to increase the physical activity levels during the 10 week period.~Weekly contact is made using the video function/ telephone with clinical specialists/ researchers. Two home visits will occur, the first one week prior to the intervention and at the 5-week period. Participants receive motivational messaging and reminders via the app during the intervention period."
45355748|NCT01007344|Dietary Supplement|flaxseed|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
45355749|NCT01007344|Dietary Supplement|whole wheat flour|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
45355750|NCT01007422|Behavioral|telephone-based intervention|
45355751|NCT01007422|Other|communication intervention|
45355752|NCT01007422|Other|intervention by caregiver|
45686979|NCT05814835|Drug|6-8 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 6-8 mCi 68Ga/64Cu-FAPI-XT117 injection.
45355753|NCT01007422|Other|medical chart review|
45355754|NCT01007422|Other|survey administration|
45355755|NCT01007422|Procedure|end-of-life treatment/management|
45355756|NCT01007422|Procedure|pain therapy|
45355757|NCT01007422|Procedure|psychosocial assessment and care|
45355758|NCT01007500|Drug|Dexamethasone|Experimental: Dexamethasone 8 mg IV after induction of anesthesia, Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
45355759|NCT01007500|Drug|Ondansetron|Active comparator: Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
45355760|NCT01007578|Device|Paclitaxel-coated balloon catheter angioplasty|Paclitaxel-coated balloon catheters for the treatment of peripheral arterial occlusive disease (POAD) of the femoro-popliteal arteries
45686980|NCT05814783|Behavioral|supported digital CBTI|in session support for adherence to and engagement with digital CBTI
46046741|NCT01523977|Drug|Prednisone|40 mg/m2/day orally 3 x daily days 4-32
46046742|NCT01523977|Drug|Vincristine|1.5 mg/m2 IV daily on days 4, 11, 18, and 25
45355761|NCT05730322|Other|Click City®: Tobacco|A computer-based program assigned to students designed to prevent subsequent tobacco use. Students complete one 15 to 20 minute lesson two times a week for four weeks.
45355762|NCT05730322|Other|Usual tobacco curriculum|Students complete their usual curriculum designed to prevent tobacco use
45355763|NCT05130814|Device|blue light photobiomodulation|1 minute irradiation of blue light performed with EmoLED device.
45355764|NCT05130814|Procedure|cleansing|cleaning of the wound area with saline or ringer's lactate
45355765|NCT05130814|Combination Product|hyaluronic acid gauze plus polyurethane foam|every 48 hours or as needed
45355766|NCT05130814|Drug|zinc cream or hyaluronic acid sodium salt + metallic silver|applied to prevent and/or treat the skin maceration of the surrounding area
45355767|NCT05130814|Procedure|topical treatment|topical treatment indicated for that stage of the lesion
45355768|NCT05130814|Procedure|bandage|"it consists of a polyurethane film -thin hydrocolloid plate or a pressure discharge system made with hydrocolloids and polyurethane foam, known as pressure relief system"
45355769|NCT05726188|Procedure|Colonic resection|Elective or urgent colonic resection; minimally-invasive or open surgery; completion surgery for endoscopically resected pT1 colon cancer with high risk features
45355770|NCT05725252|Drug|NVP-2203|NVP-2203(Combination of NVP-2203-R1 and NVP-2203-R2)
45355771|NCT05725252|Drug|NVP-2203-R|administration of active comparator
45355772|NCT05725096|Diagnostic Test|Coronary Computed Tomography Angiography|Intervention strategies were selected according to CCTA results
45478313|NCT05601661|Device|Active VNS|An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used. An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) . All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc. The device is programmed to stimulate for 0.5s on each button push. After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0.8 mA)
45478314|NCT05601661|Device|Sham VNS|An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used. An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) . All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc. The device is programmed to stimulate for 0.5s on each button push. After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0 mA)
45478315|NCT05601661|Other|Arm rehabilitation|. The rehabilitation therapy involves arm and hand exercises with objects. The therapist will select these exercises based on movement abilities. Tasks will be selected from six functional task categories: reach and grasp, gross movement, object flipping, simulated eating tasks, inserting objects, and opening containers. Approximately 30-50 repetitions will be performed in each category. On average, 300-500 repetitions will be performed during each session within 1.5-2hours.
45355773|NCT05725096|Other|No Intervention|China-PAR score
46046743|NCT01523977|Drug|PEG-Asparaginase|2,500 U/m2 IV 1 x daily on days 5 and 18
46046744|NCT01523977|Drug|Doxorubicin|30 mg/m2 IV on days 4 and 5
46046745|NCT01523977|Drug|Dexrazoxane|300 mg/m2 IV on days 4 and 5
46046746|NCT01461837|Drug|CD34 selected T-cell depleted allogeneic SCT|Hydroxyurea (60 mg/kg/day) and azathioprine (3 mg/kg/day) day -59 to day -11; fludarabine (30 mg/m2) Days -17, -16, -15, -14, -13; busulfan (3.2 mg/kg/day) Days -12, -11, -10, -9; thiotepa (10 mg/kg IV) day -8; cyclophosphamide (50 mg/kg) Days -7, -6, -5, -4; TLI on day -3; rabbit ATG (2.0 mg/kg/day) day -5,-4,-3, and -2; Stem Cell infusion day 0
45355774|NCT05724004|Radiation|SBRT/SRS/radiation therapy|Consolidation radiation therapy (SBRT/SRS/moderately hypofractionated radiation therapy)
45355775|NCT05721742|Other|virtually administered dietitian consults for IBS patients.|Participants will receive virtual one on one consults with a dietitian who has training in the dietary management of IBS.
45355776|NCT05721742|Other|IBS Group Online Session|IBS online group session run by Happy Bellies Nutrition
45355777|NCT00642954|Drug|Vorinostat|Vorinostat 300 mg or 400 mg QD via oral capsule on Days 1-7 and Days 15-21 of each 28-day cycle.
45355778|NCT00642954|Drug|Lenalidomide|Lenalidomide 10 mg, 15 mg, 20 mg or 25 mg QD via oral capsule on Days 1-21 of each 28-day cycle.
45355779|NCT00642954|Drug|Dexamethasone|Dexamethasone 40 mg QD via oral tablet on Days 1, 8, 15 and 22 of each 28-day cycle.
45355780|NCT01007890|Other|ChemoFX Assay|Test of an algorithm to predict pathologic response in patients treated with neoadjuvant chemotherapy for breast cancer.
45355781|NCT00816660|Biological|Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)|Single dose, dose escalation, various cohorts
45355782|NCT00816660|Biological|Marketed plasma-derived VWF/FVIII concentrate|Cross-over: recombinant FVIII (rVWF:rFVIII) and marketed plasma-derived VWF/FVIII concentrate
45355783|NCT00819000|Drug|Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b|MS therapies (listed above) used according to prescribers' instructions.
45355784|NCT00640146|Drug|Methylnaltrexone bromide|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
45355785|NCT00640146|Drug|Placebo|Placebo matching to methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
45355786|NCT05701150|Other|Minimal documentation|Minimal data documentation only of patients without targeted therapy based on NGS results
45355787|NCT05701150|Other|Extended documentation|Extended data documentation of patients with targeted therapy based on NGS results
45355788|NCT00819078|Drug|Bupropion|300 mg/d
45355789|NCT00819078|Drug|Placebo|no dosage
45355790|NCT01008046|Drug|combined N-acetyl cysteine -CC|N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
45355791|NCT01008046|Drug|combined metformin-CC|Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
45355792|NCT00819312|Drug|YAZ (SH T00186, BAY86-5300)|20ug ethinylestradiol, 3mg drospirenone, tablet, orally, opd
45355793|NCT01008124|Other|Liberatory Maneuver|3 cycles of the liberatory maneuver initial session.
45355794|NCT01008124|Other|Placebo maneuver|3 cycles placebo maneuver initial session.
45355795|NCT05006560|Other|Pulmonary Rehabilitation (usual care)|Participants receive the standard inpatient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention implemented by an interdisciplinary rehabilitation team. PR is based on a patient assessment followed by a combination of patient-tailored therapies. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current guidelines; physical training (endurance training, strength training, whole body vibration muscle training); structured education; respiratory physiotherapy. PR lasts on average 25 days.
45355796|NCT05006560|Other|Pulmonary Rehabilitation (usual care) + familiarization with components of the aftercare program|Participants receive the standard inpatient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention implemented by an interdisciplinary rehabilitation team. PR is based on a patient assessment followed by a combination of patient-tailored therapies. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current guidelines; physical training (endurance training, strength training, whole body vibration muscle training); structured education; respiratory physiotherapy. PR lasts on average 25 days. Additionally, participants use several functions of the aftercare program's mobile application. This includes using the application during endurance and strength training (as part of usual care) and using a consumer activity monitor to count daily steps.
45355797|NCT05006560|Other|After care: Exercise and physical activity promotion|"Participants will agree with their therapist on an exercise plan (endurance and resistance training) that are made available for participants through the study's mobile app. Frequency and duration of endurance and strength training are prescribed in accordance with exercise guidelines for persons with COPD. However, they can be adjusted according to participants needs.~Next to the exercise, participants receive physical activity counseling. This consists of phone or video calls with a therapist, group video calls with a therapist, a complementary e-learning course as well as complementary functions of the study's mobile app."
45355798|NCT05005624|Other|ADL performance|"All validation groups address the following ten ADL tasks in 9 different combinations of light temperature (in Kelvins - K) and light intensity (in foot candles - fc) in order possible differences to be revealed among the validation groups and light combinations:~1. Phone Book Search (PBS), 2. Supermarket receipt (SupRe), 3. Book reading (BR), 4. Cellular message (CM), 5. Cellular entry search (CES), 6. Reading computer screen (RCS), 7. Drops bottle reading (DR), 8. Subtitles reading (SubRe), 9. Open door test (ODT), and, 10. Screwdriver test (ST).~The 9 light combinations are the following:~3000 K - 25 fc, 3000 K - 50 fc, 3000 K - 75 fc 4000 K - 25 fc, 4000 K - 50 fc, 4000 K - 75 fc 6000 K - 25 fc, 6000 K - 50 fc, 6000 K - 75 fc"
45355799|NCT00317473|Biological|FMP1/AS02A Malaria vaccine|Subjects vaccinated with FMP1/AS02 vaccine
45355800|NCT00317473|Biological|Imovax Rabies vaccine|Subjects vaccinated on corresponding FMP1/AS02A vaccination days
45686981|NCT05814783|Device|digital CBTI|CBTI app
45686982|NCT05814770|Drug|Finerenone|The participants were randomized in an equal ratio to receive finerenone 10 mg once daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP < 140/90 mmHg at week 4, the dose of study medication was increased to finerenone 20 mg once daily. If BP > 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
46046747|NCT01316146|Drug|CAR.CD30 T cells|"Three dose levels will be evaluated:~Group One, 2x10^7 cells/m^2~Group Two, 1x10^8 cells/m^2~Group Three, 2x10^8 cells/m^2;~Cell Administration: CAR+ ATL will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line. The expected volume will be 1-50cc."
46046748|NCT01233661|Other|short AVD pacing ; prior (stable) programming|short AVD pacing prior (stable) programming
46046749|NCT01136343|Other|lifestyle modified project|education, counseling
46046750|NCT01107717|Drug|metformin\pioglitazone\exenatide|metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) are started and dose is up titrated to achieve HbA1c < 6.5%
46046751|NCT01107717|Drug|metformin, glyburide and glargine|subjects are started on metformin 500 mg bid and dose is up titrated and glyburide (up to 5 mg) and glargine are sequentially added to maintain HbA1c < 6.5%
46046752|NCT00782574|Drug|AZD2281|Tablets Oral BID
46046753|NCT00782574|Drug|Cisplatin|IV every 3 weeks
46046754|NCT00753545|Drug|AZD2281|Tablets Oral BID
46046755|NCT00753545|Drug|matching placebo|matching placebo bid
46046756|NCT00674882|Other|Data Collection|Data Collection, Outcomes Research, Statistical Data Analysis, Longitudinal Study
45355801|NCT00530218|Drug|Ganciclovir|Following the first CMV-positive blood culture on day 21 or later, or the first two consecutive CMV-positive PCR tests on day 21 or later, 5mg/kg/bid x 7 days of Ganciclovir is given intravenously, followed by oral Ganciclovir 1000 mg tid 7 days per week x 5 weeks
45355802|NCT00761267|Drug|Anidulafungin|"Day 1: loading dose of 3 mg/kg (not to exceed 200 mg) Day 2 onwards: maintain a dose of 1.5 mg/kg (not to exceed 100 mg). Minimum total treatment duration is 14 days. Minimum IV anidulafungin treatment duration is 10 days for subjects with microbiologically confirmed ICC and 5 days for subjects at risk of candidiasis; followed by oral fluconazole 6-12 mg/kg/day (not to exceed 800mg/day).~Maximum treatment duration with anidulafungin is 35 days."
45355803|NCT00761267|Drug|Fluconazole|Subjects may be switched to oral fluconazole [6-12 mg/kg/day (not to exceed 800mg/day] provided they meet specified criteria. Maximum total treatment duration is 49 days.
45355804|NCT03982303|Drug|Hemay102|Hemay102 was administered through i.v. infusion for 4hrs.
45355805|NCT04099979|Other|No Intervention|There is no intervention for this study
45355806|NCT00303667|Biological|aldesleukin|Administered subcutaneously (SQ) 9 million units every other day beginning Day -12 through -2 (evening of natural killer cell infusion) for a total of 6 doses.
45355807|NCT00303667|Biological|natural killer cells|Infusion given on Day -12; The targeted infused cell dose of CD3- CD19- selected NK product is within the range of 2-3 x 10^7 cells/kg.
45355808|NCT00303667|Drug|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Day -15
45355809|NCT00303667|Drug|fludarabine phosphate|Administered intravenously (IV) 40 mg/m^2 on Days -18 through -14
45355810|NCT00303667|Procedure|allogeneic hematopoietic stem cell transplantation|On day 0, patients will receive an allogeneic transplant using pool cells from the day -1 and day 0 PBSC which will be CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes.
45355811|NCT00303667|Radiation|total body irradiation|Administered on Day -13, 200 cGy two times.
45355812|NCT00303667|Biological|Thymoglobulin|intravenous (IV) 3 mg/kg on Day 0 (day of donor CD34 cell infusion)
45355813|NCT00303667|Drug|Cyclosporin A|1.5 mg/kg by mouth or intravenously for target dose range of 150-250; day -15 through day -8.
45355814|NCT00303667|Drug|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Days -16 and -15
45355815|NCT00303667|Drug|fludarabine phosphate|Administered intravenously (IV) 35 mg/m^2 on Days -18 through -14
45686983|NCT05814770|Drug|Spironolactone|The participants were randomized in an equal ratio to receive spironolactone 20 mg twice daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP < 140/90 mmHg at week 4, the dose of study medication was increased to spironolactone 40 mg twice daily. If BP > 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
45355816|NCT01066741|Drug|Homeodent®|Two-minute mouthwash with 5 ml of solution diluted in 125 ml of water, 3 times per day after meals and tooth brushing.
45355817|NCT01066741|Drug|1.4% Sodium Bicarbonate solution|Two-minute mouthwash with 125 ml of solution, 3 times per day after meals and tooth brushing
45355818|NCT00761189|Drug|Paliperidone|Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
45355819|NCT01064869|Behavioral|Pyscho-behavioural|"A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:~1. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour~This will be followed by an individualised package incorporating:~A structured asthma education programme, to address any gaps in asthma knowledge or requests for information~Motivational interviewing based on stages of change model to encourage change and adherence~Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients"
45355820|NCT01062295|Device|Siesta-System|
45355821|NCT01062295|Device|Standard headrest|
45355822|NCT00529516|Biological|Fluarix|Single dose, Intramuscular injection
45686984|NCT05814731|Drug|MA-BUCY2|Mitoxantrone liposome 20mg/m2，ivgtt，d-11 ；Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2
45355823|NCT00529516|Biological|GSK Biologicals Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
45355824|NCT01008358|Biological|CP 675,206|
45355825|NCT01008436|Drug|Omni-stat Celox|Topical administration of 6 gr of Omnistat Celox
45355826|NCT01008436|Drug|Control|Traditional surgical Hemostasis
45355827|NCT00316693|Biological|HPV-16/18 vaccine (Cervarix™)|Intramuscular injection, 3 doses
45355828|NCT00316693|Biological|Aimmugen™|Intramuscular injection, 3 doses
45355829|NCT01008514|Procedure|adjuvant therapy|
45355830|NCT01008514|Radiation|accelerated partial breast irradiation|
45355831|NCT01008514|Radiation|intracavitary balloon brachytherapy|
45355832|NCT05099692|Behavioral|filling out the questionnaire|all participants in our study are invited to choose at least 1 question in 15 questions or provide their own questions regarding their doubt about the CR after filling in their personal information
45355833|NCT01008592|Drug|levocetirizine or placebo|oral administration, single tablet, 5 mg.
45355834|NCT01062373|Dietary Supplement|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by TG-DHA from Decola (products from Martek) (two soft capsules per day)
45478316|NCT05591365|Other|Structured In-Patient and Home plan|A patient education session and a protocol comprise of 3 days. It consists of three different levels having progressive activities. The in-patient protocol will start from the day of the procedure. Each level contains 2 to 6 tasks, performed in sets of 5-10 repetitions 3 times a day. Home plan: Walking 3 days a week starting from normal pace ((RPE: 8-9) for10 minutes and progressively increased intensity and duration over the period of 12 weeks (RPE: 13-14).
45478317|NCT05591365|Other|Conventional Therapy|"In-Patient: Wound care, Bed mobility:~AROMS (10 Reps*3sets*TD), Breathing Exercise (10 Reps*3sets*TD), Mobilization (Walk as per patient tolerance) Patient Education: To keep the heart healthy Diet Avoid strenuous exercise and lifting heavy objects Avoid valsalva manure, Quit smoking Lower cholesterol levels, Maintain a healthy weight Control other conditions, such as diabetes and high blood pressure Take medications as prescribed by your doctor Get regular exercise: Walking at a normal pace as per tolerance (RPE up to 10)"
45478318|NCT05591092|Procedure|Computed Tomography|Undergo a SPECT/CT scan
45478319|NCT05591092|Radiation|Iodine I-123|Given PO
45355835|NCT01062373|Dietary Supplement|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by GPL-DHA from ASL (10 g per day) (two soft capsules per day)
45355836|NCT00316303|Drug|Twinrix|This vaccine will be given in three parts: at entry and after 3 and 6 months.
45355837|NCT00316303|Behavioral|Enhanced treatment as usual|Participants will receive comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, HAV and HBV immunizations, and any necessary treatments.
45355838|NCT05609188|Other|Guaranteed Income|Monthly cash transfer of $500 per month for 12 months.
45686985|NCT05814731|Drug|BUCY2|Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2
45355839|NCT05609188|Behavioral|Peer learning circles|Participants can opt-in to attend peer learning circles (also called My Money Hour), which are discussion groups of 10-12 participants about financial topics co-led by a peer (Black youth) with experience in financial programming and an adult financial coach. My Money Hour sessions will be offered on-line multiple times throughout every month of the project, with rotating themes, to ensure that the 50-minute sessions are available different days of the week and times of the day.
45478320|NCT05591092|Procedure|Planar Imaging|Undergo planar imaging
45478321|NCT05591092|Procedure|Single Photon Emission Computed Tomography|Undergo a SPECT/CT scan
45478322|NCT05589948|Dietary Supplement|Radicle Calm Study Placebo Control 1|Participants will use their Radicle Calm Placebo Control Product 1 as directed for a period of 4 weeks.
45478323|NCT05589948|Dietary Supplement|Radicle Calm Study Placebo Control 2|Participants will use their Radicle Calm Placebo Control Product 2 as directed for a period of 4 weeks.
45478324|NCT05589948|Dietary Supplement|Radicle Calm Study Active Product 1.1|Participants will use their Radicle Calm Active Product 1.1 as directed for a period of 4 weeks.
45355840|NCT05609188|Behavioral|Financial coaching|Participants can opt-in to receive financial coaching sessions with a trained financial mentor. Meetings will occur monthly and typically include six one hour sessions. The mentor will be responsive to individual needs, but will touch on the following priority areas: building credit (credit repair, improving credit scores, credit products); savings (emergency savings plans, savings habits and strategies, understanding savings accounts); money management (creating budgets, understanding income vs expense, assessing spending, making better financial decisions); financial products (credit building products, auto loans, credit cards); and long-term goals (home ownership, investments).
45355841|NCT01062529|Drug|Somatostatin|4 h of 150 microgram infusion
45355842|NCT05617846|Other|Anti-osteoporosis therapy|Bone healing, limb function, and complications of postoperative osteolysis in patients with bone tumors of the extremities treated with anti-osteoporosis therapy.
45355843|NCT00760877|Drug|Nilotinib|Supplied in 200 mg capsules
45355844|NCT00760877|Drug|Imatinib|Supplied in 100 mg and 400 mg capsules
45355845|NCT03977545|Diagnostic Test|Actigraphy|Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.
45355846|NCT00302731|Drug|Estradiol , estriol , progesterone|
45355847|NCT00302731|Drug|estradiol, progesterone|
45355848|NCT00302731|Drug|estriol, progesterone|
45355849|NCT00302731|Drug|equine estrogens m-progesteroneacetate|
45355850|NCT00780143|Drug|Plitidepsin plus Cytarabine|Plitidepsin 0.54 mg /m2 (initial dose)daily x 5 one hour infusion every 3 weeks plus Cytarabine 1 g/m2 daily for 5 days.
45686986|NCT05814718|Drug|modified BEAM|Mitoxantrone liposome 24 mg/m2，ivgtt，d-7；BCNU 300 mg/m2，ivgtt，d-6； Ara-C 200 mg/m2 q12h，ivgtt，d-5- -2； Vp16 200 mg/m2 ，ivgtt，d-5- -2；
45355851|NCT05596630|Radiation|Stereotactic body radiation therapy|Stereotactic body radiotherapy for small intrahepatic recurrent HCC. Radiation dose: Greater than or equal to 40Gy/4-5F, complete treatment within 1 week.
45355852|NCT01581229|Procedure|noninvasive positive pressure ventilation|Patients in the NPPV group are ventilated using the CPAP or bilevel positive airways pressure S/T mode.
45355853|NCT01581229|Procedure|oxygen therapy|In the control group, Venturi masks are used to maintain SpO2 at 92% to 96% by adjusting the oxygen flow rates.
45355854|NCT01007968|Drug|LBH589|
45355855|NCT03999034|Diagnostic Test|questionnaire completion|Every patient (140) and healthy control (400) will fill in all the tests and questionnaires, except FSS, in a random order during a single appointment. The FSS will be fill in by patients only. All 400 healthy controls will be divided in 20 groups of 20 people, according to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not). 60 of them will pass the XO test at the beginning and again at the end of the consult to investigate the test-retest effect.
45686987|NCT05814718|Drug|BEAM|BCNU 300 mg/m2，-7d； Vp16 200 mg/m2，-6～-3d； Ara-C 100mg/m2 q12h，-6～-3d； Mel 140mg/m2，-2d
45686988|NCT05814679|Other|Relaxation with virtual reality|In this research, a virtual reality relaxation video will be used in which the natural wonders are presented to the audience in an immersive environment.
45686989|NCT05814679|Other|Attention match|kidney function instruction
45686990|NCT05814666|Drug|Danvatirsen|Danvatirsen is a STAT3 targeting drug.
45355856|NCT01065025|Drug|4SC-205|Repeated ascending oral doses of 4SC-205.
45355857|NCT00779909|Drug|vitamin D3|oral supplementation once per day for 12 weeks of different daily doses: 500 IU, 2500 IU, or 5000 IU after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
45478325|NCT05589948|Dietary Supplement|Radicle Calm Study Active Product 2.1|Participants will use their Radicle Calm Active Product 2.1 as directed for a period of 4 weeks.
45478326|NCT05589948|Dietary Supplement|Radicle Calm Study Active Product 2.2|Participants will use their Radicle Calm Active Product 2.2 as directed for a period of 4 weeks.
45478327|NCT05583669|Drug|DS-2325a|Subcutaneous injection (starting dose 300 mg)
45355858|NCT00779909|Other|Placebo|oral supplementation once per day for 12 weeks of a sugar pill after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
45478328|NCT05583669|Drug|Placebo|Subcutaneous injection
45478329|NCT05580003|Drug|PF-07817883|Oral suspension or solid oral formulation(s)
45478330|NCT05580003|Drug|Placebo|Placebo suspension
45478331|NCT05580003|Drug|Midazolam|midazolam oral solution
45478332|NCT05580003|Drug|Moxifloxacin|Moxifloxacin 400 mg tablet
45478333|NCT05579951|Procedure|Patient specific instrumentation|Total knee replacement with patient specific instrumentation
45478334|NCT05579951|Procedure|Conventional|Total knee replacement with conventional instrumentation
45478335|NCT05579951|Device|Patient specific instrumentation|Medacta GMK Sphere MyKnee Patient specific Instrumentation
45355859|NCT05559112|Other|Vitamin D-enriched mushrooms|Participants will consume their usual, unrestricted, self-selected diet plus 84 g of vitamin D-enriched mushrooms twice daily (for a total of 168g per day) for 12 weeks.
45478336|NCT05566431|Other|ICP|The intervention is a management protocol that includes ICP monitoring for children with severe traumatic brain injury
45355860|NCT05559112|Other|Study Powder|Participants will consume their usual, unrestricted, self-selected diet plus 1 tsp of dried study powder twice daily (2 tsp total per day) for 12 weeks. Study powder is a commercially available carbohydrate.
45355861|NCT01065103|Procedure|FFR (Fractional Flow Reserve)|Single FFR measurement in non-culprit vessel
45355862|NCT04273685|Behavioral|Cognitive remediation training, social recovery therapy|10 weeks cognitive remediation training plus social recovery therapy. One hour face to face contact time with intervention therapist per week. At-home cognitive remediation training completion.
45478337|NCT05566431|Other|CREVICE|The intervention is a management protocol that is based on imaging and clinical examinations without ICP monitoring for children with severe traumatic brain injury
45355863|NCT04273685|Other|treatment as usual|10 weeks Treatment as usual non directive counselling One hour face to face contact time with intervention therapist per week.
45355864|NCT00302107|Drug|Mirtazapine|Mirtazapine initiated at 15mg qhs and titrated in 15mg increments to a maximum of 45 mg qhs as tolerated.
45355865|NCT00302107|Drug|Placebo|Look-a-like placebo tablets under double-blind conditions
45355866|NCT02602301|Drug|Oxytocin|different oxytocin diluents and effect on fetal bilirubin&sodium levels.
45355867|NCT04097483|Behavioral|Telephone Intervention Group|Nurse-led, telephone-based, and psychoeducational intervention centered on motivational interviewing and cognitive behavioral therapy for adherence and depression.
45355868|NCT04925206|Biological|ET-01|Recruited participants will receive ET-01 IV infusion following myeloablative conditioning with busulfan.
46046757|NCT00635362|Device|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta
46046758|NCT00635362|Device|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Insertion of the LNG-IUS 4-8 weeks after cesarean delivery
45355869|NCT04908358|Other|Active transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions|Stimulation of vagus nerve in the outer ear
45355870|NCT04908358|Other|Sham transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions|Sham stimulation of vagus nerve in the outer ear
45478338|NCT05562830|Biological|Zilovertamab vedotin|Administered via intravenous (IV) infusion on day 1 and day 8 of Q3W cycles
45478339|NCT05562466|Drug|QMF149|QMF149 75/40 μg o.d via Breezhaler
45478340|NCT05562466|Drug|Budesonide|Budesonide 200 μg o.d via Breezhaler
45355871|NCT00760487|Device|AcrySof Toric IOL|Implantation with the AcrySof Toric IOL for cataract replacement and multiple follow-up assessments
45355872|NCT00316225|Drug|pemetrexed|500 milligrams per meter squared (mg/m^2) IV every 21 days for 6 cycles
45355873|NCT04097405|Drug|D-0120|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
45355874|NCT04097405|Drug|Placebo oral tablet|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
45478341|NCT05560113|Other|Continuous theta burst stimulation (cTBS)|cTBS, a patterned form of TMS, (80% active motor threshold intensity, 3 pulses at 50Hz, 200ms interval, 600 pulses, 40s duration applied over the targeted sensory cortical region using real-time neuronavigation to focally and transiently inhibit neural activity
45478342|NCT05560113|Other|Sham continuous theta burst stimulation (cTBS)|This will be a sham intervention. An active/sham stimulating coil will be used for double-blinding of stimulation condition. cTBS is safe and has established safety guidelines that will be strictly adhered to during study conduction.
45478343|NCT05559853|Diagnostic Test|CEST-MRF|CEST-MRF enables accurate quantification of both proton exchange rates and volume fractions in a fraction of the time required by conventional pulse sequences will be developed and optimized.
45478344|NCT05553834|Combination Product|Alirocumab and Cemiplimab|Combination of PCSK9 inhibitor Alirocumab 150mg SC q2weeks and PD-I inhibitor Cemiplimab 350mg IV q3 weeks
46046759|NCT00463814|Drug|AZD6244|oral capsule
46046760|NCT00418821|Biological|Aldurazyme (laronidase)|dose of 0.58mg/kg body weight intravenously (IV) every week
45478345|NCT05548283|Drug|Beta-lactam antibiotic|Intravenous (IV) β-lactam will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
46046761|NCT00408447|Drug|Busulfan|Busulfan 4 mg/kg/d x 4d
46046762|NCT00408447|Drug|Fludarabine|Fludarabine 30 mg/m2/d x 6d
46046763|NCT00408447|Drug|Alemtuzumab|Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d
46046764|NCT00408447|Procedure|Allogeneic stem cell transplant|Allogeneic stem cells will be given on day 0 (after chemotherapy conditioning)obtained either from a family donor (first degree relative) or sibling cord blood donor.
46046765|NCT00278915|Drug|Fulvestrant|intramuscular injection
45355875|NCT00586703|Device|NK-CD56|NK Cell infusion using CD56 monoclonal antibody following nonmyeloablative SCT from mismatched donors: The cells from leukapheresis will be NK selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II aGVHD at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
45355876|NCT04988152|Biological|sotrovimab|sotrovimab IV infusion, single dose
45355877|NCT04988152|Other|Placebo to Biologic|Sterile 0.9% (w/v) sodium chloride solution
45355878|NCT04988152|Biological|sotrovimab|Sotrovimab IM injection, single dose
45686991|NCT05814666|Drug|Pembrolizumab|Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2
45355879|NCT04988152|Other|Placebo to Biologic|Sterile 0.9% (w/v) sodium chloride solution
45355880|NCT04854148|Other|Smartphone Movement Health Assessment|Participants will perform the assessment using an App installed on a smartphone device. Following the smartphone assessment, gold standard clinical assessments will be performed and scored for comparison
45355881|NCT00586625|Drug|Bepreve|One drop, both eyes, twice a day
45355882|NCT00586625|Drug|Placebo|One drop, both eyes, twice a day
45355883|NCT03999502|Device|Endomina|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. The procedure will include at least one suture of the gastric cardia to tighten it. Patients will be kept overnight after the procedure.
45355884|NCT00636168|Drug|ipilimumab|IV solution, IV, 10 mg/kg, 4x every 21 days, then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
45355885|NCT00636168|Drug|Placebo|IV solution, IV, 10 mg/kg, 4x every 21 days then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
45355886|NCT04098263|Biological|LMN-101|variable heavy chain-derived binding protein designed to bind and inhibit flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, encapsulated spirulina biomass
45355887|NCT04102631|Diagnostic Test|colonoscopy with assistance of Endo.Angel|Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
45478346|NCT05548283|Drug|Aminoglycoside|Intravenous (IV) aminoglycoside will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
45686992|NCT05814640|Drug|Fluoxetine|Commonly used oral antipsychotics intervention therapy.
45686993|NCT05814640|Drug|Sertraline|Commonly used oral antipsychotics intervention therapy.
45686994|NCT05814640|Drug|Vortioxetine|Commonly used oral antipsychotics intervention therapy.
46046766|NCT02864238|Other|electronic milestone pathway|an electronic based, clinical milestone driven pathway developed to guide the care of cardiac valve surgery patients.
46046767|NCT04285320|Drug|Intravesical antibiotic instillation|"Based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol:~Amikacin-30 mg in 60 ml of sterile water~Gentamycin-80mg in 60ml sterile water~Tobramycin-80 mg in 100 ml of sterile water"
46046768|NCT04285320|Drug|Antibiotic oral suppressive therapy|"In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile:~Trimethoprim daily (100 mg)~Trimethoprim/sulfamethoxazole daily (40 mg/200 mg)~Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg)~Nitrofurantoin monohydrate/macrocrystals daily (50 mg)~Nitrofurantoin monohydrate/macrocrystals daily (100 mg)~Cephalexin daily (125 mg)~Cephalexin daily (250 mg)~Fosfomycin every 10 days (3 grams)"
46046769|NCT00970632|Drug|Tadalafil 5 mg|Tadalafil 5 mg po QD for 12 weeks
46046770|NCT00970632|Drug|Placebo tablet|Placebo tablet po QD for 12 weeks
45686995|NCT05814640|Drug|Duloxetine|Commonly used oral antipsychotics intervention therapy.
45686996|NCT05814640|Drug|Aripiprazole|Commonly used oral antipsychotics intervention therapy.
45686997|NCT05814640|Drug|Lithium Carbonate|Commonly used oral antipsychotics intervention therapy.
45686998|NCT05814640|Drug|Olanzapine|Commonly used oral antipsychotics intervention therapy.
45686999|NCT05814640|Behavioral|GCBT|Commonly used intervention therapy of psychotherapy.
45687000|NCT05814614|Other|pelvic physical therapy|Pelvic floor muscle exercises, biofeedback, bladder training
45687001|NCT05814601|Drug|norepinephrine|norepinephrine at a concentration of 5 mcg/ml is preemptively administered
46046771|NCT00970632|Drug|Tamsulosin|Tamsulosin 0.4 mg po QD for 12 weeks
45355888|NCT04102631|Diagnostic Test|colonoscopy without assistance of Endo.Angel|Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
45355889|NCT03872908|Device|Chilled gloves|Chilled glove for non-dominant hand (patients treated with paclitaxel)
45355890|NCT03872908|Device|Surgical gloves|Surgical gloves (patients treated with oxaliplatine)
45355891|NCT00759941|Drug|Brinzolamide 1% ophthalmic solution (Azopt)|One drop three times a day in both eyes for 3 months
45355892|NCT00759941|Drug|Placebo eye drops|One drop three times a day in both eyes for 3 months
45355893|NCT00759941|Drug|Latanoprost 0.005% ophthalmic solution (Xalatan)|One drop once a day in both eyes for 3 months
45355894|NCT00915863|Procedure|Billroth-II-type reconstruction|surgical procedure
45355895|NCT00915863|Procedure|Isolated Roux-en-Y type reconstruction|surgical procedure
45355896|NCT00528424|Biological|AA4500|Subjects may have received up to five injections of AA4500 0.58 mg into the cords of the affected hand, with each injection separated by at least 30 days. Individual cords may have received up to a maximum of three AA4500 injections.
45355897|NCT05476510|Drug|Postoperative management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.
45355898|NCT00315445|Drug|Buprenorphine transdermal patch|Buprenorphine 5, 10, or 20 mcg/hour patch applied transdermally for 7-day wear.
45355899|NCT00315445|Drug|Placebo oxycodone/acetaminophen tablets|Placebo oxycodone/acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
45355900|NCT00315445|Drug|OXY/APAP|5 mg oxycodone / 325 mg acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
45355901|NCT00315445|Drug|Placebo transdermal patch (TDS)|Placebo transdermal patch 5, 10, or 20 applied transdermally for 7-day wear
45355902|NCT03687736|Biological|AbobotulinumtoxinA|AbobotulinumtoxinA treatment in the glabellar region at Baseline and Month 6
45355903|NCT04861324|Behavioral|Dietary Intervention|Increasing fruit and vegetable by two servings a day and at least 30 min a day of postprandial physical activity
45355904|NCT04857580|Device|CTS Device|Coronary cryotherapy is delivered locally on eligible lesions randomized to the treatment using the CTS System.
45355905|NCT00779675|Biological|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg body weight at Weeks 0, 2, 6 and then every 8 weeks (Weeks 14, 22, 30, 38, and 46 for the Treatment Period and Week 54, 62, 70, 78, 86, and 94 for the Extended Treatment Period) as per the product monograph (PM; Canada), summary of product characteristics (SPC; European Union), or local labeling (for all other countries).
45355906|NCT05446324|Drug|Gallium-68-tilmanocept|All participants receive a cervical injection with 10 MBq 68Ga-tilmanocept in an outpatient setting (at least one week) before surgery. Within 30-90 minutes post-injection a PET with contrast enhanced CT is performed (PET/CT). Data (i.e. detection rate) from the imaging modalities are collected.
45355907|NCT03980119|Other|HITSystem 3.0|The HITSystem 3.0 is a web-based intervention that aims to improve pediatric ART retention and adherence, and viral suppression. The HITSystem 3.0 is accessed online through a computer, using mobile broadband modems that respond to a cellular signal. The primary components include: (1) action alerts to complete time-sensitive interventions; (2) real time communication of HIV PCR results to hospitals to reduce turn-around time; (3) continuous follow-up for timely ART initiation among HIV-infected infants; (4) promotion of retention in EID care via SMS text messaging and/or patient tracing; and (5) an automated and individualized SMS text messaging component to communicate with mothers. The HITSystem has a unique dashboard that proactively monitors time-sensitive interventions along the EID cascade of care, alerting clinics, laboratories and mothers when an intervention has been missed.
45687002|NCT05814562|Behavioral|Remote Intervention|The study utilizes a tailored telemetric intervention to improve adherence to medications. The telemetric intervention (administered via telephone, or interactive internet chat applications such as Zoom ©, FaceTime ® or Skype ®) will enable experienced therapists to address nonadherence from a remote location, using a structured, tailored approach that accommodates specific patient needs.
45687003|NCT05814536|Drug|AB-218 capsule|Take AB-218 orally twice daily, ideally with 12 hours between doses (and a minimum of 8 hours between doses), at a dose assigned by the study. The study treatment is defined as occurring in 28-day cycles with continuous dosing. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs earlier.
45355908|NCT04097093|Other|No intervention|No intervention
45355909|NCT04097171|Other|Diet|Participants will consume each diet for 14 days in a crossover design.
45355910|NCT00759863|Behavioral|Lifezig|Personalized Reminiscence Video
45355911|NCT03998722|Device|Vagivital|Vagivital once Daily for 12 weeks
45355912|NCT04102943|Drug|tacrolimus tablet|"Orally, twice a day in the morning and night~After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment."
45355913|NCT04102943|Drug|tacrolimus capsules|"Orally, twice a day in the morning and night~After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment."
45355914|NCT00759785|Drug|dalotuzumab (MK0646)|Single intravenous infusion
45355915|NCT00300781|Drug|neratinib|
45355916|NCT00315055|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, Intramuscular (IM)
45355917|NCT00315055|Biological|DTaP-IPV//PRP~T combined|0.5 mL, IM
45355918|NCT00315055|Biological|Hepatitis B vaccine|0.5 mL, IM
45355919|NCT00528970|Drug|MOA-728|MOA-728 will be administered per the dose and schedule specified in the arm.
45355920|NCT00528970|Drug|Placebo|Placebo matching to MOA-728 will be administered per the schedule specified in the arm.
45355921|NCT00759395|Drug|AZD2327|Tablet, Oral, Daily
46046772|NCT00970632|Drug|Placebo capsule|Placebo capsule po QD for 12 weeks
45355922|NCT00759395|Drug|Placebo|Tablet, Oral, Daily
45355923|NCT00293293|Other|healing touch|The practitioner performed a structured interview with the patient both a verbal assessment and an energy/physical assessment using pendulum and hand scan techniques. The practitioner will then provide the intervention which will consist of: chakra connection, magnetic passes (hands still and in motion), magnetic clearing.
45687004|NCT05814510|Behavioral|Asthma CHAMPS full program|Full program includes (1) education for staff, students, and caregivers (2) environmental education and intervention (3) asthma care coordination (4) resources
46046773|NCT02863302|Other|Reflexology treatment|All patients will receive reflexology (a specialized foot therapy) from a certified reflexologist twice weekly from the beginning of chemotherapy treatment.
45687005|NCT05814510|Behavioral|Asthma CHAMPS Wait List Control|Stepped wedge design
45687006|NCT05814497|Other|Multisensory Task|Reversing checkerboard, tones, and finger opposition.
45687007|NCT05814497|Other|Graphesthesia|Trace numbers on skin.
45843599|NCT05710770|Device|Immunoadsorption|IA is a well-established, safe interventional therapy broadly applied for different indications. Medical complaints of the TheraSorb Ig apheresis system are rare and none led to a long-term impairment of the patient's health. In most treatments, the patients do not report any side effects. The Ig omni adsorbers specifically remove antibodies. Other components of the blood, except for an unspecific loss of plasma during the treatment, are not removed. Main adverse effects can occur due to the necessity of a Shaldon catheter and include accidental puncture of carotid artery. The procedure is performed under sonographic control and a chest-x-ray is performed afterwards to ensure integrity of lungs.
45843600|NCT05710614|Dietary Supplement|Animal protein|Patients allocated to this arm will be submitted a supervised resistance training program in combination with the intake of three 15-g daily doses (45g. d- 1 total) animal-based protein (i.e.; whey protein) in drink form as a supplementary source of protein in their main meals of the day.
45355924|NCT00293293|Other|massage therapy|Standard massage techniques will be employed over the head, neck, shoulders, back, hands, and/or feet areas. The intensity and rapidity of massage movements will be individualized to the patient's comfort level.
45355925|NCT00293293|Other|hypnosis|Steps: 1) begins with a progressive relaxation induction; 2) suggestions for deepening are then provided; 3) offered suggestions to increase comfort with medical procedures; 4) suggestion for enhanced capacity for coping will be given as an ego strengthening suggestion, with a post-hypnotic suggestion for increasing comfort/success in coping each time.
45355926|NCT00293293|Drug|Standard chemotherapy|Patients will receive 6 cycles of taxane and platinum therapy as prescribed by their treating physician. Chemotherapy treatment is not part of this study.
45355927|NCT05774639|Drug|Omalizumab Injection|ADL-018 (Omalizumab) solution for injection 150 mg/mL prefilled syringe (PFS)
45355928|NCT05774639|Drug|Xolair Prefilled Syringe|XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution
45355929|NCT05774626|Behavioral|Contraceptive usage|Continued use of injectable contraception, administered on a quarterly basis
45355930|NCT05774613|Dietary Supplement|Effect of a Hibiscus sabdariffa beverage|Hibiscus sabdariffa concentrate 60 mL from improved Mexican variety , administered on a single occasion
45355931|NCT05774587|Behavioral|mHealth control group|Cardiac rehab control group
45355932|NCT05774587|Behavioral|mHealth technology assisted exercise counselling (mHealth)|Exercise and counselling through mHealth technology
45355933|NCT05774574|Dietary Supplement|Cannabidiol (CBD) supplementation|Daily supplementation with 1 ml hemp oil containing 60 mg CBD, applied orally
45355934|NCT05774574|Dietary Supplement|Placebo supplementation|Daily supplementation with 1 ml hemp oil containing 0 mg CBD, applied orally
45687008|NCT05814497|Other|Divided attention|Divide attention between two noxious stimuli.
45687009|NCT05813548|Other|FASTer Way Intervention|6-weeks of exercise, building healthy nutritional habits such as intermittent fasting and carb-cycling
45687010|NCT05813548|Other|Control Group Intervention|6-weeks of following general exercise and nutrition guidelines from American Heart Association (AHA) and United States Department of Agriculture (USDA), respectively.
45687011|NCT05812391|Procedure|test|the treatment start with supra-gingival erythritol powerder air polishing followed by sub-gingival erythritol powerder air polishing,supra-gingival debridement and sub-gingival debridement
45687012|NCT05812391|Procedure|conventional|the treatment start with supra-gingival debridement followed by sub-gingival debridement then finished with polishing paste
45355935|NCT05774561|Diagnostic Test|Arm A - Diagnostic test: HPV detection in liquid biopsies|Patients will be asked to perform self-collection of gargle lavage samples. Oropharyngeal swabs, breath condensate, and blood samples will be taken by trained clinicians.
45355936|NCT05774561|Diagnostic Test|Arm B - Diagnostic test: HPV detection in liquid biopsies|Patients will be asked to perform cervicovaginal self-sampling using Evalyn Brush. Blood samples will be taken by trained clinicians.
45355937|NCT05774535|Other|Experimental|"Patients will undergo thyroidectomy according to the guidelines American Thyroid Association (ATA), Randolph.~The following assessments will be performed within 10 days before the thyroidectomy procedure:~informed consent;~personal data and medical records;~registration of medical therapy and post-procedural pharmacological protocol~surgical check;~supra-aortic trunks EchocolorDoppler;~pre-procedural blood sampling.~The following assessments will be performed after 30 days, 6 months and 12 months from the thyroidectomy procedure:~surgical checks;~registration of drug therapy;~recording of all adverse events that occurred during hospitalization~supra-aortic trunks EchocolorDoppler and cIMT measurement;~blood sampling."
45843601|NCT05710614|Dietary Supplement|Plant Protein|Patients allocated to this arm will be submitted a supervised resistance training program in combination with the intake of three 15-g daily doses (45g. d- 1 total) mixed plant protein (i.e.; soy and pea) in drink form as a supplementary source of protein in their main meals of the day.
45355938|NCT05774522|Other|Measurement of pharyngeal critical airway closing pressure|The Pcrit will be measured on an automatic controlled device specially designed by the engineers of the inserm neophen team capable of varying the pressures from +4 to -20 centimeters of water, by a nasal mask whose pressures are connected to a pneumotachograph. The measurements will be performed in supine position.
45355939|NCT05774522|Other|Acoustic pharyngometry|Acoustic pharyngometry is an non-invasive technique consisting of the propagation of an acoustic wave from the lips to the larynx providing information on the lengths, cross-sectional areas and volumes of the air spaces.
45355940|NCT05774522|Other|Upper airway ultrasound|Airway ultrasound is a non-invasive imaging allowing visualization and measurements of the tongue base and retrovascular fatty infiltration. Its main interest remains the evaluation of the tongue base which is clinically difficult.
45355941|NCT05774509|Biological|Extracellular vesicle-enriched secretome of cardiovascular progenitor cells differentiated from induced pluripotent stem cells|Repeated (X3) intravenous infusions of the extracellular vesicle-enriched secretome of cardiovascular progenitor cells (differentiated from human induced pluripotent stem cells)
45355942|NCT05774457|Behavioral|Voice training|Traditional vs. virtual reality
45355943|NCT05774418|Biological|BNT162b2 COVID-19 Vaccine|BNT162b2 is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people from the age of 18 years. BNT162b2 contains tozinameran, a messenger RNA (mRNA) molecule with instructions for producing a protein from the original strain of SARS-CoV-2, the virus that causes COVID-19. BNT162b2 is given as two injections, usually into the muscle of the upper arm, 3 weeks apart.
45355944|NCT05774379|Device|virtual reality and fatigue education|virtual reality distraction for 3 days and fatigue education for children
45355945|NCT05774379|Behavioral|fatigue education|fatigue education for children
45355946|NCT05774340|Drug|CM326|CM326 injection
45355947|NCT05774340|Other|Placebo|Placebo
45355948|NCT05774327|Other|Foam Roller|Participants will be shown 7 different foot core exercises and will be instructed to do 10 repetitions 3 times a day. For 6 weeks, in addition to foot core exercises, myofascial release will be applied with foam roller 2 days a week. Myofascial release application areas; thoracolumbal fascia, iliotibial band, hamstring, gastro-soleus, peroneal, plantar fascia.
45355949|NCT05774327|Other|Foot Core Exercises|Participants will be shown 7 different foot core exercises and will be instructed to do 10 repetitions 3 times a day. Foot core exercises; short foot exercise, toe flexion exercise, heel lift exercise,toe abduction exercise, big toe and other toes extension exercise, front swing exercise, back walking exercises. Participants will do the exercises with the researcher two days a week and the other days follow-up will be provided through the online platform.
45355950|NCT05774314|Behavioral|Community Health Worker Intervention|Communities that are randomized into the Treatment arm will receive the Flourish program. Communities with a Flourish program will select and train a Community Health Worker from the Transform program participants. At the end of the Transform program, a Savings Group will be formed from the Transform program participants. The Savings Group will nominate households to participate in the Flourish program and research study. The Community Health Worker will approach the nominees and attempt to enroll them into the Flourish program and research study. If the nominees agree to be enrolled in the Flourish program, the Community Health worker will provide screening, referral, counseling, and treatment services to the household for the duration of the study.
45355951|NCT05774275|Drug|Pegylated Liposomal Doxorubicin|In phase Ib: 37.5 mg/m2, 30 mg/m2, d1, q3w; In phase II: recommended phase 2 dose (RP2D), d1, q3w.
45355952|NCT05774275|Drug|Doxorubicin|75mg/m2, d1, q3w Doxorubicin hydrochloride will be administered if subject is allergic to Doxil.
45355953|NCT05774275|Drug|Anti-PD-1 monoclonal antibody|200 mg, d1, q3w
45843602|NCT05710458|Device|25 gauge 20,000 cpm Hypervit Dual Blade|Vitrectomy blade with increased cutting rate to 20,000 cut/min
45843603|NCT05710458|Device|25 gauge 10,000 cpm Ultravit Vitrectomy Cutter|Existing Vitrectomy blade with cutting rate 10,000 cut/min
45355954|NCT05774275|Radiation|Radiotherapy|BED=50-60Gy(α/β=10); Radiation dose depends on tumor characteristics and organs at risk.
45355955|NCT05774262|Procedure|Pacemaker implantation|Elective pacemaker implantation (DDDR) for functional AVB according to the 2021 ESC Guidelines for Cardiac Pacing
45355956|NCT05774262|Procedure|Cardioneuroablation (CNA)|"Experimental method; elective implantable loop recorder (ILR) and biatrial, binodal, atomically and electroanatomically guided CNA with extracardiac vagal nerve stimulation (ECVS) prior and after procedure monitoring (disappearance of ECVS-induced AVB with the goal of achieving post-procedure and maintaining a target heart rate > 50 beats per minute). CNA procedure is performed with radio-frequency generators and irrigated catheters and with support of 3D-electroanatomic mapping system.~CNA group will receive external ECG recorders. The major reason for external ECG recorders is to provide documentation of clinical AVB, as well as monitoring of patients before and after CNA (or PM implantation, if accepted). In case of severe AVB symptoms always the emergency system will be called."
46046774|NCT04285710|Device|Phototherapy|The key intervention aspect of this study is the application of 15 J/cm2 of 410 nm pulsed light directly onto the infected diabetic wounds of subjects every week over the course of 3 months, allowing for the cumulative exposure of around 180 J/cm2 for the entire study. This 15 J/cm2 weekly dosage of blue light will split up into two sessions every week, with each session applying 7.5 J/cm2 of light treatment. Phototherapy will be applied twice per week, with one phototherapy session occurring directly following the debridement surgery during the first visit of the week and the other session occurring after the study clinician removes the subjects wound dressings at the second visit.
45355957|NCT05774249|Procedure|Ultrasound guided pecto-intercostal Fascial Plane Block using bupivacaine|while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of 0.25% bupivacaine with adrenaline 1:400,000 will be administered in increments bilaterally.
45478347|NCT05539352|Behavioral|Problem Solving Therapy (PST) plus EUC|"All caregivers are assigned to this condition and receive EUC and PST. EUC is delivered along with the treatment to ensure the safety of all caregivers enrolled in the study. In addition to EUC, caregivers receive PST, which teaches patients a structured planful problem solving approach to: 1) identify problems and set goals, 2) generate alternative solutions, 3) select a solution based on cost-benefit analysis, and 4) devise and implement a plan for the solution and assess its effectiveness in solving the problem. This contemporary PST protocol also teaches tool kits to address obstacles highly pertinent to the challenges faced by caregivers and active suicidal ideation: emotion dysregulation, hopelessness, and feeling overwhelmed by too much information (brain overload) or stress."
45478348|NCT05529966|Device|NGENUITY|Device for 3-D viewing during placement of micro-stent placement.
45478349|NCT05529966|Device|Conventional microscope|Device for stereoscopic viewing during placement of micro-stent placement.
45478350|NCT05521022|Drug|AT-02|AT-02 via IV infusion
45478351|NCT05521022|Other|AT-02 (Placebo)|Normal saline solution via IV infusion
46046775|NCT04285710|Procedure|Debridement Surgery and Wound Dressing|All patients enrolled in the study will undergo standard care and treatment for infected diabetic wounds, which includes the weekly surgical removal of infected necrotic tissue from the diabetic wounds. In addition to debridement, both groups will utilize an antimicrobial wound dressing to cover and treat the infected diabetic wound. The subject's wounds will be dressed with Aquacel Ag Advantage Wound Dressings to protect and treat their diabetic wounds. These dressings will be changed twice a week by clinicians.
46046776|NCT02862756|Other|diffusion-weighted MRI and clinical examination|
45478354|NCT05517304|Device|tcVNS|active stimulation with transcutaneous Vagal Nerve Stimulation (tcVNS)
45478355|NCT05517304|Device|sham|sham stimulation
45355958|NCT05774249|Procedure|Ultrasound guided pecto-intercostal Fascial Plane Block using normal saline|Sham Block will be done while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of normal saline 0.9 % will be administered bilaterally.
45355959|NCT05774171|Other|no intervention|no intervention
45478356|NCT05515536|Drug|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
45478357|NCT05513560|Drug|Ibudilast|10mg pills, 2 pills twice per day
45478358|NCT05513560|Drug|Pentoxifylline|400mg pill 3 times per day
45478359|NCT05513560|Other|Placebo|Placebo matching ibudilast, 2 pills twice per day OR placebo matching pentoxifylline 1 pill 3 time per day.
45478360|NCT05509595|Drug|Burosumab|Human recombinant monoclonal antibody to fibroblast growth factor-23 (FGF23)
45478361|NCT05509062|Procedure|Pressure|Subjects are randomized to one of three treatment groups
45478362|NCT05492227|Diagnostic Test|Left-overs|Totally nasal swab leftovers were stored from the biobank of Hospital Puerta del Hierro. The coded specimens were kept at -80°C and analyzed using the SARS-CoV-2 NAD Kit. Previously these specimens were analyzed using the gold-standard RT-PCR.
45478363|NCT05489796|Drug|Fentanyl selector|Selector (1 ml; Lock out 10 min): Fentanyl 200 mcg + N/S 16 ml = total 20 ml
45478364|NCT05489796|Drug|Fentanyl continuous|Continuous (2 ml/hr): fentanyl 700 mcg + N/S 86 ml = total 100 ml
45478365|NCT05489796|Drug|Ketorolac continuous|Continuous (2 ml/hr): Ketorolac 180 mg + N/S 94 ml = total 100 ml
46046777|NCT04285008|Device|Pure-Vu System|The Pure-Vu System is Food and Drug Administration (FDA) approved device (K191220), intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
45355960|NCT05774158|Other|Physiotherapy assessment|Of the individuals included in the study; Information about age, height, body weight, type of congenital heart disease, surgical history, drug use, comorbid chronic disease, education level and occupation will be obtained. Functional Capacity, Peripheral Muscular Strength, Hand Grip Strength, Fatigue, Physical Activity Level, Quality of Life, Social Participation, Depression Anxiety Stress Level and Physical Activity Barriers will be evaluated
45355961|NCT05774132|Procedure|ultrasound guided Subgluteal sciatic nerve block|Patients will be positioned in lateral decubitus and the ultrasound scanning for the sciatic nerve in the subgluteal region will be started between the two bony landmarks (greater trochanter and ischial tuberosity ) using high frequency linear probe then approached via 5 cm block needle under ultrasound guidance after which bupivacaine 0.25% (0.3 ml/kg) will be administered in increments .
45355962|NCT05774132|Procedure|ultrasound guided Caudal block|Patients will be positioned in lateral decubitus and their sacral hiatus will be palpated under the scanning of the ultrasound using high frequency linear probe then approached via 5 cm block needle that pierce the sacrococcygeal ligament then will be advanced to caudal canal under ultrasound guidance after which bupivacaine 0.25% (1 ml/kg) will be administered in increments.
45355963|NCT05774119|Other|breakfast with coffee|breakfast with coffee with 6 mg/caffeine/kg body weight
45355964|NCT05774119|Other|breakfast with water|breakfast with 250 mL of water
45355965|NCT05774106|Behavioral|Participatory action research|First, a participatory intervention with nurses through the recording of four focus groups with the aim of understand, plan, change and maintain the practices surrounding the relationship therapy with their patients. Second, this intervention will be measured by administering scales to patients linked to the mental health case management program that provides service to different areas of the Barcelona Metropolitan Area. The variables to measure will be the quality of the therapeutic relationship, the recovery of the person and the overall functionality. These variables will be measured before and after finishing the participatory intervention.
45355966|NCT05774028|Drug|Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen|P-GEMD regimen (Every 3 weeks as a cycle, a total of 6 cycles) : Pegaspargase 3750 IU, d2; Gemcitabine 1000mg/m2, d1; Etoposide 65mg/m2, d2-d4; Mitoxantrone hydrochloride liposome 12mg/m2, d1; Dexamethasone 40mg/d, d1- d4.
45355967|NCT05774015|Dietary Supplement|Magnesium Oxide tablet 500 mg|To supplement T2DM with Mg oxide tablets (500 mg total, 302 mg elemental) regardless on their magnesium level
45355968|NCT05773937|Drug|9MW2821|All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
45355969|NCT05773924|Device|triLift system|To evaluate the efficacy of the triLift™ treatment
45355970|NCT05773911|Device|4% chitosan gel (pH 3.48).|Reciprocal Chitosan brush with 4% chitosan gel (pH 3.48).
45355971|NCT05773911|Device|Reciprocal Chitosan brush|Reciprocal Chitosan brush
45355972|NCT05773898|Other|other|The interviewers will collect data from relatives using questionnaires and evaluation grids based on an identification form, a Life Trajectory questionnaire, an anthropological evaluation grid, a retrospective psychiatric diagnosis questionnaire (SCID), a socio-demographic questionnaire, a questionnaire on suicide risks and a questionnaire on emotional state.
45355973|NCT05773885|Device|VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)|"The patients will carry out motor, speech, and cognitive rehabilitation exercises using the VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy).~The motor exercises will be performed using inertial sensors for the acquisition and processing of the movement performed by the patient. This data is shown to the patient with visual and auditory feedback in a serious games environment. The exercises will cover the rehabilitation of balance and lower limbs, for example Balance on one leg, March in place, Stand on tiptoe, Squat, etc. The physiotherapists involved in the study will define a protocol of exercises in TR mode customized according to the characteristics and needs of the patient. The exercises in the speech therapy and cognitive domains will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week."
45478366|NCT05487651|Genetic|KUR-502|KUR-502 (CD19.CAR-aNKT cells) consists of transduced allogeneic natural killer T cells (aNKT) genetically modified with additional features to enhance their anti-tumor activity against CD19+ B-cell malignancies. Following intravenous (IV) infusion, the product is expected to kill CD19+ tumor cells by direct interaction with the chimeric antigen receptor (CAR), and activation of the NKT cells to kill tumor through their innate cell killing.
45478367|NCT05480670|Dietary Supplement|Berberine|550 mg Berberine supplement BDS for 3-months + changes in diet/life style.
45843604|NCT05710302|Other|Investigation of the diagnostic accuracy of EHMRG risk score in patients with acute heart failure|Prospective validation of the EHMRG score in patients with acute heart failure in the emergency department
45843605|NCT05710146|Drug|Tranexamic acid|1 injection of 15mg/kg of TXA in 100mL of normal saline
45843606|NCT05710146|Drug|Placebo|1 injection of 100mL of normal saline
45843607|NCT05710068|Device|RF Microneedle|Pulsed-type RF device in bipolar mode with 25 non-insulated microneedles every 2 weeks for 6 month
45843608|NCT05710068|Drug|Combination cream|5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months
45843609|NCT05709912|Behavioral|CARE Application|Self-administered, psychosocial mobile application comprised of 5 learning modules.
45843610|NCT05709912|Behavioral|Usual Care|Meeting with transplant social worker prior to HCT, consistent with standard-of-care.
46046778|NCT04286880|Procedure|PRP injection|"Clinically proven cases of Trigger points in masseter muscle will be randomly and equally divided into test group and control group. The selected subjects will be divided into two groups.~Test group will be administered 0.5 ml of PRP solution per trigger point in masseter muscle according to symptoms of patient at baseline (0 week). PRP will be prepared as per methodology mentioned by Okuda et al 2003."
46046779|NCT04286880|Procedure|Dry needling|In control group all the armamentarium and procedure will remain same except that no PRP solution will be delivered. Only dry needling will be performed on the baseline.
46046780|NCT01144364|Drug|rituximab [Mabthera/Rituxan]|Intravenous repeating dose
45843611|NCT05709678|Other|Education - Motivational factor|Will emphasize educational elements associated with motivation
45843612|NCT05709522|Behavioral|Neurocognitive tools|Neurocognitve and psychological tools
45843613|NCT05706636|Drug|oral mini pulse|5mg / week oral dexamethasone
45843614|NCT05706636|Drug|Topical cream|topical fluticasone cream for body lesions and topical tacrolimus for face lesions
45843615|NCT05706636|Device|targeted phototherapy|twice weekly targeted excimer light sessions
46046781|NCT04286490|Other|Prone position|Abdomen suspension in prone position
45355974|NCT05773885|Other|Conventional rehabilitation|"The patients will carry out conventional rehabilitation treatments (including physiotherapy, occupational therapy, speech therapy, psychotherapy) without the use of any technological devices.~The motor exercises will concern the rehabilitation of balance, trunk, and lower limbs and will be performed with a physiotherapist who will customize the treatment based on the characteristics and needs of the patient. The occupational therapy, speech therapy, psychotherapy treatments will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week."
45355975|NCT05773859|Biological|XP-DC vaccinations|Autologous cross-presenting dendritic cells loaded with autologous tumor lysate and KLH
45355976|NCT05773846|Drug|Ropivacaine|A long acting formulation of ropivacaine
45355977|NCT05773833|Behavioral|"Go Healthy program"|Weekly food boxes of fresh fruits and vegetables for 16 weeks; healthy eating and traditional foods curriculum available inside the box; monthly in-person healthy eating and traditional Indigenous foods cooking workshop; Indigenous cooking demonstration video website links to accompany recipes; and a kitchen starter kit with kitchen cooking supplies
46046782|NCT01119248|Other|axillary temperature before MRI and after the MRI|observation of body temperature changes with axillary temperature measurement with MRI compatible device
46046783|NCT01131494|Other|Motor exercises for swallowing, breathing and phonation|This exercises aimed to increase strength and range of motion of mouth, larynx and pharynx structures. All patients made sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side. Patients underwent oral motor exercises twice a day, five days a week, for five weeks.
45355978|NCT05773807|Other|Bispectral index|In the BIS group, the anesthesiologist set the target controlled infusion (TCI) parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes to maintain the BIS value at 45-60.
45355979|NCT05773807|Other|Observer's assessment alert Sedation|In the OAA/S group, the anesthesiologist set the TCI parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes maintain the OAA/S value at 1 point.
45355980|NCT05773807|Procedure|Gastroscopy|Gastroscopy would be performed when the BIS value was 45-60 or the OAA/S score was 1
45355981|NCT05773807|Drug|Propofol|Propofol infusion was administered under the guidance of the BIS or OAA/S before the gastroscopy, and the infusion was stopped at the end of gastroscopy
45355982|NCT05773794|Dietary Supplement|Soymilk, green tea, or blueberry|One dose of soymilk, green tea, or blueberry blends (460mL) with breakfast.
45355983|NCT05773794|Dietary Supplement|Control group|Breakfast with milk or water, without soymilk, green tea, or blueberry blends.
45355984|NCT05773781|Other|PuraBond|Application of PuraBond to surgical field
45355985|NCT05773768|Device|EHRA-PATHS software tool|Newly developed care pathways integrated into a care-management software tool
45355986|NCT05773755|Device|Medtronic Percept PC DBS system|Open label active Deep Brain Stimulation (DBS)
45843616|NCT05703438|Other|Nutritionally balanced low-calorie diet|Dietary interventions were given with a calorie deficit of 500-600 kcal from the participants' usual daily intake.
45843617|NCT05693922|Device|Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC|Delta-beta stimulation will be delivered via the NeuroConn DC-STIMULATOR MC, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
45843618|NCT05693922|Behavioral|Single-session behavioral activation|"Participants will take part in a single-session behavioral activation (BA) intervention. This intervention was adapted from standard BA protocols for the treatment of depression to be completed in a single, 90-minute session. This intervention will have 4 main components based on prior protocols:~Treatment overview and rationale~Tracking of daily activities~Exploration of values~Planning/scheduling activities"
45843619|NCT05693922|Device|Active sham cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC|Active sham stimulation will be delivered via the NeuroConn DC-STIMULATOR MC, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
45843620|NCT05683548|Drug|REP 2139-Mg|REP 2139-Mg is the magnesium chelate complex of REP 2139
45843621|NCT05683548|Drug|Tenofovir Disoproxil Fumarate|
45843622|NCT05683548|Drug|Pegylated interferon alpha2a|
45843623|NCT05661942|Drug|Calcium pre-treatment|The intervention is Calcium gluconate 1 gram/100ml 0.9% NaCl or 100ml 0.9% NaCl) over 5 minutes.
45843624|NCT05661942|Other|No Intervention|Placebo/ no calcium pre-treatment.
45843625|NCT05648214|Drug|ALN-PNP|Solution for subcutaneous (SC) injection
45843626|NCT05648214|Drug|Placebo (PB)|matching placebo, solution for SC injection
45355987|NCT05773729|Genetic|BD211|Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
45355988|NCT05773716|Behavioral|Pelvic floor muscle training|Participants will receive daily pelvic floor muscle training for 6 consecutive weeks. In specific, they will be instructed to perform 3 training sessions (morning, afternoon and evening) per day with an emptied bladder in a relaxed state. During each session, 10 muscle stretches are required with each contraction duration of 2~6-second and a 2~6-second relaxation following each one.
45355989|NCT05773716|Other|Electroacupuncture|Participants will also receive electroacupuncture at bilateral Zhongliao (BL33), Huiyang (BL35), Zhongji (CV3), Guanyuan (CV4) and Dahe (KI12). During each therapy session, the electroacupuncture stimulation of acupoints in the abdomen and sacral regions will last for 30 minutes in total (15 minutes for each region) with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
45355990|NCT05773716|Other|Sham electroacupuncture|Sham electroacupuncture will be carried out with pragmatic placebo needles on the same acupoints in the experimental group. Procedures, electrode placements, and other treatment settings will also stay the same but with no electrical stimulation output.
45355991|NCT05773690|Other|Movement quality|6-week-home-based training protocols designed to improve general fitness levels and postural control performed in a circuit-training mode (time of work per set 30 s, time of rest between each exercise 15 s, time of rest between sets 2 min, total volume 3 sets) for a duration of 45 min with a frequency of 3 days per week while performing mobility, stability and motor control exercises.
45355992|NCT05773690|Other|Conventional Resistance Training|6-week-home-based training protocols designed to improve general fitness levels and postural control performed in a circuit-training mode (time of work per set 30 s, time of rest between each exercise 15 s, time of rest between sets 2 min, total volume 3 sets) for a duration of 45 min with a frequency of 3 days per week while performing traditional strength training exercises
45355993|NCT05773664|Drug|Azeliragon|Given PO
45355994|NCT05773664|Procedure|Biospecimen Collection|Undergo collection of cavity fluid and blood samples
45355995|NCT05773664|Procedure|Computed Tomography|Undergo CT scan
45355996|NCT05773664|Drug|Dexamethasone|Given PO or IV
45355997|NCT05773664|Procedure|Magnetic Resonance Imaging of the Brain with and without Contrast|Undergo MRI with or without contrast
45355998|NCT05773625|Device|Just-In-Time Adaptive Intervention|Participants will be exposed to a new innovative app to test.
45355999|NCT05773612|Other|Rock Steady Boxing Class|Rock Steady Boxing is a non-contact fitness program designed specifically for people with Parkinson's Disease.
45356000|NCT05773599|Other|laughter yoga|A pre-test will be applied to evaluate sleep quality and life satisfaction. Laughter yoga will be applied one day apart to the experimental group with a low sleep quality score. After dasa, sleep quality and life satisfaction will be evaluated again with
45356001|NCT05773560|Device|virtual reality rehabilitation|All patients will receive VR-assisted rehabilitation. The VR-assisted rehabilitation is proceed with SyncVR® (Padualaan, Netherlands ) equipment, which is composed of a head set (PICO NEO 3) and one dashboard (TABLET), enabling the patients to receive stepwise rehabilitation program with 360° videos activities (SyncVR Medical Platform). The VR-assisted rehabilitation will be performed two times per day, 30 minutes per training. The first training will start on the second post-operative day.
45356002|NCT05773547|Device|MSOT measurements|Non-invasive transcutaneous imaging of subcellular muscle components via infrared and near-infrared laser pulses
45356003|NCT05773534|Diagnostic Test|MSOT|Similar as the conventional sonography, the MSOT transducer head is placed on the skin of the examined person above the target organ. But instead of sound waves, energy is applied to the tissue via laser light, leading to constant changes of minimal expansions and contractions (thermoelastic expansion) of different tissue components or molecules. The same transducer head that releases the laser flashes can also detect the emitted ultrasound waves. In the newly configured device (Acuity Echo, iThera Medical GmbH, Munich, CE-certified), an extended spectrum of laser light can be used, enabling among others the derivation of values corresponding to hemoglobin and its oxygenation levels. As hemoglobin concentration and oxygenation status are markers for perfusion, MSOT-based imaging of these parameters could be a highly sensitive and reliable method to analyze muscle perfusion.
45356004|NCT05773521|Procedure|SILAP (single incision laparoscopic appendectomy)|Appendectomy performed through transumbilical single access laparoscopy, consisting in the removal of the appendix.
45356005|NCT05773508|Device|Video regulation and emergency kit|Video regulation and emergency kit
45356006|NCT05773495|Other|I-SITE Intervention|I-SITE is a coaching facilitated implementation program that guides clinical personnel through tailored integration of teleophthalmology into primary care workflows.
45843627|NCT05647824|Device|Capillary Testing|Testing Contour Fit BGMS with capillary blood
46046784|NCT04310852|Device|BioCue Concentration Kit|The treatment will be carried out in the operating room under ordinary hospitalization and involves the application of 9 ml of autologous bone marrow concentrate in the knee affected by arthrosis. Specifically, 3 ml will be applied at the level of the bone-cartilage interface of the femur, 3 ml at the level of the bone-cartilage interface of the tibia, and 3 ml will be injected into the joint for a simultaneous action also at the level of the cartilage. To obtain the necessary amount of bone marrow concentrate, an aspirate of bone marrow will be taken from the iliac crest (60 ml) and homolateral tibia (30 ml) of the patient and concentrated by BioCue Concentration Kit, company Zimmer biomet, and centrifuge. This autologous bone marrow concentrate will be injected by means of the Perfuse at the level of the tibial and femoral bone-cartilage interface of the percutaneous arthrosis affected compartment under radiographic control.
45843628|NCT05647824|Device|Alternative Site Testing (AST)|Testing Contour Fit BGMS using blood from alternative site
45356007|NCT05773495|Other|Usual Care Teleophthalmology|All sites will initially receive usual care teleophthalmology, consisting of having an active teleophthalmology program located in the primary care clinic and access to the I-SITE online toolkit. All sites will utilize non-mydriatic retinal cameras (e.g. Topcon NW400) located in their primary care clinic to obtain a single 45-degree photo of the disc and macula with an anterior photo in each eye to provide diabetic eye screening as part of patients' usual care. Images are captured by trained primary care personnel and securely transmitted to eye doctors for evaluation.
45356008|NCT05773469|Other|Exercise|Ski traverse of Greenland polar Icecap
45356009|NCT05773469|Other|Nutrition|Maximising energy intake by consuming over the theoretical 2.4 x RMR
45356010|NCT05773443|Device|Digital biomarkers|Digital application Smartwatch Sleep monitor Movement sensor EEG-sensor
45356011|NCT05773430|Behavioral|Targeted Neurocognitive Training|Only two cognitive domains will be targeted for training (10 hrs of training in each, for a total of 20 hours). Two or more cognitive exercises may be employed within a cognitive domain. These exercises provide both immediate and intermittent feedback and are customized to the participants' individual ability; the difficulty and/or complexity of each game are systematically decreased/increased based on participants' performance to always be challenging, but not overly frustrating. Typically, in an hour session, one exercise (e.g., Mental Map) will be engaged at a time (20-30 minutes) before switching to another exercise (e.g., Hawkeye) in another domain for 20-30 minutes. This helps the participant remain engaged but avoid fatigue.
45356012|NCT05773287|Behavioral|Targeted Health Coaching Group|Participants in the THC group will receive an exercise prescription (steps/day) based on their last cardiac rehabilitation session exercise prescription. Participants will be provided a Garmin wearable device to track steps/day. Additionally, participants will partake in 6 virtual or in-person health coaching sessions lasting approximately 30-60 minutes in duration. These sessions will take place approximately every other week during the 3-month intervention period.
45356013|NCT05773287|Behavioral|Standard Care Group|Participants in the SC group will receive an exercise prescription (steps/day) based on their last cardiac rehabilitation session exercise prescription. Participants will be provided a Garmin wearable device to track steps/day. Additionally, participants will be provided with a single virtual or in-person education session, lasting approximately 30 minutes, at the beginning of the 3-month intervention period.
45356014|NCT05773261|Device|MobilLINK TrabecuLINK cup|THA with MobilLINK TrabecuLINK cup and LCU stem
45356015|NCT05773261|Device|Pinnacle Gription cup|THA with Pinnacle Gription cup and Coral stem
45356016|NCT05773235|Diagnostic Test|Combined 3- and 7 Tesla-MRI|7 Tesla-MRI including the following sequences: susceptibility weighted imaging (SWI), T1, T2, FLAIR, quantitative mapping sequences (T1mapping, qSM)
45356017|NCT05773183|Drug|Testosterone|In OBS1 20 men will be started on Testosterone replacement therapy as per routine clinical practice. Data collection will occur prior initiating therapy, and 6 months post
45356018|NCT05773183|Drug|GnRH|20 men in OBS2 planned for GnRH analogue therapy will undergo data collection prior, and 3 months post initiation of GnRH analogue therapy
45356019|NCT05773170|Drug|Refralon|1 mg/ml concentrate for solution for intravenous injection. (Prior to the administration, 2 mL of Refralon® must be diluted to 20 mL in 0.9 % sodium chloride).
45356020|NCT05773157|Behavioral|Online Modules|Participants receive modules to improve responsive feeding practices of caregivers
45356021|NCT05773144|Behavioral|Aerobic exercise|Moderate- to vigorous-intensity aerobic exercise
45356022|NCT05773144|Behavioral|Progressive stretching|Static stretching of eight major muscle groups
45478368|NCT05475366|Other|Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC|Formalin-Fixed Paraffin-Embedded (FFPE) samples will be centralized in which nucleic acids extraction (DNA+RNA) and FFPE-compatible RNA-sequencing will be performed in real-time (≤28 days). RNAseq reads will be processed and all 5 transcriptomic signatures will be applied for prediction of response to 5FU, oxaliplatin, irinotecan, gemcitabine and taxane. In addition, biomarkers status will be obtained for all patients as part of good clinical practice.
45356023|NCT05773131|Device|VR collaborative visualization system|Patients wear virtual reality head-mounted displays while family members using smart phones to interact in a same virtual space.
45356024|NCT05773118|Device|orthokeratology lens|Subjects will wear orthokeratology lens at night. Axial length elongation over a period of 12-month will be recorded.
45356025|NCT05773118|Device|multifocal soft contact lens|Subjects will wear multifocal soft contact lens during the day time. Axial length elongation over a period of 12-month will be recorded.
45356026|NCT05773118|Device|Single vision spectacles|Subjects will wear single vision spectacles during the day. Axial length elongation over a period of 12-month will be recorded.
45356027|NCT05773105|Drug|Cadonilimab+regorafenib|cadonilimab(10mg/kg, iv,Q3W,D1) + regorafenib(80mg,PO,QD,everyday)
45356028|NCT05773092|Drug|Oral S-1 + Oral Osimertinib|S-1 (40mg) will be given orally twice a day (daily) from Day 1 to 14 (21 day cycle), and Osimertinib (80mg) will be given orally daily continuously.
45356029|NCT05773027|Behavioral|SAFE|SAFE includes a motivational interviewing session addressing alcohol use and risk for sexual aggression, a workshop addressing alcohol use and sexual aggression, and a booster session review.
45356030|NCT05773027|Behavioral|Mindfulness-Based Control Condition|The program includes the same amount of contacts as SAFE, including an individual session focused on mindfulness and stress, a group session, and a booster session review.
45356031|NCT05773001|Drug|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
45843629|NCT05647824|Device|Venous Testing|Testing Contour Fit BGMS with venous blood
45843630|NCT05641740|Device|Single-session of Radiofrequency|"The experimental group continue with their usual conservative and pharmacological treatment and will receive a single-session of monopolar dielectric capacitive radiofrequency in their hands. An Biotronic Advance Develops® (ABD-S25v) with a carrier wave frequency of 800-900 KHz of 850 KHz will be used. Patients will be placed in a seated position, with the forearms supinated and resting on a wooden table. An almond oil conductor will be applied to the hands. The application will be carried out with a circular head of 5 cm2 and for a total of 10 minutes on each of the palms of the hands.~They will be evaluated at baseline and post-session."
45843631|NCT05641740|Device|Control Placebo single-session of Radiofrequency|"The control placebo group continue with their usual conservative and pharmacological treatment and will receive a placebo single-session of radiofrequency. This group will follow the same protocol and treatment time, but they will receive a placebo treatment (the device remains in paused mode), so that radiofrequency will not be applied.~They will be evaluated at baseline and post-session."
45843632|NCT05639010|Device|regular hemodialysis|Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week
45843633|NCT05639010|Device|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform once a week. The hemoperfusion apparatus will use type KHA80 hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
45843634|NCT05636436|Biological|Low Dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.
45843635|NCT05636436|Biological|High Dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.
45843636|NCT05636436|Biological|Low dose adjuvant|0.5 mL per dose, containing low dose MA105 adjuvant.
45843637|NCT05636436|Biological|High dose adjuvant|0.5 mL per dose, containing high dose MA105 adjuvant.
45843638|NCT05636436|Biological|Positive control|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
45843639|NCT05636436|Biological|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
45843640|NCT05561556|Dietary Supplement|MitoQ|One 20mg capsule daily for 8 weeks
45843641|NCT05477784|Other|Educational Intervention|Receive EC-PC program
45843642|NCT05477784|Other|Informational Intervention|Receive education booklet
45843643|NCT05477784|Other|Questionnaire Administration|Ancillary studies
46046785|NCT01131260|Device|fetal STAN monitor|The STAN monitor is a system for fetal surveillance that displays the FHR, the uterine activity and information resulting from the analysis of the ST segment of the fetal ECG.
46046786|NCT00965094|Drug|Everolimus|One tablet containing 0.25, 0.5mg or 0.75 mg. Initially 2 mg/day. Afterwards based on blood level (target 6-10 ng/mL)
45356032|NCT05772975|Biological|H-PRF (Horizontal-platelet rich fibrin)|Platelet-rich fibrin is an autologous biomaterial originating from human blood following centrifugation without additives that contains supraphysiological doses of growth factors. it serves as a biological healing matrix by supporting cell migration and cytokine release. H-PRF is obtained by horizontal centrifugation using (Bio-PRF) centrifuge on 700 g force for 8 minutes. This way the cells separate much more efficiently throughout the entire membrane/clot.
45843644|NCT05463354|Biological|Recombinant COVID-19 Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
45843645|NCT05463354|Biological|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
45843646|NCT05449470|Device|CDSS|A clinical decision support system (CDSS) that provides deprescribing advice and a personalized risk prediction
45843647|NCT05449470|Device|Patient Portal|A Patient Portal that helps patients prepare for their fall clinic visit by giving them information about falls, falls prevention, and medication-related falls. After the fall clinic visit, the Patient Portal also shows the personalized fall-risk and treatment advice.
45843648|NCT05340504|Drug|N-Acetyl cysteine|Group A and Group B will receive N-Acetylcysteine (NAC). Group A will receive NAC as their first 14 day condition and Group B will receive NAC as their second 14 day condition. Participants will take NAC for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
45843649|NCT05340504|Drug|Placebo|Group A and Group B will receive Placebo. Group A will receive Placebo as their first 14 day condition and Group B will receive Placebo as their second 14 day condition. Participants will take Placebo Oral Capsule for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
45843650|NCT05330130|Drug|Follitropin beta injection 150 IU|"Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 150 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation."
46046787|NCT00965094|Drug|Tacrolimus (FK506)|Capsules 0.5 mg, 1 mg. Dosing according to blood level.
46046788|NCT00965094|Drug|Basiliximab|One vial containing 20 mg lyophilisate. 2 x 20 mg [day 0 (2 hrs prior to Tx) and day 4 post Tx] to be applied as 10 sec. bolus injection, i.v.
46046789|NCT00965094|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|One tablet containing 180 mg or 360 mg. 1440 mg/day (2x720 mg). If tolerated, dose reduction due to side effectis were possible (min. dose at BL@: 720 mg/day)
46046790|NCT00965094|Drug|Corticosteroids|Used according to Israeli standards. A minimum dose of 5mg [prednisone, or equivalent, was used throughout the study period.
46046791|NCT04286256|Behavioral|Motivational Interviewing|Participants/caregivers will receive several telephone-based and in-person motivational interviewing sessions along with specific oral health recommendations.
46046792|NCT03634098|Device|new quantitative imaging techniques with contast products|magnetic resonance +/- Primovist and ultrafast ultrasound UFUS +Sonovue
45478369|NCT05475366|Other|Biomarkers of tumor signatures (translational studies)|Blood (serum and plasma) will be drawn at baseline, week 8, and tumor progression in order to look for surrogate biomarkers of tumor signatures in liquid biopsy
45356033|NCT05772975|Biological|E-PRF|Platelet-rich fibrin is an autologous biomaterial originating from human blood following centrifugation without additives that contains supraphysiological doses of growth factors. In order to extend its resorption period heating method is used. After centrifugation of blood using (Bio-PRF) centrifuge on 700 g force for 8 minutes top layer is heated for 10 minutes at 75°C in BIO-Heat device. When cooled it is mixed with cell rich buffy coat. This way PRF with extended life is obtained.
45356034|NCT05772936|Behavioral|Balance training|perturbation induce step training to improve reactive stepping with paretic leg.
45356035|NCT05772923|Radiation|Contact x-ray brachytherapy|With contact x-ray brachytherapy an intraluminal radiation boost up to 90 Gy is applied to the primary rectal tumour, with minimal collateral damage to the surrounding normal tissues due to minimal penetration of the 50 kVolt therapy.
46046793|NCT03634098|Diagnostic Test|blood sample|extensive clinical-biological phenotyping data; and / or data obtained by different omic approaches (metabolomics, targeted genetics, transcriptomics). Extracellular vesicle and immune cell profiling will complement this data
45356036|NCT05772923|Procedure|Local excision|Local excision will basically be performed by the TAMIS-procedure (transanal minimally invasive surgery).
45356037|NCT05772884|Other|Supervised Exercise Intervention|Exercise duration will be gradually increased as tolerated to 50 min/session, with intensity ramping up to 65-75% HRmax by week 3. On-site exercise sessions will occur along a pre-marked walking path, and a trained staff member will walk alongside the participant to monitor their heart rate. Speed will be manipulated to achieve desired intensity and to sustain heart rate in the target zone. Heart rate will be monitored and recorded via telemetry during the on-site exercise sessions. Step cadence (i.e., steps/minute) will also be monitored and recorded during the on-site sessions and discussed with participants as a way to understand and track their speed when completing off-site walking sessions on their own.
45356038|NCT05771961|Diagnostic Test|coronary pressure/temperature sensor-tipped guidewire|"In brief, a 6-F angioplasty guiding catheter without side-holes will be used first used to engage the left main coronary artery. A pressure-temperature sensor guidewire ( PressureWire™ X Guidewire) will be used for physiology measurements including IMR measurements.~Pressure measurement from the wire will be first equalized with that of the guiding catheter. Then the pressure sensor will be positioned two-thirds of the way down the LAD artery. Intracoronary nitroglycerin will be administered (100 to 200 μg). Hyperemia will be induced with adenosine intracoronary injections."
45356039|NCT05771961|Diagnostic Test|Angiography-derived index of microcirculatory resistance (IMRangio)|Angiography-derived index of microcirculatory resistance (IMRangio) will be calculated by an anticipated software
45478370|NCT05463068|Drug|NVX-Cov2373|Intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL) on Day 1
45478371|NCT05462652|Device|Active Intervention|The active intervention is a 5-week program divided into 5 levels intended to be completed weekly. Each level is expected to take about 60 minutes to complete. Activities in each level may include reading text on the screen, answering multiple choice style questions, swiping or clicking a button to move through screens, dragging and dropping elements on screen, and completing tasks outside of the app. Certain on-demand resources can be accessed in the apps at any time, including crisis resources. Where appropriate, text entries in the app that match a database of concerning words/phrases will trigger an automated pop-up suggesting participants visit the in-app crisis resources if they need additional support. Text entries will also be monitored by study staff for safety, though not in real-time. Participants will be instructed to complete a weekly PHQ-8 assessment in the mobile app.
45478372|NCT05448664|Behavioral|Family HBM- mobile messaging|The intervention will consist of two blocks of text messaging based on HBM model, the messages will be sent to the students and their parents in the following 24 weeks.
45478373|NCT05448664|Behavioral|Adolescent HBM- mobile messaging|The intervention will consist of two blocks of text messaging based on HBM model, the messages will be sent to the students in the following 24 weeks.
45478374|NCT05448664|Behavioral|Adolescent e-pamphlets|The contents of e-version of three pamphlets, published by Department of Health (http://www.toothclub.gov.hk/en/en_index.html) will be distributed in an electronic form and sent via a mobile message.
46046794|NCT03634098|Diagnostic Test|second generation tests|second generation tests NIT-NASHr et NIT-A2F2
46046795|NCT04285944|Other|Mavig X-ray Protective Drapes|Mavig X-ray Protective Drapes®
46046796|NCT01131182|Drug|Sitagliptin phosphate|Sitagliptin 100 mg tablet administered orally once daily over the Ramadan period.
46046797|NCT01131182|Drug|Comparator: Sulfonylurea|Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription
46046798|NCT01131182|Drug|Metformin|Participants could continue pre-study metformin as concomitant therapy during the study.
45356040|NCT05771571|Other|Functional olive oil, enhanced with orange peel extract|The functional olive oil was enriched with 10% w/w orange peel extract
45356041|NCT05771571|Other|Control|Refined olive oil
46046799|NCT02862444|Other|Culturally Appropriate Intervention|Women in the intervention arm will receive a culturally appropriate intervention that will be provided to them according to the five strategies of culturally appropriate interventions of Kreuter et al. (2003).
46046800|NCT04312100|Other|oxygen treatment|different kinds of oxygen treatments will be given to patients according to their state of illness
46046801|NCT00964860|Device|Glide dental floss|Glide waxed dental floss
46046802|NCT01131104|Drug|PDE5 Inhibitors|Observational study of participants who have been prescribed phosphodiesterase type 5 (PDE5) inhibitors by their physician during routine clinical practice.
45356042|NCT05771519|Behavioral|HIV disclosure intervention|This will be a biobehavioral intervention focused on helping men with HIV to disclose their HIV status to a personal confidant inclusive with specific focus on sexual partners.
45356043|NCT05771467|Other|Optical Coherence Tomography Angiography (OCTA) • Biometry • Auto refractometry • Non contact tonometry|Ophthalmologic Examination Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters, optical coherence tomography angiography (OCTA)
45356044|NCT05771389|Diagnostic Test|serum raftlin-1 protein levels|Lipid raft linker 1 (Raftlin-1) is a protein which enables double-stranded RNA binding activity. It is involved in T cell receptor signaling pathway; membrane raft assembly; and positive regulation of growth rate. It acts upstream of or within dsRNA transport; response to exogenous dsRNA; and toll-like receptor signaling pathway. Located in endosome; membrane raft; and plasma membrane.
45356045|NCT05769894|Other|No intervention given|No intervention is planned. Blood samples will be taken at different stages.
45356046|NCT05769296|Device|Headpulse measurements|Placement of headset on subject
45356047|NCT05768893|Device|Long-Pulsed Nd:YAG Laser 1064nm & Er:YAG Laser 2940nm|Warts with this intervention treated firstly with the Er:YAG laser, followed by the Nd:YAG laser in the same session.
45356048|NCT05768893|Device|Er:YAG Laser 2940nm|Warts with this intervention treated only with the Er:YAG laser.
45356049|NCT05768165|Behavioral|High intensity exercise|"Twelve weeks of supervised high intensity aerobic and resistance exercise including two sessions/week, one additional session of the patient´s own choice, non-supervised. The target of the high intensity intervals (HIIT) is 90%-95% of maximum heart rate alternated with recovery phases at 70% of maximal heart rate. The resistance exercise session of large muscle groups: 8-10 repetitions, 2-3 sets.~Exercise guidance follows principles of self-efficacy and person-centeredness."
45356050|NCT05767866|Drug|YK-029A|Daily dose of YK-029A
45356051|NCT05767398|Drug|Zanubrutinib|Administered as a tablet or capsule
45356052|NCT05766995|Device|Waterpik Water Flosser|A pulsating water flosser and jet tip designed to clean between the teeth and below the gingival margin.
45356053|NCT05766995|Device|Oral-B Water Flosser|A water flosser and specialized tip that delivers water with microbubbles of air
45356054|NCT05766995|Device|Waxed Dental Floss|Nylon string used to clean between the teeth manually
45356055|NCT05766280|Behavioral|iCareer Soft Skills Training for Employment|The telehealth iCareer intervention will be delivered during regular educational or vocational services (i.e., services from the Office of Disability Services (ODS) and/or from the school or college counseling center). Six modules of Soft Skills Training (SST), four group sessions for each module with 60 to 90 min for each session (depending on group size) will be delivered by trained project staff (graduate counseling student assistant or graduate counseling intern) via HIPAA-compliant Zoom videoconferencing. If participants are unable to join by Zoom videoconferencing, telephone (a format widely used in Cognitive Behavior Therapy (CBT) for Post Traumatic Stress Disorder (PTSD) treatment delivery and in CBT for depression) will be utilized. Ethical guidelines for providing telehealth over videoconferencing or phone will be followed.
46046803|NCT02861430|Procedure|Immunochemistry and molecular biology on sentinel lymph node specimen|
46046804|NCT04264884|Drug|Daratumumab|Daratumumab 1800 milligram (mg) will be administered as a fixed dose by subcutaneous (SC) injection.
45356058|NCT05763004|Drug|IOS-1002|monotherapy
45478375|NCT05445583|Behavioral|Motivational Enhancement System (MES)|MES is an eHealth application and focuses on asthma management behaviors with feedback on asthma symptoms, physical activity, adherence, and tailored education. The program is interactive and tailored to each participant by (1) allowing participants to choose barriers/goals related to their asthma care and (2) by sending personalized feedback based on participant daily diary responses. MES consists of 4 sessions delivered over the course of 10 weeks within 10 smaller 5-10 minute blocks.
45478376|NCT05445583|Behavioral|Supportive Accountability (SA)|Supportive accountability (SA) is an asthma management intervention delivered by asthma nurses trained in motivational interviewing skills (e.g., open-ended questions around change talk, affirmations) via participants' personal mobile devices (e.g., Skype, FaceTime, voice calls, and SMS). The theory underlying SA is that education and behavior change are most impactful when delivered by a knowledgeable yet supportive authority figure (i.e. nurse).
45687013|NCT05812287|Other|Detection of biological samples based on multi-omics analysis|In this study, we combined microbiological (16SrRNA) and metabolomic mass spectrometry to study the changes in microbial populations and metabolic profiles of various samples such as feces, serum, and saliva, and screen key differential markers.
46046805|NCT04284696|Dietary Supplement|Pregnan-C-Gum(R) chewing gum|"Using a chewing gum with 150mg vitamin C (per piece/gum) for 14 days ad libitum"
46046806|NCT04284696|Dietary Supplement|Placebo chewing gum|"Using a chewing gum without vitamin C (per piece/gum) for 14 days ad libitum"
46046807|NCT02861742|Other|Delivery of questionnaires|After patient and partner information, clinical research associate or clinical research nurse will give to the couple 2 booklets containing 5 questionnaires, respectively T1, T2, T3, T4 and T5.
46046808|NCT02861742|Behavioral|Questionnaire T1 to fill|T1 is to fill before chemotherapy.
46046809|NCT02861742|Behavioral|Questionnaire T2 to fill|T2 is to fill after the 6th cycle of chemotherapy.
46046810|NCT02861742|Behavioral|Questionnaire T3 to fill|T3 is to fill at the end of radiotherapy.
46046811|NCT02861742|Behavioral|Questionnaire T4 to fill|T4 is to fill 4 month after beginning of hormonotherapy or surveillance if no hormonotherapy.
46046812|NCT02861742|Behavioral|Questionnaire T5 to fill|T5 is to fill 1 year after the beginning of hormonotherapy or surveillance if no hormonotherapy.
45356059|NCT05763004|Drug|IOS-1002 + PD-1 mAb|combination therapy
45356060|NCT05761119|Other|Physical activity|The focus of the intervention is on exercises that can improve venous return, and consists of progressive walking training at moderate and high intensity as well as guidance on physical activity. The training program is inspired by the WHO's recommendations for physical activity. The training program consists of a 14-day introductory period based on an initial interview with a physiotherapist, where the aim is to hit 30 min. times/day at moderate intensity. After 14 days, the patient receives physiotherapeutic guidance in physical activity and is introduced to the next period of 14 days, where the activity level is maintained, and the goal is to further achieve 2 x 20 min./week of high-intensity physical activity. After one month of training, the patient will be guided on maintaining and possibly progressing physical activity.
45356061|NCT05761106|Other|Oculomotor Therapy|It will consist exercise of a convergence technique and an accommodative technique.
45356062|NCT05761106|Other|Therapy for Temporomandibular Disorder|It will consist exercise of a ATM and cervical spine.
45356063|NCT05746130|Behavioral|Plastic-free nutrition program|"Applying the plastic-free diet as four meals (three main meals, one snack) in pension kitchen. Promoting of glass water bottle giving and daily use.~Interactive education program: Slogan competition, school board preparation, short film shooting, school canteen visits and plastic-free nutrition day event with the adolescents for four weeks by the researcher.~Peer education will doing by Adolescents with Packaged Product Low Usage Feedback about BPA levels in theirs urinary sample."
45356064|NCT05746130|Behavioral|Interactive education|"Interactive education program: Slogan competition, school board preparation, short film shooting, school canteen visits and plastic-free nutrition day event with the adolescents for four weeks by the researcher.~Peer education will doing by Adolescents with Packaged Product Low Usage Feedback about BPA levels in theirs urinary sample"
45356065|NCT05746130|Behavioral|BPA exposure feedback|Feedback about BPA levels in theirs urinary sample
45478377|NCT05445583|Behavioral|Text Messaging (SMS)|SMS will target asthma knowledge. SMS messages will be sent via CIAS 3.0 to participants' personal mobile devices with facts about asthma management, links to educational web content, and videos providing information about living with asthma. Information covered includes 'What is asthma,' 'What is an asthma attack,' 'What causes an asthma attack,' 'How is asthma treated,' 'Asthma and weather,' 'Using an inhaler,' 'Using a spacer,' and 'Asthma Action Plans.'
45356066|NCT05743335|Biological|JCXH-221|Participants will be randomized to either placebo or JCXH-221 for Phase 1. For Phase 2, participants will either be randomized to JCXH-221 or a FDA approved Active comparator.
45356067|NCT05743335|Biological|Active Comparator|Participants will be randomized in Phase 2 to either JCXH-221 or a FDA approved Active Comparator,
45356068|NCT05743335|Other|Placebo|Participants will be randomized in Phase 1 to either JCXH-221 or placebo
45356069|NCT05742438|Drug|Lidocaine IV|Continuous intravenous infusion of lidocaine
45356070|NCT05742438|Drug|Dexmedetomidine IV|Continuous intravenous infusion of dexmedetomidine
45356071|NCT05742438|Drug|intrathecal morphine|intrathecal morphine injection
45478378|NCT05445583|Behavioral|Physical Activity Tracking (PAT)|All participants will be provided a wearable physical activity tracking device, which will allow them to accurately track exercise and total steps each day. Through PAT, users will be able to set daily goals and attain motivation to continue asthma management. For individuals randomized to groups that also include MES or SA, those programs will incorporate PAT data that is remotely transmitted, to facilitate asthma management motivation.
45478379|NCT05442125|Other|Using DNA methylome to select embryos|DNA methylation level Embryo with methylation level closest to the optimal level (from one couple patients) is the one for embryonic transfer to uterus
45478380|NCT05442125|Other|Using morphologic score to select embryos|blastocyst will transferred according to morphologic score or blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.
45478381|NCT05438238|Device|Oncomfort|Virtual Reality
45687014|NCT05812235|Procedure|esophagectomy|esophagectomy
46046813|NCT00630162|Genetic|amoeba|
46046814|NCT01118780|Drug|Duloxetine|Administered by mouth, daily for 10 weeks
46046815|NCT01118780|Drug|Placebo|Administered by mouth, daily for 10 weeks
46046816|NCT04285632|Other|Plyometrics exercises|"Counter Movement Jump exercise. The subject will be placed in an upright standing position, with his hands on his hip. It will perform a rapid downward movement in which it will flex the hips and knees and, immediately, a rapid extension of the legs that will result in the maximum vertical jump. During the flight phase the subject will keep the legs straight. The landing will be done with both feet at the same time. The intervention will be carried out for 300 seconds, in 2 series of 30 jumps each and with 3 minutes of rest between series.~Drop Jump exercise. The players will be placed on a step, standing and with their feet shoulder-width apart. They will drop forward, landing with both feet at the same time. Upon touching the ground they will perform a maximum vertical jump. The intervention will be carried out for 600 seconds, in 2 series of 25 jumps each, and with 3 minutes of rest between series."
46046817|NCT00629928|Drug|Esomeprazole|20mg oral capsule daily
46046818|NCT00629928|Drug|Esomeprazole|40mg oral capsule daily
45356072|NCT05739513|Diagnostic Test|miRNA analysis in plasma|blood sample
46046819|NCT00629928|Drug|Placebo|
46046820|NCT00964782|Drug|Sildenafil|oral suspension, 0.5mg/kg, taken once prior to exercise stress test. Enrolled patients will be randomized to receive Sildenafil first and then crossed over to receive the opposite intervention, placebo.
45356073|NCT05737147|Device|Zero Heat Flux Thermometer|Comparison of the accuracy and precision of a Zero Heat Flux Thermometer (SpotOn) Versus Pulmonary Artery Temperature Measurement
45356074|NCT05736796|Other|Lumber strengthening exercises|Complex Training program to Achieve the normal postural. Lumber Extension Excersie will be done to prevent the lumber straighten.
45356075|NCT05736796|Other|General cervical Exercise|Students of this group will perform general exercises of the cervical region to strengthen the Muscles.
45356076|NCT05736471|Diagnostic Test|Computational dissociation of the causes of cognitive rigidity in depression|involves a single testing session with surveys and tasks relevant to the experiment involving behavioral tasks and self-report questions through an online crowd-sourcing platform
45843651|NCT05330130|Drug|Follitropin beta injection 300 IU|"Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 300 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation."
45843652|NCT05293548|Biological|Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09) in the deltoid muscle of the upper arm
45356077|NCT05732298|Device|intermittend theta burst stimulation (iTBS)|600 pulses of iTBS per day with 120% resting motor threshold applied four weeks at Monday-Friday
45356078|NCT05732051|Dietary Supplement|Nicotinamide Riboside|Nicotinamide Riboside 500mg b.i.d as long as the patient is receiving anthracycline therapy
45356079|NCT05732051|Dietary Supplement|Placebo|Matching placebo b.i.d as long as the patient is receiving anthracycline therapy
45356080|NCT05731479|Other|Diathermy + exercise group|The Diathermy + Exercise group will receive diathermy for 15 minutes, of which 5 minutes will be applied in the capacitive method and 10 minutes in the resistive method. You will then perform 20 minutes of the following exercises: 1) Bird-Dog, 2) Crunch, 3) Obliques, 4) Drawing, 5) Half plank and 6) Side-plank. You will perform 8-12 repetitions and 3 sets of each exercise. 3 sessions of 35 minutes per week for 8 weeks.
45356081|NCT05731479|Other|Diathermy placebo + exercise group|The Placebo + Exercise group will receive 15 minutes of application of the diathermy device without energy emission. It will then perform the same therapeutic exercise protocol described in the GDE. 3 sessions of 35 minutes per week for 8 weeks.
45843653|NCT05293548|Biological|Inactivated COVID-19 vaccine (Vero cells)|Biological/Vaccine: Inactivated COVID-19 vaccine (Vero cells) Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
45843654|NCT05197998|Behavioral|Color Brave Program|The intervention will consist of a 6-week multi-module program that will be delivered via a mobile application. This program is designed for parents of children in K-2nd grade. Each module in the program will take approximately 30 minutes to complete, with lessons facilitated through interactive storytelling, videos, and games.
45843655|NCT05157360|Drug|HAT|hydrocortisone, ascorbic acid (vitamin C), and thiamine (vitamin B1); referred to as HAT
45843656|NCT05157360|Drug|Placebo|normal saline solution
46046821|NCT00964782|Drug|Placebo|Patient will receive a look-alike placebo. Enrolled patients will be randomized to receive Placebo first and then crossed over to receive the opposite intervention, Sildenafil.
46046822|NCT00964782|Drug|Sildenafil 2|oral suspension, 0.5mg/kg, taken once prior to exercise stress test. Enrolled patients will receive Sildenafil, the crossed over intervention from their initial intervention (Placebo).
46046823|NCT00964782|Drug|Placebo 2|Patient will receive a look-alike placebo. Enrolled patients will receive Placebo, the crossed over intervention from their initial intervention (Sildenafil).
46046824|NCT02882984|Drug|Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib|radiation given along with one of kind TKI
46046825|NCT02882984|Radiation|WBRT|3750 cGy in 15 fractions given within 3 weeks time.
46046826|NCT02882984|Radiation|HFSRS|All HFSRS given in 5 fractions. dose per fraction ranges from 5 to 8 Gy depending on the target volume and organs at risk tolerance.
45356082|NCT05721859|Device|revision hip arthroplasty|revision hip arthroplasty
45356083|NCT05720130|Drug|[212Pb]Pb-ADVC001|[212Pb]Pb-ADVC001 administered intravenously under the dose escalation schedule
45356084|NCT05717088|Other|24% Sucrose solution|"Infants will either receive oral sucrose (24%) 2 minutes before the procedure LUS scan. The dose will be 0.2 mL, 0.5 mL and 1 mL for infants with current weight < 1500g, 1500-2500g, and > 2500g respectively."
45356085|NCT05715099|Drug|Saffron|Dietary Supplement: saffron supplement for IBD
45356086|NCT05715099|Drug|Placebo|Dietary Supplement: placebo for IBD
45843657|NCT05136066|Other|massage with peppermint oil|Peppermint oil diluted with 1/10 pure olive oil will be applied to the pregnant to reduce labor pain.
45843658|NCT05106894|Behavioral|smartphone application to promote nurturing care|see arm description
45843659|NCT05106894|Behavioral|printed caregiving materials|see arm description
45843660|NCT05089656|Genetic|OAV101|Gene therapy
46046827|NCT00966654|Drug|Placebo|1.5 pmol/kg/min (5 ng/kg/min) saline infused continuously over 72 hours.
46046828|NCT00966654|Drug|GLP-1 (7-36) amide|1.5 pmol/kg/min (5 ng/kg/min) GLP-1 infused continuously over 72 hours.
45356087|NCT05713357|Procedure|Catheter ablation|Endocardial catheter ablation
45356088|NCT05708716|Behavioral|Modified ketogenic diet using an exogenous ketogenic formula|Participants will follow a modified ketogenic diet consuming a daily exogenous ketogenic meal replacement formula while limiting their carbohydrate intake for 12 weeks.
45356089|NCT05708716|Behavioral|Online cognitive training|Participants will complete a daily session of 5 online cognitive training tasks for 12 weeks.
45356090|NCT05708586|Behavioral|Control|This is the control condition and anxiety is addressed in a standard way of having the care taker calm the child during the intervention.
45356091|NCT05708586|Device|Virtual Reality (VR)|The child who is undergoing a procedure uses VR as a distraction during the intervention
45356092|NCT05707195|Other|Questionnaire|"A questionnaire is offered to parents of patients who meet the eligibility criteria and who have given their non-objection.~This questionnaire aims to evaluate the quality of care perceived by the parents of children hospitalized in the pediatric intensive care unit"
45356093|NCT05695027|Drug|Dietary supplements - Nicotinamide and Pyruvate|Nutritional supplements
45356094|NCT05695027|Drug|Placebo|Placebo
45356095|NCT05687396|Device|virtual reality|virtual reality designed as cycling in the forest
45356096|NCT05687396|Other|conventional pulmonary rehabilitation|pulmonary rehabilitation
45356097|NCT05685771|Device|Phase-targeted auditory stimulation|Bursts of pink noise (50 ms) played during deep non-REM sleep at specific phases of sleep slow waves.
45356098|NCT05681637|Other|Breathing mixtures of O2 and N2 and monitoring SpO2 on each finger|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of volunteer hands throughout the experiment.
45843661|NCT05089656|Procedure|Sham control|The sham procedure will consist of a small needle prick on the lower back at the location where the LP injection is normally made. The needle will break the skin, but no needle insertion for lumbar puncture will occur.
45843662|NCT04988412|Dietary Supplement|Investigational product 1|Test group 1 will receive investigational product 1 containing collagen (5 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
45356099|NCT05671848|Other|Recordings of thalamic activity|Recordings of thalamic activity will be performed at home, in ecological conditions. They will be realized during 4 distinct conditions each week between M3 and M6 post implantation: at rest and during tremor-induced movements. For these recordings, stimulation will be either turned Off or On. Three successive recordings of 30 seconds separated by 1 minute will be made for each condition.
45356100|NCT05671159|Other|Blood sample|A supplementary blood sample will be taken including a 5mL EDTA tube and a paxgene tube
45356101|NCT05667922|Drug|Tacrolimus|0.05-0.10mg/kg/d, twice orally, with an interval of 12h. The drug valley concentration is 5-10ng/ml, which will be gradually reduced to a low dose after it is effective.
45356102|NCT05667909|Drug|Rituximab|375mg/m2 once a week, 4 times in total, or 1g intravenous drip, once again after 2 weeks, twice in total.
45356103|NCT05667896|Drug|glucocorticoid + tacrolimus|Prednisone 0.4-0.5mg/kg/d; Tacrolimus 0.05-0.10mg/kg/d, oral administration in two times, with an interval of 12h. The drug valley concentration is 5-10ng/ml, which will be gradually reduced to a low dose after it becomes effective.
45356104|NCT05667883|Drug|glucocorticoid + cytoxan|The initial full dose of prednisone was 1mg/kg/d (the maximum dose was 60mg/d) for 6-8 weeks, and then slowly decreased by 10% of the original dose every 1-2 weeks, and the later small dose was maintained at 0.4-0.5mg/kg/d; Cyclophosphamide 200mg/time, intravenous drip or oral every other day, up to the cumulative dose of 6-8g.
45356105|NCT05667805|Drug|Platelet Concentrate|Liberal use (standard treatment)
45356106|NCT05667805|Drug|Prothrombin Complex Concentrate|Liberal use (standard treatment)
45356107|NCT05667805|Other|Restricitve Use|Restrictive use of human prothrombin complex and platelet concentrates. No prophylactic substitution.
45356110|NCT05660746|Device|RoadMAB|The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.
45356111|NCT05660746|Drug|Infliximab|"Conventional dosing. Induction: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance: 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.~Precision dosing. Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool."
45356112|NCT05660460|Diagnostic Test|Spirometry|The method of examination, Spirometry, is noninvasive (i.e. not an intervention that involves penetration into the body by means of incisions or injections.). It is a routine examination and there are no risks, adverse reactions, or discomforts associated with the examination.
45356113|NCT05657288|Other|Breathing mixtures of O2 and N2 and monitoring SpO2 on finger and left wrist|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the whole experiment, non-invasive SpO2 measurements will be performed on the middle finger and on the wrist of left hand.
45843663|NCT04988412|Dietary Supplement|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 25 mL: collagen: 0 mg, MSM: 0 mg, vitamin C: 0 mg; continous administration of placebo product for 12 weeks.
45356114|NCT05651542|Behavioral|Comprehensive Self-Management Intervention|In addition to standard care, participants receive content on self-management which includes cognitive behavioral therapy, relaxation, and diet. Weekly phone calls provide support for achieving the sessions goals.
45356115|NCT05651542|Other|Control|The control group will receive standard care.
45356116|NCT05644496|Drug|Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release|Instillation of the drug into the knee joint capsule and surrounding tissues after placing the knee prosthesis and before close of the surgical wound
45356117|NCT05642468|Drug|A3907|A3907 is an oral, systemically available, potent inhibitor of the apical sodium bile acid transporter (ASBT).
45478382|NCT05435950|Device|Sono-Intruments|"Spirecut's single use, pre-CE Sono-Instruments (SI) allow the percutaneous treatment of Carpal Tunnel (CT) syndrome and Trigger Finger/thumb (TF) under sonography (instead of open or endoscopic approach).~Two models will be assessed:~The Carpal Tunnel Sono-Instrument® (CT-SI), for CT syndrome release, by progressively cutting the transverse carpal ligament.~The Trigger Finger Sono-Instrument® (TF-SI), for TF release by progressively cutting the A1 annual pulley."
45356118|NCT05639634|Dietary Supplement|Chlorella supplementation|Supplementation with Chlorella (1.5 g/d) in 3 capsules for 12 weeks.
45356119|NCT05639634|Other|12 week cardiovascular training programme|Participants will be asked to complete a 12 week cycling training programme. This will consist of 4 X 50 min sessions per week. Each exercise session will include a warm-up phase (~ 5 min), a main physical conditioning phase (~ 40 min), and a cool-down phase (~ 5 min).
45356120|NCT05639634|Dietary Supplement|Placebo Supplementation|Supplementation with Placebo - microcrystalline cellulose (1.5 g/d) in 3 capsules for 12 weeks.
45356121|NCT05631938|Drug|cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
45356122|NCT05619003|Device|Biatain Silicone Sacral Bandage|Biatain Silicone sacral will be applied on the sacral area as prevention of Pressure Ulcers
45356123|NCT05616780|Other|Physiological test|Lung volume measurements will be obtained using nitrogen washout and body plethysmography
45356124|NCT05613608|Drug|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.
45356125|NCT05613608|Drug|Placebo|Placebo arm.
45356126|NCT05607498|Drug|EMB07|EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI
45478383|NCT05435547|Drug|Dexamethasone|Will take Dexamethasone pre-operatively
45478384|NCT05435547|Drug|Placebo|Will take Placebo pre-operatively
45478385|NCT05432206|Drug|Cannabis Sativa Oil|Cannabis Sativa oil standardized: 11 mg THC/g and 22 mg CBD/g.
45478386|NCT05432206|Drug|Placebo|Hemp virgin seed oil
45478387|NCT05425264|Other|Tele-exercise|Exercise training 2x/week at home. Sessions include circuit exercises of aerobic and resistive training stations which are led remotely.
45478388|NCT05422131|Device|MyCare Insite Clozapine Test|The MyCare Insite Clozapine Test is a 2 reagent system designed to evaluate the level of antipsychotic drug clozapine in a patients blood using the near patient device the MyCare Insite Analyser.
45843664|NCT04988412|Dietary Supplement|Investigational product 2|Test group 2 will receive investigational product 2 containing collagen (10 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
46046829|NCT00625196|Drug|Fluticasone foroate/ vilanterol|Fluticasone foroate/ vilanterol 800 micrograms/ 50 micrograms will be available as dry powder inhaler.
46046830|NCT00625196|Drug|Fluticasone foroate|Fluticasone foroate 800 micrograms will be available as dry powder inhaler.
46046831|NCT00625196|Drug|Vilanterol|Vilanterol will be available as dry powder inhaler.
46046832|NCT00625196|Drug|Placebo|Placebo will be supplied as dry powder inhaler.
46046833|NCT03262116|Drug|Humalog|Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
46046834|NCT03262116|Drug|Novolog|Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
46046835|NCT03262116|Drug|BC222 insulin lispro|Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.
46046836|NCT03262116|Device|Bionic Pancreas|The insulin-only bionic pancreas will be used in all three arms of the study
45356127|NCT05603416|Dietary Supplement|Perilla frutescens extract|oral dissolvable powder - dosage 300mg
45356128|NCT05603416|Dietary Supplement|Placebo|oral dissolvable powder - dosage 300mg no active ingredient
45356129|NCT05602883|Behavioral|music therapy|Music is played for 30 minutes to the pregnant woman who is hospitalized due to the threat of premature birth.
45478389|NCT05415501|Behavioral|Sentence training|Participants will be trained to read, make, and recall sentences during each session.
45478390|NCT05415228|Drug|68Ga-PSMA-11|68Ga-PSMA-11 is a radiopharmaceutical for the detection of prostate cancer using PET/CT imaging
45478391|NCT05414357|Diagnostic Test|Functional Magnetic Resonance Imaging at rest and in activation with attentional task|"Participants complete 3 successive assessments (T1: baseline, T2: at 6 months, T3: after galvanic vestibular stimulation). Assessments include:~Functional and Anatomic Magnetic Resonance Imaging at rest and in activation (only at T1 and T2).~Biological and physiological measurements~Spatial memory task~Cognitive battery~Questionnaires (sleep, quality of life)"
46046837|NCT01130168|Drug|Placebo|Placebo, capsule taken orally once daily during 4 weeks of treatment
46046838|NCT01130168|Drug|Comparator: Amlodipine|Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks
46046839|NCT01130168|Drug|Comparator: ISMN ER|ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks
45356130|NCT05601908|Other|Virtual Reality Relaxation|Participants will undergo a 5-week course of 20-min sessions of VR relaxation. The VR device used will be the Oculus Quest wireless head mounted display (HMD) with two handheld controllers. The HMD and software have been provided by a Germany based company called Magic Horizons. Participants will be asked to wear the HMD and will wear headphones to hear audio. Each session will involve participants experiencing two virtual environments designed to promote relaxation, at least one of which will have a small interactive component to aid engagement. Environments will focus on nature and will be paired with soothing music or guided meditation. For example, scenes might include dolphins dancing underwater, a beach with rock pools, waterfalls, a rainforest, green meadows with flowers, mountains with lakes and/or a sandy desert. Participants will be seated throughout all sessions.
45356131|NCT05594654|Other|Smart Phone Application|"Breathe is an app that can be used by people with asthma to promote collaborative self-management. It is a platform that empowers patients to self-manage their condition. Breathe helps patients detect when they might be exacerbating or adequately controlled based on symptoms entered by the user into the application. The application then feeds these symptoms through a rules-based algorithm that identifies the early onset of an exacerbation, based on the user's zone of control or action plan. It also stores the patient's self-management action plan and gives them relevant instructions when it sees that their symptoms are getting better or worse. These instructions are delivered through a chatbot that provides information, support, and education to the patient through a friendly, human-like text message conversation."
45356132|NCT05592613|Device|Next-generation Reader and ID-Cap System|The digital pill system (DPS) is comprised of an ingestible radiofrequency emitter, integrated into a standard gelatin capsule, which then over-encapsulates the study medication (PrEP or ART). On ingestion, the radiofrequency emitter is activated by chloride ions in the stomach, projecting a signal approximately three feet off the body. This radio signal is acquired by a wearable device (Reader) which stores and forwards data to a smartphone, enabling on-demand access to adherence data. The next-generation Reader is a wrist-borne device.
45356133|NCT05592613|Drug|Truvada for pre-exposure prophylaxis (PrEP)|Participants will ingest one Truvada digital pill as PrEP per day, for 30 days total.
46046840|NCT03260400|Device|a bipolar percutaneous intramuscular electromyography electrode|The device, a bipolar percutaneous intramuscular electromyography electrode, is intended for use in upper-limb amputation patients who have received the regenerative peripheral nerve interface surgical procedure, in order to enable the use of advanced prosthetic arms and hands.
45356134|NCT05592613|Drug|Biktarvy for antiretroviral therapy (ART)|Participants will ingest one Biktarvy digital pill as ART per day, for 30 days total.
45356135|NCT05592600|Behavioral|Neurofeedback|Participants will visualize real-time feedback of signals recorded from their brains as measured with functional MRI.
45478392|NCT05409638|Behavioral|Cognitive Behavioral Therapy to manage cancer-related fatigue|Participation will consist of attending 90-minute virtual groups for 4 consecutive weeks on cancer-related fatigue. During the 4 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework.
45687015|NCT05812105|Other|Healthy Buddy Program|The Healthy Buddy Program is a community-based initiative that pairs college students with transportation disadvantaged, community- dwelling older adults age 65 and older. The Spanish-language Healthy Buddy Program was developed to measure the transportation and health challenges of Hispanic/Latino older adults and determine the efficacy of the adapted HB program model.
45687016|NCT05812079|Diagnostic Test|skin biopsy examined by ELISA technique|skin biopsy examined by ELISA technique
45687017|NCT05812014|Biological|SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)|One dose was administered by intramuscular injection, 100μg，1.0ml/dose
45687018|NCT05812014|Drug|0.9% sodium chloride solution|One dose was administered by intramuscular injection, 1.0ml/dose
45687019|NCT05812001|Behavioral|Exergames-acceptance and commitment therapy (e-ACT)|In the e-ACT training program, participants will perform a 30-minute per session Nintendo-program on TV for three days per week and a 50-minute ACT session per week for 8 weeks which will take place in the psychology labs of AMDI, USM. The ACT session will be held after 30 minutes break following the completion of the final exergame session of the week. Hence, the total duration of each weekly e-ACT training session will be approximately 2 hours. In addition, each weekly e-ACT training session will be held at the same time (± 2 hours) and at the same venue.
45687020|NCT05812001|Behavioral|Acceptance and commitment therapy (ACT)|As for the ACT intervention, each ACT session will run for 50 minutes, one session per week for 8 weeks. Each weekly ACT session will be held at the same time (± 2 hours) and at the same venue (in the psychology lab).
45687021|NCT05810974|Dietary Supplement|Concentrated beetroot juice|Subjects will consume 70ml shot (Beet-it Sport nitrate 400 shot, James White Drinks) and this drink contains 0.4g inorganic nitrate
45687022|NCT05810974|Dietary Supplement|Nitrate depleted beetroot juice + potassium nitrate (KNO3)|Nitrate-depleted beetroot juice (70ml) and 0.4g KNO3- will be mixed. (Same appearance and taste with Beet-it sport shot)
46046841|NCT02862834|Genetic|High-throughput exome sequencing|
46046842|NCT04284852|Drug|Niraparib|PARP inhibitor
46046843|NCT04283292|Drug|Capsaicin|Topical Capsaicin for the treatment of Cannabinoid Hyperemesis Syndrome
46046844|NCT04283292|Drug|Placebo|Placebo cream that is applied once topically
45356136|NCT05591352|Dietary Supplement|Chenopodium formosanum extracts sachet|consume 1 sachet per day
45478393|NCT05405413|Other|Treatment recommendations made by Molecular Tumor Board.|"Molecular Tumor Board recommendations may include any of the following:~(A) a tumor-targeted drug (alone or in combination)~(B) an antibody-based immunotherapy (alone or in combination)~(C) neither (A) nor (B).~(D) referral to the Familial Cancer Program~(E) referral for germline genetic testing"
45478394|NCT05404308|Other|Consultation with Manipulator in Medical Radiology and a radiotherapist|Weekly consultation with Manipulator in Medical Radiology and a radiotherapist
45478395|NCT05404308|Other|Consultation with a radiotherapist|Weekly consultation with a radiotherapist
45478396|NCT05399485|Drug|Rimegepant|Randomization Phase: Rimegepant (BHV3000) 75 mg orally disintegrating tablet every other day until Week 12
45687023|NCT05810974|Dietary Supplement|Nitrate depleted beetroot juice|Subjects will consume 70ml of (Beet-it Placebo shot, James White Drinks). This drink is the same as the Beet-it Sport nitrate shot but has the nitrate removed.
45356137|NCT05591352|Dietary Supplement|Placebo sachet|consume 1 sachet per day
45478397|NCT05399485|Drug|Placebo|Randomization Phase: Placebo tablet to match Rimegepant every other day until Week 12
46046845|NCT01144052|Drug|interferon beta-1b|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 month at study entry. After a wash-out period of one month, interferon-beta-1b will be administered subcutaneously every other day as indicated by the manufacturers' instructions including the stepwise up-titration scheme as recommended for treatment start. The final dose of interferon beta-1b is 250 mcg (8 million International Units [MIU])
46046846|NCT01144052|Drug|Natalizumab|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.
45356138|NCT05573243|Other|bonding strategies|The universal adhesive can be bonded using 3 different bonding strategies. Therefore, three bonding strategies will be assigned for 3 arms: etch-and-rinse, selective enamel etching, self-etch
45356139|NCT05567562|Combination Product|dual anti-platelet therapy|dual anti-platelet therapy
45356140|NCT05567562|Drug|Placebo|Placebo
45356141|NCT05566574|Drug|RP-3500|RP-3500 on Days 1-5.
45478398|NCT05397470|Drug|Losmapimod|Losmapimod 15 mg will be administered BID by mouth along with food.
45478399|NCT05397470|Drug|Placebo oral tablet|Placebo will be administered BID by mouth along with food.
45478400|NCT05390918|Behavioral|TAILOR|"The first TAILOR session will assess existing sleep problems from both the adolescent's and parent/legal guardian's perspectives, concluding with offering a CBT strategy to try. Session 2 will involve getting feedback from the family on that specific strategy and then offering additional CBT strategies. The remaining sessions will be devoted to refining the use of CBT strategies. MI will be integrated as the communication style throughout, including reflective listening, rolling with resistance, and showing deference to the family's ultimate decisions. The interventionist will also use the elicit-provide-elicit approach from MI. The interventionist will elicit the family's own ideas for improving the adolescent's sleep, ask for permission to provide his/her own suggestions, and then gauge the family's reactions to those suggestions, versus simply recommending a CBT strategy and problem-solving barriers to implementation."
45478401|NCT05390918|Other|Enhanced Usual Care|The study clinician will conduct suicide risk screening and further assessment and safety planning where deemed necessary.
45478402|NCT05390502|Behavioral|manual monitoring and general education on use|Patients will receive a standard blood pressure monitor and education on how to use it. Data will be reported as part of usual care.
45478403|NCT05390502|Behavioral|integrated monitoring and local wrap-around hypertension program|Patients will receive a standard blood pressure monitor and a local wrap-around hypertension program. Data will be sent directly to their participating health system.
46046847|NCT02862288|Device|Microwave ablation with Acculis Accu2i pMTA Applicator|
45356142|NCT05566574|Radiation|External Beam Radiotherapy (EBRT)|Palliative radiation therapy (4Gy x 5 fractions) to a metastatic site on Days 1-5
45478404|NCT05387655|Biological|BCG|BCG vaccination
45478405|NCT05387655|Biological|Placebo vaccine|Placebo vaccination
45478406|NCT05381103|Diagnostic Test|PSMA-PET and SOC MRI|60 min continuous acquisition of PET data after 3-6 mCI injection of [68Ga]P16-093 followed by contrast-CT
45478407|NCT05381103|Diagnostic Test|SOC MRI|Standard of care MRI
45687024|NCT05810545|Other|Per- and polyfluoroalkyl substances (PFAS)|Assess the association between exposure to per- and polyfluoroalkyl substances (PFAS) via drinking water in pregnancy and birth outcomes (i.e. growth retardation, premature birth, and congenital developmental defects) and maternal morbidity (gestational hypertension, diabetes and preeclampsia) in a prospective population-wide register based cohort.
45843665|NCT04988412|Dietary Supplement|Investigational product 3|Test group 3 will receive investigational product 3 containing collagen (10 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
46046848|NCT04283526|Drug|MBG453|Intravenous. 600mg. Every first day of a 21-day cycle, or on days 8 and 29 of a 42-day cycle (when in combination with Decitabine).
46046849|NCT04283526|Drug|NIS793|Intravenous. 2100mg. Every first day of a 21-day cycle, or on days 8 and 29 of a 42-day cycle (when in combination with Decitabine).
46046850|NCT04283526|Drug|Spartalizumab|Intravenous. 300mg. Every first day of a 21-day cycle
46046851|NCT04283526|Drug|Decitabine|Intravenous. Starting dose: 5mg/m2 (dose cap at 20mg/m2). On days 1, 2 and 3 of a 42-day cycle
45356143|NCT05558215|Other|Otago Exercise Program|"The Otago Exercise Program (OEP) is a CDC endorsed evidence-based falls prevention program for older adults. It has not been well studied with individuals with dementia. It is comprised of a brief warm up/flexibility series, lower extremity strengthening, and balance exercises. The same menu of exercises is used for all participants, but exercises are progressed based upon individual performance. For the purposes of this study, three 25-minute video recorded versions of OEP will be rotated for use, all of which include brief flexibility activities, strengthening, and balance exercises. Strengthening exercises will be limited to body weight resistance for ease of instruction, safety, and consistency. Balance exercises involve changes in base of support in static and dynamic contexts, with challenge progressively increased by decreasing arm support during training (from 2-hands, to 1-hand, to no hands)."
45356144|NCT05554978|Drug|Landiolol|patient receives landiolol in addition to standard-of-care
45356145|NCT05554978|Drug|Sodium Chloride (NaCl) 0.9%|Placebo
45687025|NCT05810519|Behavioral|Active break with the proposed lumbar and hip extension exercises|Participants assigned to the experimental group will receive recommendation to take an active break with the proposed lumbar and hip extension exercises for every 30 minutes of sitting. In the experimental intervention, the exercise program include exercises and will be based on patient education. The participants will also explain the importance of regular training and receive a booklet with photographed and described exercises.
45356146|NCT05553444|Behavioral|Self-management intervention|"The procedure will be based on the A - B - A'/B' design. After recruitment, patients will attend an initial session with CLS where written and oral information about the study will be provided. In this study, the A phase will serve as baseline to establish fluctuation in pain intensity prior to initiating the treatment.~During phase A, patients will be assessed every day for a minimum of 8 days and maximum of 14 days.~During phase B, CLS will facilitate the intervention based on the initial session, pain levels during phase A and the patients' goals. During phase B, patients will attend a 1-hour weekly session over 6 weeks.~During phase A', the participants will be followed weekly for 12 weeks. During the phase A', participants will not receive treatment.~Phase B' contains 3 x 1 hour criterion-based booster sessions which are delivered over 3 consecutive weeks."
45356147|NCT05546866|Drug|Osimertinib|Subjects successfully enrolled into the study will receive 80mg osimertinib QD p.o. until completion of planned treatment duration, recurrence of disease, or other treatment discontinuation criteria is met. The maximum treatment duration period is 3 years.
45356148|NCT05545969|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
45356149|NCT05545969|Drug|Lenvatinib|Lenvatinib is an oral potent multiple RTK inhibitor that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptor (FGFR1-4), platelet derived growth factor (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET)
45356150|NCT05543642|Biological|Hepatitis A vaccine|Vaccination series administered to prevent hepA infection.
45356151|NCT05543642|Biological|Diphtheria, pertussis, and tetanus booster vaccine|Vaccination booster administered to prevent diphtheria, pertussis, and tetanus
45356152|NCT05541627|Genetic|AB-1001 Gene Therapy|One-time intracerebral bilateral injections of AB-1001 (AAVrh10.CAG.hCYP46A1), an adeno-associated viral vector serotype Rh10 containing the human cholesterol 24-hydroxylase gene
45356153|NCT05540457|Device|Intermittent Non-InvasiveBlood Pressure Monitor|"Brachial cuff integrated with theTablo Hemodialysis System. Cuffwill be placed contralateral to theaccess arm, with measurementscollected pre-dialysis, every 30minutes during dialysis, and post-dialysis.~Device: Continuous Non-InvasiveBlood Pressure Monitor VitalStream Monitor. Finger cuffwill be placed ipsilateral to theaccess arm, with measurementscollected pre-dialysis,continuously during dialysis, andpost-dialysis."
45356154|NCT05538273|Other|Early removal of urinary catheter postoperatively|removal of urinary catheter less than 24 hours after surgery
45356155|NCT05538273|Other|Late removal of urinary catheter postoperatively|removal of urinary catheter greater than 24 hours after surgery
45687026|NCT05810519|Behavioral|Self-care recommendations|Participants assigned to the control group will receive an educational self-care book containing information on low back pain, anatomy of the spine and its relation to the muscular chain, care during daily life activities and the importance of regular physical exercises. The control group will perform their regular baseline activities.
45843666|NCT04943874|Device|Technology Based Intervention Group 1|In Phase 1, all participants will use the same technology. In Phase 2, participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.
45356156|NCT05528900|Diagnostic Test|allergy test|allergy test are oral food challenge , prick test and IgE blood rate
45356157|NCT05525247|Drug|SLC-3010|Intravenous (IV) infusion over 30 minutes on day 1 of each 21-day cycle
45356158|NCT05525247|Combination Product|Gemcitabine|1000 ㎎/㎡ IV infusion over 30 minutes on day 1 and 8 of each 21-day cycle
45687027|NCT05810363|Drug|Etomidate - propofol mixture|Patients will receive etomidate - propofol mixture during induction and maintenance. Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，EP mixture（E：P=1:2） 0.1-0.25 ml/kg for induction, EP mixture 0.4~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min ~0.3 μg/kg/min for maintenance.
45687028|NCT05810363|Drug|Propofol|Patients will receive propofol during induction and maintenance.Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，propofol 0.1-0.25 ml/kg for induction, propofol 0.4~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min ~0.3 μg/kg/min for maintenance.
45356159|NCT05524428|Behavioral|Implementation Science Strategy|The investigators will be conducting focus groups and identifying barriers and facilitators, and the investigators will be matching identified barriers and facilitators to implementation strategies at the patient, provider, and system level which the investigators will be testing using rapid-cycle methods.
45356160|NCT05516212|Dietary Supplement|CAFMONO supplementation|"CAFMONO supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMONO - Caffeine (anhydrous caffeine), Ostrovit Sp. z o.o., Zambrów, POLAND"
45356161|NCT05516212|Dietary Supplement|CAFMIPS_1 supplementation|"CAFMIPS_1 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMIPS_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND~CAFMIPS_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND"
45356162|NCT05516212|Dietary Supplement|CAFMIPS_2 supplementation|"CAFMIPS_2 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMIPS_2 - Muscle Clinic Furious, Noblepharma UG, BerlinVertrieb, GERMANY."
45356163|NCT05516212|Dietary Supplement|Placebo treatment|Placebo treatment - random blind acute intake of placebo preparation. Placebo will match the remaining test preparations with taste, colour and consistency, however it will be free of caffeine and any other substances possessing ergogenic potential.
45356164|NCT05511207|Device|RECOM - hBCI training|The RECOM device is a h-BCI system that controls FES of upper limb muscles: the patient is asked to attempt simple upper limb movements (eg extension of fingers); the device recognizes (in correct trials) close-to-normal EEG-EMG activation and initiates FES of extensor muscles in the forearm. RECOM training consists in a set of trial repetition for a total duration per session of approximately 20-30 minutes (excluding set up time and calibration). FES parameters will be set specifically for each patients according to standard guidelines to achieve full movement and so as to avoid any kind of discomfort for the patients. The intervention regimen will be 2-3 times per week for 4 consecutive weeks.
45356165|NCT05511207|Other|CTRL - upper limb training with FES|An expert physiotherapist will define a set of active exercises focused on upper limb function; the exercises will be combined with FES of forearm muscles. FES parameters will be set specifically for each patients according to standard guidelines to achieve the full required movement and so as to avoid any kind of discomfort for the patients. Session duration will be approximately 20-30 minutes (excluding FES calibration time). The intervention regimen will be 2-3 times per week for 4 consecutive weeks.
45356166|NCT05509959|Behavioral|Women SHINE|Minimum of nine weekly one-on-one peer navigation sessions and 7 weekly psychoeducation support group sessions.
45687029|NCT05808426|Device|Bonus Winner Mahjong|Bonus Winner Mahjong developed by Bonus Winner Online Entertainment Co., Ltd. The participants in experimental group played three times a week, each time requiring at least lasting 30 minutes, for half of a year.
45356167|NCT05509959|Behavioral|Control|Single group session and access to website
45356168|NCT05508464|Radiation|Arm 2: SABR|SABR to all tumors 6 Gy x 5 over three weeks
45356169|NCT05508464|Radiation|Arm 1: Standard of Care|Standard of care palliative radiotherapy
45356170|NCT05508243|Other|Hyaluronic Nasal Spray|Health care product - nasal application
45356171|NCT05508230|Other|Hyaluronic Nasal Spray|Health care product - nasal application
45687030|NCT05807451|Procedure|High Tibial Osteotomy (Uniplanar and Biplanar )|High Tibial Osteotomy using monoplanar and biplanar osteotomy techniques
45843667|NCT04943874|Device|Technology Based Intervention Group 2|Participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.
45356172|NCT05505019|Other|Music listening|This intervention involves listening to participant-selected music that they have evaluated as rewarding/motivating. YouTube Music will be used to build both personalized music and podcast interventions.
45356173|NCT05505019|Other|Podcast listening|This intervention involves listening to participant-selected podcasts of neutral content. YouTube Music will be used to build both personalized music and podcast interventions.
45356174|NCT05494346|Device|Measurement of peak nasal flow.|Peak nasal flow measurements will be performed before and after the first use of the spray at D0, as well as after the use of the spray at the medical office at D3 (only for arm A).
45356175|NCT05488470|Device|LINQ/LINQ II|Algorithm developed and validated to continuously measure QT intervals for every beat using LINQ/LINQ II ECG. This study is aimed at determining if QT interval changes can be detected during and after antiarrhythmic drug loading by the designed QT detection algorithm from LINQ/LINQ II ECG.
45356176|NCT05481931|Drug|prabotulinumtoxinA|Botulinum toxin Type A powder for solution for injection
45356177|NCT05481333|Drug|REGN7999|Ascending IV or SC dose administered per protocol
45356178|NCT05481333|Drug|Placebo|Ascending IV or SC dose administered per protocol
45356179|NCT05476770|Drug|Tagraxofusp|Dose will be assigned at study entry. Give IV over 15 minutes.
45356180|NCT05476770|Drug|Fludarabine|"30 mg/m^2 will be given IV over 30 minutes on days 1-5.~Infusion will start 30 minutes after start of tagraxofusp on days 4 and 5."
45356181|NCT05476770|Drug|Cytarabine|2000 mg/m2 intravenously will be given daily over 1-3 hours for 5 days on days 1 through 5. Infusion will begin 4 hours after start of fludarabine.
45356182|NCT05476770|Drug|Dexamethasone|"20 mg/m2/day divided BID (max 40 mg/day) given orally on days 1 through 5 and 15 through 19. The two doses should be separated by at least 8 hours.~Any oral formulation of dexamethasone is acceptable.~IV may be given if oral formulation is not tolerated"
45687031|NCT05806190|Device|Continuous Glucose Monitoring|Continuous Glucose Monitoring using a Dexcom G6 Continuous Glucose Monitoring Device
45687032|NCT05804643|Procedure|Diffusion magnetic resonance imaging|Free water elimination diffusion MRI and diffusion kurtosis MRI techniques
45687033|NCT05804136|Device|Duramesh|Laparotomy closure with Duramesh
45687034|NCT05804136|Device|Polydioxanone suture|Laparotomy closure with standard PDS
45687035|NCT05803759|Dietary Supplement|Allicor|Each capsule contains 150 mg dried garlic powder
45687036|NCT05803759|Drug|Placebo|Capsules manufactured to mimic Allicor 150 mg capsules
45687037|NCT05801861|Device|Active 10-Hz TMS to the parietal cortex|The active 10-Hz TMS group will receive 10hz TMS stimulation in the first TMS session, and single pulse TMS in the second TMS session. Participants in the active stimulation group will receive 10-Hz TMS to right parietal cortex. The TMS target will be based on subject specific anatomical MRI images (diffusion imaging). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the right parietal cortex using an active/placebo figure-8 coil, an magventure TMS device.
45356183|NCT05476770|Drug|Vincristine|"1.5 mg/m2 (maximum dose 2 mg) given intravenously as an IV push over 1-5 minutes or infusion via minibag as per institutional policy on days 1, 8, 15, and 22.~Infusion will start 30 minutes after start of tagraxofusp on day 8."
45687038|NCT05801861|Device|Active single pulse TMS to the parietal cortex|The active single pulse TMS group will receive single pulse TMS stimulation in the first and second TMS session. Participants in the active stimulation group will receive single pulse TMS to right parietal cortex. The TMS target will be based on subject specific anatomical MRI images (diffusion imaging). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the right parietal cortex using an active/placebo figure-8 coil, an magventure TMS device.
45356184|NCT05476770|Drug|Azacitidine|"75 mg/m2 subcutaneously or intravenously will be given daily over 15 minutes for 5 days on days 1 through 5.~Azacitidine will be given 30-60 minutes before beginning the tagraxofusp infusion."
45356185|NCT05476770|Drug|Methotrexate|"Give intrathecally:~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients ≥9 years of age"
45356186|NCT05476770|Drug|Cytarabine IT|"Give intrathecally:~30 mg for patients age 1-1.99~50 mg for patients age 2-2.99~70 mg for patients ≥3 years of age~If given as part of Triple IT Therapy:~AML Patients:~Age 1-1.99 - 24 mg Age 2-2.99 - 30 mg Age ≥3 years of age - 36 mg~AML Patients:~Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age 3-8.99 - 24 mg Age ≥9 years of age - 30 mg"
45356187|NCT05476770|Drug|Hydrocortisone|"Given intrathecally.~AML Patients:~Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age ≥3 years of age - 24 mg~AML Patients:~Age 1-1.99 - 8 mg Age 2-2.99 - 10 mg Age 3-8.99 - 12 mg Age ≥9 years of age - 15 mg"
45356188|NCT05476289|Other|No intervention|No intervention
45356189|NCT05475678|Drug|（Carrelizumab + TCb） regimen|Carrelizumab +docetaxel + carboplatin regimen
45356190|NCT05475678|Drug|TCb regimen|docetaxel + carboplatin regimen
45356191|NCT05473962|Diagnostic Test|assessment and quantification of symptoms related to post-traumatic stress.|Semi-structured interview based on the Clinician-Administered PTSD scale for DSM-5 Child/Adolescent -CAPS-CA-5. This instrument allows for the This instrument is validated in English, and a French translation was carried out by the investigators (translation/back-translation method). The instrument uses the DSM-5 diagnostic criteria for post-traumatic stress disorder (PTSD).
45356192|NCT05466630|Diagnostic Test|Serological field test for HAT|Whole blood is tested by lateral flow or agglutination (CATT) for the presence of trypanosome specific antibody. Participants testing positive for at least one of these tests will undergo microscopic examination to detect trypanosomes (lymph, mAECT on blood) and DBS will be prepared for immunological and molecular laboratory testing.
45356193|NCT05466630|Diagnostic Test|malaria rapid test|RDT detecting HRP2 plasmodium antigen.
45843668|NCT04874532|Other|Community Paramedic Program|Patients will be seen for a 1-hr in person evaluation and follow-up will be determined on an individual basis based on patient need. During each visit, CPs will perform health status and social determinants of health assessments, physical exam, medication review/counseling, and goal setting/review.
45356194|NCT05466630|Diagnostic Test|Immunologic laboratory tests|Laboratory tests detecting trypanosoma brucei gambiense specific (VSG) antibodies in DBS. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
45478408|NCT05369741|Other|TIME™ at Home|"Components of each 1.5-hour session:~Pre-class social time (15 min): Unstructured - introductions, safety, and technology troubleshoot, and social interactions if time allows~Exercise video (1 hour pre-recorded): a) 10-minute seated warm up; b) 40-minute functional exercises in standing, with standardized progressions and variations. Exercises are selected from the original, in-person TIME™ program and are deemed safe to perform at home by rehabilitation experts; and c) 10-minute seated cool down~Post-class social time (15 min): Structured and unstructured social interactions~Facilitators: A live virtual facilitator assisted by a co-facilitator to stream video, provide verbal encouragement and technology support~Healthcare partner e-visits: A registered healthcare professional will make 2-3 e-visits. They will observe the class and engage with participants during the post-class social time and debrief with facilitators."
45478409|NCT05362929|Device|Sciton Halo|Laser treatment
45356195|NCT05466630|Diagnostic Test|Molecular laboratory tests|Laboratory tests detecting Trypanozoon specific nucleic acids. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
45356196|NCT05462132|Drug|SYNB1353|SYNB1353 IMP is formulated as a nonsterile solution intended for oral administration. SYNB1353 is subsequently lyophilized to form the bulk drug product. The lyophilized product is sieved into powder form and filled into high-density polyethylene (HDPE) bottles. Placebo will be manufactured using an inactive powder that is color matched to the SYNB1353 drug product. L-Methionine will be supplied as dry powder and will be suspended in a diluent prior to use.
45356197|NCT05458622|Biological|Blood sample|"- Total volume of blood (on each sampling occasion): 54,5mL.~Whole blood will be collected in EDTA, 1 tube of 10 mL for DNA (genotyping, methylation arrays; at baseline for genotyping and at EOS visit for methylation arrays). From this, an aliquot of 0.5 mL for baseline cell numbers (cell proportions, CyTOF/flow cytometry) at all time points; capture of leukocytes for blood single cell RNA seq. at all time points and 5 mL for cell stimulations for cell metabolome (C13 to be added), and 1 tube of 10 mL for cell stimulations (CyTOF) at baseline.Tempus tube: 1 tube of 3 mL for RNA, 1 tube of 3mL for whole blood RNA seq.; to be taken at all time points. Plasma will be obtained and aliquoted from these tubes; to be obtained at all time points.~Serum: 2 tubes of 10 mL without anticoagulant for measurements of anti-drug antibodies, hydroxychloroquine levels, cytokines and analytes, proteome, and autoantibodies; to be taken at all time points."
45356198|NCT05458622|Biological|Urine sample|- Urine: 100 mL which will be centrifuged. The pellet will be frozen, and the urine supernatant will be aliquoted;
46046852|NCT04283370|Other|Home Rehabilitation Program|It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
46046853|NCT04283370|Other|e-Health program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
45478412|NCT05357079|Drug|Tranexamic Acid|Topical application
45478413|NCT05357079|Drug|Normal saline|Topical application
45687039|NCT05801861|Device|Sham 10-Hz TMS to the right parietal cortex|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
45687040|NCT05801861|Device|Sham single-pulse rTMS the rigt parietal cortex|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
45687041|NCT05797662|Drug|Propranolol|Adults: Propanolol 120 mg tablets by mouth twice daily for up to 24 weeks Children: Propanolol 3 mg/kg suspension, divided dose twice daily for up to 24 weeks
45843669|NCT04874532|Other|Education Material|Participants will be provided with a diabetes resource card, which will provide a list of clinic and community-based diabetes resources, along with a diabetes education packet, which will include information on diabetes self-management, healthy diet, physical activity, glucose self-monitoring, and hypoglycemia.
46046854|NCT01143896|Other|Depression collaborative care model|The intervention will include a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.
46046855|NCT04283214|Other|Cardiopulmonary Resuscitation|Cardiopulmonary Resuscitation based on 2015 American Heart Association guidelines with and without protective equipment on traditional and endomorphic manikins
45356199|NCT05458622|Biological|Saliva sample|- Saliva: will be collect in special container for saliva microbiome and methylation;
45356200|NCT05458622|Biological|Stood sample|- Stool: One sample for microbiome to be sent to the biobank, frozen at -80 °C
45356201|NCT05458622|Procedure|Tissue sample|"- Tissue samples for organ-specific manifestations:~Kidney tissue in lupus nephritis: one small fragment of the fresh kidney biopsy will be stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~Skin tissue (at selected centers) from inflamed lesion and non-inflamed skin from the gluteal region will be obtained through punch biopsy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~Synovial tissue (at selected centers) will be obtained through ultrasound-directed arthroscopy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~Aspirate from swollen lymph nodes (at selected centers) will be obtained and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment."
46046856|NCT02883530|Procedure|Bronchoscopy|Flexible bronchoscopy will be performed under conscious sedation (with premedication using a mild sedative such as 1-2.5 mg IV midazolam) followed by use of topical anaesthesia (lidocaine spray) on the throat, vocal cords, and trachea in order to investigate the airways. The procedure allows sampling of the airway tissue to allow for laboratory analysis. Three brushings of a small area of the epithelial surface of an airway will be performed via a specialised channel of the bronchoscope with the use of a sterile cytology brush and up to eight 2-mm endobronchial biopsies.
46046857|NCT01118312|Drug|Mometasone Furoate monohydrate|Intranasal mometasone, 1 spray (age < 12 yr) or 2 sprays (age >= 12 yrs) each nostril once a day for 6 months
45687042|NCT05797285|Device|human keratin graft|The intervention to be applied is an advanced wound care matrix composed of human keratin to be applied at two different treatment frequencies.
46046858|NCT01118312|Other|Placebo|Intranasal placebo spray
46046859|NCT04312022|Dietary Supplement|Berry extract|Berry extract supplement (hawthorn berry extract, tart cherry extract, bromelain)
46046860|NCT04312022|Other|Placebo|Placebo (flour capsule)
45687043|NCT05795595|Biological|CTX131|CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)
45687044|NCT05795257|Procedure|Bronchoalveolar lavage|Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
45687045|NCT05794243|Drug|LY3493269|Administered orally.
46046861|NCT04311788|Device|Prophylactic self gripping mesh|Prophylactic self gripping mesh, Propgrip by Medtronic.
46046862|NCT04311788|Device|Slowly absorbable continuous monofilament suture|Fascial closure by continuous slowly absorbable 4:1 suture
45356202|NCT05450224|Behavioral|VVC-delivered Massed Imaginal Exposure|Consistent with Zoellner et al., (2017), six, 60-minute daily sessions of imaginal exposure will be conducted based on the PE manual (Foa et al., 2007). No in vivo exposure or homework will be included. Session 1 will include rationale for imaginal exposure and common reactions to trauma. Sessions 2-6 will focus on imaginal exposure (45 minutes) and processing (15 minutes), with later sessions focused on the most distressing aspect of the trauma memory. The final session will include relapse prevention. All sessions will be delivered within a 10-day window.
45356203|NCT05446051|Device|the Mandarin Version of the electronic patient self-Reporting of Adverse-events (eRAPID-MV)|Phase I Interventions：eRAPID-MV(TRAEs survey)
45356204|NCT05446051|Device|the telephone triage decision support system (TTDSS)|Phase I Interventions：TTDSS
45478414|NCT05345041|Behavioral|Keep it Movin'|Individual participants in churches randomized to the intervention arm will participate in the Keep it Movin' multi-component PA education program, as well as be encouraged by their church and study interventionist to participate in the church-wide walking program. Individuals enrolled in Keep It Movin' will attend weekly 90-minute sessions for 24 weeks. All sessions will include the structured physical activity component from the LIFE study intervention, with the following components, which were added to address needs of the target community: functional education, social support and problem-solving. To increase the functional gains seen in the LIFE pilot study and add content addressing self-management and PA with multiple chronic conditions (MCCs), the number of sessions in the proposed trial has been increased from 16 to 24 weeks.
45478415|NCT05345041|Behavioral|Go 4 Life Self Guided Education|Individual participants in churches randomized to the comparator arm will receive the church-wide walking program and the Go4Life Your Everyday Guide to Exercise and Physical Activity which was developed by the National Institutes of Health National Institute on Aging to promote physical activity in older adults. This includes an evidence-based exercise guide and motivational tips to help older adults start and sustain an exercise program. The Go4Life guide will add individual level education and encouragement to the interpersonal and community levels of intervention provided by the church-wide walking program.
45478420|NCT05336279|Drug|famitinib malate T(5 mg*4)、famitinib malate R(20 mg)|TR Group: famitinib malate T on day 1, famitinib malate R on day 13.
45478421|NCT05336279|Drug|famitinib malate T(5 mg*4)、famitinib malate R(20 mg)|RT Group: famitinib malate R on day 1, famitinib malate T on day 13.
45356205|NCT05441267|Drug|Semaglutide Oral Tablet|Oral semaglutide 14mg daily (option to reduce to 7mg daily)
45356206|NCT05441267|Drug|Placebo oral tablet|Placebo oral semaglutide
45356207|NCT05438888|Drug|Warfarin|This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.
45356208|NCT05438888|Drug|Apixaban|This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.
45356209|NCT05430074|Device|HM Cast|Subjects assigned to this arm will be treated via cast immobilisation with the use of HM casts.
45356210|NCT05430074|Device|Fibreglass Cast|Subjects assigned to this arm will be treated via cast immobilisation with the use of Fibreglass casts.
45356211|NCT05427487|Biological|IVX037|Bioselected oncolytic RNA virus
45356212|NCT05424406|Behavioral|Active phototherapy|Timed bright light exposure delivered in a controlled laboratory setting (10,000 photopic lux) designed to delay the DLMO to 4 am or later.
45478422|NCT05329441|Behavioral|Trier Social Stress Test (TSST)|In this mechanistic study, all participants will undergo a modified version of the Trier Social Stress Test (TSST), which is a well-validated psychosocial stress paradigm, adapted for adolescents that involves no deception and is considered a very mild stressor. The TSST comprises of two stress tests: a 5-minute arithmetic task and a 5-minute speech task. Due to repeated testing of the TSST, participants will be randomized to one task at T1 and complete the second task at T2 (counterbalanced design). Every 5 minutes, participants will provide ratings of their mood using a visual analogue scale (1-10) of eight mood states (Afraid, Confused, Sad, Angry, Energetic, Tired, Happy, and Tense) that will be used as potential behavioral responses to social stress. Glutamate and inflammation outcomes will be examined acutely and from T1 and T2.
45478423|NCT05329441|Behavioral|Social Processing Test (SPT)|Participants will complete the SPT once at T1 and once at T2. The task will occur in 3 phases. Phase 1: At V1, participants will be told that a component of the study evaluates how adolescents interact via social media platforms. Participants will create a profile and photograph, view profiles and photos of 100 similar-aged sex-matched adolescents, then select 50 adolescents they are 'interested' in chatting with online at the end of the study. Phase 2: At V2, participants will be told the 'peers' will also be rating their interest in chatting with the participant; the participant will be asked to rate how much each peer is interested in them (these expectation ratings will be covariates). Phase 3: At V2, during the 20-min fMRI scan, participants will be shown each peer's photo and their Phase 1 interest rating, then pseudorandomized feedback of the peer's interest in the participant (50% 'interested'). Participants will be debriefed after study procedures at T2V2.
45843670|NCT04873830|Biological|volume stable collagen matrix placement|volume stable collagen matrix placement to augment the buccal defect.in class I siebert at the same time of implant placement
45843671|NCT04873830|Procedure|connective tissue grafting|connective tissue placement to augment the buccal defect.in class I siebert at the same time of implant placement
45843672|NCT04676802|Drug|NSAID capsules|1, Ibuprofen 400-mg and 1, Acetaminophen 500-mg capsule per dosage
45356213|NCT05424406|Behavioral|Control phototherapy|Timed less intense light exposure delivered in a controlled laboratory setting (100 photopic lux) that still has a perceptible alerting effect but is not designed to shift circadian phase.
45356214|NCT05424406|Behavioral|Cognitive Behavioral Therapy (CBT)|Cognitive strategies will identify stressors (e.g., dysfunctional beliefs about sleep) and intervene on worry and rumination with cognitive reappraisal and active coping. Sessions will be conducted by a trained behavioral sleep medicine provider via telemedicine to increase accessibility.
45356215|NCT05424406|Behavioral|Sleep education control|Sleep duration recommendations will be equivalent to the CBT group (8 hours of sleep opportunity) to ensure that outcomes are not confounded by time in bed. Materials in the sleep education control condition will be separated into weekly electronic materials monitored for engagement and completion.
45356216|NCT05423327|Procedure|No Intervention|Single blood draw
45356217|NCT05419934|Behavioral|EMDR therapy|"Children will receive an EMDR psychotherapy comprising 8 treatment phases. As the treatment progresses, the child will proceed to desensitize the events of adversity experienced.~Phase 1 and 2, before the desensitization phases:~History of the patient (collection of anamnesis)~Securing the patient, preparing for the desensitization phases~Desensitization phases, to be repeated for each traumatic event to be desensitized:~Evaluation of the target to be treated~Desensitization~Installation of positive beliefs~Body scanner (verification of body non-response)~Closure, verification that the patient is in a stable emotional state allowing him to leave the session~Reassessment phase, to be repeated for each traumatic event that has been desensitized:~Reassessment of the traumatic target, verification of complete desensitization."
45356218|NCT05419934|Behavioral|Routine Care|Children in the routine care group receive psychological monitoring administered by the Lenval Foundation (CHU de Nice - France) within the Pediatric Psychotrauma Assessment Center (Centre d'évaluation du psychotraumatisme pédiatrique - CE2P). The proposed treatment is a psychological follow-up associated with relational support psychotherapy
45478424|NCT05326997|Device|Photobiomodulation group|Participants will have their face sanitized with micellar water (a cosmetic product for cleaning and makeup remover), followed by cleaning with soap. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light. After the session the face will receive sunscreen. A placebo cosmetic will be given to the participant to be applied twice a day and daily sunscreen.
45356219|NCT05418972|Drug|Relatlimab and nivolumab fixed dose combination (FDC)|Lymphocyte activation gene-3 (LAG-3) and programmed death-1 (PD-1) are two distinct inhibitory immune checkpoints that are often co-expressed on tumor-infiltrating lymphocytes, thus contributing to tumor-mediated T-cell exhaustion. The combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) results in increased T-cell activation compared to the activity of either antibody alone.
45478425|NCT05326997|Other|Group control (Tranexamic acid)|Participants will have their face sanitized with micellar water. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light sham. The person responsible for applying the PBM will simulate the irradiations by positioning the device in the same places described for the PBM group, however, the equipment will be kept off. After the session the face will receive sunscreen. Will be delivered to patients, liposomal tranexamic acid with use 2 x a day home care and daily sunscreen.
45478426|NCT05326438|Behavioral|CIRCLE mHealth app|For the intervention, participants will be given access to an mHealth sobriety app that has been modified for Alaska Native/American Indian people. The app allows people to track their sobriety, learn new recovery skills, track treatment plans, set reminders, journal about their recovery, and discover helpful videos and testimonials through an extensive resource library that includes culturally meaningful content, graphics, music, videos, recovery tools, and testimonials. Users can also participate in an interactive peer platform and/or participate in group chats to engage participants in facilitated discussions about sobriety, lifestyle changes, cultural content, and Community Reinforcement Approach skill-building.
45478427|NCT05325476|Other|JomPrEP App|The JomPreP app will be ideally designed to optimize HIV prevention cascade by providing a virtual platform to access to HIV prevention (e.g., HIV testing and PrEP) and other support services (e.g., mental health). The JomPrEP app will be available on the Apple Store and the Google Play Store for the users to download. However, access to the app will be restricted to the research participant using a unique registration code.
45478428|NCT05325476|Other|Inactivated JomPrEP app|Participants will have access to the JomPrEP app with major intervention features inactivated. Information and resources for HIV testing, PrEP, and available mental health and addiction services will be available along with access to risk assessment tools. The RA will assist in downloading the app and provide a tutorial in using the assessment tool of the app.
45687046|NCT05791227|Diagnostic Test|Sonographer Evaluation|A sonographer will assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd).
45687047|NCT05791227|Diagnostic Test|AI Evaluation|An AI model will assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd).
45843673|NCT04676802|Drug|Opioid capsule|1, Oxycodone 5-mg capsule and 1, placebo capsule per dosage
45843674|NCT04627896|Device|Katty focal therapy|Microwave ablation with TATO3 generator (Katty system) under guidance of ultrasound/mpMRI fusion image device Trinity
45356220|NCT05414136|Drug|BAT1006|Intravenous fluids
45356221|NCT05411731|Other|Conventional physical therapy treatment|"The control group (group A) will receive the exercise program which focused on improving the arm function as well as shoulder abduction and external rotation for 10 week.~stretching Aeroplan positioning"
45356222|NCT05411731|Other|Constraint induced movement therapy|The study group (group B) who will receive Modified constraint induced movement therapy for 3 hrs. a day 12 hrs. a week in addition to the same exercise program given to the control group for 10 weeks.
45356223|NCT05407480|Other|Observational|Descriptive data will be collected to evaluation compliance with the protocol and to evaluate outcome
45356224|NCT05407064|Drug|MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
45356225|NCT05407064|Other|Placebo|A substance that is designed to have no therapeutic value.
45356226|NCT05399043|Other|Multidisciplinary Conventional Neuromotor Rehabilitation|Patients will receive conventional treatment consisting of two daily one-hour session (4 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. Procedures will be adapted according to patient's medical diagnosis, disability severity, and to the consequent rehabilitation objectives in favor of an individualized rehabilitation project and program. If necessary, patients might therefore undergo parallel rehabilitation activities (ie, occupational therapy, speech therapy, cognitive stimulation) that will be kept under control throughout data collection and analyses.
45478429|NCT05315193|Other|Structured In-patient and Home plan|A patient education session and a protocol comprise of 3 days. It consists of three different levels having progressive activities. The in-patient protocol will start from the day of the procedure. Each level contains 2 to 6 tasks, performed in sets of 5-10 repetitions 3 times a day. Home plan: Walking 3 days a week starting from normal pace ((RPE: 8-9) for10 minutes and progressively increased intensity and duration over the period of 12 weeks (RPE: 13-14).
46046863|NCT05085236|Procedure|Fu's subcutaneous needling (FSN)|physician will use a disposable Fu's subcutaneous needling (FSN) to penetrate the subject's skin in the middle from elbow lateral epicondyle to radial styloid process. Then physician will push forward the needle parallel to the skin surface. the physician will sway the needle 100 times in a minute. After procedure of swaying needle, the physician will instruct subject to do several movements, and each movement will perform 10 seconds and rest 10 seconds for 3 repetitions. The movements are active isometric elbow flexion, active isometric shoulder internal rotation, passive shoulder external and internal rotation. After above re-perfusion approach of muscles, the physician will take out the needle to finish the treatment.
45356227|NCT05399043|Device|Technology-based Rehabilitation|"According to their individualized rehabilitation project, patients will undergo RAT or non-immersive VR-based rehabilitation.~RAT will consist of three times a week one-hour session (4 weeks) and will be conducted by the implementation of an exoskeleton device for the upper limbs (Armeo-Spring™) or for the lower limbs (Lokomat™).~VR-based rehabilitation will consist of one daily one-hour session (4 weeks) and will be conducted by the implementation of a single non-immersive VR device among the Riablo™ (Corehab, Italy), the ProKin 252™ (TechnoBody SRL, Italy), the D-Wall™ (TechnoBody SRL, Italy), the Walker View™ (TechnoBody SRL, Italy).~Part of the duration of the whole treatment will be dedicated to the use of the device, resulting in the same amount of rehabilitation for all participants."
45356228|NCT05392504|Other|Core stability exercise|The core stability training consist of three phases
45356229|NCT05392504|Other|Scroth's Program|The Schroth program include exercises for rotational breathing, spinal elongation, deflexion, stretching, de-rotation, and strengthening
45356230|NCT05388604|Device|RF device|The entire defined treatment area will then be treated by delivering adjacent pulses with minimal overlap of 10% or less. Parameters may be adjusted throughout the treatment in order to increase subject comfort.
45356231|NCT05388604|Device|Microneedling device|"Test spots may be performed prior to the first treatment. Test spots may be performed prior to the first treatment. It will follow a similar procedure to treatment but only in an inconspicuous place, such as behind the ear, in an area no larger than 2in x 2in.~The tip will be placed in contact with the skin, and parameters may be adjusted throughout the treatment and will determined by the Clinician."
45356232|NCT05385484|Behavioral|Receives mobile banking account with incentives to save|Participants will receive assistance in opening and using a mobile savings account, will be given education emphasizing saving practices and will be told about lottery-based incentives opportunities.
45478430|NCT05315193|Other|Conventional Therapy|"In-Patient: Wound care, Bed mobility:~AROMS (10 Reps*3sets*TD), Breathing Exercise (10 Reps*3sets*TD), Mobilization (Walk as per patient tolerance) Patient Education: To keep the heart healthy Diet Avoid strenuous exercise and lifting heavy objects Avoid valsalva manure, Quit smoking Lower cholesterol levels, Maintain a healthy weight Control other conditions, such as diabetes and high blood pressure Take medications as prescribed by your doctor Get regular exercise: Walking at a normal pace as per tolerance (RPE up to 10)"
45478431|NCT05309629|Drug|QL1706|Intravenous infusions of QL1706 5mg/kg on Day 1 of every 21-day cycle.
45478432|NCT05309629|Drug|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle for 4-6 cycles.
45478433|NCT05309629|Drug|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for 4-6 cycles.
46046864|NCT05085236|Procedure|Rehabilitation|Rehabilitation mentioned here is the regular rehabilitation programs for treating post-stroke hemiplegic shoulder pain prescribed by the rehabilitation physician.
46046865|NCT02882750|Other|EORTC QLQ-C30 (version 3.0).|Quality of Life Questionnaire
46046866|NCT02882750|Other|PS Q18|Patients Satisfaction Questionnaire
46046867|NCT02882750|Other|Decision Self-Efficacy Scale|Questionnaire
46046868|NCT01117766|Drug|Pregabalin|Dose titration according to following regimen: 75mg BID for 3 days; 150mg for 4 days; 225mg BID for 4 days; 300mg BID for 17 days. Dose reduced for renally impaired patients
46046869|NCT01117766|Drug|Placebo|BID dosing for 28 days
45356233|NCT05377541|Procedure|Surgical treatment of femur fracture|Definitive surgical treatment of femur fracture.
45478434|NCT05307380|Diagnostic Test|"functional pain scale"|French translation of the Defence and Veterans Pain Rating Scale (DVPRS)
45478435|NCT05307211|Procedure|Cervical Interlaminar Epidural Steroid Injection|Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. The injection area is cleaned 3 times with an antiseptic solution and covered with a sterile cloth. Local anesthesia with 2 ccs 3% prilocaine will be applied to the skin and subcutaneous tissues in the area of interest. Under fluoroscopy guidance, the needle is advanced into the C7-T1 intervertebral disc level. With the help of the loss of resistance technique, it is understood that the needle is in the epidural space, and second control is provided by administering contrast material. After the confirmation of needle place is done, a mixture of 12 mg dexamethasone, 1 cc 2% lidocaine, 1 cc saline is injected. The patient is taken to the restroom after the procedure and followed up for any complications.
46046870|NCT02883686|Behavioral|Alma|Alma peer-mentoring
45478436|NCT05307211|Other|Neck Stabilization Exercises|The physiotherapist will design an exercise protocol for neck stabilization. Each exercise will be applied three days a week throughout a 4-week program, accompanied by a physiotherapist, and will begin with 7 to 10 repetitions at first, increasing to 10 to 15 repetitions in the following weeks, taking into account the patient's condition. After the physiotherapist-assisted exercises are completed, the protocol will continue as home-based exercises until the assessments are completed.
45478437|NCT05307211|Other|Neck and Scapular Stabilization Exercises|The physiotherapist will design an exercise protocol for neck and scapular stabilization. Each exercise will be applied three days a week throughout a 4-week program, accompanied by a physiotherapist, and will begin with 7 to 10 repetitions at first, increasing to 10 to 15 repetitions in the following weeks, taking into account the patient's condition. After the physiotherapist-assisted exercises are completed, the protocol will continue as home-based exercises until the assessments are completed.
45478438|NCT05303467|Device|TheraSphere GBM|Single treatment of TheraSphere GBM device
45478439|NCT05297565|Biological|Nivolumab/rHuPH20|Specified dose on specified days
45478440|NCT05297565|Biological|Nivolumab|Specified dose on specified days
45478441|NCT05283044|Biological|biopsy liquid|Patient performs a blood test at treatment baseline
45843675|NCT04278768|Drug|Emavusertib|Emavusertib is formulated as a tablet for oral administration for BID dosing in consecutive 28-day cycles. Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4),IRAK4 kinase plays an essential role in toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways and these pathways are frequently dysregulated in non-Hodgkin's lymphoma and AML/MDS malignancies.
46046871|NCT04312880|Drug|Tranexamic Acid|IV and topical form of TXA will be administered to patients in the respective groups.
46046872|NCT01117454|Drug|Flecainide Acetate|oral flecainide with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml
46046873|NCT01117454|Drug|Placebo|placebo, similar in appearance to flecainide
46046874|NCT01117454|Drug|Beta blocker|Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.
46046875|NCT01116440|Drug|BGS649|0.1 mg capsules for oral administration. A total dose of 3 capsules of BGS649 0.1mg will be administered at randomization, week 4, and week 8 at the study site.
45356234|NCT05377112|Drug|SYNB8802v1|"SYNB8802v1 is an orally administered, non-systemically absorbed live biotherapeutic developed for the treatment of EH. The strain converts oxalate to formate and CO2, two naturally occurring GI metabolites.~SYNB8802 was developed by engineering a pathway for oxalate degradation in a probiotic strain of Escherichia coli Nissle 1917 (EcN). It is intended to act within the GI tract to reduce the oxalate levels in patients with EH by converting oxalate to formate and CO2, two naturally occurring GI metabolites."
45478442|NCT05279300|Drug|CS5001|CS5001 will be administered every 3 weeks (21 days) by intravenous (IV) infusion, and 3 weeks (21 days) is considered as one treatment cycle.
45843676|NCT04278768|Drug|Azacitidine|Azacitidine is a chemotherapy drug. Azacitidine 75 mg/m2 intravenous (IV) or subcutaneously (SC) will be administered as 7 doses on a 28-day Cycle.
46046876|NCT01116440|Drug|Placebo|Placebo matching BGS649 will be provided by Novartis as capsules for oral administration. Three capsules of placebo will be administered at randomization, week 4, and week 8 at the study site.
45356235|NCT05377112|Other|Placebo|placebo powder will be aliquoted into high density polyethylene (HDPE) bottles and diluted in the same formulation buffer as SYNB8802v1 lyophilized powder. The placebo consists of corn starch and dyes to color match the placebo to the SYNB8802v1 powder for oral suspension
45356236|NCT05354557|Drug|Iberdomide|Patients will receive 12 cycles of iberdomide as maintenance therapy. Cohort 1: Cycle 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles Cohort 2: Cycles 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles
45356237|NCT05354362|Combination Product|ATG-010 and ATG-008|Patients enrolled will receive consecutive daily treatment at assigned dose level. The starting dose of ATG-010 at the dose escalation phase will be 60 mg QW, which could be escalated to 80 mg QW, 100 mg QW, 60 mg BIW. In case 60 mg QW of ATG-010 with any dose of ATG-008 is NOT tolerable, 40 mg QW ATG-010 could be explored. The starting dose of ATG-008 will be 15 mg QD, which could be escalated to 20 mg QD, with maximum of 30 mg QD. SRC will be consulted before each dose escalation starts.
45356238|NCT05351736|Drug|Lurasidone|Treatment with lurasidone
45356239|NCT05343065|Device|BlueStar 10|An app that coaches individuals with diabetes and supports insulin-dosing based on continuous glucose monitor data
45356240|NCT05337098|Other|Non-Nutritive Sweetener Intake and impact on glucose homeostasis|Provision of either aspartame, sucralose, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.
45356241|NCT05335928|Drug|Abatacept plus|"Up to 4 study drug infusions at 10 mg/kg, IV~Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC"
45687048|NCT05786378|Biological|Platelet Rich Plasma|"Sample of patient's blood drawn at time of Treatment; the blood drawing occurs with addition of anticoagulant such as citrate dextrose A to prevent platelet activation prior to its use.~Obtain whole blood by venipuncture in acid citrate dextrose (ACD) tubes. Centrifuge the blood using a 'soft' spin. Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant).~Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate.~The lower 1/3rd is PRP and upper 2/3rd is platelet-poor plasma (PPP). At the bottom of the tube, platelet pellets are formed.~PRP activation prior to injection. PRP can be activated exogenously by calcium chloride."
45843677|NCT04278768|Drug|Venetoclax|Ventoclax is B-cell lymphoma-2 (BCL-2) inhibitor. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level.
45843678|NCT04278768|Drug|Emavusertib|Emavusertib is formulated as a tablet for oral administration for BID dosing for 21 days (Days 1-21) of a 28-day Cycle.
45843679|NCT04174482|Procedure|morphological and functional evaluation of adult flat foot|Evaluations are realized by weight bearing computed tomography and by Gait analysis in the pre-operative phase and at a 6-months follow-up from the surgery with Grice technique
45843680|NCT04126590|Biological|KN044|"The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg."
45843681|NCT04068948|Drug|Meperidine|This intervention assesses a child's behavioral outcome for dental procedural sedation in combination with midazolam and hydroxyzine. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
45843682|NCT04068948|Drug|Hydroxyzine|This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
45843683|NCT04068948|Drug|Midazolam|This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
46046877|NCT04311944|Other|Early fast-track care|Participants will be eligible for fast-track care at 8 weeks if their HIV-1 RNA is <200 copies/mL and they meet other eligibility criteria. If HIV-1 RNA is 200 copies/mL or higher at 8 weeks, then it will be repeated at 12 weeks, and those with HIV-1 RNA <200 copies will then be eligible for fast-track care, if they meet other eligibility criteria.
46046878|NCT04311944|Other|Standard (deferred fast-track) care|Participants will be eligible for fast-track care at 24 weeks, if their HIV-1 RNA is <200 copies.mL, and they meet other eligibility criteria.
46046879|NCT01129622|Drug|letrozole|Letrozole (12.5 mg/day ) which is higher than the dose routinely used for therapeutic indications is given for a brief duration (3 successive days) aiming to promote acute aromatase inhibition suitable for pre-diagnostic regimens.
46046880|NCT04311398|Diagnostic Test|New QIAstat-Dx fully automatic multiple PCR detection platform|We use the New QIAstat-Dx fully automatic multiple PCR detection platform to test the enrolled patients
45356242|NCT05335928|Drug|Placebo|Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC
45356243|NCT05324293|Drug|HMI-115|Once Every 2 weeks, subcutaneously injection
45356244|NCT05319561|Other|Antibiotic Use Report|"The Antibiotic Use Report uses both text and graphics to communicate successes and improvement opportunities specific to the VAMC for which it is prepared. The graphs summarize overall antibiotic use over the previous year, with additional information regarding use of broad- and narrow-spectrum agents. Further, each Antibiotic Use Report compares or benchmarks the individual VAMC for which it is prepared to other VAMCs in the same Medical Complexity Group. This approach adapts and expands peer comparison, which has proven effective at reducing inappropriate antibiotic use in outpatient settings."
45356245|NCT05310721|Behavioral|Early time-restricted eating|Participants will eat ad libitum within an 8-hour early eating window starting not later than 10am. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
45356246|NCT05310721|Behavioral|Late time-restricted eating|Participants will eat ad libitum within an 8-hour late eating window starting not earlier than 1pm. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
45356247|NCT05310721|Behavioral|Self-selected time-restricted eating|Participants will self-selected an 8-hour eating window to eat ad libitum. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
45356248|NCT05310097|Behavioral|CPT|CPT will be delivered over the course of 12 one-hour weekly sessions (maximum of 18 weeks to complete treatment). Participants will have the option of receiving CPT in-person or via videoconferencing.
45356249|NCT05310097|Behavioral|MS|The MS protocol consists of eight strategies: categorization, evaluation, application, cue-based reminders, practice remembering, attention recruitment, praising recall, and repetitions.
45356252|NCT05286957|Drug|adjuvant tislelizumab and chemotherapy for MRD+ patients|"MRD+ patients receive adjuvant tislelizumab and chemotherapy while MRD- patients just is recommended receive adjuvant chemotherapy untill be detected MRD+~adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)"
45356253|NCT05286957|Drug|adjuvant tislelizumab and chemotherapy for MRD+ patients|patients receive adjuvant tislelizumab and chemotherapy regardless of MRD status
45356254|NCT05286957|Drug|adjuvant chemotherapy for MRD- patients|MRD- patients just be recommended receive adjuvant chemotherapy untill be detected cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion, limited to ≤4 cycles
45356255|NCT05282108|Drug|Carcemia|Generic Imatinib
45356256|NCT05282108|Drug|Glivec|Imatinib
45843684|NCT03979560|Other|Intervention|Nutritional support in seven sessions spread over three months, combined with an adapted physical activity intervention (APA), also at a frequency of seven sessions spread over three months, or fourteen home sessions.
45356257|NCT05275751|Drug|TRPA1-inhibitor|Pharmacological inhibition of TRPA1 during intradermal injection of hot synthetic interstitial fluid
45843685|NCT03828708|Other|Iron in infant formula|Participants will receive the same low-iron (5 mg/L) infant formula. Infants in the standard iron group will add iron supplement to pre-made infant formula so the iron content will be 12 mg/L.
45843686|NCT03768570|Drug|Durvalumab|1500 mg IV on day 1 of 4 week cycle every 4 weeks for 12 months
45843687|NCT03685110|Device|CoreHip Total Hip Arthroplasty|Replacement of the Hip Joint
45478443|NCT05271032|Diagnostic Test|use of Trasnpulmonary termodiluetion technique|All the patients underwent to invasive hemodynamic monitoring through the transpulmonary thermodilution technique (PiCCO, PULSION medical system. Gettinge; Solna, Sweden). Briefly, the technique consists in the administration of a cold saline bolus in superior vena cava while monitoring the corresponding temperature variation through a femoral arterial catheter equipped with a tip thermistor. Accordingly, a 5 French catheter equipped with a tip thermistor was inserted into the femoral artery.
45478444|NCT05269433|Behavioral|OCAT-sham|Placebo version of the online contingent attention training preceded by a psycho-education movieclip.
45478445|NCT05269433|Behavioral|OCAT|Online contingent attention training preceded by a psycho-education movieclip.
46046881|NCT02882672|Other|Experimental|Doing exercise at 60-85% of maximal heart rate, lasted 45-60 minutes and included a 10-minute warm-up, 40 minutes of aerobic exercises, consisting of stationary cycling, walking and/or jogging
45356258|NCT05275751|Drug|TRPV1-inhibitor|Pharmacological inhibition of TRPV1 during intradermal injection of hot synthetic interstitial fluid
45478446|NCT05269433|Other|Psycho-education video|All groups watch a psycho-education video before the start of the 10-day attention training.
45478447|NCT05269433|Other|Motivational video|Participants in the OCAT+ condition watch a short motivational video before each training session.
45478448|NCT05267912|Procedure|Biopsy|We need a biopsy for PDO: PDOs are tridimensional multicellular structures expanded in vitro which retain the genotypic and phenotypic features of their tissue or tumor of origin. PDOs can be exposed to a panel of drugs (chemotherapy, hormonal therapy, targeted therapy) in order to study their sensitivity to each agent (or combination of agents) tested ('chemogram'). Recent studies showed that PDOs can accurately predict the response to treatment of solid tumors and could therefore inform clinical decision on the best therapeutic option for each patient.
46046882|NCT02882672|Other|Control|They did not do ant exercise training during 8 weeks.
45356259|NCT05275751|Drug|TRPM3-inhibitor|Pharmacological inhibition of TRPM3 during intradermal injection of hot synthetic interstitial fluid
46046883|NCT01128842|Drug|Neratinib|240 mg once daily by mouth.
45356260|NCT05275751|Drug|Placebo|No pharmacological intervention
45356261|NCT05275751|Drug|Chloride-channel inhibitor|Pharmacological inhibition of a chloride channel during intradermal injection of hot synthetic interstitial fluid
45478449|NCT05267106|Drug|Pemigatinib|13.5mg tablet taken every morning (unless otherwise directed) for 2 weeks and then 1 week off.
45478450|NCT05262517|Drug|Rimegepant|75 mg ODT
45478451|NCT05262517|Drug|Placebo|matching placebo
45478452|NCT05258578|Behavioral|Tele-CBT|The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and problem solving and challenging negative thoughts. Participants are encouraged to complete CBT homework between sessions (i.e., completing food records, pleasurable activities and worksheets).
45478453|NCT05258578|Other|Self-Help Resources|Participants will be directed to the CAMH COVID-19 Self-Help webpage (www.camh.ca/covid19) to access coping tools to help with COVID-19 associated stress and anxiety, loss, grief and healing, stigma, and physical isolation.
45478454|NCT05252052|Other|Interviews/Surveys|This is a cross sectional survey and interviews of adolescents 14- 18 years old and HCPs living in rural Haiti
45478455|NCT05248997|Drug|rimegepant 75 mg ODT|One dose of rimegepant 75 mg ODT
45478456|NCT05248997|Drug|Matching placebo|One dose of matching placebo
45356262|NCT05268133|Dietary Supplement|Aronia|As described in experimental arm
45356263|NCT05268133|Dietary Supplement|Control|As described in placebo comparator arm
45478457|NCT05245747|Device|Vitls Tego Device|The Tégo VSS Sensor is a battery-operated adhesive patch with integrated sensors and wireless transceiver which is worn on the upper body and records heart rate (HR), respiration rate, blood oxygen levels (SpO2), and body temperature. The Tégo VSS Sensor continuously gathers multiparameter physiological data from the person being monitored and then transmits the encrypted data via bi-directional communication to a third-party connectivity relay.
45478458|NCT05243537|Other|ECG (diagnostic)|ECG collection (once, at rest), in both cases and controls
45478459|NCT05235568|Device|VALVOSFT intervention|Treatment of the calcific aorta valve by non-invasive ultrasound therapy
45478460|NCT05231785|Drug|ALN-APP|ALN-APP will be administered intrathecally (IT)
45478461|NCT05231785|Drug|Placebo|Placebo will be administered IT
46046884|NCT01128842|Drug|Capecitabine|1500 mg/m^2 twice daily by mouth.
46046885|NCT00625274|Drug|Esomeprazole|40mg Oral
46046886|NCT00625274|Drug|Lansoprazole|30mg Oral
46046887|NCT00625274|Drug|Pantoprazole|40mg Oral
46046888|NCT03624036|Biological|brexucabtagene autoleucel|CAR-transduced autologous T cells administered intravenously
46046889|NCT03624036|Drug|Fludarabine|Administered intravenously
46046890|NCT03624036|Drug|Cyclophosphamide|Administered intravenously
46046891|NCT01143038|Biological|Romiplostim|Romiplostim will be administered weekly by subcutaneous injection
46046892|NCT00966264|Drug|LNG-IUS|LNG-IUS releasing 25 microg of levonorgestrel
46046893|NCT00966264|Procedure|Hysterectomy|operation
45478462|NCT05226507|Drug|NXP800|NXP800 is an anti-neoplastic, oral small molecule.
45478463|NCT05226091|Behavioral|Letter|Selected GP practices currently registered with CPRD will receive correspondence by both email and mail informing them about the result of the PLEASANT study and advising them how to implement what has been learnt. Included in the mailing would be a suggested letter and SMS text.
45843688|NCT03671304|Device|Fitbit Versa|"Participants will receive a Fitbit Versa and instructions on its use. Participants will be asked to wear the device for eight weeks, removing it only for charging and when engaging in activities in which the device could be submerged in water (bathing, swimming, etc.).~At enrollment, participants will indicate a preferred time to receive affective framing messages and EMA prompts (morning), and intention planning prompts (evenings). Participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days."
45843689|NCT03517722|Drug|Placebo|Participants will receive placebo matching to ustekinumab IV or SC.
45356264|NCT05262725|Behavioral|Values-based Behavioral Activation|Initially, patients complete a values assessment in which they identify personal values in various life domains. With the assistance of a clinician, patients set incremental behavior goals to move their daily actions to better align with their self-reported values. Goal completion allows the patient to achieve outcomes consistent with recovery, and they potentially experience enjoyment, self-efficacy, and confidence as they progress through the treatment.
45356265|NCT05255276|Drug|Sitravatinib 50 mg|50 mg Sitravatinib on Day 1 (Group 1A)
45356266|NCT05255276|Drug|Sitravatinib 100 mg|100 mg Sitravatinib on Day 1 (Group 2A)
45356267|NCT05255276|Drug|Itraconazole|Itraconazole QD from Day 9 to Day 18, and Sitravatinib 50 mg at Day 12 (Group 1B)
45356268|NCT05255276|Drug|Rifampin|Rifampin QD from Day 9 to Day 22, and Sitravatinib 100 mg at Day 16 (Group 2B)
45356269|NCT05253833|Drug|AR882 Dose 1|Solid Oral Capsule
45356270|NCT05253833|Drug|AR882 Dose 2|Solid Oral Capsule
46046894|NCT00915525|Biological|botulinum toxin Type A|Botulinum toxin Type A 100U or 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
45356271|NCT05253833|Drug|Allopurinol Tablet|Solid tablet
45356272|NCT05252858|Device|nCAP Signal Relief Patch|nCAP Signal Relief Patch post-operatively applied to the subject's surgical dressing by a trained researcher in the immediate Post Anesthesia Care Unit (PACU)
45478464|NCT05212688|Other|Acupuncture|Weekly treatment of 15 minutes for 6 weeks using Seirin 36 g 30 mm needles applied to two upper midline sternal points, thoracic paravertebral points, 5 pairs, 2 bilateral Trapezius trigger points, LI4, TE5, ST36, GB34, SP6, LR3 bilaterally, GV20 & GV24 midline.
45478465|NCT05212688|Other|Active Control|Weekly contact once per week for 6 weeks for a semi-structured telephone consultation.
45478466|NCT05209620|Drug|ICP-022|"Induction Chemotherapy: Orelabrutinib, 150mg/d continuous oral administration (3 weeks/cycle, total 6 cycles).~Maintenance Treatment: Orelabrutinib, 150mg/d continuous oral administration (28d/cycle)."
45478467|NCT05209620|Drug|Pemetrexed|Induction Chemotherapy: Pemetrexed, 500mg/m2, Intravenous administration on day 5 of each 3-week cycle (Total 6 cycles).
45478468|NCT05206695|Behavioral|Multi-condition Pathway Intervention|See Experimental/Arm 1 description
45478469|NCT05204836|Drug|Zoledronic Acid Injection|5 mg / 100 mL intravenous infusion
45478470|NCT05204836|Drug|Placebo|100 mL intravenous infusion
46046895|NCT04682379|Diagnostic Test|Repositioning|"Trunk circumduction test~Trunk flexion-hyperextension test~Trunk lateral flexion test~Trunk axial rotation test~Finger-to-Nose test~Fukuda stepping test"
45478472|NCT05192642|Drug|Larotrectinib(Vitrakvi, BAY2757556)|Clinical trials
45478473|NCT05192642|Drug|Data on other treatments|Real word data
45478474|NCT05184062|Drug|600 mg AZD7442 IV|Participants will be randomized to receive co-administration of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by a single IV infusion.
45478475|NCT05184062|Drug|600mg placebo IV|Participants will be randomized to receive co-administration of 600mg placebo by a single IV infusion.
45478476|NCT05182788|Dietary Supplement|Placebo pressed candy|consume 2 tablets per day for 8 weeks
45478477|NCT05182788|Dietary Supplement|CHOLESWISE pressed candy|consume 2 tablets per day for 8 weeks
45843690|NCT03517722|Drug|Ustekinumab (approximately 6 mg/kg)|Participants will receive ustekinumab approximately 6 mg/kg via IV route based on body weight-range.
46046896|NCT04708041|Biological|9vHPV vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
46046897|NCT04673565|Behavioral|Motivational interviewing|Each participant in the treatment group will attend a 1-hour MI group session with 9 other participants hosted by a practicing MI therapies via Zoom at one month after the initial visit. This session will utilize MI to elicit motivation in each participant. Participants will also receive standard care delivered at in-person audiology clinic visits.
46046898|NCT04669041|Drug|Rosuvastatin|Pharmaceutical form:Tablet Route of administration: Oral
46046899|NCT04669041|Drug|SPC ezetimibe/rosuvastatin|Pharmaceutical form:Tablet Route of administration: Oral
46046900|NCT04669041|Drug|Rosuvastatin active capsule|Pharmaceutical form:Capsule Route of administration: Oral
46046901|NCT04669041|Drug|Placebo|Pharmaceutical form:Tablet Route of administration: Oral
45843691|NCT03517722|Drug|Ustekinumab 90 mg|Participants will receive 90 mg ustekinumab via SC route.
45843692|NCT03447990|Drug|MYK-491|Single Ascending Dose and Multiple Ascending Dose of MYK-491
45478478|NCT05166187|Other|Best Practice Advisory|Patients in this arm will have a Best Practice Advisory displayed in the Electronic Medical Record (EMR) as part of the discharge order workflow.
46046902|NCT04669041|Drug|Placebo|Pharmaceutical form:Capsule Route of administration: Oral
45478479|NCT05160532|Drug|Placebo|5ml of normal saline (NS)
45478480|NCT05160532|Drug|Dextrose prolotherapy (DPT)|25% dextrose, mixing 2.5ml of sterile water and 2.5ml of 50% dextrose.
45478481|NCT05156346|Other|LEAVES|LEAVES consists of 10 modules of readings and exercises. Readings are filled with evidence-based information on grief-related topics (e.g., how to positively influence thoughts, emotions and behaviours), followed by exercises which encourage mourners to actively reflect on what was learned and apply their new knowledge into their grief journey and coping strategies (e.g., how to change attentional focus). Users are encouraged to work through one module per week and complete the assignments.
45687049|NCT05786378|Drug|local anesthesia in external auditory canal|local anesthesia cream (lidocaine cream) will be applied in external auditory canal for 15 minutes
45687050|NCT05786378|Procedure|Intratympanic Injection|0.5-1 ml of PRP will be injected in middle ear cavity in round window niche Using microscope or endoscope.
45687051|NCT05786300|Device|NMES+|"The Treatment Group will follow the rehabilitation protocol with the addition of the NMES+.~1st/2nd Week at 35 Hertz. 3rd/4th Week 50 Hertz. 5th/6th Week 70 Hertz."
45687052|NCT05786300|Procedure|Rehab|"The Control Group will follow a protocol based on the latest available guidelines for the rehabilitation of the hamstrings lesions.~A weight-bearing protocol with a week by week progression on load, repetitions and sets."
45687053|NCT05786157|Other|Alcohol Administration|Participants will complete an alcohol administration paradigm (peak breath alcohol concentration=.09-.10 g/dL BrAC)
45687054|NCT05785845|Radiation|Computed tomography-guided stereotactic adaptive radiotherapy|Fractions will be delivered on consecutive business days.
45843693|NCT03447990|Drug|Placebo|Single Ascending Dose and Multiple Ascending Dose of placebo
45843694|NCT03217188|Radiation|conventionally fractionated full dose re-irradiation|re-irradiation [60-70 Gy (RBE) in 2 Gy (RBE) fractions
45356273|NCT05252858|Other|Standard of Care|Subjects will undergo surgery using the approved ERAS anesthetic and post-operative pain management protocols. At Shadyside Hospital, the ERAS Protocol for these subjects involves preoperative meloxicam 15mg PO, gabapentin 300mg PO, acetaminophen 1g PO. Intra-operative, patients receive a spinal block (bupivacaine) and propofol IV sedation. Postoperative pain medication is titrated to the individual patient's level of pain (0-10). 0.2 mg IV hydromorphone can be given for breakthrough pain, oxycodone 5mg PO for moderate pain (4-6) and oxycodone 10 mg PO for severe pain (7-10). Ketorolac 15 mg IV is given Q6H during the hospital stay. Discharge medication may be Norco 5-325mg as prescribed by the surgeon.
45478482|NCT05153304|Biological|personalized vaccine|Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
45478483|NCT05153304|Drug|Nivolumab|3mg/kg nivolumab will be administered intravenous (IV) infusion every 3 weeks for 4 doses. After 4 doses, 480 mg nivolumab will be administered intravenous (IV) infusion every 4 weeks.
45478484|NCT05143203|Other|Self-hypnosis training|Self-hypnosis training will be conducted in two phases and the evaluation of effectiveness of the training will be measured using GAD7, PHQ9 and PROQOL questionnaires
45356274|NCT05243199|Drug|Sacubitril/Valsartan|The initial dose of 50mg Qd was increased to 50mg Bid after 1 week and maintained to 100mg Bid after 2 weeks if the patient could tolerate it (no follow-up exit criteria were found).
45478487|NCT05121844|Device|Continuous Glucose Monitor Device|Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.
45478488|NCT05116046|Biological|Recifercept|Recifercept
45478489|NCT05114252|Device|Vivid Vision Home|The study intervention consists of playing serious games (Vivid Vision, San Francisco, USA) embedded in a virtual reality headset in a home environment 5 days a week for 30 minutes over 8 weeks (20 h of total gaming).
45478490|NCT05114252|Behavioral|Refractive error correction|The control intervention will be refractive error correction that consists of wearing the lenses with the prescribed correction for 2 months.
45478491|NCT05109728|Drug|[177Lu]Lu-DOTA-TATE|"Group 1: [177Lu]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 4 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed.~Group 2: [177Lu]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 4 weeks (Day 1, Day 29 and Day 57) and every 3 weeks in Maintenance phase. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed.~Group 3: [177Lu]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 3 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed."
45478492|NCT05109728|Drug|[68Ga]Ga-DOTA-TATE|2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
45478493|NCT05109728|Other|Temozolomide|"Concomitant Phase: Temozolomide 75mg/m2/d p.o until last day of EBRT.~Maintenance Phase: Temozolomide p.o 150 mg/m2/d during cycle 1 then 200 mg/m2/d for the following cycles if tolerated well in Cycle 1. 6 cycles total (1 cycle = every 28 days)"
45478494|NCT05109728|Other|Radiotherapy|2 Gy/day, 5 days per week followed by 2 days of rest, for 6 consecutive weeks
45478495|NCT05103332|Drug|Olmesartan|Olmesartan administered orally
45478496|NCT05103332|Drug|Amlodipine|Amlodipine administered orally
45478497|NCT05103332|Drug|Indapamide|Indapamide administered orally
45478498|NCT05103332|Drug|Placebo|Placebo administered by subcutaneous (SC) injection
45356275|NCT05243199|Drug|Irbesartan|The Initial dose of 75 mg Qd with sand, such as patients can tolerate and follow-up exit criteria (not appear, to 75 mg Bid to maintain after 1 week, 2 weeks can still be tolerance is raised to 150 mg Bid.
45356276|NCT05235464|Other|Standard meal|Standard meal
45356277|NCT05235464|Other|High animal protein meal|Meal with high animal protein content
45478499|NCT05103332|Drug|Zilebesiran|Zilebesiran administered by SC injection
45478500|NCT05101070|Drug|S-531011|Administered by intravenous infusion
45478501|NCT05101070|Drug|Pembrolizumab|Administered by intravenous infusion
45478502|NCT05098938|Drug|Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773|Oral (upper gum area), 50mg, 1 tablet.
45478503|NCT05098938|Drug|Placebo|Oral (upper gum area), 1 table.
45478504|NCT05085210|Device|transcranial random noise stimulation (tRNS)|noninvasive current stimulation for 20 - 30 minutes stimulation on visual cortex (electrodes on surface of scalp, positioned O1 / O2 on EEG cap). 1mA max amplitude noise stimulation, frequencies from 100 Hz - 640 Hz.
45478505|NCT05085210|Behavioral|Computer Based Visual Training|Dynamic visual stimuli are presented on specific locations of the visual field. Participant holds fixation on center of screen during presentation of visual stimuli. Participants will be presented with multiple trials of a motion discrimination task. Training will be performed for 2 weeks (10 consecutive weekdays), 30 minutes each day.
45478506|NCT05085210|Device|Sham stimulation|20-30 minutes sham stimulation on visual cortex. Participants receive identical setup to real stimulation. The device provides a short ramp on period to simulate the feeling of real stimulation at the start but no current is delivered otherwise.
45687055|NCT05785845|Device|ETHOS|ETHOS is a unique ring-gantry CT-guided linear accelerator notable for having an on-board cone beam CT (CBCT) imaging unit with improved definition and resolution to enable target and organ-at-risk contouring. It also has a dedicated artificial intelligence treatment planning system to allow for online adaptive radiotherapy.
45687056|NCT05783232|Dietary Supplement|Placebo Control Form 1 Capsules|Participants will use their Placebo Control Form 1 Capsules as directed for a period of 4 weeks.
45687057|NCT05783232|Dietary Supplement|Health Active Study Product 1.1 Capsules|Participants will use their Radicle Health Active Study Product 1.1 Capsules as directed for a period of 4 weeks.
45356278|NCT05235464|Other|High plant protein meal|Meal with high plant protein content
45687058|NCT05783232|Dietary Supplement|Health Active Study Product 1.2 Capsules|Participants will use their Radicle Health Active Study Product 1.2 Capsules as directed for a period of 4 weeks.
45356279|NCT05235464|Other|High plant protein meal with additional leucine|Meal with high plant protein content and additional leucine
45687059|NCT05783232|Dietary Supplement|Health Active Study Product 1.3 Capsules|Participants will use their Radicle Health Active Study Product 1.3 Capsules as directed for a period of 4 weeks.
45356280|NCT05229211|Device|Cardiac monitoring|Continuous ECG monitoring via VitalConnect patch worn on the chest.
45478507|NCT05078970|Behavioral|Safety Planning Intervention+ (SPI+)|SPI is focused on how the risk of suicidal crisis waxes and wanes over time. At times of heightened risk, a pre-specified and individualized plan targets the internal warning signs that become the cue to use the safety plan. SPI+ strategies focus on patient's narrative of the suicidal crisis and identifying solutions that are antithetical to progressing in a suicidal crisis. The brief structured intervention is conducted in six key steps. Youth in this condition will be offered weekly follow-up, with a minimum of 4 sessions and a maximum of 8 sessions. The goal is to create a crisis response plan to reduce risk when suicidal crises emerge. With adolescents, SPI+ consists of an individual session to elicit crisis narrative and motivation to utilize the safety plan through psychoeducation and follows six steps to achieve the adolescent's goals and return to safety when suicidal urges are high.
45478508|NCT05078970|Behavioral|Collaborative Assessment and Management of Suicidality (CAMS)|CAMS strategies focus on collaborative deconstruction and treatment of the patient-defined drivers- the problems that make suicide compelling to the patient- and utilizes these problem-focused treatment sessions to treat the drivers as directly related to wish to die. Participants will be assigned to CAMS for a minimum of 4 sessions and maximum of eight sessions. This time frame, based on initial data from our pilot work with adolescents and emerging adults (18-25), suggests that a subset of participants resolve their STB in six to eight sessions. CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients.
45687060|NCT05782738|Procedure|Percutaneous Coronary Intervention|Use dedicated two stents technique for treatment of coronary bifurcation stenosis
45687061|NCT05781880|Other|Oxygen 100%|NBO therapy were given 100% oxygen via a face mask (10L/min for 4h)
45843695|NCT03217188|Radiation|hypofractionated palliative re-irradiation|"course or a hypofractionated palliative re-irradiation Quad Shot course (3.7 Gy (RBE) twice daily x 2 days, followed by a 4 week break [+/- 2 weeks], repeated up to 4 cycles)."
45356281|NCT05227716|Drug|Perioperative magnesium sulfate|Administration of magnesium sulfate as an adjunct in anesthesia
45356282|NCT05218343|Behavioral|"EHR-based nudge interventions"|Change/introduction of default drug and frequency during electronic prescribing of high-risk drugs for a patient aged ≥65 years
45356283|NCT05217433|Other|Olive leaf extract|The investigational product is a capsule containing 100mg of the active ingredient oleuropein and will be provided once daily in the form of a 250mg olive leaf extract (i.e. 100mg of oleuropein per day) product for the duration of the intervention period (36 days).
45356284|NCT05217433|Other|Placebo|The control will be a placebo capsule containing 336 mg of cellulose microcrystalline, matching the investigational product appearance.
45356285|NCT05201248|Drug|Epcoritamab|Subcutaneous Injection (SC)
45356286|NCT05201248|Drug|Cyclophosphamide|IV Injection
45356287|NCT05201248|Drug|Rituximab|Intravenous (IV) Infusion
45356288|NCT05201248|Drug|Doxorubicin|IV Infusion
45356289|NCT05201248|Drug|Vincristine|IV Infusion
45356290|NCT05201248|Drug|Prednisone|Oral; Tablet
45356291|NCT05201248|Drug|Lenalidomide|Oral; Capsule
45356292|NCT05199259|Diagnostic Test|Multi-analyte Blood Test|A clinical diagnostic test based upon the detection and quantification of DNA methylation markers in cell-free DNA (cfDNA) isolated from plasma and of tumor-specific proteins isolated from serum.
45478509|NCT05078970|Behavioral|Treatment As Usual|This assigned condition tracks the care received in typical circumstances.
45478510|NCT05074667|Device|Continuous Glucose Monitor|Participants will be provided a continuous glucose monitor for use in self-glucose monitoring as per standard clinical care
45478511|NCT05074667|Other|Patient Reported Outcome Questionnaires|Participants and their parents will be asked to complete patient reported outcome questionnaires at 3 study time points.
45478512|NCT05071183|Drug|TPX-0005|Oral TPX-0005 capsules
45843696|NCT03032640|Other|Oral Glucose Tolerance Test (OGTT)|Once we test the fasting plasma glucose (after an overnight fast), subject will receive a 75g glucose beverage they will have to drink within 5 minutes. Then after drinking the beverage, 8 blood samples will be collected through the IV catheter, over the next 3 hours.
45356293|NCT05196737|Behavioral|Dry Needling|Dry needling is a procedure in which a thin, stainless steel needle is inserted into the skin to produce a muscle twitch response. It is intended to release a knot in a muscle and relieve pain.
45356294|NCT05195996|Drug|Propranolol|intravenous propranolol for case patients
45356295|NCT05195996|Drug|Saline|intravenous saline for placebo
45356296|NCT05195359|Behavioral|Dein Schlaf. Dein Tag. sleep improvement application powered by SleepScore|The Dein Schlaf. Dein Tag. application powered by SleepScore is a validated sleep measurement application using sonar technology that also provides evidenced-based sleep advice and sleep education content based on a user's objectively measured nightly sleep data. As participants engage with the app, the Dein Schlaf. Dein Tag. application provides personalized and dynamic sleep content and sleep and circadian rhythm improvement advice based in the principles of sleep hygiene, sleep-circadian science, and cognitive behavioral psychology. Participants will also receive personalized sleep challenges tailored to improve their sleep and circadian rhythms. Each challenge lasts for 7 tracked nights, ranging from optimizing sleep habits to limiting caffeine intake, and more. Additional sleep improvement features embedded within the app include sleep sanctuary bedroom checks, sleep sounds, smart alarms, bedtime reminders, and sleep education blogs and science content.
45478513|NCT05071183|Drug|Trametinib|Oral trametinib tablets
45478514|NCT05068726|Drug|18F Fluoroestradiol Radiopharmaceutical with PET/CT|Administration of one dose of 18F FES for PET/CT imaging
45843697|NCT03032640|Other|Assessment of dietary compliance|Assessment of consumption of non-caloric artificial sweeteners
45843698|NCT03032640|Other|Stool sampling|Subjects will provide a stool sample.
45478515|NCT05060653|Other|SBRT followed by surgical stabilization within 24-48 hours|In a first step, patients will undergo SBRT with active sparing of the surgical site. Patients will receive high dose, single to few fractions radiotherapy consisting of a boost to the metastases exclusively. The bony compartment containing the metastatic lesion will receive an elective dose in order to treat subclinical disease. Treatment planning is performed on the pre-treatment CT and MRI data in radiotherapy position that are mutually registered to yield information on all relevant structures for planning. Dose constraints are set for the organ at risks based on institution specific guidelines. All patients will be treated with on online position verification protocol based on institution specific guidelines. Hereafter, surgical intervention will be performed to the standard of care.
45478516|NCT05045079|Procedure|Inferior Vena Caval (IVC) Occlusion maneuver|During standard of care right heart catheterization (RHC), a second catheter will be inserted next to the catheter that was placed for the RHC in the jugular vein or femoral vein to assess the degree of pericardial restraint from the severe tricuspid regurgitation that may increase left sided filling pressures.
45478517|NCT05038813|Drug|Anlotinib+TQB2450|"Anlotinib: 12mg, orally once a day (orally before breakfast, the daily medication time should be as the same as possible), continuous taking for 2 weeks, stopping for 1 week, 3 weeks (21 days) as a treatment cycle, until the disease progresses or Intolerable.~TQB2450: 1200mg, diluted to 250mL with normal saline, infusion time 60±10mins. The medication is taken on the first day of each cycle, and 3 weeks (21 days) is a treatment cycle. Until the emergence of disease progression or intolerable toxicity, the longest use time does not exceed 24 months."
45356297|NCT05194397|Dietary Supplement|Nicotinamide Riboside|"Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."
45356298|NCT05194397|Dietary Supplement|Placebo|The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule)
45356299|NCT05194397|Other|Exercise Intervention|The exercise program consists of at-home training sessions and will include aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strengthening over 16 weeks. For aerobic training, the eventual intensity and duration goal (adapted for each person as necessary) will be for persons to train at 70-80% of peak 2MSPT heart rate 20-45 minutes 3-5 days/week. For resistance exercises the goal will be a load/weight that results in fatigue after 3 sets of 10-12 repetitions on 8-10 exercises 2 days/week.
45356300|NCT05192876|Radiation|Radiotherapy|Outcomes and adverse events using radiation therapy
45356301|NCT05190939|Diagnostic Test|water as bladder distending media|water will be used for bladder dissension during cystoscopy
45478518|NCT05034159|Behavioral|Cognitive Behavioral Therapy for Insomnia|Same as is described previously.
45478519|NCT05029882|Drug|ABBV-400|Intravenous (IV) Infusion
45356302|NCT05190939|Diagnostic Test|intravenous dye|intravenous dye using methylene blue or fluorescein will be used for visual aid of ureteral jets during cystoscopy
45356303|NCT05190939|Diagnostic Test|No intervention|Saline only, no dye
45356304|NCT05187858|Drug|LNP3794|LNP3794 capsules administered orally once daily
45356305|NCT05181826|Diagnostic Test|Multi-analyte Blood Test|Intend for the qualitative detection of DNA methylation markers for the detection of various types of cancer
45356306|NCT05174338|Other|Registry|Observational, data collection
45356307|NCT05172752|Other|Citizen Scientist Training Program|Citizen Scientist Training Program Participants is a three year training and in-home sampling program for disinfection byproducts. Participants will be trained and assessed based on their experience in the training program.
45478520|NCT05028751|Drug|Lanraplenib|Orally via tablets
45478521|NCT05028751|Drug|Gilteritinib|Orally via tablets
45478522|NCT05022901|Combination Product|Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)|Melphalan administered directly to the liver via the Hepatic Delivery System (HDS) infused over a 30 minute period, followed by a 30 minute washout period
45478523|NCT05021835|Drug|Ziltivekimab|Administered subcutaneously (s.c., under skin) once-monthly and added to standard of care
45843699|NCT03032640|Other|Sodium Saccharin|Subjects in group 1 and group 3 will be provided with sodium saccharin.
45843700|NCT03032640|Other|Placebo|Subjects in group 2 will be provided with placebo.
45356308|NCT05172752|Other|Stakeholder Consultation Core Program|Stakeholder Consultation Core Program Participants is a five year assessments where participants will participate in quarterly meetings and deliberative activities related to disinfection byproducts. Participants will be assessed based on their experience in the program.
45356309|NCT05134571|Drug|Laronidase|Solution for injection; Intravenous
45356310|NCT05130229|Behavioral|Sleep Well Bee Well|Sleep program to help toddlers sleep better
45356311|NCT05120089|Other|muscle energy technique and myofacial release (physiotherapy techniques)|Each technique will be applied for three month (3 session/week)
45356312|NCT05113966|Drug|Trilaciclib|Single-use, sterile powder to be reconstituted and further diluted with 250 mL of normal saline (sodium chloride solution 0.9%) or dextrose 5% in water (D5W)
45356313|NCT05113966|Drug|Sacituzumab Govitecan-hziy|10 mg/kg reconstituted to a concentration of 1.1 mg/mL to 3.4 mg/mL in normal saline
45356314|NCT05110326|Other|ERGON Technique|"Hot pack for 15 minutes.~Patient position: Prone with knee flexion approximately 45◦.~Position of therapist: Standing at the affected side of patient.~Technique:Massage cream will be applied on the hamstring and overactive or short muscle fibres that are restricted.The instrument will be applied parallel to the muscle fibers, both in a distal to proximal and them proximal to distal direction as needed.Then gentle massage stroking from the origin to the insertion will be performed using the instrument. Instrument Assisted Soft Tissue Mobilization(IASTM) will be applied for 5 minutes.~Strengthening exercises for quadriceps and hamstring will then be performed.~Isometrics exercises of Quadriceps: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~Isometrics exercises Hamstrings: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~Wall sits: For 10 seconds, 5 sets."
45356315|NCT05110326|Other|Proprioceptive Neuromuscular Facilitation (PNF) stretching|"The patient will be laid down prone and moist heat will be given for 15 minutes prior to stretching the hamstrings.~Then patient will be lying supine with hip in 90⁰ of flexion. Patient's knee will be extended until a very mild stretching sensation is felt in hamstring muscles.~Then patient will be asked to flex the knee against the resistance applied by hand of therapist.~The patient will be asked to use a force of around 50% of maximal strength and an isometric form of contraction will be gained in the hamstring muscles. The patient will hold the contraction for 8 seconds and then the therapist command to relax the hamstring muscle.~Immediately after the muscle relaxation the therapist further stretches the hamstring muscles up to a point where the subject reported a mild to moderate stretching sensation without any pain and will be held for 30 seconds.~The procedure will be repeated 3 times in every session.~Strengthening Exercises:~Same as ERGON Group"
45356316|NCT05109884|Diagnostic Test|PSMA PET Scan|[68Ga]Ga-PSMAHBED-CC (Ga-PSMA) PET Scan
45356317|NCT05109884|Diagnostic Test|FDHT PET Scan|[18F]-fluoro-5α-dihydrotestosterone (18F-FDHT) PET Scan
45356318|NCT05101564|Drug|Alpelisib|Alpelisib 300 mg
45478524|NCT05021835|Drug|Placebo (ziltivekimab)|Administered subcutaneously (s.c., under skin) once-monthly and added to standard of care
46046903|NCT04253847|Procedure|Radical antegrade modular pancreatosplenectomy|"Radical antegrade modular pancreatosplenectomy (RAMPS) includes the following aspects. Firstly, the surgical approach is antegrade, which means from the right to the left, the pancreatic neck will be transected at first and the spleen will be seperated at last. Secondly, lymph nodes dissection includes not only the regional lymph nodes(No.10,11,18 lymph nodes), but also N1 station lymph nodes (N1: 6, 8a, 8p, 12a2/b2/p2, 13a/b, 14b/c/d, 14v, 17a/b), No.7, 9 lymph nodes, the lymph nodes anterior and left of superior mesenteric artery, as well as the peripheral nerve of celiac trunk. Thirdly, the transection platform is in the pancreatic neck, which is mandatory. At last, left prerenal fascia will be resected. When the tumor abuts or infiltrates the left adrenal gland, left adrenalectomy will be performed, which is also called posterior approach RAMPS. While in normal cases, left adrenal gland will be preserved."
45356319|NCT05101564|Drug|Tamoxifen|Tamoxifen 20 mg
45478525|NCT05018806|Drug|Placebo|Pharmaceutical form: Tablet Route of administration: Oral
45478526|NCT05018806|Drug|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
45478527|NCT05009862|Drug|Rivaroxaban 2.5 Mg Oral Tablet|rivaroxaban 2.5 milligrams twice daily
45478528|NCT05009862|Drug|Placebo|placebo
45478529|NCT05009862|Drug|Aspirin 81Mg Ec Tab|aspirin 81 milligrams
45478530|NCT05004363|Drug|Lokelma Oral Product|Potassium binder
45356320|NCT05101564|Drug|Zotatifin|Zotatifin 0.10mg/kg (by weight)
45356321|NCT05101564|Drug|Fulvestrant|Fulvestrant 500 mg
45356322|NCT05094505|Other|Exercise in normoxia|Exercise at sea level, 3 sessions per week, during a 8-week period intervention and will consist in 60 min on an ergometer, of continuous moderate and high intensity interval training. . All exercise testing and training sessions will be carried out at the same time of day (± 2 hours) and visits will be separated by at least 48h of recovery.
45356323|NCT05094505|Other|Control diet|Control diet: diet plans will be individualized and energy-content prescriptions will be constant throughout the study to maintain the isocaloric control between diets. The planned macronutrient compositions will be 20% of energy from fat, 20% from protein and 60% from carbohydrates for the low-fat diet during the 8 weeks. Diets emphasis on low-glycemic index foods and limited saturated fat to 10% of energy. Participants will meet individually with a dietitian two times for 8 weeks and should start the dietary intervention along with the intervention with exercise.
45356324|NCT05094505|Other|Exercise in hypoxia|Exercise at 3000m altitude, 3 sessions per week, during a 8-week period intervention and will consist in 60 min on an ergometer, of continuous moderate and high intensity interval training. . All exercise testing and training sessions will be carried out at the same time of day (± 2 hours) and visits will be separated by at least 48h of recovery.
45478534|NCT04989387|Drug|INCA00186|INCA00186 will be administered every 2 weeks or 4 weeks as per protocol
45843701|NCT03032640|Other|Lactisole|Subjects in group 3 and group 4 will be provided with lactisole.
45356325|NCT05094505|Other|Low carbohydrate diet|Low carbohydrate diet: diet plans will be individualized and energy-content prescriptions will be constant throughout the study to maintain the isocaloric control between diets. The planned macronutrient compositions will be 40% of energy from fat, 20% from protein and 40% from carbohydrates for the low-fat diet during the 8 weeks. Diets emphasis on low-glycemic index foods and limited saturated fat to 10% of energy. Participants will meet individually with a dietitian two times for 8 weeks and should start the dietary intervention along with the intervention with exercise.
45356326|NCT05086796|Behavioral|Substance Use Treatment and Recovery Team (START)|"START is a model of care based on Collaborative Care. START is team driven, population-focused, measurement based, and focused on promoting adoption of evidence-based interventions. The purpose of this model is to increase adoption of evidence-based interventions for opioid use disorder and to increase linkage to aftercare.~The components of the START intervention are as follows:~Triage~Engage, Assess, and Plan~Treat~Communicate and Coordinate~Follow up~Monitor"
45356327|NCT05086380|Behavioral|Mindfulness-based stress reduction therapy|MBSR Therapy is a structured 8-week program that employs mindfulness meditation to alleviate suffering associated with physical, psychosomatic and psychiatric disorders. The program is based upon a systematic procedure to develop enhanced awareness of moment-to-moment experience of perceptible mental processes.
45356328|NCT05086380|Device|Inhibitory TMS|The device will be used to neuromodulate the right TPJ of participants' brain using cTBS stimulation protocol for transcranial magnetic stimulation
45356329|NCT05086380|Behavioral|Psychoeducation|Participants will learn about the symptoms and how to cope with the symptoms
45356330|NCT05086380|Device|TMS sham|The device will be used to neuromodulate the right TPJ of participants' brain using transcranial magnetic stimulation over the vertex
45356331|NCT05086380|Device|Excitatory TMS|The device will be used to neuromodulate the right TPJ of participants' brain using iTBS stimulation protocol for transcranial magnetic stimulation
45356332|NCT05086380|Device|Virtual Reality|The device will be used to manipulate the perception of symptoms of patients while they are playing a game in virtual/augmented reality.
45356333|NCT05086380|Behavioral|Neurofeedback|Neurofeedback training will be applied in patients while laying in an MRI scanner. Patients will play a game, which targets the sense of agency, and will receive a real-time feedback about their performance and brain activity. They will learn to self-regulate their performance on the game in order to increase brain activity relevant for the sense of agency.
45356334|NCT05080491|Diagnostic Test|immuno analysis and neuropsychological tests|"A venous blood sample will be taken for assay in immuno-analysis including and for assay in chromatography with mass spectrometry. Patients will participate in computer neuropsychological tests: .~Venous blood collection and the administration : the tubes are transported to the biochemistry laboratory of the University Hospital Center of Nice (CHU Nice) which prepares five aliquots (4 for assays in immuno-analysis including 2 on site, and one for assay in chromatography with mass spectrometry.~Administration of two neuropsychological tests on computer(Attention Network Task and Tower of London)."
45356335|NCT05079347|Diagnostic Test|HIV rapid test|Using a rapid test to assess a patient's HIV status
45356336|NCT05073484|Drug|BAT6021|Ⅳ infusions
45356337|NCT05073484|Drug|BAT1308|Ⅳ infusions
45356338|NCT05071014|Drug|Pembrolizumab|Pembrolizumab: 200mg/dose delivered by IV infusion
45356339|NCT05071014|Procedure|Image-guided cryoablation|Cryoablation will be used to treat a designated lesion with preference given to a lesion that is symptomatic or at risk of causing symptoms. Per institutional standards, complete ablation of the lesion will be attempted.
45356340|NCT05061316|Dietary Supplement|Nestlé Impact Advanced Recovery|Immunonutrition drink that helps support the immune system: reduces risk of prolonged hospital stay and complications after surgery.
45356341|NCT05058963|Behavioral|Mantram repetition program|"Week 1: Define and describe the characteristics of a mantram as taught by Eknath Easwaran and how it relates to posttraumatic stress (PTSD) Week 2: Identify ways to choose and use mantram repetition for training attention and targeting craving.~Introduction to substance craving and identify triggers for use. Week 3: Describe the relationship between the PTSD/stress response, mantram repetition and the relaxation response Week 4: Describe at least two benefits of slowing down versus automatic pilot for stress reduction Week 5: Describe at least two benefits of one-pointed attention versus multitasking for stress reduction Week 6: Demonstrate how one-pointed attention and slowing down complement each other for making healthy choices Week 7: List at least five strategies for making mantram repetition a part of your life Week 8: Discuss applications of mantram repetition, one-pointed attention and slowing down for overall health and substance use"
45356342|NCT05047835|Diagnostic Test|electrocardiogram|Prone position electrocardiogram
45356343|NCT05036993|Behavioral|Coaching|Faculty will be paired with a certified coach who is also a faculty member and receive 6 sessions of coaching over 3 months
45478535|NCT04989387|Drug|Retifanlimab|Retifanlimab will be administered every 4 weeks as per protocol
45478536|NCT04989387|Drug|INCB106385|INCB106385 will be administered orally once or twice a day.
45843702|NCT02729298|Drug|TP-0903|Novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers
45843703|NCT02130492|Radiation|FDG|The intervention arm consists of treatment with increasing doses of [18F]-Fluorodeoxyglucose.
45843704|NCT01376778|Drug|CMV hyperimmune globulin|The study's active drug is Cytogam® which is an immunoglobulin G (IgG) containing a standardized amount of antibody to CMV. This drug contains pooled adult human plasma selected for high titers of antibody for CMV, and is administered intravenously at a dose of 100 mg/kg body weight.
45687062|NCT05779761|Behavioral|Online, Self-Directed Attention Skills Training with Coaching Support|The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
45356344|NCT05033821|Behavioral|Adapted FOY+ImPACT|The Adapted FOY+IMPACT is a selective, group-level intervention designed to prevent sexual risk-taking and substance use among adolescents affected by parental drug use. There are eight sessions for youth (FOY) and one session with youth and adults (ImPACT).
45356345|NCT05026645|Procedure|Clinical interventions performed in acute settings (contaminated environment)|Any clinical intervention performed on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic).
45356346|NCT05026645|Procedure|Protection (clinician and patient)|As interrelated competence of the clinical intervention, any protection procedure and capability applied on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic). Concerning the clinician, the protection implied for his/her own safety and for the patient to whom she/he was in closed/contact with.
45356347|NCT05026645|Procedure|Decontamination (clinician and patient)|As interrelated competence of the clinical intervention and protection, any decontamination procedure and capability applied on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic). Concerning the clinician, the protection implied for his/her own safety and for the patient to whom she/he was in closed/contact with. This crucial step is usually expected prior the patient's transfer into a clean zone like the emergency room or its equivalent.
45356348|NCT05025865|Drug|Sodium Hyaluronate|Sodium Hyaluronate of molecular weight 35 kDa will be given in capsule form to the study participants.
45356349|NCT05025865|Drug|Placebo|A placebo will be given in capsule form to study participants.
45356350|NCT05022290|Procedure|Single-syringe diluted with normal saline technique|Adenosine is mixed with normal saline up to 20 ml in a single syringe before administering to the patient by the IV bolus method.
45356351|NCT05010525|Drug|ATG-016|48 patients enrolled, orally, each 3 week (21-day) a cycle
45356352|NCT05005741|Drug|Beinaglutide|Patients received beinaglutide subcutaneously three times a day for 16 weeks, the dose of beinaglutide escalate from 0.06mg to 0.2mg per 3-7 days according to subject's specific situation.
45356353|NCT05005741|Drug|Dulaglutide|Patients received 1.5mg Dulaglutide subcutaneously once-weekly for 16 weeks.
45356354|NCT05002829|Other|Restricted Duration of SOC Antibiotic Use|Standard of Care Antibiotic use will be restricted to none or up to 24 hours of post-operative antibiotics.
45356355|NCT05002829|Other|Liberal Duration of SOC Antibiotic Use|Standard of Care Antibiotic use will be permitted for 24 hours or up to 4 days of post-operative antibiotics.
45356356|NCT04994990|Drug|OnabotulinumtoxinA Standard Dose|Active comparator group will be treated for full upper face wrinkles with standard recommended doing of onabotulinumtoxinA
45356357|NCT04994990|Drug|OnabotulinumtoxinA Half Standard Dose|Experimental group will be treated for full upper face wrinkles with half of the standard recommended doing of onabotulinumtoxinA
45356358|NCT04987229|Drug|OLZ/SAM|Olanzapine and Samidorphan fixed dose coated tablet taken once daily
45356359|NCT04974216|Drug|Tafasitamab|Administration : IV at 12mg/Kg C1 to C3: D1, D8, D15, D22 C4 to C6: D1, D15 C7 to C12: D1
45843705|NCT01376778|Other|Placebo|The matching placebo consists of AlbuRx® 5% diluted 1:9 with D5W. AlbuRx® 5% contains pooled adult human plasma.
45843706|NCT01309074|Drug|Pregabalin-Lyrica|Pregabalin in a dose up to 300mg/day in BID dosing.
46046904|NCT04253847|Procedure|Standard retrograde pancreatosplenectomy|"Standard retrograde pancreatosplenectomy(SRPS) includes several aspects. Firstly, the surgical approach is retrograde, which means from the left to the right, spleen will be seperated at first and the pancreas will be transected later on. Secondly, only the regional lymph nodes will be dissected, which include No.10, No.11, No.18 lymph nodes, and No.9 lymph nodes should be dissected only when the lesion is in pancreatic neck. Thirdly, the transection platform is in the left side of the lesion, but transection at pancreatic neck is not mandatory. At last, the surgical plane is anterior to the left renal fascia, prerenal fascia will be preserved."
46046905|NCT05227443|Procedure|Exercise aerobic training|It is a procedure that is in the form of exercise training as a part of rehabilitation. The patients were subjected to 3 supervised sessions of exercise training / week for a total duration of 6 weeks. The form of training was aerobic intensity exercise that lasts for 15 minutes of continuous exercise. In this intervention, the investigators provide only lower limbs training exercises.
45356360|NCT04974216|Drug|Lenalidomide|Oral administration: hard capsule C1 to C6: 20mg/day C7 to C12: 15mg/day
45356361|NCT04974216|Drug|Rituximab|Administration: IV at 375mg/m2 C1 to C6: D1
45356362|NCT04972552|Dietary Supplement|coenzyme Q10|Participants will take 800-1200 mg of coenzyme Q10 capsule per day
45356363|NCT04972552|Other|Watermelon diet|Participants will be asked to eat watermelon at a minimum of one meal per day 3-5 days a week
45356364|NCT04972552|Other|Usual Diet|Participants will be asked to eat a usual diet but not eat any watermelon as part of their usual diet
45478537|NCT04985903|Behavioral|Clinician Communication Intervention|The focus of the communication program is to help clinicians increase their use of the 5 A's by improving knowledge, self-efficacy, outcome expectations, and communication skills. Training modules include didactic information with video clips of sample conversations showing specific communication skills, feedback on clinician's usage of the 5A's, and audio clips from their Pre-Intervention recorded conversations.
45356365|NCT04972552|Other|Placebo|Participants will be asked to take 800-1200 mg of a placebo capsule per day
45356366|NCT04955925|Diagnostic Test|Ultrasound examination of the optic nerve sheath diameter|The optic nerve sheath diameter is examined using ultrasonography.
45356367|NCT04947865|Other|Peripheral nerve stimulation|Electrical stimulation of peripheral nerves to measure resulting gait kinematics and surface muscle activity
45478538|NCT04985903|Other|5A's lecture|a lecture on general information about smoking cessation for pregnant patients and smoking cessation counseling.
45478539|NCT04982302|Procedure|Non-surgical periodontal treatment|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets
45478540|NCT04977583|Behavioral|Unmet Need Screening|"Participants are screened by phone for unmet social needs (e.g., utility insecurity, social isolation), hereafter referred to as the index screen. The index screen occurs prior to randomization."
46046906|NCT05227443|Procedure|Upper, lower and breathing (ULB) exercise|It is a procedure that is in the form of exercise training as a part of rehabilitation. The patients were subjected to 3 supervised sessions of exercise training / week for a total duration of 6 weeks. The form of training was aerobic intensity exercise that lasts for 15 minutes of continuous exercise. In this intervention, the investigators provide lower and upper limbs training exercises as well as breathing exercises.
45356368|NCT04947865|Device|Commercial knee brace|Knee brace used to limit knee mobility in healthy individuals to imitate stroke survivors and measure resulting gait kinematics and surface muscle activity.
45478541|NCT04977583|Behavioral|Unmet Need Referral - Resource Sheet|Participants receive a Resource Sheet(s) tailored to the unmet need(s) identified in the index screen. For each unmet need, a Resource Sheet will include the names of available resource within the VA and/or the local community that can help address the unmet need and contact information (address, phone, website, email) and hours of operation.
45478542|NCT04977583|Behavioral|Unmet Need Referral Assistance|Participants receive assistance from a Social Worker (SW) to facilitate connection to resources that can help to address unmet need(s) identified in the index screen. Assistance includes 1) conducting a standardized bio-psychosocial assessment; 2) motivational interviewing methods to uncover details of the Veteran's unmet needs and identify barriers to resolving the unmet needs, and; 3) developing an action plan for the Veteran to connect with resources and address needs. The SW will conduct initial follow-up by phone one week after the interview/action plan development, with planned subsequent phone outreach every two weeks for up to seven weeks.
45356369|NCT04944862|Biological|CDX-0159|administered intravenously
45356370|NCT04944862|Drug|Normal saline|administered intravenously
45356371|NCT04936685|Biological|Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine|Liquid solution for injection Intramuscular
45356372|NCT04934332|Procedure|Ultrasound|Ultrasound examination at 1 week and 5 weeks after admission.
45356373|NCT04934332|Procedure|CT scan|CT scan at 5 weeks after admission. CT scan reader will be blinded to clinical data.
45356374|NCT04934332|Procedure|Clinical examination|Weekly clinical examination from week-2 to week-5.
45843707|NCT01309074|Drug|Sertraline|Sertraline in a dose up to 200mg/day in BID dosing.
45843708|NCT01074294|Drug|OPDC-34712|OPDC-34712 tablets, daily, Orally.
46046907|NCT05132595|Drug|Normal saline|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
45356375|NCT04924699|Drug|MRG002|Administrated intravenously
45356376|NCT04924699|Drug|Trastuzumab Emtansine for Injection|Administrated intravenously
45356377|NCT04920084|Other|Plant based meals|For 12 weeks, patients will receive two premade meals per day, for lunch and dinner, prepared and shipped weekly by U.S.-based WFPBD company Plantable. The meals will have a low glycemic index and contain vegetables, whole grains, and plant-based fats that have undergone minimal processing. Instructions will be provided for food storage and reheating. Detailed recommendations for snacks and breakfasts meeting the standard of a WFPBD will also be given to supplement their daily calorie needs with access to an online portal from Plantable which contains education materials and access to a coach daily for 24 weeks.
45356378|NCT04909229|Device|PEAR-003b PDT Intervention|The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.
45356379|NCT04909229|Device|Fitbit|Patients will receive a Fitbit and receive standard of care
45356380|NCT04909229|Behavioral|Sleep education materials|Patients will receive sleep hygiene and healthy sleep tips.
45356381|NCT04907539|Drug|RXC004|"RXC004 will be administered orally, 2 mg QD (Monotherapy); and 1.5 mg QD (Combination therapy)~Dose Formulation: 0.5 mg or 1 mg capsules."
45356382|NCT04907539|Biological|Nivolumab|Nivolumab will be administered via IV infusion, 480 mg q4w.
45356383|NCT04907539|Biological|Denosumab|"Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month.~Use: Prophylactic"
45356384|NCT04907097|Dietary Supplement|Monomeric and oligomeric flavanols|Monomeric and oligomeric flavanols will be derived from Vitis vinifera seeds extract.
45356385|NCT04907097|Other|Placebo|Placebo capsuled will be used as a comparator.
45356386|NCT04901325|Drug|Baricitinib|Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks.
45356387|NCT04894682|Biological|Vaccine inoculation against SARS-CoV-2|Inoculation with any type of approved vaccines according to the standard or recommended dose
45356388|NCT04892537|Device|Coronary Sinus Reducer|Coronary Sinus Reducer implantation according to standard clinical protocols
45356389|NCT04892537|Procedure|Placebo Procedure|A placebo procedure involving venous sheath implantation in the right internal jugular vein without proceeding to CSR implantation
45356390|NCT04889911|Behavioral|Narrative Enhancement and Cognitive Therapy- Young Adult, Combined with Coordinated Specialty Care|NECT is a psychosocial intervention focused on addressing the effects of self-stigma on individuals diagnosed with severe mental illnesses. For the present study, the intervention has been modified to address the needs of youth who have recently experienced a first episode of psychosis.
45356391|NCT04889911|Other|Coordinated Specialty Care|Coordinated Specialty Care is an evidence-based, multimodal intervention for persons who have experienced a first episode of psychosis.
45356392|NCT04885205|Behavioral|cognitive behavioral therapy for insomnia (CBT-I)|The CBT-I program is a 6-week, 1x/week, one-on-one program. The delivery of CBT-I will be done remotely over a secure teleconference service (Zoom) or phone. Participants will maintain a sleep diary during the course of the program to aid in tailoring the intervention. Each session lasts about 45-60min:
45356393|NCT04884087|Behavioral|Ecological Momentary Assessment (EMA; Metricwire) Prompts 3x/day|Participants receive 3 EMA survey prompts daily for the duration of the study.
45356394|NCT04884087|Behavioral|Ecological Momentary Assessment (EMA; Metricwire) Prompts 6x/day|Participants receive 6 EMA survey prompts daily for the duration of the study.
45356395|NCT04884087|Behavioral|Incentive Structure - fixed|"Those assigned to the fixed incentive condition will earn a fixed bonus based on EMA completion (50-74%=$3; 75-89%=$5; ≥90%=$10) each week."
45356396|NCT04884087|Behavioral|Incentive Structure - prize based|"Those assigned to the prize-based incentive will be rewarded for high survey completion with increasing numbers of draws depending on their level of response to EMA prompts each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws). For each draw, individuals will use the EMA app to spin the wheel to see which prize amount they earn. Out of a total of 500 total draws, 50% will be $1, 43.6% will be $3, 6% will be medium prizes ($5), and 0.4% will be a jumbo prize ($90)."
45356397|NCT04877288|Biological|Belatacept|Specified dose on specified days
45356398|NCT04877288|Drug|Tacrolimus|Specified dose on specified days
45356399|NCT04877288|Drug|Cyclosporine A|Specified dose on specified days
45356400|NCT04877288|Drug|Mycophenolate Mofetil|Specified dose on specified days
45356401|NCT04877288|Drug|Enteric Coated Mycophenolate Sodium|Specified dose on specified days
45356402|NCT04877288|Drug|Corticosteroids|Specified dose on Specified days
45356403|NCT04869670|Procedure|Gastric peroral endoscopic myotomy.|Under propofol anesthesia, EndoFLIP will be used to assess pyloric diameter and distensibility, prior to and after G-POEM, performed by an endoscopist skilled in this technique. After the procedure, the patient will be observed in the hospital for 2 days. Patients will undergo an upper GI series the next day to rule out perforation. If the patient develops a complication from the procedure, he or she will be managed per standard clinical practice by the treating (unblinded) endoscopist.
46046908|NCT05132595|Drug|Esketamine at high dose|After the induction of anesthesia, esketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h esketamine until starting skin suture.
45356404|NCT04869670|Procedure|Sham Gastric peroral endoscopic myotomy.|Patients assigned to the sham procedure will be treated identically as above, except for the performance of the G-POEM. Endoscopy and EndoFLIP will be performed and sedation will be stopped when the upper endoscopy is completed. Since sham endoscopy is expected to take less time than G-POEM, the patient should remain in the endoscopy procedure room for a minimum of 30 minutes (including the time required to complete the upper endoscopy). After the procedure, the patient will be observed in the hospital for 2 days. All patients will undergo an upper GI series radiographic examination the next day to rule out perforation in order to maintain study blind.
45843709|NCT01074294|Drug|Placebo|Matching-placebo tablets, daily, Orally.
46046909|NCT05132595|Drug|Esketamine at low dose|After the induction of anesthesia, esketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h esketamine until starting skin suture.
46046910|NCT05132595|Drug|Ketorolac at high dose|After the induction of anesthesia, Ketorolac is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h Ketorolac until starting skin suture.
46046911|NCT05132595|Drug|Ketorolac at low dose|After the induction of anesthesia, Ketorolac is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h Ketorolac until starting skin suture.
46046912|NCT01074047|Drug|Azacitidine|75 mg/m^2 subcutaneous (SC) daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
45356405|NCT04865302|Procedure|SSC|"Incubator phase I: After feeding the neonates will be brought in a prone position in the incubator and the NIRS sensor will be applied on the forehead for continuous cStO2 measurements throughout the study period. The neonate will rest in this position for 60 minutes.~SSC phase: The neonate will be brought on the mother's or father's chest (skin to skin) in a prone position and will stay in this position for 60 minutes.~Incubator phase II: The neonates will be brought back into the incubator for another 60 minutes in prone position. After 180 minutes the study period is over and the NIRS sensor will be removed."
45356406|NCT04864639|Other|Transition of Care Model|Participants with diabetes, Hispanic/Latinos, adults will receive newly developed discharge instructions.
45356407|NCT04844749|Drug|VERU-111|Based on the safety and antitumor activity of VERU-111 in the Phase 1b/2 clinical study, VERU-111 is initiating this Phase 3 clinical study of VERU-111 for the treatment of metastatic castration resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent
45356408|NCT04844749|Drug|Enzalutamide, Abiraterone|Enzalutamide and abiraterone were chosen as active comparators are both are FDA approved for the treatment of metastatic castration resistant prostate cancer
45356409|NCT04843566|Procedure|Transperineal MRI-guided prostate biopsy|Transperineal prostate biopsy will be performed under local anesthesia in the office. This approach avoids transrectal needle tracking.
45478543|NCT04973748|Behavioral|Conditioned open-label placebo (COLP)|"Placebo oxycodone will be formulated to have the same physical appearance as liquid oxycodone and will be dispensed by the inpatient pharmacy and administered by the nursing staff. At all times that oxycodone or placebo medication is administered on post-operative day (POD) 1-5, the patient will undergo conditioning via exposure to a clove oil scent:~Conditioning (i.e. exposure to clove oil scent) with each dose of oxycodone medication on POD 1-5.~Scheduled placebo oxycodone medication paired with conditioning (i.e. exposure to clove oil scent) 3 times per day on POD 2-5."
45478544|NCT04973748|Behavioral|Surveys about pain, opioid use and depression symptoms|"Surveys before surgery: Within 1 week prior to surgery, patients complete surveys about pain levels, opioid consumption, understanding of placebo effect and symptoms of depression.~Surveys after surgery: Through 6-months after surgery, patients complete surveys about pain levels, opioid consumption, side effects of opioids and symptoms of depression."
45478545|NCT04973189|Drug|SHR-1707|A single dose of SHR-1707 by intravenous (IV) infusion in healthy young adults.
45478546|NCT04973189|Drug|Placebo|A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in healthy young adults.
45478547|NCT04973189|Drug|SHR-1707|A single dose of SHR-1707 by intravenous (IV) infusion in elderly subjects.
45478548|NCT04973189|Drug|Placebo|A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in elderly subjects.
45478549|NCT04968054|Drug|Arm I (Propofol)|Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively.
45478550|NCT04968054|Drug|Arm II (Remimazolam)|Remimazolam group started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
45478551|NCT04967495|Procedure|TACE combined with lenvatinib and iodion-125 seeds brachytherapy|TACE will be performed for the patients after randomization. Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight < 60 kg, 8mg P.O. QD) will be started at 3-7 days after the first TACE and last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Iodion-125 seeds will be implanted into the PVTT under CT guidance within 14 days after the first TACE. TACE and iodion-125 seeds implantation can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination.
45478552|NCT04967495|Procedure|TACE combined with lenvatinib|TACE will be performed for the patients after randomization and it can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination. Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight < 60 kg, 8mg P.O. QD) will be started at 3-7 days after the first TACE and last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.
45478553|NCT04965766|Drug|U3-1402|First infusion for 90 minutes and then infusion duration can be progressively decreased to 30 minutes if participant doesn't experience infusion related reactions (IRR)
45478554|NCT04939610|Drug|68Ga-FAP-2286|68Ga-FAP-2286 IV administered as imaging agent for PET scan.
45478555|NCT04939610|Drug|177Lu-FAP-2286|Patients with positive uptake of 68Ga-FAP-2286 will receive a fixed dose of 177Lu-FAP-2286 IV administered every 6 weeks for a maximum of 6 doses. Doses range between 3.7 and 9.25 GBq (100-250 mCi).
45478556|NCT04939610|Drug|177Lu-FAP-2286|Patients with positive uptake of 68Ga FAP 2286 will receive a fixed dose of 177Lu FAP 2286 IV administered at the RP2D and schedule determined in Phase 1 dose escalation.
45843710|NCT01074294|Drug|Stimulant Therapy|Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.
45843711|NCT01074138|Drug|KX2-391|KX2-391 will be administered as a 40 mg oral dosing solution, twice daily, for 6 28-day cycles.
45478557|NCT04939012|Behavioral|MyPath Intervention|MyPath is a novel patient-centered, reproductive planning decision support tool developed by the research team used to facilitate postpartum contraceptive decision-making among women with SUDs. Designed to facilitate high-quality decisions regarding pregnancy and contraception, MyPath helps women a) review their thoughts about pregnancy and children, b) learn about fertility and preconception health and c) prioritize their preferences for various contraceptive method characteristics (e.g. effectiveness, side effects). As such, MyPath uses a patient-centered approach to help women frame their contraceptive decisions in the context of their goals and health and is a critical first step towards addressing reproductive health inequities among women with SUDs.
45356410|NCT04843566|Procedure|Transrectal MRI-guided prostate biopsy|Transrectal prostate biopsy is currently the most popular approach to evaluate a positive screening test for prostate cancer.
45478558|NCT04939012|Behavioral|Usual care|Standard of Care
45478559|NCT04933721|Drug|berotralstat|BCX7353 capsules administered orally once daily
45478560|NCT04928885|Behavioral|Wits Workout Program|12 week, one hour per week multi-modal, interactive training.
46046913|NCT01074047|Drug|Conventional Care Regimen|"Physician pre-selects prior to randomization from one of the following:~Intensive chemotherapy (cytarabine 100-200 mg/m^2 continuous intravenous infusion for 7 days + anthracycline IV x 3 days) + Best Supportive Care; induction with up to 2 consolidation cycles~Low-dose cytarabine 20 mg subcutaneous (SC) twice a day (BID) for 10 days, for 28 day cycles + BSC; until disease progression or unacceptable toxicity~Best Supportive Care only; until study end"
45478561|NCT04928885|Other|Control Group that receives intervention after the study|The control group will not receive the intervention during study period but will take baseline, 3 mos and 6 mos surveys. They will complete the workshop after the study period is over.
45478562|NCT04883528|Drug|Sacubitril / Valsartan Oral Tablet [Entresto]|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
45478563|NCT04883528|Drug|Placebo|sacubitril/valsartan matching placebo tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
45478564|NCT04877444|Device|Duck Duck Punch|"Duck Duck Punch (DDP) is an interactive computer game deliberately designed to enhance UE movement quality via individualized progressive movement practice. DDP is unique as it uses Microsoft Kinect skeletal tracking technology to assess movement performance. The participant sits in front of the Microsoft Kinect and controls a virtual arm with his/her physical arm; reaching forward to punch virtual ducks. The goal 'dose' of DDP will be 200 repetitions."
45478565|NCT04877444|Behavioral|Aerobic exercise|Subjects will perform 15 minutes of aerobic exercise on a recumbent stationary cycle. The target intensity of aerobic exercise is 70% heart rate reserve. Following aerobic exercise subject will play an upper extremity rehabilitation game called Duck Duck Punch.
45478566|NCT04877444|Behavioral|Lower extremity stretching|Subjects will perform 15 minutes of lower extremity stretching. Following aerobic exercise subject will play an upper extremity rehabilitation game called Duck Duck Punch.
45478567|NCT04873817|Device|IonicRF Generator andcompatible accessories|Participants will recieve IonicRFRF lesion generator, along with any country-specific market-released accessory (i.e. electrode,cannula, grounding pad, and adaptor cable) compatible with theIonicRF Generator
45478568|NCT04865341|Behavioral|IMB|Intervention content will be focused on the Information-Motivation-Behavioral Skills (IMB) model. We plan to incorporate previously developed content as much as possible and will include professionally produced videos about HIV testing and PrEP and other resources. We believe our approach of guiding YMSM through intervention modules based on theory will help improve content retention/use and ultimately influence constructs posited to result in behavior change. We foresee using multiple forms of attention-matched material, media, and programming to engage (and retain engagement) of YMSM throughout the brief single-session intervention (45-60 minutes).
45478569|NCT04856982|Drug|Tofersen|Administered as specified in the treatment arm
45478570|NCT04856982|Drug|Placebo|Administered as specified in the treatment arm
45478571|NCT04847037|Procedure|Connected tools|Use of connected tools in postoperative bariatric follow-up vs no use of connected tools.
45478572|NCT04845347|Device|Bright Light Therapy|Participants will be provided with active, unaltered Re-Timer glasses that will be worn in the morning daily for 60 minutes for 5 weeks on study.
45843712|NCT00951132|Drug|rosuvastatin|10mg tablets, once daily in three months
46046914|NCT05210907|Biological|SNUH-CD19-CAR-T|SNUH-CD19-CAR-T is an autologous CAR-T from T cells collected from each patient. Administer a single dose of SNUH-CD19-CAR-T to patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukemia, and evaluate safety and efficacy of SNUH-CD19-CAR-T for 12 months after the infusion.
45843713|NCT00951132|Drug|Placebo|tablet, once daily, three months
46046915|NCT05185401|Other|Observational study|Retrospective data-analysis
45356411|NCT04843566|Drug|Antibiotic (prophylaxis)|"For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy."
45356412|NCT04830397|Drug|QLS-101|Ophthalmic solution 1x daily
45356413|NCT04830397|Drug|Timolol Maleate|Ophthalmic solution 1x daily
45356414|NCT04821960|Behavioral|Tailored Mindfulness Program for Fear of Memory Loss|The tailored mindfulness program has been specifically created to focus on fear of memory loss compared to general mindfulness lessons and activities.
45356415|NCT04821960|Behavioral|Conventional Mindfulness Program|Routine non-tailored mindfulness lessons and activities.
46046916|NCT05226117|Drug|Sacituzumab govitecan|Sacituzumab govitecan is a humanized monoclonal antibody (mAb) with a hydrolyzable linker through which SN-38 is conjugated to the humanized mAb hRS7 IgG1κ to enhance the delivery of SN-38 to Trop-2- expressing tumors while reducing systemic toxicity. SN-38 is the active metabolite of irinotecan. Sacituzumab govitecan is administered at 10 mg/kg as an IV infusion on days 1 and 8 of a 21- day cycle till progression, toxicity or withdrawal of consent
46046917|NCT01142726|Drug|Abatacept|Injection, subcutaneous, 125 mg by syringe, once weekly, 12 months
45356416|NCT04815876|Procedure|Transperineal MRI-guided prostate biopsy|Transperineal prostate biopsy will be performed under local anesthesia in the office. This approach avoids transrectal needle tracking.
45356417|NCT04815876|Procedure|Transrectal MRI-guided prostate biopsy|Transrectal prostate biopsy is currently the most popular approach to evaluate a positive screening test for prostate cancer.
45356418|NCT04815876|Drug|Antibiotic (prophylaxis)|"For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy."
45356419|NCT04804891|Biological|Cell Therapy|Infusion of containing 1x106/kg CD34+ cells from donor bone marrow selected using the CliniMACS® CD34 Reagent System.
45356420|NCT04802590|Drug|Ibrutinib 560 mg|560mg/d continuously from C1D2 to end C24
45356421|NCT04802590|Drug|Venetoclax 10 MG Oral Tablet [Venclexta]|20mg/d from C2D1 to C2D7
45356422|NCT04802590|Drug|Venetoclax 50 MG Oral Tablet [Venclexta]|50mg/d from C2D8 to C2D14
45356423|NCT04802590|Drug|Venetoclax 100 MG Oral Tablet [Venclexta]|100mg/d from C2D15 to C2D21 200mg/d from C2D22 to C2D28 400mg/d from C3D1 to end C24
45356424|NCT04797260|Genetic|Gene therapy|Patients will be infused with autologous CD34+ cells transduced with the pCCL.MND.coRAG1.wpre lentiviral vector (RAG1 LV CD34+ cells).
45356425|NCT04785521|Radiation|Stereotactic radiosurgery|Gamma Knife stereotactic radiosurgery (SRS-GK)
45356426|NCT04785521|Diagnostic Test|Blood samples|Serum Glu levels and Glu-regulation markers assessed prior to and following SRS-GK in BM or benign lesions or at baseline in non-BM patients.
45356427|NCT04782297|Device|Long term hemodialysis catheter|There will be no interventions in this study. Strictly observational.
45356428|NCT04780477|Dietary Supplement|Experimental: High Fiber Diet (HFD)|Experimental: High Fiber Diet (HFD) pre-portioned entrées for two meals/d in mos. 1-3, and one meal/d in mos. 4-6. Participants continue on their respective diets in mos. 7-12 but assume responsibility for food preparation. The HLD will contain approximately 250g of legumes per day (~1 ½ cups cooked) in months 1-3 provided in two pre-portioned single serving entrées (i.e. ~125g each). A study nutritionist will provide in-person and written guidance for including sides that are nutritionally balanced with energy intake to lose 1-2 lbs. /wk.
45356429|NCT04780477|Dietary Supplement|Healthy American Diet|Healthy American Diet pre-portioned meal replacement entrées with legumes replaced by lean chicken/meat. A study nutritionist will provide in-person and written guidance for including sides that are nutritionally balanced with energy intake to lose 1-2 lbs. /wk.
46046918|NCT01142726|Drug|Methotrexate|Tablets, oral, 2.5 mg, once weekly, 12 months
46046919|NCT01142726|Drug|Abatacept placebo|Injection, subcutaneous, to match 125 mg by syringe, once weekly, 12 months
45356430|NCT04776993|Drug|Methimazole|Methimazole for 72 weeks
45356431|NCT04776993|Procedure|Radioiodine or thyroidectomy|Treatment with radioiodine or with thyroidectomy
45356432|NCT04771663|Other|Breathing a mixture of O2, N2 and CO2 and monitoring SpO2 on each finger|The experiment consists of two separate phases. In one phase, the volunteers inhale one of the mixtures for five minutes. After enough time of recovery, the volunteers undergo the other phase in which they inhale the other mixture of gases. Both phases of the measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of both volunteer hands throughout the experiment.
45356433|NCT04766138|Device|Fecobionics|Fecobionics is a new device to be inserted through the anal canal into rectum for studying defecation
45356434|NCT04753658|Drug|lorlatinib|Oral
46046920|NCT01142726|Drug|Methotrexate placebo|Tablets, oral, to match 2.5-mg tablet, once weekly, 12 months
45843714|NCT01710306|Behavioral|Nurse Care Manager (NCM)|Nurse care manager interventions with telephone implemented shared decision making protocol compared to outreach as usual OEF/OIF/OND outreach.
45843715|NCT01713660|Device|iFS Femtosecond Laser|corneal incisions created by the femtosecond laser
45356435|NCT04752891|Other|AOM diagnosis with app|the diagnosis made by a senior physician using a traditional otoscope. the diagnosis made by the junior physician using an otoendoscope fixed on a connected smartphone
45687063|NCT05779761|Behavioral|Online, Self-Directed Attention & Reflective Thought Skills Training with Coaching Support|The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention and reflective thinking skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
45843716|NCT01715064|Behavioral|Exercise|1 hour of moderate-intensity exercise
45843717|NCT01716468|Other|Ketogenic Diet|modified ketogenic diet
45843718|NCT01717014|Device|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients already selected to undergo an open LAR or proctosigmoidectomy using the Radial Reload Stapler
45843719|NCT01717872|Device|Laryngoscope blade|The POGO score will be used to assess the percent of the glottis that can be seen with each of the blades lifting and not lifting the epiglotis
45843720|NCT01718028|Other|Propylene glycol 0.6% ocular emulsion|
45843721|NCT01718028|Other|Sodium chloride 0.9% saline solution|
45843722|NCT01719900|Dietary Supplement|Pulse fibre|Yellow pea hull fibre incorporated into a biscuit at 5 g/serving.
45843723|NCT01719900|Dietary Supplement|Control|Control biscuit with no yellow pea hull fibre.
45843724|NCT01721226|Device|Intervention Arm (computer-based CARE+ Corrections tool)|Study participants in the intervention arm will complete the computer-based CARE+ Corrections tool at baseline. The CARE tool provides tailored feedback based on the participants' responses to a series of questions included in the counseling session. Participants in this arm of the study recruited inside the DC DOC will receive typical discharge planning services as conducted by the correctional facility. Participants will be followed for six months after release/study enrollment. At the post-release baseline visit, participants in the intervention arm will receive a cell phone/SMS text messaging intervention consisting of using cell phone-delivered SMS text messages with the intent of improving linkage to community HIV care and adherence to ART (if prescribed.)
45843725|NCT01721226|Other|Educational video on opiate overdose prevention|Participants in the Control Arm will view an educational video on opiate overdose prevention in jail prior to release. Control arm participants will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
45843726|NCT01721460|Drug|Dexmedetomidine|Dexmedetomidine infusion will be started with a loading dose of 1 mcg/Kg over ten to 20 minutes followed by a maintenance infusion of 0.7 mcg/Kg/hr until stable sedation is achieved.
45356436|NCT04752891|Other|AOM diagnosis without app|the diagnosis made by a senior physician and by the junior physician, using a traditional otoscope
45843727|NCT01722318|Drug|Plecanatide|
45843728|NCT01722318|Drug|Placebo|
45843729|NCT01722552|Behavioral|adherence feedback|
45843730|NCT01722552|Behavioral|standard of care|
46046921|NCT04526223|Other|comprehensive treatment regimen|"Diagnosis MF(includ Post-ET,Post-PV,PMF，MDS/MPN with MF)~With at least two month Ruxolitinib treatment prior to transplantation~DAC+BF as myeloablative conditioning regimen~received Rux at +5d in ASCT and continued to +60d"
45843731|NCT01723722|Drug|Methadone|Concentration is 1mg/mL administered every 12 hours given on sliding scale in response to last NAS score.
45843732|NCT01723722|Drug|Diluted Deodorized Tincture of Opium|Concentration is 1:24 dilution for a concentration of 0.4%
45843733|NCT01728636|Drug|Tranexamic Acid|intravenous administration of bolus and infusion for duration of surgical procedure
45843734|NCT01729338|Drug|Velcade|Bortezomib induction: 1.3 mg/m2, given subcutaneously (SC) on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Bortezomib maintenance (even cycles [10,12,14, etc.]: 1.3 mg/m2, given SC on days 1 and 15. For patients who required VELCADE dose reductions during induction, the last administered mg/m2 dose of VELCADE will be the starting dose for maintenance, given on days 1 and 15. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. Patients who cannot tolerate SC VELCADE will be converted to the same dose, given intravenously (IV), per discretion of the treating physician.
46046922|NCT05093127|Device|Carotid Artery Stenting|R-OneTM system is a tool available to physicians for performing CAS without changing the treatment of the pathology. R-OneTM system is designed to remotely deliver and manipulate guidewires and stent/balloon devices during Carotid Artery Stenting. The system is composed of the R-OneTM robotic platform used in combination with two accessories, the Mobile radioprotection screen and a sterile and single-use R-OneTM consumable kit. The physician, seated at the remote radio-protected control station, manipulates guidewires and/or balloon/stent catheters using joysticks on the Command unit.
45356437|NCT04741932|Other|Dementia Care Management (DCM)|"A computerized Information and Care Management System (IMS) will identify unmet nursing, medical, psychosocial and social needs of the PwD and its informal caregiver. Based on this data, the IMS generates suggestions for interventions: The DCM in cooperation with the general practitioner (GP) develops an individual treatment and care plan that is tailored to the needs of the PwD and its caregiver. The DCM will initiate the implementation of respective actions and monitor the status of implementation. Therefore, the DCMs are supposed to take on activities that were previously usually performed by doctors (redistribution of tasks between physicians and qualified nurses in primary care)."
45356438|NCT04699201|Procedure|Hincisional hernia prevention by onlay prosthesis trocar closure|Hincisional hernia prevention by onlay prosthesis trocar closure
45356439|NCT04699201|Procedure|laparoscopic cholecystectomy|Laparoscopic cholecystectomy with or without common bile duct exploration
45356440|NCT04699201|Diagnostic Test|Abdominal ultrasound|Ultrasound focused in abdominal wall defects on the trocar incisions, 12 months after the surgery
45478573|NCT04845347|Device|Dim Light Therapy|Participants on this arm will wear the placebo version of the Re-Timer fitted with neutral density filters. These will be worn in the morning daily for 60 minutes for 5 weeks on study.
45478574|NCT04828135|Drug|Hyperpolarized 129Xenon gas|Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),
45478575|NCT04823949|Device|Home blood pressure monitoring|See arm description
45478576|NCT04817605|Other|Therapeutic Exercise|Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations.To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.
45478577|NCT04815720|Drug|pepinemab + pembrolizumab|The Safety Run-in phase will begin at 20 mg/kg pepinemab with a fixed dose of 200 mg pembrolizumab. The dose of pepinemab may be reduced to 15 mg/kg or 10 mg/kg with a fixed dose of 200 mg pembrolizumab if the initial pepinemab dose of 20 mg/kg is found to not be well tolerated. Once a recommended phase II dose of pepinemab is determined it will be utilized in the Dose Expansion phase in combination with 200 mg pembrolizumab.
45478578|NCT04813484|Behavioral|Kickin it with the Gurlz|This multicomponent intervention includes a violence and gender affirmation screening tool, a peer delivered adaptation of the group-level Seeking Safety Program, and individual-level peer navigation sessions.
45478579|NCT04809740|Other|Evaluate implementation of navigator-delivered Home ePRO for all cancer patients|evaluate implementation of navigator-delivered Home ePRO for all cancer patients across multiple practice sites; 2) examine the barriers, facilitators, and implementation strategies used in implementing navigator-delivered Home ePRO; and 3) assess the impact of Home ePRO on clinical and utilization outcomes
46046923|NCT04472637|Drug|Atorvastatin|atorvastatin 10 mg, as one tablet /day for 24 weeks.
46046924|NCT04472637|Drug|Placebo|a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 24 weeks)
45478582|NCT04777851|Drug|Regorafenib in combination with pembrolizumab|Randomized patients will receive regorafenib at a dose of 90 mg per day by mouth on days 1 to 21 of a 28-day cycle, in combination with pembrolizumab 400 mg using a 30-minute intravenous infusion, on day 1 (D1) of a 6-week cycle.
45478583|NCT04777851|Procedure|Loco-regional therapy|"Patients will be treated with TACE or TARE on-demand according to site's standard of practice."
45478584|NCT04773353|Drug|Follitropin Delta (FE 999049)|FE 999049 will be administered as single daily subcutaneous injections in the abdomen. Subjects randomized to FE 999049 will have their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. For subjects with low AMH (<15 pmol/L) the daily FE 999049 dose will be 12 μg, irrespective of body weight. For subjects with high AMH (≥15 pmol/L) the daily FE 999049 dose will be on a continuous scale ranging from 0.19 to 0.10 μg/kg, i.e. dependent on actual AMH and body weight.The daily FE 999049 dose will be fixed throughout the stimulation period and maximum allowed daily dose will be 12 μg. Subjects could be treated for a maximum of 20 days.
46046925|NCT04305509|Other|no intervention|no intervention
46046926|NCT05123937|Other|BOBATH technique|In group A (BOBATH) one session per day for three days lasting 1 hour for 3 months. Position transitions such as turning from supine to prone or from prone to supine from sitting to standing are facilitated according to the needs. Balance reflexes are attempted to stimulate by using a CP ball. Ambulation training appropriate to the child's motor development. Additionally, passive stretching of spastic muscle reduces spasticity and facilitates the motor function
45356441|NCT04698291|Procedure|Blood Donation|The blood donation will take place at the Gene & Health clinical assessment centre facilities. A trained member from Gene & Health program will be responsible for taking the blood samples.
45356442|NCT04693520|Drug|ALZ-801|ALZ-801 265 mg twice daily (BID)
45356443|NCT04679961|Device|ApolloVue® S100 Image System (Apollo Medical Optics)|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group.
45356444|NCT04671875|Drug|Recombinant Humanized Monoclonal Antibody MIL93|"PART I :The patients confirming to the eligibility criteria will be assigned to the 6 dose groups (0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg,respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL93 every 3 or 2 week on Day 1.~PART II:One recommended dose will be conducted from 6 dose groups based on results of PART I."
45687064|NCT05779761|Behavioral|Online, Self-Directed Health & Wellness Education Training with Coaching Support|The initial set of modules focus on psychoeducation about stress, the impact that stress has on one's life, and self-monitoring of stress. The next set of modules focus on sleep, time management, nutrition, and exercise. All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
45687065|NCT05779241|Drug|LYN-005|Risperidone long-acting oral capsule
45478585|NCT04773353|Drug|Follitropin Alfa (GONAL-F)|GONAL-F will be administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F will be 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose will be 450 IU. Subjects could be treated for a maximum of 20 days.
45478586|NCT04765111|Drug|Acalabrutinib|Given PO
45478587|NCT04765111|Biological|Rituximab|Given IV
45687066|NCT05779241|Drug|Risperidone|Risperidone immediate release (IR) oral tablets
45687067|NCT05778344|Behavioral|Teletechnology-assisted home-based pulmonary rehabilitation|The accuracy and safety of home-based pulmonary rehabilitation will be checked regularly through technology devices such as smart watch and via videotelephony (or telephone calls if indicated).
45843735|NCT01729338|Drug|Cyclophosphamide|Cyclophosphamide: 300 mg/m2, given orally on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Patients who cannot swallow cyclophosphamide pills will be converted to the same dose, given intravenously (IV).
45356445|NCT04669249|Behavioral|PROCare|PROCare is a reward-based digital recovery management platform for individuals receiving medication treatment for opioid use disorder. Patients have the opportunity to earn both non-monetary and monetary incentives via smart debit card for a variety of clinically-indicated behaviors, including taking their medication (buprenorphine) as directed, attending clinic appointments and community-based mutual-help support group meetings, participating in routine outcomes monitoring surveys using validated measures, accessing the curated psychoeducation content library, and engaging in other recovery-oriented activities within the smartphone app.
45356446|NCT04667702|Behavioral|Interviews|We will conduct a phone or virtual interview with patients with sickle cell disease or cancer, caregivers and their healthcare providers.
45356447|NCT04666545|Behavioral|MuST AKT|A behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation.
45356448|NCT04664972|Drug|Docetaxel +doxorubicin+ cyclophosphamide|The control group was treated with TAC (docetaxel 75 mg / m2 + adriamycin 50 mg / m2 + cyclophosphamide 500 mg / m2) for 6 cycles, 21 days was a cycle.
45356449|NCT04664972|Drug|Docetaxel +Cisplatin|The experimental group was treated with TP (docetaxel 75mg/m2 day 1 + cisplatin 25 mg/m2 day 1,2,3) neoadjuvant chemotherapy for 6 cycles, 21 days as a cycle.
45356450|NCT04660162|Device|Iontophoresis|By using the PeriIont (Perimed, Jarfalla, Sweden) device, 0.5 mL of a 10 mg/ml Sodium nitroprusside solution was used transdermally and ionised with a current strength of 200 µA for 1 minute.
45356451|NCT04660162|Other|Stepwise occlusion|The upper arm was occluded for 30 seconds with a pneumatic cuff up to 50 mmHg, 80 mmHg, 110 mmHg, 140 mmHg, and 170 mmHg. The volunteer had rest for 5 minutes between each occlusion procedure.
45356452|NCT04652076|Drug|NP137|Recombinant humanized IgG1 monoclonal antibody against Netrin 1. NP137 will be administred IV, Q3W until disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, pregnancy or SMPC guidance, whichever occurs first.
45356453|NCT04652076|Drug|Pembrolizumab|Humanised monoclonal anti-programmed cell death-1 (PD-1) antibody will be administred in IV Q3W. A maximum 35 cycles of treatments (approximately 2 years) with pembrolizumab can be administered to patients.
45356454|NCT04652076|Drug|Paclitaxel|Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
45356455|NCT04652076|Drug|Carboplatin|Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
45356456|NCT04632069|Combination Product|N acetyl cysteine + vagus nerve stimulation|NAC x 14 days, taVNS x 10 days
45356457|NCT04627948|Diagnostic Test|Stockholm3 test|Diagnostic test: Stockholm3-test. Men from the study sites, diagnosed with prostate cancer and currently on AS and planned for rebiopsies will be invited to the study.
45356458|NCT04618913|Drug|Apixaban|Anticoagulant
45356459|NCT04618913|Drug|Rivaroxaban|Anticoagulant
45356460|NCT04618913|Drug|Edoxaban|Edoxaban
45356461|NCT04618913|Drug|Dabigatran|Dabigatran
45356462|NCT04618913|Drug|VKA|Vitamin K antagonist
45478588|NCT04740879|Behavioral|Be Mindful|The online 4-week Be Mindful intervention was designed to follow the same outline as typical in-person 8-week MBCT courses. Week 1 and Week 2 introduce the topic of mindfulness and encourage its daily use, whereas Week 3 and Week 4 teach the individual to decenter from thoughts and utilize mindfulness when coping with stressors. Each week focuses on a separate mindfulness topic, which is initially presented to the individual in a short (under 5 minute) video containing didactic information and an overview of the experiential activities that will be introduced in subsequent videos. The intervention is provided entirely through audio, video, and text provided on the Be Mindful website (BeMindfulOnline.com).
45478589|NCT04737889|Drug|Rituximab|Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
45356463|NCT04618913|Drug|LMWH|Low Molecular Weight Heparin
45356464|NCT04617093|Device|PrismaLung+|Overall, 50 adult patients will be initiated on ECCO2R using PrismaLung+. A minimum of approximately 15 patients will be treated with ECCO2R using PrismaLung+ as stand-alone therapy and another minimum of approximately 15 patients (maximum of 20) will receive ECCO2R using PrismaLung+ in combination with CRRT.
45356465|NCT04610892|Biological|MEDI6570|MEDI6570
45356466|NCT04610892|Biological|Placebo|Buffer
45356467|NCT04607148|Drug|Galegenimab|Intravitreal (ITV) injections of galegenimab
45356468|NCT04598165|Behavioral|Interactive two-way SMS dialogue|We will utilize Mobile WACh, a human-computer hybrid system that enables seamless two-way SMS communication and patient tracking, to provide consistent support to women and their infants during the peripartum period and 6 weeks into the baby's life. Women will receive automated theoretically grounded SMS messages targeting the appropriate peripartum period and will have the capability to respond and spontaneously message a nurse based at the clinic. During pregnancy, automated SMS will be delivered weekly. Two weeks prior to the participant's estimated due date (EDD), daily messaging will begin, and will continue for two weeks after delivery is ascertained. Thereafter, SMS will be delivered every other day for the remaining four weeks. Women who experience pregnancy or infant loss will be enrolled into an infant loss track where they will receive messages of support.
45478590|NCT04737889|Drug|Lenalidomide|"Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment: 10mg oral administration on day 1 to 21 repeated every 4 weeks until disease progression or unacceptable toxicity develops, up to 12 cycles."
45478591|NCT04737889|Drug|Methotrexate|Induction Chemotherapy: 3mg/m2, Intravenous administration (pumping for 3h) on day 1 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
45478592|NCT04737889|Drug|Temozolomide|Induction Chemotherapy: 150mg/m2/d oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
45478593|NCT04735354|Drug|sacubitril/valsartan|There was no treatment allocation. Patients administered sacubitril/valsartan by prescription that started before inclusion of the patient into the study were enrolled.
45478594|NCT04725487|Other|Standard integration program with social and health promoting intervention|"Basic language course, internships, courses in Labour market knowledge and Danish culture~Physical activity workshops~Community gardening (garden workshops)~Entrepreneurship course~MindSpring course~Family excursions~Danish language workshops"
45478595|NCT04725487|Other|Standard integration program|Standard integration program (basic language course, internships, courses in Labour market knowledge and Danish culture)
45478596|NCT04698915|Drug|Drug GC4711|15 Minute IV Infusion
45478597|NCT04698915|Drug|Placebo|15 Minute IV Infusion
45478598|NCT04679740|Device|Magmaris|MAGMARIS is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.
45478599|NCT04672291|Drug|Poly-ICLC (Hiltonol®) or Placebo|The safety cohort (Cohort A) consists of 13 patients who will be randomized to receive 2 cycles of the study drug (N10) or 2 placebo cycles (N3).
45478600|NCT04672291|Drug|Poly-ICLC (Hiltonol®) or Placebo|The expansion cohort will receive 3 cycles of therapy. A total of 30 patients will be accrued and randomized 4:1 to receive drug (N=24) or placebo (N=6).
45478601|NCT04668365|Drug|Rituximab|375mg/m2, Intravenous administration on day 0 of each 3-week cycle.
45687068|NCT05772572|Other|Questionnaires|"Questionnaires are completed only once and assess:~recorded questions about the disease and the operation for the parents and the patient, human figure drawing test and drawing of the operation for the patient~psychiatric questionnaires for parents and patients on anxiety and depression~behavior questionnaires for the parents and the patient: assessment of attachment~questionnaires for the parents and the patient concerning the family context, the quality of life"
45687069|NCT05770596|Drug|vitamin C group|patients in this group will receive 2 gm vitamin C orally 1 hour before surgery and will receive 0.5 gm vitamin C per day orally for 50 days starting from the 2nd postoperative day.
45356469|NCT04592913|Drug|Durvalumab|Human monoclonal antibody
45356470|NCT04592913|Drug|FLOT chemotherapy|A combination treatment made up of flurouroacil + leucovorin + oxaliplatin + docetaxel
45356471|NCT04570553|Procedure|surgical staging|Patients will undergo standard surgical staging for endometrial cancer utilizing either a V-care uterine manipulator or sponge stick
45356472|NCT04547907|Drug|Albumin binding paclitaxel+ trastuzumab+ patuzumab|Albumin binding paclitaxel 125 mg / m2 (1, 8, 15 days) + trastuzumab (8 mg / kg for the first loading dose and 6 mg / kg for the sequential maintenance dose) + patuzumab (840mg for the first loading dose and 420mg for the sequential maintenance dose) ，every 21 days for 6 cycles.
45356473|NCT04547907|Drug|Docetaxel+ carboplatin+ trastuzumab + patuzumab|Docetaxel 75 mg/m2 + carboplatin (AUC = 6) + trastuzumab(8 mg / kg for the first loading dose and 6 mg / kg for the sequential maintenance dose) + patuzumab (840mg for the first loading dose and 420mg for the sequential maintenance dose) ，every 21 days for 6 cycles.
45356474|NCT04546516|Device|HYAcorp Lips and HYAcorp Face|Dermal filler injection to different facial areas
45356475|NCT04546152|Device|HYAPROF® SOFT and HYAPROF® BALANCE|Dermal filler injection to different facial areas
45356476|NCT04545944|Drug|Vonoprazan|20 mg tablets administered orally
45356477|NCT04545944|Drug|Midazolam|2 mg syrup administered orally
45478602|NCT04668365|Drug|Zanubrutinib|160mg twice daily continuous oral administration.
45356478|NCT04529928|Device|Carillon Mitral Contour System|Eligible subjects will be implanted with the Carillon Device, utilizing the Carillon Mitral Contour System. The device is a permanent implant in the coronary sinus/great cardiac vein, designed to cinch the mitral annulus. The implant procedure is minimally invasive, conducted via catheter placement.
45356479|NCT04522804|Drug|Psilocybin|Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the existential issues that arise in this patient population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.
45478603|NCT04668365|Drug|Cyclophosphamide|750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
45478604|NCT04668365|Drug|Epirubicin|70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
45478605|NCT04668365|Drug|Vincristine|1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
45478606|NCT04668365|Drug|Prednisone|100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
45478607|NCT04657991|Drug|Encorafenib|Encorafenib
45478608|NCT04657991|Drug|Binimetinib|Binimetinib
45478609|NCT04657991|Drug|Pembrolizumab|Pembrolizumab
45478610|NCT04646395|Drug|Tafasitamab|200 mg powder for reconstitution with 5 ml water for injection
45478611|NCT04646395|Drug|Acalabrutinib|100 mg hard gelatin capsules
45478612|NCT04638153|Biological|Recifercept|Recifercept
45478613|NCT04633239|Drug|Abemaciclib|Given PO
45478614|NCT04633239|Procedure|Biopsy|Undergo tumor biopsy
45478615|NCT04633239|Procedure|Biospecimen Collection|Undergo collection of blood
45478616|NCT04633239|Drug|Olaparib|Given PO
45478617|NCT04626479|Biological|Pembrolizumab|Administered via IV infusion at a dose of 400 mg Q6W
45478618|NCT04626479|Biological|Favezelimab/Pembrolizumab|Administered via IV infusion at a dose of 800 mg/200 mg Q3W
45478619|NCT04626479|Drug|Belzutifan|Administered via oral tablet at a dose of 120 mg QD
45478620|NCT04626479|Drug|Lenvatinib|Administered via oral capsule at a dose of 20 mg QD
45478621|NCT04626479|Biological|Pembrolizumab/Quavonlimab|Administered via IV infusion at a dose of 400 mg/25 mg Q6W
45356480|NCT04520763|Other|5min respiratory muscle exercises|5 min of hyperpnea at a target intensity of 60-80% MVV 15-30min after ingestion of 75g of glucose
45356481|NCT04520763|Other|15min respiratory muscle exercises|5 min of hyperpnea at a target intensity of 60-70% MVV 15-30min after ingestion of 75g of glucose
45478622|NCT04626479|Drug|Vibostolimab/Pembrolizumab|Administered via IV infusion at a dose of 200 mg/200 mg Q6W
45478623|NCT04616729|Drug|Triptorelin 3.75 MG Injection|Depot Group (Group A) will receive Triptorelin 3.75mg Depot form for final oocyte maturation.
45478624|NCT04616729|Procedure|Transvaginal oocyte retrieval|Patients in both groups will undergo a transvaginal oocyte retrieval after ovarian stimulation.
45478625|NCT04616729|Drug|Triptorelin Injection|Daily Group (Group B) will receive Triptorelin 0.2mg Daily form for final oocyte maturation.
45478626|NCT04594681|Drug|Placebo|Placebo is administered once daily or three times daily.
45478627|NCT04594681|Drug|KHK4951|KHK4951 is administered once daily or three times daily.
45478628|NCT04590963|Drug|Monalizumab|Monalizumab (intravenous)
45478629|NCT04590963|Drug|Cetuximab|Cetuximab (intravenous)
45478630|NCT04586686|Procedure|Ovarian biopsy via laparoscopy|A laparoscopy will be performed to achieve an ovarian cortical biopsy of one of both ovaries. Approximately twenty % of the ovarian volume as initially measured on the baseline ultrasound at the first visit will be removed to be processed in the lab for cortex freezing. The laparoscopic procedure in order to take the ovarian cortex biopsy will be standardised as much as possible. The technique developed by ProFam will be followed and adapted if needed by the surgeon's discretion. A three to four port laparoscopy will be used. The ovarian cortex biopsy will be taken using a curved scissor. Bipolar or unipolar cauterisation will be avoided as much as possible. If necessary for approximation or for hemostatic reasons, the ovarian edges can be stitched or Surgicel ® Absorbable Hemostat can be used.
45478631|NCT04586686|Procedure|Transvaginal oocyte retrieval|After ovarian stimulation, a transvaginal oocyte retrieval will be performed either under local or general anaesthetics (patient's choice). The oocyte yield between the biopsied and non-biopsied ovary will be evaluated.
45478632|NCT04586049|Device|MRI|Participants will undergo an MRI scan while participating in a breathing test to measure brain blood flow.
45478633|NCT04586049|Device|Transcranial Doppler Ultrasound|Participants will undergo a TCD scan while participating in a breathing test to measure brain blood flow.
45356482|NCT04503395|Device|ESAR treatment: Endograft + Heli-FX Endoanchor|ESAR treatment: Endurant II or Endurant IIs endograft + Heli-FX Endoanchor
45843736|NCT01729338|Drug|Revlimid|"Lenalidomide (odd cycles [9,11,13, etc.]: 10 mg, given orally on days 1-21. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. On even cycles, patients will be prescribed enough lenalidomide to take at home, as instructed, for one cycle. This will be prescribed through the mandatory RevlimidREMS® program. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up.~Patients who take more than the prescribed dose of lenalidomide should be instructed to seek emergency medical care if needed and contact study staff immediately."
45356483|NCT04503395|Device|FEVAR treatment : Fenestrated endograft|Cook Zenith Fenestrated Graft or the Terumo Fenestrated Anaconda Graft
45843737|NCT01729494|Drug|Alemtuzumab|Alemtuzumab will be dosed on day of transplant (Study Day 1) at dose of 30 mg given intravenously (IV) over a period of 2 hours after induction of anesthesia. Methylprednisolone IV will be administered 30-60 minutes prior to the administration of alemtuzumab.
45843738|NCT01729494|Drug|rabbit antithymocyte globulin|Rabbit antithymocyte globulin will be dosed post-operatively at a total cumulative dose of 4.0-6.0mg/kg given by days 5-10 post-transplant. It will be administered by local standards of care with the following recommendations. The initial intravenous intra-operative dose will be administered approximately one hour after the methylprednisolone dose. The first dose will be administered so that approximately 25% of the dose is infused prior to revascularization of the graft. Subsequent doses will be administered over a minimum of 4 hours. Premedication with acetaminophen 650mg p.o. and diphenhydramine 25mg p.o. prior to rabbit antithymocyte globulin dose will be given to reduce the incidence of infusion reactions.
45843739|NCT01729494|Drug|Belatacept|Belatacept will be administered via intravenous (IV) infusion according to the FDA approved dosage recommendations. Subjects randomized to belatacept arms will receive the first dose of IV belatacept (10 mg/kg) within 12-24 hours post reperfusion. The second dose will be given between post-transplant days 4 -6 (Study Days 5-7), and then study days 14, 28, 56, and 84 (12 weeks) and then subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial at 24 months (104 weeks). Study Day 1 is defined as the day of transplant.
46046927|NCT05123937|Other|Task training|In group B (task training) will be applied for 60 minutes per day, 3 times per week for 3 months the individual session lasted roughly 10 minutes for each activity. Standing from a seated situation; (ii) reaching for an object high up, which required ankle plantarflexion from the standing position, and go back to the starting position with the heel leaning on the floor; (iii) stepping on and off a bench; (iv) walking up and downstairs. (10) (v) Drinking water hold the cup stable and drink it by lifting it at an appropriate speed and power (vi) Moving a rubber ball, the task involved taking a 6.5 cm diameter rubber ball and placing it in a basket with a diameter of ten cm (the basket location was moved in various directions).
46046928|NCT04310618|Other|No intervention|No intervention
45356484|NCT04484935|Drug|Nirsevimab|Single fixed IM dose of nirsevimab 50 mg if body weight < 5 kg or 100 mg if body weight ≥ 5 kg, and subjects entering their second RSV season will receive a single fixed IM dose of nirsevimab 200 mg
45356485|NCT04477356|Procedure|SU|Aliquot 1.2 ml Ferticult Flushing media (Fertipro, Belgium) into 14 ml tube and then gently add 1 ml semen sample to the bottom of the tube (in case of larger semen volume, use multiple 14 ml tubes). The tubes then will be hold at an angle of 45 degrees for 45-60 minutes at 37C. Collect 1 ml of supernatant and then wash with 2 ml Ferticult Flushing media by centrifugation at 1200 RPM for 10 minutes. Keeping 0.3 ml washed semen for IUI, sperm density counting. Prepared sperms will be transferred into uterus by soft catheter (Gynétics, Belgium).
45356486|NCT04477356|Procedure|DG|Add 1.5 ml Sil-select 90% first and then 1.5 ml Sil-select 45% (Fertipro, Belgium) into centrifuge tube, then gently add 1 - 1.5 ml semen on the top of Sil-select layer and centrifuge at 1200 RPM for 15 minutes. Discard upper layer, collect 0.5 ml lower layer into new tube and then wash with 2 ml Ferticult Flushing media at 1200 RPM for 10 minutes. Discard upper layer then collect 0.3 ml lower layer for IUI, sperm density counting. Prepared sperms will be transferred into uterus by soft catheter (Gynétics, Belgium).
45478634|NCT04586049|Other|Sympathetic Nerve Activity|Participants will undergo sympathetic nerve activity testing while participating in a breathing test.
45478635|NCT04577859|Device|ensoETM. Esophageal cooling during AF ablation|Esophageal cooling during AF ablation: The ensoETM probe is inserted via the orogastric route when the patient is under general anaesthesia. The device is set to cool during ablation of the posterior aspect of the left atrium, to protect against transmitted thermal energy and so reduce or prevent esophageal thermal injury.
45687070|NCT05770596|Other|placebo group|patients in this group will receive placebo tablets with the same manner; orally 1 hour before surgery and for 50 days starting from the 2nd postoperative day.
45687071|NCT05768100|Dietary Supplement|1,3-Butanediol|1,3-Butanediol
45687072|NCT05768100|Dietary Supplement|Placebo|Isovolumic placebo
45687073|NCT05766657|Dietary Supplement|Microbiome-targeted diet|The gut microbiota (on stool) and metabolic profile (on stool and urine) will be analyzed at time 0, and the dietary plan will contain specific directions aimed at restoring a proper metagenomic and metabolomic profile of the microbiota.
45687074|NCT05766657|Dietary Supplement|Usual care diet|Subjects on the control group will receive general dietetic advice for Obesity or T1D
45356487|NCT04472351|Behavioral|ASCEND-I|"The intervention is an inpatient version of a novel behavioral intervention named ASCEND (A Strategy and Computer-based Intervention to ENhance Daily Cognitive Functioning after Stroke). ASCEND-I combines computer-based cognitive training exercises, with structured coaching sessions within patients' occupational therapy. Computer-based training is 30 minutes in length daily, and strategy training within patients' occupational therapy ranges from 30-60 minutes (depending on patients' clinical goals). The computer exercises aim to improve working memory (WM) through a series of engaging and interactive computer games (e.g., card games, virtual shopping, mental arithmetic). The Multicontext OT sessions aim to assist the participant in generalizing and transferring skills from the computer exercises to everyday activities and to develop further strategies to compensate for WM difficulties."
45356488|NCT04460937|Drug|Adavosertib|Given PO
45356489|NCT04460937|Radiation|Radiation Therapy|Undergo radiation therapy
45478636|NCT04577859|Device|Esophageal temperature monitoring probe|An esophageal temperature monitoring probe is normally used in standard of care AF ablations. This allows any temperature rise in the esophagus to be detected during ablation. If the temperature reaches >38 degrees then it is widely recognised that ablation should be halted until the temperatures fall back to below 38 degrees. It therefore has the ability to detect esophageal temperature rise only.
45356490|NCT04455724|Device|Negative pressure incisional wound therapy|A vacuum-style dressing system that is sealed in place over a surgical wound, applying constant negative pressure to the healing tissues.
45356491|NCT04455724|Device|Standard sterile dressing|A standard, sterile island dressing
45356492|NCT04454203|Drug|Mepivacaine|An infiltration of mepivacaine superomedially to the femoral artery via perineural catheter.
45356493|NCT04454203|Drug|Saline|An infiltration of saline superomedially to the femoral artery via perineural catheter.
45843740|NCT01729494|Drug|Tacrolimus|Tacrolimus will be administered orally twice daily (BID). The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally. Tacrolimus should be started post-transplant within 48 hours or when serum creatinine drops lower than 4mg/dL, whichever comes first. The initial targeted trough level of tacrolimus will be 8 - 12 ng/mL for Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.
45356494|NCT04454203|Procedure|Perifemoral Injection of Local Anesthetic|Infiltration of mepivacaine superomedially to the formal artery via perineural catheter in an effort to numb the nerves that contribute to tourniquet hypertension intraoperatively.
45356495|NCT04454203|Procedure|Perifemoral Injection of Local Anesthetic|Infiltration of saline superomedially to the formal artery via perineural catheter that should NOT numb the nerves that contribute to tourniquet hypertension intraoperatively.
45356496|NCT04441307|Behavioral|Healthy Foundations|Healthy Foundations combines elements of a community-based parent education program with additional information about infant and child development, good parenting practices, parent health behavior, and couple support.
45356497|NCT04441307|Behavioral|Family Foundations|A modified version of Family Foundations, an evidence-based preventive intervention for couples during the transition to parenthood, will be implemented to address several aspects of parent and family adjustment, including parent health behavior, particularly alcohol use, and couple relationship dynamics, to promote a healthy parenting environment.
45356500|NCT04425434|Other|OBSERVATIONAL|We will look at the outcome of the the children treated to see if the survival is improved when these therapeutic measures are followed.
45356501|NCT04425421|Other|OBSERVATIONAL|OBSERVAITON OF THE CAPACITY OF THE GROUP TO TREAT ACCORDING TO THE PROTOCOLE AND LOOK AT OUTCOME FOR STAGE I AND II DISEASE
45356502|NCT04413461|Other|TENS|Transcutaneous Electro Neuro Stimulation
45843741|NCT01729494|Drug|Mycophenolate mofetil|The first dose of mycophenolate mofetil/EC mycophenolate sodium will be administered pre-operatively. Patients receiving mycophenolate mofetil will be dosed 1000 mg twice daily (2000mg/day). Patients receiving EC mycophenolate sodium will be dosed 720 mg twice daily (1440 mg/day). Dose may be increased for African American transplant recipients to mycophenolate mofetil 1500 mg twice daily (3000mg/day) or EC mycophenolate sodium 1080 mg twice daily (2160 mg/day).
45843742|NCT01729494|Drug|early cessation of steroids|"Glucocorticoid therapy will be administered as described. Methylprednisolone will be administered on Days 1 through 3. Additional tapering doses of glucocorticoids will continue to be given until Day 5 as below:~Day 1 (day of transplant): 500mg IV prior to alemtuzumab (Group A) or rabbit antithymocyte globulin (Groups B and C) Day 2: 250mg IV Day 3: 125mg IV Day 4: 80mg p.o. Day 5: 60mg p.o. No further steroids"
45843743|NCT05317338|Behavioral|Group-based exercise training during hospitalization|Multicomponent exercises for 5-7 days with acutely hospitalized older.
45843744|NCT05317260|Drug|Antiviral Agents|The type of antiviral agents for the individual patient was selected by physicians based on a policy to reimburse a patient's health and comorbidity.
45478637|NCT04552119|Device|HEALICOIL Knotless PEEK|HEALICOIL Knotless PEEK Self-Tapping HEALICOIL Knotless Non-Self Tapping
45356503|NCT04413461|Other|TENS Sham|placebo of Transcutaneous Electro Neuro Stimulation : similar device without electro stimulation
45356504|NCT04409925|Drug|rhDNase I|Inhaled nebulisations
45356505|NCT04405700|Other|Pharmacovigilance surveillance program|The pharmacovigilance (PV) surveillance program will prospectively monitor for adverse pregnancy and infant outcomes, including the presence of congenital abnormalities, among HIV-positive and HIV-negative women and their infants at clinical sites affiliated with the International Epidemiology Databases to Evaluate consortium (IeDEA).
45356506|NCT04394325|Behavioral|Digital information tool|The patients randomized to group A will receive verbal and written information regarding the digital information tool and how to use it, as well as verbal and written information about the study. They will also receive information about the different instruments and surveys they will be asked to answer at different occasions during the RT treatment period. The applied instruments for data collection will be administrated in person or by post at the baseline collection and by post (including pre-paid return envelope) on consecutive collections. Approximately 30 patients (in group A) will be asked to make regular notes in a notebook during the waiting period prior start of RT as well as during RT treatment period. Following completion of the RT treatment period individual in-depth and telephone interviews will take place with 10-12 patients that accept participation.
45356507|NCT04393285|Drug|Abemaciclib|Abemaciclib 150mg orally twice a day
45356508|NCT04393285|Drug|Letrozole|Letrozole 2.5mg orally once a day
45478638|NCT04552119|Device|HEALICOIL Knotless REGENESORB|HEALICOIL Knotless REGENESORB Self -Tapping HEALICOIL Knotless REGENSORB Non-Self Tapping
45356509|NCT04391283|Drug|Osimertinib|The recommended dose is 80 mg osimertinib once a day until disease progression or unacceptable toxicity according to the prescription information and clinical practice. It can be taken with or without food at the same time each day.
45356510|NCT04374799|Drug|Heparin|two doses of heparin
45356511|NCT04374799|Drug|Placebos|placebo
45356512|NCT04373382|Behavioral|Peer Resilience Champion|PRC is supplied to everyone and provides support to hospital staff during the COVID-19 pandemic in a stepped-wedge design.
45478639|NCT04535323|Other|Quality-of-Life Assessment|Ancillary studies
45478640|NCT04535323|Other|Questionnaire Administration|Ancillary studies
45478641|NCT04535323|Biological|Therapeutic Autologous Platelet-rich Plasma|Given via injection
45356513|NCT04373382|Behavioral|Enriched Survey Feedback|This intervention provides feedback based on answers to questionnaires to those in the Enriched Feedback arm of the study.
45478642|NCT04526886|Other|Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy|Chemotherapy dose-adjustment algorithm for FOLFOX chemotherapy
45478643|NCT04517877|Behavioral|Caring Response App|Participants will receive the Caring Light mobile app containing the coping skills training.
45478644|NCT04517877|Behavioral|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a workbook and online resources.
45478645|NCT04503096|Device|High-dose accelerated rTMS|A MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System will be utilized. All participants will receive open-label treatment for approximately eight, 3-minute sessions of intermittent theta burst rTMS on each of three days within an eight-day span. A single session = 600 pulses at 120% rMT, intermittent Theta Burst Stimulation (iTBS) triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 s to left dorsolateral prefrontal cortex. Total pulses = 14,400. To enable adherence and retention, the days do not need to be contiguous. Same day sessions will be separated by 10-15 minutes, but more accounting for participant comfort.
45478646|NCT04499482|Other|Food|Soy-fiber containing food
45478647|NCT04497857|Other|Coordinated Specialty Care (CSC)|CSC care is an evidenced-based, comprehensive specialty care programs for young people in the initial phases of psychotic disorders
45478648|NCT04496401|Drug|Tacrolimus and Tacrolimus Extended Release Oral Tablet [Envarsus]|"Phase 1: standard dose and frequency tacrolimus, used in accordance with licensing and local protocols. Suitable target trough level should be between 7-14 ng/ml.~Phase 2: ENVARSUS® (LCP Tacro - extended release tacrolimus), used once-daily at an initial dose of 0.17mg/kg, dose adjusted to maintain an appropriate therapeutic blood concentration (measured by trough level). Suitable target trough level should be between 7-14 ng/ml."
45478649|NCT04489303|Behavioral|Caring Response App|Participants will receive the Caring Response mobile app containing the Virtual Patient Behavioral Response Training.
45478650|NCT04489303|Behavioral|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a workbook and online resources.
45843745|NCT05316948|Other|self-questionnaire|Quantitative survey with self-administered questionnaire offered to all patients attending psychiatry study care during the month of the assessment.
45356514|NCT04367857|Other|COVID-19 Serology|Quantitate Serology enzyme-linked immunosorbent assay (ELISA) for COVID-19
45356515|NCT04367857|Behavioral|Health Care Worker Survey|The purpose of this survey is to assess how healthcare workers are experiencing and coping with the COVID-19 crisis.
45356516|NCT04367311|Drug|Atezolizumab|Atezolizumab 1200 mg
45356517|NCT04367311|Drug|Docetaxel|Docetaxel 60-75 mg/m^2
45356518|NCT04367311|Drug|Cisplatin|60-75 mg/m^2
45356519|NCT04367311|Drug|Pemetrexed|Pemetrexed 500mg/m^2
45356520|NCT04343586|Device|Blue light phototherapy|Phototherapy- Wavelength: 417±15 nm
45356521|NCT04341948|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System delivers mild electrical stimulation to nerves in the affected limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
45356522|NCT04333238|Other|New progress note template|Residents assigned to document with new progress note template
45356523|NCT04333238|Other|Standard progress note template|Residents assigned to document with standard progress note template
45356524|NCT04312945|Other|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
45356525|NCT04312945|Other|MRI|Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.
45356526|NCT04298723|Device|Percutaneous closure of the LAA (Watchman / Watchman FLX)|LAA closure procedure will be done by experienced operators according to the local SOP. LAA closure will be performed under fluoroscopic and TEE guidance within conscious sedation or general anesthesia. Antibiotic single-shot prophylaxis should be administered peri-procedurally (i.e., cefazolin 2 g). The specific anatomy of the LAA is evaluated and an appropriately sized CE-marked device (WatchmanTM or Watchman FLXTM) is deployed. LAA angiography and TEE imaging is performed to identify optimal positioning of the device and to exclude a relevant leak. Following device deployment, patients will receive a therapy according to the manufacturers IFU, currently Aspirin and clopidogrel for 3 months followed by single Aspirin up to 12 months. Alternatively, 3 months of NOAC followed by Aspirin monotherapy up to 12 months are possible.
45356527|NCT04288947|Other|Disrespect and Abuse in Maternity Care|Changing the culture of disrespect and abuse in maternity care
45356528|NCT04288570|Procedure|suture anchor socket creation with punch|suture anchor socket creation with punch
45356529|NCT04288570|Procedure|suture anchor socket creation with drill|suture anchor socket creation with drill
45356530|NCT04286386|Other|Hyperpolarized Carbon C 13 Pyruvate|Given IV
45356531|NCT04286386|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
45356532|NCT04286386|Procedure|Surgical Procedure|Undergo standard of care surgery
45356533|NCT04266275|Drug|Curcumin C3 Complex|"Curcumin (Curcumin C3 Complex prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventative and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes."
45356534|NCT04266275|Drug|Placebo|"Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes."
45356535|NCT04248920|Behavioral|Clinic to Community Education Program|The C2C program aims to improve participants' knowledge of epilepsy and access to services and to provide support. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO).
45356536|NCT04245449|Behavioral|TEAACH|"TEAACH e-learning: 3-months of online educational modules include neuroscience education (based on an effective pain educational model37) to improve patient self-efficacy, and strategy-training38 to improve patients' problem-solving abilities for at-home arm use. The course is live on the MUSC MoodleCE platform.~TEAACH in-clinic therapy: 24 in-clinic sessions; 3 times/week for 4 weeks (month 1), 2 times/week for 4 weeks (month 2) and 1 time/week for 4 weeks (month 3) with 200 movement repetitions per session. In our RCTs, this therapy dose required ~1.0-1.5 hours/session. A critical element of TEAACH is the focus on linking in-clinic therapy to out-of-clinic real world paretic arm use via MoodleCE Learning Activities."
45356537|NCT04222790|Drug|monosialic gangliosides|The experimental group received 80 mg of monosialic gangliosides (GM1) on days -1, 1, and 2 of albumin paclitaxel (GM1 is a single infusion).
45356538|NCT04222790|Other|Placebo|The control group received placebo on days -1, 1, and 2 of albumin paclitaxel (placebo as a single infusion)
45843746|NCT05316870|Behavioral|Standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions|Compared with the current anticoagulation management service, we pay more attention to early initiation of anticoagulant therapy and long-term follow-up management.
45356539|NCT04222413|Drug|Metarrestin|Phase IA: Loading dose (2, 3, 6, 9, or 12 mg PO on day 1 of cycle 1 only) with following doses (1, 2, 4 or 6 mg PO) on Mondays-Wednesdays-Fridays or Mondays-Wednesdays. Phase IB: PO according to the dose and schedule estimated during Phase IA
45356540|NCT04210700|Procedure|Fascia iliaca compartment block|"A linear ultrasound transducer is placed in a sagittal plane to identify the anterior superior iliac spine. By sliding the transducer medially, the fascia iliaca and abdominal internal oblique, sartorius, and iliopsoas muscles are identified. After identifying the bow-tie sign, a 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from caudal to cephalad until the needle tip penetrate the fascia iliaca. After negative aspiration, 0.35% ropivacaine 30mL with 1:400,000 epinephrine will be injected to separate the fascia iliaca and the iliacus muscle."
45356541|NCT04210700|Procedure|Pericapsular nerve group block|A curvilinear ultrasound transducer is initially place on the anterior inferior iliac spine and then aligned to the iliopubic eminence by rotating around 45 degree. In this view, the iliopubic eminence, iliapsoas muscle and tendon, pectineus muscle, femoral artery and vein will be identified. A 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from lateral to medial until the needle tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. After negative aspiration, 0.35% ropivacaine 20mL with 1:400,000 epinephrine will be injected.
46046929|NCT05110053|Device|Spinal Cord Stimulator|"Spinal Cord stimulation is a recognized treatment of chronic neuropathic pain. The procedure of implantation is the same in this study. Surgery is done in local anaesthesia. A small electrode is placed in the epidural space corresponding approximately at the Th8-Th10 level.~An impulsegenerator, connected to the electrode, is placed in the subcutaneus fat in the gluteal region."
45356542|NCT04207086|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
45356543|NCT04207086|Drug|Lenvatinib|Lenvatinib is an oral potent multiple RTK inhibitor that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptor (FGFR1-4), platelet derived growth factor (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET).
45356544|NCT04195451|Other|Live-Video-Supervised Exercise Intervention|The live-video-supervised exercise intervention includes exercise sessions x3/week for 3 months, and then maintenance regimen for 6 months. Maintenance includes live-video-supervised exercise sessions, only x1/week, and self-exercise x2/week following an individualized prescribed exercise program and use their heart rate monitor as an activity tracker.
45356545|NCT04195451|Other|Usual Care then Live-Video Supervised Exercise Intervention|Patients randomized to usual care at baseline will receive usual care for 9 months and will then start the live-video-supervised exercise intervention that includes exercise sessions x3/week for 3 months.
45356546|NCT04194359|Drug|Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine|Humanized PD-1 antibody (Sintilimab, IBI308)+bevacizumab+oxaliplatin+capecitabine
45356547|NCT04168008|Behavioral|WISH Adherence|The educational sessions will consist of an adherence-centered curriculum.
45356548|NCT04168008|Behavioral|WISH Parenting|The educational sessions will focus on parenting and baby care.
45478651|NCT04471064|Drug|XY0206|Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the withdrawal criteria. The duration and interval of treatment were determined according to the accumulated condition after multiple dose.
45478652|NCT04470167|Biological|TPX-115|Ultrasound-guided intratendinous injection of allogeneic fibroblasts(TPX-115)
45478653|NCT04470167|Other|Placebo|Ultrasound-guided intratendinous placebo injection
45478654|NCT04466345|Biological|Semaglutide|3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks
45478655|NCT04466345|Biological|Placebo|Semaglutide placebo capsules
45478656|NCT04437498|Device|sham stimulation|non invasive vagal nerve stimulation
45478657|NCT04437498|Device|nVNS|active vns stimulation
45478658|NCT04433156|Drug|Bortezomib|1.3 mg/m2, hypodermic injection on day 1 and day 4 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
45478659|NCT04433156|Drug|Rituximab|375 mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
45478660|NCT04433156|Drug|Epirubicin|70 mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
45843747|NCT05316870|Behavioral|Conventional general practitioner management model|The current general practitioner anticoagulation management model was continued in the control group.
46046930|NCT01073267|Radiation|TSEBT|Total skin electron beam therapy (TSEBT) to a total dose of 12 Gray (TSEBT 12 Gy), low-dose radiation to the skin 4-5 days a week for 3 weeks.
46046931|NCT04457349|Procedure|Therapeutic Plasma Exchange (TPE)|Treatment with Therapeutic Plasma Exchange (TPE)
45356549|NCT04124341|Device|Prefrontal Cortical Stimulation (PCS)|Prior to surgery, subjects will undergo a high resolution structural scan to identify anatomical landmarks for rostral anterior and lateral prefrontal cortex. Following identification of target areas, PCS quad leads will be projected over the anterior and lateral prefrontal cortex. Subjects will be kept in the hospital for a minimum of 72 hours for observation during which the investigators will obtain a high resolution spiral CT scan without contrast to confirm lead placements post-operatively and rule out any intra-cranial bleeds. Patients will receive analgesics which they may continue as an outpatient on as needed basis. During this 2-3 weeks recovery period, the attention to pain control and mood is critical. The research team will contact patients at least twice per week to check on their status.
45356550|NCT04118010|Drug|Vitamin D3|High-dose vitamin D3 50,000 IU /week for 12 weeks
45356551|NCT04118010|Drug|Placebo vitamin D3|Matching to Vitamin D3 placebo capsules for 12 weeks
45356552|NCT04118010|Drug|Inulin|Chicory-derived prebiotic inulin 12 g/day for 12 weeks
45356553|NCT04118010|Drug|Placebo Inulin|Corn-derived maltodextrin 12g/day as the prebiotic placebo for 12 weeks
45356554|NCT04114981|Radiation|Single Fraction Stereotactic Radiosurgery|Undergo SSRS
45356555|NCT04114981|Radiation|Fractionated Stereotactic Radiosurgery|Undergo FSRS
45356556|NCT04114981|Procedure|Quality-of-Life Assessment|Ancillary studies
45356557|NCT04114981|Other|Questionnaire Administration|Ancillary studies
45478661|NCT04433156|Drug|Cyclophosphamide|750 mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
45478662|NCT04433156|Drug|Prednisone|100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles
45478664|NCT04419779|Device|Duodenal Mucosal Resurfacing (DMR)|The Fractyl DMR Procedure utilizes the Revita® Catheter to perform hydrothermal ablation of the duodenum. The Catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DMR treatment are followed for 48 weeks post treatment.
45843748|NCT05316792|Other|walking|30 min walking on the treadmill and tartan floor
45356558|NCT04113863|Drug|all-trans retinoic acid|Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
45356559|NCT04113863|Drug|Anastrozole 1mg|Anastrozole will be administered orally at the dosage of 1 mg/die.
45356560|NCT04099342|Device|FEAST|FEAST with standard electrode configuration and current flow
45478665|NCT04419779|Device|Duodenal Mucosal Resurfacing (Sham)|The Sham procedure consists of placing the Revita® Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient. Subjects who receive the Sham procedure are followed for 48 weeks post treatment and are offered cross over to undergo the DMR procedure at 48 weeks and are followed for further 48 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
45478666|NCT04419519|Drug|Venetoclax monotherapy|Venetoclax monotherapy
45478667|NCT04419519|Drug|Venetoclax with anti CD20 monoclonal antibody|Venetoclax with anti CD20 monoclonal antibody
45478668|NCT04417465|Drug|ABBV-CLS-579|Oral Capsule
45478669|NCT04417465|Drug|PD-1 inhibitor|Intravenous (IV) infusion
45843749|NCT05316636|Device|Vibrational forces|
45843750|NCT05316636|Procedure|Orthodontic treatment with clear aligners|
45356561|NCT04099342|Device|FEAST RP|FEAST with standard electrode configuration and reversed current flow
45356562|NCT04099342|Device|FEAST RC|FEAST with standard current flow and reversed electrode configuration
45356563|NCT04066907|Other|Integrated Disease Management|Multidisciplinary intervention comprising of patient education, self management strategies and medication optimization
45356564|NCT04053491|Procedure|Hand surgery under regional anesthesia|In both groups, patients will benefit from an initial standardized bolus (long-acting local anesthetic, ropivacaine) to cover the operative period, via the allocated approach. Ultrasound guidance and the recommended standards monitors will be used in both groups. After the initial bolus, a catheter will be inserted via the allocated approach. Surgery will be done under regional anesthesia alone, unless there is a medical contraindication or if the patient asks for general anesthesia. Post-operative analgesia will be standardized with regular paracetamol, regular NSAID (Nonsteroidal anti-inflammatory drugs) and oxycodone if needed. The local anesthetics perfusion will be standardized. There will be a medical follow up at 24 and 48 hours where data will be collected.
45478670|NCT04417465|Drug|VEGFR TKI|Oral Tablet
45478671|NCT04417231|Device|CRP apheresis|"Selective CRP apheresis by use of the PentraSorb-CRP"
45687075|NCT05766358|Behavioral|Intensive lifestyle change therapy|Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up
45687076|NCT05766358|Drug|Tirzepatide|Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up
45687077|NCT05762926|Other|Transcranial pulse stimulation (TPS)|Clinical treatment consists in ten sessions of neuronavigation system guided halocranial application of 6000 focused sound wave pulses, with energy flux density of 0.25 mJ/mm2, depth of focus of 5 cm and useful energy between 4 to 6 cm, frequency of 4 Hz, total energy applied will be 50 Joules, for it will be used the Storz Neurolith™ equipment.
45687078|NCT05762614|Other|Dyspnea assessment|Dyspnea assessment, respiratory variability, Spirometry, Electromyography
45687079|NCT05758337|Device|Vibropneumostimulation|New vibrators and techniques of vibropneumostimulation of periimplant tissues have been developed, which will allow us to develop a new concept of the relationship of bone remodulation processes around implants of various designs.
45356565|NCT04041232|Drug|PBA|Glycerol phenylbutyrate (PBA) is a triglyceride that consists of three molecules of phenylbutrate linked to a glycerol backbone. It is a nitrogen-binding agent that has been approved by the Food and Drug Administration (FDA) for the treatment of urea cycle disorders. Oral supplementation of PBA demonstrated no severe side effects, and are found to be therapeutically effective in reducing ER stress. Patients will be instructed to take three doses of PBA per day at equally divided time intervals and rounded up to the nearest 0.5 mL. The total dose of PBA will be 4.5 to 11.2 mL/m2/day (5 to 12.4 g/m2/day) and will not exceed 17.5 mL/day (19 g/day).
45356566|NCT04038541|Dietary Supplement|Prebiotics (Prebiotin Prebiotic Fiber Stick Pac)|"Commercially available Prebiotin Prebiotic.~2 packets (Inulin 4000 mg), Twice Daily (Total of 16 g Daily)"
45356567|NCT04038541|Dietary Supplement|Probiotics (Visbiome®)|"Commercially available Probiotics Visbiome extra strength, which is a combination of live lactic acid bacteria probiotics that have been cultivated, freeze-dried and mixed in very high concentrations.~2 packets (450 billion CFU), Twice Daily (Total of 3,600 billion Daily)"
45356568|NCT04037501|Other|Care Management|A computerized Care Management System (CMS) will identify unmet needs of the informal caregiver of PwD and generates suggestions for interventions. Based on these, the treating physician develops an individualized treatment and care plan and assigns specific tasks to the care manager. Upon a home visit in the caregivers' home the care manager evaluates the need for additional tasks. Based on the complete list of tasks, the care manager initiates the implementation of respective actions. Via monthly telephone calls and optional home visits the care manager monitors the status of implementation and actively coordinates the support and care for the informal caregiver recommended intervention
45356569|NCT04036058|Other|Universal gloving|The intervention will consist of all healthcare workers (nurses, providers, respiratory therapists, radiology and laboratory technicians, etc) utilizing universal gloving (non-sterile gloves) for all patient contacts in the units that are randomized to receive the intervention. If a patient in the intervention unit is known to have CDI or a multidrug-resistant organisms, both gowns and gloves will be used as is currently recommended. Signage denoting what type of precautions are needed will be utilized.
45356570|NCT04030000|Drug|Paclitaxel/Carboplatin|IV paclitaxel in combination with IP carboplatin
45478672|NCT04416451|Drug|Rituximab|Induction:Rituximab will be administered per institutional guidelines once per week for 4 weeks at a dose of 375 mg/m^2. Maintenance: In addition, patients will receive rituximab 375 mg/m2 starting on day 1 of the maintenance phase and repeated once every 3 months for 12 months (for a total of 4 infusions). On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab.
45478673|NCT04416451|Drug|Venetoclax|"Induction: Starting one week after the last induction dose of rituximab (approximately week 5), venetoclax will be administered orally at a flat dose of 100 mg daily and escalating each week to a target dose of 800 mg daily on the following schedule:~Week 1: 100 mg~Week 2: 200 mg~Week 3: 400 mg~Week 4: 800 mg Maintenance: Following the 4-week induction phase ramp-up of venetoclax, patients will begin their target dose of 800 mg venetoclax daily and continue this dose during the 24- month maintenance treatment phase. On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab."
45478674|NCT04414306|Other|In-person cancer screening education|Participants will receive verbal instruction covering the key messages, including risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. These in-person programs will take place in a variety of settings such as community-based organizations (e.g., community businesses, libraries, faith-based organizations, senior centers), fairs and community events, and clinical centers (e.g., health centers, local hospitals). Depending on the setting, education will be facilitated with one or more of the following educational tools: inflatable colon exhibit, PowerPoint presentation, flip chart/flip book, written materials/handouts, and displays. Data will be collected via pre- and post-tests. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
45843751|NCT05316480|Drug|Nimotuzumab|nimotuzumab 200mg/week
45843752|NCT05316402|Other|training on the risks associated with sun exposure|15-minute power point and presentation on the risks of sun exposure
45843753|NCT05316402|Other|dosimetry|dosimetry
45843754|NCT05316246|Drug|Brentuximab Vedotin in Combination with Tislelizumab|Brentuximab vedotin will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a dose of 1.8 mg/kg. Tislelizumab will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a fixed dose of 200 mg. The rationale of fixed dose of Tislelizumab is according to the drug description, which is based on previous I/II phase clinical trial results of Tislelizumab. The time interval between administration of tislelizumab and brentuximab vedotin should be not less than 2 hours, and thereafter, the dosing cycle of tislelizumab is synchronized with that of brentuximab vedotin.
45356571|NCT04030000|Radiation|Pelvic radiation therapy|EBRT and vaginal brachytherapy
45356572|NCT04010539|Drug|Gepotidacin|Gepotidacin will be administered as 3000 milligram (mg) oral dose (4 X 750 mg tablets) at the study site followed by 3000 mg oral dose (4 X 750 mg tablets) as an outpatient. Each dose should be taken after food consumption and with water.
45478675|NCT04414306|Other|Online educational video and website module|Participants will receive online education via a video and website. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
45478676|NCT04414306|Other|Online educational video|Participants will receive online education via a video and website about lung cancer screening. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
45356573|NCT04010539|Drug|Ceftriaxone|Ceftriaxone is available as sterile powder for reconstitution. It will be administered as one 500-mg IM dose at the study site.
45356574|NCT04010539|Drug|Azithromycin|Azithromycin will be administered as 1000 mg oral dose (2 X 500 mg tablets) at the study site. Dose should be taken after food consumption and with water.
45843755|NCT05316168|Drug|Bupivacaine HCl 0.5% Injectable Solution|During adductor canal block participants will receive 20cc of Bupivacaine HCl 0.5%
45356575|NCT04009174|Other|Imaging Panel|"Initial Protocol (REB approval date 08-Sept-2011)~Pre-operative Imaging Panel~[18F]-FCH PET + Dynamic CT~MRI of the pelvis with endorectal coil (T1, T2, DW, DCE, MRS)~3D-Transrectal ultrasound~Optional PET/MRI (added with Protocol Amend 1, REB approval date 22-Aug-2012)~Optional Sodium (23Na) MRI (added with Protocol Amend 2, REB approval date 25-Feb-2013)~Protocol Amendment #3, REB approval date 20-Oct-2015:~Pre-operative Imaging Panel~[18-F]-DCFPyL PET+Dynamic CT~PET/MRI with endorectal coil~3D-Transrectal Ultrasound~Optional Sodium (23Na) MRI"
45478677|NCT04414306|Other|Message from healthcare system and online educational video and website module|Patients at one or more healthcare systems will receive a message from their healthcare provider or healthcare system indicating that they are due or overdue for colorectal cancer screening and receive information on how to schedule a related care (e.g. appointment with primary care provider to discuss screening options) and have the option of receiving education via on online video and website module with or without research study participation. Only recipients of this information who opt into the study through a consenting process will be considered study participants. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
45478678|NCT04411381|Other|Telemedicine|Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination
45356576|NCT03983161|Drug|Fedratinib|Fedratinib
45478679|NCT04409782|Other|Group education|Participants will receive education covering the key messages pertaining to cancer research studies and clinical trials, in a group class setting. Education will be facilitated with one or more of the following educational tools: PowerPoint presentation, written materials/handouts, and displays. Data will be collected via pre- and post-tests. The post-test includes questions to pre-screen participants for eligibility into cancer research studies and clinical trials; as appropriate, study participants will be referred to those study/trial/clinical teams for follow-up.
45478680|NCT04409782|Other|Online educational video and website module|Participants will receive online education via a video and written web content. Key messages will include information pertaining to cancer research studies and clinical trials. Data will be collected via pre- and post-tests. The post-test includes questions to pre-screen participants for eligibility into cancer research studies and clinical trials; as appropriate, study participants will be referred to those study/trial/clinical teams for follow-up.
45687080|NCT05757557|Drug|Sham treatment|Sham treatment: Oxygen-air mixture without NO after intubation, during CPB, and for six hours after surgery.
45687081|NCT05757557|Drug|80-ppm NO|NO will be supplemented at 80-ppm concentration to cardiac surgery patients perioperatively after trachea intubation, during CPB, and for six hours after surgery.
45843756|NCT05316168|Drug|Dexamethasone|During adductor canal block participants will receive 2mg Dexamethasone
45843757|NCT05316168|Procedure|Infiltration between Popliteal Artery and Capsule of the knee (iPACK)|Prior to closing the surgical wound participants will receive a local injections of 20cc 0.5% bupivacaine mixed with 2mg dexamethasone
45843758|NCT05316168|Drug|Percocet 5Mg-325Mg Tablet|Participant will receive 20 Percocet 5/325mg tablets post surgery for pain control
45843759|NCT05316090|Procedure|Core stability exercises program|Strengthening to the trunk muscles
46046932|NCT02876705|Other|Exercise|Completion of this study will took a total of three sessions, separated by one-week intervals. At week one, participants will complete a baseline incremental cycling and running tests to determine the workload and velocity values corresponding to their RPE (6-20 Borg's scale) = 15 (i.e., heavy). Participants also will be familiarized with the use of body maps and reporting procedures. At week two and three, participants will complete the constant-power cycling and constant velocity running tasks. The constant-power cycling and running will last up to volitional exhaustion. The end will be set when participants won't be able to cycle longer at the fixed cadence.
45687082|NCT05751317|Diagnostic Test|Culture|"Samples will be transported to Medical Microbiology and Immunology Laboratory and will be inoculated on MacConkey medium.~Pink colonies will be inoculated on bile esculin agar medium.~Enterococci produce blackening of the agar"
45687083|NCT05751317|Diagnostic Test|Staining:|The growing colonies on bile esculin agar medium will be examined microscopically after staining by Gram stain.
45687084|NCT05751317|Diagnostic Test|Biochemical reactions:|"Catalase test.~Salt tolerance test"
45843760|NCT05316090|Procedure|Traditional physical therapy program|Neurodevelopmental training excercises
45843761|NCT05315856|Biological|either BNT162b2 or ChAdOx1 vaccine|Either BNT162b2 or ChAdOx1 was assigned to each participant by the Korean governmental policy, not allowing personal choice. Sixty participants were vaccinated with two doses of the ChAdOx1 (AstraZeneca) at 12-week intervals, and the remaining sixty were immunized with the BNT162b2 (Pfizer-BioNTech) vaccine at 3-week interval.
46046933|NCT01142336|Drug|Simvastatin|Simvastatin 40mg qHS for 1 year
46046934|NCT01142336|Drug|Placebo|Placebo 1 tablet qHS for 1 year
46046935|NCT04699227|Procedure|Cuff application with inflation|The blood pressure cuff will be placed on the arm and inflated.
46046936|NCT04699227|Other|Sham inflation|The blood pressure cuff will be placed on the arm and not inflated.
45356577|NCT03982940|Device|BGP+ Stent Graft System as bridging stent|BGP+ Stent Graft System as bridging stent
45356578|NCT03965676|Other|Dual-Energy Computed Tomography examination|Dual-Energy Computed Tomography examination at 6 and 12 months +/- 1 month of medical treatment with uricemia < 360μmol/L (baseline DECT is in the domain of usual care).
45478681|NCT04408794|Drug|Zavegepant (BHV-3500)|10 mg IN up to 8 times per month, up to 1 year
45478682|NCT04406623|Drug|SL-172154|The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
45356579|NCT03957590|Drug|Tislelizumab|Administrated at dose of 200 mg intravenously (IV)
45356580|NCT03957590|Drug|Placebo|Placebo to match tislelizumab
46046937|NCT02875691|Dietary Supplement|green tea extract|Patients are given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules( 500 mg) for three months.
45356581|NCT03957590|Drug|Paclitaxel|Administered as 135 mg/m² IV injection
45356582|NCT03957590|Drug|Cisplatin|Administered as 25 mg/m² IV injection
45356583|NCT03957590|Radiation|Radiotherapy|Administered at a total dose of 50.4 Gy in 28 fractions
45356584|NCT03944941|Drug|Avelumab|Given IV
45356585|NCT03944941|Drug|Cetuximab|Given IV
45478683|NCT04405765|Device|NPWT and lyopreserved Stravix|Subjects will be treated with NPWT and lyopreserved Stravix
45478684|NCT04405765|Device|NPWT and cryopreserved Stravix|Subjects will be treated with NPWT and lyopreserved Stravix
45478685|NCT04398433|Drug|INO-3107|INO-3107 administered by IM injection followed by EP using CELLECTRA™ 2000 device at Day 0, Week 3, 6, and 9.
46046938|NCT02875691|Dietary Supplement|placebo|Patients in placebo group receive daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
45687085|NCT05751317|Diagnostic Test|VITEK|Automated identification of Enterococci will be done with VITEK2 system.
45356586|NCT03927027|Drug|Isosulfan Blue|Given SC
45356587|NCT03927027|Procedure|Axillary Lymph Node Dissection|Undergo ALND
45356588|NCT03927027|Procedure|Mapping|Undergo ARM
45356589|NCT03927027|Other|Quality-of-Life Assessment|Ancillary studies
46046939|NCT05080023|Device|Enhanced External Counterpulsation (EECP)|Enhanced External Counterpulsation (EECP)
46046940|NCT00915681|Drug|Silibinin|20 mg/kg continuous IV is over 24 hours
45356590|NCT03927027|Other|Questionnaire Administration|Ancillary studies
45478686|NCT04398433|Device|CELLECTRA™ 2000|CELLECTRA™ 2000 device used for EP following IM delivery of INO-3107.
45478687|NCT04394754|Device|BodyPort|Patients will receive BodyPort, a smart scale that provides advanced cardiac monitoring.
45478688|NCT04394754|Other|Noom|Patients will receive a subscription to use Noom, a personalized diet and weight management application.
45478689|NCT04394754|Other|Conversa|patients will receive a subscription to use Conversa, a personalized automated coaching and motivational application.
45687086|NCT05751317|Diagnostic Test|Antibiotic sensitivity test|Strains confirmed as Enterococci will be examined for their antibiotic susceptibility by modified Kirby Bauer's disc diffusion method on Mueller-Hinton Agar.
46046941|NCT01128296|Drug|Hydroxychloroquine|Oral dosing daily starting at 48 hours before first dose of gemcitabine (starting on Day -2) and for a total of 31 days (ending on Day 29), prior to surgical resection. Capsules are available in 200 mg strengths. Daily doses are 200, 400, 600, 800, 1000, or 1200 mg, and will be administered BID for doses above 200 mg.
45356591|NCT03921866|Drug|Palbociclib|Palbociclib
45356592|NCT03919955|Drug|Atomoxetine|Atomoxetine 80 mg, per mouth, before bed
45356593|NCT03919955|Drug|Oxybutynin|Oxybutynin 5 mg, per mouth, before bed
45356594|NCT03919955|Drug|Placebo|Placebo, per mouth, before bed
45356595|NCT03919799|Drug|Belumosudil (KD025)|ROCK-2 Inhibitor
45356596|NCT03919799|Drug|Placebo|Inactive substance
45356597|NCT03888027|Behavioral|WalkMORE group|Hospitalized Internal Medicine patients will walk with trained volunteers twice daily until hospital discharge.
45356598|NCT03887221|Drug|Safinamide 50 mg|Safinamide 50mg film-coated tablets will be administered to subjects in Cohort 1. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
45356599|NCT03887221|Drug|Safinamide 100mg|Safinamide 100mg film-coated tablets will be administered to subjects in Cohort 2. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
45478690|NCT04390451|Behavioral|Whole Health STEPS|A peer-delivered package of Whole Health services.
45478691|NCT04388176|Drug|C21|C21 as first treatment
45478692|NCT04388176|Drug|C21|C21 as second treatment
45478693|NCT04388176|Drug|Placebo|Placebo as second treatment
45478694|NCT04388176|Drug|Placebo|Placebo as first treatment
45478695|NCT04386993|Radiation|Intensity modulated radiation therapy|Radiation should be delivered over the course of 1-2 weeks (allowing for weekends/holidays).
45687087|NCT05751317|Diagnostic Test|nanoparticles effect|The effect of nanoparticles on Enterococci antimicrobial resistance pattern
45687088|NCT05751317|Diagnostic Test|The biofilm formation activity|The biofilm formation activity of Enterococci isolates will be tested using the microtiter plate technique
46046942|NCT01128296|Drug|Gemcitabine|Intravenous administration on Days 1 and 15, with the infusion given at the fixed dose rate of 10mg/m2/min (e.g. 150 min for a 1500 mg/m2 dose).
45356600|NCT03885089|Drug|Infliximab [infliximab biosimilar 3]|<Psoriasis> The usual dose is 5 mg as Infliximab (Genetical Recombination) [Infliximab Biosimilar 3] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner according to condition of patients. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks.
46046943|NCT05072379|Device|colostomy self-care app|The study will use mixed methods as the study design in which content analysis will be used to identify the content suited for the App based on interviews with participants. A systematic research and development process will be utilized to design the text, videos, and images in the App's simulations to provide accurate, consistent, and complete knowledge of the skills needed for colostomy self-care and contending with any potential emergency.
45356601|NCT03863808|Behavioral|Cognitive Behavioural Therapy|"Following assessment a one on one session will be given comprising education cognitively targeting false ideas and beliefs on the nature of pain, differentiating nociception due to a painful stimulus and the transition of such a stimulus to a centrally sensitized experience due to misinformation, maladaptive behaviour and fear avoidance. Upon completion of the session assessment using the NPQ will be done to assess the understanding of the patient and further address any shortcomings in future exercise sessions.~Another SEMG recording of the Flexion Relaxation phenomenon will be upon completion of the educational session and a SEMG biofeedback session will begin to help the patient regain their sense of control over their body and function.~After the SEMG biofeedback session a graded exposure exercise program of strengthening and functional training starting from the least feared movements to the most over 10 sessions over 5 weeks."
45356602|NCT03863808|Other|Strengthening exercises|Strengthening exercises in a gradual manner to the Multifidus and Transversus Abdominis muscles.
45356603|NCT03859648|Device|BONEBRIDGE|Bone Conduction Implant
45356604|NCT03852875|Other|Education|Same
46046944|NCT05069558|Device|Investigational PFO Closure Device|Occlutech Flex II PFO Closure Device
46046945|NCT05069558|Device|Standard of Care PFO Closure Device|Amplatzer PFO Occluder and Gore Cardioform PFO Occluder
45356605|NCT03852875|Other|Control|Same
45356606|NCT03846804|Diagnostic Test|Karius Test|Next-generation sequencing of blood and synovial fluid samples for pathogen identification in children with musculoskeletal infections
45356607|NCT03786666|Procedure|Carotid artery recanalization CEA or carotid artery stenting|Carotid artery recanalization CEA or carotid artery stenting
45356608|NCT03760588|Drug|Sacubitril/valsartan|Target dose 97/103 mg b.i.d .
45356609|NCT03758261|Drug|Paravertebral nerve block|The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound Paravertebral Nerve Block will be performed.
45356610|NCT03758261|Drug|Erector Spinae nerve block|The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound erector spinae nerve block will be performed.
45356611|NCT03729778|Biological|Prevnar-13|One time administration of prevnar-13 vaccine
45356612|NCT03718260|Diagnostic Test|[18F]-DCFPyL PET/ CT scan (PSMA PET)|Participants will undergo re-staging with [18F]-DCFPyL PET/CT Scan (PSMA PET).
45356613|NCT03710343|Drug|Metformin|Single case ABA study design. Phase B (intervention period) with metformin administered orally (or by gastrostomy tube) for 16 weeks.
45356614|NCT03698877|Diagnostic Test|Brain Natriuretic Protein (BNP) and Procalcitonin (PCT) blood tests|"For patients with suspected infection, PCT levels will be drawn at the time of suspected infection and again at the start of the next HD treatment.~For patients with shortness of breath, PCT and BNP levels will be drawn at the time of the complaint and again at the start of the next HD treatment."
45478698|NCT04354896|Drug|Levothyroxin|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH 0.4 to 4.6 mU/L, no change to dose; TSH ≥4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
46046946|NCT05082909|Drug|Probenecid|Addition of 500mg QDS to oral penicillin.
45356615|NCT03681561|Drug|Ruxolitinib|"Ruxolitinib at assigned dose* twice daily by mouth begin Day 1 and continuing daily until study treatment stop.~Dose Levels:~1 (starting) : 10mg twice daily 2: 15mg twice daily 3: 20mg: twice daily"
45356616|NCT03681561|Drug|Nivolumab|Nivolumab 480 mg IV every 4 weeks (Day 1) Until disease progression, unacceptable toxicity, patient refusal or a maximum of 2 years
45356617|NCT03656081|Drug|inhaled Ambisome®|inhaled liposomal amphotericin B = inhaled LAmB
45356618|NCT03656081|Drug|inhaled placebo|inhaled isotonic saline
46046947|NCT04594473|Behavioral|Comprehensive Oncology Rehabilitation and Exercise (CORE) Program|[see arm/group descriptions]
46046948|NCT04253145|Drug|PM 01183|Lyophilisate for solution for infusion
46046949|NCT04253145|Drug|Atezolizumab|Concentrate for solution for infusion
46046950|NCT04240509|Drug|Emtricitabine / Tenofovir|Incarcerated men identified at high risk for HIV transmission will be given a 30-day supply of the study drug and will be provided with patient navigation to follow up care upon release.
46046951|NCT04586283|Other|Maternal prone position|Women will be asked to lie in a prone position supported by a specially designed cushion for 30 minutes.
45478699|NCT04354896|Drug|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
46046952|NCT04450329|Drug|SB15 (Proposed aflibercept biosimilar)|Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48. Starting at Week 32, subjects transited from Eylea to SB15 will receive SB15 2 mg (0.05 mL) via intravitreal injection every 8 weeks.
46046953|NCT04450329|Drug|Eylea (Aflibercept)|Subjects randomized into Eylea group will receive Eylea 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
45356619|NCT03656081|Drug|Itraconazole|Itraconazole tablet
45356620|NCT03649048|Drug|High-Dose Cisplatin|Intravenous administration of High-Dose Cisplatin
45356621|NCT03649048|Drug|Low-Dose Cisplatin|Intravenous administration of Low-Dose Cisplatin
45356622|NCT03649048|Radiation|Radiotherapy|Participating centres are to follow their local radiation treatment planning and delivery techniques.
45356623|NCT03642626|Drug|KYMRIAH|FDA approved CD19-directed genetically modified autologous T cell immunotherapy comprised of autologous T cells
45478700|NCT04354168|Behavioral|mHealth Application|Nthabi mHealth Application delivers educational content and recommendations to minimize or eliminate health risks. The content is delivered via the Nthabi application downloaded on an Android phone smartphone. End-users can select from a list of topics relevant to the Lesotho population to engage with the conversational agent, Nthabi, and discuss conditions such as tuberculosis, HIV testing, healthy diet, and family planning.
45478701|NCT04354129|Drug|Cutaquig®|Immunoglobulin replacement therapy with subcutaneous injections of Cutaquig® 165 mg/mL at home.
45478702|NCT04311489|Drug|Ularitide|Continuous intravenous infusion for 48 hours at a dose of 30 ng/kg/min. Depending on effect and/or side effects dose can be adjusted to 15 ng/kg/min or 45 ng/kg/min.
46046954|NCT04826055|Other|biliary limb as fixed length|n all loop bypass procedures we will don't count the total length of small intestine and make the biliary limb as a fixed from total small intestine length as mentioned in literature
46046955|NCT04826055|Other|biliary limb as a percentage from small intestine length|in all loop bypass procedures we count the total length of small intestine and make the biliary limb as a percentage from total small intestine length rather than fixed length
46046956|NCT01115738|Drug|Prasugrel|Loading dose administered once orally and maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
46046957|NCT01115738|Drug|Clopidogrel|Loading dose administered once orally.
46046958|NCT01115738|Drug|Placebo|Loading dose administered once orally
45356624|NCT03642626|Drug|YESCARTA|CD19-directed genetically modified autologous T cell immunotherapy
45356625|NCT03642626|Drug|Fludarabine 30mg/m2 4 doses|30 mg/m2 IV daily for 4 doses
45356626|NCT03642626|Drug|Cyclophosphamide 500 mg/m2; 2 doses|500 mg/m2 IV daily for 2 doses starting with the first dose of fludarabine
45356627|NCT03642626|Drug|Fludarabine 30mg/m2 3 doses|30 mg/m2 IV daily for 3 doses
45356628|NCT03642626|Drug|Cyclophosphamide 500 mg/m2; 3 doses|500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine
45478703|NCT04311489|Drug|Placebo|Continuous intravenous infusion for 48 hours at a bodyweight-adjusted infusion rate.
45478704|NCT04310345|Behavioral|Animal-Assisted Interactions|Child and caregivers will spend approximately 10-5 minutes with a registered canine and its owner during potentially anxiety-producing visits to the clinic or hospital.
45478705|NCT04305405|Drug|Benralizumab|Dose will be stratified by body weight at screening: Patients will receive Dose 1 or Dose 2 of Benralizumab administered by SC injection at Day 0 and Weeks 4, 8, and 16, 24, 32, and 40.
45478706|NCT04270149|Biological|ESR1 peptide vaccine|ESR1 peptides plus Montanide and GM-CSF
45478707|NCT04263259|Behavioral|Attentional Bias Modification|Mobile-Delivered Cognitive Retraining Intervention
45478708|NCT04262856|Drug|Domvanalimab|Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
45356629|NCT03642626|Drug|Fludarabine 25mg/m2 3 days|25 mg/m2 i.v. daily for 3 days
45356630|NCT03642626|Drug|Cyclophosphamide 250 mg/m2; 3 days|250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine
45478709|NCT04262856|Drug|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist
45478710|NCT04262856|Drug|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
45687089|NCT05751317|Diagnostic Test|molecular diagnosis|Molecular identification of some virulence factors genes and antibiotic resistance genes of Enterococci using PCR
45687090|NCT05750082|Device|CCTA CT-FR CAG OCT|Per the protocol, patients will have a CCTA (coronary computed tomography angiography), CT-FFR (fractional flow reserve derived from CTA), ICA (invasive coronary angiography), OCT (optical coherence tomography).
45687091|NCT05748470|Other|SkinCeuticals A.G.E|Ultrasound therapy combined with SkinCeuticals A.G.E + conventional moisturizing and sunscreen.
45687092|NCT05748470|Other|standard cream|Ultrasound therapy combined with standard cream + conventional moisturizing and sunscreen
45687093|NCT05746182|Diagnostic Test|Hereditary Cancer Panel|UCSF's Internal Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified Expanded Hereditary Cancer Panel will be employed which measures a minimum 88 genes
45356631|NCT03642626|Drug|Tecartus|TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and normal B cells
45478711|NCT04258488|Drug|Rivaroxaban Oral Tablet|For 12months, Rivaroxaban oral tablet 20mg once daily For renal disorder subjects_creatinine clearance 15-49 mL/min, 15mg once daily
45478712|NCT04258488|Drug|Vitamin K antagonist(warfarin)|For 12months, keep the international normalized ratio (INR) 1.7-3.0
45356632|NCT03642626|Drug|Abecma, Intravenous Suspension|Infuse ABECMA 2 days after completion of lymphodepleting chemotherapy.
45356633|NCT03642626|Drug|Cyclophosphamide 900 mg/m2; 1 day|Administer cyclophosphamide 900 mg/m2 over 60 minutes on the second day before infusion of TECARTUS
45356634|NCT03642626|Drug|Breyanzi Injectable Product|Infuse BREYANZI 2 to 7 days after completion of lymphodepleting chemotherapy.
45356635|NCT03621982|Drug|ADCT-301|intravenous infusion
45356636|NCT03621982|Biological|Pembrolizumab|intravenous infusion
45356637|NCT03612648|Radiation|Three Fraction Accelerated Partial Breast Irradiation|"TRI-APBI simulation must take place no more than 8 weeks from final definitive breast surgery~Machines that could be used include: SAVI applicator, The ViewRay System for Radiation Therapy, The ViewRay (MRIdian) Linac System, Halcyon, True Beam, True Beam STx, Edge Radiotherapy Delivery System"
46046959|NCT04576377|Biological|FluBlok|Recombinant HA quadrivalent influenza vaccine (0.5mL Flublok®, Sanofi Pasteur) containing 180μg antigen, 45μg for each influenza strain included.
45356638|NCT03612648|Procedure|Partial mastectomy|-Standard of Care
45478713|NCT04255134|Drug|Abatacept Injection|Subjects will be randomized to treatment with either abatacept or adalimumab
45478714|NCT04255134|Drug|Adalimumab Injection|Subjects will be randomized to treatment with either abatacept or adalimumab
45478715|NCT04246281|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|The SPRINT System delivers mild electrical stimulation to the nerves in your low back. The SPRINT System includes up to two leads (small wires) that are placed through your skin into your low back. The leads attach to devices worn on your body that deliver stimulation (called Stimulators).
45478716|NCT04246281|Procedure|Standard interventional management of low back pain|Your doctor will determine which procedure or intervention is appropriate for your back pain. You may receive radiofrequency ablation, spinal cord stimulation, surgery, or another procedure or treatment, as appropriate.
46046960|NCT04576377|Other|Placebo|0.5mL saline placebo.
45478718|NCT04240639|Device|AuroShell particle infusion|Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.
46046961|NCT00632073|Drug|Vicriviroc|One tablet of vicriviroc maleate 30 mg once daily for 24 weeks (added to the subject's failing antiretroviral background regimen for 2 weeks, and then administered with optimized background therapy).
46046962|NCT04651413|Diagnostic Test|PCR Value|Data collection and interpretation
46046963|NCT01141478|Radiation|Proton Beam Radiotherapy|Fifteen consecutive sessions
46046964|NCT01141478|Drug|Sorafenib|400 mg po bid
46046965|NCT01114880|Biological|adalimumab|Prefilled syringe, 40 mg/0.8 mL administered subcutaneously every other week
46046966|NCT01114880|Other|placebo|Prefilled syringe, matching placebo administered subcutaneously every other week
46046967|NCT05188586|Other|MRI/Imaging|Blood collection and pancreatic cancer early detection testing with return of results.
46046968|NCT00625352|Drug|Gemcitabine, UFT|Gemcitabine 1,250mg/m2 IV on D1 and D8 of every 3 weeks combined with UFT 400mg daily PO for 14 days every 3 weeks. Gemcitabine will be administered to patients a maximum of 4 cycles, and then discontinued. UFT will be continued until progression.
45356639|NCT03609216|Drug|Gemcitabine Hydrochloride|Given IV
45356640|NCT03609216|Drug|Cisplatin|Given IV
45356641|NCT03609216|Biological|Pegfilgrastim|Given SC
45356642|NCT03609216|Procedure|Conventional Surgery|Undergo bladder sparing
45356643|NCT03609216|Procedure|Radical Cystectomy|Undergo radical cystectomy
45356644|NCT03609216|Other|Chemoradiotherapy|Undergo chemoradiotherapy
45356645|NCT03608163|Drug|Naloxone|Naloxone Nasal Spray
45356646|NCT03608163|Drug|Diazoxide|Diazoxide (oral)
45356647|NCT03608163|Drug|Placebo (for Naloxone)|Sterile water nasal spray
45356648|NCT03608163|Drug|Placebo (for Diazoxide)|Taste matched oral placebo for diazoxide
45356649|NCT03604445|Drug|BI 905677|Solution for infusion
45356650|NCT03604406|Biological|Varicella Zoster Vaccine|live-attenuated vaccine to prevent herpes zoster
45356651|NCT03604406|Other|Placebo Injection|Saline solution injection
45356652|NCT03604406|Biological|Varicella Zoster Vaccine|non-live vaccine to prevent herpes zoster
45356653|NCT03599635|Drug|liposomal bupivacaine|Experimental
45356654|NCT03599635|Drug|Bupivacaine|Active Comparator
45356655|NCT03581292|Radiation|Radiation Therapy|Undergo radiation therapy
45356656|NCT03581292|Drug|Temozolomide|Given PO
45356657|NCT03581292|Drug|Veliparib|Given PO
45356658|NCT03573700|Drug|Cyclophosphamide|Given IV
45356659|NCT03573700|Drug|Fludarabine|Given IV
45356660|NCT03573700|Drug|Mesna|Given IV
45356661|NCT03573700|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest.
45478719|NCT04217304|Drug|Definity® with High Mechanical Index Ultrasound|Sonothrombolysis; Echocardiographic imaging with intermittent diagnostic high mechanical index during an intravenous 5% Definity® infusion
46046969|NCT01114724|Device|Valiant Thoracic Stent Graft with the Captivia Delivery System|All subjects will be implanted with this device
46046970|NCT00964392|Procedure|Atrial fibrillation ablation|Radiofrequency ablation
46046971|NCT00965718|Biological|Activated T lymphocyte|Intravenous dripping of 200 ml (109~2 1010 lymphocytes/60 kg adult) for 1 hour.
46046972|NCT00914589|Drug|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
46046973|NCT00914589|Drug|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
46046974|NCT00914589|Drug|placebo|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
45356662|NCT03573700|Biological|CD19- specific CAR engineered autologous T-cells (SJCAR19 product)|Given IV
45356663|NCT03573024|Drug|Azacitidine|On day 1 of cycle 1, azacitidine 75 mg/m2 SC or IV will be given, and will continue for 7 days.
45356664|NCT03573024|Drug|Venetoclax|Starting on day 1 of cycle 1, venetoclax will be initiated. It will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3 and 600 mg on day 4. The patient then continues to take the 600mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day. On days the subject is given azacitidine, venetoclax must be given first.
46046975|NCT03561714|Behavioral|Cardometabolic Team Intervention|The CMC-TI team included a registered nurse/certified diabetes educator (RN/CDE) Care Manager, medical assistant (MA) Health Coach, and RN Depression Care Manager. Decision support tools guided therapy for glucose, BP, low-density lipoprotein cholesterol (LDL-c), and depression. At the intervention clinic, the 12-month CMC-TI was delivered to all qualifying patients; surveys were administered to evaluate relevant patient-reported outcomes over 12 months.
45356665|NCT03567837|Other|Fructose + Glucose Beverage|The intervention is an oral sugar challenge with blood sampling over three hours.
45356666|NCT03539848|Device|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
45356667|NCT03534947|Drug|Sonidegib|Sonidegib is a selective and orally bioavailable Smoothened (Smo) antagonist. The dose will be 200mg taken once a day for 12 weeks.
45356668|NCT03534947|Drug|Imiquimod|Imiquimod is an immune response modifier that promotes NF-kappa-B-mediated secretion of pro-inflammatory cytokines, chemokines and other mediators. These immune responses produce cytotoxic effects that are antiproliferative and anti-tumour. Imiquimod treatment requires an extended treatment period of 6 weeks for superficial BCC. Imiquimod is an option for the treatment of small, low-risk superficial BCC when surgery, curettage or cryotherapy are inappropriate. Treatment with imiquimod will be for 5 days a week for a total of 6 weeks.
45356669|NCT03534947|Procedure|Surgery|Although most BCCs are amenable to surgery, excision of large tumours in aesthetically sensitive sites may compromise function or cosmesis. Patients whose BCC has not shrunk in size or depth following 12 weeks of sonidegib will undergo surgical excision of the remaining tumour.
45356670|NCT03534947|Other|Best supportive care|Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery, imiquimod, a clinical trial treatment, radiotherapy or any combination of these interventions
45356671|NCT03530371|Drug|Dexmedetomidine Hydrochloride|intranasal administration of 2.5µg/kg of dexmedetomidine to fall asleep the patients
45356672|NCT03521830|Drug|Nivolumab|480mg IV every 4 weeks
45356673|NCT03521830|Drug|Ipilimumab|1mg/kg IV every 4 weeks for 4 doses
45356674|NCT03521830|Drug|Relatlimab|480 mg IV q4wks
45356675|NCT03496610|Drug|Liposomal Bupivicaine|Patient will receive liposomal bupivicaine mixed with non-liposomal bupivicaine directly to wound
45687094|NCT05745909|Procedure|Laparoscopic or open low-anterior resection of the rectum with TME and created loop transverse colostomy|The loop transverse colostomy is matured without torsion using a plastic retainer. The stoma protrudes 2-3 cm. The loop of the transverse colon is sutured with interrupted sutures using an absorbable 3/0 polyglactin suture without piercing the intestinal wall. The intestinal lumen is opened through a transverse incision on the antimesenteric border.
45687095|NCT05745909|Procedure|Laparoscopic or open low-anterior resection of the rectum with TME and created loop ileostomy|The loop ileostomy is matured 25-30 cm from the ileocecal angle without torsion and without a retainer, so that stoma protrudes 2-3 cm. The loop of the ileum is sutured with interrupted sutures using an absorbable 3/0 polyglactin suture without piercing the intestinal wall. The intestinal lumen is opened through a transverse incision on the antimesenteric border.
45687096|NCT05742113|Device|Masimo Radical-7|perfusion index measuring device
46046976|NCT04539873|Drug|Colchicine 0.5 MG|Patientes in this arm will receive study medication colchicine 1,5 orally on the first day (initially two pills of 0,5 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.
46046977|NCT04539873|Combination Product|CONTROL GROUP|In this case, the centers where the patients are enrolled will adhere to the Colombian guidelines (Colombian Consensus of the Colombian Association of Infectious Diseases)
46046978|NCT02861040|Other|Laboratory Biomarker Analysis|Correlative studies
46046979|NCT02861040|Other|Pharmacological Study|Correlative studies
46046980|NCT02861040|Drug|Vincristine Sulfate Liposome|Given IV
45356676|NCT03496610|Procedure|QL Block|Patient will receive ultrasound guided QL Block
45356677|NCT03489122|Behavioral|yoga|The yoga intervention consists of Iyengar yoga method and coherent breathing sessions for 90 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
45356678|NCT03489122|Behavioral|walking|The walking intervention consists of walking sessions at 2.5 miles an hour on a flat surface for 60 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
45356679|NCT03456934|Other|Modified infant formula|Test formula with lower protein content than standard formula
45356680|NCT03456934|Other|Standard infant formula|Standard infant formula
45356681|NCT03449485|Drug|Chlorprothixene|Patients are tested for their normal prescription chlorprothixene medication
45356682|NCT03448783|Drug|Apixaban|Patients are tested for their normal prescription apixaban medication
45356683|NCT03434730|Radiation|Total Body Irradiation|Participants will receive a total dose of 400 cGy on day -2 and day -1 as 2 fractions (200 cGy x 2). Participants receiving total body irradiation (TBI) are treated in a standing position, and the treatment takes about 20 to 30 minutes.
45356684|NCT03434730|Drug|Cyclosporine|Dilute in D5W or NS to make a 2.5 mg/ ml solution. Infuse slowly over approximately 1-4 hours (intermittent infusion) or 24 hours for continuous infusion.
45356685|NCT03434730|Drug|Mycophenolate Mofetil|A 1000 mg dose should be placed in 140 ml of D5W. Administer only with D5W, over at least 2 hours.
46046981|NCT02861040|Drug|Volasertib|Given IV
46046982|NCT04646187|Biological|Infliximab|Dosing interval lengthening from 8 to 12 weeks
46046983|NCT04646187|Biological|Adalimumab|Dosing interval lengthening from 2 to 3 weeks
46046984|NCT02862366|Other|Blood sampling|Blood sampling every 6 month following the routine calendar of visit
45356686|NCT03434730|Drug|Tocilizumab|For participants < 30kg, dilute with 50mL 0.9% sodium chloride. For participants ≥ 30kg, dilute to 100ml with 0.9% sodium chloride. Administer infusion over 60 minutes with infusion set.
45843762|NCT05315778|Biological|autologous anti-BCMA chimeric antigen receptor T cells|Lymphoadenodepletion chemotherapy with FC (fludarabine 30mg/ m2 for 3 consecutive days and cyclophosphamide 300mg/m2 for 3 consecutive days) will be given at day -5, -4 and -3 before CAR T-cells infusion. A total of 1.0-2.0×10e7/Kg autologous anti-BCMA CAR T-cells will be infused by dose-escalation after the lymphoadenodepletion chemotherapy. Dose of CAR T-cells are allowed to be adjusted according to the severity of cytokine release syndrome.
45687097|NCT05740228|Device|Anodal tDCS - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
45843763|NCT05315466|Procedure|Non-surgical treatment|Analgesics, anti-inflammatories, muscle relaxants, physical therapy, Global Postural Rehabilitation, magnetic therapy, laser therapy, transcutaneous electrical nervous stimulation (TENS), massage, cognitive-behavioral therapy and all those procedures that can bring benefit to back and leg pain.
45843764|NCT05315466|Procedure|Surgical treatment for spinal stenosis|Decompression of nerve structures by laminotomy or laminectomy and posterior lumbar fusion if stabilization of the column is required.
45843765|NCT05315388|Other|Immersion therapy in nature - Vitamin N|"Usual therapy group The first saliva sample will be taken upon awakening to determine cortisol concentration. At their workplace, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~Group 2A and Group 2B In the natural environment, a saliva sample will be taken upon awakening to determine cortisol concentration. After arrival at the site, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~The first phase is a session of observation of the site for 15 minutes. A slow, unhurried walk will be performed for 1 hour and 45 minutes. The order of activities (sitting and walking) will be established to ensure reliability of physiological measurements."
45356687|NCT03434730|Drug|Filgrastim|The single use prefilled syringes contain either 300 mcg or 480 mcg Filgrastim at a fill volume of 0.5 mL or 0.8 mL, respectively. For the prevention/treatment of chemotherapy induced neutropenia, the dose of filgrastim is standardized per body weight: ≤ 60 kg = 300 mcg daily subcutaneously; > 60 kg = 480 mcg subcutaneously daily.
45843766|NCT05315154|Procedure|No axillary surgery|In the study arm will be omitted surgery in axilla
45843767|NCT05315154|Procedure|SLNB|in the control arm will be realized SLNB
45843768|NCT05309850|Behavioral|Lifestyle tool|Regular use of the digital Lifestyle tool
46046985|NCT04264338|Diagnostic Test|Thyromental height test|Assessment of difficult airway
46046986|NCT04639713|Device|Tixel 2|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide dermal remodeling and collagen restructuring that promote wrinkles appearance improvement.
46046987|NCT04282902|Drug|pirfenidone|Pirfenidone is administered orally 3 times a day, 2 tablets each time, for a period of 4 weeks or longer
46046988|NCT00912405|Device|Steroid-Eluting Sinexus Intranasal Splint|Intranasal drug-coated splint placed after functional endoscopic surgery (FESS)
46046989|NCT04284618|Diagnostic Test|assessment of standardized and off axis view radiographs|Radiographic assessment of hallux valgus interphalangeus angles is performed on preoperative standing anteroposterior and on off axis view radiographs. These radiographs are taken by equalizing the hyperpronation of the greater toe.
46046990|NCT04950777|Behavioral|patient education document|The patient education will be designed to address and investigate the four domains of physical literacy including, knowledge and understanding, motivation and confidence, daily behavior, and physical competence, (i.e., referral based training/PT (passive), self-motivated/directed exercise choice (speaks to child ownership/motivation), simple play outside 60 minutes/day (middle)).
46046991|NCT02862054|Procedure|splenectomy|
46046992|NCT02860962|Drug|Dextromethorphan Hydrobromide|Dose as a single capsule preparation formulated by the Investigational Drug Service of MUSC specifically for the purposes of this trial.
45687098|NCT05740228|Device|Anodal High-Definition (HD) tDCS - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
45687099|NCT05740228|Device|Sham stimulation - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
46046993|NCT04432623|Drug|Benserazide Only Product|Investigational drug
45687100|NCT05739448|Other|nutritional intervention|The nutritional intervention will be based on the following 4 elements: nutritional follow-up by a dietician, fortified meals, tender and juicy meat dishes and fish dishes
45478720|NCT04214626|Drug|Rituximab|"Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment: Rituximab, 375mg/m2, Intravenous administration on day 0 repeated every 4 weeks until disease progression or unacceptable toxicity develops, up to 2 cycles."
45478721|NCT04214626|Drug|Lenalidomide|"Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment: 10mg oral administration on day 1 to 21 repeated every 4 weeks until disease progression or unacceptable toxicity develops, up to 12 cycles."
45687101|NCT05739448|Other|physical activity|The physical activity intervention will be based on the following 2 elements: Follow-up with a trainer for adapted exercise and physical exercise instruction sheets
45478722|NCT04214626|Drug|Cyclophosphamide|Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
45356688|NCT03433417|Device|Cutera truSculpt|One truSculpt treatment delivered 0 to 90 days before scheduled Abdominoplasty to one side of the tissue to be removed during abdominoplasty
45356689|NCT03424421|Procedure|subscapular sling|semitendinosus subscapular sling procedure
45356690|NCT03423940|Behavioral|Functional communication training|"During functional communication training (FCT), the social consequence (e.g., attention, toys, breaks from instructions) that heretofore reinforced destructive behavior (i.e., as determined through a functional analysis) is delivered contingent on an appropriate communication response, while destructive behavior is on extinction (i.e., reinforcers are no longer provided). For example, if a functional analysis shows that aggression is reinforced by escape from demands, FCT would typically involve (a) teaching the child to access breaks from demands via a functional communication response (FCR; e.g., saying, Break, please) and (b) placing destructive behavior on extinction (i.e., continuing with scheduled demands independent of destructive behavior)."
45356691|NCT03423940|Behavioral|RaC-enhanced functional communication training|We will use the quantitative predictions of Resurgence as Choice (RaC) Theory to tailor a set of reinforcement-schedule thinning steps for each subject. This quantitative prediction will allow for dynamic decisions regarding how to conduct upcoming treatment sessions, as based on both the subject's recent response to treatment and the RaC equation.
45356692|NCT03418649|Drug|Eplerenone 50 Mg Tab|50 mg PO per day for 10 days
45356693|NCT03418649|Drug|Placebo Oral Tablet|PO once daily for 10 days
45356694|NCT03406897|Drug|Cholecalciferol|Oral Administration
45478723|NCT04214626|Drug|Epirubicin|Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
45478724|NCT04214626|Drug|Vincristine|Induction Chemotherapy: 1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
45478725|NCT04214626|Drug|Prednisone|Induction Chemotherapy: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
46046994|NCT02862522|Other|Questionnaire of overall health|The standardized questionnaire was used to assess occurrence of major adverse cardiovascular events including stroke, re-hospitalization, myocardial infarction or death. Responses were verified by medical record review conducted by an investigator blinded to the results of the standardized questionnaire.
46046995|NCT03548532|Device|G210 incubator|very stable culture temperature, up to 0.1°C, in both arms
46046996|NCT03415620|Procedure|Music listening|Patient is given an ipod with earphone and with saved playlist of different music genres. Music listening session will be given for 30 minutes before, during and after surgery. Questionnaires will be asked to fill in. All the earphones will be disinfected following the hospital's infection control guideline.
46046997|NCT04214613|Procedure|non-cardiac non-neurologic surgery|non-cardiac non-neurologic surgery
46046998|NCT04176081|Drug|Darolutamide|Darolutamide will be administered orally as a tablet. Total daily dose is 1200 mg (2 tablets of 300 mg taken twice daily) for 6 months.
46046999|NCT04176081|Drug|Degarelix|Degarelix is administered by subcutaneous injection. The first dose of degarelix is 240 mg followed by monthly doses of 80 mg for a total treatment duration of 6 months.
45356695|NCT03406897|Drug|Omega 3 fatty acid|Oral Administration
45356696|NCT03395210|Drug|PRN1008|BTK inhibitor
46047000|NCT04176081|Radiation|Radiation Therapy|The total radiotherapy dose for all subjects will be: 36.25 Gy in 5Fx. The study will not include elective nodal irradiation. Every fraction will have 3D image guidance (i.e. cone-beam CT).
45356697|NCT03392324|Device|PRIMA|Implantation of PRIMA device
45356698|NCT03375307|Procedure|Biospecimen Collection|Undergo blood collection
45356699|NCT03375307|Drug|Olaparib|Given PO
45478726|NCT04214626|Drug|Methotrexate|Induction Chemotherapy: 3mg/m2, Intravenous administration on day 3 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, from 2 to 5 cycles for patients with high recurrence risk of the central nervous system.
45478727|NCT04210947|Other|30 rolls per minute(30RPM)|Participants will start using foam roller from muscle origin to insertion with a speed of 2 secs. Then comeback from insertion to origin with 2 secs. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
45356700|NCT03346343|Device|Non-invasive forced airway oscillometry|This is a non-invasive device will measure lung function in spontaneously breathing infants. Infants will have a cushioned mask placed on his/her face and the device will take measurements as the infant breathes normally.
45687102|NCT05737667|Behavioral|Youth Readiness Intervention (YRI)|The YRI is a culturally adapted group intervention that integrates common practice elements of cognitive behavioral and interpersonal therapies. The YRI's core treatment elements target improving emotion regulation skills, interpersonal functioning, and problem-solving skills. The YRI has 12 session that last about 90 minutes. The YRI will be delivered in schools by teachers receiving either mobile-based supervision or standard, in-person supervision.
45356701|NCT03327441|Other|Almonds|Almonds will be provided as 15% energy
45356702|NCT03327441|Other|Omelette|Omelettes will be provided as 15% energy
45356703|NCT03326141|Behavioral|Otago Exercise Program|The program has been adapted for groups and includes 5 flexibility movements (e.g., back extension and ankle, head, neck, trunk movements), 5 leg strengthening exercises (knee extensor, knee flexor, hip abductor, ankle plantar flexes, ankle dorsiflexes), 12 balance movements (knee bends, backwards walking, walking and turning, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, heel-toe walking backwards, sit to stand, stair walking), and a walking plan. The number, intensity and duration of movements are individualized according to preference and ability and they are gradually progressed.
45356704|NCT03326141|Device|Physical activity monitors (e.g., Fitbit)|We will use Fitbit Charge 2 (or an equivalent). Features essential for this research include built-in accelerometers that accurately measure steps and physical activity (PA) duration.Participants will have a brief orientation to these during baseline data collection and have the opportunity to return demonstrate. In addition, RAs will be available to help participants troubleshoot, as needed, via telephone and in person, after intervention meetings. Intervention meetings include discussions about the PAMs, but topics vary according to assigned study condition.
45356705|NCT03326141|Behavioral|Interpersonal Behavior Change Strategies|The interpersonal content will include facilitated discussed about including PA into social routines, identifying and problem-solving social and environmental barriers to PA, social support for exercise, and friendly social comparisons about practicing PA outside the small group setting and interpreting/ sharing data.
45356706|NCT03326141|Behavioral|Intrapersonal Behavior Change Strategies|The intrapersonal content will include encouragement and guidance to identify baseline PA patterns, develop and refine personally meaningful goals and plans, identify and problem solve personal barriers to staying physically active, integrate PA into personal routines, and monitor goal outcomes
45356707|NCT03326141|Other|Information about Health and Wellness|Information about health and wellness varies in dose, according to time spent in each condition that addresses behavior change. Topics in condition 1 include sleep, vaccinations, supplements, fall risk factors, memory, hearing and pain guided by information for older adults available on the NIA and CDC websites. Topics in conditions 2 and 3 include fall risk factors and sleep. Topics in condition 4 include fall risk factors.
45687103|NCT05737004|Diagnostic Test|functional magnetic resonance imaging examination、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II|fMRI examination 、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II were performed in these patients within 1 week before biopsy .
45687104|NCT05735327|Drug|No intervention|As this is an observational study, no intervention will be administered.
46047001|NCT04842513|Drug|Multipeptide plus XS15|The vaccine will be applied by subcutaneous injection into the abdominal skin of the study patient. Vaccination will take place monthly (V1, V2 and V3). A total of three vaccinations will be performed. Peptide vaccines should be injected into the skin at the lower part of the abdomen of the patients. The exact site of vaccination (right or left) will be determined at the time of first vaccination and should not be changed during subsequent vaccinations.
45356708|NCT03315832|Drug|Valsartan|The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
45356709|NCT03315832|Drug|Placebo Oral Tablet|The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
45356710|NCT03306680|Radiation|SBRT|Patients will be assigned to treatment doses using the TITE-CRM model.
45478728|NCT04210947|Other|15 rolls per minute(15RPM)|Participants will start using foam roller from muscle origin to insertion with a speed of 4 secs. Then comeback from insertion to origin with 4 secs. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
45687105|NCT05733013|Other|Surveillance Visit|Follow-up visits will be carried out at intervals per usual clinical practice. Tolerance of medication and adverse events will be recorded in every visit.
45356711|NCT03292601|Device|Cinch Smart Strap|"The study device is a small (with dimensions of 1.5 x 2 x 3/8 and weighing approximately 0.9-oz) Bluetooth-enabled and battery-powered monitor with Velcro strap that attaches to orthopaedic braces for scoliosis in place of the traditional strap and buckle. When the Velcro strap is tightened, the device measures tension in Newtons with the vector of force parallel to and away from the device, reflecting the pulling force required to keep the brace fitted on the patient."
45356712|NCT03292601|Other|Cinch Mobile App|The Cinch App allows patients and parents to track and edit treatment information, sync data from the Cinch Smart Strap, and view compliance data. The app connects via Bluetooth to the Cinch Smart Strap and allows patients and parents save and sync data from the device.
45356713|NCT03260920|Drug|Syntocinon|Intranasal Oxytocin
45356714|NCT03132337|Other|Serial Blood Draws|Day 0 and Day 3 blood draw for SOS biomarkers. If subject develops SOS blood draw prior to dose of Defibrotide, Day 14 after Defibrotide and Day 21 after Defibrotide.
45356715|NCT03124355|Drug|placebo sugar pill|placebo single oral dose
45356716|NCT03124355|Drug|Pyridostigmine Pill|pyridostigmine bromide 30 mg single oral dose
45356717|NCT03124355|Drug|Galantamine Pill|Galantamine hydrobromide 8mg single oral dose
45356718|NCT03124355|Device|Vagal stimulation|Vagal stimulation will be given at 50 Hz during the tilt table tests
45356719|NCT03124355|Device|Sham vagal stimulation|Sham vagal stimulation will be given at 0.01 mA during the tilt table tests
45356720|NCT03122652|Drug|Teriflunomide 14 MG Oral Tablet [Aubagio]|1 tablet once a day
45356721|NCT03122652|Drug|Placebo Oral Tablet|1 tablet once a day
45478729|NCT04210947|Other|self-determined|Participants will start using foam roller from muscle origin to insertion with self determined-speed. Then comeback from insertion to origin with same pace. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
46047002|NCT04570215|Other|Gotcha! Therapy application|"Gotcha! will provide an app-based therapy for people with dementia who have difficulty naming people they know well.~The therapy element works via mass practice and feedback to the users on a trial-by-trial basis. The DNI is very simple in a way; it just presents a long series of pictures for users to name. This DNI will use speech recognition (SR) software in order to make a binary decision as to whether the user said the correct word or not. This affects what the next trial (object to name) is and what auditory cue (if any) is provided the next time the user has to name the same item."
46047003|NCT04570215|Other|Gotcha Therapy application: Maintenance|Gotcha! Maintenance therapy is identical to Gotcha! but takes place over a longer period of time in an attenuated form.
46047004|NCT04532307|Behavioral|Standard of Care SOC|Research assistants refer the consenting participants to Isisekelo Sempilo adolescent and youth friendly services with HIV testing, treatment if positive and PrEP eligibility screening and offer if negative and family planning
45687106|NCT05726786|Drug|Immunonutrition|"Immunonutrition: Oral Impact®, Nestlé Health Science, Switzerland.~IN will be administered as per manufacturer suggestion, i.e. three times a day during 7 days preoperatively. Oral Impact® is a powdered oral feed that provides 309 kcal/bag"
45687107|NCT05724160|Other|Using sitting ellipticals|Patients will receive routine physiotherapy protocols as well as Non-weightbearing stationary elliptical
45687108|NCT05724160|Other|Physiotherapy Protocol|Routine physiotherapy protocol
46047005|NCT04532307|Behavioral|SRH enhanced Isisekelo Sempilo|Self-collected vaginal and urine samples are collected at enrolment. Research assistants then provide an Isisekelo Sempilo clinic referral appointment for results, treatment, HIV testing, sexual health, fertility, and family planning counselling, including the personal benefits of ART and Undetectable=Uninfectious among those infected, and PrEP for those eligible and who are negative.
45356722|NCT03028779|Procedure|Fast-track Total Hip and knee arthroplasty|To be able to do a total knee or hip arthroplasty and return the patient home in less then 24 hours
45356723|NCT03011268|Other|Discontinuation of anti-TNF treatment|Discontinuation of treatment with Infliximab, Adalimumab, and Golimumab in order to record time to relapse occurrences
45356724|NCT03011268|Other|Continuation of anti-TNF treatment|Continuation of treatment with Infliximab, Adalimumab, and Golimumab for 2 years after randomization, then discontinue
45356725|NCT02956031|Other|Screening|Cervical specimen obtained using speculum examination and cervical collection bush.
46047006|NCT04532307|Behavioral|Peer-support (Thetha-Nami)|The research assistants refer the participant to a Thetha Nami peer-navigator in their community. Peer navigators will assess their health, social and educational needs, provide mentorship, and help them access the services they need. The peer navigator will facilitate attendance, adherence and retention at the Isisekelo Sempilo clinic.
45478733|NCT04192370|Drug|Cannabidiol 600mg|All subjects will receive 600mg of oral cannabidiol for 3 days in an open-label fashion. Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL, and the drug will be procured by the Brigham and Women's Hospital (BWH) Investigational Drug Services (IDS) pharmacy. The first dose will be administered at the BWH Center for Clinical Investigation, while doses 2 and 3 will be self-administrated at home. The CBD will be repacked in pre-drawn syringes for the subjects to self-administer at home.
45478734|NCT04189029|Other|Extensive phenotyping|Prospective assessment of physical evaluation, biomarkers and omics, cardiac and vascular imaging and telemonitoring of cardiovascular parameters for 14 days.
45478735|NCT04183504|Behavioral|Brief parenting intervention|Coaching session on positive parenting practices and promoting child development
45478736|NCT04180930|Diagnostic Test|CAPS-5|Clinician Administered PTSD Scale for DMS-5
45478737|NCT04180930|Diagnostic Test|PSSI-5|PTSD Symptom Scale Interview for DSM-5
45478738|NCT04180930|Diagnostic Test|CAPS-IV|Clinician Administered PTSD Scale for DSM-IV
45478739|NCT04180371|Drug|BT5528|Participants will receive a 60-minute intravenous infusion of BT5528 once a week (Days 1, 8, 15, and 22) or every other week (Days 1 and 15) on a 4-week cycle at the selected dose.
45478740|NCT04180371|Drug|Nivolumab|Participants will receive nivolumab at 480mg intravenous infusion every 4 weeks.
45478741|NCT04179864|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small-molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
45478742|NCT04179864|Drug|Abiraterone/prednisone|1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily in combination with prednisone 5 mg administered orally twice daily.
46047007|NCT04532307|Behavioral|SOC + SRH + peer-support|A combination of interventions 2 and 3, to include both self-collected STI testing, nurse led testing and counseling, and referral to a Thetha Nami peer navigator to encourage clinic attendance and sexual health promotion.
45478743|NCT04179864|Drug|Enzalutamide|enzalutamide 160 mg (four 40 mg capsules) orally once daily
45478744|NCT04165083|Biological|Pembrolizumab|IV infusion
45478745|NCT04165083|Biological|MK-4830|IV infusion
45478746|NCT04165083|Biological|MK-0482|IV infusion
45478747|NCT04165070|Biological|Pembrolizumab|IV infusion
45478748|NCT04165070|Drug|Carboplatin|IV infusion
46047008|NCT04430439|Behavioral|Psychosocial stress|The TSST is a 15 minute standardized lab-based challenge task that involves speech preparation, speech delivery while being evaluated by strangers and video taped, and complex mental arithmetic with critiques if errors are made.
46047009|NCT04430439|Behavioral|Control non-stress|Participants will have a relaxed 15 minute conversation with a familiar research team member.
45356726|NCT02956031|Other|Colposcopy|Vaginal speculum examination followed by application of 2% acetic acid and lugol's iodine with inspection with colposcope and punch biopsies taken of abnormal areas.
45356727|NCT02956031|Procedure|LLETZ|The above (see colposcopy) is followed by local anaesthetic with two dentist's ampoules of lignocaine and large loop excision using coagulation of the abnormal area (usually 2 x 3 x 1 cm).
45356728|NCT02945774|Radiation|(18F)-FEPPA|PET ligand that binds to activated microglia, a marker of neuroinflammation
45478749|NCT04165070|Drug|Paclitaxel|IV infusion
45478750|NCT04165070|Drug|Pemetrexed|IV infusion
45478751|NCT04165070|Biological|Vibostolimab|IV infusion
45478752|NCT04165070|Biological|Boserolimab|IV infusion
45478753|NCT04165070|Biological|MK-4830|IV infusion
45478754|NCT04165070|Biological|MK-0482|IV Infusion
45687109|NCT05723640|Drug|177Lu-LNC1004 Injection group 1 radionuclide therapy|The treatment regimen will consist of a single dose 30mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
45478755|NCT04160910|Drug|5-Hydroxytryptophan|Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
45478756|NCT04160910|Drug|Placebo|Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
45478757|NCT04152200|Drug|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
45478758|NCT04125472|Drug|Lumasiran|Lumasiran administered as a subcutaneous (SC) injection
45478759|NCT04109027|Behavioral|BrainStrong-GSR|Goal-directed State Regulation Training (GSR)
45478760|NCT04109027|Behavioral|BrainStrong-OPT|Optimization of Brain Functioning (OPT)
45478761|NCT04094610|Drug|Oral repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005)
45478762|NCT04093323|Biological|Alpha-type-1 Polarized Dendritic Cells|Given ID
45478763|NCT04093323|Drug|Celecoxib|Given PO
45478764|NCT04093323|Drug|PD-1 Ligand Inhibitor|Given IV
45478765|NCT04093323|Drug|PD1 Inhibitor|Given IV
45356729|NCT02944578|Drug|Curcumin|"Curcumin (Curcumin C3 Complex®, prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
45478766|NCT04093323|Biological|Recombinant Interferon Alfa-2b|Given IV
45478767|NCT04093323|Drug|Rintatolimod|Given IV
45356730|NCT02944578|Drug|Placebo|"Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
45356731|NCT02943291|Behavioral|4x4 minutes high intensity interval training|Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
45356732|NCT02943291|Behavioral|10x1 minute high intensity interval training|Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
45356733|NCT02893943|Dietary Supplement|Probiotics|
45478768|NCT04090827|Other|Nurse-led transition intervention and access to the iHeartChange website|"Elements of the transition interventions include: (i) introduction to transition and its importance, (ii) creation of a MyHealth Passport, (iii) review diagram of participant's cardiac anatomy, (iv) discussion of 3 potential future cardiac complications (v) iHeartChange website (vi) discussion of the concept of self-management (vii) discussion and promotion of communication skills by the adolescent with their healthcare team via the GLADD technique (Give, Listen, Ask, Decide, Do) (viii) a 3-sentence summary about their CHD (ix) ongoing text/email support from RN"
45478769|NCT04087018|Drug|zimberelimab|zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1. Participants in each cohort will receive zimberelimab intravenously Q3W. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for which investigational product discontinuation occurs.
45356734|NCT02893943|Dietary Supplement|Placebo|
45356735|NCT02889523|Drug|Tazemetostat|Tablets 200 mg, to be administrated per os
45356736|NCT02889523|Drug|Rituximab|375 mg/m²/dose, D1
45356737|NCT02889523|Drug|Cyclophosphamide|750 mg/m²/dose, D1
45356738|NCT02889523|Drug|Vincristine|1.4 mg/m²/dose (max 2 mg), D1
45356739|NCT02889523|Drug|Doxorubicin|50 mg/m²/dose, D1
45356740|NCT02889523|Drug|Prednisolone|40 mg/m2 in the morning D1 to D5
45356741|NCT02846571|Biological|Human Pancreatic Islet Transplantation|Human Pancreatic Islet Transplantation in the Eye Anterior Chamber of legally blind Type 1 Diabetic Patients with or without a Stable Prior Kidney Transplant
45478770|NCT04083378|Procedure|Ablation Therapy|Undergo standard of care ablation
45478771|NCT04083378|Procedure|Image-Guided Therapy|Undergo software-aided imaging (Morfeus)
46047010|NCT04240119|Other|According to current clinical care standards|Enrolled subjects may be treated with medical management or surgically using indirect revascularization surgery.
46047011|NCT00878722|Drug|PXD101|
46047012|NCT00878722|Drug|idarubicin|
46047013|NCT04381455|Device|OSSIX Bone|subjects will be implanted with OSSIX Bone during sinus elevation surgery
45356742|NCT02835443|Device|Deep Brain Stimulation|Electrical stimulation of the dentate nucleus area of the cerebellum.
45356743|NCT02782741|Drug|Avalglucosidase alfa (GZ402666)|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
45478772|NCT04083378|Other|Quality-of-Life Assessment|Ancillary studies
45478773|NCT04083378|Other|Questionnaire Administration|Ancillary studies
45478774|NCT04067037|Drug|Camrelizumab|30mg, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
46047014|NCT04239183|Device|Stomatherapy|Demonstrate improvement of quality of life (difference of at least 5 points in the StomaQoL questionnaire (21)) among descending colostomy patients, establishing the following comparisons.
46047015|NCT03432897|Drug|Olaparib Pill|300 mg BID
46047016|NCT03432897|Procedure|Prostatectomy|22-42 days post Olaparib patients will undergo surgery
45356744|NCT02782741|Drug|Alglucosidase alfa (GZ419829)|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
45356745|NCT02771626|Drug|CB-839|Glutaminase inhibitor
45356746|NCT02771626|Drug|Nivolumab|PD-1 inhibitor
45478775|NCT04067037|Drug|Epirubicin|35mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
45478776|NCT04067037|Drug|Vincristine|1.4mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
45478777|NCT04067037|Drug|Dacarbazine|375mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
45478778|NCT04066699|Procedure|Percutaneous localization of suspicious lung lesion(s) using electromagnetic navigation and tools.|Transthoracic localization of suspicious lung lesion(s) in preparation for subsequent resection.
46047017|NCT02630836|Drug|XCEL-MT-OSTEO-BETA|XCEL-MT-OSTEO-BETA followed by endomedullary nailing
46047018|NCT02630836|Procedure|Surgical treatment|Isolated endomedullary nailing
46047019|NCT04238559|Other|Self-report questionnaire|Fill in the SWAMECO questionnaire
45356747|NCT02703493|Radiation|Stereotactic Radiosurgery|Patients will receive 6 weeks of IMRT (standard of care) followed by the stereotactic radiosurgery (SRS Boost). Dose of the boost is reliant on which cohort the patient is assigned to. Cohort 1 will receive 8 Gy, Cohort 2 will receive 10 Gy in a single fraction, Cohort 3 will receive 10 Gy split into two fractions.
45356748|NCT02616302|Drug|Dexlansoprazole|Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules
45356749|NCT02546661|Drug|AZD4547|AZD4547 Monotherapy vs. MEDI4736 (durvalumab) + AZD4547 1:1 Randomization.
45356750|NCT02546661|Drug|MEDI4736|MEDI4736
45356751|NCT02546661|Drug|Olaparib|MEDI4736 (durvalumab) + Olaparib
45356752|NCT02546661|Drug|AZD1775|MEDI4736 (durvalumab) + AZD1775
45356753|NCT02546661|Drug|Vistusertib|MEDI4736 (durvalumab) + Vistusertib
45356754|NCT02546661|Drug|AZD9150|MEDI4736 (durvalumab) + AZD9150
45356755|NCT02546661|Drug|Selumetinib|MEDI4736 (durvalumab) + Selumetinib
45356756|NCT02515370|Other|Friends for Life Circles (FLCs).|"The intervention 'Friends for Life Circles (FLCs) will build dynamic peer group support in the community aimed at supporting maternal adherence to appointment keeping and taking lifetime antiretroviral drugs"
45356757|NCT02501733|Device|Medacta GMK Sphere® Medial Knee Prosthesis|"There is no consensus within the Arthroplasty community as to whether a traditional post and cam-style Posterior Stabilized total knee device is superior to a medial-pivot, more congruent device. However, the majority of surgeons seem to prefer the former, though there is a minority that uses the latter device with great success.~To date, there have been few prospective trials directly comparing these devices, and none with the latest generation of Total Knee Arthroplasty implants. Almost all such studies have been retrospective and/or utilizing older generation devices."
45356758|NCT02469753|Drug|NSAIDs|continuous daily
45356759|NCT02469753|Drug|NSAIDs|on demand
45356760|NCT02469753|Drug|anti-TNF|
45356761|NCT02375204|Drug|paclitaxel|IV
45356762|NCT02375204|Drug|ifosfamide|IV
45478779|NCT04055207|Other|VVC|Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
45687110|NCT05723640|Drug|177Lu-LNC1004 Injection group 2 radionuclide therapy|The treatment regimen will consist of a single dose 60mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
46047020|NCT04266015|Dietary Supplement|Enteral nutrition formula|Intervention group will receive nasogastric feeding with commercially available liquid enteral diet (250 ml/can, Kcal/ml, 10.4 g protein/can) during free flap reconstruction at feeding rates 10-30 ml/h.
46047021|NCT02630758|Behavioral|Mindfulness-based Yoga|See study arm description.
45356763|NCT02375204|Drug|cisplatin|IV
45356764|NCT02375204|Drug|pegylated G-CSF|IV
45356765|NCT02375204|Drug|G-CSF|IV
45356766|NCT02375204|Drug|carboplatin|IV
45356767|NCT02375204|Drug|etoposide phosphate|IV
45356768|NCT02375204|Procedure|stem cell reinfusion|surgical procedure
45478780|NCT04053816|Drug|Potassium|"The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol."
45356769|NCT02374242|Drug|Nivolumab|Nivolumab is a fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity.
46047022|NCT02630758|Behavioral|Walking Control Condition|See study arm description.
46047023|NCT00964158|Biological|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections and a booster IM injection
46047024|NCT00659386|Drug|Intravenous immunoglobulin therapy|Patients received total dose of 2 g/kg of immune globulin administered as 0.5 g/kg IV over a period of 6 hours on each of 3 consecutive days.
46047025|NCT04160325|Dietary Supplement|postoperative 3-month exclusive enteral nutrition|postoperative 3-month exclusive enteral nutrition after surgery and alter to normal food after 3 months
46047026|NCT04160325|Drug|azathioprine|azathioprine
46047027|NCT04160325|Other|normal diet|normal diet
45356770|NCT02374242|Drug|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activation. Ipilimumab binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation. The mechanism of action of ipilimumab's effect in patients with melanoma is indirect, possibly through T-cell mediated anti-tumour immune responses.
45356771|NCT02370329|Other|Laboratory Biomarker Analysis|Correlative studies
45356772|NCT02370329|Other|Quality-of-Life Assessment|Ancillary studies
45356773|NCT02370329|Biological|Ropeginterferon Alfa-2B|Given SC
45356774|NCT02366598|Other|Hemp shake|Hemp protein shake
45356775|NCT02366598|Other|Soybean shake|Soybean protein shake
46047028|NCT00662584|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|transcranial magnetic stimulation (TMS) at .5 HZ for 20s
46047029|NCT03986541|Diagnostic Test|Immunohistochemistry|Assessment of tumour amphiregulin, epiregulin and EGFR expression by immunohistochemistry.
46047030|NCT04155814|Drug|Iron Sucrose Injection|USP 100 mg/5 mL (20 mg/mL), solution for IV injection, 100 mg unit dose strength
46047031|NCT04155814|Drug|Venofer Injection|(Iron Sucrose 20 mg/mL), solution for IV injection, 100 mg unit dose strength
46047032|NCT02860884|Procedure|liver biopsy|
46047033|NCT02860884|Other|infrared spectroscopy|
46047034|NCT00662662|Behavioral|Questionnaire|The questionnaire contains 18 questions and is estimated to take approximately 10-15 minutes to complete.
45356776|NCT02366598|Other|Control|Non-protein shake
45356777|NCT02314988|Drug|Tranexamic Acid|"3.0 grams of tranexamic acid will be poured in the surgical field and left in contact for five minutes. Subsequently, excess study solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~TXA solution will be prepared using a dose of 3 grams of tranexamic acid combined with 70 mL of sterile normal saline, for a total volume of 100 mL."
45843769|NCT05257356|Behavioral|psychophysical tasks|"Substudy 1: All participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simulta-neously. The responses and the reaction times of chronic pain patients will be compared to those of healthy participants to characterize possible altera-tions in the patients. Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of the pain, which is assumed to be already increased in the patients.~Substudy 2: As in Substudy 1, all participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously combined with MRI assessing the effects of the counterconditioning on fronto-striatal circuits."
45843770|NCT05250258|Other|Telephone peer support by telephone|"Peer support by telephone from experienced father to new father with depressive symtoms.~4 times or more if requested during 4 months"
45843771|NCT05237232|Other|Magnetic Resonance Angiography (MRA) additional acquisition time|Additional acquisition time, time of flight, during brain MRA of the care allowing to obtain the same quality of vascular anatomical visualization as the brain MRA with gadolinium contrast medium injection performed for the care of the patients treated with jugulocarotid ECMO.
45843772|NCT05237232|Other|Modeling cerebral vascularization|"The modeling of cerebral vascularization from CRIMSON software (CaRdiovascular Integrated Modeling & Simulation) requires several inputs:~The MRA images~The cardiac function curve~The cerebral blood flow~Measurement of systolic, diastolic and mean arterial blood pressure"
45843773|NCT05202366|Drug|CGB-400 Topical Gel|CGB-400 Gel contains two main ingredients: geranic acid and choline. Geranic acid, a naturally occurring essential oil/terpenoid, is a key ingredient in lemon grass and is also found in other natural materials such as cardamom. The other main ingredient in CAGE is choline, which is an essential dietary component and found in foods as free choline and as several esterified forms such as phosphocholine and phosphatidylcholine.
46047035|NCT04547439|Drug|Melatonin|Melatonin 3 mg will be taken nightly for 8 weeks
46047036|NCT04547439|Other|Placebo|Placebo will be given nightly for 8 weeks
46047037|NCT02630524|Behavioral|eHealth Behavioral Lifestyle Intervention Device: Telecoach|Participants will receive weekly/biweekly coaching sessions with a telecoach and use eHealth platform to log food and exercise, review daily goals, and find strategies for reaching goals.
46047038|NCT00666094|Behavioral|Endurance training|supervised endurance training. Three sessions per week in three months.
46047039|NCT00666094|Behavioral|strength training|Supervised strength training. Three sessions per week in three months.
46047040|NCT04529031|Behavioral|Reminder Focused Positive Psychiatry|The focus of RFPP is on enhancing contextual discrimination and emotional regulation, and promoting the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices
45356778|NCT02314988|Drug|Placebo|"Placebo will be poured in the surgical field and left in contact for five minutes. Subsequently, excess solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~The placebo solution will be 100 mL of sterile normal saline."
45356779|NCT02272790|Drug|Adavosertib|Adavosertib will be taken as oral capsules with water, approx. 2 hours before or 2 hours after food.
45356780|NCT02272790|Drug|Paclitaxel|"Paclitaxel will be administered as a 1-hour IV infusion (± 10 minutes) at a dose of 80 mg/m2 according to institutional standards on Days 1, 8, and 15 of each 28 Day cycle.~Patients should be pre-medicated with corticosteroids, diphenhydramine and/or H2 antagonists according to institutional standards."
45687111|NCT05723640|Drug|177Lu-LNC1004 Injection group 3 radionuclide therapy|The treatment regimen will consist of a single dose 80mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
45687112|NCT05723640|Drug|177Lu-LNC1004 Injection group 4 radionuclide therapy|The treatment regimen will consist of a single dose 100mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
45687113|NCT05723107|Drug|Chemotherapy|Patients will receive continuation of second or initiate third-line chemotherapy regimen at the discretion and decision of treating oncologist.
45687114|NCT05723107|Device|Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)|"EUS-RFA will be delivered using the EUSRA RF Electrode, which is a sterile, single-use electrosurgical accessory for coagulation and ablation of soft tissue when used in conjunction with compatible radio frequency generator (VIVA Combo RF Generator).~The device will be used during a routine EUS, which is a minimally invasive procedure used to assess gastrointestinal diseases. Each EUS-RFA procedure will last approximately 60 minutes."
45356781|NCT02272790|Drug|Carboplatin|Carboplatin, at a dose calculated to produce an AUC of 5 will be administered by intravenous infusion according to institutional standards on Day 1 of each 21 Day cycle. The carboplatin dose will be calculated using the Calvert Formula based on the patient's glomerular filtration rate (GFR) which is estimated by using the creatinine clearance.
45356782|NCT02272790|Drug|Gemcitabine|Gemcitabine 800 mg/m² will be administered IV on Days 1, 8, and 15 of each 28-Day cycle.
45843774|NCT05009706|Other|Self-care in Older frail Persons with Heart failure Intervention (SOPHI)|Patients who are randomized to the Self Care group will receive oral and written information, advice and support on following activities: excercise (from physiotherapist), nutrition (dietician) and symptom management (nurse), based on patient´s individual needs and abilities. The Self Care group will perform the activities daily at home. Once a week, patients come to the hospital to exercise with the support of a physiotherapist. Once a week or every other week patients will meet (at hospital or by phone) the dietician and nurse to solve possible problems and to follow-up food/nutrition intake and symptoms/symptom management.
45356783|NCT02272790|Drug|PLD|PLD (pegylated liposomal doxorubicin) 40 mg/m² IV will be given on Day 1 of each 28-Day cycle.
45356784|NCT02256904|Procedure|Anatomical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan.The anatomical cutting blocks will be design to resurface the femoral and tibial bones to restore each patient's pre-arthritic anatomy within specific margins: maximum of 5 degrees valgus/varus tibial or femoral cut and overall lower limb alignment within +/-3 degrees of varus/valgus). GMK sphere TKA will be implanted using the manufactured cutting blocks.
45843775|NCT04925856|Other|blood sample|"•Blood sample:~1 heparinized tube (4 mL) for collection of plasma and storage~1 heparinized tube (4 mL) for immunophenotyping,~4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation."
45356785|NCT02256904|Procedure|Mechanical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan. In the mechanical group, femoral and tibial cutting blocks will be designed for a 0-degree angle according to the mechanical axis. Femoral rotation will be aligned with the femoral trans-epicondylar axis. Tibial rotation will follow femoral rotation. GMK sphere TKA will be implanted using the manufactured cutting blocks.
45356786|NCT02190500|Other|Mobile Stroke Unit Management|Mobile Stroke Unit is a standard 12' Houston Fire Department ambulance equipped with point of care lab, CT scanner and staffed by a Vascular Neurologist, Registered Nurse with acute stroke and research experience, CT Technician and a Registered EMT-P. The MSU is dispatched in coordination with Houston, Bellaire and West University fire department/emergency medical services.
45356787|NCT02174055|Behavioral|Patient Interviews|participate in a brief interview
45356788|NCT02174055|Behavioral|newly developed questionnaire|10-16 patients will review draft items and participate in a cognitive interview. 15 older patients will complete the draft measure in order to generate preliminary psychometric data. All interviews will be audio recorded and transcribed by Ubiqus Transcription Company. The audio recordings are uploaded through Ubiqus's secure server and the transcribed audio is returned to the research staff within 48 hours.
45356789|NCT02174055|Behavioral|Pilot Testing the Draft Measure|The draft measure (approximately 35 items, described above) will be administered to a large sample of older cancer patients (n=150) to generate data to evaluate preliminary psychometric properties (item properties including measures of central tendency, skewness/kurtosis, internal consistency, test/re-test reliability, and construct validity (i.e, convergent and discriminant).and known group differences) to further winnow the measure to include approximately 20 items.
45356790|NCT02113657|Drug|Ipilimumab|3 mg/kg by vein once every 3 weeks for a total of 4 doses.
45356791|NCT02091583|Dietary Supplement|Butter, sunflower and safflower oil|
45356792|NCT02091583|Dietary Supplement|High Oleic Canola Oil and DHA (HOCO-DHA)|
45843776|NCT04894188|Radiation|radiation therapy|Intensity modulated radiation therapy (IMRT), with 50 Gy in 25 daily fractions (2 Gy/fraction, 5 fractions weekly) for 5 weeks (week 1 - week 5).
45843777|NCT04894188|Drug|Goserelin 3.6 MG|Gosereline 3.6mg sc injection at week 1, week 5, and week 9
45843778|NCT04894188|Procedure|radical prostatectomy|Eligible patients will undergo robotic-assisted radical prostatectomy and pelvic lymph node dissection
45843779|NCT04866420|Behavioral|The MenFAS Study|A cross over repeated exposure randomized design observational study
46047041|NCT04529031|Behavioral|attentional control condition (group process)|This group process will undergo telehealth relaxation therapy twice a week for 6-week. Subjects will receive progressive muscle relaxation and other relaxation techniques as well as education about PTSD and supportive psychotherapy
46047042|NCT00666172|Behavioral|Exercise|
45356793|NCT02091583|Dietary Supplement|Barley beta-glucan|
45356794|NCT02091583|Dietary Supplement|HOCO-DHA and Barley beta-glucan|
46047043|NCT00666172|Behavioral|Weight Loss|
46047044|NCT04598139|Other|Study group|The study group uses a web-based medication error notification system
46047045|NCT04158076|Drug|Ezetimibe/Rosuvastatin|PO, Once daily(QD), 8weeks
45356798|NCT02035787|Drug|Metformin|Metformin added to standard non-surgical treatment with levonorgestrel-Releasing Intrauterine Device.
45356799|NCT02032953|Dietary Supplement|Travasol (amino acid injection)|an amino acid supplementation infused intravenously containing essential and non-essential amino acids
45356800|NCT02032953|Drug|Insulin|After the insertion of an arterial catheter and obtaining a baseline arterial blood glucose value, 2 units of insluin will be administered iv followed by an infusion of 2 microunits/kg*min. Ten minuts after starting the insulin, and when the the blood glucose is<6 mmol/L, dextrose 20% supplemented with phosphate (30mmol/L) will be infused. Blood glucose levels measured every 15 minutes and the dextrose infusion rate adjusted to maintain arterial glycemia between 4 and 6 mmol/L until end of study.
45356801|NCT02029833|Other|Regular Canola Oil|
45356802|NCT02029833|Other|High Oleic Canola Oil|
45356803|NCT02029833|Other|Western Type Diet - Common Dietary Oils|
45843780|NCT04775628|Procedure|Inferior glide humerus in GH joint|Supine inferior glide GH joint
46047046|NCT04158076|Drug|Telmisartan|PO, Once daily(QD), 8weeks
46047047|NCT04158076|Drug|Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET|PO, Once daily(QD), 8weeks
46047048|NCT00911404|Behavioral|Low CHO|"Diet with 40% total calories from carbohydrates. In the Low-CHO arm, 15% of calories from carbohydrates will be substituted by monounsaturated fat."
45356804|NCT01850355|Drug|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial (dose maintenance pahe). During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
45356805|NCT01582776|Drug|Lenalidomide and GA101|1000mg of GA101 on D8, D15 and D22of cycle 1 and on D1 of cycles 2 to 6. Oral lenalidomide once daily at 10/15/20/25mg (phase I part) or at recommended dose (phase II part) on days 1 to 21 of a 28-day cycle for the first cycle and on days 2 to 22 of a 28-day cycle for cycles 2 to 6.
45356806|NCT01464164|Drug|Sotatercept|"Cohort 4a: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks. If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:~Cohort 5a: 3 patients on Sotatercept 1 mg/kg every 3 weeks"
45356807|NCT01464164|Drug|Sotatercept with prednisone boost|"Cohort 4b: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks with a three week prednisone boost of 1 mg/kg/day (max 60 mg). If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:~Cohort 5b: 3 patients on Sotatercept 1 mg/kg every 3 weeks with a 3 week prednisone boost of 1 mg/kg/day (max 60 mg)."
45356808|NCT01377389|Drug|Ipilimumab|10 mg/kg by vein over 90 minutes once every 4 weeks, for 4 weeks.
45356809|NCT01377389|Drug|Leuprolide|7.5 mg intramuscular once a month for 8 months
45356810|NCT01377389|Drug|Goserelin|3.6 mg subcutaneous once a month for 8 months
45356811|NCT01377389|Drug|Degarelix|80 mg subcutaneous once a month for 8 months
45356812|NCT01194271|Drug|Leuprolide Acetate|22.5 mg administered as a single intramuscular 3 month depot.
45356813|NCT01194271|Drug|Ipilimumab|10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy.
45478781|NCT04051346|Dietary Supplement|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them
45478782|NCT04051346|Dietary Supplement|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
45478783|NCT04035980|Behavioral|Telemedicine based healthcare programme|Two-way videoconference to evaluate the need of screening with DBS, disease stage evaluation and treatment of HCV RNA positive patients at drug addiction centers
46047049|NCT00911404|Dietary Supplement|High CHO diet|Diet with 55% total calories from carbohydrates.
46047050|NCT00961350|Drug|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
45356814|NCT01194271|Procedure|Radical Prostatectomy|Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
45356815|NCT01119508|Drug|Ipilimumab|Induction Phase: 10 mg/kg by vein (IV) over approximately 90 minutes on Day 1 only repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose repeated every 12 weeks.
45356816|NCT01119508|Drug|Temozolomide|Induction Phase, 200 mg/m^2 by mouth (PO) on Days 1 to 4, repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose delivered on Days 1 to 5, repeated every 4 weeks.
45356817|NCT00602459|Drug|Cyclophosphamide|Given IV
45478784|NCT03997123|Drug|Capivasertib|400 mg (2 oral tablets) given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Study treatment will be continued until disease progression unless there is evidence of unacceptable toxicity, or if the patient requests to stop the study treatment.
45478785|NCT03997123|Drug|Paclitaxel|80 mg/m2 concentrate for solution for infusion, 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle. Paclitaxel treatment will be continued for at least 6 cycles unless the patient experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel.
45843781|NCT04769544|Device|total knee arthroplasty with medial pivot tibial insert or symmetrical insert|standard surgical implantation of total knee arthroplasty
46047051|NCT00961350|Drug|EC Aspirin 325|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
46047052|NCT04408521|Other|NEUROFEEDBACK|EEG recording during alpha-related TV viewing
46047053|NCT04408521|Other|CONTROL|EEG recording during passive TV viewing
46047054|NCT00666250|Dietary Supplement|Xocai Activ drink|proprietary blend of cocoa powder and extracts of acai, grape and blueberry
45356818|NCT00602459|Drug|Fludarabine Phosphate|Given IV or PO
45356819|NCT00602459|Other|Laboratory Biomarker Analysis|Correlative studies
46047055|NCT04155970|Other|Manual therapy|Manual therapy, which includes spinal manipulation; spinal mobilisation; light massage; and trigger point therapy.
45356820|NCT00602459|Drug|Lenalidomide|Given PO
45356821|NCT00602459|Biological|Rituximab|Given IV
45478786|NCT03997123|Drug|Placebo|Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week offtreatment within each 28-day treatment cycle
45356822|NCT00591175|Behavioral|Standard Care only|Dentist Provided Standard Care, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
45356823|NCT00591175|Behavioral|Dental Hygienist provided counseling + Brief Questionnaire|Dental Hygienist provided + Brief Questionnaire, 3-month follow-up assessment,Clinic visit salivary cotinine test, 12-month follow-up, Clinic visit salivary cotinine test assessment
46047056|NCT04155970|Other|Evidence-informed home management booklet|The home management booklet includes advice on posture, over the counter pain medication, cold and heat packs. The booklet also includes a section on patient reassurance and where to seek help from a medical professional in an emergency.
45843782|NCT04767750|Other|Blood sample collection|"5ml of peripheral blood samples will be collected into tubes containing EDTA from all subjects and the following procedures will be performed:~Peripheral blood mononuclear cells (PBMCs) will be isolated from blood samples.~Total RNA extraction from PBMCs by Trizol reagent and spin column.~Reverse transcription to cDNA.~The expression levels of lncRNA H19, IGF-1R mRNA and GAPDH gene (control gene) will be determined by Real-Time Quantitative PCR"
45478787|NCT03996616|Device|Head UP Position|"CPR will be performed manually before the patient is placed on a controlled mechanical elevation device who raises the head and thorax, also known as the head-up position (HUP-Elegard, Minnesota Resuscitation Solutions LLC, USA).~Rescuers will perform CPR as continuously as possible during the placement of the Elegard, with a <10 second pause in chest compressions during the placement of this device. After performing (LUCAS AD + ITD CPR, see other interventions below) for 2 minutes with the head in the 'flat' position, the Elegard device will be turned on and the head will begin to rise as long as the patient is being treated with the ResQPOD-16 and the LUCAS AD. The head will be elevated to approximately 22 cm from the ground to the back of the occiput."
45478788|NCT03996616|Device|Impedance Threshold Device|An an impedance threshold device ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the head is elevated.
45478789|NCT03996616|Device|New Automated CPR|Automated CPR will be initiated as soon as feasible using a new automated CPR mechanical compression device that provides full active compression-decompression CPR (LUCAS-AD, Stryker, USA).
45843783|NCT04766502|Other|Blood sample (20 ml) and EORTC QLQC30 survey|"Blood sample (20ml) will be taken before and 24h after PIPAC procedure~EORTC QLQC30 during pre operative consultation and at each post operative consultations"
45356824|NCT00591175|Behavioral|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
45478790|NCT03948256|Procedure|Control intervention|Prompt closure of EVD with subsequent observation period
45478791|NCT03948256|Procedure|Experimental intervention|Gradual weaning of EVD with 5 cmH2O increase in drainage resistance daily until complete closure with subsequent observation period
46047057|NCT04408287|Other|WebEx Physical Activity Program|The program will be delivered twice-weekly through 45-minute sessions over 6 weeks. An experienced fitness instructor with lived experience and a graduate student from the Department of Health and Rehabilitation Sciences, will lead a class of 4-6 participants. The sessions will be comprised of a 10-minute warm-up phase, a 25-minute aerobic phase and a 10-minute cool-down phase that will incorporate upper-extremity flexibility exercises and mindfulness meditation. Over the duration the instructor will be sensitive to varying levels of function and fitness and will structure the classes to enable a slow progression of intensity. Individual semi-structured interviews will be completed over the WebEx platform to garner feedback and improve study programming for future implementation of a health care service at Parkwood Institute Outpatient Clinic.
45687115|NCT05723029|Other|Bowen Technique|A Bowen moves challenges the muscles for several seconds by the application of a gentle lateral pressure applied by the therapist thumb, against its medial edge. The muscle fibres and its fascia are disturbed from their neutral position and they are slightly stretched. The therapist apply gentle pressure towards the muscles using the skin slack available, and then rolls the thumb across the muscles and gently compressing it, the muscle will bounce back to its original position.
46047058|NCT03537690|Other|Laboratory Biomarker Analysis|Correlative studies
46047059|NCT03537690|Drug|PEOX-based Polymer Encapsulated Paclitaxel FID-007|Given IV
46047060|NCT03537690|Other|Pharmacokinetic Study|Correlative studies
45478794|NCT03943537|Drug|Intranasal Insulin|40 units Novolin R administered intranasally using ViaNase device.
45843784|NCT04724772|Drug|Tranexamic acid injection|Injection of tranexamic acid preoperatively
45843785|NCT04717518|Other|Measurement of Pain|Patients will fill out a brief survey concerning the current visit to the ED.
45843786|NCT04696614|Behavioral|exercise|intervention groups provided different sequential modality of exercise
45843787|NCT04648878|Other|Hybrid combination of physical therapy and powered exoskeleton|18 alternating visits of conventional physical therapy and powered exoskeleton gait training with a wearable robotic powered exoskeleton , three times a week for approximately 6 weeks
46047061|NCT02630680|Drug|Eziclen®/Izinova®|
45356825|NCT00199069|Drug|Asparaginase|
45356826|NCT00199069|Drug|Vincristine|
46047062|NCT03947541|Other|Thoracolumbosacral (TLSO) brace|Patients will be required to wear the TLSO brace when out of bed, beginning on postoperative day 2 through 6 week follow-up period.
46047063|NCT03947541|Other|No Bracing|Participants will not wear a brace in the study.
45356827|NCT00199069|Drug|Daunorubicin, Adriamycin|
45356828|NCT00199069|Drug|Cyclophosphamide|
45356829|NCT00199069|Drug|Ifosfamide|
45356830|NCT00199069|Drug|Cytarabine|
45356831|NCT00199069|Drug|Mitoxantrone|
46047064|NCT04032184|Other|Fluoride toothpaste|regimen using fluoride toothpaste
45356832|NCT00199069|Drug|Methotrexate|
45356833|NCT00199069|Drug|6-Mercaptopurine|
45478795|NCT03905694|Drug|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
45478796|NCT03867903|Device|Babysparks Application|mHealth application, BabySparks©, will be implemented for infant and toddler developmental activities through 24 months of age. (Currently, BabySparks is only designed to work on the developmental milestones through 24 months of age, and therefore the use of the application will no longer be applicable to the patient after reaching a developmental age of 24 months. If the subject has not reached a developmental age of 24 months at the time he/she is chronologically 24 months, the subject/family will be able to continue to utilize the application for a maximum of 24 months from the time they began to use the application or until reaching a study endpoint of reaching 24 months developmentally or death, whichever the infant reaches first.)
46047065|NCT04032184|Other|fluoride toothpaste and chlorhexidine mouthwash|regimen using fluoride toothpaste and chlorhexidine mouthwash
46047066|NCT04032184|Other|fluoride toothpaste, chlorhexidine mouthwash, MI varnish|regimen using fluoride toothpaste, chlorhexidine mouthwash, MI varnish
45356834|NCT00199069|Drug|6-Thioguanine|
45356835|NCT00199069|Drug|VM26|
45356836|NCT00199069|Drug|Dexamethasone / Prednisolone|
45356837|NCT00199069|Procedure|CNS Irradiation|
45356838|NCT00199069|Procedure|Mediastinal Irradiation|
45356839|NCT00199069|Procedure|Stem Cell Transplantation|
45356840|NCT00199043|Drug|Allopurinol|
45356841|NCT00199043|Drug|Rasburicase|
45356842|NCT02601989|Drug|Tadalafil|
45356843|NCT02601989|Drug|Placebo|Per oral intake of placebo for six weeks
45356844|NCT01067053|Drug|bevacizumab, capecitabine, oxaliplatin|"6 cycles (3 weeks each one) of:~bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.~capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.~oxaliplatin: 130/mg/m2(iv),1st day of each cycle.~After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine"
45356845|NCT04097015|Device|Alpha-Stim M|Alpha-Stim M with and Ocular Interface and a Spinal Interface
45356846|NCT01067131|Biological|PEV7C1|capsule intravaginal application contains antigen coupled to virosomes
45356847|NCT01067131|Biological|PEV7C9|capsule intravaginal application contains excipient only
45356848|NCT01067131|Biological|PEV7B2|reconstituted lyophilisate intramuscular application contains antigen at low dose coupled to virosomes
45356849|NCT01067131|Biological|PEV7B1|reconstituted lyophilisate intramuscular application contains antigen at high dose coupled to virosomes
45356850|NCT02601287|Biological|Botulinum Toxin Type A|Botulinum Toxin Type A into detrusor muscle on Day 1
45356851|NCT01067365|Drug|Androxal|12.5 mg once daily
45356852|NCT01067365|Drug|Androxal|25 mg once daily
45356853|NCT00568776|Drug|Placebo Control|ELND005 matched placebo capsules for oral administration, bid for 78 weeks
45356854|NCT00568776|Drug|ELND005|ELND005 capsules for oral administration at a dose of 2000 mg bid for 78 weeks
46047067|NCT04246437|Drug|[18F]FDOPA|Patients will receive a 3-D emission scan following a 6-8 mCi slow bolus injection of [18F]FDOPA over a 30 second period. Serial scans are started simultaneously with the bolus injection of radiotracer and are obtained for approximately 95 minutes.
46047068|NCT04246437|Drug|Carbidopa 200mg oral dose|30 minutes prior to the PET scan, patients will receive the 200mg oral dose of carbidopa to prevent peripheral [18F]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
45478797|NCT03867903|Other|pre and post-test Redcap Survey|Prior to starting the use of the application, parents will be given a REDCap survey to complete to determine their current awareness and interventions being implemented with their child related to reaching developmental milestones. Data entered into application by the subject's caregivers will be stored by BabySparks.After completion of the use of the application (subject reaches a study endpoint), the caregivers will be asked to complete a REDCap survey asking them about their experience with the application.
45478798|NCT03776487|Drug|Fluorouracil|Given IV
45478799|NCT03776487|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45478800|NCT03776487|Biological|Ipilimumab|Given IV
45478801|NCT03776487|Biological|Nivolumab|Given IV
45478802|NCT03776487|Drug|Oxaliplatin|Given IV
45478803|NCT03776487|Procedure|Therapeutic Conventional Surgery|Undergo partial or total gastrectomy and lymphadenectomy
45478804|NCT03764878|Diagnostic Test|functional MRI|Participants will undergo a functional MRI using multiple imaging modalities.
45478805|NCT03681184|Drug|Placebo|Placebo by SC injection
45478806|NCT03681184|Drug|Lumasiran|Lumasiran by SC injection
45478807|NCT03669640|Drug|RO6889450|Participants will receive a once-daily, oral dose of RO6889450 for 12 weeks.
45478808|NCT03669640|Drug|Placebo|Participants will receive a once-daily, oral dose of placebo matched to RO6889450 for 12 weeks.
45478809|NCT03668119|Biological|Nivolumab|Specified dose on specified days
45478810|NCT03668119|Biological|Ipilimumab|Specified dose on specified days
45478811|NCT03668028|Biological|TPX-114|Subjects will be treated with autologous fibroblasts (TPX-114) during arthroscopic surgery.
45478812|NCT03668028|Procedure|Arthroscopic surgery|Subjects undergo conventional arthroscopic surgery for rotator cuff repair.
46047069|NCT04246437|Drug|Entacapone 400mg oral dose|30 minutes prior to the PET scan, patients will receive the 400mg oral dose of entacapone to prevent peripheral [18F]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
46047070|NCT00662896|Drug|naproxcinod 375 mg bid|naproxcinod 375 mg bid
46047071|NCT00662896|Drug|naproxcinod 750 mg bid|naproxcinod 750 mg bid
46047072|NCT00662896|Drug|naproxen 250 mg bid|naproxen 250 mg bid
45356855|NCT00568776|Drug|ELND005|ELND005 capsules for oral administration at a dose of 250 mg bid for 78 weeks
45356856|NCT00568776|Drug|ELND005|ELND005 capsules for oral administration at a dose of 1000 mg bid for 78 weeks
45356857|NCT04021511|Other|OAR application by a nurse|As per protocol, in the Phase B, nurses will be allowed to apply OAR which can lead to an early radiography prescription.
45356858|NCT01067443|Drug|Liposomal amphotericin B (AmBisome®) and sodium stibogluconate|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
45356859|NCT01067443|Drug|Liposomal amphotericin B + miltefosine|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
45356860|NCT01067443|Drug|Miltefosine|Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
45478813|NCT03632941|Biological|VRP-HER2|VRP (alphavirus-like replicon particles) containing self amplifying replicon RNA for HER2
45478814|NCT03632941|Biological|Pembrolizumab|A humanized antibody specific for the programmed cell death 1 (PD-1) receptor.
45478815|NCT03623893|Procedure|Contralateral exploration|Surgery eventually performed when a patent processus vaginalis or hernia exists on the other side than the side on which the child has to be operated on, will be exactly the same as the inguinal hernia repair on the 'symptomatic' side. Exploration of the contralateral side will increase anaesthesia time by 10-15 minutes.
45478816|NCT03608670|Device|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
45478817|NCT03601507|Drug|Alpelisib|Given PO
45478818|NCT03601507|Other|Laboratory Biomarker Analysis|Correlative studies
45478819|NCT03601507|Other|Pharmacodynamic Study|Correlative studies
45478820|NCT03601507|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45478821|NCT03596866|Drug|Brigatinib|Brigatinib Tablets.
45478822|NCT03596866|Drug|Alectinib|Alectinib Capsules.
45478823|NCT03595059|Drug|ABBV-155|Intravenous (IV) Infusion
45478824|NCT03595059|Drug|Paclitaxel|Intravenous (IV) Infusion
46047073|NCT00662896|Drug|naproxen 500 mg bid|naproxen 500 mg bid
46047074|NCT00662896|Drug|ibuprofen 600 mg tid|ibuprofen 600 mg tid
46047075|NCT04797897|Device|CORI|unicondylar knee arthroplasty (UKA) treated with CORI
46047076|NCT04797897|Device|Conventional|unicondylar knee arthroplasty (UKA) treated with conventional approach with conventional manual instrumentation
45478825|NCT03595059|Drug|Docetaxel|Intravenous (IV) Infusion
45478826|NCT03578367|Drug|Asciminib add-on|Asciminib 60 mg or 40 mg taken orally once daily.
45478827|NCT03578367|Drug|Imatinib|Imatinib 400 mg taken orally once daily
45478828|NCT03578367|Drug|Nilotinib|Nilotinib 300 mg taken orally twice daily (total daily dose of 600 mg)
45478829|NCT03578367|Drug|Asciminib single agent|Asciminib 80 mg taken orally once daily
45478830|NCT03568058|Drug|personalized vaccine|Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
46047077|NCT00963924|Drug|D-cycloserine|50 mg by mouth one hour before first cognitive remediation session each week for eight weeks.
45356861|NCT01065259|Drug|OROS MPH|The dosage began with 18mg Qd. It can be increased with 18mg every week until an optimal response achieved. The maximum dosage was no more than 54mg/d. The optimal dosage will maintain for 4 to 6 weeks
45356862|NCT01065259|Drug|Atomoxetine|The dosage begins with 0.5mg/kg.d. It can increased to 0.8mg/kg.d at the second week, 1.2mg/kg.d at the third week, and 1.4mg/kg.d at the 5th week according to the patients response. The optimal dosage will maintain for 4 to 6 weeks.
45356863|NCT00822666|Drug|clopidogrel|comparison of two loading strategies of clopidogrel (300mg vs 900mg) in the two genetic profiles
45356864|NCT00816816|Drug|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy: docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly."
45356865|NCT00816894|Drug|D-serine|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes
45356866|NCT00816894|Drug|Olanzapine|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
45356867|NCT00922350|Other|HELIOX|The nebulization was conducted in the same way that heliox + posture group, except the attitude of trunk, where the patients in this group did the Nebulizer with the trunk upright.
45356868|NCT00922350|Other|OXYGEN|The NEBULIZATION was performed the same way as the heliox group, except for torso posture, where the patients in this group with the trunk upright Nebulizer Oxygen for cars have A NEBULIZATION.
45356869|NCT00922350|Other|HELIOX+POSTURE|"Patients underwent two carried by heliox nebulization associated with fenoterol (2.5 mg) and ipratropium bromide (0.25 mg). We used three ml of saline solution at 0.9%. For nebulization with heliox or oxygen, was used a system of distribution not invasive, semi-closed in a mask that is non toxic connected to a piece Y with a nebulizer in a follow and a bag of tank with a capacity for 2.5 L in the other connected with a valve action. This system was used so that there was a dilution gas. The proportion of 80:20 heliox was used (80% helium: 20% oxygen). To postural change in groups and heliox Oxygen + posture + posture, oriented to the participants to maintain an angle of inclination of the trunk and elbows supported on the thighs, measured from the anterior axillary line and lateral epicondyle of the femur, between 50th and 60th ."
45356870|NCT00922350|Other|OXYGEN + POSTURE|The NEBULIZATION was conducted in the same way that heliox + posture GROUP, however the patients in this group have the Oxygen for Carr A NEBULIZATION
45356871|NCT00635154|Biological|Anakinra (IL-1Ra)|100mg daily subcutaneously administered
45356872|NCT00635154|Drug|Dexamethasone acetate|"Low dose - 20 mg/week~High dose - 40mg days 1-4, 9-12, 17-20 every 28 days ODD cycles OR 40 mg days 1-4 every 28 days EVEN cycles. (Starting dose was determined by treating physician)"
45356873|NCT00778895|Biological|GSK Biologicals' influenza vaccine GSK1557482A|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
45356874|NCT00778895|Biological|Vaxigrip|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
45356875|NCT02550678|Biological|ASN-002|ASN-002, is made of a suspension of recombinant adenoviral particles carrying a gene coding for the human interferon-gamma (IFN). Study participants will receive protocol defined dose of ASN-002 as intra-tumoral injections.
45356876|NCT02550678|Drug|5-FU|5-FU is chemotherapeutic agent used to treat various cancers.
45356877|NCT00293215|Drug|111-Indium-CMD-193|111-In-CMD-193 (3-7 mCi) was administered as an IV infusion over 60 (± 5) minutes.
45356878|NCT00293215|Drug|CMD-193|CMD-193 was administered as an IV infusion over 60 (± 5) minutes.
45356879|NCT00822744|Drug|SSR411298|"Form: capsule~Route: oral administration with food"
45478831|NCT03568058|Drug|Pembrolizumab|200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.
45843788|NCT04648878|Other|Powered Exoskeleton Only|18 visits of powered exoskelton only, three times a week for approximately 6 weeks
45843789|NCT04648878|Other|Physical Therapy only|18 visits of physical therapy only, three times a week for approximately 6 weeks
46047078|NCT00963924|Drug|Placebo|Placebo by mouth one hour before first cognitive remediation session each week for eight weeks.
46047079|NCT00963924|Behavioral|Cognitive Remediation|40 one-hour daily sessions of cognitive remediation (Brain Fitness Program) over eight weeks.
45356880|NCT00822744|Drug|Escitalopram|"Form: capsule (commercial escitalopram tablets were encapsulated within opaque capsules)~Route: oral administration with food"
45356881|NCT00822744|Drug|Placebo (for SSR411298)|"Form: capsule~Route: oral administration with food"
45356882|NCT04102787|Other|cardiac educational program|"Love your Heart is a Heart Foundation program (2016), the Arabic version will be used as the educational program in this study. The programme has been adopted from relevant articles in the evidence- based literature. The program is a guide to support recovery and good heart health. It includes the following: anatomy and physiology of the heart, causes, symptoms and risk factors of CAD, healthy diet, physical activity, weight management, and risk factors management."
45356883|NCT01065337|Biological|tissue repair cells (TRC)|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells
45356884|NCT01065337|Biological|bone marrow stem cells (BMC)|bone marrow stem cells
46047080|NCT04513899|Behavioral|Community health worker (CHW)/ registered nurse (RN) [CHW/RN]|A team of 2-3 CHWs and a research RN will deliver all components of the program including daily DOT delivery of Direct Acting Antiviral (DAA) and assess HCV side effects all under the guidance of their RN. Recruitment will be continuous: each CHW may be assigned up to 7-8 participants every 2-3 months until the target sample size (n=54 for the intervention group) is achieved. After the first dose of the DAA, the CHW will run a brief weekly 1:1 education and case management session over the 8 or 12 weeks (total 20 minutes). The CHW/RN team will assist the participant in picking up the monthly medication and storing the medication in a secure, locked cabinet at the research office. The CHW will rigorously track participants who have missed a dose, and will also be involved in facilitating medical, mental health, substance use, social service, legal appointments for participants, housing referrals, and accompany the participants to the appointments.
45356885|NCT00819468|Drug|Teduglutide|Participants will receive 20 mg dose of lypholized powder of teduglutide mixed with sterile water and injected subcutaneously into the abdomen.
45356886|NCT04102553|Drug|F-18-PSMA-1007|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
45356887|NCT04102553|Drug|F-18-Fluorocholine|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
45356888|NCT01067599|Other|Low nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
45356889|NCT01067599|Other|Medium nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
45356890|NCT01067599|Other|High nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
45356891|NCT00822822|Behavioral|First Questionnaire|Complete questionnaire before completing health history
45356892|NCT00822822|Behavioral|Health History|Complete electronic health history
45356893|NCT00822822|Behavioral|Second Questionnaire|Complete questionnaire after completing electronic health history
45356894|NCT02601131|Biological|Platelet transfusion|
45356895|NCT00778817|Biological|IMC-A12|Given IV
45356896|NCT00778817|Drug|mitotane|Given orally
45356897|NCT00293059|Drug|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placeboA blister card consists of 28 pills taken orally once a day for 28 days (one cycle)
45356898|NCT00293059|Drug|Placebo|Matching placebo to be taken orally daily.
45356899|NCT00756275|Drug|Nicotine Replacement Treatment (NRT)|Nicotine replacement treatment (NRT) will follow the clinical practice guidelines for nicotine patch for people smoking at least 10 cigarettes per day (USDHHS, 2000), modified to allow 12 weeks use (tapering recommended for people with AUDs by Hughes et al., 2003b): 21 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks.
45356900|NCT00756275|Drug|varenicline|Varenicline (VAR, 2 mg/d in divided doses) will be administered as follows. VAR: participant takes 0.5 mg/d for the first 3 days, 1 mg/d (0.5 mg 2x/d) for the next 4 days, and 2mg/d (1.0mg 2x/d) for 12 weeks.
45687116|NCT05723029|Other|Post Isometric Relaxation|Post Isometric Relaxation is performed in supine position on treatment table. The therapist passively flexed the hip and knee at the 90 degrees and then passively extends the knee until the point of tissue resistance. Patient placed their leg on therapist shoulder and contracts his hamstring muscles by pushing down on the therapist shoulder for 10 seconds. After the contraction, patient is asked to relax, then therapist passively stretch to gain new range of muscles.
45687117|NCT05720377|Device|continuous glucose monitor (Freestyle Libre|15 minute phone interview by health care provider to assess health goals set at clinic visits.
45356901|NCT00756275|Behavioral|Behavioral counseling for smoking cessation|The counseling consists of 10 sessions of Brief Advice (BA).BA is a simple smoking cessation counseling strategy: Assess smoking and initial interest in cessation, advise patient to quit smoking, assist patient in quitting, discussion of sobriety specific concerns, and cognitive-behavioral skills training. Medication management is conducted in every session, smoking cessation pamphlets are available. Session 1 (60 min, in-person) will be 1 week before Quit Day.Session 2 (30 min, in-person) takes place on Quit Day. Session 3 (10 min, in-person) will be 1 week later. Sessions 4-10 will be 5-10 min. telephone contacts at Weeks 2, 3, 4, 6, 8, 10, and 12 after Quit Day.
45356902|NCT02601053|Other|Dull movie|A dull movie (duration approximately 90 minutes)
45356903|NCT02601053|Other|Scary (horrifying) movie|A scary movie (duration approximately 90 minutes)
45356904|NCT02601053|Other|Heart rate measurement|Heart rate measurement using a actiheart device
45356905|NCT01065493|Other|QuitAdvisorMD Software Algorithm|QuitAdvisorMD, a set of brief clinical assessments, counseling scripts and intervention instruments for smoking cessation in primary care settings
45356906|NCT01065493|Behavioral|Standard Smoking Cessation Counseling|Standard Smoking Cessation Counseling
45356907|NCT00758459|Drug|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
45356908|NCT00758459|Drug|Placebo|Dosing to match AZD1236
45356909|NCT03977389|Procedure|Total wrist denervation|Study of the files
45356910|NCT05460143|Other|Near-infrared Spectroscopy scan|Near-infrared spectroscopy is a non-invasive neuroimaging technique which uses light in the near-infrared spectrum to measure changes in brain oxygenation and metabolism.
45356911|NCT05460143|Other|Magnetic Resonance Imaging scan|Magnetic Resonance Imaging is a non-invasive neuroimaging technique which provides detailed structural images of the brain.
45356912|NCT04096547|Drug|Rivaroxaban|rivaroxaban for stroke prevention of atrial fibrillation
45356913|NCT02600975|Biological|R21 with ASO1B|R21 with ASO1B
45356914|NCT00298831|Drug|Sugammadex|At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg Org 25969 was administered.
45356915|NCT00298831|Drug|Rocuronium|Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was/were administered.
45356916|NCT02532595|Procedure|manual therapy and exercise|soft tissue mobilization, stretches, concentric and eccentric strengthening
45356917|NCT02532595|Procedure|trigger point dry needling|trigger point dry needling to trigger points located in the gastrocnemius, soleus and tibialis posterior
46047081|NCT04513899|Behavioral|Clinic-based Standard of Care (cbSOC) Program (control group)|This program will be delivered by a clinic-based MD or clinic-based NP at the clinic site. Evaluation Staff (ES) will be hired and trained to do the interviewing/survey administration and follow-ups at the clinic-based site. The clinic NP will conduct, per usual care at the study clinics, the education and monitoring of these participants who will interact with the clinic-based-MD and/or NP monthly over the 8 or 12-week program. Usual care will include: 1) HCV pre-treatment education; 2) two month supply of DAA; 3) monitoring adverse events; and 4) responding to questions on HCV. Referral to drug/alcohol and housing programs will be provided over the standard of care. The cbSOC participants will not receive the community delivery of the DAA, or case management, or accompaniment to needed services. The cbSOC Program will receive the medication on a monthly basis from the clinic MD or NP.
46047082|NCT00659542|Procedure|cyanoacrylate glue|1 ml glue
46047083|NCT02862678|Other|diffusion-weighted MRI|Two diffusion-weighted MRI will be performed (one 8 days before chemoradiotherapy treatment and one 3 months after the end of chemoradiotherapy treatment).
45356918|NCT00758069|Drug|sitagliptin phosphate|100 mg once daily (QD), taken orally for 4 weeks
45356919|NCT00758069|Drug|Comparator: Placebo|Placebo tablet, QD, taken orally for 4 weeks
46047084|NCT00659620|Biological|mesenchymal stem cell|transplantation of mesenchymal stem cell
46047085|NCT03265665|Behavioral|ACTION Intervention|The intervention is based on the Women's Lifestyle Physical Activity Program, a culturally sensitive lifestyle physical activity intervention for African American (AA) women. There are 2 phases to the intervention: Adoptive (24 weeks) and Maintenance (12 weeks). 3 motivational/reminder texts will be made each week during the adoption phase. 5 Group sessions(adoptive): Participants will be given individualized step goals, watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking. 1 Group session (maintenance): watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking, reinforce barriers and facilitators to walking. An interventionist will lead a discussion on role-modeling and encouraging problem solving. Each intervention group will have 10 women with 1 interventionist. Data will be collected at 3 time points: baseline, 24-weeks and 36-weeks.
46047086|NCT03265665|Other|Enhanced usual care|"Participants will attend 1 two hour asthma education/physical activity session at community location near them. Participants will review basic asthma topics in a didactic session and will include exercising with asthma and exercise-induced asthma. Participants will be given Fitbit and provided instructions on how to use it. Participants may receive 2 newsletters with information on asthma and reminder texts regarding data collection visits.~Data will be collected at 3 time points: baseline, 24-weeks and 36-weeks."
45356920|NCT00758069|Drug|Comparator: Sitagliptin|50 mg twice daily (BID), taken orally for 4 weeks
45356921|NCT01067677|Drug|Metaclopramide|0.5 mg/kg for rescue after PONV
45356922|NCT01067677|Drug|Ondansetron|0.1 mg/kg (max 4 mg0
45356923|NCT01067677|Drug|diphenhydramine|0.25 mg/kg (max 25 mg)
45356924|NCT01067677|Drug|Saline|equal volume (5 ml)as experimental rescue medications
45356925|NCT04097795|Other|Prehabilitation|According to our definition, prehabilitation consists of exercise therapy during at least 2 weeks. This is combined with optimalisation of the patients' nutritional status at least 2 weeks before surgery.
45356926|NCT03979651|Drug|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level -1 = Hydroxychloroquine 400 mg by mouth once a day"
45356927|NCT03979651|Drug|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 1 (starting dose) = Hydroxychloroquine 800 mg by mouth once a day"
45356928|NCT03979651|Drug|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 2 = Hydroxychloroquine 600 mg by mouth two times a day"
45356929|NCT02600741|Other|Caregiver psycho-education and skills training|Caregivers will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period.
45356930|NCT02600741|Other|Caregiver support available at the study site|Caregivers will receive whatever caregiver support that is customarily available at the study site, if any.
45356931|NCT02600741|Drug|Paliperidone palmitate|Patients enrolled in this study will continue to receive routine treatment of paliperidone palmitate, as directed by their treating physician.
45356932|NCT02600741|Drug|Chlorpromazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45356933|NCT02600741|Drug|Droperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45356934|NCT02600741|Drug|Fluphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45356935|NCT02600741|Drug|Haloperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45356936|NCT02600741|Drug|Loxapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45356937|NCT02600741|Drug|Perphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45356938|NCT02600741|Drug|Pimozide|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45356939|NCT02600741|Drug|Prochlorperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45356940|NCT02600741|Drug|Thiothixene|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45478832|NCT03543410|Drug|SEP-4199 200 mg|SEP-4199 200 mg/day (supplied in two 100mg tablets)
46047087|NCT02861196|Procedure|Intensity modulated radiation therapy, Radical cystectomy|Postoperative Intensity modulated radiation therapy(IMRT) will be applied to effective team.Radical cystectomy will be applied to ineffective team.
46047088|NCT04155658|Other|Experimental Toothpaste containing 1450ppm SMFP|Experimental Toothpaste containing 1450ppm SMFP
45356941|NCT02600741|Drug|Thioridazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45356942|NCT02600741|Drug|Trifluoperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45356943|NCT02600741|Drug|Aripiprazole|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45356944|NCT02600741|Drug|Asenapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45356945|NCT02600741|Drug|Clozapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
46047089|NCT04155658|Other|Toothpaste containing 1450ppm SMFP|Toothpaste containing 1450ppm SMFP
45356946|NCT02600741|Drug|Iloperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45356947|NCT02600741|Drug|Olanzapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45356948|NCT02600741|Drug|Paliperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45356949|NCT02600741|Drug|Quetiapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45356950|NCT02600741|Drug|Risperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45356951|NCT02600741|Drug|Ziprasidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
45356952|NCT03979573|Diagnostic Test|Multiparametric MRI|Multiparametric prostate MRI (mp-MRI)
45356953|NCT03979573|Diagnostic Test|Radiomics|Radiomics analyses will consist of image intensity normalization, image coregistration and resampling, radiomic feature extraction, combination with clinical and molecular parameters, feature extraction and machine learning, model testing on validation and test cohorts and comparison to existing clinical risk models.
45478833|NCT03543410|Drug|SEP-4199 400 mg|SEP-4199 400 mg/day (supplied in two 200mg tablets
45478834|NCT03543410|Drug|Placebo|Placebo (supplied in two tablets/day)
45478835|NCT03514017|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously (IV) at 200 mg every 3 weeks for 1 year and up to 2 years.
45478836|NCT03514017|Drug|Ibrutinib|Ibrutinib will be administered orally once daily at approximately the same time each day at the dose of 420 mg daily (3 capsules of 140 mg daily).
45478837|NCT03502785|Biological|INO-5401|INO-5401 (9 milligram [mg] dose IM): mixture of 3 synthetic plasmids that target Wilms' tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) antigen.
45478838|NCT03502785|Biological|INO-9012|"INO-9012 (1 mg dose IM): A synthetic plasmid that expresses human interleukin-12 (IL-12).~INO-5401 + INO-9012 will be administered IM followed by EP with CELLECTRA™ 2000 device every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, thereafter every 12 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator."
45478839|NCT03502785|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator.
46047090|NCT04155658|Other|Toothpaste with no fluoride|Toothpaste with no fluoride
46047091|NCT02861976|Other|Opioid risk screen development & implementation|Development of a screening tool for the risk of opioid misuse in patients with traumatic injury.
46047092|NCT00631839|Radiation|Thoracic 3-D Conformal Radiotherapy|Thoracic RT tailored for each patient, about 60Gy (NSCLC) or 55Gy (SCLC) with photon energies >=6MV.
46047093|NCT00666484|Drug|cyclophosphamide|
46047094|NCT00666484|Drug|doxorubicin hydrochloride|
46047095|NCT00666484|Drug|etoposide|
46047096|NCT00666484|Drug|prednisolone|
46047097|NCT00666484|Drug|procarbazine hydrochloride|
46047098|NCT00666484|Drug|vincristine sulfate|
45356954|NCT03979573|Diagnostic Test|MR-guided Biopsy|MR-guided targeted prostate biopsies as well as systematic TRUS-guided biopsies (at least 12 cores) will be performed on a fusion-guided biopsy system. The biopsy cores can either be obtained transrectal or transperineal.
45356955|NCT03979573|Diagnostic Test|Molecular Markers|Molecular markers will be analyzed on the initial and final targeted and systematic biopsy cores. The molecular panel consists of a methylation-specific PCR and a set of highly selected markers that can be detected by immunohistochemistry. The resulting data will be prospectively recorded to enable a retrospective analysis of the prognostic value.
45356956|NCT01325545|Other|Mobile cardiac rhythm monitoring|Continuous ambulatory cardiac rhythm monitoring using the CardioNet MCOT device
45356957|NCT01067755|Device|LungPoint Virtual Bronchoscopic Navigation (computer-assisted image-guided bronchoscopic navigation)|LungPoint Virtual Bronchoscopic Navigation is a product that displays images and information to aid bronchoscopists in guiding the bronchoscope and other instruments to a target location in the lung airways.
45356958|NCT01065649|Drug|Nortriptyline|It will be administered per oral 10 mg a day in the first 7 days and then 25 mg a day in the last 14 days
45356959|NCT01065649|Drug|Placebo arm|Placebo per oral for 21 days, equal to nortriptyline
45356960|NCT01062685|Diagnostic Test|Near-infrared spectroscopy assessment|"The InSpectra StO2 Tissue Oxygenation Monitor (model 650; Hutchinson Technology, Hutchinson, MN, USA) with probes spaced at 15 mm will be utilized to obtain StO2 measurements.~Following a minimum initial five-minute stabilization period, the initial StO2 will be measurement and then a Vasoocclusive Testing Procedure (VOT) will be performed using an automated tourniquet (Delfi Tourniquet System; Delfi Medical Innovations, Inc, Vancouver, BC, Canada), insufflated to 50 mmHg over the patient's SBP for a period of three minutes."
45478840|NCT03502785|Device|CELLECTRA™ 2000|IM injection of INO-5401 and INO-9012 is followed by EP with the CELLECTRA™ 2000 device.
45356961|NCT01065727|Other|mitoxantrone - immunomodulator|mitoxantrone during 6 months and followed by immunomodulator during 2 years and half
45356962|NCT01065727|Other|natalizumab|monthly natalizumab during 3 years
45356963|NCT01067833|Drug|K201 Tablet|oral tablet, x28 days
45478841|NCT03495960|Drug|Rituximab|"PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Rituximab is given 375 mg/m2 as standard infusion at days -6, 1, 15 & 29. Rituximab on day -6 will be delivered only during the first course; it will be delivered between day -6 and day 0 according to clinical requirements and patient's conditions. Some patients would need for a fast chemotherapy starting.~PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Rituximab is given 375 mg/m2 in 4 weekly doses, starting on day 2 of radiotherapy."
45356964|NCT01067833|Drug|Placebo Tablet|oral tablet, x28 days
45478842|NCT03495960|Drug|Methotrexate|During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Methotrexate is given 3 g/m2 as infusion (0.5 g/m2 in 15 min. + 2.5 g/m2 in 3-hr infusion) on days 2, 16 & 30
45478843|NCT03495960|Drug|Procarbazine|"PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Procarbazine is given oral 60 mg/m2/d from days 2 to 11~PART A - MANTEINANCE PHASE (control arm) Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Procarbazine represents the control arm and is given oral 100 mg/d from day 1 to 5 for 6 courses, every 4 weeks."
45478844|NCT03495960|Drug|Lenalidomide|"Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Lenalidomide represents the experimental arm and is given oral 25 mg/d from day 1 to 21 for 24 courses; every 4 weeks."
45843790|NCT04602858|Device|Reactive Balance Training|Reactive balance training involves the use of the Trip and Slip walkway that is able to expose participants to unpredictable trips and slips. Trips and slips will occur at random location on the walkway and times within the gait cycle, with the participants receiving 3-monthly retraining sessions along with an educational booklet.
45843791|NCT04602858|Other|Control|The control intervention will be receiving an educational booklet as part of standard care. The education component will target a variety of fall risk factors and provide strategies to mitigate these risk factors.
45843792|NCT04525716|Other|COVID-19 infection status|We will compare patients with/without confirmed COVID-19 infection
46047099|NCT00666484|Radiation|radiation therapy|
46047100|NCT04508751|Other|"3T Free-Breathing Fetal Magnetic Resonance Imaging"|Subject will have a one time MRI scan.
46047101|NCT00662974|Other|perineal massage with Wheat Germ Oil during the second stage of labor|30 ml of oil applied during labor
46047102|NCT00662974|Other|perineal massage with almond oil during the second stage of labor|30 ml of oil applied during labor
46047103|NCT04507893|Other|Clinical, laboratory and imaging characteristics of pneumonia|"Evaluation of the clinical, laboratory and imaging characteristics in patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay for COVID-19 on naso-pharyngeal swab as COVID-19 patients and negative COVID-19 patients."
46047104|NCT00666640|Device|DXA scan of hip|Dual-energy X-ray Absorptiometry scan
46047105|NCT00666640|Device|CT scan of hip|Computed Tomography scan
46047106|NCT00663130|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg, taken orally within 1 hour prior to sexual intercourse
46047107|NCT00663130|Drug|Tadalafil|Tadalafil 10mg, taken orally within 1 hour prior to sexual intercourse
46047108|NCT01114646|Device|Cemented Hip Hemiarthroplasty|The cemented femoral prosthesis is a VerSys LD/Fx, Zimmer, Warsaw, IN.
46047109|NCT01114646|Device|VerSys Beaded FullCoat, Zimmer|The press-fit component is a VerSys Beaded FullCoat, Zimmer, Warsaw, IN,
46047110|NCT00965562|Drug|Fluoxetine|Fluoxetine 20 mg per day for 4 menstrual cycles. For the fifth menstrual cycle, all women will receive calcium. Women on Fluoxetine will continue taking it in addition to 1200mg of calcium.
46047111|NCT00965562|Drug|Calcium|1200 mg of calcium to be taken for 5 menstrual cycles.
45478845|NCT03495960|Radiation|Radiotherapy|Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the eyes. Photons of 4 - 10 MeV, 180 - 200 cGy per day, 5 weekly fractions will be employed
46047112|NCT00965562|Drug|Placebo|For 5 cycles, women will receive placebo. At the end of the fourth cycle, all women will receive 1200 mg of calcium in addition to the placebo medication.
46047113|NCT02631382|Procedure|wet cupping|"In double cupping (traditional technique): Cupping (suction) then scarification then cupping (suction).~In single cupping (Asian): puncture using auto lancet then cupping (suction). In both techniques 4 out of 6 acupoints (BL23, BL24, BL25 bilateral) will be selected."
46047114|NCT00659698|Device|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
46047115|NCT00666796|Drug|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
45356965|NCT01065805|Biological|18F-FLT|"Phase I: Radioactive dose of 2.59 MBq/kg (111-222 MGq)per injection. A single injection of 18F-FLT and PET scan will be permitted per patient.~Phase II: Radioactive dose of 2.59 MBq/kg (100-350) MBq per injection. Up to five separate injections of 18F-FLT and PET scans will be permitted per patient"
45356966|NCT01067911|Dietary Supplement|Butter and Vegetable oils from soy, flaxseed, high oleic safflower and canola|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
45356967|NCT01067911|Dietary Supplement|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
45356968|NCT01067911|Dietary Supplement|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
45356969|NCT01067911|Dietary Supplement|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
45356970|NCT00311623|Drug|Rapamycin 3mg|Rapamycin 3mg (Wyeth Pharmaceuticals, 1mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
45356971|NCT00311623|Drug|Rapamycin 6mg|Rapamycin 6mg (Wyeth Pharmaceuticals, 2mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
45356972|NCT00311623|Procedure|Radical prostatectomy|Radical prostatectomy performed on Day 15
45356973|NCT01067989|Drug|Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)|"Cyclophosphamide Tab. 50mg, 1x1/day, continuously.~Capecitabine Tab. 500mg, 1+2/day, continuously.~Methotrexate Tab. 2.5mg, 1x2/day, 2 days every week.~Celecoxib Tab. 200mg, 1x2/day, continuously.~Pamidronate I.V. 90mg, every 4 weeks; or Zoledronate I.V. 4mg, every 4 weeks)"
45356974|NCT00528112|Drug|LCS12|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 12 microg/24 h
45356975|NCT00528112|Drug|LCS16|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 16 microg/24 h
45356976|NCT00633594|Drug|Rituximab|"DL 1, DL 2, and DL 3: 375 mg/m2 IV Days 1, 8, and 15; Cycles 2-6: 375 mg/m2 IV Day 1~Same for DL-1."
46047116|NCT00666796|Drug|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
46047117|NCT00666796|Drug|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
46047118|NCT00666796|Drug|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
45356977|NCT00633594|Drug|Bortezomib|"DL 1, DL 2, and DL 3: 1.3 mg/m2 IV Days 1, 4, 8, and 11~Same for DL-1."
45478846|NCT03495960|Drug|Temozolomide|"PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Temoyolomide is given 75 mg/m2/d, every day for the whole duration of radiotherapy.~PART B - MAINTENANCE PHASE Temozolomide is also given as maintenance in Part B. The treatment consists of 12 courses where temozolomide is administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses,"
45356978|NCT00633594|Drug|Lenalidomide|"DL 1: 15 mg PO daily Days 1-14 followed by 7 days of rest~DL 2: 20 mg PO daily Days 1-14 followed by 7 days of rest~DL 3: 25 mg PO daily Days 1-14 followed by 7 days of rest~DL-1: 10 mg PO daily Days 1-14 followed by 7 days of rest"
45356979|NCT03742648|Other|Physiotherapy|Chest physiotherapy in burn patients in order to treat and prevent post burn respiratory complications like pneumonia etc
45356980|NCT00817128|Procedure|PEPT|Pain Exposure Physical Therapy
45356981|NCT00817128|Procedure|CBO standard|Standard therapy as defined in CBO guideline 2006
45478847|NCT03491683|Biological|INO-5401|INO-5401 is a combination of 3 separate DNA plasmids targeting Wilms tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) genes. Starting on Day 0 three milligrams (mg) of each plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by immunotherapy Response Assessment in Neuro-Oncology (iRANO), unacceptable toxicity, withdrawal of consent, or death.
45478848|NCT03491683|Biological|INO-9012|INO-9012 is a DNA plasmid for expression of human interleukin-12 (IL-12). Starting on Day 0 one mg plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.
45478849|NCT03491683|Biological|Cemiplimab|Cemiplimab is an antibody to programmed death-1 (PD-1) protein. Starting on Day 0 cemiplimab will be administered intravenously (IV) every three weeks at a dose of 350 mg per dose in the absence of dose holding, until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.
46047119|NCT00666796|Drug|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
45478850|NCT03491683|Radiation|Radiation Therapy|Radiation therapy (RT) will begin no later than 42 days after surgical intervention, and should start approximately 2 weeks after Day 0. RT will be given for three weeks.
45478851|NCT03491683|Drug|Temozolomide|Temozolomide (TMZ) will be given daily during radiation therapy (RT) at a dose of 75 milligrams per square meter (mg/m^2).
45478852|NCT03471247|Device|In-Bed Cycle Ergometer|Physiotherapists will place the patient's legs in a specialized in-bed cycle ergometer allowing for gentle leg exercise. Exercise can performed in passive, active-assisted, or active mode.
45478853|NCT03471247|Other|Routine PT|Includes, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out- of bed mobility, ambulation, and assistance with optimizing airway clearance and respiratory function.
45478854|NCT03471234|Device|Angioplasty|Inspiron Drug Eluting stent implantation
45478855|NCT03448692|Drug|PF-06730512|Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV. Subjects in cohort 3 will receive Dose 3 IV infusion.
45478856|NCT03438656|Behavioral|Behavioral Activation|The Adolescent Behavioral Activation Program (ABAP) will be used as the BA protocol. ABAP was developed and validated by McCauley, Dimidjian et al. to adapt BA to adolescents. ABAP is a 12-week protocol that utilizes an idiographic approach to foster rewarding experiences, effective problem solving, and goal attainment, and decrease avoidance, barriers to activation, and depressive rumination that may be contributing to depression severity and maintenance.
45478857|NCT03351296|Drug|LV5FU2|LV5FU2 (Folinic Acid D, L 400 mg/m² day 1, 5FU 400 mg/m² IV bolus, 5FU 2400 mg/m² 48 hours continuous infusion)
45478858|NCT03351296|Drug|Streptozocin|streptozotocin 800 mg/m² day 1 every 14 days
45478859|NCT03351296|Drug|Capecitabine|Capecitabine 750 mg/m² twice daily, days 1-14
46047120|NCT00666796|Drug|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
46047121|NCT00666796|Drug|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
45356982|NCT04840888|Drug|LY3484356|Administered orally.
45356983|NCT04840888|Drug|Omeprazole|Administered orally.
45356984|NCT04840888|Drug|Itraconazole|Administered orally.
45356985|NCT04840888|Drug|Carbamazepine|Administered orally.
45356986|NCT04714840|Other|Exercise testing results|Tailored, home-delivered aerobic and strengthening intervention,exercise intolerance,Both groups of participants will be provided with the results of their exercise testing.
46047122|NCT00666796|Drug|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
46047123|NCT00912093|Drug|Icatibant|Single subcutaneous injection of icatibant, 30 mg
46047124|NCT00912093|Drug|Placebo|Single subcutaneous injection of matching placebo
45356987|NCT04714840|Other|Individually tailored exercise program (INT)|Individuals randomized to receive an individually tailored exercise program will meet with an exercise specialist. Written instructions, videos of each strengthening exercise, a blue tooth enable heart rate monitor, all necessary exercise equipment, and an iPad pre-loaded with heart rate monitor software, exercise videos and ZOOM app (for video conferencing) will be provided. After returning home, the exercise specialist will supervise and provide guidance to the individual via the ZOOM app during the first 2 weeks (3 sessions per week). Supervision will slowly decrease to twice a week in weeks 3-4, once a week in weeks 5-8, every other week in weeks 9-16, and to one time midway between weeks 17-20. The exercise program will be adjusted depending on the individuals progress.
45356988|NCT04714840|Other|Generalized exercise recommendations (AC)|Individuals randomized to receive the generalized exercise recommendations will receive a copy of the Physical Activity Guidelines for Americans. At the baseline visit, a study staff will review these guidelines and answer questions about their exercise testing and encourage them to be physically active. The staff will contact them via telephone to complete a short questionnaire weekly during weeks 1-8 and monthly for weeks 9-20.
45356989|NCT04944160|Other|Medical records analysis|To review of medical records to describe diagnosis and severity of the disease.
45356990|NCT04944160|Other|Comparison of cohorts|To compare pre and post Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
45356991|NCT04707976|Device|Navina Smart|CE-marked NavinaTM Smart including Navina Smart App.
45356992|NCT04707976|Other|Standard Bowel Care|Bowel care will be scheduled at least every 2nd day according to a defined study specific standard bowel care protocol. Diet, fluids, abdominal massage, regular physical activity and medications will be used if non-interventional treatment is insufficient.
45356993|NCT00755807|Drug|Duloxetine Hydrochloride (HCI)|Participants received 30 mg duloxetine (po, QD) for 1 week followed by 5 weeks at 60 mg in the acute placebo-controlled period. If the participant completes the double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 mg QD for 12 weeks).
45356994|NCT00755807|Drug|Placebo|Participants received placebo oral (po), once daily (QD) for 6 weeks (acute phase). If the participant completes the 6-week double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 milligrams [mg] QD for 12 weeks).
45356995|NCT03998644|Other||
45356996|NCT05372224|Drug|Cholecalciferol|4000 IU were administrated once a day for 3 months.
45478860|NCT03351296|Drug|Temozolomide|temozolomide 200 mg/m² once daily, days 10-14, every 28 days
45356997|NCT04831606|Procedure|debridement|Cleaning of the wound area
45356998|NCT04831606|Device|Offloading|Offloading performed with a standard brace to the calf (Optima Diab, from Molliter).
45478861|NCT03351296|Drug|Bevacizumab|bevacizumab 5 mg/kg every 14 days
45356999|NCT04831606|Device|Advanced dressing|Protect the wound with Advanced dressing
45357000|NCT04831606|Device|Blue Light Photobiomodulation|2 minutes irradiation of blue light performed with EmoLED device
45357001|NCT04638322|Other|HIFT Group|An experimental group (EG) that after an initial evaluation will be subjected to a physical training program based on the HIFT method, for 12 weeks with 2 weekly sessions (Tuesday and Thursday), with a duration of 45 min per session. Once the intervention is finished, you will undergo a final evaluation to see if there is a difference or not with the results obtained at the beginning.
46047125|NCT00659776|Drug|Ferumoxytol|Ferumoxytol will be injected as i.v. bolus(es) at 3ml/s followed by a saline flush. The maximum total dose over 30 to 60 minutes will be 510mg Fe. Separate boluses will be used for perfusion MR and MRA. Ferumoxytol may be diluted up to 28 fold in normal saline to reduce T2* effects in the MR angiography. Rate of administration can be varied based on the subject's iv site, but will never exceed 510mg Fe /17s (as was done in phaseIII trials)
46047126|NCT03500484|Drug|Liraglutide|Liraglutide will be supplied in the following package sizes containing disposable, pre-filled, multidose pens. Each individual pen delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg (6 mg/mL, 3 mL). Liraglutide will be self-administered daily for 12 weeks under the following regimen: 0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, 3.0mg until week 12.
45357002|NCT04819594|Other|Elequil aromatabs ®|100% pure essential oils in a unique controlled delivery system for relaxation, comfort, and sleep. Scented tabs on a self-adhesive label will be placed on the nurses's uniform for 4 hours to provide aromatherapy for the clinical setting.
45357003|NCT00916019|Other|exercise training|60 min of low-intensity exercise, 5 days/week, 12 weeks
45478862|NCT03345823|Drug|Upadacitinib|Oral; Tablet
45478863|NCT03345823|Drug|Placebo for Upadacitinib|Oral; Tablet
45478864|NCT03338920|Drug|sumatriptan nasal powder|nasal powder administered via nosepiece
45478865|NCT03338920|Drug|Placebo|lactose monohydrate powder administered via nosepiece
45478866|NCT03294590|Other|OHT Parent targeted text messages|For the Oral health text message (OHT) group, the parent targeted text messaging program will include two core topics and a menu of options to choose from, all of which pertain to oral health.
45478867|NCT03294590|Other|CWT Parent targeted text messages|For the CWT group, the parent targeted text messaging program will include two core topics and a menu of options to choose from, all of which pertain to child wellness.
45478868|NCT03282461|Drug|ABY-029|A sample size of 6-12 patients in this open label, single center, clinical trial of ABY-029. Administration will occur as a single intravenous injection to subjects with operable head and neck cancer approximately 1-3 hours prior to surgery.
46047127|NCT00659854|Dietary Supplement|Non milk or soy based formula|Babies will be given a non milk or soy base formula for 12 weeks
46047128|NCT00659854|Dietary Supplement|milk based formula|Babies will be given a milk based formula for 12 weeks
45478869|NCT03275454|Drug|BIVV009 6.5 grams|Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009.
45478870|NCT03275454|Drug|BIVV009 7.5 grams|Participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009.
45478871|NCT03263260|Device|implant|coronary stent implantation
45478872|NCT03223753|Other|Educational Intervention|Receive educational handouts about to physical activity
45478873|NCT03223753|Other|Internet-Based Intervention|Access limited version of device app/website
45478874|NCT03223753|Other|Internet-Based Intervention|Access full version of interactive reward-based device app/website
45478875|NCT03223753|Other|Laboratory Biomarker Analysis|Correlative studies
45478876|NCT03223753|Device|Medical Device Usage and Evaluation|Wear physical activity tracking device
45478877|NCT03223753|Other|Quality-of-Life Assessment|Ancillary studies
45478878|NCT03223753|Other|Questionnaire Administration|Ancillary studies
45478879|NCT03219879|Behavioral|Telephone-administered continuation therapy|The intervention includes eight therapy sessions of approx. 50 minutes duration delivered over the telephone by trained psychotherapists over a time period of six months. The intervention is grounded in the principles of psychological continuation therapy and relapse prevention, and includes strategies such as transferring helpful elements of acute-phase cognitive-behavioral therapy (CBT) for depression to daily life. T-CT is offered in addition to usual care.
45478880|NCT03219879|Other|Usual care|Usual care without any study-related intervention
45478881|NCT03203850|Drug|Deferasirox FCT|Taken orally once per day (QD)
45478882|NCT03203850|Procedure|Phlebotomy|according to investigator's decision
45478883|NCT03138161|Drug|Trabectedin|Trabectedinis an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
45478884|NCT03138161|Drug|Ipilimumab|Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for (1) treatment of unresectable or metastatic melanoma, and (2) adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.
45478885|NCT03138161|Drug|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-medicated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
45843793|NCT04442646|Behavioral|multidisciplinary lessons|the multidisciplinary lessons will be conducted by study staff, formed by pneumologist, nurse, biologist and respiratory therapist once a week within 1 month after randomization. Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary. Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day
45357004|NCT00631410|Drug|sunitinib + mFOLFOX6|37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2)
45478886|NCT03131817|Device|Activa PC+S Prefrontal|
45478887|NCT03093337|Other|Early post hospital discharge psychomotor therapy|The intervention consisted on 20 psychomotor therapy sessions between 2 and 9 months, in order to support infants' development, and parent-infant interactions and adjustment. The therapy was based on body and emotional positive feelings and experiences, leading to improve sensory motor and perceptive integration, interactive and exploratory behaviors, physiological and tonic-emotional self-regulation, motor organization and early coordination. The intervention was a partnership with the parents, leading to decode the baby needs and expectations, for the parents to experiment more positive feelings, to become more confident in their own skills and more sensitive, and in synchrony with their baby. Intervention was supported by a detailed assessment scale implemented in the regional network related to the follow-up for vulnerable babies.
45478888|NCT03093116|Drug|Oral repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005) capsules.
45478889|NCT03091075|Drug|Oxandrolone|Treatment group will receive Oxandrolone daily for 12 weeks postoperatively
46047129|NCT03372954|Drug|BMAC|retrograde administration on non-selected BMAC via coronary sinus
45357005|NCT00631410|Drug|sunitinib + mFOLFOX6|50 mg/day, oral, administered on an outpatient basis for 2 weeks on, 2 weeks off (Schedule 2/2)
45357006|NCT04097951|Drug|Combinations|Montelukast and Bepotastine Combination
45357007|NCT05301712|Drug|Naloxone hydrochloride 5.0mg/5ml|"Initial dose: 4mg, Intravenous injection~Continuous dose: 8mg(mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~Total dose: 4mg+8mg/day*7=60mg"
45357008|NCT05301712|Drug|Sodium Chloride 45mg/5ml|"Initial dose: 4ml, Intravenous injection~Continuous dose: 8ml (mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~Total dose: 4ml+8ml/day*7=60ml"
45357009|NCT04096469|Behavioral|Motivational Interviewing|The motivational interviewing strengthens the motivation and commitment to achieve a specific change through the induction and exploration of the reasons for modifying behavior. All this within an atmosphere of acceptance and compassion. It is about extracting the possible solutions to the change that is faced from the individual and his environment and not from the professional. This strategy is achieved by looking for the patient to feel motivated, and to express their problem and thus create discrepancy so that they evaluate their actions and reflect on the changes they should make.
45478890|NCT03091075|Drug|Placebo|Placebo group will receive placebo for 12 weeks postoperative
45478891|NCT03031821|Drug|Metformin|Metformin Duration: 18 months 850 mg PO OD x 30 days then 850 mg PO BID for duration
45478892|NCT03031821|Drug|Placebo Oral Tablet|"Placebo Oral Tablet Duration 18 months~1 tablet (850 mg) PO OD x 30 days then 1 tablet PO BID for duration"
46047130|NCT02630446|Other|in-home respite care program|During the respite care period, lasting at least five days, a trained or experienced care worker for persons with dementia takes over all caregiving tasks while the informal caregiver is absent. The care worker thus temporary moves into the house of the person with dementia. The care worker also writes down his/her observations in a diary as well as daily experiences and strategies on how to manage the difficult behaviors the caregivers listed before. So additionally to the provision of respite, this program also includes caregiver support and psycho-education. This support enables the caregiver to validate theirs perceptions, to learn how to deal with difficult behaviors and to feel understood by somebody.
45357010|NCT04096469|Behavioral|Traditional Education|Traditional education refers to the normal care given to breast cancer survivors. That is, they receive recommendations about their physical activity and diet but without any motivational approach.
45357011|NCT00822978|Drug|ACHN-490 Injection vs placebo|Escalating doses beginning with test dose given once, followed by 4 mg/kg with a single dose then multiple dose. Dose escalation to continue up to 15 mg/kg as long as the treatment is deemed safe.
45357012|NCT02599883|Radiation|Low-Dose Computed Tomography|Low-Dose Computed Tomography will be administered to COPD patients as part of COPD phenotypization.
45357013|NCT03686176|Other|Virtual Reality|A child life specialist will fit the patient with the goggles, select a game, and initiate play once the medical procedure begins.
45357014|NCT00817284|Drug|bevacizumab and Irinotecan and radiotherapy|"Bevacizumab 10 mg/kg is administered on days 1 and 15.~Irinotecan:~Irinotecan 125 mg/m2 is administered on days 1 and 15 to patients NOT receiving enzyme-inducing antiepileptic drugs (EIAED).~Irinotecan 340 mg/m2 is administered on days 1 and 15 to patients receiving EIAEDs.~During concomitant chemoradiotherapy, bevacizumab and irinotecan are given in the same doses and schedules as before and after chemoradiotherapy.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
45357015|NCT00817284|Drug|Bevacizumab and Temozolomide and radiotherapy|"Bevacizumab 10 mg/kg is administered on days 1 and 15. Temozolomide dosing before start concomitant chemoradiotherapy: 150 mg/m2/day on days 1-5 during the first 28 days treatment cycle, then 200 mg/m2/day on the subsequent cycles until radiotherapy.~Temozolomide administered concomitantly with the radiotherapy: Temozolomide 75 mg/m2/day for 7 days per week is administered on each day of radiotherapy.~After completed chemoradiotherapy, temozolomide is dosed and administered as it was prior to start chemoradiotherapy, i.e. temozolomide 200 mg/m2/day on days 1-5 out of a 28 days schedule, taking into consideration any previous dose-reductions already made.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
45357016|NCT04096235|Other|RAM Nasal Cannula|The RAM Nasal Cannula is a means of providing CPAP and Bi-PAP to infants 28-42 weeks gestation to prevent nasal septal erosion.
46047131|NCT03929601|Drug|Rituximab|Participants will receive Rituximab dosing from Week 1 to Week 4 of the trial. Rituximab will be given by IV infusion over a 3-8 hour period, at a dose of 375mg/m2 on four visits each one week apart.
46047132|NCT03929601|Drug|Abatacept|Participants will receive initial Abatacept dosing at Week 16 of trial. Abatacept will be given by a subcutaneous (SC) formulation weekly for two years, and dosing be will determined according to weight: Up to 25 kg: 50 mg (0.4 mL); 25 to <50 kg receive 87.5 mg (0.7 mL), and > 50 kg receive 125 mg (1.0 mL). Abatacept treatment will continue for full 24-month period regardless of whether participants have progressed to stage 3 type 1 diabetes during treatment.
45357017|NCT00823056|Dietary Supplement|probiotics|placebo
45357018|NCT00823056|Dietary Supplement|probiotics|0,53 ml MCT oil containing BB12 and TH4 in daily dosage in 9 months
45357019|NCT04096157|Drug|Isavuconazonium sulfate IV|Intravenous (IV) via nasogastric (NG) tube
45357020|NCT04096157|Drug|Isavuconazonium sulfate capsules|Oral
45357021|NCT04609332|Diagnostic Test|Endothelial damage and angiogenic biomarkers|Blood samples for biomarkers study
45357022|NCT00819624|Other|Interactive Voice Response System (IVRS)|Telephone based system
45843794|NCT04398264|Other|COVID-19 positive via testing|Pregnant women admitted to Obstetric Units undergo RT-PCR testing for the detection of SARS-Cov2 (COVID-19 infection)
45357023|NCT00819624|Other|Personal Digital Assisstant (PDA)|Electronic Hand Held diary
45357024|NCT00823290|Drug|Sorafenib + LBH589|Sorafenib standard regimen + oral LBH589
45357025|NCT00823368|Drug|STX209|
45357026|NCT00755417|Drug|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
45843795|NCT04379076|Drug|Interleukin-7|Intramuscular (IM) administration of CYT107 at 3 μg/kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or
45843796|NCT04379076|Drug|Placebos|Intramuscular (IM) placebo (normal saline) at the same frequency
45843797|NCT04320498|Biological|prp injection|PRP was injected locally in the anal fissure area and glyceryl trinitrate was administered twice daily in the perianal region as in the control group.
45843798|NCT04320498|Drug|Anrecta|self-administered topical glyceryl trinitrate (anrecta), in the perianal area twice a day
45478893|NCT03016169|Device|Trifecta GT (Glide Technology) Valve|Surgical aortic valve replacement with Trifecta GT Valve.
45478894|NCT02908074|Drug|BGS649|Capsules will be taken weekly for a maximum of 24 weeks
45843799|NCT04320498|Behavioral|sitz bath|participants were told to take a hot water sitz bath once a day
45843800|NCT04320498|Dietary Supplement|nutrition regulation|The study participants were told to eat a fiber-rich diet and to drink least 2 liters of water daily
46047133|NCT00659932|Behavioral|Immediate Cognitive behavioural therapy (CBT)|The Dealing with Anxiety CBT Group Program comprises 7 group sessions: an initial five hour session followed by 6 three hour sessions over a three month period
45357027|NCT00755417|Drug|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
45357028|NCT00755417|Drug|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
45357029|NCT03685708|Biological|HEPLISAV-B|HEPLISAV-B (Hepatitis B Vaccine [Recombinant ], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
45357030|NCT00819702|Other|Model Care|The Model Care provided training to pediatric health care providers to assess parental psychosocial risk factors to child maltreatment.
45357031|NCT04565028|Behavioral|Contingency Management (CM)|Contingency management is an intensive behavioral therapy in which participants are paid to reduce substance use.
45357032|NCT03684928|Device|Comfilcon A (test)|Daily wear contact lenses
45357033|NCT03684928|Device|Senofilcon C (control)|Daily wear contact lenses
45357034|NCT00817440|Other|Exercise|1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
45357035|NCT00817440|Other|Fasting|3 days of fasting and then the same as arm 1
45357036|NCT04493034|Behavioral|Art Therapy|"The art therapist will assist each participant in producing a bound collection of participant art works/writings for personal, group and/or caregiver inspiration, at the participant's request. For in-person sessions, a variety of studio-based art and writing materials will be available for participant selection and creation. Each session will be directed in the following manner:~New therapeutic prompt or bridge from prior session~Creative expression, opportunity for reflection, verbal sharing / processing, and a session summary~Discussion of action plan for the next consecutive, at-home session (weekly assignment).~Possible wellness themes for each session (in-person or at-home) may include: mental health, physical health, emotional health, spiritual health, relational health (family and social), or occupational health/financial health."
46047134|NCT00659932|Behavioral|Delayed CBT|Commencement of the CBT Group Program is delayed 3 months
46047135|NCT02631460|Drug|S1 80-120 mg/d|d1, every 3 weeks
46047136|NCT02631460|Drug|pemetrexed 500 mg/m2|d1, every 3 weeks
46047137|NCT02631460|Drug|carboplatin AUC=5|d1, every 3 weeks
45357037|NCT04493034|Behavioral|Music Therapy|"Participants have the opportunity to engage in: learning an instrument, active music-making, receptive music-listening, singing, improvisation, song-writing, education on music technology, or music discussion. During in-person musical sessions the six psychosocial goals promoted by the music therapist include: 1) self-care/self-love, 2) support systems, 3) practicing positivity 4) gratitude 5) mindfulness/living in the moment, and 6) goal-setting.~For at-home assignments, participants will be asked to pick a song of the week that coincides with the theme/goal discussed in previous session(s). They will be asked to write a journal entry about the topic discussed. Journal entries can be freely written or a prompt/question can be provided. If participants do not have access to search for songs or listen to music as at home, they may select a piece from the session and be given lyrics and/or a recording on an .mp3 player returned at conclusion of study."
45478895|NCT02907359|Drug|Guadecitabine|
45687118|NCT05720299|Drug|Treatment with Akkermansia muciniphila|120 subjects were randomly assigned to ZY19 low-dose group, ZY19 high-dose group and placebo group at a ratio of 1:1:1. They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks) in ZY19 low-dose group, ZY19 high-dose group and placebo group respectively.
45687119|NCT05720299|Other|Treatment with placebo|120 subjects were randomly assigned to ZY19 low-dose group, ZY19 high-dose group and placebo group at a ratio of 1:1:1. They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks) in ZY19 low-dose group, ZY19 high-dose group and placebo group respectively.
45687120|NCT05719701|Drug|ICP-490|The initial dose of ICP-490 is 0.1 mg, five dose groups are planned for the dose exploration (0.1 mg to 1.5 mg).
45687121|NCT05716984|Drug|recombinant human brain natriuretic peptide|rhBNP 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
45687122|NCT05716984|Drug|Placebo|placebo 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
45843801|NCT04270500|Behavioral|Prehabilitation program|The preoperative period (prehabilitation) represents a more appropriate time than the postoperative period to implement an intervention. Prehabilitation is a process of enhancing an individual's functional capacity before the scheduled surgery, aimed at improving the patient's tolerance to upcoming physiologic stress, by three principal elements: exercise training, nutritional intervention, and psychological support.
45843802|NCT04196868|Drug|Metformin treatment|1500 mg once a day, per os, during six months
45843803|NCT04196868|Other|Placebo|per os, during six months
46047138|NCT00965484|Device|New Genotropin Pen|Subjects will use the genotropin pen for 2 months. After 2 months patients and caregiver will be asked to fill out a questionnaire to assess perception of the genotropin pen
46047139|NCT02630602|Dietary Supplement|Functional goat cheese|60 g per day during 12 weeks
46047140|NCT02630602|Dietary Supplement|Control cheese|60 g per day during 12 weeks
45843804|NCT04196868|Drug|Methotrexate treatment|per os
45478896|NCT02907359|Other|Treatment Choice|"BSC: according to standard/institutional practice; included RBC or platelet transfusions; growth factors, i.e. erythropoiesis stimulating agents, granulocyte stimulating factors, iron chelating therapy; broad spectrum antibiotics and/or antifungals.~LDAC: 20 mg/m^2 SC or IV once daily (QD) for 14 days in 28-day cycles. Other schedules were allowed per institutional practice. Treatment for ≥4 cycles absent disease progression/toxicity. BSC per institutional/standard practice.~Standard Intensive Chemotherapy: recommended regimen of 7+3 was given as cytarabine 100-200 mg/m^2/day continuous infusion for 7 days and an anthracycline for 3 days. Anthracyclines per institutional practice included daunorubicin (45-60 mg/m^2/day) or idarubicin (9-12 mg/m^2/day) or mitoxantrone (8-12 mg/m^2/day) by IV infusion. Participants with complete or partial response after IC induction received ≥1 additional cycles with reduced cytotoxic doses then BSC per standard /institutional practice."
45478897|NCT02749981|Procedure|blood and tissue sampling|
45478898|NCT02714205|Drug|transdermal nitroglycerin|Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
45478899|NCT02714205|Drug|Placebo|Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
45478900|NCT02697396|Behavioral|Assessments|All participants, after consent, will be asked to complete the study contact form and then complete a baseline assessment with the RSA. This baseline assessment will take approximately 5 minutes.
45478901|NCT02697396|Other|Text Message Reminder|Participants randomly assigned to the text messaging group will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after exposure to the social marketing campaign and time of consent.
45478902|NCT02697396|Other|No Text Messaging|Participants in this arm will receive no additional vaccination reminders.
45478903|NCT02669173|Drug|Capecitabine|Drug given orally. Dose to be determined by phase 1 dose escalation, cycle length 28 days. Treatment until progression
45478904|NCT02669173|Drug|Bevacizumab|Drug given by IV, 10 mg/kg days 1, 15 every 28 days, until progression.
45687123|NCT05715177|Other|Cura Kinesio-taping|Cura tapes, a cotton strip with an acrylic adhesive. allows for unidirectional elasticity up to 60% beyond its resting length will be applied on origin to insertion on the superficial muscles of Quadriceps femoris (QF) (Vastus Medialis (VM), Vastus Lateralis (VL), Rectus Femoris (RF)
45687124|NCT05715177|Other|Placebo kinesio-taping|Placebo kinesiotaping
46047141|NCT00666874|Behavioral|lifestyle changes|Detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity.
46047142|NCT00666874|Behavioral|Control - general information|General information about healthy food choices and exercise
46047143|NCT00666952|Other|Video Decision Aid|Participants randomized to the video decision aid group will be asked to view the video portion of the decision aid, Weight loss surgery: Is it right for you? in a private room The content of the video and accompanying booklet was based on a systematic-review of the efficacy and safety of bariatric surgery, input from experts in bariatric surgery, internal medicine, psychology, nutrition, and nursing, and from a series of focus groups and interviews with 30 morbidly obese patients, some of whom had elected not to have bariatric surgery.
46047144|NCT00666952|Other|Booklet Decision Aid|General educational booklet on gastrointestinal surgery developed by the NIH titled, 'Gastrointestinal Surgery for Severe Obesity'.
45478905|NCT02666781|Other|ApneaLink Plus, BIA Device|The study is only observational. No interventions will be performed. ApneaLink Plus will be used to diagnose Obstructive Sleep Apnea in potential candidates and grade its severity on Postoperative night 2 in participants. A BIA Device will be used to detect segmental fluid shifts. A 3-D accelerometer will be used to detect head and neck position.
45478906|NCT02647437|Drug|Levetiracetam|
45478907|NCT02647437|Drug|Placebo|
46047145|NCT04233723|Other|peripheral blood samples|venous puncture
46047146|NCT04282824|Procedure|Biospecimen Collection|Undergo collection of saliva
45478910|NCT02611206|Device|Active Repetitive Transcranial Magnetic Stimulation (rTMS): intensity 80% MT|"rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS"
45687125|NCT05715034|Behavioral|Compassionate Care|Single-session web-based program
45687126|NCT05715034|Behavioral|Relaxing with Nature|Single-session web-based program
45687127|NCT05713448|Other|No intervention|No intervention
45687128|NCT05713305|Procedure|Online-based self-help psychological intervention|Daily members of the intervention group were thought to provide three different forms of daily sessions each day, averaging 10-20 minutes. These sessions included psycho-educational and cognitive-behavioral exercises, music therapy, sleep hygiene, stress relief methods. Weekly online lecture sessions presented by professional mental health therapists
45687129|NCT05713305|Procedure|Provide online mental health knowledge|They will receive official mental health recommendations on how to cope mentally with the pandemic. These recommendations inform about the importance of a daily structure, social contact, acceptance of negative emotions and strengthening of positive emotions, and stimulus control to assimilate SARS-CoV-2 Omicron-related news
45687130|NCT05712096|Drug|EVUSHELD|EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
45687131|NCT05707390|Drug|Mezigdomide|Specified dose on specified days
46047147|NCT04282824|Procedure|Computed Tomography|Undergo PET/CT
45357038|NCT00777803|Drug|NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®))|NT201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), active ingredient: Clostridium botulinum neurotoxin type A free from complexing proteins, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
45357039|NCT00777803|Drug|OnabotulinumtoxinA (Vistabel®)|OnabotulinumtoxinA (Vistabel®), active ingredient: Clostridium botulinum neurotoxin type A, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
45357040|NCT00819858|Dietary Supplement|RUTF (Plumpynut®)|Intervention group receives 500 kcal/day of RUTF for 2 weeks Control group receives no food supplement
45357041|NCT00819936|Procedure|forward walking|comparison forward walking vs backward walking in the physiotherapy after after abdominal surgery
45357042|NCT00819936|Procedure|backward walking|physiotherapy with use a backward walking type of physiotherapy
45357043|NCT03993587|Other|Ultrasound assessment of vessels|Subclavian vein and related structures are examined using ultrasonography
45357044|NCT00527488|Drug|Degarelix|Two doses of 16 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
45357045|NCT00527488|Drug|Degarelix|One dose of 32 mg administered as a single administration will be evaluated for 42 days.
45843805|NCT04187742|Behavioral|Social Comparison Email vs. Standard Email|Evaluate whether emails with social comparison incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
45357046|NCT00527488|Drug|Degarelix|Two doses of 32 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
45357047|NCT00527488|Drug|Degarelix|One dose of 64 mg administered as a single administration will be evaluated for 42 days.
45843806|NCT04187742|Behavioral|Maintenance Certification Email vs. Standard Email|Evaluate whether emails with maintenance certification incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
46047148|NCT04282824|Drug|Gallium Ga 68-labeled PSMA-11|Given IV
46047149|NCT04282824|Dietary Supplement|Monosodium Glutamate|Given PO
45357048|NCT00820014|Drug|Placebo|Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery
45357049|NCT00825864|Drug|diclofenac drops|one drop 4 times a day for 3 months
45357050|NCT00825864|Drug|dexamethasone sodium phosphate 0.1% eye drops|for first week after the operation : one drop 6 times a day. Then tapering by reducing one drop for a week
45357051|NCT00916799|Device|Use of Telehealth equipment (Viterian V-100)|Patient will daily enter answers to questions generated from a home telehealth monitor
45357052|NCT00825942|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 180 days
46047150|NCT04282824|Procedure|Positron Emission Tomography|Undergo PET/CT
46047151|NCT02631304|Procedure|Elective cardiac surgery|Coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery
46047152|NCT04236297|Device|bite block|Physicians performing transesophageal echocardiogram in patients under sedation or general anesthesia will use either standard or modified bite block.
45357053|NCT05286112|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|8 sessions focused on increasing mindfulness awareness to address thoughts, emotions, and behaviors that maintain functional impairment and risk of suicide.
45357054|NCT05286112|Behavioral|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
46047153|NCT00663286|Drug|IDP-110|Topical application for 12 weeks
46047154|NCT00663286|Drug|Clindamycin|Topical application for 12 weeks
45357055|NCT00823446|Device|Revera Wound Care|Revalesio Part Number MDW0060
45357056|NCT00823446|Device|Normal Saline|Sodium Chloride for Irrigation
45357057|NCT00527332|Drug|Bupivacain|5 mg/mL, 4 mL intrathecally as a single dos
45357058|NCT00527332|Drug|Morphine|0.4 mg/mL; 0.5 mL intrathecally as a single dosage
45357059|NCT00527332|Drug|Propofol|2-5 mg/kg body weight/hours IV (intravenously) for sedation during the surgery
45357060|NCT00527332|Drug|Propofol|Induction of anesthesia with 1-2 mg/kg body weight IV (intravenously). After intubation maintenance dosage of 6-10 mg/kg/hour IV during the surgery
45357061|NCT00527332|Drug|Fentanyl|100-200 microgram IV (intravenously) at start of anesthesia. 50-100 microgram IV on demand during surgery.
45357062|NCT00527332|Drug|Rocuronbromid|0.6 mg/kg body weight IV (intravenously) at induction of anesthesia. If additional muscle relaxation is needed during surgery 5-10 mg is injected IV. The drug is given only at induction of anesthesia and during surgery
45357063|NCT00527332|Drug|Morphine|5 mg is given IV (intravenously) before end of surgery
45357064|NCT00820092|Drug|Xerecept 1.0|24 hour infusion
45357065|NCT00820092|Drug|Xerecept 2.0|24 hour infusion
45357066|NCT00820092|Drug|Xerecept 3.0|24 hour infusion
45357067|NCT00823524|Biological|donor natural killer cell infusion|give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
45357068|NCT05269810|Drug|SA001 Low dose|3 tablets b.i.d for 8 weeks
45357069|NCT05269810|Drug|SA001 Mid dose|3 tablets b.i.d for 8 weeks
45357070|NCT05269810|Drug|SA001 High dose|3 tablets b.i.d for 8 weeks
45357071|NCT05269810|Drug|Placebo|3 tablets b.i.d for 8 weeks
45357072|NCT04017156|Procedure|implant installation|All site preparations will be performed deeper compared to the length of the implant so that the implant apex cannot reach the bottom of the osteotomy.
45357073|NCT00823602|Drug|ganirelix|These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).
45357074|NCT00823602|Drug|suprefact|GnRH agonist, standard protocol
45357075|NCT00820326|Drug|Dolasetron|Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
45357076|NCT00820326|Drug|Placebo|Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
45357077|NCT04602286|Other|Meditation (1 x 20-minute guided audio training)|Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.
45357078|NCT00752609|Drug|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous or intravenous injection, once every 4 weeks for up to 24 weeks. Initial dose based on patient's previous total weekly darbepoetin alfa dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
45357079|NCT03684304|Device|Abdominal binder|The abdominal binder is an elastic abdominal compression / support device that will be placed on the patient after surgery has been completed.
45357080|NCT04023539|Dietary Supplement|Cinnamomum zeylanicum|Capsules of 2 g cinnamomum zeylanicum orally
45357081|NCT04023539|Other|Placebo|Placebo capsules
45357082|NCT05255068|Behavioral|OPTIMAL|A person-centered mealtime care intervention
45357083|NCT04093583|Procedure|Exodontia|Atraumatic exodontia followed by simple suture
45843807|NCT04187742|Behavioral|Report Opening Status Email vs. Standard Email (among previous report openers and non-openers)|Evaluate whether emails informing physicians of their report opening status (among those who have previously opened at least one report and those who have never opened a report) will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without report opening status information
45357084|NCT04093583|Drug|Alveolar ridge preservation with a PRP (PRGF-Endoret)|Filling of the alveolus with PRGF clot and fibrin plug.
45357085|NCT04093583|Device|Preparation of PRGF using Endoret technology|Preparation of PRGF using Endoret technology following manufacturer instructions
45357086|NCT00916097|Drug|DOCETAXEL(XRP6976)|docetaxel 75mg/m2 by intravenous infusion over 60 minutes on Day 1 of a 3-week cycle
45357087|NCT00629772|Drug|Placebo|Patients receive placebo on weeks 0, 2 and 6. They receive infliximab 5mg/kg at weeks 14, 16 and 20.
45357088|NCT00629772|Drug|Infliximab|Patients in infliximab group receive infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22. Patients in placebo then infliximab group receive placebo at weeks 0, 2, 6, then receive infliximab at weeks 14, 16 and 20.
45357089|NCT00526630|Drug|Methylphenidate (MPD)|Participants will be given 1 mg/kg of MPD divided in three doses (at 8 am, 12 noon, and 4 pm). A four-week titration period will be used, using 0.25-mg/kg increments per week until achieving the weight-adjusted target dosage, which may range from five to eight 10-mg tablets per day. The maximum daily dose will be 80 mg/day.
45357090|NCT00526630|Drug|Placebo|Participants will be given placebo instead of active MPD.
45357091|NCT00755183|Drug|testosterone ophthalmic solution|testosterone ophthalmic solution for 128 days
45357092|NCT00755183|Drug|vehicle of testosterone ophthalmic solution|vehicle of testosterone ophthalmic solution for 128 days
45357093|NCT00826254|Drug|Vitamin K|180 micrograms vitamin K daily
45357094|NCT00826254|Drug|Vitamin K|"2 capsules daily 180 micrograms vitamin K daily or placebo~1 year"
45357095|NCT00823758|Behavioral|Focus Groups|6 to 8 participants per group.
45357096|NCT00823758|Behavioral|Personal Interviews|Conducted by phone and audiotaped.
45357097|NCT00826332|Procedure|transabdominal ultrasound|transabdominal ultrasound
45357098|NCT00826332|Procedure|transvaginal ultrasound|transvaginal ultrasound
45357099|NCT00526162|Device|Bi-ventricular Implantable Cardioverter Defibrillator|Implantation of a Bi-ventricular Implantable Cardioverter Defibrillator
45357100|NCT02600195|Behavioral|Evidence-based Practice for Improving Quality (EPIQ) method|The intervention NICUs (n = 12) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes to reduce hospital-acquired infection. Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
46047155|NCT00663286|Drug|Benzoyl peroxide|Topical application for 12 weeks
45357101|NCT02550600|Procedure|iLA activve treatment|"iLA activve is aimed at efficient extracorporeal membrane oxygenation with an initial blood flow of ≥2L/min. The length of therapy is at the discretion of the treating physician.~Treating physicians are recommended to use a pre-specified algorithm to optimize the extracorporeal lung assist (choice of cannulas and oxygenator, titration of blood flow and sweep gas flow). Primary/mandatory goals are pO2≥65mmHg, P_peak ≤30cm H2O, TV ≤6ml/kg PBW and pH ≥7.25. Secondary suggested goals are setting the PEEP level within the limits suggested by the ARDSnet low and high PEEP strategy, 35mmHg ≤ pCO2 ≤45mmHg, Delta-pressure (= P_peak - PEEP) ≤15 cm H2O and P_peak ≤25 cm H2O.~iLA activve treatment also requires anticoagulation with un-fractionized heparin (PTT-goal 45s-60s depending on blood flow)."
45357102|NCT02550600|Procedure|Control group|"The controls will be treated according to the recent guideline of the German Sepsis Society and the German Interdisciplinary Association of Intensive Care and Emergency Medicine and good clinical practice including lung-protective ventilation with low tidal volume (LTV), moderate hypercapnia, PEEP according to ARDSnet, adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) and treatment of the underlying disease as applied in the experimental group.~There will be no sham treatment of iLA activve.in the controls. All adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) are also available for the intervention group."
45687132|NCT05701163|Other|Abstinence followed by semen sample collection.|Abstinence is the intervention. Semen samples will be collected after abstinence periods.
45357103|NCT03875482|Drug|Risankizumab|Risankizumab 150 mg (150 mg/mL) in prefilled syringes, self-administered subcutaneously
45357104|NCT03875482|Drug|Placebo solution for risankizumab|Placebo solution in prefilled syringes, self-administered subcutaneously
45357105|NCT04093427|Other|softSTOPP|Non-invasive ventilation device setting in prismaVENT 30 device enabling an inverse pressure ramp after therapy end
45478911|NCT02611206|Device|Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 100% of MT|"rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS"
45478912|NCT02611206|Device|Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 120% of MT|"rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS"
45478913|NCT02477124|Device|transvaginal digital colposcope (TVDC)|TVDC is a miniature colposcope used to obtain images of cervical tissue.
45478914|NCT02477124|Other|Standard of care screening|Standard of care screening varies from institution to institution but is either visual inspection with the naked eye, colposcopy, or visual inspection with a camera or microscope
45478915|NCT02369458|Drug|Mitomycin-C|
45478916|NCT02369458|Drug|Pegfilgrastim|
45478917|NCT02342613|Biological|Activated PTCy-MILs|The activated PTCy-MILs will be infused through standard blood tubing containing a 170-260 micron filter without an additional leukoreduction filter into a central IV site. Each of the bags will be infused at a rate of approximately 10 ml per minute. The IV line will be flushed with normal saline immediately after completion of PTCy-MILs infusion to ensure that all product has been infused into the patient.
45687133|NCT05700344|Drug|Avelumab|Single Group Assignment
45843808|NCT04168320|Radiation|SBRT-PATHY (SBRT-based PArtial Tumor irradiation targeting HYpoxic segment)|Novel stereotactic high-dose partial irradiation of the hypoxic segment of bulky tumors.
46047156|NCT00663286|Drug|Vehicle|Topical application for 12 weeks
46047157|NCT04284462|Other|Flavored carbonated soft drink (CSD)|1-2 cans/day (330 ml per can)
46047158|NCT00660088|Other|Ketasyn|10g for 7 days, 20g for 7 or 14 days
45687134|NCT05694676|Other|Assessment of the quality of Genaral Movements (GMs)|The variation, complexity and fluency of movements over a video recording is done and the quality of GMs is classified as normal-optimal, normal-suboptimal, mildly abnormal, and definitely abnormal movements.
45687135|NCT05694676|Other|State-Trait Anxiety Inventory-Trait, (STAI-T)|The scale consists of 20 items in total and provides a four-point Likert type measurement (1- anxiety symptom is not present, 4- the symptom lasts all the time). Scores range from 20 (low anxiety) to 80 (high anxiety).
46047159|NCT03237702|Dietary Supplement|Multi-Carotenoids|All participants in the second stage will receive multi-carotenoids 30 mg qd for 8 weeks.
46047160|NCT00667108|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
46047161|NCT00667108|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
46047162|NCT00667108|Drug|Placebo|Matched placebo 30 minutes prior to bedtime
46047163|NCT00961116|Drug|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered after an overnight fast of at least 10 hours
46047164|NCT00961116|Drug|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
45357106|NCT04095767|Device|Neurothrombectomy|Intra-arterial recanalization therapy or mechanical thrombectomy (MT) is a therapeutic option for patients who are not candidates for t-PA or in whom t-PA has failed. MT is performed by means of various devices (Merci Revive, Penumbra, etc.). There are currently two major approaches to MT: the so-called stent retrievers (used with or without a balloon catheter), and catheters used for direct aspiration (manual with syringe or by aspiration pump via distal access catheters [DACs]). Moreover, both techniques can be combined. MT may be performed following IV t-PA, as a stand alone therapy, or in conjunction with IA thrombolysis.
45357107|NCT00820404|Drug|BLI-489|
45357108|NCT00820404|Drug|Placebo|
45357109|NCT00820482|Drug|Menopur®, Ferring|75 UI/day of Hp-hMG (Menopur®)
45357110|NCT00820482|Drug|rFSH (Gonal®,|75UI/day of rFSH (Gonal®, Serono) + 75UI/day of rLH (Luveris®, Serono)
45357111|NCT00754793|Drug|escitalopram|10mg - 30mg daily titrated as tolerated over 12 weeks
45357112|NCT00754793|Drug|placebo|inactive comparator; titrated as per protocol over 12 weeks
45357113|NCT00826410|Device|Redon drain|subcutaneous suction drain after laparotomy for two days
45357114|NCT00826488|Device|Digital Breast Tomosynthesis|Women with a positive screening mammogram called back for additional views will be asked to undergo an additional Digital Breast Tomosynthesis (3D mammogram) on the affected breast. Radiation dose is somewhat less than that of a screening mammogram.
45478918|NCT02329080|Drug|Methotrexate|methotrexate 3.5 g/m2 on day 1 courses 1, 2,3 of MATRIX regimen
45478919|NCT02329080|Drug|Rituximab|Rituximab 375 mg/m2 as conventional IV infusion on day 0 courses 1, 2,3 (MATRIX regimen) and on day 1 courses 4,5,6 (R-ICE)
45478920|NCT02329080|Drug|Cytarabine|Cytarabine 2 g/m2 every 12 hours, in 3-hr infusion on days 2,3 courses 1, 2,3 (MATRIX regimen)
45478921|NCT02329080|Drug|Thiotepa|Thiotepa 30 mg/m2 in 30 minutes infusion on day 4 courses 1, 2,3 (MATRIX regimen) and 5 mg/kg in 250 ml of saline sol. in 2-hrs infusion every 12 hours on day -5 and -4 of conditioning and ASCT
46047165|NCT04158232|Other|Method|treatment of mature teeth with apical periodontitis
45357115|NCT04102397|Procedure|Vojta therapy after standard therapy|Vojta Therapy ~20 minutes/session: Application of the Reflex Creeping complex, activating several stimulus points on the facial and the nuchal sides (Figure 3a), and then the activation of the Reflex Rolling complex in both the supine position and with the patient lying on his or her side, alternating between nuchal and facial stimulation and guiding from the head.
45357116|NCT04102397|Procedure|Standard therapy|"~50 minutes/session:~TENS Current (20 minutes, phase duration=0.10 microseconds, frequency=50 Hz). The intensity applied depended on the patient's tolerance for the treatment (Figure 2a).~Pulsating ultrasound (5 minutes around the shoulder, frequency=1MHz, intensity=1 W/cm2) (Figure 2b).~Kinesiotherapy. In stages: at first assisted (with isometric exercises), then free, and finally, with resistance, usually with elastic bands (Figure 2c).~Cryotherapy (5 minutes)."
45357117|NCT00826566|Dietary Supplement|Caffeine|2 times 250 mg caffeine per day
45357118|NCT00826566|Dietary Supplement|placebo|2 times 250 mg per day
45357119|NCT03999190|Drug|NPA radiotracer|"[11C]NPA radiotracer, 2 injection per subject~Antagonist ([11C]raclopride) and agonist ([11C]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC)."
45357120|NCT03999190|Drug|Raclopride radiotracer|"[11C]raclopride radiotracer, 2 injections per subject~Antagonist ([11C]raclopride) and agonist ([11C]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC)."
45357121|NCT03999190|Drug|Dextroamphetamine|Dextroamphetamine, one oral administration of 0.5 mg/kg per subject Antagonist ([11C]raclopride) and agonist ([11C]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).
45357122|NCT04093817|Device|cardio pulmonary bypass machine|cardio pulmonary bypass machine is a machine that work to compensate for the function of the heart and the lungs in the operation
45357123|NCT02550366|Drug|MRI Contrast|MRI Contrast
45478922|NCT02329080|Drug|liposomial cytarabine|Intrathecal liposomial cytarabine 50 mg on day 5 courses 1, 2,3 (MATRIX regimen) and on day 4 courses 4,5,6 (R-ICE)
45478923|NCT02329080|Drug|Etoposide|Etoposide 100 mg/m2/d in 500 mL saline sol. in 30 minutes on day 1-2-3 courses 4,5,6 (R-ICE)
45478924|NCT02329080|Drug|Ifosfamide|Ifosfamide 5 g/m2 in 1.000 mL saline sol. in 24-hour infusion on day 2 courses 4,5,6 (R-ICE)
45478925|NCT02329080|Drug|Carmustine|BCNU (carmustine) 400 mg/m2 in 500 mL glucose 5% sol. in 1-hr infusion on day-6 of conditioning and ASCT
45478926|NCT02329080|Radiation|whole brain radiotherapy|whole-brain irradiation 36 Gy + tumor- bed boost 10 Gy in patients with residual disease in the parenchymal brain/cerebellum.
45478927|NCT02302833|Drug|Cabozantinib S-malate|Given PO
45478928|NCT02302833|Other|Laboratory Biomarker Analysis|Correlative studies
45478929|NCT02302833|Other|Questionnaire Administration|Ancillary studies
45478930|NCT02231515|Device|Selective laser trabeculoplasty (SLT)|Selective laser trabeculoplasty
46047166|NCT04492449|Other|congenital malformation|congenital malformation
46047167|NCT04158388|Other|Mediterranean-diet enriched with a higher dose of tryptophan and magnesium|That gruop eaten at both breakfast and dinner from walnuts (3-5 units), as food with high values of tryptophan and magnesium
46047168|NCT04158388|Other|Isocaloric diet|That group eaten isocaloric diet plan based on Mediterranean diet.
46047169|NCT04158388|Other|Manual therapy|That group received moderate pressure digital manual therapy.
46047170|NCT04158388|Other|Placebo therapy|That group was treated with a US (in off mode) without conductive gel.
46047171|NCT04283136|Drug|Padsevonil type 1 Tablet 200 mg|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Subjects will receive a padsevonil type 1 tablet in a pre-specified sequence during the Treatment Period."
45478931|NCT02231515|Device|Pattern laser trabeculoplasty (PLT)|Pattern laser trabeculoplasty (PLT)
45478932|NCT02229331|Other|Gait analysis|
45478933|NCT02227927|Drug|Domperidone|10-30mg oral dose, four times daily.
45478934|NCT02152995|Procedure|Computed Tomography|Undergo iodine I-124 PET/CT
45478935|NCT02152995|Other|Iodine I 124|Undergo iodine I-124 PET/CT
45478936|NCT02152995|Radiation|Iodine I-131|Given PO
45478937|NCT02152995|Other|Laboratory Biomarker Analysis|Correlative studies
45478938|NCT02152995|Other|Pharmacodynamic Study|Correlative studies
45478939|NCT02152995|Procedure|Positron Emission Tomography|Undergo iodine I-124 PET/CT
45478940|NCT02152995|Drug|Trametinib|Given PO
45478941|NCT02117791|Drug|Riociguat (ADEMPAS, BAY63-2521)|The treatment of Riociguat should comply with the local product information (start dose: 3 mg/day, maximum dose: 7.5 mg/day)
45478942|NCT02025543|Device|MRI|R2 MRI scan
45478943|NCT01922635|Other|Valadation of the metrological properties of questionnaire of quality of life|
45478944|NCT01820910|Drug|Doxycycline|All enrolled patients will be treated with doxycycline 100 mg bid daily, orally, for four weeks followed by four weeks rest, repeated for three cycles. Response will be assessed by MRI (magnetic resonance imaging) and ophthalmologic examination at the end of the planned treatment. Patients who will achieve complete response, partial response or have a stable disease at 3 months from upfront doxycycline will be monitored for infection re-occurrence and assessed for response with MRI and ophthalmologist evaluation every six months for the first five years.
45478945|NCT01808599|Drug|Chlorambucil|
45478946|NCT01808599|Drug|Rituximab i.v.|
45478947|NCT01808599|Drug|Rituximab s.c.|
45478948|NCT01704859|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
46047172|NCT04283136|Drug|Padsevonil type 2 Tablet|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Subjects will receive a padsevonil type 2 tablet in a pre-specified sequence during the Treatment Period"
46047173|NCT04283136|Drug|Padsevonil type 3 Tablet|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Subjects will receive a padsevonil type 3 tablet in a pre-specified sequence during the Treatment Period."
46047174|NCT04283136|Drug|Padsevonil type 4 Tablet|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Subjects will receive a padsevonil type 4 tablet in a pre-specified sequence during the Treatment Period."
46047175|NCT04283136|Drug|Padsevonil type 5 Tablet|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Subjects will receive a padsevonil type 5 tablet in a pre-specified sequence during the Treatment Period."
46047176|NCT03727893|Behavioral|Roller-based Intervention Group (IG)|A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education and a 12-week (3 sessions per week) evidence-based high-intensity interval training (HIIT) program using the roller-based WheelMill (WMS) system.
46047177|NCT03727893|Behavioral|Control Group (CG)|A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education session and enroll in a 12-week (3 sessions per week) independent workout program at an accessible community-based fitness facility.
46047178|NCT00663364|Drug|Physiogel AI Lotion, Physiogel Lotion|Physiogel AI Lotion and Physiogel Lotion is a cosmetic, applied twice daily to dry skin
45357124|NCT04559464|Device|AeriSeal|The AeriSeal Foam functions by blocking both small airways and collateral channels causing absorption atelectasis in the treated region of the lung. Occlusion with the foam also yields a targeted fibrotic response which durably reduces lung hyperinflation. The reduction in hyperinflation allows the healthier parts of the lung to re-inflate and improve breathing mechanics and gas exchange. In this study, the AeriSeal delivery will be limited to three segments that contain the collateral channel(s) between lung lobes. A minimum 10 mL volume of AeriSeal will be delivered per segment, with a total delivered volume limit of 40 mL per subject (including re-treatment, if needed) in a total of three segments.
45478949|NCT01704859|Dietary Supplement|Fish oil placebo|Fish oil placebo
45478950|NCT01704859|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
45478951|NCT01704859|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
45478952|NCT01345539|Radiation|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size, the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Patients may have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met.
45478953|NCT01345539|Drug|Chemotherapy|Chemotherapy choice of agents is at the discretion of the treating medical oncologist.
45478954|NCT01186367|Behavioral|Linear Aerobic Training|The 130-180 minutes/week will be achieved via either 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes per/session (± 10 minutes).
45478955|NCT01186367|Behavioral|Nonlinear Aerobic Training|The 130-180 minutes/week will be achieved via 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes/ per session (+/- 10 minutes).
45478956|NCT01186367|Behavioral|Progressive Stretching|All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
45478957|NCT01186367|Other|Cardiopulmonary exercise test (CPET)|
45478958|NCT01186367|Other|Blood draws|Complete blood count
45478959|NCT01034670|Device|Dual axis endoscopic microscope|This is a device that is used in the accessory port of a standard endoscope and allows visualization of microscopic areas of mucosa.
45478960|NCT01034670|Device|wide field fluorescence system|This is a modification to the existing narrow band endoscope from Olympus that incorporates different filters on the source and collecting optics to enable fluorescence imaging. It is used as is a standard endoscope.
45478961|NCT01034670|Device|CellVizio|Minimicroscope--this is an FDA approved fiber-based microscope that we will use according to the manufacturers protocols.
45478962|NCT01034670|Drug|fluorescent Peptide|microdosing; Topical through the endoscope
45478963|NCT01034670|Drug|fluorescein|100 mcg topical
45478964|NCT01034670|Drug|indocyanine green|100 mcg topical
45687136|NCT05694676|Other|Beck Depression Inventory, (BDI)|BDI contains 21 items and rates the depressive symptoms for the last week. Each item has four options and is scored between 0 and 3. The total score ranges from 0 to 63. Higher scores indicate more severe depression
45687137|NCT05691530|Drug|rDENdelta30/31-7164|The rDEN3delta30/31-7164 vaccine is a live attenuated virus constructed by creating two deletions in the 3 UTR of the DENV3 Sleman/78 strain. The rDEN3delta30/31-7164 vaccine will be delivered subcutaneously into the left deltoid area on day 0. The vaccine dose will consist of 0.5 mL of 10^3 PFU/mL of rDEN3delta30/31-7164 plus Plasma-Lyte A pH 7.4 diluent.
45687138|NCT05690984|Drug|Dexamethasone|Dexamethasone will be used for the double purpose of premedication and therapeutic effect. On Day 1 of Cycle 1, subjects will be administered 40 mg dexamethasone as an IV infusion. On Days 8, 15, 22 of Cycle 1 and Days 1 and 15 of Cycles 2-4, dexamethasone will be given as a single oral dose of 40 mg. For Cycles 5-12, dexamethasone will be given as a single oral dose of 4 mg on Days 1 and 15.
45843809|NCT04086732|Procedure|High-frequency electrical stimulation|High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be milliampere. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).
45843810|NCT04007874|Drug|Ethinylestradiol/levonorgestrel|Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
45843811|NCT04007874|Drug|Vitamin E|Vitamin E 400 IU oral capsules once daily for 3 months
45843812|NCT03984084|Other|no intervention|no intervention
45843813|NCT03878472|Drug|SHR1210|The patients will receive at least two cycles of SHR-1210 (200 mg, invdrip d1) every two weeks and be accessed for operational suitability every two cycles.
45843814|NCT03878472|Drug|Apatinib|The patients will received apatinib (250mg po qd) until 10 ± 2 days before surgery.
45843815|NCT03878472|Drug|S1|The patients will received S1 (50 mg/m2, po, bid, d1-d10) every two weeks and be accessed for operational suitability every two cycles.
45478965|NCT00977860|Radiation|Stereotactic Body Radiation Therapy|36.25 Gy in 5 fractions (7.25 Gy/fx) delivered over a 2-week period
45687139|NCT05690984|Drug|Isatuximab|Following premedication (if applicable), subjects will be given isatuximab 10 mg/kg body weight as an intravenous (IV) infusion on Days 1, 8, 15, and 22 (i.e., weekly) during Cycle 1 and on Days 1 and 15 (i.e., Q2W) during Cycles 2-12.
45687140|NCT05690984|Drug|Lenalidomide|On Days 1-21 for all 12 cycles, lenalidomide will be given to subjects as a single daily oral dose.
45687141|NCT05689879|Drug|STOP arm|TNF-alpha antagonists withdrawal
45687142|NCT05688904|Drug|Imipramine|Topical 4% Imipramine
45687143|NCT05688904|Other|Vehicle|Vehicle
45687144|NCT05687357|Drug|Tislelizumab|IV infusion
45687145|NCT05687357|Drug|S-1|Oral tablets
46047179|NCT04283058|Drug|Ketamine|d. Ketamine 0.5mg/kg* dose IV in 50 mL NS will be infused at a set non-titratable rate over 40 minutes or Ketamine 1mg/kg* dose IV in 50 mL NS will be infused at a set rate non-titratable over 90 minutes. The dose that the subject will receive will be determined by the Intensive Care Unit Attending based on patient symptoms. Ketamine administered at these doses may result in the following adverse reactions such as excessive sedation or drowsiness, or unpleasant hallucinations, agitation or dysphoric reaction, nausea or increased oral secretions.
45687146|NCT05687357|Drug|Oxaliplatin|IV infusion
45687147|NCT05687357|Drug|Nab paclitaxel|IV infusion
45478966|NCT00920387|Drug|200 mcg LSD|Administering 200 mcg LSD orally once at the start of each of two day-long psychotherapy session
45478967|NCT00920387|Drug|20 mcg LSD|Administer 20 mcg LSD orally once at the start of each of two day-long psychotherapy session
45478968|NCT00920387|Behavioral|Therapy|Therapy provided by male and female co-therapists
45687148|NCT05687357|Radiation|Radiation|TOMO/VMAT
45687149|NCT05686902|Other|CLEANING SOLUTION|The difference in peristomal skin integrity between the groups will be examined.
45843816|NCT03878472|Drug|Oxaliplatin|The patients will receive at least two cycles of oxaliplatin (85 mg/m2 d1) every two weeks and be accessed for operational suitability every two cycles.
45478969|NCT00583752|Biological|Adenovirus/PSA Vaccine|1x10E8pfu in Gelfoam subcutaneously on day 0, 30, 60
45357125|NCT04559464|Device|Zephyr Valves|The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
45357126|NCT02549976|Procedure|Abdominal MRI|Abdominal MRI to realize within 4 months following inclusion
45357127|NCT02549976|Procedure|Upper endoscopy|Upper endoscopy to realize within 4 months following inclusion
45357128|NCT02549976|Procedure|Colonoscopy|Colonoscopy to realize within 4 months following inclusion
45357129|NCT02549976|Procedure|Pelvic MRI|Pelvic MRI to realize within 4 months following inclusion
45357130|NCT00586469|Biological|Fluviral|One dose, Intramuscular injection
45357131|NCT00820560|Drug|INCB007839|INCB007839 100 or 200 mg/dose as IR capsules
45357132|NCT05244694|Drug|Insulin|Priming dose then a constant infusion at 40 mU•m-2•min-1
45357133|NCT00820638|Device|myomo e100|use of the myomo e100 in home
45357134|NCT04023383|Drug|40 cc HyaRegen NCH gel|After an extensive bleeding control the patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity.
45357135|NCT04023383|Drug|40 cc sterile saline solution|After an extensive bleeding control the patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
45478970|NCT00071071|Drug|HuMax-CD4|HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 18 weeks.
45357136|NCT00626028|Drug|Nitric Oxide for inhalation|Nitric Oxide (NO) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system
45478971|NCT00071071|Drug|HuMax-CD4|HuMax-CD4 560 mg was administered as a SC infusion OD up to 18 weeks.
45357137|NCT00626028|Drug|Oxygen|100% oxygen (O2) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system
45357138|NCT00626028|Drug|Nitric Oxide plus Oxygen|Nitric Oxide (NO) for inhalation plus oxygen, given at 80ppm over 10 minutes using an INOvent® delivery system
45357139|NCT00777257|Biological|T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap)+ Placebo, Intramuscular; Day 28: 0.5 mL (Menactra®) Intramuscular
45357140|NCT00777257|Biological|Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap) + 0.5 mL (Menactra®) Intramuscular; Day 28: Placebo 0.5 mL Intramuscular
45478972|NCT03333070|Dietary Supplement|probiotic - Lactobacillus reuteri|The treated arm will receive 5 drops per day for 48 weeks
46047180|NCT04154254|Diagnostic Test|PET/MR|The PET will be performed with one of the following tracers: 18F-FDG, 18F-DOPA or 18F-flutemetamol (Vizamyl). Proper tracer will be determined by the physician according to the condition. Patients that will agree, will be asked to perform two scans each with different tracer. The 3 tesla magnet of the MRI should allow acquisition of several contrasts within a reasonable time frame. The protocol will include T1 and T2-weighted images, perfusion and diffusion images. Images will be analyzed visually and quantitatively. Quantitative analysis will include MR parameters such as DWI apparent diffusion coefficient (ADC) and PET quantitative metabolic data such as standard uptake values (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Hidden image parameters will also be extracted for texture analysis purposes. Quantitative data will be correlated to clinical and pathological data to check accuracy, specificity and sensitivity.
45478973|NCT03333070|Other|placebo - with no active ingredient|The control arm will receive 5 drops per day for 48 weeks
45478974|NCT05156957|Other|physiotherapeutic intervention|The intervention consists of a brief physiotherapeutic assessment by a short physical performance battery, a brief information on the expected course of the condition and instructions on self-management regarding back friendly behaviour (eg. respecting the pain, staying active and back friendly movement strategies). Additionally, three exercises for daily self-guided therapy are included to the intervention: Turning in bed and coming to a sitting position, sit to stand and squats standing in front of a wall.
45478975|NCT03332992|Behavioral|Viral changes|Telephone script language provided pre-questions regarding the fact that influenza viruses change each year
45478976|NCT03332992|Behavioral|Protect others|Telephone script language provided pre-questions emphasizing the need to protect vulnerable others
46047181|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
46047182|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
46047183|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
46047184|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
45357141|NCT00777257|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap|Day 0: 0.5 mL (Menactra®)+0.5 mL Placebo, Intramuscular; Day 28: 0.5 mL (T dap) Intramuscular
45357142|NCT00820716|Other|Exercise training|Comparison of two methods of exercise training: alternate load versus constant load realized at moderate or high intensities
45357143|NCT05240794|Device|ABM-01|Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT)
45357144|NCT05240794|Device|Digital Control|Placebo control for ABM-01
45357145|NCT00826644|Drug|Belotecan|Belotecan : 0.5mg/㎡/day for Day 1 to 4, repeated every 3 weeks
45357146|NCT00826644|Drug|Etoposide|Etoposide 100mg/㎡/day for Day 1 to 3, repeated every 3 weeks
45357147|NCT00826644|Drug|Cisplatin|Cisplatin 60mg/㎡/day for Day 1, repeated every 3 weeks
45478977|NCT03332992|Behavioral|General intentions|Question language asking about general interest in getting influenza vaccination
45478978|NCT03332992|Behavioral|Behavioral intentions|Question language asking individual to make specific plans to be vaccinated
45357148|NCT04095533|Other|Tibialis anterior muscle cross-sectional area assessment by ultrasound|"Assessed using bedside ultrasound with repeat assessments every second day up to 2 weeks of ICU admission, or until discharge from ICU to yield an overall rate of muscle area decline reported as a %/day average muscle atrophy rate.~Tibialis anterior cross-sectional area assessments will be assessed by measurement ultrasound to both legs with portable bedside ultrasound. The cross sectional area will be measured in cm^2 at 5 cm distal to the lateral eminence of the tibial tuberosity along the muscle belly. Image processing will be performed at the bedside using features available on the ultrasound device. Muscle boundaries will be marked on the device and the cross-sectional area (computed from the perimetral contour of the muscle section) will be determined. This process will be repeated for two times for each leg."
45357149|NCT04095533|Other|Muscle strength assessment|Assessed using clinical bedside evaluation every second day with the Medical Research Council Sum Score. This is a clinical assessment of strength of 6 different muscle groups (shoulder abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and ankle dorsiflexors) on each side of the body and recorded as a score between 0 (flaccid) and 5 (full strength).
45357150|NCT04018560|Behavioral|Al-Anon Intensive Referral (AIR)|AIR is intended to facilitate Al-Anon participation.
45357151|NCT00916877|Radiation|Prophylactic Cranial Irradiation|Prophylactic Cranial Irradiation
45357152|NCT00824148|Device|Guardian REAL-Time Continuous Glucose Monitoring System|One group will use the glucose monitoring system for 1 month
45357153|NCT00824148|Other|Conventional self-monitoring of plasma glucose|Finger prick blood glucose measurements
45357154|NCT04925050|Drug|VB0004|Each study part (A,B and C) will be completed sequentially or with partial overlapping. Safety and PK data through at least day 8 from a subsequent cohort will be reviewed by the SMC prior to dosing the fed period of FE cohort. Safety data will be assessed by SMC after completing each cohorts in MAD healthy volunteers and MAD mild Hypertension patients.
45357155|NCT04925050|Other|Matching Placebo for VB0004|Matching Placebo
45357156|NCT05437055|Device|Mechanical Thrombectomy (Penumbra System with Thunderbolt)|Subject will receive Penumbra System with Thunderbolt
45357157|NCT00826722|Drug|Levetiracetam|1000 mg tablet
45357158|NCT04922944|Drug|COVID-19 vaccine|Two-dose COVID-19 vaccine
45478979|NCT03332992|Behavioral|Accountability|Question language asking individual whether their care team can learn about their vaccination intentions
45843817|NCT03772626|Device|Heated Humidified High-flow Nasal Cannula|Patients will receive heated high humidity air through the AIRVO(TM) device starting in hospital and continuing for 60 days after hospital discharge. Oxygen will be titrated to target SpO2 between 88-92%, patients not requiring oxygen will receive heated high humidity air without oxygen. Temperature and flow rate will titrated to patient comfort with a target temperature 37 degree Celsius and flow rate of ≥20 l/minute. Patients will be encouraged to use the device overnight and when needed during the day with a target duration of at least 6 hours per night
45843818|NCT03721926|Other|Usual Care|Participants assigned to receive usual oncology care will not meet with the study nurses, though they may receive geriatric or palliative care consults at their request or at the discretion of their treating oncologist.
45357159|NCT02549586|Drug|Autologous Hematopoietic Stem Cell Transplant|"Step 1: Participants will receive intravenous chemotherapy and cytokine-based treatment for mobilization of hematopoietic stem cells (HSC) into the circulation, followed by collection using peripheral vein leukopheresis. The HSC graft product will undergo ex vivo purification with CD34 selection using Miltenyil CliniMACS and cryopreserved.~Step 2: Intravenous busulphan, cyclophosphamide and anti-thymocyte globulin will be administered to participants to achieve immune ablation prior to the infusion of the participants' own thawed HSC graft product (HSC transplant). Routine supportive measures will be employed during the recovery from the chemotherapy and HSCT. Participants' immune suppression will be stopped at the time of immunoablative therapy and will be switched to everolimus which will be discontinued at 6 months post HSCT."
45357160|NCT05198050|Drug|Letrozole tablets|Letrozole is a third-generation non-steroidal aromatase inhibitor
45357161|NCT05198050|Drug|Misoprostol Tabets|a synthetic prostaglandin medication
45357162|NCT05198050|Drug|Placebo tablets|Placebo tables with a similar appearance to letrozole
45357163|NCT00820794|Drug|Lithium|300 mg lithium, oral, once initially and then again at day 4 of PD 0332334 treatment
45357164|NCT00820794|Drug|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
45357165|NCT00820794|Drug|Lithium|300 mg lithium, oral, at day 4 of PD 0332334 treatment and after 7 day washout
45357166|NCT00820794|Drug|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
45478980|NCT03812393|Drug|Neratinib|For cycle 1 subjects will receive Neratinib 240mg daily for 21 days. For cycle 2-5, subjects will receive carboplatin AUC of 1.5 and Paclitaxel 80mg/m2 on day one in combination with Neratinib 240mg daily for 21 day.
45478981|NCT05465278|Drug|Alirocumab|18 months treatment with alirocumab
45478982|NCT01302275|Drug|Oxcarbazepine|Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
45478983|NCT03332914|Device|Microcurrent therapy|The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
45478984|NCT02318784|Drug|Carfilzomib|
45478985|NCT03332836|Biological|HM12460A|HM12460A is a long-acting insulin
45357167|NCT04516876|Other|Camp-based bimanual intensive training(BIT)|The day-camp BIT model will be delivered in a group-based design. In day-camp model, each child is assigned to a trained therapist to maintain at least a 1:1 to 1:2 ratios of therapy and child. The therapist will monitor and modify the activities to fit each individual's ability and need to make sure the intervention quality is equivalence to the individualized treatment method. The chosen tasks of each intervention session have to be considering the child's preference, age-appropriated, and at the right level of difficulty. Target movements are embedded in the functional activities, whereby the environment is manipulated to vary task requirement and the difficulty is graded to match the child's capacity.
45357168|NCT04044378|Drug|Famitinib|famitinib with RP2D orally daily
45357169|NCT04044378|Drug|Ifosfamide|ifosfamide 1.8g/m2/d d1-3, 15-17 Q4W infusion
45357170|NCT04044378|Drug|Camrelizumab|camrelizumab 200mg infusion once Q2W
45357171|NCT04512586|Procedure|Conduction System pacing and AV node ablation|See study arm description.
45357172|NCT04512586|Procedure|Atrial fibrillation ablation by pulmonary vein isolation|See study arm description
45357173|NCT04914052|Other|Filming facial expressions|Study participants' facial expressions will be videoed by a camera placed in front of the patient's bed during their stay in the post anesthesia care unit.
45357174|NCT00628758|Drug|Symbicort TBH - Turbuhaler|Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
45357175|NCT00628758|Drug|beta-II-agonist, inhale steroid|Salbulin inh. 200-400 dosage 100 microgram (mcg)/dosage Salbutamol Sustained Release(SR)capsule 4 mg/8 mg Salbutol tablet (tb) 2 mg Salbutol forte syrup 2 mg/5 ml Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp) Ventolin inhaler (inh) 200 dosage, 100 mcg/dosage Ventolin nebul 2.5 mg Volmax tb 4 mg/8 mg Vent-o-sal inh 100 mcg/200 dosage Combivent inh 100 mcg/dosage Combivent neb 2.5 mg/dosage Bricanyl tb 2.5 mg Bricanyl durules ret tb 5 mg Bricanyl syrup 30mg Bricanyl inhaler 0.25 mg/dosage, 400 dosage Bricanyl turbuhaler 0.5 mg/dosage, 200dosage
45357176|NCT04491604|Biological|Topical Beremagene Geperpavec|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
45357177|NCT04491604|Other|Placebo|Matching masked inactive topical gel
45357178|NCT00824226|Dietary Supplement|magnesium|magnesium 350 mg tablets once a day for 3 weeks
45357179|NCT03999112|Other|Metacognitive Reflection and Insight Therapy (MERIT)|A psychological therapy aiming to increase the ability of individuals to synthesise perceptions about themselves and others; to then form complex narratives which recognise the occurrence of these within particular social contexts; and to use these to form responses to psychological problems.
45357180|NCT00821028|Drug|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery. Dosing will be based on ther lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm^3
45357181|NCT00821106|Procedure|Right radial|diagnostic or interventional procedures performed through right transradial approach
45357182|NCT00821106|Procedure|left radial|diagnostic or interventional procedures performed through left transradial approach
45357183|NCT00826878|Drug|Tivozanib (AV-951)|"Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) once daily continuously beginning on Day 1 for 4 weeks. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicity.~Minimum of 8 weeks (2 consecutive dosing cycles), if tolerated."
45478986|NCT03332758|Procedure|Pars plana vitrectomy|Standard of care treatment for retinal detachment, macular hole, or epiretinal membrane.
46047185|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
45357184|NCT00826956|Procedure|one lung ventilation|measure the pulmonary blood flow in nondependent lung during 30min one lung ventilation
45357185|NCT00827034|Drug|Warfarin|A: a single oral dose of warfarin 25 mg administered on Day 1 of the relevant dosing period, as tablets.
45357186|NCT00827034|Drug|Dimebon|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
45357187|NCT00827034|Drug|Warfarin|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
45357188|NCT00754559|Drug|Tocilizumab|8mg/kg iv every 4 weeks
45357189|NCT02600585|Biological|Recombinant Influenza Vaccine|Intramuscular injection of study vaccine
45357190|NCT02600585|Biological|Inactivated Influenza Vaccine|Intramuscular injection of study vaccine
45357191|NCT00525148|Drug|BIBW 2992|This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs
46047186|NCT00631995|Dietary Supplement|Meningococcal polysaccharide group C conjugated|0.5 mL, Intramuscular
45357192|NCT00754325|Drug|Dasatinib|Tablets, Oral, 100 mg, once daily (QD), upto 2 years
45357193|NCT00754325|Drug|Fulvestrant|Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years
45357194|NCT00524680|Dietary Supplement|cholecalciferol|Given orally
45357195|NCT04794322|Diagnostic Test|Uterine lavage, or a wash of the womb|Uterine lavage is performed during surgery using a flexible, 3-way balloon tipped catheter. The catheter is inserted through the cervix, the balloon expanded and the uterine cavity lavaged using 10 cc of sterile saline which is collected, processed and stored for later analysis.
45357196|NCT04794322|Diagnostic Test|Blood sample|Participants undergo two blood draws (one required, one optional) up to 31 days before surgery
45357197|NCT04794322|Diagnostic Test|Pap smear|Participants undergo a standard Papanicolaou smear to collect cells and fluid from the cervix.
45478987|NCT03332758|Procedure|External drainage|Standard of care treatment for retinal detachment.
45478988|NCT01301573|Biological|rAAV-GAD|
46047187|NCT00663442|Drug|OROS methylphenidate|18, 36, 54 mg
46047188|NCT03004755|Other|Tissue Harvest|
46047189|NCT00912015|Drug|Tramadol OAD|
46047190|NCT00912015|Drug|Tramadol OAD|
46047191|NCT00912015|Drug|Tramadol OAD|
46047192|NCT00912015|Drug|Tramadol OAD 100mg|
45357198|NCT00628212|Drug|Teneligliptin 10mg|
45357199|NCT00628212|Drug|Teneligliptin 20 mg|
45357200|NCT00628212|Drug|Teneligliptin 40 mg|
45357201|NCT00628212|Drug|Placebo|
45478989|NCT05623397|Other|Acquisition of a digitized ECG by four modalities within 20 minutes|"Patients will have three visits during the cycle for a given dose (600mg/day, 400mg/day or 200mg/day): Baseline , Day 14, Day 28~At each visit, the patient will have the acquisition of a digitized ECG by four modalities within 20 minutes (A 10 second triplicate ECG with WELCH-ALYN ELI-280® with the three 10sec ECGs collected at approximatively 2-minute intervals, 10 min holter acquisition with a CGM HI-patch ®, a 3 minutes acquisition with AliveCore 6L® device and a 5 minutes acquisition with QT-medical ® device).~Concomitantly with the ECG acquisition, patients will have blood sampling for measurements of variables clinically important for assessment of QTc including potassium, fasting blood glucose, calcemia, magnesium, estradiol, progesterone, FSH, LH, D4-androstenedione, total and free testosterone, SHBG and TSH. Blood concentration of ribociclib will be also assessed."
45478990|NCT02263014|Behavioral|Questionnaires|Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, 12, and 18 months after the surgery is completed.
45478991|NCT03339544|Drug|Celebrex premedication|celebrex (celecoxib) 200mg is a non-steroidal anti-infalmmatory drug with selective COX-2 inhibition.
45478992|NCT03339544|Drug|Placebo|placebo is given as a tablet before initiation of endodontic treatment
45478993|NCT03332680|Biological|EmbryoGlue® (laboratory culture medium)|Embryos placed in this medium prior to transfer
45478994|NCT03332680|Biological|Standard control medium|Embryos placed in this medium prior to transfer
45478995|NCT05157594|Biological|Blood sample|Evaluation of plasma hPG80 concentrations by fasting blood samples. A total of seven 5 mL blood samples will be taken: Before radiation therapy; at the end of radiation therapy; at cycle 3 of chemotherapy; at cycle 6 of chemotherapy; 3 months after the end of treatment; 6 months after the end of treatment; and 9 months after the end of treatment.
45478996|NCT02499718|Device|BiPAP mode|Noninvasive ventilator
45478997|NCT03815747|Device|High-Intensity Focused Electromagnetic (HIFEM) Field Device|The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
45478998|NCT03339466|Device|Inspiratory muscle therapy|6 weeks of inspiratory muscle therapy
45478999|NCT02526264|Other|Education program|Verbal education prior tu surgery administered to all patients in order to inform about the surgery and outcomes
45357202|NCT05160610|Behavioral|Multilevel intervention|Multilevel intervention based on AACTT theory
45357203|NCT00298363|Drug|Tenofovir disoproxil fumarate (tenofovir DF; TDF)|300-mg tablet QD
45479000|NCT05123417|Diagnostic Test|Follow up|Each group participants will be tested with questionnaire before the training and two weeks after the training they will get post test with the same questionnaire.
45357204|NCT00298363|Drug|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC 200 mg/TDF 300 mg fixed-dose combination (FDC) tablet QD
45357205|NCT00298363|Drug|Entecavir (ETV)|0.5-mg or 1-mg tablet QD
46047193|NCT00960804|Biological|Tanezumab|IV, 5 mg dose, q 8 weeks, for up to 80 weeks
46047194|NCT00960804|Biological|Tanezumab|IV, 10 mg dose, q 8 weeks, for up to 80 weeks
46047195|NCT00960804|Other|Placebo|IV, q 8 weeks, for up to 80 weeks
45357206|NCT00298363|Drug|TDF placebo|Placebo to match TDF QD
45357207|NCT00298363|Drug|FTC/TDF placebo|Placebo to match FTC/TDF QD
45357208|NCT00298363|Drug|ETV placebo|Placebo to match ETV QD
45357209|NCT00821262|Drug|sevoflurane|
46047196|NCT04299945|Dietary Supplement|concentrated beetroot juice (400mg of nitrate per serving)|Dietary nitrate supplementation includes consumption of two beverages daily for 7 consecutive days.
46047197|NCT04299945|Dietary Supplement|concentrated beetroot juice (trace amounts of nitrate per serving)|Dietary placebo supplementation includes consumption of two beverages daily for 7 consecutive days.
46047198|NCT00630006|Genetic|TNF-alpha and IL-10|
46047199|NCT02859948|Drug|SKLB1028|SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
45357210|NCT00821262|Drug|propofol|
45357211|NCT00824694|Other|Targeted Self-Monitoring Of Blood Glucose (SMBG)|SMBG will alternate between 2 strategies: glucose profiling and target monitoring.
45357212|NCT00824694|Other|Provider Training|Focused on normalizing the most significant glucose abnormalities at any given time.
45357213|NCT00824694|Other|Patient Education|Focused on normalizing the most significant glucose abnormalities at any given time.
45357214|NCT00830622|Other|Cell Phone Intervention|Participant receives weekly SMS text messages from the health care provider.
45357215|NCT01065883|Behavioral|community health worker|community health workers will provide education in the home
45357216|NCT01065883|Behavioral|mailed information|information will be mailed to the home on the same schedule as the experimental intervention
45479001|NCT03332602|Dietary Supplement|free FeSO4|Testmeal with free FeSO4
45479002|NCT03332602|Dietary Supplement|free FeSO4 and empty microspheres|Testmeal with free FeSO4 and empty micropsheres
45479003|NCT03332602|Dietary Supplement|free FeSO4 and hylauronic acid|Testmeal with free FeSO4 and hyaluronic acid
45479004|NCT03332602|Dietary Supplement|free FeSO4 and eudragit polymer|Testmeal with free FeSO4 and eudragit polymer
45479005|NCT03332602|Dietary Supplement|encapsulated FeSO4 3.2%|Testmeal with encapsulated FeSO4 with 3.2% Fe loading
45479006|NCT03332602|Dietary Supplement|encapsulated FeSO4 20%|Testmeal with encapsulated FeSO4 with 20% Fe loading
45479007|NCT03332602|Dietary Supplement|encapsulated FeSO4 3.2%, encapsulated Vitamin A|Testmeal with encapsulated FeSO4 with 3.2% Fe loading, and encapsulated Vitamin A
45357217|NCT00830700|Other|CATMH intervention|This intervention is comprised of 6-tandem-sessions of pharmacotherapy and a behavioral intervention conducted over 4-5 months. The telepsychiatrist makes prescribing decisions during the intervention following consensus guidelines for ADHD treatment. The telepsychiatrist also provides education about how neurobiological deficits of ADHD relate to observed behavioral learning and difficulties. After the 6th session, the PCP resumes care of the patient. The behavioral intervention component is delivered by therapists at each participating clinic. The therapists are trained and supervised remotely by a telepsychologist . The 6-session behavioral intervention consists of approaches to managing children's behaviors and coordination with schools and other community agencies to advocate for the child.
45357218|NCT00830778|Procedure|Pancreaticojejunostomy|Pancreaticojejunostomy (PJ) reconstruction/anastomosis
45357219|NCT00830778|Procedure|Pancreaticogastrostomy|Pancreaticogastrostomy (PG) reconstruction/anastomosis
45357220|NCT03981913|Behavioral|Simon Task with high-density EEG recording|"The scalp electrical activity will be collected by a 256-electrodes EEG montage (Electrical Geodesics Inc).~During the task, participants will be asked to answer on a right or left button according to the color of a circle (yellow or blue) presented on the left or right side of a screen. Participants will have to ignore the stimulus position and respond only according to its color. This leads to two experimental conditions When the color of the circle and its position indicate the same answer, the situation is congruent and the answer is facilitated. Conversely, when they indicate two opposite responses, a conflict between the two alternative actions appears and must be resolved to provide a correct answer. This situation is said to be incongruent. At each trial, the stimulus is shown to the left or right of a central fixation cross. The participants then have to answer on a right or left button. At each trial, the reaction time and the accuracy of the response will be collected."
45357221|NCT02548572|Device|Transcorneal Electrical Stimulation using Okustim device|"The Okustim® stimulation device is a battery-powered electronic neuro-stimulator, which delivers a weak electrical pulse. This current is delivered to the eyes by the OkuStim® device using the OkuEl® electrodes, which are held in place via the OkuSpex® frame. In this study the treatment level will be held constant at 0.8 mA for all study subjects. After switching on the neuro-stimulator, the subject's retina will be stimulated through specific electrodes (OkuEl, held in position by the OkuSpex) worn on the face with the predetermined intensity and time period (delivered by the OkuStim device)."
45357222|NCT00524368|Drug|Darunavir (DRV)|DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.
45357223|NCT00524368|Drug|Ritonavir (rtv)|DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.
45357224|NCT00777101|Drug|Neratinib|Tablets 240 mg orally once per day until disease progression or unacceptable toxicity
45357225|NCT00777101|Drug|Lapatinib|Tablets 1250 mg orally once per day until disease progression or unacceptable toxicity.
45357226|NCT00777101|Drug|Capecitabine|Tablets 2000 mg/m² given orally in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity.
45357227|NCT00830856|Drug|Fluconazole|Fluconazole 800mg po qday
45357228|NCT00830856|Drug|Fixed dose - Stavudine, lamivudine and Nevirapine|Initiation within 72 hours of diagnosis of Cryptococcal meningitis.
45357229|NCT00830856|Drug|Fixed dose - Stavudine, Lamivudine, Nevirapine|Delayed initiation of ART defined as 10 weeks after initiation of high dose fluconazole therapy.
45479008|NCT03332602|Dietary Supplement|encapsulated FeSO4 3.2%, encapsulated Vitamin A, free Folic Acid|Testmeal with encapsulated FeSO4 with 3.2% Fe loading, and encapsulated Vitamin A, with free folic acid.
45357230|NCT01068067|Other|drug (tacrolimus and SchE) and genetics|Patients were genotyped for the polymorphisms that can influence tacrolimus pharmacokinetics before transplantation. After transplantation, initial tacrolimus dosage was based on an algorism guided by pharmacogenetics and SchE.
45357231|NCT01068067|Drug|tacrolimus|After transplantation, patients received standard initial dose of tacrolimus (0.050-0.075 mg/kg).
45357232|NCT00827190|Drug|ILS-920|
45357233|NCT00297427|Procedure|Acupuncture|Acupuncture twice weekly for 6 weeks.
45357234|NCT00297427|Other|Sham acupuncture|Twice a week for 6 weeks
45357235|NCT00830934|Procedure|Individual care|The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
45357236|NCT00830934|Procedure|group care|The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
45357237|NCT00524134|Drug|Carvedilol-CR|Week 1: 20mg capsule once daily Week 2-3: 40mg capsule once daily Week 4-15: 80mg once daily Week 16: tapering (40mg/day x 4d, then 20mg/day x 3d), unless the patient wishes to continue receiving the medication.
45357238|NCT00777023|Drug|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
45357239|NCT00777023|Drug|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
45687150|NCT05684068|Procedure|Gum Graft Placed on Denuded Bone|The provider will administer local anesthesia into the subject's gum in order to numb both the subject's donor and recipient areas for gum grafts. Next, the provider will use a surgical blade to dissect the gum graft from the subject's donor site. At the subject's recipient gum recession defect site, the provider will remove all of the subject's tissue, so that the bone is fully exposed before placing a gum graft from the donor site. Afterward, the provider will place sutures in the subject's recipient site in order to promote healing/re-growth.
45357240|NCT00777023|Drug|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
45357241|NCT05062330|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days
45687151|NCT05684068|Procedure|Gum Graft Placed on Split Thickness Periosteal Bed Preparation|The provider will administer local anesthesia into the subject's gum in order to numb both the subject's donor and recipient areas for gum grafts. Next, the provider will use a surgical blade to dissect the gum graft from the subject's donor site. At the subject's recipient gum recession defect site, the provider will dissect some of the tissue at the subject's recipient site but still keep a small layer of tissue at the subject's recipient site before placing a gum graft from the donor site. Afterward, the provider will place sutures in the subject's recipient site in order to promote healing/re-growth.
45687152|NCT05683457|Biological|mRNA-1647|Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline).
45687153|NCT05683457|Biological|Placebo|0.9% sodium chloride (normal saline) injection
46047200|NCT04466787|Diagnostic Test|Spectral Photon Counting Computed Tomography (SPCCT)|"The acquisition for the assessment of the brain parenchyma and for the evaluation of the cervical and intracranial arteries will be performed without and with iodine based contrast media, respectively. The same parameters will be used for both conditions but for a large volume, from the aortic arch to the top of the head. The iodinate contrast agent's injection (Iomeron 400, Bracco Imaging France) will be performed at 5mL/s into an 18G catheter, followed by a 20 mL saline flush that will be injected at the same rate. The bolus volume will be determined according to the patient's body weight : 70 mL for patients < 80 kg and 1 mL/kg for patients > 80 kg, with a maximum of 90 mL.~The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field of View (FOV) of 168 mm in-plane, and a z-coverage of 2 mm."
45357242|NCT05062330|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered 7 times over two consecutive days
45357243|NCT00297037|Drug|Pimecrolimus 1% cream|pimecrolimus cream or matching placebo BID for 6 weeks
45357244|NCT03978065|Diagnostic Test|Confocal microscopy|"For this purpose live stains will be combined with a confocal imaging setup equipped with 6 laser lines. A major advantage of this technique is that tissue specimens do not need to be fixed prior to analysis. Such an approach does not only allow tissue viability and integrity assessment in an unprecedented speed and accuracy, but also promises to shed new light into quality assessment and prognosis in kidney transplantation. The investigators herein wish to establish the predictive values of this technology in kidney transplantation.~The methodology used in this trial is referred to as BIOPSYCHRONOLOGY - as a reference to dendrochronology, or tree ring dating. Leaving the biopsy sample intact facilitates its analysis, just as drills are used for tree-ring counting."
45357245|NCT04093193|Procedure|Debridement|Debridement or cleaning of the sinuses post-operatively has been described as a regular post-surgery procedure .
45357246|NCT00292981|Drug|C1 Esterase Inhibitor|Lyophilisate containing approximately 500 U C1-INH to be reconstituted with 10 mL water for injection; Single Dose: 20 U/kg b.w. iv
45357247|NCT02598869|Drug|Triamcinolone Acetonide|injection of triamcinolone acetonide
45357248|NCT04095455|Procedure|pectoral nerves block group|ultrasound guided block of nerve supply of surgical site
45479009|NCT03332602|Dietary Supplement|FeSO4 embedded in Hyaluronic acid|Testmeal with FeSO4 embedded in Hyaluronic acid
45479010|NCT01302353|Drug|Emulsified Isoflurane|
45479011|NCT03339310|Device|Optimizer Smart System with 2-leads|The Optimizer Smart System with 2-leads delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Implanted subjects receive five non-contiguous one-hour periods of CCM signals per day.
45479012|NCT03812315|Combination Product|Propolis chewing gum|Children who will use chewing gum will be instructed to chew a gum for 20 minutes once after breakfast and another before bed time for two weeks.
45479013|NCT03812315|Combination Product|Propolis mouthwash|Children who will use mouthwash will be instructed to rinse with 10 ml for 60 seconds twice daily once after breakfast and another before bedtime for two weeks.
45357249|NCT04095455|Drug|Ketamine plus magnesium group|Patients received 40 mg/kg of magnesium sulphate infusion in 100cc normal saline, as a bolus dose, in addition to 0.2mg/kg of ketamine as a bolus dose, 15 min before the induction of general anesthesia. This was followed by intraoperative continuous infusion of 10 mg/kg/h of magnesium sulphate combined with infusion of 0.1mg/kg/h ketamine that was started before skin incision and continued until completion of skin closure via infusion pump (Atom Syringe Pump S-1235).
45479014|NCT03332524|Drug|SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg|2 Ibuprofen and capsules Chlorpheniramine maleate 3 time per day for 72 hours
45479015|NCT03332524|Drug|2 capsules Ibuprofen and 1 placebo|Ibuprofen and placebo
45479016|NCT03332524|Drug|capsule Chlorpheniramine 4mg and 1 Placebo|Chlorpheniramine 4mg and one capsule Placebo 3/72days
45687154|NCT05682144|Biological|Autologous Plasmablasts (B cells)|Autologous plasmablasts (B cells) engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty (SB) transposon system.
45687155|NCT05679492|Biological|Meplazumab foe injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
45687156|NCT05679492|Other|Normal saline|Normal saline
45687157|NCT05677048|Behavioral|Free genetic testing and counseling group|Option to access no-cost telegenetic counseling and genetic testing
45687158|NCT05677048|Behavioral|IGNITE-TX Group|Access online educational materials through the IGNITE-TX platform and receive assistance from a family genetic navigator
45843819|NCT03721926|Other|Geriatric Oncology Collaborative Care|Patients receive three visits with a trained study nurse. At each visit, the study nurse will assess the patient's symptom burden, functional status, comorbid conditions, psychosocial issues, and medication use. The nurses can refer patients to specialists as needed. The study nurses will meet with a supervising support team, consisting of clinicians from geriatrics, palliative care, social work, and pharmacy to discuss each patient and review documentation. Following the team meetings, the nurses will document recommendations in the medical record and communicate with the primary oncology team, either in person or via phone, as appropriate. The study nurses will contact the supervising team in between meetings for any urgent issues or questions that arise.
45843820|NCT03681912|Behavioral|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS)|"Coaching feedback will be triggered by a provider falling below the competency threshold on the standardized patient interaction. Everyone will receive coaching for two assessments in the month following training. After that, if mean scores fall below competency, then the provider will receive a 45-minute coaching session by the external Motivational Interviewing Network of Trainers (MINT) facilitator.~Feedback on two highest and two lowest ratings, review of the audio recording and interactive coaching activities (e.g., fidelity assessments) targeting the lowest ratings. While many aspects of this implementation strategy are adaptable, organizational leadership will review data on completion of coaching feedback sessions and will determine corrective action for suboptimal adherence."
46047201|NCT04466787|Diagnostic Test|Dual Energy CT (DECT)|"The acquisition for the assessment of the brain parenchyma and for the evaluation of the cervical and intracranial arteries will be performed without and with iodine based contrast media, respectively. The same parameters will be used for both conditions but for a large volume, from the aortic arch to the top of the head. The iodinate contrast agent's injection (Iomeron 400, Bracco Imaging France) will be performed at 5mL/s into an 18G catheter, followed by a 20 mL saline flush that will be injected at the same rate. The bolus volume will be determined according to the patient's body weight : 70 mL for patients < 80 kg and 1 mL/kg for patients > 80 kg, with a maximum of 90 mL.~DECT : IQon, Philips"
46047202|NCT01126580|Drug|Metformin|
46047203|NCT01126580|Drug|LY2189265|
46047204|NCT01126580|Drug|Placebo (oral)|
46047205|NCT01126580|Drug|Placebo (subcutaneous)|
46047206|NCT04204356|Behavioral|Language treatment for improving discourse production|All participants will receive a 6-week block of language treatment for improving verb retrieval in discourse production by a professional speech and language therapist. The treatment goals for this block of treatment are to 1) improve verb retrieval and language quantity and complexity in discourse production 2) improve functional communication skills and; 3) improve quality of life and psychological state in people with post-stroke chronic aphasia.
45357250|NCT04095455|Drug|Control group|Normal saline infusion with similar rate and volume to KM infusion was used as a placebo.
45357251|NCT04095299|Radiation|50.4 Gy to the tumor and elective volume|Standard radiotherapy
45357252|NCT04095299|Radiation|62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume|Experimental radiotherapy
45479017|NCT01301651|Behavioral|balance training|30 minute each time, 2 times per week for 6 weeks.
45479018|NCT03332446|Other|cold water immersion|10 min at 12-15°C
45479019|NCT03815513|Other|brain MRI|both case and control groups received brain MRI to evaluate cerebrovascular reactivity
45687159|NCT05677048|Behavioral|IGNITE-TX and free genetic testing and counseling group|Option to access no-cost telegenetic counseling and genetic testing, access to online educational materials through the IGNITE-TX platform, and assistance from a family genetic navigator
45357253|NCT04095299|Drug|Capecitabine 825 mg/m2 twice daily on weekdays|Standard chemotherapy
45357254|NCT00296725|Drug|Fluoxetine|Phase 1: Fluoxetine: wk 1: 10 mg/day; wks 2-3: 20 mg/day; wks 4-5: 40 mg/day; wk 6: 60 mg/day; wks 7-12: 80 mg/day *All increases only if tolerated.
45357255|NCT00296725|Drug|Imipramine|Phase 2: Imipramine wk 1: 25 mg/day; wk 2: 50 mg/day; wk 3: 100 mg/day, 150 mg/day after 3 days; wk 4: 200 mg/day, 250 mg/day after 3 days; wks 5-6: 300 mg/day. *All increases only if tolerated.
45357256|NCT00625872|Drug|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
45357257|NCT00625872|Drug|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
45357258|NCT00523978|Device|Arctic Front® Cryoablation Catheter|Experimental Subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci with the cryoablation catheter system.
45357259|NCT00523978|Drug|Flecainide or Sotalol or Propafenone|Flecainide 200 mg / day Propafenone 450 mg / day Propafenone-SR 650 mg / day Sotalol 240 mg / day
45479020|NCT02499640|Other|immersion cold water|immersion cold water at different temperatures and exposure times
46047207|NCT04204356|Device|Transcranial direct-current stimulation (tDCS)|Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. The use of tDCS as an adjunct to speech and language therapy has been found to improve aphasia treatment effects in post stroke patient populations.
46047208|NCT00911157|Drug|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (< 50 kg, 5 mg; 50 to 100 kg, 7.5 mg; >100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
45357260|NCT02599727|Other|Isometric exercises|subjects will perform specific isometric exercises for 10-20 minutes, three times a week throughout the enrollment period
45357261|NCT02599727|Other|No exercise|Subjects will go on with their life without any specific isometric exercise regimen during the enrollment period
45357262|NCT00296647|Drug|nicotine patch|Decreasing dosages from 21 to 7 mg over 12 week period
45357263|NCT00296647|Drug|nicotine patch|Decreasing dosage from 21 to 7 mg over 12 weeks
45357264|NCT00296647|Drug|nicotine lozenge|4 mg nicotine lozenge: dosage according to package directions for 16 weeks
45357265|NCT00296647|Drug|bupropion|dosage according to prescription directions: 12 weeks
45357266|NCT00296647|Drug|patch + lozenge|dosage of each according to package insert directions (12 weeks patch, 16 weeks lozenge)
45357267|NCT00296647|Drug|bupropion + lozenge|dosage of each according to prescription or package insert (12 weeks bupropion, 16 weeks lozenge)
45357268|NCT00754013|Drug|Aricept (Donepezil hydrochloride)|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil.~All doses will be administered orally."
45357269|NCT00754013|Drug|Placebo|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) placebo.~All doses will be administered orally."
45357270|NCT04094987|Device|inter-fascial pressure|The pressure between the fascia and the pressure line added to the catheter tip will be measured.
45357271|NCT01062919|Procedure|Epidural analgesia|patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
45843821|NCT03681912|Behavioral|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity monitoring, and prevent drift. In addition to CoP, half the sites will be randomized to receive an internal facilitator who will be trained to continue quarterly fidelity monitoring and coaching feedback when scores fall below competency.
45357272|NCT01062919|Procedure|Wound catheter|patients in the epidural analgesia group will receive 0.2%ropivacaine through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
45357273|NCT00523744|Drug|Amlodipine|Amlodipine supplied as 5 mg tablets, taken orally once a day during Treatment Phase 1 only.
45357274|NCT00523744|Drug|Olmesartan medoxomil|Olmesartan medoxomil supplied as 10 mg tablets taken once a day during Treatment Phase 1 only.
45357275|NCT00523744|Drug|Amlodipine+valsartan|Fixed-dose combination of amlodipine 10 mg plus valsartan 160 mg tablet taken orally once a day during Treatment Phase 2 and Extension Phase.
45479021|NCT01302431|Other|Manualised nurse-led telephone support|The manualised nurse-led telephone support intervention is designed to provide proactive support and enable caregivers of people with multiple sclerosis manage problems encountered with caregiving
45479022|NCT02499484|Drug|glyceryl trinitrate|Topical GTN will be used daily in combination with a eccentric home exercise program
45479023|NCT02499484|Other|Placebo ointment|Topical placebo ointment will be used in combination with a eccentric home exercise program
45479024|NCT02499484|Other|Eccentric exercise program|All participants will complete the eccentric exercise program as a home exercise program daily.
45479025|NCT03170154|Device|Clareon aspheric hydrophobic acrylic monofocal IOL|Ultraviolet-absorbing and blue light-filtering IOL composed of high refractive-index foldable and flexible acrylic material. IOLs are implantable medical devices intended for long term use over the lifetime of the cataract subject.
46047209|NCT00911157|Drug|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
45357276|NCT00523744|Drug|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg tablets taken once a day during the Extension Phase.
45479026|NCT01302509|Dietary Supplement|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
45479027|NCT03339232|Dietary Supplement|BCAA Supplement|Each teaspoon contains 1788 mg of BCAA and participants will take 7 teaspoons (12.5 grams of BCAA) per day divided into three separate servings. Each teaspoon contains L-leucine, isoleucine and valine in a 2:1:1 ratio.
45357277|NCT03979625|Other|Hospitalization for more than 3 days with high clinical suspicion of HIT and positive anti-PF4/heparin antibodies|Patients are classified according to results of functional tests as having either Confirmed or Excluded HIT.
45357278|NCT04094831|Other|Health education|The intervention group will receive health education through CKD campaign and mHealth technology. During the half day CKD campaign, health education materials (leaflet and short textbook and recording notebook) will be provided to the study participants. A nephrologist will facilitate the campaign and contents (Annex-3) of the text book and leaflet (Annex-4) will be discussed. Important message from the text book (such as stage, risk factor, preventive measures) will be used to develop the leaflet. In addition,Basic health education information about CKD is included in the contents to help patients gain knowledge, awareness, and improve their behaviors. Discussion on basic kidney diseases, risk factors, and preventive measures of CKD is performing by CHWs over a mobile phone call to the study patients. The patients have the liberty to discuss their health-related issues with the CHWs over a period of 10 minutes
45357279|NCT00831012|Biological|rDEN3delta30/31-7164|A live attenuated, recombinant DEN3 candidate vaccine virus
45357280|NCT01068145|Drug|SCH 527123|Very low dose SCH 527123, once daily for 7 days
45357281|NCT01068145|Drug|SCH 527123|Low dose SCH 527123, once daily for 7 days
45479028|NCT03339232|Other|Physical Activity|Supervised low impact aerobic physical activity for one hour each week.
45479029|NCT03812237|Other|(EWB) Early Weight Bearing (2 Weeks Post-op)|Patient were permitted to progressively weightbear on their heel at 2 week post-op.
45479030|NCT03339154|Other|Dietary Intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from chickpeas and 3 levels from chickpeas with rice.
45479031|NCT04875624|Diagnostic Test|Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4)|Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) will be administered by one of the 2 blinded examiners who are unaware of neonatal glycemia status. Bayley-4 examines Cognitive, Language, Motor, Social-Emotional and Adaptive Behavior domains of development and may require up to 120 minutes to complete.
45479032|NCT03812003|Drug|Remifentanil|remifentanil 1mcg/kg added in 0.9% saline and diluted to 50ml
45687160|NCT05675943|Biological|Anti-COVID-19 Antibody SA55 for Injection|After the subjects are successfully screened, according to the group they belong to, they will be given the corresponding drug by intramuscular injection once (the dose of SA55 injection for subjects 40kg and above in the test group is 600mg (4ml), and the dose of SA55 injection for subjects in the test group below 40kg is 300mg (2ml), the subjects in the placebo group who are 40kg and above are injected with 4ml of placebo, and those in the test group under 40kg are injected with 2ml of placebo.The injection is allowed in both deltoid muscle of the upper arm or the buttocks muscle.
46047210|NCT00960570|Drug|Efavirenz 600 mg|Efavirenz 600 mg administered as a single oral dose on the morning of Day 1.
45687161|NCT05674617|Behavioral|Written Exposure Therapy|WET will be conducted in accordance with the Written Exposure Therapy for PTSD: A Brief Treatment Approach for Mental Health Professionals Manual and the VA evidence-based practice (EBP) rollout training.
46047211|NCT00960570|Drug|Efavirenz 600 mg|Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
46047212|NCT00960570|Drug|Fenofibric Acid|Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
45357282|NCT01068145|Drug|SCH 527123|Medium dose SCH 527123, once daily for 7 days
45357283|NCT01068145|Drug|SCH 527123|High dose SCH 527123, once daily for 7 days
45357284|NCT01068145|Drug|Placebo|Placebo capsules to match SCH 527123, once daily for 7 days
45357285|NCT01068145|Drug|SCH 527123|Low dose capsule SCH 527123, once daily for 14 days
45357286|NCT01068145|Drug|SCH 527123|Medium dose capsule SCH 527123, once daily for 14 days
45357287|NCT01068145|Drug|SCH 527123|High dose capsule SCH 527123, once daily for 14 days
45357288|NCT01068145|Drug|Placebo|Placebo capsules to match SCH 527123, once daily for 14 days
46047213|NCT04463511|Other|Polyethylene bag before the umbilical cord is clamped|"11 x 16 (279mm x 406mm) sterile resealable PB (Resealable Polybag, Helapet Ltd, Bedfordshire, UK)"
46047214|NCT04204278|Device|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose in a 5-mL glass syringe.
45357289|NCT05059132|Behavioral|Tele-rehabilitation|The tele-rehabilitation intervention will include education, inspiratory muscle training, and behavioral support to promote walking.
45357290|NCT05059132|Other|Education only|The education only arm will receive information on the importance of general exercise following lung cancer treatment.
45687162|NCT05674617|Behavioral|PTSD Education|"The 5-session PTSD psychoeducation and skills protocol we will be utilizing for our PTSD education control condition was developed by PTSD clinical team (PCT) clinicians at the Washington DC VA Medical Center as a group protocol for Veterans admitted to the PCT and who were on the waitlist for individual therapy with an EBP for PTSD. The PTSD 101 protocol consists of psychoeducation on topics related to PTSD symptoms and an introduction to PTSD-related coping skills. Its duration and structure will be similar to WET (5 weekly individual 50-minute sessions). To parallel the time an attention given in individual WET sessions more closely, participants will quietly review any written materials or videos that are a part of the manualized curriculum for 30 minutes of the session, bookended by a 10-minute check-in with their provider on symptoms and introduction to new materials at the start of session and another 10-minute debrief of reviewed materials at the end of session."
45843822|NCT03681912|Behavioral|CoP development without internal facilitation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity
45843823|NCT03667170|Biological|KN035|subcutaneous injection
45357291|NCT05428475|Diagnostic Test|[18F]FDG-PET Scan|185 MBq of [18F]FDG will be administered IV 30 minutes prior to PET scan. Images will be acquired for 30 minutes. Resulting images will be evaluated for patterns of FDG-uptake to support the diagnosis of the participant symptoms of cognitive impairment.
45357292|NCT00824928|Procedure|Cryoablation / Cryotherapy|Salvage Cryoablation of the prostate
45357293|NCT01063231|Device|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
45357294|NCT02599103|Other|Fat-free milkshake|participants drinks a fat-free milk shakes
45357295|NCT02599103|Other|Olive oil|participants drinks the milk shakes prepared from 60g of olive oil
45357296|NCT02599103|Other|Soybean oil|participants drinks the milk shakes prepared from 60g of soybean oil
45357297|NCT02599103|Other|Fried soybean oil|participants drinks the milk shakes prepared from 60g of fried soybean oil
45357298|NCT02599103|Other|Palm oil|participants drinks the milk shakes prepared from 60g of palm oil
45357299|NCT02599103|Other|Fried palm oil|participants drinks the milk shakes prepared from 60g of fried palm oil
45357300|NCT02599103|Other|Camellia oil|participants drinks the milk shakes prepared from 60g of camellia oil
45357301|NCT02599103|Other|Fried camellia oil|participants drinks the milk shakes prepared from 60g of fried camellia oil
45357302|NCT02599103|Other|Tallow|participants drinks the milk shakes prepared from 60g of tallow
45357303|NCT02599103|Other|Fried tallow|participants drinks the milk shakes prepared from 60g of fried tallow
45357304|NCT04352140|Device|Tetragraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
45357305|NCT04352140|Device|ToFscan|ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured
45479033|NCT03332368|Other|Traditional Chinese medicine|Chinese medicine has a long history of prevention and treatment of breast cancer, the effect is obvious. Chinese medicine its mechanism of action is from the whole, adjust the body yin and yang, blood, viscera function balance, emphasizing the combination of governance and external treatment of the combination of thinking, according to different clinical syndromes, using syndrome differentiation.
45479034|NCT04874610|Drug|Methylprednisolone|Administration of methylprednisolone Prescribed per Standard of care
46047215|NCT04235829|Procedure|Laparoscopic sleeve gastrectomy|Form of obesity surgery
46047216|NCT04181229|Procedure|Deep brain stimulation|Patients will receive surgical implantation of the Medtronic DBS device (Device # 37601). Two (2) electrodes will be implanted bilaterally in the centromedian nucleus.
46047217|NCT00625430|Biological|Gene Directed Enzyme Prodrug Therapy, FP253/Fludarabine|"Subjects within a treatment group will be administered a single transrectal intraprostatic injection of FP253.~Group A: 1 x 10Exp9 virus particles (VP); Group B: 3.2 x 10Exp9 VP; Group C: 1 x 10Exp10 VP; Group D: 3.2 x 10Exp10 VP; Group E: 1 x 10Exp11 VP; Group F: 3.2 x 10Exp 11 VP.~If there are no dose-limiting toxicities, three additional patients may be treated at the highest dose.~Twenty four hours following administration of the FP253, subjects will receive a first dose of fludarabine phosphate (20mg/m2 administered as an intravenous bolus). The first dose of fludarabine phosphate will be followed by 4 further doses at 24 hour intervals on treatment Days 3 to 6."
45357306|NCT00831168|Behavioral|Effects of Active Dissemination|No medical intervention involved. It is purely information based.
45357307|NCT05049382|Procedure|Extraction of impacted mandibular third molar|surgical extraction of impacted mandibular third molar tooth
45357308|NCT02548494|Drug|Glargine|The control group will receive all traditional methods of treatment for DKA, including a placebo subcutaneous injection. The study group will receive the same treatment, but will be supplemented with a subcutaneous glargine injection.
45357309|NCT02548494|Drug|IV insulin|The intravenous infusion of insulin at a weight-based fixed rate until ketosis has subsided.
45479035|NCT03518125|Biological|BioThrax|"Other Names:~Anthrax Vaccine Adsorbed (AVA)"
45479036|NCT03518125|Biological|AV7909|Anthrax Vaccine Absorbed plus CPG 7909 Adjuvant
45357310|NCT02548494|Other|Electrolyte Correction|If the potassium level is greater than 6 mEq/L, do not administer potassium supplement. If the potassium level is 4.5-6 mEq/L, administer 10 mEq/h of potassium chloride. If the potassium level is 3-4.5 mEq/L, administer 20 mEq/h of potassium chloride.
45357311|NCT02548494|Other|Correction of Fluid Loss|"Initial correction of fluid loss is either by isotonic sodium chloride solution or by lactated Ringer solution. The recommended schedule for restoring fluids is as follows:~Administer 1-3 L during the first hour.~Administer 1 L during the second hour.~Administer 1 L during the following 2 hours~Administer 1 L every 4 hours, depending on the degree of dehydration and central venous pressure readings"
45357312|NCT05049148|Other|Platelet count in excised tumors|Tumors excised in patients requirering a brain or medullary surgery will be assess to determine their platelet count.
45357313|NCT02548416|Procedure|Positive end-expiratory pressure|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium.~As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure is set to 6 or 8 cm H20 (8 if BMI>25) in the intervention group.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
45357314|NCT02548416|Procedure|Control group, zero PEEP|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Zero PEEP is used.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
45357315|NCT00752219|Drug|ceftazidime/NXL104 + metronidazole|IV TID
45357316|NCT00752219|Drug|meropenem|IV TID
45357317|NCT00827268|Behavioral|One-on-one treatment of reading difficulties|Multimodal behavioral treatment focused on retraining sound to letter associations and skills in sounding out words when reading. Treatment has been pilot-tested in published papers since 1998.
45357318|NCT00825006|Device|Triple site pacing mode|"The experimental Triple site pacing mode includes pacing with Cardiac resynchronization therapy device using two leads; one in the right ventricle (RV) and one in the left ventricle (LV) but stimulates three sites: LV tip, RV tip and RV ring (instead of the usual two sites: LV tip and RV ring.~Patients with evidence of improved LV dyssinchrony parameters during the triple pacing mode (anodal stimulation) will be programmed to anodal stimulation for 3 months."
45357319|NCT02599805|Device|Natrox™ Oxygen Delivery System (ODS)|Natrox™ ODS will be applied to the subject's diabetic ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. The Natrox™ oxygen delivery system (ODS) is a device designed to overcome a number of problems associated with previous methods of oxygen therapy by delivering continuous oxygen to the ulcer bed through a dressing.
45357320|NCT04774354|Diagnostic Test|POSSUM|These scales will be calculated and compared to the outcomes obtained in our center.
45357321|NCT02598791|Other|IIGI+GIP|Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia
45687163|NCT05673330|Other|Spinal Mobilizations|"Headache SNAG: A posteroanterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s with the aim to reduce headache intensity at the time of application. (6)~Maitland's C1-C7 PA Glide: A posteroanterior (PA) mobilization of the first till seventh cervical vertebra is achieved by applying a force on to a vertebral segment in a posteroanterior direction (Back to front).~The patients will receive Spinal Mobilizations consisting of 1 set of 6 repetitions once daily thrice per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks"
46047218|NCT04282746|Drug|JNJ-54135419|Single dose of JNJ-54135419 oral solution will be administered sublingually.
45357322|NCT02598791|Other|IIGI+GLP-1|glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia
45357323|NCT02598791|Other|IIGI+NaCl (placebo)|i.v. NaCl during isoglycemia
45357324|NCT02598791|Other|OGTT|50 g oral glucose tolerance test
45357325|NCT02598791|Other|IIGI+GIP+GLP-1|i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia
45357326|NCT00827346|Drug|Clopidogrel|600 mg now
45357327|NCT00827346|Drug|Clopidogrel|600 mg now and 600 mg in 3 hours
46047219|NCT03786549|Other|pediatric-adult care transition program|"Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent~Three axes are :~Educative, family (patient and parent), at home~Psychological, with the patient individually~Medico-social orientation, group of patients"
46047220|NCT02882360|Device|Kerlix-AMD|Application of PHMB impregnated gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
46047221|NCT02882360|Other|placebo--normal gauze|Application of gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
46047222|NCT03773445|Diagnostic Test|Golimumab trough levels|Golimumab trough levels taken immediately before the administration of the next subcutaneous dose of golimumab
46047223|NCT03773445|Diagnostic Test|Antibodies to golimumab|Antibodies to golimumab taken immediately before the administration of the next subcutaneous dose of golimumab
46047224|NCT03773445|Diagnostic Test|Histology|Histology of colonic biopsies using the Geboes Index
46047225|NCT03773445|Diagnostic Test|Colonoscopy|Colonoscopy to evaluate the endoscopic activity by a Mayo endoscopic subscore
46047226|NCT00630084|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
46047227|NCT00630084|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
45357328|NCT00827346|Drug|Clopidogrel|900 mg now
45357329|NCT00827346|Drug|Clopidogrel|600 mg now and 300 mg in 3 hours
45479037|NCT03518125|Drug|Sodium chloride injection USP, 0.9% (placebo)|"Other Names:~Saline Solution"
45479038|NCT03812081|Device|Group A : Baska Mask Airway|Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment. The Baska Mask is available in four sizes: size three (30 to 50 kg), size four (50 to 70 kg), size five (70 to 100 kg),The membranous cuff of the Baska Mask appears bulkier than the equivalent inflatable cuff on cuffed laryngeal masks. The mask can easily be decreased in size during insertion by compressing the proximal, firmer part of the mask below the airway tube, between the thumb and two fingers
45479039|NCT03812081|Device|Group B: Proseal Laryngeal Mask Airway|Proseal LMA (size 3,4,5) was used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment.
45687164|NCT05673330|Other|Myofascial Release Technique|"Suboccipital Inhibition Technique: While the patient will be in the supine position, the physician sitting at the top end of the table will place the fingers of both hands on the patient's suboccipital region. Flexi-perpendicular long fingers exerting an inhibitory pressure on the muscle insertions of the neck extensors in the occiput, perpendicularly to muscle fibers, while the thumbs counterbalance the head against rotation. A deep and progressive pressure would be applied perpendicular to the fibers until a decrease in muscle tone would be detected. This deep and progressive pressure would be maintained for a total of 10 min until release of suboccipital tissues is achieved.~The patients will receive myofascial release with the frequency of 1 set and 10 repetitions once a day three times per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks."
45843824|NCT03485820|Behavioral|COMPASS|The data from the baseline assessment will be used to develop an environmental modification intervention plan. Environmental modifications will be installed before discharge if possible. Problem areas addressed are participant specific (tailored), but the process to identify and address the target area is systematic. All participants will receive identical intervention components. The standardized components include assessment, identification of problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
46047228|NCT03699501|Other|Questionnaires|"A validated oral health-related quality of life self-assessment questionnaire: the GOHAI~A validated oral health-related quality of life self-assessment questionnaire to be validated: SOHP~A validated depression scale: the Beck scale~A self-assessment questionnaire for oral health coping to be validated: the SCOOHP~A validated self-assessment questionnaire for coping: The Brief cope)"
46047229|NCT03699501|Procedure|Oral examination|"An evaluation of dental health using the CAO index~An evaluation of oral hygiene with the IHO-S index"
45357330|NCT02549274|Other|self-rehabilitation + physiotherapy|2 training sessions in self-rehabilitation at the hospital and then a self-rehabilitation / day session + 14 physiotherapy sessions (2 by week)
45357331|NCT02549274|Other|physiotherapy|14 physiotherapy sessions (2 by week)
45357332|NCT00997750|Drug|Lornoxicam|lornoxicam 8mg/day and 12mg/day for 15 days
45357333|NCT03998956|Procedure|CPVI|Circumferential PV isolation only
46047230|NCT03699501|Other|questionnaires (test-retest)|SCOOHP and SOHP questionnaires
46047231|NCT01126424|Drug|Solifenacin|tablet
46047232|NCT01126424|Drug|Oxybutynin|capsule
46047233|NCT01126424|Drug|Placebo|tablet
46047234|NCT04204902|Drug|Tepotinib 100 mg|Participants will receive a single oral dose of test treatment of tepotinib TF3 (5 * 100 mg) in either treatment period 1 or 2.
46047235|NCT04204902|Drug|Tepotinib 250 mg|Participants will receive a single oral dose of reference treatment of tepotinib TF3 (2 * 250 mg) in either treatment period 1 or 2.
45357334|NCT03998956|Procedure|CPVI+BOX|Circumferential PV and BOX isolation
45357335|NCT03998956|Procedure|CPVI+BOX+SUB|Atrial substrate ablation apart from circumferential PV and BOX isolation
45357336|NCT00622908|Drug|ISV-403|0.6% TID, 5 days
45357337|NCT00622908|Drug|Vehicle|Vehicle of ISV-403 TID, 5 days
45357338|NCT00997828|Device|everolimus-eluting stent|Xience V stent
45357339|NCT00997828|Procedure|coronary artery bypass graft surgery|coronary artery bypass graft surgery
45357340|NCT02548338|Procedure|argon plasma coagulation|On the first group we use the regular electric scalpel to perform the surgery , and on the second group we use the argon plasma coagulation scalpel to perform the procedure.
45357341|NCT00827424|Behavioral|Lifestyle counseling by applying a modified PACE protocol|Lifestyle counseling by applying a modified PACE protocol to obese Arab women
45357342|NCT04251052|Procedure|Bilateral Salpingectomy|Undergo bilateral salpingectomy
45357343|NCT04251052|Procedure|Bilateral Salpingectomy with Oophorectomy|Undergo bilateral salpingo-oophorectomy
45357344|NCT04251052|Procedure|Biospecimen Collection|Undergo blood sample collection
45357345|NCT04251052|Other|Quality-of-Life Assessment|Ancillary studies
45357346|NCT04251052|Other|Questionnaire Administration|Ancillary studies
45357347|NCT04251052|Procedure|Transvaginal Ultrasound|Undergo transvaginal ultrasound
45357348|NCT04095065|Behavioral|itMatters|Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing & treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse & sexual risk taking.
45357349|NCT04095065|Behavioral|itMatters and itMatters Sexual Violence Prevention|Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing & treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse & sexual risk taking. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increased knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
45479040|NCT02492230|Device|Left Atrial Appendage Closure Device (Watchman)|This device is a self-expanding nickel titanium (nitinol) frame structure with fixation barbs and a permeable polyester fabric cover. The device ranges in diameter from 21 mm to 33 mm to accommodate varying LAA anatomy and size. It will be implanted via a trans-septal approach by use of a catheter based delivery system to seal the ostium of the LAA. The implantation will be guided by fluoroscopy and TEE to verify proper positioning and stability. The dose of warfarin will be adjusted to maintain INR 2.0 - 3.0 for 45 days. If TEE data shows no additional flow in LAA, warfarin will be discontinued: Aspirin dose: 75 mg for all period of study; Clopidogrel dose: 75 mg for 6 months after procedure.
45479041|NCT02492230|Drug|Warfarin|"Warfarin dose adjusted to maintain INR 2.0-3.0 for all period of study; Aspirin dose-75mg for 45 days after randomization; Clopidogrel dose-75mg for 6 months after procedure.~All drugs will be started before PCI procedure. Low molecular weight heparins will be used before procedure and will be stopped when INR reach 1.8-2.0."
45357350|NCT04095065|Behavioral|itMatters Well-being and itMatters Sexual Violence Prevention|Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increase knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
45357351|NCT04095065|Behavioral|itMatters Well-being|Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines.
45357352|NCT00825084|Drug|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
45357353|NCT00825084|Drug|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
45357354|NCT00825084|Drug|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
45357355|NCT00825084|Drug|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
45357356|NCT02598635|Drug|Cholecalciferol|Patients on peritoneal dialysis and 25-(OH) levels <20 ng/mL will received one capsule of cholecalciferol (4800 U) once a day for 16 weeks.
45357357|NCT02598635|Drug|Placebo|An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks.
45479042|NCT03169530|Other|Alcohol|~15 gm daily of beer, wine, or spirits for ~6 years
45479043|NCT03339076|Device|"M3 MINI CATHETER"|"Participants in the study are using either a foley catheter or Clean Intermittent Catheter devices to facilitate bladder drainage. The study is an alternative method of facilitating bladder drainage with the M3 Mini Catheter."
45479044|NCT05623241|Diagnostic Test|Liquid Biopsy|Venous blood sampling for liquid biopsy in breast cancer patients after segmentation of the lesion on mammography
45479045|NCT02499094|Other|Behavioral-data driven support|Phone-based support (e.g. triaging of the situation, emotional support, and guidance on next steps for the patient) and in-app support (health education content based on cognitive behavioral therapies, mindfulness, and behavioral activation)
45479046|NCT03721783|Procedure|Cryoablation|Image guided cryoablation therapy of soft tissue lesions
45479047|NCT03819881|Biological|STMC-103H|Live bacterial product
46047236|NCT04284228|Biological|Infusion of NEXI-001 T Cells|"Procedure: A single IV infusion of NEXI-001 T Cells at Day 1 after Lymphodepletion(LD) Therapy.~At dose Level 1: 1.0 x 108 total viable T cells At dose Level 2: 2.0 x 108 total viable T cells~Procedure: Lymphodepletion: IV administration of fludarabine 30 mg/2 and cyclophosphamide 300 mg/m2 for 3 days.~lymphodepletion (LD) Therapy: Subjects will received bridging therapy agents during lymphodepletion for 3 consecutive days prior to receiving the NEXI-001 product~Drug: Fludarabine~Fludarabine infusion~Other Name: Fludarabine monophosphate~Drug: Cyclophosphamide~Cyclophosphamide infusion~Other Name: Cytoxan"
46047237|NCT02860806|Drug|JNJ-63623872|3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
46047238|NCT02860806|Drug|Placebo|Intravenous infusion of matching placebo.
45357358|NCT00831246|Other|chewing gum - Extra Winterfresh|Patients are given standard post-op care with clear liquid diet as tolerated plus chewing gum q8 for 30minute chewing intervals.
45479048|NCT03819881|Biological|Placebo|Inactive placebo substance
45479049|NCT02513238|Drug|Mesenchymal stem cell|Stemcells injected into submandibularis
45357359|NCT00831246|Other|Standard Post-Op Care|Patients are given standard post-op care with clear liquid diet as tolerated.
45357360|NCT04093271|Dietary Supplement|Rest-ZZZ|A dietary supplement containing melatonin, valerian root, chamomile, passion flower, GABA, hawthorn berry, and lemon balm
45479050|NCT02513238|Drug|Isotonic NaCl|
45357361|NCT04093271|Drug|Active Comparator - Diphenhydramine HCl|DIN 02229960 encapsulated for blinding purposes
45357362|NCT04093271|Other|Placebo|No active ingredients
45357363|NCT00831402|Dietary Supplement|Oligobs Maxiode|The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
45357364|NCT00831402|Dietary Supplement|controll group|50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
45357365|NCT00825240|Behavioral|One-time Questionnaire + Recorded Qualitative Interview|One-time questionnaire + recorded qualitative interview, approximately 45 minutes total.
45357366|NCT04090307|Behavioral|TLC Group Prenatal Care|TLC will start in the late first trimester or early second trimester and run for ~6-10 sessions. Groups of 2-10 consented women, with two or more GDM risk factors, will meet under the supervision of an obstetric provider (nurse practitioner or MD) and co-facilitator (health educator, nutritionist, or nurse) for two-hour sessions. A major focus of TLC will be education, and much of each visit will be spent on pregnancy, exercise/nutrition education, and behavioral health.
45357367|NCT04093115|Drug|CX1106|administration of CX1106 at 740 mg/m2 as a 24-hour continuous infusion for 5 days (120 h, d1-5), 21 days per cycle, no more than 6 cycles
45357368|NCT02548026|Behavioral|High Eating Frequency (High EF)|Free-living participants complete a 21-day high eating frequency (high EF) Phase in which they consume all daily energy at 8 eating occasions.
45357369|NCT02548026|Behavioral|Low Eating Frequency (Low EF)|Free-living participants complete a 21-day low eating frequency (low EF) Phase in which they consume all daily energy at 3 eating occasions.
45357370|NCT04092959|Behavioral|Walking|Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β- blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
45357371|NCT04092959|Behavioral|Chinese square dancing group|Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study. Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13.
45357372|NCT04092959|Behavioral|Control group|Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
45357373|NCT00827580|Drug|Eniluracil|
45357374|NCT00827658|Procedure|Volar Wrist Block|"Injection medial to Flexor Carpi Ulnaris Tendon at volar proximal wrist crease~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)"
45357375|NCT00827658|Procedure|Hypothenar Palm block|"Injection at Hook of the Hamate on Palmar surface~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)"
45357376|NCT04094909|Drug|Rh-endostatin|"Squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +[nab]-paclitaxel during the treatment. Rh-endostatin+Pembrolizumab during the maintenance period.~Non-squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +pemetrexed during the treatment. Rh-endostatin+Pembrolizumab + pemetrexed during the maintenance period."
45357377|NCT05424731|Combination Product|DBV712 250 mcg|Daily epicutaneous delivery.
45357378|NCT02599571|Other|Very low nicotine content cigarettes|Cigarettes containing a reduced amount of nicotine
45357379|NCT02599571|Other|Conventional nicotine content cigarettes|Cigarettes containing a normal amount of nicotine
45357380|NCT00296491|Drug|fluticasone propionate/salmeterol (FSC)|fluticasone propionate/salmeterol DISKUS combination
45357381|NCT00296491|Drug|montelukast (MON)|montelukast capsule
45357382|NCT00296491|Drug|fluticasone propionate (FP)|fluticasone propionate aqueous nasal spray
45357383|NCT00296491|Drug|placebo nasal|vehicle placebo nasal spray
45479051|NCT03338842|Device|Distractor and Lower limb VR|In the first phase (A), subjects will receive the Distraction VR treatment during 5, 6, or 7 one-hour-long sessions occurring twice weekly. After the A phase, the remaining sessions (B phase) will consist of Lower-Limb VR treatment. This number includes a mean of 6 (range 5-7) phase A sessions and mean of 11 (range 10-12) phase B sessions.
45357384|NCT00296491|Drug|ADVAIR DISKUS|ADVAIR DISKUS
45357385|NCT00296491|Drug|placebo capsule|placebo capsule
45357386|NCT00296491|Drug|placebo DISKUS|placebo DISKUS
45357387|NCT00747617|Drug|recombinant human chorionic gonadotropin|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of human chorionic gonadotropin administered intravenously on 5 separate occasions.
45357388|NCT02599493|Drug|Rifampicin|Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group or high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
45357389|NCT02599415|Device|TL01 light treatment|Patients received treatment in TL01 cabinet three sessions weekly according to a standard escalating protocol based on minimal erythema dose. Standard dose ranges between 0.55 and 3.13J/cm2.
45357390|NCT04092725|Drug|DAB|Single oral 150-mg dose of DAB on Day 1 AM.
45357391|NCT04092725|Drug|SCY-078 plus DAB|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078.
45357392|NCT00296335|Drug|Mitomycin, doxifluridine and cisplatin|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
45479052|NCT03723187|Other|normal saline|experimental group use normal saline sealing tube
45479053|NCT03723187|Other|normal saline+heparin|normal saline+heparin(Currently, Regular used in hospital)
45357393|NCT00296335|Drug|Mitomycin and doxifluridine|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
45357394|NCT04094597|Drug|Lactoferrin|lactoferrin is given orally in comparsion to placebp
45479054|NCT05659511|Diagnostic Test|MRI|MRI data was acquired with a GE discovery MR750 3.0 T scanner using an eight-channel phased- array head coil. Foam padding was used to restrict head movement and ear plugs were used to eliminate scanner noise. During the acquisition period, all participants were asked to keep their eyes closed and not to think anything.
45479055|NCT02440230|Drug|OFS + Anastrozole|"Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.~Patients will take anastrozole 1mg qd."
45479056|NCT02440230|Drug|OFS + Exemestane|Patients will take exemestane 25mg qd. Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.
45479057|NCT02499250|Device|remote ischemic conditioning (TDFT-12-A2)|"The subjects will receive twice daily of 4×5min/5min ischemic/reperfusion of both arms (remote ischemic conditioning) over 30 days using the TDFT-12-A2 device produced by Shenzhen TDF Tai Smart technology Co., Ltd."
45843825|NCT03485820|Behavioral|Stroke education|The control group will experience the same effects of time and attention in the home but no effect on the outcome of interest.
45357395|NCT04094597|Drug|Placebos|placebp is given in 2 ml saline
45357396|NCT04093037|Diagnostic Test|Time #1: Non Invasive Break-Up Time (NIBUT)|"A LacryDiag examination without dye will be realized. All measurements are made without contact. It's calculates the Non Invasive Break-Up Time (NIBUT), Tear Meniscus (TM) height (in millimeters) and number of Meibomian Gland.~These are different pictures taken with LacryDiag and analyzed."
45479058|NCT02499250|Drug|Optimal medical treatment|The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.
45479059|NCT05623163|Device|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (up to 5 sutures) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
45479060|NCT03036462|Drug|Iron|i.v. iron administration
45479061|NCT03036462|Drug|Saline|i.v. NaCl administration
45479062|NCT03332290|Behavioral|sport practice|the intervention was a training course lasting 10 days. It included 10 days of sports practice. For divers, diving was carried out using air at a maximum depth of 40-meters, with a maximum of one dives a day. For the multisport group (the non-divers), the course included kayaking, mountain climbing or hiking with a maximum of two activities a day.
45479063|NCT01300325|Other|3% hypertonic saline solution|Patients receive every 6 hours the nebulized 0.9% saline (Placebo comparator) (group I) or the 3% hypertonic saline solution group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
45843826|NCT03484182|Behavioral|Web-based Home Exercise Program|Home exercises that are guided by a web-based program
45843827|NCT03484182|Behavioral|Standard Home Exercise Program|Standard paper-based home exercise program
45843828|NCT03404076|Diagnostic Test|Dual Energy CT|Dual Energy CT is performed for diagnostic evaluation in gastrointestinal stromal tumor (GIST) patients undergoing tyrosine kinase inhibitor (TKI) treatment
45843829|NCT03245580|Diagnostic Test|Core Liver Biopsy|Diagnostic EUS examination followed by liver biopsy to obtain core sample in benign liver disease.
45357397|NCT04093037|Diagnostic Test|Time #2: MicroInstillation Break-Up Time (MIBUT) + Oxford score|"The MicroInstillation of fluorescein Break-Up Time (MIBUT) will be calculated by manual MIBUT and LacryDiag MIBUT.~The Oxford score will be calculated. It's used to clinically determine the severity of dry eyes with minimum score at 0 (none) and maximum score at 5 (very severity)."
45479064|NCT03332134|Behavioral|Intimate Partner Violence (IPV) Prevention Intervention|The IPV intervention consists of six sessions. Each session will cover one of 6 major modules to enhance transformation of motivation: 1) You, Me, and Us: Spending Meaningful Time Together, 2) I'm a Champion: I Can't Be Broken and I don't Accept Defeat! 3) Building Communication and conflict management strategies, and 4) Empowerment of the Couple: Planning Ahead, 5) Sexual communication and the sexual relationships, and 6) A Lens into Domestic Violence. The sessions will be audio-recorded and include a combination of didactics, interactive discussions, media use, and role play. The expected durations of session 1, 2-6, and the 3-month follow-up are 120 minutes, and 60-90 minutes, respectively.
45687165|NCT05671406|Behavioral|Sensor-controlled digital game|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid hospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal Hypertension health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
45357398|NCT04093037|Diagnostic Test|Time #3: Standard Break-Up Time (SBUT)|The Standard Break-Up Time (SBUT) with fluorescein macroinstillation will be calculated by manual SBUT and LacryDiag SBUT.
45357399|NCT04093037|Diagnostic Test|Time #4: Schirmer test|The Schirmer test will be performed. It consists of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes.
45357400|NCT04093037|Diagnostic Test|Satisfaction questionnaire to the patient|A satisfaction questionnaire to the patient will be completed at the end of the participation at the study.
45357401|NCT01065961|Drug|Decadron|Decadron will be given at a dose of 0.2 mg/kg intraoperatively, followed by Decadron 4 mg. every 6 hours for 24 hours.
45357402|NCT01065961|Drug|Saline|Placebo saline will be given intraoperatively as well as 4 doses every 6 hours for 24 hours.
45357403|NCT04092881|Device|Laser|Application of four laser sessions one month apart using short pulsed mode of 1064 nm Nd-YAG laser (Fotona XP® - Accelera mode) using parameters (fluence 20-40 J/Cm2, pulse duration= 0.25 ms and spot size 3-5 mm) for one side.
45357404|NCT04092881|Device|Laser|Application of four laser sessions one month apart (in the same day after Nd-YAG session) using 10600 nm ablative fractional CO2 laser (Deka SmartXide DOT®) using -parameters (fluence 17-20 J/Cm2, pulse duration 700-1000 µs, spacing 600-700 µm and stacking 1-2) on the other. Sessions are separated by one month interval plus three months for clinical follow up.
45357405|NCT01068223|Drug|A:JNJ-39758979/Placebo #1|Single oral dose of JNJ-39758979 600 mg and Placebo
45357406|NCT01068223|Drug|C:Cetirizine/JNJ-39758979 Matching Placebo|JNJ-39758979 Matching Placebo and Placebo #2
45357407|NCT01068223|Drug|B: JNJ-39758979 Matching Placebo /Placebo #2|A single dose of 2 different Placebos
45357408|NCT04234360|Drug|5 days of systemic corticotherapy (prednisone)|Patients randomized to this arm will receive 40 mg prednisone per os per day for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
45357409|NCT04234360|Drug|5 days of placebo|Patients randomized to this arm will receive an appropriate placebo per os for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
45687166|NCT05671406|Behavioral|Sensor only|Real-time behaviors of physical activity will be tracked by an off-the-shelf sensor and app (Withings). This group will also be provided with standardized evidence-based Hypertension educational material. However, the data from the Withings sensor will not be routed to the SCDG.
45843830|NCT03162510|Drug|Oxaliplatin|Oxaliplatin 60 - 85 mg/m2 IVD 2hr at D1, every 14 days as a cycle till disease progression
45843831|NCT03162510|Drug|Albumin-Bound Paclitaxel /nab-Paclitaxel|150 mg/m2 IVD 30 min bi-weekly.
45843832|NCT03162510|Drug|S-1|Tegafur,oral S-1 35mg/m2 twice daily from D1 to D7, every 14 days as a cycle till disease progression.
46047239|NCT01126268|Drug|Retapamulin (Altabax)|Retapamulin ointment, applied topically twice daily for five days
46047240|NCT04372251|Procedure|Sinus tarsi approach (STA)|Osteosynthesis
46047241|NCT04372251|Procedure|Percutaneous Arthroscopically Assisted Osteosynthesis (PACO)|Osteosynthesis
46047242|NCT00630318|Device|MRI|15-20 minutes MR imaging
46047243|NCT04284150|Drug|Dexmedetomidine; Midazolam;|Treatment of supraventricular tachycardia in patients with non-cardiac surgery by dexmedetomidine during the perioperative period
45357410|NCT03976609|Procedure|Maxillary Expansion|The patients with maxillary transverse deficiency were treated with Haas expander is a tooth and tissue-borne appliance with a jackscrew located at the anterior region of the arch with its arms bent posteriorly and soldered to the first permanent molar bands. Once activated, the appliances opens the palatal suture and increase the transverse dimension of the maxilla.
45357411|NCT02600273|Other|Usual brand cigarettes|Usual brand cigarettes
45357412|NCT02600273|Other|Lower nicotine content cigarettes|SPECTRUM research cigarettes
45357413|NCT02600273|Other|Electronic cigarettes 1|Electronic cigarette with 0 g/mL e-liquid
45357414|NCT02600273|Other|Electronic cigarettes 2|Electronic cigarette with 18 g/mL e-liquid
45687167|NCT05669365|Behavioral|Care Ecosystem|"Applying the principles of person-and-family centered and collaborative care to dementia, the Care Ecosystem (CE) offers proactive, protocol-guided phone- and web-based caregiver support, guidance, and care coordination that extends the reach of dementia primary and specialty care. Care is delivered primarily via the phone and web by unlicensed Care Team Navigators (CTNs), who are trained and supervised by a team of dementia specialists with nursing, social work, and pharmacy expertise. Care Protocols guide proactive, quality care that is documented in the electronic health record (EHR).~The CTN is an unlicensed, trained dementia care guide who served as the PWD's and caregiver's primary point of contact to the program under nurse supervision. Care team navigators respond to caregivers' immediate needs first, then screen for common problems and provide personalized support and standardized education using the care plan protocols."
45357415|NCT01069393|Other|DAFNE course (Timing of delivery of education)|Education delivered over one day a week for 5 consecutive weeks, as opposed to 5 consecutive days over 1 week.
45357416|NCT00747461|Device|CryoSpray Ablation|Cryospray Ablation up to 4 -5 second cycles for up to 4 treatments in the first 30 days
45357417|NCT04187872|Combination Product|LITT + Pembrolizumab|Each patient will undergo brain biopsy and laser interstitial thermotherapy (LITT). As soon as possible, no later than two weeks after LITT, pembrolizumab will be administered via infusion and continue q3wks for up to two years.
45357418|NCT01063387|Radiation|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive+ Para-aortic lymph node metastasis Experimental : Radiation: Extended-field Irradiation (EFI) Prophylactic irradiation of supraclavicular lymph node
45357419|NCT01063387|Radiation|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive +Common iliac lymph nodes metastasis Experimental :Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation)
45357420|NCT01068301|Drug|Plerixafor|Plerixafor in combination with fludarabine, thiotepa and melphalan as a conditioning regimen for patients undergoing a second allogeneic transplant procedure (bone marrow or peripheral blood). A traditional 3+3 phase I design will be employed during this study, where dose escalations are planned in groups of 3 participants. No intra-participant escalation will be allowed and dose escalation will not be considered until toxicity information is available from at least 3 evaluable participants at the current dose level.Plerixafor will be given intravenously (IV) rather than subcutaneously (SQ) to minimize discomfort associated with repeated daily injections (up to 3) to the pediatric population of this study.
45357421|NCT04999228|Drug|Infliximab|Infliximab will be administered intravenously at a dose of 5 mg/kg for 0, 2, and 6 weeks, then every 8 weeks for 1 year.
45357422|NCT04999228|Drug|Corticosteroids|Corticosteroid will be given at a dose of 1-2mg/kg/day (maximum 60 mg/kg/day),oral or intravenously for 12 to 14 weeks.
45357423|NCT04092491|Other|blood sample|"1 blood sample during a consultation carried out as part of a medical follow-up:~2 PAXgene RNA tubes of 2 ml each~1 dry tube for creatinine and IgA assay~1 tube of NFs (5ml)"
45357424|NCT01068379|Procedure|criopexy|he cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
45357425|NCT01068379|Procedure|laser|Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
45357426|NCT04866550|Other|Data collection|Daily record of temperature, weight, heart rate, systolic blood pressure and oxygen saturation
45357427|NCT04092569|Behavioral|Pre-medical consultation structured diabetes self-care education programme|"The findings of integrative review revealed positive effects of DSME in improving glycemic control and promoting self-care among people with type 2 diabetes.~An evidence-based protocol is developed based on these findings to generate a DSME program for newly referred patients to SOPCs and before their first medical consultation to improve glycemic control and enhance self-care of people with type 2 diabetes in Hong Kong. The investigator will ensure that this study is conducted in compliance with ICH-GCP and in compliance with the Declaration of Helsinki."
45479065|NCT03819725|Device|Glucose monitoring|FreeStyle® Libre Pro Interstitial Glucose Meter will be applied after skin preparation with anesthetic cream (Emla®) . Interstitial glucose measurements will be recorded during 2-5 days and during meals.
45479066|NCT03478891|Biological|VRC-EBOMAB092-00-AB (MAb114)|VRC-EBOMAB092-00-AB (MAb114) is a human immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire ebolavirus (EBOV) glycoprotein (GP).
45357428|NCT01063465|Device|Early weightbearing|Patients in the intervention group are after 2 weeks supposed to remove the cast twice a day and use a special training pedal for 5 weeks (until cast removal).
45357429|NCT03873766|Drug|Intrapleural Medications|The IPFT group will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg twice daily x 3 days. delivered through a chest tube or small bore catheter into the pleural space. The doses will be given twice a day. If the first IPFT dose is given in the evening on the first day, they will only receive a total of 5 doses of the dual-agent IPFT (alteplase and DNase).
45479067|NCT01585103|Device|Cytosponge|An ingestible gelatin capsule containing a compressed mesh attached to a string. The capsule is swallowed and once in the stomach, the gelatin dissolves and a spherical mesh of 3 cm diameter is released. The mesh is withdrawn through the mouth by the attached string and a cytologic specimen is collected.
45357430|NCT03873766|Procedure|Surgery|The surgical arm will have either open surgery or a Video assisted Thoracoscopic Surgery (VATS) approach at the discretion of the surgeon
45357431|NCT03873766|Procedure|Pleural Sampling|Pleural fluid may be sampled by the responsible clinical service in the course of clinical care for patients with suspected pulmonary infection or by consulting service after identification of patient. Some patients will have a thoracentesis or tube drainage, and others will have no intervention at the time of referral for study eligibility review. Enrollment reflects real world clinical care and patients will be considered for enrollment regardless of sampling techniques or timing prior to evaluation
45357432|NCT03873766|Procedure|Pleural fluid drainage|All patients in the study must have tube thoracostomy for drainage of the pleural space. This may have been done by the clinically responsible team or by the study team. Physicians may select chest tubes of any type, but the minimum size is 14 French. For patency, chest tubes 14-20 French should be kept at negative 20 suction and flushed daily. Large bore chest tubes (>20French) may be kept at negative 20 suction at the discretion of the physician managing the chest tube and do not require daily flushing. Supportive care will follow Institutional Guidelines.
45479068|NCT03168906|Drug|NEOD001|NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
45479069|NCT03168906|Drug|Placebo|Saline bag
45479070|NCT05281133|Other|The group using virtual reality glasses|The video chosen by the children in the experimental group was started 1-2 minutes before the splint with virtual reality glasses and watched for an average of 7 minutes.
45479071|NCT03811925|Procedure|Angioplasty and drug coated balloon of the superficial femoral artery (SFA)|In case of drug coated balloon (DCB) there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA)
45479072|NCT03811925|Procedure|Angioplasty and stenting of the superficial femoral artery (SFA)|In case of stent application there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). In case of stenting there should be a strong effect on vasomotion of the treated vessel area. All Stent lengths (40mm to 200 mm) and Diameters (5mm to 7mm) are eligible for the trial as long as used in the superficial femoral artery (SFA)
45479073|NCT00706966|Drug|dutasteride|6 months of dutasteride 3.5 mg daily
45479074|NCT03478657|Drug|Placebo DPI|Subjects will receive placebo via oral inhalation route using ELLIPTA once daily. Placebo DPI will be available in two strips of 30 blisters per strip. First strip will contain lactose monohydrate and second strip will have lactose monohydrate blended with magnesium stearate.
45479075|NCT03478657|Device|ELLIPTA DPI|Subjects will receive placebo DPI via ELLIPTA. ELLIPTA is trademark of GSK
45479076|NCT03478657|Other|Ease of use questionnaires|Subjects from both stratum after use of ELLIPTA DPI will be randomized to receive either version A or B of the questionnaires. Subjects will be asked questions on ease of use of ELLIPTA. Parent/guardian will also complete a questionnaire about the ELLIPTA DPI.
45479077|NCT01330524|Drug|Avastin and Triamcinolone|1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal
45479078|NCT01330524|Other|placebo|2mg placebo
46047244|NCT02883842|Behavioral|Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week. Prior to study commencement, a bank of 270 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
45479079|NCT01560065|Dietary Supplement|myo-inositol + folic acid|4000mg myo-inositol + 400 µg folic acid
45479080|NCT01560065|Dietary Supplement|myo-inositol + folic acid|4000mg myo-inositol + 400 µg folic acid
45843833|NCT03162510|Drug|LV|LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
45357433|NCT03873766|Radiation|Protocol Image #1|"Once the chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage. The choice of image, either Chest X-ray or CT Chest, is up to the discretion of the treating physician. Based on the imaging, patients will be separated into 2 groups:~A: Complete drainage/re-expansion of the lung: If there is complete drainage of the pleural fluid collection and lung re-expansion based on image #1, patients will follow usual clinical care without randomization and be observed until discharge. Patients will remain in the study and their data will be collected.~B: Incomplete drainage/incomplete lung re-expansion: For those patients that have incomplete drainage of the pleural fluid collection on image #1 and/or the lung does not re-expand."
45357434|NCT03873766|Other|Surgical Consultation|A thoracic surgery consultation will be obtained on all patients with incomplete drainage and/or the lung does not re-expand, to determine surgical candidacy. Those patients that the surgical team deem unsafe for surgery will receive clinically appropriate guideline centered, non-surgical, care. These patients will not be randomized but they will remain in the study and their data will be collected. Criteria deeming patients unfit for surgery include, but are not limited to: inability to tolerate single lung ventilation, severe chronic obstructive pulmonary disease (COPD), and risk of surgery prohibitive. Patients not excluded from surgery will be randomized.
45357435|NCT03873766|Radiation|Protocol Image #2: Chest X-ray PA/Lateral|The morning after intervention completion (surgery or last dose of IPFT), a chest X-ray PA/lateral will be obtained (protocol image #2). Based on Image #2 the patient will be categorized into one of three groups: satisfactory improvement of pleural fluid collection, unsatisfactory improvement in pleural fluid collection on imaging, or treatment failures.
45357436|NCT03873766|Behavioral|Quality of Life|Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires
45357437|NCT02598479|Other|IPTLD and nutrition therapy|The measurement of Quality of Life in patients who choose to use Insulin Potentiation Low Dose Therapy and Nutritional Therapy in the treatment of cancer
45357438|NCT01069471|Biological|Shigella vaccine|Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.
45357439|NCT04094129|Dietary Supplement|Wismemo|Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-89, Lactobacillus paracasei GMNL-133 and Lactobacillus plantarum GMNL-141.
45357440|NCT04094129|Dietary Supplement|Placebo|placebo
45357441|NCT03683758|Other|FIFA11+|"The FIFA11+ has three parts and consist of 15 exercises.~Part 1 consists of active stretching, running and controlled partner contact drills.~Part 2 has three difficulty levels for 6 sets of exercises. The exercises consist of core and leg strength exercises, balance and plyometric drills. The exercises in this section are perhaps the most unique element to the FIFA11+ warm-up, as strength-specific exercises like the Nordic Hamstring Curl are not generally included in soccer warm-ups.~Part 3 consists of higher intensity running drills, compared to those covered in Part 1.~Unlike many soccer warm-ups, the FIFA11+ has been studied rigorously in terms of its injury reduction potential."
46047245|NCT04282512|Other|Sodium bicarbonate-rich mineral water|St-Yorre, a sodium bicarbonate-rich mineral water, is a commercial mineral water that contains 4368 mg/l sodium bicarbonate. The study intends to evaluate the effect on blood pressure of the sodium bicarbonate intake due to this mineral water consumption.
45687169|NCT05666193|Device|CBCT Imaging|Subjects are scheduled for two imaging sessions on the Ethos system with the HyperSight CBCT. One session is on the same day as the CT simulation scan for treatment planning. The second session is on the same day as the delivery of ther 21st treatment fraction. If the subject is sent for a mid-treatment FBCT for re-planning, a third HyperSight CBCT imaging session will be scheduled on the same day as the mid-treatment FBCT.
45687170|NCT05662800|Diagnostic Test|Assessment of peanut, tree nuts and sesame allergy|"Children will undergo skin prick testing with the following allergens: commercial extracts for peanut, hazelnut, almond, cashew, pistachio, walnut, macadamia, sesame, Timothy grass, and birch pollen; positive and negative control; peanut butter and tahini (sesame) paste.~Specific IgE levels will be quantified to all the above-listed tree nuts, peanuts, sesame seed and peanut components (Ara h 1, Ara h 2, Ara h 3, Ara h 6, Ara h 8, Ara h 9).~Children will undertake cumulative or incremental oral food challenge with peanut, sesame and tree nuts, depending on the risk assessment based on patient's medical history and results of diagnostic tests."
45687171|NCT05661734|Drug|VX-548|Tablets for oral administration.
46047246|NCT02883608|Procedure|cap assisted forward-viewing endoscope|a cap fitted to the to top of the forward-viewing endoscope
46047247|NCT02860026|Other|Marketed cow's milk-based infant formula|
46047248|NCT02860026|Other|Cow's milk-based infant formula with added nutrients|
46047249|NCT05115812|Procedure|Pre-Operative Information|Demographics (e.g., age, gender), patient characteristics (e.g., BMI, American Society of Anesthesiologists class), and pre-operative medical history (e.g., tobacco use; comorbidities: hypertension, cardiopulmonary disease, diabetes; indication for RAT; lesions; previous renal revascularization; serum creatinine level).
46047250|NCT05115812|Procedure|Intra-Operative Data|Operative time, total OR time, concomitant procedures, transfusions, conversions, intraoperative adverse events, autotransplantation technique
45357442|NCT03683758|Other|'Usual' Soccer Warm-up|"This warm-up is time-matched to the FIFA11+ (approximately 20 minutes) and is considered 'usual' for the team.~This warm-up consists of stretching, running and agility drills, in addition to small sided games with a soccer ball, which is not a part of the FIFA11+.~The 'usual' warm-up is decided by the coach with no standardization nor any formal research on its effectiveness in injury reduction or performance enhancement."
45479081|NCT05045430|Device|Silver II Non-Woven Dressing|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with Silver II Non-Woven dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over six-week period (per Advanced Medical Solution Product) or until the wound is healed to extent that the use of Silver II Non-Woven dressing is no longer indicated from the time that the patient has been recruited.~The assessment of the presence and reduction of the signs and symptoms of Infection."
45479082|NCT03331900|Drug|COR388|Administered as oral capsule
45479083|NCT03331900|Drug|Placebo|Administered as oral capsule
45479084|NCT05664997|Behavioral|playing assessment|Investigators used Edinburgh Handedness Inventory, the Wong-Baker Faces Pain Rating Scale, the Disability of Arm, Shoulder and Hand - Sports/Musicians (DASH-SM), the Rapid Upper Limb Assessment, and the 11-item revised version of the Occupational Balance Questionnaire (OBQ11 - T). All have their Turkish validity studies. A correlation analysis was performed to examine the relationship between the variables.
45479085|NCT03121066|Device|Active Transcranial Magnetic Stimulation|The intervention consists of a 2-week treatment during which TMS will be applied for 10 days (every working day). The stimulation protocol will be intermittent TBS (iTBS). 600 pulses in each area will be applied at intervals of 2 seconds of stimulation and 8 seconds of rest; the total number of pulses per session will be 1200. The stimulation duration is 3 minutes and 12 seconds. This protocol allows the induction of long-term potentiation effects, promoting plasticity in the stimulated areas. To perform the stimulation a 70 mm, figure of 8-coil will be used. In order to precisely locate the stimulated areas a stereotactic image guidance will be used during the stimulation (Brainsight™ 2)
45479086|NCT03121066|Device|Sham Transcranial Magnetic Stimulation|The Sham intervention will be carried out using the same stimulation protocol as in the active condition but with the coil rotated 90º to prevent the magnetic field inducing electrical activity in the cortex.
45479087|NCT02369016|Drug|Copanlisib (BAY 80-6946)|60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle
45479088|NCT01302587|Drug|Albuterol|Albuterol MDI with integrated dose counter. Each participant will use 2 oral inhalations of 90 micrograms each of albuterol twice a day for the length of the study.
45479089|NCT03723109|Procedure|Induction of anesthesia|Standardized TCI and RSI anesthesia induction
45479090|NCT03338608|Procedure|Anterior Cervical Decompression and Fusion|Patients will receive the anterior cervical decompression and fusion as part of their standard of care. They will be randomized to either receive the vertical or transverse platysma incision.
45479091|NCT03338608|Procedure|Vertical Platysma Incision|A vertical platysma Incision will be used for the anterior cervical decompression and fusion surgical procedure
45479092|NCT03338608|Procedure|Transverse Platysma Incision|A transverse platysma incision will be used for the anterior cervical decompression and fusion surgical procedure
45479093|NCT03018288|Drug|Pembrolizumab|Pembrolizumab at 200mg will be administered on day 1 as a 30 minute IV infusion (prior to RT) every 3 weeks during RT on days 1, 22 and 43. At one year, if patients are doing well they may continue pembolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
45687172|NCT05657769|Device|Medwell Preventive Care Application|Regular diabetes treatment with additional Medwell application and wearable device.
45687173|NCT05657769|Device|Manual Records|Regular diabetes treatment only with a diary card to record daily activities manually.
45357443|NCT03976921|Diagnostic Test|Integration of CCTA with stress CTP when indicated|When judged indicated, functional assessment with stress CTP perfusion will be performed on top of CCTA.
45357444|NCT03976921|Diagnostic Test|Standard of care approach|(a) functional non-invasive tests (stress ECG, or imaging-based tests such as Stress Echo, Stress CMR, SPECT or PET) as a gatekeeper for ICA; (b) direct referral to ICA.
45479094|NCT03018288|Biological|HSPPC-96|One week post RT, patients will receive weekly x 4 a dose of HSPPC-96 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of TMZ. HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Patients who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if patients are doing well they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
45687174|NCT05656924|Device|digital prosthetic interface technology|Individuals randomized to this group will receive a socket and liner that are manufactured using a novel technique meant to achieve a better distribution of pressure on the residuum. The study is based on the hypothesis that an improvement in pressure distribution on the residuum will enable high adherence to an exercise program meant to improve health status in dysvascular amputees.
45843834|NCT03049644|Procedure|Mechanical Diagnosis and Therapy|Identification of directional preference.
45843835|NCT03049644|Procedure|Manual Therapy|Mechanically based treatment based on taking joint to end range and thrusting or soft tissue manipulation.
45357445|NCT04092023|Other|nursing education|Participants will be recruited to attend 2 group sessions; each group will have 10-12 participants and each session will be lasted for 120 minutes. Two subsequent phones follow up to participants will be arranged.
45357446|NCT04767958|Diagnostic Test|Spartan COVID-19 Platform|Nasal-pharyngeal swab for testing on the Spartan Covid-19 platform
45357447|NCT02599259|Device|Monitored (M+)|Patients assigned to the intervention arm will use the AiCure Platform to monitor ingestion of all prescribed doses of oral anticoagulants. If a patient misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by the Study Coordinator or AiCure study team.
45357448|NCT02600039|Other|ELTGOL|Individuals will be placed in the lateral decubitus position and instructed to perform slow expirations with an open glottis through a nozzle attached to the mouth from the residual functional capacity to residual volume. Concurrently, a trained and subsequently positioned relative to the voluntary physical therapist will perform a manual compression of the abdominal region dependent and the rib cage to enhance contralateral lung deflation. This intervention is performed so that the time is homogeneous between each repetition interval of one minute between each set. To this end, three sets of ten repetitions will be performed on each lateral decubitus (left and right)
45479095|NCT03018288|Drug|Temozolomide|TMZ will be administered on day 1 of radiation therapy (before RT treatment) and continue throughout RT at the dose of 75 mg/m2. Post RT: The starting TMZ dose will be 150 mg/m2/day for cycle 1, days 1-5, with a single dose escalation to 200 mg/m2/day (days 29-33) and for all subsequent treatment if no treatment-related adverse events greater than Grade 2 are noted. TMZ will be given for 6 cycles.
45479096|NCT03018288|Other|Placebo|One week post RT, patients will receive weekly x 4 a dose of HSPPC-96 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of TMZ. HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Patients who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if patients are doing well they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
45479097|NCT03811613|Other|Transcranial photobiomodulation|Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength (which has proven to penetrate the skull)
45357449|NCT02600039|Device|Acapella|Participant should be comfortably seated and with his elbows on a table. The mouthpiece is attached properly to not allow leaks. The resistance load will be one in which the individual is able to maintain uninterrupted expiration of 3 seconds. Then the patient will be instructed to inhale slowly and deeply, with lung volumes between the residual volume and total lung capacity. The air exhaled by Acapella is directed toward an orifice which opens and closes periodically, promoting oscillations in the air stream throughout the expiratory phase. The expiration is always performed to the VR, and without performing the active contraction of the abdominal muscles. Still prompted an inspiratory pause of 2 seconds for the end of the inspiratory phase. This procedure will be performed in 4 sets of 5 minutes with interval of 1 minute between the series.
45357450|NCT01564810|Drug|Cetuximab|On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of cetuximab (initial dose 400 mg/m2 in week 1, and 250 mg/m2 weekly during 1 hour thereafter) followed after 1 hour by chemotherapy of FOLFOX or FOLFIRI until progressive disease or unacceptable toxicity.
45357451|NCT01564810|Drug|chemotherapy of mFOLFOX6 or FOLFIRI|FOLFOX-4 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV200mg/m2ondays 1and 2 infused during 2 hours, together with or following oxaliplatin; followed by FU 400 mg/m2 intravenous bolus then 600 mg/m2 intravenous infusion over 22 hours on days 1 and 2) FOLFIRI(irinotecan 180mg/m2 on day 1 infused during 2 hours; fluorouracil in a bolus of 400 mg/m2 and then continuous infusion for 46 hours of 2400 mg/m2)
45357452|NCT04092101|Other|Cigarettes with varying nicotine content|1) Altering the nicotine content of the tobacco research cigarette
45357453|NCT04092101|Other|E-Cigarettes|1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
45357454|NCT04091945|Drug|LT3001 Drug Product|Active comparator
45357455|NCT04091945|Drug|Placebo|Placebo comparator
45357456|NCT04091789|Drug|Pure Femme Tablets|A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene, beta-caryophyllene, humulene, linalool, and limonene and peppermint oil.
45357457|NCT04091711|Device|ReX-C system|Oral oncolytic medications are dispensed to patients via ReX-C system
45479098|NCT03331822|Other|Bright Light|high illuminance white lights positioned at each nursing station throughout the hallway to generate a uniform exposure of approximately 1,000-3,000 lux. To achieve this illuminance, a Day*Light Classic Light will be positioned at each nursing station in the ICU hallway.
45479099|NCT05035290|Device|Negative pressure ventilation|Negative pressure ventilation - cuirass will be applied on the patient´s ches and abdomen immediately after extubation
45843836|NCT02996760|Drug|Growth Factor, Platelet-Derived|0,5 mL, vaginal use , 3 dose number
45843837|NCT02987946|Device|IPD Device delivered by Converis|After randomization patients will be subjected to perioperative (48 hrs) intermittent pneumatic compression.
45357458|NCT00916955|Other|Observation|Observe development of syndrome over time
45843838|NCT02987946|Drug|Fraxiparine|All patients receive Fraxiparine 2850 IE daily, starting preoperatively compatible with current practice.
45843839|NCT02733900|Procedure|femoral head removal|
45843840|NCT02718300|Drug|Parsaclisib|Up to 3 oral once a day (QD) doses of parsaclisib. Doses will be taken once daily for 8 weeks, followed by once weekly dosing at the same dose level.
45357459|NCT04094051|Drug|Ibrutinib|In the retrospective period, clinical information of approximate 500 patients with CLL/SLL prior to the study initiation will be collected retrospectively through chart review. There will be one time follow-up to collect data on disease progression, survival status and patient-reported outcomes.
45357460|NCT04093895|Drug|PerioSept(r)|Scaling and root planing followed by 3% PerioSept(r) administration
45357461|NCT00522418|Device|Vagal Nerve Simulation (VNS) Therapy|VNS Therapy + Best Medical Practice including anti-epileptic drugs
45357462|NCT00522418|Drug|Best Medical Practive|Best Medical Practice including anti-Epileptic Drugs
45357463|NCT00624780|Drug|Pregabalin|Pregabalin 150-300 mg given twice a day
45357464|NCT00624780|Drug|Lorazepam|Lorazepam 3-4 mg given twice a day
45357465|NCT00624780|Drug|Pregabalin|Pregabalin 450-600 mg given twice a day
45687175|NCT05655325|Behavioral|Home-based walking exercise|A 6-month partially supervised walking exercise program using a tapered approach.Participants will begin exercise (walking) at a relatively low intensity and progress to moderate intensity. Intensity will start at 40% and progress as tolerated up to 60-70%. Rating of perceived exertion of 12-14 (fairly light to moderate) will be used to aid intensity (Rating of perceived exertion 6-20 scale). This is an accepted method for achieving desired exercise intensity. Participants will progress over time to exercise 3-4/week for 30-45 minutes. The exercise program may need to be adjusted for (e.g. 10 minutes of exercise 3 times), to achieve the minimum exercise dose of 30 minutes. This will be determined for each individual participants as needed.
45357466|NCT00624780|Drug|Placebo|Placebo
45357467|NCT00750893|Biological|Rotarix or Rotarix liquid formulation|GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine (oral suspension or prefilled syringe).
45357468|NCT01564888|Procedure|Ulnar artery compression|Compression of ulnar artery for 2 hours with radial artery hemostasis
45357469|NCT00753623|Drug|Ramelteon|ramelteon (8 mg)
45357470|NCT00753623|Drug|Placebo|In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.
45357471|NCT04766866|Diagnostic Test|sFlt1/PlGF screening in maternal blood at 35 to 36.6 weeks of gestation|A ratio cutoff of >p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation
45357472|NCT02599337|Drug|Nexavar|"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."
45357473|NCT02599337|Drug|Sorafenib|"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."
45687176|NCT05655325|Other|Attention control|Health education and stretching
45687177|NCT05653934|Behavioral|Pre-operative use of virtual reality headset|Patient use the virtual reality headset the day before and / or the day of the surgery
45687178|NCT05653934|Procedure|Standard surgery|Patient are operated as needed for treatment of colorectal cancer (usual care)
45687179|NCT05653934|Behavioral|Post-operative use of virtual reality headset|Patient use the virtual reality headset as many time as they want after the surgery during a maximum of 30 days
45687180|NCT05653570|Diagnostic Test|Electrical stimulation|Electrical stimulation will be used to confirm needle and catheter placement within the interfascial plane between the erector spinae muscle and thoracic transverse process.
45687181|NCT05653570|Diagnostic Test|Ultrasound|Ultrasound guidance will be used to visualize needle and catheter placement within the interfascial plane between the erector spinae muscle and thoracic transverse process.
45843841|NCT02718300|Drug|Parsaclisib|Two recommended oral QD doses of parsaclisib. Once daily doses of parsaclisib will be taken for 8 weeks, followed by once weekly dosing at the same dose level.
45843842|NCT02718300|Drug|Ruxolitinib|The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of parsaclisib.
45357474|NCT00831636|Drug|CP-4055|D1-5 and D8(+2)-12(+2) q4w
45357475|NCT00831636|Drug|CP-4055|IV administration day 1-5 and day 8-12 in a 4 week schedule
45357476|NCT00750737|Drug|Posaconazole|200 mg three times daily by mouth up to 6 weeks (Days 1-42)
45357477|NCT00750737|Drug|ABLC|7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)
45357478|NCT04044612|Other|Medial Unloader Brace|medial knee unloader braces use a three point bending system to increase space in the medial tibiofemoral compartment during weight bearing
45357479|NCT04119934|Behavioral|Smoking Cessation Intervention Tool|A personalized smoking cessation infographic is provided to the physician/NP alongside the patient's regular spirometry report.
45357480|NCT04093505|Drug|Gemtuzumab Ozogamicin 147|Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7
45357481|NCT04093505|Drug|Gemtuzumab Ozogamicin 1|Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1
45357482|NCT04093505|Drug|Glasdegib|Consolidation & Maintenance therapy Glasdegib 100mg on days 4 to 27
45357483|NCT04093505|Drug|Placebo Oral Tablet|Consolidation & Maintenance therapy Placebo 100mg on days 4 to 27
45357484|NCT00622440|Drug|AIJP (Arnebia Indigo Jade Pearl)|Participants will administer their own treatment using 1/4 teaspoon of the cream twice daily for 48 weeks.
45357485|NCT00622440|Drug|Placebo|Placebo twice daily for 48 weeks.
45357486|NCT04759690|Behavioral|Action observation|Action observation group: The participants will first watch the conventional balance exercises with the action observation method on video for 15 minutes.After watching of conventional balance exercise for 45 minutes in 5-10 repetitions.
45357487|NCT04759690|Behavioral|Exercise group|Exercise group is the control group.TheParticipants will only do the conventional balance exercise without action observation for 45 minutes in 5-10 repetitions.
45357488|NCT05417477|Device|use of an e-health application|Use of the e-health application throughout the duration of the study combined with the usual management of the disease and 20 physiotherapy sessions.
45357489|NCT02597777|Other|Acetyl Hexapeptide-8|Acetyl-Hexapeptide-8 peptide solution will be diluted to a final concentration of 10% using Cetaphil facial lotion base
45357490|NCT02597777|Other|Placebo vehicle|Water will be diluted to a final concentration of 10% using Cetaphil facial lotion base.
45357491|NCT00831714|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made
45357492|NCT00831714|Drug|Standard care treatment for VTE prophylaxis|Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment other than rivaroxaban has been made
45357493|NCT02597699|Drug|Remifentanil + Lidocaïne|
45479100|NCT03338530|Behavioral|Comprehensive School-Based Intervention|School staff administered the 5 components during the school year. Social Skills Groups were conducted 2-3x/wk. for a total of 60-90 min./wk.; each group contained 3-6 students with social impairments. The Individual Daily Note was administered across the school day to reinforce new skills and reduce problem symptoms. Students' performance on targets was linked to home rewards. Mind Reading computer instruction targeting emotion recognition skills was conducted 3x/wk. for a total of 60 min./wk. Therapeutic Activities were conducted 2x/wk. for a total of 40-60 min./wk.; these cooperative activities were designed to practice targeted skills. Parent Training was conducted 1x/month for 60-90 min./session in order to increase home-school communication and integrate the CSBI across settings.
45357494|NCT02597699|Drug|Sufentanil + Lidocaïne|
45357495|NCT02574910|Drug|Abiraterone acetate|This is a dose escalation study. Up to 3 successive cohorts of 8 subjects each will receive 7 days of 1, 2 or 4 mg/kg/d of abiraterone acetate, until 7/8 subjects have met the desired endpoint.
45357496|NCT00827736|Procedure|Botox|injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline.
45357497|NCT00827736|Drug|ISDN ointment|application of ISDN 1% ointment 6 times a day
45357498|NCT00827736|Drug|Placebo|"Injection of placebo into internal anal sphincter (ISDN ointment arm)~Applied to the anoderm six times a day (Botox injection arm)"
45479101|NCT05013294|Other|Intervention|Text messages through a basic phone or smart phone
45479102|NCT02492152|Device|Study group|Dianatal
45479103|NCT03515941|Drug|Oxaliplatin|130 mg/m2 by IV (Arm 1)
45479104|NCT03515941|Drug|Capecitabine|625 mg/m2 (Arm 1), 1000 mg/m2 (Arm 1), 750 mg/m2 by PO (Arm 2)
45479105|NCT03515941|Drug|Leucovorin|400 mg/m2 by IV (Arm 1 & Arm 2)
45479106|NCT03515941|Drug|5-fluorouracil|400, 2400 mg/m2 by IV (Arm 1), 400,1200 mg/m2 by IV (Arm 2)
45479107|NCT03515941|Radiation|radiation|45 Gy in 1.8 Gy/fraction
45479108|NCT01300403|Other|Flutter valve|Flutter valve is a physiotherapy device commonly used for the treatment of pulmonary hypersecretive conditions. The patients is taught to exhale through the device, producing positive expiratory pressure and flow oscillations. In this study the intervention took 15 minutes. During this period the patients were free to cough.
45479109|NCT01300403|Other|expiration with the glottis open in lateral posture (ELTGOL)|This technique is a maneuver of slow expiration with the glottis open, with the subject in lateral posture. The patients performed three sets of 10 repetitions in left and right lateral decubitus.
45479110|NCT01300403|Other|Control|Patients were instructed to stay comfortably seated during 15 minutes. After this period they were stimulated to cough during a five minutes period.
45479111|NCT02492074|Drug|Delta-9-tetrahydrocannabinol|oral administration of delta-9-tetrahydrocannabinol
45687182|NCT05648539|Device|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals' cerebral cortex, hypothalamus and limbic system, further improve the mood of daily tension and anxiety.
45687183|NCT05646654|Procedure|Erector spinae plane block|Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 20 ml bupivacaine 0.5% will be injected
45357499|NCT00744653|Procedure|Electrochemotherapy|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz. Drug used is Bleomycin.
45357500|NCT00998218|Drug|Ranolazine|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
45357501|NCT00998218|Drug|Placebo|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
45479112|NCT02492074|Drug|Cannabidiol|oral administration of cannabidiol
45479113|NCT02492074|Drug|Placebo|oral administration of placebo
45479114|NCT03819647|Drug|stiripentol (Diacomit)|Administration of stiripentol per os
45479115|NCT02498782|Drug|Fexinidazole|
45357502|NCT00825396|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 150 days
45357503|NCT01565044|Other|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped is programmed to move in order to stimulate automatic motricity.
45357504|NCT01565044|Other|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped will remain static in order to involve intentional motricity.
45357505|NCT04044300|Procedure|Single screw fixation|A single trans-iliac, trans-sacral screw will be inserted at the sacral one or sacral two level based upon fracture location.
45357506|NCT04044300|Other|Conservative|Continued pain management and physical therapy.
45479116|NCT02498782|Drug|Placebo|
45479117|NCT05623085|Other|Aerobic exercise|Individuals in this group will be given 8-week individualized exercise according to the Karvonen protocol (heart rate reserve percentage-% HR). Exercise training will be 30 minutes at 50% of HR between weeks 0-2, 45 minutes at 50% of HR between weeks 2-4, 45 minutes at 60% of HR between weeks 4-6 and 6-8 weeks It will be done on the treadmill 3 days a week, for 60 minutes at 60% of HR between weeks. The treadmill speed will be adjusted during exercise to maintain the set target heart rate level.
45479118|NCT05623085|Other|Yoga exercise|Individuals in this group will be given 8-week individualized yoga exercise including stretching, relaxing, strength training. Exercise training will be done 3 days a week. The duration of the exercise will be adjusted to be the same as the aerobic exercise group.
45843843|NCT02718300|Drug|Parsaclisib|20 mg oral QD dose of parsaclisib for 8 weeks. After 8 weeks patients will take either 20 mg once weekly or 5 mg once daily.
45357507|NCT00311311|Drug|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. The target trough level of TAC will be maintained at 3-10 ng/mL through to the end of the study.
45357508|NCT00311311|Drug|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
45357509|NCT00311311|Drug|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
45357510|NCT00311311|Drug|sirolimus|"The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol.~On study Day 1 Conversion, the daily dose of TAC will not be taken, and SRL is initiated as a single 5-10 mg loading dose, followed by 3 mg/day on subsequent days, adjusted to maintain a SRL target trough level of 8-15 ng/mL through to month 24 post-transplant, then 5-12 ng/mL to the end of month 36 post-transplant."
45687184|NCT05646654|Procedure|Interscalene brachial plexus block|Using a lateral-to-medial approach, the 25-gauge needle will be inserted into the middle scalene muscle, advanced, and placed immediately lateral to the nerve roots. the needle will be visualize using an ultrasound beam to avoid intraneural and intravascular injections. After confirming negative blood aspiration, we will inject 15 mL of 0.5% bupivacaine around the nerve roots
45357511|NCT00311311|Drug|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. Reintroduction of TAC or introduction of CsA is not permitted in the SRL Therapy group.
45357512|NCT00311311|Drug|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
45687185|NCT05645159|Other|Blended learning in heart disease|The intervention included face-to-face classes and online resources (Moodle, online syllabus, videos, websites, podcasts, activities, apps, forums, emails, tutoring).
45687186|NCT05644093|Drug|SPL026 IV|IV dosing
45687187|NCT05644093|Drug|SPL026 IM|IM dosing
45687188|NCT05643482|Device|Hyperbaric Oxygen Treatment|Pressurization at 2.0 ATA with 100% oxygen
45357513|NCT00311311|Drug|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
45357514|NCT05413655|Drug|EX039|The dosage form of EX039 is the capsule for oral use
45357515|NCT05413655|Drug|Placebo|The dosage form of Placebo is the capsule for oral use
45357516|NCT03854604|Other|postoperative pain assessment|evaluation of the efficacy of PI as an objective measure for postoperative pain assessment in pediatric population undergoing adenotonsillectomy.
45357517|NCT02599181|Other|propanol-biphenol: Kodan|WITH-group, the skin is disinfected with an aerosolized alcoholic solutionpropanol-biphenol: Kodan, Schülke & Mayr, Zurich, Switzerland.
45357518|NCT04089605|Drug|dexamethasone implant|intravitreal dexamethasone implant injections in vitrectomized patients with DME
45357519|NCT04089605|Drug|Ranibizumab|intravitreal ranibizumab injections in vitrectomized patients with DME
45357520|NCT02597621|Other|no intervention|no intervention
45357521|NCT02599025|Device|Innowalk cycling system|Innowalk is a unique, motorized medical device
45357522|NCT02599025|Device|APT cycling system|APT is used as a rehabilitative device that cycles the feet automatically or by the individual
45357523|NCT00521404|Drug|CS-1008 (humanized anti-DR5 antibody)|CS-1008: 8mg/kg loading dose followed by 3mg/kg weekly.
45357524|NCT00521404|Drug|gemcitabine|Gemcitabine - 1000mg/meter sq
45357525|NCT00311155|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary|Olmesartan medoxomil oral tablets 20 mg for 4 weeks followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 12.5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 10 mg for 4 weeks. All study medications are to be taken once daily. The subject's participation completes when blood pressure goals are achieved.
45357526|NCT03977077|Drug|Albumin binding taxol|125mg/m2, d1, 8, intravenous infusion for 30min, 1 cycle every 3 weeks;Other combined chemotherapy drugs and drug doses shall be administered by clinicians according to the guidelines and the actual situation of clinical patients.
45357527|NCT03981679|Other|Biological collection|The biological collection will also include samples of blood samples collected before colonoscopy
45357528|NCT03981601|Drug|Lovastatin 40 MG|after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket
45357529|NCT03981601|Procedure|without drug with Bone graft|after tooth extraction, put teh bone graft wifin tooth socket
46047251|NCT05115812|Other|Post-Operative Data (up to discharge)|Postoperative adverse events, discharge status, hospital length of stay, information on enhanced recovery program
46047252|NCT05115812|Other|Short-Term Follow-Up Data|Adverse events, re- admissions, re-operations related to the index procedure
46047253|NCT03311334|Drug|DSP-7888 Dosing Emulsion|DSP-7888 Dosing Emulsion will be administered intradermally (ID) every 7 days until cycle 3, and then every 14 days for combination with Nivolumab arm or every 21 days for combination with Pembrolizumab arm.
45357530|NCT00292045|Biological|NY-ESO-1 protein/CpG 7909|Patients received vaccinations consisting of the NY-ESO-1 protein (100 µg) combined with CpG 7909 (2.5 mg) as an adjuvant administered intradermally every 3 weeks for 4 doses (i.e., 12-week cycle).
45357531|NCT00274651|Drug|belinostat|
45357532|NCT01068691|Procedure|Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)|"Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)~Blood pressure~Obstructive sleep apnea syndrome (OSAS)~Carotid-to-femoral pulse wave velocity (PWV)~Biological parameters"
46047254|NCT03311334|Drug|Nivolumab|Nivolumab will be administered in the approved dose and schedule starting on Day 29 of the study.
46047255|NCT03311334|Drug|Pembrolizumab|Pembrolizumab will be administered in the approved dose and schedule starting on Day 22 of the study.
45357533|NCT00274261|Drug|C31G|The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study.
45357534|NCT00274261|Drug|nonoxynol-9 (N-9)|The subject will insert one applicator of Conceptrol® vaginal gel (nonoxynol-9) prior to each episode of vaginal intercourse during her participation in the study.
45357535|NCT00624468|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
45357536|NCT00624468|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
45357537|NCT03976687|Drug|EYP001a|Oral tablets
45357538|NCT03976297|Other|Control Tower|A workstation and software tool that extracts medical data from Mayo's data mart and electronic health record, and processes it through a prediction model that determines whether a patient is suited for a palliative care consult.
45479119|NCT03338452|Behavioral|Low energy ketogenic diet|Low energy ketogenic diet lasting 12 weeks with a previous preparation period including detailed instructions during classes and individual counselling by a dietitian. Participants were provided with a list of suitable foods with very low carbohydrate content. Furthermore, the subjects shared cooking recipes and links to helpful webpages. They were free to follow a KD according to their personal preferences but limit their carbohydrate intake to 5-10 % of total energy from carbohydrates, but derive at least 70 % of total energy from fat.
45479120|NCT05623007|Dietary Supplement|Probiotics|Combination of 3 probiotic strains: Lactobacillus rhamnosus (LGG), Bifidobacterium animalis subsp. lactis (BB-12), and Lactobacillus acidophilus (LA-5)
45479121|NCT05623007|Behavioral|Counselling on healthy eating, physical activity, and psychosocial stimulation|Counselling on healthy eating, physical activity, and psychosocial stimulation.
45479122|NCT05623007|Dietary Supplement|Placebo probiotics|Maltodextrin
45479123|NCT02499016|Procedure|suprapubic single-incision laparoscopic appendectomy|the approach of appendectomy
45479124|NCT03815201|Dietary Supplement|Group 2|leucine-enriched protein supplementation during the first 1/2 hour post-training
45479125|NCT03815201|Other|Group 1|placebo, an energy-matched mixture, during the first 1/2 hour post-training
45479126|NCT02493790|Other|Cognitive and motor performances|
45479127|NCT03342976|Other|My-AHA platform|ICT strategy for early detection of frailties
45479128|NCT03819335|Device|mySugr app|mySugr is a mobile medical app for diabetes management. It has been developed by Roche Diabetes Care and it has two versions, free and Pro. It allows to carry out the diary of diabetes, including the collection and analysis of data on glycaemia, food, physical activity or insulin dose. In addition, it is compatible with continuous glucose measurement systems. It has the possibility to add functionalities such as estimation of HbA1c levels, more detailed data analysis or integration with Google Fit type motion sensors, as well as a bolus calculator, reminders for measuring blood glucose or photo gallery in the Pro version, which is the one that will be provided to the patients for the study.
45479129|NCT03819335|Other|Standard care|Face-to-face visits
45479130|NCT02498938|Genetic|SERPINA1 gene|2ml blood sample collected from patients to extract DNA for assessment of SERPINA1 gene polymorphism
45479131|NCT03811691|Diagnostic Test|MRI exam|Pacing system safety and stability under MRI scan environment
45479132|NCT02498860|Drug|Pemebit|500mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
45479133|NCT02498860|Drug|Cisplatin|75mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
45479134|NCT03811457|Genetic|Welgenaleucel|Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.
45687189|NCT05643482|Other|Placebo gas|Pressurization at 2.0 ATA with 10.5% oxygen to mimic normal air
45687190|NCT05637723|Other|schroth exercise|The schroth exercise program will be given 3 days a week for 6 weeks.
45687191|NCT05637723|Other|traditional scoliosis exercises|The traditional scoliosis exercises program will be given 3 days a week for 6 weeks.
45687192|NCT05636280|Other|schroth exercise|In this study, Schroth exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist trained in schroth.
46047256|NCT04313036|Drug|Defibrotide|25 mg/kg/day at 4 divided doses of 6.25 mg/kg, 2-h infusion given for 5 days, if not in CR treatment continued for >/= 21 days or per discretion of enrolling physician.
46047257|NCT02882438|Drug|infected group|Ginkgo Biloba in different dosage forms
46047258|NCT02882438|Drug|control group|placebo without Ginkgo Biloba
46047259|NCT02859870|Device|FUSE-TM colonoscope|Colonoscopy in conditions of normal security including patient clinical examination before leaving the hospital. Data collection by each operator.
45357539|NCT00827814|Drug|Dutasteride|Dutasteride 0.5 mg od.
45357540|NCT01069783|Drug|A3309|A3309 in two different dosage levels
46047260|NCT04310696|Other|Buteyko Breathing exercises|Buteyko breathing technique was performed by asking the patient to take a small breath in and then out and hold his/her breath and count the time in seconds, as long as he or she can, until first signs of air hunger start to appear, followed by normal breathing once again. This procedure was repeated 15 times, three sets of 15 repetitions were given to the patient per day, 3 days per week and the treatment was continued for 4 weeks.
46047261|NCT04310696|Other|Pursed lip breathing|Pursed lip breathing was performed as nasal inspiration followed by expiratory blowing against partially closed lips. Participants received a total of 3 sets of 15 repetitions per day, 3 times a week and the treatment was continued for 4 weeks.
46047262|NCT00879658|Drug|BAF312|
46047263|NCT00879658|Drug|Placebo|
45357541|NCT01069783|Drug|A3309|A3309 in two different dosage levels for the duration of the study
45357542|NCT01069783|Drug|Placebo|Placebo comparator once daily for the duration of the trial
45357543|NCT00825474|Other|operation;TACE plus PEI|Under normal rules, the operation group open abdomen to perform operation through subtotal incision while the patient has been general anesthesia with trachea cannula. The operation range on hepatic tissue of un-tumor tissue around tumor should maintain at least 1cm. As for the micro-create treatment combination group, taking TACE all through arteria cruralies super-elect arteria hepatica and injecting MITO、FUDR、iodipin. By B transonogram guiding to nyxis liver biopsy,and perform per cutem absolute alcohol injection treatment.
45357544|NCT03976765|Other|Rehabilitation program|The patients follow different rehabilitation programs (surgery, anesthetic, post-operative). Hospital discharge is authorized only after validation of objective, clinical and para clinic criteria
45479135|NCT02498704|Procedure|Dry Needling|Trigger point dry needling to hamstring muscle group.
45357545|NCT01068847|Drug|2-4 of the drugs listed below|Cycloserine: 500, 675, 750 mg oral capsules may possibly given. Naloxone: 0.15mg/70Kg or 0.2mg/70kg I.M. injection may possibly be given. Nifedipine: 10, 20 mg oral capsules may possibly be given. Placebo (sugar pill or microcrystalline cellulose): oral capsules may be given. Saline: I.M. injection may possibly be given. Tizanidine: 4, 8, 12 mg oral capsules may possibly be given. Verapamil: 30, 60, 120 mg oral capsules may possibly be given.
45357546|NCT00827892|Drug|Pioglitazone|Escalating doses for 3 days, then 30 mg orally daily for the duration of the study as determined by MRI
45357547|NCT00827892|Drug|Placebo Control|Lactose Capsule administered by mouth daily for the duration of the study as determined by MRI
45357548|NCT00831948|Genetic|mitochondrial DNA mutations diagnosis|Identification of large-scale mutations of POLG gene by QMPSF in patients with mitochondrial DNA instability.
45479136|NCT02498704|Other|Sham Needling|Superficial palpation of trigger point, skin is not punctured.
45357549|NCT01070875|Drug|Variation of heparin dose|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
45357550|NCT01070875|Drug|Variation of heparin dose|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
45357551|NCT04043676|Drug|Ponatinib|All patient will take 15 mg/day ponatinib oral during 48 weeks.
45357552|NCT01325935|Drug|Clopidogrel|DAPT using aspirin 81 mg/day (minimal dose) and clopidogrel 75 mg/day should be conducted for 3 months (+ 30 days) after stenting.
45357553|NCT02549742|Procedure|Electrochemotherapy|Electroporation by a device, Cliniporator, combined with chemotherapy, Bleomycin.
45357554|NCT02549742|Device|Cliniporator|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz.
45357555|NCT02549742|Drug|Bleomycin|Administered intravenously or injected into the tumour before electroporation.
45479137|NCT03011034|Drug|Talacotuzumab|Talacotuzumab 9 mg/kg will be administered as an IV infusion.
46047264|NCT00660166|Biological|NK-Cell Infusion|The infusion of natural killer (NK) cells will be performed in the Infusion Center at New England Medical Center. The NK cells will be given to the subject intravenously (into a vein). In addition, a balanced salt solution will be infused beginning about two hours prior to and continuing for two hours after the infusion of NK cells to keep the fluid level in the body well balanced. The subject will also receive Benadryl by injection 15-30 minutes prior to infusion to counteract and prevent any unwanted allergic side effects. The subject will be observed for any side effects during this time. If the subject feels well, he/she can go home. However, there may be a requirement to keep him/her overnight.
45357556|NCT00521014|Biological|filgrastim|
45357557|NCT00521014|Biological|rituximab|
45357558|NCT00521014|Biological|sargramostim|
45357559|NCT00521014|Drug|carmustine|
45479138|NCT03011034|Drug|Daratumumab|Daratumumab 16 mg/kg will be administered as an IV infusion.
45479139|NCT04984499|Device|Dental implant|"The procedure used to accomplish its intended use is as follows :~The recipient implant site is prepared using a drilling sequence, then the implant is placed at the crestal level with a cover screw to allow the tissues healing. After this healing phase, the final prosthesis will be loaded on the implant."
45479140|NCT05232760|Device|Supera™ Peripheral Stent System|The device will be employed for treatment of juxta-anastomotic stenosis in failing AV fistula after previous percutaneous angioplasty procedures
45479141|NCT03815123|Diagnostic Test|cardiac CT|The cardiac CT examinations are indicated by the referring physician. The participation in this study has no influence on the further diagnostic and therapeutic regimen.
46047265|NCT00959946|Drug|Bosutinib|Doses in part 1 include bosutinib 200 mg QD; bosutinib 300 mg QD. Depending on safety bosutinib can be administered at 200 mg/m2 QD. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
45357560|NCT00521014|Drug|cytarabine|
45357561|NCT00521014|Drug|etoposide|
45357562|NCT00521014|Drug|melphalan|
45357563|NCT00521014|Procedure|autologous hematopoietic stem cell transplantation|
45357564|NCT00825552|Drug|Risperidone|0,5-4 mg/day for 8 weeks (twice a day)
45357565|NCT00560235|Drug|CP-751,871|Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity
45357566|NCT00827970|Behavioral|Screening for urogenital Chlamydia trachomatis|Receeiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
45357567|NCT00825708|Device|rTMS|42 2 sec trains of 20HZ rTMS in 100% MT
45357568|NCT00825708|Device|shamTMS|sham TMS session
45357569|NCT00291577|Drug|Sunitinib (Sutent)|Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision
45357570|NCT00291577|Drug|Taxotere|Taxotere 75 mg/m2 iv, once every 3 weeks
45357571|NCT00520936|Drug|pemetrexed|1910 milligrams per meter squared (mg/m^2) (or 60 milligrams per kilogram [mg/kg] if patient <12 months old), intravenous (IV), for 21 days x 17 cycles
45357572|NCT02549430|Drug|Palbociclib|Palbociclib 125 mg/day orally in an ongoing 3:1 schedule (3 weeks on/1 week off)
45357573|NCT02549430|Drug|Anastrozole|Continuation of prior anastrozole 1mg/day orally in a continuous regimen
45357574|NCT02549430|Drug|Letrozole|Continuation of prior letrozole 2.5mg/day orally in a continuous regimen
45357575|NCT02549430|Drug|Exemestane|Continuation of prior exemestane 25mg/day orally in a continuous regimen
45357576|NCT02549430|Drug|Fulvestrant|Continuation of prior fulvestrant 500mg intramuscular injection every 4 weeks in a continuous regimen
45479142|NCT05464966|Drug|Glucose insulin potassium|After induction of anaesthesia,cardiac systolic-diastolic function was first measured by TEE, GIK solution was continuously pumped until the end of the procedure at a dose of 30 mU/kg/h of insulin, 0.12 g/kg/h of glucose and 0.06 mmol/kg/h of potassium chloride
45479143|NCT01330602|Behavioral|IMPRESS intervention|"The key elements of the IMPRESS intervention include:~Promoting a healthy lifestyle~Supporting lifestyle and risk modification~Encouraging active self-management of risk and chronic disease~Improving coordination of care~Pharmacological therapy"
45479144|NCT03331588|Procedure|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections
45357577|NCT00828126|Procedure|PET-CT Scan|Positron emission tomography-computed tomography (PET-CT) scan performed within 30 days of contrast-enhanced CT.
45357578|NCT00947037|Drug|AP-CD/LD|
45479145|NCT03331588|Procedure|Intercostal uniportal VATS|The surgical procedures followed principles of pulmonary resections
45479146|NCT01301885|Procedure|Laparoscopy/laparotomy|Surgical treatment of endometriosis (laparotomy/laparoscopy) or laparoscopic sterilisation. Sample collection in both groups.
45479147|NCT03515629|Drug|REGN2810/ipi|REGN2810 plus ipilimumab
45479148|NCT03515629|Drug|REGN2810/chemo/ipi|REGN2810 plus chemotherapy plus Ipilimumab
45479149|NCT03515629|Drug|Pembrolizumab|Reference drug administered IV infusion
45687193|NCT05636280|Other|traditional scoliosis exercise|In this study, traditional scoliosis exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist.
45357579|NCT03867760|Behavioral|Recorded Hypnosis Intervention|The RHI consists of four digital recordings developed by the investigator using standardized hypnosis scripts for pain reduction and uploaded to a MP3 player. The scripts were developed for patients with chronic pain and tested by a psychologist who is an expert in hypnosis research. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days). The script includes an induction, suggestions for how to access inner resources and manage pain, and post-hypnotic suggestions for permanence of hypnosis benefits and self-hypnosis practice.
45357580|NCT03867760|Behavioral|Recorded Relaxation Intervention|The recorded relaxation intervention consists of four digital recordings developed by the investigator using standardized relaxation scripts and uploaded to a MP3 player. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days).
45357581|NCT02548104|Other|ACB|ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with normal saline 15 ml
45357582|NCT02548104|Other|ACB + iPACK|ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
45357583|NCT00943839|Drug|sunitinib malate|
45357584|NCT00943839|Other|laboratory biomarker analysis|
45357585|NCT00943839|Other|pharmacological study|
45357586|NCT00832182|Drug|insulin aspart|Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
45357587|NCT00832182|Drug|insulin NPH|Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
45479150|NCT02498626|Other|venous saturations|Samples of venous saturations from the central venous line (CVP), from venous side of the heart lung machine and from the pulmonary artery were taken at 10 min after being on CPB and after correction of the cardiac defects.
45479151|NCT04581954|Drug|Ruxolitinib|Ruxolitinib is a Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor approved for clinical use in the treatment of splenomegaly, myelofibrosis, polycythaemia vera and graft-versus-host disease. It is an oral agent with a rapid mode of action.
45357588|NCT05280171|Other|Teach back|"Discharge information was explained by the principal investigator. On the day of discharge, pictographs teach back regarding medication, exercise, diet and follow-up was given and they were asked teach back.~Teach back is a approach which is used in cognitive psychology experiments describing repeating short sequences of information helps to improve repeat back of information. This teach back technique is recommended as a universal precaution by the agency for healthcare research and quality and the national quality forum."
45357589|NCT05280171|Other|Standard of care|Standard of care
45357590|NCT00952497|Drug|Cisplatin, Capecitabine, Telatinib|Subjects will receive: Chemotherapy (capecitabine and cisplatin) and telatinib Capecitabine will be administered (1000 mg/m2) twice daily for 14 days followed by a 7-day rest period. Cisplatin (80 mg/m2) will be given as a 1-3 hour infusion once every 3 weeks. Telatinib (3 tablets) will be administered orally, twice daily as a continuous administration. After a maximum of 6 cycles of cisplatin, subjects continue with capecitabine and telatinib or monotherapy with either study drug,depending on the toxicity experienced by the subject, until disease progression.
45357591|NCT04018716|Device|MTA|Indirect capping with MTA
45357592|NCT04018716|Device|Dycal|Indirect capping with Dycal
45357593|NCT00943995|Drug|somatropin|0.35 mg/Kg/week divided into 3 doses, each dose being given at the end of the dialysis treatment.
45357594|NCT00828282|Drug|Simvastatin|Treatment will be administered on an outpatient basis. Subjects will be given 7.5 mg/kg twice daily of Simvastatin for 7 days on a 21-day cycle with a goal of 6 cycles.
45357595|NCT00952575|Drug|polyclonal anti-D immunoglobulin|single injection of 300 µg
45357596|NCT00952575|Drug|monoclonal anti-D immunoglobulin|Comparison of different dosages of LFB-R593
45357597|NCT04012125|Device|flexible thoracolumbar brace|Subjects would wear the flexible thoracolumbar brace over 18 hours a day
45357598|NCT03865732|Drug|Ganaxolone|active drug
45357599|NCT03865732|Drug|Placebo|inactive
45357600|NCT05300607|Other|Cross-cultural adaptation, validity, and reliability|evaluation, translation, cultural adaption, validation, and investigation of the reliability of Arabic version of The Western Ontario Rotator Cuff Index (WORC) to be used in Arabic countries.
45357601|NCT00944151|Procedure|TAP Catheter and Infusion of Study Solution|Subject will be randomized to one of two groups: Saline infused TAP catheter following surgery for 0-2 days or ropivacaine infused TAP catheter following surgery for 0-2 days. All patients will be given a single injection of ropivacaine prior to surgery. Research staff will follow all patients for two days following surgery or while they have TAP catheter in.
45357602|NCT00998452|Behavioral|MOVE*VETS|Receiving 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from peer counselors.
45357603|NCT00944307|Drug|raltegravir|raltegravir 400mg orally once
45479152|NCT04581954|Drug|Fostamatinib|Fostamatinib is a tyrosine kinase inhibitor with activity against spleen tyrosine kinase (SYK). It has approved for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
46047266|NCT00959946|Drug|Capecitabine|Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14; capecitabine 625 mg/m2 BID on days 1-14. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
45479153|NCT04581954|Other|Standard of care|Standard of care treatment as per site-level policies and guidelines.
45479154|NCT05016089|Other|The 16-style simplified Pilates exercise programme|The 16-style simplified Pilates exercise programme was developed by a group of experienced Pilates and rehabilitation experts from our completed pilot work.
45479155|NCT04494178|Device|2.0g G-PUR®|Oral administration (Intervention period I)
46047267|NCT00667264|Procedure|perineural ropivacaine|Subjects will be randomized to one of two groups: ropivacaine 0.4% or normal saline (placebo). The basal rate will be set at 7 mL/h.
46047268|NCT00660244|Drug|anastrozole|Oral
46047269|NCT04282200|Drug|Ketorolac|intravenous ketorolac 30 mg every 6 hours
46047270|NCT04157764|Device|HomeChoice Claria APD machine with SHARESOURCE|HomeChoice Claria APD machine with SHARESOURCE software. SHARESOURCE is a software can telemonitor patients' compliance
45357604|NCT00944307|Drug|antacid|aluminum, magnesium, simethicone-containing antacid 30mL orally once
45357605|NCT00520546|Other|18F-Ethylcholine Positron Emission Tomography (FEC-PET)|"PET scans were performed on a LSO scanner (ECAT ACCEL, Siemens, Erlangen, Germany) by using a multiphase protocol starting with a cold transmission scan of the lower pelvis. This was followed by a list mode emission scan with 10 frames à 1 minute starting immediately after the administration of 3.3MBq [18F]Fluoroethylcholine chloride (FEC; Eckert & Ziegler EURO-PET Berlin GmbH) as a bolus through the cubital vein. After a short gap due to computer processing time the whole body scan was performed starting at the upper thoracic aperture down to the proximal femur. Acquisition parameters were 3 minutes emission scan and 2 minutes transmission scan for each bed position. Therefore the prostate region was scanned again at 45 minutes p.i. (post injection) A delayed local acquisition at 65 minutes over the lower pelvis with 6 minutes emission and 2 minutes transmission finished the diagnostic acquisition procedure."
45479156|NCT04494178|Device|2.0g G-PUR®|Oral administration (Intervention period II)
45843844|NCT02718300|Drug|Parsaclisib|"2 dose strategies will be compared:~5 mg parsaclisib beginning on Day 1 until end of treatment.~20 mg oral QD dose of parsaclisib for 8 weeks; after 8 weeks patients will take 5 mg once daily."
45843845|NCT02542644|Device|Ultrahigh resolution Spectral Domain OCT|"The area of graft detachment will be measured by a customized ultra high-resolution OCT for the cornea.~A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed."
45843846|NCT02394132|Drug|Imiquimod|
45843847|NCT02394132|Radiation|Radiotherapy|
45843848|NCT02102880|Genetic|the polymerase chain reaction (PCR)|
45843849|NCT01894542|Dietary Supplement|Cod protein from presscake|6g protein per day for 8wk
45479157|NCT04494178|Other|Placebo|Intervention period I
45479158|NCT04494178|Other|Placebo|Intervention period II
45479159|NCT05002751|Other|UCSD Vaginal Dilator Questionnaire|14 question survey
45479160|NCT05002751|Other|EORTC Sexual Health Questionnaire|22 question survey
45479161|NCT04541940|Other|Telerehabilitation Therapy|Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - Quadriceps isometrics exercises, straight leg raises, and range of motion exercises.
45843850|NCT01894542|Dietary Supplement|Cod protein from presscake + stickwater|6 g protein per day for 8 wk
45843851|NCT01894542|Dietary Supplement|Control|
45843852|NCT00700596|Drug|Salvinorin A|Low dose: Active SA 250μg Medium Dose: Active SA 500μg High Dose: Active SA 750μg
45843853|NCT00700596|Drug|Placebo|Control or Placebo SA (30 % ethanolic solution)
45843854|NCT01733472|Drug|GA-arm, remifentanil|"Remifentanil and propofol will be delivered intravenously via TCI pumps according to the Marsh and Minto algorithm"
45843855|NCT01733472|Drug|RA-arm|Intrathecal (i.e. spinal) anesthesia with isobaric bupivacaine 15 mg administered intrathecally at L4-L5.
45843856|NCT01736358|Drug|Intranasal Ketoralac|15.75 mg of Sprix in each nostril 20 minutes before end of surgery
45843857|NCT01736358|Drug|Placebo|15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery
45843858|NCT01737684|Drug|Vibegron|50 mg tablet, oral
45843859|NCT01740258|Radiation|Radiation Therapy|
45687194|NCT05635292|Behavioral|Tele-CBT|8 weekly 1-hr telemedicine visits with a licensed Ph.D. psychologist from the University of Pennsylvania (permissible to practice across state lines under PSYPACT), plus usual care and referral to an IBD Help Center (email, phone, online chat with IBD information specialist)
45687195|NCT05634161|Other|Cognitive improvement software|Cognitive improvement software
46047271|NCT04281966|Behavioral|Ability School Engagement Program Conference|"The ASEP conference focuses on understanding the reasons behind why the young person is not attending school regularly, understand how the young person's non-attendance affects other conference participants, highlight the legal consequences of parents and/or guardians to ensure that their child attends school, and the development of a young person-centered Action Plan, which will specifically detail the actions that all parties are to take over the next three months to ensure that the young person re-engages with school and/or transitions into paid work."
45357606|NCT00520546|Other|Endorectal Magnetic Resonance Imaging (1.5Tesla) (eMRI)|The MRI examination was performed on a 1.5Tesla MRI system (Gyroscan ACS-NT, Philips, Hamburg, Germany) with combined QBody and endorectal coil. Pelvic assessment and lymph node staging was effected with 5mm T2 weighted (T2w) turbo spin echo (TSE) transversal and a coronal short-tau inversion recovery (STIR) sequence. For prostate assessment, 3mm endorectal T2w spin echo (SE) sagittal, transversal and coronal sequences were acquired.
45357607|NCT00952887|Biological|ACE-031|Either 2 or 3 subcutaneous doses of ACE-031 over a period of one month, or 7 subcutaneous doses of ACE-031 over a period of 3 months.
45357608|NCT00952887|Biological|Placebo|Either 2 or 3 subcutaneous doses of placebo over a period of one month, or 7 subcutaneous doses of placebo over a period of 3 months.
45357609|NCT00555009|Drug|Genotropin|Subcutaneous injection, starting dose 0.2mg/day for males and 0.3mg/day for female with dose titration at 0.1mg to 0.2 mg increments in accordance to IGF-1 results for a total duration of 36 weeks.
45357610|NCT00555009|Drug|Placebo|Subcutaneous injection, with dummy dose titration for a total duration of 36 weeks.
45357611|NCT04000516|Behavioral|Time restricted feeding|Restricting the eating window to about 8 hours a day, during waking hours.
45357612|NCT00944385|Drug|ulinastatin|Administer 30000U/ulinastatin. Comparison of different dosages of drug.
45479162|NCT04541940|Other|In-person Rehabilitation Therapy|Quadriceps isometrics exercises, straight leg raises, and range of motion exercises.
45479163|NCT02498470|Procedure|percutaneous coronary intervention|All the patients receiving coronal artery angiography or percutaneous coronary intervention therapy by standard protocol
45479164|NCT01330680|Dietary Supplement|Coffee|40 mL dose of a decaffeinated preparation spiked with the addition of caffeine, at a dose of 3 mg/kg
45687196|NCT05633693|Behavioral|Counterpressure Maneuvers|Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating two clinically recommended isometric maneuvers (crouching, and leg crossing with muscle tensing) and two novel dynamic maneuvers that comprise discrete movement that the investigators have identified in prior work (exaggerated anterior-posterior postural sway, rhythmic gluteal clenching).
45687197|NCT05633693|Behavioral|Baseline Stand|Participants will stand quietly for 5-minutes on a force platform to allow the investigators to assess their typical response to orthostasis.
45687198|NCT05633446|Biological|PepGNP-COVID19 (One vaccination)|One dose with 7.5 nmol total peptide/dose with 38.3ug gold base particle in 50 µl WFI
45687199|NCT05633446|Other|Water for injection (One vaccination)|Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
45687200|NCT05633446|Biological|PepGNP-COVID19 (Two vaccinations)|Two vaccinations with 7.5 nmol total peptide/dose with 38.3ug gold base particle in 50 µl WFI
45687201|NCT05633446|Other|Water for injection (Two vaccinations)|Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
45843860|NCT01740258|Drug|Temozolomide|
45357613|NCT01529775|Device|Osseotite Certain Tapered Prevail|Osseotite implant with platform switching feature
45357614|NCT01529775|Device|Osseotite Certain Tapered|Osseotite implant with non-platform switching feature
45357615|NCT00953277|Other|Processed Human Nerve Tissue Scaffold|Implantation of appropriate length of processed human nerve scaffold at the time of surgery.
45357616|NCT00953355|Drug|Folate plus metformin|A six-month course of metformin (1700 mg daily) plus folic acid (400 microgram daily).
45479165|NCT01330680|Dietary Supplement|Decaffeinated coffee|40 mL dose of decaffeinated coffee
45843861|NCT01740258|Drug|Bevacizumab|
45479166|NCT03331510|Other|Strength testing before and after arthroscopic Latarjet|After patients, based on the ISI-Score, were assigned to treat their shoulder instability with an arthroscopic Latarjet procedure, they are eligible for this study. Strength of different involved muscles, as well as ROM will be measured before and at several time points after surgery.
45687202|NCT05632133|Drug|Lacosamide 50 mg|50 migraine patients who needed preventive treatment received 50 mg lacosamide Bid for 3 months, and we assessed the CGRP level before and after treatment
45479167|NCT01330758|Drug|AZD8931|40 mg AZD8931 wet granulation tablet formulation
45479168|NCT01330758|Drug|AZD8931|40 mg AZD8931 roller compacted tablet formulation
45479169|NCT01302821|Biological|Adenovirus-p53 transduced dendritic cell vaccine|The Ad.p53 DC vaccine will be injected intradermally (through the skin) into four separate sites. The patient's vaccine will be the same dose throughout the study.
45357617|NCT00953355|Drug|Placebo plus metformin|A six-month course of metformin (1700 mg daily) plus placebo
45357618|NCT00944463|Drug|Gemcitabine+simvastatin|Gemcitabine and simvastatin
45357619|NCT00944463|Drug|Gemcitabine+Placebo|Gemcitabine plus Placebo
45357620|NCT00947583|Biological|Osteocel Plus|biologic
45357621|NCT00956397|Drug|Rifaximin|rifaximin 550 mg TID PO x 10 days
45479170|NCT01302821|Drug|1-methyl-D-tryptophan|Each treatment cycle is comprised of 21 days. The treatment is continuous with no breaks in between cycles. Patients would not be allowed to take any tryptophan containing supplements while participating on this study.
45687203|NCT05629585|Drug|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion
45687204|NCT05629585|Drug|Durvalumab|Experimental drug. Provided in 50mg vials. IV infusion
45687205|NCT05629585|Drug|Capecitabine|Active Comparator. Tablet. Oral route of administration
45687206|NCT05629585|Drug|Pembrolizumab|Active Comparator. Provided in 100mg vials. IV infusion
45843862|NCT01740414|Drug|MN-166 (50 mg) First|In this arm of the study participants were first maintained on 50 mg MN-166 BID for approximately 14 days, and were then switched onto placebo maintenance. The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo & MN-166).
45357622|NCT00956397|Procedure|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
45357623|NCT00956397|Drug|Placebo|placebo TID x 10 days
45357624|NCT00953433|Device|Endoflex tube|Size decided upon gender.
45357625|NCT00953433|Device|Polyvinyl chloride endotracheal tube with a stylet|Size decided upon gender.
45479171|NCT01302821|Radiation|Carbon C 11 alpha-methyltryptophan|The experimental examination for this research is the administration by a needle in a vein of Tryptophan labeled with a radioactive tracer (a substance is believed to enhance imaging for easier detection and measurement), Carbon 11, when when the patient has not eaten for five hours. A standard PET/CT scanner is then used to create images of the tracer a few minutes later.
45357626|NCT00953511|Genetic|ERCC1 pathways analysis|The gene polymorphism of ERCC1 rs11615 and the pathways of ERRC1 will be analyzed in endoscopic tumor biopsies as well as in normal tissues prior to therapy. The results will be compared with histopathologic response after neoadjuvant therapy.
45357627|NCT05300373|Diagnostic Test|ADENOSINE DEAMINASE TEST|ADENOSINE DEAMINASE DEFICIENCY TEST
45357628|NCT00956475|Behavioral|telephone-based intervention|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
45357629|NCT00956475|Other|questionnaire administration|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
45357630|NCT00956475|Procedure|assessment of therapy complications|questionnaire via telephone
45357631|NCT00956475|Procedure|fatigue assessment and management|questionnaire via telephone
45357632|NCT00956475|Procedure|psychosocial assessment and care|questionnaire via telephone
45357633|NCT00956475|Procedure|quality-of-life assessment|questionnaire via telephone
45357634|NCT00956553|Biological|Cervarix|Three doses of Cervarix at month 0, 1 and 6.
45357635|NCT00956553|Biological|Gardasil|Three doses of Gardasil at month 0, 1 and 6.
45687207|NCT05626803|Drug|Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose|The first 10 sentinel subjects will receive open label high dose of active vaccine. Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets; total dose is 2×10 to the power 11 IU/dose
45687208|NCT05626803|Drug|Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose|50 subjects will receive high dose of active vaccine. Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets; total dose is 2×10 to the power 11 IU/dose
45357636|NCT00953589|Drug|ribavirin|Ribavirin - oral administration Subjects with body weight < 65 kg: 800 mg/day Subjects with body weight 65-85 kg: 1000 mg/day Subjects with body weight 86-105 kg: 1200 mg/day Subjects with body weight > 105 kg: 1400 mg/day
45479172|NCT03331432|Dietary Supplement|Tauroursodeoxycholic acid|Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks.
45479173|NCT03331432|Dietary Supplement|Placebo|Taking daily placebo capsules for 4 weeks.
45479174|NCT03512353|Drug|Dexamethasone|Dexamethasone will be taken orally or by IV infusion at a dose of 20 mg once-daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1-6, and at a dose 40 mg once-daily on days 1, 8, 15 of cycles 7-12.
45479175|NCT03512353|Drug|Carfilzomib|Carfilzomib will be administered at 20 mg/m² on days 1 and 2 of the first cycle. After that, carfilzomib will be administered at 56 mg/m² on days 8, 9, 15, and 16 of the first cycle, and then on days 1, 2, 8, 9, 15, and 16 on each 28-day cycle for the cycles 2 through 6. Starting with cycle 7 through cycle 12, carfilzomib will be administered at 70 mg/m² on days 1, 8, and 15 of each 28-day cycle. All
45479176|NCT04948307|Device|OXD01 digital therapy|OXD01 digital therapy, 1-2 times per week 15-30 minutes each time.
45479177|NCT04948307|Other|Standard of Care|sublingual buprenorphine/naloxone Medication-assisted treatment, the current standard for opioid addiction; the use of medications in combination with counseling
45479178|NCT04959006|Dietary Supplement|Antioxidant supplement|Short term (16d) supplementation of either the antioxidant supplement (Oliphenolia) or placebo. Participants required to consume 2x25ml drinks, one mid-morning, one mid-afternoon between meals.
45479179|NCT04959006|Dietary Supplement|Placebo|Placebo
45479180|NCT03331276|Other|BBN|BBN to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
45479181|NCT03331276|Other|Brand|Brand to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
45479182|NCT02498314|Other|Grade I-II SZ mobilization|Hip grade I-IISZ traction in a resting position is applied using gentle repetitive traction movements during 10 minutes. The mean peak force applied is 2,71N (S.D= 0,94), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
45479183|NCT02498314|Other|Grade II TZ mobilization|Hip grade IITZ traction in a resting position is applied during 10 minutes. The traction force is applied during 45 seconds with 15 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 5.94 N (S.D= 1), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
45479184|NCT02498314|Other|Grade III mobilization|Hip grade III traction in a resting position is applied during 10 minutes. The traction force is applied during 30 seconds with 30 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 7.04 N (S.D= 0.32), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
45479185|NCT01974804|Procedure|MRI|
45479186|NCT01300637|Drug|Metformin|metformin 500 mg/pill; target dose 1500 mg/day for 24 weeks
45479187|NCT01300637|Drug|placebo|identical-appearing pill of placebo
45479188|NCT02493634|Procedure|pressure gradient measurement|A guidewire is used to introduce and position a pressure catheter under magnetic resonance guidance to conduct flow and pressure measurement in the aortic arch to evaluate vascular resistance.
45479189|NCT02493634|Device|MRWire|
46047272|NCT00667498|Drug|Metformin|"The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia."
45357637|NCT04011501|Procedure|Continuous Erector spinae block|Erector spine block and catheter placement will be performed for continuous analgesia prior to the surgical procedure.A initial bolus of 20 ml of Levobupivacaine 0.25% will be administered. Subsequently a 22G catheter will be introduced. At the end of the surgery, an elastomeric pump will be installed at a flow rate of 7 ml / hr with a 1.3% Ropivacaine solution.
45479190|NCT02981940|Drug|Abemaciclib|Abemaciclib capsule
45479191|NCT02981940|Procedure|Surgery|Surgery
45479192|NCT03819257|Diagnostic Test|Endoanal ultrasound|For the assessment of the internal and external anal sphincter integrity. To evaluate fistulas/perianal abscess and seton placement.
45479193|NCT03819257|Diagnostic Test|High-resolution anorectal manometry|"rest - basal anal pressures at rest over 60 s~squeeze - anal pressure during voluntary effort; long squeeze - anal pressure during sustained voluntary effort~cough - anorectal pressure changes during cough~push - anorectal pressure changes during simulated defecation~rectoanal inhibitory reflex - reflex anal response to rectal distension~rectal sensation - assessment of rectal sensitivity to distension."
45479194|NCT03819257|Diagnostic Test|Balloon expulsion test|A non-latex balloon will be inserted in the rectum after applying lubricating gel. This balloon is then filled with 50ml of warm water. The patient is ask to sit on a commode and to try to expel the device in privacy, while the time is being recorded. The test ends when the patient expelled the balloon or when 3 minutes are reach.
45479195|NCT03342820|Procedure|Muscle fatigue|Isokinetic quadriceps muscle fatigue of the paretic lower limb
45479196|NCT04539509|Behavioral|Exercise Prescription|A specific exercise prescription, based on the results of a treadmill test.
45479197|NCT04539509|Behavioral|Treadmill Test|A symptom-limited treadmill test, using the Buffalo Concussion Treadmill Test (BCTT) protocol.
45357638|NCT00947739|Drug|Camptothecin-20-O-Propionate Hydrate (CZ48)|CZ48 will be administered in successive cohorts of 1 patient per participating site until hints of toxicity (grade 2 or worse adverse events related to the drug) are observed. Then cohort of 3+3 patients will be treated. CZ48 will be administered orally daily for 3 weeks followed by a 1 week rest. (1 course = 4 weeks). No pre-medications will be administered. Patients will be asked to drink 2 liters of fluid daily to flush the bladder.
45357639|NCT00956787|Drug|AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)|Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days. In patients with stable disease, treatment may continue for up to a total of 12 courses of therapy; about 1 to 2 years.
45479198|NCT04539509|Device|Monitoring|Activity monitoring using a Fitbit.
45479199|NCT04851522|Drug|Di-Dak-Sol|Topical solution applied externally.
45479200|NCT04851522|Other|White Petrolatum|Topical ointment applied externally
45479201|NCT03331120|Device|ambulatory mirror image functional re-training through wearing 3D adjustable cervicothoracic Posture Corrective Orthotic(CTPCO)|Ambulatory a mirror image functional re-training This way of functional training will deliver via the use of adjustable cervicothoracic orthosis with the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image exercise.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill Based on Harrison et al and Hawes et al., approach, this program will be repeated 3 Times /week for 10 weeks.
45479202|NCT03512275|Drug|Bermekimab Monoclonal Antibody 400 mg|subcutaneous injection
45479203|NCT03809897|Drug|Varenicline|All participants randomized to varenicline will be titrated to the full dose during the first week and continued up to week 12 following standard dosage. This would be independent of time of discharge, so patients will continue the same treatment after discharge up to complete the 12 weeks.
45479204|NCT03809897|Drug|Nicotine patch|Patients randomized to nicotine patch will receive 8 weeks of 21mg patch followed by 2 weeks of 14 mg patch and 2 weeks of 7 mg patch.
45479205|NCT02491918|Procedure|cataract surgery|cataract surgery in children
45479206|NCT02491918|Procedure|Intraocular lens implantation|intraocular lens implantation in the capsular bag or optic capture
45479207|NCT02491996|Behavioral|desire satisfaction-targeted intervention for disordered gamblers|This intervention consists of an initial psychiatric assessment, followed by psychoeducational approach based on desire satisfaction-targeted intervention by psychiatrists, and three group sessions based on CBT by psychologists. Patients with psychiatric comorbidities are treated with the appropriate pharmacological regimens.
45479208|NCT03809195|Behavioral|Clinical Hypnosis|See information in arm/group description. Four different audio recordings are provided electronically, each approximately 20 minutes in length. Participants are encouraged to listen to one daily.
45687209|NCT05626803|Drug|Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose|50 subjects will receive Bivalent GII.4/GI.1 medium dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 5×10 to the power 10 tablets; total dose is 1×10 to the power 11 IU/dose
45687210|NCT05626803|Drug|Placebo|25 subjects will receive matching placebo
46047273|NCT00667498|Drug|Placebo|"The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia."
46047274|NCT02860650|Biological|Ad26.Filo|Ad26.Filo intramuscular (IM) injection at a dose of 9*10^10 viral particles (vp).
46047275|NCT02860650|Biological|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 5*10^8 infectious units (Inf U).
45687211|NCT05619289|Drug|Ergocalciferol|One-time, oral dose of 300,000 IU of Ergocalciferol administered via 6 capsules.
45687212|NCT05619289|Drug|Placebo|One-time, oral dose of 6 inert capsules matched to the active comparator
45687213|NCT05618938|Other|Rocabado's approach|"Group A will be treated with Rocabado's approach. Rocabado' approach will be comprised of six exercises.~Rest position of the tongue~Control of TMJ rotation~Rhythmic stabilization technique~Axial extension of the neck The patients will receive Rocabado's approach consisting 6 repetitions six times a day thrice per week for four weeks"
46047276|NCT02860650|Biological|Ad26.ZEBOV|Ad26.ZEBOV intramuscular (IM) injection at a dose of 5*10^10 vp.
46047277|NCT02860650|Biological|Placebo|IM injection of 0.9 percent saline.
46047278|NCT02860650|Biological|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 1*10^8 Inf U.
45357640|NCT00947817|Other|ULTRASONOGRAPHY trans-esophageal and trans-thoracic , blood test and clinic test|
45357641|NCT00947895|Drug|Methylprednisolone|IV 1000 mg daily for 3 days
45357642|NCT00947895|Drug|ACTH|IM ACTH 80 mg/day for 5 days.
45357643|NCT00947895|Other|IV placebo|IV placebo (saline) daily for 3 days.
45357644|NCT00947895|Other|IM placebo|IM placebo (saline) daily for 5 days.
45357645|NCT00623766|Drug|Ipilimumab|10 mg/kg, administered as an intravenous infusion every 3 weeks during induction and every 12 weeks during maintenance
45357646|NCT00623766|Drug|Corticosteroid: Betamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with betamethasone
45357647|NCT00623766|Drug|Corticosteroid: Dexamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with dexamethasone
45357648|NCT00623766|Drug|Corticosteroid: Fludrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with fludrocortisone
45357649|NCT00623766|Drug|Corticosteroid: Hydrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with hydrocortisone
45357650|NCT00623766|Drug|Corticosteroid: Meprednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with meprednisone
45357651|NCT00623766|Drug|Corticosteroid: Methylprednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with methylprednisolone
45357652|NCT00623766|Drug|Corticosteroid: Prednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisolone
46047279|NCT00660322|Behavioral|Telephone Asthma Program|"The parent will have access to a trained asthma coach for 12 months. The coach will call the parents at mutually convenient times (up to 12 times a year) to work on 4 targeted asthma behaviors:~Using asthma controller medications as prescribed~Having and Asthma Action Plan available to all who may need it.~Using asthma rescue medications with the child's first symptoms.~Having a collaborative relationship with the child's primary care provider that includes asthma check-ups at least twice a year."
46047280|NCT00667966|Drug|Vardenafil (Levitra, BAY 38-9456), 10 mg|10 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
45357653|NCT00623766|Drug|Corticosteroid: Prednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisone
45357654|NCT00623766|Drug|Corticosteroid: Triamcinolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with triamcinolone
45357655|NCT00953901|Drug|Fresh Frozen Plasma Transfusion|
45357656|NCT00832494|Drug|DMXAA in combination with carboplatin and paclitaxel|Administered every 21 days
45357657|NCT00953979|Drug|kunxian capsule|The main element of kunxian capsule is Tripterygium. Patients should take 2 tablets per time and 3 times per day for 12 weeks.
45357658|NCT00832728|Other|Standard of Care|Standard hospital protocol for the treatment of acute liver failure
45357659|NCT00832728|Device|ELAD®|ELAD therapy
45357660|NCT00956865|Other|Voucher|Vouchers given to reimburse transportation
45357661|NCT00956865|Other|Telephone Call|Telephone reminder calls
45357662|NCT00956865|Other|Contact|Contact at senior center to encourage follow up
45357663|NCT00837564|Other|CBASP psychotherapy|specific psychotherapy for chronic depression
46047281|NCT00667966|Drug|Placebo|10/20 mg placebo in sequence in respective arm
46047282|NCT00667966|Drug|Vardenafil (Levitra, BAY 38-9456), 20 mg|20 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
46047283|NCT04283916|Drug|Botulinum Toxins|Botulinum toxin injection to abdominal wall
45357664|NCT00837564|Drug|Escitalopram|Escitalopram 10-20 mg once daily for the treatment of depression in combination with clinical management
45357665|NCT00954135|Drug|letrozolo+cyclophosphamide|Letrozole 2,5 mg/daily + metronomic cyclophosphamide 50 mg/daily for 6 months
45357666|NCT00954135|Drug|letrozolo+sorafenib+cyclophosphamide|"Letrozole (2,5 mg/daily) + metronomic cyclophosphamide (50 mg/daily) + Sorafenib (400 mg/bid/daily) for 6 months"
45357667|NCT00832806|Behavioral|Extended IVR (integrated voice response technology)|See detailed description
45357668|NCT00832806|Drug|Varenicline (Champix)|See detailed description
45357669|NCT00832806|Behavioral|IVR treatment|See detailed description
45357670|NCT00954213|Behavioral|DIR/Floortime parent intervention|Parent will be trained to observe their autistic child's cues, follow their child's lead and techniques to enhance his/her development.
45357671|NCT00832884|Drug|Lacosamide|"0.7 mg/kg (up to maximum of 50 mg) x 5 subjects x 30 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 30 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 30 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 30 minutes.~0.7 mg/kg (up to a maximum of 50 mg) x 5 subjects x 15 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 15 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 15 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 15 minutes"
45357672|NCT00832962|Genetic|Genotyping|Whole blood sample
45357673|NCT00832962|Other|Usual prophylaxis|Prophylactic anti-RhD
45479209|NCT03473197|Drug|Diacerein 1% ointment|During the 3-week Induction Phase, diacerein 1% ointment and vehicle ointment were applied under fully occlusive patch conditions to two randomly assigned skin sites on the infrascapular region of the back twice each week for approximately 24 hours (±4 hours). After patch removal, one application site and an untreated control site was irradiated, and all sites were evaluated 24 hours, 48 hours, and 72 hours later. Following a rest period, during the Challenge Phase, the study products were applied to two naive sites once for approximately 24 hours (±4 hours). After patch removal, one application site and an untreated control site was irradiated, and all sites were evaluated 24 hours, 48 hours, and 72 hours later. A Re-Challenge was to be performed if a response observed during the Challenge Phase indicated photosensitization.
45479210|NCT02493556|Device|LLLT before muscle damage|
45479211|NCT02493556|Device|Placebo LLLT before muscle damage|
45479212|NCT02493556|Device|LLLT after muscle damage|
45479213|NCT02493556|Device|Placebo LLLT after muscle damage|
45357674|NCT00947973|Behavioral|Challenging Horizons Program (CHP) after-school model|Interventions delivered by a counselor 2 days a week as an after-school program. Interventions will strengthen skills in materials organization, homework management, studying, note taking, and socialization.
45357675|NCT00947973|Behavioral|Challenging Horizons Program (CHP) consultation model|Interventions delivered by a mentor (e.g., a teacher or school counselor) as needed, with expert consultation available
45357676|NCT02549118|Drug|Tenoxicam|
45479214|NCT01560299|Drug|Methimazole|Methimazole was stopped 24-48 before radio-iodine therapy
45479215|NCT01560299|Drug|Methimazole|methimazole discontinued 49-72 hours before radioiodine treatment
45479216|NCT01560299|Drug|Methimazole|methimazole discontinued 73-168 hours before radio-iodine treatment
45479217|NCT02491762|Procedure|respiratory function tests|FVC, FEV1, MVV, FRC, RV, TLC, MIP, MEP
45357677|NCT02549118|Drug|Pethidine|
45479218|NCT03511105|Drug|GSK2798745|GSK2798745 will be available as white to slightly colored, round biconvex tablets to be administered via the oral route.
46047284|NCT00911937|Drug|Fesoterodine|Fesoterodine 4mg and 8 mg tablets taken daily.
45687214|NCT05618938|Other|Kraus exercises|"Group B will be treated with Kraus exercises. Kraus exercises will be comprised of eight exercise programs.~Tongue position at rest~Teeth apart: the patient will be educated to maintain the teeth apart can be therapeutic, which facilitates the resting tongue position~Nasal-diaphragmatic breathing~Tongue up and wiggle~Strengthening~Touch and bite: Proprioceptive re-education: Lateral deviation The patients will receive Kraus exercises with the frequency of 2 sets and 10 repetitions twice a day three times per week for four weeks"
45357678|NCT00957177|Drug|Pregabalin|300mg pregabalin orally 1 hour before operation
45357679|NCT00957177|Drug|Placebo|Placebo
45357680|NCT00837642|Diagnostic Test|Transthoracic echocardiography|Full transthoracic echocardiography will be performed.
45479219|NCT03511105|Drug|Placebo|Placebo matching to GSK2798745 will be available as white to slightly colored, round biconvex tablet to be administered via the oral route.
45479220|NCT03511105|Drug|Lipoplysaccharide from Escherichia Coli|LPS will be used as challenge agent. About 4 nanogram per kilogram of LPS will be instilled into the right middle lung segment via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.
45479221|NCT03511105|Drug|Saline|Sterile saline (0.9%) will be used as control challenge. Saline will be instilled into the lingula segment of contralateral side of lung via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.
45479222|NCT03811379|Drug|Toripalimab|Drug: Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
45479223|NCT05433701|Radiation|Stereotactic Body Radiotherapy|"Verify the setup position and respiration of patients as in the simulation CT image.~To precisely align the tumor prior to each treatment, cone-beam CT and gated fluoroscopy using the On-board Imager mounted on the linear accelerator are performed.~The Real-time Position Management system is used to monitor the accuracy of breathing phase during treatment."
46047285|NCT00911937|Drug|Placebo|Placebo sham 4mg and 8 mg tables taken daily.
45357681|NCT00948051|Dietary Supplement|Follow-on formula supplemented with fructo-oligosaccharides|Follow-on formula supplemented with fructo-oligosaccharides
45357682|NCT00948051|Dietary Supplement|Follow-on formula enriched with placebo (maltodextrins)|Follow-on formula enriched with placebo (maltodextrins)
46047286|NCT00663598|Drug|Levitra (Vardenafil, BAY38-9456)|Treatment according to US PI
45357683|NCT04044066|Biological|Plasma biomarker|New emerging plasma biomarkers carrying prognositic information
45357684|NCT00954369|Drug|[F-18]W372|"The individual doses of [F-18]W372 contain a maximum of 20 mCi for normal volunteers and 10 mCi for high probability AD subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
45357685|NCT00828438|Drug|Lorcaserin 10mg|
45357686|NCT00957255|Device|OrthoADAPT|soft tissue augmentation device
45479224|NCT05433701|Procedure|Radiofrequency Ablation|- RFA are performed under local anesthesia or monitored anesthesia care with either a 15-gause or 17-gause internally cooled electrode, depending on the size of the tumor.
45479225|NCT05417711|Device|Transcutaneous Vagus Nerve Stimulation Paired with Tailor-Made Notched Music Therapy|The pulse frequency of vagus nerve stimulation is 25 Hz, the pulse width is 200 US, and the intensity is 1-10 mA. Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. The tVNS and TMNM begin at the same time during treatment.
45479226|NCT05417711|Device|Tailor-made Notched Music Training|Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. At the beginning of TMNMT, 10 seconds sham vagus nerve stimulation is output, whose parameters are as same as experimental group.
45357687|NCT00957255|Procedure|Standard of care|Standard of care rotator cuff repair
45479227|NCT03342742|Behavioral|Weight Loss|Weight loss behavioral intervention via one of two strategies.
45479228|NCT03807869|Procedure|combined glaucoma surgery|phacoemulsification of cataract and I-stent by-pass implantation
45479229|NCT03807323|Behavioral|Lifestyle counselling and exercise|"The program consists of:~Instructor-led training twice a week,~One individual nutritionist counselling session of followed by three group based two-hour nutritionist counselling focusing on practical food purchase and preparation and~Three two-hour psychologist-led group counselling sessions based on implementation intentions theory and practical help to make if-then plans focusing on changing food and activity habits."
45479230|NCT03337828|Other|Alcohol-free beer with regular composition|Subjects are provided with 2 alcohol-free beers with regular carbohydrates composition per day and healthy diet counselling during 10 weeks.
45479231|NCT03337828|Other|Alcohol-free beer with modified composition|Subjects are provided with 2 alcohol-free beers with modified carbohydrates composition per day and healthy diet counselling during 10 weeks.
45479232|NCT03510715|Drug|Alirocumab SAR236553 (REGN727)|"Pharmaceutical form: solution for injection in pre-filled syringe,~Route of administration: subcutaneous (SC)"
45479233|NCT03510715|Drug|Atorvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
45479234|NCT03510715|Drug|Simvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
45479235|NCT03510715|Drug|Fluvastatin|"Pharmaceutical form: capsule,~Route of administration: oral"
45479236|NCT03510715|Drug|Pravastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
45479237|NCT03510715|Drug|Lovastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
45479238|NCT03510715|Drug|Rosuvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
45479239|NCT03510715|Drug|Ezetimibe|"Pharmaceutical form: tablet,~Route of administration: oral"
45479240|NCT03510715|Drug|Cholestyramine|"Pharmaceutical form: oral suspension,~Route of administration: oral"
45479241|NCT03510715|Drug|Nicotinic acid|"Pharmaceutical form: tablet,~Route of administration: oral"
45479242|NCT03510715|Drug|Fenofibrate|"Pharmaceutical form: tablet,~Route of administration: oral"
45479243|NCT03510715|Drug|Omega-3 fatty acids|"Pharmaceutical form: capsule,~Route of administration: oral"
45479244|NCT03815279|Drug|Carfilzomib|Carfilzomib will be administered intravenously three times per cycle (28 day cycles) for cycle 1-12. Thereafter twice per cycle for cycle 13-24
45479245|NCT03815279|Drug|Lenalidomide|Lenalidomide PO once daily on days 1-21 of a 28 day cycle
45479246|NCT03815279|Drug|Dexamethasone|Dexamethasone will be administered weekly
45479247|NCT02498548|Behavioral|Trained SCI Knee or Trained SCI Hip|Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of knee control or hip control, members of this group will be trained at slow to moderate gait speeds.
45479248|NCT03342508|Device|Fetal Pillow|see arm description
45479249|NCT03814733|Drug|Rapastinel|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
45687215|NCT05618691|Drug|GFH312|Oral tablet, GFH312 will be administered at 3 dose levels, each patient in one of three groups will be given a dose of 40mg, 80mg, 120mg of the study drug.
45687216|NCT05618691|Other|Placebo|Placebo will be administered to subjects in the placebo group
45357688|NCT04337580|Drug|Omeprazole 80 mg twice daily|Participants will be treated with omeprazole 80 mg twice daily on Day 0. Within 10 days of starting omeprazole, participants will be treated with standard prostate cancer dosing of every three week docetaxel or cabazitaxel based on package insert. Participants that have only had docetaxel will be retreated with docetaxel along with concurrent omeprazole. Patients that have had both docetaxel and cabazitaxel will be retreated with either cabazitaxel or docetaxel (investigators choice) along with concurrent omeprazole. However investigators encourage investigator to choose cabazitaxel in patients previously treated with cabazitaxel.
45357689|NCT00828594|Drug|RAD001|
45357690|NCT00828594|Drug|RAD001, sorafenib|
45843863|NCT01740414|Drug|Placebo First|This arm of the study participants were first maintained on placebo for approximately 14 days, and were then switched onto 50mg MN-166 BID maintenance. . The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo & MN-166).
45843864|NCT01740726|Behavioral|Behavioral Activation|18 weeks of 1-hour individual therapy focused on increasing rewarding behaviors. Therapy follows Behavioral Activation manual supported through previous research of this therapy for adolescents. BA intervention includes monthly booster sessions offered throughout 6-month follow up.
45843865|NCT01740726|Drug|Fluoxetine|Initial 10mg dose titrated as necessary to 40mg daily; weekly visits for 4 weeks, biweekly visits for next 6 weeks, monthly visits for remaining 8 weeks of active treatment and through 6-month follow up. Therapists will be available between sessions and throughout the follow-up interval to manage clinical concerns or emergencies.
45843866|NCT01741272|Procedure|Sling|Patients will use a sling for 6 weeks as per usual care. No active ROM allowed.
45843867|NCT01741272|Procedure|No sling|Patients may discontinue use of the sling as early as pain and comfort allow. Early active ROM is allowed for activities of daily living.
45843868|NCT01741350|Behavioral|Community-friendly Health Recovery Program|Four weekly HIV risk-reduction groups and routine clinical services (i.e., daily methadone and case management).
45357691|NCT00833118|Procedure|Jaw thrust maneuver (Intubation)|Visualization of Larygnoscopic anatomy during intubation
45357692|NCT00550407|Drug|lamotrigine|lamotrigine 100mg/day or 200mg/day
45687217|NCT05618002|Drug|Lemborexant|For insomnia treatment, each patient ingests Lemborexant or Zopiclone or Clonidine on alternate nights. Each patient uses a special validated sleep diary to collect data.
45687218|NCT05616065|Other|Blinding to academic performance of candidate|Each candidate applying to our program will be interviewed by three core faculty. One of them will be selected, a priori, to be asked not to view a candidate's academic performance (medical school transcripts, standardized test scores). This will not be randomized. Instead, it shall be set up so that each assessor has two blinded candidates to interview each day scheduled. Given that different faculty will be scheduled each day, it may end up that certain faculty will be blinded more than others.
45687219|NCT05616065|Other|Usual Interview methodology|Each candidate applying to our program will be interviewed by three core faculty. Two of them will be selected, a priori, to be asked to interview their candidates as they see fit.
45687220|NCT05615844|Drug|Antibiotic Cement Bead Pouch|The antibiotic bead pouch provides an antibiotic delivery mechanism. It is made by combining polymethyl methacrylate (PMMA) cement with generic forms of vancomycin and tobramycin powder.
45843869|NCT01741350|Behavioral|Time-and-Attention-Matched Control Condition|Four weekly support groups and routine clinical services (i.e., daily methadone and case management).
45843870|NCT02052882|Biological|romiplostim|
45843871|NCT01742208|Drug|Sotagliflozin|Participants received sotagliflozin once daily for 29 days. Pioneer Group participants were to have completed dosing prior to any study drug administration in Expansion Groups.
45357693|NCT00550407|Drug|Placebo|placebo once daily
45843872|NCT01742208|Drug|Placebo|Participants received placebo-matching sotagliflozin tablets once daily for 29 days.
45843873|NCT01742208|Drug|Sotagliflozin|Participants received sotagliflozin once daily for 29 days; pioneer participants completed dosing prior to dosing any other study participants.
45357694|NCT00837798|Device|CRM Device|Pacemaker, ICD, or CRT device
45357695|NCT02548884|Procedure|Biliary cannulation|
45357696|NCT02547558|Procedure|Arterial blood gases|Measured through radial arterial catheter
45357697|NCT02547558|Procedure|Cardiac Output|Measured through bioimpedance: FloTrac pressure transducer (FloTrac sensor; Edwards Lifesciences) using the third-generation (3.01) FloTrac software for continuous CO display.
45357698|NCT02547558|Procedure|Vital signs|As measured in clinical practice
45843874|NCT01742364|Device|Bioject ID Pen|Participants in this arm will receive a standard dose of BCG via the Bioject ID needle-free jet injector device (investigational administration technique).
45843875|NCT01742364|Device|Needle and syringe|Participants in this arm will receive a standard dose of BCG via syringe and needle by the Mantoux technique (standard of care administration technique).
45843876|NCT01744704|Drug|rhNGF 0.5 µg/mL Sentinel|In Part 0, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration in the study eye (right or left) according to the randomisation list to achieve the required dose level
45843877|NCT01744704|Drug|rhNGF 5 µg/mL Sentinel|Part 0 represented a sentinel group.
45843878|NCT01744704|Drug|rhNGF 20 µg/mL Sentinel|In Part 0, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration in the study eye (right or left) according to the randomisation list to achieve the required dose level
45357699|NCT02547558|Procedure|Exhaled breath|Were recorded using a pneumotachograph (CPX/D; Med Graphics, St. Paul, MN, U.S.A.).
45357700|NCT02547558|Procedure|Spirometry|In a daily calibrated spirometer.
45357701|NCT02547558|Drug|Indacaterol|Indacaterol Breezhaler@ 300 mcg (1 inhalation)
45357702|NCT00948207|Behavioral|My Living Story|"Components include:~1. Life Review Interview by phone (questions based on Chochinov, 2002 dignity enhancing interview);~2) Edited transcript is delivered in a word format on...;~3) miLivingStory, a personal social network, where participants can manage content, design and layer; invite and manage their fiends and family.~4) miStory, a life review education website and portal to websites for: cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks."
45479250|NCT03814733|Drug|Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
45843879|NCT01744704|Drug|rhNGF 20 µg/mL Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
45357703|NCT00948207|Behavioral|My Own Resources|"miOwnResources is a personalized, password-protected web portal to high quality websites that provide cancer information, cancer research databases for do your own research, social support, and interactive planning tools. miOwnResources also has a page for participants to add their own weblinks."
45357704|NCT00957411|Biological|cetuximab|Given IV
45357705|NCT00957411|Drug|cisplatin|Given IV
45357706|NCT00837954|Device|Lyostypt® AND Surgicel®|"The investigational products are the hemostats Lyostypt® and Surgicel® (=Tabotamp® ). Lyostypt® will be provided in the size 5cm x 8cm, Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
45357707|NCT00837954|Device|Lyostypt®|"The investigational product is the hemostat Lyostypt®. Lyostypt® will be provided in the size 5cm x 8cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII."
46047287|NCT04155736|Behavioral|Renew|Renew is a behavioral health self-management app/too that focuses on three core activities: 1) in vivo exposure (to help participants approach safe situations they have been avoiding that they want to feel comfortable in), 2) expressive writing (to help participants emotionally process trauma memories), and 3) Self-Care exercises (designed to promote behavioral activation, social connectedness and relaxation; includes a breathing relaxation tool). Users have access to psychoeducation via a whiteboard video and short texts as well as Motivation content (quotes, videos, images, and songs) related to confronting challenges and overcoming fears. For each exercise that is completed, the user earns points that are connected to levels and visually reinforcing images (i.e., a growing tree).
46047288|NCT04281264|Behavioral|Passive Hypoxia|During 30 minutes of session, the participants will perform an intellectual activity while they will be exposed to normobaric hypoxic conditions in a hypoxic chamber (CAT 310, Lousiville, Colorado). They will inspire oxygen fraction (FiO2) set to 16.1% (0.16)
46047289|NCT04281264|Behavioral|Normoxia Circuit Training with Elastic Bands|"Each training sessions will consist of a circuit training with elastic bands, where different muscle groups will be involved (pectoral, shoulders, back, arms, thighs, legs and abdominals). Duration of the session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles at the end of the sessions. Main section of the sessions will be a circuit that will be composed by 3 sets of 12-15 repetitions of nine different exercises.~Subjects will inspire FiO2 of 21.0% (0.21)"
45357708|NCT00837954|Procedure|Surgicel®|"The investigational product is the hemostat Surgicel® (=Tabotamp® ). Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
45357709|NCT00948285|Procedure|MRI|magnetic resonance imaging (MRI)
45357710|NCT00954525|Drug|Gemcitabine and Erlotinib|Gemcitabine (dose according to study protocol), Erlotinib (100 mg/day)
45479251|NCT03814733|Drug|Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
45479252|NCT03814733|Drug|Rapastinel Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
45687221|NCT05615844|Device|Negative Pressure Wound Therapy|Standard application of negative pressure wound therapy
45687222|NCT05612139|Device|JTIN implantation surgery|The JTIN is a self-extending intramedullary nail (telescopic rod) designed to provide fixation of femoral and/or tibial fractures, osteotomies, malunions and non-unions. The design of the JTIN includes a female and a male component, which are anchored to the proximal cortex and distal epiphysis through screw-type fixation. These two components slide from each other, allowing for extension of the JTIN as the bone structures remodel and patient growth occurs.
45687223|NCT05608824|Device|Shear wave elastography and microvascular flow imaging.|Subjects will undergo serial SWE and MFI imaging throughout their rehabilitation episode of care to assess changes over time, status in rehabilitation and comparison to the contralateral extremity.
45687224|NCT05608421|Behavioral|1MoreStep|Cognitive behavioral intervention to reduce HIV and IPV stigma.
45687225|NCT05608421|Behavioral|1MoreStepControl|This is an equal attention control group.
45479253|NCT03814733|Drug|Alprazolam Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
45479254|NCT03814733|Drug|Ketamine Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
46047290|NCT04281264|Behavioral|Hypoxia Circuit Training with Elastic Bands|"Each training sessions will consist of a circuit training with elastic bands, where different muscle groups will be involved (pectoral, shoulders, back, arms, thighs, legs and abdominals). Duration of the session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles at the end of the sessions. Main section of the sessions will be a circuit that will be composed by 3 sets of 12-15 repetitions of nine different exercises.~Subjects will inspire FiO2 of 21.0% (0.21)"
45357711|NCT00954525|Dietary Supplement|Intravenous Vitamin C|50 grams, 75 grams, or 100 grams of intravenous vitamin C, three times per week for 8 weeks.
45357712|NCT00833274|Behavioral|computerized test|Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
45357713|NCT00833352|Device|CRT-D Therapy|Implant of a defibrillator with cardiac resynchronization therapy to detect and terminate ventricular arrhythmias and resynchronize ventricles.
45357714|NCT00838032|Drug|Quetiapine fumarate|Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
45479255|NCT03721627|Drug|Ledipasvir/Sofosbuvir|Direct acting anti HCV drugs
45479256|NCT02498158|Device|MRI scans|"20 subject (10 tolerant and 10 intolerant to heat) will undergo MRI scans (GE healthcare manufacturer) as follows:~anatomical scan according to standard protocol~functional scan according to the standard protocol of rest-state fMRI.~scans of 10 healthy subjects will be taken from existing scans at the imaging department."
45357715|NCT00838032|Drug|Haloperidol|Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
45357716|NCT00954603|Drug|quetiapine|25-100 mg
45357717|NCT00954603|Drug|haloperidol|0.5-2 mg
45357718|NCT00531934|Drug|Doxycline|100mg po daily
45357719|NCT00531934|Drug|erlotinib [Tarceva]|150mg po daily
45357720|NCT02548806|Drug|Clonidine MBT 50µg|Clonidine MBT 50µg, single dose
45357721|NCT02548806|Drug|Clonidine MBT 100µg|Clonidine MBT 100µg, single dose
45357722|NCT02548806|Drug|Catapres 100μg|Catapres tablet 100μg, single dose
45479257|NCT03806855|Diagnostic Test|Bladder diary|3-day bladder diary
45479258|NCT02498080|Procedure|DEB PTA|paclitaxel drug eluting balloon PTA
45479259|NCT02498080|Procedure|Standard PTA|Standard PTA
45357723|NCT00828828|Biological|Influenza Vaccine|One 0.5 ml dose of influenza vaccine injected intramuscular.
45357724|NCT00833508|Other|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing involves cycling on an exercise bicycle whilst oxygen consumption and carbon dioxide generation are measured from expired gases. This is used to calculate patient fitness from their peak oxygen consumption and their anaerobic threshold.
45357725|NCT00549939|Drug|Alfuzosin|"Form: solution or tablet according to age~Route: oral~Dose: daily dose adjusted to body weight"
45479260|NCT03508843|Behavioral|interactive virtual presence|installing the car seat with advice via interactive virtual presence
45479261|NCT03811223|Drug|Evolocumab Auto-Injector [Repatha]|Evolocumab 140 mg every 2 weeks for 12 weeks
45479262|NCT03811223|Drug|Placebos|Placebo subcutaneous injection every 2 weeks for 12 weeks
45479263|NCT04915391|Diagnostic Test|Skin biopsy and blood sample for inflammation markers, RNA and proteins|A skin biopsy will be performed at the baseline visit from which primary cell cultures of fibroblasts and keratinocytes will be obtained. Four to six weeks later a second biopsy on the scar will be performed and analyzed anatomically and pathologically. In addition, at the initial visit, blood samples will be drawn for analysis of inflammation markers, RNA and proteins.
45479264|NCT03508609|Biological|CLBS16|GCSF-mobilized autologous CD34 cells
45479265|NCT03639337|Dietary Supplement|Multi-strain probiotic|30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63
45357726|NCT00549939|Drug|Placebo|"Form: matching solution or matching tablet according to age~Route: oral~Dose: daily dose adjusted to body weight"
45357727|NCT02154412|Other|Respiratory Training|Assembled together using a T-shaped connector, a threshold Positive Expiratory Pressure Device (Respironics, Inc.) & an Inspiratory Muscle Trainer (IMT, Respironics Inc.) with mouthpiece will be used. During inhalation, the subjects will initiate each breath from residual volume (RV) and to sustain the effort until their lungs feel full. During exhalation, the subjects will breathe from total lung capacity and sustain their effort until their lungs feel empty. Participants will be asked to train 45 minutes per day, 5 days per week, for 4 weeks. The training will be initiated with a load equal to 20% of their individual PImax and PEmax with progressive increases as tolerated up to 40% of their baseline PImax or PEmax.
45357728|NCT00838188|Other|Way of Feeding - Breast feeding vs. Bottle feeding|Each infant was evaluated twice, once after breastfeeding and once after bottle feeding of breast. Computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
45357729|NCT00833742|Behavioral|Intensive Short-term Dynamic Psychotherapy|A brief psychotherapy format
45357730|NCT04580368|Drug|CFTR Modulators|Participants with rare mutations will receive active therapy in N-of-1 design with participants serving as their own control
45357731|NCT00833820|Procedure|Real rTMS of the brain|Repetitive transcranial magnetic stimulation will be performed using a focal coil held over motor cortex on each hemisphere. Stimulation protocol used will be the cTBS in which three pulses of stimulation are given at 50 Hz, repeated every 200 ms for a total of 300 pulses delivered over the right motor cortex. The stimulus intensity will be set at 80% of Action Motor Threshold.
45357732|NCT00833820|Procedure|Sham rTMS of the brain|Sham repetitive transcranial magnetic stimulation will be performed using the same stimulator connected to the placebo butterfly coil MCF-P-B-65 which has no stimulating effect on the cortex but produces similar auditory and tactile sensations as the active coil. The site of stimulation and the number of stimuli will be identical to those used for the active magnetic rTMS.
45357733|NCT00272779|Drug|ATV|300mg Oral capsules for 96 weeks
45357734|NCT00272779|Drug|RTV|100mg Oral Capsules for 96 weeks
45357735|NCT00272779|Drug|Tenofovi-Emtricitabine (TDF/FTC) tablet|One tablet with 300 mg - 200 mg once a day for 96 weeks.
45479266|NCT03508193|Other|Nutritional therapy|Whole-foods based smoothie designed to emulate formulas used in EEN
45479267|NCT03723031|Drug|Misoprostol|400 microgram (2 tablets) misoprostol ( cytotec, Pfizer, G.D. Searle LLC) inserted rectally (before CS) in rectal group or intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta in intrauterine group.
45479268|NCT03811067|Procedure|Transversus abdominis plane block|Transversus abdominis plane block will be performed bilaterally after the surgery.
45479269|NCT03811067|Procedure|Rectus sheath block|Rectus sheath block will be performed bilaterally after the surgery.
45479270|NCT03722875|Drug|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
45357736|NCT00272779|Drug|LPV|400 mg (3 133mg capsules) BID for 96 weeks
45357737|NCT04036006|Behavioral|Group-Based Program|The Group-based Program uses an ecologically valid setting in which participants exercise, prepare foods, and eat together to facilitate the emergence of old habits and replace them with healthy alternatives. The intervention team consists of a health psychologist, registered dietitian, and health coach. They co-facilitate group meetings for 15 participants that are held weekly for 3 months, bi-weekly for 3 months, and then monthly in participant-led maintenance meetings. Each session includes: weigh-in and physical activity (20 min), cooking demonstration (20 min), and a shared vegetable dish with discussion (50 min). The maintenance phase (months 7 to 24 post randomization) consists of support and health-related topics of the participants' own choosing. Progress reports with lab results are sent to participants and primary care physicians.
45357738|NCT04036006|Behavioral|Self-Directed Program|The Self-Directed lifestyle program represents enhanced usual care based upon what is currently offered in primary care in the United States for lifestyle treatments for adults with metabolic syndrome. Usual care is enhanced by: 1) lifestyle education for management of metabolic syndrome provided in evidence-based tip sheets from nationally recognized organizations; 2) provision of a Fitbit for self-monitoring physical activity; 3) access to a website containing all education materials; and 4) progress report letters with lab results sent to participants and primary care physicians after completion of each assessment.
45357739|NCT04011423|Other|Unstable shoes plus Whole-body vibration|Wearing unstable shoes during the whole-body vibration training
45357740|NCT04011423|Other|Stable shoes plus Whole-body vibration|Wearing stable shoes during the whole-body vibration training
45357741|NCT00828906|Drug|DuoTrav|DuoTrav Eye Drops
45357742|NCT00948363|Other|Kiwi fruits|Daily intake of 3 kiwi fruits for 8 weeks
45357743|NCT00948363|Other|Apple|Daily intake of 1 apple (equivalent in energy) for 8 weeks
45357744|NCT00829062|Device|Continuous glucose glucose sensor- physician ordered|Charts will be reviewed to identify recipients of Missouri Medicaid who receive daily injections to manage their diabetes. Children who have submitted an application for the Medtronic MiniMed insulin pump will be identified by the PI and Medtronic Diabetes. They will be asked to wear a 72 hour continuous glucose monitor. The children who wear the sensor will be asked to keep a daily logbook of their blood sugars, activities, food intake, and insulin doses during this 72 hour period. The families of the children will be provided with a pre-addressed FedEx envelope for them to return the digital recorder and daily logbooks to the PI. The results of the glucose sensor will be downloaded by the PI. The families will be contacted by the PI with the results and treatment recommendations.
45357745|NCT03850704|Drug|Selinexor|
45357746|NCT00957879|Dietary Supplement|Ergocalciferol|Ergocalciferol 50000 international units by mouth weekly for 12 weeks
45357747|NCT00957879|Dietary Supplement|Calcitriol|Calcitriol 0.5 mcg by mouth daily for 12 weeks
45357748|NCT00838266|Drug|mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)|Antiplaque mouthrinse containing active component three times a day, during 1 minute, for 4 days
45357749|NCT00838266|Other|mouthrinse containing non-active component|Antiplaque mouthrinse containing non-active component three times a day, during 1 minute, for 4 days
45357750|NCT00834054|Procedure|Double-lung transplantation|Double-lung transplanted patients
45357751|NCT00838344|Other|Medication Adherence Program (MAP)|Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
45357752|NCT04011033|Biological|iNKT cells|5×10^8-10^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 8th and 12th week.
45357753|NCT04011033|Drug|Cyclophosphamide|CTX will be administered intravenously at a dose of 750mg/m2 2 days before the first iNKT cells infusion.
45357754|NCT04011033|Drug|Human recombinated Interleukin-2|IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days after iNKT cells infusion.
45357755|NCT04011033|Procedure|TACE|TACE will be conducted to all patients at 0th week and 4th week.
45357756|NCT00829140|Drug|Placebo|
45357757|NCT00829140|Drug|Lorcaserin 10mg BID|
45357758|NCT00998608|Drug|risperidone|risperidone 4mg/d
45357759|NCT02547324|Radiation|Slump sitting|Patients are asked to sit slumped on the chair as much as possible without leaning forwards, and place you hands below your thighs.
45357760|NCT02547324|Radiation|Forward bending|Patients are asked to stand with both feet placed together, hands behind their heads, and bend forward in this position as much as possible without falling
45357761|NCT04011813|Other|Hypotaurine : antioxidant and osmoregulator|"Hypotaurine has protective effects on sperm motility, capacitation and acrosome reaction and reduces apoptotic markers.~Hypotaurine (50mM) was added in density gradient centrifugation, washing and cryopreservation media washing and cryopreservation media before spermatozoa freezing"
45357762|NCT00998686|Drug|dutogliptin|400 mg
45357763|NCT00998686|Drug|sitagliptin|100 mg
45357764|NCT00829218|Other|Glutamate additive-free diet|All subjects will follow a diet for one month where all foods containing the additive glutamate have been removed. At the end of the one month diet, subjects who have responded positively to the diet will go onto the challenge arms of the study, where they will be randomized to receive placebo (mixed juice alone) for three days on one week, and 5 grams of glutamate in the mixed juice for three days on the other week.
45357765|NCT00829218|Other|Placebo diet|Juice with nothing added.
45479271|NCT03722875|Drug|apatinib|Apatinib is a selective VEGFR2 inhibitor
45479272|NCT03054350|Drug|Vadadustat|Daily oral dose
45479273|NCT03054350|Drug|Placebo|Daily oral dose
45479274|NCT04867733|Other|Micropatch (microneedle patch)|Each micropatch contains an array of 50 microneedles.
45479275|NCT04860713|Drug|aspirin and ketamine|Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin
45479276|NCT04860713|Drug|Nurtec (Rimegepant)|Drug: 75 mg of ODT
45479277|NCT03528577|Drug|Zero-dose|Treatment A
45479278|NCT03528577|Drug|90 mcg of PROAIR® HFA|Treatment B
45479279|NCT03528577|Drug|180 mcg of 90 mcg of PROAIR® HFA|Treatment C
45479280|NCT03528577|Drug|90 mcg of albuterol sulfate inhalation aerosol|Treatment D
45479281|NCT03796715|Diagnostic Test|Red Cell Distribution Width (RDW)|A total of 100 sepsis patients, Red Cell Distribution Width (RDW) was used as prognostic marker.
45357766|NCT00948519|Device|Laser + ICG|ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments
45357767|NCT00948519|Device|Laser only|same only without ICG
45357768|NCT00958269|Drug|dutogliptin|100 mg QD
45357769|NCT00958269|Drug|dutogliptin|200 mg QD
45479282|NCT03796715|Diagnostic Test|Presepsin (sCD14-ST)|: A total of 100 sepsis patients, Presepsin (sCD14-ST) was used as prognostic marker.
45479283|NCT03722719|Other|the Knack|The Knack consists of voluntary PFM contractions before and during activities that increase abdominal pressure. Such contraction elevates the pelvic floor cranially, with consequent closure of the urethra, vagina and rectum, stabilization of the pelvic floor and avoidance of urine leakage.
45479284|NCT03722719|Other|PFMT|The rationale underlying intensive PFM strength training is that it might develop the structural support of the pelvis by raising the levator plate to a permanent, higher position within the pelvis and promoting PFM and connective tissue hypertrophy and stiffness. These conditions facilitate automatic and more efficacious activation of motor units (neural adaptation), which impedes descent during activities that increase abdominal pressure.
45479285|NCT03722719|Other|The Knack + PFMT|These participants will perform the exercises described for both the Knack and PFMT groups at the outpatient clinic and at home.
45479286|NCT03626948|Drug|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (52 weeks), with individual dose adjustment.
45479287|NCT01303289|Dietary Supplement|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
45479288|NCT01303289|Dietary Supplement|Jevity|JEVITY is a diet for tube-fed patients in the medium to long term, to varying degrees of malnutrition with gastrointestinal disorders.
45479289|NCT05281055|Procedure|Endovascular thrombectomy|Timely thrombectomy for acute ischemic stroke patients with large vessel occlusion by either stent retriever, thrombosuction, others, or combination methods.
45479290|NCT05452226|Device|neuromuscular electrical stimulation (NMES)|Electrical stimulation will be applied using two adhesive pads affixed to the front of both of the thighs. The intensity will be progressively increased to a level that provokes a strong contraction. The stimulation intensity will be increased until the stimulation is uncomfortable, but does not hurt. Care will be taken to make sure that the level of stimulation will be adjusted such that the intensity does not cause pain. Contractions will last 10 seconds, with 30 seconds of rest between. NMES will occur 6 days per week for 60 minutes per day. Patients will self-administer NMES 6 days per week after discharge for up to 6 weeks.
45479291|NCT03810989|Device|infra-red sauna|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna of 15 minutes duration separated by ten minutes rest outside the sauna.
45479292|NCT03810989|Device|argometer and treadmill|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of physical exercise (by treadmill and argometer) of 20-30 minutes duration separated by 10 minutes rest.
45479293|NCT03810989|Device|combination of sauna and hot bath|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna as the first group then the patients will be immersed up to neck for one hour in water at 37-43 C.
45479294|NCT05432414|Drug|pomalidomide|Pomalidomide was administered orally at a dose of 4 mg on days 1-14 of each cycle.
45357770|NCT00958269|Drug|placebo|
45357771|NCT00958269|Drug|sitagliptin|25 mg QD
45357772|NCT00958269|Drug|sitagliptin|50 mg QD
45479295|NCT05432414|Drug|Bortezomib|Bortezomib was administered intravenously or subcutaneously at a dose of 1.3mg/m2 on days 1, 4, 8, 11 of each cycle.
45479296|NCT05432414|Drug|Dexamethasone|Dexamethasone was administered orally at a dose of 20mg on days the same and next day of bortezomib administration.
45687226|NCT05608044|Drug|Botensilimab|An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
45687227|NCT05608044|Drug|Balstilimab|An anti-programmed death (ligand) 1 [PD-(L)1] monoclonal antibody.
45357773|NCT02547402|Drug|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
45357774|NCT02547402|Drug|pravastatin|It is statin medicine used to lower cholesterol and triglycerides in the blood.
46047291|NCT04281264|Behavioral|Normoxia Vibration|"The subjects will perform dynamic and static vibration exercise provide by a commercially available device (Galileo 2000, Novotec GmbH, Pforzheim, Alemania). The duration of the WBV session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles.~Repetitions of 30 seconds with a frequency of 18.5 Hz will be performed. The rest interval will be 60 seconds between 4 repetitions during weeks 1-12 and 45 seconds between 5 repetitions during weeks 12-24. The vertical amplitude of WBV was set at 2.5 mm. Four stance will be performed on platform.~Subjects will inspire FiO2 of 21.0% (0.21)"
46047292|NCT04281264|Behavioral|Hypoxia Vibration|"The subjects will perform dynamic and static vibration exercise provide by a commercially available device (Galileo 2000, Novotec GmbH, Pforzheim, Alemania). The duration of the WBV session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles.~Repetitions of 30 seconds with a frequency of 18.5 Hz will be performed. The rest interval will be 60 seconds between 4 repetitions during weeks 1-12 and 45 seconds between 5 repetitions during weeks 12-24. The vertical amplitude of WBV was set at 2.5 mm. Four stance will be performance on the platform.~Participants will inspire a fraction of inspired oxygen (FiO2) of 16.1% (0.16)"
45357775|NCT02547402|Drug|Vytorin® (combination of simvastatin and ezetimibe)|It lowers bad cholesterol in the blood, and raises good cholesterol
45357776|NCT01068925|Drug|GSK1349572|"GSK1349572 QD x 5 days~TPV/RTV 500/200mg BID x 7 days~GSK1349572 50mg QD and TPV/RTV 500/200mg BID x 5 days"
45843880|NCT01744704|Drug|rhNGF 60 µg/mL Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
45357777|NCT00511810|Drug|Low Dose Fish Oil|Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)
45357778|NCT00511810|Drug|High Dose Fish Oil|Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
45357779|NCT00834600|Drug|olmesartan, hydrochlorothiazide, amlodipine|hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP >140 mmHg
45357780|NCT00834600|Drug|hydrochlorothiazide (HCTZ) or olmesartan|HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure >140/90 mmHg at 6 weeks, amlodipine 5 mg may be added
45357781|NCT00958425|Device|Hyaluronic acid gel|Hyaluronic acid gel (20 mg/mL), 0.9 mL, intradermal over 2 cm area, once
45357782|NCT00958425|Device|Saline|Normal saline, 0.9 mL, intradermal over 2 cm area, once
45479297|NCT03796403|Other|Diclofenac|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
45357783|NCT02547480|Device|TACE with irinotecan loaded LifePearl|Arterial embolization will be performed through lobar infusion and using a microcatheter. LifePearl microspheres of 200 µm will be used as preferred beads. They will be loaded with the appropriate dose of irinotecan hydrochloride injectable solution, mixed with the contrast media and distributed to the targeted lobe. The targeted dose is 100 mg of irinotecan per lobe treated, meaning that when treated unilobarly at baseline the total dose received will be 100 mg ( all in one lobe) and in during bilobar treatment, 200 mg in both lobes.
45357784|NCT00291499|Drug|Chondroitin 4&6 sulfate (Condrosulf)|800 mg/day for 6 months
45357785|NCT00291499|Other|Placebo|800 mg placebo/day for 6 months
45357786|NCT00838500|Drug|Immediate spa treatment|1st year, soon after randomization: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
46047293|NCT00663754|Behavioral|Dissonance-based eating disorder prevention program|Participants will engage in verbal, written, and behavioral exercises in which they will critique the thin ideal. These exercises will be conducted in sessions and in homework activities. The exercises will aim to increase body image satisfaction by helping participants to think critically about the thin ideal and to discuss some of the problems associated with the pursuit of this ideal.
45357787|NCT00838500|Drug|Late spa treatment|2nd year, soon after 12 months visit: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
45357788|NCT00838656|Drug|carboplatin|Given IV in one of two schedules
45357789|NCT00838656|Drug|gemcitabine hydrochloride|Given IV in one of two schedules
45357790|NCT00838656|Drug|paclitaxel|Given IV in one of two schedules
45357791|NCT03964636|Diagnostic Test|OCT-A (optical coherence tomography)|Included patients will have an OCT-A and will be questioned about their medical and ophthalmologic history, and their oestro-progestative contraceptive intake.
45357792|NCT03998098|Diagnostic Test|Oxygen Saturation (Oximetry)|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
46047294|NCT00663754|Behavioral|Educational brochure|Participants will receive a mailed educational brochure about a healthy body image only.
45357793|NCT03998098|Diagnostic Test|Heart Rate (Pulse)|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
45357794|NCT03998098|Diagnostic Test|Respiratory Rate|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
45479298|NCT03627182|Drug|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
45479299|NCT03627182|Drug|Placebo|"Placebo, orally, 1 tablet once a day for 24weeks with D150 and D745.~CKD-501 placebo will be changed to CKD-501 from extension stydy to EOS(end of study)."
45479300|NCT01302977|Procedure|Fetal tracheal occlusion|Insertion of a detachable balloon inside fetal trachea by percutaneous fetoscopy
45687228|NCT05608044|Drug|Standard of Care|Regorafenib or trifluridine and tipiracil.
46047295|NCT00660478|Device|Endeavor|Comparison of two different drug eluting coronary stents
46047296|NCT00660478|Device|Cypher Select|Comparison of two different drug eluting coronary stents
46047297|NCT02859714|Other|screening data|
46047298|NCT04168437|Other|Health-Related Quality of Life Report|Two page report and interpretation guide based on SPADE cluster scores
46047299|NCT03678129|Drug|AZD7325_10|Single oral dose (10mg)
46047300|NCT03678129|Drug|AZD7325_20|Single oral dose (20mg)
45479301|NCT05419232|Other|Short Message Service (SMS) + Website Link Strategy|The intervention we are evaluating is the effectiveness of a participant receiving a SMS + Website Link as a vaccine uptake strategy
45479302|NCT05419232|Other|Phone Call with Peer Strategy|The intervention we are evaluating is the effectiveness of a participant having a phone call with a peer as a vaccine uptake strategy
45357795|NCT03998098|Diagnostic Test|Blood Pressure|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers For participants only participating in the Blood Pressure Arm of the trial, they will not be required to enter the normobaric chamber but will have their blood pressure readings taken in the ambient environment including lying supine in order to generate hypotensive readings."
45479303|NCT03810833|Device|Brilliance device sensor|Two separate sensors will be attached via standard, single-use adhesive pads to the left and right pectoralis major on each participant.
45479304|NCT05415800|Behavioral|Quality Improvement Practice Facilitation Intervention|"The practice facilitation intervention (implementation strategy package) consists of QI projects designed for primary care providers with external practice facilitation and technical support provided by a QI Coach and Data Coach on our team.~The QI projects focus on the implementation of cancer prevention and early detection guidelines in primary care settings, specifically one QI project for each of the following clinical guidelines: colorectal cancer screening, lung cancer screening, and tobacco treatment. The study participants are the healthcare providers and staff, not the patients, since the goal of the practice facilitation intervention (implementation strategy package) is to improve the implementation of existing standard of care."
45357796|NCT00829608|Biological|Human Papillomavirus Vaccine|0.5 mL of quadrivalent HPV vaccine will be given intramuscularly at three separate intervals. Dose 2 is given 2 weeks after dose 1 and dose 3 is given 4 weeks after dose 1 for a total of 3 doses over 2 months.
45357797|NCT00838812|Drug|application of the topic gel|Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.
45357798|NCT00553605|Drug|Ketoprofen 100mg|Ketoprofen 100 mg diluted in 100 ml of normal sodium chloride solution into the established patient's IV line by slow injection in a 20-minute period; and IV dose of 2 ml of normal sodium chloride solution as placebo for Parecoxib by bolus injection
46047301|NCT03678129|Drug|Placebo|Single oral dose placebo (capsule)
45357799|NCT00553605|Drug|Parecoxib 40mg|Parecoxib 40 mg diluted in 2 ml of normal sodium chloride solution administered by bolus injection; and an IV dose of 100 ml of normal sodium chloride solution as placebo for ketoprofen administered in a in a 20-minute period
45357800|NCT02547246|Device|rTMS session|One session of rTMS at a frequency of 10 Hz during 20 minutes
45479305|NCT00706654|Drug|Aripiprazole depot 300 or 400 mg|Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
45479306|NCT00706654|Drug|Aripiprazole 10-30 mg orally|Aripiprazole was supplied as 10, 15, and 20 mg tablets. The dose that the patient received was based on the investigator's judgment and the subject's clinical need.
45479307|NCT00706654|Drug|Aripiprazole depot 25 or 50 mg|Aripiprazole depot was supplied in 200 mg lyophilized vials. Patients received aripiprazole 25 mg if they were unable to tolerate aripiprazole 50 mg.
45357801|NCT02547246|Device|rTMS Placebo (SHAM)|One session of placebo (SHAM) rTMS during 20 minutes
45479308|NCT00706654|Drug|Placebo depot|Placebo depot was supplied in lyophilized vials.
45357802|NCT00838968|Drug|interferon-alpha|interferon-alpha is intramuscularly or subcutaneously injected at 3,000,000-5,000,000 U three times a week for 18 months
45479309|NCT00706654|Drug|Placebo tablets|Placebo tablets were identical in appearance to the aripiprazole tablets.
45479310|NCT03811145|Biological|Tendoncel|Platelet lysate gel
45479311|NCT03811145|Other|Placebo control gel|Placebo control gel
45479312|NCT03471871|Drug|Placebo|HV: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off).
46047302|NCT04166877|Drug|Magnesium Sulfate in Parenteral Dosage Form|IV bolus followed by continuous infusion for 24 hours
46047303|NCT04166877|Drug|Normal saline placebo|IV bolus followed by continuous infusion for 24 hours
45357803|NCT00829842|Other|oral hygiene|oral hygiene with 0.12% chlorexidine
45357804|NCT00829842|Other|placebo|oral hygiene placebo
45357805|NCT00954759|Procedure|Chiropractic treatment|
45357806|NCT00954759|Procedure|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.
46047304|NCT02860572|Other|follow-up without intervention|
46047305|NCT02860572|Other|fluid bolus|
46047306|NCT04161417|Other|Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling|Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling. This will enable patient enrolment into a currently available PRIMUS study
45479313|NCT03471871|Drug|Lemborexant 10 mg|HV: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
45479314|NCT03471871|Drug|Lemborexant 25 mg|HV: 25 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
45479315|NCT03471871|Drug|Placebo|OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
45479316|NCT03471871|Drug|Lemborexant 10 mg|OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
45357807|NCT02548182|Device|smartcare|Fit.life™ wireless physical activity tracker can measure daily physical activity including activity strength and time. It was chosen for its small size, accuracy in the measurement of physical activity, and convenient data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer. Fit.life™ wireless physical activity tracker has been validated for measurement of free-living physical activity in adults [REF]. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group. The version for the latter group included the feature for the monitoring and feedback of financial incentives.
45357808|NCT02548182|Other|financial incentives|Financial incentives are provided in the form of process-based and outcome-based incentive.(maximum 320,000KRW) Process-based incentives were based on daily physical activity level. Participants in the 'smart care plus financial incentive' arms could earn incentives of up to 10,000 KRW per week according to the following schedule: 1,000 KRW if a participant reached target amount of physical activity in a day / An additional 3,000 KRW if a participant reached target amount of physical activity every day in a week. Outcome-based incentives were based on achievement of weight loss target at each visit. 50,000 KRW if a participant reached weight loss target of 3% from the baseline body weight at visit 2 (4 week)/ 50,000 KRW in weight loss target of 5% from the baseline body weight at visit 3 (8 week) / 100,000 KRW in weight loss target of 7% from the baseline body weight at final visit 4 (12 week)
45479317|NCT04354922|Behavioral|Exercise intervention|Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly. All walking exercise session will be performed on motor-driven treadmill. Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs). Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs). Warm-up and cool-down will be provided before and after the training. Participants who failed to achieve 80% attendance will be excluded from the study. All exercise sessions were supervised by qualified athletic coach.
46047307|NCT04283838|Behavioral|Humanistic Care|Psychological and physical rehabilitation based humanistic care regimen
45357809|NCT05352477|Other|Balneotherapy with thermal water|Bath with Acquabios thermal water at 33°C, 20 minutes daily for a total of 12 days, 6 days a week (from Monday to Saturday, Sundays excluded)
45357810|NCT05352477|Other|Balneotherapy with tap water|Bath with tap water at 33°C, 20 minutes daily for a total of 12 days, 6 days a week (from Monday to Saturday, Sundays excluded)
45357811|NCT00835302|Procedure|Cervicothoracic manipulation|Thrust and non-thrust manipulation to the cervical and thoracic spine
45357812|NCT04010955|Drug|Edoxaban Monotherapy|when the patients will be initially registered in this study, duty physicians will make a decision to give additional antiplatelet therapy in addition to standard edoxaban therapy.
45357813|NCT03851328|Other|BPMH structured interview|creating a standardized medication list by interviewing patient and/ or relatives according to Best Possible Medication History (BPMH) after patient transfer to medical ward
45479318|NCT03627104|Dietary Supplement|Normoprotein diet with animal protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with percentage of standard protein (12-18%) with a predominance of animal protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
45687229|NCT05608005|Biological|Panblok + MF59 Dose 1|Pharmaceutical form: suspension for injection Route of administration: intramuscular
45687230|NCT05608005|Biological|Panblok + MF59 Dose 2|Pharmaceutical form: suspension for injection Route of administration: intramuscular
46047308|NCT00880048|Drug|orvepitant|neurokinin-1 antagonist
46047309|NCT00880048|Other|Placebo|Placebo to match orvepitant 30 mg and 60 mg
46047310|NCT02859480|Drug|Rosuvastatin 5mg|Rosuvastatin 5mg tablet, q.d., for 30 months
46047311|NCT02859480|Drug|Rosuvastatin 20mg|Rosuvastatin 5mg tablet, q.d., for 30 months
46047312|NCT00962208|Device|orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error for a period of two years
46047313|NCT00962208|Device|single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
46047314|NCT02861508|Other|Point-of-care ultrasound|
46047315|NCT02861508|Other|Usual care|
46047316|NCT03121248|Radiation|WBI 5 fractions|External beam radiotherapy in 5 fractions of 5,7Gy
45357814|NCT04016688|Procedure|ESPB and TAP block|"bilateral TAP block: while the patient in the supine position, a linear ultrasound (US) transducer (Phillips Saronno Italy) is placed transversally on the anterolateral abdominal wall in the midaxillary line between the iliac crest and the costal margin identifying external oblique, internal oblique and transversus abdominis muscles. The TAP is between internal oblique and transversus abdominis.~A 22-G needle (spinocan, B.Braun, melsungen AG, Germany) is introduced anteriorly to the transducer and advanced to reach the TAP between internal oblique muscle and transversus abdominis muscle. After careful aspiration to exclude vascular puncture, 20 ml 0.5 % bupivacaine is injected causing an elliptical separation of the two muscles. The same procedure is done on the other side."
45479319|NCT03627104|Dietary Supplement|Normoprotein diet with vegetable protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with percentage of standard protein (12-18%) with a predominance of vegetable protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
45479320|NCT03627104|Dietary Supplement|High-protein diet with animal protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with high-protein percentage (25-35%) with a predominance of animal protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
45479321|NCT03627104|Dietary Supplement|High-protein diet with vegetable protein|ach patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with high-protein percentage (25-35%) with a predominance of vegetable protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
45479322|NCT04313153|Drug|Vadadustat|oral tablets
45479323|NCT04313153|Drug|Darbepoetin alfa|intravenous or subcutaneous solution
46047317|NCT03121248|Radiation|WBI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
46047318|NCT03121248|Radiation|LNI 5 fractions|External beam radiotherapy in 5 fractions of 5,4Gy
46047319|NCT03121248|Radiation|LNI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
45479324|NCT03337750|Behavioral|Web-PE Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
45479325|NCT03804983|Device|Hybrid Closed Loop (HCL)|Participants will use Control-IQ with Hybrid Closed Loop (HCL) with their own insulin parameters during the entire two-week study, including the 72-hour ski admission and the at-home study collection times. Parameters will be reduced 20% during the ski admission to adjust for the increased activity.
45687231|NCT05608005|Biological|Unadjuvanted Panblok Dose 3|Pharmaceutical form: liquid for injection Route of administration: intramuscular
45687232|NCT05607030|Combination Product|VT-X7 Treatment System|Seven-day local antibiotic irrigation (alternating vancomycin hydrochloride and tobramycin sulfate) via the temporary VT-X7 Knee or Hip Spacer.
46047320|NCT03121248|Radiation|SIB 5 fractions if needed|Simultaneous boost of 5 x 6,2Gy (6,5Gy in case of involved resection margins) if needed
46047321|NCT03121248|Radiation|SIB 15 fractions if needed|Simultaneous boost of 15x3,12Gy (3,33Gy in case of involved resection margins) if needed
45357815|NCT00948831|Biological|Osteocel Plus|biologic
45357816|NCT05300061|Behavioral|Personal Values Intervention|A 15 minute personal values intervention. Aim is to help participants clarify their own values around flying and promote committed action towards airplanes.
45479326|NCT03804983|Device|Control-IQ with MyTDI|Participants will use their own insulin parameters during the first 5 days of the study. After randomization at the ski admission, the participants insulin parameters will be modified using the MyTDI calculations. Additionally, parameters will be reduced 20% during the ski admission to adjust for the increased activity.
46047322|NCT03121248|Radiation|TWI 5 fractions|External beam radiotherapy in 5 fractions of 5,7Gy
46047323|NCT03121248|Radiation|TWI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
46047324|NCT00660556|Device|Archimedes Constant Flow Pump & System|Pump implanted in abdomen with intrathecal delivery (catheter) for pain.
46047325|NCT01076543|Other|Laboratory Biomarker Analysis|Correlative studies
46047326|NCT01076543|Drug|Lenalidomide|Given PO
46047327|NCT01076543|Drug|Temsirolimus|Given IV
46047328|NCT00922558|Other|Evaluation of postural control|Children will be measured once using a Tetra-aximetric posturography method
45479327|NCT03330964|Other|electro-acupuncture|Electroacupuncture was administrated immediately after completion of oxaliplatin infusion,once a day for 3 days,30 minutes each time.
45687233|NCT05607030|Procedure|Two-stage exchange arthroplasty|Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis, followed by systemic administration of postoperative antibiotics for 42 days (inclusive) to 90 days (inclusive).
45687234|NCT05607030|Drug|Standard of Care|Forty-two days (minimum) systemic antibiotic administration adjuvant to two-stage exchange arthroplasty with temporary antibiotic-impregnated cement spacer per standard of care (SOC). Antibiotics will be selected by treatment provider and administered in accordance with national and local treatment guidelines.
45687235|NCT05605470|Biological|ChulaCov19 BNA159 vaccine (50 mcg)|Single dose of ChulaCov19 BNA159 vaccine 0.5 ml will be given by IM at Day 1
45687236|NCT05605470|Biological|Pfizer/BNT vaccine (30 mcg)|Single dose of Pfizer/BNT vaccine 0.3 ml will be given by IM at Day 1
46047329|NCT02861274|Device|pacemaker|
45357817|NCT05300061|Behavioral|Prosocial Values Intervention|A 15 minute prosocial values intervention. Aim is to help participants clarify their prosocial values around flying and promote committed action towards airplanes.
45357818|NCT05352087|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is minimally invasive surgery to remove the gallbladder.
45357819|NCT00948987|Drug|Aspirin|325 mg enteric coated single dose p.o.
45357820|NCT00954837|Procedure|Fine needle aspiration|Classical needle biopsy techniques will be used, with patients lying on their backs with their necks in hyperextension. An initial ultrasound scan will be used to determine the site or sites at which the needle should be inserted. Following extensive disinfection of the skin of the neck, the needle will be inserted under ultrasound guidance. The needle will be moved gently backwards and forwards and displaced radially in a clockwise direction to recover cellular material by capillarity. In general, several (two or three) passages of the needle are required for a given nodule. It is possible to carry out FNA on up to three nodules in a single session. For each passage, a new, sterile, single-use needle will be used. The insertion of each needle will be preceded by an ultrasound scan.
45357821|NCT05351931|Dietary Supplement|Salovum and SPC-flakes or corresponding placebo|Salovum and SPC-flakes are foods approved for specific medical purposes.
45357822|NCT05351697|Drug|BR105 injection|0.2mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 40mg/kg respectively
45357823|NCT00744497|Drug|Placebo|
45357824|NCT00744497|Drug|Dasatinib|
45357825|NCT00744497|Drug|Docetaxel|
45357826|NCT00744497|Drug|Prednisone|
45357827|NCT00949065|Biological|intravenous immunoglobulins|0.36-0.44g/Kg IvIg intravenous, 3x, every 4 weeks
45357828|NCT05351619|Procedure|oral care bundle implementation|oral care bundle encompasses oral assessment, tooth brushing, oral / lip moisturization, and suctioning oropharyngeal secretions above the cuff.
45357829|NCT05351463|Procedure|papila suture technique|simple interupted vs internal horoizontal matress suture
45357830|NCT00949143|Other|rear axle position|Wheelchair axle position located as far towards the rear of the wheelchair as possible.
45479328|NCT04312529|Other|Isokinetic test + EMG|Isokinetic test:The isokinetic device is used to evaluate the strength of a subject. The test will be performed in two positions. This will determine the best position to activate shoulder muscles EMG (electromyography):it's a device that measures the electrical activity of muscles. This will allow us to record the maximum activity of the shoulder muscles during force tests.
46047330|NCT04154176|Other|CAM, Nu-DESC|Two trained raters, who are blinded and have no access to each other's evaluation, administer the CAM and Nu-DESC questionnaires in each shift, during the first postoperative day after the discharge from the post-anaesthesia care unit, independently. The two assessments are completed within 60 minutes of each other. If the research team set the diagnosis of POD, the appropriate treatment will be initiated, according to the Hospital's protocol
46047331|NCT04281732|Device|Virtual Reality Headset based tests|Visual task tests based on Oculus Rift
46047332|NCT00668044|Drug|Ciprofloxacin (BAYO9867)|400 mg iv BID
45357831|NCT00949143|Other|forward axle position|Wheelchair will have the axle at least 5cm farther forward than the most rear axle position.
45357832|NCT00955071|Other|Exercise: LVLI|low volume, low intensity
45357833|NCT00955071|Other|Exercise: HVLI|high volume, low intensity
45357834|NCT00955071|Other|Exercise: LVHI|low volume, high intensity
45357835|NCT00955149|Drug|Erlotinib (Tarceva)|Patients with PSC found to be positive for Trisomy 7 on biliary brushings will be treated with Erlotinib (Tarceva) at a dose of 25 mg or 50 mg by mouth once daily for 6 months.
45357836|NCT00747227|Device|modified light transmission intraocular lens|violet visible light blocking acrylic intraocular lens
45357837|NCT00747227|Device|monofocal acrylic intraocular lens|conventional hydrophobic acrylic intraocular lens
45357838|NCT05351385|Procedure|Hematolgy and Chemistry analysis|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
45357839|NCT05351385|Procedure|Real Time PCR|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
45357840|NCT05351385|Procedure|PROS assay COVID+|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
45357841|NCT05351385|Procedure|Sflt1 assay COVID+|Samples will be collected at Day 0 and Day 10
45357842|NCT05351385|Procedure|PROS assay CONTROL|Samples will be collected at Day 0 (+5)
45357843|NCT05351385|Procedure|Sflt1 assay CONTROL|Samples will be collected at Day 0 (+5)
45357844|NCT04090541|Other|Rigid Tape|Non-Elastic Tape
45357845|NCT04090541|Other|Kinesiology Tape|Tape can be elongate only one direction
45357846|NCT04090541|Other|Biomechanical Tape|Tape can be elongate only two direction
45357847|NCT04011657|Other|Compulsory CDSS|Compulsory CDSS use with prospective review feedback in patients prescribed with piperacillin tazobactam or carbapenems
46047333|NCT00668044|Drug|Ciprofloxacin (BAYO9867)|400 mg iv TID
46047334|NCT02860494|Drug|Everolimus|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
45357848|NCT04019951|Dietary Supplement|Ca-propionate 1 g|1 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
45357849|NCT04019951|Dietary Supplement|Ca-propionate 3 g|3 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
45357850|NCT04019951|Dietary Supplement|Placebo|2.6 g of cellulose will be mixed in 203 mL of a standardized liquid breakfast
45357851|NCT05351073|Drug|NBO|Oxygen inhalation through a mask at a rate of 10 L/min at 1 absolute atmosphere pressure (1 ATA = 101.325 kPa)
45357852|NCT04091399|Drug|Stamatological tamponade Contipro|The drug is composed from the Hyaluronic acid and Octenidine dihydrochloride. It is designed to perform comparatively in pain alleviation and to promote healing of the alveolar osteitis while avoiding the side effects.
45357853|NCT00955227|Dietary Supplement|Flax seed oil (ALA)|2 capsules each containing 500mg of ALA will be taken once per day for 6 weeks
45357854|NCT00955227|Drug|Ezetimibe|In total, 30 patients will receive ezetimibe as a drug intervention. The dosage is 10mg pod for 6 weeks
45357855|NCT00949299|Drug|buprenorphine|intradermal injection
45479329|NCT03337672|Drug|Dexmedetomidine|Intravenous dexmedetomidine 0.3mcg/kg is slowly infused at 5 minutes before the end of surgery
45357856|NCT00747149|Drug|Rosuvastatin|Oral
45479330|NCT03337672|Drug|Midazolam|Intravenous dexmedetomidine 0.03mg/kg is slowly infused at 5 minutes before the end of surgery
45479331|NCT05363930|Device|Novel motorized spiral enteroscopy|Novel motorized spiral enteroscopy (Olympus Medical Systems Corporation, Tokyo, Japan) procedures would be performed under general anaesthesia with nasotracheal intubation under fluoroscopic guidance. Four litres of PEG was given to all patients with at least 8 hours of fasting prior to NMSE. Initially antegrade enteroscopy would be performed failing which retrograde enteroscopy would be done to reach the lesion. If the desired lesion is not reached via antegrade/retrograde route, hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anesthesia using the same overtube. The time of procedure will be calculated from insertion of NMSE to its withdrawal. The depth of insertion would be measured by sequential withdrawal technique.
45479332|NCT05363930|Device|Single balloon enteroscopy|Single balloon enteroscopy will be performed with single balloon video-enteroscope (Olympus Medical Systems, Tokyo, Japan) under monitored anaesthesia (deep sedation with propofol). Initially antegrade/retrograde enteroscopy would be performed based on pre-procedure localization failing which enteroscopy would be done from opposite route to reach the lesion. Hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anaesthesia using the same overtube. Duration of procedure would be calculated from the time of introduction of the enteroscope to time of removal. The depth of insertion would be measured using the push and pull technique.
45479333|NCT03503591|Device|Hummingbird Tympanostomy Tube System|Insertion of a ventilation tube under sedation and local anesthetic
46047335|NCT02860494|Drug|Placebo|Placebo topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months, by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
46047336|NCT04801823|Other|Home introduction|Cautious, graded introduction of individual tree nuts
46047337|NCT04801823|Other|Multi Nut oral food challenge|In hospital multi nut oral food challenge (almond, cashew, hazelnut, walnut)
45357857|NCT00271609|Drug|Bevacizumab|10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
45357858|NCT00548847|Biological|GM-CSF|Dosing schedule: 250 mcg/m² subcutaneously Mon-Wed-Fri. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
45357859|NCT00548847|Biological|Interferon-α-2b|Dosing schedule: 1.5 mcg/kg subcutaneously Monday weekly. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
45357860|NCT00949377|Drug|Methylnaltrexone Bromide (MNTX)|The recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg.
45357861|NCT00949377|Drug|Placebo|Normal saline
45357862|NCT00290407|Drug|Rituximab|375 mg/m2, IV (in the vein), once a week for 4 weeks
45357863|NCT00290407|Dietary Supplement|Beta-Glucan|250 mg, orally (tablet), three times a day for 9 weeks
45357864|NCT05350683|Procedure|Remote ischemic preconditioning|In the 12 hours prior to surgery, the principal investigator performed the remote ischemic preconditioning (RIPC) following the protocol: 4 cycles of inflation/deflation of a pneumatic arterial tourniquet on the non-dominant upper extremity. Considering inflated a pressure of 50mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of deflation. Patients included in the preconditioning group were randomized at a rate of 1:1 consecutively.
45357865|NCT01070017|Other|DOT-HAART|For 8 months, DOT-HAART of all doses in the participant's home or alternate location. DOT worker ensures that HIV medications are taken as indicated and witnesses ingestion of all medications including other medications prescribed by physician. The worker will be trained to identify, triage and notify providers of any psychosocial and medical problems/complications. Transition to self-administration begins in months 9-12 when DOT will be tapered and greater participation of treatment supporter to prepare patients for self-administration.
45357866|NCT00955383|Drug|GSK2190915|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
45479334|NCT05351138|Device|TENS|In the study, CE certified tens device with Biolito brand, which is used specifically for incontinence treatment, will be used. The electrodes used during the intervention will be placed to the parasacral region (S2-S4). While the current is given, the power of the device will be gradually increased in 1 mA intervals. The lower value of the stimulation will be 10 mA and the upper value will be 25 mA, and the treatment will be continued with any value that the child can tolerate in this range.
45479335|NCT05351138|Other|Massage|The massage will be applied to the abdominal area between the subcostal lower border and the anterior superior of the spina iliaca. Massage techniques are as follows: Abdominal patting, colon patting, colon kneading, colon patting again, abdominal patting again. It will be advanced with deep abdominal strokes, then the starting point will be returned with transverse superficial strokes for the transversus abdominis muscle and oblique superficial strokes for the rectus abdominis muscle, and these strokes will be repeated 3 times each, a total of 6 times. Afterwards, 3 times column brushing, 3 times column kneading and 3 times column plastering will be done, respectively. At the end, a total of 6 abdominal strokes will be performed for both the transversus abdominis and oblique abdominal muscles as in the beginning.
45479336|NCT04280393|Device|Colonoscopy procedure with endocuff|Colonoscopy procedure with the use of ENDOCUFF VISION
45479337|NCT03337516|Biological|Blood sampling|Blood sampling in order to assess cytarabine pharmacokinetics
45479338|NCT03337516|Genetic|Genetic analysis|Genetic analysis in order to determine genetic polyporphism of Deoxycytidine Kinase and Cytidine Deaminase
45479339|NCT03330808|Other|Epidural anesthesia|After anesthesia induction, epidural catheter is inserted into lumbar epidural in epidural with general anesthesia group. A 10 ml of 0.2% ropivacaine should be given in epidural space via a catheter when anastomosis of free flap is finished in epidural with general anesthesia group.
45479340|NCT03330730|Other|IsereADOM service package|Objects connected to patients' homes (thermometer, weight scale, tensiometer +/- oximeter, glucose meter or pedometer), Digital liaison booklet, Sentinel referent, Motivational coaching
45479341|NCT03810599|Other|Early cardiac rehabilitation|"This is an early cardiac rehabilitation programme starting 1-2 weeks after hospital discharge (Phase 2A rehabilitation). The programme provided by a multidisciplinary team includes individual counseling, educational sessions and discussion in groups, and exercise training sessions three days a week for five weeks.~For additional analysis there will be a comparison group that did not receive the intervention for practical reasons."
45479342|NCT03810677|Device|ELVeS® Radial® 2ring slim fiber|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
46047338|NCT04281810|Device|transcutaneous electric diaphragm stimulation|The electrodes were placed on the parasternal region beside the xiphoid process; and the sixth and seventh intercostal spaces in line with the mid-axillary line. TEDS was set as biphasic waves, frequency of 30 Hz, pulse width of 400 μs, and rise time of 0.7s.
46047339|NCT00663832|Drug|LBH589 (i.v. panobinostat)|"i.v. LBH589 dose levels: 10, 15, or 20 mg/m2~i.v. docetaxel 75 or 60 mg/m2~oral prednisone 5mg bid.~LBH589 i.v. administered on days 1 and 8 in combination with docetaxel i.v. on day 1 and prednisone p.o 5mg bid every day of a 21-day cycle"
46047340|NCT04281576|Device|NovoTTF-100L(P)|Patients receive continuous TTFields treatment using the NovoTTF-100L(P) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.
45479343|NCT02497924|Drug|GBT440|GBT440 capsules followed by single dose of [C14] GBT440 oral suspension
46047341|NCT04281576|Drug|Oxaliplatin|Oxaliplatin 130 mg/m^2 intravenous infusion will be administered once every 3 weeks
46047342|NCT04281576|Drug|Capecitabine|Capecitabine 1000mg/m^2 taken by mouth, twice daily on day 1-14, 3 weeks per cycle
45479344|NCT01303055|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily : two years
46047343|NCT04281576|Drug|Trastuzumab|Trastuzumab (HER-2 positive patients only) intravenous infusion will be administered once every 3 weeks on Day 1 of each cycle. First dose is 8mg/kg, followed by 6 mg/kg.
45357867|NCT00955383|Drug|Placebo|Matching placebo
45479345|NCT01303055|Drug|Metformin 750 mg|"Metformin 750 mg, tablets, orally, thrice daily: two years~The dose increase is possible up to its maximum, 2250 mg, so that HbA1c is maintained below 6.9 %."
45479346|NCT05491096|Other|Proprioceptive Neuromuscular Training|Proprioceptive exercises will be divided into three components. The first component will be comprised of standing on Foam with eyes open and eyes closed and passing any object from one subject to the other for 10 minutes. The second component consists of activity that will be performed in groups of two. Throwing and catching a ball will be performed while standing on foam for additional10 minutes. The third component, throwing and catching a ball, will be performed on trampoline to further challenge the balance system. After each set of 10-minute exercise, the subjects will be given two-minute resting periods. In the end, 10 minutes will be given for cooling down in which deep breathing exercises and static back extensor stretching exercises will be performed to avoid fatigue and to bring the heart rate back to the normal resting level.
45357868|NCT02597387|Drug|Mitoxantrone HCL Liposome Injection|
45357869|NCT01069081|Drug|Arm C|Docetaxel and cisplatin chemotherapy combined with high dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 200mg p.o. d1-3 every week for 66 weeks.
45357870|NCT01069081|Drug|Arm B|Docetaxel and cisplatin chemotherapy combined with lower dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 160mg p.o. d1-3 every week for 66 weeks.
45357871|NCT01069081|Drug|Arm A|Docetaxel and cisplatin chemotherapy. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.
45357872|NCT05350605|Behavioral|Breastfeeding position education with lactation simulation model|pregnant women will receive training with a lactation simulation model once in the last trimester.The pregnant woman will wear the lactation simulation model during the education period and show what she has learned practically on the model.Mothers who have given birth will be supported to practice the breastfeeding position in the postpartum service.
45357873|NCT04019795|Device|REVIAN 101|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 101 delivers 625 nm and 660 nm wavelengths of red light."
45357874|NCT04019795|Device|REVIAN 102|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 102 delivers 425 nm wavelength of blue light."
45843881|NCT01744704|Drug|rhNGF 180 µg/mL Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
45357875|NCT04019795|Device|REVIAN 103|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 103 delivers 425 nm wavelength of blue light and 625 nm and 660 nm wavelengths of red light."
45357876|NCT04019795|Device|REVIAN 100|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 100 contains LEDs that are not powered for light therapy"
45357877|NCT01581463|Drug|Liothyronine, Sodium|Single 100-microgram (2 X 50 microgram) dose.
45357878|NCT00955461|Procedure|RevLite laser treatment|Electro-optic Q-Switched Nd: YAG Laser treatment
45357879|NCT00955461|Procedure|Fractionated Laser treatment|
45357880|NCT00917033|Device|GlideScope|Orotracheal intubation
45479347|NCT05491096|Other|Conventional Physical Therapy|Conventional treatment protocolconsists of a structured exercise protocol Each training session consisted of three parts, the first part included the main movements (warming up 10 minutes plus 5 minutes stretching exercises), the second part consisted of specific movements (exercises with theraband and physioball, 20 minutes), and the third part composed of cool down exercises (10 minutes).(22)Experimental treatment protocolwill be proprioceptive training program. PTP will be based on earlier studies, and will be carried out for eight weeks, with two 60-minute sessions per week. It will start with 10 minutes of Warm-up activities when the subjects will be advised to do light manual stretches and to step up and down on foam to get their body warmed up to have improve muscular flexibility. This will be followed by 30 minutes of proprioceptive exercises targeting lower extremities.
45687237|NCT05604222|Drug|Mirabegron 50 MG|Medication to treat overactive bladder
45687238|NCT05604222|Behavioral|Brief Behavioral Treatment for Insomnia|A behavioral intervention for insomnia
45687239|NCT05603910|Drug|Lenvatinib|Lenvatinib capsules taken daily by mouth
45687240|NCT05603910|Drug|Pembrolizumab|200 mg Pembrolizumab administered intravenously (IV) once on Days 1, 22 and 43.
45843882|NCT01744704|Drug|rhNGF 20 µg/mL Part B|In Part B, as planned 3 dose levels of rh-NGF or placebo eye drops were studied in a total of 40 healthy subjects.
45357881|NCT00917033|Device|Macintosh direct laryngoscope|Orotracheal intubation
45357882|NCT00949455|Drug|lapatinib ditosylate|Given orally
45357883|NCT00949455|Other|Placebo|Given orally
45357884|NCT04010799|Drug|CHF 6333|CHF 6333 - Part I - SAD CHF 6333 - Part II - MD
45357885|NCT04010799|Drug|Placebo|Placebo - Part I - SAD Placebo Part II - MAD
45687241|NCT05603910|Radiation|Hypofractionated External Beam Radiation Therapy|HypoFx whole pelvic EBRT begins on Day 22 and continues for a total of 16 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 40.0 Gy delivered to the pelvis. A pelvic boost HypoFx EBRT consisting of 7 fractions of radiation given at a dose of 2.5 Gy per fraction that will be delivered to site(s) of gross disease of at least 1.0 cm in size. An additional boost total dose of 17.5 Gy administered will be administered over a period of 1.5 to 2.0 weeks.
45687242|NCT05654610|Device|Halova|Halova is a class I medical device formulated as vaginal ovules and intended for intravaginal administration in order to promote and/or accelerate the hydration, healing, re-epithelialization and/or soothing of injured, atrophic or irritated vaginal mucosa. The ovules melt evenly in the vaginal mucosa forming a cream with a moisturizing and calming effect that support the restoration of the vaginal epithelium.
45687243|NCT05602649|Drug|Cannabis|Cannabis will be orally ingested
45843883|NCT01744704|Drug|rhNGF 60 µg/mL Part B|In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
45843884|NCT01744704|Drug|rhNGF 180 µg/mL Part B|In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
45843885|NCT01744704|Drug|Placebo Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
45479348|NCT03810521|Biological|umbilical cord derived-mesenchymal stromal cells|Intra-articular infiltration of umbilical cord derived-mesenchymal stromal cells
45479349|NCT05484388|Device|SN2|Investigational device absorption level Normal
45843886|NCT01744704|Drug|Placebo Part B|In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
45843887|NCT01745952|Device|figure-of-eight active rTMS coil|navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil
45843888|NCT01745952|Device|round active rTMS coil|navigated rTMS over epileptogenic focus using round active rTMS coil
45843889|NCT01745952|Device|sham rTMS coil (figure-of-eight)|commercially available placebo coil that provides slight sensory stimulation and discharge noise without stimulating cortical tissue
45843890|NCT01746264|Dietary Supplement|Vitamin D3|Vitamin D 3 at 100,000 IU once a month for 3 months
45843891|NCT01746420|Drug|rhPDGF-BB Injection|Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
45479350|NCT05484388|Device|SP3|Investigational device absorption level Plus
45479351|NCT03796169|Behavioral|Personal notification|Baseline quality indicators of each endoscopist were measured and those were notified individually.
45843892|NCT01746420|Drug|Placebo|sodium acetate buffer (0 mg rhPDGF-BB)
45843893|NCT01748916|Other|Papaya|Post-prandial study feeding 400-506 g papaya (1.6 mg beta-carotene, 2.1 mg beta-cryptoxanthin, 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
45843894|NCT01748916|Other|Carrot|Post-prandial study feeding 25-35 g carrot (= 1.6 mg beta-carotene), 150 g yogurt (10% fat), and 45 g of fat free bread.
45843895|NCT01748916|Other|Tomato|Post-prandial study feeding 256-396 g tomato (= 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
45687244|NCT05602649|Drug|Placebo|Placebo will be orally ingested
45687245|NCT05600101|Behavioral|Care.Coach|"Care.coach is a human-in the-loop conversational agent (avatar) used to interact and converse with patients through natural dialogue and text-to-speech software that is powered by a team of trained human staff, called health advocates."
45687246|NCT05590949|Other|Physical Evaluation|Participants will be assessed at Timepoint 0 (last dose of denosumab injection) and then at 9,12,18 and 24 months following discontinuation of denosumab. The evaluation will include history and pain assessment for development of new fractures, weight and height measurement with BMI (body mass index) calculation, and blood work for bone turnover markers (including serum carboxy-terminal collagen crosslinks (CTX) in serum and bone specific alkaline phosphatase). Bone turn-over markers should be drawn in the morning, after at least 8 hours of fasting (water, black coffee and plain tea allowed).
45843896|NCT01749930|Drug|BOL-303259-X|BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning
45843897|NCT01749930|Drug|Timolol|Timolol will be administered BID once in the morning and once in the evening.
45843898|NCT01749930|Drug|BOL-303259-X|All participants will receive a topical ocular BOL-303259-X QD in the evening from 3 months (Visit 6) through 6 months (Visit7).
45843899|NCT01750086|Drug|Teriparatide 40-mcg subcutaneous injection|
45843900|NCT01750086|Drug|Denosumab Injection|One-time Denosumab injection
45843901|NCT01750086|Drug|Alendronate Oral Tablet|weekly alendronate for 8 weeks
45843902|NCT01750398|Drug|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
45843903|NCT01750398|Drug|Goserelin|"Goserelin is a hormone therapy, for intramuscular injectionis. It is classified as an LHRH agonist."
45843904|NCT01750398|Drug|Leuprolide|Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist. For intramuscular injection.
45843905|NCT01751022|Device|Device: Attain Performa Pacing Lead (along with a standard CRT-D system)|Implant and follow-up of study lead, separate analysis for each lead model
45479352|NCT03796169|Behavioral|Open notification|Quality indicators were measured for 3 months after 1st interventions and those were notified openly
45479353|NCT03796169|Behavioral|Education|Quality indicators were measured for 3 months after 2nd interventions and educated the importance of colonoscopy quality by a GI faculty
45843906|NCT01752426|Other|Heavy Water (2H2O)|50 ml 70% 2H2O 3 times a day for the first 5 days followed by 60 ml daily for a total of 4 weeks. After the 5-day loading period, a 60 ml maintenance dose of 2H2O will be drunk at bedtime. At end of the 4th week, subjects stop drinking 2H2O (washout phase) and be followed from 6-12 weeks until beginning treatment with PCI-32765.
45843907|NCT01752426|Drug|PCI-32765|420 mg orally once daily.
45843908|NCT01753362|Drug|liraglutide|
45843909|NCT01753362|Drug|placebo|
45843910|NCT01757964|Biological|Bacteriotherapy|
45843911|NCT01758432|Combination Product|PRT064445/Apixaban|
45843912|NCT01758432|Combination Product|Placebo/Apixaban|
45357886|NCT04011579|Other|MSFIT|MSFIT, by using the Microsoft Kinect Motion Controller Xbox to deliver adapted physical activity, offers the possibility to transform the Pilates exercises into a virtual reality game. Each exercise is implemented with different levels of difficulty in order to allow the adaptation to the capacities of the user.
45843913|NCT01758432|Drug|Placebo|
45843914|NCT01758588|Drug|Peginterferon alfa-2a|50 mcg subcutaneous injection once per week
45357887|NCT00749411|Drug|Placebo|matching placebo
45357888|NCT00749411|Drug|GSK233705/GW642444|The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.
45687247|NCT05590949|Diagnostic Test|Dual-energy X-ray absorptiometry scans|Dual-energy X-ray absorptiometry (DEXA) scans will be performed at the 12 months timepoint , and then at the 24 month timepoint.
45843915|NCT01759602|Drug|C1-esterase inhibitor (Cinryze)|
45687248|NCT05590949|Diagnostic Test|Trabecular Bone Score|TBS is an innovative gray-level texture measurement that utilizes lumbar spine DEXA images to discriminate changes in bone microarchitecture. Specifically, TBS measures bone quality through tridimensional bone areas with different trabecular and microstructural characteristics. The combination of TBS microstructure evaluation with bone density measured by DEXA has been shown to be superior to either measurement alone in the assessment of fracture risk.
45687249|NCT05589350|Other|saturated fat intake|Intake of saturated fat from yogurt and animal butter daily for 4-week period
45687250|NCT05586776|Drug|4% Chlorhexidine Gluconate|Used for daily showering/bathing for 30 days after hospital discharge.
45687251|NCT05586776|Drug|2% Mupirocin|Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
45687252|NCT05586776|Drug|Soap Without Antiseptic Properties (Placebo)|Used for daily showering/bathing for 30 days after hospital discharge.
45843916|NCT01760304|Drug|Budesonide / Formoterol|"Budesonide/ formoterol (B/F) 160/4.5 mcg per activation. Subject who met inclusion criteria will be have at each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of either Budesonide/formoterol (B/F) 160/4.5 mcg per activation (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated."
45843917|NCT01760304|Drug|Placebo|"Each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of placebo (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated."
45843918|NCT01761084|Behavioral|Exercise and behaviour change strategies|"cardiovascular exercise (e.g., marching, walking) for ≥10 minutes per day~postural retraining and balance exercises ≥3 days a week (will be encouraged to do these daily)~perform muscle strengthening and balance training exercises ≥ 3 days a week~the exercise intervention was developed using the Bone Fit program as a framework (http://www.bonefit.ca/). The physical therapist will tailor exercises and work with participant to integrate them into their day."
45843919|NCT01762722|Device|Reduction of inspired oxygen|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
45843920|NCT01763346|Drug|Metformin|metformin 1000 mg bid
45843921|NCT01763346|Device|gastric banding|LAP-BAND
45843922|NCT01763970|Radiation|SBRT|
45843923|NCT01765530|Device|ETT cleaning maneuver|"EndOclear device will be used for ETT cleaning maneuver. This is a commercially available device. It consists of an ETT cleaning apparatus with a flexible central tube and a cleaning device at its distal end. The cleaning device has a mechanically expandable mesh structure which can be adapted to selectively move between a radially-collapsed position and a radially-expanded one. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the ETT. The cleaning apparatus is then pulled out of the ETT removing mucus deposits and secretions.~We will add endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period."
45843924|NCT01766076|Other|atorvastatin, Lipitor®|PBMC collected for immune activation assays using flowcytometry
45843925|NCT01766076|Drug|Placebo|PBMC collected for immune activation assays using flowcytometry
45357889|NCT05342805|Procedure|Narrow gastric tube|At the lesser curvature, the resection began at the point that was 5-cm from the pyloric, toward to the greater curvature, then the stomach was divided along 3 cm from the greater curvature using linear stapler
45357890|NCT00955539|Device|AV-optimization followed by AV- and VV-optimization|Patients are AV-optimized the first 4 months,then AV- and VV-optimized the next 4 months.
45357891|NCT00955539|Device|AV- and VV-optimization followed by AV-optimization only.|Patients are AV- and VV-optimized the first 4 months,then AV-optimized the next 4 months.
45357892|NCT05296161|Drug|Ocrelizumab|Personalized B cell tailored ocrelizumab treatment
45687253|NCT05586776|Drug|Placebo Nasal Ointment|Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
45843926|NCT01766466|Drug|cangrelor|Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.
45843927|NCT01766466|Drug|Ticagrelor|"Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion~Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion."
45843928|NCT01767636|Drug|Pazopanib Hydrochloride|Given PO
45843929|NCT01767792|Drug|Bevacizumab|"Treatment will be administered on an outpatient basis. Bevacizumab is administered by IV infusion at a dose of 10 mg/kg every 2 weeks for 24 weeks (induction therapy, see Schema). One cycle lasts 28 days and includes two infusions of bevacizumab. Clinical response will be assessed by audiology and MRI at weeks 12 and 24. Subjects with hearing decline at weeks 12 and 24 will be taken off of protocol. After week 24, patients with a clinical response or stable disease (together comprising clinical benefit) will transition to maintenance therapy with bevacizumab.~During the maintenance phase, subjects will be treated with open-label bevacizumab 5 mg/kg every 3 weeks for up to 72 weeks. Subjects will be followed with audiology and MRI scans every 12 weeks. The total time of the study will be 96 weeks (24 weeks induction + 72 weeks maintenance)."
45843930|NCT01769274|Drug|PF-05089771|A single oral dose of PF-05089771 1600 mg solution to be administered on Day 1 of each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of PF-05089771 will be adminstered.
45687254|NCT05586360|Drug|Simvastatin 40mg|Simvastatin 40mg taken orally daily for 8 weeks
45843931|NCT01769274|Drug|Placebo|Placebo for PF-05089771 1600 mg solution administered in each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of placebo will be administered.
45843932|NCT01769352|Drug|PredA + Kelac|At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.
45843933|NCT01769586|Drug|Diphenhydramine|
45843934|NCT01769586|Drug|Midazolam|
45843935|NCT01770366|Device|Weight and Exercise Lifestyle Support (WELS)|Intervention patients will receive a suite of devices manufactured by the FitLinxx company, including their Pebble activity monitor, ActiScale weight scale, and access to their ActiHealth.com patient portal website. Intervention participations will be able to use the features of this website, including widgets displaying their device data as well as challenge invitations to interact with other participants, as desired.
45843936|NCT01770366|Device|Usual Care|
45357893|NCT00949611|Behavioral|FRAX + Decision Aid|Clinicians will present patient's with their individualized risk of osteoporotic fracture in 10 years, based on the FRAX risk calculator, as well as sharing a decision aid with them, which shows their risk of fracture, risk reduction on medications, as well as the downsides of the medications.
45357894|NCT00949611|Behavioral|FRAX estimated fracture risk|The clinician is provided with the patient's estimated risk of fracture as computed by the FRAX
45357895|NCT03958149|Device|spinal collar|cervical collar to immobilise the cervical spine
45687255|NCT05586152|Drug|INV-102|INV-102 Ophthalmic Solution
45687256|NCT05586152|Drug|Vehicle|Vehicle Ophthalmic Solution
45687257|NCT05585307|Drug|GS-5894|Administered orally
45687258|NCT05585307|Drug|B/F/TAF|Administered orally
45843937|NCT01773954|Drug|Intravitreal Aflibercept Injection|Increased or decreased time between visits
45843938|NCT01778634|Drug|Azithromycin|Azithromycin intravenous 20 mg/kg every 24 h x 3 days
45687259|NCT05585307|Drug|Standard of Care (Substudy 01)|"Antiretroviral therapy, administered orally~Non-NNRTIs, examples: ABC/DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)"
45843939|NCT01778634|Drug|Placebo|D5W
45843940|NCT01779024|Drug|Ghrelin|
45843941|NCT01779024|Drug|Placebo|
45843942|NCT01779024|Procedure|fMRI|
45843943|NCT01779024|Drug|Alcohol|
45843944|NCT01780350|Device|ResQGARD ITD|Patients eligible for the device will receive the ResQGARD attached to a facemask or mouthpiece. The patient will use the device, provided it is tolerated, until their blood pressure is stabilized as determined by EMS personnel.
45843945|NCT01781208|Device|Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)|Research scans using ultrasound-based acoustic radiation force impulse (ARFI) will image the liver non-invasively.
45687260|NCT05585307|Drug|GS-1720|Administered orally
45687261|NCT05585307|Drug|Standard of Care (Substudy 02)|"Antiretroviral therapy, administered orally~Example INSTIs: DTG/ABC/3TC or DTG/3TC"
45843946|NCT01783080|Behavioral|Behavioral Activation for return to work|See Arm Description
45843947|NCT01783236|Drug|IV Acetaminophen|1000mg IV Ofirmev given every six hours for a total of four doses.
45843948|NCT01783236|Drug|Saline Placebo|Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.
45843949|NCT01783470|Drug|beta3-adrenergic receptor agonist|single dose. The subjects were randomized to receive placebo on one study day and active beta3-adrenergic receptor agonist on the other study day.
45843950|NCT01783860|Drug|Azithromycin|
45843951|NCT01783860|Drug|Doxycycline|
45843952|NCT04420182|Other|Virtual Care at Home|Participants will have access to the VIRTUES platform for COVID-19 Virtual Care at Home
45357896|NCT00949689|Behavioral|Cognitive Behavioral Therapy for insomnia and depression|Experimental arm: Participants will receive sessions of cognitive behavioral treatment for insomnia followed by sessions of cognitive behavior treatment for depression for a total of about 10-12 therapy sessions Control arm: Participants will receive brief sleep hygiene and time management techniques and cognitive behavior treatment for depression for a total of about 10-12 therapy sessions.
45357897|NCT00955695|Drug|erlotinib hydrochloride|
45687262|NCT05579886|Device|Control Contact Lens|Control Contact Lens - first period of 2 weeks (14-21 days)
45687263|NCT05579886|Device|Test Contact Lens|Test Contact Lens - second period of 2 weeks (14-21 days)
45687264|NCT05574127|Behavioral|Behavioral Activation|"Sessions for both arms (BP & SP) will be administered remotely via video-conference and/or telephone (per patient preference) at the following timeline:~Full participants (not training cases): Ten sessions (30-50 minutes each) will be delivered approximately weekly over a 10-week period (+10 weeks).~Training case participants: Ten sessions (30-50 minutes each) will be delivered over an approximately 5-week period (+10 weeks)."
45843953|NCT01784796|Behavioral|Mindfulness Based Stress Reduction|8 week Mindfulness Based Stress Reduction Program
45479354|NCT01957176|Drug|Eltrombopag (ELT)|Subjects were dosed with ELT tablets or powder for oral suspension (PfOS) based on the dosage form used in the parent study. ELT tablets were white, round film coated tablets containing ELT olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg of ELT. ELT PfOS was a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet contained ELT olamine equivalent to 20 mg of ELT per gram of powder.
45479355|NCT05474560|Drug|Allopurinol (100 mg/day) plus lifestyle intervention|participants accept allopurinol treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
45479356|NCT05474560|Drug|Febuxostat 40 mg plus lifestyle intervention|participants accept Febuxostat treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
45843954|NCT01784796|Behavioral|Health Education Program|8 week Health Education Program
45687265|NCT05574127|Behavioral|Supportive Psychotherapy|"Sessions for both arms (BP & SP) will be administered remotely via video-conference and/or telephone (per patient preference) at the following timeline:~Full participants (not training cases): Ten sessions (30-50 minutes each) will be delivered approximately weekly over a 10-week period (+10 weeks).~Training case participants: Ten sessions (30-50 minutes each) will be delivered over an approximately 5-week period (+10 weeks)."
45843955|NCT01785186|Drug|SQ109|SQ109 300 mg
45843956|NCT01785186|Drug|Rifampicin|Rifampicin 10 to 35 mg/kg
45843957|NCT01785186|Drug|Moxifloxacin|Moxifloxacin 400mg
45843958|NCT01785186|Drug|isoniazid|isoniazid 75 mg
45843959|NCT01785186|Drug|pyrazinamide|pyrazinamide 400 mg
45479357|NCT05474560|Behavioral|Life style intervention|According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
45843960|NCT01785186|Drug|ethambutol|ethambutol 275 mg
45687266|NCT05568225|Drug|Etavopivat|400 mg once daily
45843961|NCT01785186|Dietary Supplement|pyridoxine|pyridoxine 25 mg
45843962|NCT01785810|Drug|Maraviroc 300 mg|Patients enrolled on this trial will receive a standard conditioning regimen with fludarabine and busulfan followed by a peripheral blood stem cell infusion from an unrelated donor, standard GVHD prophylaxis and standard antiviral and antifungal prophylaxis. In addition, all patients will receive maraviroc from day -3 to d+ 90.
45843963|NCT01786902|Drug|DA-3002|
45843964|NCT01787604|Procedure|Aortic Root Reimplantation Procedure|Modified Florida Sleeve.
45843965|NCT01787604|Procedure|Aortic Valve Reimplantation Procedure|David I
45843966|NCT01787916|Drug|Liraglutide|Liraglutide will be compared to placebo for 24 weeks in a cross-over design
45687267|NCT05567094|Drug|Dexamethasone|Patients will receive 0.2 mg/kg dexamethasone, administered as an intravenous bolus within 5 minutes after induction of anesthesia
45843967|NCT01787916|Drug|Placebos|placebo will be compared to liraglutide for 24 weeks in a cross-over design
45687268|NCT05567094|Drug|Saline placebo|Patients will receive 2ml saline placebo, administered as an intravenous bolus within 5 minutes after induction of anesthesia
45843968|NCT01788150|Device|Coronary Stenting|
45479358|NCT03810443|Diagnostic Test|Hyperventilation test|The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
45479359|NCT03337438|Other|Personalized Feedback Intervention with Values|The PFI with values will include information commonly included in personalized feedback interventions for alcohol use, such as norms information and drinking profile, as well as feedback on three of the assessed values that are highly important to the participant.
45843969|NCT01790178|Procedure|Ultrasound|The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.
45843970|NCT01790490|Drug|Ketamine 0.41 mg/kg|52 minute iv infusion of ketamine 0.41 mg/kg
45843971|NCT01790490|Drug|Ketamine 0.71 mg/kg|52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.
45843972|NCT01790490|Drug|Lorazepam 2 mg|52 minute infusion of lorazepam 2 mg. This serves as an active control.
45843973|NCT01791972|Drug|Albuterol Spiromax|Albuterol Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) containing a blend of albuterol sulfate with alpha-lactose monohydrate. Each actuation represents a dose of 90 mcg of albuterol sulfate. Participants received one dose of two inhalations (180 mcg).
45843974|NCT01791972|Drug|Placebo Spiromax|Placebo Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) delivering placebo to match the experimental drug. Participants received one dose of two inhalations.
45843975|NCT01792986|Behavioral|water-only 24-hour fasting once per week for 6 weeks|
45843976|NCT01794312|Device|T4020|
45843977|NCT01794312|Device|Vehicle|
45843978|NCT01794702|Drug|Decitabine|Phase I and II - 20 mg/m2 by vein daily for 5 days (days 1-5)
45843979|NCT01794702|Drug|Idarubicin|Phase I and II - 10 mg/m2 by vein daily for 3 days (days 6-8)
45843980|NCT01794702|Drug|Cytarabine|Phase I and II - 1 g/m2 by vein daily for 5 days (days 6-10)
45687269|NCT05566899|Procedure|esophagogastroduodenoscopy (EGD)|"After colonoscopy, the patient will undergo the EGD at which time biopsy specimens will be obtained.~Participants will also be provided with a home stool collection kit which they can bring to the endoscopy visit or mail back. Satisfaction questions will be administered 3-7 days after EGD-SC"
45687270|NCT05565222|Drug|Piperacillin/tazobactam or temocillin|"Piperacillin/tazobactam : 4.5 g by intravenous route every 6 hours (adjusted in case of renal failure).~Temocillin : 6g/24 hours infused continuously by intravenous route after 2 g loading dose (adjusted in case of renal failure)"
45357898|NCT00955695|Drug|gefitinib|
45687271|NCT05565222|Drug|Meropenem|2 g every 8 hours by intravenous route (adjusted in case of renal failure)
45357899|NCT00955695|Other|questionnaire administration|
45357900|NCT00955695|Procedure|quality-of-life assessment|
45843981|NCT01794702|Drug|Clofarabine|"Phase I Starting Dose - 15 mg/m2 by vein daily for 4 days (days 6-9)~Phase II Starting Dose - Maximum tolerated dose from Phase I (number of days selected based on Phase I portion)."
45843982|NCT01795716|Drug|mesylate imatinib capsule|Single and multiple oral mesylate imatinib capsule 400mg qd
45357901|NCT00955695|Radiation|whole-brain radiation therapy|
45357902|NCT05240001|Device|Thulium Fibre Laser|Participants will undergo treatment using the TFL
45357903|NCT05240001|Device|MOSES Holmium Laser|Participants will undergo treatment using the MOSES Holmium laser.
45687272|NCT05563766|Drug|Itraconazole|Itraconazole 300 mg po bid for two weeks prior and 6-8 weeks after completion of standard of care neoadjuvant chemoradiation
45687273|NCT05562492|Device|CamAPS FX|"The automated closed loop system (CamAPS FX) will consist of:~YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor Cloud upload system to review CGM/insulin data."
45687274|NCT05562492|Other|Standard insulin therapy with CGM|Usual insulin therapy and study CGM.
45687275|NCT05562427|Behavioral|Gold-Standard Online Behavioral Obesity Treatment|Rx Weight Loss (RxWL) is an online BOT that consists of: (a) tailored weight loss, calorie, and physical activity goals. (b) 12 weekly 10-15 minute multimedia lessons for training in behavioral weight loss skills followed by 9 monthly lessons for continued weight loss. Lessons incorporate video, animation, audio, quizzes, and exercises for goal setting, planning, and problem-solving. Example topics include restaurant eating, changing the home environment, and obtaining social support. (c) Online tools for self-monitoring weight, diet, and physical activity that interface with popular tracking apps; and (c) Weekly, and eventually monthly, automated feedback on progress to date (delivered as text appearing on the platform). If goals are not met participants receive strategies to improve weight loss, along with encouragement. To ensure engagement, email reminders are sent to participants who have not visited the platform on a given week.
45843983|NCT01795716|Drug|Glivec|Single and multiple oral Glivec 400mg qd
45843984|NCT01797822|Drug|Dexamethasone|
45843985|NCT01797822|Drug|Artificial tear|
46047344|NCT04795271|Other|Orthopedic intervention|"In each custom insole, modifications can be included in the following aspects according to the requirements of each participant :~Forefoot specifications: a) Retrocapital bar, b) Retrocapital support, c) Claw toe correction element, d) Pronating wedge, e) Supinator wedge, f) Metatarsal head pad, g) Selective perforations in the insole, h) Others.~Midfoot specifications: a) Internal arch, b) External arch, c) Full support, d) Excavations, e) Others.~Hindfoot specifications: a) Heel cup, b) Supinator wedge, c) Pronating wedge, d) Lifter, e) Cup, f) Others.~Insole type and lining material~Materials of the added corrections~Insole base: a) soft ethylene vinyl acetate (eva), b) semi-soft eva, c) hard eva, d) rubber, e) cuerolite."
46047345|NCT00668122|Drug|Cipro XR (Ciprofloxacin, BAYQ3939)|Ciprofloxacin XR 1000 mg orally once a day
46047346|NCT00668122|Drug|Cipro IR (Ciprofloxacin, BAYQ3939)|Ciprofloxacin IR 500 mg orally twice a day
46047347|NCT04304807|Drug|Melatonin 20 mg|Melatonin was given as a total dose of 20 mg via enteral route in two doses of 10 mg each with a 1 hour interval in between.
46047348|NCT04304807|Drug|Traditional antibiotic treatment|Traditional antibiotic treatment was given to both groups with feeding intolerance according to treatment protocols by neonatal intensive care units of Ain Shams University
46047349|NCT04280874|Drug|Dinoprostone 0.5 MG|0.5mg dinoprostone applied intracervically
46047350|NCT04280874|Drug|Dinoprostone 2 MG/2.5 ML Vaginal Gel/Jelly|2mg dinoprostone applied intravaginally
45357904|NCT00955773|Drug|GSK1120212 plus everolimus|Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts. Dose escalation will continue until a recommended combination dose is identified. The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.
45357905|NCT00549549|Drug|Indomethacin|indomethacin 50 mg three times a day (TID) for 8 days.
45357906|NCT00549549|Drug|Celecoxib|An initial dose of celecoxib 800 mg followed by a second dose of 400 mg 12 hours later on Day 1 (celecoxib 800/400 mg regimen) and continuing 400 mg two times a day (BID) for 7 days.
45357907|NCT00549549|Drug|Celecoxib|An initial dose of celecoxib 400 mg followed by a second dose of 200 mg 12 hours later (celecoxib 400/200 mg regimen) and continuing 200 mg two times a day (BID) for 7 days.
45357908|NCT00549549|Drug|Celecoxib|Celecoxib 50 mg two times a day (BID) for 8 days
45357909|NCT00270205|Biological|LC002 standard vaccination|0.1 mg DNA/participant, 0.8 ml total administered subcutaneously
45687276|NCT05561517|Other|5 K running|The 5 K running competition will induce increased stress levels and thereby lead to increased levels of hyperglycemia.
45357910|NCT00270205|Biological|LC002 high-dose vaccination|0.4 mg DNA/participant, 3.2 ml total administered subcutaneously
45357911|NCT00270205|Biological|LC002 placebo vaccination|Placebo vaccination administered subcutaneously
45357912|NCT00955851|Other|Pre and post vaccination titers|Titers will be obtained pre vaccination and 4 weeks post vaccination
45357913|NCT00949767|Drug|BMS-866949|(Panel 1 - 0.5 mg) - Oral Solution, Oral, once, 14 days
45357914|NCT00949767|Drug|BMS-866949|(Panel 2 - 2.5 mg) - Oral Solution, Oral, once, 14 days
45357915|NCT00949767|Drug|BMS-866949|(Panel 3 - 10 mg) - Oral Solution, Oral, once, 14 days
45687277|NCT05558059|Device|Handheld Optical Coherence Tomography with OCT Angiography|"OCT systems are in vivo optical imaging technology that allows non-contact imaging of early-stage ocular pathology. They create real-time, non-invasive images of ocular microstructure and have become standard-of-care instruments in ophthalmic imaging in clinics and operating rooms. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are analyzed for depth-resolved information and can also be stacked to create a volume and the stack may be summed up to create a retinal image.~OCT angiography (OCTA) is an extension of the OCT systems, by taking images at the same location over time to extract retinal vascular flow information. It has been utilized to assess the ocular blood flow in many adult and pediatric patients."
45687278|NCT05557448|Drug|TYNADOTE|Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
45687279|NCT05557448|Drug|Placebo Oral Tablet|Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
45687280|NCT05552820|Device|Verum Electroacupuncture|Acupoints: Cuanzhu (BL2), Taiyang (EX-HN5), Sibai (ST1), Sizhukong (TE23), Baihui (GV20), Fengchi (GB20), Hegu (LI4), Zusanli (ST36), Guangming (GB23), Sanyinjiao (SP6), and Taichong (LR3). All acupoints will be taken bilaterally, except Baihui (GV20). The subject is placed in the supine position with eyes close. After routine sterilization, the sterile polyethylene cylindrical needle pad will be adhered to the acupoints. Then, the sterile acupuncture needles (0.25 mm×0.40 mm, Hwato brand, China.) will be inserted into the skin through the needle pad. Twirling and lifting-thrusting manipulations will be performed on the acupoints until Deqi is reported by the subject. Two pairs of electrodes will be connected at the needle handles on BL2 and EX-HN5 with a 2 Hz, continuous-wave electro-stimulation provided by the electroacupuncture apparatus (SDZ-Ⅲ type, Hwato brand, China). The pulse amplitude is about 1-2 mA.
45357916|NCT00949767|Drug|BMS-866949|(Panel 4 - 25 mg) - Oral Solution, Oral, once, 14 days
45479360|NCT03337438|Other|Personalized Feedback Intervention Traditional|This PFI will include information on drinking profile, norms, behavioral strategies used while drinking, and practical costs related to drinking reframed as monetary values and caloric values.
45479361|NCT03636048|Drug|Bupivacaine Hcl 0.5% Inj|The patients undergo surgery under spinal anesthesia and a catheter would be inserted into epidural space during the procedure. 0.5% bupivacaine is injected into intrathecal space for spinal anesthesia. For pain control, 0.2% ropivacaine is continuously infused into epidural space postoperatively.
45357917|NCT00949767|Drug|BMS-866949|(Panel 5 - 50 mg) - Oral Solution, Oral, once, 14 days
45357918|NCT00949767|Drug|BMS-866949|(Panel 6 - 100 mg) - Oral Solution, Oral, once, 14 days
45357919|NCT00949767|Drug|BMS-866949|(Panel 7 - 150 mg) - Oral Solution, Oral, once, 14 days
45357920|NCT00949767|Drug|Placebo|(Matching volume) - Oral Solution, Oral, once 14 days
45357921|NCT05299827|Other|The same evaluation methods were used for both groups.|No treatment applied to participants and same evaluation methods used in both groups. Trunk muscle strength, muscle endurance, posture, flexibility and pelvic floor muscle activity of participants was evaluated with stabilizer pressurized biofeedback unit, sit-ups and modified push-ups test; trunk flexors endurance test and Modified Biering Sorensen Test; Posture Screen Mobile And Foot Posture Index; sit-reach-test and Beighton Score; and NeuroTrac-Myoplus4Pro,
45357922|NCT00949845|Drug|Endotoxin|
45357923|NCT05206929|Other|Self Managed Care|Self Managed Care
45357924|NCT00622284|Drug|Placebo identical to BI 1356 5mg|Placebo tablet once daily
45357925|NCT00622284|Drug|Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg|Placebo tablets once daily
45843986|NCT01800318|Device|NESAP|Electrical stimulation will be administered via the Empi Select, a standard TENS unit. To produce analgesia, small electrodes will be placed in treatment groups on the baby's legs at specific acupuncture points: ZuSanLi (ST36), SanYinJiao (SP6), Shen Mai (Bl60), and Shui Quan (KI3)46. StimCare electrodes with a gel base will be applied to the skin ; the skin will not be punctured by these procedures. A low continuous current will be provided with minimal voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 2 minutes after the heel stick. The display will be hidden from view to prevent the rater from being able to observe whether the unit is on.
45843987|NCT01800318|Behavioral|24% oral Sucrose|One ml 24% sucrose will be given approximately two minutes before the heel stick. Sucrose will be given via oral syringe along with a pacifier.
45479362|NCT03636048|Drug|Propofol 10 milligram/ML|The patients undergo surgery under general anesthesia and a catheter would be inserted to abdominal incision site at the end of the operation. Propofol is used for induction of general anesthesia, and sevoflurane is used for maintenance of anesthesia. At the end of the operation, the surgeon inserts wound catheter in the surgical site and connects wound patient-controlled analgesia device filled with 0.5% ropivacaine.
45843988|NCT01800318|Device|Sham NESAP|Four electrodes will be placed on the infant's lower leg, but the TENS unit will not be turned on. The TENS unit will be covered and investigators will not know whether the TENS unit is turned on or not (sham NESAP).
45843989|NCT01800318|Behavioral|Oral water|For infants in the control group, 1 ml of water will be given via oral syringe along with a pacifier 2 minutes before the heel stick. Investigators will be blinded on whether the infants are receiving water or oral sucrose.
45843990|NCT01800786|Device|CPAP|
45687281|NCT05552820|Device|Sham Electroacupuncture|Sham acupoints: SA1(1 cm above BL2), SA2 (1 cm above SJ23)，SA3 (1 cm above EX-HN5), SA4 (1 cm lateral to ST2), SA5 (the midpoint of the line between GV20 and right EX-HN1), SA6 (the midpoint of the line between GB20 and SJ16), SA7 (1 cm lateral to LI4), SA8 (the midpoint of the line between ST36 and GB34), SA9 (the midpoint of the line between GB37 and BL58), SA10 (1 cm backward to SP6), SA11 (the midpoint of the line between LR3 and SP4). After routine sterilization, placebo needles will be used (Streitberger, Asia-med GmbH). The tingling sensation produced when the Streitberger needle is fixed on the skin causes the subject to believe that the needle is piercing the skin, simulating a skin puncture. The electric stimulator is applied to bilateral SA1 and SA3 with no current output. The exterior appearance, indicator light, prompt tone of the sham device, and stimulation parameters are all indistinguishable from the normal one.
45843991|NCT01803204|Other|Booklet - Preoperative Educational|the patients receive a booklet during the preoperative phase. The educational session with a booklet will occur before the surgery.
45843992|NCT01805154|Device|CRT Patients|This is a group of patients who are receiving bi-ventricular pacing therapy from CRT device.
45479363|NCT03804047|Other|kinesio tape|kinesio tape is a therapeutic method used in the treatment of various musculoskeletal and neuromuscular deficits to provide support for muscles and increase or inhibit muscle recruitment, to correct joint malalignment, decrease swelling, and pain relieve
45843993|NCT01809054|Drug|Arixtra|
45843994|NCT01809054|Device|Pneumatic compression stockings|Pneumatic compression stockings (MCS, Active Care, medical compression systems Inc., Israel)
45843995|NCT01809054|Drug|Aspirin|
45843996|NCT01809834|Device|Etafilcon A|
45843997|NCT01809834|Device|Stenfilcon A|
45479364|NCT03527173|Biological|S.sonnei vaccine|Subjects receiving 2 doses of the study vaccine by intramuscular route, 28 days apart (at Day 1 and Day 29).
45479365|NCT03527173|Drug|Placebo|Subjects receiving 2 doses of placebo by intramuscular route, 28 days apart (at Day 1 and Day 29).
45843998|NCT01810692|Device|Group1:Spiriva® Respimat®|COPD patients using Respimat®
45843999|NCT01810692|Device|Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®|COPD patients using Breezhaler®®
45844000|NCT01811004|Device|miraDry|miraDry
45844001|NCT01811004|Device|Nd:YAG Laser|Nd:YAG 1440 nm Laser
45844002|NCT01811004|Device|Botox®|Botox®
45844003|NCT01811316|Other|Probiotics|
45479366|NCT03527173|Biological|S. sonnei 53G challenge strain|Subjects receiving the challenge dose of S. sonnei 53G strain, orally, at Day 57.
45844004|NCT01811940|Drug|Adderall-ER|MAS-ER 60mg/day
45844005|NCT01811940|Drug|Topiramate|Topiramate 100 mg bid.
45479367|NCT01952262|Other|diaphragm ultrasound|we'll perform diaphragm ultrasound in ICU critically ill patients
45479368|NCT04254302|Other|WECARE web platform|The WECARE intervention allows families of children with motor difficulties to access rehabilitation therapists. The primary therapist will be an occupational therapist or a physiotherapist who will have one day a week to deliver the intervention. The therapist will act as case manager to connect families with community-based services available in their region and work, according to a transdisciplinary model, with an interdisciplinary team on a needs-based basis. Patient engagement with the therapists and in the WECARE intervention will be ensured by the collaborative coaching approach used by therapists to attain meaningful motor outcomes, as selected by the primary respondent.
45844006|NCT01811940|Other|Placebo|Placebo
45844007|NCT01813110|Drug|4 g prescription omega-3 concentrate|4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks
45844008|NCT01813110|Drug|Placebo|olive oil
45844009|NCT01813734|Drug|Ponatinib|28 day cycle
45844010|NCT01816230|Drug|NiCord®|
45844011|NCT01816776|Device|Treatment Group (transvenous stimulation of the phrenic nerve)|device implant, optimal medical therapy and device initiation 1 month post implant.
45844012|NCT01816776|Device|Control Group (Optimal Medical Therapy)|device implant, optimal medical therapy and delayed device initiation (7 months post device implant)
45844013|NCT01817712|Behavioral|Individual Placement & Support|"IPS uses an integrated place-train approach to help people obtain and maintain community-based competitive employment in their chosen occupation."
45357926|NCT00622284|Drug|BI 1356|5mg, once daily in the morning for 104 weeks
45357927|NCT00622284|Drug|Glimepiride|1mg or 2mg or 3mg or 4mg in the morning for 104 weeks
45357928|NCT00269113|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv monthly for 8 cycles
45357929|NCT00269113|Drug|Standard chemotherapy|As prescribed
45357930|NCT04010487|Genetic|whole exome sequencing and RNA-sequencing|The specimens from adenomyosis, endometrial cancer, and eutopic endometrium will be tested by whole exome sequencing and RNA-sequencing
45357931|NCT00949923|Dietary Supplement|tea capsule|3 tea capsules daily for 3 weeks
45357932|NCT01069159|Drug|Propranolol Hydrochloride|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) or placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Subjects will be randomized in a 1:1 ratio to either Propranolol treatment or placebo.
46047351|NCT00663910|Drug|Aminolevulinic Acid|On Day 1, ALA will then be applied topically to the center of the tumor surface (at the location of its greatest diameter) in a standardized manner with great care not to include normal skin. The solution will be applied directly to the lesions by dabbing gently with a wet applicator tip. Enough solution will be applied to uniformly wet the exposed lesion surface. Once the initial application has dried, the ALA will be applied again in the same manner. The ALA will be left on for 2 hours under occlusion with Duoderm Extra Thin®.
45357933|NCT01069159|Drug|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
45479369|NCT04778436|Dietary Supplement|T7082|Patients will take food supplementation for 12 months. For each patient : 5 visits with ophthalmogist and 6 phone call
45479370|NCT04718922|Drug|Chlorhexidine Gluconate 0.12 % Mouthwash|Intervention with chlorhexidine mouthrinse will be performed approximately 10 min before the start of EBUS-TBNA
46047352|NCT00663910|Procedure|biopsy|Then local anesthesia, lidocaine 1% with epinephrine 1:100,000, will be administered and before the tumor is excised by one of the Cleveland Clinic MOHS surgeons, a 2mm punch biopsy will be taken from the area where the ALA was previously applied. The punch biopsy will be full thickness, extending to the subcutaneous fat.
45357934|NCT03975205|Drug|Doxorubicin|To measure bioavailabity of Doxil versus Doxorubicin
45357935|NCT01325779|Drug|heparin|subcutaneous heparin 5000 units every 8 hours
45479371|NCT05344196|Behavioral|Modified EAET for prediabetes|Attempts to reduce stress and improve health behavior by engaging in emotional awareness and expression leading to changes in interpersonal relationships and health behavior
45687282|NCT05551728|Behavioral|ESDM-informed caregiver coaching|The coaching intervention is informed by the Community-Early Start Denver Model (C-ESDM). The intervention has been adapted for the South African context. Training procedures have been adapted for delivery by non-specialist coaches. Twelve session-specific visuals with simple-text (for caregivers) and session scripts (for non-specialist coaches) have been developed. Over 12, 1-hour caregiver coaching sessions that are delivered by non-specialists, caregivers are coached in strategies to increase child attention to their social world, increase child communication, create and build joint activity routines, and understand and use the ABCs to support the development of new behaviors.
45687283|NCT05550948|Device|Transcranial photobiomodulation (tPBM) - Mobile System|The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.
45687284|NCT05549661|Procedure|Biospecimen Collection|Undergo collection of blood samples
45687285|NCT05549661|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
45357936|NCT01325779|Drug|enoxaparin|subcutaneous enoxaparin 40 milligrams every 24 hours
45479372|NCT03722641|Other|Bread reference|Commercially available white wheat bread
45687286|NCT05549661|Drug|Onvansertib|Given PO
45687287|NCT05549661|Procedure|Ultrasound Imaging|Undergo ultrasound imaging
45687288|NCT05547932|Procedure|RIB+SAP blocks|RIB block will be performed after endotracheal intubation, then a SAP block will be performed. No other intervention will be performed to the patients.
46047353|NCT00663910|Procedure|diagnostic imaging technique|Two hours after the amniolevlulenic acid was applied, the measurements of surface fluorescence will be repeated with the hand held dosimeter.
46047354|NCT00663910|Procedure|therapeutic conventional surgery|The non-melanoma skin cancer will be excised using the MOHS procedure.
45357937|NCT05170659|Drug|Relatlimab|
45479373|NCT03722641|Other|Product 1: Milk|Developed reference product based on milk
45479374|NCT03722641|Other|Product 2: Full fat milk + oat|Developed product based on full fat milk with addition of oat
45479375|NCT03722641|Other|Product 3: Skim milk + oat, high fibre|Developed product based on skim milk with addition of oat giving a high fiber content to the product
45479376|NCT03722641|Other|Product 4: Skim milk + oat, low fibre|Developed product based on skim milk with addition of oat giving a lower fiber content to the product
46047355|NCT02875769|Procedure|Dental prophylaxis|Full mouth dental prophylaxis (FMDP) was conducted in one appointment lasting 10 minute, using an ultrasonic scaler at a frequency of 25 kHz (Cavitron Select SPC, Dentsply professional, York, PA, USA) at less than 50% power. The FMDP performed without anesthesia and in order to eliminate supragingival plaque, calculus and stainings.
46047356|NCT02875769|Drug|Mouthwash CPC+Zn+F|The volunteer rinsed with pre-procedural mouthwash containing 0.075% cetylpyridinium chloride, 0.28% zinc lactate and 0.05% sodium fluoride in an Alcohol-free base for one minute, 20 ml of solution and then expectorated all remaining liquid.
45844014|NCT01817712|Behavioral|VA Transitional Work Program|"The long-standing approach to vocational rehabilitation in VHA and state programs is the train-place or stepwise model that is founded on the assumption that the patient or client benefits from some form of pre-vocational training, instruction, or practice in a protected, but artificial, work setting prior to entering or being placed in a competitive work role."
45357938|NCT05352165|Drug|standard long-term therapy|The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.
45844015|NCT01818414|Drug|Misoprostol|400 mcg of buccal misoprostol, 3 hours prior to planned D&E
45357939|NCT05352165|Drug|FOLFOX and standard long-term radiotherapy|FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity
45687289|NCT05546502|Biological|SARS-CoV-2 Protein Subunit Recombinant Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
45687290|NCT05546502|Biological|Active Comparator|Covovax
45357940|NCT05352165|Drug|FOLFIRI and standard long-term radiotherapy|FOLFIRI and standard long-term radiotherapy based on organoids drug sensitivity
45357941|NCT05352165|Drug|5-FU and standard long-term radiotherapy|5-FU and standard long-term radiotherapy based on organoids drug sensitivity
45687291|NCT05537233|Drug|Semaglutide|Semaglutide up to 1 mg per week in addition to standard closed-loop therapy
45357942|NCT05352165|Drug|5-FU and pembrolizumab and standard long-term radiotherapy|5-FU and pembrolizumab and standard long-term radiotherapy based on organoids drug sensitivity
45357943|NCT05352165|Drug|Other individualized treatments|Other individualized treatments based on organoids drug sensitivity
45357944|NCT02548260|Device|Syndactyly without compression|three week relative immobilization by syndactyly
45687292|NCT05537233|Drug|Placebo|Injection placebo up to 1 mg per week in addition to standard closed-loop therapy
45844016|NCT01818414|Drug|Folic Acid|4 mg of buccal folic acid, 3 hours prior to planned D&E
45844017|NCT01818804|Dietary Supplement|n-3PUFA|
46047357|NCT02875769|Drug|Mouthwash CHX|The volunteer rinsed with pre-procedural mouthwash containing 0.12% CHX with 10% alcohol for one minute, 20 ml of solution and then expectorated all remaining liquid.
46047358|NCT02875769|Other|No rinsing|The volunteer did not rinse with any pre-procedural mothwash.
46047359|NCT02875769|Other|Water|The volunteer rinsed with pre-procedural mouthwash containing water from a three-way syringe for one minute, 20 ml of water and then expectorated all remaining liquid.
46047360|NCT00663988|Procedure|human transplantation|Allograft composite tissue transplantation. procedure. medication
46047361|NCT04304885|Diagnostic Test|Sonication method|Sonication dislodges adherent bacteria from explanted prosthetics by ultrasound and may improve the diagnosis of periprosthetic joint infection.
45357945|NCT02548260|Device|Syndactyly with compression|three week relative immobilization by syndactyly and compression
45357946|NCT02548260|Device|Rigid splint without compression|three week rigid immobilization by splint
45357947|NCT02548260|Device|Rigid splint with compression|three week rigid immobilization by splint and compression
45357948|NCT00291187|Drug|20 mg VEC-162|20 mg VEC-162
45357949|NCT00291187|Drug|50 mg VEC-162|50 mg VEC-162
45357950|NCT00291187|Drug|100 mg VEC-162|100 mg VEC-162
45357951|NCT00291187|Drug|Placebo|Placebo
45357952|NCT00956163|Procedure|magnetic resonance imaging|Undergo whole-body MRI
45357953|NCT00956163|Radiation|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
45357954|NCT00956163|Procedure|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
45357955|NCT00956163|Procedure|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
45687293|NCT05532865|Other|Blood samples|80 ml of blood samples collected at inclusion and at 18 months
45687294|NCT05532865|Other|Stool samples|A stool sample for collection of digestive microbiota at inclusion
45687295|NCT05532865|Other|Skin swab samples|A skin swab sample for collection of skin microbiota at inclusion and at 18 months
45687296|NCT05532865|Other|Questionnaires on quality of life, pain and disability|At inclusion and each year for 5 years
45844018|NCT01818804|Dietary Supplement|olive oil|
45844019|NCT01820754|Drug|Ipilimumab|"Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes~Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery)~Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses"
46047362|NCT04157998|Drug|normal saline|intrvenous administration of 10ml normal saline preoperative
46047363|NCT04157998|Drug|Metoclopramide 10mg|intrvenous administration of 10mg metoclopramide diluted in 10ml normal saline preoperative
46047364|NCT04304963|Other|NO intervention - observational study|NO intervention - observational study
46047365|NCT02861352|Other|Diet zinc|4 mg zinc, as zinc sulfate, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period when an ad lib diet was consumed
45357956|NCT00956163|Radiation|technetium Tc 99m methylene diphosphonate|Undergo technetium Tc 99m methylene diphosphonate bone scan
45357957|NCT00956163|Other|laboratory biomarker analysis|Correlative studies
45357958|NCT04016766|Behavioral|Mobile app prepartying intervention|The intervention is comprised of a theoretically-informed and empirically-supported, brief, accessible, and personalized intervention to address prepartying drinking. the prepartying intervention app will be tailored toward an individual's personal goals, beliefs (perceptions, expectancies, self-efficacy), and behavior (protective strategies), and focus on the core components of brief interventions that have been cited as constructs that mediate the effects of multiple component intervention programs (e.g., correcting perceived norms, use of protective behavioral strategies, increased self-efficacy, challenging expectancies, feedback on blood alcohol level).
45357959|NCT00839046|Behavioral|Community Health Worker Intervention|The Community Health Worker (CHW) intervention consists of visits by CHWS to help families reduce children's exposure to common asthma triggers (allergens and irritants) in the indoor environment. The content of the CHW visits and the materials distributed will follow NHLBI Expert Panel Report 2 recommendations. Each household will receive 6 visits over a 12-month period in which the CHW will provide education on environmental triggers (e.g., reduction of dust mites, cockroaches, cat and dog dander, and environmental tobacco smoke); materials including vacuum cleaners with HEPA filters, mattress and pillow covers, and cleaning supplies; social support to the caregivers; and, if indicated, referrals to other services.
45357960|NCT00839046|Other|Air Filter|Fifty households will receive an Air Filter, in addition to receiving the standard community health worker intervention. These households will receive a HEPA room AF (Whirlpool 510 or equivalent), a relatively high capacity unit that can be quietly operated. Similar to other studies the filter will be placed in the room where the child sleeps. The HEPA AF will be installed at the beginning of the intervention period.
45479377|NCT01303601|Drug|olanzapine|"Tablet The initial dose of olanzapine was 5mg daily and raised to 10 mg/day. After week 1, flexible dosing was allowed based on symptom response, up to 20 mg daily, as tolerated.~daily 6 weeks"
45479378|NCT01303601|Drug|Starch|
45479379|NCT01330992|Other|Ocular light or darkness exposure|Ocular light or darkness exposure
45479380|NCT00707980|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
45479381|NCT03795935|Other|No side-effect stimulator settings with directional lead|Individuals in this arm will have their stimulator settings programmed to the point in which they have maximum tremor control with no side effects.
45479382|NCT05339360|Procedure|Femoral fixation with intramedullary nails|Femoral fracture fixation Femoral Osteotomy
45479383|NCT04970459|Biological|collection of samples of blood and urine|extra samples of blood and urine will be collected and stored for research utilisation
45479384|NCT05330468|Device|Abbott Mechanical Heart Valve (MHV) Regent™|SJM Regent™- Standard cuff (Model number AGN-751); SJM Regent™- FlexCuff™ (Model number AGFN-756)
46047366|NCT00668278|Device|Insertion of laryngeal mask airway (AuraOnce mask)|Insertion of laryngeal mask airway under anaesthesia: Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg; AuraOnce disposable laryngeal mask
45479385|NCT01304537|Drug|Alpha-1 Antitrypsin 40mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
45479386|NCT01304537|Drug|Alpha-1 Antitrypsin 60mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
45479387|NCT01304537|Drug|Alpha-1 Antitrypsin 80mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
46047367|NCT00668278|Device|Insertion of I-gel airway|Insertion of I-gel airway under anaesthesia; Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg
46047368|NCT00668278|Other|Measurement of airway pressures|Measurement of peak airway pressure under steady state; measurement of device seal pressure
46047369|NCT04280796|Behavioral|psychophysical tasks|"All participants perform two psychophysical tasks to assess sensory-discriminative and emotional-motivational pain responses independently from each other.~In addition, in Substudy 1 an operant learning paradigm will be implement to dissociate these responses, increasing the sensory-discriminative pain responses compared to emotional-motivational pain responses by contingent monetary reinforcement or vice versa.~In Substudy 2, responses of chronic pain patients will be compared to those of healthy participants to characterize possible alterations and operant learning will be operationalized to decrease emotional-motivational pain responses, which are assumed to be already increased in the patients."
46047370|NCT04280796|Behavioral|cognitive task|In Substudy 3 participants will perform a psychophysical task to assess metacognition in pain perception as an indicator of the cognitive-evaluative pain component.
46047371|NCT04157842|Procedure|total hip replacement with subtrochanteral osteotomy|applying subtrochanteral osteotomy during the operation to release the tension of vessels and nerve
45687297|NCT05530070|Other|Dietary intervention|Patients will participate in a structured, group-based dietary counseling, which is planned to take place every two months for 1 year. We will also use info-communication tools (online) depending on the epidemiological situation. The aim of the counseling is to maintain a GFD and to develop a healthy lifestyle, in line with the Mediterranean diet.
45844020|NCT01820754|Drug|Paclitaxel, Cisplatin, Carboplatin|"Neoadjuvant (Pre-Surgery) Cycle 1: Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 1 cycle)~Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes, Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 2 cycles)"
45844021|NCT01821378|Drug|Lurasidone|Lurasidone 20 mg once daily
45844022|NCT01821378|Drug|Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2|Lurasidone 80 mg once daily
45687298|NCT05530070|Other|Standard of care|Patients will receive standard of care and baseline dietary education.
45687299|NCT05530070|Diagnostic Test|Cardiovascular risk-related parameters|Anthropometric measurements (body height, body composition assessment-InBody 770), questionnaires (symptoms, quality of life, dietary adherence, diet quality, cardiovascular risk), assessment of sarcopenia (handgrip dynamometer), urine collection (dietary adherence - urine gluten immunogenic peptide detection), blood collection (immunological tests, hormone levels complemented with routine laboratory panel), transabdominal US examination to assess the extent of fatty liver disease.
45844023|NCT01821378|Drug|Placebo|Once Daily
45844024|NCT01821534|Other|No Intervention|No treatment (intervention) was administered.
45844025|NCT01822548|Drug|Vildagliptin|100 mg daily
45844026|NCT01822548|Drug|Glibenclamide|2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.
45844027|NCT01822548|Drug|Metformin|concomitant therapy with metformin is present in each arm (MAX dose: 2500 mg/die)
45844028|NCT01825122|Drug|Nadolol|
45687300|NCT05529823|Behavioral|warm shower|A warm shower will be applied for 20 minutes to the pregnant woman whose cervical dilatation reaches 4-5 cm and 7-8 cm.
45687301|NCT05526989|Drug|Dostarlimab|300 mg Dostarlimb will be administered by IV, increasing to 1000 mg after cycle 4.
45687302|NCT05526989|Drug|Niraparib|200 mg Niraparib will be taken once daily by mouth days 1-21 of all cycles.
45844029|NCT01825122|Drug|Placebo|
45844030|NCT01825512|Drug|Deferiprone|Deferiprone 80 mg/mL oral solution
45844031|NCT01825512|Drug|Deferasirox|Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg
45844032|NCT01827306|Drug|Biofreeze|
45844033|NCT01827462|Biological|Trivalent, inactivated influenza vaccine (TIV)|Licensed Seasonal Influenza Vaccine TIV
46047372|NCT04157842|Procedure|total hip replacement with no osteotomy|just total hip replacement
46047373|NCT02860260|Biological|Blood samples|
46047374|NCT02860260|Other|Cerebral MRI|
46047375|NCT04155268|Behavioral|Flotation-REST|Floating in a specialized device (float pod or float cabin) used to attenuate sensory input.
45844034|NCT01827462|Biological|Quadrivalent, inactivated influenza vaccine (IIV4)|Licensed Seasonal Influenza Vaccine IIV4
45844035|NCT01827462|Biological|High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)|Licensed Seasonal High-Dose Influenza Vaccine TIV
45844036|NCT01827930|Drug|Imatinib Mesylate 600 MG Oral Tablet|Imatinib Mesylate for CP CML
45844037|NCT01827930|Drug|Imatinib Mesylate 400 MG Oral Tablet|Imatinib Mesylate for CP CML
45844038|NCT01827930|Drug|Imatinib Mesylate|Imatinib Mesylate for CP CML
45844039|NCT01828164|Device|Ultrasound|The Aevo System™ is an ultrasound emitting dental device.
45844040|NCT01828164|Device|Sham comparator|Ultrasound not activated in the comparator side of the device.20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated while the comparator arm has the transducers deactivated.
45844041|NCT01828476|Drug|Abiraterone|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
45844042|NCT01828476|Drug|ABT-263|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
45844043|NCT01828476|Drug|Hydroxychloroquine|ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
46047376|NCT04155268|Behavioral|Dark Room|Participants will lay on an air mattress in a dark room with no cell phone and reduced sensory input.
46047377|NCT01072877|Drug|Polidocanol injectable foam (PEM)|Injection of Polidocanol injectable foam
46047378|NCT01072877|Drug|Placebo Vehicle|Placebo vehicle
45687303|NCT05525468|Drug|TDM-180935|TDM-180935 topical ointment
45687304|NCT05525468|Drug|Placebo|Placebo for TDM-180935 topical ointment
45687305|NCT05524623|Other|percutaneous microelectrolysis in myofascial trigger points of the trapezius|percutaneous microelectrolysis with or without current emission in the treatment of cervical pain in myofascial trigger points of the trapezius
45687306|NCT05518396|Diagnostic Test|CoDE-HF decision support tool|We will assess the diagnostic performance of the CoDE-HF decision support tool
46047379|NCT02875847|Dietary Supplement|HMO1|
46047380|NCT02875847|Dietary Supplement|HMO2|
46047381|NCT02875847|Dietary Supplement|Dextropur|
46047382|NCT00961896|Drug|Vehicle|Placebo cream
46047383|NCT00961896|Drug|LDE225 0.25%|
46047384|NCT00961896|Drug|LDE225 0.75%|
46047385|NCT02858388|Device|Sinuclean Nebules 45|Nebulization of solution
45844044|NCT01828554|Drug|Xeloda|"Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage."
45357961|NCT00839046|Other|Air Filter and Air Conditioner|Fifty households will receive the air filter and the air conditioner, in addition to receiving the standard community health worker intervention. The air filter will be installed at the beginning of the intervention, after baseline measurement. In the spring of the year (2009), a small window AC unit (Whirlpool Designer Style ACQ058MM or equivalent) will also be installed in the room where the child sleeps.
45357962|NCT00956241|Procedure|j-pouch coloanal anastomosis|
45357963|NCT00956241|Procedure|side-to-end coloanal anastomosis|
45844045|NCT01832610|Device|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
45357964|NCT00835458|Procedure|gastro-gastric fistula closure|The mucosa surrounding the orifice of the fistula will be ablated using standard endoscopic techniques. Remnants of mucosa will be treated with argon-plasma coagulation. The mucosa free orifice of the fistula will be closed using the Tissue Apposition System. Tissue anchors with attached threads will be deployed through the intestinal wall full thickness using delivery needles through the working channel of the endoscope. After two anchors are deployed on both sides of the fistulas' orifice a knotting element will be cinched down to approximate the two sides of the fistulas' orifice. The procedure will be repeated until the fistulas' orifice is securely closed.
45357965|NCT00956319|Drug|Zolpidem MR|oral
45357966|NCT00956319|Drug|Estazolam|oral
45687307|NCT05512208|Drug|Avutometinib (VS-6766) + defactinib|"Avutometinib (VS-6766): will be administered at 3.2 mg orally twice a week Defactinib: will be administered at 200 mg orally twice a day (BID).~Treatment will be for 3 weeks, followed by a 1-week rest period, in each 4-week (28 day) cycle."
45687308|NCT05506345|Behavioral|Creative Drama Workshop|"The host introduces the theme and stressor scene of this workshop~Nursing students group discussion~Nursing student group performance practice ④Nursing group formal performance ⑤Nursing student group discussion ⑥The representative of the nursing student group made a speech ⑦ The host summarizes the positive coping methods of nursing students in stressor events"
45687309|NCT05503238|Behavioral|Skin-to-skin contact|Preterm infants will receive maternal-infant skin-to-skin contact at least 1 continuous hour everyday from infant 3 days of life until discharge, and other nursing care will be same as the routine group. During skin-to-skin contact, place naked baby only with diaper on the mother's bare chest in an upright position and tilt the baby's head to one side in a slightly extended position to keeps the airway open, cover the infant with a blanket to keep them warm. A neonatal nurse will be stay with mother and infant to observe and support.
45357967|NCT02547948|Biological|CD19-targeting CAR T Cells infusion|CD19-targeting 2nd generation CAR t cells infusion for refractory B cell lymphoma
45844046|NCT01833078|Drug|ghrelin|ghrelin administration subcutaneously for 7 days
45844047|NCT01833546|Drug|Evofosfamide|Evofosfamide infusion intravenously at an escalated dose of 240, 340 or 480 milligram per square meter (mg/m^2) on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
45844048|NCT01833546|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
45844049|NCT01833936|Device|Compex® muscle stimulator|The Compex® muscle stimulator is a commercially available muscle stimulator that is approved by the Food and Drug Administration (FDA), a governmental body. It is not investigational. The investigational part of this study aims to evaluate if the use of muscle simulation after Achilles tendon surgery will reduce calf atrophy.
45844050|NCT01833936|Device|(inactive) muscle stimulator|A placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
46047386|NCT02858388|Other|Saline solution|Nebulization of solution
46047387|NCT02859090|Procedure|tonsillectomy|
45687310|NCT05503238|Other|Routine care|Preterm infants will receive standard nursing care provided by neonatal nurses in accordance with hospital principles during hospitalization.
45687311|NCT05501522|Biological|GBP510 adjuvanted with AS03|injection volume of 0.5mL on Day 0
45687312|NCT05501522|Other|Placebo (Normal Saline)|injection volume of 0.5mL on Day 0
45687313|NCT05497778|Drug|Gemcitabine|Given by IV (vein)
45844051|NCT01834326|Biological|EVPOME (autogenous ex vivo produced oral mucosa equivalent)|EVPOME is manufactured from the subjects own oral cells and is implanted back in the subjects mouth after an approximately 30 day manufacturing process.
45844052|NCT01834326|Biological|POM (Palatal oral mucosa)|POM is a tissue graft harvested from the palate and surgically placed into the defect area
45844053|NCT01834404|Drug|Phentermine-Topiramate ER|The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
45844054|NCT01834404|Drug|Placebo|Placebo pills matched the study drug in appearance for the 2 dose levels.
45844055|NCT01834716|Behavioral|Aerobic vs. Non-Aerobic exercise|
45844056|NCT01835262|Drug|Morphine|Morphine: 0.1 mg /kg given as IVP
45844057|NCT01835262|Drug|Ketamine|Ketamine:0.3 mg/given as IVP
45844058|NCT01835496|Drug|single 1500 mg dose of Ferriprox|A single dose of 1500mg of Ferriprox (three 500mg tablets) administered under fasting conditions
46047388|NCT02859090|Biological|blood sample|
45844059|NCT01837524|Behavioral|KP Personal Shopper Visits|Testing co-shopping visits conducted in the grocery store (1:1 visits with dietitian while grocery shopping) versus in-office visits which are the current standard of care.
45687314|NCT05497778|Drug|Nab paclitaxel|Given by IV (vein)
45844060|NCT01837524|Behavioral|In-Office Dietitian Visits|Participants will have 3, 1 hour in-office sessions with the dietitian during which targeted curriculum on nutritional knowledge, weight management, healthier eating, menu and label reading, will be delivered. These visits will take place monthly over a three month period.
45357968|NCT00961779|Drug|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with bicarbonate buffer and normal saline.
45844061|NCT01838226|Behavioral|Problem Solving|A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to CVD-related behaviors (e.g., smoking and weight reduction).
46047389|NCT02706288|Other|Weight loss with very low fat plant-based diet and regular exercise|Participants will lose ~7-10% of their body weight while on a calorie-restricted very low fat plant-based (PB) diet and performing exercise 6 days/week (4 sessions/week under direct supervision). The macronutrient composition of the diet is approximately 70% of energy from carbohydrate, 15% from protein, and 15% from fat. Food will be provided in the form of take-out meals and will be picked up by participants during weekly study visits with a weight management dietitian. To promote adherence to the diet and exercise intervention, subjects will participate in a lifestyle intervention program that includes dietary and behavioral education topics. Treatment will be provided in weekly individual or group sessions depending on subject availability. (Note: this is the only intervention for the study; the hyperinsulinemic euglycemic clamp is not an intervention but is the gold standard for evaluating insulin sensitivity, a primary study outcome.)
46047390|NCT00630474|Drug|xylometazoline|xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
45357969|NCT00961779|Drug|Placebo|Normal saline infusion
45357970|NCT00835848|Drug|Exenatide|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 25 μg Byetta (Lilly, Exenatide) and 0.1% human albumine are added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
45357971|NCT00835848|Drug|Saline|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 0.1% human albumine is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
45357972|NCT00961857|Drug|sitagliptin phosphate (+) metformin hydrochloride|place holder - do not post
45844062|NCT01838304|Device|Probability ramp control|Decision support software that calculates propofol doses appropriate for age and weight of the patient
45844063|NCT01838304|Device|Monitoring|Manual recording of drug doses determined by CRNA
45844064|NCT01839318|Device|Nelfilcon A contact lenses|
45844065|NCT01839318|Device|Omafilcon A contact lenses|
46047391|NCT02860182|Other|measure the elastic properties of aortic wall|
45357973|NCT00961857|Drug|Comparator: metformin 500 mg|A single dose of metformin 500 mg tablets
45844066|NCT01839318|Device|Etafilcon A contact lenses|
45357974|NCT00961857|Drug|Comparator: sitagliptin|A single 50 mg tablet of sitagliptin
45687315|NCT05497778|Drug|IM156|Given by PO
45687316|NCT05497635|Drug|STSA-1002 Injection|Intravenous injection
45687317|NCT05497635|Drug|Placebo|Intravenous injection
45357975|NCT00961857|Drug|Comparator: FMI sitagliptin/metformin 50 mg/500 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
45357976|NCT00961857|Drug|Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
45687318|NCT05493501|Drug|Aumolertinib monotherapy|Administered orally, once daily as two 55-mg tablets for a total dose of 110 mg.
45687319|NCT05493501|Drug|Osimertinib monotherapy|80 mg tablet administered orally, once daily
45687320|NCT05493501|Drug|Pemetrexed|Administered by IV Infusion per prescribing information. Maybe be continued as maintenance therapy
45687321|NCT05493501|Drug|Cisplatin|Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
45687322|NCT05493501|Drug|Carboplatin|Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
45844067|NCT01839708|Behavioral|Lifestyle Counseling|The intervention will determine the differential outcomes of reading generic materials versus viewing custom DVDs containing targeted health information and discussions with MI-trained moderators on weight gain prevention.
45844068|NCT01840722|Other|MI-based HIV Risk Reduction|As the only MI-based intervention identified by the CDC as a best-practice model, the MI-HIV intervention has been shown to demonstrate positive outcomes for criminal justice-involved women randomly assigned to the intervention group for risky sexual activity and drug use with sustained behaviors through 9 months.
45357977|NCT00961857|Drug|Comparator: metformin 1000 mg|A single dose of metformin 1000 mg tablets
45357978|NCT02547792|Biological|VXA-BYW.10 (Low Dose) Oral Vaccine|Enteric coated tablet for oral delivery
45357979|NCT02547792|Biological|VXA-BYW.10 (High Dose) Oral Vaccine|Enteric coated tablet for oral delivery
45357980|NCT02547792|Other|Placebo Tablets|Enteric coated tablet for oral delivery
45357981|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 0.5mg given once daily for 14 days.
45844069|NCT01842594|Drug|Sirolimus and hydroxychloroquine|"Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally QD for 2 cycles .~Each treatment cycle is 28 days."
45357982|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 1mg given once daily for 14 days.
45357983|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 4mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 4mg will be administered once daily for 14 days.
45357984|NCT00836082|Drug|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
45687323|NCT05493501|Drug|Paclitaxel|Administered by IV Infusion given over 4 -6 fixed cycles per prescribing information.
45687324|NCT05493501|Drug|Nab paclitaxel|Administered by IV Infusion given over 4 fixed cycles per prescribing information.
45844070|NCT01842906|Device|Theravent|nasal EPAP device
46047392|NCT02860104|Device|microwave ablation|ultrasound guided percutaneous microwave ablation for breast lesions
46047393|NCT00957528|Drug|Testosterone|Weekly im injections of 100 mg testosterone enanthate.
46047394|NCT00957528|Drug|Placebo|Weekly IM injections of sesame oil.
46047395|NCT02857062|Device|E45 Eczema Repair Emollient|E45 Eczema Repair Emollient
45844071|NCT01842906|Device|Control|Sham device without EPAP
45844072|NCT01843920|Drug|Timolol-dorzolamide (Glaucoma drops)|Patients will receive the standard post-operative drops regardless of what group you are in. The glaucoma drops will only be given to the experimental group.
46047396|NCT00958776|Drug|Peramivir+SOC|"Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.~Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care."
46047397|NCT00958776|Drug|Placebo+SOC|Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
46047398|NCT02858856|Drug|Sipjeondaebo-tang|Herbal medicine which is a compound of 10 herbs.
46047399|NCT02858622|Drug|bupivacaine|bupivacaine 0.25% at a dose 2 mg/kg in the transversus abdominis plane
45844073|NCT01843920|Drug|standard post-operative topical drops|Patients will receive the standard post-operative drops regardless of what group ther are in. The standard post-operative drops are Prednisolone acetate,Polymyxin B and Trimethoprim
46047400|NCT02858622|Drug|Pethidine|pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
46047401|NCT02858622|Drug|perfalgan|intravenous paracetamol
46047402|NCT02858622|Drug|fentanyl|
46047403|NCT04278456|Behavioral|postpartum depression|melatonin levels in c-sections with different anesthesia modalities.
45357985|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 8mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 8mg will be administered once daily for 14 days.
45357986|NCT00836082|Drug|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
45357987|NCT04009941|Drug|PEG-rhG-CSF|4.5mg per cycle, 24 hours after chemotherapy
45357988|NCT00830466|Drug|Laser and rapamycin versus laser alone|Laser and rapamycin versus laser alone
45687325|NCT05493501|Drug|Gemcitabine|Administered by IV Infusion over 4 fixed cycles per prescribing information.
45687326|NCT05486962|Behavioral|Remote Patient Monitoring|Patients undergoing elective abdominal surgery will be asked to use a wearable activity tracker, vivosmart®HR by Garmin, pre and post-operatively to help remotely monitor health metrics. Data collected through the Garmin device will be reviewed to assess compliance and improvement in activity. Aggregate data will be analyzed to assess feasibility and effectiveness of this device in improving patient recovery.
46047404|NCT02191566|Drug|S-1 (452500ACH)|S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months
45687327|NCT05483491|Drug|KK-LC-1 TCR-T cells|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. KK-LC-1 TCR-T cells will be administered as a single intravenous infusion.
45687328|NCT05483491|Drug|Aldesleukin 720,000 IU/kg IV every eight hours|Aldesleukin 720,000 IU/kg IV every eight hours after KK-LC-1 TCR-T cell infusion for up to six doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
45844074|NCT01844388|Drug|carboxymethylcellulose based eye drop formula|1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
45844075|NCT01844388|Drug|carboxymethylcellulose sodium based eye drop solution|1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
45844076|NCT01845636|Drug|Donepezil|Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
45844077|NCT01845636|Drug|Atropine|A single acute dose of 1 mg of atropine nasal spray is administered to the nostril. The dose chosen reflects clinical doses typically used by Ear, Nose, and Throat (ENT) physicians.
45357989|NCT04412265|Other|Relation between frailty and clinical outcomes in elderly patients with COVID-19.|"To evaluate whether a tool built to measure frailty in elderly patients hospitalized in COVID + hospital departments are more accurate in predicting clinical outcomes compared to a clinical evaluation based on age and comorbidity. If the assessment of fragility were actually more accurate, the tool developed could be implemented in hospitals to support the clinician 's choices regarding the roof of care and actions to be taken undertake to prevent deterioration."
45357990|NCT00830544|Drug|Neoadjuvant chemotherapy|Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100 cc NS over 90 min day 1 and day 8 Capecitabine 825 mg/M2 p.o. bid from day 1-14. Trastuzumab
45357991|NCT00830544|Drug|Chemotherapy|Neoadjuvant chemotherapy
45479388|NCT03506425|Drug|Triheptanoin|Triheptanoin is a medium chain triglyceride (MCT) that can improve mitochondrial function and energy production and therefore has potential for slowing ALS progression. Indeed, triheptanoin slowed motor neuron loss and delayed the onset of weakness in a mutant SOD1 model of ALS. The Triheptanoin we will use is a colorless to light yellow oil. The target triheptanoin dose for this study is 1g/kg/d. This target dose was selected because it was safe and tolerable and altered brain MR spectroscopy in patients with Huntington's Disease.
45844078|NCT01845792|Drug|Cabazitaxel with Abiraterone Acetate|Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.
45844079|NCT01845792|Drug|Cabazitaxel|Cabazitaxel intravenously every 3 weeks
45844080|NCT01846728|Drug|Estrogen suppression|Estrogen production will be suppressed for 3 months by administering a drug, lupron, that suppresses ovarian function
45844081|NCT01847196|Device|Angel® Catheter|The Angel® Catheter combines the functions of an inferior vena cava (IVC) filter and a multi-lumen central venous catheter (CVC). The device is designed to be placed in the inferior vena cava, via the femoral vein, for the prevention of Pulmonary Embolism (PE), and for access to the central venous system. The device is intended for short-term use (less than 30 days) and must be removed before hospital discharge.
45357992|NCT00830544|Drug|Neoadjuvant chemotherapy|Experimental chemotherapy regimen
45357993|NCT04407897|Radiation|Stereotactic radiotherapy|Three different dose fractionation schemes will be available: 45 Gy in 3 fractions, 50 Gy in 5 fractions, and 60 Gy in 8 fractions.
45687329|NCT05482789|Drug|Exenatide|10 microgram injected sub-cutaneously once
45844082|NCT01847430|Biological|Engerix™-B Kinder|Single dose administered intramuscularly in the deltoid region of non-dominant arm at Day 0.
45357994|NCT04382235|Device|Non-invasive ventilatory support|All non-invasive ventilatory support wll be recorded. All collected data is taken and monitored during normal clinical practice without adding any other tests.
45357995|NCT00843570|Drug|Nafarelin acetate, Oestradiol Valerate, Progesterone|Nafarelin acetate, Nasal spray, 400 mcg b.d., 4 weeks Oestradiol Valerate, tablet, 2mg o.d day 1-5, 2mg b.d. day 6-9, 2mg t.d.s day 10-13 (step-up protocol), 2mg q.d.s (if pregnancy confirmed, 4-10 weeks Progesterone, pessary, 200mg b.d. and t.d.s. (if pregnancy confirmed), 2-10 weeks
45687330|NCT05476211|Device|BTL-785F|Radiofrequency
45687331|NCT05474950|Drug|minocycline|minocycline capsule (100mg) per day orally
45687332|NCT05664386|Drug|propofol|propofol 2～2.5mg/kg was used for anesthesia induction. propofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthesia of induction and maintenance.
45357996|NCT04010877|Biological|CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells|Infusion of CLL-1, CD33 and/or CD123-specific CAR-T cells
45479389|NCT03051620|Drug|Discontinue alendronate|136 patients with osteoporosis stopping treatment with alendronate.
45479390|NCT03337360|Dietary Supplement|Impryl|Food supplement with betaine, cystine, zinc, niacin, folic acid (5MTHF-glucosamine), Vitamin B12 (cobalamin), Vitamin B6, Vitamin B2 (riboflavin)
45687333|NCT05664386|Drug|ciprofol|Ciprofol 0.4～0.5mg/kg was used for anesthesia induction. Ciprofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthetic induction and maintenance agents include rapid induction of general anesthesia, rapid recovery of consciousness, minimal residual effects on the central nervous system and less injection pain.
45687334|NCT05472090|Drug|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
45687335|NCT05472090|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
45844083|NCT01848054|Drug|Buprenorphine/naloxone sublingual tablets|Advanced-formulation buprenorphine/naloxone sublingual tablets
45844084|NCT01848054|Drug|Buprenorphine|Buprenorphine sublingual tablets
45844085|NCT01848366|Device|Biowave Treatment|Twelve weekly treatments
45844086|NCT01849068|Drug|Ezetimibe|Ezetimibe 10 mg/d for 12 weeks
45844087|NCT01849068|Drug|Placebo|Placebo for 12 weeks
45844088|NCT01849692|Drug|ESBA1008 solution|Intravitreal injection or infusion
45687336|NCT05471973|Other|Multidisciplinary Team|Multidisciplinary team will be established that will define gaps in care, monitor ongoing data, identify barriers to guideline-directed care, and develop and implement multifaceted intervention to address the barriers
45844089|NCT01849692|Drug|Ranibizumab|Intravitreal injection
45844090|NCT01849770|Drug|Mexiletine|
45844091|NCT01849770|Drug|Placebo|
45844092|NCT01850394|Drug|Tranexamic Acid|Inject tranexamic acid solution intra-articularly after fascia closure
45844093|NCT01850394|Drug|Physiologic saline|Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
45687337|NCT05471973|Other|Outreach Visits|An outreach visit consulting group from the coordinating center and trial leadership will provide external guidance on reviewing data, defining barriers, and implementing interventions
45844094|NCT01850550|Behavioral|Weight loss Groups|The intervention will consist of 12 weekly one-hour weight loss sessions led by successful volunteer peers. Participants are provided with a modified version of the Diabetes Prevention Program manual and are mentored by peer leaders at weight loss sessions.
45844095|NCT01851876|Device|Endometrial injury|Endometrial injury with Endometrial Suction Curette (pipelle) will be performed.
45844096|NCT01852032|Radiation|Tomosynthesis Breast Scanning|The breast is positioned and compressed the same way it is in a conventional mammogram using a compression paddle device. The subject will be instructed to hold their breath and not move during the 7- second 3-D tomosynthesis acquisition. The affected breast is positioned with MLO compression. The radiation dose levels for each scan are equivalent to mammography
45844097|NCT01852032|Radiation|Breast CT Scanning|"CT scanning will be performed before and after I.V. iodine contrast injection. The subject will lie prone on a large table (which is covered by a foam pad), and she will place the breast to be scanned in a small hole in that tabletop. The hole is surrounded by a soft neoprene hammock, which will allow the subject's entire upper torso to slump into the scan plane of the device. After positioning of the affected breast by a female mammography technologist, the subject will be instructed to hold their breath for 16 seconds and the pre-contrast scan will commence. There will be no breast compression. Other than the sound of the relatively noisy x-ray system in the room, the subject will not feel or sense any aspect of this scan."
45844098|NCT01852344|Drug|Methylphenidate|20 mgs of methylphenidate or placebo to be administered one hour before task performance
45844099|NCT01852344|Drug|Placebo|20 mgs of methylphenidate or a placebo to be administered one hour before task performance
45844100|NCT01852344|Behavioral|Easy Behavioral Task|Subjects do an easy version of the Letter E Task.
46047405|NCT02191566|Drug|OXALIPLATIN (205803BIJ)|Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
46047406|NCT00596830|Drug|CP-751,871 (Figitumumab)|CP 751,871 is a potent and selective fully human monoclonal antibody against the insulin like growth factor 1 receptor (IGF-1R). Patients in Arm A will receive CP-751, 871 intravenously every 21 days for up to six cycles.
46047407|NCT00596830|Drug|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive carboplatin intravenously every 21 days for up to six cycles.
46047408|NCT00596830|Drug|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive paclitaxel intravenously every 21 days for up to six cycles.
46047409|NCT00596830|Drug|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive carboplatin intravenously every 21 days for up to six cycles.
46047410|NCT00596830|Drug|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive paclitaxel intravenously every 21 days for up to six cycles.
46047411|NCT00957372|Drug|eslicarbazepine acetate|oral tablet, 800 mg or 1200 mg once daily
45844101|NCT01852344|Behavioral|Hard Behavioral Task|Subjects do a hard version of the Letter E Task.
46047412|NCT00957372|Drug|placebo (Part I)|once daily placebo comparator
45844102|NCT01854138|Device|Prevena Incision Management System|Prevena Incision Management system will be applied to clean surgical wounds of patients undergoing Total Knee Arthroplasty or Total Hip Arthroplasty, immediately post-operatively. The unit will remain in place and functional for 7-8 days.
45844103|NCT01856712|Drug|Naltrexone|Naltexone was chosen for this study because naltrexone is the only medication available in both oral daily and injectable monthly formulations, which will allow the study to examine issues around medication adherence.
45844104|NCT01857258|Dietary Supplement|Green Tea Concentrate|Green tea concentrate is being examined as a dietary supplement that can regulate postprandial excursions in blood glucose
45687338|NCT05471973|Other|Multifaceted Intervention|These interventions are not limited to targeted engagement with non-extractors, electronic health record (EHR) decision support, creation of OR block time, use of opinion leaders, and development of clinical pathways. In addition, once patients are identified and referred to extraction centers, clinical pathways are needed to provide prompt care without clinical delay
45844105|NCT01857882|Other|Decision Support Workshop|"Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.~Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities~Registered nurse (30 mins): preparing for surgery, postoperative recovery and how to navigate the health care system~Social worker (30 mins): values clarification exercise~Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience"
45844106|NCT01858428|Device|Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
45844107|NCT01858428|Device|EverCross Percutaneous Transluminal Balloon Catheter|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
45844108|NCT01861002|Drug|Azacytidine|Dose assigned at study entry (75 mg/m2/day). Given subcutaneously, once daily on days 1 to 5, for a total of 5 doses.
46047413|NCT00957372|Drug|ESL - Open-label Extension (Part II)|Part II was a 1-year open-label extension for patients who had completed Part I. Starting at 800 mg/day, the dosage could be titrated at 400 mg intervals down to a minimum of 400 mg/day or up to a maximum of 1200 mg/day
46047414|NCT02858778|Other|Early order of palliative care consultation|
46047415|NCT02610582|Drug|rAAV.hCNGA3|Single subretinal injection of rAAV.hCNGA3
45357997|NCT05169723|Behavioral|Exertional respiratory activities|participants will perform a series of exertional respiratory activities
45357998|NCT00839124|Biological|Clinical Center Reference Endotoxin (CCRE)|inhalation challenge with 20,000 EU CCRE
46047416|NCT04270968|Device|extra-corporeal shock wave therapy|Extracorporeal Shock Wave Therapy (ESWT) has been introduced efficiently for more than twenty years as a treatment modality in orthopedic and musculoskeletal disorders. ESWT has mechanical and cellular impacts on tissues regeneration and pain management through cavitation bubbles, acoustic micro streaming, and hyper-vascularity that can directly affect tissue calcifications, and modulate cell activity.
46047417|NCT04270968|Drug|topical none steroidal anti-inflammatory drug|participants received 1% topical diclofenac gel on the tender points 3 times /day for 4 weeks.
45357999|NCT00839124|Biological|Clinical Center Reference Endotoxin (CCRE)|inhalation of 20,000 EU CCRE
45358000|NCT05156463|Combination Product|PAI Tool and Exercise Coaching|Use of PAI tool and self-monitoring tools to increase physical activity and reduce sedentary behaviors. Participants will receive a personalized physical assessment and counseling from healthcare provider, exercise logs and a Garmin activity tracker to use between visits and 9 exercise coaching calls between clinical visits.
45687339|NCT05471973|Other|Measurement and Feedback|The coordinating center will provide ongoing feedback related to the site's data. This will include time to diagnosis, treatment, and outcomes related to the device infection.
45358001|NCT05029869|Diagnostic Test|ctDNA|The blood samples for ctDNA and other tumor markers will be first collected within 14 days before surgery, and then be tested after gastrectomy in scheduled interval
45358002|NCT02547870|Drug|Rilpivirine (RPV)|Participants will receive one oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1.
45358003|NCT02547870|Drug|Rilpivirine Long-Acting Parenteral Formulation (RPV-LA)|Participants will receive one intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
45358004|NCT02547870|Drug|Aged RPV-LA|Participants will receive one intramuscular (IM) injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
45687340|NCT05466916|Behavioral|Exercise and diet education and instruction|1:1 or small group sessions consisting of educational materials and exercise instruction.
45687341|NCT05465096|Procedure|Micro-fragmented adipose tissue injection|Intra-articular ultrasound-guided injection of MF-AT
45844109|NCT01861002|Drug|Fludarabine|30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 6 to 10, total 5 doses
45844110|NCT01861002|Drug|Cytarabine|2000 mg/m2/dose intravenous infusion over 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 6 to 10, total 5 doses.
46047418|NCT02857998|Drug|HMPL-523|Oral administration, once daily
45844111|NCT01861002|Drug|Intrathecal (IT) Cytarabine|"Intrathecally to AML patients on day 1 of course 1 and 2.~Omit on day 1 of course 1 if patient received IT therapy within 7 days prior to study enrollment~IT therapy may be given during the end of course 1 disease evaluation and repeated every 7 days~For patients with CNS disease, IT cytarabine can be given weekly until the CSF is clear. Two additional doses of IT cytarabine should be given weekly after the initial CSF clearing. It is permitted to change to intrathecal triple therapy (ITT) if persistent blasts are present in the CSF based on the treating physician's clinical judgment. Cytarabine dose defined by age:~30 mg for patients age 1-1.99~50 mg for patients age 2-2.99~70 mg for patients >3 years of age~ITT Dosing:~Age (yrs) - Dose Methotrexate (MTX), Hydrocortisone (HC), Cytarabine (ARAC):~- 1.99 MTX: 8 mg, HC: 15 mg, ARAC: 30 mg~- 2.99 MTX: 10 mg, HC: 25 mg, ARAC: 50 mg~3 - MTX: 12 mg, HC: 35 mg, ARAC: 70 mg"
45358005|NCT04251897|Device|Novel support surface|This is a magnetorheological elastomer that can dynamically redistribute the pressure over a bony prominence to be lower than the critical closing pressure while at the same time providing sufficient support.
45844112|NCT01861002|Drug|Intrathecal Methotrexate (IT MTX)|"Intrathecally to patients with ALL on day 1 of course 1 and 2.~Omit IT MTX on Day 1 of course 1 if patient received IT therapy within 7 days prior to study enrollment~IT therapy may be given during the end of course 1 disease evaluation and repeated every 7 days~For patients with CNS 2 or 3 disease, IT MTX can be given weekly until the CSF is clear. Two additional doses of IT MTX should be given weekly after the initial clearing of the CSF. It is permitted to change to ITT if persistent blasts are present in the CSF. Methotrexate dose defined by age~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age~Triple IT Therapy Dosing:~Age (yrs): Dose Methotrexate (MTX), Hydrocortisone (HC), Cytarabine (ARAC):~- 1.99 MTX: 8 mg, HC: 8 mg, ARAC: 16 mg~- 2.99 MTX: 10 mg, HC: 10 mg, ARAC: 20 mg~- 8.99 MTX: 12 mg, HC: 12 mg, ARAC: 24 mg~9 MTX: 15 mg, HC: 15 mg, ARAC: 30 mg"
45358006|NCT00836238|Behavioral|Interview|Physical Function and Symptom Assessment Interviews
45844113|NCT01861704|Device|Lyric|Extended wear hearing instrument
45358007|NCT00836238|Other|Physical Function Tests|3 physical function tests.
45358008|NCT02547168|Device|iRhythm ZIO XT patch|The iRhythm ZIO XT patch is an ECG monitor that has to be worn by study participants. It will be used to track any incidence of atrial fibrillation.
45358009|NCT04016610|Device|Soliton's Acoustic Scar Reduction (SAR)|Treatment of keloid scars for the temporary improvement in appearance.
45844114|NCT01861704|Device|Lyric2|Extended wear hearing instrument
45844115|NCT01863030|Device|Phasix mesh implant|
46047419|NCT05143164|Device|hydrocolloid dressing|Duoderm Extra Thin hydrocolloid dressing will be used to cover the catheter exit-site of participants in the intervention group. The dressing will be changed every 7 days or early if the dressing is no longer adhesive.
45358010|NCT00836316|Drug|levobupivacaine|intraperitoneal administration of levobupivacaine on pain after laparoscopic cholecystectomy
45358011|NCT00962169|Other|Behavioral and managerial|The quality improvement program is a multi-level intervention program to increase adherence to the Dutch physical therapy Guidelines for Low Back Pain. It consists of two program parts, one for practice quality managers and the other for individual therapists. The management part aims to increase commitment amongst practice owners towards high quality of care, including the appropriate use of guidelines, and addresses the structure and the culture of the physical therapy practice. This part of the program is based on the INK management model and the colour model of De Caluwé. The individual part of the intervention is aimed at increasing physical therapists' guideline adherence by raising awareness and improving recording and clinical reasoning. This part of the intervention is based on psychosocial and educational theories and especially on the principles of Self Regulation.
46047420|NCT05143164|Drug|Gentamicin Sulfate, Topical|Application of gentamicin to exit site daily
45358012|NCT00962169|Other|Behavioral and IT|The interventions makes use of an improved EPD for physical therapists. Compared to the existing EPDs, the EPD for the present study presents decision information for physical therapists. This decision information is directly based on the recently revised physical therapy guidelines for Low Back Pain and attached to the subsequent steps of clinical reasoning that are inherent to the diagnostic and treatment stages of the usual process of physical therapy care.
46047421|NCT04278222|Drug|Anlotinib Plus Toripalimab|Anlotinib 12mg oral administration daily d1-d14, q3w; Toripalimab 240mg iv drop d1, q3w
45687342|NCT05462509|Device|bCPAP with blenders|The intervention device is a low-cost bCPAP kit which includes two fixed-ratio oxygen blenders that do not require a source of pressurized air. These simple and inexpensive devices sit in-line from the oxygen source and dilute the flowing stream of oxygen with room air, obviating the need for a pressurized source of air. The oxygen may be supplied from either high-pressure sources or low-pressure sources such as oxygen concentrators. Each of the two blenders are single plastic parts, injection moulded from a biocompatible, medical-grade polyethylene resin. No electricity is required for the blenders to provide a stable and constant mix of air and oxygen over the full range of clinically relevant pressure and flows for newborns.
45844116|NCT01863498|Other|Epidural|Patients will have an epidural for pain control
45844117|NCT01863498|Other|PCA|Patients will have PCA for pain control
46047422|NCT00664144|Drug|Rasburicase (SR29142)|
46047423|NCT04280484|Other|Intermittent Hypoxia|1 minute of 9% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.
45844118|NCT01864434|Device|Stryker posterior cruciat retaining (PCR) total knee arthroplasty (TKA)|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
45844119|NCT01864434|Device|Zimmer PCR TKA|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
45844120|NCT01866306|Biological|RV16UB|RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.
45844121|NCT01866306|Drug|LABA|Asthmatic participants were treated with LABA as part of their standard of care
45844122|NCT01867164|Drug|Gynoclin V|One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
45844123|NCT01867164|Drug|Vagitrol V|One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
45844124|NCT01867632|Device|Acellular Dermal Matrix|
45844125|NCT01868334|Behavioral|Pillar 1: Convenient Vaccination Services|"Extend Vaccination Season: Begin vaccinating for influenza as soon as vaccine arrives; use every visit as opportunity to vaccinate; extend the season for influenza by vaccinating in January and beyond.~Use Express Vaccination services such as influenza vaccination clinics, Open access vaccine scheduling (for all vaccines), or dedicated vaccination station. When giving influenza vaccination, screen for need for PPSV/Tdap."
45358013|NCT00836394|Device|Galileo (whole body vibration (WBV) therapy)|6 minutes of training on 5 days a week for 3 months
45687343|NCT05461404|Other|Topical Emollient Therapy|Application of high-linoleate (>60% linoleic acid) SSO to the epidermis.
45687344|NCT05458557|Diagnostic Test|Rapid Antigen Testing|Community testing for SARS-COV-2 using rapid Antigen test
45687345|NCT05457413|Procedure|Sleeve gastrectomy|Bariatric surgery
45687346|NCT05452213|Drug|Ribociclib|"All patients will receive ribociclib in combination with standard endocrine therapy according to the current SmPC and local in-house standard.~Ribociclib will be administered once daily for 21 consecutive days followed by 7 days off treatment (28-day cycle). The daily dose is 600 mg/day.~Ribociclib and standard of care endocrine treatment will be prescribed and administered according to investigator's discretion."
45687347|NCT05450744|Drug|131I-IPA|131I-IPA: injection/solution administrated intravenously via infusion in ascending doses 18F-FET: injection/solution administrated intravenously
45844126|NCT01868334|Behavioral|Pillar 2: Patient notification|"Patient Education: notifying patients of doctor recommendations for vaccination; providing information on express vaccination services via email, autodialer, on-hold messages, clinic websites, and/or social media"
45844127|NCT01868334|Behavioral|Pillar 3: Enhanced Office Systems|Routine assessment for office systems flow to ensure staff consistently promoting vaccination: utilization of EMR prompts, review of Immunization tabs within EMR, and/or checking vaccination status as part of vital signs when rooming. Empower staff to vaccinate by use of a standing orders program (SOP). Order a sufficient supply of vaccination to cover increased rates
46047424|NCT04280484|Other|Sham Hypoxia|1 minute of 21% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.
46047425|NCT00660634|Procedure|Endovascular Revascularization|Angioplasty/Stenting of femoro-popliteal lesions
46047426|NCT02858700|Biological|dosage of the umbilical cord blood Procalcitonin for diagnosing of IBNP|
45358014|NCT00843960|Behavioral|behavioral adaptation and symptom management|behavioral adaptation and symptom management
45358015|NCT00962325|Behavioral|Intervention to increase physical activity|This will be a 6-week preoperative intervention to increase structured walking activity. This will be accomplished through weekly individual face-to-face sessions involving tailored instruction in use of standard behavior change strategies such as self-monitoring, goal-setting, stimulus control, etc.
45687348|NCT05449392|Drug|Neosporin|Neosporin is neomycin, bacitracin and polymyxin B with formulation 3.5mg/400 units/5,000 units. The subject will self-apply a small amount (approximately 0.5 g) of the ointment topically into each nostril (intranasal) twice daily (morning and evening) for seven days. Subjects are to pinch the nose to spread the cream.
45687349|NCT05449392|Other|Vaseline|The subject will self-apply a small amount (approximately 0.5 g) of the ointment topically into each nostril (intranasal) twice daily (morning and evening) for seven days. Subjects are to pinch the nose to spread the cream.
45687350|NCT05447689|Behavioral|Integrative-Mind-Body Skills Group|Integrative-Mind-Body Skills Group (I-MBS-G) is an 8-week group that teaches skills to build inner resources for effective mood management. This group incorporates a holistic approach to wellness through meditation and mindfulness practices, guided imagery, breath and body awareness, relaxation techniques, self-reflection, and mindfulness-based cognitive-behavioral skills. Mind-body approaches have demonstrated effectiveness in reducing stress mood symptoms and improving quality of life.
46047427|NCT04157452|Procedure|flexible ureteroscopy|flexible ureteroscopy is used to removed the stone. If a double-J stent was inserted pre-operatively, it was removed at the beginning of surgery. Rigid ureteroscopy was routinely used for ureteral dilatation before fURS. A 0.035 mm guidewire was advanced through the urethral and ureteral meatuses to the renal pelvis under direct rigid ureteroscope vision. A 14-Fr ureteral access sheath (Cook Medical, Bloomington, IN) was then passed over the wire to the ureteropelvic junction, and 7.5-Fr fURS (Flex-X2, Karl Storz, Germany) was performed through the sheath. Intrarenal pressure was stabilized by a pressure-sensitive pump (Shenda Medical, China). Holmium: yttrium-aluminum-garnet laser was used to fragment the stones. After lithotripsy, 6-Fr double-J stent was routinely inserted in all cases for 2-4 weeks.
45358016|NCT00839202|Other|FVIII immuno-assay|There is no intervention. This is a study of the differences in assays.
45358017|NCT00962403|Behavioral|Yoga treatment|The 10-week Kripalu-style yoga treatment will consist of 20 biweekly 90-minute group training/practice sessions. In addition, subjects will also receive CD's and written instructions for the daily 15-minute sessions, which they will use to guide them through the yoga procedures to be done at home.
45479391|NCT03337360|Other|Placebo|Inactive ingredients, placebo
45844128|NCT01868334|Behavioral|Pillar 4: Motivation|Utilization of an Office Immunization Champion who will track overall progress towards their goal - setting a goal of increased rates of 20 to 25% for influenza vaccine; monitoring and sharing progress with staff regularly; and changing office systems flow as needed to increased vaccination rates.
45844129|NCT01870596|Drug|Cytarabine|Given IV
45844130|NCT01870596|Drug|CHK1 Inhibitor SCH 900776|Given IV
45844131|NCT01870596|Other|Laboratory Biomarker Analysis|Correlative studies
45844132|NCT01874262|Device|Mobile-phone based patient support|The mobile-phone based patient support (investigational medical device) is a stand-alone software product used on the patients' own smart phone and used in addition to medical treatment.
45844133|NCT01874262|Device|e-diary|All patients (active and control group) participating in the study will report their daily use of ticagrelor in an e-diary which will be initiated on all study patients' smart phones.
45844134|NCT01875510|Dietary Supplement|Fish-oil emulsions|"Fish -oil emulsions:~Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg."
45844135|NCT01875510|Dietary Supplement|soybean-oil emulsion|soybean-oil emulsion
45844136|NCT01875978|Dietary Supplement|Phytosterols & placebo|Group A:Phytosterols 1.8g/day with one meal for 4 weeks first;group B:placebo first
45844137|NCT01876212|Biological|DC vaccine|
45844138|NCT01876212|Drug|Dasatinib|
45844139|NCT01876992|Drug|Metformin|
45479392|NCT02861183|Device|OVT (Sodium Hyaluronate)|A Peri-osteotendinous injection of OVT will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
45479393|NCT02861183|Device|Saline|A Peri-osteotendinous injection of sterile saline will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
45479394|NCT05290454|Other|mNGS-guided treatment|mNGS detect the causative microorganisms using appropriate lower respiratory tract (LRT) specimen. LRT specimen, such as endotracheal aspiration (ETA), bronchoalveolar lavage fluid (BALF), or protected specimen brush (PSB), will be obtained within 24 hours after the participants entering the ICU. Clinicians apply the definitive treatment based on mNGS results, as well as results of conventional microbiology diagnostic techniques.
45687351|NCT05446740|Biological|GSK4382276A Dose level 1|Dose level 1 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 1 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
45687352|NCT05446740|Biological|GSK4382276A Dose level 2|Dose level 2 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 2 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
45687353|NCT05446740|Biological|GSK4382276A Dose level 3|Dose level 3 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 3 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
45844140|NCT01877148|Device|tDCS|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability.
46047428|NCT02819856|Drug|Placebo|0 mg SPI-1005 bid po x 21d
45687354|NCT05446740|Biological|GSK4382276A Dose level 4|Dose level 4 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 4 and OA GSK4382276A Dose level 4 groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
45687355|NCT05446740|Biological|GSK4382276A Dose level 6|Dose level 6 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 6 group, at Day 1.
45687356|NCT05446740|Biological|GSK4382276A Dose level 7|Dose level 7 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 7 group, at Day 1.
45687357|NCT05446740|Biological|GSK4382276A Dose level 8|Dose level 8 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 8 group, at Day 1. Potential intermediate dose levels may be evaluated with the total number of dose levels not exceeding 10 in YA and 1 in OA.
45844141|NCT01877148|Behavioral|Physiotherapy|Physiotherapy protocol followed the guidelines outlined in clinical practice guideline for physical therapy in Parkinson disease of the Royal Dutch society for physical therapy (Keus, 2007). This guideline proposes some objectives for motor rehabilitation in patients with PD, such as: flexibility, strength, coordination, balance, posture and gait. The difficulty of exercises ranged according with Hoehn and Yahr (HY) staging scale. In this way, each stage of HY had a specific physical therapy protocol following the guideline.
45844142|NCT01877538|Other|[11C]donepezil PET|Positron Emission Tomography (PET) imaging of acetylcholinesterase with the ligand [11C]donepezil
45844143|NCT01878006|Drug|Morphine|
45844144|NCT01878006|Drug|Placebo|
45844145|NCT01879176|Device|CytoSorb|
45844146|NCT01879332|Drug|Placebo|Matching placebo tablets for oral administration
45844147|NCT01879332|Drug|BIA 2-093 3000 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
45844148|NCT01879332|Drug|BIA 2-093 3600 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
46047429|NCT02819856|Drug|SPI-1005 Ebselen 200mg Capsule x1|200 mg SPI-1005 bid po x21d
46047430|NCT02819856|Drug|SPI-1005 Ebselen 200mg Capsule x2|400 mg SPI-1005 bid po x 21d
46047431|NCT02819856|Drug|SPI-1005 Ebselen 200mg Capsule x3|600 mg SPI-1005 bid po x 21d
46047432|NCT02630290|Drug|Ropivacaine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine
45844149|NCT05329272|Other|Virtual Reality Cognitive Training Intervention (VRCTI)|The VRCTI was developed to improve cognitive function. The intervention was designed that simulated schema of underwater world fish swimming. Each 1-hour session was typically divided into three parts: easy, medium and difficult, each with 4 different tasks, so there are 12 tasks/session in total. In some tasks, the VRCTI also distinguished between the real lure (e.g. a red triangle fish with a half-moon pattern) as well as unrelated lure items (i.e., blue square fish with polka dot pattern and other irrelevant items). The use of hardware elements for this study included visual (head-mounted display [HMD] in delivering the VR intervention), audio, and motor equipment.
45844150|NCT05328960|Other|Diagnosed during or not during the pandemic|We will create a group of patients that are diagnosed before and after the pandemic and one group diagnosed during the pandemic
45687358|NCT05446740|Biological|GSK4382276A Dose level 9|Dose level 9 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 9 group, at Day 1. Potential intermediate dose levels may be evaluated with the total number of dose levels not exceeding 10 in YA and 1 in OA.
45687359|NCT05446740|Combination Product|FDQ21A-NH|Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 1 and OA Control groups, at Day 1.
45844151|NCT05328882|Other|Monitoring of paroxysmal atrial fibrillation recurrence after pulsed field catheter ablation|We will interrogate implanted loop recorder to see how many patients had an early recurrence of AF (up to 3 months after the procedure). Then we will compare the late recurrence rate (3-12 months post-procedure) between groups with and without early recurrences.
45844152|NCT05327478|Procedure|NRP|Normothermic Regional Perfusion
45844153|NCT05327478|Procedure|DHOPE|Dual Hypothermic Oxygenated Perfusion
45844154|NCT05327478|Procedure|COR-NMP|Controlled Oxygenated Rewarming Normothermic Machine Perfusion
45844155|NCT05327088|Drug|Dexmedetomidine|Dexmedetomidine, a highly selective α₂ receptor agonist, has a sympatholytic, sedative and opioid sparing effect.
45358018|NCT05010837|Other|Kinesio taping with abdominal exercises|"Experimental group was given kinesio taping along with abdominal exercises. Kinesio taping was applied in I-band technique. the first band is applied on rectus abdominis from origin to insertion starting from pubic symphysis till the xiphoid process. the second band is applied bilaterally on the left and right side external oblique muscles.~Abdominal exercises consist of 2-3 sets of 8 to 12 repetitions of head lift with bracing, head lift with pelvic tilt, pelvic clock, bridging, knee rolling and deep breathing exercises for 1 to 4 weeks.~From 5 to 8 weeks Same abdominal exercises with 5 sets and 15 to 20 repetitions were performed along with kinesio taping."
45844156|NCT05327088|Drug|Nalbuphine|Nalbuphine, a derivative of 14-hydroxymorphine is a strong analgesic with mixed k agonist and µ antagonist properties. The analgesic potency of nalbuphine has been found to be equal to morphine
45844157|NCT05310474|Device|Knee Glider|The purpose of this study is to study the efficacy of a remote range of motion monitor, the Knee Glider, alongside a patient engagement platform, Force Therapeutics, on clinical improvements and cost following primary TKA.
45844158|NCT05302050|Device|BT-001|"BT-001is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. BT-001 is accessed via the participants' smartphone.~The behavioral intervention process involves:~Identifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs.~Each week, BT-001 asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily."
45844159|NCT05302050|Device|Control Mobile Application|The app asks patients brief questions about their health but does not include any behavioral therapy.
45358019|NCT05010837|Other|Abdominal exercises|"Abdominal exercises consist of 2-3 sets of 8 to 12 repetitions of head lift with bracing, head lift with pelvic tilt, pelvic clock, bridging, knee rolling and deep breathing exercises for 1 to 4 weeks.~From 5 to 8 weeks Same abdominal exercises with 5 sets and 15 to 20 repetitions were performed."
45844160|NCT05290194|Radiation|SBRT radiotherapy + Conventionally fractionated radiotherapy|Radiotherapy was performed 3-6 weeks after the end of first-line treatment, followed by conventional fractionated radiotherapy of the primary tumor and cervical lymph node metastases, SBRT radiotherapy of distant organ metastases 3-6 weeks later.
45844161|NCT05290194|Drug|PD-1 inhibitor|Immunotherapy of PD-1 inhibitor is used during the whole time of this trial until subjects were withdrawn from the trial or the trial complete
45844162|NCT05290194|Drug|Capecitabine|Capecitabine is treated for patients 3-6 weeks after radiotherapy, which combines with PD-1 inhibitor as the maintenance regimen in the trial.
45844163|NCT05279196|Other|Quadriceps microbiopsy and blood collection|"Microbiopsy of the quadriceps muscle using a needle, Tru-cut biopsy, associated with a blood sampling at the start and after 6 months of a muscle strengthening training program"
45358020|NCT04043754|Procedure|Procedure/Surgery: Periodontal surgery with Membrane|Patients will be treated by periodontal surgical flaps with the addition of Membrane+ bone graft
45358021|NCT04043754|Procedure|Periodontal surgery with Platlet Rich fibrin|Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
45687360|NCT05446740|Combination Product|FDQ22A-NH|Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 2, at Day 1.
45844164|NCT05228574|Dietary Supplement|Sodium chloride (NaCl)|Sodium chloride capsules 6 grams per day for 4 weeks.
45844165|NCT05228574|Dietary Supplement|Placebo|Placebo capsules, 6 grams per day for 4 weeks.
45844166|NCT05228574|Drug|Amiloride Hcl 5mg Tab|Amiloride 5mg tablets, 20 mg per day for two weeks in open-label setting.
45844167|NCT05029674|Device|Whoop|Wear WHOOP Strap, complete surveys
45358022|NCT00836550|Behavioral|Video|The participants saw a 6 minute video
45358023|NCT00836550|Behavioral|in-person HIV pre-test counseling|
45358024|NCT02546778|Device|Dermosux RF|The radio frequency was used for 20 min in the abdomen and flanks, once per week for 7 weeks.
45358025|NCT00546819|Biological|Zoster Vaccine, Live|A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1
45687361|NCT05445947|Behavioral|The EASEL (Enhancing And Supporting Early Development to Better Children's Lives) Approach|"The EASEL Approach consists of a set of educator-led practices that can be incorporated into the daily classroom environment for children three to six years of age. The overall purpose of this approach is to enhance early childhood educators' teaching practices that would promote children's SEB+EF development.~Nine EASEL practices were selected for inclusion in the EASEL Approach. These are a) core fundamental practices that are evidence-based, b) practices that expert stakeholders identified as ones for which local early childhood educators may need additional training, c) practices that are not already covered in pre-service training to avoid replication for educators, d) a combination of practices that educators may already be implementing and can enhance, and new practices, and e) a balance of antecedent and consequential practices (i.e., practices that can be implemented before and after a target behavior)."
45687362|NCT05445076|Biological|anti-TRBV9 monoclonal antibody, low dose|infusion
45687363|NCT05445076|Biological|anti-TRBV9 monoclonal antibody, high dose|infusion
45844168|NCT04774068|Drug|Parsaclisib|Given PO
45844169|NCT04774068|Drug|Romidepsin|Given IV
45844170|NCT04621344|Diagnostic Test|Guided bronchoscopy and/or endosonography|Endoscopic procedures aimed at sampling of intrathoracic lymph nodes or pulmonary lesions
45844171|NCT04304742|Procedure|hip standard radiography/ CT scan/ MRI|hip standard radiography/ CT scan/ MRI
45844172|NCT04260672|Behavioral|Child Centred Health Dialog (CCHD)|"The universal part of CCHD means a structured dialogue between the nurse and the child in presence of its parents using eight illustrations based on the most important practices associated with overweight in preschool children: fruit and vegetables consumption, intake of sweetened beverages and portion size, physical activity, sedentary behaviour tooth brushing and sleep routines. The health dialog is completed by demonstrating the BMI-growth chart to show BMI development to give parents an accurate weight perception, identify overweight and support parental readiness towards a healthy lifestyle.~When the child is identified with an overweight or obesity, the entire family is invited to participate in the targeted part of CCHD: the Family Guidance, a family consultation based on the evidence based Standardized Obesity Family Therapy (Nowicka, 2011)."
45844173|NCT04233138|Other|SUPPORT online platform for people with type 1 diabetes|"All participants accepting the SUPPORT study will receive the full intervention for 6 months. Their learning is individualized depending on the way they take their insulin (injection or pump) and the way they measure their blood sugar (finger prick or continuous glucose monitoring).~The training program starts with mandatory module on hypoglycemia. Once completed, participants will unlock all level 1 (out of 3 levels) modules from the 6 categories (medication, blood sugar monitoring, nutrition, physical activity, hypo- and hyperglycemia, health and other situations). The platform contains functionalities such as discussion forum, quizzes, videos, downloadable forms, etc. During the first 6 months, participants will receive a bi-weekly newsletter to inform them about what's new on the platform."
45844174|NCT04132362|Behavioral|Personalised music listening|People will be sequentially recruited to discover their favourite music playlist, monitor their emotional responses to specific songs and explore the impact of listening to the music, on their behavioural and psychological symptoms. This will be done through a one hour music listening session, to discover the top 10-20 songs they respond to. It will then be followed by multiple shorter music listening sessions, initiated by the dementia resident themselves or their carer, where they listen to their favourite songs during their day, before difficult moments of care or during visits with their families.
45358026|NCT00546819|Biological|Comparator: Placebo|A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1.
45358027|NCT04010643|Behavioral|online cognitive behavioural therapy|oCBT: MoodGym is a 5-week oCBT program developed by the Centre for Mental Health Research at the Australian National University. This program has been shown to be clinically effective at reducing mood symptoms in depression studies (see meta-analytical review of Twomey & O'Reilly, 2017). MoodGym consists of a number of interactive modules to be completed sequentially and including work on own feelings, thoughts, methods to change dysfunctional thinking patterns, de-stressing, and relaxation. Each module is followed by an associated practical homework, while a personalised workbook allows the participant to track their mood profile and progress throughout the modules.
45687364|NCT05445076|Other|placebo|infusion
45687365|NCT05443347|Behavioral|Aerobic exercise|Supervised aerobic exercise
45687366|NCT05443347|Behavioral|Newsletter|Biweekly newsletter
45687367|NCT05436912|Drug|Selpercatinib|Administered orally.
45687368|NCT05425030|Dietary Supplement|Low-Sodium Salt Substitute|Tata SuperLite low-sodium salt substitute has 30% of the weight of the product replaced with potassium chloride (KCl) which is itself a non-prescription dietary supplement. Each household randomized to the intervention arm will receive one bag (1.5kg) per month to utilize instead of their usual table/cooking salt.
45687369|NCT05425030|Behavioral|Information/Education|Community health workers will provide basic information on high blood pressure, the health consequences of excessive salt consumption, and feedback to the participant on the likely quantity of salt s/he consumes (estimated using a questionnaire)
45844175|NCT04132362|Behavioral|Using fMRI to investigate the effect of listening to personalised music evoking positive emotional response on brain activation|12 of the recruited participants, who have symptoms and signs of mild to moderate dementia will be invited to take part in this sub-study. Using an amended version of a previously employed fMRI paradigm, each study participant will be presented inside the MRI scanner with short 30 second epochs of music (identified as evoking a positive or neutral emotional response) in a block design. Each 30 second epoch of music will be followed by a 16 second period when participants will be asked to rate subjective changes in their affective state using a computerised visual analogue scale. Epochs of positive emotional stimuli will alternate with epochs of neutral emotional stimuli in a counterbalanced order of presentation in 2 runs of 10 epochs each (5 positive and 5 neutral in each run).
46047433|NCT02630290|Drug|Ropivacaine + Dexmedetomidine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine plus low-dose (30 microg) dexmedetomidine
45844176|NCT04132362|Behavioral|Personalised music listening in the community|1000 families affected by dementia will be invited to use our WebApp to create a personalised playlist for their loved one with dementia and share their perceptions of how the music has affected the well-being of their loved one.
45358028|NCT04010643|Behavioral|online neurocognitive remediation therapy|NCRT involves the behavioural application of structured exercises targeting neurocognitive processes by mobilising neuroplasticity that is the brain's ability to adjust its function in response to environmental change. Computerised NCRT has demonstrated efficacy to improve attention, working memory and global functioning in depression (Motter et al., 2016; Semkovska et al., 2015). NCRT is delivered through the Cognifit online programme. The Cognifit modules were selected as targeting remediation of neurocognitive domains known to be impaired in depression, i.e. selective and divided attention, visual and verbal working memory, and everyday planning (Hammar and Ardal, 2009; Semkovska et al., 2019).
45844177|NCT04132206|Other|stool sampling|Participants will provide two stool samples: one collected the day of inclusion and a second, six months later
45358029|NCT00962481|Drug|Bimosiamose|
45844178|NCT04103034|Drug|BT200|BT200 is a PEGylated synthetic RNA oligonucleotide
45844179|NCT04103034|Drug|Desmopressin|Sterile solution for injection
45844180|NCT04103034|Drug|Placebo|Sterile saline for injection
45844181|NCT03916614|Behavioral|Screening Tool for Relief of Trauma (START)|The Screening and Tool for Awareness and Relief of Trauma (START) was developed for patients that come from communities with sustained and persistent trauma. It consists of six screening questions adapted from the validated Primary Care PTSD Screen,[30] with input from focus groups, surveys and in-depth interviews with victims of violence. The full START intervention requires 30-45 minutes of structured conversation at the end of which the participant leaves with a better understanding of trauma symptoms as well as on-the-spot instruction on a set of techniques designed to alleviate the symptoms of PTSD. Based on the results of their screening, the participant will be offered up to four techniques to alleviate their symptoms
45844182|NCT03916614|Behavioral|standard of care|Screening for PTSD and referral for outpatient services if warranted as well as usual care from Violence Prevention and Outreach Program (VPOP) staff.
45844183|NCT03820596|Drug|Sintilimab|"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects."
45844184|NCT03820596|Drug|Chidamide|"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects."
45844185|NCT03776760|Device|Fingerstick GeneXpert HCV RNA quantitative assay|All participants at risk of HCV infection will receive HCV RNA testing using the GeneXpert finger-stick point-of-care HCV quantitative assay 6 monthly
45358030|NCT00962481|Drug|Placebo|
45358031|NCT05299437|Drug|Radioiodine optimized therapy|"124-I blood and lesion dosimetry will be used to optimize the 131-I therapeutic activity. Both 124-I and 131-I administration will be performed after hormon withdrawal.~Primary tumour tissue and circulating miRNA will be analyzed to check the genetic status."
45358032|NCT00621504|Drug|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours, for 5 to 7 days
45687370|NCT05423093|Behavioral|Single-Session Virtual Group Psychoeducational Session about Postpartum Depression|Session contents include (1) Introduction to clinic staff, contacts, and resources (2) A video-recorded testimonial of a patient with a history of perinatal depression followed by a group discussion about/reflection on the video; (3) Review of prevalence and signs of PPD; (4) Discussion of clinic PPD screening procedures and rationale for screening; (5) Discussion of self-care and mood monitoring; (6) Discussion of relevant local resources, including information about availability of primary care resources for parents (including uninsured parents) and information about resources addressing social needs.
45687371|NCT05421741|Drug|Antibiotic coated intramedullary Nail|"Antibiotic coated intramedullary nail:~A mixture of 40gm bag of acrylic cement, antibiotic powder (Vancomycin 2gm) and 560mg gentamicin liquid. The intramedullary is coated with the mixture using a cement gun tube."
45687372|NCT05421741|Other|Standard Intramedullary Nail|Standard Intramedullary Nail
45687373|NCT05413928|Behavioral|Time Restrictive Eating- late|Eating window will be 10 hours or less, starting 3 hours after waking up. Same monitoring as Baseline phase.
45844186|NCT03776760|Drug|sofosbuvir/velpatesvir|Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
45844187|NCT03776760|Drug|glecaprevir/pibrentasvir|Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
45844188|NCT03423888|Device|high-flow nasal cannula oxygen therapy (HNFC)|"Set up of high-flow nasal oxygen for patient with dyspnea for a respiratory disease without possibility of curative care. Patients who require a treatment by oxygen are included.~After 7 days of treatment, acceptability is evaluated by the duration of use of HNFC."
45844189|NCT03394248|Device|Vector Mouthguard|The mouthguard will be used by athletes to measure the magnitude and number of impacts throughout one season.
45358033|NCT00621504|Drug|IV Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours, for 5 to 7 days
45358034|NCT00621504|Drug|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
45358035|NCT00621504|Drug|Clarithromycin|In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.
45358036|NCT00548145|Drug|Pitavastatin|2 mg by orally/day Duration: 12 months
45358037|NCT00548145|Drug|cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)|duration: 12 months
45687374|NCT05413928|Behavioral|Time Restrictive Eating- early|Eating window will be 10 hours or less, starting 30 min after waking up. Same monitoring as Baseline phase.
45687375|NCT05413928|Behavioral|Time Restrictive Eating- early with early caloric intake|Same as TRE-early, but concentrating caloric intake early in the eating window Same monitoring as Baseline phase.
45687376|NCT05413928|Other|Macronutrient-controlled meals|Meals with a determined amount of protein, carbohydrates, and fat.
45687377|NCT05413837|Diagnostic Test|anotomy and variation of venous sinus|Contrast enhanced-magnatic resonance venography（CE-MRV）and other magnetic resonance imaging methods are used to estimate the anatomy of cerebral venous sinus.
45687378|NCT05413837|Diagnostic Test|the level of biomarker in bood|Elisa or omics analysis is used to test the level of biomarker in blood.
45687379|NCT05413785|Behavioral|Telehealth in Parole/Probation Office|Onsite (telehealth) linkage toHep C treatment in a Probation and Parole office setting via an onsite nurse navigator. The navigator will provide Hep C education, draw labs, and facilitate a telemed visit with a UK GI provider.
45687380|NCT05412212|Other|LTBI video intervention|3-minute educational video about latent tuberculosis and importance of taking and completing treatment
45844190|NCT03393390|Diagnostic Test|Clinical Assessment Visit|Subjects will meet with a clinician who will determine if they meet diagnostic criteria for an externalizing disorder.
45844191|NCT03393390|Other|fMRI scan|Subjects will undergo an fMRI scan where images will be taken for observational purposes only, not as a means of diagnosis.
45844192|NCT03252834|Diagnostic Test|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI1 will be analyzed. Quantitative Sensory Test, QST, will be used to determined if there is abnormal thermal sensation.
45844193|NCT03191526|Drug|KW-0761 0.3 mg/kg IV|Intravenous injection every 12 weeks.
45844194|NCT03191526|Drug|Placebo (saline)|Intravenous injection every 12 weeks.
45844195|NCT03158298|Other|Specimen collection|Maternal blood sample of 10 ml collected by venepuncture upon delivery
45358038|NCT00547911|Drug|Droxidopa|
45358039|NCT00547911|Drug|Carbidopa|
45358040|NCT00547911|Drug|Entacapone|
45358041|NCT00839280|Drug|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
45358042|NCT00839280|Drug|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
45358043|NCT00836628|Drug|Busulfan|
45687381|NCT05411120|Other|Western Diet|Western Diet is by high intakes of pre-packaged foods, refined grains, red meat, processed meat, high-sugar drinks, candy and sweets, fried foods, conventionally-raised animal products, butter and other high-fat dairy products, and low intakes of fruits, vegetables, whole grains.
45687382|NCT05411120|Other|CLEAN-MED|Mediterranean like diet is a high consumption of vegetables, oil and moderate consumption of protein, with no processed foods.
45687383|NCT05408520|Procedure|Targeted Muscle Reinnervation|When a nerve is severed or injured, it attempts to regenerate. The TMR procedure will transfer the transected nerves to adjacent muscle nerves in efforts to encourage the nerve to regenerate in an organized fashion.
45687384|NCT05407779|Biological|BCD-180, dose 1|anti-TRBV9 monoclonal antibody single infusion at dose 1
45687385|NCT05407779|Biological|BCD-180, dose 2|anti-TRBV9 monoclonal antibody, single infusion at dose 2
45844196|NCT03021096|Other|Surveys|The study is just using validated surveys to assess pain and mood states after surgery
45844197|NCT02885220|Other|Conventional Program|No scheduled intermediate weight loss goals provided to patient
46047434|NCT04157530|Device|wang-bu-liu-xing|wang-bu-liu-xing applied on the surface of Jinming and Qiuhou acupoints
46047435|NCT04157530|Device|acupuncture|acupuncture applied to Qingming and Qiuhou with Der-qi
46047436|NCT04157530|Device|Electroacupuncture|acupuncture, but the needles of Qinming and Qiuhou connected to the electroacupuncture machine after Der-qi, the frequencies of stimulus were 6 Hz, the intensity of stimulus was minimal visible muscle twitch
46047437|NCT00953160|Device|Cutera Radio Frequency Device|Up to three treatments, one pass, dosage range of 15-60 kJ.
46047438|NCT02856906|Other|occlusal adjustment|
45358044|NCT00962637|Drug|Androxal|12.5 mg once daily
45358045|NCT00962637|Drug|Androxal|25 mg once daily
45358046|NCT00962637|Drug|AndroGel|5 g applied topically daily. The subject was to return to the clinic every 2 weeks for the first 2 months to monitor serum testosterone levels. If testosterone concentration remained below the normal level, the dose of AndroGel® could have been increased to 10 g and then to 15 g according to the guidance provided in the product package insert.
45687386|NCT05407779|Biological|BCD-180, dose 3|anti-TRBV9 monoclonal antibody, single infusion at dose 3
45844198|NCT02885220|Other|Goal-directed Program|Scheduled program with intermediate weight loss targets reinforced to patients during follow up.
45844199|NCT02232282|Device|standard acupuncture treatment|A standardized acupuncture treatment will be assigned, and both groups will receive 7 acupuncture treatments that follow a standardized protocol on classical acupuncture points, with or without mild electrical stimulation versus sham/minimal acupuncture. Acupuncture needles are single use, sterile and disposable. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.
45844200|NCT02232282|Device|Control Sham/Minimal Acupuncture|"Control group will receive sham/minimal acupuncture with low level electrical stimulation. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including minimal acupuncture, therefore, the control group will not be aware of receiving sham acupuncture. These described acupuncture treatments are well accepted treatment protocols for women with pelvic pain and bladder complaints."
45844201|NCT01643460|Procedure|98% Ethanol & Paclitaxel injection|Pancreatic cyst injection via Endoscopic Ultrasound (EUS)of 98% Ethanol with Paclitaxel (dose determined in relation to cyst size & amount of fluid aspirated from the cyst.
45844202|NCT00954876|Drug|capecitabine and cetuximab|"Cetuximab 500 mg/m2 IV infusion over 1-2 hours Once every 2 weeks~Capecitabine 1500 mg/m2 PO BID Days 1-7 followed by 7 days of no treatment and repeated every 2 weeks"
45844203|NCT01879800|Behavioral|Acceptance and Commitment Therapy plus Illness Management|
46047439|NCT00668356|Drug|didanosine|28 days 400 mg/m2/day during the meal 28 days 240 mg/m2/day during fasting
46047440|NCT00668356|Drug|didanosine|28 days 240 mg/m2/day during fasting 28 days 400 mg/m2/day during the meal
46047441|NCT00952848|Other|questionnaire administration|Pain Rating Score
46047442|NCT00952848|Other|Sensory Neuropathy Scale instrument|ECOG Common Toxicity Criteria for Sensory Neuropathy scale
46047443|NCT00952848|Other|Quality of Life instrument|Uniscale 0-100 scale global quality of life
45687387|NCT05407779|Biological|BCD-180, dose 4|anti-TRBV9 monoclonal antibody, single infusion at dose 4
45687388|NCT05407779|Biological|BCD-180, dose 5|anti-TRBV9 monoclonal antibody, single infusion at dose 5
46047444|NCT00952848|Device|MC5-A Scrambler device|Electrical stimulation for 60 minutes
46047445|NCT00664222|Drug|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks
46047446|NCT04157374|Other|Action Observation training|They have to watch a video showing a person carrying out exercises (12 exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional). then they have to practice them. The observation of the exercises and their performance last 8 minutes (4 minutes for observation and 4 minutes for practice). They have to repeat the exercises 5 times per week for 3 weeks.
46047447|NCT04157374|Other|Active Exercises|Execution of exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional activity. Patients of the control group recieve a brochure with the same exercises the patients of the experimental group received through the video. They will be asked to read the exercise 3 times and to practice it for 4 minutes. They have to repeat the exercises 5 times per week for 3 weeks.
46047448|NCT00668512|Biological|Antimelanoma injection of GSL alpha-Gal|Single arm, phase 1 trial of escalating doses of GSL alpha-Gal (0.1mg, 1mg, 10mg)injected into a melanoma metastasis at day 0 and then again 4 weeks later.
46047449|NCT00664300|Behavioral|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
45358047|NCT00962637|Drug|Placebo|1 capsule daily
45687389|NCT05407779|Biological|BCD-180, dose 6|anti-TRBV9 monoclonal antibody, single infusion at dose 6
45687390|NCT05407779|Biological|BCD-180, dose 7|anti-TRBV9 monoclonal antibody, single infusion at dose 7
45687391|NCT05406219|Drug|BAY2395840|Immediate release (IR) tablet, oral administration
45687392|NCT05405439|Drug|TQB3823 tablets|TQB3823 tablet is an inhibitor of poly ADP-ribose polymerase (PARP).
45687393|NCT05405439|Drug|Abiraterone acetate tablets|Abiraterone acetate tablet is an inhibitor of cytochrome P450 17（CYP17）
45687394|NCT05405439|Drug|prednisone acetate tablets|Prednisone acetate tablet is a kind of glucocorticoids
45358048|NCT00839358|Drug|albumin|albumine 40 g every 15 days
45844204|NCT05748366|Procedure|Serratus Anterior Plane Block (SAPB)|The ultrasound-guided serratus anterior plane block (SAPB) will be performed in a manner previously described in published medical literature. Patients will be consented and monitored. Bupivacaine 0.5% (5 mg/ml) diluted to 30-40 ml will be used in a dose not to exceed 2 mg/kg. The serratus anterior fascial plane will be identified in the 4th/5th intercostal space. The needle will be advanced under real-time ultrasound guidance targeting the superficial serratus anterior fascial plane. The procedure assistant will inject small volumes to hydrodissect the muscle bellies evenly under direct visualization, indicating local anesthetic spread within the fascial plane. Anesthetic will then be injected in 5 ml increments and the needle will be removed. Patient will be continuously monitored on telemetry and pulse-oximetry. Reassessment of the patient will continue for 30 minutes to monitor for signs of local anesthetic systemic toxicity.
46047450|NCT00668590|Behavioral|Patient video decision aid & telephone coaching|The decision aid is a 30 minute video program that educates patients about their role in diabetes care. Telephone coaching will assist patients in initiating behavior change.
45687395|NCT05393973|Other|Core stability exercises along with conventional physical therapy|"Core stability exercises included neck isometric exercises(flexion, extension, lateral flexion, rotation), chin tuck, chin tuck into towel, cervical extension + 10 minutes hot pack+ 10 minutes stretching (cervical flexors, extensors, rotators), session will be of 30-40 minutes, three times a week, for 4 weeks duration.~Chin Tuck: In standing subject pulls back the chin( as if trying to make a double chin) while keeping the eyes level. This will be done for 15 repetitions.~Cervical extension: In a standing position, the subject grasps the base of the neck, with both hands while extending the neck as far as possible. This will be done for 15 repetitions"
45844205|NCT05748366|Drug|Standard Analgesic Medications|Analgesic medications will be administered via the intravenous, intramuscular or oral route at the discretion of the medical treatment team.
46047451|NCT00668590|Behavioral|Printed educational brochure|The printed brochure is an educational brochure developed by the NIH.
46047452|NCT02856516|Other|Boost Glucose Control (A)|Oral nutrition supplement
46047453|NCT02856516|Other|Boost Glucose Control (B)|Oral nutrition supplement
46047454|NCT02856516|Other|Boost Original|Oral nutrition supplement
46047455|NCT04280250|Other|Volitional Help-Sheet|Self-help sheet in order to form implementation intentions
46047456|NCT04280250|Other|Control condition|Psychoeducational self-help sheet
46047457|NCT02858544|Other|The Concussion Identification Index|Patient completion of the Concussion Identification Index, a report of crash characteristics, injuries sustained, and post-accident neurological signs and symptoms
46047458|NCT02858544|Other|ImPACT|Patient- completed computerized neurocognitive test battery
46047459|NCT02630134|Other|These patients receive the Baeta device and take it home|
46047460|NCT00952614|Device|fluocinolone acetonide (Retisert Implant, Bausch and Lomb)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
46047461|NCT00668668|Drug|Lactic acid (Dermacid)|
46047462|NCT00911859|Drug|Siltuximab11 mg/kg|Participants will receive siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks in Part 1.
45687396|NCT05393973|Other|Swiss ball exercises along with the conventional physical therapy protocol|Swiss ball exercise will be executed in the following order, assume supine posture on the treatment bed by fully extending their legs and putting them back on the bed in the most comfortable posture with hands on the abdomen. Second, while in the supine posture, support the head with one hand and insert a small Swiss ball near the back of the head with the other hand. Third, after having contacted the ball to the area below the back of the head, slowly turn the head and neck in the shape of the number '8'. Fourth, after having set 3 repetitions of rotating the head and neck for 10 seconds and then taking 10 seconds of general resting as 1 set of exercise, a total of 3 sets of exercise were executed with 1 minute of general resting taken between each set of exercise. Then perform neck flexion, extension, side bending, and rotation, hold each movement for 10 seconds + Hot pack (10 minutes) + 10 minutes of cervical stretching. Perform the exercise three times a week for 4 weeks duration.
45687397|NCT05389722|Drug|CC-92480|Specified dose on specified days
46047463|NCT00911859|Drug|Siltuximab 8.3 mg/kg or 11 mg/kg|Participants will receive siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks for 9 cycles of treatment in Part 2, Arm A and in maintenance period.
46047464|NCT00911859|Drug|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert in Part 1.
46047465|NCT00911859|Drug|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection for 9 cycles of the treatment period in Part 2. It will be administered twice weekly for first 4 cycles (on Days 1, 4, 8, 11, 22, 25, 29, and 32, followed by a 10-day rest period) and once weekly for next 5 cycles (on Days 1, 8, 22, and 29, followed by a 13-day rest period)
45687398|NCT05389722|Drug|Rifampin|Specified dose on specified days
45358049|NCT00839358|Drug|Midodrine|Midodrine 5mg/8 hs, can be increase up to 8mg/8hs if there is a lack of increase in at least 10mmHg in mean arterial pressure after 15 days of treatment.
45358050|NCT00839358|Drug|Placebo|saline solution
45358051|NCT00962715|Biological|Influenza Vaccine Trivalent Inactivated (TIV)|15 μg (0.5 ml) through needle into arm muscle on Days 1 and 28.
45358052|NCT00962715|Drug|Pegylated interferon (PEGrIFN-α, Pegasys)|180 μg (0.5 ml) before receiving TIV, through a needle under the skin.
45687399|NCT05389722|Drug|Itraconazole|Specified dose on specified days
45687400|NCT05389722|Drug|Digoxin|Specified dose on specified days
45687401|NCT05389722|Drug|Rosuvastatin|Specified dose on specified days
45687402|NCT05387980|Drug|CIBINQO|Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.
45687403|NCT05385913|Other|Multivitamin-no intervention|No intervention. All participants will be given a multi-vitamin to take for the duration of the study
45687404|NCT05383170|Drug|CyPep-1|Intratumoral injection
45687405|NCT05383170|Drug|Pembrolizumab 25 MG/ML [Keytruda]|IV infusion
46047466|NCT00911859|Drug|Melphalan|Participants will take melphalan 9 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
45687406|NCT05378464|Biological|Dendritic Cell (DC1) Vaccine|Participants will receive a DC1 vaccine injection at 1.0-2.0 x 10^7 cells, either to groin lymph notes or to tumor if accessible once a week for 3 weeks on days 1, 8 and 15. Participants will receive DC1 vaccine boosters every 3 weeks x 3.
45844206|NCT05748210|Other|Symptom management mobile health application with personalised support|"Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.~The app will comprise several interactive elements to provide children and their caregivers with real-time symptom management support. Comprehensive educational materials regarding cancer and its treatment side effects, including possible symptoms, functional limitations, and psychological responses, will be provided in the app for the children and their caregivers to gain a thorough understanding of the potential symptom burden that they may experience."
45844207|NCT05748210|Other|Wait-list Symptom management mobile health application with personalised support|To ensure the equity of access to a potentially desirable and effective intervention (i.e., mHeath app for symptom management), participants in the wait-list control group will be invited to receive the same intervention as participants in the intervention group after the completion of all assessments on a voluntary basis.
45844208|NCT05748132|Procedure|combined conventional and pulsed RF|"the classic Hartle technique is used to reach the Gasserian ganglion~Sensory stimulation with the RF equipment is conducted and parathesia of the affected branch is achieved at 0.1-0.2 V (50 Hz), keeping in mind that the mandibular part of the Gasserian ganglion is ventrolateral and the ophthalmic rootlets are postrolateral. Motor pre-stimulation (2 Hz) is achieved with masseter contraction at 0.1-0.3 V .~After sensory and motor stimulation, RF therapy is conducted by use of the RF generator , in the sequence:~Conventional RF 1st lesion at 60 °C for 60 s then 2nd lesion at 65°C for 60 seconds then 3rd lesion at 70°C for 60 seconds~Finally, PRF is applied for 360 second repeated at 45 V, with a pulse width of 10 ms and a pulse frequency of 4 Hz. The cut-off needle tip temperature is set at 42 °C.~Before withdrawal of needle 1 cc xylocaine 1% + 0.5 cc dexamethasone 4mg to be given"
45687407|NCT05378464|Drug|Trastuzumab|Participants will receive trastuzumab 8 mg/kg by IV week 1, then 6 mg/kg by IV beginning week 4 and continuing every 3 weeks until disease progression or intolerable toxicity.
45687408|NCT05378464|Drug|Pepinemab|Participants will receive pepinemab 20 mg/kg by IV beginning week 1 and continuing every 3 weeks until disease progression or intolerable toxicity.
45844209|NCT05747898|Procedure|cannula- based subcision|Insertion of a needle into the base of a cutaneous scar to cut fibrous tissue and help new collagen formation.
45844210|NCT05747898|Procedure|common- needle based subcision|Insertion of a cannula into the base of a cutaneous scar to cut fibrous tissue and help new collagen formation.
45844211|NCT05747820|Other|Observational study|This is an observational study designed to assess the evolution of multiple markers of congestion over 4 weeks after a WHF event treated in an outpatient unit
45844212|NCT05747664|Drug|DWP16001|0.3mg
45844213|NCT05747508|Combination Product|INOpulse®|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
45844214|NCT05747508|Combination Product|Placebo|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
45844215|NCT05747508|Combination Product|Long Term Follow Up|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
45844216|NCT05747274|Other|No intervention|It is a retrospective study using samples and clinical data from the Divat Cohort
46047467|NCT00911859|Drug|Melphalan|Participants will receive melphalan according to currently approved package inserts. Melphalan 9 mg/m2 will be administered orally for 9 cycles of treatment period in Part 2, Arm A.
46047468|NCT00911859|Drug|Prednisone|Participants will take prednisone 60 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
46047469|NCT00911859|Drug|Prednisone|Participants will take prednisone 60 mg/m2 orally for 9 cycles of treatment period in Part 2, Arm A.
46047470|NCT00911859|Drug|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert.
46047471|NCT00911859|Drug|Melphalan|Participants will take melphalan 9 mg/m2 orally according to currently approved package insert.
46047472|NCT00911859|Drug|Prednisone|Participants will take prednisone 60 mg/m2 orally according to the package insert.
46047473|NCT00664612|Device|AirTraq|Laryngoscopy with AirTraq
46047474|NCT00956592|Device|CMAC video laryngoscope|Intubation utilizing the assistance of video enhancement
46047475|NCT00956592|Device|Macintosh laryngoscope|Patients will be intubated utilizing either a Macintosh 3 or Macintosh 4 designed blade
46047476|NCT00668824|Drug|Vasovist|
45687409|NCT05378464|Biological|T-Cell therapy|Participants will receive IL-15 expanded CD4 T cells infusion by IV Day 1 at week 8, 2 weeks from last DC1 vaccine, and IL-7 expanded CD4 T cells infusion IV at week 8 day 8.
45687410|NCT05373680|Drug|Metformin|Patients will receive metformin 1000 mg PO daily added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
45687411|NCT05373680|Drug|Empagliflozin|Patients will receive empagliflozin 10 mg daily PO added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
45687412|NCT05373680|Other|Control|Patients will receive their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
45687413|NCT05372718|Drug|Recombinant non-immunogenic staphylokinase (Fortelyzin®)|lyophilisate for preparation a solution
46047477|NCT02632162|Other|screening|Screening for sleep disordered breathing with the ApnoeLink Air device
46047478|NCT04231383|Other|dental caries, growth parametres|"The comparison of growth parameters before and after 6 months of treatment of dental caries will be compared.~Children's Sleep Habits Questionnaire and Early Childhood Oral Health Impact Scale will be compared before and at the 6th month of dental treatment."
46047479|NCT02739555|Device|Thermal destruction with radiofrequency or laser|
46047480|NCT02739555|Drug|Acide Zoledronique|
45687414|NCT05372718|Procedure|surgical methods of treatment|Endovascular intervention, open surgery and/or bypass surgery in accordance with the current National Guidelines
45479395|NCT03803189|Behavioral|Usual care plus eToolkit|The intervention arm will receive repeated e-surveys via email to collect the Edinburgh Postpartum Depression Scale (EPDS) score at baseline and 2, 4, 6, 8, and 12 weeks. Those with EPDS<10 will be triaged as low risk. Those with EPDS 10-18 (without suicidality) will be triaged as symptomatic for non-urgent clinical assessment with a message delivered via the EMR. Those with EPDS≥19 or suicidality will be triaged as requiring immediate follow-up, with an urgent message to their PCP via EMR, phone (if suicidal) and fax. Prompts in the EMR will enable evidence-based clinical care for PPD and PPA, highlight treatment preferences to support shared decision making, and identify appropriate referrals. Intervention arm participants will receive a personalized eToolkit after the completion of each survey. Patients in the intervention group with symptoms will be invited to a telephone interview at 12 weeks postpartum to describe their experience with the intervention.
45479396|NCT05050760|Drug|Camrelizumab|Camrelizumab 200mg IV D1，Q3W,and preoperative therapy with three cycles.
45479397|NCT05050760|Drug|DCF|DCF:Oxaliplatin (85mg/ m^2, IV D1,Q3W.Docetaxel: 60 mg/m^2 intravenous infusion for 60 minutes, D1,Q3W.Tegafur:BSA<1.25^2,40 mg/time,1.25^2<BSA<1.5^2,50 mg/time,BID ,after breakfast and dinner, continuous administration for 14 days, rest for 7 days, as a treatment cycle;Repeat every 3 weeks
45479398|NCT02498002|Device|Physical Activity Monitoring (Actiheart)|Monitor physical activity using an Actiheart monitor during the required periods.
46047481|NCT03300141|Other|Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
46047482|NCT03300141|Other|Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
46047483|NCT03300141|Other|Healthy Comparative Reaching Task|Reaching while sitting at the Looking Glass system. This will occur over the course of 1 hour.
46047484|NCT03659955|Other|Autologous blood applied to dry eye|See previous description for the study arm.
46047485|NCT00955968|Drug|Highly active antiretroviral therapy (HAART)|"A combination of three or more HIV medications belonging to two or more drug classes.~The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC). Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose combination tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV), didanosine (ddI), atazanavir (ATV), raltegravir (RAL), and ritonavir (RTV). While LPV/RTV plus TDF/FTC was the preferred study-supplied regimen, the study clinicians in conjunction with participants would determine the optimal drug combination for each participant."
45358053|NCT00962715|Drug|Interferon (IFNα, Roferon-A)|3 million units (0.5 ml) before receiving TIV, through a needle under the skin.
45358054|NCT00836784|Other|old toothbrush|All children will receive new tooth brush 3 months before starting the study, at the end of 3 month the worn tooth brushes will be returned and the surface area within the outline will be determine using NIH (national institutes of health) image software.
46047486|NCT02725593|Drug|Dapagliflozin|Dapagliflozin 10 mg tablets administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, for the 28-week site and subject blinded long term extension.
46047487|NCT02725593|Drug|Dapagliflozin placebo|matching placebo tablets, administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily,for the 28-week site and subject blinded long term extension.
45358055|NCT00836784|Other|New tooth brush|"The tooth brush which will be use in this study is Jordan. A new Jordan toothbrush will be give to all children, and in new tooth brush group they will use these toothbrushes."
45358056|NCT00836862|Other|Biologic specimens|Banking of serum, DNA and tissue
45358057|NCT04886271|Drug|HX009|Eligible participants will receive HX009 treatment at 5mg/Kg via IV infusion over 60-120 minutes, and the scheduled dosing cycle is once every 2 weeks.
45358058|NCT00844116|Device|spirometry|Conventional and telematic spirometry
45358059|NCT00963027|Drug|Treprostinil diethanolamine|Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth immediately following breakfast before and after repeated daily dosing with esomeprazole.
45358060|NCT00963027|Drug|Esomeprazole|Each subject will receive a single 40 mg capsule of esomeprazole by mouth in the morning for seven days.
45358061|NCT00836940|Drug|GRC 8200|Capsules, 25 to 100mg, once/ twice a day, 12 weeks
45358062|NCT00837018|Other|physical exercise program|45 min, 3times a week
45479399|NCT02498002|Other|Energy Intake Monitoring|Monitor energy intake by weighing and recording all foods/drinks consumed during the required periods.
45479400|NCT02498002|Other|Body Weight Monitoring|Monitor body weight during monitoring phase to ensure stability despite other monitoring activities.
45479401|NCT02498002|Procedure|Intravenous Cannulation|Fitting of an intravenous cannula to a vein on the forearm for blood sampling during laboratory protocols.
45479402|NCT02498002|Procedure|Adipose Tissue Biopsy|This is an optional feature which if included involves the removal of a 0.5 gram sample of adipose tissue from just below the skin using a needle.
45358063|NCT00839592|Other|Electroacupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
45358064|NCT04796649|Device|B-Cure laser pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
45358065|NCT04796649|Device|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
45358066|NCT00837174|Drug|Vorinostat in combination with Bortezomib|Patients will be treated with oral vorinostat on days 1 through 14 followed by a 7-day rest period, for a 21-day treatment cycle for up to 6 cycles in the absence of disease progression or unacceptable toxicity. The patients will receive once-daily oral vorinostat (400 mg) with bortezomib 1.3 mg/m2 as an IV push on days 1, 4, 8, 11.
45358067|NCT00963183|Drug|AZD5423|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD5423 or placebo. Starting dose 8.4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
45358068|NCT00963183|Drug|Placebo|Solution for nebulisation, inhaled. Each subject will receive a single-dose.
45358069|NCT04042974|Drug|vaginal dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
45358070|NCT04042974|Drug|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
45358071|NCT00844272|Behavioral|Psychoeducation|"Group-therapeutic intervention with 12 sessions plus 5 update sessions with 24-week therapy duration and/or 12 sessions plus 10 update sessions with 48-week therapy duration Module I: Create understanding, resources, problems and solutions Module II: Information on hepatitis C infection Module III: Information on treatment Module IV: Specific information on depression and withdrawal symptoms under interferon The meetings take a minimum of 60 min. time, should be once weekly. The group size should lie between 6 and 12 participants.~The group leaders are trained in performance of the psycho-education."
45687415|NCT05371509|Device|Myofunctional therapy (MT) nozzle|Water bottle nozzle designed to allow the user to repeatedly perform the tongue suction, tongue press, and swallow exercise movements while also providing targeted resistance to train and improve tongue, soft palate, and pharyngeal muscle strength and endurance.
45687416|NCT05371509|Other|Placebo nozzle|The placebo bottle nozzle will look similar to the MT nozzle; but is not expected to function the same as the MT nozzle.
45844217|NCT05747040|Diagnostic Test|monitoring|"The intervention consists of 48-h monitoring by using two types of monitoring: an objective monitoring, through a class IIa wearable medical device recording four physiological signals, and a subjective monitoring through a questionnaire developed with Microsoft Forms that can be compiled with a smartphone. The monitoring will be conducted during a motor neurorehabilitation treatment, 24 hours before and 24 hours after the treatment at the participant's home. Besides this monitoring, stratification questionnaires will be administered to each participant to be stratified in one of the three categories (absence of pain, nociceptive pain, or neuropathic pain) based on the following timeline:~t0: baseline t1: pre-treatment t2: post-treatment t3: follow-up"
46047488|NCT00911625|Drug|0.5 units/kg daily insulin|Participants randomized to receive this intervention will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
46047489|NCT00911625|Drug|0.25 units/kg daily insulin|Participants randomized to receive this intervention will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
46047490|NCT00596752|Drug|Alprostadil|"Active Substance: Prostaglandin E1~Pharmaceutical Form: solution for infusion~Concentration: 40 μg b.d.~Route of Administration: intravenous infusion"
46047491|NCT00596752|Other|Placebo|"Active Substance: Lactose~Pharmaceutical Form: solution for infusion~Concentration: 40 μg b.d.~Route of Administration: intravenous infusion"
45358072|NCT04783545|Drug|VLX-1005|VLX-1005 infusion
45358073|NCT04783545|Drug|Placebo|Placebo infusion
45358074|NCT00844350|Drug|letrozole , oxytocin,hCG,clomiphene citrate|
45358075|NCT00963261|Behavioral|psycho-oncological intervention|stepped care treatment program with different elements (patient information, exercise, psychoeducation, individual and group therapy, psycho-pharmacology)
45358076|NCT02547636|Other|Observational study|No intervention will be used in this study.
45358077|NCT00839670|Other|Light constraint induced therapy|90 minutes of motor training with a physical or occupational therapist and 270 minutes of self-rehabilitation, 5 days/week/2 weeks.
45358078|NCT00839670|Other|Standard constraint induced therapy|360 minutes of motor training with a physical or occupational therapist, 5 days/week/2 weeks
45358079|NCT04704609|Other|Standard of Care Imaging|We are collecting imaging that is standard of care for uveitis patients
45479403|NCT02498002|Drug|Lidocaine Hydrochloride|The anaesthetic that will be used to numb the site of the adipose tissue biopsy in the event it is included.
45687417|NCT05364970|Combination Product|VR_Training_1PP|Immersive VR scenario of physical training with avatar embodiment
45358080|NCT00963339|Device|Foresee Home|Home Monitoring
45358081|NCT01563393|Other|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
45358082|NCT01563393|Other|No intervention|The Placebo Comparator arm children got the classic care that practiced in hospitalization
45479404|NCT02498002|Other|Post-Prandial Meal Tests|Consume two successive meals with regular blood samples throughout the ensuing hours (2-3 hours each).
45479405|NCT02498002|Radiation|DEXA Scan|Undergo a dual energy x-ray absorptiometry scan to examine body composition.
45687418|NCT05364970|Combination Product|VR_Training_3PP|Immersive VR scenario of physical training without avatar embodiment
45687419|NCT05363865|Behavioral|Virtual Community Intervention|Modules of community building, HIV/HCV prevention, drug and service stigma, identification of mental health problems
45687420|NCT05363865|Behavioral|Standard of Care|health websites and county information provided to participants
45687421|NCT05362682|Other|Sinopharm Vaccine|Sinopharm Vaccine will be administered by the Govt as part of COVID-19vaccination campaign
45844218|NCT05746884|Procedure|duodenal mucosectomy|Standard resection technique will be performed for duodenal mucosectomy, as well as the usual hemostasis at the discretion of the operator.
45844219|NCT05746884|Procedure|ampullectomy|Standard resection technique will be performed for ampullectomy, as well as the usual hemostasis at the discretion of the operator.
45844220|NCT05746728|Drug|Surufatinib|"Safety run-in phase: 200-250mg, QD, Q3W~Dose expansion phase: according to the dose determined in the safety run-in phase"
46047492|NCT04202523|Radiation|Radiofrequency ablation|Liver cancer radiofrequency ablation is a clinical treatment method that uses electrode needles to penetrate the skin and liver into the tumor and completely destroy the tumor through the principle of heat production to achieve the purpose of treating tumors.
46047493|NCT04202523|Device|IMRT & SBRT|Tumor radiation therapy is a local treatment method using radiation to treat tumors. Radiation includes alpha, beta, and gamma rays produced by radioactive isotopes and x-rays, electron beams, proton beams, and other particle beams produced by various types of x-ray therapy machines or accelerators. Current mainstream radiotherapy technologies include stereotactic radiation therapy (SRT). Stereotactic radiation therapy (SRT) includes three-dimensional conformal radiation therapy (3DCRT) and three-dimensional conformal intensity modulated radiation therapy (IMRT).
46047494|NCT04151277|Drug|FOLFOX-A|Patients will recieve nab-paclitaxel, oxaliplatin, Folinic Acid and 5-FU in a 14 day cycle
46047495|NCT04151277|Drug|Gemcitabe and Abraxane|Patients will receive gemcitabine and nab-paclitaxel 3 weeks out of 4
45358083|NCT00844506|Drug|P53-SLP vaccine|The P53-SLP vaccine is a vaccine consisting of a total of 10 long (30 amino acids on average length) peptides, covering the p53 protein sequence from amino acid 70 to 251, combined with Montanide ISA51 an adjuvant with a sustained dendritic cell activating ability. Patients will be immunised subcutaneously with the peptide vaccine four times with a three week interval (300μg/peptide).
45479406|NCT02498002|Other|Actiheart Calibration|Submaximal treadmill test to calibrate monitoring equipment.
45479407|NCT02498002|Other|Daily Calorie Restriction|Reduce energy intake by 25% on a daily basis.
45358084|NCT00844506|Drug|Cyclophosphamide|Two days prior to each peptide vaccination, patients will receive 300mg/m2 cyclophosphamide i.v.
45358085|NCT04009707|Other|MoCA (Montreal Cognitive Assessment) test|the MoCA questionnaire is used to assess cognitive disorders
45844221|NCT05746728|Drug|Tislelizumab|200mg, d1, iv, Q3W
46047496|NCT04151277|Drug|G-CSF|Patients in the FOLFOX-A arm will also receive daily G-CSF as primary prophylaxis for all cycles. This will be given as per local site policy for 14 day chemotherapy regimens
46047497|NCT00958074|Drug|vorinostat|Given PO
46047498|NCT00958074|Other|flow cytometry|correlative study
46047499|NCT00958074|Other|laboratory biomarker analysis|correlative study
45479408|NCT02498002|Other|Intermittent Fasting with Weight Loss|Alternate between 24 hour cycles of fasting and feeding with 150% of normal intake when feeding.
45844222|NCT05743686|Device|Application|The participants will have access to an app allowing them to report their adverse effects to oral chemotherapy. Basic advices will be given and the hospital pharmacists will be warned.
45687422|NCT05361122|Dietary Supplement|Maternal Use of Xylitol Chewing Gum During Pregnancy|There are no current interventions within this follow-up study. However, the mothers enrolled in the parent PPaX trial received xylitol-containing chewing gum (1 gram per stick of gum and instructed to chew 1-2 sticks of gum twice daily for a total dose of 2-4 grams/day of xylitol throughout pregnancy starting pre-conception or at <20 weeks gestation).
45479409|NCT02498002|Other|Intermittent Fasting without Weight Loss|Alternate between 24 hour cycles of fasting and feeding with 200% of normal intake when feeding.
45479410|NCT03810209|Drug|Magnesium Sulphate|adding magnesium sulphate to local anaesthetic in SAP Block
45687423|NCT05361122|Dietary Supplement|No Maternal Xylitol Chewing Gum Use During Pregnancy|There are no current interventions within this follow-up study. Children born to mothers who received access to a dentist and prenatal education (oral health, prevention of preterm birth) are in the active comparator group
45687424|NCT05359640|Other|quality of pain|We will recorded the pain by using a short pain questionnaire and a McGill pain questionnaire.
45687425|NCT05353348|Drug|Iron Sucrose, recombinant human erythropoietin, ascorbic acid|During the 1 week period following admission, 3 consecutive dosing regimens were administered, 200 mg of iron sucrose by intravenous infusion at 8am daily in combination with 150 IU/kg of recombinant human erythropoietin by subcutaneous injection and 2 g of ascorbic acid by intravenous infusion.
45687426|NCT05353348|Drug|Iron sucrose|Within 1 week of admission, 3 consecutive combination regimens of 200mg of iron sucrose and saline combined with subcutaneous saline infusions at 8am daily
45844223|NCT05725746|Diagnostic Test|Point of care device to measure HbA1c|After consent the participant will meet with the research team virtually to obtain HbA1c. The HbA1c self check equipment will be sent to the participant. During the video call the research team will talk the participant through obtaining their HbA1c with the point of care device.
45844224|NCT05714670|Drug|Curcumin Oral Capsule|Curcumin 1000 mg Oral Capsule beside the standard of care
46047500|NCT00660868|Drug|Pentoxifylline retard 400mg|Agapurin retard 400mg 3/day per os for 3 weeks
46047501|NCT02632240|Other|Surgery:The tunnel technique for covering gingival recession|The surgery starts with the sulcular incisions in the region of recessions, which enable access for the supraperiosteal preparation. The procedure is extended into the mucosal tissue using the tunneling knives. The partial-thickness flap is performed at the buccal site. Only the papillary regions are fully detached with the periosteum. The graft is placed into the tunnel and stabilized with absorbable sutures.The mobilized mucous flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
45479411|NCT03810209|Drug|Normal saline|adding normal saline to local anaesthetic in SAP block
45479412|NCT03053492|Device|Duck Duck Punch Play|The behavioral intervention will include playing a hands-free video game custom designed for stroke survivors.
45479413|NCT03053492|Behavioral|Commercially Available Game Play|The behavioral intervention will include playing a hands-free video game available off-the-shelf.
45687427|NCT05339594|Device|NeuraGen|NeuraGen nerve guide is an absorbable implant for the repair of peripheral nerve gaps.
45687428|NCT05339594|Device|NeuraGen 3D|NeuraGen 3D Nerve guide matrix is a resorbable implant for the repair of peripheral nerve gaps.
45844225|NCT05712018|Drug|Hydroxyethyl starch coload - 0 ml/kg|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
45844226|NCT05712018|Drug|Hydroxyethyl starch coload - 5 ml/kg|5 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
46047502|NCT04343157|Radiation|Cognitive Sparing Brain Stereotactic Radiosurgery (SRS)|In this proposal, the investigators introduce advanced diffusion and volumetric imaging techniques along with innovative, automated image parcellation methods to identify critical brain regions, incorporate into cognitive-sparing SRS, and analyze biomarkers of radiation response. This work will advance the investigators' understanding of neurocognitive changes after brain SRS and help create interventions that preserve cognitive-function in brain metastases patients.
46047503|NCT00664690|Drug|celebrex|400 mg celebrex given 1 hour preop and celebrex 200 mg BID postop
46047504|NCT00664690|Drug|placebo|placebo given preop and BID postop
45687429|NCT05338281|Device|Negative Pressure Wound Therapy|The negative pressure wound therapy will be placed in addition to usual care of the abdominal donor site, such as closure with resorbable sutures, drain placements.
45358086|NCT04009707|Other|BEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) Test|This questionnaire is used to assess cognitive disorders
45358087|NCT00844584|Procedure|epicardial radiofrequency ablation|epicardial radiofrequency ablation to treat atrial fibrillation under totally thoracoscope
45687430|NCT05497024|Behavioral|Interviews|"Participants will discuss background, such as race, education, and living situation.~Participants will discuss Prostate cancer Participants will discuss feedback on the educational material"
45687431|NCT05497024|Behavioral|Surveys|Participants may answer questions that are sensitive in nature.
46047505|NCT00664768|Dietary Supplement|Neocate Infant|minimum of 8 fl. oz daily
46047506|NCT00664768|Dietary Supplement|new Neocate|minimum of 8 fl oz daily
46047507|NCT04202913|Behavioral|Coaching|Child will receive 1:1 coaching with health coach.
46047508|NCT00809965|Drug|Rivaroxaban 2.5 mg|One tablet twice daily
46047509|NCT00809965|Drug|Rivaroxaban 5 mg|One tablet twice daily
45479414|NCT04663607|Behavioral|Use of PretermConnect App|Participants will receive health education via a mobile app, PretermConnect, in addition to the standard of care, and complete additional surveys on the social determinants of health
46047510|NCT00809965|Drug|Placebo|One placebo tablet twice daily
46047511|NCT00809965|Drug|Standard of care|
46047512|NCT02630914|Device|The AtriCure Synergy Ablation System|The AtriCure Synergy Ablation System will be used on all patients for AF ablation.
46047513|NCT04338165|Drug|Evolocumab 140 MG/ML [Repatha]|3 injections of evolocumab 140 milligrams performed within 30 minutes and self-administered (subcutaneously in the abdomen, thigh, or upper arm)
46047514|NCT04054804|Diagnostic Test|D-Foot|A digital foot check i assessed by using the software D-Foot.
45358088|NCT00963417|Other|laboratory biomarker analysis|Serial serum levels of several biomarkers will be analyzed at different time points, up to 72 months after randomization.
45358089|NCT00963417|Procedure|dual x-ray absorptiometry|Serial bone mineral density measurements of the L1-L4 (postero-anterior, PA) region of the spine and hip by dual-energy X-ray absorptiometry (DEXA).
45358090|NCT00839826|Drug|Rivaroxaban (BAY59-7939)|2,5 mg bid,5 mg bid,10mg bid, 20 mg bid, 20 mg tid, 30 mg bid, dose escalation trial
45358091|NCT00839826|Drug|Enoxaparin|40 mg bid
45358092|NCT00963495|Drug|Clioquinol|Patients will take Clioquniol at escalating doses depending on when they enter into the trial.
45358093|NCT04042896|Behavioral|exergame|Exergame is 'exercise + game'.
45358094|NCT04042896|Behavioral|treadmill exercise|traditional aerobic exercise
45358095|NCT00844662|Drug|Fermagate|Film coated tablet 500mg
45358096|NCT00844662|Drug|Sevelamer hydrochloride|Tablet 800mg
46047515|NCT04117269|Device|External shoe lift|Height compensation will be made with cork or EVA (polyurethane + Ethylene Vinyl Acetate) depending the characteristics of the shoe. It will be made by the same orthophaedic technician. The prescription of the heigh of the lift will be made with the patient in a barefoot standing position, a calibre will be used to mark the femoro-tibial joint in both lower limbs in order to rule out the asymmetry. After this, the patient will shod the offloading device in the ulcerated feet and their conventional footwear in the other foot (with the use of their own foot orthosis). 5 millimeters splints will be added under the non affected footwear until the previous mark in both limbs been balanced. The difference in the heigh between limbs will be assessed measuring all the splints used previously
45687432|NCT05334836|Diagnostic Test|MRI for pancreatic fat and liver fat quantitation|MR imaging would be performed using a 3.0 T scanner (Achieva X series, Philips Healthcare, Best, The Netherlands) with a 16-channel SENSE-XL-Torso array coil. 3D spoiled chemical-shift water-fat mDixon sequence (TR = 5.7 ms, first TE/echo spacing = 1.2-1.4 (ms)/1.0-1.2 (ms), number of echoes = 6, flip angle = 3°, SENSE acceleration = 2, a breath hold technique would be employed to acquire co-registered water, fat, fat-fraction and T2* image series and would be reconstructed with slice thickness/number of slices = 3.0 mm/50. The field of view (FOV) covered the upper abdomen, i.e. region from the dome of the diaphragm to the iliac crest covering the entire extent of the liver and pancreas. Image reconstruction would be completed online using Philips mDixon product implementation with the multi-peak spectral model of fat to increase accuracy and sensitivity.
45687433|NCT05331820|Other|weekly mobile reminder|a weekly reminder will be sent to participants in the intervention group via mobile internet applications
45687434|NCT05330988|Device|anodal transcranial direct current stimulation (a-tDCS)|The 1x1 platform is the most state-of-the-art, customizable, and reliable platform for pad-based Transcranial Electrical Stimulation.
45687435|NCT05330988|Device|sham stimulation|The 1x1 platform is the most state-of-the-art, customizable, and reliable platform for pad-based Transcranial Electrical Stimulation.
45687436|NCT05326256|Other|Exercise training- PSSE|Barcelona Scoliosis Physical Therapy School (BSPTS) method exercises
45687437|NCT05326256|Other|Exercise training- PSSE with vestibular exercises|Vestibular exercises added to Barcelona Scoliosis Physical Therapy School (BSPTS) exercises
45687438|NCT05320419|Other|Amniotic membrane preparation and injection (AM group)|The dehydrated AM product used in this study is derived from donated human placental tissue following healthy, live, caesarian section, full-term births which are then cleaned of blood under aseptic conditions. The product comes as a 20mg dry powder in a small vial stored at room temperature and mixed with 2 mL 0.9% sterile normal saline. Then the suspended AM will be injected to the injured tendon and the surrounding area with ultrasound-guidance via a 7cm, 23-gauge needle.
45358097|NCT04678089|Drug|Bortezomib|Objective To observe the safety and efficacy of bortezomib related biomarkers. Including genes, metabolites, etc
45358098|NCT00963573|Drug|Loratadine|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
45358099|NCT00963573|Drug|Betamethasone|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
45358100|NCT05299593|Drug|tafluprost/timolol|"One ml active drug contains: 15 micrograms of tafluprost and 5 mg of timolol (as maleate).~A single-dose container (0.3 ml) of eye drops, solution, contains 4.5 micrograms of tafluprost and 1.5 mg of timolol. One drop (about 30 µl) contains about 0.45 micrograms of tafluprost and 0.15 mg of timolol. Patients will be administrered with one drop in the conjunctival sac of the affected eye (s) once a day."
45479415|NCT02497846|Device|TEOSYAL® PureSense Redensity [I]/MicronJet®|According the instruction of use, 3 injections of TEOSYAL® PureSense Redensity [I]will be performed all the 3 weeks. The used needle will be the MicronJet® microneedles for product injection. And the last visit (of control) will be performed 3 weeks after the last injection.
45479416|NCT04630925|Other|isCGM|As previously described
45358101|NCT00839904|Behavioral|exercise|two supervised, 60-minute weekly exercise sessions + instructions to perform additional physical activities throughout the day
45479417|NCT05574296|Drug|Hydrogen|Hydrogen gas (2%) in air or oxygen administered for 72 hours via ventilator and ECMO membrane. Oxygen concentration titrated per clinical team.
45479418|NCT05574296|Other|Usual care|Usual care post-ECPR event, including targeted temperature management.
45844227|NCT05712018|Drug|Hydroxyethyl starch coload - 10 ml/kg|10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
45844228|NCT05674500|Other|Educational Training on standardized coaching language|The faculty trainer participants in training groups will watch a 15-min long video between the two simulated endoscopy teaching encounters. The video link will be emailed to them 1 week before the second simulated encounter, and they can watch it in their own time. The training video will demonstrate the use of recommended coaching language for endoscopy instruction (e.g., recommended 14 standard terms, need to refer to the screen when directing a trainee as opposed to their hands, use of a clockface analogy) and communication best practices (e.g., checking to ensure understanding, avoidance of cognitive overload, task deconstruction).
45844229|NCT05674500|Other|Educational Training on goal setting|The faculty trainer participants in the control groups will watch a 15-min long video between the two simulated endoscopy teaching encounters. The video link will be emailed to them 1 week before the second simulated encounter, and they can watch it in their own time. The video will be a 'dummy' colonoscopy training video which outlines how to set goals ahead of an endoscopy training session. The video will not discuss standardized coaching language and/or communication best practices.
45844230|NCT05671380|Behavioral|Longitudinal Proactive Outreach (LPO).|All participants will receive personalized invitation materials (in their preferred language) with messages culturally and linguistically tailored to BIPOC communities, guided by the literature on culturally adapting evidence-based interventions. The study team will tailor these resources in collaboration with the CE core. The tailored mailed packet will include an invitation letter and a brochure describing the types of tobacco treatment services available from their health system and from Quit Partner. One week after the written materials are sent, participants assigned to this condition will receive LPO by a MI-trained coach. The MI outreach call protocol will consist of 6 contact attempts over two weeks.The MI outreach call protocol will be repeated at 3, 6, and 9 months for a total of four outreach cycles because participants may not have quit or may have relapsed.
46047516|NCT00664846|Drug|Aspirin / Clopidogrel, Atorvastatin / Simvastatin|Standard Medical Management,including antiplatelet agents(Aspirin 75~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .
46047517|NCT00664846|Drug|Asprin / Clopidogrel, Atorvastatin / Simvastatin|Antiplatelet agents(Aspirin 75~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary
46047518|NCT02617563|Device|Minimally invasive lumbar fusion|Patients will receive a single or double level instrumented fusion using a minimally invasive/MAST™ PLIF, TLIF, DLIF, OLIF, ALIF or MIDLF surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either mini-open and/or percutaneous.
45358102|NCT04667403|Other|Telemedicine|"In addition to his standard follow-up, the patient benefits from a home follow-up of his pain for 6 months from his inclusion in the study.~The patient has to log on via the application, every week. to fill in the questionnaire to evaluate the pain over the past week.~The questionnaire consists of 4 questions to which the patient answers using a numerical scale from 0 to 10.~If the patient's pain is not controlled, the patient can log on in emergency mode as many times as he or she deems necessary.~A nurse path coordinator will be informed of each connection. Depending on the type of alert received, she may initiate a telephone consultation with the oncologist or pain specialist:~If necessary within 24 hours of the connection if it is a weekly connection,~Systematic within 3 hours if it is an emergency connection or if the data entered at the time of the weekly connection requires medical intervention."
45687439|NCT05320419|Other|Physiotherapy (PT group)|Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretching, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, and scapular stabilization exercise, 3 times a week, and will be continued for 12 weeks.
45687440|NCT05314543|Other|Hypoxia|Subjects will be subjected to mild hypoxia simulating an altitude of 1750 m (normobaric hypoxia). Hypoxia decreases oxygen supply to tissue and limit exercise capacity. For this, the subjects will inhale a gas mixture depleted in oxygen (enriched in nitrogen). The barometric pressure at 1500 m being 621 mmHg, PIO2 at this altitude (PIO2 = (621 - 47) x 21%) is 120.5 mmHg. For sea level altitude where the barometric pressure is 760 mmHg, the hypoxic gas mixture should contain (x = 120.5 / (760 - 47)) 16.8% O2. Thus, by inhaling a gas mixture that is oxygen-depleted from 21 to 16.8%, subjects (will simulate the altitude of 1750 and) will experience the equivalent of a 20% reduction in oxygen supply.
45687441|NCT05313022|Biological|ZR-202-CoV|Adjuvanted Recombinant SARS-CoV-2 S-protein Subunit Vaccine
45687442|NCT05313022|Other|Placebo|Normal saline solution
45687443|NCT05304520|Drug|Natalizumab|Administered as specified in the treatment arm.
45358103|NCT00844740|Drug|Cinacalcet|Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood nand urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
45479419|NCT03330340|Procedure|Percutaneous Vertebroplasty|The procedure takes place under sterile conditions. Local anesthesia is administered from skin to the periosteum of the targeted pedicle. Polymethylmethacrylate bone cement (Mendec Spine; Tecres SPA, Sommacampagna, Italy) is injected under continuous fluoroscopic imaging guidance using 1.0 ml syringes and 13 Gauge bone biopsy needles by bilateral procedures. The amount of injected cement in each treated vertebral body and any cement leakage is recorded.
45358104|NCT04657575|Procedure|Narcotrend|ECT stimulation within an anaesthesia depth range of 41-64
45358105|NCT00840138|Procedure|Surgical reconstruction|"Hepaticojejunostomy~End-to-end anastomosis~Duct suture over T-tube"
45479420|NCT05585879|Device|Pure-Vu EVS|"Subjects will be enrolled until 115 inadequate bowel prep cases via SOC are accrued and subsequently treated with Pure-Vu EVS. Inadequate OCs defined as such if any of the following are met:~Boston Bowel Preparation Score (BBPS) < 6 (Adequacy is defined as BBPS of 2 or greater in each segment)~Inability to identify > 5mm polyps"
45687444|NCT05300152|Procedure|pulpotomy procedure and Histological evaluation|Sixty primary teeth in thirty children aged 7-9 years selected from Outpatient dental clinic Pedodontic and Endodontic Departments, Suez Canal University. divided into group I includes 30 teeth treated with ACTIVA BioACTIVE Base/Liner and group II includes 30 teeth treated by MTA with standard pulpotomy procedure Patients will be recalled after 15 and 30-days . 15 teeth from group I and 15 teeth from group II will be extracted after 15 days then subjected to decalcification then15 teeth from group I and 15 teeth from group II will be extracted after 30 days & subjected to decalcification procedure in 20% EDTA at 4 °C for approximately 5 weeks then embedded in paraffin. Serial sections will be cut at 5 µm thickness. Deparaffinize the sections by 2 changes of xylene for 10 minutes each. Stain in Harris hematoxylin solution for 8 minutes. mount with xylene based mounting medium for conventional histological assessment using light microscope
45358106|NCT01563159|Other|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2010- May 31st 2011) and analysed for rotavirus, in children aged ≤5 years.
46047519|NCT00669058|Drug|Lactic acid (Dermacid)|
45358107|NCT00844818|Behavioral|Telephone Quitline Enrollment|The intervention included a brief motivational interview (MI), enrollment in the proactive state quitline, and follow-up faxes to the pediatric, OB, and PCP providers with tailored treatment messages.
46047520|NCT04229745|Device|THRIVE pre-oxygenation|Clinical Trial of Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) Oxygen in Women having Planned Caesarean Delivery
45358108|NCT00963651|Device|Chest tomosynthesis and X-ray|VolumeRAD tomosynthesis; Conventional Chest X-ray; Dual energy (bone and soft tissue PA chest images)
45358109|NCT02546700|Drug|Lebrikizumab|Lebrikizumab 125 milligrams (mg) will be administered subcutaneously once in every 4 weeks.
45358110|NCT02546700|Drug|Placebo|Matching placebo will be administered subcutaneously once in every 4 weeks.
46047521|NCT00597376|Other|Cerefolin NAC (a medical food)|Cerefolin NAC one tablet each day
46047522|NCT00597376|Other|Cerefolin NAC placebo|Placebo tablet once a day
46047523|NCT00669136|Drug|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
46047524|NCT00661024|Procedure|intraoperative RLN visualization|intraoperative RLN visualization
46047525|NCT00661024|Procedure|intraoperative neuromonitoring of the RLN|IONM
45358111|NCT00963729|Drug|cyclophosphamide|Given IV
45358112|NCT00963729|Drug|docetaxel|Given IV
45479421|NCT04186988|Drug|Fluorine F 18 Ara-G|Given IV
45479422|NCT02491294|Behavioral|School|students receive Cooking With Kids (CWK) - Colorado cooking & tasting lessons, SPARK active recess, and Cafeteria Connections
45479423|NCT02491294|Behavioral|Family|students receive the FFF family component - family nights, parent blog, and action packs that go home after each CWK-Colorado lesson
45479424|NCT02491294|Behavioral|About Eating|parents who completed the parent survey are invited to access the 6 lesson online About Eating program
45479425|NCT01303679|Drug|Paclitaxel|IV, 80mg/m² at d1, d8, d15
45479426|NCT01303679|Drug|Bevacizumab|IV, 10 mg/kg at d1, d15 or IV, 15 mg/kg every 3 weeks
45479427|NCT01303679|Drug|Exemestane|daily 25 mg (1 pill) oral intake
45358113|NCT00963729|Drug|epirubicin hydrochloride|Given IV
45358114|NCT00963729|Drug|fluorouracil|Given IV
45358115|NCT00963729|Drug|letrozole|Given orally
45358116|NCT00851214|Device|NexfinHD Monitor|Finger cuff device (NexfinHD Monitor, BMEYE, Amsterdam) that can measure hemodynamics on a beat to beat basis and that can be easily applied to acutely ill individuals.
45358117|NCT00851292|Device|TRUS probe|end-firing and side-firing vary in the angle in which they sample the prostate
46047526|NCT04799821|Other|Control|Participants will be asked to refrain from walnut intake and to follow an isocaloric meal plan that complies with the recommendations of a healthy Mediterranean-style eating pattern.
46047527|NCT04799821|Other|Walnut intake|Participants will be asked to consume walnuts along with an isocaloric meal plan that complies with the recommendations of a healthy Mediterranean-style eating pattern.
45844231|NCT05671380|Behavioral|Ask-Advice-Connect (AAC)|Licensed Practical Nurses will be trained to ask all patients if they smoke, document smoking status in the EHR, advise patients to stop smoking, and complete an electronic referral to Quit Partner or the smoking cessation clinic. AAC will be designed to connect participants to Quit Partner Minnesota to receive tobacco cessation counseling. Quit Partner™ is a family of programs available to help Minnesota residents quit commercial tobacco, administered by the Minnesota Department of Health (MDH). Quit Partner programs are provided by National Jewish Health (NJH). Any Minnesota resident can access a free 2-week supply of Nicotine Replacement Therapy (NRT). Uninsured and underinsured residents can access the full Quit Partner programs, including free one-on- one coaching, more NRT, and additional supports. Quit Partner also offers four population- specific programs and calls are available in several languages.
45844232|NCT05670132|Other|Neurocardiac rehabilitation program|Patients receiving a neurocardiac rehabilitation program for 12 weeks.
45844233|NCT05670132|Other|Standard of care|No intervention during the neurocardiac rehabilitation program
45844234|NCT05634954|Drug|GEH121224 (18F) Injection|Single GEH121224 (18F) Injection
45844235|NCT05634954|Diagnostic Test|Dynamic and Static - PET/CT Scan|Group 1: Dynamic whole-body PET/CT scan will start at the time of injection (8 sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 120 minutes and 240 minutes after injection.
45687445|NCT05300152|Diagnostic Test|Immunohistochemistry Protocol for Fibronectin Antibody|"Deparaffinization/Rehydration~Slides heated in an oven at 65C for 1 hour.~De-paraffinization~Antigen Retrieval~Immersion of slides into staining dish containing Antigen Retrieval Solution.~Placing the staining dish into rice cooker.~When turned to warm, unplug cooker~Allow to cool down for 20 min~Staining~Wash slides with TBST for 5 min on a shaker.~Inactivate endogenous peroxidase by 3% hydrogen peroxide for 10 min.~Block slides with blocking solution for 1 hour.~Dilute primary antibody in blocking buffer~Apply primary antibody to each section and incubate overnight in humidified chamber~Wash slides three times with TBST"
45358118|NCT00963963|Behavioral|Healthy Futures parent education|Multi-year audio CD parent education
45358119|NCT00844974|Other|Prevalence|Mood and cognitive assessments
45358120|NCT00964041|Drug|D-cycloserine|50 mg by mouth weekly, one hour before assessments, for eight weeks.
45358121|NCT00964041|Drug|Placebo|Placebo by mouth, weekly, one hour before any assessments, each week for eight weeks.
45358122|NCT00840372|Procedure|Buttonhole cannulation with semi-blunt needles|Use of semi-blunt needles, compared to blunt needles, at every dialysis session
45358123|NCT04009317|Drug|TQ-B3139|a multi-target protein kinase inhibitor.
45844236|NCT05634954|Diagnostic Test|Static - PET/CT Scan|Group 2: Static whole-body scans
45358124|NCT04009317|Drug|Crizotinib|a multi-target protein kinase inhibitor.
45844237|NCT05606718|Drug|Dapagliflozin|dapagliflozin 10mg once daily for 3 months after randomization
45844238|NCT05606718|Other|guideline-directed medical therapy (GDMT)|guideline-directed medical therapy (GDMT)
45844239|NCT05603442|Procedure|Thoracic intervertebral foramen block|The thoracic intervertebral foramen block is performed by placing the needle tip over and behind the transverse process of vertebra, via the thoracic intervertebral foramen.
45358125|NCT03641547|Drug|M6620|M6620 is an unlicensed small molecule ATR inhibitor which can be used in combination with DNA damaging agents. In pre-clinical models it has substantial activity when given with DNA damaging drugs or ionising radiation. The clinical agent (M6620) is currently studied in a phase I trial in Oxford and other centres in combination with gemcitabine, cisplatin, gemcitabine/cisplatin and cisplatin/etoposide.
45358126|NCT03641547|Drug|Cisplatin|Cisplatin is a platinum based chemotherapy drug licensed to treat a number of different types of cancer. Cisplatin use is not considered standard practice in Stage A2 & B, therefore Cisplatin is considered an investigational medicinal product for the purpose of this trial.
45358127|NCT03641547|Drug|Capecitabine|Capecitabine is a chemotherapy drug licensed to treat a number of different types of cancer, it is a noncytotoxic pre-cursor of the cytotoxic 5-fluourouracil. Capecitabine use is not considered standard practice in Stage A2 & B, therefore Capecitabine is considered an investigational medicinal product for the purpose of this trial.
45358128|NCT03641547|Radiation|Radiotherapy|Stage A1 uses palliative radiotherapy. Stage B uses definitive radiotherapy.
45358129|NCT00851370|Drug|Omalizumab (Xolair)|Bi-weekly
45358130|NCT00851370|Drug|Placebo|Bi-Weekly
45687446|NCT05300152|Diagnostic Test|Immunohistochemistry Protocol for Osteopontin Antibody|will be carried out via avidin-biotin-peroxidase complex method using a VECTASTAIN ABC Kit . Sections will be deparaffinized by xylene and graded ethanol then treated with 20 µg/ml Proteinase K for 10 min. to prevent endogenous peroxidase activity, sections is incubated for 30 min in 0.3% H2O2/methanol then treated with 0.1% blocking serum albumin and incubated with primary antibody for 30 min. Rabbit polyclonal anti-osteopontin and goat polyclonal anti-RANKL will be used. dilution of primary antibodies used will be osteopontin (1 : 6000-8000). After being washed with phosphate-buffered saline several times, sections will be incubated with biotinylated IgG for 30 min and subsequently with streptavidin-horseradish peroxidase for 30 min. Following several washes with phosphate-buffered saline, 3,3'-diaminobenzidine substrate will be applied. As a negative control, non-immune serum will be used instead of primary antibody.
45687447|NCT05298384|Other|Compression stockings|Graduated compression stockings (GCS) are used to treat chronic venous diseases and edema. They help to improve blood flow and prevent blood pooling in the legs. The use of GCS will be in accordance with this indication. The greatest pressure is exerted at the ankle with gradually decreasing pressures up the length of the stockings. GCS are designed for use out of bed and are manufactured using strict medical and technical specifications.
45844240|NCT05592522|Other|External oblique intercostal block|EOI block:Under guidance of the linear high frequency transducer, sagittal plane between anterior axillary line and midclavicular line at the level of the 6th rib, In-plane approach between external oblique and intercostal muscles Hydrodissection with 30 ml of 0.25% bupivacaine hydrochloride .
45844241|NCT05592522|Other|Oblique subcostal TAP block|OSTAP block: The needle was inserted in plane through the rectus adjacent to costal margin Once the tip of the needle was visualized in between the rectus muscle and transversus abdominus muscle and negative pressure aspiration was demonstrated, 30 ml bupivacaine 0.25% was deposited within the plane and hydrodissection was noted.
45844242|NCT05592522|Other|Posterior Rectus sheath block|Posterior rectus sheath block: Under linear ultrasound probe, the needle was advanced gradually through the rectus muscle posteriorly toward its medial edge, approaching the rectus sheath. After negative aspiration,12.5 mL bupivacaine 0.25% was injected until the rectus muscle was separated from the posterior rectus sheath by hydrodissection.
45844243|NCT05584566|Device|OSSIX Breeze|barrier membrane
45844244|NCT05584566|Device|Jason membrane|barrier membrane
45844245|NCT05548374|Device|Acupuncture|The acupoints of Shangyintang, Danzhong(RNl7), Jvque(RN14), Liangmen(ST21), Zhongwan(RNl2), Hegu(LI4), Waiguan(SJ5), Zusanli(ST36), Sanyinjiao(SP6), Taichong(LR3) are selected as main acupoints and used per treatment. The other three acupoints will be chosen one each session according to the syndrome differentiation: Taixi (KI3) for liver and kidney deficiency, Fenglong (ST40) for spleen deficiency and phlegm coagulation, and Xuehai (SP10) for qi-stagnation and blood-stasis. Sterile adhesive pads will be placed on the acupoints after skin disinfection. Hwato-brand disposable acupuncture needles (size 0.30×40mm) will be inserted into the acupoints through the adhesive pads. Afterwards, the acupuncture will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes during 30-minute maintenance.
45844246|NCT05548374|Device|Sham acupuncture|The acupoints of Shangyintang, Danzhong(RNl7), Jvque(RN14), Liangmen(ST21), Zhongwan(RNl2), Hegu(LI4), Waiguan(SJ5), Zusanli(ST36), Sanyinjiao(SP6), Taichong(LR3) are selected as main acupoints and used per treatment. The other three acupoints will be chosen one each session according to the syndrome differentiation: Taixi (KI3) for liver and kidney deficiency, Fenglong (ST40) for spleen deficiency and phlegm coagulation, and Xuehai (SP10) for qi-stagnation and blood-stasis. Sterile adhesive pads will be placed on the acupoints after skin disinfection. The needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrusted and twirled gently for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
45844247|NCT05505630|Drug|Ketamine|A single dose of IV ketamine will be administered.
45844248|NCT05505630|Drug|Midazolam|A single dose of IV midazolam will be administered
45844249|NCT05472948|Drug|Surufatinib|Surufatinib will be given 200/250 mg po. qd.
45844250|NCT05472948|Drug|Sintilimab|Sintilimab administered IV at a dose of 200mg every 3 weeks.
45844251|NCT05472948|Drug|Capecitabine|Capecitabine will be given 2 weeks on/1 week off (1000 mg/m2 BID po.)
45479428|NCT03337282|Procedure|Protocolized general anesthesia|Induction and maintenance of general anesthesia, post-operative analgesia with protocolized drugs and doses. Maintenance of MAP +/- 20% of baseline with vasopressors as needed.
45687448|NCT05296889|Device|posterior stabilization for the cervical spine|The Ennovate® Cervical Spinal System is a posterior stabilization for the cervical and upper-thoracic spine. The implants are used for the posterior monosegmental and multisegmental stabilization of the occipitocervical junction and of the cervical and upper thoracic spine.
45687449|NCT05295173|Drug|Injection of recombinant human tissue plasminogen kinase derivatives|18mg/10ml/stick, provided by Angde Biotech
45687450|NCT05295173|Drug|Recombinant human tissue plasminogen activator|20mg/stick, 50mg/stick, provided by Shanghai Boehringer Ingelheim Pharmaceutical Co. Ltd.
45687451|NCT05294263|Drug|Varenicline|Varenicline is a selective nACHr partial agonist of the 4 2 subtype and a full agonist of the 7 subtype
45687452|NCT05294263|Drug|Placebo|Matching, inactive medication
45687453|NCT05294068|Other|standard of care for patients with cognitive impairments|clinical examination, radiological, biological and physiological examinations.
45844252|NCT05460624|Other|Egg-containing breakfast|Involves participants eating six premade egg-containing breakfast meals per week for 12 weeks. Each meal contains 2 eggs to provide 12 eggs per week.
45844253|NCT05460624|Other|Typical American-style breakfast excluding eggs|Involves participants eating six premade egg-excluding breakfast meals per week for 12 weeks. Breakfast meals are matched to the intervention egg-containing breakfast meals on total energy and saturated fat and to the 'What We Eat in America' on percent energy from macronutrients.
45844254|NCT05448534|Diagnostic Test|Eletroencephalography|We used Sinek and Young Scale to classify electroencephalographic patterns and cognitive outcome with MOCA score.
45844255|NCT05377554|Drug|ALM-488|ALM-488 will be infused during the pre-operative period.
45479429|NCT03801707|Drug|Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]|fixed dose combination medication once a day for 12 weeks for the treatment of hepatitis C
45687454|NCT05294068|Other|standard of care for patients with neuromotor impairments|clinical examination, radiological, biological and physiological examinations.
45358131|NCT00967629|Drug|Sevelamer Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
45358132|NCT00967629|Drug|Calcium Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
45358133|NCT00851448|Dietary Supplement|oral nutritional supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
45358134|NCT00289783|Biological|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
45358135|NCT00289783|Biological|ActHIB|3-dose intramuscular injection at 2, 4 and 6 months of age.
45358136|NCT00289783|Biological|PedvaxHIB|1 booster dose by intramuscular injection at 12 to 15 months of age.
45358137|NCT00289783|Biological|Pediarix|3-dose intramuscular injection at 2, 4 and 6 months of age.
45358138|NCT00289783|Biological|Prevnar|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
45358139|NCT00289783|Biological|M-M-R II|1 booster dose by subcutaneous injection at 12 to 15 months of age.
45358140|NCT00289783|Biological|Varivax|1 booster dose by subcutaneous injection at 12 to 15 months of age
45358141|NCT00840528|Other|ozone|0.4 ppm ozone for 2 hours
45687455|NCT05294068|Other|standard of care for patients with sensory impairments|clinical examination, radiological, biological and physiological examinations.
46047528|NCT00669292|Biological|URLC10-177, TTK-567, CpG-7909|peptide, peptide, TLR-9 agonist
46047529|NCT00913783|Drug|Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)|
46047530|NCT00913783|Drug|Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)|
45358142|NCT02546466|Procedure|Functional Star-shape taping (SFT)|For the SFT procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
45687456|NCT05292625|Biological|UC-MSC infusion via intravenous route|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the intravenous (IV) route with a 3-month intervening interval
45687457|NCT05292625|Biological|UC-MSC infusion via intrathecal route|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the intrathecal route with a 3-month intervening interval
45687458|NCT05292625|Other|standard stroke treatment and rehabilitation therapy|Each patient can receive up to 30 days of rehabilitation therapy
46047531|NCT00661102|Drug|Corticosteroids|As prescribed
46047532|NCT00661102|Drug|Placebo|As prescribed
46047533|NCT00661102|Drug|capecitabine [Xeloda]|As prescribed
46047534|NCT00661102|Drug|dexpantenol [Bepantol]|As prescribed
46047535|NCT05297383|Dietary Supplement|Omega-3 Polyunsaturated Fatty Acid.|4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA).
46047536|NCT05297383|Dietary Supplement|Safflower Oil|4 grams safflower oil (AlaskOmega®) per day.
46047537|NCT05297383|Behavioral|High-Intensity Interval Training|A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max.
45844256|NCT05377554|Other|Intraoperative Visualization using White Light Reflectance (WLR) with Fluorescence (FL) Overlay|Intra-operative real time nerve visualization will be undertaken using WLR with FL Overlay.
45687459|NCT05285579|Biological|Blood collection|Systematic extra blood sampling at inclusion, 6 weeks after inclusion and in case of progression of the cancer
45687460|NCT05285579|Other|Tumour samples|reuse of tumour tissue collect in usual patient care
45687461|NCT05281757|Device|posterior stabilization for the cervical spine|The Ennovate® Complex Spinal System is a posterior stabilization for the Complex and upper-thoracic spine. The implants are used for the posterior multisegmental correction and stabilization over all sections of the spine.
45687462|NCT05280886|Procedure|therapeutic drug monitoring(TDM)|Based on this data, population pharmacokinetic models of antibiotics drugs that can be applicable to TDM will be developed.
45687463|NCT05271981|Other|Retrospective data collection|Data collection from the medical file of the patients
45844257|NCT05377554|Other|Intra-operative Visualization using White Light Reflectance (WLR)|Intra-operative real time nerve visualization will be undertaken using WLR.
45844258|NCT05357508|Behavioral|Intervention brochure|Provide participants with information about their personalized risk for colorectal cancer and appropriate screening recommendations to facilitate their screening option choice.
45844259|NCT05357508|Behavioral|Control brochure|Provide participants with general information about options for colorectal cancer screening.
45844260|NCT05350488|Other|Informational Interview|Interview topics will fall in the broad categories of assessing medical knowledge and understanding of stroke, knowledge of medical and community resources, understanding and experience of post-stroke rehabilitation barriers faced upon reintegrating back home and ability to continue management of stroke diagnosis and suggestions for improvement.
45687464|NCT05271981|Other|Phone interview|Call for collecting fertility data and obstetrical issues of the patients
45687465|NCT05271916|Drug|Dacomitinib+Anlotinib|The dose of each drug in the combination Decomitinib and Anlotinib will be escalated or de-escalated until the recommended phase II dose (RP2D) is reached. Patients will then be treated with RP2D orally once a day.
45687466|NCT05271916|Drug|Dacomitinib|Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg once a day until progressive disease.
45844261|NCT05350488|Other|Focus Group|Focus group topics will fall into the same broad categories as the informational interviews, however will be asked from a caregiver's perspective
45844262|NCT05294796|Combination Product|Short course of antibiotherapy|Short duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material
45687467|NCT05271656|Device|C-Scan System|Subjects will be provided with contrast agent and dietary fiber pills, and instructed to start intake of fiber pills 5 days, and contrast agent 48 hours prior to scheduled C-Scan capsule ingestion. C-Scan system intervention includes ingestion of the C-Scan Cap and attachment of the C-Scan Track to the subject's lower back. The subject is required to keep the C-Scan Track attached to the lower back and to continue intake of contrast agent and dietary fiber pills until the C-Scan Cap's natural excretion. Standard of care optical colonoscopy will be performed within 60 days from the C-Scan Cap ingestion.
45844263|NCT05294796|Combination Product|Long course of antibiotherapy|Long duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material
45687468|NCT05265728|Drug|Natalizumab|Administered as specified in the treatment arm
45844264|NCT05251896|Procedure|Plasma-free procedure|Use albumin solution, lactated Ringer's solution, normal saline as replacement fluid
45844265|NCT05215470|Drug|Nivolumab|Nivolumab is called an anti-PD-1 (Programmed Cell Death Ligand 1) or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
45844266|NCT05215470|Drug|Ipilimumab|Ipilimumab is called an anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
45844267|NCT05206500|Drug|Antibiotic|FDA approved and marketed antibiotic treatment for the patients with UTI symptoms and CC >0 and <10,000
45844268|NCT05206500|Device|Next Gen|Next Generation Sequencing (NGS) is available to detect bacteria in urine based on bacterial genomes.
45844269|NCT05198076|Device|High Frequency Repetitive Transcranial Magnetic Stimulation|The High Frequency repetitive TMS will be delivered to the scalp over the primary motor cortex contralateral to the more affected side using a MAGSTIM rapid2 machine (Model P/N 3576-23-09, MAGSTIM Company LTD, UK) connected with a figure - of- eight shaped coil. Each patient will receive 12 sessions over four weeks. Position of the coil will be adjusted to find the optimal scalp position and the location of stimulation that will be marked to maintain consistency among sessions. The session will consist of 24 trains of 50 stimuli each delivered at five Hz. The procedure will be conducted with the patients in the ''On'' state (75 min. after medications)
45844270|NCT05166720|Behavioral|NIDCAP care|NIDCAP care was performed according to the best evidence of NIDCAP
45844271|NCT05163522|Drug|VH4004280|VH4004280 will be administered.
45844272|NCT05163522|Drug|Placebo|Placebo will be administered.
45844273|NCT05163522|Drug|Midazolam|Midazolam will be administered
45844274|NCT05151588|Drug|Docetaxel|Docetaxel 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
45844275|NCT05151588|Drug|Cis Platinum|Cisplatin 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
45844276|NCT05151588|Drug|5-FU|5-FU 750mg/m2 intravenous infusion from day 1 to day 5 every 3 weeks for 3 cycles as induction therapy
45687469|NCT05261594|Dietary Supplement|Caffeine|Caffeine capsule 150 mg, oral intake
45844277|NCT05151588|Drug|Tazemetostat|Tazemetostat 800mg twice per day orally in continuously for 3 cycles as induction therapy and maintenance therapy
45844278|NCT05151588|Procedure|Surgery|Radical surgery
45844279|NCT05151588|Other|Chemoradiation|Chemoradiation as either radical treatment or post-operative treatment after surgery
45844280|NCT05117892|Other|Training, certification and marketing scheme|The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
46047538|NCT05297383|Behavioral|Flexibility Training|30 min of stretching 3 days/week for 6 weeks
46047539|NCT00665158|Behavioral|UC (Usual Care Group)|Usual Care Group - Treatment Implementation by Primary Care Physician
46047540|NCT00665158|Behavioral|BI (Behavioral Intervention Group)|Behavioral Intervention Group - Treatment Implementation by Health Educator
46047541|NCT02609347|Other|Manual Therapy Group|The manual therapy intervention will be based on the typed of fracture the patient sustained, and their limitations in joint mobility.
45479430|NCT03801707|Drug|Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]|Three tablets once a day for 12 weeks for treatment of hepatitis C
45687470|NCT05261594|Drug|Placebo|Placebo capsule, oral intake
45687471|NCT05256290|Drug|BDTX-1535 monotherapy|BDTX-1535 is a mutant-selective, irreversible 4th generation EGFR inhibitor
45844281|NCT05083416|Behavioral|Prolonged Nightly Fasting|Limiting daily period of food intake to 10 hours and nightly fasting period to 14 hours.
45844282|NCT05083416|Behavioral|Regular Eating pattern|Food intake not limited to a specific time during day/night.
46047542|NCT02609347|Other|Control Group|The sham intervention will consist of soft tissue mobilization and Grade I mobilization at the proximal tib/fib joint.
46047543|NCT00911638|Behavioral|Patient decision aid|"Patients will receive i) Patient education:usual take home education brochure from recruiting hospital ii)a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form:an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referred onward to the surgeon with their preferences for surgery using a standardized report of their clinical findings plus decisional data (knowledge, values, preference)."
45844283|NCT05034354|Device|Remote physiological monitoring|Participants will be provided with a Bluetooth capable weight scale (A&D Medical UC-352BLE or Beurer BY90), oxygen saturation monitor (Contec Medical Systems CMS50D-BT) and automatic blood pressure monitor (A&D Medical UA- 651BLE) to use daily for at least 10 days of a 14-day trial period. Data will be sent via the Sphygmo App to the pediatric cardiology for monitoring. Parents and healthcare providers will be asked to participate in a qualitative interview and the end of the 14-day period to provide feedback on the devices and Sphygmo™ platform.
45358143|NCT02546466|Procedure|Sham Functional Taping (Sham-FT)|For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
45358144|NCT02546466|Behavioral|Minimal Intervention Strategy (MIS)|The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
45358145|NCT00840606|Drug|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fasting
45479431|NCT03337204|Behavioral|Technology-assisted self-monitoring|Participants receive a Fitbit Zip, an iPad Mini tablet device, training on how to use the Fitbit and iPad, and are asked to complete brief surveys each night on their activity engagement that day (for two 7-day periods).
45687472|NCT05256290|Drug|BDTX-1535 in combination with temozolomide|BDTX-1535 is a mutant-selective, irreversible 4th generation EGFR inhibitor. Temozolomide is an alkylating agent considered standard-of-care for treatment of GBM.
45358146|NCT00840606|Drug|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fasting
45358147|NCT00845286|Behavioral|Munich Marathon|42,195 km marathon run
45479432|NCT03337204|Behavioral|Workshop and Peer Mentoring|Participants receive a 3-hour Engaged4Life Workshop (psychoeducation + goal setting) and one-on-one peer mentoring via phone 2X/week for 3 weeks.
45687473|NCT05254743|Drug|Pirtobrutinib|Administered orally.
45687474|NCT05254743|Drug|Ibrutinib|Administered orally.
45687475|NCT05254431|Behavioral|Exercise|"Novel Moderate Intensity Interval Exercise~The Experimental Design is a randomized trial of moderate intensity interval training (5-minute intervals at 50% VO2peak 3 times weekly for 12 weeks) in Veterans with COPD and OSA compared with standard of care controls"
45687476|NCT05252702|Device|Aveir DR Leadless Pacemaker System|Patients will undergo a dual chamber leadless pacemaker system implant wherein a leadless pacemaker will be implanted in the right ventricle and right atrium
45844284|NCT04929834|Other|Hydrating emollient + body lotion for immunotherapy-related side effects|Hydrating, hypo-allergenic, and anti- itching emollient and body lotion for immunotherapy-related skin reactions
45844285|NCT05260788|Procedure|Cystoscopy|Standard of care cystoscopy procedure
45844286|NCT04921332|Device|Bright Light Therapy (BLT) Lamp|With its built in automatic timer shut-off function, the bedside registered nurse (RN) would not need to return to the room to turn off this lamp after 30 minutes because the lamp will automatically shut off on its own.
46047544|NCT00911638|Behavioral|Usual care|"Patients will receive i) the usual take-home educational brochure available at the recruiting hospital describing preparation for surgery after the decision is made, recovery after surgery, and discharge plans.~ii) Referral onward to surgeon with a standardized report of clinical findings only"
46047545|NCT02609191|Device|"Whole body exam using the Discovery A"|"Whole body exam using the Discovery A machine made by Hologic."
46047546|NCT02609191|Device|"First whole body exam using the Stratos DR"|"First whole body exam using the Stratos DR machine made by the DMS group."
46047547|NCT02609191|Device|"Second whole body exam using the Stratos DR"|"Second whole body exam using the Stratos DR machine made by the DMS group. This second exam is required for reproducibility purposes."
46047548|NCT04157218|Device|HIFU device (Doublo, HIRONIC Co., Sungnam, Korea)|The areas treated with HIFU will include: The forehead, temples, and malar area, cheeks and submental area .
45479433|NCT03330184|Drug|Berberine Hydrochloride group|
45479434|NCT03330184|Drug|Bifidobacterium group|
45479435|NCT03330184|Drug|Berberine Hydrochloride and Bifidobacterium group|
45479436|NCT03330184|Drug|placebo|
45687477|NCT05247567|Biological|serum punction|A blood sample inclusion and at the end of study visit
45687478|NCT05247567|Biological|skin swab in elbow folds|passage of a cotton swab in the crease of the elbow at the inclusion
46047549|NCT04157218|Device|Threads used in this study are absorbable Aptos|The threads will be inserted to the cheeks
46047550|NCT02609893|Other|modified directly observed therapy (mDOT)|
46047551|NCT02609893|Other|unobserved dosing|
46047552|NCT02609893|Other|Motivational Interviewing-based counseling|Motivational Interviewing-based risk reduction and medication adherence counseling
45687479|NCT05246111|Drug|[14C]M6620|Participants will receive single intravenous infusion of [14C]M6620 on Day 1 in Period 1 and stay in clinical research unit (CRU) is required until the discharge criteria are met with a maximum confinement period of 15 days.
45844287|NCT04894734|Device|EES on|Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
45844288|NCT04894734|Device|EES off|Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
45844289|NCT04883814|Diagnostic Test|18F-fluoroestradiol PET/CT|Estrogen receptor targeted imaging
45479437|NCT04577573|Device|Cognition glove|The investigators have developed and tested a functional prototype of an instrumented glove to alert the user about secure grasp of objects. Onboard force and flex sensors provide inputs to a machine learning algorithm (artificial neural network, ANN) to estimate secure grasp based on previously collected training data. The glove enhances agency by alerting the user to secure grasp through sensory feedback modules (visual - LED, audio - beeper, tactile - vibrator).
45358148|NCT03850002|Other|Early detection of CLAD by Lung Clearance Index (LCI)|Lung transplant candidates without prior CLAD (evaluated in study part I) will be followed over a period of 3 years to evaluate the potential of LCI to detect early CLAD
45479438|NCT04577573|Device|Sensory brace|"A a size- and position-adjustable arm brace with weight-support capability and housing for vibration motors and EMG sensors. Position adjustment allows for physical therapists to find and recommend arm postures that are clinically relevant to~each person. The participant can then isometrically push/resist against the brace to strengthen target muscles while performing VR reach-to-touch. The person will receive visual feedback from the virtual environment to train movement performance and vibrotactile feedback at tendons to subconsciously adjust their muscle activation patterns"
45844290|NCT04863924|Diagnostic Test|Liquid Biopsy|All patients will have a liquid biopsy with ctDNA molecular profiling
45479439|NCT04117490|Other|Epiitalis|Two capsules twice daily 30 mins before meals (breakfast & dinner).
45844291|NCT04576182|Behavioral|Supportive-expressive treatment|Sixteen weeks of a time-limited psychodynamic therapy adapted for depression that includes the use of expressive techniques, such as interpretation, confrontation, clarification and the use of supportive techniques, such as affirmation and empathic validation. This treatment postulates insight as its core mechanism of change.
45844292|NCT04576182|Behavioral|Emotions-Focused treatment|Sixteen weeks of a brief experiential therapy for depression that combine client-centered relational elements (unconditional positive regard, congruence, and empathy) with marker-guided experiential interventions designed to facilitate and deepen emotional processing and emotion regulation.
45844293|NCT04569240|Device|Dexcom G6 continuous glucose monitor|Dexcom G6 continuous glucose monitor will be applied to the upper outer arm before cardiovascular surgery. Data will be collected for 10 days or upon discharge from the ICU.
46047553|NCT00669370|Drug|docetaxel and capecitabine|biweekly docetaxel iv (50 mg/m2) on day 1 and 15 and capecitabine po 1250 mg/m2 x 2/day days 1-7 and 15-21, treatment cycle consisting of 21 days
46047554|NCT04797871|Behavioral|Resistance training|Participants will complete a 2-days-a-week training routine: Resistance training (RT, 50-75% 1RM (one-repetition maximum), 4 sets, 8-12 repetitions, 4 exercises). The warn up include Light Intensity Continuous Training (8-10 min, 65-70% HRR). Progressions will be individualized and consistent with patient tolerance. Sessions will be supervised by Physiotherapists and Graduated in Sports Sciences.
46047555|NCT04797871|Behavioral|Standard care|This group will be allocated to standard care and therefore no supervised exercise regimen according to scientific guidelines for general physical activity and return to sport provided by the ACSM guidelines for Chronic Obstructive Pulmonary Disease and Cardiovascular Disease.
45358149|NCT03975127|Other|SMS text|A single SMS text sent to women under 30 who are eligible for the cervical screening programme and who have been invited by letter
45358150|NCT00840684|Drug|amsacrine|
45358151|NCT00840684|Drug|busulfan|
45358152|NCT00840684|Drug|cytarabine|
45479440|NCT04117490|Other|Placebo|Two capsules twice daily 30 mins before meals (breakfast & dinner).
45844294|NCT04556838|Drug|VVN001 Ophthalmic Solution 1%|VVN001 Ophthalmic Solution 1%
45358153|NCT00840684|Drug|daunorubicin hydrochloride|
45358154|NCT00840684|Drug|laromustine|
45358155|NCT00840684|Drug|melphalan|
45358156|NCT00840684|Drug|mitoxantrone hydrochloride|
45358157|NCT00840684|Procedure|allogeneic hematopoietic stem cell transplantation|
45358158|NCT00840684|Procedure|autologous hematopoietic stem cell transplantation|
45358159|NCT00574080|Drug|Interim/Maintenance Dexamethasone|20 mg Days 1-4 every 3 weeks in the interim between treatment phases and during maintenance
45358160|NCT00574080|Drug|Induction/Consolidation Dexamethasone|40 mg Days 1-4
45358161|NCT00574080|Drug|Induction/Consolidation Cisplatin|10 mg/m2 by continuous infusion Days 1-4
45358162|NCT00574080|Drug|Induction/Consolidation Adriamycin|10 mg/m2 by continuous infusion Days 1-4
45844295|NCT04556838|Drug|VVN001 Ophthalmic Solution 5%|VVN001 Ophthalmic Solution 5%
45844296|NCT04556838|Drug|Vehicle|VVN001 Ophthalmic Solution Vehicle
45844297|NCT04470804|Drug|Sirolimus|Sirolimus treats in experimental group
45844298|NCT04470804|Drug|Cyclosporine A|Cyclosporine A uses for active comparator group.
45844299|NCT04418466|Combination Product|Risperidone|Risperidone Implant
45687480|NCT05246111|Drug|M6620|Participants will receive intravenous infusion of M6620 on Day 2 and Day 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation are met.
45844300|NCT04389918|Other|Tality|Synthetic meal replacements, delivered in many varieties of 400 kCal packets, Manufacturer: Filtricine, Inc.
45844301|NCT04360044|Drug|THC ~5%|4 puffs of vaporized flower containing THC ~5%
45844302|NCT04360044|Drug|CBD ~12%|4 puffs of vaporized flower containing CBD ~12%
45358163|NCT00574080|Drug|InductionConsolidation Cyclophosphamide|400 mg/m2 by continuous infusion Days 1-4
45687481|NCT05246111|Drug|Topotecan|Participants will receive intravenous infusion of topotecan on Day 1 through Day 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation are met.
45687482|NCT05245617|Device|JuniOrtho™ Plating System™|The patient underwent surgery for the application of JPS for treatment of deformity or traumatic fracture.
45687483|NCT05242965|Biological|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
45358164|NCT00574080|Drug|Induction/Consolidation Etoposide|40 mg/m2 by continuous infusion Days 1-4
45358165|NCT00574080|Drug|Induction Pegfilgrastim|6 mg Days 6 and 13
45687484|NCT05242965|Biological|Sargramostim|Given ID
45687485|NCT05241288|Combination Product|Albuterol eMDPI DS|"Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) Digital System (DS) with 3 component devices:~Device 1: Albuterol eMDPI Device 2: Albuterol eMDPI Patient-facing smart device application (App) Device 3: Digital Health Platform (DHP, Cloud solution)"
45844303|NCT04360044|Drug|THC ~5% and CBD ~12%|4 puffs of vaporized flower containing THC ~5% and CBD ~12%
45844304|NCT04360044|Drug|Sham Cannabis|4 puffs of vaporized flower from which the THC and CBD have been extracted
45844305|NCT04337814|Drug|EMLA Cream|Topical anaesthetic cream
45844306|NCT04337814|Drug|Ibuprofen|Oral analgesic syrup (non-steroidal anti inflammatory drug)
45844307|NCT04337814|Drug|Placebo syrup|Placebo syrup similar to Ibuprofen
45844308|NCT04337814|Drug|Placebo cream|Placebo cream similar to EMLA
45844309|NCT04336332|Combination Product|Hydroxychloroquine Sulfate + Azithromycin|Given PO
45844310|NCT04336332|Drug|Hydroxychloroquine Sulfate|Given PO
45844311|NCT04310358|Other|4 short PLMs group 1|Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 1 (pre-test), Test 2 (immediate post-test), Test 1 (remote post-test)
45844312|NCT04310358|Other|4 short PLMs group 2|Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 2 (pre-test), Test 1 (immediate post-test), Test 2 (remote post-test)
45844313|NCT04230408|Drug|Durvalumab|Intensified chemo-immuno-radiotherapy with durvalumab in combination with carboplatin, paclitaxel and radiation
45358166|NCT00574080|Drug|Transplant 1 Dexamethasone|20 mg Days -4, -3, -2, -1 and +4, +5, +6, and +7
45358167|NCT00574080|Drug|Transplant 1 Cisplatin|20 mg/m2 by continuous infusion Days -3 and -2
45358168|NCT00574080|Drug|Transplant 1 Adriamycin|20 mg/m2 by continuous infusion Days -3 and -2
45358169|NCT00574080|Drug|Transplant 1 Cyclophosphamide|800 mg/m2 by continuous infusion Days -3 and -2
45687486|NCT05240235|Other|Education, compression and exercise therapy|Education; It includes information about the disease, information about risk factors, information that one should pay attention to, and skin care. For compression, sponge-shaped pads that create compression into the bra and prepared by the lymphedema physiotherapist will be used. The exercises will include breathing and upper extremity joint movement exercises determined by Casley-Smith, and the other days to be applied by the physiotherapist when the patient comes to the session will be applied by the patient once a day at home.
45687487|NCT05240235|Other|Education, compression and exercise therapy manual lymph drainage|Education; It includes information about the disease, information about risk factors, information that one should pay attention to, and skin care. For compression, sponge-shaped pads that create compression into the bra and prepared by the lymphedema physiotherapist will be used. The exercises will include breathing and upper extremity joint movement exercises determined by Casley-Smith, and the other days to be applied by the physiotherapist when the patient comes to the session will be applied by the patient once a day at home. In addition, patients will be given manual lymph drainage for one and a half hours every day for the first two weeks. Afterwards, patients will be taken to the same therapy in the hospital for 1 day a week, and on other days they will do self manual lymph drainage at home for 10 minutes.
45358170|NCT00574080|Drug|Transplant 1 Etoposide|80 mg/m2 by continuous infusion Days -3 and -2
45479441|NCT03795779|Biological|CLL1-CD33 cCAR T cells|CLL1-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CLL1 and CD33 CARs.
45844314|NCT04119258|Behavioral|Cognitive-behavioral therapy|Cognitive-behavioral therapy including both behavioral and cognitive interventions.
46047556|NCT02632006|Biological|PIK-PD-1 cells|"DC cell suspension (1×10*7 DC+ physiological saline~+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-PD-1 cell suspension (1-6×10*9 PIK-PD-1 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
45358171|NCT00574080|Drug|Transplant 1 Melphalan|50 mg/m2 Days -2 and -1
46047557|NCT02632006|Biological|DC-PMAT|"DC cell suspension (1×10*7 DC+ physiological saline~+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×10*9 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
45358172|NCT00574080|Drug|Transplant 1 and 2 Pegfilgrastim|6 mg Day +6
46047558|NCT00665236|Other|Craniosacral therapy|Eight weekly 45-minute sessions with therapist
46047559|NCT00665236|Procedure|Low strength static magnets|Placement of magnets on/around subject body by therapist; frequency: weekly for 45-minutes x 8 weeks
45358173|NCT00574080|Procedure|Autologous Peripheral Blood Stem Cell Transplant (ASCT)|Day 0
45358174|NCT00574080|Drug|Transplant 2 Carmustine|300 mg/m2 Day -5
45479442|NCT03329872|Other|Data collection|data collection about symptoms without any specific clinical or biological intervention
45479443|NCT04576871|Drug|225Ac-J591|In this study, subject enrollment will be done in a re-treatment design. A single dose of 225Ac-J591 given at the specified dose per cohort. The initial cohort will receive 90 KBq/Kg, or approximately the highest dose administered in prior studies, at which there are 0 of 6 with DLT.
45479444|NCT04239872|Drug|Fluoride mouthwash|Sodium fluoride, at a concentration of 0.05% (226 parts per million (ppm) of fluoride), will be used to rinse the mouth for 1 minute and expectorated.
45479445|NCT04239872|Drug|Calcium and fluoride mouthwash|Calcium lactate, at a concentration of 150 milimolar, will be used to rinse the mouth for 1 minute and expectorated; immediately after, a sodium fluoride rinse, at a concentration of 0.05% (226 ppm of fluoride), will be used to rinse the mouth for 1 minute, and expectorated.
45479446|NCT03164772|Drug|Durvalumab|anti-PD-L1
45844315|NCT03953508|Other|Cigarette flavor type|Participants will smoke several puffs (each) of a menthol Camel Crush and several puffs of a non-menthol Camel Crush cigarette.
45844316|NCT03931356|Other|Pulmonary function tests|analysis of lung volume and diffusion capacity
45844317|NCT03882840|Biological|NK cell therapy|Infusion of itNK cells
46047560|NCT03497637|Diagnostic Test|measurement of FFR|use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses
45358175|NCT00574080|Drug|Transplant 2 Etoposide|200 mg/m2 Days -5, -4, -3, -2
45358176|NCT00574080|Drug|Transplant 2 Cytarabine|400 mg/m2 Days -5, -4, -3, -2
45358177|NCT00574080|Drug|Transplant 2 Melphalan|140 mg/m2 Day -1
45358178|NCT00574080|Drug|Transplant 2 Dexamethasone|20 mg Days -5, -4, -3, -2, +4, +5, +6, +7
45479447|NCT03164772|Drug|Tremelimumab|anti-CTLA-4
45479448|NCT03164772|Biological|BI 1361849|mRNA Vaccine
45358179|NCT00574080|Drug|Transplant 1 and 2 Bortezomib|1 mg/m2 Days -4, -1, +3, +7
45358180|NCT00574080|Drug|Transplant 1 and 2 Thalidomide|200 mg Days -4 to +5
45358181|NCT00840762|Other|VircoType HIV-1 genotypic interpretation|VircoType HIV-1 genotypic interpretation
45479449|NCT03164772|Device|PharmaJet Tropis® device|The PharmaJet Tropis® device was used for the intradermal administration of the BI 1361849 vaccine components.
45479450|NCT02497690|Behavioral|Telemedicine|Half of subjects will undergo six months of ART administered via telehealth. Therapy will be provided in the usual manner, except a computer will be used to facilitate the interaction.
45358182|NCT00840762|Other|Local Expert Review of HIV Genotypic resistance testing|Local Expert Review of HIV Genotypic resistance testing
45358183|NCT00845364|Drug|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
45358184|NCT00845364|Drug|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
45358185|NCT00546351|Drug|Lacosamide|50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years
45479451|NCT02497690|Behavioral|In-person ART|Half of subjects will undergo six months of ART administered in person. Therapy will be provided in the usual manner.
45479452|NCT03801317|Dietary Supplement|BC/ egg|4.3 egg powder + 5.7 g bovine colostrum
45479453|NCT03801317|Dietary Supplement|Control|15 grams corn-soya blend
46047561|NCT03497637|Diagnostic Test|measurement of Pd/Pa|use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
46047562|NCT00669448|Behavioral|Minfulness-based cognitive therapy|Mindfulness Based Cognitive Therapy (MBCT) is a group intervention that integrates elements from primarily Mindfulness-based Stress Reduction programme (MBSR)and cognitive therapy.The MBCT programme includes 2½ hours of training once a week for 8 weeks. In addition participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course.
46047563|NCT04790617|Behavioral|Community Health Navigator Program|Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
45358186|NCT04043052|Other|Psychological evaluation|Psychological evaluation including: MINI (current diagnosis) ; HDRS ; MDQ ; GAD-7 ; PC-PTSD-5 ; Quality of Sleep (item 6 of the Pittsburgh Sleep Quality Index) ; CES-D ; BAI ; RRS-short form ; IES-R ; mYFAS2.0;
45358187|NCT04043052|Other|Functional evaluation|Functional evaluation including : EQ5-D ; MFI ; LUNS ; SSQ ; Physical activity (IPAQ)
45358188|NCT04043052|Biological|Biological assessment|Biological assessment : White and red blood cells count ; platelets count ; Haemoglobin ; CRPus ; Glycaemia ; Plasmatic HbA1c ; Plasmatic LDLc ; HDLc and triglyceride ; Creatinin clearance, Transaminases.
45358189|NCT04043052|Other|Ecological Momentary Assessment|During 3 months after inclusion, a 3 to 5 minutes daily interview will administer questions concerning mood symptoms, activities, stress experience, substance use, social relationships and medication intake, activities, social interaction, environmental conditions, experience of depressed mood, anhedonia, changes in weight, appetite, sleep, fatigue, feelings of worthlessness or inappropriate guilt, concentration or decision-making difficulty
45358190|NCT00267865|Drug|Methotrexate|6000 mg/m^2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patients urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.
45358191|NCT00267865|Drug|Rituximab|375 mg/m^2 intravenous (IV) day 1 of each cycle prior to administration of high-dose methotrexate
45358192|NCT00267865|Drug|Leucovorin|Leucovorin calcium doses will be administered orally or by short intravenous (IV) infusion over 15 minutes
45358193|NCT00851760|Procedure|Consecutive surgery|Consecutive surgery for epiretinal macular membrane and cataract extraction
45358194|NCT00851760|Procedure|Combined surgery|Combined surgery for epiretinal macular membrane and cataract extraction
45479454|NCT03801317|Dietary Supplement|multiple micronutrient|multiple micronutrient sprinkle powder
45479455|NCT02497768|Other|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (pistachios or Brazils) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
45479456|NCT03795545|Procedure|SWL|Shock wave lithotripsy
45479457|NCT02493400|Other|No intervention in the follow up study.|
45479458|NCT01331070|Other|cerebral fMRI|the central breathing control with cerebral fMRI in COPD patients
45479459|NCT01331070|Other|cerebral fMRI|the central breathing control with cerebral fMRI in Accepts Healthy Volunteers
45479460|NCT03337126|Drug|Metronidazole Tablet|Comparator Drug
45844318|NCT03870672|Device|Contralaterally Controlled Functional Electrical Stimulation|Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses electrical stimulation to open the weak hand. Sticky patches called electrodes are placed on the participant's affected arm to stimulate the hand muscles, and a special glove is worn on the participant's strong hand and controls the stimulator. When the participant opens the gloved hand, stimulation opens the weak hand; when they close the gloved hand, stimulation turns off and the weak hand relaxes. During the clinic visits, participants will use CCFES to assist hand opening during functional training. During participant home sessions, they will use CCFES to perform hand opening exercise.
45844319|NCT03870672|Device|New rTMS approach|Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
45687488|NCT05238103|Combination Product|Corrie Virtual Cardiac Rehabilitation Program|The Corrie Virtual Cardiac Rehabilitation Program is multi dimensional intervention. It consists of the Corrie smartphone app for cardiovascular health optimization which is paired with wristband device (Apple Watch or Fitbit), Bluetooth-enabled Omron blood pressure monitor and exercise resistance bands. The program also includes individualized treatment plan development, setting health goals and communication with trained Corrie Health Coach. Furthermore, the intervention includes motivational text messages sent to participants throughout the study to aid with risk factor modification.
46047564|NCT00669526|Behavioral|BCBT|Brief Cognitive Behavioral Therapy. This BCBT protocol consists of up to 8 CBT sessions to be conducted over a maximum of 12 weeks.
46047565|NCT00669526|Behavioral|SMHC referral|Referral to local Speciality Mental Health Care. Families were referred to local mental health care providers, and could freely choose any treatment or combination of treatments offered (e.g., anti-depressant medication, individual psychotherapy, family psychotherapy, etc.).
46047566|NCT02416011|Behavioral|GENERIC|The initial Stop Smoking for Good brochure, 10 Stop Smoking for Good booklets and 9 supportive My Story pamphlets delivered over 18 months, as used in our previous cessation study.
46047567|NCT02416011|Behavioral|eTARGET|The product of Study I is expected to include the initial If You Vape brochure, a series of 10 If You Vape: Guide to Quitting Smoking booklets, distributed over 18 months, and 9 supportive My Story pamphlets, delivered in the months between booklets.
45358195|NCT00851838|Drug|L-Carnitine|Instillation of glucose-based (1.5 or 2.5 w/v) PD solution containing L-carnitine during the nocturnal exchange in APD treated patients. L-Carnitine (0.1% w/v) is present only in the first 5 Liter APD bag. PD solutions are instilled for 5 days.
45358196|NCT01069237|Device|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
45479461|NCT01331226|Behavioral|telephone counseling 3 sessions|3 sessions of telephone counseling
45358197|NCT01069237|Device|Clear Care|Lens Care Solution for contact lenses
45479462|NCT01331226|Behavioral|telephone counseling 1 session|1 session of telephone counseling
45687489|NCT05236179|Other|Integrative therapies|Integrative therapy methods used at the Filderklinik, such as music therapy, therapeutic painting, therapeutic sculptural forming, speech therapy, eurythmy therapy, rhythmical massage, external applications, coloured light therapy
45687490|NCT05235815|Procedure|Retro SCTL compartment block|"For phase 1, healthy human volunteers will be positioned in the lateral position with the side to be scanned in the non-dependent position. An ultrasound scan sequence to describe the retro SCTL space will be performed on both sides.~During phase 2, participants who are scheduled for video-assisted thoracoscopic surgery (VATS) will receive an ultrasound-guided multi-level (T3-4, T5-6 and T7-8) retro SCTL compartment block. After positioning the participants, cleaning and draping the injection site, under sterile aseptic precautions and local anaesthetic infiltration, the block needle is inserted at the corresponding vertebral level (T7-T8) under ultrasound guidance in-plane to the ultrasound beam. Once the needle tip reaches the lateral aspect of the inferior articular process and behind the SCTL ligament, the desired volume (6ml/each level) of LA will be injected. This process will be continued at the remaining two vertebral levels (T5-T6 and T3-T4)."
45358198|NCT00840918|Drug|Lidocaine|Intravenous Lidocaine Group - Lidocaine administered intravenously throughout surgery and during the 24 hours following surgery.
45358199|NCT00840918|Other|Placebo|Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
45358200|NCT00546117|Drug|lansoprazole|Prevacid SoluTab 15 mg daily by mouth for 2 months (patients weighing 10-30 kg),or Prevacid SoluTab 30 mg daily by mouth for 2 months (patients weighing >30 kg) is the experimental arm. Placebo Solutabs will be given in the same dosage, frequency, and duration for the placebo arm.
45358201|NCT00546117|Drug|placebo|Placebo Solutab in 15 and 30 mg dosages.
45358202|NCT01582165|Drug|Rosuvastatin|Rosuvastatin 20 mg once daily vs placebo for 6 months
45479463|NCT01331226|Behavioral|written materials only|written materials only
45479464|NCT05016050|Device|HPDT-DA-013|Digital program with therapeutic interventions based on Cognitive Behavioral Therapy (CBT).
45358203|NCT01582165|Drug|Placebo.|Placebo once daily vs rosuvastatin for 6 months
45358204|NCT00851916|Radiation|CyberKnife Radiosurgery|CyberKnife Radiosurgery
45358205|NCT03975049|Radiation|Chemoradiation|Fluorouracil 225 mg/m2/day continuous intravenous infusion on weekdays for five weeks; local irradiation 2GY/day on weekdays, totally 50GY.
45479465|NCT03325036|Diagnostic Test|Serum levels of immunologic profiles|Serum levels of immunologic profiles before and after chemoradiotherapy
45687491|NCT05234515|Diagnostic Test|Microbiology swab|Patients will have swabs taken from the nose, mouth, umbilical skin, groin skin, fistula(e), stoma(s) and vascular access device prior to surgery. Patients will be followed for 90 days postoperatively for surgical site infection (SSI) as defined by the centre for disease control (CDC) criteria 2021. Patients who develop an SSI will have both preoperative and postoperative samples sent for genome sequencing.
45358206|NCT03975049|Drug|FOLFOXIRI Protocol|Oxaliplatin 85 mg/m2 on day 1; irinotecan 150 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days; prophylactic G-CSF support is recommended.
45844320|NCT03870672|Device|Conventional rTMS approach|Facilitation of M1 will be achieved using 5Hz rTMS. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
45358207|NCT03975049|Drug|Folfox Protocol|Oxaliplatin 85 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 400 mg/m2 bolus and 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days.
45844321|NCT03870672|Device|Sham rTMS approach|In the sham rTMS group, ipsilesional motor hotspot will be targeted in half the patients and cHMC location will be targeted in the other half (based on random assignment). Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
45687492|NCT05234515|Other|Questionnaire|Patients will complete baseline preoperative questionnaires which will be repeated at 30 days and 90 days. These will evaluate generic and wound specific quality of life as well as decision conflict/decision regret.
45844322|NCT03734016|Drug|Zanubrutinib|160 mg orally twice daily
45844323|NCT03734016|Drug|Ibrutinib|Ibrutinib 420 mg orally once daily
45844324|NCT03730818|Other|Water-based Exercise Group|The intervention consist will of a water-based exercise protocol
45844325|NCT03730818|Other|Land-based Exercise Group|The intervention will consist of a land-based exercise protocol
45844326|NCT03671148|Biological|Placebo|Placebo for risankizumab administered by subcutaneous (SC) injection
45844327|NCT03671148|Biological|Risankizumab|Risankizumab administered by subcutaneous (SC) injection
45844328|NCT03564522|Procedure|cardiac catheterization|cardiac catheterizations will be clinically indicated and the study will collect this clinical data.
45844329|NCT03564522|Radiation|Cardiac MRI|If clinically indicated, the study will collect data from MRIs.
45844330|NCT03486444|Diagnostic Test|Phillips Lumify Diagnostic Ultrasound System|portable ultrasound device
45844331|NCT03486444|Other|Surveys|surveys assessing perception of ultrasound
45844332|NCT03465852|Behavioral|ChiCAS|Promotes access to and participation by HIV negative Hispanic/Latina transgender women who have sex with men in PrEP, medically supervised hormone therapy, and consistent condom use.
45844333|NCT03428646|Drug|Dupilumab|Dupixent 1 dose at Baseline required for eligibility; otherwise, no therapeutic intervention required during the course of the study. In addition to (or substituting for) DUPIXENT®, participants may receive marketed drugs as deemed necessary by their physicians for the treatment of AD or comorbid conditions.
45844334|NCT03295344|Other|Diaphragm ultrasonography|"Spontaneously breathing patients in the ½ seated position Heart transducer at the medio axillary position, parallel to the axis of the body, last intervertebral spaces~US mode:~2D = Evaluation of the pulmonary parenchyma Time-Movement (TM) = Evaluation of diaphragm muscle shortening in the apposition zone + Evaluation of diaphragm mobility in the posterior 1/3 of the diaphragm dome Tissue Doppler Imaging (TDI) = Evaluation of diaphragm mobility in the diaphragm dome Collection of different daily clinical data"
45687493|NCT05234437|Drug|tigilanol tiglate|"Single or multiple Intratumoural treatments of tigilanol tiglate up to a fixed dose level of 3.6mg/m2.~Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours."
45687494|NCT05225675|Biological|ARGX-117|Intravenous administration of ARGX-117
45687495|NCT05225675|Other|Placebo|Intravenous administration of placebo
45687496|NCT05223166|Drug|Pitolisant|Wakix tablet
45844335|NCT03295344|Other|Tissue Doppler|Determine the threshold value for diaphragm mobility
45844336|NCT03198546|Biological|GPC3 and/or TGFβ targeting CAR-T cells|Engineering GPC3 or/and TGFβ targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Tigit secreting vector into T cells with knockdown of PD1/HPK1, which are isolated from patients with advanced HCC, and then transfusing them back the patients.
45844337|NCT03064542|Drug|carbimazole (CMZ) or thiamazole (TMZ)|CMZ or TMZ will be used to treat the hyperthyroidism till the FT4/TSH is in normal range.
45844338|NCT02718066|Drug|HBI-8000 in combination with nivolumab|"Phase 1b: HBI-8000, orally, twice a week, dose escalation 20mg, 30mg, 40mg; in combination with nivolumab 240mg intravenous infusion every 2 weeks.~Phase 2: HBI-8000 MTD or 40mg; in combination with nivolumab in accordance with the manufacturer package insert and institution's prescribing practice."
45844339|NCT02004522|Drug|Duvelisib|PI3K Inhibitor
45844340|NCT02004522|Drug|Ofatumumab|monoclonal antibody
45358208|NCT00841074|Drug|chlorhexidine|0.12% chlorhexidine mouthwash spray, ~1.3 ml, twice a day.
45358209|NCT00841074|Drug|Placebo mouthwash|Placebo mouthwash spray application of ~1.3 ml twice a day.
45844341|NCT02000622|Drug|Olaparib|Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
45358210|NCT00964197|Device|FemmeJock|The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
45358211|NCT00967707|Drug|gabapentin and venlafaxine|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Venlafaxine 75 mg once daily is added."
45687497|NCT05223166|Drug|Placebo oral tablet|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
45687498|NCT05220748|Combination Product|RM-1995|RM-1995 will be administered by intravenous (IV) infusion followed approximately 24 hours later by tumor illumination with 690 nm non thermal red light using the PIT690 Laser System. The starting dose of RM-1995 will be 0.25 mg/kg and escalated up to 2.0 mg/kg over 6 dosing cohorts
45844342|NCT02000622|Drug|Physician's choice chemotherapy|"Investigators will declare one of the following regimens:~Capecitabine 2500 mg/m2 po daily (divided in 2 doses) x 14 days, repeat every 21 days~Vinorelbine 30 mg/m2 IV Day 1 and Day 8, repeat every 21 days~Eribulin 1.4 mg/m2 IV Day 1 and Day 8, repeat every 21 days"
45844343|NCT01472562|Drug|lenalidomide|"Induction phase: 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.~Maintenance phase: Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle."
45358212|NCT00967707|Drug|gabapentin and donepezil|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Donepezil 5 mg once daily is added."
45358213|NCT04176120|Biological|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
45479466|NCT04710732|Drug|Standard Enoxaparin 40 mg once-daily before randomization|"Once-daily subcutaneous injection of a standard prophylactic dose of Enoxaparin 40 mg according to the set schedule:~12 hours before the surgery (if applicable) on a postoperative day -1 (POD -1)~6-12 hours after the surgery (key injection 1) on the surgery day (POD 0)~12 hours after the previous key injection 1 (key injection 2) on the POD 1~24 hours after the previous key injection 2 on the POD 2"
45844344|NCT01472562|Biological|rituximab|"Induction phase: Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.~Maintenance phase: Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52."
45844345|NCT01430442|Drug|Rimegepant|Rimegepant capsules
45844346|NCT01430442|Drug|Placebo|Rimegepant placebo-matching capsules
45844347|NCT01430442|Drug|Sumatriptan|Rimegepant matching sumatriptan and Rimegepant matching placebo capsules
45844348|NCT01420926|Drug|Bortezomib|Given SC
45844349|NCT01420926|Drug|Decitabine|Given IV
45844350|NCT01420926|Other|Laboratory Biomarker Analysis|Correlative studies
45844351|NCT01420926|Other|Pharmacological Study|Correlative studies
45844352|NCT01420926|Other|Quality-of-Life Assessment|Ancillary studies
45687499|NCT05220748|Biological|Pembrolizumab|Pembrolizumab (200 mg) will be administered by intravenous (IV) infusion one week before the first RM-1995 PIT treatment and the second dose three weeks later for patients in the combination arm. Once the DLT window is complete, pembrolizumab dosage will be maintained at either 200 mg Q3w, or shift to 400 mg Q6w, per investigator discretion.
45844353|NCT01420926|Other|Questionnaire Administration|Ancillary studies
45844354|NCT00941538|Diagnostic Test|Experimental: Screening with EBV VCA/EBNA1-IgA testing|Participants in the screening towns will be offered screening tests. Those with high-risk scores will be referred to a diagnostic workup examination using fiberoptic endoscopy examination and nasopharyngeal biopsies if suspicious lesions is observed.
45844355|NCT00626964|Procedure|Bariatric Surgery|Bariatric Surgery Treatment: Duodenal Switch, Gastric Sleeve or Gastric bypass.
45687500|NCT05217420|Behavioral|Moving Well|Experimental arm
45844356|NCT00626964|Behavioral|Conservative Treatment:|Intensive Lifestyle Intervention Program
45844357|NCT01881828|Drug|Metformin (glucophage)|The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
45844358|NCT01881828|Other|oral placebo|
45844359|NCT01882062|Drug|Triheptanoin 1g/kg/day|
46047568|NCT05075395|Device|PARO therapy seal|PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
45687501|NCT05217420|Behavioral|Staying Well|Active comparator arm
45479467|NCT04710732|Drug|Standard Enoxaparin 40 mg once-daily after randomization|Once-daily subcutaneous injection (every 24 hours) of a standard prophylactic dose of Enoxaparin 40 mg since POD 3 and until discharge
45479468|NCT04710732|Drug|Escalated Enoxaparin 30 mg twice-daily after randomization|Twice-daily subcutaneous injection (every 12 hours) of an escalated prophylactic dose of Enoxaparin 30 mg since POD 3 and until discharge
45687502|NCT05215288|Biological|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
45844360|NCT01882764|Drug|HMPL-004|Remitters and responders from HMPL-004 Induction study and patients complete the 8-week Open Label Induction Phase will be given HMPL-004 orally three times per day with total daily dose of 1800 mg for 52 weeks.
45844361|NCT01882764|Drug|Placebo|Remitters and responders from HMPL-004 Induction study and patients complete the 8-week Open Label Induction Phase will be given Placebo orally three times per day with total daily dose of 1800 mg for 52 weeks.
45844362|NCT01883856|Device|Silicone plate Ahmed Glaucoma Valve (Model FP7)|This intervention is conducted as a surgical intervention.
45844363|NCT01883856|Device|Porous Plate Ahmed Glaucoma Valve (Model M4)|This intervention is conducted as a surgical intervention.
45687503|NCT05209230|Procedure|Continuous renal replacement therapy|Continuous renal replacement therapy (veno venous hemofiltration) without net ultrafiltration, through a dedicated central venous catheter
45687504|NCT05209230|Other|Control group|Continuous renal replacement therapy is differed from 6 hours to allowed 2 control echocardiographic evaluations
46047569|NCT00665314|Drug|Plerixafor (AMD3100)|0.24mg/kg SC for 2 to 7 days.
46047570|NCT00665314|Drug|Can be any registered nonpegylated form of G-CSF|10mcg/kg SC for 4 days followed by an additional 2 to 7 days.
45687505|NCT05199610|Drug|aumolertinib|A single dose of 55-mg EQ143 tablet will be administered in the morning on Day 1, and participants will remain for 5 days (4 nights) in the study center for collection of blood samples and safety monitoring. Participants will attend outpatient follow-up visits on Days 5, 6, 8, and 9 for additional blood sampling and safety assessments.
45687506|NCT05195008|Drug|BIIB113|Administered as specified in the treatment arm.
45687507|NCT05195008|Drug|BIIB113-Matching Placebo|Administered as specified in the treatment arm.
45844364|NCT01887132|Drug|Donepezil|
45844365|NCT01887132|Drug|Placebo|
45844366|NCT01887990|Drug|Ketamine|single dose IV 0.2 mg/kg ketamine
45844367|NCT01887990|Drug|placebo|saline infusion
45844368|NCT01890642|Device|J tip|This is a Jet Injection system which for our study will be loaded with 1% buffered lidocaine
45844369|NCT01890642|Other|Pain Ease Spray|Cold Spray used to anesthetize the skin
45844370|NCT01890642|Drug|1% buffered lidocaine|Lidocaine placed using Jet Injection
46047571|NCT03133377|Behavioral|Early activity and mobilisation|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
46047572|NCT04778371|Other|Almonds|64 g total dry roasted, unsalted almonds per day for a total of 12 weeks
45844371|NCT01890642|Other|placebo cooling spray (normal saline spray)|Normal Saline Sprayed as placebo for Pain Ease spray
45844372|NCT01890642|Other|Sucrose|Oral Sucrose used for children < 1 year
46047573|NCT04778371|Other|Placebo|200 g total calorie matched granola bar per day for total of 12 weeks
46047574|NCT04154722|Drug|Meropenem Injection|inj meropenum for 10 days
46047575|NCT04154722|Drug|Azithromycin Powder|syp azithromycin for10days
45844373|NCT01891734|Other|Problem Solving Therapy plus Moving Forward|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
45687508|NCT05195008|Drug|11^C]BIO-1819578|Administered as specified in the treatment arm.
45844374|NCT01891734|Other|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
45844375|NCT01891968|Drug|Bortezomib|1.3 mg/m2 subcutaneously on days 1, 4, 8 and 11 of a 21 day cycle.
45687509|NCT05194332|Device|LIFUP sonication to the amygdala|LIFUP sonication to amygdala will be performed.
45687510|NCT05193786|Procedure|Different level of PEEP|Different level of PEEP (low versus high) was applied in noninvasive ventilation.
45687511|NCT05187364|Behavioral|COPE|The COPE therapy is a talk-therapy in which individuals are asked about their trauma, alcohol use, mood, and behavior. The therapy occurs over 12 sessions and will be paired with a telehealth technology system to determine if it enhances the COPE therapy. The telehealth system is worn on the arm and hand during the out-of-office COPE homework assignments. It consists of a small camera (about the size of a pencil eraser), Bluetooth earpiece with microphone, monitors to measure and record heart rate and skin conductance, and a breathalyzer to assess blood alcohol content. The device will connect to an application on password protected cell phone that will monitor and record the above listed information as well as reported subjective units of distress and craving. A study coach will virtually guide participants through one out-of-office assignment per week using this technology. Interviews and surveys will be collected at study baseline and weekly during treatment.
45687512|NCT05182060|Behavioral|Transition Intervention|"We will implement a bundle of care transition safety strategies with the assistance of home care coordinators at the study site and corresponding home health provider teams (nurses, rehabilitation therapists).~Home care coordinators will approach patients at the study site being referred for home health and provide resources to assist them with preparing for their transition home. These resources include a link to a video about home health services, a caregiver assessment, a care task role assignment sheet, and a shopping list. The study team will contact the older adult and caregiver by telephone within 48 hours of the home visit to confirm eligibility, explain the study, obtain consent for participation, and ask them to complete the the Hospital-to-Home Health Transition Quality Index (H3TQ) over the phone. Home health providers in the home will also complete the H3TQ."
46047576|NCT02631928|Drug|human biphasic insulin|investigational insulin, biosimilar human insulin suspension of 30% normal insulin and 70% basal protamined insulin
46047577|NCT02631928|Drug|human biphasic insulin, reference|marketed product, human insulin suspension of 30% normal insulin and 70% basal (NPH) insulin
45844376|NCT01893372|Drug|Eltrombopag|200 mg by mouth daily in a 28 day cycle.
45844377|NCT01893372|Drug|Hypomethylating Agent (HMA)|The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.
45844378|NCT01895088|Device|AcuFocus Corneal Inlay ACI 7000 PDT|Inlay implanted in cornea for improvement of near vision
46047578|NCT02609035|Behavioral|Telephonic prompt|
45844379|NCT01895634|Device|Rev-01|Treatment arm patients have used Rev-01 at least once
45844380|NCT01895946|Drug|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off: tablet formulation for one week, followed by two weeks with capsule formulation.
45844381|NCT01895946|Drug|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off, tablet formulation. On day 4 AZD5363 tablet without food. On day 11 AZD5363 tablet with food.
45844382|NCT01898754|Other|Pre-ART Oligonucleotide Assay (OLA)|Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART
45844383|NCT01899300|Device|Metal Stent (WallFlex™ Esophageal RX)|
45844384|NCT01900392|Behavioral|Financial incentive|Participants in the direct payment and lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
45844385|NCT01900704|Drug|SER120 750 ng|SER120 750 ng
45844386|NCT01900704|Drug|SER120 1500 ng|SER120 1500 ng
45844387|NCT01900704|Drug|Placebo|Placebo
46047579|NCT00632385|Drug|Eletriptan|40 mg oral tablet for migraine attack, followed by 40 mg oral tablet if migraine reoccurred >2 hours from first dose and within 24 hours of first dose
46047580|NCT04757259|Drug|cerdulatinib|Participants will receive oral cerdulatinib at the starting dose he or she was receiving at completion of Study 13-601 (30, 25, 20, or 15 milligrams [mg] twice daily [BID]).
46047581|NCT03980457|Device|Indego Exoskeleton|Powered generated orthosis
46047582|NCT03980457|Other|Standard Rehabilitation|Standard Rehabilitation
46047583|NCT05579613|Device|Interactive virtual reality device|The Kinect sensor is an infrared camera that can recognize the positions and motions of the player without the need for special controller. The console controls the various games .For the VR training, the Xbox Kinect, console, and monitor will set up in a dedicated space. The patient will placed 1.5-2 m away from the Kinect sensor.
45358214|NCT04176120|Other|Standard Care|"Standard care is defined in this protocol to consist of the following:~Debridement;~Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~Appropriate use of systemic antibiotics."
45687513|NCT05180357|Other|FASENRA(benralizumab)|This is a retrospective, observational study with secondary data collection utilizing medical chart review in hospitals or clinical centres that treated SEA + NP patients with benralizumab. Patient data including demographics, clinical characteristics, medication history, biologic treatment, and NP and asthma clinical outcomes will be abstracted from patient medical charts onto a pre-approved electronic case report form. No personal identifiable data will be collected. Data from all participating centres will be combined into a single anonymised dataset for analysis.
45358215|NCT00964275|Procedure|diagnostic procedure|Standard diagnostic procedures followed
45358216|NCT00964275|Radiation|fludeoxyglucose F 18|PET with flueoxyglucose F 18
45687514|NCT05180253|Diagnostic Test|Esophageal studies|Healthy subjects will undergo esophageal and blood testing.
45687515|NCT05179408|Behavioral|Telerehabilitation|Telerehabilitation intervention consisting of exercise training, education, and behavioral support
46047584|NCT00910689|Drug|Propranolol or nadolol|Treatment initiated with 1 capsule (60 mg long acting propranolol hydrochloride) and increased to 3 capsules (180 mg) at week 12 as tolerated. If subject does not tolerate at least 2 capsules (120 mg) of propranolol hydrochloride-LA, and in treating neurologist's judgment are unimproved, subject switched to second medication (nadolol). Participants initially receive a single 40 mg capsule of nadolol and increased to 2 capsules (80 mg) as tolerated. At week 12 dose stabilized at highest tolerated level. In evaluation phase, an increase to 4 capsules of long acting propranolol hydrochloride (240 mg) or 3 capsules of nadolol (120 mg) permitted.
46047585|NCT00910689|Drug|Placebo control|Placebo
45687516|NCT05175521|Other|Eucalyptus Oil Scent|Eucalyptus oil in mineral (1:20) will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack
45687517|NCT05175521|Other|Isopropyl Alcohol Vapors|Isopropyl Alcohol 70% will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack
46047586|NCT00910689|Behavioral|Behavioral Migraine Management (BMM)|"Session 1: Overview of the pathophysiology of migraine; introduce muscle stretching, deep breathing, PMR, imagery; Session 2: Development trigger management strategy; Use early warning signs as a cue to use behavioral migraine management and acute medication; Session 3:(a) continue with basic migraine management skills if these skills have not been mastered;(b) introduce cognitive-behavioral stress-management, if stress is a salient migraine trigger;(c) introduce thermal biofeedback (hand warming) training with a portable home thermal biofeedback device, if stress is not a notable migraine trigger. Session 4: Review problems using various behavioral migraine management skills; Prepare written migraine management plan; Relapse prevention addressed"
45358217|NCT00845598|Drug|Azelastine , fluticasone|"Azelastine Hydrochloride BP 0.10% w/v AND Fluticasone propionate BP 0.0357% w/v as combination~1 squirt in each nostril twice daily"
45358218|NCT00845598|Drug|Fluticasone propionate|Fluticasone propionate 0.05% w/w 2 squirts in each nostril (50 μg per squirt)
45687518|NCT05169684|Biological|BMS-986218|Specified dose on specified days
45358219|NCT00251719|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
45358220|NCT00251719|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
45687519|NCT05169684|Drug|Docetaxel|Specified dose on specified days
45687520|NCT05169684|Biological|Nivolumab|Specified dose on specified days
45687521|NCT05166837|Drug|STSA-1002 injection|Intravenous injection
45687522|NCT05166837|Drug|Placebo|Intravenous injection
45687523|NCT05166837|Drug|STSA-1002 injection|Intravenous injection
45687524|NCT05166837|Drug|Placebo|Intravenous injection
45844388|NCT01901250|Dietary Supplement|Xylitol gummy bears|The children receive xylitol gummy bears 3 times/day within the supervised school environment.
45844389|NCT01901250|Dietary Supplement|Sugar free fiber gummy bears|The children receive sugar free fiber gummy bears 3 times/day within the supervised school environment.
45358221|NCT00251719|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
45358222|NCT00968097|Drug|123-I MNI-340|To assess the dynamic uptake and washout of 123-I MNI-340, a potential imaging biomarker for β-amyloid burden in brain
45358223|NCT02547090|Procedure|The use of two attending surgeons during posterior spinal fusion|Patients in the experimental group received posterior spinal fusion with two attending surgeons. Patients in the control group received posterior spinal fusion with one attending surgeon and one first assist, which could be a resident, PA, or nurse.
45358224|NCT00964587|Behavioral|Education + Problem-Solving Training Self-Study|"Education + Problem-Solving Training Self-Study~One session of Literacy-Adapted Diabetes and CVD Risk Education~Instructions and a schedule for use of the Literacy-Adapted Problem-Solving Workbook for self-study will be given to each participant."
45358225|NCT00964587|Behavioral|Education + Group Problem-Solving Training|"Education + Group Problem-Solving Training~One session of the Literacy-Adapted Diabetes and CVD Risk Education~Group problem-solving training eight, 90-minute sessions"
45358226|NCT00964587|Behavioral|Education + Individual Problem-Solving Training|"Education + Individual Problem-Solving Training~One session of the Literacy-Adapted Diabetes and CVD Risk Education~Individual problem-solving training (eight, 60-minute sessions)"
45358227|NCT00964587|Behavioral|Usual Care|"Packet of print patient education materials about CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA)given at baseline following randomization to Arm 1~Scripted set of instructions will be given along with a verbal description of the materials and the content provided."
45358228|NCT00845754|Drug|ketorolac|15mg IV every6 hours for 4doses
45687525|NCT05166837|Drug|STSA-1002 injection|Intravenous injection
45687526|NCT05166837|Drug|Placebo|Intravenous injection
45687527|NCT05166837|Drug|STSA-1002 injection|Intravenous injection
45687528|NCT05166837|Drug|Placebo|Intravenous injection
45687529|NCT05166837|Drug|STSA-1002 injection|Intravenous injection
45687530|NCT05166837|Drug|Placebo|Intravenous injection
45844390|NCT01901250|Behavioral|Oral health education|Oral health education, toothbrush, and fluoride toothpaste
45844391|NCT01901250|Device|Fluoride varnish|The study dentists apply the varnish on all children twice a year during the study period. The varnish is 5% sodium fluoride and contains 2.26% by weight fluoride ion in a colophony base.
45844392|NCT01901250|Device|Dental sealant|The study dentists apply the sealant on the children in the second grade when the permanent first molars are fully erupted.
45687531|NCT05166694|Other|Drug-Drug Interaction Profile|A profile based on genetic testing that shows information about how the participant's medications they are taking interact with each other.
45687532|NCT05166694|Other|Drug-Gene Interaction Profile|A profile based on genetic testing that shows information about how the participant's genes interact with/respond to certain medications they are taking.
45358229|NCT00845754|Drug|saline|15mg IV every 6hrs for 4 doses
45358230|NCT00964665|Drug|albinterferon alfa-2b|
45358231|NCT00964665|Drug|albinterferon alfa-2b|
45358232|NCT00964665|Drug|albinterferon alfa-2b|
45358233|NCT00964665|Drug|albinterferon alfa-2b|
45358234|NCT00964665|Drug|Pegasys®|
45358235|NCT00841152|Device|Bioactive glass|Surgical implantation
45687533|NCT05166694|Other|Standard of Care|The standard treatment and prescribing for the participant's specific type of cancer.
45687534|NCT05164744|Diagnostic Test|Cardiac MRI|Patients participate in an NIH funded cardiac MRI to assess their symptoms.
45687535|NCT05164744|Diagnostic Test|Echocardiogram|Patients participate in an NIH funded cardiac echocardiogram to assess their symptoms.
45687536|NCT05164744|Diagnostic Test|6-minute walk test|Patients participate in a 6-minute walk test to assess their symptoms.
46047587|NCT00910689|Drug|Optimal Acute Therapy|This acute therapy protocol emphasized treatment with a 5-HT1B/D-agonist or triptan. Nonsteroidal anti-inflammatory (NSAID; ibuprofen) and anti-emetic (metoclopramide) medication could be added as needed. The choice of triptans (rizatriptan®, sumatriptan®), the route(s) of triptan administration (oral, nasal spray, subcutaneous injection), and the addition of a NSAID, or anti-emetic were tailored to participant preference, treatment history and acute therapy response. Individualized handouts and a phone call (week 3) of the OAT Run-in were used to help participants evaluate and optimize their acute therapy.
45687537|NCT05164744|Diagnostic Test|Questionnaire|Patients answer a survey-based questionnaire to assess their symptoms.
45687538|NCT05161000|Other|Oral Nutritional Supplement|ONS plus dietary counseling
46047588|NCT00807001|Drug|IDX184|oral dose, active or placebo
45358236|NCT00841152|Device|Beta-tricalcium phosphate (ChronOs)|Surgical implantation
45358237|NCT00841152|Procedure|Autograft|Surgical transplantation from iliac crest
45358238|NCT00841152|Procedure|Allograft (frozen femoral head)|Surgical transplantation
45358239|NCT02545686|Behavioral|Chest wall movement assessment without CPAP|While subject is breathing normally, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
45358240|NCT02545686|Behavioral|Breath hold assessment without CPAP|While subject is breathing normally, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
45687539|NCT05161000|Other|Dietary counseling|dietary counseling
45752010|NCT01794481|Procedure|Resistance Exercise Training (RET)|"If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy.~There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique."
45844393|NCT01904448|Device|Auditory Brainstem Implantation in Children|
46047589|NCT04164979|Drug|Cabozantinib|Given PO
45358241|NCT02545686|Procedure|Chest wall movement assessment with CPAP|While subject is breathing via CPAP machine, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
45358242|NCT02545686|Procedure|Breath hold assessment with CPAP|While subject is breathing via CPAP machine, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
45358243|NCT00841230|Drug|Deanxit|Deanxit 1x/day
45358244|NCT00841230|Drug|Lactose placebo|Lactose used as placebo
45358245|NCT00841308|Other|Decision to start and titrate drug treatment based only on home blood pressure monitoring|"Drug Treatment according to current Hypertension Guidelines. Decision to start and titrate drug treatment based on clinic and ambulatory blood pressure (Usual care arm) versus based on home blood pressure monitoring only (Home blood pressure monitoring arm)."
45358246|NCT00852072|Procedure|Single-operator cholangioscopy-guided laser lithotripsy|Ability to clear the bile duct of all stones in one ERCP session using laser lithotripsy-based technique, including use of mechanical lithotripsy
46047590|NCT04164979|Drug|Pembrolizumab|Given IV
45844394|NCT01904526|Drug|Guanfacine|3mg/day IR with 3-week lead-in period. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 4mg/day ER. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 6mg/day ER. Maintained at steady state to complete lab session. 5-day taper after lab.
46047591|NCT04222335|Other|Blood samples|"Each participant will be followed-up regularly as part of the usual practice for imaging and medical consultations. During their visits, from inclusion (T0) to the end of study participation (T progression), each patient will have a blood sampling specifically for the research to analyze tumor DNA and circulating tumor cells: T0, T1month, T3 months, Tn months, T DNA C+, T progression.~This research does not include any other act or intervention specifically required for its purposes."
46047592|NCT02608957|Device|Latella Knee Implant System|
46047593|NCT04688515|Behavioral|Nutrition program developed using positive deviance approach|It is a 3-month nutrition program including nutrition education session and rehabilitation session. The education session consists of half hour education lesson and one and half hours peer-led cooking session. The cooking demonstration will be led by volunteers from PD family. Participating mothers will need to bring along their children during this session, prepare meal according to pre-planned menu and feed their children with the prepared meal after cooking as snack or additional meal. The rehabilitation session will be the rest of the days following each education session until the next education session. Growth monitoring session will also be conducted in each session, whereby mothers will be taught and trained to weigh their children.
45358247|NCT00852072|Procedure|Balloon Sphincteroplasty|Ability to clear the bile duct of all stones in one ERCP session using large balloon sphincteroplasty-based technique, including use of mechanical lithotripsy
45358248|NCT02545920|Other|no intervention|observational study
45358249|NCT00841386|Drug|Riboflavin-5-phosphate|Riboflavin 0.1% (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) will be applied to the cornea every 2-3 minutes for 15 minutes prior to starting UV irradiation. The UV irradiation will be given in six 5 minute intervals. Additional riboflavin will be administered following each 5 minute UV treatment.
45358250|NCT00841386|Drug|Sham cross-linking|Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and 2% methylcellulose solution with 1% sodium fluorescein will be applied to the cornea every 5 minutes for 15 minutes, and then every 5 minutes during the sham UV treatment. The patient will be placed under the UV device, and the aiming beam applied.
45358251|NCT00848094|Radiation|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 46 Gy in 2 Gy per fractions for arm I . Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 62 Gy for arm I.
45358252|NCT00848094|Radiation|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 40 Gy in 2 Gy per fractions for arm II. Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 52 Gy for arm II.
45687540|NCT05158907|Other|Patient reported Adverse event scale|Participants will be given a patient reported AE scale with numbers from 0 to 10 before start of each chemotherapy cycle. The PRAE scale will be like a Visual Analogue Scale and the patients will be given instructions how to record AEs that they experience after each chemotherapy cycle, until the first radiological assessment is done (palliative settings) or after 4 cycles of chemotherapy in adjuvant settings. Participants will take scale home to record the adverse effects and give it a number. Only the most severe will be analyzed. When patient reports for the next cycle of chemotherapy they will be asked to deposit the scale before meeting the physician. The physician will ask patient about the AEs experienced with the chemotherapy and record them using CTCAE grade. The study participants, at the start of chemotherapy cycle, will be informed, as a standard practice, to report to the emergency or contact nearest local clinic/hospital if the AE is severe or can't be managed at home.
45752011|NCT02843568|Other|Laboratory Biomarker Analysis|Correlative studies
45752012|NCT02843568|Radiation|Standard fractionation|60-66y Gy delivered in 1.8-2.0 Gy fractions over 30-36 treatments
45752013|NCT02843568|Radiation|Stereotactic Body Radiation Therapy (SBRT)|40-60 Gy delivered in 5-20 Gy fractions over 3-8 treatments
45844395|NCT01906866|Drug|Circadin 2/5/10 mg|Active arm
45844396|NCT01906866|Drug|Placebo|
45844397|NCT01907334|Drug|Advair Diskus100/50 µg|Advair Diskus 100/50 µg
46047594|NCT04669717|Drug|3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 7 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
45358253|NCT03952143|Drug|LY900014|Administered SC
45358254|NCT03952143|Drug|Insulin Lispro|Administered SC
45358255|NCT03952143|Drug|Insulin Glargine|Administered SC
45358256|NCT03952143|Drug|Insulin Degludec|Administered SC
45358257|NCT00968175|Procedure|Ultrasound guided celiac plexus neurolysis (CPN)|Initial procedure and rescue procedure if applicable
45358258|NCT03071757|Drug|ABBV-368|Intravenous infusion
45358259|NCT03071757|Drug|ABBV-181|Intravenous infusion
45844398|NCT01907334|Drug|Flovent Diskus 100 µg|Flovent Diskus 100 µg
45358260|NCT00968331|Drug|Lenalidomide plus Rituximab|Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles. Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles.
45358261|NCT00852228|Drug|IV cetuximab|Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).
45358262|NCT00852228|Drug|HAI chronomodulated chemotherapy|"Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00~Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.~5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.~Treatments will be repeated every 2 weeks."
45752014|NCT02843568|Procedure|Four Dimensional Computed Tomographic Imaging (4DCT)|Subjects undergo a total of 7 research-ordered four dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning.
45358263|NCT00852228|Drug|HAI conventional chemotherapy|"Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then~Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then~5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.~Treatments will be repeated every 2 weeks."
45752015|NCT05242679|Other|Myofascial release technique along with conventional physiotherapy exercises|Myofascial release technique was performed using a tennis ball along with conventional physiotherapy exercises.
45844399|NCT01907334|Drug|Methacholine Chloride|Methacholine Chloride in quadrupling concentrations from 0.25 to 64 mg/mL will be given based upon subject's baseline response.
45752016|NCT05242679|Other|Conventional physiotherapy exercises|Conventional physiotherapy exercises were performed including the range of motion/flexibility exercises, strength training, postural control, functional exercises, and gait training.
45844400|NCT01907334|Drug|Albuterol|Albuterol will be administered at the end of each methacholine challenge.
46047595|NCT04669717|Drug|3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 3 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
45752017|NCT04270981|Drug|[14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250 nCi) 14C|960 mg (4 × 240 mg capsules)of acoziborole in oral and fasted condition
45752018|NCT01793675|Procedure|transplant with haploidentical donor|patients with advanced MDS without identical sibling donor receive haploidentical transplant
46047596|NCT04669717|Drug|1/d 500 mg Azithromycine Pfizer for 3 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
46047597|NCT05755009|Radiation|High- and Low-dose radiotherapy|High- and Low-dose radiotherapy combined with immunotherapy and maintain immunotherapy. Immunotherapy (Envafolimab) once every week (maintain a total of two years). Continuous high-(8Gy×5F) and low-dose (1.33Gy×5F) Radiotherapy starts at the second week after immunotherapy.
46047598|NCT00809341|Biological|Rituximab|375 mg/m^2 on Day 1 of each cycle as part of R-CHOP or R-ICE. Also given 375 mg/m^2 on Days 1, 30, and 37 as part of HiCy.
46047599|NCT00809341|Drug|Cyclophosphamide|750 mg/m^2 on Day 1 of each cycle as part of R-CHOP.
46047600|NCT00809341|Drug|Doxorubicin|50 mg/m^2 on Day 1 of each cycle as part of R-CHOP.
45752019|NCT04345939|Diagnostic Test|Detection method|Different methods for pathogen diagnosis
45844401|NCT01907490|Drug|Ha44 Gel|Eligible subjects will be treated at the study site on Day 0 with a single application of the maximum feasible amount of Ha44 Gel, to ensure saturation of the scalp and hair.
45844402|NCT01908972|Drug|Prednisolone|2mg/kg/day for 16weeks
45844403|NCT01908972|Drug|Propranolol|2mg/kg/day for 16weeks
46047601|NCT00809341|Drug|Vincristine|1.4 mg/m^2 on Day 1 of each cycle as part of R-CHOP.
46047602|NCT00809341|Drug|Prednisone|100 mg/day on Days 1-5 of each cycle as part of R-CHOP.
46047603|NCT00809341|Drug|Ifosfamide|2000 mg/m^2/day on Days 1-3 of each cycle as part of R-CHOP.
46047604|NCT00809341|Drug|Carboplatin|Given on Day 2 of each cycle as part of R-CHOP. Dosed according to renal function.
46047605|NCT00809341|Drug|Etoposide|100 mg/m^2/day on Days 1-3 of each cycle as part of R-CHOP.
45844404|NCT01910064|Drug|GK530G|
46047606|NCT00809341|Drug|High-dose cyclophosphamide|50 mg/kg/day on Days 2-5 of HiCy.
46047607|NCT00809341|Procedure|PET scan|Performed once between Days 16-20 of cycle 3 of R-CHOP.
46047608|NCT04648111|Diagnostic Test|Vital sign measurement|Vital signs measurement will be obtained by the research staff using hospital standard medical devices and the Anura Research App will also be used to measure vital signs. Measurement will take place before surgery and post surgery (1 ±2hrs and 2 ±4hrs after surgery).
46047609|NCT01125800|Drug|LDE225|LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.
46047610|NCT04025827|Other|Dietary intake|We will collect detailed data on dietary intake and weight for healthy newborns in four low income countries.
46047611|NCT05046145|Behavioral|speech therapy for chewing + real tDCS|participants will be instructed to chew their food correctly during the tDCS session, but the participant does not know if the tdcs is real or sham.
45687541|NCT05157477|Behavioral|CBT-based VR exporsure program|This project seeks to establish a 8-week CBT-based VR exposure program to tackle sensory problems in ASD according to the theory of exposure and desensitization (both social and non-social scenarios) as well as identifying dysfunctional thought and searching for alternative thinking. In brief, this program aims to build up the core competence of the ASD individuals in facing the sensory environment, including (1) Relaxation skills (2) Ranking the fearful sensory situations (3) Anxiety coping strategy (3) Graded exposure (4) Cognitive appraisal and restructuring: identifying the dysfunctional thought when facing the social situations and figuring out alternative thinking.
45687542|NCT05152485|Drug|BIIB104 Reference Formulation|Administered as specified in the treatment arm
45687543|NCT05152485|Drug|BIIB104 Test Formulation|Administered as specified in the treatment arm
45844405|NCT01910688|Device|RFA treatment|If eligible for enrollment, a focal ablation device is selected as an intervention(size according to physician preference) and mounted on the end of the endoscope and introduced via the mouth into the esophagus and gastric pouch. The gastric pouch is treated from the top of the gastric folds to and just through the stomal anastomosis.
45844406|NCT01911390|Dietary Supplement|Bean powder|Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders.
45844407|NCT01911390|Dietary Supplement|Rice bran|USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
45844408|NCT01911390|Dietary Supplement|Control arm|No bean or rice bran additive in smoothie or muffin.
45844409|NCT01911390|Dietary Supplement|Bean powder and rice bran|Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders. USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
45844410|NCT01912716|Drug|high dose indomethacin|patients randomized to this intervention receive 200mg indomethacin
45844411|NCT01912716|Drug|standard dose indomethacin|patients randomized to this intervention receive 100mg indomethacin
45844412|NCT01914510|Drug|ENMD-2076|
45752020|NCT02812524|Drug|Intratumoral Ipilimumab|Patients with a planned resection of SCCHN will have a biopsy procedure 7-10 days prior to surgery and receive an injection of ipilimumab directly into a tumor.
45844413|NCT01918800|Behavioral|Fatigue: Take control|Fatigue: Take Control, is the first formal education program modeled on the MS-related fatigue guideline
45844414|NCT01918800|Behavioral|MS: Take Control|MS: Take Control includes topics of interest to people with MS other than fatigue.
45844415|NCT01920282|Drug|Nebivolol|
45844416|NCT01920282|Other|Lifestyle Modification|
45844417|NCT01920282|Other|Nebivolol plus Lifestyle Modification|
45844418|NCT01921296|Drug|Cyclobenzaprine|5 milligrams orally 2 hours before bedtime
45844419|NCT01921452|Device|Quantitative POC TSH Kit|A drop (approximately 30 microliter [mcL]) of blood will be taken from subject's fingertip to test TSH quantitatively by using the quantitative POC TSH test kit according to the product specification on Day 1 to Day 5.
45844420|NCT01921452|Device|Qualitative POC TSH Kit|A drop (approximately 30 mcL) of blood will be taken from subject's fingertip to test TSH qualitatively by using the qualitative POC TSH test kit according to the product specification on Day 1 to Day 5.
45844421|NCT01921452|Device|Third generation TSH Kit|One milliliter (mL) of subject's venous blood will be taken to test both qualitative and quantitative TSH levels, by using the third generation TSH test kit on Day 1 to Day 5.
45844422|NCT01929642|Drug|Sirolimus|
45844423|NCT01929642|Drug|Everolimus|
46047612|NCT01125722|Device|Non-invasive neurostimulation device|Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the investigator.
46047613|NCT01125722|Device|Non-invasive neurostimulation device|Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the subject.
46047614|NCT04030351|Other|food - dried fruit|raisins, apricots, figs, and pineapple
45479469|NCT04710732|Device|Anti-embolic elastic compression stockings|Applied before or just after the surgery and used around the clock until discharge
45479470|NCT04710732|Diagnostic Test|Thrombodynamic test (TD)|"Blood sampling for TD:~12 hours after key injection 1 (TD-12) on the POD 1~24 hours after key injection 2 (TD-24) on the POD 2~24 hours after each daily injection on the POD 4 (TD-4) and POD 5 (TD-5)"
45844424|NCT01932060|Drug|Oxytocin Infusion|Patient will receive a blinded infusion of oxytocin after the time of delivery of the fetus which will terminate at the time of discharge from the post-anesthesia care unit.
45358264|NCT00267007|Drug|PROCRIT 40,000 IU QW|Epoetin alpha (PROCRIT) 40,000 IU every week (QW) for 18 weeks (IV or SC)
45844425|NCT01932606|Drug|Nitrite|Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
45844426|NCT01932606|Drug|Saline Placebo for Nitrite|Normal saline placebo will be infused for 5 minutes during the cardiac catheterization procedure. Hemodynamics will then be measured at baseline after study drug infusion and again during low level exercise (20 Watts).
46047615|NCT02609581|Drug|Sublingual Immunotherapy with tablets (mites)|Sublingual immunotherapy involves putting a tablet of allergen extracts (mites) under the tongue to swallow the extract.
46047616|NCT05326399|Behavioral|renal biospy|Standard percutaneous biopsy has been performed in all participants. Modification of treatment will be jointly decided by hepatologists and nephrologists based on the pathological results. All participants will be followed up for 96 weeks.
46047617|NCT00811135|Drug|bevacizumab [Avastin]|15mg/kg iv on day 2 of first 3-week cycle,and on day 1 of subsequent cycles
45358265|NCT00267007|Drug|Placebo|Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
45358266|NCT00841620|Procedure|Haemorrhoidectomy a.m. Milligan|Surgery
45358267|NCT00841620|Procedure|Stapled anopexy|Surgery
45358268|NCT00964821|Biological|trivalent influenza vaccine|Patients or normal volunteers who will be vaccinated against the flu.
45358269|NCT00964821|Other|Immunoenzyme technique|This test will determine the level of antibodies in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
45358270|NCT00964821|Other|Laboratory biomarker analysis|This test will count the number of T cells (the cells that kill the flu virus) in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
45479471|NCT02497456|Behavioral|Follow-up counselling|
45479472|NCT05014334|Drug|Berberine|berberine 500 mg, twice daily for 14 days
45479473|NCT05014334|Drug|Vonoprazan|Vonoprazan 20 mg, twice daily for 14 days
45479474|NCT05014334|Drug|Amoxicillin|amoxicillin 1000mg, twice daily for 14 days.
45479475|NCT05014334|Drug|Rabeprazole|Rabeprazole 10mg, twice daily for 14 days.
45479476|NCT05014334|Drug|Bismuth|Bismuth 220mg, twice daily for 14 days.
45479477|NCT05014334|Drug|Clarithromycin|clarithromy 500mg, twice daily for 14 days.
45752021|NCT03533465|Behavioral|Complicated Grief Therapy (CGT)|CGT is an evidence based 16 session targeted grief therapy delivered in individual one hour weekly sessions. Treatment will end at 16 sessions (offered over the course of 20 weeks)
45752022|NCT01793753|Drug|Propofol|
46047618|NCT00811135|Drug|capecitabine [Xeloda]|1000mg/m2 bid po on days 1-14 of each 3-week cycle
46047619|NCT00811135|Drug|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, followed by 6mg/kg iv maintenance dose on day 1 of subsequent cycles
45844427|NCT01933230|Device|Excel Cryo Cooling System|"An Excel Cryo Cooling System collar will be place around the neck for two hours. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level, and pressure both in the head and in the blood.~2 hour neck cooling period"
45844428|NCT01933464|Drug|Cromolyn Sodium|
45752023|NCT04310202|Other|Abbreviated Profile of Hearing Aid Benefit (APHAB)|An intervention in this study which is outside the routine clinical practice of the clinics is the APHAB questionnaire that will be completed by the subjects on two occasions.
45844429|NCT01933464|Drug|Normal Saline|
45358271|NCT00852306|Procedure|oocyte freezing|retrieved oocytes from the donor will be split in half and frozen by both existing egg freezing methods: slow freezing and vitrification. The recipients will then be randomized as to which group of eggs will be thawed out for their first attempt at achieving a pregnancy.
45358272|NCT01071031|Biological|HIV-v (Low Dose)|"Low Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences) with water for injection or adjuvant~Administration: A single subcutaneous injection"
45358273|NCT01071031|Biological|HIV-v (High Dose)|"High Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences with water for injection or adjuvant~Administration: A single subcutaneous injection"
46047620|NCT05011981|Device|Left Atrial Appendage Occlusion|Interventional left atrial appendage occlusion with the Amulet or Watchman device
46047621|NCT00811057|Drug|1 Magnesium Sulfate|Participants randomized to this arm will receive a loading dose of 6gms intravenously followed by a maintenance dose of 2-4gm/hr, per physician discretion, until uterine quiescence is achieved. The Magnesium Sulfate dosage is then titrated down until discontinued per physician discretion.
46047622|NCT00811057|Drug|Nifedipine|Participants randomized to receive nifedipine will receive an initial 30mg loading dose, then 10 - 20mg q 4 - 6 hours as needed, per physician discretion, until uterine quiescence is achieved.
46047623|NCT00811057|Drug|Indomethacin|Participants randomized to receive indomethacin will receive an initial 100mg per rectum X1, may repeat x1, and then 25 - 50mg orally every 6 hours over 48 hours as needed per physician discretion until uterine quiescence has been achieved.
46047624|NCT00879970|Drug|pioglitazone|Pioglitazone30 mg and 45 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
46047625|NCT00879970|Drug|rosiglitazone|Rosiglitazone 4 mg and 8 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
46047626|NCT00879970|Drug|placebo|Placebo to match is Swedish orange size DB-AA capsule filled with white to off-white non-active powder blend.
46047627|NCT00879970|Dietary Supplement|Vitamin D|Vitamin D factor intervention
46047628|NCT00879970|Dietary Supplement|Placebo|Vitamin D factor intervention
45358274|NCT01071031|Biological|HIV-v (Control)|"Adjuvant only or Water for injection only~Administration: A single subcutaneous injection"
45358275|NCT00968409|Radiation|PET|PET imaging following injection of F18-FFNP to image hormone receptor status in patients with newly diagnosed breast cancer
45358276|NCT00968409|Other|Laboratory Testing|Blood and urine samples for standard laboratory testing and radioactive counts will be obtained during the imaging sessions. Testing will include: urinalysis, complete blood count, comprehensive metabolic panel, and progesterone levels
45752024|NCT04310202|Other|Glasgow Benefit Inventory (GBI)|An intervention in this study which is outside the routine clinical practice of the clinics is the GBI questionnaire that will be completed by the subjects on two occasions.
46047629|NCT00808639|Drug|Methotrexate|intravenously 30mg/m2 over 30 minutes
46047630|NCT00808639|Drug|Doxorubicin|intravenously 30mg/ms over 15 minutes
46047631|NCT00808639|Drug|vinblastine|intravenously 3mg/m2 over 30 minutes
46047632|NCT00808639|Drug|cisplatin|intravenously 70mg/m2 in 1 liter NS with 12.5gm Mannitol over 2 hours after vinblastine completion
46047633|NCT00808639|Drug|Pegfilgrastim|Given subcutaneously 24 hours after last chemotherapy dose
46047634|NCT05008705|Dietary Supplement|Protein supplementation|Patients will receive diary 2 doses of the protein supplement
46047635|NCT05008705|Device|Neuromuscular electrostimulation.|Patients will receive diary sessions of neuromuscular electrostimulation.
46047636|NCT05008705|Dietary Supplement|Placebo (isocaloric supplement)|Patients will receive diary 2 doses of the isocaloric supplement
45358277|NCT00968409|Other|Safety Testing|ECG tracings and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during and after the imaging sessions.
45358278|NCT00968409|Drug|F18-FFNP|injection of F18-FFNP
45752025|NCT04310202|Other|Additional follow-up visits after surgery|There are 1-2 additional follow-up visits after surgery (compared to the routine clinical practice of the surgeons/clinics).
45752026|NCT00360685|Drug|Tac+MTX|Tacrolimus- 0.03mg/kg/24h IV beginning day-3 Methotrexate- 15mg/m2 IV day +1 then 10mg/m2 IV on days 3, 6, 11 post transplant.
46047637|NCT05008705|Device|Sham for neuromuscular electrostimulation.|Patients will not receive neuromuscular electrostimulation.
45358279|NCT04010019|Behavioral|Enhanced Facebook Condition|The intervention (enhanced Facebook condition) will consist of several training components that were selected based on pain research and platform affordances. The first component will be psychoeducation on pain neurobiology. Emotional validation training will follow. The third component will consist of facilitating patients' emotional disclosure about their pain journeys and lives. The fourth and final intervention component will include prompts to engage participants in activities that they have been avoiding because of their pain.
45358280|NCT04010019|Behavioral|Control Facebook Condition|The control condition will instruct participants to offer mutual support and will not offer psychosocial intervention.
45358281|NCT00841854|Drug|pantoprazole|pantoprazole 40mg bid
45358282|NCT00841854|Drug|bismuth|bismuth 300mg qid
45358283|NCT00841854|Drug|metronidazole|metronidazole 500mg tid
45358284|NCT00841854|Drug|tetracycline|tetracycline 500mg qid
45358285|NCT05299281|Device|Micropulse transscleral cyclophotocoagulation (MP-TSCPC)|"patients undergone micropulse laser transscleral cyclophotocoagulation. The laser settings ranged from 2000- 2500 mW of 810 nm infrared diode laser radiation set on micro- pulse mode (Iris Medical Instruments, Mountain View, CA, USA), delivered over 100-200 s (envelope of micropulses) depending on severity of the case and other patient factors.~Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively."
45844430|NCT01933776|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
45844431|NCT01933776|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
45358286|NCT04043130|Behavioral|Pulse|The intervention provides participants access to Pulse, a web-based mobile health app designed for Black and Latinx women ages 18-20. Participants can access the app autonomously and on their own schedule. The app for the experimental arm, the Pulse treatment app, provides information on birth control, healthy relationships, sexual health and physiology, pregnancy, and utilization of clinical services. The app for the comparator arm, the Pulse control app, provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Participants receive MMS messages that reinforce app content and remind them to visit the app.
45844432|NCT01935180|Device|Colonoscopy Cap|4mm transparent cap (Olympus) mounted to the tip of a colonoscope.
45844433|NCT01936662|Device|LMA|Patients randomized to the LMA group had their airways maintained with a LMA device
45844434|NCT01936662|Device|ETT|Patients assigned to this group had an ETT placed to maintain their airway, as is standard of care at this hospital
45844435|NCT01936896|Drug|Alpha 1-Antitrypsin|
46047638|NCT05005195|Radiation|Low dose abdominal computed tomography scan|A policy of invitation to a targeted community-based non-contrast CT screening of the abdomen in those at risk of kidney cancer
46047639|NCT00810901|Behavioral|Organ Donor|Subjects receive information about becoming a designated organ donor -via DVD, email, text messaging, website, and US mail.
46047640|NCT00810901|Behavioral|Alcohol Prevention|Use DVD, website, text messaging, email and US mail to educate teenagers about the consequences associated with purchasing and using alcohol.
45844436|NCT01937520|Device|acupuncture|One half of subjects will receive a standardized acupuncture regiment
45844437|NCT01937520|Device|no acupuncture|placebo
45844438|NCT01937598|Drug|Placebo|Patients administered a single dose of placebo during a mixed meal challenge.
46047641|NCT00910299|Drug|Prasugrel|One time 60 milligram (mg) oral loading dose and 10 mg once daily oral maintenance dose up to 6 months.
46047642|NCT00910299|Drug|Clopidogrel|75 mg oral daily maintenance dose up to 6 months.
46047643|NCT00669760|Other|non-interventional study|does not apply
46047644|NCT04158895|Other|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
45358287|NCT00968487|Biological|Lyophilized Plasma|Lyophilized Plasma is serves as a source of plasma proteins for subjects who are deficient in plasma proteins. The donor and recipient are the same person, therefore the process is autologous. HemCon's lyophilized plasma originates from FFP from screened individual donors to significantly reduce the risk of bloodborne disease transmission and undesired transfusion-associated reactions. Each single-donor unit is tested (per required of the blood supply) to reduce the risk of transmission of infectious agents and hence, maximize subject safety.
45358288|NCT00968487|Other|Fresh Frozen Plasma|The fluid portion of one unit of human blood that has been centrifuged, separated, and frozen solid at -18 °C (-0.4 °F) (or colder) within 6 hours of collection.
45358289|NCT00848562|Drug|Nicorandil|Oral administration of nicorandil (15 mg/day)
45687544|NCT05149950|Behavioral|Active internet treatment|The patient gets access to the internet treatment via a secure login to 1177 The care guide e-services on 1177.se. The treatment lasts for six months and includes 12 treatment modules. The patient works with each module for two weeks. The modules have different numbers of sections, but most have 4-5 sections. The modules consist mainly of text but also films and pictures are included. It is also possible to listen to the text. The modules end with one or more exercises to be performed before the next module is activated for the patient. Participants receive feedback on the information from therapists via the email function in the treatment program. The therapist provides individual feedback on completed exercises and answers questions that the patient has.
45358290|NCT02879409|Drug|Metformin|Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2,000 mg once daily
45358291|NCT02879409|Drug|Gliclazide|"There is no fixed-dosage regimen for the management of diabetes mellitus with gliclazide. Dose will be individualized based on frequent determinations of blood glucose during dose titration and throughout maintenance. The 30 mg modified-release tablet equals the 80 mg immediate-release tablet.~Immediate-release tablet: Initial: 80 mg twice daily; titrate based on blood glucose levels. Usual dosage range: 80 to 320 mg/day (maximum dose: 320 mg/day); dosage of ≥160 mg should be divided into 2 equal parts for twice-daily administration.~Modified-release tablet: Initial: 30 mg once daily; titrate in 30 mg increments every 2 weeks based on blood glucose levels. Maximum dose: 120 mg once daily"
45358292|NCT02879409|Drug|Sitagliptin|Oral: 100 mg once daily
45358293|NCT02879409|Drug|Liraglutide|SubQ: Initial: 0.6 mg once daily for 1 week; then increase to 1.2 mg once daily; may increase further to 1.8 mg once daily if optimal glycemic response not achieved with 1.2 mg daily.
45687545|NCT05144542|Procedure|Participants smoke their usual brand of cigarettes for 26 weeks.|Participants smoke their usual brand of cigarettes for 26 weeks.
45687546|NCT05144542|Procedure|Participants will vape electronic cigarettes for 26 weeks.|Participants will vape electronic cigarettes for 26 weeks.
45687547|NCT05144542|Drug|Nicotine Replacement|Smoke usual brand of cigarettes
46047645|NCT00671086|Drug|Ramelteon|Subjects 65 yrs of age and older will take Ramelteon 8 mg, tablets, orally, once nightly for up to one year.
46047646|NCT00671086|Drug|Ramelteon|Subjects between 18 and 64 years of age will take Ramelteon 16 mg, tablets, orally, once nightly for up to one year.
46047647|NCT04024189|Other|Survey|Patients were given a questionnaire/survey to complete in respect of their satisfaction of the consent process for their surgical procedure
45358294|NCT02879409|Drug|Pioglitazone|"Oral, Monotherapy or combination therapy: 15-30 mg once daily~Patients with heart failure (NYHA Class I or II): Monotherapy or combination therapy: 15 mg once daily"
45358295|NCT02879409|Drug|Dapagliflozin|5mg once daily increasing to 10mg once daily as required
45358296|NCT02879409|Drug|human insulin|insulin dosage and administration according to physician
45358297|NCT02546154|Drug|10% Iron Isomaltoside 1000|Standard clinical practice and following the Monofer® label (SPC)
45358298|NCT03943095|Other|Potassium Nitrate|The test dentifrice contains 5% w/w potassium nitrate.
45844439|NCT01937598|Other|Mixed meal test|Subjects will be instructed to consume the mixed meal test within 20 minutes. The exact start and stop time of the mixed meal test consumption will be recorded in the CRF. The mixed meal test procedures will be identical for all subjects randomised in the study. To detect the plasma glucose excursion after mixed meal test, plasma glucose will be closely monitored
46047648|NCT02608723|Device|Standard shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
46047649|NCT02608723|Device|Austere shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
45358299|NCT03943095|Other|Stannous Fluoride|The test and control dentifrices contain 0.454% w/w stannous fluoride (1100 ppm fluoride).
45358300|NCT00852384|Procedure|NIPPV and IRM|"non invasive positive pressure support ventilation (NIPPV group)~alveolar recruitment maneuver (IRM group)"
46047650|NCT02608723|Device|Sophisticated shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
46047651|NCT04154566|Other|Aerobic Exercises|Aerobic exercise refers to exercise that involves or improves oxygen consumption by the body. It is the type of activity that uses large muscle groups. Its performance is in a continuous and rhythmic way with a main goal to make the heart and lungs work harder than they do when the person at rest
46047652|NCT00665548|Radiation|X-ray; magnetic resonance imaging|"Knee x-rays: acquired in both a standard or weight-bearing position and in non-weight-bearing position to measure joint space width and look at signs of osteoarthritis.~3 Tesla MRI: magnetic resonance imaging of the study knee during weight-bearing conditions and traditional non-loaded condition all acquired with the same sequences."
45358301|NCT00841932|Procedure|Fractional Flow Reserve|Fractional Flow Reserve performed without anticoagulation
45358302|NCT00852462|Behavioral|SAMI|Patients and Health care providers use Symptom Assessment and Management Intervention: patient report symptoms by answering validated questionnaires in a secure online program. The system generates a report for providers that displays symptoms and customized suggestions for their clinical management.
45358303|NCT02850939|Behavioral|Mobile phone app + patient navigation|The intervention group will receive two components: 1) a culturally sensitive, personalized and easy to use smartphone app; and 2) support from a patient navigator. The intervention is based in Social Cognitive Theory and principles of motivational interviewing - and will feature basic components of individual empowerment, motivation and engagement, including knowledge, attitudes, skills, peer modeling, social support/reinforcement and self-efficacy beliefs and expectations
45358304|NCT00848640|Drug|Sorafenib|400 mg twice daily
45358305|NCT00968565|Drug|sodium citrate|Continuous infusion of 4% sodium citrate at 300 ml/hour into ECMO circuit
45358306|NCT04042818|Diagnostic Test|Rehabilitative Ultrasound|Ultrasound imagining
45358307|NCT04010331|Dietary Supplement|Nokyong Mixture Extract(CME-PI)|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
45358308|NCT04010331|Dietary Supplement|Placebo|Placebo for 8 week
45687548|NCT05144542|Drug|Nicotine Replacement|Vape e-cigarettes
46047653|NCT03007329|Drug|Exenatide|Exenatide will be combined with Dapagliflozin
45358309|NCT00965133|Other|Endurance training intervention|High intensive interval training of walking / running on treadmill for 1 1/2 - 4 minute,repeated minimum 4 times, at an intensity equalling at least 80% of maximal heart frequency. Performed 2-5 times per week for 4-8 weeks, totally 24 sessions.
45358310|NCT00848796|Drug|Heparin Leo and Hepalean|Dosage based on Heparin does response curve obtained from the Medtronic HMS plus
45358311|NCT00968643|Radiation|radiation therapy|Given in multiple fractions or as a single fraction
45358312|NCT02545764|Other|Strength and neuromuscular exercise programme|12 weeks strength and neuromuscular exercise programme for the lower extremity
45358313|NCT05251155|Diagnostic Test|Distant best corrected visual acuity assessment|Measuring distant visual acuity on snellen's chart using two methods and results were converted to equivalent logarithm of minimum angle of resolution to compare accuracy of mobile based chart to the standard vision chart.
45358314|NCT00848874|Behavioral|PVGS|Student use of SymTrend PVGS daily then tapering off for 14 weeks in conjunction to ratings by a coach.
45358315|NCT00965211|Device|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 1 Hz to the supplementary motor cortex and then a 2 minute recess.each subject would undergo 5 sessions a week for 4 weeks.
45358316|NCT00842166|Other|BLOOD DRAW|specific interview, sequential blood collection to allow virus isolation, molecular and serological diagnostics in patients
45687549|NCT05144542|Other|Questionnaire Administration|Use smartphone to answer questions about nicotine cravings and mood, and log daily smoking activity every day.
45687550|NCT05144035|Drug|PEG-rhGH|the subjects were given PEG-rhGH injection 0.2 mg / kg / week (initial dose), once a week, subcutaneously before going to bed for 104 weeks. Each follow-up, the researchers adjusted the dosage according to the IGF-1 results of the center and other individual conditions.
46047654|NCT03007329|Drug|Exenatide matching Placebo|Exenatide matching Placebo will be combined with Dapagliflozin
46047655|NCT03007329|Drug|Dapagliflozin|Dapagliflozin, in both arms
45358317|NCT00848952|Other|3 imaging techniques are done|all patients have : MRI, CTscanner, enhanced contrast ultrasound
45358318|NCT00965289|Drug|Rituximab|Rituximab infusion on day 1 dose: 375mg/m²
45358319|NCT04042506|Drug|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|480mg IV every 4 weeks
45358320|NCT04042506|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT dose of 8-10 Gy x 3 fractions (at maximum 3 doses per week) delivered to 1 extracranial site between days 1-14 of Cycle 1.
45358321|NCT00251641|Drug|infliximab|The infliximab dose will be prepared according to the subject's weight (5 mg/kg). Each intravenous (IV) infusion will be administered over a period of not less than 2 hours. The infusion must be given via a separate line using the administration set with a 1.2 micron filter. Subjects will be infused at Weeks 0, 2, 6, 14, and 22.
45358322|NCT00251641|Drug|methotrexate|Methotrexate will be supplied as 2.5 mg tablets. Subjects are to take 15 mg/week orally for the first 6 weeks of the study. Subjects will be advised to take their MTX as a single dose (weekly) on the same day of the week. If subjects randomized to MTX 15 mg/week experience a <25% reduction in PASI score at Week 6 (Visit 4) as compared with Baseline, their MTX dose will be increased to 20 mg/week. Subjects will be treated for 22 weeks.
45358323|NCT00842322|Behavioral|high fluid intake|fluid intake of 4 litres per day
45687551|NCT05141708|Drug|Talazoparib|Receipt of talazoparib as treatment for HER2-negative metastatic breast cancer with germline BRCA1/2 mutations anytime between January 1, 2018 and September 30, 2020
45358324|NCT00842322|Behavioral|normal fluid intake|Fluid intake of 2 litres per day
45358325|NCT00250705|Drug|Aripiprazole|The initial dose depending on the weight of the patient will be as follows: < 25 kg = 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; > 70 kg = 10 mg/d (Data on File, 2003, Bristol-Myers Squibb). Thereafter the dose will be flexible based on response and tolerance for the duration of the 6 week study. All subjects initially received either a 5 or 10 mg/d (7.0 ± 2.6 mg/d) dose of aripiprazole. Thereafter the dose was individualized based on response and tolerance. Maximum dose was 20 mg.
45358326|NCT00849030|Drug|Anastozole (Arimidex)|1mg, orally, once daily
45358327|NCT00849030|Drug|Tamoxifen (Nolvadex)|20mg, orally, once daily
45358328|NCT00849030|Drug|Anastozole (Arimidex) placebo|1mg, orally, once daily
45358329|NCT00849030|Drug|Tamoxifen (Nolvadex) placebo|20mg, orally, once daily
45687552|NCT05141565|Other|No intervention|No intervention
45358330|NCT00842400|Drug|Metformin, VI-0521, Sitagliptan, Probenecid|"This trial is an open-label, non-randomized, one-sequence crossover study.~metformin 500 mg tablet twice daily on Days 1 to 5 and on Days 30 to 34~sitagliptan 100 mg tablet once daily on Days 6 to 10 and on Days 35 to 39~VI-0521 (phentermine/topiramate) capsule once daily each morning at 3.75/23 mg for 2 days (Days 11-12), 7.5/46 mg for 3 days (Days 13-15), 11.25/69 mg for 3 days (Days 16-18) and 15/92 mg for 21 days (Days 19-39)~2 g (four 500 mg) probenecid tablets on Day 29."
45358331|NCT00842478|Procedure|Toothbrushing|
45358332|NCT02545296|Other|In-vitro Diagnostics|Ex-vivo performed diagnostic blood based test.
45358333|NCT02545374|Other|Telemedicine|
45687553|NCT05137925|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT is an 8-week group-based treatment modality designed specifically to prevent recurrence of depressive symptoms. MBCT combines principles of cognitive behavioral therapy and mindfulness meditation to help participants change the way in which they relate to automatic negative thinking patterns that trigger symptom recurrence. Through awareness and acceptance of negative thoughts and emotions, participants learn how to dismiss negative thoughts and to tolerate distress and uncertainty.
45687554|NCT05137925|Behavioral|Treatment as Usual (TAU)|TAU (the control group) provides participants with information about the benefits of mindfulness in pregnancy and offers referrals for psychotherapy in the community. Participants in TAU are contacted monthly via phone or videoconference call to maintain engagement.
45687555|NCT05137119|Drug|Cefazolin|Cefazolin
45687556|NCT05137119|Drug|Penicillin|benzylpenicillin
45687557|NCT05137119|Drug|Clindamycin|Clindamycin
46047656|NCT04072341|Drug|Propolis Period (Green Propolis 250mg/day)|Randomized, cross-over, open-label. Patients will go through two 4 week periods with 1 week washout between them. During the intervention period will use 250mg of green Propolis per day. In the control period they will only follow standard treatment for their comorbidities.
45687558|NCT05137119|Drug|Vancomycin|Vancomycin or Daptomycin
45687559|NCT05137119|Other|Effectiveness of early switch to oral antibiotics|This involves testing a strategy rather than individual antibiotic agents
45687560|NCT05128006|Other|New patient teledermatology visit|new patient teledermatology visits
45687561|NCT05127291|Other|Dual-task|In the study, both groups are going to evaluate with and without dual-task. The dual-task will be counting back down 3 by 3 from a three-digit number.
46047657|NCT04072341|Other|Control Period|In the control period they will only follow standard treatment for their comorbidities.
45358334|NCT02545374|Other|Control|
45358335|NCT00266695|Drug|Ruboxistaurin|32-milligram (mg) tablet, orally, once daily (QD) for up to 2 years.
45358336|NCT00849264|Drug|chemotherapy with endostar|15mg/d×14d
45358337|NCT00849264|Drug|treatment with CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d
45358338|NCT00849264|Drug|treatment with endostar, CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d ，Endostar 15mg/d×14d
45358339|NCT00849342|Drug|insulin detemir|Safety and effectiveness (weight and HbA1c) data collection in connection with the use of the drug Levemir® in daily clinical practice.
45358340|NCT00842556|Drug|Dapagliflozin|Tablets, Oral, 20 mg, Single Dose
45358341|NCT00842556|Drug|Glimepiride|Tablets, Oral, 4 mg, Single Dose
45358342|NCT00842556|Drug|Sitagliptin|Tablets, Oral, 100 mg, Single Dose
45358343|NCT00842634|Biological|ZFN modified T cells|A single infusion of 5-10 billion ZFN Modified CD4+ T Cells
45752027|NCT00360685|Drug|TAC + MMF|Tacrolimus- 0.03 mg/kg/24h as a continuous IV infusion, beginning day -3. Mycophenolate Mofetil- 30 mg/kg/day IV in 2 divided doses (q12 hours) beginning day 0 at least 2 hours after the end of the hematopoietic stem cell transplant
45752028|NCT05487456|Other|P4M3 CA35|Ad libitum use of P4M3 with CA35 cartridges
46047658|NCT00595504|Drug|Ramelteon|Two week supply of ramelteon 8mg/day first dispensed at baseline. New two week supply of study medication dispensed at each biweekly visit for 8 consecutive weeks.
45358344|NCT00842634|Other|Structured Treatment Interruption|Stop Taking HAART Medication for up to 12 weeks (4 weeks after infusion to 16 weeks after infusion)
45358345|NCT00620022|Drug|Indacaterol 300 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
46047659|NCT00595504|Drug|Placebo|Two week supply of placebo tablets first dispensed at baseline. New two week supply of placebo dispensed at each biweekly visit for 8 consecutive weeks.
45687562|NCT05127109|Combination Product|Nutrition Ecosystem pathway|"parenteral nutrition initiated within 72 hours of operative intervention~Provided as clinically appropriate: Ensure Enlive, Ensure High-Protein, Nepro with Carb-Steady/ProSource Gelatein Plus, and/or ProSource Gelatein Plus~metabolic cart assessments to determine resting energy expenditure (REE) and guide registered dietitians (RDs)~Q-NRG Metabolic Cart (Indirect Calorimeter) and Quark RMR Metabolic Cart (Indirect Calorimeter)~BWA 2.0 Advanced Bioelectric Impedance Spectroscopy (BIS)~Philips Lumify L12-4 broadband linear array transducer ultrasound~expedited delivery of oral nutrition supplements and~a team-based approach on proper documentation of nutrition delivery and intake"
45358346|NCT00620022|Drug|Placebo|Placebo was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
45358347|NCT00852852|Behavioral|Electronic Self-Report Assessment - Cancer (ESRA-C)|The Electronic Self-Report Assessment-Cancer (ESRA-C) is a program allowing patients to report symptoms and quality of life issues and learn information about how to deal with these experiences.
45358348|NCT00849654|Drug|PCI-32765|"In the dose-escalation cohorts, PCI-32765 will be administered in 1.25, 2.5, 5.0, 8.3, 12.5, and 17.5 mg/kg/d dose orally once per day for 28 days followed by a 7-day rest period to determine the MTD. If MTD is not reached, dosing levels may be increased beyond 17.5mg/kg/d by 33% increments.~In the continuous dosing cohorts, PCI-32765 will be administered in 8.3 mg/kg/day and 560 mg/day (fixed dose) dose orally once per day for 35 days."
45358349|NCT00849732|Biological|V520|Intentionally Blank
45358350|NCT00849732|Biological|Comparator: V520 (1x10^9 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10^9 vp/d given at Day 1, Week 4, and Week 26
45358351|NCT00849732|Biological|Comparator: V520 (1x10^10 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10^10 vp/d given at Day 1, Week 4, and Week 26
45358352|NCT00849732|Biological|Comparator: Placebo|Placebo to MRKAd5 HIV-1 gag vaccine 1.0 mL intramuscular injection given at Day 1, Week 4, and Week 26
45358353|NCT00849966|Drug|Celebrex suspension|"Patients will be randomized to receive celecoxib suspension 6 mg/kg one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of celecoxib (3 mg/kg) to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
45358354|NCT00849966|Drug|Placebo|"Patients will be randomized to receive placebo by mouth one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of the placebo to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
45687563|NCT05127109|Other|Comparator|retrospective cohort of 300 historical matched control subjects
45687564|NCT05117489|Drug|Miricorilant 150 mg|Miricorilant 150 mg for oral dosing
45687565|NCT05117489|Drug|Miricorilant 100 mg|Miricorilant 100 mg for oral dosing
45358355|NCT00853008|Drug|Vincristine|Vincristine (VCR): 1.5 mg/m2 (max 2 mg) IV d 1, 8, 15, 22 in induction VCR 2 mg, IV, d 1,8 in consolidation (cycle 1, 2)
45358356|NCT00853008|Drug|Daunorubicin|Daunorubicin (DNR): 60 mg/m2 IV d 1, 8, 15, 22
45687566|NCT05117489|Drug|Miricorilant 50 mg|Miricorilant 50 mg for oral dosing
45687567|NCT05117489|Drug|Miricorilant 10 mg|Miricorilant 10 mg for oral dosing.
45687568|NCT05116761|Biological|Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Intravenous administration of Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
45358357|NCT00853008|Drug|Prednisone|Prednisone (PDN): 60 mg/m2/d IV or PO, d 1-28
46047660|NCT00808483|Other|Walking skill training program|12 individualized training sessions containing functional exercises like walking, stair climbing, balance training and with supervision and guidance from a physiotherapist.
46047661|NCT03952533|Dietary Supplement|Dav|Daily oral administration of a food supplement constituted by α-lipoic acid, magnesium, vitamin B6 and vitamin D in tablets of 1,2 g (Dav®, Lo.Li. Pharma, Rome, Italy)
46047662|NCT02629978|Procedure|CT-guided percutaneous radiofrequency ablation|Percutaneous radiofrequency ablation (RFA) is a minimally invasive technique will be performed in patients with malignant pulmonary nodules in this group. RFA kills the tumors by causing coagulation necrosis via tissue heating. The electrode delivers thermal energy will be inserted into the target tissues under the CT guidance to ensure the area of ablation should cover the targets and the lung tissues 0.5-1.0 cm around the tumors. Post-operative scan and laboratory test will be conducted in time.
45358358|NCT00853008|Drug|Mitoxantrone|Mitoxantrone:12 mg/m2, IV d 15-17 in induction 12 mg/m2, IV,d 5 in cycle 2 consolidation
45358359|NCT00853008|Drug|Cytosine Arabinoside|ARA-C 2,000 mg/m2/12h IV, d18,19 (4 doses) in induction
45358360|NCT00853008|Drug|Dexamethasone|Dexamethasone 20 mg/m2,IV, d 1-5,10 mg/m2,IV, d 6 and 5 mg/m2,IV, d 7 in Consolidation (3 cycles)
45358361|NCT00853008|Drug|Methotrexate (MTX)|Methotrexate (MTX)3 g/m2,IV, d1 (24h)in consolidation, cycles 1 and 2 MTX (15 mg/m2/wk, IM)in maintenance MTX 15 mg, IT
45687569|NCT05116761|Other|Saline|Placebo Saline
46047663|NCT04067271|Other|Analyze changes in intestinal microbiome|Descriptive Analysis
46047664|NCT04980625|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
45358362|NCT00853008|Drug|Cytarabine|Cytarabine 2g/m2/12h, IV d5 in cycle 1 consolidation Cytarabine 2g/m2/12h, IV d 1,2 in cycle 3 consolidation Cytarabine 30 mg, intrathecal
45358363|NCT00853008|Drug|ASP|ASP 25,000 IU/m2, IV, d5 in consolidation (cycle 1, 2, 3)
45358364|NCT00853008|Drug|Mercaptopurine|Mercaptopurine 100 mg/m2, PO, d 1-5 in consolidation
45358365|NCT00853008|Drug|Teniposide|Teniposide 150 mg/m2, IV d 3,4 in consolidation cycle 3
45358366|NCT00853008|Drug|Hydrocortisone|Hydrocortisone 20 mg, IT d 1, 28, 49, 77, 105, 175, 203, 231, 259,287, 311 intrathecal
45358367|NCT00853086|Drug|activated recombinant human factor VII|Safety data collection in connection with the use of the drug NovoSeven® in daily clinical practice
45358368|NCT00853164|Behavioral|walking exercise|Subjects will be given an exercise prescription for walking 3 times a week for eight weeks
45687570|NCT05103631|Genetic|CATCH T cells|"Four different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 3x10^7/m2~DL2: 1x10^8/m2~DL3: 3x10^8/m2~DL4: 1x10^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
45687571|NCT05090891|Drug|INCB000928|INCBG000928 will be administered QD orally.
45687572|NCT05090891|Drug|placebo|placebo will be administered QD orally
45687573|NCT05085808|Drug|Trazodone|Trazodone will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the trazodone arm.
45687574|NCT05085808|Drug|Quetiapine|Quetiapine will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the quetiapine arm.
45358369|NCT00853164|Behavioral|weight training|participants will be given a weight training prescription to do 3 times a week for eight weeks.
45687575|NCT05085808|Drug|Placebo|Placebo will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the placebo arm.
45358370|NCT00853164|Behavioral|Usual Care|Subjects in this arm will continue with their usual care and not start any exercise program for eight weeks.
45687576|NCT05084625|Other|Digitized support|Access to information about the disease, treatment, side effects and self-care
45358371|NCT00923988|Other|secondhand smoke exposure|Participants will be exposed to secondhand smoke for one hour. As a measure of secondhand smoke exposition, room carbon monoxide concentration will be continuously measured using an Ambient Carbon Monoxide Monitor APMA-360 and kept constant between 4.5-6.0 ppm. Levels in this magnitude are typically seen in smoking areas of restaurants and bars.
45358372|NCT02545530|Drug|transdermal clonidine|2.5mg/patch per week
45844440|NCT01937598|Drug|Liraglutide|Patients on metformin monotherapy will, after screening and randomization, enter a run-in period of 2 weeks with the additional treatment of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week) that will be continued for the entire duration of the study.
46047665|NCT04980625|Procedure|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
46047666|NCT03753711|Procedure|Multifidus muscle biopsy during minimally invasive back surgery|Bilateral biopsy of the multifidus muscle in patient with a unilateral disc hernia.
46047667|NCT00676000|Procedure|Interrupted vaginal closure|Horizontal mattress closure of vaginal mucosa over mesh
46047668|NCT00676000|Procedure|Continuous vaginal closure|Running closure of vaginal mucosa over mesh
46047669|NCT04030039|Drug|Interferon|chronic hepatitis B patients with interferon therapy
46047670|NCT04030039|Drug|nucleoside analogues|chronic hepatitis B patients with interferon therapy
46047671|NCT04154098|Device|Scapula orthosis assistance|Participants are elevating their arm while their scapula is assisted by the scapula orthosis
46047672|NCT04154098|Procedure|Manual scapula assistance|Participants are elevating their arm while their scapula is assisted by a trained personnel
46047673|NCT04154098|Other|No assistance|Participants are elevating their arm without being assisted
46047674|NCT04154098|Other|Functional Test|Participants perform a functional test once without (NO) and once with (OA) the orthosis
46047675|NCT00810511|Device|Lotrafilcon A contact lens|Silicone hydrogel contact lens
46047676|NCT00810511|Device|Comfilcon A contact lens|Silicone hydrogel contact lens
46047677|NCT02628574|Drug|TRX518 monotherapy|comparison of different (ascending) doses of TRX518 monotherapy
46047678|NCT02628574|Drug|TRX518 with gemcitabine|comparison of different (ascending) doses of TRX518 in combination with gemcitabine
46047679|NCT02628574|Drug|TRX518 with pembrolizumab|comparison of different (ascending) doses of TRX518 in combination with pembrolizumab
45844441|NCT01937598|Drug|Sitagliptin|Patients administered a single dose of Sitagliptin during a mixed meal challenge.
46047680|NCT02628574|Drug|TRX518 with nivolumab|comparison of different (ascending) doses of TRX518 in combination with nivolumab
46047681|NCT00596362|Drug|AVASTIN|a single injection of Avastin at the outpatient clinic. This will be done as follows: the pupil in the eye being treated will be enlarged with a liquid solution. Thirty minutes later, a numbing solution and then a cleansing solution will be put in to the eye. Finally, an injection of Avastin will be given into the eye. Right after this injection, your eye will be examined by your doctor. The pressure in your eye will also be tested before and after the injection. Patients will use antibiotic drops for 5 days following the injection. Following the injection, you will have weekly examinations for four weeks in the office.
46047682|NCT00907803|Drug|ST-246 400 mg|Capsules, 400 mg daily for 14 days
45358373|NCT00853320|Drug|Oxycodone hydrochloride tablet 15 mg|Oxycodone hydrochloride tablet 15 mg, single dose fasting
45358374|NCT00853320|Drug|Roxicodone™ tablet 15 mg|Roxicodone™ tablet 15 mg, single dose fasting
45358375|NCT00853398|Procedure|surgical technique|
45844442|NCT01938066|Device|Procellera|bioelectric wound dressing
45844443|NCT01938066|Device|negative pressure therapy|
46047683|NCT00907803|Drug|ST-246 600 mg|Capsules, 600 mg daily for 14 days
45358376|NCT00547521|Drug|abatacept|solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open
46047684|NCT00907803|Drug|Placebo|Capsules, once daily for 14 days
46047685|NCT00669994|Drug|Ciprofloxacin|Cipro XR 500 mg tablets taken once daily
46047686|NCT00808249|Drug|AZD7325|2 tablets taken twice a day for 28 days
46047687|NCT00808249|Drug|AZD7325|2 tablets taken twice a day for 28 days
46047688|NCT00808249|Drug|AZD7325|2 tablets taken twice a day for 28 days
46047689|NCT00808249|Drug|Placebo|2 tablets taken twice a day for 28 days
46047690|NCT04058457|Device|DBS|Patients are tested pre-operatively and the post-operatively with their implanted neurostimulators ON and OFF. DBS implantation itself is part of routine care, and not part of the study.
46047691|NCT02628262|Procedure|Vitrectomy with internal limiting membrane removal and gas tamponade|Vitrectomy with internal limiting membrane removal and gas tamponade
46047692|NCT02790723|Drug|sc-rAAV2.5IL-1Ra|Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.
45358377|NCT00547521|Drug|Methotrexate (MTX)|Participants who were currently receiving methotrexate at a stable dose ≥ 10 mg for at least 4 weeks
45844444|NCT01938378|Biological|Octaplas™|octaplas™ infusion solution for IV administration, ABO compatibile. Recommended dose for a plasma exchange is 40 to 60 ml/kg.
46047693|NCT00676156|Drug|oral lipoic acid (LA)|A single 1200 mg dose of oral LA will be administered.
46047694|NCT00676156|Drug|lipoic acid (LA) with fish oil and LA without fish oil|Subjects will be randomized to receive either 1 dose of 1200 mg LA with fish oil and then will be crossed-over to receive 1 dose of 1200 LA without fish oil. There will be a 1-week wash out period between the cross over.
45358378|NCT02546310|Drug|HTL0009936|
45358379|NCT02546310|Drug|HTL0009936 matching placebo|
45358380|NCT00850044|Drug|ABT-450|capsules,QD, one dose, see Arm Descriptions for more information
45358381|NCT00850044|Drug|ritonavir|capsules, QD, one dose, escalating doses, see Arm Descriptions for more information
45358382|NCT00850044|Drug|placebo for ABT-450|capsules, QD, one dose
45358383|NCT00850044|Drug|Placebo for ritonavir|capsules, QD, one dose
45358384|NCT00266227|Drug|placebo|Intravenous repeating dose
45358385|NCT00266227|Drug|rituximab|Intravenous repeating dose
45358386|NCT00266227|Drug|methotrexate|Oral or parenteral repeating dose
45358387|NCT00266227|Drug|folate|Intravenous repeating dose
45498089|NCT04648293|Device|Starling|Starling is a portable, non-invasive, cardiac output detector system. The Starling monitor measures the cardiac output by employing electrical bioreactance that measures the electrical characteristics of a volume of tissue and fluid. In the case of cardiac output measurements, the relevant tissue includes the heart and the immediate surrounding volume of the thorax. The relevant fluid is blood. Baxter Healthcare's Starling electrode is a double electrode sensor. Within each sensor, one electrode is used to transmit a high frequency sine wave into the body, while the resulting voltage is measured at the adjacent electrode. Four electrodes are placed at specific areas of the thorax, the impedance to the current flow calculated, and the electrical bioreactance waveform constructed. This information is used to determine cardiac output, and measures and displays associated hemodynamic parameters based on calculations of measurements already incorporated into the Starling device.
45687577|NCT05081609|Drug|TransCon IL-2 β/γ|TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion
45687578|NCT05081609|Drug|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion
46047695|NCT00676156|Drug|R lipoic acid|A single oral dose of 1200mg R enantiomer LA will be administered.
45687579|NCT05081609|Drug|Chemotherapy drug|SOC chemotherapy will be administered as an intravenous (IV) infusion
45752029|NCT05487456|Other|P4M3 CM35|Ad libitum use of P4M3 with CM35 cartridges
45358388|NCT04233216|Drug|ISL|ISL 0.75 mg capsule taken by mouth.
45358389|NCT04233216|Drug|DOR|DOR 100 mg tablet taken by mouth.
45358390|NCT04233216|Drug|DOR/ISL|100 mg DOR/0.75 mg ISL FDC taken by mouth.
45358391|NCT04233216|Drug|Placebo to ISL|Placebo capsule matched to ISL taken by mouth.
45358392|NCT04233216|Drug|Placebo to DOR|Placebo tablet matched to DOR taken by mouth.
45358393|NCT00968877|Drug|Cholecalciferol|capsule 40 000 IU (p.o.) once per week, in 8 weeks.
45358394|NCT02729727|Device|CryoBalloon Ablation System|Tissue Ablation using CryoBalloon Ablation System
45358395|NCT00965367|Device|Acustimulation|Acupressure in P6 bilaterally given after induction of anaesthesia for 20 minutes, followed by acupressure wrist bands applied on the same acupoints for 24 hours.
45358396|NCT00287365|Drug|ozone|2 hour exposure to 0.4 ppm ozone
45358397|NCT00850122|Drug|cefazolin|"Cefazolin dosing - administered for 48 hours Dosage~≤28 days of age 25 mg/kg IV q12 29-120 days of age 25 mg/kg IV q8"
45358398|NCT00968955|Drug|Ropivacaine|Local infiltration with ropivacaine 0,2% (150 ML)
45358399|NCT00843258|Device|Abduction treatment|Abduction treatment with a Frejka's pillow for 6 weeks
45358400|NCT01072279|Other|Tubaramure (Burundi)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
45358401|NCT01072279|Other|Procomida (Guatemala)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
45358402|NCT00850278|Other|FLT-PET imaging|Prior to surgical resection, patient will undergo [11C]MET PET imaging, [18F]FLT PET imaging, MRI, and spectroscopy imaging.
45358403|NCT05279625|Device|exercise training|using either elastic band, dumbbells, treadmill, cycling, machines for 6 months
45358404|NCT00853554|Drug|Hydromorphone Hydrochloride tablet 8 mg|Hydromorphone Hydrochloride tablet 8 mg, single dose fasting
45358405|NCT00853554|Drug|Dilaudid® tablet 8 mg|Dilaudid® tablet 8 mg, single dose fasting
45358406|NCT02586597|Device|Transcranial magnetic stimulation & median nerve stimulation|"Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation.~PA25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. 240 paired TMS and median nerve stimulation at a frequency of 0.2 Hz over 20 min.~PAS10: 240 paired TMS and median nerve stimulation with interval of 10 min second at a frequency of 0.2 Hz over 20 min.~PAS100: 240 paired TMS and median nerve stimulation with interval of 100 min second at a frequency of 0.2 Hz over 20 min."
45358407|NCT00843336|Behavioral|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that provides three levels of fertility; low, high, and peak. Monitor is based upon urinary levels of E3G (estrogen) and LH. Monitor readings are placed in an electronic charting system on the Internet.
45358408|NCT00843336|Behavioral|Self-monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
45687580|NCT05081609|Drug|TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist will be administered as an IT (Intratumoral) injection
45687581|NCT05081609|Procedure|Surgery|Surgery will take place 4-6 weeks after last dose of study treatment.
45687582|NCT05079750|Biological|ChAdOx1 biEBOV|ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
45844445|NCT01939938|Device|Nasal and Oronasal PAP Mask|Subjects will be imaged via MRI wearing a nasal and oronasal PAP mask at 5, 10 and 15 cm H20.
45358409|NCT01071109|Procedure|Therapeutic Massage|Therapeutic Massage--subjects randomized to this group will receive weekly, one-hour therapeutic massage
45498090|NCT03752814|Device|SYNOSTE Nitinail System|Mode of application: 1. Implantation surgery: osteotomy and antegrade implantation of SNS in femur for distraction osteogenesis (callotasis), 2. distraction osteogenesis (implant lengthening phase), 3. Bone healing (implant as stabilizing element during consolidation phase), 4. Explantation after consolidation.
45752030|NCT05487456|Other|CIG|Ad libitum use of subject's own preferred brand of cigarettes
45752031|NCT05487456|Other|Smoking Abstinence|Abstention from cigarette smoking
45844446|NCT01942668|Drug|Estradiol|
45844447|NCT01942668|Drug|Progesterone|
45844448|NCT01942668|Drug|Placebo|
45844449|NCT01944930|Device|Laparoscopic narrow band imaging|
45844450|NCT01944930|Device|Standard white-light laparoscopy|
45844451|NCT01948518|Drug|Oral sildenafil 20 mg|A single dose of sildenafil will be given after recording baseline diffusion capacity and 6 minute walk. Measurements will be repeated one hour after the drug.
45358410|NCT04025463|Behavioral|HHMB|Blended, culturally-congruent, evidence-informed care model to increase patient and clinic participation in CVD risk reduction for patients with HIV
45752032|NCT04270825|Behavioral|Group CBT with IPT|Group treatment designed to target relationships with both possessions and people.
45752033|NCT01793831|Procedure|FMT|Standard FMT
45752034|NCT05477160|Drug|STAR-0215 (SC)|STAR-0215 will be administered as an SC bolus injection.
45752035|NCT05477160|Drug|Placebo (SC)|Placebo will be administered as an SC bolus injection.
45844452|NCT01948986|Drug|Ertugliflozin|Single oral administration of 3 X 5 mg tablets.
45844453|NCT01949844|Drug|regadenoson|Lexiscan® is being used off-label. The FDA Issued IND # is 119898. For the cardiac MRI, Lexiscan® will be used at the same dosage and administration as prescribed in the package insert - 5 mL (0.4 mg regadenoson) as packaged and supplied by the manufacturer, Astellas Pharma U.S., in single-use pre-filled syringes administered by rapid intravenous injection, followed immediately by saline flush.
45358411|NCT00853710|Other|PSA assay|rapid prostate specific antigen assay.
45358412|NCT00969033|Drug|CS-1008|CS-1008
45687583|NCT05078944|Device|Active acupuncture|Acupoints: Principal: GV20, EX-HN1, GV24 and bilateral PC6, HT7, ST36, KI3, SP6. Additional: CV6 and bilateral GB39, ST40, SP10 Sterile stainless steel disposable acupuncture needles (size 0.30 × 50 mm, Hwato brand, China) are used. After sterilization, a small plastic ring will be fixed over the acupuncture point with plaster to facilitate maintenance of blinding for the participant, and then the needle will be inserted through the plaster inside the ring. The electric stimulator (SDZ-Ⅲ electroacupuncture apparatus, Hwato brand, China) is applied to GV20, GV24, bilateral PC6 and HT7, dilatational wave, 10/50 Hz and tolerable electric current. Needles placed in other acupoints will be manually stimulated by rotation every 15 minutes. Each session lasts for 45 min.
45687584|NCT05078944|Device|Sham acupuncture|"Sham acupoints: SA1 (5 cun lateral to GV5), SA2 (5 cun lateral to GV4), SA3 (1 cun lateral to BL56).~After sterilization, pragmatic placebo needles with blunt tip (size 0.30 × 50 mm, Hwato brand, China) are used. When their tips are pressed against the skin through plastic rings, participants will feel a pricking sensation. The electric stimulator is applied to bilateral SA1 and SA2 with no current output. The mental wire has been cut off with a same outlook as the electroacupuncture group. Needles placed in SA3 will be manually rotated every 15 minutes. Each session lasts for 45 min."
45844454|NCT01949844|Drug|Optimark®|For the cardiac MR, the contrast agent, Optimark® is administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual injection.
45844455|NCT01949844|Device|Myocardial perfusion MRI|
45844456|NCT01950780|Drug|Ruxolitinib|A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
45844457|NCT01951326|Drug|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
45844458|NCT01951326|Drug|Placebo|5 placebo capsules administered orally BID
46047696|NCT05753527|Behavioral|Progressive Relaxation Exercises|Deep abdominal breathing will be done three times and the breath will be given slowly. The fists will be clenched, keep the fists clenched in this way for 7-10 seconds, and then release them for 15-20 seconds. By opening the arms to the side and locking the elbows, the triceps muscle will be stretched and relaxed. The forehead muscles by raising the eyebrows The eyes will be closed and relaxed. The mouth will be opened and closed. The head will be stretched back and relaxed. The shoulders will be lifted and relaxed. Both hips will be tightened and relaxed by bringing them closer together. The thigh muscles will be tightened and relaxed.
45358413|NCT00969033|Drug|irinotecan|irinotecan
45358414|NCT00965601|Behavioral|Cognitive Behavioral Therapy|Subjects randomized to the Active Arm will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
45687585|NCT05078944|Drug|Donepezil Hydrochloride|Donepezil hydrochloride (5 mg/capsule, Weicai Pharmaceutical Co., Ltd, China) is to be taken 5 mg daily.
45844459|NCT01951950|Drug|Nicardipine|
45844460|NCT01951950|Drug|Esmolol|
45844461|NCT01952418|Device|Monitor size|"Subjects will be randomized to perform their colonoscopy procedures while viewing a large (32) video monitor or the standard (24) video monitor."
45844462|NCT01953432|Drug|Doxazosin|Doxazosin is initiated at 2 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 4 weeks. Participants will be maintained on 8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
45844463|NCT01953432|Drug|Placebo|Matched placebo daily dosing
46047697|NCT03970629|Device|PERSONA Total Knee|Primary Total Knee Arthroplasty
46047698|NCT00670150|Drug|NRX 195183 (retinoid analogue)|30mg/m2 PO daily x 3mo.in Induction, then daily with consolidation
45358415|NCT00573768|Drug|Diclofenac diethylamine 2.32% gel|Diclofenac diethylamine 2.32% gel twice daily
45358416|NCT00573768|Drug|Placebo|Vehicle 2 times daily
45358417|NCT00573768|Drug|Diclofenac diethylamine 2.32% gel / Placebo|Diclofenac diethylamine 2.32% gel once daily / Vehicle once daily
45358418|NCT04042428|Drug|Somatropin injection|Subjects receive a daily subcutaneous dose of 0.2 IU/kg (0.067 mg/kg) of recombinant somatropin (rhGH) during 14 days.
45358419|NCT02546076|Device|Laser coagulation|The treatment consists in performing Er:Yag laser with long-pulsed Erbium mode
45358420|NCT02546076|Device|Laser w/o coagulation|The treatment consists in performing Er:Yag laser with true pulsed Erbium mode
45358421|NCT02415387|Biological|typhoid vaccine|Given IM
45358422|NCT02415387|Other|Placebo|Given IM
45358423|NCT00969267|Other|ear-acupuncture A|with needle stimulation
46047699|NCT00670150|Drug|Arsenic Trioxide|0.15mg/kg/day over 2hrs VI on day 1-5 x 4 weeks. 2 weeks rest then repeat x 3 more cycles.
45844464|NCT01955382|Drug|Actidose Aqua|Actidose Aqua (oAC) (Paddock Laboratories is sold over the counter in the United States in bottles containing 25 g/120 mL (NDC # 0574-0121-04) or 50 g/240 mL (NDC # 0574-0121-08). oAC is stable at room temperature.
46047700|NCT00914017|Drug|Atorvastatin|Atorvastatin, 40 mg daily for 1 year
45358424|NCT00969267|Other|stimulation B|with bread stimulation on ear acupuncture point
45358425|NCT00969267|Other|stimulation C|without needle stimulation
45687586|NCT05076019|Drug|Atorvastatin 80mg|Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
45687587|NCT05076019|Drug|Placebo|Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
45687588|NCT05073913|Diagnostic Test|Vascular remodeling characterization|Pulse wave velocity measure High frequency ultrasonography for vascular imaging Endothelial function test Left ventricular mass by echocardiography Measurement of GFR (Glomerular Filtration Rate) with decrease in plasma of Iohexol
45687589|NCT05071937|Drug|ZEN003694|ZEN003694 has shown promising activity in the treatment of solid tumors and hematologic (blood) cancers by reducing the multiplication of cancer cells.
45687590|NCT05071937|Drug|Talazoparib|Talazoparib kills cancer cells by inhibiting and trapping the enzyme PARP, which is known to be involved in the development of many types of cancers.
45687591|NCT05069922|Other|Fresh Frozen Plasma|Fresh Frozen Plasma
45687592|NCT05067075|Device|Blinded CGM|CGM that records blood glucose but is not visible to patient or provider in real-time
45752036|NCT05477160|Drug|STAR-0215 (IV)|STAR-0215 will be administered as an IV bolus injection.
45752037|NCT05477160|Drug|Placebo (IV)|Placebo will be administered as an IV bolus injection.
45752038|NCT03797209|Device|EUS-guided fistulization AXIOS|By using a convex type ultrasonic endoscope to form a fistula by gastrointestinal puncture, to perform various drainage.
45844465|NCT01955382|Drug|Artesunate|Artesunate (AS) obtained from Guilin Pharma (Shanghai), the only pharmaceutical company GMP pre-qualified by the WHO. The product artesunate for injection + 5% sodium carbonate inj + 0.9% sodium chloride inj will be delivered in vials of 30 mg and 60- mg vials, respectively, and will be dosed at 2.4 mg/kg as recommended for SM treatment by the WHO
45844466|NCT01955382|Drug|Amodiaquine|Amodiaquine obtained from Pfizer (Dakar), is provided as 200-mg tablets or syrup (50 10 mg/mL), and will be provided as age-based doses per the manufacturer's directions.
46047701|NCT00914017|Drug|Placebo|sugar pill daily for 1 year
46047702|NCT00676234|Drug|epoetinum|Administration of intravenous rhu Epo on Day 0 20000 IU rhu Epo (20 patients) administered by the i.v. route 40000 IU rhu Epo (20 patients) administered by the i.v. route
46047703|NCT04036851|Behavioral|Peer support intervention|Peer support groups will meet monthly for the duration of follow-up, with separate groups for pregnant and postpartum women. Groups will be facilitated by women who are living with HIV and have experience of PMTCT services in this setting. Group sessions will include brief information and a structured discussion about a relevant topic, followed by opportunities for unstructured discussion.
46047704|NCT00671320|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth twice daily (BID) on Day 1 and then once daily (QD) on Days 2 to 7
46047705|NCT00671320|Drug|diclofenac|diclofenac 75 mg capsule by mouth twice daily (BID) for 7 days
46047706|NCT04229667|Other|Improved Community Health Volunteer (CHV) program|"Multi-modal intervention targeting intensive household monitoring of high-needs patients using monthly visits to measure blood pressure and blood sugar, adherence to treatments and compliance with clinics visits, and motivational interviewing to facilitate behavior change and psychosocial support."
45752039|NCT00558519|Drug|cyclophosphamide|
46047707|NCT05753449|Device|Burst-type DBS electrical stimulation programming|Burst-type DBS is defined as a novel stimulation protocol in which intermittent bursts of traditional high-frequency rectangular wave stimulation are delivered.
46047708|NCT05753449|Device|Standard of care DBS programming|Standard of care DBS stimulation programming
46047709|NCT00670384|Biological|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)|Sublingual drops
46047710|NCT00670384|Biological|Placebo|Sublingual drops
45358426|NCT00850434|Device|Modified AutoSet Algorithm|"The modified AutoSet algorithm responds to more patient non-normal flow types than the standard AutoSet algorithm"
45358427|NCT00850434|Device|Standard AutoSet Algorithm|The standard AutoSet used for treatment of OSA
45358428|NCT00969345|Other|Stretching Exercises|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
45752040|NCT00558519|Drug|cytarabine|
46047711|NCT03930147|Procedure|ASV ventilation|Ventilation on ASV mode
45687593|NCT05065333|Other|Septic Shock Clinical Decision Support|The intervention will be activating a septic shock clinical decision support tool (CDS) in the Electronic Health Record at the site, making it available to trigger and alert Emergency Department providers during clinical care. Patients will be identified when providers suspect sepsis and initiate a sepsis evaluation, using the institutional, clinically-standard, sepsis pathway/orderset. After the CDS is triggered, it will use available Electronic Health Record data to calculate the risk of septic shock, using previously-published predictive models [Ref 1, 2]. The CDS will notify providers if the patient is at elevated risk of septic shock and prompt them to follow institutional standard care for septic shock (including close monitoring, complete laboratory evaluation for organ dysfunction, and immediate clinical involvement of an attending Pediatric Emergency Physician). All clinical care decisions will be determined by the providers.
45844467|NCT01957410|Drug|Ketamine|During Cohorts 1 and 2, a single ketamine 0.5 mg/kg dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. The predefined dose and infusion rate/duration should not be adjusted. If a patient is unable to tolerate the study medication, the infusion should be stopped. Within 1 week of completion of the open-label treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
46047712|NCT05754697|Other|Instrument assisted soft tissue mobilization in addition to traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
46047713|NCT05754697|Other|Positional release technique in addition to traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
46047714|NCT05754697|Other|Traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
46047715|NCT00671398|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally for one night only.
46047716|NCT00671398|Drug|Ramelteon|Ramelteon 16 mg, tablets, orally for one night only
46047717|NCT00671398|Drug|Placebo|Ramelteon placebo-matching tablets, orally for one night only
45358429|NCT00969345|Other|Respiratory Exercises conducted twice a day for 10 minutes|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
45752041|NCT00558519|Drug|daunorubicin hydrochloride|
45358430|NCT00850512|Drug|CHOP21-R|Four months for CHOP21-R and two treatment days one week apart
46047718|NCT03926247|Behavioral|Immigrant Well-Being Project|The IWP intervention emphasizes a sustainable and replicable partnership model between community-based organizations and universities that involves Mexican immigrants and undergraduate advocates working together to: a) increase immigrants' abilities to navigate their communities; b) improve immigrants' access to community resources; c) enhance meaningful social roles by valuing immigrants' culture, experiences, and knowledge; d) reduce immigrants' social isolation; and e) increase communities' responsiveness to immigrants through changes in policy and practice. The IWP is administered by university students enrolled in a service learning course, and has two elements: 1) Learning Circles, which involve cultural exchange and one-on-one learning opportunities, and; 2) Advocacy, which involves collaborative efforts to mobilize community resources related to health, housing, employment, education, and legal issues.
45358431|NCT00850512|Drug|Zevalin|12-week safety period for Zevalin
46047719|NCT00676312|Drug|PTH134|
45358432|NCT00969423|Device|5mm videoscope|use of 5mm videoscope
45358433|NCT00969423|Device|10mm videoscope|use of 10mm videoscope
46047720|NCT00908895|Procedure|Radio-radial fixator|Using the Distal Radius Fixator from Synthes. A single splint for 5 days.
45358434|NCT00850590|Drug|NRL001|Four single doses of NRL001 or placebo. NRL001 is administered at lower (5, 7.5 and 10 mg) or higher (10, 12.5 and 15 mg) doses in a slow release rectal suppository weighing either 1 g or 2 g.
45358435|NCT00965913|Drug|Nicotine Patch|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
45358436|NCT00965913|Drug|Nicotine Patch Comparator|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
45358437|NCT00965913|Drug|Placebo Patch|Placebo patch applied on the lower back, according to treatment sequence, daily for 21 days
45358438|NCT00853866|Drug|reboxetine|single dose of 4mg reboxetine 80 minutes before assessment of Jebsen Taylor test
45358439|NCT00853866|Drug|Placebo|placebo, 80 min before assessment of Jebsen Taylor test
45752042|NCT00558519|Drug|dexamethasone|
45752043|NCT00558519|Drug|doxorubicin hydrochloride|
45752044|NCT00558519|Drug|mercaptopurine|
45752045|NCT00558519|Drug|methotrexate|
45752046|NCT00558519|Drug|pegaspargase|
45752047|NCT00558519|Drug|thioguanine|
45752048|NCT00558519|Drug|vincristine sulfate|
45752049|NCT00558519|Radiation|radiation therapy|
45752050|NCT03380195|Other|Watermelon juice|Subject drinks 355ml of watermelon juice 1 hour prior to submaximal exercise
45844468|NCT01957410|Drug|Placebo|During Cohort 2, a single placebo dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. Within 1 week of completion of the double-blind treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
45358440|NCT00853866|Device|tDCS verum|20 minutes of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
45358441|NCT00853866|Device|tDCS sham|30 seconds of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
45844469|NCT01958112|Drug|GSK1120212 (trametinib)|Trametinib dose is 1.5 mg orally once per day
45844470|NCT01958112|Drug|GSK2141795|The dose of GSK2141795 is 50 mg orally once per day
46047721|NCT00908895|Procedure|Percutaneous pinning|Insert two K-wires in the distal radius, one in the fracture line dorsally and one from the styloid. A cast for 6 weeks.
46047722|NCT00676390|Other|doubly labelled water and questionnaire|0.075 g.kg-1 and 2H2O et 0.15 g.kg-1 de H218O per oral at inclusion visit. physical activity questionnaire at inclusion visit
45358442|NCT00855660|Drug|Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg|Riociguat administered in a dose of 2.5 mg (single tablet), thrice daily, over 14 days.
45479478|NCT04337034|Behavioral|Mobile phone supported and family-centred rehabilitation|Participants in the intervention group will receive an eight-week mobile phone supported and family-centred rehabilitation intervention (F@ce 2.0).The participants will be introduced to a problem-solving strategy intended to facilitate the learning and problem-solving process to be used during the intervention. The strategy will provide a structure for healthcare professionals delivering the intervention. Three targets (goals) in daily activities will be formulated that the person wants and needs to do within the home environment. Each activity will be practiced together with the healthcare professionals and family members. Family members will be informed about the participant's target activities and the planned strategies for reaching the targets. The participants will practice the target activities in their home environment supported by mobile phone calls and SMS. In addition they will be given information about stroke and their blood pressure will be measured.
46047723|NCT00676468|Other|Active Montelukast + Fish Oil Placebo|Montelukast (1 x 10 mg tablet) per day + 10 tablets of fish oil placebo (soy bean oil) per day for a duration of 3 weeks
45358443|NCT00855660|Drug|Placebo|Placebo administered as a single tablet, thrice daily, over 14 days.
45479479|NCT04337034|Procedure|Information and blood pressure measurement|Control group participants will be given information about stroke and their blood pressure will be measured.
45752051|NCT03380195|Other|Sport drink|Subject drinks 355ml of Gatorade 1 hour prior to submaximal exercise
46047724|NCT00676468|Other|Active Fish Oil + Montelukast Placebo|10 tablets (3.2 g EPA + 2.0 g DHA) per day and 1 x 10 mg Montelukast Placebo tablet per day for a duration of 3 weeks.
46047725|NCT00676468|Other|Active Montelukast + Active Fish Oil|1 x 10 mg Montelukast tablet per day and 10 tablets of active fish oil (3.2 g EPA + 2.0 g DHA) for a duration of 3 weeks.
46047726|NCT00591253|Drug|Azilsartan medoxomil|Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks.
46047727|NCT00591253|Drug|Azilsartan medoxomil|Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks.
46047728|NCT00591253|Drug|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 6 weeks.
45358444|NCT00965991|Drug|metformin|patients received glyburide initial dose of 500 mg PO BID. Increased as necessary to a maximum dose of 2000 mg QD to control blood glucose
45358445|NCT00965991|Drug|Glyburide|Initial dose of 2.5mg PO BID increased as necessary to a maximum dose of 20 mg (10mg BID) QD to control blood glucose
45358446|NCT00853944|Drug|sitagliptin|Subjects receive sitagliptin 100 mg po daily from the day of islet transplant until completion of the study
45358447|NCT02545452|Drug|Anastrozole / Levonorgestrel (BAY98-7196)|Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG
45358448|NCT02545452|Drug|Gyno-Daktarin|400 mg miconazole nitrate per day for 3 consecutive days
45358449|NCT02545452|Drug|Sobelin vaginal creme|100 mg clindamycin 2-dihydrogen phosphat per day for 3 consecutive days
45358450|NCT02545452|Drug|Patentex oval|75 mg Nonoxynol-9 per day for 3 consecutive days
45358451|NCT02545452|Other|Tampon|
45358452|NCT00547365|Biological|Human immune globulin intravenous (IGIV)|Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis
45752052|NCT03380195|Other|Sugar water|Subject drinks 355ml of sugar water (22.5g) 1 hour prior to submaximal exercise
45752053|NCT03380195|Other|Water|Subject drinks 355ml of water 1 hour prior to submaximal exercise
45752054|NCT04309110|Device|or geko™ X-T3|The geko™ X-T3 is a next generation self adhesive medical device incorporating a new formulation skin adhesive. It is about the size of a wrist watch which attaches to the side of the knee and when switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg. The only difference between the currently used geko™ T3 device and the new geko™ XT-3 device is the adhesive used to attach each device to the skin.
45358453|NCT00854178|Drug|Comparison of two anesthetic drugs|Isoflurane 1,0 minimum alveolar concentration Propofol 2mg/kg and 4ug/ml
45358454|NCT00850668|Biological|E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3|Up to 7 mL solution administered rectally
45358455|NCT04009473|Combination Product|SEGOVA procedure|SEGOVA procedure includes - Stem cell therapy, G - Growth factor Platelet Plasma Rich therapy and in Vitro Activation of the ovaries.
45358456|NCT00850746|Drug|YM443|Oral
45358457|NCT00850746|Drug|Placebo|Oral
45358458|NCT00850746|Drug|Moxifloxacin|Oral
45358459|NCT00969735|Device|Pulmonary vein cryoablation|A deflectable over-the-wire cryoablation balloon catheter (Arctic Front®) will be inflated and be positioned at each PV antrum. Then, cryoenergy will be delivered for 300 seconds. During cryoablation of the right PVs, the right phrenic nerve integrity will be monitored by the observation of right hemi-diaphragm contractions in response to right phrenic nerve pacing at the superior vena cava. Once the 4 PVs are cryoablated, the Arctic Front® catheter will be replaced by a decapolar PV mapping circular catheter (Lasso®, Biosense Webster, Diamond Bar, California, EEUU) to evaluate PV conduction. A second cryoablation application may be delivered at each PV, if necessary. Crossover to RF ablation to complete PV isolation is discouraged.
45358460|NCT00969735|Device|Pulmonary vein radiofrequency ablation|Ablation approach is ostial electrical isolation of all PVs with simultaneous use of the CARTO® electroanatomic mapping system (Biosense Webster, Tirat-Ha-Carmel, Israel). PV isolation will be performed by delivering RF energy at ostial sites with earliest PV potentials. Flow rate during the RF applications will be set at 15 mL/min (baseline 2 mL/min). Temperature and power limits will be set at 45ºC and 35 W. It will be allowed a 5 W reduction in power limit setting for small PVs (angiographic supero-inferior diameter > 12 mm), and a 5 W increase in areas located away from the esophagus, and for focal applications at sites resistant to ablation or recurrent gaps. The end-point of ablation will be to achieve bidirectional PV conduction block.
45358461|NCT00850824|Behavioral|Community Health Worker home visits|Community health workers will educate diabetes patients and families about need for regular medical care, taking medications, increasing exercise patterns, improving diet, keeping medical referral exams for specialty.
45358462|NCT00966069|Other|Parent collection|Parent collection of anterior nose specimen when child has an acute respiratory illness, and mailed return of the specimen to the laboratory.
46047729|NCT02629900|Behavioral|Time restricted feeding|Participants will consume their daily calories only between 12:00 and 20:00 for 4 weeks
45358463|NCT00966069|Other|Healthcare worker home visit|Healthcare worker performs home visit for collection of respiratory specimen (anterior nose) when study child has an acute respiratory illness.
45358464|NCT00850902|Other|High Humidity (HH)|High Humidity Level
46047730|NCT00676702|Dietary Supplement|Ensure Plus|A high-fat liquid meal of 500 ml of Ensure Plus
46047731|NCT00676702|Drug|Pancrelipase in combination with Ensure Plus|3 pancrelipase MT 21 capsules containing a total of 63,000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
46047732|NCT04152070|Other|No intervention|There was no intervention to be administered, only collection of data through various tests and questionnaires.
45358465|NCT00850902|Other|Moderate Humidity|Moderate Humidity Level
45358466|NCT04041882|Drug|68Ga-DOTATATE|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-DOTATATE. Tracer doses of 68Ga-DOTATATE will be used to image lesions of NET PET/CT scan.
45358467|NCT00969813|Drug|CP-690,550|Single 10 mg dose of CP-690,550
45358468|NCT00969813|Drug|CP-690,550|Single 10 mg dose of CP-690,550
45358469|NCT00969813|Drug|CP-690,550|Single 10 mg dose of CP-690,550
45358470|NCT00854256|Procedure|Canaloplasty|Canaloplasty surgery
45358471|NCT00854256|Procedure|Trabeculectomy with mitomycin C|Trabeculectomy with mitomycin C surgery
45358472|NCT00966147|Other|Increasing oxygen delivery .|The target is increasing oxygen delivery above 600ml/min/mr2 by either bolus of iv colloid or a continuous infusion of dopamine, dobutamine or noradrenaline. The fluids and drug administration will be directed and monitored by the lidco system and transesophageal echocardiography.
46047733|NCT05753371|Drug|Metformin Hydrochloride 500 MG|Metformin is an antihyperglycemic drug used in the management of type-2 diabetes. Metformin hydrochloride improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
45358473|NCT04042662|Other|no intervention|no intervention
45358474|NCT00969891|Other|PK-PD analysis|The danish medicines agency regards new knowledge in pharmacokinetics and pharmacodynamics as an intervention.
45358475|NCT00855972|Drug|Low Dose Naltrexone|
45358476|NCT00966225|Dietary Supplement|LIP-01|comparison of different dosages of natural health product
45358477|NCT00966303|Other|Cardiac Rehabilitation with diaphragmatic muscle training|Stretching and aerobic exercises and respiratory muscle training with a Threshold ® device, with load of 40% of the maximal inspiratory pressure (MIP), two times a week during one hour.
45358478|NCT00854412|Other|Weight loss|Very low-calorie diet (VLCD) of 800 kcal/day for 8 weeks
45358479|NCT00619866|Drug|Elagolix|Elagolix tablets administered orally
45358480|NCT00619866|Drug|placebo|Placebo tablet administered orally
45358481|NCT00851058|Behavioral|Brief group counseling|Four group counseling sessions and six hours of direct observations of the emergency and trauma services in a busy urban hospital.
45844471|NCT01958346|Other|Lingual Traction|The tongue pulling maneuver consists of grasping the tongue with 4x4cm gauze and gently pulling the tongue out until resistance is met.
45844472|NCT01958346|Other|Sham|Standard of care fiberoptic intubation without any additional experimental maneuvers
45844473|NCT01958346|Device|Fiberoptic Intubation|
45844474|NCT05740098|Behavioral|Best Practices|Five As plus referral to a quit line
46047734|NCT04151836|Other|Exercise education|"weekly telephone or mobile application LINE consultations concerning exercise. we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects."
46047735|NCT05754541|Device|WeFlow-Tribranch Aortic Arch Stent Graft System|Endovascular treament in patients with aortic arch dissection by WeFlow-Tribranch Aortic Arch Stent Graft System
46047736|NCT00671476|Drug|pegylated liposomal doxorubicin hydrochloride|
46047737|NCT00671476|Genetic|DNA methylation analysis|
46047738|NCT00671476|Genetic|TdT-mediated dUTP nick end labeling assay|
46047739|NCT00671476|Genetic|fluorescence in situ hybridization|
45358482|NCT00851058|Behavioral|Community Counseling|Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital
45358483|NCT00851058|Behavioral|Prototypic community service|Two educational session on road safety and 16 hours of volunteering in a local not for profit community service.
45358484|NCT00851058|Behavioral|Prototypic community service|Four hours education about road safety and 16 hours volunteering at a local not for profit community service
45358485|NCT02544906|Drug|Propofol|Infusion of propofol to prevent emergence agitation in liver transplanta recipients
45844475|NCT05740098|Behavioral|Financial Incentives|Financial incentives provided contingent on biochemically confirmed smoking abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks following quit date.
46047740|NCT00671476|Genetic|loss of heterozygosity analysis|
45358486|NCT02544906|Drug|dexmedetomedine|Infusion of dexmedetomedine to prevent emergence agitation in liver transplanta recipients
45358487|NCT00861276|Drug|Nasal Spray Nicotine Substitute (Experimental)|During the first month, subjects in the intervention group received instruction from the physician to use NNS regularly (at least 2 puffs/hour, for an average of 1 mg nicotine/hour when awake).
45358488|NCT00861276|Drug|Nasal Spray Nicotine Substitute (ad libitum)|In the control group, participants were instructed to use NNS as needed to suppress withdrawal symptoms when cravings appeared.
45358489|NCT00861354|Device|Microlife blood pressure monitor with AF detection (Microlife AFIB MLU3MQ1)|Monitoring heart rhythm daily for 30 days using the blood pressure monitor and the ECG recorder.
45358490|NCT02544828|Drug|Iron Sucrose 200mg|Iron Sucrose 200mg is administered after anesthesia induction.
45358491|NCT02544828|Drug|placebo|placebo (normal saline) is administered after anesthesia induction
45358492|NCT00861432|Other|additive homeopathic treatment|These patients receive additive homeopathic treatment
45358493|NCT00861510|Drug|ON01910 Na|
45844476|NCT05740098|Drug|Nicotine Replacement Therapy|Nicotine patches and gum/lozenge provided together for dual therapy
46047741|NCT00671476|Genetic|polymerase chain reaction|
46047742|NCT00671476|Other|immunoenzyme technique|
46047743|NCT00671476|Other|immunohistochemistry staining method|
46047744|NCT00671476|Other|laboratory biomarker analysis|
46047745|NCT00671476|Procedure|breast duct lavage|
46047746|NCT00671476|Procedure|neoadjuvant therapy|
45687594|NCT05065333|Other|Clinical Diagnosis Only|Emergency Department sites in this arm will not have Clinical Decision Support for septic shock visible in the Electronic Health Record for providers at the site. Providers will follow usual institutional standards of sepsis care.
45687595|NCT05063097|Other|urine test|The following illicit drugs will be evaluated for all consecutive patients by urine drug assay (NarcoCheck®, Kappa City Biotech SAS, Montluçon, France) within two hours of admission to the ICCU: i) cannabinoids (tetrahydrocannabinol [THC]), including cannabis and hashish; ii) cocaine and metabolites, including cocaine and crack; iii) amphetamines; iv) MDMA; and v) heroin and other opioids. In addition to the analysis of psychoactive drug use, the investigators will also use the NarcoCheck® urine drug assay to evaluate the associated use of the following psychostimulant drugs: barbiturates, benzodiazepines, tricyclic antidepressant drugs, methadone and buprenorphine.
45687596|NCT05063097|Other|Fagerström questionnaire|Tobacco consumption will also be evaluated for each patient using a Fagerström questionnaire.
46047747|NCT00671476|Procedure|therapeutic conventional surgery|
45358494|NCT01095003|Drug|Vinflunine plus Capecitabine|"Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks~Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks"
45358495|NCT01095003|Drug|Capecitabine|Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
45358496|NCT00854568|Drug|CEOP regimen|cyclophosphamide 750mg/m2 IV day 1 epirubicin 70mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
45479480|NCT02497378|Drug|JNJ-54767414 (Daratumumab)|JNJ-54767414 (Daratumumab) will be administered as an Intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, on Day 1 of Cycles 4-8 (every 3 weeks), and then on Day 1 of subsequent cycles (every 4 weeks). First 8 Cycles are 21-day cycles; Cycles 9 and onwards are 28-day cycles.
45687597|NCT05063097|Other|Exhaled carbon monoxide (CO) measurement|Active smoking will also be systematically investigated in all patients using a standardized exhaled carbon monoxide (CO) measurement with a CO-Check Pro device (Bedfont Scientific Ltd, Kent, UK) on arrival, with a measure of > 3 parts per million (ppm) signifying active smoking.
45844477|NCT05739864|Biological|FMT|This intervention is represented by the administration, in the recipients' gut, of super - donor microbiota through FMT
45844478|NCT05739864|Other|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
46047748|NCT00908583|Drug|plasmapheresis|Patients will receive plasmapheresis 1.5 x plasma volume prior to each Bortezomib dose. Plasma volume replacement will be per physician discretion.
46047749|NCT00908583|Drug|Bortezomib|Patients will receive bortezomib as described in protocol
46047750|NCT00908583|Drug|Rituximab|Patients will receive rituximab as described in protocol
46047751|NCT00908583|Drug|Methylprednisolone|Each bortezomib dose will be preceded by intravenous methylprednisolone (100mg for first two doses and 50mg for following doses).
46047752|NCT04030117|Procedure|ACTIVA Bioactive restoration|Removal of Class II decay in second primary molars and placement of ACTIVA restoration.
46047753|NCT04030117|Procedure|Compomer restoration|Removal of Class II decay in second primary molars and placement of Compomer restoration.
46047754|NCT04153162|Device|Stereotactic body radiation therapy|Stereotactic body radiation therapy delivered to reduce LVOTO in patients with HCM
46047755|NCT05753293|Other|breathing exercise|"Buteyko breathing technique developed to control hyperventilation and anxiety which leads to shortness of breath. It uses series of exercises to teach patients to breathe less deeply and less rapidly /Bhastrika Bellow Breathing is diaphragmatic breathing - deep breathing involving the diaphragm rather than the accessory muscles. Regulated pranayama exercises require inhalation, maintaining isometric contraction of respiratory muscles and forceful expiration. These techniques will strengthen respiratory muscles"
46047756|NCT05519241|Drug|PLZ4-coated paclitaxel-loaded micelles (PPM)|PPM will be administrated weekly for 6 times through intravesical instillation into the bladder cavity
46047757|NCT00671632|Drug|Ramelteon, triazolam, and placebo (56 possible combinations total)|"Randomized sequence over eight consecutive days to include the following:~Ramelteon 16 mg, tablets, orally, one day only;~Ramelteon 80 mg, tablets, orally, one day only;~Ramelteon 160 mg, tablets, orally, one day only;~Triazolam 0.25 mg, capsules, orally, one day only;~Triazolam 0.50 mg, capsules, orally, one day only;~Triazolam 0.75 mg, capsules, orally, one day only;~Ramelteon placebo-matching tablets, orally, one day only, OR Triazolam placebo-matching capsules, orally, one day only;~Additional dose of study medication or placebo, tablets or capsules, orally, one day only."
46047758|NCT05754463|Other|The effect of plyometric training on balance and proprioception in athletes in different branches|Investigating the effect of plyometric training on balance and proprioception in athletes in different branches
45358497|NCT00854568|Drug|CHOP regimen|cyclophosphamide 750mg/m2 IV day 1 doxorubicin 50mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
45687598|NCT05062239|Drug|Discontinuance of treatment with statins 7 to 14 days prior to surgery until 30 days postoperative|Discontinuance of prior statin therapy
45687599|NCT05062239|Drug|No-intervention.|Continuance of prior statin therapy
45687600|NCT05061277|Drug|Recifercept|A lyophilized powder for solution for injection
45687601|NCT05059470|Drug|Pembrolizumab|Given by IV
45687602|NCT05056740|Biological|Data analysis|Analysis of the data from routine care at the end of the diagnostic work-up
45687603|NCT05051345|Other|Informational Intervention|Receive information on the services provided for pregnant women and smoking cessation
46047759|NCT03989505|Diagnostic Test|blood-draw for biomarker analyses|Blood will be drawn at three time-points: immediately before catherization, 12-24 hours after catheterization and 4-8 weeks after discharge. Creatinine will be measured for endpoint definition, while the markers urea, CRP (C-reactive protein), NGAL (neutrophil gelatinase-associated lipocalin), KIM-1 (kidney injury marker-1), cystatin C, suPAR (soluble urokinase-type plasminogen activator receptor), and penKid will be measured as biomarkers of interest.
46047760|NCT02628340|Other|Ex-vivo analysis|
46047761|NCT04153708|Behavioral|Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by phone call.|Patients assigned to strategy 1 will be called to schedule an appointment with the hepatologist over a period of 14 days.
45358498|NCT00854646|Drug|ON 01910.Na|The drug is a sterile, concentrated 75mg/mL solution in polyethylene glycol 400, in labeled, sealed glass vials. The Concentrate must be diluted with aqueous infusion solutions (0.9% NaCl, USP and Water for Injection, USP according to instructions) immediately prior to intravenous administration.
45358499|NCT00856362|Drug|Moxidectin|
45358500|NCT00856362|Drug|Midazolam|
45358501|NCT00854802|Drug|Debio 025|Debio 025 supplied in soft gel capsules
45358502|NCT00854802|Drug|Peg-IFNα2a|Peg-IFNα2a supplied in pre-filled syringes
45358503|NCT00854802|Drug|Ribavirin|Ribavirin supplied in tablets
45358504|NCT00854802|Drug|Debio 025 placebo|Debio 025 placebo supplied in soft gel capsules
45687604|NCT05051345|Other|Informational Intervention|Receive tobacco cessation self-help materials
45687605|NCT05051345|Other|Informational Intervention|Receive Smoke-Free Homes mailings
45687606|NCT05051345|Other|Media Intervention|Download and use the Wellness app
45687607|NCT05051345|Other|Questionnaire Administration|Ancillary studies
45687608|NCT05051345|Behavioral|Smoking Cessation Intervention|Receive Smoke-Free Homes kit
45687609|NCT05051345|Other|Survey Administration|Ancillary studies
45687610|NCT05051345|Behavioral|Telephone-Based Intervention|Receive telephone counseling sessions
45687611|NCT05051345|Behavioral|Telephone-Based Intervention|Receive a coaching call from a Baby Steps for Health counselor
45687612|NCT05051345|Other|Tobacco Cessation Counseling|Receive telephone counseling sessions
45844479|NCT05739786|Drug|liq nitrogen|In Group A patients were subjected to liquid nitrogen cryotherapy (-196 0C) for 3 sessions at every 3 weeks interval. Effectiveness in was ascertained in terms of > 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
46047762|NCT04153708|Behavioral|Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by mail letter|Patients assigned to strategy 2 will receive an invitation letter with an appointment with the hepatologist over a period of 14 days.
45358505|NCT00969969|Device|Arthrodesis|arthrodesis using screws and/or a plate
45358506|NCT00969969|Device|Cartiva|Cartiva Synthetic Cartilage Implant
45358507|NCT00854880|Drug|PDC339|
45358508|NCT00854880|Drug|Placebo|
45358509|NCT00966459|Procedure|Computed Tomography|1 low-dose CT is taken
45358510|NCT00958503|Drug|Thiamphenicol|750 and 1500 mg/day;tablets
45358511|NCT00958503|Drug|Placebo|Matched tablets without active ingredient
45358512|NCT04119024|Drug|Cyclophosphamide|Given IV
45358513|NCT04119024|Drug|Fludarabine Phosphate|Given IV
45358514|NCT04119024|Biological|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given IV
45358515|NCT04119024|Drug|Recombinant Interleukin-2|Given SC
45358516|NCT00861588|Drug|isoflavones (Soylife 25)|40mg of soy isoflavones capsule (once daily)
45358517|NCT00861588|Drug|placebo|starch placebo
45358518|NCT00970125|Behavioral|video|outline of the goals of care
45358519|NCT00966615|Other|double-chamber bag Stay-Safe Balance system|2-L exchange; three times a day
45358520|NCT00966615|Other|glucose-based dialysis solution|2-L exchange; three times a day
46047763|NCT00909363|Drug|Promacta|"WAS Patients receiving treatment will start on 1 mg/kg of eltrombopag daily and be seen weekly for 12 weeks. Dose adjustment will be based on the weekly monitoring of the platelet count as utilized in ongoing studies in ITP as well as on liver tests.~they will also have diagnostic blood testing prior to initiating treatment"
46047764|NCT00909363|Diagnostic Test|blood drawing in patients with WAS|blood will be drawn for platelet parameters in WAS patients not receiving treatment either because they declined or because they were ineligible
46047765|NCT00909363|Diagnostic Test|blood drawing in healthy controls|blood will be drawn once in healthy children as controls for platelet parameters
45358521|NCT00861666|Behavioral|Forgiveness-Based Writing|"Participants will be asked to complete self-report measures during the initial session, will be given writing instructions and will complete the first writing task on-site. The first writing task will focus on describing an offense in which someone hurt or angered the participant, and about which the participant is still hurt and angry.~Eleven additional writing tasks will be completed at home, three per week for a month. Writing assignments will include topics such as describing thoughts and feelings about the offense, identifying possible motives or mitigating circumstances, identifying benefits of the offense itself, identifying times when one has offended others and how one felt afterwards, identifying benefits of letting go of the offense, and writing a letter to the offender.~Participants will return each written assignment to the study staff. All participants will be tracked closely by the study coordinator and receive a reminder phone call on the day of each writing task."
45358522|NCT00861822|Other|Advanced red blood cell transfusion|"Sixty anemic (Hg 100-120 g/L) adult patients undergoing cardiac surgery with CPB will be randomized to the 'advance RBC transfusion' (ART) group or the standard-of-care RBC transfusion' (SRT) group (1:1 ratio).~In the ART group, subjects will receive 1-2 units of stored RBCs 1-2 days before surgery to reach a target Hb of 130-140 g/L. Each unit of blood will be transfused over 2 hours under medical supervision, with appropriate monitoring and management of fluid status to ensure patients are not over-hydrate"
45358523|NCT00970437|Behavioral|Cognitive Behavioral Analysis System of Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
45358524|NCT00970437|Behavioral|System of Supportive Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
45358525|NCT02545218|Procedure|Perineorraphy|Surgery for improperly healed perineal tear
45358526|NCT02545218|Other|Pelvic floor exercise|Pelvic floor exercise tutored by physio therapist.
45358527|NCT00966771|Drug|Copper T380 IUD|copper T 380 IUD
45358528|NCT00966771|Drug|Oral levonorgestrel|1.5 mg
45358529|NCT00856440|Drug|Fleets Oral Sodium Phosphate Solution (OSPS)|Osmotic preparation for colonoscopy
45358530|NCT00856440|Drug|Colyte|Lavage preparation for colonoscopy
45358531|NCT00856440|Drug|Dual (OSPS & Colyte)|Combined, two-day preparation utilizing both preparations
45358532|NCT00958659|Other|laboratory biomarker analysis|Correlative studies
45358533|NCT00856596|Drug|Sertaconazole nitrate cream 2%|Once a day topical cream
45358534|NCT00970515|Procedure|Laparoscopic mesh hernia repair|The mesh is intraperitoneal
45358535|NCT00970515|Procedure|Open anterior approach|The mesh is placed by an anterior approach. It is placed after incision of the skin over or under the abdominal muscles, or is intraperitoneal
45358536|NCT04042350|Other|Non-interventional|Exploring clinical risk factors associated with the risk for cardiovascular events and mortality, rather than to evaluate specific drugs.
45844480|NCT05739786|Drug|intralesional vitamin D3|Group B were subjected to vitamin D3 (5mg/ml) for 3 sessions at every 3 weeks interval. Effectiveness was ascertained in terms of > 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
45358537|NCT00855114|Drug|everolimus|5 mg/day x 7 days by mouth
45358538|NCT00855114|Procedure|therapeutic conventional surgery|Definitive excision of breast cancer tissue
45358539|NCT00856674|Biological|OPL-CCL2-LPM|"CCL2-LPM~intravenous 0.001 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg~2 doses one week apart"
46047766|NCT00676936|Drug|Methylprednisolone|Custom made capsules, Methylprednisolone 16 mg twice daily, intervention period 7 days.
46047767|NCT00676936|Drug|Placebo|Custom made capsules, Lactose, administered twice daily, intervention period 7 days
46047768|NCT00810355|Behavioral|Support Group|General support and problem solving for work activity
45358540|NCT00855192|Behavioral|mindful meditation|interpersonal and psycho-educational
46047769|NCT00810355|Behavioral|Cognitive Behavior Therapy|Individual and group therapy focused on identifying and correcting maladaptive beliefs about work
45358541|NCT00855192|Behavioral|interpersonal therapy|psycho-educational
45358542|NCT00856752|Drug|NRL972|Single intravenous administration of 2 mg NRL972 after pre-treatment with 600 mg p.o. rifampicin once daily from the evening of Day D-7 until the evening of Day D-1
45358543|NCT00856752|Drug|NRL972|Reference test: Single intravenous administration of 2 mg NRL972
45358544|NCT00856752|Drug|NRL972|Single intravenous administration of 2 mg NRL972 injection after pre-treatment with 100 mg cyclosporine on the evening of Day D-1 and on the morning of Day D01 one hour before administration of NRL972
45844481|NCT05739708|Other|Questionnaires|The time to complete the different questionnaires is estimated to be 60 minutes.
46047770|NCT00810355|Behavioral|Cognitive Remediation|Computerized training to enhance cognitive functioning.
45358545|NCT04042272|Diagnostic Test|S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP)|S100β is 10.4 kDa protein. Synthesized with end-feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium-binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction. Glial fibrillary acidic protein (GFAP) is the intermediate filament cell skeleton protein found in astrocytes. It originates from the same root structure as S100β.
46047771|NCT02629744|Drug|Etrolizumab|Single SC dose of etrolizumab at 105 milligrams (mg) on Day 1.
46047772|NCT02629744|Device|Prefilled Auto-injector (Rotaject)|Participants self-administered etrolizumabSC injection using a prefilled auto-injector.
46047773|NCT05579691|Biological|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
45358546|NCT04041960|Other|Transcranial magnetic stimulation (TMS)|The TMS protocol to be used, excitatory intermittent theta burst stimulation (iTBS), has been shown to have minimal risk in children as young as 6 (Hong et al., 2015), as well as adults (Huang et al., 2005). This stimulation paradigm uses a series of theta burst stimulation (TBS) units. Each unit consists of 3 pulses of stimulation given at 50 Hz (Huang et al., 2005). Excitatory iTBS consists of 20 sets of 10 TBS units (2 second duration) repeated every 10 seconds for a total of 190 seconds. One session of excitatory stimulation delivers a total of 600 pulses.
45358547|NCT00855270|Drug|Placebo|IV saline will be used as placebo for control
46047774|NCT05579691|Other|Placebo|Placebo Comparator
46047775|NCT05326321|Other|Study Group|The patients in the intervention group were shown a video with virtual reality glasses for an average of 5 minutes, 2 minutes before the start of the AVF cannulation procedure and 3 minutes throughout the procedure.
46047776|NCT03665493|Drug|PD patients H&Y=1.5-2 Medications ON|Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
46047777|NCT03665493|Drug|PD patients H&Y=1.5-2 Medications OFF|Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
46047778|NCT03665493|Behavioral|Healthy age-matched controls|Healthy controls will perform the stop signal task and the go-only task in the same day. The order of administration will be counterbalanced.
45358548|NCT00855270|Drug|Hydrocortisone|A single dose 90-150mg of Intra Venous Hydrocortisone. 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg.
46047779|NCT03665493|Drug|PD patients H&Y=3 Medications OFF|Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
45358549|NCT03937479|Drug|Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.375 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
45358550|NCT03937479|Drug|Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.75 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
45358551|NCT03937479|Drug|Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 1.5 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
45358552|NCT03937479|Drug|Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 3.0 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
45358553|NCT03937479|Drug|Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● Placebo twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
45358554|NCT00855348|Other|All eligible subjects will provide blood for SEPT9 biomarker testing|A single blood sample per participant selected according to analysis plan is tested for evidence of methylation of a specific DNA sequence, SEPT9.
45687613|NCT05047185|Drug|Deucrictibant low dose|Deucrictibant softgel capsules for oral use (PHVS416)
46047780|NCT03665493|Drug|PD patients H&Y=3 Medications ON|Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
45358555|NCT00970671|Other|Laser treatment with Purpuric settings|Pulsed dye laser treatment at purpuric settings with pulse duration of 1.5msec.
45358556|NCT00970671|Other|Laser treatment with Nonpurpuric settings|Pulsed dye laser treatment with nonpurpuric settings with pulse duration 10msec.
45358557|NCT00970671|Other|No treatment|No laser treatment
45358558|NCT00967083|Behavioral|Questionnaires/Interviews|Baseline assessment of distressed caregivers within 4-6 weeks a new visit to the thoracic clinic. Three-month follow-up assessment of caregivers. Qualitative phone interviews with a subsample of 30 caregivers within 3 weeks of follow-up.
45687614|NCT05047185|Drug|Deucrictibant high dose|Deucrictibant softgel capsules for oral use (PHVS416)
45687615|NCT05047185|Drug|Placebo|Matching placebo capsules for oral use
45752055|NCT04660721|Combination Product|sFilm-FS|sFilm-FS is a sterile bio-compatible bio-absorbable patch embedded with lyophilized powders of Human Fibrinogen, Human Thrombin and calcium chloride.
45358559|NCT00967161|Procedure|Total Knee Arthroplasty|Total Knee Arthroplasty
45358560|NCT00967161|Procedure|Motion analysis|Motion analysis (Gait/EMG during walking and functional tasks)
45358561|NCT00967239|Genetic|DNA analysis|
45358562|NCT00967239|Genetic|polymorphism analysis|
45358563|NCT00967239|Other|laboratory biomarker analysis|
45844482|NCT05739630|Drug|mitoxantrone liposome|Mitoxantrone liposomes with 36mg/m2 and Bu 3.2mg/kg -5 to -4, Flu 30mg/m2 -12 to -9, Ara-C 1.5g/m2 -12 to -9，CTX 15mg/kg/d -3 to -2, was used as conditioning regimen, Post Transplant Cyclophosphamide 50 mg/kg IV daily on days +3 and +4.
46047781|NCT00677170|Drug|MLN4924|IV dose escalation for 5 consecutive days followed by a rest period of 16 days for a 21 day cycle. Treated may continue until disease progression or unacceptable toxicity develops.
46047782|NCT03917433|Behavioral|Virtual Reality Exposure Therapy|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.
45358564|NCT00967239|Other|pharmacogenomic studies|
46047783|NCT03917433|Behavioral|Tactile Feedback|In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world.
45358565|NCT00967317|Drug|Auris-Sedina|"Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.~The medication should be used for a maximum of 3 days when they should return to the doctor."
45358566|NCT00967317|Drug|Otosynalar®|Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
45358567|NCT00959127|Drug|ARRY-438162 (MEK162), MEK inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
45844483|NCT05739630|Drug|ATG|Control group:the conditioning regimen involved Ara-C 2g/m2 q12h -8, BU 3.2 mg/kg -7 to -5,CTX 1.8 g/m2 -4 to -3, to prevent GVHD, MTX 15mg/m2 +1d, 10mg/m2 +3,+6,+11,CsA 3mg/kg/d from -8d,MMF 1g q12h from -8d， ATG 2.5mg/kg/d -5 to -2.
45844484|NCT05739474|Biological|Influenza vaccine [inactivated]|solution for intramuscular injection, 1 dose (0.5 mL)
45844485|NCT05739474|Biological|Influenza vaccine [inactivated]|suspension for intramuscular and subcutaneous injection, 1 dose (0.5 mL)
46047784|NCT03917433|Behavioral|Point-based Rewards|Participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
46047785|NCT05753215|Drug|Omadacycline Pill|Omadacycline will be administered 300 mg orally daily without the loading dose.
46047786|NCT05753215|Drug|Standard of Care|Prior to randomization, SOC antibacterial therapy will be selected by the subject's treating physician.
45358568|NCT00959205|Device|CARTO 3D|CARTO (3D Electroanatomic imaging)
45358569|NCT00959205|Device|Angiography|Conventional fluoroscopically guided activation mapping
45358570|NCT00967395|Other|Healing|"Healing in our study is given be a healer no-touch, who just has to be present in the room."
45358571|NCT00967395|Other|Sham healing|"Sham Healing in our study is given be a student no-touch, who just has to be present in the room."
45358572|NCT00970827|Procedure|remote ischemic postconditioning|Three 5- minute cycles of blood pressure cuff inflation according to the assigned group. The cuff is inflated to 200 mm Hg (and at least 20 mmHg above the systolic blood pressure) for 5 minutes followed by a 5-minute deflation (reperfusion).
45844486|NCT05739318|Device|The cuff of endotracheal and endobronchial is collapsed|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial when the cuff is collapsed as the diameter of double-lumen tube and select a double-lumen tube that matches the patient's trachea and bronchial innerdiameter based on this diameter
45844487|NCT05739318|Device|The cuff of endotracheal and endobronchial is inflated|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial when the cuff is inflated as the diameter of double-lumen tube and select a double-lumen tube that matches the patient's trachea and bronchial innerdiameter based on this diameter
45844488|NCT05739084|Radiation|pre-operative radiation|As per standard of care and institutional guidelines
45358573|NCT00970905|Drug|aprepitant|aprepitant 125 mg po (Mondays), 80 mg po (Wednesdays), 80 mg po (Fridays) with doses scheduled 1-2 hours prior to the day's radiation fraction. Aprepitant will not be administered on weekend days. Aprepitant administration will continue until the last day of radiotherapy.
45358574|NCT00970905|Drug|Ondansetron|Ondansetron 8 mg po bid, with the morning dose scheduled 1-2 hours prior to the day's radiation fraction. Ondansetron will not be administered on weekend days. Ondansetron administration will continue until the last day of radiotherapy.
45358575|NCT00619476|Drug|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
45358576|NCT00619476|Drug|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
45687616|NCT05036005|Drug|Ontruzant|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.
45844489|NCT05739084|Procedure|Standard surgery after rpreoprative radiation|As per standard of care and institutional guidelines
45844490|NCT05739006|Drug|BCD-201|up to 8 treatment cycles
45844491|NCT05739006|Drug|Keytruda|up to 8 treatment cycles
45844492|NCT05738928|Diagnostic Test|blood and sputum culture|Noninvasive sampling ( Endo Tracheal Aspiration) for staining and culture. Blood culture .
45844493|NCT05738772|Diagnostic Test|serum sample for ELIZA|Assay of AFP, AFP-L3, DCP and Soluble PDGFRβwill be done by enzyme-linked immunosorbent assay (ELISA).
45844494|NCT05738616|Combination Product|Lenvatinib combined with TACE and Camrelizumab|After all subjects sign informed consent and pass screening, they are randomized in a 1:1 ratio to either the experimental arm (lenvatinib combined with TACE and camrelizumab) or the control arm (lenvatinib alone), and randomization is stratified according to the number of tumors (single versus multiple) and portal vein tumor thrombus (Vp1 ~ 3 vs. Vp4). Eight sites in China will be included in this study with follow-up of 2 years.
45358577|NCT00619476|Drug|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
45844495|NCT05738538|Drug|ziftomenib|
45358578|NCT00619476|Drug|Placebo|placebo
45358579|NCT00970983|Procedure|quadrantectomy and axillary dissection|standard quadrantectomy and axillary dissection
45844496|NCT05738460|Drug|antibiotics|Reproductive tract GBS colonization group of mothers during pregnancy，Use of antibiotics
45358580|NCT00970983|Procedure|quadrantectomy + sentinel node biopsy|standard quadrantectomy and selective axillary dissection only if sentinel node biopsy is positive
45358581|NCT04009083|Device|Standard of Care MRI|Prostate MRI, serum Prostate Specific Antigen (PSA), in field and random systemic prostate biopsies
45687617|NCT05036005|Drug|Chemotherapy|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Choice of chemotherapy is at the discretion of the investigator
45844497|NCT05738382|Drug|BG2109|oral administration once daily
45844498|NCT05738382|Drug|Cetrorelix|0.25 mg, Subcutaneous injection once daily.
46047787|NCT02629510|Drug|Tachosil|
46047788|NCT02629588|Behavioral|Multimodal or Unimodal Sensory stimulation|multimodal sensory stimulation, unimodal sensory stimulation, auditory stimulation, complex stimulation, median nerve stimulation.
45358582|NCT04009083|Other|Fluciclovine PET scan added to MRI|18F-Fluciclovine (Axumin) is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment
45358583|NCT00971061|Device|Ahmed valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
46047789|NCT00908349|Drug|Oxcarbazepine XR|Open Label Study
46047790|NCT01125566|Drug|BIBW 2992|patients receive BIBW 2992 tablets once daily and can reduce dose for adverse event management
46047791|NCT01125566|Drug|trastuzumab|patients receive trastuzumab 2mg/kg intravenously every week
45358584|NCT00971061|Device|Molteno single-plate implant (MSPI)|134 mm2 surface area single-plate Molteno implant (Molteno Ophthalmic Limited, Dunedin, New Zealand)
45358585|NCT00973635|Other|Web-based education|"Patients of subjects who were required to complete 10 web-based, independent learning modules. Each subject given a course packet which includes 13 required core articles pertaining to handoff skills. Each subject receives immediate feedback to each web-case with correct answers and suggested readings. Each subject given individualized feedback on their scores for summaries, instructions, and sign outs."
45479481|NCT02497378|Drug|Bortezomib|Bortezomib will be administered at a dose of 1.3 mg/m^2 subcutaneously (SC) on Day 1, 4, 8 and 11 of each 21-day cycle. Eight Bortezomib treatment cycles are to be administered.
46047792|NCT01125566|Drug|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
46047793|NCT01125566|Drug|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
46047794|NCT04031872|Drug|LY3200882|Combination treatment with LY3200882 and capecitabine
46047795|NCT03414255|Biological|Micronized DHACM|1 mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM).
46047796|NCT03414255|Drug|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
46047797|NCT00810277|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
45358586|NCT00861978|Drug|St. John's Wort extract|Coated tablets (batch no. 02080277) containing 300 mg of St. John's Wort extract LI 160 (drug-extract ratio 3-6:1; extraction solvent: 80% Methanol in water; batch no. 02019073) administered orally twice daily (morning and evening) with some liquid for 8 weeks
46047798|NCT04151758|Drug|Docosahexaenoic Acid Supplementation|Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day (2 ml per day DHA RICH OIL 25% aroma mandorla FoodAR Limbiate, Italy;50% DHA oil obtained from Schyzochitrium sp ; Martek Biosciences Corporation, Columbia, Maryland, USA) to all participants of the study. DHA 2 ml will provide about 16 kcal of energy.
46047799|NCT04151758|Other|Promotion of physical activity|All participants will underwent a visit at t0, t1 and t2 in which physical activity will be promoted according to Italian dietary guidelines for childhood obesity.
45687618|NCT05036005|Drug|Pertuzumab|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.
45687619|NCT05035823|Device|Motor Neuroprosthesis (MNP)|Type of implantable brain computer interface
45687620|NCT05033769|Drug|Eribulin Injection [Halaven]|on days 1 and 8 q21d
45358587|NCT00861978|Drug|Placebo|Coated placebo tablets (batch no. 01010177) that were identical in shape, size, taste and color were administered orally twice daily (morning and evening) with some liquid for 8 weeks.
45358588|NCT00971139|Behavioral|Access to an OPPC service|Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
45358589|NCT00862056|Procedure|Cardiac CT|All participants will undergo a coronary artery CT angiogram with contrast.
46047800|NCT04151758|Other|Promotion of healthy food habits|All participants will underwent a visit at t0, t1 and t2 in which healthy food habits will be promoted according to Italian dietary guidelines for childhood obesity.
46047801|NCT05754385|Behavioral|Ambulatory monitoring of liver fat|Participants will be given a novel portable, home-based device called the Gense-EIT liver scan the participants and will practice ambulatory liver fat monitoring for 6 months.
46047802|NCT05754385|Behavioral|Standard of care|Subjects will have follow-up every 6 months by hepatologists for routine care
46047803|NCT00670696|Drug|Rapydan|Topical anaesthetic plaster
46047804|NCT00670696|Drug|tetracaine gel|Topical tetracaine gel
46047805|NCT05753137|Other|Acupuncture|The treatment will take place once a week, over six weeks. The needles will placed in the body for 20 minutes. A total of 12 Needles(6 acupoints, bilaterally) will be used in each session.
46047806|NCT05753137|Other|Acupuncture placebo|A total of 12 Needles(6 acupoints, bilaterally) will be used in each session. Acupuncture points are different from the experimental group.
45358590|NCT00959361|Behavioral|pharmaceutical care|consultation with the pharmacists and usual care
45358591|NCT04040712|Other|Donor FMT|Fecal microbiota transplantation using stools from healthy donors
45687621|NCT05033769|Drug|Paclitaxel injection|on days 1, 8, and 15 q21d
45687622|NCT05030142|Procedure|Mechanical Thrombectomy|Mechanical thrombectomy (using a stent retriever among the following:Trevo NXT ProVue Retriever, Catchview mini, pReset Lite, Tigertriever 13) in association with the best medical treatment (usual care)
45687623|NCT05030142|Drug|Best medical treatment alone|Best medical treatment alone (usual care)
45358592|NCT04040712|Other|Sham FMT|Sham fecal microbiota transplantation
45358593|NCT00973713|Drug|RAD001|10mg/d
45687624|NCT05026372|Behavioral|Mindfulness Compassion (MC)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
45844499|NCT05738226|Device|EpiCare@Home, wearable multimodal seizure monitoring system|"Two wearable devices (Byteflies Sensor Dots) will be used. One Sensor Dot will be placed in the neck with a skin adhesive and will be connected to EEG electrodes placed behind each ear. The second Sensor Dot will be placed on the chest with an adhesive ECG electrode (i.e., a cardiac patch)."
45844500|NCT05737680|Drug|Hydroxychloroquine|Hydroxychloroquine 400mg daily
46047807|NCT04153630|Biological|mesenchymal stem cells derived from bone marrow (BM-MSCs)|Procedure: Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg
46047808|NCT00677248|Drug|Ezetimibe and placebo|Placebo or three different doses of eprotirome added to ezetimibe treatment
45358594|NCT00857142|Drug|oxymorphone hydrochloride|
45358595|NCT00857142|Drug|Opana|
46047809|NCT00677248|Drug|Eprotirome and ezetimibe|Placebo or three different doses of eprotirome added to ezetimibe treatment
45844501|NCT05737680|Drug|Colchicine|Colchicine continued
45479482|NCT02497378|Drug|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Day 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles (except for Cycles 1-3). In Cycles 1-3, participants receive dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, 12 and 15. During weeks when the participants receives an infusion of daratumumab, dexamethasone will be administered at a dose of 20 mg IV or orally (PO) (only if IV is not available) before the daratumumab infusion as preinfusion medication.
45844502|NCT05737290|Device|Clear aligners|Patients with mild anterior crowding will be treated with non-extraction treatment using clear aligners.
45358596|NCT00971217|Other|Exercise|Moderate intensity aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines, twice per week for 10 weeks.
45479483|NCT05001620|Other|Palliative Care Consultation|The PC provider conducts the structured PCC-PAC via videoconference or telephone with the PLWD and/or their care partner and the social work (SW) champion in the NH. The SW and PC provider will set up a mutually agreed upon consultation day/time with the PLWD and/or care partner, within 5 business days of NH admission and follow up visits will occur no more than 30 days later (if needed).
45844503|NCT05737290|Device|Fixed appliances|Patients with mild anterior crowding will be treated with non-extraction treatment using fixed appliances.
46047810|NCT05754307|Procedure|Access Flap|Intrasulcular incisions at the teeth adjacent to the defect, using the simplified papilla preservation technique (SPPT) or modified papilla preservation technique (MPPT). Granulation tissue is excised and debridement via hand and power-driven instruments follows. Flaps are repositioned and papilla are sutured with horizontal internal mattress doubled by a single interrupted interdental suture.
45358597|NCT00971217|Behavioral|Online Cognitive Behavioural Therapy|Participants will be asked to log-on to a website aimed at young men once per week. Participants will be asked to read a vignette or watch a specific video clip, which will be updated each week by the researcher. Participants will be asked to respond to the vignette/video clip on the website. This should take no longer than 10-15 minutes to complete. Different themes (such as those addressed by traditional cognitive behavioural therapy) will be introduced each week. Themes include: relaxation, identifying positive strengths, body image, goal-setting, problem-solving, resilience, self-care behaviour and sources of support.
45358598|NCT00865176|Drug|Eplerenone 50 mg Tablets Sandoz Inc., USA|
45358599|NCT00865176|Drug|Inspra 50 mg Tablets GD Searle LLC, USA|
45358600|NCT00973791|Drug|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after spinal anesthesia in cesarean section
45358601|NCT00973791|Drug|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after spinal anesthesia in cesarean section
45479484|NCT02497144|Other|NMES Group|Neuromuscular electrical stimulation
45479485|NCT02497144|Other|Control Group|Breathing exercises
45479486|NCT04986956|Dietary Supplement|Whole coffee cherry extract|200mg WCCE
45479487|NCT04986956|Dietary Supplement|Placebo|Placebo for comparison to WCCE
45687625|NCT05026372|Behavioral|Mindfulness Gratitude (MG)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
45687626|NCT05026372|Behavioral|Mindfulness Value-Based Living (MV)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
46047811|NCT05754307|Procedure|Closed Surgical Technique|"Strictly intrasulcular incisions are performed at the teeth adjacent to the defect (mid-buccal to mid-lingual) without incising the interdental papilla. Full thickness gingival flaps, at the base of the papilla, which is retained intact, are elevated in a closed-tunneling manner, granting access to the interdental osseous defect. Debridement is performed via power-driven tips and mini curettes, without intentionally excising the granulation tissue that lines the osseous defect. Flaps are repositioned by gentle pressure and suturing is not required."
45358602|NCT00865254|Behavioral|Standard Treatment|Brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
45358603|NCT00865254|Behavioral|Traditional Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (50% of draws are prizes). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
45358604|NCT00865254|Behavioral|Early Enhanced Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (100% of draws are prizes in week 1; 33% are prizes in weeks 2-4). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
45358605|NCT00973869|Dietary Supplement|curcumin|
45358606|NCT00973869|Other|high performance liquid chromatography|
45358607|NCT00973869|Other|laboratory biomarker analysis|
45844504|NCT05736510|Other|Binaural sound|"When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the experimental group, the allocated file is binaural sound with 40Hz beat. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation."
46047812|NCT00637598|Radiation|Mammography and tomosynthesis imaging|All subjects receive the same radiation dose associated with mammography and tomosynthesis imaging (which is comparable to mammography).
46047813|NCT00671710|Drug|Aminolevulinic Acid|Escalating doses (10mg/kg, 20mg/kg, 30mg/kg) of Aminolevulinic Acid administered orally 3 hours prior to surgery to enhance visualization of malignant brain tumor.
46047814|NCT04311476|Other|Autologous Umbilical Cord Blood Mononuclear Cells infusion Therapy|Evaluate Autologous cord blood cells infusion on prevention of bronchopulmonary dysplasia in very preterm neonates
46047815|NCT04311476|Drug|0.9% Sodiun Chloride|0.9% Sodiun Chloride in control group
46047816|NCT00670852|Procedure|X-rays and CT scan|CT Scan x-rays
46047817|NCT00671008|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46047818|NCT00671008|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46047819|NCT00911716|Biological|bevacizumab|
45358608|NCT00973869|Other|pharmacological study|
45358609|NCT00973869|Procedure|diagnostic endoscopic procedure|
45358610|NCT00973869|Procedure|therapeutic conventional surgery|
45358611|NCT02544672|Device|Myoelectric Elbow-Wrist-Hand orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
45358612|NCT00959439|Drug|Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)|
45358613|NCT00959439|Drug|Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)|
45358614|NCT04041492|Dietary Supplement|Supplementation with Vitamin D3 y K2|Supplementation at a dose of 1 capsule every 24 hours x 3 months
46047820|NCT00911716|Drug|cyclophosphamide|
46047821|NCT00911716|Drug|docetaxel|
46047822|NCT00911716|Procedure|adjuvant therapy|
45358615|NCT00971373|Other|Vestagen scrubs|antimicrobial impregnated textile
45479488|NCT04319094|Behavioral|PEERS|Peer mentors deliver depression care that include social support and coping skills, focused on goal setting and small behavioral changes.
45479489|NCT04319094|Other|Social interaction|Study staff will provide a combination of 8 social interaction visits and phone calls to the participants randomized to this condition.
45687627|NCT05019846|Drug|Triptorelin Embonate|single administration before SRT starting
45687628|NCT05019846|Drug|Bicalutamide 50 mg|1 dose each day, 7 days before LHRH until 10 days after LHRH administration
46047823|NCT00912184|Device|Standard polyamide high flux membrane|Standard haemofiltration; CVVH; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hr, anticoagulation as clinically indicated, bicarbonate buffered replacement fluid
45687629|NCT05017298|Biological|Allogeneic adipose-derived stem cells|Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
45687630|NCT05014971|Behavioral|Tele-neurohub|Interdisciplinary care delivered using telemedicine (zoom) technology which includes neurologist, physical, occupational and speech therapy, social worker and dietician.
45479490|NCT02497222|Drug|RNS60|
46047824|NCT00912184|Device|High cut-off (super high flux) polyamide membrane|CVVH with standard haemofiltration settings; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hour, anticoagulation as clinically indicated, bicarbonate-buffered replacement fluid
45479491|NCT02497222|Drug|Normal Saline|
45687631|NCT05014256|Behavioral|STEPS Health System Outreach intervention|STEPS Transplant Social Worker Education and Outreach, STEPS Transplant Coordinator Outreach
45687632|NCT05011578|Radiation|Radiographic assessment|Radiographic assessment after at least 10 years after radiocapitellar surgical treatment
45687633|NCT05006482|Other|Best Practice|Receive usual follow-up survivorship care
46047825|NCT00677326|Biological|VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
46047826|NCT00595582|Dietary Supplement|curcumin + bioperine|Subjects who are currently in the primary Mild Cognitive Impairment study will be asked to be treated with 5.4 grams of curcumin + bioperine per day (900 mg pills, two pills 3x/day with meals) for 24 months concordant with the last two years of the primary longitudinal Mild Cognitive Impairment study.
46047827|NCT00677404|Biological|BM-MNC injection|Bone marrow aspiration A total volume of 400 ml bone marrow will be aspirated from the iliac crest under epidural anaesthesia
46047828|NCT04031482|Other|No intervention, only standard care|"The aim of this registry is to expand on previous findings in the field of diagnostic and therapeutic pathways for patients with Crohn's disease, ulcerative colitis and indeterminate colitis undergoing routine administration of a targeted therapy (biologics or another targeted therapy such as Janus kinase therapy) and various different treatment approaches. A data pool is to be generated for this purpose, in order to~analyse disease progression~systematize findings about treatment processes~identify potential influencing factors~review any new diagnostic procedures~identify potential test subjects for further study~evaluate the safety of various treatment concepts"
46047829|NCT04153474|Procedure|large-bore nephrostomy tube (LBNT)|large-bore 22 french nephrostomy tube (LBNT)
46047830|NCT04153474|Procedure|small-bore nephrostomy tube (SBNT)|small-bore 14 french nephrostomy tube (SBNT)
46047831|NCT00671944|Other|Low protein diet|Low protein diet for 6.5 weeks
46047832|NCT00680446|Drug|Immunoglobulin G (Ig NextGen 16%)|Weekly or Bi-weekly subcutaneous administration of Immunoglobulin G
46047833|NCT00672022|Drug|Zavesca (Miglustat)|
46047834|NCT04150666|Dietary Supplement|Hydration|the same with arm descriptions
46047835|NCT00677638|Device|Ventor Embracer|Implantation of Ventor Embracer
46047836|NCT00680602|Behavioral|Group Cognitive Behavior Therapy|Structured protocol described by Cordioli et al., 2003
46047837|NCT00680602|Drug|SSRI (fluoxetine, sertraline, paroxetine, citalopram)|Fluoxetine (80mg/day or maximum tolerated dosage) Sertraline (200mg/day or maximum tolerated dosage) Paroxetine (60 mg/day or maximum tolerated dosage) Citalopram (60 mg/day or maximum tolerated dosage)
46047838|NCT00677716|Drug|131I-chTNT-1/B MAb (Cotara)|Given as a single interstitial infusion over approximately 25 hours at a dose of 2.5 mCi/cc.
46047839|NCT00677794|Drug|Clear fluids|Clear fluids only after lunch.
46047840|NCT00677794|Drug|Picosalax|Two sachets the evening prior to Video Capsule Endoscopy (VCE).
46047841|NCT00677794|Drug|Polyethylene glycol|Two (2) litres the evening prior to Video Capsule Endoscopy (VCE).
46047842|NCT02628496|Drug|Fluorescein injection, USP 10%|-2.5 ml intravenous 10 minutes before procedure
45687634|NCT05006482|Other|Comprehensive Geriatric Assessment|Complete geriatric assessment
45687635|NCT05006482|Other|Educational Intervention|Participate in survivorship health education sessions
45687636|NCT05006482|Other|Exercise Intervention|Participate in EXCAP program
46047843|NCT02628496|Device|Confocal laser microlaryngoscopy|
46047844|NCT02628496|Procedure|Biopsy (standard of care)|
46047845|NCT02628496|Procedure|KTP laser photoablation (standard of care)|
45479492|NCT04948112|Device|real time continuous glucose monitor|CGM sensor will read blood glucose every 10 minutes
45479493|NCT04948112|Device|blinded continuous glucose monitor|CGM that records blood glucose but not visible to patient
45687637|NCT05006482|Other|Questionnaire Administration|Ancillary studies
45687638|NCT05006482|Procedure|Tailored Intervention|Participate in GEM consultation
45687639|NCT05004233|Biological|Blood collection before antiplatelet treatment|Blood sample (17ml) will be collected in the neurovascular department to be processed for platelet ultrastructural analysis before the onset of an antiplatelet treatment
45687640|NCT05004233|Biological|Blood collection after antiplatelet treatment|"A follow-up will be carried out 5 to 8 days after the initiation of the treatment.~A blood test will be taken in the NeuroVascular Unit"
45687641|NCT05004025|Device|Novocure Optune|Novacure Optune with Opdivo and Yervoy
45687642|NCT05004025|Drug|Opdivo|Novacure Optune with Opdivo and Yervoy
45687643|NCT05004025|Drug|Yervoy|Novacure Optune with Opdivo and Yervoy
45687644|NCT04999163|Device|Aortix System|Aortix is indicated as a partial circulatory support device to increase renal perfusion and reduce the incidence of acute kidney injury (AKI) in patients undergoing cardiac surgery who are at heightened risk of developing AKI.
45844505|NCT05736510|Other|Control|"When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the control group, the allocated file is silent. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation."
45844506|NCT05736432|Dietary Supplement|Blueberries|Experimental condition
45844507|NCT05736432|Dietary Supplement|Placebo|Placebo condition
46047846|NCT00680680|Drug|Dutasteride|Patients will continue on their alpha blocker in addition to Dutasteride 0.5mg daily for a maximum of 3 months
45687645|NCT04998240|Biological|BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|"The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~Mode of Administration:~Intramuscular~Storage Conditions: 2°C to 8°C"
45687646|NCT04998240|Biological|Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein),|"Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein), manufactured by Johnson and Johnson in the United States of America.~Dose formulation: One dose (0.5 ml) contains contains 5 x 10 10 virus particles~Mode of administration: Intramuscular~Storage Conditions: 2°C to 8°C"
45687647|NCT04998240|Biological|Placebo - Normal saline (0.9% sodium chloride solution)|"Placebo - Normal saline (0.9% sodium chloride solution)~Dose formulation: Not Applicable~Mode of administration: Intramuscular~Storage conditions: 15°C to 30°C"
45752056|NCT04660721|Combination Product|TACHOSIL®|TACHOSIL® is a fibrin sealant patch composed of an equine collagen patch coated with Human Fibrinogen and Human Thrombin.
45752057|NCT04271137|Combination Product|3D printed PEEK onlay|3d computer-designed Orbital onlay
45752058|NCT04271137|Combination Product|Pre-bent orbital mesh|Pre-bent orbital mesh on 3d printed template
45844508|NCT05735964|Drug|Indocyanine green|Intravenous and endoluminal dosing
45844509|NCT05735808|Behavioral|Physician based education|Regular education provided by physician
45844510|NCT05735808|Behavioral|VR based education|VR based education
45844511|NCT05735574|Other|IPG infections|Infected IPGs
46047847|NCT04150588|Drug|Efrin drops|The amount that the eyelid rise after Erin drops before surgery
46047848|NCT04150744|Combination Product|radiofrequency ablation|take advantage of RFA to destroy hepatocellular carcinoma by high temperature
46047849|NCT04150432|Device|Edmon|New device for exhaled propofol concentration measurements
46047850|NCT00808015|Drug|varenicline|Champix will be prescribed as per usual practice and at the sole discretion of the physician
46047851|NCT00680758|Drug|cisplatin|"Dose Level: -3 20mg/m2/week 3-6 patients~Dose Level: -2 20mg/m2/week 3-6 patients~Dose Level: -1 25mg/m2/week 3-6 patients~Dose Level: 1 25mg/m2/week 3-6 patients~Dose Level: 2 25mg/m2/week 3-6 patients~Dose Level: 3 25mg/m2/week 3-6 patients"
45358616|NCT00862212|Behavioral|Brief Alcohol Intervention|At the Week 6 visit, all subjects who are randomized to the Experimental Group will receive the experimental brief alcohol intervention. The intervention will be in addition to a standard 20-minute physician visit, for a maximum of 30 minutes. The physician will use the Updated NIAAA Clinician's Guide to ask about drinking and will draw the connection between social anxiety and drinking and how they relate to each other. Subjects will be asked to consider making changes in their drinking and if they agree, a goal will be set and progress toward that goal will be monitored at subsequent visits.
45358617|NCT00973947|Other|questionnaire administration|
45358618|NCT00973947|Radiation|3-dimensional conformal radiation therapy|
45358619|NCT00973947|Radiation|radiation therapy treatment planning/simulation|
45358620|NCT00857298|Behavioral|Dietary Intervention|The nutrition curriculum will involve weekly group and individual sessions. The initial calorie goal will be ~750 kcal below the resting energy equivalent, and adjusted as needed to achieve weight loss targets.
45358621|NCT00971451|Other|cryotherapy|20 minutes of knee joint cryotherapy - ice bag application
45358622|NCT00971451|Other|TENS|continuous use of TENS during the exercise session
45358623|NCT00857376|Dietary Supplement|Alpha lipoic acid at 3 doses compared to placebo|This is a randomized study comparing the antioxidant effects of 3 doses of alpha lipoic acid (total of 600 mg daily, 1200 mg daily and 1800 mg daily) compared to placebo. These doses will be taken as 2 pills 3 times a day for 8 to 10 weeks.
45687648|NCT04997824|Procedure|Artificial Intelligence-based atrial fibrillation catheter ablation|"Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~AI-guided prediction for poor responder of AFCA in the outpatient clinic~Sharing information on the AI prediction with the patient and family member~AFCA after consent to the procedure~Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~Monitoring esophageal temperature~Evaluation of Procedure and ablation time, and complication afer procedure~Post-procedure rhythm follow-up is carried out according to the study design above."
45687649|NCT04997824|Procedure|Medical Therapy|"Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~Decision for AFCA based on clinical guidelines and the experience of the attending physician~AFCA after consent to the procedure~Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~Monitoring esophageal temperature~Evaluation of Procedure and ablation time, and complication afer procedure"
45844512|NCT05735418|Dietary Supplement|GI Biome #7|It comprises probiotics (Lactobacillus fermentum, Lactobacillus acidophilus, Lactobacillus plantarum, and Bifidobacterium animalis ssp. lactis) and prebiotics (vitamin B2., Korean red ginseng, and etc.). The administration dosage of probiotics is 5×10^8 CFU/day.
46047852|NCT00680758|Drug|everolimus|"Dose Level: -3 20mg/m2/week 3-6 patients~Dose Level: -2 20mg/m2/week 3-6 patients~Dose Level: -1 20mg/m2/week 3-6 patients~Dose Level: 1 20mg/m2/week 3-6 patients~Dose Level: 2 25mg/m2/week 3-6 patients~Dose Level: 3 30mg/m2/week 3-6 patients"
46047853|NCT00680758|Drug|paclitaxel|"Dose Level: -3 65mg/m2/week 3-6 patients~Dose Level: -2 70mg/m2/week 3-6 patients~Dose Level: -1 70mg/m2/week 3-6 patients~Dose Level: 1 80mg/m2/week 3-6 patients~Dose Level: 2 80mg/m2/week 3-6 patients~Dose Level: 3 80mg/m2/week 3-6 patients"
46047854|NCT04150198|Device|TEP/IRM|All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes). These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions. This visit lasts about 3 hours.
46047855|NCT00677872|Drug|PRX-08066|
45358624|NCT00974025|Dietary Supplement|Vitamin C|High-dose Vitamin C will be administered in 4 age-based dosing groups
46047856|NCT00677950|Procedure|Spinal fusion|Surgical procedure for lumbar spinal posterior decompression with concomitant posterolateral intertransverse process arthrodesis
45358625|NCT00974025|Dietary Supplement|Placebo|Placebo will be administered twice daily for four weeks
45358626|NCT00618072|Drug|metformin and rosiglitazone|4 week dosage escalation of metformin, 500 mg/day (or placebo) to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day(or placebo) added at weeks 3 and weeks 4 to a a total dose of 4 mg/day
45358627|NCT00959517|Drug|artesunate (AS)|Recommended dosage over 3 days (for all interventions)
45358628|NCT00959517|Drug|sulphadoxine-pyrimethamine (SP)|
45358629|NCT00959517|Drug|Chloroquine (CQ)|
45358630|NCT00959517|Drug|primaquine (PQ)|
45358631|NCT04008771|Device|SeeQ CdSe 655 ALT|SeeQ CdSe 655 Alt is a sterile colloidal solution of coated CdSe nanoparticles in a borate buffer suitable for intraocular injection.
45358632|NCT00959595|Drug|EMLA cream|The study subjects are treated either by 50 g of a local anesthetic agent containing 2.5% Lidocaine and 2.5% Prilocaine (EMLA®, AstraZeneca - Södertälje, Sweden) or a placebo cream, applied to the lower leg. The cream is applied under occlusive bandage (plastic foam and a tube) for 1.5 hours circumferential to the lower leg 10-12 cm distally of the tibial tuberosity and the malleolus at ankle level. Administration of the treatment cream as well as removal after 1,5 hour and at sensory assessment after 1.5 hour and 24 hours, and interviewing the patient about subjective experience from the treatment are performed by an independent research nurse, not involved in the sensory assessment.
45358633|NCT00959595|Drug|EMLA cream|50g applied according to description of intervention
46047857|NCT05754229|Device|AI-assisted colonoscopy|The patients will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
46047858|NCT02628184|Other|Maternity Services Development Programme|The Maternity Services Development Programme was implemented to improve care for local families (service users) involved with maternity services. The aim was to improve care during the early stages of a family's development and to establish foundations for long-term well-being. One aspect of the programme worked to improve the delivery of care by facilitating collaboration and joint-planning between service providers. The programme uses local city Children's Centres to co-locate services (different agencies or professionals who are working within the same locality). The aim of co-location was to promote stronger collaboration between maternity services and other service provider agencies to develop stronger partnerships, and to help identify those who are (or who may become) vulnerable.
46047859|NCT00678106|Drug|Dalbavancin|Subjects weighing > 60 Kg: 1 gram IV single dose Subjects weighing < 60 Kg: 15 mg/Kg IV
46047860|NCT00810199|Drug|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg IV every 4 weeks.
45358634|NCT00666926|Drug|PF00562271|125 mg twice daily [BID] with food, tablet
45358635|NCT00666926|Drug|PF00562271|125 mg BID with food, tablet
45358636|NCT00666926|Drug|PF00562271|125 mg BID with food, tablet
45358637|NCT00666926|Drug|PF00562271|125 mg BID with food, tablet
45358638|NCT00974103|Other|exercise advise|Exercises
45358639|NCT00974103|Other|chiropractic treatment and exercises|Manipulation, mobilisation, soft tissue work, ergonomic and exercise advise. Maximum 12 treatments
45358640|NCT00865410|Drug|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fasting conditions
45358641|NCT00865410|Drug|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
45358642|NCT00974181|Device|Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (10 µg Paclitaxel)
45358643|NCT00974181|Device|Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (30 µg Paclitaxel)
45358644|NCT00971607|Drug|Oxygen + Sevoflurane|Oxygen with end-tidal MAC of Sevoflurane 0.5 during PCI.
45358645|NCT00971607|Drug|Oxygen (placebo)|Control will receive oxygen only.
45479494|NCT02491606|Drug|Tafenoquine|Tafenoquine 200mg and 400 mg
46047861|NCT00810199|Drug|methotrexate|Approximately 15-17 mg methotrexate capsule orally once a week.
45358646|NCT00865488|Biological|ADHEXIL|Adhesions prevention
45358647|NCT00862368|Behavioral|PAM|Visit 1 included asthma education (or child wellness for healthy children), expired air carbon monoxide feedback, Motivational Interviewing, and techniques to accelerate the participants readiness to quit. Visit 2 included a follow up on the child's asthma (PAM and PAM-Enhanced only), assessing the smoker's motivation to quit, feedback on CO readings and air sampler results (smoke exposure to the child), risks of smoking, and benefits of quitting. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
45479495|NCT02491606|Other|Placebo|Placebo
45479496|NCT05429944|Other|Motor Relearning Program|The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks.
46047862|NCT00810199|Drug|placebo|Placebo matching methotrexate capsule taken orally once a week.
45479497|NCT05429944|Other|Proprioceptive Neuromuscular Facilitation|"The techniques administered included Rhythmic Initiation, Slow Reversal and Agonistic Reversal.~The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks."
45479498|NCT05429944|Other|Conventional Physical Therapy|The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks.
45479499|NCT05255354|Device|ClonoSEQ|Cancer clonotype sequences are identified in diagnostic 'ID' samples and then sequence frequencies are measured in follow up samples.
45479500|NCT03353753|Drug|DCC-2618|Oral KIT/PDGFRA kinase inhibitor
45479501|NCT03353753|Drug|Placebo Oral Tablet|Placebo
45479502|NCT03329638|Drug|DE-127 Ophthalmic Solution low dose|Low dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
45479503|NCT03329638|Drug|DE-127 Ophthalmic Solution medium dose|Medium dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
45479504|NCT03329638|Drug|DE-127 Ophthalmic Solution high dose|High dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
45479505|NCT03329638|Drug|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution dosed once daily for 12 months
46047863|NCT00877006|Drug|bendamustine|
46047864|NCT00877006|Drug|rituximab|
46047865|NCT00877006|Drug|vincristine|
46047866|NCT00877006|Drug|prednisone|
46047867|NCT00877006|Drug|cyclophosphamide|
46047868|NCT00877006|Drug|doxorubicin|
46047869|NCT00678184|Drug|Atorvastatin|80 mg atorvastatin on two following days each
46047870|NCT02608255|Other|blood samples|
46047871|NCT00876928|Drug|vitamin D|liquid vitamin D3 dissolved in medium chain triglyceride once a week
46047872|NCT00876928|Drug|placebo|medium chain triglyceride given once per week
46047873|NCT02627950|Drug|Morphinhydrochloricum|5 mg morphine intravenously
46047874|NCT02627950|Drug|Metoclopramide|10 mg MCP intravenously
46047875|NCT02627950|Drug|Ticagrelor|180 mg ticagrelor orally
45358648|NCT00862368|Behavioral|PAM-Enhanced/Asthma Counseling Phone Calls|PAM-Enhanced/Asthma counseling calls were made over the 4 months following in-home counseling and focused on: 1) checking in on the child's asthma, 2) motivating quit attempts, and 3) preventing relapse among quitters. The final phone call (#6) included feedback on the 2nd set of air samplers placed in the home and with the child after phone call 5. Only the PAM-Enhanced/Asthma condition received this 2nd round of ETS feedback. A printed feedback report was provided to participants. If still smoking, counseling focused on ETS reduction and motivation to change. If quit, counseling focused on reinforcement of successful behavior change and motivation to stay quit. Motivational Interviewing techniques were used. Free nicotine patch tx was given if they were ready to quit within 30 days.
45358649|NCT00862368|Behavioral|Follow-Up Phone Calls - Child Wellness Topic|Over the 4 months following in-home counseling visits, subjects in the PAM-Asthma and PAM-Healthy conditions received 6 phone calls that included an asthma check-in (PAM-Asthma only) and discussion of a child wellness topic. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
45358650|NCT00971685|Drug|Lenalidomide and dexamethasone|RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
45358651|NCT03861052|Drug|Tirzepatide|Administered SC
45358652|NCT03861052|Drug|Dulaglutide|Administered SC
45358653|NCT00971763|Biological|rituximab|
45358654|NCT00971763|Drug|cyclophosphamide|
45358655|NCT00971763|Drug|gemcitabine hydrochloride|
46047876|NCT02627950|Drug|Isotonic sodium chloride|10 ml NaCl 0.9% intravenously
46047877|NCT00807937|Drug|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
45358656|NCT00971763|Drug|prednisolone|
45358657|NCT00971763|Drug|vincristine sulfate|
45358658|NCT04018170|Drug|Study drug|oral administration, once daily. The doses will be ascending per cohort from 10 mg to 600 mg
45358659|NCT04018170|Drug|Placebo|oral administration, once daily. The matching placebo doses will be ascending per cohort from 1 to 4 tablets
45358660|NCT00785252|Device|Powered Intraosseous device (EZIO)|EZIO
45358661|NCT00785252|Device|standard central line|placement of a central line
45358662|NCT00857688|Drug|Bismu-Jet|Bismuth sodium tartrate, neomycin sulfate, procain hydrocloride
45844513|NCT05735418|Dietary Supplement|Placebo|The placebo consists of daily administration of the placebo pills made up of 100% maltodextrin for four weeks.
46047878|NCT00807937|Drug|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
46047879|NCT00807937|Drug|Lorazepam|4 tablets and 1 capsule taken twice a day for 28 days
46047880|NCT00807937|Drug|Placebo|4 tablets and 1 capsule taken twice a day for 28 days
45358663|NCT00857688|Other|Placebo|Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
45358664|NCT00959829|Other|Music and message|Experimental group: music and message Control group: silence
45358665|NCT00781196|Drug|folic acid|capsule 0.5 mg once a day
45358666|NCT00781196|Drug|placebo|capsule, once a day
45358667|NCT00865644|Drug|Imiquimod 5% Cream|Applied topically to three tumors 5 times per week for a full 6 weeks
45358668|NCT00971919|Other|questionnaire administration|
45358669|NCT00971919|Procedure|assessment of therapy complications|
45358670|NCT00971919|Procedure|psychosocial assessment and care|
45358671|NCT00971919|Procedure|quality-of-life assessment|
45358672|NCT00785330|Drug|standard GVHD prophylaxis|Application of tacrolimus from day -1 with a goal of tacrolimus serum concentration of 10 ng / ml Aplication of mycophenolat mofetil from day +1 to day +28 in a dose of 2 x 1g per day
45358673|NCT00785330|Drug|rituximab|Patients receiving 375 mg/ m2 of rituximab at weeks 3, 4, 5, 6, 25, 26, 27, 28 after allogeneic stem cell transplantation in addition to standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
45358674|NCT00974649|Behavioral|self-report questionnaire|validated self-report questionnaires on psychosocial determinants
45358675|NCT02555150|Drug|PRC-063|Oral extended-release capsule
46047881|NCT00678340|Device|WACA and PVI|Wide area circumferential ablation (WACA) in the pulmonary vein antrum with subsequent pulmonary vein isolation (PVI) with a single tip irrigated catheter.
46047882|NCT00678340|Device|PVAC|Circumferential ablation with a circular ablation catheter (Ablation Frontiers) to electrical silence.
46047883|NCT00681070|Other|Arm 2: Absorbable sutures|use of absorbable catgut sutures in pediatric facial lacerations
45358676|NCT02555150|Drug|lisdexamfetamine dimesylate|Oral capsule
45358677|NCT02555150|Drug|Placebo|Oral placebo capsule
45358678|NCT05279469|Other|no intervention, just observational for D-Dimer level in blood|observation for basal D-Dimer and 48 hours later D-Dimer in blood for ICU SARS.COV.2 patients
46047884|NCT00681070|Other|Arm 1: non-absorbable sutures|Use of non-absorbing sutures
45358679|NCT00790946|Drug|Valsartan|Valsartan 80 to 160 mg
45358680|NCT05263102|Device|Vaginal Moisturizing Gel|All eligible subjects will received the Vaginal Moisturizing Gel twice per week, total in 8 weeks
46047885|NCT00681148|Drug|Botox injection|Intraprostatic injection of Botox (100 units for < 30 cc prostate; 200 units for > 30 cc prostate) administering 2 transperineal injections into both lateral lobes of the prostate (25-50 units per injection), just 5-10 mm proximal to the bladder neck.
46047886|NCT00681148|Drug|Saline injection|Saline injection, administering 2 transperineal injections into both lateral lobes of the prostate (1-2 cc per injection), just 5-10 mm proximal to the bladder neck.
46047887|NCT04935229|Drug|SD-101|SD-101 doses will be delivered via hepatic artery infusion using pressure enabled drug delivery using the TriNav device
45358681|NCT05179239|Drug|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102
45358682|NCT05179239|Drug|SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102|SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102
45358683|NCT05179239|Drug|Placebo + paclitaxel + cisplatin/carboplatin ± BP102|Placebo + paclitaxel + cisplatin/carboplatin ± BP102
45358684|NCT04046666|Device|Functional near infrared spectroscopy|Functional near infrared spectroscopy will be adopted to assess the metabolic characteristics of the Heart and Lung meridians. The probes will be left at 4 measurement sites, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
46047888|NCT04935229|Biological|Nivolumab|During Cohort B, nivolumab will be administered together with SD-101 and during Cohort C, it will be administered with ipilimumab and SD-101
46047889|NCT04935229|Biological|Ipilimumab|During Cohort C, ipilimumab will be administered together with nivolumab and SD-101
46047890|NCT04935229|Biological|Nivolumab and Relatlimab|During optional Cohort C1, nivolumab and relatlimab will be administered with SD-101
45358685|NCT04046666|Procedure|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Heart meridian along the forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the forearm."
45358686|NCT04527874|Behavioral|VITAL model|"The concept of the VITAL, an automated differentiated service delivery model (aDSDM), is to use viral load results, other clinical characteristics (TB screening results and CD4 cell counts, comorbidities) and participants' preference to automatically triage participants into groups requiring different levels of attention and care. Innovatively, triaging of participants will be done automatically making use of a dedicated mobile App and a viral load database platform.~To ensure effective flow of information and empowerment of patients, viral load results and other relevant information is sent directly to participants' phones, whereas health care providers receive results directly on their study tablet together with the recommended action. Further features of the platform are preference-based tailored adherence reminders and automated calls to participants for symptomatic tuberculosis screening."
45844514|NCT05735028|Drug|Centipeda minima+PD-1/PD-L1 inhibitor|Before routine anti-PD-1/PD-L1 treatment, patients were treated with Centipeda minima, and15g Centipeda minima decoction was taken twice a day for 5 consecutive days.
45358687|NCT00972075|Drug|melatonin (Circadin)|2 mg prolonged release melatonin tablets once daily 2 hours before going to bed
45358688|NCT00972075|Drug|placebo|one tablet per day 2 hours before going to bed
45358689|NCT00974727|Other|Garden Fit|8-week summer gardening program. 9am-12pm on Monday, Wednesday, Friday and 9am-12:30pm on Tuesday and Thursday. Activities included gardening (preparing soil for planting, planting seeds and seedlings, mulching, weeding, watering, and harvesting), preparing meals with fresh foods from the garden, and other garden activities and games.
45358690|NCT00785408|Drug|AC2307|subcutaneous, twice daily, low dose
45358691|NCT00785408|Drug|placebo|subcutaneous, twice daily, low dose
45358692|NCT00785408|Drug|AC2307|subcutaneous, twice daily, middle dose
45358693|NCT00785408|Drug|placebo|subcutaneous, twice daily, middle dose
46047891|NCT02627716|Procedure|SOS Plan|"It is a customised procedure that involves a meeting (crisis planning meeting) with the patient, their various medical and social referrers and any other person who they may have desired to invite.~The booklet outlines four avenues to consider:~Contact details / contact person~Treatment and current follow-ups~Medical care in the event of a crisis~Practical aid in the event of a crisis~Updating the SOS Plan every 6 months in the absence of hospitalisation or after each relapse that leads to an unscheduled psychiatric hospitalisation lasting more than two weeks."
45358694|NCT00785408|Drug|AC2307|subcutaneous, twice daily, high dose
45358695|NCT00785408|Drug|placebo|subcutaneous, twice daily, high dose
45358696|NCT00974805|Drug|Seretide 500 Accuhaler|Seretide 500 accuhaler one inhalation BD
45358697|NCT00781352|Drug|nitrous oxide|65% nitrous oxide administered during surgery
45358698|NCT00781352|Drug|nitrogen|Nitrogen administration during surgery
45358699|NCT00960219|Drug|D-amino acid oxidase inhibition (DAAOI-1)|1g/day(500mg BID), oral, for 6 weeks
45358700|NCT00960219|Drug|placebo|1# BID, oral, for 6 weeks
45358701|NCT02555774|Behavioral|cognitive training|cognitive training is held 2 times a week for 3 months, 90 minutes per 1 session. It includes cognitive exercise of multiple cognitive domains such as memory, attention, calculation, executive function and visuospatial function.
45358702|NCT02555774|Behavioral|lifestyle modification|education about lifestyle modification is done by investigators at the first day of the trial and the investigators conduct weekly phone call to participants to educate the lifestyle modifications
45358703|NCT00972231|Other|Medical Chart Summary|Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.
45687650|NCT04997200|Behavioral|One night's sleeplessness|A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.
46047892|NCT02608333|Behavioral|ESDM-12|"ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery."
45358704|NCT00791024|Drug|CRC-Pharma 001|50 mg
45358705|NCT00791024|Drug|lidocaine suspension|5.0 ml lidocaine suspension(20mg/ml) adm. 10 min. before oesophagogastroduodenoscopy.
45358706|NCT03897244|Drug|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)
45358707|NCT03897244|Drug|Bismuth High-dose dual therapy (rabeprazole, amoxicillin, tripotassium dicitrate bismuthate)|Bismuth-High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate bismuthate 300 mg qid, for 14 days)
45358708|NCT03897244|Drug|Amoxicillin-Metronidazole Bismuth quadruple therapy|Amoxicillin-Metronidazole Bismuth quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid + amoxicillin 1000 mg bid + metronidazole 500 mg tid, for 14 days)
45358709|NCT00974883|Procedure|Ultrasound of temporal and axillary arteries|Standardised assessment of temporal arteries and axillary arteries using high resolution ultrasound to detect halo, stenosis or occlusion
45358710|NCT00974883|Procedure|Temporal artery biopsy|Biopsy of temporal artery from symptomatic side
45358711|NCT00664742|Drug|Fluvastatin XL®|Fluvastatin extended release 80 mg
45358712|NCT04046354|Device|Ultrasound-guided Percutaneous Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
45358713|NCT04046354|Device|Ultrasound-guided Percutaneous Radiofrequency Ablation|Ultrasound-guided Percutaneous Radiofrequency Ablation
45479506|NCT03050450|Drug|25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 25 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
45687651|NCT04996823|Drug|Ipilimumab|Participants will receive ipilimumab 3mg/kg IV every 3 weeks for up to 4 doses.
46047893|NCT02608333|Behavioral|control group|"heteregenous as usual community intervention"
45358714|NCT00781430|Drug|Neratinib (HKI-272)|Neratinib 40-mg oral tablets. SINGLE DOSE of 120-mg (3 x 40-mg tablets)
45358715|NCT00511342|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
45358716|NCT00511342|Drug|LNG-EE|Levonorgestrel and Ethinyl Estradiol Tablets, 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
46047894|NCT04149652|Diagnostic Test|Lung Elastosonography|Bedside lung ultrasound integrated with lung elastosonography, performed by using the convex probe of an Esaote Mylab Seven ultrasound system (Esaote, Genova, Italy), equipped with the strain elastography module ElaXto©.
45358717|NCT03931785|Drug|MD-7246|Oral tablet
45358718|NCT03931785|Drug|Placebo|Matching oral tablet
45358719|NCT00666536|Drug|valsartan and amlodipine|
45358720|NCT00666536|Drug|valsartan and amlodipine|
45358721|NCT00519532|Drug|Rotigotine|"Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum rotigotine dose allowed is 16mg/24h"
45358722|NCT00666458|Drug|saxagliptin|tablet, per oral, once daily
45358723|NCT00666458|Drug|sitagliptin|capsule, per oral, once daily
45358724|NCT00974961|Drug|bupivacaine, levobupivacaine|intrathecal injection 15~20mg(for Levobupivacaine) or 10~15mg(for Bupivacaine) once
45358725|NCT00975039|Drug|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2.5 and 5 mg/kg, using 753nm laser light at a fixed power (150 mW/cm) and light energy (200 J/cm). Illumination in the bile duct is performed by inserting a diffusing fiber, with cylindrical uniform light distribution, in a transparent standard ERCP catheter and by positioning, under radioscopy, the illumination tip of the diffusing fiber in front of the lesion.
45358726|NCT00511108|Drug|Comparator: sitagliptin phosphate|sitagliptin phosphate 100 mg as oral tablets. Each patient will be administered 1 tablet once daily.
45479507|NCT03050450|Drug|50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 50 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
45687652|NCT04996823|Drug|Axitinib|Participants will take 5 mg Axitinib twice daily by mouth for up to 35 cycles (24 months)
46047895|NCT02627482|Device|Fetal heart rate monitor (Monica AN24)|"The AN24 is a portable, battery powered device, developed in the UK and designed to monitor passively an unborn baby in the antenatal period. The device is CE marked and is attached via a cable assembly which in turn attaches to five standard disposable electrodes placed on the abdomen of a pregnant woman. It is intended for ambulatory use in either the home or hospital environment.~The AN24 has had rigorous checks in the UK and has been used in many European countries. No hazards have been identified that could compromise the safety of, or cause harm to the fetus or the mother. The only potential issue identified is a local reaction under the electrodes. Nonetheless, the electrodes used are the standard disposable ECG electrodes, used routinely for adult ECG measurements."
45358727|NCT00511108|Drug|Comparator: pioglitazone|pioglitazone 30 mg will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
45358728|NCT00511108|Drug|Comparator: placebo to pioglitazone|pioglitazone 30 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
45358729|NCT00511108|Drug|Comparator: placebo to sitagliptin|sitagliptin phosphate 100 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
45687653|NCT04995341|Device|Investigational ultracompact OCT and OCTA system|Handheld bedside retinal OCT and OCT angiography imaging with an investigational portable system with ultracompact handpiece
45358730|NCT00785642|Drug|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)|
45358731|NCT00781586|Dietary Supplement|One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350)|One A Day Weight Smart Advanced 1 tablet at 1st visit
45358732|NCT00781586|Drug|Caffeine|Caffeine 100 mg 1 tablet at 1st visit
45358733|NCT00781586|Drug|Placebo|Placebo 1 tablet at 1st visit
45358734|NCT00785720|Drug|Dermacyd PH_DETINBACK (Lactic Acid)|
45358735|NCT00781664|Other|AN2718|AN2718 Cream SF Vehicle, Daily for up to 21 days
45844515|NCT05735028|Drug|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor
45358736|NCT00781664|Drug|AN2718|AN2718 Cream SF, 0.3%, Daily for up to 21 days
45358737|NCT00781664|Drug|AN2718|AN2718 Cream SF, 1%, Daily for up to 21 days
45479508|NCT03050450|Drug|100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 100 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
46047896|NCT04029259|Diagnostic Test|Brain MRI|Brain MRI diagnoses tromboembolic lesions or bleeding to the cerebrum and is part of preoperative diagnostic tests before carotid surgery. After surgery brain MRI may present New lesions related to surgery, clinically significant or insignificant. Our goal is to evaluate the relevance of this modality in carotid surgery..
46047897|NCT00681226|Drug|Ramipril or matching placebo|10 mg Ramipril or matching placebo once daily for 6 months
46047898|NCT00681304|Other|ultrasound scan|The only study procedure involved in this project is for subjects to undergo an ultrasound scan during their radiation therapy simulation. The ultrasound is done at this time, so it can be co-registered to the routine breast treatment planning CT scan.
45358738|NCT00781664|Other|AN2718|AN2718 Gel Vehicle, Daily for up to 21 days
45358739|NCT00781664|Drug|AN2718|AN2718 Gel, 1.5%, Daily for up to 21 days
45358740|NCT00781664|Drug|AN2718|AN2718 Gel, 2.5%, Daily for up to 21 days
45358741|NCT00781664|Drug|AN2718|AN2718 Gel, 5%, Daily for up to 21 days
45358742|NCT00781664|Drug|AN2718|AN2718 Gel, 7.5%, Daily for up to 21 days
45358743|NCT00781664|Other|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
45687654|NCT04995341|Device|retinal photographs|retinal photographs with a commercial portable bedside widefield fundus camera system
45844516|NCT05734950|Other|Translational study|Non-interventional, translational study
45358744|NCT00785876|Other|LRAR Implementation|"Pre-LRAR - no changes in the usual procedures for the first 26 weeks except for flagging of all paediatric charts with ankle injuries, ED documentation which will not refer to the LRAR and phone follow up.~Post-LRAR: At 27 weeks, in addition to the aforementioned ED collection sheet and phone follow up, the implementation strategy for the LRAR rule and related management will be introduced at the intervention hospitals."
45358745|NCT02554916|Behavioral|Dual-Belt Exercise|The dual-belted exercise treadmill can control the speeds of the right and left legs individually. When asymmetric, the dual-belt treadmill imposes mechanical and sensory perturbations independently to each leg such that the central nervous system (CNS) must solve and adapt to the challenge to maintain walking.
45358746|NCT02554916|Behavioral|Treadmill Exercise|The treadmill exercise will maintain the speed of the right and left leg together while walking.
45358747|NCT02554916|Other|Usual Care|This group will not be assigned to a treadmill but is as a non-exercising control group.
45358748|NCT02554916|Device|Dual-Belt Treadmill|
46047899|NCT04302961|Other|Auditory Feedback|Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving no feedback. Participants will be instructed to walk on a treadmill at their desired pace in a manner that does not cause the auditory tool to elicit a noise.
45358749|NCT00791570|Biological|VEGFR1 and VEGFR2|Biological: VEGFR1 and VEGFR2 Patients will be vaccinated once a week for 12 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
45358750|NCT00510952|Drug|Insulin Lispro Protamine Suspension|Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
45358751|NCT00510952|Drug|Insulin Glargine|Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
46047900|NCT04302961|Other|No Feedback|Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving no feedback. Participants will be instructed to walk on a treadmill at their desired pace in a manner that they perceive to be their normal walking speed and mechanics.
45844517|NCT05734872|Device|Virtual Reality Technology|Make a pair of glasses through virtual reality technology, through which participants can observe and participate in the treatment process.
46047901|NCT04148950|Other|Kinesio Tape|
45358752|NCT00617604|Drug|Alefacept|IV and subcutaneous injection
45358753|NCT00617604|Drug|placebo|IV and subcutaneous injection
45358754|NCT00617604|Drug|Tacrolimus|The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.
45358755|NCT00617604|Drug|Mycophenolate Mofetil|Mycophenolic mofetil was administered as 750 mg twice per day orally
46047902|NCT04148950|Other|Compression Stockings|
45358756|NCT00617604|Drug|Steroids|"Methylprednisolone or equivalent:~Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus~Prednisone or equivalent:~Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally"
45358757|NCT00865722|Procedure|Remote Postconditioning|Lower limb compression using a cuff inflated to 200 mmHg for 5 ' followed by 5' of reperfusion fo three times during 30'
45358758|NCT01012570|Drug|Application of Adalimumab|Adalimumab will be applied according to manufacture's instruction and official guidelines.
45358759|NCT01012648|Drug|Fluid resuscitation|Volume resuscitation
45358760|NCT01012648|Drug|HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution|Volume Resuscitation
45358761|NCT02544594|Device|Extra-Corporal Life Support (ECLS)|Extra-Corporal Life Support (ECLS) (from Sorin)
45844518|NCT05734872|Other|Routine mental health course training|Conduct mental health education for patients by making a speech.
46047903|NCT04148950|Other|Exercise Program|
46047904|NCT02627014|Other|Manual therapy|"6 treatments: 2 treatments for week~1 treatment = 30 minutes"
46047905|NCT02627014|Other|Home physical therapy|once a day: 15 minutes
46047906|NCT02627014|Other|Manual therapy in cervical region|"6 treatments: 2 treatments for week~1 treatment = 30 minutes"
45358762|NCT00858000|Other|Retrospective analysis of already archived samples|RNA extracted from tissue samples already archived
45358763|NCT02544438|Drug|Astarabine (BST-236)|"Cohort # Astarabine Dose Number of Patients~0.5 gr/m2 (0.3 age>50) 3~1.5 gr/m2(0.8age>50) 3~3.0 gr/m2(1.5 age>50) 3~4.5 gr/m2(2.3 age>50) 6~4.5 gr/m2 (no age limit) 3 up to 6~6 gr/m2 (no age limit) 3 up to 6~Total number of patients: up to 24"
45358764|NCT03843216|Other|observation|patients not treated
45687655|NCT04992611|Behavioral|Sleep Extension (Early)|Following a periods of time meant to stabilize their sleep patterns and to induce mild sleep restriction, participants will be randomly assigned to one of two sleep extension conditions, both of which are designed to allow recommended sleep duration. The Early Sleep Extension condition does so by keeping rise time the same as the sleep restriction period, but extending sleep by going to bed earlier. This produces a sleep extension that is aligned for Morning Larks and misaligned for Night Owls.
46047907|NCT02627014|Other|Home physical therapy in cervical region|once a day: 15 minutes
46047908|NCT02608411|Drug|ARQ197|
46047909|NCT00678964|Drug|Erlotinib|Erlotinib 150 mg, p.o., once daily
46047910|NCT00678964|Drug|Vinorelbine and Carboplatin|Vinorelbine 25 mg/m2, i.v., day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v., day 1 of every cycle
46047911|NCT04253977|Behavioral|HEALTH-P2|The HEALTH-P2 curriculum includes evidence based lifestyle change strategies to prevent excess gestational weight gain and postpartum weight retention embedded within and delivered as part of home visits.
46047912|NCT04253977|Behavioral|Usual Care|The Foundational (usual care) curriculum uses a strength-based, solution-focused model to provide parents with child development knowledge and parenting support, empowering parents as their child's first and most influential teacher.
45358765|NCT03843216|Other|Physiotherapic scoliosis specific exercise|Specific exercise according to the SEAS (Scientific Exercises Approach to Scoliosis) protocol
45358766|NCT03843216|Device|brace|different kind of braces being elastic, rigid or very rigid. All devices are custom made. The hours of application per day varied from 18 to 24h.
45358767|NCT00865878|Drug|Aminolevulinic Acid|20% aminolevulinic acid HCL (ALA) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) ALA-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
45358768|NCT00865878|Other|Vehicle|Vehicle ingredients only (VEH) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) VEH-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
45358769|NCT00661622|Drug|GM-CSF|2,000 mcg injected into the liver every 4 weeks alternating between right or left lobe when tumors present throughout liver.
45358770|NCT00661622|Procedure|Embolization|A catheter will be introduced to one of the hepatic arteries by way of the femoral artery (groin) to allow injection of GM-CSF in combination with ethiodized oil and gelatin sponge providing a temporary blockage of the blood supply from the hepatic (liver) artery
45358771|NCT00781820|Drug|Bifonazole cream 1%|1 squeeze of Bifonazole cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
46047913|NCT05299138|Behavioral|Marriage and Relationship Enhancement Skills (MRES) Intervention|The Intervention group will be assigned a Case Manager and placed in the next available Marriage and Relationship Enhancement Skills (MRES) class that is convenient for their schedule. Intervention participants will attend classes weekly and meet with their Case Manager weekly, bi-weekly, or monthly, as needed. Study measures will be gathered from intervention participants at baseline, 10 weeks after baseline, and then 22 weeks after baseline. The following tools will be utilized at baseline and follow-up assessment: (1) REACH program eligibility screening (only conducted at baseline), (2) Information, Family Outcomes, Reporting, and Management (nFORM) system, (3) Family Environment Scale (FES), (4) Revised Dyadic Adjustment Scale (RDAS), and (5) Economic Self-Sufficiency Scale (ESS).
45358772|NCT00781820|Drug|Placebo cream|1 squeeze of Placebo cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
45687656|NCT04992611|Behavioral|Sleep Extension (Late)|Following a periods of time meant to stabilize their sleep patterns and to induce mild sleep restriction, participants will be randomly assigned to one of two sleep extension conditions, both of which are designed to allow recommended sleep duration. The Early Sleep Extension condition does so by keeping bedtime the same as the sleep restriction period, but extending sleep by rising later. This produces a sleep extension that is misaligned for Morning Larks and aligned for Night Owls.
45479509|NCT03050450|Drug|150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
46047914|NCT04912453|Procedure|Primary anastomosis|At laparotomy, the diseased segment of intestine will be resected and the patients will then receive primary anastomosis
45479510|NCT03050450|Drug|150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 230 mg/m2 days 1-7 and 15-21 of a 28 day cycle
45479511|NCT03329560|Biological|Oral fecal microbiota transplantation|All subjects will receive one dose per week for 6 weeks (6 total doses) of PRIM-DJ2727 oral capsules containing lyophilized microbiota product derived from 150 grams of healthy donor stool.
45687657|NCT04991506|Drug|ES102|The active ingredient of ES102 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4)
46047915|NCT04912453|Procedure|Enterostomy|At laparotomy, the diseased segment of intestine will be resected and the patients will then receive enterostomy
45358773|NCT00786110|Drug|Sorafenib|Treatment scheme consisted of oral Sorafenib 400 mg p.o. bid until disease progression.
45687658|NCT04991506|Drug|JS001|JS001 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
45687659|NCT04990544|Biological|202-CoV low adjuvant dose|standard dose of 202-CoV with low dose CpG / alum adjuvant
45687660|NCT04990544|Biological|202-CoV low antigen dose|low dose of 202-CoV with CpG / alum adjuvant
45687661|NCT04990544|Biological|202-CoV standard dose|standard dose 202-CoV with CpG / alum adjuvant
45687662|NCT04990544|Biological|Placebo|Normal saline solution
45687663|NCT04990427|Drug|CLBS201|1 x 10^6 to 300 x 10^6 autologous CD34+ cells
45687664|NCT04987502|Other|Virtual Reality|8 sessions of virtual reality with 3D audio and visual rendering
45687665|NCT04987502|Behavioral|Standard treatment|counselling, relaxation techniques, sound enrichment
46047916|NCT04031638|Other|Radioactive Iodine treatment|Patients with a thyroid tumor who received radioactive Iodine treatment.
46047917|NCT02627170|Device|dynamic Scheimpflug analyzer (corneal visualization Scheimpflug technology [Corvis ST], OCULUS, Wetzlar, Germany)|
46047918|NCT04151368|Procedure|Robotic Nipple-Sparing Mastectomy (RNSM)|RNSM will be performed by previously described method using 3 cm extra-mammary axillary incision along the mid-axillary line in the axillary fossa. We will use Da Vinci Si Surgical System® (Intuitive Surgical, Sunnyvale, CA).
46047919|NCT02627248|Drug|Huaier Granule|20g tid, orally
46047920|NCT02627248|Drug|Epirubicin|70 mg/m² ivdrip, d1 for both TEC and ET regimes
46047921|NCT02627248|Drug|Docetaxel|75 mg/m² ivdrip, d2 for both TEC and ET regimes
45358774|NCT00786110|Drug|Paclitaxel|Intravenous Paclitaxel 60 mg/mq/weekly i.v., until disease progression.
45358775|NCT00781976|Drug|AZD7295|700mg per day maximum
45358776|NCT00781976|Drug|Placebo|matched placebo
45358777|NCT00782054|Other|Provase|NDC:60230-8573-0 Over the counter (OTC) moisturizer containing 2% dimethicone and a blend of endopeptidases. Use topically to affected area every 8 hours.
45358778|NCT00782054|Other|Control moisturizer|Over the counter (OTC) moisturizer containing 2% dimethicone. Use topically to affected area every 8 hours. Does NOT contain endopeptidases. Placebo intervention is identical to active intervention EXCEPT it does not contain endopeptidases.
45358779|NCT00791804|Drug|AeroLEF|"Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 mcg/mL)~for nebulized administration as required by the patient.~Up to a 6 mL volume (2 x 3 mL doses) containing 500 mcg/ml fentanyl."
45687666|NCT04987489|Drug|Etavopivat tablets|Etavopivat 400 mg once daily
45687667|NCT04984759|Drug|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization (GPO), Thailand) 0.5 mg/kg will be given once daily with food for 14 days. This is the dose recommended for radical cure of P. vivax in tropical areas with high rates of relapse, such as the study design setting. Doses will be directly supervised (DOT).
45358780|NCT00791882|Behavioral|Social Skills Training|A program developed during 20 weeks according to adapted BELLACK 's manual (1997),including sessions in group one hour per week.
45358781|NCT02544516|Other|cognitive tasks + PANSS+ IQ|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale, Kay et al., 1987
45358782|NCT02544516|Other|cognitive tasks|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971),
45358783|NCT00791960|Drug|Dimenhydrinate|single dose, 25mg, IV, diluted in 9.5mL normal saline.
45358784|NCT00791960|Other|Placebo|single dose, 10 mL normal saline, IV
45358785|NCT00792194|Other|Exercise training|"Subjects will be randomised in two groups:~a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.~a training group, where subjects are asked to exercise three times a week, whenever they want during the day."
45479512|NCT05463718|Device|Virtual Reality|children treated by Virtual Reality for 15 min. besides the traditional physical therapy program
45358786|NCT00792350|Drug|Sorafenib (Nexavar, BAY43-9006)|Treatment of Hepatocellular Carcinoma with Nexavar (HCC)
45358787|NCT04046198|Other|Educational program|The Professional Values Education Program was developed in accordance with the Professional Values Model. For nurses in the intervention group program continued for three months. Group training was given before. Then, three individual interviews were conducted. After the post test was applied to the control group, group training was performed.
45844519|NCT05734638|Behavioral|MIM-DASH|Randomized participants will receive the MIM DASH, MIM or DASH intervention in eight weekly, 1-hour group sessions via telehealth (video and telephone access). Participants will receive session materials such as PowerPoint presentations so they can follow along by phone or videoconferencing. After completion of the eight weekly sessions, the participants will receive one follow-up call every other week for 8 weeks. The 3- and 6-month data will be collected as listed in the study AIMs. A manual of operations will detail all procedures related to the protocol, including participant recruitment, data collection, database usage, and database management.
45479513|NCT03795077|Other|Experimental group|Experimental group followed the 3-months programme based in professional ethics. A specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six related activities were created: to solve situations related to real clinical practices. Face to face group sessions based on cooperative learning were planned. Students were divided in small groups, and active participation techniques were used.
45479514|NCT03799679|Drug|Chemotherapeutic Agent|"Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1. Patients will receive this as a single-agent for the first twelve weeks, then followed by epirubicin in combination with cyclophosphamide.~Drug: Epirubicin 90 mg/m² given IV~Drug: Cyclophosphamide 600 mg/m² given IV"
45687668|NCT04984759|Drug|Tafenoquine|Tafenoquine (Kodatef, Biocelect Pty Ltd.) 300 mg will be given as a directly observed single dose with food. This is the standard dose recommended globally for radical cure of P. vivax.
45687669|NCT04982068|Biological|202-CoV low adjuvant dose|standard dose of 202-CoV with low dose CpG / alum adjuvant
45844520|NCT05734638|Behavioral|MIM Only|"The MIM-only intervention group will receive the MIM education only in eight weekly sessions of 30 minutes each. To maintain equipoise among the intervention groups, this group will also have 30 minutes of social time to interact with the trainer and peers. To avoid cross contamination, the interventionist will not also deliver the intervention to the MIM DASH group. Each participant will have access to the digital meditations with mindfulness practice recordings as well as a weekly diary to document study activities. Participants will be instructed to perform mindfulness meditations at least five times a week and record the time in their diary. After completion of the eight weekly sessions, these participants will receive six coaching calls (two per month for 3 months) focused on mindfulness practice."
45687670|NCT04982068|Biological|202-CoV low antigen dose|low dose 202-CoV with CpG / alum adjuvant
46047922|NCT02627248|Drug|Cyclophosphamide|600 mg/m² ivdrip, d2 for TEC regimes
46047923|NCT03993535|Drug|selective serotonin reuptake inhibitor|open treatment based on patient preference and treatment availability
46047924|NCT02626936|Other|Dual-hormone closed-loop|Interventions will be undertaken one to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00 am. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, CLS will be initiated. At 9:00, a standardized breakfast (75g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions.The intervention day will end at 13:00.
46047925|NCT02626936|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
45358788|NCT00792584|Drug|etravirine|Patient receives etravirine/ placebo or efavirenz / placebo
45687671|NCT04982068|Biological|202-CoV standard dose|standard dose 202-CoV with CpG / alum adjuvant
45687672|NCT04982068|Other|Placebo|Normal saline solution
45687673|NCT04978480|Other|no intervention|There is no intervention. We are only collecting standard of care data.
45687674|NCT04975152|Drug|Cemiplimab-Rwlc|Flat dose of cemiplimab-rwlc 350 mg IV every 3 weeks, up to 9 cycles.
45687675|NCT04971044|Behavioral|COACH|Multi-Level Behavioral Intervention
45687676|NCT04971044|Behavioral|School Readiness Intervention|Multi-Level Language and School Readiness Intervention (Control Group)
45844521|NCT05734638|Behavioral|DASH Only|"The DASH-only group will receive the DASH education only in eight weekly sessions of 30 minutes each. This group will also have 30 minutes of social time to interact with the trainer and peers, will receive their education from a different interventionist (also a registered dietician) and receive two coaching calls per month for 3 months, in this case focused on healthy eating DASH principles."
45844522|NCT05734482|Biological|Secukinumab|for subcutaneous injection only
45844523|NCT05730972|Device|Transcutaneous electrical acupoint stimulation|The patients are taken in the recumbent or sitting position, and the local skin at the acupoints is routinely disinfected. A pair of conductive gel patch, connecting to the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, are respectively affixed to the ipsilateral acupoint group, so as contralateral side.
45358789|NCT00792584|Drug|efavirenz|patient receives efavirenz / placebo or etravirine / placebo
45358790|NCT00792662|Drug|Methylphenidate|Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
45358791|NCT00792662|Drug|Placebo|Standard inactive pill.
45358792|NCT00792740|Drug|ITF2357|ITF2357 will be supplied as hard gelatin capsules for oral administration at the dose strength of 50 mg.
45844524|NCT05730972|Device|Sham transcutaneous electrical acupoint stimulation|The electroacupuncture instrument has a normal screen display as the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, but could not output current normally.
45844525|NCT05730972|Drug|Routine palliative treatment|The patients in both groups received routine palliative treatment of tumors, such as chemotherapy, immunotherapy, targeted therapy, drug analgesic therapy, nutrition support, and so on.
46047926|NCT02626936|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
45358793|NCT00792740|Drug|Placebo capsules|Placebo will be supplied as matching capsules for oral administration with the same outer appearance
46047927|NCT02626936|Device|Dexcom G4 Platinum glucose sensor|
45358794|NCT00782366|Genetic|SNP analysis|The patients in the intervention group will obtain genetic risk assessments based on genome-wide association studies.
46047928|NCT02626936|Device|Accu Chek Combo insulin pump|
46047929|NCT00679198|Behavioral|nurse-patient communication|"We will train home health nurses to act as patient advocates by communicating the risks and benefits of osteoporosis treatment to patients and their healthcare providers.~Thus, we will provide a comprehensive, integrated approach to the management of osteoporosis among patients with a history of insufficiency fractures that is highly generalizable to a national setting."
45358795|NCT02556086|Drug|Daclatasvir|
46047930|NCT04881565|Other|Reactive balance training|During each one-hour session, participants will experience 40-50 perturbations (i.e. approximately one perturbation per training minute) during standing and/or walking activities. The perturbations will be applied in any direction (e.g. forwards, sideways, backwards, etc.) To create a perturbation, the researcher will apply unexpected pushes or pulls to a safety harness at waist level. The perturbation will be sufficient in magnitude to elicit a stepping response from the participant. Throughout the session, participants will complete challenging balance tasks, customized to their ability level. Balance tasks will be organized into five categories: stable, quasi-mobile, mobile, unpredictable and participant-selected.
45687677|NCT04967729|Device|Device: Butterfly iQ|The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
46047931|NCT02627326|Procedure|open flap debridement|periodontal surgery in the form of open flap debridement was done in both the groups
45358796|NCT02556086|Drug|Sofosbuvir|
45358797|NCT00782522|Procedure|Eccentric training program|Eccentric training program
45358798|NCT00782522|Procedure|Traditional training program|Traditional training program
45358799|NCT00782600|Drug|suspension IR|50 mg IR suspension once daily for one day
45687678|NCT04963413|Biological|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
45687679|NCT04960618|Drug|Gemcitabine|Participants will receive gemcitabine 1000 mg/m2 on days 1 and 8 on 21-days cycles for up to 6 cycles
45687680|NCT04960618|Drug|Pembrolizumab|Pembrolizumab 200 mg will be introduced with cycle 2 and will be given on day 1 of each 21-day cycle for up to 35 cycles
45752059|NCT01792271|Other|Inhaled 7% HS (NaCl) home treatment|Administering inhaled 7% NaCl for two weeks of home treatment vs. a placebo of 0.12% NaCL during a separate home treatment period, and assessing the effects of each primarily by MCC study.
45844526|NCT05730582|Behavioral|Parkland Diabetes Detection Program (PDDP) Screening Invitation|"The PDDP is designed to supplement and close screening gaps that persist despite opportunistic screening. Program staff order diabetes screening tests for randomized patients, then mail screening invitation letters to inform patients that they are at risk for diabetes. The letter informs them that a screening test has been ordered, and requests that they complete testing at their clinic lab. Patients who were mailed the letter but have not completed screening after 30 days are tracked and are send a second reminder invitation. Patients randomized to the targeted-tailored intervention study arm receive an additional phone call after 30 days."
45358800|NCT00782600|Drug|CR 1|50 mg shorter release CR once daily for one day
45358801|NCT00782600|Drug|CR 2|50 mg medium release CR once daily for one day
45358802|NCT00782600|Drug|CR 3|longer release SR formulation once daily for one day
45358803|NCT05025020|Other|interactive 3D tool|The study tool displays 3-dimensional step-by-step animations of autologous and implant-based breast reconstruction procedures.
45844527|NCT05730192|Device|CADDIE|A colonoscopy is an examination of the bowels using a colonoscope, or a thin, flexible tube with a light and camera. It can help identify issues like colorectal cancer, polyps, and ulcers.
45844528|NCT05725200|Drug|Alectinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current Summary of Product Characteristics (SMPC) and package Insert.
45844529|NCT05725200|Drug|Cetuximab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
45358804|NCT05025020|Other|BREAST-Q Reconstruction Module|The BREAST-Q Reconstruction Module1-3 has 6 domains that cover various aspects of patient satisfaction and quality of life. BREAST-Q is part of our standard of care for patients treated for breast cancer and referred for reconstruction.
45687681|NCT04956159|Device|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of depression and anxiety.
45358805|NCT05025020|Other|DQI|The DQI has 3 domains that cover decision-specific questions about what it is like for a patient to make decisions about reconstruction after breast cancer treatment.
45358806|NCT05025020|Other|Ottawa Decision Regret Scale|The validated Decision Regret Scale measures distress or remorse after a health care decision by the use of 5 items to indicate the extent to which the respondent agrees or disagrees with the statements in the regret scale.
45358807|NCT00786266|Behavioral|Sleep Enhancement Training System|4 week program of readings and relaxation programs
45358808|NCT00786266|Behavioral|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
45358809|NCT04093752|Drug|Tirzepatide|Administered SC
45687682|NCT04956159|Device|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
45687683|NCT04955990|Drug|PAH Therapies|PAH therapies will be administered in a routine clinical setting and data will be collected from participants who newly initiate any PAH therapy(ies), or have already been receiving macitentan 10 mg for at least 3 months prior to the index date. Participants will receive PAH therapies such as Macitentan, Ambrisentan, Bosentan, Tadalafil, Sildenafil, Riociguat, Selexipag, Epoprostenol, Iloprost, Treprostinil, and Beraprost.
45358810|NCT04093752|Drug|Insulin Glargine|Administered SC
45358811|NCT00865956|Behavioral|Contingency Management|Rite Aid vouchers (stepped value) for reinforcement of adherence to primary care
45358812|NCT00865956|Other|Case management|Nurse case manager assigned to participant
45687684|NCT04955743|Drug|Pembrolizumab|200 mg intravenous (IV) is administered every 3 weeks
45844530|NCT05725200|Drug|Crizotinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
45844531|NCT05725200|Drug|Dasatinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
45358813|NCT02545062|Other|MoCa test|The MoCa test is actually used for the screening of Mild Cognitive Impairment . It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic. The MoCa assesses several cognitive domains, and it is available in hebrew language.
45358814|NCT00866112|Other|Educational session to promote physical activity|Educational session, goal setting, self monitoring of daily engagement in physical activity
45358815|NCT00866112|Other|Minimal contact|Self guided education manual about adopting physical activity, self monitor daily engagement in physical activity
45358816|NCT00862602|Behavioral|Stepping Up to Health|Internet-mediated pedometer-based intervention with gradually increasing goals and feedback on step counts. Also includes educational content targeted at women who have had gestational diabetes about exercise, diet & nutrition and prevention.
45358817|NCT00858156|Drug|BG9928|Oral 75 mg single dose
45358818|NCT00858312|Other|high dairy diet|12 week energy restriction with 3-4 servings of dairy foods/day.
45687685|NCT04955743|Drug|Lenvatinib|20 mg orally (PO) is administered daily
45844532|NCT05725200|Drug|Everolimus|Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
45358819|NCT00858312|Other|Low Dairy|less than 1 serving of dairy foods per day.
45844533|NCT05725200|Drug|Encorafenib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
45844534|NCT05725200|Drug|Gemcitabine|Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
45844535|NCT05725200|Drug|Idelalisib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
45844536|NCT05725200|Drug|Larotrectinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
45844537|NCT05725200|Drug|Methotrexate|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
45844538|NCT05725200|Drug|Palbociclib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
45844539|NCT05725200|Drug|Panobinostat|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
45844540|NCT05725200|Drug|Pembrolizumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
45358820|NCT00862680|Procedure|4-Dimensional Computed Tomography|Undergo 4D PET/CT
45358821|NCT00862680|Procedure|4D PET Scan|Undergo 4D PET/CT scan
45358822|NCT02544282|Drug|Levobupivacaine|Pecs II Block
45844541|NCT05725200|Drug|Petrozumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
45358823|NCT02544282|Drug|NaCl 0.9%|Placebo Pecs II block
45358824|NCT02544282|Drug|Sevoflurane|General Anesthesia
46047932|NCT05753995|Diagnostic Test|PET imaging|The evaluation of PET imaging using PET ligand [18F]JNJ-64413739 or a [18F] labeled equivalent in vivo in patients.
45687686|NCT04952324|Other|Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and HS CRP|Periferal Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and high sensitive CRP
45844542|NCT05725200|Drug|Trastuzumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
45844543|NCT05725200|Drug|Talazoparib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
45844544|NCT05725200|Drug|Venetoclax|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
46047933|NCT00912262|Drug|Capsaicin Topical Liquid|
45358825|NCT02544282|Drug|Propofol|General Anesthesia
45358826|NCT02544282|Drug|Sufentanil|General Anesthesia
45358827|NCT02544282|Drug|Atracurium|General Anesthesia
45498091|NCT05370027|Device|Transcutaneous Auricular Vagus Nerve Stimulation|Vagus nerve stimulation will be applied with the Vagustim device for 20 (10+10) minutes, with a biphasic frequency, a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current intensity where the participant feels the current comfortably.
46047934|NCT04151212|Drug|BAT5906 injection|Signal dose escalation starting from 0.3mg. Route of administration: intravitreal injection
46047935|NCT00679276|Procedure|Prolift|surgical repair of vaginal prolapse
46047936|NCT02626702|Other|Observational|Excess blood from subjects will be analyzed to explore the relationship between Immune Modulators and IVF outcomes.
46047937|NCT02627638|Other|Ostheopathic treatment|Once their clinical data were collected and their symptoms were assessed, all the enrolled patients had an osteopathic session a week during two weeks. After those sessions, they had an interview (scheduled between D11 and D14) with a psychologist
46047938|NCT00906945|Drug|G-CSF|
46047939|NCT00906945|Drug|Plerixafor|
46047940|NCT00906945|Drug|Mitoxantrone|
46047941|NCT00906945|Drug|Etoposide|
46047942|NCT00906945|Drug|Cytarabine|
46047943|NCT00807235|Drug|Aerosolized lucinactant|Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 3 hours.
46047944|NCT00807235|Drug|Aerosolized lucinactant|Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 1 hour.
46047945|NCT02627560|Drug|Tranexamic Acid|moisten the surgical wound surface with 20 ml tranexamic acid 25 mg/ml
46047946|NCT02627560|Drug|saline|moisten the surgical wound surface with 20 ml placebo (0.9% saline)
45358828|NCT02544282|Drug|Paracetamol|Pain Relief
45358829|NCT02544282|Drug|Tramadol|Pain Relief
45358830|NCT02544282|Drug|Piritramide|Pain Relief
45358831|NCT00866190|Drug|SQ109|SQ109 150 mg is an oval, coated, white, scored tablet. Dosages: 75 mg administered once daily for 14 days; 150 mg administered once daily on Days 1-5, 9, and 14; and 150 mg administered once daily for 14 days.
45358832|NCT00866190|Drug|Placebo|Placebo is an oval, coated, white, scored tablet administered once daily for 14 days or on Days 1-5, 9, and 14.
45358833|NCT05227482|Radiation|Personalized dosimetry approach|The radionuclide activity to administer is calculated using personalized voxel-based dosimetry approach
45687687|NCT04951726|Drug|Neostigmine|cholinesterase inhibitor
45687688|NCT04950764|Drug|Seladelpar 10 mg|Seladelpar 10 mg single oral dose
45687689|NCT04950764|Drug|Seladelpar 10 mg or less|Seladelpar 10 mg or less, once daily for 28 days
45687690|NCT04948892|Other|Prescence of the father during cesarean section in general anesthesia|The father is now present in the OR during cesarean section category 1, instead of waiting outside
45687691|NCT04943341|Procedure|Eco-guided Triamcinolone-Acetonide injection|"The treatment consists in injecting 1 ml of Kenacort (corresponding to 40 mg of Triamcinolone Acetonide) diluted in about 1 ml of local anesthetic (Lidocaine) directly into the medial fold of the knee. Through an ultrasound guidance with in plane technique, the flute beak of the needle will be positioned between the two sheets of the synovial fold and the injection will be performed."
45687692|NCT04941664|Drug|0.5% levobupivacaine|"This study adopts a Modified Narayana rule (MNR), a sequential up-and-down pharmacodynamics method (UDM) to estimate the minimum effective local anesthetic volume of 90% (MELVA90) of cases of the aforementioned local anesthetic (LA), in order to produce the surgical anesthesia of the patients scheduled for shoulder surgeries. Based on the principal investigator's clinical experience, the initial volume of 8ml will be used. Depending on the success or failure of the superior trunk block, which is defined as the readiness for surgery at 30 minutes after the block, the volume for the next patient will be adjusted up or down by 2ml. The upper dose limit of the study to minimize the potential for local anesthetic systemic toxicity will be 16ml and the lower dose limit will be 4ml, which will be of no clinical importance."
46047947|NCT03784027|Device|CamAPS FX|"CamAPS FX closed loop system comprises:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~Cloud upload system to monitor CGM/insulin data"
45844545|NCT05724966|Device|mHealth app|We wish to examine the perspectives of patients with multiple myeloma and healthcare professionals of this new method for reporting side effects, and to assess organizational aspects. Usual procedure to assess side effect prior to cancer treatment with Bortezomib is a telephone call the day before.
45844546|NCT05722080|Other|Eyesi simulator|Eyesi simulator learning curve for new ophthalmology residents
46047948|NCT03784027|Other|Sensor augmented therapy|Study insulin pump and study CGM.
45687693|NCT04937478|Other|Observation|Only observational study, no intervention.
45687694|NCT04936919|Device|BroadBand Light|Treatment arm will receive Broadband light treatment
45844547|NCT05722080|Other|Sleep deprivation|See how experienced residents perform after sleep deprivation using the Eyesi simulator
46047949|NCT00681460|Drug|human recombined insulin|multiple injections protocol (functional intensive insulin therapy), variable doses following dietary conditions and current metabolic status
46047950|NCT00681460|Drug|metformin|pills given orally twice up to three times a day, a total daily dosage 1000-2400 mg
46047951|NCT05332119|Device|VR glasses|Patients will watch a virtual world in VR glasses during the painful procedure. They will be able to choose between 3 VR content based on their preferences.
46047952|NCT05332119|Other|Control group|Patients will not receive distraction during chest drain removal
45358834|NCT05227482|Radiation|Standard dosimetry approach|The radionuclide activity to administer is calculated using standard (BSA or MIRD) dosimetry approach
45358835|NCT04041804|Procedure|semirapid maxillary expansion (SRME)|A Banded Hyrax is going to be used in order to provide an increase in the maxillary transverse dimension
45358836|NCT00858546|Device|Repetitive transcranial stimulation|Repetitive transcranial stimulation
45358837|NCT04041648|Drug|L606 (Liposomal Treprostinil) Inhalation Solution 51ug|Single ascending dose
45687695|NCT04933266|Procedure|Subpectoral plexus block (low dose)|It is one type of peripheral nerve blocks for surgery over the chest. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (0.25% levobupivacaine 10ml) injected 2 target sites through one skin puncture. One at the myofascial plane between the pectoralis major and minor (5ml of LA) and then under direct ultrasound visualization, the needle will be redirected and the remaining 5ml of LA will be injected at the plane between the pectoralis minor and the serratus anterior muscle, close to the origin of thoracoacromial artery from the axillary artery at the level of the third rib.
46047953|NCT05749939|Behavioral|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) combines the skills of acceptance, cognitive defusion, being present, self as context, values, and committed action to help individuals engage with a meaningful life. A goal of ACT is to help people develop psychological flexibility, meaning they can experience and live with difficult thoughts and emotions, and still pursue what matters to them. The current project is an online, self-guided, 6-session intervention. Each session is expected to take about 30 minutes each, and the entire course will take approximately 3-4 weeks to complete, as users are encouraged to take a few days in between sessions. Within each session, participants will read about concepts and ACT metaphors, apply ACT concepts to general and care- specific vignettes, and apply ACT concepts to their own lives and care situations. Interactive experiences are included in each session and ends with a printable summary with practice skills before proceeding.
45358838|NCT04041648|Device|L606 Inhalation System|Single ascending dose
45752060|NCT00403117|Drug|Placebo + Inactive Marijuana (0% THC)|One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
46047954|NCT05332041|Other|Predicta Bioactive bulk fil composite restoration|Predicta Bioactive bulk fil resin composite restoration material
46047955|NCT03653325|Device|ORI measurement|Oxygen (FiO2) will be titrated according to ORI index and Oxygen saturation.
46047956|NCT03653325|Device|oxygen saturation measurement|Oxygen (FiO2) will be titrated according to oxygen saturation
45358839|NCT04041648|Other|Placebo Solution|Single ascending dose
45358840|NCT02544360|Behavioral|Photoaging mobile app promoting poster campaign.|"Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie)."
45358841|NCT00862758|Drug|Tocilizumab|8 mg/kg would be administered IV every 2 weeks for six weeks.
45752061|NCT00403117|Drug|Placebo + Active Marijuana (3.27% THC)|One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before administration of a marijuana cigarette containing 3.27% THC (ca. 800 mg) provided by the National Institute on Drug Abuse.
46047957|NCT05752981|Device|multichannel time-resolved (tr) functional near infrared spectroscopy (fNIRS) (tr-fNIRS)|Participants will be monitored during surgery using the multichannel time-resolved (tr) functional near infrared spectroscopy (fNIRS) (tr-fNIRS). This study is observational in nature and no intervention will be applied based on the results of the tr-fNIRS device.
46047958|NCT00876694|Drug|Indacaterol 300 µg|Indacaterol 300 µg once daily (od) via SDDPI
46047959|NCT00876694|Drug|Salmeterol 50 µg|Salmeterol 50 µg twice daily (bid) via Diskus®
46047960|NCT05752903|Drug|Dexmedetomidine-propofol|1 mg/kg dexmedetomidine+0.125 mL/kg propofol intravenous (IV) bolus, 0.5 mg/kg/h dexmedetomidine+0.125 mL/kg/h propofol infusion
45358842|NCT03928821|Biological|PGT121|20 mg/kg administered intravenously
46047961|NCT05752903|Drug|Ketamine-Propofol|1 mg/kg ketamine+0.125 mL/kg propofol iv bolus, 0.25 mg/kg/h ketamine+0.125 mL/kg/h propofol infusion
45358843|NCT03928821|Biological|PGDM1400|20 mg/kg administered intravenously
45358844|NCT03928821|Biological|10-1074|20 mg/kg administered intravenously
45358845|NCT03928821|Biological|VRC07-523LS|20 mg/kg administered intravenously
45358846|NCT00666224|Drug|Glatiramer Acetate (DB)|Double blind period (DB): glatiramer acetate (GA) by subcutaneous injection, 20mg, once daily, for up to 36 months or until conversion to clinically definite multiple sclerosis (CDMS).
45358847|NCT00666224|Drug|Placebo|Double blind period (DB): subcutaneous injection of placebo, once daily, for up to 36 months or until conversion to CDMS
45498092|NCT03689556|Diagnostic Test|FLT PET/CT|Patients will receive 3'-deoxy-3'-[18F]fluorothymidine (FLT) PET/CT scans before CIRT and after completion of CIRT.
45498093|NCT05351151|Procedure|bilateral ultra-sound guided maxillary and mandibular nerve blocks|Interventional group will receive bilateral ultra-sound guided maxillary and mandibular nerve block with ROPIVACAINE 4,75 mg/ml.
45844548|NCT05721144|Drug|Nitric Oxide Gas|Inspired NO/N2 will be delivered at 80 parts per million (ppm) after anesthesia induction and intubation and lasted until the end of surgery and leave the operating room.
45498094|NCT05351151|Procedure|Infiltration of Lidocaine 1%|Intervention requiring the infiltration of LIDOCAINE 1% at incision sites by surgeon after general anesthesia induction during maxillo-mandibular osteotomy
45498095|NCT03685656|Other|Slimming gel|On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
45687696|NCT04933266|Procedure|Subpectoral plexus block (High dose)|It is one type of peripheral nerve blocks for surgery over the chest. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (0.25% levobupivacaine 20ml) injected 2 target sites through one skin puncture. One at the myofascial plane between the pectoralis major and minor (10ml of LA) and then under direct ultrasound visualization, the needle will be redirected and the remaining 10ml of LA will be injected at the plane between the pectoralis minor and the serratus anterior muscle, close to the origin of thoracoacromial artery from the axillary artery at the level of the third rib.
45687697|NCT04931212|Procedure|FETO with Smart-TO balloon|Fetal endoscopic tracheal occlusion using the Smart-TO balloon Unplug procedure by peripheral course around the MR scanner
45687698|NCT04930562|Drug|BN101|BN101 is an orally ROCK2 selective inhibitor
45687699|NCT04926792|Device|Leadless Pacemaker|Leadless pacemaker implantation
45687700|NCT04926571|Drug|Dexamethasone Oral|New users of Dexamethasone
45687701|NCT04924127|Diagnostic Test|Detection of IDH and TERT mutation|Detection of IDH and TERT mutation using frozen glioma tissues
45687702|NCT04919382|Biological|Atezolizumab|Given IV
45687703|NCT04919382|Drug|Temozolomide|Given PO
45844549|NCT05714592|Other|Blood sample|The referring haematologist will suggest that the patient participate in the study during the consultation. In these patients, the investigators will perform OGM on the cytogenetic sample
45844550|NCT05695092|Behavioral|Progressive muscle relaxation|Progressive Muscle Relaxation (PMR): This method involved efficiently relaxing global muscles of body with the objective of mental and physical relaxation.
45844551|NCT05695092|Other|control|control group will not receive any intervention
45844552|NCT05685732|Drug|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
45844553|NCT05685732|Other|placebo|matching placebo
45844554|NCT05653518|Device|Tandem t:slim X2 with Control-IQ Technology|FDA approved Tandem t:slim insulin pump with Control-IQ Technology and the Dexcom G6 CGM
45358848|NCT00666224|Drug|Glatiramer Acetate (OL)|Open label period (OL): glatiramer acetate (GA), 20 mg, subcutaneous injection, once daily, given for up to an additional 24 months.
45358849|NCT00866268|Device|low pressure suction drainage|In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter. Duration: Drains were removed after bleeding had ceased (48-72h).
45358850|NCT00866268|Device|High pressure suction drainage|In order to mask the type of intervention from the patient and the investigators, both drainage systems had two drain catheters. One catheter allowed the blood to flow from the wound to the bottle. The second catheter connected the bottle to the vacuum source. In the experimental arm the second catheter was open, while in the control group it was closed. So that the system used could not be distinguished, the connection of the second catheter to the bottle was covered with opaque adhesive tape.Drains were removed after bleeding had ceased.
45358851|NCT00866346|Biological|PR1-primed lymphocyte (PR1-CTL) Infusion|"Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.~Starting infusion dose 1 x 106 nucleated cells/kg."
45358852|NCT00866424|Procedure|Hyperbaric oxygen, Mock hyperbaric chamber|"Hyperbaric oxygen treatment for 10 days in treatment groups and mock hyperbaric chamber treatment for 10 days in control groups.~Hyperbaric oxygen treatment: While in the hyperbaric chamber the subjects breathe 100% oxygen saturation with mask at 2.0bars.~Mock hyperbaric chamber treatment: The subjects breathe air freely in the imitation environment chamber at 1.0bars."
45358853|NCT00663962|Drug|Pregabalin|"PHASE 1 (N=3) Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.~PHASE 2 (N=4) Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op."
45498096|NCT03685656|Other|Slimming gel placebo|On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
45687704|NCT04919135|Biological|Umbilical Cord Mesenchymal Stem Cells transplantation|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the IV route with a 3-month intervening interval
45844555|NCT05653518|Device|Sensor augmented pump (SAP) therapy|Sensor augmented pump (SAP) therapy that includes the use of a study CGM and the participant's personal insulin pump
45358854|NCT00663962|Drug|Placebo|An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op (N=8)
45358855|NCT00866502|Drug|sNN0031|Continuous ICV infusion for two weeks
45358856|NCT00866502|Drug|Placebo|Continous ICV infusion
45358857|NCT00975117|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) twice a day, for 12 weeks.
45687705|NCT04919135|Drug|standard frailty treatment and supplementary medication|Hightamine (Hankook Korus Pharm, Korea), Total calcium (Nugale Pharmaceutical, Canada), Bioflex (Ausbiomed, Australia)
45687706|NCT04918823|Drug|Restasis|Subject will use one drop of Restasis in the lens before insertion
46047962|NCT05749159|Behavioral|physiotherapy|New physical therapy: a disposable cup (soft cup) to take 1/3 cup of room temperature water and place it on a table. The patient takes a sitting or standing position. The middle finger of both hands press tightly against the nose to seal the nasal cavity. At the same time, press the ear screen with both hands to close the ear canal. After that, bite the cup with teeth (hands do not touch the cup), and drink up 1-2 mouthfuls of water.
46047963|NCT03778489|Other|Training|10 weeks of high intensity exercise training. 2-3 trainings per week of approx. 40 min.
45687707|NCT04917874|Biological|Open Label Topical Beremagene Geperpavec (B-VEC)|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
45687708|NCT04912492|Behavioral|RealConsent1.0|A web-based multi-media sexual violence prevention program that enhances knowledge and skills for effective consent for sex and for prosocial bystander behaviors.
45687709|NCT04912492|Behavioral|RealConsent2.0|A revised and updated web-based multi-media sexual violence prevention program that enhances knowledge and skills for effective consent for sex and for prosocial bystander behaviors, but also integrates new program segments into RealConsent 1.0 specific to how alcohol use can inhibit SV intervention at multiple steps of the decision-making process.
45844556|NCT05650008|Drug|Intrathecal local anesthesia|Administration of local anesthetic into intrathecal space to achieve surgical anesthesia
46047964|NCT02607007|Other|2% M.F. Milk|
46047965|NCT02607007|Other|White Bread|
46047966|NCT02607007|Other|Strawberry Jam|
46047967|NCT02607007|Other|31% M.F. Cheddar Cheese|
45358858|NCT00975117|Dietary Supplement|Spermotrend|One Spermotrend tablet (Orally administered) twice a day, for 12 weeks
46047968|NCT02607007|Other|2% M.F. Plain Greek yogurt|
46047969|NCT02607007|Other|Soy Beverage|
46047970|NCT02607007|Other|Water|
46047971|NCT00805441|Drug|LY686017|50 milligrams (mg) daily by oral route for 12 weeks
46047972|NCT00805441|Drug|Placebo|Daily by oral route for 12 weeks
45358859|NCT00786344|Behavioral|Lifestyle Redesign|"For a six-month period, each elder participated in weekly 2-hour sessions involving groups of size 8-10, and also received up to 10 hours of individualized treatment over this time period.~Modular treatment units included the following content areas: (1) Introduction to the Power of Activity; (2) Aging, Health, and Activity; (3) Transportation; (4) Safety; (5) Social Relationships; (6) Cultural Awareness; (7) Finances; and (8) Integrative Summary: Lifestyle Redesign Notebook. The methods of program delivery consisted of didactic presentation, peer exchange, direct experience, and personal exploration. Treatment materials were translated into Spanish and culturally adapted for approximately 15% of the subjects."
45358860|NCT00858624|Drug|ketamine|Administration of low dose intravenous ketamine. Dose: 0.075mg/kg over 10 minutes followed by 0.005mg/kg/min over 20 minutes. Given as single infusion.
45358861|NCT04008459|Other|Therapeutic exercise class|Physiotherapy exercise class includes education, stretching, strengthening, posture and balance interventions.
45358862|NCT00782990|Procedure|Surgical treatment: TVT|
45358863|NCT00782990|Procedure|Surgical treatment: colposuspension|
45358864|NCT00960453|Drug|Sitagliptin|"Dosage form: 25mg, 50mg ,100mg~Amount: 25mg, 50mg, 100mg~Frequency and duration: once a day, for 4 days, including 5 days washout periods"
45358865|NCT00265759|Drug|anastrozole|Given PO
45358866|NCT00265759|Drug|exemestane|Given PO
45358867|NCT00265759|Drug|letrozole|Given PO
45358868|NCT00265759|Procedure|Therapeutic Conventional Surgery|Undergo partial or radical mastectomy or lumpectomy with or without lymph node dissection
45844557|NCT05649306|Other|Additional Education|Study-Specific Patient Handouts, Treating-Provider led counseling, Women's Bladder Cancer Support Group, Women's Bladder Cancer Educational Series, and referrals for additional support services
45358869|NCT00786500|Dietary Supplement|Gynostemma pentaphyllum tea|3 grams twice daily, orally
45844558|NCT05649306|Other|Questionnaires|Female Sexual Function Index, Demoralization Scale-II
46047973|NCT00590317|Drug|Prochlorperazine|Patients receiving Prochlorperazine
46047974|NCT00590317|Drug|Ondansetron|Patients receiving Ondansetron
46047975|NCT01139762|Drug|Tadalafil|5 milligrams (mg) administered orally, once daily for 26 weeks
46047976|NCT01139762|Drug|Placebo|Administered orally, once daily for 26 weeks
46047977|NCT01139762|Drug|Finasteride|5mg administered orally, once daily for 26 weeks
46047978|NCT00805285|Drug|Combination Oral Budesonide and Rectal Hydrocortisone|Budesonide 9 mg PO (oral) daily and hydrocortisone 100 mL PR (enema) for an 8-week period. The doses of each drug to be used in the pilot study are standard doses used in clinical practice. After 8-weeks, the budesonide will be tapered in the following manner: 1) budesonide 6 mg PO daily and hydrocortisone 100 ml PR every other day (EOD) for 3 weeks then 2) budesonide 3 mg PO daily and hydrocortisone 100 ml PR 2 x per week for 3 weeks then 3) discontinue budesonide.
46047979|NCT02606773|Drug|Ascorbic Acid|Ascorbic acid in different ways and doses
46047980|NCT05715307|Other|Intensive experiential training in T2DM management|One-week intensive experiential training for endocrinologists, means 1-week hospitalization experience in leading center (Ruijin Hospital) including health examination and results interpretation, and attending integrated training courses for T2DM management. During patient intervention period, endocrinologists will attend the follow-up and experience sharing meeting regularly.
46047981|NCT05715307|Other|Regular training in T2DM management|Regular training and communication implemented by MMC leading center (Ruijin Hospital) under the guidance of T2DM diagnosis and treatment.
46047982|NCT04310774|Drug|Tegafur, Gimeracil and Oteracil Potassium Capsules (one drug)|CCRT followed by Tegafur, Gimeracil and Oteracil Potassium Capsules consolidation chemotherapy
46047983|NCT01139450|Drug|0417|Topical 0417 test product applied twice daily for 4 weeks
45358870|NCT00786500|Dietary Supplement|Placebo tea|3 grams twice daily, orally
45358871|NCT00972387|Dietary Supplement|CHO, CHO-P, CHO-CHO, PLA|The CHO supplement will be administered during trial 1. The CHO-P will be administered during trial 2. The CHO-CHO supplement will be administered during trial 3. The PLA supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
45687710|NCT04912492|Behavioral|Stress Management|A web-based multimedia program designed to help individuals recognize the symptoms and sources of stress and provide them with a wide variety of powerful tools for managing stress.
45687711|NCT04912492|Behavioral|Alcohol intoxication|Men assigned to moderate alcohol dose condition (target BrAC .08%) with NIAAA approved alcohol administration procedures
45687712|NCT04912492|Behavioral|No-Alcohol Placebo|Men assigned to an no-alcohol placebo control condition.
45687713|NCT04909073|Drug|Afatinib|Continuous treatment of afatinib 30mg tablet once daily in the absence of disease progression or unacceptable treatment-related toxicity, Investigator decision or patient decision to discontinue study treatment.
45687714|NCT04903288|Genetic|Eladocagene Exuparvovec|Four 0.08 milliliters (mL) infusions at a dose of 0.45×10^11 vg and a volume of 80 microliters (μl) per site to 4 sites (2 per putamen), for the total dose of 1.8×10^11 vg and a total volume of 320 μl per participant.
46047984|NCT01139450|Drug|Vehicle of 0417 test product|Vehicle of 0417 test product applied twice daily for 4 weeks
46047985|NCT01139450|Drug|Tacrolimus Ointment 0.03%|Reference product for 0417 test product. Apply twice daily for 4 weeks
46047986|NCT05748067|Procedure|SDF|Silver diamine fluoride
46047987|NCT05748067|Procedure|HVGIC restoration|High viscosity glass ionomer restoration
46047988|NCT05748067|Procedure|SSC|Stainless steel crown
45358872|NCT00972387|Dietary Supplement|CHO-P, CHO-CHO, PLA, CHO|The CHO-P supplement will be administered during trial 1. The CHO-CHO will be administered during trial 2. The PLA supplement will be administered during trial 3. The CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
45687715|NCT04902872|Drug|CBX-12|CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety
46047989|NCT05110742|Drug|Fludarabine Phosphate|Given by IV
46047990|NCT05110742|Drug|Cyclophosphamide|Given by IV
46047991|NCT05110742|Drug|CAR.5/IL15-transduced CB-NK cells|Given by IV
46047992|NCT04021069|Diagnostic Test|Radiomic, pathomic, and clinical markers|This is a non-interventional study.
45358873|NCT00972387|Dietary Supplement|CHO-CHO, PLA, CHO, CHO-P|The CHO-CHO supplement will be administered during trial 1. The PLA will be administered during trial 2. The CHO supplement will be administered during trial 3. The CHO-P supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
45358874|NCT00972387|Dietary Supplement|PLA, CHO, CHO-P, CHO-CHO|The PLA supplement will be administered during trial 1. The CHO will be administered during trial 2. The CHO-P supplement will be administered during trial 3. The CHO-CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
45358875|NCT00866580|Biological|GSK's candidate influenza vaccine 1562902A|Intramuscular dose on Day 0 and Day 21
45358876|NCT00866580|Biological|FluarixTM|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
45358877|NCT00866580|Biological|Placebo|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
45358878|NCT00744263|Biological|VACCINE: placebo|0.5 mL, single intra-muscular injection
45358879|NCT00744263|Biological|VACCINE: 13-valent pneumococcal conjugate vaccine|0.5 mL, single intra-muscular injection
45358880|NCT00975273|Behavioral|Capnometry Assisted Respiration Training|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly, and shallowly in order to raise their PCO2 levels with the assistance of a biofeedback device.
45358881|NCT00975273|Behavioral|Breathing Awareness|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly using a biofeedback device.
45358882|NCT00783068|Drug|GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride]|Subjects will receive GTS-21 or placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of GTS-21 or placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0)
45844559|NCT05649306|Other|Attendance Diary|Attendance Diaries for the Women's Bladder Cancer Support Group, Women's Bladder Cancer Educational Series, and additional educational and support services utilized
46047993|NCT00805207|Drug|Progesterone|Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.
46047994|NCT00805207|Drug|testosterone|Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
46047995|NCT00805207|Drug|glucocorticoid|Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
46047996|NCT00805207|Device|continuous positive airway pressure|Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks. Testing is performed before and at the end of the 6 week intervention.
46047997|NCT00805207|Drug|Estrogen|Estrogen treatment (100 ug Estradiol daily) administered transdermally by using continuous delivery patches. The intervention lasted 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.
46047998|NCT00805207|Other|Control|No treatment with studies performed 31 to 72 days apart
46047999|NCT05747755|Behavioral|ADEPT Program|Integration of surveillance for diagnostic errors into usual care, benchmarking and sharing of results across hospitals, expert mentoring of quality and safety personnel in change management, pilot testing and refinement of Safety I and Safety II interventions to reduce systemic causes of diagnostic errors and to increase resilience, thus promoting diagnostic excellence.
46048000|NCT05714761|Device|Dexcom glucose sensor|Use of a Dexcom G6 Pro
46048001|NCT03016351|Other|Aerobic Training|After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration.
46048002|NCT03016351|Other|Resistance Training|After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration.
46048003|NCT00805675|Drug|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
46048004|NCT00805675|Drug|Tenofovir|Tenofovir disoproxil fumarate was supplied in 300 mg tablets
45358883|NCT00783068|Drug|Placebo|Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
45358884|NCT00783068|Drug|Lipopolysaccharide E. Coli 113:H 10:K negative|Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0). One hour after ingestion of the last dosage of the study drug, purified LPS prepared from E coli O:113 (2 ng/kg iv) will be injected intravenously.
45358885|NCT00866736|Drug|dasatinib|100mg QD
45358886|NCT02532049|Biological|ChAd63 Pfs25-IMX313|
45358887|NCT02532049|Biological|MVA Pfs25-IMX313|
45358888|NCT04008849|Other|Safety and efficacy assessments|Long term safety and clinical outcomes
45358889|NCT00792818|Drug|Curcuma domestica extracts|1,500 mg per day (oral)divided into 3 times for 28 days
45358890|NCT00792818|Drug|Ibuprofen|1,200 mg/days (oral) divided into 3 times for 28 days
45358891|NCT00972465|Drug|Nimotuzumab and chemotherapy|"Experimental: Nimotuzumab and Irinotecan~the chemotherapy treatment: Irinotecan (180 mg/m2/time, 1 time/14 days, until disease progression)~the nimotuzumab treatment: 3 levels (200 mg/w, 400 mg/w, 600 mg/w, weekly, until disease progression)"
45358892|NCT00975351|Dietary Supplement|13C5-labelled 5-methyltetrahydrofolic acid|"one intravenous bolus dose of no more than 500nmole 13C5-labelled 5-methyltetrahydrofolic acid, followed by multiple blood samplings at regular time intervals. Total 2hr intervention."
45358893|NCT01071187|Drug|Varenicline|Varenicline 0,5mg daily on day 1-3, Varenicline 1mg daily on day 4-7 and Varenicline 2mg on day 8-84.
45358894|NCT01071187|Drug|Placebo|Placebo
45358895|NCT00618774|Drug|telmisartan40/amlodipine5|
45358896|NCT00618774|Drug|telmisartan80/amlodipine5|
45358897|NCT04008693|Dietary Supplement|Aged Garlic Extract|2.400 mg (four capsules) of a nutritional supplement of aged garlic extract (Kyolic® Hi-Po Formula - Kyolic)
45358898|NCT04008693|Other|Placebo|800 mg of maltodextrin (four capsules)
45358899|NCT00792896|Behavioral|family conference|family conference
45358900|NCT01071265|Procedure|Remote Ischemic Preconditioning|Occlusion of leg blood flow using a pneumatic tourniquet on the thigh. Tourniquets are inflated to 300 mmHg for 5 minutes followed by deflation for 5 minutes then repeated for a total of 3 inflations.
45358901|NCT01071265|Procedure|Sham|Sham procedure. A pneumatic tourniquet is placed on an upper arm and/or thigh but not inflated.
45358902|NCT00792974|Behavioral|A brief psycho-educational intervention|"A brief (3 single sessions) psycho-educational program with cognitive-behavioral and disease self-management techniques.~This study is an open pilot study (feasibility study) to develop a palliative psychological program for end-of-life fears in COPD, therefore all participants will be given the opportunity to receive treatment."
45358903|NCT00858936|Drug|IK-1001|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
45358904|NCT00858936|Drug|Normal Saline|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
45358905|NCT03974893|Other|Vegetarian Diet|Dietary information will be collected utilizing a food record at four time points in therapy reflecting different intensities/drug exposures of treatment.
45358906|NCT00917345|Drug|captopril test|The blood samplings were obtained one hour after the administration of 50 mg of captopril.The testing is performed in the morning on a seated ambulatory patient
45687716|NCT04894656|Diagnostic Test|Labs, urine tests, upper endoscopy with biopsy and confocal laser endomicroscopy|Tests to assess intestinal permeability
45844560|NCT05606484|Other|Exercise with non-immersive virtual reality|Patients will exercise for 30 minutes with non-immersive virtual reality (VR) with a perceived exertion between 12-15 (somewhat hard-hard) on the Borg scale. Patients will perform 3 weekly sessions during the second hour of hemodialysis, on simultaneous days.
45844561|NCT05606484|Other|Exercise with a static pedal|Patients will exercise with a stationary pedal for 30 minutes at an intensity of 12-15 (somewhat hard-hard) on the Borg scale of perceived exertion. The patients will carry out an exercise session 3 times a week on alternate days, coinciding with the patients of the exercise with VR.
46048005|NCT00805675|Drug|Telbivudine plus tenofovir|Telbivudine 600 mg and Tenofovir 300 mg were purchased in commercial packs. Patients were instructed to take medication(s) orally every morning either with or without food.
45844562|NCT05599698|Other|Chemotherapy|Standard chemotherapy protocols for adjuvant & neoadjuvant treatment for different types of solid malignancies
46048006|NCT03958201|Combination Product|Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex|The protocol includes specified appropriate rocuronium dosing and a valid pre-reversal assessment of the adductor pollicis response guides optimal neostigmine vs. sugammadex reversal.
46048007|NCT04015453|Procedure|Mohs micrographic surgery|All participants will have received Mohs micrographic surgical treatment for a facial skin cancer.
46048008|NCT00589303|Drug|FDA approved rate and rhythm control drugs|"Any approved rate or rhythm control drugs for treatment of atrial fibrillation may be prescribed under the primary physician's discretion.~Rate Control:~Beta-Blocker:~metoprolol~atenolol~carvedilol~Calcium Channel Blocker:~verapamil~diltiazem~Rhythm Control:~procainamide~quinidine~disopyramide~propafenone~flecainide~sotalol~dofetilide~amiodarone"
45687717|NCT04893772|Dietary Supplement|Intermittent fasting|"Three fasting days a week, whereby participants consume 600-800 kcal/day from 4 meal replacement products: breakfast, lunch, a snack and dinner. During the other 4 non-fasting smart days each week, participants are instructed to consume 2 x 300 kcal meals and 2 x 100 kcal snacks, from a selection of recipes, plus one meal of their own choosing."
45687718|NCT04887519|Other|No Intervention|This is a non-interventional study.
45752062|NCT00403117|Drug|Naltrexone 12 Mg+ Active Marijuana (3.27% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.
45358907|NCT00793052|Drug|Etodalac, Etoricoxib and Dexamethasone|"Dexamethasone sodium phosphate 8 mg 1 hour before the extraction, 4 mg the day after the extraction and another 4 mg at second day to the extraction.~Etoricoxib 120 mg 1 hour before the extraction, 120 mg the day after the extraction and another 120 mg at second day to the extraction.~Etodalac 600 mg 1 hour before the extraction, 600 mg the day after the extraction and another 600 mg at second day to the extraction."
45358908|NCT00859092|Dietary Supplement|Simply Thick|Simply Thick® added to each bottle of formula or beast milk to create nectar or honey consistency
45358909|NCT01071343|Device|Transcutaneous electrical muscle stimulation|After randomization of the quadriceps muscles TEMS is applied on the intervention side for 7 consecutive days, 60 minutes per day.
45358910|NCT02555852|Drug|esomeprazole|Exposure to esomeprazole (ATC A02BC05, B01AC56, M01AE52, A02BD06) will be defined as a prescription for esomeprazole on the same day as a ≥ 30 day NSAID prescription.
45358911|NCT02555852|Drug|omeprazole|Exposure to omeprazole (ATC A02BC01, A02BD01) will be defined as a prescription for omeprazole on the same day as a ≥ 30 day NSAID prescription.
45358912|NCT02555852|Drug|pantoprazole|Exposure to pantoprazole (ATC A02BC02, A02BD04) will be defined as a prescription for pantoprazole on the same day as a ≥ 30 day NSAID prescription.
45358913|NCT02555852|Drug|lansoprazole|Exposure to lansoprazole (ATC A02BC03, A02BD07, A02BD03, A02BD02) will be defined as a prescription for lansoprazole on the same day as a ≥ 30 day NSAID prescription.
45358914|NCT02555852|Drug|rabeprazole|Exposure to rabeprazole (ATC A02BC04) will be defined as a prescription for rabeprazole on the same day as a ≥ 30 day NSAID prescription.
45358915|NCT02555852|Drug|cimetidine|Exposure to cimetidine (ATC A02BA01) will be defined as a prescription for cimetidine on the same day as a ≥ 30 day NSAID prescription.
45358916|NCT02555852|Drug|ranitidine|Exposure to ranitidine (A02BA02) will be defined as a prescription for ranitidine on the same day as a ≥ 30 day NSAID prescription.
45358917|NCT02555852|Drug|famotidine|Exposure to famotidine (A02BA03) will be defined as a prescription for famotidine on the same day as a ≥30 day NSAID prescription.
45358918|NCT02555852|Drug|nizatidine|Exposure to nizatidine (A02BA04) will be defined as a prescription for nizatidine on the same day as a ≥ 30 day NSAID prescription.
45358919|NCT02555852|Drug|niperotidine|Exposure to niperotidine (A02BA05) will be defined as a prescription for niperotidine on the same day as a ≥ 30 day NSAID prescription.
45358920|NCT02555852|Drug|roxatidine|Exposure to roxatidine (A02BA06) will be defined as a prescription for roxatidine on the same day as a ≥ 30 day NSAID prescription.
45844563|NCT05574894|Drug|Growth hormone|Growth hormone is supplemented during the ovarian stimulation till the day of trigger
46048009|NCT00589303|Device|AV Node ablation and device implant|"Pacing Systems:~Enpusle Premarket Approval Number (PMA#) P980035~EnRhythm PMA# P980035~Adapta PMA# P980035~Cardiac Resynchronization Therapy (CRT) Pacing Systems:~- InSync III/ Insync Maximo/InSyncII Marquis PMA# P010031~Implantable Cardioverter-Defibrillator (ICD) Pacing Systems:~EnTrust PMA# P980016~Virtuoso PMA# P980016~ICD CRT Pacing Systems:~InSync Maximo PMA# P980016~InSync Sentry PMA# P890003~Concerto PMA# P980016"
46048010|NCT05752747|Other|Cold Massage Group|Just before the application, it will be taken out of the cabinet and the area to be vaccinated will be massaged with rollers with back and forth movements.
45358921|NCT02555852|Drug|ranitidine bismuth citrate|Exposure to ranitidine bismuth citrate (A02BA07) will be defined as a prescription for ranitidine bismuth citrate on the same day as a ≥ 30 day NSAID prescription.
45844564|NCT05574894|Drug|GnRH antagonist|GnRH antagonist protocol for ovarian stimulation
45358922|NCT02555852|Drug|lafutidine|Exposure to lafutidine (A02BA08) will be defined as a prescription for lafutidine on the same day as a ≥ 30 day NSAID prescription.
45844565|NCT05567952|Drug|nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir every 12 hours
45844566|NCT05567952|Drug|ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
45358923|NCT02555852|Drug|cimetidine combinations|Exposure to cimetidine combinations (A02BA51) will be defined as a prescription for cimetidine combinations on the same day as a ≥ 30 day NSAID prescription.
45687719|NCT04885166|Other|Web-based placebo presentation|This presentation will discuss the prevalence of psychological disorders in college students, their etiologies, psychiatric medications, and students' personal experiences navigating college with a diagnosis of an anxiety and learning disorder, respectively. Attention-deficit/hyperactivity disorder and stimulant medications will be addressed, but diversion and medication misuse will not be discussed.
45687720|NCT04885166|Behavioral|Web-based simulation active intervention|This intervention engages students in interactive discussions with virtual humans to (a) learn about the actual prevalence of NMUPS and diversion and their related risks, (b) practice using refusal strategies when approached for their medication in high-risk situations, and (c) understand how to effectively communicate with prescribers and avoid medication misuse.
45687721|NCT04884607|Other|subthreshold low-level autonomic nerve stimulation using external auditory canal electrodes|"Evaluation of electrocardiogram measurement from external auditory canal electrodes: Participants are required to attach specially designed external auditory canal electrodes to their both ears to record electrocardiogram. Both electrocardiogram from the precordium and the ear would be simultaneously recorded and compared.~Evaluation of low-level autonomic nerve stimulation using external auditory canal: Using the electrodes described above, Arnold's nerve will be stimulated with low-level electric impulses using TENS device. During and after the stimulation, heart rate variability will be measured to investigate the impact of nerve stimulation on autonomic function modulation on the heart."
46048011|NCT05752747|Other|ShotBlocker© Group|It is a small flexible drug-free plastic tool. It is a small, flat-shaped instrument with a short, blunt, skin-contact ridge on the bottom and a hole in the center to inject. It is placed on the skin before injection. The protrusions on the inside do not harm the skin.
46048012|NCT02607943|Drug|Insulin Glargine|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
45358924|NCT02555852|Drug|famotidine combinations|Exposure to famotidine combinations (A02BA53) will be defined as a prescription for famotidine combinations on the same day as a ≥ 30 day NSAID prescription.
46048013|NCT02607943|Drug|Regular Insulin|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
46048014|NCT02970877|Biological|Fecal filtrate from 150 g stool from healthy lean donors|150 g stool from healthy lean donors will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
46048015|NCT02970877|Biological|Fecal filtrate from 150 g of the recipient's own stool|150 g stool from the recipient will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
45358925|NCT04091009|Drug|Buprenorphine|"Participants will be randomly assigned to be maintained on their daily dose of buprenorphine or to have their buprenorphine reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided"
45358926|NCT04091009|Drug|Buprenorphine/naloxone|"Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone or to have their buprenorphine/naloxone reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided"
45358927|NCT00866892|Procedure|Irrigation|irrigation
45358928|NCT00866892|Procedure|No irrigation|no irrigation
45358929|NCT00859170|Device|Accordion device|an antiretropulsion device
45358930|NCT02597231|Dietary Supplement|Melatonin|Melatonin is the dietary supplement we are using in delirium prevention.
45687722|NCT04876651|Other|177Lu-DOTA-rosopatamb|Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best SoC
45687723|NCT04869683|Other|description of MDS pzatient cohort|description of MDS patient cohort
45687724|NCT04869514|Procedure|spinal manipulation|intervention will consist of either lumbar manipulation, thoracic manipulation or lumbar mobilisation
46048016|NCT03932305|Dietary Supplement|Lutein|Lutein is a common oral supplement that may have neuroprotective effect on the human retina
46048017|NCT03932305|Dietary Supplement|Placebo|Inactive placebo tablet
46048018|NCT02606617|Drug|Mosapride|Mosapride(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
46048019|NCT02606617|Drug|Placebo|Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
45358931|NCT02597231|Other|Placebo|Patients in this group will receive a matching placebo pill.
45358932|NCT00866970|Biological|ALD518|ALD518 80 mg on Day 1, Week 8 and Week 16
45358933|NCT00866970|Biological|ALD518|ALD518 160 mg IV on Day 1, Week 8 and Week 16
45358934|NCT00866970|Biological|ALD518|ALD518 360 mg IV on Day 1, Week 8, and Week 16
45687725|NCT04863599|Other|Questionnaire|Patients will be asked to complete the Bauer and Brice questionnaire at post-operative day 1.
46048020|NCT00914095|Drug|methylphenidate|10 mg tablet of methylphenidate 3 times a day (1 mg/kg/day)
46048021|NCT00914095|Drug|placebo|tablets of placebo 3 times a day
45358935|NCT00866970|Biological|Infusion of 0.9% Saline without ALD518|Infusion of 0.9% Saline without addition of ALD518
45358936|NCT00545571|Drug|Methoxy polyethylene glycol-epoetin beta|Mircera will be administered intravenously every 4 weeks for a total of 52 weeks. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
45358937|NCT00783380|Biological|Virosomal influenza vaccine|Influvacplus 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
45358938|NCT00783380|Biological|Subunit influenza vaccine|Influvac 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
45358939|NCT00793130|Dietary Supplement|Coltect|Two tablets twice daily (BID) during the 2 months of the study. Each tablet contains 500mg Curcumin, 250mg Green tea and 100mcg Selenomethionine.
45358940|NCT04008225|Procedure|Bronchoalveolar lavage|
46048022|NCT03903835|Drug|Enzalutamide Oral Capsule [Xtandi]|Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
46048023|NCT03903835|Drug|Abiraterone Oral Tablet [Zytiga]|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
45358941|NCT00748709|Drug|BIBW 2992 (Afatinib)|BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation
45358942|NCT00793208|Biological|semi-allogeneic human fibroblasts (MRC-5) transfected with DNA|"Each vaccine consists of 1 x 10e7 DNA-transfected irradiated fibroblasts. A total of 4 weekly immunizations will be delivered to each patient. Each vaccine will be administered i.d. using a 1 mL syringe and a 25 gauge needle.~Subjects will have immunizations administered at 4 different sites for each vaccination as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh Approximately equal numbers of transfected fibroblasts will be administered at each site."
45358943|NCT04041024|Other|tasks and questionnaires|"Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer."
45358944|NCT04041024|Other|tasks and questionnaires|"Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer."
45358945|NCT00793286|Procedure|Mesh fixation by staples|Mesh fixation by staples
45358946|NCT00793286|Procedure|Mesh fixation by glue|Mesh fixation by glue
45358947|NCT00859404|Drug|oglemilast|Tablet oglemilast or placebo once a day, for 12 weeks
45358948|NCT02597309|Drug|Canagliflozin|
45358949|NCT04008381|Biological|Ex-vivo Expanded γδ T Lymphocytes|Patients receive ex-vivo expanded γδ T Lymphocytes (Dose escalation, 2*10^6, 4*10^6, 8*10^6 of cells per kg of body weight).
45358950|NCT00863148|Drug|Clofarabine in combination with IV busulfan and ATG|A conservative approach has been used for the determination of the dose due to the high risk studied population, e.g., decrease to 30 mg m²/day for a 4-day course of clofarabine. Clofarabine will be started at Day -8 to allow improvement of liver function tests, if any, by time of allo-HSCT. Clofarabine (C) 30 mg/m²/day for 4 days (day -8 to day-5). Busilvex (B): 3.2 mg/kg/day for 2 days (day -4 and day-3)Thymoglobuline (T): 2.5 mg/Kg/day for 2 days (day -2 and day-1). Graft (G) at day 0 GVHD prophylaxis: Cyclosporine 3 mg/kg/day starting day-1. Genzyme provided supplies of clofarabine for all patients included in the study.
45358951|NCT00786734|Drug|Pitavastatin|4mg daily for 5-7 days before Percutaneous Coronary Intervention(PCI) and 4mg daily for 28 days after PCI
45358952|NCT00786734|Drug|Pitavastatin|4mg daily for 28 days after PCI
45358953|NCT03974581|Other|Primary percutaneous coronary intervention|Patient receives primary percutaneous coronary intervention as part of his treatment; decision to allocate by treating physician.
45358954|NCT03974581|Other|Pharmacoinvasive strategy|Patient receives primary fibrinolysis and subsequent coronary angiography (pharmacoinvasive strategy) as part of his treatment; cases with failed fibrinolysis are scheduled for immediate rescue PCI. Decision to allocate by treating physician.
45358955|NCT04089995|Other|data collection|No intervention
45358956|NCT00960609|Procedure|Ultrasound guided liver resection|
45358957|NCT02544204|Biological|JVS-100|Biological/Vaccine: JVS-100 Intramuscular Injection
45358958|NCT02544204|Biological|Placebo|Biological/Vaccine: Placebo Intramuscular Injection
45358959|NCT00263887|Drug|Alpha1-Proteinase Inhibitor (Human)|Weekly infusion of 60 mg/kg body weight for 2 years
45687726|NCT04861766|Device|STYLAGE® L|Injection in both NLFs
45358960|NCT00263887|Drug|Albumin (Human) 20%, United States Pharmacopeia (USP)|Weekly infusion for 2 years. Albumin (Human) 20% will be diluted with 5% glucose to a final concentration of 2.0%.
45687727|NCT04861766|Device|Active Comparator|Injection in both NLFs
45358961|NCT00972699|Behavioral|Peer support and mentoring|The intervention will be delivered in 4 non consecutive visits during pregnancy and 4 visits post-partum. The sessions will be delivered to mothers living with HIV on the days of their health care appointments either individually or in groups that can accommodate up to 30 mothers living with HIV. The intervention will focus on enhancing the mother-baby relationship through increasing the health of the mother and baby, maintaining the mother's mental health, and reducing HIV transmission.
45358962|NCT00867126|Drug|pioglitazone hydrochloride|
45358963|NCT00867126|Other|laboratory biomarker analysis|
45358964|NCT00867126|Other|questionnaire administration|
45358965|NCT00867126|Procedure|quality-of-life assessment|
45358966|NCT00748553|Drug|Azacitidine (Vidaza)|50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle
46048024|NCT03903835|Drug|Carboplatin|Carboplatin will be administered every 3rd week with an AUC (area under curve) = 5 with a dose calculated according to the Carboplatin AUC Dose calculation (Calvert formula):Dose (mg) = TargetAUC (mg/ml x min) x [GFR ml/min + 25].
45358967|NCT00748553|Drug|Nab-paclitaxel (Abraxane)|100mg/m2 weekly for 3 weeks of each 4-week cycle
45358968|NCT03974815|Device|ACTIVE|"We will use 28.26cm^2 round electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials."
46048025|NCT03903835|Drug|Cabazitaxel 60 mg Solution for Injection|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
45358969|NCT03974815|Device|SHAM|"We will use 28.26cm^2 round electrodes and a 0mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials."
45358970|NCT00661388|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
45358971|NCT00867204|Procedure|ERCP|Patients with clinical indication for ERCP were invited to participate in the Study
46048026|NCT03903835|Drug|Docetaxel Injectable Solution|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
46048027|NCT03903835|Drug|Radium Chloride Ra-223|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
45358972|NCT00975429|Drug|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 4mg/kg using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
45687728|NCT04857996|Drug|UBX1325|Patients will be administered a single 50 μL UBX1325 IVT injection
45687729|NCT04857996|Other|Sham|Sham procedure
45687730|NCT04857814|Device|ADAMM- RSM Device|All participants will wear the ADAMM- RSM device for a 6 month period
45687731|NCT04848961|Behavioral|LungTalk|MSK developed LungTalk, a novel computer-tailored health communication and decision support tool to (1) increase awareness and knowledge about lung screening; (2) decrease perceived barriers to screening based upon misinformation; and (3) increase screening rates.
45687732|NCT04842747|Drug|VERU-111|Subjects in the VERU-111 treatment groups will receive standard of care, plus oral daily VERU-111 9mg for 21 days or until released from hospital.
45358973|NCT00975429|Drug|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 6mg/kg in patients using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm ) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
45687733|NCT04839991|Drug|CB307|Tri-specific Humabody targeting CD137, prostate specific membrane antigen and human serum albumin
45687734|NCT04839458|Device|Dental Prescale II|"The participant will bite Dental Prescale II for about 3 seconds, using a force for  chewing beef . And the Dental Prescale II will be taken out from the mouth. Then the trial is end."
45844567|NCT05567952|Drug|placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
45358974|NCT04040478|Device|Transcutaneous monitoring|"Transcutaneous monitoring of oxygen and carbon dioxide by using Radiometer TCM5 flex monitor with 3 electrodes on the patient.~Abdominal patients are monitored for 4 hours during surgery and for 2 hours in the Post-Anesthesia Care Unit. Arterial blood gasses are drawn from the arterial line 4 times during surgery and 4 times after surgery.~Patients undergoing vascular surgery are monitored for up to 4 hours during surgery."
45358975|NCT02597465|Drug|SPARC1507|The administered dose is calculated based on the BSA calculated for the subject on Day 1 of the Cycle
45358976|NCT02597465|Drug|Reference1507|Investigators choice including chemotherapy or supportive therapy
45358977|NCT00972855|Drug|Bicalutamide|50 mg Tablet
45358978|NCT00972855|Drug|Casodex®|50 mg Tablet
45358979|NCT04090931|Procedure|Orthodontic treatment|leveling and aligning stage in orthodontics
45358980|NCT00786812|Drug|Nilotinib|
45358981|NCT04008147|Drug|100mg iron sulfate|100mg iron sulfate b.i.d. for 4 consecutive days
45358982|NCT00859716|Biological|ACE393|ACE393 250 micrograms as intra muscular injection at day 0 and day 21
45358983|NCT00859716|Biological|Placebo vaccine|Placebo 500 micrograms Alhydrogel as intra muscular injection at day 0 and day 21
46048028|NCT03903835|Drug|Niraparib plus Abiraterone acetate plus Prednisone|Niraparib and Abiraterone acetate will be provided by Janssen and will be provided either as a fixed dose combination or as single agents. Detailed use of the study treatment including dose and dosages are described in the Investigator's brochures and SmPC.
46048029|NCT05745337|Drug|As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)|Patients will stop their daily beta-blocker and take as-needed rate control (beta-blocker or calcium channel blocker) guided by their implantable cardiac monitor
45358984|NCT00743483|Drug|rhBSSL|oral suspension, 170 mg BSSL, 3 times daily for 5-6 days
45358985|NCT00972933|Drug|ipilimumab|Excisional Biopsy - baseline Induction ipilimumab 10 mg/kg IV day 0, 21 - baseline and week 3 Complete lymph node dissection - week ≥ 6 Maintenance Ipilimumab 10 mg/kg IV - Days 63 (+28 days) and, 84 (+28 days) - (3 weeks apart, starting 2-4 weeks following definitive lymphadenectomy)
45358986|NCT00867282|Drug|Treatment A|PF-00241939 750ug using inhaler A
45358987|NCT00867282|Drug|Treatment B|PF-00241939 750ug using inhaler B
45687735|NCT04833855|Biological|Tezepelumab Dose 1|Subcutaneous injection.
45687736|NCT04833855|Biological|Tezepelumab Dose 2|Subcutaneous injection.
45687737|NCT04833855|Biological|Omalizumab|Subcutaneous injection.
45358988|NCT00263575|Drug|EN3267|EN3267 will be available in 100, 200, 300, 400, 600 (two 300 ug tablets), and 800 ug (two 400 ug tablets) doses
45358989|NCT00975663|Drug|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
45687738|NCT04833855|Biological|Placebo|Subcutaneous injection.
45687739|NCT04831580|Device|da Vinci|Minimally invasive robotic-assisted surgical device
45687740|NCT04831580|Other|open surgery|open radical hysterectomy
45752063|NCT00403117|Drug|Naltrexone 25 Mg + Active Marijuana (3.27% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.
45752064|NCT00403117|Drug|Naltrexone 50 Mg+ Active Marijuana (3.27% THC)|One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
45752065|NCT00403117|Drug|Naltrexone 100 Mg+ Active Marijuana (3.27% THC)|One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
46048030|NCT05744791|Behavioral|Active Play planned movement program|Teachers will implement an addition two physical activity opportunities that incorporate active play each day for a potential dose of 20-30 minutes per day and 100-150 minutes per week.
46048031|NCT00952380|Drug|dalteparin|dalteparin subcutaneous injection
46048032|NCT03866161|Device|Continuous positive airway pressure|Continuous positive airway pressure treatment
46048033|NCT03859921|Drug|Dydrogesterone|Progesterone
45358990|NCT00975663|Drug|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
45358991|NCT00748241|Device|Astra Tech Fixture ST|Astra Tech Fixture ST Ø 3.5 and 4.5 cm in lengths of 9, 11, 13, 15, 17 and 19 mm.
45358992|NCT00863226|Device|Resonator Device|Application of Magnetic Fields Using the Resonator Device
46048034|NCT03859921|Drug|Placebo|Placebo with appearance similar to Dydrogesterone
45358993|NCT00570128|Drug|Donepezil HCl|Blinded donepezil 2.5 milligram per day (mg/day) (2.5 milliliter per day [mL/day]) orally for participants with body weight (BW) 20 and less than (<) 25 kilogram (kg), 5 mg/day (5 mL/day) orally for participants with BW 25 to <50 kg, and 10 mg/day (10 mL/day) orally for participants with BW greater than or equal to (>=) 50 kg liquid formulation (1 milligram per 1 milliliter [1 mg/1 mL]) (titrated to 0.1 to 0.2 milligram per kilogram per day [mg/kg/day] based on BW).
45358994|NCT00570128|Drug|Placebo|Liquid formulation matched to active treatment for oral administration.
45479515|NCT03329482|Other|PULSE ULTRASOUND|For group A, The PUS group received pulse mode of ultrasound (sonoplus 490s), with frequency of 1MHZ and intensity of 1.5w/cm according to Ebadi et al 10). Grey's formula was used to estimate the duration of ultrasound (US) for each patient 21). The average local exposure time was one minute and the effective radiating area of the transducer head was 5 cm2. For a patient with an area of low back pain of 40 cm2, the required total treatment time was: 1 min × (40 cm2/5 cm2) = 8 minutes. US was applied using slow circular movements, with the transducer head placed over the painful paravertebral low back region and Lofnac gel used as coupling medium.
45687741|NCT04810481|Device|BIS Complete Monitoring System|The BIS™ complete monitoring system is a user-configurable patient monitoring system designed to monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS™ complete system processes raw EEG signals to produce a single number, called the BIS™ index, which correlates with the patient's level of hypnosis. A sensor placed on the patient's head transmits EEG signals to the BISx™ unit. The BIS™ unit filters and digitizes the signal, analyzes it for the artifact, and processes it using digital signal processing techniques to derive processed EEG parameters to a single Bispectral Index (BIS™), and finally sends the processed data to the monitor for display. The purpose of processing the EEG waveform data is to extract characteristic features from the complex signal that the BIS™ algorithm can utilize to derive BIS Index.
45687742|NCT04806724|Behavioral|Opening the Conversation|The intervention includes 5 weekly sessions (1.5 hours each), plus participant educational materials, and is delivered to couples via videoconference by a trained interventionist. Participants are asked to complete home activities between sessions. Sessions focus on development of communication and coping skills, with a focus on reproductive and sexual health distress.
45844568|NCT05563506|Behavioral|Healthy Kids +|Three times a week for 30 weeks.
46048035|NCT02856750|Drug|Gabapentin|Gabapentin 300 mg three times daily x30 days
46048036|NCT02607709|Procedure|Lymphadenectomy in conjugation with nephroureterectomy|"Lymphadenectomy (intervention group only):~Lymphadenectomy performs in four fractions on the right side and two fractions on the left side according to Dissection template (Appendix 1). Renal hilar nodes are included in fraction 1 and 3, respectively."
46048037|NCT02607709|Procedure|Nephroureterectomy without lymphadenectomy|Removing the kidney, ureter and bladder cuff
46048038|NCT04277832|Diagnostic Test|Questionary|All patients will answer two different questionary (TUPAST, TOPAS 2)
46048039|NCT05751967|Drug|Placebo Combined With Ursodeoxycholic Acid|1 tablet/ day
46048040|NCT05751967|Drug|Fenofibrate Combined With Ursodeoxycholic Acid|200 mg/day
46048041|NCT02857920|Drug|Bevacizumab|7.5 mg/kg, i.v, once every 3 weeks (continuous)
46048042|NCT02857920|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfusion in 3 times, i.v.
46048043|NCT03847831|Behavioral|Active School Flag Program|Schools enrolled in the program take part in the 17 actions described in the PPASF.
45358995|NCT04042194|Procedure|Placement of Implants and Thickening Peri-Implant Mucosa with T-PRF|A total of 40 ml blood sample was collected from the antecubital vein of the patients' right or left arms with 10 ml injectors. 40 ml blood was transferred to a grade-IV titanium tube for the T-PRF group. The titanium tubes containing the blood samples were instantly centrifuged in a tabletop centrifuge at room temperature. The blood samples of the T-PRF group were centrifuged clockwise at 2700 RPM for 20 minutes. Subsequent to the centrifugation process, the clots of the T-PRF group were removed from the tubes with sterile tweezers, separated from the RBC base with scissors, and left for over 20 minutes on sterile woven gauze to release the serum slowly from the collected clots. The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with T-PRF.
45358996|NCT04042194|Procedure|Placement of Implants and Thickening Peri-Implant Mucosa with CTG|The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with CTG. Autogenous connective tissue graft was harvested according to a single incision technique.
45358997|NCT04090619|Other|Questionnaire Administration|Complete questionnaires
45358998|NCT00960921|Drug|Iron sucrose|An intravenous infusion of 100 mg of iron is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six iron infusions for each participant in the iron group over the course of the 28-day study period.
45358999|NCT00960921|Drug|Normal saline|An intravenous infusion of 100 ml of normal (0.9 %) saline is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six saline (placebo) infusions for each participant in the saline group over the course of the 28-day study period.
45359000|NCT00863382|Device|Standard Event Monitor|Standard Event Monitor
45359001|NCT00863382|Device|Sleuth Monitor|Implantable Sleuth Recorder
45359002|NCT00743249|Device|MINI MONOKA canalicular stent, 10 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 10 mm length
45359003|NCT00743249|Device|MINI MONOKA canalicular stent, 20 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 20 mm length
45359004|NCT00973089|Other|Incomplete caries removal in primary teeth|Comparison between the success rate and cost-effectiveness of complete caries removal in treatment of deep carious lesions that might include wide preparations and involve pulpotomy versus incomplete removal of caries and avoiding pulp treatment.
45359005|NCT00863460|Radiation|cranial radiotherapy|40 Gy
45844569|NCT05562570|Behavioral|Physical activity intervention coupled with standard post-cancer directed treatment care|AYACS will participate in a 16-week physical activity program. AYACS will be instructed to start with a session duration of <15-min, three days per week at low intensity (e.g., activities expending >1.5 to 3 METs or intensity <5 on a scale of 0 to 10). Any type of physical activity will be acceptable. The program will be individualized, and activity increased according to patients' health status, results from the physical function assessment, and most recent week's achieved physical activities. The program will include support calls and texts from research staff (exercise physiologist). The program will be modified and adapted during support calls or texts, including frequency, intensity, time and type to maximize AYACS' success. AYACS will receive a Fitbit at the beginning of the intervention.
46048044|NCT02858466|Radiation|MRI scan|
46048045|NCT05750953|Behavioral|eHealth@Hospital-2-Home|At hospital discharge, the intervention group will receive a wireless, portable personal computer system (i.e., IPAD) that includes the eHealth application MyDignio supplied by a certified m-Health company. MyDignio app is linked to monitoring devices by Bluetooth for each patient to daily and weekly measure clinical measures such as blood pressure, pulse, temperature, and weight, and self-reported symptoms and well-being, and daily report clinical measurements to the Nurse Navigators employed in the two hospitals. The patients will receive training from the nurses on how to log on and use the MyDignio app and the monitoring devices. Telephone contact details including information about how to access technical support will be provided to each study participant shortly following discharge.
46048046|NCT02607631|Drug|Pembrolizumab|treated with Pembrolizumab 200 mg every 3 weeks
46048047|NCT02858232|Biological|MASCT-I|Dendritic cells(DC) loaded with antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
46048048|NCT02857842|Drug|Prednisolone|
46048049|NCT00914407|Drug|Oxygen|100% Oxygen inhalation for 30 minutes
45359006|NCT00863460|Drug|intensive chemotherapy and hematopoietic stem cell rescue|intensive chemotherapy and hematopoietic stem cell rescue
45359007|NCT00863460|Drug|MTX based chemotherapy|R-MBVP 2 cycles day1 and day28 followed by R-Aracytine 2 cycles days58&59 and days79&80
45359008|NCT00262951|Biological|recombinant interferon alfa|administered subcutaneously (SQ)at a dose of 3 million units Day 1,3, and 5 each week in Cycle 1
45359009|NCT00262951|Drug|cisplatin|administered at a dose of 30 mg/m2 intravenously (IV) day 1 each week in Cycle 1
45359010|NCT00262951|Drug|fluorouracil|administered at a dose of 175 mg/m^2/day continuous infusion (CI) for 38 days in Cycle 1 and then 500 mg/m^2 intravenously (IV) each week for 6 weeks followed by a 2 week rest (1 cycle = 8 weeks)in Cycle 2 and 3
46048050|NCT03635437|Drug|Gamma-Aminobutyric Acid (GABA)|Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
46048051|NCT03635437|Drug|Alprazolam|Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
45359011|NCT00262951|Radiation|radiation therapy|5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday -Friday, for 5½ weeks (days 1-5, 8-12, 15-19, 22-26, 29-33, 36-38).
45687743|NCT04806724|Behavioral|Side by Side|The intervention includes 4 weekly sessions (1.5 hours each), plus participant educational materials, and is delivered to couples via videoconference by a trained interventionist. Participants are asked to complete home activities between sessions. Sessions focus on development of communication and coping skills, with a focus on general cancer-related distress.
45687744|NCT04800913|Diagnostic Test|Multimodal imaging|Preoperative 2D/3D TOE and MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
46048052|NCT03796663|Behavioral|Mindful Parenting Program|"The Mindful Parenting Program consists of 7, 2.5 hour weekly group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children. Parents are introduced to formal meditation practices, including the bodyscan; choiceless awareness; mindful walking; and yoga. They are also introduced to mindfulness of everyday activities from the beginning of the sessions, with an added focus on day-to-day parenting and family activities. Additionally, short self-compassion practices occur throughout the weekly sessions, culminating in the teaching of formal loving-kindness meditation.~Additionally, the program encourages parents to engage in home practice, where parents can experience and practice many of the new skills they are learning. This includes both formal, longer meditation practices, as well as shorter practices, which can occur throughout the day, such as mindfulness of daily routines."
45359012|NCT00262951|Procedure|Resection of tumor|After Cycle 1 treatment (if resectable)- In the absence of metastatic disease, special emphasis will be paid to the local tumor. Evaluation of the growth/regression of the tumor will be made as it relates to resectability. Surgical exploration will start with a diagnostic laparoscopy. If no evidence of carcinomatosis, liver metastases or other evidence of metastatic disease is encountered, then a laparotomy will be performed. In the absence of clear technical unresectability, a radical pancreaticoduodenectomy, distal or total pancreatectomy (and resection of any involved structures) will be performed as mandated by tumor anatomy.
45359013|NCT00793364|Dietary Supplement|Stanol ester spread|Stanol ester spread 20 g every day
45359014|NCT00793364|Dietary Supplement|Placebo spread|Placebo spread 20 g every day
45359015|NCT00793364|Dietary Supplement|Mediterranean Diet|Mediterranean Diet every day
45359016|NCT02597153|Drug|Mitoxantrone HCL Liposome Injection|
45359017|NCT00867438|Procedure|Sigmoidoscopy|
45359018|NCT00975741|Device|OXIMAX|
45359019|NCT00975741|Device|ASMANEX TWISTHALER|
45359020|NCT00786890|Other|observational, no intervention needed|observational, no intervention needed
45359021|NCT04089215|Biological|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|JWCAR029 be administered at dose level: 1 x 10^8 CAR+T cells and 1.5 x 10^8 CAR+T cells
45359022|NCT00262873|Drug|bortezomib|
45359023|NCT00867516|Biological|ALD518|Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8
45479516|NCT03329482|Other|KNEADING MASSAGE|Kneading massage was done with the two hands maintaining a slow circular compression of soft tissues against underlying bone. Pressure was applied as the hands moved proximally, continuously maintaining a contact with the skin, according to Goat22). Lofnac gel was used as a coupling medium for the massage. This was done for an approximately ten and 12 minutes.
45479517|NCT03505021|Drug|Levosimendan|Levosimendan 1 mg capsule for oral administration
45479518|NCT03505021|Drug|Placebo for levosimendan|Placebo capsule for oral administration
46048053|NCT03796663|Behavioral|MATCH BPT Program|The MATCH BPT Program consists of 8-12 weekly (depending on how long it takes for individual parents and their assigned trainer to get through the material), 60 minute individually-implemented sessions.The sessions will consist of the coach obtaining and reviewing weekly assignments completed by the parent, followed by activities and discussions that focus on a particular parenting skill (i.e. praise, active ignoring, giving effective instructions). The discussions will emphasize benefits and possible problems that the parent may encounter throughout the week while implementing the new skill. The coach will assign to the parent a practice assignment to further encourage use of the concept.
46048054|NCT05750797|Drug|Oral corticosteroids|The prescription of OCS will be analyzed. OCS included betamethasone, deflazacort, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, and triamcinolone.
46048055|NCT05701267|Device|MRI research|3T MRI protocol of ~1 hour
45479519|NCT02497066|Other|Neuropathic pain cream|Subjects will apply the cream to the painful area.
45479520|NCT02497066|Other|Nociceptive pain cream|Subjects will apply the cream to the painful area.
45479521|NCT02497066|Other|Mixed pain cream|Subjects will apply the cream to the painful area.
45479522|NCT04217603|Device|Continuous positive airway pressure (CPAP) device|Use of a CPAP during a 6 minute walk test to maintain the airways open during the respiratory cycle
45479523|NCT04217603|Device|Sham-continuous positive airway pressure (CPAP) device|An enlarged air leak incorporated into the exhalation valve will be positioned between the mask and the CPAP tubing, allowing airflow resistance of the exhalation port to be almost eliminated by increasing its area, thereby virtually cancelling positive pressure. Also an orifice restrictor in the CPAP circuit will be connected between the CPAP unit and the tubing in order to load the blower with the same airflow resistance as in true CPAP.
45479524|NCT05463640|Biological|ADGRE2 CAR-T|ADGRE2 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
45359024|NCT00867516|Biological|Infusion without ALD518'|250 cc Normal saline IV over one hour Weeks 1 and 8.
45359025|NCT00786968|Drug|laronidase|1.74 mg intrathecally every 1-3 months for 1 year
45687745|NCT04800913|Diagnostic Test|Standard imaging|Preoperative MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
45359026|NCT00975819|Drug|sirolimus|liquid dosing based on trough levels
45359027|NCT02598323|Device|ultrasound|
45359028|NCT00793442|Diagnostic Test|Blood Collection and Assays|The researchers will sample blood upon enrollment, at 6 and 24 hours after the baseline sampling. The researchers will measure 6 different endothelial related biomarkers compromising different components of endothelial permeability and hemostasis.
45359029|NCT03974737|Device|CRI device (non-invasive vitals sign measurement)|Survey administration, Orthostatic vital measurements
45359030|NCT00973167|Device|Low-magnitude high-frequency vibration treatment|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5 days/week
45359031|NCT00859872|Drug|risperidone oral solution|risperidone oral solution (2-6mg/d) combination clonazepam (4-8mg/d) oral
45359032|NCT00859872|Drug|haloperidol|haloperidol IM injection (5-20mg/d)
45359033|NCT02555696|Drug|nab-paclitaxel|nab-paclitaxel by IV infusion every 3 weeks until progression or toxicity
45359034|NCT00961077|Drug|S-1 (TS-1) and Oxaliplatin (Oxalitin)|"S-1(TS-1) 60mg/m2/day (D1-14) Oxaliplatin: 85mg/m2 + 5DW 250mL MIV over 2-hours~every 3 weeks"
45359035|NCT00867594|Drug|ORMD 0801|1 capsule ORMD 0801 3 times a day, before each meal
45359036|NCT03974659|Combination Product|Transcranial magnetic stimulation|1.Patients were given 10 consecutive days bilateral cerebellar VIIa lobules Theta Burst Stimulation which was a special mode of Transcranial magnetic stimulation from one week after surgery Intermittent Theta Burst Stimulation(Positive stimulation) is used in right cerebellar VIIa lobule.Each stimulus had three 50 Hz monopulses, which were repeated every 200 ms. Each stimulation continued for 2 seconds and rested for 8 seconds. The total intervention time was 200s (600 pulses) Continuous Theta Burst Stimulation(Negative stimulation) is used in left cerebellar VIIa lobule,three 50 Hz monopulses in each stimulus, each with an interval of 200 ms, and each intervention lasted 40s (600 pulses).
46048056|NCT00803179|Drug|Nutropin AQ|Based on recommendations from the 2007 GH Deficiency Consensus Workshop on adult GH deficiency, the recommended initiation of treatment for adult males is 0.2mg/d and for women 0.4mg/d, with a titration upwards based on insulin-like growth factor (IGF-1) (product of GH stimulation at target tissues) levels and patient response. IGF-1 will be monitored at the 3,4,5 and 11 month intervals. For subjects under the age of 25 with an open epiphysis of the hand and/or wrist we will treat with the dose of 0.3mg/kg/week. Subjects will be on growth hormone for 8 months with a baseline visit prior to initiation of therapy and a 3 month follow-up visit after stopping therapy.
46048057|NCT00914173|Device|Scanlaf Circulator and water bath|Cold Pressor Test
46048058|NCT00914173|Device|Medoc TSA 2000|Thermal stimuli pain
46048059|NCT00804193|Drug|Ciclopirox Olamine Topical Suspension|topical suspension
46048060|NCT00804193|Drug|Ciclopirox Topical Suspension 0.77%-Reference Product|topical suspension
46048061|NCT00804193|Drug|Ciclopirox Olamine Topical Suspension-Placebo|topical suspension
46048062|NCT05697211|Drug|Ferric maltol 30 mg (Feraccru®)|In this trial Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects.
46048063|NCT02607787|Behavioral|Exercise|The exercise programme aims to gradually increase participants physical activity levels so that they start achieving the recommended levels of at least 150 minutes moderate intensity aerobic activity per week and strengthening exercise for all major muscle groups at least twice per week.
45359037|NCT02598245|Device|TOT 8/4|placement of transobturator sling according to the TOT 8/4 technique
45359038|NCT02598245|Device|TOT 6/3|placement of transobturator sling according to the TOT 6/3 technique
45359039|NCT00787280|Behavioral|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
45359040|NCT00787280|Behavioral|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
45359041|NCT05147493|Drug|Isatuximab|Route of administration: Intravenous (IV). Dose regimen: Isatuximab will be given at a dose of 10 mg/kg once weekly (QW) on Days 1, 8, 15, and 22 in Cycle 1, on Days 1 and 15 during Cycles 2-6 and on Day 1 from Cycle 7 onwards.
45359042|NCT05147493|Drug|Bortezomib|Route of administration: Subcutaneous (SC). Dose regimen: Bortezomib will be given at 1.3 mg/m2 on Days 1, 4, 8, 11 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
45687746|NCT04798339|Drug|Canakinumab Injection|Participants will be treated at 1 of 2 dose levels of Canakinumab, beginning at 150 mg and increasing to 300 mg or the Maximum Tolerated Dose
45687747|NCT04798339|Drug|Darbepoetin Alfa|Participants will receive Darbepoetin alfa subcutaneously at a dose of 300mg on days 1 and 15 of each cycle
45687748|NCT04795713|Drug|MT-6402|Experimental Treatment
45687749|NCT04792385|Drug|E4/DRSP 15/3 mg combined tablet|One E4/DRSP 15/3 mg combined tablet once per day for 24 days followed by 4 days of placebo tablets; this 28-day cyclic regimen should be taken for 6 consecutive cycles.
46048064|NCT02607787|Other|Control|The control group will receive usual care whilst attending for the same 4 visits as the intervention group and have the same outcome measures tested. They will however receive the intervention information on their last visit.
45359043|NCT05147493|Drug|Cyclophosphamide|Route of administration: Intravenous (IV). Dose regimen: Cyclophosphamide will be given at 300 mg/m2on Days 1, 8, 15 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
45359044|NCT05147493|Drug|Dexamethasone|Route of administration: per os (PO)/Intravenous (IV). Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) on Days 1-4 and 9-12 of Cycle 1 and Days 1, 8, 15 and 22 of Cycles 2-6.
45359045|NCT05147493|Drug|Lenalidomide|Route of administration: per os (PO). Dose regimen: Lenalidomide will be given at 10 mg (or according to renal function) daily from Cycle 7 onwards.
45359046|NCT00573534|Drug|Vyvanse|Patients will be titrated from 30 mgs to 50 mgs to 70 mgs over four weeks, as tolerated and as needed to control ADHD symptoms
45687750|NCT04785651|Drug|Tibial osteotomy with Tranexamic acid|"Patients who will be in the treatment arm after randomisation will receive 100ml saline with a dosage of 20 mg/kg tranexamic acid intravenously at induction. An additional administration of tranexamic acid (10 mg/kg in 100ml intravenous saline) will be given as a booster at the end of the surgical procedure.~All the patients will undergo to the same tibial osteotomy procedure."
46048065|NCT04115215|Behavioral|Physical exercise (PE)|This arm includes 10 sessions of multi-component exercise sessions (including aerobic, resistance, flexibility, dual-tasking) of 1 hour/week of functional group exercise, directed to foster empowerment for subsequent continuation of exercise in community-dwelling older adults referred by primary care to a geriatrician and an expert physical therapist. Participants will receive a leaflet with instructions to perform five strength-based exercises and instructors will recommend participants to perform the exercises and walk at least 15 minutes daily.
45359047|NCT03974191|Other|Change in function, activity, participation and other health related factors in CLBP and to identify predictors for pain, activity and work ability after 13 years.|13-year prospective longitudinal cohort study
45359048|NCT04090385|Device|Transcranial Direct Current Stimulation|Participants will receive 15 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, 5 times a week. The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². These parameters are within the safe limits established in previous human studies.
45359049|NCT03974425|Drug|Aflibercept Injection [Eylea]|intravitreal injection of Aflibercept in resistant DME.
46048066|NCT04115215|Device|Transcranial current stimulation (tCS)|This arm includes 1 application/week for 10 weeks during PE, through an adapted commercial helmet. Transcranial current stimulation (tCS) is a neural stimulation technique based on electrical stimulation of selected parts of the brain with direct or alternated electrical current (tDCS or tACS) of very low intensity of 1,5 milliamps (mA), using one or more electrodes placed on the skull. tCS is non-invasive (no surgical procedures) and it is painless, as applied in the proposed protocols.
46048067|NCT04115215|Other|Control|Participants of similar profile, randomized to the control group, will undergo weekly 30 minutes educational sessions on healthy aging, including relevant aspects of nutrition, self-care, physical activity, plus measurement of blood pressure, heart rate and peripheral oxygen Hb saturation. These participants will be offered to join the PE program after the 6-months follow-up (end of the study).
46048068|NCT00957996|Drug|Peramivir|300 mg twice daily
45359050|NCT00975897|Biological|bevacizumab|
45359051|NCT00975897|Biological|cetuximab|
45359052|NCT00975897|Drug|fluorouracil|
45687751|NCT04785651|Procedure|Tibial osteotomy without Tranexamic acid|Patients in this arm will undergo to the tibial osteotomy procedure as by clinical practice
45687752|NCT04781114|Drug|JS002|JS002: 150mg(1mL) Q2W; Placebo 1mL Q2W.
45687753|NCT04781114|Drug|Placebo|JS002: 300mg(2mL) Q4W; Placebo 2mL Q4W.
45359053|NCT00975897|Drug|irinotecan hydrochloride|
45359054|NCT00975897|Drug|leucovorin calcium|
45359055|NCT00975897|Drug|oxaliplatin|
45359056|NCT00975897|Genetic|RNA analysis|
45359057|NCT00975897|Genetic|cytogenetic analysis|
45359058|NCT00975897|Genetic|fluorescence in situ hybridization|
45359059|NCT00975897|Genetic|gene expression analysis|
45359060|NCT00975897|Genetic|mutation analysis|
45359061|NCT00975897|Genetic|protein expression analysis|
45359062|NCT00975897|Other|diagnostic laboratory biomarker analysis|
45359063|NCT00975897|Other|immunohistochemistry staining method|
45687754|NCT04780204|Drug|Treatment|Tenofovir Alafenamide 25 mg oral once daily
45687755|NCT04770480|Behavioral|Standard Care (SC)|No attempt will be made to change usual care practice after surgery
45359064|NCT00975897|Other|questionnaire administration|
45359065|NCT00975897|Procedure|cognitive assessment|
45359066|NCT00867672|Drug|Decitabine|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
45359067|NCT00867672|Drug|VPA|VPA starting on day 6 of first cycle continuously throughout all treatment cycles
45359068|NCT00867672|Drug|ATRA|ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
45359069|NCT01071421|Device|abbreviated polysomnography|Both groups will be studied with in-hospital respiratory polygraphy during the sleep. The group A will be studied with another respiratory polygraphy in the home one month after the resolution of CAP. Some questionnaires to measure the sleepiness (Epworth test), FOSQ test, in-home sleepiness questionnaire and symptoms questionary will be obtained in Group A and B
45359070|NCT00917657|Procedure|Photorefractive keratectomy|
45359071|NCT05145231|Other|GÖZLEMSEL|The scales will be filled by asking the family.
45359072|NCT00783926|Biological|H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)|2 x 0.5 mL intramuscular injections 21 days apart (one of six different doses of hemagglutinin antigen without adjuvant)
45359073|NCT01071499|Drug|Morphine|One dose of morphine (0.1 mg/kg)
45359074|NCT01071499|Drug|Morphine|One dose of morphine (0.2 mg/kg)
45359075|NCT01071499|Drug|Morphine|One dose of morphine (0.3 mg/kg)
45359076|NCT04040868|Device|the TiRobot system|The TiRobot system (TINAVI Medical Technologies Co. Ltd.) is a multi-indication orthopedic surgical robot that can be used in spinal, pelvic, and limb surgeries performed via an open or a minimally invasive approach
45359077|NCT04040868|Device|Freehand|conventional fluoroscopy-assisted
45359078|NCT05142813|Diagnostic Test|Diagnostic Test: Blood specimen collection|Diagnostic Test: Blood specimen collection Study samples must be collected within before treatment with antibiotics or antivirals.
45359079|NCT03974269|Procedure|TAVI : Transcatether Aortic Valve Implantation|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
46048069|NCT00957996|Drug|Peramivir|600 mg once daily
46048070|NCT02607553|Drug|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle until disease progression
46048071|NCT04017949|Drug|Corticosteroid injection|1 cc (40 mg) of a corticosteroid (kenalog) is given
46048072|NCT04115137|Device|pelvic varicose veins plug embolization|pelvic varicose veins plug embolization
45359080|NCT00917189|Behavioral|Challenging Our Minds Program|A computerized cognitive intervention that provides training in attention, memory, and executive function
45359081|NCT00961155|Drug|cyklezonid|160 mcg once daily
45359082|NCT00961155|Drug|montelukast sodium|5 or 10 mg according to age once daily
45359083|NCT00961155|Drug|placebo|fluticasone placebo twice daily, montelukast placebo once daily
45359084|NCT00961155|Drug|formoterol 12 mcg twice daily|formoterol 12 mcg twice daily will be given to children for 3 months
45359085|NCT00793676|Other|spirometry|
45359086|NCT00793676|Other|blood test|
45359087|NCT00863538|Drug|KPS-0373|
45359088|NCT00260533|Drug|atomoxetine|Flexible dose, up to 50 mg per day
45359089|NCT00260533|Drug|placebo|placebo (matching to atomoxetine)
45479525|NCT05155358|Diagnostic Test|Peripheral blood test|Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis
45687756|NCT04770480|Behavioral|Enriched Pain Management Pathway (EPM)|Enriched Pain Management Pathway will be delivered by physical therapists trained to integrate physical therapy and mindfulness techniques grounded in a biopsychosocial context. The intervention will be delivered within the context of the post-operative physical therapy routine (the mindfulness approach will be integrated into the post-operative physical therapy care).
46048073|NCT02606539|Procedure|Total abdominal hysterectomy and methotrexate|After written consent laparotomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG (the cycle may be repeated until normalization of B-HCG)
46048074|NCT02606539|Drug|Methotrexate plus folinic acid alone|methotrxate 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG and cycle repeated until normalization of B-HCG
46048075|NCT00589693|Drug|Doripenem|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 4-hour infusion of doripenem will be administered every 8 hours for 7 days.
46048076|NCT00589693|Drug|Imipenem-Cilastatin|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 1-hour infusion of imipenem-cilastatin will be administered every 8 hours for 10 days.
45359090|NCT02596919|Other|photography|photography of meibomian glands
45687757|NCT04767880|Dietary Supplement|Whey|Doses of 10, 15, 20 and 30 gram protein of a regular whey protein compound (whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients))
45687758|NCT04767880|Dietary Supplement|Placebo|The placebo contains <1 kcal and 0 g protein
46048077|NCT00589693|Drug|Placebo|Form=solution, route=intravenous. Doripenem pacebo will be administered from Days 1 to 7 in imipenem-cilastatin arm and imipenem-cilastatin placebo will be administered in doripenem arm.
45359091|NCT00863616|Device|HFCWO - SmartVest|SmartVest with vest administered for 20min at 11-13Hz
45359092|NCT00973245|Drug|Xarelto (Rivaroxaban, BAY59-7939)|10mg od
45359093|NCT00973245|Drug|Xarelto (Rivaroxaban, BAY59-7939)|15mg od
45359094|NCT00973245|Drug|Xarelto (Rivaroxaban, BAY59-7939)|20mg od
45359095|NCT00973245|Drug|Warfarin|Dose-adjusted warfarin based on target INR values
45359096|NCT00793754|Drug|Aspirin|100 mg / day for 8 weeks
45359097|NCT00793754|Drug|Atorvastatin|40 mg / day for 8 weeks
45359098|NCT00793754|Drug|Aspirin + Atorvastatin|Aspirin 100 mg / day + Atorvastatin 40 mg / day for 8 weeks
45359099|NCT02596763|Drug|Baclofen|Patient receiving an off-label baclofen treatment for alcohol use disorder for less than 1 month.
45359100|NCT03976141|Diagnostic Test|mri|knee mri
45359101|NCT00793832|Behavioral|supervised exercise|supervised exercise
45359102|NCT00793832|Behavioral|Diet advice|Diet Advice
45359103|NCT00860106|Other|ED, DDimers and phone follow up|ED score, DDimers level and phone questionnary
45359104|NCT00973323|Drug|Xarelto (Rivaroxaban, BAY59-7939)|2.5mg bid
45359105|NCT00973323|Drug|Xarelto (Rivaroxaban, BAY59-7939)|5mg bid
45359106|NCT00973323|Drug|Xarelto (Rivaroxaban, BAY59-7939)|10mg bid
45359107|NCT00973323|Drug|Warfarin|Dose-adjusted warfarin based on target INR values
45479526|NCT03793283|Device|CSII|Currently receiving CSII therapy during 6 or more months.
45479527|NCT03793283|Drug|Multiple dose insulin injections|Currently receiving MDI therapy during 6 or more months.
45479528|NCT02496988|Drug|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
45479529|NCT02496988|Biological|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
45844570|NCT05562570|Other|Standard post-cancer directed treatment care control|AYACS in the control group will not participate in a 16-week physical activity program and will not receive support calls or texts. Physical activity advice according to the Exercise Guidelines for Cancer Survivors will be offered to AYACS following completion of 16-week follow-up. Moreover, AYACS will receive a Fitbit following completion of 16-week follow-up
45687759|NCT04763564|Drug|Liraglutide Pen Injector|Treatment will be initiated at 0.6 mg per day for one week. The patient will be instructed to increase the dose to 1.2/day and 1.8 mg /day in week 2 and in week 3, respectively. From week 3 after the start of the drug until week 6 the patient will apply 1.8 mg/day liraglutide. In case of intolerance (e.g. occurrence of refractory nausea) at a higher dose (e.g. 1.8 mg daily, the highest dose in this trial) liraglutide can be reduced to the previous level.
46048078|NCT05735509|Device|Rubber dam|Intraoral impressions can be taken with rubber dam in place. The care provider will take two impressions, one with the rubber dam in place and one without. The investigator will randomly chose one of the two impressions for crown manufacturing, and the crown will be delivered by the care provider blindly
45359108|NCT00793988|Procedure|Vibration-assisted anaesthesia|"All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The vibration device and placebo will be operated by a single oculoplastics fellow. The vibrating device / placebo will be placed on the middle of the forehead 1 cm above the mid-brow point 1 second before the anaesthetic injection is commenced. It will be lifted off the skin every time the injection needle exits the skin and it will be replaced on the same point 1 second before the needle reenters the skin at a new injection site."
45359109|NCT00793988|Procedure|Switched-off vibrating device|The placebo consists of a switched-off vibrating device applied to the test site and a second identical switched-on vibrating device held close (but not touching) the first, which will therefore make the same sound. Care will be taken to ensure that the devices are out of the participants' view. The test and placebo will be randomly assigned to either the first or second eyelid; the right eyelid will be injected first in all patients, as is our routine practice.
45359110|NCT00973401|Other|Insulin pump|Patients receive an insulin pump that optimizes their glucose control.
45359111|NCT04040322|Drug|Placebo IV infusion|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
46048079|NCT02606383|Drug|Dapaconazole|
46048080|NCT02606383|Drug|Ketoconazole|
46048081|NCT02606695|Device|NuvaMap O.R.|Clinical imaging software used to assess intraoperative spinal alignment
45359112|NCT04040322|Drug|Iloprost Injection, for intravenous use|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
45359113|NCT00787358|Drug|ZT-031|80 ul subcutaneous injection per day
45687760|NCT04763564|Drug|Placebo Pen Injector|Matching placebo pens used to administer normal saline in the same fashion as for liraglutide
46048082|NCT02606695|Device|NuvaMap|Clinical imaging software used to assess spinal alignment
46048083|NCT05663359|Procedure|EVLA 1940 nm|Treatment of varicose veins by endothermic ablation with an endovenous laser at 1940 nm
45359114|NCT00787358|Other|placebo|80 ul daily subcutaneous injection of vehicle only
45359115|NCT00794066|Procedure|measuring the ankle brachial index|"Assessment of the ankle brachial index using the boso-ABI-system 100 (www.boso.de)."
45359116|NCT04035408|Other|Skin health assessment|Assess and measure the natural history of facial skin changes in pre and perimenopausal women undergoing chemotherapy and/or endocrine therapy for breast cancer
45359117|NCT00784004|Other|Breathing Patterns|"All subjects will breathe in four different breathing patterns which are provided by specific masks. Patterns are as the following:~Breathing in through the nose only and out through the mouth only~Breathing in through the mouth only and out through the nose only~Breathing in and out through the nose only~Breathing in and out through the mouth only"
45687761|NCT04762719|Drug|PET/CT Scan with 11C-ER176|Subjects will have a low-dose, non-gated, non-contrast-enhanced, free-breathing CT from the orbits to upper thigh for attenuation correction (CTAC) and anatomic co-localization. Immediately following the start of the PET scan, 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi) of 11C-ER 176 will be administered intravenously followed by a saline flush. A whole-body PET scan from the orbits to upper thigh will then be acquired.
45687762|NCT04762719|Diagnostic Test|Core biopsy of gastric muscle|The echoendoscope (Aloka Arietta 850; Olympus, Center Valley, PA) will be advanced into the gastric lumen and a site targeted for EUS-guided core biopsies based on findings of the PET scan. Fine needle biopsy of the gastric wall will be performed.
45687763|NCT04757220|Other|Cognitive tasks with EEG recording|questionnaires and cognitives tasks
46048084|NCT05663359|Procedure|EVLA 1470 nm|Treatment of varicose veins by endothermic ablation with an endovenous laser at 1470 nm
46048085|NCT00914719|Behavioral|Information only|
46048086|NCT00914719|Behavioral|Sexual risk reduction intervention|
46048087|NCT00914719|Behavioral|sexual risk reduction + alcohol risk reduction component|
46048088|NCT02607475|Device|Robotic telesonography (MELODY Patient System, AdEchoTech)|Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix).
45359118|NCT00867750|Device|Radioembolisation (SIR-Spheres® microspheres)|Yttrium-90 SIR-Spheres microspheres
45359119|NCT00867750|Drug|Transarterial Chemoembolisation|TACE with embolising agent Embospheres (150-300 μm or 300-500 μm diameter) with 50 mg of chemotherapeutic agent epirubicin admixed with 5 ml lipiodol.
45687764|NCT04755231|Device|AcrySof IQ PanOptix Presbyopia Correcting IOL|UV and blue-light filtering foldable multifocal IOL with a +2.17 diopter (D) addition power of intermediate visual acuity and a +3.25 D addition power of near visual acuity. This device is approved in China.
45844571|NCT05554614|Behavioral|BTW app with reward-based feedback|Teen drivers will be notified of their weekly driving performance via a driving safety score with information on the types of high-risk driving behaviors committed as well as progress on maintaining and/or improving weekly safe driving behaviors. Educational materials on different driving situations and scenarios associated with the high-risk driving behaviors (e.g. 90-second videos) will be provided for the driver to review at any point and time. Information on these driving behaviors and the education material will be provided via push notifications from the BTW app. Weekly leader boards will show the driver's driving safety score in comparison to other drivers of the same age. Consistently high driver safety scores in certain driving skill areas (e.g., cornering) and a total overall score above 70% of other users on that skill or total score will unlock gamification-based rewards (e.g., driving safety badges, driving safety score leader board, group challenges with winners).
45359120|NCT00787436|Drug|Thalidomide|Medical therapy has been used to decrease upper gastrointestinal bleeding in cirrhotics Non Selective beta blockers have been shown to effectively decrease the portal venous pressure
45359121|NCT03945981|Drug|Dolutegravir + Lamivudine FDC|Dolutegravir + Lamivudine FDC is available as white oval film-coated tablets which are packed in high density polyethylene (HDPE) bottles with induction seals and child-resistant closures. Each 60 milliliter (mL) bottle contains 30 tablets
45359122|NCT00784082|Drug|Hydroxycarbamide, Hydroxyurea (drug)|hydroxyurea 20-25 mg/kg/day since at least 3 months
45359123|NCT03926598|Behavioral|Patient and/or Family Member Intervention|On the Patient Login Screen, log in using your last name and session ID provided by the research team on the Surveys Screen, click on a pending survey when the survey opens, respond to the survey submit the survey log out of the Guide-Goals Application.
45359124|NCT03926598|Behavioral|Certified Diabetes Educator Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.
45359125|NCT03926598|Behavioral|Physician Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patient Screen, add a new patient on the Edit Patient Screen, add the Diabetes Family Responsibility Questionnaire on the Edit Patient Screen, create a survey access code to share with the patient.
45359126|NCT03926598|Behavioral|Front Desk Staff Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.
45687765|NCT04755231|Procedure|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ PanOptix Presbyopia Correcting IOL
45479530|NCT03050372|Device|LFMS - Active|A non-invasive form of brain stimulation administered from a device resembling a bird cage. The device covers the top part of the head for the duration of stimulation (in the current study, 20 minutes)
45479531|NCT03050372|Device|LFMS - Sham|A simulation of the LFMS-Active intervention, using the same device that produces a sound similar to the sound made by the device during the active treatment, for a similar duration (in the current study, 20 minutes)
45479532|NCT01647971|Drug|Ublituximab|Ublituximab is a novel monoclonal antibody targeting cluster of differentiate 20 (CD20)
45479533|NCT03329326|Other|Functional tests and self-reported questionnaires|In this observational study no intervention is initiated. Patients included are only assessed with the non-invasive tests described earlier.
45687766|NCT04753853|Procedure|Stromal Vascular Fraction injection|intra- and peri-tendon ultrasound-guided injection of Stromal Vascular Fraction
45752066|NCT00403117|Drug|Naltrexone 12 Mg + Inactive Marijuana (0% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
45359127|NCT03926598|Behavioral|Nurse Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status screen, change HbA1C value to 10% on the Visit Status screen, change Nephropathy evaluation to Abnormal log out of Guide to Goals application.
45359128|NCT00784160|Drug|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
45359129|NCT00976053|Procedure|Myocardial perfusion imaging|Randomization assignment to one of SPECT or PET myocardial perfusion imaging
45359130|NCT00794222|Device|Mobile Tracking Young People's Experiences (mobiletype)|A mobile phone self-monitoring program, based on momentary sampling techniques, that prompts young people to complete it four times a day. The program asks several questions about daily activities, mood, stress, eating and exercise.
46048089|NCT02607475|Device|Conventional sonography (EPIQ 5, Philips or LOGIQ E9, GE Healthcare)|Conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare) ultrasound systems.
46048090|NCT02606227|Behavioral|Financial incentive|Vouchers
45359131|NCT03906747|Other|Interviews, questionnaire and focused group discussions|"To determine the effectiveness of the quality of care as perceived by relatives, we will perform a survey during the ED stay, with the next-of-kin to patients who was on the EOL pathway using a questionnaire developed for ED settings. The questionnaire will be administered by the research assistant face-to-face in the emergency department to assess the quality of care and the level of support provided to patients and their families in the last days of life.~We will also determine the level of staff's knowledge and perception of the EOL care using a locally-designed self-administered anonymous survey.~A focus group discussion (FGD) will be formed in each hospital to identify the gaps to the current EOL care by structured questionnaire. The group will also make recommendations to improve the quality of the EOL care. There will be separate FGD for: (i) healthcare professionals (ii) family members and (iii) general practitioners who will care for the patient if terminally discharged."
45479534|NCT03721315|Behavioral|Intervention|"The health literacy enhancement will comprise of the following:~Practical day to day information to help manage the disease~Benefits of medication and adherence~Tips to improve managing shortness of breath~Proper use of inhalers (if applicable)~Managing daily activities"
46048091|NCT02606227|Other|No financial incentive|No financial intervention
45479535|NCT03793205|Drug|Long-acting G-CSF|Long-acting G-CSF will be given 48 hours after the chemotherapy. A supplement of short-acting G-CSF will be given as required.
45479536|NCT03793205|Drug|Short-acting G-CSF|Short-acting G-CSF will be given as required 24 hours after the chemotherapy.
45479537|NCT03324568|Behavioral|Parent Education Videos|Participants will receive educational videos describing behavioral techniques to improve parent and child eating behavior.
45479538|NCT03324568|Behavioral|Educational Handout|Participants will receive educational handouts describing behavioral techniques to improve parent and child eating behavior.
45479539|NCT01550861|Procedure|in vitro maturation|Maturation of immature oocytes in the laboratory following oocyte retrieval
45479540|NCT01550861|Procedure|Polar Body Biopsy with preimplantation genetic screening|Polar body biopsy is performed on the day that the oocyte is retrieved. Microarray analysis will will be performed and compared with FISH and microarray analysis of day 3 or day 5 biopsy.
45687767|NCT04748588|Drug|Anti-SARS-CoV-2 mAb|"Casirivimab/imdesimab 1200mg/1200mg OR sotrovimab 500mg OR bamlanivimab 700mg IV x1.~Casirivimab/imdesimab (REGN) and sotrovimab will be the default agents used (according to local availability) unless both unavailable AND virus strain known to be native or alpha (B.1.1.7) in which case bamlanivimab can be used."
45687768|NCT04741997|Drug|Encorafenib Pill|Encorafenib 450 mg will be administered orally once per day in continuous 28-day cycles
46048092|NCT05660473|Drug|Vincristine|Anti-tumor alkaloids
46048093|NCT05660473|Drug|Daunorubicin|Anthracycline
46048094|NCT05660473|Drug|Cyclophosphamide|Alkylating agent
46048095|NCT05660473|Drug|Pegaspargase|Polyethylene glycol (PEG) conjugated to L-asparaginase
46048096|NCT05660473|Drug|Prednisone|Glucocorticoids
45359132|NCT03906747|Other|Review of medical records|"Electronic medical records will be reviewed to collect the following data:~Proportion of patients who fits criteria of EOL who died within 48 hours;~Proportion of patients on EOL pathway who have documentation that patient and/or family are given opportunities to discuss an individualised care plan;~Proportion of patients on EOL pathway who have documentation of an individualised care plan that is followed;~Proportion of patients on EOL pathway who have symptoms who are prescribed with medicines with individualised indications for use, dosage and route of administration"
45359133|NCT00794300|Device|second magnetic resonance imaging scan|
45359134|NCT00979563|Drug|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
45359135|NCT00745901|Drug|Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol|
45359136|NCT00787670|Other|Diabetes Support and Education|The subjects will attend three educational/social support sessions for 1 year after enrollment. The educational sessions include informational sessions on diet/nutrition and exercise. These sessions are informational and do not teach behavioral self-regulation skills.
45359137|NCT00787670|Procedure|gastric bypass surgery|gastric bypass surgery to induce weight loss in obese patients with type 2 diabetes
45359138|NCT00787670|Other|Tissue Control Group|During the abdominal surgery we would like to take 5 ml blood from the IV line and small pea-sized samples of the fat tissue just under the skin and around the stomach area. These samples will be stored so that we can compare these tissue with other patients.
45359139|NCT00863850|Drug|bendamustine|Bendamustine 120 mg/m2 on Days 1 and 2 every 28 days (one cycle) for up to 6 cycles. Radiolabeled [14C] bendamustine will be given on day 1 of cycle 1 only.
45359140|NCT00794456|Drug|Passiflora ; Crataegus and Salix|1 tablet PO twice a day
45479541|NCT03329248|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
45687769|NCT04741997|Drug|Binimetinib Pill|Binimetinib 45 mg will be administered orally twice per day in continuous 28-day cycles
45359141|NCT00794456|Drug|Valeriana|1 tablet PO twice a day
45359142|NCT00860340|Drug|Spironolactone|100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.
45359143|NCT00867828|Dietary Supplement|Neptune Krill Oil|Softgels 1g QD. Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
45687770|NCT04741997|Drug|Nivolumab|Nivolumab will be administered at a dose of 480 mg IV infusion over 30 minutes every 4 weeks.
45687771|NCT04735510|Drug|cyclosporine ophthalmic emulsion 0.05%|All subjects will receive restasis
46048097|NCT05660473|Drug|Cytarabine|Pyrimidine antimetabolites
45359144|NCT00867828|Dietary Supplement|Fish Oil|Softgels 1g QD. Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.
45359145|NCT00867828|Dietary Supplement|Placebo (soy oil)|Softgels 1g QD. The soy oil placebo will provide neither EPA nor DHA.
45359146|NCT00784316|Drug|metoprolol, amiodarone|to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery
45359147|NCT04040556|Other|Simulation class|Pediatric anesthesia simulation class for anesthesia residences
45479542|NCT03329248|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
45479543|NCT03329248|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
45479544|NCT03329248|Biological|haNK for infusion|NK-92 [CD16.158V, ER IL-2]
45687772|NCT04734015|Behavioral|Together Overcoming Diabetes (TOD)|Curriculum approaches health through a holistic lens of spiritual, mental, physical and emotional wellness. American Indian Family Health Coaches conduct motivational interviewing to help participant dyads (adult caregivers with Type 2 diabetes and their youth) set attainable goals and work through obstacles to reach those goals.
46048098|NCT05660473|Drug|6-mercaptopurine|Cell cycle-specific antitumor drug
45479545|NCT03329248|Biological|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
46048099|NCT05660473|Drug|Dexamethasone|Glucocorticoids
46048100|NCT05660473|Drug|Methotrexate|Antifolate antineoplastic drug
46048101|NCT05660473|Drug|Venetoclax|Selective inhibitor of B-cell lymphoma 2 (Bcl-2)
46048102|NCT04013035|Procedure|cervical length measurement|cervical length measurement at second trimester pregnancy termination in nulliparous pregnant women.
46048103|NCT00803101|Biological|Beriplex® P/N (Kcentra)|Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body-weight.
46048104|NCT00803101|Biological|Fresh frozen plasma|Intravenous infusion, dosage depending on baseline INR and body weight
46048105|NCT03518827|Other|Asymmetry measurement|There is no intervention, the study will prospectively assess associations between asymmetries and injury risk. Asymmetry measurement will be conducted, then injuries will be tracked.
45359148|NCT00286429|Drug|Alogliptin and insulin|Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.
45359149|NCT00286429|Drug|Alogliptin and insulin|Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.
45479546|NCT03329248|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
45687773|NCT04730739|Device|FastFrame External Fixation System - Knee Spanning or Damage Control Kit|The FastFrame External Fixation Systems - Knee Spanning Kit and Damage Control Kit are single-use external fixators that are sterile packed with all required components for convenience of the end user.
45687774|NCT04709705|Biological|Human platelets|Platelets given to control bleeding
45687775|NCT04696523|Drug|Xenon|Xenon arm will be treated with xenon inhalation with endtidal concentration of 50 % in air/oxygen and with standard of care
45687776|NCT04696523|Drug|air/oxygen|Control group will be treated with air/oxygen
46048106|NCT02607241|Device|OCT-guided BRS implantation|Implantation of a BRS using OCT to measure vessel size, choose BRS size and length and assess implantation results and the need of further postdilations
46048107|NCT02607241|Device|FFR-guided DCB-only PCI|PCI performed under FFR guidance using following algorithm: (1) predilation followed by angiographic assessment of residual stenosis and dissections; (2) evaluate suitability for DCB-only, which is deemed feasible if the FFR > 0.8, residual diameter stenosis < 40% and no flow-limiting dissections are observed; (3) DCB dilation and (4) assessment of final results using FFR and QCA measurements. Provisional stenting is allowed only if the final PCI results are not acceptable (flow-limiting dissection, residual stenosis > 40% or FFR < 0.8).
45359150|NCT00286429|Drug|Insulin|Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.
46048108|NCT00801229|Drug|Vyvanse|Vyvanse 30, 50, or 70 mg daily
46048109|NCT00801229|Drug|Placebo|Placebo 30, 50, 70 mg daily
46048110|NCT04114825|Biological|RV001V|RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51. RV001 Vaccine 0.1 mg/mL (RV001V).
46048111|NCT04114825|Other|Placebo|Placebo consist of the vaccine vehicle and the adjuvant Montanide ISA 51. Placebo
46048112|NCT03444259|Procedure|Cardiac surgery|Open heart surgery
46048113|NCT02606149|Behavioral|Truthful information on chemotherapy risks|One of two trained oncologist will meet the patient and inform him following an interview-guideline
46048114|NCT02606149|Behavioral|Standard of information|
45359151|NCT00665444|Drug|Aripiprazole|All subjects will be assessed at baseline and then switched from their current antimanic agent to aripiprazole. Arpipirazole will be titrated from a starting dose of 5 mg/day up to a target dose of 15 mg/day over a period of up to 2 months (approximately 8 weeks). Concomitant medication will not be changed unless medically necessary. If a subject is taking an antipsychotic in addition to divalproex, aripiprazole will replace the antipsychotic.
45359152|NCT00860418|Behavioral|Pediatric Asthma Alert (PAAL)|Asthma nurse conducts 2 home visits and accompanies the child to primary care provider visit after ED visits
45359153|NCT00860418|Behavioral|Standard asthma education|Standard asthma education during 2 home visits.
45359154|NCT00867906|Biological|Cat-PAD|Cat-PAD dose 1x8 administrations 2 weeks apart
45359155|NCT00867906|Biological|Placebo|Placebo comparator, 1x8 administrations 2 weeks apart
45479547|NCT03329248|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
45479548|NCT03329248|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
45479549|NCT03329248|Drug|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
45479550|NCT03329248|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
45687777|NCT04688320|Drug|Recombinant nonimmunogenic staphylokinase|15 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
45359156|NCT00864006|Drug|Divalproex Sodium|
45359157|NCT00864006|Drug|Depakote DR Tablets|
45479551|NCT03329248|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
45479552|NCT03329248|Drug|lovaza|Omega-3-acid ethyl esters
46048115|NCT04269954|Drug|Batroxobin combined with low molecular weight heparin|Standard treatment of Batroxobin combined with low molecular weight heparin
46048116|NCT02856672|Device|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
45359158|NCT02554448|Other|ISET system|Use ISET system to test the number of CTCs from patients before and during treatment.
45479553|NCT03329248|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
45479554|NCT03329248|Procedure|SBRT|Stereotactic Body Radiation Therapy
46048117|NCT02856672|Device|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
46048118|NCT00630630|Drug|Levetiracetam|
46048119|NCT00630630|Other|Placebo|
45479555|NCT04222556|Behavioral|Thiwáhe Gluwáš'akapi|Thiwáhe Gluwáš'akapi (TG, sacred home in which family is made strong) is a cultural adaptation of the Strengthening Families Program for Parents and Youth 10-14 (SFP 10-14). TG, like SFP 10-14, is a 7-week family-based prevention program with separate youth and adult sessions followed by family sessions. Videos teach content and spark discussion; games and activities foster interaction and provide opportunities to practice skills. Four key adaptations were made to create TG: (1) cultural kinship teachings and tribal language kinship words were embedded throughout; (2) a parent session on coping with stress was enhanced to teach recognizing and responding to trauma reactions in youth; (3) a session on listening was moved earlier in the curriculum, given cultural oral tradition; (4) session videos were remade with local actors and adapted scenarios. A multiphase optimization strategy design was used to test potential adaptations, resulting in the optimized TG program.
46048120|NCT01254864|Drug|Abiraterone Acetate|1000 mg by mouth each day of a 28 day cycle.
46048121|NCT01254864|Drug|Prednisone|5 mg by mouth twice daily of a 28 day cycle.
46048122|NCT01254864|Drug|Sunitinib|37.5 mg by mouth daily for two weeks followed by a week of rest in a 28 day cycle.
46048123|NCT01254864|Drug|Dasatinib|100 mg by mouth each day of a 28 day cycle.
46048124|NCT02857608|Drug|Lymphoseek|
46048125|NCT04269564|Device|stepwise PEEP|"a PEEP of 4 cmH2O will be used after intubation till 5 minutes after pneumoperitonium, and adjusted in a step wise approach after lung ultrasound by adding 2 cmH2O, repeating ultrasound 5 minutes after every change in peep till no lung collapse is detected by lung ultrasound with a maximal peep of 10 cmH2O, or if hemodynamic instability occurs.~Lung ultrasound examination will be performed at a minimum three times in each patient; the first will be performed 1 min after starting mechanical ventilation of the lungs, 5 minutes after pneumoperitonium, 5 min after every peep increase in stepwise peep group and the last time at the end of the surgery.~We define anaesthesia-induced atelectasis to be significant if any region has a consolidation score of ≥ 2."
46048126|NCT02854722|Drug|Deferasirox and calcium-vitamin D3|"deferasirox and calcium-vitamin D3 Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.~Calcium 500 mg and vitamin D3 800 IU should also be taken daily as a basic therapy."
45359159|NCT02544126|Device|Electronic Self-Management Resource Training for Mental Health|eSMART-MH is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. Overtime, coaching is decreased to build the the subject's self-confidence. eSMART-MH will be used once a month, for three months.
45359160|NCT02544126|Behavioral|Screen-based health education|Screen-based health education will be used and cover topics like depression, nutrition, physical activity, and sleep hygiene at the same frequency as the eSMART-MH intervention, which is used once a month, for three months.
45359161|NCT00794612|Drug|Dermacyd Femina Pocket BR (Lactic Acid)|Dermacyd Femina Pocket BR (Lactic Acid) during 21 consecutive days
45687778|NCT04688320|Drug|Alteplase|Alteplase® is administered in accordance with the instructions for use for pulmonary embolism ( 10 mg bolus and 90 mg as IV infusion over 2 hours, maximum 100 mg). In patients weighing less than 65 kg, the total dose should not exceed 1.5 mg / kg.
45687779|NCT04669899|Drug|JTX-8064|Specified dose on specified days
45359162|NCT00794690|Drug|Cimicifuga racemosa extract for the group|40 mg of Cimicifuga racemosa extract daily dor 12 months
45359163|NCT00860496|Drug|CP- 690,550 and Tacrolimus|10 mg, single dose of CP-690,550 on Day 1 5 mg, every 12 hours of Tacrolimus on Days 1-8 10 mg, single dose of CP-690,550 on Day 8
45479556|NCT04222556|Behavioral|Woyute Waśte|Woyute Waśte (WW) was adapted from the Colorado School of Public Health's Integrated Nutrition Education Program (INEP) for the culture and context of the reservation. Families will meet for 1 session to participate in hands-on activities - preparing healthy meals, family physical activity, and sugary drinks. They will discuss setting healthy goals and tracking progress, receive recipes and water bottles, and for 6 weeks after the session, will get text messages with additional program content.
45687780|NCT04669899|Drug|pimivalimab|Specified dose on specified days
45687781|NCT04669197|Drug|Paclitaxel protein bound|combination therapy
45687782|NCT04669197|Drug|Gemcitabine|combination therapy
45687783|NCT04669197|Drug|Cisplatin|combination therapy
46048127|NCT02854722|Drug|Calcium-vitamin D3|Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.
45687784|NCT04669197|Drug|Hydroxychloroquine|combination therapy
45687785|NCT04664400|Behavioral|Symbolic conditioning|Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) through symbolic conditioning (no actual heat stimuli, only pictures of thermometers)
45687786|NCT04664400|Behavioral|Conditioning|Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) from experience (with actual heat stimuli).
46048128|NCT00948246|Device|Easyband®|The Easyband adjustable gastric band device is implanted laparoscopically around the top of the stomach to create a small pouch. Adjustments to increase or decrease the stoma size are made non-invasively by telemetric connection between an internal and external antenna.
46048129|NCT00800683|Drug|BI 1356|BI 1356 dosed once daily
46048130|NCT00800683|Drug|placebo|placebo matching BI 1356 taken once daily
46048131|NCT01124864|Drug|AUY922|AUY922 was supplied in individual 10 mL amber colored glass ampoules containing 10 mL of a 5 mg/mL active drug substance in 5% aqueous glucose solution. AUY922 was administered intravenously (i.v.) weekly at 70 mg/m2.
46048132|NCT01113710|Drug|Neupro®|Neupro® is the exposure/intervention of interest in this non-interventional study.
46048133|NCT05726773|Procedure|Robot Assisted Therapy|In robotic rehabilitation, continuous passive range of motion (CPM), active assistive exercises and assistive continuous passive range of motion (CPM Plus) programs will be used.
45359164|NCT00860496|Drug|CP- 690,550 and Cyclosporine|10 mg, single dose of CP-690,550 on Day 1 200 mg, every 12 hours of Cyclosporine on Days 1-6 10 mg, single dose of CP-690,550 on Day 6
45479557|NCT03792893|Other|Ergometry H|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure."
45687787|NCT04664400|Behavioral|Instructions|Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) from verbal instructions.
45687788|NCT04664400|Behavioral|Counterfactual|Thermal stimuli will be either the better outcome or the worse outcome out of two possible outcomes.
46048134|NCT05726773|Procedure|Conventional Therapy|In the Conventional Therapy group, an exercise program consisting of passive and active assistive range of motion exercises, strengthening exercises and task-oriented exercises for 30 minutes for both hands was planned, accompanied by a physiotherapist experienced in spinal cord injury rehabilitation for at least 5 years.
46048135|NCT04114591|Procedure|anterior resection|The distance from anal verge, preoperative radiotherapy and presence of stoma were analysed
46048136|NCT04008823|Other|Retrospective and observational epidemiological study, by review of clinical histories,|Retrospective and observational epidemiological study, by review of clinical histories,
46048137|NCT01124162|Drug|Losartan|100 mg Tablet
46048138|NCT01124162|Drug|Cozaar®|100 mg Tablet
46048139|NCT00923533|Drug|Fimasartan|Fimasartan (7day) Fimasartan + Hydrochlorothiazide (7day)
46048140|NCT00923533|Drug|Hydrochlorothiazide|Hydrochlorothiazide (7day) Fimasartan + Hydrochlorothiazide (7day)
46048141|NCT05104112|Other|The M.E.R. program|"The M.E.R program is a therapeutic education intervention for mothers of children with ASD during a new pregnancy. This program, which is a pilot in France and in Europe, involves several dimensions, both pedagogical and behavioral (strategies for stimulating the baby, use of specific communication and interaction tools) and psychological (reduction of stress, anxiety, etc. in the mother).~It includes 8 individual interviews of 1h30 every 15 days. The first and the last one are for evaluation purposes, the 6 intermediate sessions constitute the accompaniment. The structure of the program and the sessions are based on what is recommended in therapeutic education. The sessions can take place on the hospital site or at home."
46048142|NCT04312568|Drug|Fadanafil|Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
45359165|NCT00864162|Drug|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
45359166|NCT00864162|Drug|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fed conditions
45359167|NCT00787826|Biological|Live Francisella Tularensis Vaccine|"Approximately 0.0025 mL of vaccine will be administered percutaneously with a bifurcated needle using 15 pricks on the volar surface of the forearm. Vaccination may be repeated up to two times within the year if successful vaccination is not demonstrated by a positive take reaction and a MA titer of ≥ 1:20."
45359168|NCT00795314|Drug|Fentanyl Citrate|Combined anesthesia with propofol (2-2.5mg/kg) and fentanyl (5 μg)
45844572|NCT05554614|Behavioral|BTW app with situational supervised driving practice|Teen drivers will be provided bi-weekly push-notifications from the BTW app notifying them of situational supervised driving practice activities that are to be completed during the assigned week. There are 12 situational supervised driving activities and six skill-building driving activities (Table 1). Skill-building sessions are assigned for off weeks during the first half of the six months (weeks 2-12), allowing for skills to be further developed when the situations are encountered for a second time (weeks 15-23). Parents will be prompted to directly log situational supervised and skill-building driving activities in the app after the session within the BTW app to obtain the module completion date and duration time.
45844573|NCT05554614|Behavioral|Sham BTW app|Teens will be provided links to passive education materials and information on car maintenance every week. They will not be given feedback on their driving performances.
45844574|NCT05533554|Behavioral|Brief Intervention Based on the Theory of Planned Behavior to Reduce Alcohol Consumption in University Students|Cognitive-behavioral intervention where the key concepts of the Theory of Planned Behavior were operationalized from which two intervention sessions were formed and the most appropriate techniques were chosen to influence the key concepts of the theory: behavioral beliefs, subjective norms, perceived behavioral control and self-efficacy. The program is made up of 3 evaluation sessions (pre, immediate post and post post a month later) and 2 intervention sessions with a duration of 120 minutes each.
45844575|NCT05530278|Drug|Galicaftor|Oral
45844576|NCT05530278|Drug|ABBV-576|Oral
45844577|NCT05530278|Drug|Navocaftor|Oral
45844578|NCT05530278|Drug|Midazolam|Oral
45844579|NCT05489484|Device|MD-Shoulder Collagen Medical Device|"Only one experimental group is scheduled by the Investigation Plan to be treated with 2-mL volume ultrasound-guided infiltrations of MD-Shoulder Collagen Medical Device (GUNA, Milan-Italy).~Subjects will be treated with number one ultrasound-guided infiltration at the time of enrollment, 2 weeks after enrollment, and 4 weeks after enrollment.~Intra-articular infiltrations will be performed with 5cc syringes and 22-gauge needles.~MD-Shoulder Collagen Medical Device will be infiltrated within the scapulohumeral joint under conditions of complete asepsis."
45844580|NCT05459298|Dietary Supplement|Placebo|Placebo is normal saline, given in the first 28 days after birth, prepared to have the same volume and appearance as vitamin D, which is a clear odorless solution.
45359169|NCT00795314|Drug|Butorphanol Tartrate|Combined anesthesia with propofol (2-2.5 mg/kg) and butorphanol (1mg)
45359170|NCT03926169|Drug|Risankizumab|Risankizumab is administered as a SC injection in pre-filled syringe (PFS)
45844581|NCT05459298|Dietary Supplement|800 IU/day vitamin D supplementation with feedings in the first 28 days after birth|800 IU/day Vitamin D supplementation until 400 IU/day are provided as part of usual care (started when infants receive full feedings of about 120-160 mL/kg/day). At that point the intervention becomes a supplement of 400 IU/day above that given with usual care. In this way all infants in the intervention group receive 800 IU/day of vitamin D total supplementation in the first 28 days after birth with feedings.
45844582|NCT05459298|Other|Usual Care|Care will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices. When the infant receives about 120 to 160 mL/kg/day of fortified milk at 24 kcal/ounce, the infant will receive supplementation with 400 IU/day of vitamin D as usual care.
45844583|NCT05438628|Diagnostic Test|Point of care ultrasound|Measurement of thickness of rectus abdominis, biceps brachii muscles
45359171|NCT03926169|Drug|Placebo for risankizumab|Placebo for risankizumab is administered as a SC injection in PFS
45844584|NCT05436288|Drug|KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)|KIO-201 is a stand-alone drug therapy that acts as a barrier that minimizes mechanical lid friction and mechanically protects the ocular surface thereby reducing repeat injury and providing an environment that enables the body to repair the ocular surface whether the corneal epithelial defects are large or small.
45844585|NCT05434962|Device|Cardiac resynchronization therapy|"Standard BiV-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's manual provided with the devices. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. The LV lead should be implanted at a lateral or posterolateral CS branch in a basal or mid ventricular position confirmed by ortogonal fluoroscopic views (RAO and LAO 40º). Acceptable LV pacing threshold should be <3V@0,5ms and phrenic nerve stimulation (PNS) margin should be >1V with respect to the pacing threshold.~LBBAP-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's standard practice. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. During the implant procedure lead impedances, pacing and sensing parameters will be measured using a pacing system analyzer (PSA). For LBBAP, the Medtronic 3830 lead will be used. Acceptable LBBAP threshold should be <2,5V@0,5ms"
46048143|NCT04312568|Drug|Placebo|Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
46048144|NCT04310306|Device|Thrombectomy using EmboTrap II|The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, using a stent retriever, contact aspiration EmboTrap II. The number of thrombectomy attempts is at the operator's discretion. Combination of balloon guide catheter or intermediate catheter is recommended.
46048145|NCT04309604|Biological|IC14|monoclonal antibody directed against CD14
46048146|NCT00906399|Drug|BIIB017 (peginterferon beta-1a)|Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.
45359172|NCT00860808|Drug|AM-101|Triple intratympanic injection (one on each day 1, 2, and 3)
45359173|NCT00787982|Device|MRI-Guided Laser Induced Thermal Therapy|LITT uses laser light to heat and destroy the affected tissue; this is sometimes referred to as tissue ablation. In LITT, small fiber-optic applicators are placed directly into the tumor and heating is performed from the inside out, which may lead to the destruction of the tumor
46048147|NCT00906399|Drug|Placebo|Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.
46048148|NCT01111838|Drug|STA-9090|Patients will be enrolled and receive 200mg/m2 of STA-9090. Patients will receive single agent STA-9090 intravenous (I.V.) infusion (an indwelling catheter may not be used) over 60 minutes weekly (three weeks on and one week off). Follow-up imaging will be performed every 8 weeks to evaluate response.
45479558|NCT03792893|Other|Ergometry L|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure."
45479559|NCT05482022|Device|Shiley™ phonate speaking valve|The device connects to the tracheostomy tube. Usually used to aid vocalization.
46048149|NCT02562469|Other|ACTIVATE|A home-based computerized brain training intervention for youth.
45359174|NCT00285649|Other|HVLA-SM|HVLA-SM, Experimental, high-velocity low amplitude spinal manipulation
45359175|NCT00285649|Other|LVVA-SM|LVVA-SM, Experimental, low velocity variable amplitude spinal manipulation
46048150|NCT00947856|Drug|brentuximab vedotin|Every 3 weeks by IV infusion (1.2 or 1.8 mg/kg) until disease progression, unacceptable toxicity, or study closure
46048151|NCT02605525|Biological|SM101|Human soluble recombinant Fcγ Receptor IIB
46048152|NCT02605525|Other|Placebo|L-histidine-buffered saline with mannitol, sucrose, and polysorbate 20
46048153|NCT05658523|Biological|Bivalent Moderna|A single standard dose of the bivalent Moderna (mRNA-1273.214) COVID-19 vaccine containing equal amounts of mRNAs (25μg of each mRNA sequence) that encode the prefusion stabilized spike glycoproteins of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (B.1.1.529 [BA.1]) with mRNAs encapsulated in lipid nanoparticles, will be administered on day 0 of the study.
46048154|NCT05658523|Biological|Novavax|A single dose of Novavax contains 5μg of SARS-CoV-2 spike protein and is adjuvanted with Matrix-M. Adjuvant Matrix-M contains, per 0.5 mL dose: Quillaja saponaria saponins fraction A (42.5 micrograms) and Quillaja saponaria saponins fraction C (7.5 micrograms), will be administered on day 0 of the study.
46048155|NCT05332977|Device|CAD-CAM fabricated provisional prosthesis|Insertion of CAD-CAM fabricated provisional prosthesis (CAD-CAM) on axially placed or titled implants for rehabilitation of atrophic maxilla
46048156|NCT05332977|Device|DC (denture conversion) provisional prosthesis|Insertion of denture conversion (DC) provisional prosthesis on axially placed or titled implants for rehabilitation of atrophic maxilla
46048157|NCT00947544|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (~17.4mL) delivers equivalent amount of PBA that 40 tablets of NapBA do.
45359176|NCT00285649|Other|Usual Medical Care|Arm: Active Comparator: Usual Medical Care Usual Medical Care, Active Comparator, advice, exercises and medications (Celebrex, Aleve, Bextra, Naptoxen)
45359177|NCT00864240|Drug|Clobex TM (Clobetasol) 0.05% Lotion, single exposure|Subjects received Galderma Laboratories, L.P. formulated products
45359178|NCT00795392|Other|ASA scale|ASA scale evaluation before operation
45359179|NCT00795392|Other|Full-scale psychological assessment|Full-scale psychological evaluation before operation
45359180|NCT02554370|Behavioral|Psychoeducational programme|4 sessions of psychoeducation before and 3 after surgery for subthalamic deep brain stimulation
45479560|NCT05482022|Other|control|no intervention
45687789|NCT04662944|Drug|brolucizumab|There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
45359181|NCT04018404|Other|FRI CLINICAL PROGRAM|University Le Bonheur Pediatric Specialists and Le Bonheur Community Health and Well-Being, Maternal Child Department, have started the Family Resilience Initiative (FRI) in the ULPS General Pediatrics Clinic. This clinical program screens children 9 months to less than five years of age for ACES and SDH at the time of presentation for well child checks. There are two outreach coordinators who screen and enroll children attending clinic for a well-child check during morning clinics 3 to 4 days per week. Children with positive screens for ACES and/or SDH, and their adult caregivers, receive community resource referrals with warm handoffs to vetted organizations. In addition, if indicated, psychological services are offered for children based upon the presence of one or more of ACEs and current health and behavioral problems.
46048158|NCT00947544|Drug|NaPBA|NaPBA tablets for oral administration and NaPBA powder for oral, nasogastric, or gastrostomy tube administration contain the active ingredient sodium phenylbutyrate. NaPBA is a prodrug and is rapidly metabolized to PAA, the metabolically active compound that conjugates with glutamine via acetylation to form PAGN, which is excreted by the kidneys.
45359182|NCT04936880|Device|Experimental : Virtual reality + analgesia-sedation|Use of a virtual reality device + analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
45687790|NCT04662944|Drug|ranibizumab|There is no treatment allocation. Patients administered Ranibizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
45687791|NCT04662944|Drug|aflibercept|There is no treatment allocation. Patients administered Aflibercept by prescription that have started before inclusion of the patient into the study will be enrolled.
45687792|NCT04659421|Drug|combined therapy with rh-ES and CV|"All the patients receive combined therapy with recombinant human endostatin and traditional weekly CV regimen.~Carboplatin is administered at a dose of 220 mg/m2. Vincristine is administered at a dose of 1.5 mg/m2 (maximum dose 2 mg). Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks."
45687793|NCT04657770|Device|Telerehabilitation|The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned remote-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system. During some of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
45687794|NCT04655222|Drug|Interferon Beta Therapy|Administered as specified in the treatment arm.
45687795|NCT04653194|Drug|Biktarvy|Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg
46048159|NCT00907335|Drug|Retin-A Micro 0.04% facial acne treatment|Retin-A Micro 0.04% facial acne treatment used once daily
46048160|NCT00907335|Drug|Vehicle control|Color-matched facial gel vehicle control used once daily
46048161|NCT05332899|Biological|Influenza Virus Type A H3N2 Challenge|The intervention product is a live challenge virus that is manufactured in the USA under Good Manufacturing Practice (GMP). The challenge will be administered intranasally using a sprayer device. Participants will be admitted to the hospital and quarantined for 8 days for monitoring, and will receive care and supportive treatment as necessary. Participants will be followed for a total of 12 weeks.
46048162|NCT00947154|Drug|aripiprazole|aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
46048163|NCT05490303|Other|recording of the probe position|For each patient, a cardiac ultrasound acquisition will be performed with an optical tracking system (infrared) recording the probe's position in real time.
46048164|NCT02856360|Other|Moderate Stiffness Footwear|Standard moderately stiff footwear for typical high school football players will be randomly allocated to each group
45687796|NCT04653194|Drug|Symtuza|Combination single tablet anti-retroviral therapy: darunavir 800mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg
45687797|NCT04652440|Drug|PD-1 monoclonal antibody|The enrolled patients received intravenous injections of PD-1 monoclonal antibody (Tislelizumab 200mg) on the 1 day before radiofrequency or microwave ablation treatment, and 21(±7) days, 42(+7) and 63(+7) after ablation.
46048165|NCT02856360|Other|High Stiffness Footwear|Standard highly stiff footwear for typical high school football players will be randomly allocated to each group
46048166|NCT01124006|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
46048167|NCT01124006|Other|Water for injection|Sterile water for injection
45359183|NCT04936880|Drug|Control: Analgesia-sedation|Use of analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
45359184|NCT00979641|Drug|Docetaxel|
45687798|NCT04652440|Procedure|Radiofequencey or microwave ablation|The enrolled patients received primary radiofrequency or microwave ablation on the day after the first dose of PD-1 antibody treatment.
45359185|NCT00864318|Drug|Paclitaxel|200mg/m2 for 3 hours at Cycle 1 day 1 and Cycle 2 day 1 with 14 days between cycles
45359186|NCT00864318|Drug|Ifosfamide|2g/m²/day in 1 liter of G5 for 3 hours at Cycle 1 and Cycle 2 from day 2 to day 4 with 14 days between cycles
45359187|NCT00864318|Drug|Carboplatine|"From cycle 3 to cycle 5 :~Carboplatine is administered with AUC = 24 mg/mL x min from Day 1 to Day 3. Day 3 Carboplatine dose is calculated taking into account real creatinine clearance defined at day 1 for each patient"
45359188|NCT00864318|Drug|Etoposide|From Cycle 3 to cycle 5, 400mg/m2/day from day 1 to day 3
45359189|NCT00864318|Procedure|cytapheresis + transfusion of autologous peripheral blood stem cells|"Cytapheresis occured between day 11 and day 13 of the 2 first cycle (Taxol® +Holoxan®). Cytapheresis total objective is 9X106 CD34+/kg of patient weight.~At cycle 3, 4 and 5 at day 5 : Re-injection of stem cells (1/3 with minimum 2.106 CD34/kg) 48 hours after chemotherapy end"
45687799|NCT04650867|Device|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous MSOT imaging of the bowel wall (terminal ileum, ascending caecum/colon, transverse colon, descending colon, and sigmoid colon).
45844586|NCT05378568|Other|the selection scheme of peripheral venous access devices|"Based on the Facilitator Toolkit of the promoting action on research implementation in health services integrated framework(i-PARIHS), the implementation plan of peripheral intravenous infusion device selection in hospitalized children was formulated and applied, so as to change the practice behavior of nurses in the intervention group. The specific process mainly includes: tailoring evidence; baseline review; situational analysis; promotion and implementation strategy like lectures, group discussions, operation demonstrations, and scenario simulations."
45359190|NCT00788060|Drug|Everolimus (RAD001)|5mg per day, continuously
45359191|NCT00788060|Drug|Sunitinib (Sutent)|37.5 mg per day, 14 days on, 7 day break
45844587|NCT05378568|Other|the existing nursing routine|To choose infusion device according to nurse's working experience. First, nurse placed a peripheral intravenous catheter. The patients and family decide whether to place the central intravenous infusion device according to the recommendation of the medical staff.
46048168|NCT03593889|Behavioral|Collaborative stepped care and peer support programme|"For at-risk group, 4 weeks of selective prevention group sessions will be provided at the elderly service level by trained peer supporters with registered social worker supervision, on wellness topics tailored to the person's concern as entry point, packaged with mental health information, followed by a review.~For mild group, 6-8 weeks of indicated prevention with psychoeducation or low-intensity psychotherapy would be provided. For moderate group, 6-8 weeks high-intensity cognitive behavioral therapy (CBT) would be provided. All intervention for depressed elderly would be conducted by registered social workers. The trained peer supporters will be matched to individual older adults to walk them through the process with regular follow-up for 1 year."
45844588|NCT05360706|Genetic|AAV5-hFIX|AAV5 containing a codon-optimized human factor IX gene
45359192|NCT00788138|Dietary Supplement|Vitamin D3|250,000 IU of vitamin D3
46048169|NCT03593889|Other|Treatment as usual|The control group will receive treatment as usual, which will be determined by the responsible workers from NGO units.
45359193|NCT00788138|Dietary Supplement|Placebo|Matching Placebo
45359194|NCT00864396|Drug|Prevacid|30mg of Lansoprazole twice daily (or placebo)for eight weeks.
45359195|NCT00745823|Drug|Comparator: Raltegravir 400 mg b.i.d.|Raltegravir 400 mg tablet by mouth (PO) twice daily (b.i.d.) + two raltegravir placebo tablets + one tablet of TRUVADA™ once daily (q.d.)
45359196|NCT00745823|Drug|Experimental: Raltegravir 800 mg q.d.|Raltegravir 800 mg tablet PO q.d. + two raltegravir placebo tablets + one tablet TRUVADA™ q.d.
45359197|NCT00745823|Drug|TRUVADA™|One tablet TRUVADA™ q.d. (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)
45359198|NCT00961467|Drug|Revlimid, Melphalan, Prednisone, Thalidomide|Thalidomide was administered at 50 mg/day.
45359199|NCT00961467|Drug|Revlimid, Melphalan, Prednisone, Thalidomide|Thalidomide was administered at 100 mg/day.
45359200|NCT00979797|Other|Community-based interventions to promote maternal and child health|Promotion of antenatal and postnatal care and safe delivery Essential Newborn care Community case management, and feeding for children.
45359201|NCT04090073|Procedure|Electroacupuncture|As above
45359202|NCT04090073|Other|Fast-track Perioperative program|As above
46048170|NCT03589989|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
45359203|NCT00980031|Drug|Eplerenone|25mg PO daily (QD)for 6 months
45359204|NCT00980031|Drug|Lactose Tablet|Lactose tablet
45359205|NCT02595671|Other|Digital Super Coach|Receive Digital Super Coach during 12 weeks
45359206|NCT02595671|Other|Conventional face to face PA & dietitian|Receive 7 face-to-face contacts (dietary and physical activity advice)
45359207|NCT02595671|Other|Digital Super Coach + minimal coaching|Receive 3 face-to-face contacts (dietary and physical activity advice)
45359208|NCT02595671|Other|Waiting Group|Receive Digital Super Coach during 12 weeks, after 12 weeks of no treatment
45359209|NCT02598401|Other|observation|Observational study with no intervention
45687800|NCT04643951|Behavioral|Interview|Interview study using Grounded theory, to investigate dental professionals' and students' perception of child patient's experience and need for treatment regarding procedural and postoperative pain.
45844589|NCT05312658|Procedure|External aortic compression|External aortic compression by assistant in cesarean section.
45844590|NCT05256966|Other|Sauna (steam)|Steam Sauna
45844591|NCT05245734|Drug|Human Anti-D (rh) immunoglobulin|prevention of Rh-sensitization in pregnant women in the antenatal and postnatal period in routine clinical practice. The study drug is administered twice at a dose of 300 mcg - at 28 weeks of gestation and within 72 hours after delivery.
46048171|NCT03589989|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
46048172|NCT01862952|Other|starting of anti-epileptic drug treatment|
45687801|NCT04619472|Device|Pulmonary Radiofrequency Ablation System and the Disposable Pulmonary Radiofrequency Ablation Catheter|The conjunction of the pulmonary RFA system with the disposable pulmonary RFA catheter developed by Hangzhou Broncus Medical Co., Ltd. is aim to specifically target lung tumors. The ablation catheter is designed to reach the tumor through the bronchial pathway.
46048173|NCT02882516|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
45687802|NCT04615013|Drug|Capecitabine|Not applicable to this study
45844592|NCT05242692|Drug|S-ketamine|Loading dose: 0.25mg/kg in 10 minutes Maintenance dose: 0.1mg/kg/h
45844593|NCT05242692|Drug|Dexmedetomidine|Loading dose: 0.2 ug/kg in 10 minutes Maintenance dose: 0.2 ug/kg/h
45844594|NCT05242692|Drug|Normal saline|Refer to either S-ketamine or Dexmedetomidine
45687803|NCT04615013|Drug|Carboplatin|Not applicable to this study
45687804|NCT04615013|Drug|Docetaxel|Not applicable to this study
45687805|NCT04615013|Drug|Fluorouracil|Not applicable to this study
45844595|NCT05236062|Behavioral|Exercise|aerobic and resistance exercise
45844596|NCT05236062|Behavioral|Attention control|stretching
45687806|NCT04615013|Other|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT or IN
45359210|NCT00976287|Procedure|Hepatic artery infusion|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
45359211|NCT00976287|Procedure|Conserved Therapy|Conserved Therapy
45479561|NCT03795311|Drug|FOLFIRINOX Bevacizumab|"In phase 1, the goal is to define the DLT (maximum tolerated dose). 3 levels of doses will be evaluated with a different dose of irinotecan in each level.~Level -1: Bevacizumab + Oxaliplatine + Acide folinique + Irinotecan: 60mg / m2~Level 0: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 70mg / m2~Level 1: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 90mg / m2~The inclusion of patients will start at level 0. Dose-limiting toxicities will be identified during the first 2 cycles."
45687807|NCT04615013|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45687808|NCT04615013|Drug|Leucovorin|Not applicable to this study
45687809|NCT04615013|Drug|Oxaliplatin|Not applicable to this study
45844597|NCT05235282|Device|IQoro|An acrylic mouth guard with a pulling loop. The mouth guard is placed in the mouth of the patient on the outside of the teeth. The therapist pulls the loop in different directions and the patient try to close his/her mouth on the mouth guard to keep it inside the mouth.
45687810|NCT04615013|Drug|Paclitaxel|Not applicable to this study
45687811|NCT04614389|Other|Contrast-enhanced ultrasound|Non Invasive Imaging Technique. CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion informatio
45844598|NCT05235282|Other|Usual care for swallowing function|Cuff deflation, speaking valve, masako exercises, shaker exercises, coughing, stimulation of the oral cavity, neuromuscular electrical stimulation, postural control
45359212|NCT00976365|Dietary Supplement|THL-P|20ml/bottle, TID, 24weeks
45359213|NCT02596529|Device|Fixation|Fixation of the posterior malleolus with lag-screws or platefixation (usually by Drittelrohr plate).
45359214|NCT02596529|Other|NO Fixation|NO Fixation of the posterior malleolus.
45359215|NCT00663260|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once Daily, 104 weeks
45359216|NCT00663260|Drug|Dapagliflozin|Tablets, Oral, 5 mg, Once Daily, 104 weeks
45844599|NCT05175534|Procedure|monitoring|peroperative transesophageal echocardiography for monitoring in liver transplant surgery
45844600|NCT05150184|Other|Non-interventional|observational study, thus no different arm/groups
45359217|NCT00663260|Drug|Placebo|Tablets, Oral, 0 mg, Once Daily, 104 weeks
45359218|NCT00980109|Drug|active oseltamivir|Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
45359219|NCT00980109|Drug|placebo capsule|Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
45359220|NCT00980109|Drug|zanamivir for inhalation|Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
45359221|NCT00980109|Drug|placebo for inhalation|Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
45359222|NCT00740597|Genetic|gene expression analysis|
45359223|NCT00740597|Genetic|polymerase chain reaction|
45479562|NCT03329014|Drug|Remimazolam|For induction and maintenance of sedation
45479563|NCT03329014|Drug|Placebo|Control arm
45687812|NCT04614389|Other|Shear Wave Elastography|Non Ivasive Imaging Technique. Shear Wave Elastography (SWE) is a recently developed technique that uses ultrasound to noninvasively assess the mechanical stiffness of tissue by measuring tissue distortion in ponse to an acoustic radiation force impulse from a focused ultrasound beam.
45687813|NCT04614389|Device|Sequoia System|UltraSound System Cleared by FDA 510 (k) K180067
45359224|NCT00740597|Genetic|western blotting|
45359225|NCT00740597|Procedure|neoadjuvant therapy|
45359226|NCT00740597|Procedure|therapeutic conventional surgery|
45687814|NCT04612725|Biological|Benralizumab|2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
45687815|NCT04612725|Biological|Placebo and Benralizumab|2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
45359227|NCT00740597|Radiation|intensity-modulated radiation therapy|
45479564|NCT03792971|Drug|Dextromethorphan HBr|A single 60 mg dose of DM capsules liquid-filled on Day 1 and Day 3
45359228|NCT00976443|Drug|BTA|BTA 100 or 300 U, endoscopic ultrasound (EUS) guided injections into gastric antrum
45359229|NCT00976443|Drug|Placebo (normal saline)|Placebo (normal saline), gastric injections of normal saline
45359230|NCT04988841|Drug|MaaT013|study is an experimental drug , produced by MaaT Pharma, and composed of pooled-donor, full-ecosystem intestinal microbiome (455 species approximately against 274 on average)
45479565|NCT03792971|Drug|GC4419|Daily 90 mg IV infusions over 60 minutes on Day 3 and Day 4
46048174|NCT03875625|Procedure|Bariatric surgery|Use of the normal bariatric surgery procedures commonly conducted in our hospital, such as: Laparoscopic Roux-en-Y gastric bypass (RYGB) and Laparoscopic sleeve gastrectomy (LSG)
45479566|NCT03470545|Drug|mavacamten|mavacamten capsules
45359231|NCT04988841|Drug|Ipilimumab|Anti cytotoxicT-lymphocyte-associated protein 4 ( immunothérapy)
45359232|NCT04988841|Drug|Nivolumab|AntiPD1 ( immunothérapy)
45479567|NCT03470545|Drug|Placebo|placebo oral capsule
45687816|NCT04612192|Device|Active luminette|receive an active blue-enriched light-glasses of 1500 lux (an average of 180 photons/s/cm2, with a maximum wavelenght at 468 nm), 30-minute long light therapy in the morning, in a time period defined by sleep log and chronotype questionnaire, on a 4-week period
46048175|NCT03875625|Behavioral|Dietitian led life style modification intervention|Intensive 6 months life style changes supervised by diatitians.
45359233|NCT04988841|Drug|MoviPrep|Osmotic laxative solution : patients take a single dose of two liters of Moviprep® or equivalent the night before the first administration of experimental treatment (Fecal microbiota transfer or placebo)
45359234|NCT04988841|Drug|Normacol|hypertonic enema solution
46048176|NCT03875625|Behavioral|Conventional care (control)|receive routine care
45359235|NCT04988841|Drug|Placebo of Maat013|expérimental drug placebo of MaaT013
46048177|NCT00952068|Drug|Tramadol Contramid® OAD 200mg|1 Tramadol Contramid® OAD 200mg tablet daily.
46048178|NCT01123850|Device|Copios|Bone Void Filler
45844601|NCT05131620|Procedure|Virtual Reality|It is planned that VR glasses are put on 5-10 minutes before the procedure and continued throughout the procedure, and the total monitoring time will continue for 30 minutes.
46048179|NCT05572047|Device|Arga Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System|Use of coherent sine-burst electroporation to ablate paroxysmal and persistent AF
45359236|NCT00800618|Drug|PF-02413873 100 mg QD|100 mg of PF-02413873 oral suspension once daily for 14 days
45359237|NCT00800618|Drug|PF-02413873 1500 mg QD|1500 mg of PF-02413873 oral suspension once daily for 14 days
45359238|NCT00800618|Drug|PF-02413873 20 mg QD|20 mg of PF-02413873 oral suspension once daily for 14 days
45359239|NCT00800618|Drug|PF-02413873 500 mg QD|500 mg of PF-02413873 oral suspension once daily for 14 days
45687817|NCT04612192|Device|Placebo luminette|receive a dim red-light placebo light (an average of n photons/s/cm2, single- band spectrum with a narrow peak at 660 nm under 50 lux), with the same modality as the experimental group
46048180|NCT01123382|Device|Intramuscular Electrical Stimulator|A sterile percutaneous IM electrode is implanted in the shoulder using a 20-gauge hypodermic needle and connected to an external cable. The exit site and electrode are covered by a bandage, but the cable extends out. After a one week stabilization period, the cable is connected to a stimulator. A self-adhesive surface electrode serves as the indifferent electrode. Stimulation intensity is set by the investigator. The prescription for daily stimulation treatment will be 6 hrs. The duty cycle and daily dose will remain constant throughout the treatment, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period will be 3 weeks, after which the electrode will be removed. Total time of electrode implantation is no more than 29 days.
46048181|NCT01123382|Other|Outpatient Therapy|Subjects will receive 8 hrs of outpatient therapy over a four week period from a treating therapist, coupled with prescribed daily home exercises. The therapist will implement an individualized treatment plan consistent with the needs of the participant.
46048182|NCT00951912|Dietary Supplement|Placebo|10g soy protein isolated per day
46048183|NCT00951912|Dietary Supplement|Daidzein|50mg daidzein +10g soy protein isolated per day
45359240|NCT00800618|Drug|PF-02413873 Placebo|PF-0241383 Placebo once daily for 14 days
46048184|NCT00951912|Dietary Supplement|Genistein|50mg genistein +10g soy protein isolated per day
46048185|NCT05332665|Device|AS-OCT|Anterior segment optical coherence tomography (AS OCT) is an imaging device that can acquire an anterior segment image using a noncontact method with the patient in a sitting position. This device provides reproducible and quantitative measurements of the AC angle and other anterior segment parameters.
45359241|NCT00800696|Procedure|oral care|The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx
45359242|NCT00980187|Drug|Hydrochlorothiazide|orally, 25 mg, once a day, with Quinapril 10-40 mg, 6 months
45498097|NCT05339919|Diagnostic Test|gait speed; ct scan;grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
45752067|NCT00403117|Drug|Naltrexone 25 Mg + Inactive Marijuana (0% THC)|One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
45844602|NCT05131620|Procedure|Acupressure|Acupressure will be applied 10 minutes before catheter extraction after CAG.
45359243|NCT00980187|Drug|Indapamide|1.5 mg SR, orally, once a day,with Quinapril 10-40 mg, 6 months
45359244|NCT00795470|Drug|Antimicrobial|Appropriate antimicrobial based on urine culture results
45359245|NCT00795470|Device|Catheter change|Change urine catheter
45359246|NCT00980421|Dietary Supplement|Iron Supplementation|Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit
45359247|NCT00284089|Drug|Ranibizumab|Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.
45687818|NCT04607967|Device|High Flow Nasal Oxygen|"Study participants are suffering from an acute hypoxemic respiratory distress. They have to be treated with oxygen-therapy that could be administered using a conventional oxygen device (study group CO) or High Flow Nasal Oxygen (study group HNFO). During the first 60 minutes following patients admission, patients will be randomized to one of the two study groups. In both groups, the failure of the treatment will be evaluated by the need for a therapeutic escalation fours hours after the treatment initiation."
45687819|NCT04605159|Biological|RSV MAT|One dose of RSV MAT vaccine reconstituted with NaCl solution administered intramuscularly in the non-dominant arm.
45687820|NCT04605159|Drug|Placebo|One dose of lyophilized sucrose reconstituted with NaCl solution administered intramuscularly in the non-dominant arm.
46048186|NCT05332665|Procedure|YAG laser PI|medical procedure which uses a laser device to create a hole in the iris, thereby allowing aqueous humor to traverse directly from the posterior to the anterior chamber and, consequently, relieve a pupillary block
46048187|NCT03575169|Device|BIS Monitor|Unilateral BIS electrode
46048188|NCT02882594|Behavioral|Observing patient behaviors for anesthesia induction compliance|Observing patient behaviors for anesthesia induction compliance so to test reliability and validity of the CIBA Tool
46048189|NCT01123148|Device|Using a BCI to control wheelchair tilt|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) during each session and use a P300 based BCI to type words and control wheelchair tilt. Subjects will be asked to participate in 3 sessions.
46048190|NCT03858777|Diagnostic Test|cell free DNA|All groups will have blood draws and cfDNA measured
46048191|NCT02856204|Other|Cytology Specimen Collection Procedure|Undergo collection of blood
46048192|NCT02856204|Other|Laboratory Biomarker Analysis|Correlative studies
46048193|NCT03275493|Biological|Humanized CD19 CAR-T cells|Express a Second Generation 4-1BB:humanized CD19 CAR-T cells
46048194|NCT03275493|Biological|Humanized CD19 CAR-T cells with CRS suppression technology|Express a Second Generation 4-1BB:humanized CD19 CAR-T cells with CRS suppression technology
46048195|NCT02856048|Drug|Triptorelin (GnRHa) + Chemotherapy|During her chemotherapy, the patient in the experimental arm will have regular injections of Triptorelin (DECAPEPTYL LP 3 mg, IPSEN) in order to preserve her fertility
46048196|NCT03209583|Device|Medtronic|Pacing is done by the implanted device after seeing how the electrical system is functioning giving energy when needed to maintain a stable state or rhythm
46048197|NCT02854410|Dietary Supplement|Sodium nitrate|Dietary intake:Sodium nitrate 0.5mmol/kgbodyweight,bid
46048198|NCT02854410|Dietary Supplement|sodium chloride|Dietary intake:sodium chloride 0.5mmol/kgbodyweight,bid
46048199|NCT03844815|Drug|Decitabine|"Decitabine will be administered intravenously at a dose of 20mg per day for 10 days during Cycle 1 (28 day cycle)~Decitabine will be administered intravenously at a dose of 20mg per day for 10 days of Cycle 2 (28 day cycle).~Decitabine will be administered intravenously at a dose of 20mg per day for 5 days of each 28 day maintenance cycle"
46048200|NCT03844815|Drug|Venetoclax|Venetoclax administered orally on days 1-21 of cycle 1, cycle 2 and maintenance (28 day cycles). Dose levels will be assigned at time of enrollment anywhere from 100mg-400mg. Dose escalation will follow the 3+3 study design.
46048201|NCT01123070|Biological|TL011, anti CD20, for the treatment of rheumatoid arthritis|TL011 administered by 2 infusions, 2 weeks apart
46048202|NCT01123070|Biological|MabThera infusions|MabThera, administered by 2 infusions, 2 weeks apart
45359248|NCT00984633|Drug|Rocuronium bromide (Org 9426)|0.6 mg/kg injection intubation dose
45359249|NCT00984633|Drug|Rocuronium bromide (Org 9426)|0.9 mg/kg injection intubation dose
45359250|NCT00984633|Drug|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
45359251|NCT00984633|Drug|Propofol|4-10 mg/kg/hr maintenance anesthesia
45359252|NCT03975751|Diagnostic Test|The Glasgow Coma Scale (GCS)|Use the common GCS, RASS and self-reported pain assessment for evaluating consciousness, agitation/sedation and analgesia.
45359253|NCT00659984|Drug|UltratraceTM Iobenguane I 131 Imaging|0.1 mCi/kg [3.7 MBq/kg] (minimum dose 1mCi [37MBq] but not to exceed 5 mCi [185 MBq]) of UltratraceTM Iobenguane I 131 given 7 -28 days before therapeutic dose administration on day 0. Thyroid protection will be administered per institutional protocol for I-131-MIBG however, thyroid blocking must be started prior to the Ultratrace imaging dose. Anterior and posterior whole body images will be taken to assess organ distribution, tumor uptake and dosimetry calculations.
45359254|NCT00659984|Drug|UltratraceTM Iobenguane I 131 Therapy|Therapeutic dose will be given on Day 0 if dosimetry scans showed that the prescribed or adjusted dose will not exceed > 23 Gy to the kidneys, > 30 Gy to the liver, or > 15 Gy to the lungs. and tumor uptake confirmed with UltratraceTM imaging dose. Only one treatment course of therapeutic UltratraceTM will be given in this study.
45359255|NCT00976755|Drug|everolimus|"Everolimus:~10mg daily"
45752068|NCT00403117|Drug|Naltrexone 50 Mg + Inactive Marijuana (0% THC)|One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
45359256|NCT00864474|Drug|CELSENTRI® Tablets|"CELSENTRI ® Tablets 150mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage is 300 mg twice daily. Maraviroc must be used in combination with other anti-HIV drugs. The dosage may be adjusted according to co-administered medical products. Maraviroc can be taken with or without food."
45687821|NCT04604067|Drug|Acalabrutinib|"Cohort A: 6 cycles of acalabrutinib-R-CHOP~Cohort B: 2 cycles of R-CHOP and 2 cycles of acalabrutinb-R-CHOP followed by 2 cycles of acalabrutinib single agent~Cohort C: 4 cycles of R-CHOP followed by 2 cycles of rituximab single agent~Cohort D: 6 cycles of R-CHOP~Rituximab 375 mg/m2 IV Day 1, cyclophosphamide 750 mg/m2 IV Day 1, doxorubicin 50 mg/m2 IV Day 1, vincristine 1.4 mg/m2 (maximum 2 mg) IV Day 1; prednisone 100 mg PO d1-5; Acalabrutinib 100 mg BID Day 1-21, cycles repeated every 21 days"
45844603|NCT05126472|Drug|2141-V11|All subjects will receive the anti-CD40 antibody 2141-V11 administered by intravesical instillation once weekly for 3 consecutive weeks, at weeks 1 (±3 days), 2 (±3 days), and 3 (±3 days) for a total of 3 doses. As discussed further below, depending on disease status at week 13 and week 25 evaluations, subjects may be eligible for re-treatment (once weekly for 3 doses) at these time points. Dose escalation of 2141-V11 will proceed incrementally from the initial dose of 0.7 mg to doses of 2 mg, 7 mg, 21 mg, and 70 mg using an MCRM design to assess AEs/DLTs (according to CTCAE version 5.0) and to determine the MTD and/or a RP2D. There will be no intra-patient dose escalations or dose reductions of 2141-V11. Subjects with evidence of HG disease at the week 25 evaluation will not continue on treatment, but be followed on study for survival data.
45359257|NCT00283387|Drug|Betaine|Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
45359258|NCT00283387|Drug|Placebo|Subjects received oral lactose placebo, in two doses daily, for 2 months.
45359259|NCT00788216|Other|Discussion & scoring of health states related to the treatment of cervical cancer|Subjects will be interviewed using the visual analog score and time trade off methods.
45359260|NCT00976833|Other|Standardized Rehabilitation|3 component Rehabilitation approach, Passive Range of Motion, Physical Therapy and Progressive Resistance Training
45359261|NCT00976833|Other|Usual Care|Usual Physical Therapy care
45359262|NCT00788294|Biological|tanezumab|Drug solution given intravenously only once at dose of 10 mg
46048203|NCT02857686|Procedure|intravenous regional anaesthesia|tourniquet over the arm and intravenous lidocaine with a dose of 4 mg/kg
45359263|NCT00788294|Biological|tanezumab|Drug solution given subcutaneously only once at dose of 5 mg.
46048204|NCT02857686|Procedure|forearm IVRA|tourniquet over the forearm and lidocaine with a dose of 1.5 mg/ kg
46048205|NCT03841929|Other|Hemodynamic report|The multimodal data comprising the clinical, biochemical, NIRS data and TNE where available will be used by the study team in such cases to reach a description of the hemodynamic status of the study infant and will be provided to the Clinical team.
45359264|NCT00788294|Biological|tanezumab|Drug solution given subcutaneously only once at dose of 10 mg.
45359265|NCT00788294|Biological|tanezumab|Drug solution given subcutaneously only once at dose of 19 mg.
45359266|NCT00795548|Drug|5-Azacitidine|"5-Aza will be administered at doses of 100mg/m2 via subcutaneous injection over a period of 5 days. The total amount per treatment cycle, consisting of 5 days, is 500mg/m². Each treatment cycle is repeated every 28 days, with a treatment pause of 23 days between each 5-Aza cycle, to a total of 6 (optional 8 cycles) cycles.~DLI will be transfused on day +34 with a total count of CD3+ cells of DLI 1-5x10E6CD3+/kg bodyweight. In absence of GvHD DLI transfusion is repeated on day +90 with DLI 1-5x10E7CD3+/kg bodyweight and on day +142 with DLI 1-5x10E8CD3+/kg bodyweight. Additional DLI may be given."
45359267|NCT00980577|Device|NUUS|Sonosite Micro Maxx
45359268|NCT00282919|Drug|Azithromycin plus chloroquine|dose of 2000 mg Azithromycin plus 600 mg chloroquine base
45359269|NCT00800774|Procedure|LASIK|Nine eyes of nine patients (3 male and 6 female) with high anisometropia (>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.
45687822|NCT04603443|Dietary Supplement|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine
46048206|NCT04275648|Diagnostic Test|AsthmaTuner exercise field test|AsthmaTuner consist of a a bluetooth spirometer and smartphone app with protocol for measuring lung function (FEV1) and perform 8 min exercise challenge test and a healthcare web interface.
46048207|NCT05330403|Procedure|Moxibustion|"In this study, suspended moxibustion was performed by holding an ignited moxa stick at a certain distance (about 3-4 cm) over the skin surface, keeping the moxibustion Site warm without burning the skin.~In the heart meridian intervention group, moxibustion was applied over Site 4 (HT3) of the heart meridian.~In the lung meridian intervention group, moxibustion was performed over Site 1 (LU5) of the lung meridian."
46048208|NCT02854254|Device|peripherally inserted central catheter|peripherally inserted central catheter
46048209|NCT02854254|Device|peripherally venous access|standard over-the-needle intravenous catheter
45359270|NCT00984789|Drug|Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)|0.55mg ethinylestradiol and 2.1mg gestodene
45359271|NCT00984789|Drug|Norelgestromin/Ethinylestradiol (EVRA)|0.6mg ethinylestradiol and 6mg norelgestromin
45844604|NCT05116722|Device|Shoulder Pacemaker|Shoulder pacemaker treatment for 15 - 30 minutes at 3-months, 6-months and 12-months during physical therapy.
45359272|NCT00864552|Drug|Kogenate (BAY14-2222)|Patients with severe haemophilia A (<2% FVIII:C baseline level) treated with Kogenate Bayer as their only source of recombinant FVIII
45359273|NCT03975673|Procedure|hip replacement|Osteoarthritic patient undergoing the conventional technique or the kinematically aligned technique
45359274|NCT04046822|Drug|Liraglutide 6 MG/ML [Saxenda]|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
45479568|NCT04919330|Behavioral|Family Acceptance and Commitment Therapy-based Eczema Management Programme|"The parent-child dyads will receive four weekly 2-hour sessions of family ACT-based eczema management programme (FACT-EMP). In each session, a group of 6-8 parent-child dyads will receive 90 minutes of ACT, followed by 30 minutes of education related to eczema management. Throughout the sessions, ACT strategies will help the dyads achieve the following therapeutic processes: To weaken the rumination cycle and fused thoughts related to eczema with body-image concern, shame and self-criticism for extending kindness and understanding to oneself; to build self-perspective-taking when seeing one's experience as part of the larger human experience; to strengthen their stands for their values related to self-kindness with acceptance of one's experience; and to take steps to act on values while practising kindness and compassion. Same as the waitlist control, the dyads will receive routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation."
45687823|NCT04603443|Dietary Supplement|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 20 g BID x 12 weeks
45844605|NCT05110404|Other|The high-volume HIIT|patients will undergo a warm up at 65%-70% of HRpeak for 5 minutes, and then they will walk on a treadmill for 4 intervals of 4 min each at an intensity corresponding to 85%-90% of HRpeak with 3 min active recovery interval interval in between at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted. The speed and the inclination of the treadmill will be adjusted between intervals to ensure that all patients are exercising at the desired target heart rate monitored by Pulse Oximeter.
46048210|NCT03198741|Drug|Aspirin + clopidogrel|After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + clopidogrel 75mg/d for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
46048211|NCT03198741|Drug|Clopidogrel monotherapy|After randomization(6 months±2 weeks after enrollment),receive clopidogrel 75mg/d + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
46048212|NCT03198741|Drug|Aspirin monotherapy|After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
45359275|NCT04046822|Drug|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
45359276|NCT04007835|Drug|Anlotinib Hydrochloride|anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of EGFR-TKIs
45687824|NCT04603443|Dietary Supplement|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 30 g BID x 12 weeks
45687825|NCT04603443|Dietary Supplement|Protein Control|Protein placebo control - all amino acids except for BCAA, 30 g BID x 12 weeks
45687826|NCT04594109|Behavioral|Tailored behavioral counseling|Participants in the intervention arm were provided a one-time tailored cognitive-behavioral therapy in-person cessation counseling intervention lasting approximately one hour, a 30-day supply of nicotine replacement therapy (consisting of nicotine patches and nicotine gum; dosage according to current smoking intensity according to manufacturers instructions), and a tailored bi-directional text messaging program delivering two messages per day for four weeks. The TI session was adapted from the clinical practice guidelines to include behavioral elements rooted in the minority stress model. The intervention used addressed issues of stress related to HIV stigma, minority status and socioeconomic condition.
45844606|NCT05110404|Other|The low-volume HIIT|Each session will start with a 5-minute warm up at 65-70% of peak HR. Then they will walk on a treadmill for 4 intervals of 2 min each at an intensity corresponding to 85%-90% of HRpeak with three intervals of active recovery in between for 2 min at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted.
45844607|NCT05087940|Drug|Add-on therapy|Add-on drugs prescribed by internal medicine specialists within the routine health care and independently from the study investigators - one of the following: an aldosterone receptor blocker, a loop diuretic, a thiazide in large daily dose, an alpha 1 selective blocker or a beta 1 selective blocker
45844608|NCT05077566|Other|Exercise at 60% vo2|15 minutes of exercise at 60% VO2 max.
45844609|NCT05077566|Other|Exercise at 90% vo2|15 minutes of exercise at 90% VO2 max.
46048213|NCT01122680|Drug|Tiotropium bromide|inhalation solution, dose of 1.25 mcg (2 puffs of 0.625 mcg)
45359277|NCT05226936|Diagnostic Test|Cell free DNA analysis|samples will be analysed using molecular techniques including sequencing for measuring dd-cfDNA or analysis of the presence of HLA-antibodies using commercial bead-technologies (Luminex or Immucor)
45687827|NCT04594109|Behavioral|Standard of Care|One-time standard of care in-person behavioral counseling lasting approximately one hour, plus a 30-day supply of nicotine replacement therapy consisting of nicotine patches and nicotine gum (dosage according to current smoking intensity according to manufacturers instructions). The standard of care behavioral counseling was adapted from the current U.S. clinical practice guidelines.
46048214|NCT01122680|Drug|tiotropium bromide|inhalation solution, dose of 2.5 mcg (2 puffs of 1.25 mcg)
45359278|NCT00795626|Behavioral|Systematic education in the reduction of the risk estimate to cardiovascular events|Systematic education during 4 assessment throughout one year
46048215|NCT01122680|Drug|tiotropium bromide|inhalation solution, dose of 5 mcg (2 puffs of 2.5 mcg)
45359279|NCT00867984|Other|Torsion optimized|Torsion optimized VV timing plus AV optimization (VTI)
45687828|NCT04593121|Drug|BIIB107|Administered as specified in the treatment arm.
46048216|NCT01122680|Drug|Placebo|placebo inhalation solution
45359280|NCT00867984|Other|Usual Care|AV optimization (VTI) only
45359281|NCT00800930|Biological|Sodium Butyrate|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
45479569|NCT04919330|Behavioral|Wait-list Control Group|The parent-child dyads will receive routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation. To ensure equity of access to potentially effective treatment (i.e., family ACT-based eczema management programme), the dyads in the wait-list control group will receive the same programme after the completion of all assessments of the intervention arm.
45479570|NCT03163446|Biological|CF-301|CF-301, 0.25 mg/kg, given as a single 2 hour iv infusion
45479571|NCT03163446|Drug|Placebo|Placebo, given as a single 2 hour iv infusion
45687829|NCT04593121|Drug|Placebo|Administered as specified in the treatment arm.
45687830|NCT04593069|Behavioral|Neurocognitive assessment|6 months after admission to the intensive care unit of Ziekenhuis Oost-Limburg, the patients will be tested on cognitive impairment
45687831|NCT04592744|Drug|Angiotensin II|Angiotensin II infusion for Intraoperative management during liver transplantation
45687832|NCT04592744|Drug|Norepinephrine|Vasopressor infusion for management of Intraoperative hypotension in liver transplantation.
45752069|NCT00403117|Drug|Naltrexone 100 Mg + Inactive Marijuana (0% THC)|One capsule containing 100mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
45752070|NCT03023631|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
45752071|NCT00353795|Procedure|MR Imaging of the Coronary Arteries|
46048217|NCT03186339|Procedure|TAVI|transfemoral transcatheter aortic valve implantation
46048218|NCT03186339|Procedure|SAVR|isolated surgical valve replacement
46048219|NCT03186339|Other|MM|management of aortic stenosis by medical treatment only
46048220|NCT00946998|Drug|Sertraline|Sertraline is a serotonin-selective reuptake inhibitor (SSRI) used to treat major depression. Dosage will begin at 50 mg/d and will be escalated by 50 mg increments every 2 weeks to a maximum of 200 mg/d
45687833|NCT04591015|Behavioral|Hospital: DD-CA|In the DD-CA group, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with educational, motivational and medication adherence messaging that is currently an arm of our parent DD-ME grant with added COVID support messages that provide information addressing identified barriers in Hispanic underserved communities (e.g. obtaining testing supplies and medications, accessing routine medical care, and completing other important diabetes self-management behaviors such as healthful eating, exercise, social distancing, quarantine, and stay-at-home/lockdown guidelines).
46048221|NCT00946998|Drug|placebo|Placebo tablet will be identical and matched to sertraline tablet.
45359282|NCT00800930|Biological|Saline|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
45359283|NCT00868062|Other|Succinylated gelatine, 40g/L, (Gelofusine - B Braun)|1 litre infusion following induction of anaesthesia
45479572|NCT03799133|Device|Florence device|The Florence catheter will be placed at the beginning of the surgery and up to 72 hours in ICU.
45479573|NCT03328936|Other|Laboratory Biomarker Analysis|Correlative studies
45359284|NCT00742859|Drug|betrixaban|orally, once daily for at least 3 months
45844610|NCT05069220|Drug|18F-MFBG|Patients with neuroendocrine malignancies receive 2-4 MBq/kg of 18F-MFBG intravenously followed by PET/CT after 60min of injection.
45359285|NCT00742859|Drug|Warfarin|Warfarin will be prescribed by the investigator according to the standard of care.
45687834|NCT04591015|Behavioral|Hospital: Usual Care (UC)|In the UC group, participants will not receive the added COVID support messages, both groups will have a referral placed to the Diabetes Transitions Service (DTS) at the time of discharge as part of usual care. Participants will be contacted by a peer health coach following protocol to coordinate care with outpatient health and other community resources.
45687835|NCT04586712|Drug|High dose CBD|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing CBD-extract oil at concentrations of 1000mg/30mL (high).
45844611|NCT04993326|Behavioral|emPOWERed To Change Program|Online Diabetes Self-Management Education and Support along with COVID-19 prevention and protection (vaccination) education and resource information
45359286|NCT00282295|Biological|Boostrix®|GlaxoSmithKline (GSK) Biologicals' registered tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
45479574|NCT03328936|Drug|Melphalan Hydrochloride|Given personalized dose IV for predicted 3-day duration of severe neutropenia
45687836|NCT04586712|Drug|Low Dose CBD|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing CBD oil at concentrations of 500mg/30mL (low)
45687837|NCT04586712|Drug|Vehicle Control Group|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing placebo containing no CBD oil (0mg/30 mL).
45687838|NCT04585711|Drug|Etanercept Optimal dosing|Patients will receive Etanercept on an optimal dose interval over a 6-week period based on a PK/PD model.
45479575|NCT03328936|Drug|Melphalan Hydrochloride|Given personalized dose IV for predicted 5-day duration of severe neutropenia
45479576|NCT03328936|Other|Pharmacological Study|Correlative studies
45479577|NCT03626480|Other|No treatment|No treatment
45479578|NCT01303757|Behavioral|Dietary counselling|
45479579|NCT02496754|Drug|GnRH-a|In experimental group, patients use long term GnRH-a; Patients' serum or follicle fluid will be collected if needed.
45479580|NCT02496754|Drug|GnRH-a|In control group, patients use short term GnRH-a. Patients' serum or follicle fluid will be collected if needed.
45479581|NCT04887194|Drug|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
46048222|NCT03147261|Other|Lifestyle intervention|Intensive changes in lifestyle with a reduced calorie mediterranean diet, physical activity and behavioral therapy
46048223|NCT01138826|Drug|Amlodipine - reference|10 mg tablet, single dose, with water
46048224|NCT01138826|Drug|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, with water
46048225|NCT01138826|Drug|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, without water
46048226|NCT00906087|Drug|Cosopt (combination eyedrop of dorzolamide and timolol)|One drop in each eye every twelve hours for six weeks
46048227|NCT02854332|Device|tDCS session|Direct current transcranial magnetic stimulation
45687839|NCT04581824|Drug|Dostarlimab|Dostarlimab will be administered through a 30 minute infusion at a dose of 500 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) up to a maximum of 35 cycles (each cycle of 21 days).
45844612|NCT04964934|Drug|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally
45359287|NCT00282295|Biological|Menactra™|Aventis Pasteur's me ningococcal polysaccharide diphtheria toxoid conjugate vaccine containing Neisseria meningitidis serogroups, A, C, Y and W-135.
45359288|NCT00742781|Dietary Supplement|Vitamin D|Oral supplementation daily with up to 5000 IU over 6 months.
46048228|NCT02854332|Device|rTMS session|Repetitive transcranial magnetic stimulation.
45359289|NCT00663026|Drug|bapineuzumab|5 mg bapineuzumab subcutaneous injection once per week for 6 months
45359290|NCT00663026|Drug|bapineuzumab|10 mg bapineuzumab subcutaneous injection once per week for 6 months
45359291|NCT00663026|Drug|placebo|Placebo subcutaneous injection once per week for 6 months
46048229|NCT03525795|Drug|CPI-1205|Administered orally
45359292|NCT00280735|Drug|carboplatin|Carboplatin will be given intravenously,once,every 3 weeks. The carboplatin area under curve (AUC) dose will be calculated using the Calvert Equation 19 as follows: Carboplatin dose (mg) = 6x (GFR + 25)
45359293|NCT00280735|Drug|docetaxel|75 mg/m² intravenously, once, every 3 weeks
45359294|NCT02555462|Device|Real-Ear Measurement system integrated in hearing aid fitting software|The subjects individual response of the ear canal gets measured with the help of a probe tube and a following hearing aid fitting.
45359295|NCT00979719|Behavioral|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
45359296|NCT00979719|Behavioral|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, W. & Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.)
45359297|NCT01070251|Behavioral|Participatory parent-focused intervention|Parent workshops and internet-based support to establish healthy physical activity routines, added to existing state-sponsored PA program
45359298|NCT01070251|Behavioral|State-sponsored PA program|Preschool children receive twice a week 60 minutes of physical activity lessons over 6 months by an external gym trainer
45359299|NCT00801008|Behavioral|Exercise and relaxation intervention|Comparison of an exercise and relaxation intervention to a wait-list control condition
46048230|NCT03525795|Drug|ipilimumab|Administered intravenously
46048231|NCT02883374|Drug|Chidamide|
46048232|NCT02855736|Behavioral|Positive Psychology|"Gratitude Journal (Emmons and Stern, 2013)~Every evening, patients have to write down the things they feel grateful about."
46048233|NCT02855736|Behavioral|Placebo (food journal)|"Food journal (i.e. alimentary list):~Patients have to write down the list of foods eaten during the day."
45359300|NCT03975283|Drug|Exparel 266 MG Per 20 ML Injection|266mg of liposomal bupivacaine 266 mg, 20 mL volume, will be diluted with 20 ml of 0.25% bupivacaine (50 mg of bupivacaine) and 20 ml saline, thereby totalling 60mL volume. Total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
45359301|NCT03975283|Drug|Bupivacaine Hcl 0.25% Inj|0.25% bupivacaine, 60mL total, divided into two 30mL syringes and delivered via TAP block on either side.
45479582|NCT04887194|Drug|Warfarin|CYP2C9 probe substrate
45479583|NCT04887194|Drug|Dextromethorphan|CYP2D6 probe substrate
45687840|NCT04581824|Drug|Pembrolizumab|Pembrolizumab will be administered through a 30 minute infusion at a dose of 200 mg Q3W up to a maximum of 35 cycles (each cycle of 21 days).
45752072|NCT04602299|Other|Set the minimum time of gastroscopy|This study contains 2 stages. At the first stage, no interventions are implemented. The researchers just observe the actual procedure time of gastroscopy. At the second stage, a minimal procedure time is set based on the observational results of the first stage.
45752073|NCT00558285|Drug|indacaterol/glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
45844613|NCT04964934|Drug|AZD9833 Placebo|Dosage formulation: AZD9833 placebo tablets will be administrated orally.
45844614|NCT04964934|Drug|Anastrozole|Dosage formulation: anastrozole tablets will be administered orally.
45844615|NCT04964934|Drug|Anastrozole placebo|Dosage formulation: anastrozole placebo tablets will be administrated orally.
45844616|NCT04964934|Drug|Letrozole|Dosage formulation: letrozole tablets will be administered orally.
45844617|NCT04964934|Drug|Letrozole placebo|Dosage formulation: letrozole placebo tablets will be administered orally.
46048234|NCT03522831|Drug|Salbutamol|Administration of 400 μg meter-dose inhaler of salbutamol performed using large-volume spacer
45359302|NCT00795782|Procedure|Prophylactic central lymph node dissection|prophylactic ipsilateral versus bilateral central lymph node dissection
45359303|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10^8vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24.
45359304|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10^9vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24.
45359305|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 2.5 x 10^10vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24.
45479584|NCT04887194|Drug|Midazolam|CYP3A4 probe substrate
46048235|NCT03522831|Drug|Placebo|Administration of 400 μg meter-dose inhaler of placebo performed using large-volume spacer
45479585|NCT04887194|Drug|Digoxin|P-gp probe substrate
45479586|NCT04887194|Drug|Rosuvastatin|BCRP probe substrate
45479587|NCT04887194|Drug|Nivolumab|Nivolumab is a programmed death receptor (PD-1) blocking antibody
45479588|NCT03301337|Dietary Supplement|Meat protein absorption|Meat protein absorption when digested together with a full meal.
45359306|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10^8vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24.
45359307|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10^9vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24.
45359308|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 2.5 x 10^10vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24.
45359309|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|1 dose Ad6NSmut 2.5 x 10^10vp at week 0 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 8.
45479589|NCT02496910|Drug|YH22162|
45687841|NCT04581824|Drug|Chemotherapy|"Pemetrexed will be administered at 500 milligram per meter square (mg/m^2 ) IV through a 10 minute IV infusion Q3W, up to a maximum of 35 cycles (each cycle of 21 days).~Cisplatin will be administered at 75 mg/m^2 through a 30 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.~Carboplatin will also be administered at area under the concentration time curve 5 milligram/milliliters/minute (mg/mL/min) (maximum dose: 750 mg) through a 15 to 60 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision."
45687842|NCT04566484|Drug|BBV87 Chikungunya vaccine|BBV87 Chikungunya vaccine is a whole virus inactivated vaccine formulated with 0.25 mg aluminum (as aluminum hydroxide) per single human dose.
45687843|NCT04566484|Drug|Normal Saline|Normal saline is the placebo
45687844|NCT04564833|Drug|Low Dose RBT-1|intravenous administration
45687845|NCT04564833|Drug|High Dose RBT-1|intravenous administration
45687846|NCT04564833|Drug|Placebo|intravenous administration
45752074|NCT00558285|Drug|indacaterol|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
46048236|NCT05183282|Device|Tarsus Patch|The Tarsus Patch is a flexible adhesive device that is applied to the closed upper eyelid and conforms to the curvature of the eyelid to help keep the eyelid in a closed position.
46048237|NCT03504501|Drug|Lovastatin|oral application prior to transcranial magnetic stimulation intervention
45359310|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 2.5 x 10^10vp at week 0 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 8.
45359311|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 7.5 x 10^10vp at week 0 and 1 dose Ad6NSmut 7.5 x 10^10vp at week 8.
45359312|NCT00801086|Drug|7% (w/v) Tempol alcohol-based gel (MTS-01)|200mL gel applied daily prior to radiation dose and removed immediately thereafter.
46048238|NCT03504501|Drug|Lamotrigine|oral application prior to transcranial magnetic stimulation intervention
46048239|NCT02855970|Other|completion of a quality of life questionnaire|
45359313|NCT00801086|Drug|alcohol-based gel|200mL gel applied daily prior to radiation dose and removed immediately thereafter
45479590|NCT02496910|Drug|Telmisartan/Amlodipine 80/5 mg (FDC)|
45479591|NCT02496910|Drug|Chlorthalidone 25mg|
45479592|NCT01310959|Other|Database|Database
46048240|NCT05318001|Other|Evaluation of biomechanics and viscoelastic properties of plantar fascia|"The biomechanical (Tone-Hz, Stiffness-N/m and decrement) and viscoelastic (creep and relaxation time-ms) properties of the plantar fascia will be measured in the side lying position.~Measurements will be made with the ankle in neutral position."
46048241|NCT05318001|Other|Evaluation of Foot Morphological Characteristics|Foot length and width will be measured.
45359314|NCT00788606|Drug|bevacizumab, Rituximab|6 cycles of treatment. Bevacizumab at a dose of 15 mg/kg, diluted in normal saline will be administered as a intravenous infusion over 30 to 90 minutes on Day 1 of each cycle. Rituzimab 375 mg/m2 is given as a intravenous infusion after the administration of prednisolone and before the other cytotoxic drugs on Day 1 of each cycle.
45844618|NCT04964934|Drug|Palbociclib|Dosage formulation: palbociclib tablets/capsules will be administered orally
46048242|NCT05318001|Other|Evaluation of navıcular mobility|The amount of navicular drop of both feet will be measured.
46048243|NCT05318001|Other|Evaluation of Foot Posture|Foot posture will be evaluated according to Foot Posture Index.
45359315|NCT00801164|Drug|Frio Mouth Rinse Placebo|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
45359316|NCT00801164|Drug|Frio Mouth Rinse|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
45359317|NCT00801320|Procedure|Tumor collection|Tumor collected at the time of planned surgery
45359318|NCT00795860|Behavioral|Weight loss - diet only|Subjects adhere to a reduced calorie diet until they lose exactly 12% of their initial body weight. After they achieve this weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
45687847|NCT04559334|Device|Tetrasodium EDTA Catheter Lock Solution|KiteLock™ 4% Sterile Catheter Lock Solution is a single use, clear, colorless and sterile solution. It is free of preservatives, alcohol and latex and is non-pyrogenic. KiteLock™ 4% is an aqueous solution containing a mixture of edetate tetrasodium and edetate trisodium. The solution composition is equivalent to 28 mg/mL edetate. EDTA is a known chelator. This means it has an affinity for metals and elements such as calcium. As a primary mechanism of action, it acts as a space occupying solution to prevent blood from entering the tip of the catheter when the catheter is not in use. As a secondary mechanism of action, it acts as an in vitro anticoagulant. This dual action decreases the risk of clot formation, consequently thrombolytic occlusions and by extension decreases the risk of CLABSI.
45687848|NCT04551495|Drug|Entrectinib|Entrectinib is administered orally at a dose of 600 mg once a day from days 1 to 28 of a 28-day cycle for four cycles
45687849|NCT04551495|Drug|Letrozole|Letrozole is administered orally at a dose of 2.5 mg once a day from days 1 to day 28 of a 28 day cycle for four cycles
45687850|NCT04551495|Drug|Goserelin|Goserelin is administered subcutaneously at a dose of 3.6 mg at the beginning of each cycle for 4 monthly cycles to pre-menopausal women
45844619|NCT04964934|Drug|Abemaciclib|Dosage formulation: abemaciclib tablets will be administered orally
45844620|NCT04964934|Drug|Luteinizing hormone-releasing hormone (LHRH) agonist|Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
45844621|NCT04939038|Procedure|Revascularization|Depending on the condition of the patients, patients will have either endovascular or surgical revascularization
45844622|NCT04939038|Procedure|Standard wound care|Standard wound care according to guidelines
46048244|NCT02420574|Drug|albendazole BENDEX|randomized clinical trial with 2 parallel arms
46048245|NCT02420574|Drug|albendazole OVIS|
45479593|NCT01304615|Behavioral|Decrease Energy Density of the Diet|Participants will be given goals to help guide their food choices to decrease the energy density of the overall diet. The goals are to eat 10 or more foods with an ED less than 1.0 and 2 or less foods with an ED of great than 3.0 each day and to reduce portion sizes.
45479594|NCT01304615|Behavioral|Increase Steps per Day|Participants will increase their steps per day by at least 3,000 steps per day above their baseline levels.
46048246|NCT02855502|Drug|Prednisolone|
46048247|NCT02855502|Drug|Placebo|
46048248|NCT05332431|Device|Optical coherence tomography (OCT)|"Patient with different types of migraine and age and sex matched control group will be subjected to OCT in the ophthalmology department in Assiut University Hospital to assess the following parameters:~Optic nerve head parameters and retinal nerve fibre layer thickness and measuring macular thickness in migraine patients will be measured using optical coherence tomography (OCT) after pupillary dilatation. Retinal nerve fiber layer thickness included average thickness (360° measurement), temporal quadrant thickness (316-45°), superior quadrant thickness (46-135°), nasal quadrant thickness (136-225°) and inferior quadrant thickness (226-315°) will be measured by OCT."
45359319|NCT00795860|Behavioral|Weight loss plus exercise|Subjects adhere to a reduced calorie diet and perform 4 session of endurance exercise training per week until they lose exactly 12% of their initial body weight. Exercise training consists of stationary bicycle exercise. the exercise duration and intensity ramp up over the first few weeks of training until subjects exercise 45 min per session at an intensity of 85% of their maximal heart rate. 3 of the 4 exercise session each week are supervised by an Exercise physiologist. After they achieve the 12% weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
45359320|NCT00795938|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
45359321|NCT00795938|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
45359322|NCT00795938|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
45359323|NCT00260065|Drug|Decitabine|20mg/m^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops.
45359324|NCT00796094|Other|Ultrasound examination|Sonoelastrography is an ultrasound examination that can determine the elasticity of soft tissue. This examination takes approximately 10 minutes to complete.
45844623|NCT04930770|Drug|MRNA-1273|Renal or renopancreatic transplant's patient will receive a third dose of mRNA 1273 (Moderna) vaccine from 28 days after administration of the second dose and after the seronegativity has been verified.
46048249|NCT02853864|Drug|0.0 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.0 ng/ml
46048250|NCT02853864|Drug|0.4 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.4 ng/ml
45359325|NCT01072435|Device|Patient-controlled sedation|Administration of short-acting anesthetic propofol via self-administration device.Single bolus-dose 1ml(10mg)of propofol,lockout time 0sec.,no background infusion or dose-limit.
45359326|NCT01072435|Device|Target-controlled infusion|Anaesthesiologist´s managed target-controlled infusion of short-acting anesthetic propofol
45359327|NCT01072513|Other|Semen analysis|Semen analysis before and after proton radiation therapy.
45359328|NCT00796172|Behavioral|Medication Adherence System (MAS)|Participants will receive individualized reports from the MAS and counseling from their doctors. The counseling will focus on adherence to blood pressure and cholesterol management medications.
45359329|NCT00796172|Behavioral|Usual Care|Participants will receive usual care from their doctors and written materials on CVD risk factors.
45687851|NCT04551378|Other|Quality-of-Life Assessment|Ancillary studies
45359330|NCT01071655|Drug|BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX|"BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1~BVZ + XELIRI. Bevacizumab 7,5 mg/kg day 1; Capecitabine 800 mg/m2/12 h days 1-14; Irinotecan 200 mg/m2 day 1~BVZ + FUIRI. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Irinotecan 80 mg/m2 weekly~BVZ + FUOX. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Oxaliplatin 85 mg/m2 biweekly"
45687852|NCT04551378|Other|Survey Administration|Complete survey
45687853|NCT04548778|Diagnostic Test|BÜHLMANN fPELA assay|BÜHLMANN fPELA assays are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
45687854|NCT04546295|Other|Brushlink application|Brushlink application + Interproximal brush
45359331|NCT01071655|Drug|BVZ+XELOX|BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1
45359332|NCT00801476|Procedure|Pre-operative bilateral breast MRI|After the standard mammogram and ultrasound testing, the surgeon is asked which surgical procedure they feel is appropriate for the patient. A bilateral breast MRI is then performed prior to surgery. The surgeon is again asked which surgery they feel is appropriate based on the new information provided by the MRI. The study is trying to see if this pre-operative breast MRI helps define the tumour leading to a better first surgical decision.
45687855|NCT04546295|Other|Water-flosser|Water-flosser
45687856|NCT04546295|Other|Interproximal brush|Interproximal brush alone
45844624|NCT04922658|Drug|Surufatinib|Surufatinib,300mg, qd, po, 21 days for a cycle; continuous administration until PD, death or intolerable toxicity.
46048251|NCT02853864|Drug|0.6 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.6 ng/ml
46048252|NCT02853864|Drug|0.8 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.8 ng/ml
46048253|NCT02853864|Drug|Propofol|The propofol infusion was started to provide an effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness
46048254|NCT04269642|Drug|PT320 2.0mg Placebo|PT320 2.0mg Placebo
46048255|NCT04269642|Drug|PT320 2.0 mg|Exenatide slowly released formulation
46048256|NCT04269642|Drug|PT320 2.5 mg|Exenatide slowly released formulation
46048257|NCT00907257|Drug|benzoyl peroxide wash|5% benzoyl peroxide wash
46048258|NCT00907257|Drug|Tretinoin gel|0.04% tretinoin gel
45359333|NCT02531581|Drug|Furosemide|furosemide 40 mg bolus with second bolus to 4 hours so inadequate diuretic response defined as urine output <500cc
45359334|NCT02531581|Drug|NaCl 9% isotonic|normal saline 500 cc / 4 hours and 1 L / 24 hours
45359335|NCT04046510|Drug|Ocytocin|Administration of lower doses of Ocytocin in bolus and continuous infusion
45359336|NCT00506350|Biological|Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose|A single dose of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
45359337|NCT00506350|Biological|Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses|Two doses of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21.
45359338|NCT00788840|Drug|Insulatard|Insulatard insulin used as long-acting insulin for 16-week treatment phase of study.
45359339|NCT00788840|Drug|Detemir|Detemir insulin used as long-acting insulin in treatment phase of study.
45359340|NCT00258895|Biological|DAPTACEL®: DTaP|0.5 mL, Intramuscular
45359341|NCT00258895|Biological|DAPTACEL®: DTaP|0.5 mL, Intramuscular
45359342|NCT00742625|Drug|daunorubicin hydrochloride|Given IV
45359343|NCT00742625|Drug|cytarabine|Given IV
45844625|NCT04922658|Drug|Surufatinib Plus Vinorelbine|Surufatinib, 250mg, qd, po; Plus Vinorelbine, 40 mg , each week d1, d3, d5; 21days for a cycle; continuous administration until PD, death or intolerable toxicity.
45359344|NCT00742625|Drug|bortezomib|Given IV
45359345|NCT00801710|Device|BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire)|"Revascularization of coronary artery chronic total occlusion.~Use of the BridgePoint Medical System to cross coronary CTOs prior to definitive revascularization treatment via angioplasty and/or stent implant"
45359346|NCT00801788|Drug|Oxycodone hydrochloride|Extended release tablet
45359347|NCT00801788|Drug|Oxycodone hydrochloride|Extended release tablet
45359348|NCT01070485|Drug|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight (50 kBq/kg b.w.).
45359349|NCT00618618|Drug|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
45359350|NCT00618618|Drug|Placebo|
46048259|NCT01138046|Drug|Lapatinib in combination with weekly paclitaxel|These subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle) plus lapatinib (1500 mg once daily, starting on the second day of phase I). Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Study completion is defined as deaths after administering study treatment for more than once. Subjects will be treated with paclitaxel for standard of 6 cycles, and may be continued at the discretion of investigators. If the subject experiences progression, an unacceptable toxicity related to paclitaxel, or termination of lapatinib therapy, paclitaxel therapy must be terminated any time of study period, even before 6 cycles of paclitaxel are given.
46048260|NCT02854176|Procedure|Somatosensory electrical stimulation|
45359351|NCT00796250|Biological|Infliximab|Patients in this group were treated with azathioprine (AZA), infliximab, and placebo prednisolone. Infliximab was to be administered at a dose of 5 mg/kg at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
45359352|NCT00796250|Drug|AZA|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
45359353|NCT00796250|Drug|Placebo Prednisolone|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. Placebo prednisolone was to be administered by oral use.
45359354|NCT00796250|Drug|Prednisolone|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Prednisolone was to be administered by oral use, with the decreasing dose of 40 mg a day, 35 mg a day, 30 mg a day and 25 mg a day every week for each dosage, respectively; 20 mg a day for five weeks; 15 mg a day, 10 mg a day and 5 mg a day for one week for each dosage respectively, until discontinuation.
45359355|NCT00796250|Drug|AZA|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
45359356|NCT00796250|Biological|Placebo Infliximab|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Placebo infliximab was to be administered at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
45687857|NCT04545424|Device|Hypothermia|Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.
45687858|NCT04545424|Drug|Neuromuscular Blocking Agents|Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
45844626|NCT04915404|Drug|Berubicin Hydrochloride|Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base (equivalent to 7.5 mg/m2 Berubicin HCl) as a 2-hour intravenous (IV) infusion once daily for 3 consecutive days followed by 18 days off study drug (each cycle = 21 days).
45844627|NCT04883346|Drug|Liraglutide|Liraglutide by subcutaneous injection administered daily. Dose will be initiated at 0.6mg per day and increased to a maximum of 3.0 mg per day as tolerated.
45844628|NCT04879602|Behavioral|suction with bronchoscopy|suction with bronchoscopy
45687859|NCT04545424|Device|Standard of care|Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature >38°C will receive 650 mg acetaminophen and, if temperature remains >38°C, surface cooling will be initiated to return core temperature to 37-38°C.
45359357|NCT01070563|Other|Transcranial doppler|A TCD is performed on all cerebral arteries (mean cerebral arteries, anterior cerebral arteries, basilar trunk, vertebral arteries and carotid arteries) until a flow pattern compatible with brain death is found
45359358|NCT01012726|Procedure|Colonoscopy|During the colonoscopy, we instill Acetylcystein and Doxycyline into the fistula.
45479595|NCT01304615|Behavioral|Consumption of Self-made Meals|Participants will have the goal of increasing the number of self-prepared meals that they consume to 10 or more lunch and dinner meals each week.
45359359|NCT00788918|Drug|Interferon and ribavirin|Interferon 180 microgram weekly s.c. and ribavirin (800/100/1200 mg daily) p.o.
45359360|NCT02596373|Drug|Mitoxantrone Hydrochloride Liposome Injection|
45359361|NCT00246805|Device|Vitatron pacemaker C20 SSIR or T20 SSIR models|VRS: special function that automatically adapts pacing rate to regularize cardiac cycles
45359362|NCT00801866|Drug|Bevacizumab|Intravitreal administration
45359363|NCT00801866|Procedure|Panretinal Photocoagulation|Panretinal Photocoagulation
45359364|NCT04088747|Diagnostic Test|Ultrasound Imaging|B-mode ultrasound pictures of the upper Trapezius were collected from both left and right sides.
45359365|NCT03973879|Biological|PVSRIPO|Oncolytic polio/rhinovirus recombinant
45359366|NCT03973879|Drug|Atezolizumab|Antibody
45687860|NCT04543279|Drug|Fostamatinib|Fostamatinib will be supplied by Rigel Pharmaceuticals.
45359367|NCT00519376|Drug|GW642444M|drug
45844629|NCT04862910|Other|Kinect Based Virtual Reality Training|"STEP I: The participant will receive the game instructions from the examiner. STEP-II: Warm Up (Walk on Treadmill for 5 Minutes) STEP III: The participant will play the games under the supervision of the researcher.~Kinect games Kinect Sports Kinect Adventures Your Shape Fitness Evolved Three treatment sessions per week will be given to each participant. Total duration of each treatment session will be 45 Minutes. Routine Medication and routine diet will be continued."
45359368|NCT00519376|Drug|GW642444H|drug
45359369|NCT00519376|Drug|placebo|
45687861|NCT04543279|Drug|Ruxolitinib|Ruxolitinib is commercially available.
45844630|NCT04862910|Other|Control Group|"They will be educated that Moderate-level regular physical activity can significantly impact the maintenance of bone density.~They will continue their daily activities with a routine diet and routine Medication"
45359370|NCT00860964|Drug|Placebo|Placebo, calcium 900mg/d, VitD200iu/d and exercise
46048261|NCT02854176|Procedure|Control|
46048262|NCT02853942|Biological|Autologous adipose stem cell therapy|
46048263|NCT02853942|Drug|Mecobalamin|
45359371|NCT00860964|Drug|estradiol valerate|estradiol valerate 1mg/d,medroxyprogesterone 6mg/d for 10 days,calcium 900mg/d, VitD200iu/d and exercise
45359372|NCT00745121|Device|OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ implants Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm
45687862|NCT04542616|Device|Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation|Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation for the treatment of severe uncontrolled glaucoma.
45752075|NCT00558285|Drug|glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
46048264|NCT03484533|Behavioral|HIV self-test kit|We will conduct a randomized trial to evaluate whether provision of oral HIV self-test kits to HIV-positive pregnant women overcomes their male partners' reluctance to be tested in PMTCT clinics. Pregnant women who are randomized to the HIVST arm will be trained in the use and interpretation of HIVST, and given two oral fluid-based HIVST kits to use with or give to their partners, along with information about HIV testing and prevention and care services. We will offer men confirmatory testing regardless of their HIV test result through HIVST, counseling, and if negative, PrEP and if positive, ART.
46048265|NCT03484533|Behavioral|Standard of Care|In the standard of care arm, we will give women invitation letters to deliver to their male partners to come to the ANC clinic for fast-tracked HIV testing. We will offer men counseling and if negative, PrEP and if positive, ART.
46048266|NCT02350764|Drug|nivolumab|
46048267|NCT02350764|Drug|pilimumab|
46048268|NCT00876460|Drug|BIBF 1120 M + docetaxel M|BIBF 1120 Medium dose bid + docetaxel 60 mg/m2
46048269|NCT00876460|Drug|BIBF 1120 M + docetaxel H|BIBF 1120 Medium dose bid + docetaxel 75mg/m2
45359373|NCT00864630|Behavioral|Computer-based problem solving therapy|Computer program developed by Dr. James Cartriene at Beth Israel Deaconess Hospital, Boston, MA.
45359374|NCT00861042|Drug|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation
45359375|NCT04088903|Drug|Daratumumab|>Daratumumab 16 mg/kg intravenous weekly for 8 weeks and then every other week for 2 doses.
45359376|NCT02545140|Other|No intervention|
45359377|NCT05395871|Behavioral|Behavioural Message|Messaging involving increased salience, increasing positive emotions and information on health consequences
45479596|NCT03342352|Drug|Nivolumab|Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
45479597|NCT03342352|Drug|Epacadostat|Epacadostat administered orally at the protocol-defined dose twice daily.
45479598|NCT03342352|Drug|Placebo|Matching placebo for epacadostat administered orally twice daily.
45479599|NCT03342352|Drug|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
45479600|NCT03342352|Drug|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
45479601|NCT03342352|Drug|Cetuximab|Cetuximab administered intravenously at the protocol-defined dose weekly.
46048270|NCT00876460|Drug|BIBF 1120 H + docetaxel H|BIBF 1120 HIgh dose bid + docetaxel 75 mg/m2
45359378|NCT05395871|Behavioral|Behavioural Message + Video|Messaging as above. The video also includes information on emotional consequences, problem solving, anticipated regret, reducing negative emotions and credible source techniques.
45359379|NCT05395871|Other|Usual Care Message|Standard usual care message involving link to non-behavioural science informed video
45359380|NCT01009372|Behavioral|IPP|Institution of intraoperative breaks for the surgeon with release of pneumoperitoneum for patient
45359381|NCT00861120|Drug|Pegylated liposomal doxorubicin|40 mg/m2 on day 1 of a 28 days cycle
45687863|NCT04536779|Other|Training in the local departments of TT and cycling trips with CUA|in a minimum of 3 months, the individuals with low physical mobility will conduct a minimum of 8-10 training and cycling sessions.
45844631|NCT04794660|Diagnostic Test|HPV DNA Test|Screening for HPV using a HPV DNA test
45844632|NCT04794660|Diagnostic Test|VIA triage test|"VIA is a technique in which cervical neoplastic lesions are visually diagnosed after application of 3-5% acetic acid without using any magnification device.~After application of 3 - 5% acetic acid, using the naked eye, the cervix is examined for the presence of an aceto-white lesion located in the transformation zone. The results are classified as either positive or negative, inadequate or suspicion of cancer"
45844633|NCT04794660|Procedure|Treatment by ablative treatment|Cryotherapy or Thermal Ablation are performed on the cervix.
45844634|NCT04794660|Procedure|Colposcopy|Colposcopy visit are offered to women with non visible squamous columnar junction or ineligible for ablative treatment.
45844635|NCT04660968|Behavioral|Dyadic health behaviour change intervention|The dyadic behaviour change intervention adopts a dyadic coping perspective wherein appraisal of shared responsibility, agreement on tasks, and collaboration are fostered throughout the intervention. The intervention will target four behaviour goals: reducing overall caloric intake, substituting empty calorie foods with healthier alternatives, reducing sedentary behaviour, and increasing physical activity. The specific behavioural change strategies will include motivational interviewing, self-monitoring, goal setting, stimulus control, problem solving, and relapse prevention. Each session will also include a short education component on healthy eating to improve participants' adherence to the updated Canada's Food Guide. Participants will have access to web-based exercise training sessions. Intervention sessions will be delivered online.
45847664|NCT02820870|Behavioral|Statin Decision Support Intervention|"The investigators have developed a mock medical record decision support tool for this project. Each week the investigators will pull a list of patients scheduled for a primary care visit at the Ann Arbor VAMC then calculate each patient's risk based on the clinical guidelines algorithm and compare the statin recommendation against their current prescriptions. For each patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant), a brief recommendation will be generated. Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the providers for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guideline."
46048271|NCT00876460|Drug|BIBF 1120 L + docetaxel M|BIBF 1120 Low dose bid + docetaxel 60 mg/m2
46048272|NCT00876460|Drug|BIBF 1120 H + docetaxel M|BIBF 1120 HIgh dose bid + docetaxel 60 mg/m2
46048273|NCT00908115|Biological|GSK Biologicals' Infanrix™|Primary and booster vaccination according to vaccination schedule. Intramuscular injection
46048274|NCT05551611|Other|Playgroup|The mobile game will be sent to the students via a link and the students are allowed to install it on their mobile phones with android and ios operating systems. The internet required for the download was provided by the researcher. For the students who did not have a smart phone in the playgroup, the game would be started from the researcher's phone and the game was played sequentially. All students were allowed to use headphones while playing the game. In order to log in to the game, an account was created on behalf of each student, and the game user name and password were sent to the students by e-mail. It was ensured that they did not communicate with anyone and did not receive help during the game with the supervision of the researcher. Waited until each participant completed the game. Then, the mobile game was deleted from the smartphones of all participants, and the download link was inactive until the research process was completed.
46048275|NCT05551611|Other|Control group|The researcher gave a theoretical lesson through the presentation prepared in the powerpoint program about the birth management of a breech-presented fetus in the classroom as in the traditional education method.
46048276|NCT01137812|Drug|Sitagliptin 100 mg|One 100 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
46048277|NCT01137812|Drug|Canagliflozin 300 mg|One 300 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
46048278|NCT01137812|Drug|Metformin|Patients will continue to take background therapy with Metformin for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
45359382|NCT00861120|Drug|Panitumumab|6 mg/kg on days 1 and 15 of a 28 days cycle
45359383|NCT00864786|Drug|PF03635659|Inhaled doses of 200 mcgQD
45359384|NCT00864786|Drug|PF03635659|Inhaled doses of 600 mcg QD
45359385|NCT00864786|Drug|PF03635659|Inhaled doses of 1000 mcg QD
45359386|NCT00864786|Drug|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
45479602|NCT03342352|Drug|5-Fluorouracil|5-Fluorouracil administered intravenously at the protocol-defined dose on Days 1-4 for 6 cycles.
45687864|NCT04533659|Behavioral|ADA-based nutrition education with digital self-monitoring|Diabetes nutrition education developed by the American Diabetes Association with digital self-monitoring for diet and physical activity
45687865|NCT04533659|Behavioral|Personalized Behavioral Nutrition (PBN) intervention group|Personalized behavioral nutrition intervention consisting of digital self-monitoring for diet and physical activity, personalized nutrition change goal and recommendation, and diabetes nutrition education developed by ADA
45687866|NCT04526665|Drug|Elafibranor 80mg|Elafibranor 80mg for double blind period (52 to 104 weeks). After completion of the double blind period, participants will be offered the opportunity to enter an open label long term extension study for up to 5 years. Participants will continue the elafibranor dose received during the double blind period.
45847665|NCT02821338|Drug|Lamotrigine Extended Release|Lamotrigine Extended Release (generic) and Lamictal XR (brand).
45687867|NCT04526665|Drug|Placebo|Placebo for double blind period (52 to 104 weeks). After completion of the double blind period, participants will be offered the opportunity to enter an open label long term extension study and to switch to elafibranor 80mg for up to 5 years.
45359387|NCT00864786|Drug|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
45359388|NCT03841656|Procedure|PARORISKIMPLANT|Patients attending periodontal and implant treatment at the Department of Periodontology of the Dental Faculty at Strasbourg, France, between 2000-2015.
45359389|NCT00740051|Drug|Linagliptin|5mg once daily
45687868|NCT04523558|Device|Implantation of LuxSmart hydrophobic IOLs (Bausch + Lomb) in both eyes|Extended depth of field intraocular lens made form hydrophobic material
45687869|NCT04520087|Procedure|allograft fixation|Patients with anteroinferior shoulder instability will be clinically treated with a mini-open arthrotomic technique involving the fixation of the corticospongeous bone graft on the glena.
46048279|NCT01137812|Drug|Sulphonylurea|Patients will continue to take background therapy with Sulphonylurea for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
45687870|NCT04515316|Device|OPM sensors|Optically-pumped magnetometers (OPM) sensors, which are based on optical probing of alkali atoms in the vapor phase at (or slightly above) room temperature, have recently demonstrated sensitivity levels comparable with SQUID magnetometers in the laboratory. These sensors require no cooling and can potentially be fabricated at much lower cost than SQUIDs. Beginning in the late 1990s, optically-pumped magnetometers began to be used for biomagnetic applications, first for measurement of heart magnetic fields and more recently for measurement of brain fields by several groups around the world.
45687871|NCT04515316|Device|SQUID sensors|Magnetic sensors based on superconducting quantum interference devices (SQUIDs) have been the dominant sensor in the field of magnetoencephalography since its birth in the early 1970s. SQUIDs have exceptional sensitivity to enable the detection of these very weak signals. Current FDA-approved MEG devices contain liquid helium gas in a big container that is mounted over the head of the subject
46048280|NCT00679510|Drug|rosuvastatin|tablet 10 mgs once daily
45687872|NCT04513132|Device|active-dTMS|The dTMS using H-coil with 5Hz stimulate ACC. The sessions of dTMS will be conducted twice daily for 5 consecutive days, and twice sessions of a day will be separated by 3 hours at least.
45687873|NCT04513132|Device|sham-dTMS|The sham-dTMS has the same appearance with the real stimulation coil, which can not generate magnetic field. A sound generator is built in the coil beat to simulate the sound of the real stimulation.
46048281|NCT00679510|Drug|placebo|placebo
46048282|NCT02626858|Device|extra treatment planning CT-scan|Beside the standard post-operative CT-scan, an extra pre-operative CT-scan is performed.
46048283|NCT04146220|Drug|Prednisolone|Patients of the low and the high dose groups recieved prednisolone in different dose for initial 4 weeks, then tapered gradually. Both groups received pulse I/V methylprednisolone 500 mg/day daily for initial 3 days and monthly cyclophosphamide infusion 750-1000 mg/m2 body surface area.
45687874|NCT04508647|Drug|Ublituximab|"Ublituximab will be administered as an intravenous infusion through a dedicated line. All infusions will be administered per institutional guidelines.~During ublituximab monotherapy (initial treatment), Cycle 1 Day 1 administration time frame: Over 4 hours. Cycle 1 days 8 and 15 will be over 3 hours, and Cycle 1 Day 22 will be over 90 minutes. During combination treatment with umbralisib, ublituximab will be administered over 90 minutes."
45847666|NCT02823600|Device|RetinaVue 100 camera|Images of the subject's eye will be obtained using the RetinaVue 100 camera and uploaded to a secure network. The study doctor, a board-certified ophthalmologist, will interpret the patient images and return a diagnosis and management plan to the dialysis unit.
45847667|NCT02829294|Device|E002 - cerumen removal aid|topical treatment
45847668|NCT02830074|Behavioral|Best practices PAP + patient Education +ongoing Support and Training|"This is a combined sleep and PAP adherence program, called the BEST program (Best practices PAP + Education + ongoing Support/Training"
45847669|NCT02830074|Behavioral|Sleep Education|This program includes non-directive sleep education plus standard treatment of SDB.
45359390|NCT00740051|Drug|Linagliptin Placebo|0 mg placebo comparator for part 1 of study (to 18 weeks)
45359391|NCT00740051|Drug|Glimepiride|1-4mg for part 2 of study (weeks 19-52)
45359392|NCT00864864|Drug|Sunitinib|Taken orally on days 1-7 prior to surgery and then starting again on Day 22 for 4 weeks followed by a 2 week rest period
45359393|NCT00868686|Device|Volar aluminum splint|Alumafoam strip with padding removed, placed on the VOLAR aspect of the digit spanning the middle and distal phalanges only.
45359394|NCT00868686|Device|Dorsal aluminum splint|Alumafoam strip with padding removed, placed on the DORSAL aspect of the digit spanning the middle and distal phalanges only.
45359395|NCT00868686|Device|Custom thermoplastic|Customized thermoplastic splint with circumferential contact proximal to the joint and volar contact distal to the joint. This is a similar design to the original Stack splint, except that it is custom molded.
45359396|NCT00868764|Drug|granisetron|3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days
45359397|NCT00518986|Drug|armodafinil|200 mg/day
46048284|NCT00681616|Device|Compartment Monitoring System (CMS)|The CMS consists of an Introducer, Pressure Measurement & Fluid Collection (PMFC) catheter, a Fluid Collection (FC) catheter and Compartment Pressure Monitor. The PMFC catheter removes fluid and monitors pressure via a solid-state fiber optic transducer at the tip of the catheter. The FC catheter only removes fluid and does not have a pressure transducer at the tip. The CMS Monitor senses, displays and records compartment pressure as measured by up to two PMFC catheters. In addition, the CMS Monitor measures subject blood pressure using a provided cuff for calculating the perfusion pressure of the muscle compartment.
46048285|NCT00681616|Device|Compartment Monitoring System with Active Fluid Removal|Compartment Monitoring System with Active Fluid Removal
45359398|NCT00518986|Drug|placebo|placebo
45359399|NCT00870324|Device|OptiSense Lead|"The OptiSense™ Model 1699 lead is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in the right atrium. The tip-to-ring spacing in the OptiSense lead is 1.1mm and narrow-spaced compared to the Tendril lead."
45359400|NCT00870324|Device|Tendril Lead|"The Tendril® is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in either the atrium or the ventricle. The tip-to-ring spacing in the Tendril is wide spaced compared to the OptiSense lead."
46048286|NCT00681616|Device|Compartment Monitoring System without fluid removal|Compartment Monitoring System without fluid removal
45359401|NCT04089683|Other|Swab stick|Swab sticks collected from Web Spaces, Scrub, Anterior Nares
45359402|NCT00864942|Drug|bendamustine and lenalidomide|Lenalidomide is given daily orally for one week followed by bendamustine HCL 90 mg/m2 IV over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
45359403|NCT00864942|Drug|BL-NHL|Bendamustine HCL 90 mg/m2 given intravenously over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
45359404|NCT00864942|Drug|BLR-CLL|Lenalidomide is given orally for 7 days followed by rituximab 375 mg/m2 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
45687875|NCT04508647|Drug|Umbralisib|Umbralisib will be administered orally once daily within 30 minutes of starting a meal.
45359405|NCT00864942|Drug|BLR-NHL|Rituximab 375 mg/m2 is given on day 1 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
45359406|NCT00870402|Drug|Spironolactone|25 mg per day for 9 months
45359407|NCT00870402|Drug|Placebo|Placebo 1 tablet per day for nine months
45359408|NCT00742391|Drug|PEP005 (ingenol mebutate) Gel|two day treatment
45359409|NCT00742391|Drug|Vehicle gel|two day treatment
45479603|NCT03722563|Procedure|total laparoscopic hysterectomy with sacrocolpopexy|Surgical correction of anterior and/or apical pelvic organ prolapse by laparoscopy
45479604|NCT03722563|Procedure|total laparoscopic hysterectomy with lateral suspension|Surgical correction of anterior and/or apical pelvic organ prolapse by laparoscopy
45479605|NCT03636360|Device|Light|15 hours of light exposure
45687876|NCT04508478|Behavioral|Aerobic training|Aerobic training
46048287|NCT00681694|Radiation|brachytherapy|An experimental arm using MRI imaging and excluding the transition zone from the target volume
46048288|NCT00681694|Radiation|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
45687877|NCT04508478|Behavioral|Resistance training|Resistance training
45479606|NCT03795389|Drug|DM199|Single SC dose
46048289|NCT00681694|Radiation|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
45479607|NCT03719443|Biological|VIS649|Single IV dose of study product on Day 1 of study
46048290|NCT04145596|Drug|HSK3486|HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
46048291|NCT01137578|Procedure|Ultrasound|Ultrasounds to be performed on children with central venous catheters
46048292|NCT01137578|Drug|Magnetic Resonance Imaging with Contrast|Contrast-enhanced Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
45359410|NCT05227560|Other|Complementary Therapies|The emotional freedom technique was applied to the experimental group.
45359411|NCT02596139|Other|No Interventions|
45359412|NCT03841266|Diagnostic Test|recurrence risk evaluation|Recurrence score were obtained by 21-gene detection kits from different biological companies. The expression of ER, PR, and Her-2 were also detected by IHC.
45359413|NCT00742235|Drug|ergocalciferol|Ergocalciferol 50,000 IU given every other day for 5 total doses
45479608|NCT03719443|Biological|Placebo|Singe IV dose of placebo administered via IV on Day 1 of study
45479609|NCT03636204|Biological|AL001|Active dose of AL001
45687878|NCT04508478|Behavioral|Control physical exercise|Control physical exercise
46048293|NCT01137578|Procedure|Magnetic Resonance Imaging without Contrast|Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
46048294|NCT00679666|Drug|Riboflavin|01% riboflavin drops for 30 minutes q 3 minutes before and during the procedure with exposure to UVA light for the second 30 minutes
46048295|NCT00679666|Drug|Placebo|Drops are given q 3 minutes before (30 minutes) and during the procedure (30 minutes) but without the use of UVA light. No activation of cross linking occurs.
46048296|NCT00679744|Drug|Pyrimethamine|Pyrimethamine will be given PO once daily for 8 consecutive weeks.
45479610|NCT03636204|Other|Placebo|Saline solution administered as a single infusion as palcebo.
45479611|NCT03120442|Drug|Propofol|target-controlled infusion starting for Cet 0.1 mcg/ml to achieve MOAA/S 3-4
45479612|NCT03120442|Drug|Dexmedetomidine|Incremental titration of dexmedetomidine starting from 0.1 mcg/kg/hr to achieve MOAA/S 3-4
45479613|NCT03120442|Drug|Fentanyl|0.25 mcg fo Fentanyl for anxiolysis
45479614|NCT03722485|Device|Negative Pressure Therapy w/ instillation and dwell (NPWTi-d)|Negative Pressure Therapy at -125mmHg for 3.5 hours followed by 10 minute dwell of saline solution for 6-9 days.
45479615|NCT03722485|Biological|Collagenase Ointment|Collagenase ointment applied daily to the wound and covered with secondary dressing for 6-9 days.
45479616|NCT00852696|Drug|Solifenacin|Solifenacin is used to treat overactive bladder. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Take orally once daily for 9 weeks.
45479617|NCT00852696|Other|Placebo|Take orally once daily for 9 weeks.
45752076|NCT00558285|Drug|placebo|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
45752077|NCT01792921|Behavioral|COG - FUN|
45479618|NCT02496832|Drug|18F-Fluoroazomycin arabinoside|
45359414|NCT00868920|Other|patient control of pump|Patient controls sedation pump during colonoscopy.
45479619|NCT04640246|Biological|TBX-3400|Autologous transfusion
45479620|NCT03324490|Procedure|Thoracic Spinal Anesthesia|"Spinal anesthesia will be performed for patients of the TSA group at the T7-T8 intervertebral space, using a 27 G pencil point needle with an introducer (Braun Melsungen, Melsungen, Germany).~When correct placement is confirmed by the free flow of clear CSF, 1.5 ml of hyperbaric Bupivacaine 0.5% (7.5 mg) in addition to 0.5 ml Fentanyl (25 μg) & 5 μg dexmedetomidine will be injected."
46048297|NCT00681772|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1 hours before sexual intercourse
45359415|NCT00868920|Other|anesthesiologist controlled sedation|Anesthesiologist will control the sedation pump during colonoscopy.
45359416|NCT00742079|Drug|D-cycloserine|Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session
45359417|NCT00742079|Behavioral|Cognitive Behavioral Therapy|One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations
45847670|NCT02835846|Drug|Estrogen Cream|Participants are provided a vaginal estrogen cream (i.e., Premarin Cream® 0.625 mg conjugated estrogen/gram) and instructed to use 0.5 grams with an applicator twice weekly for 12 weeks.
46048298|NCT00946920|Drug|Degarelix|The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. A starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations).
45359418|NCT04730362|Device|guedel airway|"Anesthesia will be conducted by induction with 1-2~• Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%. The goal is to maintain the patient spontaneous ventilation throughout the procedure. Monitoring of the patients is done by MRI compatible pulse oximetry for heart rate and oxygen saturation which is connected to MRI control room."
45359419|NCT04730362|Device|supraglottic airway|supraglottic airway
45359420|NCT04730362|Drug|propofol bolus and then anesthesia sevoflurane|Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%
46048299|NCT00946920|Drug|Goserelin acetate|The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. An initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants).
46048300|NCT04145830|Device|Ultrasound Cyclo Plasty (UCP)|Cyclocoagulation using High Intensity Focused Ultrasound
46048301|NCT00946530|Device|Bright light|Participants uses bright light
45359421|NCT00876096|Other|Catch of blood then PCR|To optimize the technology of extraction of nucleic acids of origin fongique by collaborating with the laboratories of Parasitologie and Mycology of the TEACHING HOSPITAL of Rennes and Toulouse.
45359422|NCT00662792|Drug|Tiotropium (Tio18GEL)|18 µg Tiotropium (Tio18GEL) inhalation powder
45359423|NCT00662792|Drug|Salmeterol MDPI (Salm50DPI)|50 µg Salmeterol MDPI (Salm50DPI) twice daily (BID)
45847671|NCT02837328|Drug|Oral Magnesium Supplement|400 mg Magnesium Citrate 1x daily for 12 weeks
45847672|NCT02837328|Drug|Placebo|Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
45847673|NCT02839902|Drug|TAK-085|Omega-3-acid ethyl esters (TAK-085) capsule
45847674|NCT02839902|Other|Not treated with omega-3-acid ethyl esters|Not treated with omega-3-acid ethyl esters
46048302|NCT00946530|Device|Control|Participants uses dim light
46048303|NCT00946296|Drug|Potassium Iodide|8 drops of Potassium Iodide in a glass of water taken daily for 7 days prior to thyroidectomy. This is the current standard of care.
45359424|NCT00662792|Drug|Tiotropium (T18GEL) + Salmeterol MDPI (S_DPI)|18 µg Tiotropium (T18GEL) inhalation powder plus 50 µg Salmeterol MDPI (S_DPI) twice daily (BID)
45359425|NCT00662792|Drug|Tiotropium/Salmeterol (T+S_PE)|Fixed-dose combination of 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE) inhalation powder
45359426|NCT01009450|Procedure|LC was done using traditional method|LC was done using traditional method by dissection of calot's triangle and clipping of both cystic duct and artery by metal clips. Then dissection of gall bladder from its bed by hook using electrocautery technique. Finally we insert abdominal drain in Morrison pouch.
45359427|NCT01009450|Procedure|LC was done using harmonic ACE|LC was done using harmonic ACE (Ethicon Endo-Surgery) by dissection of calot's and then occlusion of both cystic duct and artery using harmonic ACE. For closure of and division of cystic pedicle we set the instrument at a power 2 i.e. more coagulation. And when dissecting the gall bladder from the bed we set it to the level 5 i.e. more cutting power. And control of any bleeding from the bed using the active blade of harmonic ACE. Finally we insert abdominal drain in Morrison pouch.
45359428|NCT00870480|Drug|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fasting conditions
45359429|NCT00870480|Drug|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fasting conditions
45359430|NCT01009528|Device|Electronic feedback system on diabetes care|An electronic feedback system was introduced in randomized primary care clinics providing an overview of quality of care. The intervention ran for 15 months.
45359431|NCT00742001|Biological|Mirasol System for Whole Blood.|Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects
45359432|NCT00870558|Drug|ethiodized oil|Given as an intra-arterial infusion
45359433|NCT00870558|Radiation|iodine I 131 ethiodized oil|Given as an intra-arterial infusion
45359434|NCT00869076|Other|Pharmacist Management|Pharmacist Managed the patient's diabetes in collaboration with their primary care physician
45359435|NCT00869076|Other|Usual care|Patient was managed by their primary care physician as usual
45359436|NCT01565278|Drug|Soybean oil (Standard treatment)|1. Standard treatment: Soybean oil based emulsion: 0.25 g/kg/TPN day
45359437|NCT01565278|Drug|Soybean oil + Fish oil|Intralipid+Omegaven: 0.25 g/kg/TPN Intralipid day+0.4 g/kg/TPN Omegaven day for 6 months
45479621|NCT03324490|Procedure|Thoracic Epidural Anesthesia|"Epidural anesthesia will be performed for patients of the TEA group at the T7-T8 intervertebral space, using the Prefix Custom Epidural Anesthesia Tray with an 18 G Tuohy epidural needle & a 20 G epidural catheter.~Patients will initially receive 5-10 ml of a mixed preparation of 0.5% isobaric Bupivacaine with 2 μg Fentanyl per ml volume as a bolus dose via the epidural catheter, this will be followed by a continuous infusion of 5-10 ml/hr started 1 hour after the bolus dose & continued throughout the procedure."
45479622|NCT03324490|Drug|Bupivacaine 0.5% (hyperbaric)|Neuro-axially injected
45479623|NCT03324490|Drug|Bupivacaine 0.5% (isobaric)|Neuro-axially injected
45479624|NCT03324490|Drug|Fentanyl|Neuro-axially injected
45479625|NCT03324490|Drug|Dexmedetomidine|Neuro-axially injected
45479626|NCT04286412|Biological|Nonacog alfa|Nonacog alfa is indicated in India for the treatment and prophylaxis of bleeding in patients with hemophilia B (congenital factor IX deficiency).
45479627|NCT03798899|Drug|Methoxyflurane|PENTHROX 3mL inhalation vapour, liquid
45479628|NCT03798899|Drug|Normal Saline|Placebo
45479629|NCT03274661|Drug|Pembrolizumab 200 mg Q3W|Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
45479630|NCT02496598|Procedure|In Vitro Follicle Activation (IVA)|Laparoscopic removal of ovarian tissue, followed by in vitro activation of dormant ovarian follicles and autografting back to the patient for follicle growth and egg retrieval.
45479631|NCT02496598|Drug|Follicle Activation|Ovarian cortical pieces will be treated in vitro with a PTEN activator (bpV(hopic)) and a PI3K inhibitor (740YP) in vitro to activate primordial ovarian follicles, prior to autografting.
45479632|NCT03636126|Device|VR + TACS|TACS- A regulated class of transcranial alternating current stimulation (tACS), called Cranial Electrotherapy Stimulation (CES) by Fisher Wallace Laboratories (FWL) is FDA-Cleared to treat depression, anxiety, and insomnia (Proof of FDA clearance and 510k provided in the appendix). FWL tACS delivers weak non-invasive electrical stimulation (1-4 milliamps at 15, 500, and 15,000 Hz) to the frontal/temporal brain regions by electrodes placed above the temples. Land's End Virtual Reality Game Meta-analyses show Virtual Reality (VR) is an effective non-pharmacological method that reduces obstacles to human performance such as pain, insomnia, anxiety, sleep deprivation, and a variety of other stress responses.
46048304|NCT02853786|Behavioral|LENA and advice|Language recording with the LENA device, with the LENA results, we will advise the parents how to improve the language environment to help their children with CIs for their language development
46048305|NCT02853786|Other|LENA without advice|Language recording with the LENA device. Regular speech therapy follow blindly the results of LENA
46048306|NCT00679900|Drug|eplivanserin (SR46349)|5 mg/day
46048307|NCT00679900|Drug|lormetazepam|1 mg/day
46048308|NCT00945906|Biological|FXIII Concentrate (Human) (FXIII)|"Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who have not received at least 3 doses of FXIII Concentrate in a previous study of this product (i.e., NCT00640289, NCT00885742, or NCT00883090) will initially receive a dose of 40 U/kg by intravenous (IV) infusion."
46048309|NCT00681928|Drug|anastrozole|As determined by the subject's physician
46048310|NCT00681928|Drug|letrozole|As determined by the subject's physician
45359438|NCT00616902|Drug|paricalcitol injection 4 mcg/mL|Paricalcitol Injection 4 mcg/mL intravenously three times a week during dialysis
45359439|NCT00616902|Drug|Placebo Injection 4 mcg/mL|Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
45359440|NCT00869154|Behavioral|primary care follow up|Multidisciplinary examination, good advice from rehabilitation specialists and follow up by the family doctor.
45359441|NCT00869154|Behavioral|Multidisciplinary follow up|Multidisciplinary examination and follow up by rehabilitation specialists, a multidisciplinary team following an individual rehabilitation programs.
45359442|NCT00876174|Procedure|Blood sampling of peripheral blood mononuclear cells|Group 1, (Patients): PMBC (20 ml blood) to be drawn at baseline, weeks 4 and 12 during antiviral therapy and 24 weeks following the end of antiviral therapy
45359443|NCT00876174|Procedure|Blood draw, 20ml peripheral blood mononuclear cells|One time blood draw of 20 ml
45359444|NCT00801944|Drug|Solifenacin succinate|oral
45359445|NCT00801944|Drug|Placebo|oral
45359446|NCT00870636|Drug|Bevacizumab (Avastin)|Dosage of 0.75mg/0.03ml intravitreal injectable, one time only.
45359447|NCT00741611|Device|HD Mesh Ablation System|Ablation using the HD Mesh Ablation System
45359448|NCT00741611|Drug|Anti-arrhythmic drugs|5 anti-arrhythmic drugs administered at the labeled dosage for atrial fibrillation
45479633|NCT01560455|Device|single stent|single stent
45479634|NCT01560455|Device|two stent|culotte
45479635|NCT02491372|Behavioral|Acceptance and Commitment Therapy|ACT is a psychological intervention that aims to promote adaptive coping and encourages participants to move their focus away from trying to control emotions to accepting and adapting to them. It is relevant to all patients, not just those who are currently distressed.
45479636|NCT05436132|Behavioral|VR and AR oral healthcare curriculum training|HCWs in the VR/AR group received 2.5 hours VR and AR oral healthcare curriculum training. VR oral care training system was training the standard oral healthcare procedure for different physical and oral conditions in elderly people.AR oral care training system was training for the manual Bass brushing technique.
45479637|NCT05436132|Behavioral|traditional teaching methods oral healthcare curriculum|HCWs in the control group received 2.5 hours traditional teaching methods of oral healthcare curriculum training.
45479638|NCT03324412|Drug|Treatment of MTX|Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg， 3 times a day, oral, for 24 weeks.
45844636|NCT04660968|Behavioral|Dyadic nutrition counselling intervention|The couples-based education nutrition intervention will provide extensive information on healthy eating. However, it will not include any behavioural change principles. Topics will be based on Dietitians of Canada's Practice-based Evidence in Nutrition (PEN) discussions in the database that focus on healthy eating for older adults. The topics covered will include increasing fruits and vegetables, hidden (empty) calories, how to read food labels, portion control, reducing salt and saturated fat, plant-based proteins, and eating for healthy bones. Participants in this group will also be told to increase their levels of physical activity to 150 minutes of moderate to vigorous physical activity per week, as per the Canadian Guidelines. Participants will have access to web-based exercise training sessions. However, physical activity will not be discussed explicitly during the intervention. Intervention sessions will be delivered online.
46048311|NCT00681928|Other|questionnaire administration|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
46048312|NCT00681928|Procedure|cognitive assessment|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
46048313|NCT00681928|Procedure|psychosocial assessment and care|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
46048314|NCT04269252|Other|CHI-907|CHI-907 is a high CBD extract.
46048315|NCT04269252|Other|CHI-804|CHI-804 is the placebo formulation.
46048316|NCT00594646|Drug|TRUVADA + Raltegravir|TRUVADA (tenofovir disoproxil fumarate (DF) 300mg + emtricitabine 200mg) + RALTEGRAVIR 400mg
46048317|NCT00680134|Drug|AN2690|AN2690 1% Solution, once daily for 180 days
46048318|NCT00680134|Drug|AN2690|AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days
46048319|NCT02855658|Drug|SS-1|The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12 weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12 weeks SS-1 treatment. SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day.
45359449|NCT00876252|Biological|IC43|
45359450|NCT00876252|Drug|Placebo|NaCl
45359451|NCT00870714|Drug|Docetaxel|Docetaxel 55mg/m2 to be given IV as a one-hour infusion to be repeated every 21 days for four treatment cycles.
45359452|NCT00870714|Drug|Ketoconazole|Ketoconazole 400mg P.O. BID daily to start on day 2 following the first docetaxel treatment. In patients who experience no grade 2 or higher toxicity, the ketoconazole dose will be increased to 400mg TID on day 2 following cycle #2 of docetaxel. This will be continued daily until completion of study treatment.
45359453|NCT00796484|Drug|XL888|Administered orally
45359454|NCT02596217|Drug|ABBV-066|SC injection
45359455|NCT02596217|Drug|ABBV-066|IV infusion
45359456|NCT02596217|Drug|Placebo|SC injection (stage 1)
45359457|NCT02596217|Drug|Placebo|IV infusion (stage 2)
45359458|NCT00876330|Other|Clinical Decision Support for Hypertension|Clinical decision support alerts for antihypertensive therapy
45359459|NCT00876330|Other|Automated Telephone Outreach for Antihypertensive Therapy|Automated Telephone Outreach to patients for antihypertensive medication therapy.
45359460|NCT00876330|Other|Clinical Decision Support for Lipid-lowering Therapy|Clinical Decision Support alerts for Lipid-lowering medication therapy.
45359461|NCT00876330|Other|Automated Telephone Outreach for Lipid-lowering Therapy|Automated telephone outreach to patients for Lipid-lowering medication therapy.
45359462|NCT04088669|Other|Home-based Pulmonary Rehabilitation|Patients will admit a home-based pulmonary rehabilitation program for 8 weeks, with a minimum of 3 days per week and one session of this is under the supervision of a physiotherapist. The pulmonary rehabilitation program includes stretching exercises, strengthening exercises for upper and lower extremities, breathing exercises and aerobic exercises (walking). All of these exercises will be equipped with equipment that the patients can easily provide at home. In addition, patients will be provided with a pedometer and exercise diary.
45359463|NCT04088669|Other|Education and Recommendations|The control group will be given a training session on the course of the disease and the correct inhaler use and will be given booklets on breathing exercises, aerobic exercises (walking) and physical activity recommendations for a minimum of 2-3 days per week for 8 weeks. Patients will be given a pedometer and exercise diary.
45359464|NCT02598011|Biological|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
45359465|NCT02598011|Drug|Toca FC|"Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side"
45359466|NCT00869310|Drug|aprepitant + dexamethasone|Dexamethasone 8 mg orally: 24 hours after chemotherapy (day 2) and then at 8 am on days 3-4 plus Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3.
45359467|NCT00869310|Drug|metoclopramide + dexamethasone|dexamethasone 8 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on days 3-4 plus Metoclopramide 20 mg orally 4 times a day: 24 hours after chemotherapy and then at 4 pm, 7 pm, 10 pm on day 2 then at 7 am, 12 am, 5 pm, 10 pm on days 3-4.
45359468|NCT00662558|Drug|celecoxib|200 mg capsules BID for 6 weeks
46048320|NCT02855658|Drug|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
45359469|NCT00662558|Drug|tramadol HCL|50 mg capsules QID for 6 weeks
45359470|NCT00869388|Biological|rBBX-01|
45359471|NCT00870792|Behavioral|Adherence report|During the intervention phase, the data collected at the study visit were summarized in a 3-page report that was given to the provider before each intervention visit. The report included data on self-reported adherence, MEMS adherence, reminder use, beliefs about ART, reasons for missed doses, alcohol and drug use, and depression.
45479639|NCT03324412|Drug|Treatment of MTX and TwHF|Methotrexate : 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）：20mg， 3 times a day, oral, for 24 weeks.
45479640|NCT03769116|Genetic|SRP-9001|Single IV infusion of SRP-9001
45479641|NCT03769116|Genetic|Placebo|Single IV infusion of matching placebo
45479642|NCT03798821|Dietary Supplement|Lactobacillus rhamnosus, Lactobacillus casei y Bifidobacterium longum (100MG)|six weeks of consumption
45479643|NCT03798821|Dietary Supplement|Lactobacillus rhamnosus, Lactobacillus casei y Bifidobacterium longum (300MG)|six weeks of consumption
45479644|NCT03798821|Dietary Supplement|maltodextrin and sucrose (PLACEBO)|six weeks of consumption
45479645|NCT03324334|Diagnostic Test|Thyroid antibodies|Thyroid antibodies: Antithyroperoxidase(Anti-TPO), Anti-thyroglobulin (anti-TG) to detect graves disease in study and control groups
45479646|NCT03324334|Diagnostic Test|Thyroid sonography|Thyroid sonography to detect anatomical changes in thyroid
46048321|NCT00680212|Dietary Supplement|dietary carotenoids|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene 0.5 mg oil capsule
46048322|NCT00680212|Dietary Supplement|spinach, rice, and synthetic beta-carotene|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene, 0.5 mg oil dose
45479647|NCT03798665|Drug|Pegfilgrastim（PEG-rhG-CSF）|From the first chemotherapy cycle using PEG-rhG-CSF (which can be any chemotherapy cycle of the patient), record the use of PEG-rhG-CSF in this cycle and each subsequent chemotherapy cycle, including dosage, administration time and dosing frequency
46048323|NCT02855424|Other|the low-intensity exercise group|Totally 20-time training, frequency 2-6 time/week, total 20 times.
45359472|NCT00869466|Behavioral|behavioral dietary intervention|
45359473|NCT00869466|Behavioral|exercise intervention|
45359474|NCT00869466|Other|counseling intervention|
45359475|NCT00869466|Other|educational intervention|
45359476|NCT00869466|Other|laboratory biomarker analysis|
45359477|NCT00869466|Other|questionnaire administration|
45359478|NCT00869466|Procedure|quality-of-life assessment|
45359479|NCT00869466|Procedure|support group therapy|
45359480|NCT05226546|Drug|Platelet rich plasma (PRP)|PRP injections were performed in each olfactory cleft by nasal endoscopy and under local anesthesia, a sniffing stick test was performed before the injection and one month after
45359481|NCT05226546|Other|olfactory training|"The investigators compare the result of the PRP group to a control group how underwent simple olfactive training for one month.~The control group matched for age, gender and olfactory score at baseline. The patients had a sniffing stick test at the beginning and also after one month of olfactory training."
45359482|NCT00802022|Device|spinal cord stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (50% of more pain reduction)a definite spinal cord system will be implanted.
45359483|NCT00869700|Drug|Artemether/Lumefantrine|"80mg artemether/480mg lumefantrine~Trade name: Coartem~Indication: for management of non-severe malaria"
45479648|NCT05434416|Other|mobile app|mobile app self-guided psychological interventions
45844637|NCT04633200|Other|DOT mobile app|DOT is a mobile phone app that has daily pill reminders and supportive texts, as well as various features designed to support PrEP medication adherence.
45359484|NCT00788996|Behavioral|Brief intervention based in clinical practice guide|Minimal counseling at smoking parents with babies minor 1 year-old
45359485|NCT00869856|Drug|HX575 solution for s.c. administration|Containing different strengths of epoetin alfa (1 to 10 KIU), s.c. injection, 1x per week (qw) or 1x every two weeks (q2w), injection into abdomen or upper thigh
45359486|NCT00802256|Procedure|pulpotomy|removal of caries and cronal pulp tissue and then restoring of tooth
45359487|NCT00876486|Drug|Genexol-PM®|Genexol-PM® 260mg/m2, intravenous infusion over 3 hours, every 3 weeks
45359488|NCT00876486|Drug|Genexol®|Genexol® 175mg/m2, intravenous infusion over 3 hours, every 3 weeks
45479649|NCT03792815|Drug|Busulfan|busulfan 3.2mg/kg iv on day -8, -7, and -6,
45687879|NCT04501718|Drug|Apatinib Combined With Temozolomide and Etoposide Capsules|"Apatinib mesylate tablets: Oral, 250mg, qd. Take the medicine with warm water half an hour after a meal (the daily medicine should be taken at the same time as possible).~28 days is a cycle, and the medication is administered until the disease progresses (PD), intolerable toxicity occurs or the patient withdraws informed consent. The longest period does not exceed 12 cycles. The treatment after 12 cycles is determined by the investigator."
45844638|NCT04594902|Behavioral|Infant Behavior Program (IBP)|Infant Behavior Program (IBP) is a home-based adaptation of the Child-Directed Interaction (CDI) phase of Parent-Child Interaction Therapy (PCIT), an evidence-based intervention for early externalizing problems. Consistent with recommendations we maintained core features of CDI and addressed the unique developmental needs of infants. All IBP sessions will completed remotely.
45844639|NCT04594902|Other|Enhanced Pediatric Primary Care (EPPC)|Families in EPPC will receive six one-hour home visits where they will receive information about normative developmental and health expectations for their infant. Specifically, therapists will provide education on six topics: (1) cognitive and emotional development; (2) language and social development; (3) safety; (4) feeding and nutrition; (5) sleep; and (6) fitness and activity. All EPPC sessions will completed remotely.
45359489|NCT00802334|Drug|generic lopinavir/ritonavir|"Screening visit~• Clinical and safety laboratory assessment. Viral load for patients on a PI-based regimen, if a VL results ≤ 3 months is not available~Baseline visit~• (Within 30 days after screening) Baseline clinical and laboratory assessment, patients who were on a Kaletra SGC formulation before baseline will undergo TDM. Start generic lopinavir/ritonavir tablets 200/50 in a 400/100mg bid dosage. Backbone will be chosen on the discretion of the study physician~Week 4~Steady state TDM lopinavir and ritonavir, at 10-12 hr after the last intake (Cmin)~Clinical, safety and laboratory assessment~Week 12: Clinical, safety and efficacy laboratory assessment Week 24: Clinical, safety and efficacy laboratory assessment Week 48: Clinical, safety and efficacy laboratory assessment"
45359490|NCT00876564|Other|Trauma patients|
45359491|NCT00796640|Drug|ER Paliperidone|
45359492|NCT00876642|Drug|Aloe vera gel|The aloe vera gel which was commercially available, contained water, aloe vera, D-panthenol, triethanolamine, carbomer 934P, hyaluronic acid, potassium sorbate, diazolidinyl urea, methylparaben, and propylparaben.
45359493|NCT00796796|Drug|Temsirolimus|
45359494|NCT00796796|Radiation|Radiation therapy|
45359495|NCT03794076|Drug|Cromoglycate|Cromoglycate will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray
45359496|NCT03794076|Drug|Placebo|Normal saline nasal spray will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray)
45844640|NCT04441086|Behavioral|eMotion|Content is delivered within the context of emotion provoking situations common in those recovering from a first MI and in maintaining MVPA. The new on-demand access to asynchronous content sessions provides didactic presentation of video and written material based on weekly needs assessments. Weekly scheduled synchronous video chat sessions, led by a nurse interventionist, will provide further individualization and application of content materials.
45844641|NCT04441086|Behavioral|Healthy Living Active Control|The attention control group will receive their usual cardiac rehabilitation and a comparable dose matched (to that of the eMotion intervention) of healthy living web content and video chat with a nurse.
45479650|NCT03792815|Drug|Melphalan|melphalan 50mg/m2/day i.v. on day -3 and -2
45479651|NCT03792815|Drug|Etoposide|etoposide 400 mg/m2 i.v. on day -5 and -4
45359497|NCT00802490|Device|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played twice a week, 1 hour per session for a period of ten weeks.
45359498|NCT00802490|Device|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played once for 1 hour.
45359499|NCT00870948|Drug|ABT-874|See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively.
45359500|NCT00739973|Drug|Placebo|
45359501|NCT00739973|Drug|Aliskiren 150 mg tablet|
45359502|NCT00739973|Drug|Aliskiren 300 mg tablet|
45687880|NCT04501705|Drug|Apatinib Mesylate|"Apatinib mesylate tablets: Orally, 500 mg, once a day, with warm water for half an hour after a meal (the time of taking the medicine every day should be the same as possible).~Continue to use 28 days as a cycle, medication until disease progression (PD), intolerable toxicity occurs or the patient withdraws informed consent. However, the longest period does not exceed 24 cycles, and the treatment after 24 cycles is determined by the investigator."
45687881|NCT04498767|Radiation|Stereotactic body radiotherapy|Each lesion may be treated with 1, 3, or 5 SBRT fractions of 16-24 Gy, 24-33 Gy or 25-40 Gy, respectively, depending on the local practice and size & location of oligometastases. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments must be completed within 2 weeks (10 working days) in order to avoid delays in starting systemic therapy.
45844642|NCT04438902|Drug|osimertinib mesylate tablets and anlotinib hydrochloride capsules|osimertinib mesylate tablets 80mg qd and anlotinib hydrochloride capsules 10mg qd day 1-14 of a 21-day cycle
45359503|NCT00739973|Drug|Amlodipine 5 mg capsule|
45479652|NCT03328858|Other|Ketogenic Diet|Once tolerance to the diet has been assessed, participants will be placed in the ketogenic diet, followed-up every three months until the one year completion.
45844643|NCT04346394|Drug|Yohimbine HCl|Yohimbine hydrochloride will be used to manipulate the noradrenergic system during some of the assessments. By measuring the amounts of hormones the body produces before and after yohimbine hydrochloride administration, researchers can assess how well the noradrenergic system is functioning
45844644|NCT04329390|Drug|Anticoagulant drugs|Prescription of, or already on oral anticoagulant treatment.
45359504|NCT00739973|Drug|Amlodipine 10 mg capsule|
45359505|NCT00739973|Drug|Aliskiren/amlodipine 150/5 mg tablet|
45359506|NCT00739973|Drug|Aliskiren/amlodipine 150/10 mg tablet|
45359507|NCT00739973|Drug|Aliskiren/amlodipine 300/5 mg tablet|
45359508|NCT00739973|Drug|Aliskiren/amlodipine 300/10 mg tablet|
45359509|NCT00876720|Device|rTMS - Intervention 1|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 20Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
45359510|NCT00876720|Device|rTMS - Intervention 2|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
45359511|NCT00789230|Procedure|primary suture closure|primary suture closure of hernia
45359512|NCT00789230|Device|mesh enforced closure|mesh enforced closure of hernia
45359513|NCT00869934|Other|Cognitive-Behavior Therapy|Sleep restriction, stimulus control, cognitive therapy
45359514|NCT00869934|Other|Behavior Therapy|Sleep restriction and stimulus control
45359515|NCT00869934|Other|Cognitive Therapy|Cognitive restructuring therapy
45359516|NCT00802568|Biological|anti-thymocyte globulin|
45359517|NCT00802568|Drug|busulfan|
45359518|NCT00802568|Drug|fludarabine phosphate|
45359519|NCT00802568|Procedure|allogeneic bone marrow transplantation|
45359520|NCT00802568|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
45359521|NCT00870012|Drug|Lepicol probiotic & prebiotic formula|NAFLD patients treated with Lepicol probiotic and prebiotic formula for 24 weeks.
45479653|NCT04381364|Drug|Ciclesonide Inhalation Aerosol|Ciclesonide 320 µg twice daily for 14 days.
45687882|NCT04498767|Radiation|Palliative RT|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions. Patients in this arm should not receive stereotactic doses or radiotherapy boosts, unless there is a clearly known clinical benefit (e.g. stereotactic radiation to a new brain metastases when all disease is controlled on systemic therapy).
45479654|NCT01331382|Dietary Supplement|Trans- resveratrol|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
45687883|NCT04496453|Other|Childhood vaccination decision support tool|Participants receive childhood vaccination decision support tool
45359522|NCT00870012|Other|Simple lifestyle advice|NAFLD patients treated with lifestyle advice.
45359523|NCT00510874|Biological|Pumarix™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
45359524|NCT00510874|Biological|Pandemrix ™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
45359525|NCT00802724|Behavioral|Classification-directed treatment|People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
45359526|NCT00802724|Behavioral|Non-specific treatment|People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
45359527|NCT00871026|Procedure|orthodontic treatment with customized archwires|orthodontic treatment with customized archwires
45359528|NCT00871026|Procedure|orthodontic treatment with prefabricated archwires|orthodontic treatment with prefabricated archwires
45479655|NCT01331382|Other|Placebo (silica)|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
45687884|NCT04483791|Combination Product|DynamX Novolimus Eluting Coronary Bioadaptor System|up to two de novo native coronary artery lesions measuring between 2.25 and 3.5 mm in diameter and<=34 mm in length receiving the DynamX Novolimus Eluting Coronary Bioadaptor System
45844645|NCT04326036|Procedure|Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Use of Disposable Microcannula Closed System (Tulip Med, 2.2 mm) Harvest of Autologous Adipose Stroma and Stem/Stromal Cell Content
45844646|NCT04326036|Device|Centricyte 1000|Centricyte 1000 (Healeon Medical) Digestive (sterile Roche Liberase TM) Isolation/Concentration Protocol, Rinsing/Neutralization, and Pelletize the cSVF For Deployment Via Sterile Saline IV fluid Standard Protocol
45479656|NCT03328780|Device|Hemocue and Rad-67 measurement|Measurement of the hemoglobin level
45687885|NCT04482647|Other|Media Intervention|View instructional video
45359529|NCT00802802|Drug|Efavirenz (EFV)|Participants will be administered oral EFV at a dose ranging from 50 mg to 800 mg once daily, based on weight and CYP 2B6 genotype. EFV capsules will be opened into a small amount of a compatible food or liquid vehicle; the smallest amount of food or liquid that will enable the child to swallow the capsule contents should be used (i.e., EFV should not be taken with a meal).
45359530|NCT00802802|Drug|Rifampin-containing anti-TB therapy|Treatment with rifampin-containing anti-TB treatment regimen. Treatment will last at least 24 weeks and up to 36 weeks.
45359531|NCT00870168|Drug|chemotherapy|
45359532|NCT00870168|Genetic|gene expression analysis|
45687886|NCT04482647|Procedure|Meditation Therapy|Perform meditation
45687887|NCT04482647|Other|Quality-of-Life Assessment|Ancillary studies
45687888|NCT04482647|Other|Questionnaire Administration|Ancillary studies
45687889|NCT04482647|Procedure|Yoga|Perform breathing techniques
45687890|NCT04463394|Drug|Vasopressin|Vasopressin administered intravenously
45359533|NCT00870168|Other|laboratory biomarker analysis|
45479657|NCT03794765|Drug|Ceftriaxone|Injection ceftriaxone 1 gm will be prepared by reconstitution of the crystallised powder form in 100 ml of normal saline. This preparation will then be infused slowly over thirty minutes, after intradermal testing for hypersensitivity. Inj ceftriaxone 1gm IV will be given twelve hourly.
45844647|NCT04326036|Procedure|IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Sterile Normal Saline Suspension cSVF in 250cc for Intravenous Delivery Including Use of 150 micron in-line filtration
45844648|NCT04326036|Drug|Liberase Enzyme (Roche)|Sterile Collagenase Blend to separate cSVF from the AD-SVF
46048324|NCT02855424|Other|the moderate-intensity exercise group|Totally 20-time training, frequency 2-6 time/week,total 20 times.
46048325|NCT00682006|Drug|4% Chlorhexidine|4% Chlorhexidine was provided to be applied in this arm to Mothers through TBAs.
46048326|NCT00682006|Other|Hand washing Soap|Hand washing soap was provided to Mothers through TBAs.
46048327|NCT00682006|Drug|4% Chlorhexidine|4% Chlorhexidine was provided to be applied by Mothers through TBAs.
46048328|NCT02855346|Combination Product|200 mg of DPV + 320 mg LNG|DPV VR, containing 200 mg DPV
46048329|NCT02855346|Combination Product|200 mg of DPV|DPV-LNG VR, containing 200 mg of DPV + 320 mg LNG
46048330|NCT00682084|Procedure|Surgery|Surgical removal of either a pituitary or ectopic ACTH producing tumor or an adrenal tumor
46048331|NCT02855190|Other|68Ga-citrate and 18F-FDG PET scans|68Ga-citrate and 18F-FDG PET/CT or PET/MR scans before operations
46048332|NCT00680290|Procedure|Exercise|Exercise x 8 weeks
45359534|NCT00870168|Procedure|breast biopsy|
45359535|NCT05174572|Procedure|IMR|Patients undergoing coronary sinus reducer implantation (Reducer) undergo evaluation of the index of microcirculatory resistance (IMR) at the time of implantation, and at 4 months follow-up.
45359536|NCT00802958|Drug|Halobetasol Propionate 0.05% Ointment-Reference Product|Small amount applied and evaluated over the course of a day
45359537|NCT00802958|Drug|Halobetasol Propionate 0.05% Ointment-Test Product|Small amount applied and evaluated over the course of a day
45359538|NCT00876876|Drug|Lixivaptan|Capsules containing 25, or 50 mg doses of oral lixivaptan to be administered BID or QD Lixivaptan will be administered for 12 weeks in the Open-Label Period which will be followed by a 4 week Randomized, Placebo-Controlled period.
45359539|NCT01012804|Genetic|western blotting|
45359540|NCT01012804|Other|immunohistochemistry staining method|
45359541|NCT01012804|Other|laboratory biomarker analysis|
45359542|NCT00796874|Other|active surveillance|Correlative Study
45359543|NCT00796874|Other|imaging biomarker analysis|Correlative Study
45359544|NCT00796874|Procedure|biopsy|Tissue Removal
45359545|NCT00796874|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Radiolical Medical Imaging
45479658|NCT03794765|Drug|Metronidazole|Injection metronidazole 500 mg is available from pharmacies in solutions of 100 ml. It will be infused slowly over thirty minutes, three times per day
45479659|NCT03794765|Other|Placebo infusion|Similar placebo infusion
46048333|NCT00682162|Device|Acupuncture|The treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). The acupuncture treatment was semi-standardised. It consisted of a basic pool of 6 body acupuncture points. Five additional acupuncture body points together with auricular points formed an individual pool. After needle insertion, the needle was manipulated until the subject obtained the de-Qi response (a deep aching or full feeling at the needle, [22]). After obtaining the de-Qi response, there was no further manipulation of the needle. Each session lasted 20 minutes.
45844649|NCT04326036|Drug|Sterile Normal Saline for Intravenous Use|Sterile Normal Saline IV solution to provide suspension of cSVF in 250 cc via standard IV line, including sterile 150 micron in-line standard filter
45844650|NCT04309188|Device|Senaptec Strobe Glasses|The glasses use liquid crystal technology that causes a flicker from clear to opaque to enhance vision.
45844651|NCT04309188|Other|Standard softball drills|Control group, which will perform normal hitting and fielding drills without stroboscopic training
45844652|NCT04303572|Drug|Eloctate ITI|This is a factor VIII-Fc infusion protein.
45844653|NCT04303572|Drug|Emicizumab|This is a bispecific monoclonal antibody FVIII mimic.
45844654|NCT04177602|Combination Product|Trifluridine/tipiracil chemoradiation|Trifluridine/tipiracil based chemoradiation
45844655|NCT04177602|Combination Product|Capecitabine based chemoradiation|Capecitabine based chemoradiation
45359546|NCT00796874|Procedure|magnetic resonance imaging|Radiolical Medical Imaging
45359547|NCT00796874|Procedure|magnetic resonance spectroscopic imaging|Radiolical Medical Imaging
45359548|NCT00876954|Procedure|Normothermia|Warming without increase in core temperature
45359549|NCT00876954|Procedure|Hyperthermia|Core hyperthermia (39 °C) for 2,5 hours
45359550|NCT01565434|Other|CR1 impact|
45359551|NCT04898036|Device|Blue Light Therapy|This phototherapy device (PTD-1) consists of a Plexiglas hand compartment (cleanable) enclosed in a powder-coated steel cabinet. Within the cabinet are two blue LED panels located above and below the hand compartment to illuminate the hands.
45844656|NCT04150068|Drug|Oral Lenacapavir|Tablets administered without regard to food
45359552|NCT04898036|Device|Sham Light Therapy|To turn the device into a sham mode, a thin opaque liner can be inserted which will block light from illuminating the hands.
45359553|NCT01565512|Drug|Bupivacaine|A total of 100 mg bupivacaine (20 mL of 5 mg/mL solution) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
45359554|NCT01565512|Drug|Saline|A total of 20 mL on injectable saline(0.9% NS) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
45359555|NCT00739661|Drug|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
45359556|NCT00739661|Drug|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
45359557|NCT04895930|Drug|Furmonertinib|80mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (40mg).
45359558|NCT04895930|Drug|Anlotinib|10mg/day orally from day 1 to 14 of a 21-day cycle. If subjects suffer from AEs, they can get declined dosage (8mg).
45359559|NCT00615030|Drug|Indacaterol|300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)
45359560|NCT00615030|Drug|Salmeterol|50 µg twice daily delivered via dry powder inhaler (DPI)
45359561|NCT00615030|Drug|Placebo to Indacaterol|Placebo matching indacaterol was delivered via SDDPI.
45359562|NCT00615030|Drug|Placebo to Salmeterol|Placebo matching salmeterol was delivered via DPI
45479660|NCT04280744|Other|Music therapy|Patient preferred song will be provided in a sedative manor (e.g., 60-80 beats per minute) using live music (singing with guitar accompaniment) by a board certified music therapist.
45844657|NCT04150068|Drug|Oral Lenacapavir Placebo|Tablets administered without regard to food
45844658|NCT04150068|Drug|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
45844659|NCT04150068|Drug|Failing ARV Regimen|Failing antiretroviral (ARV) regimen defined by the lack of efficacy. Any combination of approved and unapproved agents that could potentially be part of the failing regimen.
46048334|NCT00682162|Device|Sham-laser acupuncture|The sham-laser acupuncture treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). Sham-laser acupuncture was applied at the same points as the acupuncture treatment. A deactivated laser pen (Seirin, 3B Scientific GmbH, Hamburg, Germany) that could only beam normal red light rather than laser was used. The total number of acupuncture points utilized was equal to the acupuncture group. Every point was treated for 30 sec with the total treatment time of 20 minutes.
46048335|NCT02627404|Other|Blood sample|A blood sample is taken at inclusion of patients in the study to perform DNA analysis
45359563|NCT02596061|Behavioral|Deposit Contract|Contracts prompt patients to put money they have earned at stake on a commitment to remain smoke-free for a longer period of time.
45359564|NCT02596061|Other|Incentives|Patients receive incentives for completing smoking cessation activities.
45359565|NCT00789308|Drug|Low Molecular Weight Sulfated Dextran (LMW-SD)|Inhibitor of IBMIR
45844660|NCT04150068|Drug|Optimized Background Regimen (OBR)|Optimized background regimen as prescribed by the Investigator
45844661|NCT04148352|Drug|Dupilumab|Dupilumab injected every 2 weeks for 18 weeks
45844662|NCT04148352|Other|Placebo|Placebo injected every 2 weeks for 18 weeks
45844663|NCT04135482|Other|colonic tissue biopsy|colonic tissue biospy of patients with severe crohn's disease using colonoscopy
46048336|NCT02627404|Device|actometer|To evaluate the quality of sleep, questionnaires are completed and patients wear an actometer for 21 days. They will also complete a sleep diary
45359566|NCT00789308|Drug|Heparin|Anticoagulation
45359567|NCT00789308|Drug|CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)|Cell proliferation inhibitor
45359568|NCT00789308|Drug|Prograf® (Tacrolimus) OR Cyclosporine|Calcineurin inhibitor
45359569|NCT00789308|Drug|Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant|
45359570|NCT00789308|Drug|Simulect® (Basiliximab) - at 2nd or 3rd transplant|Monoclonal IL-2 receptor blocker
45359571|NCT00789308|Drug|Klexane® (Enoxaparinsodium)|Anticoagulation Prophylaxis
45359572|NCT00789308|Drug|Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)|Anticoagulation Prophylaxis
45359573|NCT00789308|Drug|Enbrel® (Etanercept)|Anti-Inflammatory Therapy
45359574|NCT00518284|Drug|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, 45 mg/m^2.
45359575|NCT02595359|Drug|Moxifloxacin|Moxifloxacin intracameral
45498098|NCT04059432|Diagnostic Test|Tooth Wear and Musculoskeletal Disorders evaluation|"Evaluation of dental wear by BEWE (Basic Erosive Wear Examination: score 0-3) examination and Musculoskeletal disorders are listed by the NORDIC questionnaire developed by Kuorinka et al. (2001)"
45359576|NCT00871104|Drug|Fosfomycin and imipenem|IV Fosfomycin 2 gr./6 hours and IV Imipenem 1 gr./6 hours adjusted acoording to renal function during 4-8 weeks
45359577|NCT00871104|Drug|Vancomycin|IV Vancomycin 30 mg/kg twice a day with valley leves higher than 15 mcg/kg
45844664|NCT04098822|Device|Virtue male sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from in-trinsic sphincter deficiency (ISD). The sling is manufactured from polypropylene and is sold for single use only. The device is a quadratic sling and consists of a knitted monofilament polypropylene mesh. The body of the device provides surface area for supporting the bulbous urethra.
45844665|NCT04084080|Biological|Red Blood Cell|Red blood cell exchange transfusions will be performed every 3-6 weeks to maintain a target post-transfusion hemoglobin S level of <20% and a pre-transfusion hemoglobin S of <30%.
45359578|NCT02554292|Device|Drug Coated Balloon Angioplasty, Scoring Balloon Dilatation|Percutaneous Coronary Intervention
45359579|NCT02595515|Other|Chiropractic treatment|Procedure: chiropractic treatment.
45359580|NCT02595515|Other|Visit without active treatment|Procedure: Visit without active treatment. The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
45359581|NCT03868566|Drug|SNP-612 dose1|Subjects will take dose1 once a day orally for 12 weeks
45359582|NCT03868566|Drug|SNP-612 dose2|Subjects will take dose2 once a day orally for 12 weeks
46048337|NCT04150978|Other|High Protein Polymeric Formula|Component: 22.4% protein from total calorie Preparation of Peptisol: 5 spoons of Peptisol powder diluted in 200 ml warm water to have 250 ml Peptisol (equal to 250 kcal). Given as written in the group descriptions
45359583|NCT00796952|Behavioral|focused attention sessions|"Patient management by the attending Radiation oncologist as usual. Patients assigned to this condition received focused attention sessions during the total course of their CRT treatment from a Speech Language Pathologist, consisting of weekly phone calls to monitor their swallowing outcome during the radiotherapy period."
45844666|NCT04084080|Other|Standard of care|NHLBI/ASH/ATS Expert Panel recommended guidelines
46048338|NCT04150978|Other|Oligomeric Formula|Component: Component: 22.4% protein from total calorie Preparation: 5 spoons of Peptamen powder diluted in 165 ml warm water to have 200 ml Peptamen (equal to 200 kcal). Given as written in the group descriptions
46048339|NCT04150978|Drug|5% Dextrose|500 ml of 5% Dextrose administered to a peripheral vein.
46048340|NCT04051138|Other|Voxx socks and sleeves|participants will be tested with a true device as well as with a placebo device
46048341|NCT00682240|Procedure|laser treatment with PASCAL®|panretinal laser treatment - single-session
45359584|NCT00796952|Behavioral|Valchuff|"Standardised sham or placebo swallowing therapy comprised a buccal extension maneuver (valchuff) and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of CRT treatment."
45498099|NCT01749709|Behavioral|Music listening|
45498100|NCT01749709|Behavioral|Audiobook listening|
45844667|NCT03868956|Diagnostic Test|Colour doppler ultrasound with or without D-dimer test|"Positive CDUS: anticoagulant treatment~Negative CDUS: no anticoagulant treatment~Non diagnostic CDUS : reference to routine D-dimer test~Negative test : no anticoagulant treatment~Positive test : second CDUS 7 days (±2) after first one~No change in CDUS : no anticoagulant treatment~Change in CDUS : anticoagulant treatment"
46048342|NCT00682240|Procedure|laser treatment with PASCAL®|panretinal laser treatment - multi-session
46048343|NCT00682240|Procedure|laser treatment with PASCAL®|grid / focal laser treatment
46048344|NCT00682240|Procedure|laser treatment with conventional laser system|panretinal laser treatment - multi-session according to the conventional protocol, using a conventional laser system
46048345|NCT00684502|Drug|AZD2066|Oral solution administered orally once per day on day 1, and then day 3 through to day 12. Specific dose depends on dose panel.
45498101|NCT01568931|Drug|Urokinase|intracoronary, urokinase, 200,000 Units, bolus
45687891|NCT04461691|Procedure|Cryoballoon Pulmonary Vein Isolation|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
45359585|NCT00796952|Behavioral|Pharyngocise|Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their CRT treatment (up to a maximum of 6 weeks)
45359586|NCT02595827|Other|Conditional Advice|Caretakers are told to return in 2-3 only (Conditional Advice) if the child's symptoms continue.
45479661|NCT03723876|Behavioral|Body awareness therapy|"The physiotherapist uses body awareness techniques, i.e. guiding the participant in movement qualities such as stability, breathing, flow and grounding. Conscious awareness focused on bodily experiences is a key component to be able to reflect on what your body signals.~As a baseline a standardized observation of the movement quality of the individual is performed. The physiotherapist needs special education in the body awareness technique used, to rightly perform and analyse the observation and administer the intervention.~The aim of the body awareness therapy is to raise physical and mental awareness by strengthening the interplay between sensory impressions and motor ability and to gain knowledge of own movement patterns that are not functional and to form alternatives to these."
45479662|NCT03324256|Other|energy drink|16 oz cold commercially-available energy drink
45479663|NCT03324256|Other|caffeinated drink|16oz cold commercially-available caffeinated drink
45844668|NCT03849066|Other|Parent-Reported Symptom Assessment|As the basis for PRSA, the investigator will use the PediQuest Memorial Symptom Assessment Scale (PQ-MSAS), which is an adapted pediatric-specific version of the validated adult MSAS that assesses 28 physical and psychological symptoms over the past week. The study instrument is designed to be completed by a full-proxy parent, and 2 versions tailored for specific age groups are available (0-3, 3-18 years-old). Spanish versions are available for both instruments. The PQ-MSAS contains 28 symptom items, each with 4-point scores for domains of frequency, severity, and extent of bother. Based on these components, a global symptom score and individual symptom scores can be calculated (0-100 scale, with 100 being the worst).
45844669|NCT03834168|Other|standardized Study Diet|Standardized diet consisted with eucaloric meals with 4.5 gm of sodium per day for 5 days.
45844670|NCT03816618|Drug|Medihoney Gel in A Tube|TREATMENT1
45844671|NCT03816618|Drug|Hydrogel|PURLOIN GEL
45359587|NCT00871416|Device|NovoFine® needle 6 mm|
45359588|NCT00871416|Device|NovoFine® needle 12 mm|
45687892|NCT04459104|Other|Low glycemic load|Participants will be given test beverages containing 50gr of isomaltulose (low glycemic index = 32). Isomaltulose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
45844672|NCT03816618|Drug|Fucidin Ointment|FUCIDIN ANTIBIOTIC OINTMENT 10%
45359589|NCT00614874|Drug|rosiglitazone|2mg, 4mg, 8mg
45479664|NCT03324256|Other|Energy gum|2 pieces of commercially-available energy gum
45479665|NCT03324256|Other|placebo gum|2 pieces of commercially-available placebo gum
45479666|NCT03324256|Other|Control drink|16oz cold control drink
45479667|NCT03324256|Other|Total sleep deprivation|24-hour total sleep deprivation prior to consumption of energy drink and placebo gum
45498102|NCT01568931|Drug|Saline|intracoronary, saline, bolus 1 cc
45479668|NCT03792581|Device|EV1000 and closed-loop system|This system will recommend when patients need fluid or not and adjust vasopressor administration automatically
45479669|NCT01622712|Device|Rebound HRD Mesh|Patients with unilateral inguinal hernia receive a nitinol containing large pore polypropylene mesh.
45359590|NCT02553980|Behavioral|Follow Your Virtual Trainer (FYVT) program|"Participants in intervention group will under the instruction of a web-based computer software termed Virtual Trainer, which interact with their smartphone apps, to conduct a 3-month self-planned PA training program. A serious of online video seminars related to healthy lifestyle advice will be released to the participants among 3 months. After that, 6 months observation will be followed."
45479670|NCT03342118|Drug|Phloroglucin(Flospan®)|The experimental group was taken with Phloroglucin(Flospan®) before endoscopy.
45479671|NCT03342118|Drug|Normal saline|The control group was treated with normal saline before endoscopy
45479672|NCT03324178|Behavioral|Neurofeedback training|Sixteen 30-minute sessions of neurofeedback training over four weeks: 7 x 3-minute blocks of training flanked by a 3-minute resting state block with eyes-open.
45687893|NCT04459104|Other|High glycemic load|Participants will be given test beverages containing 50gr sucrose (high glycemic index = 65). Sucrose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
45687894|NCT04454905|Drug|Camrelizumab|Camrelizumab (Jiangsu HengRui Medicine Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.
45479673|NCT03324178|Behavioral|Video game|Sixteen 30-minute sessions of video game playing over four weeks: 7 x 3-minute blocks flanked by a 3-minute seated relaxation.
45479674|NCT01331460|Behavioral|RBT|"Intervention for Injection Drug Using Women:~Incorporates elements of Reinforcement-Based Treatment and Women's Health CoOp to help prevent drug abuse (and promote drug abstinence) and lower risk of Human Immunodeficiency Virus, violence, and high-risk sexual behaviors."
45359591|NCT02553980|Other|Daily PA recommendation & healthy lifestyle suggestions|A written advice of daily PA recommendation, and the textual content of the healthy lifestyle seminars will be provided to the participants.
45359592|NCT00727415|Drug|Cyclophosphamide|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
45479675|NCT01331460|Other|Case-Management|"Standard Intervention:~Incorporates standard practice elements like accessing resources, service linkage, monitoring the success of patient-service linkages, and advocating for the patient to help her meet her needs"
45479676|NCT03798509|Drug|Human CD19 targeted T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
45479677|NCT04202159|Drug|Perampanel|Perampanel tablets.
45479678|NCT04202159|Drug|Perampanel|Perampanel oral suspension.
45479679|NCT02496364|Other|Observational|
45479680|NCT01605552|Behavioral|Beating the Blues (BtB)|BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
45498103|NCT04364269|Drug|VIT-2763 once a day (QD)|Participants will receive VIT-2763 QD at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
45498104|NCT04364269|Drug|VIT-2763 twice a day (BID)|Participants will receive VIT-2763 BID at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
45687895|NCT04454905|Drug|Apatinib|Apatinib is a novel angiogenesis inhibitor vascular endothelial growth factor 2.
45359593|NCT00727415|Drug|Fludarabine phosphate|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
45359594|NCT00727415|Drug|Lenalidomide|"All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).~In the first phase of the study, the dose of Lenalidomide given with FC will be gradually escalated to reach the MTD. In the second phase of the study, FC will be given in combination with the Lenalidomide escalated to the MTD or the maximum planned dose."
45359595|NCT00803192|Drug|Famotidine Tablets, 40 mg|
45359596|NCT00544557|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
46048346|NCT00684502|Drug|Placebo|Administered orally as a solution once per day on day 1, and then day 3 through to day 12.
45687896|NCT04448106|Biological|Celltex- AdMSCs|Autologous adipose-derived stem cells Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
45359597|NCT02554214|Device|Glafkos drainage device|
45479681|NCT01605552|Other|Usual Care|Patients randomized to usual care will be informed that they have clinically significant depressive symptoms and will be encouraged to follow-up with their primary care physicians, who will receive a letter from our team indicating that their patient has elevated depressive symptoms and was randomized to the control condition. The letter will also encourage physicians to follow-up with their patients and will provide a list of local mental health services. Like those in the intervention group, usual care patients will continue to have access to and will receive any medical and mental health services that are part of usual care in the targeted health care systems. Thus, there are no restrictions regarding the care that these patients can receive.
45479682|NCT02496442|Device|Aqueduct|Using Aqueduct in procedures to continuously supply the irrigation solutions
45479683|NCT03794687|Procedure|Left heart catheterization|Catheterization via the distal radial artery
46048347|NCT01111604|Biological|Ramucirumab|8 mg/kg IV Q2W
45687897|NCT04446481|Device|Neurofeedback|Neurofeedback will be tested in both groups of Vets
45687898|NCT04440163|Biological|MenABCWY|N meningitidis groups A, B, C, W, and Y vaccine
45687899|NCT04440163|Biological|Saline|Placebo
45687900|NCT04440163|Biological|Trumenba|Bivalent recombinant lipoprotein 2086 vaccine
45844673|NCT03770598|Behavioral|Standard of Care Distressed in study Arm Distressed|Social worker evaluation and possible referral to Psychiatry/Psychology for evaluation and further treatment.
46048348|NCT01111604|Biological|Icrucumab|15 mg/kg IV Q2W
46048349|NCT01111604|Drug|mFOLFOX-6|"Oxaliplatin: 85 milligram per square meter (mg/m²) IV every 2 weeks (Q2W)~FA: 400 mg/m² IV Q2W (or LFA: 200 mg/m² Q2W if FA is unavailable).~5FU: 400 mg/m² bolus + 2400 mg/m² IV Q2W"
46048350|NCT00950742|Drug|Trastuzumab|Load: 4mg/kg-maintain:2mg/kg/week
45479686|NCT02496286|Drug|Intraperitoneal Bevacizumab|Bevacizumab 200mg diluted in 250 ml of normal saline
45479687|NCT01489176|Drug|Regadenoson; Optison|A one-time intravenous bolus of Regadenoson 400 mcg; continuous intravenous infusion of Optison of 2-4 mL/minute.
45479688|NCT03792503|Drug|Apatinib|Apatinib 500 mg Po qd
45479689|NCT03792503|Drug|Pemetrexed|Pemetrexe 500 mg/m2 d1×q3w
45479690|NCT05625113|Device|neuroprosthesis|Use at least one time every day the gripping neuroprosthesis in daily life activities.
45498105|NCT04364269|Drug|Placebo|Participants will receive hard capsules of Placebo, twice a day.
45687901|NCT04440163|Biological|MenACWY-CRM|Meningococcal group A, C, W-135, and Y conjugate vaccine
45687902|NCT04438512|Drug|MDMA|Administration of 80 or 120 mg MDMA in combination with psychotherapy and a supplemental dose offered 1.5/2 hrs later of 40 or 60 mg MDMA respectively
45687903|NCT04438512|Behavioral|Psychotherapy|Standardized non-directive psychotherapy performed by therapist team
45687904|NCT04436601|Drug|Polyethylene Glycols|Polyethylene glycol will be administered to half of the study patients, and their response recorded and compared with that of the Lactulose arm.
45844674|NCT03770598|Behavioral|Psycho-Education|Mindfulness based stress reduction class, yoga and education material
45844675|NCT03770598|Behavioral|Team Based Care|Psychiatrist, Oncologist, clinical social worker, study coordinator
46048351|NCT00950742|Drug|BIBW 2992|Increased dose cohorts from low dose to MTD
46048352|NCT05061368|Drug|Sildenafil Citrate|Phosphodiesterase Type 5 inhibitor. Known to potentiate nitric oxide mediated vasodilation.
46048353|NCT05061368|Other|Placebo|Placebo
45687905|NCT04436601|Drug|Lactulose|Lactulose (standard of care) will be administered to half of the study patients and their response recorded.
45359598|NCT00877110|Drug|cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8|Patients will receive combination chemotherapy with intravenous (IV) cyclophosphamide 70mg/kg/day (for patients with body weight<70kg) or 2100mg/m2/day (for patients with body weight ≥70kg) for two days, IV vincristine 0.067mg/kg or 2mg/m2/day (lower of the two doses to be chosen; maximum 2mg) for one day, and IV topotecan 2.4 mg/m2/day for 3 days during their first cycle. If receiving a second and/or third cycle, the only chemotherapy patients will receive is cyclophosphamide at 50 mg/kg/day for 2 days. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor. On day +3, the patient will start daily infusion of 3F8 for 5 days. The treatment schedule may require minor adjustment by ±1 day as clinically indicated (e.g. due to PDH closure for holidays or due to inclement weather).
45359599|NCT00727259|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b will be administered according to the products' labeling.
46048354|NCT04310228|Drug|Favipiravir Combined With Tocilizumab|"Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.~Tocilizumab:The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg."
45359600|NCT00727259|Drug|Ribavirin (SCH 18908)|Ribavirin will be administered according to the products' labeling.
45359601|NCT00789386|Drug|Remifentanil|Remifentanil (Ultiva ®; Glaxo-Smith-Kline; Vienna, Austria) at an initial dose of 0.24 µg kg-1 min-1 will be applied iv during 60 minutes.
45359602|NCT00789386|Drug|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied iv as active placebo at a dose of 7.5 µg.kg-1.min-1 over 10 minutes to mimic typical central nervous side effects of remifentanil.
45359603|NCT05157282|Device|TESS|Small stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
45359604|NCT05157282|Other|Training|The participant will be instructed to do repetitive motor movements with their arm or hand.
45359605|NCT05157282|Other|Motor Task|Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.
45687906|NCT04430075|Device|Edwards PASCAL Transcatheter Valve Repair System and Edwards PASCAL Precision Transcatheter Valve Repair System|Transcatheter Valve Repair with Edwards PASCAL and PASCAL Precision System
45687907|NCT04428801|Biological|autologous adipose-derived stem cells|Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
45844676|NCT03770598|Behavioral|Standard of Care Non-Distressed|No psycho-education about wellness promotion or health. These patients will be monitored only.
45359606|NCT05157282|Device|sham-TESS|Small sham stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
45359607|NCT00789464|Dietary Supplement|Lactobacillus reuteri DSM 17938|DSM 17938 drops (10^8 cfu/dose of 5 drops) + placebo elixir once daily for 1 year.
45359608|NCT00789464|Drug|trimethoprim/sulfamethoxazole|Trimethoprim/sulfamethoxazole elixir (TMP/SMZ) (2 mg/kg), a standardized oral antibiotic prophylaxis, plus placebo capsule once daily for 1 year.
45359609|NCT03967067|Procedure|liver resection|Open or laparoscopic, major or minor hepatectomy performed using the clamp-crush technique and intermittent clamping of hepatic pedicle
45359610|NCT00977067|Drug|GDC-0152|Intravenous escalating dose
45359611|NCT00797030|Drug|cyclosporine and sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethylcellulose 0.5% (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) during six months
46048355|NCT04310228|Drug|Favipiravir|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
45359612|NCT00797030|Drug|sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethycellulose (1 drop 4 times per day) during six months
45359613|NCT00877188|Other|exercise|supervised combined aerobic and progressive resistance training for 12 weeks
45844677|NCT03692208|Behavioral|My Diabetes Goal Survey and Optional Care Management|The intervention is already described in the intervention arm description.
45844678|NCT03662646|Other|no intervention performed- observational only|no intervention performed- observational only
46048356|NCT04310228|Drug|Tocilizumab|The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.
45359614|NCT02593955|Behavioral|PD exercise|Supervised high intensity exercise 3x/week for 16 weeks
45359615|NCT02593955|Behavioral|Sleep Hygiene|Sleep medicine physician will provide discuss sleep habits with participants, provide tips for improving sleep hygiene, and provide reading materials.
45844679|NCT03655470|Behavioral|Safety Planning|Safety planning is an individual coping intervention to reduce suicidal risk in adolescents
45844680|NCT03655470|Behavioral|Standard care|Standard care entails sending an adolescent for an emergency evaluation for suicidal risk in an Emergency Department
46048357|NCT02881502|Other|severe asthma group|No intervention
46048358|NCT00955110|Drug|Oxymorphone ER|15mg or 30mg
46048359|NCT00955110|Drug|Oxycodone CR|30mg or 60mg
45498106|NCT05300763|Device|senofilcon A prototype|Test
45498107|NCT05300763|Device|Dailies Total 1|Control
45498108|NCT04800367|Drug|Romosozumab Prefilled Syringe [Evenity]|2 syringes of 105 MG/1.17 mL subcutaneous solution injected one after the other, once a month from study baseline through 11 month visit
45844681|NCT03616236|Drug|Buprenorphine/Naloxone|Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
46048360|NCT00955110|Drug|Placebo|The placebo was a sugar pill.
46048361|NCT00955110|Drug|Hydromorphone|8 mg
45359616|NCT00977145|Biological|A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1|"Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, 15. During cycle two, three vaccines will be administered over a 9-week period on days 24, 43, 64. All participants will receive 12-MP (100 mcg each peptide) plus Peptide-tet (Peptide-tet; 200 mcg) administered in Montanide ISA-51 VG adjuvant. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.~Intratumoral Interferon regimen: On day 22, patients will have one or more tumor sites injected with 0.5-2 million IU of IFN-gamma each, with a maximum dose of 2 million IU of IFN-gamma administered per patient. The number of lesions that are injected will be dependent on the availability and size of the lesions."
45359617|NCT05226000|Drug|Benaglutide Injection|All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing. The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.
45359618|NCT00803348|Drug|Bolus of 0.2% ropivicaine 20 mls followed by 0.2% ropivicaine at an infusion rate of 5mls/hr until 0600 on postoperative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.2% ropivicaine at an infusion rate of 5mls/hr with patient controlled boluses of 5ml available every 30 mins, until 0600 on the morning of postoperative day 2
45687908|NCT04421989|Behavioral|Emotion Coaching|Participants randomized to FBT + EC parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The EC intervention is designed to reduce expressed emotion (e.g., critical comments) and increase parental warmth. The intervention includes emotional awareness and emotion regulation skills for parents, and emotion communication skills for parents to use with their teens undergoing FBT including active listening, emotion support, labeling emotions, and coping with emotions. The structure of EC parent group sessions will begin with review of homework as applicable, a didactic component to teach new skills, followed by role plays between parents in the group and interventionist, and live coaching and feedback from the interventionist.
46048362|NCT05057312|Behavioral|Experimental arm 1|Video narrative persuasion
45687909|NCT04421989|Other|Support Group|Participants randomized to FBT + Support Group parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The support group will have a facilitator introduce each topic weekly and parents will discuss. The facilitator's role is to ensure the group remains on topic and on time. Weekly discussion topics include: co-morbid medical diagnoses, understanding levels of care in treatment, taking time off from work, and medications.
45687910|NCT04419558|Drug|Pamrevlumab|Sterile solution for injection
45687911|NCT04419558|Drug|Placebo|Sterile solution for injection
45687912|NCT04417036|Drug|BAY1097761 Active Dose 1|Participants will receive a lower dose ADM by inhalation
45687913|NCT04417036|Other|Placebo to BAY1097761|Participants will receive Placebo to BAY1097761 by inhalation
45687914|NCT04417036|Drug|BAY1097761 Active Dose 2|Participants will receive a higher dose ADM by inhalation
45844682|NCT03616236|Other|Treatment as usual|Participants will receive a referral to buprenorphine treatment in the community
45844683|NCT03605550|Drug|PTC596|Oral tablets
45844684|NCT03605550|Radiation|Radiotherapy|Cycle1
45844685|NCT03602820|Biological|AAV2-hRPE65v2|
46048363|NCT05057312|Behavioral|Experimental arm 2|Written narrative Persuasion
46048364|NCT05057312|Other|Experimental arm 3|Enhanced Access to HPV vaccines
46048365|NCT05057312|Other|Experimental arm 4|Video narrative persuasion; Enhanced Access to HPV vaccines
46048366|NCT05057312|Other|Experimental arm 5|Written narrative Persuasion; Enhanced access to HPV vaccines
46048367|NCT05056142|Procedure|Epidural Anesthesia|Patients will receive epidural analgesia with 15 ml isobaric bupivacaine 0.125% plus fentanyl 2 μg/mL.
46048368|NCT05056142|Procedure|Spinal Analgesia|Patients will receive Spinal analgesia with 5 mg bupivacaine and 25 μg of fentanyl in a 2 ml volume.
46048369|NCT00950664|Drug|Dysport® (abobotulinumtoxinA)|Cross over injection of Dysport® (<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
46048370|NCT00950664|Drug|Botox® (onabotulinumtoxinA)|Cross over injection of Dysport® (<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
46048371|NCT02855112|Biological|Adipose derived mesenchymal stem cell|Allogeneic Adipose derived Mesenchymal Stem cell transplant
45359619|NCT00803348|Drug|Bolus of 0.2% ropivicaine 20 mls followed by 0.1% ropivicaine at an infusion rate of 10mls/hr until 0600 on post-operative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.1% ropivicaine at an infusion rate of 10mls/hr with patient controlled boluses of 10mls available every 30 mins, until 0600 on the morning of postoperative day 2
45359620|NCT00803348|Drug|Saline control|Bolus of 0.375% ropivicaine 30 mls followed by saline infusion until 0600 on postoperative day 2
45359621|NCT00918047|Drug|SPN-804O|Open Label study
45359622|NCT00980733|Dietary Supplement|Fortified Yoghurt|The study group would receive yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.
45359623|NCT00980733|Dietary Supplement|Yoghurt|Plain yoghurt same as in intervention group without fortification
45359624|NCT00877266|Procedure|perineural mepivicaine catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: catheter placement via ultrasound or nerve stimulation. Placement of the catheter will be timed by research staff and discomfort level asked after placement of catheter. If the catheter is not placed by the randomized method within 15 minutes, the practitioner my switch to the alternate method. Patients will be called the morning after surgery by research staff to assess discomfort levels.
45498109|NCT04800367|Drug|Denosumab 60 MG/ML Prefilled Syringe [Prolia]|1 subcutaneous injection of 60 mg/mL every six months from study 12 month visit through the 24 month visit. Injections occur at the 12 and 18 month visits.
45687915|NCT04416243|Behavioral|Recumbent Stepping, High-Intensity Interval Training|"The intervention will involve 12 weeks of supervised, progressive (i.e., intensity increases after midpoint testing based on reassessment of aerobic fitness) HIIT sessions two to three times per week. HIIT exercise sessions will be manualized and led by exercise leaders. Secondary outcomes testing will occur at baseline (week 0), midpoint (following week 6 of training), and post-intervention (following week 12 of training).~The individual HIIT sessions will involve 10 cycles of 60s intervals at the wattage associated with 90% VO2peak followed by 60s of active recovery intervals at 15 watts, totaling 20 min in length. All exercise sessions will begin and end with a 5-minute warm-up and cool-down, respectively. Required power output for each interval of the exercise session will be individualized and completely automated. VO2peak from baseline and midpoint testing will be used to determine exercise intensity for weeks 1-6 and weeks 7-12, respectively."
45687916|NCT04410900|Biological|Wistar Rabies Virus Strain PM-1503-3M Vaccine|Given IM
45359625|NCT02553824|Drug|Phentermine/Topiramate-First|Patients randomly assigned to this Arm will have a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated). Then will have a 2 week washout followed by a crossover to 12 weeks of control medication/ placebo.
45498110|NCT05279859|Drug|ERAS-007|Administered orally
45498111|NCT05279859|Drug|ERAS-601|Administered orally
45498112|NCT05279859|Drug|Gilteritinib|Administered orally
45498113|NCT05233995|Procedure|Damage Control Surgery|Delayed anastomosis
45498114|NCT03713658|Drug|Risperidone 3 mg|Participants will receive 3 mg oral risperidone tablets once daily for up to one Week.
45359626|NCT02553824|Drug|Placebo|Patients randomly assigned to this Arm will have begin with 12 weeks of placebo followed by a 2 week washout. They will then crossover to Qsymia and receive a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated).
45359627|NCT00980889|Device|Steel|ERCP procedure insertion of Metalic Steel Stent, Wallstent®
45359628|NCT00980889|Device|Nitinol|Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
45359629|NCT04039854|Drug|Isoflurane, Sevoflurane or Desflurane|"The volatile anaesthetic agent will be administered via inhalation, i.e. ventilation through alveolar membrane in lungs) during the maintenance of anaesthesia. During CPB the volatile anaesthetic agent will be administered through the oxygenator oxygen inflow of the CPB machine.~The maintenance dose of the volatile anaesthetic agent will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia and blood pressure.~The administration of the volatile anaesthetic agent will be started after induction of anaesthesia and it will be ended at the end of surgery, before the patient is transferred to the CCU."
45359630|NCT04039854|Drug|Propofol|Patients will receive propofol only during the surgical procedure. The maintenance dose of the propofol infusion will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia (titrated to a depth of anaesthesia with BIS 30-60) and mean arterial pressure (MAP) of 50-80mmHg by the treating anaesthetist.
45359631|NCT04045730|Drug|Gemcitabine|All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab.
45359632|NCT00977223|Drug|aprepitant/placebo|Aprepitant, 125 MG at day 1 then 80 MG day 2-7, once a day, per os, at 8 AM during breakfast
45359633|NCT00803426|Procedure|Sciatic nerve blockade for ankle/foot surgery|Injection of local anesthetic near the nerve to achieve anesthesia.
45359634|NCT00977301|Drug|fosamprenavir/ritonavir|16 days 700mg/100mg RTV BID
45687917|NCT04410900|Procedure|Biospecimen Collection|Undergo collection of blood samples
46048372|NCT01111526|Drug|Panobinostat (LBH589)|"Phase I Initial Treatment Plan - Intravenous (IV) Formulation: Up to 4 dose levels (DL) of LBH589 IV formulation to establish LBH589 Maximum Tolerated Dose (MTD) in acute GVHD treatment. The first 4 participants began this treatment plan, before the IV Formulation became unavailable.~DL -1: 1.25 mg/m^2 IV; DL 1: 2.5 mg/m^2 IV; DL 2: 5 mg/m^2 IV; DL 3: 7.5 mg/m^2 IV; DL 4: 10 mg/m^2 IV.~Phase I Revised Treatment Plan - Oral Formulation (to replace IV Formulation): Dose escalation levels for LBH589; participants treated with LBH589 by mouth (PO) 3 times a week (48 hours apart) every week for 4 weeks.~DL -1: 5 mg PO; DL 1: 10 mg PO (starting dose level); DL 2: 15 mg PO; DL 3: 20 mg PO; DL 4: 25 mg PO.~Phase II Treatment Plan: LBH589 PO at MTD, 3 times a week (48 hours apart) every week for 4 weeks."
45687918|NCT04410224|Drug|ASN004|ASN004 is an antibody-drug conjugate for the treatment of advanced or metastatic solid tumors.
45844686|NCT03590574|Biological|AUTO4|AUTO4 (RQR8/aTRBC1 CAR T cells) Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine), patients will be treated with doses from 25 to 900 x 10^6 RQR8/aTRBC1 CAR T cells in Phase I. Following dose determination patients will be treated with the selected doses of RQR8/aTRBC1 CAR T cells (AUTO4) in Phase II.
46048373|NCT01139892|Procedure|Surgical management|
45359635|NCT00977301|Drug|olanzapine|15 mg olanzapine single dose
45359636|NCT00977301|Drug|olanzapine|10 mg olanzapine single dose
45359637|NCT00803504|Procedure|ocular blood flow measurement|
45498115|NCT03713658|Drug|Paliperidone Palmitate 50 mg eq.|Participants will receive 50 mg eq. PP1M intramuscular injection for 17 Weeks.
45844687|NCT03551730|Combination Product|PRT064445/Enoxaparin|
45844688|NCT03551730|Combination Product|Placebo/Enoxaparin|
45844689|NCT03551730|Drug|Placebo|
45479691|NCT03047720|Device|Lully Sleep Guardian|"In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod.~During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness.~In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study."
46048374|NCT01139892|Procedure|Endovascular management|
45359638|NCT00735371|Drug|LDX 30 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
45359639|NCT00735371|Drug|LDX 50 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
45359640|NCT00735371|Drug|LDX 70 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
45359641|NCT00735371|Drug|Placebo|Placebo will be identical to test product.
45359642|NCT00518206|Biological|NY-ESO-1 ISCOMATRIX® vaccine|NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
45479692|NCT03047720|Device|Lully Sleep Guardian|"In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod.~During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness.~In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study."
45479693|NCT04494724|Drug|Clazakizumab|Infusion
45479694|NCT04494724|Drug|Placebo|Infusion
45479695|NCT03794843|Drug|Nimodipine Injection|Nimodipine injection (trade name: Nimotop) manufactured by Bayer Pharma AG was used as the reference preparation
45479696|NCT03794843|Drug|Nimodipine Injection (II)|Nimodipine Injection (II) was supplied by Shenyang Dongxing Pharmaceutical Technology Co., Ltd
45479697|NCT03635970|Procedure|celular therapy|application of cell therapy with a concentrate of hematopoietic progenitor cells or celular therapy
45479698|NCT04220216|Other|H4H fitness program|4 weekly, 1 hour exercise sessions
45479699|NCT04494802|Behavioral|lower pressure|During the operation, cuff pressure of LMA flexible is maintained to 30cmH2O
46048375|NCT02881346|Drug|Enstilar®|Once daily application of cutaneous foam to plaques on body and/or extremities
45479700|NCT04494802|Behavioral|higher pressure|During the operation, cuff pressure of LMA flexible is maintained to 50cmH2O
45479701|NCT01333800|Drug|Beclomethasone|200 to 400 mcg per day for 6 months
45479702|NCT01333800|Drug|Ciclesonide|80 to 160 mcg per day for 6 months
45479703|NCT04926077|Device|DreamKit|The DreamKit device is a single-use device intended to aid the diagnosis of sleep-disordered breathing; however, this study is intended only to validate the respiratory effort signal and does not assess diagnostic performance.
45498116|NCT03713658|Drug|Paliperidone Palmitate 75 mg eq.|Participants will receive 75 mg eq. PP1M intramuscular injection for 17 Weeks.
46048376|NCT00630708|Drug|Benazepril|20 mg per day
46048377|NCT00630708|Drug|Losartan|100 mg per day
46048378|NCT00630708|Drug|Benazepril+Losartan|combination treatment of 10 mg benazepril and 50 mg losartan per day
46048379|NCT04258878|Procedure|Sternotomy|Procedure: Sternotomy for coronary artery bypass graft, valvuloplasty, aortic surgery or combined procedures, under extracorporeal circulation or not, in emergency or scheduled.
46048380|NCT01111292|Drug|Inositol|Given PO
46048381|NCT01111292|Other|Placebo|Given PO
46048382|NCT04269330|Procedure|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
45359643|NCT00518206|Drug|Cyclophosphamide|Cyclophosphamide (300 mg/m^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
45359644|NCT00984945|Biological|H5 VLP pandemic influenza vaccine 5 µg|0.5 mL, IM, 2 injections 21 days apart
45359645|NCT00984945|Biological|H5 VLP pandemic influenza vaccine 10 µg|0.5 mL, IM, 2 injections 21 days apart
45359646|NCT00984945|Biological|H5 VLP pandemic influenza vaccine 20 µg|0.5 mL, IM, two injections 21 days apart
45359647|NCT00984945|Biological|Placebo|0.5 mL, IM, two injections 21 days apart
45359648|NCT00871650|Other|Sleep data recording|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking [18F]-FDG PET scan, and one REM sleep PET scan according to published methods.
45359649|NCT00871650|Other|PET scan - waking|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking [18F]-FDG PET scan, and one REM sleep PET scan according to published methods.
45359650|NCT00871650|Other|PET scan - REM Sleep|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking [18F]-FDG PET scan, and one REM sleep PET scan according to published methods.
45359651|NCT04046588|Diagnostic Test|Infrared thermography|A thermal imager (NEC InfRec R450, Avio Infrared Technologies Co., Ltd., Tokyo) will be used to record thermal images. The temperature of corresponding sites on the Heart and Lung meridians will be analyzed.
45359652|NCT04046588|Procedure|Moxibustion|"Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian, respectivey. During moxibustion, the temperature change of relevant sites in the Heart and Lung meridians will be measured by infrared thermal imaging.~Intervention in the Heart meridian: moxibustion will be performed above the acupoint HT3 of the Heart meridian~Intervention in the Lung meridian: moxibustion will be performed above the acupoint LU5 of the Lung meridian."
45359653|NCT04981431|Drug|Elinzanetant (BAY3427080)|Oral administration
45359654|NCT04981431|Drug|Placebo|Oral administration
45498117|NCT03713658|Drug|Paliperidone Palmitate 100 mg eq.|Participants will receive 100 mg eq. PP1M intramuscular injection for 17 Weeks.
46048383|NCT02881736|Other|electroencephalographic,magnetic resonance imaging|
46048384|NCT02853630|Drug|Metformin|Participant will be instructed to take Metformin tablets as per instructions given by the physician.
46048385|NCT02853630|Drug|Vildagliptin|Participant will be instructed to take one tablet of Vildagliptin 50mg per day, 30 minutes after breakfast in the morning and second tablet at night, 30 minutes after dinner
46048386|NCT04310384|Device|ShuttleScope|Alternative intervention
45359655|NCT00879918|Drug|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
45359656|NCT00803582|Procedure|Traditional Chinese acupuncture|Acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions
45359657|NCT00803582|Procedure|Placebo acupuncture|Placebo acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions.
45479704|NCT04494100|Procedure|TRONC|injection of 3 to 7 mL of Ropivacaine 3.75 mg/ml per nerve (median and ulnar nerves) and infiltration of 2 ml of Ropivacaine 3.75 mg/ml laterally above the flexion fold of the wrist in order to block the branches of the lateral cutaneous nerve of the forearm, the terminal sensory branch of the musculocutaneous nerve.
45479705|NCT04494100|Procedure|WALANT|infiltration with 3 to 7 ml of 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine and 8.4% sodium bicarbonate in the subcutaneous area in front of the transverse ligament, between the thenar and hypothenar eminences, from the flexion fold of the wrist over a length of 5 cm.
45479706|NCT04494100|Procedure|Tourniquet|inflation pressure 75 to 100 mmHg above systolic blood pressure.
45479707|NCT04494100|Drug|Ropivacaine|troncular blocks with Ropivacaine 3.75 mg/ml
45479708|NCT04494100|Drug|Lidocaine + Epinephrine|WALANT technique with 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine
45687919|NCT04402151|Drug|PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC|"Patients enrolling on the protocol will undergo prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR) prior to start of the radiation treatment planning process. PSMA tracer is administered by IV injection and PET images are acquired.~Any patients found to have possible metastatic disease will undergo a standard of care confirmatory biopsy (if feasible) and receive treatment appropriate for their stage.~The PSMA PET/MR scan will be performed prior to initiation of androgen deprivation therapy (ADT)."
46048387|NCT04310384|Device|MacIntosh Laryngoscope|Gold Standart
46048388|NCT04309838|Combination Product|Treprostinil via implanted pump|Patients, diagnosed with PAH classified in stagnating intermediate-risk status after triple therapy including Selexipag for at least three months will receive the implantation of LENUS pro that enables permanent infusion of Treprostinil.
46048389|NCT05367206|Drug|Albumin-Bound Paclitaxel|260mg/m2 q3w *2 circles
46048390|NCT05367206|Drug|Carboplatin|AUC 5-6 q3w * 2 circles
46048391|NCT00637286|Drug|Zolmitriptan|5mg Nasal Spray
45844690|NCT03491592|Behavioral|Enhanced Physical Activity Intervention|Participants in the Enhanced Intervention arm will receive all the intervention components of the Original Intervention described above plus: 1) text messages and adaptive goal-setting to drive participants back to the website and keep them there longer, and 2) data-driven, technology supported enhanced intervention content targeting theoretical constructs that influenced PA behavior in Latinas from the parent study.
46048392|NCT00944658|Drug|Apremilast|10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks
46048393|NCT00944658|Drug|Placebo (sugar pill)|twice a day
45359658|NCT01565590|Drug|Dexmedetomidine|0.2-1.5 mcg/kg/hr
45359659|NCT01565590|Drug|propofol|5-80 mcg/kg/min
45359660|NCT00877422|Dietary Supplement|Vitamin D3|Group A and Group C are followed without drugs and Group B is followed with vitamin D3.
45359661|NCT00980967|Other|Study of predictive factors|Identification of predictive factors for lung chronic rejection outcome in lung transplant recipients
45359662|NCT04088201|Device|Glucose measurements|We will not conduct an intervention, but will obtain measurements from a continuous, non-invasive glucose sensor, and compare with those from a glucometer.
45359663|NCT04007133|Other|Girerd test|This is a simple and quick questionnaire, composed of 6 questions with a binary yes/no answer. It allows to assess the degree of compliance with the prescribed treatment to better identify the constraints related to the treatment.
45359664|NCT00797186|Other|Intensive risk factor management|Aggressive medical and lifestyle therapy.
45479709|NCT01333878|Biological|Subcutaneous Abatacept|Subcutaneous Abatacept 125 mg once weekly for 6 months
45687920|NCT04402151|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive standard of care radiation therapy (SBRT)
46048394|NCT00637364|Procedure|High intensity focused ultrasound, HIFU|"The FEP-BY02 HIFU system uses extracorporeal generated high intensity ultrasound, focused on a tumor region of interest, to ablate tissue. A stand-alone B-mode ultrasound is used to locate and define the tumor region of interest. Once defined, the acoustic energy is delivered using a large aperture; fixed focus; sparse transducer array. The concentration of acoustic energy may result in thermal and/or mechanical bioeffects including tissue necrosis, apoptosis, and/or disruption (temporary or permanent) of normal cellular function within the targeted volume (such as nerve conduction).~The FEP-BY02 High Intensity Focused Ultrasound (HIFU) system is intended to ablate ductal adenocarcinoma of the pancreas with ultrasound-guided targeted delivery of focused ultrasound energy to effect thermal and/or mechanical bioeffects leading to ablation (destruction) of the targeted tumor tissue."
46048395|NCT04269798|Other|Traditional Treatment|conventional rehabilitation program for lower limb, balance and gait training
45359665|NCT00586313|Device|Tru-cut biopsy|Tru-cut biopsy may be an alternative to percutaneous and transjugular liver biopsy.
45359666|NCT00586313|Procedure|Tru-cut|Tru-cut may be an alternative to percutaneous and transjugular liver biopsy.
45359667|NCT00871806|Drug|Commercial tablet with water|40 mg tablet, given once to each subject
45359668|NCT00871806|Drug|ODT #1 without water|40 mg tablet given once to each subject
45359669|NCT00871806|Drug|ODT #2 without water|40 mg tablet given once to each subject
45359670|NCT00871806|Drug|ODT #1 with water|40 mg tablet given once to each subject
45359671|NCT00871806|Drug|ODT #2 with water|40 mg tablet given once to each subject
45359672|NCT02553668|Drug|Oxygen (FiO2 1,0)|Participants will inhale Oxygen (FiO2 1,0) via Facemask for 3 hours.
45359673|NCT02553668|Device|Facemask|
45359674|NCT00877578|Dietary Supplement|Nutri-Energie ®, Aliscience society|Nutri-Energie ® is a new cake of high caloric density and palatability, enriched in different specific pharmaco nutrients.
45844691|NCT03491592|Behavioral|Original Physical Activity Intervention|Participants in the Original Physical Activity intervention arm of the study will receive the original Spanish language, motivationally-tailored, Internet-based physical activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
45687921|NCT04397484|Drug|0.5% Levobupivacaine|The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
45844692|NCT03462342|Drug|Olaparib Pill|"For Cohorts A, B, and C: 300 mg twice daily by mouth which is taken continuously for 28 days, which is one cycle.~Cohort D 1-2: prescribed lower dose of olaparib (100-200mg daily for a 28-day cycle). Three to five dosing schedules will be evaluated. Dose Levels 1-3: olaparib 100 mg twice daily, Days 1-28. For Dose Levels 4-5: 100-200 mg twice daily, Days 1-28. Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth."
46048396|NCT01110200|Drug|ADVAIR DISKUS 250/50 mg BID|Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.
45498118|NCT03713658|Drug|Paliperidone Palmitate 150 mg eq.|Participants will receive 150 mg eq. PP1M intramuscular injection for 17 Weeks.
45847675|NCT02840916|Procedure|laser acupuncture|Subjects were treated at acupoints including the Stomach and Hunger points of the ear, ST25, ST28, ST40, SP15, CV9, and SP6 by using laser acupuncture (GaAlAs laser, maximal power, 150 milliwatt; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; 5.625 J/ cm2) over 5 sessions per week, 12 treatment sessions in total.
46048397|NCT01110200|Drug|SEREVENT 50 mcg BID|Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
45498119|NCT03713658|Drug|Paliperidone Palmitate 175 mg eq.|Participants will receive 175 mg eq. PP3M intramuscular injection for 24 Weeks.
45498120|NCT03713658|Drug|Paliperidone Palmitate 263 mg eq.|Participants will receive 263 mg eq. PP3M intramuscular injection for 24 Weeks.
45498121|NCT03713658|Drug|Paliperidone Palmitate 350 mg eq.|Participants will receive 350 mg eq. PP3M intramuscular injection for 24 Weeks.
45359675|NCT00877578|Dietary Supplement|Clinutren 1.5 ®, Nestlé Clinical Nutrition|Clinutren 1.5 ®, isocaloric commercially available supplement, twice a day for 4 weeks, in addition to an enriched diet
45359676|NCT03967145|Behavioral|Determining quality of life|Quality of Life
45479710|NCT03798431|Behavioral|M-ROCC|"LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder.~MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 8 weeks & 120 minutes/wk.~MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for grads of LDM for 50 mins/wk.~After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness."
45479711|NCT03328390|Other|Quadratus lumborum block|15 ml of 0.5% isobaric bupivacaine + 10 ml saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
45479712|NCT03328390|Other|Transversus abdominis plane block|15 ml of 0.5% isobaric bupivacaine + 10 ml of saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
45479713|NCT03167879|Behavioral|safer conception counseling|Multi-component counseling to help HIV-affected couples to make an informed decision about childbearing, and to provide counseling to use contraception or safer conception methods, depending on whether the couples chooses to seek or prevent pregnancy after initial consultation.
45847676|NCT02840916|Procedure|sham laser acupuncture|Subjects underwent sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in verum laser acupuncture group.
45847677|NCT02842242|Drug|MYK-461|
45847678|NCT02844582|Drug|Cabazitaxel|Given IV
46048398|NCT04309994|Other|Myocardial protection system (MPS)|cardioplegia solution, A separate pumpsystem by which Blood cardioplegia with individually composable additives as cardioplegia solution can be used
46048399|NCT04309994|Other|Cardioplexol|cardioplegia solution
46048400|NCT01108718|Other|Tempur-Pedic Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the Tempur-Pedic mattress first, then the Control Mattress.
46048401|NCT01108718|Other|Control Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the control mattress first, then the Tempur-pedic Mattress.
46048402|NCT04312646|Device|Elastography .|Performance of US, elastography
46048403|NCT01137110|Other|Brief LEV|Levetiracetam 1000mg BID x 3 days for prophylaxis
46048404|NCT01137110|Other|Extended LEV|Levetiracetam 1000mg BID for length of hospital stay for prophylaxis
46048405|NCT05367050|Behavioral|Lucid Lane Therapy Program|This intervention is designed to aid participants with pre-surgery anxiety management and surgery prep and pain management post-surgery. Participants will be assigned a Lucid Lane pain coach who will utilize mindfulness, cognitive behavioral therapy, group therapy, and mind-body therapies, to accomplish those goals.
45359677|NCT04007913|Behavioral|teleCBIT|Eight sessions of individual behavior therapy
45359678|NCT04046432|Dietary Supplement|Vigiis 101-LAB|examined the effects of the Vigiis 101-LAB capsules I or II (5 or 10 billion CFU/day)
45359679|NCT04046432|Dietary Supplement|Placebo|Maltodextrin was used as a placebo.
45359680|NCT02593799|Procedure|Endoscopy|Upper gastrointestinal endoscopy to evaluate the presence of any grade varices and high-risk varices.
45359681|NCT04039698|Other|Telemedicine|Telemedicine monitoring and teleconsultation by video calls
45359682|NCT04039698|Drug|Velpatasvir/Sofosbuvir|Velpatasvir 100mg / Sofosbuvir 400mg once a day for twelve weeks
45359683|NCT04006821|Drug|PD-1 antibody|Camrelizumab will be administered 200mg iv every 2 weeks until disease progression or lasts for two years.
45359684|NCT04006821|Drug|Apatinib mesylate|Apatinib mesylate will be administered 250mg or 500mg (according to the patient's tolerance), qd, oral, until disease progression.
45359685|NCT00871884|Behavioral|Psychoeducation|Education about the common prognostic considerations, normal symptoms experienced and etiology of symptoms following mild head injury. Includes some basic suggestions surrounding methods to diminish the impact of symptoms on one's life.
45359686|NCT00871884|Behavioral|Relaxation Training|Includes Progressive Muscle Relaxation, Guided Visualization, and various other relaxation techniques to induce deep relaxation.
45359687|NCT00871884|Behavioral|Interoceptive Exposure|Includes a variety of exercises used to elicit somatic sensations which may be feared by the participant, in an attempt to extinguish or lessen the fear reaction to these sensations.
45479714|NCT03328312|Drug|Sugammadex|Time period from administration of the reversal agent to recovery of TOFR >0.9
45479715|NCT03328312|Drug|neostigmine+atropine|Number and time of bradycardic episodes (HR<60 bpm) as well as that of tachycardic episodes (HR>100 bpm) before tracheal extubation
45479716|NCT03328312|Drug|neostigmine+atropine+sugammadex|4. Time of extubation
45479717|NCT04051580|Drug|Lactated Ringer|Comparison of Lactated Ringer's Solution and PlasmaLyte-A as a Base Solution for Del Nido Cardioplegia
45844693|NCT03462342|Drug|AZD6738|"For Cohorts A, B, and C: 160 mg orally once daily for first 7 days of every cycle (Days 1-7 of each 28-day cycle).~Cohort D 1-2: Prescribed higher dose of AZD6738 (120-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated.~Dose Levels 1-3: 120-160 mg twice daily, Days 1-14, in combination with olaparib twice daily, Days 1-28. Alternatively, AZD6738 at 160 mg once daily Days 1-14 with olaparib at 100-150 mg Days 1-28 may be evaluated.~Dose Levels 4-5: Alternative dosing schedule of AZD6738 at 80-160 mg once or twice daily, weekly intermittent schedule (Days 1-5, 8-12, 15-19) in combination with olaparib 100-200 mg twice daily, Days 1-28 may be evaluated. AZD6738 at 160 mg twice daily, Days 1-7 or 240 mg once daily Days 1-14 with olaparib 100-200 mg twice daily Days 1-28 may be evaluated.~Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth."
46048406|NCT05367050|Behavioral|Surgical Preparedness Course|This intervention is designed to help the participant prepare for their upcoming surgery. Classes will include discussions around managing chronic pain before surgery, building mental resilience, dealing with the uncertainty of a new diagnosis or treatment plan, questions to ask their anesthesiologist before and on the day of surgery, what to expect during their potential stay at the hospital, and how to optimize their recovery after surgery. Sessions will often include expert doctors who focus on surgery and medical management around it.
45479718|NCT03328234|Radiation|SIB-IMRT|Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
45479719|NCT03328234|Drug|Paclitaxel|45-50mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
45687922|NCT04397484|Drug|2% Xylocaine with adrenaline 1:200,000|The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
45687923|NCT04373785|Radiation|Intensity-modulated radiation therapy|Intensity-modulated radiation therapy (IMRT) in daily fractions of 2.67 Gy given 5 days per week for 3 weeks, for a total of 40.05 Gy.
45479720|NCT03328234|Drug|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
45359688|NCT02554994|Other|Multifactorial intervention|"There are six components of intervention in this study.~For all participants:~Group exercise~Nutritional supplement(commercial liquid formula will be provided every day).~For selected participants:~Wellness visit in primary care setting, polypharmacy and multi-morbidity every month.~At risk of depression(the people identified as high risk of depression would meet psychiatrist every month).~Domestic safety(If there are possible hazards in participants' home, social worker provide amendments for getting rid of it)."
45359689|NCT02554994|Other|Usual care|"Experienced nurses will visit all participants every month during 6 months of study period, and will conduct an interview and comprehensive geriatric assessments to collect information regarding physical, nutritional, mental, mood condition and health related quality of life.~According to ASPRA cohort schedule, all participants will be assessed by the composite measurement method composed of K-FRAIL frailty scare, Mini-Nutritional Assessment Short Form(MNA-S), the Korean version of Mini-Mental State Examination(K-MMSE), Center for Epidemiological Studies depression(CES-D), EQ-5D 3 level version from EuroQol Research Foundation(EQ-5D 3 level), Short Physical Performance Battery(SPPB), and the Cardiovascular Health Study(CHS)."
45479721|NCT03328234|Drug|Paclitaxel|135-150mg/m2 on day1,every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
45844694|NCT03366480|Drug|ABTL0812 in combination with paclitaxel and carboplatin|ABTL0812 in combination with paclitaxel and carboplatin.
45479722|NCT03328234|Drug|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin,50mg on day1 ),every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
45687924|NCT04373785|Drug|Temozolomide|"Oral temozolomide (75 mg/m2), given 5 days per week, for 3 weeks during radiotherapy.~1 month after the discontinuation of radiotherapy, oral temozolomide is restarted at 150 to 200 mg/m2 for 5 days during each 28-day cycle for 12 cycles."
45687925|NCT04373785|Drug|NG101m|Oral NG101m capsule continuously twice daily.
45844695|NCT03284892|Behavioral|PED care|A once daily, 7-day PED Care intervention on reducing time to resume oral intake, rates of penetration and intervention at 10 days postextubation, and incidences of 30-day aspiration pneumonia in adult patients with prolonged intubation (≥48 hours)
45844696|NCT03284892|Diagnostic Test|FEES test|Using FEES to see if participants have any aspiration or penetration and the level of it.
45479723|NCT03328234|Other|Involved Field Irradiation (IFI)|CTV was defined as GTV with a 3.0-5.0 cm craniocaudal margin and a 0.6-0.8 cm lateral margin and GTVnd with a 0.5-1.0 cm margin.
45479724|NCT03626168|Dietary Supplement|100% watermelon juice|Participants drank two 12-ounce servings of 100% watermelon juice per day for a four-week period.
45479725|NCT03626168|Other|Placebo beverage|Participants drank two 12-ounce servings of a placebo beverage per day for a four-week period.
45479726|NCT03798275|Dietary Supplement|coffee|2 g Nescafe Clasico contains approximately 65 mg caffeine
46048407|NCT05182112|Radiation|Whole liver irradiation (WLI)|Whole liver irradiation (WLI) to a total dose 1800cGy in 10 fractions will be given over 2 weeks with simultaneously integrated boost (SIB) to deliver focal doses of 3600cGy (dose level 1) and 4800cGy (dose level 2) to select gross lesions. SIBl dose assignment will be according to the dose escalation scheme, with all patients in dose level 1 receiving boost of 3600cGy to select lesions and those in dose level 2 receiving boosts of 4800cGy to select lesions. At least one lesion will be selected for dose escalation.
46048408|NCT05182112|Drug|Gemcitabine and Cisplatin|Patients will start cisplatin 10 mg/m2 and gemcitabine 600 mg/m2 intravenously q2 weeks for 1 cycle while undergoing simulation and radiation treatment planning procedures. After completion of CRT, adjuvant cisplatin 25 mg/m2 and gemcitabine 600 mg/m2 q2 weeks will be continued until progression or unacceptable toxicity.
46048409|NCT01136954|Drug|Zonisamide|Transition Period from Study E2090-E044-312: Placebo Open-Label Period: 1 to 8 mg/kg orally per day for approximately 59 weeks.
45479727|NCT05625035|Drug|Lianhua Qingwen capsules|Lianhua Qingwen capsules: 4 capsules once, three times daily
45479728|NCT04781192|Drug|Durvalumab|Intra-Venous(IV) once every 28 days (approximately every 4 weeks [q4w])
45687926|NCT04367571|Other|Osteopathic Manipulative treatment (OMT)|"OMT techniques were focused on correcting the dysfunctions found before each OMT session and included myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field.~OMT group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3)."
45844697|NCT03284892|Other|usual care|usual care means the original care given by the ward the participants stay.
46048410|NCT01136876|Drug|Iopamidol|Iopamidol 370, one time administration for percutaneous coronary intervention
45479729|NCT04781192|Drug|Regorafenib|Oral once per day, Days 1 - 21 every 28 days
45844698|NCT03267108|Combination Product|INOpulse®|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
45844699|NCT03267108|Combination Product|Placebo|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
45844700|NCT03267108|Combination Product|Open Label Extension|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
45844701|NCT03239808|Procedure|Incremental haemodialysis|It consists in reducing the frequency or number of sessions per week with which patients start the HD treatment. The experimental group will start with one session/week, then the number of weekly sessions will be increased to two and later to three as per criteria for progression
45498122|NCT03713658|Drug|Paliperidone Palmitate 525 mg eq.|Participants will receive 525 mg eq. PP3M intramuscular injection for 24 Weeks.
45847679|NCT02844582|Drug|Prednisone|Given PO
46048411|NCT01136876|Drug|Iodixanol-320|Iodixanol-320 single administration for percutaneous coronary intervention procedure
45359690|NCT04007679|Other|Pain neuroscience education|Pain neuroscience education (PNE) was conducted in physical conditions similar to the university classrooms where the study was performed. The sessions were conducted as 70-minute didactic group lessons with the same content held in separate sessions for students in each class. PowerPoint (Microsoft Corp., Redmond, WA, USA) presentations prepared by the instructor were used in all sessions. Metaphors, anecdotes, graphics, and pictures were used in an attempt to convey the information and messages about pain physiology and theory more permanently and effectively. In the PNE sessions, it was explained that the nervous system can be overprotective and that in addition to the sensitivity of the central nervous system, nociceptive transmission can be affected by an individual's thoughts, beliefs, and surroundings. At the end of the session, the students were given time to ask questions, but group discussion was limited to 15 minutes due to time restrictions.
45479730|NCT03323710|Drug|Propranolol|Propranolol will be administered orally at a starting dose of 40 mg (one tablet) two times a day (total daily dose of 80 mg). In case of acceptable safety profile, the dose may be increased to 80 mg (two tablets) two times a day (total daily dose of 160 mg) or farther to 80 mg (two tablets) three times a day (total daily dose of 240 mg).
45687927|NCT04367571|Other|Manual Placebo (MP)|"The MP treatment consists of passive touch without joint mobilization in a protocolled order. The practictioners will be standing next to the bed, they'll touch lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they'll touch for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest for 5 minutes each.~MP group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3)."
46048412|NCT02880332|Other|Usual care|During usual care therapy, children and their parents will receive a +/- 1 h session containing bio-medical directed education and information about the gastro-intestinal system and its function. This knowledge will be brought to bear with a hypnotic journey through their body, guided by a nurse with specific expertise in pediatric abdominal pain. Furthermore, the influence of stress on the gastro-intestinal system will be explained, combined with exercises to practise abdominal respiration.
46048413|NCT02880332|Other|Pain Neuroscience education|"This therapy will consist out of a +/- 1 h one-on-one educational session about neurophysiology of pain, adjusted to the child's comprehension status. The content of the education sessions and pictures will be based on the book Explain Pain by Butler and Moseley and will include explanation and reassurance about the cause of pain, a brief summary of relevant pain mechanisms and the integral role of psychosocial and physical factors in precipitating and maintaining pain. Metaphors, leaflets, books and audio-visual media will be used in a supportive function to consolidate verbally transmitted information. Parents will participate in the PNE session as well."
45479731|NCT03323710|Drug|Sunitinib|Sunitinib will be administered orally at a starting dose of 50 mg once daily, for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks.The schedule may be changed to 2 weeks on / 1 week off (schedule 2/1) and a daily dose may be reduced to 37.5 mg or 25 mg to decrease the level of toxic side effects.
45479732|NCT04771676|Drug|Oncorine (H101)|A modified human recombinant type 5 adenovirus with genetic modifications.
45479733|NCT03328000|Radiation|CTU and MR urethrography|computed tomographic and Magnetic Resonance Urethrography.
45479734|NCT03792269|Drug|Irinotecan|intraperitoneal
45479735|NCT03792269|Drug|Oxaliplatin|intravenous
45479736|NCT03792269|Drug|Capecitabine|
45479737|NCT02488564|Drug|Liposomal doxorubicin|50 mg/m2 by intravenous infusion over a period of 1 hour on day 1 of each cycle repeated every 21 days. A final concentration of between 0.4 to 1.2 mg/ml doxorubicin hydrochloride, is required
45479738|NCT02488564|Drug|Docetaxel|30 mg/m2 by intravenous infusion over a period of 1 hour on day 2 and 9, every 3 week.They will be given for 6 cycles.
45479739|NCT02488564|Drug|Trastuzumab|4 mg/kg for the first administration (day 2 cycle 1) and 2 mg/kg for subsequent administrations. Trastuzumab will be given weekly for the duration of chemotherapy (day 2, 9, 16), then will be administered at the dose of 6 mg/Kg every 3 weeks until completion of 52 weeks of treatment.
45479740|NCT02488564|Drug|Metformin|It is administered as single agent from day -13 to 0. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10, Metformin 1000 mg will be administered twice a day continuously until end of the study treatment.
45479741|NCT02966873|Drug|N-Acetylcysteine (NAC) Treatment|Participant will receive 12 weeks of Active Treatment NAC (2400 mg) daily. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
45359691|NCT02592785|Drug|BAY1163877|"Cohort 1: Single dose 600 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.~Cohort 2: Single dose 800 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose."
45359692|NCT00871962|Other|OXYGEN SUPPLEMENTATION|Patients treated by LTOT, with or without clinically fulfilled criteria for LTOT, with PaO2<55mmHg or less at rest or during sleeping or less during exercise, if supplemental oxygen is demonstrated to improve the exercise-associated hypoxia. Patients with PaO2 56-59mmHg if they also have dependent edema, pulmonary hypertension or hematocrit higher than 56%
45359693|NCT00803816|Drug|everolimus|everolimus 1.0 - 2.5mg oral daily dosage
45359694|NCT00872040|Other|Ultrasound assessment of pelvic floor|Sample of women will undergo ultrasound examination of their pelvic floor before and after delivery. The assessment will be performed by transperineal probe.
45359695|NCT04087499|Device|Acupuncture|acupuncture treatment on selected acupoint
45359696|NCT00797264|Drug|Ketamine-Morphine|Ketamine bolus preoperative and syringe pump peroperative, and morphine postoperative (PCA)
45359697|NCT00797264|Drug|Morphine|Bolus preoperative of NaCl and syringe pump peroperative of NaCl, and morphine postoperative (PCA)
45359698|NCT00797264|Drug|Postoperative PCA of Ketamine and morphine|Bolus preoperative of NaCl and syringe pump peroperative of Ketamine, and morphine postoperative (PCA)
45359699|NCT00981201|Drug|Celecoxib|"Months 1-3:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
45359700|NCT00981201|Drug|Celecoxib|"Months 4-6:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
45479742|NCT02966873|Behavioral|Cognitive Behavioral Therapy (CBT)|Participant will receive 12 weeks of weekly cognitive-behavioral therapy, medication management, and AE monitoring.
46048414|NCT02880332|Other|Extra care|During this therapy session, all the patient's/ parents questions that arose from the previous session (Usual care) will be answered. Afterwards, the educated content from this previous session will be revised. Nothing new will be taught. At the end of the session, the participant will be asked to demonstrate the previously learned exercises on abdominal respiration. If the exercises are not well performed, the therapist will correct them.
45359701|NCT00981201|Drug|Placebo|"Months 1-3:~By mouth twice daily."
45359702|NCT00981201|Drug|Placebo|"Months 4-6:~By mouth twice daily."
45359703|NCT04842708|Diagnostic Test|vaccination against COVID19|subjects will undergo breath biopsy sampling before, 4-7 days post-first vaccination dose, and 7-10 days post-second vaccination dose.
45359704|NCT00727025|Device|wound closure device (Steri-Strip™)|wound closure with steri-strip S
45359705|NCT00797342|Drug|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the first cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
45359706|NCT00797342|Drug|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the second cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
45359707|NCT00797342|Drug|PF-04629991|Oral; sequential single dose escalation; three fourteen-day treatment periods per subject in the third cohort; randomized assignment to treatment (placebo or PF-04629991)
45359708|NCT00872118|Behavioral|Brief Intervention for Socially Anxious Drinkers (BISAD)|integrated alcohol and social anxiety individual intervention
45359709|NCT00872118|Behavioral|Enhanced Alcohol Skills Building and Education Program|alcohol-focused group intervention
45359710|NCT05279391|Drug|Dexamethasone|Dexamethasone 6-8 mg once daily
45687928|NCT04366310|Device|capillary refill index|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
45687929|NCT04366310|Procedure|rewarming|warming fingertip skin temperature using an instant hot pack
45752078|NCT01389596|Drug|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
45479743|NCT02966873|Drug|Inactive Placebo Oral Capsule|Participant will receive 12 weeks of inactive placebo. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
45479744|NCT02966873|Other|Functional magnetic resonance imaging (fMRI)|Participants will be given the option to complete Functional magnetic resonance imaging (fMRI) at two timepoints (pre-treatment and end of treatment).
45359711|NCT05279391|Drug|Low molecular weight heparin|Therapeutic doses of LMWH (e.g. Tinzaparin 175IU/kg)
45359712|NCT05279391|Drug|Anakinra 100Mg/0.67Ml Inj Syringe|IV administration of Anakinra 200 mg/twice daily for 3-6 days, then 100 mg/twice daily, for up to 10 days in total.
45359713|NCT05279391|Drug|Tocilizumab|IV administration of Tocilizumab as a single dose of 8mg/kg
45359714|NCT05279391|Drug|Baricitinib|4 mg per os once daily, for up to 14 days (2 mg if GFR: 30 to <60 ml/min/1.73 m2)
45359715|NCT05279391|Drug|Dornase Alfa Inhalant Product|Inh. 2,500 U/twice daily, for up to 14 days.
45359716|NCT00789542|Device|Intermittent Pneumatic compression|Thigh length sleeves applied to both legs from randomization to Day 30 (Day and night) whilst sitting and lying
45359717|NCT00789542|Other|Routine care|Routine care which might include: early mobilization, adequate hydration, aspirin if ischemic stroke and graduated compression stockings according to local protocols.
45359718|NCT04087733|Drug|OZODROP|3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the contralateral eye will be treated with a saline solution and it will serve as a control. Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory
45359719|NCT00880152|Behavioral|Mindfulness-based stress reduction|An 8-week course in mindfulness training
45359720|NCT00922220|Other|stationary bike|Participants rode a stationary bike for five minutes
45359721|NCT00922220|Other|lumbar extension exercise|Participants performed four sets of fifteen lumbar extension exercises over fifteen minutes
45359722|NCT00922220|Other|spinal manipulative therapy|participants received spinal manipulative therapy to the low back
45479745|NCT02966873|Other|Proton magnetic resonance spectroscopy (MRS) Imaging|Participants will be given the option to complete magnetic resonance spectroscopy (MRS) at two timepoints (pre-treatment and end of treatment).
45359723|NCT00977847|Other|Electronic Health Portals for collecting Family History data|Comparison of multiple portals for integrating patient generated family history data into the electronic health record.
45359724|NCT02595203|Drug|[14C-pos 1]-Debio 1450 BES Solution|A solution containing Debio 1450 bis ethanolamine salt (BES) radiolabelled with carbon-14 (14C) at position 1
45359725|NCT02595203|Drug|[14C-pos 25]-Debio 1450 BES Solution|A solution containing Debio 1450 BES radiolabelled with carbon-14 (14C) at position 25
45359726|NCT04828746|Procedure|Ultrasound Guided Skin Marking|Using ultrasound for skin marking pre-procedure
45359727|NCT00789620|Drug|lidocaine|1.5 mg/kg as Bolus intraoperative: 2 mg/kg/h postoperative: 1.3mg/kg/h during 24h
45359728|NCT00789620|Drug|placebo|Bolus 0.15 ml/kg NaCl 0.9% NaCl 0.2 ml/kg/h Perfusor NaCl 0.9% 0.13 ml/kg/h Perfusor
45359729|NCT03970265|Diagnostic Test|extraction of ELF and ILF from explanted lung tissue; meropenem concentration in ELF and ILF; ELF on postoperative day 1-5 when bronchoscopy is performed within clinical routine.|Interventions will only be performed on explanted lung tissue ex vivo and on supernatant of bronchoscopy and are therefore non-invasive
45359730|NCT00877656|Biological|HuMax-CD4|Active treatment
45359731|NCT00803894|Drug|MK0752|Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments.
45359732|NCT00803894|Drug|Comparator: MK0752.|Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments.
45359733|NCT00803894|Drug|Comparator: Placebo|Single dose placebo capsules: there will be a 7-day washout period between treatments.
45359734|NCT05371925|Drug|Sulodexide|one 250LRU sulodexide capsule twice a day for 8 weeks
45479746|NCT03626636|Drug|Risuteganib|Subjects injected intravitreally with 1.0mg of Luminate®
45479747|NCT03626636|Other|Sham|Sham injection
45479748|NCT03323632|Device|MyndMove|During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non-damaged pathways of the central nervous system.
45479749|NCT03792347|Drug|Pembrolizumab|Arm1：Pre-operative Pembrolizumab+chemoradiotherapy
45359735|NCT00985023|Procedure|Steel screw fixation of Lisfranc fracture-dislocation.|Stainless steel screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
45359736|NCT00985023|Procedure|Absorbable screw fixation of Lisfranc fracture-dislocations.|Bioabsorbable (poly-levo-lactic acid) screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
45479750|NCT04697186|Drug|Berberine|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
45479751|NCT04697186|Drug|Amoxicillin|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
45847680|NCT02845674|Drug|OTX-101 0.09%|0.09% cyclosporine nanomicellar solution
45847681|NCT02845752|Drug|Stiolto Respimat|Oral inhalation spray
45359737|NCT00797420|Drug|Fluconazole Loading Dose|Single Fluconazole loading dose 25 mg/kg
45359738|NCT00797420|Drug|Fluconazole Loading Dose & High Dose|Fluconazole loading dose 25 mg/kg, followed by fluconazole 12 mg/kg q24 hours for total of 5 days
45359739|NCT00981513|Biological|Trivalent live attenuated seasonal influenza vaccine|One dose
45359740|NCT00981513|Biological|Monovalent live attenuated pandemic influenza vaccine|One dose
45359741|NCT00981513|Biological|Saline|One dose
45359742|NCT00872274|Drug|sumatriptan 100mg|
45359743|NCT00734747|Device|Medigus SRS endoscopic stapling system|The system is designed to staple the stomach to the esophagus in 2 or 3 locations using a quintuplet of standard B shaped, 4.8 mm titanium staples in each location.
45359744|NCT00805688|Behavioral|Questionnaires|Questionnaires including symptom review (MDSAI-GI) via personal or telephone interviews (interactive voice response telephone system - IVRS)
45359745|NCT00805688|Procedure|Blood Draws|Blood sample (3½ tbs.)to measure levels of cytokines (biomarkers in the blood) and DNA (the genetic material in cells) before treatment starts.
45359746|NCT00805688|Device|Pedometer|Worn daily to measure physical activity.
45359747|NCT00880308|Drug|LDE225|
45359748|NCT00797498|Other|Xerostomia questionnaire|All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
45359749|NCT04006899|Device|Bioelectrical Impedance Monitor|Subjects had been under the test of three commercially available devices and the device that the investigators had developed.
45359750|NCT02595047|Procedure|tissue/ organ prefabrication|tissue/ organ is prefabricated in vivo independent of exogenous factors for replacement/ reconstruction purposes
45359751|NCT00872352|Procedure|EMG|Nerve conduction study will be consisted of sequential evaluation of the motor nerves: median, ulnar, peroneal and tibial; and the sensory nerves: median, ulnar, superficial peroneal and sural nerves using a standardized protocol
45359752|NCT00985179|Behavioral|Intervention Group (IG)|Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
45359753|NCT00872586|Drug|olmesartan medoxomil + hydrochlorothiazide|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 20mg oral tablets + hydrochlorothiazide 12.5 mg oral tablets, once daily for up to 8 weeks
45359754|NCT00872586|Drug|olmesartan medoxomil|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 40mg oral tablets, once daily for up to 8 weeks
45359755|NCT00726557|Biological|PegIntron (pegylated interferon alfa-2b; SCH 54031)|PegIntron 1.5 μg/kg/week administered for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue PegIntron therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
45359756|NCT00726557|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered at 10.6 mg/kg/day for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue Rebetol therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
45359757|NCT00977925|Biological|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
45359758|NCT00977925|Procedure|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control severe bleeding.
45359759|NCT00803972|Drug|rHuPH20|recombinant human hyaluronidase PH20
45359760|NCT00803972|Drug|Insulin Human Injection|injection
45359761|NCT00803972|Drug|Insulin Lispro Injection|injection
45359762|NCT00880386|Drug|Losartan|50 mg Losartan will be taken daily by subjects for 24 weeks
45359763|NCT00978081|Drug|aminolevulinic acid hydrochloride|Patients undergo continuous or fractionated photodynamic therapy.
46048415|NCT04987814|Other|HD-sEMG|high definition surface electromyography, allowing the recording of muscle activation signals sensitive to the intensity of the contraction and indirectly to the muscle strength as well as to the muscular fatigability, but also capable of measuring the modifications of the recruitment modalities of the motor units. This recording will be made on the rectus femoris during knee extension, either in the lying position or during chair lifts, depending on the patient's functional state.
45359764|NCT00804050|Drug|infusion A: rEPO|rEPO 40.000 unit/week for 4 mounths, then patients who have obtained an erythroid response, will continue for another 4 months with therapy rEPO. Patients who have not obtained an erythroid response, will increase the dose rEPO to 80,000 units per week for an additional 4 months.
45359765|NCT00804050|Drug|B Infusion rEPO combined with vitamins pills|rEPO 40.000 unit/week plus acid 13 cis-retinoic (20 mg/die) plus Dihydroxyvitamin D3 (1 μg os/die), for 4 mounths. Patients who have obtained an erythroid response will continue for another 4 months with the same therapy. Patients who have not obtained an erythroid will increase the dose of rEPO to 80,000 units per week for additional 4 months.Patients also will continue with the same doses of acid 13-cis-retinoic acid and Dihydroxyvitamin D3
45479752|NCT04697186|Drug|Rabeprazole|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
45479753|NCT04697186|Drug|Amoxicillin|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
45479754|NCT04697186|Drug|Clarithromycin|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
45479755|NCT04697186|Drug|Rabeprazole|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
45479756|NCT04697186|Drug|Bismuth|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
45479757|NCT02488642|Drug|Isosorbide Dinitrate|
45479758|NCT02488642|Drug|Misoprostol|
45359766|NCT00877734|Drug|baclofen|10 mg Baclofen administered tid for 11 weeks
45359767|NCT00877734|Drug|placebo|Placebo administered tid for 11 weeks
45359768|NCT00877734|Behavioral|BRENDA counseling|
45359769|NCT00981591|Drug|Iloprost|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours; uptitrated to effect, to maximum dose of 30 mcg every 30 minutes
45359770|NCT00981591|Drug|Placebo|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours or more
45479759|NCT02488642|Drug|Oxytocin|Oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.
45359771|NCT04545216|Other|Long-distance mountain running|Impact of a mountain race on the knee cartilage
45359772|NCT00978159|Drug|esomeprazole|esomeprazole 20 mg po for 4 weeks
45359773|NCT00978159|Drug|Famotidine|Famotidine 40 mg po for 4 weeks
45359774|NCT00804206|Drug|bevacizumab|Intravitreal bevacizumab before panretinal photocoagulation
45479760|NCT03792425|Procedure|Connective tissue graft and implant placement|Augmenting soft tissue with connective tissue graft
45479761|NCT03798197|Drug|30 mg estetrol (E4)|All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or at the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (sequence AB), or Treatment B followed by Treatment A (sequence BA).
45687930|NCT04359563|Behavioral|Mindfulness-Based Intervention|"The MBI consists of four 2h online group sessions spread over eight weeks. In between sessions, online support will be offered to assist participants in their practice. Each session consists of guided mindfulness exercises (e.g., focus on the breath, body scan, breathing space, mindful yoga, insight meditation, walk meditation), sharing of experiences of these exercises, reflections in small groups, psycho-education (e.g., stress, depression, self-care), and review of home practices. An overview of core elements is given in Van der Gucht et al. (2017b).~The MBI is supported by homework assignments and audio material. Groups will include 5 participants, yielding 6 groups in total. The MBI will be delivered by highly qualified certified trainers with more than 10 years of experience in mindfulness meditation and extensive experience working with adolescents. Trainers will attend inter- and supervision moments on a regular basis to check treatment fidelity and trainer adherence."
45847682|NCT02845752|Drug|Placebo Respimat|Oral inhalation spray
46048416|NCT04987814|Other|- Quadriceps muscle ultrasound|Muscle Ultrasound with Philips Lumify Wireless Handheld Ultrasound for Android - Model - L12-4 linear probe, allowing performance at the patient's bed.
46048417|NCT04987814|Other|IPAQ Physical Activity Questionnaire.|physical activity assessment questionnaire/adapted version for seniors
46048418|NCT02881580|Other|No intervention : descriptive study|
46048419|NCT01105130|Other|Placebo|Given orally
46048420|NCT01105130|Drug|Oral L-Arginine|Given orally 3 capsules ArginMax and 3 Placebo capsules
45359775|NCT00804206|Drug|bevacizumab|Intravitreal Bevacizumab after panretinal photocoagulation
45359776|NCT00877812|Dietary Supplement|Arm 1 glycine and leucine|Arm 1 glycine and leucine: A subset of 14 participants out of the total enrolled participants with an adequate nutritional status will undergo the tracer infusion of glycine and leucine amino acids protocol while an adequate vitamin pyridoxine, B6 status. After the first infusion each participant will then begin a diet low in vitamin B6 (<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by a repeat of fasting blood sampling and tracer infusion protocol.
45359777|NCT00877812|Dietary Supplement|Arm 2 Intervention of Serine and methionine infusion|Arm 2 Intervention of Serine and methionine infusion: A subset of 14 participants out of the total enrolled participants. Received an adequate nutritional status will undergo the tracer infusion of methionine and serine amino acids protocol while in adequate vitamin pyridoxine, B6 status. After the first infusion each subject will then begin a diet low in vitamin B6 (<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by repeat of fasting blood sampling and tracer infusion protocol.
46048421|NCT01105130|Drug|Oral L-Arginine|Patients will take 6 capsules of ArginMax twice daily
46048422|NCT04984304|Behavioral|Lifestyle modifications and Antireflux diet|Patients in Arm 1 - mild cough only slightly worsening the quality of life (VAS 1-3) will undergo treatment using lifestyle modifications and an Antireflux diet for 3 months.
46048423|NCT04984304|Diagnostic Test|Extraesophageal reflux diagnostic|Patients in Arm 2 - moderate and severe cough that significantly worsen the quality of life (VAS 4-10) will undergo extraesophageal reflux diagnostics consisting of esophageal 24-hour pH/Impedance Reflux Monitoring and peptest study on fasting
46048424|NCT01108094|Drug|Itraconazole|"Cohort A: oral itraconazole 400 mg as 200 mg twice daily; for 1 month~Cohort B: oral itraconazole 200 mg as 100 mg twice daily; for up to 3 months"
46048425|NCT04310072|Device|Neuromuscular electrical stimulation|NMES therapy induces visible rhythmic and repeated muscle contractions without volitional effort from the patient by applying electrodes to the thigh and/or calf muscles.
46048426|NCT00954174|Drug|Carboplatin|Given IV
46048427|NCT00954174|Drug|Ifosfamide|Given IV
45359778|NCT00981903|Drug|Tinzaparin sodium|Subcutaneous injection 175 U/Kg/day
45359779|NCT00738881|Drug|Erlotinib Hydrochloride|Given PO
45359780|NCT00738881|Drug|Pemetrexed Disodium|Given IV
45359781|NCT00797654|Behavioral|Information-motivation-behavior skills and cognitive processing therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors and reducing post-traumatic stress disorder (PTSD) symptoms.
45359782|NCT00797654|Behavioral|Pre and Post HIV-Test Counseling|Treatments are aimed at assessing and reducing behaviors that put participants at high risk of HIV infection.
45359783|NCT00877968|Dietary Supplement|Whole wheat banana bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 62.8 g Available CHO: 51.7 g"
45359784|NCT00877968|Dietary Supplement|Whole pea flour banana bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 67.8 g Available CHO: 52.0 g"
45359785|NCT00877968|Dietary Supplement|Whole wheat biscotti|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 79.8 g Available CHO: 53.1 g"
45359786|NCT00877968|Dietary Supplement|Whole pea flour biscotti|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 86 g Available CHO: 51.7 g"
45359787|NCT00877968|Dietary Supplement|Whole wheat pasta|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion (Dry): 70 g Available CHO: 51.1 g"
45359788|NCT00877968|Dietary Supplement|Whole pea pasta|"Dose was portioned so that subjects received 50 g available carbohydrate Pea pasta is 30% whole pea pasta, 70 white wheat durum~Portion (Dry pasta) : 90 g Available CHO: 53.1 g"
45359789|NCT00877968|Dietary Supplement|White bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g Available CHO: 50 g"
45359790|NCT00877968|Dietary Supplement|Boiled yellow peas|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g (dry) --> 250 g cooked Available CHO: 52.8 g"
45359791|NCT00878046|Device|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
45359792|NCT00657020|Drug|Nicotine|Nicotine lozenge containing 4 mg of nicotine
45359793|NCT00657020|Drug|Placebo|Placebo lozenge
46048428|NCT00954174|Drug|Paclitaxel|Given IV
45359794|NCT04773288|Other|Live feedback during handwashing|Live feedback provided during handwashing on display
45359795|NCT03921723|Drug|Dolutegravir dispersible tablet|DTG will be available as an oral tablet with dosing strength of 5 mg 2 tablet will be dispersed in water will be administered orally for prescribed regimen.
45359796|NCT03921723|Drug|Dolutegravir oral suspension|DTG will be available as an oral suspension with dosing strength of 5 mg per milliliter (ml) or 2 mg per ml with miglyol 812N or ethyl cellulose in miglyol 812N as vehicle for suspension administered orally for prescribed regimen.
45359797|NCT03921723|Drug|Dolutegravir oral solution|DTG will be available as an oral solution with dosing strength of 2 mg per ml will be administered orally for prescribed regimen.
45359798|NCT00872664|Dietary Supplement|carotenoids|beta-carotene, lycopene, lutein
45359799|NCT00872742|Behavioral|Acceptance enhanced behavior therapy (AEBT)|Ten 1-hour sessions over 12 weeks, enhancing awareness of hair-pulling behavior and teaching strategies to deal with hair pulling
46048429|NCT00954174|Other|Quality-of-Life Assessment|Ancillary studies
46048430|NCT02854878|Device|The Lucy ultrasonic comb models A and B combined with the LucyGel|
45359800|NCT00872742|Behavioral|Psychoeducation and supportive therapy (PST)|Ten 1-hour sessions over 12 weeks, teaching the participant about hair pulling and discussing how hair pulling affects those who do it
45359801|NCT05056155|Other|Systane Complete|Propylene glycol 0.6% eye drops for replenishing deficiencies in both the lipid and aqueous layers of the tear film
45359802|NCT00878124|Dietary Supplement|Coenzyme Q10 co treatment|CoenzymeQ10 300mg twice a day continuously. Ceased when patient conceives or at the end of the study.
45359803|NCT00878124|Other|Placebo Caps|3 caps twice a day continuously until pregnant or at the end of the study.
45359804|NCT00978237|Drug|EFV|one pill QD VO.
45359805|NCT00978237|Drug|LPV/r|2 pills QD VO
45359806|NCT00872820|Behavioral|Acceptance- and commitment-based behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; strategies for dealing with anxiety will include mindfulness and acceptance of negative feelings
45359807|NCT00872820|Behavioral|Cognitive behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; methods for dealing with anxiety will include cognitive and breathing strategies
45359808|NCT00978315|Dietary Supplement|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
45359809|NCT00978315|Dietary Supplement|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
46048431|NCT01107626|Drug|Paclitaxel|Given IV
46048432|NCT01107626|Drug|Carboplatin|Given IV
46048433|NCT01107626|Biological|Bevacizumab|Given IV
46048434|NCT01107626|Drug|Pemetrexed Disodium Heptahydrate|Given IV
45359810|NCT00878202|Device|SCAD information system|Clinical follow-up and continuation of therapeutic education by telemedicine during 3 months
45359811|NCT00978393|Drug|liraglutide|High dose liraglutide treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
45359812|NCT00978393|Drug|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
45359813|NCT00978393|Drug|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high placebo treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
45359814|NCT00978393|Drug|liraglutide|High placebo treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
45359815|NCT00978393|Drug|liraglutide|High dose liraglutide treatment (3.0) followed by low placebo treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
45359816|NCT00978393|Drug|liraglutide|Low placebo treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
45359817|NCT04740996|Drug|Pembrolizumab|Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.
45479762|NCT02488486|Device|Automated postoperative sedation|
45479763|NCT02488486|Drug|propofol|
45479764|NCT02488486|Drug|remifentanil|
45479765|NCT04144517|Drug|ALKS 4230|Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period
46048435|NCT04312724|Device|Direct Socket TF|"The device is Class I, a low-risk product, and is a further development of a well-established technology. Össur Direct Socket (DS) technology has been on the market since 1996 (ICEX first generation) for the manufacture of leg prosthesis. This prosthetic socket for trans-femoral amputees (referred hereby to as DS-TF) has the same basic functional design as the Direct Socket (MSS) for trans-tibial amputees (referred hereby to as DS-TT) that is available on the market today in addition to the newly added silicon brim.~A prosthetic socket is a non-invasive, non-sterile, single user reusable device, which is used as part of prosthetic system. The aspect of the prosthesis that is in direct physical contact with the amputee is usually not the socket, to which a prosthesis is connected to, but the liner that serves as an interface between the amputee and the rest of the prosthesis. An amputee typically wears a prosthesis and thereby utilizes a socket, for up to 18 hours a day."
46048436|NCT04312334|Other|Control|Soap: Non-antimicrobial bar soap will be used as a reference product for four of the the experiments. Hand-cleaning with SuperTowel will be the reference produce for two of the experiments.
45479766|NCT04144517|Drug|Pembrolizumab|IV infusion over 30 minutes administered on Day 1 of each cycle
45847683|NCT02849184|Drug|suvorexant|Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.
45359818|NCT04040010|Dietary Supplement|Colostrum supplementation for bone loss|Participants in the interventions groups (i.e. colostrum supplementation) will take a colostrum mixture for 5 months (5 times per week; a total of 250ml per day in liquid form). Participants in the placebo groups (i.e. controls) will be taking a placebo mixture (a total of 250ml per day in liquid form per dose) for the same period of time.
45359819|NCT00872976|Drug|Dasatinib|One Week Initial Treatment for Cohort #1: Dasatinib - Tablets/Oral Solution, at assigned dose level, once daily (QD)
46048437|NCT04312334|Other|Treatment|The Supertowel is a durable fabric with a permanent anti-microbial treatment. The treated fabric must be dipped in water and then rubbed against the hands so that pathogens will be transferred to the fabric where they will be killed.
46048438|NCT04309058|Drug|Vitamin D drops|Vitamin D-deficient UC patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
46048439|NCT01136408|Drug|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, twice a day, oral administration
45479767|NCT01389024|Drug|Hydroxyurea|Hydroxyurea solution 100 mg/ml with a starting dose of 20 mg/kg/day by mouth once daily and escalation by 5 mg/kg/day every 8 weeks until hematological toxicity, an Absolute Neutrophil Count of 2000 to 4000/ul, or a maximum dose of 35 mg/kg/day.
45479768|NCT01389024|Drug|Placebo|Sucrose solution 0.2 ml/kg/day by mouth once a day with blinded dose escalation of 0.05 ml/kg/day to match the frequency of dose escalation in the hydroxyurea arm.
45498123|NCT03681522|Procedure|Pelvic plexus block|Injections of 2.5 mL of 2% lidocaine were made to the pelvic neurovascular plexus located at the end of the seminal vesicle under Doppler US guidance on each side
45847684|NCT02849184|Other|Placebo|Placebo once daily before bedtime.
46048440|NCT01136408|Drug|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, twice a day, oral administration
46048441|NCT01136408|Drug|Warfarin|Dose-adjusted warfarin based on target INR values
46048442|NCT01136174|Drug|Placebo|Placebo BID for cohort 1,2,3
45359820|NCT00872976|Drug|Combination of Bendamustine + Dasatinib|"Dasatinib, Tablets/Oral Solution, Oral, 50 mg, then at 80 mg, at 80 mg, and at 100 mg, once daily (QD), at assigned ascending dose, for 28 day cycles for a maximum of six cycles~Bendamustine, injection, IV injection, 50 mg/m²/Day 1 and Day 2, then at 50 mg/m², at 70 mg/m², at 70 mg/m², at assigned ascending dose, once daily 30 minute IV infusion Day 1 and Day 2 for a maximum of six cycles"
45359821|NCT00872976|Drug|Dasatinib|One Week Initial Treatment for Cohort #2: Dasatinib - Tablets/Oral Solution, at 100 mg, once daily (QD)
45359822|NCT00872976|Drug|Combination of Bendamustine + Dasatinib|"Dasatinib, Tablets/Oral Solution, Oral, at 100 mg, once daily (QD), for 28 day cycles for maximum of six cycles~Bendamustine, injection, IV injection, 100 mg/m²/Day 1 and Day 2, once daily 30 minute IV infusion Day 1 and Day 2 for maximum of six cycles"
45359823|NCT00544167|Drug|Doxorubicin|
45359824|NCT00544167|Drug|Cyclophosphamide|
45359825|NCT00544167|Drug|Paclitaxel|
45359826|NCT00544167|Drug|Sorafenib|
45359827|NCT00659438|Drug|ZD6474 (Vandetanib)|300mg orally, once daily
45359828|NCT00659438|Drug|Bicalutamide|150mg orally, once daily
45359829|NCT00659438|Drug|Placebo|orally, once daily
45359830|NCT00878358|Other|Hydrotherapy|
45359831|NCT00878358|Other|Physiotherapy|
45359832|NCT02553200|Device|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
45359833|NCT02553200|Device|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
45359834|NCT02553200|Device|BreatheMAX (unload and non-oscillated)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
45359835|NCT05225844|Drug|Camrelizumab|Camrelizumab ，200mg/㎡，d1，ivgtt，every 21 days as a cycle
45359836|NCT05225844|Drug|Apatinib Mesylate|Apatinib Mesylate，250mg/㎡，po，d1-5 on/d2 off，every 21 days as a cycle
45359837|NCT00878514|Drug|Alprazolam|Alprazolam 1 mg tablet
45359838|NCT00878514|Drug|Xanax|Xanax 1 mg tablet
45359839|NCT00804284|Biological|DTaP-IPV/Hib|0.5 mL, Intramuscular
45359840|NCT00804284|Biological|Other DTap Vaccines|0.5 mL, Intramuscular
45359841|NCT00804440|Drug|Ibuprofen Tablets, 800 mg|
45359842|NCT00880854|Drug|BCG and CP-675,206|"Dose level -1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 3 mg/kg I.V. week 3, week 15~Dose level 1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 6 mg/kg I.V. week 3, week 15~Dose level 2: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 10 mg/kg IV week 3, week 15~Dose level 3: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 15 mg/kg IV week 3, week 15"
45479769|NCT03327766|Diagnostic Test|4-Measurment of serum 25(OH)D3 using Vidas by ELFA meathod.|A specialized test of the 25(OH)D serum level was conducted and the blood samples were collected in the months of November to April. The winter months were chosen intentionally in order to limit the impact of the sun light upon 25(OH)D serum level.The test VIDAS® 25 OH Vitamin D Total was used-enzyme immunoassay with highly fluorescent measurement ELFA. According to the reference values of this method the 25(OH)D < 20 ng/ml serum levels are considered as deficiency and the serum levels between 20 - 30ng/ml are defined as insufficiency. It's sufficient if the level of 25(OH)D is 30 to 100 ng/ml.
45359843|NCT00804518|Other|Aerobic interval training|High intensity aerobic interval training consists of 10 minutes warm up at ~60% of maximal heart rate, 4x4 minutes intervals at 90-95 % of maximal heart rate corresponding to 85-90% of VO2max) walking/running uphill on a treadmill, with three minutes active pause between the exercise bouts at 60-70% maximal heart rate. The session is terminated with 3 minutes cool down. Total exercise time is 38 minutes.The training is supervised by an exercise physiologist and the subjects train 3 times per week for 12 weeks.
45359844|NCT00880932|Behavioral|Electronic Alert|
45359845|NCT00543855|Drug|3 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
45687931|NCT04357574|Other|Telehealth|patients have virtual visits with Radiation Oncology providers in lieu of in person clinic visits as a necessary response to COVID-19
46048443|NCT01136174|Drug|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
46048444|NCT01136174|Drug|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
45359846|NCT00543855|Drug|5 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 84 (10 weeks)."
45479770|NCT03798119|Drug|Tenofovir Alafenamide|Subjects in this group will switch prior nucleot(s)ide analogs to Tenofovir Alafenamide 25 mg/day for 96 weeks
45687932|NCT04319237|Other|Handgrip strength test|The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles.
46048445|NCT01136174|Drug|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
46048446|NCT01135394|Drug|Pioglitazone|30 mg tablet once daily for 4 weeks, then increased to 45 mg once daily for an additional 8 weeks. Total dosage period is 12 weeks.
46048447|NCT04309760|Other|MRI|Subjects will receive structural and functional (resting state) MRI
46048448|NCT02881190|Drug|RC48-ADC|
46048449|NCT02881034|Drug|Triple therapy|
46048450|NCT00949884|Drug|olmesartan medoxomil|Oral tablets, once daily, at either 20mg or 40mg daily.
45687933|NCT04319237|Behavioral|Neuropsychological Assessment - Wechsler Test of Adult Reading (WTAR)|"The Wechsler Test of Adult Reading (WTAR) is a neuropsychological assessment tool used to provide a measure of Intellectual function. Participants are presented with 50 irregularly spelled words and prompted to pronounce each; the irregular grapheme-to-phoneme translations (such as the gh in the word tough) in the prompts make it difficult to pronounce without having previously learned the word. A high WTAR score is correlated with higher general intelligence as measured by the Wechsler intelligence scales."
45687934|NCT04319237|Behavioral|Neuropsychological Assessment - Repeatable Battery for the Assessment of Status (RBANS)|The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) consists of twelve subtests which give five scores, one for each of the five domains tested (immediate memory, visuospatial/constructional, language, attention, delayed memory).
45479771|NCT03323554|Device|Ustrap®|Patients will receive Ustrap® under general or loco-regional anaesthesia, by perineal approach.
45687935|NCT04319237|Behavioral|Neuropsychological Assessment - Color Trails|The Color Trails test measures sustained attention and sequencing. Numbered circles are printed with vivid pink or yellow backgrounds that are perceptible to color-blind individuals. Participants rapidly connect circles numbered 1-25 in sequence and rapidly connect numbered circles in sequence, but alternates between pink and yellow. The length of time to complete each trial is recorded, along with qualitative features of performance indicative of brain dysfunction, such as near-misses, prompts, number sequence errors, and color sequence errors.
45687936|NCT04319237|Behavioral|Neuropsychological Assessment -Stroop Color and Word Test|The Stroop Color and Word Test is based on the observation that individuals can read words much faster than they can identify and name colors. The test-taker reads color words or names ink colors from different pages as quickly as possible within a time limit. The test yields three scores based on the number of items completed on each of the three stimulus sheets. An Interference score is useful in determining the individual's cognitive flexibility, creativity, and reaction to cognitive pressures.
45687937|NCT04319237|Behavioral|Patient Reported Outcomes Measurement Information System-29 (PROMIS-29) Questionnaire|The PROMIS-29 questionnaire assesses each of 7 domains (Depression, Anxiety, Physical Function, Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social Roles and Activities). A higher score equals more of the concept being measured.
45479772|NCT03323554|Device|AMS 800®|Patients will receive AMS 800® under general or loco-regional anaesthesia. Small openings are made near the scrotum and below the abdomen to insert an inflatable cuff, a pump and a small balloon (pressure regulating balloon).
45359847|NCT00543855|Drug|10 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 42 (4 weeks).~Followed by two 5 mg Donepezil hydrochloride tablets (10 mg) by mouth, once daily after breakfast for Day 43 - Day 84 (6 weeks)."
45359848|NCT00543855|Drug|Placebo|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: Two Donepezil hydrochloride Placebo tablets by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
45359849|NCT00797810|Drug|Rituximab|
45359850|NCT03831048|Device|OCS Heart System|Preserving and assessing donor after circulatory death hearts for transplant
45359851|NCT03831048|Other|Cold Storage|Active comparator intervention
45359852|NCT00881010|Behavioral|Telephone Intervention|Automated Telephone Interactive Voice Response (IVR) system taking approximately 5 minutes, 2 times week for 10 weeks, to rate pain and symptoms.
45359853|NCT00881010|Behavioral|Questionnaires|Surveys approximately 1 hour each at 2 regularly scheduled clinic visits to rate pain and symptoms. Regardless of group, all symptoms are to be reported.
45359854|NCT04921605|Device|DragonFly transcatheter mitral valve clamping system|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
45359855|NCT00656474|Drug|Placebo gel|Administration of Placebo gel on Day 1, 3 and 5 post ablation.
45359856|NCT00656474|Drug|GLYC-101 gel (1.0 %)|Administration on Day 1, 3 and 5 post laser ablation.
45359857|NCT00873210|Drug|Sutent|50 mg per day for 4 consecutive weeks, followed by 2 weeks treatment pause
45359858|NCT00978471|Drug|Thiotepa|Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg.
45359859|NCT04017416|Behavioral|I-PLAN|The I-PLAN is a behaviour change intervention that consists of; information on consequences of hearing aid use/non-use, reminder prompt and behavioural plan to promote hearing aid use.
45359860|NCT00804674|Drug|bupivacain|
45359861|NCT00804674|Drug|placebo|
46048451|NCT00949884|Drug|Placebo|placebo oral tablets once daily for two weeks
46048452|NCT00949884|Drug|losartan potassium|losartan potassium oral tablet at either 50mg or 100 mg daily dose.
45359862|NCT00881088|Drug|Nadroparin|nadroparin 0,3 cc once daily during immobilization period
45359863|NCT00881088|Drug|Fondaparinux|Fondaparinux 2,5 mg daily during immobilization period
45359864|NCT00981981|Dietary Supplement|Wheat bran|21g per day of ready to eat breakfast cereal containing wheat bran with 8g of total dietary fiber and 0.5g beta-glucan.
45359865|NCT00981981|Dietary Supplement|3g high MW|20.2 grams per day of ready to eat cereal containing 6g total dietary fiber and 3g oat beta glucan with high molecular weight
45359866|NCT00981981|Dietary Supplement|4g medium MW|28.5g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with medium molecular weight
45359867|NCT00981981|Dietary Supplement|3g medium MW|21.1g of ready to eat cereal containing 6g total fiber and 3g oat beta glucan with a medium molecular weight
46048453|NCT00949650|Drug|Pemetrexed|Pemetrexed IV given once every 3 weeks for up to 6 cycles
46048454|NCT00949650|Drug|BIBW 2992|BIBW 2992 once daily until progression
46048455|NCT00949650|Drug|Cisplatin|Cisplatin IV given once every 3 weeks for up to 6 cycles
46048456|NCT00908037|Drug|eltrombopag|thrombopoietin receptor agonist
46048457|NCT00908037|Drug|Placebo|placebo for comparison
46048458|NCT00631098|Procedure|venous cannulation|External jugular and cubital vein cannulation
45359868|NCT00981981|Dietary Supplement|4g low MW|28.7g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with low molecular weight
45359869|NCT00878592|Behavioral|Dietary and life style modification|This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of ~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
45359870|NCT00978549|Drug|docetaxel|
45359871|NCT00978549|Drug|steroid therapy|
45359872|NCT00978549|Other|questionnaire administration|
45359873|NCT00978549|Procedure|nausea and vomiting therapy|
45359874|NCT00978549|Procedure|pain therapy|
45359875|NCT00978549|Procedure|quality-of-life assessment|
45359876|NCT00978549|Procedure|standard follow-up care|
45359877|NCT00978549|Radiation|radiation therapy|
45359878|NCT00873444|Device|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
45359879|NCT00873444|Device|Pinnacle™ Acetabular System|A cementless acetabular cup with metal liner for use in total hip replacement
46048459|NCT03082755|Drug|Gabapentin Enacarbil|1 to 2 GEn tablets (300 milligrams per tablet) will be administered once a day in the evening (about 5pm) for 8 weeks.
46048460|NCT03082755|Drug|Placebo Oral Tablet|1 to 2 Placebo Oral Tablets will be administered once a day in the evening (about 5pm) for 8 weeks.
46048461|NCT05332353|Drug|Bacillus Calmette-Guerin|Bacillus Calmette-Guerin (BCG) is immunotherapy to prevent recurrence and progression of non muscle invasive bladder cancer.
46048462|NCT05351853|Dietary Supplement|Omnivore|This study will evaluate effects of plant based diets (vegan and vegetarian). 60 omnivore individuals will be included. 20 of the participants will continue their omnivore diet as control group. 20 of the participants will change their diet to vegetarian, and 20 of them will change their diet to vegan.
45359880|NCT00656084|Drug|gemcitabine|900 mg/m2 on Days 1 and 8 of each 21-day cycle The order of administration will be: Gemzar-->Novantrone-->Rituxan.
45359881|NCT00656084|Drug|mitoxantrone|"Novantrone 10 mg/m2on Day 1. The order of administration will be:~Gemzar-->Novantrone-->Rituxan."
45359882|NCT00656084|Drug|rituximab|"Rituxan 375 mg/m2 on Day 1. The order of administration will be:~Gemzar-->Novantrone-->Rituxan."
45359883|NCT00985335|Other|Neem Based External Application Cream|Apply externally 3-4 times per day
45359884|NCT00982059|Other|Colonoscopic examination|All patients enrolled in the study will undergo a colonoscopic examination and complete a baseline questionnaire.
45359885|NCT00873600|Drug|chemotherapy|
45359886|NCT00873600|Other|medical chart review|
45359887|NCT00873600|Other|questionnaire administration|
45359888|NCT00873600|Procedure|adjuvant therapy|
46048463|NCT05351853|Dietary Supplement|Vegetarian|20 of the participants will change their diet to vegetarian diet. In this group participants will not eat any meat or meat product but can eat/drink milk products, egg and other animal products.
46048464|NCT05351853|Dietary Supplement|Vegan|20 of the participants will change their diet to vegan diet. In this group participants will not eat any kind of animal products.
46048465|NCT05332197|Biological|17D Yellow fever vaccine|This vaccine contains the Rockefeller17D-substrain 204 strain of Yellow fever virus. The exact potency of each batch is released with the certificate of analysis that accompanies each batch and the potency confirmed at time of release closest to internal minimum specification. This vaccine is the same vaccine used by the national EPI program
46048466|NCT00904215|Drug|telmisartan/telmisartan + HCTZ (Hydrochlorothiazide)|
45359889|NCT00873600|Procedure|assessment of therapy complications|
45359890|NCT00873600|Procedure|cognitive assessment|
45359891|NCT00873600|Procedure|psychosocial assessment and care|
45359892|NCT00873600|Procedure|quality-of-life assessment|
45359893|NCT04016948|Device|Probe-based confocal laser endomicroscopy optical biopsy|In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
45359894|NCT04016948|Device|Intra-operative frozen section|In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
45359895|NCT04007211|Device|ABT13107|Dose: 3mL, maximum 10mL
46048467|NCT05234073|Behavioral|SEE Learning Online Training|This intervention includes classes about socioemotional learning theory and practice, topics related to ethics and well-being practices
45359896|NCT04007211|Device|Hyalobarrier|Dose: 10mL
45359897|NCT00881166|Drug|MP-470 + topotecan|Topotecan 1.5 mg/m2 IV infusion over 30 minutes on Days 1-5
45359898|NCT00881166|Drug|MP-470 + docetaxel|Docetaxel 75 mg/m2 IV infusion over 1 hour on Day 1
45687938|NCT04319237|Behavioral|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-3) and the add-on EORTC QLQ Non-Hodgkin's Lymphoma (EORTC QLQ-NHL-HG29) module. All scales range from 0-100, a high scale score represents a higher response level. For example, a high functional score represents a high level of functioning.
46048468|NCT05234073|Behavioral|Waiting list|This group will wait for one month to receive SEE Learning Online Training
46048469|NCT05317689|Drug|Psilocin|17.5mg oral psilocin with psychological support and physiological monitoring
46048470|NCT05317689|Drug|Psilocybin|25mg oral psilocybin with psychological support and physiological monitoring
46048471|NCT05317689|Drug|Sublingual Psilocin|2.18mg - 4.36mg sublingual psilocin with psychological support and physiological monitoring
46048472|NCT03026127|Behavioral|Cognitive Reappraisal Intervention for Suicide Prevention|Cognitive Reappraisal Intervention for Suicide Prevention, or CRISP, is a psychosocial intervention aimed to reduce suicide risk in middle-aged and older adults who have been hospitalized for suicidal ideation or suicide attempt. CRISP offers a combination of emotion regulation techniques, including changing the subject's perspective or the way he/she thinks to improve emotion reactions. Additional strategies taught include the provision of environmental adaptation tools (notes, checklists, calendars, etc), phone calls, and a tablet application called WellPATH.
46048473|NCT03026127|Behavioral|Supportive Therapy|ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors
45359899|NCT00881166|Drug|MP-470 + erlotinib|150 mg PO once daily at least 1 hour before or 2 hours after eating
45359900|NCT00881166|Drug|MP-470 + paclitaxel/carboplatin|Paclitaxel 200 mg/m2 IV infusion over 3 hours followed by carboplatin IV infusion over 1 hour to a target AUC of 6 mg∙min/mL on Day 1
45359901|NCT00881166|Drug|MP-470 + carboplatin/etoposide|Carboplatin IV infusion over 1 hour to target AUC of 5 mg min/mL on Day 1 followed by etoposide 100 mg/m2 IV infusion over 2 hours on Days 1-3
45359902|NCT00804752|Drug|Adding vitamin D|Adding 1000IU/Vitamin D daily
45359903|NCT00804752|Drug|Vitamin D|Addition of 1000IU/day Vitamin D
45359904|NCT05225766|Other|bupivacaine|used for peripheral block
45359905|NCT00804830|Drug|Bevacizumab|Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w
45359906|NCT00982215|Drug|Kinetics of plasma concentrations of paracetamol|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
45359907|NCT00982215|Drug|Placebo|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
45359908|NCT00873678|Biological|Whole blood sample|Whole blood sample (10 ml)
46048474|NCT03015753|Behavioral|Tai Chi training|The 12-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 32-short form Yang-style Tai Chi Chuan will be adopted. The instructor-led sessions will be operated by qualified Tai Chi masters. The training activity will be delivered in group. The group size is 15 to 18 persons.
46048475|NCT03015753|Other|Waiting list control group|At the end of the trial, participants in this arm will be offered Tai Chi training similar as Tai Chi training (TC) group.
45359909|NCT00798044|Behavioral|Other: quality improvement feedback system|Surveys patients regarding treatment experiences.
46048476|NCT05166915|Device|UVA Light Emitting Catheter|Experimental Device intended to eliminate microorganisms using UV-A light, thereby reducing the viral burden of SARS-CoV-2
45359910|NCT00798044|Behavioral|Patient Feedback|Weekly feedback reports provided to counselors
45359911|NCT00978705|Drug|Autologous cultured keratinocyte cell|3x10^7 cell/ vial
45359912|NCT00805922|Other|No treatment given|Capillary or venous blood will be drawn for analysing HbA1c.
45359913|NCT00978783|Device|Passy Muir Valve|The Passy Muir Valve was fixed on the tracheostomy tube
45359914|NCT00978783|Device|Positive end expiratory pressure|5 cm H2O PEEP was adjusted
46048477|NCT05166915|Device|Sham Control Catheter|Sham Control Device
45359915|NCT00982293|Device|Resonator device|Low level electromagnetic fields for whole body immersion, 3 times weekly for 13 weeks (39) sessions of approximately 11/2 hours each.
45359916|NCT00982293|Device|Resonator device - sham|"Treatment, 3 times weekly for 13 weeks (39) sessions - device will not be on"
45359917|NCT02553278|Device|VelaShape device|Modified VelaShape radiofrequency device for non invasive fat reduction treatment.
45359918|NCT02553278|Device|Contour I V3 device|Contour I V3 device are non invasive for fat reduction.
45359919|NCT00613938|Drug|Tapentadol (CG5503)|50mg capsule q4-6 hrs for 3 days
45359920|NCT00613938|Drug|Tapentadol (CG5503)|75mg capsule q4-6 hrs for 3 days
45359921|NCT00613938|Drug|oxycodone|10mg capsule q4-6 hrs for 3 days
45359922|NCT00613938|Drug|placebo|1 capsule q4-6 hrs for 3 days
45359923|NCT00978861|Drug|Hydrogen Peroxide|Whitening product syringe type
45359924|NCT00805064|Drug|triamcinolone and bevacizumab|
45359925|NCT04007445|Behavioral|Formally Directed Group (Exercise Group)|This group will receive a 12-week exercise intervention that will educate and support the person's ability to exercise. Working with a trainer, the participant will attend a 12-week (3 x week) exercise program that has been personalized to their goals. Each session will include warm-up, stretching, cardiovascular exercises, strength exercises, and cool-down. Each session will be 1-2 hours in duration. The participants may wear accelerometers and heart rate monitors to help determine the level of intensity of the exercises, as they should be performing at least 150 minutes of moderate to vigorous exercise each week. By the end of the 12-week program, the goal is for participants to guide their own exercise regimens.
45359926|NCT04007445|Other|Self-Directed Group (Control Group)|This group will receive a 1-hour education session during which they will learn about the National Council on Health, Physical Activity and Disability (NCHPAD) website, an information and resource center on health promotion for people with disabilities. During the session participants will be given an overview of the website and asked to find three resources they find of interest. Their strength and fitness will also be assessed by completing a 1-rep max test. The participants will then be asked to maintain their regular physical activity for the next 12 weeks and complete a weekly physical activity log to track their exercise participation. A staff member will phone each person every week for the 12-week period and have the participant report his or her physical activity during the week.
45359927|NCT00881244|Drug|AS1411|I.v. 4-7 days, 1-40 mg/kg/day
45359928|NCT00655928|Drug|N-acetylcysteine|N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively
45359929|NCT00655928|Drug|0.9% saline|0.9% saline 1 litre intravenous over 12 hours pre-operatively
45359930|NCT04038762|Procedure|cuff deflation-inflation -deflation method|Nasotracheal intubation placed with video-laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps
45359931|NCT00805220|Other|Nordic Walking|Walking training with and without poles will be twice a week. The sessions last 20 minutes each and consist of walking, stretching and mobility exercises. This will last 8 weeks in a total of 16 sessions. A therapist will closely monitor your exercises and modify them according to your needs and comfort
45359932|NCT05224908|Device|EOS|pelvimetry by EOS in standing and sitting position
45359933|NCT00798200|Other|Exercise program|All exercise programs will include endurance and strength exercises.
45359934|NCT00873756|Drug|FOLFOX regimen|Intravenous repeating dose
45359935|NCT00873756|Drug|bevacizumab|Intravenous repeating dose
45359936|NCT00873756|Drug|dulanermin|Intravenous repeating dose
45359937|NCT00798278|Drug|Urokinase|Chest tube with intrapleural urokinase infusion for 3 days
45359938|NCT00798278|Procedure|Video-Assisted Thoracoscopic|Video-Assisted Thoracoscopic decortication
45359939|NCT00873834|Drug|fluoxetine|"Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized"
45359940|NCT00873834|Drug|placebo|Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
45479773|NCT03794219|Other|Kinesio Tape|To all patients,750 mg/day oral naproxen is administered for 10 days. Additionally, in intervention group kinesio tape is applied 3 times a week for 2 weeks with a total of 6 sessions.
45479774|NCT03794219|Drug|oral naproxen|750 mg/day oral naproxen is administered for 10 days.
45844702|NCT03239808|Procedure|Conventional haemodialysis|It is controlled through usual clinical practice, based on starting the HD treatment with three sessions per week (control group).
45359941|NCT00873990|Other|Total etch bonding agent (5th generation)|"Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch and rinse bonding system (two step bonding agent) will be treated with 37% phosphoric acid (Total Etch Ivoclar Vivadent) for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved.~Adper Single Bond 2 (3M ESPE) will be applied to occlusal fissure using applicator brushes followed by curing for 10 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds."
45359942|NCT00873990|Other|Self etch (7th generation ) bonding agent|For teeth selected for application of self etching bonding agent (Adper Easy Bond 3 M), the bonding agent will be applied to occlusal surface with microbrushes and will be left undisturbed for 20 seconds followed by air drying for 5 seconds and then will be light cured for 10 seconds. Fissure sealant (Clinpro 3M ESPE) will be applied in a similar manner as for etch and rinse group and light cured.
45359943|NCT00655850|Drug|Paclitaxel|"Prior to receiving paclitaxel, all patients will receive the following premedications one hour before the infusion:~Dexamethasone 20mg, intravenously (IV)~Diphenhydramine 50 mg IV~Ranitidine 50 mg IV~Paclitaxel will be administered after the gemcitabine infusion as a 1 hour (IV) infusion.~The initial dose of paclitaxel is 80 mg/m2/weekly for 3 out of 4 weeks (Day 1, 8, 15)~Paclitaxel Dose Levels:~Dose Level 1 ________80 mg/m2/weekly~Dose Level -1 ________70 mg/m2/weekly"
45359944|NCT00655850|Drug|Gemcitabine|"Premedication~Prophylactic antiemetics: 5-HT3-receptor antagonist prior to infusion with gemcitabine.~Prior to receiving paclitaxel chemotherapy~Gemcitabine will be given at the initial dose of 200mg/m2/week (Dose Level 1) for 3 out of 4 weeks (Day 1, 8, 15), as a 30 minute (IV) infusion.~The dose of gemcitabine can be escalated to 300mg/m2/weekly (Dose Level 2) after the first cycle of treatment if no significant toxicity is experienced.~Gemcitabine Dose Levels:~Dose Level 2 ________300 mg/m2/weekly~Dose Level 1 ________200 mg/m2/weekly~Dose Level -1 ________150 mg/m2/weekly"
45359945|NCT00655850|Biological|Avastin|"The dose of Avastin is 10 mg/kg IV every 2 weeks~It will be administered following the administration of chemotherapy~The first infusion will be administered over 90 minutes; if well tolerated, the second and subsequent doses will be administered as a 60-minute and 30-minute infusion, respectively.~It should not be administered or mixed with dextrose solutions."
45359946|NCT00881322|Dietary Supplement|BC-130 (Gas Defense)|"Product Dosing:~Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)~Gas Defense Serving Size: 1 tablet Active Ingredients: B. Coagulans, Enzyme Blend (Cellulase - Trichoderma longibrachiatum, Cellulase - Aspergillus niger, Hemicellulase, Alpha Galactosidase, Invertase) Inactive Ingredients: vegetable capsule, Magnesium Stearate, Silicon Dioxide, Maltodextrin Contains: Wheat, Fish."
45359947|NCT00881322|Dietary Supplement|Placebo|"Product Dosing:~Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)~Placebo - matched in size and color to the active product Inactive Ingredients: microcrystalline cellulose, FD&C yellow #5 Lake, FD&C blue #1 Lake, FD&C red #46 Lake and vegetable capsule"
45359948|NCT02553434|Device|Pigtail catheter|Insertion of pigtail catheter
45359949|NCT04038918|Other|progressive muscle relaxation exercise|In addition to standard postoperative rehabilitation, intervention group will receive PMR exercises focusing on reduce overall body tension, anxiety. The intervention group will perform the PMR exercise in accompanying with a qualified physiotherapist for postoperative 3 days (2 times/day; along 30 minutes for one session).
45359950|NCT04038918|Other|standard postoperative physiotherapy program|After surgery, patients will receive standard postoperative rehabilitation program including active-assistive and active range of motion exercises, isometric and isotonic strengthening exercises, gait training and transfer training.
45359951|NCT02553122|Drug|Evicel|Fibrant Sealant to apply on the soft tissue to control intra-operative blood loss
45359952|NCT02553122|Device|tourniquet|A tourniquet is applied to the thigh to stop/ decrease blood flow
46048478|NCT02664207|Procedure|Open Fetal Repair of Myelomeningocele|Fetal repair of myelomeningocele in women with additional medical factors that would have excluded them from this treatment under the MOMs trial inclusion/exclusion criteria
45359953|NCT00874068|Other|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
45687939|NCT04319237|Behavioral|Quality of Life (EQ-5D-5L) Questionnaire|The EQ-5D-5L questionnaire is a self assessed quality of life questionnaire. The scale measures quality of life on a 5 component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The rater selects a number between 1-100 to describe the condition of their health, 100 being the best imaginable.
45687940|NCT04319237|Behavioral|PROMIS Cognitive Function 4a Questionnaire|The PROMIS measures function, symptoms, behavior and feelings.
45844703|NCT03206814|Other|Usual care|Antihypertensive therapy is adjusted every 3 months on the basis of office blood pressure values.
46048479|NCT05273541|Biological|Coronavirus vaccination|Patients in this trial need to accept a prime-boost vaccination against SARS-CoV-2 after 6 to 8 months of the first vaccination
46048480|NCT05190549|Drug|CVA regimen bridging to HSCT|The enrolled patients will be firstly given CVA bridging regimen (cladribine 5mg/m2/ day for 3 days, venetoclax 400mg/day for 7 days, and cytarabine 20mg q12h for 7 days). Then, preconditioning regimen will be administrated, and allogeneic hematopoietic stem cell transplantation would be performed 2 days after the end of preconditioning regimen.
46048481|NCT05293665|Biological|UB-612|UB-612 (100µg), 0.5mL suspension, intramuscular injection
46048482|NCT05293665|Biological|BNT162b2 vaccine|BNT162b2 vaccine (30µg), 0.3mL suspension, intramuscular injection
46048483|NCT05293665|Biological|ChAdOx1-S vaccine|ChAdOx1-S vaccine, 0.5 mL suspension with approximately 5.0 × 10˄10 viral particles, intramuscular injection
45359954|NCT00874068|Other|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
45359955|NCT00805298|Drug|methylprednisolone|32 mg before surgery, 16 mg twice daily the day after surgery
45359956|NCT00805298|Drug|placebo|two tablets before surgery, one tablet twice daily on the day after surgery
45359957|NCT00805298|Drug|xyloplyin adrenalin|lidocaine local anaesthetic lidocaine 20 mg/ml, adrenalin 12,5 µg/ml maximum dosage 10 ml.
45359958|NCT00805298|Drug|marcain adrenalin|bupivacaine local anaesthetic bupivacaine 5 mg /ml, adrenaline 5 µg/ml maximum dosage 10 ml
45359959|NCT00726323|Drug|foretinib (formerly GSK1363089 or XL880)|treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule
45359960|NCT00881400|Drug|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
45359961|NCT00881400|Drug|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)|
45359962|NCT00805376|Drug|DNX-2401|Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
45359963|NCT00805376|Procedure|Tumor Removal|Surgical Tumor Resection
46048484|NCT05293665|Biological|Sinopharm BIBP|Sinopharm BIBP COVID-19 vaccine, 0.5mL (4µg) suspension, intramuscular injection
45359964|NCT00246571|Drug|SU011248|SU011248 capsules administered orally, daily in a continuous regimen, 3-week cycles, starting dose of 37.5 mg daily. 1-week treatment rests and dose reductions allowed for dose-limiting toxicity. Dose escalate SU011248 to 50-mg daily if minimal toxicities . Study will continue until disease progression. Patients randomized to or crossed over to SU011248 may continue beyond the time of Response Evaluation Criterion in Solid Tumors (RECIST) -defined progression at the discretion of the investigator in the case of clinical benefit.
45359965|NCT00246571|Drug|Chemotherapy|"The choice of chemotherapy will be at the discretion of the investigator within the limits outlined below.~Capecitabine - 1000-1250 mg/m2 twice daily days 1-14 every 3 weeks~Vinorelbine - 25-30 mg/m2 rapid intravenous infusion or 60-80 mg/m2 oral weekly, expressed in 3-week cycles~Docetaxel - 75-100 mg/m2 every 3 weeks~Paclitaxel - 175-200 mg/m2 every 3 weeks~Paclitaxel - 80-90 mg/m2 weekly, in a continuous regimen expressed in 3-week cycles or administration of 3 weeks of treatment followed by 1 week of rest. Use of the 3/1 regimen will require extra care in scheduling disease assessments.~Gemcitabine - 800-1250 mg/m2 Days 1 and 8 every 3 weeks Study will continue until disease progression or it is in the best interest of the patient to discontinue based on achievement of maximum benefit or tolerability issues. At the time of progression patients randomized to chemotherapy will be offered crossover to single agent SU011248."
45359966|NCT00805454|Drug|OPC-34712|Single oral dose, 0.5 to 25 mg
45359967|NCT02553356|Drug|PT2385|
45359968|NCT00805610|Biological|Hepatocyte Transplantation|Briefly, prepared hepatocytes from a single donor will be transplanted into the liver via intraportal or intrasplenic routes.
45359969|NCT00798356|Other|Yoga training|Yoga training for 12 weeks
45359970|NCT00734591|Drug|Exubera|Subjects who had been treated with Exubera in a prior Exubera controlled trial. Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
45844704|NCT03206814|Other|POST-strategy|Antihypertensive therapy is adjusted every 15 days on the basis of home blood pressure values.
46048485|NCT03013257|Device|Echopulse|Replacing HIFU for the Graves' disease patients who traditionally have RAI to remission
46048486|NCT00905307|Drug|OPC-34712|oral, once daily
46048487|NCT00905307|Drug|Placebo|Placebo
46048488|NCT00905307|Drug|Aripiprazole|oral, once daily
46048489|NCT02988453|Other|MBT-CD|MBT-CD is a disorder-specific modification of MBT, initially developed for patients with Borderline Personality Disorder. It is a manualized and psychodynamically oriented psychotherapy with the aim to increase the mentalization capacity of adolescents in close relationships. The therapy consists of 2 psychoeducational group sessions, 30 individual therapy sessions and 10 family sessions. The average duration of therapy is 6 months.
45359971|NCT00734591|Other|Randomized diabetes therapy|"Subjects who had been treated with a comparator (other diabetes treatment including one or more of: subcutaneous insulin, sulfonylureas, biguanides, or thiazolinediones) in a prior Exubera controlled trial.~Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice)."
45359972|NCT02554058|Device|Cycling and Mechanical stimulation|Cycling and Mechanical stimulation : 30 minute cycling training, 3 times a week for 8 weeks.
45359973|NCT00798512|Device|Carotid artery stenting|"The MO.MA is a cerebral protection catheter based on the proximal flow blockage concept which is achieved by endovascular clamping of Common Carotid Artery (CCA) and External Carotid Artery (ECA). The MO.MA proximal flow blockage cerebral protection device is indicated to be used in patients eligible for carotid angioplasty and/or the carotid bifurcation and is aimed to prevent brain embolism during the stenting procedure.~For the purpose of this study the Cristallo Ideale™ Carotid Stent System (Invatec S.R.L. Roncadelle, Italy) will be exclusively used. Cristallo Ideale™ consists of a carotid dedicated self-expanding stent pre-mounted on a rapid exchange delivery catheter. The stent platform is made of a Nitinol alloy and characterized by a hybrid design with closed cell in the central zone and open cell in both end zones (proximal and distal)."
45359974|NCT00798668|Dietary Supplement|Liquid Supplements|Liquid supplement that provides 12.5% of the subjects total energy requirement.
45359975|NCT00798668|Dietary Supplement|Solid Supplement|Solid supplement that provides 12.5% of the subjects total energy requirement.
45359976|NCT02553044|Dietary Supplement|Cholecalciferol (Vitamin D3)|Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.
45359977|NCT00569270|Drug|Placebo|Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
45359978|NCT00545103|Drug|SPD476, MMX™ mesalazine, 1.2g extended release tablet|SPD476 1.2g administered Once Daily (QD)
45359979|NCT00545103|Drug|SPD476, MMX™ mesalazine, 2.4g extended release tablet|SPD476 2.4g administered Once Daily (QD)
45359980|NCT00545103|Drug|SPD476, MMX™ mesalazine, 4.8g extended release tablet|SPD476 4.8g administered Once Daily (QD)
45359981|NCT00545103|Drug|Placebo|Placebo administered Once Daily (QD)
45359982|NCT00586157|Drug|Methylphenidate Transdermal System|Medication skin patch titrated to 20mg (at 10 mg and 20 mg doses)
46048490|NCT00907881|Drug|Sulfonylurea|The dose and frequency of administration of study drug (sulfonylurea) was decided by the investigator according to the individual need of each participant.
45687941|NCT04319237|Behavioral|Comprehensive Score for Financial Toxicity (COST) measure|The COST is a questionnaire made up of 11 statements around topics including costs, concerns and resources and is designed to measure financial toxicity. The user answers questions about their concern over finances numbered from 0-4, with 0 being not at all and 4 being very much.
46048491|NCT00904917|Behavioral|Prevention Intervention Project|Eight 1-hour sessions focused on psychoeducation, coping with stress, and cognitive-behavioral strategies. The sessions were tailored as required to meet the clinical and cultural needs of each family; other family members, such as fathers, spouses, and grandparents, were invited to participate in the intervention.
46048492|NCT00904917|Behavioral|Psychoeducation|Two 1-hour sessions focusing on psychoeducation about depression and its impact on children and the family.
45359983|NCT00586157|Drug|Placebo|Placebo skin patch titrated to 20mg (at 10 mg and 20 mg doses)
45359984|NCT00809432|Device|Face mask (Dust Respirator)|Subjects to wear a simple face mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask as much as possible when indoors and at all times when outdoors.
45359985|NCT00809432|Other|No Face mask|Subjects will not wear a face mask to reduce their personal exposure to air pollution
45687942|NCT04317755|Behavioral|AdhaFULL body image comics|The comics were co-created with the expertise of four stakeholders: the investigators, UNICEF, BBC Media Action, and the Dove Self-Esteem Project. There are six different comics, which target issues relating to gender stereotypes and appearance concerns amongst adolescents in rural India. Based on 'Dove Confident Me', each comic tells a story which targets a specific established risk factor for body dissatisfaction. Specifically, they focus on gender prejudice (Comic 1), societal appearance ideals (Comic 2), media literacy (Comic 3), appearance comparisons (Comic 4), appearance-related conversations and teasing (Comic 5), and promoting 'body activism' (Comic 6). In each session, students will read the respective comic as a class. At the end of each comic, the teacher will facilitate one or two activities with the students based on the key learnings from the comics. These activities will encourage students to think critically about what they have read and consolidate their learning.
45844705|NCT03024996|Drug|Atezolizumab|Atezolizumab 1200 mg IV infusion q3w
45359986|NCT02595125|Device|IUD|copper IUD or levonogestrel IUD insert by the conventional technique or by direct technique
45359987|NCT02552654|Behavioral|Stress Film|Film scene with severe physical and sexual violence.
45359988|NCT02552654|Drug|Hydrocortisone|10mg
45359989|NCT02552654|Drug|Placebo|
45359990|NCT04045574|Procedure|The 1T1T concept versus conventional implant loading protocol|Implant placement followed by either a conventional or a delayed loading of a PICN screw-retained crown.
45359991|NCT00809666|Device|Automated blood pressure recording device Omron HEM 705CP|All subsequent blood pressure recordings done using the automated device
45359992|NCT00978939|Other|Standard Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid every other day
45359993|NCT00978939|Other|Aggressive Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid daily
45359994|NCT00809744|Drug|cholecalciferol|capsules, 20 000IU, twice a week, 6 months duration
45359995|NCT00809822|Drug|NPB-01|Intravenous immunoglobulin
45359996|NCT00809822|Drug|Placebo|Physiological saline
45359997|NCT04006587|Device|incentive spirometer|patients were instructed how to use the IS in a seated or semi-seated position, and to maintain sustained maximal inspiration for 3-5 seconds before exhalation, ten times per hour, and for at least eight hours a day.
45359998|NCT00246337|Drug|Comparator: Placebo|Placebo to match assigned treatment arm; one orally-administered dose
45359999|NCT00246337|Drug|MK0974|MK0974 25 mg; one orally-administered dose
45360000|NCT00246337|Drug|MK0974|MK0974 50 mg; one orally-administered dose
45360001|NCT00246337|Drug|MK0974|MK0974 100 mg; one orally-administered dose
45360002|NCT00246337|Drug|MK0974|MK0974 200 mg; one orally-administered dose
45360003|NCT00246337|Drug|MK0974|MK0974 300 mg; one orally-administered dose
45360004|NCT00246337|Drug|MK0974|MK0974 400 mg; one orally-administered dose
46048493|NCT04735653|Behavioral|Personalized Glaucoma Coaching|This is a six-month personalized glaucoma coaching program where a coach trained in motivational interviewing (MI)-based counseling uses a web based tool that generates tailored education to help glaucoma patients identify their barriers to optimal medication adherence and explore potential solutions during three in-person coaching sessions. The coach provides between-session support through four phone calls, with two phone calls between the first and second session and one phone call after each subsequent session. Participants can elect to receive any of the following type of alarm when a dose of medication is due: visual or audible alert or automated text or phone call reminder. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
46048494|NCT04735653|Behavioral|Enhanced Standard care|Participants will receive non-tailored educational materials about glaucoma from leading sources by mail every 2 months for a total of 3 mailings during the 6-month study period. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
46048495|NCT05253339|Procedure|target-controlled infusion (one of the administration methods)|a method of administering cefoxitin while maintaining a constant target concentration.
46048496|NCT05253339|Procedure|Standard administration method|Standard method of administering cefoxitin in the current clinical setting
46048497|NCT00904839|Drug|BIBF 1120|BIBF 1120 100 and 150 mg capsules
46048498|NCT00904839|Drug|BIBF 1120|BIBF 1120 100 and 150 mg capsules
46048499|NCT00904839|Drug|mFolfox|standard i.v chemotherapy
45360005|NCT00246337|Drug|MK0974|MK0974 600 mg; one orally-administered dose
45360006|NCT00246337|Drug|Rizatriptan|Rizatriptan 10 mg; one orally-administered dose
45360007|NCT02552576|Biological|Voncento|Human coagulation VWF / coagulation factor VIII (FVIII) complex concentrate
45360008|NCT00809900|Dietary Supplement|Experimental|Administration of of 480 mL cranberry juice
45360009|NCT05012943|Biological|ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine|ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine
45360010|NCT05012943|Other|Placebo (normal saline)|Normal saline with the same volume as of ARCT-154
45360011|NCT05012943|Biological|Astra Zeneca COVID-19 vaccine|Astra Zeneca COVID-19 vaccine (ChAdOx1 nCoV-19)
45360012|NCT01581853|Drug|Lopinavir/ritonavir 800 mg / 200mg|Lopinavir/ritonavir 800 mg / 200mg will be change from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
45360013|NCT02594969|Other|Bleach Bath and Moisturizers|All subjects will have one forearm in a bleach bath and the other forearm in a water bath for 10 minutes. Following the bath, skin barrier function will be evaluated. Secondly, moisturizers will be applied to the arms and the skin barrier will be evaluated overtime.
45360014|NCT00798746|Behavioral|Telephone Questionnaire|Ten questions regarding symptoms of reflux
45360015|NCT01070641|Drug|Carvedilol|Carvedilol 12.5mg QD
45360016|NCT01070641|Procedure|Esophageal variceal band ligation|Each patient will undergo for variceal band ligation after 3 weeks till the eradication of varices
45360017|NCT00982449|Other|FIAU-PET-CT-2|1-3 days after chemotherapy, subject get I-FIAU 2 mCi, then have FIAU-PET-CT done 2 - 4 hours after I-FIAU
45360018|NCT00982449|Other|FIAU-PET-CT-4|1-3 days after any chemotherapy that may activate viral TK, 4 mCi, rather than 2 mCi, of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT
45360019|NCT02593721|Procedure|Median Nerve Neural Mobilization|Non-surgical non-invasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
45360020|NCT02593721|Drug|Ibuprofen|The active comparator group received an oral Ibuprofen treatment. The starting dose was of 400 mg/day and it was increased to a maximum of 1200 mg/day divided in 3 oral intakes every 8 hours depending on patient tolerance.The intervention was applied during a period of 6 weeks.
45479775|NCT01297764|Drug|Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone|"Dose Escalation Schema Cohort Carfilzomib (mg/m2) Lenalidomide (mg) Vorinostat (mg) Dexamethasone (mg)~15 15 300 40~20 15 300 40~20 25 300 40~20/27* 25 300 40~20/27* 25 400 40"
45479776|NCT03327688|Diagnostic Test|Point-of-care ultrasound|Point-of-care ultrasound performed by an emergency physician
45479777|NCT01304771|Biological|Synbiotic AKSB|AKSB is a novel synbiotic that contains a probiotic bacterium (Enterococcus faecium, microencapsulated SF68 or Ventrux ME 30), a probiotic yeast (Saccharomyces cerevisiae, Lynside® Pro-Lay 1), and a prebiotic (fructo-oligosaccharide [FOS], NutraFlora®).
45479778|NCT01334034|Drug|NNC 0123-0000-0338|Subjects will be randomised to receive a single dose of NNC 0123-0000-0338 (tablet), at 7 escalating dose levels. Progression to next dose level will be based on a safety evaluation.
45844706|NCT03024996|Other|Placebo|Placebo matching to atezolizumab q3w
46048500|NCT00904839|Drug|Bevacizumab|100 mg/Kg solution , IV infusion
46048501|NCT00904839|Drug|mFolfox 6|IV standard chemotherapy
46048502|NCT00904839|Drug|bevacizumab|100 mg/4 ml solution
46048503|NCT02505711|Behavioral|Homestead Food Production program|Training and support for vegetable gardening and poultry rearing, and education on young child nutrition, hygiene and health topics, in women's groups, as designed by the international non-governmental organization (NGO) Helen Keller International (HKI).
46048504|NCT04724265|Biological|collection of sample of perilymphatic fluid during cochlear implantation|collection of sample of perilymphatic fluid during cochlear implantation and to analyse it with a CMV polymerised-chain-reaction to evaluate the involvement of CMV in hearing loss.
46048505|NCT02923011|Device|MRgFUS|Magnetic resonance-guided focused ultrasound ablation of osteoid osteoma
46048506|NCT02923011|Device|CTgRFA|Computed tomography-guided radiofrequency ablation of osteoid osteoma
46048507|NCT04985955|Drug|Tofacitinib|Tofacitinib tablet will be administered orally.
46048508|NCT02821923|Dietary Supplement|E967-Xylitol|24g xylitol/d
46048509|NCT02821923|Dietary Supplement|E968-Erythritol|36g erythritol/d
46048510|NCT04713813|Other|Therapeutic exercise program via hippotherapy mechanical stimulator|Patients were planned to complete hippotherapy exercises sessions 3 times a week for 12 weeks, each lasting 35 minutes per sessions.
46048511|NCT04713813|Other|Therapeutic home exercise program|Patients were planned to complete home exercises sessions 3 times a week for 12 weeks, each lasting 35 minutes per sessions.
46048512|NCT02850549|Other|Procedure: physical therapy and Neck Pain Classification|Physical therapists treated patients in phase one as they usually do and in phase two were trained to follow a neck classification and matched intervention system.
46048513|NCT00903357|Drug|Montelukast first, then placebo|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
46048514|NCT00903357|Drug|Placebo first, then Montelukast|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
46048515|NCT02446665|Device|MR Elastography (MRE) and FibroScan|
46048516|NCT02796573|Behavioral|cognitive behavioural therapy|
46048517|NCT05119023|Behavioral|Observational Learning|All participants will complete a computer-based serial response time task intended to measure observational (implicit) learning ability. In this task, participants look at a dot move from one of 4 positions on a computer screen. Unbeknownst to participants, dot movement followed a 12-movement pattern for most experimental blocks. Eye-tracking data is collected and eye fixations within regions of interest trigger trial advancement. Learning ability is evaluated as a comparison of saccadic response times during sequenced trials relative to pseudorandomized trials.
46048518|NCT05119023|Behavioral|Rule-based Learning|All participants will complete a computer-based rule-based learning task intended to measure rule-based (explicit) learning ability. In this task, participants look at sequences of geometric shapes on a computer screen. Through visuals and verbal instruction, they are taught 5 rules that govern sequences. After learning rules, participants are asked to judge via button press whether novel sequences adhere to rules or not.
46048519|NCT04651725|Other|Exercises|Patients were planned to complete exercise sessions 3 times a week for 12 weeks, each lasting 35 minutes per day.
46048520|NCT04632771|Other|N/A (observational study)|N/A (observational study)
45360021|NCT00798824|Procedure|Indwelling nasogastric tube placement|The premature infant is fed with an indwelling nasogastric tube during feeding transition.
45360022|NCT00798824|Procedure|Intermittent orogastric tube placement|The premature infant is fed with an intermittently placed orogastric tube during feeding transition.
45360023|NCT00798824|Device|Nasogastric tube|Premature infants will be fed with a nasogastric tube in place and their feeding behaviors will be noted till discharge.
45360024|NCT00798824|Device|Oral gastric tube|Premature infants will be fed with intermittent orogastric tube placement and their feeding behaviors will be noted till discharge.
45360025|NCT00798902|Device|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micrograms/cc BVF
45360026|NCT00798902|Other|Iliac crest autograft|autograft
45360027|NCT00979173|Drug|AC480|Subjects will be initiated on AC480 300mg orally BID for 14 (+/-2 days) before surgery. After surgery, subjects will continue to be dosed with AC480 until either disease progression or intolerance, and will be evaluated every other cycle (i.e., every 4 weeks).
45360028|NCT00985647|Drug|Lamivudine (3TC)|"3TC 300mg/150mg participants will receive 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days.~3TC 150mg/300mg participants will receive 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days."
45360029|NCT00806468|Drug|Desmotabs|Desmotabs encapsulated, 0,2 mg once daily for one week, 0,2 mg bid for one week
45360030|NCT00982527|Drug|Placebo|Saline continuous infusion during cardiopulmonary by pass at 1 ml/h
45360031|NCT00982527|Drug|Fenoldopam|Fenoldopam continuous infusion at 1 mcg/kg/min during cardiopulmonary bypass. Infusion preparation is mad in order to match the rate 1 ml/h of placebo infusion.
45360032|NCT00798980|Drug|Mirena (BAY86-5028)|Nulliparous Women
45360033|NCT00243919|Behavioral|Early locomotor training program|The early locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 2 months post-stroke.
45360034|NCT00243919|Behavioral|Late locomotor training program|The late locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 6 months post-stroke.
45360035|NCT00243919|Behavioral|Home Exercise Program|Participants in the early home exercise group will receive a non-specific low intensity exercise program beginning at 2 months post stroke.
45360036|NCT00725621|Biological|Infliximab|Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians.
45360037|NCT00613626|Drug|Cisplatin|Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
46048521|NCT02754063|Device|PbtO2 probes|PbtO2/ICP/CPP-directed therapy according to international recommendations
45360038|NCT00613626|Drug|Etoposide|Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
45360039|NCT00613626|Drug|Placebo|Matched placebo oral daily
45360040|NCT00613626|Drug|ZD6474|ZD6474 100mg oral daily to be continued for the duration of the study.
45360041|NCT00985803|Other|Physical Activity: Cardio training (CT)|"The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.~The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling."
45360042|NCT00985803|Other|Physical Activity: Endurance exercise training (ET)|"The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.~The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling."
45360043|NCT00810056|Other|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
45360044|NCT00810056|Behavioral|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
45360045|NCT00979329|Other|Questionnaires|During the study three questionnaires must repeatedly be completed in by the patients: the BDI (PC) a depression scale, the EORTC-QLQ a quality of life assessment and the CIS20r, a fatigue scale and patients must fill in their medication on a list.
45360046|NCT00810134|Procedure|Thrupass|Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
45360047|NCT00810134|Procedure|Bypass|Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
45360048|NCT04008303|Procedure|Migraine surgery|Surgical decompression of neuromuscular structures causing migraine headaches.
45360049|NCT00806780|Procedure|on table cholangiography|x-ray imaging of common bile duct
46048522|NCT02754063|Other|No PbtO2 probes|ICP/CPP-directed therapy according to international recommendations
46048523|NCT02320929|Procedure|Intraoperative flexor tendon sheath irrigation|
46048524|NCT02320929|Procedure|Postoperative flexor tendon sheath irrigation|
46048525|NCT02749305|Other|Collection of patient-reported outcome measures|Preoperative and postoperative metabolic and bariatric surgery patients will be asked to electronically complete a set of PROMs up to 21 days before surgery and annually on their surgical anniversary they will be asked to complete a postoperative PROM.
46048526|NCT02208765|Device|Stress Single Photon Emission Computed Tomography|
45360050|NCT02592239|Device|Functional brain MRI|Functional brain MRI before and after test meal ingestion
45479779|NCT01334034|Drug|placebo|Subjects will receive a single dose of placebo (tablet), as a comparator to NNC 0123-0000-0338 at all dose levels. Placebo dose remains the same at all dose levels.
46048527|NCT02847351|Dietary Supplement|Arabinoxylan Diet|"19 free-living subjects (16 F/ 3M) attending from one year the Outpatient Obesity Clinic Policlinico S. Matteo were enrolled. All subjects were already reached weight loss and were in a sort of weight steady state. Based on 7-day food diary, a nutritionist composed 19 isocaloric diets, replacing all consumed carbohydrates with normal or AX crackers. The mean carbohydrates intake was 189.5g, with total fiber 20.6g. In AX diet total fiber was 25.3g/day (20.6 plus 4.68g of AX).~Height, weight, waist circumference were obtained at time 0, at week 4 and 8. At every time were collected blood samples for glucose, insulin, total cholesterol, HDL-chol., tryglicerides, plasma acyl and des-acyl ghrelin. Glucose and insulin were , also collected 2 h after a 75 g oral glucose tolerance test (OGTT)."
45360051|NCT02592239|Dietary Supplement|A warm ham and cheese sandwich and a 200 ml fruit juice|
45360052|NCT00874146|Genetic|Fluorescent in-situ hybridization (FISH)|Dual color FISH test to assess ratio of HER2/neu amplification
45360053|NCT00982605|Procedure|EBUS_TBNA|EBUS during bronchoscopy
45360054|NCT00874224|Procedure|laparoscopic left lateral hepatic sectionectomy|laparoscopic left lateral hepatic sectionectomy
45360055|NCT00874224|Procedure|open left lateral hepatic sectionectomy|open left lateral hepatic sectionectomy
45360056|NCT00725543|Biological|Infliximab|Remicade induction therapy consists of 3 infusions given at weeks 0, 2, and 6 in specialized centers. Maintenance therapy will consist of a maximum of 6 infusions given in doses and intervals due to discretion of physicians.
45360057|NCT00881478|Other|Nutrition counseling + portion control tool|Nutrition counseling with registered dietician in addition to teaching about how use of a portion control tool
45360058|NCT00881478|Other|Nutrition counseling|Nutrition counseling with registered dietician
45360059|NCT00985881|Device|Custom prosthetic socket with mechanical vibrators (stochastic resonance)|Application of mechanically-induced sub-threshold vibration applied to the amputee's residual limb using a custom prosthetic limb system
45360060|NCT00985881|Device|Conventional prosthetic socket (current clinical practice)|No sub-threshold vibration applied to residual limb. Amputee wears conventional prosthetic socket.
45360061|NCT00917813|Drug|KD-247|Cohort 1 - 4 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 2 - 8 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 3 - 16 mg/kg KD-247 IV on Days 1, 8, and 15
45360062|NCT00917813|Drug|Physiological saline|Cohort 1 - Physiological saline IV on Days 1, 8, and 15; Cohort 2 - Physiological saline IV on Days 1, 8, and 15; Cohort 3 - Physiological saline IV on Days 1, 8, and 15
45360063|NCT00239005|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
45360064|NCT00239005|Drug|Mycophenolate Mofetil (MMF)|
45360065|NCT02594891|Device|endoscopic retrograde biliary drainage|A 8.5 F plastic stent with proximal flap （XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
45360066|NCT02594891|Device|endoscopic nasobiliary drainage|A nose bile duct（XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
45360067|NCT00616434|Drug|BG9418 (Interferon beta-1a)|Avonex IM injection, self-administered per protocol
45360068|NCT00616434|Drug|Placebo|Placebo IM injection, self-administered per protocol.
45360069|NCT01581697|Dietary Supplement|Oat bran|
45360070|NCT00652340|Drug|apricoxib/erlotinib|"apricoxib: 100 mg tablets, 400mg/day~erlotinib: per package insert"
45360071|NCT00652340|Drug|erlotinib/placebo|"erlotinib: per package insert~placebo: 100 mg tablets, 400 mg/day"
45360072|NCT00257725|Drug|B-MPH|Dosage form is a 20 mg capsule to be given once daily in the morning for 30 days
45360073|NCT00544869|Drug|OPC-41061 （Tolvaptan)|15-30mg/day,daily for 14days
45360074|NCT00725075|Drug|MK-8435 (Org 25935) 4-8 mg|Administered orally 2 times a day (BID) for a final concentration of 8-16 mg/day
45360075|NCT00725075|Drug|Placebo|Matching placebo for MK-8435 (Org 25935) administered orally BID
45360076|NCT00725075|Drug|MK-8435 (Org 25935) 12-16 mg|Administered orally BID for a final concentration of 24-32 mg/day
45360077|NCT00874302|Drug|Proellex|One 25mg capsule taken orally once every day.
45360078|NCT00874302|Drug|Proellex|Two 25mg capsules Proellex (50mg) taken orally once every day
45360079|NCT02593643|Drug|Ketamine|
45360080|NCT02593643|Drug|Midazolam|
45498124|NCT03681522|Procedure|Periprostatic nerve block|Injections of 2.5 mL of 2% lidocaine were made to the neurovascular bundles at the junction of the prostate-bladder-seminal vesicle on each side.
45360081|NCT02593643|Other|Treatment as usual (TAU)|TAU includes any current treatment a patient is receiving from their primary care practitioner. In the major depressive disorder (MDD) group, TAU may include a newly initiated or longstanding antidepressant. In the bipolar depression (BD) group, TAU may include a mood stabilizer such as lithium or valproate that is a first or second line agent as per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines (Yatham et al., 2013).
45479780|NCT01334034|Drug|insulin glargine|As an open label active comparator, a single dose of insulin glargine will be administered subcutaneously (under the skin), at all dose levels. Insulin glargine dose remains the same at all dose levels.
45687943|NCT04315545|Diagnostic Test|meal tolerance test|In addition to the standard oral glucose tolerance (which is normally performed between 24-28 weeks of pregnancy), is used to test the metabolic resilience capacity of glucose, we will provide our participants with a different diagnostic tool named 'meal tolerance test' in an earlier stage of pregnancy (12-16 weeks), mid pregnancy (24-28 weeks) and 3 months postpartum.
45687944|NCT04313712|Drug|ibogaine with magnesium treatment|Participants will receive magnesium sulfate intravenously and ibogaine orally.
45360082|NCT05261087|Other|No intervention|Individuals will not receive any interventions
45360083|NCT00881556|Drug|Palifermin|60 mcg/kg/day for 6 days
45360084|NCT00881556|Drug|Fludarabine|30 mg/m2 IV x 1 for 6 days
45360085|NCT00881556|Drug|Busulfan|4 mg/kg/day IV divided BID for 4 days
45360086|NCT00881556|Drug|Lorazepam|0.02-0.05 mg/kg for 5 days
45479781|NCT03050060|Drug|Atezolizumab|Given IV
45479782|NCT03050060|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
45479783|NCT03050060|Other|Laboratory Biomarker Analysis|Correlative studies
45479784|NCT03050060|Drug|Nelfinavir Mesylate|Given PO
45360087|NCT00881556|Drug|Alemtuzumab|20 mg/m2 IV for 5 days
45360088|NCT00881556|Drug|Tacrolimus|0.03mg/kg/24 hours as continuous infusion for 4 days
45360089|NCT03969797|Device|RADIAQBIO Heart Guardian HR-501|Arm one offers ECG data and electric shocks recorded during AED operation.
45479785|NCT03050060|Biological|Nivolumab|Given IV
45479786|NCT03050060|Biological|Pembrolizumab|Given IV
45687945|NCT04312997|Drug|PUL-042 Inhalation Solution|20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042)
45687946|NCT04312997|Drug|Placebo|Sterile saline for inhalation
45687947|NCT04311086|Device|Renal Denervation (Symplicity Spyral™)|Device: Symplicity Spyral™ multi-electrode renal denervation system. After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
45687948|NCT04310995|Drug|Nicorandil 5mg tid|oral Nicorandil Tablets 5mg (5mg per tablet) three times daily for 24 weeks
45687949|NCT04310995|Drug|Diltiazem 180mg qd|oral Diltiazem Sustained-release Tables180mg (90 mg per tablet) once daily for 24 weeks
45360090|NCT00874380|Other|Increasing total fiber intake in patient's diet|Second counsel patients biweekly about their compliance with a high fiber diet, target being 25 to 30 gm of fiber a day.Follow them for a period of 2 years and assess if their is any significant decrease in their cardiovascular events and profile, in addition to assessing the effect of high fiber on kalemia.
45687950|NCT04310995|Drug|Isosorbide Mononitrate 50mg qd|oral Isosorbide Mononitrate Sustained-release Capsules 50 mg (50mg per capsule) once daily for 24 weeks
45844707|NCT02923362|Procedure|Laparoscopic Fundoplication|The gastric fundus of the stomach is wrapped or plicated around the lower end of the esophagus and and stitched in place reinforcing the closing function of the lower esophageal sphincter. The hiatus is also narrowed down with sutures or mesh to prevent or treat a concurrent hiatal hernia.
45844708|NCT02923362|Device|LINX Antireflux|The LINX is a flexible band of interlocked titanium beads with a magnetic core. The LINX is placed around the lower esophageal sphincter to help restore the function of the LES by preventing reflux into the esophagus.
45844709|NCT02890758|Biological|Natural Killer (NK) Cells|Dose escalation of Natural Killer (NK) Cells from two infusion of starting at Dose Level 1 (1x10^7 cells/kg), dose Level-1 (1x10^6 cells/kg) if 2 of 6 patients at Level 1 develop DLTs. Escalation to dose level 2 (2.5X10^7) and Dose level 3 (5X10^7) is dependent on DLT
45844710|NCT02890758|Biological|ALT803|given at 6mcg/kg weekly for four weeks
46048528|NCT04202289|Device|Nile Tilapia Fish Skin|In the search of new therapies for burns, the skin of Brazil's most cultivated fish, the Nile tilapia, which was mostly a waste product (although sometimes used as a resistant material for artisanal handicraft), was suggested as a possibility for the development of a low-cost xenograft. Apart from non-infectious microbiota, Nile Tilapia Fish Skin presented histomorphological similarities with human skin in pre-clinical studies. It was shown to have a deep dermis formed by thick collagen fibers organized on parallel/horizontal and transversal/vertical arrangement and composed, in comparison, by larger amounts of type I collagen. Nile Tilapia Fish Skin did not present variations in its microscopic structure and tensile strength after glycerolization, irradiation and posterior rehydration, recovering its natural consistency after glycerol removal.
45360091|NCT00881634|Drug|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)|
46048529|NCT04202289|Drug|Silver Sulfadiazine Cream 1%|Topical antibiotic commonly used for the treatment of superficial and deep partial-thickness burns.
46048530|NCT02850003|Drug|IDP-120 Gel|Gel
46048531|NCT02122185|Drug|metformin hydrochloride|Given PO
46048532|NCT02122185|Drug|placebo|Given PO
45844711|NCT02867124|Drug|XR-NTX|Vivitrol
45360092|NCT00881634|Drug|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
45360093|NCT00874458|Procedure|magnetic resonance imaging|
45360094|NCT00874458|Procedure|radiomammography|
45360095|NCT00874458|Procedure|ultrasound imaging|
45360096|NCT00878670|Drug|EPOGAM 1000|One capsule of EPOGAM 1000 contains 932-1073 mg Oenothera seminis oleum, equivalent to 80 mg gamma-linolic acid. Children (2-12 years) take 2 capsules in the morning and evening, whereas persons over 12 years take 3 capsules in the morning and evening. The duration of the treatment is 12 weeks.
45360097|NCT00874536|Dietary Supplement|omega-3 fatty acid alpha-linolenic acid (ALA)|3 grams of ALA-containing plant oil
45360098|NCT00874536|Dietary Supplement|Placebo|
45360099|NCT00733499|Device|LCS Complete Duofix|Orthopaedic implant for total knee replacement with Duofix biological fixation surfaces
45360100|NCT00733499|Device|LCS Complete Porocoat|Orthopaedic implant for total knee replacement with Porocoat biological fixation surfaces
45687951|NCT04309552|Drug|18F-FMISO PET|Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
45479787|NCT01304849|Drug|Escalated BEACOPP|"Escalated BEACOPP chemotherapy will be delivered for those patients who are interim PET CT positive after 2 cycles of ABVD chemotherapy. The patients will receive 2-4 cycles of Escalated BEACOPP once in 3 weeks. The cycles will be delivered as follows:~Bleomycin 10mg/m2 IV in day 8, Etoposide 200mg/m2 Day 1 to Day 3, Adriamycin 35mg/m2 on Day 1 IV, Cyclophosphamide 1200mg/m2 on Day 1 IV, Vincristine 1.4mg/m2 on Day 8 IV, Cap Procarbazine 100mg/m2 Day 1 to Day 7 PO, T Prednisolone 40mg D1-D7 of a 21 day cycle. With Inj Mesna 400mg/m2 0, 4 and 8 hours on the day of Cyclophosphamide Inj G-CSF will be started routinely from Day 9 till recovery of Absolute neutrophil counts ≥5000/cmm or Total WBC counts≥ 8000/cmm"
45687952|NCT04309552|Drug|18F-FLT PET|Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
46048533|NCT02122185|Drug|Chemotherapy|Participants will received standard chemotherapy (6-8 cycles). Specific regimen to be given is at the discretion of their treating physician.
45844712|NCT02867124|Other|place of residence|One injection of XR-NTX in prison, followed by 6 monthly injections post-release at place of residence
45844713|NCT02867124|Other|opioid treatment program|One injection of XR-NTX in prison, followed by 6 monthly injections post-release at a community opioid treatment program
46048534|NCT02087865|Drug|donepezil HCL|
46048535|NCT02087865|Drug|Placebo|
46048536|NCT01949883|Drug|CPI-0610|
46048537|NCT01889199|Drug|Flutamide|Flutamide 125 mg orally each 28 day cycle for 6 cycles
46048538|NCT01889199|Other|Placebo|Placebo orally each 28 day cycle for 6 cycles
46048539|NCT01730313|Drug|Pyridoxine|
45360101|NCT00878748|Drug|Effexor XR|
45360102|NCT00878748|Other|Effexor XR discontinue|
45360103|NCT04088045|Device|Autologous platelet rich plasma and 5% dextrose solution injections.|"One group of patients will receive autologous platelet rich plasma injection into the knee joint and pes anserinus complex. The other group will receive both PRP injections into the knee joint and pes anserinus complex, and prolotherapy of 5% dextrose solution to the genicular nerves.~Dextrose solutions are injected to the genicular nerves."
45360104|NCT00652028|Drug|Dexmedetomidine, midazolam; fentanyl|Dexmedetomidine for sedation; midazolam for rescue sedation according to label; fentanyl for rescue pain according to the label
46048540|NCT01730313|Drug|Sodium Valproate|
46048541|NCT01730313|Drug|Phenytoin|
46048542|NCT01730313|Drug|Placebo|
46048543|NCT02849925|Drug|Sealants to arrest microcavitated caries.|Carious lesions will be treated by minimally invasive dentistry by the use of sealants instead of eliminating carious tissues and using conventional restorative materials.
46048544|NCT02849769|Device|Implant of an MR-conditional Tachy device system|
46048545|NCT02849379|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
46048546|NCT02849379|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
46048547|NCT02847663|Device|Kryosauna Space Cabin|The whole body cryotherapy device is able to generatue temperatures up to -195°C for 3 minutes. In this study, we generate temperatures of -135°C for 2 minutes as proposed in the manual. The participant will enter the cabin in cold-resistant shoes and will remain in standing position during the whole procedure. The cold temperature is generated by vaporization of liquid nitrogen.
46048548|NCT02847663|Other|cold water tub|The tub will be filled with cold water up to the sternal level of the participants. Adding ice will ensure a constant temperature. The participant will sit inside the tub during the whole procedure.
46048549|NCT01104662|Drug|Vancomycin|
46048550|NCT01104662|Drug|Daptomycin|
45360105|NCT02592473|Device|Embozene Microspheres|Minimally invasive intra-arterial administration of particle embolics into prostate arteries under fluoroscopy and cone-beam CT imaging guidance.
45360106|NCT00738101|Drug|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 5 years. If the infant no longer is requiring any TPN, then the Omegaven will be stopped regardless of bilirubin. If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
45360107|NCT00810212|Procedure|PLF with autograft|6 subjects
45687953|NCT04309461|Behavioral|Stress Management Control|The Stress Management Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target stress, relaxation, and sleep. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. The Stress Management Program, including the use of the app and assessments, is identical to the Adapted MBC2 program, with the exception of the content.
45360108|NCT00810212|Biological|PLF with NeoFuse|6 subjects low dose
45687954|NCT04309461|Behavioral|Adapted MBC2 Program|The Adapted MBC2 Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target fruit and vegetable intake, dietary fat intake, physical activity, and high sedentary leisure screen time. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor goal thermometers to meet targets.
45360109|NCT00810212|Biological|PLF with NeoFuse|6 subjects medium dose
45844714|NCT02723994|Drug|Ruxolitinib|In Part 1, ruxolitinib will be administered at a protocol-defined starting dose in combination with chemotherapy, with dose escalation and de-escalation following the rolling 6 study design. The established recommended starting dose will be taken forward into Part 2.
45844715|NCT02723994|Drug|Asparaginase Erwinia Chrysanthemi|
45844716|NCT02723994|Drug|Cyclophosphamide|
45844717|NCT02723994|Drug|Cytarabine|
45844718|NCT02723994|Drug|Dexamethasone|
46048551|NCT01104662|Drug|Semi-Synthetic Penicillin|
45844719|NCT02723994|Drug|Doxorubicin|
45844720|NCT02723994|Drug|Leucovorin Calcium|
46048552|NCT02849301|Device|Arabin cervical pessary|
46048553|NCT02849613|Other|Adipose Derived Stem Cells|
46048554|NCT02849613|Other|Vehicle media|
45844721|NCT02723994|Drug|Mercaptopurine|
45844722|NCT02723994|Drug|Methotrexate|
46048555|NCT01461291|Device|iStent inject|Implantation of two GTS400 stents using G2-M-IS iStent inject
46048556|NCT01461291|Procedure|Cataract surgery|Cataract surgery alone
46048557|NCT02847195|Device|pupillometry|This is a safe and painless examination (the device is simply placed on the orbit of the eye). The optical pupillometer is cleaned by doctors before and after each use, using cleaning wipes containing antibacterial, antiviral and antifungal drugs; such wipes are already in use in the service for cleaning equipment.
46048558|NCT01104584|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M; 0.1 mmol/kg body weight
46048559|NCT05062785|Drug|Intranasal insulin|"This will be given intranasally at differing doses depending on study day. A total of 11 possible doses will be tested, ranging from 0 to 1000 U insulin. Each volunteer will come for 5 visits.~On the first treatment day participants will receive placebo (sterile water) in each nostril followed by a 4-hour observation period. After this observation period participants will receive the initial dose of insulin squirted in each nostril followed by a a 4 hour observation period. Participants will have at least 7 days in between the other 4 visits. Subsequent visits will include increased doses of insulin (depending on how this is tolerated) and will take approximately 4 hours at these visits."
46048560|NCT01407627|Dietary Supplement|Fructose|"Subjects will be randomized to one of 2 sequences:~Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d"
46048561|NCT02849535|Behavioral|PRISM care program|PRISM care is a multidisciplinary program that includes sessions with a hospital pharmacist about the oral chemotherapy: information is given to the patient on adverse events occurrence and management, optimizing drug dosage plan, including drug-drug interactions. Physical sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion, then telephone interviews of physical sessions will be planned at month 4, month 5 and month 6. During all these sessions and during the final physical session at the end of month 6, data will be recorded for outcomes assessment.
46048562|NCT01103960|Drug|Telmisartan80mg+Amlodipine5mg|combination therapy
46048563|NCT01103960|Drug|amlodipine 5mg|monotherapy
46048564|NCT01103960|Drug|Telmisartan80mg+Amlodipine 5mg|combination therapy
46048565|NCT04413279|Procedure|LipiFlow Thermal Pulsation|To manage patients with dry eye disease secondary to MGD
45360110|NCT00810212|Biological|PLF with NeoFuse|6 subjects high dose
45687955|NCT04304508|Drug|BAY2433334|Tablet, taken orally once a day.
45687956|NCT04304508|Other|BAY2433334 matching placebo|Tablet, taken orally once a day.
45844723|NCT02723994|Drug|Pegaspargase|
45844724|NCT02723994|Drug|Prednisone|
45844725|NCT02723994|Drug|Thioguanine|
45844726|NCT02723994|Drug|Vincristine Sulfate|
45844727|NCT02683200|Radiation|Image-Guided Adaptive Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
45844728|NCT02683200|Radiation|Stereotactic Body Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
45844729|NCT02656290|Device|Edwards Pericardial Aortic Bioprosthesis Model 11000A|Edwards Aortic Bioprosthesis Model 11000A in the pulmonary position; a trileaflet bioprosthesis comprised of bovine pericardium
45844730|NCT02534844|Drug|Parts A/B: Adrabetadex|900 - 1800 milligram (mg) of adrabetadex administered every 2 weeks via lumbar intrathecal infusion
45844731|NCT02534844|Other|Parts A/B: Sham Control|No experimental drug is administered to participants - intrathecal administrations are simulated by skin prick
45360111|NCT00799136|Drug|R-EPOCH and cART|This is a prospective, single-arm, multi-centre, phase II trial of immuno-chemotherapy (rituximab and EPOCH) with mandatory combination antiretroviral therapy for initial treatment of AIDS-related lymphoma.
45360112|NCT02592395|Drug|FOLFIRINOX|"The chemotherapy schedule will include administration of FOLFIRINOX (5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin) will be:~Day 1: Oxaliplatin at 85mg/m2 over 120 minutes, Irinotecan 180mg/m2 over 90 minutes, Leucovorin 400mg/m2 over 90minutes, 5-Fluorouracil (5-FU) 1200mg/m2/day continuous infusion (CIV) over 46 hours. Day 3: 5-FU CIV pump will be disconnected. Neulasta injection 6mg subcutaneous"
45360113|NCT02592395|Device|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
45687957|NCT04292145|Behavioral|Relaxation Application|The use of an application for relaxation.
45687958|NCT04292145|Behavioral|Relaxation Only|The individual's personal method to relax.
46048566|NCT04413279|Drug|Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation|to investigate the benefit of managing patients with DED secondary to MGD with a sustained release intracanalicular dexamethasone (0.4 mg) insert in addition to LipiFlow Thermal Pulsation
46048567|NCT02847039|Genetic|Blood samples|Blood samples at baseline.
46048568|NCT05006144|Other|sequenced trunk co-activation exercises|"Sequenced trunk co-activation exercises were basically used for facilitation of functional activities through trunk musculature dynamic co-activation of in the lateral plane which is required for basic developmental milestones. In the frontal plane, encourage the child to actively shift his/her weight to maintain the weight-bearing side straight while keeping proper active co-activation of trunk musculature. Efficient trunk rotation is essential for acquiring of equilibrium reactions and balance. Enhancement of efficient active trunk rotation as the child could achieve active trunk musculature co-activation while maintaining the weight-bearing side straight (Arndt et al., 2008).~Righting and protective reactions~Functional stretching exercises."
46048569|NCT05006144|Other|Standard Orthotic Management|A custom-made articulating ankle foot orthosis with a hinge at the level of the medial malleolus of the ankle is fabricated for each child from the same copolymer thermoplastic mold after casting with the subtalar joint in neutral position. The orthosis extended distally to the tip of the toes and proximally on the posterior surface of the leg to about 5 cm below the knee and secured to the foot by three straps across the forefoot, the front of the ankle, and to the anterior upper tibial portion. It is fabricated to permit free ankle dorsiflexion and lock the plantar flexion at 0 dorsiflexion. The splinting schedule started gradually for 2 h/day in the first month, 4 h/day in the second month to the entire wake-up time of the day in the third and fourth months to accommodate children to the orthosis.
46048570|NCT05006144|Other|selective dorsal rhizotomy|All SDRs were performed by a single neurosurgeon through an osteoplastic laminotomy from L2 to L5 that left the facet joints intact. After opening the dura, the posterior nerve roots of L2 to S1 were identified and divided into 3 to 6 rootlets. At L2, from 30% to 50% of the posterior nerve rootlets were sectioned without selective stimulation. Selective electric stimulation of each nerve rootlet was performed from L3 to S1. The percentage of rootlets sectioned at each level (table 3) was determined by the surgical team based on the electromyographic results obtained intrasurgically and knowledge of the presurgical assessment results. The laminae were replaced on the completion of the rootlet stimulation and secured with sutures in the yellow ligament and the supraspinous ligament.
46048571|NCT02880098|Biological|Troponin T blood level|assess Troponin T blood level for every child born from the same sample of blood (after clamping the umbilical cord) used for assessment of pH and lactate.
46048572|NCT04309448|Behavioral|Perturbation-based balance training with functional electrical stimulation|The PBT program will consist of repetitive practice of reactive stepping for one hour. The participants will be equipped with the Odstock 2-Channel stimulator on one or both sides depending on their deficits. One channel of stimulation may be applied to the common fibular nerve to elicit a flexor withdraw reflex and elicit a step. The second channel of stimulation may be applied to the quadriceps muscles to assist with the supporting phase of the reactive step, as required. Participants will experience about 60 perturbations per session during balance exercises. To create a perturbation, the researcher will apply unexpected pushes or pulls to a safety harness around the participant's trunk. Throughout the hour-long session, participants will complete challenging balance tasks, customized to their ability level, during standing and walking. The training will be supervised by a licensed physiotherapist and administered by a licensed physiotherapist or registered kinesiologist.
46048573|NCT04886505|Device|Electrolytic eCLIPs Bifurcation System|The electrolytic eCLIPs bifurcation system will be implanted into patients with bifurcated saccular intra-cranial aneurysms.
46048574|NCT04975256|Drug|MRTX849|KRAS G12C inhibitor
46048575|NCT04975256|Drug|BI 1701963|SOS1 Inhibitor
46048576|NCT00951951|Procedure|Anterior Approach|Anterior Minimal Invasive Surgery (AMIS)
46048577|NCT00951951|Procedure|Posterior Approach|
46048578|NCT02849067|Other|Group Treatment|Patients in this group will watch a comedy show that will will not exceed 30 minutes. This group will have until five patients.
46048579|NCT02849067|Other|Group Control|patients in this group will watch a documentary that will not exceed 30 minutes. This will have until five patients
46048580|NCT02880800|Drug|Morphine as IVPCA|"Morphine as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of morphine as below:~Morphine bolus 1mg with a lockout interval of 5 minutes, no background infusion and maximum 30 mg in 4 hours"
46048581|NCT02880800|Drug|Hydromorphone as IVPCA|"Hydromorphone as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of Hydromorphone as below:~Hydromorphone bolus 0.2 mg with a lockout interval of 5 minutes and a maximum dose of 6 mg in 4 hours."
45687959|NCT04291560|Behavioral|Stretching Exercise Intervention|Sequential static stretching of the large skeletal muscle group 5 days per week. Each skeletal group is stretched for 20 seconds for 3 repetitions.
45687960|NCT04291300|Drug|Lutetium-177-PSMA-I&T|4 cycles of 7.4 GBq 177Lu-PSMA every 6 weeks.
45844732|NCT02534376|Drug|ezetimibe 10mg-simvastatin 40mg|Vytorin (ezetimibe 10mg-simvastatin 40mg) will be given on an outpatient basis. The drug will be taken orally each day until the subject undergoes radical prostatectomy. The start of Vytorin is timed so that patients get the last dose the day before surgery. Subjects receive a two to four weeks of Vytorin.
46048582|NCT02880800|Drug|Morphine|IV opioids: Morphine 2 to 5 mg every 1h PRN (max. 20 mg/4h)
45687961|NCT04289753|Behavioral|EHR clinical decision support nudges|Clinical decision support nudges delivered within the EHR when conditions meet alert triggering criteria.
45687962|NCT04289753|Behavioral|Brief clinician education|Clinicians will be invited to view brief education material.
45360114|NCT00810290|Behavioral|lifestyle intervention|A group-based intervention including 13 group sessions complemented by three individual home visits was developed using principles of social learning theory and patient-centered counseling. The intervention was intended to increase awareness of diabetes prevention strategies, foster positive diabetes prevention attitudes (i.e., self-efficacy) and promote healthy lifestyle behaviors in the target Latino population using literacy-sensitive and culturally-tailored strategies and materials.
45360115|NCT00799214|Drug|Placebo|1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
45687963|NCT04288856|Drug|BIIB078|Administered as specified in the treatment arm.
45687964|NCT04275180|Drug|Argatroban|Argatroban plus standard medical treatment
45687965|NCT04271332|Drug|Arbaclofen|Arbaclofen tablet
45687966|NCT04271332|Drug|Placebo oral tablet|Manufactured to match Arbaclofen in size, shape, color and taste
45687967|NCT04268875|Device|Optical Coherence Tomography (OCT)|"The OCT fibre is an optical fibre catheter containing a lens located at its extremity and positioned distal to the arterial segment to be examined. This is an intracoronary, very high-resolution section technique based on absorption and reflection of close infrared light by stents and tissues.~OCT analysis is performed during a usual coronary angiography procedure. It is a common technique already used and recommended for intrastent restenosis to establish the mechanism of the process. No new product is being tested. The examination performed is the same."
45844733|NCT02391324|Procedure|Lokomat (LOK)|Physical therapy provided using a robotic gait training system (Lokomat).
45844734|NCT02391324|Procedure|Gait focused physical therapy (fPT)|Overground physical therapy focussed on enhancing gait related motor skills
45844735|NCT02391324|Procedure|LOK + fPT|A combination of robotic gait training and gait focussed functional physical therapy.
46048583|NCT02880800|Drug|Hydromorphone|Hydromorphone 0.5 - 1 mg every 1h PRN (max. 4 mg/4h)
46048584|NCT04383873|Device|Training by means of Armeo Spring device|This patients group receive 40 experimental sessions. Each session is based on 30 min by using Armeo Spring device.
45844736|NCT02216838|Drug|botulinum toxin A|A total of 10U will be injected at 1cm increments by the blinded dermatologist into the respective randomized side.
46048585|NCT04383873|Other|Current treatment based on conventional therapy|All the patients enrollment in the study receive 30 min of conventional therapy during 40 sessions.
46048586|NCT04383873|Other|Additional treatment based on conventional therapy|This intevention was added for providing the same amount of therapy than those patients randomly enrolled in the intervention group. So, patients in the control group receive other 30 min of conventional therapy added on current treatment during 40 sessions.
46048587|NCT02849145|Biological|Blood sampling|7,5 ml of patient peripherical blood will be collected at each blood sample.
45360116|NCT00799214|Drug|Boric acid|Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
45360117|NCT00799214|Drug|Metronidazole|Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
45360118|NCT00733421|Drug|etoricoxib|90 mg once daily
45360119|NCT00733421|Drug|tramadol|100 mg twice daily
45360120|NCT00613080|Drug|capecitabine|1650 mg/m^2/day orally 5 days/week during radiotherapy.
45360121|NCT00613080|Drug|oxaliplatin|
46048588|NCT02847117|Other|Mastiha|The volunteers will follow a low-phytochemical diet for five days, meaning that they will exclude fruits, vegetables, legumes, coffee, tea, alcoholic beverages and chocolate. On the day of the experiment and after overnight fasting, the volunteers will consume 10g of natural Mastiha and blood samples will be obtained on timepoints 0h, 30min, 1h, 2h, 4h, 6h and 24h after Mastiha intake. Until timepoint 6h, will be allowed to consume only water. Urine samples will also be collected on timepoints 0h, 4h, 8h and 24h.
46048589|NCT01107392|Drug|botulinum toxin Type A|botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
45360122|NCT00613080|Procedure|resection|All patients undergo surgery 4 to 8 weeks following the completion of radiation therapy. The choice of procedure (abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis) is at the discretion of the surgeon.
45360123|NCT00613080|Radiation|radiation therapy|Pelvic intensity modulated radiation therapy (IMRT): 45 Gy in 25 fx Three dimensional conformal radiation therapy (3D-CRT) boost: 5.4 Gy in 3 fx to total dose of 50.4 Gy in 28 fx
45360124|NCT00613080|Drug|FOLFOX|"Postoperative chemotherapy is administered to all patients who have a complete resection of rectal cancer with negative surgical margins and begins within 4-8 weeks following surgical resection, consisting of a total of 9 14-day cycles. Oxaliplatin 85 mg/m^2, IV over 2 hours, day 1.~Leucovorin 400 mg/m^2, IV over 2 hours, day 1. 5-fluorouracil bolus 400 mg/m^2, IV push, day 1. 5-fluorouracil infusion 2400 mg/m^2, IV continuous infusion over 46 hours, day 1."
45752079|NCT01389596|Drug|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
46048590|NCT01107392|Drug|Normal saline|Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
45360125|NCT00806858|Device|NovoPen® 4|Insulin administration by means of a NovoPen® 4 pen device
45360126|NCT00917891|Drug|dapivirine|"dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks"
45360127|NCT00917891|Drug|placebo|"dosage form: vaginal gel~frequency: once daily~duration: 6 weeks"
45360128|NCT03871166|Other|Blood transfusion|"Observational post-ad-hoc design to compare patients admitted with an ARDS and separated into different groups according to their mean hemoglobin concentration during their stay on the intensive care unit.~Approximately 1000 adult patients admitted from 2007 to 2018 to the Charite ARDS center will be enrolled in the study. They are followed up until their discharge from the ICU.~[Time Frame: 01/2007 - 12/2018]"
45360129|NCT02554136|Drug|HGP0918|
45360130|NCT02554136|Drug|HGP0816|
45360131|NCT02554136|Drug|HGP0918 + HGP0816|
46048591|NCT04924803|Behavioral|No video|Weekly text messages
46048592|NCT04924803|Behavioral|Video Text|Weekly text messages including links to intervention videos
46048593|NCT05037279|Drug|Bacillus Calmette-Guerin: Strain Russian BCG-I|"Induction: 80 mg weekly for 6 weeks.~Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months.~Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months."
46048594|NCT05037279|Drug|Bacillus Calmette-Guerin: Strain TICE|"Induction: 50 mg weekly for 6 weeks.~Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months.~Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months."
45360132|NCT00732875|Biological|Infliximab + methotrexate (MTX)|Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
45360133|NCT00799370|Procedure|Early weight bearing|Weight bearing performed immediately after surgery
45360134|NCT00799370|Procedure|Delayed weight bearing|Weight bearing performed 2 months after surgery
45360135|NCT00874692|Other|BMS and sterilisation programme|BMS with reduced hot water temperature and sterilisation programme
45360136|NCT00881790|Other|Fluoride varnish|the topical application of fluoride varnish to all surfaces of exposed teeth
45360137|NCT05097456|Device|carbon dioxide laser|carbon dioxide laser
45360138|NCT05097456|Device|sham laser|sham laser
45360139|NCT00810446|Drug|rifabutin|"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily.~3.Inhibition of disseminated Mycobacterium avium complex (MAC) disease associated with HIV infections : The usual adult dosage for oral use is 300 mg of rifabutin once daily.."
45360140|NCT05093868|Device|Electrographic Flow Mapping|Electrographic Flow Mapping will be collected
45360141|NCT00810524|Drug|lamivudine|100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
45360142|NCT00810524|Drug|Telbivudine|600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
45360143|NCT00810524|Drug|Enticavir|0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
45360144|NCT00810524|Drug|Adefovir Dipivoxil Tablets|10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
46048595|NCT01106846|Drug|Group A: Saline Group|Saline continuous infusion
46048596|NCT01106846|Drug|Group B: 1% Ketamine group|Administration of 1% ketamine intravenously.
46048597|NCT05034783|Drug|[68Ga]Ga-HBED-CC-exendin-4|Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) [68Ga]Ga-HBED-CC-exendin-4. Tracer doses of [68Ga]Ga-HBED-CC-exendin-4 will be used to image lesions of insulinoma by PET/CT.
45360145|NCT00810680|Drug|Valproic acid|Tab. Valproic acid will be started at a dose of 10 mg per kg per day in two or three divided doses. If well tolerated the dose will be increased to a maximum of 20 mg per kg per day and continued for a period of 3 months. The drug will be continued for another 3 months for a maximum of 6 months in responding patients. The drug will be stopped in all those who develop intolerable side effects or develop disease progression during therapy.
45360146|NCT00799448|Drug|repaglinide|
45360147|NCT00799448|Drug|biphasic human insulin 30|
45360148|NCT00799448|Drug|insulin NPH|
45360149|NCT00806936|Drug|human insulin|Any kind of human insulin administered at the discretion of the physician
45360150|NCT00806936|Drug|insulin analogue|Any kind of insulin analogue administered at the discretion of the physician
45360151|NCT00807170|Drug|ZD6474 (Vandetanib)|100 mg as a once daily oral dose, 21 days
45360152|NCT00807170|Radiation|Whole Brain Radiotherapy (WBRT)|
45360153|NCT00807170|Drug|ZD6474|200 mg as a once daily oral dose, 21 days
45360154|NCT00807170|Drug|ZD6474|300 mg as a once daily oral dose, 21 days
45360155|NCT00799526|Procedure|Autologous Ex Vivo Conjunctival for Symblepharon Transplantation|Safety and efficacy of conjunctival ex vivo for reconstruction of the ocular surface.
45360156|NCT00799526|Procedure|Ex Vivo Conjunctival for Symblepharon Transplantation|The safety and efficacy of human conjunctival epithelial autologous cultivated ex vivo for reconstruction of the ocular surface with symblepharon.
45360157|NCT02553902|Device|Sleep position trainer|
45360158|NCT02553902|Device|Mandibular advancement device|
45360159|NCT02553902|Device|Continuous positive airway pressure|
45479788|NCT03327610|Other|VC-CMV20|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 20Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
45844737|NCT02216838|Other|Saline Control|A total of 0.5cc benzyl alcohol containing saline will be injected at 1cm increments by the blinded dermatologist into the respective randomized side
45360160|NCT00615264|Drug|DiaPep277|1.0mg dose, administered as subcutaneous injection, on 0, 1, 3, 6, 9, 12, 15, 18 and 21 months
45360161|NCT00615264|Drug|Placebo|Mannitol (excipient) 40 mg, administered as subcutaneous injection on 1, 3, 6, 9, 12, 15, 18 and 21 months.
45360162|NCT00799682|Drug|Xalatan|0.005% 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
46048598|NCT05034783|Drug|[68Ga]Ga-NOTA-exendin-4|Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) [68Ga]Ga-NOTA-exendin-4. Tracer doses of [68Ga]Ga-NOTA-exendin-4 will be used to image lesions of insulinoma by PET/CT.
46048599|NCT04309526|Drug|NCO-48 Fumarate|NCO-48 Fumarate
45360163|NCT00799682|Drug|Travatan Z|0.004%, 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
45687968|NCT04267978|Drug|recombinant human endostatin,temozolomide,irinotecan|"Temozolomide was given orally 200mg/m2 for 5 days in each cycle. Day 1 TMZ was administered 3-6 hours prior to irinotecan.~Irinotecan was administrated 125mg/m2 on day 1 and day 15. Recombinant human endostatin was administrated 15mg/d, daily for 14 days. One treatment cycle was defined as 28 days (4 weeks), even if treatment is held mid-cycle for toxicity.~Treatment was continued until disease progression, patient withdrawal, or unacceptable toxicity.~The maximum number of treatment cycles was 12. After 12 cycles of treatment, if the investigator judges that the subject may continue to benefit from the regimen, the duration of treatment may be extended with the subject's consent."
45687969|NCT04251533|Drug|alpelisib|300 mg orally once per day (QD)
45687970|NCT04251533|Drug|placebo|300 mg orally once per day (QD)
45687971|NCT04251533|Drug|nab-paclitaxel|100 mg/m² as IV infusion on Days 1, 8 and 15 of a 28-day cycle
46048600|NCT04309526|Drug|Placebo|Placebo
46048601|NCT05019729|Drug|VRC-MALMAB0114-00-AB|VRC-MALMAB0114-00-AB is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozite protein.
46048602|NCT05019729|Other|CHMI|Negative control designed to test the infection ability of the CHMI.
46048603|NCT00902577|Drug|FMISO|FMISO PET scans
46048604|NCT00902577|Other|MRI|Undergo MRI
45360164|NCT00810758|Drug|PF-04878691 3mg|Oral solution, 3mg, twice weekly, 2 weeks
45360165|NCT00810758|Drug|PF-04878691 6mg|Oral solution, 6mg, twice weekly, 2 weeks
46048605|NCT00902577|Other|PET|Undergo FMISO PET scan
46048606|NCT00902577|Other|MRS|
46048607|NCT04568889|Behavioral|A $10 Survey Incentive|Individuals see a 10 dollar incentive on the flyers advertising the baseline survey.
46048608|NCT04568889|Behavioral|A $20 Survey Incentive|Individuals see a 10 dollar incentive on the flyers advertising the baseline survey.
46048609|NCT04568889|Behavioral|Emphasis of Government Involvement|Individuals see a message emphasizing the involvement of the government in the study,
45360166|NCT00810758|Drug|PF-04878691 9mg|Oral solution, 9mg, twice weekly, 2 weeks
45360167|NCT00732641|Drug|Peginterferon|Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
45360168|NCT03829020|Drug|Bortezomib|Given SC
45360169|NCT03829020|Drug|Metformin Hydrochloride|Given PO
45360170|NCT03829020|Drug|Nelfinavir Mesylate|Given PO
46048610|NCT04568889|Behavioral|Emphasis of Academic Researchers Involvement|Individuals see a message emphasizing the involvement of academic researchers in the study,
46048611|NCT04568889|Behavioral|Cost-Benefit Frame|Individuals will see messaging that emphasizes the public health benefits of answering the survey questions in the baseline survey (cost-benefit frame).
45360171|NCT00810836|Drug|BG00012|oral
45360172|NCT00810836|Drug|BG00012|Oral
45360173|NCT00810836|Drug|placebo|oral placebo
45360174|NCT00874926|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Haemophilia A patients
45360175|NCT00810914|Drug|bupivicaine epidural|bupivicaine continuous epidural infusion
45360176|NCT00810914|Drug|bupivicaine epidural infusion patient epidural|bupivicaine
45360177|NCT00810914|Drug|bupivicaine|patient controlled anesthesia only
45360178|NCT00878904|Drug|epirubicin hydrochloride|
45687972|NCT04250233|Device|Respiratory Monitor|All women receive a respiratory rate monitor after cesarean delivery. We anticipate that at least 30 women will receive standard dose neuraxial block, and aim to have a cohort of 20-30 women who receive non-standard dose (Group 20 in order to compare respiratory rates.
46048612|NCT04568889|Behavioral|Duty Frame|Individuals will see messaging that emphasizes an individual's responsibility to their community in the baseline survey (duty frame),
45360179|NCT00878904|Drug|panobinostat|
45360180|NCT00878904|Genetic|gene expression analysis|
46048613|NCT04568889|Behavioral|Racial/Ethnic Frame|Individuals will see messaging that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups in the baseline survey.
45360181|NCT00878904|Genetic|protein expression analysis|
45360182|NCT00878904|Genetic|western blotting|
45479789|NCT03327610|Other|VC-CMV50|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 50Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
45360183|NCT00878904|Other|immunologic technique|
45360184|NCT00878904|Other|laboratory biomarker analysis|
45360185|NCT00878904|Other|pharmacological study|
45360186|NCT00810992|Behavioral|Nutritional and behavioral program A|Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
45360187|NCT00810992|Behavioral|Nutritional and behavioral program B|Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
45479790|NCT03327610|Other|PC-CMV1|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 1 second and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
45687973|NCT04242238|Drug|DCC-3014|DCC-3014 will be administered in pill form. Start Day 1 on first cycle and continue with dosing of DCC-3014.
45687974|NCT04242238|Drug|Avelumab|Start Day 1 on first cycle with further infusions of avelumab every 14 days
45687975|NCT04241068|Drug|Aducanumab|Administered as specified in the treatment arm.
45687976|NCT04230252|Drug|Acetaminophen|Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
45844738|NCT02065596|Drug|Fludarabine|the study will begin with enrollment of an initial safety cohort of at least 10 subjects at the lowest dose, after which enrollment will pause until the dose-limiting toxicity (DLT) period has been completed. If a patient experiences DLT, defined as failure to engraft. In which case, the patient may be advanced to two higher doses.
46048614|NCT04568889|Behavioral|No Messaging|Individuals will see no messaging in the baseline survey.
46048615|NCT04202601|Drug|Sintilimab|"Arms 1: Neoadjuvant therapy group 20 patients Drug: Sintilimab Weight<60Kg: 3mg/kg Q3W Weight>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Perioperative Sintilimab+IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .~Arms 2: first-line therapy group, 30 patients Drug: Sintilimab Weight<60Kg: 3mg/kg Q3W Weight>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.~Arms 3: ≥second-line therapy group, 30 patients Drug: Sintilimab Weight<60Kg: 3mg/kg Q3W Weight>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years."
45360188|NCT00737711|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|iv 0.6 micrograms/kg every 2 weeks
45360189|NCT00881946|Drug|GSK21110183|Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops
45360190|NCT00807326|Drug|Loperamide/simeticone 2 mg/125 mg caplets|Oral, 2 caplets taken initially at investigator site followed by one caplet after each unformed stool, maximum 4 caplets in a 24 hour period for a maximum of 48 hours (per product label)
45360191|NCT00807326|Drug|Loperamide/simeticone 2 mg/125 mg chewable tablets|Oral, 2 chewable tablets taken initially at the site followed by one chewable tablet after each unformed stool, maximum 4 chewable tablets in a 24 hour period for a maximum of 48 hours (per product label)
45360192|NCT00807326|Drug|Probiotic Saccharomyces boulardii 250 mg capsules|Oral, 1 capsule twice a day, maximum 2 capsules in a 24 hour period for a maximum of 5 days (per product label)
45360193|NCT00875082|Drug|Montelukast|Montelukast, chewing tablets 5mg, once daily, 8 weeks
45360194|NCT00875082|Drug|placebo|placebo chewing tablets once daily, plus inhaled short acting beta2 agonist as needed, 8 weeks
45360195|NCT02552342|Drug|methylprednisolone|
45360196|NCT02552342|Drug|Normal saline|
45360197|NCT00811226|Drug|olmesartan medoxomile alone or combined with hydrochlorothiazide,|olmesartan medoxomile 20mg/daily or 40mg/daily; olmesartan medoxomile 20mg plus 12.5 mg of hydrochlorothiazide daily; olmesartan medoxomile 40mg plus 12.5 mg of hydrochlorothiazide daily
45360198|NCT00238303|Drug|vorinostat|Given orally
45360199|NCT00238303|Procedure|conventional surgery|Patients undergo surgery to remove tumor
45360200|NCT00737633|Drug|VI-0521|Phentermine 15 mg/Topiramate controlled release (CR) 92 mg, oral capsule, once daily, 58 weeks
45360201|NCT00811460|Drug|Placebo|sc for 4 days
45360202|NCT00811460|Drug|taspoglutide|300micrograms/day sc for 2 days
45360203|NCT00811460|Drug|taspoglutide|800 micrograms/day sc for 2 days
45360204|NCT00875238|Biological|trastuzumab|
45360205|NCT00875238|Drug|doxorubicin hydrochloride|
45360206|NCT00875238|Genetic|polymorphism analysis|
45360207|NCT00875238|Other|laboratory biomarker analysis|
45360208|NCT00875238|Other|questionnaire administration|
45687977|NCT04223505|Diagnostic Test|Contrast enhanced ECG-gated cardiac CT (CCT)|Contrast enhanced ECG-gated cardiac CT (CCT) is a sensitive, noninvasive alternative method used to exclude of left atrial and LAA thrombus. CCT provides high spatial and good temporal resolution and its ability to detect thrombus has been evaluated. CCT, compared to TEE, for the exclusion of thrombus in the LAA had a sensitivity and specificity of 100% and 99.3%, respectively. A high sensitivity is needed to minimize risk of embolus, and if a thrombus is detected on CT, a confirmatory TEE may be performed or patients may receive anticoagulation. Some argue that the potential benefits of CT and its lower associated procedural risk, the risk:benefit ratio would still favour CT.
45687978|NCT04223505|Diagnostic Test|Transesophageal Echocardiography (TEE)|TEE is considered the reference standard to rule-out left atrial (LA) and left atrial appendage (LAA) thrombus prior to cardioversion. Several studies have examined the accuracy of TEE for detecting LAA thrombus. Compared to autopsy and intraoperative findings, TEE has a mean sensitivity of 100% and mean specificity of 99%. Although the gold standard, a TEE-guided therapy is still associated with an embolic rate of 0.8%.
45687979|NCT04217317|Drug|CPI 613|CPI-613 is to be given as 2-hr IV infusion via a central venous catheter. The starting dose of CPI-613 will be 2500 mg/m2 which was determined to be the MTD in the previous phase I clinical trial.
45687980|NCT04217317|Drug|Bendamustine|Bendamustine at 90 mg/m2 is infused by IV over 10 minutes on Days 1 and 2 of each treatment cycle. Bendamustine is given immediately after CPI-613 administration.
45687981|NCT04206332|Drug|VRC-MALMAB0100-00-AB|VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.
45687982|NCT04206332|Other|Plasmodium falciparum (P. falciparum) sporozoite challenge|Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).
45844739|NCT02065596|Procedure|Hematopoietic Stem Cell Transplant (HSCT)|Three weeks after Immunomodulation patients will be infused with matched bone marrow from a sibling, unrelated donor, haploidentical donor, or cord blood. Patients will be followed for the following year.
46048616|NCT04202601|Drug|IBI310|"Arms 1: Neoadjuvant therapy group, 20 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Perioperative Sintilimab+ IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .~Arms 2: first-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.~Arms 3: ≥second-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years."
46048617|NCT04215315|Other|Retrospective observation|Case note and imaging review
45360209|NCT00875238|Procedure|assessment of therapy complications|
45360210|NCT00875238|Procedure|magnetic resonance imaging|
45360211|NCT02552498|Procedure|strangulation|The strangulation is applied on the attached gingiva with an angulated manual instrument. The force of the occlusion is standardized by a calibrated spring connecting the head with the handle of the tool. The head is overlaid onto the gingiva covering 10mm long and 1mm width surface. The amount of the applied pressure is 100 gram.
45360212|NCT00732251|Drug|Allopurinol|Allopurinol: 300-600 mg/day over a 24 month period
45360213|NCT00811538|Procedure|Intravenous Thrombolysis|i.V. thrombolysis with rtPa
45360214|NCT00811538|Procedure|Intraarterial Thrombolysis|Endovascular treatment with i.a. Urokinase or i.a. rtPA or mechanical recanalization techniques
45360215|NCT00811616|Device|Supralimus-Core™|Sirolimus Eluting Cobalt Chromium based coronary stent system
45360216|NCT00882024|Drug|Tranilast|150 mg tranilast tablets, bid, 12 weeks
45360217|NCT00882024|Drug|Tranilast|75 mg tablets, bid, 12 weeks
45360218|NCT00882024|Drug|Placebo|Placebo tablets, bid, 12 weeks
45360219|NCT00799760|Drug|oseltamivir + zanamivir|oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
45479791|NCT03327610|Other|PC-CMV3|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 3 seconds and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
45479792|NCT03327610|Other|PSV10|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 10% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
45479793|NCT03327610|Other|PSV25|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 25% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
45479794|NCT01334112|Drug|Axitinib (AG-013736)|5mg, oral, twice daily, continuous dosing. A dosing cycle is defined as 4 weeks. Treatment may continue until disease progression/relapse
45479795|NCT03791957|Other|Blood Haemoglobin|Routine haemotological investigation of blood haemoglobin levels in gm/dL will be recorded from withdrawn venous blood
45479796|NCT01315314|Drug|Balance, Fresenius Medical Care, Germany|low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF)
45360220|NCT00799760|Drug|oseltamivir + zanamivir's placebo|oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 day
45360221|NCT00799760|Drug|oseltamivir's placebo + zanamivir|oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
45360222|NCT00875316|Drug|Cogane™ (PYM50028)|Orally active neurotrophic factor inducer
45360223|NCT00799838|Drug|Ketoprofen|"Formulation: oral solution 20mg/mL~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
45360224|NCT00799838|Drug|Placebo (for Ketoprofen)|"Formulation: oral solution~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
45479797|NCT02491450|Drug|Heterosofir|1 tablet contains 400 mg sofosbuvir
45479798|NCT02491450|Drug|Sovaldi|1 tablet contains 400 mg sofosbuvir
45479799|NCT03626090|Biological|Autologous BM MSC|A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.
45479800|NCT05624645|Device|Pelex Upp|Patients were given the Pelex Upp is a non-invasive device that is designed to guide a user through personalized pelvic floor strengthening exercises. Patients used device for four weeks to treat stress urinary incontinence
46048618|NCT04202367|Drug|1 mg.kg-1 bupivacaine 0.25%|Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.
45360225|NCT00799838|Drug|Amoxicillin|"Formulation: suspension 125mg/5 mL~Route of administration: oral~Dose regimen: 20-40mg/Kg/day administered t.i.d"
45360226|NCT00799916|Drug|Resuscitation (Voluven)|Resuscitation aimed at venous oxygen saturation higher than 70%
45360227|NCT00799916|Drug|Resuscitation (Saline)|Resuscitation aimed at venous oxygen saturation higher than 70%
45360228|NCT00737477|Drug|Methoxy polyethylene glycol-epoetin beta|Mircera will be administered SC every 4 weeks for a total of 48 weeks. The first dose of 120 or 200 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
45360229|NCT00256867|Drug|GSK523338|
45360230|NCT00800072|Device|NOWOX|one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
45479801|NCT01274442|Other|anamnesis|To update the anamnesis.
45479802|NCT01274442|Procedure|oral examination|A brief clinical oral examination will be performed.
45479803|NCT01274442|Procedure|Blood sample|A blood sample will be taken to identify relevant genetic polymorphisms.
45687983|NCT04189263|Other|Carbohydrate restricted dietary intervention|Carbohydrate restricted dietary intervention (<20 g carbohydrates/day)
45844740|NCT02058420|Drug|Low tocotrienols group|300 mg tocotrienols daily
45844741|NCT02058420|Drug|High tocotrienols group|600 mg tocotrienols daily
46048619|NCT04202367|Drug|1 mg.kg-1 bupivacaine 0.125%|Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.
46048620|NCT02846805|Procedure|implant-retained overdentures|subjects will receive two-implant-retained overdentures in the mandible,and they continue wearing their complete denture in the maxilla.
45360231|NCT00882180|Drug|ALN-VSP02|IV infusion administered every two weeks
45360232|NCT00800150|Drug|fludarabine phosphate|
45360233|NCT00800150|Drug|melphalan|
45360234|NCT00800150|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
45360235|NCT00800150|Radiation|intensity-modulated radiation therapy|
45360236|NCT00800150|Radiation|tomotherapy|
45360237|NCT00800150|Radiation|total marrow irradiation|
45360238|NCT00800150|Radiation|total nodal irradiation|
45360239|NCT04019717|Drug|AT-527|Nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase
45360240|NCT04019717|Drug|Daclatasvir|Inhibitor of HCV nonstructural protein 5A (NS5A)
45844742|NCT01976286|Other|Salicylic Acid Peels|
46048621|NCT00119847|Procedure|PCI|
46048622|NCT00119847|Drug|Optimal Medical Therapy|Guideline-directed drug therapies after MI
45687984|NCT04189263|Drug|standard of care aromatase inhibitors|standard of care aromatase inhibitors
46048623|NCT02846493|Drug|bromocriptine|Patients in this group will receive rectal bromocriptine at a daily dose of 2.5 mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT), Vascular Endothelial Growth Factor(VEGF),drink intake (Intake) and urine volume.
45360241|NCT00879216|Drug|VA106483|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
45360242|NCT00879216|Drug|Placebo|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
45687985|NCT04174157|Other|Prospective observational registry|This prospective observational registry will assess long-term outcomes of patients with a diagnosis of SMA.
45687986|NCT04174157|Drug|Zolgensma|Zolgensma will be given to patients as per normal clinical practice and clinical care will not be mandated by the protocol. As such, the decision to prescribe Zolgensma is separate from the decision to include the patient in this study
45687987|NCT04170426|Biological|autologous adipose derived stem cells|Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue
45687988|NCT04159194|Other|Control Diet|Players during the control trial will be instructed to maintain their normal food intake (~55% CHO) and the type and amount of ingested food will be recorded.
45687989|NCT04159194|Other|Experimental Diet|The experimental diet will be administered by the investigators after M1, daily for the next 48 hours (three main meals, i.e. breakfast, lunch, and dinner, and snacks such as energy bars and raisins), and before M2 (breakfast and lunch)
45360243|NCT00807404|Procedure|histopathologic examination|
45360244|NCT00807404|Procedure|optical coherence tomography|
45360245|NCT02592161|Drug|Experimental|"Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks~Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)~Three times a day, oral administration for 24weeks"
45687990|NCT04157192|Other|Real acupuncture|The patient will be treated for migraine with real acupuncture.
45687991|NCT04157192|Other|Sham acupuncture (placebo group)|Sham acupuncture is used as a control in scientific studies to test the efficacy of acupuncture in the treatment of various disorders, in this case, migraine. In this study, the subjects will not know whether they are getting true acupuncture or not. In the placebo group, the acupuncture needles will not actually be inserted into the skin. Placebo needles consisting of a sliding tube and a retractible needle are applied to the acupunture reference point (marked by a pastille stuck on the skin). The patient should not be able to feel the difference between real acupuncture and sham acupuncture.
45844743|NCT01976286|Other|Glycolic Acid Peels|
46048624|NCT02846493|Drug|dexamethasone|Patients in this group will take oral dexamethasone at a daily dose of 3mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT),Vascular Endothelial Growth Factor(VEGF), drink intake (Intake) and urine volume.
46048625|NCT03636789|Other|Neurological consultation|study of horizontal, vertical, reflex and voluntary saccades, and of horizontal and vertical ocular pursuit by a BrainTracker eye-oculography system
46048626|NCT01106690|Drug|Placebo|One matching placebo capsule orally (by mouth) once daily for 26 weeks with stable doses of metformin and pioglitazone.
46048627|NCT01106690|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with stable doses of metformin and pioglitazone.
46048628|NCT01106690|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 with stable doses of metformin and pioglitazone.
46048629|NCT01106690|Drug|Metformin|The patient's stable dose of metformin background therapy should be continued throughout the study.
46048630|NCT01106690|Drug|Pioglitazone|The patient's stable dose of pioglitazone background therapy should be continued throughout the study.
46048631|NCT02850315|Device|optimal coherence tomography|
46048632|NCT02690805|Device|MR-compatible scinti-mammography (MRI-SMM) system|
46048633|NCT02850393|Other|Functional magnetic resonance imaging|
46048634|NCT02850393|Behavioral|behavioral measures|
46048635|NCT02850393|Other|physiological measurements|
46048636|NCT02880566|Procedure|Scalp block|Full scalp block
46048637|NCT04308356|Behavioral|Dedicated Discussions on Anticipating preferences of care in the event of Aggravation (DDA)|interview 2
46048638|NCT04308356|Other|Autonomy Preference Index (API ) questionnaire - Information|part of interview 1
46048639|NCT04308356|Other|anxiety and depression (HADS) questionnaire|part of interview 1
46048640|NCT04286529|Drug|Calcitriol capsules|0.25micrograms, taken daily for eight weeks, orally
46048641|NCT04286529|Drug|Oral Placebo|Placebo will be created to mimic the appearance of the study drug
46048642|NCT01103180|Drug|Escitalopram|10-20 mg of escitalopram daily for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
46048643|NCT02848911|Drug|AFM11|Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 2 weeks
46048644|NCT00625898|Drug|Docetaxel|"75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B~100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B"
46048645|NCT00625898|Drug|Trastuzumab|"First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B~First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B"
46048646|NCT00625898|Drug|Carboplatin|6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6
45360246|NCT00800306|Drug|Levosimendan|Intravenous administration of Levosimendan 0,2 µg•kg-1•min-1 for 24 hrs followed by the addition of 35 ppm of inhaled nitric oxide
45687992|NCT04155398|Procedure|EUS elastography|A forward view radial echoendoscope or a forward oblique view linear echoendoscope would be used to perform focused luminal examination of varices and EUS elastography for measurement of liver stiffness and spleen stiffness.
45687993|NCT04152343|Device|RFA Physics Library -- a Planning and Guidance Platform (PGP)|Research software used to support liver RFA of HCC lesions >2cm
45360247|NCT00800306|Drug|dobutamine|Intravenous administration of dobutamine 5 µg•kg-1•min-1 for 36 hrs. At the end of the first 24 hrs drug infusion, inhaled nitric oxide at the concentration of 35 ppm will be added for further 12 hrs.
45479804|NCT03320590|Diagnostic Test|Time Lapse (material to observe embryonic development)|The embryonic kinetics are recorded by Time lapse Primovision™ (Vitrolife). These kinetic parameters are analysed and annotated by only one person with expertise in this technology.
45360248|NCT01581775|Drug|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
45687994|NCT04152239|Procedure|Motorized spiral enteroscopy (MSE)|Endoscopic Procedures MSE is a 1.6m enteroscope equipped with a single-use short spiral overtube propelled by a user-controlled motor contained in the handle of the endoscope. The endoscopist controls the left-right and up-down movements by the usual manuvers while the forward or backward advancement of the enteroscope would be contolled by a foot pedal that activates the spiral overtube rotation. Antegrade MSE, retrograde MSE, or combined antegrade and retrograde MSE would be performed as clinically indicated for diagnostic +/- therapeutic procedures.
46048647|NCT00625898|Drug|Bevacizumab|"15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B~15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B"
46048648|NCT00625898|Drug|5-Fluorouracil|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
46048649|NCT00625898|Drug|Epirubicin|90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
46048650|NCT00625898|Drug|Cyclophosphamide|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
45360249|NCT04039152|Other|Clinical pharmacists recommendations to optimize antibiotics use|Optimal dosing, drug bug mismatch
45360250|NCT04046276|Behavioral|High Intensity Aerobic program|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
45360251|NCT04046276|Other|Conventional Physical Therapy|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
45360252|NCT04046276|Behavioral|Medium Intensity Aerobic program|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
46048651|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
46048652|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
46048653|NCT00944034|Biological|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
46048654|NCT00944034|Biological|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
46048655|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 months of age
45360253|NCT00731939|Device|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction.
45360254|NCT01072591|Drug|MEDI-578|intravenous infusion, once
45360255|NCT01072591|Drug|Placebo for MEDI-578|Intravenous infusion, once
45360256|NCT00882258|Drug|12.5 mg Proellex|12.5 mg Proellex administered orally daily
45360257|NCT00882258|Drug|25 mg Proellex|25 mg Proellex administered orally daily
45360258|NCT00882258|Drug|Placebo|Administered orally daily
45360259|NCT00811694|Other|ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters, laser Doppler flowmetry and laser Doppler velocimetry
45360260|NCT04038606|Other|Determination of acceptance and / or rejection of mastectomy|Blood exams,Participants completed a questionnaire translated in French language : Rosenberg,SF-36, QLQC30, Big Five Inventory,BPI-SF.:-)
45360261|NCT03741595|Behavioral|Item spacing|Spatial proximity of items to one another
45360262|NCT00879294|Device|Motion sickness wristband|No drugs are involved.
45360263|NCT00879294|Dietary Supplement|Chewing Gum|Patients will be asked to chew gum for 20 minutes, four times daily.
45479805|NCT03792113|Procedure|Periodontal Flap Surgery|Periodontal access flap surgery will be performed in both test site followed by control site in each subject
45479806|NCT03792113|Other|Autologous fibrin glue|Autologous fibrin glue procured from the subject's own venous blood will be used to approximate periodontal flaps following access periodontal surgery
45479807|NCT03792113|Other|4-0 silk suture|Conventional 4-0 black silk suture will be used to approximate periodontal flaps following access flap surgery
45360264|NCT01072747|Biological|bovine heparin|5.000UI/mL bottle with 5mL
45360265|NCT01072747|Biological|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
45360266|NCT02594657|Procedure|pedal rate on 50 RPM|All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
45479808|NCT02491528|Biological|insulin Aspart injection|Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
45479809|NCT02491528|Biological|insulin Aspart injection (NovoRapid)|Subcutaneous injection of insulin Aspart injection (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
45479810|NCT01304927|Drug|Cholecalciferol and calcium|Initial one dose oral mixture of 300.000 IU Cholecalciferol followed by 5 months treatment with one tablet daily containing 35 ug Cholecalciferol and 500 mg calcium
45479811|NCT01304927|Other|Placebo|microcrystalline cellulose maltodextrin Arachidis oil
45479812|NCT05464940|Other|Intravenous caffeine|"Group assigned to receive caffeine will receive intravenous(IV) caffeine and sodium benzoate infusion starting at 250-500 mg.~This method will use an automated algorithm that adjusts the flow of the infusion depending on the individual's sex and weight and then in a serial fashion in response to blood caffeine measurements. Serial blood caffeine measurements at pre-determined intervals according to the algorithm will be until a steady state is obtained."
46048656|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 18 months of age
45687996|NCT04140396|Drug|Saline infusion|Normal saline infusion at 10mL/hour
45687997|NCT04140396|Drug|Lidocaine infusion|Lidocaine infusion at 1.0mg/kg/hr
46048657|NCT00944034|Biological|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age.
45687998|NCT04121650|Behavioral|Collaborative Problem Solving|CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.
45687999|NCT04117178|Drug|Donepezil|Adjustment of treatment with donepezil according to serum level.
45688000|NCT04117178|Drug|Memantine|Adjustment of treatment with memantine according to serum level.
46048658|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
46048659|NCT00944034|Biological|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 18 and 20 months of age
46048660|NCT00944034|Biological|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
46048661|NCT00944034|Biological|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 24 and 26 months of age
46048662|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 (Group 3a), 18 (Group 3b) or 24 (Group 3c) months of age
46048663|NCT02853240|Procedure|Muscle biopsy|A biopsy (specifically done for the study) of a muscle that has already been injected with botulinum toxin before inclusion of the patient in the study will be performed, taken during a planned surgery (for tendon transfer or muscle lengthening). A biopsy of a muscle that has never been injected with botulinum toxin may be performed during surgery. No biopsy will be made on a member that would not require surgery. Thus sampling will be conducted on a muscle requiring a surgery: 2 to 3 millimeters will be taken on 10 mm muscle before transfer or lengthening.
46048664|NCT02853552|Drug|Misoprostol|800mcg misoprostol taken sublingually
46048665|NCT02850471|Device|electroacupuncture|Transcutaneous Electric Acupoint Stimulation which is a device of electroacupuncture was used on patients in TEAS group with the stimulator parameters set as 2/100Hz, 2V, 30min.
46048666|NCT04202055|Other|Biomarker analysis|Detection of biomarker in cerebrospinal fluid
46048667|NCT02853396|Other|Cognitive Behaviour Therapy|
46048668|NCT02853396|Other|Psychoeducation|
46048669|NCT02846727|Device|skin perfusion image|Upon enrollment following written, informed consent, the patient will receive an injection of 7.5 mg of Indocyanine Green (ICG) intravenously (Dilute 25 mg of Indocyanine Green (ICG) with 10 cc of solvent to achieve a 2.5 mg/cc concentration.) Following injection, Novadaq's LUNA™ fluorescence angiography system will be utilized to map a standard skin perfusion image (SPI) over the upper extremities and anterior chest wall.
45360267|NCT02594657|Procedure|pedal rate on 80 RPM|All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
45360268|NCT00875628|Drug|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 100 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
45360269|NCT00875628|Drug|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 300 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
45360270|NCT00875628|Drug|PF-00868554 or Placebo|Dosage Form: Tablet Dosage: PF-00868554 600 mg or placebo under fed conditions Frequency: BID (twice daily) Duration: 14 days
45360271|NCT00879372|Drug|tianeptine|tianeptine 12,5mg TID
45360272|NCT00879372|Drug|Placebo|Placebo 12.5 mg TID
46048670|NCT02857296|Other|interview and observation|
46048671|NCT02846649|Behavioral|PIER|Daily text message queries with tailored support
45688001|NCT04117178|Diagnostic Test|Measurement of serum level of anti-dementia drug|"Participants allocated to the intervention arm are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention group not experiencing side effects will have their treatment adjusted after 6 months based upon serum levels of the drug in question.~Participants allocated to the standard of care arm follow the usual routines of the dementia clinic but are requested to have the serum level of the prescribed drug and CYP2D6-genotype measured after 12 month."
45360273|NCT00731783|Drug|2% Mupirocin Ointment|Apply ointment to the anterior nares twice daily for 5 days.
45360274|NCT00731783|Drug|4% Chlorhexidine liquid soap|Bathe with liquid soap daily for 5 days.
45688002|NCT04115826|Procedure|Per-oral Pancreatoscopy-guided Lithotripsy|Per-oral Pancreatoscopy-guided lithotripsy will be administered for a maximum of 4 sessions (1 hour max per session). Either electrohydraulic lithotripsy or laser lithotripsy will be allowed during the session at the discretion of the endoscopist.
45688003|NCT04115826|Procedure|Extracorporeal Shock-Wave Lithotripsy|ESWL will then be performed with the patient in either slight left or right lateral decubitus with shock waves entering the body from the ventral side. The shockwaves will be focused first on the most distally located stone within the main duct and then on other calculi moving from the head towards the body. If a stent has been inserted during preceding ERP then this may also serve as a guide to target main pancreatic duct stones by ESWL. A total of one hour of ESWL at a rate of 60-120 shocks/minute will be delivered in one treatment session.
45688004|NCT04109820|Dietary Supplement|MitoQ|Oral; 20mg once a day for 14 days
45360275|NCT00731783|Behavioral|Hygiene protocol|"Follow key hygiene tips indefinitely. Tips are:~Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~Use liquid(pour or pump) soaps instead of bar soaps.~Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~Do not share personal care items such as razors and brushes.~Wash all sheets and towels in hot water. Wash sheets every week.~Use towels and wash cloths only once before washing and do not share."
45360276|NCT00879450|Other|Booklet|booklet given to parents for home exercises
45360277|NCT03691350|Procedure|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with bronchoalveolar lavage
45360278|NCT03691350|Drug|Cigarette|Smoke usual brand
45360279|NCT03691350|Other|Electronic Cigarette|Smoke SREC with nicotine
45360280|NCT03691350|Other|Electronic Cigarette|Smoke SREC without nictoine
45360281|NCT03691350|Other|Laboratory Biomarker Analysis|Correlative studies
45360282|NCT03691350|Drug|Nicotine Replacement|Receive NRT comprising patch, gum, or lozenge
45360283|NCT03691350|Other|Questionnaire Administration|Ancillary studies
45360284|NCT02592083|Drug|Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin|
45360285|NCT02592083|Drug|Palbociclib|
45360286|NCT04589676|Behavioral|Naloxone training|The naloxone training will teach participants about how to appropriately use naloxone in the event of an opioid overdose.
45360287|NCT00724451|Biological|Peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling
45360288|NCT00724451|Drug|Ribavirin|Ribavirin administered in accordance with approved labeling
45360289|NCT00724451|Biological|Peginterferon alfa-2a|Peginterferon alfa-2a administered in accordance with approved labeling
45360290|NCT00724373|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
45360291|NCT00724373|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
45688005|NCT04099836|Drug|Atezolizumab|1200 mg IV
45688006|NCT04099836|Drug|Bevacizumab|15 mg/kg IV
45688007|NCT04094961|Drug|Ixazomib|Oral, administered four times per cycle
45360292|NCT02594579|Drug|Vitamin D3|Vitamin D3 100,000 u per day on day 1,3 then 50,000 u/day on day 5,7,9,12 and continue 50,000 u 3 times/ week for 4 weeks
45688008|NCT04094961|Drug|Pomalidomide|Oral, administered 14 times per cycle
45688009|NCT04094961|Drug|Dexamethasone|Oral, fixed dose administered 8 times per cycle
45688010|NCT04073420|Device|Surgical Heart Valve Repair Products|Surgical heart valve repair products.
46048672|NCT02854956|Behavioral|Neuropsychological, cognitive and behavioral assessment|"The assessment includes mainly :~The Raven's Progressives matrices test which allow to assess the non-verbal reasoning mental age of the patient~The Wechsler scale or Brunet Lézine scale which allow to assess The Intellectual Quotient~The Peabody Picture Vocabulary Test Revised which allow to determine the Vocabulary age (receptive language).~The Vineland adaptive behavioral scale which allow to assess the adaptive behavior~The Nisonger child behavior rating form which allow to assess the behavior disorders~Analogical visual reasoning task (eye-tracking assessment and behavior assessment) which allow to identify the strategy used to solve the task and provides an objective and quantitative assessment of visual analogical reasoning and cognitive inhibition.~Kinematic analysis of a grasping movement which allow to study the effect of the orientation and the type of pinch on the movement duration and both the transport component and the grasp component."
46048673|NCT04258917|Device|Study withdrawn|Study withdrawn
46048674|NCT02857452|Other|SLA Questionnaire|
46048675|NCT02857452|Other|Lupus Qol Questionnaire|
45360293|NCT02594579|Drug|Placebo|Placebo on day 1,3,5,7,9,12 then 3 times/ week for 4 weeks
46048676|NCT04268472|Drug|GP30101|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
46048677|NCT04268472|Drug|Prezista®|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
46048678|NCT04268472|Drug|GP30101|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
45360294|NCT02593409|Drug|TDF/FTC|All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
45360295|NCT00724061|Biological|Pegylated interferon α-2b|PEG-IFN-α-2b will be administered subcutaneously once a week. The starting dose of PEG-IFN-α-2b will be 1.5μg/kg. Each patient will undergo dose escalation to 3, 4.5, 6, 7.5, and up to 9μg/kg every 2 weeks or to maximum tolerated dose will be allowed. If no dose limiting toxicity (DLT) is observed, the maximum dose reached will be expanded. Once this dose has been given weekly for 2 weeks with no DLT, therapy will continue at this dose for up to 1 year depending on response.
45688011|NCT04073420|Device|Surgical Heart Valve Replacement Products|Surgical heart valve replacement products.
45688012|NCT04070040|Drug|Camrelizumab|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
45688013|NCT04063085|Device|PROTAHERE Absorbable Adhesion Barrier|40 mg/ml (4%) cross-linked hyaluronan
45688014|NCT04063085|Device|Hyalobarrier Gel|Laparotomy: 40 mg/ml (4%) cross-linked hyaluronan Endoscopy: 30 mg/ml (3%) cross-linked hyaluronan
45688015|NCT04063085|Other|No treatment|No anti-adhesion agent applied
45688016|NCT04063085|Device|Seprafilm Adhesion Barrier|a hyaluronate carboxymethylcellulose-based bioresorbable membrane
45688017|NCT04063085|Device|Gynecare Interceed (TC7) Absorbable Adhesion Barrier|an oxidized regenerated cellulose absorbable membrane
45688018|NCT04055948|Behavioral|One-on-one teaching sessions|One-on-one teaching sessions with the caregiver during radiation treatments. (note - intervention sessions 2 & 3 delivered by phone during COVID-19)
45688019|NCT04055948|Behavioral|Telephone booster contact|Telephone booster contact 2 weeks post-treatment.
45688020|NCT04054817|Device|Lamellar keratoplasty-ABCcolla® Collagen Ophthalmic Matrix|Lamellar keratoplasty was done by removing stromal layer, ABCcolla® Collagen Ophthalmic Matrix was sutured to the defective part of the cornea.
45360296|NCT00724061|Other|Psoralens with ultraviolet light A|Oral psoralen (8-methoxypsoralen, 0.6-1.0 mg/kg) will be taken 1.5 to 2 hours prior to UVA treatment. The initial UVA dosage will be approximately 0.5 to 1.5 J/cm2, and will be increased in increments as determined by skin type and tolerability. PUVA therapy will be given 2-3 times per week until complete remission (CR) is achieved. Afterwards, additional maintenance therapy will be given with a gradual reduction from once a week to every 4-6 weeks up to 1 year after CR was achieved.
45479813|NCT05464940|Other|Masked Placebo|"The patients assigned to the masked placebo will receive 5% dextrose in 0.45% saline using the same infusion protocol for a random length of time that was within 1 standard deviation(SD) of the mean time to achieve a steady state using the caffeine protocol (17+4 min).~To maintain blinding, caffeine blood concentration measurements that will be randomly generated within 2 SDs of the predicted values calculated by the algorithm will be used and verbally communicated for placebo infusions."
45360297|NCT00724061|Other|Narrowband-ultraviolet light B|The initial NB-UVB dose will be 70% of the patient's MED and approximately 0.2 J/cm2 and will be increased by 15% of each subsequent treatment as determined by skin type and/or tolerability. Therapy will be given 3 times per week until complete remission (CR) is achieved. Additional maintenance therapy will be administered while gradually reducing NB-UVB from thrice weekly to once a week. All patients will continue maintenance NB-UVB therapy until 1 year after they have achieved CR.
45360298|NCT04936386|Behavioral|Survey|The survey is composed of 4 different sections: the first section included questions about demographic data of participants; the second part evaluated responders' knowledge about FGM; the third section focused on participants' working experience with patients affected by FGM and personal attitude related to this topic.
45479814|NCT01305551|Drug|Saxagliptin|Tablet, Oral, 5 mg, once on Day 1 only
45479815|NCT01305551|Drug|Metformin XR|Tablet, Oral, 500 mg, once on Day 1 only
45479816|NCT01305551|Drug|Saxagliptin/Metformin XR FDC|Tablet, Oral, 5/500 mg, once on Day 1 only
45688021|NCT04053946|Device|Next Science Wounds Gels|SurgX will be applied once at closure while BlastX will be applied everyday until day 28 with each dressing change.
45688022|NCT04046406|Device|MR neurography-guided cryoanalgesia|Treatment will be performed using a FDA-approved Galil Medical cryoablation system and FDA-approved Galil Medical cryoablation needles.
45844744|NCT01858740|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
45844745|NCT01858740|Drug|Fludarabine Phosphate|Given IV
46048679|NCT04268472|Drug|Prezista®|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
45688023|NCT04056013|Device|Vicryl Rapide absorbable suture|"In general, most laceration repair has been done with sutures on the surface of the skin that do not break down and fall off on their own, so after enough days have passed for the laceration to heal properly, the patient needs to return to the ED to have the sutures removed by cutting them off. These sutures are called nonabsorbable. Some newer sutures have been designed to slowly dissolve on their own and fall out over several days. These are called absorbable sutures. You do not normally need to return to the ED for removal as these should slowly dissolve and fall out on their own."
45360299|NCT05195424|Diagnostic Test|Estimation of central venous pressure by echocardiography in intubated children in pediatric intensive care|Estimation of central venous pressure by echocardiography in intubated children in pediatric intensive care
45688024|NCT04044248|Device|TIPS-obliteration|Transjugular intrahepatic portosystemic shunt (TIPS) decompression of portal hypertension coupled with transvenous obliteration of gastric varices (GVs).
46048680|NCT02846337|Procedure|ULTRAFILTRATION|"Peritoneal dialysis: at least one daily contact, 5 days a week minimum, with a hypertonic solution. Le number of contact et the stasis duration will be decided by the practitioner.~Hemodialysis: at least one hemodialysis per week, one hemofiltration and/or hemodiafiltration per week, and at least 2 liter of ultrafiltrate extraction per week. In case of serious interdialytic weight gain, and/or hemodynamic unsteadiness, sessions can be up to 6 per weeks. Sessions duration will be adjusted to the needful ultrafiltrate and hemodynamic tolerance.~Isolated ultrafiltration: at least once a week, and includes an extraction of minimum 2 liter ultrafiltrate in less than 4 hours. It could be done, according to routines and department capacity, on a hemodialysis generator, plasmatic exchange generator, or mobile ultrafiltration device."
46048681|NCT02846337|Procedure|ENHANCED MEDICAL TREATMENT|"Close cardiologic and nephrologic follow-up, minimum 4 times a year, This incidence matches the heart failure, and chronic kidney failure care guidance for our sample~Medical care adjustment in order to apply European and American guidance for chronic heart failure care~Hydric, caloric, peptic and sodium input evaluation by a dietician, and adjustment if needed~Physical rehabilitation suggestions by a physiologist~Evaluation of an interventional approach requirement, and implementation if needed (pacemaker, defibrillator, cardiac resynchronization, diagnosis and therapeutic coronary angiography, ventricular stimulator) according to European and American guidance."
45360300|NCT02594423|Device|Fine Needle Diathermy|Fine needle diathermy is a surgical procedure that is used in the treatment of corneal NV. It is a safe and effective method for corneal vessels occlusion.
45479817|NCT03897296|Diagnostic Test|High resolution anorectal manometry, water perfused catheter|High resolution anorectal manometry with the use of water-perfused catheter will be performed to eligible subjects willing to participate in the study
45479818|NCT03791879|Drug|Caudal dexamedatomidine analgesia|"Technique performance (Caudal block): classical technique; palpation, identification and puncture with the patients in the lateral position (permits easy access to the airway under general anesthesia) using a 22-G short-beveled needle under sterile conditions advancing needle pierces the sacrococcygeal ligament.~After needle insertion, pre-calculated volume of Levob plus DEXM bolus was injected as follow; Group A Caudal Levob 0.125%+ DEXM 0.5µg/kg. Group B Caudal Levob 0.125%+ DEXM 1µg/kg. Group C Caudal Levob 0.125%+ DEXM 1. 5 µg/kg. Group D Caudal Levob 0.125%+ DEXM 2µg/kg."
45479819|NCT03896360|Behavioral|Food order behavioral intervention plus standard care|Subjects in the Food order behavioral intervention plus standard care will receive standard counseling by a registered dietitian and additional carbohydrate last food order behavioral counseling by a member of the research team at baseline and Weeks 4, 8 and 12.
45479820|NCT03896360|Behavioral|Standard Care|Subjects will receive standard counseling by a registered dietitian at the baseline visit. Standard counseling will be similarly reinforced at weeks 4, 8 and 12.
45479821|NCT03799757|Drug|40ml of 0.25% bupivacaine|
45479822|NCT03799757|Drug|40ml of 0.9% normal saline|
45688025|NCT04040413|Procedure|bariatric surgery|All bariatric procedures
45360301|NCT02594423|Drug|Bevacizumab|Bevacizumab is a humanized monoclonal antibody that binds to isoforms of VEGF-A .
45360302|NCT04038840|Drug|[11C]UCB-J radiotracer|I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein
45360303|NCT04038840|Device|PET-MR|Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
45360304|NCT04087187|Drug|Treatment A|Subject will be given AZD5718 Dose A tablet once daily
45479823|NCT03844646|Device|CGM|Intermittent use of a continuous glucose monitor (CGM)
45479824|NCT03844646|Other|Dietitian|Monthly meetings with a dietitian
45479825|NCT03825692|Drug|Zhizhu Kuanzhong Capsule|Zhizhu Kuanzhong Capsule, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
45688026|NCT04039633|Procedure|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
45688027|NCT04039633|Procedure|Sham spinal cord stimulation|A pulse generator is implanted, but no spinal cord stimulation is provided
45360305|NCT04087187|Drug|Treatment B|Subjects will be given AZD5718 Dose B tablet once daily
45360306|NCT04087187|Drug|Treatment C|Subjects will be given AZD5718 Dose C tablet once daily
45360307|NCT04924764|Other|Conventional physical therapy.|Conventionally used intervention for subacute and chronic neck pain.
45360308|NCT02592005|Other|amount of fine dust and other environmental exposure|this study compares levels of exposure to to fine dust PM 2.5 by individual measurement both at home and at work
45360309|NCT00882414|Drug|FERINJECT® (Ferric carboxymaltose)|FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.
45360310|NCT00882414|Drug|Placebo|Placebo will be administered i.v. into a peripheral vein in the arm. A total volume of 100mL 0.9% saline will be administered over 15 minutes duration.
46048682|NCT04269018|Behavioral|Cancer specific Mobile text message|The intervention is cancer specific lifestyle mobile text messages daily for 2 months
45844746|NCT01858740|Other|Laboratory Biomarker Analysis|Correlative studies
46048683|NCT04269018|Behavioral|General health messages|Daily text related with general health message
45360311|NCT02593487|Drug|Rosuvastatin 10mg/d group|rosuvastatin 10mg tablet,q.d. for 12 weeks.
45360312|NCT02593487|Drug|Rosuvastatin 20mg/d group|rosuvastatin 20mg tablet,q.d. for 12 weeks.
45360313|NCT00875784|Drug|TREXIMA™|sumatriptan succinate / naproxen sodium tablet
45360314|NCT00875784|Drug|IMITREX® (4mg)|sumatriptan succinate injection (4mg) administered using the IMITREX STATdose System®
45360315|NCT00875784|Drug|IMITREX® (6mg)|sumatriptan succinate injection (6mg) administered using the IMITREX STATdose System®
45844747|NCT01858740|Drug|Methotrexate|Given IV
45360316|NCT00875784|Drug|IMITREX Tablet 100mg|IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
45360317|NCT00875862|Procedure|Interscalene catheter with Ropivicaine or normal saline|Patients will be randomized to one of two groups: 0.2% Ropiviciane or normal saline in the infusion pump, following a shoulder manipulation for adhesive capsulitis. The patients will be followed by doctors and study staff to assess pain, range-of-motion and quality-of-life.
45360318|NCT00882492|Biological|GLP 1|This a continuous intravenous infusion of GLP-1 (7-36) amide infusion (1.5 pmol/kg/min)
45360319|NCT00882492|Biological|normal saline solution placebo|This is a continuous intravenous infusion of normal saline solution as placebo (1.5 pmol/kg/min) during cardiac surgery
45360320|NCT04038450|Other|No intervention|No interventions separated the groups. Each group reviewed pictures and wrote down their estimated ROM of the joint pictured.
45360321|NCT00879528|Other|Patients with negative PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.~After the end of salvage therapy, consolidation depends on the outcome of PET:~PET negative: These patients will follow a standard treatment that includes high-dose chemotherapy with reinfusion of autologous peripheral stem cells."
45479826|NCT03825692|Drug|Zhizhu Kuanzhong Placebo Capsule|Placebo, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
45360322|NCT00879528|Other|Patients with positive PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.~After the end of salvage therapy, consolidation depends on the outcome of PET~PET positive, the consolidation therapy consists of 2 phases:~phase1:common to all consists in a series of high-dose chemotherapy with Melphalan 200 mg/sqm, followed by reinfusion of autologous peripheral stem cells~phase2:depends on the availability of a compatible donor. If there is a donor, the patient will continue with an allogeneic transplant preceded by a reduced intensity conditioning.~If there is not a donor, the patient will continue with a second round of high-dose chemotherapy with BEAM with reinfusion of autologous peripheral stem cells."
45360323|NCT00731549|Drug|Aripiprazole IM Depot|300mg or 400mg
45360324|NCT00875940|Other|Diagnostic imaging procedures.|
45360325|NCT00882570|Drug|Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
45360326|NCT00882570|Drug|Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)|
45360327|NCT00885456|Behavioral|PREVENT program|12-week program of aerobic/strengthening exercises and education designed to induce physiological and behavioral changes deemed necessary to reduce vascular risk
45360328|NCT00885456|Behavioral|Usual Care|Three or more out-patient visits to the neurovascular clinic for assessment, counseling and referral to appropriate health care professionals.
45360329|NCT00882726|Drug|CNTO 3649 IV (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (1, 3, 10, 30, 100 or 300 microgram per kilogram, subject to change) as a 2-hour IV infusion.
45360330|NCT00882726|Drug|CNTO 3649 SC (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (10, 30, 100 or 300 microgram per kilogram, subject to change) as a SC injection.
45360331|NCT00882726|Drug|CNTO 3649 SC (Diabetic patients)|Diabetic patients will receive multiple doses of CNTO 3649 (30, 100 or 300 microgram per kilogram, subject to change) as subcutaneous injections once weekly for 4 consecutive weeks.
45360332|NCT00882726|Drug|Placebo|Participants within each dosing group who are randomized to placebo will receive a corresponding IV infusion or SC injection of placebo.
45688028|NCT04033614|Device|Fasciotens-Abdomen|The basic principle of Fasciotens Abdomen is the ventrally directed pulling force on the two fascial edges via an external device with support on the thorax and pelvis. A commercially available resorbable surgical mesh is sewn into the fascia margin. Commercial surgical sutures attached to this net are then attached to a height-adjustable suspension, which is connected to an external support on the thorax and pelvis. This ensures continuous traction to the two fascial edges. The remaining wound surface can then be treated with conventional dressing material.
45688029|NCT04030676|Procedure|Biopsies|Two more biopsies in inflammatory zone will be collected.
45479827|NCT04025255|Dietary Supplement|Braini|A novel, neuro-protective and neuro-restorative dietary supplement composed of a combination of active ingredients which have been commercially-available since at least 2015 or have achieved FDA new dietary ingredient notification (NDIN) status in 2018
45479828|NCT04025255|Dietary Supplement|Placebo|Matched placebo
45479829|NCT04655924|Device|Clinical Decision Support System|Clinical Decision Support System using Measurement-Based Care and Digital Decision Support Platform
45479830|NCT02960009|Device|HD-tDCS|Different stimulation protocols will be applied to the primary motor cortex of stroke patients. After 20-minute stimulation, EMG-driven robot hand training will be conducted.
45360333|NCT00882804|Drug|Hemin infusion|Hemin (Panhematin®, Ovation Pharmaceuticals, Deerfield, IL) will be administered through a large-caliber peripheral vein at a dose of 1.25 mL/kg and at a rate of 60 mL/hour. To enhance stability, Panhematin® will be diluted in ~ 132 mL of 25% albumin to obtain a hemin concentration of 2.4 mg/mL.
45688030|NCT04030676|Biological|Blood samples|Blood samples will be performed necessary at QuantiFERON-CMV (QF-CMV) test.
46048684|NCT04308980|Dietary Supplement|Specialized product for medical nutrition (SPP-1)|"Patients randomly allocated to this group will use specialized product for medical nutrition (SPP-1). This product contains: soy protein, whey protein concentrate, microcapsulated rapeseed oil, maltodextrin, inulin, Polydextrose, soy lecithin, potassium citrate, magnesium lactate, ω-3 PUFA (docosahexaenoic acid), sweetener mixture (stevia extract, erythritol), natural flavor Yogurt-vanilla, calcium carbonate, betaine hydrochloride, natural flavor raspberry, vitamin premix (vitamins a, e, C, D3, B1, B2, B6, B12, PP, folic acid, Pantothenic acid, K1, Biotin), beet juice concentrate, carrageenan, mineral premix (iron, zinc, copper, manganese, iodine, selenium, molybdenum, chromium), alpha-lipoic acid. The product is packed in approved by sanitary rules bags by 30 g. The instant drink obtained by the mixture of the bag content with warm (30-60C) water should be used immediately after being prepared. The daily dose is 1 pack TID"
46048685|NCT04308980|Behavioral|individualized diet|All the patients enrolled to the study will be provided with recommendations on diet. Individualized requirements will be calculated based on the results of indirect calorimetry (resting energy expenditures) and measurements of urea in daily urine
46048686|NCT02844621|Drug|Omeprazole|20mg orally once daily
45360334|NCT00882804|Drug|placebo infusion|25 % albumin will be administered through a large-caliber peripheral vein at a dose at a rate of 60 mL/hour.
45360335|NCT00882882|Drug|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
45360336|NCT00882882|Drug|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
45360337|NCT00882882|Drug|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
45360338|NCT00882882|Drug|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
45360339|NCT00882960|Drug|intravenous fentanyl|An IV will be established and used to deliver Fentanyl at 50 micrograms to patients who meet pre-hospital protocol for pain management. Examples of this may be burn patients, fractures, trauma.
45688031|NCT04025216|Biological|CART-TnMUC1|Single intravenous administration of genetically modified autologous T cells engineered to express a TnMUC1-Targeted Genetically-Modified Chimeric Antigen (CAR)
45688032|NCT04025216|Drug|Cyclophosphamide|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1
45688033|NCT04025216|Drug|Fludarabine|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1
45688034|NCT04020185|Drug|IMSA101|IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.
45688035|NCT04020185|Drug|Immune checkpoint inhibitor (ICI)|Administered according to product label
45688036|NCT04020185|Drug|Immuno-oncology (IO) therapy|Administered according to product label
45688037|NCT04014205|Drug|Orelabrutinib (ICP-022)|ICP-022 The drug product is a white, round, uncoated tablet
45688038|NCT04010422|Diagnostic Test|no intervention|no intervention
45479831|NCT00706342|Drug|Fostamatinib Disodium / R935788|R935788 tablets
46048687|NCT04971278|Behavioral|Supportive care program|Community Health Workers, a home visiting doctor service, a supportive care nurse, and behavioral health specialist engage the population to address a range of biopsychosocial needs with end goal in increasing support in the community and engaging palliative and hospice care when appropriate to prevent hospital readmissions, shorten length of stay, reduce hospital utilization, and decrease overall patient cost with a focus on hospital spend.
45360340|NCT00882960|Drug|intra-nasal fentanyl|a mucosal atomization device will be used to deliver 50 mcg of Fentanyl to patients who have been identified at requiring pre-hospital pain management
45360341|NCT00883038|Other|diabetic diet following the DNSG guidelines|The DNSG diet consists of 15-20% protein, ≤7% saturated fat, 60-70% carbohydrate and monounsaturated fats, cholesterol ≤200 mg/day, fiber content 20-30g/day.
45360342|NCT00883038|Other|low-fat vegetarian diet|The low-fat vegetarian diet (~10% of energy from fat, 15% protein, and 75% carbohydrate, fiber content 40-50 g/day) consists of vegetables, fruits, grains, legumes and small amounts of nuts. Participants will be asked to avoid animal products and added fats and to favor low-glycemic index foods, such as beans and green vegetables.
45688039|NCT04010409|Other|no intervention|no intervention
45688040|NCT04009447|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|6-week CBT-I therapy to help improve sleep quality
45360343|NCT00883194|Drug|PRF-108|Ropivacaine
45360344|NCT00883194|Drug|Placebo|PRF-108 Placebo
45360345|NCT00883194|Drug|Ropivacaine|Solution
45360346|NCT00883194|Drug|PRF-110|
45479832|NCT01303991|Other|Hexvix PDT with Karl Storz T-Light|
45479833|NCT03611738|Drug|Ceritinib|Ceritinib daily by mouth (PO) with food, according to the dosage schedule outlined in the treatment arm.
45360347|NCT04038528|Behavioral|telemonitoring of T2DM|"Baseline record of:~Weight~Height~BMI~Abdominal circumference~Winsor Index~ECG~Retinography~Blood level of (fasting values): total cholesterol, HDL cholesterol, LDL cholesterol, blood sugar, triglycerides, glycated hemoglobin These parameters will be checked again at 3, 6 and 18 months in the two groups.~Telemedicine group (intervention):~Blood sugar (two measurements per week).~Body weight (weekly)~Blood pressure (weekly) Use of devices that allow the automatic upload of data via wi-fi or web is allowed~Control group (control):~Routine appointments scheduled by their GPs and specialists in outpatient clinics to record blood sugar levels as per standard GP or specialist physician's indications.~Blood sugar level is measured in mg/dl in a drop of capillary blood with the use of standard glucose meter"
45479834|NCT03611738|Drug|Docetaxel|Docetaxel intravenously (IV) every 3 weeks, according to the dosage schedule outlined in the treatment arm.
45479835|NCT03327454|Biological|Benepali|Administered as specified in the treatment arm.
45479836|NCT04612478|Behavioral|Self-Directed Exercise Program|The full SDEP program, which will be developed by physical therapists, orthopaedic trauma surgeons, and investigators with experience in health behavior change, will be designed to maximize adherence/compliance with the program
45479837|NCT04612478|Behavioral|Clinic-Based Physical|Patients will be referred to PT by the orthopaedic surgeon for enrollment into a clinic-based PT program per usual referral patterns at the surgeon's center. Patients will receive services based on their health care benefits defined by his or her insurance plan.
45479838|NCT05624411|Device|CU T380A IUD|post-placental insertion of intrauterine contraceptive device
45479839|NCT05624411|Device|multiload 375 IUD|post-placental insertion of intrauterine contraceptive device
45479840|NCT03323242|Device|LigaSure|The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with LigaSure
45479841|NCT03323242|Device|Harmonic Ultrasonic dissector|The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with Harmonic Ultrasonic dissector
45688041|NCT04008563|Procedure|Bariatric Surgery|Patients who are randomized to the intervention group will receive a progestin intrauterine device and be referred for bariatric service to undergo bariatric surgery within 3 months of their study consent.
45688042|NCT04005651|Device|POD L GF IOL|Cataractous lens will be removed in the study eyes and the POD L GF IOL will be implanted in the capsular bag
45688043|NCT04005651|Device|Symfony® IOL|Cataractous lens will be removed in the study eyes and the Symfony® IOL will be implanted in the capsular bag
45688044|NCT04005651|Device|AcrySof® IOL|Cataractous lens will be removed in the study eyes and the AcrySof® IOL will be implanted in the capsular bag
45688045|NCT03991936|Drug|Placebos|Normal saline intralesional injection
45688046|NCT03991936|Drug|Triamcinolone Acetonide 2.5 mg/mL|2.5 mg/mL intralesional injection
46048688|NCT02853162|Radiation|ARREST-study|Radiotherapy will be delivered in five fractions of 7 Gy every other day. An additional contrast enhanced MRI scan will be performed after the 2nd treatment fraction, and after 6 and 12 months
46048689|NCT01106534|Drug|placebo + aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
45688047|NCT03991936|Drug|Triamcinolone Acetonide 5.0 mg/mL|5.0 mg/mL intralesional injection
45688048|NCT03991936|Drug|Triamcinolone Acetonide 7.5 mg/mL|7.5 mg/mL intralesional injection
45688049|NCT03991936|Drug|Triamcinolone Acetonide 10 mg/mL|10 mg/mL intralesional injection
45688050|NCT03987581|Behavioral|Cognitive Behavioral Therapy (CBT)|Twelve in-person counseling sessions designed to assist participants with becoming abstinent from alcohol use (or reduce use).
46048690|NCT01106534|Drug|clopidogrel + aspirin OR prasugrel + aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine (clopidogrel or prasugrel) treatment in addition to aspirin.
45360348|NCT04037436|Other|Strength and Balance Training & Nutrition Education|Exercise:A kinesiologist-led twice-weekly program. Prior to attending the program, each attendee gets a 1:1 session with the kinesiologist to decide exercise starting levels. Group exercises start with a warm-up stepping game. Participants then perform 2 sets of 8 repetitions of each exercise, gradually progressing to an intensity of 3-8 repetitions maximum. Exercises include one each of a push, pull, squat, reach/press, lunge/step-up, lift and carry movement. After, there is a 10-minute group discussion to prompt making exercise routine at home. Nutrition:Two dietitian-led interactive group seminars to promote strategies to increase protein intake and sampling of protein-rich snacks and protein supplements. Seminar topics consider the cost to prepare high protein foods, the ability of retirement home residents to alter diet, how and why to spread protein intake through the day, how much protein is in their usual choices, and easy-to-consume protein-rich snacks.
45360349|NCT04037436|Other|Usual Care|During periods when a site is not involved in the MoveSTroNg program, participants will continue with their usual care routine. Usual care routines should not involve strength and balance exercises.
46048691|NCT01106534|Device|XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)|XIENCE V Everolimus Eluting Coronary Stent System assigned to both the arms.
46048692|NCT02844699|Drug|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
46048693|NCT02844699|Drug|Placebo|5% infusion solution of dextrose (glucose)
45479842|NCT01305629|Behavioral|Spiritual Self-Schema Therapy|"The Spiritual Self Schema therapy (3S+) intervention will consist of a series of 12 one hour-long sessions delivered individually to participants over a four-month period. The 3S+ approach combines cognitive and behavioral therapy techniques with elements of non-theistic Buddhist philosophy to increase motivation for treatment adherence, alcohol and/or substance use reduction or abstinence and the prevention or reduction of HIV risk behaviors. 3S+ draws from self-regulation theory, self-schema theory, and self-discrepancy theory to assist participants in defining and perceiving their addict self, when their addict self is active, and its resulting negative affect state. 3S+ remediates the addict schema by proposing the construction of an alternate and competing schema: the spiritual self. This spiritual self schema is compatible with HIV self-care, alcohol and drug use reduction or abstinence, adherence to treatment, and a compassionate life."
45688051|NCT03987581|Behavioral|Mobile Contingency Management (mCM)|Abstinence (measured by breath alcohol) will be intermittently reinforced. For each breath alcohol concentration reading that tests negative, a participant will earn a virtual scratch-off lottery ticket that contains 100 different values.
45688052|NCT03987581|Behavioral|Long-term incentive|This incentive is $300 for self-reported and bioverified 30-day abstinence from heavy drinking at the follow-up scheduled for 6-months after the initial quit date
45360350|NCT04038060|Behavioral|WhatsApp Group|Participants will receive peer adherence support through WhatsApp groups
45360351|NCT04038060|Behavioral|2-way SMS|Participants will receive healthcare worker adherence support through 2-way SMS
45360352|NCT04038060|Behavioral|Drug level feedback|Participants will receive adherence counseling based on tenofovir drug levels
45360353|NCT04038060|Behavioral|Monthly counseling sessions|Participants will receive monthly counseling on a variety of issues that may be impacting their PrEP adherence
45360354|NCT00888732|Drug|Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin|0.2 U/IU/kg subcutaneous injection, single dose
45360355|NCT00730925|Drug|BIBW2992|tablet BIBW high dose
45360356|NCT00730925|Drug|BIBW2992 + paclitaxel|tablet BIBW 2992 in combination with i.v. paclitaxel 3 weekly
45688053|NCT03982082|Procedure|Physical Therapy|Undergo physical therapy
45688054|NCT03982082|Other|Questionnaire Administration|Ancillary studies
46048694|NCT02848677|Behavioral|Nutritional counseling|Nutritional counseling implemented by a dietitian for a low sodium diet rich in fruits, vegetables, low fat dairy foods, and low in processed foods.
45360357|NCT00883272|Dietary Supplement|DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel]|a unique enzymatic isolate of the active complex in Tofu
45688055|NCT03982082|Procedure|Ultrasound|Undergo ultrasound via MuscleSound technology
45688056|NCT03979599|Procedure|ultra-sound guided transversus abdominis plan block|comparing ultrasound guided transversus abdominis plan block using combination of magnisum sulphate and levobupivacaine versus levobupivacaine
45688057|NCT03979599|Drug|magnesium sulphate& levobupivacaine|magnesium sulphate& levobupivacaine
45688058|NCT03979599|Drug|Levobupivacaine|levobupivacaine
45360358|NCT00236899|Drug|Gemcitabine|"Arm A: 1000 mg/m², 30 minute (min) intravenous (IV) infusion on Days 1 and 8, repeated every 21 days for 10 cycles for complete responders (CRs=disappearance of all target lesions) or partial responders (PRs≥30% decrease in sum of longest diameter of target lesions); 6 cycles for stable disease (SD=small changes that do not meet the above criteria); or until progressive disease (PD≥20% increase in sum of longest diameter of target lesions).~Arm B: 1250 mg/m², 30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm C: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm D: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
45360359|NCT00236899|Drug|Docetaxel|"Arm A: 75 milligram per square meter (mg/m²), 60 min IV infusion on Day 1 only, to be given 30 min prior to Gemcitabine, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm C: 30 mg/m², 30-60 min IV infusion on Days 1, 8, and 15, to be given 30 min prior to Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
45688059|NCT03974230|Other|Collection of datas|Collection of datas of examination for diagnosis and follow-up of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
45688060|NCT03974230|Biological|blood sample|Blood sample will be performed (genetic analyses).
45688061|NCT03974230|Other|slit lamp examination|Slit lamp examination will be performed.
45844748|NCT01858740|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
46048695|NCT02848677|Behavioral|usual care|usual care of hypertensive patients.
46048696|NCT00941304|Drug|Oxycodone|Single-dose of over-encapsulated oral 5-mg oxycodone capsule
45479843|NCT03049748|Device|Mobile phone app (VAD Care App)|"VAD Care App is a novel self-management tool being tested for patients with implantable LVADs. The app has daily push notifications (alerts), cues for daily self-management tasks, two-way communication using text messages and videoconferencing (virtual clinic), and links to LVAD self-management skills and videos easily accessible for self-management skill review."
45360360|NCT00236899|Drug|Paclitaxel|"Arm B: 175 mg/m², IV infusion over approximately 3 hours, followed by Gemcitabine, on Day 1, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm D: 80 mg/m², IV infusion over approximately 1 hour, Days 1, 8, and 15, followed by Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
45360361|NCT00611130|Drug|vigabatrin|Tablets twice a day for 9 weeks
45479844|NCT03049748|Other|Usual LVAD Care|Routine clinic follow-up visits over 6 months. Patients and caregivers will both receive self-management education post discharge and as needed throughout the duration of the study.
45479845|NCT02491216|Other|Acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
45479846|NCT03794063|Other|Robson 10 group classification system|WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.
45479847|NCT02491138|Behavioral|Appearance-based intervention|
46048697|NCT00941304|Drug|Buprenorphine|Single-dose of buprenorphine HCl buccal film
45479848|NCT02491138|Other|Pamphlets|
45479849|NCT03320356|Other|the French version of the Oxford Shoulder Score|
45479850|NCT03792035|Drug|Tongxinluo|tid, po.
45479851|NCT03792035|Drug|Placebos|tid, po.
45479852|NCT02488252|Drug|Semi-individualised Chinese Medicine treatment|"A: Panax ginseng, Atractylodes macrocephala, Pinellia ternate, Pericarpium citri reticulatae, Herba Pogostemonis, Glycyrrhiza uralensis, Rehmannia-6 decoction~B: Cortex magnoliae officinalis, Atractylodes macrocephala, Common Floweringquince Fruit, Common Vladimiria Root, Tsaoko Amomum Fruit, Palmae Fruit, Radixaconiti laterlis perparata, Zingiber officinale Rosc., Glycyrrhiza uralensis, Rehmannia-8 decoction~C: Root of Pilose Asiabell, Astragalus membranaceus, Rehmannia glutinosa, Common Macrocarpium Fruit, Dioscorea opposita , Barbary Wolfberry Fruit, Cortex eucommiae, Chinese Angelica, Glycyrrhiza uralensis~D: Rehmannia-6 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb~E: Rehmannia-8 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb"
45479853|NCT02488252|Drug|Routine medical care (active comparator)|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker at stable dose
45479854|NCT03799913|Biological|anti-MESO CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-MESO CARs
45688062|NCT03969693|Radiation|Standard treatment protocol with combined chemoradiation|As for consolidative RT used in patients with early-stage Hodgkin lymphoma, the RT field must essentially include the mediastinum.
45688063|NCT03966651|Drug|PRRT with 177Lu-DOTATATE|Children will receive 2 Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTATATE administered intravenously at 6 weeks interval.
45688064|NCT03961854|Drug|L. johnsonii Probiotic|Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
45688065|NCT03961854|Drug|Placebo Capsule|Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
45360362|NCT00611130|Drug|placebo|tablets twice daily for 9 weeks
45360363|NCT00885690|Drug|Sertindole|Sertindole 16-24 mg once daily
45479855|NCT03799913|Drug|Fludarabine|30mg/m2/d
45479856|NCT03799913|Drug|Cyclophosphamide|300mg/m2/d
45479857|NCT03323008|Other|Prototype|Usability testing and System Usability Scale
45479858|NCT03814382|Device|Acupuncture needle|Acupuncture needle
45479859|NCT01304069|Drug|Placebo|The subjects will be given orally placebo twice a day for 7 days prior to the study.
45844749|NCT01858740|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
45844750|NCT01858740|Drug|Tacrolimus|Given IV or PO
46048698|NCT00941304|Drug|Placebo Film|Single-dose of placebo buccal film
46048699|NCT00941304|Drug|Placebo Capsule|Single-dose of oral placebo capsule
46048700|NCT02845869|Device|THOR Laser LX2 System|Treatment session will take up to 25 minutes and will include stimulation of local lymph nodes and soft tissue, de-activation of trigger points, and eliciting analgesia.
45360364|NCT00885690|Drug|Olanzapine|Olanzapine 10-20 mg
45360365|NCT00888810|Drug|TOPOTECAN|IV administration on Day 1, day 8 and day 15, at the dose level of 3.2 mg/m² for 6 cycles of 28 days(up to 8 cycles)
46048701|NCT02845869|Device|Sham Therapy|The therapeutic light will be turned off but the system will produce similar noises and mild heat.
46048702|NCT02852460|Other|rapid recovery|
46048703|NCT04308824|Other|clipping|a single clip will be placed in every case of polypectomy for large colorectal polyps
46048704|NCT04308824|Other|nebulization of glue|After clipping, a cyanoacrilate glue will be nebulized using a spray catheter
46048705|NCT02846025|Dietary Supplement|Folate and capsule of oil hazel|rich diet aministracao folate and capsule of oil hazel
46048706|NCT02846025|Dietary Supplement|Folate and placebo|rich diet aministracao folate and placebo
46048707|NCT02846025|Dietary Supplement|antioxidant and placebo|antioxidant diet (90μg folate) and placebo capsule
46048708|NCT02880410|Device|NeuroBlate System|Laser Interstitial Thermal Therapy
46048709|NCT02880410|Drug|Radiation therapy and temozolomide|Radiation therapy and temozolomide
45688066|NCT03956784|Device|E-assessed clinical and biological follow up|"Clinical questionnaire: self-evaluation of pain (0 to 10), resumption of transit, bleeding, fever, pulse. In case of no filling, the patient is contacted.~An automatic alert system is defined and divide the patient according to three situations:~Normal situation~Situation requiring the nurse to call back the patient and contact the surgeon if the assessment requires medical advice~Disturbing situation requiring contact of the first-line surgeon if a potentially serious event is suspected. Each speaker's place is described for each item in the detailed protocols~Biological questionnaire:~Biological monitoring (blood count, Ionogram, C-Reactive Protein, urea, creatinine) is performed on D1, D3 and D7.~All information is accessible in real time by the surgeon who receives notifications by email and on his smartphone in case of clinical or biological abnormality on patient monitoring."
46048710|NCT02848755|Device|Cranial ultrasonography|
45844751|NCT01858740|Drug|Thiotepa|Given IV
45844752|NCT01858740|Radiation|Total-Body Irradiation|Undergo TBI
45844753|NCT01818492|Biological|NI-0501|
45844754|NCT01688076|Procedure|Botulinum Toxin A|Forehead will be injected with Botox.
46048711|NCT02879006|Drug|Chinese Herbal Medication|Capsules, 26 month course, starting 2 months pre-OIT
46048712|NCT02879006|Drug|Placebo|Placebo capsules that look identical to E-B-FAHF-2, 26 month course, starting 2 months pre-OIT
46048713|NCT02879006|Drug|Omalizumab|4 months course, starting 2 months pre-OIT through the 2 month build-up phase
46048714|NCT02879006|Drug|Multi OIT|24 months of multi OIT (maintenance dose of 1gm each food allergen)
46048715|NCT02846181|Drug|[14C]-SK-1405|
46048716|NCT00941070|Drug|triapine|Given IV
46048717|NCT00941070|Drug|cisplatin|Given IV
46048718|NCT00941070|Radiation|external beam radiation therapy|Undergo pelvic external beam radiation therapy
45360366|NCT00888810|Drug|LAPATINIB|Daily oral administration during all the study. 1250 mg/day
45360367|NCT02542176|Other|Freeze-dried Whole Grape Powder|60 g of whole grape powder for 4 weeks
45360368|NCT02542176|Other|Grape Powder Placebo|60 g of grape powder placebo for 4 weeks
45360369|NCT00256243|Drug|Doxorubicin|60 mg/m2 IV, bolus once every 14 days x 2-4 cycles
45360370|NCT00256243|Drug|Cyclophosphamide|600 mg/m2 IV once every 14 days x 2-4 cycles
45360371|NCT00256243|Drug|Paclitaxel|80 mg/m2 IV over 1 hour once weekly for 9-12 doses beginning two weeks after completion of last AC dose
46048719|NCT00941070|Procedure|quality-of-life assessment|Ancillary studies
45844755|NCT01556490|Device|TheraSphere|Yttrium 90 microspheres
46048720|NCT00941070|Other|questionnaire administration|Ancillary studies
46048721|NCT00941070|Radiation|fludeoxyglucose F 18|Undergo FDG-PET/CT
46048722|NCT00941070|Procedure|positron emission tomography|Undergo FDG-PET/CT
46048723|NCT00941070|Procedure|computed tomography|Undergo FDG-PET/CT
46048724|NCT02857218|Drug|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
46048725|NCT02857218|Procedure|Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
45688067|NCT03956784|Other|Usual at home follow up|"An information sheet on the clinical parameters to be monitored will be given to patients and will include the following information:~Immediate complications and warning signs:~Tachycardia> 120 bpm~Dyspnea~Rectorragies and / or melena~Vomiting with or without presence of blood~Major abdominal pain (visual analogue scale> 6/10)~Fever> 38~Management to deal with complications: call the service and / or the surgeon~Actions to be performed by the patient after the exit:passage of the nurse during 10 days for anticoagulant morning and evening (identical in both study groups)~Each patient will be given a prescription to perform a C-Reactive Protein assay on D1, D3 and D7, similarly."
46048726|NCT01098812|Device|Tecnis ZCB00 IOL (control)|Tecnis 1-piece acrylic IOL
46048727|NCT01098812|Device|Toric Intraocular lens|Toric acrylic intraocular lens with various cylinder powers
45360372|NCT00256243|Drug|Carboplatin|Area under the concentration curve (AUC) 2 IV once weekly for 9-12 doses beginning two weeks after completion of last AC dose
46048728|NCT00602316|Drug|gadolinium-chelate|
46048729|NCT00602316|Procedure|conventional surgery|
46048730|NCT00602316|Procedure|magnetic resonance imaging|
46048731|NCT00602316|Procedure|magnetic resonance spectroscopic imaging|
46048732|NCT02879786|Other|Posturographic tests|
45360373|NCT00256243|Drug|GM-CSF|250 μg/mL IV on day 5-14 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
46048733|NCT02879786|Other|Questionnaire of motion sickness susceptibility|
45360374|NCT00256243|Drug|Trastuzumab|AUC 2 IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
45479860|NCT01304069|Drug|Selecoxib|The subjects will be given orally selecoxib 200mg twice a day for 7 days prior to the study.
45479861|NCT01304069|Drug|Etoricoxib|The subjects will be given orally etoricoxib 120mg once a day for 7 days prior to the study.
45479862|NCT05459402|Drug|Methadone (100% dose)|Methadone for the treatment of opioid use disorder
46048734|NCT02857530|Drug|rhTPO|rhTPO
46048735|NCT02857530|Drug|placebo|without rhTPO
46048736|NCT02878928|Genetic|IDgenetix Neuropsychiatric Test Panel|The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
45479863|NCT05459402|Drug|Methadone (50% dose)|Methadone for the treatment of opioid use disorder
46048737|NCT00602394|Drug|Lithium|
46048738|NCT00903201|Drug|SB656933|20 mg
46048739|NCT00903201|Drug|SB656933|50mg
46048740|NCT00903201|Drug|Placebo|placebo
45360375|NCT04037202|Other|Foot massage|Foot massage includes classical massage techniques such as effleurage, petrissage and friction techniques. Effleurage is the movement of stroking and lubricating superficial tissues. Therefore, it is performed at the beginning and ending of the massage. Petrissage is the slow and rhythmic movement to apply direct pressure to the soft tissue underlying the skin with the balls of the fingers and thumbs. Friction is the application of pressure through small circular movements only in small areas, using hand or fingers. While muscle tissue is compressed and relaxed, blood and lymph circulation increases. Thus, lactic acid in the muscle fibers is diminished and fatigue and stress are decreased.
45360376|NCT01325857|Procedure|Bilateral superficial cervical plexus block|Bilateral superficial cervical plexus block with 0.525% ropivacaine 20ml
45360377|NCT01325857|Procedure|placebo|Procedure: Bilateral superficial cervical plexus block with normal saline 20ml
45360378|NCT01325857|Procedure|Control group|Procedure: Local anesthetic infiltration at incision site with 0.525% ropivacaine 20ml
45360379|NCT00888888|Procedure|Right hemicolectomy with or without primary anastomosis|During open classic appendectomy (McBurney incision) the surgeon decided to convert to midline extended laparotomy to perform a right hemicolectomy
45360380|NCT00236197|Drug|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally,placebo once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
45360381|NCT00236197|Drug|placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
45360382|NCT02541708|Drug|Ferric carboxymaltose|Intravenous Ferric carboxymaltose given at a calculated dose of 20mg/kg body weight in 1-3 infusions according to severity of anemia
45360383|NCT02541708|Drug|Ferrous sulfate + folic acid|Three dried ferrous sulfate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia
45360384|NCT00278629|Biological|hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
45360385|NCT00883350|Behavioral|RIDE e-health application|The RIDE e-Health application utilizes the latest technology to obtain near real-time food intake, body weight, and exercise data from participants living in their natural environment. The application also provides personalized and timely feedback and treatment recommendations based on participants' data. The application relies on the Remote Food Photography Method (Martin, 2009), which was developed by our research team, to collect freeliving food intake data that is transmitted to the researchers in near realtime using a camera and Bluetooth-enabled cell phone. A scale is used to collect daily body weight data from participants and these data are automatically transmitted to the researchers via the same cell phone. The e-Health application collects exercise data from participants and these data are delivered to the researchers via the internet; personalized feedback and treatment recommendations are sent to the participant every 1 to 3 days via the cell phone.
45360386|NCT03973567|Drug|selective serotonin reuptake inhibitor (SSRI) or serotonin noradrenaline reuptake inhibitor (SNRI) antidepressants|On the basis of routine treatment for 8-12 weeks, according to the characteristics of symptoms, a combination of SSRI or SNRI antidepressant drugs was given for 12 weeks.
45360387|NCT03973567|Other|conventional therapy|Anti-HP, acid suppression, gastrointestinal motility regulation, etc.
45360388|NCT00883428|Other|Set of questionnaires|A set of questionnaires to determine the existence of low back and pelvic pain during the pregnancy, and to identify possible risk factors.
45688068|NCT03955991|Behavioral|R-CBSM|10 weekly educational modules via an electronic tablet. A participant workbook is also provided that contains a summary of the rationale for each module, outline of each technique, and homework exercises.
45688069|NCT03955991|Biological|Influenza vaccine|Standard of care Influenza vaccine for that given year.
45688070|NCT03948698|Other|Innovative approached to pediatric TB care|Includes integration of TB care in non-TB entry points in facilities, decentralization from higher level clinics to lower levels, strengthening screening activities and building diagnosis and treatment capacity among healthcare workers
45688071|NCT03946514|Drug|losartan/hydrochlorothiazide|losartan 100 mg/hydrochlorothiazide 25 mg single-pill combination
46048741|NCT04309214|Dietary Supplement|MCT fats|Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period
46048742|NCT04309136|Drug|Anlotinib|All patients will receive Anlotinib for at least two cycles of neoadjuvant treatment
45688072|NCT03946514|Drug|amlodipine/hydrochlorothiazide|amlodipine besylate tablets (5 mg / tablet) + hydrochlorothiazide tablets (25 mg / tablet)
45688073|NCT03945279|Drug|BIIB100|Administered as specified in the treatment arm.
46048743|NCT04309136|Procedure|surgery|Perform surgery if operable after neoadjuvant therapy
46048744|NCT04309136|Procedure|core needle biopsy|Perform core needle biopsy if inoperable after neoadjuvant therapy
46048745|NCT04956302|Drug|Bortezomib|Given SC
46048746|NCT04956302|Drug|Daratumumab and Hyaluronidase-fihj|Given SC
46048747|NCT04956302|Drug|Dexamethasone|Given PO or IV
46048748|NCT04956302|Drug|Panobinostat Lactate|Given PO
46048749|NCT04202133|Behavioral|WW (formerly Weight Watchers)|The WW intervention will consist of weekly group workshops for 16 weeks with WW Coaches and Guides.
46048750|NCT04202133|Behavioral|Waitlist|The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered the WW intervention
45360389|NCT03975361|Other|Bliss-Believe|The samples from the blood samples carried out within the framework of Bliss Believe will be collected for a biological collection. Only one sample of patients included in BLISS BELIEVE STUDY will be obtained during a standard of care visit. It will be 21ml of blood.
45360390|NCT00885924|Drug|Desmopressin|Desmopressin 0.3 microgram/kg as an intravenous infusion given during 20 min.
45479864|NCT03327298|Procedure|pedicle screw fixation|One hundred forty four screws were placed in the lumbosacral pedicles of 32 patients using free hand technique depending on direct visualization of the pedicles, roots, and intervertebral disc ( IVD) after doing full laminectomy, then postoperative CT was done for evaluation of pedicle violation.
45360391|NCT00885924|Drug|Placebo|NaCl 0.9%
45688074|NCT03945279|Drug|Placebo|Administered as specified in the treatment arm.
46048751|NCT02848443|Drug|Trifluridine/tipiracil hydrochloride (S 95005)|Film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride, given orally at the dose of 25 or 30 or 35 mg/m2/dose, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
45360392|NCT01071811|Behavioral|Pedometer-based intervention|The participants were randomly assigned to either a pedometer group or a control group by drawing a sealed envelope with a unique randomizing number. The participants in the pedometer group received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program(18), a handout with a summary of the pedometer program, and a calendar for registration of daily steps. During the trial period they were asked to reset the pedometer every morning and to wear it during the entire day. In the evening they should take the pedometer off and register the accumulated steps in the calendar. After three, six, and nine weeks, the participants in the pedometer group got a mail to encourage them to keep using the pedometer and follow the program.
46048752|NCT02848443|Drug|Oxaliplatin|Concentrate for solution for infusion containing 5mg/ml of oxaliplatin, administered intravenously at the dose of 65 to 85 mg/m2, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
45360393|NCT01071889|Drug|Flumazenil|Flumazenil- 0.4 mg per 100 µl in a sublingual spray administration
45844756|NCT01372566|Device|Harvest PRP Separation System|Platelet-rich plasma (PRP) is a blood-derived therapy that consists of platelets and growth factors. PRP can be formed by drawing blood from a vein and spinning it at a high speed in a specialized device called a centrifuge.
46048753|NCT02848443|Drug|Bevacizumab|Concentrate for solution for infusion containing 25mg/ml of bevacizumab, administered intravenously at the dose of 5 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
46048754|NCT02848443|Drug|Nivolumab|Concentrate for solution for infusion containing 10mg/ml of nivolumab, administered intravenously at the dose of 3 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
45360394|NCT01071889|Drug|Placebo|Placebo - only excipients with no API
45479865|NCT03799601|Drug|Anlotinib|Anlotinib which has shown an affirmatory efficacy in ALTER0303 controlled trial as a 3rd-line treatment on advanced NSCLC is a tyrosine kinase inhibitor with a favorable safety profile in phase I trial which mainly targets VEGFR1/2/3, FGFR, PDGFR and c-kit.
45479866|NCT03799601|Drug|Docetaxel|a chemotherapy medication used to treat a number of types of cancer.This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer.It may be used by itself or along with other chemotherapy medication.It is given by slow injection into a vein.
45688075|NCT03935958|Dietary Supplement|Curcumin|Patients will receive curcumin 2000 mg a day, for 12 months
46048755|NCT04954586|Other|Pain Informed Movement|Participants will attend a twice weekly exercise program.
46048756|NCT00632697|Drug|pentoxifylline|800 mg daily for six months
46048757|NCT00632697|Drug|placebo|
46048758|NCT02848209|Procedure|TCA 20% Peeling|TCA peel at a concentration of 20% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
45360395|NCT00612690|Behavioral|Community mental health consultation model program|The community mental health consultation model program included collaboration among community mental health providers and (1) parent advocates to effectively maintain families in a school-based mental health program, (2) classroom teachers to enhance children's academic performance, and (3) peer-identified influential teachers to influence classroom teachers' use of behavior management strategies. This model further focused on the strongest teacher and parent predictors of student learning.
45360396|NCT00612690|Behavioral|Treatment as usual (TAU)|TAU included referral to community mental health clinic-based services, where participants received standard care for mental health-related problems.
45360397|NCT03973411|Drug|Prophylactic ondansetron|Pacients will receibe prophylactic ondansetron plus standard spinal anesthesia
45360398|NCT03973411|Drug|Placebo|Pacients will receibe standard spinal anesthesia
45360399|NCT00883506|Drug|Lisinopril 40 mg Tablet (Zestril) under fed conditions.|
45360400|NCT00883506|Drug|Lisinopril 40 mg Tablet under fasting conditions.|
45360401|NCT00883506|Drug|Lisinopril 40 mg Tablet under fed conditions.|
45360402|NCT04268784|Drug|DNL343|Single and repeating oral dose(s)
45360403|NCT04268784|Drug|Placebo|Single and repeating oral dose(s)
45360404|NCT00278473|Behavioral|Meta-Cognitive Therapy|Cognitive Behavioral Group Treatment
45360405|NCT00278473|Behavioral|Supportive Therapy|Social Support Problem-Solving Group Treatment
45360406|NCT04037280|Other|Exercise|Four type of exercises will be delivered to patients. These exercises differ for posology and typology.
45360407|NCT00278395|Drug|Vorinostat|Given orally
45360408|NCT00889044|Drug|clopidogrel by chewing|600 mg clopidogrel by chewing
45360409|NCT00889044|Drug|Placebo|Placebo p.o
45360410|NCT00889122|Behavioral|Exergame (DDR)|Use of an active videogame vs. pedometers given to entire families to promote physical activity.
45360411|NCT00886002|Drug|Fentanyl; Buprenorphine; Naloxone|
45360412|NCT00883584|Drug|IMD-1041|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
45360413|NCT00883584|Drug|Placebo|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
45360414|NCT00883662|Drug|Levonorgestrel (Mirena, BAY86-5028)|Patients older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications
45360415|NCT03669822|Other|Standard of care|Care decisions driven by local physicians; this is an observational cohort.
45360416|NCT00883818|Drug|azithromycin, doxycycline|"azithromycin 1g once for women with positive cultures at baseline~doxycycline 100 mg twice daily for 7 days for women with persistent infection after treatment of azithromycin 1g"
45360417|NCT00889356|Drug|Clindamycin 100mg and Ketoconazole 400mg|1 vaginal capsule once a day at night
45360418|NCT00889356|Drug|Tetracycline 100mg and Amphotericin B 50mg|One full applicator, once a day at night
46048759|NCT02848209|Procedure|Phenol/croton oil Peeling|Phenol/croton oil is applied on subcutaneous undermined skin samples and occluded with silicone tape for 24 hours and not neutralized.
45688076|NCT03935958|Other|Placebo|Patients will receive placebo capsule identical in appearance and taste to the supplement, for 12 months
45360419|NCT00886080|Procedure|Pulmonary vein isolation using microwave energy|The surgical ablation procedure is the first step during surgery and is performed before institution of cardiopulmonary bypass allowing off-pump beating heart ablation. The off-pump beating heart ablation procedure is performed according to a specific box lesion surrounding the pulmonary veins, using microwave energy. Afterwards cardiac surgery is performed as usual in both treatment arms.
45360420|NCT00889434|Dietary Supplement|ECGC|1 cycle will comprise 28 days of continuous daily treatment with EGCG given once/day(total 375 mg) /day in the morning with food followed by a 14 day wash out period without drug.
45688077|NCT03935295|Drug|AbobotulinumtoxinA|Paraspinal abobotulinumtoxinA injections (compared to placebo)
45688078|NCT03935295|Drug|Placebos|Placebo prepared by Ipsen for use as control
45688079|NCT03935295|Device|Custom Thoracolumbosacral Orthosis|Non-operative external bracing for scoliosis curves
45688080|NCT03928236|Other|Limited Intraoperative Benzodiazepine|policy for limited use of intraoperative benzodiazepine
45688081|NCT03928236|Other|Liberal Intraoperative Benzodiazepine|policy for liberal use of intraoperative benzodiazepine
45844757|NCT01372566|Other|Sterile Saline injection|Sterile Saline will be injected multiple times in a different area of the arm (Part 1) or on the opposite side of the face from where the platelet rich plasma is injected.
45844758|NCT01239030|Drug|Methylphenidate Hydrochloride Extended Release Capsules|Biphentin Methylphenidate ER Once-A-Day Capsules
45844759|NCT01239030|Drug|Placebo|Placebo capsules
45844760|NCT01129050|Dietary Supplement|Fish Oil|Fish oil capsule
45844761|NCT01129050|Dietary Supplement|Flaxseed Oil|Flaxseed oil capsule
46048760|NCT02848209|Procedure|TCA 40% Peeling|TCA peel at a concentration of 40% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
46048761|NCT05337969|Drug|Metformin and Vildagliptin 850/50 mg|50 mg Vildagliptin + 850 mg Metformin as single-dose per study period
46048762|NCT02844153|Other|modalities of metformin prescription|Metformin prescription or not, in each CKD stage
45360421|NCT00889434|Dietary Supplement|Tocotrienol|One cycle will comprise 28 days of continuous daily treatment with Tocotrienol given 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.
45360422|NCT00889434|Dietary Supplement|EGCG + Tocotrienol|combination of both arms 375 mg EGCG + 600mg/day Tocotrienol
45360423|NCT00612534|Drug|Sufentanil NanoTab|5 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
45360424|NCT00612534|Drug|Placebo NanoTab|Placebo NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
45360425|NCT00612534|Drug|Sufentanil NanoTab|10 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
45360426|NCT00612534|Drug|Sufentanil NanoTab|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
45360427|NCT02542254|Drug|Salbutamol|200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)
45360428|NCT02542254|Drug|Ipratropium|40 micrograms ipratropium administered using a pMDI
45360429|NCT02542254|Drug|RPL554|6 mg RPL554 administered using a nebuliser
45360430|NCT02542254|Drug|Salbutamol matched placebo|Placebo pMDI
45360431|NCT02542254|Drug|Ipratropium matched placebo|Placebo pMDI
45360432|NCT02542254|Drug|RPL554 matched placebo|Nebulised placebo
46048763|NCT02844387|Dietary Supplement|L-arginine hydrochloride solution|Patients with unresectable brain metastases from solid tumors that are candidates from twice-daily fractionated radiation therapy will be randomized to receive either oral arginine supplementation one-hour prior to each fraction of radiation. Radiation therapy consist in whole-brain treated by two lateral fields to a total dose of 32 Gy in 20 fractions of 1.6 Gy each two times a day with a 6 hours interval between treatments (10 days), followed by a 22.4 Gy boost over the evident lesions with the same fractionation schedule (7 days). The spinal cord dose will be limited to 40 Gy
46048764|NCT02844387|Other|Placebo|Patients with unresectable brain metastases from solid tumors that are candidates from twice-daily fractionated radiation therapy will be randomized to receive oral placebo one-hour prior to each fraction of radiation. Radiation therapy consist in whole-brain treated by two lateral fields to a total dose of 32 Gy in 20 fractions of 1.6 Gy each two times a day with a 6 hours interval between treatments (10 days), followed by a 22.4 Gy boost over the evident lesions with the same fractionation schedule (7 days). The spinal cord dose will be limited to 40 Gy
46048765|NCT02844231|Other|Single-photon emission computed tomography|
45360436|NCT00883974|Behavioral|Sensitivity Training|"The parent sensitivity training program was delivered in NICU (9 sessions) with a home-booster session. Therapists worked with parents following a manualized protocol. Targets of intervention included: recognizing signs of infant stress, shut-down mechanisms, alert-available behavior, motor behaviors, facial expressions,posture/muscle tone; graded stimulation; how to optimize interactions; touch, movement and massage; kangaroo care (nesting infants skin-to-skin against their mother); vocal, visual and multi-sensory stimulation; normalizing parental feelings; challenging dysfunctional thinking, and diary keeping."
45360437|NCT00889590|Drug|Zoledronic acid|4 mg, monthly for 3 months followed by a 3-monthly schedule for up to one year after surgery
46048766|NCT04209465|Drug|BDTX-189|Participants will receive a daily, oral dose of BDTX-189 as part of a 3 week cycle.
46048767|NCT02844075|Drug|MK-3475(pembrolizumab)|"Neo-adjuvant chemoradiation period:The treatment consisted of taxol, carboplatin, pembrolizumab and radiation. The radiation treatment comprises 44.1Gy (2.1Gy/Fr, total 21Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery:Before surgery, abdomen/chest CT scan, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 12 weeks after last neo-adjuvant treatment.~Adjuvant period:Adjuvant treatment with pembrolizumab 200mg every 2week (maximum 2 years) should be performed within 8 weeks after surgery (recommended period : 3-6 weeks after surgery). Gastroscopy and abdomen/chest CT scan will be performed at 6 month after surgery."
45360438|NCT00736853|Drug|Tramadol Hydrochloride Plus Acetaminophen (Open-Label)|Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily will be given for one week; dose level will be fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose will be 8 tablets).
45360439|NCT00736853|Drug|Tramadol Hydrochloride Plus Acetaminophen (Double-Blind)|Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) will be given 4 times daily up to 4 weeks.
45360440|NCT00736853|Drug|Placebo (Double-Blind)|Matching placebo will be given up to 4 weeks.
45360441|NCT04037514|Drug|Paracetamol|Intravenous paracetamol 15 mg/kg/6h
45360442|NCT04037514|Drug|Ibuprofen|Intravenous ibuprofen 10 mg/kg/24h (day 1) and 5 mg/kg/24h (day 2 and 3)
45360443|NCT00889668|Device|GlucoTrack|comparison of different glucose monitoring devices
45360444|NCT00884130|Procedure|laparoscopic colorectal resection|
45360445|NCT00884130|Procedure|open colorectal resection|
45360446|NCT00730847|Biological|Cervarix|Three doses of Cervarix administered intramuscularly in the deltoid region, according to a 0, 1, 6-month vaccination schedule.
45360447|NCT04034004|Behavioral|Mindfulness|A well-validated brief meditation-based mental training regimen [four sessions; 20 min/session] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
45360448|NCT04034004|Drug|Naloxone|A 0.15 mg/kg bolus dose of naloxone (Naloxone hydrochloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion will cease till the end of the experiment.
45360449|NCT04034004|Other|Saline|A 0.15 mg/kg bolus dose of saline in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion will cease till the end of the experiment.
45360450|NCT04034004|Behavioral|Meditation|A well-validated brief meditation-based mental training regimen [four sessions; 20 min/session] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
45360451|NCT00573066|Drug|Dexmedetomidine|Dosage levels: Dose Level 1: Loading dose 0.35mcg/kg and CIVI 0.25mcg/kg/hr Dose Level 2: Loading Dose of 0.7mcg/kg and CIVI 0.5mcg/kg/hr and Dose Level 3: Loading Dose 1 mcg/kg and CIVI 0.75 mcg/kg/hr.
45360452|NCT00889980|Other|Biospecimen banking|SLN and one non-SLN (8mm and larger in longest dimension). fourteen 10cc tubes or a total of 140mL of blood will be collected from subjects weighing over 102.6 pounds. If the subject weighs less than 102.6 pounds, the amount of blood drawn will be based on exact body weight. The amount of blood drawn will be no more than 3mL/kg of body weight.
45360453|NCT02541552|Drug|Ropivacaine 0.5%|Varying volume according to motor response of previous subject
46048768|NCT02844309|Drug|Thalidomide|thalidomide 50-150 mg per night
46048769|NCT02845713|Drug|Ivermectin, Diethylcarbamazine Albendazole (IDA)|To evaluate the safety and tolerability of triple drug therapy (a single dose of ALB, IVM and DEC)
45688082|NCT03927651|Drug|ICG|Indocyanine green (ICG) is a Food and Drug (FDA)-approved tricarbocyanine dye that is fluorescent under near-infrared (NIR) light. ICG solutions for injection often contain sodium iodide. ICG is water soluble and when introduced intravenously, it is bound by plasma proteins, namely albumin. The intravascular half-life of ICG is 3-4 minutes with rapid hepatic clearance.
45360456|NCT00886314|Drug|midazolam|Children in this group will be premedicated with oral midazolam syrup (0.3 mg.kg) at least 15 minutes before the surgical procedure and one of the parents will be present throughout the anesthesia induction process.
45360457|NCT00886314|Other|clown doctor|Children will interact with clowns before entering the operating room and will stay with them and one of the parents throughout the anesthesia induction process.
46048770|NCT05337813|Device|"Storz Medical Extracoporeeal Shock Wave Therapy System"|A. B. C. D. groups need to Low Energy Extracorporeal Shock Wave (LiESWT) therapy once a week, duration 8 weeks(B.、C. groups needs to be combined PRP treatment at 1, 5, 9 weeks)
46048771|NCT02845557|Other|OGTT and IVGTT tests|
46048772|NCT04139967|Radiation|Short course radiation therapy|25 Gray in 5 fractions over 5-7 days
45844762|NCT01129050|Dietary Supplement|Placebo|Soybean oil capsule
45360458|NCT00890214|Drug|prostacyclin|prostacyclin was infused as CRRT circuit anticoagulant into the arterial-line of the circuit at 4 ng/Kg/min
46048773|NCT05243121|Diagnostic Test|MRI|undergoing enhanced MRI
45360459|NCT00890214|Drug|heparin|was prepared using our standard protocol: 2 ml of an already-stored solution containing 5000 IU/ml of UFH were diluted in 20 ml of saline obtaining a final concentration of 500 IU/ml, and infused pre-filter at 6 IU/Kg/h, according to the post-filter activated clotting time measured hourly, and adjusted to obtain a value between 180 and 200 sec.
46048774|NCT02845245|Other|3D printed plastic model prototype|
46048775|NCT02845245|Other|3D CT scan|
46048776|NCT02845245|Other|Plain film radiographs|
46048777|NCT00902265|Drug|desmopressin|desmopressin (Nocturin®) 0.1 mg tablet per day for 12 weeks
46048778|NCT02845401|Other|Stop NA therapy|Cases will stop antiviral therapy
46048779|NCT04510779|Device|Apple Watch|Apple Watch is a smartwatch developed by Apple Inc. The heart rate variability function will be used.
46048780|NCT02848365|Device|Endotracheal intubation|Endotracheal intubation will be done with any of these equipments
46048781|NCT04490109|Biological|B244|B244 suspension
45360460|NCT00890292|Drug|JNJ-31001074|
45844763|NCT01086540|Biological|Rituximab|"Participants receive rituximab intravenous (IV) infusions, 1000 mg each, 14 days apart (Day 0 and Week 2).~Rituximab is supplied as a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials, which must be diluted before administration~Standard rituximab pre-medications will be provided in preparation for the rituximab infusions."
45844764|NCT01086540|Other|Placebo|"Participants receive placebo intravenous (IV) infusions 14 days apart (Day 0 and Week 2).~Standard pre-medications will be provided in preparation for the infusions."
45844765|NCT01086540|Diagnostic Test|CMRI|Up to 20 participants from each treatment arm will be assessed by CMRI at Baseline and at Week 24.
46048782|NCT04490109|Biological|Vehicle|Vehicle suspension
46048783|NCT02848287|Drug|normal saline|1*2 gauze is soaked with 5 cc of 0.9 % normal saline, applied in tonsillar fossae for 3 min, then removed.
46048784|NCT02848287|Drug|ropivacaine|1*2 gauze is soaked with 5 cc of 0.75% ropivacaine, applied in tonsillar fossae for 3 min, then removed.
46048785|NCT02847897|Device|CO2 AcuPulse Laser|Each subject will receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
46048786|NCT05242731|Device|MSmonitor, a self-management/education program with e-health interventions|A self-management/education program with e-health interventions
45360461|NCT02543736|Device|Instrumented Treadmill System|Patients will perform twice a gait and a balance analysis on an instrumented treadmill system combined to a photoelectric cell system while controls will only perform once.
45360462|NCT00923520|Drug|DMS 612|DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
45360463|NCT02543424|Behavioral|Motor, cognitive and neuropsychological assessment|Cognitive and motor testing and/or experimental cognitive or motor changes and/or cognitive or motor rehabilitation depending on part of the study investigated.
45360464|NCT00612456|Drug|Pazopanib|Pazopanib eye drops formulation
45360465|NCT00730691|Drug|Placebo|Placebo-matching capsules
45360466|NCT00730691|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
45360467|NCT00730691|Drug|Duloxetine|Overencapsulated duloxetine capsules
45360468|NCT02543502|Procedure|periodontal treatment|treatment of periodontal cleaning
45360469|NCT00890370|Procedure|Airway clearance technique|
45360470|NCT00890448|Other|Pharmacogenomic whole blood sampling|10 mL, whole blood, one sample on Visit 2
45360471|NCT00235495|Biological|Albumin|human albumin, 25%, 2.0g/kg intravenously (or equivalent volume of saline control), infused over 2 h, commencing within 5 hours of stroke onset
45360472|NCT00235495|Drug|Saline|equivalent volume of isotonic saline control
45360473|NCT02541474|Other|Integrated care|The PACT model facilitates better care by : 1) a structured person centered needs assessment , 2) individual care plans , and 3) and an inter- professional team that coordinates services across specialties and levels of care.
45360474|NCT03017105|Other|Cross-education of strength-training|Strength-training exercises using isometric contractions and resistance bands to be performed with the uninjured arm
45360475|NCT03017105|Other|Usual rehabilitation|Exercises to improve range of movement, strength and movement control (as standard for non-operatively managed proximal humerus fractures)
45360476|NCT02541630|Behavioral|Big Mind|mindfulness based intervention
45360477|NCT03968471|Behavioral|Scoring tool in Chemotherapy-induced necrosis in Ewing sarcoma|"The aim of the present study is to evaluate which is the best scoring tool to determine the histological response to chemotherapy in localized Ewing sarcoma of bone.~The study will exam all the different systems to evaluate the histological necrosis after neo-adjuvant chemotherapy in all patients with localized Ewing sarcomas of bone surgically treated between 1982 and 2012."
45360478|NCT00884364|Other|Aerobic exercise|The patients will carry out an aerobic exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The training will be carried out three times a week.
45360479|NCT00884364|Behavioral|Fatigue counseling|The patients will receive a counseling regarding the causes of fatigue, how to cope with this symptom, and general recommendations about exercise. However, they will not participate at a structured exercise program.
45360480|NCT04088279|Diagnostic Test|MRI|Oxygen enhanced and fourier decomposition MRI
45360481|NCT00886860|Drug|misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 cm
45360482|NCT00886860|Drug|misoprostol|misoprostol 20 micrograms oral every hours until cervical dilatation 3 cm
45479867|NCT03799601|Drug|Carboplatin|Carboplatin is used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It may be used for some types of testicular cancer but cisplatin is generally more effective.
45688083|NCT03919214|Other|Automated Messaging|This is a 12-week prospective study with two phases. Participants will use the QardioArm device to obtain 3 separate blood pressure measurements per week (2 morning, 1 evening). The QardioArm device will only be used as a tool to gather data. In Phase 1 (Weeks 1-4), participants will self-monitor their blood pressure using the Qardio Bluetooth device. In Phase 2 (Weeks 5-12), we will implement the auto-messaging system triggered by a weekly average systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg.
45688084|NCT03915444|Drug|nab-Paclitaxel + Cisplatin + Gemcitabine|"Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days.~Gemcitabine 1000mg/m2 in 500 mL* over 30 minute IV infusion on days 1 and 8 repeated every 21 days.~Post cisplatin hydration: IV fluids up to 1000 mL (with additives as clinically indicated) IV given as infusion on days cisplatin is administered on days 1 and 8 repeated every 21 days."
45752080|NCT01389596|Drug|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
46048787|NCT05242731|Device|"Video calling program Better-close"|Video calling program.
46048788|NCT05242731|Device|Researchmanager program|Case Report Form, Datamanagement program
46048789|NCT05337657|Drug|GB491+Letrozole|Drug：The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart
46048790|NCT05242575|Behavioral|The information provided in the iVFT and control book parallel one another.|"An immersive virtual fled trip (iVFT) is a form of virtual reality (VR). The term immersive refers to an experience where the senses become heightened through multisensory input (e.g., visual, auditory, proprioceptive). When adding peripherals such as a head-mounted device (HMD) (e.g., goggles with 3D-lenses), a mobile phone becomes a pseudo-theater providing a 360-degree view that mimics the real world. For example, one can experience a simulated rollercoaster or visit the moon that may otherwise be inaccessible in day-to-day life. Also, a VFT provides for context and aids in background knowledge that is a crucial aspect of learning.~Participants will receive three interventions sessions each last 15-minutes."
45360483|NCT04087031|Other|control arm|Each session will include 50 minutes of traditional physical rehabilitation therapy
45360484|NCT04087031|Other|virtual reality games|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic Tymo system (Tyromotion, Austria), a wireless static and dynamic platform, for evaluating and rehabilitating posture.
46048791|NCT02690961|Drug|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
45844766|NCT01086540|Drug|prednisone|Prednisone dose of 40 mg (or equivalent) by mouth administered the night before and the morning of each study drug infusion.
45360485|NCT04087031|Other|robotic treadmill|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic Walker View (TecnoBody, Italy) a treadmill equipped with a sensorized belt with eight load cells and a 3D camera
45360486|NCT00884442|Drug|Nifedipine (Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL)|60 mg nifedipine
45360487|NCT00884442|Drug|Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)|60 mg nifedipine
45360488|NCT04087265|Diagnostic Test|Transabdominal ultrasound|Transabdominal ultrasound will be performed 30 minutes before colonoscopy
45360489|NCT02543580|Other|transcutaneous electric acupoint stimulation|electrodes are attached o the skin and electric stimulation is given
45360490|NCT02543580|Other|electrode attached but no stimulation|electrodes are attached o the skin but no stimulation is given
45360491|NCT02543034|Device|Betafoam Wound Dressing|Foam dressing including Betadine iodine
45360492|NCT02543034|Device|Petrolatum Gauze|Gauze dressing
46048792|NCT02690961|Drug|placebo multiple doses|
46048793|NCT05242263|Behavioral|Attention Control Training (ACT) with ABV feedback|At the beginning of each session, participants will complete 45 standard dot-probe trials as described above. Participants' ABV on these trials will be calculated and set as their personal baseline (see below for ABV calculation). In the following 165-training trials, participants will receive feedback: when their online-calculated ABV will be below their baseline screen background will be green whereas its color will be red when their online ABV score will be higher than their baseline. Patients will be instructed to try to keep the background green for as long as possible.
45844767|NCT01086540|Drug|methylprednisolone|Methylprednisolone (or equivalent corticosteroid) administered intravenously 30 minutes prior to each study drug infusion.
45360493|NCT02543034|Device|Allevyn Wound Dressing|Foam dressing
45360494|NCT02594345|Other|in vitro study|Exosomes will be mixed with healthy volunteers' blood in vitro
45360495|NCT00278161|Biological|Pegfilgrastim|6 mg SQ 24-48 hours after last dose of cyclophosphamide.
45360496|NCT00278161|Biological|Rituximab|375 mg/m^2/day on Days 1, 4, 8, 11, 45, and 52.
45360497|NCT00278161|Drug|Cyclophosphamide|50 mg/kg/day on Days 15, 16, 17, and 18.
45360498|NCT04038216|Procedure|Single-stage surgery|the bone-anchored hearing implant will be inserted in one surgery
45479868|NCT03322852|Other|Vascularization indices observation|The mid-luteal endometrial thickness and volume, uterine vascularization indices of uterine artery pulsatility index and resistance index, endometrial and subendometrial vascularization index, flow index, and vascularization flow index, and serum estradiol and progesterone levels were calculated in spontaneous then stimulated cycles in the same group of infertile patients
45688085|NCT03911986|Device|R Test 4 External Loop Recorder|The R-Test 4 is an externally worn, re-usable, battery-powered, lightweight ECG monitor, which records events triggered by cardiac arrhythmias. It is worn for 7 days. Cardiac monitoring is triggered by tachycardia or detection of irregular pulses or patient may trigger recording, if the participant experience symptoms (e.g. palpitations). The patient wears 2 chest leads (on one, the R-Test device is attached, weight 42g). The R-Test 4 is CE marked, and uses an FDA-approved algorithm for automatic detection of atrial fibrillation, and permits 5 minutes of pre-event recording and 5 minutes of post-event recording.
45688086|NCT03904134|Other|Donor Search Prognosis Score|Patients will be placed on a study arm after receiving a Donor Search Prognosis Score, which is based on HLA allele frequencies and race/ethnicity. This score predicts the likelihood of successfully identifying a 10/10 matched unrelated donor.Worse search prognosis is associated with racial and ethnic minority status but not with other patient and disease biology characteristics that might influence the success of hematopoietic cell transplantation (HCT). Thus, the use of donor search prognosis in this trial as a tool for biologic assignment to matched unrelated donors vs. mismatched donors provides a mechanism to minimize bias from disease characteristics.
45844768|NCT01086540|Drug|diphenhydramine|"Diphenhydramine 50 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed."
45844769|NCT01086540|Drug|acetaminophen|"Acetaminophen 650 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed."
45360499|NCT04038216|Other|Two-stage surgery|Two-stage surgery has already been performed, data will therefore be retrospectively collected
45844770|NCT01959048|Drug|fecal microbiota transplantation|
45844771|NCT01962558|Device|VNS Treatment|VNS is given in brief bursts over a 2.5 hour period. The subject also has headphone connected to a computer, and hears audio tones through the headphones that occur during VNS.
45844772|NCT01962558|Device|VNS Control|This is the sham-control group; subjects in this group will receive both tones and VNS, but in a manner that is expected to be ineffective.
45360500|NCT02541396|Drug|Wafermine|35 or 70 mg ketamine in a sublingual wafer
45479869|NCT03327142|Diagnostic Test|Endoscopic Ultrasound-Guided FNA|Endoscopic Ultrasound Guided Fine Needle Aspiration of Puncture of Adrenal Glands
45479870|NCT03793985|Drug|T|CKD-391 40/10mg
45844773|NCT01962714|Behavioral|Loving-Kindness Meditation|12-week loving-kindness meditation course
45844774|NCT01962714|Behavioral|Cognitive Processing Therapy|12-week CPT course
45479871|NCT03793985|Drug|R|D086 and D337 co-administration
45844775|NCT01962870|Drug|Vasopressin|Participants aged 6 to 9.5 years of age will receive the maximum dose of 24 IU (12 IU twice daily). Participants aged 9.6 to 12 years of age will receive the maximum dose of 32 IU (16 IU twice daily).
45844776|NCT01962870|Drug|Placebo|
45844777|NCT01965288|Device|comfilcon A|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
45479872|NCT03326908|Device|Spectral Domain Optical Coherence Tomography|Five SD-OCTs will be performed with various conditions of enlightenment.
45479873|NCT03607526|Other|Barriers|NGT sessions identifying barriers to vegetable intake.
45479874|NCT03607526|Other|Facilitators|NGT sessions identifying facilitators to vegetable intake.
45479875|NCT03791801|Drug|Sugammadex|the reversal of neuromuscular blockade with sugammadex compared to neostigmine.
45360501|NCT02541396|Drug|Oxycodone|5 mg oxycodone capsule
45844778|NCT01965288|Device|lotrafilcon B|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
45360502|NCT02541396|Drug|Placebo|Placebo capsule or placebo wafer
45360503|NCT00890526|Other|Sound Therapy (Tinnitus Retraining Therapy)|The conventional sound therapy will be achieved with commercially available noise generators. Our clinic uses General Hearing Instruments (OHI) model Tranquil devices as noise sources for TRT. These flexible devices offer an adjustable volume control, with a frequency response extending from ~500 to 8000 Hz. Matched devices will be fitted binaurally and adjusted to each individual ear to achieve audibility of the noise sources (assessed by slight threshold shifts. typically 10- 15 dB, across the audiometric frequency range above 500 Hz). The sound pressure level output and frequency response of each noise source will be measured and documented using both real ear and standard electroacoustic methodologies. Each subject will be carefully instructed as to care of the instruments and correct volume setting. The bilateral noise generators will be used chronically during the intervention period except during sleep.
45360504|NCT00890526|Other|Counseling (Tinnitus Retraining Therapy)|The directive counseling to be used will include an in-depth participatory discussion with the patient to review audiometric and functional test results, along with the anatomy and physiology of the auditory system. A minimum of two hours will be scheduled to impart this information to the patients so that they will have a clear understanding of the disorder based upon the most current scientific data. The counseling will be focused on educating the patient, neutralizing their negative emotional association with the hyperacusis, and discussing their treatment.
45360505|NCT00890526|Other|No Counseling|Patients who are enrolled in Arms 3 and 4 of this study will not be offered directive counseling, but will be fitted with either conventional or placebo noise generators for their sound therapy components. These patients will be told only that their treatment for hyperacusis uses sound therapy. Otherwise, in the instrument fitting appointment (either for the conventional instrument or the placebo device), these patients will receive the same instruction in the care and use of sound generators as those patients enrolled in Treatment Arms 1 and 2 of the clinical trial.
45688087|NCT03894631|Procedure|KDB/Phacoemulsification|50 eyes of 50 patients will receive combined KDB/phaco surgery
45688088|NCT03894631|Procedure|Trabectome/Phacoemulsification|The contralateral 50 eyes of the same 50 patients will receive combined Trabectome /phaco surgery
45688089|NCT03892785|Drug|Prednisone treatment|tapering prednisone regimen
45688090|NCT03892785|Drug|Tocilizumab treatment|Tocilizumab 162 mg/week subcutaneous from W0 to W51 (52 injections)
45688091|NCT03892785|Drug|Methotrexate treatment|"Methotrexate subcutaneous from W0 to W51 (52 administrations).~W0: 7.5 mg/week~W1: 0.2 mg/Kg/week~W2 to W51: 0.3 mg/Kg/week (without exceeding 20 mg/week) Folic acid 10 mg/week, 48h after taking Methotrexate, from W0 to W51"
45688092|NCT03892785|Other|Questionnaires|HAQ, SF-36, FACIT-fatigue
46048794|NCT05242263|Behavioral|Attention Control Training (ACT) with yoked sham feedback|Participants in this group will be exposed to the same task as in the active group but will receive sham feedback that is unrelated to their ABV during task performance. They will be presented with a feedback that is yoked to the one given to a participant in the training group.
46048795|NCT05242107|Dietary Supplement|Omega-3 supplement group|35 Neonates were given Omega 3 in a dose of 40mg/kg/day (8), after establishment of full-feeding and for 2 weeks duration. Omega-300 (Montana pharmaceutical industry) capsule was used which contains 1000mg Omega 3 fatty acids.
45479876|NCT03791801|Drug|Neostigmine|the reversal of neuromuscular blockade with sugammadex compared to neostigmine.
45479877|NCT03791801|Drug|Rocuronium|Both groups will receive rocuronium for paralysis during intubation
45479878|NCT03791801|Drug|Glycopyrrolate|The reversal of neuromuscular blockade with sugammadex compared to neostigmine/glycopyrrolate
45688093|NCT03892785|Biological|Blood samples|Additionnal blood samples for immunomonitoring
45688094|NCT03888287|Device|Watch Rx system|The Watch Rx system consists of a Watch Rx smartwatch, Watch Rx application and a WatchRx Web Interface. The Watch Rx smartwatch will be worn on the patient's wrist. The smart watch will send alerts to the caregivers through the Watch Rx app when it is time to administer the medication. The Web Interface will be used to store the medical documentations
45688095|NCT03888287|Other|Parkinson's Disease Inpatient Clinical Knowledge and Management Program|Parkinson's Disease Inpatient Clinical Knowledge and Management Program educates clinical staff and measures difference in knowledge of medication adherence and compliance for hospitalized Parkinson's Disease patients
45688096|NCT03880058|Drug|SLI-F06|Active treatment
46048796|NCT05242107|Other|Full feeding without receiving any supplementation group|35 full term Growth Restriction( IUGR) neonates who were followed up to full feeding without receiving any supplementation.
45360506|NCT00890526|Other|Placebo Sound Therapy|The placebo sound therapy will use factory-modified GHI Tranquil noise generators, which will appear identical to the conventional Tranquil devices. The placebo Tranquil devices will have a control sensor installed to detect insertion of the device in the ear canal. When the sensor detects the insertion of the placebo device into the ear canal it will trigger gradual decay of the sound output from the placebo device, The time constant of the decaying noise output will be sufficiently long to allow the clinician time to set the volume of each binaural set of devices and to instruct the patient in their use before any noticeable sound attenuation occurs.
45688097|NCT03880058|Drug|Formulation buffer|Placebo treatment
45360507|NCT00890604|Drug|Acetaminophen|APAP 650mg q4h prn; RTC dosing
45360508|NCT00890604|Other|Usual Care|Care per attending physician discretion for fever management
45688098|NCT03876795|Biological|Bone Marrow Concentrate|Bone Marrow Concentrate injection
45688099|NCT03872128|Drug|Pregnenolone300|300mg
45360509|NCT00890604|Drug|Ibuprofen|Ibuprofen 600mg q6h
45688100|NCT03872128|Drug|Pregnenolone500|500mg
45844779|NCT01965366|Behavioral|Virtual reality exposure therapy|Virtual reality exposure (VRE) therapy is a form of exposure therapy in which participants are helped to confront their traumatic memories in a therapeutic manner. They describe the events out loud and their therapist attempts to match what they are describing in the virtual reality. This is done repeatedly, allowing distress associated with these memories to decrease. Material that emerges during the VRE exposure is processed, or discussed, after the exposure, allowing participants to think about themselves and the event differently.
45360510|NCT00890604|Other|Physical Cooling Measures|Fan, Ice Packs
45360511|NCT00890604|Device|Cooling Blanket|Water Circulating Cooling Blanket
45360512|NCT00890604|Device|Hydrogel Cooling Pads|Application to torso and extremities
45360513|NCT00255151|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
45360514|NCT00255151|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
45688101|NCT03872128|Drug|Placebo|placebo
45752081|NCT02832323|Biological|Reticera|A blood sample (before dialysis) under the usual conditions will be performed at D0 (= the day of Mircera® injection) 9 days (+/- 1 day) after each injection Mircera® for hemoglobin and reticulocytes dosage for a period of 6 months.
45752082|NCT04567277|Procedure|External ventricular drainage (EVD) conversion into ventriculo-peritoneal shunt (VPS)|EVD in high grade SAH patients were converted into VPS with 7-10 days of EVD insertion
45360515|NCT00255151|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
45360516|NCT00890760|Biological|AdCh63 ME-TRAP|5 x 10*10 vp IM
45360517|NCT00890760|Biological|MVA ME-TRAP|2 x 10*8 pfu ID
45360518|NCT00890760|Other|Sporozoite challenge|Infected mosquito bite
45360519|NCT00890760|Biological|Mixture of AdCh63 ME-TRAP and MVA ME-TRAP intramuscularly|AdCh63 ME-TRAP 5 x 10*10 vp MVA ME-TRAP 2 x 10*8 pfu
45360520|NCT00890838|Dietary Supplement|Omegaven-IV FO|will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
45360521|NCT04037670|Procedure|SASI bypass|Sleeve gastrectomy with single loop anastomosis between gastric antrum and ileum, 3 meters away from ileocecal junction
45360522|NCT03973957|Device|Indwelling pleural catheter placement|Indwelling pleural catheter placement by interventional pulmonologist
45360523|NCT03973957|Drug|Fentanyl Citrate|Administration of intravenous fentanyl prior to talc slurry instillation in order to avoid pain associated with talc slurry application
45360524|NCT03973957|Drug|Talc Slurry|Administration of 5 grams of medical grade sterile talc mixed in 50 milliliters of normal saline solution via indwelling pleural catheter for purposes of talc slurry pleurodesis
45360525|NCT03973957|Device|Drainage collection bag|Attachment of one-way Heimlich valve with drainage collection bag circuit to indwelling pleural catheter after talc slurry application for purposes of drainage and pleurodesis in the outpatient setting rather than the inpatient setting.
45844780|NCT01965366|Drug|0.5 mg DEX|A dose of DEX will be given the night before (approximately 10 hours before) each of 5 to 11 individual virtual reality exposure (VRE) therapy sessions.
46048797|NCT02845167|Other|Preoperative exercise|Patients will perform 3 consecutive days of 60 min submaximal cycling exercise at a moderate exercise intensity. During the 60 min of exercise, patients will be provided with three equally spaced 3min rest periods
46048798|NCT05241951|Other|Structured hand-off|A clinical pharmacist will be utilized to provide a structured handoff at the end of the hospital stay between hospital and SNF skilled nursing facility.
46048799|NCT05241951|Other|Medication Management|The clinical pharmacist consults with hospital and SNF teams to reconcile, adjust and monitor medications to provide comprehensive medication management during care transitions.
46048800|NCT04114071|Behavioral|TOSS Feasibility + Fitbit Community = Reduced Obesity in Older Black Women|See arm description
46048801|NCT05337579|Other|Supplemental Micro Breaks|Supplemental Micro Breaks, of 30 seconds after every 15 minutes of working on a static computer workstation in addition to the two 'Conventional Rest Breaks' of 15 minutes twice a day during the work hours
45360526|NCT00658658|Biological|Panitumumab|Panitumumab administered by intravenous infusion
45360527|NCT00723203|Drug|panobinostat|40 mg Monday, Wednesday and Friday of every week in a 28 day cycle
45360528|NCT00723203|Genetic|gene expression analysis|Day 1 and day 28 samples
45360529|NCT00723203|Genetic|reverse transcriptase-polymerase chain reaction|Day 1 and day 28 samples
45360530|NCT00723203|Other|laboratory biomarker analysis|Day 1 and day 28 samples
45360531|NCT00891072|Drug|R-(-)-gossypol acetic acid|Given orally
45360532|NCT00891072|Drug|paclitaxel|Given IV
45360533|NCT00891072|Drug|carboplatin|Given IV
45360534|NCT00891072|Other|pharmacological study|Correlative studies
45360535|NCT02591927|Drug|Glucose-Insulin-Potassium|Rackley's GIK formula by continuous I.V. infusion at 1.5 ml/Kg/hour for 12 hours (about 100 ml/hour for a 70 kg patient).
45360536|NCT02591927|Drug|Glucose 5%|Glucose 5% (Placebo) by continuous I.V. infusion at 1.5ml/kg/hour for 12 hours (about 100 ml/hour for 70 Kg patient)
45360537|NCT04037046|Behavioral|Screening HCV attached onto CCR screening|Patients assigned to this strategy will receive an invitation letter for HCV screening with DBS and CCR screening with FOT at the primary care center to be performed by the general practitioner
45752083|NCT00558207|Drug|ARQ 197|120 mg capsule administered twice daily for 240 mg total daily dose
45844781|NCT01965756|Drug|Metformin|
45360538|NCT04037046|Behavioral|Screening HCV attached onto CCR screening by self-testing|Patients assigned to this strategy will receive an invitation letter for self-testing for HCV screening with DBS, and CCR screening with FOT
45360539|NCT04037046|Behavioral|Screening HCV at primary care center|DBS for HCV screening at primary care center
45360540|NCT00807716|Other|walking skill group|12 Individualized group training sessions with focus on functional exercises like walking and stair climbing including balance training under physiotherapy guidance, 12 times 70 minutes.
45844782|NCT01965756|Drug|Placebos|
45844783|NCT01966380|Device|Leia|
45844784|NCT01966458|Device|HeartWare® VAS (HVAD)|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
45360541|NCT00807716|Other|usual physiotherapy care|physiotherapy, mostly in non-weight bearing, 12 times 40 minutes
46048802|NCT05337579|Procedure|Exercise Breaks|Exercise Breaks, of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.
45360542|NCT00891150|Drug|Oxytocin|"Pre-mixed, oxytocin solutions with either 20U/500ml, 30U/500ml or 40U/500ml of Lactated Ringer's solution will be available in the pharmacy department. The bags will be identical in appearance. Each bag will be labeled with a study identification number, from which the pharmacy could determine the administered dose. Subjects as well as the medical providers will be blinded to the assignment of the solution used.~Immediately after delivery of the infant, the study solution will be infused over 30 minutes using a continuous infusion pump (666 mU/min versus 999 mU/min versus 1332mU/min)."
45360543|NCT00800462|Drug|Oxybutynin Cl|15 mg qd for 3 months
45360544|NCT00800462|Drug|Trospium Cl|20mg bid for 3 months
46048803|NCT04061577|Device|Transcranial Direct Current Stimulation (tDCS)|20 minutes of Cathodal tDCS after +/- before endovascular thrombectomy (EVT)
45360545|NCT00800462|Drug|Darifenacin Hydrogen Bromide (HBr)|15 mg qd for 3 months
45360546|NCT00233389|Drug|Rebamipide|
45360547|NCT00884520|Drug|[F-18] VM4-037|"The individual doses of [F-18]VM4-037 contain a maximum of 20 mCi for normal volunteers and 10 mCi for cancer subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
45360548|NCT02551952|Device|MentalPlus®|Validate the MentalPlus® digital game as neuropsychological test of cognitive assessment pre and postoperative on study the internal consistency and validity of content and construct (convergent) MentalPlus® of the evaluated patients. Study the influence of age, gender and level of education of surgical patients in performance for the use of electronic devices (laptop, tablet, mobile) and digital games. Investigate the rehabilitation capacity of cognitive functions after training sessions with MentalPlus® game. Evaluate the effect of training with MentalPlus® game in brain networks involved in executive function, memory and attention by means of fMRI this is a brain imaging study.
45844785|NCT01966458|Device|Control LVAD|Any FDA-approved LVAD for destination therapy.
45844786|NCT01966770|Device|Pair 1 (ocufilcon D / ocufilcon D)|Randomized to contra lateral lens pair 1 (ocufilcon D hydrogel / ocufilcon D hydrogel)
46048804|NCT04041921|Procedure|Percutaneous coronary intervention|
46048805|NCT04041921|Procedure|Coronary Artery Bypass Grafting|
46048806|NCT04041921|Drug|Medical treatment|
46048807|NCT04432077|Behavioral|DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR)|DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR) - a parent-mediated cognitive-behavioral treatment modified for young children with ASD
46048808|NCT02690883|Drug|Exenatide|Exenatide (Astrazeneca ) 5 μg(initial dose)/10ug(maintenance dose) Subcutaneous injection Bid
45844787|NCT01966770|Device|Pair 2 (ocufilcon D / enfilcon A)|Randomized to contra lateral lens pair 2 (ocufilcon D hydrogel / enfilcon A silicone)
45844788|NCT01966770|Device|Pair 3 (ocufilcon D / comfilcon A)|Randomized to contra lateral lens pair 3 (ocufilcon D hydrogel / comfilcon A silicone)
45844789|NCT01966770|Device|Pair 4 (methafilcon A / methafilcon A)|Randomized to contra lateral lens pair 4 (methafilcon A hydrogel sphere / methafilcon A hydrogel asphere)
45688102|NCT03869034|Combination Product|HAIC+PD1|Sintilimab ( 200mg Q3W iv D1)+FOLFOX-HAIC（oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3), maximally 8 cycles Multi-disciplinary consultation was organized to decide the chance of surgery and subsequent treatment per 2 treatment cycles. Patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection. After recovery from operation , sintilimab monotherapy was given per three weeks for maximally 16 doses. Patients who were ineligible for resection would continue to receive the combination therapy.
45844790|NCT01966770|Device|Pair 5 (methafilcon A / comfilcon A)|Randomized to contra lateral lens pair 5 (methafilcon A hydrogel / comfilcon A silicone)
45360549|NCT01326091|Other|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
45752084|NCT00558207|Drug|gemcitabine|1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 4 weeks for the first 28 days (cycle). Each subsequent cycle will consist of 1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 3 weeks with no drug administered in the 4th week.
45844791|NCT01966770|Device|Pair 6 (omafilcon A / comfilcon A)|Randomized to contra lateral lens pair 6 (omafilcon A hydrogel / comfilcon A silicone)
45844792|NCT01966926|Behavioral|weighing frequency instructions and tips|Weekly emails with nutrition, physical activity, and weight tracking tips sent for 24 weeks
45360550|NCT02543190|Behavioral|compliance surveillance and improvement strategy|External monitor to ensure compliance with an educational protocol.
45360551|NCT03973801|Other|Auricular acupuncture|National Acupuncture Detoxification Association (NADA) protocol for auricular acupressure will be initiated within 24 hours of delivery and continued until withdrawal symptoms measure 6 or less for 12 hours on the modified Finnegan score and/or the morning of expected discharge as in line with standard of care.
46048809|NCT02690883|Drug|Lispro|Lispro (Eli Lilly), the dosage is initiated according to the previous treatment plan and weight of the patients, distribute the dosage to 1:1:1 before 3 meals, titration following PPG <10.0mmol/L.
45844793|NCT01967784|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
45844794|NCT01967862|Procedure|computed tomography|Undergo CT
45844795|NCT01967862|Procedure|bone scan|Undergo bone scan
45844796|NCT01967862|Procedure|3-Tesla magnetic resonance imaging|Undergo axial MRI
45844797|NCT01967862|Procedure|diffusion-weighted magnetic resonance imaging|Undergo WB MRI
45844798|NCT01967862|Radiation|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT
45360552|NCT00887094|Behavioral|Acute aerobic exercise|Aerobic exercise (on a cycle ergometer, for 50 min)
45844799|NCT01967862|Procedure|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT
45844800|NCT01967862|Procedure|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT
45844801|NCT01967862|Other|laboratory biomarker analysis|Correlative studies
45844802|NCT01974102|Behavioral|Lifestyle counseling|Active control group will receive weekly session for viewing relaxing video and discussion plus nutritional and physical activity counseling for 8 weeks.
45844803|NCT01974102|Behavioral|Parenting Mindfully for Health (PMH)|Active participants will receive 8 weeks of mindfulness based parenting stress reduction (PMH) plus nutritional and physical activity counseling for 8 weeks.
46048810|NCT02942823|Other|"The serious game KOP"|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
45479879|NCT03494192|Other|Scapula Retraction Exercise Group|"physiotherapy program consists of manual therapy, supervised stretching and scapulothoracic muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions.~After 24 sessions completed, patients will proceed to reduced exercise program until the 6-month follow-up."
45360553|NCT00887094|Behavioral|Acute aerobic-resistance exercise|Aerobic-resistance exercise (on a cycle ergometer plus strength training, for 50 min in total)
46048811|NCT05241639|Diagnostic Test|Pentacam|Pentacam (Oculus GmbH, Wetzlar, Germany) is used to image both the anterior and posterior corneal surfaces, providing a complete pachymetry map. Furthermore, it includes the corneal densitometry program in its software, which detects the amount of backscattered light in different regions of the cornea, providing an objective assessment of corneal transparency, and it is hypothesized that corneal densitometry may be altered in the presence of a systemic inflammatory disease, even in the absence of any corneal haze or scar
46048812|NCT02848053|Other|no intervention|
45360554|NCT00811772|Device|Percutaneous coronary intervention (PCI)|Implantation of one or more bare metal stent(s)
45360555|NCT00811772|Device|Percutaneous coronary intervention (PCI)|Implantation of one or more drug eluting stent(s)
45360556|NCT02542878|Device|Foam roller|A bout of 60 seconds of myofascial release with foam roller
45479880|NCT03494192|Other|Scapula Retraction +Glenohumeral Rotational Exercise Group|"physiotherapy program consists of manual therapy, supervised stretching and scapulothoracic and also rotator cuff muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions.~After 24 sessions completed, patients will proceed to reduced exercise program until the 6-month follow-up"
45360557|NCT00884598|Drug|cilengitide|
45360558|NCT00884598|Other|pharmacological study|
45479881|NCT01305083|Drug|Udenafil|Placebo-control
45479882|NCT01305083|Drug|Placebo|Placebo
45479883|NCT03319888|Device|CPAP|continuous positive pressure in the airway
45479884|NCT03319888|Other|conservative treatment|conservative treatment group with lifestyle modifications
45360559|NCT00884598|Radiation|radiation therapy|
45360560|NCT02552264|Behavioral|Acceptance and Commitment Therapy for the Workplace|Acceptance and Commitment Therapy
45360561|NCT00891306|Genetic|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
45360562|NCT00891306|Drug|mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
45360563|NCT00891306|Drug|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
45360564|NCT00891306|Drug|methylprednisolone|single intravenous bolus of methylprednisolone (1 mg/kg bodyweight)
45360565|NCT02552186|Other|Caliper measurement|Clinical caliper measurements will be taken and used to calculate the Clinical PI
45360566|NCT02552108|Behavioral|Behavioural experiments for intolerance of uncertainty (BE-IU)|
45360567|NCT00807794|Drug|MEDI-507|0.012 mg/kg dose given twice between 60 to 72 hours apart
45360568|NCT00807794|Drug|MEDI-507|0.06 mg/kg dose given twice between 60 to 72 hours apart
45360569|NCT00807794|Drug|MEDI-507|0.12 mg/kg dose given twice between 60 to 72 hours apart
45360570|NCT00807794|Drug|MEDI-507|0.24 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
45479885|NCT05452616|Other|ART first- Therapeutic use trial|ART initiation on the day of enrolment independent of TB investigations in PLHIV with presumptive TB but no signs of CNS disease. The trial uses treatments and drug-doses as per international and national guidelines. All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.
46048813|NCT02847975|Dietary Supplement|Sodium nitrate|Sodium nitrate will be ingested orally
46048814|NCT02754375|Procedure|rTMS|
45844804|NCT01975974|Device|Ultrasound|Using ultrasound as a guide for peripheral venous cannulation in obese patients
45360571|NCT00807794|Drug|MEDI-507|0.50 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
45360572|NCT00812162|Other|Energy Restriction|Energy restricted diet of 750 kcal less than subjects requirement with a high protein diet.
45844805|NCT01976988|Drug|Heparin|Subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
45360573|NCT00812162|Other|Energy Restriction|Energy restricted diet of 750 kcal less than subjects requirement with a lower protein diet.
46048815|NCT04210401|Other|Duodenoscope Culture|Culture of reusable duodenoscopes following each use.
46048816|NCT02845011|Device|Audiovisual compression feedback|The Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) is a handheld device consisting of three components. The rescuer-side has a red palm-sized push-button with a pictogram illustrating proper use. The center unit is composed of a stable plastic base containing an arrangement of springs, and the patient-side consists of liquid-absorbent polyurethane foam. Application of 400 ± 30 Newtons of force results in an audible click alerting the rescuer to cease compression, and an additional click on decompression alerts the rescuer to resume compression.
46048817|NCT02845011|Other|Standard Manual Chest Compression|Cardiopulmonary resuscitation according to published international guidelines.
46048818|NCT02384265|Behavioral|IM/SMS + Incentive Condition|See description of Intervention arm protocols above.
46048819|NCT02847819|Device|airway ultrasound for vocal cords movement assessment.|Glottic aperture will be scanned using 7.5 megahertz (MHz) linear transducer portable ultrasound machine. after getting the best acoustic window, true, false vocal cords arytenoid movements will be visualized. Individual cord will be focused and doppler velocity will be measured for both the cords.
46048820|NCT02844855|Behavioral|Cognitive tests|MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
46048821|NCT05337111|Other|Cardiorespiratory fitness test|Progressive submaximal exercise test on a treadmill to predict cardiorespiratory fitness
46048822|NCT05337111|Other|Resting measure of fat oxidation|Use of ventilated hood attached to automated metabolic cart to measure substrate oxidation at rest
45360574|NCT04045418|Device|Laser doppler|"A laser doppler flowmetry will be used to measure the microcirculatory characteristics of meridian phenomena. The probes will be left at relevant measuring sites. Blood flow curve and Perfusion units (PU ) will be recorded constantly.~Healthy control group and COPD group The probes will be left at Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian for 5 minutes.~Healthy intervention group Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively."
45360575|NCT00807872|Biological|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2 mCi (1 mg)
45360576|NCT00813722|Behavioral|phone call|patients received or not phone calls to give orientation abou treatment
45360577|NCT00813722|Drug|amlodipine (calcium chanel blocker) and losartan (at1 antagonist)|2,5 mg tid and 25 mg tid
45360578|NCT00813722|Drug|atenolol (beta blocker) and hydrochlorothiazide (diuretic)|25 mg tid and 12,5 mg tid
45360579|NCT00812318|Drug|GSK1265744 10 mg oral solution|GSK1265744
45360580|NCT00812318|Drug|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fasted
45360581|NCT00812318|Drug|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fed
45360582|NCT00812396|Drug|Comparator: low dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 200 mg (0.8 mL) testosterone.
45360583|NCT00812396|Drug|Comparator: high dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 600 mg (2.4 mL) testosterone.
45360584|NCT00812396|Drug|Comparator: placebo|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 0.8 mL placebo saline solution.
45360585|NCT00807950|Drug|Simvastatin|
45844806|NCT01978314|Device|75 mg / 6 mL VFI™|Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
45844807|NCT01980654|Drug|Ibrutinib|All subjects will receive 560 mg of Ibrutinib orally.
45844808|NCT01980654|Drug|rituximab|All subjects will receive rituximab 375 mg/m2 intravenously
45360586|NCT02552030|Device|cuff device (Omron HBP-1300-E Pro)|Comparison of systolic blood pressure results measured with an oscillometric cuff device (Omron HBP-1300-E Pro) and iPhone 4s
46048823|NCT05337111|Other|Maximum fat oxidation test|Progressive exercise test to determine maximum fat oxidation during exercise
45360587|NCT02552030|Device|iPhone 4s|
46048824|NCT02844933|Drug|Cannabidiol|Oral solution
45360588|NCT00649220|Drug|Memantine|memantine tablets, twice a day (bid), for 20 weeks
45688103|NCT03869034|Drug|HAIC|FOLFOX-HAIC: oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3, for maximally 8 cycles, and the safety parameters are reviewed before the start of each course of HAIC treatment. Patients who achieve partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and are assessed as eligible for R0 resection go on to undergo surgical resection. No other anti-tumor therapies are allowed before PD or postoperative relapse is confirmed.
45688104|NCT03868618|Device|Genio™ system|The Genio™ device is a permanent implant. It is implanted in the chin area and delivers stimulation to both hypoglossal nerve branches (i.e., the left and right branches). The implant does not include a battery or an embedded software and is externally powered.
45688105|NCT03861975|Other|Breast Cancer-Related Lymphedema Measurements|All patients will receive bilateral arm measurements using the LymphaTech Scanner and the Perometer.
45360589|NCT00812630|Drug|MENT or placebo|A dose of 1600µg/d of MENT will be delivered daily using a gel formulation containing 8.0 mg of MENT per 1.0 mL (delivering 800µg/d). Two mLs of gel will be applied daily for four weeks in the pilot study (by 6 men) and for 12 weeks in the main trial (by 62 men).
45360590|NCT00813878|Genetic|protein analysis|protein analysis
45360591|NCT00813878|Genetic|protein expression analysis|protein expression analysis
45360592|NCT00813878|Genetic|proteomic profiling|proteomic profiling
45360593|NCT00813878|Other|diagnostic laboratory biomarker analysis|Performed one time on study
45360594|NCT00813878|Other|immunohistochemistry staining method|Performed one time on study
45360595|NCT00813878|Other|liquid chromatography|Performed on samples collected one time on study
45360596|NCT00813878|Other|mass spectrometry|Performed on samples collected one time on study
45360597|NCT00813878|Procedure|fine-needle aspiration|Samples collected one time on study at the appointment for fine-needle aspiration where applicable
45360598|NCT00813878|Procedure|needle biopsy|Samples collected one time on study at the appointment for needle biopsy where applicable
45360599|NCT00813878|Procedure|radiomammography|Samples collected one time on study at the appointment for radiomammography where applicable
45360600|NCT02551640|Other|FeatForward App (on study smartphone)|"The FeatForward mobile app will have the following features:~Messaging: Educational messages tailored to user's medical conditions and motivational messages tailored to user's stage of change.~Tracking: Ability to track physical activity, weight, blood pressure, blood glucose and heart rate.~Community: Users in later stages of change able to encourage and motivate one another through groups.~Educational Library: To provide educational tips and health information. Provider Engagement: Ability for physicians to view patient data, and send messages to patients.~Monthly depression assessments: The app will prompt users to complete a monthly voluntary depression assessment.~Social Support: Those using the FeatForward app will also have access to a Facebook group."
45360601|NCT00654368|Biological|Etanercept|Commercially available etanercept administered subcutaneously at 50 mg/week.
45360602|NCT00654368|Drug|Methotrexate|Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)
45360603|NCT04017026|Device|Implantation|Implantation of 6 mm short implants
46048825|NCT02844933|Drug|Placebo|Matching oral solution
45360604|NCT00812864|Drug|Capecitabine|"Pharmacokinetic of its metabolites.~Capecitabine, 1250 mg/m2 twice a day"
45360605|NCT00808184|Drug|CPT-11, Raltegravir (Isentress®), Midazolam|
46048826|NCT00943722|Biological|V503|Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.
46048827|NCT05190237|Dietary Supplement|TMD21-16 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
46048828|NCT05190237|Dietary Supplement|TCD21-55 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
46048829|NCT05190237|Dietary Supplement|TFD21-1 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
45360606|NCT02551562|Other|NuDerm® System|The Nu-Derm® System (Valeant Pharmaceuticals North America, LLP) is a skin care system that helps correct and reduce visible signs of aging such as age spots, rough skin, erythema, sallowness, and hyperpigmentation.
45844809|NCT01981590|Device|Stimulating the phrenic nerve intravenously using high frequency electrical pulses using an EP catheter connected to external pulse stimulator.|Intravenously stimulating the phrenic nerve with an EP catheter using high frequency electrical pulses as generated by the model 19039 external neurostimulator.
45479886|NCT05452616|Other|TB results first- Therapeutic use trial|Deferral of ART initiation until active TB has been refuted or confirmed. PLHIV presenting with symptoms (cough, fever, night sweat, weight loss) are defined as presumptive TB, and should have microbiological TB investigations. Routine TB investigations in Malawi and Lesotho usually consist of two sputum bottles for analysis using nucleic acid amplification tests (Xpert MTB/RIF (Ultra)).The trial uses treatments and drug-doses as per international and national guidelines. All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.
45360607|NCT02551562|Other|Placebo|Basic skin care regimen
45360608|NCT00814190|Other|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
45360609|NCT00812942|Procedure|colonoscopy|colonoscopy screening
45360610|NCT00812942|Procedure|faecal test|faecal occult blood test for screening
45360611|NCT00647426|Drug|Sorafenib + Docetaxel/Carboplatin|400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
45360612|NCT00647348|Drug|Simvastatin|80mg simvastatin oral once daily for 24 months
45360613|NCT00647348|Drug|Placebo|Oral placebo tablet once daily for 24 months
45360614|NCT00813020|Drug|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 1 administered in equimolar doses
45360615|NCT00813020|Drug|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 2 administered in equimolar doses
45688106|NCT03861351|Device|Mini WELL Toric Ready intraocular lens|The aim of cataract surgery is to remove the cloudy lens and replace it with the artificial intraocular lens called Mini WELL Toric Ready to correct presbyopia and to correct corneal astigmatism.
46048830|NCT05164731|Biological|SARS-CoV-2 Vaccine, Inactivated (Vero Cell)|the third does was given 3, 4, 5 or 6 months after two doses
45360616|NCT00813020|Drug|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 3 administered in equimolar doses
45360617|NCT00647270|Drug|adalimumab|Pre-filled syringe. See arm for more detail
45360618|NCT00647270|Drug|Placebo|Pre-filled syringe. See arm for more detail
45360619|NCT00647270|Drug|adalimumab|Pre-filled syringe. See arm for more detail
45360620|NCT00813254|Behavioral|Questionnaire|Questionnaires 1 - 5 will be completed on Day 1 of study as a Baseline.
46048831|NCT00632775|Drug|Hypotonic (0.45% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:~100 mls/kg/day for children weighing <10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those >20kg."
46048832|NCT00632775|Drug|Isotonic (0.9% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:~100 mls/kg/day for children weighing <10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those >20kg."
46048833|NCT02847741|Other|patient's routine care|Interview by psychiatrists, questionnaires, blood analysis
46048834|NCT04272918|Behavioral|Caregiver Support Model|Examine the effectiveness of the Caregiver Support Model (CSM) on improving caregivers' well-being.
45360621|NCT00645944|Drug|Eszopiclone|Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
45688107|NCT03858608|Dietary Supplement|Counterweight Plus|Total diet replacement followed by food reintroduction and weight maintenance.
45688108|NCT03858608|Other|Usual asthma care|Usual asthma management
46048835|NCT04272918|Behavioral|Psycho-education Program|Examine the effectiveness of the Psycho-education Program (PP-E) on capacity building, empowerment, and improving well-being.
45360622|NCT00645944|Drug|Placebo|"Placebo or inactive substance (sugar pill)taken each night for all weeks of the study"
45360623|NCT03869840|Device|Sensor to spot check blood levels|Sensor to check blood levels, not used as intervention
45360624|NCT00813332|Drug|Endostar(rh recombinant endostatin) plus Docetaxel|7.5mg/m2, IV( in the vein) on day1-14 of each 21-28 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
46048836|NCT01630785|Device|Intraoperative Neurophysiological Monitoring IONM|Intraoperative Neurophysiological Monitoring IONM device. Manufacturer: Inomed, Emmendingen, Germany
45360625|NCT00813332|Drug|Placebo plus Docetaxel|Placebo plus Docetaxel
45688109|NCT03849638|Other|Gait training with real time biofeedback|"Patients presenting asymmetry of the kinematic parameters of the step to the evaluation with sensorized treadmill, will undergo gait training program.~The training program consists of 20 session (1 session/day) of gait training. Daily gait training will last 30 minutes as distributed:~5 minutes of heating at a comfortable speed for the patient~Three 5-minute sessions of gait training with biofeedback interspersed with a break of 5 minutes each."
46048837|NCT02847585|Dietary Supplement|Water-soluble Ubiquinol|10 mg/kg BW/d, by oral drops
46048838|NCT05104047|Other|Moxibustion - Traditional (Active)|Traditional Moxibustion (Moxa) is a technique in which the herb, artemisia, in a cigar shape (pole moxa) is lit (burned) and applied over specific acupuncture points which follows a specific protocol aimed at reducing neuropathic lower limb pain/discomfort.
46048839|NCT05104047|Other|Moxibustion - Smokeless - (Active)|Smokeless Moxibustion uses the same technique as traditional moxa however, the moxa is smokeless. Smokeless moxa allows for use in a broad range of treatment settings. The protocol is aimed at reducing neuropathic lower limb pain/discomfort.
46048840|NCT05104047|Other|Placebo Moxibustion|Participants receive Placebo Moxibustion - a protocol that mimics the active protocol but is not active.
46048841|NCT04420689|Drug|ALM-488|ALM-488 Sterile Solution is an intravenously administered, synthetic, peptide dye conjugate indicated for the real-time intraoperative fluorescence detection and localization of nerve tissue.
46048842|NCT05047653|Diagnostic Test|RALE score vs. severity score|RALE score vs. severity score and CORADS
45360626|NCT04708496|Drug|Artemether-lumefantrine|"A three-arm single blind Randomized Clinical Trial in which HIV-malaria co-infected individuals with uncomplicated malaria receiving efavirenz-based ART will be randomized to one of three arms; a standard dose of artemether-lumefantrine, or a double dose of artemether-lumefantrine, or a 5-day course of artemether-lumefantrine for treatment of uncomplicated malaria. Participants will be followed up for 42 days to determine safety, drug pharmacokinetics and malaria treatment outcomes.~The 4th objective focuses on the interaction between Dolutegravir and Artemether Lumefantrine hence this will be a single blind pharmacokinetic trial among HIV-malaria co-infected individuals receiving Dolutegravir based ART and standard dose of artemether-lumefantrine for treatment of uncomplicated malaria."
45360627|NCT00646958|Drug|Radezolid|450mg PO QD
45360628|NCT00646958|Drug|Radezolid|450mg PO BID
45360629|NCT00646958|Drug|Linezolid|600mg PO BID
45688110|NCT03842475|Procedure|Roux-en-Y gastric bypass (RYGB)|Bariatric surgery
45688111|NCT03841097|Drug|Extended Release Tacrolimus Tablets|The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
45360630|NCT00813410|Procedure|Glucose measurement at the sc. insulin delivery site|Overnight fasting and oral glucose tolerance test (OGTT) combined with simultaneous subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.
45360631|NCT04045808|Other|radiographic evaluations were done|For radiographic analysis, periapical radiographs were taken from teeth with ≥ 4mm PPD using a hand held intra-oral x-ray system operating at 60kVp, 1.5 mA . The alveolar bone loss was measured by a personal computer with the Microsoft Windows XP operating system with original software.
45360632|NCT04692818|Diagnostic Test|GE Logiq E10 clinical ultrasound scanner|2D B-mode, Doppler, and shear wave elastography images of the lesion
45360633|NCT04692818|Diagnostic Test|Verasonics research scanner|3D B-mode imaging, microvessel imaging, and shear wave elastography
45360634|NCT00817544|Drug|ORM-12741|3 mg of ORM-12741 as a single dose. Contains 0.73 mg (2.5 MBq) 14C labelled ORM-12741
45360635|NCT00642746|Drug|Erlotinib|"Erlotinib oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. In addition to the active ingredient, erlotinib contains lactose (hydrous), microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate.~Tablets containing 25 mg, 100 mg, and 150 mg of erlotinib are available. Each bottle will contain 30 tablets, a quantity sufficient for 4 consecutive weeks of dosing, with overage."
45360636|NCT00642746|Drug|Fluorouracil|Antimetabolite used as a chemotherapy. Administered intravenously as a bolus injection at 400mg/m2 on Day 1 followed by 2400 mg/m2 continuously over 46 hours.
45360637|NCT00642746|Drug|Leucovorin|Chemotherapy agent given as a supplement to Fluorouracil. Given intravenously 400mg/m2 in combination with Fluorouracil dosing.
45360638|NCT00642746|Drug|Oxaliplatin|Platinum-based antineoplastic chemotherapy agent given intravenously at 85 mg/m2.
45479887|NCT02490826|Other|Table-based T2T intervention|"Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on table top materials. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:~Auditory Bombardment;~Auditory and discrimination;~Letter-sound knowledge;~Phoneme identity and phoneme matching;~Blending;~Segmentation;~Rhyme;~Phoneme manipulation."
45360639|NCT00642746|Drug|Irinotecan|Chemotherapy agent given intravenously at 180 mg/m2.
45360640|NCT00814268|Drug|Clopidogrel|75mg tablet, oral administration once daily
45360641|NCT00814268|Drug|Clopidogrel placebo|Matching tablet, oral administration once daily
45360642|NCT00814268|Drug|Aspirin|100mg tablet, oral administration once daily
45479888|NCT02490826|Other|Tablet-based T2T intervention|"Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on digital materials presented on a tablet. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:~Auditory Bombardment;~Auditory and discrimination;~Letter-sound knowledge;~Phoneme identity and phoneme matching;~Blending;~Segmentation;~Rhyme;~Phoneme manipulation."
45479889|NCT05238857|Other|Assessment|There will be no intervention. Only assessments will be taken from the patients and data will be analyzed.
45479890|NCT03464396|Other|Bedside Physiology study|A 90-minute recording in conjunction with the respiratory evaluations using standard recording equipment that includes a conventional pulse oximeter, an EEG, an airflow sampling catheter near the nose, and respiratory inductance plethysmography (RIP) bands. Standard clinical bedside monitoring will continue during the respiratory evaluations.
46048843|NCT04385589|Drug|Dapagliflozin|Patient will receive oral Dapagliflozin then monitoring of its efficacy on heart failure symptoms and outcome.
46048844|NCT04385589|Drug|insulin|insulin
46048845|NCT05032443|Other|Awareness survey|The 33-item questionnaire will sent to pediatric endoscopy nurses in our country. Questionnaires will be delivered to nurses through hospital visits or electronic media.
46048846|NCT04201977|Other|Foam Roller Recovery|Myofascial self-release will be developed through the foam roller (FR), where participants will use a custom-made foam roller constructed from a hollow polyvinyl chloride tube that will have an outside diameter of 10cm and a thickness of 0.5cm and will be surrounded by neoprene foam with a thickness of 1cm. Each volunteer will be shown the technique for the 5 muscle groups involved and the technique used for each muscle group. FR will consist of 45s of rolling for each muscle in the left lower extremity, 15s of rest, 45s in the lower right extremity. They will be instructed to begin with the practice on the most distal portion of the muscle. They will be instructed to place as much tolerable body mass on the FR at all times and to roll their body mass back and forth along the roller as smoothly as possible at a rate of 50 beats per minute (ie , 1 rolling motion for 1 to 2s). The total technique time is estimated at 10 to 15min (PEARCEY et al., 2015).
45360643|NCT00808262|Biological|TNFa Kinoid|TNFa kinoid at days 0, 7, 28
45479891|NCT03464396|Other|Carotid Body Function Test|Infants without nasal cannula will have a nasal cannula placed in their nares. After a 15-minute baseline period and during quiet sleep, the infant will then be exposed to 30 seconds of 100% oxygen (O2) by increasing FiO2. This test will be repeated 3 times, with at least 3 minutes between tests to allow for return of oxygen saturation (SpO2) to baseline values. If oxygen saturations increase to 99% for 15 seconds or the infant is apneic for greater than 5 seconds following initiation of 100% oxygen (O2), the test will be stopped and FiO2 brought back to baseline. Infants in the NICU will be monitored continuously with heart rate, respiratory rate, and SpO2% for 12 hours after Carotid Body Function Test according to NICU standards. Infants discharge who return for Carotid Body Function Test at 40 and 52 weeks PMA will be monitored continuously for 1 hour after the test is finished.
45360644|NCT00817622|Dietary Supplement|EPA, Vitamin E|EPA pearls, 500 mg QID for 12 Weeks (2000 mg per day) Vitamin E pearls, 400 mg per day for 12 weeks
45360645|NCT00808418|Drug|Elesclomol Sodium|Chemotherapy agent
45360646|NCT00808418|Drug|Docetaxel|Chemotherapy agent
45360647|NCT00817700|Other|Sleep restriction|Sleep restriction.
45360648|NCT04572152|Biological|AK119|Subjects will receive AK119 by intravenous administration.
45360649|NCT04572152|Biological|AK104|On the same day subjects will receive AK104 by intravenous administration.
45688112|NCT03841097|Drug|Immediate Release Tacrolimus Capsule|The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
45688113|NCT03831776|Drug|Bosutinib|Bosutinib, provided by Pfizer, starting dose of 200mg QD and stepwise dose escalation (> 300 mg/d > 400 mg/d) during the first three months. A pharmacological study will be performed in the French cohort (BOSUSTEP Substudy). BOS residual plasma concentration (Cmin) will be checked after initiation, before each dose step in the French cohort, and at M3 also for Nordic patients in ancillary studies.
46048847|NCT04201977|Other|Active recovery|Active recovery for 20 minutes (MIKA et al., 2016) will consist of pedaling on a stationary bike at a speed of 50 to 60 rpm. The load (49 ± 9 W) will be adjusted individually so that the heart rate is close to 100 bpm (about 50% of the theoretical maximum heart rate). This effort intensity is similar to that used in the literature (CRISAFULLI et al., 2003; FAIRCHILD et al., 2003; VANDERTHOMMED; MAKROF; DEMOULIN, 2010)
46048848|NCT04201977|Other|Immersion in cold water|Immersion in cold water will consist of the individual sitting in a plastic pool with water at the water level of the umbilical scar. Water temperature is between 11 and 15ºC, for a period between 10 and 15 minutes immediately after the exercise protocol (MACHADO et al., 2016b; MCDERMOTT et al., 2009). Water temperature will be controlled by adding or removing ice. This method has been applied by studies conducted by our research group (MISSAU; SIGNORI, 2017).
46048849|NCT04201977|Other|Passive recovery|Volunteers will be seated for 20 min after the resistance exercise session (TEIXEIRA et al., 2014a, 2014b).
46048850|NCT05336331|Procedure|SG or a RYGB|operation type differed between a partial gastrectomy (SG)or a combined restrictive/malabsorptive
46048851|NCT04995939|Procedure|Laboratory parameters and Scoring systems|Neutrophil/ Lymphocite ratio, albumin level and scoring systems has been evaluated.
46048852|NCT04951401|Other|lipid profile|lipid profile
45360650|NCT00642668|Drug|methoxy polyethylene glycol-epoetin beta|1.2 mcg/kg administered subcutaneously (sc) monthly for 36 weeks (initial recommended dose)
45360651|NCT00817934|Drug|AB PREP|Potassium phosphate and Sodium Phosphate,(in the form of K-phos neutral 8 tablets.(Bisacodyl)6tablets. The third medication is (Metoclopramide).
45360652|NCT00814424|Device|monitored using currently marketed smart biteblock o2|oral nasal CO2 monitoring and oxygen delivery
45360653|NCT00814424|Device|monitored using investigational smart biteblock|monitored during ERCP procedure with nasal CO2 sampling and oral oxygen delivery at a flow rate up to 10 lit/min
45360654|NCT00729833|Drug|CP-751,871|CP-751,871 IV, every 3 weeks
45360655|NCT00729833|Drug|Sunitinib|Sunitinib - daily dosing
45360656|NCT00645788|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|32.5 mg ciprofloxacin DPI corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days
46048853|NCT04951401|Other|ECG|ECG
45360657|NCT00645788|Drug|Placebo|50 mg matching placebo powder formulation twice a day for 28 days
45360658|NCT00645788|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
45360659|NCT00645788|Drug|Placebo|75 mg matching placebo powder formulation twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
46048854|NCT04948359|Other|Group I (The patients intubated with cuffed ETT of ID number 4.5)|Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 4.5 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
45688114|NCT03831776|Drug|Ropeginterferon|Ro-Peg-Interferon α2b will be supplied by AOP Orphan to be administered by subcutaneous injections from prefilled injection pens. RoPegIFN will be given in an open-label fashion. Patients assigned to RoPegIFN will start with 50 μg injected subcutaneously every 14 days, in combination with Bosutinib.
45360660|NCT00808496|Other|MRI|"Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline. Scored using the Xie-modified rheumatoid arthritis magnetic resonance imaging score (RAMRIS).~MRI intervention group also undergoes radiography imaging. Only protocol determined smallest detectable changes on MRI reported."
45688115|NCT03831425|Dietary Supplement|Coenzyme Q10|6 week trial of either treatment with CoenzymeQ.
45360661|NCT00808496|Other|Radiography|"Biannual disease progression monitoring with radiography of both hands and wrists. Scored using the van der Heijde-modified Sharp score.~Radiography intervention group also undergoes MRI imaging. Only protocol determined smallest detectable changes on radiography reported."
45498125|NCT04543773|Device|rTMS|rTMS will be delivered to the fMRI-determined DLPFC hotspot according to conventional parameters for clinical treatment (e.g., excitatory: 75 trains of 40 pulses, 10Hz, up to 3000 pulses). Magnetic field strength will be up to 120% of resting motor threshold. Ramp up of magnetic field strength may be utilized in the first week for tolerability. Side effects will be monitored and coil angle adjusted to improve tolerability if necessary.
45498126|NCT03681444|Other|Regular diet|Patients will be provided with any type of food preferred at any time in any quantity
45688116|NCT03831425|Other|Placebo|6 week trial of either treatment with Placebo
45688117|NCT03830866|Biological|Durvalumab|IV infusion every 4 weeks
45688118|NCT03830866|Drug|Cisplatin|Platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
45688119|NCT03830866|Drug|Carboplatin|For patients enrolled under CSP v2 and prior - platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
45360662|NCT00808496|Other|Standard of Care|Diagnostic imaging results (MRI or radiography) reported upon requisition. Standard of Care intervention group undergoes both MRI and radiography imaging. Upon requisition of either MRI or radiography, radiology reports are delivered as per institutional standard of care
45360663|NCT00814736|Drug|UK369,003|oral tablet, once a day
45360664|NCT00814736|Drug|sildenafil|single oral dose on day 14 or day 17
45479892|NCT03464396|Other|Room Air Challenge|Infants receiving nasal cannula high flow support 3 liters per minute (LPM) or less with or without supplemental O2 at 36 weeks PMA will be eligible. After a 15-minute quiet sleep period, infants' FiO2 will be weaned, in 0.20 decrements for 5 min intervals. Flow then decreased in 10 min intervals, initially in 1 Liter Per Minute (LPM) decrement until nasal cannula flow is 1LPM, and then decreased by 50% decrements to 0.125 LPM then off. If the infant is weaned to room air alone for 15 minutes, not meeting failure criteria, he/she has passed the RAC. Failure of the RAC is defined as occurring when SpO2% falls below 80%, even briefly, or remains less than 90% for 5 consecutive minutes any time during the test, bradycardia (Heart rate [HR] < 80 bpmx 10 sec) or persistent apnea despite stimulation. Infant is returned to the level of support provided before the RAC begun if meets any failure criteria.
45360665|NCT00814736|Drug|sildenafil matching placebo|single oral dose on day 14 or day 17
45479893|NCT03464396|Other|Hypoxia Challenge Test|"A physician investigator will review 30 minutes of continuous recording made 24 hours prior to test scheduled to identify infants that are at high risk for significant oxygen desaturations during Hypoxemia Challenge.~If subject passes the screening test, the hypoxic challenge will be performed. For the hypoxemia test, a nasal cannula will be placed prior to a 15 minute period of quiet sleep recorded to confirm antecedent stability of ventilatory pattern and SpO2%. During the 15 minutes of quiet sleep, the infant is required to maintain a SpO2 of > 92% in order to undergo the HCT. After the 15-minute baseline recording, HCT will begin using FiO2 = 0.18 for 5 minutes, unless failure criteria is met: SpO2% < 80% even briefly, or SpO2% 80% to 85% for 15 seconds. If infant does not meet failure criteria, infant will be given FiO2 0.15 for 10 minutes. If an infant meets even a single criterion for failure, Hypoxic mixture will be stopped."
45360666|NCT00818090|Drug|paclitaxel and cisplatin|paclitaxel and cisplatin every 3 weeks
45688120|NCT03830866|Radiation|external beam radiation therapy (EBRT) + brachytherapy|Radiation therapy per standard of care
45688121|NCT03807765|Drug|Nivolumab|480 mg intravenous Nivolumab administered every 4 weeks.
46048855|NCT04948359|Other|Group II (The patients intubated with cuffed ETT of ID number 5.0)|Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.0 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
45360667|NCT03869606|Device|NICOM by Cheetah Medical|Observational measurement, Cardiac Output, Pre- and Post Anesthesia
45360668|NCT00642356|Drug|Carbidopa/levodopa/entacapone|Carbidopa/levodopa/entacapone 25/100/200 mg tablets plus placebo immediate release carbidopa/levodopa capsules, administered orally for 8 weeks. Total daily dosage and frequency of dosing for each patient was determined by the investigator and stabilized upon entry into the study.
45360669|NCT00642356|Drug|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 25/100 mg capsules plus placebo carbidopa/levodopa/entacapone tablets, administered orally for 8 weeks. The maximum daily dose is 800 mg. Total daily dosage and frequency of dosing for each patient was determined by the investigator.
45360670|NCT00642278|Drug|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.
45360671|NCT00642278|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
45360672|NCT00642278|Drug|Placebo|One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.
45360673|NCT00808574|Behavioral|Obstructive sleep apnea screening intervention|Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
45360674|NCT00543543|Biological|Comparator: GARDASIL|GARDASIL (quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen
45360675|NCT00543543|Biological|Experimental: V503|V503 (9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen (and a fourth injection for Cohort 1 only).
45360676|NCT00812786|Drug|cyclosporine, tacrolimus, mycophenolate mofetil and everolimus (immunosuppressive drugs)|
45360677|NCT00645164|Other|Ointment Vehicle|Subject acts as own control. 20 mg under Finn chambers
45688122|NCT03807765|Radiation|Stereotactic Radiosurgery|"Patients will receive single session SRS to intact brain metastases and post-operative cavities.~A linear accelerator (LINAC)-based frameless delivery system will be used to deliver the stereotactic radiation. The lesion will be defined using gadolinium enhanced MRI with 1 mm slices for treatment planning purposes prior to the delivery of radiation. The MRI image will be co-registered and fused with CT imaging. Doses will be prescribed to ensure coverage of at least 95% of the planning target volume (PTV) with the prescription dose. Treatments will be delivered using dynamic conformal arcs or intensity modulated radiotherapy."
45360678|NCT00645164|Drug|Xenaderm|20 mg under Finn chambers
45360679|NCT00815048|Drug|Atropine/Remifentanil|"Atropine 20mcg/kg~Remifentanil 3mcg/kg"
45360680|NCT00815048|Drug|Fentanyl/Atropine/Succinylcholine|"Atropine 20mcg/kg~Fentanyl 2mcg/kg~Succinylcholine 2mg/kg"
45360681|NCT02551796|Procedure|lenticule extraction|Four femtosecond incisions will be created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction is released, the flap will be opened using a thin, blunt spatula and the free refractive lenticule will be subsequently grasped with a forceps and extracted, after which the flap will be repositioned carefully.
45360682|NCT02551796|Procedure|laser in situ keratomileusis|During LASIK surgery, the eye will be gently proptosed and a hinged corneal flap will be cut using a microkeratome. The flap will be lifted and the stromal bed will receive a 6 mm diameter and stroma ablation. Finally reposition the flap carefully.
45498127|NCT03681444|Other|Clear fluid diet|"Patients will be provided with~Plain water~Fruit juices without pulp, such as grape juice, filtered apple juice, and cranberry juice~Soup broth (bouillon or consommé)~Clear sodas, such as ginger ale and Sprite~Gelatin (Jell-O)~Tea or coffee with no cream or milk added~Sports drinks that don't have color"
46048856|NCT04948359|Other|Group III ( The patients intubated with cuffed ETT of ID number 5.5)|Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.5 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
46048857|NCT02847429|Drug|Crenolanib|
46048858|NCT02847429|Drug|Placebo|
46048859|NCT03959007|Other|Aesthetic therapy sessions|Only for experimental arm at 3 times during hospitalization
45360683|NCT02551796|Procedure|FS assisted laser in situ keratomileusis|Track distance and spot distance will be 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter will be 8.0 mm, and flap thickness will be set to 105 μm. Side-cut angle and hinge angle will be 90°and 50° respectively. The flaps will be created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system will be used in the subsequent ablation of thstromal bed with a 6.0 mm optical zone. Once the excimer. ablation is completed, the flap will be repositioned in a similar fashion as in routine LASIK.
45360684|NCT00808652|Other|Measurement of flow mediated dilation of brachial artery.|"Flow-mediated brachial artery reactivity will be measured and flow-mediated vasodilatation will be assessed with the subject's arm using a 15 MHz linear array ultrasound.~Study Phases:~Flow-mediated (endothelial-dependent) vasodilatation (FMD): Following a 2-minute baseline period, a longitudinal image of the artery will be obtained. A tourniquet placed around the forearm proximal to the target artery will be inflated to a pressure 50 mmHg higher than the subject's systolic blood pressure and held for 5 minutes. Cuff will be then deflated. A continuous scan will be performed at deflation, 60 and 90 seconds after cuff deflation, with frozen and Doppler measurements recorded at similar intervals to the baseline phase.~NTG-induced (non-endothelial-dependent) vasodilatation (NTG): After vessel recovery, sublingual 375 mg of isosorbide dinitrate spray will be administered, and scanning will be performed continuously for 5 minutes thereafter."
45360685|NCT02551484|Device|Measurements using NIRS|
45360686|NCT02551484|Device|TCPO2 measurements|
45360687|NCT02551484|Other|2-minute walk test|
45360688|NCT00723125|Drug|Abraxane|Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks
45360689|NCT00723125|Drug|Carboplatin|Carboplatin at AUC 6 over 30 min IV weeks 1,4,7, and 10
45360690|NCT00723125|Drug|Avastin|Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
46048860|NCT03959007|Other|Questionnaire|Both arm at 3 times during hospitalization
45360691|NCT00815126|Procedure|Lysine-ASA Nasal ProvocationTest|Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette
45360692|NCT02594189|Other|Live recombinantly derived A/Bethesda/MM1/H3N2 virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
45360693|NCT04044638|Other|Resistance trainining|Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale. In the first, fourth and eighth week, pre-exercise blood pressure (BP) was verified, in which the participants sat for a period of 10 minutes at rest, in a comfortable chair, with legs uncrossed, feet flat on the floor, back leaning on the chair, left arm at heart level and palm up to measure BP using a G * Tech-branded automatic digital device (MASTER model).
45360694|NCT00808730|Procedure|fiberoptic fibroscopy|Bronchial specimens will be obtained by fiberoptic bronchoscopy within 15 days after the enrolment
45360695|NCT00722423|Behavioral|Integrated care model|The integrated care intervention follows a manualized protocol consisting of a series of brief intervention tailored to the patients' main barriers to treatment along with a case management approach in which the integrated care mental health provider actively tracks each patients progress through the evaluation and treatment process. The integrated care mental health provider can be a clinical nurse specialist, psychologist, or licensed clinical social worker that has experience and training in the provision of psychiatric and SUD interventions. They will receive additional training on the integrated care protocol. Data will be collected at baseline, pre-treatment, and post-treatment intervals.
45360696|NCT00722423|Behavioral|Usual Care Model|
45360697|NCT02593331|Drug|BFKB8488A|Participants will receive either a single escalated dose of BFKB8488A administered SC or a single dose of BFKB8488A administered IV on Day 1.
45360698|NCT02593331|Other|Placebo|Participants will receive a single dose of placebo on Day 1.
45360699|NCT00640562|Drug|Quetiapine Extended Release|Uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
45360700|NCT00640562|Drug|Risperidone|Uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.
45360701|NCT00585923|Device|Fixed hole C-Tek™ Plate|Fixed hole C-Tek™ Plate
45360702|NCT00585923|Device|Slotted hole C-Tek™ Plate|Slotted hole C-Tek™ Plate
45360703|NCT04019639|Device|application of CG Paste+EasyFoam|Prior to application of CG paste, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. After this, hemostasis is performed by an electrocoagulator and the medical device is applied to the affected area. During the procedure, remove the packaging material and remove the syringe to remove the protective cap in front of the syringe. Slowly push the syringe plunger and apply the contents to the area where you want to use. Depending on the location and size of the wound area, an injection cap can be used. Apply CG paste and apply Easyfoam to finish the dressing.
45360704|NCT04019639|Device|application of EasyFoam|Prior to applying EasyFoam, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. Marginal resection is performed until the necrotic tissue is removed sufficiently and pin point bleeding is seen on the wound. After that, hemostasis is done with an electrocoagulator and EasyFoam is applied to the affected area.
45844810|NCT01983228|Behavioral|Intervention Condition|Intervention participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
45360705|NCT00818558|Biological|ISET Methode|Sampling of blood - ISET Methode
45688123|NCT03804944|Radiation|Focal Radiation therapy|Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
45688124|NCT03804944|Drug|Pembrolizumab (200mg IV for 30 minutes|Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
45688125|NCT03804944|Biological|CDX-301|Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days.
45360706|NCT03955679|Genetic|AVXS-101|AVXS-101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). AVXS-101 will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
45360707|NCT00815204|Procedure|MRI of the pituitary|Patients will undergo a T1 weighted MRI of the pituitary to measure pituitary volume
45360708|NCT00815204|Procedure|DEX/CRH test|Subjects will have blood drawn for baseline ACTH, cortisol, and other hormones and then undergo a DEX/CRH test. Will then measure ACTH and cortisol on test.
45688126|NCT03790111|Drug|telotristat ethyl|XERMELO (telotristat ethyl) tablets administered as 250 mg (1 x 250-mg tablet) three times a day plus first line therapy for 7 days, then XERMELO (telotristat ethyl) tablets administered as 500 mg (2 x 250-mg tablets) three times a day plus first line therapy for the duration of the study
46048861|NCT04827381|Other|Annotated Audio|In addition to usual care, patients will be given access to an annotated audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit which will be annotated with key information discussed (e.g., medications). The recording will also contain hyperlinks related to annotations, that will direct participants to the online health information resource at Medline Plus. Access to their HealthPAL can also be shared with a caregiver.
45360709|NCT00721955|Drug|Inhaled Placebo|Inhaled loxapine Placebo, may repeat after 2 hours x 2
45360710|NCT00721955|Drug|Inhaled loxapine 5 mg|Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2
45360711|NCT00721955|Drug|Inhaled loxapine 10 mg|Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2
45360712|NCT00585689|Drug|ABI-007|ABI-007 will be administered at a dose of 260 mg/m2 over a 30 min IV infusion on day 1 of each 21 day cycle.
45360713|NCT00585689|Drug|Carboplatin|Carboplatin will be administered at a dose of TARGET AUC=5 over a 15 min IV infusion of day 1 of each 21 day cycle.
45360714|NCT00585689|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 800 mg/m2 over a 30 min IV infusion on days 1 and 8 of each 21 day cycle.
45360715|NCT00585689|Procedure|Radical Cystectomy|
45360716|NCT00721799|Drug|18F-Fluorothymidine PET scan|18F-Fluorothymidine (0.04 - 0.08 mCi / kg to a maximum dose of 5 mCi) administered once intravenously for a positron emission tomography (PET) scan.
45360717|NCT00653432|Device|Monovisc®|Intra-articular injection
45360718|NCT00653432|Other|Saline|0.9% Sterile Saline
45360719|NCT00815282|Other|Human papilloma virus vaccine (cervarix)|vaccination at 0, 1 and 6 months
45688127|NCT03780543|Drug|standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)|Participants will continue on their SOC NrtI, Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) tablet QD (once daily) orally as per approved package insert.
45360720|NCT02591693|Behavioral|Caregiver training|Occupational therapy training focuses on improving confidence to manage practical aspects of care in areas of daily life important to patient and caregiver, in which caregiver reports or anticipates low levels of confidence.
45360721|NCT00818636|Behavioral|Expressive writing (in addition to group therapy as usual).|Participants in the expressive writing condition write about their feelings about an issue of their choosing three times, for at least 20 minutes each time, during a two week period.
45688128|NCT03772314|Drug|Modafinil|Participants will received 100-400 milligrams (mg) per day of modafinil for 12 weeks.
45688129|NCT03772314|Drug|Amphetamine-Dextroamphetamine|Participants will receive 10-40 mg/day of oral amphetamine salts for 12 weeks.
45844811|NCT01984398|Drug|12.5 mg Androxal Formulation A|Single dose of 12.5 mg Androxal formulation A
46048862|NCT04827381|Other|Audio|In addition to usual care, patients will also be given access to an audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit (no annotations or hyperlinks). Access to their HealthPAL can also be shared with a caregiver.
46048863|NCT04750005|Other|Listerine Cool Mint|Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing twice a day.
45688130|NCT03760575|Drug|Pembrolizumab|Pembrolizumab 200mg via IV infusion every 3 weeks for 2 cycles 3 pre-surgery, for 4 cycles post-surgery and then every 3 weeks during maintenance.
45360722|NCT02593019|Drug|AZD1775|"AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.~Tumour evaluation using RECIST 1.1 will be conducted at screening (within 28 days prior to first dose) and every 6 weeks relative to the date of first dose, up to week 42, then every 9 weeks until objective disease progression (within a window of +/- 7 days of the scheduled date)."
45688131|NCT03760575|Procedure|Indocyanine Green (ICG) Image-Guided Surgery|Standard surgery with image guided resection.
45360723|NCT00818714|Radiation|SBRT|"SBRT x 3 (start 6-9 weeks following standard ChemoRT; Time between SBRT Boost treatments: 40 hours to 8 days)~Dose Escalation Schema:~Cohort -3: 4 Gy x3 Cohort -2: 5 Gy x3 Cohort -1: 6 Gy x3 If de-escalation is required after initial cohort~Cohort 1: 7 Gy x 3 INITIAL COHORT Cohort 2: 8 Gy x 3 Cohort 3: 9 Gy x 3~Continue +1 Gy x 3 until reach MTD"
45360724|NCT00818792|Device|Coronary stent|Comparison of bare-metal stent (Vision) and drug-eluting stent (Xience V)
45360725|NCT00729365|Drug|Ramipril|"ACE inhibitor known as Ramipril~Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into this group and given an ACE inhibitor (study medication). Therefore, the Non-Dippers groups II and III will be randomized to receive either drug or placebo."
45688132|NCT03760575|Drug|Cisplatin|75 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
45479894|NCT03464396|Other|Effects of Nasal Cannula Flow|"Infants will have nasal catheter in place (NeoTech Premature RAM Cannula). A 15-minute baseline recording of physiologic study parameters prior to initiation. Tested in three groups of infants.~28 and 32 weeks PMA flow rates increased after a 15-minute baseline period to 3LPM, or by 1LPM to a max of 5LPM for 15 minutes. Infant on Bubble CPAP will be increased 1cm H2O to max 8 cm H2O for 15 minutes.~Infant's that fail the RAC or HCT at 36 weeks with periodic breathing, high flow at 3LPM will be started for 2 minutes or until periodic breathing stops. Infants on Bubble CPAP will not undergo the RAC or HCT. Their pressure is increased by 1cm H20 to max of 8 cm H2O for 15 minutes.~Infant on RA at 40 and 52 weeks PMA with periodic breathing lasting longer than 1 minute during the 15-minute baseline period, flow at 3LPM will be started for 2 minutes or until periodic breathing stops."
45479895|NCT03464396|Diagnostic Test|Magnetic Resonance Imaging|A non-sedating MRI scan will be performed on 3 subsets of infants at 37-40 weeks Post Menstrual Age (PMA), or when infant is within one week of discharge from the NICU. Standard images as well as research images will be obtained. The research images use the same MRI scanner and collection techniques as standard clinical imaging, but provide a more detailed examination of brain anatomy and injury. Collection of these sequences using our standard non-sedated acquisition practices for infants is well tolerated. Infants will be placed in scanner by registered nurse accompanied by radiology technician to assure infants' comfort during scan. Infant will remain on cardio-respiratory monitor during MRI via a pulse oximetry probe. It will take no longer than one hour to complete MRI scan including transportation to radiology unit.
45479896|NCT03464396|Diagnostic Test|Echocardiogram|An echocardiogram (referred to as an ultrasound of the heart on the consent form) will be performed to assess cardiac structure and function. Echocardiograms are performed routinely in premature newborns in the NICU. The Echocardiogram will be performed at the infant bedside and will be coordinated with bedside nurse. The infant will remain on a cardio-respiratory monitor during the echocardiogram for approximately 15 minutes.
45688133|NCT03760575|Drug|Pemetrexed|500 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
45688134|NCT03750981|Behavioral|12 week pilot intervention study.|Participants will begin a 12-week high-intensity functional training program conducted at CrossFit® in the D, located in downtown Detroit, Northville Athletix in Northville and Five Lakes CrossFit® in Farmington Hills.
45688135|NCT03747393|Behavioral|DoD/VA CPG Core Set + PT|Participants randomized to receive the core set management class and physical therapy will be scheduled for their initial physical therapy evaluation approximately 1 week from their enrollment date. The purpose of the evaluation will be to identify relevant impairments that can be addressed during the physical therapy treatments. After this initial evaluation, the goal is for the patient to receive approximately 4 weeks of physical therapy (about 8-10 sessions in the clinic 2-3 times per week). Consistent with a pragmatic study we will not use placebos to blind patients or attempt to balance provider contact.
45844812|NCT01984398|Drug|12.5 mg Androxal Formulation B|Single dose of 12.5 mg Androxal Formulation B
46048864|NCT04750005|Other|Colgate Cavity Protection Toothpaste|Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.
46048865|NCT04750005|Other|Reach Unflavored Waxed Dental Floss|Participants after brushing for 1 minute, rinse mouth with water and FLOSS once a day in first use.
46048866|NCT04750005|Other|American Dental Association (ADA) Ref Toothbrush|Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
45360726|NCT00729365|Drug|Placebo|Dippers (category of subjects with a nighttime dip in blood pressure) will all be given Placebo. Control group.
45360727|NCT00729365|Drug|Placebo|"Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into the control group and given Placebo."
45360728|NCT00818870|Drug|Omeprazole|20 mg capsule, orally, once daily (before breakfast) for 5 days.
45360729|NCT00818870|Drug|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
45360730|NCT00818870|Drug|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
45360731|NCT00922376|Device|Mobile phone telehealth application: Think Positive (T+)|T+ consists of the Glucometer paired with a cradle that transmits via Bluetooth blood glucose results to a mobile phone. Data is stored and sent to a secure website. The website can be accessed by the patient as well as by health care providers (HCP). HCP can discuss data on the phone and make recommendations via text messages to patients. Visual feedback (graphs and statistics) illustrating recent blood sugar levels patterns is automatically and immediately sent to the patient when data is transferred from the T+ phone.
45360732|NCT02594267|Drug|Pralatrexate Injection|"Drug: Folotyn (Pralatrexate Injection)~CHOP : Cyclophosphamide, Doxorubicin, Vincristine, & Prednisone"
45360733|NCT02594501|Device|COBRA PzF|
45360734|NCT02594501|Device|Drug Eluting Stent|
45360735|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC Solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 75 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
45360736|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC Solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
45479897|NCT03464396|Other|Blood Sample|Infants that have echocardiograms will have a blood sample collected near the time the echocardiogram is obtained, 3-blood samples total. The blood sample will only be collected with parental permission on an opt-in or out-basis and collected only with routine clinical labs.
45479898|NCT05133245|Other|Diagnostic study only|Diagnostic study only
45479899|NCT03791723|Drug|Sacubitril-Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 50 mg LCZ696 for 2-4 weeks, then uptitrated to 100 mg bid for 2-4 weeks, and thereafter, uptitrated to 200 mg bid or tolerable maximum dose ≥6 months.
45479900|NCT03791723|Drug|Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 40 mg Valsartan daily (qd) for 2-4 weeks, then were uptitrated to 80mg qd or tolerable maximum dose ≥6 months.
45479901|NCT05452070|Device|HArmonyCa Lidocaine Injectable Gel|Subdermal or deep dermal injection
45360737|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 750 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
45360738|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
45360739|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 200 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
45360740|NCT00254293|Drug|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly
45360741|NCT00736385|Drug|Glucophage (Metformin)|metformin XR 2000 mg daily for 12 months
45360742|NCT00736385|Drug|Placebo|placebo 2000 mg daily for 12 months
45360743|NCT00585221|Drug|Peginterferon-alpha 2b (PegIFNa2b);|Treatment include PegIFNa2b high dose (3 mcg/kg/wk) X 4 doses and low dose (1.5 mcg/kg/wk) X 18 doses, followed by surgical evaluation to render pt disease free if possible.
45360744|NCT00585221|Drug|Imatinib|Continue imatinib until progression.
45360745|NCT02594033|Drug|insulin aspart|All subjects make three intervention visits with at least 5 days between individual intervention visits. At each intervention visit the subject receives one insulin aspart injection with only one type of needle.
45479902|NCT03797885|Other|No treatment given|No treatment is administered to the participants for this study
45479903|NCT05410912|Procedure|Great saphenous vein stripping and ambulatory phlebectomy|All patients included in the study were treated with great saphenous vein stripping and ambulatory phlebectomy.
45844813|NCT01984398|Drug|25 mg Androxal Formulation A|Single dose of 25 mg Androxal formulation A
45844814|NCT01984398|Drug|25 mg Androxal Formulation B|Single dose of 25 mg Androxal formulation B
45360746|NCT00253747|Drug|Osmotic-Release Methylphenidate|OROS-MPH dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
45360747|NCT00253747|Drug|Placebo|OROS-MPH (placebo) dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
45360748|NCT00252733|Drug|candesartan cilexetil|32 mg once daily oral tablet given over 60 months
45360749|NCT03974035|Drug|Second infiltration pre-extubation with ropivacaine|The surgeon will proceed firstly with pre-incisional infiltration with lidocaine and adrenaline after intubation, and secondly with pre-extubation infiltration with ropivacaine at the intraoral and intranasal submucosal level in the maxilla and jaw to block the terminal branches of the maxillary and mandibular nerve
45360750|NCT01071967|Other|Community-based nurse care management|The community-based nurse care management program developed by Health Quality Partners uses nurses working in the community to provide the following integrated set of services to older adults with chronic illness over the long term in order to prevent avoidable complications of their diseases and aging; geriatric assessment, care coordination, health education, self-management coaching, weight management, physical activity, gait and balance training, medication adherence, care transition support, ongoing monitoring and symptom detection, collaborative problem solving with patients, families and health care providers.
45844815|NCT01985958|Device|Radiation therapy|
45360751|NCT00275821|Drug|Ranibizumab 0.3 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.3 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
45360752|NCT00275821|Drug|Ranibizumab 0.5 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
45360753|NCT00275821|Drug|Ranibizumab 0.3 mg monthly|Subjects received monthly intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
45360754|NCT01070797|Biological|Multi-virus Specific T cells|"Subjects will receive Multivirus specific T cells on one of the following dose levels:~Level One: 5 x 10^6 rCTLs/m2~Level Two: 1 x 10^7 rCTLs/m2~Level Three: 2 x 10^7 rCTLs/m2~Level Four: 5 x 10^7 rCTLs/m2~If a patient has a partial response (as defined by a 50% fall in viral load) or receives medication (such as steroids) which may affect the persistence or function of the infused CTL they are eligible to receive up to 2 additional doses at the same initial dose. The minimum time between additional doses is 28 days."
45360755|NCT03973099|Dietary Supplement|PM011|PM011 is a 400 mg hard gelatin capsule containing water extracts of Nelumbinis Semen. The sprayed-dry extract of the herbal medicine used was purchased from Sun Ten pharmaceutical company in Taiwan. Each participant received twelve capsules of PM011, which divided into 2.4 g treatment or 4.8 g treatment group or placebo daily for two weeks and was instructed to take six capsules after breakfast and six capsules after dinner. Subjects in the placebo group received the equivalent amount of starch and lactose mixture capsules and administered with the same schedule.
45844816|NCT01987752|Drug|brimonidine tartrate/timolol maleate Ophthalmic Solution|brimonidine tartrate/timolol maleate (Combigan®) Ophthalmic Solution as per local standard of care in clinical practice.
45844817|NCT01988376|Device|Surepath|A liquid-base method of Pap smear for screening the recurrence of cervical cancer
45844818|NCT01988376|Device|Conventional Pap smear|Conventional Pap smear
45844819|NCT01988922|Drug|ketamine|0.4 mg/kg oral racemic ketamine
45360756|NCT00275509|Drug|Thymoglobulin|
45360757|NCT00275509|Drug|Daclizumab|
45360758|NCT00275509|Other|Plasmapheresis|Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
45360759|NCT00275509|Drug|Mycophenolate mofetil|2 gm/day. Standard of care
45360760|NCT00275509|Drug|Tacrolimus|To achieve serum level of 8-10 ng/ml.
45360761|NCT00275509|Drug|Dexamethasone|100 mg intra-operatively, and 25 mg every 6h post-operatively for six doses
45844820|NCT01991808|Radiation|Radiotherapy|
45844821|NCT01992354|Device|PET MR Device|GE PET/MRI system
45844822|NCT01994538|Other|Longer therapy duration|14 days of antimicrobial treatment
45844823|NCT01994538|Other|Shorter therapy duration|7 days of antimicrobial treatment
45844824|NCT01996644|Drug|Placebo vs Setraline|Placebo
45844825|NCT01996644|Drug|Setraline|250mg DCS
45479904|NCT03432806|Other|blood draws|Patients will have 10 mL of peripheral venous blood drawn immediately prior to surgery, in the post anesthesia care unit (PACU), and at the first postoperative clinic visit for a total of 30 mL.
45688136|NCT03747393|Behavioral|DoD/VA CPG Core Set|The published clinical practice guideline recommends early use of a core set of management strategies to include patient education about their condition and the role of obesity in disease progression, activity and lifestyle modification focusing on physical activity, and a therapeutic exercise program. Implementation of the core set is recommended prior to any referral for consultation about invasive procedures such as intra-articular injections or TKA surgery. All patients with knee pain will be scheduled to receive the core set management strategy class as a part of the usual care route.
45479905|NCT03432806|Procedure|colectomy or hepatectomy|"Three small pieces of otherwise normal-appearing liver of 0.5-1 cm3 collected intraoperatively from patients in all four groups (including Group D). Because liver biopsy is less frequently performed during operations for benign colon lesions or Stage I-III colon cancers, this single aspect of the protocol can be made optional at the discretion of the surgical attending or the patient, however bloods and tissue from pathology will still be collected."
45688137|NCT03745820|Drug|BIIB104|Administered as specified in the treatment arm
45479906|NCT03432806|Diagnostic Test|Fibroscan test|This may be done either at a preoperative clinic setting or immediately prior to surgery.
45360762|NCT00275509|Drug|Prednisone|Taper over three months to 5 mg daily
45360763|NCT00275509|Drug|Cytogam|Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
45360764|NCT01072045|Drug|Propranolol|Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
45479907|NCT04442932|Device|Blood Collection|K3-EDTA venous whole blood 9 mL 1 venous draw
45479908|NCT03920657|Drug|Deferasirox|Fixed dose of 3.5 mg/kg/day of DFX FCT
45479909|NCT03420950|Other|Rapid sequence intubation: sedative first|Sedative first
45360765|NCT01072045|Drug|Prednisone|Oral prednisone, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
45479910|NCT03420950|Other|Rapid sequence intubation: paralytic first|Paralytic first
45479911|NCT03319654|Diagnostic Test|DNA fragmentation by TUNEL assay|Direct DNA fragmentation testing with terminal deoxyuridine nick end labeling (TUNEL) assay.
45688138|NCT03745820|Other|Placebo|Administered as specified in the treatment arm
45360766|NCT01072123|Other|Quest for the Code|interactive asthma-based computer program
45360767|NCT01073059|Drug|Valproic acid and Ertapenem|
45360768|NCT00252577|Drug|Lithium treatment|Lithium is a standard treatment for bipolar disorder. Patients will be stabilized on lithium monotherapy over a 3 month period, observed for one month, and then followed every 2 months in maintenance phase for 2 years
45360769|NCT00252499|Drug|rosiglitazone|PPAR-gamma agonist, insulin sensitizer
45360770|NCT00252499|Drug|fenofibrate|PPAR-alpha agonist, reduces triglycerides
45360771|NCT00252499|Drug|placebo for rosiglitazone|placebo tablets that are matched to look like rosiglitazone
45360772|NCT00252499|Drug|placebo for fenofibrate|placebo matched to look like fenofibrate tablets
45360773|NCT00252187|Drug|B-type Natriuretic Peptide (BNP)|BNP hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
45360774|NCT00252187|Other|Placebo|Placebo self-administered subcutaneously twice daily for 8 weeks.
45360775|NCT00572910|Biological|Comparator: Placebo (PBO)|Group 6: Placebo (PBO / PBO / PBO)
45479912|NCT03501277|Drug|Alogliptin|Alogliptin tablets.
45479913|NCT03501277|Drug|Pioglitazone|Pioglitazone tablets.
45479914|NCT03501277|Drug|SYR-322-4833 BL|SYR-322-4833 BL FDC tablets.
45479915|NCT04568850|Diagnostic Test|Plasma IgG levels|Plasma IgG levels of subjects who tested reactive for IgG SARS CoV-2 antibodies will be monitored every month for 4 months for IgG levels
45479916|NCT01304225|Procedure|Panretinal photocoagulation|Panretinal photocoagulation utilizing 100ms pulse duration, moderate intensity burns, in a single-shot fashion
45479917|NCT01304225|Procedure|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, moderate intensity burns, in a multiple-shot fashion
45479918|NCT01304225|Procedure|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, barely visible intensity burns, in a multiple-shot fashion
45688139|NCT03738579|Device|Next Science Group|TorrentX Wound Wash will be used for irrigation and then BlastX Wound Gel will be applied to the wound after debridement/irrigation during in-clinic visits. BlastX Wound Gel will be re-applied again during mid-week dressing change. Dressing used will be plain foam dressing from control group arm.
45688140|NCT03738579|Device|Control Group|Foam Dressing will be used in conjunction with standard of care for chronic wound management, such as debridement and irrigation.
45479919|NCT03447626|Device|MAKO Robotic UKA|Prospective UKA patient receiving unilateral knee arthroplasty using the MAKO robotic machine
45479920|NCT02488174|Other|PROOFcheck|
45688141|NCT03738579|Device|Antibacterial Control Group|Foam Dressing AG will be used in conjunction with standard of care for chronic wound management, such as debridement and irrigation.
45360776|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 5A: V710 (90 mcg / 90 mcg / 90 mcg) with MAA~Group 5B: V710 (90 mcg / 90 mcg / PBO) with MAA"
45688142|NCT03722407|Drug|Ruxolitinib|Ruxolitinib 5 mg tablets, 4 per dose
45360777|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 4A: V710 (60 mcg / PBO / 60 mcg) with MAA~Group 4B: V710 (60 mcg / PBO / PBO) with MAA"
45360778|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 3A: V710 (60 mcg / 60 mcg / 60 mcg) with MAA~Group 3B: V710 (60 mcg / 60 mcg / PBO) with MAA"
45360779|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 2A: V710 (60 mcg / PBO / 60 mcg) without MAA~Group 2B: V710 (60 mcg / PBO / PBO) without MAA"
45479921|NCT02488174|Other|Standard Care|
45479922|NCT03870425|Other|Distribution pattern of dietary proteins (minced meat)|Study effect of an even or skewed distribution pattern of dietary protein
45688143|NCT03720522|Procedure|Short cardiovascular MRI (CMR)|A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).
45688144|NCT03720522|Procedure|Adenosine-perfusion cardiovascular MRI (CMR)|An adenosine-perfusion CMR using contrast medium (gadolinium) will be performed in all patients (except group 1) between 48h and 6 days after admission.
46048867|NCT04711083|Diagnostic Test|overnight pulse oximetry|"Wrist worn Overnight oximetry was performed using portable Nonin 2500 (Nonin Medical Inc., USA) pulse oximeters. The test was explained to the subjects and their caregiver by experienced health-care staff from the sleep unit. The recording was done at home and started just before going to bed and ended on awakening; the recommended duration was a minimum of 5 h and a maximum of 7 h. The awake SpO2, mean SpO2. The data were analysed to calculate the overnight minimum SpO2, mean SpO2, dip frequency (defined as a fall in SpO2 of > 4%), the percentage of oximetry sleep time spent with a SpO2 of < 90%, and the total oximetry time. Recordings were classified as normal (< 4.9 desaturation events an hour), equivocal (5 to 14.9 desaturation events an hour), or abnormal (> 15 desaturation events an hour) according to the severity and pattern of nocturnal desaturation observed ."
45688145|NCT03720522|Procedure|Blood draw|"The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis~Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months."
45360780|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 1A: V710 (60 mcg / 60 mcg / 60 mcg) without MAA~Group 1B: V710 (60 mcg / 60 mcg / PBO) without MAA"
45360781|NCT00163657|Drug|Daclizumub|anti-rejection drug
45360782|NCT00163657|Drug|Tacrolimus|anti rejection drug
45360783|NCT00163657|Drug|Cyclosporine|anti rejection drug
45360784|NCT00163657|Drug|MMF|anti rejection drug
45479923|NCT03322228|Other|Music Therapy|Music therapy is tailored to subject preference. Examples are active music-making, supportive listening, and includes opportunities for legacy building to decrease caregiver distress and promote self-care.
45479924|NCT03797729|Drug|Tirofiban|Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive Tirofiban(0.05mg/ml) intravenous drip in a dosage of 4ml/hour (patients weight<50kg) or 6ml/hour (patients weight > 50kg) lasting for 24 hours.
45479925|NCT03797729|Drug|Normal saline|Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive normal saline intravenous drip in a dosage of 4ml/hour (patients weight<50kg) or 6ml/hour (patients weight > 50kg) lasting for 24 hours.
45479926|NCT03500419|Device|RestoreX|PTT - Penile traction therapy in the straight position.
45479927|NCT03500419|Other|No treatment|Control group. No treatment will be given for the 6 months post-prostatectomy
45688146|NCT03720522|Procedure|Urine (collection over 24h)|"The following study-specific parameters will be tested: catecholamines.~Time points for collection: at 24h, 72h, and 3 months"
45688147|NCT03720366|Drug|enasidenib|enasidenib
45360785|NCT03971149|Behavioral|EMPOWER|EMPOWER includes 4 weekly home visit and 4 follow up booster phone calls every other week for the following 8 weeks. The trained nurse interventionist will address identified adherence barriers related to knowledge deficits about heart failure and its treatment including psycho-social barriers and logistic barriers with their primary care physician if necessary.
45360786|NCT01073683|Procedure|laryngoscopy|Treatment of advanced larynx cancer with induction TPF, in order to decide between chemoradiation and laryngeal preservation surgery
45360787|NCT01073683|Drug|Taxotere (Docetaxel), Cisplatin, 5FU|Taxotere 75 mg/m2 D1, Cisplatin 75 mg/m2 D1, 5FU 750 mg/m2 D1-4
45360788|NCT00887172|Drug|Jing Fang Bai Du san|The Jing Fang Bai Du san can relieve external symptoms and effectively clear up the pathogenic cold. It contains 13 herbs including, Radix Angelicae Pubescentis, Radix Peucedani, Radix Ginseng, Smilacis Glabrae Rhizoma, Rhizoma Chuanxiong, Fructus Aurantii, Radix Platycodi, GlycyrrhizaeRadix, Herba Schizonepetae, Fructus Arctii, MenthaeFolium, Radix Saposhnikoviae, Rhizoma et Radix Notopterygii.The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
45360789|NCT00887172|Drug|Placebo|The sachets of the CHM formulae and placebo were identical in appearance except for the randomization numbers. The placebo contains Maltose-dextrine granules that are identical in weight, appearance, flavour and texture as the CHM granules. Both the Chinese medicine practitioner who assessed the subjects and the subjects were blinded to the nature of the treatment. The pharmaceutical supplier kept the medication and placebo codes, which were broken at the end of the study after completion of all the assessment and data analyses.
45360790|NCT00887172|Drug|Ying Qiao san|The Ying Qiao san can relieve external symptoms and effectively clear up the pathogenic heat. It contains 10 herbs: Fructus Forsythiae, LoniceraeFlos, Radix Platycodi, MenthaeFolium, GlycyrrhizaeRadix, Herba Schizonepetae, Sojae Semen praeparatum, Fructus Arctii, PhragmitisRhizoma and LophatheriHerba. The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
45360791|NCT00609492|Biological|GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)|Single dose, intramuscular injection
45360792|NCT00609492|Biological|Infanrix™-IPV/Hib|Single dose, intramuscular injection
45360793|NCT00230971|Drug|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
45360794|NCT00230971|Drug|ceftriaxone plus metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
45360795|NCT02541318|Behavioral|Duo-in exercise|Duo-in exercise was originated from China and with a 5000-years history. Ancient people adopted Duo-in to treat and prevent diseases.
45360796|NCT02542722|Behavioral|Control|General recommendations about a healthy diet and physical activity and referral to their general physician with a report of the study results in the event of detecting any risk factor or pathological finding
45360797|NCT02542722|Behavioral|Intensive Intervention|Based on office visits each 3 months during the first year, as well as monthly telephone calls during the first year. Each subject will also attend a group educational meeting each 6 months. At each visit they will be given a series of recommendations and their degree of adherence evaluated and the evolution of their weight checked. The recommendations are designed to re-educate the subjects concerning their dietary and physical activity habits
45688148|NCT03720366|Drug|Arm 1 probes|caffeine, dextromethorphan, flurbiprofen, midazolam, and omeprazole
45479928|NCT02487940|Drug|Intralipid 20%|Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
45360798|NCT00211081|Drug|Spironolactone (drug)|1 mg/kg/day; afer 2 weeks doubled to 2/mg/kg/day. Patient's with endothelium-dependent brachial artery vasodilation and single-ventricle should show improvement within 4-8 weeks. Patients and their labs who are receiving Spironolactone will be followed.
45479929|NCT02487940|Drug|Normal saline|Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
45479930|NCT03625934|Biological|VVX001|5 s.c. injections of 20 micrograms of VVX001 four weeks apart
45479931|NCT03625934|Biological|Placebo|5 s.c. injections of matching Placebo four weeks apart
45479932|NCT03797573|Device|tDCS|tDCS will be applied during 20 minutes with a current of 1 mA preceded and followed by a behavioral assessments (Modified Ashworth Scale and Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3 and F4 and the cathodes over C3 and C4.
45360799|NCT05278806|Other|Equity Dashboard, Population Health Coordinator and Community Health Worker Support|"Providers will be given access to an equity dashboard that displays their practice's performance on ambulatory quality metrics stratified by race and language.~Population health coordinators (PHCs) will lead equity huddles with providers to review list of patients who are not at goal for their hypertension control and meet the inclusion criteria. Providers will formulate a follow up plan for each patient that the PHCs will help implement. For example, PHCs may contact patient via the online patient portal or phone to obtain recent home blood pressure readings, facilitate scheduling of follow up visits, etc.~In addition, patients may be referred to the community health worker (CHW) hypertension management program. Patients will work with the CHW for 3-6 months. During this time the CHW will focus their efforts on patient education/coaching, remote blood pressure monitoring, addressing psychosocial and socioeconomic barriers to care and care coordination."
45688149|NCT03720366|Drug|Arm 2 Probes|digoxin and rosuvastatin
45844826|NCT01998360|Procedure|Surgical Control|The study is quasi-experimental, because the open surgical controls are not contemporaneous. They were performed at the same center as part of Unicirc 001 trial with the same conditions as the subsequent 50 Unicirc circumcisions.
46048868|NCT02845791|Behavioral|Interactive Lifestyle programme workshop|Participants will attend eight 90 minute sessions of an interactive lifestyle programme along with their parent(s)/guardian(s).
45479933|NCT03797573|Device|sham tDCS|Indentical to the active tDCS, except that the stimulation is terminated after 5 seconds.
46048869|NCT05336721|Drug|Chiauranib|25mg/35mg/50mg orally once daily
46048870|NCT05336721|Drug|capecitabine|1000mg/m2 on Days 1-14 in a repeating 21-day cycle
45688150|NCT03720366|Drug|Arm 3 probes|pioglitazone
45844827|NCT01998360|Procedure|Unicirc with tissue adhesive|Excision of foreskin with Unicirc device and wound sealing with tissue adhesive
45844828|NCT01998438|Drug|Tranexamic Acid|The loading doses were given in 15 minutes when incision.
45844829|NCT01999530|Drug|Prazosin Hydrochloride|Gradual upward titration to 15mg/day for approximately three weeks.
45844830|NCT01999920|Drug|Vilazodone|10mg to 40mg per day for 12 weeks
46048871|NCT04691115|Drug|AM1476|AM1476 Capsules
46048872|NCT04691115|Drug|Placebo|Placebo Capsules
45688151|NCT03713268|Device|Microscope integrated optical coherence tomography|This is translational study in which subjects will either be imaged with a microscope integrated optical coherence tomography (MIOCT) system or they will use MIOCT during surgical procedures. OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, cornea, optic nerve head and retinal blood vessels. The MIOCT has been integrated into the surgical microscope used in retinal and anterior segment surgeries so it does not touch the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the patient is not disturbed by the light.
46048873|NCT04080999|Device|r-TMS|The interventions have a total administration time of 75 minutes per day.For TMS stimulation, the coil will be positioned tangentially on the target area. Each r-TMS session will last 15 minutes and will be administered every other day (e.g. Monday-Wednesday-Friday, Monday-Wednesday-Friday, Monday). The visual scanning treatment involves the presence of a therapist, who administers various visual scanning tasks, used to increase patient's awareness and to teach strategies to improve spatial exploration abilities (Pizzamiglio et al.,1992).Trainings include three increasing levels of difficulty (9 possible combinations). Each level of difficulty will be exercised until the patient reaches a level of accuracy of 75%. The CCT will be carried out in 50 minutes sessions for 5 days a week within 15 days (11 sessions in total). On the days when the r-TMS is also administered, the administration of the CCT will immediately follow the brain stimulation.
46048874|NCT04080999|Device|SHAM|Device: SHAM Stimulation and Visual Scanning training. In the control group, the coil of the r-TMS will be positioned at 90° on the target area, thus no specific cortical modulation will be implemented (SHAM stimulation). For the SHAM group, the CCT protocol will be administered with the same modalities and time frame as detailed for the intervention group.
45479934|NCT02488096|Device|TRUS-Guided Biopsy|The standard care TRUS-guided biopsy is a schematic 12 core biopsy scheme with 2 cores taken from each of standard 6 zones. In some cases, the radiologist may take additional cores beyond 12 if suspicious areas are suspected from clinical findings or TRUS. TRUS-guided biopsies will be performed by a designated group of radiologists. An overall score out of 5 of likelihood of clinically significant prostate cancer will be recorded for each individual patient. The biopsy will be scheduled within 1 week of referral.
45360800|NCT05278806|Other|Equity Dashboard and Population Health Coordinator Support|"Providers will be given access to an equity dashboard that displays their practice's performance on ambulatory quality metrics stratified by race and language.~In addition, population health coordinators (PHCs) will lead disparities focused huddles with providers. During the huddle, they will review list of patients who are not at goal for their hypertension control and meet the inclusion criteria. Providers will then formulate a follow up plan for each patient that the Population Health Coordinators will help implement. For example, PHCs may contact patient via the online patient portal or phone to obtain recent home blood pressure readings, facilitate scheduling of follow up visits, etc."
45479935|NCT02488096|Device|MRI + TRUS-Guided Biopsy|"A designated radiologist will perform all MRI exams. The radiologist will identify locations of the prostate gland of the standard 12 cores to be taken and any additional lesions deemed to be suspicious for cancer.~The procedure for the MRI-targeted biopsy will be exactly the same as the TRUS-guided biopsy except that an additional 2 cores per area may be taken beyond the standard 12 cores in areas that were previously identified by MRI on the map. The systematic 12-core biopsy will always be performed first. The radiologist performing the MRI-targeted biopsy will review the MRI targets prior to the biopsy as per standard of care, and he/she will also perform the TRUS-guided biopsies for this group. Patients will be scheduled for their biopsy ~ 1 week after the MRI."
45360801|NCT03971227|Device|Acuity 200 (Fluoroxyfocon A) contact lens|Daily wear rigid gas permeable contact lens
45479936|NCT03500341|Device|INVSENSOR00014|Noninvasive pulse oximeter sensor
45479937|NCT03365102|Device|anodal tDCS over the rIFG,|tDCS at a constant current of 1.5 milliampere (mA) will be applied for one 20-minute session over the right inferior frontal gyrus . Resting-state EEG for 10 minutes will be recorded immediately prior to and after tDCS. After post-tDCS resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
45479938|NCT03365102|Device|anodal tDCS over the lOFC,|tDCS at a constant current of 1.5 mA will be applied for one 20-minute session over the left orbitofrontal cortex . Resting-state EEG for 10 minutes will be recorded immediately prior to and after tDCS. After post-tDCS resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
45688152|NCT03712943|Drug|Regorafenib|Regorafenib orally 80 mg daily for 21 days (3 weeks on, 1 week off).
45688153|NCT03712943|Drug|Nivolumab|Nivolumab 240 mg administered intravenously every 2 weeks.
45688154|NCT03706664|Other|Machine learning algorithm|Study will develop and test a machine learning algorithm using MR Enterography images labelled by Radiologists.
45688155|NCT03704922|Biological|Transfusion|Red cell units for transfusion
45688156|NCT03699631|Drug|Tacrolimus|Tacrolimus will be given intravenously at a dose of 0.03 mg/kg/day starting Day -3. Subsequent dosing will be based on blood levels.
45688157|NCT03699631|Drug|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic cell infusion.
45844831|NCT01999920|Drug|Placebo|One to two pills per day for 12 weeks
46048875|NCT04210635|Other|ZEN cart|essential oils + relaxing music + dim light
46048876|NCT04646655|Drug|Enoxaparin|subcutaneous injections
46048877|NCT04573413|Device|Inhibitory repetitive transcranial magnetic stimulation|"r-TMS Parameters: International 10/20 system for the location of the target area (left parietal cortex) 60% Power Frequency: 1 Hz 90 pulse trains with 10 pulses each (total 900 stimuli), resulted in a total stimulation period of 15 minutes.~Visual Scanning Visual-spatial training; Reading and copying training; Copying of line drawings on a dot matrix. Barrage"
45688158|NCT03699631|Drug|Tocilizumab|Tocilizumab will be administered intravenously (IV) at a dose of 8 mg/kg (maximum dose of 800 mg) once on the Day -1 approximately 24 hours prior to the estimated time of the hematopoietic cell infusion, and subsequently, on Day +100 (+/- 14 days, i.e., Days +86 to +114) post-alloHCT. The infusion will be administered over 60 minutes through a dedicated IV line and must not be administered by IV bolus.
45688159|NCT03686488|Drug|TAS 102|TAS 102 35 mg will be administered orally twice daily every 2 weeks.
45688160|NCT03686488|Drug|Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]|Ramucirumab 8 milligrams/kilogram will be administered as a 60 minute intravenous (IV) infusion every 2 weeks.
45688161|NCT03686150|Dietary Supplement|Vitamin D3 oral regimen|Vitamin D3 oral regimens supplementation
45688162|NCT03680781|Device|Intermittent theta-burst stimulation (iTBS)|"Participants will receive iTBS to the left DLPFC or bilateral DLPFC, to the right and left DLPFC. The DLPFC will be targeted utilizing either Localite's neuronavigation system or Nexstim's eField neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC or bilateral DLPFC using either a MagVenture MagPro X100 or a Nexstim TMS device."
46048878|NCT04573413|Device|Sham Group|Sham stimulation and Visual scanning training Intervention: Device: SHAM
45688163|NCT03678233|Drug|AndroGel 16.2 mg/L|Testosterone gel 1.62 % will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women.
46048879|NCT05336643|Device|Radiofluorescence|Assessment of pelvic sidewall with Firefly and Sensei
46048880|NCT00723723|Drug|Statin|Statin
45360802|NCT03971227|Device|Acuity 100 (Hexafocon A) contact lens|Daily wear rigid gas permeable contact lens
45360803|NCT00884676|Drug|Ixabepilone|"Administered intravenously. Dosage assigned by Phase I center as determined by dose-escalation schedule:~Schedule A: Weekly for 3 weeks each cycle (Days 1, 8 and 15)~Schedule B: Day 1 of each 3-week cycle."
46048881|NCT05335395|Behavioral|SUNRISE radio campaign|"The SUNRISE radio campaign will be promoting responsive caregiving and providing opportunities for early learning to support child development during the first 3 years of life.~The SUNRISE campaign will follow DMI's established intervention approach with:~60-second radio spots, tailored to increase awareness, knowledge, motivation, skills and opportunity regarding the target behaviours, will include scripted dramas and modelling of responsive parent-child interactions. Each spot will be broadcast 10 times a day for a week; the content of the spots will be changed on a weekly basis. This weekly cycle will continue for three years.~Long format 60-minute programmes broadcast 2-3 times a week, incorporating longer dramas, real life testimonials and practical 'how to' advice, with space for listeners to call in, express opinions and uncertainties and ask questions."
45360804|NCT00884676|Drug|Sunitinib|For both Schedules A and B, daily, orally, starting on Day 8 of Cycle 1
45688164|NCT03671226|Other|Questionnaire Administration|Given questionnaire
45360805|NCT02542800|Behavioral|Episodic memory task|
45360806|NCT02542800|Device|fMRI|
45360807|NCT04036812|Procedure|Superficial cervical plexus block|superficial cervical plexus nerve block will be performed under the guidance of ultrasound
45360808|NCT04036812|Other|Control group|ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml normal saline.
45360809|NCT00891384|Drug|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm: 25 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression.
45844832|NCT02000154|Drug|SyB L-1101|SyB L-1101 (rigosertib sodium) will be administered intravenously 72 continuous hours (3 days), followed by 25-day observation period. The treatment period of 28 days (3 days of administration + 25 days of observation) constitutes 1 cycle. The dose at cycle 8 in the study 2011005 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 9). From cycle 10 on, the dose of SyB L-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle.
45360810|NCT00891384|Drug|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm:5 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression
45360811|NCT00887328|Drug|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
45360812|NCT00887328|Drug|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
45360813|NCT00609336|Drug|gemcitabine hydrochloride|Given IV
45360814|NCT00609336|Drug|docetaxel|Given IV
45360815|NCT00609336|Drug|capecitabine|Given PO
45360816|NCT00609336|Radiation|intensity-modulated radiation therapy|Undergo IMRT
45360817|NCT00609336|Drug|oxaliplatin|Given IV
45360818|NCT00609336|Procedure|pancreatic surgical procedure|Undergo pancreaticoduodenectomy
45688165|NCT03663218|Radiation|Dose escalation|This is a modified dose escalation and de-escalation study with an expansion of 3 or 6 pts to allow the recommended phase II dose (RP2D) be examined in a total of 9 pts. The dose limiting toxicity (DLT) is defined as Grade 3 or higher toxicity related to preoperative radiotherapy according to the Clavien-Dindo Classification. 3 radiation dose levels, 5 Gy, 6 Gy and 6.5Gy are considered. At the start of each dose level, 3 pts will be enrolled and treated for five days. If none of the 3 pts develop the DLT, the testing dose will escalate to the next level. If 1 of the 3 pts develops the DLT, the current dose will be tested in an additional 3 pts. If no additional pts develop the DLT, the dose will escalate.
45360819|NCT00609336|Procedure|therapeutic conventional surgery|Undergo therapeutic conventional surgery
45688166|NCT03657771|Other|DED|DED: Diet eliminating dairy
45360820|NCT00609336|Other|laboratory biomarker analysis|Correlative studies
45688167|NCT03657771|Other|FREE|FREE: Diet eliminating dairy and food additives
45688168|NCT03650478|Device|NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)|Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (1 hour). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted
45688169|NCT03650478|Device|NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)|Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (3 hours). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted
45688170|NCT03632616|Other|PANQOLI (quality of life instrument)|A quality of life instrument, the PANQOLI, will be administered prior to endoscopic intervention, and at 1,3, and 6 months post-intervention.
45688171|NCT03629327|Drug|ASA 81mg|Participants will be randomized to take 81mg orally on a daily basis for a duration of 6 months
45844833|NCT02001714|Behavioral|Group Behavioral Treatment|Group Behavioral Treatment class is a two hour class taught by certified interventionist covering urinary system anatomy, bladder health and self management strategies, pelvic floor training, pelvic floor muscle contracting techniques, and bladder training. Slides and handouts supplement the content of the class.
45688172|NCT03629327|Other|Control Group|Participants will be randomized to take nothing on a daily basis for a duration of 6 months
45688173|NCT03629327|Drug|ASA 325mg|Participants will be randomized to take 325mg orally on a daily basis for a duration of 6 months
45360821|NCT02542566|Procedure|Physiotherapy rehabilitation|Physiotherapy rehabilitation
45360822|NCT00612066|Drug|rosiglitazone maleate|
45360823|NCT02541084|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF therapy following the Summary of Product Characteristics
45360824|NCT02542488|Other|STOPBANG Questionnaire|"8 question screening tool comprised of the following questions:~S: Do you Snore loudly? T: Do you often feel tired during daytime? O: Has anyone observed you stop breathing during your sleep? P: Do you have high blood pressure? B: Is your BMI >35 kg/m2? A: Are you >50 years old? N: Is your neck circumference >40cm? G: Is your gender male?"
45360825|NCT02542488|Diagnostic Test|Overnight pulse oximetry|All participants will be given a Masimo Rad8 pulse oximeter to take home and apply to their finger overnight to measure their heart rate and oxygen saturations while they sleep.
45360826|NCT02542488|Other|Epworth Sleepiness Scale|A questionnaire that rates how tired they are doing everyday tasks
45844834|NCT02002494|Other|Different positions|Jugular venous blood flow in healthy volunteers in 3 different positions- supine, prone and park bench
45844835|NCT02002650|Drug|Pre-ERCP rectal Indomethacin|Rectal Indomethacin was administrated within 30min before ERCP in all patients.
45844836|NCT02002650|Drug|Post-operational Rectal Indomethacin|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
45360827|NCT00887406|Drug|GSK961081 15mcg SD|Single dose delivered via solution for nebulisation
45360828|NCT00887406|Drug|GSK961081 3mcg SD|single dose delivered via nebulsier
45688174|NCT03628209|Drug|Nivolumab|Participants will be treated with Nivolumab intravenously (IV), 3 mg/kg on days 1 and 15 of each cycle.
45688175|NCT03628209|Drug|Azacitidine|Phase I Dose Escalation - Dose level 1: NA. Dose level 2: 60 mg/m^2. Dose level 3: 75 mg/m^2. Phase II Expansion - Treated at recommended Phase II dose (RP2D).
45688176|NCT03628209|Procedure|Post Treatment Surgery|Resection surgery at end of Cycle 1 treatment, day 28-35.
45688177|NCT03618641|Drug|CMP-001|A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).
45360829|NCT00887406|Drug|GSK961081 50mcg SD|single dose delivered via solution for nebulisation
45360830|NCT00887406|Drug|Placebo SD|single dose via nebuliser
45360831|NCT00887406|Drug|GSK961081 100mcg SD|single dose delivered via solution for nebulisation
45360832|NCT00887406|Drug|GSK961081 200mcg SD|single dose via nebuliser
45360833|NCT00887406|Drug|GSK961081 300mcg SD|single dose via nebuliser
45360834|NCT00887406|Drug|GSK961081 100mcg RD|repeat dose via nebuliser
45360835|NCT00887406|Drug|GSK961081 300mcg RD|repeat dose vai nebuliser
45688178|NCT03618641|Biological|Nivolumab|A fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.
45688179|NCT03617718|Drug|Glycine Buffer|Subjects will be asked to perform an Inhaled Glycine Buffer followed by a series of Pulmonary Function Tests (PFTs) and then a research bronchoscopy will happen at visit 3.
45688180|NCT03610256|Procedure|SADI-S|Laparoscopic SADI-S, recently described as an evolution of the BPD-DS, combining the physiological advantages of pylorus preservation and the technical benefits of single-loop reconstruction, associating a sleeve gastrectomy and a duodeno-ileal bypass at 2.5 meters from the ileo-caecal valve if BMI ≥ 50 kg/m² or at 3 meters if BMI < 50
45688181|NCT03610256|Procedure|RYGB|"The laparoscopic Roux-en-Y Gastric Bypass will consist of:~a small gastric pouch (about 30cc)~an antecolic alimentary limb~a gastro-jejunal anastomosis using a linear stapler~a 150cm long alimentary limb~a 50cm biliary limb~a latero-lateral jejuno-jejunal anastomosis~closure of the mesenteric defects"
45688182|NCT03610061|Drug|Durvalumab|"All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing."
45688183|NCT03610061|Radiation|Radiotherapy|"All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing."
46048882|NCT00653913|Drug|SCH 58235|SCH 58235 10 mg (once daily)
46048883|NCT00653913|Drug|pitavastatin|Pitavastatin 2 mg (once daily)
46048884|NCT00652431|Drug|Vytorin + Niaspan|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days + Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
45360836|NCT00887406|Drug|Placebo RD|repeat dose via nebuliser
45360837|NCT04397406|Drug|levobupivacaine|The patients will receive 15 ml of 0.125% levobupivacaine.
45360838|NCT04397406|Drug|Dexmedetomidine|The patients will receive 13 ml of 0.125% levobupivacaine and 0.5μg/kg dexmedetomidine diluted in 2 ml saline.
45360839|NCT04397406|Drug|Fentanyl|The patients will receive 13 ml of 0.125% levobupivacaine and 25μg fentanyl diluted in 2 ml saline.
46048885|NCT00652431|Drug|Vytorin|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days
46048886|NCT00652431|Drug|Niaspan|Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
46048887|NCT03372525|Device|HFOV|Infants were randomized to HFOV
46048888|NCT03372525|Device|CMV|Infants were randomized to CMV
46048889|NCT04068363|Other|non interventional|non interventional study
45360840|NCT02542332|Other|With Data|The participants received statistical data about lung cancer screening in order to help them answer the questionaire
45360841|NCT00891540|Drug|Ropivacaine|Ropivacaine 0.5%
45360842|NCT00891540|Drug|Ropivacaine|Ropivacaine 0.2%
45360843|NCT00891540|Drug|placebo|Isotonic NaCl
45360844|NCT00887718|Biological|PET Scan|18F-Fluorodeoxyglucose (FDG) injection
45360845|NCT00573144|Drug|Nesiritide|Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.
45360846|NCT00573144|Drug|Placebo|Infusion of 72 hours of saline solution (packaged to match active comparator)
45360847|NCT00891696|Drug|Rapamycin|Single 16-mg oral dose
45360848|NCT00891696|Other|Amino acid supplementation|Nutritional drink containing essential amino acids
45360849|NCT00891696|Other|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
45360850|NCT00891696|Drug|Sodium nitroprusside|Variable rate for 3 hours
45360851|NCT00891696|Device|Blood flow restriction cuff|Blood flow restriction for 5 minutes after the second biopsy
45360852|NCT00891696|Other|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
45360853|NCT00640328|Drug|Ofatumumab 100|100mg
45360854|NCT00640328|Drug|Ofatumumab 300|300mg
45360855|NCT00640328|Drug|Ofatumumab 700|700mg
45688184|NCT03610061|Radiation|Radiotherapy (cohort 6 only)|"Cohort 6 patients (only) will receive:~Day 8-Day 10: External Beam Radiotherapy to target site(s)- daily (ie. 5 further fractions to a total of 10 fractions)"
45360856|NCT00640328|Drug|Placebo|matching placebo
45360857|NCT00163189|Drug|Somatropin|Liquid, daily, during 3 years and extended to 5 years Dosage: 0,46 mg/kg/week - the maximum dose should not exceed 50 µg/kg/day
45688185|NCT03606642|Drug|Dual Antiplatelet (DAPT) Therapy|"DAPT - one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient) with Aspirin.~Aspirin loading dose (LD) = 325 mg. Aspirin maintenance dose (MD) = 81 mg.~P2Y12 Inhibitor Loading Dose (investigator preference):~Clopidogrel 600 mg PO x 1 or 75 mg PO daily x 4; Prasugrel 60 mg PO x 1; Ticagrelor 180 mg PO x 1.~P2Y12 Inhibitor Maintenance Dose (investigator preference):~Clopidogrel 75 mg PO daily; Prasugrel 10 mg PO daily; Ticagrelor 90 mg PO BID."
45688186|NCT03606642|Device|The Synergy® stent|IVUS guided stent
45688187|NCT03604172|Behavioral|Cognitive behavioral therapy|The cognitive behavioral therapy intervention will consist of weekly, 50-minute individual meetings for 16 weeks with a clinician trained in cognitive behavioral therapy for binge eating disorder.
45688188|NCT03604172|Behavioral|Waitlist|The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered cognitive behavioral therapy.
46048890|NCT00901485|Device|AutoVPAP|Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.
46048891|NCT00901485|Device|VPAPIIIST-A|Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.
46048892|NCT04067739|Other|non interventional study|non interventional study
46048893|NCT04060641|Genetic|Geneticure for RDN Genetic Panel|This retrospective trial will include the collection of DNA using buccal swabs and the assessment of 22 genotypes for scoring to assess response to renal denervation
46048894|NCT05336253|Behavioral|EVERYbody Project-Connect|3-week dissonance-based, group, online body image program (4.5 hours total)
46048895|NCT05336253|Behavioral|Self-Help Workbook|Time-matched 3-week passive, individual workbook condition (4.5 hours total)
46048896|NCT02842593|Behavioral|Lower-repetition, heavier-load|8-12 reps/set at ~80% 1 repetition maximum
46048897|NCT02842593|Behavioral|Higher-repetition, lighter-load|20-25 reps/set at ~30% 1 repetition maximum
46048898|NCT02842515|Other|teeth avulsion|
45360858|NCT04036890|Drug|2% minocycline hydrochloride controlled-delivery system (MHS)|The test product is a highly viscous gel for local subgingival placement composing of an ointment containing micro-capsule type particles for sustained release and the active ingredient 2% minocycline gel (10mg in each syringe of 0.5g) (Periocline, SUNSTAR, Osaka, Japan). The other ingredients include magnesium chloride, hydroxyl-ethylcellulose, aminoalkylmethacrylaye copolymer, triacetin and concentrated glycerine, giving the preparation a sustained-released property. It will be applied to experimental teeth and the adjacent teeth by gently inserting the tip of a specially designed applicator until the paste flows over the gingival margin.
45360859|NCT04036890|Drug|Placebos|It is the same gel as MHS but without active ingredient minocycline hydrochloride.
45360860|NCT00887874|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
45360861|NCT00887952|Procedure|Partial removal of carious dentine|All procedures will be carrying out under local anesthesia and rubber dam. The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to test group: cavity floor covered with calcium hydroxide cement; restoration using amalgam or steel crown following their usual clinical procedures based on the instructions of the manufacturer
45688189|NCT03591263|Other|Pulmonary rehabilitation|Pulmonary rehabilitation as routine care includes, airway clearance techniques, breathing exercise, and physical training instruction
45688190|NCT03572322|Other|Focus Group|Focus Group
45688191|NCT03572322|Other|Interviews|Interviews
45752085|NCT05343351|Other|Technique of injection method|"In 'out of plane group', the ultrasound probe will be placed at the entrance level of the proximal carpal tunnel (scaphoid-pisiform plane), the ulnar edge of the median nerve will be taken to the midpoint of the probe, and then the needle will be inserted from the middle point of the probe with the out of plane method. Then the needle will be advanced towards the ulnar side of the median nerve and the injection content will be given into the tunnel.~In 'in plane group group', the ultrasound probe will be placed at the proximal carpal tunnel entrance level (scaphoid-pisiform plane), it will be entered at a cross angle between the ulnar artery and the median nerve with the in-plane method, and be advanced under the median nerve, and then the injection content will be given into the carpal tunnel."
46048899|NCT00896337|Device|Epic™ Nitinol Stent System|The Epic™ Nitinol Stent System is comprised of two components: the implantable nitinol endoprosthesis and the stent delivery system.
46048900|NCT00896337|Drug|Anti-platelet therapy|Investigators must prescribe concomitant anti-platelet medication consistent with current clinical practice. Anti-platelet therapy should be administered preprocedure and continued throughout participation in the trial.
45360862|NCT00887952|Procedure|Stepwise excavation|The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to SE: indirect pulp capping with calcium hydroxide cement; temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling following the same procedures described to test group.
45688192|NCT03561012|Behavioral|Team-Based Goals and Incentives|The intervention included 3 main components. 1) The intervention fostered a sense of team collective responsibility and solidarity (TEAM) by emphasizing the value of teamwork and front-line community health workers (FLWs) reciting a pledge at meetings to serve beneficiaries. 2) To establish goals and coverage targets related to maternal and child health outcomes (GOALs), 7 targets were identified related to delivery preparations, newborn care, exclusive breastfeeding, and family planning. 3) Small non-cash incentives were awarded to FLWs each quarter if their team met greater than 70% of the collective subcenter goals; incentives were most common cookware products (e.g., dish, cooking vessel, steamer). Non-cash incentives also included a certificate of recognition for teams that met their targets in all quarters (INCENTIVES). In the areas of the intervention and control arms, the Ananya program was also underway (see Brief Summary of the project).
45688193|NCT03561012|Other|Control Condition|Standard of care
45360863|NCT02550860|Drug|soybean oil (SO)-based IVFE (Medialipide)|The soybean oil (SO)-based IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
45360864|NCT02550860|Drug|fish oil (FO)-containing IVFE (Lipidem)|The fish oil (FO)-containing IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
45688194|NCT03531957|Drug|ASN002|Daily dose of ASN002 for 12 weeks
45360865|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
45360866|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
45688195|NCT03531957|Drug|Placebo Oral Tablet|Placebo of ASN002 for 12 weeks
45688196|NCT03530124|Biological|PCV13|Advisory Committee on Immunization Practices (ACIP) Recommended vaccine
46048901|NCT00896337|Drug|Anti-coagulation therapy|Anti-coagulation therapy must be administered during the procedure consistent with current clinical practice.
46048902|NCT00380523|Drug|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
45360867|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
45360868|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
45360869|NCT02550782|Drug|Bupivacaine|patient- controlled infraclavicular perineural marcaine infusion
45360870|NCT02550782|Drug|Dexmedetomidine|patient- controlled infraclavicular perineural marcaine with dexmedetomidine infusion
45360871|NCT04037982|Procedure|laparoscopic pancreaticoduodenectomy|During laparoscopic surgery, the surgeon makes several smaller incisions in your abdomen and inserts special instruments, including a camera that transmits video to a monitor in the operating room. The surgeon watches the monitor to guide the surgical tools in performing the Whipple procedure. Laparoscopic surgery is a type of minimally invasive surgery.
45360872|NCT04037982|Procedure|Open pancreaticoduodenectomy|During an open procedure, your surgeon makes an incision in your abdomen in order to access your pancreas. This is the most common approach and the most studied.
45360873|NCT00888030|Other|there are no interventions currently listed for this study|
45360874|NCT03862820|Diagnostic Test|dynamic ultrasound|move abdomen with ultrasound probe to predict intraabdominal adhesions
45360875|NCT00884988|Drug|Lymphomyosot|20 drops X3/day, until discharge
45360876|NCT00884988|Drug|Placebo remedy|20 drops X3/day, until discharge
45688197|NCT03530124|Biological|DTaP|ACIP Recommended vaccine
45688198|NCT03530124|Biological|HBV|ACIP Recommended vaccine
45688199|NCT03530124|Biological|IPV|ACIP Recommended vaccine
45688200|NCT03530124|Biological|Hib|ACIP Recommended vaccine
45688201|NCT03527043|Drug|Escitalopram|10mg by mouth daily for 6 weeks
45688202|NCT03527043|Other|Placebo|matched placebo control by mouth for 6 weeks
45752086|NCT00407485|Biological|ziv-aflibercept|Given IV
45752087|NCT00407485|Other|pharmacological study|Correlative studies
46048903|NCT04201743|Drug|Acellular amniotic membrane derived allograft injection (NuDYN)|Injectable acellular amniotic membrane derived allograft (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) in the treatment of knee osteoarthritis.
46048904|NCT00319995|Drug|loratadine; montelukast|
46048905|NCT03304821|Drug|GM-CSF|Participants will self-administer 500 μg/day of GM-CSF, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of subcutaneous GM-CSF, three times per week for another 3 weeks and then will be followed for another 3 months.
45688203|NCT03521154|Drug|Osimertinib 80mg/40mg|The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
45688204|NCT03521154|Drug|Placebo Osimertinib 80mg/40mg|"The initial dose of Placebo Osimertinib 80mg once daily can be reduced to 40mg once daily.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met"
45844837|NCT02003352|Procedure|Functional Neurological Rehabilitation|Functional Neurological Rehabilitation Includes vestibular rehabilitation and physical rehabilitation. Vestibular rehabilitation utilizes strategies that involves movement of the head and eyes at various speeds and directions while the subject looks at a target. Physical rehabilitation involves exercises to increase mobility and increase strength.
45688205|NCT03505723|Drug|Tranexamic Acid|Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous TXA at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
45844838|NCT02004132|Drug|Axiron|Solution administered topically using pump and applicator
45360877|NCT00818948|Drug|AMG 811|Part A of the study will enroll SLE without GN (non-renal) subjects into 3 cohorts (6 AMG 811: 2 placebo). All subjects will receive a dose of AMG 811 or placebo every 4 weeks beginning with day 1 (D1) for a total of 3 injections. Subjects will be followed through to study day 197, 5 months from the last dose of study medication. Part B of the study will enroll SLE subjects with GN into Cohorts 4, 5 and 6 (6 AMG 811: 2 placebo). Similar to Part A, subjects in Cohorts 4, 5 and 6 will be dosed every 4 weeks with AMG 811 or placebo for a total of 3 injections followed by a 5 month follow-up period. For Cohort 6, subjects will be followed by a 6 month follow-up period.
45688206|NCT03505723|Drug|Placebo (Saline)|Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous placebo (0.9% normal saline) at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
45360878|NCT04036734|Diagnostic Test|Longitudinal|Longitudinal orientation of ultrasound to long axis of vein to guide access needle
45688207|NCT03505723|Other|Perioperative hypotension-avoidance strategy|"Perioperative hypotension-avoidance strategy includes:~Preoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg before surgery,~Intraoperative blood pressure targeting a mean arterial pressure (MAP) ≥80 mm Hg~Postoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg during the first 48 hours after surgery."
45360879|NCT04036734|Diagnostic Test|Transverse|Transverse orientation of ultrasound to long axis of vein to guide access needle
45688208|NCT03505723|Other|Perioperative hypertension-avoidance strategy|Perioperative hypertension-avoidance strategy (i.e., routine care) continues all antihypertensive drugs before and after surgery and an intraoperative BP strategy targeting a MAP ≥60 mm Hg.
45688209|NCT03503032|Procedure|Extracardiac Fontan|Extracardiac Fontan (Total cavo-pulmonary connection) will be constructed with a tube graft from the inferior vena cava to the pulmonary artery [applied to both arms]
45688210|NCT03503032|Procedure|Fontan fenestration|Fontan fenestration created as a single 3 to 6mm communication between fontan channel and pulmonary venous atrium [Fenestrated arm]
45688211|NCT03496207|Drug|Placebo|Placebo
45688212|NCT03496207|Drug|Sotatercept|Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
45844839|NCT03697278|Device|Smith medical CADDsolis|This group will be monitoring from a network.
45844840|NCT02004288|Dietary Supplement|Lactobacillus reuteri Protectis DSM17938|One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.
45844841|NCT02004366|Drug|Linagliptin|Linagliptin once daily + correction doses of rapid acting insulin if needed
46048906|NCT03304821|Drug|Placebo|Participants will self-administer 500 μg/day of a placebo, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of a placebo administered subcutaneously, three times per week for another 3 weeks and then will be followed for another 3 months.
46048907|NCT03832413|Diagnostic Test|DELPhI (TMS-EEG analysis)|We perform an evaluation not an intervention. the DELPhI evaluation comprises of an automated analysis to EEG data recorded during TMS (Transcranial Magnetic Stimulation) to the M1L (Primary motor cortex).
46048908|NCT03301467|Drug|Avacopan|Orally administered
46048909|NCT03301467|Drug|Avacopan Matching Placebo|avacopan matching placebo
46048910|NCT02842281|Other|Fructan|Short-chain oligosaccharide primarily composed of fructose polymers
46048911|NCT02842281|Other|Maltodextrin|Polysaccharide produced from starch
46048912|NCT00633165|Drug|Brostallicin|Patients will receive Brostallicin administered intravenously (IV) over 10 minutes at a dose of 10 mg/m2 on day one of a 21-day cycle. Safety and efficacy will be closely monitored and assessed.
45479939|NCT03365102|Device|sham tDCS stimulation condition|In the sham condition, the current will be ramped up to 1.5 mA for 30 seconds and then ramped back down to 0. As this commonly used sham procedure produces a brief tingling sensation, participants are kept unaware of their experimental condition. Resting-state EEG for 10 minutes will be recorded immediately prior to and after the sham tDCS. After post-sham stimulation resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
45688213|NCT03496207|Other|SOC|SOC therapy refers to approved PAH-specific medications and may consist of monotherapy or combination therapy with endothelin-receptor antagonists, phosphodiesterase 5 (PDE5) inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogues or receptor agonists.
45688214|NCT03494868|Dietary Supplement|Carbohydrate Drink|2 - 12 oz drinks
45688215|NCT03481985|Other|Fenestration status|The exposure variable will be status of the Fontan fenestration
45360880|NCT01073215|Behavioral|Family-Based Lifestyle Modification|The Self-Guided condition will receive the same manual content and recommendations for eating and physical activity as the Group Condition. Since this approach is primarily home-based, participants in this condition will also receive additional tips and guidelines to assist the family in following the program at home. There will be 6 visits with the health coach at weeks 01, 04, 08, 24, 40, and 52. Participants will receive 2 phone calls from health coach at weeks 16 and 32. Parents and teens will be encouraged to hold weekly meetings at home to discuss program goals and progress.
45688216|NCT03458221|Drug|Letrozole Oral Product|Letrozole 2.5mg tablet - 2.5mg once dailty until progression of disease.
46048913|NCT03721341|Radiation|Palliative Radiation|Investigators should follow the principles of palliative radiotherapy as per the individual institution in order to alleviate symptoms or prevent complications. If radiotherapy is indicated, recommended doses are 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
46048914|NCT03721341|Drug|Chemotherapy|Chemotherapy may be given as indicated.
45688217|NCT03458221|Drug|Bicalutamide Oral Product|Bicalutatmide 150mg tablet - 150mg once daily until progression of disease.
45688218|NCT03458221|Drug|Everolimus Oral Product|Everolimus 10mg tablet - 10mg once daily until progression of disease.
46048915|NCT03721341|Drug|Immunotherapy|Immunotherapy may be given as indicated.
46048916|NCT03721341|Drug|Hormones|Hormones may be given as indicated.
45360881|NCT01073215|Behavioral|Family-Based Lifestyle Modification Program|"The Group condition will consist of a comprehensive family based lifestyle modification program of 23 visits (8 weekly, 8 bi-weekly, 7 monthly).~Intervention visits include a combination of 17 group sessions and 6 individual meetings with health coach. There will be 7 phone calls two weeks after each monthly visit. Adolescents and their parents attend concurrent group meetings. The content of the sessions will include topics related to nutrition, physical activity, and behavior modification for weight management."
45360882|NCT05278728|Drug|Nimotuzumab|200,400,600 or 800mg weekly until progression or AEs
45360883|NCT05278728|Drug|Irinotecan|180mg/m2 d1, Q2w until progression or AEs or maximum 6 cycles
45360884|NCT01073761|Drug|darunavir/ritonavir then atazanavir/ritonavir|"Phase 1: Oral darunavir/ritonavir 800/100 mg once daily for 10 days~Phase 2: Oral atazanavir/ritonavir 300/100 mg once daily for 10 days"
45360885|NCT03862664|Procedure|Collection of data|The investigators will retrieve retrospectively the medical record of donors who underwent hepatic lobectomy for liver transplantation
45360886|NCT00819104|Drug|Metoprolol XL 50mg + Amlodipine 5mg|tablet,oral,OD,8 weeks
45688219|NCT03458221|Drug|Itraconazole Oral Product|Itraconazole 100mg capsule - 300mg twice daily until progression of disease.
45360887|NCT00819104|Drug|Metoprolol XL 25 mg + Amlodipine 2.5mg|tablet,oral,OD,8 weeks
45360888|NCT00819104|Drug|Metoprolol XL 50mg|tablet,oral,OD,8 weeks
45479940|NCT02487862|Behavioral|Stress Reduction Protocol|Stress Reduction Protocol
45688220|NCT03451487|Drug|Panadol®|Acetaminophen 500mg Tablet
45688221|NCT03451487|Drug|SafeTynadol®|Acetaminophen 500mg Tablet
45688222|NCT03444870|Drug|Gantenerumab|Gantenerumab will be administered as per the schedule specified in the respective arm.
46048917|NCT03721341|Other|Observation|Observation only is acceptable if this is the standard practice.
46048918|NCT03721341|Radiation|Stereotactic Ablative Radiotherapy|Total dose of radiation and number of fractions will depend on the site of disease. Doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every 2 days), or 35 Gy in 5 fractions (daily).
46048919|NCT03789513|Diagnostic Test|HPV test with partial genotyping and VIA triage|HPV testing with the GenXpert platform VIA Biopsies of VIA+ lesions or random Treatment with thermal ablation of women with precancerous lesions
45688223|NCT03444870|Drug|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
45752088|NCT00354887|Drug|Capecitabine|Oral capecitabine 750 mg/m^2 twice daily (total daily dose 1500 mg/m^2) on Days 1-14 in 21 Day Cycle.
45752089|NCT00354887|Drug|Oxaliplatin|130 mg/m^2 by vein Day 1 over 2 hours in 21 Day Cycle
46048920|NCT02091843|Procedure|DBS of the Basolateral Nucleus of the Amygdala|
46048921|NCT02091843|Device|Medtronic Activa PC DBS of the Basolateral Nucleus of the Amygdala|
46048922|NCT02842437|Drug|dexmedetomidine|receive a loading infusion of dexmedetomidine (1ug/kg) for 10min follow by a maintenance infusion (0.5ug/kg·h) continued until the end of the surgery
45752090|NCT04768803|Biological|acylated and unacylated ghrelin dosages|realization of plasma samples to evaluate of levels of ghrelin and collection of plasma and cells
45844842|NCT02004366|Drug|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
45360889|NCT00819104|Drug|Metoprolol XL 25 mg|tablet,oral,OD,8 weeks
46048923|NCT02842437|Other|normal saline|receive matching placebo (equal volume of normal saline)
46048924|NCT00157911|Drug|MK0653; ezetimibe / Duration of Treatment: 12 weeks|
45360890|NCT00819104|Drug|Amlodipine 5mg|tablet,oral,OD,8 weeks
45360891|NCT02542098|Drug|HYD tablets|Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets.
45360892|NCT03617094|Device|Early percutaneous vertebroplasty (EPV)|Treatment consists of percutaneous acrylic bone cement injection using a trocar under scope control and general anesthesia.
46048925|NCT00157911|Drug|Comparator: simvastatin / Duration of Treatment: 12 weeks|
45360893|NCT03617094|Device|Standard Conservative treatment (CT)|Treatment consists of using a made-to-measure 3 point thoracolumbar corset,that is worn for 3 months: night and day during the first 6 week period of the treatment, and then only the day for the next 6 week period.
45360894|NCT02541162|Behavioral|Oral information and interviews|interviews about sexuality and self experience during the disease
45360895|NCT04036656|Drug|SYHA136 0.5 mg|oral tablet
45360896|NCT04036656|Drug|SYHA136 1 mg|oral tablet
45360897|NCT04036656|Drug|SYHA136 2.5 mg|oral tablet
45360898|NCT04036656|Drug|SYHA136 5 mg|oral tablet
45360899|NCT04036656|Drug|SYHA136 10 mg|oral tablet
45360900|NCT04036656|Drug|SYHA136 20 mg|oral tablet
45360901|NCT04036656|Drug|SYHA136 35 mg|oral tablet
45360902|NCT04036656|Drug|SYHA136 50 mg|oral tablet
45360903|NCT04036656|Drug|Placebo matching SYHA136 0.5 mg|oral tablet
45360904|NCT04036656|Drug|Placebo matching SYHA136 1 mg|oral tablet
45360905|NCT04036656|Drug|Placebo matching SYHA136 2.5 mg|oral tablet
45360906|NCT04036656|Drug|Placebo matching SYHA136 5 mg|oral tablet
45360907|NCT04036656|Drug|Placebo matching SYHA136 10 mg|oral tablet
45360908|NCT04036656|Drug|Placebo matching SYHA136 20 mg|oral tablet
45360909|NCT04036656|Drug|Placebo matching SYHA136 35 mg|oral tablet
45360910|NCT04036656|Drug|Placebo matching SYHA136 50 mg|oral tablet
46048926|NCT05336175|Drug|Angiotensin 1-7|"A substance, Angiotensin-(1-7) [Ang-(1-7)], is known to decrease inflammation in the brain. This substance is naturally produced in the body and works by activating areas in the brain involved in memory. Previous studies examining the ability of Ang-(1-7) treatment to prevent memory loss post open-heart surgery found that 21 days of treatment with Ang-(1-7) protected memory post-surgery. Participants treated with Ang-(1-7) were protected from post-surgery increase in NfL levels. This clinical sub-project within the existing study will allow us to obtain preliminary data to evaluate the safety and efficacy of treatment with Ang-(1-7) to improve cognitive function and determine if this treatment is associated with changes in plasma levels of NfL protein.30 participants will take 100 micrograms of Ang-(1-7) per day via subcutaneous injection for 90 days."
46048927|NCT05336175|Drug|Saline solution|Saline solution will be given as a placebo intervention to 10 participants. These participants will take 100 micrograms of saline solution per day via subcutaneous injection for 90 days.
46048928|NCT02842125|Drug|Ad-P53|Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic capecitabine
45360911|NCT02541240|Other|Resilience Curriculum|The Resilience Curriculum consists of 4 modules, with one 2-hour module presented each week.
45360912|NCT04036422|Device|Rejoyce (Rehabilitation Joystick for Computerized Exercise)|Rejoyce (Rehabilitation Joystick for Computerized Exercise), is a computer game based task specific exercise system developed by Rehabtronics Inc. for use as part of the treatment of stroke and spinal cord injury patients. Rejoyce aims to improve upper extremity and hand function by encouraging neuroplasticity through repeated task specific games.
45360913|NCT04036422|Other|Conventional physical therapy|A physical therapy session customised to the patient's needs overseen by a physical medicine and rehabilitation specialist and conducted by a physiotherapist which includes range of motion, neurophysiological and strengthening exercises, balance and coordination training and walking exercises.
45360914|NCT04036422|Other|Occupational therapy|Task based exercises overseen by a physical medicine and rehabilitation specialist and conducted by an occupational therapist aimed at improving upper arm dexterity, coordination and strength.
45360915|NCT00892164|Device|harmonic scalpel device (FOCUS)|hemostatic device utilized intraoperatively
45360916|NCT00892164|Device|electrothermal bipolar vessel sealing system (LIGASURE PRECISE)|hemostatic device utilized intraoperatively
45360917|NCT00640016|Other|Placebo|Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.
45360918|NCT00640016|Biological|CAT-354 1 mg/kg|CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
45360919|NCT00640016|Biological|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
45360920|NCT00640016|Other|CAT-354 10 mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
45360921|NCT04036578|Device|A 12-week PFMT bio-assisted surface electromyographic program|
46048929|NCT02842125|Drug|Xeloda|Oral metronomic chemotherapeutic agent
45360922|NCT00892242|Drug|Zoledronic acid|
45360923|NCT00885066|Drug|capecitabine|
45360924|NCT00885066|Drug|erlotinib hydrochloride|
45360925|NCT00885066|Drug|gemcitabine hydrochloride|
45360926|NCT00885144|Dietary Supplement|Nutributter|"Test dose of standard supplementary lipid based nutrient supplement (LNS). 15 grams of Nutributter will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation."
45360927|NCT00885144|Dietary Supplement|LNS-20gM|Test dose of modified LNS-20gM supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-20gM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
45360928|NCT00885144|Dietary Supplement|LNS-20gNoM|Test dose of modified LNS-20gNoM (milk free) supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-20gNoM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
45360929|NCT00885144|Dietary Supplement|LNS-10gM|Test dose of modified LNS-10gM supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-10gM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
45360930|NCT00885222|Device|DBS parameters setting|DBS parameters will be set to increase the DBS affected volume to include both the cognitive and limbic territories in addition to the dorso-lateral motor territories of the STN. This novel approach to parameter selection is directed to achieve improvement in cognitive and limbic as well as motor domains of PD. The patients will therefore be assessed for cognitive, limbic and motor state at multiple time points; there will be a baseline assessment prior to starting treatment (prior to DBS surgery and/or prior to parameters changes); thereafter assessments will follow the stimulation parameter changes; thereafter follow-up assessments at 6 - 12 months. Stimulation parameters will be changed every 2 weeks or earlier if an urgent clinical state emerges. Patients with depression will be monitored for antidepressant effects of stimulation changes. Patients without depression will be monitored for evidence of treatment emergent depression.
45360931|NCT00888108|Drug|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-5 or Days 1-3 of each 21 day cycle. 150 mg of ABT-263 on Days 1-3, 8-10 and 15-17 of each 28-day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
46048930|NCT02842125|Drug|Keytruda|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
46048931|NCT02842125|Drug|Opdivo|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
46048932|NCT03708549|Drug|Berberine|The patients will randomly assigned to receive berberine (900 mg day-1, three times a day) and metformin simulant（750mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
46048933|NCT03708549|Drug|Metformin|The patients will randomly assigned to receive metformin (750 mg day-1, three times a day) and berberine simulant（900mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
45360932|NCT00888108|Drug|Docetaxel|75 mg/m2 will be given by intravenous infusion on day 1 of each 21 -day cycle. 30 mg/m2 will be given by intravenous infusion on day 1, 8, 15 of each 28 -day cycle.
45360933|NCT00885300|Drug|cloxacillin|cloxacillin 100mg/ml as catheter lock at the end of hemodialysis
46048934|NCT03616431|Diagnostic Test|Pancreo-KIT breath test|"Pancreo-Kit (Isomed Pharma, Madrid, Spain) is a breath test devised to measure Pancreatic Enzyme Insufficiency. It is a non-invasive method to obtain information about the digestion of consumed lipids; this in turn is informative about the exocrine enzyme activity of the pancreas (specifically pancreatic lipase). This kit is manufactured to EC directive 98/79/EEC and carries the CE mark.~The test is based on measurement of 13C which is a stable naturally occurring environmental isotope of carbon with a nucleus containing 6 protons and 7 neutrons (note, it is not radioactive)."
46048935|NCT00156117|Drug|asenapine|5 mg BID or 10mg BID
46048936|NCT00156117|Drug|Placebo|Placebo
46048937|NCT00156117|Drug|olanzapine|olanzapine 15 mg QD
45360934|NCT00885300|Drug|heparin|heparin 1000iu/ml as catheter lock at the end of hemodialysis
46048938|NCT00140985|Drug|MK0954, losartan potassium/Duration of Treatment: 20 weeks|
46048939|NCT00140985|Drug|Comparator: amlodipine / Duration of Treatment: 20 weeks|
45360935|NCT00888186|Drug|levodopa/carbidopa|intestinal gel, for continuous daytime infusion
45360936|NCT00892320|Drug|ER OROS paliperidone|
45360937|NCT00892398|Drug|ranibizumab|Two ranibizumab subconjunctival injections (0.5 mg ∕ 0.05 mL). The first injection at the end of the surgery (intraoperative) and the second two weeks post-operatively.
45360938|NCT00892398|Procedure|standard care|standard post-operative care after trabeculectomy with mitomycin C
45360939|NCT00892476|Dietary Supplement|Calcium Supplementation|"Ca-gluconate powder (molar weight 430.4 g) will be measured with household measuring spoons and added to the feeding mixtures as follows:~Amount of feeding Actual Weight < 1000 g Actual Weight < 1000 g~25 ml ¼ tsp 1/8 tsp~50 ml ½ tsp ¼ tsp~100 ml 1 tsp ½ tsp~200 ml 2 tsp 1 tsp"
45360940|NCT00892476|Other|Standard of Care|Infants are feed breast milk with fortifier or 24 cal/oz formula per standard of care
45360941|NCT00892554|Dietary Supplement|Docosahexaenoic Acid|Capsules providing 10 mg DHA/kg body weight/day taken once daily
46048940|NCT03255057|Device|Hemolung Respiratory Assist System|Treatment with a medical device called the Hemolung RAS. The Hemolung RAS includes three components: the Hemolung Controller, the Hemolung Cartridge, and the Hemolung Catheter. The intervention is use of the Hemolung RAS to provide partial lung support for acute hypercapnic lung failure by filtering carbon dioxide from venous blood using a central venous catheter through which venous blood is pumped at flows of 350-550 milliliters per minute to and from an external circuit containing a hollow fiber membrane blood gas exchanger (with heparin-coated fibers) integrated with a centrifugal pump.
45360942|NCT00892554|Dietary Supplement|Corn/soy oil|Capsules taken once daily
45360943|NCT02541786|Drug|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily+clarithromycin 500 mg twice daily+ amoxicillin 1 g twice daily for 7 days
45360944|NCT02541786|Drug|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily + clarithromycin 500 mg twice daily + amoxicillin 1 g twice daily for 7 days
45360945|NCT00888342|Drug|supplementary oxygen|Supplementary oxygen 2 L/min if SpO2 < 90%. If SpO2 < 90 % the oxygen dose is titrated until SpO2 reads 88-92%. For patients on LTOT the oxygen dose is doubled for intervention.
46048941|NCT03255057|Device|Invasive mechanical ventilation|Lung support for acute lung failure applied with a mechanical ventilation device that uses positive pressure to mechanically inflate the lungs and facilitate exhalation via an endotracheal tube or tracheotomy.
46048942|NCT05336097|Other|Pathways to Empowerment|Pathways to Empowerment (PTE) is a program for person-centered intervention. The general aim of PTE is to improve the quality of the daily lives of persons who experience loss of control in their lives by focusing on their strengths and stimulating their personal agency, participation in society, and self-direction in life. The main task of professionals is to help create the conditions in which growth and recovery are likely to occur.
46048943|NCT00140907|Drug|losartan potassium|25 mg of oral losartan once daily, with an up-titration to 50 mg of losartan once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
46048944|NCT00140907|Drug|Comparator: Placebo|25 mg of oral placebo once daily, with an up-titration to 50 mg placebo once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
46048945|NCT00132717|Drug|MK0653A (ezetimibe [+] simvastatin)|
46048946|NCT00132717|Drug|Comparator: atorvastatin|
45360946|NCT00888342|Drug|zopiclone|5 mg sedative given approximately 1 hour before sleep
45360947|NCT00888342|Other|alcohol|5 mg alcohol/kg body-weight approximately 1 hour before sleep
45360948|NCT00892632|Procedure|ERCP and Confocal imaging|A major new advancement in cancer imaging is the development of a probe-based confocal endomicroscopy (pCLE) system capable of cellular and sub-cellular imaging of the biliary tree.
45360949|NCT00608868|Drug|Gefitinib|Gefitinib tablet 250mg once daily orally
45360950|NCT00888420|Other|Performance Improvement Measures|PDSA (Plan, Do, Study, Act) performance improvement measures
45360951|NCT00895518|Behavioral|Prolonged Exposure (PE) Therapy|Three PE sessions lasting 1 hour each, delivered 1 week apart
46048947|NCT00132717|Drug|Comparator: fluvastatin|
46048948|NCT00132717|Drug|Comparator: lovastatin|
46048949|NCT00132717|Drug|Comparator: pravastatin|
46048950|NCT00132717|Drug|Comparator: rosuvastatin|
46048951|NCT00132717|Drug|Comparator: simvastatin|
46048952|NCT00127179|Drug|MK0906, finasteride / Duration of Treatment: 48 weeks|
46048953|NCT00127179|Drug|Comparator: placebo / Duration of Treatment: 48 weeks|
46048954|NCT02842047|Behavioral|Stop, Breathe & Think™|online daily meditations delivered using smart phone or other computer based application
46048955|NCT02842047|Behavioral|End of Life Planning Videos|Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though key aspects of end of life planning.
46048956|NCT02842047|Behavioral|Caregiver wellness videos|Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though general caregiver wellness.
45688224|NCT03435510|Behavioral|Live Donor Champion Program|Even with adequate education of live donation, many KT candidates still feel ill equipped to ask others to consider donating. Friends and family are often eager to help and may not be able to serve as donors themselves, but might be able to provide substantial instrumental support. An LDC is a friend or family member who serves as an advocate for the candidate in their pursuit of live donation. The Johns Hopkins Comprehensive Transplant Center has developed a 6-month program that provides education and advocacy training to waitlist candidates and their LDCs. The instrumental support provided by the LDC bridges a critical link between education and action.Using LDCs to increase live donation is a novel approach that has garnered widespread enthusiasm.
46048957|NCT05334771|Device|Dual band pure tune audiometer|Orbiter 922 Tympanometry
45688225|NCT03435380|Behavioral|Patient activation|Smartphone-based materials including text messages and supplemental short videos focusing on how to find a primary care doctor, the importance of medical screening, and how to talk to a doctor about medical screening. Guidelines for monitoring and maintaining health, such as a survivorship care plan, will also be included in the smartphone-based materials.
46048958|NCT02841813|Other|No intervention|No intervention
46048959|NCT02680821|Procedure|ALL reconstruction (Anterolateral ligament)|
46048960|NCT02680821|Procedure|ACL revision (Anterior cruciate ligament )|
45688226|NCT03435380|Behavioral|Primary care physician activation|Mailed educational print materials sent to the participants' primary care doctors about health risks and recommendations for medical screening for adult women who were treated for a childhood cancer with chest radiation.
46048961|NCT00953706|Drug|Ivacaftor|Tablet
46048962|NCT00953706|Drug|Placebo|Tablet
46048963|NCT02853084|Drug|HL2351|The dose will be adjusted based on disease activities
45688227|NCT03435380|Behavioral|Control|Mailed educational materials.
45360952|NCT00888498|Other|Passive Positioning|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
45688228|NCT03429322|Behavioral|Medical Care and Resource Facilitation|The intervention expands on an established web-based platform and uses other information and communication technology (ICT) devices, incorporating synchronous direct clinical care and asynchronous intervention. Participants will use their own devices and internet access for any and all interactions with Mayo Clinic providers. The specific ICT modes used and services provided to interact with participants will be determined by clinical need, individual preference, and technological capacity.
45479941|NCT03816293|Device|Negative Pressure Wound Therapy|Occlusive dressing with attached Prevena incision management with 125mmHg of negative pressure and cartridge to manage secretions
45479942|NCT02487628|Device|HQ® Matrix Soft Tissue Mesh|
45688229|NCT03429322|Other|Usual Care|Participants will receive and provide usual and customary care in their communities.
45688230|NCT03410030|Drug|Ascorbic Acid|combination therapy
45688231|NCT03410030|Drug|Paclitaxel protein-bound|combination therapy
45688232|NCT03410030|Drug|Cisplatin|combination therapy
45688233|NCT03410030|Drug|Gemcitabine|combination therapy
46048964|NCT02853006|Biological|Blood and respiratory fluids sampling|In order to extract RNA (LungCancerTest) and DNA (mutation, reassortment).
46048965|NCT02853006|Procedure|Biopsy|
46048966|NCT02853006|Procedure|Excised tissues|
46048967|NCT02852382|Drug|Bupivacaine|In the scalp block and local infiltration arms; bupivacaine %0,5 will be used.
46048968|NCT02852382|Drug|morphine patient controlled analgesia|End of the surgery all of the patients in 3 groups will receive morphine patient controlled analgesia (PCA) including 1mg/ml morphine. The PCA was set to administer a bolus dose of 1 mg on demand with a lockout period of 10 minutes and maximum 25 mg for 4 hours.
46048969|NCT00630942|Drug|Minocycline|Minocycline 100 mg capsules twice a day before breakfast and before dinner.
46048970|NCT00602550|Drug|Zidovudine|
46048971|NCT02852148|Device|ACTICOAT|ACTICOAT is a silver coated antimicrobial barrier dressing. ACTICOAT dressings consist of three layers: an absorbent inner core of polyester and rayon sandwiched between outer layers of silver coated, low adherent, high density polyethylene mesh.
46048972|NCT00604110|Other|Biventricular pacing post cardiac surgery|Determine which biventricular pacing after cardiac surgery, in patients with reduced left ventricular function (EF<45%), is hemodynamically favourable.
45844843|NCT02004366|Drug|Linagliptin|Patients with admission A1C < 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.
45844844|NCT02004366|Drug|Linagliptin + 50% Glargine dose on discharge|Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.
45688234|NCT03406221|Behavioral|Information Communication Technology Continuum of Care Service|Mobile phones were made available to community health workers in the intervention arms that integrated a comprehensive set of functions to assist them in their duties, including registration and tracking of beneficiaries, automated scheduling of home visits, provision of health information through videos, guided protocols for conducting home visits through checklists, a feature to track child immunizations, and supervisory tools.
45360953|NCT00888498|Other|High-Velocity, Low-Amplitude Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
45360954|NCT00888498|Other|Slow, Mobilization Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
45360955|NCT00892788|Behavioral|contingency management|Prize-based contingency management for weight loss
45360956|NCT00892788|Behavioral|weight loss manual-guided individual therapy sessions|once weekly counseling sessions with research staff
45479943|NCT02487628|Device|ULTRAPRO® Partially Absorbable Lightweight Mesh|
45688235|NCT03406221|Other|Control Condition|Standard of care
45688236|NCT03400553|Diagnostic Test|Blood analysis|The blood of the patients will be analyzed for troponin T measured with 3 different devices: 1) a point-of-care (POC) test performed in the ambulance or MUG, a handheld cobas h232 POC system® (Roche Diagnostics, Switzerland), 2) a POC test at the emergency room, a table top AQT90 FLEX® (Radiometer, The Netherlands) and 3) a central laboratory test performed on cobas® 8000 (Roche Diagnostics, Switzerland).
45688237|NCT03397017|Other|Transfusion|
45688238|NCT03382301|Drug|Ciclosporin A preconditioning before renal artery stenosis dilation|Ciclosporin A perfusion (2.5 mg/kg) for 1 hour before renal artery dilation
45844845|NCT02004366|Drug|Linagliptin + 80% Glargine|Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.
45844846|NCT02004990|Procedure|Single cleansing procedure of 10% Povidone Iodine|Single cleansing procedure of 10% Povidone Iodine prior to an in-office 5% Sodium Fluoride varnish application
45844847|NCT02005536|Biological|IMOVAX POLIO®: Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
45844848|NCT02006160|Drug|dalfampridine|10 mg bid
45844849|NCT02006160|Drug|placebo|10 mg bid
45844850|NCT02010216|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg by intravenous infusion every 4 weeks
45844851|NCT02010996|Procedure|vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
45844852|NCT02010996|Procedure|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
46048973|NCT00602628|Other|questionnaire administration|
45688239|NCT03382301|Drug|NaCl preconditioning before renal artery stenosis dilation|NaCl perfusion (Saline perfusion) for 1 hour (2.5 mg/kg) before renal artery dilation
45688240|NCT03379870|Device|Electric Acoustic Speech Processor: EAS fitting|Electric Acoustic Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or better,
45688241|NCT03379870|Device|Electric Acoustic Speech Processor: Electric only fitting|Electric Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or poorer and pre-operative low frequency hearing averages of 75 dB HL or better.
45844853|NCT02011464|Drug|Exparel|Exparel is infiltrated into posterior compartment for pain control
45844854|NCT02011464|Other|Saline|Saline is infiltrated into posterior compartment for control
45844855|NCT02015442|Dietary Supplement|Sucrose|
45844856|NCT02016612|Device|Seri Surgical Scaffold|An FDA approved Bioabsorbable mesh Seri Surgical Scaffold will be utilized in the study as an internal hammock mesh support of the breast.
45844857|NCT02020278|Drug|Tolvaptan|"Tolvaptan 3.75-, 7.5-, 15-, and 30-mg spray-dried tablets. Dosage: Depending on age and weight, Tablet (3.75 mg - 60 mg daily). Frequency: Once daily.~Duration: Participants may be eligible to receive short-term or long-term optional tolvaptan treatment at any time during their participation in the trial, with one or more treatment cycles over a 6-month period."
46048974|NCT00602628|Procedure|adjuvant therapy|
46048975|NCT00602628|Procedure|biopsy|
46048976|NCT00602628|Procedure|computed tomography|
46048977|NCT00602628|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
46048978|NCT00602628|Procedure|magnetic resonance imaging|
46048979|NCT00602628|Procedure|therapeutic conventional surgery|
46048980|NCT00602628|Procedure|ultrasound imaging|
46048981|NCT00602628|Radiation|radiation therapy|
45360957|NCT00900978|Biological|7 valent pneumococcal conjugate vaccine (7v-PCV) - Prevenar|The 7v-PCV will be given to children below 2 years of age. Nasopharyngeal swabs will be taken from the children before vaccination and after finishing the vaccination. The vaccine will be given in a 2+1 scheme.
45479944|NCT03719365|Device|NAVAPSV|During the first trial, PSV will be set in order to obtain a Vt between 6 and 8 ml/kg; this support level will be defined as PSV100. Subsequently, the corresponding NAVA level (NAVA 100) will be determined using a dedicated ventilator function (NAVA Preview) which is able to estimate NAVA level in order to deliver an equivalent inspiratory peak pressure (Paw peak) compared to that obtained during PSV mode. Afterwards, PSV100 and NAVA100 will be first increased (PSV150 and NAVA150) during the second trial and then decreased during the third trial (PSV50 and NAVA150) by 50% from basal value. During the study period, PEEP and FiO2 will be kept equal to the values in use before patient enrollment.
45360958|NCT04036500|Drug|Estradiol Tablets|Patients will be given estradiol: 1 mg oral or 1 mg sublingual.
45360959|NCT00895596|Drug|LB80380|Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg
45688242|NCT03348670|Drug|Licorice DS plus Ginkgo DS plus Ginger DS plus Aloe DS for Oral|"Oral~Licorice DS plus Ginkgo DS plus Ginger DS plus Aloe DS Combination Separate~Licorice Combination Separate Dietary Supplements"
46048982|NCT00602706|Biological|sargramostim|
46048983|NCT00602706|Drug|melphalan|
46048984|NCT00602706|Procedure|autologous hematopoietic stem cell transplantation|
46048985|NCT00602706|Procedure|peripheral blood stem cell transplantation|
46048986|NCT00602706|Radiation|samarium Sm 153 lexidronam pentasodium|
46048987|NCT00604344|Drug|insulin detemir|
46048988|NCT00604344|Drug|insulin NPH|
46048989|NCT02852226|Other|Pre Exposure Prophylaxis|Uptake will be measured as the proportion of female patients at the LifeLong clinic who are approached that start PrEP after being offered PrEP, the numbers and rate of PrEP discontinuation, the reasons given for PrEP discontinuation (side effects, no longer at risk, fear of stigma, inability to adhere), and drug concentrations. Drug concentrations are monitored using dried blood spots, which have a large dynamic range capable of detecting use of a few pills every month up through daily use. The main measure of PrEP utilization is the proportion of time that PrEP is used effectively among those attempting to use PrEP.
45360960|NCT00901056|Device|Extracorporeal Shockwave Therapy|Energy Density - 0.02 - 0.15 mJ/mm2
45360961|NCT00895674|Drug|Nexavar (Sorafenib, BAY43-9006)|Patients with a diagnosis of advanced RCC
45360962|NCT00892944|Drug|AZD2516|Fractionated single oral dose
45360963|NCT04035330|Combination Product|etidronate in sodium hypochlorite|using etidronate in sodium hypochlorite solution with a volume of 5 ml between each instrument to reach a total volume of 25 ml
45360964|NCT04035330|Combination Product|sodium hypochlorite|irrigation with 25 ml 2.5% sodium hypochlorite . 5ml between each instrument.
45360965|NCT02540694|Device|Endosonography|
45360966|NCT04035096|Drug|Ascorbic Acid|"Start with IVC (intravenous ascorbic acid) 25 g biweekly, 50 g biweekly, and 75 g biweekly. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level.~The final dose will be kept for 12 weeks.~Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks"
45360967|NCT04035096|Other|Control group|"Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs~Usual care"
45479945|NCT05451836|Other|Patient education leaflets|Patients who attend the emergency department with upper respiratory tract infections will be provided with patient education leaflets on appropriate antibiotic use and antimicrobial resistance. The leaflets are available in the four national languages in Singapore.
45688243|NCT03301506|Drug|Seladelpar 5 mg Capsule|Subjects will be assigned to a treatment group if tolerability issues noted in the previous study.
45688244|NCT03301506|Drug|Seladelpar 10 mg Capsule|Subjects will be assigned to a treatment group unless there are tolerability issues.
45688245|NCT03290391|Other|Rapid ART initiation|The infectionist will streamline the approval with the ultimate goal of starting participants on ART while they are still hospitalized at the City Addiction Hospital.
46048990|NCT02852226|Behavioral|Characteristics of women who enroll|The investigators are interested in characterizing the women who decide to take PrEP through this project. Demographic and psychosocial variables will be used to describe the population who enroll. Sexual and behavioral risk profiles of those who decide to initiate PrEP will also be described as part of this study. Demographics of women who uptake PrEP through community partners will also be compared to the demographics of Alameda County women who have incident HIV infection. In addition to demographics and risk behavior, the investigators will also describe the contraceptive use and intentions of women on PrEP towards future pregnancies as these may be important factors driving interest in PrEP among women.
45360968|NCT00608322|Drug|Inhaled nitric oxide|Inhaled nitric oxide, 40 parts per million, for six hours.
45360969|NCT00608322|Other|Sham inhaled nitric oxide|Sham inhaled nitric oxide administration, 0 parts per million, for six hours.
46048991|NCT02852226|Behavioral|referral sources of women who enroll|Process data will capture the outreach efforts made to recruit participants for this study. At the time of baseline visit, the investigators will capture the source of referral for each woman screened, as well as the primary reason for joining the study. Enrollment progress will be carefully tracked against outreach activities to monitor the relationship between outreach efforts and demand generation. This will help to inform future implementation of PrEP among women.
45688246|NCT03290391|Drug|Pharmacotherapy for opioid use disorder|Thirteen months of naltrexone treatment for opioid use disorder (injection at baseline, followed by 4 implants).
45688247|NCT03290391|Behavioral|Strengths-based HIV case management|Strengths-based case management: 10 sessions over 12 months in which a trained case manager (CM) meets individually with patients to motivate them to engage in HIV medical care by supporting the recognition of their own strengths to make positive changes in their lives and ultimately improve their HIV outcomes.
45844858|NCT02020590|Drug|ALLOB® implantation|Each patient will undergo a single administration of ALLOB® into the delayed-union site under anesthesia.
45688248|NCT03280030|Drug|Midostaurin|Midostaurin 50 mg [two 25 mg capsules] will be administered twice per day by mouth on day 8-21 during induction and consolidation phase; then continuously during continuation phase
45844859|NCT02023944|Other|Memory and Aging Course|This is a 12-week course that will provide participants with an understanding of what normal and pathological aging processes look like. It will also provide participants with methods to maintain healthy lifestyles as they continue to grow older.
45844860|NCT02024646|Drug|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection.
45844861|NCT02024646|Drug|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection.
46048992|NCT00940992|Drug|DER 45 EV|Topical application to face for 12 weeks
45688249|NCT03280030|Drug|Placebo|Placebo two capsules will be administered twice per day by mouth on day 8-21 during induction and consolidation phase ; then continuously during continuation phase.
45688250|NCT03263481|Procedure|Intraductal secretin test (IDST)|If pancreatic duct entry incidentally occurs during the clinically scheduled ERCP and the pancreatic duct appears normal, an IDST will be performed for study purposes. An IDST consists of the administration of human secretin, after which pancreatic juice is collected intraductally. In this study, the fluid will be collected through continuous aspiration in 5 minute intervals for 30 minutes. Samples will be collected at 5, 10, 15, 20, 25, and 30 minutes after secretin administration (6 collections in total).
45844862|NCT02024646|Drug|Placebo|Placebo administered via subcutaneous injection until week 24.
45844863|NCT02024724|Drug|Bupivacaine|4 mL of 0.25% bupivacaine
45844864|NCT02024724|Drug|Triamcinolone|40 mg of Triamcinolone
46048993|NCT00940992|Drug|Vehicle|Topical application to face for 12 weeks
46048994|NCT02851914|Drug|"Tricyclic Antidepressants (TCA)"|if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
46048995|NCT02851914|Drug|"Selective Serotonin Uptake Inhibitors (SSRI)"|if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
46048996|NCT00938964|Drug|Lidocaine|Lidocaine versus placebo infusion for 48 hours
45360974|NCT04035018|Procedure|pharmacopuncture therapy|The participants in the treatment group will be receive one or more pharmacopuncture therapy according to the physician's decision.
45360975|NCT04035018|Procedure|Physical therapy|The participants in the control group will be receive one or more physical therapy according to the physician's decision.
45360976|NCT00608244|Drug|LCP Tacro|"In the morning of Day 8 (after completing one week treatment with Prograf), all patients will be converted to LCP Tacro QD with a conversion ratio of 0.66-0.8.~LCP-Tacro will be administered for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro will be administered orally once daily in the morning, with an interval of 24 ± 1 h between doses.~Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL."
45360977|NCT00608244|Drug|Prograf|Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day 0 through Day 7 to maintain target trough levels of 5-12 ng/mL.
45688251|NCT03260842|Diagnostic Test|Bio-Specimen Collection|Collection of bio-specimens and observation over time.
45688252|NCT03245892|Drug|Carboplatin and Paclitaxel|Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle.
45844865|NCT02024724|Drug|Dexamethasone|4 mg of Dexamethasone
45844866|NCT02025426|Drug|Phenylephrine|
45844867|NCT02025426|Drug|Ephedrine|
45844868|NCT02026206|Device|low-level light therapy|we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
45844869|NCT02026206|Device|Placebo|we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
46048997|NCT00938964|Drug|Placebo|Lidocaine versus placebo infusion for 48 hours
46048998|NCT04268160|Diagnostic Test|Blood draw to measure GPx activity|Routine blood draw to measure levels of blood markers.
46048999|NCT04268160|Diagnostic Test|Blood draw to measure SOD activity|Routine blood draw to measure levels of blood markers.
46049000|NCT04268160|Diagnostic Test|Blood draw to measure Lp(a) levels|Routine blood draw to measure levels of blood markers.
45688253|NCT03245892|Drug|Nivolumab|Nivolumab 360mg will be infused IV over approximately 30 min on Day 1 of Cycles 1-6 (to 8) of each 21 day cycle. During the maintenance phase, Nivolumab 480mg will be infused IV over approximately 30 min on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks
45688254|NCT03245892|Procedure|Cytoreductive surgery|Cytoreductive surgery
46049001|NCT00938886|Drug|Naltrexone|Daily 50 mg naltrexone
45688255|NCT03245892|Drug|Ipilimumab|Ipilimumab 1mg/kg every 6 weeks x 3-6 cycles in the neoadjuvant setting (maximum 2 doses of ipilimumab)
46049002|NCT00938886|Drug|Placebo|Matched naltrexone placebo
45688256|NCT03239496|Biological|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
45688257|NCT03239496|Biological|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
45688258|NCT03235219|Drug|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
45688259|NCT03235219|Drug|Placebo|Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
45844870|NCT02028780|Drug|Placebo to dose|placebo
45844871|NCT02028780|Drug|Idarucizumab|short infusion
46049003|NCT04268082|Device|Visual biofeedback with the use of sensorized insoles|Between the 4th and the 10th day post surgery, both groups performed the same rehabilitation protocol. The experimental group was re-educated to the correct gait dynamics by wearing the sensorized insoles and by using a specific software's graphical interface as a visual biofeedback.
45360981|NCT00893100|Drug|Diltiazem|2%,3 times daily
45360982|NCT00895908|Behavioral|Friendship Group|Social skills training for 30 sessions, held twice per week over 4 to 5 months
45360983|NCT00895908|Behavioral|Academic tutoring|Tutoring to support emergent literacy skills, held 1 to 2 times per week over 4 months
45360984|NCT00895986|Behavioral|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, Inc (Healthy I) and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) Diabetes Overview, 2) Diabetes and Healthy Eating, 3) Blood Glucose and Monitoring, and 4) The Natural Course of Diabetes (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program.
45688260|NCT03224624|Other|self-management protocol for hypertension care|participants in this arm will be taught to monitor and record their blood pressure. On a regular basis they will evaluate their blood pressure record and follow an algorithm to decide whether to adjust their medication.
45688261|NCT03217006|Procedure|Single arterial graft|This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
45844872|NCT02028780|Drug|Placebo to Idarucizumab|Placebo to Idarucizumab
46049004|NCT04268082|Other|Standard rehabilitation based on physiotherapist's verbal instructions|Between the 4th and the 10th day post surgery, both groups performed the same rehabilitation protocol.The Control group did not wear the insoles, but it carried out the rehabilitation programme under the physiotherapist supervision and with his verbal feedbacks.
45360985|NCT00895986|Behavioral|Heart Healthy Living Diabetes Education|The Joslin Clinic offers a series of two 120-minute classes specifically for people with diabetes that address dyslipidemia and blood pressure problems. A registered nurse and/or a registered dietitian teach the classes, which have a formal written curriculum, including PowerPoint slides.
45360986|NCT02539914|Other|Virtual Reality|Virtual reality based upper-limb motor and cognitive task
45360987|NCT02539914|Other|Standard|Standard upper-limb motor and cognitive rehabilitation tasks
45688262|NCT03217006|Procedure|Multiple arterial grafting|This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
45844873|NCT02028780|Drug|dabigatran|2 capsules dabigatran
45844874|NCT02028780|Drug|Idarucizumab|short infusion
45844875|NCT02029872|Drug|Chlorhexidine gluconate soap|4% chlorhexidine gluconate (soap)
46049005|NCT05381688|Procedure|VIM DBS|Stereotactic deep brain stimulation of ventral intermediate nucleus of thalamus
46049006|NCT02852070|Procedure|bronchoalveolar lavage 120ml|120mL sterile saline solution instilled into the distal bronchial tree in 3 times
46049007|NCT02852070|Procedure|bronchoalveolar lavage 60ml|60mL sterile saline solution instilled into the distal bronchial tree in 3 times
45360988|NCT03324984|Drug|1% chloroprocaine|In 2018, 1% Chloroprocaine was approved by the FDA for spinal anesthesia use.
45360989|NCT03324984|Drug|0.75% bupivacaine|Bupivacaine is used on label
45360990|NCT00901212|Device|Device programming|6-month period
45479946|NCT05451836|Other|Physician feedback|All physicians working in the emergency department will receive a text message from their department head on their antibiotic prescribing rates every two months.
45688263|NCT03204188|Drug|Ibrutinib|Ibrutinib will be administered daily by mouth starting cycle -3 at 420 mg until end study or disease progression or intolerable side effects occur.
45688264|NCT03204188|Drug|Fludarabine|Fludarabine will be administered intravenously only on cycle -2 at 25mg/m^2 x5 days.
45688265|NCT03204188|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks at 200 mg starting from cycle 1 through cycle 17 or 1 year of immunotherapy phase.
46049008|NCT02851836|Behavioral|image visualization and quotation|"two sets of 60 pictures are shown to the adolescents. we ask them to quote for their valence, hedonicity, arousal and to characterize the emotion elicited in each picture.~This evaluation takes approximately 1hour."
46049009|NCT00602784|Biological|IC41|
46049010|NCT02851680|Biological|blood samples|
46049011|NCT00938340|Dietary Supplement|"Walnut meat"|Separated, ground walnut de-fatted nut meat incorporated into inert food carrier
45360991|NCT00896376|Biological|trastuzumab|
45360992|NCT00896376|Other|laboratory biomarker analysis|
45360993|NCT00896376|Other|pharmacological study|
45360994|NCT00901290|Drug|monophasic oral contraceptive|mg, oral dose
45360995|NCT00901290|Drug|AZD7325|mg, oral dose
45360996|NCT04018014|Other|CT angiography|CT angiography in detection of pulmonary embolism
45360997|NCT00893256|Drug|Risperidone|Risperidone: tablet; oral; 4-6 mg/day; once daily; 12 weeks
45360998|NCT00893256|Drug|risperidone|Risperidone: tablet; 4-8 mg/day; once daily; 12 weeks
45360999|NCT00893256|Drug|Citalopram|Citalopram: tablet; oral; 20 mg/day; once daily; 12 weeks
45361000|NCT00893256|Drug|Placebo|Placebo: once daily
45479947|NCT03801395|Other|There is no intervention|No intervention
45688266|NCT03194867|Drug|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45688267|NCT03194867|Drug|Cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45688268|NCT03193970|Behavioral|Post-Operative Recovery Registry|Multi-institutional prospective database of patients with bladder cancer undergoing radical cystectomy.
45688269|NCT03184870|Drug|BMS-813160|Specified dose on specified days
45688270|NCT03184870|Biological|Nivolumab|Specified dose on specified days
45688271|NCT03184870|Drug|Nab-paclitaxel|Specified dose on specified days
45688272|NCT03184870|Drug|Gemcitabine|Specified dose on specified days
45688273|NCT03184870|Drug|5-fluorouracil (5-FU)|Specified dose on specified days
46049012|NCT00938340|Dietary Supplement|Walnut Oil|Walnut oil extracted from nut meat and incorporated into inert food carrier
46049013|NCT00938340|Dietary Supplement|Walnut Skins|Separated, ground walnut skins incorporated into inert food carrier
46049014|NCT00938340|Dietary Supplement|Whole walnut|85g whole walnuts, ground, incorporated into inert food carrier
46049015|NCT00602862|Drug|Sorafenib|Sorafenib 200 mg 2dd2 po for 4 weeks before surgery
46049016|NCT00602862|Drug|111Indium-bevacizumab|100 MBq / 1 mg 111Indium/bevacizumab iv
45361001|NCT00605280|Drug|Standard of Care|Clinicians decision to use optional laser therapy.
45361002|NCT00605280|Drug|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks up to 2 years.
45361003|NCT00901368|Drug|FOSTER|CHF1535 (beclometasone dipropionate 100 µg plus formoterol 6 µg) pMDI aerosol via HFA-134a propellant 2 inhalations b.i.d. (daily dose 400 µg + 24µg)
45361004|NCT00901368|Drug|Seretide|Fluticasone 250 µg + salmeterol 50 µg DPI (Seretide® Diskus®) 1 inhalation b.i.d. (daily dose 500+100 µg)
45361005|NCT00607386|Biological|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg weekly
45361006|NCT04034940|Other|Dosing Oxidative stress biomarkers & hFABP in STEMI pPCI patients|Dosing oxidative stress biomarkers and hFABP in STEMI pPCI
45361007|NCT00901446|Device|Intravascular ultrasound and spectroscopy|Intracoronary imaging with a catheter based ultrasound transducer and near infrared spectroscopy tip that is pulled back at an automated rate of 0.5 millimeters per second.
45479948|NCT02487706|Drug|Dolutegravir|Dolutegravir 50mg/day per 5 days
46049017|NCT00602862|Drug|111Indium-cG250|100 MBq / 10 mg 111Indium-cG250 iv
45844876|NCT02029872|Drug|Chlorhexidine gluconate oral rinse|chlorhexidine gluconate oral rinse 0.12%
45844877|NCT02029872|Drug|Mupirocin calcium 2 % ointment|nasal mupirocin calcium 2% ointment
45844878|NCT02030574|Drug|Gemcitabine and fractionated cisplatin (combination treatment)|1 Cycle = 21 days. GC x 4 cycles ----> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8
45844879|NCT02030886|Device|Sensimed Triggersfish® (TF)|All subjects will be monitored by Sensimed Triggerfish (TF) for 24 hours.
45688274|NCT03184870|Drug|Leucovorin|Specified dose on specified days
45844880|NCT02032212|Other|EVP unflavoured|
45844881|NCT02032212|Other|EVP flavoured|
45361008|NCT00901524|Drug|Peg-interféron alpha 2a + ribavirin|Pilot study, multicenter, open label
45688275|NCT03184870|Drug|Irinotecan|Specified dose on specified days
45361009|NCT00893412|Drug|Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)|1 tablet of 50 mg Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)
46049018|NCT04268238|Procedure|Hygiene Guidance|Two weeks before the start of the study, the volunteers will go through a wash out period, where they should only use oral care products donated by the researchers, which should be used until the end of the study. The oral hygiene kit will contain 1 toothbrush (Professional Lab Series, Colgate Palmolive), 1 toothpaste without desensitizing agent, but with fluorine (Elmex) and 1 dental floss (Colgate).
46049019|NCT04268238|Procedure|Sealant Application|Permaseal (Ultradent) is an unloaded resin based on methacrylate and photopolymerizable. The teeth that will be sealed will be isolated. 35% phosphoric acid will be applied for 20 seconds and then it will be necessary to wash and dry the tooth surface. Apply a thin layer of PermaSeal for 5 seconds to the tooth surface and light curing for 20 seconds. After that, it is necessary to evaluate occlusion.
45361010|NCT00893412|Procedure|Hysterosalpingography (HSG)|One HSG using a metal canula or balloon catheter, 30 minutes after tablet
45361011|NCT00893412|Drug|Placebo|
45361012|NCT00896688|Procedure|cervical medial branch blocks using the Quincke spinal needle|#25 gauge 1 and 1/2 inch long needle and #25 gauge 10cm long Quincke spinal needle will be used for placement.
45361013|NCT00896766|Genetic|loss of heterozygosity analysis|
45361014|NCT00896766|Genetic|microarray analysis|
45361015|NCT00896766|Genetic|polymorphism analysis|
45361016|NCT00896766|Genetic|tumor replication error analysis|
45361017|NCT00896844|Behavioral|emotional disclosure|writing about emotional events from the past
45361018|NCT00896844|Behavioral|placebo writing|writing about how they spent their time the previous day
45479949|NCT04551950|Drug|M7824|Participants will receive bintrafusp alfa until confirmed disease progression, death, unacceptable toxicity and study withdrawal maximum of 2 years (at the discretion of the Investigator).
45479950|NCT04551950|Drug|Carboplatin|Carboplatin will be administered intravenously as per standard of care.
45479951|NCT04551950|Drug|Paclitaxel|Paclitaxel will be administered intravenously as per standard of care.
45479952|NCT04551950|Drug|Bevacizumab|Bevacizumab will be administrated as indicated for standard of care.
45479953|NCT04551950|Drug|Cisplatin|Cisplatin will be administered intravenously as per standard of care.
45688276|NCT03176394|Device|BLASTX Gel|Foley Catheter lubricated with BLASTX Gel
45688277|NCT03176394|Device|McKesson Jelly|Foley Catheter lubricated with McKesson Jelly
45688278|NCT03143647|Other|Collect a study-specific blood sample of healthy subjects|One heparin tube (4ml) and one hirudin tube (4ml) blood sample will be collected through standard venipuncture. After applying a tourniquet with moderate pressure around the arm of the patient's choice, skin will be disinfected over a suitable vein in the elbow or fore-arm. A hirudin and a heparin tube will be filled with venous blood through a single puncture with a 22 Ga needle (manufacturer, location). After release of the tourniquet, bleeding will be stopped by applying local pressure for 5 minutes with a sterile gauze.
45844882|NCT02032212|Other|Nicotine inhalator|15 mg nicotine Nicorette
45844883|NCT02032212|Other|Conventional cigarette|
45844884|NCT02032680|Behavioral|Web-based multi-family psychoeducational treatment|This intervention uses a website to provide multi-family psychoeducational treatment to Veterans and their family members or other supporters.
45844885|NCT02032680|Behavioral|In-persons Multi-Family Group Psycho-Education treatment|This intervention will provide the VA's evidence-based MFG. This intervention is delivered to Veterans and their families or other supporters using an in-person format.
45688279|NCT03143504|Diagnostic Test|Skin Testing for Atopic eczema|"FTIR Spectroscopy. This will involve placing the assessment tool briefly in contact with the baby's skin on the arm and thigh.~Transepidermal Water Loss. This will involve placing a probe on the baby's skin for approximately 60 seconds on the arm and thigh. The probe measures the rate of water loss from the baby's skin, which indicates how well it acts as a barrier.~Collection of skin samples. This will involve collecting surface skin samples using small sticky-tape discs to collect only the very top skin cells that are already dead and about to be shed naturally by the body.~Microbial swab. The researchers will rub the baby's skin gently with a wet sterile swab to collect a sample of the microbes on the baby's skin surface.~Buccal swab / saliva sample. The researchers will collect a sample of the baby's saliva using a buccal swab. This sample will be used to analyse the baby's genes (DNA) to assess their inherited risk of eczema."
45688280|NCT03138720|Drug|Paclitaxel Protein Bound (Abraxane)|Participants will be treated with the regimen prior to having surgery. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization. If CA19-9 is normalized, then participant will be scheduled for surgery and moved to standard of care. If CA19-9 is not normalized then participants will complete another 3 cycles.
45688281|NCT03131726|Drug|Simvastatin 40mg|see arm description
45688282|NCT03112590|Biological|Interferon-gamma (IFN-γ)|Phase 1: IFN-γ 50 or 75 mcg/m^2 SQ x 3 days/week for 12 weeks. Phase 2: IFN-γ at Recommended Phase II Dose (RP2D) subcutaneously (SQ) x 3 days/week, for 12 weeks.
45844886|NCT02032680|Other|Treatment as usual (TAU)|Treatment as Usual (TAU) is considered the usual care at the VA. Participants assigned to be in the Treatment as Usual arm will complete assessments at all data collection time points, (baseline, 6, 12, and 15 months.) These participants will not receive any study treatment but will continue to receive their treatment as usual through the VA.
45844887|NCT02032758|Drug|Propranolol|Single oral dose of 10 mg propranolol
45688283|NCT03112590|Drug|Paclitaxel|Phase 1 and Phase 2: Paclitaxel 80 mg/m^2/week, for 12 weeks.
45844888|NCT02032758|Device|Opal Device|The Opal Device (APDM, Inc.) will be used to measure wrist movement.
45361019|NCT04036344|Behavioral|Peer Mentorship Program|Mentee participants are paired with a previous MMS patient (Mentor) who is greater than 1 year status post MMS treatment for a facial skin cancer. Mentors and mentees maintain regular contact by telephone, video chat, or in-person meetings throughout the mentee's facial skin cancer treatment with MMS.
45688284|NCT03112590|Drug|Trastuzumab|Phase 1 and Phase 2: Trastuzumab 8 mg/kg intravenous (IV) loading dose on cycle 1/day 1 (C1D1), followed by 6 mg/kg on subsequent cycles every 3 weeks, for 12 weeks.
45688285|NCT03112590|Other|Pertuzumab|Phase 1 and Phase 2: Pertuzumab 840 mg IV loading dose on C1D1, followed by 420 mg on subsequent cycles every 3 weeks, for 12 weeks.
46049020|NCT04268238|Radiation|Low Level Laser Application|Volunteers will receive irradiation with AsGaAl laser, wavelength of 780nm (Laser XT Therapy, DMC, São Carlos, SP) with fixed power of 100mW, density of energy of 35 J/cm2 (considering a spot size of 0.028cm2 of this equipment), the dose will be 1 J per point. Irradiation will be performed at a cervical, an apical point, and another point exactly on the injury, totaling a dose of 3J. Treatment should be performed in 3 sessions with an ideal 72-hour interval between them.
45844889|NCT02032758|Procedure|Science and Motion PuttLab (SAM)|The SAM will be used to study putter stroke movement and ball movement.
45844890|NCT02032758|Device|Surface Electromyography EMG|The surface EMG will be used to evaluate co-contraction of the wrist flexor/extensor muscle groups and the wrist pronator/supinator muscle groups.
46049021|NCT04257942|Procedure|carotid endarterectomy|carotid endarterctomy that is being used for carotid stenosis disease
45361020|NCT00893490|Device|Ahmed Glaucoma Valve (AGV)|AGV implantation
45361021|NCT00893490|Drug|Mitomycin C (MMC)|3 minute MMC application
45844891|NCT02033694|Device|NIRS-IVUS Imaging (TVC Imaging System)|Diagnostic Imaging Catheter
45361022|NCT00893490|Procedure|amniotic membrane coverage|single layer coverage of amniotic membrane
45361023|NCT00901758|Drug|IV Nitroglycerin|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL.
45361024|NCT00901758|Drug|Normal saline|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL
45479954|NCT04551950|Radiation|Radiotherapy|Participants will receive radiotherapy as per standard of care.
45844892|NCT02036424|Drug|Ozurdex|intravitreal steroid
45844893|NCT02036424|Drug|Bevacizumab|antiVEGF
45361025|NCT00893568|Other|resonance magnetic imaging (fMRI),|a cerebral study will be performed at the neuroanatomic and functional levels by resonance magnetic imaging (fMRI) realized in three times (before, one week and six months after treatment)
45361026|NCT00896922|Genetic|microarray analysis|
45361027|NCT00896922|Other|immunohistochemistry staining method|
45361028|NCT00896922|Other|laboratory biomarker analysis|
45361029|NCT02539680|Procedure|endoscopy|duodenal biopsies
45688286|NCT03112590|Procedure|Post Therapy Surgery|Phase 2: Participants will be assessed for surgery following the fourth cycle of study therapy (or earlier if study treatment is cancelled due to unmanageable side effects).
45361030|NCT00901836|Radiation|Preoperative proton therapy|28 daily fractions of 1.8 cobalt gray equivalent(CGE)/fx for total of 50.4 CGE over 5.5 weeks.
45361031|NCT00901836|Procedure|Surgery|Standard of care surgery will be performed 4-6 weeks after completion of radiation.
45361032|NCT04017780|Device|Single-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a single limb circuit and intentional leak (vented mask) delivered with a turbine-driven ventilator (Astral 150 [ResMed]).
45688287|NCT03099005|Drug|Cannabis|vaporization of cannabis
45688288|NCT03085394|Drug|tranexamic acid|Preoperative intravenous administration of 2 grams tranexamic acid in 10 ml saline
45688289|NCT03085394|Drug|Placebo|Preoperative intravenous administration of 10 ml saline
45688290|NCT03065621|Drug|Palbociclib|Each cycle will be 28 days. Patient will take study drug daily during 21 days and then have a rest period of 7 days.
45688291|NCT03060629|Biological|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5x10^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) into the left deltoid on Months 0, 3, 6, and 12.
46049022|NCT00631176|Behavioral|Just-In-Time Training|On-call pediatric residents from 7 south PICU (24 beds) will receive 20 minutes of just-in-time pediatric airway management training. This training will occur before their shift starts before the morning round. This training will cover direct laryngoscopy technique, orotracheal intubation technique, confirmation of the tube placement and recognition of associated events. This training will be done with or without high fidelity simulation function.
46049023|NCT02851602|Biological|Blood sample|
45361033|NCT04017780|Device|Double-Limb Intensive Care Unit ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a pediatric/neonatal intensive care unit ventilator (Babylog VN500, Draeger).
45361034|NCT04017780|Device|Double-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a turbine-driven ventilator (Astral 150 [ResMed]).
45361035|NCT00897078|Other|laboratory biomarker analysis|
45361036|NCT00897078|Other|medical chart review|
45361037|NCT00897078|Other|metabolic assessment|
45361038|NCT00897078|Other|questionnaire administration|will be obtained at a single clinic visit
45361039|NCT00897078|Procedure|assessment of therapy complications|
45361040|NCT00638690|Drug|Placebo|Four tablets once daily until disease progression
45361041|NCT00638690|Drug|Abiraterone acetate|Four 250-mg tablets once daily until disease progression
45361042|NCT00638690|Drug|Prednisone/prednisolone|5 mg twice daily until disease progression
45361043|NCT02540928|Drug|AMG 319 hydrate|
45361044|NCT02540928|Drug|Placebo|
45361045|NCT00893646|Behavioral|weight loss counseling|individual monthly lifestyle counseling, face-to-face (6 times, each 45 min) and by telephone (7 times, each 30 min), on how to decrease energy intake and change eating habits to improve quality of dietary fat and carbohydrate, how to increase daily walking steps; and how to improve sleep quality (sleep hygienic tips)
45479955|NCT02487784|Procedure|Block allograft|A cancellous block allograft plus corticocancellous particulate allograft will be used as the positive control treatment.
45479956|NCT02487784|Procedure|Particulate allograft + autogenous bone chips|The test arm of this study will include a mix of particulate bone allograft and autogenous bone chips.
46049024|NCT00602940|Procedure|Acupuncture|12 treatments over 8 weeks
46049025|NCT00602940|Procedure|Sham Acupuncture|12 treatments over 8 weeks
46049026|NCT00942708|Drug|Fluoxetine|"Total dose How to take:~Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-6 40 mg BID Week 7-12 40mg BID"
45688292|NCT03060629|Biological|Clade C gp140|Participants will receive Clade C gp140 (250 mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
45844894|NCT02037204|Other|Cartilage repair surgery|Single-stage surgery, After debridement, the cartilage defect is filled with the fibrin glue carrier containing autologous chondrons and allogeneic MSCs
46049027|NCT05381298|Procedure|Deep Margin Elevation using resin composite|After completion of the root canal treatment of the offended tooth and comprehensive evaluation of the obtained treatment, the randomly allocated patients will undergo deep margin elevation procedure where rubber dam isolation will be accomplished Followed by proper matricing and wedging ) followed by selective enamel etching for 10 seconds then universal adhesive application following the manufacturer instructions followed by application of flowable resin composite for the first 1 mm and light cured for 20 seconds according to the manufacturer recommendations followed by application of packable bulk fill composite to elevate the margins and light cured following the manufacturer instructions.
45361046|NCT03600324|Behavioral|T-REV|For any intervention that involves physical exercise, four parameters must be specified to complete the prescription; Type (mode), Intensity, Frequency, and Time. o The standard of care vestibular rehabilitation exercise program consists of three types of treatments that target the specific impairments and limitations discovered during the examination. The three types are: 1) gaze stabilization for vestibulo-ocular reflex dysfunction, 2) visual-vestibular habituation exercise for visual motion sensitivity, and 3) balance exercises for standing balance or gat dysfunction.
45361047|NCT00893724|Drug|Neutral pills with no medicinal effect|Neutral pills with no medicinal effect
45361048|NCT00893724|Dietary Supplement|Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals|Inosine [SR] - 1[500mg] tablet bid Tocopherols [200IU], Tocotrienol [10mg], CoQ10 [50mg] - combination capsule bid Sustained Release Niacinamide - 1 [750mg] tablet bid Vitamin C - 1 [1000mg] sustained release tablet bid N-acetyl Cysteine - 1 [600mg] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid
45361049|NCT00893724|Drug|Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline|Inosine [SR] - 1 [500mg] tablet bid Tocopherol [200IU], Tocotrienol [10mg], CoQ10 [50mg] combination capsule bid Sustained Release Niacinamide 1 [750mg] tablet bid Vitamin C 1 [1000mg] sustained release tablet bid N-acetyl Cysteine 1 [600mg] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid Minocycline 1 [50mg] tablet qd
45361050|NCT00893802|Other|Scaling and root planning|Intervention will consist of supra and subgingival scaling and root planning performed by a single trained periodontist using Gracey curettes (Hu-Friedy, Chicago, USA) without local or general anesthesia during the second trimester of gestation, followed by professional prophylaxis and oral hygiene instruction. Treatment will be performed only once during study.
45361051|NCT00819338|Dietary Supplement|Efamax|5g daily as capsules for 3 months
45361052|NCT00893880|Drug|1% gaseous Nitric Oxide blended in Oxygen|1% gaseous nitric oxide blended in oxygen applied for 30-60 minutes over 1-2 consecutive days.
45688293|NCT03060629|Biological|Placebo|Participants will receive matching placebo.
45688294|NCT03060434|Drug|Pentoxifylline Oral Tablet|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid; pentoxifylline 400 mg bid
45688295|NCT03060434|Drug|Ibuprofen|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid
45688296|NCT03049033|Other|Neurologic Music Therapy|Neurologic Music Therapy uses rhythms to change brain activity and function.
45688297|NCT03049033|Other|Occupational Therapy|Occupational Therapy uses traditional motor training.
45844895|NCT02037438|Other|CONV care for the diagnosis and treatment of sleep disorders|The Conventional (CONV) intervention utilized standard-of-care diagnostic and treatment procedures for new patients with sleep disorders at the Stanford Sleep Medicine Center
46049028|NCT05381298|Procedure|Surgical Crown Lengthening|Participants in this group will undergo surgical crown lengthening in which an internal bevel incision will be done buccally and lingually followed by full thickness flap reflection using mucoperiosteal elevator, then interproximal bone removal will be done using end cutting bur to the planned position away from the margins by 3 mm. The flap will be displaced apically with apically positioned sutures. Postoperative instructions will be given to the patient aiming to control postsurgical complications including pain and swelling. Suture removal and assessment of the surgical site will be done after two weeks
45688298|NCT03049033|Other|Music Supported Therapy|Music Supported Therapy uses musical instruments to train fine motor movements.
45688299|NCT03617354|Procedure|Total Laparoscopic Hysterectomy|The trainee gynaecologists are undertaking a training program in performing Total Laparoscopic Hysterectomy
45361053|NCT00815438|Procedure|cholecystectomy.|Patients enrolled in the study will have a flexible transvaginal endoscopy used during laparoscopic cholecystectomy.
45361054|NCT00815594|Drug|bevacizumab|0.05ml, 1.25mg
45361055|NCT00897234|Other|Mass Spectrometry|Levels of Cathepsin D (CD) and fatty acid synthase (FAS) will be measured using isobaric tag labeling coupled with mass spectrometry. RNA concentration will be measured using spectrophometer and purity will be analyzed.
45479957|NCT03797339|Other|risk factors of adverse cardiovascular events|During the follow-up period,general information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters will be collected
45479958|NCT03797339|Other|multi-omics target discovery|Genome-wide genotype , DNA methylation and metabolomes were determined using illumina high-density genotyping chips, high-throughput sequencing, and high-resolution mass spectrometry respectly. Blood exposure of statins and metoprolol and its metabolites was determined by UPLC-MS/MS.
45688300|NCT03022825|Drug|N-803 and BCG|BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.
45688301|NCT03022825|Drug|N-803|N-803 will be administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.
45688302|NCT03021486|Drug|Chlorpromazine|Given IV
46049029|NCT00937950|Other|Gynaecological follow-up|Subjects received a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to four years in this gynaecological follow-up study (HPV-052 EXT 008). No vaccine was administered in this extension study. Subjects received 3 doses of Cervarix/Havrix vaccine, administered intramuscularly, according to a 0, 1, 6-month vaccination schedule in the HPV-008 (NCT00122681) primary study.
46049030|NCT00942162|Biological|Immunotherapeutic GSK2132231A|Intramuscular administration
45361056|NCT00815672|Behavioral|Exercise|Progressive walking and resistance exercise treatment
45361057|NCT00897312|Biological|infliximab|
45361058|NCT00897312|Biological|pegylated interferon alfa|
45361059|NCT00897312|Biological|ticilimumab|
45361060|NCT00897312|Drug|ribavirin|
45361061|NCT00897312|Other|high performance liquid chromatography|
45688303|NCT03021486|Drug|Haloperidol|Given IV
45688304|NCT03021486|Other|Quality-of-Life Assessment|Ancillary studies
45361062|NCT00897312|Other|laboratory biomarker analysis|
45688305|NCT03021486|Other|Questionnaire Administration|Ancillary studies
46049031|NCT02852772|Behavioral|Cognitive function tests|
45361063|NCT02540460|Drug|LCB01-0371 800mg|LCB01-0371 800mg
45361064|NCT02540460|Drug|LCB01-0371 800mg BID|LCB01-0371 800mg BID
45361065|NCT02540460|Drug|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
45361066|NCT02540460|Drug|Placebo|Placebo
45479959|NCT03797339|Other|validation|The genome-wide genotype of patients with coronary heart disease was detected using the illumina chip. The methylation level of the functional region was detected by the target region enrichment methylation sequencing method. Intestinal flora differences were detected using 16SrDNA high-throughput sequencing.
45479960|NCT03797339|Other|Predictive mathematical models|Machine learning algorithms such as multiple linear regression or Bayesian classification are used to optimize clinical factors and multi-group targets to establish predictive mathematical models.
45479961|NCT03319576|Other|Feeding at 4 hours|Patients will be fed 4 hours after their gastrostomy tube placement procedure.
45361067|NCT00543387|Drug|MK-5108|MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.
45688306|NCT02999789|Device|SmartInhaler with reminder function turned on|The SmartInhaler is a medication monitoring system that functions as a patient reminder device. It monitors asthma medication adherence and also functions by providing an audiovisual reminder.
45361068|NCT00543387|Drug|docetaxel|Docetaxel will be administered intravenously (I.V.) at a dose of 60 mg/m^2 Q12H during the first 2 days of each 21-day cycle.
45361069|NCT02551250|Device|annual noncontrast MRI|liver MRI without contrast agents T2 weighted image, T1 in/out of phase, diffusion weighted images with b-values of 0, 500 mm2/s
45688307|NCT02999789|Device|SmartInhaler|The SmartInhaler is a medication monitoring system manufactured by Adherium that also functions as a patient reminder device. It monitors asthma medication adherence and also functions by providing an audiovisual reminder.
45688308|NCT02970331|Drug|pefcalcitol ointment, 0.005%|pefcalcitol ointment, 0.005%
45688309|NCT02962076|Drug|[C-11] Meta-hydroxyephedrine radioactive tracer (MHED)|this tracer detects the distribution of sympathetic nerve fibers in the left ventricle
46049032|NCT00942084|Drug|Acyclovir|"Protocol V2 & up: Acyclovir 7mg/ml to be administered IV at 10 mg/kg IV q12 or 20 mg/kg IV q12 or 20 mg/kg IV q8 for a total of 6-9 doses(3 days).~Protocol V1: Acyclovir 5 mg/mL to be administered IV at 500 mg/m2 IV q8h for a total of approximately 15 doses (10 days)."
46049033|NCT00941928|Drug|Epratuzumab|360 mg/m^2 once a day by vein on Day -4, Day -1 and Days 3, 6, 10, 13 and 17.
46049034|NCT00941928|Drug|Fludarabine|25 mg/m^2 once a day by vein on Day -6 through Day -2 over 30 minutes.
46049035|NCT00941928|Drug|Cyclophosphamide|60 mg/kg once a day by vein on Days -5 and -4 over 2 hours.
46049036|NCT00941928|Drug|Mesna|12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
46049037|NCT00941928|Procedure|Infusion of NK cells|Transplant of Haploidentical NK cells by vein on Day 0.
46049038|NCT00941928|Drug|Interleukin-2|Subcutaneous injections three times a week for 9 doses on Days 0 to 21.
46049039|NCT02851524|Other|posturography|
46049040|NCT05381064|Device|artificial intelligence assistance system|A deep learning-based bile duct scanning system that can prompt endoscopists to scan standard stations, identify bile ducts and stones in real time
45361070|NCT02551250|Device|biannual ultrasonography|liver ultrasonography for HCC screening performed by experienced sonologists
45361071|NCT03455556|Biological|Anetumab Ravtansine|Given IV
45361072|NCT03455556|Biological|Atezolizumab|Given IV
45361073|NCT03455556|Other|Laboratory Biomarker Analysis|Correlative studies
45361074|NCT04045106|Other|Proprioceptive Neuromuscular Facilitation Patterns|The participants were asked to sit on a chair, the therapist performed the pattern of movement himself then passively applied the pattern on the participant then asked the participant to perform the pattern, and the therapist observed and corrected the movement if it was done improperly.Then participants were told that the therapist will resist their movement, they were also told to keep breathing normally and to report any discomfort and/or pain.After mastering the pattern,the therapist placed one hand on the participant's mandibular and the other hand approximately between parietal and occipital bones to apply resistance through out the ROM, each pattern performed for 3 sets of 10 repetitions with 1-2-minute rest between sets.
45479962|NCT03772925|Drug|Belinostat|Given IV
45479963|NCT03772925|Drug|Pevonedistat|Given IV
45688310|NCT02949128|Biological|Ravulizumab|Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight: ≥ 40 to < 60 kilograms (kg), 2400 milligrams (mg) loading, then 3000 mg every 8 weeks; ≥ 60 to < 100 kg, 2700 mg loading, then 3300 mg every 8 weeks; ≥ 100 kg, 3000 mg loading, then 3600 mg every 8 weeks.
45688311|NCT02945631|Radiation|PTV56|total dose of 56 Gy in 2.0 Gy/fraction x 28 fractions.
45688312|NCT02945631|Radiation|PTV50.4|total dose of 50.4 Gy in 1.8 Gy /fraction x 28 fractions.
45688313|NCT02944682|Other|Liquefied petroleum gas (LPG) cookstove|The intervention consists of a high-quality locally-available liquefied petroleum gas (LPG) stove having at least two burners, a continuous supply of LPG fuel for 18 months, and the promotion of stove use on an exclusive basis for cooking. The intervention will be provided free of charge to all intervention households upon enrollment. On a weekly basis, study staff will examine stove condition, perform any repairs necessary, and measure and record weight of LPG tanks in order to anticipate need for refills.
45688314|NCT02944617|Other|Laboratory Biomarker Analysis|Correlative studies
45688315|NCT02944617|Dietary Supplement|Micronutrient-Fortified Probiotic Yogurt|Receive Activia yogurt
45688316|NCT02944617|Drug|VEGF-TKI|Must be received as standard of care chemotherapy
45688317|NCT02935556|Other|no intervention|database and epigenetic study
45688318|NCT02923115|Drug|DS-1040b|Single, continuous intravenous infusion over 12 to 24 hours (depending on cohort)
45688319|NCT02923115|Drug|Placebo|Single, continuous intravenous infusion of 0.9% sodium chloride over 12 to 24 hours
45688320|NCT02923115|Drug|Enoxaparin|Subcutaneous injection 1 mg/kg twice daily
45688321|NCT02910583|Drug|ibrutinib|ibrutinib administered orally once daily (three 140 mg capsules)
45688322|NCT02910583|Drug|venetoclax|venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.
45688323|NCT02910583|Drug|Placebo|placebo capsules to match ibrutinib administered orally once daily
46049041|NCT04203966|Diagnostic Test|12-item General Health Questionnaire (GHQ-12)|Structured validated screening tools to assess for the presence of CMDs, administered to participants who have consented to take part in the study by completing responses either via survey monkey, or if they prefer through paper questionnaires posted to them
45361075|NCT04045106|Other|Proprioceptive Neuromuscular Facilitation stretching|was done for 6 repetitions with hold for 6 seconds in position of stretch and sub maximal isometric contraction for 6 seconds, 1-2-minute rest was given before changing the target muscle group
45361076|NCT04045106|Other|Passive range of motion|ineffective passive ROM for 10 repetitions for flexion, extension, right and left side bending and right and left rotation, it was done from neutral position to the limit of motion without causing any stretch to the muscle.
45361077|NCT04017624|Other|Fresh Truck with stipend|"Linkage to Community Partner Organization~Investigators will partner with a community organization, Fresh Truck, that deploys mobile fresh produce trucks throughout Boston neighborhoods. Participants randomized to the intervention arm will receive a monthly stipend of $80 to purchase fresh produce available at any Fresh Truck mobile market location."
45361078|NCT04017624|Other|THRIVE screening and referral|The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
45361079|NCT00815828|Other|Resistance exercises|Resistance exercises program consisting of 08 different exercises.
45361080|NCT04006197|Other|laryngostroboscopy and histoh-pathology|videolaryngoscopy and laryngostroboscoby will be performed .the latter will be pathological in case of highly reduced or abolished amplitudes of vocal fold vibration and if there is reduction of mucosal wave propagation.also direct microlaryngoscopy under general anathesia will be done and excesional biobsy will be taken followed by histopatholpgical examination .the histological finding will be catagorized into the following categories according to (WHO): squamous cell hyperplasia with non dysplasia,mild dysplasia,moderate dysplasia,sever dysplasia,carcinoma in situ and squamous cell carcinoma.
45479964|NCT03326752|Drug|DV281|- Dose Escalation will be the preliminary dose finding phase of the study. Subjects will be enrolled to available Dosing Cohorts.
45688324|NCT02896348|Device|SynPhNe platform|SynPhNe is a non-invasive device. It consists of a piece worn around the forearm, a head component and it communicates wirelessly with the computer to provide feedback while performing motor tasks with the hemiparetic hand. The head cap records brain activity and gives feedback to help relaxing while exercising. The arm and the head component communicate wirelessly with the computer via Bluetooth. The head component reads brain signals while the arm gear senses your muscle signals when performing the exercises. The computer software adopts the appropriate difficulty level, speed and duration of the exercise depending on brain and muscle status to minimize fatigue.
46049042|NCT04203966|Diagnostic Test|WHO AUDIT (World Health Organization- Alcohol Use Disorders Inventory Tool)|Structured validated screening tools to assess for the presence of alcohol use disorders, administered to participants who have consented to take part in the study by completing responses either via survey monkey, or if they prefer through paper questionnaires posted to them
46049043|NCT00603096|Device|GoodKnight 425ST - Mallinckrodt DF, Tyco Healthcare|The aim of this randomized controlled trial is comparing the improvement of diurnal PaCO2 in OHS patients after one month of NIV treatment depending upon the tools used for adjusting settings. In one arm settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas in the other arm patients will benefit from a complete polysomnography under NIV.
46049044|NCT00603174|Device|neurally adjusted ventilatory assist (NAVA)|Following the titration of PEEP and the NAVA level, the infant will be ventilated on NAVA with the titrated levels. The following will be monitored and recorded for 20 min at 1 hour intervals: Phasic EAdi, tonic EAdi, tidal volume, ventilator-delivered pressure, respiratory rate, oxygen saturation, end tidal PCO2, and heart rate.
46049045|NCT02852616|Behavioral|Narrative Exposure Therapy|8 - 15 sessions: 1 lifeline session, 5 - 12 sessions narrative exposure, 1-2 sessions of future-oriented counselling
46049046|NCT02852694|Drug|Methotrexate|Subcutaneous methotrexate once weekly 15mg/m2 body surface area (19, 30), with a maximal dose of 25mg/week. Odansetron (Zofran) premedication (4-8mg 1Hour prior to injection) is recommended, folate acid substitution (15mg po, 3 days after Methotrexate injection, for children <20kg: 1x 5mg) is recommended.
46049047|NCT02852694|Drug|Adalimumab|Subcutaneous Adalimumab started at a dose of 160mg followed by 80mg 2 weeks later and then 40mg every 2 weeks in patients over 40kg. In patients < 40kg sc doses of Adalimumab are as follows: induction 160mg/1,73m2 BSA (max 160mg), followed by 80mg/1,73m2 Body surface area (max 80mg) 2 weeks later and maintenance of 40mg/1,73m2 Body surface area (max 40mg) every 2 weeks, all doses rounded up to the nearest 5 multiplications.
45479965|NCT03326752|Device|Breath Actuated Nebulizer|Breath-actuated, electronic system designed to aerosolize liquid medication.
45361081|NCT02540304|Behavioral|Reducing the Risk|Safer Sex is a clinic-based intervention intended to reduce the incidence of STIs and increase condom use among high-risk sexually active female adolescents and delivered in face-to-face individualized sessions by a female health educator. Reducing the Risk is a sexuality-education curriculum, most often delivered in a school setting that provides instruction and practice in the social skills needed to put into action what students learn about preventing pregnancy and reducing unsafe behavior in future high-risk situations. ¡Cuidate! is adapted from the Be Proud! Be Responsible! curriculum and culturally tailored for Latino youth. It aims to reduce HIV risk and unintended pregnancies by affecting sexual behaviors such as intercourse, number of partners, and condom use.
45361082|NCT00808964|Drug|NU172|NU172 administered IV bolus followed by continuous infusion during CABG surgery
45361083|NCT00982839|Procedure|Syringe Conditioning|A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.
46049048|NCT02852694|Drug|Azathioprine / 6 Mercaptopurine|Oral Azathioprine /6mercaptopurine at a dose of 2.5 mg/kg once daily rounded to the nearest multiplication of 12.5mg or oral 6mercaptopurine at a dose of 1.5mg/kg once daily rounded to the nearest multiplication of 12.5mg.
46049049|NCT00604578|Drug|Pioglitazone Hydrochloride|
45361084|NCT00982839|Procedure|Barostat Conditioning|A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
45688325|NCT02896348|Other|Conventional therapy|Exercise program established with a therapist (8 sessions under therapist direct supervision and 10 sessions at home). Low functioning subjects will be given more proximal joint-muscle exercises and activities while higher functioning subjects will have a greater component of distal tasks and activities. The therapist will review the exercises therapy plan with the subject and re-adjust it.
45361085|NCT00897468|Other|laboratory biomarker analysis|Tissue samples will either be collected at the time of medically indicated surgical procedures or through research core biopsies. A sample of urine will also be obtained. Blood will be collected via venipuncture and lymphocytes (mononuclear cells) separated and processed as a source of normal DNA and normal cells.
46049050|NCT00937560|Drug|Bevacizumab|Bevacizumab was supplied as a sterile solution for infusion.
46049051|NCT00937560|Drug|Paclitaxel|Paclitaxel was supplied locally in commercial batches.
46049052|NCT00937560|Drug|Carboplatin|Carboplatin was supplied locally in commercial batches.
45361086|NCT00897468|Other|medical chart review|patient chart review will occur in conjunction with patient data collection for final analyses.
45361087|NCT02551406|Device|Capno-oxymetry monitoring|Monitoring of home mechanical ventilation by capno-oximetry
45361088|NCT00988299|Other|exercise|exercise sessions at 45% and 60% of maximum effort
45361089|NCT00809042|Drug|hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day).
45361090|NCT00809042|Drug|L-carnitine and hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day).
45361091|NCT00809042|Drug|hydroxyurea and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day.
45479966|NCT03326752|Drug|DV281 (RP2D)|- Dose Expansion will be enrolled into 4 groups based on NSCLC characteristics.
45688326|NCT02866461|Other|No treatment|Observation
45752091|NCT01794559|Device|PEER Interactive Report|The PEER Interactive Report provides information comparing the subject's Quantitative Electroencephalography (QEEG) to a database of outcomes from patients with similar QEEG results, and how they responded to on-label treatments. This report provides a probability of how this subject will respond to treatment based upon a comparison of similar subjects in the database.
46049053|NCT00603252|Biological|Twinrix|
46049054|NCT00603252|Biological|Engerix-B|
46049055|NCT00603252|Biological|Havrix|
46049056|NCT00603252|Biological|HBVAXPRO|
46049057|NCT00603252|Biological|Vaqta|
46049058|NCT04268394|Drug|CC-99677|CC-99677
46049059|NCT04268394|Drug|Methotrexate|Methotrexate
46049060|NCT04268394|Drug|Sulfasalazine|Sulfasalazine
46049061|NCT04268394|Drug|Itraconazole|Itraconazole
46049062|NCT04268394|Drug|Rifampin|Rifampin
46049063|NCT04268394|Drug|Midazolam|Midazolam
46049064|NCT04268394|Drug|Digoxin|Digoxin
46049065|NCT04268394|Drug|Metformin|Metformin
46049066|NCT04268394|Drug|Rosuvastatin|Rosuvastatin
46049067|NCT02851368|Device|near infrared fluorescence imaging (NIFI)|The NIFI system will be evaluated for its ability to 1) visualize nodules and their margins 2) differentiate between benign and malignant nodules and 3) identify additional undiagnosed nodules after receiving an injection of indocyanine green 1 day prior to planned surgery.
46049068|NCT02851368|Drug|Indocyanine Green|Indocyanine Green will be administered intravenously 1 day prior to NIFI.
45361092|NCT00809042|Drug|hydroxyurea,L-carnitine and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day
45361093|NCT02539602|Behavioral|The Need to Know students received the N2K curriculum as described previously|
45361094|NCT00988377|Other|dietary intervention|whey protein 10-40 g
45361095|NCT00988377|Other|water control|Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
45361096|NCT02551328|Drug|sevofluorane|Continuous infusion of sevofluorane
45361097|NCT00897546|Other|laboratory biomarker analysis|
45361098|NCT00982917|Behavioral|Stamp-in-Safety Curriculum|30 minute curriculum on playground safety
45361099|NCT00982917|Behavioral|Stamp-in-Safety curriculum|30 minute lesson on playground supervision
45361100|NCT00901914|Biological|Placebo|One sublingual tablet of matching placebo daily during approximately 5.5 months
45361101|NCT00901914|Biological|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 12.5 µg daily during approximately 5.5 months
45752092|NCT02985320|Biological|Single-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
45752093|NCT02985320|Biological|Single-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
46049069|NCT02851212|Drug|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
45361102|NCT00901914|Biological|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 25 µg daily during approximately 5.5 months
45361103|NCT00901914|Biological|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 50 µg daily during approximately 5.5 months
45361104|NCT00815906|Drug|SBI-087|IV, Single dose
45361105|NCT00815906|Drug|SBI-087|IV, Single dose
45361106|NCT00815906|Drug|SBI-087|SC, Single dose
46049070|NCT02851212|Drug|Canagliflozin|Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablets) under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
45688327|NCT02863172|Behavioral|Questionnaires|"Consenting Proband Group: Participants fill out questionnaires about work, family history, medical history, and health habits at baseline. It should take about 20 minutes to complete the questionnaires. Participants also complete a health and lifestyle questionnaire, which contains 20 questions for men and 22 questions for women. Questionnaire should take about 10 minutes to complete. Follow-up questionnaire at least 1 time in 5 years to update medical, cancer, and family history.~Family Members (MDA Registered Patients) Group and Family Members (Not MDA Registered Patients) Group: Participants complete a health questionnaire, which collects information about their personal medical history, demographics (age, race, sex, and so on), and questions about their alcohol and tobacco use at baseline. Questionnaire should take about 20 minutes to complete. Participants complete follow-up questionnaire at least 1 time in 5 years to update their medical, cancer, and family history."
45688328|NCT02863172|Procedure|Blood Draw/Saliva Sample|About 2-3 tablespoons blood drawn. Participants may give a saliva sample instead.
45688329|NCT02821299|Other|Laryngeal transplantation|Laryngeal transplantation
45688330|NCT02820857|Drug|Folfiri-bevacizumab|Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
45847685|NCT02849418|Drug|GSK1358820|GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams [mg]), and human serum albumin (0.5 mg). The 30 mL of study drug will be administered as 30 injections each of 1.0 mL, evenly distributed at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents.
46049071|NCT02851212|Drug|Canagliflozin|Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
46049072|NCT02851212|Drug|Metformin Extended Release (XR)|Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
46049073|NCT02851134|Genetic|genetic analysis|genetic (Whole Exome Sequencing )
45361107|NCT00815906|Drug|SBI-087|SC, Single dose
45361108|NCT00988455|Radiation|photodynamic therapy|5-ALA cream 20% topical administration + photodynamic therapy (red light) 120 j/cm2
45361109|NCT00897624|Genetic|gene expression analysis|
45361110|NCT00897624|Genetic|reverse transcriptase-polymerase chain reaction|
45361111|NCT00897624|Other|laboratory biomarker analysis|
45361112|NCT00815984|Procedure|measurements of lung function tests|Measurement of the concentration of FeNO , measurement of spirometry, plethysmography, exercise challenge test (ECT -spirometric), bronchial obstruction reversibility pharmacological test
45361113|NCT00986037|Drug|ABT-308|Single IV doses
45361114|NCT00986037|Drug|ABT-308|Multiple SC doses x 3
45361115|NCT00986037|Drug|Placebo|Single IV dose
45361116|NCT00986037|Drug|Placebo|Multiple SC doses x 3
45361117|NCT00901992|Behavioral|MEDIAS 2 ICT|MEDIAS 2 ICT is a newly developed education program for the initiation of intensive conventional insulin therapy in type 2 diabetic patients (10 lessons of group sessions for 4-8 participants)
45361118|NCT00901992|Behavioral|Current ICT program (ACC-ICT)|This program is conducted in 10 lessons in a group setting (4-8 participants)
45361119|NCT00983151|Drug|Tramadol Hydrochloride & Placebo|89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours) Subject will take the study drug for about 27 weeks
45361120|NCT00897780|Behavioral|Biofeedback with virtual reality|Participant will use biofeedback technique in combination with virtual reality technique
45361121|NCT00635570|Drug|Ortho Tri-cyclen Lo|Low dose oral contraceptive
45361122|NCT00635570|Device|NuvaRing|Contraceptive vaginal ring
45688331|NCT02820857|Drug|Folfiri|Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
45688332|NCT02797457|Procedure|Bilateral allograft of the hands and forearms.|Bilateral allograft of the hands and forearms.
45688333|NCT02797457|Procedure|Prosthetic forehands|Prosthetic forehands
45688334|NCT02797314|Other|Bone biopsies|Bone biopsies
45688335|NCT02790710|Drug|Propanolol|Active treatment
45688336|NCT02790710|Drug|Placebo|
45688337|NCT02779855|Biological|Talimogene laherparepvec|Talimogene laherparepvec injection. Phase I: Dose escalation. Phase II: Treatment at Maximum Tolerated Dose (MTD) from Phase I. The MTD dose level is defined as the highest dose level with ≤1 out of 6 patients experiencing a dose limiting toxicity (DLT).
46049074|NCT02851134|Biological|blood and stools samples|biological collection
46049075|NCT02851446|Other|measure dyspnoea> Borg 7|
46049076|NCT00594568|Drug|LY450139|Administered orally once daily
46049077|NCT00594568|Drug|Placebo|Administered orally once daily
45361123|NCT00893958|Drug|Mycophenolate Mofetil|Prophylaxis of Organ Rejection
45479967|NCT03326752|Drug|Approved Anti-PD-1 Inhibitor|FDA approved Anti-PD-1 Inhibitor
45479968|NCT01304303|Drug|SPARC1023 I|IV administration
45479969|NCT01304303|Drug|SPARC1023 II|IV administration
45361124|NCT00986115|Drug|Memantine|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
45361125|NCT00986115|Drug|Placebo|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
45844896|NCT02037438|Other|PCCM for the diagnosis and treatment of sleep disorders|The Patient-Centered Outcomes and Coordinated Care Management (PCCM) intervention implemented new methodologies for the diagnosis and treatment of sleep disorders. It also incorporates the utilization of a web-based interactive portal that provides specific and relevant information and resources for patients, health care providers, and allied health professionals. The portal was designed to facilitate informed health care decisions among patients and health care providers through improved access to medical data and enhanced communications.
45844897|NCT02038218|Drug|4-Demethyl-4-cholestryloxycarbonylpenclomedine|"This will be an open-label, uncontrolled two-arm, multi-center study in patients with CNS involvement from melanoma, breast, lung cancers or primary malignancies of the CNS. Patients can be previously treated with radiation and systemic therapies and are eligible if they also have other sites of cancer involvement.~Two Cohorts of patients will be treated every 21 days with a single infusion of DM-CHOC-PEN as an out-patient:~Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;~Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.~Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance."
45844898|NCT02042274|Dietary Supplement|Fish oil supplement|Participants are instructed to consume fish oil supplements on a daily basis for a 3-month period.
45361126|NCT00983229|Procedure|Tracheal intubation|Insertion of a plastic tube under direct vision (built-in camera, intubating fibrescope) into trachea.
45688338|NCT02779855|Drug|Paclitaxel|Paclitaxel chemotherapy infusion. The paclitaxel weekly dose is fixed at 80 mg/m^2.
45844899|NCT02044380|Drug|Afatinib|40, 30, or 20mg tablets taken once daily, dosage depending on tolerability
45361127|NCT00809120|Device|Neuromuscular Electrical stimulator (Cefar rehab 4 pro)|50Hz 30 min 7 sessions
45361128|NCT04035876|Drug|Camrelizumab plus apatinib|Camrelizumab 200mg q2w iv and apatinib 250mg qd po.
45361129|NCT00902070|Drug|Rocuronium|Normally, for adults, 0.6 mg/kg of rocuronium bromide is intravenously administered to support endotracheal intubation. If additional administration is necessary, 0.1 - 0.2 mg/kg is intravenously administered. In the case of continuous infusion, infusion is initiated at a rate of 7 μg/kg/min. Dosage should be adjusted based on the age or symptom. The upper limit of this drug for the intubation is 0.9 mg/kg.
45688339|NCT02762318|Other|Samples With DNA|"After consenting, all subjects have to undergo the following procedures:~Up to 25 ml of blood will be withdrawn. If for any reason, the blood sample cannot be obtained, a swab will be applied to the inside of the cheek to obtain saliva.~A questionnaire will be used to collect information about individual A routine physical exam will be performed. The subject's medical record will be reviewed To well document some of the specific phenotypes and conditions, physicians might take photographs of the affected body area.~For secondary subjects (relatives or family members), normal examination and routine lab tests/ imagining will be done if needed as per the related standard care."
46049078|NCT00684658|Behavioral|TeenCope|Teencope consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist
45361130|NCT00635492|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
45361131|NCT00635492|Drug|any human insulin or analog insulin(s) given in any regimen by subcutaneous injection|
45844900|NCT02045238|Drug|Hypertonic Saline|Sodium Chloride 3% solution, previously prepared in 5 mL syringes.
45361132|NCT00543309|Drug|nesiritide|Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted
45361133|NCT00543309|Drug|milrinone|Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted
45361134|NCT00543309|Drug|placebo|Placebo bolus on CPB, then placebo infusion
45361135|NCT00902148|Device|Polylactic Acid Sheet|SurgiWrapTM bioresorbable sheet will be secured directly below the abdominal incision.
45361136|NCT00894114|Biological|V520|MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection
45844901|NCT02045238|Radiation|Chest X-Ray|
45844902|NCT02045238|Other|Respiratory virus screening test|Immunofluorescence analysis of nasal aspirate
45688340|NCT02680015|Behavioral|PEERS|Social-behavioral intervention designed to help individuals with Autism Spectrum Disorder make and keep friends.
45688341|NCT02661035|Drug|Allopurinol|300 mg/day (for peds -150 mg/m^2/day), day -6 and continue through day 0 or longer if clinically indicated
45844903|NCT02047032|Procedure|acupuncture|For BL33, the needle (75mm) will be inserted at the point upper and outside of BL33. Insert the needle with a 30-45°angle to a depth of 50-60 mm. The needle will be manipulated with an even lifting, thrusting and twisting method and the sense of soreness and distention will radiate to the perineal region or the anus. For BL35, the needle will be inserted upward and outward slightly with an even lifting, thrusting and twisting method. The sense of soreness and distention will radiate to the perineal region or the anus. The electric stimulator will be put on the two pair of points with a spare-dense wave, 10/50 Hz, 0.1-5.0 mA. The current intensity will be increased until the participant can not stand.
45844904|NCT02047032|Drug|solifenacin|Solifenacin used in this trial is produced by Astellas Pharma Europe B.V.(Country medicine accurate character No. J20090109 )
45844905|NCT02047032|Procedure|PFMT|Intensity of the PFMT exercises will conform to the guideline of National Institute for Health and Clinical Excellence (NICE).
45844906|NCT02047344|Drug|Antroquinonol|patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
45844907|NCT02047500|Drug|TH-302|TH-302 will be administered at a dose ranging from 170-340 milligram per square meter (mg/m^2) as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
45361137|NCT00894114|Biological|Comparator: ALVAC-HIV vaccine|A single dose 0.1 intramuscular injection
45688342|NCT02661035|Drug|Fludarabine|30 mg/m^2 IV over 1 hour, day -6, -5, -4, -3 and -2
45688343|NCT02661035|Drug|Cyclophosphamide|50 mg/kg IV over 2 hours, day -6
45688344|NCT02661035|Drug|ATG|Only for patients with an unrelated donor (URD) and NO multi-agent chemotherapy 3 months prior to transplant. ATG will be administered IV every 12 hours for 6 doses on days -6, -5, and -4 according to institutional guidelines. Methylprednisolone 1 mg/kg IV administered immediately prior to each dose of ATG (6 doses).
45688345|NCT02661035|Radiation|TBI|All patients who have had previous radiation therapy or TBI will be seen by Radiation Oncology prior to entrance on the protocol for approval for additional 200 cGy of TBI. TBI may be delivered by local guidelines provided the effective dose is equivalent to what is recommended in the TBI Guidelines. The dose of TBI will be 200 cGy given in a single fraction on day -1.
45844908|NCT02047500|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered at a dose ranging from 100-125 mg/m^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
45844909|NCT02047500|Drug|Gemcitabine|Gemcitabine will be administered at a dose ranging from 800-1000 mg/m^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
45844910|NCT02048670|Device|Balance Belt|Vestibular habituation therapy worn under the clothes around the waist that uses sensitive motion detectors and vibrates against the skin at four locations to provide information about posture and gait
45479970|NCT03326674|Drug|Tesetaxel and Capecitabine|Tesetaxel plus reduced dose of Capecitabine
45844911|NCT02051790|Drug|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in the course of clinical practice.
45844912|NCT02054754|Drug|Dexanabinol Dose Level 1|Oral formulation of dexanabinol
45844913|NCT02054754|Drug|Dexanabinol Dose Level 2|Oral formulation of dexanabinol
45844914|NCT02054754|Drug|Dexanabinol Dose Level 3|Oral formulation of dexanabinol
45844915|NCT02054754|Drug|Dexanabinol Dose Level 4|Oral formulation of dexanabinol
45844916|NCT02054754|Drug|Dexanabinol Dose Level 5|Oral formulation of dexanabinol
45844917|NCT02054754|Drug|Placebo|
45844918|NCT02057640|Drug|Panobinostat|20mg, on day 1, 3, 5, 15, 17, 19, 28
45844919|NCT02057640|Drug|Dexamethasone|20mg, on day 1, 2, 8, 9, 15, 16, 28
45844920|NCT02057640|Drug|MLN9708|4mg on day 1, 8, 15, 28
45688346|NCT02661035|Drug|Tacrolimus|"All patients will receive tacrolimus therapy beginning on day -3. Initial dosing of tacrolimus will be 0.03 - 0.05 mg/kg/day IV; if the recipient body weight is <40 kg, dosing will be 3 times daily, and if ≥ 40 kg, twice daily or per current institutional guidelines.~An attempt will be made to maintain a trough level of 5-10 ng/mL and subsequent dose modifications will be provided by the pharmacist.~Once the patient can tolerate oral medications and has a reasonable oral intake, tacrolimus will be converted to an oral form based on the current IV dose providing normal renal and hepatic function and no major drug interactions.~The timing of the tacrolimus taper will be at the discretion of the treating physician, but in general:~Taper begins at day +100 +/- 10 days, if the patient is stably engrafted and has no active GVHD.~Taper to zero by reducing dose by approximately 10% a week (rounded to nearest pill size), with a goal to discontinue by month 6 post-HCT."
45361138|NCT00986193|Procedure|Transapical Aortic Valve Implantation|Insertion of a stent valve using catheter-based technique through a mini thoracotomy
45361139|NCT00986193|Procedure|Conventional Aortic Valve Surgery|Operation using heart-lung machine, with insertion of a biological artificial heart valve
45361140|NCT02540382|Device|covered stent|A broad range of implant diameters and lengths for the treatment of in-stent restenotic peripheral and central lesions* in patients with AV grafts and AV fistulae Small incremental stent graft lengths to help maintain venous real estate and cannulation area Minimal shortening and radiopaque markers aid in excellent placement accuracy
45361141|NCT02540382|Device|bare stent|"A one piece laser cut, self-expanding nitinol stent combining a micromesh design with a multi segmental construction.~The 36 strut, 6 bridge construction of the Stent provides an unmatched balance of radial force, scaffolding, and longitudinal stability.~The design offers crush recoverable flexibility in the most challenging vasculature, with optimal wall apposition, conformability and minimal foreshortening.~It offers a broad portfolio of sizes for the treatment of routine and challenging Iliofemoral lesions."
46049079|NCT00684658|Behavioral|Managing Diabetes|Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. As with the TeenCope program, each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth complete educational sessions independently over 5 weeks. There is no online discussion board or peer interaction.
45361142|NCT00986271|Procedure|EVLI was determinated by PiCCO plus system.|
45361143|NCT00988611|Other|Women undergoing IVF/ART cycles at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma|Women undergoing an IVF/ART treatment cycle at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma, age range 18-44 years old
45361144|NCT00897936|Genetic|DNA methylation analysis|
46049080|NCT04144504|Device|Retrievable metallic stenting|Use of retrievable metallic stents for the treatment of biliary anastomotic stricture after liver transplantation
45752094|NCT02985320|Biological|Three-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
45361145|NCT00897936|Genetic|comparative genomic hybridization|
45361146|NCT00897936|Genetic|fluorescence in situ hybridization|
45361147|NCT00897936|Genetic|microarray analysis|
45844921|NCT02057952|Behavioral|Education and exercise|The active groups will meet twice a week for 75 minutes over six months. They will be followed for an addition six months to monitor maintenance.
45844922|NCT02059512|Procedure|Group 1|Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD.
46049081|NCT04144504|Device|Plastic stenting|Use of plastic stents
46049082|NCT00684892|Device|Chartis System|Assessment of airway flow and pressure
46049083|NCT04143802|Drug|LY3437943|Administered SC
45361148|NCT00897936|Genetic|polymerase chain reaction|
45361149|NCT00897936|Other|diagnostic laboratory biomarker analysis|
45361150|NCT00897936|Other|immunologic technique|
45361151|NCT00988689|Other|Dietary Intervention|soup with or without starch
45361152|NCT04006977|Dietary Supplement|a multistrain probiotic product (DSF)|In Arm 2, participants will receive standard medical therapy plus the multistrain probiotics (DSF), 4 sachets per day.
45361153|NCT04006977|Dietary Supplement|Placebo|In Arm 1, participants will receive standard medical therapy plus the placebo.
45361154|NCT04332432|Drug|belapectin|intravenous
45361155|NCT00988767|Biological|DNA vaccine|patients received 1ml of DNA vaccine (1mg/ml) at Months 0,2,4,10
45361156|NCT00898014|Genetic|fluorescence in situ hybridization|
45361157|NCT00898014|Other|immunologic technique|
45361158|NCT00898014|Other|laboratory biomarker analysis|
45361159|NCT00569582|Drug|mifepristone|Patients take mifepristone by mouth once a day. The dose is increased during scheduled timepoints during the study or until symptoms improve or the highest dosage allowed is reached. Dose escalation will be based upon weight. During clinic visits, blood pressure, glucose tolerance and blood chemistries are measured and EKG and urinalysis will be performed.
45361160|NCT00894192|Device|Izon Wavefront-guided lenses|Subjects will use prescribed eyeglasses for one week. Their visual functioning will be tested at the end of the week.
45361161|NCT00894192|Device|Conventional lenses|We will test the subjects with these lenses after they have worn them for one week. Same procedures will be followed as with the other lenses.
45361162|NCT00988845|Dietary Supplement|Indole-3-carbinol|200 mg bid po X 8 weeks
45361163|NCT00894270|Procedure|Sterile air injection|Injection of 20 microlitres using Novofine 5mm needle of sterile air into either abdomen or thigh using either a pinched or unpinched skin fold and either a vertical or angled approach.
45479971|NCT03326674|Drug|Capecitabine|Capecitabine alone at approved dose
45688347|NCT02661035|Drug|MMF|"3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.~MMF will stop at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count [ANC) ≥ 0.5 x 109 /L]). If no donor engraftment, MMF will continue as long as clinically indicated."
45688348|NCT02661035|Biological|Peripheral Blood Stem Cells|On day 0, patients will receive an allogeneic transplant using PBSC which are CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
45688349|NCT02661035|Biological|Related or Unrelated Bone Marrow Cells|On day 0, a target dose of 3 x 10^8 nucleated cells/kg recipient weight will be collected. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
45688350|NCT02650843|Other|DAT SPECT imaging|
45688351|NCT02648477|Drug|Anastrozole|Given PO
45688352|NCT02648477|Drug|Doxorubicin Hydrochloride|Given IV
45688353|NCT02648477|Drug|Exemestane|Given PO
45688354|NCT02648477|Other|Laboratory Biomarker Analysis|Correlative studies
45688355|NCT02648477|Drug|Letrozole|Given PO
45688356|NCT02648477|Biological|Pembrolizumab|Given IV
45361164|NCT00894270|Procedure|Placebo injection|Injection of either 20, 40 or 60 IU of placebo media into either abdomen or thigh using either a vertical or angled Novofine 5 mm needle. Leakage of fluid will be blotted and then weighed to establish fluid loss.
45688357|NCT02613377|Other|Blood transfusion|
45688358|NCT02604732|Procedure|Laparoscopic inguinal hernia repair with perioperative Aspirin|Patients undergoing laparoscopic inguinal hernia repair will continue on Aspirin perioperatively
45361165|NCT00894270|Device|Novofine needle|Novofine 5mm needle
45688359|NCT02604732|Procedure|Laparoscopic inguinal hernia repair without perioperative Aspirin|Patients undergoing laparoscopic inguinal hernia repair will stop Aspirin 5-7 days before the surgery
45688360|NCT02603640|Device|MRI scanning|
45752095|NCT02985320|Biological|Three-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
45752096|NCT02985320|Biological|Three-dose regimen of low dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
45752097|NCT02985320|Biological|Three-dose regimen of commercialized sIPV|The control vaccine was manufactured by Chinese Academy of Medical Sciences.
45752098|NCT02985320|Biological|Three-dose regimen of commercialized IPV|The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).
46049084|NCT04143802|Drug|Dulaglutide|Administered SC
46049085|NCT04143802|Drug|Placebo|Administered SC
46049086|NCT00684970|Drug|Hamsa-1™ TL-118|Once daily Hamsa-1™ TL-118
46049087|NCT00685048|Behavioral|10 minutes of psycho-education|Patients review with study therapist a brochure about types of gambling people engage in and relationships between gambling, drug use, moods, and legal problems.
46049088|NCT00685048|Behavioral|10 minutes of brief advice|Patients will review with study therapist a brochure and advice about problem gambling. It will also contain methods for reducing gambling.
46049089|NCT00685048|Behavioral|four 50-minute individual therapy sessions of MET & CBT|MET & CBT
45361166|NCT00819416|Drug|5% albumin|5% albumin for the first 7 days of care in the ICU
45688361|NCT02532452|Biological|Viral Specific VST Infusion|"3rd party VSTs will be infused into immunocompromised patients who have evidence of viral infection or reactivation defined as any of the following:~Blood adenovirus PCR ≥ 1,000~Blood CMV PCR ≥ 500~Blood EBV PCR ≥ 9,000~Plasma BKV PCR >1,000~Plasma JC Virus PCR > 1,000~Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity by PCR or culture in one or more sites.~Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~Evidence of EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies.~Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy.~Evidence of PML or other CNS infection due to JC virus."
45688362|NCT02498847|Behavioral|ENGAGE|"Participants are introduced to ENGAGE program by the study OT. The ENGAGE program is located on a website and has several modules. The modules include a video in which a health provider is featured. This health provider gives a short presentation on a topic related to OA, symptom management or lifestyle change. Within each module, there is downloadable homework and additional information which can be printed. The modules are:~What is Osteoarthritis?~Information about treatments~Exercise~Sleep hygiene~Relaxation~Pleasant Activity Scheduling~Goal setting~Problem Solving~Pacing~Communication"
45688363|NCT02487394|Procedure|Exhaled Breath Condensate (EBC)|Collection of EBC condensate
45688364|NCT02481648|Other|Exercise|
45688365|NCT02444429|Drug|Corticosteroid boluses Methylprednisolone|"Intensification of the corticotherapy in accordance with the validated protocol for the treatment of classic and subclinical acute rejections: 3 bolus Methylprednisolone 500 mg IV at D1, D2 and D3 then decreasing during 10-15 days at 1mg/kg/d and down to the maintenance dose.~An anti-pneumocystis and anti-CMV prophylaxis will be systemically introduced for 3 months.~The rest of maintenance immunosuppressive regimen (mycophenolate mofetil and anti-calcineurin) will remain unaltered"
46049090|NCT02626546|Procedure|Major surgical procedure|observation of postoperative outcomes
45688366|NCT02444429|Other|No therapeutic modification|No therapeutic modification: continuation of the corticotherapy at the maintenance dose and maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
45688367|NCT02444429|Other|Stop maintenance corticotherapy|Immediate withdrawal of maintenance corticotherapy. Maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
45844923|NCT02059512|Procedure|Group 0|Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.
46049091|NCT00912418|Biological|autologous tumor cells plus GM-CSF-in Adjuvant|"Autologous tumor cells plus 225 ug GM-CSF in-adjuvant: The autologous tumor cells will be administered intradermally. Subjects will be vaccinated over at least a 6 week period (at weeks 0, 1, 2, 4, 5, 6), with responders vaccinated every 4 weeks thereafter for a maximum of 9 vaccinations (up to week 18). Systemic low-dose interleukin-2 will also be administered daily for 6 weeks following the second vaccination at week 1.~Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 vaccinations in a different site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods."
46049092|NCT00682474|Behavioral|Counseling Intervention|Four 30-minute individual student-centered smoking cessation counseling intervention sessions delivered by school nurses to adolescent smokers in grades 9-12
46049093|NCT00682474|Behavioral|Information Intervention|Attention-control comparison condition consisting of four individual sessions with the school nurse to check smoking status and deliver a series of standardized pamphlets on smoking and cessation to adolescent smokers in grades 9-12
45361167|NCT00819416|Drug|Normal Saline|Normal Saline for the first 7 days of care in the ICU
45361168|NCT04005807|Drug|BPN-14967|BPN-14967 oral capsules
45361169|NCT04005807|Drug|Placebo|Oral capsules
45361170|NCT00898092|Genetic|microarray analysis|
45361171|NCT00898092|Genetic|molecular genetic technique|
45361172|NCT00898092|Genetic|mutation analysis|
45361173|NCT00898092|Genetic|polymerase chain reaction|
45361174|NCT00898092|Genetic|reverse transcriptase-polymerase chain reaction|
46049094|NCT00682552|Procedure|A cervico-vaginal cervical smear|12 and 18 months after inclusion, a cervico-vaginal cervical smear will be realized and a new examination colposcopique with a new cervical taking for the search(research) and the detection of the HPV 16 and 18.
46049095|NCT00685204|Drug|Milataxel|Milataxel is a liquid that is dosed orally at 60 mg/m2 on Day 1 of a 21 day cycle. If no toxicities of greater than Grade 1 severity occur, patients will receive 75 mg/m2 for the second and subsequent cycles.
45361175|NCT00898092|Other|diagnostic laboratory biomarker analysis|
45361176|NCT00983697|Procedure|therapeutic conventional surgery|
45361177|NCT00983697|Radiation|fludeoxyglucose F 18|
46049096|NCT00682630|Drug|pyronaridine artesunate clinical trial reference tablets|Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)
45361178|NCT00902460|Drug|midazolam; CP-690,550 + midazolam|Period 1 : 2 mg midazolam oral syrup alone Period 2: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID
45361179|NCT00902460|Drug|CP-690,550 + midazolam; midazolam|Period 1: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID Period 2: 2 mg midazolam oral syrup alone
45361180|NCT00988923|Other|group A: HYPERTHERMIA|All patients were treated for 8 sessions, twice a week, for a total of 4 weeks of treatment. All patients were evaluated at baseline (T0) and after 4 weeks (T1). The first two sessions were sham-treatment for both groups
45361181|NCT00988923|Other|No intervention|the intervention tool was switched in off, only bolus was activated
45361182|NCT02539446|Behavioral|stable condition|
45361183|NCT02539446|Behavioral|unstable condition|
45361184|NCT02539446|Behavioral|attentional focus|
45361185|NCT00989079|Drug|Ertugliflozin|Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.
45361186|NCT00989079|Drug|Placebo to Ertugliflozin|Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution
45361187|NCT00809198|Other|Sodium Hyaluronate|
45361188|NCT00809198|Other|Carboxymethylcellulose sodium|
45361189|NCT00898170|Procedure|myoma removal|surgical removal of myoma by hysterectomy
45479972|NCT02491060|Drug|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
45479973|NCT02491060|Drug|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
45479974|NCT01316900|Drug|GSK573719/GW642444 125/25|125/25 mcg once-daily
45752099|NCT04537247|Procedure|partial nephrectomy for complex renal tumor|removal of tumor with sufficient safety margin with preservation of functioning renal unit (renal tissue with its collecting system, arterial supply and venous as well as lymphatic drainage).
45361190|NCT04006743|Behavioral|The swaddling group|The newborns were placed in a supine position on a 90 cm2 soft fabric for swaddling procedure. The upper side of the bandage was aligned with the shoulder of the newborn. Newborns' arms were put in a flexion position. The top of the body was completely covered with a bandage. The infant's head can move freely. The swaddling procedure took about one minute. In the study, swaddling process was applied 10 minutes before the painful procedure. The swaddled newborns remained in the swaddling during the procedure and for 5 minutes after the procedure.
45479975|NCT01316900|Drug|GSK573719/GW642444 62.5/25|62.5/26 mcg once-daily
45479976|NCT01316900|Drug|GW642444|25 mcg once-daily
45479977|NCT01316900|Drug|tiotropium bromide|18 mcg once-daily
45844924|NCT02059512|Procedure|Group 2|Coronary artery bypass grafting with intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells intramyocardial administration 0.2 ml - 10 injection in the zone of blood supply LAD.
45479978|NCT03714815|Drug|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
46049097|NCT00682630|Drug|pyronaridine artesunate to-be-marketed tablets|Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)
45479979|NCT02490982|Drug|Teriflunomide|The prescription of Teriflunomide administered orally as a 14mg daily compound to RRMS patients.
45479980|NCT03322150|Drug|Atropine|Atropine injection (0.01 mg/kg, max 0.5 mg) 3 minutes before spinal anesthesia
45479981|NCT03322150|Drug|Glycopyrrolate|Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) 3 minutes before spinal anesthesia
46049098|NCT00685282|Behavioral|Cognitive Behavioral Therapy|The intervention (CBT) will focus on teaching specific skills which are adapted for women undergoing fertility related problems. Through the sessions the participants will learn relaxation techniques such as breathing, progressive relaxation, and guided imagery. Furthermore, suggestions for making healthier choices for coping and for releasing tension will be reviewed and discussed, with an emphasis on making healthy lifestyle changes with balance and perspective rather than in a punishing or depriving way. Each session will consist of: 20 minutes of stress-reduction behavioral relaxation, 40 minutes of cognitive restructuring and 30 minutes personal tailoring of the behavioral homework between each session.
45479982|NCT00936390|Drug|bicalutamide|Administered orally at a dose of one 50 mg tablet per day, beginning within (before, same day as, or after) 10 days of the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.
45688368|NCT02318342|Drug|Warfarin|Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
45844925|NCT02059902|Drug|Lidocaine|Lidocaine infusion runs for a total of 24 hours
46049099|NCT00875056|Drug|Vorinostat|Two 100 mg oral capsules of vorinostat, twice daily (400 mg/day), on Days 1 through 14 of each 21 day cycle
45479983|NCT00936390|Drug|flutamide|Administered orally at a dose of 250 mg (two 125-mg capsules) three times a day for a total daily dose of 750 mg, beginning within (before, same day as, or after) 10 days of with the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.
45479984|NCT00936390|Drug|LHRH agonist (antagonist) therapy|LHRH agonist (antagonist) therapy consists of leuprolide, goserelin, buserelin, triptorelin, or degarelix. The manufacturer's instructions should be followed. The first administration occurs with the start of anti-androgen treatment 8 weeks prior to the start of RT. The total duration of LHRH agonist (antagonist) therapy is 6 months.
45479985|NCT00936390|Radiation|Dose-Escalated Radiation Therapy|External beam radiotherapy (EBRT) as 3D Conformal Radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT). Brachytherapy is optional, at the discretion of the treating physician. Patients treated entirely via EBRT receive 79.2 Gy delivered in 1.8 Gy fractions. Patients who receive brachytherapy as a component of their RT receive 45 Gy EBRT in 1.8 Gy fractions. Low-dose brachytherapy boost occurs following the EBRT portion of treatment no more than 4 weeks following its completion.High-dose rate brachytherapy boost is delivered in 2 fractions separated by a minimum time span of 6 hours and the implant(s) may be performed during the EBRT portion of the treatment or within 1 week prior to its initiation or following its completion.
45479986|NCT03326596|Drug|Tranexamic Acid 1000 mg/10ml normal saline infusion|Infusion of Tranexamic Acid (Cyklokapron) to all consented women with the delivery of the anterior shoulder of the infant
45479987|NCT03499873|Drug|Nepafenac 0.3% Oph Susp|Nepafenac 0.3% Ophthalmic suspension (experimental product)
45752100|NCT05338047|Drug|Pegfilgrastim|Single 6mg dose of generic pegfilgrastim or brand name pegfilgrastim, at day +1 after autotransplant.
45752101|NCT04407884|Device|Soovu Labs Inc. Pain Relief System|Longnitual follow-up
45844926|NCT02059902|Other|Placebo|Normal saline runs for a total of 24 hours
45844927|NCT02060058|Drug|Stop trial intervention for boceprevir, PEG-IFN and RBV|"Stop trial intervention for patients with 32 week therapy (arm A): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for patients with 48 weeks therapy (arm B): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for for null responder or cirrhotic patients: (arm C) for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped."
45844928|NCT02060526|Drug|Recombinant human heparan N-sulfatase [rhHNS]|Recombinant human heparan N-sulfatase [rhHNS]
46049100|NCT00682708|Dietary Supplement|PlumpyNut|
46049101|NCT00682708|Dietary Supplement|PlumpyDoz|
46049102|NCT00685594|Drug|cholecalciferol|20.000 IU cholecalciferol per week for 5 years versus placebo
45361191|NCT04006743|Behavioral|The expressed breast milk group|In terms of the reliability of the study results, nothing was orally given to the preterm infant at least 30 minutes before the procedure. As recommended in the studies, 2 ml oral breast milk was given to preterm infants before the procedure. In the study, breast milk was given slowly to the upper part of the tongue of each preterm infant from his/her own mother as a single dose before OGT insertion. As a result, preterm was ensured to take all of 2 ml breast milk by reducing the aspiration risk of breastmilk. The breast milk was given without touching the tip of the injector to the newborn's mouth. The preterm infants were not allowed to suck the tip of the injector.
45361192|NCT04006743|Behavioral|The facilitated tucking group|Facilitated tucking was given in supine position by holding the arm and legs of the preterm infant to the body by the researcher. In line with the literature, facilitated tucking was initiated 3 minutes before OGT insertion in order for the newborn to feel the fetal position and to cope with the painful procedure. The preterm was kept in fetal position during the procedure and for 5 minutes after the procedure.
45361193|NCT04006743|Behavioral|The swaddling and expressed breast milk group|Swaddling procedure was conducted by the researcher to the preterm infant 10 minutes before the OGT insertion procedure. 2 ml breast milk was administered by the researcher to preterm using a sterile injector as a single dose for 2 minutes before OGT insertion procedure. The preterm was remained in swaddling during the OGT insertion procedure and for 5 minutes after the process.
45479988|NCT03499873|Drug|Placebos|Placebo
45688369|NCT02315703|Biological|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelop (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
45479989|NCT03499873|Drug|Nepafenac 0.3% Oph Susp (reference)|Nepafenac 0.3% Ophthalmic suspension (Innovator)
45688370|NCT02315703|Biological|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
45688371|NCT02315703|Biological|gp140 DP Low-dose|The gp140 DP vaccine containing 50 mcg of total protein, mixed with aluminum phosphate adjuvant (0.425 mg aluminum), per 0.5 mL injection administered intramuscularly.
45844929|NCT02060838|Procedure|Acute normovolemic hemodilution (ANH)|Blood is drawn from our patients pre-bypass after obtaining the arterial line and administered back to the patient after separation from cardiopulmonary bypass (CPB) and reversal of heparin with protamine.
45688372|NCT02315703|Biological|gp140 DP High-dose|The gp140 DP vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
45688373|NCT02315703|Drug|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
45688374|NCT02296216|Device|Gamma Knife radiosurgery|To determine potential long-term (superior to 10 years) extra-pituitary side-effects of Gamma Knife radiosurgery in patients treated for Acromegaly
45688375|NCT02258165|Device|PET/CT|"PET/CT (without respiratory gating) is performed on an ad-hoc basis in patients with advanced ovarian cancer in the lead up to surgery. The sensitivity of PET/CT for detecting low volume pleural disease is likely reduced by respiratory motion during the ten minute acquisition time over the chest. By freezing this respiratory motion with respiratory gating, we hope that gated PET/CT detection of pleural metastases will improve over non-gated PET images."
45844930|NCT02061384|Drug|13-cis retinoic acid|Accutane is used for the treatment of severe acne
46049103|NCT00685594|Drug|Placebo|Placebo capsule once a week, identical to cholecalciferol capsule
46049104|NCT04139746|Procedure|Scleral Buckling|Limbal 360 degrees peritomy of the conjunctiva was performed and the four recti muscles were isolated with 4 silk threads 4-0. A width-2 mm silicone encircling band was placed and sutured with 5-0 mersilene on the 4 quadrants of the sclera. Anterior chamber paracentesis was performed, draining about 0.3 mL of aqueous humour, and a buckle (220, 501, 506, or 516; Mira, Waltham, MA, USA) was sutured over the break. In all cases, the drainage puncture was executed at a distance of 11 mm from the limbus, in the area of greatest amount of subretinal fluid. Soon after the drainage puncture, a balanced salt solution (BSS) injection was performed in order to compensate the escape of the subretinal fluid.
45844931|NCT02061384|Drug|Calcitriol|Calcitriol is a form of vitamin D given twice daily (BID)
45688376|NCT02154516|Device|ODH Hip System|
45844932|NCT02061696|Device|Vascular Access Device|AXERA 2 Access System with Reduced Manual Compression
45361194|NCT04006743|Behavioral|The facilitated tucking and expressed breast milk group|Facilitated tucking method was applied right after giving 2 ml breast milk by the researcher to the preterm 3 minutes before OGT insertion procedure. Preterm newborn remained in facilitated tucking during the procedure and for 5 minutes after the procedure.
45361195|NCT00986505|Drug|Lidocaine|Intravenous lidocaine once a week
45361196|NCT00983775|Device|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
45688377|NCT02134184|Biological|Fluzone® 2012-2013 Formula NDC No 498281-012-50|This vaccine is given intramuscularly
45361197|NCT00983775|Device|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
45688378|NCT02063724|Biological|HER-2 pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 10^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
45844933|NCT02061696|Procedure|Standard Manual Compression|Closure procedure by Manual Compression
45844934|NCT02061774|Drug|Acetaminophen|1 gram of intravenous Acetaminophen
45361198|NCT04017858|Behavioral|Multiprofessional and educational Program prior to Total knee replacement TKA. (PARQVE TKA).|"Patients will participate in two days of about knee OA lectures two months apart, will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy followed by 7 sessions with the physical educators team. Following this program, patients will be operated (total knee arthroplasty).~Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively Costs will be evaluated for cost-effectiveness and cost-utility analysis"
45688379|NCT02029846|Drug|Standard Treatment|traditional drugs only
45688380|NCT02029846|Drug|Incretin-Based Treatment|incretin-based drugs
45688381|NCT02028884|Drug|Satralizumab|Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
45688382|NCT02028884|Drug|Placebo|Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
45688383|NCT02028884|Drug|Baseline Treatment|As specified in the protocol, one of the following drugs at a stable dose is required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA); mycophenolate mofetil (MMF); or oral corticosteroids (CS). For participants aged 12 to 17 years at the time of informed consent, baseline treatment with AZA or MMF in combination with oral CS is also permitted. Change or termination of baseline treatment is only permitted during the open-label extension period.
45688384|NCT02020694|Drug|Vitamin D|
45688385|NCT02020694|Drug|Placebo (for vitamin D)|
45688386|NCT02019875|Drug|Rifampin|P450 inducer
45688387|NCT02019875|Drug|Clarithromycin|CYP3A4 and Pgp inhibitor in both intestine and liiver
45688388|NCT02019875|Other|Grapefruit Juice|CYP3A4 inhibitor in intestine
45688389|NCT02019875|Other|Placebo|
45844935|NCT02061774|Drug|Placebo comparator|placebo comparator .9% NaCl (sodium chloride) 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
45844936|NCT02062008|Device|PET-MRI|PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
45844937|NCT02062710|Drug|diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo|diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg; placebo.
45361199|NCT04017858|Behavioral|Patients will be submitted to total knee replacement.|"Patients will be submitted to total knee replacement, without Multiprofessional and educational Program Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform the STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively"
45361200|NCT03687333|Drug|ALGLUCOSIDASE ALFA (MYOZYME)|"Pharmaceutical form: cake or powder for injection~Route of administration: intravenous infusion"
45361201|NCT00902616|Dietary Supplement|L-arginine|3gm TDS for three months
45361202|NCT00902616|Dietary Supplement|Placebo Lactose powder|3gm TDS for 3 months
45361203|NCT00984087|Device|TMS with Neurostar TMS Therapy System|20 sessions with 1680 pulses per session at 10 Hz with a 4-second pulse train, stimulation at 100% motor threshold,
45361204|NCT00898326|Other|biopsy|Conduct prostatic needle biopsy at 36-39 months-after brachy therapy. Basic method is by transectal ultra-sound-guided systematic biopsy,; systematic sextant biopsy which involves samples from both seminal vesicles is adopted as much as possible.
45361205|NCT00989313|Drug|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
45361206|NCT04035954|Other|exercise|The control group will continue the routine NDT: Neurodevelopmental Therapy-based physiotherapy program twice a week. The treatment group will participate in clinical pilates exercises for 2 hours / day for 1 hour / 8 weeks. They will also continue their weekly routine physiotherapy programs.
45361207|NCT02539524|Other|Yoga bhastrika pranayama breathing exercise|Bhastrika Pranayama is formed by a set of 20 nasal forced and rapid expirations, followed by passive nasal inspirations, followed by 1 alternate nasal breath which always begins through the right nostril, and has a retention between intake and outflow. The set of this breathing exercise is supposed to bring respiratory relief.
45844938|NCT02062710|Drug|diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan|diphenhydramine 25 mg and phenylephrine 10 mg; placebo; dextromethorphan 30 mg.
45844939|NCT02062710|Drug|dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo|dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg; placebo
45479990|NCT01305707|Device|C-ECT|"C-ECT will be administered through a Thrymatron System IV device (Somatics, LLC, ISO 13485:2003). Electrode placement will be bilateral and energy administered during consolidation treatment will be same used in the acute episode. C-ECT will be given weekly for the first month, fortnightly for the following two months and monthly during the next 6 months. A total of 14 C-ECT sessions will be given over 9 months of treatment.~Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Drugs will be obtained as usually from the National Health System and will be prescribed according to data sheet and it will have a duration of 15 months."
45479991|NCT01305707|Drug|PHARMACOTHERAPY|Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Psychotropics will be obtained as usually from the National Health System and will be prescribed according to data sheet and will have a 15 month duration.
45688393|NCT01907009|Drug|Melphalan|Patients will receive Melphalan in three cycles In the first cycle they recieve 60mg/m2 and then 40mg/m2 in the next two cycles.
45688394|NCT01907009|Drug|Lenograstim|"Starting Lenograstim will be at 10mcg/kg/day and between cycles at 10mcg/kgs/day.~After the third cycle patient will receive 263mcg/day for 10 days."
45688395|NCT01882933|Drug|HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin|After the D2 resection is complete HIPEC can start. A roller pump forces the chemotherapy solution (oxaliplatin 250 mg/m² with 2 Liters of G5%/m²) into the abdomen through the inflow catheter and pulls it out through the drains. A heat exchanger keeps the intraperitoneal fluid at 42°-43°C.
45688396|NCT01882933|Procedure|Curative gastrectomy|All the patients will undergo a D1-D2 gastrectomy carried out according to Japanese guidelines and to the European recommendations for the preservation of spleen and pancreas
45688397|NCT01821976|Procedure|Ertl Procedure|
45688398|NCT01821976|Procedure|Burgess Procedure|
45361208|NCT02539524|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
45688399|NCT01787929|Procedure|hemiarthroplasty for displaced femoral neck fractures|Hemiarthroplasty is a surgery for displaced femoral neck fractures
45688400|NCT01778738|Procedure|Bariatric surgery, either gastric bypass surgery or sleeve gastrectomy|Vertical sleeve gastrectomy or a gastric bypass surgery in morbidly obese individuals with type 2 diabetes. Random allocation to surgical intervention
45361209|NCT00984243|Procedure|PHOTODYNAMIC THERAPY (PDT)|"Photodynamic Procedure:~Photofrin II will be injected at a dosage of 2 mm/Kg intravenously. Laser treatment will take place 40-50 hours later. An argon-dye or an excimer-dye laser tuned to 620-630 nm will be used.~It is anticipated that a microlens fiber will be used in almost all cases, but a cylinder-diffusing fiber can be used to treat lesions in segmental bronchi if needed.~Argon-dye laser: Power settings 200 milliwatt (mW) microlens and 400 mW for cylinder Excimer laser: 4 milliJoules (mJoules)/pulse at 30 hertz for the microlens~Energy density:~Argon-dye laser: 200-300 Joules/cm^2 Excimer-dye laser: 100-200 Joules/cm^2"
45361210|NCT00815750|Other|Information Gathering|An information gathering phase leading to development of a new decision aid.
45479992|NCT04523168|Device|The Neovasc Reducer™ System|A stainless-steel mesh pre-mounted on a customized hourglass shaped balloon catheter, is designed to create a focal narrowing in the lumen of the CS to generate a pressure gradient across it.
45688401|NCT01778738|Procedure|Sleeve gastrecomy|Vertical sleeve gastrectomy
45688402|NCT01778738|Procedure|Bastric bypass|Gastric bypass surgery
45688403|NCT01744145|Other|Interventional 40-60|This group will receive the intervention aged 40-60
45688404|NCT01744145|Other|Interventional 60 and above|This group will receive the intervention aged 60 and above.
45688405|NCT01726582|Drug|Milestone 1: Targeted chemotherapy prior to surgery|The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
45688406|NCT01726582|Radiation|Milestone 2: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or intensity-modulated radiation therapy (IMRT) techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
45688407|NCT01726582|Drug|Milestone 3: Targeted chemotherapy prior to surgery|The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
45361211|NCT00815750|Other|Decision Aid|To test the newly developed decision aid.
45688408|NCT01726582|Radiation|Milestone 3: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
45361212|NCT00894582|Procedure|Components separation hernia repair|Components separation is one method currently employed for repair of massive ventral hernias. In this study we simply measured the volume of patients' abdomen (who were already undergoing this surgery) as well as their pulmonary function both pre and postoperatively.
45361213|NCT05712681|Drug|JP-1366 20mg tablet|T : JP-1366 20mg tablet after the meal
45479993|NCT04493086|Diagnostic Test|FFRCT-angio|According to invasive coronary angiography (CAG) images, image databases of critical lesions, diffuse lesions, left main trunk lesions, ostium lesions and bifurcation lesions were established. In order to ensure that the position of the pressure guide wire sensor is consistent with that of FFRCT-angio, a professional with unknown FFR results is used to mark the position of the pressure wire sensor on the CAG image. The clinical information and characteristics of coronary artery lesions were collected, and the baseline data of patients were completed. The accuracy and diagnostic performance of FFRCT-angio in the diagnosis of functional stenosis (FFR < 0.8) were evaluated with FFR value measured by pressure guide wire as reference standard.
45688409|NCT01726582|Drug|Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery|A biopsy of the borderline tumor does not provide a molecular profile that can be used to target treatment. The treatment will be standard FOLFIRINOX chemotherapy regimen.
45688410|NCT01726582|Radiation|Milestone 4: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
45361214|NCT05712681|Drug|JP-1366 20mg tablet|R : JP-1366 20mg tablet under fasting condition
45688411|NCT01726582|Drug|Milestone 5: Targeted chemotherapy after surgery|The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
45688412|NCT01726582|Radiation|Milestone 5: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
45688413|NCT01726582|Drug|Milestone 6: Gemcitabine after surgery|Chemotherapy treatment with Gemcitabine.
45688414|NCT01726582|Radiation|Milestone 6: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
45688415|NCT01726582|Radiation|Milestone 7: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
45688416|NCT01726582|Drug|Milestone 8: Targeted chemotherapy after surgery|The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
45688417|NCT01726582|Drug|Milestone 9: Gemcitabine after surgery|Chemotherapy treatment with Gemcitabine.
45688418|NCT01726582|Other|Milestone 10: No additional therapy after surgery|The molecular profile of the tumor that was removed during surgery points to a lack of treatment affect for available therapies. No additional therapy is recommended.
45688419|NCT01718743|Drug|Ixazomib Citrate|Given PO
45361215|NCT00898404|Other|laboratory biomarker analysis|Correlative studies
45361216|NCT05712603|Diagnostic Test|FIB4-score|A score which estimates the risk for advanced liver fibrosis, based on: age, ALT, AST and thrombocytes
45361217|NCT05712603|Diagnostic Test|Vibration controlled transient elastography|VCTE measures the speed of a mechanically generated shear wave across the liver to derive a liver stiffness measurement (LSM), a marker of hepatic fibrosis
45361218|NCT05712603|Diagnostic Test|Enhanced Liver Fibrosis test|The ELF-test is a non-invasive blood test that measures three direct markers of liver fibrosis: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1).
45361219|NCT00898482|Other|This is a non-intervention study for all groups.|This is a non-intervention study.
45361220|NCT00898482|Other|study of socioeconomic and demographic variables|Non-intervention study.
45361221|NCT03667443|Dietary Supplement|Myo-inositol + folic a. + α-lactalbumin|3 months of treatment
45361222|NCT03667443|Dietary Supplement|Myo-inositol + folic a.|3 months of treatment
45361223|NCT00902694|Behavioral|ACHIEVE Intervention|Group and individual weight loss counseling and group physical activity classes for 18 months
45361224|NCT00902694|Other|Control|group health classes quarterly with topics not related to weight
45361225|NCT03646071|Drug|RX108|RX108
45361226|NCT00902772|Drug|Lorazepam|mg, oral dose
45361227|NCT00902772|Drug|AZD7325|mg, oral dose
45361228|NCT00902772|Drug|Placebo|
45361229|NCT03637647|Diagnostic Test|Cardiopulmonary exercise testing|The CPET involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.
45844940|NCT02062710|Drug|dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa|dextromethorphan 30 mg; placebo; diphenhydramine 25 mg and phenylephrine 10 mg
45844941|NCT02062710|Drug|placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan|placebo; diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg
45361230|NCT00894660|Drug|Amodiaquine (Test)|Oral tablet, single dose, 1 X 300 MG
45361231|NCT00894660|Drug|Amodiaquine (Comparator)|Oral tablet, single dose, 2 X 150 MG
45361232|NCT05712525|Diagnostic Test|G-Tech Wireless Patch System (WPS)|Noninvasive monitoring of myoelectrical signals
45361233|NCT02539212|Device|microwave ablation|ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
45361234|NCT02539212|Device|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat hepatocellular carcinoma patients
45361235|NCT00721409|Drug|PD 0332991|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
45361236|NCT00721409|Drug|letrozole|2.5 mg/d tablets orally on a continuous regimen
45361237|NCT00721409|Drug|letrozole|2.5 mg/d tablets orally on a continuous regimen
45844942|NCT02062710|Drug|placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa|placebo; dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg
45844943|NCT02063178|Behavioral|Phone-based sessions (28 total) on a structured schedule|28 sessions will be reviewed weekly and then bi-weekly with a trained motivational interviewing counselor for those individuals randomly assigned to the counselor-initiated condition.
45844944|NCT02063178|Behavioral|Phone-based sessions upon request|For those individuals randomly assigned to the self-paced condition, the 28 sessions are still available to them, the participant has to call to initiate sessions.
45361238|NCT05712369|Other|Blood sampling|"Before the anti-CD20 monoclonal antibodies treatment (e.g. Rituximab/Ofatumumab) and after 6, 9 and 12, 24 months from the first infusion the following blood samples will be collected for the analysis of lymphocyte subpopulations:~50/100 mL of blood (20 mL for pediatric patients) for Peripheral Blood Mononuclear Cells (PBMCs) isolation.~8 mL of blood (both adult and pediatric) to obtain serum. Serum will be obtained by standard centrifugation and PBMC will be isolated by Ficoll-Paque® density gradient centrifugation, according to manufacturer's instruction."
45844945|NCT02063178|Behavioral|Weight self-monitoring|Each randomized participant will be given a Body Trace scale that will electronically record their weight.
45361239|NCT02539290|Behavioral|Detection of ovulation|Detecting the luteinizing hormone surge using test sticks in a urine sample
45361240|NCT02539290|Procedure|Uterine flushing|Injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge
45361241|NCT02539290|Procedure|Vaginal flushing|Injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge
45361242|NCT02539290|Behavioral|Sexual intercourse|Sexual intercourse within 12 hours after intervention
45688420|NCT01718743|Drug|Lenalidomide|Given PO
46049105|NCT04139746|Procedure|Drainage-Injection-Pneumoretinopexy|According to the location of the sub-retinal fluid, a quadrant-flap of conjunctiva was opened. Indirect ophthalmoscopy evaluation was also used intraoperatively to localize the break and the subretinal fluid drainage site: in this area a vicryl 6-0 thread was passed through the sclera, about 9-10 mm posteriorly from the limbus, to facilitate the surgical maneuvers. The drainage puncture was performed 11 mm posteriorly from the limbus, having attention not to perform it directly above the site of the retinal break. In detail, a 2 mm radial sclera incision was created with a 15° disposable knife. The incision was cautiously deepened down to the choroid, which was finally perforated by a lachrymal dilator having a blunt tip. Soon after beginning the subretinal fluid drainage, an injection of BSS was performed in the opposite quadrant of the sclera (4 mm from the limbus) in order to allow an optimal spillage of the subretinal fluid and to flatten the retina.
46049106|NCT00685672|Drug|adrenalin|adrenalin 2 microgram pr ml placebo
46049107|NCT00685672|Drug|placebo|Saline instead of adrenaline in the epidural mixture
45361243|NCT00898716|Drug|BMS-754807|Tablets, Oral, 20 mg, 30 mg, 50 mg, 70 mg, 100 mg, 130 mg, 160 mg, 200 mg once daily, 3-5 months, depending on response
46049108|NCT04143178|Other|Expressive Writing|The expressive writing is a form of writing therapy developed primarily by James W. Pennebaker in the late 1980s consisting of writing about stressful and traumatic experience for 15-20 min for 3 consecutive days, including one's thoughts and feelings. The expressive writing allows people to express and process emotions, feelings, and thoughts related to the life events and consequent changes and this may favor a mental reorganization of the negative events, a greater expression and regulation of the emotions related to them. This intervention could provoke social, emotional, and consequently, psychophysical changes as is showed in patients with chronic diseases and cancer. In the present study, to all participants in the writing group, 5 days after the transplant, has been asked to write for 3 consecutive days, 20 minutes each days about their deepest emotions and feelings related to the chronic failure, the transplant and their expectations after that.
45361244|NCT05277948|Other|active thumbtack needle|"The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY).~The patients were receive a treatment of 2 menstrual cycles"
45361245|NCT05277948|Other|sham thumbtack needle|"The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile sham thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile sham electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY).~The patients were receive a treatment of 2 menstrual cycles"
45361246|NCT00894816|Dietary Supplement|Lactobacillus F19|Infant cereals with the addition of Lactobacillus paracasei subsp. paracasei strain F19 (LF19)10E8 CFU per serving
45361247|NCT00894816|Dietary Supplement|Placebo|Infant cereals without any addition
46049109|NCT04143178|Other|Neutral Writing|Five days after the transplant, to the control group participants has been asked to write for 3 consecutive days 20 minutes a day on an assigned neutral theme (eg. describe 1 object in the room) as objectively as possible, without mentioning their emotions or thoughts related to it.
45361248|NCT00542997|Biological|Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)|IgPro20 is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
45361249|NCT04035720|Other|Quantitative risk|Participants will be able to see a square box that represent the estimated risk of disease progression. They will have to elect making a therapeutic decision based on the description of the case-scenario or based on the estimated prediction as represented in the square box.
45361250|NCT00903084|Drug|Tenofovir Disoproxil Fumarate|300-mg tablet
45361251|NCT00984477|Drug|AZD5122|A single dose of oral suspension
45688421|NCT01718743|Other|Questionnaire Administration|Ancillary studies
46049110|NCT00683176|Drug|Choline Fenofibrate|135 mg
45361252|NCT00984477|Drug|Placebo|A single dose of oral suspension
45361253|NCT00984477|Drug|AZD5122|A single intravenous infusion
45361254|NCT02541006|Drug|Tiotropium 18 mcg|tiotropium 18 mcg once a day
45688422|NCT01713062|Device|Vitelene|THA
45688423|NCT01713062|Device|XLPE|THA
46049111|NCT00683176|Drug|Placebo|Placebo
45688424|NCT01701674|Drug|Ipilimumab|Pre-treatment with ipilimumab (cycle 1): Before the participant's tumor sample is taken to send to the lab for growing the TILs, they will start their first cycle of ipilimumab. This drug is given as an intravenous infusion (through a vein) over a period of about 90 minutes (an hour and a half). Cycle 2 of ipilimumab: About a week after the sample of the participant's tumor was collected for TIL growth (and 3 weeks after their first cycle of ipilimumab), participants will have their second cycle of ipilimumab. This will be another IV infusion, lasting about 90 minutes.
45752102|NCT02111863|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
46049112|NCT02626234|Drug|INC280|
45752103|NCT02111863|Drug|Fludarabine|Fludarabine 25 mg/m^2/day (intravenous piggyback) IVPB daily X 5 days.(The fludarabine will be started approximately 1-2 hours after the cyclophosphamide on Days -5 and -4)
46049113|NCT02626234|Drug|digoxin|
46049114|NCT02626234|Drug|rosuvastatin|
46049115|NCT00685828|Drug|imatinib mesylate|By mouth
46049116|NCT05298982|Behavioral|Early activity and Mobilisation Intervention|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
46049117|NCT00685906|Drug|AZD6140|90 mg tablet taken by mouth 2 times a day for 21 days per cycle
46049118|NCT00685906|Drug|Levonorgestrel and Ethinyl Estradiol (Nordette®)|1 tablet taken by mouth once a day for 28 days per cycle
46049119|NCT00683488|Behavioral|Focus Group|Focus group using and collecting feedback on the CBT/CM intervention.
45361255|NCT02591771|Drug|adrenaline|i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
45361256|NCT00986817|Drug|Terlipressin|Albumin perfusions at the dose 8 g/l of removed ascites and Terlipressin (1mg), administrated before and at the end of the paracentesis.
45361257|NCT00986817|Drug|Placebo|albumin perfusion at the dose 8 g/l of removed ascites and placebo, administrated before and at the end of the paracentesis.
45361258|NCT00572832|Biological|Quadrivalent human papillomavirus vaccine on-time administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given six months after dose 1.
45361259|NCT00572832|Biological|Quadrivalent human papillomavirus vaccine delayed administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given 12 months after dose 1.
45688425|NCT01701674|Procedure|Tumor Infiltrating Lymphocytes (TIL)|Tumor sample for TIL growth in the lab: About 2 weeks after the participant's first cycle of ipilimumab, a sample of their tumor will be collected and sent to the lab for TIL growth. Growing the TILs takes about 6 weeks. If their sample has grown enough TIL cells, participants will continue with the next part of the study. Depending on how long the TILs take to grow in the lab, they may need to repeat some of their laboratory and imaging tests (blood draws, X-rays, and CT or magnetic resonance imaging [MRI] scans). TIL Infusion (inpatient): After completing lymphodepletion, participants will be admitted back into the hospital for IV infusion of the TIL cells.
45752104|NCT02111863|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml 5% dextrose in water (D5W) over 1 hr.
45361260|NCT02591849|Dietary Supplement|Glucagon-like peptide-1 (GLP-1)|
45361261|NCT02591849|Other|Isotonic saline|
45361262|NCT02591849|Other|Hyperglycemic clamp|
46049120|NCT00683488|Behavioral|First Intervention Trial|"Intervention will comprise of approximately 15 weekly sessions.~Exit interviews at the end of each session will assess acceptability, feasibility, and relevance of the intervention.~Quantitative assessment (ACASI) pre and post intervention will document immediate changes in substance use, sexual risk, and adherence to medical care.~Qualitative feedback from interviews with mental health providers and study coordinators will address acceptability and feasibility."
46049121|NCT00683488|Behavioral|Intervention Trial 2|Evaluations/assessments will be similar to those involved for the first intervention trial. Study participants will return for a follow-up visit 3 months after the last intervention session to complete the ACASI.
46049122|NCT00686062|Other|Control - computerized age-appropriate prenatal testing educational brochure|Computerized version of the age-appropriate prenatal testing educational brochure distributed by the State of California.
45361263|NCT00898794|Biological|bevacizumab|
45361264|NCT00898794|Other|coagulation study|
45361265|NCT00898794|Other|laboratory biomarker analysis|
45361266|NCT00898794|Other|platelet aggregation test|
45361267|NCT00986895|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbuteric acid (PBA). PBA is converted to phenylacetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (~17.4mL) delivers an equivalent amount of PBA to40 tablets of NaPBA.
45361268|NCT00898872|Other|cryopreservation|
45361269|NCT02593877|Device|VHA algorithm|Analysis of more than 2,200 trauma subjects has enabled the definition of clinically-relevant VHA thresholds (i.e. ROTEM® and TEG® parameters) and patterns by which it is possible to rapidly identify coagulopathic patients and anticipate the need for massive transfusion. These threshold parameters have been defined and applied to the generation of an evidence-based targeted treatment algorithm (i.e. the Intervention)
45361270|NCT05712135|Other|supine position|The patient group whose cuff pressure was measured in the supine position
45752105|NCT02111863|Biological|4-1BB Selected Tumor Infiltrating Lymphocytes (TIL)|On day 0, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (one to four days after the last dose of fludarabine).
45361271|NCT05712135|Other|prone position|The patient group whose cuff pressure was measured in the prone position
45361272|NCT05712135|Other|semi-fowler position|The patient group whose cuff pressure was measured in the semi-fowler position
45844946|NCT02063178|Behavioral|Dietary and physical activity self-monitoring|Each randomized participant will be given a free account to Lose It! Premium, an online food/activity diary for self-monitoring.
45844947|NCT02063178|Behavioral|Scheduled tailored interventionist feedback|Randomly assigned participants to the counselor-initiated condition will receive feedback on their progress throughout their sessions with their assigned interventionist.
45844948|NCT02063178|Behavioral|Dietary goals|Each randomized participant will receive a daily calorie goal range based on their current weight, gender, and BMI.
45844949|NCT02063178|Behavioral|Meal replacements|Randomized participants will receive coupons for meal replacements including oatmeal and popcorn.
45361273|NCT03948113|Other|Dialysis|
45361274|NCT02540148|Device|Nova Oculus™ Micro-current electrical stimulation|Active treatment with transpalpebral micro-current electrical stimulation device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
45361275|NCT02540148|Device|Nova Oculus™ Micro-current electrical stimulation - Sham treatment|Non-active treatment with transpalpebral micro-current electrical stimulation SHAM device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
45361276|NCT04086719|Drug|BMS-986165|Oral administration of tablet BMS- 986165
45361277|NCT04086719|Drug|Pyrimethamine|Oral administration of Pyrimethamine in combination with BMS-986185
45361278|NCT00898950|Drug|Aspirin|Aspirin 75mgs/day orally for 2 weeks.
45361279|NCT00898950|Drug|Aspirin|300mgs/day orally for 2 weeks
45361280|NCT00898950|Drug|Aspirin|aspirin 900mgs QID orally for 2 weeks
45361281|NCT00898950|Other|placebo tablet|placebo tablet with lactose and excipients.
45361282|NCT04086797|Dietary Supplement|IQP-AE-103|1980 mg
45361283|NCT04086797|Dietary Supplement|Placebo|Placebo
45361284|NCT04034784|Device|Discrete(TM)|A designated volume of Discrete(TM) (according to cohort) is applied intraperitoneally
45361285|NCT04034784|Other|Control Lactated Ringer's Solution (Control LRS)|A designated volume of LRS (according to cohort and equivalent to volume of Discrete(TM)) is applied intraperitoneally
45361286|NCT03622515|Combination Product|Anesthesia level and cerebral perfusion pressure|Anesthetic dose and blood pressure
45361287|NCT00899028|Genetic|comparative genomic hybridization|
45361288|NCT00899028|Genetic|fluorescence in situ hybridization|
45688426|NCT01701674|Drug|Administration of Lymphodepletion|Lymphodepletion (inpatient hospital stay for about 2 days plus outpatient drug dosing for 5 days): About 4 weeks after their second cycle of ipilimumab, participants will be admitted to the hospital for their first two days of receiving the chemotherapy drug, cyclophosphamide. This drug will be given as an intravenous (IV, meaning through the vein) infusion. After 2 days of receiving cyclophosphamide, if their study doctor thinks that they are well enough, you will be discharged from the hospital and will return for the next 5 days in a row for outpatient IV infusions of the second lymphodepletion chemotherapy, fludarabine.
45361289|NCT00899028|Genetic|gene expression analysis|
45361290|NCT00899028|Genetic|microarray analysis|
45688427|NCT01701674|Drug|Cyclophosphamide as Part of Lymphodepletion|
45361291|NCT00899028|Genetic|protein expression analysis|
45361292|NCT00899028|Other|immunohistochemistry staining method|
45361293|NCT00899028|Other|laboratory biomarker analysis|
45361294|NCT00899028|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
45361295|NCT00899028|Other|medical chart review|
45361296|NCT00899028|Procedure|diagnostic bronchoscopy|
45361297|NCT05279235|Drug|JT001|Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days
45688428|NCT01701674|Drug|Fludarabine as Part of Lymphodepletion|
46049123|NCT00686062|Other|PT Tool - interactive, computerized, prenatal testing decision tool|An interactive, computerized prenatal testing decision-assisting tool (PT Tool).
46049124|NCT04139824|Drug|Xanthine Oxidase Inhibitor|LC350189 200mg qd
45361298|NCT05279235|Drug|JT001 placebo|Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days
45361299|NCT05279235|Drug|Favipiravir|Day 1: 1600mg, Q12H X 1 day; Day 2~5: 600mg, Q12H X 4 days
45361300|NCT05279235|Drug|Favipiravir placebo|Day 1: 1600mg, Q12H X 1 day; Day 2~5: 600mg, Q12H X 4 days
45361301|NCT00903318|Behavioral|Questionnaire|Questionnaire about family's characteristics taking about 30-35 minutes to complete.
45361302|NCT03597165|Other|Incidental Genomic Sequencing Results|"Patient will receive GS results related to their primary indication (cancer), as well as the option to learn incidental GS results. Incidental results will be categorized into five bins based on Berg et al.'s framework (medically actionable and pharmacogenetic, common disease SNPs, Mendelian conditions, early-onset brain diseases, and carrier status). In pre-test counseling, patients will have the option to select which bins of incidental results they would like to learn, if any."
45688429|NCT01701674|Drug|High Dose IL-2|High dose IL-2 (continued inpatient): Participants will remain in the hospital following TIL infusion for receiving high dose IL-2 and recovery. The IL-2 will be given three times per day for about 3-5 days as an IV bolus (meaning through the vein, more quickly than other infusions - in about 15 minutes each dose). Participants will remain in the hospital for approximately 7-14 days until they have recovered from the IL-2 treatments.
45688430|NCT01701674|Biological|Adoptive Cell Therapy with TIL|
45688431|NCT01686126|Drug|Levonorgestrel|Intrauterine device
45688432|NCT01686126|Drug|Metformin|oral medication
45752106|NCT04031768|Other|Timing of rest prior to blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which they rest prior to each set of measurements.
46049125|NCT04139824|Drug|nonsteroidal anti-inflammatory drug|Naproxen 500mg BID
46049126|NCT00940602|Drug|Deferasirox|Deferasirox provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
46049127|NCT00940602|Drug|Placebo|Inactive ingredients used as a placebo comparator, provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
45361303|NCT03597165|Other|GS Results for Primary Indications only|Patients will receive GS results related to the primary indication (cancer) only.
45361304|NCT04035252|Diagnostic Test|Carotid artery reactivity test (CAR-test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved. During this test as well the carotid artery as the abdominal aorta will be visualized using ultrasound.
45361305|NCT03917823|Device|Cryoneurolysis|The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods for the target intercostal nerves.
45361306|NCT03917823|Device|Sham comparator|For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
45361307|NCT00229723|Drug|gefitinib (Iressa)|250 mg oral tablet
45361308|NCT00229723|Drug|cisplatin|intravenous infusion
45361309|NCT00229723|Radiation|radiotherapy|radiation therapy
45361310|NCT00229723|Drug|Gefitinib (Iressa)|500 mg oral tablet
45361311|NCT04035798|Drug|Memantine or placebo|BP-II patients who are older than 40 years old will be recruited, and allocate them to add-on memantine or placebo plus standard valproic acid treatment in a 1: 1 ratio. The participants will receive memantine 5mg/day or placebo treatment for 12 weeks.
45361312|NCT00894894|Drug|MP-470|escalating daily doses of amuvatinib
45361313|NCT00894894|Drug|amuvatinib (MP-470)|escalating doses of daily amuvatinib
45361314|NCT00903474|Other|questionnaire administration|
45361315|NCT00903474|Other|study of socioeconomic and demographic variables|
45361316|NCT00903474|Procedure|CAM exercise therapy|
45361317|NCT00903474|Procedure|psychosocial assessment and care|
46049128|NCT02626390|Other|Frequent instructions/feedback and an Internal Focus of Attention|
46049129|NCT02626390|Other|Minimal instructions/feedback and an External Focus of Attention|
45361318|NCT00903474|Procedure|quality-of-life assessment|
45361319|NCT00903474|Procedure|stress management therapy|
45361320|NCT03799653|Other|No intervention|This is a prospective observational study, and there is no intervention.
45361321|NCT01075477|Drug|rituximab [Mabthera/Rituxan]|As prescribed by physician
45361322|NCT04006275|Drug|Sonovue and Sonazoid|"Subjects were randomized to receive SonoVue firstly and Sonazid secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at our department for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
45361323|NCT04006275|Drug|Sonazoid and Sonovue|"Subjects were randomized to receive Sonazoid firstly and SonoVue secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at our department for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
45361324|NCT00987051|Procedure|Detection of sentinel node|Coelioscopy or laparotomy (based on the tumor size) after a colorimetric tracer injection
45361325|NCT01075555|Drug|pravastatin sodium|
46049130|NCT00686140|Drug|celecoxib|400mg/day, twice a day, 12 weeks
45361326|NCT01075555|Drug|sorafenib tosylate|
45361327|NCT05517837|Drug|BMS-986421|Specified dose on specified days
45688433|NCT01531582|Drug|minocycline|The participant's parent or guardian will be instructed to administer minocycline caplets by mouth twice daily. Parents or guardians will be instructed to avoid dairy products, antacids, or any vitamin preparation that contains any divalent or trivalent cations (e.g. Aluminum, Calcium, Magnesium, etc.) for one hour prior to, and two hours after study medication administration.
45361328|NCT05517837|Other|Placebo|Specified dose on specified days
46049131|NCT00686140|Drug|Placebo|twice a day, 12 weeks
45361329|NCT03972787|Device|Proactive social robot|ElliQ, is a new type of robotic technology aimed at reducing loneliness and social isolation in older adults. It differs from other social/companion robots on the market, as it leverages artificial intelligence to create personalized and interactive experiences for the user, while also proactively offering prompts (such as reminding the user to stay hydrated) and suggesting and initiating various activities for the user (such as offering to play a game). This social companion adapts to the personalities and interests of the older adult, creating a personalized experience and recommending content the user may enjoy such as news, music, TED talks, and cognitive games.
45361330|NCT00606684|Drug|GW642444 6.25|GW642444 6.25
45361331|NCT00606684|Drug|GW642444 3mcg|once daily
45361332|NCT00606684|Drug|GW642444 12.5mcg|GW642444 12.5mcg
45361333|NCT00606684|Drug|GW642444 25mcg|GW642444 25mcg
45361334|NCT00606684|Drug|GW642444 50mcg|GW642444 50mcg
45688434|NCT01512888|Genetic|CL20-i4-EF1α-hγc-OPT|Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human γc gene.
46049132|NCT00686218|Drug|imatinib mesylate|Given orally
45361335|NCT00606684|Other|placebo|placebo
45688435|NCT01512888|Drug|Busulfan|Given intravenously (IV).
45844950|NCT02063178|Behavioral|Physical activity goals|Each participant will complete the Global Physical Activity Questionnaire which will determine their weekly exercise goals.
46049133|NCT00686218|Drug|panobinostat|Given orally
46049134|NCT00686218|Genetic|polymerase chain reaction|Testing
46049135|NCT00686218|Genetic|protein expression analysis|Testing
46049136|NCT00686218|Genetic|western blotting|Testing
46049137|NCT00686218|Other|flow cytometry|Testing
46049138|NCT00686218|Other|laboratory biomarker analysis|Testing
46049139|NCT00686218|Other|pharmacological study|Testing
45361336|NCT01075633|Procedure|Immunochemical fecal occult blood test And colonoscopy if test is positive|Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.
45361337|NCT01075633|Procedure|Colonoscopy with sedation|Colonoscopy with sedation
45361338|NCT00627926|Biological|Pegylated Interferon Alfa 2a|subcutaneous injection, 180 micrograms once per week
45361339|NCT00627926|Drug|Telaprevir|375 mg tablets administered orally every 8 hours at a dose of 750 mg
45361340|NCT00627926|Drug|Ribavirin|200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg
46049140|NCT00683566|Procedure|electrostimulation|Stimulate STN (at 0, 5, 10, 15, 20, 25, 30, 40, 70 and 130 Hz) in chronically implanted patients at rest and during simple and complex motor tasks
46049141|NCT00683956|Device|ReinLoop control software for patient-specific induction and maintenance of anesthesia|
46049142|NCT00683956|Drug|Propofol|
46049143|NCT00686296|Other|Taliderm™|taliderm™ dressing application once
45361341|NCT00627926|Other|Placebo|Telaprevir matching placebo
45361342|NCT03973021|Biological|Very small embryonic-like stem cell(VSEL)|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
45361343|NCT05711589|Procedure|CBA was performed under intracardiac echocardiography guidance without fluoroscopy|Zero-X group: Patients undergoing ICE-guided CBA
45361344|NCT05711589|Procedure|cryoablation (CBA) was performed under fluoroscopic guidance|cryoablation (CBA) was performed under fluoroscopic guidance
45361345|NCT05711511|Procedure|conventional obturation technique|cold lateral condensation ,this technique involves placing a single cone of gutta-percha (GP) with sealer in the prepared root canal and adding secondary GP cones that are compacted together with the use of a spreader. The cones stay together due to frictional grip and the presence of a sealer
45361346|NCT05711511|Device|Obtura II|"is a popular warm gutta-percha technique that uses a gun to warm and inject the gutta-percha filling into the root canal.Obtura 2 system: The gutta-percha is heated from temperature range of 160C to 200C which is then injected through the needle"
45361347|NCT02539056|Device|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
45361348|NCT05711433|Procedure|pancreatic surgery|pancreaticoduodenectomy and distal pancreatectomy
45361349|NCT05278182|Drug|Naoxintong Capsule|Patients with acute myocardial infarct on the basis of optimal medical therapy will take Naoxintong capsules following directions for 12 months
45361350|NCT05278182|Drug|Placebo|Patients with acute myocardial infarct on the basis of optimal medical therapy will take placebo following directions for 12 months
45361351|NCT00228553|Drug|Armodafinil 100 to 250 mg/day|Armodafinil 100-250 mg: once daily in the morning for patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) or narcolepsy, once daily only on nights worked for patients with shift worker sleep disorder (SWSD).
45688436|NCT01512888|Device|CliniMacs|Isolation and purification of CD34+ stem cells will be done after the unmodified frozen backup is obtained and in accordance with our FDA IND and in accordance with the CliniMacs manual of operations.
46049144|NCT00686296|Other|Taliderm™|Taliderm™ dressing application up to three applications
46049145|NCT00686296|Other|standard wet to dry dressing with gauze|wet to dry dressing standard of care
45688437|NCT01500733|Drug|PCI 32765|420 mg daily
45688438|NCT01493453|Genetic|aCD19z cells, IL2, pre conditioning Cyclophosphamide & Fludarabine|aCD19z T cells IV Day 1. The dose of aCD19z T cells will be determined by dose escalation scheme, starting at 10*9 IL2 given as 15 minute IV infusion every eight hours for up to 12 doses Cyclophosphamide (C) 15mg/kg day -7 and day -6, Fludarabine (F) 25mg/m2 day -5 to day -1.
45688439|NCT01467427|Drug|nonacog beta pegol|A single dose of 40 U/kg will be administered intravenously, i.v. (into the vein) once weekly.
45688440|NCT01436864|Biological|Recombinant Human VEGF Receptor-Fc Fusion Protein|Intravitreal injection of KH902 once per month
45688441|NCT01422187|Drug|Taliglucerase alfa|Taliglucerase infusion every two weeks for 21 months
46049146|NCT00603486|Device|GE DINAMAP with SuperSTAT algorithm monitor|Apply cuff on a limb, cuff is inflated and deflated, monitor will displays non-invasive blood pressure values (systolic, diastolic, MAP, and pulse rate)
46049147|NCT02850744|Drug|PQR309|80mg capsules p.o. once daily and possibly Standard Treatment with temozolomide
45361352|NCT00922506|Drug|doxazosin plus tolterodine SR|doxazosin plus tolterodine SR(2 mg, qd)for 12 weeks or (4 mg, qd) for 12 weeks
45361353|NCT00816140|Drug|Cravit based triple therapy|"Levofloxacin based triple therapy~LALa regimen: levofloxacin 750mg (levofloxacin500 1.5 tablets) once daily, amoxicillin 1000mg twice daily, lansoprazole 30mg twice daily for 7 days"
45361354|NCT00816140|Drug|Klaricid based triple therapy|"Clarithromycin based triple therapy~CALa regimen: clarithromycin 500mg twice daily, amoxicillin 1000mg twice daily, and lansoprazole 30mg twice daily for 7 days"
45479994|NCT04051970|Drug|Antiretroviral|"Antiretroviral treatments (ART) will be allocated through central randomization (1:1:) according to the following two strategies:~Tritherapy-Bitherapy (TRI-BI) strategy:~TRI between D0 and W16: 3-drug combination (3-DR) including 2 NRTI (either TDF or TAF+XTC) and a once daily integrase inhibitor (Stribild® or Genvoya® or Biktarvy®) or TDF/XTC Gé + Tivicay® or TDF/XTC Gé + Isentress® QD 1200 mg when available) during 16 weeks BI between W16 and W96: if pVL viral load <500 cp/mL at W4 and <50 cp/mL at W12, participants will start the 2-DR regimen TDF or TAF / XTC (TDF/XTC Gé or Descovy®) at W16, until W96.~(Descovy® : provided that it is available in France), (XTC = FTC or 3TC)~Immediate Bitherapy (BI) strategy Dolutegravir (DTG, Tivicay® 50 mg QD) plus lamivudine (3TC, 300 mg QD) between D0 and W96.~Antiretroviral drugs will be prescribed in the context of standard of care."
45844951|NCT02063178|Behavioral|Toolbox|The toolbox includes additional treatment options for those who wish to take advantage of them. Items may include: food scales, cookbooks, etc. These items may be checked out and must be returned prior to the completion of the study.
45844952|NCT02063178|Behavioral|Challenges|There will be several challenges designed to increase participant interest and provide a specific goal (e.g., increase self-monitoring). Participants who successfully completed the challenges will be given a small award.
45361355|NCT00903708|Drug|LY2275796|100 mg administered by vein as a loading dose daily over 3 days, and then as a maintenance dose weekly thereafter.
45361356|NCT00899184|Genetic|polymorphism analysis|
45361357|NCT00899184|Other|laboratory biomarker analysis|
45361358|NCT00899262|Other|immunohistochemistry staining method|
45688442|NCT01208662|Drug|Lenalidomide|"Oral, 25 mg/day, days 1-14 for 8 total cycles for Arm A. Oral, 25 mg/day, days 1-14 for 5 total cycles for Arm B.~Oral, 10-15 mg/day, daily for 12 months in maintenance for Arm A and Arm B."
45688443|NCT01208662|Drug|Bortezomib|IV, days 1, 4, 8 and 11 for 8 total cycles for Arm A. IV, days 1, 4, 8 and 11 for 5 total cycles for Arm B.
45688444|NCT01208662|Drug|Dexamethasone|"Oral, days 1, 2, 4, 5, 8, 9, 11 and 12 for 8 total cycles for Arm A. Oral, days 1, 2, 4, 5, 8, 9, 11 and 12 for 5 total cycles for Arm B.~Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles."
45361359|NCT00899262|Other|laboratory biomarker analysis|
45688445|NCT01208662|Procedure|Autologous Stem Cell Transplant|Stem cell transplant
45688446|NCT01191775|Drug|PNT2258|Patients will receive PNT2258 as an intravenous infusion once daily for 5 consecutive days (Days 1-5) of every 21-day cycle (3 weeks). The treatment cycle repeats every 3 weeks for up to 6 cycles in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the study.
45844953|NCT02063178|Behavioral|Tailored interventionist feedback upon request|Randomly assigned participants to the self-paced condition have the option to receive feedback on their progress upon request.
45361360|NCT00899262|Other|sputum cytology|
45361361|NCT00899262|Procedure|Fourier transform infrared spectroscopy|
45361362|NCT00899262|Procedure|diagnostic bronchoscopy|
45361363|NCT00899340|Genetic|gene expression analysis|profiles of HPV(+) and (-) HNSCCs
45361364|NCT00899340|Genetic|microarray analysis|microarray analysis
45361365|NCT00899340|Genetic|protein expression analysis|protein expression analysis
45361366|NCT00899340|Other|immunohistochemistry staining method|immunohistochemistry staining method
45361367|NCT00899340|Other|laboratory biomarker analysis|laboratory biomarker analysis
45361368|NCT00899418|Genetic|gene expression analysis|
45361369|NCT00899418|Genetic|polymerase chain reaction|
45361370|NCT00899418|Genetic|polymorphism analysis|
45361371|NCT00899418|Other|immunohistochemistry staining method|
45361372|NCT00899496|Other|immunological diagnostic method|
45361373|NCT00899496|Other|physiologic testing|
45361374|NCT00894972|Other|Rehabilitation following lumbar disc surgery (discectomy)|Exercise: walking, range of motion, and general trunk strengthening with or without specific trunk muscle motor control exercises.
45361375|NCT04035642|Radiation|IGRT 24 Gy Single dose|Previously untreated patients with prostate cancer will be treated with 24Gy in in one session.
45361376|NCT04035642|Procedure|Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)|Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.
45844954|NCT02064270|Device|Single-Use Negative Pressure Wound Therapy|Application of PICO Single-Use Negative Pressure Wound Therapy
45361377|NCT04035642|Device|Rectal balloon with air filling|A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.
45688447|NCT01116765|Other|no stimulation of the oral structure|
45688448|NCT01116765|Other|stimulation of the oral structure|
45361378|NCT04035642|Device|Urethral catheter loaded with beacon transponders|A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.
45361379|NCT00895050|Other|Review of clinical records|
45361380|NCT00895128|Drug|Erlotinib Hydrochloride|Starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients.
45361381|NCT00895128|Drug|Dasatinib|Starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
45361382|NCT00895206|Drug|individual adapted immunosuppression|individual adapted immunosuppression
45361383|NCT00895206|Drug|golden standard therapy|golden standard therapy
45688449|NCT01041989|Behavioral|Nutritional guidance|Individual counseling sessions and group meetings will be organized.
45688450|NCT01041989|Behavioral|Exercise|Guided muscle strength training and aerobic exercise.
45688451|NCT01041989|Behavioral|Cognitive training|Cognitive training will be implemented through 8 group sessions lead by a psychologist and a computer-based cognitive training program available to participants via the internet.
45688452|NCT01041989|Other|Reduction of vascular risk factors|Monitoring and maintenance of metabolic and vascular risk factors
45844955|NCT02064270|Device|Standard postsurgical dressings|Use of Standard postsurgical dressings
45844956|NCT02064582|Drug|Enzalutamide|160mg by mouth each day
45361384|NCT00899652|Genetic|Southern blotting|
45361385|NCT00899652|Genetic|chromosomal translocation analysis|
45361386|NCT00899652|Genetic|cytogenetic analysis|
45361387|NCT00899652|Genetic|gene rearrangement analysis|
45361388|NCT00899652|Genetic|mutation analysis|
45361389|NCT00903942|Radiation|radiation therapy|1) PTV = CTV (GTV + 1.5-cm margins and the most adjacent nodal regions) + 0.5 cm margins to 5,040 cGy in 180 cGy daily fractions; and (2) Cone Down PTV = GTV +1.5 cm margins to 6,480 cGy.
45361390|NCT00903942|Drug|Paclitaxel Protein-Bound, and CARBOPLATIN|Induction Chemotherapy Abraxane(260 mg/m2) / Carboplatin (AUC of 6) x one cycle Concurrent Chemotherapy(with radiation)--for first 3 pts--20 mg/m2 Abraxane, 3 times per week then for next group of 3 pts--30 mg/m2 Abraxane twice a week
45361391|NCT05278026|Other|guideline recommended routine treatment|
45361392|NCT00904020|Drug|Lidoderm|Patients participated in a 2-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
45361393|NCT00899964|Behavioral|Physical activity|6-month physical activity intervention (endurance activities) delivered by internet with tailored training schedules
45361394|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 12 months)
45688453|NCT00920621|Dietary Supplement|Vitamin D 3 cholecalciferol|Dosage form oral Dosage 4000IU Vitamin D 3 cholecalciferol
45688454|NCT00920621|Dietary Supplement|Vitamin D3|4000 IU of vitamin D3 administered orally once a day during pregnancy
45752107|NCT04536857|Other|Biomarker assay|Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in cerebrospinal fluid from patients with Parkinson's disease, multiple system atrophy, progressive superanuclear palsy and controls.
45752108|NCT03832881|Diagnostic Test|ADAMTS13, VWF assay|
45844957|NCT02064582|Drug|Leuprolide acetate|22.5 mg intramuscular every 3 months or 45mg intramuscular every 6 months
45844958|NCT02064582|Radiation|radiation|External beam radiation will be delivered as per standard radiation therapy protocol
45844959|NCT02067000|Behavioral|Obstructive Sleep Apnea|Questionnaire about CPAP perceptions
45844960|NCT02067468|Device|HPV test|QIAGEN - The Digene HPV test®
45844961|NCT02067468|Procedure|COLPOSCOPY|Colposcopy routine health services
45844962|NCT02067468|Device|cytology|Cytology routine health services
45844963|NCT02067858|Radiation|Stereotactic Radiosurgery|
45844964|NCT02069184|Drug|IV Acetaminophen|1gm IV. 1st dose at the cord clamping and 3 more doses given every 6th hourly
45361395|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 15 months)
45361396|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 12 and 15 months)
45844965|NCT02069184|Other|Saline as placebo|100ml saline IV. 1st dose of 100 ml at cord clamping and 3 more 100ml doses every 6th hourly.
46049148|NCT04266834|Other|Experimental Arm|"First, these providers will receive educational materials (e.g. a slide deck and one-page fact sheet) meant to mimic what physicians will receive in the real-world market as they learn about the Hikari DX L-FABP test.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the L-FABP test at the clinically-appropriate point in each case."
45361397|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 15 months)
45361398|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 18 months)
45361399|NCT00643916|Biological|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.5 mL, Subcutaneous (at 3 years to <6 years of age)
45361400|NCT00900042|Genetic|DNA ploidy analysis|
45361401|NCT00900042|Genetic|DNA stability analysis|
45361402|NCT00900042|Genetic|chromosomal translocation analysis|
45361403|NCT00900042|Genetic|cytogenetic analysis|
45361404|NCT00900042|Other|flow cytometry|
45361405|NCT00900042|Other|laboratory biomarker analysis|
45361406|NCT00895362|Drug|Erlotinib|Starting dose 100 mg by mouth 1 time every day for 28-day cycle (Pediatric starting dose 50 mg).
45361407|NCT00895362|Drug|Cetuximab|Loading dose of 200 mg/m^2 (maintenance 125 mg/m^2) by vein 1 day every week of 28-day cycle, on Days 1, 8, 15 and 22. First dose given over 2 hours and over 1 hour each subsequent time.
45361408|NCT02538978|Biological|Autologous Bone Marrow Concentrate (aBMC)|"Aspirated bone marrow will be processed by centrifugation, separating out a concentrate (aBMC) comprising primarily white blood cells and platelets. These cells will be injected i.m. to loci determined by the operating physician using imaging and vascular flow criteria.~Device: SurgWerks-CLI Kit~Device: VXP System"
45361409|NCT02538978|Biological|Placebo Control (diluted autologous peripheral blood)|Diluted peripheral blood prepared in a blinded fashion to resemble bone marrow will be injected intramuscularly per the same procedure used for the Experimental Device Arm.
45361410|NCT00904098|Drug|Frovatriptan|"This study employed a prospective, non-randomized, open-label single-sequence design. The study was conducted in two phases:~A Usual Care phase (approximately 1 month in duration) included one menstrual period during which female patients treated all episodes of migraine headaches using their current treatment (referred to as the Baseline phase in the protocol)~An Acute Treatment phase (approximately 1 month in duration), following the Usual Care phase, included one menstrual period during which female patients used frovatriptan 2.5 mg to treat all episodes of migraine headache when their headache reached IHS Grade 1. If needed, a second dose of frovatriptan 2.5 mg was administered; however, this second dose could not be administered within 2 hours of the initial dose (i.e., there must have been at least 2 hours between doses of frovatriptan). The total daily dose of frovatriptan was not to exceed 3 tablets over a 24-hour period."
45844966|NCT02070276|Procedure|Trans-thoracic echocardiography|Subcostal evaluation of inferior vena cava dimensions and colorability with cyclic spontaneous breathing in order to determine if the patients will be fluid responsive or not.
46049149|NCT04139668|Drug|Naltrexone 380 MG [Vivitrol]|Three 4ml intramuscular injections of naltrexone 380mg (Vivitrol) administered over 12 weeks (one injection every 4 weeks)
46049150|NCT04139668|Behavioral|Motivational Enhancement Therapy and Cognitive Behavioral Therapy|Weekly Motivational Enhancement Therapy and Cognitive Behavioral Therapy (MET/CBT), based upon the Brief Counselling for Marijuana Dependence Manual published by the Substance Abuse and Mental Health Services Administration (SAMHSA), for 12 weeks
45361411|NCT00904098|Drug|Usual Care|Current treatment used to treat all migraine headaches
45361412|NCT00904176|Drug|Dapagliflozin|Tablets, Oral, 20 mg, followed by 10 mg, Single Dose
45361413|NCT00904176|Drug|Warfarin|Tablets, Oral, 25 mg, Single Dose
45361414|NCT00904176|Drug|Digoxin|Tablets, Oral, 0.25, Single Dose
45844967|NCT02070276|Procedure|Passive Leg Raising Test|Application of this test in a standard manner in order to determine if our spontaneous breathing patients are fluid responsive before spinal anesthesia.
45844968|NCT02134314|Drug|C1 Esterase Inhibitor|C1 Esterase Inhibitor 50 units per kilogram intravenous infusion administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
45844969|NCT02134314|Drug|Placebo|Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
45752109|NCT02660411|Drug|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.
45844970|NCT02135016|Drug|1% lidocaine|epidural anesthesia with 1% lidocaine 10ml before propofol TCI
45844971|NCT02135016|Drug|2% lidocaine|epidural anesthesia with 2% lidocaine 5ml before propofol TCI
45844972|NCT02135016|Drug|0.9% normal saline|epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
45844973|NCT02135094|Device|Active ultrasound therapy device|low intensity continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 for treatment duration of 4 hours per day
45844974|NCT02135094|Device|Placebo ultrasound therapy device|The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
45844975|NCT02137512|Device|Closed-Loop Control System|"This investigational device system included the following components:~DiAs - a smart-phone medical platform;~Dexcom G4 Platinum CGM system connected to DiAs via CGM receiver and USB-Bluetooth relay hardware;~Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth;~Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network~Modular Closed-Loop Control Algorithm Running on DiAs, which is of Control-to-Range (CTR) class"
45844976|NCT02137512|Device|Sensor-Augmented Pump (SAP)|"This commercial device system included the following components:~Dexcom G4 Platinum CGM system;~Roche Accu-Chek insulin pump"
45844977|NCT02139228|Biological|Hib-CRM197|No vaccine administered in V37_07E2 study
45844978|NCT02139228|Biological|Hib-TT|No vaccine administered in V37_07E2 study
45844979|NCT02139540|Drug|Nitrous Oxide|"Patients will receive either up to 50% nitrous oxide/50% oxygen for 1 hour or placebo (50% nitrogen [inert]/50% oxygen) in two separate sessions. Both sessions will be 1 week apart."
45844980|NCT02139540|Drug|Placebo|50% nitrogen [inert]/50% oxygen - otherwise completely identical administration and setup
45844981|NCT02146482|Other|Sit-stand computer workstation|A sit-stand computer workstation allows one to sit or stand throughout the day while maintaining continued use of one's computer.
45844982|NCT02148588|Drug|Ultrasound-guided peripheral nerve block with 2% lidocaine|"Patients will have a peripheral nerve blockade with a local anesthetic (lidocaine)~Assessment of spontaneous and evoked pain responses~Completion of NPSI questionnaire~Mapping of the affected limb"
45844983|NCT02149290|Device|Trends-equipped LifeVest 4000|LifeVest 4000 monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy. Trends modifications for heart failure monitoring include: body position data collection; heart rate measurements, activity data collection; ability to perform a health survey; ability to guide patients through a walk test
45844984|NCT02149524|Drug|Herceptin (trastuzuamb)|Intravenous administration
45844985|NCT02149524|Drug|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
45361415|NCT00900276|Other|immunologic technique|
45361416|NCT00900276|Other|laboratory biomarker analysis|
45361417|NCT00900276|Other|mass spectrometry|
45361418|NCT02540070|Procedure|Periarticular|
45752110|NCT02660411|Drug|Propofol|Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
45844986|NCT02150460|Procedure|One-site peribulbar injection|injection into the inferior medial orbital compartment
45844987|NCT02150460|Procedure|Two- site peribulbar injection|Two injections into the infero-temporal and supero-nasal orbital compartments
45844988|NCT02154048|Drug|Ropivacaine|
45844989|NCT02154048|Drug|Dexamethasone|
45752111|NCT05325879|Other|VAGUS-NDT|Neurodynamic test for vagus nerve
45844990|NCT02154048|Other|Placebo|
46049151|NCT04140838|Behavioral|Acceptance and Commitment Therapy (ACT)|Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Presentation of the general concept of ACT therapy. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis III. Session 5: Values and feelings. Session 6: Taking a direction. Session 7: Dare and change. Session 8: Ready to act with ACT.
45361419|NCT02540070|Procedure|Motor free|
45752112|NCT02078492|Drug|10 mg of Ketorolac|Patients will receive 10 mg of Ketorolac for pain control.
45361420|NCT02540070|Procedure|Motor free with dex|
45752113|NCT02078492|Drug|15 mg of Ketorolac|Patients will receive 15mg of Ketorolac for pain control.
45752114|NCT02078492|Drug|30 mg of Ketorolac|Patients will receive 30mg of Ketorolac for pain control.
45752115|NCT02988921|Device|MRI and CT|
45752116|NCT02988921|Radiation|Ratiotherapy|
45752117|NCT02988921|Drug|Paclitaxel, platinum-based drug|
45688455|NCT00823654|Other|Blood draw and questionnaires|"At the start of the study: blood draw, questionnaire and menstrual calendar ↓ Start planned therapy (or observation/surveillance) for cancer treatment~↓~Tests in the middle of chemotherapy (if applicable):~Blood draw and collection of monthly menstrual calendars ↓~Tests when chemotherapy is over (if applicable):~Blood draw and collection of monthly menstrual calendars~↓~Tests every 4 months for about 1 year:~Blood draw, collection of monthly menstrual calendars, and questionnaire ↓~Tests every 6 months for about 1 year:~Blood draw, collection of monthly menstrual calendars, and questionnaire~↓~Yearly follow-up for about 2 years:~Blood draw collection of monthly menstrual calendars, and questionnaire"
45688456|NCT00823654|Other|Blood draw and questionnaires|"Study Schema for Unaffected High Risk Women with BRCA mutations Identify eligible premenopausal patients and obtain informed consent~↓ Register patients at Memorial Sloan-Kettering Cancer Center~↓ Baseline evaluation: Blood draw and baseline reproductive health and sexual questionnaires (Appendix A)/menstrual calendar (Appendix C)~↓ Annual follow-up x 4 years Blood draw and collection of monthly menstrual calendars/follow-up reproductive health and sexual health questionnaires~↓ Year 1 follow up Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires~↓ Optional annual follow-up years 2-5 Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires"
45361421|NCT02540070|Drug|Ropivacaine|
45361422|NCT02540070|Drug|epinephrine|
45361423|NCT02540070|Drug|morphine|
45844991|NCT02154906|Device|DFDBA|
45844992|NCT02154906|Device|autologous platelet rich fibrin|
45688457|NCT00667199|Drug|Radium-223 dichloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight, the dose (5 , 25 , 50 or 100 kBq/kg b.w.)
45844993|NCT02156154|Drug|Intravenous Acetaminophen|
45361424|NCT02540070|Drug|Ketorolac|
45844994|NCT02157168|Behavioral|Community health worker|"Community health workers (CHWs) in Hispanic communities, often referred to as promotoras, are members of the community who use resource sharing, partnership development, education, outreach, health promotion, and disease prevention strategies to improve the health of their communities.~IG1: The intervention itself consists of a 45-minute one-on-one presentation and tailored planning session delivered by a CHW in a community setting of the new member's choosing. Presentations (in English or Spanish) will be delivered using a tablet computer or a hand held flipchart. Two booster telephone interactions will be performed at 2 and 4 months. At month 6, the participant will receive a call from the telephone interviewer to administer the informed patient choice survey."
46049152|NCT04140838|Behavioral|Behavioral Activation Therapy for Depression (BATD)|"Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Collection of information regarding areas of activity and interaction contexts.~Session 2: Identification of information related to depressive behaviours. Session 3 Obtaining complementary information regarding the characteristics of the history of patient interactions and any contexts.~Session 4: Explanation of the hypotheses of problematic behaviour, its maintenance and change throughout the intervention.~Session 5: Once the 10 target activities have been identified, a record is made to track and their progress weekly.~Session 6: Discussion of what was obtained from the records in general and of the satisfaction obtained, and explanation of the contexts and reinforcers.~Session 7: Psycho-education Session 8: New behaviours, the goals achieved and the maintenance of the weekly activity are inquired about."
46049153|NCT04140838|Other|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients suffering chronic pain and mild-moderate depression.
46049154|NCT04266678|Behavioral|Resistance exercise program|Exercise sessions with exercise science professional. Target hypertrophy repetition range and progressive resistance exercise.
45844995|NCT02158494|Device|Balance and Gait Training using neurostimulation modulation.|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
45361425|NCT02540070|Drug|Dexmedetomidine|
45361426|NCT02540070|Drug|saline|
45361427|NCT00900354|Genetic|molecular genetic technique|
45844996|NCT02158494|Device|Sham Device|The sham device is visually identical to the CN-NINM device, and offers a non-zero, minimally perceivable stimulation.
45844997|NCT02158572|Drug|AG200-15|Transdermal contraceptive delivery system
45361428|NCT00900354|Other|mass spectrometry|
45361429|NCT00900354|Other|pharmacological study|
45361430|NCT00904254|Radiation|EP 1645/Solution For Injection, 99mTC|(Fab-fragment of Anti-human CD4,technetium-99m)
45361431|NCT00905814|Drug|AG-013736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
45361432|NCT00905814|Drug|AG-103736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
45361433|NCT00905892|Dietary Supplement|Hyperlipidic overfeeding|100g per day of cheese + 40g per day of almonds + 20g per day of butter
45361434|NCT00900432|Other|immunoenzyme technique|
45361435|NCT00900432|Other|laboratory biomarker analysis|
45361436|NCT00900510|Procedure|Incision and drainage|
45361437|NCT00900510|Drug|Trimethoprim/Sulfamethoxazole (Bactrim)|Trimethoprim/Sulfamethoxazole, oral
45361438|NCT00900510|Drug|Placebo|
45361439|NCT00904410|Other|FDG-PET|370 MBq of FDG one hour before imaging acquisition PET just before neo-adjuvant chemotherapy and just before the second cycle
45688458|NCT00639301|Behavioral|Questionnaires|The survey will be administered by mail or telephone interview, based upon the participant preference. The survey has been adapted from the 2008 questionnaire being administered through the CCSS (11); it has been supplemented with questions addressing areas of interest specific to the retinoblastoma survivor population (eg, validated instruments that assess visual impairment).
46049155|NCT04266756|Drug|Selexipag matrix tablet|Participants will receive single oral dose of Selexipag tablet(with fast, medium, and slow release profile) under fasted condition.
46049156|NCT04266756|Drug|Selexipag encapsulated pellets|Participants will receive single oral dose of Selexipag pellets (with fast, medium, and slow release profile) under fasted condition.
46049157|NCT04266756|Drug|Selexipag Immediate-release (IR) tablet|Participants will receive Selexipag immediate-release tablet orally under fasted condition.
46049158|NCT00606060|Drug|Kogenate (BAY14-2222)|100 IU/mL (250 IU/vial nominal potency) continuous infusion over 6-11 days in 12 patients. 400 IU/mL (1000 IU/vial nominal potency) continuous infusion over 6-11days in 3 patients.
46049159|NCT05379192|Other|Group 1, Group 2, Group 3, Group 4|The total amount of antiemetic,the time of first antiemetic use and VAS scores at 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours postoperatively will also be recorded according to circadian rhythm
46049160|NCT04266444|Device|Exergaming in virtual environment|"The 10Cubes game (by I. Cikajlo) will be used. In the game, the motion of the hand, wrist and fingers is tracked by an infra-red camera (by LeapMotion, Inc.) and hand motion is reflected in the virtual environment. The software will run on a powerful computer with a 19 display. Each group will have the game set to a different level of difficulty."
45361440|NCT00160693|Biological|Certolizumab Pegol|400 mg of Certolizumab Pegol subcutaneously every 4 Weeks
45361441|NCT00900588|Biological|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
45361442|NCT00906048|Drug|Levofloxacin (HR355) and Rifampicin Therapy|"Film-coated scored tablet measured at 500 mg of levofloxacin and capsule at 300 mg of rifampicin per os once a day~Weight < 70 kg: 1 tablet of levofloxacin and 2 capsules of rifampicin Weight > 70 kg: 1 tablet of levofloxacin and 3 capsules of rifampicin"
45688459|NCT00605982|Procedure|MRI|The patient will then undergo a breast MRI as part of their preoperative work-up of DCIS. Biopsy of any suspicious areas by needle biopsy or at the time of surgery. If appropriate, repeat MRI after biopsy or surgery. Follow-up for 10 years (you will be contacted once a year to see how you are doing).
45688460|NCT00537225|Behavioral|exercise|tailored multifactor CVD risk reduction
45688461|NCT00472212|Device|Spectacles|Hyperopic spectacle lenses
45361443|NCT00906126|Drug|Misoprostol|Oral misoprostol
45361444|NCT04034472|Other|Interdisciplinary intervention in obesity|Interdisciplinary weight loss intervention associate to the use of digital technology to treat obesity and related disorders
45688462|NCT00472212|Device|Control|Plano (no power, control) spectacle lenses
45688463|NCT00460486|Biological|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
45688464|NCT00378105|Drug|Bortezomib|Intravenously on days 1, 4, 8 and 11 of a 21 day cycle for a minimum of 8 cycles (dosage will vary depending upon when the participant enters the trial)
45688465|NCT00378105|Drug|Lenalidomide|Taken orally twice a day for 2 weeks (days 1-14) of each 21-day cycle for a minimum of 8 cycles (dosage will vary depending upon when participant enters trial).
45688466|NCT00378105|Drug|dexamethasone|Taken orally on days 1,2,4,5,8,9,11 of a 21-day cycle for a minimum of 8 cycles.
46049161|NCT00875524|Biological|CYD dengue vaccine serotypes (1, 2, 3, 4).|0.5 mL, Subcutaneous
46049162|NCT00875524|Biological|Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide|Each at 0.5 mL, Subcutaneous, respectively
45361445|NCT05277870|Device|Nanodropper adaptor|Patients will use their standard prescription for open-angle glaucoma or ocular hypertension with a Nanodropper attachment on the medication bottle.
45361446|NCT05277870|Device|control|Patients will use their prescribed IOP-lowering medication using standard eyedropper on the medication bottle.
45361447|NCT00900744|Drug|Tamoxifen|20 mg daily
45361448|NCT02539758|Other|ocular massage|ocular massage could be applied over the globe over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.
45688467|NCT00139477|Drug|Metformin|Metformin, 250mg by mouth twice a day with meals will be started and if tolerated increased to 500mg twice a day in 3 days in those less than 12 years old and titrated further to 1000mg twice a day if tolerated.
45844998|NCT02159118|Device|Manual bone marrow aspiration and biopsy device|Use of the manual bone marrow aspiration and biopsy device to collect bone marrow aspiration and bone marrow biopsy specimens.
46049163|NCT04266600|Procedure|Extensive mesentery resection|Surgeons will perform a high ligation of the ileocolic pedicle, between the superior mesenteric artery and the bifurcation of the ileal and right colic branches, and to fully mobilize the mesentery off of the retroperitoneum prior to bowel transection and anastomosis
46049164|NCT01094288|Drug|Alisertib|Alisertib ECT
45361449|NCT02539758|Device|LenstarLS900|observed changes of anterior chamber depth before and after ocular massage by LenstarLS900
45361450|NCT02539758|Device|Goldmann tonometer|observed changes of intraocular pressure before and after ocular massage by Goldmann tonometer
45361451|NCT00643760|Drug|Placebo|placebo
45361452|NCT00643760|Drug|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
45688468|NCT00139477|Behavioral|Dietary modification with caloric restriction|The life style intervention changes will include a hypocaloric diet representing at least a 500 kcal/day reduction based on their dietary histories and Resting Energy Expenditure (REE) determined by the initial calorimetry.
45752118|NCT04498949|Behavioral|UP|"The unified protocol modules are as follows:~Module 1: Setting the treatment goals and motivation augmentation Module 2: Using psychoeducation to learn the function of emotions and their development Module 3: Mindful (present-focused and non-judgmental) emotional awareness- Core module Module 4: Cognitive flexibility- Core module Module 5: Identifying and countering emotional avoidance behaviors- core module Module 6: Increasing awareness and confronting physical sensations/ interoceptive sensitivity- core module Module 7: Both situational and interoceptive emotion-focused exposures- Core module Module 8: Recognizing accomplishments and looking to the future (relapse prevention)"
45752119|NCT04498949|Other|Treatment as usual|Diagnostic test. Psychoeducation Supoortive care
45752120|NCT04528563|Drug|Ketorolac Tromethamine 10 MG/ML|Non-Steroidal-Anti-Inflammatory given intravenously.
45361453|NCT00643760|Drug|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
45361454|NCT00643760|Drug|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
45844999|NCT02159118|Device|Powered bone marrow aspiration and biopsy device|Use of the powered bone marrow aspiration and biopsy device to collect bone marrow aspiration specimens and bone marrow biopsy specimens.
45845000|NCT02159898|Device|EndoMAXX Endoluminal Valve Technology (EVT)|
45845001|NCT02159898|Device|EndoMAXX|
45845002|NCT02159976|Drug|Pantoprazole|Pantoprazole 40mg bid
45845003|NCT02159976|Drug|Amoxicillin|Amoxicillin 1000mg bid
45845004|NCT02159976|Drug|Clarithromycin|Clarithromycin 500mg bid
45845005|NCT02159976|Drug|Metronidazole|Metronidazole 500mg tid
45845006|NCT02159976|Drug|Tetracycline|Tetracycline 1000mg bid
45845007|NCT02159976|Drug|Bismuth|Bismuth 600mg bid
46049165|NCT01094288|Drug|Docetaxel|Docetaxel IV infusion
46049166|NCT02690298|Device|ExSpiron|Non-Invasive respiratory volume monitoring
46049167|NCT00686530|Procedure|MR Imaging|Postmortem MR will be included as part of the autopsy examination in cases of suspected brain malformations. Imaging will be done using 1.5T GE CV/I MRI magnet. The specimen is scanned, following fixation, using an 8-channel head coil or 8-channel knee coil, depending on the size of the brain. Structural postmortem MR will include spin-echo T1, axial SPGR, and T2 imaging in three planes. Diffusion tensor imaging will be performed in the coronal plane.
45361455|NCT00643760|Drug|Pregabalin|pregabalin 300mg/day
45361456|NCT00904644|Drug|Raltegravir|Raltegravir standard dosage of 400mg tablets every 12 hours together with an optimized backbone antiretroviral drug regimen
45361457|NCT02539836|Dietary Supplement|Dietary nutrition based on plant fermentation extract|The main ingredient of dietary nutrition is plant fermentation extraction which is from many fruit and vegetable fermented by probiotics.
45361458|NCT02539836|Diagnostic Test|MRI in quantifying liver fat with MRS|To investigate the accuracy of MRI in quantifying liver fat with magnetic resonance spectroscopy (MRS) as a reference.
45361459|NCT04034628|Device|Peritoneal Catheter Insertion - Laparoscopic|Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
45361460|NCT04034628|Device|Peritoneal Catheter Insertion - Percutaneous|Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
45361461|NCT00906360|Drug|sunitinib malate|Given orally or by percutaneous gastrostomy tube
45361462|NCT00906360|Other|pharmacological study|Correlative studies
45361463|NCT00906360|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
45361464|NCT00906360|Biological|cetuximab|Given IV
46049168|NCT00686530|Procedure|Autopsy|Autopsy will be performed according to accepted standards, based on clinical indications. Macroscopic examination of the fetus will be performed initially , followed by organ removal for tissue fixation for a period of two weeks.
45361465|NCT00643682|Other|Educational card|"A 4x6 inch educational card containing a photo of an unprepared colon and a clean colon with the caption: Drinking all the bowel cleaning medicine as described in the enclosed instructions lets the doctor see your colon better during your colonoscopy."
45361466|NCT00904800|Drug|AZD0837|tablet, oral, once daily, 1+5 days
46049169|NCT02850822|Drug|Demethylation drug|Demethylation drug,such as Decitabine
45361467|NCT00904800|Drug|Placebo|Placebo
45361468|NCT00906438|Dietary Supplement|2006-RD-05|300 mg daily, once a day for 28 consecutive days
46049170|NCT02850822|Drug|Chemotherapy regimen|Chemotherapy regimen,such as CAG, G-CSF 5-10ug/kg/day on days 4 and 17；Aclacinomycin 7mg/m2/day on days 4 and 11；Cytarabine 20mg/m2/day on days 4 and 17.
46049171|NCT00684034|Other|Sampling of blood|A sampling of blood will be made
45361469|NCT00906438|Dietary Supplement|Placebo|Capsule similar in shape, weight and color from active, once a day for 28 consecutive days
45361470|NCT00643604|Drug|treprostinil sodium|rapid switch from intravenous epoprostenol on CADD ambulatory pump to intravenous treprostinil sodium
45361471|NCT00819494|Procedure|Skin tests with radiocontrast media|Skin prick tests and intradermal test will be performed in patients with a history of immediate reactions to iodinated radiocontrast media
45361472|NCT00603798|Drug|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
45361473|NCT00603798|Drug|Placebo cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
45361474|NCT00603798|Drug|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
45479995|NCT04442854|Other|cognitive behavioral group therapy|A 8-session cognitive behavior group intervention tailor-made for Mainland Chinese university students in Hong Kong
45479996|NCT03722329|Drug|Eculizumab|Eculizumab Injection. 300 mg, single dose
45752121|NCT04528563|Drug|Morphine Sulfate 10Mg/1mL Injection|Opioid commonly used for acute abdominal pain given intravenously.
45845008|NCT02160288|Drug|Botulinum Toxin-A|100 Units diluted in a 5 cc syringe at a concentration of 20U/mL
46049172|NCT00684034|Other|Sampling of blood|A sampling of bood will be made before the dialysis
46049173|NCT00684034|Other|Sampling of blood|A sampling of blood will be made.
46049174|NCT05380986|Drug|Camrelizumab combined with apatinib mesylate|Camrelizumab 200 mg, IVGTT D1, apatinib mesylate, once daily. The specific prescription is determined by the investigator. Continued use until disease progression, unacceptable toxicity, or withdrawal for other reasons.
45361475|NCT00819572|Biological|DLX105, a single-chain (scFv) antibody fragment against TNF-alpha|Comparison of two different doses of intra-articular DLX105
45479997|NCT03791333|Other|injury severity score|injury severity score of multi trauma patients
45479998|NCT03326440|Other|VERT system|3D images of radiotherapy planning and administration using the VERT (Virtual Environment Radiotherapy) system is shown either prior to Radiotherapy (study arm) or post Radiotherapy (control arm)
45752122|NCT01405898|Dietary Supplement|beetroot juice|Beetroot juice 4 weeks 250ml daily
45752123|NCT01405898|Dietary Supplement|Nitrate-free beetroot juice|Nitrate-free beetroot juice 4 weeks 250ml daily
45688469|NCT00139477|Behavioral|Establishment of exercise protocol|Participants will attend the Fitness Center 3 times per week and supervised by an exercise technician or exercise specialist. Exercise will be individually prescribed for each participant based on their functional abilities. Exercise will consist of 5-10 minutes for warm up and stretching, followed by 15-30 minutes of cardiovascular exercise (i.e. treadmill, bicycle ergometer, rower, nustep, etc), 10-20 minutes of strength training (supervised using weight stack equipment), and 5-10 minutes of cool down and stretching. As children typically do not need an exercise prescription based on heart rate, we will familiarize them with perceived exertion scales and monitor that they are exercising in the moderate to hard range of perception of effort. Participants will be started at 15 minutes of cardiovascular exercise and 10 minutes of strength training exercise, progressing by 2-3 minutes every week until 30 and 20 minutes is achieved for each respectively.
45688470|NCT00082706|Drug|5-Fluorouracil (5-FU)|Day: 1 - 5 Dose: 200 mg/m2 IVCI daily x 5 days
45688471|NCT00082706|Drug|Leucovorin|Day: 1 - 5 Dose:10 mg/m2 daily x 5 days
45688472|NCT00082706|Drug|Cisplatin|Day: 1 - 5 Dose: 20 mg/m2 daily x 5 days
45688473|NCT00082706|Drug|Gemcitabine|Day: 1 & 5 Dose: 200 mg/m2 (Two doses only)
45688474|NCT00004935|Drug|Herceptin™ (Her)|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
45688475|NCT00004935|Drug|Herceptin™ (Her) + chemo|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
45688476|NCT00119158|Drug|Combination of pimecrolimus and fluticasone|Pimecrolimus cream twice a day and fluticasone cream once a day
45688477|NCT00119158|Drug|pimecrolimus|apply daily with fluticasone cream for flares
45688478|NCT00119392|Biological|rituximab|Given IV
45361476|NCT00819572|Drug|Placebo|
45361477|NCT00908622|Procedure|Percutaneous autologous myoblast implantation|Endocavity implantation of autologous myoblasts
45361478|NCT00908622|Procedure|Cardiac revascularization|Cardiac revascularization
45361479|NCT02538588|Device|Nebulizer 1|
45361480|NCT02538588|Device|Nebulizer 2|
45688479|NCT00119392|Drug|cyclosporine|Given orally
45688480|NCT00119392|Drug|fludarabine phosphate|Given IV
45688481|NCT00119392|Drug|mycophenolate mofetil|Given orally
46049175|NCT00684112|Drug|Gabapentin|Patients in this arm of the study will receive two identical capsules, containing 300 mg of oral gabapentin each, 1 hour before surgery.
46049176|NCT00684112|Drug|Placebo|Patients in this arm of the study will receive two identical placebo capsules 1 hour before surgery.
46049177|NCT04306796|Device|3D printed splints|3D printed made to measure splints
46049178|NCT04306796|Device|Thermoplastic splints|thermoplastic splints individually adjusted by occupational therapists
46049179|NCT00684190|Drug|AZD3355|150 mg bid, oral, 7 days
46049180|NCT00684190|Drug|Esomeprazole|40 mg od, oral, 7 days
45688482|NCT00119392|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
45688483|NCT00119392|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
45688484|NCT00119392|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
45845009|NCT02160288|Drug|Normal Saline|Dispensed in a 5 cc syringe
45361481|NCT03323502|Behavioral|ACP Specialist Program|New structured role with responsibility for ACP
45361482|NCT00630812|Drug|inhaled mannitol|400 mg BD for 26 + 26 weeks
45361483|NCT00630812|Drug|Placebo comparator|BD for 26 weeks followed by 26 weeks of inhaled mannitol in the open label phase
45688485|NCT00119392|Radiation|total-body irradiation|Undergo TBI
45688486|NCT04752280|Radiation|Proton irradiation|proton irradiation applied as follows: 30 x 2 Gy(RBE) 33 x 1,8 Gy (RBE), or 15 x 2,67 Gy (RBE)
45688487|NCT04752280|Radiation|Photon irradiation|proton irradiation applied as follows: 30 x 2 Gy 33 x 1,8 Gy, or 15 x 2,67 Gy
45688488|NCT00218062|Drug|D-Amphetamine 30mg|
45845010|NCT02160990|Drug|Exenatide|5 mcg exenatide subcutaneously twice daily for 30 days
45845011|NCT02160990|Drug|Placebo|placebo subcutaneously twice daily for 30 days
45845012|NCT02161536|Device|Motus Cleansing System|
45845013|NCT02163486|Device|Group U (UNIQUE)|Before LMA-Unique was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LMA-Unique cuff.
45845014|NCT02163486|Device|I-GEL|"Before I-gel was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the I-GEL cuff.~I-GEL: K-Y Jelly® is a registered trademark of Johnson and Johnson Inc"
45845015|NCT02164422|Drug|Guanfacine 3mg/day|3 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
45361484|NCT00906516|Drug|Neuradiab in combination with Bevacizumab (Avastin)|"Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient."
45688489|NCT00218062|Drug|D-Amphetamine 60mg|
45688490|NCT00218062|Drug|Modafinil 200mg|
45688491|NCT00218062|Drug|Modafinil 400mg|
45688492|NCT00218062|Behavioral|Therapy|Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills.
45688493|NCT00218062|Drug|Placebo|
45688494|NCT00121186|Drug|fludarabine phosphate|30 mg/m^2 on days -6 to -2 (2-6 days before transplant).
45688495|NCT00121186|Drug|melphalan|70 mg/m^2 on days -3 and -2 (2-3 days before transplant).
45688496|NCT00121186|Drug|methotrexate|5 mg/m^2 on days 1, 3, and 7 post-transplant.
45688497|NCT00121186|Drug|tacrolimus|0.03 mg/kg bid on days -3 to 100 post-transplant.
45688498|NCT00121186|Procedure|allogeneic bone marrow transplantation|if donor bone marrow stem cells are harvested
45845016|NCT02164422|Drug|Guanfacine 1.5mg/day|1.5 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
45845017|NCT02164422|Drug|Placebo|
45361485|NCT03299478|Other|Will look for immune infiltration|
45361486|NCT00908700|Procedure|Surgical occlusion of the left atrial appendage|Study intervention: Within the trial, occlusion must be performed using either amputation and closure (cut and sew) or stapler device.
45361487|NCT00908700|Procedure|Best medical practice|Best medical practice for atrial fibrillation related stroke prevention as per guidelines.
45361488|NCT03291522|Procedure|Ultrasound-guided rete testis flushing and aspiration|Ultrasound-guided rete testis flushing and aspiration is performed first. If no sperm is found, the patient can choose to do a standard of care procedure (but not required).
45688499|NCT00121186|Procedure|peripheral blood stem cell transplantation|if donor peripheral blood stem cells are harvested
45688500|NCT00121810|Drug|mycophenolate mofetil [CellCept]|1.0-1.5 g oral dose twice daily
45688501|NCT00121810|Drug|Corticosteroids|As prescribed
45688502|NCT00121810|Drug|Calcineurin inhibitors|As prescribed
45688503|NCT00121810|Drug|Sirolimus|As prescribed
45688504|NCT00053014|Biological|therapeutic allogeneic lymphocytes|
45845018|NCT02165124|Device|Artificial Embolization Device|Embosphere Microspheres
45845019|NCT02165904|Biological|Adult Autologous Mesenchymal Bone Marrow Cell|Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells.
45688505|NCT00053014|Drug|cyclosporine|
45361489|NCT00629798|Drug|Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant|Patients will receive Palifermin 60 mcg/kg/day IV on three consecutive days with the last dose administered no less than 24 and no more than 48 hr prior to start of cytoreduction. The preparative regimen to be used for transplants will consist: of busulfan administered in 12 doses over three days of 0.8 mg/kg IV for patients > or = to 4 years of age or 1.0 mg/kg IV for patients < 4 years of age; melphalan 70 mg/m2 IV x 2 days; and, fludarabine 25 mg/m2 IV x 5 days
45361490|NCT00160615|Drug|Levetiracetam|"Pharmaceutical form: Film-coating tablets~Concentration: 250 mg/ 500 mg~Route of administration: oral use"
45688506|NCT00053014|Drug|fludarabine|
45688507|NCT00053014|Drug|mycophenolate mofetil|
45688508|NCT00053014|Procedure|peripheral blood stem cell transplantation|
45688509|NCT00053014|Radiation|radiation therapy|
45688510|NCT00123604|Drug|Carvedilol|25 mg twice daily for five months.
45688511|NCT00123604|Drug|Metoprolol|200 mg twice daily for five months.
45845020|NCT02167074|Device|25G FNA needle|
45845021|NCT02167074|Device|20G ProCore FNB needle|
45845022|NCT02170662|Drug|Bimatoprost|Bimatoprost 0.03% ophthalmic solution as purchased from the manufacturer will be the active drug.
45845023|NCT02170662|Drug|Placebo|
45845024|NCT02173392|Drug|Brodalumab|Brodalumab is a large molecule for the treatment of inflammatory diseases
45845025|NCT02178540|Drug|Placebo|one dose (4 capsules) of placebo
45361491|NCT03158454|Procedure|Capsula Closure|The capsular closure is performed with a minimum of two vicryl # 2 resorbable sutures
45361492|NCT03158454|Procedure|Non-Capsula Closure|No capsular closure procedure is performed.
45688512|NCT00123682|Procedure|Proactive outreach to counseling|Project staff reach out to engage referred smoker into telephone counseling
45688513|NCT00123682|Procedure|Reactive outreach to counseling|Project staff send a letter to referred smoker, asking them to call to engage in telephone counseling
45688514|NCT00123682|Procedure|Intensive counseling|Multi-session telephone counseling, delivered by California Smokers' Helpline
45688515|NCT00123682|Procedure|Self-help|Project staff send out self-help materials for smoking cessation
45688516|NCT00125788|Drug|L-glutamine|Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
45688517|NCT00125788|Drug|Placebo|Approximately 0.3 g/kg total daily dose of maltodextrin placebo will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
45688518|NCT00221338|Drug|Gabapentin|This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days
45688519|NCT00223678|Drug|Rapamycin|Rapamycin will start within 24 hours of last calcineurin inhibitors (Cya, Prograf). Initial dose of Rapamune 10mg will be given for 3 days and then dose will be adjusted to attain a target whole blood trough of 5-15
45688520|NCT04752436|Behavioral|Supra high intensity interval training|The exercise program will consist of eight 20-second all-out exercise bouts followed by 10 seconds of rest for a total of 4 minutes of total exercise duration. The intensity of exercise is all out. The exercise will be conducted 3 times a week for 8 weeks.
45361493|NCT00819650|Drug|Licartin (generic name,[131I]metuximab injection)|Licartin, radioiodination of Metuximab with Na[131I],with radiochemical purity above 95% and specific activity between 173.25-288.75 MBq/ml.All patients in the treatment group received Licartin 3 times at an interval of 28 days beginning from the 4th week after liver resection
45361494|NCT00906594|Drug|latanoprost|
45361495|NCT03970759|Drug|Stannous Fluoride Dentifrice|Experimental stannous fluoride (0.454%) dentifrice
45361496|NCT03970759|Drug|Positive control dentifrice|Positive control dentifrice containing (0.3%) triclosan.
45688521|NCT00053482|Biological|ACAM2000 Smallpox Vaccine|Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml
45361497|NCT03970759|Drug|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
45688522|NCT00053482|Biological|Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®|Group 5 dose: 1.0x10-8th PFU/ml
45361498|NCT00905112|Other|Manual Therapy|Receives manual therapy, stabilization exercise and patient education
45361499|NCT00905112|Other|Standard OB Care|Receive standard obstetrical care
45688523|NCT00130780|Drug|Pre-surgical Treatment with Bevacizumab plus Chemotherapy|On Cycle 1 Day 1,patient will receive bevacizumab 15 mg/kg. On Cycle 1 Day 15, patients receive docetaxel (75 mg/m2), cisplatin (75 mg/m2). Cycle 2 begins 21 days after administration of docetaxel and cisplatin in Cycle 1. In Cycles 2 thru 3, patients will receive 2 preoperative 21-day cycles of docetaxel (75 mg/m2), cisplatin (75 mg/m2), and bevacizumab (15 mg/kg), all given on Day 1 of each cycle. The sequence of administration will be docetaxel, followed by cisplatin, followed by bevacizumab according to MSKCC Chemotherapy Guidelines. In Cycle 4 Day 1, patients will receive docetaxel (75 mg/m2) and cisplatin (75 mg/m2). Bevacizumab will not be given with Cycle 4. During Cycle 4, the only scheduled clinic visit will be on Day 1. Surgery will occur at least 42 days after the last treatment with bevacizumab. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
46049181|NCT02877992|Procedure|Ovarian puncture|Donors and patients are subjected to ovarian puncture as part of their donation procedure or IVF treatment. Oocyte are retrieved in this procedure along with granulosa and cumulus cells. Donors and patients sign an informed consent in order to donate their granulosa and cumulus cells for the study.
46049182|NCT05380908|Other|None of any intervention|The patients did not have any intervention.
46049183|NCT02626078|Other|observation and interview of residents|Residents will be observed during lunch to evaluate their behavior, verbal interactions between residents. The food intake during 24 hours will be evaluated also. In an interview after lunch, the appreciation of the meal by residents will be assessed by a questionnaire and the score of the nutritional state will be defined.
45361500|NCT00643448|Drug|AZD1305|AZD1305 loading dose 250 mg + 125 mg evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
45361501|NCT00643448|Drug|AZD1305|AZD1305 loading dose 500 mg + placebo evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
45361502|NCT00643448|Drug|Placebo|Placebo corresponding to AZD1305 loading dose + evening dose on Study Day 1, maintenance dose twice daily from Study Day 2
45361503|NCT03972631|Behavioral|Lifestyle education|Lifestyle education include the diet principles, physical activity guideline and behavioral strategies.
45361504|NCT03972631|Behavioral|Intensive lifestyle intervention|One to one intensive lifestyle intervention according to the diet and activity plan
45361505|NCT03972631|Behavioral|Hypocaloric low-carbohydrate diet plan|A diet plan with restricted calorie and carbohydrate intake
45361506|NCT00908778|Drug|Vitreosolve|intravitreal injection
45361507|NCT00908778|Drug|Vitreosolve|intravitreal injection
45361508|NCT00905190|Drug|Ondansetron|24 mg one time
45361509|NCT00908856|Biological|autologous bone marrow mononuclear cell transfusion|a single intravenous transfusion approximately 2 days after bone marrow aspiration, and 4 days after stroke onset; the full amount of autologous mononuclear cells derived from 30 cc of bone marrow
45361510|NCT00908856|Biological|marrow stromal cells|a single intravenous transfusion approximately 21 days after bone marrow aspiration, and 23 days after stroke onset; the full amount of marrow stromal cells cultured over 21 days from 30 cc of bone marrow (expected to be approximately 1,000,000 cells/kg body weight)
45361511|NCT00908856|Drug|placebo|a single intravenous transfusion of saline, approximately 2-21 days after bone marrow aspiration, and 4-23 days after stroke onset; the full amount of mononuclear cells derived from 30 cc of bone marrow
45361512|NCT00905502|Drug|Lactated Ringer's solution|Patients in the RG received 4 ml/kg•hr of Lactated Ringer's solution (RL) throughout the intra-operative period
45361513|NCT00905502|Drug|Lactated Ringer's solution|patients in the LG received 10 ml/kg•hr of RL solution intraoperatively
45361514|NCT00908934|Drug|AZD9056 formulation Phase III 50 mg (T)|Given as 50 mg tablet (T)
45361515|NCT00908934|Drug|AZD9056 formulation Phase IIb 50 mg (R)|Given as 50 mg tablet (R)
45361516|NCT00908934|Drug|AZD9056 formulation Phase III 200 mg (T)|Given as 400 mg (2 x 200 mg tablet (T))
45688524|NCT00130780|Drug|Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab|Patients will receive preoperative 21-day cycles of cisplatin (75 mg/m2) and docetaxel (75 mg/m2) both given on Day 1 of each cycle.Patients will undergo repeat CT imaging after 2 cycles of therapy and patients with at least 10% reduction in bidimensional tumor volume will receive 2 additional neoadjuvant cycles of therapy (total 4 cycles of therapy).Surgery will occur at least 4 weeks after the last treatment with docetaxel and cisplatin.Adjuvant bevacizumab (15 mg/kg q21 days for 1 year, total 18 cycles) will be administered to all patients who undergo resection. Adjuvant bevacizumab will begin between days 42 and 56 after surgery.Patients may be referred for post-operative radiation therapy at the discretion of the treating physician. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
45361517|NCT00908934|Drug|AZD9056 formulation Phase IIb 200mg (R)|Given as 400 mg (2 x 200 mg tablet (R))
45361518|NCT00604500|Drug|SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )|MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MF/F MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
45361519|NCT00905658|Dietary Supplement|therapeutic nutritional supplementation|Patients receive systematic nutritional supplementation
45845026|NCT02178540|Device|Tobi Podhaler|The capsule containing the study medication has to be released from the blister card, be inserted into the Podhaler device, actuated and the study drug be inhaled according to instructions for use
46049184|NCT04307888|Device|Perclose Proglide (Abbott)|Common Femoral Artery percutaneous access closure by means of Perclose Proglide device
45361520|NCT00905658|Procedure|standard follow-up care|Patients undergo standard monitoring
45361521|NCT00906672|Device|INTEGRA®|A plaque of dermal substitute Integra® is adjusted to the size of the wound and sutured. A negative pressure bandage is placed on the wound. 7 to 11 days post surgery, the Integra® silicone layer is removed and the neoderm is covered with a skin graft.
45361522|NCT00906672|Procedure|Flap technique|A flap is a part of skin, cutaneous tissue or muscle that is taken from an healthy area of the body and put on the damaged area for coverage.
45361523|NCT00627458|Biological|Infanrix Hexa|Vaccine administered as a booster dose at 16-20 months of age
45361524|NCT00909168|Drug|FLAIMy - Fluda, Ida, Ara-C, Mylotarg|"FLUDARABINE: 25 mg/m2/day, 250 FS in 30', start h 9 - 1, 2, 3, 4, 5~ARABINOSYL-CYTOSINE (Cytarabine): 2 g/m2/day, 500 FS in 3 h, start h 13 - 1, 2, 3, 4, 5~IDARUBICIN: 10 mg/m2/day, 100 FS in 1 h, start h 16 - 1, 3, 5~GEMTUZUMAB OZOGAMICIN (Mylotarg): 5 mg, single dose 500 FS in 4 h - 6"
45361525|NCT00905736|Procedure|Microcurrent treatment (controlled current)|primarily monophasic waveform of average amplitude 40 microamps, 1 hr daily for 3 weeks
45845027|NCT02178696|Other|Placebo, identified as placebo to participants|White tablets
46049185|NCT05379036|Drug|prescribing anapproved drug, examination|"Blood test to assess serum zonulin levels;~Esophagogastroduodenoscopyand colonoscopy with biopsy from the small and large intestine followed by histological examination;~Stool sample collection to assess short-chain fatty acid levels and the composition of the gut microbiota.~Then the patients were prescribed therapy with the approved drug trimebutin (trimedat) with placebo or trimebutine with rebamipide or rebamipide with placebo for 2 months."
46049186|NCT00686608|Dietary Supplement|glucose|0.3mg/kg of glucose
46049187|NCT00686608|Dietary Supplement|fructose|fructose IV bolus
46049188|NCT00686608|Dietary Supplement|saline|IV saline
46049189|NCT02879474|Behavioral|Melanoma scale questionnair|
45361526|NCT00905736|Procedure|Micocurrent treatment (controlled voltage)|Microcurrent delivered for 6 hours daily for 3 weeks
45361527|NCT00906750|Biological|FluMist|FluMist is a live attenuated intranasal influenza vaccine
45361528|NCT00906750|Biological|Inactivated influenza vaccine|Inactivated influenza vaccine
45361529|NCT00816218|Drug|Pioglitazone|pioglitazone, 45 mg daily
45361530|NCT01562964|Behavioral|Hypnotherapy|Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
45361531|NCT01562964|Behavioral|Supportive therapy|Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min.
45361532|NCT00819728|Drug|Docetaxel|35mg/m2 IV each week for 4 weeks
45361533|NCT00819728|Drug|Irinotecan|50mg/m2 IV each week for 4 weeks
45361534|NCT00906828|Drug|levodopa/carbidopa|intestinal gel, continuous infusion (daytime or 24-hour)
45361535|NCT00906828|Drug|entacapone|Tablet, 200 mg, given twice during the study at t=0h and t=5hrs
45361536|NCT00906828|Drug|tolcapone|Tablet, 100 mg, given twice during study, at t=0h and t=5hrs.
45361537|NCT00819806|Biological|Vaccine only|PF-3512676, Montanide ISA 720 VG and MHC class I peptides from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. The remaining 1.5 ml will be used for sterility testing. Each injection will be done in the vicinity of the nodal drainage of one extremity.
45361538|NCT00819806|Biological|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I-restricted epitopes from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) and cyclophosphamide. The vaccine preparation is identical to arm A. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
45479999|NCT03791177|Other|Music Therapy|"Patients in the study group were exposed to flute music therapy (Sufi musical recital - Huseyni mode) at low tempo (60-80 rhythm / min) with weak beats and calm rhythms during the UDS.~This audition involves both vocal and instrumental music performed by a reed flute called 'Ney'. A competent lecturer who was specialized in music suggested all the musical compositions during the therapy"
46049190|NCT02850666|Behavioral|Interdisciplinary process drama|Process drama program (5 days/week, 1 week, 25-3 hour sessions) of movement-based activities combining music, art, and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists.
46049191|NCT00684268|Drug|Silibinin|"comparison of different dosing schedule of Silibinin infusions (20 mg/kg/d infused over 2 hours) A: 3x5days B: 14 days C: 21 days D: 28 days~sequential the infusion duration will be shortened - 2 hours, then 1 hr and then 1/2 hr/infusion"
46049192|NCT00684268|Drug|Silibinin|20 mg/kg Silibinin iv /d /21 days, antiviral combination therapy will be continued
46049193|NCT04302662|Drug|MS1819-SD|Patients will receive increasing doses from the lowest to a maximum dose of MS1819-SD on top of a stable dose of PPEs. The total treatment phase will range from 39 to 51 days.
45688525|NCT04752748|Drug|Drug protocol|"The following drug scheme was carried out: The patients began with methotrexate (MTX) 15 mg / week, which was increased to 25 mg / week until week 12. Subsequent steps for patients with an insufficient response (DAS28 score> 3.2 and the Physician's Global Assessment (PGA)> 4.0 [0-10 cm]) were leflunomide 20mg / day with MTX 15 mg / week from week 12 to week 24 and adalimumab twice a month and MTX 15mg / week from week 24 to week 48. The use of 5mg folic acid was advised once a week during the 48 weeks of the study. Three treatment failures were considered over these 48 weeks:~Failure 1: failure of the first DMARD (MTX) in week 12.~Failure 2: failure of the second DMARD (leflunomide) at week 24~Failure 3: failure of the first immunobiological (adalimumab) at week 48."
45361539|NCT00819806|Biological|Vaccine only|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102) and three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
45361540|NCT00819806|Biological|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102), three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) and cyclophosphamide. The vaccine preparation is identical to arm C. Low-dose cyclophosphamide (300mg/m2) IV will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
45361541|NCT00819806|Biological|Vaccine only|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injection (i.e. 3 mg of PF-3512676 or 300 μl of PF-3512676 at 10mg/ml, 300 μg or 900 μl of protein NY-ESO-1 at 0.35 mg/ml + Montanide ISA 720 VG). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml SC injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
45361542|NCT00819806|Biological|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injections and cyclophosphamide. The vaccine preparation is identical to arm E. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
45361543|NCT00909402|Drug|BMS-833923|Capsule, Oral, Starting dose 30 mg, Once daily, continuous until discontinuation from study
45361544|NCT00909402|Drug|Cisplatin|Vial, intravenous (IV), 80 mg/m² IV, Once every 21 days, 1 day per cycle until discontinuation from study
45361545|NCT00909402|Drug|Capecitabine|Tablets, Oral, 1000 mg/m², twice a day (BID), 14 days per cycle, until discontinuation from study
45361546|NCT00821366|Behavioral|ARV peer adherence support (PAS)|Adherence support provided during twice weekly visits to the patient by an experienced ART patients who received basic training in ARV peer adherence support
45361547|NCT00821366|Dietary Supplement|Nutritional support|Weekly delivery by peer adherence supporter (PAS) of two 400g cans of meatballs and spaghetti in tomato sauce
45361548|NCT00821366|Drug|ARV treatment|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme
45688526|NCT00041392|Drug|Magnesium|100 mg/kg
45361549|NCT02538120|Other|Microvascular assessment|Microvascular assessment
45361550|NCT03862118|Other|PRP|platelet rich plasma will be delivered by intradermal method using mestherapy needle.
45688527|NCT00041392|Drug|0.9% saline|Placebo
45688528|NCT02091778|Device|Fast gelling dressing|
45361551|NCT02537964|Other|washcloths impregnated with 2% chlorhexidine gluconate|All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
45361552|NCT00819884|Drug|AZD1656|Oral suspension
45361553|NCT00821444|Drug|ziprasidone|40 mg capsule, single dose x 3
46049194|NCT04256226|Procedure|Tumor excision|Excision of GIST
46049195|NCT00686764|Other|Observational|"Using ultrasound, we will measure the cross-sectional area of the neuroma at its widest point and compare to the cross-sectional area of the same nerve at the lesser trochanter.~We will be using four different metrics for quantifying the pain experience of each subject: Questionnaire for Persons with Transfemoral Amputation (Q-FTA), Trinity Amputation and Prosthesis Experience Scales (TAPES), Visual Analog Scale (VAS), and the Short-Form 36 (SF-36)."
46049196|NCT00604656|Drug|insulin aspart|
46049197|NCT00684346|Other|18-FDG|The administered intravenous dose of 18-FDG is 0.14mCi/kg up to a maximum of 10mCi before each PET imaging scan is performed.
46049198|NCT00874120|Drug|Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg|Phenylephrine HCl Extended-Release tablets 30 mg taken twice daily (12 hours apart) for 7 days.
46049199|NCT00874120|Drug|Placebo|Placebo taken twice daily (12 hours apart) for 7 days.
45688529|NCT04752046|Procedure|maxillary cancer resection|patient with maxillary cancer will resected and reconstructed
45688530|NCT04752202|Behavioral|Individually balanced elimination/reducing diets|Participants received diets in the range of 1400-1600 kcal/day (with a deficit of about 1000 kcal/day, depending on the resting metabolism and energy expenditure during the day). At the initial visit and every subsequent month, the women received individually balanced elimination/reducing diets, in accordance with the previously performed food sensitivity tests for 6 months. Laboratory tests for type III food sensitivity in the IgG1-3 class using the ELISA method were performed in an accredited medical laboratory. Diets were designed by a qualified dietitian using the Aliant (Poland) diet calculator. Each diet had the same macronutrient content - 25% protein, 30% fat, and 45% carbohydrate, and met the daily requirements for micro and macro elements for the given age group.
45688531|NCT04752202|Behavioral|Individually balanced reducing diets (without elimination)|Participants received diets in the range of 1400-1600 kcal/day (with a deficit of about 1000 kcal/day, depending on the resting metabolism and energy expenditure during the day). At the initial visit and every subsequent month, the women received individually balanced reducing diets (without elimination) for 6 months.Diets were designed by a qualified dietitian using the Aliant (Poland) diet calculator. Each diet had the same macronutrient content - 25% protein, 30% fat, and 45% carbohydrate, and met the daily requirements for micro and macro elements for the given age group.
45688532|NCT02091856|Behavioral|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT) represents a psychotherapeutic approach that helps patients understand the thoughts and feelings that influence behaviors. The underlying concept behind CBT is that thoughts and feelings play a fundamental role in behavior. Beyond the conventional CBT techniques proven effective for MDD, the Positive CBT intervention includes set of exercises devised from the positive psychology paradigm. Similarly, the Christian CBT intervention includes a comparable set of exercises rooted on the general Christian belief.
45688533|NCT00225784|Drug|Cetuximab/Gemcitabine|Once weekly Cetuximab, twice weekly Gemcitabine for six weeks
45688534|NCT00225784|Procedure|Radiotherapy|Daily radiotherapy for 28 days
45688535|NCT02092168|Drug|BIA 9-1067|
45688536|NCT00132964|Device|Below knee walking cast|Not required
46049200|NCT00939822|Drug|Simvastatin|40 mg Simvastatin/day
46049201|NCT00939822|Drug|Placebo|Matching Placebo
45688537|NCT00132964|Device|Removable ankle brace|not required
45688538|NCT01897246|Procedure|Corrective osteotomy with computer-assisted pre-operative planning|The corrective osteotomy will be planned with computer-assisted pre-operative planning and virtual osteotomy.
45361554|NCT00821444|Drug|B16 Fasted|40 mg tablet, single dose X 3
45361555|NCT00821444|Drug|B16 Fed|40 mg tablet, single dose X 3
45361556|NCT00909558|Biological|Autologous Natural Killer / Natural Killer T Cell Immunotherapy|"The study drug is derived from ex vivo expansion of each subject's own white blood cells and is therefore autologous.~The current study proposes a 3-course treatment of doses administered at one week intervals with monitoring at each administration plus 2 weeks after the last dose. The total study time (apheresis through last follow-up) is estimated at 15 weeks."
45361557|NCT00819962|Drug|Bupivacaine|Local anesthetic
45480000|NCT05420896|Other|Manual Therapy|Upper cervical spine mobilization Posterior-anterior mobilization of the fifth cervical vertebra Suboccipital inhibition Suboccipital mobilization Trigger point application to my masseter, temporal and sternocleidomastoid muscles Intraoral and extraoral myofascial release Intraoral sphenopalatine ganglion technique TMJ mobilization Massage for chewing muscles The 45-minute treatment program, which includes applications including the techniques above, will be applied to the patients randomly assigned to the study group once a week for a total of 4 weeks.The changes in muscle activity of the masseter and anterior temporalis bilaterally will be recorded with EMG.
45688539|NCT01897246|Procedure|Corrective osteotomy with conventional preoperative planning|The corrective osteotomy will be planned with conventional preoperative planning.
45688540|NCT00133978|Other|Glutamine|0.35 gm/kg/day parenterally and 30 gms/day enterally
45688541|NCT00133978|Other|Antioxidants|500 micrograms of selenium/day parenterally and selenium 300 microgram, zinc 20 mg, beta carotene 10 mg, vitamine E 500 mg and vitamin C 1500 mg per day enterally
45688542|NCT00133978|Other|Glutamine + Antioxidants|0.35 g/kg/day glutamine parenterally and 30 g/day of glutamine enterally. 500 mcg selenium parenterally plus the following administered enterally: selenium 300 mcg, zing 20 mg, beta-carotene 10 mg, vitamin E 500 mg and vitamin C 1500mg
45688543|NCT00133978|Other|Placebo|Normal saline intravenously and EN placebo formula (from Fresenius Kabi, Germany)
46049202|NCT04139512|Procedure|guided surgery|placement of implant with local anesthesia using full guided surgery protocol versus free- hande one
46049203|NCT04139512|Procedure|conventionnel implant placement|placement of dental implant with conventionnal freehand technic
46049204|NCT00687154|Procedure|Scatter Laser Photocoagulation in 1 Sitting|1 sitting with a minimum of 1200 to a maximum of 1600 burns, with one burn width separation of burns and scatter extending from the peripheral arcades to beyond the equator.
46049205|NCT00687154|Procedure|Scatter Laser Photocoagulation in 4 Sittings|4 sittings, each separated by four weeks (+4 days), with approximately 300 burns in each of the first two sittings and investigator judgment for number of burns for the third and fourth sittings as long as the total for the four sittings is between 1200 and 1600 burns.
46049206|NCT05382936|Drug|SL-901|Patients will take study medication daily, with dosage based on their assigned cohort and regimen.
46049207|NCT00690352|Behavioral|Specialized Substance Abuse Supervision (SSAS)|Six months participation in SSAS which may include cognitive behavioral therapy (CBT) in groups; use of incentives, positive reinforcement, and/or motivational interviewing.
45361558|NCT00819962|Other|TAP|
45361559|NCT00927342|Other|Vivostat|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Vivostat sealant applied to the surface of the lung in an attempt to eliminate air leak
45361560|NCT00927342|Other|BioGlue|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Bioglue sealant applied to the surface of the lung in an attempt to eliminate air leak
45361561|NCT00542919|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily until progressive disease
45361562|NCT03861962|Other|"DNA sequencing called new generation (or NGS)"|"Redo HLA-typings with a method exploring all the genes (add DQA1, DRB3 / 4/5, DPB1 and DPA1), i.e. DNA sequencing called new generation, when this has not been done after the graft as part of the standard care"
45382218|NCT05220709|Diagnostic Test|bio impedance spectroscopy by means of the Body Composition Monitor (Name of the device is BCM from Fresenius Medical Care D GmbH)|The Body Composition Monitor provides information about the hydration status by a bioimpedance spectroscopy measurement of the body composition from which the level of overhydration can be derived. Four electrodes are used per measurement. All subjects get electrodes attached, following the wrist-ankle approach, in a tetrapolar arrangement. Two electrodes are placed on the hand: one on the wrist, and the second on the dorsal side of the metacarpalia, close to the phalanges. The other two electrodes are placed on the foot: one on the ankle, and the second on the dorsal side of the metatarsals, close to the phalanges of the toes. Age, gender, height, weight and blood pressure are registered in the device before starting the measurement. If the quality calculated by BCM is < 60%, the measurement will be repeated again. Measurements are taken under supervision of a trained technician or nurse.
45382219|NCT05218863|Other|No intervention|No intervention
45382220|NCT05217303|Drug|HL-085|HL-085 capsule administered orally twice daily (BID) in a 21-day treatment cycle
45382221|NCT05216393|Other|RecTech Match Website|Participants will have access to the Rectech Match website. These participants will receive 9 health coaching calls. Fitbit physical activity data will be collected on an ongoing basis during the intervention.
46049208|NCT00685126|Drug|Levalbuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, low dose (0.15 mg, 0.31 mg or 0.63 mg), adjusted for body weight
46049209|NCT00685126|Drug|Levalbuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, high dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
46049210|NCT00685126|Drug|Albuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
45382225|NCT05205252|Drug|Tazemetostat|Orally, twice daily in continuous 28-day cycles.
45688544|NCT01897324|Drug|Growth hormone (Norditropin, Novo nordisk)|
45688545|NCT01897948|Other|Milk-based beverage without DHA|
46049211|NCT00606216|Procedure|MRI and cognitive evaluation|Patients will undergo a brain MRI study and a brief neuropsychological evaluation, at the time of enrollment for controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients. A follow-up MRI and cognitive evaluation will be performed approximately 12 months after the transplant for patients.
46049212|NCT00606216|Procedure|MRI and cognitive evaluation|Pt will undergo a Magnetic Resonance Imaging (MRI) study of the brain and a brief neuropsychological evaluation, at the time of enrollment for healthy controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients (Baseline/Time 1).
46049213|NCT00606216|Procedure|brain MRI study and a brief neuropsychological evaluation|A brain MRI study and a brief neuropsychological evaluation will be performed at baseline (Time 1). A follow-up MRI and cognitive evaluation will be performed and about 12 months after the baseline for healthy controls
46049214|NCT00687232|Drug|AZD4818|Dry powder, inhalation, b.i.d, 10 + 1/2 days or 20 + 1/2 days
46049215|NCT00687232|Drug|Placebo|
46049216|NCT05382780|Other|The breather respiratory muscle trainer|The breather respiratory muscle training device is a high quality and effective trainer designed to specifically train the inspiratory and expiratory muscles in one same breathing action. The device allows for adjustable levels of resistance using easy-to-read dials, which allows you to adjust the device to the settings you require. The inhale settings allow for adjustment 1-6 with 1 being the easiest and 6 being the hardest, while the exhale settings allow for adjustment 1-5, where 1 in the easiest and 5 the hardest.
46049217|NCT05382780|Other|Diaphragmatic and localized breathing exercises|"A. Diaphragmatic breathing exercises:~Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.~B. Localized Breathing:~Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.~C. Mild Interval training exercise"
46049218|NCT05382780|Other|interval aerobic training and respiratory training|mild intensity interval aerobic training and respiratory training on treadmill
46049219|NCT04138654|Dietary Supplement|Processed meat product|300 grams per day during 2 weeks
45688546|NCT01897948|Other|Milk-based beverage with DHA at mid level|
45382226|NCT05205252|Drug|Tafasitamab|Intravenously, 12 mg/kg, once daily on Cycle 1: Days 1, 4, 8, 15 and 22 of the 28-day cycle. Cycles 2 and 3: Days 1, 8, 15 and 22 of each 28-day cycle. Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle.
45382227|NCT05205252|Drug|Lenalidomide|Orally, 10 mg or 20 mg based on kidney function, once daily from Days 1 to 21 of continuous 28-day cycles for up to 12 cycles.
45382228|NCT05205252|Drug|Acalabrutinib|Orally, 100 mg, twice daily.
45688547|NCT01897948|Other|Milk-based beverage with DHA at high level|
46049220|NCT04138654|Dietary Supplement|White meat wash-out|300 grams per day during 2 weeks
46049221|NCT04138654|Dietary Supplement|Processed meat products enriched with natural compounds|300 grams per day during 2 weeks
45382229|NCT05205252|Drug|Daratumumab (Intravenously)|Intravenously, 16 mg/kg actual body weight, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
45382230|NCT05205252|Drug|Mosunetuzumab|Subcutaneously, step-up doses on Cycle 1 Days 1 (5 mg), 8 (45 mg) and 15 (45 mg) and then 45 mg from Cycle 2 through 12 on Day 1 of the 28-day cycle.
45688548|NCT00253708|Procedure|management of therapy complications|
45688549|NCT00253708|Procedure|massage therapy|
45688550|NCT00253708|Procedure|pain therapy|
45688551|NCT00253708|Procedure|psychosocial assessment and care|
45688552|NCT00253708|Procedure|quality-of-life assessment|
45688553|NCT00254410|Drug|Fludarabine|Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6
46049222|NCT04138654|Dietary Supplement|Drinking water containing nitrate up to acceptable daily intake level (ADI = 3.7 mg/kg bw) in combination with 300 grams of processed meat, white meat or processed meat enriched with natural compounds|3.7 mg nitrate/kg bw per day plus 300 grams of meat for 1 week
46049223|NCT00604734|Device|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
45361563|NCT00820118|Drug|Structured treatment interruption|"The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir~Usual dosage recommended :~atazanavir : 300 mg/d~ritonavir : 100 mg/d~abacavir 600 mg and lamivudine 300 mg : once a day~tenofovir 245 mg and emtricitabine 200 mg : once a day"
45688554|NCT00254410|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6.
46049224|NCT05380674|Behavioral|The short questionnaire of healthy habits|collects sociodemographic data, weight, height, and physical activity, self-reported.
46049225|NCT00687310|Behavioral|Educational intervention|Tailored asthma education based on needs assessment
46049226|NCT00690508|Procedure|Supra-Sternal Tube-Tip Palpation (SSTTP)|The supra-sternal palpation of the tube after tracheal intubation.
45361564|NCT00927498|Drug|conventional chemotherapy (AraC + Daunorubicin),|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4."
45361565|NCT00927498|Drug|Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1."
45361566|NCT00820196|Drug|Nexagon®|
45361567|NCT00820196|Drug|Nexagon® vehicle|
45361568|NCT00909636|Drug|ABT-333|See arm description for more information
45361569|NCT00909636|Drug|Placebo|See arm description for more information
45361570|NCT05711355|Procedure|Use of Platelet-Rich Plasma after meningomyelocele sac repair|Wound healing with the use of Platelet-Rich Plasma after surgical meningomyelocele pouch repair
45361571|NCT05711355|Procedure|meningomyelocele sac repair|meningomyelocele sac repair without Platelet-Rich Plasma
45361572|NCT00816296|Other|Blood Draw|2 tablespoons of blood will be drawn from participants at study entry, 3 months after study entry, and 6 months after study entry.
46049227|NCT05382624|Procedure|Abdominal circumference was measured at the umbilical level in the standing position at the end of a normal expiration.|The operation time (the time from the beginning of the surgical incision until the end of surgery), anesthetic complications, such as nausea or vomiting, the number of patients requiring ephedrine and atropine, the total amount of intravenous fluid used, and the total amount of ephedrine used during surgery were recorded.
46049228|NCT04139590|Device|Panda|
45361573|NCT00816296|Other|Stool collection|Stool will be collected from participants 3 times during the study -- at study entry, 3 months from study entry, and 6 months after study entry.
46049229|NCT04139590|Device|Visual Analogue Scale - Original|
45361574|NCT00816296|Other|BodPod Measurement|Body composition will be measured using a BodPod at study entry, 3 months after study entry, and 6 months after study entry.
45361575|NCT00816296|Other|Liver Ultrasound|A liver ultrasound will be performed at study entry and 6 months after study entry.
45361576|NCT00909714|Device|DC-Stimulator to apply tDCS|Anodal tDCS (20 minutes) stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
45688555|NCT00254410|Drug|Mitoxantrone|Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6.
45688556|NCT00254410|Drug|Rituximab|Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6.
45688557|NCT00254410|Drug|Filgrastim|Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
45688558|NCT00254488|Drug|Lithium (LI)|The starting LI dose will be 150 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma LI level ranges between 0.40 and 0.99 mEq/L (target 0.80 to 0.99 mEq/L).
45361577|NCT00909714|Device|DC-Stimulator to apply Sham tDCS|Sham stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
45688559|NCT00254488|Drug|Divalproex (DV)|Dosage of DV will be 250 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma DV level ranges between 40 and 99 mcg/mL (target 80 to 99 mcg/ml).
46049230|NCT05382468|Other|Intradialytic exercise|Intradialytic exercise comprised of a set warm up, aerobic, active,passive & cool down activities performed by patients during dialysis for a period of 30 min twice or thrice a week regularly for one month & supervised by principle investigator.
45361578|NCT00816374|Other|Reading materials and discussions|"We will send 3 sets of materials via mail, containing information about melanoma prevention and detection, 1 set each month for 3 months. Materials published by:~The American Cancer Society~The American Academy of Dermatology~The Skin Cancer Foundation~The pamphlets contain information about ways to reduce risk for skin cancer including:~Sun protection practices~Risk factors for melanoma~Information about what melanoma looks like~How to do skin self-examinations~There will also be a telephone discussion with a health educator, discussing melanoma and other information contained in the pamphlets."
45361579|NCT00816374|Other|Reading materials and discussions|"We will send 3 separate pamphlets created specifically for participants. We will send 1 pamphlet each month for 3 months. The information in the pamphlets will be based on answers from the first survey. These pamphlets will contain information about:~Melanoma and skin cancer protection guidelines~The benefits of skin screening practices~Ways to protect yourself from the sun~In addition to these pamphlets, there will be a telephone discussion with a health educator to discuss melanoma and other information contained in the pamphlets."
45361580|NCT00816374|Other|Questionnaires|"Both groups will complete 3 surveys; at the beginning, 3 months later, 6 months after the second survey. Each survey will ask about:~knowledge of melanoma~current and past skin cancer screening practices~current and past sun protection practices~attitudes about skin cancer and sun protection~feelings about relative's melanoma diagnosis and treatment"
45361581|NCT00906906|Device|Doppler probes|Probes to be placed on CPB tubing to measure blood flow
45361582|NCT00159913|Drug|Sildenafil citrate|oral; 20mg, 40mg and 80 mg; 3 times a day(TID)
45688560|NCT00255970|Other|DFDBA|Demineralized Freeze Dried Allograft bone
45688561|NCT00255970|Device|Regenafil|Demineralized Freeze Dried Bone in a porcine gel carrier
45361583|NCT00159913|Drug|Sildenafil citrate|oral; 10mg, 20mg and 40mg; 3 times a day(TID)
46049231|NCT00603876|Dietary Supplement|Almonds|100-110 grams (about 3/4 cupful)of almonds consumed daily for 28 days
45361584|NCT00159913|Drug|Placebo|oral; 3 times a day(TID)
45361585|NCT00159913|Drug|Sildenafil citrate|oral; 10 mg; 3 times a day(TID)
46049232|NCT00687388|Drug|selective alpha 1-blockers|Continued medication that the patient had before the enrollment of this study (tamsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks)
45361586|NCT05498259|Drug|Orelabrutinib|Orelabrutinib 150mg qd PO
45361587|NCT05498259|Biological|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle
45361588|NCT05498259|Drug|CHOP-like Regimen|cyclophosphamide, anthracene nucleus chemotherapeutics（doxorubicin，liposomal doxorubicin, etc.）, vinca alkaloids（vincristine, vindesine, etc.），and glucocorticoid （dexamethasone，prednison, etc.）.
45688562|NCT01899118|Radiation|Preoperative irradiation|50.4Gy/28F/5.5w
45688563|NCT01899118|Drug|Nimotuzumab|400mg/w，0-5w
45688564|NCT01899118|Drug|Oxaliplatin|130mg/m2 d1
45688565|NCT01899118|Drug|Capecitabine|825mg/m2 bid d1-5/w,1-5w
45688566|NCT00256984|Procedure|Stapled Transanal Resection (STARR) with Transtar (PROXIMATE®) 33 mm Circular Stapler|
45688567|NCT00231868|Drug|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
46049233|NCT00687388|Drug|celecoxib|200mg daily for 8 weeks
46049234|NCT00687388|Drug|alpha-blocker and NSAID|amsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks and celecoxib 200mg daily for 8 weeks
45361589|NCT00820274|Procedure|amniotic membranes|The amniotic membrane is taken with a sterile crowbar then applied side foetal face against the ulcer and displayed in a homogeneous way
45361590|NCT00821600|Drug|risperidone IR and LAI formulation|1 mg risperidone IR single injection, followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
45480001|NCT03467971|Drug|Metformin/Gliclazide Fixed Combination|Participants will receive single oral dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fasting or fed state.
45361591|NCT00987207|Drug|cyclosporine A|a single bolus of 2.5 mg/kg, administered before aortic cross-declamping
45361592|NCT00987207|Other|No injection|No cyclosporine A is administered before aortic cross-declamping.
45361593|NCT04044326|Procedure|The Solero Microwave Ablation|The Solero Microwave Ablation system (Angiodynamics Ltd, USA) with a single microwave applicator operating at a 2.45 GHz will be used to perform MWA
45361594|NCT00604188|Drug|Suboxone (SCH 000484)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride and Naloxone. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
45361595|NCT00604188|Drug|Subutex (SCH 028444)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
45361596|NCT03913377|Device|Spectacles|Subjects' own habitual spectacles
45361597|NCT03913377|Device|ACUVUE OASYS®1-Day with HydraLuxe™ Technology|Test 1
45361598|NCT00820352|Drug|bosentan|4 weeks of oral bosentan 62,5 mg b.i.d., followed by 8 weeks of 125 mg b.i.d.
45480002|NCT03138590|Device|Transcranial Direct Current Stimulation- Neuroconn DC Stimulator PLUS|Transcranial Direct Current Stimulation targeting the trigeminal nerve
45480003|NCT03319498|Other|Peppermint Oil Vapor|"2ml of the oil will be placed in the urine collection hat that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum."
45480004|NCT03319498|Other|Mineral Oil Vapor|"2ml of the mineral oil will be placed in the urine collection hat that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum."
45480005|NCT02487550|Biological|DC-CIK|Patients with renal cell carcinoma will receive autologous dendritic cells loaded with autologous tumor lysate (dendritic cell vaccine) by venous infusion of CIK cells.
46049235|NCT02625688|Other|Delayed cord clamping|We have decided to delay cord clamping in the intervention group to 3 minutes and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
45480006|NCT02487550|Biological|IL-2/IFN-α|Patients with renal cell carcinoma will receive IL-2/IFN-α by venous infusion.
45688568|NCT00231868|Procedure|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
45361599|NCT00820352|Drug|placebo|placebo twice a day for 12 weeks
45361600|NCT00927654|Drug|Iloprost (Ventavis)|Twice 20 µg at day 0 (total dose 40 µg) intraoperatively
45361601|NCT00927654|Drug|Isotonic Sodium Chloride solution 0.9 % (placebo)|Twice at day 0 intraoperatively
45361602|NCT05709327|Other|Integrating Smart Ring Wearable Technology in Pregnancy Health Monitoring (I-SMART)|Single-arm observational study where all participants in the study will be given a smart ring (Oura Ring) to wear throughout the duration of the study.
45361603|NCT02550704|Procedure|Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability|Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin, occludin and ZO-1.
45361604|NCT00927732|Drug|hydroquinidine|capsules of 300 mg LP, 1 or 2 or 3 times per day : frequency will be determined by tests after patient inclusion before her/his randomization
45361605|NCT00927732|Drug|placebo (sugar)|capsules of placebo have same design and color than capsules of hydroquinidine except for their content as they contain sugar and not hydroquinidine
45361606|NCT04423575|Other|Outpatient health care pathway|A surgical procedure performed as an outpatient procedure means that the patient leaves the hospital before 8pm the same day. The surgery is identical but the standard care pathway is reinforced to insure a safe return to home.
45361607|NCT00227539|Drug|cisplatin|
45361608|NCT00227539|Drug|pemetrexed disodium|
45361609|NCT00227539|Procedure|adjuvant therapy|
45361610|NCT00227539|Procedure|therapeutic conventional surgery|
45361611|NCT00227539|Radiation|fludeoxyglucose F 18|
45361612|NCT00816530|Device|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography|After density > 50% is confirmed by routine digital screening mammography, ABUS will be performed.
45361613|NCT02936622|Device|Zilver® Paclitaxel-Eluting Peripheral Stent|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
45361614|NCT02936622|Device|Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
45480007|NCT04442776|Behavioral|D-AIP|Intervention on change motivation, insight, medication adherence, drug consumption abstinence or reduction, therapeutic alliance, hopelessness and anxiety
46049236|NCT02625688|Other|Cord milking|If cord milking will be the allocated intervention, the recruiter will supervise the midwife, or obstetrician preforming the procedure, and count out loud the number of times the cord has been milked. During vaginal deliveries midwifes will be asked to maintain the infant at least 10 cm above the uterus until the cord is clamped. In case of caesarian sections the baby will be placed on the mother's laps and swaddled in sterile towels to prevent heat loss.
45361615|NCT02936622|Device|Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
45361616|NCT00927966|Drug|RAD001|Taken orally once a day.
45361617|NCT00927966|Drug|CP-751,871|Given intravenously on Day 1 of a 21-day cycle
45361618|NCT00227305|Drug|quetiapine fumarate|Oral dosing, flexible dosing
45361619|NCT00720941|Drug|Pazopanib|800 mg administered once daily orally continuous dosing
45361620|NCT00720941|Drug|Sunitinib|50 mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment
45361621|NCT05704335|Other|Questionnaire administration|A trained physician will administer a structured questionnaire
45361622|NCT00821756|Behavioral|OPAC (Outreach, Problem solving, Adherence, Continuity)|Assertive outreach immediately after the suicide attempt with about 8 home visits plus contact by telephone, phone messages, e-mails. Duration of intervention 6 months.
45361623|NCT00924222|Drug|Sevoflurane|Sedation with sevoflurane
45361624|NCT00924222|Drug|Propofol|Sedation on intensive care unit with propofol
45361625|NCT03866642|Device|Cadence Total Ankle Replacment|Cadence Total Ankle prosthesis
45361626|NCT00987285|Behavioral|CASM +|Computer Assisted Self Management plus Social Support
45361627|NCT00987285|Behavioral|CASM|Computer Assisted Self Management using and interactive, automated self-management program that uses web and interactive voice recognition (IVR) media
46049237|NCT02625688|Other|Early cord clamping|We have decided to clamp the cord in the early intervention group at 30 seconds and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
46049238|NCT00939510|Biological|sargramostim|All patients will receive GM-CSF at a dose of 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week. No dose escalation or de-escalations will be made to GM-CSF.
45361628|NCT03972319|Dietary Supplement|2 capsules of Concentrated omega-3 triglycerides- fish 1000mg (600mg Eicosapentaenoic acid (EPA), 1400mg Docosahexaenoic acid (DHA)) per day|4 weeks course of Omega-3 (2 capsules of Blackmores Omega Daily Concentrated Fish Oil per day
45361629|NCT00928122|Device|Intrastromal Correction of Presbyopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
45361630|NCT00928122|Device|Intrastromal correction of Myopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
45361631|NCT00928122|Device|Intrastromal Correction of Hyperopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
45361632|NCT00928122|Device|Intrastromal Correction of Myopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
45361633|NCT00928122|Device|Intrastromal Correction of Hyperopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
45480008|NCT03791021|Diagnostic Test|draw a person (DAP)|the subjects will be given a blank sheet of white paper and a pencil, and will be asked to draw themselves with no other additional instructions.
45480009|NCT03791021|Diagnostic Test|Edinburgh Postnatal Depression Scale (EPDS)|measure of postpartum depression symptoms.
45688569|NCT00231868|Drug|Carboplatin and Paclitaxel and Radiation Therapy|Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
45688570|NCT00257686|Drug|Pitavastatin|
46049239|NCT00939510|Drug|lenalidomide|Lenalidomide will be administered at 25 mg/day orally on days 1-21 of a 28-day cycle. Initially 6 patients will be entered at the 25 mg/day level. If 0 or 1 patients have a dose limiting toxicity, then the 25 mg lenalidomide + GM-CSF 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week will be accepted as the phase II dose.
46049240|NCT00939510|Other|laboratory biomarker analysis|Prior to the initiation of each cycle of therapy for the first 3 cycles, and at discontinuation from study blood will be collected for assessments of a prostate cancer specific immune response.
46049241|NCT00687466|Drug|Insulin|"Insulin Glargine will be administered subcutaneously at the dosage of 0.1 U/Kg/die for three months. In case no hypoglycemic episodes occur during this period, the dosage will be increased to 0.15 U/Kg/die in occasion of the first control (T1) and will be scheduled for other three months. If even during this latter period no cases no hypoglycemic episodes occur, at the second control (T2) the dosage will be increased to the maximum of 0.2/U/Kg/die. It is generally accepted that the final dosage of glargine can be tailored to each patient, but it should be maintained between 0.1 and 0.2 U/Kg/die.~Glargine should be administered once daily in the morning and always at the same hour."
45361634|NCT00820430|Other|Magnetic Resonance Imaging|Subjects will undergo 4 sequential MRI evaluations of the target knee within a 4 week period to calculate precision error (ICC) in determination of cartilage morphometry (cartilage volume, mean thickness, and surface area), cartilage collagen (regional cartilage T2), and cartilage proteoglycan (regional cartilage T1rho).
45361635|NCT05702931|Drug|Semaglutide 14 MG [Rybelsus]|At baseline participants will initiate treatment with 3mg of oral semaglutide dosing from weeks 1 to 4. Depending on tolerability the dose will increase to 7 mg daily from weeks 5 to 8 and 14 mg from week 9. Trial medication will be dispensed to subjects for the first time immediately after randomisation and adjusted week 5 and week 9.
45361636|NCT05702931|Drug|Placebo|Saline
46049242|NCT00606372|Procedure|OPCAB - the off-pump coronary artery bypass|surgical myocardial revascularisation without use of cardio-pulmonary bypass, using stabilising devices on beating heart
46049243|NCT04266288|Drug|Ketamine|Active drug
45361637|NCT01075711|Drug|Prednisone|According to SPC
45361638|NCT00820508|Drug|CHR-2845|Once daily oral ingestion of capsules (10, 40 or 80mg), dose depending on cohort, treatment cycle of 28 days
45361639|NCT00907062|Dietary Supplement|Ginkgo biloba|60 mg Ginkgo biloba per capsule, standardized to 15 mg ginkgofavonglycosides per pill
45361640|NCT01073371|Drug|Prilocaine|1.8mL infiltration of liposome-encapsulated 3% prilocaine, 3% plain prilocaine or 3% prilocaine with 0,03IU/mL felypressin in the buccal sulcus of the maxillary right canine
45361641|NCT00820586|Procedure|Mononuclear bone marrow derived cells|Direct intramyocardial percutaneous delivery of autologous bone marrow-derived total mononuclear cells or selected CD34+ cells
45361642|NCT00928278|Drug|Treatment A|Inhaled, 300/150, single dose
45361643|NCT00928278|Drug|Treatment B|Inhaled, 300/150, single dose
45480010|NCT03791021|Diagnostic Test|Beck Depression Inventory- II (BDI-II)|BDI-II is based on clinical observations of behaviors associated with depression, and it retains the somatic items in accordance with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria related to loss of energy. ansd sleep disturbances.
45845028|NCT02178696|Drug|Celexa or other antidepressant as clinically indicated|Open label s-citalopram, 20 mg start up dose, increasing to 40 mg as clinically indicated; If prior non-response to this medication is noted by the patient, alternative treatments may include another first-line antidepressant:fluoxetine 20 mg; paroxetine up to 60 mg; sertraline up to 200 mg; bupropion up to 300 mg
46049244|NCT04266288|Drug|Sodium Chloride 0.9%|Placebo
46049245|NCT02625532|Procedure|Follicular phase|Controlled ovarian stimulation starts on day 2-3 of the menstrual cycle with recombinant recombinant FSH + LH, adding cetrorelix when the follicles reach 14 mm size and ovarian maturation with triptorelin acetate
46049246|NCT02625532|Procedure|Luteal phase|Controlled ovarian stimulation is started between 3rd and 5th day after the first LH positive urine test, adding cetrorelix when follicles reached 14 mm size and ovarian maturation with triptorelin acetate
45361644|NCT00928278|Drug|Treatment C|Inhaled, 300/150, single dose + oral activated charcoal block
45361645|NCT00928278|Drug|Treatment D|Inhaled, 300/150, single dose + oral activated charcoal block
45361646|NCT03970369|Behavioral|Usual care|Personalized goals and an activity prescription.
45361647|NCT03970369|Behavioral|Monitor|Participants wear a step counter to track activity goals.
45361648|NCT04034394|Other|Electromoxibustion|Electromoxibustion is a electric device that mimic the burning or moxa. Subjects in this group will receive electromoxibustion using a knee-brace-like device which produces thermal stimulation with a moxa pad inside. The treatment will be delivered 3 times per week for 4 weeks.
45480011|NCT03791021|Diagnostic Test|Traumatic Events Questionnaire (TEQ)|The TEQ assesses experiences with nine specific types of traumatic events (e.g., accidents, crime, adult abusive experiences) reported in the empirical literature as having the potential to elicit PTSD symptoms.
45688571|NCT00257686|Drug|Pravastatin|
45845029|NCT02178696|Other|"Placebo, identifed to participants as Active medication"|Blue Capsule
46049247|NCT00687622|Drug|GSK1120212|Part 1-dose-escalation Part 2 - Recommended Part 2 dose Part 3 - characterize the range of biologically effective doses
45361649|NCT04034394|Other|Knee health education|Subjects in this group will attend 2 lessons (120 minutes each) of health education related to knee OA symptom management in a small group of 5-7 subject. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR.
45361650|NCT04005573|Dietary Supplement|VD3|VD3 50000 IU/ week for 8 weeks
45361651|NCT04005573|Dietary Supplement|omega 3- FA|Omega 3 FA group 300 mg once daily for 8 weeks
45361652|NCT04005573|Dietary Supplement|VD3 and omega- 3FA|50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks
45361653|NCT04005573|Other|no intervention|no intervention is given
45361654|NCT03970213|Drug|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|IV TXA given during surgery
45361655|NCT03970213|Drug|Normal Saline 0.9% Infusion Solution Bag|IV saline given during surgery
45361656|NCT00821834|Drug|clopidogrel (SR25990)|"Form: tablets~Route: oral"
45361657|NCT00821834|Drug|ticlopidine|"Form: tablets~Route: oral"
45361658|NCT00821834|Drug|Placebo|"Form: tablets~Route: oral"
45361659|NCT00924534|Drug|Placebo|Placebo
45361660|NCT00924534|Drug|SLV337|SLV337 400 mg/day
45361661|NCT00924534|Drug|SLV337|SLV337 800 mg/day
45361662|NCT00924534|Drug|SLV337|SLV337 1400 mg/day
45480012|NCT03049280|Device|Transoral robotic surgery|Transoral robotic surgery for T1 & T2 oropharyngeal cancers
45845030|NCT02179788|Behavioral|Standard care|Mothers will be instructed to thoroughly empty their breasts at least 8 times per 24 hours by breastfeeding, followed by breast expression with a combination of hand -expression and the use of a hospital-grade electric breast pump (provided by study).
46049248|NCT01098266|Drug|NGR-hTNF plus Best Investigator's Choice (BIC)|"NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
46049249|NCT01098266|Drug|Placebo plus Best Investigator's Choice (BIC)|"Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
46049250|NCT00687700|Drug|GSK961081|GSK961081 multidose dry powder inhaler (Diskus inhaler) will be available with dosing strengths of 400 micrograms and 1200 micrograms administered once daily in the morning.
45361663|NCT04005417|Drug|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
45361664|NCT04005417|Drug|Positive control dentifrice|Positive control dentifrice containing potassium nitrate or arginine.
45361665|NCT04005417|Drug|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
45361666|NCT01073839|Drug|Cisplatin and Gemcitabine|Cisplatin 25 mg/m2 days 1 and 8; next cycle starting day 22. Gemcitabine 1000 mg/m2 days 1 and 8; next cycle starting day 22. Total of 8 cycles.
45361667|NCT00820742|Drug|Macugen|Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks
45361668|NCT05356715|Procedure|Ultrasound guided bilateral ESBP|Patients in group A will be positioned in the lateral position , ESPB will be done under complete aseptic conditions , using , linear ultrasound probe(Philips HD11XE Ultrasound System) , to locate the ESP at the level of the fifth dorsal vertebrae , 22 G spinal needle will be used to inject 20 ml of 0.25% of bupivacaine in the ESP bilaterally, block will done by an expert anesthesiologist , who will not be included in the data collection
45361669|NCT00928356|Procedure|Hybrid CABG/PCI|Same sitting hybrid, robotic CABG/PCI
45361670|NCT00928356|Procedure|Off Pump CABG|Standard of Care Off Pump CABG
45361671|NCT03743454|Other|No intervention|No intervention will be applied.
45847686|NCT02849418|Drug|Placebo|Placebo injection contains sodium chloride (0.9 milligrams [mg]); 30 mL of the injection will be injected at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents
45847687|NCT02856828|Device|DIE|digital image enhancement
45847688|NCT02861118|Other|No Intervention|
45361672|NCT05698251|Behavioral|Uncertainty distress model|Psychological therapy intervention based on elements of traditional Cognitive Behaviour Therapy (CBT) for anxiety, illness uncertainty and intolerance of uncertainty.
45361673|NCT00585533|Drug|Erlotinib (Tarceva)|Erlotinib
45361674|NCT00924690|Other|Behavioral Messages|Participants will read 10 behavioral messages about colon cancer screening and physical activity.
45361675|NCT00924690|Other|Generic Messages|Individuals will read 10 generic messages about colon cancer screening and physical activity.
45361676|NCT04719741|Other|Parallel Assignment|Prospective, Triple blinded, randomized, controlled trial
45361677|NCT04085861|Behavioral|Mental health literacy in dancers|Receive a designed informative intervention (3 workshops of 90min each) aimed at improving their knowledge and skills on proper recovery, performance nutrition, and mental health literacy.
45361678|NCT04085861|Behavioral|Mental health literacy in dance teachers|Receive a designed informative intervention (3 workshops of 60min each) aimed at improving their knowledge and skills on how to identify and deal with mental health- and nutritional issues in dancers.
45361679|NCT00628862|Drug|Formoterol Turbuhaler® 4.5mg|4.5 mg inhaled twice daily
45361680|NCT00628862|Drug|Formoterol Turbuhaler® 9 mg|9 mg inhaled twice daily
45845031|NCT02179788|Drug|Metformin|"The metformin arm will be consuming Glucophage XR (metformin hydrochloride extended release, 750 or 500 mg, encapsulated in #00 opaque capsules for 4 weeks according to the following schedule:~Days 1-7, take one 750 mg capsule with evening meal (750 mg/day)~Days 8-14, take three 500 mg capsule with evening meal (1500 mg/day)~Days 14-28 (or through completion of post-intervention data collection), take four 500 mg capsules with evening meal (2000 mg/day)~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator.~The trial duration is 28 days (with a +/- 3 day cushion)"
45688572|NCT00234286|Behavioral|Comfort care education intervention|Comfort care education intervention, consisting of intensive, on-site staff training together with an electronic order set for palliative care and educational materials
45688573|NCT01469013|Drug|Placebo|
45847689|NCT02862912|Drug|Chloroprocaine|Administered as a single injection or continuously through an indwelling catheter - 50 mg
45847690|NCT02862912|Drug|Bupivacaine|A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)
46049251|NCT00687700|Drug|GSK961081 matching placebo|GSK961081 matching placebo multidose dry powder inhaler (Diskus inhaler) will be available to be administered once daily in the morning.
46049252|NCT00687700|Drug|Propranolol|Propranolol over encapsulated tablet will be available with dosing strengths of 40 milligrams administered orally with 240 milliliters of water.
46049253|NCT00687700|Drug|Propranolol matching placebo|Propranolol matching placebo over encapsulated tablet will be available to be administered orally with 240 milliliters of water.
46049254|NCT00935532|Drug|exenatide once weekly|subcutaneous injection, 2.0mg, once a week;
46049255|NCT00935532|Drug|insulin glargine|subcutaneous injection, titrated to achieve fasting serum glucose target, once a day
45847691|NCT02862912|Drug|Fentanyl|15 mcg Fentanyl will be included int he spinal anesthetic in both groups
45361681|NCT00628862|Drug|Turbuhaler® placebo|placebo inhaled twice daily
45361682|NCT00907140|Procedure|Positron Emission Tomography|FDG PET/CT imaging is performed at baseline, after 2 and 4 weeks of radiation therapy and approximately 3 months after chemoradiation is completed
45361683|NCT05420727|Drug|Ga-68-PSMA-11 PET/CT|Ga-68-PSMA-11 PET/CT imaging
45361684|NCT05420727|Drug|Lu-177-ITG-PSMA-1|Lu-177-ITG-PSMA-1 treatment
45361685|NCT04085783|Procedure|PRP|Platelet Rich Plasma
45361686|NCT00987363|Other|Intraarterial infusion of autologous bone marrow cells|Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x10 E8, 5x10E8 and 1x10 E9 in the low,intermediate and high dose arms respectively
45361687|NCT04086563|Other|Action observation|look at a clip of a hand doing neurodynamic exercises.
45361688|NCT04086563|Other|Mirror therapy|With a mirror glasses on, do the neurodynamic exercises with the non-dominant hand while the patient is looking at the dominant hand
45361689|NCT04086563|Other|Neurodynamic exercises|active movement of the dominant hand. Do neurodynamic exercises.
45361690|NCT04086563|Other|Strength|Execute a short strength training for the dominant hand
45361691|NCT00820820|Biological|ROUVAX|Measles vaccine (ROUVAX ®), Schwarz strain (>1000 DICC 50) in 0.5 ml of water for injection. One single subcutaneous injection.
45361692|NCT00820820|Biological|placebo|Vehicle (water for injection), 0.5 ml, once
45361693|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.3 microgram
45361694|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.4 microgram
45361695|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.5 microgram
45688574|NCT01469013|Drug|Baricitinib|
45688575|NCT01469013|Drug|Baricitinib|
45688576|NCT01469013|Drug|Baricitinib|
45688577|NCT01469013|Drug|Methotrexate|Administered orally as background therapy
45688578|NCT01493427|Drug|Travoprost 0.004%|Travoprost 0.004% without benzalkonium chloride (BAK), containing Polyquad (PQ) preservative
45361696|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.0625% plus sufentanil 0.4 microgram
45361697|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.1875% plus sufentanil 0.4 microgram
45688579|NCT01523457|Drug|Folfirinox|"Oxaliplatin 85 mg/m2 IV infused over two hours, followed by~Leucovorin 400 mg/m2 IV over two hours~Irinotecan 135 mg/m2 IV over 90 minutes (concurrent with leucovorin during the last 90 min of the leucovorin infusion)~5-FU 300mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46 hours~FOLFIRINOX is a chemotherapy regimen. It is made up of the following four drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; IRIN - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating; and OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis."
45361698|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.25% plus sufentanil 0.4 microgram
45361699|NCT00928824|Dietary Supplement|traditional Japanese diet|10 days of nitrate rich diet (Japanese traditional). After that switch to nitrate low diet for 10 days (European foods). Study nitrate/nitrite in blood, saliva and blood pressure 3 times in each person (10 min each time). A list of Nitrate rich foods are provided.
45361700|NCT00816686|Biological|AGS-16M18|IV Infusion
45361701|NCT00924768|Biological|20K EU CCRE|Inhalation of CCRE
45361702|NCT00584987|Drug|Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
45361703|NCT00584987|Drug|Placebo Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
45361704|NCT00584987|Drug|Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
45361705|NCT00584987|Drug|Placebo Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
45361706|NCT00924846|Procedure|High frequency oscillatory ventilation|Mechanical ventilation as high frequency oscillatory ventilation for 8h periods
45361707|NCT00924924|Behavioral|Act Healthy!|Six-week class of 50 minute sessions of self-management training for health behaviors
45361708|NCT00924924|Behavioral|Delayed treatment control|Delayed self-management training group - begins following completion of the experimental group training
45361709|NCT05373537|Behavioral|Cognitive behavioral therapy for Insomnia|Caregiver with insomnia will receive CBT-Insomnia and will be trained to implement CBT-I tailored for their child with Autism Spectrum Disorder and Insomnia
45847692|NCT02862912|Drug|Saline|Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml
45847693|NCT02864706|Drug|Everolimus|"All patients, independent of their initial randomization in the core study, were followed up as in one single group~Commercially available everolimus (Certican®), oral route, was used."
45361710|NCT00727961|Drug|Pegylated Liposomal Doxorubicin hydrochloride|Caelyx Intravenous, 50 mg/m^2 (60 minute infusion) on day 1, every 4 weeks, during 6 cycles
45361711|NCT00568958|Behavioral|BASICS counseling|Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.
45361712|NCT00568958|Drug|naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) naltrexone, 25mg each for a total possible dose of 50mg (the FDA-approved dose for alcohol dependence) in a given day for a period of 8 weeks.
45361713|NCT00568958|Drug|placebo naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) placebo for a period of 8 weeks.
45361714|NCT03540771|Other|Palliative Care|"The intervention will comprise an approach to render palliative care, as taught to hepatologists through an on-line learning platform, and as delivered by PC providers as routine care. The elements of the intervention, which will be guided by a checklist and implemented over the course of interactions with the patient and caregivers at the initial, 1, 2, and 3 month visits, to include:~Patient/caregiver understanding of diagnosis, illness and prognosis~Symptom assessment and management~Psychosocial assessment and management~Distress screening and management~Discussion of goals of care~Advanced directives"
45382231|NCT05205252|Drug|Daratumumab (Subcutaneously)|Subcutaneously, 1800 mg, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
45382232|NCT05205252|Drug|Hyaluronidase-Fihj|Subcutaneously, 30,000 units, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
45845032|NCT02179788|Drug|Placebo|"The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~Days 1-7, take 1 capsule with evening meal~Days 8-14, take 3 capsules with evening meal~Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator."
46049256|NCT04139356|Procedure|Deep breaths|Patients will undergo a 6 minutes protocol. Baseline: 1 minute normal breaths. Intervention: 1 minute with 10 deep breaths, 1 each 6 secs. Pulse-oxymetry will be continuously recorded.
46049257|NCT02878226|Procedure|repair of rupture|
46049258|NCT04138420|Drug|Bevacizumab Injection|Three monthly intravitreal injections of bevacizumab (1.25 mg/0.05 mL)
45688580|NCT01523301|Drug|Rotigotine|"Transdermal Patch~Content:~2 mg /24 h (10 cm^2), 4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)~For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period~For advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period"
45688581|NCT01523301|Drug|Placebo|"Transdermal Patch~Size:~10 cm^2, 20 cm^2, 30 cm^2, 40 cm^2~Subjects randomized to placebo received matching placebo patches"
45688582|NCT02985567|Other|Intraocular pressure evaluation|Intraocular pressure checked with Icare rebound tonometer at 25 minutes after induction, followed by every 10 minutes until sedation was complete.
46049259|NCT05378646|Drug|Interferon gamma human recombinant (IFN-G)|received by microbiological synthesis; specific antiviral activity on cells is 2x10*7 Units per mg of protein
46049260|NCT01093586|Procedure|double-unit umbilical cord blood transplantation|Undergo transplantation
46049261|NCT01093586|Other|cytogenetic analysis|Correlative studies
46049262|NCT01093586|Procedure|bone marrow aspiration|Correlative studies
46049263|NCT01093586|Other|fluorescence in situ hybridization|Correlative studies
45688583|NCT01806506|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure. LSG involves resection of a large part of the body and fundus of the stomach starting from the antrum up to the angle of His. The remaining part of the stomach (the gastric sleeve) is calibrated with a 36 French bougie.
45845033|NCT02180100|Drug|Terconazole Vaginal Suppository|Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
45382233|NCT05205252|Drug|Pomalidomide|Orally, 4 mg, once daily on Days 1 to 21 of continuous 28-day cycles.
46049264|NCT01093586|Drug|busulfan|Given orally
46049265|NCT01093586|Drug|cyclophosphamide|Given IV
46049266|NCT01093586|Drug|anti-thymocyte globulin|Given IV
46049267|NCT01093586|Drug|methylprednisolone|Given IV
46049268|NCT01093586|Drug|cyclosporine|Given IV
46049269|NCT01093586|Drug|mycophenolate mofetil|Given orally or IV
46049270|NCT01093586|Other|flow cytometry|Correlative studies
46049271|NCT01093586|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
46049272|NCT04266132|Procedure|General anaesthesia|General anaesthesia will be induced with 8% sevoflurane in oxygen and maintained with 1 MAC sevoflurane via a laryngeal mask.
45382234|NCT05205252|Drug|Dexamethasone 20mg|Orally, 20 mg or 40 mg, once daily on Days 1, 8, 15, and 22 of continuous 28-day cycles.
45382235|NCT05204537|Procedure|Lung parenchyma resection|Lung parenchyma removal
45382236|NCT05204537|Procedure|Empyemectomy|Intrapleural cavity effusion removal, parietal pleura removal.
45361715|NCT02590835|Procedure|Orthodontic procedures (for both groups : Control group and Test group)|Damon self-ligating systems (Ormco, Orange, Calif) were used for all patients. The patients were allowed to choose between clear or metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in copper-nickel-titanium Damon arch forms were placed. The subjects were recalled every two weeks, and the archwires were changed only when full bracket engagement was achieved. The sequence of archwires was as follows: 0.018-in, 0.014x0.025-in and 0.018x0.025-in copper nickel-titanium archwires for alignment; and 0.019x0.025-in stainless steel archwires for fine-tuning. Following the alignment steps, impressions were taken, and blinded orthodontic consultants validated appliance removal or provided advice regarding further adjustments. Alginate impressions were taken after the removal of the appliances, and both fixed and removable retainers were placed.
45480013|NCT04442698|Procedure|Mini-Gastric Bypass Original Technique|Follow up of the Surgical procedure outcomes in diabetics. Procedure Mini-Gastric Bypass Original Technique
45480014|NCT03791099|Drug|Metronidazole|After subgingival ultrasonic scaling is performed, metronidazole in polymer matrix is applied to the selected periodontal pockets.
45480015|NCT03326362|Other|Resistance training|Comparison between high and low intensities trainings described in arms
45480016|NCT03185000|Drug|TR004 (Treg immunotherapy)|Administered Intravenously (IV)
45480017|NCT02653313|Drug|Parvovirus H-1 (H-1PV)|"Parvovirus H-1 administered at three increasing dose levels , according to the following schedule: i) 4 daily intravenous infusions of 10% of the total dose over 2 hours on 4 consecutive days, ii) direct injection of 60% of the total dose into a hepatic metastasis of the pancreatic cancer.~The total dose levels are: 1E09, 5E09 and 1E10 pfu."
45480018|NCT03322072|Device|Real-Time Position Transponder Beacons|The anchored lung tracking beacons are passive electromagnetic transponder beacons which are placed immediately adjacent to a lung tumor using a bronchoscope. Three beacons will be placed in the small airways of the lung adjacent to the target tumor (within 3 cm of the tumor). Each beacon measures 2 mm in diameter and 8 mm in length and consists of a miniature electrical circuit that is encapsulated in a biocompatible glass capsule. Each beacon has an affixed five-legged anchoring system which expands to 5mm diameter once deployed. The Calypso transponder beacon is placed endobronchially using the working channel of a bronchoscope. Navigational bronchoscopy can be used to pre-plan the optimal location for each beacon to be placed within the airways by using a pre-bronchoscopy CT scan.
45480019|NCT03791255|Drug|Calcium silicate liner|new light-cured resin-modified calcium silicate-filled base/ liner material designed for direct and indirect pulp capping
45688584|NCT01806506|Procedure|Roux-en-Y Gastric Bypass|Roux-en-Y gastric bypass (RYGB) is an intermediate (restrictive and malabsorptive) operation. RYGB involves creation of a 15-20 mL gastric pouch that is anastomosed to a 100cm Roux limb created at 100cm from the ligament of Treitz.
46049273|NCT04266132|Procedure|Ultrasound-guided RLB|The suggested ultrasound transducer orientation is sagittal paramedian (cephalacaudad direction). We begin our ultrasound scanning in a paramedian sagittal plane by finding desired level (T12- L1).The transverse process view, the costotransverse ligament can be visualized above the paravertebral space. Continuing to scan from lateral to medial, the vertebral laminae come into view.
46049274|NCT04266132|Procedure|Ultrasound-guided INB|A high-frequency probe is placed medial to the anterior superior iliac spine with the axis facing the umbilicus. A needle is inserted toward the ilioinguinal nerve as it runs between the transversus abdominis and internal oblique.
46049275|NCT04266132|Drug|Bupivacaine|0.3 ml.kg of 0.25% bupivacaine will be injected under visualization.
46049276|NCT02625454|Drug|Intravenous Acetaminophen|1000 mg Acetaminophen q 6 hours, given intravenously
46049277|NCT02625454|Drug|Oral Acetaminophen|1000 mg Acetaminophen q 6 hours given orally
46049278|NCT00606450|Drug|CC-10004|20 mg CC-10004 taken 1 time per day for 12 weeks
45480020|NCT03791255|Drug|Calcium hydroxide liner|Calcium hydroxide is the gold standard for pulp capping, allows for the formation of a reparative dentin bridge
46049279|NCT00606450|Drug|CC-10004|20 mg of CC-10004 taken 2 times per day for 12 weeks
45480021|NCT03326284|Other|15 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 15 g of protein
45480022|NCT03326284|Other|35 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 35 g of protein
45480023|NCT03326284|Other|60 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 60 g of protein
45480024|NCT03326284|Other|35 g protein energy balance|Following a 5 day energy balanced diet one group of 10 women will ingest 35 g of protein
45688585|NCT01766336|Drug|Group 1 ELND005|
45688586|NCT01766336|Drug|Group 2 ELND005|
45688587|NCT01797536|Drug|Elbasvir|
45688588|NCT01797302|Dietary Supplement|Vitamin D3|Tablet form
45845034|NCT02180100|Drug|Fluconazole|orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
45845035|NCT02180646|Other|High protein breakfast|a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
46049280|NCT00606450|Drug|Placebo|matching placebo taken either 1 or 2 times per day for 12 weeks
46049281|NCT00687934|Drug|STA-9090|This is a dose-escalation study. The first cohort will consist of three patients who will receive STA 9090 (ganetespib)during a 1-hour infusion once per week for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive higher amounts of STA-9090 (gantespib) provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Dose escalation will continue until the maximum tolerated dose (MTD) is determined.
45361716|NCT02590835|Procedure|Piezo-assisted orthodontics (only the Test group)|The piezocisionTM surgery was performed one week after orthodontic appliance placement . The patients received local anesthesia in both arches, and vertical interproximal micro-incisions were created below each interdental papilla. In cases of root proximity (i.e., less than 2 mm of interdental bone), this procedure was not applied. These incisions were kept to a minimum (varying from 5 mm to 8 mm). Next, using a vertical piezoelectric device, 5-mm long and 3-mm deep corticotomies were made, and no subsequent sutures were required needed (figure 1). The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intakes for one week. Anti-inflammatories were prohibited to avoid interference with the RAP. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
45361717|NCT00821912|Drug|Docetaxel|30 mg/m2, administered as a 30 min. i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule
45361718|NCT00821912|Drug|Capecitabine|1650 mg/m2 /day orally b.i.d., day 1-14 every 3 weeks.
45361719|NCT05690997|Other|Intensive treatment|If the mean home SBP preceding clinic follow-up is >130mmHg, BP lowering treatment will be stepped up, and if the mean SBP preceding clinic follow-up is <120mmHg, BP lowering treatment will be stepped down, until the target SBP of 120-129mmHg is achieved, or symptoms of hypotension prevent treatment to be further intensified.
45361720|NCT05690997|Other|Standard treatment|If the mean home SBP preceding clinic follow-up is >140mmHg, BP lowering treatment will be stepped up, and if the mean SBP preceding clinic follow-up is <130mmHg, BP lowering will be stepped down, until the target SBP 130-140mmg is achieved or symptoms of hypotension prevent treatment being intensified.
45361721|NCT02593253|Other|Audit and Feedback Bundle|The intervention arm teams will receive the new audit and feedback bundle, which includes access to the electronic dashboard and weekly feedback rounds in which they review their performance on several inpatient quality metrics via the dashboard.
45361722|NCT02593253|Other|Bi-weekly audit and feedback emails|The control arm will undergo audit and feedback per the current system, which is biweekly feedback emails with performance on selected quality measures.
45361723|NCT00816764|Biological|AGS-8M4|IV Infusion
46049282|NCT02879552|Procedure|Traditional upper blepharoplasty|The skin incisions were marked using a skin marking pen. Preseptal orbicularis skin and muscle were removed using a size-15 scalpel blade and scissors. Hemostasis was achieved with conservative electrocuatery. The skin was closed with a running 6-0 nylon suture.
46049283|NCT02879552|Procedure|Brassiere suture with blepharoplasty|"Prior to skin closure as above, three 6-0 polyglactin sutures are passed along the lateral fourth of the orbital rim. The sutures attach the inferior orbicularis oculi edge to the arcus marginalis of lateral ROOF. Sutures are placed until there is a visible plumping of the sub-brow tissues."
45361724|NCT05325905|Diagnostic Test|Gingival crevicular fluid sampling|GCF sampling and clinical periodontal measurements were performed
45361725|NCT00820976|Drug|G-CSF|Filgrastim(5 µg/kg intravenously over 30 minutes ) was administered starting from day 8 until neutrophil recovery
45361726|NCT00727649|Drug|Psyllium powder|2 teaspoons with 8 ounces of liquid daily for 28 days (weekly adjusted dose)
45845036|NCT02180646|Other|High carb breakfast|a high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat)
45688589|NCT01805180|Device|Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System)|In Arm 1 the first PMN cell collection will be performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System.
46049284|NCT04138888|Drug|Olmesartan Medoxomil/Hydrochlorothiazide 40 Mg/25 Mg film-coated tablets for oral use|Olmesartan Medoxomil/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
46049285|NCT04138888|Drug|Olmetec® Plus 40 Mg/25 Mg film-coated tablets for oral use|Olmetec® Plus is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
46049286|NCT04266210|Device|Fuji Bulk|Restorative system
46049287|NCT04266210|Device|G-ænial Posterior|Restorative system
46049288|NCT04139044|Procedure|Balance Exercise Training for Stable Ankle|Balance and hop stabilization exercises were administered for 30 minutes of each exercise session.
46049289|NCT04139044|Procedure|Balance Exercise Training for Unstable Ankle|Balance and hop stabilization exercises were administered for 30 minutes of each exercise session.
46049290|NCT00688012|Drug|SPC3649|
46049291|NCT00937404|Biological|Poliorix|All subjects receive three doses of Poliorix vaccine, administered intramuscularly into the upper right side of the thigh.
46049292|NCT00688090|Biological|Biological: MKC1106-MT|Cancer Vaccine, Immunotherapy
45361727|NCT00727649|Drug|Loperamide|1 capsule daily for 28 days (weekly adjusted dose)
45361728|NCT00987597|Behavioral|Technique of in-vivo exposure (cigarette) and mental image exposure (craving)|Nicotine replacement
45688590|NCT01805180|Device|Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)|In Arm 2 the first PMN cell collection will be performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System.
45847694|NCT02864706|Drug|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
46049293|NCT00688090|Biological|Biological: MKCC1106-MT|Cancer Vaccine, Immunotherapy
46049294|NCT00688168|Behavioral|Questionnaire|Questionnaires measuring pain and other symptoms, mood, and quality of life.
46049295|NCT00688168|Behavioral|Neurocognitive Testing|A neurocognitive exam (tests to check your memory and thinking abilities, for example) will be performed.
46049296|NCT00688168|Behavioral|Neurosensory Testing|Neurosensory testing will be performed to find out how sensitive you are to things such as touch, coolness, warmth, pinprick on the finger, and squeezing of the skin on the finger, hand, or arm.
46049297|NCT05382234|Diagnostic Test|CBC, ESR ,CRP,Liver Function ,renal function ,ABG,Na,K,D-dimmer ,cardiac enzyme,ferritin ,blood and urine culture in negative cases|cllinical and laboratory evaluation of MIS-C,Effectivness of different therapeutic modalities,Outcome of cases (morbidity,mortality)
45361729|NCT00987597|Behavioral|conventional follow-up|nicotinic substitutes
45361730|NCT00568334|Biological|Varilrix (inactivated varicella vaccine)|subcutaneously injection
45361731|NCT04006041|Drug|Toripalimab|Patients received toripalimab 240 mg IVDRIP on days 1 and 22 during neoadjuvant radiotherapy.
45361732|NCT04006041|Drug|Paclitaxel/cisplatin|Patients received 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 during neoadjuvant radiotherapy.
45361733|NCT04006041|Radiation|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 44 Gy in 20 fractions over 4 weeks.
45361734|NCT04006041|Procedure|Esophagectomy|A transthoracic (Ivor-Lewis) esophagectomy is performed 6-8 weeks after CRT completion.
45361735|NCT00727571|Other|Observations|This is a non-interventional, observational study; no investigational product is being used
45361736|NCT00225277|Drug|Pioglitazone|Up to 45 mg pioglitazone (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
45688591|NCT04413968|Diagnostic Test|Rapid detection test|Rapid serological test by taking 3 drops of blood from the fingertip via the TDR device (rapid detection test) for children, supervising nursery staff and hospital laboratory and administrative staff
45688592|NCT04413968|Diagnostic Test|Nasopharyngeal swab|Posterior nasopharyngeal swabbing in children
45688593|NCT04413968|Diagnostic Test|Stool collection|Stool collection in children
45688594|NCT01804946|Drug|Ergoferon|Safety and Efficiency of Ergoferon in treatment of Influenza
45688595|NCT01804946|Drug|Oseltamivir|Safety and Efficiency in treatment of Influenza
45688596|NCT01737398|Drug|Inotersen|
45688597|NCT01737398|Drug|Placebo|
45688598|NCT01795898|Drug|Fentanyl|Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
45688599|NCT01736696|Drug|tofacitinib|5 mg BID For 13 days and once on Day 14
45688600|NCT01736696|Drug|tofacitinib|10 mg BID for 13 days and once on Day 14*
45688601|NCT01736696|Drug|tofacitinib|20 mg BID for 13 days and once on Day 14
46049298|NCT00690976|Behavioral|Proyecto SOL|Group intervention
46049299|NCT00690976|Behavioral|HCT|Offer of HIV counseling and testing
46049300|NCT02625142|Other|Family-centered rounds checklist tool|A printed checklist containing 9 key tasks associated with effective delivery of family-centered rounds. A previously-identified member of each rounding team was responsible for holding the printed checklist during morning rounds. Team members were trained the in the use of this checklist prior to the post-intervention period, and a brief refresher training was conducted mid-way through the period.
46049301|NCT01098110|Drug|Asenapine 5 mg|Asenapine 5 mg fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), on Day 1 only or for 6 weeks.
46049302|NCT01098110|Drug|Asenapine 10 mg|Participants receive on Day 2, 10 mg BID of fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), for 6 weeks.
46049303|NCT01098110|Drug|Placebo|A matching placebo of asenapine sublingual tablet not containing asenapine
45361737|NCT00225277|Drug|Glimepiride|Up to 4 mg of glimepiride (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
45361738|NCT00821054|Drug|Lapatinib|Treatment A: one dose of 1250mg lapatinib 1 hour before starting a low-fat breakfast; Treatment B: one dose of 1250mg lapatinib 1 hour after finishing a low fat breakfast; or Treatment C: one dose of 1250mg lapatinib 1 hour after finishing a high-fat breakfast.
45361739|NCT04391673|Behavioral|Vestibular rehabilitation|Vestibular rehabilitation (treatment as usual).
45361740|NCT00567996|Drug|Indacaterol 150 μg|Indacaterol 150 μg once daily (o.d) inhaled
45361741|NCT00567996|Drug|Salmeterol 50 μg|Salmeterol 50 μg twice daily (b.i.d) delivered via a proprietary dry powder inhaler
45688602|NCT01736696|Drug|tofacitinib|30 mg BID for 13 days and once on Day 14
45688603|NCT01736696|Drug|tofacitinib|60 mg tablet once a day (QD) for 14 days
45688604|NCT01736696|Drug|tofacitinib|50 mg tablets two times a day (BID) for 13 days and once on day 14
45688605|NCT01736540|Device|MRI scan|MRI was used to measure both liver and cardiac iron loading (R2 by FerriScan and T2*, respectively).
45688606|NCT01794338|Device|Strattice Arm|Biologic mesh to be placed during hernia repair surgery
45688607|NCT01794338|Device|Bio-A Arm|Bioabsorbable mesh to be placed during hernia repair surgery
45688608|NCT01609478|Drug|indacaterol|indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler
45688609|NCT01609478|Drug|placebo|placebo delivered via Concept 1 inhaler
45688610|NCT01609478|Drug|mometasone furoate|via Twisthaler inhaler
45688611|NCT01764854|Drug|AZD1722 (in-patient)|doses between 5 and 60 mg BID may be administered based on tolerability in a CPU setting
45688612|NCT01764854|Drug|Placebo (in-patient)|Placebo, size and color matched to experimental drug administered in a CPU
45688613|NCT01764854|Drug|AZD1722 (out-patient)|doses between 5 and 45 mg BID
45688614|NCT01764854|Drug|Placebo|Placebo, size and color matched to experimental drug
45688615|NCT01764464|Drug|Gralise®|14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
46049304|NCT04138966|Device|Nol-Index|Multiparametric monitor that studies that establishes an index as a surrogate to nociception
46049305|NCT04138966|Device|Skin Conductance|Measures skin conductance as a surrogate to nociception
45688616|NCT01764464|Drug|Placebo|14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
45688617|NCT01764386|Drug|NB|Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)
45361742|NCT00567996|Drug|Placebo to Indacaterol|Placebo to Indacaterol inhaled via SDDPI.
45361743|NCT00567996|Drug|Placebo to Salmeterol|Placebo to salmeterol delivered via a proprietary dry powder inhaler
45688618|NCT01764386|Behavioral|CLI|The Comprehensive Lifestyle Intervention (CLI) program includes telephone counseling, internet education, goal setting, and online tracking tools.
45361744|NCT00821990|Drug|Chemotherapy|The administration of chemotherapy regimen (docetaxel or irinotecan) will be determined at the discretion of investigator, and depends on the patient's previous chemotherapy.
45361745|NCT00821990|Other|Best supportive care|It includes nutritional support, analgesics, antibiotics, antiemetics, transfusions, or any other symptomatic therapy (with the exception of cytotoxic chemotherapy) and/or assistance of a psychological support. Localized radiotherapy to alleviate symptoms such as pain is allowed provided that the total dose delivered is in a palliative range.
45688619|NCT01764386|Behavioral|Usual Care|Usual Care is a self-directed lifestyle intervention program
45688620|NCT01763918|Biological|Evolocumab|Administered by subcutaneous injection
45688621|NCT01763918|Drug|Placebo|Administered by subcutaneous injection
45688622|NCT01763684|Device|Signature Custom Guides|Signature Custom Guides: Signature Custom Guides are intended to be used as a surgical instrument to assist in the positioning of knee replacement components intraoperatively and in guiding the marking of bone before cutting provided that anatomic landmarks necessary for alignment and positioning of the implant are identifiable on patient imaging scans (preoperative MRI).
45688623|NCT01763684|Procedure|Conventional Instrumentation|Traditional partial knee arthroplasty without the use of Signature technology.
45847695|NCT02864706|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
46049306|NCT00912496|Biological|MF-59|Doses of A/Anhui/05 vaccine (A) will be administered with or without MF59 adjuvant.
46049307|NCT00912496|Biological|A/Anhui/05|Monovalent inactivated surface antigen influenza A/H5N1 (modified Hemagglutinin and Neuraminidase of A/Anhui/01/2005) vaccine supplied in 5mL multi-dose vials with thimerosal [0.01%(w/v)] as a preservative. Each dose level includes both unadjuvanted and MF59C.1 adjuvanted formulations: 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) with MF59C.1, and 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) without MF59C.1 adjuvant.
46049308|NCT00912496|Drug|Placebo|Sterile normal saline for injection (0.9% Sodium Chloride Injection, USP Preservative-Free).
45361746|NCT04388319|Drug|Zonisamide|Zonisamide (100 mg/daily) for 12 weeks.
45361747|NCT04388319|Drug|Bupropion|Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 12 weeks.
45361748|NCT04388319|Other|Halo G6 e-cigarette|G6 e-cigarette for ad libitum use for two weeks prior to complete switch day.
45361749|NCT04085627|Drug|Valsartan and Amlodipine Tablets|1 tablet contains Valsartan 80mg& Amlodipine 5mg
45361750|NCT00821210|Device|Sham CPAP|CPAP with pressure of 3cm H2O
45361751|NCT00821210|Device|CPAP of optimal pressure|CPAP of optimal pressure
45361752|NCT03970135|Other|Fasting|Fasting for 24 hours or until hypoglycemia (blood glucose < 3mmol/L) or symptoms of hypoglycemia
45361753|NCT04086173|Dietary Supplement|Probiotics|Probiotics will be administered at night and will consist of 4 capsules
45361754|NCT04086173|Other|Placebo|Placebo
45361755|NCT04005261|Diagnostic Test|C-peptide concentrations|The patients will be grouped by their C-peptide concentrations
45361756|NCT00821288|Behavioral|Survivorship Intervention|"Survivorship Consultation is a one hour consultation in a survivorship clinic. The consultation will be performed by a nurse practitioner under the supervision of a medical oncologist. The consultation will result in a detailed written document outlining the individuals Survivorship Prescription including treatment summary, surveillance recommendations, risk for late-effects, cancer screening recommendations, genetic risk, and life style recommendations. This written document will be provided to the patient and her treating physician. In addition, referrals will be made to appropriate adjunct services as needed (e.g. psychologist, nutritionist, social worker)."
45361757|NCT00821288|Behavioral|Facing Forward|Facing Forward: Life after Cancer Treatment is a guide for people who were treated for cancer published by the NCI. It is a 24-page manual that summarized many key issues of interest to cancer survivors during the re-entry phase, and contains sections on medical care after treatment, symptoms after treatment, feelings after treatment, social relationships after cancer treatment, and dealing with practical matters such as insurance and employment. The manual is available in English and Spanish. This will be given at the time of registration and the table of contents will be reviewed with the patient.
45361758|NCT00224887|Behavioral|In home nutrition counseling|In home family-based behavioral counseling
46049309|NCT02879396|Behavioral|PA4LE Program|"Medication self-management including medication reconciliation, therapy recommendations, and education by pharmacist (chronic conditions and medications including Beers Criteria)~Use of a patient-centered health record that helps guide patients through the care process (portable, health and medication record for elders)~Primary care provider and specialist follow-up (patient awareness of discharge action plan and follow-up)~Patient understanding of red flag indicators of worsening condition and appropriate next steps~Behavioral interventions - Adherence, Lifestyle modifications, Mindfulness & Lovingkindness meditations to combat anxiety, insomnia and other behavioral symptoms"
46049310|NCT00688246|Other|biologic sample preservation procedure|Increased bone turnover may be a risk factor for fracture [Lønning 2005]. However, it is uncertain whether markers of bone resorption and markers of bone formation are both associated with fracture risk [Looker 2000]. Therefore, we will measure bone formation and bone resorption markers at baseline, year 1 and year 5. Blood specimens will be shipped to and stored in a central laboratory for future assays of bone biomarkers. For markers of bone formation, the N-terminal Propeptide of Type I Collagen (PINP) will be measured. For bone resorption markers, serum levels of cross-linked N-telopeptides of type I collagen (NTx) will be measured. Note: Subjects must fast 12-14 hours prior to blood draw.
46049311|NCT00688246|Procedure|dual x-ray absorptometry|BMD of the spine (L1-L4) and total hip will be done within 12 months prior to randomization to the MAP.3 core protocol. BMD by DEXA of the spine (L1-L4) and total hip will be repeated at year 2 and year 5 of the MAP.3 core study on the same Lunar or Hologic scanner.
46049312|NCT04138342|Drug|Quantum dots coated with veldoreotide|The active group will receive Quantum dots coated with veldoreotide in different topical dosage forms as an anti-cancer drug.
45361759|NCT00224887|Other|standard nutrition education curriculum|video and lesson plans based on USDA Food Guide Pyramid
45361760|NCT04085393|Drug|GRANISETRON EXTENDED RELEASE INJECTION (GERSC)|GERSC is a new, subcutaneously (SC) administered polymeric formulation of granisetron that was developed to provide slow, controlled, and sustained release of granisetron to prevent both acute and delayed CINV associated with MEC and HEC. Due to the prolonged efficacy, GERSC may potentially improve CINV in the acute and delayed periods and the single dose regimen may improve patient adherence to antiemetic therapy
45361761|NCT00987675|Other|pharmacological study|
45361762|NCT00987675|Other|questionnaire administration|
45361763|NCT00987675|Procedure|assessment of therapy complications|
45361764|NCT00987675|Procedure|high-intensity focused ultrasound ablation|
45361765|NCT00987675|Procedure|quality-of-life assessment|
45361766|NCT00928902|Drug|low-dose IL-2|low-dose IL-2, administered daily for 6 weeks, to begin either at week 1 (group 1) or week 4 (group 2)
45361767|NCT00928902|Biological|melanoma vaccine|six melanoma vaccines given over a 6-week period
45480025|NCT04442048|Biological|IMM-101|Three doses of IMM-101 on days 0, 14, and 45.
45480026|NCT04442048|Other|Observation|No active treatment. Observation only
45480027|NCT03794141|Behavioral|information on the risk gene status|information on risk gene status (APOE4 allele or not) was given before intervention
45688624|NCT01606748|Biological|Necitumumab|"PK Run-In Period: Necitumumab administered on Day 3 of the 3-week PK run-in period as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Treatment Cycles: Necitumumab administered on Days 1 and 8 of every 3-week cycle as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Participants in Cohort 1 will receive necitumumab Process C drug product and participants in Cohort 2 will receive necitumumab Process D drug product"
45688625|NCT01606748|Drug|Gemcitabine|"PK Run-In Period: Gemcitabine administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 1250 milligram per square meter (mg/m2)~Treatment Cycles: Gemcitabine administered on Days 1 and 8 of every 3-week cycle as an I.V. infusion at a dose of 1250 mg/m2"
45361768|NCT00816920|Other|Ultrasound examination of leg veins|Outpatients symptomatic for leg DVT follow the standard diagnostic procedure (ultrasound examination of proximal deep veins, pre-test clinical probability and D-dimer, and a second US after 5-7 days) to exclude proximal DVT; they also receive by another doctor a complete US examination of the deep leg veins to assess the presence of isolated calf DVT, the results of the latter examination are kept blind to the patient and to the treating doctor, and disclosed after three months
45845037|NCT02181426|Drug|Ketorolac Dose|Subjects will be assigned an enrollment number. Enrollment numbers will be assigned consecutively in the order of study enrollment. Based on the enrollment number, subjects will be randomized by a pre-determined computer randomization list created by a statistician to receive a ketorolac dose (0, 7.5, 15, 30 mg).
45361769|NCT04004949|Other|Assessment of scapular balance angle and upper extremity sensorimotor function|The patients were diagnosed with the Lateral scapular slide test using Palpation meter (PALM) device, Fugl-Meyer upper extremity (FMUE) Scale scores & scapular balance angle test (SBA).
45845038|NCT02184624|Device|ELLIPTA|Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
45845039|NCT02184624|Device|DISKUS/ACCUHALER|Placebo inhaler with one blister strip containing lactose monohydrate.
45845040|NCT02184624|Device|MDI|Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane).
45845041|NCT02184624|Device|TURBUHALER|Placebo inhaler containing lactose monohydrate.
45845042|NCT02184624|Device|HANDIHALER|Placebo inhaler containing lactose monohydrate in a capsule.
46049313|NCT04138342|Drug|Topical approved placebo|The placebo group will receive topical FDA approved in different dosage forms as a negative control drug.
46049314|NCT00688402|Drug|AZD3355|Single dose
45845043|NCT02184624|Device|BREEZEHALER|Placebo inhaler containing lactose monohydrate in a capsule.
45361770|NCT00148759|Drug|LPV/r|LPV/r 800/200 mg once daily
45480028|NCT03794141|Behavioral|life style advise|all test persons were given information on healthy diet and life style
45688626|NCT01606748|Drug|Cisplatin|"PK Run-In Period: Cisplatin administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 75 mg/m2~Treatment Cycles: Cisplatin administered on Day 1 of every 3-week cycle as an I.V. infusion at a dose of 75 mg/m2"
45688627|NCT01597622|Drug|Belimumab|10 mg/kg administered intravenously over 1 hour every 4 weeks
45688628|NCT01761266|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
45688629|NCT01761266|Drug|Sorafenib|400 mg twice daily (BID) oral dosing.
45688630|NCT01760954|Drug|Elagolix|Elagolix tablets administered orally
45845044|NCT02185404|Device|wearing the iStride device|The device mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. This research aims to test the iStride on individuals with stroke in their own home in order to determine if the related effects that we saw in the clinic, can also benefit patients at home.
45845045|NCT02186808|Device|Procera® Bridge Zirconia|Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
45845046|NCT02189382|Device|Potassium Oxalate|
45845047|NCT02189382|Other|Water|
45845048|NCT02189850|Drug|BLI800 - Dose 1|BLI800 oral solution
45845049|NCT02189850|Drug|BLI800 - Dose 2|BLI800 oral solution
45845050|NCT02190552|Device|EmboTrap® Revascularization Device|
46049315|NCT04138264|Other|Preoperative opioid counseling|preoperative counseling consists of education with a brief multi-media presentation in the preoperative area on the day of surgery using a handheld tablet. The message of the preoperative counseling consisted of: 1) Background on the opioid epidemic including basic facts and consequences, 2) Description of risk factors for opioid abuse and how to consume opioids safely, 3) Information on the specific opioid the patient was prescribed and the anticipated amount and duration of use postoperatively, 4) Encouraging the use of non-opioid therapy prior to taking the prescribed opioids or quickly transitioning to non-opioid medications postoperatively, and 5) Contact information and instructions to call if the patient experienced any adverse events and/or if additional pain medication is needed.
46049316|NCT00688480|Drug|Placebo|1 capsule, orally for 9 months
46049317|NCT00688480|Drug|Allopurinol|Allopurinol 300 mg once/day orally, 9 months
46049318|NCT01092728|Drug|Dasatinib|100 mg daily.
45361771|NCT00925080|Device|IVBG|Venous blood glucose measurement every 7.5 minutes for 72-hours
45361772|NCT00717275|Drug|Temozolomide|75 mg/m2 taken by mouth once a day for 14 out of 28 consecutive days until progression or unacceptable toxicity.
45361773|NCT00822068|Device|anodal tDCS|anodal transcranial direct current stimulation
46049319|NCT01092728|Procedure|Surgical Resection|Complete surgical resection of tumor(s).
46049320|NCT00688558|Drug|JTT-705 600 mg and simvastatin 40 mg|"JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~Simvastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, immediately following breakfast and/or assessments"
45361774|NCT00822068|Device|cathodal tDCS|cathodal transcranial direct current stimulation
45361775|NCT00822068|Device|sham stimulation|sham stimulation
45361776|NCT04006353|Drug|ABT|320 mg, Intravenous infusion
45361777|NCT04006353|Drug|RIF|600mg q.d.
45361778|NCT00925158|Procedure|Dissector Assisted Malar Elevation|Malar dissector - Surgical instrument for video endoscopic rhytidoplasty.
45361779|NCT01075789|Drug|Lignocaine|Lignocaine 10% solution administered intra nasally plus lignocaine 2% solution administered orally.
45361780|NCT01075789|Drug|Placebo|Viscous, coloured, sucrose flavoured gel solution to match xylocaine viscous in appearance, normal saline administered intranasally to the nasal turbinates and nasopharynx.
45361781|NCT04515849|Drug|Cotadutide 100 micrograms|Cotadutide 100 micrograms administered subcutaneously
45361782|NCT04515849|Drug|Cotadutide 300 micrograms|Cotadutide 300 micrograms administered subcutaneously
45361783|NCT04515849|Drug|Cotadutide 600 micrograms|Cotadutide 600 micrograms administered subcutaneously
45361784|NCT04515849|Drug|Semaglutide|Semaglutide 1.0 miligrams administered subcutaneously
45361785|NCT04515849|Drug|Placebo|Placebo administered subcutaneously
45361786|NCT04034316|Other|Cord-blood mesenchymal stromal cells|The product is packaged in bags suitable for the cryopreservation of cell products. Before administration the cells must be thawed and diluted in an appropriate vol:vol solution: made by saline 78%, human albumin 10%, Acyl-CoA dehydrogenase-A (ACD-A) 12%.
45361787|NCT03972241|Device|foot insole|arch support and toe extension
45361788|NCT04085159|Biological|Antigen-specific T cells CART/CTL and DCvac|Antigen-specific T cells CART/CTL and DCvac cells to treat cancer
45361789|NCT00928980|Behavioral|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy is an 8-week during group intervention encompassing meditation practice and cognitive therapy techniques.
45688631|NCT01760876|Device|coronary intervention|The BioFreedom drug coated stent (DCS) Coronary Stent Delivery System is comprised of three key components
46049321|NCT00688558|Drug|Placebo and simvastatin 40 mg|"Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~Simvastatin 40 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments"
45361790|NCT00928980|Drug|Optimal Medical Care|Therapeutic dose of antidepressant medication
45688632|NCT01759862|Drug|Aminophylline|Aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.
45688633|NCT01759862|Other|Theophylline drug levels|Theophylline drug levels will be monitored every morning from all patients for the first 4 days post- transplant.
45688634|NCT01759862|Drug|Placebo|Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.
45688635|NCT04579874|Diagnostic Test|LIVERFASt|blood draw
45688636|NCT01793792|Device|LVIS™ and LVIS™ Jr|The LVIS Device is intended for use with embolization coils for the treatment of wide neck, intracranial aneurysms.
45688637|NCT01790984|Other|High sugar low starch diet|
45688638|NCT01790984|Other|Low sugar high starch diet|
45361791|NCT03972085|Other|Neural gliding exercises|"Neural gliding exercises: In addition to the Electrotherapy procedure, patients were asked to actively perform knee extension, ankle dorsiflexion and head extension in the slumped posture followed by simultaneous ankle plantar flexion together with knee and head flexion (10 repetitions in 1 minute). Patients performed the exercises under a home-based program for 5 days of the week during a total period of 3 weeks.~Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach."
45361792|NCT03972085|Other|Electrotherapy sessions|Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach.
45361793|NCT00826046|Drug|Prochymal®|Patients will be treated with Prochymal twice per week at a dose of 2 x 106 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
45361794|NCT00584909|Drug|Paclitaxel and carboplatin combination|Paclitaxel will be administered at an appropriate dose (175 mg/m2) as a 3-hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing the Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate (GFR).
45361795|NCT02551172|Drug|HCP1105|Rosuvastatin + Omega-3-acids ethyl esters
45361796|NCT02551172|Drug|HGP0816|Rosuvastatin
45361797|NCT02551172|Drug|Placebo of HCP1105|Soybean Oil
45361798|NCT02551172|Drug|Placebo of HGP0816|Exclusion of Rosuvastatin in HGP0816
45361799|NCT03947099|Drug|Ketamine Hydrochloride|Participants are treated with six one-hour infusions of ketamine hydrochloride over a three week period in hopes of treating symptoms of PTSD.
45361800|NCT00147823|Device|Vitoss Alone|Synthetic bone graft material
45361801|NCT00147823|Device|Vitoss with Bone Marrow Aspirate|Vitoss mixed with Bone Marrow aspirate
45361802|NCT05361915|Drug|Abivertinib|Abivertinib is a small molecule inhibitor
45361803|NCT05361915|Drug|Abiraterone|Hormone-based chemotherapy
45361804|NCT00929058|Drug|Bevacizumab|Intra-arterial infusion during 6 minutes
45361805|NCT03860246|Diagnostic Test|Portable ECG monitor|Recording of ECG rhythm on a portable monitor (Kardia Mobile)
45361806|NCT05375669|Device|ISIS IOM System|"The constant-current TES stimulators will be used in this study with a high-precision oscilloscope. The calibration will assess 5-pulse trains with a 4 ms ISI and 100 mA output across a 1000 Ω resistor at 250, 500, and 1000 µs D. Measurements will include actual I and D of each pulse, and actual ISI.~Total intravenous anesthesia (TIVA), surgery and TES MEP monitoring will proceed routinely without modification and normally involves acquiring many MEPs over several hours. The only departure from standard care will be the placement of two small accelerometers and a brief MEP sequence before skin incision to determine chronaxie and compare the effect of an equivalent increase of I or D on MEP amplitude and movement."
46049322|NCT04031326|Behavioral|LENA Home|LENA Home is a 13-week curriculum designed to add an early-language focus to existing home visiting or parent education programs for children ages birth to three. It employs LENA wearable audio recorder technology and targeted content to help parents and other caregivers increase interactive talk. There are 13 weekly one-on-one sessions, including modules on parent-child reading and increasing verbal interaction during typical home activities. Sessions include videos, practical techniques, and feedback from LENA recordings via intuitive reports to help parents talk more with their children. LENA Home reports provide data on adult words spoken to the child (AWC) and conversational turns (CTC). LENA Home has been shown to increase interactive talk and child language ability and informs parents how much they are talking with their children in an objective way.
46049323|NCT01096550|Behavioral|Outpatient|Buprenorphine patients receiving 2 to 8 hours of outpatient counseling.
46049324|NCT01096550|Behavioral|Intensive Outpatient|Buprenorphine patients receiving 9 or more hours of outpatient counseling.
46049325|NCT02625376|Dietary Supplement|Resvega|Dietary supplementation with Resvega BD
46049326|NCT02625376|Dietary Supplement|Trans-Resveratrol|Dietary supplementation with resveratrol 250 mg BD
45361807|NCT00925314|Biological|CB-10-01 (Transgenic Lymphocyte Immunization)|1 Primary Infusion and 2 Booster Infusions
45361808|NCT00822146|Device|CRT|classified
45688639|NCT01735994|Behavioral|Healthy Weight|Eating Disorder Prevention Program for Athletes
45688640|NCT01735994|Other|Brochure|Brochure on the Female athlete triad
45688641|NCT01790828|Drug|Xyntha : coagulation factor IIIV (recombinant)|Xyntha will be administered according to physician's discretion.
45688642|NCT01790594|Biological|Belatacept|The first dose of belatacept will be administered approximately 24-48 hours after the last dose of Anti-Thymocyte Globulin (Rabbit).
45688643|NCT01790594|Drug|methylprednisolone|
45688644|NCT01790594|Biological|Anti-thymocyte Globulin (Rabbit)|
45845051|NCT02192814|Drug|Lacosamide (200 mg/20 mL)|"Active Substance: Lacosamide~Pharmaceutical form: Solution for intravenous (iv) infusion~Concentration: adapted on concentration of oral dose in EP0009~Route of Administration: Drip infusion"
45845052|NCT02195232|Drug|Isoquercetin|
45688645|NCT01790594|Drug|Tacrolimus|There may be an opportunity to withdraw tacrolimus at week 40
46049327|NCT02625376|Dietary Supplement|placebo|Dietary supplementation with a placebo BD
46049328|NCT00688714|Drug|AZD6482|0,9-364,5 mg administrated through intravenous infusion over 3 hours
45361811|NCT00816998|Procedure|Physical therapy|Physical therapy to instruct participant with exercises to assist in return to normal activities following the healing of their wrist fracture
45361812|NCT00816998|Procedure|Physical Therapy|Physical therapy to include exercises to help a participant improve the range of motion, grip and pinch strength following the fracture of their wrist
45361813|NCT00907452|Drug|melphalan-prednisone-thalidomide|
45361814|NCT00907452|Drug|lenalidomide-dexamethasone|
46049329|NCT00688714|Drug|Placebo|
45480029|NCT03326206|Other|COPE Program|The COPE Program is a programmatic model that is designed to support to providers, Community Health Representatives, and patients/family members. Patients are referred to the COPE Program under program auspices. COPE referral and participation is part of routine care at all service units in Navajo Area Indian Health Services, and enrollment is not influenced by study participation. Patients receive the same health care services in the same manner and intensity, whether or not they are not enrolled in this observational study.
45361815|NCT00822224|Drug|MEOPA|inhalation of MEOPA during the painful care
45361816|NCT00907530|Drug|MULTIHANCE:|MULTIHANCE ® 0.5 M,0.1 mmol/kg
45480030|NCT03742349|Biological|spartalizumab|LIVI (Liquid in vial) Concentrate for Solution for infusion
45688646|NCT01790594|Drug|Mycophenolate mofetil|Mycophenolate mofetil will be administered at a target dose of 1000 mg by mouth twice daily (e.g., BID) beginning on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed (maximum MMF dosing is 2G per day). MMF will be adjusted based on clinical complications (such as neutropenia). Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
45688647|NCT01790516|Drug|Cisplatin|Cisplatin 100 mg/m2 during weeks 1,4, and 7 of radiation therapy
46049330|NCT01101542|Biological|Cervarix.|Subjects will receive three doses of the Cervarix vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in routine clinical practice settings.
46049331|NCT01101542|Other|Data collection|All adverse events will be recorded by all subjects or the subject's parents/guardians using diary cards.
45688648|NCT01790516|Drug|cetuximab|Cetuximab beginning at a dose of 400 mg/m2 the week before radiation commences and then 250 mg/m2 weekly during weeks 1 and 7 of radiation.
45688649|NCT01790516|Radiation|Radiation|daily radiation for 7 weeks
45688650|NCT01790438|Drug|LY2605541|
45688651|NCT01790438|Drug|Human Insulin NPH|
45688652|NCT01790438|Drug|Oral Antihyperglycemic Medications (OAM)|
46049332|NCT04881578|Other|continuous cardiac monitoring before and after transcatheter PFO closure|Data will be assessed from patients with cryptogenic stroke and planned PFO occlusion who undergo the contemporary ICM protocols to search for silent AF
46049333|NCT04153084|Drug|Polyethylene Glycol 4000 with electrolytes|The high volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
45845053|NCT02195622|Device|Lumenis VersaCut Morcellator|
45845054|NCT02195622|Device|Wolf Piranha Morcellator|
45361817|NCT00907530|Drug|GADOVIST|GADOVIST ® 1.0 M,0.1 mmol/kg
45361818|NCT05331885|Biological|Suvratoxumab|Monoclonal antibody
45361819|NCT05331885|Drug|Placebo|Placebo contains only excipients
45361820|NCT00717197|Drug|Capecitabine|1,000-1,250 mg/m2 taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
45361821|NCT00929136|Biological|USP endotoxin|Continuous intra-arterial infusion
45361822|NCT00925392|Drug|Doripenem|Intravenous 500 mg every (q) 8 hours for 3 doses
45361823|NCT00925392|Drug|Doripenem|Intravenous 1000 mg q 8 hours for 3 doses
45361824|NCT05315271|Drug|Bupivacaine-ketamine injection|20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus ketamine (1 mg/kg) with maximum dose 100mg ; the total volume is 30 ml with the infusion of 100 ml normal saline at a rate of 100ml/h.
45361825|NCT05315271|Drug|Bupivacaine injection with intravenous ketamine infusion|20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus 10 ml saline ; the total volume is 30 ml with the infusion of ketamine 0.15 mg/kg added to 100 ml normal saline and will be infused at a rate of 100 ml/h, which will be stopped 5 min before the end of surgery.
45361826|NCT00147745|Drug|Colesevelam|Colesevelam 3.8g for 12 weeks
45361827|NCT00147745|Drug|Colesevelam matching placebo|Colesevelam matching placebo for 12 weeks
45361828|NCT00147745|Drug|Insulin glargine (Lantus)|Insulin glargine for 12 weeks
45361829|NCT04542486|Procedure|"Excision of gingival hyperplasia using Soft tissue trimmer ."|Gingivoplasties and removal of excess gingival tissues using Soft tissue trimmer.
45361830|NCT04542486|Procedure|Excision of gingival hyperplasia using the conventional scalpel technique|Excision of gingival hyperplasia in gingivoplasties using the conventional technique reverse bevel using 15c blade.
45845055|NCT02196168|Drug|Cisplatin|Given IV
45845056|NCT02196168|Other|Laboratory Biomarker Analysis|Correlative studies
45845057|NCT02196168|Other|Pharmacological Study|Correlative studies
46049334|NCT04153084|Drug|PEG-3350 with electrolytes|The low volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
45361831|NCT00929292|Other|Modilac Dahlia 1|Infant formula used for non breastfed children with colic
45361832|NCT00929292|Other|Modilac 1|Infant formula used for non breastfed children
45361833|NCT01326169|Behavioral|Brief intervention|Telephone-delivered counseling
45480031|NCT03742349|Biological|LAG525|LAG525 LIVI (Liquid in vial) Concentrate for Solution for infusion
45480032|NCT03742349|Drug|NIR178|Capsule
45480033|NCT03742349|Drug|capmatinib|Tablet
45480034|NCT03742349|Biological|MCS110|LIVI (Liquid in vial) Concentrate for Solution for infusion
45480035|NCT03742349|Biological|canakinumab|LIVI (Liquid in vial) Solution for injection
45688653|NCT01735916|Device|CRT-P Implant|"The Medtronic Consulta CRT-P (models C3TR01, C4TR011) dual chamber implantable pacemaker with cardiac resynchronization therapy (CRT-P) is a multi-programmable cardiac device that monitors and regulates the patient's heart rate by providing single or dual chamber rate-responsive bradycardia pacing, and sequential biventricular pacing.~The device senses the electrical activity of the patient's heart using the electrodes of the implanted atrial and right ventricular leads. It then analyzes the heart rhythm based on selectable detection parameters. The device responds to bradyarrhythmias by providing bradycardia pacing therapy.~Simultaneous or sequential biventricular pacing is used to provide patients with cardiac resynchronization therapy. The device also provides diagnostic and monitoring information that assists with system evaluation and patient care."
46049335|NCT04153084|Drug|Sodium picosulfate|"The Sodium picosulfate will be administered the day before the procedure at different doses depending on the patient´s age:~From 1 to 2 years old: ¼ sachet reconstituted in ¼ glass of water/juice in the afternoon (15:00 h) and ¼ sachet reconstituted in ¼ glass of water/juice 6 hours later (21:00 h)~From 2 to 4 years old: ½ sachet in ½ glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~From 4 to 9 years old: 1 sachet in 1 glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~Of 9 years old and older: 1 sachet in the afternoon and 1 sachet at night."
46049336|NCT00691288|Drug|Omega Pure followed by placebo|Subjects in this arm will begin the study on active capsules (containing Omega Pure). Subjects in the 5-11 age group will take 2 capsules containing 500mg EPA/DHA twice daily for 12 weeks. Subjects in the 12-18 age group will take 2 capsules containing 1.0g EPA/DHA twice daily, also for a period of 12 weeks. Both age groups will then be switched to the placebo capsules containing citrus-flavoured soybean and corn oil, identical in appearance to the active agent, to be taken on an identical regimen to the active pills, for a period of 12 weeks.
45688654|NCT01735916|Device|CRT-P OFF|Device programmed to minimal pacing at 40 beats/minute. Device and arrhythmia diagnostics may remain enabled.
45688655|NCT01790126|Drug|ARN-509|
45688656|NCT01790126|Drug|LHRH Agonist|
45688657|NCT01734902|Drug|Hyoscine butylbromide|sugar coated tablets for oral administration
45688658|NCT01734902|Drug|Hyoscine butylbromide|drops for oral administration
45688659|NCT01790048|Dietary Supplement|Whey permeate RUSF|"Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of whey RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.~Whey RUSF contains whey permeate, WPC 80 (contains at least 80% protein), peanut paste, sugar, soy oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier."
45361834|NCT01326169|Behavioral|Standard care|No intervention
45361835|NCT00642902|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 32 weeks.
45361836|NCT00642902|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 32 weeks.
45361837|NCT00642902|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
45361838|NCT00642902|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
45361839|NCT05313477|Drug|Ergocalciferol Capsules|Depend on initial 25(OH) vitamin D level If <10ng/mL, 60000U of Ergocalciferol capsules per week If 10-19.9ng/mL, 40000U of Ergocalciferol capsules per week If >20 ng/mL, 20000U of Ergocalciferol capsule per week
45480036|NCT03326128|Drug|Bupropion hydrochloride extended release|Antidepressant that is also effective in smoking cessation
45361840|NCT05313477|Drug|Calcium carbonate|1000mg of Calcium carbonate daily
45361841|NCT02531815|Biological|PF-06741086|PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)
45480037|NCT03797105|Behavioral|School-Based Obesity Intervention (FLOW)|The intervention consisted of nutrition lessons based on the traffic light diet, circuit-based physical activity, behavior modification techniques (token economy system, goal setting, self-monitoring), and parental involvement (materials sent home and monthly parent meetings). 80% of time was spent on physical activity and 20% was spent on nutrition. Behavior modification was incorporated into both physical activity and nutrition time. Specifically, instruction and activity time during PE class lasted approximately 40 minutes.
45480038|NCT03319420|Drug|LO2A eye drops|Sodium hyaluronate
45480039|NCT03319420|Drug|Systane Ultra UD|Active Ingredients; Polyethylene Glycol Propylene Glycol
45480040|NCT03794297|Drug|Dabrafenib Mesylate|Given PO
45480041|NCT03794297|Other|Quality-of-Life Assessment|Ancillary studies
45688660|NCT01790048|Dietary Supplement|Soy Protein RUSF|"Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of soy RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.~Soy RUSF contains extruded soy flour, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate (Roche, Mumbai, India). Soy RUSF has no protein from animal sources."
45688661|NCT01789970|Drug|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
45688662|NCT01789970|Drug|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
45688663|NCT01788566|Drug|Necitumumab|Administered IV
45688664|NCT01788566|Drug|Gemcitabine|Administered IV
46049337|NCT00691288|Drug|Placebo followed by Omega Pure|Patients assigned to this arm of the study will begin on placebo followed by Omega Pure (identical dose and regimen as arm 1), also for a period of 12 weeks each.
45688665|NCT01788566|Drug|Cisplatin|Administered IV
45688666|NCT01733732|Other|SYSTANE® BALANCE Lubricant Eye Drops|
46049338|NCT00688948|Drug|Alfuzosin|Alfuzosin 10 mg once daily po for 12 weeks
45361842|NCT02531815|Drug|Placebo|Placebo for PF-06741086, single dose
45480042|NCT03794297|Other|Questionnaire Administration|Ancillary studies
45688667|NCT01733732|Other|SYSTANE® Gel|
45688668|NCT01732874|Drug|Expecta 200 mg|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 200mg Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
45688669|NCT01732874|Drug|Expecta 1 gram|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 1 gram of Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
45688670|NCT01732796|Drug|Ribavirin (RBV)|24 weeks of active RBV
46049339|NCT00672334|Drug|Sodium Bicarbonate|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
46049340|NCT00672334|Drug|Sodium Chloride|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
46049341|NCT04137952|Behavioral|size of error visual feedback|The strategies are expected to enhance opportunities of error experience and motor exploration via modified visual feedback, underlying facilitations of attentional resource and error-related neural networks.
46049342|NCT00937326|Drug|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg.
46049343|NCT00937326|Drug|Placebo|Placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
45361843|NCT00826124|Procedure|Epidural steroid injection|Injection based solely on history and physical exam
45361844|NCT00826124|Procedure|Epidural steroid injection|Two epidural steroid injections two weeks apart based on history, physical exam and MRI
45480043|NCT03794297|Drug|Trametinib Dimethyl Sulfoxide|Given PO
45688671|NCT01732796|Drug|BI 201335 (Faldaprevir)|16 weeks of BI 201335 followed by 8 weeks placebo to BI 201335
46049344|NCT04152694|Other|Ceftaroline levels in CRRT|Levels of ceftaroline measured in patients receiving CRRT
45361845|NCT00826124|Procedure|Magnetic Resonance Imaging (MRI)|Imaging of lumbar spine
45361846|NCT00224107|Drug|Silodosin|8 mg daily for 12 weeks
45361847|NCT00224107|Other|Placebo|1 capsule daily for 12 weeks
45361848|NCT04696731|Genetic|ALLO-316|ALLO-316 is an allogeneic CAR T cell therapy targeting CD70
45688672|NCT01732796|Drug|Ribavirin (RBV)|24 weeks of active RBV
46049345|NCT00689182|Procedure|monthly phlebotomy x 12 months|All patients will receive monthly phlebotomies.
46049346|NCT04138186|Device|2.0g G-PUR®, oral administration|tid for 12 weeks
45361849|NCT04696731|Biological|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
45361850|NCT04696731|Drug|Fludarabine|Chemotherapy for lymphodepletion
45361851|NCT04696731|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
45361852|NCT00822302|Drug|Reconstituted High Density Lipoprotein|RecHDL (Lot Nos 05422-00006)is provided as a lyophilised powder and reconstituted with sterile water at 25 mg/ml. The infusion is made at 40 mg/kg over a period of 4 hours.
45361853|NCT00822302|Drug|Saline|Saline (0.9%) is provided as a sterile infusion bag and infused over a period of 4 hours, 24 hours prior to carotid endarterectomy
45480044|NCT04531020|Diagnostic Test|PAED measurement|The incidence of emergence delirium, defined as PAED score above 10 points minimally in one of the PAED score measurements. PAED score will be measured in 0., 5., 10., 15., and 20. minute after PACU admission.
45480045|NCT03321994|Device|stereotaxic unit, navigation|CT-guided needle guidance using stereotaxic unit, navigation
45480046|NCT03321994|Device|conventional biopsy technique|CT-guided needle guidance using conventional biopsy technique
45480047|NCT03048500|Other|Laboratory Biomarker Analysis|Correlative studies
45480048|NCT03048500|Drug|Metformin Hydrochloride|Given PO
45480049|NCT03048500|Biological|Nivolumab|Given IV
45480050|NCT01331772|Other|Control arm|Dietetic follow-up only
45688673|NCT01732796|Drug|BI 207127|24 weeks of BI 207127
45688674|NCT01732796|Drug|BI 201335 (Faldaprevir)|24 weeks of BI 201335
45688675|NCT01732796|Drug|Ribavirin (RBV)|16 weeks of Ribavirin followed by 8 weeks of placebo to Ribavirin
45688676|NCT01732796|Drug|BI 207127|16 weeks BI 207127 followed by 8 weeks placebo to BI 207127
45688677|NCT01732796|Drug|Faldaprevir (BI 201335)|24 weeks of 201335
45688678|NCT01732796|Drug|BI 207127|24 weeks of BI 207127
45845058|NCT02196168|Other|Placebo|Given PO
46049347|NCT04138186|Device|Placebo, oral administration|tid for 12 weeks
46049348|NCT00691522|Drug|Xerecept|
46049349|NCT02629666|Behavioral|ERS and/or Self-management Strategies|
46049350|NCT00873730|Drug|etanercept|Etanercept 50 mg twice a week (BIW) for 12 weeks
46049351|NCT00873730|Drug|etanercept/placebo|Etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks
45361854|NCT04004871|Drug|Nab-paclitaxel, Cisplatin and Fluorouracil|Patients receive Nab-paclitaxel (200mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before concurrent chemoradiotherapy.
45361855|NCT04004871|Radiation|concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
45361856|NCT00826358|Drug|ABT-143|Once, please see Arm Description for more details.
45361857|NCT00826358|Drug|ABT-335|Once, see Arm Description for more detail
45845059|NCT02196168|Drug|WEE1 Inhibitor AZD1775|Given PO
45845060|NCT02200458|Device|VeinViewer|Updated software on the VeinViewer device will be used to project an image of the vasculature on the skin.
45845061|NCT02200536|Other|Infant oral health promotion package|Infant oral health promotion package includes an infant oral health pamphlet, a baby toothbrush, fluoride toothpaste (1000 ppm) and a trainer cup.
45845062|NCT02200536|Other|Infant oral health pamphlet|Infant oral health pamphlet
45845063|NCT02201394|Drug|Ticagrelor loading dose|Single loading dose of Ticagrelor 180 mg
45845064|NCT02201394|Drug|Aspirin loading dose|Single loading dose of Aspirin 325 mg
45845065|NCT02201394|Drug|Ticagrelor maintenance dose|Ticagrelor 90 mg twice daily x 7 days
45361858|NCT00826358|Drug|rosuvastatin|once, see Arm Description for more detail
45361859|NCT03972007|Device|Fotobiomodulation|A 16x28 cm LED blanket containing 160 LEDs will be used and will use a total energy per area of 60J, with a wavelength of 940nm, just before the muscle fatigue protocol and will be applied throughout the Biceps extension.
45361860|NCT00987909|Biological|Specific allergen immunotherapy (placebo)|Drops for sublingual administration, 0 mcg (placebo), once daily administration for 16 weeks
45361861|NCT00987909|Biological|Specific allergen immunotherapy|Drops for sublingual administration, 4.5 mcg Fel d1/day, once daily administration for 16 weeks.
45361862|NCT00987909|Biological|Specific allergen immunotherapy|Drops for sublingual administration, 9.0 mcg Fel d1/day, once daily administration for 16 weeks
45361863|NCT00987909|Biological|Specific allergen immunotherapy|Drops for sublingual administration, 18.0 mcg Fel d1/day, once daily administration for 16 weeks
45361864|NCT00822380|Dietary Supplement|Iron|Daily 20mg of ferrous sulfate in liquid solution during 4 months
45361865|NCT00822380|Dietary Supplement|Multiple micronutrients supplement|Daily supplement with 10mg of iron plus several micronutrients following a formula designed to treat anemia in indigenous population in Mexico. During 4 months.
45361866|NCT00822380|Dietary Supplement|micronutrient fortified porridge powder|Daily powdered complementary food designed for a national program in Mexico with 10mg of iron plus several micronutrients during 4 months
45361867|NCT00822380|Dietary Supplement|Iron and ascorbic acid fortified water|A drink water product fortified with 6.7 mg ofiron, zinc and ascorbic acid. This product was asked to be used for drinking and for cooking for the child during 4 months.
45361868|NCT00822380|Dietary Supplement|Iron plus folic acid supplement|Daily liquid solution following the daily iron (12.5mg)and folic acid recommendation of UNICEF to treat anemia during 4 months
45361869|NCT00720083|Drug|cisplatin|Given IV
45361870|NCT00720083|Drug|vandetanib|Given orally
45361871|NCT00720083|Radiation|radiation therapy|Patients undergo radiotherapy 5 times a week for up to 6.5 weeks.
45845066|NCT02201394|Drug|Aspirin maintenance dose|Aspirin 81 mg once daily x 7 days
45845067|NCT02202252|Procedure|Insertion of a single drain|A negative pressure drain will be inserted below the lower flap directing to the axilla.
45361872|NCT05621811|Drug|Naronapride|Naronapride is a 5HT-4 agonist
45361873|NCT05621811|Drug|Placebo|Placebo
45361874|NCT00209131|Drug|Flomax|0.4mg Flomax pills will be given to patients to take once daily for one month following shock wave lithotripsy to aid the stone passage.
45361875|NCT00209131|Drug|Sugar pill|Comparable sugar pills will be given to the placebo group to take daily for one month following shock wave lithotripsy to aid stone passage.
45361876|NCT05619471|Device|VIO|Skin conditions that are candidates for skin biopsies
45361877|NCT00925626|Procedure|Sub-Vastus arthrotomy|Sub-vastus arthrotomy
45688679|NCT01732640|Drug|Afatinib|Afatinib will be supplied as film-coated tablets. Available dosage strengths will be 20, 30, or 40 mg. Tablets will be supplied in HDPE, child-resistant, tamper-evident bottles.
45688680|NCT01732640|Drug|Paclitaxel|Induction chemotherapy: 175 mg/m2 day 1 every 21 days for 2 cycles (IV infusion as per institutional standard).
45688681|NCT01732640|Drug|Carboplatin|Carboplatin is available as a sterile lyophilized powder in single-dose vials containing 50 mg, 150 mg, or 450 mg of carboplatin. Each vial contains equal parts by weight of carboplatin and mannitol. Commercial supplies of carboplatin will be used in this trial.
45845068|NCT02202252|Procedure|Insertion of double drains|Two drains will be inserted into the axilla and below the lower flap in the double drains group.
45845069|NCT02202252|Procedure|Ultrasonography after removal of the drains|One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography.
45845070|NCT02203578|Drug|romidepsin|Given IV
45845071|NCT02203578|Other|laboratory biomarker analysis|Correlative studies
45845072|NCT02204124|Device|Thunderbeat|Thunderbeat uses ultrasonic and high frequency bipolar energy simultaneously to seal and cut tissue compared to placebo comparator.
45845073|NCT02204124|Device|Standard of care scissors, ligatures, clips, and sutures|
45361878|NCT00925626|Procedure|Mid - Vastus arthrotomy|Mid-vastus arthrotomy
45480051|NCT01331772|Other|Intervention arm|Dietetic follow up + adapted physical activity
45480052|NCT03319342|Behavioral|Behavioral Intervention|Perform acts of kindness to others
45688682|NCT01732640|Drug|Cisplatin|Concurrent chemotherapy: 40 mg/m2 once weekly for 7 cycles (IV infusion as per institutional standard).
45845074|NCT02204748|Device|DePuy Attune posterior stabilizing fixed bearing knee system|
45845075|NCT02206776|Drug|Intranasal Ketamine|A single dose of intranasal ketamine up to 50 mg
45361879|NCT04044950|Biological|E7 TCR|The injection will be approximately 3x10^8 E7 TCR T cells, unless fewer cells are generated, at each site of organ involvement (i.e. primary tumor, palpable lymph node (s)) in approximately 1-2 mL of volume.
45361880|NCT00907608|Drug|Darbepoetin alfa|Starting dose of 20 microgram per week, to be titrated over a 3-month period until target hemoglobin level is reached (female: 11 g/dL and male: 12 g/dL). Route of administration is subcutaneous injection.
45361881|NCT00224029|Drug|Oxybutynin transdermal system|3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day transdermal per titration
45480053|NCT03319342|Behavioral|Behavioral Intervention|Perform acts of kindness to self
45480054|NCT03319342|Behavioral|Behavioral Intervention|Perform self-kindness meditation
45480055|NCT03319342|Behavioral|Behavioral Intervention|Keep track of daily activities
45480056|NCT03319342|Other|Questionnaire Administration|Ancillary studies
45480057|NCT01305161|Other|Blood simple|Single Blood simple at Day 1
45480058|NCT03790787|Drug|Empagliflozin|Empagliflozin as Jardiance® 25 mg film-coated tablets for oral administration
45480059|NCT03790787|Drug|Dorzagliatin|Glucokinase activator currently under development
45480060|NCT01334268|Device|Taxus Liberte Paclitaxel-Eluting Coronary Stent System|Taxus Liberte Paclitaxel-Eluting Coronary Stent System Implantation
45688683|NCT01732640|Radiation|Intensity Modulated Radiation Therapy|Standard Fractionation 70 Gy /35 fractions at 2 Gy/day for 5 days per week.
45688684|NCT01732484|Procedure|intraocular lens implantation|
45480061|NCT01334268|Device|Resolute Zotarolimus-Eluting Coronary Stent System|Resolute Zotarolimus-Eluting Coronary Stent System Implantation
45480062|NCT04493398|Procedure|Gracey curette.|Root planed was performed with curettes (Gracey SAS, Hu-Friedy, Chicago, IL, USA).
45688685|NCT01786148|Behavioral|mobile phone application|
45688686|NCT04560686|Drug|Bintrafusp Alfa|Given IV
45688687|NCT04560686|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45688688|NCT01785602|Drug|QAW039|Capsules
45688689|NCT01785602|Drug|Placebo|Capsules
45688690|NCT01785524|Drug|Beetroot Juice (Beet-It Stamina Shot) and Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
45688691|NCT01785524|Other|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
45688692|NCT01757288|Drug|NAB-PACLITAXEL|nab-Paclitaxel 50 mg/m2 IV/30min/wk x6 wks
45688693|NCT01757288|Drug|PACLITAXEL|
45845076|NCT02206776|Drug|Intranasal Midazolam|A single dose of intranasal Midazolam up to 4 mg
45845077|NCT02207322|Other|transplant with early palliative care|the intervention include integrating early palliative care with standard transplant care to evaluate and treat patients' symptoms during stem cell transplantation
46049352|NCT00689416|Drug|rosuvastatin|40 mg, tablet, once daily for 3 months.
46049353|NCT00689416|Drug|placebo|40 mg, tablet, once daily for 3 months
46049354|NCT01092416|Device|Diamondback 360 Orbital Atherectomy System|Diamondback 360 Orbital Atherectomy System. The (OAS) utilizes a diamond-coated eccentric crown that, while rotating over an atherectomy guide wire, expands the lumen diameter laterally via centrifugal forces (up to a maximum orbit diameter for a given rotational speed and crown diameter). It is a minimally invasive PCI procedure.
46049355|NCT00689494|Other|Nanopaz contraception device|levonorgestrel and levonorgestrel device for cervical contraception-nantechnolgy method
46049356|NCT00672568|Drug|4975 - Highly purified capsaicin|Solution, 0.5 mg, single dose, injection
46049357|NCT00672568|Drug|4975 - Highly purified capsaicin|Solution, 0.75 mg, single dose, injection
45361882|NCT00826592|Other|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on atopic dermatitis. In the active comparison arm (control arm), the comparison intervention is written patient educational material on atopic dermatitis.
45361883|NCT04085081|Other|E-mail|Receive brief motivational text or email messages
45361884|NCT04085081|Behavioral|Exercise Intervention|Receive personalized walking program plus strength exercises
45361885|NCT04085081|Other|Quality-of-Life Assessment|Ancillary studies
45361886|NCT04085081|Other|Questionnaire Administration|Ancillary studies
45361887|NCT04085081|Behavioral|Telephone-Based Intervention|Receive intervention coaching sessions via telephone
45361888|NCT04085081|Other|Text Message|Receive brief motivational text or email messages
45361889|NCT03969979|Diagnostic Test|Shear wave elastography|shear wave elastogrophy will be performed
45361890|NCT00817154|Behavioral|HOPES-I|The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
45361891|NCT02591381|Procedure|Artificial Urinary Sphincter Placement|The AUS is the gold standard for treatment of severe stress urinary incontinence, particularly in patients following surgical resection of the prostate for prostate cancer. AUSs are small devices that prevent urinary flow via compression of the urethra, thus mimicking the native urinary sphincter.
45361892|NCT00929370|Drug|Glycine Transporter-1 inhibitor|GSK1018921 is a potent and selective inhibitor of the glycine transporter-1 (GlyT-1).
45361893|NCT05605275|Diagnostic Test|PCT levels|All patients will have their serum PCT level recorded on the day of the positive blood culture and in the next three days.
45361894|NCT05605275|Diagnostic Test|CRP levels|All patients will have their serum CRP level recorded on the day of the positive blood culture and in the next three days.
45361895|NCT05605275|Diagnostic Test|White blood cell count|All patients will have their white blood cell (WBC) count recorded on the day of the positive blood culture and in the next three days.
45361896|NCT05605275|Diagnostic Test|Platelet count|All patients will have their platelets count recorded on the day of the positive blood culture and in the next three days.
45361897|NCT00817232|Device|Microcurrent (Elexoma Medic)|monophasic frequency modulated square wave current applied for 99 minutes daily for 21 days
45361898|NCT03967795|Drug|N2-L-Alanyl-L-Glutamine (Substance)|20 gr of 10% N2-L-Alanyl-L-Glutamine, dilution in 200 ml of water for injection, intravenous perfusion over 30 minutes
46049358|NCT00672568|Drug|4975 - Highly purified capsaicin|Solution, 0.1 mg, Single dose, injection
45361899|NCT04086251|Other|Gaido|Patients will participate for up to 21 days. Over the course of the study, 25-100 patients will be enrolled.
45688694|NCT01757288|Drug|NAB-PACLITAXEL|nab-Paclitaxel 40 mg/m2 IV/30min/wk x6 wks
45688695|NCT01756898|Drug|5 mg ASB17061|Oral administration of 5 mg ASB17061 taken once daily for 28 consecutive days.
46049359|NCT00672568|Drug|Placebo|Solution, single dose, injection
46049360|NCT00922714|Drug|Glutamine|Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
46049361|NCT00922714|Drug|saline (placebo)|NaCl 0.9 g/L
45361900|NCT00907764|Drug|regadenoson|400 ug, IV
45361901|NCT02550314|Drug|fiblast,gelatin sponge,fibrin glue|
45361902|NCT00987987|Procedure|donor lymphocyte infusion|regulatory T cells depletion
45361903|NCT01073527|Drug|hypertonic saline-salbutamol combination|hypertonic saline 5% with 0.5cc salbutamol
45361904|NCT01073527|Drug|Normal saline-salbutamol combination|normal saline - 4cc with salbutamol 0.5cc
45480063|NCT04493398|Procedure|Ultrasonic scaler.|Debridement was performed with an ultrasonic scaler (Piezon Master 400 Perio Slim Tip®; Electro Medical System, Nyon, Switzerland).
45480064|NCT04493398|Procedure|Erythritol air-polishing.|Treatment was performed with a low abrasive erythritol powder (Air-flow powder plus®, EMS, Nyon, Switzerland ) applied through a Perio-Flow hand piece connected to an airflow unit (Air-Flow Master®, EMS, Nyon, Switzerland).
45688696|NCT01756898|Drug|Placebo|Oral administration of placebo taken once daily for 28 consecutive days.
46049362|NCT00691834|Biological|Intracoronary delivery of unfractionated bone marrow mononuclear cells|Maximal intracoronary cell dose: 50 x 10e7 cells diluted in 10 ml Maximal intracoronary volume: 10 ml (diluted in plasma and culture medium)
46049363|NCT00691834|Biological|Placebo|Plasma and culture medium (10 ml)
46049364|NCT02629276|Other|neurodynamic testing|
45845078|NCT02207478|Procedure|ENB|ENB is performed using an electromagnetic navigation system (LK-DW-NK-Z; Suzhou Lungcare Medical Technology Inc., China) with an internal locatable guide (LG; Lungcare) with diameter of 1.45 mm. Bronchoscopes with a working channel diameter of 2.0 mm are used (BF-260 and BF-P260F; Olympus, Japan). The LG is inserted into the GS(K-201; Olympus) beforehand, and the GS-covered LG is introduced via the working channel of the bronchoscope and navigated to the PPL finally. The LG and GS are confirmed to reach the lesion by radiograph fluoroscopy.
45845079|NCT02207478|Procedure|GS-TBLB-X-ray|A GS is introduced in the working channel of the bronchoscope alone. The GS is confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
45361905|NCT04504968|Other|Multimodal intervention|"Optimal control: HbA1c between 7.6-8.5% (60-69 mmol/mol) and Blood Pressure<150/90 mmHg~The physical exercise program that will be used will be the Vivifrail program (Erasmus + UE). Vivifrail includes: Strength for arms and legs, balance and gait, flexibility and resistance. The duration will be 16 weeks. (3 weeks to explain the program in the Trial site and the rest of weeks, it will be carried out at home).~Nutritional and educational program to increase diabetes knowledge, develop practical self-care skills for diabetes and increase the likelihood of improving glycemic control safely. The intervention aims to minimize the risk of hypoglycemia, ensure optimal nutritional status and help to maintain functional status. Seven separate sessions of 45 minutes each one twice a week for a period of 3-4 weeks in small groups. They will be moderated by a physician or diabetes educator and focused on behavioral changes and key points."
45361906|NCT04504968|Other|Usual care group|The level of usual health care that a patient with diabetes receives from their local national health system
45845080|NCT02209272|Drug|bacteriostatic saline|
45845081|NCT02209272|Drug|buffered lidocaine|
46049365|NCT00672724|Drug|Ramelteon|Ramelteon 8 mg tablets, taken orally, once daily for up to 2 weeks.
46049366|NCT00672724|Drug|Placebo|Ramelteon placebo-matching tablets, taken orally, once daily for up to 2 weeks.
45361907|NCT00822458|Drug|vismodegib|Given orally
45361908|NCT00822458|Other|laboratory biomarker analysis|
45845082|NCT02210052|Device|Radiofrequency cannula|Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
45361909|NCT00822458|Other|pharmacological study|
45845083|NCT02210286|Dietary Supplement|Magtein|
45361910|NCT00223795|Device|Single point cane|Participants with symptomatic knee osteoarthritis will undergo gait evaluation with and without a single point cane.
45361911|NCT02538432|Drug|RQ-00000007|RQ-07 250 mg will taken orally, with or without food, each morning and evening, approximately 12 hours apart. Drug administration will be continuous. Every 21 day period will be considered one cycle of treatment.
45688697|NCT01756898|Drug|10 mg ASB17061|Oral administration of 10 mg ASB17061 taken once daily for 28 consecutive days.
45688698|NCT01756898|Drug|20 mg ASB17061|Oral administration of 20 mg ASB17061 taken once daily for 28 consecutive days.
45688699|NCT01731938|Biological|Fibrin Sealant (FS) Grifols|Fibrin Sealant (FS) Grifols: The maximum total volume of FS Grifols allowed to be applied at the target bleeding site by dripping or spraying was approximately 12 mL (equivalent to the full content of 2 FS Grifols kits).
46049367|NCT05380596|Behavioral|Telepharmaceutical Care|The intervention will be carried out through three teleconsultations, one per month, with a pharmacist (Times 0, 1, 2 and 3). In the opportunities, aspects related to pharmacotherapy and health status, non-pharmacological approaches, treatment adherence and evaluation of problems related to pharmacotherapy (PRM) will be discussed.
46049368|NCT00689650|Device|1540 nm fractional laser|
46049369|NCT05382156|Drug|Osilodrostat|oral administration of Osilodrostat tablets at different doses according to patient's need
46049370|NCT00604032|Drug|Atralin (tretinoin) Gel, 0.05%|Assess potential of tretinoin gel, 0.05% to produce phototoxic reactions, measured 24 and 48 hours after UV radiation of drug on the skin.
46049371|NCT00874432|Drug|angiotensin converting enzyme inhibitor|Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day
45688700|NCT01731938|Device|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
45688701|NCT01731470|Biological|Liposomes|Intravesical instillation of liposomes.
45688702|NCT01756352|Drug|18F-FET|Radiotracer, surrogate marker for protein synthesis
46049372|NCT00874432|Drug|lisinopril|1 x 40 mg per day
46049373|NCT00606528|Other|No intervention|None. This is an observational study.
45361912|NCT02538432|Drug|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be administered at 1000 mg/m2 IV over 30 minutes for 3 out of 4 weeks after appropriate pre-medications. Every 4 week period (28 days) will be considered one cycle.
45361913|NCT01563627|Other|blood sampling for drug resistance biomarkers|comparison of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy
45361914|NCT01563627|Device|Magnetic Resonance Imaging|
45361915|NCT00826670|Drug|Decolonization|"Colistin sulphate (50mg 4x/d PO) + Neomycin (250mg 4x/day PO) for 10 days~plus In the presence of urinary tract colonization choice of one of the following agents (according to susceptibility profile, creatinine clearance and individual contraindications) Nitrofurantoin (100mg 3x/day PO) or Norfloxacin (400mg 2x/day PO) for 5 days"
45361916|NCT00826670|Drug|Placebo (Decolonization)|Placebo
45361917|NCT05238519|Behavioral|Motivational interview (MI)|"The MI intervention is adapted from the CHEERS study intervention (M Health Fairview) found to be effective in promoting lipid screening in patients at increased risk for FH.~Within one month of completion of the baseline survey, a study coordinator, who received training in motivational interview integrity, will conduct a 20-40-minute (depending on participant needs) telephone or virtual (zoom) interview with participants randomized to this arm. Participants will be assessed on their readiness to get their cholesterol checked and discuss with family members the risk of FH."
45361918|NCT00719849|Biological|anti-thymocyte globulin|30mg/Kg Days -6 to -4
45361919|NCT00719849|Drug|cyclophosphamide|50 mg/Kg Day -6
45845084|NCT02211456|Procedure|Atrial Fibrillation/flutter (AF) or Ventricular Tachycardia (VT) ablation with multi-site pacing protocol|Pacing at several endocardial sites in isolation and individually will be performed, with response to this assessed by LV dp/dt max
46049374|NCT04138108|Other|Psychoeducation|The parents of each child were educated as couples and each training session lasted 45-60 minutes for each family. Approximately the first five minutes of the training were used for warm-up, 25 minutes were used for basic ADHD knowledge and the last 15 minutes were catechetic and conducted interactively. The psychoeducation included discussion about the causes, symptoms and signs of ADHD, the course and characteristics of the disease according to age, the treatment process, the drugs used in the treatment and their side effects, correct and incorrect information about drugs, the other symptoms which can coexist with ADHD and their treatment, and what the parents can do about these issues.
45361920|NCT00719849|Drug|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
46049375|NCT00935220|Drug|linagliptin QD (once daily) for 7 days|dipeptidyl peptidase IV (DPP-4) activity will be measured as PD response to drug administration
46049376|NCT00691912|Drug|liposomal Doxorubicin|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
46049377|NCT00691912|Drug|Myocet / Paclitaxel|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
46049378|NCT00874276|Drug|Dichloroacetate (DCA)|Dichloroacetate 2.5.ug/kg will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
46049379|NCT00874276|Genetic|Genetic Marker on Chromosome 14q24.3|Individuals were genotyped at the beginning of the study and their haplotypes were defined. The study is looking at individuals with genetic markers on Chromosome 14q24.3 to determine if there will be a difference in how the DCA will be metabolized.
45361921|NCT00719849|Drug|fludarabine phosphate|40mg/m2 Days -6 to -2
45361922|NCT00719849|Drug|mycophenolate mofetil|1 gram every 8 hours for patients who are ≥ 40 kg. Pediatric patients (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours. Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
45361923|NCT00719849|Procedure|umbilical cord blood transplantation|Single or double unit umbilical cord blood transplant
45361924|NCT00719849|Radiation|total body irradiation|200 cGy Day -1
45688703|NCT01756274|Device|Contour® NEXT BGMS|Lab professionals tested the BG concentration using Contour® NEXT BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
45688704|NCT01756274|Device|Contour® PLUS BGMS|Lab professionals tested the BG concentration using Contour® PLUS BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
45847696|NCT02864706|Drug|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
45361925|NCT02549612|Device|Moniri Otovent|Please see arm description.
45361926|NCT03775239|Behavioral|Mindfulness in Sex Therapy and Intimate Relationships (MSIR)|"Mindfulness is a mental discipline inviting intentional, non-judgmental attending of the stream of experience. Mindfulness can be seen as an adjunct to sexual therapy. Firstly, it is a way of teaching the patients and the couples to carry out sensate focus so that it can achieve its goals. Beyond this, Mindfulness may invite a stance to one's own and a partner's physical and emotional experience that is more widely beneficial. The MSIR intervention was originally developed from the Mindfulness Based Cognitive Therapy (MBCT) protocol and consists of:~Week 1: Moving into the Body Week 2: Sensing & Exploring Week 3: Avoidance & Intimacy- Midway individual session. Week 4: Recognising our automatic mind Week 5: Spacious Awareness Week 6: Expanding new learning"
45361927|NCT03775239|Behavioral|Treatment-as-usual|"The current treatment in Sexological Clinic is an eclectic, synthetic therapy form conducted by psychiatrists, other medical doctors, psychologists and bodytherapists.~In order to implement the bio-psycho-social character of sexual dysfunctions, the current treatment takes advantage of different elements from different therapy forms combined with pharmacological treatment if necessary.~The integrated treatment combines elements from therapy's such as cognitive behavioural therapy (CBT), psychodynamic therapy and systemic therapy together with Master and Johnson's sensate focus training, body exercises training as pelvis floor exercises, introduction of sexual aids and if necessary pharmacological treatment. The therapy can be individual treatment, couple therapy (marital therapy) or group therapy."
45688705|NCT01756274|Device|Contour® Next EZ BGMS|Lab professionals tested the BG concentration using Contour® Next EZ BGMS (Blood Glucose Monitoring System). All meter BG results were compared with plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
46049380|NCT05382390|Drug|rhTPO|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count > 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
45361928|NCT00907842|Device|Parietex Parastomal Mesh|mesh placed intraperitoneally around the stoma
45361929|NCT00822536|Drug|Aspirin and Clopidogrel|Aspirin <= 325 mg/j Clopidogrel = 75 mg /j
45361930|NCT00822536|Drug|Aspirin|Aspirin : <= 325 mg/j
45688706|NCT01731002|Drug|AR-13324 Ophthalmic Solution 0.01%|Administered to study eye, once daily (QD) in the evening (PM) for 28 days
46049381|NCT05382390|Drug|Decitabine|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
45361931|NCT04015752|Diagnostic Test|culture from infected site|ESR ,CRP,CBC, Renal and Liver function will be done on admission and follow up Culture: On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections.
45361932|NCT00826826|Procedure|Catheter ablation|(Pulmonary vein isolation)
46049382|NCT04265820|Device|unilateral implantation of IOL|unilateral phacoemulsification and implantation of IOL.IOL may be monofocal,bifocal ,or trifocal，according to the patients preference and the eyes condition.
45361933|NCT00826826|Drug|Amiodarone|From the day of the catheter ablation procedure and 8 weeks forward.
45361934|NCT00826826|Drug|Placebo|From the day of the catheter ablation procedure and 8 weeks forward.
45688707|NCT01731002|Drug|AR-13324 Ophthalmic Solution 0.02%|Administered to study eye, QD in the PM for 28 days
45688708|NCT01731002|Drug|Latanoprost ophthalmic solution 0.005%|Administered to study eye, QD in the PM for 28 days
45688709|NCT04559984|Device|JUVÉDERM VOLUX®|JUVÉDERM VOLUX® injectable gel
46049383|NCT04265820|Device|bilateral implantation of IOL|bilateral phacoemulsification and implantation of IOL.IOL may be monofocal,bifocal ,or trifocal，according to the patients preference and the eyes condition.
45361935|NCT00925860|Procedure|non positive pressure mechanical ventilatory support|
45361936|NCT05217615|Behavioral|ezParent|The ezParent Program is a 6-module web-based adaptation of the group-based Chicago Parent Program (CPP). ezParent uses multiple strategies to promote skill development in parents. Each module includes (a) video narrator descriptions of parenting strategies, (b) video vignettes of parents and children as examples of how parenting strategies work, (c) questions following each vignette for parents to reflect upon, (d) interactive activities for parents to complete, (e) knowledge questions to assess parent understanding of the strategies, and (f) practice assignments. To tailor to the former VPT population, developmental tips are included. Parents are instructed to complete the 6 modules over 10-weeks, approximately 1 module every 1.5 weeks. At the end of each module, parents receive a practice assignment linked to the module content. To encourage and support program completion, parents receive automated text messages and badges.
45688710|NCT01783886|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
45688711|NCT01783886|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
45688712|NCT01783886|Procedure|Macular Laser Photocoagulation|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
45847697|NCT02865720|Drug|CINRYZE 500 U|IV infusion administered twice weekly
45361937|NCT05217615|Behavioral|Coaching calls|The purpose of the brief (~15 min) telephone coaching calls is to provide parents with clarification of program content, encouragement and reinforcement of program completion, and support tailoring of intervention content (ezParent or Active Control)for their child. Coaching calls are guided by a semi-structured script aimed at supporting parent learning and motivation. Calls will be scheduled every week for 10 weeks. Each call will include an opportunity for parents to identify and discuss:(a) questions regarding the materials and content received in their respective groups,(b) identification of potential barriers and strategies to overcome barriers for completion of intervention (ezParent or control) content in their respective group, and (c)follow up on discussion points from previous calls. In both conditions, coaches will have access to a web-based usage portal to guide the discussion.
45688713|NCT01609556|Drug|Mirvetuximab soravtansine|Mirvetuximab soravtansine IV infusion will be administered as per dose and schedule specified in the respective arms.
45688714|NCT00234832|Drug|Sibutramine hydrochloride|One 10 mg tablet QD plus country-specific standard care for weight management. (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
45688715|NCT00234832|Drug|Placebo|1 tablet QD plus country-specific standard care for weight management (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
45688716|NCT00234832|Drug|Sibutramine hydrochloride|10 mg tablet QD during the 6-week Lead-in Period plus country-specific standard care for weight management
45688717|NCT00259090|Drug|Fulvestrant|500 mg intramuscular injection
45688718|NCT00259090|Drug|Anastrazole|oral tablet
45688719|NCT00235456|Procedure|Perioperative supplemental oxygen|Patients were assigned to 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
45688720|NCT00235456|Procedure|Standard oxygen|Patients were assigned to 30% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
45845085|NCT02211534|Device|Pulsed Electromagnetic Field Device (Provant)|The PEMF device delivers non-thermal, non-ionizing pulsed electromagnetic energy to the target tissue, using 27.12 megahertz pulses lasting 42 microseconds and delivered 1000 times per second. The system generates an electromagnetic field that is continuously monitored and regulated to ensure consistent dosing. The therapeutic electromagnetic field is delivered by means of an applicator pad that is placed against the treatment site. The active and sham devices will be identical in appearance and all other physical characteristics in order to maintain the masking of the treatment.
45845086|NCT02211534|Device|Sham Pulsed Electromagnetic Field Device|The Sham device will be identical in appearance, physical characteristics and operation to the Active device.
46049384|NCT05378412|Behavioral|3Cs|The 3Cs program is an educational strategy aimed at fostering resilience and compassion in people. It is based on improving the mental well-being of the participants by transforming their attitudes and behaviors through increased consciousness.
45688721|NCT00236938|Drug|Venofer and stable erythropoietin (EPO) regimen|Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
46049385|NCT00689806|Drug|Lovastatin|Lovastatin 20 mg extended release (or placebo) by mouth once daily for weeks 1-4. Liver function test will be checked at week 4 follow up visit. If LFTs are not > 3 times the upper limit of normal, then the subject will have the dose of extended release lovastatin increased to 60 mg once a day for weeks 4-12
45688722|NCT00236938|Drug|stable erythropoietin (EPO) regimen|Stable erythropoietin (EPO) dose and no supplemental iron.
45688723|NCT01898728|Drug|topical povidone-iodine after premedication with topical liquid eye drops|
45688724|NCT01898728|Drug|topical povidone-iodine after premedication with topical gel|
45688725|NCT00260962|Drug|Olanzapine|After a 2-week baseline period, olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of at 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of of 10 mg/day.
45688726|NCT00260962|Behavioral|Day Hospital|Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
45688727|NCT00261040|Procedure|Minimally Invasive Surgery|In minimally invasive surgery, the surgeon makes a shorter incision (about 10 cm or less) along the side of the thigh and replaces the hip through this smaller incision. The surgeon is able to do the surgery through a shorter incision by using special instruments which can guide him or her.
45688728|NCT00261040|Procedure|Standard Surgery|The standard way that an orthopaedic surgeon performs a hip replacement surgery is that they make a long incision (about 20 cm) down the side of the thigh and then replaces the hip joint through this long incision.
45688729|NCT00237718|Drug|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 6 months
45845087|NCT02213250|Drug|BENEFIX|Single dose of 50 IU/kg of BeneFIX by intravenous infusion within 10 minutes.
46049386|NCT00689806|Drug|Placebo|Placebo by mouth once daily for weeks 1-4.
46049387|NCT00606606|Other|Clinical Decision Support|
46049388|NCT05380362|Other|Venous Angioplasty|venous angiogram to look for lesions or flaps and then plastying vessels open.
45688730|NCT00237718|Drug|Alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 6 months
45361938|NCT05217615|Behavioral|Active Control|The active control is an adaptation of a web-based application developed in our previous study (R01-HS024273). The program will include general information typically provided during well-child or NICU follow up visits. Six topic areas are: Immunizations, Common Childhood Illnesses, Nutrition, Dental Health, and Indoor and Outdoor Injury Prevention/Safety. The program includes handouts, websites, and resources provided to parents of children in this age group. Parents will be instructed to review each topic over 10-weeks, approximately 1 topic every 1.5 weeks
45361939|NCT02592941|Drug|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
45361940|NCT00817388|Other|No intervention|No intervention
45361941|NCT05013996|Behavioral|MIDSA|Multidimensional Inventory of Development, Sex, and Aggression
45361942|NCT05013996|Behavioral|Usual methods of evaluation|Usual methods of evaluation of each of the participating centers (CMP / CRIAVS / private practitioners, etc.).
45361943|NCT03762291|Biological|CVD908ssb-TXSVN|"TXSVN may activate the immune system which is the participants body's ability to fight disease, and help develop a response against cancer cells that express Survivin. Survivin has been safely targeted using immune cells, drugs or direct inhibitors in over 50 patients with cancers in published reports.~Survivin belongs to the group of proteins known as tumor-associated antigens (TAAs). These are cell proteins that are specific to the cancer cell. They either are not found or are found in low levels normal cells in the human body. More than 90% of myeloma cancer cells have been shown to possess large quantities of Survivin."
45361944|NCT00822614|Drug|Fentanyl TAIFUN|Inhalation of Fentanyl via TAIFUN inhaler
45361945|NCT00822614|Drug|Opioid|Current optimized BTP treatment
45361946|NCT00907920|Other|laboratory biomarker analysis|Correlative studies
45361947|NCT04087967|Drug|Decitabine plus HAAG regimen|"Decitabine:20mg/m2/d,d1~5, intravenous infusion; Homoharringtonine:1mg/d,d3~16,intravenous infusion; Aclarubicin:10mg/d, d3~d10, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-16, subcutaneous injection;~Granulocyte colony-stimulating factor (G-CSF):~50-300μg/d (when WBC counts are less than 20×10^9/L ),subcutaneous injection;"
45688731|NCT00237718|Drug|Placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 6 months
45361948|NCT04087967|Drug|Idarubicine plus Cytarabine regimen|Idarubicine :12mg/m2, d1-3, intravenous infusion; Cytarabine :100mg/m2, d1-7, 24-hours continuous intravenous infusion
45361949|NCT03735693|Diagnostic Test|Ulstrasound|measurement of right femoral cross-section
45361950|NCT02549456|Procedure|natural orifice specimen extraction|Conventional laparoscopic resection of colorectal cancer is done then specimen is extracted through natural orifice (anal or vaginal orifice).
45688732|NCT00237718|Drug|Placebo|placebo for alpha lipoic acid; 2 pills daily for 6 months
45688733|NCT00238108|Drug|Melatonin|2,5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
45688734|NCT00238108|Drug|Placebo|Placebo
45688735|NCT01899196|Biological|blood sampling,|
45688736|NCT01898962|Procedure|Complete Surgical Removal|
45688737|NCT01898962|Radiation|Stereotactic Radiosurgery|
45688738|NCT01898962|Radiation|Ablative external beam radiation dose|
45845088|NCT02214420|Drug|Simeprevir|
45845089|NCT02214420|Drug|Sofosbuvir|
45361951|NCT02549456|Procedure|Laparoendoscopic resection|"Endoscopic phase: Transanal platform is inserted into the rectum, and pneumorectum is established. The lumen is occluded below the level of the tumor. The avascular ''oncologic'' presacral plane is entered posteriorly, and dissection proceeds cephalad in the total mesorectal excision planes. Next, the abdominal cavity is entered at the peritoneal reﬂection. The superior rectal artery is divided. The rectal stump then is reﬂected into the abdominal cavity, and retrograde dissection is performed until the procedure is limited by instrument length.~Laparoscopic phase: Colon mobilization, lymph node dissection, and mesenteric excision are performed laparoscopically. Mobilization of the splenic ﬂexure is done if needed."
45361952|NCT04087577|Other|conventional physical therapy|includes electrical stimulation for denervated muscles, and soft tissue massage, joint range of motion exercises to maintain the flexibility of the affected joint, muscle or connected tissues, sensory relearning
45361953|NCT04087577|Other|mirror therapy|mirror therapy
45361954|NCT04196751|Other|Clinical Supervision|After baseline data collection, participants will be invited to attend training on clinical supervision (CS). Education will be delivered in 3 phases. 1-Orientation to the CS model 2-Integration of theory into practice and 3-Skill advancement for supervisors. After training, participants will be encouraged to choose a supervisor, identify objectives for skill development. They will be advised to meet their supervisor once a month for 60 minutes (Due to COVID 19 pandemic the participants can have either one-to-one session in-person or virtually (Microsoft Team), however, if the supervisor and the supervisee working in the same campus can have their one-to-one session as per their preferences. Supervisor-supervisee will be working together to achieve the stated goals. Only the recorded attendance and nature of the session will be used for research purpose. Data will be collected at baseline, 6&12 month with pre-specified tools.
45845090|NCT02214420|Drug|Ribavirin|
45688739|NCT01898962|Procedure|Subtotal surgical removal plus ablative radiation dose|Residual tumor or close/positive margins should be followed by ablative radiation doses (by either stereotactic radiosurgery or convential EBRT) to constitute definitive locoregional treatment
45688740|NCT01898962|Radiation|Radioembolization|radioembolization of the liver with Y-90 microspheres or other site-appropriate techniques
45688741|NCT04752124|Other|Exercise Therapy|High intensity speed based interval treadmill training
45688742|NCT04752124|Other|conventional therapy|conventional physical therapy
45845091|NCT02215200|Drug|Anti-Thymocyte Globulin (ATG)|Thymoglobulin
45845092|NCT02215200|Drug|Granulocyte colony stimulating factor (GCSF)|Granulocyte colony stimulating factor (GCSF)
45845093|NCT02215200|Drug|Placebo (for ATG)|Normal saline administered by IV infusion to mimic ATG
45845094|NCT02215200|Drug|Placebo (for GCSF)|Placebo prepared to mimic 6mg subcutaneous injection of GCSF
45845095|NCT02217618|Drug|LY2409021|
45845096|NCT02218242|Device|Intraoperative ultrasound|Intraoperative ultrasound will be performed at the completion of the standard lung cancer resection with mediastinal lymph node dissection. This evaluation will be performed by a different surgeon from the primary surgeon performing the operation to minimize operator variability with the ultrasound system and help control for bias. Additional lymph nodes identified will be resected and sent for pathologic evaluation. It is anticipated that this additional evaluation and treatment should take no more than 30 minutes and as such a time limit of 30 minutes from introduction of the ultrasound probe into the surgical field will be set.
46049389|NCT05380362|Other|Sham Angioplasty|Patients will be brought to the angio suite and will not know if they are having the venous angioplasty or not.
45845097|NCT02218320|Drug|Raltegravir|
45845098|NCT02218320|Drug|Dolutegravir|
45845099|NCT02218320|Procedure|Colonoscopy with biopsy|This procedure is not standard of care for patients receiving combination antiretroviral therapy (cART), but is necessary to obtain tissue samples.
45845100|NCT02219256|Drug|TAK-079|TAK-079 solution
45845101|NCT02219256|Drug|Placebo to TAK-079|Placebo to TAK-079 solution
45845102|NCT02222610|Drug|0.5 mg ranibizumab|
45845103|NCT02222610|Procedure|Targeted Retinal Photocoagulation (TRP)|TRP to areas of retinal ischemia
45845104|NCT02223702|Drug|Amoxicillin|500 mg, 3 times per day for 7 days
45845105|NCT02223702|Drug|Metronidazole|500 mg, 3 times per day, for 7 days
45845106|NCT02223702|Drug|Moxifloxacin|400 mg, once in a day for 7 days.
45845107|NCT02224404|Device|Fast Gelling Dressing (Exufiber)|
45845108|NCT02224482|Behavioral|PROGRESS|PROGRESS is a multimedia website designed to help prostate cancer survivors.
45845109|NCT02225106|Drug|Methylphenidate|Subjects will be treated with oral methylphenidate, using a forced titration up to a dose of 30 mg given twice daily for 4 weeks. At that point, the neuropsychologic tests are repeated.
45845110|NCT02227836|Device|Allergy Patch Testing|
46049390|NCT05381922|Other|blood laboratory investigation(coagulation profile- platelet function test)|blood laboratory investigation including ( complete blood count, coagulation profile, platelet function test, level of factor decrease
46049391|NCT00594958|Biological|IC51|6 mcg, intramuscularly [i.m.], 0.5 mL
45845111|NCT02229318|Dietary Supplement|FruitiVits|Daily administration of FruitiVits dietary supplement
45847698|NCT02865720|Drug|CINRYZE 1000 U|IV infusion administered twice weekly
46049392|NCT04204044|Drug|Metformin Hydrochloride|Metformin Hydrochloride is used in PCO
46049393|NCT04204044|Drug|Myo-inositol|Myo inositol used in PCO
46049394|NCT02625064|Other|Blood samples collection before treatment|
46049395|NCT02625064|Other|Blood samples collection after treatment|
46049396|NCT02625064|Other|laboratory biomarker proteomic analysis|
45361955|NCT00926016|Drug|Pioglitazone (Actos)|pioglitazone 45 mg a day
45361956|NCT04017104|Diagnostic Test|18F-FDG PET/CT|"For 18F-FDG as fasting period of 6 hours is required before the scan. Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.The participant will rest in a comfortable chair for 20 minutes. The participant will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. The participant will then be taken to the PET/CT scanner.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
45361957|NCT04017104|Diagnostic Test|68Ga-DOTATOC PET/CT|Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for up to 90 minutes. There are no dietary restrictions. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. A CT topogram will be acquired followed by very low dose whole body CT for attenuation correction and localization of PET emission data. The participant will receive a bolus intravenous dose of the radiotracer 68Ga-DOTATOC from an approved study supplier site. Simultaneously a 6 minute dynamic acquisition of the heart will be started, then followed by several whole body static acquisitions. After the DWB scan, participants may go to the washroom again and their vital signs will be recorded. After this, a new PET/CT acquisition, as specified in the 68Ga-DOTATOC PET/CT protocol, will immediately follow.
45361958|NCT04017104|Diagnostic Test|18F-DCFPyL PET/CT|Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for 90 minutes of the DWB acquisition. They will be unable to use the washroom during this time. As with the main study, participants will be instructed to fast for 4 hours prior to their appointment. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. The participant will receive a bolus intravenous dose of 18F-DCFPyL from an approved supplier. This will then be followed by several whole body static acquisitions for a total scan time that will not be longer than 90 minutes. After the scan is finished, the participant will be allowed to rest in a comfortable chair or bed for 30 minutes. The participants will return to the scanner room and undergo the planned PET/CT imaging described in the main study.
45480065|NCT01304381|Other|Integrated care|Intervention Multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers, in a shared structured person-centred and identity-promoting care during 6 months
45688743|NCT00266110|Biological|sargramostim|All patients will receive Leukine (GM-CSF) at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. Patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3.
45688744|NCT00266110|Biological|therapeutic autologous dendritic cells|patients will receive (10 x 106) peptide-pulsed DCs given by i.d injection into either axilla or the inguinal region with each peptide given into a separate site. The total dose will be 20 x 106 DCs given per treatment.
45688745|NCT00266110|Biological|trastuzumab|Trastuzumab will be infused in the side-port of a freely flowing IV over 90 minutes and at 6mg/kg if the subject has not previously received Trastuzumab, or if it has been more than 30 days since any prior trastuzumab administration. If the subject has previously received Trastuzumab within 30 days and has no adverse history with the drug, the infusion will be given over 30 minutes. If the subject is currently receiving Trastuzumab, the first study infusion will be given at 4mg/kg over 30 minutes. Subsequently, Trastuzumab will be infused at 4 mg/kg in the side-port of a freely flowing IV over 30 minutes.
45688746|NCT00266110|Drug|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered IV over six to ten minutes into the side port of a freely flowing IV line.
45688747|NCT00240526|Biological|Engerix™ -B|3 (Groups A and C) or 4 (Groups B and D) intramuscular injections during the primary study
45688748|NCT00240526|Biological|Hepatitis B immunoglobulin (HBIg)|1 intramuscular injections at birth (primary study)
45688749|NCT01899274|Device|bant iPhone application|
45845112|NCT02229474|Behavioral|CST Intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
45845113|NCT02230566|Drug|UX003|UX003 is a sterile concentrate formulation of rhGUS for intravenous infusion
46049397|NCT05378256|Other|Clinical scales of CIPN|Patients with lymphoma will be evaluated before chemotherapy (T1), after 4 cycles (T2), at the end of the chemotherapy treatment (If more than 4 cycles) (T3) and 6 month after the end of chemotherapy (T4).
46049398|NCT00672802|Drug|Ramelteon and Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
46049399|NCT04267614|Drug|Etanercept|Patients who received etanercept for RA
46049400|NCT00691990|Procedure|Total thyroidectomy|Comparison of the safety and cost-effectiveness of classic thyroidectomy with or without drains
46049401|NCT00689962|Device|Linvatec 4.5 mm Smart Screw|Linvatec 4.5 mm Smart Screw to surgically fix the foot's Lisfranc ligaments
46049402|NCT00689962|Device|Synthes 4.0 mm steel screw|Standard steel screw use to surgically fix the foot's Lisfranc ligaments.
46049403|NCT00692146|Drug|AZD1386|Oral solution fixed dose (95 mg given orally on two occasions)
46049404|NCT00692146|Drug|Placebo|Oral solution fixed dose (95 mg given orally on two occasions)
45361959|NCT05237531|Behavioral|Standardized Preoperative Education|"The standardized preoperative education includes a brief video, an interactive quiz, and a written handout.~The video will provide information on the proper use and common side effects of opioid pain medications, the expected effects of a peripheral nerve block, and the concept of multimodal postoperative pain management with non-opioid medications and non-pharmaceutical pain management strategies. The interactive quiz will reinforce the critical components of the video in a question-and-answer format which requires active participation. The written handout will summarize the educational content in a form which can be easily referenced by patients at home."
45361960|NCT05237531|Behavioral|Standard of care|Education per provider preference (no standardization, current standard of care)
45361961|NCT05237531|Behavioral|Preoperative and postoperative questionnaires|Preoperative questionnaire: Demographic questions plus specific questions about chronic pain, prior opioid use, and mental health diagnoses Postoperative questionnaire: Questions about pain control after surgery, satisfaction with pain control, healthcare contact since surgery, opioid consumption since surgery, and satisfaction with education
45361962|NCT04015206|Other|Group Interpersonal Psychotherapy|Group Interpersonal Psychotherapy added to usual treatment (Pharmacotherapy + clinical management)
45361963|NCT04799223|Other|Four-foods eating guidelines|To follow a healthy eating pattern and consume four (4) foods designed for the study (extra virgin olive oil with olive leaf extract, chickpea dish with spinach, vegetable cream dish, and olive fiber) and to follow a healthy eating pattern.
45361964|NCT04799223|Other|No designed-foods eating guidelines|To follow a healthy eating pattern. Their diet is not accompanied by the four newly designed foods of the other group.
45688750|NCT00242632|Drug|Namenda|Namenda has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.
45688751|NCT01899352|Procedure|Tracheostomy|Percutaneous and surgical tracheostomies will be performed with the procedure currently available in clinical practice.
45688752|NCT01899040|Device|neuromodulation for episodic migraine headache|
45688753|NCT01899430|Drug|liraglutide|
45688754|NCT01899430|Drug|metformin|
45688755|NCT01899508|Procedure|Virtual Reality Training Session|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
45845114|NCT02230566|Other|Placebo|Placebo consisting of the UX003 formulation buffer (without rhGUS)
45361965|NCT04765449|Drug|Cytotoxic T Lymphocytes|Given IV. Cytotoxic T Lymphocytes collected from healthy volunteer donors who have recovered from COVID-19. The T cells are collected, manufactured to be COVID-specific, and stored frozen at Thomas Jefferson University.
45361966|NCT00827138|Drug|DCC-2036|150 mg BID tablets, continuous dosing of 28 day cycles
45361967|NCT00907998|Drug|APL180|
45361968|NCT00907998|Drug|APL180|
45361969|NCT00907998|Drug|Placebo|
45361970|NCT02549378|Device|confocal microscopy|microvessel diameter measured by confocal microscopy
45688756|NCT01899508|Device|3D viewer with iPod Touch/iPhone (or similar smartphone)|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
45845115|NCT02232126|Other|SWIFT home intervention|1 in-home assessment performed by study social worker, another in-home visit performed if needed. Up to 4 telephone contacts performed by study social worker. A maximum of 6 contacts
45361971|NCT03907683|Behavioral|Short Message with Text and Optional Image|"Messages can be up to 256 characters of text and with or without an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity)."
45361972|NCT00929604|Other|HIV-1 viral load testing|Plasma HIV-1 RNA viral load testing performed at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30, and 36 months thereafter. Routine viral load results are provided to clinicians for the management of the participant's HIV treatment.
45361973|NCT02549534|Procedure|Axon Reflexes|"*Axon reflexes will be evoked in the palmar surface of the right great toe using local skin heating with a 0.33 cm2 heat probe using the following protocol:~Baseline: Heating the skin of the toe for a minimum of 5 minutes at 33*C.~Heat Ramp: Increasing the heat in the heat probe to 42*C at approx. 0.1*C/10 sec.~Skin Heating: Heating the skin of the toe for 30 minutes 42*C.~Heat Ramp: Increasing the heat in the heat probe to 44*C at 0.1*C/10 sec..~Skin Heating: Heating the skin for an additional 5 minutes at 44*C.~The size of the axon reflex during this skin heating protocol will be imaged using Laser Doppler Flowmetry (LDF). In the case that participants develop CIPN on their left side only, the left toe will be substituted."
45845116|NCT02233296|Drug|Lasmiditan|2 discrete doses separated by 6 days.
45845117|NCT02233530|Behavioral|CST intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
45845118|NCT02233842|Behavioral|Participant interview|People with cancer and who have survived cancer will have a 1 hour interview about using cigarettes and other tobacco products.
45845119|NCT02233998|Other|Mouth Rinse 1|
46049405|NCT04152928|Diagnostic Test|PET/MR scan|The patient will be positioned in the PET/MR with the field of view of the PET including the abdomen, and IV administration of 68Ga-DOTATATE will take place, with initiation of dynamic PET simultaneous with start of IV injection. Dynamic PET imaging will consist of 22 time frames of increasing durations (6 x 10, 3 x 20, 3 x 60, 5 x 180, and 5 x 300 s). The dynamic PET examination will be followed by a whole-body PET/MR scan ranging from the proximal femur to the base of the skull (3 min per bed position) starting at 60 min after injection. MR will be used for attenuation correction of the PET images of the abdomen/pelvis and whole-body. MR protocol will include three plane fast spin echo T2 weighted, DWI, DCE and ASL. The addition of PET/MR to the standard use of PET/CT adds no radiation exposure.
46049406|NCT00594880|Drug|Pegylated Interferon-alpha 2a, 180 mcg/week sc|Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL < 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
45361974|NCT02549534|Procedure|Axon Flares|Axon flares will be generated on the palmar surface of the right great toe using the same local skin heating protocol described above, and imaged using a laser speckle contrast imager (LSCI) (also known as full-field laser perfusion imager, or FLPI).
45688757|NCT00245518|Drug|Isoflavone|
45688758|NCT00245518|Drug|Placebos|
45688759|NCT00267670|Drug|Pentoxifylline|400mg PO TID
45688760|NCT00267670|Drug|Placebo|1 pill PO TID
45688761|NCT00247624|Drug|Eszopiclone|Eszopiclone 3 mg every night for 8 weeks
45688762|NCT00247624|Drug|Fluoxetine|Fluoxetine 20 mg every morning for 9 weeks
45845120|NCT02233998|Other|Mouth Rinse 2|
45845121|NCT02233998|Other|Mouth Rinse 3|
45688763|NCT00247624|Drug|Placebo|Placebo every night for 8 weeks
45688764|NCT00248560|Drug|docetaxel|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
45688765|NCT00248560|Drug|Gemcitabine|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
45845122|NCT02235870|Device|Obalon Intragastric Balloons|Intragastric Balloon System to aid in portion control.
45845123|NCT02235870|Device|Sham Device|Sham Intragastric Balloon
46049407|NCT00594880|Drug|Pegylated Interferon-alpha 2a, 90 mcg/week sc|Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL < 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
45361975|NCT02549534|Procedure|Self-Reported Signs & Symptoms of CIPN|Self-reported signs & symptoms of CIPN such as the presence and location of (1) tingling, (2) numbness, and (3) neuropathic pain, along with information about (4) deficits in vibration thresholds, and (5) loss of deep tendon reflexes will be assessed at each study visit using the 5-item, modified Total Neuropathy Score (mTNS).
45361976|NCT04173195|Other|Comfort Talk|A short and brief conversation based on the principles of clinical hypnosis.
45688766|NCT00248638|Drug|Glutamine dipeptide with 15% Clinisol|Subjects randomized to AG-PN will receive PN containing 0.5 g/kg/day of L alanyl L GLN (AG) dipeptide (Dipeptiven 20%; Fresenius-Kabi) and 1.0 g/kg/day of 15% Clinisol (Baxter Inc., Deerfield, IL) AA solution (total = 1.5 g/kg/day, with AG replacing 1/3 of Clinisol AA). The amount of GLN dipeptide administered each day will be determined by daily PN volume intake data.
45688767|NCT00248638|Drug|15% Clinisol|Subjects randomized to STD-PN will receive 1.5 g/kg/day of 15% Clinisol. The amount of Clinisol administered each day will be determined by daily PN volume intake data.
46049408|NCT00690118|Drug|pioglitazone|45 mg/day, 18 months
46049409|NCT00690118|Drug|placebo|once daily, 18 months
45361977|NCT00929682|Drug|Randomization between two referenced treatments|"Levobupivacaine 0.568 mg.mL-1 and sufentanil 0.45 g.mL-1, 20 mL epidurally for induction, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1.~Same protocol, with levobupivacaine 1.136 mg.mL-1 and sufentanil 0.45 g.mL-1."
45361978|NCT05175885|Device|Ex vivo normothermic perfusion|Ex vivo normothermic perfusion (EVNP) of the renal graft with the Ark Kidney System
45688768|NCT00249496|Behavioral|Contingency management|Participants in the Contingency Management group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary.
45688769|NCT00249496|Behavioral|Employment Only|Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work.
45688770|NCT00268762|Drug|argatroban|Argatroban IV Infusion at 1mcg/kg/min for 48 hours.
45688771|NCT00252382|Drug|SNS-595 Injection|Vosaroxin (formerly voreloxin or SNS-595) is a first in class anticancer quinolone derivative, non anthracycline topoisomerase II inhibitor. It induces replication dependent DNA damage by intercalating DNA and inhibiting topoisomerase II, leading to apoptosis.
45688772|NCT00270634|Drug|Voclosporin|voclosporin 0.4, 0.6, 0.8 mg/kg po BID
46049410|NCT04139278|Other|Observational|Observational retrospective study
46049411|NCT00694252|Drug|Lapatinib|Patients will receive lapatinib monotherapy 1500 mg/day for a period of at least one month depending on their response and the clinical status of their disease.
45688773|NCT00270634|Drug|tacrolimus|tacrolimus 0.05 mg/kg po BID
46049412|NCT00871858|Drug|anastrozole|Given orally
46049413|NCT00871858|Drug|fulvestrant|Given intramuscularly
46049414|NCT00692224|Drug|zinc gluconate|zinc gluconate syrup - 10mg/day in two divided doses from day 2 to day 7 of life
46049415|NCT00692224|Drug|placebo|placebo was packed in similar looking bottles and ad similar taste as zinc gluconate drug
45361979|NCT05175885|Device|Cold preservation|Static cold storage (SCS) or hypothermic machine perfusion (HMP) of the renal graft
45361980|NCT03659721|Behavioral|FACAM|Support person
45361981|NCT03659721|Behavioral|Care as Usual|Usual care
45361982|NCT03659721|Behavioral|COS-P|Attachment based therapy
45688774|NCT01899586|Other|Regional Specific Training Stimulus (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
45688775|NCT01899586|Other|Aerobic Exercise Regimen (AE)|Whole-body aerobic exercise at >50% of heart rate reserve (HRR) for 45 minutes, three days per week.
45688776|NCT04110340|Drug|Ciprofloxacin|"Adults: Ciprofloxacin 500mg orally twice daily (or 400mg IV twice daily for those who cannot take oral medication) for 10 days;~Children:Ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 10 days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
45361983|NCT04015674|Other|Exercise group|Aerobic exercise on a stationary bicycle
45361984|NCT04015674|Other|Control group|In a rest
45361985|NCT03656133|Radiation|Radiotherapy fractionation|Standard fractionation at 2Gy once daily or Hyperfractionation at 1.2 Gy twice daily (≥ 6 hours apart)
45361986|NCT04044404|Diagnostic Test|Ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography)|Compare the ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography) with the diagnostic gold standard of kidney disease---kidney biopsy
45688777|NCT04110340|Drug|Streptomycin|"Adults: streptomycin 1g twice daily for three days, followed by ciprofloxacin 500mg orally twice daily (or ciprofloxacin 400mg twice daily by IV for those unable to take orally) for an additional 7 days.~Children: streptomycin 15mg/kg twice daily for three days followed by ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 7 additional days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
45688778|NCT04110340|Drug|Gentamicin|"Adults: 2.5mg/kg IV gentamicin twice daily for 3 days followed by ciprofloxacin 500 mg orally twice daily (or ciprofloxacin 400 mg twice daily IV for those who cannot take oral) for a further 7 days.~Children: 2.5mg/kg IV gentamicin twice daily for 3 days, followed by ciprofloxacin 15mg/kg (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take the oral route) for a further 7 days."
46049416|NCT00694330|Biological|GM-K562 Vaccination|Lethally irradiated autologous glioma cells combined with GM-K562 cells as vaccine therapy given once a week for three weeks then every other week.
46049417|NCT04136938|Other|Social marketing campaign|A social marketing campaign of prevention workshop sessions will be performed.
46049418|NCT00673036|Other|Blood sample|60 ml of whole blood
45688779|NCT00270790|Drug|Amifostine|Amifostine will be given at dose of 500 mg IV within one hour before radiation
46049419|NCT00692302|Behavioral|SAFETY|Participants will receive a family-based cognitive behavioral therapy intervention called SAFETY for 12 weeks. The SAFETY intervention is an individually tailored intervention strategy that integrates (1) family- and community-based interventions aimed at mobilizing family and community networks that support youth safety, adaptive behavior, and reasons for living; (2) cognitive behavioral treatment modules that focus on decreasing suicidality and preventing repeat suicide attempts; and (3) an individualized care linkage strategy that links youth to needed services and resources.
46049420|NCT00692302|Behavioral|Enhanced usual care|Enhanced usual care will include treatment as usual enhanced by study support.
45688780|NCT00270790|Drug|Carboplatin|Carboplatin for 100 mg/m2 and will be administered after the taxol infusion
45361987|NCT00929760|Behavioral|specialised renal care|"Combined management PCP - nephrologists (at least 4 nephrology visits/year). Agreement of the PCP is required for this combined management.~Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG. Requested Email or over the phone advices to PCPs will be provided by the nephrology division of HUG."
45845124|NCT02235870|Behavioral|Nutrition and Lifestyle Program|Nutrition and lifestyle program reviewed with subjects every 3 weeks for 6 months.
45361988|NCT00817466|Drug|Racemic adrenaline|"For inhalation.~Dosing (as in previous study):~1) 0,1ml<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml >10kg of racemic adrenaline 20mg/ml diluted in 2ml NaCl 9mg/ml.3~Maximum 12 inhalations/24 hours. One bottle (10ml) per patient. The bottles will be marked with the name of the study and a randomisation number."
45361989|NCT00817466|Drug|Isotonic saline|2ml NaCl 9mg/ml.
45845125|NCT02236338|Procedure|Ablation of the Incompetent Greater Saphenous Vein|For each patient, the Greater Saphenous Vein (GSV) will be accessed just below the knee. After liberal use of anesthesia, the patient will undergo an ablation of the GSV. Half the patients will have this procedure performed using the Laser Ablation device and half will be treated using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
45845126|NCT02236338|Device|ClosureFAST radiofrequency catheter|
46049421|NCT00673192|Procedure|peripheral blood isolation|to isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
46049422|NCT00692380|Radiation|Fractionated radiation therapy followed by chemotherapy|Increasing doses of radiation therapy
46049423|NCT00673270|Drug|Fludrocortisone|50 µg of fludrocortisone per os
46049424|NCT00673270|Drug|Hydrocortisone|50 mg of intravenous hydrocortisone
45361990|NCT00926250|Dietary Supplement|Oral PS-IPC supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
45688781|NCT00270790|Drug|Taxol|Taxol will be given at a dose of 40 mg/m2 as a 3 hour infusion dose
45688782|NCT00270790|Device|Radiotherapy|Radiation will be given at a dose of 1.8 Gy. for a total of 70.2 Gy
45688783|NCT00271570|Drug|Infliximab (Remicade)|Remicade was 5 mg/kg IV (single dose)
45688784|NCT00271570|Biological|Intravenous immunoglobulin (IVIG)|2nd dose of IVIG (2g/kg)
45688785|NCT00273364|Procedure|Hematopoietic Stem Cell Therapy|After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen
46049425|NCT00673270|Drug|Placebo of Fludrocortisone|Tablet of placebo of Fludrocortisone
46049426|NCT00673270|Drug|Placebo of Hydrocortisone|2 ml of isotonic saline solution
45361991|NCT00926250|Dietary Supplement|Placebo supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
45361992|NCT04582370|Behavioral|theater program|10-week theory-based theater program designed to improve their physical functioning and reduce emotional stress.
45361993|NCT00908154|Drug|Placebo|Tablets to match GSK1014802
45361994|NCT00908154|Drug|GSK1014802|Sodium channel blocker
45845127|NCT02236338|Device|EVLT 980nm diode laser system|
46049427|NCT04152850|Behavioral|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and Traditional Chinese Medicine
46049428|NCT00871780|Drug|BG00002 (natalizumab)|
46049429|NCT00694408|Drug|methyl prednisolone, hydrocortisone, prednisolone|Will be specific dependant on weight of patients
46049430|NCT00694408|Other|No steroids|Children undergoing primary liver transplant will receive monoclonal antibodies and tacrolimus as per protocol
45361995|NCT03594981|Biological|CMV/AdV /EBV/BKV specific T cells|Each cohort of 2 patients will be treated and observed for 45 days for toxicity, dose escalation, and GvHD. The algorithm of sequentially adaptive EffTox trade-off-based design of Thall et al will be used to determine the dose for each cohort. If 1x107CTL/m2 results in unacceptable toxicity or efficacy, the study will be closed to accrual.
45361996|NCT00830648|Biological|Live Attenuated Varicella Virus Vaccine|0.5 mL, Subcutaneous
45361997|NCT04268901|Device|Samsung Gear VR|Participants 13 -21 years old can use the Samsung Gear VR. The VE to be used in this study is mobile based (Samsung with the Gear VR) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
45688786|NCT00273364|Drug|Standard treatment with a conventional drug|Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)
45688787|NCT05237596|Drug|Glucosamine Sulfate|Treatment for at least 6 months with prescription-grade crystalline Glucosamine Sulfate in addition to conventional treatment
45688788|NCT02102932|Drug|5 mg empagliflozin/850 mg metformin FDC|5 mg empagliflozin/850 mg metformin FDC
45688789|NCT02102932|Drug|12.5 mg empagliflozin|10 mg empagliflozin tablet and 2.5 mg empagliflozin tablet
45688790|NCT02102932|Drug|12.5 mg empagliflozin|10mg empagliflozin tablet and 2.5 mg empagliflozin tablet
45361998|NCT04268901|Device|Merge VR|Participants 10-21 years can use the Merge. The VE to be used in this study is mobile based (Pixel with the Merge) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
45361999|NCT04268901|Device|Oculus Go|Participants 7-21 years can use the Oculus Go. The visual a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a handheld remote. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
45845128|NCT02237898|Behavioral|MoMba Live Long app & Sensordrone™ carbon-monoxide sensor|MoMba Live Long application & Sensordrone™ carbon-monoxide sensor to deliver contingency management remotely
45362000|NCT00926406|Drug|lead chelation therapy|Patients with lead poisoning (BLL> 20μg/dl) are randomly assigned to a control or chelation group, on the 1:1 proportion. During the 3 months, 50 chelation group patients receive 2-hour weekly intravenous infusions of one vial (1 g) of calcium di-sodium EDTA mixed with 200 ml of normal saline until BLB is BLL < 5 μg/dl. Fifty control patients receive weekly 2-hour infusions of one vial (20 ml) of 50% glucose mixed with 200 ml of normal saline over a period of 12 weeks9.
45688791|NCT02102932|Drug|850 mg metformin|850mg metformin tablet
45688792|NCT02102932|Drug|5 mg empagliflozin|5 mg empagliflozin
45845129|NCT02237898|Behavioral|Office contingency management|A control group which will receive financial incentives at an in-person office/clinic visit based on expired CO levels obtained through the piCO sensor.
45688793|NCT02102932|Drug|5 mg empagliflozin|5 mg empagliflozin
45688794|NCT02102932|Drug|850 mg metformin|850 mg metformin
45688795|NCT02102932|Drug|12.5 mg empagliflozin/850 mg metformin FDC|12.5 mg empagliflozin/850 mg metformin FDC
45688796|NCT02102932|Drug|12.5 mg empagliflozin/500 mg metformin FDC|12.5 mg empagliflozin/500 mg metformin FDC
45688797|NCT02102932|Drug|5 mg empagliflozin/500 mg metformin FDC|5 mg empagliflozin/500 mg metformin FDC
45688798|NCT02102932|Drug|500 mg metformin|500 mg metformin
45688799|NCT02102932|Drug|500 mg metformin|500 mg metformin
45688800|NCT00273754|Drug|Caffeine|Children in group one will receive caffeine benzoate 20 mg/kg i.v., which is equal to a 10 mg/kg caffeine base.
45845130|NCT02237898|Device|Sensordrone™ carbon-monoxide sensor|A custom breath CO meter built by Sensorcon Inc. (Sensordrone, part No. SDRONEG1) that uses an electrochemical CO gas sensor to measure environmental CO. The Sensordrone is accurate to within 10% with a resolution of 1 parts per million (ppm). The Sensordrone pairs via Bluetooth with the MoMba Live Long application.
45688801|NCT00273754|Drug|Placebo|Children in group two will receive an amount of normal saline equal to Caffeine
45688802|NCT04751344|Drug|Liposomal bupivacaine|Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 8cc of liposomal bupivacaine (13.3mg/mL) will be injected around the surgical site.
45845131|NCT02237898|Device|MoMba Live Long Smartphone application|The MoMba Live Long app provides an interface for the Sensordrone which allows participants to complete a breath test and see results of smoking status. The app verifies the user is correctly taking the tests by recording pictures using the front facing camera as well as recording audio to verify that the participants where exhaling while taking the test. The app also provided a platform for social interaction based on a previous system where app users can interact with each other and provide support during the quitting process.
45847699|NCT02867202|Device|Intrauterine balloon|After the completion of hysteroscopic adhesiolysis, intrauterine balloon was inserted and inflated with 3-5 mL normal saline which was removed after 1 week.
45688803|NCT04751344|Drug|Bupivacaine HCl|Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 10cc of bupivacaine HCl (5mg/mL) will be injected around the surgical site.
45845132|NCT02239380|Drug|Lorazepam|"intravenous administration. Dosage for adult subjects (16 years aged and over): 4 mg Dosage for pediatric subjects (3 months to < 16 years): 0.05 mg/kg (but not exceeding 4 mg) Frequency: Intravenous administration of lorazepam. Subjects whose seizure does not stop or recurs within 10 minutes after the initial dose may receive the same amount of lorazepam injection no earlier than 10 minutes following the initial dose.~Also, subjects whose seizure stops within 10 minutes after the initial dose, but recurs thereafter (within 12 hours) may receive the same amount of lorazepam injection; a total of 2 doses will be permitted in this study."
45362001|NCT04708899|Behavioral|arabic version of differential processing training program|comprehensive training program for central auditory processing disorder contains auditory and linguistic tasks (language organization, phonemic and phonetic awareness, dichotic listening,temporal patterning and auditory discrimination).
45362002|NCT04708899|Behavioral|Arabic computer based auditory traing program(CBAT)|comprehensive computer based traing program for central auditory processing disorder contains auditory memory, temporal processing, dichotic listening , selective attention and phonemic awareness games.
45362003|NCT00930072|Drug|Cervical Sympathetic Block (bupivicaine, clonidine)|12-15ml solution of bupivicaine .5% containing 50 mcg of clonidine for cervical sympathetic block administered in a single injection.
45362004|NCT00626522|Drug|Aclidinium bromide and formoterol|once daily
45362005|NCT00626522|Drug|Aclidinium bromide and formoterol placebo|once daily
45362006|NCT00926562|Drug|Iopromide (Ultravist)|Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM
45362007|NCT00926562|Drug|Iodixanol (Visipaque)|Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM
45362008|NCT04366791|Radiation|Low Dose Radiation Therapy|Undergo low-dose radiation therapy
45362009|NCT00926640|Drug|Belinostat|6 cycles of belinostat 400 mg/m2/24h X2 administered by CIV
45362010|NCT00926640|Drug|Cisplatin|6 cycles at 60mg/m2 IV on day 2
45362011|NCT00926640|Drug|Etoposide|6 cycles 80 mg/m2 IV daily X3 beginning day 2.
46049431|NCT04136782|Drug|Albumin-bound paclitaxel combined with carboplatin|Albumin-bound paclitaxel combined with carboplatin: Albumin-bound paclitaxel (Abraxis BioScience, LLC., Mclrose Park, IL, USA; certificate number: H20091059) will be intravenously administered at 125 mg/m2 for 30 minutes on days 1 and 8 of each 21-day session of treatment. There will be six 21-day sessions of treatment. At the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; National Drug Approval Number: H20020181) will be intravenously administered at AUC = 2 mg•min/mL for 120 minutes on days 1 and 8 of each 21-day session of treatment. Carboplatin must be hydrated for 3 days before use to prevent nephrotoxicity.
46049432|NCT04136782|Drug|Epirubicin combined with docetaxel|Epirubicin (Pfizer Pharmaceutical (Wuxi) Co., Ltd., China; National Drug Approval Number: H20000496) will be intravenously administered at 90 mg/m2 for 120 minutes on day 1 of each 21-day session of treatment. At the same time, docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; National Drug Approval Number: J20150083) will be intravenously administered at 75 mg/m2 for 120 minutes. Drug administration will be performed once every other 3 weeks for four times.
46049433|NCT04137874|Diagnostic Test|eSTROKE model|The eSTROKE model includes an electronic learning module, a full day course with practical teaching of National Institute of Health Stroke Scale and a mobile application which will be used for communication with in-hospital stroke physician
46049434|NCT04137874|Other|Control|Conventional prehospital care
45362012|NCT04656171|Radiation|MRI of the hand and forearm,|MRI of the hand and forearm,
45362013|NCT00830726|Drug|Pharmacologic and mechanical heart failure treatment|Optimised, standard, evidence based heart failure therapy including the use of biventricular pacing.
45362014|NCT00830726|Procedure|Aortic valve replacement|Standard aortic valve replacement as per standard criteria in the department of thoracic surgery.
45688804|NCT05211232|Drug|Tislelizumab|GP combine with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
45688805|NCT05211232|Drug|Placebo|GP combine with Placebo neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
45688806|NCT00273910|Drug|gp100:209-217 (210M)|
45688807|NCT00273910|Drug|Montanide ISA-51|
45688808|NCT00273910|Drug|Imiquimod|Apply imiquimod 5% cream to the skin at the site of injection daily for 5 days
45688809|NCT05167396|Device|Retinaute (BioSerenity)|Wearable device in the form of a virtual reality headset for the recording of electrophysiological measurements such as electroretinogram (ERG) and electrocenphalogram (EEG), ISCEV standards
45688810|NCT05167396|Device|EEG Headset 64 electrodes (BioSemi)|EEG headset with 64 electrodes for the recording of visual cortical electrophysiological signals
45362015|NCT00830726|Procedure|Revascularisation in Acute Coronary Syndrome|Standard percutaneous or surgical revascularisation in ACS.
45362016|NCT00830726|Procedure|Revascularisation in chronic stable angina pectoris|Standard percutaneous or surgical revascularisation
45362017|NCT00931398|Drug|methylphenidate HCl (Concerta)|Concerta 18 mg, 36 mg, 54 mg, and 72 mg q.am.
45362018|NCT00931398|Drug|Placebo|Matched placebo for all Concerta doses.
45362019|NCT00827216|Drug|Placebo|For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min.
45362020|NCT00827216|Drug|Erythromycin|For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min. The regimen corresponds to 3 mg/kg of erythromycin.
45362021|NCT00931476|Drug|somatropin|
45362022|NCT00931476|Drug|placebo|
45362023|NCT00827294|Behavioral|Mirror Therapy|The study is an uncontrolled pilot. Subjects receive instruction in performing mirror therapy at home, either in person or by viewing a DVD. Subjects will be asked to practice mirror therapy 20 minutes daily. Subjects will complete questionnaires for phantom pain, function, depressive symptoms, anxiety, catastrophizing, and sleep quality at baseline and post treatment at 1 month, 2 months, 3 months, and 6 months. Subjects will keep a diary of their practice and study staff will check in with subjects weekly for the first month, and monthly thereafter.
45362024|NCT03760692|Device|i-gel|Evaluation of clinical performance in terms of insertion, ventilation and complications
45362025|NCT03760692|Device|Ambu AuroGain|Evaluation of clinical performance in terms of insertion, ventilation and complications
45688811|NCT05167396|Device|MonPackOne (Metrovision)|"Standard device for the recording of electroretinography (ERG) measurements, ISCEV standards~WARNING : Device used only in 3 healthy controls to address the secondary objective"
45688812|NCT04389034|Drug|Pollinex Quattro with tree- and grass pollen extracts and their mixtures|retrospective analysis of patient records of allergen-specific immunotherapy
45688813|NCT00274768|Drug|capecitabine|A total of 115 cycles of therapy were administered and five patients did not complete cycle 1. The median number of cycles initiated was four (range 1-16).
45688814|NCT00280384|Drug|E2014 (Botulinum toxin type B)|A single-dose injection solution containing 20 units (U), 100 U, or 500 U/ 0.2 milliliters (mL) of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
45688815|NCT00280384|Drug|E2014 (Botulinum toxin type B) Placebo|A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
45688816|NCT05161546|Device|EEG and ERG measurements (Retinaute®, BioSerenity)|"The Retinaute® is a portable medical device developed by BioSerenity, France, for performing flash and pattern ERG. It comes in the form of a virtual reality headset, which can be used in outpatient facilities. It is non-invasive and uses skin electrodes for the collection of parameters.~ERG signals will be supplemented with 4 EEG channels, via cup electrodes applied to the skull and allowing the concomitant performance of an EEG."
45688817|NCT05161546|Device|Actigraphy (Motion Watch 8®, CamNtech)|"Actigraphy is an ecological and non-invasive method allowing a reliable characterization of the sleep/wake cycle. It is a portable system for continuously measuring the motor activity of an individual and appreciating the alternation of activity periods (wakefulness) and rest periods (sleep).~An actigraph (MotionWatch8®, CamNtech) looks like a wristwatch that will be worn continuously, by convention on the wrist of the non-dominant hand, over periods ranging from several days to several weeks (here 21 days). Actigraphy does not present a known risk."
45362026|NCT05097729|Device|Transcranial Magnetic Stimulation|The brain stimulation can be delivery using different devices; in this project a MagPro X100 stimulator connected to a MagPro Cool-B65 liquid-cooled butterfly coil (MagVenture A/S, Farum, Denmark) will be used. Resting motor threshold (M1-rTMS) will be determined during the visit 1 or visit 2 and used along all visits. The rTMS pulse sequences and intensities used are all within the published safety guidelines
45362027|NCT00822848|Drug|epirubicin hydrochloride|I.V., days 1-3 of each cycle. Epirubicin to be omitted during cycle 2 (concomitant chemoradiation)
45362028|NCT00822848|Drug|ifosfamide|Over 90 minutes I.V., days 1-3 of each cycle. Administered with hydration and Mesna.
45688818|NCT05161546|Behavioral|Neuropsychological assessments|The purpose of this assessment is to establish a cognitive profile for each participant. It uses a series of tests widely described in the literature and commonly used today.
45752124|NCT03086317|Device|Standard Catheter-Directed Thrombolysis|Catheter-directed thrombolysis requires placement of a multi-sidehole infusion catheter within the pulmonary arterial thrombus burden, under angiographic guidance. Thrombolytic medications are slowly infused through the catheter, which is left in place for the duration of the treatment. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
45362029|NCT00822848|Drug|sorafenib tosylate|P.O. daily beginning 2 weeks before first chemotherapy cycle, held 1 week before and after surgery.
45362030|NCT00822848|Other|immunoenzyme technique|
45362031|NCT00822848|Other|immunohistochemistry staining method|
45362032|NCT00822848|Other|laboratory biomarker analysis|
45362033|NCT00822848|Procedure|adjuvant therapy|Preoperative administration has been the preference at our institution.
45362034|NCT00822848|Procedure|neoadjuvant therapy|
45362035|NCT00822848|Procedure|therapeutic conventional surgery|Surgery should be planned for 2-4 weeks after the initiation of chemotherapy for cycle 3.
45362036|NCT00822848|Radiation|hypofractionated radiation therapy|28 Gy (350 centigray (cGy) x 8 fractions in 10 days) beginning at the start of cycle 2. *Boost: postoperative boost of 12 Gy (200 cGy x 6 fractions) for patients with positive surgical margins only.
45362037|NCT00931554|Procedure|Postoperative drain removal|removal of postoperative drainages at different time points (postoperative day 3 versus postoperative day 5)
45362038|NCT00926718|Drug|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 2ng ml-1
45362039|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 2ng ml-1
45362040|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 2ng ml-1
45362041|NCT00926718|Drug|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 8ng ml-1
45362042|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 8ng ml-1
45362043|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 8ng ml-1
45362044|NCT00823004|Drug|letrozole|letrozole 5mg/day from day 3 to day 7 of menstrual cycle
45362045|NCT00823004|Drug|oral contraceptive (Marvelone)|oral contraceptive, first 21 days
45362046|NCT00823004|Drug|GnRH agonist (buserelin)|50 µg SC twice daily
45688819|NCT05161546|Device|Optical Coherence Tomography (OCT)|The Spectral Domain Optical Coherence Tomography (SD-OCT) is a modern ocular imaging process using infrared radiation and allowing to obtain in a few seconds, and in a non-invasive way, images in section of the eye. The OCT-Angiography (OCT-A) module increments on the OCT. It can detect the movement of the blood elements from sequential SD-OCT slices taken at the same location of the retina and obtain a map of the retinal and choroidal vessels, without injection of fluorescent dye. The device used for both exams will be the OCT spectral RS 3000 Advance 2 + Angioscan (NIDEK, Gamagori, Japan). SD-OCT and OCT-A examinations are fast, painless, non-contact and last less than a minute. There is no particular risk.
45480066|NCT01304381|Other|Integrated care|One group with 31 participants is offered a multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers in a shared structured person-centred care at home. Assessment of need, length of visits and phone calls are planned to be adapted for each patient. After 6 months (+ - two weeks) the patients will be transferred to usual care provider following an established individual care plan.
45480067|NCT00908076|Drug|LUBIPROSTONE|Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.
45480068|NCT03319264|Other|Dynamometry exam|Prehension strength of the main hand will be assessed thanks to dynamometry, in order to evaluate patient's muscular strength
45362047|NCT00823004|Drug|recombinant FSH or hMG|recombinant FSH or hMG 300-450 IU/day
45480069|NCT03319264|Other|Walking test|A 4 metres walking test will be performed to assess patient's walking speed
45362048|NCT00823004|Drug|ganirelix acetate|GnRH antagonist (ganirelix acetate) when a leading follicle reaches a mean diameter of 14 mm, 0.25 mg per day (Antagon, Organon, West Orange, NJ)
45480070|NCT03319264|Radiation|DXA measurement|DXA measurement will be performed to assess patient's body composition
45480071|NCT03319264|Other|SARQOL questionnaire|Patient's quality of life will be assessed thanks to the SARQOL questionnaire
45480072|NCT03319264|Behavioral|Life habits Questionnaire|Life habits Questionnaire
45362049|NCT00930150|Behavioral|Targeted cognitive training|Adaptive computer exercises that systematically increase in task difficulty as each participant's performance ability improves
45480073|NCT02664740|Drug|Topical anti-Staphylococcus bacteriophage therapy|Patients randomized to the experimental arm will receive sterile compress dressings impregnated with a phage solution of 10^7 PFU/ml on days 0, 7 and 14 (unless the wound is already healed, i.e. phage solutions are not applied to healed wounds).
45688820|NCT01763996|Drug|Febuxostat|Febuxostat capsules
45362050|NCT00930150|Behavioral|Computer control|Commercially available computer games selected based on quality, ability to hold interest, and lack of disturbing content
45362051|NCT00930150|Behavioral|Bridging groups|Weekly group meetings that help participants apply their cognitive skills to everyday functioning, promote group identity, and promote socialization
45688821|NCT01763996|Drug|Febuxostat placebo|Febuxostat placebo-matching capsules
45688822|NCT01790464|Drug|2% Lidocaine|2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
45362052|NCT00930150|Behavioral|Health and wellness groups|Weekly group meetings that teach participants health and wellness skills
45362053|NCT00827450|Dietary Supplement|Ctl|Control, isocaloric diet; no coffee
45480074|NCT02664740|Drug|Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy|Patients randomized to the placebo arm will receive sterile compress dressings impregnated with a placebo solution on days 0, 7 and 14 (unless the wound is already healed, i.e. placebo solutions are not applied to healed wounds).
45480075|NCT03721237|Other|EBC-assisted|"After definitive catheter positioning, esophageal balloon calibration will be performed in:~volume-controlled mode with tidal volume set to obtain 6-8 lm/kg of ideal body weight (reference),~pressure support ventilation (PSV) with support set to obtain a tidal volume ranging between 6-8 ml/kg of ideal body weight at equal PEEP of volume control mode (PSV baseline);~PSV + sigh ventilation (sigh setting: total inspiratory pressure equal to 35 cmH2O at a rate of 1/ minute; inspiratory time equal to 4 seconds)."
45480076|NCT03797027|Device|Percutaneous Nephrolithotomy without an abdominal cushion|patients undergo prone PNCL without an abdominal cushion
45480077|NCT03797027|Device|Percutaneous Nephrolithotomy with an 5 cm abdominal cushion|patients undergo prone PNCL with an 5 cm abdominal cushion
45480078|NCT03797027|Device|Percutaneous Nephrolithotomy with an 5 cm abdominal cushion|patients undergo prone PNCL with an 10 cm abdominal cushion
45688823|NCT01790464|Drug|placebo|
45688824|NCT01790542|Other|Iron fortified cereal|Infants will be assigned to one of the three interventions: A (iron fortified cereal), B (iron fortified cereal with fruit), C (Meat)
46049435|NCT04137640|Drug|palbociclib combined with letrozole|Endocrine group will receive palbociclib combined with letrozole: palbociclib (Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; license number: H20180040) 125 mg/d, every 28 days as a cycle (medication for 3 consecutive weeks and withdrawal for 1 week); letrozole (Novartis Pharma Schweiz AG, Stein, Switzerland; license number: H20140149) 2.5 mg/d, for 6 consecutive months.
45362054|NCT00827450|Dietary Supplement|High fructose diet; no coffee|Hypercaloric, high fructose diet; no coffee
45362055|NCT00827450|Dietary Supplement|fully torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
45362056|NCT00827450|Dietary Supplement|partially torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
45362057|NCT00827450|Dietary Supplement|Partially torrefied, caffeinated coffee|Hypercaloric, high fructose diet + coffee
45362058|NCT00827528|Procedure|Traditional correction of anterior vaginal wall prolapse|"Traditional repair.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
45362059|NCT00827528|Procedure|Biologic Graft (SIS)|"Biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
45362060|NCT04015284|Procedure|Suprascapular Nerve Block + Posterior Cord Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of ropivicaine 0.5%. The posterior cord is readily visualized when performing an infraclavicular brachial plexus block. It is blocked using 10mL of ropivicaine 0.5%.
45362061|NCT04015284|Procedure|Interscalene Brachial Plexus Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of ropivacaine 0.5%.
45362062|NCT00930306|Drug|AZD2066|12 doses, Given as capsule, 2 mg & 8 mg
45362063|NCT00930306|Drug|Caffeine|2 doses, Given as Tablet, 2x50 mg
45362064|NCT00930306|Drug|Tolbutamide|2 doses, Given as Tablet, half of 500 mg
45362065|NCT00930306|Drug|Omeprazole Tablet, 20 mg|2 doses, Given as Tablet, 20 mg
45688825|NCT01790542|Other|Iron fortified cereal with fruit|
45362066|NCT00930306|Drug|Midazolam Tablet, 7.5 mg|2 doses, Given as Tablet, 7.5 mg
45362067|NCT00830882|Drug|levosalbutamol|2 puffs four times a day for 2 weeks
45362068|NCT00830882|Drug|racemic salbutamol|2 puffs four times a day for 2 weeks
45362069|NCT00830882|Drug|placebo|2 puffs four times a day for 2 weeks
45362070|NCT04044092|Other|Conservative physical therapy|Moist hot packs, TENS, Cervical Traction, Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
45688826|NCT01790542|Other|Meat|
45688827|NCT01899820|Drug|Artemether lumefantrine|Artemether 20mg Lumefantrine 120mg
45688828|NCT01899820|Drug|Dihydroartemisinin piperaquine|Dihydroartemisinin 20mg Piperaquine 160mg
45688829|NCT02099266|Device|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
45688830|NCT04511338|Device|Dialyzer with Endexo|"Sequence AB:~Period 1 Circuit A (Five Visits: 1,2,3,4,5) Period 2 Circuit B (Five Visits: 9,10,11,12,13)~Sequence BA:~Period 1 Circuit B (Five Visits: 1,2,3,4,5) Period 2 Circuit A (Five Visits: 9,10,11,12,13)"
45688831|NCT02100280|Drug|deep block|sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
45688832|NCT04480528|Other|Blood Flow Restriction Training (BFRT)|A pressurized cuff is applied to the proximal thigh in order to partially occlude blood flow as the patient exercises.
45362071|NCT04044092|Other|ELDOA stretching exercise|Experimental group was given ELDOA stretching exercise protocol along with the moist hot packs, TENS, Cervical Traction, and Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
45688833|NCT04480528|Other|Sham Blood Flow Restriction Training (Sham BFRT)|A minimally pressurized cuff is applied to the proximal thigh in order to mimic the active blood flow restriction unit as the patient exercises.
46049436|NCT04137640|Drug|epirubicin combined with cyclophosphamide and sequential docetaxel|Chemotherapy group will receive epirubicin combined with cyclophosphamide and sequential docetaxel: epirubicin (Pfizer Wuxi Pharmaceutical Plant, Wuxi, China; license number: GYZZ H20000496), 90 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times; cyclophosphamide (Baxter Oncology GmbH, Halle, Germany; license number: H20160468), 600 mg/m2, once every four weeks, totally four times; sequential docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; license number: GYZZ J20150083) 75 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times.
46049437|NCT04137718|Other|nonIntervention|nonIntervention
46049438|NCT00692458|Drug|Comparator: odanacatib|odanacatib; 5mg oral, once daily for approximately 60 months.
45688834|NCT04054180|Other|CPAP associated with connected devices: blood pressure monitor , scales and activity monitor|CPAP associated with connected devices: blood pressure monitor , PROMs and activity monitor Patients will use their connected devices for one year. Data from the connected devices will be transmitted to their smartphone application Sefam Access. At the beginning of the study, patients will have a dietary assessment and start a support program for nutrition counselling and physical activity. At each study visit the dietician and physical exercise coach will give the patient advices on diet and for adjusting physical activity.
45362072|NCT00823160|Procedure|Sternotomy|Sternotomy performed after finding blood in the pericardial sac
45362073|NCT00823160|Procedure|Subxyphoid window|Subxyphoid window performed after the finding of blood in the pericardial sac
45362074|NCT03584724|Drug|Norflo Oro|Norflo Oro is highly bioavailable curcumin complexed into phytosomes
45688835|NCT02100748|Drug|TRV130|TRV130 1 - 4 mg will be administered every 4 hours
45688836|NCT02100748|Drug|Morphine|Morphine 4 mg will be administered every 4 hours
46049439|NCT00692458|Drug|Comparator: placebo|placebo; oral, once daily for approximately 60 months
46049440|NCT00911794|Other|Disclosure Writing (Written Disclosure Therapy)|Patients write about a stressful life experience
46049441|NCT00911794|Other|Neutral (Sham) Writing|Patients write about neutral subjects
46049442|NCT00692536|Behavioral|NNR (Nordic Nutrition Recommendations)|Diet with equal amounts of fat, protein and carbohydrates
45362075|NCT03584724|Drug|Placebo for Norflo Oro|Placebo consist of look-alike single foil pouches without active ingredient of Norflo.
45362076|NCT00823238|Drug|ceftazidime and tobramycin|
45362077|NCT00823238|Drug|inhaled tobramycin|
45362078|NCT00931788|Drug|Antihypertensive agents and lipid lowering therapy|The above agents will be initiated/titrated in accordance to guidelines approved by Canadian Hypertension Education Program and the Canadian Best Practice Recommendations for Stroke Care
45362079|NCT00931788|Other|Usual Care|Monthly education and reinforcement of risk factor modification, and blood pressure measurement.
45688837|NCT02100748|Drug|Placebo|Placebo will be administered every 4 hours
46049443|NCT00692536|Behavioral|MPD (Modified paleolithic diet)|A diet high in protein and fat, but low in carbohydrates
46049444|NCT00911872|Device|collagen (EVOLENCE)|injectable collagen
46049445|NCT00694642|Biological|Selected CD 133+ cells|Endothelial progenitor cell CD 133
46049446|NCT02624830|Drug|Sulfonylurea|See Arm description.
46049447|NCT00912652|Behavioral|lifestyle intervention|Three doses of lifestyle intervention will be compared to an education control condition.
45362080|NCT00831038|Procedure|Infant Pulmonary Function Tests|Tests will be performed on study patients within 1 week of study enrollment and again 6 months later.
45362081|NCT00827684|Drug|Irinotecan|
45362082|NCT00827684|Drug|Temsirolimus|
45362083|NCT00823316|Biological|Human umbilical cord blood-derived mesenchymal stem cells|1x1,000,000 hMSC/kg, IV after unrelated HSCT
45362084|NCT00823316|Biological|Human umbilical cord blood-derived mesenchymal stem cells|5x1,000,000 hMSC/kg, IV after unrelated HSCT
45362085|NCT00927030|Drug|supplemental liquid melatonin|Liquid melatonin will be given to the parent. There are 4 dose levels (1mg, 3mg, 6 mg, and 9mg)of melatonin that will be used at 3 week intervals. The child will start with 1mg and the dose will be increased at 3 week intervals until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. Once this goal is reached the child will stay on that dose through the remainder of the study.
45362086|NCT00927030|Drug|flavored liquid or liquid supplemental melatonin|Single blind for parents at initial 3-weeks dose period of 1 mg melatonin for 18 children where 3/18 children will receive placebo and 15/18 children will receive melatonin study drug. Each bottle will be labeled as: Flavored liquid placebo/or liquid melatonin. After this initial 3-week period all children will receive known melatonin in bottles that state this.
45362087|NCT00827762|Drug|Kuvan|20/mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
45362088|NCT00931866|Drug|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
45362089|NCT00931866|Drug|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
45362090|NCT00831116|Device|Intravascular Near Infrared Spectroscopy|Intravascular imaging with a catheter based spectroscopy system.
45362091|NCT04885452|Other|biobank|"Blood samples (biobank) at Day 0, Day 7, Month 1 and possibly Month 3 (only for the first 100 participants) (serum, plasma and whole blood)~For participants in the immunological ancillary study: additional blood sampling at Day 0, Day 7 and Month 1 (PBMC)~Nasopharyngeal swabs: Day 0, Day 7 (Day 14 and Day 21 if RT-PCR positive respectively at Day 7 and Day 14)~Specific nasopharyngeal swabs in hospitalized patients: Day 3, Day 5"
46049448|NCT00912652|Behavioral|Health Education Control|Health education control group will receive 16 session of health education related to diet and exercise over a two-year period.
45362092|NCT00823394|Behavioral|Questionnaire|Completed privately via computer at Windsor Village Church, approximately 75 minutes. Repeated at Months 12 and 24.
45362093|NCT00823394|Other|Body Measurements|Waist, hip, height, and weight measured privately. Repeated at Months 12 and 24.
45362094|NCT00823394|Behavioral|Self-help Materials|Information on how to lower risk for developing cancer.
45362095|NCT00831194|Behavioral|Personalized diet plan and PDA self reporting.|Participants will be given personalized diet plan with a 0.5- 1 lb weight loss/week, based on each person's goals. He/she will also be prompted by a pre programmed PDA to enter dietary lapses and stress inducing events. Saliva samples will be collected as per the study plan.
45362096|NCT04366544|Other|Part A1: Survey|Online
45362097|NCT04366544|Other|Part A2: Sample collection|Blood and Stool
45362098|NCT04366544|Other|Part B:|EEG and fMRI
45362099|NCT00930462|Device|Cap (Olympus Medical Systems: D-201-15004, D-201-14304 and D-201-12704)|Plastic cap fitted on the colonoscope
46049449|NCT02624752|Dietary Supplement|Ensure|Comparison of enhanced oral nutrition supplementation versus standard of care
46049450|NCT02629042|Procedure|Partial endodontic treatment under local and/or locoregional anesthesia|The reference management consists in local and locoregional anesthesia of the molar and partial endodontic treatment. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
45362100|NCT00827840|Drug|Paliperidone ER|3mg to 12mg of Paliperidone ER once a day
45362101|NCT00827840|Drug|Risperidone|1 to 6 mg of risperidone once or twice a day
46049451|NCT02629042|Drug|prednisolone|The evaluated intervention consists in per-os administration of prednisolone (1 mg / kg) during the emergency visit followed-up by one morning dose by day during three days. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
46049452|NCT02624674|Device|Multi-spectral Imaging Device (MSID)|
46049453|NCT00692614|Drug|triamcinolone acetonide|100 mcg; 500 mcg; 925 mcg triamcinolone acetonide on helical coil implant to elute over 12 months.
46049454|NCT00694720|Drug|AVE0657|capsules once a day at bedtime
46049455|NCT00694720|Drug|placebo|capsules once a day at bedtime
45362102|NCT05280288|Device|Bone@BC app|Participants in the intervention group will be asked to use the Bone@BC app daily it will take them 1-3 minutes to answer the daily questions in the app concerning symptoms and physical activity. They will have access to a Questionnaire Prompt List in the app Bone@BC.
45362103|NCT00927108|Other|Progenitor Stem Cell Culture|
46049456|NCT04136470|Biological|Collection of stool, blood (PBMC) and biopsy (FFPE)|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
45362104|NCT02549300|Other|Connective tissue massage|It is a manual reflex therapy in that it is applied with the therapist's hands which are in contact with the patient's skin. The assessment of the patient and the clinical decision-making that directs treatment is based on a theoretical model that assumes a reflex effect on the autonomic nervous system which is induced by manipulating the fascial layers within and beneath the skin.
45362105|NCT00930618|Drug|IMN|Administration of 2 x 20 mg of isosorbide mononitrate at each administration with a maximum of three administrations
45362106|NCT00930618|Drug|Placebo|Administration of 2 X 20 mg of placebo of IMN at each administration with a maximum of three administration
46049457|NCT04136392|Device|ABIOMED, Inc. hemodynamic support devices|ABIOMED, Inc. hemodynamic support technology are the smallest and least invasive percutaneous ventricular support blood pumps available on the market. They are routinely used in clinical practice in a variety of clinical scenarios to support patients in prophylactic or emergent settings.
45362107|NCT00827996|Drug|adalimumab|Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12
45362108|NCT00936780|Device|Infinnium-Core™ Paclitaxel eluting Coronary Stent|Infinnium-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Drug concentration is 1.36 µg/mm2.
45688838|NCT00283504|Drug|ANTI-IGE THERAPY (XOLAIR)|Xolair dosing is based on body weight and baseline serum total IgE concentration(0.016 x kg body weight x IgE levels), with a maximum dose per 4 weeks of 750mg.Depending on their weight and IgE levels, patients get their Xolair shots every 2 or every 4 weeks.
46049458|NCT04137250|Procedure|Hamstring|The intervention will consist of make an incision on the medial side of the proximal portion of the leg approximately 3 centimeters to dissect by planes until the tendons of the hamstrings are located, which will be removed surgically with specialized instruments and the wound will be closed, for later These tendons be used as an autograft for the reconstruction of the anterior cruciate ligament
46049459|NCT04137250|Procedure|Quadriceps tendon|orThe intervention consisted in making an incision in the anterior aspect of the distal portion of the thigh of approximately 3 centimeters to dissect by planes until locating the membranous portion of the quadriceps tendon, from which will be removed a portion of surgical way with specialized instruments and the Wound will be closed, for later this tendon to be used as an autograft for the reconstruction of the anterior cruciate ligament.
46049460|NCT04136236|Diagnostic Test|The diagnosis of Artificial Intelligence and endoscopist|When suspected esophageal mucosal lesion is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI.
46049461|NCT00694798|Biological|Mycobacterium w|Immunomodulator
46049462|NCT00594178|Device|Motorized bicycle exercise training|Passive exercise with a bicycle to bilateral legs. 5 days per week for 3 months
46049463|NCT05298826|Drug|recombinant factor VIIa|using recombinant factor VIIa
46049464|NCT00673426|Biological|Enoxaparin sodic|
45362109|NCT00823550|Drug|Entecavir|entecavir 0.5 mg QD
45688839|NCT04407676|Other|Summary PIS and Online Video Modules|Complex trial information presented in alternative and more accessible formats
45362110|NCT00823550|Drug|Lamivudine|lamivudine 100 mg QD
45688840|NCT04370236|Drug|INB03|Patients will receive up to two once per week subcutaneous injections of 1mg/kg INB03
45688841|NCT04370236|Drug|Placebo|Patients will receive up to two once per week subcutaneous injections of Placebo
45688842|NCT00283816|Drug|Metformin|Metformin 500 mg. tabs 2 tabs BID for duration of study
45362111|NCT00937014|Other|standard infant formula|Standard infant formula given during the first 9 months of life, as per standard requirement
45362112|NCT00937014|Other|Test formula|Test formula enriched in lactoferrin given during the first 9 months of life, as per standard requirement.
45362113|NCT00828152|Behavioral|Internet-delivered CBT.|12 weeks. Therapist contact through e-mail.
45362114|NCT00828152|Behavioral|On line discussion group|Placebo. On line discussion group.
45362115|NCT00932100|Drug|REG1|IV form, bolus dose. May be redosed. Control agent given as single re-dose at completion of intervention
45362116|NCT00932100|Drug|Heparin|IV dose per standard of care at the local institution
45362117|NCT00828230|Drug|budesonide|One application of 2mg budesonide once daily for 8 weeks
45362118|NCT00828230|Drug|Placebo foam|One application of placebo foam once daily for 8 weeks
45362119|NCT02548988|Other|Neuromuscular Electrical Stimulation|Selective Neuromuscular Electrical Stimulation on VMO
45362120|NCT04469556|Drug|Folfirinox|Chemotherapy
45362121|NCT04469556|Drug|Gemcitabine/nab-paclitaxel|Chemotherapy
45362122|NCT00540423|Drug|SB-497115-GR 12.5mg|SB-497115-GR 12.5mg tablet once a day
45362123|NCT00540423|Drug|SB-497115-GR 25mg|SB-497115-GR 25mg tablet once a day
45688843|NCT00283816|Drug|Oral Contraceptive Pill|"Yasmin, drospirenone and ethinyl estradiol 28 tablets~1 tab daily for duration of study"
45688844|NCT00283816|Behavioral|Lifestyle Management Program|Subjects and a parent/guardian will participate in a series of classes for training in diet, exercise & behavior modification skills on a regular weekly basis over the 24 week study
46049465|NCT00673504|Drug|Gemcitabine + Sunitinib|Gemcitabine 1.000 mg/m2, d1,8q3weeks Sunitinib 50 mg/day (2weeks on/1weeks off)
46049466|NCT00673504|Drug|Gemcitabine|1.000 mg/m2 d1,8,15q4weeks
46049467|NCT00673582|Drug|Rosuvastatin|10 mg/day rosuvastatin
46049468|NCT00673582|Drug|Placebo|Placebo, 10 mg a day for 96 weeks
46049469|NCT00694954|Device|Diagnostic Test - Given Imaging Pillcam|"Procedure performed once only after randomization. If procedure is incomplete due to a number of variables, procedure may possibly need to be repeated.~Diagnostic possibilities: normal exam, active bleeding, potential source of bleeding (angiodysplasia, ulcer, tumor)"
45688845|NCT00283816|Behavioral|Quality of Life Questionnaire|Quality of Life questionnaire designed for women with Polycystic Ovary Syndrome. Questions concern health and health related issues Performed twice during study, at baseline and conclusion
46049470|NCT00694954|Other|Diagnostics|Any other diagnostic tests (if not already performed) that the referring or attending physician deems necessary aside from Wireless Capsule Endoscopy.
46049471|NCT04137094|Behavioral|Persuasive Health Communication Intervention|A persuasive health communication intervention will be performed
45362124|NCT00540423|Drug|SB-497115-GR 12.5mg matching placebo|SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day
45362125|NCT00540423|Drug|SB-497115-GR 50 mg|SB-497115-GR 25mg tablet x2 once a day
45362126|NCT00932178|Behavioral|Calmer Life|Calmer Life is a modified version of an existing Cognitive Behavioral Treatment manual. Participants have the option of including religion and spirituality into coping skills taught as a way of treating anxiety with or without depression in older adults.
45362127|NCT04014504|Diagnostic Test|Neonatal Hearing Screening Test|neonatal hearing screening test results will be evaluated.
45362128|NCT03710850|Dietary Supplement|Inulin|Inulin is a dietary fibre. Will be supplemented in a dose 10g/d for a period of 3 moths.
45362129|NCT00932256|Drug|STAHIST NDC #58407-536-01|Oral tablet containing Pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, atropine sulfate .24mg, one tablet BID.
45362130|NCT00932334|Behavioral|TALK PLUS|Participants receive and educational video and booklet about living kidney donation and meet with a social worker
45362131|NCT00932334|Behavioral|TALK Standard|Participants receive and educational video and booklet about living kidney donation
45362132|NCT00932334|Behavioral|Usual Care|Participants receive their usual care
45362133|NCT03091725|Procedure|Roux-en-Y gastric bypass surgery|A bariatric surgery procedure which will help individuals achieve 16-18% weight loss
46049472|NCT00912574|Drug|GM-CSF-in-adjuvant|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1 ml saline~specified dose of GM-CSF in 1 ml saline~an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
46049473|NCT00912574|Drug|Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1 ml saline~specified dose of GM-CSF in 1 ml saline~an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
45688846|NCT00283816|Procedure|Oral Glucose Tolerance Test|"Insulin response to a glucose challenge in an oral glucose tolerance test (OGTT), as measured by area under the curve (AUC). In this study we will administer an OGTT and calculate the AUC as a measure of insulin resistance.~Performed twice during study, at baseline and conclusion"
45688847|NCT00283816|Procedure|Blood work|Initial and conclusion blood draws include; comprehensive metabolic profile, CBC and platelet,hormonal assessment and lipids.
45688848|NCT00283816|Procedure|Abdominal Ultra Sound|"transabdominal transducer, which contains integrated software for volume calculation will be used to assess ovarian volume.~Performed twice during study, at baseline and conclusion"
45688849|NCT00283816|Procedure|Dual-energy x-ray absorptiometry (DEXA scan)|Dual-energy x-ray absorptiometry (DEXA) will be used to assess percent body fat Performed twice during study, at baseline and conclusion
45362134|NCT03091725|Behavioral|Very low-calorie diet|Subjects will meet with a dietitian and/or behaviorist over 4-6 months to lose 16-18% of their body weight.
45362135|NCT00937092|Drug|Furosemide|High-dose furosemide(HDF, furosemide 20 mg/h intravenously)
45362136|NCT00937092|Drug|low-dose dopamine + low-dose furosemide|low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5μg/kg/min intravenously)
45688850|NCT00283816|Drug|placebo|placebo capsules, two capsules BID
45688851|NCT00284518|Biological|botulinum toxin Type A|Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1.
45362137|NCT04124601|Radiation|Chemoradiotherapy|Capecitabine tablet with fractionated radiotherapy
45362138|NCT04124601|Drug|Ipilimumab|Infusion
45688852|NCT00284518|Drug|normal saline|Normal Saline (Placebo) transperineal or transrectal injection on Day 1.
45688853|NCT04339426|Drug|Atovaquone/Azithromycin|Atovaquone 750 mg PO Q12H for up to 10 Days Azithromycin 500 mg PO Daily 1 followed by 250 mg PO Daily for up to 10 days (days 2-10)
46049474|NCT00912574|Biological|GM-CSF and Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1 ml saline~specified dose of GM-CSF in 1 ml saline~an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
46049475|NCT00912574|Drug|Saline|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1 ml saline~specified dose of GM-CSF in 1 ml saline~an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
46049476|NCT00692848|Other|Procalcitonin dosage PCT-Q test (Brahms, Germany)|Procalcitonin result available to the attending physician
46049477|NCT00695032|Drug|cisplatin|
46049478|NCT00695032|Drug|ifosfamide|
46049479|NCT00695032|Other|laboratory biomarker analysis|
45362139|NCT04124601|Drug|Nivolumab|Infusion
45362140|NCT00930696|Procedure|Extensive abdominal lavage|Extensive lavage of the abdomen with 8 liters of saline at the end of the surgical procedure
45362141|NCT00930696|Procedure|Rinsing of the abdomen|Standard rinsing of the abdomen with some 0,5 liters of saline at the end of the surgical procedure
45362142|NCT00937170|Device|Zimmer LPS flex Gender Specific Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
45688854|NCT01899898|Other|Simplified Modified Atkins Diet|"Modified Atkins diet with the following modifications:~Pictorial representation of various food items and exchange lists will be provided.~Instead of weights, we will provide standardized measures~We will calculate the amount of carbohydrates of daily readily available foods in the standardized measures~We will formulate recipes and diets based on locally available and culturally acceptable foods.~We will develop a parent instruction manual.~We will also develop methods for parents with low levels of literacy to maintain seizure logs. This will be done by using bars and color codes.~We will develop methods for parents with low levels of literacy to measure and record urine ketones. This will be done by using color codes."
45362143|NCT00937170|Device|Zimmer High Flex LPS Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
45688855|NCT01899898|Drug|Antiepileptic drugs alone|The anti-epileptic drugs will be continued alone for 3 months following which they will be offered Simplified Modified Atkins Diet
45362144|NCT00937170|Device|Stryker Triathlon Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
45362145|NCT00932412|Drug|CLARA|Clofarabine 30 mg/m2/day IV (2h) on days 2 to 6 (administered as a 2h infusion in 250 ml of 0.9% normal saline solution) Cytarabine 1 g/m2/day intravenous (2h) 4 hours later on days 1 to 5 (administered as a 2h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 6 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
45362146|NCT00932412|Drug|HDAc|Cytarabine 3 g/m2/12h intravenous (3h) on days 1, 3, 5 (administered as a 3h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 5 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
45362147|NCT05046639|Drug|10 mL 2% lidocaine|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL 2% lidocaine.
45362148|NCT05046639|Drug|10 mL preservative free saline|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL preservative free saline.
45362149|NCT04565613|Dietary Supplement|Enteral protein supplementation|"The participants in the study interventional group will receive protein supplementation to reach a final goal of 1.5 g/kg/day of protein on full feeds. This will be via 100% whey protein isolate (Nestle Beneprotein). Doses will be calculated on the patient's admission weight and rounded up to the nearest 1g. Doses will not be adjusted to account for weight changes in the PICU.~Protein supplementation will continue for a total of 7 days from the start of enrolment into the study or until PICU discharge, whichever is earlier. If the patient is able to take solid feeds during the study intervention period, the intervention will be stopped. However, if the device required for feeding is removed but the patient takes milk/liquid feeds fully, protein supplementation will continue."
45362150|NCT04014036|Device|low energy extracorporeal shockwave therapy|Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
46049480|NCT04137172|Procedure|laparoscopic (IPOM) hernioplasty without repair|"Under general anesthesia, supine position, lateral visiport 12mm was inserted at the left anterior axillary line . Other two 5mm ports were inserted under vision. A 30-degree optics were used. Adhesiolysis was done . The contents of hernia were reduced . The borders of the defect were illuminated and outlined. The abdominal wall was marked from outside for measurement of defect size and for corners fixation of mesh with 5cm away from defect edge. Defect with axis from 9 to 12 cm is considered big defect.~Group I:~Proline (1) sutures were applied at the corners of the mesh introduced into the peritoneal cavity. Endoclose passed at the marked site from abdominal wall, sutures hanged and tied subcutaneously, completion of mesh fixation using secure strap ."
45362151|NCT05007951|Biological|GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)|injection volume of 0.5mL on days 0 and 28 (stage1)
46049481|NCT04137172|Procedure|aparoscopic IIPOM hernioplasty with intracorporeal repair using proline 0 versus stratifix PDS|"Group II:~Using PDS 0, a stratifix suture (STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device) versus proline 1 , used to repair and plicate the defect then mesh fixation"
45362152|NCT05007951|Biological|ChAdOx1-S not less than 2.5 × 10^8 infectious units|injection volume of 0.5mL on days 0 and 28 (stage1)
45362153|NCT05007951|Biological|GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)|injection volume of 0.5mL on days 0 (stage2)
45362154|NCT04014816|Other|MDR bacteria positivity|A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
45688856|NCT00286078|Device|Precision|Implantable neurostimulator
45362155|NCT04014816|Other|negative fluid balance|A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
45847700|NCT02867202|Device|Intrauterine Contraceptive Device Plus Foley Catheter|After the completion of hysteroscopic adhesiolysis, Intrauterine Contraceptive Device Plus Foley Catheter were inserted into the uterine cavity. Foley Catheter was removed after three days and Intrauterine Device was removed at the second time of hysteroscopy.
45362156|NCT00932490|Behavioral|Nurse Coaching|Tailored adherence intervention that will be based on the particular needs of patients and advanced practice nurses will suggest individualized strategies to overcome barriers to adherence
45362157|NCT04521621|Biological|Gebasaxturev|Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.
45362158|NCT04521621|Drug|Pembrolizumab|Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.
45362159|NCT00932724|Drug|CY-503|Ampoules with 1 ml 350 ng CY-503 solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
45362160|NCT00932724|Drug|Placebo|Ampoules with 1 ml placebo solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
45362161|NCT00931008|Drug|SID530, Taxotere|75mg/m2
45362162|NCT01563705|Procedure|Different motor function tests|Time to rise from a chair, time to go from lying to sitting, time to go from lying to standing, time to cover 10 meters, time to climb 4 steps
45362163|NCT01563705|Procedure|Manual dexterity assessment|Purdue pegboard test
45688857|NCT04217902|Other|Description of patients' experiences of diabetes care delivery and planning|Semi-directed interviews will be conducted with people living with type 1 or type 2 diabetes in person or by phone to assess and describe the care delivery pathway they have been through. Information on 3 domains will be assessed: clinical (information they consider essential for health care professionals to systematically have access to during consultations and other health-related interventions such as therapeutic education sessions), technological (what kind of digital services and technologies they use or are willing to use), and behavioural (the decision-making process and the key interactions that build the care delivery pathway).
45752125|NCT03086317|Device|Ultrasound-Accelerated Thrombolysis|USAT is a modification of standard catheter-directed thrombolysis utilizing a proprietary system of local high frequency, low-power ultrasound to dissociate the fibrin matrix of the thrombus, allowing deeper penetration of lytic medication. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
45752126|NCT00355199|Drug|Rituximab-HDS|Rituximab-HDS
45752127|NCT00355199|Drug|Rituximab-CHOP|Rituximab-CHOP
45362164|NCT00932802|Drug|Moxifloxacin (Avelox, BAY12-8039)|AECB patients under daily life treatment receiving moxifloxacin according to the local product information.
45362165|NCT03439449|Device|CLEOS software program|Computer-assisted history taking program
45362166|NCT03439449|Procedure|Physician taken history|Conventional history taking by physicians
45362167|NCT00932880|Drug|Amlodipine Besylate|10 mg tablets (Torrent Pharmaceuticals, India)
45362168|NCT00932880|Drug|Norvasc|10 mg dose (Pfizer, USA)
45362169|NCT05360199|Behavioral|PROMs|evaluate the impact of recall bias on post proms scores
45362170|NCT00937482|Drug|cediranib maleate|Given orally
45362171|NCT00937482|Radiation|whole-brain radiation therapy|Undergo whole-brain radiotherapy
45362172|NCT01563861|Genetic|RNA analysis|
45847701|NCT02871570|Drug|Rivipansel|A single dose of IV Rivipansel over 20 minutes
45362173|NCT01563861|Genetic|gene expression analysis|
45362174|NCT01563861|Other|immunohistochemistry staining method|
45362175|NCT01563861|Other|laboratory biomarker analysis|
45362176|NCT00937638|Dietary Supplement|BOLD Diet|Low-fat, high fruit and vegetable diet that includes lean beef (5oz/day)
45362177|NCT00937638|Dietary Supplement|BOLD-X Diet|Low-fat, moderate-high protein diet (BOLD+) that is higher in total protein (from mixed sources including lean beef, 7oz/day) than the BOLD diet. Also high in fruits and vegetables
45362178|NCT00937638|Dietary Supplement|Modified DASH Diet|Low-fat, high fruit and vegetable diet which has become the Gold Standard for the management of cardiovascular disease (CVD) risk factors and metabolic syndrome
45362179|NCT03401853|Other|Laboratory Biomarker Analysis|Correlative studies
45362180|NCT03401853|Biological|Pembrolizumab|Given IV
45362181|NCT03401853|Biological|Rituximab|Given IV
45688858|NCT04217902|Other|Description of health care professionals needs and experiences in diabetes care delivery and planning|Semi-directed interviews will be conducted with health care professionals working in diabetes care in person or by phone to assess and describe their needs and experiences in diabetes care. Information on 3 domains will be assessed: clinical (the information they consider to be essential to inform decisions in diabetes care, where and if they currently find that information and problems they might encounter), technological (which software they currently use and how data is input into clinical information systems), and behavioural (how care coordination is currently managed, how interactions with patients and other professionals are undertaken).
46049482|NCT04137172|Procedure|laparoscopic IPOM hernioplasty with transfacial closure using PDS LOOP 0|The PDS loop sutures were prepared by cutting the needles, keeping two detached ends and one blind end. A small curved supraumbilical incision was done. The endoclose passed through upper border of incision penetrating the abdominal wall above the defect, hanging the blind end of the PDS Loop to outside. It passed through the lower border of the wound crossing the defect. It hanged one detached end of the PDS Loop suture to outside, passed again through lower border of incision to catch the other detached end. The two ends were hanged not tied to avoid incision closure. The process is repeated by passing 1-2 cm lateral or medial to the previous sutures, then blind ends were divided. Lastly, all sutures are tied. Mesh was fixed as before.
46049483|NCT04137328|Drug|Liraglutide|0.6mg/day in the first week, if there is no obvious discomfort, 1.2mg/day in the second week, subcutaneous injection, lasting for 3 months
45362182|NCT03401853|Biological|Obinutuzumab|Given IV
45362183|NCT00931086|Drug|belimumab|IV 10mg/kg q28days
45362184|NCT00933036|Device|Crosstrees Pod system for PVA|Minimally invasive spine surgery
45362185|NCT04453839|Drug|ZYESAMI (aviptadil acetate)|Patients will be treated with 12 hour infusions of ZYESAMI at ascending doses of 50/100/150 pmol/kg/hr on 3 or more successive days
45362186|NCT04004559|Other|No interventions|As this is a patient registry, there are no interventions.
45847702|NCT02873286|Biological|MVA-BN-RSV|MVA-mBN294B
45362187|NCT00566982|Drug|Ospemifene 60 mg|60 mg/day (QD) dose of ospemifene (1 tablet) will be taken for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52). Dosing will be oral and the ospemifene 60 mg tablet will be taken once daily, in the morning, with food.
45362188|NCT00566982|Drug|Placebo|Dosing will be oral and placebo will be taken once daily, in the morning, with food for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52)
45362189|NCT00624338|Drug|Atacicept 75 mg|75 milligram (mg) atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
45362190|NCT00624338|Drug|Atacicept 150 mg|150 mg atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
45362191|NCT00624338|Other|Placebo Comparator|Placebo matched to atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
45362192|NCT00933114|Procedure|MRI and PET imaging|Dynamic Enhanced Magnetic Resonance Imaging (DEC-MRI) and positron emission tomography (PET) scan at baseline and after 1 week of radiation therapy
45362193|NCT00933192|Device|Siemens Acuson Antares ultrasound|skeletal muscle ultrasound of the musculus quadriceps, on two different days, two observers
45362194|NCT03977454|Procedure|Nerve Block|"Nerve blocks (QLB/LFCNB) to be placed preoperatively with DEX/MPA, per standard of care of anesthesia block service.~QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA~LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA"
45847703|NCT02873286|Other|Placebo|Tris Buffered Saline, sterile
45847704|NCT02874066|Drug|PTV/r/OBV/DSV|Viekirax/Exviera for 12 weeks
45362195|NCT03977454|Procedure|Periarticular Injection (PAI)|"Intraoperatively, the surgeon will perform PAI per standard of care with the medications:~1. 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA"
45362196|NCT03977454|Drug|Ropivacaine|60 ml 0.2% ropivacaine
45362197|NCT03977454|Drug|Dex|10 mg DEX/ 80 mg MPA
45362198|NCT00828386|Procedure|Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy|Induction chemotherapy (Docetaxel, Cisplatin and 5-Fluorouracil) + concurrent radiochemotherapy
45362199|NCT02549066|Procedure|Increased cardiopulmonary bypass flow|In randomized order, CPB flow will be adjusted to 2,4, 2,7 and 3,0 L/min/m2. After 10 minutes of steady conditions at each level, measurements will be made.
45362200|NCT02549066|Drug|Milrinone|"After weaning from CPB, patients with signs of cardiac failure (as defined below) will be given milrinone (0,04 mg/kg as a loading dose and 0,50 ug/kg/min as subsequent infusion). Measurements of systemic and renal variables will be made before and 30 minutes after the dose.~Indication: Central venous pressure (CVP) ≥ 12 mmHg AND/OR Pulmonary Capillary Wedge Pressure (PCWP) ≥ 16 mmHg AND Cardiac Index (CI) ≤ 2,1 L/min/m2 AND Pulse Pressure Variation (PPV) < 12 %."
46049484|NCT04137328|Drug|insulin|Add or adjust insulin (when basic insulin is preferred for those who do not use insulin, such as those who have already used insulin, adjust the dosage or program according to the condition, inject subcutaneously) for 3 months
45362201|NCT00831350|Drug|Ranibizumab|Subjects will receive study medication ranibizumab 0.5mg. Re-treatment will occur monthly through 6 injections
45362202|NCT00933348|Drug|OPAL A|OPAL A will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the OPAL A Filtrate will only be administered once every 72 hours.
45688859|NCT00287716|Drug|Pirfenidone|1197 or 2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
45688860|NCT00287716|Drug|Placebo|Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
45688861|NCT00287872|Drug|bortezomib|
46049485|NCT00692926|Biological|ALDHbr Umbilical Cord Blood Cells|ALDHbr sorted Umbilical Cord Blood Cells
46049486|NCT00693004|Drug|PRX-03140|
46049487|NCT00693004|Drug|Donepezil|
45688862|NCT00287872|Drug|thalidomide|
45688863|NCT00288574|Drug|Fluoxetine|
45688864|NCT00288574|Drug|Placebo|
45688865|NCT01791010|Other|Inspiratory muscle training|
45688866|NCT01791010|Other|Training sham|Conducting fake training with the aim of blind the control group
45688867|NCT00288886|Behavioral|Contracting, Prompting and Reinforcement arm|Contracting, prompting and reinforcement of continuing care and abstinence.
45688868|NCT00288886|Behavioral|Control arm|Routine residential treatment and orientation to continuing care.
45847705|NCT02874846|Drug|Netarsudil ophthalmic solution 0.02%|Once daily in both eyes (OU) in the evening (PM) for 7 days
46049488|NCT00693004|Drug|Placebo|
46049489|NCT04152538|Other|not intervention but investigation|possible differences in quadriceps muscular activity
46049490|NCT00695344|Drug|everolimus|Everolimus 2 times per day, v.o., 2 years treatment.
46049491|NCT00695344|Drug|azathioprine or mycophenolate mofetil|2 times per day during 2 years
45362203|NCT00933348|Drug|Placebo|Placebo will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the Placebo Filtrate will only be administered once every 72 hours.
45362204|NCT00823628|Drug|contrast agent (iopromide)|coronary angiography using the allocated contrast agent
45362205|NCT00823628|Drug|contrast agent (iodixanol)|coronary angiography using the allocated contrast agent
45362206|NCT00937872|Drug|250 mg SRT2104 Suspension|Single 10 mL oral dose of 250 mg SRT2104 delivered as a suspension formulation.
45688869|NCT00289120|Drug|Cola beverage|Subjects will be given 500cc of Cola beverage twice daily to be ingested with breakfast and dinner for six days while on a metabolic diet.There will be a three weeks interval before crossover to the other treatment arm.
45688870|NCT00289120|Drug|Deionized water|Subjects will be given 500cc of deionized water to be ingested twice daily with breakfast and dinner for three weeks while on a metabolic diet. There will be a three weeks interval before crossover to the other treatment arm
45688871|NCT04079218|Drug|Estradiol Vaginal Insert|Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.
45688872|NCT04061590|Drug|Cisplatin|Given IV
46049492|NCT00693082|Dietary Supplement|flaxseed|1 tablespoon a day for first three days, increasing to two tablespoons a day for the next three days. On the 7th day start with 3 tablespoons per day and maintain dose throughout the duration of the study (11 weeks).
46049493|NCT04047550|Diagnostic Test|Ventilatory chemosensitivity|Using this technique, the patient first voluntarily hyperventilates to a PETCO2 value of 20-25 mmHg, then undergoes a rebreathing test allowing the PCO2 to rise to 55-60 mmHg while PETO2 is maintained at 150 mmHg. The procedure is then repeated with PETO2 clamped at 50 mmHg. Parameters derived from this method include slopes of the ventilatory response during hyperoxia and hypoxia.
45362207|NCT00937872|Drug|Carbon-14 radio-labeled SRT2104|Single 10 mL IV dose containing 100 microgram (not more than 250 nCi, 9.25 kBq) Carbon-14 radio-labeled SRT2104, administered by IV infusion over 15 minutes, starting 2 hours and 45 minutes after the oral dose is administered.
45362208|NCT00938184|Drug|Paroxetine 12.5 milligrams tablet|Single dose of paroxetine 12.5 milligrams controlled release tablet will be administered orally.
45362209|NCT00938184|Drug|Paroxetine 25 milligrams tablet|Single dose of paroxetine 25 milligrams controlled release tablet will be administered orally.
45362210|NCT00938184|Drug|Paroxetine 50 milligrams tablet|Single dose of paroxetine 50 milligrams controlled release tablet (as two tablets of 25 milligrams) will be administered orally.
45362211|NCT00938262|Drug|Fimasartan, Ketoconazole, Rifampicin|"Fimasartan (1 day)~Ketoconazole (3 days) Ketoconazole + Fimasartan (1 day)~Rifampicin (9 days) Rifampicin + Fimasartan (1 day)"
45362212|NCT00933426|Drug|Lenalidomide|Lead-In beginning dose of 5 mg capsules by mouth once a day for 21 days in a row, followed by 7 days of rest (Days 22-28) for a 28 day cycle.
45688873|NCT04061590|Biological|Pembrolizumab|Given IV
45688874|NCT04061590|Drug|Pemetrexed|Given IV
45688875|NCT04061590|Drug|Pemetrexed Disodium|Given IV
45688876|NCT04061590|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45688877|NCT01791088|Drug|sirolimus|Given PO
45688878|NCT01791088|Other|pharmacological study|Correlative studies
45688879|NCT01791088|Other|laboratory biomarker analysis|Correlative studies
45362213|NCT00933426|Drug|Paclitaxel|50 mg/m^2 given by vein over 1 hour on Days 1, 8, and 15 of each 28 day cycle.
45688880|NCT00289744|Biological|TWINRIX™ ADULT|2 doses IM injection in primary study
45480079|NCT03319186|Procedure|EDIT Management|"EDIT management~Volumetric Pleural MRI for pre-aspiration pleural cavity volume~Large volume pleural aspiration with recording of intra-pleural pressure during aspiration~Volumetric Pleural MRI for post-aspiration pleural cavity volume~Computation of PEL250, defined as the rolling average of pleural elastance over the preceding 250ml aspirated.~MaxPEL250 ≥ 14.5 cm H2O/L: allocated to 1st-line IPC MaxPEL250 < 14.5 cm H2O/L: allocated to 1st-line TP~EDIT-directed 1st-line treatment to be delivered within 24 hours; if insufficient residual pleural fluid to allow standard Seldinger insertion technique then Boutin-type needle used for pneumothorax induction and guide wire insertion."
45362214|NCT04014582|Behavioral|Communal Coping Intervention|This intervention aims to foster a shared appraisal and collaboration through: the discussion of past joint coping, education about communal coping (e.g. what it is and why it is beneficial), and discussions to foster the perception of diabetes as shared. Participants in the intervention group will also create collaborative action plans to increase collaboration. Couples in the intervention group will also receive two daily text messages-one a general reminder to engage in communal coping and the other one of the collaborative intentions they created during the in-person session. These couples will also receive a brief diabetes education.
45362215|NCT04014582|Behavioral|Diabetes Education|Couples in the diabetes education group will receive a brief diabetes education and complete individual implementation intentions. Patients will create implementation intentions related to diabetes and partners will create implementation intentions that are not related to health.
45480080|NCT03319186|Procedure|Chest drain and talc pleurodesis|Intercostal chest drain insertion and talc slurry instillation according to British Thoracic Society guidelines
45480081|NCT01305317|Drug|Lipitor|Atorvastatin 20mg daily for 6 months
45480082|NCT02613416|Drug|Denosumab|monthly subcutaneous injections
45480083|NCT00897702|Other|Blood draw|A single 10ml tube of blood will also be obtained for a comparison of patient's normal DNA for genomic analyses either at the time of the procedure or at a followup appointment if feasible.
45480084|NCT00897702|Other|immunoenzyme technique|
45688881|NCT00289744|Biological|Engerix TM|If a subject has become seronegative for anti-HAV antibodies or lost anti-HBs seroprotection concentrations at the long-term blood sampling time point (i.e. Years 6, 7, 8, 9 or 10), he/ she will be offered an additional vaccine dose.
45688882|NCT00291226|Drug|Glycine|Glycine 0.4 g/kg bid
45688883|NCT00291226|Drug|Placebo|Placebo
45688884|NCT01791166|Biological|Blood test for detecting the circulatory anti-HLA antibodies by ELISA and LUMINEX tests|
45688885|NCT00291694|Drug|celecoxib|Celecoxib 400 mg BID
45480085|NCT00897702|Procedure|biopsy|
45480086|NCT00897702|Procedure|histopathologic examination|
45480087|NCT03326050|Drug|Gemifloxacin|Gemifloxacin 320Mg Oral Tablet once daily
45480088|NCT03326050|Drug|Ciprofloxacin|cipro 750 tablet twice daily
45480089|NCT03326050|Drug|Rifampicin|Rifampicin 150Mg Capsule twice daily
45480090|NCT03614585|Behavioral|12 weeks of High-intensity Interval Training|Cardiovascular exercise
45480091|NCT03614585|Behavioral|12 weeks of Moderate-Intensity Continuous Training|Cardiovascular exercise
45688886|NCT00291694|Other|placebo|placebo
45688887|NCT00292162|Procedure|radiofrequency ablation|isolation of the pulmonary veins with radiofrequency ablation (RFA)
45688888|NCT00292162|Drug|ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril|Evidence based treatment for heart failure. Dose and type will depend on patient tolerability.
45362216|NCT04013958|Drug|IV Ketamine|IV Ketamine 0.1 mg/kg with IV morphine -0.1 mg/kg with IM Sailne 0.9%
45362217|NCT04013958|Drug|IM Ketamine|IM Ketamine 0.3 mg/kg with IV morphine -0.1 mg/kg
45362218|NCT00933504|Drug|LACTIC ACID(ND)|Treatment duration: 6 weeks.
45362219|NCT00933582|Drug|JNJ-39439335; Placebo; Naproxen|
45362220|NCT00933660|Other|ERC-training by instructor|Standard way of training with an instructor
45362221|NCT00933660|Other|Web-based training only|Experimental way of training with a web based training application
45362222|NCT00933660|Other|Web-based training with a personal training manikin|Experimental way of training with a web based training application and a simple personal training manikin
45362223|NCT00938418|Radiation|Dose escalated, accelerated, hypofractionated radiotherapy|Intensity modulated radiotherapy with concurrent chemotherapy
45362224|NCT00938574|Drug|Atu027|
45362225|NCT00938730|Drug|YM150|oral
45362226|NCT00938730|Drug|Warfarin|oral
45362227|NCT00933816|Drug|sorafenib, cisplatin, fluorouracil|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued.
45362228|NCT00538785|Biological|Motavizumab|15 mg/kg IM administered at monthly intervals
45362229|NCT00538785|Biological|Palivizumab|15 mg/kg IM administered at monthly intervals
45362230|NCT02058459|Device|Holaira™ Lung Denervation System with energy delivery|
45362231|NCT02058459|Device|Holaira™ Lung Denervation System without energy delivery|
45362232|NCT00990015|Drug|PF-04308515|Oral solution/suspension 0.1 mg up to potentially 350 mg QD at a single dose.
45362233|NCT00990015|Drug|Placebo|Placebo solution/suspension to match active drug QD at a single dose.
45362234|NCT04237545|Device|T3 short and restoration (prosthesis)|A qualified patient will be treated with a T3 short implant according to randomization assignment during implant placement surgery visit. The implant will then be restored with a prosthesis and followed up for yearly visits for a total of 4 years.
45362235|NCT04237545|Device|T3 standard length and restoration (prosthesis)|A qualified patient will be treated with a T3 standard length implant according to randomization assignment during implant placement surgery visit. The implant will then be restored with a prosthesis and followed up for yearly visits for a total of 4 years.
45362236|NCT05360121|Other|Muscle energy technique of erector spinae muscle|"Therapist will develop cross hand position left hand on lower thoracic and right hand on sacrum. Patient will asked to lift shoulder out of couch to contract the lumber erector spinae and apply force twenty percent against therapist force and keep this position of muscle contraction 7 to 10 seconds then 5 second relax .~Then therapist will take new position of muscle restriction by slacking and will hold 30 second that position at the end of restriction then will finally end stretch with three repetition. Muscle energy technique of erector spinae muscle."
45362237|NCT05360121|Other|Muscle energy technique of quadratus lumborum muscle|Therapist will take step over the patient off leg and squeezes gently with their thigh. Patient will abduct leg with 20 percent force against the resistance of therapists thigh for 7 to 10 second. the therapist gently and passively will move patient leg towards adduction by squatting down slowly. Therapist at same time with both hands cradling the iliac crest of pelvic for 30 second stretch and 3 repetition.
45688889|NCT00292162|Drug|Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol|Evidence based treatment for heart failure. Dose and type will depend on patient tolerance.
46049494|NCT00693316|Drug|ORM-12741|Alternating panel single dose escalation.
46049495|NCT00933270|Device|SUPERA® Nitinol Stent System|Percutaneous Angioplasty of the Superior Femoral Artery with placement of a SUPERA® Stent at time of PTA
46049496|NCT00695422|Genetic|polymerase chain reaction|PCR for HPV DNA detection, performed on specimens collected at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
46049497|NCT00695422|Other|cytology specimen collection procedure|Detection of HPV-associated neoplasia at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
45362238|NCT05360121|Other|Stretching of erector spinae muscle|The therapist standing on the side in a way to place his elbow placed on erector spine and apply stretching on the muscle belly in the direction of longitudinal or transverse plane( figure 1).Duration of stretch will be 15 seconds and four repetition.
45362239|NCT05360121|Other|Stretching of quadratus lumborum muscle|Placing patient's legs to one side of the table and upper body also move to the same side in lateral flexion. This position generate a basic gentle stretch of the muscle. The therapist use elbow on tight/ flat part of muscle belly to stretch out the muscle(figure 2). Duration of stretch will be 15 seconds and four repetition
46049498|NCT00695422|Other|histological technique|Detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
46049499|NCT00695422|Procedure|colposcopic biopsy|Where observed during HRA, collection of tissue for detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
46049500|NCT04137016|Other|Mobile application|
46049501|NCT02624362|Behavioral|Therapeutic Suggestion|suggestions about potential beneficial effects of the odor are given
45362240|NCT05360121|Other|Back strengthening exercises|"Supine Abdominal Draw In~Supine Butt Lift with Arms at Side~Abdominal Draw In with Heel Slide~Abdominal Draw In with Knee to Chest~Abdominal Draw In with feet on the ball~Abdominal Draw In with feet on the ball- add movement"
45362241|NCT05360121|Other|Thermotherapy|Ten minute duration of hot pack given on low back for local superficial heat.
45362242|NCT01563939|Drug|Remifentanil|"Remifentanil IV for continuous infusion: 0.025mcg/kg/min, increased by 0.025mcg/kg/min every 15 min if patient is not satisfied, to a maximum of 0.15mcg/kg/min.~Remifentanil IV for demand bolus: 0.2 mcg/kg, lockout 2 min, incrementally increased if patient is not satisfied by 0.2 mcg/kg to a maximum of 1.2 mcg/kg."
45362243|NCT04004715|Dietary Supplement|Essential Amino Acid Enriched Whey Protein|protein powder formulation that includes whey and free-form essential amino acids
45362244|NCT04004715|Dietary Supplement|Whey Protein|commercially available whey protein isolate
45362245|NCT04004715|Dietary Supplement|Military Ration Entree|chili and beans entree; current meal component of the meals ready to eat rations
45362246|NCT05360043|Device|laser treatment|All subjects were treated with a 1565-nm NAFL on their left faces for one pass, A 34-40 mJ per microbeam laser was used, and density was 250-300 microbeam per cm2. Their right faces were treated with a 1064-nm LPNY for one pass. We used a spot size of 10 mm in diameter, an energy density of 45-50 J/cm2, pulse width of 300 microseconds, and a repetition rate of 2 Hz. 1064-nm LPNY was equipped with a dynamic cooling device (DCD), the parameter was set as 40/20/0 ms. A total of 5 treatments were carried out at 2-week intervals, and one follow-up session at two months after last treatment. Before each treatment, subjects were asked to wash their face with clean water, and no topical lotion was applied. For post-treatment care, all subjects were advised to use their own moisturizing cream and avoid sun exposure.
45362247|NCT04004637|Drug|CD7 CAR-T cells infusion|"Biological: CD7 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD7 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD7 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD7 CAR-T cells are infused into patients for one or two times, the number of infused CD7 CAR-T cells are 0.5-5×10^6/kg."
45362248|NCT03287271|Drug|VS-6063|"Phase 1:~First 3 patient cohort: VS-6063 200 mg PO twice daily~IF TOLERATED, Second 3 patient cohort: VS-6063 400 mg PO twice daily,~Phase 2:~VS-6063 400 mg PO twice daily of a 28 day cycle until disease progression or unacceptable toxicity."
45362249|NCT03287271|Drug|Paclitaxel|"Phase 1:~First 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~IF TOLERATED, Second 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~Phase 2:~Paclitaxel 80 mg/m2 infused continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle until disease progression or unacceptable toxicity."
45688890|NCT00292162|Drug|Aldosterone Antagonists - spironolactone|Evidence based treatment for heart failure. Dose and type will depend on patient to treatment.
45688891|NCT00296296|Drug|Cyclosporin|Dose adjustment to pre-established targets
46049502|NCT02624362|Behavioral|Asthmogenic Suggestion|suggestions about potential negative effects of the odor are given
46049503|NCT02624362|Other|Phenylethyl Alcohol odor|Over the course of 15 minutes, participants, receive 15 short sniffs of Phenylethyl Alcohol odor
46049504|NCT00607542|Drug|baclofen|2.5 mg oral baclofen tablets given three times a day; dose gradually escalated as specified in the protocol
46049505|NCT00605046|Drug|SPECT scan|AV151-01: Evaluation of [123I] AV151 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
45688892|NCT00296296|Drug|Tacrolimus|Dose adjustment to pre-established targets
46049506|NCT04265898|Device|The Digital Virginia Tech Carilion Cognitive Examination|Completion of a newly developed digital cognitive screen
46049507|NCT00936858|Drug|RAD001|
46049508|NCT00606762|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed at either 8 mm Hg or 12 mm Hg intra-abdominal pressure
45362250|NCT03287271|Drug|Carboplatin|"Phase 1:~First 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~IF TOLERATED, Second 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~Phase 2: carboplatin (AUC of 5 mg/mL/min) infused continuously over 1 hour on day 1 of a 28 day cycle until disease progression or unacceptable toxicity."
45362251|NCT00538629|Other|no intervention|no intervention
45362252|NCT00538629|Other|no intervention|no intervention
45362253|NCT03163095|Device|Open Abdomen Management with ANPPT dressing|"The abdominal fascia will not be closed, but a temporally abdominal closure (TAC) dressing, such as AbThera dressing, will be placed to protect the viscera with active Negative Pressure Peritoneal Therapy.~The time that the TAC dressing will be changed will be left to the discretion of the attending surgeon, but practice guidelines mandate either formal abdominal closure or dressing change at 24-72 hours from placement.~Blood samples and peritoneal fluid will be drawn up to 72 hours after enrollment."
45362254|NCT03163095|Other|Closed Abdomen Management|"Primary closure of the abdominal fascia with placement of an intra-peritoneal drain (such as a Jackson-Pratt drain).~This strategy will allow drainage of intra-peritoneal fluid for both clinical reasons and to facilitate intra-peritoneal fluid testing. Closure or not of the skin will be left to the attending surgeons discretion. Any decision to perform a relaparotomy (Relaparotomy on Demand) will be at the discretion of the treating critical care teams, and in no way mandated by this recruitment.~Blood samples and peritoneal fluid (if available) will be drawn up to 72 hours after enrollment."
45480092|NCT01334346|Other|Nike Pegasus|Conventional neutral supportive running footwear. Non minimalist.
45480093|NCT01334346|Other|Nike Free 3.0|Partial minimalist shoe with partially elevated heel, but with increased mid-sole flexibility.
45480094|NCT01334346|Other|Vibram Five Fingers Shoe|Full minimalist shoe. Virtually no mid-sole, therefore no heel elevation or forefoot rockering. A proxy for a barefoot running condition.
45688893|NCT00296296|Behavioral|'Diabetes Education / Management'|therapeutic adjustment to target ADA criteria
46049509|NCT00605124|Other|Knee muscle exercises|Home exercises three times a week, control every three months
46049510|NCT00693550|Other|metal patch tests|Twenty - seven (27) metal patch tests will be applied to the patient's back and left in place for 3 days
46049511|NCT02624440|Drug|Standard myeloma treatment|The choice of myeloma standard treatment is at the discretion of the treating investigator guided by the national Danish guidelines for treatment of multiple myeloma
46049512|NCT02624440|Drug|Clarithromycin|P.o. clarithromycin 250 mg twice daily
46049513|NCT02624440|Drug|Sulfamethoxazole/trimethoprim|P.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily
46049514|NCT02624440|Drug|Observation|Observation without prophylactic antibiotic
45362255|NCT04232163|Behavioral|Arm Boot Camp|The intervention involves a combination of daily homework based upper limb exercises and feedback from an activity monitor to motivate use of the affected upper limb. Participants will be supported through virtual sessions with a therapist.
45480095|NCT03467425|Drug|FF/UMEC/VI|FF is a dry white powder containing 100 mcg GW685698 blended with lactose in one blister in the first strip of the DPI. UMEC/VI is a dry white powder containing 62.5 mcg of UMEC and 25 mcg of VI per blister, both blended together with lactose and magnesium stearate in the second strip of the DPI.
45688894|NCT03880786|Device|pudendal PNE test lead|All patients eligible for release surgery will be implanted a PNE test lead (Medtronic) which will be placed (transforaminal or transgluteally) next to the pudendal nerve, at the level of the ischial spine, after surgical release and connected to an external stimulation device. The PNE lead will be fixed at the ischial-spinal ligament with an absorbable suture to prevent dislocation. If a bilateral dissection is needed, bilateral test leads will be placed. Stimulation will be switched on at the second postoperative day, according to the sensory threshold described by the patient. After three weeks the PNE test lead will be removed at the outpatient clinical visit.
45845133|NCT02239770|Drug|Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
45362256|NCT04188327|Procedure|Stellate ganglion block|"While the patient is in a supine position with slight neck extension and rotation to the contralateral side, in-plane ultrasound guided stellate ganglion block will be performed with injection of 7 ml injectate (6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg).~Each patient will receive:~Acyclovir 800 mg orally every 5 times per day 7 days.~Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours"
45362257|NCT04188327|Procedure|Sham Stellate ganglion block|"The patient will be positioned supine with slight neck extension and rotation to the contralateral side. Under US guidance, a sham stellate ganglion block will be performed with injection of a 1ml injectate of normal saline will be done while observing the dissection between the carotid artery and the longus colli muscle.~Each patient will receive:~Acyclovir 800 mg orally every 5 times per day for 7 days.~Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours"
45362258|NCT00990405|Drug|Lansoprzole+Amoxicillin+Clarithromycin|Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
45362259|NCT00990639|Drug|candesartan for hepatic fibrosis|"Candesartan group(42 patients): oral candesartan at a daily dose of 8 mgin addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months.~UDCA group(43 patients): oral ursodeoxycholic acid (UDCA, 600 mg/day) only for 6 months"
45362260|NCT04211727|Diagnostic Test|Capillary finger prick blood sample|Patients will have a blood finger prick sample
45480096|NCT03467425|Drug|Inhaled Corticosteroid|Inhaled Corticosteroid (ICS) as prescribed by the physician.
45480097|NCT03467425|Drug|LAMA|LAMA as prescribed by the physician.
45480098|NCT03467425|Drug|LABA|LABA as prescribed by the physician.
45480099|NCT03467425|Drug|COPD rescue medications|Rescue medications for COPD will be prescribed and obtained according to usual practice.
46049515|NCT04264572|Other|Medically Tailored Meals|MTM are meals designed by a Registered Dietitian Nutritionist to reflect appropriate dietary therapy according to evidence-based nutrition practice guidelines. They address medical diagnoses, symptoms, allergies, inability to chew or swallow, medication management, and side effects to ensure the best possible nutrition-related health outcomes.
46049516|NCT04264572|Behavioral|Tele-Medical Nutrition Therapy (tele-MNT)|Medical nutrition therapy (MNT) is offered as a component of usual care in many health systems, and consists of individuals receiving nutrition education tailored to their unique medical needs. Tele-MNT is the use of video technology to deliver MNT.
45480100|NCT04490850|Procedure|Blood sample|Blood sample
45480101|NCT03606941|Device|electroacupuncture treatment|"Participants in the electroacupuncture group received acupuncture (0.30mm×70mm) at bilaterally Shenmen (HT7) acupoints (0.3-0.5 inch), Neiguan (PC6) acupoints (0.5-1 inch), Baihui (DU20) acupoint (0.5-0.8 inch) and Yintang (EX-HN3) acupoint (0.3-0.5 inch) 30 minutes before anesthesia induction. After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 ~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of operation."
45847706|NCT02874846|Other|Netarsudil Ophthalmic Solution Vehicle|Once daily in both eyes (OU) in the evening (PM) for 7 days
46049517|NCT04136704|Procedure|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
46049518|NCT00606840|Behavioral|large changes in eating and activity|Behavioral self-regulation interventions to prevent weight gain in young adults.
46049519|NCT00606840|Behavioral|small changes in eating and activity|Behavioral self-regulation interventions to prevent weight gain in young adults.
45362261|NCT03742947|Diagnostic Test|peripartum haemostasis|Three blood samples of 20 ml each at T0 after the anaesthesia for the caesarean section and before the administration of the product (TXA or placebo), T15 fifteen minutes after the administration of the product and T120, 2 hours after the administration of the product.
45362262|NCT04003935|Other|Juice Plus+ Complete|Plant-based smoothie; maintaining habitual diet.
45845134|NCT02239770|Drug|Placebo Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
45845135|NCT02241486|Drug|Sublingual Fentanyl Spray|Patients with burn injuries will receive sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement).
45845136|NCT02241720|Drug|regorafenib|
45845137|NCT02244840|Device|Electronic bidet|commercial electronic bidet
45845138|NCT02244840|Device|Sitz bath|Conventional sitz bath
45362263|NCT04003935|Dietary Supplement|Juice Plus+ Premium|Fruit and vegetable juice concentrate; maintaining habitual diet.
45362264|NCT00990717|Biological|NK-92 cells|"Cells are administered as an intravenous infusion over one hour on days 1, 3 and 5 of each cycle of treatment. Patients can receive up to 6 cycles, which are administered monthly. Cell dosage is as follows:~Level I: 1x10^9 cells/m^2~Level II: 3x10^9 cells/m^2~Level III: 5x10^9 cells/m^2"
45362265|NCT04004013|Dietary Supplement|Lifenol®|"Lifenol®, powdered extract obtained from female hops flowers (Humulus lupulus L.) standardized in 8-PN content (100 µg /day) + maltodextrin = 500 mg/capsule~+ 1000 mg of calcium and 800 IU of vitamin D per day"
45688895|NCT01791400|Drug|metoclopramide, injection,20mg, one time|metoclopramide, intravenous injection,20mg, one time
45688896|NCT01791400|Drug|Sumatriptan, injection, 6 mg, one time|Sumatriptan, subcutaneous injection, 6 mg, one time
45362266|NCT04004013|Dietary Supplement|Placebo|"Maltodextrin = 500 mg/capsule~+ 1000 mg of calcium and 800 IU of vitamin D per day"
45688897|NCT00298090|Device|StO2 monitoring|placement of the StO2 device/ external noninvasive
45845139|NCT02244918|Drug|Nicotine Replacement Therapy|Participant has choice of from over-the-counter nicotine patch, nicotine gum or lozenge.
45845140|NCT02244918|Behavioral|Smoking Cessation Counseling|
45845141|NCT02246010|Dietary Supplement|Lactose- free milk|Lactose- free milk
45845142|NCT02247336|Behavioral|Family health history platform (MeTree)|Participants will enter their family health history information into a family health history platform, patients and providers will receive a decision support document and pedigree
45845143|NCT02249052|Drug|AA4500|Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously
45362267|NCT05359497|Diagnostic Test|Liver Multiscan sequences baseline|Additional Liver Multiscan sequences at baseline besides standard care MRI liver /MRCP prior to ERCP.
45688898|NCT03962452|Genetic|Next Generation Sequencing (NGS)|Determining the nucleic acid sequence
45688899|NCT00298558|Behavioral|Cognitive Training|Memory, Reasoning, or Speed of Processing cognitive training interventions
45688900|NCT00299416|Drug|Caffeinol|Infusion of caffeinol (9mg/kg caffeine + 0.4g/kg ethanol) over 2 hours.
45688901|NCT00299416|Procedure|hypothermia|External or internal cooling for 24 hours and rewarming over 12 hours.
45688902|NCT00300430|Drug|ABT-335 and rosuvastatin calcium|ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks
45688903|NCT00300430|Drug|ABT-335 and atorvastatin calcium|ABT-335 135 mg plus atorvastatin calcium daily, 52 weeks
45688904|NCT00300430|Drug|ABT-335 and simvastatin|ABT-335 135 mg plus simvastatin daily, 52 weeks
45845144|NCT02249052|Drug|placebo|Placebo
45845145|NCT02250612|Drug|1 drop of 0.375% SYL040012 (bamosiran)|
45845146|NCT02250612|Drug|1 drop of 0.750% SYL040012 (bamosiran)|
45845147|NCT02250612|Drug|1 drop of 1.125% SYL040012 (bamosiran)|
45845148|NCT02250612|Drug|1 drop of 1.5% SYL040012 (bamosiran)|
45845149|NCT02250612|Drug|1 drop of 0.5 % timolol maleate|
45845150|NCT02251236|Drug|Stribild|To be administered orally, once daily with food.
45845151|NCT02251236|Drug|Genvoya|To be administered orally, once daily with food.
45845152|NCT02251938|Drug|DE-109 440 μg|Medium Dose
45845153|NCT02252562|Device|Sage Personal Hand Hygiene System|Utilization of a health care provider worn personal hand hygiene system during routine practice in the intra-operative setting with provider specific individual feedback.
45845154|NCT02252718|Other|Stool Assessment|"After passing a stool by the child participating in the study, within a short-time interval (<5 min), the stool will be assessed independently by one of the parents and the medical doctor. At the same time a parent will take 2 photos with phone photographic camera. Then the photographs will be independently evaluated by another doctor who will be unaware of both the in vivo stool appraisal and child condition."
45845155|NCT02255604|Drug|Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|4
45845156|NCT02255604|Drug|alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|3 injection into a lymphnode
45845157|NCT02255604|Drug|0.1 ml Isoton saline|4 injection into a lymphnode
45847707|NCT02880228|Drug|Dexamethasone|Given PO
45362268|NCT05359497|Device|MRCP+ analysis baseline|Post processing tool (Software) for quantifying MRCP images after MRCP is performed. Patient involvement is not necessary during this procedure.
45362269|NCT05359497|Device|Liver Multiscan analysis baseline|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
45362270|NCT05359497|Diagnostic Test|MRI liver with MRCP|An extra MRI liver with contrast and MRCP is performed 8 weeks after the ERCP following standard care protocol
45362271|NCT05359497|Diagnostic Test|Liver Multiscan sequences follow-up|Additional Liver Multiscan sequences are performed at 8 weeks after ERCP.
45362272|NCT05359497|Device|MRCP+ analysis follow up|Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
45362273|NCT05359497|Device|Liver Multiscan analysis follow up|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences from the follow up scan are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
45362274|NCT05279079|Diagnostic Test|Assessment of accuracy of microRNA and pancreatic enzyme markers in blood and/or urine in the detection and/or prediction of severity of drug-associated acute pancreatitis|Panel of microRNA and pancreatic enzyme biomarkers
45688905|NCT02104414|Drug|Exparel|266 mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
45688906|NCT02104414|Drug|Bupivacaine HCl with Epinephrine|75mg/30mL 0.25% Bupivacaine HCl with epinephrine
45688907|NCT02104414|Drug|Normal Saline|30mL Normal Saline
45688908|NCT02100826|Drug|Cephalexin|Administered orally.
45362275|NCT00990795|Drug|cyclosporine|Cyclosporine Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.
45362276|NCT00990795|Drug|saline solution|Placebo Group: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
45688909|NCT03587272|Drug|Alemtuzumab intravenously, low dose total body irradiation, Sirolimus|"The conditioning regimen (SUN regimen) will consist of alemtuzumab intravenously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on Days -5 to -3) and low dose total body irradiation (TBI) 300 cGY on Day -2 with gonadal shielding if possible. The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x106/kg recipient weight, goal of 10 x 106/kg (no upper limit). A peripheral blood stem cell (PBSC) graft was selected as it engrafts faster than bone marrow and would lead to shorter period of neutropenia and infection and less thrombocytopenia and need for platelet transfusion.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus will be continued at 1 mg/m2/day starting on day 0 and dose adjusted to maintain a target trough level 5-15 ng/mL for the first 3 months and 5-10 ng/mL for the remainder of the first year."
45688910|NCT02101918|Radiation|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
45688911|NCT02101918|Other|Laboratory Biomarker Analysis|Correlative studies
45688912|NCT02101918|Biological|Ziv-Aflibercept|Given IV
45688913|NCT03895450|Behavioral|Aerobic Exercise Protocol|Participants randomized to AEP will be asked to exercise 30 minutes per day or until symptom exacerbation, 5-6 days per week either at home, outdoors or at a fitness facility of choice. The assigned exercise prescription target will be 70-80% of the maximum HR achieved during the treadmill test. HR monitors will be provided to monitor exercise intensity.
45847708|NCT02880228|Other|Laboratory Biomarker Analysis|Correlative studies
45847709|NCT02880228|Drug|Lenalidomide|Given PO
45847710|NCT02880228|Biological|Pembrolizumab|Given IV
45362277|NCT00622700|Drug|Teriflunomide|Film-coated tablet Oral administration
45362278|NCT00622700|Drug|Placebo|Film-coated tablet Oral administration
45362279|NCT00538473|Biological|GSK Biologicals' influenza vaccine GSK576389A|Single dose, intramuscular injection
45362280|NCT00538473|Biological|Fluarix™|Single dose, intramuscular injection
45362281|NCT04004091|Biological|Spermine|Spermine is a polyamine. It is an organic molecule that is involved in cellular metabolism and development.
45362282|NCT00990873|Genetic|gene expression analysis|
45362283|NCT00990873|Genetic|microarray analysis|
45362284|NCT00990873|Genetic|reverse transcriptase-polymerase chain reaction|
45362285|NCT00990873|Other|laboratory biomarker analysis|
45362286|NCT04025229|Behavioral|HIIT exercise|High intensity interval training (4 to 6 sessions) prior to surgery
45362287|NCT00831506|Drug|digoxin|digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
45362288|NCT00831506|Drug|digoxin|digoxin once daily (0.125 mg QD) for 14 days.
45362289|NCT00831506|Drug|dimebon|Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
45362290|NCT02816697|Other|CEASE|"Clinical and Community Effort Against Secondhand Smoke Exposure (CEASE)~CEASE is a system-level intervention that integrates tobacco-use screening, cessation assistance, and referral to outside services into routine visits"
45362291|NCT02816697|Other|Usual Care Tobacco Treatment Services|
45362292|NCT02548130|Other|MELD score|introduction of MELD score
45480102|NCT03606941|Device|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at bilateral sham HT7, PC6, DU20 and EX-HN3 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle until the end of surgery."
45480103|NCT05464108|Diagnostic Test|The diagnosis of Artificial Intelligence and endosopists|Endosopists and AI will assess the EGGIM score independently when the patients is eligible. In addition, they can not see the OLGIM score of the patients.
45362293|NCT00990951|Drug|Senna alexandrina and associations|"Drugs: Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub~1 tablet PO twice a day"
45362294|NCT00828620|Other|Imaging study|PET-CT
45480104|NCT01560611|Device|Near infrared spectroscopy|
45480105|NCT01334424|Drug|propofol|2-2.5 mg/kg for induction plus or not plus 2 mg/kg.h for maintenance
45480106|NCT04493008|Behavioral|Experimental: Educational session|Each patient will receive educational session consisting of face-to-face interview, administration of posters, brochures and pamphlets.
45480107|NCT03789227|Procedure|ganglion impar block|the patient will be in the prone position with a pillow under the abdomen The pre-injection planning images will be obtained using CT with 2 mm axial section thickness. Under aseptic technique, a skin wheal will be raised with 2 ml lignocaine 0.5% using 23 G needle either in midline or paramedian approach. After identifying the ganglion impar, usually at the level of the sacro-coccygeal disc, a 25 G, 9 cm long spinal needle will be introduced at approximately 6-9 cm from midline and a small amount of non-ionic contrast medium (0.5 ml iopamidol; 300 mg/ml) will be injected. The midline approach may be selected according to patient position and operative condition. In the midline approach the sacro-coccygeal disc is identified and needle will be introduced perpendicular through the disc and just encroaching upon presacro-coccygeal space. Thereafter, 3 ml lidocaine 2% will be injected, three minutes later 5 ml absolute alcohol 95%.
45688914|NCT03895450|Behavioral|Stretching Protocol|Participants will follow a stretching protocol for 30 minutes a day, 6 days a week. Individuals in the SP group will be given a booklet explaining a low-impact breathing and stretching program developed at the University of Buffalo. All stretches will explained and demonstrated by a member of the study team prior to commencement of the program. Stretches focus on lower extremity muscles. During the protocol HR should be low as to not exceed 50% of age predicted max. A HR monitor will be worn during stretching.
45362295|NCT02842359|Drug|Irbesartan/atorvastatin fixed dose combination|Pharmaceutical form:Tablet Route of administration: Oral
45480108|NCT05083637|Drug|L- carnitine oral solution|The L-carnitine syrup formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up
45480109|NCT05083637|Other|Placebo|The placebo formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up
45480110|NCT04492696|Other|Education|Education
45480111|NCT02178072|Drug|5-Azacitadine|
45688915|NCT04271722|Other|Cervical ripening|Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
45362296|NCT02842359|Drug|Irbesartan SR47436|Pharmaceutical form:Tablet Route of administration: Oral
45362297|NCT02842359|Drug|Atorvastatin|Pharmaceutical form:Tablet Route of administration: Oral
45362298|NCT00823784|Procedure|Transanal doppler hemorrhoidal ligation|THD technique involves identification and ligation of the terminal hemorrhoid arteries (about 6) followed by mucopexy
45362299|NCT00823784|Procedure|stapled hemorrhoidopexy|Staple hemorrhoidopexy involves resection of a ring of low rectal mucosa an lifting the hemorrhoids up in the anal canal with a stapled suture
45362300|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension fpor subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 1: 0.25 SPT"
45362301|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 2: 0.5 SPT"
45362302|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 3: 1 SPT"
45362303|NCT01564017|Biological|Allergovac depot|"depot sterile suspension for subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 4: 2 SPT"
45362304|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 5: 4 SPT"
45362305|NCT01564017|Biological|Allergovac depot|"Sterile suspension for subcutaneous injection.~Same number of administration as the active groups"
45362306|NCT00828698|Other|No intervention|
45362307|NCT02783625|Drug|Romidepsin|
45362308|NCT02783625|Drug|Bortezomib|
45362309|NCT02783625|Drug|duvelisib|
45362310|NCT04044014|Device|Gellan sheet|Gellan sheet.
45362311|NCT04044014|Device|Gellan fluid gel|Gellan fluid gel.
45480112|NCT03722251|Behavioral|Glucose beverage, control beverage, glucose beverage and active video game playing, control beverage and active video game playing|
45480113|NCT03319108|Other|Exercise|Pulmonary Rehabilitation Program for 8 weeks
45688916|NCT02102230|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This is a group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains.
45847711|NCT02880852|Drug|Belimumab|Belimumab will be provided as white uniform lyophilized cake in vials with unit dose strength of 400 mg/vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate) for reconstitution in 4.8 milliliter sterile water for injection (SWFI). Belimumab will be administered as 10 mg/kg intravenous infusion for over 1 hour on Day 0.
45362312|NCT04044014|Device|Mepitel One|Control dressing-- Mepitel One.
45480114|NCT01804998|Procedure|Laparoscopic Sentinel Node Biopsy|Laparoscopic Sentinel Node Biopsy or Stomach Preserving Surgery could be performed in the experimental arm.
45480115|NCT01804998|Procedure|Laparoscopy Assisted Gastrectomy|In the control arm, laparoscopy assisted gastrectomy with lymph node dissection (D1+ or more) will be performed.
46049520|NCT00673972|Radiation|gastric scintigraphy|"All tests start after overnight fast. Test meals consists of 120g scrambled egg, two slices of toasted bread, 30g of strawberry jam and 120ml of water. 12MBg (0.33mCi) of 99mTc sulfur colloid is mixed with egg thoroughly before the mixture cooked in a microwave oven for 2 minutes. All meals are prepared on the morning of examination and consumed within 20 minutes.~Anterior and posterior images of the gastric region are taken within one minute after completion of test meals. Subsequent images are taken every 2 minutes in the first 60 minutes and at 120 minutes and 180 minutes. One-min images of gastric region at upright position are taken in the 140keV 99mTc peak with a 20% window."
45362313|NCT00991107|Drug|HE3286|HE3286 20 mg (10 mg BID) for 28 days
45362314|NCT00828776|Biological|Heparin sodic - Cristália|5000UI/mL
45362315|NCT00828776|Biological|heparin - Liquemine (Roche)|5000UI/mL
45362316|NCT00622466|Drug|paclitaxel|The chemotherapy drug called paclitaxel (Taxol) treats breast cancer, lung cancer, ovarian cancer and Kaposis sarcoma
45362317|NCT00622466|Drug|sorafenib tosylate|Sorafenib is a type of targeted therapy known as a kinase inhibitor used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma
45362318|NCT02617251|Other|No intervention|
45362319|NCT04004247|Device|High Flow Nasal generator (AirVO2)|High Flow Nasal Oxygenation
45362320|NCT02550158|Procedure|Educational program EDU-MICI|
45362321|NCT04043858|Drug|Midodrine 2.5 mg tab|Patients receive an oral daily dose of 2.5 mg midodrine if age 7-12 years and receive 2.5 mg twice daily of more than 12 years
45362322|NCT05359419|Combination Product|aminolevulinic acid hydrochloride gel, 10%|10% ALA with Red Light
45362323|NCT05359419|Combination Product|aminolevulinic acid HCl topical solution, 20%|20% ALA with Blue Light
45362324|NCT00823862|Drug|SD-101|Intramuscular (IM)
45362325|NCT00823862|Drug|ribavirin|oral, 2 times per day, for 2 months
45362326|NCT00991263|Genetic|gene expression analysis|
45362327|NCT00991263|Genetic|polymerase chain reaction|
45362328|NCT00991263|Other|laboratory biomarker analysis|
45362329|NCT02548598|Procedure|Endoscopic sinus surgery|This is an observational trial of patients with and without asthma who have concomitant chronic rhinosinusitis requiring endoscopic sinus surgery.
45362330|NCT00828932|Drug|Lorcaserin|
45362331|NCT00537771|Drug|Anastrozole|1 mg once daily oral dose
45362332|NCT00537771|Drug|Tamoxifen|20 mg once daily oral dose
45688917|NCT02102230|Behavioral|Cognitive Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA)|This is a mobile-app-augmented, group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains. The mobile-app augmentation substitutes a smartphone-based sleep diary with time-stamping of records to mitigate the common postponement of diary recording and consequent loss of validity. The app also records the sleep prescription, making it, along with links to web-based psychoeducational materials, easily accessible to users. The app also provides plots of bed times, wake times, and sleep efficiency over time, with the goal of promoting adherence.
45688918|NCT02102230|Behavioral|Desensitization Treatment for Insomnia|"This is a group-delivered version of the sham sleep improvement treatment developed by Edinger which purports to desensitize the patient to the various aspects of the sleep experience which are presented as distressing."
45480116|NCT05664685|Drug|Optimized bismuth quadruple therapy|Scheme that have high dosage of amoxicillin, metronidazole and omeprazole, with bismuth. The rationale of this scheme is that in Chile, amoxicillin resistance is low, clinical metronidazole is low in the doses used and the high doses ob Proton Pump Inhibitor enhanced the antimicrobial drugs
45480117|NCT05664685|Drug|Control|Standard eradication therapy using omeprazole, clarithromycin and amoxicillin
45480118|NCT03321838|Behavioral|accommodative/vergence therapy|Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.
45480119|NCT03793517|Drug|Decitabine|Decitabine 200mg.m-2.d-1 intervanously on days -12 and -11
45480120|NCT03793517|Drug|mBU/CY and ATG|Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
45480121|NCT03793517|Drug|mBU/CY|hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3
45688919|NCT00300742|Drug|Topiramate|Topiramate up to 300 mg per day.
45362333|NCT00829088|Drug|AZD2066|1 dose oral solution
45362334|NCT00831740|Other|Speech and Language Therapy (SLT)|Participants randomised into the treatment arm will receive early SLT of up to three sessions per week for a maximum duration of 16 weeks. The SLT intervention has been developed by a team of expert Speech and Language Therapists according to 'Best Practice Standards'. The intervention procedure is manualised to allow replicability by other Speech Therapy Departments if it is shown to be effective.
45362335|NCT00831740|Other|Attention Control|Those in the attention control arm of the trial will receive similar levels of contact as those in the SLT arm. However contact will be with an ACT NoW Visitor who has no specific knowledge about communication therapy. They will provide empathy and spend time with the patient, without any input from Speech and Language Therapists.
45688920|NCT00301756|Drug|Belinostat|Given IV
45688921|NCT00301756|Other|Laboratory Biomarker Analysis|Correlative studies
45688922|NCT00302068|Behavioral|Supervised Aerobic Exercise|Supervised aerobic exercise, three times per week, for 16 weeks.
45362336|NCT00831896|Biological|TAK-701|"Either 2, 5, 10, or 20 mg/kg IV. Cycle 1: single dose at 2x the dose assignment; Cycle 2 and beyond: dose once every two weeks~Dosing continues until disease progression, unacceptable toxicity related to TAK-701, or maximum of 12 cycles, unless determined that patient would benefit from continued therapy."
45362337|NCT00823940|Drug|GSK1362885|5 - 100mg of GSK1362885 or placebo
45362338|NCT00823940|Drug|GSK1362885|100 - 600mg or placebo
45362339|NCT00823940|Drug|Glucagon|0.5mg IV bolus
46049521|NCT04152616|Other|Instrumental evaluation of posture|"After a time of installation of the Optitrack® device's and two accelerometers (one placed on the subject's trunk facing the sternum fixed with a headband and the second at the level of the head also held with a headband), the subject will perform an evaluation of the balance sitting on the sensor pad; the movements of the head and trunk will be analyzed by the Optitrack® device and by the two accelerometers.~The subject will perform 4 30-second tests, two with eyes open and two with eyes closed. A rest period may be taken between each assessment depending on the subject.~During these evaluations, a physiotherapist will be present to avoid the risk of falling.~After a rest period of 30 minutes, a new assessment of the sitting posture will be carried out to assess the reproducibility of the tools (sensor pad, accelerometers, Optitrack®)."
46049522|NCT04265352|Other|No intervension|There is intervention at all.
46049523|NCT04136080|Other|vasopressors|control the mean arterial pressure with vasopressors
46049524|NCT05380128|Genetic|Genotype analysis for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms|Genomic DNA was extracted from peripheral blood samples using a Wizard Genomic DNA Purification Kit (Promega, Madison,Wisconsin, USA) as per the product instruction. VDR (rs731236, rs1544410, rs7975232, rs2228570) polymorphisms were genotyped by the improved Multiple Ligase Detection Reaction (iMLDR) developed by Genesky Biotechnologies Inc. (Shanghai, China).
46049525|NCT00693862|Drug|levodopa, carbidopa, entacapone|
45362340|NCT00823940|Drug|Glucagon + GSK1362885|0.5mg Glucagon IV bolus + selected dose of GSK1362885
45362341|NCT03857828|Other|semen sample|• seminal sample for measuring clusterin level.
46049526|NCT00693862|Drug|levodopa, carbidopa|
45362342|NCT04043546|Behavioral|aerobic+resistance exercise training program|Personalized exercise program based on the inclusion testing and patient screening will be provided to the patient. The program will consist of a gradual walking program as well as a gradual resistance training program using therabands.
45362343|NCT00831974|Drug|masitinib (AB1010)|3 mg/kg/day
45362344|NCT00831974|Drug|masitinib (AB1010)|6 mg/kg/day
45362345|NCT00829322|Drug|Modafinil|Modafinil 100mg once daily for 14 days, increasing to 200mg once daily for a further 14 days
45362346|NCT00829322|Drug|Placebo|One capsule daily for 14 days, increasing to two capsules daily for 14 days
45362347|NCT00623480|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylaxis treatment includes three times per week administration of 25 IU/kg of Kogenate FS. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
46049527|NCT05377788|Drug|Lazertinib|Treatment of EGFR T790M mutant-positive local progressive or metastatic non-small cell lung cancer patients who have previously been treated with EGFR
45362348|NCT00623480|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Treated according to the Kogenate FS package insert indications and study physician recommendations
45362349|NCT02513667|Drug|Ceritinib|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months.
45362350|NCT02513667|Radiation|Stereotactic ablative body radiation|Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination).
45362351|NCT00829400|Behavioral|Cognitive Remediation|Brain Fitness, Insight, and Aristotle Cognitive Remediation Software Suites Targeting 100 hours of training
45362352|NCT00829400|Behavioral|Nintendo Brain Age|Brain Age 2 Software Nintendo DS Portable for home or office use Targeting 100 hours of training
45688923|NCT00302068|Drug|Sertraline|Sertraline (Zoloft), daily, for 16 weeks.
45845158|NCT02256072|Other|Plan Your Lifespan Website|Participants in the intervention arm will navigate the advance planning tool, Plan Your Lifespan, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating this website.The Plan Your Lifespan website is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
45362353|NCT00829478|Behavioral|Decision Aid for Atrial Fibrillation|Single contact educational session
45362354|NCT00829478|Other|Usual Care|Usual Care
45362355|NCT00991419|Drug|[18F]AZD4694|[18F]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.
45362356|NCT00829556|Device|Integuseal|
45688924|NCT00302068|Drug|Placebo Pill.|Placebo pill, daily, for 16 weeks.
45688925|NCT03212404|Drug|CK-301 (cosibelimab)|CK-301 will be administered in periods of 28-day cycles.
45688926|NCT00302848|Drug|Drospirenone|
45688927|NCT00302848|Drug|Levonorgestrel|
45688928|NCT00302848|Drug|Other progestin containing oral contraceptive|
45688929|NCT01791556|Other|HIV-1 viral load testing|
45688930|NCT00138034|Procedure|Percutaneous coronary intervention (PCI)|PCI with bare metal stent placement of the culprit lesion the in the infarct related artery
45688931|NCT00303862|Drug|cediranib maleate|Given orally
45688932|NCT00303862|Other|laboratory biomarker analysis|Correlative studies
45362357|NCT03823911|Drug|Elbasvir / Grazoprevir Oral Tablet [Zepatier]|All approved direct-acting antivirals for hepatitis C will be used as the intervention.
45362358|NCT03823911|Procedure|Cardiac MRI|Cardiac MRI to assess for myocardial function and fibrosis
45362359|NCT00829634|Drug|l-methamphetamine|5mg of l-methamphetamine per day throughout the 2 week study
45362360|NCT00829634|Drug|d-methamphetamine|15mg on Study Day 9, 30mg on Study Day 11, 45mg on Study Day 13
45362361|NCT05277753|Biological|Antigen-specific T cells CAR-T/CTL and DCvac|Antigen-specific T cells CAR-T/CTL and DCvac cells to treat T-ALL
45362362|NCT00824096|Procedure|Bronchoscopy|The patients in our ICU intubated for > 24h and met weaning criteria, will be examined by bronchoscopy. Five ㏄ blood will be collected for checking CRP and cytokines before performing bronchoscopy. The proposed grading of post-extubation vocal cord finding were shown (Figure 1). The patients will be classified to two groups (Figure 2). The first group is these patients without swelling or swelling area ≦50% who will be extubated after bronchoscopic examination. These patients will be followed for 48 hours to monitor the incidence of PES. The second group is those patients who develop laryngeal edema with swelling area ≧50% or swelling in the whole vocal cord. Bosmin 2 ml local injection and Solu-medrol 40 mg I.V. Q6h for 1~4 days will be given. Bronchoscopy will be done if CLV ≧24% or after treatments for 3~4 days even with CLV <24%. The above treatments will be applied again if stridor develops. Extubation will be performed if no presence of laryngeal edema.
45362363|NCT00991497|Device|Compression bandaging|Cotton wool padding will then be placed over the treated vein and secured in place by crepe bandaging. An above-knee TED stocking will be applied on top of this.
45362364|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 5 mg q12 hours for 7 days.
45362365|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 15 mg q12 hours for 7 days.
45362366|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
45362367|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
45362368|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 14 days. Actual dose may be adjusted downward based on pharmacokinetic and other data from prior dose cohorts.
45362369|NCT00824174|Behavioral|Questionnaire|1 questionnaire, about 15-20 minutes.
45362370|NCT04003467|Drug|EBP05|tablets
45480122|NCT03789149|Radiation|Intraoperative Radiotherapy|Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG) consisting of a small source of low energy x-rays (30-50 kV) mounted on a mechanical arm with six degrees of freedom. The resulting dose distribution is isotropic around the tip of the X-ray source. A set of spherical applicators with diameters ranging from 1.5 to 5 cm is available to connect to the source. The treatment time may vary from 20-30 minutes with the suggested dose of 18 Gy to the resection cavity to a depth of 1 mm.
45362371|NCT04003467|Drug|Placebo of EBP05|tablets
45688933|NCT00304096|Biological|synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine|
45688934|NCT05267392|Drug|Durvalumab|Patients will receive 1500 mg of durvalumab (MEDI4736) via IV infusion
45688935|NCT05267392|Other|standard of care RT/RCT|standard of care RT/RCT
45362372|NCT00832208|Drug|Liposomal amphotericin B (Ambisome)|21.0 mg/kg total dose. Given iv as 3mg/kg/day on days 1,2,3,4,5, and 14 and 21
45480123|NCT04493944|Behavioral|Culinary workshop|A 3-hour culinary workshop will be led by a chef. The aim of this workshop will be to develop participants' culinary skills related to the preparation and consumption of recipes based on seaweeds, through various practical activities in the kitchen (starter, main course, dessert). An evaluation questionnaire will be completed at the end of the workshop.
45688936|NCT00142168|Drug|CC-5103 (lenalidomide)|Taken orally once a day for 21 days followed by 7 days of no CC-5103 (lenalidomide)
45847712|NCT02886234|Behavioral|Mindfulness Training (MT)|Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. ). In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 15 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
45362373|NCT00832208|Drug|Liposomal amphotericin B (Ambisome)|liposomal amphotericin b given intravenously as single dose at 7.5 mg/kg increasing to 10, 12.5 and 15.0mg/kg depending on results of interim analyses.
45362374|NCT05361057|Drug|Venetoclax, Azacitidine|The patients were administrated with azacytidine 75 mg/m2 d1-7，venetoclax: 100mg d1, 200mg d2, 400mg d3-21;
45362375|NCT05361057|Drug|Venetoclax, daunorubicin, cytarabine|The patients were administrated with daunorubicin：45mg/m2 d1-2, cytarabine:100mg/ m2 d1-5, venetoclax: 100mg d1, 200mg d2, 400mg d3-14
45362376|NCT00832286|Drug|Ciprofloxacin|Licensed medication, dose: 500 mg every 12 hours for 3 days.
45362377|NCT00991653|Procedure|Fasting blood sample.|Fasting blood sample taken following informed consent for genotyping, glucose and insulin levels.
45362378|NCT00829946|Behavioral|Physical activity|Participants in the intervention group were enrolled in two training sessions per week for 12 weeks. The core portion of the training session consisted of 11 strength exercises engaging the major muscle groups, i.e. bench press, shoulder press, leg extension, leg press, leg curl, abdominal crunch, low back extension, arm curl, elbow extension, seated row and lateral pull-down. For each exercise, the participants performed one set of 8-15 repetitions (total of ~ 20s duration) with resting periods of 1-2 min between exercises. The load was gradually increased as the strength of each child improved, i.e. from 20-30% of 6 repetition maximum (6RM) at the start of the program to 50-60% of 6RM at the end. Participants also performed isometric contractions of large muscle groups (6 sets of 3 repetitions each, 20-30s duration per repetition) with their own body weight (for lower body exercises) or barbells (1-3kg) for upper body.
45362379|NCT02548520|Other|Blood and breastmilk samples|The investigators collected maternal and infants blood samples from birth, and 4 and 9 months forward, including breastmilk from the mothers at all visits
45362380|NCT04016792|Drug|Placebo|Placebo will be administered once daily
45362381|NCT04016792|Drug|200 mg SPN-812|200 mg SPN-812 will be administered once daily and compared to Placebo
45362382|NCT04044170|Drug|Poziotinib|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
45362383|NCT00832364|Drug|Acitretin (also called U0279)|Capsules containing 25 mg U0279 taken once a day.
45362384|NCT00832364|Drug|Placebo|Placebo capsules
45362385|NCT00832364|Biological|Etanercept|Injectable Biologic
45362386|NCT00832442|Drug|Beta blocker|as determined by individual study
45362387|NCT00832442|Other|Placebo|in addition to usual care
45362388|NCT00824330|Behavioral|Control Phase; Exercise Phase|After the completion of the control phase and at the start of the titration phase of the study, participants will be given pedometers and log books, then contacted on a regular basis to help insure compliance with the goal of walking 10,000 steps per day.
45480124|NCT03789071|Diagnostic Test|External ultrasound evaluation of the airway|Patients scheduled to have surgery under general anesthesia in whom tracheal intubation is planned, will have a clinical and ultrasound assessment of the airway before surgery. Information regarding laryngoscopy in the operating room will be recorded.
46049528|NCT00631254|Procedure|Allergen challenge|"Conventional allergen challenge: increasing allergen doses given by nebulisation through the mouth and stopped when a 20% fall in forced expiratory volume in one second is obtained.~Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
46049529|NCT00631254|Procedure|Allergen challenge|"Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
46049530|NCT02624206|Dietary Supplement|Juice A|Subjects to be given juice daily for 3 weeks.
45362389|NCT00830414|Drug|medroxyprogesterone acetate|IM Injection
45362390|NCT00830414|Drug|medroxyprogesterone acetate|IM injection
45362391|NCT00830492|Drug|clomiphene citrate|100 mg from cycle day 3 through 7
45362392|NCT00830492|Procedure|Ultrasound|cycle day 8
45362393|NCT00830492|Drug|GnRH antagonist|Daily, started with dominant follicle greater than 14 mm (Ganirelix , Organon, Netherlands).
45362394|NCT00830492|Drug|gonadotopin (HMG)|75 IU human menopausal gonadotropin (Menogon, ferring, pharmacenticals , Germany)
45480125|NCT02490748|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
45480126|NCT02490748|Biological|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
45480127|NCT02886702|Drug|Tazarotene Cream 0.05%|Tazarotene Cream 0.05% to cover only the lesions with a thin film.
45480128|NCT02886702|Drug|TAZORAC® (tazarotene) Cream 0.05%|TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.
45480129|NCT02886702|Drug|Placebo|Placebo (vehicle of the test product) to cover only the lesions with a thin film.
46049531|NCT02624206|Dietary Supplement|Juice B|Subjects to be given juice daily for 3 weeks.
45362395|NCT00830492|Drug|buserelin|Buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg.
45362396|NCT00830492|Drug|rFSH|150-225 IU recombinant FSH (r_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
45362397|NCT00830570|Other|CYP 2C9 and VKORC1 Testing for Warfarin|Test patients for their warfarin sensitivity and provide this information to their physician authorizing the test.
45362398|NCT00837356|Drug|Advate®|Subjects will receive Advate® at a dose of 50 IU/kg body weight in the first session
45362399|NCT00837356|Drug|turoctocog alfa|After a washout period of 4 days, subjects will subsequently receive turoctocog alfa (recombinant factor VIII (N8)) at a dose of 50 IU/kg body weight in the second session
45362400|NCT04472000|Drug|Vitamin C|Study participants in the verum group receive one capsule of Burgerstein Vitamin C retard 500mg b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.
45362401|NCT04472000|Drug|Placebo|The placebo group receives one placebo capsule b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.
45362402|NCT00832754|Device|RDT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
45362403|NCT00832754|Other|Clinical Judgement as basis for treatment of malaria with ACT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
45362404|NCT00824486|Behavioral|Injury prevention education (TIPP)|using TIPP materials
45362405|NCT00824486|Behavioral|Injury prevention education (safe home)|using safe home model
45362406|NCT00832832|Other|Eyelid closure|Eyelid will be closed after eye drop instillation
45362407|NCT00832832|Other|No intervention will be assigned|No intervention will be assigned to this arm
45362408|NCT00824642|Device|Transcutaneous electrical nerve stimulation (TENS)|Applied 45 minutes prior to exercise
45688937|NCT00142168|Drug|Rituximab|Begins on week 2 of treatment and is given intravenously once a week for 4 weeks
45688938|NCT02501434|Drug|Continuous Low-Dose IV Unfractionated Heparin Infusion|Continuous intravenous infusion of a low-dose unfractionated heparin drip
46049532|NCT04135924|Other|Rehabilitation|physical exercise and respiratory muscle training
45362409|NCT00824642|Device|placebo|placebo TENS applied prior to exercise
45362410|NCT00837746|Drug|risedronate|risedronate tablet, 5 mg daily or 35 mg once weekly for 5 years
45688939|NCT02247232|Drug|Z-100|
45688940|NCT02247232|Drug|Placebo|
45688941|NCT01791634|Procedure|proximal chevron osteotomy|
45688942|NCT01791634|Procedure|proximal open wedge osteotomy with LPS system|
46049533|NCT05379894|Procedure|Percutaneous nephrolithotripsy|Extraction of kidney stones through skin using nephroscope
46049534|NCT00607776|Drug|(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400|Drops
45688943|NCT02159560|Device|Epidural catheter|The intervention is the use of an end-holed epidural catheter or three-holed side port epidural catheter
46049535|NCT00607776|Drug|Systane|Drops
46049536|NCT00674050|Drug|Technosphere Insulin (TI) Inhalation Powder|3.0 U of human insulin. 5 or 10 mg or Technosphere Inhalation Powder, containing 15 0r 30 U of insulin.
46049537|NCT00674050|Drug|Albuterol (Salbutamol)|2 puff= 200ug total dose
46049538|NCT00674050|Drug|Fluticasone|2 puffs= 500ug total dose
45688944|NCT05267314|Device|pharyngeal exerciser + standard therapy|Use of Pharyngeal exerciser
45688945|NCT01594372|Procedure|Laparoscopic supracervical hysterectomy with sacropexy|Will involve laparoscopic entry to the abdomen to remove the uterus and suspension of the cervix and vaginal cuff to the sacrum with mesh. We will allow surgeons to conduct the surgery as they have perfected it
46049539|NCT04267458|Other|evaluation of sofuspovir containing DAA regien expected insult on kidney|to use different kidney biomarkers to evaluate acute kidney damage after using sofuspovir containing DAA regimen in treatment of HCV
46049540|NCT02628652|Dietary Supplement|GOS|
46049541|NCT02628652|Dietary Supplement|GLOS|
46049542|NCT02628652|Dietary Supplement|FOS|
45362411|NCT04043702|Drug|The intervention being studied|Intervention Other Names have not been specified
45362412|NCT00832988|Other|VentricularAutoCaptureTM & ACapTM Confirm|The testing algorithms allow the device to display threshold measurements at time of device interrogation. These will be evaluated against manual testing results.
45362413|NCT02550080|Drug|Dapsone|For the HLA-B*1301 positive subjects, dapsone will not be administrated.
45362414|NCT02550080|Genetic|HLA-B*1301|The prospective genetic screening group will be tested before administrating dapsone
45362415|NCT00833066|Biological|gpASIT+TM|entero-coated capsules containing 25µg of gpASIT+TM
45480130|NCT03498313|Drug|Transdermal Estradiol + Placebo|.1mg/24hr transdermal estradiol for 14 days starting day 7 after positive urine luteinizing hormone test, plus twice daily placebo pills during the same time frame.
45688946|NCT01594372|Procedure|Vaginal hysterectomy with uterosacral colposuspension|Will involve removing the uterus vaginally followed by suspending the vaginal cuff to the high (proximal) uterosacral ligaments bilaterally restoring the vagina to its normal axis.
46049543|NCT04152460|Device|Viscalor Bulk (VOCO,Cuxhaven)|Viscalor Despenser (Preheating dispenser for composite Viscalor Bulk Caps)
46049544|NCT04152460|Other|Grandioso x-tra|Nanohybrid Bulk Resin Composite
46049545|NCT00872170|Drug|Sildenafil|"Participants will receive sildenafil for 12 weeks with the following therapy:~50 mg of oral sildenafil three times a day (TID) increased to 100 mg TID as tolerated in adults and children greater than 50 kg; 1 mg/kg sildenafil TID without dose escalation in children less than 50 kg"
46049546|NCT00936702|Drug|carboplatin|Given IV
46049547|NCT00936702|Drug|everolimus|Given PO
45362416|NCT00833066|Biological|Placebo|placebo entero-coated capsules
45362417|NCT00833066|Biological|gpASIT+TM|entero-coated capsules containing 100µg of gpASIT+TM
45362418|NCT00833066|Biological|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM
45362419|NCT02547272|Procedure|Nasal and rectal bacterial samples|Bacterial nasal and rectal samples at admission and one weekly for the presence of S Aureus
45362420|NCT00838058|Drug|CE-224,535|one 250mg tablet, once in the morning in fasted state
45362421|NCT00838058|Drug|CE-224,535|2x250 mg tablets, once in the morning, in fasted state
45362422|NCT00838058|Drug|CE-224,535|4x250mg tablets, once in the morning, in fasted state
45362423|NCT00838058|Drug|CE-224,535|2x250mg tab, once in the morning, after being fed a high fat meal
45362424|NCT00838058|Drug|CE-224,535|4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
45362425|NCT00838058|Drug|CE-224,535|4x125 mg IR once in the morning after being fed a high fat meal
45362426|NCT00838058|Drug|CE 224,535|2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state
45362427|NCT00838058|Drug|CE 224,535|2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal
45362428|NCT02550392|Behavioral|Psychoeducation|A time-limited group psychoeducational intervention that will aim to offer educational, psychological and social support.
45362429|NCT02547350|Drug|pharmorubicin or pirarubicin|pharmorubicin 50mg pirarubicin 30mg
45362430|NCT00838214|Drug|budesonide|3mg capsule, 3x per day for 6 months
45362431|NCT00838214|Drug|prednisone|5mg tablet, 40mg starting dose per day, titration to 10mg per day within 3 months
45362432|NCT00621764|Biological|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 Plaque forming units (PFU), Subcutaneous (SC; Day 0); 0.5 mL intramuscular (IM; Day 28)
45362433|NCT00621764|Biological|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
45362434|NCT00621764|Biological|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 PFU SC (Day 0); 0.5 mL IM (Day 28)
45480131|NCT03498313|Drug|Oral Micronized Progesterone + Placebo|100mg oral micronized progesterone twice daily for 14 days starting day 7 after positive urine luteinizing hormone test, plus weekly application of a placebo patch during the same time frame.
45480132|NCT03498313|Drug|Placebos|Twice daily placebo pills for 14 days starting day 7 after positive urine luteinizing hormone test, plus weekly application of a placebo patch during the same time frame.
45688947|NCT00147316|Drug|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
46049548|NCT00936702|Drug|paclitaxel|Given IV
46049549|NCT00693940|Behavioral|Group mediated cognitive behavioral (GMCB) sessions|GMCB will include weekly group exercise sessions, lasting approximately 60 to 75 minutes each for a 6 month period. During these sessions, participants will be asked to exercise by walking around a track. There will also be a group discussion, led by a facilitator, who will help participants find ways to increase the frequency of their walking exercise at home. After completing the GMCB sessions, which will last about 6 months, participants will be telephoned regularly by a study coordinator for another 6 months.
46049550|NCT00693940|Other|Health education sessions|Health education will include weekly educational sessions on a health-related topic, lasting approximately 60 minutes each. After completing the health education sessions, which will last about 6 months, participants will be telephoned regularly by a study coordinator for another 6 months.
45845159|NCT02256072|Other|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating the website. The website is interactive and comparable to the intervention tool: http://go4life.nia.nih.gov/get-started).
45845160|NCT02258256|Device|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
45362435|NCT00621764|Biological|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
45362436|NCT00838292|Dietary Supplement|fortified blended flour - Insta Foundation Plus (with whey protein concentrate)|300 grams/day for 6 months
45362437|NCT00838292|Other|nutrition counseling|
45362438|NCT00838370|Drug|Capecitabine, 5-fluorouracil|"Patients to treat with capecitabine/5-FU will be screened prior to start of therapy for DPYD*2A. Patients heterozygous or homozygous mutant for DPYD*2A receive dose reductions of capecitabine/5-FU of at least 50% in the first two courses. In case this dose is tolerated well, doses will be increased.~In addition, the pharmacokinetics of capecitabine/5-FU and their metabolites will be assessed in these patients."
45362439|NCT00838448|Behavioral|Exercise|Exercise performed on a treadmill for 20-30 minutes
45362440|NCT00510718|Drug|MDV3100|MDV3100 daily until progression or dose-limiting toxicity
45362441|NCT00537381|Drug|Docetaxel|Docetaxel 75 mg/m^2 as intravenous infusion every 3 weeks.
45362442|NCT00537381|Drug|Prednisone|Prednisone 5 mg orally twice daily.
45362443|NCT00537381|Biological|Intetumumab|Intetumumab 10 mg/kg as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
45362444|NCT00537381|Drug|Placebo|Placebo matching to intetumumab, as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
45688948|NCT00148798|Drug|cetuximab + cisplatin + vinorelbine|cetuximab given as an intravenous (i.v.) infusion every week (400mg/m^2 initial dose and 250mg/m^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
45688949|NCT00148798|Drug|cisplatin + vinorelbine|cisplatin 80mg/m^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
45688950|NCT00148954|Device|VITALITY 2 Implantable Cardioverter Defibrillator|VITALITY 2 ICD
45688951|NCT00148954|Device|Medtronic Implantable Cardioverter Defibrillator|Maximo, Marquis, Intrinsic, Virtuoso, or Entrust ICD
45362445|NCT00833300|Drug|Haloperidol|"2.5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40mg in 24 hours.~Reassess in 24 hours.~Delirium absent - Continue dose for 24 hours then discontinue.~Delirium present - Increase dose 5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40 mg in 24 hours.~Reassess in 24 hours.~Delirium absent - Continue dose for 24 hours then discontinue.~Delirium present - Discontinue current drug therapy and select one of:~Quetiapine up to 100 mg/day~Risperidone up to 6 mg/day~Loxapine up to 50 mg/day~Methotrimeprazine up to 75 mg/day~Reassess in 24 hours.~Delirium absent - Continue for 24 hours then discontinue.~Delirium present - Treatment at discretion of attending physician."
45362446|NCT00833300|Drug|Olanzapine|"2.5 mg-10 mg po/ng/og bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~Reassess in 24 hours.~Delirium absent - Continue dose for 24 hours then discontinue.~Delirium present - Increase dose 5 mg-10 mg bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~Reassess in 24 hours.~Delirium absent - Continue dose for 24 hours then discontinue.~Delirium present - Discontinue current drug therapy and select one of:~Quetiapine up to 100 mg/day~Risperidone up to 6 mg/day~Loxapine up to 50 mg/day~Methotrimeprazine up to 75 mg/day~Reassess in 24 hours.~Delirium absent - Continue for 24 hours then discontinue.~Delirium present - Treatment at discretion of attending physician."
45362447|NCT00833378|Drug|Eltrombopag|Eltrombopag 100 mg single oral dose
45688952|NCT00149734|Drug|Ondansetron followed by placebo|Participants will take 16mg of ondansetron daily for the first three months followed by 3 months of placebo. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
45845161|NCT02258412|Drug|hand antiseptic with CHG and alcohol|HCWs will be randomized to use one product on one day and the other product on another day at least 3 days apart. Each product will be applied using 1 pump from its dispenser and rubbed over the hands until dry. Gloves will be worn while the HCW is in the patient room. Upon exit from the room, HCW will washoout with that same product. One imprint will be made of the non-dominant hand onto media containing neutralizers. That hand will be gloved with a white cotton glove. The HCW will work in the common areas with timing recorded. Upon leaving the common area, the dominant ungloved hand will be imprinted onto a fresh media plate containing neutralizers.
45845162|NCT02258412|Drug|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day
45845163|NCT02260440|Drug|Pembrolizumab|Pembrolizumab will be given at 200 mg every 21 days
45362448|NCT00833378|Drug|Lopinavir/Ritonavir|Lopinavir/Ritonavir 400/100 mg oral dose given twice a day for 14 days
45362449|NCT00833378|Drug|Eltrombopag and Lopinavir/Ritonavir|Elrombopag 100 mg single oral dose and Lopinavir/Ritonavir 400/100 mg oral dose given in the AM and PM
46049551|NCT05298904|Diagnostic Test|Genetic Health Screen Panel|This panel covers cardiomyopathy genes, and cancer genes. The results of this panel are reported as Positive (pathogenic or likely pathogenic mutation identified in one or more genes) or Negative (no pathogenic/likely pathogenic mutations identified).
45362450|NCT05359341|Drug|Sitagliptin 50 mg|Adding on sitagliptin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
45362451|NCT05359341|Drug|Empagliflozin 12.5 MG|Adding on empagliflozin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
45362452|NCT05359341|Drug|Sitagliptin 50 mg + Empagliflozin 12.5 MG|Adding on another 12 weeks of therapy of empagliflozin to sitagliptin 50mg group not well controlled (HbA1c 7-10%)
45688953|NCT00149734|Drug|Placebo followed by Ondansetron|Participants will take placebo daily for the first three months followed by 3 months of 16mg of ondansetron daily. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
45688954|NCT00198328|Combination Product|Medpulser Electroporation with Bleomycin|Patients receive injections of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area followed by electroporation.
46049552|NCT02623894|Other||No intervention study is an observational study
45362453|NCT05359341|Drug|Empagliflozin 12.5 MG + Sitagliptin 50 mg|Adding on another 12 weeks of therapy of sitagliptin 50mg to empagliflozin group not well controlled (HbA1c 7-10%)
45362454|NCT00824954|Procedure|ECP (performed on Themos UVAR-XTS or external UVA irradiator after cell collection by apheresis)|ECP (performed on Thermos UVAR-XTS or external UVA irradiator after cell collection by apheresis)
45362455|NCT05398731|Other|Covid_19|Duration, type of response, and the time period between the begining of drug and the emergence of symptoms of COVID-19
45362456|NCT00838760|Drug|TMC558445; TMC310911; Darunavir; Placebo|
45362457|NCT05384301|Other|Urban Afforestation Program|An afforestation program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
45362458|NCT00825032|Procedure|comprehensive PR|Inpatient comprehensive PR program that lasted lasted 3 weeks and included a minimum of 15 daily sessions of specific training for lower extremities, education, nutritional intervention, psychosocial intervention. It complied with the recommendation of the ATS/ERS.
45362459|NCT00825032|Procedure|UEET|Experimental program consisting of 15 additional daily sessions of unsupported UEET.
45362460|NCT05380089|Other|Increasing water intake|Participants randomly assigned to the experimental group will be instructed to maintain habitual solid food choices and to increase water intake to achieve a total water intake of ≥45ml/kg/day.
45362461|NCT03791398|Drug|Dose level 1 ONC201 625mg|ONC201 625mg + Nivolumab 240mg IV flat dose
45362462|NCT03791398|Drug|Dose level 2 ONC201 500mg|ONC201 500mg + Nivolumab 240mg IV flat dose
45362463|NCT03791398|Drug|Dose level 3 ONC201 375mg|ONC201 375mg + Nivolumab 240mg IV flat dose
45362464|NCT00838838|Drug|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients > 18yrs in medical practices fulfilling all criteria for documentation.
45688955|NCT00198328|Procedure|Surgical Excision|Patients have their tumor surgically removed.
45362465|NCT00838994|Other|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
45362466|NCT05360979|Drug|envafolimab|Envafolimab: 300 mg, D1, Q3W, subcutaneously administered
45362467|NCT00991731|Behavioral|Faith-based|The faith-based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered with biblical references to further guide the participants.
45362468|NCT00991731|Behavioral|Non-faith-based|The non-faith based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered without biblical references as in the faith-based intervention.
45362469|NCT00833534|Biological|rituximab|Given IV
45362470|NCT00833534|Drug|lenalidomide|Given orally
45362471|NCT05356377|Drug|Pegvaliase-Pqpz|Participants will have been prescribed pegvaliase-pqpz (Palynziq) by their primary metabolic care providers as part of their standard care. [Note that prescription and standard care are independent of the present study.]
45688956|NCT00305578|Drug|Memantine|Memantine will be given orally. Subjects will be started at a dose of 5 mg for the first week and then increased by 5 mg every week up to a maximum of 20 mg depending on response and tolerance and will be kept at that level for the rest of the study. This is an 8 week study.
45688957|NCT00305578|Drug|Placebo|No active medication, only placebo
45688958|NCT01790074|Other|TrP therapy|TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
45688959|NCT01790074|Other|TrP manual control therapy|The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
45362472|NCT00833612|Device|Counterpulsation with IAB|IABC pre-reperfusion PCI
45688960|NCT01492101|Drug|NKTR-102|145 mg/m2 NKTR-102 will be delivered q21day as a 90-minute intravenous (IV) infusion on day 1 of each treatment cycle.
45688961|NCT01492101|Drug|Treatment of Physician's Choice (TPC)|"One of the following Treatment of Physician Choice will be administered per standard of care:~eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel"
45362473|NCT05591001|Drug|ketamine and dexmeditomidine combination|Dexmedetomidine( 0.4 -0.6 μg/.kg /.hr)) ketamine,( 1 -2m/.kg/.hr) infusion
45362474|NCT05591001|Drug|Propofol|propofol (100 ug /kg/min) infusion
45362475|NCT00517192|Drug|Tipranavir|
45362476|NCT00517192|Drug|Darunavir|
45362477|NCT00517192|Drug|Ritonavir|
45688962|NCT01468311|Procedure|Auto stem cell transplant|Auto stem cell transplant (ASCT) is given after 90Y-daclizumab
46049553|NCT00696046|Procedure|Intrabone Marrow Injection|Cord blood CB units will be thawed in a 37° CB cells will be resuspended in 20ml salinesolution + dextran/albumin, and aliquoted in 4 syringes of 5ml Pts were prepared in a surgical & steril room The anaesthesia consist in a short propofol sedation The injection will last 8-15 minutes. 1° sedation is established, a standard needle for bone marrow aspiration (14 gauge) was inserted few cms in the supero-posterior iliac crest then, an aspiration of about 0.5-1 ml will be performed to assess that the needle was securely introduced in the bone marrow cavity After, we will insert the syringe containing 4-5ml of CB cell suspension which will be gently infused This procedure will be then repeated for all the remaining aliquots at a distance of 2-3cm from the previous one following the iliac crest
46049554|NCT00674518|Behavioral|One on one counseling|Motivational Interviewing
45362478|NCT05283369|Device|Videogame therapy|The usual dose of conventional physical therapy, plus 300 minutes a week of in-home videogame therapy for 8 weeks.
45362479|NCT05283369|Other|Conventional therapy|The usual dose of physical and occupational therapy, for 8 weeks.
45362480|NCT00625820|Drug|6R BH4|400 mg 6R BH4 oral BID for 6 weeks then 400 mg of 6R BH4 for another 6 weeks in all arms
45362481|NCT00625820|Dietary Supplement|Vitamin C|500 mg Vitamin C oral BID for another 6 weeks
45362482|NCT00145327|Drug|Zoledronic Acid|Zoledronic Acid 5 mg in 100 mL physiologic 0.9% normal saline for intravenous infusion.
45362483|NCT00145327|Drug|Placebo|100 mL physiologic 0.9% normal saline for intravenous infusion.
45362484|NCT05408793|Device|Transcranial Pulse Stimulation|A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on autism symptoms.
45362485|NCT00833768|Drug|Sevelamer carbonate|800mg tablets to be taken orally with meals three times per day
45362486|NCT00833768|Drug|Placebo for sevelamer carbonate|Placebo tablets to be taken orally with meals three times per day
45480133|NCT02569229|Other|Diagnostics for glucose tolerance with 3 different methods.|"A 7-day course of subcutaneous continuous glucose monitoring system (CGMS).~An oral glucose tolerance test done within the 7 day period of CGMS.~Optionally a intravenous glucose tolerance test done within the 7 day period of CGMS."
45480134|NCT04494022|Diagnostic Test|contrast enhanced ultrasound|Perflubutane enhanced ultrasound for evaluating hepatic tumor
45688963|NCT01468311|Drug|BEAM|BCNU, etoposide, cytarabine and melphalan (BEAM) chemotherapy are given after 90Y-daclizumab
45688964|NCT01468311|Radiation|111In-daclizumab|111In-daclizumab will be administered to patients with each therapeutic infusion of 90Y-daclizumab in order to define the distribution of radiolabeled daclizumab, and to allow visualization by scans.
45688965|NCT01468311|Radiation|90Y-daclizumab|90Y-daclizumab administered with a fixed dose of pentetate calcium trisodium (Ca-DTPA) followed by BEAM Chemo and Auto stem cell transplant
45845164|NCT02260440|Drug|Azacitidine|Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days.
45845165|NCT02262078|Drug|Sodium Nitrite Inhalation Solution|90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.
45362487|NCT01009606|Other|Usual strategy|Usual strategy
45362488|NCT01009606|Other|Modified strategy|Proposition to a relative to witness the cardiopulmonary resuscitation of a family member and debriefing ot the situation
45362489|NCT05590611|Other|Dietary Intervention with Brown Bread|The participants in this group will be asked to replace all their habitual bread intake by standard brown bread. The duration of the study for each participant is 4 weeks. Apart from the change in type of bread, participants will maintain their habitual diet.
45362490|NCT05590611|Other|Dietary Intervention with Sourdough Bread|The participants in thisgroup will be asked to replace all their habitual bread intake by wholemeal sourdough bread. The duration of the study for each participant is 4 weeks. Apart from the change in type of bread, participants will maintain their habitual diet.
45362491|NCT05358405|Other|Müller maneuver|The Müller maneuver allows maximum inspiratory pressure measurement via a one-way valve connected to the intubation tube and is currently used in routine care for diaphragmatic assessment. Ventilation through the one-way valve results in forced inspiration for about 20 seconds. The endothoracic depression induced by this test is likely increasing venous return and cardiac output in patients with preload reserve, i.e. in preload-dependent patients. The observation of an increase in cardiac output during a Müller maneuver could reflect the existence of a dependent preload state, i.e. with a reserve of preload, and de facto lower risk of pulmonary oedema. This test would be an easy alternative to the passive leg raising test used in current practice to evaluate the preload dependency and the risk of weaning induced pulmonary edema.
45362492|NCT05590533|Other|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the F-2-MS
45688966|NCT00306202|Drug|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m^2; Escalated/Dose Level 2 of 80 mg/m^2. Once daily (QD), as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment > 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after end-of-treatment (EOT)."
46049555|NCT00674518|Behavioral|Group/team - based health education|peer led, scripted health promotion curriculum in groups of 4-5 individual, with team building activities and health education for 12, 1-hour sessions per year.
46049556|NCT00674518|Behavioral|PACE physician counseling|PACE format for physician exercise and nutrition counseling annually.
46049557|NCT00607854|Drug|Ibritumomab Tiuxetan (Zevalin)|"Conditioning regimen followed by allogeneic hematopoietic stem cell transplantation.~Ibritumomab Tiuxetan(Zevalin): 0.4 mCi/kg IV at day -14 (Day 0 is the transplantation)"
46049558|NCT00694174|Drug|sucrose 24% oral solution|sucrose 24% oral solution 2 ml one time only dose administered by mouth prior to heel lance
46049559|NCT00694174|Drug|sterile water|sterile water 2 ml single dose to be administered orally one time prior to heel lance
46049560|NCT00607932|Behavioral|behavioral dietary intervention|
46049561|NCT00607932|Dietary Supplement|Brassica vegetable|
46049562|NCT00607932|Drug|indole-3-carbinol|follow up at 2,4,6 months post baseline.
46049563|NCT00607932|Other|counseling intervention|2, 4, 6 months post baseline
46049564|NCT00607932|Other|medical chart review|2,4,6 months post baseline
46049565|NCT00607932|Other|questionnaire administration|
46049566|NCT00607932|Procedure|adjuvant therapy|
46049567|NCT00674596|Drug|ramipril|ramipril 10 mg/day during 3 months
46049568|NCT00674674|Drug|Topotecan|"Induction (4 weeks): Patients will receive IT topotecan for 5 consecutive days during weeks 1 and 3.~The Induction period is the first 4 weeks of therapy."
46049569|NCT00674674|Drug|Topotecan|Consolidation (6 weeks): Patients will receive IT topotecan for 5 consecutive days during weeks 1 and 4. The Consolidation period is 6 weeks in duration. Consolidation begins immediately after completion of the 4th week of Induction.
46049570|NCT00674674|Drug|Topotecan|Maintenance (4 weeks for 11 courses): Patients will receive IT topotecan for 5 consecutive days during week 1. Each course of Maintenance is 4 weeks in duration. Maintenance begins immediately after completion of the 6th week of Consolidation.
46049571|NCT00606996|Behavioral|Group interpersonal psychotherapy (IPT-G)|
46049572|NCT00606996|Behavioral|Psychoeducation on co-occurring disorders (PSYCHOED)|
46049573|NCT02628730|Device|PVI using ThermoCool® SmartTouch® Catheter|PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index.
45362493|NCT00510484|Drug|Pancrelipase Delayed Release|24000 unit Capsule
45480135|NCT05464121|Behavioral|• Blended treatment for AjD combining a self-applied Internet-based program (TAO) with face-to-face sessions via videoconference.|"The self-applied Internet-based program called TAO is accessible online from the platform https://psicologiaytecnologia.labpsitec.es. It is organised into 7 sequential modules of approximately 60 minutes. The patient will do a treatment module every 10-12 days, plus an individual session via videoconference with a therapist (approximately 20-30 minutes long). During these sessions, the therapist will explain the main contents of each module, resolve doubts and motivate the patient to continue with the therapy. It takes about 12 weeks to complete the intervention.~TAO is the optimised version of the original intervention protocol for AjD developed by Botella et al. by Botella et al. (2008) and includes the following therapeutic components: psychoeducation, emotion regulation techniques, exposure, problem-solving techniques, Mindfulness, acceptance and elaboration of the stressful event, positive psychology strategies and relapse prevention."
45362494|NCT00510484|Drug|Placebo Comparator|Placebo
45362495|NCT00839228|Drug|Perhexiline|100mg o bd for 3 months
45362496|NCT00839228|Drug|Placebo|Placebo one tablet bd for 3 months
45362497|NCT05408637|Device|Transcranial Phoobiomodulation (tPBM)|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
45362498|NCT00839384|Device|Advisa IPG|Implantable Pulse Generator will be implanted
45362499|NCT05408481|Diagnostic Test|Serum cortisol level|Biochemical test
45480136|NCT03721081|Drug|Lidocaine 1%/Epi 1:200000|Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Lidocaine 1%/Epi 1:200000 Inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
45845166|NCT02262078|Other|Placebo|Normal saline will be administered (by inhalation) to participants prior to exercise.
45362500|NCT00839462|Drug|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
45362501|NCT00839462|Drug|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
45362502|NCT05590221|Biological|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
45362503|NCT05590221|Drug|Fludarabine|Administered according to package insert
45362504|NCT05590221|Drug|Cyclophosphamide|Administered according to package insert
45688967|NCT00306202|Drug|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m^2; Escalated/Dose Level 2 of 80 mg/m^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment > 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
45362505|NCT01009996|Procedure|Kissing DEB|Provisional bare metal stenting followed by kissing drug-eluting balloons
45362506|NCT05590143|Drug|Dapagliflozin 10 MG Oral Tablet [Farxiga]|One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).
45362507|NCT05590143|Drug|Placebo|One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).
45362508|NCT01789983|Behavioral|Walk With Ease Program|"The primary activity required of study subjects is a 6-week self-directed (non-group) WWE walking program that study participants do at a place and time that is convenient for them. To start the intervention/program, we schedule a brief baseline meeting with study participants to discuss the program, provide the WWE workbook, secure printed informed consent, and complete various questionnaires. Study participants are also asked to maintain a daily walking diary that is provided to them.~The WWE program includes a workbook with strengthening and stretching exercises, basic facts about arthritis and PA, and information on how to individualize the program."
45362509|NCT01789983|Other|Collect Blood, GA and Other Survey Tools|"Geriatric Assessment (GA) (Version 5)~Functional Assessment of Cancer Therapy-General (FACT)~Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue36~Outcome Expectations for Exercise (OEE) scale29~Self-Efficacy to Manage Arthritis or Joint Pain (ASE/Arthritis Self-Efficacy)~Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM)34,35~Visual Analog Scales (VAS)~Surveys included in study are listed above. Whole Blood Sample will be collected for p16 analysis."
45362510|NCT00622388|Drug|Ofatumumab|8 weekly intra-venous (i.v.) infusions, 1 x 300mg and 7 x 1000mg
45362511|NCT01156389|Drug|Ritonavir and Pyramax|100 mg ritonavir (one soft gelatin capsule twice per day over 17 days, the evening capsule on day 1 will be omitted) and Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
45362512|NCT01156389|Drug|Pyramax|Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
45845167|NCT02267226|Drug|Octafibrin|
45845168|NCT02267382|Drug|VT-1161|
45845169|NCT02267382|Drug|Placebo|
45362513|NCT04043624|Drug|Lidocaine|regimen of lidocaine administration of 1.5 mg/kg, IV bolus, followed by continuous infusion at 2 mg/kg/h
45362514|NCT04043624|Drug|Saline|IV bolus of saline, followed by continuous infusion of saline
45362515|NCT01105767|Drug|Chlorhexidine gluconate|Self applied chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) once a week to wash/cover the body (except the face and genitalia).
45362516|NCT01105767|Other|Supplemental training, education and hygiene|Supplemental SSTI education for trainees and drill sergeants included pocket cards and posters. Drill sergeants received briefings on SSTI and skin inspection/minor wound care. Trainees were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit.
45362517|NCT00834002|Biological|injection of antigen-loaded cultured dendritic cells|intradermal injection of WT1-RNA-electroporated autologous dendritic cell vaccine (therapeutic cell vaccine)
45688968|NCT00306202|Drug|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m^2; Escalated/Dose level 2 of 80 mg/m^2, Escalated/Dose level 3 of 100 mg/m^2, and Escalated/Dose level 4 of 120 mg/m^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment > 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
45688969|NCT05267002|Procedure|Suture removal timing|Cutaneous nylon suture removal of each half of the split-scar at one and two weeks.
45688970|NCT00308230|Procedure|Six minute walk test|
45362518|NCT05589987|Device|power mobility|"Sessions of adjustment, adaptation and choice of the device for training will be carried out. Once the cars are fully adapted and conditioned to the environment and needs of the family and the child, the intervention will begin.~The study will take place in the child's natural environment for 12 weeks. Three 40-minute sessions per week will be held, each session includes: 1) configuration of the environment (families will be instructed by the therapists to adapt the environment to the child's situation and their conditions for driving the car): 5 min ; 2) natural play as a warm-up activity: 5 min; and 3) mobility and social training with cars: 30 min. The 30-minute driving session will involve participants learning cause and effect concepts by driving the toy car (press the button to move and release to stop). The therapist and caregivers will use verbal cues to encourage children to drive and explore the environment. All sessions will be video and audio recorded."
45688971|NCT00308230|Behavioral|Minnesota Living with Heart Failure Questionnaire|
45362519|NCT00834158|Procedure|TACE|1 time
45362520|NCT00834158|Procedure|PVE|1 time
45362521|NCT05589909|Diagnostic Test|IL27, PCT, CRP, Blood culture|magnetic bead multiplex platform
45362522|NCT05589675|Other|Dispatch of the screening test along the invitation letter to the national colorectal cancer screening program|The individuals eligible for the colorectal cancer screening program will receive at home an invitation letter to participate to the program along with a FIT test. The follow-up will be similar to the standard of care, i.e. reminder letters at 5 and 10 months if there is no participation, and reminders if no coloscopy after a positive FIT test
45362523|NCT05589675|Other|Sending of a prior notification to the new entrants of the national program|Dispatch of a notification, one month prior the dispatch of the screening test along the invitation letter. This intervention is among the new entrants to the national program
45688972|NCT00325078|Drug|Infliximab|
46049574|NCT02628730|Device|RFA ablation data comparison|Ablation data from previous ablations, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), that members of this group had in the past, will be compared with those of the Active Comparator Group.
46049575|NCT00605436|Behavioral|Restorative yoga therapy|3-hour workshop at study initiation. Then twice-weekly group yoga classes for 5 weeks, then once-weekly group yoga classes for 5 weeks. Home yoga practice for 90 minutes/week throughout the 10 week trial.
46049576|NCT02628886|Biological|13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid|pregnant women will be given intramuscular PCV 13 vaccine between 28-34 weeks
45362524|NCT03693430|Drug|Semaglutide|Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
45688973|NCT00325780|Drug|Pitavastatin|Pitavastatin 4 mg once daily
45688974|NCT00326170|Drug|5-Azacytidine (5-aza)|Start at 75 mg/m^2 subcutaneously daily for 7 days.
45688975|NCT00326170|Drug|Valproic Acid|50 mg/kg daily by mouth for 7 days, same days as 5-aza.
45362525|NCT03693430|Drug|Placebo (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
45480137|NCT03721081|Other|Na Cl 0.9%/Epi 1:200000|Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Na CI 0.9%/Epi 1:200000 inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
45688976|NCT00326170|Drug|All-Trans Retinoic Acid (ATRA)|45 mg/m^2 orally daily (in two divided doses) for 5 days starting on day 3 of the administration of 5-aza and VPA.
45688977|NCT00326872|Drug|Cediranib Maleate|
45688978|NCT05266690|Dietary Supplement|Roquette Glucidex 2|Roquette Glucidex 2: Maltodextrins with high degree of polymerization
45362526|NCT00625742|Behavioral|Graded Resistance Training|Resistance training sessions twice weekly using Thera-bands.
45362527|NCT00625742|Behavioral|Aerobic Exercise|Walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate.
45362528|NCT00625742|Drug|Melatonin|20 mg by mouth (PO) Daily
45480138|NCT04493554|Drug|Vasopressin|Administration of vasopressin (20 IU) intranasally
45480139|NCT04493554|Drug|Placebo|Administration of placebo intranasally
45480140|NCT02601014|Biological|Ipilimumab|Given 1 mg/kg IV
45480141|NCT02601014|Biological|Nivolumab|Given 3 mg/kg IV
45480142|NCT02601014|Drug|Enzalutamide|given orally per standard of care
45480143|NCT03721003|Device|ICP monitoring|"4- Use the Touhy needle to tunnel under the scalp from the Burr Hole site to the desired MICROSENSOR exit site.~5- Place the tip of the MICROSENSOR in the Parenchyma through the puncture in the Dura"
45480144|NCT01307046|Drug|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
45480145|NCT01307046|Drug|Losartan|Tablet containing losartan potassium (100 mg), once daily
45480146|NCT01307046|Drug|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
45362529|NCT00625742|Dietary Supplement|Juven|90 calories of Juven, twice a day.
45362530|NCT00625742|Drug|Atenolol|Atenolol will only be taken if there's evidence of increased sympathetic activity (resting heart rate >110 beats/min) or resting energy expenditure (REE) > 110% of predicted.
45362531|NCT00625742|Drug|Ibuprofen|Ibuprofen 1200mg/day in three divided doses.
45688979|NCT05266690|Dietary Supplement|Pharmacosmos Dextran 10|Pharmacosmos Dextran 10: Dextran with high degree of polymerization
45688980|NCT05266690|Dietary Supplement|Roquette Glucidex 40|Roquette Glucidex 40: Glucose syrup
45688981|NCT05266690|Dietary Supplement|Promitor 70|Promitor 70: Resistant Dextrin with a complex structure containing 70% non-digestible dietary fiber
45688982|NCT00328042|Behavioral|Self-Management Workshop|The workshop is a once per week 2.5 hour group that meets for six weeks.
45688983|NCT00328042|Behavioral|Information Only|This is an individual self-paced at home study program.
45362532|NCT00834314|Procedure|Vacuum-Pack-technique for temporary abdominal closure|"Negative-pressure-wound-therapy applying a method described by Brock, Barker et al 1995: Temporary Closure of Open Abdominal Wounds - the Vacuum Pack (see citations)."
45362533|NCT00834314|Procedure|Abdominal-dressing-technique for temporary abdominal closure|Negative-pressure-wound-therapy for temporary abdominal closure applying a device of KCI International (V.A.C.® Abdominal Dressing System). see: http://www.kci-medical.com/kci/corporate/kcitherapies/vactherapy/dressings/abdominal/#
45688984|NCT00329524|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS will initially be targeted to asymmetric cortical activation in one hemisphere, as defined by PET-CT imaging. TMS will then be optimized by identifying the area of maximal tinnitus suppression, within the area of asymmetry, by delivering single 1-Hz pulses of TMS at the MT. The area of maximal tinnitus suppression, as reported by the patient, will then be targeted for treatment with rTMS at 1-Hz frequency, delivering 1800 pulses at 110% MT on each of 5 consecutive treatment days.If no area of maximal tinnitus suppression can be found in the hemisphere initially targeted for treatment based on PET, we will perform the optimization procedure in a homologous region of the opposite cerebral hemisphere to determine if a maximal area of suppression can be found there. Each group will then crossover to sham and active stimulation conditions, respectively, 7 days following the completion of the first treatment session.
45688985|NCT01730534|Drug|Dapagliflozin 10 mg|Oral dose (od)
45688986|NCT01730534|Drug|Placebo tablet|Oral dose (od)
45362534|NCT05589441|Drug|salbutamol|10 mg salbutamol diluted to 2 ml with distilled water and inhaled as aerosolized for 15 min before the start of the hepatic-free phase.
45362535|NCT05589441|Drug|Insulin|Intravenous injection of 8U of insulin complex 10% glucose solution 250 ml before the start of the hepatic phase was completed in 15 minutes.
45362536|NCT00825188|Drug|eplerenone, amlodipine|Eplerenone 25mm qd versus amlodipine 5mg qd x 4weeks the Eplerenone 50mg qd versus amlodipine 10mg qd x 4weeks
45362537|NCT00825188|Drug|eplerenone|Eplerenone 25-50mg daily x 8 weeks
45362538|NCT00825188|Drug|eplerenone|eplerenone 25- 50 mg daily for 8 weeks
45362539|NCT00825188|Drug|amlodipine|amlodipine 5-10mg daily for 8 weeks
45362540|NCT05407623|Behavioral|PAX Good Behavior Game|"PAX GBG is packaged into ten specific tools that the teachers are trained to introduce in in their classroom management practice. The program introduces verbal and visual cues that facilitate prosocial and attentive behaviors One of the core elements of the program is the PAX-game, meaning that the children - while focusing on ordinary school tasks like math - get to play a game in teams where each team tries to make as few classroom rules infractions as possible during a certain period of time. The teams that succeed in achieving predetermined goals get a reward (often a fun and desirable activity) that serves as a reinforcer of prosocial and task-oriented behaviors.~Supervision is performed individually with each teacher and included that the PAX-trainer observes a lecture given by the teacher before each supervision session."
45362541|NCT05407623|Behavioral|Count on Me!|"Count on me! is set in adventure game where the child has an avatar that travels thru different worlds/platforms by using their mathematical skills. The child starts of in the home of the avatar, in a house like environment, where the child discovers a magical map that brings the child into a different world called Numberia. During the adventures in Numberia the child learns that it has certain skills, called the mathemagical powers, that will be used to liberate Numberia from the evil Prince Claw that has captured all the beautiful things (e.g., the birds that used to sing in the forest).~Count on me! was developed within a behavior analytic framework using a nonlinear programming process."
45362542|NCT05407623|Behavioral|Collegial Learning Community|"Collegial learning community is a feasible way of professional learning for teachers according to the five cyclical steps. The teachers go through the first step that is to assess the skill or knowledge gaps for students, using various data sources (for example testing, grades, surveys, student interviews). The second step is to reflect upon what skills the teacher needs to acquire in order to help the students to meet the goals. The third step is to deepen the professional knowledge and skills. The fourth step is engaging the students in the new practice, and in the fifth step to evaluate the impact the new practice has had on student outcomes.~In Collegial learning community teachers take help from their peers in each of these steps in a structured way. For example, way of deepening tacit or procedural knowledge (in step two) is to visit a colleague during class and make observations on their classroom practice."
45480147|NCT01307046|Drug|Placebo to losartan 100 mg|Placebo tablet to match losartan 100 mg, once daily
45480148|NCT01307046|Drug|Placebo to losartan 50 mg|Placebo tablet to match losartan 50 mg, once daily
45688987|NCT00329836|Other|There are no interventions in the observational study. The symptom of allodynia was measured.|No intervention. Description of allodynia testing appears elsewhere in this document
45688988|NCT00330382|Drug|Bowman-Birk inhibitor concentrate|Given orally
45688989|NCT00330382|Other|placebo|Given orally
45688990|NCT00330382|Other|laboratory biomarker analysis|Correlative studies
45688991|NCT01791712|Procedure|On-line hemodiafiltration|pre-dilution 40% of blood flow rate blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
45688992|NCT01791712|Procedure|High-flux Hemodialysis|blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
45362543|NCT00834392|Behavioral|Exercise|Walking exercise
45362544|NCT05589363|Drug|ABC block with bupivacaine/liposomal bupivacaine|Patients will be randomized to receive an ABC block using bupivacaine/liposomal bupivacaine solution
45480149|NCT03719209|Other|HealthVoyager|HealthVoyager is a virtual reality application that allows providers to create customized representations for patients and share the results of endoscopic procedures via an interactive platform. The app can show both normal and abnormal endoscopic findings and anatomy. Families will also receive a web link so that they may access the procedure results via the app at home on their smartphone or tablet.
45480150|NCT03719209|Other|Standard Practice|Patients and families will receive handouts with printed images of their endoscopic findings, as per standard practice at Boston Children's Hospital.
45362545|NCT05589363|Drug|ABC block with saline|Patients will be randomized to receive an ABC block using normal saline
45480151|NCT03318796|Device|Coronary Artery Stenting|Interventional coronary artery stent placement in De novo bifurcation lesions of the MB & SB
45362546|NCT00834470|Drug|Atropine|Ketamine 2mg/kg IV + Atropine 0.01mg/kg or Same volume of Normal saline
45480152|NCT05419115|Drug|SQIN-Furosemide|The investigational furosemide formulation (SQIN-Furosemide) is a Captisol®buffered solution of 80mg furosemide in 2.7 mL (30 mg/mL) at pH 7.4 (range: 7.0 to 7.8). SC infusion will be performed using the SQIN-Infusor which will deliver 2.7 mL of the SQIN-Furosemide formulation (80mg) over approximately 5 hours, using a biphasic delivery profile.
45688993|NCT05266534|Drug|Terlipressin|the efficacy of intramyometrial Terlipressin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
45688994|NCT05266534|Drug|Carbetocin|the efficacy of intramyometrial carbetocin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
46049577|NCT02628886|Biological|placebo 0.9% sodium chloride plus tetanus toxoid|pregnant women will be given intramuscular saline injection between 28-34 weeks
45362547|NCT03997864|Drug|Prazosin|"Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved, max dose is reached, or side effects are problematic.~Tapering Decrease prazosin 1 mg every 3 days or 3 mgs per week until off completely. Tapering will take approximately 2-3 weeks."
46049578|NCT02628886|Other|tetanus toxoid|new born babies will be given PCV13 vaccine at birth
46049579|NCT04265508|Other|Assessment of hemostatic profile|To assess the hemostatic profile, platelet function was analyzed by multiple electrode aggregometry (MEA) using Multiplate (ADP-, ASPI- and TRAP-test) and thrombelastometry using ROTEM (EXTEM, INTEM, FIBTEM)
45362548|NCT03997864|Drug|Placebos|Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved max dose is reached, or side effects are problematic.
45362549|NCT05407467|Dietary Supplement|Curcumin and virgin coconut oil extract (KurCo Smart)|we give 2 tablets of curcumin and virgin coconut oil extract thrice a day for 30 days and evaluate the result
45362550|NCT04043468|Other|Audit and feedback|Audit and feedback (A&F) is an intervention that aims to improve professionals practices by providing professionals with a summary of their performance over a period of time.
45362551|NCT01010152|Drug|Codeine Sulfate|30 mg Tablet
45362552|NCT00834548|Procedure|Whole body magnetic resonance angiography (WB-MRA)|WB-MRA will be performed once in each patient.
46049580|NCT02623738|Drug|Placebo ophthalmic solution|
46049581|NCT02623738|Drug|DE-117 ophthalmic solution low|
45480153|NCT05419115|Device|SQIN-Infusor|The investigational device (SQIN-Infusor) is an on-body delivery system that consists of a RU, DU, plus a charger (Figure 2). For the purpose of SUBCUT-HF II trial, the RU will be used for multiple infusions for a single participant. The DU will be used only once per infusion and disposed of. The RU must be charged after each use and will not restart for the next infusion without charging. Charging takes up to 15 minutes. SQIN-Infusor is a bespoke system, adapted from the design of a SC insulin pump. The RU consists of the drive-unit, the controllers, the rechargeable battery, and the user interface.
45480154|NCT02536118|Device|Micra Transcatheter Pacing System|The Micra system is a miniaturized single chamber pacemaker system that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart. The Micra implantable device is a self-contained, hermetically enclosed, miniaturized single chamber pacemaker. The device is fixated via four electrically inactive nitinol tines, located on the distal end of the device.
45688995|NCT05266534|Drug|Saline|the efficacy of intramyometrial saline injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
45688996|NCT01730378|Biological|Prepandrix™|2 doses administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).
46049582|NCT02623738|Drug|DE-117 ophthalmic solution high|
46049583|NCT02623738|Drug|Latanoprost ophthalmic solution 0.005%|
46049584|NCT00607074|Drug|Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)|Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) or a placebo was administered Every 12 weeks: Albendazole (syrup, 200mg)
46049585|NCT00607074|Drug|Anti-Giardia treatment only (secnidazole or albendazole)|Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) Every 12 weeks: placebo of Albendazole
46049586|NCT00607074|Drug|Control group (placebo)|Every 4 weeks: Secnidazole placebo Every 12 weeks: Albendazole placebo
46049587|NCT02623582|Biological|Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes|Given IV
46049588|NCT02623582|Drug|Cyclophosphamide|Given IV
45362553|NCT05407233|Device|Does not reuse the syringe for insulin application|Does not reuse needles for insulin application Patients will be given quantity of needles for use during the study period according to the allocated group and a collector for sharps descarpack to collect the used syringes and needles. Initially, all patients will be instructed on the indication and importance of insulin use, aspects of conservation, preparation and administration, reviewing the dose aspirated in the syringe. They will also be instructed in relation to the use of the collector for sharps. Patients will also receive the booklet specially designed for this registry where they must indicate the number of hematomas, bruises, lipodystrophies, or inflammation that they identify whenever they occur. This booklet will be given to the team of researchers at each visit (monthly), who will review the records with the patient and guide them for subsequent completion.
45382237|NCT05195619|Biological|Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine)|"Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.~Each dose of vaccine (PEP-DC) will be split into two injections, which will be administered on W2D2 of each cycle, subcutaneously. Patients will be vaccinated until vaccine exhaustion, disease progression, major toxicity or patient withdrawal, whichever is earlier. Additional DC vaccines may be administered Q3W (±3 days) if available until vaccine exhaustion or disease progression, whichever is earlier."
45382238|NCT05195619|Drug|Low dose cyclophosphamide|Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.
45480155|NCT05664607|Other|for excise, nutrition consultant, nutrition supplement and psychologic intervention.|for excise, nutrition consultant, nutrition supplement and psychologic intervention.
46049589|NCT04264416|Device|WB-EMS|16 weeks of WB-EMS
46049590|NCT02623660|Device|ODIN1|"Shortly after surgery, electrodes will be applied to the lower extremity in such a way that the current will flow from the ankle through the knee replacement and pass through the thigh. The frequency of the treatments will vary over the period of time from post-op recovery to end of rehab.~All treatments are applying current that consists of different combinations of intensities within the micro to nano ampere ranges."
46049591|NCT02623660|Other|Standard Care|Anti-thrombotic medication. Elevation and ice. Pain medications as needed. Dressings changes. Topical antibiotics. Progressive physical therapy.
46049592|NCT02623660|Device|Diagnostic Device Testing|Diagnostic interventions include: the Perometer which scans the lower extremity and determines its volume to a high degree of accuracy; the Impedimed Bioimpedance Spectroscopy (BIS) device that measures intra and intercellular fluid movement; the Microfet muscle force testing device that provides a digital output of the number of pounds exerted by the quadriceps upon extension; the Acumar digital digital Inclinometer that accurately measures the ROM of the knee; and the K.I.S.S. wound measuring system to measure rate of incision healing.
45382239|NCT05189171|Device|MicroOrganoSphere (MOS) drug screen|Patient-derived models of cancer, called MOS, will be generated from a biopsy of a subject's adenocarcinoma of the colon and/or rectum that is metastatic to the liver and a drug screen using standard-of-care drugs used will be completed (oxaliplatin, irinotecan, 5-FU/capecitabine (Xeloda), bevacizumab, panitumumab or cetuximab, trifluridine/tipiracil (Lonsurf), regorafenib and pembrolizumab or nivolumab). Subjects will receive standard-of-care therapy for CRC dictated by their treating physicians.
45688997|NCT01730378|Biological|Fluarix™|1 dose administered intramuscularly in the deltoid region of non-dominant arm.
45845170|NCT02267538|Drug|dexmedetomidine hydrochloride for injection|"Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of [0.9*kg] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 μg/kg in 10 minutes), followed by continuous infusion at a rate of [0.1*kg] ml/h (i.e., dexmedetomidine at a rate of 0.4 μg /kg/h) until the end of surgery.~At the end of surgery, the infusion rate will be decreased to [0.025*kg] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation after surgery."
45845171|NCT02267538|Drug|0.9% sodium chloride for injection|"Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of [0.9*kg] ml/h for 10 minutes, followed by continuous infusion at a rate of [0.1*kg] ml/h until the end of surgery.~At the end of surgery, the infusion rate will be decreased to [0.025*kg] ml/h and continued until the end of mechanical ventilation after surgery."
45845172|NCT02267772|Drug|IV Acetaminophen|IV Acetaminophen
45845173|NCT02267772|Drug|IV Morphine|IV Morphine
46049593|NCT04264494|Procedure|PRP intra articular injection|Fifty RA patients were injected intra-articularly with 3 doses of PRP at 4 weeks intervals for the joints with only tenderness (arthralgia without swelling or effusion) and revaluated at 3 and 6 months post the last injection regarding the same evaluating tools.
46049594|NCT04264494|Procedure|NACL intra articular injection|and 50 patients who serve as a control and injected intra-articularly with 3 doses of placebo (NaCl saline) at 4 weeks intervals for the joints with only tenderness (arthralgia without swelling or effusion) and revaluated at 3 and 6months post last injection regarding the same evaluating tools.
46049595|NCT04047316|Device|Digital dermoscopy|Acquire skin images with a new digital dermatoscope
45688998|NCT01783496|Device|Thermage CPT|Treatment with Thermage patterned, total, or framed tip
46049596|NCT00696124|Biological|VM202 2mg|2mg intramuscular injection with the first half of the total dose given on Day 1 and the second half on Day 15
46049597|NCT00696124|Biological|VM202 4mg|4mg intramuscular injection, with half of the total dose given on Day 1 and the second half given on Day 15
45480156|NCT02490592|Other|Fluoride Foam|Fluoride foam - Flúor Care (NaF 1.23%) (G1)
45480157|NCT02490592|Other|Fluoride gel|Fluoride gel - Flugel FFA (NaF 1.23%) (G2)
45688999|NCT04559750|Behavioral|Internet delivered behavior therapy (I-BT)|10 weeks of I-BT
45689000|NCT00314236|Device|BST-CarGel with Microfracture|Microfracture performed with BST-CarGel added to the treated defect
45689001|NCT00314236|Procedure|Microfracture without BST-CarGel|Microfracture performed without BST-CarGel added to the treated defect.
45689002|NCT01729208|Device|Dual Focus Soft Contact Lens|
45689003|NCT01729208|Device|Single Vision Soft Contact Lens|
46049598|NCT00696124|Biological|VM202 8mg|8mg intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
46049599|NCT00696124|Biological|VM202 16mg|16mg dose intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
45480158|NCT03790475|Other|Offering a choice for colorectal cancer screening|Persons randomized to the multiple options screening strategy group will receive a postal invitation offering a choice between FIT and colonoscopy.
45689004|NCT00331162|Drug|Alemtuzumab|30 mg/100ml NS intraoperatively. Start after dexamethasone administration and prior to reperfusion of the allograft. Infuse over a minimum of 2 hours.
45689005|NCT00331162|Drug|Anti-Thymocyte Globulin|"1.5 mg/kg per dose through a central line intraoperatively and on POD# 2 and 4, then continue on alternate days until a therapeutic tacrolimus(or cyclosporine) level is achieved, or until the SCr < 3-4 mg/dL.~Give first dose over 6 hours, subsequent doses over 4 hours.~Premedication to be given with the first 3 doses:~Tylenol 650mg PO/PR Benadryl 25-50mg PO/IV Daily scheduled corticosteroid dose or other corticosteroid as deemed appropriate.~Hold infusion if temperature > 100.5ºF; Adjust dose for low WBC or Plt count Peripheral Thymoglobulin administration: Prepare dose in 500cc NS; Add heparin 1,000 units and hydrocortisone 20mg to the bag; Infuse over a minimum of 6 hours"
46049600|NCT04264650|Behavioral|an mHealth intervention|The Care & Organize Our Lifestyle (COOL) program, a self-regulation theory-based mHealth program
45689006|NCT01790230|Device|LifeSeal™ Kit|Application of LifeSeal™ Kit for staple line reinforcement during open GI surgeries in Low Anterior Resection
45689007|NCT01790308|Drug|CSII|continuous subcutaneous insulin infusion for 2~4 weeks
45689008|NCT01790308|Drug|Liraglutide|CSII for 2~4 weeks combined with Liraglutide 0.6mg/d for 1 month and 1.2mg/d for next 2 months
45689009|NCT01609010|Drug|rituximab|375 mg/m2 rituximab i.v. weekly for 4 weeks
45689010|NCT01609010|Drug|interferon-a-2a|3 MIU/day interferon-a2a s.c. during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5
45689011|NCT01608308|Drug|IV Acetaminophen|1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.
45689012|NCT01608308|Drug|Placebo|100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.
45689013|NCT00332644|Drug|nicotine patch|used according to FDA package label
45689014|NCT00332644|Drug|nicotine lozenge|used according to FDA-approved package directions
45689015|NCT00332644|Drug|nicotine patch + nicotine lozenge|dosage of both according to FDA-approved dosing schedule
45689016|NCT00332644|Drug|bupropion|dosage according to FDA-approved instructions
46049601|NCT05379660|Device|transcutaneous electrical acupoint stimulation|Basing on the theory of traditional Chinese medicine, bilateral Zusanli (ST 36), Shangjuxu (ST 37) and Sanyinjiao (SP 6) are elected as the acupuncture points,the electrode pads with wire are attached to the corresponding acupoints, which are connected with Hwato electric acupuncture treatment instrument,TEAS stimulation uses a dense-dispersed wave with frequencies of 2 and 100 Hz alternating every 3 s, and the intensity 5 ~ 12mA,on the first and second days after surgery, the doctor who is responsible for acupuncture will arrive at the ward in the morning and afternoon to administer TEAS stimulation at the same acupoints for 30 min in the TEAS groups
46049602|NCT00605514|Drug|VRC-EBODNA023-00-VP|
46049603|NCT00605514|Drug|VRC-MARDNA025-00-VP|
45689017|NCT00332644|Drug|bupropion + lozenge|dosage according to FDA approved standard instructions
45689018|NCT00332644|Drug|placebo|dosage same as active drug conditions
45689019|NCT01755416|Drug|Closed loop with sensor and Insulin|Subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
45689020|NCT01755416|Drug|Closed loop with sensor, Insulin and Liraglutide|In this study visit the subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner on Day 1.
45689021|NCT01755026|Drug|cefazolin|2 gram dose for pre-operative prophylaxis
45689022|NCT01755026|Drug|cefazolin|4 gram dose for pre-operative prophylaxis
45689023|NCT00332722|Procedure|Cervical facet joint nerve blocks|
45480159|NCT03790475|Other|Offering an alternative colorectal cancer screening method|Persons randomized to the sequential screening strategy group will receive a postal invitation to the colonoscopy followed by a postal invitation for screening using FIT for non-responders and subjects refusing colonoscopy.
45689024|NCT01491945|Device|Ventana Fenestrated Stent Graft System|"The Ventana Fenestrated Stent Graft System consists of the following:~bifurcated stent graft, Ventana fenestrated proximal extension stent graft, and Xpand renal stent grafts"
45689025|NCT00333814|Drug|Dexamethasone|Dexamethasone 350 µg; injection drug delivery system at Day 0
45689026|NCT00333814|Drug|dexamethasone|Dexamethasone 700 µg injection drug delivery system at Day 0
45689027|NCT00333814|Drug|Sham injection|Sham injection at Day 0
45845174|NCT02267850|Other|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
45845175|NCT02267850|Device|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
45689028|NCT01728584|Drug|Rocuronium|NMB will be induced by intravenous (IV) administration of a bolus dose of 0.45 mg/kg rocuronium. NMB will be maintained using rocuronium infusion or additional bolus doses as needed for the management of NMB to the targeted depth according to the assigned treatment condition. - Standard NMB - administration of neuromuscular blocking agent (NMBA) titrated to a depth of blockade at a targeted TOF ratio of 10% (range: TOF count 2-3 to TOF ratio of 20%). - Deep NMB - administration of NMBA titrated to a targeted depth of 1-2 Post Tetanic Counts (PTCs) (range: 1-5 PTC).
45689029|NCT01728584|Other|Insufflation|"Insufflation (injection) of carbon dioxide will be used to induce pneumoperitoneum, which is presence of air or gas in the abdominal (peritoneal) cavity.~Standard insufflation pressure - a starting pressure of 12 mmHg will be used.~Low insufflation pressure - a starting pressure of 8 mmHg will be used."
45689030|NCT01728584|Drug|Sugammadex|NMB will be reversed with IV administration of 2 or 4 mg/kg sugammadex (depending on the depth of NMB) according to the approved label for sugammadex.
45689031|NCT00315328|Drug|Atropine|Atropine 1% each weekend day in the sound eye
45689032|NCT00315328|Device|Patching|Patching 2 hours per day
45689033|NCT00315328|Procedure|Near activities|near visual activities for at least one hour per day
46049604|NCT04135534|Drug|group A|mutonpain 0.05 mg/kg
46049605|NCT04135534|Drug|group B|mutonpain 0.1 mg/kg
45689034|NCT05265988|Drug|Cabozantinib|Cabozantinib at initial dosage of 40 mg per day and continuation of androgen deprivation therapy
45689035|NCT04345822|Procedure|Decompression surgery|The surgeries aim to relieve the myelopathy from cord compression
45689036|NCT01522443|Drug|cabozantinib|Tablets taken orally once daily.
45689037|NCT01522443|Drug|mitoxantrone|Given by IV once every 3 weeks.
45689038|NCT01522443|Drug|prednisone|Taken twice a day orally by mouth. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
45689039|NCT00334204|Device|measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy|measuring Platelet Function Analyser (PFA) -100 platelet function before kidney biopsy
45689040|NCT00336232|Drug|Vitamin K|phylloquinone (vitamin K1) 500 mcg daily in third month
45689041|NCT00336700|Drug|Gemcitabine|1500mg/m2 IV over 150 min IV q 2 weeks 4 months
45689042|NCT00336700|Drug|Erlotinib|150 mg/d Daily, oral 12 months
45689043|NCT01468233|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
45689044|NCT01468233|Biological|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
45689045|NCT01468077|Drug|Tocilizumab|8 mg/kg infusion
45689046|NCT01522365|Device|Abutment-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge placed directly on an abutment
46049606|NCT04135534|Drug|group C|mutonpain 0.2 mg/kg
46049607|NCT00696202|Drug|Mirena (BAY86-5028)|Intrauterine levonorgestrel containing device (market product)
46049608|NCT00608010|Procedure|Vitrification|Embryos were vitrified according to a previously described technique
46049609|NCT00608010|Procedure|Slow freezing|Embryos were frozen with slow freezing technique
45362554|NCT05407233|Device|Uses the syringe for insulin delivery five times|Uses the needles for insulin application five times. Patients will be given quantity of needles for use during the study period according to the allocated group and a collector for sharps descarpack to collect the used syringes and needles. Initially, all patients will be instructed on the indication and importance of insulin use, aspects of conservation, preparation and administration, reviewing the dose aspirated in the syringe. They will also be instructed in relation to the use of the collector for sharps. Patients will also receive the booklet specially designed for this registry where they must indicate the number of hematomas, lipodystrophies, or inflammation that they identify whenever they occur. This booklet will be given to the team of researchers at each visit (monthly), and they will review the records with the patient and guide them for subsequent completion.
45362555|NCT05589129|Dietary Supplement|Whey Protein Supplement|Participants assigned to the intervention will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
45362556|NCT05589129|Dietary Supplement|Carbohydrate Placebo Control|Participants assigned to the placebo control will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
45362557|NCT00839774|Other|Whole yellow pea flour|Whole pea flour was administered at 50 g/day.
45362558|NCT00839774|Other|Fractionated pea flour|Fractionated pea flour was administered according to the level of fiber in whole pea flour treatment. 12 g/day
45362559|NCT00839774|Other|White wheat flour|White wheat flour will be administered at 50 g/day
45689047|NCT01522365|Device|Implant-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge fixed directly on the implant
45689048|NCT03026673|Other|NSAID use|The purpose of the study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
45689049|NCT01754402|Drug|Bendamustine|Bendamustine will be administered intravenously over 1 hour (if using Treanda) or over 10 minutes (if using Bendeka) on day 1, every 28 days for 12 cycles.
45689050|NCT01754402|Drug|Pomalidomide|Pomalidomide will be administered once daily orally (PO) on days 1-21, every 28 days until disease progression or death.
45362560|NCT02549846|Drug|Statin|Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke
45480160|NCT04492930|Behavioral|14:10 Regimen|14 hours of fasting, followed by a 10-h diet regimen that includes a fasting snack at 12 hours from the start of the fasting period
45480161|NCT04492930|Behavioral|12:12 Regimen|12 hours of fasting, followed by a 12-h diet regimen
45480162|NCT03075462|Drug|Fluzoparib|Fluzoparib either at 40,60,80mg twice daily,capsule oral.
45480163|NCT03075462|Drug|Apatinib|Apatinib at 250mg once daily, tablet oral
45689051|NCT01754402|Drug|Dexamethasone|Dexamethasone will be administered weekly orally or intravenously on days 1, 8, 15, and 22 every 28 days until disease progression or death. After 6 cycles of treatment, the dose may be reduced to 20mg at investigator's discretion. For subjects ≥ 75 years of age, the starting dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
45689052|NCT01783418|Behavioral|Mindfulness Intervention|Mindfulness-based intervention adapted for teenagers
46049610|NCT00608088|Behavioral|Usual Care|"The usual care group will received standard care from the Johns Hopkins Hospital lactation consultant and nurses, which may have included a visit in the hospital by the lactation consultant if mothers delivered Monday through Friday. The lactation consultant was also available by request. A warm-line was also standard. This was a telephone line that was connected to an answering machine; the lactation consultant checked this line once daily (Monday through Friday) and returned calls."
45362561|NCT01888653|Behavioral|Attention Bias Modification (ABM)|The training protocol consisted of 160 trials per session with 120 angry-neutral and 40 neutral-neutral trials. Each participant was trained with an alternative set of faces to the one used in the assessment task (i.e. if measured with set A then trained with set B and vice-versa). In the ABM condition, training was contin- gent on the bias measured at pre-treatment. Specifically, for those showing a bias toward the threat, the target appeared at the neutral-face location in 100% of the threat-neutral trials, while for those showing a bias away from the threat, the target appeared at the threat-face location in 100% of the threat-neutral trials.
45689053|NCT01521897|Biological|7-valent vaccine injection|For primary immunization, three doses of Prevenar 0.5 mL should be injected subcutaneously with an interval of at least 27 days between each dose. For booster immunization, one dose of Prevenar 0.5 mL should be injected subcutaneously, at least 60 days after the 3rd dose.
45362562|NCT01888653|Behavioral|Attention control training (ACT)|In the ACT condition, threat- face location, probe location, and probe type were fully counter- balanced with no contingency between face valence and probe location, thus resembling the assessment task.
45362563|NCT00840008|Other|Educational intervention|As per detailed protocol.
45689054|NCT01782872|Procedure|Interscalene Block (ISB) - 0.375% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.375% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous (IV): saline
45689055|NCT01782872|Procedure|Interscalene Block (ISB) - 0.2% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.2% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous: saline
45689056|NCT01782872|Procedure|Interscalene Block (ISB) - 0.1% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.1% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous: saline
45689057|NCT01782872|Procedure|Interscalene Block (ISB) - Systemic Control|Ultrasound-guided single-injection ISB: ropivacaine 0.375%; Intravenous: clonidine (100 mcg) + dexamethasone (4 mg) + buprenorphine (150 mcg)
45689058|NCT01490697|Drug|Mifepristone|1800 mg tablet, single dose 90 minutes prior to script preparation on Day 7.
45689059|NCT01490697|Drug|d-Cycloserine|100 mg capsule, single dose, taken 4 hours prior to to mifepristone on Day 7.
45689060|NCT01490697|Drug|Placebo-matching Mifepristone|Placebo-matching mifepristone tablets
45362564|NCT05407155|Combination Product|bevacizumab plus nab-paclitaxel and platinum|Bevacizumab is given as 15mg/kg every 3 weeks. Nab-paclitaxel is given as 260 mg/m2 every 3 weeks for 4 cycles at most. Platinum includes caboplatin or cisplatin, which is chosed by phycisians. Carboplatin was calculated using AUC equals 5 for 4 cycles at most, and cisplatin was given as 75mg/m2 for 4 cycles at most. Bevacizumab is given untill disease progression or intolerated toxicities.
45362565|NCT00840242|Drug|Nicotine gum|8-12 pieces per day, maximum 24 daily
45362566|NCT00840242|Drug|Placebo gum|8-12 pieces per day, maximum 24 daily
45362567|NCT00840242|Drug|Nicotine inhaler|6-12 cartridges per day, maximum 12 daily
46049611|NCT00608088|Behavioral|Community Health Nurse/Peer Councelor Team|"Visits by a community health nurse/peer counselor team during the first six postpartum months. Based on prior research and experience, the team was developed to provide culturally relevant support and health-care education to low-income mothers, who were a high percentage of African American women. The goals of this team were to 1) increase the duration of breastfeeding while emphasizing ways to decrease fatigue, and decrease breast discomfort; 2) strengthen maternal competence with breastfeeding and commitment to breastfeeding; 3) provide parent education about the infant regarding breastfeeding; 4) provide/find social support needed for continued breastfeeding; and 5) foster linkages to community services that will facilitate the maintenance of breastfeeding.~The specific activities of the CHN/peer counselor team included hospital visitation after enrollment, home visiting during the first postpartum month, and telephone support throughout the first six postpartum months."
46049612|NCT00674752|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
45362568|NCT00840242|Drug|Placebo inhaler|6-12 cartridges per day, maximum 12 daily
45689061|NCT01490697|Drug|Placebo-matching d-Cycloserine (DCS)|Placebo-matching DCS capsules
45689062|NCT01728194|Drug|Escitalopram|20 mg target dose for 12 weeks
45689063|NCT01728194|Other|Magnetic Resonance Imaging|Structural and functional MRI of the brain for research purposes.
46049613|NCT00674752|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
46049614|NCT00674752|Drug|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime
46049615|NCT05370456|Device|Local application of a HA gel for the treatment of MAGRs with mCAF technique and XCM|After local anaesthesia, mCAF technique with two releasing vertical incisions will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction and HA gel will be applied.
46049616|NCT05370456|Procedure|Treatment of MAGRs with mCAF technique and XCM|After local anaesthesia, mCAF technique with two releasing vertical incisions will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
46049617|NCT05298514|Other|Not applicable - qualitative research study|We are not delivering interventions. This is a qualitative study in the form of focus groups.
45362569|NCT00621296|Drug|MP-424 (Telaprevir)|Three tablets of MP-424 250mg tablet at a time, every 8 hours, 24 weeks administration (dose in a day: 2250 mg)
45362570|NCT00840320|Drug|1278863|15mg, 25mg, 50mg, 150mg
45362571|NCT00840320|Drug|Placebo|matching placebo
45362572|NCT00840398|Drug|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fed
45689064|NCT04408911|Drug|Midazolam vs. Lormetazepam|In this retrospective analysis we compared critically ill ICU patients receiving midazolam to those receiving lormetazepam.
45689065|NCT01782482|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
45689066|NCT01782482|Device|Phemfilcon A contact lens with color|Hydrogel contact lens with color
45362573|NCT00840398|Drug|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fed
45362574|NCT00537303|Drug|insulin detemir|Treat-to-target dose titration scheme (individually adjusted dose) for a once daily injection s.c. (under the skin)
45362575|NCT00537303|Drug|insulin aspart|Administered 1 - 3 times daily, at largest prandial increment, injection s.c. (under the skin)
45362576|NCT00537303|Drug|insulin aspart|Administered 1 - 3 times daily, at largest meals, injection s.c. (under the skin)
45362577|NCT00840554|Other|Clinic-based physical therapy program.|All patients will receive a routine clinic-based physical therapy program. This program may include supervised aerobic conditioning, strengthening exercise, balance retraining, functional activity training, therapeutic exercise, and manual therapy.
45845176|NCT02267850|Device|Non-Functional OrthoPulse™|Patients carry out daily sham-OrthoPulse™ treatments at home. This is a non-functional device so patients do not receive photobiomodulation therapy.
46049618|NCT00674830|Behavioral|professionally administered cognitive-behavioral therapy|professionally administered CBT-I consisting of six weekly sessions
46049619|NCT00674830|Behavioral|self-administered form of cognitive-behavioral therapy|self-administered CBT-I consisting of six short booklets and videotapes
45362578|NCT00840554|Other|Home exercise program.|In addition to the clinic-based physical therapy program, patients will perform home exercises. Home exercise will include a walking and strengthening program 5 days per week. The home exercise routine will be recorded in an exercise diary.
45362579|NCT02548286|Drug|Candesartan 8mg|PO, 1day or 22day
45362580|NCT02548286|Drug|Amlodipine 5mg|PO, 1day or 22day
45362581|NCT02548286|Drug|CKD-330 8/5mg|PO, 1day or 22day
45689067|NCT01466673|Drug|Ethinyl estradiol/Norgestimate (EE/NGM)|Ethinyl estradiol/Norgestimate encapsulated oral tablet will be administered once daily at bed time as 0.035/0.18 milligram (mg) for Days 1-7, 0.035/0.215 mg for Days 8-14, and 0.035/0.250 mg for Days 15-21 of EE/NGM, respectively up to 6 consecutive menstrual cycles consisting of 21 days each.
46049620|NCT00674830|Behavioral|placebo|usual care
45362582|NCT05586087|Other|Experimental group|The High-Speed Resistance Training program has 16 weeks, with three sessions per week with 50-60min, each session being comprised of five-six exercises, two-three sets, and six-ten reps/exercise. The intensity is gradually increased after each session in accordance with the movement velocity (>1.3 to 0.75 m/s) representing approximately 20% to 60% of one repetition maximum. Participants execute the exercises rapidly and explosively making all repetitions for each shortening phase (concentric phase) performed as quickly as possible with the lengthening phase of the muscle (eccentric phase) being controlled for 2-3 s. The velocity of the concentric phase in each exercise is monitored through a BEAST™ sensor (Beast Technologies, Brescia, Italy).
45362583|NCT00834704|Drug|PEGPH20|PEGylated recombinant human hyaluronidase
45362584|NCT05360433|Drug|Oxycodone oral capsule|Reduced initial prescription of oxycodone for postoperative pain management following cesarean section.
45362585|NCT00834782|Procedure|IOP measurement|Measuring IOP
45362586|NCT00989391|Drug|PF-03654764|5mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
45689068|NCT01466673|Drug|Ethinyl estradiol/Desogestrel (EE/DSG)|Ethinyl estradiol/Desogestrel oral formulation will be administered once daily at bed time as 0.040/0.025 mg for Days 1-7, 0.030/0.125 mg for Days 8-22 of EE/DSG, respectively up to 6 consecutive menstrual cycles consisting of 22 days each.
45689069|NCT01753856|Drug|Teriparatide|Administered SC
45689070|NCT01753856|Drug|Denosumab|Administered SC
45689071|NCT01753856|Drug|Demeclocycline|Administered orally
46049621|NCT05379582|Other|Implement nutrition therapy according a procedure assisted by gastrointestinal ultrasound|Once the critical ill patients is stable, enteral nutrition was initiated following a procedure assisted by gastrointestinal ultrasound.
46049622|NCT02623270|Device|Noninvasive Ventilator, V60 (Philips)|The noninvasive ventilator will be set to deliver 10 breaths per minute with a pressure setting of 8 cm H2O during exhalation and 20 cm H2O during inspiration. The inspired oxygen fraction given by the ventilator will be set at the maximum level (100% oxygen).
46049623|NCT02623270|Device|Manual Bag|Oxygen will flow through the standard breathing circuit with the fresh gas flow rate set at 10 L/min and the patient will be ventilated. The anesthesia provider will manually bag mask ventilate the patient until the anesthesiologist feels comfortable that the patient can be ventilated appropriately.
46049624|NCT00605592|Procedure|Pancreatic Islets of Langerhans Cell Transplant|Transplantation of islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
46049625|NCT04265274|Drug|Disulfiram|dosing 400mg daily
46049626|NCT04265274|Drug|Vinorelbin|25mg/m2 day 1 and 8,
46049627|NCT04265274|Drug|Cisplatin|75mg/m2 day 1
45689072|NCT01753856|Drug|Tetracycline|Administered orally
45689073|NCT01753856|Drug|Calcium Supplement|Administered orally
45689074|NCT01753856|Drug|Vitamin D|Administered orally
45689075|NCT01464255|Device|ocufilcon D|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
45362587|NCT00989391|Drug|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
45362588|NCT00989391|Drug|PF-03654764|12mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
45362589|NCT00989391|Drug|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
45689076|NCT01464255|Device|ocufilcon B|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
45689077|NCT04559204|Biological|IIV4 and PPV23|imultaneously immunization of 23-valent pneumococcal polysaccharide vaccine (PPV23) and quadrivalent inactivated influenza vaccine (IIV4)
45689078|NCT04559204|Biological|IIV4|administrated with IIV4 only
45689079|NCT04559204|Biological|PPV23|administrated with PPV23 only
45689080|NCT01753310|Biological|Botulinum toxin type A|Intramuscular injection, between 250 and 500 units (U)/vial using 2mL dilution, 1 cycle only
45689081|NCT01753310|Drug|Placebo|Up to 2mL
45689082|NCT01463631|Drug|LY3007113|Administered orally
45689083|NCT04100577|Other|Today Not Tomorrrow Pregnancy and Infant Support Program|The Today Not Tomorrow Pregnancy and Infant Support Program (TNT-PISP) is a collaborative community-based support group uniquely designed to serve black women and infants through once monthly group sessions delivered prenatally and in the immediate postpartum period.
45689084|NCT01521507|Device|LipiFlow System|In-office device treatment for meibomian gland dysfunction by a physician
45689085|NCT01521507|Device|Warm Compress Therapy + Lid Scrub|At-home daily warm compress therapy and lid hygiene
45689086|NCT01521117|Drug|Donepezil|Use 1 capsule (5 mg) of donepezil once per day for first 21 days than donepezil 10mg qday for 21 days.
45689087|NCT01521117|Drug|Placebo|Use 1 capsule (5 mg) once per day for first 21 days than 10mg qday for 21 days.
45689088|NCT04100109|Dietary Supplement|Polylactose|Polylactose 15 g/day
45689089|NCT04100109|Other|Placebo|Cellulose 15 g/day
45689090|NCT01466595|Drug|Rifaximin|Participant were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
45689091|NCT02073747|Drug|Normal Saline|One hour inhaled normal saline
45689092|NCT02073747|Drug|Albuterol|One hour inhaled ten milligrams of albuterol
45689093|NCT01728116|Device|EndoBarrier|Endoscopically-delivered and removable device comprised of an anchor that is placed in the duodenal bulb and a 60 cm long impermeable liner that passes distal from the anchor point
45689094|NCT01728116|Procedure|Sham Procedure|Endoscopic evaluation but no device placement
45689095|NCT01465659|Drug|temozolomide|Given PO
45689096|NCT01465659|Drug|pazopanib hydrochloride|Given PO
46049628|NCT04265274|Drug|Copper|2 mg of elementary Copper daily
46049629|NCT00594100|Device|GORE Flow Reversal System (GFRS)|Carotid artery angioplasty and stenting with embolic protection
46049630|NCT05365386|Device|Tixel C|This is a non-invasive thermo-mechanical treatment to the scalp and/or face using the Tixel technology.
46049631|NCT00607152|Drug|Rasburicase|0.20mg/kg per day IV
46049632|NCT00607152|Drug|Allopurinol|100mg tablets
46049633|NCT00696748|Drug|Nebido (testosterone undecanoate)|Nebido (testosterone undecanoate) intramuscular 4 ml by scheme
46049634|NCT00696748|Drug|Placebo|Placebo 4 mL intramuscular
46049635|NCT00605670|Behavioral|questionnaires|patients will fill out two questionnaires post surgery
45480164|NCT03788915|Behavioral|Online dietetic lifestyle counseling|"The certified clinical dieticians provide individual therapy online and offline according to their patients' needs and based on information supplied via the website www.livalife.dk. The dietician generates a daily caloric reduction plan of approximately 1600-4800 KJ based on the patients' diet record. The dietary advice will be standardized and follow the dietary guidelines given at www.livalife.dk and the Danish Health Administration (Sundhedsstyrelsen)."
45689097|NCT03027531|Behavioral|eKISS: electronic KIOSK for Safer-Sex|An interactive computer-based intervention for safer-sex which provides individualized feedback about protective and risky sexual behaviors; offers instructive video modules for safe-sex; elicits change behavior and identification of behavior change goal using elements of motivational interviewing.
45689098|NCT01753076|Drug|Ozanezumab|Ozanezumab injection solution
45845177|NCT02268942|Device|HeartWare HVAD|Implant of HeartWare HVAD via thoracotomy implant technique
45362590|NCT00989391|Drug|PF-03654764|12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
45362591|NCT00989391|Drug|placebo|oral twice daily on Days 1-9 and once on Day 10. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
45480165|NCT03788915|Behavioral|Usual care|Patients randomized to the control group will be offered to receive usual municipal secondary or tertiary preventive offers.
45480166|NCT03325660|Other|whole body vibration|pelvic floor exercises
45689099|NCT01753076|Drug|Placebo|Normal saline (0.9% sodium chloride) infusion
46049636|NCT00605670|Behavioral|questionnaires|Patient will fill out questionnaire before and 3 to 6 months after treatment.
46049637|NCT00696280|Behavioral|Functional Living Index - Emesis|
46049638|NCT05363124|Other|PEWS calculation by parents using AI-based smartphone app|After patient registration, the patient will be installed in the nursing office with one of his parents . After screening a potential life-threatening patient for which treatment would be started first of all, the nurse will collect the signed parental consent for participating to the study. Explanations will be given to the parents regarding the use of the application and the way to calculate the PEWS through a very brief and standardized education. Parents should then proceed to the calculation of PEWS, as far as possible before the intervention of the nurse, using the Caducy® appl with a smartphone dedicated to the study .
45362592|NCT00834860|Drug|peginterferon alpha-2a and ribavirin|They received peginterferon alpha-2a (180 μg/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period.
45480167|NCT01305395|Drug|Sirolimus|Will initiate sirolimus within 6 months of heart transplant
45480168|NCT01305395|Drug|Sirolimus|Will start sirolimus after CAV has been diagnosed by angiogram
45689100|NCT01463007|Radiation|Accelerated partial breast irradiation|Accuboost APBI 34.0 Gy in 10 fractions
45689101|NCT01463007|Other|Extended Follow up|This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
45689102|NCT01462929|Drug|Aclidinium bromide|Dosage form: Dry powder. Route of administration: Oral inhalation by Genuair multidose dry powder inhaler Dose and regimen: 1 puff of 400 micrograms in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
45845178|NCT02268942|Procedure|Thoracotomy|Thoracotomy implant technique
45845179|NCT02269488|Drug|MEDI3250|MEDI3250
45845180|NCT02271906|Drug|BIBW 2992|40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
45362593|NCT00834938|Other|No intervention|No intervention
45362594|NCT00835016|Behavioral|Early psychosocial stimulation (LTP)|Learning through Play (LTP) groups will be conducted weekly for the first eight sessions and two fortnightly sessions. Parenting issues will be discussed with the mothers and play activities will be demonstrated with the children using LTP and home made materials.
45480169|NCT01305395|Drug|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
45362595|NCT04696575|Biological|Atezolizumab|Given IV
45362596|NCT04696575|Drug|Carboplatin|Given IV
45362597|NCT04696575|Drug|Etoposide|Given IV
45362598|NCT04696575|Drug|Lamivudine|Given PO
45362599|NCT00825422|Drug|Ropivacaine / Placebo|Wound infiltration with local anesthesics/placebo through a parietal paravertebral catheter
45362600|NCT04003545|Radiation|LED Photobiomodulation|A total of twelve laser applications (3 sessions per week) will be provided to the patients as treatment. A LED board with wavelengths of 660nm and 850nm at 5mW of power will be used for 30 minutes, resulting in a total energy of 3J per point in each session. The application site will be the lumbar region, in contact with the skin. The LED cluster (light-emitting diodes) has 72 LEDs.
45362601|NCT04003545|Other|Placebo LED Photobiomodulation|For the placebo group, the procedures will be the same, however the LED equipment will remain off.
45362602|NCT00835250|Procedure|Transvaginal hybrid NOTES cholecystectomy|Cholecystectomy performed by using a combination of working tools inserted through the entry port for the minilaparoscopy and the videogastroscope, inserted into peritoneal cavity by transvaginal approach. The gallbladder is removed transvaginally through the videogastroscope.
45362603|NCT00835250|Procedure|Cholecystectomy|Extirpation of the gallbladder by a surgical procedure
45362604|NCT03853226|Procedure|All monitoring|For all patients, data from trans-esophageal Doppler, trans-thoracic echocardiography (TTE) and hemodynamic data are collected at the end of the procedure. During catheter withdrawal, pressure waveforms are recorded at two predefined aortic locations: in the ascending aorta and in the descending thoracic aorta just in front of the esophageal Doppler probe.
45362605|NCT05358015|Procedure|vascularized bone graft for scaphois nonunion|vascularized bone graft for scaphois nonunion
45362606|NCT04043780|Device|Decompression prototype splint for carpal tunnel syndrome|This group will wear during 6 weeks a decompression prototype splint. They we be informed to wear it as long as possible during the 6 weeks.
45362607|NCT04043780|Device|Standard splint for carpal tunnel syndrome|This group will wear during 6 weeks a standard splint. They we be informed to wear it as long as possible during the 6 weeks.
45362608|NCT00505414|Drug|Tapentadol in the Titration Phase|
45362609|NCT00505414|Drug|Morphine in the Maintenance Phase|"Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted. In the maintenance phase participants continued on the dose level established in titration phase.~Participants randomized to the morphine arm remained on morphine if they qualified for the maintenance phase of the study. The participants were maintained on the dose established at the end of the titration phase. The adverse events listed were documented in the maintenance phase."
45362610|NCT00505414|Drug|Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase|Participant randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off of the tapentadol dose they had received in the titration period. From the fourth day of the maintenance period onwards they received placebo twice daily.
45362611|NCT00505414|Drug|Tapentadol in the Maintenance Phase|The participants re-randomized to receive tapentadol prolonged release in the maintenance phase were maintained on the dose established in the titration phase.
45362612|NCT00505414|Drug|Morphine in the Titration Phase|After signing informed consent eligible subjects were randomized to receive morphine controlled release. The oral medication was taken twice daily, morning and evening every 12 hours (with a minimum of 6 hours between doses). Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted.
45362613|NCT00840788|Procedure|octyl-2-cyanoacrylate adhesive glue|use of octyl-2-cyanoacrylate adhesive glue for perineal skin repair after episiotomy
45362614|NCT00840788|Procedure|Subcuticular suture of perineal skin|Use of continuous subcuticular suture with rapidly absorbable polyglactin 910 for closure of the perineal skin in episiotomy repair
45362615|NCT02549924|Drug|Resveratrol|Resveratrol capsules, 500 mg 3 times daily with the first bite of each meal
45362616|NCT02549924|Drug|Placebo|Placebo capsules, 500 mg 3 times daily with the first bite of each meal
45480170|NCT01305395|Drug|Sirolimus|Will start sirolimus after they develop CAV by angiogram
45480171|NCT01305395|Drug|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
45480172|NCT03495817|Drug|ATI-50002|ATI-50002 Topical Solution
45480173|NCT02490514|Other|No intervention|No intervention was administered in this study.
45480174|NCT02886624|Drug|Grazoprevir/Elbasvir|Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks
45845181|NCT02272686|Drug|Ibrutinib|560 mg by mouth daily.
45845182|NCT02273310|Behavioral|Problem-Solving Skills Training for Disease Management|Children and caregivers participated in a multi-family group to learn problem-solving skills as applied to disease management and school functioning in the context of sickle cell disease.
46049639|NCT05363124|Other|PEWS calculation by nurse using conventional procedure|After patient registration, the patient will be installed in the nursing office with one of his parents . After screening a potential life-threatening patient for which treatment would be started first of all, the nurse will collect the signed parental consent for participating to the study. the nurse proceed to the calculation of PEWS in blind of parents and to triage process by priorityzing patient in 5 level of gravity (from 1-vital emergency to 5-nonurgent patient). If the medical examination was not proceeded directly after the triage process, nurses were asked to proceed a new triage if the optimal delay of the medical examination was passed.
45362617|NCT01813227|Drug|Carfilzomib|If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.
45362618|NCT01813227|Drug|Rituximab|"If you decide to participate in the study, in addition to the carfilzomib and possible dexamethasone administration, If less than a partial remission (PR) after 4 cycles is achieved, rituximab 375 mg/m2 on day 16 of each subsequent cycle will be added to the treatment. Subjects who meet the criteria for progression prior to 4 cycles of therapy will have rituximab 375 mg/m2 weekly for 4 consecutive weeks every 3 cycles added to the treatment. Subjects will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.~At the beginning of every cycle, your study doctor will see if your general health is satisfactory. You will be asked to report any side effects or problems you have had since the start of the last treatment cycle as well as any medication change(s)."
45362619|NCT01813227|Drug|Dexamethasone|"If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.~You will also receive dexamethasone weekly on Days 1, 2, 8, 9, 15 and 16 starting with cycle 1 and continuing every cycle thereafter."
45480175|NCT03790241|Procedure|insertion of a catheter|Analysis the palpation and perforation motion performed by the practitioner during the insertion of a catheter while measuring the loads applied on the skin and the veins
45689103|NCT01462929|Drug|Tiotropium|Dosage form: Dry powder hard gelatin capsule. Route of administration: Oral inhalation by HandiHaler single-dose dry powder inhaler Dose and regimen: 1 capsule (18 μg) in the morning (09:00 ± 1h)
45689104|NCT01462929|Drug|Placebo|Dosage form: Dry powder Route of administration: Oral inhalation by Genuair multidose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h) AND Oral inhalation by HandiHaler single-dose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h).
45689105|NCT01462695|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
45689106|NCT01462695|Other|Pharmacological Study|Correlative studies
45689107|NCT01462695|Drug|Sunitinib Malate|Given PO
45689108|NCT01465347|Drug|Trans Sodium Crocetinate (TSC)|TSC administered intravenously as a bolus injection prior to radiation therapy sessions during 6 weeks of radiotherapy.
45689109|NCT04079751|Procedure|Neutral Mechanical Alignment|Hip-knee-ankle angle of 180° ± 3°.
45689110|NCT04079751|Procedure|Anatomical Alignment|Restoring a patient's pre-diseased limb alignment
45689111|NCT03027687|Device|tDCS|tDCS is an electrical brain stimulation method
45689112|NCT01465191|Drug|Morphine|Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section
46049640|NCT00674908|Biological|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
45689113|NCT01519947|Drug|Methoxy polyethylene glycol-epoetin beta|Participants received 50-250 mcg SC according to local label
45689114|NCT01462227|Drug|Naltrexone High Dose|Naltrexone 100mg for two administrations.
46049641|NCT00674908|Biological|Easy Five|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib conjugate pentavalent liquid combination vaccine
46049642|NCT00607230|Biological|BCG|BCG vaccination at 0 and 4 weeks
45689115|NCT01462227|Drug|Naltrexone Low Dose|Naltrexone 50mg for two administrations.
45689116|NCT01464879|Drug|Testosterone Gel (FE 999303)|
45689117|NCT01519869|Drug|neoadjuvant chemotherapy|platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
45689118|NCT03026205|Drug|ARMS-I|
45689119|NCT01519791|Biological|Certolizumab Pegol|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at a dosage strength of 200 mg/ml.~Injections will be given subcutaneously. CZP 400 mg at Baseline, Week 2 and Week 4, followed by a maintenance dose of 200 mg every 2 Weeks until Week 50."
45689120|NCT01519791|Other|Placebo|2 syringes Placebo at Baseline, Week 2 and Week 4, followed by 1 syringe Placebo every 2 Weeks.
45845183|NCT02274870|Drug|Liposome Bupivacaine|Administered via local tissue infiltration around the knee joint
45845184|NCT02274870|Drug|Bupivacaine HCl|Administered via CFNB
45845185|NCT02276274|Drug|SYR-322-MET|Oral administration of SYR-322-MET
45362620|NCT00825578|Device|Intra-bronchial valve (Spiration IBV)|Device: Intra-bronchial valve (Spiration IBV) The IBV is comprised of a Nitnol frame and a polymer membrane, which is held against the airway mucosa by six elastic struts and will expand and contract with airway movement during breathing. The valve is designed to conform to the size and shape of the airways. The frame has 5 flexible anchors that gently secure to the mucosal wall at a controlled depth. Valves are available in 5, 6 and 7mm diameters appropriate for different airways. During a minimally invasive procedure, a catheter is passed through a bronchoscope (a flexible tube passed into the airways through the mouth) to deploy the umbrella-shaped valves into the airways. Only flexible bronchoscopy equipment is required. The valves are designed to be removed if indicated.
45689121|NCT01519791|Biological|Methotrexate|The MTX treatment is to be initiated at a dose of 10 mg per Week (oral tablets at the strength of 2.5 mg/tablet). The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Patients who could not tolerate ≥ 15 mg/week MTX by Week 8 were withdrawn while the maximum tolerated dose per patient (optimized dose) was maintained to Week 52.
45362621|NCT01012882|Biological|sublingual immunotherapy with allergen extract|sublingual application
45362622|NCT01012882|Biological|sublingual immunotherapy with placebo|sublingual application
45362623|NCT00841022|Other|Information with comics|Information of children with comic leaflet
45362624|NCT00989469|Drug|Nexavar (Sorafenib) and irinotecan (Campto)|Sorafenib administrated continuously orally 400 mg twice daily (a daily total dose of 800 mg). Irinotecan 180 mg/m² will be administered IV for 90 minutes every 2 weeks. The first dose of sorafenib will be administered after the first perfusion of irinotecan 180 mg/m² at the first infusion
45689122|NCT01461993|Biological|rLP2086 and Gardasil|Gardasil vaccine and rLP2086 injection will be given to the subject concomitantly in Group 1 at Months 0, 2 and 6.
45689123|NCT01461993|Biological|rLP2086|Injections of rLP2086 and saline will be given to the subject concomitantly in Group 2 at Months 0, 2 and 6.
45362625|NCT04709458|Biological|TBX-2400|Hematopoietic stem cells transplantation
45362626|NCT02546882|Biological|stromal vascular fraction|1million stromal vascular fraction was resuspended in 1 ml saline and transplanted for 1 cm2 area.
45362627|NCT02546882|Drug|saline|1 ml saline was injected for 1 cm2 area.
45362628|NCT00989547|Other|Umbilical Cord Blood VITA 34|Intervention type: Autologous Umbilical Cord Blood Transfusion
46049643|NCT00607230|Biological|Saline|Saline vaccination at 0 and 4 weeks
46049644|NCT02621710|Other|Questionnaire 3 months post-operatively|
46049645|NCT04265118|Device|Sidewards Tilting Bed|Sidewards tilting of the bed is hypothesized to induce a body position change in sleeping subjects.
46049646|NCT02621632|Device|(Socknleg)To done of a novel compression system|To done a novel compression system.
46049647|NCT04264104|Other|neural mobilization|This is a type of mobilization that uses a specific combination of joint movements
46049648|NCT00696358|Radiation|308nm excimer lamp|50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks
45845186|NCT02277054|Device|Collagen-MPC cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to approximately 50-90% of corneal thickness (depending on corneal ulcer or scar depth) and then a lamellar dissection will be created. Trephine diameter will depend on ulcer or leukoma maximal size. Alternatively a femtosecond laser may be used to create the dissection. A collagen-phosphorylcholine cornea 250-500 microns thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
45362629|NCT01010308|Drug|Nadolol|Nadolol will be administered orally at home starting at 0.5 mg/kg/day divided into 2 doses. Weekly, if BP and heart rate are acceptable, the dose will be increased by 0.5 mg/kg/day up to 2 mg/kg/day.
45362630|NCT04002687|Drug|ATV-PG 1000-400 mg + AQ 612 mg|The dosing will be carried out by an unblinded member of the investigator's staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. ATV-PG (or placebo) will always be given first, then AQ (or placebo).
45362631|NCT02548052|Drug|GSK2981278 0.03%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.03%. Approximately 200 microliters of the GSK2981278 0.03% ointment will be applied topically to the assigned test field once daily.
45689124|NCT01461993|Biological|Gardasil|Injections of saline and Gardasil vaccine will be given to the subject concomitantly in Group 3 at Months 0, 2 and 6.
45689125|NCT01782326|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI.
45845187|NCT02278146|Device|ParaPatch|A device for the treatment of urinary incontinence
45689126|NCT01782326|Drug|Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)|Salmeterol/fluticasone dry inhalation powder delivered via the Accuhaler device.
46049649|NCT00696358|Radiation|308nm excimer laser|50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks (same doses will be used between the 2 arms)
45689127|NCT01439373|Drug|GSK2336805|Active Investigational Drug
45689128|NCT01439373|Drug|Pegylated interferon alfa-2a|Standard of Care drug
45845188|NCT02279082|Drug|DFN-02|Active Experimental Drug
46049650|NCT05269212|Other|Usual Care trajectory|Usual care after Spinal Cord Stimulation implantation
46049651|NCT05269212|Other|A biopsychosocial rehabilitation program|A personalized biopsychosocial rehabilitation program specifically targeting return to work.
45362632|NCT02548052|Drug|GSK2981278 0.1%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.1%. Approximately 200 microliters of the GSK2981278 0.1% ointment will be applied topically to the assigned test field once daily.
45362633|NCT02548052|Drug|GSK2981278 0.8%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.8%. Approximately 200 microliters of the GSK2981278 0.8% ointment will be applied topically to the assigned test field once daily.
45362634|NCT02548052|Drug|GSK2981278 4%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 4%. Approximately 200 microliters of the 4% ointment will be applied topically to the assigned test field once daily.
45362635|NCT02548052|Drug|Vehicle|GSK2981278 vehicle will be supplied as a white to off-white ointment containing no drug substance. Approximately 200 microliters of the vehicle will be applied topically to the assigned test field once daily.
45362636|NCT02548052|Drug|Betamethasone valerate 0.1%|Betamethasone valerate will be supplied as a cream. Approximately 200 microliters of the 0.1% betamethasone valerate cream will be applied topically to the assigned test field once daily.
45362637|NCT03630328|Dietary Supplement|Cogni.Q|AGN
45689129|NCT01439373|Drug|Ribavirin|Standard of Care drug
45689130|NCT01439373|Drug|GSK2336805 Matching Placebo|Placebo of Investigational Drug
45689131|NCT04077801|Diagnostic Test|diagnostic test|diagnostic test
45689132|NCT01461369|Drug|Diclofenac|35 mg bid Capsules
45689133|NCT01461369|Drug|Diclofenac|35 mg tid Capsules
46049652|NCT02621554|Dietary Supplement|resveratrol supplementation|6 months of resveratrol supplementation
45362638|NCT03630328|Other|Placebo|Placebo
45689134|NCT01461369|Drug|Placebo|Capsules
45845189|NCT02279160|Drug|APD811|
45845190|NCT02279160|Drug|Placebo|Placebo
45845191|NCT02281344|Drug|MMV390048 20mg|Supplied as a powder to be prepared as a suspension for oral use
45845192|NCT02281422|Drug|BIA 2-093|
46049653|NCT02621554|Dietary Supplement|Placebo|6 months of placebo intake
46049654|NCT02623036|Drug|Equivalent dose enalapril|Chronotherapy with enalapril.
46049655|NCT02623036|Drug|Equivalent dose lisinopril|Chronotherapy with lisinopril
45480176|NCT03717025|Procedure|SUCTION BLISTER EPIDERMAL GRAFTING|"Preferred donor sites for making blister is lateral aspect of upper thigh. The area is shaved and cleansed with surgical spirit.~Blister formation is induced by using suction apparatus.~Recipient site is surgically prepared by doing dermabrasion.~After formation of blisters, each blister is gently cleansed with normal saline and cut all along its border with curved iris scissors parallel to the skin surface. The roof is everted over the thumb with dermal surface facing upwards and then with the help of blunt end of forceps it is placed on the recipient area.~The graft is firmly pressed with sterile moist gauze to remove any underneath serous collection.~The pressure dressing is done with double layer framycetin tulle, moist gauze and bandage.~Donor area is dressed with dry sterile pads.~The part is immobilized and Antibiotics and Analgesic are given till dressing are removed (after 5-7 days)."
45845193|NCT02282514|Biological|Autologous Hematopoietic Stem Cells|The stem cells will be collected from patient's blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous Hematopoietic Stem Cell Transplantation is to re-infuse immature cells that can re-establish blood production and patient's immune system.
45480177|NCT03717025|Procedure|MINI PUNCH GRAFTING|"Recipient area is prepared first after shaving and cleaning with surgical spirit. 2 % lignocaine with or without adrenalin will be infiltrated as local aneasthetic.~The punched out chambers are spaced at a gap of less than 5 mm (preferably 2 - 2.5 mm) from each other.~The donor area is either upper lateral portion of thigh or gluteal region.~Grafts are placed directly from donor to the recipient area. Care is taken, so that graft edges are not folded, the tissue is not crushed or placed upside down.~Hemostasis is achieved by pressing a saline soaked gauze piece over the area.~For the recipient area 3 layers of dressing from inside out are : paraffin embedded non adherent sterile gauze, sterile surgipad, and micropore.~For the donor area only surgipad and micropore are used.~Immobilisation of recipient area is advised along with antibiotics and analgesics till removal of dressing (after 4-7 days)."
45689135|NCT04414124|Other|KB109 + Self Supportive Care (SSC)|KB109 is a novel glycan
45362639|NCT04590417|Drug|Estradiol valerate 2 mg, cyproterone acetate 25 mg|The entire study period will be approximately 1 year, which will include around 2 months of document preparation, 5 months of recruitment, 3 months of follow-up, and 2 months of data analysis.
45689136|NCT04414124|Other|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
45845194|NCT02282514|Drug|Cyclophosphamide|An alkylating agent which causes prevention of cell division by forming adducts with DNA
45845195|NCT02282514|Drug|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
46049656|NCT00696826|Drug|sitagliptin phosphate|sitagliptin phosphate 100 mg MK0431 (2 x 50 mg tablets) taken orally after overnight fast; Duration of Treatment: 5 Weeks
45845196|NCT02282514|Drug|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
46049657|NCT01092182|Drug|EPOCH-R|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
46049658|NCT01092182|Drug|EPOCH-RR|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 3 cycles
45362640|NCT00825656|Drug|Sinol or Sinol-M nasal spray|"One spray in each nostril up to a maximum of 12 times / day on an as needed basis"
45362641|NCT01010386|Procedure|Atmospheric oxygen tension|Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere
45362642|NCT01010386|Procedure|Physiologic oxygen tension|Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
45362643|NCT00989625|Drug|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
45689137|NCT04575662|Radiation|STAR Treatment|Radiation therapy that delivers non-invasive, image-guided, precise high-dose of radiation to targets reducing dose exposure to adjacent normal tissue and minimizing the treatment toxicity.
45689138|NCT01727258|Device|Mouth Rinse|Mouth rinse 12027-033 used twice daily for 28 days after brushing.
45689139|NCT01727258|Drug|Fluoride Toothpaste|Fluoride Toothpaste used daily for 28 days.
45845197|NCT02282514|Drug|Methylprednisolone|Steroid
45845198|NCT02282514|Drug|G-CSF|Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
45845199|NCT02282514|Drug|Rituxan|A chimeric monoclonal antibody used in the treatment of B cell non-Hodgkin's lymphoma, B cell leukemia, and some autoimmune disorders
46049659|NCT02623192|Other|Patients who have performed the ARDS pulmonary function test|
46049660|NCT04135378|Drug|ascorbic acid|Study Group :- ascorbic acid ( 500 mg per day) for one week before presentation
45362644|NCT00989625|Drug|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
45845200|NCT02282904|Drug|Sirolimus|"For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).~Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum)."
45845201|NCT02282904|Biological|Donor peripheral blood stem cells.|Infuse donor graft.
46049661|NCT04135378|Other|placebo|:- included 30 students given placebo for one week before presentation.
46049662|NCT04135690|Procedure|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
46049663|NCT04135690|Drug|Toripalimab|240mg intravenously every 3 weeks
46049664|NCT04135690|Drug|Sorafenib|400mg bid po
45362645|NCT00989625|Drug|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
45362646|NCT02548208|Device|Verum focused extracorporeal shockwave|the concentrated shockwave energy per unit area (energy flux density EFD) can vary from 0.06 to 0.09 mJ/mm2. The pulse ratio per point is 200.
45689140|NCT01727258|Drug|Potassium Nitrate Toothpaste|Potassium Nitrate Toothpaste used daily for 28 days.
45689141|NCT04583306|Other|Raman analysis of saliva, characterization of the Raman database and building of the classification model|Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
45689142|NCT01781390|Other|Placebo|Matching placebo solution for infusion.
45689143|NCT01781390|Biological|Mesenchymal Precursor Cells (MPC) 12.5 M|MPC 12.5 M solution for infusion.
46049665|NCT02878772|Drug|vinpocetine|30 mg of the drug by intravenous infusion once daily, for fourteen consecutive days, beginning within one hour after the baseline MRI and no later than 48 hours after the onset of symptoms.
45362647|NCT02548208|Device|Sham shock wave|Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy.
45362648|NCT01010464|Procedure|Adhesion Reduction Plan|Lysis of adhesions and application of a minimum of 4 sheets of a sodium hyaluronate-based bioresorbable membrane
45689144|NCT01781390|Biological|Mesenchymal Precursor Cells (MPC) 25 M|MPC 25 M solution for infusion.
45689145|NCT01781234|Drug|Intranasal Insulin|
46049666|NCT02878772|Drug|Aspirin|100mg, once daily, oral medication
46049667|NCT02623114|Drug|methylphenidate|The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
45362649|NCT00841256|Biological|Grass pollen allergens in a water/glycerol solution|In total up to 4 drops (dose for maintenance therapy) are administered under the tongue.
45362650|NCT00841256|Drug|Placebo|Placebo was given in the same way as the sublingual active treatment. Symptomatic standard treatment, i.e. antihistamines and glucocorticoids as well as alphamimetics is allowed during grass pollen season.
45362651|NCT05360355|Procedure|total face reconstruction surgery and intraoperative indocyanine green angiography|Patients with total facial scarring following burn injury were treated with monoblock pre-expanded prefabricated flaps for total face restoration. The opening of nostrils, oral and palpebral orifices, together with organ fabrication, were conducted under the guidance of intraoperative ICGA for hemodynamic evaluation.
45362652|NCT01010542|Drug|ILV-095 300 mg in a 4 to 1 ratio|Single dose of ILV-095 300 mg
45362653|NCT01010542|Drug|ILV-095 300 mg in a 4 to 1 ratio|Single dose of Placebo
45362654|NCT00989703|Drug|placebo|oral solution, daily for 14 days
45362655|NCT00989703|Drug|GLPG0259|oral solution
45362656|NCT00989703|Drug|Methotrexate|7.5 mg (3 tablets, 2.5 mg/tablet) on study days D-1 and D14
45362657|NCT01012960|Drug|methylnaltrexone|0,15 mg/kg sc ( subcutaneously)once per volunteer
45689146|NCT01781234|Drug|Placebo|
45689147|NCT01752842|Drug|Fenofibrate|
45689148|NCT01752842|Drug|Placebo for fenofibrate|
45689149|NCT01461057|Drug|Capecitabine|1000 mg/m2 twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle
45689150|NCT01461057|Drug|Cisplatin|80 mg/m2 on Day 1 of each cycle
45689151|NCT01461057|Drug|Pertuzumab|loading dose of 840 mg, then 420 mg once every three weeks
45689152|NCT01461057|Drug|Pertuzumab|840 mg once every three weeks
45689153|NCT01461057|Drug|Trastuzumab|loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles
45689154|NCT01460901|Biological|GD2 CAR modified Tri-virus specific cytotoxic t-cells|This is a feasibility study to assess safety of an infusion of chimeric-antigen receptor gene modified allogeneic virus specific T lymphocytes after reduced intensity allogeneic stem cell transplant. Three patients were treated and safety was evaluated. Patients received a single infusion of 2x10e6/m2 donor derived, GD2 CAR modified, tri-virus specific CTL performed 30-120 days after allogeneic stem cell transplantation
45362658|NCT04572009|Other|Bio-mathematical model|bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
45362659|NCT04572009|Other|Without bio-mathematical model|No bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
45362660|NCT03610906|Procedure|Tumor and Blood Specimens|If available, specimen will be sampled from within the tumor, and not include portions of the tumor capsule. If the tumor includes a cyst, fluid from the cyst will be sampled if available. For each tumor specimen, a companion sample of blood that would otherwise be disposed of through usual clinical practice in the operating room will also be collected.
45689155|NCT04567407|Drug|Bilateral erector spinae blocks using ropivacaine|Bilateral chest wall nerve blocks using ropivacaine.
46049668|NCT02623114|Drug|atomoxetine|The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
46049669|NCT00932646|Drug|BI 1744 (Olodaterol) Low Dose|BI1744 Respimat low dose once daily and placebo Foradil
46049670|NCT00932646|Drug|BI 1744 (Olodaterol) Medium Dose|BI1744 Respimat medium dose once daily and placebo Foradil
45362661|NCT00625586|Biological|RAV12 plus gemcitabine|"Initial dose of gemcitabine plus RAV12 at 0.375 mg/kg qw escalated to 0.75 mg/kg qw.~During the efficacy segment, 63 pts were to be treated with gemcitabine 1000 mg/m2 iv over 30 min., weekly days 1, 8, 15, 22 of the first cycle and 1000 mg/m2 iv over 30 min., weekly days 1, 8, and 15 of each subsequent cycle of 28 days plus RAV12 at Maximum Tolerated Dose (MTD) iv days 1; 4 or 5; 8, 11 or 12; and 15, 18 or 19 of each 28-day cycle until progression."
45362662|NCT01683825|Drug|F-18 florbetapir PET|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)
45362663|NCT00841334|Behavioral|ACTION|Overweight/obese adolescents enrolled in ACTION will meet with SBHC providers over a 6 month period in one school year. SBHC providers will use Motivational Enhancement Therapy to motivate overweight/obese adolescents to adopt strategies for improving nutrition and physical activity.
45362664|NCT00841334|Behavioral|Usual care|Overweight/obese adolescents in the second arm will receive a well child check with usual anticipatory guidance.
45362665|NCT02547116|Drug|Rifampin|Addition of Rifampin to standard anti-Staphylococcal treatment regimen
45362666|NCT05377047|Radiation|SABR|Stereotactic Ablative Radiotherapy is delivered to all metastatic lesions.
45362667|NCT05363397|Drug|AZD6482|AZD6482 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation, thereby specifically inhibiting thrombosis without interfering with normal haemostasis.
45362668|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|0.58 mg/kg every week
45362669|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every week
46049671|NCT00932646|Drug|Placebo|Placebo Respimat once daily and placebo Foradil
46049672|NCT00932646|Drug|Foradil|12 mcg twice daily and placebo Respimat
46049673|NCT02878460|Other|monitoring with ORI + SpO2|"If ORI is equal to 0.00, the FiO2 (or oxygen flow) is not changed. if ORI is ≥ 0.01, Nurses must decrease the FiO2 (or oxygen flow) by 10%, until ORI is =0.~if SpO2 is < lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called."
46049674|NCT02878460|Other|monitoring with SpO2|"If SpO2 is below the upper individualized limit, the FiO2 (or oxygen flow) is not changed.~If SpO2 is equal or above this limit, Nurses must reduce the FiO2 (or oxygen flow) by 10% every 10 minutes until SpO2 is ≤ upper individualized limit, with FiO2≥25 %.~if SpO2 is < lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called."
46049675|NCT00871234|Drug|Etravirine|Two one-hundred mg tablets orally twice daily for four weeks
45362670|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every other week
45362671|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.8 mg/kg every other week
45362672|NCT00835562|Procedure|Non-surgical management|Non-surgical management (physiotherapy and self-training)
45689156|NCT01519635|Drug|Aliskiren|Drug therapy will be started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
45689157|NCT01519635|Drug|Hydrochlorothiazide|Drug therapy will be started with an initial 2 weeks HCTZ 12.5 mg followed by a titration to 25 mg HCTZ if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
45689158|NCT01519323|Drug|vemurafenib|Cohort 1 (participants >=45 kg): starting dose level 720mg; next dose level 960 mg Cohort 2 (participants <45 kg): starting dose 480 mg
45845202|NCT02282904|Drug|Cyclophosphamide post transplant|50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
45845203|NCT02282904|Radiation|Total body 200cGy|Day -1
46049676|NCT04941482|Behavioral|Periodic health check program for post-stroke|The stroke survivors will be assessed their physical and mental health, recurrence risks, and harmful behaviors at 0, 1, 3, and 6 months by specific scales.
45362673|NCT00835562|Procedure|Osteosynthesis|Osteosynthesis with angle-stable plate followed by physiotherapy and self-training
45362674|NCT00835562|Procedure|Hemiarthroplasty|Primary modular hemiarthroplasty followed by physiotherapy and self-training
45362675|NCT05359107|Behavioral|"The Free From Pain Exercise Book"|Contains educational information and exercises to improve musculoskeletal pain and reduce sarcopenia.
45362676|NCT05359107|Behavioral|"The Back Book"|Contains advice and guidance on how to deal with and reduce back pain.
45689159|NCT01519245|Drug|Tranexamic Acid|Solution containing 2 grams (20mL) tranexamic acid + normal saline (50mL), for a total volume of 70mL poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction.
46049677|NCT04941482|Behavioral|Guiding the appropriate rehabilitation exercises|The appropriate rehabilitation exercises will be designed and guided for each patient and they will be followed up by the daily online report.
45689160|NCT01519245|Drug|normal saline|A total volume of 70mL of normal saline poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction. Identical in appearance to the trial drug, and is visually indistinguishable.
45689161|NCT01519167|Drug|Dexmedetomidine|0.1 - 1.0 mcg/kg/hr IV
45689162|NCT01519167|Drug|Midazolam|0.025 - 2 mg/kg IV
45689163|NCT01519167|Drug|Fentanyl|0.5 - 3 mcg/kg IV
46049678|NCT04941482|Behavioral|Motivational Interviewing|Motivational Interviewing will carry out on post-stroke patients in the first three months (one time per week in the first month and one time per the second and third month). This intervention method aims to discover and resolve patient's conflicts by a standardized communication skill to improve their mental health and change negative behaviors.
46049679|NCT04941482|Device|Functional near-infrared spectroscopy|The fNIRS devices as an effective monitoring and therapeutic tool, evaluating the evolution of neural activity and stroke rehabilitation and recovery. Moreover, the cortex hemodynamic measure by fNIRS may detect early various mental disorders such as depression, anxiety, schizophrenia... through cognitive tasks.
45362677|NCT03971695|Drug|BI 706321|Capsule or Oral Solution
45362678|NCT03971695|Drug|Placebo|Capsule or Oral solution
45689164|NCT00343564|Drug|SB-743921|Phase 1: I.V. dose on Days 1 and 15 of a 28 day cycle starting at 2mg/m2 and increasing by 1 mg/m2 with possible prophylactic granulopoietic support until unacceptable toxicity develops.
45362679|NCT02549690|Drug|Testosterone gel|Apply 10mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 6-8 weeks until next IVF treatment.
45362680|NCT02549690|Drug|DHEA|Take DHEA 25mg tablet orally, three times per day. Continue the treatment for 6-8 weeks, until next IVF treatment.
45362681|NCT05357937|Behavioral|standard physiotherapy program|A qualified physical therapist administered a structured physiotherapy program from day 1 to day 7 in both groups
45362682|NCT02549768|Drug|Dexmedetomidine|At start of anesthesia, bolus of 1 mcg/kg of dexmedetomidine over 10 minutes and then infusion of 0.7 mcg/kg/h during surgery will be administered.
45362683|NCT02549768|Drug|Sodium Chloride 0.9%|Sodium chloride 0.9% with a pump programmed in same way as Dexmedetomidine pump
45362685|NCT04551651|Device|ApplTree|App downloaded on the participants phone, a short video tutorial session to explain use, and technical support throughout trial period.
45689165|NCT00343564|Drug|SB-743921|Phase 2: I.V. dose and regimen will be determined based on Phase 1 findings.
45689166|NCT00318136|Drug|Bevacizumab|15 mg/kg administered intravenously on Day 1 of each 21- to 28-day cycle, beginning on Cycle 3
45362686|NCT04551651|Device|Google Calendar|App downloaded on the participants phone, a short video tutorial session to explain use, and technical support throughout trial period.
45362687|NCT00841646|Biological|Monovalent inactivated influenza vaccine|2 doses of monovalent inactivated influenza vaccine with adjuvant
45689167|NCT00318136|Drug|Carboplatin|Dose based on Calvert formula, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
45689168|NCT00318136|Drug|Paclitaxel|Dose based on patient's body surface area, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
45362688|NCT04464213|Other|Single dose experiments|In single dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient only receive treatment once time.
45362689|NCT04464213|Other|Multi-dose experiments|In multi-dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient receive treatment on six consecutive days.
45689169|NCT00318292|Drug|bupivacaine and epinephrine|20 ml of 0.5% bupivacaine with 1:200,000 epinephrine paracervical injection.
46049680|NCT04135612|Other|Smartphone based communication|Each patient will document each evening her lactation performance during the day, and the App will generate a daily report transmitted by email every evening to our computerized research database. Every evening the patient will receive via email an individualized feedback from our team regarding her lactation. This feedback could include: reassurance and positive feedback and lactation tips in attempt to optimize specific obstacles.
45689170|NCT00318292|Drug|Placebo|20 ml normal saline injection.
45689171|NCT01791868|Drug|Intravenous Sodium Valproate|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
45362690|NCT00841724|Drug|Fludarabine, Busulfan, Thymoglobuline|
45362691|NCT00843362|Drug|Dinoprostone vaginal pessary|10 mg controlled-release dinoprostone pessary applied for 24 hours
45362692|NCT00843362|Drug|Dinoprostone vaginal gel|2 mg vaginal dinoprostone gel, two daily doses with a 6 hours interval
45362693|NCT04003233|Device|SDS|The SDS will be added to a traditional growing rod (TGR) of 4.5 or 5.5mm.
45362694|NCT04003233|Device|MID-C|The MID-C system consists of a unilateral one-way ratchet rod that is connected to the spine with polyaxial connectors
45689172|NCT01791868|Drug|Placebo|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
45845204|NCT02282904|Drug|Cyclophosphamide|14.5 mg/kg IV over one hour Day -6 and -5
45845205|NCT02282904|Drug|Fludarabine|30 mg/m2 over 30 minutes Day -6 through Day -2
46049681|NCT02877914|Other|Observational study|This is a non-interventional study, patients receive their usual treatment as determined by the physician.
46049682|NCT00675064|Drug|GSK369796|Anti-malarial
46049683|NCT00675064|Drug|Placebo|Placebo matching GSK369796
46049684|NCT02879240|Other|Animated Cartoon|An animated cartoon chosen by the parents is displayed on a smartphone attached on the spacer of the child.
46049685|NCT02879240|Other|Black screen|A video displaying a black screen is used as control, and displayed on a smartphone attached on the spacer of the child.
45480178|NCT03717025|Procedure|NON CULTURED EPIDERMAL CELL SUSPENSION|"About one-tenth the size of recipient area is selected as the donor site.~Split thickness skin graft is taken under aseptic precautions with the help of a shaving blade held firmly by a straight artery forceps.~The area is dressed with Bactigras gauze.~Split thickness skin specimen is transferred under aseptic conditions to a container with Normal Saline and transferred to laboratory for preparing suspension.~Recipient site is dermabraded under aseptic precautions until tiny pinpoint bleeding spots are seen.~Epidermal cell suspension is carefully transferred to a tuberculin syringe.~With 18 gauge needle attached to this syringe, suspension is spread evenly on dermabraded recipient site.~This is then covered with Collagen dressing, followed by bactigras, guaze and tegaderm dressings from inside to outside.~The patient is observed for 2 hours after performing the procedure and given antibiotics and analgesics for 5-7 days till dressing removal."
45480179|NCT02487238|Biological|Fecal Microbiota Enema|Active intervention.
45362695|NCT00841802|Drug|Prednisone|Prednisone 30mg once daily x 5 days
45362696|NCT05300295|Behavioral|Mentoring Program|The Autism Mentorship Program is a psychosocial intervention that pairs adults and adolescents with autism spectrum disorder (ASD) in one-to-one mentoring relationships. AMP involves weekly meetings in an afterschool setting and targets the socio-emotional health and social connectedness of adolescents and adults with ASD.
45362697|NCT00989859|Device|Plethysmographic monitoring|Plethysmographic monitoring
45689173|NCT01791946|Procedure|Binocular Treatment|The binocular treatment involves the completion of visual tasks via virtual reality goggles. The stimulus is presented to each eye separately, allowing for varying levels of contrast to be presented to each eye. (The visual task is therefore made more or less difficult with the variation of contrast presented to either eye.) Subjects will complete the computer-based visual tasks for approximately 36 hours total over the course of six weeks, or six hours per week for six weeks.
45689174|NCT01791946|Procedure|Sham Binocular Treatment|The sham treatment involves the same computer-based visual tasks and timeframe as the binocular treatment training but there will be no variation in contrast presentation to either eye.
45845206|NCT02282904|Drug|Busulfan|Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2
45362698|NCT00621140|Drug|linagliptin|active
45362699|NCT00621140|Drug|placebo|placebo
45362700|NCT00207727|Drug|CNTO 1275|
45362701|NCT00841880|Drug|Ramipril + Felodipine|Ramipril 5mg + Felodipine 5mg once a day
45362702|NCT00841880|Drug|Ramipril|10 mg once a day
45362703|NCT00841880|Drug|Ramipril|5mg once a day
45362704|NCT03971851|Other|Frailty risk groups|Patients older than 65 will be separated into groups of varying frailty risk
45480180|NCT02487238|Biological|Normal Saline Enema|Placebo comparator.
45362705|NCT00835874|Drug|Probiotics|Lactobacillus acidophilus, b.lactis capsule. Once daily.2X 10 by the power of 10 bacteria per dose.
45362706|NCT03969745|Behavioral|Time restricted feeding|Restrict energy intake window to between 8am and 4pm
45362707|NCT03969745|Behavioral|Caloric restriction|Follow a prescribed daily energy deficit of 400 kilocalories without altering nutrient timing
45362708|NCT00835952|Drug|ATX-101|ATX-101 single doses
45362709|NCT03971773|Other|hypnosis|patient with cancer will undergo sessions of hypnosis
45362710|NCT05035173|Other|Survivorship Clinic Assessments|"Patients will visit in person the Survivorship Clinic at the baseline and end of the study (12-month) at the ORCHID center in the Cork University Hospital (Cork, Ireland).~During these visits, baseline and end of the study assessments will be made. Patients will receive routine standard information, a care plan and resources about survivorship at the baseline visit."
45480181|NCT01305863|Device|ASC coated ePTFE vascular graft|An ePTFE vascular graft in which the lumen of the graft has been coated with an autologous coating of adipose-derived stromal cells (ASC) prepared using an automated point-of-care processing instrument to facilitate isolation and concentration of autologous adipose-derived stromal cells and subsequent sodding of small-diameter vascular grafts.
45480182|NCT01305863|Device|Propaten graft|6 mm Gore PROPATEN® graft (heparin-coated ePTFE vascular graft, thin-walled removable-ring stretch)
45845207|NCT02283528|Device|Stryker Hybrid|Place Hybrid arch bars
45845208|NCT02283528|Device|Erich|Control group is Erich arch bars
45845209|NCT02283840|Drug|BIA 2-093|
45362711|NCT05035173|Other|Survivorship Clinic Nurse Resource|"Patients will receive a Survivorship Personal Treatment Plan by the nurse from the Women's Health Initiative Survivorship Clinic according to the results from the baseline ePROs. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The nurse will undertake an intervention when needed based as per the Trigger system (developed form ePROs responses) or clinical judgement.~- ePRO Symptom Survey Instrument (nurse questions): A core list of symptoms/adverse events that are identified including gastrointestinal, attention/memory, pain, fatigue and insomnia, mood-emotional distress/depression, anxiety, fear of cancer recurrence, gynaecological, urinary, sexual issues, hot flashes."
45480183|NCT02280902|Biological|Blood samples|Systematic follow-up (M3, M6, M12, M18, M24, M30) will be implemented to complete epidemiologic, clinical, therapeutic and biological data during a 30 months period. Specific measure of immune cells, markers of immune activation, immunoglobulins as described above will be performed at M3, M6, M12 and M24. A biologic collection (serum and cells) will be performed at the same time points for future prognostic studies.
46049686|NCT04267224|Drug|Ticagrelor 90mg|Ticagrelor is a direct-acting inhibitor of the platelet P2Y12 receptor with a rapid antiplatelet effect. It has been shown to reduce the rate of major cardiovascular events among patients with acute coronary syndromes, as compared with Clopidogrel, and has the potential to improve coronary reperfusion and the prognosis for patients with STEMI treated with primary PCI.
45480184|NCT02311673|Drug|RM-493|subcutaneous injection
45480185|NCT02311673|Drug|Placebo|subcutaneous injection
45480186|NCT02487316|Drug|crizotinib|crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.
45480187|NCT05669105|Diagnostic Test|Specimen sample|Participants will have up to 100 mL of whole blood collected.
45480188|NCT02490436|Drug|Cetuximab|Randomized cross-over between cetuximab and placebo
45480189|NCT02490436|Drug|Placebo|Randomized cross-over between cetuximab and placebo
45480190|NCT03793595|Device|Seated Battle Ropes Protocol|Participants will begin swinging the rope as previously described in the seated position using the double arm swing technique for 15 seconds at a cadence of 100 beats/ minutes with a 45 second rest break repeated 10 times.
45480191|NCT03793595|Device|Seated Upper Extremity Arm Bike|A modified Young Men's Christian Association (YMCA) cycle test will be performed.
45480192|NCT03318718|Drug|Anesthesia with non-depolarizing NMBA Rocuronium|Non- depolarizing NMBA Rocuronium will be used until full paraspinal muscle Relaxation. Muscle relaxation during surgery will be performed using intraoperative boli intermediate duration non-depolarizing NMBA, rocuronium (0.3 mg/kg) until good surgical conditions are achieved.
45480193|NCT03318718|Diagnostic Test|TOF measurement|TOF (Train-of-four) measurements will be performed at baseline 5 minutes after induction after the effect of succinylcholine will have run off. Moreover, TOF measurements will be performed 5 minutes after each rocuronium bolus
45480194|NCT03318718|Diagnostic Test|MEP measurement|MEPs (motor evoked potentials) are routinely obtained after intubation and before surgery, then every 10min during the critical preparation and closing phases of surgery and every 5min during the correction phase. In addition MEPs will be measured after the administration of the NMBA rocuronium. Baseline values for amplitudes and latencies are obtained directly prior to the start of the correction phase of the surgery.
45480195|NCT03790319|Behavioral|The Power of Feelings|"Three workshops of three days each teach about the five basic feelings rage, sadness, fear, shame and joy and talk about the powerful and destructive qualities they can have. In addition to that they are about how to deal with emotions, which are defined as unfelt feelings of the past.~Smaller lectures give the participants an overview about the themes. Through exercises the participants can make experiences p.e. about each of the feelings. Another element is the sharing in dyads or small groups about actual feelings to practice emotional disclosure and to build a culture of openness and compassion."
46049687|NCT00675142|Procedure|Intrauterine Insemination|Changing the time span between ovulation induction and IUI during fertility treatment.
46049688|NCT04267068|Behavioral|Growth Mindset and Modifiable Risk Factor Information|15 minute interactive article describing neuroplasticity followed by 15 minute interactive article describing modifiable risk factors for depression and anxiety
45480196|NCT03790319|Behavioral|The Emotional Backpack|"One workshop of three days teach about how to deal with emotions, which are defined as unfelt feelings of the past. They show a way to work in couples with a form of emotional disclosure that helps process emotions that have been overwhelming in the past.~Smaller lectures give the participants an overview about the themes. Through exercises the participants can make experiences p.e. about each of the feelings. Another element is the sharing in dyads or small groups about actual feelings to practice emotional disclosure and to build a culture of openness and compassion."
45480197|NCT03325348|Drug|Nifedipine 10 mg|Nifedipine 10mg oral tablet with 1 ml 0.9% n/saline will be given to patients every 15 min uptil one hour
46049689|NCT04267068|Behavioral|Control|30 minute interactive article describing symptoms of depression and anxiety, common concerns of college student
46049690|NCT00675220|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
46049691|NCT00608400|Dietary Supplement|Clarinol CLA|0, 1.5 or 3.0 g/d dietary conjugated linoleic acids glycerides for 4 months, capsule form
46049692|NCT04264260|Drug|Colchicine Tablets|three times or two times per day after meal with the daily total dose ranging from 1.5 to 3 mg
46049693|NCT04152304|Other|Sinex program (neuromuscular training program)|The SINEX program is a three months neuromuscular training program aiming to increase neuromuscular stability of the shoulder
46049694|NCT04152226|Drug|J. Lividum|Investigational Product
45480198|NCT03325348|Drug|Labetalol|IV labetalol 20 mg & mint tablet will be given to patients every 15 min until one hour
45480199|NCT03790163|Drug|Levobupivacaine|Drug: levobupivacaine at room temperature ( 23˚C) and second group levobupivacaine warmed to the (30˚C) while the third group levobupivacaine warmed to the body temperature (37˚C)
45362712|NCT05035173|Other|Survivorship Clinic Dietitian Resource|"Patients will receive Diet Education and Personalised Nutrition Counselling by the dietitian from the Women's Health Initiative Survivorship Clinic at the baseline. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The dietitian will undertake an intervention when needed as per the Trigger system (developed form ePROs responses) or clinical judgement.~- ePRO Symptom Survey Instrument (diet questions): nutritional risk (lack of appetite; worry regarding weight loss; worry regarding weight gain), weight, and exercise."
45362713|NCT00843440|Drug|Bevacizumab|5 mg / kg every 14 days with a total of 6 injections.A two-phase Gehan method will be used with a first phase designed to eliminate a non effective treatment quickly and a second phase allowing assessment of efficacy.
45362714|NCT00504556|Drug|Edoxaban (DU-176b)|30mg tablet once daily
45480200|NCT01775657|Device|Thopaz (Digital drainage)|
45480201|NCT01775657|Device|Pleur Evac (Analogue drainage)|
45480202|NCT03321448|Drug|TMTP1-ICG|Detection of SLN
46049695|NCT00607308|Biological|PF-04360365|Single dose of 0.1 mg/kg IV on Day 1
45362715|NCT00504556|Drug|Edoxaban (DU-176b)|60mg tablet once daily
45362716|NCT00504556|Drug|Edoxaban (DU-176b)|30mg tablet two times a day
45362717|NCT00504556|Drug|Edoxaban (DU-176b)|60mg tablet two times a day
45362718|NCT00504556|Drug|warfarin|warfarin tablets
45362719|NCT05274009|Other|No cooling (control)|Participants are exposed to 35°C, 60% relative humidity for 8 hours.
45362720|NCT05274009|Other|Recommended cooling|Participants are exposed to 35°C, 60% relative humidity for 3 hours, are then moved to an air-conditioned room for 2 hours (~23°C, ~50% relative humidity), and then return to the heat for a final 3 hours.
45362721|NCT05274009|Other|Hybrid cooling|Participants are exposed to 35°C, 60% relative humidity for 2 hours, are moved to an air-conditioned room for 1 hour (~23°C, ~50% relative humidity), return to the heat for 2 hours, move back to the air-conditioned room for 1 hour, and then return to the heat for a final 2 hours
45480203|NCT03321448|Drug|ICG|Detection of SLN
45480204|NCT03325270|Dietary Supplement|labeled ferrous fumarate|labeled iron as Ferrous Fumarate
45480205|NCT03325270|Dietary Supplement|labeled ferrous fumarate + prebiotics|labeled iron as Ferrous Fumarate + galacto-oligosaccharides
45480206|NCT03325270|Dietary Supplement|labeled ferrous sulfate + prebiotics|labeled iron as Ferrous Sulfate + galacto-oligosaccharides
45480207|NCT04493710|Diagnostic Test|Sarcopenia estimation|Analysis of pre-existing CT imaging
45480208|NCT04493788|Other|Blood test, ultrasound and egg retrieval|Blood tests will be performed to determine free testosterone levels, anti-mullerian hormone (AMH) and lipid profile including fasting plasma glucose and insulin. Women from both PCOS and control groups will be minimally stimulated with gonadotrophins and cumulus-oocytes complexes (COCs) will be aspirated from small antral follicles (2-8mm) without any ovulation triggering. Specifically, administration of highly purified human menopausal gonadotropin (HP-hMG) will start on cycle Day 3 of the menstrual period or a withdrawal bleeding. A pelvic ultrasound scan will be performed in the morning of the last stimulation day to schedule the oocyte collection. Cumulus-oocyte complexes retrieved 42 hours after the last gonadotropin injection will be collected, washed, denuded and individually stored for further molecular characterization.
45480209|NCT03318640|Behavioral|Mindfulness|Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month
45362722|NCT00836030|Other|No treatment given|No treatment given
45362723|NCT00206323|Drug|Topiramate (drug)|Topiramate 25 mg titrated to 200 mg
45362724|NCT00206323|Drug|placebo/sugar pill|placebo
45480210|NCT03318562|Drug|eFT508|200 mg eFT508 dosed BID for 3 week cycles
45480211|NCT03318484|Drug|Optimal Medical Care|Aspirin 100mg once a day, Atorvastatin 20mg once a day and Antihypertensive Agents if necessary.
45689175|NCT02105740|Behavioral|Hypnosis|The hypnosis intervention consists of two 40-minute sessions, with an interval of 7 days between them, emphasizing the pain blocking, the well-being of the patient and the reduction of the symptoms of anxiety and depression of the same.
45845210|NCT02284386|Drug|Bupivacaine SNB|SNB with a single 1.6 mL dose of bupivacaine HCl 7.5 mg/mL within 2 hours prior to the surgical procedure.
46049696|NCT00607308|Biological|PF-04360365|Single dose of 0.5 mg/kg IV on Day 1
45362725|NCT00841958|Procedure|Autologous bone marrow mononuclear stem cells or peripheral blood stem cells|Cells concentration is 150х106 cells/ml (2ml) with CD34+ cells=2.5±1.44%
46049697|NCT00607308|Biological|PF-04360365|Single dose of 1 mg/kg IV on Day 1
46049698|NCT00607308|Biological|PF-04360365|Single dose of 5 mg/kg IV on Day 1
46049699|NCT00607308|Drug|Placebo|Single dose of placebo IV on Day 1
46049700|NCT00607308|Biological|PF-04360365|Single dose of 10 mg/kg IV on Day 1
46049701|NCT04135144|Other|Group 1 (printed materials)|Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
45480212|NCT03318484|Combination Product|Sonodynamic therapy|SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.8W/cm2 for femoral lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
45480213|NCT02963766|Drug|Dulaglutide|Administered SC
45362726|NCT03903159|Behavioral|Positive Peer Journaling (PPJ)|"PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve quality of life in recovery and reduce relapse. PPJ uses standard lined journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing good and bad things that happened and things for which one is grateful. Wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as recovery, work/school, spirituality, home and household, and health."
45362727|NCT04043000|Dietary Supplement|Super 13 Pro & Prebiotics|"Super 13 Pro & Prebiotics was given three times a day for four weeks."
45362728|NCT02546804|Procedure|HOT SALT WATER|25ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
45362729|NCT02546804|Procedure|POTASSIUM PERMANGANATE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
45480214|NCT02963766|Drug|Placebo|Administered SC
45480215|NCT02490280|Behavioral|Trier Social Stress Test|The TSST is the gold standard social stress test and involves speaking in front of confederate judges and completing arithmetic tasks. The task takes 10-15 minutes.
45480216|NCT02487004|Device|hemodialysis|
45480217|NCT04493476|Drug|Chinese herbal formula|Chinese herbal formula
45480218|NCT03325192|Drug|Rapid pleurodesis protocol|"The pleural space will be evacuated completely through the newly placed IPC~20mL of 10% iodopovidone and 80mL of normal saline will be instilled into the pleural space~The patient will be transferred to the recovery unit~Two hours after instillation the pleural space will be drained~After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged~Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis."
45480219|NCT03325192|Other|Placebo|"The pleural space will be evacuated completely through the newly placed IPC~Only placebo (normal saline) will be instilled into the pleural space~The patient will be transferred to the recovery unit~Two hours after instillation the pleural space will be drained~After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged~Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis."
46049702|NCT04135144|Other|Group 2 (video phone reminder)|Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
46049703|NCT00605748|Procedure|Segmental PV-Isolation of the arrhythmogenic vein(s)|isolation of pulmonary veins for curing atrial fibrillation
46049704|NCT00605748|Procedure|Segmental PV-Isolation of all veins|isolation of pulmonary veins for curing atrial fibrillation
45362730|NCT02546804|Procedure|CHLORHEXIDINE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
45362731|NCT00205855|Device|Precision SCS|Advanced Bionics totally implantable Spinal Cord Stimulation (SCS) System, the Stimulus System. This system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain.
45480220|NCT01334502|Biological|rituximab|PO
45480221|NCT01334502|Drug|cyclophosphamide|IV
45480222|NCT01334502|Drug|doxorubicin hydrochloride|IV
45480223|NCT01334502|Drug|everolimus|PO
45480224|NCT01334502|Drug|prednisone|PO
45480225|NCT01334502|Drug|vincristine sulfate|IV
45480226|NCT03318328|Other|survey|
45480227|NCT04839965|Biological|Ampion|Ampion administered via intravenous infusion
45689176|NCT02105740|Behavioral|Control|The control and experimental groups respond in 3 different moments to Visual Analogue Scale (VAS) for the evaluation of pain, and to Hospital Anxiety and Depression Scale (HADS) to evaluate depression and the anxiety. The first meeting will be made before the hypnosis. In the second meeting, within an interval of 7 days, the scales will be applied in all patients. Before applying the scales, the hypnosis group will be submitted to the session. The third meeting will occur two weeks later, where the scales will be only applied to compare the groups.
45480228|NCT04839965|Other|Saline|Placebo administered via intravenous infusion
45480229|NCT02490046|Dietary Supplement|D Mannose|Patients in both arms will receive D-mannose powder to be used 1.5 gm (one level-teaspoon) twice daily, to be added to any beverage, for 16 weeks.
45480230|NCT05390333|Behavioral|Self-Care Sampler for Family Carer Partners|The 6-week Self-Care Sampler for Family Caregivers program was created to provide a variety of evidence-based self-care practices that improve the mental and physical health of caregivers by relieving stress. Sessions will take place once a week for 90 minutes, each starting with a centering exercise and focusing on a new form of self-care. The first 30 minutes will be used for a support group and the last 60 minutes will be for a self-care practice. Self-care practices that will be offered throughout the 6 weeks include mindfulness, mindful drawing, exercise, and health prevention and promotion.
45480231|NCT02487082|Drug|Melatonin and Donepezil|The duration depends on group assignment.
45480232|NCT02487082|Other|Placebo|The duration depends on group assignment.
45689177|NCT01792180|Behavioral|Mobility feedback device with use of instruction book|Weekly use of the mobility feedback device to measure gait speed. Two infrared sensors will be placed in the line of walking, a photo frame containing a display, symbols and lights will tell the participant when and how to perform the test. Gait speed is shown on the display and will serve as feedback to the participant. Participant can use their gait speed to decide which exercises from the instruction book he performs. Participants will be asked to keep an activity diary.
45689178|NCT03793114|Diagnostic Test|Cosyntropin stimulation test|Blood samples are taken before (0 min), and 30 and 60 min after intravenously administration of 250 µg cosyntropin (tetracosactide acetate) with the patient placed in the recumbent position. The test will be performed non-fasting (but medication-fasting) between 08:00 and 10:00 a.m.
45689179|NCT03793114|Diagnostic Test|Baseline blood tests|Medication-fasting morning levels of adrenocortical hormones.
45689180|NCT03793114|Device|30-hour ambulatory sampling of intestinal fluid|30-hour ambulatory sampling of intestinal fluid for analysis of adrenocortical hormones.
45480233|NCT03788681|Drug|Estradiol Valerate|"oral estradiol  estradiol valerate  (Cyclo-Progynova)"
45480234|NCT03788681|Drug|Placebo Oral Tablet|placebo
45480235|NCT01308203|Drug|Extended release niacin/laropiprant|Randomized patient will received 1 tablet of 1g ERN/20 mg LRPT for the first 4 weeks of treatment. At week 4 (± 2 days)the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 tablets of 1 g ERN/20 mg LRPT that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to placebo.
45362732|NCT01013038|Procedure|Thrombus aspiration followed by stent implantation|Export aspiration catheter 6F (Medtronics)
45362733|NCT01013038|Procedure|conventional PCI|balloon angioplasty and/or stent implantation
45362734|NCT04526704|Drug|Pexidartinib|200 mg capsules administered orally twice daily on an empty stomach (at least 1 hour before or at least 2 hours after a meal or snack)
45362735|NCT00842114|Biological|R+CVP+IFN|Immunochemotherapy
45362736|NCT00842192|Drug|insulin detemir|Insulin detemir for s.c. injection, once daily, in addition to current OAD treatment. Dose to be determined by physician.
45362737|NCT00536991|Dietary Supplement|Calcitriol|Given PO
45362738|NCT00536991|Drug|Ketoconazole|Given PO
45362739|NCT00536991|Other|Laboratory Biomarker Analysis|Correlative studies
45362740|NCT00536991|Other|Pharmacological Study|Correlative studies
45362741|NCT00536991|Drug|Therapeutic Hydrocortisone|Given PO
45362742|NCT00842270|Drug|AB1010|3 mg/kg/day
45362743|NCT00842270|Drug|AB1010|4,5 mg/kg/day
45480236|NCT01308203|Drug|placebo|Randomized patient will received 1 oral 1 g tablet of placebo for the first 4 weeks of treatment. At week 4 (± 2 days), after randomization the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 oral 1 g tablets of placebo that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to active medication.
45480237|NCT03788603|Drug|Rogaratinib (BAY1163877)|Rogaratinib will be administered on 20 days in Cycle 1 (single dosing on Day 1 and twice daily dosing on Days 3-21). In Cycles ≥2, rogaratinib will be administered twice daily for 21 days, with cycles repeated every 21 days. Treatment will be continued until death, tumor progression, unacceptable toxicity, consent withdrawal, or until another criterion is met for withdrawal from the study at the discretion of the investigator.
45362744|NCT00842270|Drug|AB1010|6 mg/kg/day
45480238|NCT03789929|Behavioral|The Emotional Backpack|In this 4 weeks course participants learn how to process difficult emotions that has been overwhelming in the past. They learn how they can use the support of other people and support other people in the processing emotions within a simple and easy to learn setting.
45362745|NCT00842270|Drug|placebo|matching placebo to AB1010 dosages
45362746|NCT00836108|Behavioral|breathing strategy|Subjects will practice a rhythmic overhead arm exercise, during which they will be taught to inspire when they elevate their arms or they will be taught to expire when they elevate their arms or, a third group, will practice a rhythmic overhead arm exercise, during which they will not be provided with any instruction regarding a specific breathing pattern. The arm exercise practiced by all groups will be identical.
45480239|NCT03789929|Behavioral|Feelings as Powers|In this 3 months course participants learn about the empowering potential of their feelings as well as the difficult aspects of them. In addition to that they learn techniques how to deal with difficult emotions.
45480240|NCT03790085|Drug|Risperidone|Risperidone tablet
45480241|NCT03790085|Drug|Olanzapine|Olanzapine tablet
45480242|NCT03790085|Drug|Aripiprazole|Aripiprazole tablet
45480243|NCT01306097|Drug|Zinc Supplement|10mg daily for under 1 years old children and 20mg daily for above 1 years old children
45480244|NCT03466099|Drug|KVD001 Injection|Intravitreal KVD001 Injection
46049705|NCT01091246|Biological|Q/LAIV (MEDI3250)|10 ^7.0 ± 0.5 FFU/dose of each of 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria
46049706|NCT01091246|Biological|FluMist/B/Yamagata|10 ^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Yamagata
46049707|NCT01091246|Biological|FluMist/B/Victoria|10 ^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Victoria
46049708|NCT02622958|Drug|PH94B|"PH94B is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg PH94B).~Dosing is sex-specific:~Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg"
45362747|NCT03902613|Drug|Lurasidone|Participant will have an open label trial of lurasidone for eight weeks.
45362748|NCT00504166|Drug|alendronate sodium|alendronate sodium 70 mg tablet once week for 24 months
45362749|NCT00504166|Other|placebo comparator|placebo to match alendronate sodium one tablet once a week for 24 months
45362750|NCT02547584|Procedure|Catheter ablation|Pulmonary vein antrum isolation (PVAI) plus entire posterior wall plus coronary sinus plus left part of the septum. This intervention will be received by all as standard of care
45362751|NCT04342520|Other|Dyads Patient / caregiver|adult patient / caregiver couples, patient are 55 years of age or older and have Alzheimer's disease or a related disease
45362752|NCT01013116|Biological|modified allergen extract of house dust mites|subcutaneous injections
45362753|NCT01013116|Biological|placebo|subcutaneous injections
45362754|NCT04002765|Diagnostic Test|pulmonary function tests|"Lung function tests (standard of care)~Dynamic and static volumes (FVC, FEV1, TPC, RV)~Lung diffusion capacity for CO (DLCO)~Chest Xrays~High resolution CT scanner (HRCT)"
45362755|NCT02546648|Drug|Tranexamic Acid|
45362756|NCT02546648|Drug|Tranexamic Acid Placebo|
45480245|NCT03466099|Other|Sham Procedure|Sham Procedure
45480246|NCT01308281|Procedure|PCI with IVUS guidance|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
45480247|NCT01308281|Procedure|PCI without IVUS guidance|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
45480248|NCT03790007|Drug|Bupivacaine|In our study this local anesthetic agent will be applied for postoperative pain relief
45480249|NCT03716947|Procedure|Device: ZACK|Surgical procedure with total disc replacement using ZACK disc prostheses
46049709|NCT02622958|Other|Placebo|"Placebo is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg Placebo).~Dosing is sex-specific:~Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg"
46049710|NCT05260086|Device|Neuronavigated aiTBS|Accelerated intermittent theta burst stimulation (aiTBS, 4 sessions per day with at least 20 minutes pause between sessions) in the left dorsolateral prefrontal cortex (DLPFC)
46049711|NCT02622880|Dietary Supplement|immunomodulatory supplement|Experimental Group (immunomodulatory supplement STUDY)
45689181|NCT03793114|Other|Blood test|Cardiovascular and inflammatory biomarker profiles
45689182|NCT00320242|Device|1 mo baseline before visual cue|Laser Cane with Laser Accessory and/or U-Step Walker with Laser Accessory
45689183|NCT00347308|Behavioral|Eyebrow Position|Photography of brow positions
45689184|NCT00348946|Drug|androgen oxandrolone|Oxandrolone ,06 >mg/kg/day, orally, for 2 years
45362757|NCT02546648|Drug|Rosuvastatin or matching placebo|Subjects who are not on a statin will also be randomized to Rosuvastatin or Rosuvastatin placebo. 40mg preoperatively, followed by 20mg postoperatively (4-6 hours after surgical close) and 20mg/day for 30 days postoperatively.
45362758|NCT03998020|Other|scale of severity|assessment of the severity of the sleep disorders by scale
45362759|NCT03998020|Genetic|blood sample|Genetical study, serum and sample
45480250|NCT03716947|Procedure|Device: ORBIT|Surgical procedure with total disc replacement using ORBIT disc prostheses
45480251|NCT03716947|Procedure|Device: SASCA|Surgical procedure with anterior intracorporal fusion (ALIF) combined with adjacent level total disc replacement (TDR) (using either ORBIT mechanical disc prosthesis or ZACK viscoelastic disc prosthesis)
45480252|NCT03789695|Drug|Dabigatran Etexilate|Study drug dabigatran etexilate. There are two dosage regimens of dabigatran etexilate used in the study: 150 mg b.i.d. and 110 mg b.i.d. The dose of dabigatran etexilate will be chosen by the investigator in accordance with Russian PRADAXA SmPC
45480253|NCT05693831|Other|Cellworks Report|Survey physicians and molecular tumor board perspectives of the benefit of Cellworks Singula™ and Ventura™ reports in facilitating treatment decisions in pan-cancer patients.
45480254|NCT03720769|Behavioral|Step-by-Step|Guided self-help programme delivered through an app/website for the treatment of depression
45480255|NCT03720769|Behavioral|Enhanced care as usual|Psychoeducation and information about where to get help (i.e., mhGAP trained primary health care centres)
45689185|NCT00348946|Other|placebo|an inactive substance
45480256|NCT03720691|Device|Real rTMS Supplementary motor area|There will be a series of four rTMS blocks separated by 10 minutes. Each block will consist of 15 to 25 pulse trains of 1-second duration at 25 Hz, with an intertrain interval of 10 seconds.
45362760|NCT03997942|Other|Effect of exercise|Once the data are available, we hope to have information about which of the exercise practices included in the rehabilitation program of acute upper extremity burn patients is more effective.
45480257|NCT03720691|Device|Sham rTMS Supplementary motor area|There will be no real brain stimulation in Sham rTMS, and participant will be blinded.
45689186|NCT00349336|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
45362761|NCT00843596|Procedure|cardiac surgery requiring ECC|the vacuum device is left on the 2 wounds (caused by the ECC cannulas) for 15 min (possible a second time of 15 min : 30 min max.)
45480258|NCT05663437|Other|Core stabilization exercises|6 core stabilization exercises including: dead bug, side lying, prone, bird dog, bridging, planks (1x10 reps for 15-30 secs each exercise) 3 alternative days a week, for 4 weeks.
45480259|NCT05663437|Other|Core stabilization exercises + neural mobilization technique|"6 core stabilization exercises including: dead bug, side lying, prone, bird dog, bridging, planks (1x10 reps for 15-30 secs each exercise) 3 alternative days a week, for 4 weeks.~Neural mobilization technique (SLR intervention for first 2 weeks and slider intervention for last 2 weeks)."
45689187|NCT00349336|Drug|XELOX|As prescribed
45689188|NCT00349336|Drug|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
45689189|NCT00349336|Drug|FOLFOX-4|As prescribed
45689190|NCT04888468|Biological|pCAR-19B cells|Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
45689191|NCT04751188|Drug|Bezafibrate 200 MG Oral Tablet|Bezafibrate one tablet every 12 hours for six months.
45689192|NCT04751188|Drug|Placebo|Placebo one tablet every 12 hours for six months.
45689193|NCT04751188|Drug|Ursodeoxycholic Acid|At a dose of 13 to 15 mg per Kg per day.
45689194|NCT00352612|Drug|clindamycin|clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days
46049712|NCT02622880|Dietary Supplement|IMPACT|IMPACT (Nestle Healthcare Nutrition, Minnesota USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
45689195|NCT00352612|Drug|cephalexin|cephalexin suspension or tablets, 40mg/kg/day, given by mouth, divided TID, for 7 days
45362762|NCT00842426|Behavioral|Self-management program (SM)|"Participants will attend a group orientation where the study nutritionist will provide an overview of the self-management lifestyle intervention program. Participants will receive instructions on how to use HeartHubTM, the American Heart Association's patient portal for information, tools, resources about cardiovascular risk assessment, goal setting, action planning, and self-monitoring.~During the remainder of the 15-month intervention, participants will receive reminders on a regular basis to use the patient portal to assist in their ongoing self-management."
45689196|NCT01793584|Procedure|Laparoscopic hysterectomy|LAVH, TLH
45689197|NCT01793584|Procedure|Abdominal hysterectomy|TAH
46049713|NCT04267146|Drug|Nivolumab|"Solution for intravenous injection 10 mg/ml. Initial dose : 3 mg/kg Nivolumab will be given at 3 mg/kg/injection every two weeks from the first day of radiotherapy to the last day of chemotherapy.~One de-escalation dose : 1 mg/kg"
45689198|NCT01793740|Behavioral|Cogmed|Computer based program that aims to improve children's memory, attention, and processing speed.
45689199|NCT00323284|Device|iStent plus Cataract Surgery|ab interno trabecular bypass stent surgery
45689200|NCT00323284|Procedure|Cataract surgery only|Cataract surgery only
45689201|NCT00323362|Drug|gemcitabine hydrochloride|1000 mg/m2 given intravenously at a FDR of 10 mg/m2/min on Days 3 and 10, every 21 days.
45689202|NCT00323362|Drug|imatinib mesylate|400 mg/day orally, given Days 1-5 and 8-12 every 21 days
45689203|NCT01793896|Behavioral|Control period|Analysis at recruitment and after a month without any intervention
45689204|NCT01793896|Behavioral|Diet Group|selected subjects will adopt a Mediterranean low-AGE diet. We will not include red wine in the Mediterranean diet (7 Kilocalories (KCal)/g), in order to attain more weight loss. Each subject will be instructed to reduce 500 Kcal of their estimated total daily energy requirements, so theoretically they will be able to reduce 5 - 10 % of their body weight in 3 months.
45689205|NCT01793896|Behavioral|Exercise group|The intervention will consist of 3 weekly 1 hour sessions (5 minutes of preconditioning, followed by 20 minutes cycling, brisk walking or jogging at 65-70 % maximal aerobic capacity, then 25 minutes resistance weight-lifting exercises and finally 10 minutes of stretching). Exercise intensity will be increased weekly according to the Borg Scale intensity. The exercise intervention will be supervised by physical education teachers, registering attendance at every session.
45689206|NCT01793896|Behavioral|Diet + Exercise|these patients will be incorporated to receive both Mediterranean diet plus exercise interventions
45689207|NCT00390364|Drug|everolimus|
45689208|NCT00390364|Procedure|antiangiogenesis therapy|
45689209|NCT00390364|Procedure|biopsy|
46049714|NCT04267146|Drug|Temozolomide|Capsules: 5, 20, 100, 140, 180 and 250 mg orally. Temozolomide will be given at 75mg/m2/day from the day of start of radiotherapy to the last day of radiotherapy, then, after one month rest at 200mg/m2/day for five consecutive days for 12 cycles (28 days cycle).
46049715|NCT04267146|Radiation|Radiotherapy|Total dose of 54 Gray(Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation period.
46049716|NCT00912106|Other|Synovial fluid composition and lubrication analysis|Before HA injection, synovial fluid must be drawn to increase treatment effectiveness. The drawn synovial fluid was then analyzed in the lab. There was no influence for patients enrolled because the drawn synovial fluid would usually be discarded.
45480260|NCT03789851|Device|core needle biopsy|Because the ultrasound was unable to accurately position the marker clip, I125 coud be placed at the position of the marker clip under the guidance of preoperative mammography. The gamma detector was used to locate the tumor bed to guide the ultrasound-guided multi-point CNB. Ultrasound-guided multipoint CNB was used directly after breast conserving surgery or mastectomy. Centering on the marker clip, the range of 0.5 cm was the first area, and then the range of 0.5 cm was the second area, and so on, until the extent of the expansion reached the long diameter of the original tumor, and 4 pieces were uniformly taken in each area.
45480261|NCT00739674|Drug|losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])|"Losartan 50 mg or 100 mg once daily for 40 weeks with sequential titration including HCTZ 12.5 mg or 25 mg and CCB only as needed to achieve target blood pressure, as follows:~Patients with mild-moderate hypertension, uncontrolled hypertension on monotherapy, or diabetes:~Losartan 50 mg~Losartan 100 mg~Losartan 100 mg/HCTZ 12.5 mg~Losartan 100 mg/HCTZ 25 mg~Losartan 100 mg/HCTZ 25 mg + CCB~Patients with severe hypertension:~Losartan 50 mg/HCTZ 12.5 mg~Losartan 100 mg/HCTZ 12.5 mg~Losartan 100 mg/HCTZ 25 mg~Losartan 100 mg/HCTZ 25 mg + CCB~Losartan 100 mg/HCTZ 25 mg + increasing CCB"
45480262|NCT00739674|Behavioral|Low Salt Diet|"Low-salt intake diet (Dietary Approaches to Stop Hypertension [DASH]) including:~Healthy diet~Reduction in sodium intake to less than 2300 mmol/day~Low alcohol consumption (less than 2 standard drinks/day)"
45689210|NCT00390364|Procedure|diagnostic procedure|
45362763|NCT00842426|Behavioral|Care management program (CM)|"In addition to participating in the activities described above, with the exception of the orientation session, participants in the Care Management Program will attend 12 weekly weight management classes during the initial 3 months. Classes will be co-led by a dietician and exercise specialist and will include a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by individual action-planning and goal-setting.~During the remainder of the 15-month intervention, participants will continue to monitor their body weight, caloric intake, physical activity, and other data according to their care plan. In addition, study interventionist will follow up with participants regularly, via secure messaging or by phone, to provide ongoing counseling and support."
45362764|NCT01010620|Behavioral|Various Screening psychiatric and medical assessments|Possibly blood draws, urine samples, toxicology screens, computer-based and written psychological, psychiatric, and behavioral questionnaires and assessments.
45689211|NCT00390364|Procedure|gene expression analysis|
45362765|NCT00842504|Drug|Micafungin|3 mg/kg IV once over 1 hour
45689212|NCT00390364|Procedure|immunohistochemistry staining method|
45689213|NCT00390364|Procedure|laboratory biomarker analysis|
45689214|NCT00390364|Procedure|mutation analysis|
45362766|NCT00842582|Drug|Azacitidine|Azacitidine 20 milligrams per meter squared subcutaneous once daily for 7 days.
45480263|NCT03639181|Biological|GB226|3mg/kg treat every 2 weeks
45480264|NCT01306409|Drug|cera, darbepoetin, epoetin-beta|Epoetin once/ 2wk, cera once/ month, darbepoetin once/ 2wk
45480265|NCT01306409|Drug|ESA|Sequential application of three different ESA
45480266|NCT01331928|Drug|Capecitabine (Xeloda, Roche), Oxaliplatin (Sanofi-Aventis), Docetaxel (Sanofi-Aventis)|capecitabine orally 1000 mg/m2 twice daily, day1 to day 10, every 2 weeks plus oxaliplatin 85mg/m2 (2hrs IV infusion)on day1, every 2 weeks for 6 cycles, then shift to docetaxel 30 mg/m2(over 30-minute intravenous infusion) on day 1 and day 8 plus oral capecitabine 825 mg/m2 twice daily on day 1 to 14, every 3 weeks for 4 cycles.
45689215|NCT00390364|Procedure|protein tyrosine kinase inhibitor therapy|
46049717|NCT04263324|Behavioral|Self-hypnosis/self-care|Learning phase of self-hypnosis/self-care.
46049718|NCT05258214|Other|Mulligan Bent Leg Raise|Mulligan's bent leg raise, as well as the extreme Straight Leg Raise, can be used to relieve Low Back Pain. It can be used to treat leg discomfort that is above the knee. Bent Leg Raise methods are used where there is a restricted range of motion in the hip flexion joint, as well as low back pressure with or without referred leg pain.
45480267|NCT03785795|Device|Uncertain diagnosis of true labor|Multichannel EMG of uterine bioelectrical signals will be recorded using area sensors. The output of the synchronization calculations will be correlated with the time to delivery
45480268|NCT01329822|Behavioral|Caloric restriction|Caloric restriction
45689216|NCT00390364|Procedure|reverse transcriptase-polymerase chain reaction|
45689217|NCT00354484|Drug|Ferric Carboxymaltose (FCM)|Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
45689218|NCT00354484|Drug|Ferrous Sulfate tablets|325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
45689219|NCT00354640|Drug|anastrozole|1 milligram tablet PO QD for 14 days
45689220|NCT00354640|Drug|simvastatin|40 milligram tablet PO QD for 14 days
45689221|NCT00354640|Other|pharmacological study|laboratory analysis
45689222|NCT00354640|Procedure|adjuvant therapy|laboratory analysis
45752128|NCT01389128|Other|Non-pharmacological resources|"A sequence of non-pharmacological resources were applied to the patient by the researcher according to uterine cervical dilation, as follows:~Pelvic mobility on the exercise ball oriented and accompanied by the researcher for 40 minutes;~Lumbosacral massage for a period of 40 minutes, when dilation was between 5 and 6 cm. During the procedure, the woman in labor was allowed to freely choose the most comfortable position; and,~Warm shower with the water flow directed to the lower-back of the woman in labor, for 40 minutes, when uterine cervical dilation was equal to or higher than 7cm."
46049719|NCT05258214|Other|Mulligan Traction Straight Leg Raise|Mulligan traction leg raise exercises are a non-invasive treatment that has been shown to help people with low back pain and reduced hip flexion range. Conservative sciatica therapy focuses on pain relief, but increasing Straight Leg Raise range will help restore normal mobility and reduce the severity of low back disability.
45689223|NCT04559932|Other|Tracheostomy Training Course|A standardized competency-based education tracheostomy module has been developed by the investigator group in collaboration with Respiratory Medicine, Complex Care, Respiratory Therapy, Nursing Education, Family Advisory Network and the Learning Institute at SickKids. Instructional methods for the full module are based on principles of adult learning and evidence from the procedure education literature and include the use of interactive, small-group teaching, hands-on simulation-based learning stations with relevant equipment as well as a formal assessment of knowledge and skills using simulation. Pre-learning packages are sent to course attendees at the time of registration to facilitate higher level discussions on the day of the course. While investigators have rigorously developed the curriculum and evaluation measures, the course outcomes remain unknown.
45689224|NCT02107300|Drug|NeutraSal|NeutraSal is a powder that when dissolved in water creates a supersaturated calcium phosphate rinse.
45689225|NCT02107300|Drug|Placebo Comparator|Placebo is a powder consisting of sodium chloride only; chosen to mimic NeutraSal
45689226|NCT00392236|Device|2-way pager|Participants will receive messages daily to take their medication via a 2-way pager for 6 months. Once the message is received the participant will respond whether or not he/she took the medication and reason for not taking.
45689227|NCT00392236|Behavioral|Treatment as usual|Participants will receive treatment as usual.
45689228|NCT00392392|Drug|nab-paclitaxel|ABI-007
45689229|NCT00392392|Drug|Bevacizumab|Bevacizumab
45689230|NCT00392392|Drug|Trastuzumab|Trastuzumab
46049720|NCT05258214|Other|Neural Mobilization|These techniques are designed to mobilize a nerve with as little pressure down, resulting in a larger longitudinal excursion than techniques that actually lengthen the nerve bed, such as tensioning procedures.
45689231|NCT01519089|Drug|CP-690,550|10 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
45689232|NCT01519089|Drug|CP-690, 550|5 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
45689233|NCT00392704|Drug|Bevacizumab|"Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 & Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
46049721|NCT00626132|Dietary Supplement|Eucommia|two capsules three times a day orally for 2 weeks
46049722|NCT02622646|Drug|Recombinant VIII factor|"Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a personalized pilot program with a 1 year follow up to act on the specific causes.~Describe PK parameters in patients on prophylaxis treatment with Advate®~Analyze differences in PK parameters in non-controlled vs well controlled patients~Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).~Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence)."
45362767|NCT00842582|Drug|Azacitidine|Azacitidine 40 milligrams per meter squared subcutaneous once daily for 7 days.
45845211|NCT02284386|Drug|EXPAREL Infiltration|Local infiltration of EXPAREL 266 mg into the surgical site at the end of the surgery just prior to wound closure.
45845212|NCT02284464|Drug|Prednisone withdrawal|Withdrawal of steroids
45480269|NCT03494725|Dietary Supplement|Lpc-37|Lacticaseibacillus paracasei Lpc-37 at 1.75 x 10^10 colony forming units (CFU) per day, microcrystalline cellulose, magnesium stearate, silicon dioxide
45480270|NCT03494725|Dietary Supplement|Placebo|microcrystalline cellulose, magnesium stearate, silicon dioxide
45480271|NCT01306487|Procedure|Vitrectomy|Macular hole surgery
45480272|NCT01334580|Behavioral|Cognitive-Behavioral Therapy for Pain and Opioid Dependence|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
45480273|NCT01334580|Behavioral|Methadone Drug Counseling|Methadone Drug Counseling (MDC)is provided by skilled drug counselors over a 12-week period. The primary goal of MDC is cessation of illicit drugs.
45689234|NCT00392704|Drug|Erlotinib|"Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 & Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
45845213|NCT02284464|Drug|Prednisone continuation|Continuation of steroids
45845214|NCT02284854|Drug|BIA 2-093|
45845215|NCT02284854|Drug|Carbamazepine|
45845216|NCT02285634|Drug|Oxymetazoline 0.05%|sterile gauze soaked in 5 milliliters (mL) of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
45845217|NCT02285634|Drug|Phenylephrine 0.25%|sterile gauze soaked in 5 milliliters (mL) of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
45845218|NCT02285634|Drug|Lidocaine 1% plus epinephrine 1:100,000|sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
45362768|NCT00842582|Drug|Azacitidine|Azacitidine 75 milligrams per meter squared subcutaneous once daily for 7 days.
45362769|NCT00843908|Device|Tension Free Vaginal Tape|Tension Free Vaginal Tape inserted in the conventional manner in a theatre environment
45362770|NCT00843908|Device|Miniarc|The Miniarc suburethral sling will be inserted in the conventional manner in a theatre environment under general anaesthesia
45362771|NCT00842660|Drug|Gemzar (gemcitabine)|Gemzar(gemcitabine) Hcl has 2'deoxy-2,2'-difluorouridine monohydrochloride
45362772|NCT00509236|Drug|Sitagliptin|25 mg (one 25-mg tablet) once daily
45362773|NCT00509236|Drug|Glipizide|2.5 mg (1/2 of a 5-mg tablet) once daily, up to 10 mg twice daily (four 5-mg tablets), for a maximum of 20 mg
45362774|NCT00836420|Procedure|no intervention|the value of the clinical use of microdialysis monitoring of the brain
45362775|NCT00842738|Behavioral|Mindfulness meditation|Mindfulness meditation
45362776|NCT00842738|Other|No meditation|Health care services as usual
45362777|NCT00842738|Other|Controls|No intervention
45362778|NCT00842816|Drug|ST101|10 mg; administered once/day
45362779|NCT00842816|Drug|ST101|60 mg; administered once/day
45362780|NCT00842816|Drug|ST101|120 mg; administered once/day
45362781|NCT00842816|Drug|Placebo|placebo tablets to match ST101 tablets
45362782|NCT00842894|Drug|insulin detemir|Safety and effectiveness data collection in connection with the use of the drug.
45362783|NCT00842894|Drug|biphasic insulin aspart 30|Safety and effectiveness data collection in connection with the use of the drug in daily clinical practice.
45689235|NCT00392704|Drug|Paclitaxel|"Neoadjuvant: 200 mg/m2 IV, 1-3 hour infusion, Days 1 and 22~Combined Modality: 50 mg/m2 IV, 1 hour IV infusion, weekly x6, beginning day 1 of radiation therapy"
45480274|NCT00705718|Device|Endurant Stent Graft System|Abdominal Aortic Aneurysm Repair
45362784|NCT02546726|Behavioral|Heat & Aerobic Training (HEAT)|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise steam-room therapy. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
45362785|NCT02546726|Behavioral|Exercise Only|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise sitting in the lobby of the fitness facility. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
45362786|NCT04043390|Diagnostic Test|CRP and Molbio Truenat MTB|A molecular assay to detect M tuberculosis DNA Truenat is currently undergoing the process of endorsement by the WHO.
45362787|NCT04043390|Diagnostic Test|CRP and Xpert ULTRA MTB/RIF|A molecular assay to detect M tuberculosis DNA ULTRA is already endorsed by the WHO. However the tests are still considered experimental in Nigeria and Ethiopia.
45480275|NCT05523713|Biological|Peripheral venous blood samples|10 ml in a sodium heparin tube and 5 ml in an EDTA tube
45480276|NCT02694588|Drug|Infliximab|HD-endoscopy, CLE, endoscopic ultrasound after application of TNF alpha antibody
45480277|NCT02694588|Drug|Vedolizumab|HD-endoscopy, CLE, endoscopic ultrasound after application of Anti-Integrin antibody
45689236|NCT00392704|Drug|5-FU|Neoadjuvant: 200 mg/m2 24 hour continuous infusion days 1-43
45689237|NCT00392704|Radiation|Radiation Therapy|Combined Modality Therapy: 1.8 Gy/day, Monday-Friday, total dose 68.4 Gy
45689238|NCT00392782|Biological|anti-thymocyte globulin|Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2. The first dose of thymoglobulin will be given over six (6) hours and subsequent doses over four (4) or more hours as tolerated or, per institutional anti-thymocyte globulin (ATG) administration guidelines.
45362788|NCT04043390|Diagnostic Test|standard test Xpert|The investigators will use Xpert to compare its agreement with scheme 1 (CRP plus Truenat MTB) and scheme 2 (CRP plus ULTRA).
45480278|NCT03789539|Biological|LD Universal Influenza Vaccine Uniflu|low dose Universal Influenza Vaccine Uniflu
45480279|NCT03789539|Biological|HD Universal Influenza Vaccine Uniflu|High dose Universal Influenza Vaccine Uniflu
45480280|NCT03789539|Biological|Placebo|Placebo saline
45689239|NCT00392782|Drug|fludarabine phosphate|Fludarabine 40 mg/m^2/day intravenously (IV) over 30-60 minutes on days -7,-6,-5,-4,-3 (total dose 200 mg/m^2).
45689240|NCT00392782|Drug|thiotepa|Thiotepa 5 mg/kg/day intravenously (IV) over 4 hours on days -8, -7 (total dose 10 mg/kg).
46049723|NCT02691078|Other|99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide|The patient will undercome an PET/CT exam with 99m Tc - HYNIC -TOC EDDA, after 20 days of wash out, the same patient will undercome the same exam with 111In - DTPA-octreotide in order to compare both radiopharmaceuticals
46049724|NCT02621320|Dietary Supplement|Vitamin D|Vitamin D3 (Vi-De 3®. WILD) 6000IU daily over a period of 12 weeks.
46049725|NCT02621320|Dietary Supplement|Placebo|alcohol-based solution 1.3ml daily over a period of 12 weeks.
46049726|NCT01097330|Procedure|Ablation|Catheter based radiofrequency ablation for ischemic ventricular tachycardia scheduled to occur within 4 weeks after randomization
46049727|NCT01097330|Drug|Amiodarone|Amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study
46049728|NCT02622490|Other|two test meals with two different macronutrient compositions|Either a high or a low carb meal either as one large or as 5 small meals. ie a crossover trial with one arm
46049729|NCT02878616|Drug|LFG316|LFG316 single dose
46049730|NCT02878616|Drug|IVIG|IVIG single dose
46049731|NCT04016194|Diagnostic Test|Lung function testing|Multiple-breath washout (MBW) is a safe, easy and sensitive lung function test using inert gases such as Nitrogen (N2) to assess efficiency of ventilation distribution. The latter can be estimated by the lung clearance index (LCI), an established study end-point in patients with CF
46049732|NCT00934440|Drug|Bevacizumab|"First treatment: 10 milligram per kilograms (MG/KG) intravenously (IV) on Day 1every two weeks over 90 minutes.~Second treatment: 10 MG/KG IV on Day 1 every two weeks over 60 minutes.~Third and subsequent treatments: 10 MG/KG IV on Day 1 every two weeks over 30 minutes (minimum of two cycles)."
45480281|NCT01334658|Procedure|Phacoemulsification cataract surgery|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) [500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation [BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
45362789|NCT04043390|Diagnostic Test|Culture as reference standard|The investigators will use culture to assess the sensitivity of schemes 1 and 2
45362790|NCT00843128|Device|robot-assisted gait training (RAGT)|20 patients will be treated with RAGT, 12 sessions over three weeks.
45362791|NCT00843128|Device|conventional walking training (CWT)|The control group will be treated by CWT, 12 sessions in three weeks.
45362793|NCT00508924|Drug|Argatroban|
45480282|NCT01334658|Drug|Glucose-bicarbonate-Ringer Lactate (GBRL)|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) [500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation [BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
45480283|NCT01334658|Drug|Balanced Salt Solution (BSS®)|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) [500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation [BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
45480284|NCT01308359|Drug|IV glucose 5%|500 ml glucose 5% within 30 minutes
45480285|NCT01308359|Drug|saline|saline
45480286|NCT02490202|Drug|SANGUINATE|Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
45480287|NCT02490202|Drug|Normal Saline|Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
45480288|NCT01334736|Behavioral|Usual care|After participants have completed the data collection portion of the SHIELD visit, the research assistant will provide the participant with an informational flyer regarding the risks of tobacco smoking and benefits of tobacco cessation. The participant will be provided the phone number for the Tobacco Quit Line in Maryland as well as a list of local tobacco cessation programs. Any questions will be answered by the research assistant. If the participant inquires about nicotine replacement therapy, they will be advised to contact their primary care provider to discuss potential therapeutic options. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
45689241|NCT00392782|Procedure|peripheral blood stem cell transplantation|Peripheral Blood Stem Cell (PBSC) Infusion. All patients will receive granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC on day 0 (or day+1 when available) following CD34 cell selection for ex vivo T cell removal. PBSC is infused via a central venous catheter using blood infusion tubing.
45689242|NCT00392782|Radiation|total-body irradiation|The total-body irradiation (TBI) will be given in 2 fractions of 400 cGy each administered on day -10 and -9 via anterior and posterior fields for a total dose of 800 cGy.
45845219|NCT02285634|Drug|Bacteriostatic 0.9% NaCL|sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
45845220|NCT02287350|Drug|diclofenac potassium oral solution|Administration of diclofenac potassium oral solution, taken by mouth, as needed for mild to moderate acute pain.
45845221|NCT02288364|Drug|1% Lidocaine|
45845222|NCT02288364|Drug|1% Lidocaine plus sodium bicarbonate|
45362794|NCT00508924|Drug|Argatroban|
45362795|NCT00508924|Drug|Argatroban|
45362796|NCT00508924|Drug|Heparin|
45362797|NCT00836576|Drug|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fasting
45362798|NCT00836576|Drug|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fasting
45362799|NCT00836654|Biological|Catumaxomab (Removab)|Puncture free survival
45362800|NCT00836654|Procedure|paracentesis|
45362801|NCT03599752|Drug|Chemotherapy|Receive chemotherapy
45362802|NCT03599752|Procedure|Metastasectomy|Undergo pulmonary metastasectomy
45362803|NCT00836732|Procedure|harvest of a small bone marrow sample|harvest of a small bone marrow sample during open chest surgery
45362804|NCT00844064|Drug|AP 12009|"Initial scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (7 days), every other week, up to 10 cycles.~Modified scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (4 days), every other week, up to 10 cycles"
45362805|NCT04688788|Drug|Rituximab|Rituximab is a chimeric mouse/human monoclonal immunoglobulin gamma-1 (IgG1) antibody which depletes cluster of differentiation antigen 20 (CD20)-positive cells. Rituximab is approved for non-hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangitis and microscopic polyangitis, and pemphigus vulgaris.
45845223|NCT02289222|Drug|MK-3475|Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.
45362806|NCT04688788|Drug|Ocrelizumab|Ocrelizumab is a recombinant humanised monoclonal IgG1 antibody which depletes CD20-positive cells. Ocrelizumab is approved for multiple sclerosis.
45362807|NCT04688788|Drug|Fexofenadine|Premedication with oral fexofenadine 360 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
45362808|NCT04688788|Drug|Paracetamol|Premedication with oral. paracetamol 1000 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
45480289|NCT01334736|Behavioral|Lung age|For individuals randomized to spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be verbally informed of spirometric results. It will be explained that lung function normally reduces with age and that smoking can damage lung as if they were aging more rapidly than normal using visual depictions. Their lung function estimates based on their chronological age and lung age will be provided. They will be informed that smoking cessation would slow the aging of their lungs. After questions are answered, the participant will receive a written report that includes enumeration of their lung age and chronological age. At initial and follow-up visits, the research assistant will provide the participant with the same informational flyer and Tobacco Quit Line in Maryland as the usual care intervention.
45480290|NCT01334736|Behavioral|Contingency Management|For individuals randomized to CM, after completion of data collection, it will be explained to the participant that they will receive monetary compensation for biological confirmation of tobacco cessation. At each visit, exhaled carbon monoxide levels will be checked. If the subject has a negative CO level, they will be compensated. If a participant has a CO consistent with recent tobacco use, (s)he will receive the payment for attending the visit, but no additional payment at that visit. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
45480291|NCT01334736|Behavioral|Lung age + Contingency Management|For individuals randomized to the combined contingency management + spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be described the process of contingency management as outlined above. Following this, the research assistant will then describe lung age to the participant as described above. At the end of this process, the participant will then receive the informational flyer, quit line and local tobacco cessation program information similar to the usual care intervention. At each follow-up visit, after obtaining CO level and questionnaire outcomes, appropriate CM payment, review of participant's baseline lung age and informational flyer will occur.
45689243|NCT01795300|Radiation|Carbon Ion Radiotherapy|"Patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.~The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV."
45480292|NCT05654389|Other|Application of teleconsultation for a patient with a provisional diagnosis of myocardial infarction at the district hospital|Using teleconsultation for a patient with a provisional diagnosis of myocardial infarction during referral from the district hospital to the cardiac centre
45480293|NCT02484586|Device|Etafilcon A|Prototype lens material
45480294|NCT02484586|Device|Etafilcon A|Control lens for presbyope group
45845224|NCT02289222|Drug|Pomalidomide|Pomalidomide is given at standard dose of 4 mg daily orally for 21 days
45845225|NCT02289222|Drug|Dexamethasone|Dexamethasone is given at 40 mg orally weekly
45845226|NCT02291016|Drug|Formoterol|Comparison of dosage administered via a nebulizer versus dosage administered via a dry powder inhaler. 12 µg Formoterol with the dry powder inhaler and 20 µg (solution form) of Formoterol with the nebulizer. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
45845227|NCT02291016|Other|Placebo|Comparison of drug administered via a nebulizer versus a dry powder inhaler. The placebo used will be sterile, preservative free, normal saline for inhalation for the nebulizer and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
45845228|NCT02291718|Drug|Isovue|iodine contrast
45845229|NCT02292186|Drug|Revusiran (ALN-TTRSC)|
45845230|NCT02293044|Device|Crest® Sensi-Stop™ Strips|
45845231|NCT02293512|Behavioral|Coping Effectiveness Training|A CET psychoeducational intervention is provided to increase understanding of stress and coping with tinnitus, and to better learn how to match appropriate coping strategies, based on whether the stressful situation is changeable or not.
46049733|NCT00934440|Drug|Azacitidine|"Dose level 1: 35 mg/m2/day for 7 days.~Dose level 2: 55 mg/m2/day for 7 days.~Dose level 3: 75 mg/m2/day for 7 days.~mg/m2/day = dose based on height and weight"
45362809|NCT04688788|Drug|Methylprednisolone|Premedication with oral methylprednisolone 100 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
45362810|NCT04003077|Device|laser meridian massage|The participants will undergo 12 sessions of laser meridian massage, thrice a week, for 4 weeks, using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.5cm^2; power density, 300mW/cm^2; pulsed wave; RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany). The laser treatment will be applied to the back including Bladder meridian (BL11-25) and Governor vessel (GV3-14) for 15 minutes, to deliver a total treatment dose of 67.5J/cm^2.
45362811|NCT05221593|Drug|Lithium Carbonate|400 mg tablet in controlled released formula
45362812|NCT00844142|Drug|Etanercept 25mg|patients will receive etanercept 25mg twice weekly
45362813|NCT00844142|Drug|Sulfasalazine|in this arm patients will receive sulfasalazine 2000- 3000mg per os daily
45362814|NCT04688554|Diagnostic Test|fMRI and DTI|Neurologic imaging correlates
45362815|NCT04688554|Behavioral|Behavioral questionnaires|RAND 36-item Quality of Life survey, Mini Mental Status Exam, MOCA Cognitive Exam
45845232|NCT02293512|Behavioral|Cognitive-behavioral therapy|CBT treatments for tinnitus target the reduction of psychopathology by altering cognitive distortions, automatic thoughts, and core beliefs, as well as behavioral techniques to reduce physiological arousal.
45845233|NCT02293512|Behavioral|Acceptance and Commitment Therapy|An ACT psycho-educational intervention to reduce distress and resistance about having tinnitus and to increase committed actions based on one's values.
46049734|NCT02622802|Drug|paracetamol|In an ex vivo placenta perfusion study, placental tissue is exposed to paracetamol
46049735|NCT02622802|Drug|Erythromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to erythromycin
46049736|NCT02622802|Drug|Azithromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to azithromycin
46049737|NCT04134988|Other|Medimoov|The Medimoov game platform (created by NaturalPad©) is a physio-gaming medical device, which comes in the form of functional and postural rehabilitation software. Associating movement capture and videogames, Medimoov contributes to the older adults' motivation and engagement and offers adapted physical activities.
45845234|NCT02296164|Drug|Valchlor|Valchlor gel 0.016%
45845235|NCT02297100|Drug|Onabotulinumtoxin A|100 units of botox spread out among 10 separate injections
45845236|NCT02297100|Procedure|injections upper aspect of trigone of urinary bladder|We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
45845237|NCT02297100|Procedure|injections on posterior bladder wall excluding the trigone|We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
46049738|NCT04134988|Other|Standard psychomotor therapy|Psychomotor therapists are among the professionals recommended by the French national health authority. They intervene on psychomotor dimensions of falls, namely the motor, sensory and cognitive aspects.
46049739|NCT05158374|Drug|Aspirin tablet|75mg Aspirin once per day
46049740|NCT05158374|Drug|Metformin|500mg Metformin once per day
46049741|NCT05158374|Drug|Aspirin and Metformin|75mg Aspirin and 500mg Metformin once per day
45480295|NCT02484586|Device|Nelfilcon A|Control lens for presbyope group
45480296|NCT02484586|Device|Nesofilcon A|Control lens for presbyope group
45845238|NCT02299050|Drug|Cycloset|Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR
45845239|NCT02302092|Drug|Flomoxef|Flomoxef intravenous infusion
46049742|NCT00675532|Behavioral|Primary Care Counseling|Subjects in this condition will attend bi-weekly 15 minute sessions with the study nurse for primary care counseling which is a brief manual-guided, medically focused counseling approach to the treatment of opioid dependent individuals seen in primary care settings. The brief counseling sessions involve repeated support for and monitoring of medication compliance, and the provision of advice regarding established methods for coping with psychological and social factors that lead to drug use.
45480297|NCT02484586|Device|Nelfilcon A|Control lens for non-presbyope group
45480298|NCT02484586|Device|Etafilcon A|Control lens for non-presbyope group
45480299|NCT02484586|Device|Somofilcon A|Control lens for presbyope group
45845240|NCT02302092|Drug|Cefepime|Cefepime intravenous infusion
45845241|NCT02303184|Drug|4 mg CLS-TA|40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
45480300|NCT02484586|Device|58% Poly-HEMA|Control lens for presbyope group
45480301|NCT02484586|Device|Omafilcon A|Control lens for non-presbyope group
45480302|NCT00400218|Drug|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks|
45480303|NCT01332006|Procedure|Intrabone injection|All adults patients with hematological malignancies, lacking a HLA matched donor fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
45480304|NCT01332006|Biological|Intra-bone cord blood hematopoietic stem cell transplantation|
45480305|NCT01332006|Biological|Intra-bone cord blood hematopoietic stem cell transplantation|Intra-bone injection of CB hematopoietic SCs after conditioning regimen
45480306|NCT03716869|Other|Universal Screening Arm|"Students with PHQ-9 score >10, corresponding to a positive MDD screen, will proceed through the same SAP triage process as students referred by traditional means.~SAP triage will determine MDD identification. As SAP triage is not diagnostic, MDD identification is based on SAP recommendations for MDD related school or community services.~Treatment engagement will be tracked per current SAP processes.~To immediately identify and address suicidal intent, the survey will flag a positive response to PHQ-9 question 9 in real time. A suicidal student would proceed directly to management through the school crisis plan.~Students in the intervention arm will also be tracked for behavior concerning for MDD at any point in the school year prompting SAP triage referral."
45480307|NCT02486848|Drug|5% Topical Minoxidil Solution|5% Topical Minoxidil Solution
45689244|NCT01795300|Radiation|Proton Therapy|"As described previously, patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. Dose constraints of normal tissue will be respected according to Emami et al. (33). The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.~The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV."
45752129|NCT01389128|Other|Routine care|Routine care of the institution performed by the staff, without the presence of the researcher that included offering a balanced meal, continuous support with the presence of a partner or family throughout labor, use of oxytocin when prescribed by the staff, use of drug analgesia when requested by the patient.
45845242|NCT02303184|Drug|Sham|suprachoroidal sham procedure
45845243|NCT02303184|Drug|IVT aflibercept|2 mg intravitreal injection of aflibercept
46049743|NCT00675532|Behavioral|Cognitive-behavioral psychotherapy|Subjects in the CBT condition will participate in bi-weekly 50-minute-long individualized cognitive-behavioral psychotherapy sessions with a CBT trained clinician. The general purpose of the therapy is to: (1) acquire information about important concepts and aspects of recovery from opioid addiction; (2) increase self-awareness of specific problems and issues in relation to addiction and recovery, and (3) learn new coping skills to deal with problems contributing to or resulting from the addiction and to improve overall psychosocial functioning. The primary focus of this approach is to provide patients with frequent supportive contact and to teach cognitive-behavioral relapse prevention skills.
46049744|NCT02621086|Dietary Supplement|Cellodextrin|Gastrointestinal tolerability of single ascending doses of Cellodextrins
46049745|NCT00934362|Drug|Lucinactant first|lucinactant 120 mg (20 mg/ml) x 5 doses over 24 hours, then washout period x 14 days, then vehicle x 5 doses over 24 hrs
46049746|NCT00934362|Drug|Placebo first|6 mL normal saline x 5 doses over 24 hours, then washout period x 14 days, then lucinactant x 5 doses over 24 hours
46049747|NCT00675610|Behavioral|communication training|providers are trained to communicate with patients about adherence and patients are coached to discuss adherence with providers
46049748|NCT00675688|Drug|Bazedoxifene/Conjugate Estrogens (CE)|
46049749|NCT00675688|Drug|Raloxifene|
45480308|NCT02486848|Drug|15% Topical Minoxidil Solution|15% Topical Minoxidil Solution
45845244|NCT02304432|Drug|D-cycloserine|Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
45845245|NCT02304432|Drug|DCS or placebo|Double-blind placebo-controlled exposures to DCS or placebo x 6 weeks. One participant received exposure to DCS x 6 weeks and then received placebo dosing x 6 weeks. The other participant received exposure to placebo dosing x 6 weeks and then DCS x 6 weeks.
45480309|NCT01334814|Device|Deep Brain Stimulation (Model 7438 Therapy Controller)|Deep brain stimulation (DBS) is a surgical procedure used to treat a variety of disabling neurological symptoms
45480310|NCT01306565|Drug|Low dose Atorvastatin|80mg atorvastatin followed by two 20mg daily atorvastatin
45845246|NCT02304432|Drug|D-cycloserine|Both participants received second open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
45480311|NCT01306565|Drug|High dose atorvastatin|80mg daily atorvastatin for 72 hours
45480312|NCT03716791|Dietary Supplement|methylsulfonylmethane|3g per day
45480313|NCT03716791|Dietary Supplement|placebo|white rice flour
45480314|NCT05186610|Procedure|FDG PET/CT guided metabolic core needle biopsy|The target lesion to be biopsied was chosen based on accessibility and the highest metabolic activity (Highest standardized uptake value) on FDG PET/CT imaging. The final needle course was based on the anatomic location of the lesion, FDG avidity, and its relation with vital organs. The procedures were performed under full aseptic precautions and under adequate local anesthesia. The biopsy needle was placed to the target lesion using an automated robotic arm (ARA) workstation (ROBIO-EX, Perfint healthcare Pvt Ltd, Chennai, India).
45689245|NCT01795300|Radiation|Hypofractionated Photon Radiotherapy|"Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations >3mm are corrected prior to radiotherapy.~To the target volume defined for photon treatment, a total dose of 52.2 Gy E - 57.6 Gy E is applied in single fractions of 1.8Gy E. In the 3Gy E Photon arm, photon radiotherapy will be delivered to a total dose of 45 Gy E in 15 fractions."
45480315|NCT02486770|Biological|Aerucin 2.0mg/kg|IV Aerucin 2.0 mg/kg over 1 hour
45752130|NCT04493567|Drug|BMS-986036|Specified dose on specified days
45480316|NCT02486770|Biological|Aerucin 8.0mg/kg|IV Aerucin 8.0 mg/kg over 1 hour
45752131|NCT01793987|Device|Coblation polypectomy|
45480317|NCT02486770|Biological|Aerucin 20.0 mg/kg|IV Aerucin 20 mg/kg over 1 hour
45752132|NCT01961531|Device|Accuboost APBI|28Gy delivered in 5 daily fractions
45752133|NCT00363805|Dietary Supplement|green tea|Given orally
45752134|NCT00363805|Drug|Polyphenon E|Given orally
45845247|NCT02306928|Other|Blood draw|
45845248|NCT02307318|Device|SoftSeal Hemostatic Pad|Use of SoftSeal hemostatic device at a transradial access site with a 4 French system with with manual pressure by compression of the ulnar artery.
46049750|NCT00675688|Drug|Placebo|
46049751|NCT00934128|Device|Vapotherm|Deliver air in and out of the lungs, warmed, filtered for bacteria, and then delivered through the nose using a tube under the nostrils.
45480318|NCT03786029|Drug|Acetaminophen|"Patients will receive 320mg (10ml) Acetaminophen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
45752135|NCT00363805|Other|placebo|Given orally
45752136|NCT01388816|Drug|DRL-17822 or placebo|DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast
45845249|NCT02307552|Device|UreScan|The TUUS Foley/catheter will be inserted into the urethra via the ultrasound visualization onto the apex prostate, and the ultrasound extended through the urethra until the bladder neck and stopped. This is recorded twice automatically, and this should take 5-10 minutes for completion, and the prostate ultrasound data stored in memory. The ultrasound/subject interaction is now complete, and the study should add 30-60 minutes to the preoperative visit. No local or general anesthesia is used. The subject will be given 500 mg of Ciprofloxacin as a preventative measure against a urinary tract infection.
46049752|NCT00934128|Device|BIPAP|Air given through a mask, and amount can be set to different levels allowing more air in and out of lungs without using as much effort as regular breathing.
46049753|NCT02622334|Drug|Latanoprost|Latanoprost is a ophthalmic solution, available in dose strength as 0.005%.
46049754|NCT02622334|Drug|Placebo|Matching placebo formulation will be administered in Part A.
45845250|NCT02312154|Device|Restylane Vital|stabilized hyaluronic acid (HA)-based gel of nonanimal origin
45845251|NCT02312310|Dietary Supplement|Cocoa Flavanol|12 weeks administration of cocoa flavanol
45845252|NCT02312622|Drug|Pegylated Irinotecan|Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)
45480319|NCT03786029|Drug|Placebo|"Patients will receive 10ml Strawberry Juice (placebo), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
45480320|NCT03786029|Drug|Ibuprofen|"Patients will receive 200mg (10ml) of Ibuprofen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
45845253|NCT02314104|Drug|ropivacaine|Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.
45845254|NCT02314260|Other|bishop score calculation|Assessment of bishop score by vaginal examination
45845255|NCT02314260|Other|Trans-vaginal ultrasound|trans-vaginal ultrasound assessment of cervical length.
45845256|NCT02314260|Other|Modified bishop score calculation|using the cervical length and the original bishop score to calculate modified bishop score
45845257|NCT02314260|Procedure|labour induction|Induction of labor was carried out as per our hospital's standard protocol.
45845258|NCT02320812|Biological|human retinal progenitor cells|single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)
45845259|NCT02321748|Drug|Montelukast|
45845260|NCT02321748|Drug|ASP2151|
45845261|NCT02322528|Drug|Administration of Lotemax|An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.
45845262|NCT02323854|Device|Ablation|Percutaneous antenna will be placed into the target tumor under CT image guidance. Target tumor will be ablated and the antenna will be removed.
45845263|NCT02323854|Procedure|Surgical Resection|The planned surgical resection of the lung tumor will be conducted as scheduled post ablation procedure.
45845264|NCT02327052|Other|No intervention was performed.|No intervention was performed.
46049755|NCT02622334|Drug|RO5093151|RO5093151 is a ophthalmic solution, available in dose strengths as 0.1%, 0.5% and 1%.
46049756|NCT00696514|Dietary Supplement|Vitamin B12, folic acid, Vitamin D3|500 µg vitamin B12; 0.4 mg folic acid; 600 IU vitamin D3 in one capsule, once per day
46049757|NCT00696514|Dietary Supplement|Placebo (Vitamin D3) - 600 IU per day|600 IU vitamin D3 in one capsule, once per day
46049758|NCT02621164|Biological|NBP607-QIV|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
46049759|NCT02621164|Biological|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
46049760|NCT04263870|Drug|sintilimab|oral capecitabine 1000mg per m2 bid d1-14, intravenous oxaliplatin 130mg d1 per m2, sintilimab 200mg (every 3 weeks)
46049761|NCT02620930|Device|All market approved CRT-D or ICD systems endowed with the APNEA Scan algorithm|
46049762|NCT05247606|Device|Mobile application|Lifestyle intervention through web-based mobile application
45480321|NCT01334892|Drug|Cyclosporine Inhalation Solution|Cyclosporin for inhalation twice daily
45480322|NCT03435211|Device|INVSENSOR00006|Noninvasive pulse oximeter sensor
45480323|NCT02484508|Drug|Guli capsule|Guli capsule,as the experimental drug,is taken 3 grains each time, 3 time per day
45480324|NCT02484508|Drug|Kangguzengsheng capsule|Kangguzengsheng capsule, as the active comparator, is taken 3 grains each time, 3 time per day
45480325|NCT05186532|Radiation|Dry Heat Application|50 postnatal women they were encouraged to place an infrared lamp at distance of 45 cm from the perineum and the heat produced with 230 volts for ten minutes. But the mother is checked after the first five minutes to make sure that she was not being burned. The researchers were demonstrated for each woman how to use infrared lamp, and it was followed by re demonstrations and discussions. After 12 hours of episiotomy this procedure was carried out in the morning and evening for ten consecutive days. The researcher gives the infrared lamp device for each woman then restore it after completion of the study.
45752137|NCT01665521|Other|HEART Pathway|During ED evaluation, patients are randomized to HEART Pathway or usual care arms.
45752138|NCT01791647|Drug|metformin 1500 mg|
45752139|NCT01791647|Drug|myoinositol 1500 mg|
45752140|NCT00363883|Drug|vorinostat|Given orally
45362816|NCT04688554|Behavioral|Disease-Specific Patient-Reported Outcomes|Y-BOCS Survey, QUEST, PDQ39, PHQ2 Depression Screening, PHQ9 Depression Inventory, Beck's Depression Inventory, PROMIS Pain Intensity Short Form 3, McGill Pain Scale, Visual Analog pain scale, FTM (Tremor Scale)
45362817|NCT04688554|Behavioral|Behavioral tests|Behavioral tests may include one or more of the following procedures: Upper extremity testing, Perdue Peg Board testing, Hand tactile detection and discrimination test, Temperature and pain threshold testing, Lower extremity Testing, Myomotion Inertial Motion Testing.
45362818|NCT00837044|Drug|Treximet|Treximet
45362819|NCT00837044|Drug|Migraine rescue medication of choice|Migraine rescue medication of choice
45362820|NCT01013272|Drug|Entecavir|Entecavir 0.5mg orally daily
45362821|NCT01013272|Drug|Lamivudine|Lamivudine 100mg orally, daily
45362822|NCT04232085|Drug|Alemtuzumab|Preparative regimen
45362823|NCT04232085|Drug|Fludarabine|Preparative regimen
45362824|NCT04232085|Drug|Melphalan|Preparative regimen
45362825|NCT04232085|Radiation|Low Dose Total Body Irradiation|Preparative regimen
45362826|NCT04232085|Drug|Cyclophosphamide|GVHD prophylaxis
45362827|NCT04232085|Drug|Tacrolimus|GVHD prophylaxis
45362828|NCT04232085|Drug|Mycophenolate Mofetil|GVHD prophylaxis
45689246|NCT01795300|Radiation|Conventional Photon Radiotherapy|Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations >3mm are corrected prior to radiotherapy.
46049763|NCT02622412|Other|Multi-professional breathlessness service (MBS)|Patients visit the MBS twice. At week 1, delivered by palliative care specialists and respiratory disease specialists, patients receive an detailed assessment of breathlessness, relevant symptoms beyond breathlessness, psychosocial issues and carer burden. Recommendations are provided, and reviewed at the concluding visit in week 6 with palliative care specialists. In between these visits, weekly physiotherapy sessions focus on positioning, breathing techniques, exercise as well as pacing and fatigue management. Further support from the multi-professional expert team is given as needed.
45689247|NCT01518699|Drug|Ha44|Abametapir Lotion 0.74%
45689248|NCT01518699|Drug|Ha44 Placebo|Ha44 Vehicle Gel without Abametapir
45689249|NCT01518699|Drug|Moxifloxacin Placebo|Moxifloxacin Placebo
45689250|NCT01518699|Drug|Moxifloxacin|Moxifloxacin 400mg
45689251|NCT04556266|Biological|CAR T-Cell Infusion|Dose Level -1: 1 x 10^4 cells/kg Dose Level 1: 1 x 10^5 cells/kg Dose Level 2: 2 x 10^5 cells/kg Dose Level 3: 4 x 10^5 cells/kg
45689252|NCT01792648|Other|Standard reference diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat
45689253|NCT01792648|Other|Almond supplemented diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat, 20% energy from almonds
45689254|NCT01792648|Other|Low carbohydrate reference diet|26% energy from carbohydrate, 29% energy from protein, 45% energy from total fat
45689255|NCT01792726|Radiation|Boost to the tumour bed|Boost to the tumour bed, with whole breast EBRT delivered according to local policy.
45752141|NCT00363883|Other|laboratory biomarker analysis|Correlative studies
46049764|NCT02622412|Other|Delayed MBS Intervention|Patients will wait 8 weeks for start of intervention and will receive standard care in the meantime with access to respiratory medicine, general practitioners and palliative care services as needed. Standard care includes support by their general practitioners and disease orientated treatment (e.g. anti-obstructive treatment, oxygen supply if indicated, chemotherapy).
46049765|NCT04262700|Device|LifeScan's new BGMS|LifeScan new Blood Glucose Monitoring System (BGMS)
45362829|NCT02546024|Drug|Standard care|Standard care according to Care Pathway for depression by Mental Health of Older Adults Services Clinical Academic Group of the South London and Maudsley NHS Foundation Mental Health Trust
45362830|NCT01010698|Drug|cimetidine (or acyclovir)|cimetidine (or acyclovir) 200mg (single dose)
45362831|NCT04905849|Behavioral|Adaptive Cognitive Control Trainer (ACCT)|"Module 1: Attention=> This module demands an active scan of the screen in search for a target, much like traditional visual search tasks. Participants quickly identify the direction that a probe target is facing (up, down, left, right), and are aided by the presence of directional cue indicating where the location of the target will appear.~Module 2: Goal Management=> Requires participants to rapidly switch their focus based on distinct rules. Participants are presented with exemplar objects along with a target, and are asked to indicate which exemplar presented is most like the target.~Module 3: Working Memory=> Engages spatial working memory resources similar to the Corsi block task. Participants memorize the location of objects on screen followed by a 5-7 second delay period, with a correct response leading to a greater number of potential targets to be memorized on the next trial (and vice versa)."
45362832|NCT04905849|Behavioral|Active Control App|The app used here is undergoing expectancy-matching at the present time, will be updated with the final app characteristics when completed out of a list of several possibilities
45362833|NCT00851162|Biological|Trinity multipotent stem cells|Enough to fill voids which vary in size
45362834|NCT00851162|Biological|Demineralized bone matrix(DBM)|Enough DBM to fill a bone void defect
45845265|NCT02330094|Drug|Gabapentin|"Gabapentin capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications."
45689256|NCT01518309|Drug|pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth at 20, 40, or 60 mg doses
45362835|NCT04905537|Other|No intervention|It's only observational study. No interventions.
45689257|NCT04067895|Procedure|epiphysiodesis|All patients undergo surgical treatment of leg lengths discrepancies or primordial gigantism. Human bone graft screws will be used to stop the distraction of the growth plate.
45362836|NCT03541486|Drug|Ascorbate|75 gram infusion daily (M-F) on days when radiation therapy is administered. The infusion occurs during the 'beam on' of the radiation therapy.
45689258|NCT01419717|Drug|Denosumab|Administered by subcutaneous injection every 4 weeks (Q4W)
45689259|NCT04748133|Device|acupuncture needles|"Site of acupuncture points:~Du 26: At junction of the upper and middle third of philtrum.~Ren 17: On the midline level with the 4th intercostal space midway between the nipples.~LI4 (Large Intestine 4): On the dorsum of the hand, between the 1st and 2nd metacarpal bones~HT7 (Heart 7): On the ulnar end of the transverse crease of the wrist, in the small depression between the pisiform and ulna bones~LV3 (Liver 3): On dorsum of the foot in a depression distal to the junction of the 1st and 2nd metatarsal bones.~ST36 (Stomach 36): Antero-lateral leg, 1 middle-finger breadth next to the anterior crest of tibia, 3 cun under the depression lateral to the patellar ligament.~PC6 (Pericardium 6): Palmar aspect of the forearm, between the tendons, 2 cun away from the transverse crease of the wrist"
45689260|NCT04748133|Other|placebo|no treatment
45689261|NCT01458951|Drug|tofacitinib|10 mg oral BID
45689262|NCT01458951|Drug|Placebo|Placebo oral BID
45689263|NCT01458639|Drug|Technegas V SPECT imaging|Technegas V SPECT imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
45362837|NCT03541486|Drug|Gemcitabine|600 mg/m2 once weekly for up to weeks
45362838|NCT03541486|Radiation|radiation therapy|Prescribed to 50 Gy in 25 fractions. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
45362839|NCT00851240|Drug|BTT-1023|intravenous
45362840|NCT00851240|Drug|Placebo|Intravenous
45362841|NCT03535324|Behavioral|PROA for optimization|The development of a ASP based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations.
45362842|NCT03535324|Other|Control|There will be no intervention
45362843|NCT00620750|Drug|Extended release injectable naltrexone (Vivitrol)|Three sequential monthly injections of extended release injectable naltrexone (Vivitrol), with option to extend participation for an additional 12 months.
45362844|NCT04884243|Drug|CBT-006|Cyclodextrin
45362845|NCT04867707|Drug|Zanamivir|5 days of treatment with 10mg zanamivir inhaler BID
45845266|NCT02330094|Drug|Placebo|"Placebo capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications."
45845267|NCT02330172|Other|Injection of neostigmine or sugammadex|"At anesthetic induction, rocuronium 0.45 to rocuronium 0.45 - neostigmine group or rocuronium 0.9 mg/kg to rocuronium 0.9 - sugammadex group will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. After operation, neostigmine 50 mcg/kg or sugammadex 4 mg/kgl be injected."
46049766|NCT05317182|Other|Occlusal Splints Analogic-Analogic|Take a conventional impression to the patient and conventional fabrication of the splint.
46049767|NCT05317182|Other|Occlusal Splints Analogic-Digital|Take a conventional impression to the patient and digital fabrication of the splint.
46049768|NCT05317182|Other|Occlusal Splints Digital-Digital|Take a digital impression to the patient and digital fabrication of the splint.
45362846|NCT02547896|Drug|Codeine + Diclofenac|The patients will receive codeine and diclofenac as pain relief medicine after the surgery
45362847|NCT02547896|Drug|Diclofenac|The patients will receive only diclofenac
45362848|NCT04002999|Device|3D printed ceramic bracket and tray|The 3D ceramic bracket being investigated is the only available customized ceramic bracket. This will be a first for the orthodontic speciality. This will also be the first and only customized bracket system that includes customization of the bracket base. This helps in the control of first order orthodontic movements and allows brackets to be bonded on any labial surface of the tooth while maintaining an ideal prescription. As 3D printing is not limited by the mold-ejection in CIM, [24] the bracket system being tested here has the potential to achieve a more accurate slot dimension.
45362849|NCT04002999|Device|Stock ceramic bracket + 3D printed tray|Traditionally, indirect bonding, starts with creating a mold of all the teeth as an exact replica of the mouth of the patient. From there, in the lab, the orthodontist positions each bracket precisely where it should go on each tooth and then creates a custom tray that allows transfer of the brackets from the lab model to the patient's teeth. By taking the time to place the brackets in a proper position on the lab model, orthodontists eliminate the inaccurate process of placing orthodontic brackets directly on the teeth. It theoretically also takes less chairside time and is more comfortable for the patient. It is however more technique sensitive. In this study, indirect bonding setup will be done virtually using commonly-available orthodontic software. The trays/jigs will then be 3-D printed
45689264|NCT01458639|Drug|Xenon-133 Ventilation Planar imaging|Xenon-133 Ventilation Planar imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
45689265|NCT01437423|Biological|TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio|0.5 mL, Intramuscular at 2, 4, 6 months (Primary) or at 4 to 6 years (Booster) vaccination
45689266|NCT00393796|Drug|SUTENT|"50 mg/PO once daily for four consecutive weeks with a two week rest period. Study participants who show evidence of disease progression (or are considered for removal from study for any other reason) will be unblinded. Participants receiving SU011248 will be removed from the study. Participants receiving placebo will be given the opportunity to crossover and receive SU011248."
45689267|NCT00393796|Other|Placebo|
46049769|NCT00871000|Biological|Boostrix Polio™ 711866|Single dose, intramuscular administration.
46049770|NCT00871000|Biological|Priorix Tetra TM 208136|Single dose, subcutaneously.
46049771|NCT00871000|Biological|Tetravac TM|Single dose, intramuscular administration.
46049772|NCT05157828|Other|No intervention|No intervention
46049773|NCT05154084|Behavioral|Performance feedback and education|Hospitals and surgeons will have an online interactive performance feedback dashboard provided to them along with educational components.
46049774|NCT01096784|Drug|rhIGF-I/rhIGFBP-3|Continuous intravenous infusion
46049775|NCT02621008|Other|Stress Reduction& Healthy living|Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
45480326|NCT05186532|Other|Moist Heat Application|included 50 postnatal women they were encouraged to sit in a basin (tub) of warm water (45 o C -59 o C) without pressure on the perineum and with the feet flat on the floor for 10 minutes. The researchers were demonstrated for each woman how to do warm sitz bath, and it was followed by re demonstrations and discussions. After 12 hours of episiotomy this procedure was carried out in the morning and evening for ten consecutive days.
45480327|NCT04730219|Drug|Tislelizumab|Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles
45480328|NCT04730219|Drug|Nab paclitaxel|Nab paclitaxel 200mg will be administered on Day 2 every 3 weeks for 3 cycles
45689268|NCT00393874|Behavioral|Behavioral Sleep Intervention|Participants will receive a workbook with information related to the intervention. The three core components are presented and discussed during these sessions are:1) education about sleep and nightmares; 2) imagery rehearsal; 3) stimulus control and sleep restriction. Session 1 focuses on education on PDSD-related insomnia, nightmares, and sleep avoidance behaviors. The rationale for imagery rehearsal will then be presented, and the technique will be practiced once. Strategies for managing intrusive thoughts and images during the practice of imagery rehearsal will be discussed. Participants will be instructed to practice this technique at least three times each day for the duration of the treatment phase. During the second 45-minute session (Week 3), sleep schedules extracted from the pre-intervention sleep diary will be used to identify goals to reduce insomnia, i.e., for sleep restricted schedules, and activities to be performed out of bed when awake.
45362850|NCT04002999|Device|Stock bracket, no tray|Direct bonding is the traditional way of placing orthodontic brackets, in which orthodontists clinically eyeball the tooth and place the bracket where they deem most appropriate
45362851|NCT01564251|Drug|GDC-0575|Participants will receive GDC-0575 orally at a starting dose of 15 mg.
46049776|NCT02622256|Behavioral|Health System: HTN Intervention|Interested participants can enroll online via a Twitter link. Patients will consent to having their electronic health records accessed to validate clinical data. Participants will complete short surveys. The project Twitter account would follow tweeters with high impact CV messages and tweet daily high impact and accurate CV health messages (identified in aim 3). Participants will follow the study team & may receive daily private heart health messages via Twitter. This would allow participants to see CV health messages posted in the words and context of patients that may be similar to them, participate in online CV health discussions, and access CV health networks that they may not otherwise know about. Participants will also tweet heart health messages weekly.
45362852|NCT01564251|Drug|Gemcitabine|Participants will receive gemcitabine intravenously at a dose of 1000 mg/m^2 and/or 500 mg/m^2.
45362853|NCT00844220|Procedure|CT/MR|CT/MRI-directed clinical management strategy
46049777|NCT04016038|Other|a psycho-social investigation|The design of this project is based partly on the UNBIASED international study and is based on an in-depth case study in a prospective and retrospective dimension of deceased cancer patients for whom sedation has been established, and this, during a given period in different care settings: home, care center, hospital and palliative care unit.
45362854|NCT00844220|Procedure|Catheterization|Standard clinical management directed by conventional coronary angiography
45362855|NCT00508144|Drug|Alimta|500 mg/m^2 by vein Once Over 10 Minutes Every 3 Weeks
45480329|NCT05654311|Other|Nasal surgery|Nasal surgery under general anesthesia using inhalational agent (sevoflurane)
45480330|NCT04492774|Combination Product|Goldic serum|epidural injections
46049778|NCT00696592|Drug|Bevacizumab (Avastin), Verteporfin (Visudyne)|
46049779|NCT02617108|Device|Foley balloon|a Foley balloon with 4 ml of normal saline solution will be placed into the uterine cavity at the end of the operation for five days.
46049780|NCT02617264|Procedure|SPOT|Injecting the ink (SPOT) to the axillary lymph node prior the surgery. During the surgery the lymph nodes will be tasted to diagnose the marked node.
46049781|NCT02617420|Device|Propeller Health Monitoring Device|
45362856|NCT00844454|Procedure|multi-pronged ethanol ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then inject ethanol to destroy the whole tumor tissue.
45362857|NCT00844454|Procedure|radiofrequency ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then deliver radiofrequency energy to destroy the whole tumor tissue.
46049782|NCT02620696|Drug|netazepide|
46049783|NCT02622022|Drug|Morphine hydrochloride|
46049784|NCT02622022|Other|Placebo|
46049785|NCT02621866|Device|Ultraviolet A radiation|Twice daily with 10 Joules/cm2. Half body (one side) with Waldmann 100L phototherapy lamp fitted with UVA bulbs (main emission 320-410nm)
45362858|NCT02545712|Other|Exposure to ethanol|The drug source(s) and amount administered daily are noted.
45480331|NCT04492774|Drug|Steroid injections|epidural injections
45480332|NCT04492774|Procedure|Manual therapy|Veno-lymphatic drainage
45480333|NCT01332084|Other|HA wheat cereals|HA wheat cereals used in SOTI test and as part of desensitization plan
46049786|NCT02621866|Device|Sham irradiation|As active, but lamps to be shielded with Amber 81 museum film which prevents transmission of <500nm, but permits visible light to pass.
45480336|NCT01928732|Behavioral|Cognitive Processing Therapy (CPT)|CPT consists of cognitive therapy and a written trauma narrative. Patients are taught to challenge their beliefs through Socratic questioning and the use of daily worksheets. The initial focus is on beliefs such as denial and self-blame, and then shifts to overgeneralized beliefs about self and the world. Patients process their trauma directly by writing a narrative of their traumatic event(s) that they read to themselves and to therapists. The typical protocol consists of 12 1-hr sessions. In this study, the 12-session protocol will be followed, but participants who improve more rapidly may finish in 10 sessions and those who improve more slowly may receive up to 2 additional sessions to continue working on stuck points with challenging beliefs worksheets.
45362859|NCT02545712|Other|Exposure to propylene glycol|The drug source(s) and amount administered daily are noted.
45362860|NCT02545712|Other|Exposure to benzyl alcohol|The drug source(s) and amount administered daily are noted.
45362861|NCT02545712|Other|Exposure to acesulfam potassium|The drug source(s) and amount administered daily are noted.
45689269|NCT00393874|Drug|Prazosin|Participants randomized to PRZ will take 4 capsules each night (PRZ dose complemented with placebo capsules ). The target dose of prazosin is 10 mg. Some individuals may require doses up to 15 mg, (Murray Raskind, M.D., personal communication, February 4, 2005). Prazosin will be administered in an initial oral dose of 1 mg (Week 1), with titration to a maximum of 15 mg. The first increment will be of 1 mg (Week 2: 2 mg), and subsequent weekly increments according to the following schedule: Week 3: 4 mg; Week 4: 6 mg; Week 5: 10 mg; Week 6: 15 mg; Week 7: 15 mg; Week 8: 15 mg. A maximum dose of 15 mg may be necessary. Medication will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose.
45689270|NCT00393874|Drug|Placebo|Participants randomized to PLA will take 4 capsules each night for eight weeks, all capsules will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed.
45689271|NCT01458249|Drug|eribulin mesylate|Administration of eribulin mesylate at a dose of 1.4 mg/m^2 as an IV bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
45689272|NCT00394888|Device|MRI|MRI of the spine.
46049787|NCT00934050|Drug|ELND005 (scyllo-inositol)|"Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks~After 15Dec2009: ELND005 250 mg PO BID for 48 weeks"
46049788|NCT02620618|Drug|Intravitreal Infliximab|ocular safety and efficacy in treating inflammation in uveitis patients with Behcets Disease
46049789|NCT04135456|Drug|Mannitol|When the neurosurgeon starts the skin incision, 20% mannitol administered through the venous catheter with fulldrip in 5-10 minutes. Neurosurgeons evaluate the degree of brain relaxation after dura opening in 4 point scale (1=bulging brain, 2=firm brain, 3=satisfactorily relaxed, 4=perfectly relaxed).
45689273|NCT00394888|Device|MRI of head and neck|MRI of head and C-spine
45689274|NCT00394888|Other|Dermatological Examination|Complete dermatological examination to identify and characterize nature of dermatological anomalies
45362862|NCT02545712|Other|Exposure to aspartame|The drug source(s) and amount administered daily are noted.
45362863|NCT02545712|Other|Exposure to glycerol|The drug source(s) and amount administered daily are noted.
45689275|NCT00394888|Other|Cardiac examination|Complete cardiac examination
45689276|NCT00394888|Device|Abdominal ultrasound|Abdominal ultrasound to detect hepatic hemangiomas
45845268|NCT02331108|Drug|Selection of anesthetic induction technique|Standard anesthesia care will be provided after induction based on randomization. Temperatures will be monitored every 15 minutes
45845269|NCT02332902|Drug|Everolimus|Everyone in the study will receive Everolimus at a starting dose of 10 mg daily and will be adjusted up or down by 2.5 mg at 2 week intervals to attain a trough concentration of 5-15 ng/ml
46049790|NCT00607464|Device|Polyethylene occlusive skin wrap|Polyethylene occlusive skin wrap applied immediately after birth and removed after the infant has been admitted to a stable thermoneutral environment
46049791|NCT01091168|Drug|vinflunine|280 mg/m2 on day 1 of each cycle every 3 weeks
45362864|NCT02545712|Other|Exposure to sorbitol|The drug source(s) and amount administered daily are noted.
45362865|NCT02545712|Other|Exposure to methyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
45362866|NCT02545712|Other|Exposure to propanyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
45362867|NCT02545712|Other|Exposure to polysorbate-80|The drug source(s) and amount administered daily are noted.
45480337|NCT01928732|Behavioral|Prolonged Exposure (PE)|"PE is a manualized, 90-minute, 8-15 week treatment program based on emotional processing theory, which posits that anxiety disorders, including PTSD, reflect pathological fear structures in which emotional and cognitive associations among different elements do not accurately represent reality and renders the individual dysfunctional and distressed. PE is designed to correct erroneous connections in the targeted memory structure. PTSD sufferers typically experience two key pathological emotional response sets and related cognitions: The world is an utterly dangerous place, and I am completely incompetent and unable to cope with stress. In this study, the 12-session protocol will be followed, but participants improve more rapidly may finish in 10 sessions and those who improve more slowly may have up to 2 additional sessions to continue working on exposure."
45480338|NCT03321292|Drug|L-arginine 1000 mg and Acetylesalicylic acid75mg|l-arginine 1000mg capsule will be given every 8 hours till delivery and acetylesalicylic acid75mg tablet once starting of diagnosis till birth.
45689277|NCT01458171|Biological|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human immunoglobulin for subcutaneous (SC) use. Subjects will receive weekly infusions of IgPro20 for a total of 24 weeks at a dose based on the subject's IgPro20 dose in the pivotal study ZLB06_002CR (NCT01199705).
45689278|NCT00395044|Drug|Placebo|Placebo
46049792|NCT01091168|Drug|Alkylating agent of physician choice registered in cancer|cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin
46049793|NCT04135768|Procedure|Wrist joint haematoma washout|After plating of the distal radius is performed, a small incision is made on the wrist joint capsule. This is the portal for fluid efflux. An intravenous cannula is used to puncture the wrist joint capsule adjacent to the first incision and normal saline is infused through this cannula into the wrist joint. The infusion continues until the fluid efflux from the first portal is clear and no longer blood stained. This will be the point at which the washout is considered to be complete.
45362868|NCT01011010|Drug|doxorubicin hydrochloride|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
45362869|NCT01011010|Drug|mitomycin C|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
45362870|NCT01011010|Drug|sorafenib tosylate|Sorafenib 400mg BID continuously post TACE beginning when LFTs return to entry criterion. Discontinue at time of disease progression (progression in a lobe that has already been embolized, new lesions in an untreated lobe, or evidence of extrahepatic progression).
45689279|NCT00395044|Drug|Gabapentin|
45689280|NCT01457703|Drug|Cetrorelix|Abolishes pituitary sensitivity to GnRH.
46049794|NCT04135768|Procedure|Volar locking plate insertion of the distal radius|An anatomical locking plate is applied to the distal radius fracture using screws
46049795|NCT05239572|Combination Product|screening, prevention and counselling|Screening in Intergenerational solidarity clubs in Myanmar and Vietnam and in Posbindu programme in Indonesia
45362871|NCT01011010|Other|laboratory biomarker analysis|Serum VEGF levels are required: pre TACE (day of procedure, time B), 24 hours post TACE (+/- 6 hours, time C), day 7 post first TACE (± 1 day, time D), day 28 post reinitiation of sorafenib (± 3 days, time E). These levels will not be repeated for patients receiving a second TACE procedure.
45362872|NCT01011010|Other|pharmacological study|Treatment with sorafenib will continue on a daily basis until disease progression (see definition protocol Section 7) or unacceptable toxicity is encountered. At the end of treatment, no further therapies are currently recommended.
45362873|NCT05357391|Device|The Pressure Injury Prediction and Education model using a mobile application system|Data from the medical records will be used to analyze the probability and risk of wound healing for creating a Pressure Injury Prediction and Education Model using a mobile application system.
45362874|NCT00851708|Drug|N-acetylcysteine|600 mg bid orally from day 1 to 7 postoperative
45362875|NCT05018481|Drug|Sodium Hyaluronate|Sodium hyaluronate of molecular weight 35kDa will be given in capsule form to study participants
45845270|NCT02340156|Genetic|SGT-53|SGT-53, at 3.6 mg DNA per infusion, will be administered twice per week for 3 weeks (on Day 1, 4, 8, 11, 15 and 18 of each cycle) for 3 cycles. If SGT-53-related toxicity occurs, the dose of SGT-53 will be de-escalated to 2.4 or 1.2 mg DNA/infusion when appropriate.
45845271|NCT02340156|Drug|Temozolomide|TMZ will be administered orally on days 9-13 of each cycle. In cycle 1, the dose of TMZ will be 150 mg/m². If the TMZ-related toxicities are tolerated in cycle 1, the dose of TMZ will be escalated to 200 mg/m² for cycle 2 and beyond. If TMZ-related toxicity occurs, the dose if TMZ will be de-escalated to 125 mg/m² (dose level -1), 100 mg/m² (dose level -2) or 75 mg/m² (dose level -3) when appropriate.
45689281|NCT01457703|Drug|Gonadorelin-GnRH|GnRH is used to stimulate the pituitary gland to produce LH and FSH.
45845272|NCT02343276|Drug|Nitroglycerin|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
45845273|NCT02343276|Other|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
45480339|NCT03321292|Drug|acetylsalicylic acid 75 mg|acetylsalicylic acid 75 mg will be given orally once daily for group B starting of diagnosis till birth.
45845274|NCT02347410|Device|SIFS graft containment device|The SIFS mesh is a graft containment and reinforcement device. Following conventional thorough discectomy, the disc space is entered through a small portal in the annulus, the SIFS mesh is introduced, deployed and then filled with bone graft. Bilateral commercially available posterior lumbar fixation is applied.
45362876|NCT05018481|Drug|Placebo|A placebo will be given in capsule form to study participants
45362877|NCT01011088|Other||Not any artificial interventions were given
45845275|NCT02347488|Device|Haider ETT Tube Holder and Bite Guard|Surgery patients will have endotracheal tubes secured with a novel combined endotracheal tube holder and bite guard change in ETT tip position caused by traction up to 15N was measured prior to surgery.
46049796|NCT02621788|Behavioral|Stress Management and Resiliency Training for Residents (SMART-R)|The SMART-R is a mind-body Educational Program for residents that is aimed at reducing the impact of stress and enhancing coping strategies through skill building exercises. The intervention consists of 3, 2 hour sessions over the course of 12 months.
46049797|NCT05321576|Procedure|Erector spinae plane block (ESPB) technique without opioid use|Local anesthetic injection to the erector spinae muscle plane at T5 level on the operation side.
45362878|NCT05011851|Drug|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
45362879|NCT01011166|Drug|IDX184|IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.
45362880|NCT01011166|Drug|Placebo|Placebo white opaque capsules taken by mouth from Day 1 to Day 14.
45362881|NCT01011166|Biological|Peginterferon alfa-2a (Peg-IFN)|Peg-IFN was supplied as 180 ug single-use, pre-filled syringes administered once weekly from Day 1 to Day 28.
45362882|NCT01011166|Drug|Ribavirin (RBV)|RBV 200 mg capsules at a total daily dose of 1000 mg to 1200 mg (based on participant body weight) from Day 1 to Day 28.
45689282|NCT01457703|Drug|Recombinant LH|Used to stimulate ovarian function in women.
45689283|NCT01457703|Drug|Letrozole|An aromatase inhibitor.
45362883|NCT00621842|Drug|Lamotrigine regular tablet formulation|Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.
45480340|NCT03785717|Procedure|ROG|Bone width augmentation using bone grafting and membrane non cross linking.
45689284|NCT04445428|Biological|oral polio vaccine + information|Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
46049798|NCT00864916|Drug|Combination antiretroviral therapy (cART)|Participants will receive the appropriate cART medications, as prescribed by their primary HIV doctor for 48 weeks. (cART medications may be prescribed beyond the length of this study.)
45480341|NCT03785717|Procedure|ROG & ESWT|Before the bone width augmentation using bone grafting and membrane non cross linking, the patient was received ESWT (Extracorporeal shockwave therapy).
45480342|NCT02484742|Behavioral|Insomnia symptom induction|Several nights during the 18-day stay will be disrupted, such that we delay sleep onset, advance sleep off set, and the sleep period will be disrupted by frequent nighttime awakenings.
45480343|NCT01306721|Drug|fexofenadine HCL (M016455)|Pharmaceutical form:tablet Route of administration: oral
45480344|NCT01306721|Drug|pseudoephedrine|"Pharmaceutical form:tablet~Route of administration: oral"
45480345|NCT01306721|Drug|fexofenadine HCL matching placebo|"Pharmaceutical form:tablet~Route of administration: oral"
45480346|NCT01306721|Drug|pseudoephedrine matching placebo|"Pharmaceutical form:tablet~Route of administration: oral"
45689285|NCT04445428|Behavioral|Information|Advice regarding how to protect oneself from COVID-19
45689286|NCT00356434|Device|Kendall A-V foot impulse pump, model 6060|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
45362884|NCT00621842|Drug|Lamotrigine novel formulation|"Participants will have the option of trying a novel formulation of lamotrigine tablets instead of the lamotrigine regular formulation tablets. The dosing will remain the same regardless of which type of lamotrigine tablet is used.~Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds."
45480347|NCT01337466|Radiation|[124I]FIAU|This is a single dose study of 2 mCi [124I]FIAU in healthy volunteers or subjects with prosthetic joint infection of the knee or hip who will undergo serial PET-CT scanning.
45480348|NCT02486926|Other|Sevoflurane|Anesthesia of patients was maintained only with sevoflurane.
45480349|NCT02486926|Drug|Remifentanil|Anesthesia of patients was maintained with both sevoflurane and continuous remifentanil infusion.
45480350|NCT02486926|Drug|Alfentanil|Anesthesia was maintained with both sevoflurane and continuous infusion of remifentanil. Alfentanil was administrated (5ug/kg) to patients 10 minutes before the end of surgery.
45362885|NCT05356143|Drug|Rupatadine|Oral single dose 10 mg tablet
45480351|NCT02486926|Drug|Thiopental|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
45480352|NCT02486926|Drug|Rocuronium|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
45480353|NCT01335048|Drug|atorvastatin and clopidogrel|Atorvastatin 80 mg daily + clopidogrel 150 mg daily
45480354|NCT01335048|Drug|Clopidogrel|Clopidogrel 150 mg daily
45480355|NCT03318250|Device|Dorsal Root Ganglion Stimulation|During the Dorsal Root Ganglion implant , SCS leads will be implanted using a TransGrade Dorsal Root Ganglion Technique. Antibiotic prophylaxis is performed prior to surgery for both trial and permanent implant phase. Using the technique lead placement will be performed through a small skin incision under local anaesthesia supplemented by conscious sedation. The leads will be placed along the DRG to obtain stimulation coverage over as much of the pain area as possible. After the leads have been implanted, x-ray or fluoroscopy images will be taken to record the final lead locations. Once intervention is completed participants will assigned either DRG-LF and Burst3D device programme.
45845276|NCT02347488|Procedure|Tape|Surgery patients will have endotracheal tubes secured with adhesive tape, as the current clinical procedure; change in ETT tip position caused by traction up to 15N measured prior to re-securing the ETT with the Haider device.
45845277|NCT02348658|Drug|TAK-536TCH|TAK-536TCH tablets
45845278|NCT02349438|Device|senofilcon A|A soft spherical contact lens
45845279|NCT02349438|Device|lotrafilcon B|
45845280|NCT02350998|Drug|OTO-201|
45845281|NCT02351700|Drug|IV Caldolor|IV Caldolor (IV ibuprofen) intraoperatively and postoperatively
45845282|NCT02351700|Drug|IV Placebo|IV Placebo intraoperatively and postoperatively
45845283|NCT02353806|Drug|Amlodipine besylate|Pregnant and postpartum women will continue taking amlodipine besylate 5 mg for treatment of chronic hypertension as prescribed by their clinician.
45845284|NCT02354352|Drug|Eplerenone|26 Subjects will take Eplerenone, one 50mg capsule by mouth once daily for 12 months.
46049799|NCT00864916|Drug|Pentoxifylline|Participants will receive 400 mg of pentoxifylline three times per day for 48 weeks.
46049800|NCT00864916|Drug|Placebo|Participants will receive placebo three times per day for 48 weeks.
46049801|NCT04130386|Behavioral|Motivational Interviewing|Participants receiving MI
46049802|NCT04130386|Behavioral|e-education|Participants receiving e-education
45362886|NCT01013428|Other|Ultrasound|Ultrasound will be used to evaluate tendons.
45480356|NCT01335126|Other|Emulsion type artificial tear|2 types of artificial tears
45480357|NCT03465709|Drug|Pegcetacoplan|Study Drug
45480358|NCT02489812|Behavioral|Music|This cross over trial aimed to analyze the use of music as a distraction resource during children dental treatment, evaluating their cardiac and respiratory frequency. Thirty-four children took part in this study, 16 boys and 18 girls, from 4 to 6 years old, with no previous dental experience, who had two carious lesions on occlusal surfaces of molars,
45480359|NCT01567475|Drug|Everolimus and rituximab|One injection of Rituximab 375 mg/m2 per week during 28 days followed by one Rituximab infusion every other cycle at 375 mg/m2 associated with everolimus at 5mg or 10 mg every day or 5 mg every other day.
45480360|NCT01337544|Other|HAPLOIDENTICAL IL-15 STIMULATED NK CELLS|ONE MEGADOSE 30 DAYS AFTER TRANSPLANTATION (DOSE WILL DEPEND ON PATIENT BODY WEIGHT)
45480361|NCT03716713|Device|CeraShield Endotracheal Tube|Subjects requiring mechanical ventilation with be intubated with the CeraShield ETT
45480362|NCT03316144|Biological|Toripalimab|Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS001. Subjects will be assigned to a dose schedule in the order of study entry.
45752142|NCT00356057|Device|Protos DR/CLS and Stratos LV CRT pacemakers|Protos DR/CLS is a dual chamber pacemaker with CLS rate adaption, Stratos LV is a biventricular pacemaker with accelerometer based rate adaption
45752143|NCT00364819|Drug|rituximab|rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours
45752144|NCT04524351|Drug|Posiphen|Solid oral dosage form, capsule
45752145|NCT04524351|Drug|Placebo|Solid oral dosage form, capsule
45752146|NCT02107157|Device|755nm Laser with Cap Array|
45752147|NCT04523961|Drug|2.5 g of lidocaine 23% / tetracaine 7% ointment without occlusion|Topical anesthetic used to numb the skin prior to laser procedures
45845285|NCT02354352|Drug|Spironolactone|26 Subjects will take Spironolactone, one 50mg capsule by mouth once daily for 12 months.
45845286|NCT02355210|Dietary Supplement|Bifidobacteria adolescentis BD1|packet containing 10^9 cells of Bifidobacteria adolescentis BD1
46049803|NCT00864682|Drug|Saline|3.3 mL normal saline
46049804|NCT00864682|Drug|Lidocaine / propofol admixture|lidocaine 50 mg plus propofol 50 mg intravenous (iv)
46049805|NCT00864682|Drug|lidocaine pretreatment|lidocaine 50 mg iv under tourniquet-control
45845287|NCT02355210|Dietary Supplement|Bifidobacteria animalis subsp. lactis BB-12|packet containing 10^9 cells of Bifidobacteria animalis subsp. lactis BB-12
45845288|NCT02355210|Dietary Supplement|Bifidobacteria adolescentis BD1 and galactooligosaccharide|packet containing 10^9 cells Bifidobacteria adolescentis BD1 and 5 g galactooligosaccharide
45689287|NCT00356434|Device|Kendall sequential compression device, model 9525|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
45689288|NCT01419015|Device|SAPIEN XT NovaFlex delivery system|Transcatheter aortic valve implantation via transfemoral approach.
45689289|NCT00357214|Dietary Supplement|Potassium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
45689290|NCT00357214|Dietary Supplement|Sodium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
45689291|NCT00357214|Dietary Supplement|Potassium Chloride|67.5 mmol/d given as three tablets after each meal, with a full glass of water
45689292|NCT00357214|Dietary Supplement|placebo (microcrystalline cellulose)|Given as three tablets after each meal, with a full glass of water
45689293|NCT01418937|Biological|CervarixTM (GSK580299)|Three intramuscular injections
45689294|NCT04439032|Other|NanoBone Bone Graft Substitute|Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.
46049806|NCT00698386|Dietary Supplement|Zinc supplement|Zinc miconutrient supplements have been prepared by Cadila pharmaceutical Ltd., India, in the form of capsules.Each micronutrient capsule contains 50mg zinc (as zinc sulphate) in a lactose matrix.In this clinical trial one tablet of zinc as oral supplement will be given everyday during the entire course in line with the directly observed treatment, short-course (DOTS) strategy recommended by the World Health Organization.
45689295|NCT02076321|Drug|Acetaminophen|acetaminophen for pain control with dose and frequency of 10-15mg/kg/dose, Maximum dose 1000mg. Maximum amount per day: 75mg/kg (not to exceed 4g/day).
45689296|NCT02076321|Drug|Ibuprofen|ibuprofen for pain control with dose and frequency 4-10mg/kg/dose. Maximum of 40mg/kg/day, not to exceed 3,200mg/day. Maximum one-time dose of 800mg.
45689297|NCT01417377|Drug|Mircera|Participants with chronic kidney disease receiving methoxy polyethylene glycol-epoetin beta (Mircera) and previously on treatment with short-acting epoetin alpha will be observed for a period of 6 months.
45689298|NCT00358462|Drug|Azithromycin|two 500mg tablets or four 250mg tablets administered as a single dose
46049807|NCT00698386|Dietary Supplement|Placebo|Placebo have been prepared by Cadila pharmaceutical Ltd., India, in the form of capsules.The placebo consisted of lactose alone. Supplement and placebo capsules were indistinguishable in appearance both externally and internally.
46049808|NCT04130308|Other|Retrun to run protocol|Progressive return to run protocol for patients after ACL-R
45689299|NCT00358462|Drug|Doxycycline|one 100mg capsule administered twice daily for seven days
45689300|NCT00396292|Drug|Oral iron tablets|325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
45752148|NCT04523961|Drug|7.5 g lidocaine 2.5%/ prilocaine 2.5% cream with occlusion|Topical anesthetic used to numb the skin prior to laser procedures
45362887|NCT04849455|Drug|0.2% ropivacaine local anesthetic continuous erector spinae plane block|Treatment- continuous erector spinae block catheter followed by an infusion of ropivacaine 0.2% at 10ml automatic set bolus per 60 minute with 2ml/hr continuous infusion (12mls/hr total per catheter)
45480363|NCT05527028|Other|Occupational Therapy Services|Investigators will complete an initial assessment based on a thorough chart review and observation of the participants activities of daily living during week one. The resident will receive approximately 30 minutes a day of direct student OT service delivery. Additional intervention may be delivered through an indirect, collaborative, or consultative service delivery model. Students will use a workload measurement tool to track the amount of time and types of intervention provided to these residents. The intervention will be delivered by two pairs of OT students under the direction of a registered OT. Student OTs will have access to Point Click Care and will document daily and will be required to document indirect and non-direct time for each resident.
45480364|NCT01332162|Device|Biventricular pacing|All patients will be pacing during two years
45480365|NCT01332162|Device|No Pacing|No Pacing during the first year. In the second year all patients will be pacing
45480366|NCT02484196|Behavioral|Questionnaires|Questionnaires
45480367|NCT03788369|Procedure|Hybrid Coronary Revascularization|Hybrid coronary revascularization (HCR) combines minimally invasive surgical coronary artery bypass grafting of the left anterior descending artery with percutaneous coronary intervention (PCI) of non-left anterior descending vessels.
45362888|NCT04849455|Drug|0.2% ropivacaine local anesthetic superficially taped continuous erector spinae plane block|Placebo- Superficially placed (taped to the surface) erector spinae block catheter with a ropivacaine 0.2% infusion at 0.1ml /hr
45480368|NCT03435055|Drug|Nitrous Oxide Gas for Inhalation|Each volunteer will participate in one scanning visit in which simultaneous functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) data will be collected wherein they receive placebo (20 minutes) followed by inhaled nitrous oxide at subanesthetic levels (35% inhaled concentration) over 40 minutes.
45480369|NCT05693246|Drug|Glycopyrrolate|At 10 minutes after endotracheal intubation, the Glycopyrrolate group was injected intravenously with 0.004mg/kg glycopyrrolate.
45480370|NCT05693246|Other|normal saline|At 10 minutes after endotracheal intubation, the Control group was intravenously injected with equal dose of normal saline.
45689301|NCT00396292|Drug|VIT-45|A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
45689302|NCT00397150|Behavioral|Peer-support for exclusive breastfeeding|Counselling to support exclusive breastfeeding up to the age of 6 months of age by the use of peer-counsellors in the local community
45689303|NCT01437267|Biological|Vi-CRM197 vaccine|
45689304|NCT01437267|Biological|Pneumococcal conjugate vaccine|
45689305|NCT01437267|Biological|Vi Polysaccharide (PS) vaccine|
45362889|NCT04849455|Drug|Spinal Morphine|200-300 mcg of spinal morphine
45480371|NCT01337622|Procedure|No check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on clinical examination of the abdomen and gastric aspirates containing blood or significant vomiting.
45480372|NCT01337622|Procedure|Routine check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on current practice of clinical examination of the abdomen and checking residual before every feed. Volume and color of gastric residual will be considered according to the current guideline.
45480373|NCT02489656|Device|Double Loop Ureteral stent endoscopic placement.|A JJ stent placement may be indicated at the end of the endourological removal of kidney stones to ensure urine drainage and cicatrisation
45689306|NCT00397462|Device|calf muscle pump stimulation|Micromechanical stimulation of the postural reflex arc to activate the soleus muscle to enhance lower limb fluid return to the heart
45752149|NCT01792505|Biological|Dendritic Cell Vaccine in combination with Imiquimod cream|After a successful complete resection of malignant glioma, patients will receive a total of 3 vaccines, each are 2 weeks apart. Imiquimod cream will be applied prior to and after each vaccination.
45752150|NCT01794221|Procedure|stitches and skin adhesive|In addition to stitches, 2-octyl cyanoacrylate skin adhesive will be applied to the circumcision wound.
45845289|NCT02355210|Dietary Supplement|Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide|packet containing 10^9 cells B animalis subsp. lactis BB-12 and 5 g galactooligosaccharide
45845290|NCT02355210|Dietary Supplement|galactooligosaccharide|5 g galactooligosaccharide
45845291|NCT02355210|Dietary Supplement|Placebo|lactose powder, 5 grams
45845292|NCT02356692|Device|enfilcon A|Test lens
46049809|NCT00931944|Drug|KNS-760704|150 mg Q12H KNS-760704 given orally (300 mg total daily dose)
46049810|NCT02614378|Procedure|air insufflation|modulated air insufflation of the ear canal
46049811|NCT02614378|Procedure|placebo|no air will be introduced in the ear canal
45480374|NCT03788447|Other|High end-tidal CO2|maintaining of end-tidal CO2 with the range of 40-45 mmHg
45480375|NCT03788447|Other|Low CO2 group|maintaining of end-tidal CO2 with the range of 30-35 mmHg
45480376|NCT03991182|Other|SMAGs trained on ECD curriculum|50 volunteers (primarily SMAGs- Safe Motherhood Action Group members) associated with the health facility will be trained using a training -of-trainers approach on the e ECD (early childhood development) curriculum
45480377|NCT03991182|Other|Head women trained on ECD curriculum|Each of the 50 trained SMAGs will train 10 head women on the ECD curriculum
45480378|NCT03991182|Behavioral|Head women led parent groups|Every two weeks 500 trained head women lead parent group meetings on childhood development and nutrition to caregiver-child dyads
45752151|NCT01794221|Procedure|stitches only|standard of care
45845293|NCT02356692|Device|senofilcon A|Control lens
45845294|NCT02357394|Device|Arabin Pessary|Arabin pessary is a ring manufactured from medical grade silicone. It comes in 13 different sizes. Participants will be fitted to the appropriate size by the study team.
46049812|NCT02614456|Drug|interferon-gamma and nivolumab|
46049813|NCT04130230|Drug|Neostigmine|Neostigmine continuous infusion plus standard therapy for sepsis and septic shock.
46049814|NCT04130230|Drug|Standard therapy|Standard therapy for sepsis and septic shock
45689307|NCT01456221|Dietary Supplement|Omega3 and an hypocaloric diet.|Thirty caps with the supplement will be provided every mo during three mo. Supplement will be administered as gel caps containing 1.1 g of DHA and EPA (®MaxEpa, Merck Laboratory) Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
45845295|NCT02357706|Device|APAP A (ResMed AirSense AutoSet)|Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
45845296|NCT02357706|Device|APAP B (Apex iCH Auto)|Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
45845297|NCT02359110|Drug|Gabapentin|Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
45845298|NCT02359110|Other|Placebo|Patient will receive placebo tab less than 1 hour before surgery
46049815|NCT00929994|Behavioral|Cardiac Rehabilitation|Individualized cardiac rehabilitation for 6 months, including health education sessions, as well as supervised exercise classes which include aerobic and resistance training.
46049816|NCT02614300|Other|Pulmonary Rehabilitation and Chest Physiotherapy|The patient will come 3 times per week during 12 weeks Each session 1h15min
45480379|NCT03991182|Other|Usual care of children 0-5 months|The traditional care and education of caregivers/parents for children 0-5 months
45480380|NCT03316066|Procedure|stellate ganglion block with ropivacaine 0.2% 5 mL|Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
45845299|NCT02360124|Drug|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
45845300|NCT02360124|Other|Water as placebo|topical application of water as a placebo in the control arm
45845301|NCT02360124|Other|saturated potassium iodide solution|topical application of SDF solution followed by KI solution onto tooth root surfaces
46049817|NCT02614300|Other|Pulmonary Rehabilitation|The patient will come 3 times per week during 12 weeks Each session 45min
46049818|NCT02614300|Other|Chest Physiotherapy|The patient will come 3 times per week during 12 weeks Each session 30min
45752152|NCT00365053|Drug|belinostat|Given IV
45752153|NCT00365053|Other|laboratory biomarker analysis|Correlative studies
45845302|NCT02364570|Other|Glucose (100g)|Ingestion of glucose (100g)
45845303|NCT02364570|Other|Glucose (75g)|Ingestion of glucose (75g)
45845304|NCT02364570|Other|Whole Eggs|Ingestion of 1.5 whole eggs
45845305|NCT02364570|Other|Egg Whites|Ingestion of 7 egg whites
45689308|NCT01456221|Dietary Supplement|Sunflower oil with an hypocaloric diet.|Thirty caps with the placebo will be provided every mo during three mo. Placebo will be administered as gel caps containing 1g of sunflower oil, which is omega-3 free, and is not expected to produce anti-inflammatory or insulin sensitivity effects. Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
45845306|NCT02364570|Other|Egg Yolks|Ingestion of 2 egg yolks
45845307|NCT02367066|Drug|AR-C165395XX|Oral dose of AR-C165395XX (tablets)
46049819|NCT05148702|Drug|Antibiotic - standard duration|Clinician decided antibiotic and duration of treatment
45689309|NCT01794052|Other|Evidence based, DSS enabled, health care delivery model|"The study focus on preliminary work before a definitive randomised controlled trial. In this phase, we are developing an intervention for the evidence based management of hypertension and diabetes at primary care setting in India.~The components of the interventions that we are developing are:~A structured training of the health care staff for identifying people at risk of developing diabetes or hypertension~Treating patients as per a standard clinical guidelines~Giving health education to patients on lifestyle changes for better self-care~Optimizing the care pathways at the health facilities to enable better delivery of the intervention and~Development and implementation of a smartphone based decision support system (DSS) with inbuilt diagnostic and treatment algorithm"
45689310|NCT01437111|Drug|MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet|One combination tablet orally once a week
45752154|NCT05309967|Other|GLUMA DESINSITIZER|GLUTARALDEHYDE
45752155|NCT05309967|Other|PLACEBO|DESTILLED WATER
46049820|NCT05148702|Drug|Antibiotic - fixed-extended-duration|Clinician decided antibiotic for a fixed duration of 28 days.
45845308|NCT02367066|Other|Placebo|Oral dose of placebo for AR-C165395XX (tablets)
45845309|NCT02369172|Drug|Bupropion|
45845310|NCT02369172|Drug|ASP2151|
45845311|NCT02369796|Drug|TAK-448|TAK-448 solution for subcutaneous injection
46049821|NCT02616796|Behavioral|Social gaze training|Appropriate social gaze behavior will be shaped using the principles of Applied Behavior Analysis.
45845312|NCT02370810|Behavioral|CBT-based internet-intervention for tinnitus|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
45845313|NCT02371668|Biological|CR6261|50 mg/kg administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
45845314|NCT02371668|Biological|Placebo|Administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
45845315|NCT02372682|Device|Shear wave sonoelastography|Sonoelastography is to be performed on the liver.
45845316|NCT02373852|Device|Saphenous vein graft (SVG) stenting|Opening and stenting of blocked SVG with the use of the WIRION embolic protection filter
45845317|NCT02374164|Drug|Febuxostat XR|Febuxostat XR capsules
45845318|NCT02374398|Drug|Tranexamic Acid|see arm/group descriptions
45845319|NCT02374398|Device|Aquamantys System|see arm/group descriptions
46049822|NCT05058768|Diagnostic Test|The lungs causes and extrapulmonary factors|Acute lung injury due to internal and external pulmonary causes can be used as intervention items in this study, and intervention items can be excluded according to inclusion criteria and exclusion criteria.
46049823|NCT02616874|Drug|MVA.HIVconsv vaccine|Dose: 2x10e8 pfu, Interval: weeks 0 and 9.
46049824|NCT02616874|Drug|Romidepsin|Dose: 5mg/m2 over 4hours, Interval: weeks 3, 4 and 5
46049825|NCT04263636|Procedure|Phacoemulsification with bilateral trifocal diffractive IOLs|Uneventful bilateral pseudophakic presbyopic correction with trifocal diffractive IOLs
46049826|NCT02616718|Radiation|Repeated computed tomography scan of abdomen|Repeated computed tomography scan of abdomen within two weeks prior to surgery or 28-32 weeks after initial scan
46049827|NCT01090310|Drug|AIN457|AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake
46049828|NCT01090310|Drug|Placebo|Matching placebo to AIN457
45362890|NCT02545010|Drug|Paclitaxel|"All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices.~Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. Post treatment assessments will be conducted starting Day 43.~Patients will then continue chemotherapy off trial protocol with weekly paclitaxel without concurrent LDWART starting Day 50 till disease progression, intolerable toxicity, patient refusal or deemed inappropriate to continue treatment by treating physician."
45845320|NCT02374398|Other|Control|Standard Electro-cautery and Saline
46049829|NCT02616952|Dietary Supplement|Chinese herbal therapy|Participants take a Chinese herbal decoction, Yiqi Suoquan Tang, 200ml orally twice a day for 12 weeks. The Yiqi Suoquan Tang are composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g. All the decoctions are provided by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, and are packed in opaque plastic bags with 200 ml for each one.
46049830|NCT02616952|Behavioral|Pelvic floor muscle training|In intensive exercises, participants are taught how to identify the muscles: 1) identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; 2) identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; 3) contract levator ani with a position of sitting, lying, and standing; 4) contract anal sphincter with a position of sitting, lying, and standing. Once the participants can identify the muscles, they are asked to do a set consists of 10 contractions, each lasting 5 seconds, with a 5 seconds break between contractions. Then they need to do same procedure 3 times daily as the home exercises.
45689311|NCT04767477|Other|Face-to-face rehabilitation|Aerobic training will be performed with 60% to 80% of the maximum VO2 obtained through the CPET. The exercise will be performed on the treadmill, with a total time of 40 minutes, with 5 minutes of warm-up, 30 minutes of conditioning, 5 minutes of cooling down. Resistance training will be performed for upper and lower limbs and the load used in the exercises will be 60% of the maximum repetition test (1RM), with load progression every six sessions. The exercises are performed in three series of 12 repetitions.
45362891|NCT02545010|Radiation|LDWART (Low Dose Whole Abdominal Radiation Therapy)|"LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.~LDWART will not be administered if doses of weekly paclitaxel are withheld for any reason since it functions as a chemosensitizer. LDWART will be administered together weekly paclitaxel immediately at point of recovery from toxicity and patient is deemed to be able to continue with treatment by investigator."
45362892|NCT05356065|Other|survey administration|Outcome Measures
45362893|NCT01013506|Drug|IGF-1R inhibitor OSI-906|Given orally
45362894|NCT01013506|Drug|erlotinib hydrochloride|Given orally
45689312|NCT04767477|Other|Telerehabilitation|The telerehabilitation protocol will consist of stretching the muscles of the upper and lower limbs and accessory muscles of breathing. The conditioning phase will consist of stationary walking, side running, jumping jump and stationary running, 3 times of 40 seconds with a 30-second passive rest interval between them. Resistance training will be applied to the muscles of the upper limbs and lower limbs, with specific exercises for each musculature, using elastic bands as resistance.
45689313|NCT04065555|Drug|TAK-981|Intratumoral microdose injection by the CIVO device.
45689314|NCT04065555|Biological|Cetuximab|Intratumoral microdose injection by the CIVO device.
45689315|NCT04065555|Biological|Avelumab|Intratumoral microdose injection by the CIVO device.
45362895|NCT01013506|Drug|goserelin|Given subcutaneously
45362896|NCT01013506|Drug|letrozole|Given orally
45689316|NCT04065555|Combination Product|TAK-981 + Cetuximab|Intratumoral microdose injection by the CIVO device.
45845321|NCT02377752|Biological|Olaratumab|Administered IV
45845322|NCT02377752|Drug|Doxorubicin|Administered IV
45480381|NCT03316066|Procedure|stellate ganglion block wit ropivacaine 0.2% 2 mL|Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
45480382|NCT03716635|Procedure|cryotherapy|2.5c cold saline is used as a final flush after chemomechanical preparation
45480383|NCT03716635|Procedure|normal saline|a room temperature saline is used as a final flush after mechanical preparation
45480384|NCT03315988|Other|Adoption of a vegan diet|Adoption of a vegan diet The participants of this study wil be asked to adopt a vegan diet under the supervision of a Registered Dietitian.
45480385|NCT05186298|Device|AcrySof® IQ PanOptix®|The AcrySof IQ PanOptix® (Alcon) mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL
45480386|NCT05186298|Device|Synergy®|The TECNIS Synergy™ IOLs mitigate the effects of presbyopia by providing far vision comparable to an aspheric monofocal IOL. Compared to an aspheric monofocal IOL, the lens provides significantly improved intermediate and near vision, including in low-light conditions.
45480387|NCT05186298|Procedure|Cataract Surgery|IOL implantation will be performed
45480388|NCT05695157|Device|Suture-TOOL|Suture device for fast and standardized closure of the abdominal fascia
45480389|NCT03318016|Drug|Cyclophosphamide|"ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide on day 4 as a single IV dose along with Mesna (in subjects receiving >1000mg/m2 Cy) and hydration for a maximum of 6 doses in the following dose escalation schema:~Cohort -1 (3-6 subjects, if needed): Cyclophosphamide 500 mg/m2~Cohort 1 (3-6 subjects): Cyclophosphamide 1000 mg/m2~Cohort 2 (3-6 subjects): Cyclophosphamide 2000 mg/m2~Cohort 3 (3-6 subjects): Cyclophosphamide 3000 mg/m2~Cohort 4 (3 subjects): Cyclophosphamide 4000 mg/m2"
45480390|NCT03434977|Drug|TAK-536|TAK-536 granule formulation
45480391|NCT01308515|Device|Vanguard Knee System with AS Bearing|FDA cleared Tibial bearing that stabilizes the knee with an anterior lip, and is used with FDA cleared Vanguard CR (Cruciate Retaining) Femoral Component.
45480392|NCT01308515|Device|Vanguard Knee System with PS Bearing|FDA cleared Tibial bearing that stabilizes the knee with a post that articulates with the FDA cleared Vanguard PS(Posterior Stabilizing) Femoral Component.
45689317|NCT04065555|Combination Product|TAK-981 + Avelumab|Intratumoral microdose injection by the CIVO device.
45689318|NCT00359944|Drug|AC-3933|5mg twice daily
45689319|NCT00359944|Drug|AC-3933|AC-3933, 20 mg twice daily
45689320|NCT00359944|Other|Sugar Pill|Sugar Pill twice daily
45845323|NCT02377986|Behavioral|BIT+in-home decluterring|BIT Workshop + In-home decluttering practice
45689321|NCT04388800|Other|Confront and Navigate Depression Online (CANDO)|This study adopts a blended mode of service delivery, which included both online and offline intervention. The online intervention includes 8 weekly online model, animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, reminder, online assessment, session review and online booking system. The offline intervention includes two face-to-face sessions and two telephone follow-ups.
45689322|NCT00360724|Drug|Duloxetine (Cymbalta)|duloxetine medication up to dose of 120 mg/day
45689323|NCT00398398|Drug|Capecitabine, Oxaliplatin, Cetuximab|Xelox(Capecitbine, Oxaliplatin) and Cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
45689324|NCT00398476|Drug|fluticasone propionate (FP)|200 micrograms (mcg); an aqueous suspension of microfine FP
45689325|NCT00398476|Drug|fluticasone furoate (FF)|110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
45689326|NCT01436643|Drug|Venlafaxine|Venlafaxine starting dose was 75 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 150 Mg
45845324|NCT02377986|Behavioral|In-Home Decluttering|In-home decluttering practice
45845325|NCT02377674|Device|Vascular Graft, Model COR-VG-001|The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.
45845326|NCT02378844|Device|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
45845327|NCT02378844|Device|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
45480393|NCT02489578|Other|other|retrospective cohort study
45480394|NCT01335360|Drug|Nevirapine|200mg twice daily of nevirapine
45480395|NCT02489890|Biological|Cytokine-induced Killer Cells|chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
45480396|NCT03788057|Other|ICS dose reduction|"If control of symptoms is maintained (evaluation based on clinical symptoms solely), every 3 months the dose of ICS is halved according to GINA guidelines, until the control is lost or the lowest daily dose is reached (200 mcg, calculated as budesonide equivalent).~In the case of loss of asthma control, beta-mimetic will be administered (temporarily) and return to the chronic administration of the previous, twice higher dose of ICS is restored (or further increase of treatment). In severe exacerbations, inclusion of oral steroids will be considered."
45845328|NCT02379858|Drug|Alvimopan|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
45845329|NCT02379858|Drug|Placebo|Placebo (sugar pill-will be the same size and color as the Alvimopan capsule), 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
45845330|NCT02381418|Biological|Trivalent influenza subunit vaccine Influvac|"3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1 "
45845331|NCT02382744|Device|Ultrasound Guidance|Ultrasound guidance will be used to place a saphenous nerve block
45845332|NCT02382744|Device|Ultrasound guidance + nerve stimulation|Ultrasound guidance and nerve stimulation will be used to place a saphenous nerve block
45845333|NCT02384070|Procedure|FFR|Fractional flow reserve tracings were calculated using a Volcano pressure wire intra-coronary system after ensuring proper calibration of the aortic pressure transducer and the guidewire, using 6 Fr-guide catheters. Before crossing the stenosis, baseline pressure was measured by the guide catheter and the pressure guidewire were equalized according to the manufacturer's specifications. After advancing the pressure sensor across the stenosis, coronary hyperemia was induced using intravenous adenosine (140μg/kg/min until a steady state was reached for at least 3 minutes). Fractional flow reserve was considered positive if it was less than 0.80.
46049831|NCT04133428|Drug|Sacubitril-Valsartan|"Evaluation of the Sacubitril-Valsartan treatment effectiveness.~As there are three possible doses, during the first 30 days of treatment 3 evaluations will be carried out (every 10 days) for dose titration based on safety and tolerability as well as a blood test the 30rd day of treatment.~Afterwards the patient will be evaluated after 3 and 6 months of treatment with a blood test and in the final visit (6 months) an echocardiography will be carried out and the final clinical evaluation will be made."
46049832|NCT02878070|Behavioral|Calls from a Peer Health Coach for 6 months|Weekly calls for 2 months, bi-weekly calls for 2 months, monthly calls for 2 months.
45362897|NCT00855452|Procedure|one - three cycles of cell therapy during 4-6 weeks (3-5x10^7 cells/kg will be given through IV systemically|Patients will be eligible to participate in a treatment program based on systemic administration of mismatched lymphocytes activated in vitro with rIL-2(LAK) followed by rIL-2 inoculation in vivo
45480397|NCT01332240|Procedure|Endoscopic ultrasonography|in order to stage the mediastinum
45689327|NCT01436643|Drug|Fluoxetine|Fluoxetine starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
45689328|NCT01436643|Drug|Citalopram|Citalopram starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
45689329|NCT01436643|Drug|Fingolimod|Dosage of 0.5 mg per capsule (hard gelatin capsules) was taken p.o. once daily. Fingolimod was supplied in bottles containing 35 capsules each.
45689330|NCT00399880|Behavioral|Health literacy intervention|Illustrated medication schedules, pill boxes, pharmacist counseling
45689331|NCT04316494|Drug|Hydroxychloroquine|"White, round, film-coated tablets marked 'HCQ' on one side and 200' on the other side.~Excipients:~Lactose monohydrate Maize Starch Magnesium Stearate Polyvidone Opadry OY-L-28900"
45689332|NCT04316494|Drug|Placebo|"Placebo to match Hydroxychloroquine.~Excipients:~Microcrystalline cellulose Lactose Magnesium Stearate"
45845334|NCT02384070|Drug|Aspirin|All patients received a chewable aspirin of 325 mg at least 6 hours before the procedure
46049833|NCT04133350|Behavioral|Active Patient Engagement|The APE intervention will be delivered through a patient-facing application and website called myAir, which provides patients with access to their own usage data, educational tips, and coaching.
46049834|NCT01090076|Dietary Supplement|Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)|Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d
45480398|NCT02489266|Biological|AKTi-treated TIL|On day 0, cells will be infused intravenously (IV) over 20-30 minutes (between 1 and 4 days after the last dose of fludarabine).
45480399|NCT02489266|Drug|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days.
45480400|NCT02489266|Drug|Fludarabine|Patients will receive Fludarabine 25 mg/m2/day for 5 days.
45845335|NCT02384070|Drug|Clopidogrel|All patient receiving clopidogrel, were loaded with 600 mg at least 6 hours before the procedure
45845336|NCT02384070|Drug|Bivalirudin|Dosed based on the weight at 0.75 mg/kg I.V. bolus dose followed by a 1.75 mg/kg/hr I.V. infusion for the duration of the procedure
45845337|NCT02385240|Drug|Brimonidine Topical Gel, 0.33 percent (Perrigo)|
45845338|NCT02385240|Drug|Brimonidine Topical Gel, 0.33 percent (Reference)|
45845339|NCT02385240|Drug|Placebo gel|
45845340|NCT02385318|Drug|Ingenol Mebutate (Perrigo)|
45845341|NCT02385318|Drug|Ingenol Mebutate (Reference)|
45845342|NCT02385318|Drug|Placebo gel|
45845343|NCT02387268|Device|CleanC system|Cleansing liquid and fecal matter during a standard colonoscopy procedure
45845344|NCT02387502|Device|Intubation- Macintosh laryngoscope|Difficult intubation was simulated by using rigid neck collar. Then patients were intubated according to the assigned laryngoscopes. In Macintosh group, tip of the laryngoscope blade was placed in the vallecula and epiglottis was lifted. After visualization of the vocal cord, patients were intubated.
45845345|NCT02387502|Device|Intubation- MacCoy laryngoscope|In MacCoy group, tip of the laryngoscope blade was placed in the vallecula and lever was pressed to flex the tip. After visualization of the vocal cord, patients were intubated.
45845346|NCT02387502|Device|Intubation- Airtraq laryngoscope|In Airtraq group, the laryngoscope was loaded with endotracheal tube. Airtraq laryngoscope was inserted through midline and after visualization of image of vocal cord through its eyepiece, endotracheal tube was passed.
45845347|NCT02387814|Drug|Abemaciclib|Administered Orally
45689333|NCT04309942|Other|Guided Clinical Pharmacy Consultation|These patients will have the benefit of a Guided Clinical Pharmacy Consultation
45362898|NCT00844688|Drug|sorafenib|"Patients will be treated with 400 mg oral sorafenib twice a day on a continuous basis. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~Progression of disease.~The patient is unlikely to benefit from further treatment as~Judged by the Investigator.~Intolerable toxicity of the drugs.~Withdrawal of consent for any reason."
45845348|NCT02391714|Procedure|IUD insertion|The IUD (Mirena® or ParaGard®) insertion procedure will occur in the usual manner for both arms. A bimanual exam will be performed, the speculum placed and the cervix visualized. The cervix will then by cleaned with iodine solution. If you are allergic to iodine, we will use chlorhexidine instead. A tenaculum will be placed on the cervix and a uterine sound will be used to measure cavity length. The Mirena® or ParaGard® IUD will be inserted with the specific introducer.
46049835|NCT00869050|Drug|Capecitabine|"Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
46049836|NCT00869050|Drug|Temozolomide|"Temozolomide 150-200 mg/m2/day (PO divided BID).~Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
46049837|NCT02878148|Device|Diagnostic imaging modalities for suspected renal colic|"All patients with suspected acute uncomplicated renal colic included will undergo ultrasonography in addition to unenhanced CT of pelvis and abdomen and plain X-ray of the abdomen.~Imaging examination will be performed according to current guidelines.~Ultrasonography study and colour doppler will include the kidney, ureterovesical joint and ureters. Unenhanced CT will be performed using a dedicated low-dose protocol."
45480401|NCT02489266|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
45689334|NCT04239196|Drug|tocilizumab and IV steroids combination|"Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.~Patients will receive in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week)."
45689335|NCT04239196|Other|IV steroids combination alone|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.
45689336|NCT01795378|Biological|donor natural killer cell infusion|"Donor NK cells will be generated at the GCP laboratory at Asan Institute of Life Science by a team from Stem Cell Research Center, Korea Research Institute of Bioscience and Biotechnology.~The patients will receive donor NK cell infusion (DNKI) around on days 6 and 9 (generated from the first collection), and around on days 13 and 20 (generated from the second collection).~For DNKI to be given on days 6 and 9, a 3-patient cohort each will receive escalating dose of 2x10e7/kg, 5x10e7/kg, 1x10e8/kg, and 1-4 x10e8 cells.~The dose of DNKI to be given on days 13 and 20 will be 1-4 x10e8/kg."
45689337|NCT00361972|Drug|lansoprazole|30 mg of lansoprazole twice daily for 6 weeks
45689338|NCT00361972|Drug|placebo|placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks
45689339|NCT00362440|Drug|Leptin|
45689340|NCT00362440|Drug|Pioglitazone or metformin|
45689341|NCT00362440|Drug|Placebo|
45752156|NCT03668561|Device|Caligaloc|15 days of wearing of the Caligaloc orthosis
45752157|NCT00555789|Drug|AEB071|200mg oral b.i.d.
45845349|NCT02391714|Drug|Povidone-Iodine|Povidone-Iodine 10% w/w antiseptic swab for the cervix prior to IUD insertion.
45845350|NCT02391714|Drug|Chlorhexidine|For patients with allergy to iodine - 2% w/v chlorhexidine gluconate and 70% v/v isopropyl alcohol antiseptic swab for the cervix prior to IUD insertion.
45845351|NCT02391714|Other|Oxygen|100% oxygen via nasal mask.
45845352|NCT02391714|Other|Nitrous oxide|Given in a fixed dose ratio of 50% nitrous oxide/50% oxygen via nasal mask.
45845353|NCT02392494|Drug|MK-1075|MK-1075 supplied as 10 mg or 100 mg tablets for oral administration.
46049838|NCT04133506|Drug|Aspirin 300mg|see earlier (only half of healthy volunteers receive aspirin)
46049839|NCT04872218|Drug|Abatacept|24 week treatment of IV abatacept following recommended dosages from the monograph
45845354|NCT02392806|Device|Bubble CPAP- BabiPlus, Respiralogics|Infant will be randomized to BabiPlus Bubbler at time of extubation
45362899|NCT00844688|Drug|Gemcitabine|"Patients will be treated with Gemcitabine 1000mg/m2 administered on day 1 & 8 of a 4 week cycle. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~Progression of disease. The patient is unlikely to benefit from further treatment as~Judged by the Investigator.~Intolerable toxicity of the drugs. Withdrawal of consent for any reason."
45362900|NCT04541680|Drug|Nintedanib 150 MG [Ofev]|Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.
45362901|NCT04541680|Other|Placebo|Placebo
45362902|NCT00855530|Drug|amibegron (SR58611A)|oral administration of 300 mg twice daily
45362903|NCT03883191|Other|L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder|Taking 1 pack of L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder three times a day before meals for three months.
45362904|NCT03883191|Other|Placebo|Taking 1 pack of placebo powder three times a day before meals for three months.
45362905|NCT00855608|Drug|adalimumab|intravitreal adalimumab injection 0.03 ml in volume (1.5mg) one dose to one eye
45362906|NCT00851864|Drug|Tinzaparin|"LMWH (tinzaparin-Innohep, Leo Pharma A/S) 175 anti-factor Xa units per kilogram of body weight sub-cutaneously once daily.~Treatment will be done for the duration of the pregnancy."
45362907|NCT00851942|Drug|Synacthen (Tetracosactrin)|IV injection of 250 micrograms of Synacthen in 1ml
45362908|NCT04190186|Device|Insertable Cardiac Monitor|Implantable device that provides accurate daily transmission of cardiac electrical data for arrhythmia detection.
45689342|NCT00401518|Device|Non-randomized ACADIA® Facet Replacement System|Non-randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
45689343|NCT00401518|Device|Randomized ACADIA® Facet Replacement System|Randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
45689344|NCT00401518|Device|Randomized Instrumented posterolateral fusion (PLF)|Randomized control treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis
45689345|NCT02109640|Drug|Targinact|Post-operative analgesia
45689346|NCT02109640|Drug|Oxycodone|Postoperative analgesia
45689347|NCT02109640|Procedure|Laparoscopic segmental colectomy|
45689348|NCT00401986|Device|Bronchial thermoplasty with the Alair System|Treatment of airways with the Alair System in PREDECESSOR STUDY (NCT00214539).
45689349|NCT00365872|Biological|Dendritic Cell (DC) Injections|"DCs (10^7 cells) were injected intratumorally three times on the second, third, and fourth Friday during the course of radiation.~One additional DC injection was given before surgery to assess DC migration~Patients were assigned to one of three cohorts:~Group 1 - DC injection # 4 given 24 hours prior to surgery Group 2 - DC injection # 4 given 48 hours prior to surgery Group 3 - DC injection # 4 given 72 hours prior to surgery"
46049840|NCT04872218|Drug|Placebo|24 week treatment of IV placebo following recommended dosages from the abatacept monograph
46049841|NCT04872218|Other|Peanut oral immunotherapy|Peanut oral immunotherapy, following a patient-driven protocol, starting 24 to 72h after the first administration of abatacept or placebo.
45362909|NCT04793373|Device|Syringe|A syringe will be used to detect the loss of resistance and needle's entry of epidural space.
45689350|NCT00365872|Procedure|Radiation therapy|Radiation was delivered 5 days per week (Monday-Friday).
46049842|NCT04133194|Drug|Mesalazine|1600 mg Asacol [mesalazine]
46049843|NCT04133194|Drug|Mesalazine|800 mg Asacol [mesalazine]
45362910|NCT02545790|Procedure|Echocardiogram|2 and 3-dimensional echocardiographic images will be obtained to estimate LV mass, ejection fraction (Simpson's biplane), fractional shortening (M mode Doppler), and pulse-wave estimated pressure gradient across the outflow obstruction.
45362911|NCT02545790|Biological|Serology|protein analysis targeting several potential protein biomarkers for cardiac remodeling and hypertrophy as well as targeting known miRNAs.
45689351|NCT00365872|Procedure|Complete Resection - Surgery for tumor removal|Tumors were surgically resected 3-6 weeks after the completion of EBRT.
45689352|NCT00366028|Behavioral|Organization Model|The organizational model contains three components: leadership support, a multidisciplinary redesign team, and management structures and processes to link the two.
45689353|NCT00366028|Behavioral|Data Feedback Model|The research team will periodically interview the facilities and provide them with reported hand hygiene data.
45689354|NCT01454739|Drug|rFVIIIFc|Administered as specified in the treatment arm.
45689355|NCT00366106|Drug|bortezomib|Patients will be treated with bortezomib at 1.3mg/m^2 on Days 1, 4, 15, and 18 every 28 days (cycle).
45689356|NCT00366106|Drug|dexamethasone|Dexamethasone tablets will be given at 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days (cycle).
45689357|NCT00366106|Drug|doxorubicin HCl liposome|Patients will receive intravenous doxorubicin HCl liposome injection given at 30 mg/m^2 on Day 4 every 28 days (cycle).
45845355|NCT02392806|Device|Bubble CPAP- B&B Bubbler, B&B Medical devices|Infant will be randomized to B&B Bubbler at time of extubation
45845356|NCT02394912|Device|vena cava filter implantation (LUMIFI with Crux VCF System)|
45845357|NCT02395692|Other|Treatment|Correlative studies
46049844|NCT04308746|Behavioral|Online Individualistic Prime (statement writing)|Participants write 3 statements each about (1) themselves, (2) why they are not like others, and (3) why it is beneficial to stand out from others
45845358|NCT02395692|Drug|Methoxyamine|Given PO
45845359|NCT02395692|Drug|Temozolomide|Given PO
45845360|NCT02396160|Dietary Supplement|Urox|Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs
46049845|NCT04308746|Behavioral|Online Collectivistic Prime (statement writing)|Participants think about a social group and write 3 statements each about (1) their social group, (2) why they are like others, and (3) why it is beneficial to blend in with others
46049846|NCT00698464|Drug|Pasireotide|Single subcutaneous injection of 600 µg of Pasireotide.
46049847|NCT04938050|Diagnostic Test|Ultrasound|Ultrasound evaluation, with grayscale and color Doppler imaging.
45362912|NCT00503776|Behavioral|exercise intervention|Patients undergo low weight resistance training.
45362913|NCT00503776|Drug|amifostine trihydrate|Given subcutaneously
45689358|NCT01794286|Other|Provider bulletins|
45689359|NCT01794286|Other|Trigger alerts|
45689360|NCT03858868|Behavioral|Church and park-based intervention|Multiple components involving motivational messages and concrete opportunities for physical activity at the church and the local park.
45689361|NCT03858868|Behavioral|Standard health education on physical activity|Participants will receive publicly available brochures, tip sheets, etc. about physical activity
45689362|NCT00368290|Drug|Modafinil|300mg a day for 8 weeks
45689363|NCT00368290|Drug|placebo|placebo pills for 8 weeks
45689364|NCT00368290|Behavioral|Cognitive Behavioral Therapy (CBT)|Weekly cognitive behavioral therapy sessions for a period of 8 weeks.
45689365|NCT00369226|Drug|Bortezomib (Velcade)|Infusion for a total of 3 doses
45362914|NCT00503776|Procedure|therapeutic dietary intervention|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
45362915|NCT03752697|Behavioral|metacognitive performance|Paper and pencil/computerized tests of metacognition
45689366|NCT00369226|Drug|Tacrolimus|Taken until Doctor determines it is not necessary any more
45362916|NCT00852020|Dietary Supplement|oral nutrition supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
45362917|NCT04002531|Other|General and Neurological examination|Information about your general health, neurological symptoms and current medications with be collected
45362918|NCT04002531|Other|Vital signs|Height, weight, blood pressure, heart rate, and respiratory rate and temperature will be measured.
45689367|NCT00369226|Drug|Methotrexate|Infusion for a total of 4 doses
45752158|NCT00555789|Drug|mycophenolic plus tacrolimus|720mg b.i.d. 2yrs
45845361|NCT02396160|Other|Placebo|Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment
45845362|NCT02397564|Device|Er:YAG laser, traditional and fractional settings|Half the scar will be treated with traditional ablative setting and the other half will be treated with the fractional ablative setting
45845363|NCT02397954|Drug|Zimura|Subjects will receive monthly intravitreous injections of Zimura in combination with Lucentis, Avastin or Eylea.
45845364|NCT02401464|Drug|TAK-536 Tablet|TAK-536 10 mg tablet
45845365|NCT02401464|Drug|TAK-536 Dry Syrup Formulation|TAK-536 dry syrup formulation
45845366|NCT02401464|Drug|TAK-536 Ganule Formulation|TAK-536 granule formulation
45845367|NCT02401542|Drug|Vofatamab|
45845368|NCT02401542|Drug|Docetaxel|
45845369|NCT02401542|Drug|Placebo|
45845370|NCT02408796|Drug|OTO-201|
45845371|NCT02411916|Biological|misoprostol|rectal insertion
45845372|NCT02413008|Drug|estriol|0.005% estriol vaginal gel
45845373|NCT02413008|Drug|Placebo|placebo vaginal gel
45845374|NCT02413320|Drug|Paclitaxel|
45845375|NCT02413320|Drug|Carboplatin|
45845376|NCT02413320|Drug|Doxorubicin|
45845377|NCT02413320|Drug|Cyclophosphamide|
45845378|NCT02413320|Drug|Docetaxel|
45845379|NCT05719116|Behavioral|Physical exercise|The physical exercise will be aerobic and strength training. The sessions will last app. 1 hour.
45845380|NCT05719038|Diagnostic Test|observational study|observational study
46049848|NCT00696904|Drug|ABT-333|Capsule, see arms for intervention description
46049849|NCT00696904|Drug|Placebo|Capsule, see arms for intervention description
46049850|NCT04933682|Drug|ALXN2050|Oral tablet.
46049851|NCT04933682|Drug|Fluconazole|Oral tablet.
46049852|NCT04933682|Drug|Rifampin|Oral capsule.
46049853|NCT04306718|Procedure|membrane peeling|ERM and ILM are peeled routinely during surgery
46049854|NCT04307966|Behavioral|The CIrCLE of Life Initiative|HIV and obesity prevention programme delivered directly to Grade 6 preadolescents and indirectly to their parents.
45845381|NCT05718882|Drug|Lenvatinib Oral Product Plus VIC1911|"Lenvatinib: 8mg/day (≤ 60Kg), oral. VIC-1911:Groups were divided: 100mg bid（DL1, dose level 1）; 150mg bid（DL2）; 200mg bid(DL3), oral. 50mg bid is defined as DL(-1), 250mg bid is defined as DL(+1). A Bayesian Optimal Interval design schema will be followed to establish the maximum tolerated dose (MTD) of lenvatinib plus VIC-1911 combination and RP2D of VIC-1911 in HCC patients. The study would follow the Bayesian Optimal Interval Design with level size of 2 patients. The R package BOIN is available from CRAN."
45845382|NCT05718804|Other|Whether renal injury occurred and differences in intestinal flora|Whether renal injury occurred and differences in intestinal flora
45845383|NCT05718726|Other|Questionnaire, interview or observation study|Questionnaire administered by telephone
45845384|NCT05718492|Procedure|digital subtraction angiography.|Each patient received an artery catheter procedure guided by digital subtraction angiography.
45845385|NCT05718492|Drug|FOLFOX (oxaliplatin , leucovorin , fluorouracil , and fluorouracil )|Hepatic artery infusion chemotherapy. The FOLFOX (oxaliplatin 130 mg/m2, leucovorin 200 mg/m2, fluorouracil 400 mg/m2, and fluorouracil 2,400 mg/m2) regimen was sequentially infused through the catheter every cycle (3 weeks).
45845386|NCT05718414|Device|Ultrasound via artifical intelligence|"The peripheral nerve and plan block regions (adductor canal, axillary brachial plexus, PECS, popliteal, rectus sheath, ESP, femoral, and superficial cervical plexus regions) and related anatomical landmarks are practised by 3 anesthesiology residents who were in the training program of regional anesthesia and qualified to perform ultrasound guided techniques . Then, scans of 8 block types for all 40 volunteers; when the scan success gauge on the AI software was 100% at the time the images were saved. Using this procedure, 960 ultrasound images were acquired in both raw and AI-processed forms for expert assessment ."
45845387|NCT05718336|Other|Integrated care|multi-discipline care program
45845388|NCT05718258|Drug|Venglustat (GZ402671)|"Pharmaceutical form: tablet~Route of administration: oral"
45845389|NCT05718024|Drug|Dexmedetomidine-esketamine|Dexmedetomidine-esketamine combination will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
45362919|NCT04002531|Procedure|12 lead electrocardiogram|A non-invasive test that measures the electrical activity of the heart
45845390|NCT05718024|Drug|Propofol-remifentanil|Propofol and remifentanil will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
45480402|NCT03785483|Behavioral|Motivation|8 weeks of either action planning or mindfulness in addition to a treatment as usual which is a physical activity program of 120 minutes per week.
45845391|NCT05717868|Other|Kinesiology taping|5 cm wide and 0.5 mm thick waterproof, porous and adhesive tape will be applied to the posterior neck of the participants while sitting comfortably in a neutral position. The first tape (Y-strip) is placed over the posterior cervical extensor muscles with approximately 25% tension. The top strip will be placed perpendicular to the Y strip on the mid-cervical region. The participant's cervical spine is flexed to obtain tension in the posterior structures.
45362920|NCT04002531|Procedure|Echocardiogram|A non-invasive sonogram of the heart
45480403|NCT03317938|Device|Fecobionics|Fecobionics is a new device for studying defecation
45480404|NCT01337778|Behavioral|Primary care for Daughters-in-Law|Primary care for DILs will be offered based on national and international standards and include access to critical support services for women who have experienced GBV.A comprehensive health examination for MILs will include a gynecological exam and screening for diabetes and hypertension, along with appropriate information, prescriptions, and/or referrals. We will routinely offer GBV-related resources, such as information, counseling, and referrals to all participants. Referrals will be documented using a Referral Care Form and reviewed on a routine basis to ensure that appropriate care is being provided and to detect any potential study-related risks.
45689368|NCT00369226|Procedure|blood stem cell transplantation|Allogeneic Non-myeloablative peripheral blood stem cell transplantation
45689369|NCT01416441|Drug|Aripiprazole|Aripiprazole tablets orally once daily.
45689370|NCT01793194|Other|Compression Stockings|20-30mmg Hg maternity pantyhose compression stockings
45689371|NCT04050579|Device|on-pump intracardiac echocardiography|Subjects will be patients with hypertrophic cardiomyopathy with interventricular septae less than 2.0cm who are undergoing septal myectomy. The patients will have already had a number of preoperative transthoracic echocardiographs as part of their normal hypertrophic cardiomyopathy care. Before cardiopulmonary bypass, the basal anterior septal thickness will be measured by transesophageal echocardiograph as is performed in all septal myectomy procedures. The Principal Investigator will then use the OPIE probe to measure the anterior basilar septal thickness. Myectomy will be performed and OPIE will be repeated. The post-myectomy anterior basilar septal thickness will again be measured by transesophageal echocardiography.
45689372|NCT00406276|Drug|RAD001|RAD001 will be given at a dose of 5mg/day in combination with docetaxel
45689373|NCT00406276|Drug|Docetaxel|In combination with RAD001
45752159|NCT04288895|Drug|Vortioxetine|5 - 20 mg/day flexible-dose vortioxetine, tablets, orally
45845392|NCT05717868|Other|Self-mobilization|The towel will be placed on the posterior arch of the fifth cervical vertebra and pulled horizontally across the face. The participant will be instructed to apply pressure to the towel and turn their head to the restricted side, then maintain the finishing interval for three seconds. The participant will be asked to apply extreme pressure in the bending position with towel support. The procedure should be painless and repeated 10 times.
46049855|NCT00625976|Behavioral|Graded exposure in vivo|Graded exposure in vivo according to the protocol of de Jong et al. (2005)
46049856|NCT00625976|Behavioral|Physiotherapy|Physiotherapy according to the protocol of Oerlemans, Oostendorp, de Boo and Goris (1999)
45362921|NCT04002531|Procedure|Blood draw|Blood will be drawn to evaluate general health and renal function (kidney health)
45362922|NCT04002531|Procedure|Urine collection|Urine will be collection to evaluate renal function (kidney health)
45362923|NCT04002531|Procedure|2-hour Holter Monitor|A non-invasive test that measures the electrical activity of the heart continuously over 2 hours
45362924|NCT04002531|Other|Brief Pain Inventory questionnaire|A questionnaire about daily pain
45845393|NCT05717790|Drug|Nimotuzumab|"Drug: Nimotuzumab Experimental: Nimotuzumab arm Induction chemotherapy:Nimotuzumab 200mg will be given weekly for 6 cycles, started on day 1 of induction chemotherapy.~Concurrent chemotherapy: Nimotuzumab 200mg/week in concurrent with IMRT. Adjuvant therapy: Nimotuzumab (200mg ) will be given every 3 weeks for 8 cycles.~Active Comparator: Control Nimotuzumab 200mg/week in concurrent with IMRT ."
45845394|NCT05717790|Drug|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 2 cycles
45845395|NCT05717790|Drug|Cisplatin|"Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles.~Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles."
45480405|NCT01337778|Behavioral|The Dil Mil Intervention|The Dil Mil intervention will be implemented during the second and third trimesters of the DILs' pregnancy. It consists of 2 half-day group sessions with DILs, 5 half-day group sessions with MILs, and one joint half-day session with DILs and MILs. The sessions are based on participatory learning and action principles and use stories, role-play, and discussion to enhance participants' knowledge, skills, and social support. Participants are encouraged to critically analyze their relationships and to develop and implement responses appropriate to their families and communities. The DIL-MIL joint session ends in a short celebration (based on a traditional ritual) in which MILs bless their DILs, and the MIL sessions culminate in a ceremony in which MILs' position in the family and community is recognized and celebrated. MILs draw up a family health action plan and take a pledge to reduce GBV and protect and promote their family's health.
45480406|NCT03787979|Other|Lumbopelvic stiffening technique|"Participants will stretch their hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense your back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
45480407|NCT03787979|Other|Lumbopelvic relaxing technique|"Participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax your back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
45480408|NCT03434119|Drug|Insulin glargine/Lixisenatide|Insulin glargine (100 units per milliliter [U/mL]) and lixisenatide (33 micrograms per milliliter [mcg/mL]) self administered by a subcutaneous injection using a prefilled pen. Dose was individually titrated to achieve target fasting self-monitoring of plasma glucose (SMPG) of 80 to 100 milligrams per deciliter (mg/dL) (4.4 to 5.6 millimoles per liter [mmol/L]) while avoiding hypoglycemia.
45480409|NCT03434119|Drug|Insulin glargine (HOE901)|Insulin glargine 100 U/mL self-administered by a subcutaneous injection using a prefilled pen. Dose was individually titrated to achieve target fasting SMPG of 80 to 100 mg/dL (4.4 to 5.6 mmol/L) while avoiding hypoglycemia.
45480410|NCT03434119|Drug|Background therapy|Oral Anti diabetics Drugs (OADs) administered orally according to the locally approved label.
45480411|NCT02484352|Drug|saline|different dosage of IV oxycodone was given before intubation
45480412|NCT02484352|Drug|0.05 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
45480413|NCT02484352|Drug|0.1 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
45689374|NCT01436253|Behavioral|Lifestyle Changes|Diet, increased physical activity, and weight reduction as per European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology were encouraged in addition to pharmacological measures at the discretion of the treating physician.
45689375|NCT01436253|Drug|Hypolipemics|Pharmacological measures at the discretion of the treating physician and in accordance with the respective authorized label and European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology.
45689376|NCT03854656|Other|Time-restricted eating|"Participants will be instructed to eat within a self-selected 10-hour timeframe between 6AM and 8PM every day. All food/beverages except water must be consumed within the time-interval. Staff will help participants select a time-interval that fits into their daily life and optimally fulfil the following guiding principles:~The first food item/beverage of the day should optimally be ingested at least 2 hours after usual wake-up time~The last food item/beverage of the day should optimally be ingested at least 3 hours before usual bed time~Diet is ad libitum and with no further dietary restrictions. Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority."
45689377|NCT00408070|Drug|Bevacizumab|cycle 2 (6 cycles re-evaluated and follow up)
45845396|NCT05717790|Radiation|Intensity-modulated radiotherapy|Definitive IMRT of 68-78 Gy, 30-33 fractions, 5 fractions/week, 1 fraction/day
45689378|NCT00408070|Drug|Carboplatin|cycle #1 and continuous through entire regimen; treated every 3 weeks
45689379|NCT00408070|Drug|Paclitaxel|cycle #1 and continuous through entire regimen; treated every 3 weeks
45689380|NCT00408460|Drug|imatinib mesylate|Given PO
45689381|NCT00408460|Drug|paclitaxel|Given IV
45689382|NCT02111200|Drug|Sodium Benzoate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
45845397|NCT05717712|Biological|Ad-TD-nsIL12|This is a novel adenovirus 5-based Ad-TD, which had three gene deletions (E1ACR2, E1B19K and E3gp19K) but retains the E3B gene. This new mutant oncolytic adenovirus exhibited strong anti-tumor efficacy in vivo. On the basis of Ad-TD, Ad-TD-nsIL12 is armed with human non-secretory interleukin-12 (nsIL12, deletion of the signal peptide).
45845398|NCT05717634|Diagnostic Test|Hysteroscopy|Patients with suspected endometrial pathology, will undergo hysteroscopy with endometrial biopsy or endometrial lesion excision.
45845399|NCT05717556|Procedure|Internal Jugular Vein Catheterization|Inserting a cannula into the internal jugular vein
45845400|NCT05716386|Dietary Supplement|Low salt diet|Low salt diet less than 2 gram per day
45845401|NCT05711160|Diagnostic Test|Plaster models|The impressions taken of the dental arches will be poured with hard gypsum in order to make use of the models for taking measurements. These measurements will be considered the gold standard.
45480414|NCT02484352|Drug|0.15 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
45480415|NCT02484352|Drug|0.2 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
45845402|NCT05711160|Diagnostic Test|CBCT images|All patients have been undergoing CBCT scans for both jaws
45845403|NCT05711160|Diagnostic Test|IOS images|The patient's teeth have been dried with air syringe and scanned with the Intraoral scanner
45689383|NCT02111200|Drug|Sodium Phenylbutyrate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
45689384|NCT02111746|Drug|Exparel|Participants will receive 266mg of liposomal bupivicaine (equivalent of one 1.3% 20ml vial of EXPAREL®) diluted in 60ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
45689385|NCT02111746|Drug|Bupivacaine hydrochloride|Participants will receive 125mg of bupivacaine hydrochloride (equivalent of one 0.25% 50ml or five 0.25% 10ml vials ) diluted in 30ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
45845404|NCT05707728|Device|intraoperative ultrasound|intraoperative cranial ultrasound
45845405|NCT05679258|Drug|HLX15|A single dose (8 mg/kg) of HLX15 via intravenous infusion.
46049857|NCT04308200|Other|CO-OP approach|"There are 3 stages in the CO-OP approach. Stage I, the Preparation Stage, is primarily concerned with establishing the goal. Before the first interview, the child was contacted, the family and the child were informed, and it was checked whether they met the prerequisites. At this stage, 3 targets were selected and the basic performance level was determined. Stage II, the Acquisition Stage, is essentially the plan and do stage, in which the work of using strategies to acquire skills is done. This stage originally comprised 10 sessions. At this stage, the first session enabling principles were implemented and the global strategy goal-plan-do-check was introduced. The family attended this process with observation. Parents / caregivers were encouraged to make observations to generalize strategies. Stage III, the Verificatíon stage usually consists of only one session in which control is performed; the progress made was revised as learned strategies."
45845406|NCT05679258|Drug|US-sourced DARZALEX®|A single dose (8 mg/kg) of US-sourced DARZALEX® via intravenous infusion.
45845407|NCT05679258|Drug|CN-sourced DARZALEX® -|A single dose (8 mg/kg) of CN-sourced DARZALEX® via intravenous infusion.
45845408|NCT05616858|Behavioral|Complex exercise program|Stretching exercise, aerobic exercise, strengthening and balancing exercise
45845409|NCT05602272|Procedure|General anesthesia for per-oral endoscopic myotomy|Intra-abdominal pressure measurement
45845410|NCT05589792|Drug|Placebo oral capsule|Placebo before sleep for 3 nights before the study (inclusive)
45845411|NCT05589792|Drug|Acetazolamide|Acetazolamide 250 mg 3 nights before the study at bedtime, Acetazolamide 500 mg for 2 nights before the study (inclusive) at bedtime.
45845412|NCT05587530|Behavioral|Treatment engagement and retention intervention for suicidal clients|The manualized behavioral intervention for treatment engagement and retention of suicidal clients will be based on client and staff stakeholder preferences, informed by data from qualitative participatory interviews and secondary data analysis of administrative databases (conducted in phase 1). In addition to factors identified by stakeholders, if deemed feasible and acceptable during phase 1, the intervention will include structured phone outreach, shared decision-making, and peer support.
45847713|NCT02886234|Behavioral|Health Coaching (HC)|The HC condition will consist of educational modules designed to control for the contact time and attention received in the MT condition. To match the time MT participants will spend doing mindfulness exercises at home, HC participants will be assigned a 15-minute daily activity that is aligned with the HC topics
45847714|NCT02887404|Other|Spine surgery analgesic pathway|Enhanced pain management care
45847715|NCT02887404|Other|Usual Care|Standard of pain management care
45847716|NCT02889510|Drug|liraglutide|7-week subcutaneous liraglutide once daily
45847717|NCT02889510|Drug|placebo|7-week subcutaneous placebo once daily
45362925|NCT04002531|Other|Quality of Life questionnaire|A questionnaire about the impact of disease on their activities of daily living and quality of life
45362926|NCT02545634|Dietary Supplement|L. helveticus R0052 and B. longum R0175|See arm descriptions for intervention description.
45362927|NCT02545634|Other|Placebo|
45845413|NCT05562648|Other|Manual therapy techniques|"Myofascial trigger points are determined and the physiotherapist applies a light and continuous local pressure on them with his/her finger, usually not more than 30 seconds, until the moment of muscle relaxation, and as a result, the pain is expected to decrease to 0 (zero) and he withdraws his finger. He can do 3-5 repetitions until he sees relaxation in the muscle and reduction/disappearance of the pain.~Spinal mobilization is defined as low-speed, non-trust, passive movement within or at the limit of joint range of motion. Mobilization is low-speed, non-trust, passive joint movement.~MUSCLE ENERGY TECHNIQUES The muscle energy technique is a treatment technique that includes alternating periods of resistant muscle contractions and active-assist stretching, mostly used by osteopaths, physiotherapists, and chiropractors."
45845414|NCT05562648|Other|Electrophysical agents|"TENS TENS is a low-frequency electrical current applied to the stimulation of sensory nerves, used for the inhibition of pain sensation. Pain inhibition of TENS is based on 3 basic mechanisms. These; gate control mechanism (segmental inhibition), release of endogenous opioids and reduction of excitability with repetitive stimulation (inhibition from pattern).~Ultrasound is an effective electrotherapy modality with a deep heating feature. In addition, it has been suggested that the analgesic effect of ultrasound occurs with the stimulation of sensory afferents and the activation of the gate control mechanism in the posterior horn of the spinal cord."
45845415|NCT05543694|Drug|Bupivacaine Hydrochloride|Subjects will receive a dose of bupivacaine as described in the arm section of this trial
45845416|NCT05542602|Behavioral|Social intervention|The social intervention consists of four 90-minute sessions per week delivered over eight weeks by paraprofessional staff as part of the children's existing after-school program. The sessions follow a schedule and include social skills groups, social recreational games, and a reinforcement system to teach, practice, and reinforce targeted social knowledge and social skills. The sessions are manualized and include a specific instructional sequence and treatment (lesson) plan for the paraprofessional staff to implement. The children also earn points for use of the targeted skills (frequency of use) and each can earn a home or site-based reinforcer for reaching her/his targeted number of points each session. Each group is facilitated by two paraprofessionals, and includes 12-15 children including two with hfASD (the remaining will be typically-developing peers).
45362928|NCT00852098|Procedure|Lap Nissen fundoplication with division of short gastric vessels|Dividing short gastric vessels
45362929|NCT00852098|Procedure|Laparoscopic Nissen fundoplication without division of short gastric vessels|non-dividing short gastric vessels
45362930|NCT05356689|Other|mechanical traction|Group A: This group will get 3-dimensional lumbar traction on multi-dimensional traction bed spine MT. Group B: This group will get 2-dimensional lumbar traction on 2-dimensional traction bed. Common Treatment: Hot pack (for 10 minutes), and US 1mhz for 7 minutes, Mackenzie exercises and cold pack will applied for 15 minutes after traction.
45362931|NCT05260671|Drug|Penpulimab combined with cetuximab|PD-1 antibody combined with EGFR inhibitors, biweekly
45689386|NCT02111746|Drug|Patient Controlled Analgesia (PCA)|Patients will have access to the standard Patient Controlled Analgesia (PCA) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10 minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs. Patients will receive PCA until the third postoperative day
45689387|NCT02111980|Device|RF Assure Scanning|CIED and temporary pacemaker patients will be scanned with RF surgical sponge detection wand and mat as well as with and without the RF sponge. The scanning will only be conducted on the device scheduled for removal. Patients will have device interrogated before and after scanning (for CIEDs) to determine if there have been any clinically significant changes in programming or settings due to scanning with RF technology. Vitals will be monitored and recorded before, during, and after scanning.
45689388|NCT01793272|Other|effect of pentoxifylline on ICSI outcome|semen processing with pentoxifylline prior to ICSI
45689389|NCT00369928|Drug|PG-760564|100 mg BID, of oral PG-760564
45845417|NCT05537142|Drug|BV100|Rifabutin for Infusion
45845418|NCT05519748|Behavioral|Online psychoeducational program|The intervention group will receive an online psychoeducational program for 8 weeks. The psychoeducation package consists of 16 different sets of reading materials and post-session writing/reflection exercises, which will be delivered to the participants twice a week.
45362932|NCT00855686|Drug|Memantine|20mg once daily oral dose
45362933|NCT00855686|Drug|Placebo|Daily oral dose
45362934|NCT04041908|Other|Experimental Product|2 sachets per day
45362935|NCT04001283|Drug|Sodium Nitrite|Intravenous drug infusion
45362936|NCT04001283|Drug|0.9% Sodium-chloride|Matched placebo
45362937|NCT03523377|Other|prolonged overnight fasting|Three phone calls using motivational interviewing, support via SMS text.
45362938|NCT03523377|Other|usual care|Eat a heart-healthy diet and exercise for at least 30 minutes five days a week
45362939|NCT02546414|Other|Platelet count/spleen diameter ratio|Platelet count were evaluated by complete blood count, and ultrasound was used to measure the longest diameter of the spleen.The platelet count/spleen diameter ratio was calculated
45362940|NCT00991965|Device|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
45362941|NCT00844922|Drug|SCH 900636|"Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the usual treatment for psychotic major depression."
45689390|NCT00369928|Drug|Placebo dose|placebo, BID, oral for 12 weeks
45845419|NCT05495568|Biological|CT-P17|CT-P17 40mg will be subcutaneous administered
45845420|NCT05495568|Biological|EU-approved Humira|subcutaneous administration
45689391|NCT00369928|Drug|PG-760564|25 mg BID, of oral PG-760564
45362942|NCT00844922|Drug|Placebo|Placebo
45362943|NCT04534335|Device|SNOO Smart Sleep from Happiest Baby, Inc|Data related to the use of the SNOO itself (collected electronically) such as the amount of movement provided by the SNOO, etc., will be examined with the hemodynamic data obtained during the use of the SNOO. Clinical care data as it relates to the child will also be evaluated as it pertains to the use of the SNOO (this information will focus on the amount and frequency of narcotics administered to the infant). feasibility of use is the device intervention.
45362944|NCT00619112|Drug|temozolomide|single arm study
45362945|NCT03500757|Device|HoloLens|use the HoloLens to evaluate new 3D holographic guidance and navigation for percutaneous ablation of solid tumors
45362946|NCT03457701|Drug|Daprodustat|Daprodustat will be available as 1 milligram (mg), 2 mg and 4 mg tablets strengths. One tablet to be taken daily without regard for food.
45480416|NCT05186220|Procedure|Cardioneuroablation|After 3D mapping of the surface of the left and right atrium and the superior vena cava (Ensite Navx, Carto), localization of ganglion plexus (GP) will be performed either anatomically and/or by means of high frequency stimulation (HFS). The anterior and superior right sided GP will always be ablated per protocol. Other GP will be ablated according to interventional electrophysiologist judgement. The endpoint of the ablation procedure will be 1) absence of a vagal response after HFS from the right jugular vein and 2) an increase in at least 10 bpm as compared to baseline.
45362947|NCT03457701|Drug|rhEPO|rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.
45362948|NCT03457701|Drug|Ferrous sulfate containing the stable iron isotope (57Fe)|57Fe will be available in oral solution. An oral solution will be administered containing 10 mg of 57Fe as ferrous sulfate.
45480417|NCT05186220|Device|Permanent dual chamber pacemaker implantation|Under local anesthesia and using a subclavian or cephalic vein approach a dual chamber pacemaker implantation with a lead in the right atrium and a lead in the right ventricle will be performed. The device will be programmed in a AAI-DDDR mode to avoid unnecessary ventricular pacing.
45362949|NCT03457701|Drug|Ferrous sulfate containing the stable iron isotope (58Fe)|58Fe will be available in oral solution. An oral solution will be administered containing 3 mg of 58Fe as ferrous sulfate with 7 mg of 56Fe as ferrous sulfate (natural abundance Fe).
45480418|NCT05693441|Other|Active berry product|Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.
45480419|NCT05693441|Other|Reference berry-like product|Subjects should consume a reference product (isocaloric to active product, containing berry aromas and colouring but no actual berry compounds) daily during the 12 week intervention period.
45480420|NCT02484274|Biological|Blood samples|1 blood sample of 9 ml. 3-day food diary , according to the European Food Safety Authority methodology
45480421|NCT02489188|Procedure|arthroplasty|patients, who are scheduled for arthroplasty, will be measured before and on average 6 months after surgery
45480422|NCT02489188|Other|manual therapy|patients, who are scheduled for manual therapy, will be measured before, immediately and on average 1 week after treatment
45480423|NCT02489188|Procedure|lumbar spinal stenosis decompression|patients, who are scheduled for lumbar spinal stenosis decompression, will be measured before and on average 6 months after surgery
45689392|NCT03650920|Procedure|Liver Transplantation|A HCV negative or previously successfully treated recipient with a HCV positive liver graft
45689393|NCT00409240|Other|MEDIC|Multidisciplinary Education and Diabetes Intervention for Cardiac risk reduction (MEDIC; a pharmacist-led behavioral and pharmacologic intervention in groups.
46049858|NCT04308200|Other|NDT|All participations received NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist. The NDT protocol is improving muscular tone and movement patterns. Although the treatment activities varied for each CP participant, the overall goals (improved smoothness and efficiency of movement), which included improved trunk, hip, knee and ankle control, were the same for all CP participants. All sessions incorporated handling techniques that aimed to alter muscle tone during movement and to facilitate anti-gravity, weight-shifting and postural reactions.
45480424|NCT01308593|Device|Juvederm XC|Filler
45845421|NCT05493774|Other|Multi-person virtual reality simulation scenario training|Using multi-person virtual reality simulation scenario training to evaluate the learning effectiveness of nursing care for emergency burn and scald patients.
45845422|NCT05493774|Other|Multi-person high-fidelity simulation scenario training|Using multi-person high-fidelity simulation scenario training to evaluate the learning effectiveness of nursing care for emergency burn and scald patients.
45845423|NCT05488548|Drug|EP31670|EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.
45845424|NCT05482386|Other|Statin discontinuation|Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
46049859|NCT04927598|Device|plasmapheresis|patients of Gullian Barrie syndrome undergo plasmapharesis
45362950|NCT00845156|Dietary Supplement|Alpha Lipoic Acid|Two 400 mg tablets of Alpha Lipic Acid are taken 3 times daily
45480425|NCT01308593|Drug|Botox|26 units dosed one time
45480426|NCT03716557|Device|Spinal Cord Stimulation 4000Hz|Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
45480427|NCT03716557|Device|Spinal Cord Stimulation 10000Hz|Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
45480428|NCT03716557|Device|Spinal Cord Stimulation 40Hz|Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
45689394|NCT02110108|Device|Revlite Laser System|Revlite Laser System for the Treatment of Facial Solar Lentigines
45689395|NCT05287750|Diagnostic Test|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
45689396|NCT05287438|Diagnostic Test|Next-Generation DNA Sequencing|NGS is a technique of microbiological sequencing, using 16s ribosomal RNA molecular identification has been implemented to detect bacteria and fungi present in the sample
46049860|NCT04307108|Device|Magic Glass|MAGIC-GLASS is a VR-based home system for stroke rehabilitation, developed by Ulster University (UK) in collaboration with Tech4Care srl (Italy) and miThings AB (Sweden) in the context of the EU-funded Project Magic (grant agreement No 687228). It includes a number of mini-games grounded on rehabilitation paradigms such as mirror therapy [29] and can adapt to the capability of a person. In addition, the games will include an automatic coaching system for giving feedback both on rehabilitation results (e.g. achievement of exercise goals) and performance (during the exercise itself, the system will give real time advice on the execution of the exercise).
45362951|NCT04001985|Other|No clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function the NG tube will be removed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger.
45362952|NCT04001985|Other|Clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function, a 4 hour clamp trial will be performed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger. The NG tube will be taken off of suction and clamped. The NG tube is then reconnected to suction at the end of the four hour clamp trial and removed if less 125 mL drains or kept in place if greater than 125 mL drains. The same initial criteria are used again to determine if a clamp trial will be performed after 24 hours.
45362953|NCT00856154|Biological|Peptides on autologous Dendritic Cells|"10 Peptides Pulsed onto 10e7 autologous macrophage-derived maturated dendritic cells administered s.c. week 0, 2, 4, 8.~Gag150 RLLNAWVKV~Gag433 FLGKIWPV~Env 67 NIWATHACV~Pol606 KLGKAGYVV~Vpu66 ALVEMGHHV~Vif101 GLADQLIHL~Vif23 SLVKHHMYV~Gag298 KRWIILGLNKIVRMY~gp41 VWGIKQLQARVLAVERYLKD~Padre AKXVAAWTLKAAA"
45362954|NCT00852332|Dietary Supplement|Curcumin|
45362955|NCT00852332|Drug|Taxotere|
45689397|NCT05287438|Diagnostic Test|Standard Culture|Standard of care culture and sensitivity
45362956|NCT00992043|Dietary Supplement|creatine|
45689398|NCT00410488|Drug|Palonosetron - Single Dose|0.25 mg by vein for 1 dose (day 0).
45362957|NCT00992043|Other|Exercise training|
45362958|NCT00845234|Behavioral|Intervention|Intervention consisted of a brief, educational CBT intervention and included the following domain areas: ICD knowledge and post-discharge care, understanding shock, stress management, family and relationships, device recall, and survivorship. The intervention was provided at baseline (0 weeks). Intervention was led by investigator and lasted 15 minutes in duration.
45362959|NCT00852410|Drug|1% lidocaine with 1:100,000 adrenaline|high dose
45480429|NCT01308671|Drug|Varenicline|Varenicline will be administrated 0.5 mg Qd for 3 days,0.5 mg Bid for 4 days, and then 1 mg Bid for 14 days
45480430|NCT01308671|Behavioral|Counseling and psychosocial support|Blank group will receive the same counseling and psychosocial support as varenicline group
45480431|NCT02484118|Procedure|Hemodialysis blood flow|The impact of blood flow rates of 320 ml/m and 380 ml/m will be compared to determine any impact on hemodialysis urea clearance
45480432|NCT00378378|Drug|Mometasone Furoate Nasal Spray (MFNS)|100 mcg nasal spray
45480433|NCT00378378|Drug|Placebo nasal spray|One spray of placebo nasal spray in each nostril once daily for 4 months.
45689399|NCT00410488|Drug|Palonosetron - Triple Dose|0.25 mg by vein for 3 doses (days 0, 2, 4).
45689400|NCT00410488|Drug|Adriamycin|75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0.
45480434|NCT03720457|Drug|Human CD19 targeted T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
45480435|NCT01306955|Drug|methylorednisolone|intravenous infusion of 1000 mg methylprednisolone in 100cc D/w 5% on 3 consecutive days at beginning of treatment
45689401|NCT00410488|Drug|Ifosfamide chemotherapy (AI)|Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2). Cycle is 3 weeks, up to 6 cycles.
45689402|NCT00410488|Drug|Zinecard|750 mg/m2 as an IV bolus.
45689403|NCT00410488|Drug|Mesna|500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hour for days 0, 1, 2, and 3 (infusion completing on day 4).
45752160|NCT01792739|Drug|Lactobacillus casei variety rhamnosus granules|"Lactobacillus casei variety rhamnosus granules~: 3 gram per day (1g-1g-1g, 3 times per day)"
45845425|NCT05481762|Device|Aided read with contextflow DETECT Lung CT|Radiologists read chest CT scabs with and without the aid of contextflow DETECT Lung CT as a second reader
45689404|NCT00410488|Drug|Vincristine|"2 mg IV by rapid administration on day 0 (for patients with small cell histology).~For patients with certain types of sarcoma, vincristine will be given through the catheter by rapid infusion on Day 0 only."
45362960|NCT00852410|Drug|1% lidocaine with 1:200,000 adrenaline|1% lidocaine with 1:200,000 adrenaline
45689405|NCT00410488|Drug|Dexamethasone|IV piggyback (IVPB) daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy.
45362961|NCT00992121|Drug|Bevacizumab|Bevacizumab - 3 infusions of 10mg/kg administered at 2 week intervals - Part I
45362962|NCT00992121|Drug|Pazopanib 2 week|"Pazopanib for first 2 weeks of each 3-week cycles as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
45362963|NCT00992121|Drug|Pazopanib 3 week|"Pazopanib throughout each 3-week cycle as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
45362964|NCT00852488|Procedure|Placement of transthoracic catheter|Placement of transthoracic catheter into the inferior vena cava
45362965|NCT04002609|Other|oxygen|oxygen supplementation during brronchoscopy
45689406|NCT01794598|Behavioral|Receiving educational material of depression care|The educational material provides patients about depression management
45689407|NCT00412516|Biological|Live attenuated SA 14-14-2 vaccine|Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)
45689408|NCT01793350|Drug|BC-DN-01 topically applied cream|Phase 1 - week 1 - total daily dose 160mg benfotiamine as 8g BC-DN-01 Phase 1 - week 2 - total daily dose 320mg benfotiamine as 16g BC-DN-01 Phase 2 - for 12 weeks - total daily dose 320mg benfotiamine as 16g BC-DN-01
45689409|NCT03303898|Procedure|Blood sampling|sampling of 7 blood tubes
45689410|NCT01794676|Genetic|Blood draw|Blood draw
45689411|NCT05286970|Drug|AK115|Abdominal subcutaneous injection
45689412|NCT05286970|Drug|Placebo|Abdominal subcutaneous injection
45689413|NCT03127774|Drug|Cisplatin|"Route of administration: Intraperitoneal for tumor treatment. Dose of 250 mg/m2~Drug 1 of the hyperthermic intraperitoneal chemotherapy (HIPEC)"
45689414|NCT03127774|Drug|Sodium thiosulfate|"Route of administration: Intravenous Loading dose of 7.5 gm/m2 over 20 minutes followed by 2.13 gm/m2/hr for 12 hours~Drug 2 given intravenously during hyperthermic intraperitoneal chemotherapy (HIPEC)"
45689415|NCT03127774|Procedure|Cytoreductive surgery|Standard of care: Surgical procedure used to remove tumors from patients with peritoneal tumors.
45752161|NCT01792739|Drug|Placebo|"Placebo granules~: 3 gram per day (1g-1g-1g, 3 times per day)"
45845426|NCT05476536|Behavioral|self-management skills and healthy technology APP|self-management skills and healthy technology APP
45845427|NCT05458050|Device|PU sensor|Device to assess microcirculation in sacrum area to find subjects at risk for pressure ulcer
45362966|NCT02545946|Device|vessel loop|using the vessel loop to hold the place of the surgical wound that is made during I&D
45362967|NCT02545946|Other|traditional I&D with or without packing|abscess will be drained with a traditional I&D with or without packing (as deemed appropriate by ER doctor)
45362968|NCT03131193|Other|Physician|Study primary health centers will be staffed with an additional physician
45362969|NCT03131193|Other|Mid-level provider|Study primary health centers will be staffed with an additional mid-level provider
45480436|NCT01306955|Other|dextrose water 5%|intravenous infusion of 100cc D/w 5% on 3 consecutive days at beginning of treatment
45845428|NCT05429424|Other|Verum acupuncture group|"The acupuncturist disinfected the skin of the selected acupoints with alcohol, then vertically penetrated the skin with disposable stainless-steel needles (size, brand, Taiwan) to the depth predetermined for each point (between 8-25 mm, depending on the location of the acupoint) and achieved a deqi response, often described as a pressure, fullness, or achiness feeling around the acupoints."
45847718|NCT02893878|Other|Vaccine safety surveillance|Extraction of routinely collected primary care data from approximately 10 volunteer English general practices by using an improved card-based ADR reporting system to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
45845429|NCT05429424|Other|Sham control group I|The needle does not penetrate the skin and retract in the handle while the acupuncturist needling into the skin. The participants easily believe their intervention owing to the sensation of needling into the skin that the device mimics. The needles were fixed with a plastic ring and micropore on the body of the participants without manipulation.
45845430|NCT05429424|Other|Sham control group II|"The acupuncturist disinfected the skin of the selected acupoints with alcohol, then vertically penetrated the skin with disposable stainless-steel needles (size, brand, Taiwan) to the depth predetermined for each point (between 8-25 mm, depending on the location of the acupoint) and achieved a deqi response, often described as a pressure, fullness, or achiness feeling around the acupoints."
45480437|NCT03315676|Drug|Oral Bonoprazan|To examine the efficacy of oral Bonoprazan in patients with NSAIDs-induced Erosions and/or Ulcers
45480438|NCT03315676|Drug|Oral Esomeprazol|To examine the efficacy of oral Esomeprazol in patients with NSAIDs-induced Erosions and/or Ulcers
45845431|NCT05367102|Behavioral|Supporting Healthy Relationships program|"The investigator will provide the following 4 activities: 1) marriage and relationship education [using a modified version of the empirically supported Loving Couples, Loving Children (LCLC); 2) pre-marital education and marriage skills; 3) marriage enhancement and marriage skills for married couples; and 4) divorce reduction and relationship skills.~All couples will be expected to participate in 24 hours of core relationship education workshops (including parenting education). Since parental financial support represents a core element of family stability, relationship education workshops will address motivation for providing financial support through employment for all couples (employed and unemployed) as well as how to manage conflicts over money. All couples will be invited to supplemental workshops (with couples from other cohorts) on topics of specialized interest, including employment services and financial literacy (i.e. budgeting, debt, etc.)"
45847719|NCT02899650|Other|exercise|acute downhill running
45689416|NCT00414700|Drug|ChondroCelect implantation|"10.000 cells/µl cell suspension for implantation (Autologous Chondrocyte Implantation). ChondroCelect consists of characterised autologous cartilage-forming cells expressing a specific marker profile.~The dose depends on the size of the lesion. Recommended dose is 0.8 to 1.0 million cells/cm²."
45689417|NCT00414700|Procedure|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
45847720|NCT02899884|Other|No Intervention|
45847721|NCT02902146|Device|Bougie|
45689418|NCT00415870|Behavioral|Printed Material|Printed Material
45689419|NCT00415870|Behavioral|Weekly Weighing|Weekly Weighing
45689420|NCT00415870|Behavioral|Cell phone will serve as a self monitoring device|Cell phone will serve as a self monitoring device
45689421|NCT00415870|Device|Text Message|Text Message
45480439|NCT03317782|Device|NoL index|The NoL/PMD-200 (Medasense Biometrics Ltd, Ramat Yishai, Israel) is a multi-parameter index (0-100) that incorporates heart rate, heart rate variability (0.15-0.4 Hz band power), plethysmograph wave amplitude, skin conductance level, number of skin conductance fluctuations (NSCF), and their time derivatives9 using a non-linear regression technique. A higher index indicates higher nociception, and an index <20 indicates adequate analgesia.
45480440|NCT01335438|Device|Cementless (Nexgen)|Cementless fixation of Nexgen CR TKR
45480441|NCT01335438|Device|Cemented (Nexgen)|Cemented fixation of Nexgen CR TKR
45480442|NCT01307189|Drug|Tiotropium|Tiotropium diskus inhalation powder, 18ug, once daily
45480443|NCT01307189|Drug|Placebo|Placebo diskus inhalation powder, once daily
45480444|NCT03720379|Device|Fluor Protector S|. All of the elements of a clinical trial and the varnish applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
45689422|NCT00415870|Behavioral|Diet Goals via Cell Phone|Diet Goals via Cell Phone
45689423|NCT00415870|Behavioral|Food Monitoring|Food Monitoring
45689424|NCT01795612|Other|physical activity|
45689425|NCT00416182|Drug|Pulmozyme (dornase alfa)|2.5 mg/2.5 mL of Pulmozyme (dornase alfa) delivered via Sinustar nasal nebulizer device
45689426|NCT00416182|Drug|Placebo|2.5 mL of placebo delivered via Sinustar nebulizer device
45845432|NCT05365308|Behavioral|Clinical supports|Quality improvement tools for iron deficiency anemia that include computer-assisted identification, an EHR registry, facilitated GI referral, an EHR tool for documentation, and physician education
45845433|NCT05358834|Dietary Supplement|Melatonin|Oral melatonin administered as a single pill.
45362970|NCT03131193|Behavioral|Conditional Cash Transfer|Study participants (who are pregnant women) will receive a cash transfer conditional upon: registering for and attending antenatal care in the study clinic, giving birth in the study clinic and completing a postnatal visit with the new infant
45362971|NCT04420299|Drug|Bemiparin|Bemiparin at therapeutic dose for 10 days
45362972|NCT04420299|Drug|Bemiparin|Bemiparin at prophylactic dose for 10 days
45480445|NCT03720379|Device|Placebo|All of the elements of a clinical trial and the placebo applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
45480446|NCT02486458|Drug|5% sodium fluoride varnish|Fluoride varnish containing 22,600 ppm F, as NaF, in a neutral base
45480447|NCT02486458|Drug|1.23% sodium fluoride acidic gel|Fluoride gel containing 12,300 ppm F (as NaF) in an acidic pH (by addition of phosphoric acid)
45480448|NCT01307345|Behavioral|contingency management for abstinence|For each breath sample submitted that reads below the cut point, participants will receive a voucher that can be exchanged for a check or gift card. Amounts earned will increase for each consecutive negative sample submitted, up to a maximum amount.
45845434|NCT05358834|Dietary Supplement|Placebo|Oral placebo administered as a single pill.
45480449|NCT03720301|Procedure|Osteopathic Manipulation Treatment|"All techniques with patient supine and physician at head of the bed:~Soft tissue massage to the posterior cervical musculature for approximately 1 minute~Muscle energy to the muscles of neck extension approximately 1 minute~Muscle energy to the Occipital Atlanto (OA) joint 1 minute~Muscle energy to the jaw. Approximately 1 minute~Occipital decompression approximately 1 minute~With time remaining complete another round of soft tissue massage.~Intraoperative techniques:~Myofascial Steering wheel Technique~Sibson's Fascia Release~Occipital decompression"
45480450|NCT03720301|Procedure|Sham|"Sham protocol:~Patients randomized into the sham arm of the study will undergo a controlled trial tested sham treatment that was shown to induce no statistical improvement in cervical pain or mobility with zero adverse effects with the subjects unable to tell the difference between sham and actual protocol treatment."
45689427|NCT00416494|Biological|bevacizumab|10 mg/kg intravenously over 30-90 minutes on day 1
45845435|NCT05336682|Procedure|Lesion Sterilization and Tissue Repair with radicular instrumentation|Coronal and accessible radicular pulp tissue are extirpated using rotary files. After proper drying, the paste is placed in the cavity and the canals.
45845436|NCT05336682|Procedure|Lesion Sterilization and Tissue Repair without radicular instrumentation|Only the coronal pulp is removed, the pulpal floor is covered with triple antibiotic paste with propylene glycol mix.
45845437|NCT05336682|Procedure|Conventional pulpectomy|Pulp tissue extirpation is done. Biomechanical preparation is done using rotary files with frequent irrigation with Chlorhexidine. The canals are dried using sterile absorbent paper points followed by obturation by the paste of ZOE.
45845438|NCT05333016|Behavioral|Multimodal exercise|Multimodal exercise programming including aerobic, resistance, balance, and flexibility exercises
45845439|NCT05317806|Drug|Metformin Extended Release Oral Tablet|daily metformin treatment vs. no treatment with metformin
45362973|NCT00619502|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
45480451|NCT02486614|Procedure|CRRT|citrate based continuous renal replacement therapy
45689428|NCT00416494|Drug|oxaliplatin|85 mg/m2 intravenously over 2 hours on day 1.
45689429|NCT00416494|Drug|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
45689430|NCT00416494|Drug|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort
45752162|NCT05289765|Other|A natural neutral Ecological Extra Virgin Olive Oil based gel|A natural neutral Ecological Extra Virgin Olive Oil based gel will be applied to the peristomal skin area at the time of peristomal skin care. Hygiene shall be performed by patients themselves following a standardised procedure recommended by Clinical Guideline.
45845440|NCT05295108|Other|Caring Connections|peer-based letter writing social connectedness intervention to improve social health outcomes
45845441|NCT05295108|Other|Attention control|informational materials provided to educate on life domains that are important to social health
45845442|NCT05273346|Behavioral|Traditional Chinese medicinal ointment|The Group1 will be treated using the Comprehensive Conservative TCM Treatment Group protocol.The special TCM ointment will be applied to the waist, and then Tuina, in order to play the comprehensive therapeutic role of Tuina and medicine, promoting blood circulation and removing stasis, warming and dispersing cold, strengthening tendons and strengthening bones, regulating qi and blood. The method of ointment is generally used with rubbing method, rubbing method, flat pushing method and kneading method. Treatment time: 7 minutes.
45847722|NCT02902146|Device|Endotracheal tube|
45362974|NCT00992199|Drug|cisplatin, Fluorouracil|cisplatin,60mg,plus 5-Fu,1.0g,intraperitoneal administration,once a week for 3 times
45362975|NCT04041986|Device|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that uses constant, low (1-2mA), direct current delivered via electrodes on the head.
45845443|NCT05273346|Behavioral|Acupotomy|It is in the special acupoints or Ashixue for cutting, stripping and other different stimulation, in order to reduce the tension of soft tissue outside the spinal canal, reduce the trend of dynamic and static spinal canal stenosis, to achieve the purpose of relieving pain and removing disease, opening points and collaterals. Acupotomy can separate the adhesive tissue, which can improve the blood circulation of the local tissue and promote the absorption of inflammation. Most acupotomy points are tenderness points or induration points, such as yaojiaji and Shenshu. Treatment time: 3 minutes.
45845444|NCT05273346|Behavioral|Cupping therapy with bamboo cup|Put the bamboo cup with the thickness of the thumb into the cup and boil it, then find the meridian and select the acupoint, Pierce the skin with a needle at the appropriate acupoint, and remove the heated bamboo cup from the cup while it is hot. When the temperature of the steam in the bamboo cup is reduced, steam will condense into water quickly, which produces strong negative pressure. Through the medicinal force, heat and the suction of the bamboo cup, the blood stasis in the affected area is smoothly discharged, so that qi and blood can be unblocked and pain can be eliminated. Treatment time: 20 minutes.
45845445|NCT05273346|Other|Oral Chinese medicine granules|Oral Chinese medicine granules use to nourish liver and kidney, improve qi and blood. Patients voluntarily take it when they think it is necessary.
45845446|NCT05273346|Behavioral|Epidural Steroid Injections (ESIs)|The Group2 will be treated using the Modern Medicine Conservative Treatment Program Group protocol.All Epidural Steroid Injections(ESIs) will be performed by a physician in an outpatient surgical setting(a sterile operating room),the patient will be in prone position,while monitored the vital signs. After aseptic treatment, 1mg non-granular betamethasone plus 5mL 0.9% sodium chloride solution will be injected. Patients will repeat ESIs up to four times within three months after randomization, depending on the response to the previous ESIs, when the degree of pain increases or the degree of relief is less than 50%.
45845447|NCT05273346|Behavioral|Interferential current therapy|The 30-50cm padded electrode will be properly fixed on the left and right sides of the lumbar spinal stenosis, and the two groups of current will be crossed at the lesion. Constant frequency output 90Hz, frequency conversion output 90-100Hz, the current intensity is generally suitable for patient tolerance, each treatment for 10min, a total of 20 minutes. Twice a week for 3 months.
45847723|NCT02902770|Drug|Lidocaine|1.5 mg/kg IV lidocaine drip (given over 10 minutes)
45362976|NCT00992277|Procedure|Ablation and skin resurfacing|
45362977|NCT00856310|Biological|REGN475 (SAR164877)|Subcutaneous administration REGN475 (SAR164877)
45362978|NCT02773485|Radiation|High Dose Radiation|The aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
45689431|NCT02845882|Drug|Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine|Prednisone 60 mg/m2 per day,d1-28, then taper over 9 days; Vincristine 1.5 mg/m2 per day (max 2 mg),d1,8, 15, 22; Daunorubicin 30 mg/m2 per dose,d5,12,19; Pegylated-asparaginase 2000 IU/m2 per dose,d16,36,57; Cyclophosphamide 1000 mg/m2 per dose, d36, 57; Cytarabine 75 mg/m2 /d, d36-42,d 57-63; 6-Mercaptopurine 60 mg/m2 per day, d36-42, 57-63; Triple it, d8,29,36,57 1,8, 15, 22
45689432|NCT02845882|Drug|6-mercaptopurine,Methotrexate|6-Mercaptopurine 25 mg/m2 per day, d1-56; Methotrexate 5g/m2 per dose, d1, 15, 29, 43; Triple it, d1, 15, 29, 43;
45689433|NCT02845882|Drug|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Doxorubicin, 6-mercaptopurine|Dexamethasone 10 mg/m2 per day, d1-7, d15-21; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 8, 15; Doxorubicin 30 mg/m2 per dose, d1, 8, 15; Pegylated-asparaginase 2,000 IU/m2 per dose, d3, 24; Cyclophosphamide 1000 mg/m2 per dose, d29; Cytarabine 75 mg/m2 /d, d29-35; 6-Mercaptopurine 60 mg/m2 per day, d29-35; Triple it, d1, 29;
45689434|NCT02845882|Drug|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Methotrexate|Dexamethasone 20mg/m2/day, d1-5; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 6; Methotrexate 5000mg/m2, d1; Cyclophosphamide 200mg/m2/dose, q12h×5, d2-4; Cytarabine 2000mg/m2/dose, ，q12h×2, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
45362979|NCT02773485|Drug|Systemic chemotherapy|This arm will receive maximum 8 cycles of gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 delivered on day 1 and 8 every 3 weekly.
45362980|NCT04042220|Drug|Glucocorticoids|Effect of glucocorticoids (which are often prescribed for cerebral edema) on clinical outcome
45362981|NCT00992355|Drug|Tobramycin 0.3% - Dexamethasone 0.1%|
45362982|NCT00992355|Drug|Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%|
45362983|NCT02545556|Procedure|HepaSphere combined with cryosurgery|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
45689435|NCT02845882|Drug|Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginase|Dexamethasone 20mg/m2/day, d1-5; Vindesine 3mg/m2（MAX 5mg）, d1, 6; Methotrexate 5000mg/m2, d1; Ifosfamide 800mg/m2/dose, q12h×5,d2-4; Daunorubicin 25mg/m2/dose, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
45689436|NCT02845882|Drug|Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase|Dexamethasone 20mg/m2/day, d1-5; Cytarabine 2000mg/m2/dose，q12h× 4, d1, 2; Etoposide 100mg/m2/dose，q12h×5, d3,4,5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d5;
45689437|NCT02845882|Drug|Methotrexate, 6-mercaptopurine|6-mercaptopurine 50 mg/m2 per day, Daily; Methotrexate 20 mg/m2 per dose, Once a week; Triple it, Once every 4 weeks for 12 times;
45362984|NCT04341909|Procedure|ERCP|endoscopic retrograde cholangiopancreatography
45362985|NCT04042922|Device|GENUS device (Active Settings)|Participants in the experimental group will use the GENUS device configured to active settings for 30 - 60 minutes.
45845448|NCT05273346|Behavioral|Thermal therapy|After the interferential current therapy, the patient will receive Bohm light for 5 minutes at the site of lumbar spinal stenosis and massage for 5 minutes at low back. Twice a week for 3 months.
45845449|NCT05273346|Other|Oral painkillers|NSAID drugs, if necessary.
45845450|NCT05248776|Drug|CPL207280|IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
46049861|NCT00927186|Drug|Teriparatide|"20 microgram (mcg) subcutaneous (SC) injection per day for 12 months. Placebo intravenous (IV) infusions were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension."
45362986|NCT04042922|Device|GENUS device (Sham Settings)|Participants in the control group will use the GENUS device configured to sham settings for 30 - 60 minutes.
45362987|NCT00852566|Drug|Imatinib|Per oral imatinib 400mg once daily (continuous medication)
45362988|NCT00852566|Drug|Dasatinib|Per oral dasatinib 100mg once daily (continuous medication)
45362989|NCT04042454|Other|milk based anti-regurgitation infant formula|Cow's milk-based infant formula containing the thickener locust bean gum containing prebiotic oligosaccharides and postbiotics
45480452|NCT01335516|Other|Glypressin (terlipressin)|Study drug (without placebo)
45480453|NCT03317704|Behavioral|Speed endurance training|Speed endurance training
45689438|NCT02616172|Genetic|Autologous Bone Marrow Infusion|The subjects autologous bone marrow cells harvested at Florida Hospital will be infused intravenously by gravity
45689439|NCT02463760|Other|Medical imaging|
45689440|NCT02460484|Biological|Autologous Cord Blood Infusion|Intravenous infusion
45689441|NCT00416572|Behavioral|Education Intervention|Sessions were led by two professionals with expertise in the topic. The sessions began a with presentation of informational material followed by guided discussion of related topics. The first session discussed what to say and not say to children about cancer and how to create a safe environment for them; the second session discussed carrying on with life after the diagnosis of breast cancer, including strategies for managing stress and anxiety and developing meaning in life; the third session talked about how to maintain closeness with a partner and ways to talk about breast cancer; the last session focused on the effects of treatment on reproductive status, and the genetic bases of breast cancer. Participants were also given related booklets and brochures to take home to read.
45689442|NCT00416572|Behavioral|Nutrition Education Intervention|The nutrition sessions were presented by a professional trained in nutritional science. Sessions included the presentation of information and guided discussion of related topics. The first session discussed information on choosing fruits, vegetables, and low-fat foods and incorporating them into a diet; the second session involved a demonstration of low-fat cooking methods; the third session provided information on the nutritional make-up of a healthy diet and how to shop for it; the last session included information on how to maintain a healthy, low-fat diet while eating out. Women were also asked to keep a four-day food diary, to focus them on their dietary intake and control over it.
46049862|NCT00927186|Drug|Zoledronic Acid|"5 milligram (mg) intravenous (IV) infusion administered once during 1 year study. Placebo subcutaneous (SC) injections were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension."
45362990|NCT04042454|Other|Milk based infant formula|Cow's milk-based infant formula containing prebiotic oligosaccharides and postbiotics
45480454|NCT01335594|Procedure|clinical, endoscopical and manometric evaluation|clinical evaluation: questionnaire endoscopical analysis manometry
45480455|NCT05694923|Drug|Empagliflozin 10 MG|non fatty liver non alcoholic patients Will receive empaglifizon sodium glucose cotransporter in minimum dose 10 mg
45480456|NCT03490981|Other|Treatment as usual (TAU)|Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
45689443|NCT00417274|Drug|Quinacrine|100 mg daily
45689444|NCT01793428|Other|Capillary lactate level|Use of capillary sample to determine lactate level upon arrival at vital emergency unit and at 2 hours
45845451|NCT05248776|Drug|Placebo|Matching placebo tablet.
45845452|NCT05228730|Biological|Tozinameran - Standard dose|Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2). A standard dose will be administered on day 0 of the study.
45847724|NCT02902770|Drug|Ketorolac Tromethamine|IV ketorolac 30mg push
46049863|NCT02877602|Device|MRI|
46049864|NCT02877602|Device|Transient Elastography|
46049865|NCT00593554|Radiation|Total Body Irradiation|8 Gy on Day -9
46049866|NCT00593554|Drug|Thiotepa|5 mg/kg/d on Day -8 to -7
45480457|NCT03490981|Behavioral|Brief Cognitive Behavioral Therapy for Chronic Pain (Brief CBT-CP)|Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6 weeks. Brief CBT-CP session outlines and patient handouts are included in the appendix. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
45480458|NCT02483806|Procedure|PEEP|After induction of anesthesia, including insertion of TEE probe, change position from supine to lateral position. Measure ABGA and cardiac indices for the baseline value. Apply each PEEP (0, 5, 10 cmH2O) serially at the random order. 6 sequences (0->5->10, 0->10->5, 5->10->0, 5->0->10, 10->5->0, 10->0->5) are equally applied to 6 patients (total 6x6=36 patients) who agreed to this study. Measure ABGA and cardiac indices after 20 min at each step of peep apply(3 times).
45480459|NCT01332396|Drug|Lapatinib|
45480460|NCT03787667|Diagnostic Test|CT or MRI based Radiomics|Radiomic features were extracted from enhanced CT or MRI of colorectal cancer.
45689445|NCT04749940|Other|Half of the harvested area will be dressed with PRF dressing, and half with Aquacel®.|Half of the harvested area will be dressed with PRF dressing, and half with Aquacel®.
45689446|NCT01976962|Radiation|Stereotactic body RT with MR-guided boost|Patients will receive radiotherapy over 5 fractions delivered once per week over 29 days, with 7.25 Gy per fraction to the whole prostate and 8 Gy per fraction to the dominant intraprostatic lesion. There will be a minimum of 120 hours and maximum of 192 hours between fractions. The entire course of treatment should be completed within no less than 27 days and no longer than 30 days.
45689447|NCT05286346|Drug|Tenofovir disoproxil 245mg|1 tablet q.d. for 48 weeks
45689448|NCT05286346|Drug|Tenofovir disoproxil fumarate 300mg|1 tablet q.d. for 48 weeks
45689449|NCT05286268|Diagnostic Test|Ischemia Modified Albumin|"Blood sampling at admission for measurement of IMA and suPAR levels and at day 10 from symptom onset (peak of symptoms) for IMA level. Samples will be collected in blood collection tubes containing K2EDTA as anticoagulant and serum separation gel tubes for SuPAR and IMA assays respectively. The samples will be centrifuged (at 3000 x g for 10 minutes) within the first 3 hours of sampling. Then, both plasma and serum samples will be placed in Eppendorf tubes and stored at -80oC. IMA levels will be determined according to the principles of the ACB assay, using the commercially available Ischemia Modified Albumin Assay Kit method (Abbexa LTD, Cambridge, UK), on the Architect c8000 automatic analytical system (Abbott, USA). SuPAR levels will be determined by the suPARnostic TurbiLatex quantitative turbidimetric immunoassay (ViroGates A/S, Denmark), also on the Architect c8000 automatic analytical system."
45689450|NCT00422032|Drug|Clofarabine|"Group A: 15 mg/m^2 IV over 1 hour daily for 5 days~Group B: 30 mg/m^2 IV over 1 hour daily for 5 days"
45689451|NCT01856140|Biological|ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection|
45689452|NCT01388920|Drug|Tesamorelin|
45689453|NCT01388920|Drug|Placebo|
45689454|NCT00422656|Drug|Perifosine|
45689455|NCT00422812|Drug|Inhaled Placebo|Inhaled Staccato Placebo
45689456|NCT00422812|Drug|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
46049867|NCT00593554|Drug|Fludarabine|40 mg/m2/d on Day -6 to -3
46049868|NCT00593554|Biological|Rabbit ATG|2.5 mg/kg/d on Day -5 to -2
46049869|NCT00593554|Drug|Palifermin|60 ug/kg (actual body weight) on Day -9 to -7 and Day 0 to +2
46049870|NCT04129918|Behavioral|light and sound modification (earplugs and eye masks)|In the experimental group，the patients used earplugs and eye masks during nighttime sleep.
45362991|NCT00852722|Other|Low fat study diet|The low fat study diet is a very low-saturated-fat, plant food based diet. It will be approximately 10% fat, 14% protein and 76% carbohydrate.The diet is is starched based and also contains fresh or frozen fruits and vegetables and there is no animal meat used, including no use of fish. This diet is very low in saturated fats and enriched in unsaturated fats. Subjects do not take dietary supplements.
46049871|NCT01101308|Drug|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Totowa) x 1 dose taken in the fasted state.
45362992|NCT00856622|Drug|i. Fixed combination of latanoprost 0.005% and timolol 0.5%|one drop in the morning and placebo in the evening
45362993|NCT00856622|Drug|timolol 0.5% ophthalmic solution|one drop in the morning and evening
45362994|NCT00856622|Drug|latanoprost 0.005% ophthalmic solution|placebo in the morning and latanoprost .005% in the evening
46049872|NCT01101308|Drug|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Wilson) x 1 dose taken in the fasted state.
46049873|NCT04133116|Drug|LY3471851|Administered SC
46049874|NCT04133116|Drug|Placebo|Administered SC
46049875|NCT02616328|Other|No intervention|No intervention administered in this study
46049876|NCT02620462|Device|Wearable sensor-based exercise training|The device provides real-time visual feedback of joint movement during balance exercise
45362995|NCT00856700|Drug|GLP-1 infusion|Participants will receive intraarterial infusion of GLP-1 (20 pmol/ml solution) for 100 min.
45362996|NCT00618956|Drug|Milnacipran hydrochloride|Milnacipran 100 to 200 mg/day tablet (administered in divided doses, twice daily [BID]), oral administration.
45689457|NCT00422812|Drug|Inhaled PCZ 7.5 mg|Inhaled Staccato Prochlorperazine 7.5 mg
45689458|NCT00422812|Drug|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
45362997|NCT00618956|Drug|Placebo|Placebo
45689459|NCT00423358|Dietary Supplement|Vitamin D|Ergocalciferol 50,000 IU loading dose then twice monthly for one year
45689460|NCT00423358|Dietary Supplement|placebo|matching placebo
45362998|NCT00852800|Drug|Albumin|1.5 g/kg IV on day 1 and 1 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
45362999|NCT00852800|Drug|Albumin|1 g/kg IV on day 1 and 0.5 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
46049877|NCT02877524|Other|Adaptive support ventilation|ASV during NIV
45363000|NCT00845546|Drug|10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets|
45689461|NCT00423436|Behavioral|Questionnaire|Questionnaires taking about 30-45 minutes to complete.
45689462|NCT00423436|Behavioral|Interactive Voice Response Telephone System|IVR Only = Phone calls twice weekly, each call lasting less than 5 minutes.
45689463|NCT00423436|Behavioral|IVR Plus Triage|"IVR system will triage, or sort, the symptom data by symptom severity, notifying health care professionals when a symptom is greater than the set threshold limit."
45689464|NCT00424840|Drug|Bortezomib 1.3 mg/m2|"Level I (every 21 day cycle, D8), 1.3 mg/m2:~Day 1: bevacizumab 15 mg/kg ,carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.3 mg/m2 Day 8 : bortezomib 1.3 mg/m2~Level II (every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.6 mg/m2 Day 8 : bortezomib 1.6 mg/m2~Level III(every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.8 mg/m2 Day 8 : bortezomib 1.8 mg/m2"
45689465|NCT00424840|Drug|Bortezomib 1.6 mg/m2|Level II (every 21 day cycle, D8), 1.6 mg/m2
45363001|NCT00852878|Behavioral|Biofeedback|Biofeedback will teach resonant frequency breathing for 6-8 sessions
45689466|NCT00424840|Drug|Bortezomib 1.8 mg/m2|Level III (every 21 day cycle, D8) 1.8 mg/m2
45689467|NCT00424840|Drug|Carboplatin AUC 6|Carboplatin AUC6
45689468|NCT00424840|Drug|Bevacizumab|Bevacizumab 15 mg/kg
45689469|NCT00424840|Drug|Taxotere|Taxotere 70 + G-CSF
45689470|NCT00425386|Drug|erlotinib hydrochloride|"Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;~100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;~150 mg/day, continuous daily"
45689471|NCT00425386|Drug|sunitinib malate|Will be administered at 50 mg daily, 4 weeks on, 2 weeks off
45847725|NCT02902770|Drug|Normal Saline Drip|Normal Saline Drip Placebo given over 10 minutes
46049878|NCT02877524|Other|Pressure support ventilation|PSV during NIV
46049879|NCT00697606|Device|Seprafilm®|Seprafilm® placed at time of primary cesarean
46049880|NCT00697606|Other|Control|no Seprafilm® used at primary cesarean
45845453|NCT05228730|Biological|Tozinameran - fractional dose|Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2). A fractional dose (15mcg) of the intervention will be administered on day 0 of the study.
45363002|NCT00852878|Behavioral|Behavioral Protocol|Behavioral protocol will teach a variety of pain management techniques such as relaxation, distraction, and coping statements over 6-8 sessions
45845454|NCT05228730|Biological|Elasomeran - standard dose|"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A single standard dose (50mcg) of the intervention will be administered on day 0 of the study."
45845455|NCT05228730|Biological|Elasomeran - fractional dose|"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A fractional dose (20mcg) of the intervention will be administered on day 0 of the study."
45363003|NCT00852956|Drug|Betahistine|"The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:~Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated)~On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio:~Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00"
45363004|NCT00853034|Dietary Supplement|FOS-IN|"prebiotic fructo-oligosaccharide enriched inulin~intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
45689472|NCT00425386|Procedure|biopsy|Paraffin block (or unstained slides) of the primary tumor and/or metastatic lesions (as available) and a plasma sample for future correlative studies will be collected. A paraffin block (or at least 10 unstained slides, each of 10 micromillimeter thickness) from the original paraffin-embedded biopsy material taken at the diagnosis will be stored at 4 degrees Celsius.
45689473|NCT05286034|Behavioral|Decision aid tailored to women with lower educational attainment,accessible via artificial intelligence-based Chatbot platforms|"Non-compliant women those that have not been screened for more than 4 years and living in the disadvantaged areas will be sent screening reminder letters to perform HPV self-sampling (HPVss) test, with access to decision aid tailored to women with lower education attainment and available via Chatbot platforms.~ChatBot will deliver information in a responsive, conversational way via text and spoken language in multiple languages through multiple mobile channels."
45689474|NCT04345978|Behavioral|Fasting hours|Normal Fasting hours before CRC surgery for 8 hours and feeding 8 hours after surgery; Prolong fasting hours before CRC surgery for 24 hours and feeding 24 hours after surgery.
45689475|NCT01164202|Drug|sunitinib malate|placebo 3cps/days 4 weeks over 6 during 1 year
45689476|NCT01164202|Drug|Placebo|placebo 3cps/days 4 weeks over 6 during 1 year
45689477|NCT01164202|Procedure|transarterial chemoembolization|Chimioembolisation
45689478|NCT01794910|Other|Pelvic floor muscle therapy|The women performed perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions
45845456|NCT05226234|Device|MRI|Late gadolinium enhancement cardiac magnetic resonance (LGE-MRI)
45752163|NCT05289765|Other|A conventional neutral gel, without Ecological Extra Virgin Olive Oil or any other olive oil-derived products|A conventional neutral gel, without Ecological Extra Virgin Olive Oil or any other olive oil-derived products will be applied to the peristomal skin area at the time of peristomal skin care. Hygiene shall be performed by patients themselves following a standardised procedure recommended by Clinical Guideline
45845457|NCT05225220|Device|Parasym Device (of Parasym Ltd, UK) using Transcutaneous Vagus Nerve Stimulation (t-VNS)|Electrode clip will be placed on the left ear.
45845458|NCT05218356|Drug|Covidir injections|administration of the investigational product CODIVIR/Placebo at a dose of 20 mg twice a day subcutaneously at visits Day0-Day6 (7 days total)
45845459|NCT05218356|Diagnostic Test|Quantitative PCR SARS-CoV-2|detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
45845460|NCT05218356|Diagnostic Test|IgM and IgG dosage|lood collection for dosage of Anti SARS-CoV-2 antibodies.
45847726|NCT02902770|Drug|Normal Saline Push|Normal Saline Push Placebo
45847727|NCT02903394|Device|mLCI Device|imaging of cervical epithelium using mLCI device
45845461|NCT05218356|Diagnostic Test|Screening Blood tests|omplete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; troponin, fibrinogen,Coagulogram (TP, aPTT); D-dimer, Pregnancy test for non-sterile women.
45845462|NCT05218356|Diagnostic Test|Electrocardiogram|valuation by the principal investigator or assistant physician with a complete physical examination
45689479|NCT05281588|Procedure|Micro-osteoperforations|All micro-osteoperforations were performed only one time in the experimental group on the same day of the installation of the upper incisors' retraction mechanics. Perforations were performed with an individualized surgical guide and a 1.6 mm diameter stainless steel surgical drill perpendicular to the alveolar bone, 3 mm deep on the buccal surface, and 5 mm, on the palate. The depth of the perforations was controlled and standardized by a cursor developed and patented by the research group. Two micro-osteoperforations were aligned vertically distally from each upper incisor. Due to the proximity of the roots in the cervical third, only the most apical perforation was performed between the two central incisors. The first perforation was performed 6 mm away from the gingival margin, and the second, 5 mm from the first, in the vertical direction.
45845463|NCT05218356|Other|NEWS-2 score|assessment of the participant by the NEWS-2 score.
45363005|NCT00853034|Dietary Supplement|AXOS|"arabinoxylan-oligosaccharides (AXOS)~intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
45845464|NCT05218356|Other|WHO score|assessment of the participant by the score of the World Health Organization.
45845465|NCT05218356|Other|Physical examination|evaluation by the principal investigator or assistant physician
45363006|NCT00716417|Drug|BIBW 2992|In each arm, BIBW 2992 dose will be escalated to determine MTD. Starting dose will be 20mg daily followed by 40 mg (with the option of an intermediary dose of 30 mg) then 50mg daily. Dose escalation will stop at 50 mg. No intra patient dose escalation.
45363007|NCT00716417|Drug|BIBW 2992|low to high dose, daily
45689480|NCT02112370|Drug|Ropivacaine with epinephrine injection|1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection for the experiment group.
45689481|NCT02112370|Other|Placebo|100cc normal saline is injected into the subcutaneous layer for the initial flap dissection for the placebo group.
45845466|NCT05218356|Other|COVID-19-Related Symptoms assessment|will be completed by the study staff member based on patient status and answers.
45845467|NCT05211960|Behavioral|Mindfulness-based meditation|AmDTx is a mindfulness-based meditation app that includes lessons, interactive exercises, and additional in-app features to practice mindfulness.
45845468|NCT05194254|Other|MRI-ET|coupled fMRI and Eye Tracking tools
45845469|NCT05146986|Device|Non surgical and Surgical|"For non-surgical group, patients will receive non-surgical treatment (analgesia and symptomatic management treatment).~For surgical group, patients will receive surgical treatment using RibFix Blu Thoracic Fixation System."
45845470|NCT05132244|Procedure|Endocrinologist-directed target blood glucose level 4-10 mmol/L using data from a continuous glucose monitor (CGM)|Standard anti-hyperglycemic treatment given as directed by an endocrinologist to maintain blood glucose level within 4-10 mmol/L based on data from a continuous glucose monitor (CGM) and standard blood work drawn prior to each cycle of chemotherapy. Participants will have access to their glucose data from the CGM.
45845471|NCT05132244|Other|Standard Care|Standard anti-hyperglycemic treatment given only if blood glucose level is greater than 15 mmol/L as measured from standard blood work drawn prior to each cycle of chemotherapy. Participants will wear a continuous glucose monitor (CGM) but will not have access to their glucose data. Participants may be referred to an endocrinologist at the discretion of their medical oncologist.
45845472|NCT05131776|Device|EUS-guided oncosil injection|All patients will receive OncoSilTM during the 4th week of the first chemotherapy cycle.
45845473|NCT05131074|Behavioral|Collabree Mobile Phone Application Medication Adherence Booster|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
45845474|NCT05131074|Behavioral|Collabree Mobile Phone Application Medication Adherence Booster (simplified version)|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
45845475|NCT05118906|Drug|BP1.4979 active drug|2 tablets 15 mg of BP1.4979 per day
45363008|NCT02592863|Drug|Pentoxifylline|Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
45363009|NCT02592863|Drug|Placebo|Patients will take placebo 3 times per day for 12 weeks
45363010|NCT00719537|Drug|Aspirin|Aspirin 81 mg once a day
45363011|NCT00719537|Drug|Placebo Oral Tablet|Placebo 1 tab Daily
45363012|NCT00719537|Drug|Progesterone|Oral Progesterone 200 mg Twice Daily
45363013|NCT02591459|Other|Using the app to assist routine anticipation|Using the app to assist routine anticipation for autistic children in Android mobile devices
45845476|NCT05118906|Drug|Placebo|2 tablets of placebo per day
45363014|NCT00853190|Drug|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose with food
45363015|NCT00853190|Drug|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose with food
45363016|NCT02591225|Drug|Dabigatranetexilate|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
46049881|NCT04306640|Other|Sagittal Cervical Posture Corrective Orthotic Device|The subjects in the traction group will receive the deneroll extension traction. The subjects will be asked to lie supine on the ground with their legs straight, upper arms by their sides and forearms gently folded across their trunk. The therapist will place the apex of the denneroll either in the mid cervical region or the lower cervical region depending on the apex of cervical curvature deformity of each subject. Initially, participants begin with three minutes of sustained denneroll extension traction and progressed to the goal of 20 min per session with one to two additional minutes per session
45363017|NCT02591225|Drug|Phenprocoumon|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
45480461|NCT03321214|Other|Gluten Sensor Dose-Finding Intervention|"Nima is a small portable sensor that detects gluten in a small amount of liquid and solid foods in about three minutes. Nima combines an electronic sensor with antibody-based detection in a disposable capsule. Nima displays a smiley face if the food or beverage is < 20 ppm or a wheat icon for > 20 ppm (low or high gluten).~Each of the 30 participants will receive a Nima along with 3 months of disposable capsules. At the baseline visit, research staff will provide participants with the Nima and capsules and review instructions on how to properly use the device with all participants."
45363018|NCT03962153|Diagnostic Test|Obstetric Ultrasonography|Obstetric Ultrasonography
45363019|NCT04085003|Procedure|Endovascular repair or Open surgery|The outcomes of different types of repair will be obtained for intact and ruptured abdominal aortic aneurysm
45363020|NCT02590679|Device|Venues-P Valve|a Novel Self-Expanding Percutaneous Stent-Valve in the Native Right Ventricular Outflow Tract
45363021|NCT05302895|Device|All-in-one health monitoring device|The staff will use the new monitoring device to carry out the health monitoring on every day during the 12-week period. After each round of health monitoring by the traditional and the new devices, the staff will need to fill in log sheets designed by HKU to document the time consumed for the entire process.
45363022|NCT04085939|Other|Online survey|Anonymous survey using the online survey tool, JotForm
45363023|NCT03951389|Other|Non-interventional|Non-interventional
45363024|NCT02590445|Device|deep brain stimulation system|
45689482|NCT02112838|Drug|Fostamatinib 150 mg|Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
46049882|NCT04128358|Diagnostic Test|Serological assay for blood born viral hepatitis|Qualitative PCR for patients with hepatitis C antibody positive
46049883|NCT04128358|Diagnostic Test|Quantitative microbiological test for HCV|Quantitative PCR in those with proven HCV infection
45480462|NCT01332474|Drug|BOTOX|BOTOX
45480463|NCT03787823|Procedure|robotic Prostatectomy (RARP)|Modification of robotic Prostatectomy Arm A classic technique/ anterior transperitoneal RARP Arm B Transdouglas Technique/retzius-sparing RARP
45480464|NCT03719053|Drug|Tenofovir|pre- and post-dosing measurements of TFV and TFV-DP in plasma and PBMCs.
46049884|NCT00626054|Drug|PEG solution in a single dose of 3 liters|Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
46049885|NCT00626054|Drug|PEG solution|PEG solution: half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test
46049886|NCT04262622|Device|Group TEA: thoracic epidural analgesia group|in this group TEA will be performed by the insertion of transthoracic epidural catheter before induction of general anesthesia. Analgesia will be started on wound closure by injecting local anesthetic mixture into the epidural catheter
45363025|NCT04086095|Device|Neofact application aid|The Neofact application aid is a specifically for the LISA procedure designed guide of a soft catheter and replaces the Magill forceps. Catheter (3.5 Fr.) and guide are already combined and packed together sterile. The catheter tip is marked in black (1cm).
45480465|NCT03788135|Behavioral|cooling|the participants in the experimental group will receive a cold pack (gel pack, temperature -6 degrees to -12 degrees Celsius) will be placed on the target muscles for 20 minutes.
45689483|NCT02112838|Drug|Fostamatinib 100 mg|Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
45689484|NCT02112838|Drug|Placebo|Placebo tablet twice daily by mouth, over the course of 24 weeks
45689485|NCT00427336|Drug|Fludarabine|30 mg/m^2 by vein daily over 30 minutes
45689486|NCT00427336|Drug|Cyclophosphamide|300 mg/m^2 by vein daily over 2 hours
45689487|NCT00427336|Drug|Antithymocyte Globulin|3.75 mg/kg by vein daily over 4 hours
45689488|NCT00371176|Behavioral|Exposure therapy|A manualized form of treatment that involves vividly visualizing indexed trauma with the guidance of a therapist
45845477|NCT05112198|Device|Use of Noona web- based symptom tracking tool|Noona patient reported outcome (PRO) platform tool that summarizes symptoms and distress
45847728|NCT02907918|Drug|Palbociclib|Palbociclib is an oral drug given at a dose of 125 mg daily on Days 1-21 of each 28-day cycle for a total of 4 cycles.
45845478|NCT05105802|Behavioral|Mindfulness-Based Intervention|Using AmDtx MBI-based app, targeted MBI training will consist of a 4-week custom-made program that include, setting intentions and check-in with mood, audio-recorded lectures, guided meditations such as body scans, and writing events journal (Appendix 5). Each standardized course will be unlocked as the child progresses through the program. Users will be encouraged to participate in the app-based activities for a total of 10-15 minutes every day, with a minimum of 4 days in a week, over a period of 4 weeks.
45845479|NCT05105802|Behavioral|Cognitive Sham + Usual Care|Usual care recommends that the patient refrain from physical and cognitive activities for 24-48 hours after injury. After the rest period, it is recommended that low to moderate levels of physical and cognitive activity be gradually started 24-48 hours after injury. The activities should be performed at a level that does not result in recurrence or exacerbation of symptoms. Children must refrain from any activities that increase the risk of re-injury (drills with body contact or that risk falls) until fully asymptomatic and cleared by their primary care or other medical provider. The sham journey will consist of playing an open-source cognitive math game delivered through the same app as MBI, but without the mindfulness content.
45689489|NCT00371176|Drug|D-Cycloserine|A partial NMDA agonist that has been shown in human trials to facilitate and strengthen extinction with CBT.
45845480|NCT05105256|Drug|Prednisolone|Patient will have 1 infiltration of 3mL to 5 mL corticosteroids on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with corticosteroids will be performed at inclusion
45845481|NCT05105256|Drug|Platelet-rich plasma|Patient will have 1 infiltration of 3mL to 5 mL of PRP on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with PRP will be performed at inclusion.
45845482|NCT05083260|Drug|NE3107|NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Parkinson's disease
45845483|NCT05083260|Drug|placebo|Hard gelatin capsule containing only common excipients for oral formulations
45847729|NCT02907918|Drug|Letrozole|Letrozole is an oral drug given at a dose of 2.5 mg orally once a day. It will be taken continuously (Days 1-28 of each cycle) until the day of definitive surgery.
46049887|NCT04262622|Device|Group RSB: rectus sheath block group|Two sets of epidural catheters which have multiple perforations at the end of the tubing will be surgically applied bilaterally into the rectus sheaths for each patient in this group on wound closure. By the end of surgery,injection of local anesthetic mixture will be started.
46049888|NCT04134676|Drug|Conditioned Media|Conditioned Media represents the complete regenerative milieu of cell-sourced secretome and vesicular elements. The soluble components of the secretome may be separated from the microvesicle fraction by centrifugation, filtration, polymer precipitation-based methodologies, ion exchange chromatography and size-exclusion chromatography. Both of these components may be capable of independently triggering regeneration and repair as well as of mediating the de novo organogenesis of tissue-engineered organs ex vivo.
46049889|NCT02878694|Biological|Myoblast autologous graft|30 million autologous myoblasts in 6 intramuscular injections No treatment in the second eye
46049890|NCT05009316|Other|Questionnaires|Online-based questionnaires
46049891|NCT02620540|Device|Accuracy of an algorithm and the Broselow Tape|Computer based comparison of the two devices based on collected patient data
45480466|NCT03526848|Drug|3BNC117|Intravenous infusion of 3BNC117
45689490|NCT00371176|Other|Placebo pill|
45689491|NCT00371644|Behavioral|Cognitive Processing Therapy|CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the rape.
46049892|NCT00926796|Drug|Azithromycin|Four 500 mg tablets will be administered orally to equal a 2 gm dose.
46049893|NCT00926796|Drug|Gentamicin|Fixed dose of 240 mg intramuscular one time for patients >45 kg and a 5 mg/kg dose for patients less than or equal to 45 kg based on their measured weight in clinic. Most patients will require 2 injections of gentamicin in separate large muscle groups.
46049894|NCT00926796|Drug|Gemifloxacin|One 320 mg tablet administered orally.
46049895|NCT00696982|Drug|sitagliptin|sitagliptin 100 mg once daily for 3 months
46049896|NCT00696982|Drug|glibenclamide|glibenclamide 5 mg once a day titrated as neede up to 20 mg a day
45480467|NCT03526848|Drug|10-1074|Intravenous infusion of 3BNC117
45480468|NCT03526848|Other|Analytical treatment interruption|Analytical treatment interruption
45480469|NCT02486536|Drug|polyethylene glycol|
45480470|NCT02486536|Device|capsule endoscopy|
45480471|NCT03718975|Device|Successor of Phonak Audéo B90|Successor of the most recent Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
45480472|NCT03718975|Device|Phonak Audéo B90|The Phonak Audéo B90 is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
45480473|NCT03787355|Combination Product|Morse connection Implants|2 neighboring morse connection Implants of Zinedent - Strauman
45480474|NCT03321136|Drug|LSD|0.025 mg LSD per os, single dose
45480475|NCT03321136|Drug|LSD|0.05 mg LSD per os, single dose
45363026|NCT05325827|Procedure|ultrasound-guided high fascia iliaca compartment block|H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 ~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct. If the needle tip was correctly positioned, 0.375% ropivacaine 30 mL of local anesthetic was injected. The H-FICB was performed under ultrasound guidance by the same anesthesiologist.
45480476|NCT03321136|Drug|LSD|0.1 mg LSD per os, single dose
45480477|NCT03321136|Drug|LSD|0.2 mg LSD per os, single dose
45689492|NCT00371644|Behavioral|Present-Centered Therapy|PCT consists of general support and education focused on current issues in the patient's life. It emphasizes the focus on the individual's current life, and conceptualizes the problems addressed as manifestations of PTSD that, in some cases, may have been present for long periods of time. Emphasis is on problem solving and improving relationships. Connections are made between current problems and PTSD symptoms. PCT provides the emotional support for the trauma patient that is thought to help in recovery and helps the victim gain a better understanding of the nature of the patient's problems and connection with PTSD.
45480478|NCT03321136|Drug|LSD|0.2 mg LSD plus 40 mg ketanserin per os, single doses each
45480479|NCT03321136|Drug|Placebo|Capsules containing mannitol looking identical to the other drugs.
45480480|NCT01332552|Drug|GSK2485852 70 mg|single dose
45480481|NCT01332552|Drug|GSK2485852 420 mg|single dose
45480482|NCT01332552|Drug|placebo|single dose
45480483|NCT01332552|Drug|placebo|Repeat dose, once daily for 3 days
45480484|NCT01332552|Drug|GSK2485852 420 mg|Repeat dose, twice daily for 3 days
45480485|NCT01332552|Drug|GSK2485852 420 mg|Repeat dose, TIDfor 3 days
45480486|NCT01332552|Drug|GSK2485852 630 mg|Repeat dose, twice daily for 3 days
45480487|NCT01332552|Drug|GSK2485852 70 mg + Ritonavir 100mg|single dose, day 1
45480488|NCT01332552|Drug|GSK2485852 210 mg + Ritonavir 100mg|single dose, day 1
45480489|NCT01332552|Drug|GSK2485852 210 mg +Ritonavir 100mg|single dose daily for 3 days
45480490|NCT03720223|Drug|Liposomal Bupivacaine|20ml of Liposomal Bupivacaine 1.3% (13.3mg/mL)
45845484|NCT05081622|Behavioral|Interaction Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
45845485|NCT05068128|Other|Flow MRI|"4 flow acquisitions based on the 2D cine phase contrast sequence (present on all MRI systems) will be performed.~This sequence requires a cardiac synchronization by a plethysmograph put on the patient's finger.~32 cardiac phases are reconstructed per acquisition. The processing of the flow MRIs and the analysis of the flow curves of the LCS and blood during the cardiac cycle will be performed using the Amiens software.~Parameters measured via flow MRI are:~- Cerebral vascular flow, intracranial LCS dynamic volume, extracranial LCS dynamic volume"
45363027|NCT00715949|Other|Immediate Post-concussion Assessment and Cognitive Testing|ImPACT© utilizes a battery of neurocognitive tests to assess neurologic deficits.
45363028|NCT04084535|Other|High intensity interval training|Participants will perform 3 HIIT sessions per week, involving 10 min of intense exercise within a time commitment of 30 min per session, including warm-up, recovery between intervals and cool down.
45689493|NCT00428584|Drug|New Formulation of rebif - human interferon beta-1a|New Formulation of rebif- 44 mcg, SC (sub-cutaneous) thrice weekly (tiw) injection.
45689494|NCT00428584|Drug|Interferon beta -1b|Betaseron - 250 mcg, SC (sub-cutaneous) every other day injection.
45847730|NCT02907918|Biological|Trastuzumab|"Or FDA approved biosimilar~Trastuzumab will be administered on a weekly basis for 16 weeks (on Days 1, 8, 15, and 22 of each 28-day cycle for a total of 4 cycles). The first dose of trastuzumab on Cycle 1 Day 1 will be a loading dose of 4 mg/kg IVPB over 90 minutes. Subsequent doses of trastuzumab will be 2 mg/kg IVPB over 30 minutes. Weekly trastuzumab will continue after the completion of Cycle 4 of palbociclib until surgery."
45363029|NCT04084535|Other|Inspiratory muscle training|Participants will perform 3 inspiratory resistance training sessions per week, involving 30 min per session, including warm-up, recovery between intervals
45847731|NCT02907918|Drug|Goserelin|Goserelin is given subcutaneously at a dose of 3.6 mg on Day 1 of each cycle. Goserelin will be continued (once every 28-days) after the completion of Cycle 4 of palbociclib if required.
46049897|NCT01087736|Drug|Topiramate|After random assignment, topiramate will be titrated up over 5 weeks. Dosing begins at 25 mg per day, and increase in the second week to 25 mg twice per day; in the third week to 50 mg twice/day; in the fourth week to 75 mg twice/day; in the 5th week to 100 mg twice/day; and in weeks 6-11 increased to and maintained at 100 mg in the morning and 200 mg at night. Patients will receive the highest dose tolerated, not to exceed 300 mg per day. Adjustments are permitted throughout titration. Once maximum tolerated dosage is reached, subjects will be asked to maintain dosage for remainder of the treatment phase. Upon completing the 6 week maintenance period subjects will taper off over a 7-day period (Week 12). If subjects experience significant side effects, the dosage may be adjusted.
46049898|NCT01087736|Other|Placebo administration|Placebo pills will be prepared by the UCSF pharmacy which will be indistinguishable from the topiramate pills used in that arm. Both topiramate and placebo will then be delivered to the VA pharmacy. A consulting biostatistician will randomly assign participants to either the topiramate or placebo group. The dosing of placebo pills will follow the same regimen as outlined for the topiramate arm. In the event of a safety issue, there will be a procedure for unblinding only that participant.
45363030|NCT00503698|Drug|somatropin|20 mcg/kg/day, injected s.c. (under the skin)
45363031|NCT00503698|Drug|placebo|Placebo injected s.c (under the skin)
45363032|NCT02589899|Other|Needle placement in different tissue types|Bioimpedance will be measured for needle positions in different tissue types
45363033|NCT00573794|Biological|adalimumab|adalimumab prefilled syringes administered as subcutaneous injection EW or EOW
45363034|NCT00715793|Drug|Decitabine|"In Part I patients will be treated on a standard 3+3 phase I dose-escalation design starting at 0.075 mg/kg until a decitabine dose level of 0.15 mg/kg is reached, or, in case unacceptable toxicities are observed, at the maximum tolerated dose (Phase II recommended dose). Decitabine will be administered at the specified dose level, intravenously, daily 5 days a week for the first 2 weeks of a 6-week cycle."
45689495|NCT00428974|Drug|CF101 1mg|CF101 1 mg q12 hours for 12 weeks
45689496|NCT00428974|Drug|CF101 2mg|CF101 2 mg q12 hours for 12 weeks
45689497|NCT00428974|Drug|CF101 4mg|CF101 4 mg q12 hours for 12 weeks
45689498|NCT00428974|Drug|Placebo|Placebo tablets q12 hours for 12 weeks
45689499|NCT05187286|Drug|Apixaban|Administered as directed by treating physician
45689500|NCT00372970|Drug|Botulinum toxin A|200 U given by injection into the pylorus.
45689501|NCT00372970|Drug|Placebo|saline injection into pylorus.
45689502|NCT00373360|Drug|treprostinil sodium|rapid switch from intravenous epoprostinol to intravenous remodulin on the CADD ambulatory pump
45689503|NCT00430768|Biological|rAAV1-CB-hAAT|
46049899|NCT04263558|Behavioral|Emotion child|The MFS will include an idiographic measure of personal aims, symptom burden, displayed on a visual data dashboard to guide further intervention. The EMOTION intervention for children 9 to 12 years with symptoms of anxiety and/or depression will be used in a standard/long version (16 sessions) and a short (8 sessions) but optimized version, using a partial web-based solution with virtual reality (VR)-technology for behavioral experiments and exposure (in short and long version). Parental involvement: Parental participation in a 5-session parent group (high involvement) versus sharing information with parents via a brochure (low Parental involvement).
45689504|NCT00455650|Drug|Mecamylamine|A single dose of 10 mg of mecamylamine (via two 5 mg capsules) is given at the start of the mecamylamine arm of the study. This is the only administration of mecamylamine given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
46049900|NCT04262388|Biological|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
46049901|NCT04262388|Biological|Oleclumab|Oleclumab is a human immunoglobulin G1 lambda monoclonal antibody (mAb) with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab selectively binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. This, in turn, leads to increased antitumor immunity.
45689505|NCT00455650|Drug|Varenicline|A single dose of 1 mg of varenicline (via two 0.5 mg capsules) is given at the start of the varenicline arm of the study. This is the only administration of varenicline given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
45845486|NCT05068128|Other|PERFUSION TEST|"The test will be performed will include:~Inserting a needle into the lumbar space, Ommaya reservoir or valve pre-chamber, as appropriate~Connect the needle to the pressure transducer via saline filled manometer lines connected via a 3-way valve. The other end of the 3-way connection will be connected to a saline~Recording of the opening pressure for 10 minutes~The infusion test is terminated either when the pressure stabilizes again on a new plateau, or when the average pressure exceeds 40 mmHg, or in case of adverse effects or symptoms such as headache, nausea/vomiting or visual disturbances.~At the end of the test, a depletion of 30 to 50 mL of CSF will be performed.~The pressure recording during the test is then used to calculate the parameters of the mechanical properties of the CSF circulation and reported to the neurosurgeon ordering the test."
45689506|NCT00455650|Drug|Placebo|The placebo contains no active medication. The placebo dose is given via two capsules at the start of the placebo arm of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance. The placebo has no effects that last for any duration of time.
45689507|NCT01794988|Behavioral|Group Cognitive Behavioral Therapy|Each CBT session will last 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
45845487|NCT05062668|Procedure|cataract operation and istent|a cataract operation and the placement of one or two iStent inject or inject W at the same time
45845488|NCT05062668|Procedure|cataract operation only|Patients have a classic postoperative treatment after cataract.
45845489|NCT05058690|Diagnostic Test|Oral Glucose Tolerance Test|"Obtain blood sample for glucose assessment (time 0 sample). This may be obtained via venepuncture or after cannula insertion.~Test a small sample using a near patient glucose testing meter. If the result on the glucose meter is greater than or equal to 11mmol/L, send the blood sample urgently to lab. If it is confirmed by biochemistry to be above 11mmol/L, there is no need to continue test.~If the result is less than 11mmol/L on meter, give the patient the glucose solution to drink.~Collect a further blood sample at 120 minutes.~Send samples all together to laboratory for glucose measurement."
45845490|NCT05047692|Biological|AdCLD-CoV19-1|Replication deficient adenoviral vector based COVID-19 prevention vaccine containing recombinant gene of SARS-CoV-2 spike protein
45845491|NCT05046288|Other|Virtual guided tours|The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 6 to 7 participants. They meet online one time per week for a 30 to 45 min of a guided tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
45845492|NCT05016258|Device|KONTACT MB|Dental implant surgery
45845493|NCT05717946|Dietary Supplement|Probiotic composed of two bacteria strains: Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell.|We plan to investigate the impact of the Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell on clinical and biochemical parameters in the experimental group.
45845494|NCT05717946|Other|control group|We plan to investigate the impact of a placebo on clinical and biochemical parameters in the control group.
45845495|NCT05002218|Behavioral|Aerobic Training|Aerobic training on stationary bike 5x a week for 30 minutes a day.
45845496|NCT05002218|Behavioral|Balance Training|Balance training 5x a week for 30 minutes as instructed by a therapist. Standard of care.
45845497|NCT04992546|Drug|PRN473 (SAR444727)|White to off-white gel suspension
45845498|NCT04992546|Drug|Placebo|White to off-white gel suspension
45847732|NCT02907918|Procedure|Breast surgery|Standard of care
45363035|NCT00715793|Drug|Temozolomide|Temozolomide is available in 25 mg and 100 mg tablets that will be administered orally; doses will be rounded to the nearest 25 mg. Temozolomide will be administered orally at 75 mg/m2 daily for 4 weeks starting on week 2 of a 6-week cycle.
46049902|NCT04262076|Other|Pulpine with Polyamidoamine Dendrimer|Removal of infected dentin in class I Cavities followed by application of Polyamidoamine Denrimer on caries affected Dentin that is washed out of the cavity after 30 secs then finally place Pulpine .
46049903|NCT04262310|Other|Small Bowel and Colonic Permeability Test|small bowel and colonic permeability based on oral probe molecules and urine excretion in 60 healthy white, female and male adults aged 18-70y
45480491|NCT05694767|Drug|CM313 Injection|"intravenous CM313 administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with CD38 monoclonal antibody (CM 313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment."
45363036|NCT00715793|Procedure|biopsy|Fine needle aspirates (FNA) and/or core biopsies of tumor samples will be obtained from consenting patients with accessible, evaluable disease, on days 1, 8, 15, and 29 of the first cycle and when patients go off study. Biopsies are optional in Phase I and required for all consenting subjects in Phase II.
45480492|NCT03718897|Diagnostic Test|Endoscopic retrograde cholangiopancreatogram|Biopsy specimens are attained via endoscopic retrograde cholangiopancreatogram in patients with suspicious biliary tract cancer.
45480493|NCT02486380|Device|Toffee full face mask/toffee nasal mask|Toffee full face mask/toffee nasal mask
46049904|NCT00608712|Drug|Esomeprazole|Esomeprazole 20mg oral tablet
46049905|NCT01079936|Drug|Lenalidomide|Beginning dose level 25 mg by mouth (PO) on Days -8 to -2
46049906|NCT01079936|Drug|Melphalan|Dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion
45363037|NCT04085549|Device|Berry Oil Cream|Cream containing berry and plant oils and humectants; a medical device product in development
45480494|NCT03160716|Device|Restylane Lyft with Lidocaine|a sterile gel of hyaluronic acid (HA)
45689508|NCT01794988|Behavioral|Pain Education|Subjects will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
45689509|NCT01794988|Behavioral|Therapeutic Interactive Voice Response|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls.
45689510|NCT01794988|Behavioral|NO TIVR|Control - no intervention
45363038|NCT04085549|Other|Reference Cream|Commercial refence cream not containing berry and plant oils.
45689511|NCT02114164|Device|AirSeal System|To analyze the results of patients randomized to either the AirSeal system or Standard Endopath trocar.
45689512|NCT02114164|Device|Standard Endopath|This group receives the Standard Endopath Trocar for intraoperative insufflation.
45363039|NCT00924014|Drug|Conivaptan|Conivaptan 20 mg IV bolus followed by a 4 hour infusion at 1.2 mg/hr
45363040|NCT00924014|Drug|Furosemide|Furosemide will be given IV at the subjects usual oral dose up to 80 mg. If the dose is 80 mg or more only 1/2 the dose will be given IV.
45363041|NCT00924014|Drug|Conivaptan and furosemide|Furosemide bolus first; conivaptan 20 mg IV bolus/infusion at 1.2 mg/hour for a total of 4 hours
45480495|NCT03720145|Behavioral|Lifestyle Medicine|Lifestyle intervention including diet, sleep, exercise, relaxation and mindfulness
45480496|NCT03317626|Diagnostic Test|Cold Stimulus (ice) Test|Standard of care epidural will be inserted. The study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen at 15 minutes and if necessary at 30 minutes after the epidural is inserted. Hypesthesia to cold will be taken a sign of successful lumbar epidural block.
45480497|NCT01332708|Behavioral|high complex carbohydrates diet given in a diet group|diet groups that meet every week for eight weeks or more.
45689513|NCT00374842|Biological|Fluarix™|GlaxoSmithKline Biologicals' licensed influenza vaccine
45689514|NCT00374842|Biological|GSK1247446A|Low-dose GlaxoSmithKline Biologicals' GSK1247446A influenza vaccine
45689515|NCT00431626|Drug|Dutasteride (Avodart)|
45689516|NCT00431626|Drug|Placebo|Placebo before and after treatment of TURP
45480498|NCT03787511|Other|Cough assessment|Cough assessment with cough visual analog scale (VAS), and Leicester Cough Questionnaire (LCQ) for Diabetic patients with chronic cough and Diabetic patients without chronic cough
45845499|NCT04981392|Behavioral|Health System Vaccination Text Messages and Provider Education|"Patients: Eligible patients will receive a series of text messages from their PCP recommending a study website as a trusted source of information about the COVID-19 vaccines and information on how and where to schedule a vaccination.~Providers: will receive educational materials to support their conversations with patients about the COVID-19 vaccines."
46049907|NCT01079936|Procedure|Stem Cell Infusion|Stem cell infusion on Day 0.
45480499|NCT03787511|Other|Neurological tests and cardiovascular tests|Neurological tests : electromyography, thermotest, QSAR + cardiovascular test for Diabetic patients with chronic cough and Diabetic patients without chronic cough
45480500|NCT03787511|Other|Skin biopsy|Skin biopsy to evaluate small fiber neuropathy for Diabetic patients with chronic cough and Diabetic patients without chronic cough
45480501|NCT02483962|Other|Gelatine capsule|Gelatine capsules containing no active ingredients.
45480502|NCT02483962|Other|Venavine Intensive®|Gelatine capsules containing 360 mg red vine leaf extract, 60 mg of horse chestnut extract, 35 mg of butchers broom extract and 3,2 mg of vitamin B6.
45480503|NCT00092664|Drug|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks|
45480504|NCT02483884|Drug|[68Ga]RM2|[68Ga]RM2 is a novel 68Ga labeled, radiopharmaceutical agent for PET imaging. It is administered intravenously as a single dose of 140 MBq (corresponding to ≤ 40 μg mass dose)
45689517|NCT01796626|Device|M22 ResurFX module|The system delivers pulsed near Infra-Red (NIR) laser light with a nominal wavelength of 1565 nm and has a unique treatment handpiece with epidermal cooling. The clinician is able to control the settings of energy, µBeams density, scan size, and shape option from the user interface (LCD GUI) display on the main M22 console.
45845500|NCT04967196|Biological|Ipilimumab|Given via DoseConnect device or IV
46049908|NCT00931710|Drug|valsartan, amlodipine, HCTZ|combination Valsartan/amlodipine160/5 mg tablet for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (6 weeks) of the study
46049909|NCT00931710|Drug|Losartan, HCTZ followed by valsartan, amlodipine, HCTZ|losartan 100mg capsule for 3 weeks; losartan 100mg capsule +HCTZ 25 mg capsule for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (3 weeks) of the study
45363042|NCT02591303|Other|Stress reactions measurement during stressful and neutral driving sessions|Stress effects will be measured during 3 driving sessions (training without events on Day 17, with neutral events on Day 18, with stressful events on Day19), through nighttime PSG and questionnaires.
45363043|NCT00853268|Drug|Controlled-Release Oxycodone Hydrochloride 40 mg|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose with food
45363044|NCT00853268|Drug|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose with food
45363045|NCT01011244|Biological|ADIPOPLUS|"autologous cultured adipose-derived stem cells~1x10e7 cells/1cm2 depending on surface area of fistula"
45363046|NCT00853346|Behavioral|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
45363047|NCT00853346|Behavioral|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
45480505|NCT02483884|Procedure|PET/CT|Patients received [68Ga]RM2 undergo PET/CT 60 min p.i. for at least 20 min
45480506|NCT03321058|Behavioral|Assessment|Assessment of patients' medication organisation and comprehension of generics
45480507|NCT03713021|Device|TraceIT Tissue Marker|The maximum injection volume of TraceIT hydrogel, for a single location, is 1mL.
45480508|NCT02483494|Other|APN-led Telemedicine|"Allocation to experimental or Usual care is 1:1.~The four study APNs will be delivering the care and have at least three years working experiences in coronary care settings. A telephonic script and study protocol is made available to ensure standardization of intervention."
45480509|NCT05694455|Diagnostic Test|Starling SV- Passive Leg Raise|All septic patients will have a passive leg raise performed with the assistance of an starling SV device to look at SV change. This will be performed at admission and 4 hours after admission. This intervention will not be performed on healthy controls
45689518|NCT00376558|Behavioral|Community Reinforcement Approach|Community Reinforcement Approach (CRA): The community reinforcement treatment program will be carried out in accordance with NIDA's therapy manual (13).During weeks 13 through 24, patients will meet once per week with their therapists. Sessions will focus on promoting continued change in the life areas addressed in the first 12 weeks of treatment or new components are added as needed.
45845501|NCT04967196|Biological|Nivolumab|Given IV
45845502|NCT04950894|Device|Hypoglossal Nerve Stimulation|Hypoglossal Nerve Stimulation started at Month 1 compared to no Stimulation (Control group will start stimulation at M7+1Day)
45847733|NCT02907918|Procedure|Research tumor biopsy|Baseline, cycle 1 day 15, and surgery
45847734|NCT02907918|Procedure|Research bone marrow (OPTIONAL)|Baseline and surgery
46049910|NCT01100528|Biological|recombinant interferon alfa-2b|Given subcutaneously (SC) 3 times a week for 24 weeks
46049911|NCT01100528|Drug|dacarbazine|Given IV on days 1 and 29
45845503|NCT04921410|Device|Biofeedback Knee Sleeve|The biofeedback knee sleeve is a device that is artificially-intelligent and utilizes determined cut-off values of knee motion and forces to determine whether a motion is 'good' or 'bad'. A 'bad' knee motion will provide a haptic output to the wearer (biofeedback) so that they can take note of what the previous motion was that caused the device to signal a warning.
45845504|NCT04921410|Device|Sham Biofeedback|The biofeedback knee sleeve is a device that is artificially-intelligent and utilizes determined cut-off values of knee motion and forces to determine whether a motion is 'good' or 'bad'. This intervention will provide sham biofeedback during training sessions.
45363048|NCT00845780|Drug|withdrawal or continuation of amiodarone therapy|withdrawal or continuation of amiodarone therapy after at least 6 months sinus rhythm maintenance on amiodarone therapy
45480510|NCT05694455|Diagnostic Test|Microscan Sublingual Microscopy|All septic patients will have sublingual microscopic images performed at admission, 8-16 hours, 48 hours and 72 hours. Control patients will have a sublingual microscope imaging perfomed after intubation for the elective procedure. This is a process of a 2cm probe tip gently placed on patients' mouth and 3 different images of 5-8 seconds are recorded.
45845505|NCT04916886|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml|Containing 0.5E10vp
45845506|NCT04916886|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml|Containing 0.3E10vp
45845507|NCT04907682|Drug|Ribavirin iv|100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day), then 25 mg/kg days 2-7, 12.5 mg/kg days 8-10
45845508|NCT04907682|Drug|Favipiravir|Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16), Day 2-10 1200mg twice daily
45845509|NCT04880304|Other|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
45845510|NCT04880304|Other|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
45845511|NCT04842084|Biological|Blood samples|sampling of 10 S-Monovette tubes (Sarstedt) 4.3 ml of blood specifically for the study representing a total blood volume of 43 ml
45845512|NCT04840992|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation|Aerogen Solo
45845513|NCT04840992|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
46049912|NCT01100528|Other|laboratory biomarker analysis|Correlative studies obtained prior to therapy, every 8 weeks while on therapy, and then every 6 months during follow-up
45689519|NCT00455962|Drug|Estradiol steroid infusion|Estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr
45689520|NCT00455962|Drug|Progesterone steroid infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr
45689521|NCT00434278|Drug|Dornase alfa|2.5 mg inhalation dose twice daily for 14±2 days
45689522|NCT00434278|Drug|placebo|2.5 mg inhalation dose twice daily for 14±2 days
45689523|NCT00434356|Drug|bevacizumab|Intravenous repeating dose
45689524|NCT00434356|Drug|sunitinib|Oral repeating dose
45689525|NCT00434356|Drug|paclitaxel|Intravenous repeating dose
45689526|NCT00376948|Dietary Supplement|genistein|
45689527|NCT00376948|Drug|erlotinib hydrochloride|
45689528|NCT00376948|Drug|gemcitabine hydrochloride|
45689529|NCT01795768|Drug|AZD 4547|
45689530|NCT01795924|Drug|PD-616|Patients may continue treatment through 1 year post-C1D1 or until withdrawal of consent or development of any toxicity meeting the definition of Dose-Limiting Toxicity or progressive disease, whichever occurs first.
45845514|NCT04840992|Biological|Placebo for Inhalation|Aerogen Solo
46049913|NCT04306406|Other|Raspberries|Red raspberry smoothies drink
46049914|NCT04306328|Device|Neurostimulation|Implantation of 2 multicontact cuff electrodes in the upper limb of patients with tetraplegia and control of the stimulation by contralateral shoulder movements
46049915|NCT01079234|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily
46049916|NCT01079234|Drug|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily
46049917|NCT01079234|Drug|insulin aspart|At least three daily doses at meal-time
46049918|NCT00931632|Drug|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be administered continuously starting at 20ppm into the inspiratory limb of the ventilator circuit in mechanically ventilated subject using an INOvent delivery system of by nasal cannula as needed for 24 days of therapy.
45480511|NCT05694455|Diagnostic Test|Vexus Ultrasound Scoring|All septic Patients will have this performed on all patients at admission, 8-16 hours, 48 hours and 72 hours. Ultrasound images and blood flow waves will be collected of the IVC diameter, hepatic vein, portal vein, renal veins and scored using the Venous Excess Ultrasound (VExUS scale). Healthy controls will not have ultrasound performed
45845515|NCT04840992|Biological|Placebo|Intramuscular administration
45845516|NCT04832802|Behavioral|ACCESS|ACCESS-Vets is a customized employment intervention adapted for use in VA healthcare to help Veterans with SCI achieve competitive integrated employment. ACCESS-Vets includes the following elements: discovery, customized employment planning, job development, customized employment negotiation, and accommodations and job retention supports.
45689531|NCT03396874|Drug|68Ga-PSMA|"PET/CT imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi)."
45689532|NCT01796080|Other|Mueller manoeuvre|
45845517|NCT04832802|Behavioral|IPS|IPS is an evidenced-based practice of supported employment that helps persons with disabilities find and maintain integrated competitive employment. IPS follows eight standardized principles: zero exclusion, integrated services, rapid job search, competitive employment, worker preferences, systematic job development, benefits planning, and time-unlimited supports.
45845518|NCT04793022|Drug|TIVA with Propofol|Total intravenous anesthesia with propofol
45845519|NCT04793022|Drug|Inhaled Anesthesia|General anesthesia given with inhaled anesthetics
45845520|NCT04776018|Drug|TAK-981|TAK-981 IV infusion.
45845521|NCT04776018|Drug|Mezagitamab|Mezagitamab SC injection.
46049919|NCT00931632|Drug|Placebo|Nitrogen gas will be administered in the same manner as the experimental drug.
46049920|NCT02877758|Other|Tomorrowlabs cosmeceutical formulation|
46049921|NCT02877758|Other|Sham cosmeceutical formulation|
46049922|NCT04306484|Diagnostic Test|FDOPA-TEP|FDOPA-TEP performed as part of the normal management of a suspected brain tumour
45689533|NCT01796080|Other|Inspiratory threshold|
45689534|NCT01796080|Other|Expiratory apnoea|
45845522|NCT04776018|Drug|Daratumumab and Hyaluronidase-fihj|Daratumumab and Hyaluronidase-fihj SC injection.
45845523|NCT04750902|Drug|0.24% Sodium Fluoride Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
45845524|NCT04750902|Drug|1.5% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
46049923|NCT04261998|Other|Service-learning program|Intervention group will perform a service-learning program with real patients with heart transplantation, and will have to perform a physical therapy program adapted to a real patient. Two meetings will be performed in order to establish groups, explain the project and search information based on evidence in scientific databases. In addition, three meetings with patients will be stated in order to establish the adapted program based on the real patient's needs and characteristics.
45689535|NCT01796080|Other|Steady state normal breathing|
45689536|NCT00438100|Drug|Capecitabine|1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
45689537|NCT00438100|Drug|S-1|80 mg/m2 orally bid daily for day 1 through day 28 followed by 14-day washout; repeat this as a course.
45689538|NCT00438490|Drug|Recombinant Human Prolactin|
45689539|NCT00456508|Drug|ecallantide|solution for SC injection, one 30 mg dose per HAE attack
45689540|NCT02115646|Device|fractionated carbon dioxide laser|patients will have serial laser treatments
45689541|NCT00457366|Drug|Quetiapine|Quetiapine 300mg PO/Initial dose and repeat dose at 2 hours if deemed clinically necessary up to a maximum dose of Quetiapine 600mg PO QD
45689542|NCT00457366|Drug|Haloperidol|given in combination with Lorazepam 2 mg IM, Cogentin 2 mg IM; repeated at 2 hours as deemed clinically necessary
45689543|NCT00457366|Drug|Lorazepam|given in combination with Haloperidol 5mg IM and cogentin 2mg IM; repeated at 2 hours as deemed clinically necessary.
45689544|NCT00457366|Drug|Cogentin|given in combination with haloperidol 5mg IM, and Lorazepam 2mg IM; repeated at 2 hours as deemed clinically necessary.
45689545|NCT00458848|Drug|asparaginase|
45689546|NCT00458848|Drug|daunorubicin hydrochloride|
45689547|NCT00458848|Drug|etoposide|
45689548|NCT00458848|Drug|idarubicin|
45689549|NCT00458848|Drug|imatinib mesylate|
45689550|NCT00458848|Drug|mercaptopurine|
45845525|NCT04750902|Drug|4.0% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
45845526|NCT04750902|Drug|8.0% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
45845527|NCT04737018|Other|Fugl-Meyer Assessment (FMA)|assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination Score from 0 to 34
45845528|NCT04737018|Other|Medical Research Concil (MRC)|evaluation of muscular strength score from 0 to 5
45845529|NCT04737018|Other|2 Minute Walk Test (2MWT)|Assess functional walking and aerobic abilities
45845530|NCT04737018|Other|Timed Up & Go Test|measures the time it takes to get up from a chair, walk 10 feet, turn around, return to the seat and sit down
45845531|NCT04737018|Other|Modified Ashworth Scale|score from 0 to 4 evaluation of spasticity
45845532|NCT04737018|Other|Postural Assessment Scale for Stroke|score from 0 to 36 measures the patient's ability to maintain stable postures and balance in changes of position
45845533|NCT04737018|Device|posturographic recording|analysis of static equilibrium parameters and positional measurement of the center of gravity on the Winposturo platform
45847735|NCT02907918|Procedure|Research blood sample|Baseline, cycle 1 day 15, surgery, and yearly post-surgery for 5 years
45847736|NCT02907918|Genetic|Research blood for germline DNA|Baseline
46049924|NCT00608790|Drug|Salbutamol|Prophylactic salbutamol administered at a dose of 200 micrograms by metered dose inhaler (MDI) via a spacer.
45480512|NCT05694455|Other|Urine Collection|The urine assay is collected passively from the patient will be ran through a DMMB assay- could provide future beneficial information to resuscitation efforts. This will be performed on all septic patients at admission, 8-16 hours, 48 hours and 72 hours. Urine will be collected on healthy controls at time of intubation for elective procedure.
45845534|NCT04737018|Other|vibration program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation. The program will apply a frequency of 100 Hz, with an amplitude of 1 mm
45845535|NCT04737018|Other|sham program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation.
45845536|NCT04682496|Procedure|Intratendon vascularization|Ultrasonic exploration by power-Doppler of the intratratendon vascularization, making longitudinal cuts of the patellar tendon and with previously pre-established Doppler optimization parameters for all patients. The optimization parameters of the power-Doppler signal will be set at a Doppler frequency of 6.7 MHz, pulse repetition frequency (PRF) of 0.7 kHz. The lowest wall filter and a standardized gain just below the level that produces random noise will be applied. This examination will be repeated several times with different probe pressures, which will be quantitatively adjusted through the force sensor and maintained with the articulated arm. A 4-second static video will be recorded of the longitudinal section that presents a higher Doppler signal in each of the scans at different probe pressures.
45845537|NCT04633356|Device|EUS-portal pressure gradient measurement (PPGM)|EUS-guided PPGM is performed under conscious sedation. An OGD would be performed to evaluate for findings consistent with portal hypertension such as varices and portal hypertensive gastropathy. The linear array echoendoscope is passed from the mouth into the stomach and duodenum, as with a standard exam. Under endoscopic ultrasound guidance, a 25 gauge EUS needle (Echotip, Cook Medical, USA) primed with heparin 100 USP/ml is then placed across the stomach or duodenal wall and through the liver parenchyma into the portal vein. A pressure measurement is then obtained from the compact pressure transducer attached to the handle of the needle. Three separate measurements are made with re-priming of heparin (less than 0.5 ml). The process is repeated for the hepatic vein. The EUS - PPG is calculated by subtracting the average of the three hepatic vein pressure measurements from the average of the 3 direct portal vein pressure measurements.
45845538|NCT04621500|Drug|cholecalciferol|Enrolled subjects will supplement with vitamin D3 at 4,000 IU daily for one year
45689551|NCT00458848|Drug|methotrexate|
45689552|NCT00458848|Drug|methylprednisolone|
45845539|NCT04592484|Biological|CDK-002|CDK-002 administered intratumorally
45845540|NCT04567524|Drug|LYN-005|LYN-005 (14 or 28 mg weekly) plus IR risperidone matched placebo.
45845541|NCT04549038|Other|12-16 hour nutrition|Cases will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. Feeding will begin in morning hours unless otherwise directed by an investigator or registered dietician.
46049925|NCT00608790|Drug|Sodium chloride 5%|30 ml sterile hypertonic saline solution (sodium chloride 5%) will be administered by jet nebulisation for 15-20 minutes.
45480513|NCT01335828|Device|Medical ultrasound device (ShearWave system)|"Echography (all modes) and elastography ShearWave system"
45480514|NCT03317548|Diagnostic Test|progesterone|according progesterone level to decide fresh or frozen embryo transfer
45689553|NCT00458848|Drug|mitoxantrone hydrochloride|
45689554|NCT00458848|Drug|prednisone|
45689555|NCT00458848|Drug|vincristine sulfate|
45689556|NCT00458848|Procedure|allogeneic hematopoietic stem cell transplantation|
45689557|NCT00458848|Procedure|autologous hematopoietic stem cell transplantation|
45689558|NCT00458848|Procedure|peripheral blood stem cell transplantation|
45689559|NCT00458848|Radiation|radiation therapy|
45845542|NCT04547790|Dietary Supplement|Psyllium|One level scoop (12.5mL) of 5.1g of psyllium fiber twice a day with 8 ounces water
45845543|NCT04547790|Dietary Supplement|Wheat Dextrin|One level scoop (12.5 mL) of 1.7g wheat dextrin fiber twice a day with 8 ounces water
45845544|NCT04506060|Other|serum withdrawal|Serum of the transplant patient. In the transplanted patient, the search for the BK virus is traditionally carried out during visits in the first year after transplantation.
45845545|NCT04481412|Drug|Topical cetirizine|Topical cetirizine 1% spray that will be prepared at Faculty of Pharmacy, Cairo University and will be applied once daily.
45845546|NCT04481412|Drug|Placebo|96% ethanol that will be applied once daily.
45845547|NCT04481412|Drug|Topical minoxidil|Topical Minoxidil 5% that will be applied once daily.
46049926|NCT01078922|Drug|Ofatumumab|The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
46049927|NCT05224206|Device|Theta burst stimulation|Cool B65 active/placebo coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
45480515|NCT03317548|Diagnostic Test|day 3 embryo|according day 3 embryo to decide fresh or frozen embryo transfer
45480516|NCT00092586|Drug|MK0653, ezetimibe|
45480517|NCT00092586|Drug|Comparator: statins|
45480518|NCT03787199|Device|Andago|The Andago is a body-weight supporting device with which a patient can walk overground
45480519|NCT03787199|Other|Treadmill|Bodyweight supported treadmill walking
45480520|NCT03320980|Procedure|RALPPS|RALPPS: split-in-situ resection with radio-frequency ablation (RFA) instead of liver partition on the first stage and major liver resection on the second stage
45689560|NCT00459862|Other|laboratory biomarker analysis|Correlative study
45689561|NCT00459862|Drug|pazopanib hydrochloride|Given orally
45689562|NCT00461734|Other|RV lead placement site|Patients randomised to RV apical or high septal lead placement site
45845548|NCT04475718|Behavioral|Fourth Trimester Mobile Tool|A mobile web-based tool for underserved women in the fourth trimester. The mobile platform teaches self-efficacy, care management, and coping skills to help reduce major health risks and provide tools and resources to maintain mental health.
45845549|NCT04473066|Procedure|Adenotonsillectomoy +/- turbinate reduction|Tonsillectomies were performed by bipolar electrocautery while adenoidectomies were done by monopolar suction diathermy. Turbinate reduction (by either submucosal bipolar diathermy or radiofrequency) would be offered if the subject had on-going history of allergic rhinitis and examination revealed at least grade II turbinate hypertrophy. (Grade I = no turbinate hypertrophy; Grade II = turbinate hypertrophy without touching the septum; Grade III = turbinate hypertrophy touching the septum).
45845550|NCT04465188|Procedure|Encircling scleral buckle surgical procedure|Encircling scleral buckle surgical procedure under general anesthesia
45845551|NCT04441554|Diagnostic Test|7 Tesla MRI|7 Tesla MRI of cervical spine
45845552|NCT04423458|Device|3D imaging|"The study will focus on the accuracy of ultrasound technology in assessing renal transplants.~The entire assessment should not take more than 25 minutes."
45845553|NCT04412616|Biological|ZZ06|"The phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg."
45845554|NCT04371276|Other|No intervention|Blood samples will be collected from recruited subjects from invited households for testing for hepatitis B (HBsAg, anti-HBs and anti-HBc) and hepatitis A (anti-HAV)
45845555|NCT04317300|Drug|Varenicline|Dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 11 weeks of treatment.
45845556|NCT04317300|Other|brief behavioral therapy|brief behavioral therapy
45845557|NCT04300218|Behavioral|internet-delivered cognitive-behavioral therapy for insomnia (iCBT-I)|"The 2-month intervention consists of educational material divided into 8 modules, which provide the rationale for the CBT-I interventions: sleep restriction; stimulus control; cognitive techniques; relaxation techniques. Information is presented in 10-minute videolectures.~The program includes a sleep diary to insert bedtime and waketime, sleep latency, total sleep time, night awakenings.~All material will be delivered through the internet program and expected to be elaborated by the patient but with the opportunity to contact a specialist via the feedback form (guidance on request) in a secured environment if they face difficulties or possible negative effects of the intervention. The content of the program is based on an already established internet-based self-help program against insomnia that was already tested in a previous study."
45480521|NCT03320980|Procedure|portal vein embolization + major liver resection|PVE on the first stage and major liver resection on the second stage
46049928|NCT05224206|Device|Theta burst stimulation|Cool B70 coil (left DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
45689563|NCT00438802|Drug|Alefacept|Dose escalation theme. 0.075mg/kg by IV Weekly x 8 to 0.30mg/kg IV Weekly x 8
45480522|NCT01335906|Other|Information|The experimental information consists of receiving verbal and written evidence-based information about the benefits and risks of mammography screening program. The standard information consists of receiving the information that public institutions provide to the women invited to the screening program.
45689564|NCT00377572|Biological|omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
45689565|NCT00377572|Biological|omalizumab placebo|Subcutaneous injections of placebo will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
45689566|NCT00438880|Drug|Agatolimod Sodium|Given IV
45689567|NCT00438880|Radiation|Indium In-111 Ibritumomab Tiuxetan|Given IV
45689568|NCT00438880|Other|Laboratory Biomarker Analysis|Correlative study
45689569|NCT00438880|Procedure|Radionuclide Imaging|Undergo imaging scans
45845558|NCT04300218|Other|Care as usual (CAU)|Intervention includes all variety of therapy methods that can be prescribed by medical doctors (MD): pharmacotherapy, behavioral recommendations, face-to-face psychotherapy. Prescriptions may be made during the first visit to MD, or at any point in the study on a next doctor visit, or during visits to the doctors of other medical centers. All concurrently applied treatments will be assessed repeatedly by self-report
45845559|NCT04251390|Device|trexo Home|12 week intervention, with weekly contact/assessments of the affects of using the trexo Home.
45845560|NCT04205370|Device|Deactivated Pregnancy Coach|Naturalistic monitoring of their typical sleep patterns and behaviors
45845561|NCT04205370|Device|Active Pregnancy Coach|The Pregnancy Coach will begin to deliver alerts when supine sleep is detected. Sleep metrics will be visible on the smartphone app.
45845562|NCT04179552|Device|PAAG-OA|Intra-articular injection with PAAG-OA (polyacrylamide hydrogel)
45847737|NCT02907918|Procedure|Blood for detection of circulating tumor cells|Baseline
46049929|NCT04305938|Diagnostic Test|Minimally invasive and non-invasive blood analyte measurement|Rapid point-of-care minimally invasive blood analyzer consisting of a spectrometer and a computer loaded with Kaligia software that controls the data acquisition and signal processing to interpret blood analyte measurement.
46049930|NCT04259580|Procedure|Endoscopic retrograde pancreatography (ERCP)|Endoscopic procedure to access biliary and/or pancreatic structures
45689570|NCT00438880|Biological|Rituximab|Given IV
45689571|NCT00438880|Procedure|Single Photon Emission Computed Tomography|Undergo imaging scans
45689572|NCT00438880|Radiation|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
46049931|NCT00609570|Dietary Supplement|NanoGreens|fruits and vegetables
46049932|NCT00609570|Dietary Supplement|Whey protein|Whey
46049933|NCT00609570|Dietary Supplement|Calcium pills|CA
46049934|NCT00863746|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
45363049|NCT00853424|Procedure|islet cell transplant|Human pancreases are retrieved from multiorgan donors and processed with intraductal collagenase perfusion, continuous digestion, and density gradient purification with impure tissue fractions cultured in vitro and then repurified to retrieve additional islets. Islets are implanted by ultrasound guided percutaneous portal embolization, to provide more than 12, 000 islet equivalents (IE) per kilogram of body weight (infusions from 1-3 donors per patient) Immunosuppression consists of antithymocyte globulin, basiliximab, mycophenolate mofetil and tacrolimus as described (Warnock et al Arch Surg 2005;140:735).
45845563|NCT04176510|Behavioral|Health Coach Intervention|A structured, manualized coaching intervention by a lay Health Coach that employs a standardized positive affect/self-affirmation intervention, not tied to specific chronic diseases, to help motivate patients to learn to implement self-management by setting life goals.
45363050|NCT00853424|Other|Medical therapy|subjects receive all recommended medical treatment for diabetes and diabetic eye disease
45480523|NCT03787433|Device|ARC - Assisted Rehabilitation Care|"ARC is a platform based on wearable inertial sensors and machine learning algorithms, designed to bring the rehabilitation at post-stroke patients' home, following hospital discharge.~The product has been created with the purpose to improve physical skills and patient independence accordingly, in the six months following the acute event. ARC aims to optimize, ease and make more accessible the path of post-stroke rehabilitation during post-acute phase, in real life settings."
45480524|NCT01337856|Other|Hand hygiene protocol|Comparison of efficacy of 3 hand hygiene protocols
45480525|NCT01307657|Other|high fat meal|Clopidogrel 600 mg loading dose at 8 am and high-fat meal at 12 pm
45480526|NCT01337934|Drug|Lactated Ringer|Lactated Ringer
45480527|NCT01337934|Drug|Albumin|Albumin 4%
45480528|NCT03786887|Drug|Nalbuphine|dosage of nalbuphine
45480529|NCT03787043|Drug|FDC(MP-513 10mg/Metformin XR 750mg)|
45480530|NCT00090168|Drug|MK0653A , ezetimibe (+) simvastatin|
45480531|NCT00090168|Drug|Comparator: atorvastatin|
45845564|NCT04143204|Other|Oral nutritional intake|The exposure are oral nutritional intake and all nutritional intake during early life (28 days), and insulin-like growth factor 1, leptin, Ghrelin, and C-peptide in serum at corrected age 40 gestational weeks.
45845565|NCT04106154|Behavioral|Kinesiology Support|12 week physical activity group led by Kinesiologist. The intervention will be used to increase confidence in the participants by providing physical activity education and a variety of activities.
46049935|NCT00863746|Drug|Placebo|Placebo - 2 tablets twice daily (BID)
46049936|NCT04259814|Behavioral|Speech-language therapy (SLT)|Age-appropriate play activities with speech-language pathologist (SLP) to elicit speech, using stimulation strategies including but not limited to recasts, expansion, parallel talk, interactive modeling, communication temptations, and phrase completions. Activities will include an age-appropriate story, pretend play (i.e., house with people, playing with a baby doll), an assembly task (i.e., building blocks, making pretend pizza), and a highly motivating, clinician-controlled activity (i.e., blowing bubbles, swing, pushing cars down a ramp).
46049937|NCT04259814|Behavioral|Modified constraint-induced movement therapy (mCIMT)|Participants will wear a removable cast and an occupational therapist will be present during therapy to focus on facilitating play with the affected arm.
45480532|NCT00090168|Drug|Duration of Treatment: 6 weeks|
45480533|NCT03786809|Drug|Cimifuga Racemosa|Experimental group will use 160mg of Cimifuga Racemosa for 28 days
45480534|NCT03786809|Drug|Placebo|patients of the placebo group will use placebo once a day for 28 days
45480535|NCT01332786|Drug|Tigecycline|"Dosage Form: one-hour intravenous infusion Dosage levels, frequency, duration: (3-week cycles)~Level 1: 50 mg daily x 10 doses; 1 week rest~Level 2: 100 mg daily x 10 doses; 1 week rest~Level 3: 150 mg daily x 10 doses; 1 week rest~Level 4: 200 mg daily x 10 doses 1 week rest~Level 5: 250 mg daily x 10 doses; 1 week rest~Level 6: 300 mg daily x 10 doses; 1 week rest~Level 7: 350 mg daily x 10 doses; 1 week rest"
45480536|NCT03786731|Behavioral|Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy.
45480537|NCT03160560|Drug|ClōSYS® Unflavored Rinse|Subjects in Test group will receive ClōSYS® Unflavored Rinse.
45480538|NCT03160560|Drug|ClōSYS® Flavored Rinse|Subjects in Test group will receive ClōSYS® Flavored Rinse.
45480539|NCT03160560|Other|Placebo|Subjects in Placebo group will receive Placebo Rinse.
45480540|NCT05694377|Behavioral|electroencephalography-based neurofeedback (EEG-NFB)|The EEG-NFB training program will involve nine training sessions (three times a week over a 3-week period) each lasting 30 min. EEG-NFB training will be conducted with ProComp Infiniti Encoder and BioGraph Infiniti Software v.5.1.3. The training protocol will be set to decrease the EEG TBR value. For the 12 training sessions, all participants will be subjected the same EEG-NFB protocol at C3 electrode. The EEG-NFB training sessions consists of a 20-s baseline period (i.e., with no feedback), 30-min feedback presentation, and another 20-s baseline period. Subjects will be seated in front of a computer screen and animations will be used as feedback; the animation starts when the subject is sufficiently focused for 20 s. Three 10-min animations (flying duck, roller coaster ride, and moving ball) will be shown to the subject during each EEG-NFB training session. The raw EEG signal, TBR value over time, EEG signal noise, and EEG theta and beta wave amplitudes will be recorded.
45480541|NCT03786575|Diagnostic Test|Next Generation Sequencing (NGS) detection|The NGS detection panel is designed by our team and covers genes that are clinically useful and have definite guiding significance for endocrine therapy
45480542|NCT03489343|Drug|Sym023|Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
45480543|NCT01338090|Drug|89Zr-bevacizumab|Intravenous injection 120 MBq
45480544|NCT01338090|Drug|Everolimus|Oral use, 10 mg per day
45480545|NCT01307969|Drug|Ropivacaine|1,8 mL of the local anesthetic formulations were injected at the apex of the maxillary right canine.
45480546|NCT01332864|Procedure|Osteopathic Manipulative Treatment (OMT)|O OMT applied to areas of somatic dysfunction other than the head region.
45480547|NCT01332864|Procedure|Light touch|Light touch applied to head region for 10 minutes with patient supine at rest.
45363051|NCT00853502|Drug|testosterone cypionate|dose dependent on pubertal stage, intramuscular injection once every 3 weeks for 12 months
45363052|NCT00853736|Drug|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose with food
45480548|NCT03786419|Drug|Atezolizumab|Participants will be given 1200 mg of Atezolizumab as single agent by IV infusion every 21 days. First infusion will be over 60 min. Subsequent Atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity
45480549|NCT01338324|Drug|Simvastatin|Simvastatin 20 mg single dose on day 1
45480550|NCT01335984|Procedure|Telemonitoring|"The subjects who are assigned in the Telemonitoring group will be provided Blood Pressure monitor, body composition analyzer, and remote monitoring device.~The subjects who are assigned in the Telemonitoring group should visit the site once per every 2 months (8 weeks), and they should measure their blood pressure using a provided blood pressure monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood pressure and body composition, the subjects should make the transmission terminals of remote monitoring device situate near transmission terminal of Smart Care PC and transmit measured information through Smart Care PC into a centralized server of Smart Care Center."
45689573|NCT00462124|Device|Absorbable perirectal spacer|biodegradable balloon implant to increase the distance between prostate and anterior rectal wall
45689574|NCT00378352|Drug|Epoetin alfa|Randomized
45689575|NCT00462280|Drug|lovastatin|Given PO
45689576|NCT00462280|Other|placebo|Given PO
45689577|NCT00462280|Procedure|biopsy|Correlative studies
45689578|NCT00462280|Procedure|laboratory biomarker analysis|Correlative studies
45689579|NCT00381004|Drug|Cyclophosphamide|Course 1: 250 mg/m^2 by vein over 5-30 minutes on Days 2, 3, and 4; Course 2 - 6: 250 mg/m^2 by vein over 5-30 minutes on Days 1 - 3
46049938|NCT05330910|Procedure|Laparoscopic sleeve gastrectomy with concomitant hiatal hernia repair arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after. A hiatal dissection will also be performed during initial surgery, followed by a cruroplasty with Ethibon 0 sutures, in an interrupted manner.
46049939|NCT05330910|Procedure|Laparoscopic sleeve gastrectomy arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after.
45363053|NCT00853736|Drug|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose with food
45363054|NCT00857168|Drug|Testosterone MD-Lotion|
45689580|NCT00381004|Drug|Fludarabine|Course 1: 25 mg/m^2 by vein over 5-30 minutes on Days 2,3, and 4; Course 2 - 6: 25 mg/m^2 by vein over 5-30 minutes on Days 1 - 3
45689581|NCT00381004|Drug|Sargramostim|Course 1: 250 mcg/m^2 subcutaneous (SQ) on Days -1 and Days 5 - 11; Course 2 - 6: 250 mcg/m^2 SQ on Days -1 and Days 4 - 10
45689582|NCT00381004|Drug|Rituximab|Course 1: 375 mg/m^2 by vein over 2-6 Hours on Day 1; Course 2 - 6: 500 mg/m^2 by vein over 2-6 Hours on Day 1
45689583|NCT00440050|Drug|DHA (Docosahexaenoic Acid)|950 mg soft-gel capsules which contain approximately 510 mg DHA, 2 capsules twice a day for 18 months
45689584|NCT00440050|Drug|Placebo|2 placebo capsules twice a day for 18 months
45689585|NCT00440596|Behavioral|Mindfulness based stress reduction|8 weeks group MBSR
46049940|NCT04992156|Drug|Palbociclib|Palbociclib 125mg/d
45363055|NCT00857324|Drug|Vorinostat|"Patients will start induction treatment with a standard dose of MP and escalating doses of Vorinostat:~Melphalan 0.18 mg/Kg for 4 days; Prednisone 1.5 mg/Kg for 4 days. Each cycle will be repeated every 28 days for a total of 6 courses~In the first part of the study, the standard oral MP will be combined with escalating doses of Vorinostat.~Level -1 Vorinostat = 100 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level 0 Vorinostat = 200 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +1 Vorinostat = 300 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +2 Vorinostat = 400 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4"
45689586|NCT00440596|Behavioral|Progressive Muscle Relaxation|8 weeks PMR in group format
45689587|NCT00381550|Drug|fludarabine phosphate|Given IV
45689588|NCT00381550|Drug|triapine|Given IV
45689589|NCT00381550|Procedure|laboratory biomarker analysis|Correlative study
45363056|NCT04043078|Other|Exercise|The exercise regime will include daily upper limb aerobic (hand bike) and inspiratory muscle training (POWERbreathe) and upper body strength training every second day until discharge.
45363057|NCT00857402|Dietary Supplement|Peanuts|30g of peanuts daily for 4 weeks (directly observed). This dose of peanuts is equivalent to 1 gram of arginine.
45363058|NCT00857402|Dietary Supplement|Daboqolo|30g of Daboqolo per os daily for 4 weeks (given supervised). 30g of Daboqolo is equivalent to 0.1 g of arginine.
45689590|NCT00440830|Drug|nicotine patch|nicotine patch (0,5,10 or 15mg/day) applied to smokers
45689591|NCT00440830|Drug|nicotine patch|nicotine patch (0,5,10,or 15mg/day) applied to nonsmokers
45480551|NCT01335984|Procedure|Telemonitoring & Telemedicine|"The subjects who are assigned in the Telemonitoring & Telemedicine group should perform the same remote monitoring procedures as the subjects in the Telemonitoring group.~Since the remote visit substitute for a face to face visit, subjects should reserve the time for remote visit in each clinical trial center. A primary doctor or remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring device and then issue electronic prescriptions."
45480552|NCT01335984|Other|control group|"- The subjects who are assigned in the control group will be provided blood Pressure Monitor (Self BP measuring).~The subjects who are assigned in the control group should perform the same blood pressure measurement (2 times a day) same as the test group during the study, and measured results should be recorded in a diary of self blood pressure measurement. In addition, the subjects should visit the site once per every two months (8 weeks)."
45480553|NCT03489109|Behavioral|Intermittent fasting|Subject will consume approximately 25% of their daily calories for 2 days per week. The other 5 days they will eat their normal diet
46049941|NCT04259268|Other|Quality of preoperative information register|Register of principal (grade ASA classification) and secondary variables (allergies, antiplatelet or blood thinners prescriptions, cardiovascular diseases, present medication)
46049942|NCT04259268|Other|Suitability of information contained in the informed consent|Register of information regarding specific individual risks and personal data (patient and doctor identification and signature)
46049943|NCT00608946|Dietary Supplement|copper|intake of copper orotate 8 mg per day per os, once daily for one year, vs. placebo under observation of the cognitive status
46049944|NCT00608946|Dietary Supplement|placebo|placebo
46049945|NCT02613832|Other|EPAP|The EPAP will be applied with a Spring Load Valve Resistor (Vital Signs, Totowa, NJ, USA), adjusted with a pressure of 10 cmH2O. The Spring Load Valve Resistor will be connected to the expiratory branch of the T-tube. Duration of intervention: 5 minutes.
46049946|NCT02613832|Other|Breath Stacking|The BS will be performed by a T-tube with a one-way inspiratory valve and the expiratory branch occluded. The expiratory occlusion is maintain until observed the presence of a plateau in the impedance plethysmogram by EIT, which corresponds to the absence of inspired air displacement or when a maximum time of 40 seconds was attained. Durantion of intervention:Three BS interventions will be performed at one minute intervals between them.
45363059|NCT00853814|Behavioral|Access to sedentary behaviors|Access to sedentary behaviors: Reduced access - reduce access to sedentary behaviors by 50% using TV Allowance technology. Usual access - monitoring only, no change in access to sedentary behaviors. Access to neighborhood parks: High access - large amount of park land very near to the child's home. Low access - little to no park land near the child's home.
45363060|NCT00853892|Drug|Controlled-Release Oxycodone Hydrochloride 40 mg tablet|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose fasting
45363061|NCT00853892|Drug|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose fasting
45363062|NCT02546336|Device|Ultrasound-Guided Cooled Radiofrequency Hip Denervation|Light neuroleptic anesthesia and skin preparation will be performed. Under Ultrasound guidance, an active probe will be inserted. Sensory and motor stimulation will be administered. Anteroposterior fluoroscopy image will be recorded. Lesioning of articular branches of femoral and obturator nerves via radiofrequency will be performed after lidocaine injection. WOMAC, EQ-5D and SF-12 questionnaires will be used for measuring outcomes postoperatively.
45845566|NCT04031508|Combination Product|lipid injectable emulsion with Fish oil|TPN will start at 2.0 g/kg/d of the lipid emulsion, increasing 1.0 g/kg/d until a maximum of 4.0 g/kg/d for at least 14 days.
45363063|NCT04164212|Drug|Flumist Quadrivalent Nasal Product|FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
45363064|NCT00854126|Drug|GDC-0980|Escalating repeating dose
45363065|NCT00857480|Drug|NRL972|Single intravenous administration of 2 mg NRL972
45363066|NCT00857480|Drug|NRL972|Pre-treatment and co-treatment with 1 g Cloxacillin t.i.d. for three days from the morning of D-3 until the morning of Day D01 0:30 hour before the intravenous administration of NRL972.
45363067|NCT00857480|Drug|NRL972|Three week pre-treatment with daily doses of 500 mg b.i.d ursodeoxycholic acid from the morning of D-20 until the evening of Day D-1
45480554|NCT03489109|Other|Standard of Care|Subject will receive standard of care recommendations for healthy diet and lifestyle
45689592|NCT00440830|Drug|placebo|placebo patch applied to smokers
45363068|NCT00857558|Drug|saxagliptin|orally administration at 1 mg once a day for 12 weeks
45363069|NCT00857558|Drug|saxagliptin|orally administration at 2.5 mg once a day for 12 weeks
45363070|NCT00857558|Drug|saxagliptin|orally administration at 5 mg once a day for 12 weeks
45363071|NCT00857558|Drug|placebo|orally administration once a day for 12 weeks
45689593|NCT00440830|Drug|placebo|placebo patch applied to nonsmokers
45689594|NCT00464464|Behavioral|cognitive-behavioral therapy|The therapy will consist of 10 weekly individual cognitive-behavioral treatment sessions, lasting 1 hour each and modified to meet the unique needs of each individual with PD.
45689595|NCT00381628|Procedure|epithelial cells and blood lymphocyte extraction|Nasal curettage will be performed from each nostril to obtain nasal epithelial cells. Venipuncture will be performed and up to 60-ml of blood will be obtained from which neutrophils will be isolated.
45689596|NCT00427804|Drug|calcitriol|0.25 mcg PO BID for 1 week for low dose then 0.25 mcg PO BID for high dose
45689597|NCT00381862|Drug|aprepitant|Aprepitant 125 mg by mouth (PO) on day 1 and 80 mg PO on days 2 and 3 of each chemotherapy cycle
45480555|NCT01336062|Drug|Nanoparticle Albumin-Bound Paclitaxel|this study evaluate 3 dose level of nab-paclitaxel:100 mg /m2;125 mg /m2;80 mg /m2;
45363072|NCT00857636|Behavioral|Health literacy, health message|The intervention will consist of three main components: (1) 2-hour in-class health literacy-focused education; (2) tailored telephone counseling; and (3) healthcare system navigation assistance tailored to the woman's specific barriers.
45480556|NCT05694221|Drug|Supaglutide injection|Administered subcutaneously in the Supaglutide arms
45480557|NCT05694221|Drug|Digoxin|Digoxin
45480558|NCT05694221|Drug|Metformin|Metformin
45480559|NCT03348150|Procedure|Cytoreductive surgery + Gastrecomy|Complete cytoreduction followed by a (sub)total gastric resection with D2 lymphadenectomy.
45480560|NCT03348150|Drug|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HIPEC: perfusion with oxaliplatin (460mg/m2 ) (42 °C) followed by docetaxel (50mg/m2 ) (37°C)
45363073|NCT00718523|Drug|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
45480561|NCT03786341|Device|with auxiliary illuminator|Ambulation training with laser quad-cane for 15 minutes and typical physical therapy with strengthening and balance training for 15 minutes.
45480562|NCT03718819|Other|exercise|Pilates and aquaplyometric exercises will be done combinedly.
45480563|NCT01338402|Device|Lotrafilcon B contact lens|Silicone hydrogel contact lens
45480564|NCT01338402|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
45480565|NCT01338402|Device|Phemfilcon A contact lens with color|Hydrogel contact lens with color
45480566|NCT01308047|Drug|Bupivacaine|single dose of 15mg by a slow injection rate of 1 ml/s
45480567|NCT03716479|Other|Low Fiber|20 g of acacia gum will be added to orange juice
45480568|NCT03716479|Other|High Fiber|40 g of acacia gum will be added to orange juice
45480569|NCT03716479|Other|Placebo/Control|No acacia gum will be added to orange juice.
46049947|NCT00609648|Behavioral|Computer Assisted Relaxation Learning|A self-paced computer program for reducing dental injection fear.
46049948|NCT00609648|Behavioral|Pamphlet|A pamphlet reassuring patients about dental injections.
45480570|NCT05186142|Other|Ultrasonography / Ultrasound elastography|Ultrasonography / Ultrasound elastography
45480571|NCT05694143|Other|Education Intervention|"This intervention is based on the Health Belief Model Theory, which examines the attitudes and beliefs of adolescents with enhanced knowledge and perceived disease risk. As a result, It aims to build on adolescents' skills and behaviours rather than increase their knowledge, beliefs, and relative skills. In order to develop the education program, health promotion experts with a special interest in changing obesity-related behaviours will assist the researcher.~The intervention is specifically designed to help adolescents:~To know facts, statistics and harmful effects of obesity and overweight.~To know facts about physical activity and its importance.~To know facts about a healthy diet and its importance.~Definition of BMI and calculating the BMI.~To read the Nutrition Facts label.~To develop decision-making and self-care education."
45480572|NCT05694143|Other|No Intervention|They will have their regular curriculums and normal physical activity routine
45363074|NCT00718523|Drug|AMG 479 Placebo|Matching placebo administered Day 1 of each 21 day cycle.
45480573|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of placebo tablet matched to the molidustat dose (BAY85-3934) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
45480574|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 5 mg of molidustat IR tablet on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
45480575|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 10 mg of molidustat ( 2x 5mg IR tablets) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
45480576|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 25 mg of molidustat (1 x 20 mg IR tablet and 1 x 5 mg IR tablet) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
45480577|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 50 mg) of molidustat (2 x 20 mg IR tablets and 2 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
45480578|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 75 mg of molidustat (3 x 20 mg IR tablets and 3 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
45480579|NCT01308125|Procedure|PICSO|"Baseline (hemodynamic) measurement~Intra coronary~Blood sampling~LAD occlusion: for 3 min or until pain with and without PICSO~Break recovery: the patient can recover from pain for 3 min~CFIp: by a ComboWire advanced in the center lumen of an occlusion balloon.~PICSO: start automatically and continued for 10 min.~PCI/PICSO: concomitantly for the whole duration of the PCI intervention.~24h Follow up: additional blood samples every 6 hours (4 times)~30 days follow up."
46049949|NCT02616016|Device|MRI Guided High Intensity Focused Ultrasound|Target treatment of bone metastases using High Intensity Focused Ultrasound
46049950|NCT00609102|Drug|Placebo|one capsule BID
46049951|NCT00609102|Drug|n-aceylcysteine|450 mgm BID
46049952|NCT02620228|Device|BIP Biopsy System|BIP Biopsy system is essentially similar as traditional biopsy systems but it enables real-time bioimpedance measurement from the tip of the biopsy needle.
46049953|NCT04259502|Procedure|Rhomboid intercostal block|The block is regional anesthesia injection techniques performed under ultrasound guidance.
45480580|NCT03785951|Dietary Supplement|Whey Protein Isolate|"Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake."
45480581|NCT03785951|Dietary Supplement|Wheat Protein|"Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake."
45480582|NCT03785951|Dietary Supplement|Wheat Protein with Leucine|"Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate.~50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks."
45480583|NCT03777449|Radiation|CBCT|Patients will be taken a CBCT as a diagnostic tool to monitor peri-implant bone loss. This is a tool used on the daily basis for the evaluation of peri-implant bone loss. Patient will not be exposed to further radiation but the regular one.
45480584|NCT03777605|Drug|Nitroglycerin 0.4 MG|"The study evaluate absorption rate of nitroglycerine 0.4 milligrams as tablets or a quickly absorbable capsuel NTG1523 determined by T-max and area under the response curve in the blood of NTG as well as from clinical effects.~Data is entered on data sheet in anonymous form and processed. The results are presented in anonymous form by publication and lecture. Experts are given the supplement: The applicant's rights in a biomedical research project"
45480585|NCT03777761|Drug|tucatinib|300mg oral dose
45480586|NCT03777761|Drug|placebo|Matching placebo for tucatinib
45480587|NCT03777761|Drug|moxifloxacin|400mg single oral dose
45480588|NCT05185908|Procedure|Measurement of the optic nerve sheath diameter by ultrasound-guidance.|Measurement of the optic nerve sheath diameter (ONSD) by ultrasound guidance can be used in the diagnosis of increased ICP. The investigators interrogated the effects of lateral 45° downward position and CO2 insufflation on ONSD in patients undergoing laparoscopic transperitoneal nephrectomy.
45480589|NCT01316861|Drug|EMS Acarbose|EMS Acarbose 50 mg 3 times a day
45480590|NCT01316861|Drug|Bayer Acarbose|Bayer Acarbose 50 mg 3 times a day
45480591|NCT01338480|Other|video|The videos will be developed and contain information on the procedure, risks, benefits, and alternatives of the surgery. The knowledge measure instrument will also be developed.
45480592|NCT03777293|Device|ultrasound viscoelasticity|use these devices to do ultrasound examination in chronic liver disease patients
45480593|NCT01336218|Drug|fostamatinib|oral tablets, 150mg (3 X 50mg) single dose per period
45480594|NCT01336218|Drug|rifampicin|oral tablets, 600mg (2 X 300mg) 8 doses over 8 days
45480595|NCT03776981|Other|Core Activation|Volitional activation of the transversus abdominis muscle during self-selected paced ambulation for both groups.
45480596|NCT03776981|Other|Core Stabilization|Six-week core stabilization program for the group of participants with knee osteoarthritis.
45480597|NCT03776903|Other|ZIKV Detect™ 2.0 IgM Capture ELISA|De-identified archive specimens are tested by ELISA and compared to reference testing (RT-PCR and CDC MAC-ELISA)
45845567|NCT03977922|Other|Diet group|The diet group will be involved in a 12-week pilot nutrition program that will be based on the anti-inflammatory diet previously studied by Allison and Ditor (2015).
45845568|NCT03971136|Diagnostic Test|pulmonary ultrasound|The subjects will have an ultrasound on admission and on day 1, 2 and 3
45480598|NCT05115461|Device|Biodex Balance System™ SD|Postural stability index values (anteroposterior, mediolateral and overall) will be measured for static and dynamic conditions.
46049954|NCT04259502|Procedure|Erector spinae plane block|The block is regional anesthesia injection techniques performed under ultrasound guidance.
46049955|NCT02615938|Drug|Hydroxychloroquine sulfate|Apply drug to modify lysosomal pH
46049956|NCT02615938|Other|Placebo|Apply Placebo not to modify lysosomal pH
45480599|NCT05115461|Other|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
45689598|NCT00381862|Drug|dexamethasone|Dexamethasone 12 mg PO on 1st day of study drug and 8 mg PO on days 2-4
45845569|NCT03946332|Behavioral|Physical exercises|patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization.
46049957|NCT00926328|Drug|Triclosan, fluoride|Six Month study, brush twice daily
45689599|NCT00381862|Drug|fluorouracil|as per institutional standard of care
45689600|NCT00381862|Drug|irinotecan hydrochloride|as per institutional standard of care
45689601|NCT00381862|Drug|leucovorin calcium|as per institutional standard of care
45689602|NCT00381862|Drug|oxaliplatin|as per institutional standard of care
45689603|NCT00381862|Drug|palonosetron hydrochloride|Palonosetron 0.25 mg IV push on day 1 only.
45689604|NCT00381862|Procedure|quality-of-life assessment|baseline
46049958|NCT00926328|Drug|Fluoride|twice daily usage
46049959|NCT04203732|Procedure|Anesthesia Type|The anesthetic type either general anesthesia or neuraxial anesthesia is the intervention type for patients undergoing primary total joint arthroplasty of the knee or hip.
46049960|NCT00863512|Drug|cisplatin|Given IV
45480600|NCT05110157|Drug|Placebo|Oral capsules
45480601|NCT05110157|Drug|Valbenazine|Oral capsules
45480602|NCT01318031|Drug|Period 1|Subjects will receive a single 45 mg dose of PF-00299804 on Day 1 of Period 1.
45480603|NCT01318031|Drug|Period 2|Subjects will receive a single 30 mg tablet of paroxetine once daily for 3 days (Days 1 to 3). Then, subjects will be co-administered a 45 mg single dose of PF-00299804 plus a single dose of 30 mg paroxetine on Day 4. Single 30 mg doses of paroxetine will be administered once daily for 6 days (Days 5-10).
45480604|NCT03776825|Device|Permacol Paste|Permacol Paste Injection
45480605|NCT03776747|Drug|Prone hyperpolarized 3 helium gas scan|Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is prone.
45480606|NCT03776747|Drug|Supine hyperpolarized 3 helium gas scan|Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is supine.
45480607|NCT03776747|Diagnostic Test|Vitals|
45480608|NCT03776747|Diagnostic Test|Pulmonary Function Tests|Pre and post spirometry, diffuse lung carbon monoxide (DLCO), lung volumes
45480609|NCT03776747|Diagnostic Test|Initial protocol MRI scan|Initial scan to determine placement
45480610|NCT03776591|Procedure|Open surgery|
45480611|NCT03776591|Procedure|Right colectomy|
45480612|NCT03776591|Procedure|Laparoscopic surgery|
45845570|NCT03946332|Behavioral|Optional physical exercises|patients will be proposed for the physical exercises and will practice them if they want.
46049961|NCT00863512|Drug|docetaxel|Given IV
45480613|NCT03776591|Procedure|Central lymphadenectomy and vascular ligation|
45845571|NCT03920982|Diagnostic Test|Determination of the blood concentration of indoxyl sulfate (IS)|IS concentration will be determined in blood of patients with septic shock and acute kidney injury. IS blood concentration will be done every day during 7 first days after patient will be admitted in intensive care unit. Relation between IS peak serum concentration and mortality at day 28 will be determined.
45845572|NCT03904914|Other|TOCI|TOCI staging evaluated
45363075|NCT02590367|Drug|FOLFOX regimen|"FOLFOX regimens are combination therapy of oxaliplatin (85 mg/m^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (different dose like FOLFOX4/FOLFOX6) via ambulatory pump administered for a period of 46 to 48 hours.~XELOX is a combination therapy of Oxaliplatin 130mg/ m^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m^2 bid, days 1-14, every 3 weeks."
45363076|NCT02590367|Drug|HD6610 Granule|the HD6610 Granule will be given 2 times a day.
45363077|NCT02590367|Drug|HD6610 Granule placebo|the HD6610 Granule placebo will be given 2 times a day.
45363078|NCT02590913|Dietary Supplement|fructose|75g fructose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
45480614|NCT05097833|Behavioral|Enhanced Saint Francis Fatherhood FIRE Program|Fathers receive an enhanced series of pro-parenting, relationship, and economic stability workshops over 16 weeks. Workshop series are based on a diverse curricula including a combination of either 24/7 Dad or Parent Project and Connections to Success and the Nurturing Fathers enhancement program.
45480615|NCT05097833|Behavioral|Services as Usual Saint Francis Fatherhood FIRE Program|Fathers receive the services as usual approach which includes a series of pro-parenting, relationship, and economic stability workshops over 13 weeks. Workshop series are based on a diverse curricula including a combination of either 24/7 Dad or Parent Project and Connections to Success.
45480616|NCT05038553|Other|No intervention|No intervention
45480617|NCT05029115|Drug|SGLT2 inhibitor|Dapagliflozin, Empagliflozin
45480618|NCT01319123|Device|Drawtex dressing|The dressing is indicated for moderately to heavily exuding wounds such as venous leg ulcers
45480619|NCT03776435|Radiation|Abdomen CT|Patients are divided into CT-exposed or unexposed group according to the presence of claims codes of abdominopelvic CT conducted within seven days before and after appendectomy. The seven-day threshold is arbitrarily determined considering the delay in the diagnosis of appendicitis and the postoperative examination for surgical complication.
45480620|NCT03776513|Behavioral|an MRI examination|The MRI examination implies the realization of an emotional associative memory task
45845573|NCT03886740|Procedure|Reducing symptoms of Eustachian tube dysfunction|One of two methods of reducing Eustachian Tube dysfunction will be performed and the Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) scores will be compared
45847738|NCT02908620|Combination Product|One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
46049962|NCT00863512|Drug|gemcitabine hydrochloride|Given IV
46049963|NCT00863512|Drug|pemetrexed disodium|Given IV
46049964|NCT00863512|Drug|vinorelbine tartrate|Given IV
46049965|NCT00863512|Procedure|standard follow-up care|Standard care
46049966|NCT04261920|Drug|Huangqi Guizhi Wuwu decoction|"The experimental group took Huangqi Guizhi Wuwu decoction twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles).~The control group took placebo twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles)."
45480621|NCT03776279|Drug|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 60min in 250 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks.
45480622|NCT03776045|Other|Standard care plus exercise|The exercise was supervised by exercise science staff in the exercise science facilities at the University of East Anglia, UK. Participants competed two weekly sessions for 12 weeks upon initiating ADT. Each session lasted ~60 min and included aerobic interval exercise on a cycle ergometer (Monark 824E; Varberg, Sweden) followed by resistance training. In addition to the supervised exercise sessions, patients were advised on how to increase their habitual physical activity levels and were encouraged to engage in 30 minutes of self-directed exercise on three days each week (e.g. brisk walking, cycling, home-based resistance training).
45480623|NCT03709823|Drug|Cytisine|film coated tablet containing 1.5 mg cytisine in a single tablet
45480624|NCT03709823|Drug|Placebo Comparator|1.5 mg cellulose powder to match final weight of the cytisine tablet
45480625|NCT03709823|Behavioral|Behavioral support|12 behavioral support sessions by a qualified staff member plus supportive literature and online resources
45480626|NCT03488563|Biological|B244|B244 Suspension
45480627|NCT03488563|Biological|Vehicle|Vehicle Suspension
45480628|NCT03775889|Behavioral|Gardening|Assist with planting and maintaining the school garden, as well as observe the school garden curriculum and dietary assessment protocols
45845574|NCT03876288|Device|GI Neuromodulation|The investigators would include follow up with: No treatment; temp GES only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
45847739|NCT02908620|Drug|One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
46049967|NCT05330832|Diagnostic Test|Thrombodynamics test|Thrombodynamics test is a global hemostasis test that allows to register the dynamics of fibrin clot formation in time and space. It requires whole blood samples from included patients.
46049968|NCT02619994|Drug|Linezolid|
45363079|NCT02590913|Dietary Supplement|glucose|75g glucose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
45363080|NCT02589743|Device|Sealant|Application of preventive agent
45363081|NCT02589743|Device|Adhesive and Sealant|Application of preventive agent and technique for control moisture
46049969|NCT02619994|Drug|Delamanid|
46049970|NCT02619994|Drug|Levofloxacin|
46049971|NCT02619994|Drug|Pyrazinamide|
46049972|NCT02619994|Drug|Locally-used WHO-approved MDR-TB regimen in Korea|
46049973|NCT04263402|Drug|Methylprednisolone|Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(<40mg/d intravenous drip for 7 days).
46049974|NCT04263402|Drug|Methylprednisolone|Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40~80mg/d intravenous drip for 7 days).
45363082|NCT00715559|Drug|cysteamine bitartrate|All enrolled participants will begin open treatment with cysteamine on the first visit of the experimental period (after screening, medical clearance and medication washout period if necessary). The dosing schedule is a flexible regimen starting at 150 mg PO three times daily. After one week, patients without intolerable side effects will increase the dose to 300 mg three times daily. The titration schedule will continue up to a maximum of 1800 mg a day. In case of adverse events, the investigator may decrease the dose by 150 mg daily.
45363083|NCT05289869|Drug|High-dose oxytocin|Starting dose 6 mU/min and increased by 6 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
45480629|NCT01561391|Drug|activated recombinant human factor VII|Infused continuously at 50 mcg/kg/hr through Day 5 then at 25 mcg/kg/hr on Days 6 to10.
45480630|NCT01561391|Drug|activated recombinant human factor VII|Injected every 2 hours during surgery through Day 5, then every 4 hours for Days 6 to 10.
45480631|NCT01561391|Other|factor IX|Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
45480632|NCT01561391|Drug|factor VIII|Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
45480633|NCT03718741|Radiation|Radiotherapy +/- CT|Adiuvant Radiotherapy +/- weekly cisplatin
45480634|NCT03775655|Drug|Dexmedetomidine|10μg dexmedetomidine will be added to the injectate to be injected intrathecally
45480635|NCT03775733|Dietary Supplement|Hydrolysed Red Ginseng Extract|Hydrolysed Red Ginseng Extract 2.4g/day for 12 weeks.
45480636|NCT03775733|Dietary Supplement|Placebo|Placebo for 12 weeks.
45480637|NCT01320059|Drug|18F-PEG6-IPQA|Radioactive injection (PET imaging agent) given by vein before PET scans.
45480638|NCT01320059|Procedure|Positron emission tomography (PET)|3 PET scans performed after injection and positioning CT. Imaging should take about 3 hours.
45480639|NCT03775031|Device|Fractional Laser and Chemical Peel|Fractional 1927 nm Laser, Fractional 1550 nm Laser, and 25% TCA (trichloroacetic acid) peel
45480640|NCT03775499|Dietary Supplement|Intervention 1 : BL NCC 2705 + Maltodextrin|2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
46049975|NCT04261374|Diagnostic Test|Measurement of sublingual microcirculation|Measurement of sublingual microcirculation
46049976|NCT04124458|Device|Radiofrequency ablation|In radiofrequency ablation arm, sensory brunch of occipital nerve will be burn with max allowable temperature: 42 degrees Celsius, real temperature: 41 degrees Celsius, power=65 volts, two cycles of 180 second.
45480641|NCT03775499|Other|Intervention 1 : Maltodextrin|2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
45480642|NCT03775499|Dietary Supplement|Intervention 2 : BL NCC 2705 + Maltodextrin|2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
45480643|NCT03775499|Other|Intervention 2 : Maltodextrin|2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
45480644|NCT01310465|Drug|zoledronic acid|zoledronic acid, 5mg(100ml), intravenous, one time at three days postoperatively
45480645|NCT01310465|Drug|sodium chloride|sodium chloride, 100ml, intravenous, one time at three days postoperatively
45480646|NCT03782441|Device|Prototype 0.5|Investigational Medical Device collecting spectral Raman data from tissue
45480647|NCT03782285|Procedure|sacrospinous Ligament Fixation|sacrospinous ligament suspension (SSLF) as a typical native tissue repair procedure is one of the most widely used vaginal procedures for correcting apical prolapse. Ischial spinous fascia fixation (ISFF) will be the replacement procedure if SSLF will not be accomplished by conventional surgical instruments due to unsatisfactory exposure of spinous fascia.
45480648|NCT05470751|Device|Intermittent self-catheterisation|Self-catheterising with GC Air Male with Feelclean technology
45480649|NCT05457179|Behavioral|Park-based physical activity|The experimental arm will optimize a 12-week intervention 3 days/wk, last approximately 60 minutes, and consist of 10 minutes of warm up, 15 minutes of simple strength training activities, 25 minutes of moderate to vigorous aerobic activities (e.g., walking), and 10 minutes of cool down. The eight full-body strength training exercises will use body weight and/or elastic bands and will include a circuit of chest press, seated row, squat, shoulder press, biceps curl, triceps extension, calf raise, and reverse crunch. Sessions will include education and skill building activities focused on Social Cognitive Theory mechanisms of change including self-efficacy, goal setting, and social support. Under the guidance of trained research staff, certified peer specialists who have experience working with peer groups, will be selected to help deliver the intervention.
45480650|NCT05457179|Behavioral|Active Control|The active control group will receive information about the importance of park-based PA and a map of local park locations but will not participate in structured park-based PA sessions. Participants in the control group will be invited to participate in park PA sessions after they have completed posttest.
45480651|NCT03782129|Biological|blood samples|Blood samples drawn during hospitalisations when needed
45480652|NCT03782129|Other|Clinical exam and DFU medical cares|Clinical exam and DFU's medical cares at each visit (planned evry 1 to 3 months), during all the 5 years follow up, or until death.
45363084|NCT05289869|Drug|Low-dose oxytocin|Starting dose 2 mU/min and increased by 2 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
45363085|NCT00620282|Drug|liraglutide|Stepwise dose increase, s.c. (under the skin) injection, once daily
45480653|NCT03782051|Procedure|combined phacoemulsification and viscocanalostomy|phacoemulsification with viscocanalostomy
45480654|NCT03782051|Procedure|combined phacoemulsification and viscocanalostomy and ologen|phacoemulsification with viscocanalostomy with ologen
45480655|NCT03781895|Drug|Cholecalciferol|"• Cholecalciferol (40,000IU),~,Microcrystalline Cellulose (58.1 gm), Butylated Hydroxy Toluene ( 0.2mg),Magnesium Stearate (3mg),Gelatin Capsule Shell (1mg)"
45480656|NCT03781739|Drug|MANP|single subcutaneous injection of MANP and monitoring of metabolic, cardiovascular and renal parameters
45480657|NCT03781661|Other|Extended information|The extended information consists out of an information leaflet and a visual go-through of the participants calcium score images. The patients are then given the normal examination result.
45480658|NCT00706030|Drug|neratinib|
45480659|NCT00706030|Drug|vinorelbine|
45480660|NCT05515367|Drug|Desidustat|Oral tablet
45480661|NCT01561001|Device|SENSIMED Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours.
45480662|NCT05409599|Other|Exercises|Exercises
45845575|NCT03876288|Drug|Immunotherapy|The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
46049977|NCT04123834|Procedure|Patella tendon & bone block autograft + press-fit femoral technique|Implantless Arthroscopic ACL reconstruction using press-fit femoral technique The investigator's study uses the press-fit graft fixation technique by Edgar Michael. A midline skin incision was made that extends from inferior pole of patella up to anterior tibial tuberosity. Patella tendon with tibial tuberosity bone block were harvested, patella bone was left intact. The tendon was fixed together with non-absorbable suture.
45363086|NCT00620282|Drug|placebo|Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily
45480663|NCT02484040|Radiation|Two-week course of radiation|33 Gy in 10 fractions for 2 weeks
45480664|NCT02484040|Drug|Two-week course of radiation|oral capecitabine, 825mg/m2, bid
45480665|NCT01312883|Behavioral|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
45480666|NCT03781505|Drug|Paracetamol +caudal ropivacaine|Paracetamol + Ropivacaine
45363087|NCT00620282|Drug|glimepiride|Tablets, 1 - 4 mg daily
45363088|NCT05684861|Drug|Isotretinoin|systemic isotretinoin was given to all 90 patients , dose was prescribed according to weight for 3 months
45480667|NCT02483728|Other|Patch Test|Patch testing is a technique used to diagnose an allergic skin disease called allergic contact dermatitis. It attempts to reproduce in small scale allergic reactions of the skin from things that come in contact with it.This is the standard of care to determine allergic contact dermatitis.
45480668|NCT03781271|Device|Electromagnetic Navigation|Electromagnetic navigation is a form of surgical navigation that can be incorporated into the cervical interstitial brachytherapy workflow to improve the current standards of guidance.
45480669|NCT05384327|Other|Interview|Interviews consist of semi-structured interviews focused on the theoretical knowledge a physician should possess before placing chest tube insertions.
45480670|NCT05384327|Other|Multiple Choice Question (MCQ) Test|"The test contains multiple choice questions based on these interviews. Participants will complete this test.~Validity evidence will be collected based on the results of this test."
45480671|NCT03317470|Other|Basic needs survey|-11 questions about food security, housing personal safety, neighborhood safety, childcare, and transportation
45480672|NCT03317470|Behavioral|Life Navigator|"The life navigator will contact women identified with unmet basic needs within two business days of completing the baseline survey.~The life navigator in our study will: (1) identify and assess women's needs; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help women access available resources by scheduling appointments and provide appointment reminders; (8) prepare women to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly."
45480673|NCT03317470|Other|Follow-up survey|-5 questions about the acceptability of the basic needs survey
45480674|NCT03317470|Other|Follow-up survey (phase II participants only)|-7 questions about the effectiveness of the life navigator
45480675|NCT03781193|Other|Questionnaires administration|Psychological and quality of life questionnaires
45480676|NCT03781193|Other|Five Facet Mindfulness Questionnaire (FFMQ)|FFMQ is a 39-item measure consisting of five subscales (observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience).
46049978|NCT04123834|Procedure|Arthroscopic ACL reconstruction|Arthroscopic ACL reconstruction with implant (using hamstring autograft fixed with bioscrew and endo-button)
46049979|NCT04123834|Device|Hamstring tendon autograft + implant fixation|Arthroscopic ACL reconstruction with implant (using hamstring tendon autograft fixed with bioscrew and endo-button)
46049980|NCT05298280|Device|Pendulum appliance|In the PG, all patients received a pendulum appliance as described by Angelieri et al. The Nance button was anchored to the first and second premolars with removable wires. The 0.032-inch TMA wires were activated 45 degrees to produce a force of 200-250g per side. On average, intraoral reactivation of the distalizing springs was performed twice during the procedure. When a super Class I molar relationship was obtained, pendulum was replaced by a Nance holding arch. The average treatment duration was 8 months followed by bracket conventional therapy.
45480677|NCT03781193|Other|Langer Mindfulness Scale (LMS)|The LMS Tis a 21-item questionnaire, assessing four domains associated with mindful thinking: novelty-seeking, engagement, novelty producing, and flexibility.
45480678|NCT03781193|Other|Cognitive Flexibility Scale (CFS)|The CFS is 12-item self-report test assessing awareness.
45480679|NCT03781193|Other|Life Orientation Test (LOT)|The LOT is a 10-item, self-administered scale assessing generalized expectancies for positive versus negative outcomes.
45480680|NCT03781193|Other|Mini Locus of Control test (MLS)|The MLS is a 6-item questionnaire that includes 3 factors : chance, powerful others, and internality.
45480681|NCT03781193|Other|Hospital Anxiety and Depression Scale (HADS)|The HADS is a 14-items rated on a four-point Likert scale. The questionnaire was designed to screen for the presence and severity of depression (HADS-D) and anxiety (HADS-A) in people with a physical symptomatology
45480682|NCT03781193|Other|Perceived Stress Scale (PSS)|The PSS is 14-item self-report tool commonly used to provide a global measure of perceived stress in daily life.
45480683|NCT03781193|Other|Toronto Alexithymia Scale (TAS)|The TSA is a 20-item scale that evaluates the three components of alexithymia: difficulty to identify feelings and distinguish between feelings and bodily sensations of emotional arousal difficulty, describing feelings to others, and a cognitive style that is literal, utilitarian, and externally oriented.
45480684|NCT02488954|Other|Probiotics in the form of cheese portion|
45480685|NCT05380349|Drug|combinations of up to 3 FDA approved drugs from a panel of compounds|personalized drug combinations
45480686|NCT02489032|Behavioral|SBIRT Training & Support Tool|Program to train EAP/behavioral health practitioners in conducting alcohol SBIRT
45480687|NCT02489032|Other|Waitlist Control|3-month wait-list and then provided access to the SBIRT training program
45480688|NCT03320746|Device|Polar Loop 2 activity tracker|"The participants were instructed to aim to reach the daily activity goal, initially set at stage 1 as per the goals set by the trackers' manufacturer. The daily activity goal was based on user's typical daily activities, gender and age. The stage 1 daily activity goal corresponded to ~1h/day of jogging or ~2h/day of walking or ~7h/day household activities or a combination of these activities. The tracker gave an inactivity alert as a vibration and text it's time to move on the screen of the tracker if the user has been still for 55 minutes."
45480689|NCT03781349|Device|MENS|
45480690|NCT03781349|Device|TENS|
45480691|NCT02483338|Behavioral|Assessment of pain|Assessment of pain using FASS but without using this score to manage pain
45480692|NCT03781115|Drug|Ziprasidone|anti-psychotic drug proposed for use as rapid diagnostic tool
45480693|NCT03781115|Drug|Olanzapine|anti-psychotic drug proposed for use as rapid diagnostic tool
45480694|NCT03781115|Drug|Placebo Comparator|A non drug oral placebo capsule will be given as a control
45480695|NCT03317236|Drug|Quetiapine|A fixed 50 mg exteded release formulation.
45480696|NCT02488798|Procedure|2D grey scale vaginal ultrasound|To assess the endometrial thickness and echogenicity (whether the endometrium is uniform or non-uniform).
45845576|NCT03876288|Procedure|Pyloric Therapies|The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
45480697|NCT02488798|Procedure|3D power Doppler vaginal ultrasound|To assess the endometrium using the IETA group criteria.
45363089|NCT05684861|Diagnostic Test|ELISA Assays of Serum TWEAK.|: From each subject, 5mL of blood was collected into vacutainers before and after treatment with isotretinoin. The blood samples were centrifuged at 3000g for 10 min at a temperature of 4°C, then . Quantitative determinations for serum TWEAK were achieved using the corresponding commercially available ELISA kit supplied by the AssayMax
45480698|NCT02488798|Procedure|Office hysteroscopy|using the vaginoscopic approach to assess the uterine cavity and take sample.
45480699|NCT01313429|Drug|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
45480700|NCT01313429|Biological|Allogenic tumor Cell Vaccine (K562)|4 vaccines consisting of approximately 2.5E7 cells each will be delivered IM every 4 weeks for 6 months. If immune response is detected after first 6 vaccinations, 2 more may be given at 3 month intervals.
45480701|NCT01313429|Drug|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each vaccine cycle.
45480702|NCT03488251|Drug|MT-3724|MT-3724 will be administered.
45480703|NCT03488251|Drug|Gemcitabine|Gemcitabine will be administered.
45480704|NCT03488251|Drug|Oxaliplatin|Oxaliplatin will be administered.
45480705|NCT02727322|Drug|Nitrofurantoin|Patients will receive nitrofurantoin 100mg once daily or a placebo. Pills will be identical.
45480706|NCT02727322|Drug|Placebo|Placebo
45480707|NCT03716401|Diagnostic Test|MRI (magnetic resonance imaging)|An MRI (or magnetic resonance imaging) scan is a radiology technique that uses magnetism, radio waves, and a computer to produce images of body structures. The MRI scanner is a tube surrounded by a circular magnet.
45480708|NCT03716401|Diagnostic Test|US (ultrasound)|An ultrasound scan is a medical test that uses high-frequency sound waves to capture live images from the inside of the body.
45480709|NCT03716401|Procedure|Renal Biopsy|A kidney biopsy involves taking one or more tiny pieces (samples) of the kidney to look at with special microscopes. The microscopes make it possible to see the samples in greater detail.
45480710|NCT03716401|Diagnostic Test|Positron Emission Tomography (PET)|Positron emission tomography (PET) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions. By identifying body changes at the cellular level, PET may detect the early onset of disease before it is evident on other imaging tests.
45480711|NCT03716401|Diagnostic Test|Microvascular Assessment|Glycocalyx (a network of membrane proteoglycans and glycoproteins lining all blood vessels) thickness is non-invasively estimated from video clips of sublingual vessels captured using a hand held microscope. Glycocalyx is vital for vascular health; perturbations in the glycocalyx are thought to contribute to numerous vascular health complications including DKD.
45480712|NCT03315520|Drug|Bendamustine|"BeEAC conditioning regimen:~bendamustine 200 mg/м2 D-6 - D-5; cytarabine 400 mg/м2 D-4 - D-1; etoposide 400 mg/м2 D-4 - D-1; cyclophosphamide 140 mg/м2 totally, divided in 4 days (D-4 - D-1)"
45480713|NCT02483182|Drug|ZEP-3 ointment 1.0%|
45480714|NCT02483182|Drug|Acyclovir cream 5%|
45689605|NCT00464698|Drug|Duloxetine|Participants received increasing amounts of Duloxetine for 7 weeks.
45845577|NCT03818256|Drug|Miricorilant|Miricorilant 600mg
45845578|NCT03818256|Drug|Miricorilant|Placebo tablets for once daily oral dosing
45480715|NCT03780491|Other|Cost Discussion|The second group of 50 patients will be the intervention group where the providers will have a discussion of cost emphasizing five points: 1) Cancer care is expensive and it is normal to be concerned about cost. 2) We will recommend treatments for your cancer based on what we think gives you the best chance of doing well, not based on the cost of the treatment. 3) Because of how complex our healthcare system is, it is very hard for your doctors to know what your costs will be, but we will do our best to give you some general information. 4) We have resources available to help you get more specific information so that you can plan appropriately. 5) Do you have any specific concerns about cost that you'd like to share with me?
45480716|NCT03316924|Procedure|Foreskin resection|During the pediatric surgery consultation, the doctor will decide between Foreskin resection, orchidopexie or inguinal hernia repair.
45480717|NCT03431857|Device|TESS V2|Patients requiring the TESS V2 prosthesis.
45480718|NCT02480062|Other|mWELLCARE|mWELLCARE intervention arm will include a software application loaded on a tablet computer that will be used by Nurse Care Coordinators (posted in community health centers) in the course of their jobs to register patients with hypertension or diabetes, to generate clinical decision support recommendations, to track these patients over time and to improve follow-up care. Decision support recommendations will be printed and given to a doctor, who will make the final call on the management plan that will be used for the patient. Registered patients will also receive customized messages on their mobile phone. In addition, at sites where network connectivity permits, the doctor may also be equipped with a doctor's app on a tablet that will be largely the same as the NCC app.
45480719|NCT02480062|Other|Usual Care|Usual care at the community health centers
45480720|NCT03780647|Other|questionnaire|Assessment of the impairment at work by a specific auto- questionnaire given after echo-Doppler that confirm the diagnosis
45480721|NCT01338558|Drug|bevacizumab [Avastin]|5 mg/kg iv on Day 1 of each 2-week cycle until disease progression, unacceptable toxicity or withdrawal of consent
45480722|NCT01338558|Drug|cetuximab|400 mg /m2 iv on Day 1, followed by 250 mg/m2 every week until disease progression, unacceptable toxicity or withdrawal of consent
45480723|NCT01338558|Drug|mFOLFOX6|Standard mFOLFOX6 chemotherapy, 2-week cycles until disease progression, unacceptable toxicity or withdrawal of consent
45480724|NCT05390866|Other|HIIT|A single HIIT on a bicycle ergometer
46049981|NCT05298280|Device|clear aligners|The standardized orthodontic intervention was represented by the maxillary molar distalization protocol proposed by Align Technology: it was planned in order to obtain a sequential distalization on the upper arch, and the staging was set at 0.25 mm per aligner. During sequential distalization aligners are set up to distalize one tooth at a time. The attachments were engineered by Align Technology to achieve predictable tooth movements. Each couple of aligners was worn for 7 days.
46049982|NCT02615704|Device|Active group with MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool and with MEMS
45480725|NCT03780569|Device|NovoTTF-200A|Patients receive continuous TTFields treatment using the NovoTTF-200A device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the scalp. The treatment enables the patient to maintain regular daily routine.
45480726|NCT03780569|Radiation|Radiotherapy|60Gy given in 30 2Gy fractions concomitant to temozolomide
45689606|NCT00465088|Drug|Niacin ER/Simvastatin Tablets|Up to 2000 mg/40 mg at bedtime
45845579|NCT03812172|Drug|99mTc-PYP or 99m Tc-HDP|10-25 mCi of 99mTc-PYP (or 99m Tc-HDP) will be administered intravenously and imaging will be performed after 3 hours.
46049983|NCT02615704|Device|Active group without MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool but without MEMS
45480727|NCT03780569|Drug|Temozolomide|"Temozolomide(TMZ) will be administered at 75 mg/m^2 concomitant to radiotherapy(RT) and NovoTTF-200A.~Maintenance treatment is to begin about 4 weeks after the end of TMZ/RT/NovoTTF-200A. TMZ is administered at the conventional dosing regimen for 5 days, every 28 days (i.e. 5 days of therapy, 23 days of rest). Cycle 1 is to be given at a dose of 150 mg/m^2 p.o. daily x 5 days, dose to be escalated to 200 mg/m^2 in the absence of toxicity."
45480728|NCT03316846|Behavioral|Internet-Delivered Cognitive Behavioral Therapy|
45480729|NCT05512559|Device|body composition analysis|Body composition analysis by bioelectrical impedance measurement, just before induction of anesthesia.
45689607|NCT00465088|Drug|atorvastatin|40 mg at bedtime
45689608|NCT01796782|Drug|Xeloda|Xeloda dose is calculated according to body surface area.The recommended dose is 1000 mg/m² administered orally twice daily (morning and evening; equivalent to 2000 mg/m² total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles
45689609|NCT01796782|Drug|QYHJ Granules|1-4 bags bid , days 1-42, every 6 weeks
45689610|NCT00441766|Drug|AGN 203818|Part A: 3 mg AGN203818 capsule every 12 hours for 4 weeks
45689611|NCT00441766|Drug|AGN 203818|Part A: 20 mg AGN203818 capsule every 12 hours for 4 weeks
45689612|NCT00441766|Drug|AGN 203818|Part A: 60 mg AGN203818 capsule every 12 hours for 4 weeks
45689613|NCT00441766|Drug|placebo|Part A: placebo capsule every 12 hours for 4 weeks
45689614|NCT00466960|Biological|sargramostim|Given SC
45689615|NCT00466960|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
45689616|NCT00466960|Other|laboratory biomarker analysis|Correlative studies
45689617|NCT00466960|Other|immunologic technique|Correlative studies
45689618|NCT00383266|Drug|Pemetrexed|
46049984|NCT02615704|Device|Control group with MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool but with MEMS
45689619|NCT00383266|Drug|Carboplatin|
45363090|NCT02591069|Device|stimulation device|All patients included in the study will undergo baseline assessment of all measures before surgery (implantation of a vagus nerve stimulation device). A second baseline assessment will take place after surgery, before the beginning of the stimulation. Stimulation intensity will start at 0.25mA and increase progressively by 0.25mA each week until reaching 1mA. Then, intensity will be set at 1.5mA (recommended by manufacturer) and will stay to this level until the end of the trial. Experimenters will keep the right to modify these parameters depending on patients' reaction to the treatment.
45480730|NCT01333020|Other|cross-linking of an emulsion drink|This study will assess whether a subtle change in food structure (cross-linking of interfacial protein) can alter gastric emptying rate.
45480731|NCT03780413|Behavioral|PR-ESSENCE treatment|
45480732|NCT03780413|Behavioral|Control (TAU)|
45480733|NCT01338714|Other|Compound Herbal Formula (RHD-1)|100 ml/per day
45480734|NCT01338714|Other|dilute RHD-1|100 ml/per day
45480735|NCT03487549|Combination Product|VP-102 Cantharidin topical film forming solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 14 days between treatments.
45480736|NCT03487549|Combination Product|VP-102 Cantharidin, topical film forming solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 21 days between treatments.
45480737|NCT02486068|Device|ABSORB scaffold|
45480738|NCT02486068|Device|Xience|
45480739|NCT01313585|Drug|Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
45689620|NCT00384670|Biological|Dengue Vaccine Formulation 17|Tetravalent live attenuated DEN vaccine candidate. Containing dengue serotypes 1,2, and 3 vaccines produced at the Salk Institute and dengue serotype 4 produced at the WRAIR Pilot Bioproduction Facility. Dosage 1 mL administered via injection at Day 0 and Day 60.
45689621|NCT00384670|Biological|Licensed Japanese Encephalitis (JE) Vaccine|Produced by the Thailand GPO using a Beijing strain of JE in liquid form; dosed at 0.5 mL ot 7 and 7.5 months.
46049985|NCT02615704|Device|Control group without MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool and without MEMS
45480740|NCT01313585|Drug|Initiation of beclometasone via the Easibreathe device plus salbutamol via and MDI device|
45480741|NCT01313585|Drug|Increase of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
45689622|NCT00467038|Behavioral|Dialectical Behavior|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
45689623|NCT00467350|Drug|PEG 3350|PEG 3350 1.5 gram/kg for disimpaction then 0.8 gram/kg for maintenance
45689624|NCT00467350|Drug|milk and molasses enema|enema 10 cc/kg per rectum (max 500 cc)then PEG 3350 0.8 gram/kg for maintenance
46049986|NCT02619916|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 60 minutes
46049987|NCT02619916|Behavioral|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 60 minutes.
45480742|NCT01313585|Drug|Increase of beclometasone via the Easibreathe device plus salbutamol via an MDI|
45480743|NCT01572714|Behavioral|Social Support Program|The social support program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Topics will include information on MS, disease modifying medications, preventive screening, community organizations, nutrition, cognitive problems, and hiring an aide.
45480744|NCT01572714|Behavioral|Physical Activity Program|The physical activity education program will consist of 3 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program.
45480745|NCT01572714|Behavioral|Physical Activity Plus Fatigue Management Education Program|The physical activity plus fatigue management education program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program. In addition, subjects in this course will learn strategies to reduce fatigue, such as taking rest breaks and re-arranging workspace.
45689625|NCT00444028|Drug|inhaled Loxapine 0.625 mg|Single 0.625 mg (lowest) dose of inhaled loxapine
45480746|NCT03779945|Biological|autologous platelet rich plasma|adding autologous platelet rich plasma to the bone graft harvested from the patient
45480747|NCT03779945|Procedure|posteriolateral lumbar fusion only|performing posteriolateral lumbar fusion without using platelet rich plasma
45480748|NCT01561235|Other|Dose-reponse effect of protein on appetite and appetite-regulating hormones|3-arm meal study for investigation of the mechanisms responsible for the satiating effects of protein in three isocaloric test meals with a protein content of 14, 25 or 50 E% protein. A possible 4-h dose-response effect of protein was investigated on a number of appetite-regulating hormones/peptides, together with changes in subjective appetite sensations and sensory desires were evaluated and ad libitum energy intake.
45689626|NCT00444028|Drug|inhaled Loxapine 1.25 mg|Single 1.25 mg (2nd) dose of inhaled loxapine
45689627|NCT00444028|Drug|inhaled Loxapine 2.5 mg|Single 2.5 mg (3rd) dose of inhaled loxapine
45480749|NCT02485990|Drug|Tremelimumab|
45689628|NCT00444028|Drug|inhaled Loxapine 5 mg|Single 5 mg (4th) dose of inhaled loxapine
45480750|NCT02485990|Drug|Olaparib|
45689629|NCT00444028|Drug|inhaled Loxapine 10 mg|Single 10 mg (5th) dose of inhaled loxapine
45689630|NCT00444028|Drug|inhaled Placebo (0 mg)|Single placebo dose of inhaled loxapine
46049988|NCT00868192|Drug|Pemetrexed|
46049989|NCT00868192|Drug|Bevacizumab|
45480751|NCT01313819|Drug|PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj|IV amantadine at 200 mg in 500 cm3 of saline solution or normal saline 500 cm3 given over a 3-h period, twice a day for 2 days along with the pre-existing dopaminergic and non-dopaminergic medication
45480752|NCT03315442|Other|Caffeine versus Energy Drink|Caffeine group consumed 200mg of caffeine one time, while the energy drink group consumed 1 16 ounces of energy drink.
45480753|NCT03464383|Drug|Escitalopram 10mg|Participants will be given escitalopram 10mg by mouth daily and will be followed up with at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
45480754|NCT03464383|Other|Referral to Psychiatry|Participants randomized to control will have a psychiatry referral order placed by the treating epileptologist under typical care circumstances. This will be an internal or external referral order based on patient preference. If external, the order will be printed along with instructions for the patient to follow to find a provider covered by insurance.
45480755|NCT03464383|Other|Survey only|One time survey will be offered to individuals who are found to have anxiety or depression symptoms on screening but who are ineligible for the treatment component of the study, or who decline the treatment study.
45480756|NCT03780335|Diagnostic Test|Computation of quantitative flow ratio|Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
45480757|NCT03315364|Drug|Oral paclitaxel|Oral administration on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
45480758|NCT03315364|Drug|Paclitaxel injection|Premedication, intravenous infusion on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
45480759|NCT03779633|Drug|Linoladiol Estradiol|"Linoladiol Estradiol Initial dose (week 1): 1 application (2g Linoladiol = 0.2mg Estradiol) every day for the first week Maintenance dose 1 (week 2) : 1 application (2g Linoladiol = 0.2mg Estradiol) every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application (2g Linoladiol = 0.2mg Estradiol) twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks"
45480760|NCT03779633|Other|Placebo vaginal cream|"Initial dose (week 1): 1 application every day for the first week Maintenance dose 1 (week 2) : 1 application every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks"
46049990|NCT00867568|Drug|TPI 287|Three patients will be enrolled to receive single agent TPI 287 IV administered on Days 1, 8 and 15 of the first and second 28-day cycle. The starting dose of 90 mg/m2 (Dose Level 1) is 75% of the established adult MTD for this schedule in adults, which is 125 mg/m2. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.
46049991|NCT02615782|Drug|CKD-397|CKD-397 1T single oral administration under fasting condition or fed condition(high fat meals)
46049992|NCT02615626|Procedure|Non-surgical Periodontal Treatment.|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
46049993|NCT04122352|Other|Ischemic compression|Ischemic compression was performed 3 times ; after the initial evaluation, after the first week evaulation and after the second week evaulations.
45363091|NCT04042688|Drug|intraarticular administration of tranexamic acid|Intraarticular administration with concentration of 30mg/mL was selected. The operation room nurses prepared 3g tranexamic acid in 100 mL of saline solution during operation. After finishing surgical wound suture and orthopaedic surgeons related to this study left operation room, the orthopaedic residents who were not involved in the postoperative evaluation administered tranexamic acid solution through suprapatellar pouch before tourniquet release in patients in the treatment group. The control group did not receive any solution. intraarticular drain was not inserted in all patients.
45363092|NCT02590133|Drug|Recombinant Human Endostatin Injection (Endostar)|15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
45363093|NCT02590133|Drug|Fluorouracil (5-Fu)|200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
45363094|NCT02590133|Drug|Nedaplatin|80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
45480761|NCT03720067|Drug|Propranolol|40mg to 320mg / day
45480762|NCT03720067|Drug|Carvedilol|6.25mg to 25mg / day
45480763|NCT03720067|Drug|Rosuvastatin|20mg / day
45480764|NCT03720067|Drug|Placebo|Placebo of rosuvastatin
45480765|NCT03779555|Other|Medication Event Monitoring System|-Microchipped bottle cap
45689631|NCT00444964|Drug|Nutropin AQ|0.0125 mg/kg/day
45689632|NCT00445588|Drug|erlotinib hydrochloride|150mg Given orally once daily
45689633|NCT00445588|Drug|sorafenib tosylate|400mg Given orally twice daily
45363095|NCT00854204|Drug|TMC114; TMC41629|
45363096|NCT02590991|Other|Prebiotics|To study the long term effect of supplementation in early life
45363097|NCT02590991|Other|Prebiotics & Probiotics|To study the long term effect of supplementation in early life
45363098|NCT00854282|Procedure|Staging surgery or debulking surgery|Staging surgery or debulking surgery
45480766|NCT03718663|Other|Physiotherapy-guided Evidence-based Exercise Therapy|Standardized supervised exercise therapy for 6-8 weeks (two times per week).
45363099|NCT02590211|Behavioral|cognitive, emotional and clinical assessment|Cognitive and emotional assessment: Posner paradigm applied to emotional information (attention and emotional perception abilities), the modified Wisconsin Card Sorting Test (mental flexibility), the Hayling Sentence Completion Task (verbal inhibition), the Go - No Go test (motor inhibition) and the expressive suppression method (facial expression inhibition) Clinical assessment: gambling course and habits, level of cognitive distortions, control attribution (locus of control), social phobia, motivation for gambling, impulsivity, co-addictions, coping and gambling related-damage
45363100|NCT00854438|Other|Multidisciplinary drug reviews by pharmacist and physician|Reduction of anticholinergic drug effects by pharmacist review
45363101|NCT00857870|Drug|Metformin|"Metformin is administered as coated tablet. Initial dose is 500 mg twice a day (morning and evening) during or after the meal. The first administration takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c.~Initial dose of 500 mg bid was increased after 4 weeks (visit 2) to 850 mg bid when the patient tolerated the initial dose. If the side effects were not tolerable, the initial dose was decreased to 500 mg once a day and where appropriate increased at a later visit.~After 8 weeks (visit 3) metformin dose was increased to 1000 mg bid when tolerated. If dose is not tolerated, it was decreased to the next lower dose."
45480767|NCT03718663|Other|Part 2: Military training|Part 2: standardized military training for 6-8 weeks in Defence Command Denmark
45363102|NCT00857870|Drug|Insulin glargine|Insulin glargine is given subcutaneously with an insulin-pen (SoloStar®). The dose was titrated to reach a fasting plasma glucose value of <5.6 mmol/l. Insulin glargine was given once a day in the evening before going to bed (bed-time injection). The first insulin injection takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c. All patients were trained in handling and storage of the insulin-pen.
45480768|NCT05714332|Other|Advanced practice physiotherapy and orthopedic surgeon management|Management of their musculoskeletal condition by an advanced practice physiotherapist and an orthopedic surgeon.
45480769|NCT05714332|Other|Orthopedic surgeon management|Management of their musculoskeletal condition by an orthopedic surgeon.
45480770|NCT03779399|Other|Assessment of percentage of Treg, Th17, NKT and serum level of HE4, CA125 and ROMA.|Treg, Th17, NKT cells in peripheral blood and ovarian tissue and serum level of HE4, CA125 and ROMA.
45480771|NCT01444092|Drug|Entocort|Entocort capsules, oral
45480772|NCT03719989|Drug|azacitidine plus R-GDP|azacitidine S.C 25 mg/m2 D1,2,3,4,5 rituximab I.V. 375 mg/m2 D8 gemcitabine I.V. 1,000 mg/m2, D8,15 dexamethasone I.V. or P.O. 40 mg D8,9,10,11 every 21 days, up to 6 cycles
45363103|NCT00848432|Drug|risperidone|Patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to a 'maintenance group' (optimal therapeutic doses continued for at least 1 year), a 4-week group (optimal therapeutic doses continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months) or a 26-week group (optimal therapeutic doses continued for 26 weeks followed by a 50% dose reduction for at least another 6 months)
45480773|NCT02480296|Drug|MYK-461|
45480774|NCT02480296|Drug|Placebo|Placebo comparator
45480775|NCT03716323|Device|immediate premolar implant with xenograft and allograft|"A peritome will be used for atraumatic extraction of remaining roots.~The extraction socket will be evaluated for absence of any fenestration or granulation tissues.~Copious normal saline irrigation and curettage will be performed.~In the study group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with cortico-cancellous allograft (MinerOss®, BioHorizons, USA)~In the control group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with anorganic bovine bone mineral xenograft (Bio-Oss®, Geistlich, USA)"
45480776|NCT05460442|Procedure|Caudal Block group|Patients will be placed in the lateral decubitus position. After local sterilization with povidone-iodine, the sacral hiatus will be visualized at the level of the sacral Cornus by ultrasound. The needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament. At this level, after confirming the absence of blood or cerebrospinal fluid on aspiration, bupivacaine 0.25% (0.5 mL/kg) will be injected over 1 minute
45480777|NCT05460442|Procedure|Pericapsular nerve group block|Patients will receive ultrasound-guided Pericapsular nerve group block in the supine position after proper sterilization of the groin region. The needle will be inserted in-plane with the transducer. The Pericapsular nerve group block group will receive 0.5 mL/kg of (0.25%) bupivacaine after a negative aspiration
45689634|NCT00445588|Other|pharmacological study|Correlative studies
45689635|NCT00445744|Drug|cyclophosphamide|Given IV
45689636|NCT00445744|Drug|busulfan|Given IV
45689637|NCT00445744|Drug|tacrolimus|Given IV or PO
45845580|NCT03623958|Device|Image guided Video-Assisted Thoracic Surgery (VATS) resection|Image guided placement of a fiducial consisting of a needle directed placement of a T-Bar next to the target lesion in order to lead the surgeon to the lung region to be removed
45845581|NCT03623958|Procedure|Video-Assisted Thoracic Surgery|Standard of Care Video-Assisted Thoracic Surgery (VATS) resection
45480778|NCT05460442|Procedure|Fascia iliaca group|Patients will receive Ultrasound-Guided fascia iliaca compartment block in the supine position after sterilization of groin area. The needle will be inserted in-plane with the transducer. The needle tip will be advanced through the fascia iliaca and inserted further cephalad just below the fascia iliaca into the iliacus muscle. 0.5 mL/kg of (0.25%) bupivacaine will be injected and visualized moving cephalad away from the needle tip
45363104|NCT00854516|Procedure|A new treatment approach is to have an effective working pressure combined with a low resting pressure.|"Procedure Schedule: The total duration for study participation will be 14 days (8 visits).~Subject eligibility will be determined at the initiation visit. All eligible subjects will receive the compression device on the study leg and will return to the clinical center at day 1, 2, 3, 4, 7, 10 and 14 to assess safety. At each clinical visit (except visit day 14) the compression device will be reapplied. The study participation ends after 14 days."
45480779|NCT03779477|Behavioral|Coping with Stress Course|The Coping with Stress Program is a group program, which is developed by Clarke and Lewinson (1995) for the prevention of depression in high-risk adolescents. It is based on cognitive-behavioral therapy principles and contains psychoeducation and cognitive-behavioral therapy interventions. There are handbooks available for the group leader of the program and the participating adolescents. In the handbook developed for the group leader, there is detailed information about the objective of each session and the implemented interventions. The adolescents will find lists organized for the fulfillment of the tasks in the handbook prepared for them. The handbooks of the program were translated in Turkish and experts were consulted for their validity.
45480780|NCT05460208|Dietary Supplement|Enriched spread|The experimental spread is made with a base made with 90% extra virgin olive oil to which plant sterols are added.
45480781|NCT05460208|Dietary Supplement|Control spread|The control spread will be the same base spread made with extra virgin olive oil without the added plant sterols.
45480782|NCT05263115|Other|Resistance Exercise intervention|12-week progressive resistance exercise intervention
45480783|NCT05263115|Other|Functional stair climbing and stepping-based exercise intervention|12-week progressive stair climbing and stepping-based exercise intervention
45480784|NCT05463328|Procedure|laparoscopic assisted pancreaticoduodenectomy|laparoscopic assisted pancreaticoduodenectomy.
45480785|NCT05463328|Procedure|Open pancreaticduodenctomy|Open pancreaticduodenctomy
45480786|NCT05462470|Procedure|Repeat Liver Surgery|repeat liver surgery included not only hepatectomy, but also ablative treatment, including radiofrequency ablation (RFA) and microwave ablation (MWA)
45480787|NCT05462470|Procedure|Non-Repeat Liver Surgery|Systemic palliative chemotherapy
45480788|NCT03774797|Other|Implementation Toolkit|Post-implementation patients and providers will be assessed after the implementation toolkit has been used to improve service delivery at the study site.
45480789|NCT02480218|Other|Neuropsychological test battery|Participants will have been prescribed their endocrine therapy for the treatment of breast cancer prior to enrollment. Neuropsychological test batteries will be administered at baseline and at one-year follow-up to assess changes in cognition.
45480790|NCT03779087|Drug|10d TL quadruple therapy|esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, tetracycline 500 mg qid, levofloxacin 500 mg qd.
45480791|NCT03779087|Drug|10d AL quadruple therapy|esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd.
45480792|NCT02479984|Procedure|Staging Laparoscopy|"Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis.~Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port."
45480793|NCT02479984|Device|Laparoscopic ultrasound|
45480794|NCT01265784|Drug|TP-434|
45480795|NCT01265784|Drug|Ertapenem|
45480796|NCT01265784|Drug|Placebo|Administered IV to maintain the blind.
45480797|NCT05692271|Drug|Propranolol|40 mg teva-propranolol taken twice daily for 12 weeks
45363105|NCT04043156|Radiation|High-precision RT|18 x 2.33 Gy of high-precision RT in 3.5 weeks
45363106|NCT00854750|Drug|ACTHAR|SQ weekly injections
45363107|NCT00854750|Drug|ACTHAR|SQ weekly injections
45363108|NCT00854750|Drug|ACTHAR|SQ weekly injections
45480798|NCT05692271|Drug|Placebo|Matching placebo
45480799|NCT02485756|Other|Educational handout|Topics include: interactions between AED and certain hormonal contraceptives, Center for Disease Control and Prevention (CDC) recommendations for alternative contraceptive methods that are not known to interact with AEDs, contraceptive failure rates
45480800|NCT01315223|Other|Lung impedence-guided treatment|One hundred fifty patients with CHF will be treated according to common practice and values of lung impedance
45689638|NCT00445744|Drug|methotrexate|Given IV
45480801|NCT02479906|Device|Deep TMS System|Deep TMS treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions.
45480802|NCT02479906|Device|Sham Treatment|Sham treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions
45480803|NCT03778853|Drug|Anlotinib Hydrochloride|"Anlotinib Hydrochloride ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.~Other Name: AL3818"
45480804|NCT02479750|Device|ColdZyme® mouth spray|
45480805|NCT02479750|Device|Placebo|
45363109|NCT00854750|Drug|ACTHAR|SQ weekly injection
45480806|NCT01315301|Other|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated one week after starting rifampicin based short course anti tuberculosis treatment.
45480807|NCT01315301|Other|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated four weeks after starting rifampicin based short course anti tuberculosis treatment
45480808|NCT01315301|Other|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated eight weeks after starting rifampicin based short course anti tuberculosis treatment.
45480809|NCT03635814|Drug|YD312 50mg|YD312 50mg * 1 + placebo 6 tablets
45480810|NCT03635814|Drug|YD312 150mg|YD312 50mg * 3 + placebo 6 tablets
45480811|NCT03635814|Drug|YD312 350mg|YD312 50mg * 7 tablets
45480812|NCT03635814|Drug|Placebo|YD312 0mg * 7 tabets
45480813|NCT02485522|Other|No Intervention|No intervention
45363110|NCT00858026|Other|Breastmilk|Exclusively breastfed babies
45363111|NCT00858026|Other|Standard milk|Weaning babies fed with the standard formula
45480814|NCT04492852|Procedure|Polypropylene (PROLENE) sutures|After total knee replacement, the skin closure of the patients in this group will be done using polypropylene (PROLENE) sutures.
45480815|NCT04492852|Procedure|Staple Sutures|After total knee replacement, the skin closure of the patients in this group will be done using staple sutures.
45480816|NCT03774953|Dietary Supplement|Protein and vitamin supplementation|The intervention group will receive 1.5 g protein/kilo/day during hospitalization and a standard dose of 27 g protein/day in 60 days after discharged together with a daily dose of vitamin/mineral supplement
45480817|NCT05185752|Procedure|SIFP Block Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by SIFP block: lateral and anterior cutaneous branches of the 2nd-6th Intercostal Nerves.~Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
45480818|NCT05185752|Procedure|PECS II block: Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by PECS-II: Lateral Pectoral Nerve and Medial Pectoral Nerve Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
45363112|NCT00858026|Other|Fermented milk|Weaning babies fed with the fermented formula
45363113|NCT00848666|Drug|Topical therapy|One time immersion of the feet in a liquid containing water, alcohol, vinegar, benzoic acid and salicylic acid for a total of 30 minutes.
45363114|NCT00858104|Procedure|Percutaneous Laser Ablation|Single session with standardized approach: Two fibers, up to 2 laser emissions; nodule volume up to 10 ml are treated by 800 Joules /ml and above 10 ml by 600 Joules/ml.The treatment is performed under local anesthesia and with diazepam sedation.
45689639|NCT00445744|Genetic|cytogenetic analysis|Correlative studies
45689640|NCT00445744|Other|flow cytometry|Correlative studies
45689641|NCT00445744|Other|pharmacological study|Correlative studies
45689642|NCT00445744|Other|pharmacogenomic studies|Correlative studies
45689643|NCT00445744|Procedure|peripheral blood stem cell transplantation|Undergo PBPC transplantation
45689644|NCT00445744|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
45363115|NCT00858182|Drug|PD solution for nocturnal exchanges|Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients. PD solutions are instilled for 4 weeks.
45480819|NCT05185752|Procedure|ESP block: Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by ESP Block: dorsal and ventral branch block of the spinal nerves; white and gray communicating branches of the sympathetic nerves that go to the thoracic sympathetic chain.~Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
45845582|NCT03601026|Behavioral|Genetic counselling|Participants will receive information on risk/protective factors and causes of mental illness. Participants are not required to receive numeric/genetic risk information. Participants who choose to receive genetic and/or numeric risk information will be counselled on their risk of NOT developing and of developing SMI based on their genetic test results and/or family history information they provide. Risk estimates will be derived by genetic counsellors, according to standard practice guidelines. Participants who receive genetic information will be counselled on the possible influence of cannabis use on risk of mental illness based on their genotype. Participants who choose to not receive genetic information will be counselled on the influence of cannabis on mental health.
45845583|NCT03370302|Drug|TAK-228|TAK-228 Capsules.
45480820|NCT02483026|Dietary Supplement|Multi vitamin|Multi vitamin
45480821|NCT02483026|Dietary Supplement|vitamin D|Vitamin D
45480822|NCT02483104|Drug|veliparib|Veliparib will be given orally, twice daily on Days 1-21, every 21 days.
45480823|NCT02483104|Drug|carboplatin|Carboplatin will be administered on Day 1 of each cycle, intravenously.
45480824|NCT02483104|Drug|paclitaxel|Paclitaxel will be administered on Days 1, 8, 15 of each cycle, intravenously.
45480825|NCT00116220|Drug|Flutamide (Eulexin) and Lupron or Zoladex|Androgen suppression therapy
45480826|NCT00116220|Radiation|External Beam Radiotherapy|Once a day, 4-5 days per week for approximately 2 months
45480827|NCT03785015|Other|Resume Aspirin within 12 hours|Resume the standard treatment within 12 hours after endoscopic haemostasis
45480828|NCT03785015|Other|Resume Aspirin 72 - 84 hours|Resume the standard treatment between 72 and 84 hours after endoscopic haemostasis
45845584|NCT03347058|Other|Supportive programming|Access to a suite of resources, including digital tools, person-to-person support, and educational resources
45363116|NCT00858182|Drug|PD solution for diurnal exchanges|Instillation of a PD solution containing xylitol (0.6%), L-carnitine (0.1%) and glucose (0.5%) for the diurnal exchanges in CAPD treated patients. PD solutions are instilled for 4 weeks.
45847740|NCT02908620|Combination Product|Two sprays CTY-5339-A|Metered spray bottle with ≈400 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 56 mg total) and 2.0% Tetracaine Hydrochloride (USP = 8 mg total). Administered in two anesthetic sprays.
46049994|NCT04122352|Other|Exercises (Rocabodo's 6x6 exercises and posture exercises)|Rocabodo's 6x6 exercises exercise was shown to be administered for 4 weeks. After the first week evaluation, posture exercises are added to the exercise programs of the patients.
46049995|NCT00930930|Drug|cisplatin|Given IV
46049996|NCT00930930|Drug|everolimus|Given orally
45363117|NCT00854984|Behavioral|Living Life to the Full|A nurse-supported, self-help, cognitive behavioural therapy with web, video and booklet formats.
45480829|NCT02485678|Other|Proactive Telephone Toxicity Management|Centres randomized to this arm will implement a pro-active telephone toxicity management program, for all eligible early stage breast cancer patients beginning neo-adjuvant or adjuvant chemotherapy within the intervention period until the end of their systemic treatment. Patients will receive a phone call from a local nurse who has been trained on the toxicity management toolkit at 24-72 hours and at 8 to 10 days following each chemotherapy administration. The provider conducting the call will be provided with a script and will complete the Telephone Follow-Up Questionnaire which includes questions from the abbreviated NCI PRO-CTCAE tool. The nurse conducting the call will also be provided with the provider version of the symptom management booklet and provide toxicity management counseling. If any toxicity-related problems are identified during the call, a second call will take place 24 hours after the initial call to ensure the problem is resolving or to provide additional support.
45480830|NCT02485678|Other|Control Arm|Centres randomized to the control arm will continue to provide routine care for chemotherapy-related toxicities as is the current standard in the centre.
45480831|NCT02485678|Other|PRO Sub-Study|A sub-set of approximately 25 patients enrolled at each participating centre will participate in a Patient Reported Outcomes (PRO) sub-study to assess the effect of the intervention on secondary outcomes.
46049997|NCT00930930|Drug|paclitaxel|Given IV
46049998|NCT00930930|Other|placebo|Given orally
46049999|NCT00930930|Procedure|Venous blood draw|Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment
46050000|NCT00698776|Drug|Lenalidomide|10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.
45363118|NCT04123340|Diagnostic Test|Additional intraprocedural pre-ablation CT-scan|In 20 patients, besides de regular post-RFA scan, a pre-RFA contrast enhanced dual phase CT-scan will be acquired to investigate the feasibility of quantitative ablation assessment.
45480832|NCT05690555|Other|Pelvic Floor Physical Therapy (PFPT)|"Patients will present to see the physical therapist 3 weeks and 6 weeks postoperatively. The following interventions will be performed:~3 weeks:~Subjective assessment of bowel and bladder function~Visual and external palpation and assessment of external pelvic floor region~Intravaginal pelvic floor assessment~Pelvic floor muscle dynamics and coordination assessment~Instruction of pelvic floor coordination and lengthening~Discussion of dilator program and progression~Home program with instructions~6 weeks:~External scar assessment and treatment if tissue healing allows~Instruction to patient of scar mobilizations~Intravaginal pelvic floor assessment and treatment if indicated~Review of pelvic floor lengthening and coordination~Review and progression of dilator program if appropriate~Assessment of current bowel/bladder symptoms; home program and instructions to address these symptoms"
45480833|NCT05690555|Other|No Pelvic Floor Physical Therapy (PFPT)|"Patients will present to see the physical therapist 3 weeks postoperatively. The following interventions will be performed:~Subjective assessment of bowel and bladder function. Visual and external palpation and assessment of external pelvic floor region. Intravaginal pelvic floor assessment. Pelvic floor muscle dynamics and coordination assessment. Review of pelvic floor anatomy and function."
45480834|NCT05690555|Other|Preoperative PFPT and Postoperative PFPT|Preoperative Diaphragmatic breathing Discuss dilator positioning/introduce dilator program External pelvic floor assessment Teach pelvic floor coordination Current bowel/bladder symptoms; home program and instructions 3 weeks Assessment of bowel and bladder function Visual and external palpation and assessment of external pelvic floor region Intravaginal pelvic floor assessment Pelvic floor muscle dynamics and coordination assessment Instruction of pelvic floor coordination and lengthening Discussion of dilator program and progression Home program with instructions 6 weeks External scar assessment and treatment if tissue healing allows Instruction to patient of scar mobilizations Intravaginal pelvic floor assessment and treatment if indicated Review of pelvic floor lengthening and coordination Review and progression of dilator program if appropriate Current symptoms; home program and instructions
45480835|NCT05690555|Other|Cross-over Treatment|Any patients in the No PFPT arm who are determined to have pelvic floor dysfunction or symptoms that may benefit from PFPT referral, will be referred after the 12-week mark. Any patient in one of the PFPT arms who is determined to still need PFPT for persistent pelvic floor dysfunction or symptoms will be referred for continued care.
45480836|NCT01336452|Radiation|DCE MRI|DCE (dynamic contrast enhanced) MRI will be obtained just before CCRTx and immediately after finishing CCRTx with 0.1mmol/kg of MR contrast media; CEUS will be obtained just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx with 2.4 mL of SonoVue. Blood sampling for biomarker analysis will be performed just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx (20mL)
45480837|NCT04492228|Other|Ketogenic diet|Eucaloric Ketogenic diet % composition : protein (27%), lipids (67%), carbohydrates (6%: <30g/day). In pts in artificial nutrition : Eucaloric Ketogenic parenteral nutrition % composition : aminoacids (27%), lipids (67%), carbohydrates (6%: <30g/day)
45480838|NCT01333176|Procedure|"Point-of-care finger-poke HbA1c determination."|"All volunteers receive finger-poke HbA1c test. Result: If < 6: Offered a requisition to have gold standard testing for diabetes screening. If 6-6.5: Given requisition for FBG, HbA1c and OGTT. If A1c result >6.5: Counseled that they may have diabetes. Given requisition as above.~Estimates about how many have undiagnosed diabetes will be calculated.~Did the clients who were counseled to do so get follow-up blood tests?~Were all the formal diagnostic tests performed?~Did the formal tests correlate to the POC HbA1c test or was there significant discrepancy? Thus is this new test for diagnosing diabetes confirmed as a valid test for screening in First Nation Communities in Canada?~Did the family physicians find this useful?"
45480839|NCT01333176|Procedure|HbA1c blood test|All candidates will have a HbA1c blood test (Finger poke)
45480840|NCT01333176|Procedure|HbA1c finger poke test|All study candidates will have the same HbA1c test performed
45480841|NCT01333176|Procedure|Blood test|HbA1c blood test
45480842|NCT01333176|Procedure|Blood test|HbA1c finger poke blood test
45480843|NCT03784859|Device|Insertion of Tissue Expander with Fluid Reservoir|Use of unique expander type in first stage of a two-stage breast reconstruction, without prolonged drain placement.
46050001|NCT00698776|Biological|Monocyte derived DCs loaded with KRN7000|10 million DCs injected intravenously
46050002|NCT04259112|Procedure|high pressure|High-pressure pneumoperitoneum is defined as intra-abdominal pressure 12-15 mmHg.
46050003|NCT04259112|Drug|deep neuromuscular block|Deep neuromuscular block is defined as PTC 1-2.
46050004|NCT04259112|Procedure|low pressure|Low-pressure pneumoperitoneum is defined as intra-abdominal pressure 7-10 mmHg.
46050005|NCT04259112|Drug|moderate neuromuscular block|Moderate neuromuscular block is defined as TOF twitch 1-2.
46050006|NCT04122040|Drug|Roxithromycin 300 MG|Roxithromycin 300 mg oral per day
46050007|NCT04122040|Drug|Placebo|Placebo one table oral once dialy
45363119|NCT02545244|Dietary Supplement|Black Tea|0.5% Black Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
45363120|NCT02545244|Dietary Supplement|Green Tea|0.5% Green Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
45363121|NCT02545244|Drug|0.12% Chlorhexidine Mouthwash.|5mL of 0.12% Chlorhexidine used as mouthwash twice daily for two weeks after scaling of teeth.
45363122|NCT00858260|Genetic|blood sample|Searching for Klotho variants in DNA
45363123|NCT00858338|Procedure|Potentially curative surgery|"Surgery:~Week 1: Potentially curative surgery. If the tumor successfully resected (microscopically disease-free margins, Ro, with regional lymphadenectomy for proper staging), the ip catheter in place.~Weeks 2-4: Recovery. Then continue to adjuvant IP chemotherapy."
45480844|NCT05185596|Device|Transesophageal Echocardiography|transesophageal Echocardiography during advanced life support
45480845|NCT04867343|Drug|HR020602 injection|HR020602 injection
45480846|NCT04867343|Drug|fentanyl injection ； remifentanil injection|fentanyl injection + remifentanil injection
45480847|NCT05185518|Device|Use of novel insulin injection port|use subcutaneous port into which glucose monitor is embedded
45480848|NCT03778775|Diagnostic Test|Liver sitffness measurement|Liver sitffness measurement is performed by FibroTouch, a new-generation of transient elastography with the tesing interval between liver sitffness measurement and esophagogastroduodenoscopy less than one week.
45480849|NCT03316690|Drug|Metformin treatment|"Daily treatment with metformin tablets for 101 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-101: Metformin tablet 1000 mg x 2"
45363124|NCT00858338|Drug|Floxuridine (IP)|"Adjuvant IP Chemotherapy:~week 1: ip Floxuridine 3 gm/day, days 1,2,3. week 2: 1 week without treatment. week 3: ip Floxuridine 3 gm/day protocol days 15,16,17. week 4: 1 week without treatment. Then continue to chemoradiation therapy."
45480850|NCT03316690|Drug|Placebo treatment|"Daily treatment with placebo tablets for 101 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-101: Placebo tablet 1000 mg x 2"
45480851|NCT03316690|Behavioral|Physical training|Twelve weeks of supervised physical training (4 times per week, 45 min per session, mean intensity at 70% of maximal oxygen consumption rate)
45480852|NCT01333254|Procedure|Intermittent urinary catheterisation|Patients randomised to the I group will urinate either in a toilet or in a bedpan or a diaper when needed. Bladder scan control will be performed on these patients at least every four hour. If the patient is unable to urinate and bladder scan indicates ≥ 450 ml urine in the bladder, the patient will be intermittent catheterised.
45480853|NCT03315052|Drug|Budesonide|Oral steroid with high first-pass metabolism in liver
45480854|NCT03315052|Drug|Tacrolimus（FK506）|Calcineurin immunosuppressant
45480855|NCT03315052|Drug|Mycophenolate Mofetil|Immunosupressant
45689645|NCT00468208|Drug|Abatacept|"A participant's abatacept dose depended on body weight and will remain the same throughout the study:~500 mg of abatacept for body weight less than 60 kg~750 mg of abatacept for body weight between 60 and 100 kg~1000 mg of abatacept for body weight greater than 100 kg~Abatacept is administered in a 30-minute intravenous infusion."
45689646|NCT00384748|Behavioral|TR intervention|The 3 tele-visits will occur within 5 weeks post randomization. Telephone call visits will occur during weeks 2, 4, 6, 8 and 12. One additional tele-visit may be scheduled as needed. The first visit is devoted to mobility assessment, goal-setting. The second visit is to review the current exercise component. Visit 3 focuses on functional mobility using adaptive strategy component.
46050008|NCT04134364|Drug|Sodium alginate|3 days oral administration of sodium alginate after gastric biopsy
45363125|NCT00858338|Procedure|Adjuvant Chemoradiation therapy|"Adjuvant Chemoradiation therapy:~week 1: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; weeks 2-4: recovery; weeks 5-9: radiation, 150 cGy x 5 fractions/week x 5 weeks; week 5: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-4; week 9: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-3; week 14: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; week 19: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days."
45363126|NCT00855140|Other|Acupuncture|Acupuncture, derived from the TCM literature, specific for insomnia
45363127|NCT00848900|Behavioral|Outdoor activity|Adding 1 hour outdoor time into school curricula
45363128|NCT00858416|Device|"Kineticure System followed by sham"|20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion) during the first 4 weeks followed by 2 weeks wash out and 4 weeks of sham device
45480856|NCT03315052|Drug|Prednisone|Immunosuppresant
45480857|NCT05187468|Device|Extracorporeal Shockwave Therapy|1000 pulses at 60 mj, 10 Hz
45480858|NCT05187468|Device|Extracorporeal Shockwave Therapy|2000 pulses at 60 mj, 10 Hz
45480859|NCT05187468|Device|Ultrasound therapy, Massage, Heat pack|Ultrasound therapy 5 min, 1,2W/cm2, 10 min Massage, 10 min heat pack
45480860|NCT03778697|Procedure|Endoscopic Sleeve Gastroplasty|Endoscopic full-thickness suture system to plicate the greater curvature of the stomach
45480861|NCT05187390|Procedure|VATS application|The chronic pain findings of the patients who underwent VATS will be questioned at the postoperative 1st and 3rd months.
45480862|NCT02482948|Device|Active Leptospermum Honey (Medihoney)|STudy agent to be applied to the wound daily.
45480863|NCT02482948|Drug|Collagenase|Study agent to be applied daily to the wound.
45480864|NCT03780881|Behavioral|Expectation confirmation|Participants receive manipulated feedback indicating that their performance was above average in the test they had previously worked on. This feedback is intended to confirm the previously induced positive expectations of their own performance.
45480865|NCT03780881|Behavioral|Expectation disconfirmation|Participants receive manipulated feedback indicating that their performance was below average in the test they had previously worked on. This feedback is intended to negatively disconfirm the previously induced positive expectations of their own performance.
45480866|NCT03779321|Other|Acceptability|Food samples two formulations (low and high acceptability levels) of custard were used as experimental meals
46050009|NCT04259034|Other|diagnosis of periodontitis in oral lichen planus patients|diagnosis of periodontitis in oral lichen planus patients
46050010|NCT04259034|Other|diagnosis of periodontitis in systemically healthy individuals without oral lichen planus|diagnosis of periodontitis in systemically healthy individuals without oral lichen planus
45480867|NCT05690477|Procedure|Corrective osteotomy of the distal radius|Corrective osteotomy of the distal radius with a palmar locking plate osteosynthesis without the use of a bone graft and without cortical contact.
45480868|NCT02482792|Other|Norwegian Psychomotor Physiotherapy|The recruited patients will after randomization receive either Norwegian Psychomotor Physiotherapy (NPMP) or COPE combined with active individual physiotherapy. In NPMP the treatment is individualized, targeting body-mind awareness through exercise, massage and therapeutic conversation
45480869|NCT02482792|Other|Cognitive Patient Education and PT|The comparison group will receive a combination of education about how to manage pain (COPE) followed by active individual physiotherapy.
45480870|NCT03778619|Drug|Rituximab|weekly administration of Rituximab 375mg/m2 during cycle 1 and 2, monthly administration from cycle 3(up to cycle 6)
45480871|NCT03778619|Drug|Fludarabine|administration of fludarabine 20mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
45689647|NCT00384748|Behavioral|In-home messaging device.|The purpose of this aspect of the intervention is to screen for unforeseen problems and to reinforce adherence to the recommended treatment. It will be used to interface with patients daily, but briefly. The in-home messaging device, which resembles a caller ID box is attached to the home telephone line and electrical outlet. Installation of the equipment involves connecting it to the phone line and plugging it into an electrical outlet. The teletherapist receives the clinical data from the in-home messaging device via the internet on a daily basis. It is used to screen for depression, lower extremity strength, self-care tasks and mobility, falls and exercise adherence.
45689648|NCT00384748|Behavioral|Usual care|Routine VA care.
45689649|NCT00385138|Drug|Cangrelor|cangrelor bolus (30 mcg/kg) & cangrelor infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
45689650|NCT00385138|Drug|clopidogrel|clopidogrel capsules (600 mg) at end of PCI
45689651|NCT00385138|Drug|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) & placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
46050011|NCT04120948|Device|Waterlase Express Laser System|10-minute treatment with the Waterlase Express (Biolase, Irvine CA). The dorso-posterior surface of the tongue is treated with the laser in 10 passes of 60 seconds each with 10 seconds of rest in between. Laser settings were 60μs pulse width, 4W, 40Hz, 10% air and 5% water irrigation. An MC12 sapphire laser tip (Biolase, Irvine CA) is held 3mm away from the tongue in a constant sweeping motion during treatment with passes overlapping passes in alternate direction, side to side motion and front to back motion with laser fluence on the tongue surface calculated at 3J/cm2. The settings were non ablative and non thermal.
45689652|NCT00385138|Drug|Placebo capsules - end of PCI|Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing
46050012|NCT04120948|Device|Tongue scraper|mechanical scraping of the dorso-posterior surface of the tongue
45480872|NCT03778619|Drug|Cyclophosphamide|administration of fludarabine 250mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
45480873|NCT03778619|Biological|MG4101(allogeneic Natural Killer cell)|administration every fortnight for each cycle, beginning with the 1st dose of rituximab for that cycle.
45480874|NCT03778619|Drug|Interleukin-2|1 x 10^6 IU/m2, together with MG4101
45689653|NCT00385138|Drug|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
45689654|NCT00446290|Drug|Docetaxel, Capecitabine and Oxaliplatin|
45689655|NCT00385216|Drug|Nicotine|Nicotine nasal spray 3mg x 1 before surgery
45689656|NCT00385216|Other|Placebo|Placebo nasal spray 0mg x 1 before surgery
45689657|NCT00385996|Drug|Tarceva (Erlotinib)|Patients will receive daily erlotinib at 150 mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
45689658|NCT01796158|Behavioral|cASBI+cMET|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit. The cMET protocol is a 2 session intervention composed of 8 exercises designed to encourage adolescents their alcohol and other substance use and develop a plan to stop or reduce their use.
45689659|NCT01796158|Behavioral|cASBI|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit.
45847741|NCT02908620|Drug|One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo)|A single spray of CTY-5339-CB in a metered spray bottle with ≈200 uL total spray volume, containing the active ingredient: 14.0% Benzocaine (USP = 28 mg). This was administered in combination with a single spray of CTY-5339-P (acting as vehicle control placebo with no active ingredient) in a metered spray bottle with ≈200 uL total spray volume. This combination was used to maintain double-blind conditions. The vehicle control was sprayed outside the circumscribed area to avoid dilution of active drug.
46050013|NCT00609882|Other|Nasal CPAP|"Infants randomized to the Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O post extubation"
45363129|NCT00858416|Device|"sham followed by Kineticure System"|sham device during the first 4 weeks then 2 weeks wash out period followed by 4 weeks for 20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion)
45363130|NCT00848978|Behavioral|8-week aerobic and strength training program|Participants allocated in the intervention group will be enrolled in three weekly non-consecutive training sessions for 8 weeks. Each session will last for about 45-50 min. The exercise program will consist of muscular strength and aerobic exercises. Each session will start and end with a low intensity ~5-7 min warm-up and cool-down period respectively, consisting mainly of stretching exercises involving all major muscle groups.
45363131|NCT00858572|Drug|STA-9090 (ganetespib)|Chemotherapy agent
45363132|NCT00858650|Other|Standard of Care|Standard of care may or may not include use of testosterone replacement therapy
45363133|NCT00515086|Drug|Everolimus|Tablets taken once a day with a full glass of water.
46050014|NCT00609882|Other|Humidified High Flow Nasal Cannula (HHFNC)|HHFNC
46050015|NCT04259190|Behavioral|interoceptive exposure|Repeated 60-second trials of voluntary hyperventilation, each followed by a 15-second rest period. Participants will complete a minimum of 8 trials and continue additional trials until ratings of their most feared predicted outcome fall less than or below 5% likelihood.
46050016|NCT04258956|Drug|Axitinib|"Avelumab 10 mg/kg will be administered every two weeks. Avelumab is administered as a 1-hour iv infusion, diluted with 0.9% saline solution; Axitinib 5 mg should be taken orally twice daily approximately 12 hours apart with or without food. They should be swallowed whole with a glass of water. If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.~The duration of treatment cycle is 28 days."
45480875|NCT05714176|Drug|Ferric Pyrophosphate Liposomal|30 pediatric patients who will receive oral liposomal iron (Novoferr) 30 mg/day for 12 weeks.
45480876|NCT05714176|Drug|Lactoferrin|30 pediatric patients who will receive oral iron supported Lactoferrin (Provan) 100 mg/day for 12 weeks.
45480877|NCT05714176|Drug|Iron Dextran Injection|30 pediatric patients who will receive IV iron dextran 50 mg /3 times weekly for 12 weeks.
45480878|NCT03156504|Drug|Ketamine Hydrochloride|Subjects will receive three IV ketamine infusions at 0.5 mg/kg, infused over 100 minutes.
45480879|NCT03316612|Dietary Supplement|Vaccinium Myrtillus L. extract|Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
45480880|NCT03316612|Dietary Supplement|Placebo|Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
45480881|NCT05187312|Procedure|Endoscopic retrograde Cholangio- pancreatography|Endoscopic intervention in the biliary or pancreatic duct
45480882|NCT05187312|Procedure|Endoscopic ultrasound|Endoscopic investigation/intervention with ultrasound
45689660|NCT00470392|Drug|Imiquimod|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
45363134|NCT00515086|Procedure|Surgery|Salvage surgical resection
45363135|NCT00849134|Drug|GSK1482160 or placebo|GSK1482160 is a P2X7 receptor antagonist
45363136|NCT00861224|Other|No Intervention for Observational Study|No intervention was used on this protocol, as this was an observational study.
45363137|NCT00861302|Behavioral|Mind-body emotional awareness program|This intervention, developed and offered by Dr. Howard Schubiner of St. John Providence Health System, consists of a single individual session with him, followed by four, classroom group sessions. The intervention includes expressive writing, mindfulness, and other techniques designed to enhance awareness and acceptance of the emotional factors underlying the chronic pain problem.
45363138|NCT01011322|Drug|LT-02|Comparison of different dosages of drug versus placebo. 4 times daily over 12 weeks
45363139|NCT01011322|Drug|placebo|placebo
45480883|NCT01333332|Drug|Capecitabine|Capecitabine
45480884|NCT01333332|Radiation|Standard Dose Acclerated Fraction Radiotherapy|Standard dose accelerated fraction radiotherapy
45847742|NCT02910102|Drug|RVT-101 35 mg|RVT-101 once daily, oral, 35-mg tablets
45480885|NCT01308827|Procedure|Blood culture|A baseline blood culture will be obtained in all participants
45480886|NCT01308827|Procedure|Other cultures per Clinical routine practice|Cultures from other sterile sites will be obtained per routine clinical practice
45689661|NCT00470392|Drug|Clobetasol|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
45689662|NCT00470548|Drug|Abraxane|ABI-007 IV administration following pemetrexed on Day 1 of each cycle (infused over 30 minutes)
45689663|NCT00470548|Drug|Alimta|Pemetrexed IV administration on Day 1 of each cycle (infused over 10 minutes)
45689664|NCT04388488|Device|CONNECT TF adaptable socket system|Prefabricated, adaptable socket system
45480887|NCT03316534|Drug|Aspirin|Aspirin (100 mg once a day)
45689665|NCT04388488|Device|Any conventional handmade socket|Subjects current socket
45847743|NCT02910102|Drug|Placebo|Placebo once daily, oral
45847744|NCT02911818|Behavioral|CMS-recommended lifestyle counseling|21 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
45847745|NCT02911818|Drug|Liraglutide 3.0mg|Liraglutide is a once-daily self-administered, subcutaneous (beneath the skin) injection.
45363140|NCT00858806|Drug|Imatinib|"Intermittent Imatinib administration.~1 week on / 1 week off for the 1st month(weeks 1-4)~2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)~1 month on / 1 month off from the 4th month thereafter (weeks 13 on)"
45480888|NCT01338948|Procedure|preoperative 3D-CT reconstruction|Robotic Surgery with CT reconstruction images using Tile-pro program.
45480889|NCT05498051|Procedure|Sentinel lymph node identification|Therefore this prospective study aims to assess the safety and feasibility of lymph node identification using bevacizumab-800CW in patients with cT1-3N0-2 tumours, using peritumoral submucosal injections.
45480890|NCT05714020|Other|Real rTMS|Repetitive transcranial magnetic stimulation (rTMS) is applied to the primary motor cortex. The protocol consists of 15 minutes of 10Hz stimulation, 10 seconds on, 20 seconds off, at 90% RMT, for a total of 3000 pulses.
45480891|NCT05714020|Other|Sham rTMS|A sham coil is also used to mimic the clicking sound of the transcranial magnetic coil and skin stimulation.
45480892|NCT04476420|Dietary Supplement|Nigella sativa oil|Using N.sativa oil as an alternative to conventional management will help us to find a treatment option which is non-invasive, cost effective, inexpensive, easy available and belongs to a natural source with almost no side effects.
45480893|NCT04476420|Drug|Betamethasone Valerate|it is a conventionally used drug for treating OSMF
45480894|NCT03778463|Other|Synovectomy|Removal of the synovium during total knee arthroplasty
45480895|NCT03314896|Procedure|Laparoscopic surgery|
45480896|NCT03778541|Drug|Temozolomide|75mg/m2/d concurrent with radiotherapy, taken for at least 20 days.
45480897|NCT03778541|Radiation|hypofractionated radiotherapy|the regular radiation dose prescription is 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.
45480898|NCT03159468|Behavioral|Cognitive Restructuring|Participants receive didactic instruction regarding cognitive restructuring skills and then practice using these skills in hypothetical situations.
45480899|NCT03159468|Behavioral|Mindfulness|Participants receive didactic instruction regarding mindfulness skills and then practice using these skills in hypothetical situations.
45480900|NCT03159468|Other|Alcohol consumption|Participants consume an alcoholic beverage in the lab.
45480901|NCT02479828|Drug|Fascia iliaca compartment block|40 ml ropivacaine 0,5% injected under fascia iliaca using ultrasound
45480902|NCT02479828|Drug|Ropivacaine|
45480903|NCT02479828|Device|ultrasound|
45480904|NCT02479828|Drug|Placebo|
45480905|NCT01320449|Drug|recombinant human erythropoietin|rHuEpo (5000 IU)is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-10.
45480906|NCT01320449|Behavioral|Training|For ten weeks participants will receive supervised endurance training on a bike three times a week. Physical effect will be examined with VO2-max tests before during and after the training period.
46050017|NCT00862654|Drug|clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo & ketoconazole shampoo
45480907|NCT01320449|Other|Placebo|placebo (saline) is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-12.
45480908|NCT02482714|Behavioral|Physical activity.|Have subject do moderate physical activity.
45480909|NCT02479672|Device|laryngoscopy|Placement of endotracheal tube. If successful intubation does not occur after the first attempt at laryngoscopy, airway equipment used in further attempts will be selected at the discretion of the attending anesthesiologist.
45480910|NCT02479672|Procedure|Manual Inline Stabilization|Manual immobilization of Patient's neck with intention to minimize movement from baseline position
45689666|NCT00472576|Drug|MK-0657|Daily double-blind administration of the NR2B antagonist MK-0657 (4-8 mg/day)
45689667|NCT00472576|Drug|Placebo|Daily double-blind administration of placebo
45689668|NCT00388414|Drug|duloxetine|30-60mg of duloxetine daily
45689669|NCT00388414|Drug|Placebo|Placebo pill once daily
45689670|NCT00475150|Drug|cediranib maleate|Given orally
45689671|NCT00475150|Other|laboratory biomarker analysis|Correlative studies
46050018|NCT00862654|Drug|clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo & ketoconazole shampoo
46050019|NCT00862654|Drug|clobetasol propionate shampoo (2/week)|Monotherapy with clobetasol propionate shampoo
46050020|NCT00862654|Drug|ketoconazole shampoo (2/week)|Monotherpay ketoconazole shampoo (2/week)
45480911|NCT02479672|Device|VividTrac®|
45480912|NCT05187234|Other|Education|Experimental: intervention group Education and training booklet based on the Roy adaptation model was given to the patients. The training was repeated at the first welcome and after the first month.
45480913|NCT03774251|Biological|Platelet-Rich Plasma Injection|The patient will undergo a single platelet-rich plasma peritendinous injection
45480914|NCT03774251|Device|Extracorporeal Shock Wave Therapy|The patient will undergo a series of three extracorporeal shock wave therapy treatments to the lateral hip
45480915|NCT03314818|Device|Ultrasound 3D Imaging|"Carotid artery ultrasound will be used to:~Determine plaque presence and plaque burden Presence of stenosis~Additionally, Carotid Intima-Media Thickness (IMT) will be measured and aortic diameter will be measured by abdominal aortic ultrasound scanning.~Ultrasound of the Abdominal Aorta will be used to determine the presence and severity of stenosis or aneurism."
45480916|NCT03430063|Drug|SDREGN2810|Standard dose intravenous (IV) infusion
45480917|NCT03430063|Drug|SDREGN2810/ipi|Combination therapy dose IV
45480918|NCT03430063|Drug|HDREGN2810|High dose IV
45480919|NCT04802057|Drug|SAR445088|Pharmaceutical form: solution for injection
45480920|NCT02485366|Drug|Rejuvesol|Blood transfused during surgery will be treated with Rejuvesol.
45480921|NCT02485366|Procedure|Cardiac surgery|The study interventions will take place during a routine admission for pediatric open heart surgery. The anesthetic technique for subjects undergoing cardiac surgery is standard care and the research study interventions will not change these practices in any way.
45480922|NCT01308905|Device|FLT-PET|PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection).
45480923|NCT03158220|Biological|V503|V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6
46050021|NCT00609180|Behavioral|Minimal (Trophic) Feeding|Enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
45480924|NCT04492462|Other|Formal Physical Therapy|Patients will undergo standard physical therapy following their surgery with a physical therapist in an office
45480925|NCT04492462|Other|Self-directed Physical Therapy|Patients will undergo self-directed physical therapy in the comfort of their own home by completing a list of exercises and stretches without the direct supervision of a physical therapist in a physical therapist office
45480926|NCT01308983|Drug|Amiloride|Amiloride 10 mg orally once a day for 16 weeks
45480927|NCT03718585|Other|whole exome sequencing analysis|Collecting peripheral blood samples (2 ml) from subjects for whole exome sequencing
45689672|NCT04388410|Biological|convalescent plasma|Plasma obtained from volunteers who have recovered from SARS-Cov-2 infection. Two 200 ml infusions will be administered with 24-72 hours in between.
45689673|NCT00450424|Other|counseling intervention|Participants in the Counseling intervention will meet with the study health educator who will provide the participant with the standard MSI informed consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. The patients will either sign (or not sign, if they do not consent to have the test, or wish to think further about the decision) after this discussion. Participants who have further questions will be referred to either the attending physician or the genetics counselor at each hospital site.
46050022|NCT00609180|Behavioral|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
46050023|NCT00609180|Dietary Supplement|Omega-3 Fatty Acids and Antioxidant Supplements|Omega-3 fatty acids, GLA, and antioxidants will be administered through a feeding tube every 12 hours as a 120-cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
46050024|NCT00609180|Dietary Supplement|Placebo|The study placebo will be administered through a feeding tube every 12 hours as a 120 cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
46050025|NCT00867490|Drug|Candesartan+HCTZ - Phase 1|4 weeks treatment with candesartan 32 mg (two 16 mg tablets) plus hydrochlorothiazide 25 mg (two 12.5 mg tablets) taken orally with water in the morning between 7 and 10 am.
45480928|NCT03316456|Diagnostic Test|Observational: Stool Sample Collection|"Observational: Stool Sample Collection~- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
45480929|NCT03316456|Diagnostic Test|Observational: Blood Sample Collection|"Observational: Blood Sample Collection~- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
45480930|NCT03316456|Diagnostic Test|Observational: Urine Sample Collection|"Observational: Urine Sample Collection~- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
45480931|NCT03774017|Procedure|one-staged hybrid operation|An integrated procedure that consists of microsurgery, intraoperative DSA, endovascular intervention techniques and other assistance tools. All the procedures are performed in a one-staged operation without any intermission or any transfer of patients.
45847746|NCT02911818|Other|Portion-Controlled Diet|A 1000-1200 kcal/day portion-controlled diet prescribed for 12 weeks.
45847747|NCT02911818|Drug|Placebo Oral Tablet|
45847748|NCT02911818|Drug|Phentermine 15 MG|
45847749|NCT02911818|Behavioral|Extension Study CMS-recommended lifestyle counseling|4 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
45480932|NCT03774017|Procedure|Traditional microsurgical operation|The classical mode of operations in neurosurgery. The operation is performed with neurosurgical instruments and microscope. Some of assisting tools can be used in the operation, such as neuro-navigation, Doppler probe, neural electrophysiological monitoring and so on. But neither the intraoperative DSA nor endovascular intervention techniques is used in the operation
45480933|NCT02484976|Behavioral|Family Based Behavioral Treatment|Obese children accompanied by at least one parent or caregiver will attend 24 weekly in-person sessions. Sessions will include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 9-11 children/families will be initiated every 3-6 mos. in study yrs. 1-3.
45480934|NCT01336842|Drug|Panobinostat, Cisplatin, Pemetrexed|"Drug: Panobinostat Oral (by mouth) once daily every Monday, Wednesday, and Friday for the first two weeks of each three week cycle (as per dose escalation schedule (dose levels 1 and 2: AUC 5; dose levels 3 and 4: AUC 6). Number of cycles: 6 maximum.~Drug: Cisplatin IV (in the vein) on day 1 of a 21-day cycle Number of cycles: 6 maximum. Drug: Pemetrexed IV (in the vein) on day 1 of a 21-day cycle Other: Correlative studies Biomarker Analysis: blood collected pre-study and Cycles 2-6, Day 1."
45480935|NCT05178407|Dietary Supplement|Multiple micronutrient-fortified bouillon cube|Bouillon cube fortified with 80 µg/g folic acid, 1.2 µg/g Vitamin B12, 3 mg/g Zinc (ZnO), 4 mg/g Iron (FePP/citric acid/trisodium citrate), 200 µg/g Vitamin A (retinyl palmitate), 30 µg/g Iodine (KIO3)
45480936|NCT05178407|Dietary Supplement|Control bouillon cube (iodine-only)|Bouillon cube fortified with 30 µg/g Iodine (KIO3)
45480937|NCT02485132|Other|Observational|Investigators propose to perform a one-week baseline testing (pre-initiation of the SU), at initiation (first week after the first dose of the SU) and after a 3 months follow-up of treatment with a SU, including CGMS reading, medical history measures, quality of life and diabetes treatment satisfaction.
45480938|NCT03785171|Procedure|surgical revascularization|Indirect revascularization procedure
45847750|NCT02912364|Drug|Eslicarbazepine|Healthy adults will be titrated onto Eslicarbazepine Acetate (800mg daily) . After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
46050026|NCT00867490|Drug|Aliskiren+HCTZ - Phase 2|Patients with uncontrolled mean sitting diastolic blood pressure (msDBP ≥ 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am.
46050027|NCT00867490|Drug|Aliskiren+HCTZ+amlodipine - Phase 3|The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP ≥ 90 mm Hg and/or msSBP ≥ 140 mm Hg) at the end of Phase 2 were offered 4 weeks treatment with aliskiren 300 mg plus HCTZ 25 mg in a single tablet plus an amlodipine 5 mg tablet taken orally with water in the morning between 7 and 10 am.
46050028|NCT04263012|Other|collection of patient data|assess mortality rate, rehospitalization and survival rate of patients after receiving an artificial heart implant
46050029|NCT00697060|Drug|Imexon + docetaxel|Imexon at 1300 mg/m2 days 1-5 Docetaxel at 75 mg/m2 day 1
46050030|NCT00930774|Device|FM system|Frequency modulation assistive device
46050031|NCT00930774|Behavioral|Auditory training|Participation in computerized auditory training program for eight weeks
46050032|NCT04248504|Other|Digital Genetic Assistant|An end-to-end digital solution to the carrier screening process from participant registration to receipt of the test results and their interpretations. These steps are provided using personalized animated videos.
46050033|NCT04261530|Behavioral|Self-hypnosis/self-care|
46050034|NCT04261530|Behavioral|Music/self-care|
46050035|NCT04261530|Behavioral|Self-care|
45363141|NCT00858884|Other|Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain|All participating subjects (patients with and without neuropsychiatric SLE and healthy controls) will undergo clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
45363142|NCT01011478|Drug|rosuvastatin|
45363143|NCT01011478|Other|placebo|
45363144|NCT02545088|Device|Hybrid Assistive Limb (HAL)|Intensive gait training with Hybrid Assistive Limb (HAL) is performed 1 session/day, 3 days/week for 6 weeks and each session will not exceed 60 min of effective walking time with HAL. In addition, each session will include conventional gait training that will not exceed 30 min effective training time.
45363145|NCT02545088|Other|1st control group|Conventional gait training performed 1 session/day, 3 days/week for 6 weeks that will not exceed 1h 30 min effective training time.
45363146|NCT02545088|Other|2nd control group|The 2nd control group will not receive an intervention.
45363147|NCT00849368|Drug|Azathioprine / Allopurinol|"Both drugs are applied orally. A pre-specified dose escalation regimen will be chosen.~Azathioprine: Imurek (R) 50 mg and 25 mg tablets~Allopurinol: Mephanol (R) 100 mg tablets"
45480939|NCT02485210|Procedure|Endodontic treatment|It will be done the endodontic treatment using the photosynamic therapy for decontamination of the root chanel.
45480940|NCT03156270|Device|Vivaer Stylus|Stylus used to deliver low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
45480941|NCT02485054|Other|Clinical, ophthalmological and neurological evaluation|Clinical : questionnaire about the symptoms and about the vascular risk factors Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography
45480942|NCT01339026|Drug|Prasugrel|Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
45480943|NCT01339026|Drug|Plavix|Clopidogrel (Plavix) Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.
45480944|NCT03429049|Drug|CNTX-4975-05|Receiving CNTX-4975-05 injection
45480945|NCT03429049|Drug|Placebo|Receiving Placebo injection
45480946|NCT03314740|Drug|Paclitaxel|Comparator active compound
45480947|NCT03314740|Drug|Cediranib|Experimental compound
45480948|NCT03314740|Drug|Olaparib|Experimental compound
45480949|NCT01336920|Drug|carfilzomib|Given IV
45480950|NCT02482558|Other|High/Low Glycaemic index test breakfast|High/Low Glycaemic index test breakfast on test days for a High/Low Glycaemic index 7-day diet
45480951|NCT01339104|Drug|Regorafenib (Stivarga, BAY73-4506)|All subjects will receive regorafenib administered from Day 1 -21 at a dose of 160 mg od (4 x 40 mg tablets) followed by a 7 days break in repeating cycles of 28 days. The drug is to be taken in the morning with approximately 240 mL of water after having a low fat breakfast. Holter ECGs with triplicate measurements will automatically be obtained at specified timepoints over 24 hours on days -1 and Cycle 1, Day 21. PK samples will be drawn on Cycle 1, Day 21. PK timepoints are time-matched with Holter ECG timepoints. 24 hour urine will be collected beginning on Cycle 1, Day 21. MUGA scans will be done at screening, Cycle 2 Day 21 (after 42 doses of BAY73-4506), then every 3 cycles starting in Cycle 5, and at end of treatment.
45480952|NCT03778151|Device|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATIO will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.
45480953|NCT03428815|Device|Prosthesis suspension liner|Liners out of phase change material will be fitted
45480954|NCT02482480|Other|Exercise|Walking in community Oropharyngeal exercises Diet recommendations Dietary recommendations Education
45480955|NCT02482480|Other|Control|Dietary and general recommendations
45480956|NCT05187078|Procedure|Allis clamp|Physicians utilized an Allis clam for cervical stabilization during IUD placement.
45847751|NCT02912364|Drug|Carbamazepine|Healthy adults will be titrated onto Carbamazepine (400 mg bid). After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
46050036|NCT04261530|Behavioral|Psycho-education|
45363148|NCT02544932|Drug|dabigatran|After randomization, patients of this group was will be treated to dabigatran 110mg or 150mg twice a day for 24months
45363149|NCT02544932|Drug|ribaroxaban|After randomization, patients of this group was will be treated to ribaroxaban 20mg once a day for 24months.
45363150|NCT02544932|Drug|Warfarin|After randomization, patients of this group was will be treated to warfarin and controlled by INR 2-3 for 24months.
45363151|NCT02544854|Drug|Propofol|"Propofol infusion will be started after inhalational induction by manual infusion by the following scheme:~First 15 minutes: 15 mg/kg/min~16 to 30 minutes: 13 mg/kg/min~31 to 60 minutes: 11 mg/kg/min~61 to 120 minutes: 10 mg/kg/min Dose will be titrated to maintain BIS between 40 - 50.~Venous sampling for plasmatic levels of propofol measuring will be made at the following moments:~5, 15 and 25 minutes of starting infusion,~1, 3, 5, 7, 9 and 12 minutes of bolus and,~5, 25, 60 and 120 minutes of infusion ended."
45363152|NCT00861458|Drug|Pharmacokinetics|Single dose of 750 mg PF-00868554 as a solution and tablets.
45363153|NCT00861536|Drug|ATG Fresenius|Day 0: 9 mg/kg bw bolus Days 1-4: 3 mg/kg bw/d
45363154|NCT00861536|Drug|Thymoglobuline Genzyme|Day 0-3: 1.5 mg/kg bw/d
45363155|NCT00849446|Device|Activity monitor (SenseWear Pro armband)|Activity monitoring during specific physical activities such as walking at different speeds
45363156|NCT02544776|Drug|Clomifene citrate ( clomid 50 mg )|
45363157|NCT02544776|Drug|Amlodipine|
45363158|NCT00859118|Drug|AG-013736|Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only)
45480957|NCT05187078|Procedure|Single-tooth tenaculum|Physicians utilized a single-tooth tenaculum clam for cervical stabilization during IUD placement.
45480958|NCT05681507|Drug|Transversus thoracic muscle plane block|Ultrasound guided bilateral parasternal injection of bupivacain 0.375%, 20ml, at 4th thoracic vertebral level.
45847752|NCT02913924|Drug|Clonazepam|fixed-flexible daily dose to a maximum of 2 mg (1 mg twice per day) for the first 8 weeks of the trial
45847753|NCT02913924|Drug|Placebo|
45480959|NCT05681507|Procedure|Standard postoperative analgesia|Standard of postoperative ICU analgesic care, per institutional protocol
45480960|NCT02482636|Biological|DTaP/IPV/Hib vaccine|Given at 2, 3 and 4 months to Group 1 and 2
45480961|NCT02482636|Biological|13 valent Pneumococcal Conjugate Vaccine|Given at 2,4 and 12 months in group 1, given at 3 and 12 months in group 2
45480962|NCT02482636|Biological|Rotavirus vaccine|Given at 2 and 3 months to Group 1 and 2
45480963|NCT02482636|Biological|4-component Meningococcal B vaccine|Given at 2, 4 and 12 months to Group 1 and 2
45480964|NCT02482636|Biological|Meningococcal C/Hib vaccine (MenC/Hib vaccine)|Given at 12 months to Group1 and 2
45480965|NCT02482636|Biological|Measles/Mumps/Rubella Vaccine (MMR vaccine)|Given at 13 months to Groups 1 and 2
45480966|NCT03716245|Procedure|supraclavicular lymph node dissection|people with supraclavicular lymph node metastasis before surgery should receive dissection of supraclavicular lymph node and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
45480967|NCT03716245|Radiation|supraclavicular area radiotherapy|people with supraclavicular lymph node metastasis before surgery should receive radiotherapy of supraclavicular area and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
45480968|NCT03155724|Device|MultiPole Pacing|CRT non-responders are programmed with MultiPole pacing ON.
45480969|NCT03784469|Other|Changing body position in bed|The first hour:Supine position. The second hour:lateral position (right or left). The third hour:Supine position. The fourth hour:lateral position (right or left).
45480970|NCT02482402|Drug|Inhaled Iloprost|Treatment effect will be controlled at each study visit and the dose and/or inhalation frequency will be adapted.
45480971|NCT02482402|Drug|Placebo|inhalation solution placebo
45480972|NCT03777839|Diagnostic Test|FDG PET/CT|FDG PET CT imaging with rest perfusion imaging
45480973|NCT03426787|Behavioral|Decision Aid|Participants will have the option to view a web or paper-based version of the decision aid.
45480974|NCT03774173|Drug|Aramchol|One Aramchol tablet (300 mg) twice daily and 2 Aramchol tablets (300 mg each) once daily
45689674|NCT00450424|Other|CD-ROM intervention|Participants who are randomized to the CD-ROM condition will complete the baseline interview and then meet with the health educator who will provide the participant with the standard MSI consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. Next, the participant will be provided with the CD-ROM to view on a laptop computer in the clinic. Participants will also be given a copy of the CD-ROM to take home and keep for future reference. The CD-ROM patients will sign (or not sign, if they do not consent or wish to think further about the decision) the consent form after this discussion.
45689675|NCT00451048|Drug|sunitinib malate|Given orally
45363159|NCT00859118|Drug|AG-013736|Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.
45363160|NCT00859196|Drug|Dexpanthenol (BAY81-2996)|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
45480975|NCT01336998|Dietary Supplement|arginine|oral L-arginine supplementation 261mg/kg/day (1,5mmol/kg/day), one dose daily ,from the 3rd day of life until the 28th day of life
45480976|NCT05713864|Device|BTL-899|The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered.
45480977|NCT05713864|Device|HPM-6000UF|The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
45689676|NCT00388804|Procedure|Radiation Therapy|Radiation treatment given over about 8 1/2 weeks; 42 treatments, 5 days per week with 2 days rest in between.
45480978|NCT03774095|Dietary Supplement|Hydrolyzed pine nut oil|Given 30 min prior to oral glucose tolerance test
45689677|NCT00388804|Drug|Bicalutamide|50 mg By Mouth (PO) Daily
45689678|NCT00388804|Drug|Leuprolide|22.5 mg Intramuscularly (IM) Every 3 Months or 7.5 mg IM Every 1 Month
45689679|NCT00388804|Drug|Goserelin|10.8 mg Subcutaneously Every 3 Months or 3.6 mg Subcutaneously Every 1 Month
45689680|NCT00388804|Drug|Flutamide|250 mg by mouth three times daily on first 21-30 Days. May be used instead of Bicalutamide.
45480979|NCT03774095|Dietary Supplement|Hydrolyzed pine nut oil and olive oil|Given 30 min prior to oral glucose tolerance test
45480980|NCT01333410|Drug|tacrolimus ointment|2 applications per days for 6 months
45480981|NCT01333410|Drug|Mometasone furoate|2 applications per day for 6 months
45480982|NCT03426631|Drug|Placebo oral capsule|Placebo capsule 30 minutes before sleep
45480983|NCT03426631|Drug|DAW1033B2 oral capsule|DAW1033B2 capsule 30 minutes before sleep
45480984|NCT02482012|Other|Survey|This was a survey
45480985|NCT04604951|Device|Transcutaneous Spinal Cord Stimulation|This non-invasive therapeutic modality uses electrodes applied over the skin to deliver electrical stimulation. It is based on the same principles of ground-breaking work from the investigator's group and others, showing that stimulation of the spinal cord can promote motor and autonomic (cardiovascular, bladder, bowel) recovery in individuals with chronic SCI.
45480986|NCT01315470|Drug|neupogen administration for women with recurrent IVF failure|neupogen 300 mcg - twice
45480987|NCT02482090|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
45480988|NCT02482090|Drug|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
45480989|NCT02482090|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
45480990|NCT02482090|Drug|Interleukin-2|Interleukin-2 is administered as a continous i.v. infusion in a decrescendo regimen (18 MIU/m3 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU/m2 IL-2 over 24 hours followed by 4,5 MIU/m2 IL-2 over another 24 hours for three days).
45480991|NCT05643313|Device|ABLE Exoskeleton|The ABLE Exoskeleton is a lower-limb overground robotic exoskeleton intended for SCI patients for rehabilitation in a clinical setting.
45480992|NCT03773861|Other|errors made in one BLS session|BLS instructors have to oversee a standardized BLS training session, where standardized errors are made by trained volunteers.
45480993|NCT01337154|Drug|Tamibarotene|Tablet, 6 mg/m2, oral, divided into twice a day dosing.
45480994|NCT01337154|Drug|Placebo|Tablets, orally, daily
45480995|NCT03719911|Behavioral|Live diabetes coaching program|Live diabetes coaching program
45480996|NCT03777683|Dietary Supplement|Dietary Supplement (OLIGOPIN)|investigators obtained ethical approval from the Research Ethics Committees of the Mashhad University of medical sciences. investigators enroll 60 patients who are admitted to ICU at hospitals of university. All eligible patients or their first degree relatives give informed consent before participating. Participants are randomly (block stratification) divided in two groups. At the first visit, baseline data are gathered and intervention group (n=30) will receive Oligopin supplement. In order to control the confounding effect of food intake, both the control and the intervention group receive the standard formulas based on their daily required energy via enteral root feeding.
45480997|NCT03777683|Other|Placebo|investigators obtained ethical approval from the Research Ethics Committees of the Mashhad University of medical sciences. investigators enroll 60 patients who are admitted to ICU at hospitals of university. All eligible patients or their first degree relatives give informed consent before participating. Participants are randomly (block stratification) divided in two groups. At the first visit, baseline data are gathered and control group (n=30) will receive oral capsules containing 130 mg Microcrystalline Cellulose. In order to control the confounding effect of food intake, both the control and the intervention group receive the standard formulas based on their daily required energy via enteral root feeding.
45480998|NCT02482324|Drug|ALZT-OP1a|Mast cell stabilizer
45480999|NCT02482324|Drug|ALZT-OP1b|anti-inflammatory
45481000|NCT02482324|Device|Dry Powder Inhaler|The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.
45481001|NCT05676437|Diagnostic Test|Stress radiography|Radiographic examination during clinical stress test of knee laxity
45481002|NCT05185284|Drug|Favipiravir|400 mg, lyophilizate for preparation of concentrate for solution for infusion
45481003|NCT05185284|Drug|Favipiravir|200 mg coated tablets
45481004|NCT05185284|Drug|Remdesivir|100 mg, lyophilizate for preparation of concentrate for solution for infusion
45481005|NCT02482168|Drug|APX005M|APX005M is a CD40 agonistic monoclonal antibody
45481006|NCT03484429|Device|Peripheral nerve stimulation|Up to 60 days of peripheral nerve stimulation
45481007|NCT03484429|Other|Standard Medical Therapy|Medications, physical therapy, or other pain treatments
45481008|NCT03784703|Drug|Atorvastatin 40 Mg Oral Tablet|40 mg per day atorvastatin (ATROVA group, n= 80) for 6 months
45481009|NCT03784703|Drug|Rosuvastatin 10 Mg Oral Tablet|10 mg per day rosuvastatin (ROSUVA group, n= 80) for 6 months
45481010|NCT05525260|Drug|Limonene capsule|Citrus foods rich in D-limonene were forbiden 2 days before taking the drug (washout period), which was maintained after taking the drug.Limonene capsules group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo control group and limonene capsule administration group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the treatment group and the placebo control group at a ratio of 1:1. The drug was administered for 12 weeks, 3 times a day, 5 capsules each time.
45481011|NCT05525260|Drug|Limonene capsules(Placebo)|Limonene capsules(Placebo)
45481012|NCT01339182|Drug|Pegylated-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-Somatropin, 10mcg/kg.
45481013|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 30mcg/kg.
45481014|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 60mcg/kg.
45689681|NCT00388804|Behavioral|Questionnaire|Questionnaires regarding health-related quality of life given before therapy begins, each taking about 15 minutes to complete.
45689682|NCT01795066|Device|EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)|
45689683|NCT00389818|Biological|filgrastim|Supportive therapy: GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
45689684|NCT00389818|Biological|pegfilgrastim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
45689685|NCT00389818|Biological|rituximab|375 mg/m2 IV Day 1 of each cycle
45689686|NCT00389818|Biological|sargramostim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
45689687|NCT00389818|Drug|cyclophosphamide|750 mg/m2 IV Day 1 of each cycle
45689688|NCT00389818|Drug|pegylated liposomal doxorubicin hydrochloride|40 mg/m2 IV Day 1 of each cycle
45689689|NCT00389818|Drug|prednisone|100 mg PO Days 1-5 of each cycle
45689690|NCT00389818|Drug|vincristine sulfate|1.4 mg/m2 IV Day 1 (2.0 mg maximum) of each cycle
45481015|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 120mcg/kg.
45481016|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 200mcg/kg.
45481017|NCT04464785|Device|CentriMag Circulatory Support System|The CentriMag Circulatory Suppose System is indicated for providing support for up to 30 days for one or both ventricles of the heart to treat post-cardiotomy patients who fail-to-wean from cardiopulmonary bypass, providing a bridge to decision when it is unclear whether the patient's heart will recover or whether the patient will need alternative, longer-term therapy.
45481018|NCT01337232|Behavioral|Complex sentence treatment protocol|Treatment: listening, speaking, reading, and writing activities that teach three types of complex sentences. Individual sessions are 40 minutes in length, delivered by or under the supervision of a certified, trained speech-language pathologist.
45481019|NCT01337310|Drug|Tesetaxel|The starting dose for the first 3 patients treated will be 24 mg/m2. In the absence of dose-limiting toxicity, the dose will be increased by 3 mg/m2 for the next group of 3 patients treated. Interpatient dose escalation will continue in this manner to 27 and 31 mg/m2 until the maximum tolerated dose or the maximum dose allowed per protocol (31 mg/m2) is reached and 6 patients are treated at this dose.
45481020|NCT03484273|Device|LifeWrap Compression Garment|Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.
45481021|NCT02724592|Device|self assembling peptide P11-4 (Curodont™ Repair)|Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions
45481022|NCT02724592|Device|fluoride varnish (Duraphat®)|Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions
45481023|NCT05186844|Behavioral|survey application|Scales and questionnaires were applied to children and their parents according to age groups.
45481024|NCT03773783|Device|Button and Bead appliance|Button and Bead appliance
45481025|NCT03773783|Device|Twin Block appliance|Twin Block appliance
45481026|NCT01333566|Behavioral|Intervention Group|The study will include one week baseline phase, 6-week intervention phase, and a 3-month follow-up evaluation. Subjects in the intervention group will go through three training sessions during the baseline phase, weekly group exercise sessions once per week and daily home exercises two times each day during the intervention phase, and a follow-up evaluation in three months after the intervention phase.
45481027|NCT01333566|Behavioral|Placebo Comparator: Control Group|Subjects in the control group will be monitored during the baseline and intervention phase without participating in the interventional exercise. At the end of intervention phase, the subjects will have the option to stop their participation or switch to the intervention group.
45481028|NCT02476864|Drug|Treatment A (adult formulation)|Single oral administration of one film-coated tablet containing 10 mg of macitentan as active substance and lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate type A, polysorbate as inactive ingredients.The film coat contains titanium dioxide, talc, xanthan gum, polyvinyl alcohol, and soy lecithin.
45481029|NCT02476864|Drug|Treatment B (pediatric formulation)|Single oral administration of two dispersible tablets, each containing 5 mg of macitentan as active ingredient and Mannitol delta polymorphic crystals, mannitol, isomalt, isomalt agglomerated, croscarmellose sodium, and magnesium stearate as inactive ingredients.
45481030|NCT05652413|Behavioral|Adapted-Engage-PA|Enhanced motivation strategies for increasing walking using personal values assessment and value-guided goal setting, adapted from Acceptance and Commitment therapy. Strategic activity pacing to increase stamina and reduce pain flares when walking, using the Activity Rest Cycle, from Pain Coping Skills Training. Culturally sensitive elements for older adults who identify as African American such as linking motivation to spirituality, family, community, and other personally-meaningful values.
45481031|NCT02761122|Procedure|Human biological samples|"Blood sample~Skin or mucosal brushing~Skin or mucosal biopsy"
45481032|NCT01320527|Dietary Supplement|Nutriceutical formulation|Two pills that collectively contain: folic acid (400µg), Vitamin B12 (6µg), Vitamin E (as alpha-tocopherol; 30 IU), S-adenosylmethionine (SAM; 400mg), N-acetyl cysteine (NAC; 600mg) and Acetyl-L-carnitine (ALCAR; 500mg). Taken once daily for duration of study (1 year).
45481033|NCT01320527|Other|Placebo|A mixture of 6 vitamins and nutriceuticals
45481034|NCT01339338|Procedure|warming the contrast media|warm the contrast media with 37℃ water-bathing
45481035|NCT05453188|Device|Experimental|Pre- and post-intervention measurement of quality of life, self-perceived fatigue and blood lactic acid concentration after each Nordic Walking session.
45481036|NCT05453188|Genetic|Control|Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine genetic profile and allele frequencies of patients with persistent COVID and association by Total Genotype Score (TGS) with fatigue status.
45481037|NCT01309061|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular infusion of Autologous Adipose Tissue derived MSCs with autologous microlipoinjection. Dose: 1x10e7 cells/500ul/lipoinjection 20ml
45481038|NCT03314428|Behavioral|Gait retraining|Over a 4-week period, runners will be asked to increase their step rate to reduce knee loading during running. Specifically, they will have to increase their preferred step rate by 10% during weekly laboratory running sessions as well as during habitual running training. In the laboratory, runners will be provided with live visual/auditory biofeedback on step rate and asked to target a specific value representing 110% or preferred step rate. During their individual running sessions, runners will be wearing a GPS-enabled watch that will provide feedback on live step rate, and they will be asked to maintain the same value as in the laboratory.
46050037|NCT00867334|Drug|Imatinib mesylate and panitumumab|Patients will be entered into sequential cohorts with escalating doses of imatinib mesylate. After approximately 28 days of monotherapy treatment with imatinib mesylate, patients will be asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). All patients in this group will then receive imatinib mesylate in combination with standard-of-care doses of panitumumab. After approximately 1-2 months of combination treatment, patients will asked to have an additional liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). Combination treatment will continue for the remainder of the subject's time in the trial.
45363161|NCT00859196|Drug|Placebo|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
45481039|NCT03773549|Other|Virtual reality experience|Expose all participants (healthy and control) to virtual reality videos while collecting reactivity and self-report outcome measures.
45481040|NCT03635736|Other|multiple-spectral-sonography as acustocerebrography (ACG)|After inclusion three times at day measurements with ACG for each 45 minutes; a (non-invasive) sonography. The measurements will be stopped after final evaluation of the neurological status using common methods like magnetic resonance tomography, transcranial doppler sonography, electroencephalography and other methods.
45689691|NCT00389818|Other|immunohistochemistry staining method|tissue specimen collected at baseline
45363162|NCT00849602|Drug|Placebo|Placebo bid for three days
45363163|NCT00849602|Drug|Chloroquine|Chloroquine bid for three days
45481041|NCT04213079|Device|re-adaptation of the vestibulo-ocular reflex|The VOR will be readapted by activating velocity storage with full-field optokinetic motion at 5°/s in a set direction while the head is oscillated with a set frequency and direction. The readaptation training will be conducted in repeated modules, each lasting for 1-5 min. The expected duration of daily sessions varies from 30 to 90 min. A day's session will be terminated if patient no longer feel symptoms of MdDS.
45481042|NCT04213079|Device|Habituation of velocity storage of the vestibulo-ocular reflex|The central (velocity storage) time constant will be reduced by inducing cancellation of two velocity storage-mediated responses: OKN and the VOR. Sinusoidal rotation at 0.017 Hz (1 revolution/min) in darkness advances the slow phase eye velocity of the VOR by 32º. In contrast, the OKN at this frequency has no phase advancement. Thus, to counteract the VOR by OKN, the optokinetic stimulus should be set to 32º phase advance the out of phased head rotation stimulus. Since the conflict stimulus is expected to be overwhelming to patients at higher chair velocities, subjects will be first trained with a 10°/s stimulus. In a previous study, no complaints were reported when subjects were tested at such low velocities. Preliminary testing show signs of symptom improvement when the peak velocity reached 30°/s to 40°/s.
45481043|NCT05451550|Procedure|Brachial plexus block|An additional ultrasound-guided suprascapular nerve block(0.375% ropivacaine) were performed before general anesthesia induction in general anesthesia combined with brachial plexus block group
45481044|NCT05451550|Procedure|General anesthesia|General anesthesia were performed according to clinical routine: induction drugs: propofol, sufentanil, rocuronium, maintenance drugs: propofol, sevoflurane and remifentanil, Laryngeal mask ventilation.
45481045|NCT05451550|Procedure|Suprascapular nerve block|An additional ultrasound-guided suprascapular nerve block(0.375% ropivacaine) were performed before general anesthesia induction in general anesthesia combined with brachial plexus block group
45481046|NCT01339494|Dietary Supplement|Arginine and citrulline supplementations|Arginine or citrulline will be given orally at dose of 10 grams per meter square body surface area per day divided every 4 hours.
45481047|NCT02476708|Dietary Supplement|curcumin 1800mg|Curcumin, derived from turmeric root, is an over-the-counter supplement which is tolerated well.
45689692|NCT00389818|Other|laboratory biomarker analysis|tissue specimen collected at baseline
45689693|NCT00452374|Drug|Cytarabine|1 g/m^2 given IV for two days (Days 2 and 3).
45689694|NCT00452374|Drug|Fludarabine|30 mg/m^2 given IV for two days (Days 2 and 3).
45363164|NCT00859274|Drug|budesonide|Budesonide is given via inhalation utilising a dry powder inhaler called Easyhaler. The dosage is 400 ug twice daily. The duration of the study is 12 weeks but very probably the patients continue the usage of this drug as a part of their routine clinical management.
45363165|NCT00859352|Drug|AZD1981|oral tablets during 14 consecutive days.
45363166|NCT00859352|Drug|Midazolam|Each subject will receive two single doses of 7.5 mg midazolam given as oral solution. The Midazolam dose will be given on Day 1 and on day 16.
45363167|NCT00861770|Other|Ultrafiltration|Ultrafiltration based on standard of care.
45363168|NCT00861770|Other|Ultrafiltration using BVM|Ultrafiltration will be guided by blood volume measurement results.
45363169|NCT00618410|Device|Carbon dioxide, USP|Carbon dioxide (CO2) delivered via a nosepiece at a flow rate of 0.5 (± 0.05) SLPM for 10 seconds /nostril
45363170|NCT00618410|Other|Placebo|Nasal placebo
45481048|NCT02476708|Dietary Supplement|Placebo|oral placebo capsule
45481049|NCT01341522|Procedure|MRI exam|MRI exam
45481050|NCT01341522|Procedure|control|waiting room
45481051|NCT03769571|Behavioral|Parental coaching program at ESDM (P-ESDM)|It will have a duration of 7 months (with an inclusion period of 1 year). Parents will come to the hospital with their child once every 15 days for one-hour parental coaching sessions on the ESDM method. Home video sessions will also be performed by parents once every 15 days. Each parent will have a Certified therapist referral to the practice of ESDM and the program is framed by a certified therapist and trained in ESDM parental coaching.
45689695|NCT00452374|Drug|Oxaliplatin|Starting dose of 17.5 mg/m^2 IV for 4 days (Days 1 through 4).
45689696|NCT00452374|Drug|Rituximab|375 mg/m^2 IV on Day 3 of the first cycle over 4-6 hours and on Day 1 on every cycle following.
45689697|NCT01454583|Drug|Aliskiren|Aliskiren (Rasilez®, Novartis) is the first clinically available substance with direct renin inhibition (DRI) which effectively lowers blood pressure.
46050038|NCT00867334|Drug|Standard-of-care treatment with panitumumab|Panitumumab as standard of care. After approximately 2-3 months of standard of care treatment, patients will asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study).
46050039|NCT04120324|Other|Eligible for Same Day Discharge|Preoperative Physiotherapy and Anesthesia Criteria met.
46050040|NCT04120324|Procedure|Primary Single Joint Total Hip Arthroplasty|Total Hip Replacement Surgery
46050041|NCT04120324|Other|Discharge Same Day|Postoperative criteria for Same Day Discharge met.
45363171|NCT00861926|Drug|Ventolin|Ventolin : salbutamol sulfate 100µg
45363172|NCT00861926|Drug|beclometasone /formoterol|BDP 100µg/FF 6µg, 1 inhalation bid
45363173|NCT04041518|Procedure|Autotransplantation|Autotransplantation of tooth with an almost fully or completely developed root with intraoperative extraoral apicoectomy.
46050042|NCT00925704|Drug|Calcitriol|Calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
45481052|NCT05182632|Behavioral|Group pelvic floor telerehabilitation|Multimodal group physiotherapy: 12 weeks of weekly group physiotherapy treatments including education and pelvic floor muscle exercises delivered online + home exercise program
45481053|NCT02479204|Drug|ACT-334441 2 mg|capsule containing ACT-334441 at a strength of 2 mg
45481054|NCT02479204|Drug|ACT-334441 4 mg|capsule containing ACT-334441 at a strength of 4 mg
45481055|NCT02479204|Drug|Placebo|ACT-33441-matching placebo
45481056|NCT02479204|Drug|Atenolol|film-coated tablet containing atenolol at a strength of 50 mg
45481057|NCT02479204|Drug|Diltiazem ER|film-coated tablet containing diltiazem at a strength of of 120 mg
45481058|NCT03784547|Drug|Ocrelizumab|already described
45481059|NCT01339572|Drug|Plerixafor|"240 mcg/kg/day based on ideal body weight will be given for the following conditions:~Pre-apheresis peripheral blood CD34+ count <20 cells/μL on day 5.~Estimated CD34+ cell collection is < 25% of target cell dose after 1 day of apheresis.~Estimated CD34+ cell collection is < 50% of target cell dose after 2 days of apheresis."
45689698|NCT01454583|Drug|ACE-I/ARB|
45689699|NCT01454583|Drug|No RAS-inhibition|
45689700|NCT03286114|Drug|Pembrolizumab|200mg IV every 21 days
45689701|NCT00476242|Drug|Vivitrol|intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)
45689702|NCT00476242|Drug|memantine|Memantine will be given in two divided doses, starting with the second day of the naltrexone induction, with the target doses of 40 mg/day (or the maximum tolerated dose), for a total of twelve weeks of medication treatment.
46050043|NCT00925704|Drug|Lanthanum carbonate + Calcitriol|Lanthanum carbonate (1000 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
45363174|NCT04041752|Behavioral|SOLID|condition with a classical meal served using solid food items
45363175|NCT04041752|Behavioral|LIQUID_P|condition with a liquid meal served using a powder solution
45363176|NCT04041752|Behavioral|LIQUID_L|condition with a pre-prepared meal served using a liquid solution.
45481060|NCT01339572|Drug|Filgrastim|"All patients will receive filgrastim starting 4 days prior to apheresis (D1-4 mobilization). The dose and schedule of filgrastim will based upon the risk category of the patient:~Standard risk: 5 μg/kg SQ BID.~High risk: 10 μg/kg SQ BID."
45689703|NCT00476788|Device|Omnipod Insulin Management System|Initiation of insulin pump therapy within three months of the diagnosis of type 1 diabetes mellitus
45689704|NCT01795144|Drug|GLP-1|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
46050044|NCT00925704|Drug|Sevelamer carbonate + Calcitriol|Sevelamer carbonate (2400 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
46050045|NCT00697138|Drug|d-Amphetamine; Atomoxetine|Dexedrine (0-60 mg/day); Strattera (0-80 mg/day)
45481061|NCT03773705|Procedure|Electrocautery versus scalpel|Electrocautery versus scalpel in the elevation of nasoseptal flaps following endoscopic transsphenoidal pituitary surgery
45481062|NCT04382118|Other|Data collection from routine medical records|Data collection from routine medical records (clinical and radiological data)
45481063|NCT01320605|Biological|Weekly wound spray with components 1 and 2 of the compound HP802-247|Weekly spray with HP802-247
45481064|NCT01341678|Drug|Lanthanum Carbonate|Diet will be supplemented with 1000mg at each meal
45481065|NCT01341678|Dietary Supplement|NeutraPhos|Diet will be supplemented with NeutraPhos
45481066|NCT01341678|Other|Diet Only|Diet containing 1500mg of phosphorus
45481067|NCT05648357|Biological|Fluarix Tetra Vaccine|A single dose of Fluarix Tetra vaccine administered intramuscularly (IM) on day 1.
45481068|NCT02481856|Drug|SQ tree SLIT-tablet|
45481069|NCT02481856|Drug|Placebo|
45481070|NCT04199117|Drug|Varenicline|Participants randomized to intensive treatment who choose to use this intervention will receive one 0.5 mg pill for the first 3 days, starting 7 days prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. This will not be used at the same time as combination nicotine replacement therapy.
45689705|NCT01795144|Drug|Exendin 9-39|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
45689706|NCT01436175|Drug|SPD489 (Lisdexamfetamine dimesylate) + Antidepressant|SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks
45689707|NCT00453388|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
45689708|NCT00453388|Drug|Cyclophosphamide|Given IV
45689709|NCT00453388|Drug|Cyclosporine|Given IV or PO
45689710|NCT00453388|Drug|Fludarabine Phosphate|Given IV
45689711|NCT00453388|Other|Laboratory Biomarker Analysis|Correlative studies
45689712|NCT00453388|Drug|Mycophenolate Mofetil|Given PO
45481071|NCT04199117|Drug|Combination nicotine patch and nicotine mini-lozenge treatment|Participants randomized to intensive treatment who choose to use this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges for use starting on the target quit date and the following 12 weeks. Participants will be instructed to use 9-20 mini-lozenges per day (one every 1-2 hours) for the first 6 weeks, then reduce to a mini-lozenge every 2-4 hours for 3 weeks, and then a mini-lozenge every 4-8 hours for 3 weeks. Combination nicotine patch and nicotine mini-lozenge treatment will not be used at the same time as varenicline.
45481072|NCT04199117|Behavioral|Monetary incentives for initiating treatment|Participants randomized to this intervention will earn a $40 incentive each time they complete a first counseling session in an available treatment, up to 2 rounds of counseling per year, and up to 4 rounds of counseling over 2 years of enrollment.
45481073|NCT04199117|Behavioral|Automated tailored outreach|Participants randomized to this intervention will receive 5 tailored letters delivered every 4-6 months. Letter content will be tailored to participant demographics and use of study treatment, and personalized with references to their primary care teams and tobacco care manager. Letters offer encouragement to quit and information about how to access available treatments.
45481074|NCT04199117|Behavioral|Care management|Participants randomized to this intervention will receive 5 live, proactive phone calls lasting 10-15 minutes from as assigned Tobacco Care Manager who will provide manualized support and motivational encouragement, discuss available treatment options, and inform the participant how to initiate treatment when ready to quit.
45481075|NCT04199117|Other|Wisconsin Tobacco Quit Line referral|This is recommended standard care that will be offered to participants who are not medically eligible for varenicline or combination nicotine patch or who are randomized to standard treatment access. The Wisconsin Tobacco Quit Line (WTQL) offers a single 20-minute counseling session to all Wisconsin residents ready to set a date to stop smoking in the next month, at no charge, and offers those who meet their medical eligibility criteria a 2-week supply of either nicotine patches, lozenges, or gums, at no charge. The WTQL assumes full clinical responsibility for participants' use of cessation medications dispensed by the WTQL.
45481076|NCT04199117|Other|Primary care provider referral|This is a form of recommended standard care that will be offered to participants who are not medically eligible for varenicline or combination nicotine patch or who are randomized to standard treatment access. Participants who choose to use this intervention will be referred electronically to their primary care provider for counseling and/or medication if they express an interest in quitting in the next 30 days and agree to this referral.
45481077|NCT04199117|Behavioral|Untailored outreach|Participants randomized to this intervention will receive 5 untailored letters delivered every 4-6 months. Letter content will not be tailored or personalized. Letters will offer information about how to access available treatments.
45481078|NCT04199117|Behavioral|Multiple smoking cessation coaching calls|Participants randomized to intensive treatment access who choose to quit will receive three 15-20-minute quit coaching calls from a trained smoking cessation health counselor. Calls will be scheduled for one week pre-quit, one day after the target quit day, and one week after the target quit day.
45481079|NCT02481778|Other|Blood sampling|
45689713|NCT00453388|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
45689714|NCT00453388|Radiation|Total-Body Irradiation|Undergo TBI
45689715|NCT04062123|Drug|Dexmedetomidine|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.15 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, & weight.
45689716|NCT04062123|Drug|Propofol|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.7 mcg/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, & weight.
46050046|NCT02615548|Other|community-based exercise class|This intervention will be held in a community centre, twice per week, for 36 weeks.The participants will have an educational session regarding importance of regular exercise.The class will consist of evidence-based exercises such as: sustained, high effort exercises, resistance exercises, and endurance training.Two trainers with specific for Parkinson Disease training will lead the class.
45363177|NCT04041206|Device|Laser doppler|"Laser doppler will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~Experimental device: Four-channel laser doppler flowmetry (PeriFlux System 5000, Sweden).~Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination. They are asked to keep silent and normal breath and avoid limb movement during the whole measuring period. The probes will be left at 4 measuring sites. Blood flow curve will be recorded constantly using Perisoft software (PeriFlux, Sweden). Microcirculatory flux in the measuring sites will be calculated [Perfusion units (PU) =concentration of moving blood cells (CMBC)×velocity (V)]. The acupoint microcirculation will be recorded for 5 minutes.~Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian"
45363178|NCT00849992|Drug|Imiquimod 5%|Imiquimod 5% cream used three days a week for 4 weeks
45363179|NCT00849992|Procedure|Photodynamic therapy|Photodynamic therapy involves applying Metvix cream to the affected area followed by illumination. It will be done twice during the study at a 2 week interval.
45363180|NCT00862004|Procedure|VATS|video-assisted thoracoscopic surgery (VATS) major pulmonary resection with systematic node dissection (SND) for clinical stage IIIA non-small cell lung cancer
45363181|NCT03846128|Biological|blood sample|blood sample performed on C1D1, C1D14, C2D1, C3D1 and C6D1
45481080|NCT05185206|Device|Class 1 cavity preparation using conventional steel bur and restoration with Cention-n(commercially available restorative material).|"Patients aged between 18 and 55 years having class 1 occlusal caries(1.2 according to G. J. Mount classification) on both sides of arch. In order to standardise the cavity preparation depth(approximately 1.5 to 2mm from the roof of the pulp chamber), the distance from occlusal surface to roof of pulp chamber will be used for measuring with the radiograph. This will be followed by caries removal with convention steel bur followed by restoration with Cention-n and checking of postoperative sensitivity using Visual Analog Scale.The Visual Analog Scale consists of a 100-mm line divided into equal intervals of 10 mm, where 0 represents absence of pain and 100 severe pain. The results of Visual Analog Scale will be classified as mild (0-30 mm), moderate (40-70 mm), or severe pain (> 70 mm)."
45481081|NCT05185206|Device|Class 1 cavity preparation using polymer bur and restoration with Cention-n(commercially available restorative material).|"Patients aged between 18 and 55 years having class 1 occlusal caries(1.2 according to G. J. Mount classification) on both sides of arch. In order to standardise the cavity preparation depth(approximately 1.5 to 2mm from the roof of the pulp chamber), the distance from occlusal surface to roof of pulp chamber will be used for measuring with the radiograph. This will be followed by caries removal with polymer bur followed by restoration with Cention-n and checking of postoperative sensitivity using Visual Analog scale.The Visual Analog Scale consists of a 100-mm line divided into equal intervals of 10 mm, where 0 represents absence of pain and 100 severe pain. The results of Visual Analog Scale will be classified as mild (0-30 mm), moderate (40-70 mm), or severe pain (> 70 mm)."
45481082|NCT02481700|Procedure|Third molar removal|The surgical removal of third molars
45481083|NCT02479282|Procedure|natural cesarean section|
45481084|NCT02479282|Procedure|traditional cesarean section|
45481085|NCT01309139|Drug|Tiotropium|Medium dose of oral inhalation
45481086|NCT01309139|Drug|Tiotropium|Medium dose of oral inhalation
45481087|NCT01309139|Drug|BI 54903|Medium dose of oral inhalation
45481088|NCT01309139|Drug|BI 54903|Medium dose of oral inhalation
45481089|NCT03154476|Drug|Sildenafil|Sildenafil will be initiated at 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week and 20 mg 3 times per day from the third week to the end of the study period, 12 months.
45481090|NCT03154476|Drug|Placebo|Placebo capsules matching study drug
45481091|NCT02479594|Behavioral|competence-feedback|competence-feedback
45481092|NCT02479594|Other|control|control group without competence-feedback
46050047|NCT02615548|Other|self-directed physical activity|Participants from this group will have an educational session regarding importance of regular exercises for Parkinson Disease and will be asked to stay as active as possible.Both groups will be asked to fill out physical activity diary.
46050048|NCT04263168|Diagnostic Test|Continuous Glucose monitoring in the perioperative period|All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').
45481093|NCT03769337|Diagnostic Test|serum biomarkers|Measurement of Serum concentrations of IL-6, TREM-1, CCL2, MMP-9, OPN, IL-1RA, GP-130, C5a, sRAGE, urokinase and presepsin before revision surgery and after 2 and 7 days after surgery
45481094|NCT02476630|Device|StO2 measurement|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
45847754|NCT02916498|Device|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System|Spinal cord stimulation for the management of chronic neuropathic pain
45363182|NCT00859664|Other|Genotyping of Cytochrome P450|Genotyping of Cytochrome P450
45363183|NCT00859742|Procedure|EBUS-TBNA, integrated PET/CT|EBUS-TBNA and integrated PET/CT will be performed for patients with non-small cell lung cancer after induction therapy. PET/CT will be performed before EBUS-TBNA. Negative findings of EBUS-TBNA will be evaluated by surgery.
45363184|NCT00618722|Drug|Deoxycholic Acid Injection|
45363185|NCT00618722|Drug|Placebo|
45363186|NCT02546180|Other|Viewing YouTube videos|The on-line patient education program will highlight postoperative care.
45481095|NCT02476630|Other|Blood Gases|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
45481096|NCT01339650|Drug|ABT-767|ABT-767 once or twice daily for a 28 day cycle
45481097|NCT03784391|Drug|Lampit (Nifurtimox, BAYA2502)|Nifurtimox is a drug already approved in some South American countries since more than 45 years
45363187|NCT02546180|Other|Standard preoperative education|Standard preoperative education will be provided by the surgeon, physician extender and paramedical staff in the clinic.
45481098|NCT01339728|Procedure|far-infrared ray|The duration of far-infrared ray is 20 minutes.
45481099|NCT05338918|Other|Mental Imagery with Virtual Reality Training|Mental Imagery TASK Practice with Virtual Reality Training: 30-40 minutes treatment sessions will be performed three times a week for six weeks, Part 1: 2-3 minutes of relaxation Part 2: Visual Imagery (external motor imagery training) for 5-8 minutes Part 3: Actual Task Practice for 10 minutes Part 4: Virtual Reality based training (including games for lower limb functions) for 10 minutes Part 5:Task Oriented training for 10 minutes Tasks for both (mental imagery + actual task practice) will be: Sit-stand task, Static stance (30 seconds), Indoor walk on a leveled surface, Walk indoor towards target, Forward / Side Stepping, Walking outdoors
45481100|NCT05338918|Other|Virtual Reality Training|Virtual Reality Training: 30-40 minutes treatment sessions will be performed three times a week for six weeks. Games will include River rush, 20000 water leaks, reflex ridge along with task oriented training. Tasks will be: Sit-stand task, Static stance (30 seconds), Indoor walk on a leveled surface, Walk indoor towards target, Forward / Side Stepping, Walking outdoors
45481101|NCT03635580|Other|Negative control|Untreated-control group
45481102|NCT02479516|Behavioral|Community Health Assessment Program Philippines (CHAP-P)|
45481103|NCT01320761|Drug|ATX-101-BA-free|ATX-101-BA-free
45689717|NCT04062123|Drug|Fentanyl|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.9 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, & weight.
46050049|NCT02619604|Other|Education Intervention|Education interventions will be delivered sporadically within the 6-month window between the time the clinician completes the pre-survey and when he/she completes the post-survey. Interventions consist of e-brief publications, teleconferences with project faculty, and evidence based resources.
46050050|NCT00609960|Behavioral|clowns present|clowns present during the proccess of induction of anesthesia
46050051|NCT00609960|Drug|midazolam|midazolam
45481104|NCT01320761|Drug|ATX-101-BA|ATX-101-BA
45481105|NCT01341756|Radiation|Palliative Radiotherapy|Palliative Radiotherapy to a total dose of 36Gy in 12 fractions
45689718|NCT04062123|Device|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired randomly with some of the experimental cues.
45363188|NCT02544698|Biological|One dose of PCV13a vaccine|
45363189|NCT02544698|Biological|One dose of PCV13a vaccine|
45363190|NCT02544698|Biological|three doses of PCV13a vaccine|
45363191|NCT02544698|Biological|three doses of PCV13a vaccine|
45363192|NCT03845816|Behavioral|Self-Compassion Scale (SCS) questionnaire|all included patients with chronic pain will answer the Self-Compassion Scale (SCS) questionnaire
45363193|NCT00862160|Device|ROCsafeTM|using minimized perfusion circuit while CABG
45363194|NCT00850148|Procedure|Anwar|Anwar surgical method
45481106|NCT02476552|Drug|Niraparib Oral Capsules (Labeled)|Single 300 mg dose of niraparib
45481107|NCT02476552|Drug|Niraparib IV (Labeled)|Intravenous (IV) infusion of 100 μg niraparib (containing approximately 1 μCi of [14C]-niraparib)
45481108|NCT02476552|Drug|Niraparib Oral Capsules (Unlabeled)|Single 300 mg dose of niraparib (unlabeled active pharmaceutical ingredient)
46050052|NCT00697840|Biological|Engerix™-B|Intramuscular injection, 2 doses
46050053|NCT00697840|Biological|HBV-MPL 208129|Intramuscular injection, 2 doses
46050054|NCT00697840|Biological|Vaccine containing HBsAg absorbed on aluminium salts - experimental formulation|Intramuscular injection, 2 doses; experimental formulation
45481109|NCT03784313|Procedure|skin repair by axillary perforator flaps|"Perforators flaps (PF) of the axillary region for the coverage the axillary defect left after radical excision for axillary Hidradenitis Suppurativa.~Perforated flap surgery does not involve any procedure or manipulation that may alter the biological characteristics and/or structural properties of the tissue (use autologue pur). A usual dressing is performed daily until complete healing."
45481110|NCT03784313|Procedure|skin repair by secondary wound healing|Secondary intention wound healing (SIWH) for the coverage the axillary defect left after radical excision for axillary Hidradenitis Suppurativa
45689719|NCT04062123|Drug|Placebo|Crystalloid IV solution will be infused, with no active drug.
45689720|NCT00389974|Drug|sunitinib malate|Given PO
46050055|NCT04879134|Drug|Apomorphine Injectable Solution|"Patients will receive the treatment while they are in an OFF period, without the effect of any antiparkinsonian medication. For this study, the initial dose of apomorphine or placebo will be 2 mg. We selected an initial standardized dose based on the pharmacological characteristics of apomorphine. Assessments will be completed 30 and 60 minutes after the initial dose. At 60 minutes from the first dose, a 3 mg dose will be administered, and again, assessments will be completed after 30 and 60 minutes. The total given dosage will be 5 mg. Blood pressure and pulse will be checked every 20 minutes after injections.~Other Names:~Movapo"
45481111|NCT03773315|Dietary Supplement|UMH extract|Schisandra chinensis extract 500 mg/day for 12 weeks
45481112|NCT03773315|Dietary Supplement|Placebo|Starch placebo 500 mg/day for 12 weeks
46050056|NCT04879134|Drug|Placebo|"0.9% saline placebo injection~Other Names:~• Saline"
46050057|NCT00697216|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection
45481113|NCT01316718|Drug|Mesalazine|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
45481114|NCT01316718|Drug|Placebo|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
45481115|NCT01339806|Behavioral|Cognitive Rehab|APT-III, Other standard individual and group interventions.
45481116|NCT01339806|Behavioral|Brainworks|POSIT
45481117|NCT01339806|Behavioral|Informational Handout/Provider Visits|Provider based visits every three weeks and informational handout given to patient in regulation with current standard of care procedures.
45689721|NCT01453725|Biological|Golimumab|Golimumab 50 mg SC injection every 4 weeks
45689722|NCT01453725|Biological|Placebo|Placebo SC injection every 4 weeks
45847755|NCT02917122|Device|active tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
45847756|NCT02917122|Drug|Sertraline|Patients will take Sertraline.
45689723|NCT04076241|Other|Osteopathic manipulative treatment|The investigators applied six different OMT techniques including rib raising, diaphragm release, suboccipital decompression, first rib mobilization, mediastinum mobilization and thoracic inlet myofascial release. Rib raising is used to increase the mobility of the rib cage and to reduce vasoconstriction by regulating sympathetic tone. Diaphragm release is used to increase diaphragm movement. Suboccipital decompression involves traction of the base of the skull. We aim to improve respiration with mobilization of the first rib which is associated with sternum, sympathetic truncus and important vascular structures. Thoracic inlet is an important structure resisting intrathoracic pressure changes during respiration. Finally, the goal of the mediastinum mobilization is to increase the mobility of the rib cage by providing relaxation in the tension of the facial tissues.
45847757|NCT02917122|Device|sham tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
45847758|NCT02917278|Dietary Supplement|Meals|High Protein renal-specific meals
45847759|NCT02921412|Device|fanfilcon A|contact lens
45847760|NCT02921490|Device|FDG PET/MR examination.|All recruited patients will undergo an FDG PET examination focused on the lumbar spine.
45481118|NCT04133909|Drug|Placebo|Placebo is a 0.9% sodium chloride solution. It will be administered as a subcutaneous (SC) injection delivered once every 4 weeks using a pre-filled safety syringe.
45847761|NCT02922582|Drug|DepoTXA|
46050058|NCT00697216|Biological|Engerix™-B|3-dose intramuscular injection
46050059|NCT04879056|Diagnostic Test|PIPS 5.1|Description: Scanning glass slides on PIPS 5.1. This intervention will be applied in the arm of intra-system and the arm of inter-system.
45847762|NCT02922582|Drug|Tranexamic Acid|
46050060|NCT04134130|Drug|Degarelix 120 MG [Firmagon]|Two doses of degarelix, 240 mg, subcutaneously once, at study start.
46050061|NCT04134130|Drug|Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector|Gonal-f 300 IU subcutaneously 3 times per week for 5 weeks.
46050062|NCT04134130|Drug|Testosterone Undecanoate|One dose 1000 mg testosterone once, after 3 weeks.
46050063|NCT04258644|Drug|Camrelizumab+Apatinib+Paclitaxel-albumin+S-1|Combination therapy of 4 drugs, 21 days for one cycle.
46050064|NCT02619448|Drug|Carboplatin|chemotherapy
46050065|NCT02619448|Drug|Paclitaxel|chemotherapy
46050066|NCT02619448|Radiation|70 Gy in 20 fractions over 4 weeks|accelerated hypofractionated RT
46050067|NCT00610038|Drug|glibenclamide|Switching the patients from subcutaneous insulin to oral glibenclamide therapy
46050068|NCT02876588|Other|Unrestricted|Users may open up to 4 patient records at a time.
46050069|NCT02876588|Other|Restricted|Users are restricted to open 1 patient record at a time.
46050070|NCT04970472|Biological|collection of blood, urines, stool and tumor samples|blood, urines, stool will be collected during routine cares. Tumor samples from surgery will also be stored.
46050071|NCT04031248|Device|Whole body vibration|In this study an axial vibratory platform will be used: POWER-PLATE pro 5 AIRdaptive TM HP®. This device is reviewed annually by the technical unit of the company itself and complies with the international regulations that regulate the Medical Devices [Devices Directive (MDD) 93/42 / EEC (ISO 2631. 2011, Powerplate.com, 2013)]. The vibration will be administered with 2 mm of amplitude and 40 Hz of frequency.
45363195|NCT00850148|Procedure|Melles|Melles surgical method
45363196|NCT00862238|Behavioral|Art Messaging|4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, & C
45363197|NCT00862238|Other|Health Promotion|4 session education which offers basic information about the prevention of hepatitis A, B, & C
45363198|NCT00860054|Dietary Supplement|Different amount of phytosterols are added into diets|Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.
45481119|NCT04133909|Biological|Mepolizumab|Mepolizumab is a sterile liquid formulation. It will be administered as a SC injection (100 mg/mL) delivered once every 4 weeks using a pre-filled safety syringe.
45481120|NCT01316952|Drug|Carvedilol immediate release only|All dosages of carvedilol immediate release
45363199|NCT00850226|Behavioral|CT|Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
45363200|NCT00850226|Behavioral|ACT|Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
45847763|NCT02922738|Other|VisualDx|VisualDx is a computerized clinical information technology with medical image and text content in dermatology.
46050072|NCT04031248|Other|EXERCISE group|The program will consist of a routine of 18 exercises that will be executed where the greatest neuromuscular recruitment is sought. Most exercises are dynamic and isotonic. It is structured following the scheduled phases (ACSM, 2013) of warm-up, development and return to calm or stretching. The total duration of the program is 22 minutes, keeping the general lines of high-intensity aerobic interval training, which establishes a rest period at least equal to that of work. The treatment protocol will consist of 11 sessions applied in 4 weeks under an intervention regime of weeks 3 sessions, with a duration per session of 22 minutes, which will be supervised by a physiotherapist with more than 15 years of clinical experience.
45363201|NCT00862316|Device|Oxford Unicompartmental Knee|Knee Arthroplasty
45363202|NCT02544620|Other|Does fulfil of discharge criteria on the day of the surgery|
45363203|NCT02544620|Other|Does not fulfil of discharge criteria on the day of the surgery|
45363204|NCT02546258|Device|A Fungal Nail Treatment|treats the signs of mild fungal nail infections
45481121|NCT01316952|Drug|Carvedilol extended release only|All dosages of carvedilol extended release
45481122|NCT01316952|Drug|Long acting β-blockers|All dosages of LA propranolol and SA metoprolol
45481123|NCT01316952|Drug|Other α1/β-adrenergic antagonists|i.e., labetalol. All dosages. Excluding carvedilol immediate release and carvedilol extended release.
45481124|NCT01316952|Drug|Short acting Non-selective β-blockers and short acting β1-Selective agents|All dosages of short acting non-selective β-Blockers (Carteolol, Levobunolol, Metipranolol, Nadolol, Penbutolol, Pindolol, Sotalol, Timolol) and short acting β1-Selective agents (Acebutolol, Atenolol, Betaxolol, Bisoprolol, Nebivolol)
45481125|NCT01316952|Other|No β-blocker|No β-blocker within the month prior to the index date
45481126|NCT02726074|Drug|Perampanel|
45847764|NCT02925078|Device|Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT)|Placement of implant in a subject with <2 mm mucosa thickness or a subject with ≥2 mm mucosa thickness.
45847765|NCT02925858|Drug|Normal Saline Flush, 0.9% Injectable Solution_#1|Normal saline infusion mimicking infusion rate of ketamine for a given weight
45847766|NCT02925858|Drug|Ketamine Hydrochloride|Ketamine IV infusion (0.5mg/kg bolus prior to incision, 0.5mg/kg/hr until the end of surgery)
45689724|NCT04076241|Other|Yoga respiratory training|Nadishodhana pranayama (Alternate nostril breathing), Ujjayi pranayama (Psychic breath) and Bhramari pranayama (Humming bee breath) were used for the study. Nadishodhana is one of the most common yoga breathing exercises and involves breathing through one nostril while closing the other one. The patients performed 2 sets of 8 breathing cycles with a resting time of 2 minutes between the sets. Ujjayi Pranayama involves soft contraction of laryngeal muscles and the partial closure of the glottis. The patients performed 2 sets of 10 breathing cycles per session with an inspiration:expiration phase as 1:2. Bhramari Pranayama includes a nasal humming sound during exhalation to create slight vibrations on the laryngeal walls, and the inner walls of the nostrils. The patients applied 2 sets of 10 breathing cycles per session with a respiration rate of 3-4/min.
45689725|NCT00454324|Drug|Carboplatin|Carboplatin will be given at a dose of target area under the concentration versus time curve in mg/mL•min (AUC)=6, on Day 1 of a 21 Day Cycle
45363205|NCT00862394|Drug|BDP/Formoterol Next DPI|BDP/Formoterol Next DPI 100/6 µg (daily dose : 200/12 µg)
45363206|NCT00862394|Drug|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 200/12 µg)
45689726|NCT00454324|Drug|Abraxane|"Abraxane will be given at a dose of 240mg/m2 on Day 1 of a 21 Day Cycle (Arm A)~Abraxane will be given at a dose of 80mg/m2 on Days 1, 8, and 15 of a 21 Day Cycle (Arm B)"
46050073|NCT05330520|Procedure|"Butterfly Medical Prostatic Retraction Device (the Butterfly device) removal/replacement"|when necessary, the device may be removed or replaced easily through the urethra due to its minimal surface and easy release from the mucosa covering it.
45363207|NCT00862394|Drug|BDP/Formoterol Next DPI|BDP/Formoterol 100/6 µg (daily dose : 400/24 µg)
46050074|NCT01076036|Device|CorPath 200|CorPath™ 200 robotically-assisted percutaneous coronary intervention
46050075|NCT01076036|Device|CorPath 200|CorPath PCI - robotic-assisted percutaneous coronary intervention
45363208|NCT00862394|Drug|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 400/24 µg)
45363209|NCT02544542|Device|Rectum cooling system|
45363210|NCT02544542|Device|Hyper-hypothermia blanket|
45363211|NCT00862472|Drug|DuoTrav APS|DuoTrav APS QD AM
45363212|NCT00862472|Drug|DuoTrav|DuoTrav QD AM
45847767|NCT02933034|Drug|Manganese-enhanced MRI contrast reagent|MRI using manganese-enhanced MRI contrast reagent (manganese 0.28 mL/kg).
45363213|NCT00860210|Device|Neurostep™ System|The Neurostep™ System is a neurostimulation investigational medical device. The entire system is designed to be implanted into the subject's leg via a surgical procedure, during which electrodes are attached to the peripheral nerves responsible for sensing and stimulating the proper muscles that lift the foot during normal walking.
45363214|NCT00850304|Drug|Cytosar|Cytosar 20 mg /q12h/ sc/10d/q28d for 2 cycle
45363215|NCT00850304|Drug|Arsenic trioxide|Arsenic trioxide 10mg/infusion2h/iv/DW5% d1-d5,d7-d11
45363216|NCT00850382|Drug|Dasatinib|"Induction cycle(s):~Dasatinib 100 mg QD on days 8-21.~Consolidation Cycles 1, 2, 3, 4:~Patients will receive dasatinib 100 mg QD on days 6-28.~Maintenance therapy:~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
45363217|NCT00850382|Drug|daunorubicin|"Induction cycle(s):~Daunorubicin 60 mg/m2/day administered on days 1 through 3"
45363218|NCT00850382|Drug|Cytarabine|"Induction cycle(s):~Cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7).~Consolidation cycles 1, 2, 3, 4:~Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours."
45363219|NCT00860366|Drug|Uric Acid|1 gram dissolved in a vehicle containing 500 ml of 0'1% Lithium Carbonate and 5% Mannitol, IV (in the vein), single dose.
45363220|NCT00860366|Other|Vehicle|Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
45689727|NCT02076399|Drug|Fostamatinib disodium|Fostamatinib (100 mg PO bid or 150 mg PO bid)
45689728|NCT02076399|Drug|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
45689729|NCT02110264|Drug|XR-NTX|Monthly injections of XR-NTX will be administered to participants assigned to either the XR-NTX or XR-NTX+PN groups.
45689730|NCT02110264|Behavioral|XR-NTX+PN|In addition to long-acting naltrexone (XR-NTX), participants assigned to the XR-NTX+PN condition will meet regularly with a patient navigator to assist in accessing psychosocial services when released from jail.
45481127|NCT05182086|Other|Group physical therapy and dietary improvements|20 patients allocated to intervention group. During 12 weeks, patients will participate in a combined lifestyle intervention, including a one-hour physical therapist guided exercise group twice a week and consultation by a nutritional scientist. In case of inadequate intake, dietary supplements will be provided.
45481128|NCT02479438|Other|Diagnosed with GERD|Recording of patient outcomes
45363221|NCT02544464|Drug|ferric carboxymaltose 1000 mg|Ferric carboxymaltose is administered after anesthesia induction
45363222|NCT02544464|Drug|placebo|placebo (normal saline) is administered after anesthesia induction
45363223|NCT00862550|Other|Acupuncture|20 Minute Acupuncture Sessions Before Radiation Therapy Treatment, 3 Days Per Week for 7 Weeks.
45363224|NCT00862628|Drug|Rebamipide|100mg tid, 4 or 8 weeks
45481129|NCT02481388|Other|Maximal exercise ramp test|The maximal exercise ramp test, symptom-limited, performed by all patients in the study was performed based on treadmill ramp protocol through ErgoPC Elite® software associated with 12-channels electrocardiogram. Respiratory variables were obtained in standard conditions of temperature, pressure and humidity (StPD), breath-by-breath, with the patient breathing through a face mask without leaks coupled to gas analyzer (Cortex - Metamax 3B, Germany).To ensure that patients reached maximum effort during the examination, only the tests which patients obtain a respiratory exchange ratio (RR) ≥1.1 were accepted .
45481130|NCT03483961|Biological|CHIKV VLP/unadjuvanted|Vaccine consists of virus-like particles of chikungunya virus antigens
45481131|NCT03483961|Biological|CHIKV VLP/adjuvanted|Adjuvanted formulation includes Alhydrogel
45481132|NCT03483961|Biological|Placebo|Placebo is vaccine diluent alone
45481133|NCT02476318|Device|ArterX Vascular Sealant|
45481134|NCT02476240|Behavioral|Parkinson's disease Sensory Attention Focused Exercise|The first half of the exercise class will include walking exercises that include large magnitude and coordinated movements. All walking will be performed slowly. Walking exercises will be followed by balance, stretching, and coordination exercises while sitting in, or standing near, standard office chairs, utilizing latex Thera-bands®. To ensure that balance and coordination are constantly challenged throughout the intervention, the exercise program progresses each week, increasing in difficulty. Depending on the task, the first set of each exercise will be performed with 'eyes-open' to familiarize participants with the task, and subsequent sets will be performed with 'eyes-closed'. If there is only one set for a specific exercise, the first half of the repetitions will be performed with 'eyes-open' and the second half with 'eyes-closed'.
45481135|NCT02478814|Dietary Supplement|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
45363225|NCT00507442|Drug|VELCADE (bortezomib)|bortezomib 1.3 mg/m^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).
45363226|NCT00507442|Drug|dexamethasone|dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop
45481136|NCT05449444|Drug|Masitinib 4.5 mg/kg/day|Masitinib 4.5 mg/kg/day
45481137|NCT05449444|Drug|Placebo|Matching placebo
45689731|NCT02110264|Behavioral|ETAU|Participants assigned to the ETAU group will receive drug education.
45689732|NCT01795222|Drug|Midazolam|Dormire: Midazolam oral solution 2 mg/mL Sedative was administered with a syringe by the anaesthesiologist
45847768|NCT02933034|Drug|Gadolinium-enhanced MRI contrast reagent|MRI using gadolinium-enhanced MRI contrast reagent (gadolinium 0.2 mmol/kg).
45363227|NCT00507442|Drug|cyclophosphamide|cyclophosphamide 500 mg/m^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop
45363228|NCT00507442|Drug|Revlimid (lenalidomide)|"lenalidomide 25 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDR arm)~lenalidomide 15 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDCR arm)"
45363229|NCT00850616|Biological|V526|0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.
45363230|NCT00850616|Biological|Comparator: Placebo to V526|0.5 mL intramuscular injections of placebo to MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4, and Week 26.
45481138|NCT05449444|Other|Best supportive care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, sodium cromoglicate, antidepressants, antileukotrienes, proton pump inhibitors, and corticosteroids.
45481139|NCT05449444|Drug|Masitinib 6.0 mg/kg/day|Masitinib 6.0 mg/kg/day
45481140|NCT02481466|Behavioral|Portfolio diet and structured exercise|"Diet: Foods will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: A program encouraging 150 minutes of exercise, based on the Quebec Heart and Lung Institute exercise program. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending on goals and tolerance). The target goal will be at least 10,000 steps daily."
45363231|NCT00862706|Drug|Telbivudine/LDT600A|Oral once daily
45689733|NCT01795222|Drug|Placebo|Magistral formula prepared to match Dormire color and consistency, without active ingredients Placebo was administered the same way as midazolam
45689734|NCT01415349|Drug|SSP-002358|1 mg, oral, once
45689735|NCT01415349|Drug|SSP-002358 + omeprazole|SSP-002358 (1 mg) + omeprazole (40 mg) given orally, once
45689736|NCT00528190|Drug|Itraconazole|Oral Itraconazole 5mg/kg/day or identical placebo for 24 weeks
45363232|NCT00860444|Behavioral|Basic Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting.
45363233|NCT00860444|Behavioral|Comprehensive Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting. They will also receive 12 months of telephone counseling and a monthly newsletter.
45363234|NCT00860522|Drug|JVRS-100|Level 1: 0.5 µg/Kg D1,8,15; Level 2: 1.0 µg/Kg D1,8,15; Level 3:2.0 µg/Kg 1,15; Level 4: 2.0 µg/Kg D1,8,15; Level 5: 4.0 µg/Kg D1,15
45363235|NCT00860522|Drug|JVRS-100|Change to Stage 2 with starting dose of 4.0 µg/Kg D1,8,15 if no toxicity level by Level 5.
45689737|NCT02334813|Drug|Prednisone|Continuous daily therapy
45847769|NCT02933502|Drug|DSXS topical product|treatment daily for 28 days
45689738|NCT02334813|Drug|Dexamethasone|4-day pulses every 3 weeks
45689739|NCT00478036|Drug|Acular LS|Details covered in arm description
45689740|NCT00478036|Drug|Pred Forte|Details covered in arm description
46050076|NCT04119856|Other|Affiliation with the outgoing lung team|"The work of the outgoing lung team takes place in the patient's home and involves the following:~The outgoing lung team teaches the patients, relatives and primary care staff about symptoms, treatments and instructions related to COPD.~The patients, relatives and primary care staff can contact the outgoing lung team by telephone day and night.~The patients report symptoms and measurements to the outgoing lung team using telemedicine as patient reported outcomes.~The outgoing lung team initiates appropriate treatment by telephone or a home visit. The outgoing lung team always consults a doctor from the Department of Respiratory Diseases and Allergy before initiating treatment.~The outgoing lung team initiates acute consultations at Department of Respiratory Diseases and Allergy based on patient reported outcomes, home visit or telephone call."
46050077|NCT04258800|Device|Music during colonoscopy|Music during colonoscopy
46050078|NCT04873128|Genetic|Multi-OMICS|Measurement of gene expression in immune cells (Human Peripheral Blood Mononuclear Cell (PBMCs) or total blood) using functional genomics, proteomics, metabolomics and lipidomics tools and compare the dynamics of immune response before and after vaccination against COVID-19.
45363236|NCT00860600|Drug|PG2|500mg/vial, iv infusion, 3 ~ 5 times/week, 2.5 ~ 3.5 hr/time
45363237|NCT02544386|Procedure|MRI and 3D CT scan|Measurement of bone microarchitecture at the legs and wrists by 3D CT Scan and measuring the proportion of fat in the imaging leg bone (MRI)
45689741|NCT00478036|Other|Refresh Tears|Placebo
45689742|NCT04048863|Device|B. Braun Peripheral Advantage (PA) Program|B. Braun PA includes: Christie VeinViewer® Vision2 , Introcan Safety® IV Catheters, STEADYCare™ Smallbore Extension Set, and the PA Education
46050079|NCT02619526|Drug|Nebivolol|Nebivolol 10mg, once a day
46050080|NCT02619526|Drug|Carvedilol|Carvedilol 25mg, twice a day
45363238|NCT04041362|Biological|UB-421|Monoclonal antibody by IV infusion plus standard ART
45363239|NCT04041362|Other|Antiretroviral Therapy (ART)|Standard ART
45363240|NCT02546102|Biological|ICT-107|Autologous dendritic cells pulsed with peptides associated with tumor antigens
45363241|NCT02546102|Biological|Placebo|Control, autologous monocytes-enriched PBMC.
45363242|NCT00860678|Other|Physical activity|
45363243|NCT00860678|Other|no Intervention|
45689743|NCT04048863|Device|Hospital Standard of Care|Standard of Care for PIVC access per hospital protocol
45689744|NCT04522557|Drug|IFNα-2a|After mastectomy, it is used in the cavity of breast before conducting implantation.
45689745|NCT01453023|Drug|Fluticasone Furoate|100mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
45689746|NCT01453023|Drug|Fluticasone Furoate/Vilanterol|100/25 mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
45847770|NCT02935062|Behavioral|Traditional Phonological Therapy|Phonological therapy based on generalizing the sounds presented by figures, repetition and naming words.
46050081|NCT04261140|Other|EQUIA Forte Fil|"Apply cavity conditioner (20% polyacrylic acid) 10 s on enamel and dentine, rinse Mix 10 s and apply bulk-fill Apply EQUIA coat and light cure for 20 s~unit"
46050082|NCT04261140|Other|Clearfil Majesty Esthetic|Apply in 2-mm increment, light cure for 20 s
46050083|NCT04261140|Other|NexComp Flow|Apply in 2-mm increment light cure for 20 s
45481141|NCT02481466|Behavioral|DASH-like diet and structured exercise|"Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.~Exercise: A physical activity/exercise program encouraging 150 minutes of exercise, based on the exercise program developed at the Quebec Heart and Lung Institute. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to develop and support a plan that aims to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending of goals and tolerance) in keeping with maximum achievable goals of participants. The target goal will be at least 10,000 steps daily recorded on their pedometers."
45481142|NCT02481466|Behavioral|Portfolio diet and routine exercise|"Diet: Foods on the dietary portfolio plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g peanuts or equivalent of tree nuts/1000 kcal (Table 1A) and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist."
45363244|NCT00860756|Other|Relaxation CD|A music CD specifically created for this study to promote effective sleep while deployed. It includes sleep instructions tailored to the military deployment environment. The CD includes a voice directed meditation component that helps focus the listener on relaxation in preparation for sleep. The second track is specifically designed music to promote slow breathing and induce sleep.
45481143|NCT02481466|Behavioral|DASH-like diet and routine exercise|"Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.~Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist."
45481144|NCT02481544|Behavioral|Gratitude Journaling Plus SOC|
45363245|NCT00850772|Dietary Supplement|Early post-operative enteral feeding|During primary surgical treatment an enteral feeding tube will be inserted through the patient's nose into their small bowel. Enteral feeding will commence 4 hours following return to ward from surgery. Feeding will start at a rate of 40 ml/hr for the first 24 hours, and then increased to goal weight. Goal will be calculated by 125 kiloJoules/kilogram adjusted body weight.
45363246|NCT00850850|Drug|physostigmine|1 mg of physostigmine time 0 min. If the condition persisted after 15 min. the same amount of active drug would be administered once again.
45481145|NCT02481544|Behavioral|Memorable Events Journaling Plus SOC|
45481146|NCT02478970|Device|Konan SP4000|current standard of care at Kellogg Eye Center
45481147|NCT02478970|Device|NIDEK CEM-350|newly marketed device
45689747|NCT04767321|Drug|LTX-109 gel, 3% w/w|LTX-109 gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
46050084|NCT04261140|Other|3M Espe Bulk-fill|Apply in single increment up to 4 mm; light curing for 20 s
45481148|NCT03482635|Drug|Spesolimab|Solution for infusion
45481149|NCT03482635|Drug|Placebo|Solution for infusion
46050085|NCT04119622|Drug|Toripalimab|toripalimab 240 mg d1; q3w, up to two cycles.
46050086|NCT04119622|Drug|oxaliplatin|oxaliplatin 130 mg/m2 QD, d1,q3w, up to two cycles
46050087|NCT04119622|Drug|capecitabine|apecitabine 1000 mg/m2 BID, d1-d14 ,q3w, up to two cycles
45481150|NCT05428852|Other|Laboratory Biomarker Analysis|Correlative Studies
45481151|NCT05428852|Other|Neurocognitive Assessment|NRG-CC
45481152|NCT05428852|Other|Questionnaire Administration|Ancillary studies
45363247|NCT00850850|Drug|Isotonic sodium chloride solution|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo) time 0 min. If the condition persisted after 15 min. the same amount of non-active drug would be administered once again.
45363248|NCT03845426|Other|Root canal treatment.|Once pulpal necrosis has been diagnosed, root canal treatment will be carried out by the patient's general practitioner. This is an end point for the tooth in the study.
45363249|NCT00860834|Behavioral|Asthma Coaching Program|Parents will have access to an asthma coach for 12 months. Telephone calls between parents and coaches will occur anywhere from once a week to once a month.
45363250|NCT00860834|Behavioral|Usual Care|Children of parents enrolled in the study will receive the normal asthma care that their pediatricians usually provide.
45363251|NCT00860912|Procedure|Collagen Matrix|surgical/reinforcing material
45363252|NCT00860990|Other|Completion of GI quality of life survey|Subjects are asked to complete a survey related to bowel care and its effects on various variables related to quality of life.
45363253|NCT00619892|Drug|quetiapine XR|Subjects will receive daily dosing at night, with a flexible dosing schedule, 50-400 mg.
45481153|NCT05428852|Device|Fitbit|Fitbit Activity Tracking
45847771|NCT02935062|Behavioral|Software Phonological Therapy- SIFALA|The phonological thearapy of this group will be based on software use with phonological model already developed, using naming and repetition of sounds.
45363254|NCT00619892|Drug|placebo|Subjects will receive daily dosing at night with caplets matching the appearance of the active drug. However, caplets will not contain any active medication.
45363255|NCT04040972|Other|Compassion Focussed Therapy|Group compassion focussed therapy. One session every week for 10 weeks. Each session lasts 2.5 hours with two breaks during this time.
45363256|NCT00507130|Biological|MEDI528 0.3 mg/kg|MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
45363257|NCT00507130|Biological|MEDI528 1 mg/kg|MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
45363258|NCT00507130|Biological|MEDI528 3 mg/kg|MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
45363259|NCT00507130|Other|PLACEBO|Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
45481154|NCT05428852|Dietary Supplement|Dietary Intervention|Undergo ketogenic diet
45689748|NCT04767321|Drug|Placebo|Placebo gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
45847772|NCT02935062|Behavioral|Placebo Therapy|No intervention to improve speech.
45847773|NCT02936076|Other|Exercise intervention|
45481155|NCT01309217|Behavioral|Tobacco Tactics Intervention|"At the intervention sites the research nurse will teach the Tobacco Tactics Intervention to nurses. For nurses, the Cessation Toolkit includes: 1) 1 CEU contact hour for training; 2) PowerPoint presentation on behavioral and pharmaceutical interventions; 3) pocket card Helping Smokers Quit: A Guide for Clinicians developed by U.S. Department of Health and Human Services, Public Health Service; 4) behavioral and pharmaceutical protocols; and 5) computerized template for nurse documentation. For patients, the Cessation Toolkit includes: 1) brochure; 2) videotape; 3); and 4) pharmaceuticals."
45481156|NCT01309217|Other|Usual Care|The comparison group will receive usual care in accordance to how the hospital responds to current Joint Commission on Accreditation of Healthcare Organization's (JC) standards. JC standards require that a patient with a smoking history receives at least one of the following: advice to stop smoking, brochures or handouts on smoking cessation, a smoking cessation aid such as nicotine patch, gum, nasal spray, inhaler, lozenge, or bupropion SR, viewed a smoking cessation video.
45481157|NCT05415124|Device|HemoPill|The HemeoPill acute capsule is a small, single use, swallowable capsule with optical sensor. Blood detection by direct measurement of blood in the sensor gap, even in an unprepared digestive tract. Wireless transmission of measured values to the HemoPill Receiver. The maximum measuring time is 9 hours. The length of the capsule is 26.3 mm and the diameter is 7.0 mm.
45481158|NCT02476162|Device|iHealth Wireless Blood Pressure Monitor|"Participants will be provided with an iHealth Wireless Blood Pressure (BP) Monitor and instructions for proper use (based on a standard protocol). The iHealth device pairs easily with a cell phone or other mobile device equipped with the iHealth app (freely available on app stores for both Apple and Android devices). Participants place the cuff on their arm and press start on their mobile device. The device measures BP using the oscillometric method and automatically downloads measurements and timing to a cloud-based server.~Participants will be educated that individual BP readings can be highly variable and that any one high or low reading has little or no significance. They will also be encouraged not to measure their blood pressure more than twice in the morning and twice in the evening."
45481159|NCT03768869|Drug|Low Risk: Oupatient Management|Intravenous Levaquin initially, then oral dosing. Patient discharged to go home to finish medication cycle after initial 120 minutes observation. Patients will be evaluated daily in the clinic, and his or her temperature must be taken and recorded four times per day. Blood cultures will be drawn at clinic visits.
45481160|NCT03768869|Drug|Low Risk: Inpatient Management|Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
45481161|NCT03768869|Drug|High Risk: Inpatient Management|Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
45481162|NCT03768791|Other|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
45481163|NCT03768791|Other|SCS is switched on|Spinal cord stimulator is on
45481164|NCT02479048|Dietary Supplement|Test meal 1|High fat meal (HF) with ½ avocado (~68g), matched to CM for energy content; not matched for macronutrient content or type (e.g., fat type).
45481165|NCT02479048|Dietary Supplement|Test meal 2|High fat meal (HF) with 1 avocado (~136g) matched for energy but not macronutrient content or type.
45363260|NCT00863096|Biological|Gardasil|HPV vaccine
45481166|NCT02479048|Dietary Supplement|Control Meal (CM)|High carbohydrate, high saturated fat control meal (CM) without avocado.
45481167|NCT02475928|Dietary Supplement|zinc gluconate|Zinc supplementation plus nutritional education
45481168|NCT02475928|Dietary Supplement|Placebo|
45363261|NCT00863174|Drug|SPARC147709|SPARC147709 injection
45363262|NCT00863174|Drug|Reference147709|Reference147709 injection
45363263|NCT00870272|Drug|Misoprostol|400mcg misoprostol taken sublingually or buccally
45363264|NCT00863252|Drug|mycophenolate mofetil|Orally at 0.75 g bd to 1 g bd for 6 months
45481169|NCT02475928|Behavioral|Nutritional education|
45481170|NCT01320917|Device|Levonorgestrel releasing device|LNG-IUD device releases levonorgestrel in circulation
45481171|NCT01320917|Device|Cu-IUD insertion|The action of a Cu-IUD does not release any hormonal compound
45481172|NCT02478658|Other|exercise training|high-intensity resistance training
45363265|NCT00863252|Drug|angiotensin blockade|Continuation of angiotensin blockade
45363266|NCT00503308|Procedure|Abbreviated HIV test counseling|abbreviated HIV pre-test counseling
45363267|NCT00870350|Biological|Td5ap|Intramuscular injection of 0.5 mL Td5ap (COVAXiS) on day 1.
45363268|NCT00870350|Biological|Td1aP|Intramuscular injection of 0.5 mL Td1aP (diTekiBooster) on day 1.
45481173|NCT02475616|Drug|PCO371|
45481174|NCT02475616|Drug|Placebo|
45481175|NCT01320995|Procedure|Perineal ultrasound|Perineal ultrasound is performed after delivery in order to better detect sphincter lesions.
45481176|NCT02481232|Biological|freeze-dried group ACYW135 MCV|Group A, C, Y and W135 Meningococcal conjugate vaccine is suitable for immune prevention of epidemic cerebrospinal meningitis more than 2 months of age population
45481177|NCT03768713|Drug|Suvorexant|Insomnia subjects will take a nightly pill of 20 mg Suvorexant for eight weeks.
45481178|NCT03768713|Drug|Placebo|Insomnia subjects will take a nightly pill of 20 mg placebo for eight weeks.
45363269|NCT04040894|Biological|Teprotumumab|Treatment with 8 infusions of Teprotumumab q3W for a total of 21 weeks. Teprotumumab 10 mg/kg will be administered on Day 1 and Teprotumumab 20 mg/kg will be administered q3W for the remaining 7 infusions.
45481179|NCT02481076|Device|Flowtron Hydroven and Coban2 Lite|The patient in the intervention group will use both compression boot and compression bandage, as described in intervention arm
45363270|NCT00863564|Dietary Supplement|Caseine|
45481180|NCT02481076|Other|Braun frame|The leg is elevated on a Braun frame
45481181|NCT02481076|Device|compression bandage|application of flowtron hydroven boot and compression bandage
45481182|NCT03768635|Other|necrotizing external otitis|description of necrotizing external otitis
46050088|NCT04258254|Behavioral|Multimodal|Multimodal intervention will involve hello songs, warm up mainly involve sensory and stretching games, music time involves playing instruments, moving game involves use of music or songs to move the whole body, yoga involves themes/songs to perform yoga poses, and good bye involves a goodbye song and reflections about the session. In all movement conditions, trainers emphasize complex and multilimb coordination (asymmetrical and ipsi/contralateral movements) and balance.
46050089|NCT04258254|Behavioral|General|The general exercise group will begin with hello games/set up and end with reflections and cleanup. Children will engage in limb and body warmup routines, specific strengthening exercises (single-joint/single-limb/symmetrical), moderate intensity endurance exercises involving various obstacle courses, and a cool down routine.
45481183|NCT02478736|Other|No actual intervention|Contact with enrolled subjects requires application of ceberal oximetry electrodes and the preoperative ultrasound (transcranial doppler) of the both MCA. No actual intervention done to subject.
45481184|NCT02475694|Other|No intervention|No treatment
45481185|NCT05713474|Diagnostic Test|Diagnostic EMG exam with microEMG|Diagnostic EMG exam with microEMG
45481186|NCT05713474|Diagnostic Test|Conventional EMG|Diagnostic EMG exam with conventional EMG
46050090|NCT04258254|Behavioral|Standard of Care|The seated play group will also begin with hello/icebreaker games and end with goodbye and cleanup. In between, they will read books and review the story line and overall message and engage in fine-motor activities involving building supplies and art-craft.
45847774|NCT02936076|Other|Delayed exercise intervention|
45363271|NCT00863564|Dietary Supplement|Cod|
45363272|NCT00863564|Dietary Supplement|Gluten|
45363273|NCT00863564|Dietary Supplement|Whey Isolate|
45363274|NCT03893565|Drug|GSK2831781 - Double Blind Phase|GSK2831781 will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
45363275|NCT03893565|Drug|Placebo|Placebo (commercial saline solution) will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
45481198|NCT02480842|Other|Alloplastic free ROM|
45481199|NCT02480842|Other|Alloplastic limited ROM|
45481200|NCT02480842|Other|Oncoplastic free ROM|
45481201|NCT02480842|Other|Oncoplastic limited ROM|
45481202|NCT05713396|Drug|Quinapril|Per os
45481203|NCT05713396|Drug|Losartan|Per os
45481204|NCT05713396|Drug|Quinapril + Losartan|Per os
45481205|NCT02480530|Behavioral|Individual Feedback|Patient gets feedback reports on adherence weekly.
45481206|NCT02480530|Behavioral|Feedback Friend|In addition to individual feedback reports this information will be sent to an assigned family/friend or reciprocal peer.
45847775|NCT02937168|Drug|Reslizumab|Reslizumab will be administered as per the dose and schedule specified in the arm.
45847776|NCT02937168|Drug|Fludeoxyglucose F 18 (FDG)|FDG will be administered by IV infusion prior to each PET/CT scan.
45847777|NCT02937168|Drug|Placebo|Placebo matching to reslizumab will be administered as per the schedule specified in the arm.
45847778|NCT02937558|Drug|Glucagon|Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide
45847779|NCT02937558|Other|Placebo|Isotonic saline
45847780|NCT02938494|Drug|IDP-123 Lotion|Lotion
45847781|NCT02938494|Drug|Tazorac Cream|Cream
45847782|NCT02938494|Drug|Vehicle Lotion|Lotion
45847783|NCT02938494|Drug|Vehicle Cream|Cream
45481207|NCT02480608|Drug|Imatinib|
45481208|NCT02480608|Drug|Hydroxyurea|
45689749|NCT01452789|Drug|sublingual buprenorphine|Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
46050091|NCT04261452|Diagnostic Test|isokinetic dynamometer|"Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. Positioning of the subjects (sitting with hips flexed to 75°) was standardized based on the length of the thigh and leg to minimize individual differences. Correction for the effect of gravity on neuromuscular performance was accomplished by incorporating limb mass into the calculation of torque production. Previous warm-up was repeated five time with an angular velocity of 400°/s. All patients randomly performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.~Measurements of torque, work (J), power (W) maximum (peak), and fatigue index were obtained in both tests. In addition, data were analysed at percent of prediction (percent pred) by reference values previously described for the Brazilian population, corrected by muscle mass and peak values."
45363276|NCT03893565|Drug|GSK2831781 - Open Label phase|GSK2831781 will be administered intravenously in the open label induction phase and subcutaneously in the open label ETP.
45363277|NCT00863642|Procedure|Laparoscopic cholecystectomy within 48 hours of admission|Patients are taken to the operating room for laparoscopic cholecystectomy within 48 hours of admission
45363278|NCT00863642|Procedure|Laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values|Patients are taken to the operating room for laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values
45363279|NCT00865358|Behavioral|Yoga Group|Reproducible standardized 12 week series of hatha yoga classes specifically developed for patients with chronic low back pain and little or no experience with yoga
45363280|NCT00502996|Drug|Methotrexate|>=15 mg po/week
45363281|NCT00502996|Drug|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
45363282|NCT00865436|Drug|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
45481209|NCT02480686|Drug|SOF+PEG+RBV|Sofosbuvir (SOF) 400 mg tablet is administered orally once daily; Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection; Ribavirin (RBV) was administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
45481210|NCT02475538|Device|Electroacupuncture|"Gradual Tapering Benzodiazepines will be tapered off over four weeks. The subjects will be told by a blinded researcher to reduce their daily dose by 25% in the 1st and 2nd week. For the remaining 50%, subjects will be asked to reduce the dose by 12.5% each time for 3-4 days in the 3rd and 4th week. Subjects who are unable to taper according to the suggested plan can reduce dose at a slower pace.~Electroacupuncture The subjects will be treated with electroacupuncture at bilateral Sishencong (EX-HN1), Anmian, Shuaigu (GB8), Touwei (ST8), Taiyang (EX-HN5), Toulinqi (GB15), Neiguan (PC6), Shenmen (HT7), Sanyinjiao (SP6), Taichong (LV3), and unilateral Yintang (EX-HN3), Shenting (GV24), and Baihui (GV20). De qi is achieved if possible. The intensity of electric-stimulation will be adjusted up to a level the subject can tolerate without undue discomfort. The needles will be left for 30 min."
45481211|NCT02475538|Device|Placebo acupuncture|"Gradual Tapering The gradual tapering procedure will be the same as in the Electroacupuncture combined with gradual tapering group.~Placebo acupuncture Placebo needles designed by Streitberger will be used. The placebo needles are inserted to the site 1 inch beside the acupoints of the electroacupuncture group in order to avoid acupressure effect. The needles are held by surgical tape or hair pin to imitate the procedure of acupuncture. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of treatment session will be the same as in the Electroacupuncture combined with gradual tapering group."
45481212|NCT02475382|Drug|Nivolumab|Specified dose on specified days
45689750|NCT01452789|Drug|oral morphine|Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
45689751|NCT01451931|Other|Point-of-care Ultrasound|Perform ultrasonography in the ED (physician).
45689752|NCT01451931|Radiation|Radiology Ultrasound|Diagnostic ultrasound completed in the radiology department at time 0.
45363283|NCT00865436|Drug|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
45363284|NCT00870506|Behavioral|video|5-minute video compared (intervention) to no video and no other intervention (control)
45363285|NCT00870662|Device|AFS System|AFS System with patient specific flow rate
45363286|NCT00715403|Drug|BIBF 1120|
45363287|NCT01013584|Dietary Supplement|cholecalciferol|daily dose
45363288|NCT00863954|Device|Resonator Device|comparison of different parameter settings of electromagnetic fields using the Resonator Device
45363289|NCT00864110|Radiation|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20 mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG will be injected
45689753|NCT01451931|Other|Radiology CT|Computed tomography of abdomen completed in the radiology department at time 0.
45689754|NCT00478192|Drug|Conivaptan|premix bag
45689755|NCT00478192|Drug|Placebo|premix bag
45481213|NCT02475460|Procedure|Less Invasive Surgery (LIS)|Less invasive HM 3 LVAD surgical implant procedure
45481214|NCT02475460|Device|HeartMate 3™|HM 3 LIS
45481215|NCT02475304|Drug|FP187|FP 187 is given as oral tablets twice daily, 500 mg daily
46050092|NCT04261452|Diagnostic Test|Cardiopulmonary Exercise Test|"All exercise tests were performed on an electronically braked cycle ergometer. Standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system.~The incremental exercise test started with 2-min unloaded cycling and increments of 3-10 Watts per min until exhaustion. The anaerobic threshold was estimated by the ventilatory equivalents and V-slope methods and it was determined in agreement by a cardiologist and pulmonologist. Heart rate was determined using the 12-lead electrocardiogram. Throughout the experiment, the pulse hemoglobin saturation (SpO2) was assessed with a pulse oximeter and the 'shortness of breath' was asked at exercise cessation using the 0-10 Borg category ratio scale. All measurements were expressed as percentage predicted for the Brazilian population."
46050093|NCT04261452|Diagnostic Test|Functional Capacity Tests|"The six-minute walk test (6MWT) was in accordance with the American Thoracic Society (ATS). The four-minute step test (4MST) consisted of going up and down a 20-cm high, 40-cm wide and 40-cm long step for 4 minutes.~The investigators measured the heart rate and pulse hemoglobin saturation at rest before each test and every minute of both tests. The investigators assessed dyspnoea and leg fatigue at rest and with the modified Borg scale immediately after finishing the test."
45363290|NCT00864110|Radiation|Technetium 99m ethylenedicysteine-deoxyglucose|99mTc EC-DG injection, single dose, slow IV push over 3-5 minutes, yielding a target activity of 20 mCi (range 20-30 mCi)
45363291|NCT00864110|Radiation|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20 mCi)
45363292|NCT00864188|Dietary Supplement|no bacterial strains|Glucono-Delta-Lactone acidified milk containing no bacterial strains
45481216|NCT02475304|Drug|Placebo|
45481217|NCT02478346|Drug|Fluorescein Sodium|Conventional microsurgical and biopsy procedures and techniques including histopathology and intraoperative imaging will be performed through the completion of the surgery. The surgeon will resect and remove what he believes is the tumor based on previously known criteria (standards of care) regardless of what the Fluorescein angiography demonstrates. For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
45481218|NCT05714566|Diagnostic Test|Clostridioides difficile toxin detection|Using Genexpert kit to detect the stool samples of IBD patients. If C. difficile toxin is positive, the patient is assigned to IBD+CDI group, or else assigned to IBD group. Every sample assigned to Health control group should have negative results for C.difficile toxin tests.
45481219|NCT05371288|Dietary Supplement|NAC (N-acetyl cysteine) , Alpha lipoic acid (ALA), liposomal glutathione (GSH)|Nutritional supplements hypothesized to help reverse some of the COVID long-haul symptoms.
45481220|NCT02478424|Drug|Cannabidiol|"Patients will receive standard GVHD prophylaxis consisting of cyclosporine A twice daily starting on day -1 with target trough levels of 200-400 ng/mL and a short course of methotrexate (15 mg/ m2 on day 1 and 10 mg/ m2 on days days 3 and 6). Patients transplanted from unrelated donors will receive ATG Fresenius at a low dose of 5 mg/kg on days -3 to -1.~Patients will be given oral CBD 150 mg BID starting 7 days before transplantation until day 100."
45481221|NCT02478424|Drug|cyclosporine|
45481222|NCT02478424|Drug|Methotrexate|
45481223|NCT02475148|Drug|JNJ 54175446|
45481224|NCT02475148|Drug|Placebo|
45481225|NCT02475148|Other|High fat/high Calorie Breakfast|
45363293|NCT00864188|Dietary Supplement|One probiotic strain - Lactobacillus paracasei NCC2461|Glucono-Delta-Lactone acidified or fermented milk containing one probiotic strain.
45363294|NCT00864188|Dietary Supplement|Two standard yogurt fermenting bacterial strains - Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus|Fermented milk containing two standard yogurt bacterial strains.
45363295|NCT00864188|Dietary Supplement|Vit B2, B3, C and E, Beta Carotene and Oil|Fermented milk containing nutritional supplements
45481226|NCT03712787|Drug|Tilavonemab|solution for IV infusion
45481227|NCT04492150|Drug|Dextrose 5%/Nacl 0.3% Inj_#3|250 mL/hour of dextrose 5% intravenous drip
45481228|NCT04492150|Drug|Saline|250 mL/hour of normal saline intravenous drip
45689756|NCT04048551|Behavioral|Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum|The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with key stakeholders representing clinics, study staff, and adolescent girls and young women (AGYW) and other formative activities. The training is a whole-site training to address barriers to accessing clinical services by AGYW. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to AGYW in order to reduce stigma-related barriers to healthcare and increase uptake of PrEP and sexual and reproductive health services among AGYW.
46050094|NCT04261452|Diagnostic Test|Lung Function Test|"Spirometry, gas transfer, and static lung volumes were measured in all patients, and airflow was measured using a Pitot-tube based on the American Thoracic Society/European Respiratory Society guidelines. Measurement of maximal inspiratory and expiratory pressures was performed from the residual volume and total lung capacity. Resting blood gases were obtained by samples from the radial artery."
46050095|NCT04261452|Diagnostic Test|Doppler Echocardiography|The same medical doctor performed all echocardiograms and all patients underwent comprehensive echocardiography.
45363296|NCT05325749|Genetic|Screening|Whole exome sequencing will be done and all infants will receive a report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset diseases for which specific care or prevention protocols are available. Families signed additional informed consent will receive an advanced report including variants with no care or prevention available, mid or low risk variants, and variants with late onset or those suggesting relatives to undergo screening.
45363297|NCT05325749|Genetic|Family history record|Families enrolled to the study will receive a genetic consult during which a family history will be taken concerning the inherited conditions.
45363298|NCT05325749|Other|Questionnaire survey|Families invited to the study will be asked to undergo a questionnaire survey regarding the reasons to accept or refuse the study, the familiarity of the aims, methods and outcomes of the study as well as the satisfaction.
45363299|NCT05325749|Genetic|Diagnostic|The results of whole exome sequencing will be analysed according to the infant's phenotype in addition the the general screening pipeline
45363300|NCT05325749|Genetic|Selective screening|The results of whole exome sequencing will be analysed according to the data of prenatal ultrasound examination, family history and other available alarming information in addition the the general screening pipeline
45363301|NCT00864266|Drug|Chemotherapy|Standard cisplatin-based chemotherapy in agreement with the ELCWP guidelines (available on the website www.elcwp.org)
45363302|NCT00918515|Drug|AZD3043|intravenous solution given once as intravenous infusion over 30 minutes
45481229|NCT02475226|Other|type of the brain injury|epidural hematoma
45481230|NCT02475226|Other|type of the brain injury|subdural hematoma
45481231|NCT02475226|Other|type of the brain injury|subarachnoid hematoma
45481232|NCT02475226|Other|type of the brain injury|intraparenchymal hematoma
45689757|NCT04048551|Behavioral|Young Women's Health CoOp (YWHC)|In this study, researchers adapted the Young Women's Health CoOp (YWHC) evidence-based empowerment intervention that addresses issues of gender-based violence (GBV), substance use, and sexual risk to include information about PrEP (pre-exposure prophylaxis) and sexual and reproductive health. AGYW will be provided with comprehensive information and will engage in activities that seek to reduce HIV risk factors and increase PrEP readiness, uptake and adherence.
46050096|NCT04261452|Diagnostic Test|Anthropometry and Body Composition|"Body composition was assessed using a body composition analyzer. Percent body fat was estimated from the resistance and reactance values.~Resistance values and the subject's height (meters), weight (kg), sex, and age (years) were entered into a computer program to estimate percentage of fat, fat mass (FM), and muscle mass (MM)."
45481233|NCT02475226|Other|type of the brain injury|scull fracture
45363303|NCT00865592|Drug|dutogliptin|dutogliptin 400 mg, once daily tablet
45363304|NCT04084223|Other|Ultrasound|"An Ultrasound exam (not performed in routine care) will be performed at Baseline, 1, 3 and 6 months for protocol.~All patients will also have CRP dosage (for DAS28 assessment), RAPID-3 and PROs (performed in routine care but analyzed for the study)."
45363305|NCT00865670|Drug|Azithromycin Monohydrate 600 mg Tablets|
45363306|NCT00865670|Drug|Zithromax (azithromycin dihydrate) 600 mg Tablets|
45481234|NCT02475226|Other|type of the brain injury|brain contusion
45481235|NCT02478268|Drug|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
45481236|NCT02478268|Device|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
46050097|NCT01096316|Behavioral|Depression Care Management|The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST, with a total of 8 PST-PC sessions. Patients with inadequate response after 8 weeks to the first choice will switch or combine treatments. Providers are given extensive feedback about the patient's health care concerns.
46050098|NCT00699166|Drug|DNK333|25 mg and 100 mg oral doses, each taken twice daily
45481237|NCT04053881|Drug|Certolizumab pegol|Active Substance: Certolizumab Pegol Pharmaceutical Form: Prefilled syringe Concentration: 200 mg/ml Route of Administration: Subcutaneous injection
45481238|NCT05713162|Behavioral|Adaptation of the Social Adjustment Enhancement Intervention of the UC Davis MIND Institute (Solomon, 2004).|The social skills intervention program was based on a consented adaptation of the Social Adjustment Enhancement Intervention of the UC Davis MIND Institute (Solomon, 2004). In order to be feasible in a hospital-based service, we adapted the program to 10 sessions. Session structure included initial greeting, free play time, didactic, joke telling, and closing activities. Topics of didactic sessions were related to social competence, such as empathy, talking about feelings, and solving social problems. We also adapted the content of the sessions, including activities proposed by Solomon (2004) but also from other experts in social cognition, such as García-Winner (2000). Each group was comprised by 7-10 participants. Children groups were conducted by a clinical psychologist, a mental health nurse and the support of two master degree students. Adolescent groups were conducted by a psychologist, a psychiatrist and the support of two master degree students.
45481239|NCT05713084|Other|mandibular setback using BSSRO|mandibular setback using BSSRO
45481240|NCT01567553|Other|USPIO MRI - Gadolinium MRI|"USPIO MRI scanning will be performed at :~baseline, month 3, month 6, month 9 and month 12 for patients recruited prior to the 1st of May 2010.~baseline, month3, month 6 and month 9 for patients recruited between the 1st of May 2010 and the 31st of July 2010,~baseline, month 3 and month 6 for patients recruited between the 1st of August 2010 and the 31st of October 2010,~baseline and month 3 for patients recruited between the 1st of November 2010 and the 31st of January 2011,~baseline for patients recruited between the 1st of February 2011 and the 30rd of April 2011.~Gadolinium MRI scanning will be performed at baseline, month 3, month 6, month 9, month 12, month 18, month 24 and month 36."
45481241|NCT05590169|Other|Exercise training|Group 1: Group exercises via Zoom application Group 2: Individual exercises via Zoom application Group 3: Routine treatment
45481242|NCT05714488|Device|blue halo coil catheter|device inserted with coil at the bladder and straight arm in the prostatic urethra proximal to the external sphincter
45481243|NCT03768557|Drug|Minocycline|Minocycline (200mg)
45481244|NCT03768557|Other|placebo|Lactose (400mg)
45481245|NCT02478190|Other|Tight control: goal glucose 350 mg/dL or lower|Goal glucose at discharge will be 350 mg/dL or less.
45481246|NCT02478190|Other|Loose control: goal glucose 600 mg/dL or lower|Goal glucose at discharge will be 600 mg/dL or less.
45481247|NCT05712928|Behavioral|Dance/movement therapy (eMove)|Ten weekly 60-minute individual dance/movement therapy telehealth sessions (eMove) delivered by a board-certified dance/movement therapist. eMove treatment protocol integrates movement techniques, creative embodiment, the non-verbal aspects of self-awareness and interpersonal communication in treatment. eMove sessions focus on helping the participant to increase physical activity level, increasing participants' energy levels and motivation to stay active and better cope with everyday activities, improving overall functioning; reducing severity of negative symptoms of schizophrenia; and providing participants with a sense of connection and social support by connecting with a therapist. In addition, sessions are individualized to the participant's presenting needs.
45481248|NCT01309373|Other|Patient assessment|2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale). The BPRS scale will be used to assess the clinical integration of patients.
45481249|NCT02480140|Other|Self-regulated constraint-induced movement therapy|There were 10 tasks to practice in total, they included fold laundry, put clothes on hanger, brush teeth, dress upper garment, dress lower garment in week one; and use telephone, prepare a cup of tea, sweep floor, wash towel, wash dishes in week two. In the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using SR strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
45689758|NCT01414257|Drug|Methotrexate (MTX)|Methotrexate should be administered at the weekly dose of 6 mg orally once a week or twice or three times a week by subdividing the weekly dose into the relevant number of portions. When administering the subdivided doses, MTX should be administered at the interval of 12 hours on Day 1 to Day 2. When the weekly dose is subdivided into two portions, suspend the administration for the remaining 6 days. When the weekly dose is subdivided into three portions, suspend the administration on the remaining 5 days. Repeat this weekly cycle. The dose should be adjusted as appropriate depending on the age, symptom, tolerability, and response to the MTX Preparation in individual patients. The weekly dose should not be higher than 16 mg.
45363307|NCT00864344|Drug|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under fasting conditions
45363308|NCT00864344|Drug|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under fasting conditions
46050099|NCT04119700|Procedure|Muco-muscular endorectal advancement flap after fistulectomy|After fistulectomy muco-muscular flap of the rectal wall will be mobilized. The muscular defect is sutured with separate interrupted sutures (Vicryl / Polysorb 2/0, 0/0, 3/0). The muco-muscular flap is fixed to the anoderm without tension by interrupted sutures (Vicryl / Polysorb 4/0). The wound of the perianal area is not sutured.
46050100|NCT04119700|Procedure|Primary sphincter reconstruction after fistulectomy|Fistulectomy will be performed. The affected gland is visualized and removed. If there are secondary extensions, they are excised also. Sphincter defect with stitches (suture material Vicryl / Polysorb 2/0, 0/0, 3/0) with restoration of the anal canal profile (suturing of the anodermal-skin border). The skin is not suturing.
45363309|NCT00870974|Drug|[18F]FPEB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of [18F]F-PEB
45363310|NCT00864422|Behavioral|Skilled motor training|This involves training subjects to independently and cognitively activate the deep abdominal muscles, transversus abdominis, with minimal or no activity in other trunk muscles. The contraction is held for 10 seconds and subjects complete three blocks of ten contractions, twice per day for two weeks. This training protocol is commonly used clinically for people with chronic back pain.
45363311|NCT00864422|Behavioral|Walking exercise|The control intervention involves walking exercises for ten minutes, twice per day. Subjects are advised to walk at their own pace with no instructions on activation of specific trunk muscles. The exercise is performed over two weeks.
45363312|NCT00864500|Drug|Clobetasol Propionate 0.05% lotion, single exposure|A: Experimental Subjects received Alpharma USPD, Inc formulated products
45363313|NCT00864500|Drug|Clobex TM 0.05% Lotion, single exposure|B:Active Comparator Subjects received Galderma Laboratories, L.P. formulated products
45689759|NCT00528268|Drug|Sodium phenylbutyrate (NaPB)|The powder form of the drug will be dispensed. The target NaPB dosing is 450-600 mg/kg/day, divided into four doses. For cohort 1, we propose to continue treatment for 18 months. For cohort 2, we propose to continue treatment for 24 months.
45689760|NCT04490044|Other|Under & Over rehabilitation tool|Under & Over is a tool consisting of a 40cm x 40cm white plastic board, two coloured laces and a series of patterns to complete. It enables people to create patterns by threading each lace under, and over the board. It has been designed and developed with people whose upper limb function is affected by their MS. Administration time can be dependent on the person completing it.
45689761|NCT00528580|Drug|Simvastatin|80 mg once daily PO/NG x 4 days
45689762|NCT00528580|Drug|Identical-appearing placebo|once daily x 4 days
45689763|NCT00529126|Drug|SKY0402|SKY0402
46050101|NCT04132726|Other|Massage therapy|Massage therapy performed by a physiotherapist
46050102|NCT04132726|Other|non-effective treatment|non-effective treatment
46050103|NCT02615392|Behavioral|Park Prescription|Please refer to the information included in the arm description.
46050104|NCT00925548|Biological|Tecemotide (L-BLP25) and Hormonal Treatment|"Investigational Arm:~Pretreatment (Single Dose) 300 mg/m^2 of intravenous cyclophosphamide in investigational arm to a maximum of 600 milligrams (mg).~Primary treatment phase:~Hormonal treatment plus 8 consecutive weekly subcutaneous vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)* (Week 1 to 8).~Maintenance treatment phase:~Hormonal treatment plus vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)* at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD).~*calculated as mass of lipopeptide (antigen)"
46050105|NCT00925548|Biological|Placebo of tecemotide (L-BLP25) and Hormonal Treatment|"Control Arm:~Pretreatment (Single Dose) NaCl 9 g/L infusion as a substitute for cyclophosphamide.~Primary treatment phase:~Hormonal therapy plus 8 consecutive weekly subcutaneous placebo doses (Week 1 to 8).~Maintenance treatment phase:~Hormonal therapy plus placebo doses at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD)."
46050106|NCT00925548|Drug|cyclophosphamide|300 mg/m^2 (to a maximum of 600 mg) of intravenous cyclophosphamide.
46050107|NCT00925548|Drug|sodium chloride (NaCl)|NaCl 9 g/L infusion
46050108|NCT00866788|Drug|omalizumab|Administered by subcutaneous injection
45363314|NCT02588963|Other|Health education session|It was created an education health session regarding the prevention of respiratory infections of children, according to caregivers needs. This session have a theoretical component, addressing especially modifiable risk factors of respiratory infections in children, and a practical component where caregivers can learn and practice nasal clearance techniques, demonstrated by the physiotherapist.
45363315|NCT02588963|Other|Nasal clearance Protocol|Nasal clearance protocol consists on the application of physiological serum in the nostrils of the child, followed by the stimulation of nasal inspiration in order to remove mucus from the nose and nasopharynx. The protocol is applied for 3 consecutive days, according to established criteria suggested by Postiaux.
45481250|NCT02480140|Other|Constraint-induced movement therapy|They practised the same 10 tasks as in the SR-CIMT and control groups. The same as the experimental intervention group (SR-CIMT), in the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using the strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
45481251|NCT02480140|Other|Conventional occupational therapy|They practised the same 10 tasks as in the SR-CIMT group described above. They received training for 2 weeks, 5 days a week (therapy days), the same as in the SR-CIMT and CIMT groups.
45481252|NCT04034381|Other|No intervention (descriptive survey only)|No intervention
45481253|NCT03783845|Combination Product|amoxicillin 500mg and metronidazole 400mg|metronidazole 400mg and amoxicillin 500mg three times daily for two weeks
45481254|NCT05349370|Other|Isotopically labeled lactate|A bolus dose of isotopically labeled lactate is given and blood samples from existing catheters are drawn
45481255|NCT03768479|Device|18F-FES-PET|18F-FES-PET/CT imaging before and after cycle 1 treatment with the first line Fulvestrant
45481256|NCT05712850|Procedure|VerteLoc|Posterolateral Fusion
45363316|NCT02588963|Other|Control|Children proceeded to their normal activities at the daycare; Caregivers did not attend to education health session.
45481257|NCT01560689|Drug|Budesonide/formoterol|800 µg/j twice a day, every day
45481258|NCT01560689|Drug|Placebo|Twice a day, every day
45481259|NCT02474914|Drug|Octreotide|Octreotide will be given after PD
45481260|NCT02474914|Drug|Placebo|Octreotide will NOT be given after PD
45481261|NCT03768401|Other|Education|Seminars about wellness and exercise, and resulting therapeutic programs, while living with a neurological physical disability.
45363317|NCT00864734|Drug|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
45689764|NCT00529126|Drug|Bupivacaine HCl|Bupivacaine HCl
45689765|NCT01434693|Biological|Trichuris suis ova|single dose
45363318|NCT00864734|Drug|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
46050109|NCT00866788|Drug|placebo|Participants received a single subcutaneous placebo injection on Day 0 of the study.
46050110|NCT00866788|Drug|H1 antihistamines|Patients received one of the following: Cetirizine 10 mg once per day (QD), Levocetirizine dihydrochloride 5 mg QD, Fexofenadine 60 mg twice per day or 180 mg QD, Loratadine 10 mg QD or Desloratadine 5 mg QD
46050111|NCT00866788|Drug|Diphenhydramine|Diphenhydramine was provided and used on an as-needed basis (25 mg per dose)
45363319|NCT04084691|Other|Physical exercice - moderate intensity|standardized physical activity (moderate intensity) lasting 30 minutes and having a warm-up portion of 5 minutes
45363320|NCT04084691|Other|Physical exercice - high intensity|standardized physical activity (high intensity) lasting 30 minutes and having a warm-up portion of 5 minutes
45363321|NCT04084691|Other|Physical exercice - workout|standardized physical activity (bodybuilding) lasting 30 minutes and having a warm-up portion of 5 minutes
46050112|NCT04132570|Drug|Budesonide|Participants will self-administer 2 nasal sprays of Budesonide (64 mcg/spray) once daily up to 10 +\- 3 Days.
46050113|NCT04132570|Other|Placebo|Participants will self-administer 2 nasal sprays of matching placebo once daily up to 10 +\- 3 Days.
46050114|NCT02619370|Behavioral|Conversation card game|
46050115|NCT02619370|Behavioral|Active Control|
45363322|NCT04084691|Other|Normal meal|- Hyperlipidic meal Energy supply: 800 kcal Distribution of macronutrients: proteins: 15% +/- 5; carbohydrates: 40% +/- 5; lipids: 45 +/- 5 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market The same meal will be taken before the 3 sessions concerned.
45363323|NCT04084691|Other|Normalized meal|"- Hyperglucidic meal Energy supply: 800 kcal Macronutrient distribution: protein 15% +/- 5; carbohydrates 60% +/- 5; lipids 25 +/- 2 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market.~The same meal will be taken before the 3 sessions concerned."
45481262|NCT03768401|Behavioral|Trial Exercise Modalities|Wellness/exercise clinics located at Mayo Clinic, Rochester will be offered to persons with neurological physical disabilities on a regular basis, at least monthly, during the last half of the trial period.
45363324|NCT04084691|Other|Fasting|non meal in the hour before exercise
45363325|NCT00864812|Drug|tiotropium with fluticasone propionate/salmeterol (FSC)|COPD patients treated with tiotropium with fluticasone propionate/salmeterol (FSC)
45481263|NCT03768323|Other|1X airtime incentive|an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 50 Bangladeshi Taka ($0.60 USD) or 5000 Ugandan Shillings (UGX; $1.35 USD as of April 3, 2018) worth of airtime for completing the survey
45363326|NCT00864812|Drug|tiotropium|COPD patients treated with tiotropium
45363327|NCT02590055|Drug|gemcitabine/docetaxel combination|
45363328|NCT00864890|Drug|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
45363329|NCT00864890|Drug|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fed conditions
45481264|NCT03768323|Other|2X airtime incentive|an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 100 Bangladeshi Taka ($1.20 USD) or 10000 UGX ($2.70 USD) worth of airtime for completing the survey
45363330|NCT00919295|Drug|mirtazapine|mirtazapine 15 mg or 30 mg tablet daily at bedtime for 13 weeks
45363331|NCT00919295|Drug|placebo|placebo
45481265|NCT03768245|Behavioral|Health Education and Physical activity program|Its objective is to empower children on healthy lifestyle, addressing four main topics: nutrition (i.e. healthy food, hydration), adequate quantities of food, physical activity, and self-monitoring. The program is implemented in the classroom through workshops planned and conducted by psychologists and nutritionists. A total of 12 workshops are planned, to be conducted once a week, and lasting 50 minutes each. The Physical activity program objective is to develop an active scholar environment, and consists of a moderate-vigorous activity, five days a week. The activities are divided into two types: (a) in the school backyard for 60 minutes, three times a week, and (b) in the classroom two days a week, for 15 minutes three times a day, adding up to 45 minutes daily.
45481266|NCT03768245|Dietary Supplement|Nutrition Program|Its objective is to maintain lean mass, decrease fat mass and ensure mineral vitamins and fatty acids intake, maintain proper growth under National Specific Action Program: Food and Activity4. From total energy, a fat intake of 25-35%, carbohydrate intake of 45-65%, protein intake of 10-30%, and total calories are adjusted according to age. The Nutrition program consists of three meals: breakfast, a snack for a mid-morning playtime, and lunch at school. Food is prepared daily following sanitary and quality standards of Mexican official regulation. Breakfast is served 40 minutes before starting class time, lunch is served 40 minutes before leaving school.
45481267|NCT05020366|Behavioral|Preventing Obesity through Parent Empowerment and the Activation of Routines|Parents will receive a report of their child's current performance and adherence to World Health Organization recommendations in each intervention area. Parents will be coached to build consistent family mealtime routines, in which children are involved in meal preparation, food exploration, and play. They will receive education on appropriate serving sizes for young children and basic information nutrition recommendations. Predictable bedtime routines will be designed to incorporate calming sensory input to improve the transition to bed. Parents will be educated on screen time recommendations and help families brainstorm alternatives to screens, including family-based routines of movement and activity. Finally, parents will be coached to incorporate play into all newly adopted routines, as young children learn though play.
45481268|NCT05020366|Behavioral|Enhanced Usual Care|For the control group, usual care will be enhanced by providing parents with a report of their child's performance and adherence to World Health Organization recommendations in the areas of healthy eating, physical activity, sedentary behavior and sleep. This report will consolidate data based on parent report, written logs, and actigraphy at baseline.
45481269|NCT03769103|Drug|Osimertinib|Daily oral osimertinib
45481270|NCT03769103|Radiation|Stereotactic radiotherapy|1-5 fractions of stereotactic radiotherapy
45689766|NCT01434693|Other|Placebo|
45363332|NCT00865748|Drug|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
45363333|NCT00865748|Drug|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
45363334|NCT00865826|Other|Standardized diagnostic evaluation|Participants will undergo a diagnostic evaluation for TB at study entry
45363335|NCT00865982|Drug|Docetaxel, Cisplatin, Capecitabine|"3 preoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks~followed by resection~and 3 postoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks."
45363336|NCT00866060|Drug|Memantine|20mg memantine
45481271|NCT03768167|Procedure|Posterolateral corpectomy|Investigators' goal in this study is to report clinical series of 26 patients in Sohag university hospital with dorsolumbar metastatic lesions from different primaries treated by single-stage posterolateral circumferential corpectomy with reconstruction by a pyramesh titanium cage and account the degree of improvement regarding the pain.
45481272|NCT03773081|Device|Implantation of the Magmaris scaffold|Subjects will undergo a PCI for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of one single ACS-causing de novo lesions in one separate major epicardial vessels is allowed.
46050116|NCT00697294|Dietary Supplement|Tri-Vi-Sol|All subjects will begin vitamin D supplementation at the first outpatient visit (at 1 week of life) and will continue through the second outpatient visit (at 3 months of age). Dosage will be 400 IU/day of vitamin D in the form of Tri-Vi-Sol vitamin drops.
45481273|NCT01561547|Behavioral|Kangaroo Mother Care|Infant wearing only diaper is held in skin-to-skin contact with mother with flannel blanket around both mother and infant. removal.
45481274|NCT01561547|Dietary Supplement|Sucrose|24% sucrose in volumes between .05 to 2 ml depending on weight of the infant, is inserted by dropper into the infants mouth two minutes before and/or during the painful procedure with up to 3 doses.
45481275|NCT04998214|Diagnostic Test|liver function , prothrombin time , INR , US .|analytic
45689767|NCT04046991|Device|high-definition transcranial direct current stimulation|High definition transcranial direct current stimulation (HD-tDCS) involves the application of low-intensity current through electrodes placed on the scalp. It is believed to elicit brain effects by producing incremental shifts in the resting membrane potential of large numbers of neurons, which alters neuronal firing rates and thus modulates patterns of brain activity in potentially behaviorally-relevant ways. HD-tDCS differs from conventional transcranial direct current stimulation (tDCS) because it employed smaller electrodes configured in such a way as to deliver more focal stimulation of the brain.
46050117|NCT02619292|Behavioral|Mindful Movement Program|Mindfulness is turning one's awareness to the present moment. Movement-dance therapy is the expression of thoughts or feelings through body movement, under the supervision of a licensed professional.
46050118|NCT00699244|Procedure|Peripheral placement of local anesthesia|Peripheral placement of local anesthesia
46050119|NCT00699244|Procedure|Central placement of local anesthesia|Central placement of local anesthesia
46050120|NCT02619214|Drug|30% of oxygen concentration.|30% oxygen concentration during one hour of general anesthesia.
46050121|NCT02619214|Drug|60% of oxygen concentration.|60% oxygen concentration during one hour of general anesthesia.
46050122|NCT00699322|Drug|Sitagliptin|100mg P.O. per day for 1month
46050123|NCT00699322|Drug|Glimepiride|2mg P.O. per day for 1 month
46050124|NCT04119466|Behavioral|Stabilizing training|The training will include the activation of the lumbar multifidus muscle (m. multifudus) and the transverse abdominal muscle (m. transversus abdominis). The performance of the individual stages of the training will be based on Richardson's methodology. One session will comprise 4 sets in which the patient will be asked to do pelvic tilts (draw-in) with simultaneous full exhalation, thus activating the aforementioned muscle groups in different positions: a) prone b) supine with lower extremities flexed c) quadruped d) standing back to the wall. The subjects will perform 3 series consisting of 10 repeats, each of which will last ca. 10 seconds.
46050125|NCT00860470|Dietary Supplement|Iron (27 mg) - folic acid (600 ug)|"Supplement serves as the Control (providing the current standard of care during pregnancy). Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum."
46050126|NCT00860470|Dietary Supplement|Multiple micronutrient|"Containing 15 micronutrients all at an RDA including: vitamin A (770 ug retinol equivalents, vitamin D (5 ug), vitamin E (15 mg), folic acid (600 ug), thiamin (1.4 mg), riboflavin (1.4 mg), niacin (18 mg), vitamin B-12 (2.6 mg), vitamin B-6 (1.9 mg), vitamin C (85 mg), iron (27 mg), zinc (12 mg), iodine (220 ug), copper (1000 ug), selenium (60 ug).~Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum."
45363337|NCT00866060|Drug|Donepezil|10mg donepezil
45363338|NCT00866060|Drug|Placebo donepezil|Placebo donepezil
45363339|NCT00866060|Drug|Placebo memantine|Placebo memantine
45363340|NCT00871052|Drug|Calcipotriol-containing cream|Topical treatment twice a day for 7 days
45363341|NCT00866138|Drug|masitinib (AB1010)|masitinib 9 mg/kg/day per os
45363342|NCT00502840|Drug|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
45363343|NCT00515008|Behavioral|Tai Chi Intervention|The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
45481276|NCT03772769|Diagnostic Test|Target Enriched Multiplex PCR (TEM- PCR)|Target Enriched Multiplex PCR (TEM- PCR) assays will be performed and will probe for the typical array of advanced deep space odontogenic infections, as well as MRSA resistance, clindamycin resistance, and the presence of Panton-Valentine leukocidin (PVL) toxin, a toxin produced by some bacteria.
45481277|NCT03772769|Diagnostic Test|Microbial culture|Standard diagnosis by microbial culture.
45481278|NCT05710354|Dietary Supplement|Nutridrink Compact Protein|Oral Nutritional Supplement, a liquid, ready-to-drink, high protein, high calorie blend. Intended for adult patients (from 18 years of age) with malnutrition or risk of its development. Produced by Nutricia
45481279|NCT05587439|Genetic|Data and Specimen Collection|"Provide blood and/or saliva sample~Answer short questionnaires~Consider consenting to other optional parts of the research such as:~use stored tissue samples related to prior cancer treatment~Allow access to deceased relatives' medical records and stored specimens~Provide blood 1x per year for up to 5 years~Provide contact information of family members"
45481280|NCT02474680|Genetic|Pharmacogenetic testing|Psychotropic genotyping panel
45481281|NCT04636151|Behavioral|Ecological momentary intervention|Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.
45481282|NCT04977700|Behavioral|Intervention Group|Test the developed algorithm that delivers location-based, tailored sun safety advice to Strava users through Strava comments for acceptability, ways of interacting with it, and barriers/willingness to allowing access.
45481283|NCT01309607|Drug|paclitaxel/carboplatin/lapatinib|"Drug doses for the neoadjuvant regimen:~Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~Carboplatin AUC of 2, day 1, 8 of a 21-day cycle~Lapatinib 750mg daily continuously"
45481284|NCT01561625|Other|exercise|resistance training exercise, 1 session, 3 exercises, 80% of max
45481285|NCT05710276|Other|abdominal infrared radiation|In a specific room (controlled temperature and humidity) with a patient lying on his back, we will determine the abdominal infrared radiation with a FLIR® thermal camera (without contact) and quantify the thermal signal by spectral analysis (in degrees Celsius).
45481286|NCT04001933|Other|CPOP Intervention|The intervention consists of two 15-minute interactive modules (maternal and infant OH), integrated into 2 group prenatal care sessions. Led by trained prenatal care providers (facilitators), the maternal module includes discussion of common OH problems during pregnancy, importance of OH, importance and safety of OH care during pregnancy, hands-on skills-building activities of learning and practicing proper tooth brushing and self-assessment of gum health, and presentation of illustrated flossing and OH promotion guides. The infant module includes discussion of infant oral hygiene, avoiding saliva sharing, proper nutrition, and importance of a dental visit by the first birthday. Activities in both modules utilize separate tool kits including tooth brushes, fluoride toothpaste, and other supplies.
45481287|NCT03767855|Drug|CK-3773274 - Granules in Capsule|CK-3773274 formulated as granules in capsule
45481288|NCT03767855|Drug|Placebo - Granules in Capsule|Placebo formulated as granules in capsule
45481289|NCT03767855|Drug|CK-3773274 - Tablets|CK-3773274 formulated as tablets
45481290|NCT03783455|Procedure|Non arthroscopic joint lavage|Instillation of 4 litters of cold physiological serum
45847784|NCT02941614|Behavioral|Distress screening|A brief depression and anxiety screening instrument, the Patient Health Questionnaire-9 (PHQ-9), will be administered to newly diagnosed breast cancer patients in the Distress Screening arm.
46050127|NCT00923364|Drug|Cyclophosphamide (CTX, Cytoxan)|14.5 mg/kg intravenous (IV) (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing) or 50/kg IV once daily x 2 doses on days +3 and +4
46050128|NCT00923364|Drug|Fludarabine(Fludara,Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
46050129|NCT00923364|Procedure|Total Body Irradiation (TBI)|200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients)
46050130|NCT00923364|Procedure|Allogeneic Hematopoietic Stem Cell (HSC)|stem cell transplant
46050131|NCT00923364|Drug|Equine Anti-Thymocyte Globulin|30mg/kg IV (in the vein) once daily x 3 days on Days -6, -5, -4 (3 doses total)
45363344|NCT00515008|Behavioral|Control Intervention|Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
45363345|NCT03326830|Device|High-flow nasal oxygen|oxygen therapy will be delivered through a dedicated system, the Airvo2™ (Fisher&Paykel, New-Zealand).
45363346|NCT03326830|Device|Standard oxygen therapy|Oxygen therapy will be delivered using standard devices such as nasal canula or face mask with or without rebreathing bag
45363347|NCT01013662|Procedure|glycemic control|exogenous insulin
45363348|NCT01011790|Behavioral|Healing Rhythms™ Meditation Program|The Healing Rhythms™ meditation program was chosen as the intervention for this study because it has a long history of use in the consumer market, it provides a dual-mode biofeedback which allows users to visually see their progress, and it provides an attractive and engaging user interface which is enjoyable to use. This is a critical factor as the research cited documents the importance of adherence in achieving optimal outcomes.
45363349|NCT00514540|Drug|Docetaxel|75 mg/m^2 IV over 60 Minutes on Day 1 of 21 day cycle.
45363350|NCT00514540|Drug|Carboplatin|AUC = 5 IV Over 30 Minutes On Day 1 of 21 day cycle.
45363351|NCT00514540|Drug|Etoposide|120 mg/m^2 daily for 3 days of 21 day cycle.
45363352|NCT00514540|Drug|Cisplatin|25 mg/m^2 for 3 days of 21 day cycle.
45363353|NCT00506662|Drug|insulin detemir|Treat-to-target, s.c. (under the skin) injection, once daily
45363354|NCT00506662|Drug|insulin NPH|Treat-to-target, s.c. (under the skin) injection, once daily
45481291|NCT03783455|Procedure|Non arthroscopic joint lavage plus corticosteroid|Instillation of 4 litters of cold physiological serum followed by intraarticular injection of triamcinolone
46050132|NCT02613676|Device|Transcutaneous bilirubin screening|Transcutaneous bilirubin screening before hospital discharge and assessment of risk category according to the Bhutani nomogram
45363355|NCT03121534|Drug|Blinatumomab|"Patients will receive blinatumomab as a continuous IV infusion, commencing on day 15 of cycle 1 and day 1 of cycle 2, for 2 courses of 4 weeks each separated by a 2 week .~blinatumomab will be initiated at 9mcg/day from day 15-21, followed by 28 mcg/day from day 22-28. This will be followed by 112 mcg/day from day 29-42. In cycle 2, patients will be admitted for the first 3 days.blinatumomab treatment-free interval."
45363356|NCT03121534|Drug|Dexamethasone|Dexamethasone 20 mg by mouth or vein 24 hours prior to and within 1 hour before start of treatment in each treatment cycle. If treatment is interrupted for >4 hours at any point, Dexamethasone treatment given before re-initiation of therapy. Dexamethasone 8 mg by mouth or vein every 8 hours given for 48 hours at the commencement of the infusion and after each dose increment.
45481292|NCT03783455|Procedure|Non arthroscopic joint lavage plus hyaluronic acid|Instillation of 4 litters of cold physiological serum followed by intraarticular injection of hyaluronic acid
45481293|NCT03783455|Procedure|Intraarticular injection of corticosteroid|Intraarticular injection containing 40 mg of triamcinolone acetonide.
45847785|NCT02941692|Drug|Oxytocin|
46050133|NCT02613676|Other|Standard care (Visual inspection)|Participants in this group will be assessed for jaundice by visual inspection. Blood draw for TsB will be drawn only if the participant is visibly jaundiced.
46050134|NCT01096160|Drug|MK-8226 BID, 1 mg|MK-8266 1 mg administered as oral capsules (0.7 mg + 0.3 mg), BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
46050135|NCT01096160|Drug|MK-8266 BID, 1.8 mg|MK-8266 1.8 mg administered as oral capsules (1 mg + 0.8 mg), BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
46050136|NCT01096160|Drug|MK-8266 TID, 1.8 mg|MK-8266 1.8 mg administered as oral capsules (0.6 mg), TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
45481294|NCT03783455|Procedure|Intraarticular injection of hyaluronic acid|Intraarticular injection containing 4 mL of a bioengineered hyaluronic acid.
45481295|NCT03783611|Behavioral|MyPlan 2.0.|eHealth intervention to increase physical activity in older adults. MyPlan 2.0 consists of five website visits. The first website visit contains pre- and post-intentional processes. The following four website visits contains mainly post-intentional processes. During the first website, participants fill in a questionnaire about their physical activity levels, and receive feedback. Furthermore, they are asked to make an action plan and think about barriers to reach their activity goals and possible solutions to tackle these barriers. During the other four website visits, participants receive feedback about their behavior change process and their action plan (did they reach their goal)? During these website visits, they can adapt their action plans.
45481296|NCT05305066|Drug|TNFi|TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein) 50 mg sc per week, adalimumab (monoclonal antibody) 40 mg sc every 2 weeks, golimumab (monoclonal antibody) 50 mg sc every month, or certolizumab (pegylated fragment of a monoclonal antibody) 400 mg sc at week 0, 2 and 4, and then 200 mg sc every 2 weeks or 400 mg sc every 4 weeks.
45481297|NCT05305066|Drug|Anti-IL6|Anti-IL6 receptor monoclonal antibodies - tocilizumab (if weight <100 kg: 162 mg SC every other week, followed by an increase to weekly based on clinical response; if weight ≥100 kg: 162 mg SC weekly) or sarilumab (200 mg SC once every 2 weeks)
45481298|NCT05305066|Drug|JAKi|JAKi - tofacitinib (JAK1/3 inhibitor) 5 mg po bid, baricitinib 2 mg po qd (JAK 1/2 inhibitor) or upadacitinib 15 mg po qd (JAK1 inhibitor)
45689768|NCT04046991|Behavioral|modified constraint-induced language therapy|Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
45845585|NCT03327324|Behavioral|Sleep Using Mentored Behavioral and Environmental Restructuring|SLUMBER is a non-pharmacological intervention program, delivered by providing mentoring to facility staff who work directly with residents. SLUMBER focuses on detecting sleep-disruptive factors including: nighttime noise and patient behaviors associated with poor sleep quality; disruptions caused by nighttime caregiving; daytime inactivity; and limited light exposure. In this model, staff-delivered interventions to improve these factors improve sleep quality thereby creating opportunities to test the impact of improving sleep quality (measured by actigraphy) on mood (depression and anxiety), pain, cognitive function, functional ability, and observed activity levels.
45847786|NCT02941692|Drug|Placebo|Placebo for Oxytocin
45847787|NCT02942160|Biological|Collagenase Clostridium Histolyticum|
45481299|NCT03767777|Device|Artery Stent Graft System|The Artery Stent Graft System consists of Ankura pro Aorta Stent Graft System along with Longuette Aortic Branch Stent Graft System for chimney technique in the aim of revascularization of aorta branches.The Ankura pro aorta stent graft and Longuette Aortic Branch Stent Graft System are pre-assembled within delivery system. During the operation, the stent graft was delivered to the target lesion location of the vascular real cavity through a delivery system, which was accurately positioned and released to isolate the ruptured opening of aortic dissection, block the continuous flow of blood into the false cavity of the dissection, and avoid further tearing or even rupture of the dissection.
45845586|NCT03252522|Combination Product|Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants|60% of participants will take 3-4 capsules of broad spectrum micronutrients three times per day for eight weeks. Following the initial 8 weeks (of the RCT), all participants will have the option to participate in an open label extension, during which time the child would take the active micronutrient treatment for 8 weeks
45363357|NCT03121534|Drug|Ibrutinib|Ibrutinib treatment will commence on cycle 1, day 1 at 420mg/d. Dose reductions to 280mg/d or 140mg/d are allowed per treating physician discretion, but the reason must be documented in the medical record. Ibrutinib will be given continuously until disease progression or toxicity.
45363358|NCT03121534|Drug|Nivolumab|Patients will receive nivolumab for up to a total of 52 weeks. Dosing will be 240mg IV every 2 weeks, commencing on day 1 until 2nd response assessment, then 480mg IV every 4 weeks.
45363359|NCT03997474|Biological|ATL001|ATL001 infusion
45481300|NCT02474836|Biological|Skin Prick Test - Atopic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
45363360|NCT03997474|Drug|Checkpoint Inhibitor|Nivolumab
45363361|NCT01012102|Biological|EMD 640744|EMD 640744 30μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
45363362|NCT01012102|Biological|EMD 640744|EMD 640744 100μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
45363363|NCT01012102|Biological|EMD 640744|EMD 640744 300μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
45363364|NCT01012102|Other|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 30ug)
45363365|NCT01012102|Other|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 100ug)
45363366|NCT01012102|Other|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 300ug)
45363367|NCT01013818|Drug|HGS1029|HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.
45689769|NCT00529204|Drug|exenatide|Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24
45845587|NCT03252522|Dietary Supplement|Placebo|40% of participants will take 3-4 capsules of inactive placebo three times per day for eight weeks.
45363368|NCT01013896|Behavioral|Motivational Interviewing|Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).
45363369|NCT01013896|Other|Cystic Fibrosis Education|"Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).~The Cystic Fibrosis Education serves as the attention control group."
45363370|NCT01013974|Drug|GSK573719 250 μg|Strip 1 of the dry powder inhaler will contain GSK573719 250 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
45845588|NCT03191370|Other|Simple distraction technique|Asking the patient to count backwards from 30 to1 in even numbers whilst the procedure is being performed.
45363371|NCT01013974|Drug|GSK573719 500 μg|Strip 1 of the dry powder inhaler will contain GSK573719 500 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
45689770|NCT01451541|Drug|Ciclesonide nasal aerosol 37 mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37
45689771|NCT01451541|Drug|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
45689772|NCT01451541|Drug|Placebo|Placebo - one dose per nostril
45689773|NCT00530764|Drug|Sativex Low Dose|Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.
45845589|NCT03191370|Drug|Local Anesthetics,Topical|Anesthetic spray
45845590|NCT03179436|Biological|Quavonlimab|Quavonlimab is administered intravenously (IV) during the Dose Escalation Phase and Dose Confirmation Phase at either DL1 or DL2, and is administered IV during the Efficacy Expansion Phase at DL2.
45481301|NCT02474836|Biological|Skin Prick Test - Non Atopic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
45363372|NCT01013974|Drug|GSK573719 1000 μg|Strips 1 and 2 of the dry powder inhaler will contain 500 μg each of GSK573719 micronized drug with lactose along with magnesium stearate. It will be available as dry off white powder for inhalation.
45363373|NCT01013974|Drug|GSK573719 matching Placebo|Strip 1 and 2 of the dry powder inhaler will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
45363374|NCT04615624|Drug|Furosemide|Furosemide, a loop diuretic
45363375|NCT04615624|Other|Placebo|Normal saline
45481302|NCT02474836|Biological|Skin Prick Test - Allergic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
45363376|NCT00713609|Drug|Benzoyl peroxide gel|5% benzoyl peroxide in a gel applied topically once a day
45363377|NCT00713609|Drug|Clindamycin gel|1% clindamycin phosphate applied topically once a day
45363378|NCT00713609|Drug|Tazarotene cream|0.1 % tazarotene in a cream applied topically once a day
45363379|NCT00713609|Drug|Vehicle gel|Vehicle gel is an identical gel without the active ingredients
45689774|NCT00530764|Drug|Sativex Medium Dose|Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
45363380|NCT00713609|Drug|Vehicle cream|Vehicle cream is an identical cream without the active ingredients
45363381|NCT00513682|Drug|Ultrase® MT20|Ultrase® MT20 capsules will be administered orally with each meal during Day 1 to 15 in screening phase at a dose based on investigator's discretion. During Day 12 to 15, participants will receive high-fat diet and Ultrase® MT20 dose will be adjusted depending on symptoms of steatorrhea. This will be followed by a washout phase of 6 to 7 days, in which participants will receive only high-fat diet; then stabilized dose of Ultrase® MT20 capsule (as identified during screening phase) will be administered orally for 7 to 11 days during treatment phase. The stabilized dose should not to exceed 2500 lipase units per kilogram body weight per meal (lipase units/kg/meal).
45363382|NCT00493012|Dietary Supplement|vitamin D|6 drops of a vitamin D containing oil
45363383|NCT00918593|Drug|Electrochemotherapy|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
45363384|NCT00918593|Radiation|Radiotherapy|Radiotherapy according to hospital procedures.
45363385|NCT00918593|Drug|Bleomycin|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
45363386|NCT04084847|Dietary Supplement|berberis vulgaris=barberry|10 grams of barberry powder will be consumed daily for 8 weeks.
45363387|NCT04084847|Dietary Supplement|Placebo|Placebo powder
45689775|NCT00530764|Drug|Sativex High Dose|Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
45689776|NCT00532480|Drug|Duloxetine|60 mg capsules
45689777|NCT00483262|Drug|CCI-779|Given by injection once a week for 5 weeks (5 weeks equals one cycle) for up to 8 cycles
45689778|NCT00483262|Drug|Bortezomib|Given by injection once a week for 4 weeks (a cycle equals 5 weeks) for up to 8 cycles
45689779|NCT00483496|Drug|Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)|
45689780|NCT00483496|Drug|Ti02 pigmentary 3% alone (formula RV3131A-MV1211)|
45689781|NCT00483496|Drug|bisoctrizole 10% alone (formula RV3131A-MV1237)|
45363388|NCT04084457|Dietary Supplement|Wild Blueberry powder|Powdered extract obtained from wild blueberries. A daily administration of 27g wild blueberry powder will be administered.
45363389|NCT04084457|Dietary Supplement|Placebo|Identical formulation as the treatment matched for fibre and vitamin C
45363390|NCT05163431|Device|Hallux Valgus orthosis|Custom designed orthosis and manufactured by 3D printing.
45689782|NCT00483496|Drug|Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)|
45845591|NCT03179436|Biological|Pembrolizumab|Pembrolizumab is administered IV at PDL1 on Day 1 of each cycle starting Cycle 2 for the Dose Escalation Phase or starting Cycle 1 of the Dose Confirmation Phase. Pembrolizumab is administered IV at PDL2 on Day 1 of each cycle for the Efficacy Expansion Phase (Arm G).
45689783|NCT00483496|Drug|Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)|
45689784|NCT00483496|Drug|Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)|
45845592|NCT03179436|Drug|Pembrolizumab/Quavonlimab|Pembrolizumab/Quavonlimab is a coformulated product composed of quavonlimab at DL1 in combination with pembrolizumab at dose level 2 (PDL2).
45689785|NCT00483496|Drug|Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]|
45689786|NCT00483496|Drug|V0096 CR vehicle (formula RV3131A-MV1197)|
45689787|NCT00484354|Drug|Sodium bicarbonate|IV bicarbonate given with amount based on patient weight
45689788|NCT00484354|Other|Normal saline|IV Normal saline with volume given determined by patient weight
45689789|NCT00484354|Other|Bicarbonate|IV bicarbonate, dosed by weight
45845593|NCT03149874|Drug|Hepatitis B recombinant DNA vaccine|Hepatitis B recombinant DNA vaccine
45845594|NCT03149874|Drug|Combined hepatitis A and B vaccine|Combined hepatitis A and B vaccine given to the patients
46050137|NCT01096160|Drug|MK-8266 TID, 2.4 mg|MK-8266 TID (Panel D), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
45845595|NCT03142074|Other|Biomechanical and microstructural analysis of ATAA|Tissue collection; microstructural testing of tissue; mechanical testing of tissue .
45845596|NCT03142074|Radiation|ECG-gated CT|Image analysis of ECG-gated CT.
45845597|NCT02834052|Drug|pembrolizumab|200mg pembrolizumab will be given intravenously on Day 1 of each 3-week cycle
45845598|NCT02834052|Drug|Poly-ICLC|"The maximum tolerated dose of Poly ICLC will be given twice weekly, in each 3-week cycle:~Week 1, Days 1 and 4~Week 2, Days 8 and 11~Week 3, Days 15 and 18"
45845599|NCT02828358|Drug|Azacitidine|Given IV
45845600|NCT02828358|Drug|Cyclophosphamide|Given IV
45845601|NCT02828358|Drug|Cytarabine|Given IV, SC, IT
46050138|NCT01096160|Drug|MK-8266 TID, 2.4 mg|MK-8266 TID (Panel E), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
46050139|NCT01096160|Drug|Placebo BID (Panel A)|Placebo administered as oral capsules BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
46050140|NCT01096160|Drug|Placebo BID (Panel B)|Placebo administered as oral capsules BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
46050141|NCT01096160|Drug|Placebo TID (Panel C)|Placebo administered as oral capsules TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
45689790|NCT00484354|Other|Placebo|Normal saline, with volume given based on patient weight
46050142|NCT01096160|Drug|Placebo TID (Panel D)|Placebo administered as oral capsules TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
45363391|NCT04083833|Drug|Tetrodotoxin|A single TTX dose in a dose ascending study
45363392|NCT04083833|Drug|Placebos|matching placebo comparator
45363393|NCT05155241|Behavioral|online health promotion video|Participants will watch an online health promotion video tailored to their current stage of change related to seasonal influenza vaccination uptake once every two weeks for four times (at week 0, 2, 4, and 6)
45689791|NCT00485836|Drug|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
45363394|NCT05155241|Behavioral|Control (same online health promotion video)|Participants will watch a same online video providing general advices related to seasonal influenza vaccination at week 0, 2, 4, and 6
45363395|NCT05144477|Behavioral|FAID Fear Intervention|Participants will receive a hard-cover diary, written instructions on diary completion, and a pen. A trained research assistant will meet with the participant face to face or via telephone and explain how to use the diary. Instructions will include recommended frequency for writing (at least twice a week) and tips on how to express themselves. Potential topics will also be addressed, including what to write about in the beginning, during the ICU, and after ICU discharge. The hard copy of the diary will remain with the family member participant, and they will be asked to continue writing in the diary at least until patient discharge from the hospital. Research assistants will check in with participants via weekly telephone calls to provide prompts to remind them to use the diary and support, as needed, if the participant reports difficulty in writing diary entries. These calls will last approximately 1-5 minutes and will continue until patient discharge from the hospital.
45363396|NCT05135663|Drug|NS-089/NCNP-02|The same dose administered in as Part 2 of Study NCNP/DMT02 (40 mg/kg) will be administered once weekly for 216 weeks (The total treatment period is 240 weeks including Part2 of Study NCNP/DMT02).
45363397|NCT05135663|Drug|NS-089/NCNP-02|The same dose administered in as Part 2 of Study NCNP/DMT02 (80 mg/kg) will be administered once weekly for 216 weeks (The total treatment period is 240 weeks including Part2 of Study NCNP/DMT02).
45363398|NCT05684237|Procedure|HiSMILE treatment option|The non-CE labeled VisuMax treatment option HiSMILE is able to modify the lenticule shape in a way that should lead to a change in spherical aberration postoperatively.
45363399|NCT02589587|Procedure|sleeve gastrectomy|Sleeve gastrectomy is an established form of bariatric (weight reducing) surgery, where the greater curvature of the stomach is removed.
45363400|NCT02589587|Other|no intervention|lean control group
45363401|NCT05246813|Other|Blood and bone marrow cell collection|Collection of blood and bone marrow
45363402|NCT05684705|Drug|BV100|Intravenous infusion
45363403|NCT05238233|Drug|Tropicamide|One drop will be given to participants
45363404|NCT05238233|Drug|1% Pilocarpine|One drop will be given to participants
45363405|NCT05238233|Drug|Proparacaine Hydrochloride|One drop will be given to participants
45363406|NCT05238233|Device|Tono pen AVIA|Participant intraocular pressures measured
45363407|NCT05238233|Device|VG4 Gonio|Participant iridocorneal angle measured
45363408|NCT05238233|Device|Reichert phoropter|Participant screened for hyperopia >+1 diopter
45363409|NCT05685017|Diagnostic Test|Nur Aisiyah Widjaja|Blood analysis for ICAM-1, VCAM-1, blood fasting insulin, lipid profile, fasting blood glucose and adiponectin investigation
45481303|NCT05708326|Behavioral|5:2 Method (intermittent fasting regimen)|"Participants will follow the 5:2 Method (an intermittent fasting regimen) for a 90 day duration. This entails eating ad libitum for five days per week (normal days) and limiting total calorie intake to 800kcals per day (fasting days) for the remaining two days per week. The fasting days can be sequential or dispersed throughout the week, based on patient preference."
45481304|NCT05708326|Behavioral|16/8 Method (intermittent fast regimen)|Participants will have already followed the 16/8 Method (an intermittent fasting regimen) for a minimum of six days per week for a 90 day duration. This entailed limiting the eating hours to an 8-hour window, then fasting for the remaining 16 hours per day, with the last time of intake being 8pm.
45481305|NCT03772535|Diagnostic Test|Pharmacogenomics Testing|The doctor will use genetic test results to prescribe medications that are a most effective for subject.
45689792|NCT00485836|Drug|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
45689793|NCT00485836|Drug|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
45689794|NCT00534118|Biological|donor lymphocytes|Given IV
45689795|NCT00487396|Device|Capsule Endoscopy|Pillcam Platform with RAPID5 software and supporting SB2 capsules
45689796|NCT04249024|Device|Laser treatment|The participants in the laser group are treated with a 970 nm diode laser and if calculus is present scaling and root planning (SRP). The peri-implant pocket will be radiated with the 970 nm laser, removing bacteria, diseased epithelium and granulation tissue. The laser will be used at a maximum of 20s intervals before water irrigation. Laser settings continuous wave mode and power between 1.0-1.3W. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.
45481306|NCT02478112|Device|Biodegradable balloon implant|Implantation under general anaesthesia of a biodegradable balloon before radiation therapy for prostate cancer
45481307|NCT05251714|Drug|CFI-402257|Oral once daily in 28 day cycles
45845602|NCT02828358|Drug|Daunorubicin|Given IV
45481308|NCT05251714|Drug|Fulvestrant|500 mg given by IM injection on Day 1 and Day 15 of Cycle 1 and Day 1 of each subsequent cycle
45481309|NCT02478034|Other|Fludrocortisone|effects of fludrocortisone on cognition compared to placebo
45481310|NCT02477956|Dietary Supplement|vitamin D3 (Replesta)|vitamin D group receive 2 replesta tablets (100,000 IU/month) of cholecalciferol.
45481311|NCT02477956|Dietary Supplement|vitamin D|
45481312|NCT02472574|Device|YL-1 type of intracranial hematoma puncture needle|YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe. To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale hematoma, gives the filament resolver interrupted for liquefication drainage afterward.
45481313|NCT02472574|Drug|rt-PA|Up to 4 doses of 0.3~1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
45481314|NCT05708248|Drug|pentoxifylline|400 mg pentoxifylline tablets twice daily with meals for 6 months
45481315|NCT04600505|Drug|Treatment A|Participants will receive 2 inhalations of BGF MDI with propellant 1.
45481316|NCT04600505|Drug|Treatment B|Participants will receive 2 inhalations of BGF MDI with propellant 2.
45481317|NCT04600505|Drug|Treatment C|Participants will receive 2 inhalations of BGF MDI with HFA propellant.
45481318|NCT05685394|Drug|Dapagliflozin|Dapagliflozin 10mg P.O. daily
45481319|NCT03772379|Device|tooth borne hyrax expander|ready made four stainless steel bands will be supported on the first premolars and first permanent molars and to which the palatal expander will be soldered to form the Hyrax,.The appliance will be activated one quarter turn per day untill reaching maximum amount of lateral expansion of the jack screw. the patients will be recalled twice per week to evaluate the progress of treatment.
45481320|NCT03772379|Procedure|microosteoperforation|"ready made four stainless steel bands supported on the first premolars and first permanent molars and to which the palatal expander will be soldered to form the Hyrax.No activation will be provided to the hyrax expander before the micro-osteoperforation is performed.~Microosteoperforation will applied bilaterally on the buccal surface between the roots of teeth at the level of mucoginival junction, starting from the distal of canine till the distal of the first permanent molar using a small sized surgical bur mounted on a hand piece ."
45689797|NCT04249024|Procedure|Mucosal flap surgery|The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.
45689798|NCT04249024|Behavioral|Oral hygiene instructions|Oral hygiene instructions of how to clean around dental implants as per individual needs in terms of access to clean and fine motor skills.
45689799|NCT04200508|Other|Targeted gown and gloves use|Gown and glove use for high risk care activities in high risk residents
45689800|NCT00488488|Drug|tigecycline|The patients will be treated in accordance with the requirements of the labeling of tigecycline in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
45689801|NCT00489268|Device|HALO Ablation System|"Phase I: 1-2 ablation visits; Phase II 1 to 12 months: 1-2 ablation visits; Phase II 12 to 30 months: 1-3 ablation visits Phase II 55-60 months: 0-1 ablation visit~******Phase I was a dosimetry study and Phase II used the preferred dose. The same intervention was used for each dose."
45689802|NCT01450761|Biological|Ipilimumab|
45689803|NCT01450761|Biological|Placebo matching Ipilimumab|
45689804|NCT01450761|Drug|Etoposide|
45689805|NCT01450761|Drug|Cisplatin|
45689806|NCT01450761|Drug|Carboplatin|
45689807|NCT04126486|Other|Zio®XT Monitor|A Zio® XT monitor will be affixed to the participant's chest
45689808|NCT04059237|Behavioral|Web based decision aid intervention|Decision aid tool (website) to assist young adult female cancer survivors in making decisions and preparing for family-building after cancer.
45845603|NCT02828358|Drug|Daunorubicin Hydrochloride|Given IV
45481321|NCT02474992|Behavioral|Microclinic|Individuals randomized to this arm will be invited to recruit members of their social network to form a health team, or microclinic. These groups will proceed through a discussion-based health education curriculum led by local community health workers. Topics will include HIV biology, medications, the importance of social support, and community outreach for reducing HIV stigma. The curriculum will conclude with an opportunity for all group members to disclose their HIV status to one another.
45481322|NCT03772223|Drug|Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 80/90 µg).
45481323|NCT03772223|Drug|Treatment B (Budesonide metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 80 µg).
45481324|NCT03772223|Drug|Treatment C (Albuterol Sulfate metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 90 µg).
45481325|NCT03783377|Drug|ARO-APOC3|single or multiple doses of ARO-APOC3 by subcutaneous (sc) injections
45481326|NCT03783377|Drug|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment
45481327|NCT02472340|Procedure|Muscle Biopsy|Muscle Biopsy
45481328|NCT02474602|Device|Active or Placebo Phototherapy (MR4)|Participants performed a strength training. Forty-eight subjects practiced a training protocol with 80% of the load, measured through 1-repetition maximum test. The strength training lasted 12 weeks and the evaluations were done monthly. Phototherapy, active or placebo, were applied in 6 different points of quadriceps muscle depending the group randomized, before and after each training session.
45689809|NCT04126018|Diagnostic Test|MRI with strain measurement|CMR measurements of left and right ventricular systolic function strain and myocardial fibrosis
45481329|NCT03783299|Diagnostic Test|Standard RDT and HS-RDT|All household members (residents and temporary visitors) aged 18 months and older will be invited to participate in an RDT and blood collection component. After consenting, the MTAT team will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Malaria Ag P.f High Sensitive Cat# 05FK140)
45481330|NCT03783299|Diagnostic Test|Standard RDT and HS-RDT|All individuals will be invited to participate in an RDT and blood collection component. Informed consent will be obtained from all participants. After consenting, the PNs will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Alere Malaria Ag Pf High Sensitive Cat #05FK140). Dried blood spots (DBS) will also be collected on all HRPs if deemed feasible.
45481331|NCT03783299|Drug|Artemether-lumefantrine|If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
45481332|NCT03783299|Drug|Primaquine Phosphate|If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
45481333|NCT03771833|Device|MARIA scan|The MARIA breast imaging system comprises of a scanning unit, housed under a patient bed. The scanning unit houses a hemispherical array, into which varying sizes of insert are fitted to ensure a close fit to the breast. The patient lies prone on the bed with their breast pendulous through an aperture in the bed and the scanning unit is risen to meet the breast. The fit is non-compressing and the scanner does not use ionising radiation.
45481334|NCT04491838|Drug|Pozelimab|Single subcutaneous (SC) injection
45481335|NCT03771911|Device|AED|Instructions provided by an AED
45481336|NCT03771911|Device|Telephone|Instructions provided by emergency Call Center (telephonically) with the help of an AED.
45481337|NCT03109054|Diagnostic Test|State-Trait Anxiety Inventory Test|All patients will take a State-Trait Anxiety Inventory Test. After the test patients will enroll low or high anxiety level.
45689810|NCT04126018|Diagnostic Test|Echocardiography|Doppler, PISA, VCA, volumetric method as performed during echocardiography
45845604|NCT02828358|Drug|Dexamethasone|Given PO, NG, IV
45845605|NCT02828358|Drug|Hydrocortisone Sodium Succinate|Given IT
46050143|NCT01096160|Drug|Placebo TID (Panel E)|Placebo administered as oral capsules TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
45845606|NCT02828358|Other|Laboratory Biomarker Analysis|Correlative studies
45845607|NCT02828358|Drug|Leucovorin|Given PO, IV
45845608|NCT02828358|Drug|Leucovorin Calcium|Given PO, IV
45845609|NCT02828358|Drug|Mercaptopurine|Given PO, NG
46050144|NCT00860158|Drug|Dasatinib|Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
46050145|NCT00860158|Drug|Leuprolide Acetate (LHRH Analogue)|Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
46050146|NCT00860158|Procedure|Radical Prostatectomy|Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.
45481338|NCT03767387|Other|Trimodal Prehabilitation|Prehabilitation before major surgery consisting of: i) motivational interview to assess patient's adherence profile and to co-design the characteristics of the physical activity program with the patient; ii) personalised program to promote daily physical activity; and iii) supervised high-intensity endurance exercise training program.
45481339|NCT02474524|Behavioral|Health intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker, in addition to their routine care. Sessions will be structured by the worker and participant using a tablet computer to view materials on mental health self-management and personal recovery on a dedicated website for the trial. These will include information, videos, audio and exercises. Online materials make particular use of videos featuring people with lived experience of psychosis discussing how they have dealt with issues in their recovery, and will allow users to post comments on videos and in a forum. Participants may access online materials both during intervention sessions and outside sessions using any Internet-enabled device.
45481340|NCT02474524|Behavioral|Social intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker in addition to routine care (treatment as usual). The social intervention will utilise a computer tablet (i.e., iPad) servicing online resources to extend a manualised befriending intervention, based upon social interaction, designed to control for therapist contact and computer use. Each session will involve interaction about non-health related topics of interest to the participants, which will be facilitated by use of viewing online material related to these interests on a tablet computer as a prompt to conversation.
45481341|NCT03771755|Drug|Ibuprofen|800 mg IV - Ibuprofen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
45481342|NCT03771755|Drug|Acetaminophen|1000mg IV Acetaminophen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
45481343|NCT02472106|Device|Post-dilatation|Post-dilatation in self-expanding TAVI device procedures
45481344|NCT02472184|Procedure|Office hysteroscopy|Office hysteroscopy is a procedure performed in the office in which a flexible hysteroscope is inserted into the uterine cavity. The patient is positioned in a dorsal lithotomy position and teh cervix is visualized with a speculum. Normal saline is used to distend the cavity, and the hysteroscope is used to visualize any abnormalities within the cavity.
45845610|NCT02828358|Drug|Methotrexate|Given IT, IV, PO
45845611|NCT02828358|Drug|Pegaspargase|Given IV
45845612|NCT02828358|Other|Pharmacological Study|Correlative studies
45845613|NCT02828358|Drug|Prednisolone|Given PO, NG
45481345|NCT02472184|Procedure|Endometrial biopsy|An endometrial biopsy is a procedure in which a pipelle instrument is inserted into the uterine cavity and suction from the pipelle is used to obtain endometrial tissue. This is performed with the patient in the dorsal lithotomy position and a speculum is used to visualize the cervix.
46050147|NCT02615314|Procedure|Particle re-positioning maneuver|Patients with posterior canal BPPV (PC-BPPV) were treated with Epley maneuver. Patients with superior canal (SC-BPPV) were treated with Li or reverse Epley maneuver. Patients with lateral canal (LC) apogeotropic or geotropic nystagmus were treated with Barbeque, Semont's or Gufoni maneuvers. If geotropic or ageotropic type nystagmus is equal intensity on both sides. The involved side was determined according to the patient sense of disturbance or lying down positioning test. If the patient has involvement of both sides according to Dix-Hallpike maneuver. Therapeutic maneuver was applied to the more severe side. All patients were re-evaluated at maximum 7 days.
46050148|NCT02615236|Device|perineal ultrasound|transvaginal probe will be used to scan the perineum immediately after vaginal delivery in primiparous women
46050149|NCT02615236|Procedure|Clinical diagnosis|diagnosis of OASIS clinically
46050150|NCT02878538|Drug|Deferiprone|Subjects will then begin an experimental No1 design: placebo-deferiprone-placebo. Study drug will be administered in three 3 month blocks. All subjects will receive 30 days of active study drug. The placebo-deferiprone contrast compares placebo to active drug initiation. The deferiprone-placebo contrast tests active drug withdrawal. All will be given placebo in months 1-3, and 6-12. This will allow the investigators to examine active drug exposure on d score up to one year and prospective time to MCI conversion. Dosing: Participants will be treated 25 mg/kg po tid (75mg /kg /d total) The dose will be rounded by the prescriber to the nearest 250 mg (half-tablet).
45363410|NCT00918905|Device|Telemonitor|"Within 24 hours after the patient was discharged due to exacerbation in COPD the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with. The patient had the equipment for approximately one week and had at least one follow-up phone call. Televideo consultations could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period.~During the televideo consultations the nurse made clinical observations (i.e. dyspnoea, anxiety), measured saturation and lung function and informed the patients how to prevent exacerbations. The telemedicine consultation was agreed on with the patient and the telemedicine nurse from day to day."
45481346|NCT03783221|Other|High-fat diet|The high-fat diet (51% fat, 27% carbohydrates, 21% proteins and 4.7 g fiber) will be administered for two weeks..
45845614|NCT02828358|Drug|Thioguanine|Given PO, NG
46050151|NCT02878538|Other|Placebo phase|Placebo tablets with inactive substance will be provided to subjects for two, 3 month blocks during the study.
46050152|NCT04134598|Radiation|Breast irradiation (RT)|Irradiation of volume's portion Index quadrant) or whole volume of the residual breast.
46050153|NCT04134598|Drug|Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen|Adjuvant endocrine therapy as per local policy (letrozole/anastrozole/exemestane/tamoxifene for 5-year or switch schedules aromatase inhibitors/tamoxifen for 5-year).
45481347|NCT03783221|Other|High-residue diet|The high-residue diet (19% fat, 62% carbohydrates, 16% proteins and 54.2 g fiber) will be administered for two weeks.
45481348|NCT03767309|Procedure|coronally advanced flap with abrasive de-epithelized graft.|SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a high-speed hand piece and diamond bur
45481349|NCT03767309|Procedure|coronally advanced flap with de-epithelized graft.|SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a blade
45481350|NCT02477566|Drug|Long-acting Triptorelin|Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal phase
45845615|NCT02828358|Drug|Vincristine|Given IV
45845616|NCT02828358|Drug|Vincristine Sulfate|Given IV
45845617|NCT02756364|Drug|Fulvestrant|Fulvestrant IM injection.
46050154|NCT00929526|Procedure|Liquid-based cytology (LBC) sampling|LBC samples will be collected at Months 36 and 48 for cytology and HPV DNA testing (by PCR)
46050155|NCT00929526|Procedure|Blood sampling|Blood samples will be collected at Months 36 and 48 for antibody determination
46050156|NCT04307342|Procedure|MIPO with Extra-articular Distal Humeral Anatomical Plate|MIPO with Extra-articular Distal Humeral Anatomical Plate
46050157|NCT02618902|Biological|tolerogenic dendritic cells (tolDC)|dose-escalation
45481351|NCT02477566|Drug|Short-acting Triptorelin|Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2<40pg/ml in serum, was initiated during the luteal phase
45481352|NCT05432531|Drug|Anti JAK1,2|Induction of remission of active lupus nephritis
45363411|NCT05232851|Biological|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Given SC
45481353|NCT05432531|Drug|Cyclophosphamid|Induction of remission of active lupus nephritis
45363412|NCT05232851|Biological|Pembrolizumab|Given IV
45481354|NCT01309685|Drug|Varenicline|
45363413|NCT04083443|Other|Additional blood sampling|Blood samples will be taken to assess antimicrobial drug concentrations and microbial DNA blood counts. Per patient, at least 5 and up to 15 samples for drug concentrations and at least 3 and up to 6 samples for DNA counts are taken for a duration of up to 3 days.
45481355|NCT03782987|Drug|BI 730357|Tablet
45363414|NCT04083677|Device|SONAR|A curved low- frequency (2-5 MHZ) probe and (simens ACUSON x 300) ultrasound system will be used. All patient will be first scanned in the supine position, followed by the right lateral decubitus (RLD) position. The gastric antrum was identified in a sagittal scanning plane in the epigastrium immediately inferior to xiphoid and superior to umbilicus. The liver anteriorly and the aorta, inferior vena cava and pancreas posteriorly were used as anatomical reference points.
45481356|NCT03782987|Drug|Itraconazole|Oral solution
45481357|NCT03767231|Diagnostic Test|Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)|The investigators will randomly assign eligible and consented patients to either to HCV POC VL Group or Reference Group. All participants will take a short survey regarding HCV care and treatment. As part of the investigators' ED HCV Screening and Linkage to Care Program, all participants will receive the standard-of-care clinical laboratory-based HCV RNA viral load testing via whole blood (i.e. patient will receive blood drawn). This standard-of-care HCV viral load testing result will be provided to participant when it is available (usually 1-2 days later). Participants in the HCV POC VL Group will receive the novel POC HCV RNA viral load testing and the result of the novel test will be disclosed to the patients approximately within 1 to 1½ hours of the testing.
45363415|NCT00919373|Procedure|Substrate modification|Catheter Ablation procedure - Substrate modification in sinus rhythm in case of unstable induced monomorphic Ventricular Tachycardia (VT) which does not allow mapping and ablation in tachycardia, or noninducible stable clinical VT.
45363416|NCT00919373|Procedure|VT ablation|Catheter Ablation of Ventricular Tachycardia (VT) in case of stable VT
45363417|NCT00919373|Procedure|ICD Implantation|Implantation of a marked released Implantable Cardioverter Defibrillator manufactured by St. Jude Medical
45481358|NCT03972527|Device|Photobiomodulation|Provide photobiomodulation therapy to subjects prior to each radiation therapy session.
45481359|NCT03972527|Other|Routine Oral Care and Analgesia|Standard oral care, oral hygiene and oral pain protocols
45363418|NCT05314439|Drug|ION904|ION904 will be administered by SC injection.
45363419|NCT05314439|Drug|Placebo|Placebo will be administered by SC injection.
45481360|NCT03772067|Device|Continuous glucose monitoring CGM|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the overall glucose levels measured with CGM installed in the arm during 14 days at baseline before diet intervention and after 14 days of the beginning of diet intervention
45481361|NCT03772067|Diagnostic Test|Clock Genes m RNA expression|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the blood levels of Clock Genes measured at baseline and after 14 days of diet intervention
45481362|NCT03772067|Diagnostic Test|Postprandial Glucose|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Glucose measured at meal test after 14 days of diet intervention
45481363|NCT03772067|Diagnostic Test|Postprandial Insulin|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Insulin measured at meal test after 14 days of diet intervention
45689811|NCT04075539|Other|Home-based cycling program|"Usual care (i.e. standardized prescription of 6 sessions of outpatient physiotherapy), and~1 supervised session of cycling aimed at explaining how to use the connected ergometric bicycle and at designing a personalized home-based cycling program~a 12-month home-based cycling program using connected ergometric bicycles which intensity and dose are self-determined~3 phone or email contacts with a care provider to deliver positive feedbacks and encouragements"
45689812|NCT04075539|Other|usual care|A prescription of 6 sessions of outpatient physiotherapy
45845618|NCT02756364|Drug|Sapanisertib|Sapanisertib capsule.
45845619|NCT02752542|Behavioral|Cognitive Behavioral Therapy|CBT will be delivered in a one-to-one face-to-face format by trained Masters or PhD level CBT therapists who will follow a protocol adapted from existing manuals and piloted in the participating centres. Up to 20 sessions will be offered over 18 weeks, initially twice per week, then weekly and later spaced to every other week. The treatment will have core obligatory modules and flexible elements adaptable to participant's maintaining factors.
45845620|NCT02752542|Drug|Pharmacotherapy|Pharmacotherapy will be prescribed and adjusted by psychiatrists in 20-30 minute pharmacotherapy sessions once every two weeks. The manual-guided best-evidence pharmacotherapy will follow current guidelines for first, second and third line treatment.41 The primary focus will be on serotonin-reuptake inhibiting antidepressant (escitalopram 5-20mg, sertraline 50-200 mg daily) monotherapy, which may remain the only treatment for the majority of participants. Augmentation (aripiprazole 2-10mg, bupropione 150-450mg) will be offered to participants with partial response. The manual, developed as part of Canadian Biomarker Integration Network in Depression (CAN-BIND).43, also specifies admissible supportive therapeutic elements and prohibits CBT-specific techniques.
45845621|NCT02679378|Device|ClearSight™ System|comparing ClearSight system to histopathological to determine negative-margins in breast conserving surgery.
45481364|NCT03772067|Diagnostic Test|Plasma GLP-1|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma GLP-1 measured at meal test after 14 days of diet intervention
45481365|NCT03772067|Diagnostic Test|DPP4 plasma activity|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial DPP4 plasma activity measured at meal test after 14 days of diet intervention
45481366|NCT03772067|Diagnostic Test|Ghrelin|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Ghrelin measured at meal test after 14 days of diet intervention
45689813|NCT04015804|Other|Clinical database|Creation of an ambispective (retrospective and prospective), multicentric and European clinical database for surgery with robotic assistance in rectal cancers with implementation in France and then in Europe
45481367|NCT03772067|Diagnostic Test|Plasma CCK|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma CCK measured at meal test after 14 days of diet intervention
45481368|NCT03772067|Diagnostic Test|Plasma PYY|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma PYY measured at meal test after 14 days of diet intervention
45481369|NCT03772067|Other|Body Weight|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the body weight at baseline and every weeks of diet intervention
45363420|NCT05684627|Dietary Supplement|Fast mimicking diet group|Test group will be assigned to follow three cycles of a fasting mimicking diet the same day after receiving the full mouth non surgical periodontal treatment. The FMD program is a plant-based diet program designed to attain fasting-like effects while providing both macro- and micronutrients to minimize the burden of fasting and adverse effects. The FMD consist 5 days regimen that provides approximately 1.100 kilocalories for the first day ; approximately 750 kilocalories per day for the second to the fifth day. FMD group will need 8 visits.
45363421|NCT05684627|Procedure|Normal diet group|Normal diet (control) group after receiving the non surgical periodontal treatment (with periodontal Gracey curettes and ultrasonic scaler) will continue with their current diet.Normal diet group will need 7 visits.
45363422|NCT00617708|Biological|cixutumumab|Given IV
45363423|NCT00617708|Drug|erlotinib hydrochloride|Given PO
45481370|NCT03772067|Diagnostic Test|Blood levels of HbA1c|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing blood HbA1c measured at baseline and after 90 days of diet intervention diet intervention
45689814|NCT02120716|Behavioral|Health Check-Up for Expectant Moms|Participants randomly assigned to the treatment condition will receive a 60-minute brief intervention on the Tablet after the baseline assessment. The software will personalize the intervention content based on the current risk status of each participant and will include a plan addressing endorsed risks. Within one month of baseline, there will be a 15-20 minute, computer-delivered booster session reviewing the personalized plan and identifying barriers in the reduction or risks and/or meeting the goals in the plan.
46050158|NCT04134052|Drug|ketamine sedation versus midazolam sedation|Sedation with ketamine 5-20 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% during surgery and the second midazolam group 5 mcg- 35 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% will be administered during surgery
45689815|NCT00491374|Drug|Mometasone Furoate Nasal Spray|Nasonex Nasal Spray 50 mcg/spray, 200 mcg (4 sprays) once daily every morning for 28 days.
45689816|NCT00491374|Drug|Placebo|Placebo Nasal Spray 4 sprays once daily every morning for 28 days.
45363424|NCT00617708|Drug|gemcitabine hydrochloride|Given IV
45363425|NCT04083209|Behavioral|Opioid counseling|The formal opioid counseling will involve reading the recommendations for postoperative opioid use established by the Pennsylvania Orthopedic Society.
45363426|NCT02589119|Drug|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
45363427|NCT00864968|Drug|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fasting conditions
45363428|NCT00864968|Drug|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fasting conditions
45481371|NCT03783065|Drug|Propranolol|Propranolol was administrated orally while keeping monitoring heart rate and blood pressure daily.
45481372|NCT03783065|Procedure|Laparoscopic splenectomy and pericardial devascularization|Including splenectomy and pericardial devascularizaion under laparoscopy
45481373|NCT03783065|Procedure|Endoscopic therapy|Either endoscopic variceal ligation (EVL) or cyanoacrylate injection was applied according to the condition of varices
45845622|NCT02649738|Procedure|Corneal tissue inlay|A mid-stomal pocket will be made into the cornea with a femtosecond laser (Intralase). A small disc of preserved corneal tissue will then be placed into the pocket
46050159|NCT04258176|Other|Multidisciplinary outpatient pathway|Coordinators, assigned to improve the care flow, review and align the patient's appointments and tests in agreement with the patient's wishes. Outpatient consultations are arranged to take place the same day and schedules for care providers are coordinated. The patients' attendance in outpatient clinics are planned sequentially where the delivering specialty writes a summary to the subsequent specialty. Afterwards, the involved physicians and nurses attend an interdisciplinary conference, resulting in a joint treatment plan, with feedback and notice of modifications, which is delivered to the patient and general practice.
46050160|NCT04307420|Procedure|Sonic Fill Restoration|Kerr's Sonic Fill is the only sonic-activated, single-step, bulk-fill composite that starts out as a low-viscosity composite.
45689817|NCT00538642|Drug|ziprasidone|Patients assigned to ziprasidone arm are cross-titrated from current antipsychotic
45481374|NCT01309763|Biological|AFFITOPE AD03|s.c. injection
45481375|NCT01309763|Biological|AFFITOPE AD03 + Alum|s.c. injection
45689818|NCT00539110|Drug|zolipidem|zolpidem dosed at 2200 and 0200 per feeding tube depending on randomization
45689819|NCT00539110|Drug|ramelteon|ramelteon dosed at 2200 and 0200 per feeding tube depending on randomization
45689820|NCT03846232|Other|No intervention|No intervention
45689821|NCT00539656|Biological|Ex vivo expansion of cord blood|Day 0: the expanded cell product will be infused to patient; Day +1: A second, unexpanded, cord blood product will be infused
45845623|NCT02519322|Biological|Ipilimumab|Given IV
45845624|NCT02519322|Other|Laboratory Biomarker Analysis|Correlative studies
45689822|NCT01433991|Drug|Golvatinib|Participants will receive E7050 50 mg and/or 100 mg tablets. E7050 will be administered orally once daily, in 28-day cycles.
45689823|NCT01433991|Drug|Lenvatinib|Participants will receive lenvatinib 1 mg and/or 4 mg and/or 10 mg capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
46050161|NCT04307420|Procedure|Composite Resin Restoration|Composite resins are polymer-based materials used in dentistry for aesthetic repairs.Polymerization is accomplished typically with a hand held curing light that emits specific wavelengths keyed to the initiator and catalyst packages involved.
45363429|NCT05227586|Procedure|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and left atrial driver ablation.
45363430|NCT05227586|Procedure|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation + right atrial driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping , left atrial driver ablation and right atrial driver ablation.
45481376|NCT03771599|Other|Intervention Group|"Traditional massage of thirty minutes duration ( five minutes of massage was provided to all four limbs, front and back of trunk area) prior to routine physical therapy.~Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks."
45481377|NCT03771599|Other|Control group|Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks.
45689824|NCT01433991|Drug|Lenvatinib|Participants will receive lenvatinib 24 mg (1*4 mg capsule + 2*10 mg capsule) capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
46050162|NCT02615080|Drug|CRD007|
45481378|NCT04586933|Dietary Supplement|Omega-3|It will be investigated whether diet optimization and supplementation of omega-3s can reduce disease activity in patients with inflammatory arthritis. A new omega-3 high concentrate from GC Rieber Oils will be used.
45481379|NCT04586933|Dietary Supplement|Placebo (soya)|Placebo (soya)
45481380|NCT04586933|Behavioral|Dietary guidance|Dietary guidance
45689825|NCT01450683|Drug|Itraconazole|"600 mg/day oral (PO)~IUPAC name: (2R,4S)-rel-1-(Butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one"
45845625|NCT02519322|Biological|Nivolumab|Given IV
45845626|NCT02519322|Biological|Relatlimab|Given IV
45363431|NCT00871130|Procedure|Bariatric surgery|gastric banding, gastric bypass or vertical gastroplasty either open or laparoscopic or a combination of any
45363432|NCT00876044|Drug|aflibercept (AVE0005)|Intravenous route
45845627|NCT02519322|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45363433|NCT00876044|Drug|placebo|Intravenous route
45481381|NCT03771443|Drug|experimental gluten free toothpaste|we prepared gluten free toothpaste in the faculty of pharmacy -Cairo university because there is no gluten free toothpaste available in the Egyptian market .
45481382|NCT03955445|Drug|LNP023|LNP023 capsules
45481383|NCT03766997|Drug|Compound Betamethasone Injection|local injection
45845628|NCT02460042|Procedure|drug coated balloon angioplasty|percutaneous transluminal angioplasty with peripheral balloon catheters
45845629|NCT02460042|Device|SeQuent® Please OTW Paclitaxel Coated Balloon Catheter|
46050163|NCT02615080|Drug|Placebo|
45481384|NCT03766997|Drug|Hydrocortisone Butyrate 0.1% Cream|topical use
46050164|NCT04903730|Drug|AER-901 Solution for Nebulization|"Part A: participants will be enrolled into 1 of up to 5 sequential cohorts (A1 to A5). Inhaled AER-901 doses of 5, 10, 20, 40, and 80mg are planned.~Part B: participants will be enrolled into 1 of up to 3 cohorts (B1 to B3).~Cohorts B2 and B3 will commence following Part D of the study and following SRC review of safety, tolerability, and PK data. A decision to dose with either a propylene glycol formulation or a sterile water formulation will be made by the SRC at the time of the review of the Part D data.~Part D has a three-part design (Treatment Periods 1 & 2 separated by a Washout period) and will compare placebo to a single-dose of AER-901 (5 mg/mL QD) followed by two doses of AER-901.~Each cohort will consist of 8 participants (6 receiving AER 901 and 2 receiving placebo)."
46050165|NCT04903730|Drug|Placebo|0.45% sterile saline for injection delivered via the FOX MOBILE device.
46050166|NCT04203654|Behavioral|cognitive-behavior group therapy|cognitive-behavior group therapy Frequency: thrice a week Treatment duration: 16 week
45363434|NCT04040114|Device|Molemap Skin Cancer Triage Artificial Intelligence Device|This device/software incorporates artificial intelligence to provide a diagnostic aide for clinicians of patients with potentially malignant skin lesions. The software is supported by the use of cameras for acquisition of images.
45363435|NCT00876122|Drug|GDC-0941|Escalating oral dose
45363436|NCT00866216|Drug|Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals|
45481385|NCT03766919|Device|Implant of the INVICTA lead|The implant or the attempt to implant an INVICTA lead
45481386|NCT03782831|Procedure|TACE|Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).
45481387|NCT03782831|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
45481388|NCT03782831|Drug|Placebos|intravenous injection every 2 weeks
45845630|NCT02272842|Dietary Supplement|Vitamin B12|Vitamin B12 in a multivitamin paste.
45363437|NCT00866216|Drug|Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.|
45363438|NCT00871208|Drug|Altabax (R)|Retapamulin 1% ointment is to be applied to lesional atopic dermatitis twice-daily in addition to a topical corticosteroid (Locoid lipocream (R))
45363439|NCT00871208|Drug|Vehicle and Locoid lipocream (R)|The vehicle base of retapamulin ointment will be applied twice-daily to active lesions of atopic dermatitis in addition to locoid lipocream (R)
45845631|NCT02210988|Other|acupuncture|Intervention with acupuncture
45845632|NCT02163408|Other|MRI with/without contrast|Bilateral carotid plaque imaging at 3.0T. Conventional MRI scans with T1-, T2-weightings and scans using the developed techniques. MR contrast may be used in conventional protocol when it is needed to evaluate the performance of the developed techniques
45845633|NCT02000934|Drug|TAK-659|TAK-659 tablet
45845634|NCT01906476|Behavioral|Stepped Care|Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist
45845635|NCT01906476|Behavioral|Telephone Cognitive Behavior Therapy|Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
45845636|NCT01793922|Procedure|PD|pneumodilation
45845637|NCT01793922|Procedure|POEM|peroral endoscopic myotomy
45845638|NCT00766584|Other|Sleep apnea/hypopnea detection|Simultaneous 24-hour ambulatory electrocardiogram and polygraphic recordings performed at home during a night.
45845639|NCT05723172|Device|active tACS|40 mins tACS for 10 consecutive daily sessions
46050167|NCT04203654|Behavioral|Individual supportive psychotherapy|Individual supportive psychotherapy 3 sessions during the 16-week treatment period
45363440|NCT04039802|Procedure|Single-stage surgery|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery.
45845640|NCT05723172|Device|sham tACS|40 mins sham tACS for 10 consecutive daily sessions
45845641|NCT05723094|Radiation|Ga-Al-As diode laser (Ilase, USA)|The laser parameter used in previous study： Laser type：Ga-Al-As Wavelength：940 nm Emission type：Continuous Irradiation dosage/per tooth：75J/cm2 Application technique：Direct contact with the mucosa Exposure time per point：6 second Laser classification：3B Laser application time：Once in a month (4-week intervals) for the maxilla and mandibular incisors and canines Output：100Mw Diameter of the optical fiber：0.04 cm2
45845642|NCT05723094|Other|placebo|Before the orthodontic retention phase, those who did not apply the Ga-Al-As diode laser (Ilase, USA) were the control group.
45845643|NCT05723016|Other|preimplantation genetic test for aneuploidies (PGT-a)|preimplantation genetic test for embryo aneuploidies after IVF
45845644|NCT05722626|Procedure|PRP|2 ml of platelet rich plasma intraarticular injection twice in one week interval
45845645|NCT05722626|Other|Normal Saline|NaCl 0.9%
45845646|NCT05722548|Drug|Indomethacin suppository|100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia
45845647|NCT05722548|Other|Standard Medical Treatment|Standard Medical Treatment
46050168|NCT04260906|Device|Vagus nerve stimulator|Vagus nerve stimulation is carried out with a TENS device, which has specially designed surface electrodes in the shape of earphones, the size of which can be selected according to ear size. Electrodes were placed to correspond with the inner and rear surfaces of the tragus and the concha for both ears (Figure 1). The application is carried out, for 30 minutes, using a biphasic, asymmetrical waveform with a pulse duration that is less than 500 microseconds and a frequency of 10 Hertz.
45363441|NCT04039802|Other|Two-stage surgery|Two-stage surgery has already been performed, data will therefore be retrospectively collected
45363442|NCT00876278|Device|*AT.Smart 46LC|Primary implantation of *AT.Smart 46 LC into the eye's capsular bag for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the *AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
45363443|NCT04083521|Dietary Supplement|Bacillus subtilis DE111®|Subjects were administered a dose of Bacillus subtilis at levels of 1x10^9 CFU once a day for 90-days.
45845648|NCT05722470|Behavioral|eating disorders|Assessment of eating disorders among adolescents
45845649|NCT05722392|Procedure|Two-step Radical Prostatectomy|The first step is enucleation of the hyperplastic adenoma, and the second step is anterograde RP to residual gland
46050169|NCT04260906|Other|exercise|The exercise group was assigned a program, which consisted of strengthening, stretching, isometric and posture exercises, targeting the body and upper and lower extremities. That program was home-based and the program was requested to be completed. Patients were asked to attend weekly face to face sessions with a total of 4 of these sessions in the study duration.
46050170|NCT00859456|Drug|Sunitinib|"Taken daily PO for a 42 day cycle. This cycle is repeated at least twice.~A small molecule, multi-targeted receptor tyrosine kinase inhibitor that selectively targets and intracellularly blocks the signaling pathways of receptor tyrosine kinase (RTKs)."
45363444|NCT00871364|Drug|VENLAFAXINE TABLETS 50 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
45363445|NCT00871364|Drug|Effexor® Tablets equivalent to 50 mg venlafaxine|B: Active comparator Subjects received Wyeth Pharmaceuticals Inc. formulated products under fed conditions
45363446|NCT00876356|Dietary Supplement|Conjugated Linoleic Acid (CLA)|CLA 4.5g/day in three divided doses p.o. for 12 weeks
45363447|NCT00876356|Dietary Supplement|Olive oil|Olive oil 4.5g/day x 12 weeks
45481389|NCT03782909|Behavioral|Behaviour change intervention|"The behaviour change intervention consists of;~Feedback via an app based food diary~Coaching with problem solving and implementation plans~The intensive phase consists of 2 home visits and 4 phone calls and the use of the app The maintenance phase consists of use of the app if the PWCF wishes to continue using it"
45481390|NCT03766841|Behavioral|Facilitated Enrollment|Research coordinator will assist patients in account creation and usage of the tool.
45363448|NCT04083053|Procedure|Perianal Exam|Perianal Exam is part of anal cancer screening. The perianal skin is also examined under magnification and, less commonly, perianal biopsies are obtained.
45481391|NCT03771365|Procedure|Standard-PCNL|percutaneous nephrostolithotomy (PCNL) with ≥24 Fr access tract for the treatment of ≥2 cm renal stone
46050171|NCT01075646|Drug|ropivacaine|"Laparotomy of colorectal surgery: 10 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 5ml/h.~Laparoscopy of colorectal surgery: 5 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 2 ml/h.~Hepatic surgery: 10 ml de ropivacaine 0,45% + infusion with elastomeric pump with ropivacaine 0,23 at a 5ml/h."
45689826|NCT01433055|Drug|Minocycline|"Minocycline Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day (minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
45689827|NCT01433055|Drug|Placebo|"Placebo Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day(minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
45689828|NCT01450137|Drug|Tocilizumab + Glucocorticoids (GCs)|Tocilizumab 8mg/kg every 4 weeks until week 52.
45689829|NCT01450137|Drug|Placebo + Glucocorticoids (GCs)|Placebo every 4 weeks until week 52.
45363449|NCT04083053|Procedure|high-resolution anoscopy (HRA) with biopsy|The HRA exam involves insertion of a plastic anoscope 4-6 cm into the anal canal, with use of 5% acetic acid and Lugol's iodine to highlight abnormal lesions for biopsy. The entire squamocolumnar junction is visualized during the exam, which lasts between 5 and 20 minutes.
45363450|NCT05227274|Other|Items completion with or without a MFM-Play|Patients will completed 3 MFM during the follow-up, two times using the MFM-Play, and one without the MFM-Play Delay between each MFM completion will be 1 month ± 15 days
45363451|NCT05113745|Drug|AXS-12 (reboxetine)|AXS-12 tablets, taken twice daily
45363452|NCT05113745|Drug|Placebo|Placebo tablets, taken twice daily
45481392|NCT03771365|Procedure|Mini-PCNL|percutaneous nephrostolithotomy (PCNL) with 12-20 Fr access tract for the treatment of ≥2 cm renal stone
45689830|NCT04075149|Drug|Spironolactone|Spironolactone is an androgen-receptor commonly used (off-label) for hyperandrogenism in girls and women. It is used in this study to determine if androgen blockade can improve ovulation rates in girls with androgen excess, who often have low rates of ovulation in the years following menarche. The spironolactone dose will be as follows: If ≤ 60 kg, 50 mg twice daily; if > 60 kg, 100 mg twice daily.
45845650|NCT05722236|Behavioral|IBD Strong Peer2Peer|Mentee participants will experience the intervention: this group will partake in peer-led sessions (peer calls) consisting of up to 10 virtual sessions on Zoom lasting approximately 20-30 minutes in duration over eight weeks. Individual peer calls will be unstructured whereby trained mentors (patients with IBD who have undergone training to be a mentor) and mentees will be given the freedom to discuss whatever issues they choose. Psychological and emotional support is provided to the mentee by the mentor.
45845651|NCT05722236|Other|Waitlist control|Wait list controls will be offered participation in the IBD Strong Peer2Peer intervention once post-control outcome measures have been completed.
45363453|NCT00866450|Dietary Supplement|Western style diet (high fat and low in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
46050172|NCT01075646|Drug|saline solution|"Laparotomy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h.~Laparoscopy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 2 ml/h.~Hepatic surgery: 10 ml de saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h"
45363454|NCT00866450|Dietary Supplement|Prudent-style diet (low fat and high in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
45363455|NCT03894969|Biological|GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E|2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm
45363456|NCT03894969|Biological|Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)|2 doses of the Shingrix vaccine will be administered at days 1 and 61 to all subjects in groups Sh_NTHi-Mcat_1, 3 and 6. The vaccine will be given intramuscularly (IM) in the upper deltoid of the non-dominant arm
45363457|NCT00876434|Drug|Sirolimus|
45481393|NCT03771365|Procedure|SMP|percutaneous nephrostolithotomy (PCNL) with 10-14 Fr access tract for the treatment of ≥2 cm renal stone
45481394|NCT03771287|Device|Oticon OpenSound Navigator speech enhancement algorithm|OpenSound Navigator (OSN) is a speech enhancement algorithm developed by Oticon. The feature is built in Oticon's current OPN™ hearing aid platform and can be adjusted and disabled in the programming. It is designed to automatically enhance speech while reducing unwanted background noise to improve communication for the user.
46050173|NCT01075412|Drug|[F18]Fluorothymidine|FLT PET scan 5 mCi (+/- 10%)
45689831|NCT01412229|Drug|Cetuximab|Weekly cetuximab given intravenously for 6 weeks during induction chemotherapy and continue during the 2-3 week break prior to definitive chemoradiotherapy.
45845652|NCT05722002|Drug|NSAID|"Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~Ibuprofen 600 milligram (mg) by mouth every six hours as needed for pain (10 doses)~Celecoxib 400 mg by mouth once then 200 mg every twelve hours as needed for pain (10 doses)~Naproxen 500 mg by mouth once then 250 mg by mouth every eight hours as needed for pain (10 doses)"
46050174|NCT00799903|Drug|Darapladib|Lp-PLA2 inhibitor administered in addition to standard therapy
46050175|NCT00799903|Drug|Placebo|Placebo administered in addition to standard therapy
45363458|NCT00871442|Other|No Basal Infusion|Group 1: Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
45363459|NCT00871442|Other|Basal infusion|Group 2 Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
45363460|NCT00871442|Drug|PCEA solution (bupivacaine and fentanyl)|PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml
45363461|NCT00871520|Other|no specific interventions|There are no specific interventions in this observational study
45363462|NCT02588729|Other|Pregnant+ app for smartphone|The Pregnant+app for smartphone with information about a healthy diet, physical activity and management of gestational diabetes mellitus.
45363463|NCT05355597|Drug|Exparel Injectable Product|Both drugs have same desired effect. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
45689832|NCT01412229|Drug|Nab-paclitaxel|Weekly nab-paclitaxel given intravenously following cetuximab infusion for 6 weeks.
46050176|NCT01075256|Device|5% calcium sodium phosphosilicate toothpaste|Low concentration calcium sodium phosphosilicate tubule occlusion agent
46050177|NCT01075256|Device|7.5% calcium sodium phosphosilicate toothpaste|High concentration calcium sodium phosphosilicate tubule occlusion agent
46050178|NCT01075256|Device|Placebo toothpaste|Placebo toothpaste
46050179|NCT02876432|Device|Electroacupuncture|"The acupuncture points selected were ST36, BL25, GB30, BL40, GB34 the needles were inserted into acupoints and the depth of needle insertion depended of the acupoints selected to achieve Deqi sensation, which is characterized as a numb, heavy, sore and/or distending sensation.~Electrical stimulation was delivered at 4 Hz. The stimulator (ITO EST-160) was then switched on, and the intensity was gradually increased to reach a strong but comfortable level the sensation of EA which is characterized for numbness, tingling and a light muscle cramp. For 15 minutes"
46050180|NCT02876432|Drug|Diclofenac sodium|100 mg Diclofenac sodium was administrated orally every 12 hours for 5 days.
45845653|NCT05722002|Drug|Opioid|"Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~Oxycodone 5 mg by mouth every four to six hours as needed for pain, 10 doses~Morphine 7.5 mg by mouth every four to six hours as needed for pain, 10 doses~Hydromorphone 2 mg by mouth every four to six hours as needed for pain, 10 doses"
45845654|NCT05722002|Drug|Acetaminophen|Acetaminophen 1000 mg by mouth every 6 hours around the clock for the first three days after surgery then as needed thereafter (20 doses).
46050181|NCT02876432|Other|Sham electroacupuncture|The investigators use 1.0 cm outside point of the real electroacupuncture, the depth of needle insertion was superficial to avoid Deqi sensation, the cables wasn't connected to the electro stimulator and was then switched on for 15 minutes. The participants were threaded separately to avoid sharing experiences about the electroacupuncture sessions
46050182|NCT02876276|Procedure|Hyaluronic acid filler|Papillary augmentation with HA dermal fillers was considered as the test group
46050183|NCT00923130|Drug|Bevacizumab|Bevacizumab will be administered intravenously every 3 weeks on an outpatient basis with the exception of admissions for the purpose of facilitating research studies. The dose of bevacizumab to be given is 15 mg/kg.
46050184|NCT00923130|Drug|Ixabepilone|Ixabepilone will be given on days 1, 2, 3, 4, and 5 of each three week cycle as a one hour intravenous infusion. The dose will be 6 mg/m(2)/day on five successive days.
46050185|NCT04258098|Drug|Oral antibiotics ( Streptomycin ,metronidazole )|Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. Streptomycin 1g plus metronidazole 0.2g was prescribed 3 times a day for 3 days before surgery in the OA+MBP group patients.
46050186|NCT04260750|Behavioral|Internet-administered Cognitive behavioral therapy (ICBT)|"The intervention consists of fifteen modules, each having a specific focus on a problem (e.g. comorbid worry alongside the depression) or containing a specific strategy or element (e.g. behavioral activation).~The fifteen modules are:~Introduction/Psychoeducation about depression, Behavioral activation 1, Behavioral activation 2, Cognitive restructuring, Acceptance, Psychoeducation about emotions, Anxiety and exposure, Comorbid social anxiety, Comorbid worrying and generalized anxiety, Comorbid panic disorder, Sleep problems, Perfectionism, Stress management, Relaxation, and Relapse prevention.~The first and last module are assigned to all participants. The rest is picked either by the participants themselves or by the therapist conducting the intake interview."
45363464|NCT05355597|Drug|Multi-Drug Cocktail (Ropivicaine, Epinephrine, Ketolorac, Clonidine)|Same desired effect as Exparel but different mechanism of action. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
45363465|NCT05684003|Other|Neuromuscular exercise based injury-prevention program|Neuromuscular exercise based injury-prevention program
45363466|NCT00866528|Drug|pazopanib|oral pazopanib once daily (Phase I starting dose 800 mg)
45363467|NCT00866528|Drug|paclitaxel|paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
45363468|NCT05355519|Other|Electronic curriculum and instructor-led course, then placebo|Electronic curriculum and instructor-led course
45363469|NCT05355519|Other|Placebo, then electronic curriculum and instructor-led course|Electronic curriculum and instructor-led course
45363470|NCT05031767|Other|Usual care|"Conventional follow-up strategy with blood tests, patient-reported outcomes, and pre-scheduled visits at the hospital every 6th month.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital."
45481395|NCT03771287|Device|Oticon omni-directional microphone algorithm|Omni-directional microphone setups come standard for all Oticon hearing aid models. The hearing microphones have equal sensitivity across all directions.
45845655|NCT05721924|Procedure|Pericapsular nerve group (PENG) block|In PENG group, the patient will be given PENG block 30mls of 0.2% ropivacaine
46050187|NCT05085678|Device|Co'moon (online website to support women with AET)|"The tool contains three parts:~e-learning based on the brochure on adjuvant endocrine therapy (AET) in the University Hospital Leuven,~serious game where patients are confronted with scenes of their daily life and motivational guidelines to stimulate their self-management,~a patient-reported-outcome questionnaire (PROMs), reported in the patient medical file.~The tool is designed to stimulate patients self-management of their menopausal AET-related complaints and to discuss them with their health care professionals ."
46050188|NCT05330208|Drug|SHR-1816|SHR-1816
45363471|NCT05031767|Other|Remote monitoring|"Hospital health professionals perform remote monitoring of frequent patient-reported outcomes, blood test results, and physical activity data available on a digital platform.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital ."
46050189|NCT05330208|Drug|Placebo|Placebo
45363472|NCT05031767|Other|Patient-initiated care|"No pre-scheduled visits or remote monitoring.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital."
45363473|NCT00871598|Drug|BTT1023|intravenous, three infusions over three weeks
45363474|NCT00871598|Drug|Placebo|intravenous, three infusions over three weeks
45363475|NCT00871598|Drug|BTT1023|Test challenge
45363476|NCT04082741|Drug|BMS-986318|Specified dose on specified days
45363477|NCT04082741|Other|Placebo|Placebo Matching BMS-986318
45363478|NCT00992667|Drug|Apocynin nebulization|6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
45363479|NCT05684549|Other|No intervention|Observational study, no intervention
45363480|NCT00992745|Drug|123-I-MIP-1072|Single 10 mCi intravenous injection
45363481|NCT00992745|Drug|111-In capromab pendetide|Single 5 mCi intravenous injection
45481396|NCT05539391|Other|Data patient|Medical History and characteristic of patient
45481397|NCT05539391|Other|Physical examination|Arterial pressure, arterial oxygen saturation, heart rate
45689833|NCT01412229|Drug|Carboplatin|Weekly carboplatin given intravenously following nab-paclitaxel infusion for 6 weeks.
45845656|NCT05721924|Procedure|Supra-inguinal fascia iliaca compartment (S-FICB) block|Patients in group B (S-FICB group) will be supra-inguinal fascia iliaca compartment block 30mls of 0.2% ropivacaine
45481398|NCT05539391|Procedure|Rapid sequence intubation (RSI) : Rocuronium /Bag-mask ventilation /GEB|Rapid sequence intubation (RSI) will be performed with use of rocuronium as paralytic agent (1.2 mg/ kg). Bag-mask ventilation between induction and laryngoscopy will be performed. The GEB will be systematically used at the first attempt to facilitate intubation.
45481399|NCT05539391|Procedure|Rapid sequence intubation (RSI) : Recommendations for emergency intubation|Rapid sequence intubation (RSI) using succinylcholine as a paralytic agent (1 mg/kg), no systematic bag-mask ventilation between induction and laryngoscopy, use of GEB to facilitate intubation in case of intubation failure under direct laryngoscopy.
45845657|NCT05721534|Other|Medication review|"Annual consultation focusing on pharmacological treatment. This specific consultation constituted the intervention. It included a structured review of the patient's health state, in addition to a structured medication review with a focus on appropriate medication and deprescribing."
45845658|NCT05721456|Biological|12-Valent Pneumococcal Conjugate Vaccine|PCV12 group 1: 550 subjects receiving the 12-valent pneumococcal polysaccharide conjugate vaccine (12Pn-PD-DiT-CRM), defined as PCV12 in this protocol
46050190|NCT00610194|Drug|RDEA119|In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
46050191|NCT02473003|Behavioral|high intensity exercise|high intensity exercise 80-90%
46050192|NCT02473003|Behavioral|low/medium intensity exercise|low/medium intensity exercise 40-50%
46050193|NCT02473003|Behavioral|Behavioral medicine strategies|Motivational and self-regulatory behavioral medicine support strategies
46050194|NCT02605915|Drug|Atezolizumab|Atezolizumab 1200 milligrams (mg) or 840 mg (Cohort 1E only) flat dose administered via intravenous (IV) infusion on Day 1 of every 21-day cycle.
46050195|NCT02605915|Drug|Carboplatin|Carboplatin will be administered at an initial target of area under the curve (AUC) of 6 milligrams per milliliter*min (mg/mL*min) via an IV infusion on Day 1 of every 21-days for 6 cycles.
45363482|NCT00992745|Drug|123-I-MIP-1072|Single 5 mCi intravenous injection
45363483|NCT05171972|Drug|Ofatumumab|This investigator-initiated study will be carried out secondary to the discussion of treatment with Ofatumumab and thus our study will not influence or impact the determination of the suitability for candidates to commence therapy with Ofatumumab. This decision will be made by the patient's physician as part of the patient's standard care, and will occur independently of this study. Patients to be enrolled in this longitudinal study will only be asked if they would like to take part if their clinician independently chooses Ofatumumab as a treatment option.
45363484|NCT00992823|Drug|iron supplementation|40 doses of 30 mg of ferrous sulfate during a 10-month intervention period
45363485|NCT00992823|Biological|iron supplementation|supplementation in two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
45363486|NCT00871676|Behavioral|Lifestyle modification|16 weekly followed by 8 monthly group behavioral weight loss sessions.
45363487|NCT00871676|Behavioral|Lifestyle modification plus gum|16 weekly followed by 8 monthly group behavioral weight loss sessions. Subjects were also given gum along with instructions for times and occasions to chew with the aim of facilitating weight loss and appetite control.
45689834|NCT01412151|Drug|Creatine monohydrate|Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose
45363488|NCT00876746|Procedure|Supraclavicular vs. Infraclavicular ropivicaine infusion|Patients will be randomized to one of two groups: nerve blocks in the supraclavicular location or the infraclavicular location. Following surgery the patient will be called by study staff to assess pain scores, sleep disturbances, infusion side effects, feeling in fingers and other study outcomes.
45363489|NCT03894813|Drug|"Probiotics and Metronidazole"|Oral probiotics (Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) (qd, 30 days)+Metronidazole Suppositories (qd, 7 days)
45363490|NCT03894813|Drug|Metronidazole Vaginal|Metronidazole Suppositories,qd, 7 days
45481400|NCT01560767|Drug|Femoral Nerve Block|Under aseptic conditions, the femoral artery will be palpated immediately below the inguinal ligament and nerve stimulation will be used to identify the femoral nerve just lateral to the artery. Once the femoral nerve has been identified the block may be performed in the routine manner, using 30 ml of levobupivacaine 0.25%. The precise technique used will be noted on trial documentation.
45689835|NCT01432275|Device|ADC blood glucose meter|Subjects used the FreeStyle InsuLinx with the insulin calculator not activated. Subjects had not previously used the FreeStyle InsuLinx meter.
45689836|NCT01432275|Device|Comparator blood glucose meter|Subjects were randomly assigned one of the comparator meters. Subjects had not previously used the assigned comparator meter.
45845659|NCT05721378|Procedure|Permissive Weight Bearing group|The Permissive Weight Bearing (PWB) protocol allows earlier post-operative permissive weight bearing, where progression of weight bearing is guided by the subjective experience (for example: pain, weight bearing tolerance) of the patient and the clinical expertise of the treating physician and therapist. Patients allocated to the PWB protocol start weight bearing after wound healing is achieved (approximately two weeks after the operation). Consequently, patients are stimulated to bear as much weight as tolerated by pain and comfort. Treatment will take place according to the PROMETHEUS protocol (treatment- and evaluation protocol). The protocol contains a number of weight bearing milestones (e.g. walking with two crutches, walking with two canes, walking with one cane and walking without any walking aids). The treating physiotherapist or physician records the dates that these milestones are reached in the study database.
45845660|NCT05721378|Procedure|Restricted Weight Bearing group|The Restrictive Weight Bearing (RWB) protocol consists of 8 to 12 weeks of postoperative restricted weight (0-10%) bearing, following the current AO Guidelines (7). After 8 weeks of restricted weight bearing, the weight bearing will be increased with 25% per week for 4 weeks. Every time the patient and the treating physical therapist or physician have contact, the weight bearing advice given to the patient at that point in time is recorded (unloaded; partial weight bearing + clarification; full weight bearing). Also, any additional advice given to the patient is recorded.
46050196|NCT02605915|Drug|Docetaxel|Docetaxel 75 mg/m^2 administered via IV infusion on Day 1 every 21-days for 6 cycles.
46050197|NCT02605915|Drug|Pertuzumab|Pertuzumab 840 mg loading dose then 420 mg administered via IV infusion on Day 1 of every 21-day cycle.
46050198|NCT02605915|Drug|Trastuzumab|Trastuzumab 8 milligram per kilogram (mg/kg) loading dose, then 6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle.
46050199|NCT02605915|Drug|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle. Dose de-escalation may occur for trastuzumab emtansine, from the full trastuzumab emtansine dose at 3.6 mg/kg on Day 1 of every 21-day cycle, potentially to 3.0 mg/kg (Cohort 1C) or 2.4 mg/kg q3w (Cohort 1D).
45689837|NCT01432275|Device|ADC blood glucose meter with insulin calculator active|Subjects used the FreeStyle InsuLinx with the insulin calculator activated.
45363491|NCT00615992|Drug|Tiotropium|
45363492|NCT05103683|Drug|TORL-1-23|antibody drug conjugate (ADC)
45363493|NCT04001361|Procedure|Laser Cell Therapy|Bone marrow aspirate combined with laser to alter the cartilage matrix to facilitate repair
45481401|NCT01560767|Drug|peri-articular infiltration|The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
45481402|NCT03770897|Procedure|3D Laparoscopic Appendectomy|surgical removal of inflamed cecal appendix by 3D laparoscopic procedure
45481403|NCT03770897|Procedure|2D Laparoscopic Appendectomy|surgical removal of inflamed cecal appendix by 2D laparoscopic procedure
45481404|NCT03782675|Device|Control|The Air Barrier System will be deployed onto the surgical field, but the airflow will not be activated, so this is a sham control comparator.
45689838|NCT03025815|Other|Intervention group|Oral stimulation program consists of the a 15 minutes stimulation program, whereby the first 12 minutes involved stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consists of sucking on a pacifier routinely.
45689839|NCT03025815|Other|Control group|sham stimulation program consists of the same researcher placing her hands for 15 minutes.
45363494|NCT02588183|Device|ArticFont Advance ST Cryoenergy Balloon Catheter|PV isolation using the ArticFont Advance ST Cryoenergy Balloon Catheter
45363495|NCT00876824|Drug|Amphotericin B Lipid emulsion|Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A for treatment of Visceral Leishmaniasis
45363496|NCT00876824|Drug|Liposomal Amphotericin B|Liposomal Amphotericin B in visceral leishmaniasis - 15 mg/kg on day 1 in group B
45481405|NCT03782675|Device|Air Barrier System|The Air Barrier System is a device that uses localized clean air flow to shield a surgery site from ambient airborne microorganisms that are shed into the air from people present in the operating room.
45481406|NCT03771131|Behavioral|Multi-domain cognitive training|Weekly sessions of multi-domain cognitive training, each lasting around one hour for an overall duration of the training of 3 months (13 sessions)
45481407|NCT03766607|Drug|Trastuzumab|Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
45481408|NCT03766607|Drug|Ramucirumab|Ramucirumab 8 mg/kg administered intravenously on days 1 and 15 every 28 days
45689840|NCT01411995|Drug|2% lidocaine gel|3-5cc of 2% lidocaine gel will be applied to the lip of the cervix and within the endocervical canal prior to Intrauterine device insertion
45689841|NCT01411995|Drug|Water based lubricant|3-5cc of water based lubricant will be applied to the lip of the cervix and within the endocervical canal prior to intrauterine device insertion
45689842|NCT01411917|Procedure|Transversus abdominis plane block|Ultrasound guidance will be utilized to inject 30ml of 0.375% bupivacaine into the muscular plane between the internal oblique and transversus abdominis muscles.
45689843|NCT01411839|Behavioral|Cognitive-Behavioral Therapy (CBT-AD)|CBT-AD is a therapy program intervention that uses one-on-one and face-to-face patient-therapist sessions.
45689844|NCT01411215|Drug|Enbrel|25mg biweekly or 50mg per week, subcutaneous injection
45689845|NCT01449279|Drug|Ipilimumab|Ipilimumab will be administered as a single agent standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments.
45363497|NCT00992979|Procedure|Therapeutic Massage|Massage therapists with at least 5 years experience will perform the massages. On each of three consecutive days, participants (while fully clothed and in a seated position) will receive a 20-minute back, shoulder, neck and head massage. Subjects will be treated with conventional light pressure Swedish massage techniques which consisted of continuous systematic strokes including kneading and stretching to loosen and rehabilitate the soft tissues of the body and to provide general relaxation. The manual techniques include: effleurage , soothing petrissage , repetitive stroking, rocking , squeezing and mild joint mobilization. As is standard practice in massage therapy delivery, room lights will be dimmed and soft, soothing music played to enhance relaxation during therapy.
45481409|NCT03766607|Drug|Paclitaxel|Paclitaxel 80 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
45363498|NCT00992979|Procedure|Relaxation Control|On each of three consecutive evenings, subjects in this group will participate in a 20 minute relaxation session. This session will be delivered in the same location and with the same lighting and music as with the therapeutic massage group. Each participant will be asked to choose a comfortable position in a chair and a massage therapist will sit quietly in the room approximately 4 feet behind the participant.
45363499|NCT05028101|Procedure|Delayed autologous breast reconstruction|SOC: Delayed autologous breast reconstruction
45363500|NCT05028101|Behavioral|Perioperative Functional Medicine (FM) Care|SOC plus FM: A food plan that encourages consumption of nutrient-dense whole foods. It provides adequate protein, balanced quality fats and foods which contain targeted nutrients essential to proper wound healing. Select dietary supplements will be provided as an adjunct to the food plan. Health coaching will support optimal sleep, adequate movement/exercise and stress reduction.
45363501|NCT00866684|Drug|Sirolimus|Dosage form: coated tablet; Dosage: 4-8 micrograms/litre; Route of administration: oral use; Frequency: one tablet per day; Duration: 24 month
45363502|NCT00866684|Drug|Azathioprine|Dosage form: Coated tablet; dosage: 1-4 milligrams/kilogram; Frequency: daily; Duration: 24 month
45363503|NCT00866684|Drug|Mycophenolate|Dosage form: Tablet; dosage: 2 gram; Frequency: daily; Duration: 24 month
45689846|NCT01449279|Radiation|Radiation Therapy|Standard of care palliative radiation therapy will start within 5 days of the first ipilimumab dose. Dose is dependent upon lesion size and is determined by the radiation oncologist.
45689847|NCT04408053|Device|Preventive fixation of the contralateral femoral neck (Stryker Trauma and Depuy Synthes screws)|6.5mm titanium cannulated self-tapping/self-drilling screws (Stryker Trauma and Depuy Synthes) : 2 screws per patients
45689848|NCT01447719|Drug|florbetapir F 18|No study drug administered in this trial. Study subjects previously dosed with 18F-AV-45 in study 18F-AV-45-A07 (NCT00857415) are followed to autopsy in this extension study.
45363504|NCT00866684|Drug|Ciclosporin|Dosage form: Capsule; Dosage: 50-80 micrograms/litre; Frequency: daily; Duration: 24 month
45363505|NCT00866684|Drug|Tacrolimus|Dosage form: Capsule; dosage: 3-5 micrograms/litre; Frequency: daily; Duration: 24 month
45363506|NCT05356455|Behavioral|motivational interview technique|Difference between pre-test and post-test
45481410|NCT03766529|Procedure|loop isolation-based uploading preconditioning (LiuPhD)|declamping was not done until heart could resume normal mechanical activities and sustain well for three minutes in terms of heart rate, rhythm, and myocardial contractility via continuous antegrade warm blood delivery closely following TWBC reperfusion.
45481411|NCT05515835|Device|body composition analysis|Patients will undergo body composition analysis using bioelectical impedance method before anesthesia.
45481412|NCT03771209|Diagnostic Test|ultrasound examination|ultrasound assessment
45481413|NCT03782597|Behavioral|Semi-structured interviews or focus groups to explore families representations and strategies about their teenagers involved in radicalisation process|A sample of representative French families (parents, siblings, and persons identified as attachment figures) of adolescents or young adults (12-25 years old) involved in the radicalisation process will be asked to participate in semi-structured interviews or focus groups to explore their representations and strategies about radicalisation. It will be supplemented by genogram draw sociodemographic data.
45689849|NCT01431963|Drug|Lamictal|No comparison.
45845661|NCT05721300|Drug|"NAs（EntecavirorTenofovirorTenofovir alafenamide） combined with interferon treatments"|"NAs（EntecavirorTenofovirorTenofovir alafenamide） combine with interferon treatments for 48 weeks, and then continue with NAs treatment（EntecavirorTenofovirorTenofovir alafenamide）"
45845662|NCT05721300|Drug|"NAs （EntecavirorTenofovirorTenofovir alafenamide） treatments"|"patients receive NAs（EntecavirorTenofovirorTenofovir alafenamide） treatment at least 48 weeks"
45689850|NCT01447407|Biological|NDV-3 vaccine with alum IM|One dose administered IM
45689851|NCT01447407|Biological|NDV-3 vaccine without alum IM|One dose administered IM
45689852|NCT01447407|Biological|Placebo with alum IM|One dose administered ID
45689853|NCT01447407|Biological|NDV-3 vaccine without alum ID|One dose administered ID
45689854|NCT04056819|Biological|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be one single IC infusion followed by one single IV infusion with 12 months of follow up after treatment.
46050200|NCT02605915|Drug|Doxorubicin|Doxorubicin will be administered at 60 mg/m^2 every 2 weeks as an IV bolus over 3 to 5 minutes or as an infusion over 15 to 30 minutes.
46050201|NCT02605915|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m^2 on Day 1 of each 21 day cycle as an IV bolus over 3 to 5 minutes or as an infusion, in accordance with local policy.
46050202|NCT02606071|Device|CRT-D|HF patients treated in clinical practice with a CRT-D device
46050203|NCT04028323|Drug|Terlipressin|Terlipressin should be administrated intravenously while monitoring heart rate and blood pressure daily.
46050204|NCT04028323|Drug|Octreotide|Octreotide should be continuously intravenously administrated while monitoring heart rate and blood pressure daily.
45689855|NCT04055025|Other|Placebo|Four-hour liquid solid meal tests and a subsequent ad libitum meal during saline infusion.
45845663|NCT05721066|Diagnostic Test|ClotPro assessment|Point-of-care viscoelastic assessment of the coagulation profile (extrinsic pathway, intrinsic pathway, fibrinogen contribution, tPA stimulated fibrinolysis)
45845664|NCT05721066|Diagnostic Test|Laboratory analysis|Blood count and standard coagulation tests (INR, aPTT, fibrinogen, D-dimers, antithrombin)
45845665|NCT05721066|Other|Interview|Questionnaire from ISS (Istituto Superiore Sanità, the National Health Institute) about the health conditions before the acute COVID-19 infection, the disease (and the hospitalization) details and the eventual health disturbances experienced after the recovery from COVID-19 infection.
45689856|NCT04055025|Other|Ghrelin|Four-hour liquid solid meal tests and a subsequent ad libitum meal during acyl-ghrelin infusion.
45689857|NCT01446237|Other|acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%|over the counter acne system
45689858|NCT04046523|Device|Video ophthalmoscope|Use of a custom video ophthalmoscope with either a CCD or CMOS camera lens. The healthy controls group (first 20 subjects) will provide data to help determine which lens might be best for measuring ICP patients (Groups A and B) in the second phase of the study.
45689859|NCT00540982|Drug|indocyanine green|0.5 mg/kg will be administered by IV push to determine clearance
45689860|NCT00540982|Drug|lidocaine|1 mg/kg will be administered to determine metabolic capacity
45689861|NCT00540982|Drug|vinorelbine ditartrate|Varying doses ranging from 30 mg/m2 to 7.5 mg/m2 will be administered based upon liver function
45689862|NCT00540982|Other|high performance liquid chromatography|Used to determine plasma concentrations of vinorelbine
45845666|NCT05720910|Other|GERONTE|The clinical model behind GERONTE is to regroup all health professionals taking care of a multimorbid patient, into a common care coordination pathway
45845667|NCT05720832|Other|WINGS-IP1 Smartphone Application|"The technology-based SSIP (WINGS) offers disease-related information and builds up social inner circles between patients, their friends, and family members while facilitating to organize, perform, and enjoy activities and content."
46050205|NCT04114201|Procedure|PSI|Implantation of a Total Knee Arthroplasty patient-specific instrumentation using Zimmer® NexGen Solutions (Zimmer Biomet, Warsaw, IN).
46050206|NCT04114201|Procedure|Conventional|Implantation of a Total Knee Arthroplasty with conventional using Zimmer® NexGen Solutions (Zimmer Biomet, Warsaw, IN).
46050207|NCT03253627|Behavioral|Health Enhancement Program|The HEP control, which was developed to serve as an active control to MBSR, will receive manualized health education from experts in physical activity, functional movement, music therapy, and nutrition-without mindfulness instruction-using similar modalities to MBSR training for a matched schedule.
46050208|NCT03253627|Behavioral|Mindfulness-Based Stress Reduction|The MBSR group will receive training from a certified instructor during a group-based, 2.5-hour manualized educational activity weekly for eight weeks. Activities include body scans, gentle stretching, yoga, and mindful awareness. Participants will be asked to complete daily 45-minute, audio-guided mindfulness activities and a one-day weekend retreat to reinforce learning.
46050209|NCT04114435|Other|Echocardiography|Diagnostic test which uses ultrasound waves to make images of the heart chambers, valves and surrounding structures
46050210|NCT03253081|Behavioral|PARENT focused intervention|The group will comprise 3 to 4 parents and will focus on psychoeducation and support/well-being for the parent. Sessions will include a 20-minute welcome and supportive discussion where parents can provide updates on their week and seek advice and support from the group, followed by a 45-minute interactive education session focused on the principles of JASPER, and close with a 20-minute Mindfulness session. The Mindfulness session will be led by a certified expert.
46050211|NCT03253081|Behavioral|CHILD focused intervention|The session will be divided into 30-minute segments and include two 30-minute individualized 1-on-1 sessions with a trained interventionist. One of these two sessions will involve the parent in hands-on training while the other will be interventionist-led while the parent observes. The remaining 30-minutes will include a snack for the child and time for the parent to discuss and ask questions of the interventionist regarding the session content.
45363507|NCT05225948|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg. RIC will be conducted twice daily during the period of hospitalization.
45363508|NCT05225948|Procedure|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg. RIC will be conducted twice daily during the period of hospitalization.
45481414|NCT03770819|Procedure|Photodynamic therapy|"Zinc oxide gel/placebo gel will be placed into the periodontal pockets using a blunt cannula ensuring that starting from the bottom, it completely fills the periodontal pockets. The gel will be retained in the pocket for 5 minutes. The perio tip will be attached to the hand piece of the light cure unit (Wavelength: 420-480nm. Light power: 1200mw/cm2 in continuous mode) and light will be activated for 60 seconds. Following this, the pockets will be irrigated with normal saline solution (0.9%Sodium chloride).~For groups 1 and 2, sham PDT will be performed by directing the Light cure device without turning on the light beam."
45481415|NCT03770975|Procedure|delayed implant with immediate provisionaliztion and soft tissue graft|delayed implant placement in the esthetic zone with immediate provisinalization and placement of a connective tissue graft buccal
45845668|NCT05720754|Drug|Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
45845669|NCT05720754|Device|Heated eye mask|Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms
45363509|NCT00993057|Drug|Insulin|Adjustable insulin infusion scale with loading doses
45481416|NCT03770975|Procedure|delayed implant placement with immediate provisionalization|delayed implant placement with immediate provisionalization
45481417|NCT04518683|Device|Perineal rehabilitation with mobile applications for women with SUI|"Physiotherapy: Sessions with the physiotherapist will consist of information on anatomy, perineal awareness and behavioural therapy. The therapist will educate the patient on pelvic floor contraction/relaxation. the sessions will remain personalized and standardized like a classic treatment, and will also aim to work on motivation. 9 sessions during 3 months.~Home Program: The home program will be done with a mobile application equipped with a vaginal probe. The exercises should be done 3x/week for 10 minutes. The correct use of the prob will have been checked during the sessions with the physiotherapist. This training will work on the strength, relaxation and endurance of the pelvic floor.The program includes 3 levels of difficulty. Once the user has successfully completed one level, she can move on to the next."
45847788|NCT02953860|Drug|Fulvestrant with Enzalutamide|500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily. Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment, with an optional 3rd biopsy at the end treatment.
45363510|NCT00866762|Drug|HDAC inhibitor (MK-0683)|400 mg once daily for 6 months
45363511|NCT04001907|Behavioral|Resistance exercise|effect of exercise and an anabolic agent on body composition, muscle strength, phenylalanine and protein oxidation.
45363512|NCT04001907|Dietary Supplement|β-hydroxy-β-methylbutyrate|
45363513|NCT04001907|Dietary Supplement|placebo|
45481418|NCT04518683|Device|Classic perineal rehabilitation for women with SUI|"Physiotherapy: Sessions with the physiotherapist will consist of information on anatomy, perineal awareness and behavioural therapy. The therapist will educate the patient on pelvic floor contraction/relaxation. The sessions will remain personalized and standardized like a classic treatment, and will also aim to work on motivation. 9 sessions during 3 months.~Home program: The home program will be done without a mobile application. The exercises will have been explained during the sessions with the physiotherapist by oral instructions. The exercises will be done 3x/week for 10 minutes. The correct realization of the exercises will have been verified during the sessions with the physiotherapist."
45481419|NCT01567709|Drug|Alisertib|Given PO
45481420|NCT01567709|Other|Laboratory Biomarker Analysis|Correlative studies
45481421|NCT01567709|Other|Pharmacological Study|Correlative studies
45363514|NCT00876902|Drug|recombinant P-selectin glycoprotein ligand Ig fusion protein|The active study drug dose includes both a 1 mg/kg IV infusion for the recipient and a 20 mg [approximately 0.27 mg/kg] as an ex vivo flush. The doses will be administered via 2 separate infusions of study agent: one 20 mg dose into the portal vein of the liver prior to implantation as an ex vivo flush with Viaspan®; and the second infusion of 1 mg/kg intravenously into the recipient, when technically feasible, prior to the hepatic artery anastomosis. Those patients that experience an intraoperative blood loss of >10 units, will receive an additional 1 mg/kg IV infusion of study agent at the end of the transplant surgery.
45847789|NCT02956044|Drug|Bexagliflozin|Bexagliflozin tablets, 20 mg
45481422|NCT01567709|Drug|Vorinostat|Given PO
45363515|NCT00876902|Drug|Viaspan® and saline|Placebo of a volume equivalent to active study drug will be prepared for administration to the control group to help maintain the blind. Those patients that experience an intraoperative blood loss of >10 units, will receive an additional 1 mg/kg IV infusion of placebo equivalent at the end of the transplant surgery.
45481423|NCT01321619|Drug|Daflon|Drug B (Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.
45689863|NCT00540982|Other|intracellular fluorescence polarization analysis|Used to determine concentration of lidocaine metabolic capacity
45689864|NCT00540982|Other|liquid chromatography|Used to determine concentrations of vinorelbine and its metabolites
45689865|NCT00540982|Other|mass spectrometry|Used to determine concentrations of vinorelbine and its metabolites
45689866|NCT00540982|Other|pharmacological study|Determination of concentrations of vinorelbine and its metabolites
45689867|NCT00542308|Drug|Zalutumumab|Individual dose titration weekly i.v. doses
45689868|NCT00542620|Drug|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin aspart
45363516|NCT04039646|Combination Product|ERAS treatment|The ERAS group had an enhanced postoperative recovery protocol. The gastric content was aspirated via the nasogastric tube by the anesthesiologist at the end of the procedure, and the nasogastric tube was withdrawn in the operating room immediately after the patient had recovered from anesthesia. and also early feeding and move.
45481424|NCT01321619|Drug|Varicell placebo|Drug C (Varicell placebo) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.
45847790|NCT02956044|Drug|Metformin|1000 mg metformin
45847791|NCT02956044|Drug|Glimepiride|4 mg glimepiride
45847792|NCT02956044|Drug|Sitagliptin|100 mg sitagliptin
45847793|NCT02956122|Biological|GLASSIA|GLASSIA [Alpha1-Proteinase Inhibitor (Human)]
45363517|NCT00993135|Drug|methotrexate|
45363518|NCT00993135|Other|medical chart review|
45363519|NCT00993135|Procedure|assessment of therapy complications|
45363520|NCT00876980|Device|nasal Continuous Positive Airway Pressure|A standard treatment for OSA. A portable machine delivers positive pressure through a mask to the upper airway during sleep at night.
45363521|NCT00993213|Procedure|Standard of Care with Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies, followed by Liposuction surgery.
45363522|NCT00993213|Other|Standard of Care without Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies. Liposuction surgery will not be performed.
45481425|NCT03766217|Combination Product|Mesenchymal stem cells associated with biomaterials|Deciduous dental pulp mesenchymal stem cells associated with hydroxyapatita/collagen.
45481426|NCT03766217|Combination Product|Iliac crest autogenous bone graft|Autogenous bone will be obtained from iliac crest.
45689869|NCT00542620|Drug|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin detemir
45847794|NCT02956122|Drug|methylprednisolone or equivalent steroid|The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.
45363523|NCT05683925|Device|Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
45363524|NCT05683925|Device|Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
45689870|NCT00542620|Drug|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin aspart
45689871|NCT00542620|Drug|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin detemir
45689872|NCT00543400|Drug|M118|intravenous (IV) infusion
45689873|NCT00543400|Drug|Unfractionated Heparin|IV infusion
45689874|NCT01796938|Drug|Lacosamide tablet|Single dose of 100 mg Lacosamide tablet
45689875|NCT00492544|Biological|Cervarix™ (HPV-16/18 L1 VLP AS04)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
45481427|NCT03886259|Other|Neuromuscular exercises (NEMEX-TJR) and pain neuroscience education|"60min. of neuromuscular exercises (NEMEX-TJR) training two times a week for 3 months (12 weeks, 24 sessions). Physiotherapists will instruct and supervise the participants during the neuromuscular exercises. The aim of the neuromuscular exercise program is to restore normal movement, improve sensorimotor control, re-establishing normal motor program strategies and muscle activation.~60min. of pain neuroscience education at the beginning of intervention period and after 6 weeks. Both sessions will take 60min. and will be conducted by physiotherapists. The aim of the pain neuroscience education is to increase the pain neuroscience knowledge of the patients leading to a better understanding of their chronic pain and thereby engaging the patients in the treatment of their chronic pain and impaired function."
45481428|NCT03886259|Other|Pain neuroscience education|60min. of pain neuroscience education at the beginning of intervention period and after 6 weeks. Both sessions will take 60min. and will be conducted by physiotherapists. The aim of the pain neuroscience education is to increase the pain neuroscience knowledge of the patients leading to a better understanding of their chronic pain and thereby engaging the patients in the treatment of their chronic pain and impaired function.
45363525|NCT05683925|Device|Noninvasive transcutaneous earlobe stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left earlobe through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
45363526|NCT00877136|Device|TheraSphere®|TheraSphere® consists of insoluble glass microspheres where yttrium-90 is an integral constituent of the glass. TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. This artery provides the main blood supply to the tumor in the liver. TheraSphere® being unable to traverse the tumor vasculature is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
45363527|NCT00993369|Other|Holter monitor|Record heart rate for 2 to 6 hours on day of life 1 or 2.
45363528|NCT00866996|Drug|Methylphenidate extended-release; Atomoxetine|
45363529|NCT02588495|Other|Food intake|Either drinking a cup of clear liquid, or having a cup of coffee and a muffin
45363530|NCT04141839|Behavioral|Safer Bars|Safer Bars, a primary perpetration prevention program based on a bystander intervention model and the theory of planned behavior. Bar staff are trained to recognize and respond to sexual aggression and its precursors among patrons.
45481429|NCT03766139|Biological|SUPERCELL GLUE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with supercell glue in test sites (randomly selected by computer generated tabulation method)
45363531|NCT00871910|Drug|SCH 727965|SCH 727965 2 hour IV infusion on Day 1 of each 3 week cycle, administered in dose-escalating cohorts (Part 1 of the trial)
45363532|NCT00871910|Drug|SCH 727965|SCH 727965 8 hour IV infusion on Day 1 of each 3 week cycle,in dose-escalating cohorts
45363533|NCT00871910|Drug|SCH 727965|SCH 727965 24 hour IV infusion on Day 1 of each 3 week cycle, in dose-escalating cohorts
45363534|NCT00871910|Drug|SCH 727965|SCH 727965 29.6 mg/m2 2 hour IV infusion on Day 1 of each 3 week cycle
45363535|NCT00871910|Drug|Aprepitant|Oral aprepitant in Cycle 1 or Cycle 2, depending on the study arm: 125 mg 1 hour prior to the SCH 727965 infusion on Day 1, and 80 mg on Days 2 and 3.
45481430|NCT03766139|Biological|PRFM ALONE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with PRFM in control sites(randomly selected by computer generated tabulation method)
45481431|NCT03766061|Procedure|Onlay mesh Hernioplasty|Patients with paraumblical hernia are treated with onlay mesh hernioplasty in which mesh is placed on anterior rectus sheath
45481432|NCT03766061|Procedure|Sublay Mesh Hernioplasty|Patients with paraumblical hernia are treated with sublay mesh hernioplasty in which mesh is placed in retromuscular space
45481433|NCT03765905|Diagnostic Test|study|Scube-1 scube-2 scube-3
45481434|NCT03765827|Drug|Vitamine E Acetate|Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass
45363536|NCT00871910|Drug|Ondansetron|Ondansetron 32 mg IV 30 minutes prior to the SCH 727965 infusion on Day 1 of Cycles 1 and 2.
45481435|NCT03765827|Drug|No application of vitamin E acetate|Vitamin E acetate ointment will not be applied in this group
45363537|NCT00871910|Drug|Dexamethasone|Oral dexamethasone in Cycles 1 and 2: 12 mg 30 minutes prior to the SCH 727965 infusion on Day 1, and 8 mg in the morning on Days 2, 3, and 4.
45363538|NCT05355441|Drug|Analgesic|Routine clinical practice treatments recommended by the medical team involved
45363539|NCT05155436|Drug|Fixed Dose Combination pill of Telmisartan 40mg and Amlodipine 5 mg|Participants without prevalent hyperkalemia will receive the fixed-dose combination pill of Telmisartan and Amlodipine, once daily for 3 months.
45363540|NCT01564329|Drug|endostar|Endostar TM 7.5mg/m2,intravenous drip, Day 1to Day 10;Pemetrexed 500mg/m2, intravenous drip, Day 6; Carboplatin AUC=5,intravenous drip, Day 6; 21 days as a cycle, 4 cycles in all.
45689876|NCT00492622|Drug|Immediate-release omeprazole|Immediate-release omeprazole 40 mg qam for 7 days
45363541|NCT05213481|Drug|Tepotinib Hydrochloride Hydrate|Participants will receive Tepotinib hydrochloride hydrate film-coated tablet once daily with food on Day 1 and Day 26 in the morning.
45363542|NCT05213481|Drug|Carbamazepine|Participants will receive Carbamazepine tablet with break-line twice daily at the same time each day in the morning and evening from Day 8 to Day 32.
45363543|NCT00872066|Device|SmartSet® HV bone cement|A high viscosity bone cement for use in total hip replacement (without gentamicin)
45363544|NCT00872066|Device|SmartSet® GHV bone cement|A high viscosity bone cement for use in total hip replacement (with gentamicin)
45363545|NCT04075461|Procedure|Arthroplasty|Arthroplasty is commonly used for a displaced femoral neck fracture.
45363546|NCT04075461|Procedure|Internal fixation|Internal fixation is commonly used for undisplaced femoral neck fracture
45363547|NCT00993525|Drug|Intravitreal injection of ranibizumab|0.5 mg at week 0 0.5mg at weeks 12,24,36,48 if fluorescein leakage from active vessels on angiography
45363548|NCT00993603|Behavioral|8-month group lifestyle programme|Dietary and lifestyle counselling (11 sessions), weekly exercise programme and 3 fasting blood samples at baseline, 4 and 8 months.
45363549|NCT00993681|Biological|TD Vaccine System|heat labile enterotoxin of E. coli (LT)
45363550|NCT00993681|Biological|TD Vaccine System|placebo
46050212|NCT02607163|Drug|dexmedetomidine|Immediately after the induction of anesthesia, patients in the dexmedetomidine group received dexmedetomidine continuous intravenous (IV) infusion of 0.4 mcg/kg/h until 24 hours after surgery.
46050213|NCT02607163|Drug|saline|same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
45363551|NCT03892707|Drug|Exposure of interest (within routine clinical practice):Vitamin B complexes Milgamma® and Milgamma® compositum|"Milgamma®: 2 mL injection solution containing thiamin hydrochloride 100 mg, pyridoxine hydrochloride 100 mg, cyanocobalamin 1 mg, lidocaine hydrochloride 20 mg.~Milgamma® compositum: 1 tablet containing benfotiamine 100 mg, pyridoxine hydrochloride 100 mg."
45363552|NCT05132049|Drug|DA-5211|single dose administration (DA-5211 one tablet once a day)
45363553|NCT05132049|Drug|DA-5211-R1 + DA-5211-R2|single dose administration (DA-5211-R1 one tablet once a day + DA-5211-R2 one tablet once a day)
45363554|NCT00993759|Drug|3804-250A|3.2 ml applied topically after hand washing and at least every 3 hours while awake.
45363555|NCT00513604|Biological|aldesleukin|Given subcutaneously every 8 hours for up to 15 doses, day 0, 720,000 IU/kg
45363556|NCT00513604|Biological|therapeutic autologous lymphocytes|Given as infusion, up to 3 x 10^11 lymphocytes (minimum of 1 x 10^9), day 0
45363557|NCT00513604|Drug|Cyclophosphamide|Given intravenously 60 mg/kg/day, day -7 to -6
45363558|NCT00513604|Drug|Fludarabine phosphate|Given intravenously 25 mg/m^2/day over 15-30 minutes, day -5 to -1
45363559|NCT00513604|Radiation|Total body irradiation|600 cGy
45363560|NCT00872144|Drug|Sativex|Sativex (or placebo) will be dispensed identical 5.5 ml containers. Participants will be instructed to start with a dose of 1 spray trans-mucosally at 1800 hrs. If there are no limiting adverse effects such as sedation or dizziness, participants will be instructed to increase the dose to 2 sprays- one in the morning and the other in the early evening on day two. Participants may increase the dose by 1-2 sprays per day to a maximum dose of 12 sprays per day given 3 sprays 4 times per day. In the initial titration phase participants will be instructed to space each dose actuation 15 minutes apart until accustomed to the preparation. Participants will titrate the dose to a level where they obtain an analgesic effect without limiting side effects.
45689877|NCT00492622|Drug|Delayed-release omeprazole|Delayed-release omeprazole 40 mg qam for 7 days
46050214|NCT00799825|Biological|GSK Biological's HPV vaccine GSK580299 (Cervarix™)|All subjects will receive a 0.5 ml dose administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
46050215|NCT05719909|Behavioral|Cognitive Training|8 sessions of web-based cognitive training
45363561|NCT05355129|Drug|TT-00920|Tablets
45363562|NCT05355129|Drug|TT-00920 Placebo|Tablets
45363563|NCT00872222|Device|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
45363564|NCT00877526|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
46050216|NCT05719909|Behavioral|Sham Training|8 sessions of web-based sham training
45363565|NCT00867152|Drug|Darunavir|Darunavir 600 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Darunavir is approved by the FDA as an HIV medication in the protease inhibitor class.
45481436|NCT03765671|Drug|Elafibranor|120mg oral single dose
45481437|NCT03765593|Procedure|Biopsy Salivary Gland|A minor salivary gland biopsy will be performed at lower lip, with the minimally invasive technique that is carried out in Rheumatology Unit as a routine procedure for the diagnosis of pSS, from there it will be taken between 2-3 glands for the study. RNAlater®(Ambion, Inc., Texas, United States of America) will be stored in solution for the stabilization and preservation of RNA at -80ºC.
45845670|NCT05720598|Procedure|Sentinel Node Assessment|The SN assessment will be conducted similarly to the method proposed by Märkl et al. All LNs will be stored in a -80 °C freezer, immediately after retrieval. Within 1 to 3 days, each LN will be individually measured and weighed. Small LNs (<5 mm in short diameter) will be bisected, and half of the node will be processed for histological evaluation while the remaining half will be used for OSNA analysis. For intermediate-sized LNs (5-10 mm), a middle slice of about 2 mm thickness will be cut out for the histology, and the remaining parts of the node will be processed by OSNA. In large LNs (>10 mm), at least two slices will be cut out for histology, and the remaining parts of the node will be analyzed by OSNA.
46050217|NCT00799591|Other|Observational study so no intervention in the patient.|Observational study so no intervention in the patient.
45363566|NCT00867152|Drug|Etravirine|Etravirine 200 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Etravirine is approved by the FDA as an HIV medication in the non-nucleoside reuptake inhibitor class.
45363567|NCT00867152|Drug|Ritonavir|Ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
45363568|NCT00867152|Drug|Lopinavir/ritonavir|Lopinavir 400 mg and ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Lopinavir/Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
45481438|NCT03765515|Device|Twinfix Ti|The purpose is to evaluate the safety and efficacy of Q-Fix in patients requiring the repair of soft tissue of shoulder who receive the arthroscopic repair of soft tissue using Q-Fix, when compared with the patients receiving the treatment with Twinfix Ti Suture Anchor. The result of this trial will be used for the Q-Fix All-suture Anchor registration in China.
45481439|NCT03765515|Device|Q-Fix|Q-Fix
45481440|NCT03765203|Diagnostic Test|Natera KidneyScan|Online educational materials on Natera Kidneyscan (dd-cfDNA) and sample test results for simulated patients
45481441|NCT03765203|Other|Clinical Performance and Value Vignettes|Online renal allograft simulated patients
46050218|NCT01075100|Drug|Ixabepilone|20 mg/m2 on Days 1 and 8
46050219|NCT01075100|Drug|Carboplatin|carboplatin AUC=2.5 on Days 1 and 8
45689878|NCT00494494|Drug|Standard Care|topical antibiotic for 10 days plus topical corticosteroids for 1 month
45689879|NCT00494494|Drug|nepafenac|liquid drops, administered three times per day for 1 month in addition to standard care use of topical antibiotic and topical corticosteroid
45689880|NCT00494806|Other|Rocking Chair Intervention|Patient out of bed rocking in a rocking chair at a constant rate of one rock cycle per second (back and forth), in ten to twenty minute increments, for at least sixty minutes per day or 3600 rock cycles and ambulate at least twice per day beginning the first postoperative day.
45689881|NCT03145558|Drug|Tirapazamine|Replacing the standard chemotherapy agent doxorubicin used in TACE with tirapazamine
46050220|NCT02876354|Drug|Menaquinone|Patients on hemodialysis will be supplemented by 360 μg /d of menaquinone for 4 weeks. At baseline they will have a lateral abdominal X-Ray and dosage of dp-ucMGP. At the end of the study patients will have a second measurement of dp-ucMGP levels.
46050221|NCT00626678|Drug|Azathioprine|It is given in a consistent dosage of 2.5 mg/kg/day throughout the study
45689882|NCT03145558|Drug|Doxorubicin|Standard of care for TACE
45363569|NCT00867152|Drug|GSK1349572|GSK1349572 50 q24h for 5 days in Period 1 and for 14 days in Period 2. GSK1349572 20 mg q12h for 14 days in Period 3 if Period 3 is done. GSK1349572 is an investigational (not approved by the FDA) HIV medication in the integrase inhibitor class.
45363570|NCT00993837|Procedure|thyroidectomy|total thyroidectomy via endoscopic approach and that convert to open procedure
45363571|NCT00867230|Drug|FTS|Starting dose of 100 mg twice a day by mouth, Days 1 through 21 of a 28-day cycle.
45689883|NCT03837496|Other|STRIDE|STRIDE is a brief, group-based, virtual (videoconference) cognitive-behavioral intervention. The intervention incorporates adherence problem-solving, cognitive restructuring, relaxation training, symptom management, coping skills training, and mindfulness techniques.
45689884|NCT03837496|Other|Medication Monitoring Control|Care provided as standard by the hospital and medication monitoring
45363572|NCT05093543|Behavioral|physical rehabilitation/physiotherapy and psychosocial group sessions|physical rehabilitation/physiotherapy and psychosocial group sessions
45363573|NCT05014841|Behavioral|Speech Tasks|Listen to 20-minutes of speech sounds in English, Spanish, and/or Mandarin.
45363574|NCT04039958|Drug|Soviredia|Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
45363575|NCT04039958|Drug|Harvoni (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
45363576|NCT04039958|Drug|Harvoni (Second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
45363577|NCT00534105|Other|Total Cholesterol|
45363578|NCT00534105|Other|Triglyceride|
45363579|NCT00534105|Other|HDL|
45363580|NCT00534105|Other|LDL|
45363581|NCT00872378|Drug|Exenatide|Exenatide titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
45363582|NCT00872378|Drug|Placebo|Placebo titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
45689885|NCT04750018|Other|surgery|Patients were divided into surgery and no disease.
45689886|NCT01797874|Drug|Pazopanib|Experimental
45689887|NCT01797874|Drug|Placebo|placebo arm
45363583|NCT00994071|Drug|Temozolomide|
45363584|NCT00994071|Drug|ABT-888|
45363585|NCT00877682|Procedure|Cryoablation|Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
45363586|NCT05084885|Other|Online therapy|Standard counseling provided over the internet.
45363587|NCT00994149|Drug|Diazoxide|10mg/kg/d divide every 8 hours
45363588|NCT00994149|Drug|Ora-plus|placebo, give every 8 hours.
45363589|NCT05084417|Other|N/A This is an observational study|As this is an observational study, there are no interventions assigned to either cohort.
45363590|NCT00573248|Drug|Nicotine|"21 mg nicotine patches for smokers for 2 days~7 mg nicotine patches for nonsmokers for 2 days"
45363591|NCT00573248|Other|Placebo|Placebo Patch
45363592|NCT00994227|Procedure|vitrectomy for macular disease|three-port pars plana vitrectomy was performed in each case using a vitreous cutter surrounded by a coaxial optic fiber connected to a xenon light source (Lausanne set, Oertli, Switzerland-developed at Jules Gonin, Lausanne, by Gonvers and Bovey). Separation of the posterior hyaloid membrane was performed when necessary. Visualization of the fundus was achieved with a special noncontact wide-angle viewing system 37 during vitrectomy and with a planoconcave contact lens for macular peeling. The MEM was peeled in the macular area using an end gripping forceps.
45363593|NCT04039880|Drug|Olorofim|single oral dose (120 mg, 3.7 MBq)
45363594|NCT04083989|Other|Integrative medicine-based multimodal treatment|Multimodal inpatient treatment program based on anthroposophic medicine, including individual and group psychotherapy, family therapy, art therapies and specific nursing applications such as embrocations, rhythmical massage and oil dispersion baths.
45363595|NCT00994305|Drug|N-acetylcysteine|600 mg bid po 0-7 PO
45363596|NCT00994305|Drug|control|No treatment: standard care provided. No N-acetylcysteine administration.
45363597|NCT00877760|Drug|pegylated interferon a-2a|180 μg, once per week s.c. for 24 weeks
45845671|NCT05720598|Procedure|Staging laparoscopy|Pneumoperitoneum (10-12mmHg) will be obtained with Veress needle or 10mm trocar after minilaparotomy. Peritoneal cavity will be thoroughly assessed after insertion of two additional trocars. In cases of macroscopic dissemination, peritoneal cancer index (PCI) will be determined. After switching the optical camera into near-infrared / indocyanine green fluorescence mode, the primary tumor will be visualized, followed by assessment and possible dissection of sentinel lymph node with a high-energy device. The lymph node will be retrieved with a sterile bag, and the area of dissection will be marked with a clip. Trocars will be removed under visual assistance, and the pneumoperitoneum will be released through trocars in order to prevent port-site metastases.
45363598|NCT00877760|Drug|Entecavir|0.5 mg once daily per os, either 72 weeks or 96 weeks
45363599|NCT04083911|Drug|Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF|"Decitabine:20mg/m2/d, d1~5, intravenous infusion; Homoharringtonine:1mg/d,d3~9,intravenous infusion; Aclarubicin:10mg/d, d3~d6, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-9, subcutaneous injection;~Granulocyte colony-stimulating factor:~50-300μg/d (when WBC counts are less than 20×10^9/L ),subcutaneous injection;"
45363600|NCT05354895|Device|Transcranial infrared laser stimulation|non-invasive, non-pharmacologic photobiomodulation device
45363601|NCT00877838|Drug|NXN-188|NXN-188 600 mg (3 gelatin capsules each containing 200 mg) when experiencing migraine aura.
45363602|NCT00877838|Drug|Placebo|Gelatin capsules resembling the ones containing the active substance
45481442|NCT03765047|Behavioral|Intervention Arm|"The physical activity intervention consists of:~School Engagement and Assessment - Based on the customized assessment, training is provided for school staff to develop the capacity to increase PA. A school PA team is established.~Training - School teams are provided with ongoing in-person and virtual training to learn strategies for increasing PA before and during the school day. A training summit meeting will occur each summer, starting with the summer prior to the intervention. Teams will create a weekly calendar of activities to increase PA time to a minimum of 40 mts/day.~PA Equipment and Resources - After training, schools are provided with PA equipment, resources and teaching aids to facilitate the integration of PA into the school day.~Ongoing Assessment and Technical Assistance - Student accelerometer data will allow for monitoring of PA levels, so that additional technical assistance for classroom teachers can be provided if needed"
45845672|NCT05720598|Procedure|Gastroscopy with indocyanine green (ICG) injection|Patients will undergo gastroscopy one day prior to staging laparoscopy. The ICG powder contains 0.125 mg/ml. Two milliliters of ICG (0.125mg/ml) solution is injected in the submucosa with into four peritumoral sites, 0.5 ml for each site.
45845673|NCT05720442|Drug|Tangweian Recipe|The Tangweian recipe is a combination of several Chinese herbs
45845674|NCT05720442|Drug|Mosapride Citrate|The mosapride citrate tablets will be administrated.
46050222|NCT00626678|Drug|Prednisone|Oral corticosteroid initiated at 2 mg/kg/day dosage. Dosage may be tapered primarily by 1/3 total dosage if no new blister, then 5 mg every three days to reach the daily dosage of 30 mg then tapered by 1.25 mg every week to reach daily dosage of 20 mg/day, then tapered by 1.25 mg every two weeks to reach daily dosage of 10 mg, then tapered by 1.25 mg monthly to reach daily dosage of 7.5 mg and continue this dosage for six months then tapered to 5 mg/day if no new lesions are observed as determined by clinical assessment of the investigator.
46050223|NCT00626678|Drug|Placebo|Placebo given in place of Azathioprine 2.5 mg/kg/day throughout the study
46050224|NCT00803023|Drug|Sodium Oxybate|4.5 grams per night taken in two equally divided doses
46050225|NCT00803023|Drug|Sodium Oxybate & 6 Tablets|4.5 grams taken as a combination of liquid and 6 Placebo tablets in two equally divided doses per night
46050226|NCT00803023|Drug|Sodium Oxybate & 8 Tablets|6 grams taken as a combination of liquid and 8 Placebo tablets in two equally divided doses per night
46050227|NCT00803023|Drug|Sodium Oxybate Oral Solution (6 grams)|6 grams per night taken in two equally divided doses
45363603|NCT03656835|Procedure|Molecular Nanotechnology|Undergo ILN biochip testing
45363604|NCT00995241|Drug|Raltegravir|Raltegravir 800 mg / 24 hours.
45363605|NCT00867542|Other|no intervention|no intervention
46050228|NCT02877290|Device|non-invasive ventilation (NIV)|
46050229|NCT04306172|Other|An US Readmission Risk Prediction Model|Logistic regression model that predicts the risk of all-cause unplanned readmissions developed by the privately held healthcare software company EPIC.
46050230|NCT04306172|Other|LACE+ score|The LACE+ score is a point score that can be used to predict the risk of post-discharge death or urgent readmission. It was developed based on administrative data in Ontario, Canada.
45363606|NCT03632343|Other|Pain Squad+ with Nurse Support|Pain Squad+ smartphone app with algorithm-driven pain management advice registered nurse (RN)-initiated pain support. Email alerts related to clinically important incoming pain reports (3 consecutive reports of pain >3/10) will be sent to the study RN who will contact the healthcare team at the participants' home center to initiate clinician-driven intervention, which may be outside of the scope of the self-management algorithm. The RN will contact the participant within 12 hours of receiving the alert, including on weekends.
45363607|NCT03632343|Other|Pain Squad+|Pain Squad+ smartphone app with algorithm-driven pain management advice without RN-initiated pain support.
45363608|NCT00872612|Procedure|EUS-FNA/EBUS-TBNA + BAL|"EUS-FNA = Endoscopic Ultrasound guided fine needle aspiration of mediastinal lymph nodes.~EBUS-TBNA = Endobronchial Ultrasound guided transbronchial needle aspiration of mediastinal and hilar lymph nodes.~BAL = bronchoalveolar lavage"
45363609|NCT00872612|Procedure|EBB + TBLB + BAL|EBB = Endobronchial biopsy TBLB = Transbronchial biopsy BAL = Bronchoalveolar lavage
45689888|NCT04750174|Other|Kinesiotaping|Kinesiotape (KT) has been used by Dr. Kenzo Kase for the first time as based on the opinion that more successful results can be obtained in a banding method similar to the structural characteristics and flexibility of human skin without limiting the joint movements for edema control, joint protection, and proprioception training. In recent years, KT have been applied with a wide variety of techniques including muscle techniques for the inhibition and stimulation of muscles, fascia correction technique which aims to reduce tension and adhesions by making vibration movement between the fascia layers and field correction technique aiming to reduce regional pressure in the presence of pain, inflammation or edema as well as lymphatic correction technique for regulating lymphatic circulation .
46050231|NCT04306172|Other|SQLAPE model|The readmission risk model (Striving for Quality Level and analyzing of patient expenditures), is a computerized validated algorithm and was developed in 2002 to identify potentially avoidable readmissions.
46050232|NCT03076021|Drug|Isotretinoin|Drug interaction study
46050233|NCT03076021|Drug|dextromethorphan|Drug interaction study
46050234|NCT04305860|Dietary Supplement|Modified starch without flavoring|Each patient of this group receives the thickener during three days of hospitalization
46050235|NCT04305860|Dietary Supplement|Mofidied starch with Bi1 aromas|Each patient of this group receives the thickener and 5 flavorings during three days of hospitalization
45363610|NCT00994383|Drug|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 15 mg tablet, morphine sulfate controlled release 120 mg
45363611|NCT05198765|Behavioral|BMI-CDS|The BMI-CDS is a sophisticated point of care shared decision support tool for patients with type 2 diabetes and high BMI. The intervention is built on existing point of care clinical decision support system that algorithmically identifies study-eligible patients and deploys patient-specific CDS output at an index visit and updated CDS all subsequent primary care office, video, and phone encounters.
45363612|NCT00877994|Behavioral|Nurture Support Group Therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists.
45363613|NCT00877994|Behavioral|Group therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists. The curriculum will focus on increasing positive healthy eating patterns in children of mothers who have had disordered eating and body image struggles.
45363614|NCT02588417|Drug|Dexamethasone|4mg dexamethasone intrathecally plus levobupivacaine 2.5 mg
45363615|NCT02588417|Drug|Levobupivacaine|levobupivacaine 2.5 mg
45363616|NCT00532935|Drug|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin phosphate (+) metformin hydrochloride 50/500 mg tablet bid, titrating up to sitagliptin phosphate (+) metformin hydrochloride 50/1000 mg tablet for an ~32 wk treatment period
46050236|NCT04305860|Dietary Supplement|Xanthan gum without flavoring|Each patient of this group receives the thickener during three days of hospitalization
46050237|NCT04305860|Dietary Supplement|Xanthan gum with Bi1 aromas|Each patient of this group receives the thickener and 5 flavorings during three days of hospitalization
46050238|NCT04114279|Procedure|Performance of laparoscopic duodenal atresia repair|completion of laparoscopic duodenal atresia repair in a surgical simulator
46050239|NCT00859222|Drug|LBH589|
46050240|NCT00859222|Drug|bevacizumab|
45481443|NCT03764969|Behavioral|standard smoking cessation program (SCP)|Each subject will receive standard SCP as group treatment once a week (1 hour) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra & Buchkremer 2004), and will be carried out by a qualified therapist.
46050241|NCT01072448|Drug|Indacaterol 75 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
46050242|NCT01072448|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
46050243|NCT00922974|Radiation|External beam radiation therapy|Single fraction dose of 8 Gy external beam radiation therapy
45363617|NCT00532935|Drug|Comparator: pioglitazone|pioglitazone 30 mg tablet qd, titrating up to 45 mg qd for an ~32-wk treatment period.
45363618|NCT00878150|Behavioral|In-person Cognitive Behavioral Therapy|12 sessions of CBT delivered in-person over 16 weeks
45363619|NCT00878150|Behavioral|Telephone Cognitive Behavioral Therapy|12 sessions of telephone-based CBT over 16 weeks
45363620|NCT00994539|Drug|morphine sulfate|morphine sulfate 15 mg and 30 mg tablets
45689889|NCT00497770|Drug|Pemetrexed|Treatment pattern and treatment initiation or changes are solely at the discretion of the physician and the patient
46050244|NCT00922974|Radiation|Radiosurgery/SBRT|Single fraction dose image-guided radiosurgery / stereotactic body radiotherapy (SBRT). The phase II component uses 16 Gy. The phase III component allows 16 or 18 Gy as preferred by the treating physician.
46050245|NCT00858988|Drug|Rifaximin|100mg of rifaxin for 7 consecutive days, twice daily
46050246|NCT00858988|Drug|Placebo|twice daily for 7 consecutive days
45363621|NCT00872846|Device|BALANCE System intestinal electrical stimulator|The BALANCE System stimulates the duodenum in a specialized way to strengthen the natural contractions and mimic the sensation of fullness (satiety). The patient is expected to feel full after eating smaller amounts of food than normal. In addition, duodenal stimulation has been shown to induce favorable changes in postprandial glucose levels, glucose tolerance testing and insulin levels.
45363622|NCT00878306|Drug|Disulfiram|62.5 mg daily x3 days, then 250 mg daily x3 days
45689890|NCT03727360|Other|Exercise Training|Supervised exercise conducted four days per week for six months.
45689891|NCT03727360|Other|Flexibility Control|Supervised exercise conducted four days per week for six months.
45689892|NCT00498550|Drug|Clozapine|Clozapine up to 550mg per day
45689893|NCT00498550|Drug|Treatment as usual|Remain on pre-study antipsychotic treatment
45363623|NCT00878306|Drug|Disulfiram + Efavirenz|Efavirenz 600 mg daily x10 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
45363624|NCT00878306|Drug|Disulfiram + Atazanavir|Atazanavir 400 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
45363625|NCT00878306|Drug|Disulfiram + Ritonavir|Ritonavir 200 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
45481444|NCT03764969|Behavioral|Cognitive remediation treatment (CRT)|Cognitive remediation treatment (CRT) employing a chess-based battery of tasks two times per week over six weeks as a group treatment in our outpatient clinic (60 min duration per session).
45689894|NCT00498628|Drug|Quetiapine fumarate|Quetiapine fumarate- taken daily, for 12 weeks
45689895|NCT00498628|Other|Placebo|Placebo
45689896|NCT04749706|Behavioral|Physical training alone|The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.
45689897|NCT04749706|Behavioral|physical training + protein intake|"The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.~15 women with constitutional leanness will, on top of the physical training, received a daily protein supplementation corresponding to 20 grams of proteins + 10 grams of Maltodextrine"
45689898|NCT04749472|Other|Sling|Participants wore six different shoulder slings in a randomized order.
46050247|NCT00858832|Drug|Methergine|Scheduled methergine 0.2 mg PO every 6hrs for duration of postpartum stay
46050248|NCT01071512|Drug|Tysabri|Infuse TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP. Tysabri will be infused every four weeks.
46050249|NCT00858442|Procedure|With PRP|Release of burn contractures and skin graft on the affected limb, a rigorous haemostasis. The surgeon must distribute the activated PRP evenly, forming a very fine clot over it. Immediately the split skin graft must be applied, duly fenestrated. The grafted zone will be measured in it's longest width and length, taking a standardized photograph. On the 5th day the nurse will evaluate the graft's conditions. The evaluation will be done following a previously established follow-up protocol. Measurements of width & length of graft and standardized photo taken at the initiation of the compressive system. Measurement of graft's width & length and standardized photo at the end of the compressive system according protocol. Statistical analysis.
46050250|NCT04256148|Biological|ALXN1830|Administered via intravenous (IV) infusion
46050251|NCT04256148|Other|Placebo|Matching placebo (sterile liquid diluent) administered via IV infusion
46050252|NCT00626834|Drug|Vigabatrin|Dose 1 BID
46050253|NCT00626834|Drug|Vigabatrin|Dose 2 BID
46050254|NCT00626834|Drug|Vigabatrin|Dose 3 BID
46050255|NCT00626834|Drug|Matching placebo|Matching placebo BID
46050256|NCT02619136|Procedure|Transfusion|Red Blood Cell Transfusion
45363626|NCT00878384|Drug|Medication to control ventricular rate in AF|Standard pharmacologic rate control. Current therapy will be adjusted to achieve rate-control targets of <80bpm and <110bpm on exercise (6 minute walk). Where necessary, additional medication will be given as per standard practice (digoxin or beta-blocker). Typical does: Digoxin 62.5-250mcg o.d. ; Bisoprolol 1.25-20mg o.d.; Carvedilol 3.125-50mg b.d. ; Nebivolol 1.25-10mg o.d.
45363627|NCT00878384|Procedure|Catheter Ablation for Persistent Atrial Fibrillation|Radiofrequency catheter ablation, which may include pulmonary vein isolation, atrial substrate modification, and/or linear ablation.
46050257|NCT04861116|Behavioral|Intervention program for test anxiety|12-week ICT-based manualized, targeted and facilitated individual intervention for adolescent students, that aims to promote compassion, acceptance and mindfulness, in order to help improve test anxiety's regulation (and consequently symptom reduction), as well as increase general and school-related well-being, while promoting valued life action.
45481445|NCT03764969|Behavioral|Implicit computer-based habit-modifying training (ICHT)|Implicit computer-based habit-modifying training (ICHT), applied twice a week for six weeks. In this training, the participants perform a two-part training. First, a subliminal presentation (20 ms) of negative valenced primes before smoking-cues in context and secondly, a subliminal presentation of positive valenced primes before potentially reinforcing events.
45363628|NCT04082975|Drug|NVP-1203|Oral dose for 7 days
45481446|NCT03764891|Procedure|Uphold|Uphold system in treating women with cystocele
45481447|NCT03764891|Procedure|Perigee|Perigee system in treating women with cystocele
45363629|NCT04082975|Drug|NVP-1203-R|Oral dose for 7 days
45363630|NCT04082975|Drug|NVP-1203 placebo|Oral dose for 7 days
45363631|NCT04082975|Drug|NVP-1203-R placebo|Oral dose for 7 days
45363632|NCT00994617|Drug|Losartan and hydrochlorothiazide|Losartan 50 -100mg Hydrochlorothiazide 12.5mg -25mg
45363633|NCT00994617|Drug|Hydrochlorothiazide switched over with Losartan at 8 weeks|Hydrochlorothiazide 12.5-25mg crossed over with Losartan 50-100mg
45689899|NCT00498706|Behavioral|Telephone-administered cognitive behavioral therapy (T-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of T-CBT administered by a therapist. Participants will undergo telephone-administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
45363634|NCT05196269|Device|Artificial Intelligence and Digital Health Arm|A previous large database repository of images having thousands of pre and post operative photographs of breast cancer patients proposed for locoregional treatment with clinical and biometric data will be matched using artificial intelligence within the CANKADO platform. Patients proposed for breast cancer locoregional treatment will have the access to the software installed and they will have access to all the information about the type of treatment they will receive. All the question and questionnaires will be filled online and they can vusalize the expected outcome from excellent to poor.
45363635|NCT00995397|Drug|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days.
45481448|NCT03771053|Drug|Ezetimibe with simvastatin|ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI
45481449|NCT03771053|Drug|Simvastatin|simvastatin 40mg everyday for 12 months after PCI
45689900|NCT00498706|Behavioral|Face-to-face administered CBT (FtF-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of FtF-CBT administered by a therapist. Participants will undergo face-to-face administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
45689901|NCT01446159|Drug|MEDI-573|Intravenous infusion of MEDI-573 (10 or 30 or 45 mg/kg) will be administered on Day 1 of each 21-day cycle until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
45481450|NCT03770429|Drug|AZD6738|MDS and CMML cells rely specifically on the ATR pathway to fix DNA damage and survive; by inhibiting ATR with AZD6738, MDS or CMML cells appear to selectively accumulate DNA damage and die, but healthy cells appear to be less sensitive to this target
45689902|NCT01446159|Drug|Aromatase Inhibitor|Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
45689903|NCT00498940|Device|Optimization Testing|Atrioventricular (AVD) and interventricular (VVD) delays and left ventricle lead site location were optimized after weaning off bypass (Phase I), after sternal closure (Phase II), and 12 to 24 hours (Phase III) after bypass. Intrinsic heart rate was also optimized in Phase III.
46050258|NCT04119076|Other|Classroom-based physical activity|
46050259|NCT04119076|Other|Control Group|
45363636|NCT00995397|Drug|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days.
45363637|NCT00919451|Drug|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
45363638|NCT05066477|Dietary Supplement|CalGo|CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and phosphorus. Furthermore it contains collagen type 2 and is enriched with vitamin D3.
46050260|NCT04255992|Dietary Supplement|Calcium Arm|1000 mg Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
45363639|NCT05066477|Other|Placebo|Pure maltodextrin
45363640|NCT05684393|Other|frequency distribution type|One group is fitted using channel filterbank frequency distribution based on anatomy data extracted from post-OP CT measurements. The second (control) group is fitted with the standard frequency distribution used in MAESTRO 9 fitting software.
45363641|NCT04968743|Device|Transcranial magnetic stimulation (TMS)|TMS will be administrated with a Magstim 70mm figure-8 coil allowing for focal stimulation. Single-pulse TMS will be applied at different phases, (0, 90, 180, 270 degrees - 4 stimulation conditions), of the ongoing mu-rhythm. Positioning of the TMS coil will be neuronavigated based on individual MRI scans. Stimulation will be applied in a closed-loop fashion while the participant is at rest and their EEG activity is recorded.
45363642|NCT03016312|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg), intravenous (IV) infusion on Day 1 of each 21-day cycle.
45481451|NCT03770585|Procedure|Fluoroscopy guided Facet joint injection|Fluoroscopy guided Facet joint injection (The patient will be placed in the prone position with a pillow under the abdomen to correct the lumbar lordosis. The joint to be injected is located and marked, the x ray tube is then slowly rotated till the joint appear in profile as two parallel lines. After cleaning and drapping and administration of local anesthesia a22-g spinal needle is inserted in line with x-ray beam till bony contact is felt. All procedures will be performed under sterile conditions. Each facet joint is infiltrated with a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml (20mg) methylprednisolone acetate injected into the joint.)
45481452|NCT03770585|Procedure|Ultrsound guided Facet joint injection|Ultrsound guided Facet joint injection (Patients will be placed in a prone position. The needle is inserted 1-2 cm laterally from the midline at the lateral end of the transducer and precisely positioned in the US plane at an angle of approximately 45o with respect to the axial plane)
45689904|NCT00498940|Device|Temporary Biventricular Pacing|Continuous temporary biventricular pacing for 24 hours at a heart rate of 90 bpm or 10 bpm above intrinsic heart rate.
45363643|NCT03016312|Drug|Enzalutamide|Enzalutamide capsules will be administered orally at a dose of 160 mg daily.
45363644|NCT05061953|Device|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
45363645|NCT05059223|Drug|AXS-12 (reboxetine)|AXS-12 tablets, taken twice daily
45363646|NCT05059223|Drug|Placebo|Placebo tablets, taken twice daily
45363647|NCT00919607|Drug|quetiapine fumarate extended-release|200mg,oral,single dose
45363648|NCT00919607|Drug|quetiapine fumarate extended-release|300mg,oral,single dose
45363649|NCT01014052|Drug|QLT091001|oral QLT091001 administered once daily for 7 days
45363650|NCT05188391|Diagnostic Test|Deltoid Gap Sign|At first deltoid sign test will be performed and the result of the test will be noted for the patients who are already scheduled open medial ankle surgery due to diagnosed as ankle fracture. During the open surgery, the test results will be evaluated.
45363651|NCT01014130|Radiation|Hypofractionated radiotherapy (HypoRT)|Highly conformal hypofractionated radiotherapy to a total dose of 54 Gy given in 3 fractions of 18 Gy each, delivered weekly on days 0, 7 and 14 with a maximum deviation of +/- 2 days from the specified time allowed.
45363652|NCT01014130|Radiation|Conventionally Fractionated Radiotherapy (ConRT)|Standard radiotherapy to a total dose of 60-66 Gy prescribed to an isodose covering the PTV. It will be delivered as 30-33 fractions over a period of six to six and a half weeks. If the use of chemotherapy is the institutional practice for this group of patients, concurrent carboplatin and paclitaxel will be given weekly (paclitaxel (45mg/m2/wk) and carboplatin (AUC=2/wk) for 6 weeks.
45363653|NCT05187611|Device|Conduction system pacing|Lead placed in the His-Purkinje system in order to achieve QRS shortening.
46050261|NCT04255992|Dietary Supplement|Vitamin D/Calcium|1000 mg/800UI of the association Vitamin D/Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
46050262|NCT02618824|Drug|Histidine Tryptophan Ketoglutarate Solution|Hearts will be arrested with Histidine Tryptophan Ketoglutarate (HTK) solution during cardiac operation. After aortic cross clamp 50-60 ml/kg HTK will be administered
45363654|NCT05187611|Device|Biventricular pacing|Lead is placed in a tributary of the coronary sinus.
45363655|NCT05187221|Behavioral|CVS Group|CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains.
45363656|NCT02587637|Device|Dorsal Root Ganglion Stimulation|
45481453|NCT04340063|Device|Gait training performed on a treadmill|Participants randomized to the Control group will complete high intensity gait training on a treadmill.
45481454|NCT04340063|Device|Gait training performed in a Movement Amplification Environment|The Experimental group will perform all gait training within the movement amplification environment. To create the movement amplification environment, the investigators have constructed a cable-driven robot, the Agility Trainer. The Agility Trainer applies small forces to the pelvis that increase the difficulty to maintain forward walking
45481455|NCT03770663|Drug|Cyclophosphamide and azathioprine|European strategy 6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day
45689905|NCT00499096|Behavioral|Chronic care model for Bipolar Disorder|The behavioral intervention is based on the Chronic Care Model (CCM) where patients receive information on managing bipolar symptoms and health habits in a group self-management session (up to 6 weekly sessions). The Care Manager then follows up with patients via phone contacts for 12 months following the intervention. The providers receive information on guidelines for care.
45689906|NCT00499408|Dietary Supplement|Vitamin D|Patients will receive oral supplementation of 2,000 IU per day of vitamin D (cholecalciferol)
45481456|NCT03770663|Drug|Tacrolimus|American strategy Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL.
45481457|NCT03770507|Other|Exercise Training|Comparison of stationary bike and treadmill exercise among adolescents and adults
45481458|NCT03048422|Drug|Dolutegravir|One 50 mg DTG tablet was administered orally once daily
45481459|NCT03048422|Drug|Emtricitabine/tenofovir alafenamide|One fixed-dose combination tablet (FTC 200 mg/TAF 25 mg) was administered orally once daily
45689907|NCT00499408|Dietary Supplement|soy|Patients will receive oral supplementation of soy (160 mg per day soy isoflavones).
45689908|NCT01446003|Drug|MK-8457|10 x 10-mg capsule BID for 10 days
46050263|NCT02618824|Other|Terminal Warm Blood Cardioplegia|Terminal warm blood cardioplegia (TWBC) contains 20% HTK solution and 80% blood from cardiopulmonary bypass machine. Before aortic cross clamp removal 10-15 ml/kg TWBC will be administered with temperature 34-36 oCelcius
45689909|NCT01446003|Drug|Placebo for MK-8457|10 x 10-mg capsule BID for 10 days
45689910|NCT03021928|Other|Time-To-Treatment Randomization|The time after symptom onset to initiate treatment will be randomized to one of four possible treatment arms: 60 hours, 132 hours, 228 hours, or 324 hours (+/- 12 hours each).
45481460|NCT03048422|Drug|Emtricitabine/tenofovir disoproxil fumarate|One fixed-dose combination tablet (FTC 200 mg/TDF 300 mg) was administered orally once daily
45481461|NCT03048422|Drug|Efavirenz/emtricitabine/tenofovir disoproxil fumarate|One fixed-dose combination tablet (EFV 600 mg/FTC 200 mg/TDF 300 mg) was administered orally once daily
45689911|NCT03025659|Other|Pyruvate levels|An additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw (Hour 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 for participants 10kg and above or only at Hour 0, 2, 4, 6, 8, and 12 for infants under 10 kg) to measure the concentration of pyruvate in blood.
45363657|NCT00512902|Drug|Imatinib|All subjects will receive gleevec. Subjects will have a clinic visit every 2 weeks for the first 20 weeks and then they will have one every 4 weeks for the remainder of the study. Gleevec will be taken by mouth everyday. It will be increased to a maximum of 600 mg every day. It will be increased 100 mg at each visit for the first 12 weeks. Your participation may last up to 1 year and participants will have approximately 18 clinic visits.
45363658|NCT00512902|Drug|Imatinib|Up to 600 mg QD PO for up to 1 year.
45363659|NCT01014364|Drug|hydrocortisone|50mg intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
45363660|NCT01014364|Drug|isotonic saline|intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
45363661|NCT04082351|Dietary Supplement|Nanotechnology structured water ( Magnalife)|Nanotechnology structured water ( Magnalife), is given as dietary supplement to the patients to drink it according to their weight .
45363662|NCT04082351|Dietary Supplement|ordinary water|Ordinary bottled water
45363663|NCT01015300|Drug|Avastin|Patients will receive Bevacizumab (Avastin) 10mg/kg IV every two weeks for 6 months
45481462|NCT03770195|Device|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
45481463|NCT03770117|Procedure|Prehabilitation|Participants who underwent Prehabilitation will have their CT scans analysed.
45481464|NCT03770117|Procedure|Standard Procedure|Patients who underwent a panctratoduodenectomy and did not receive any Prehabilitation will have their CT scans analysed and compared.
45481465|NCT01561781|Drug|Digoxin|Oral tablets 0.25mg, single dose
45481466|NCT01561781|Drug|Vandetanib|Oral tablets, 300 mg, single dose
45481467|NCT04259255|Drug|Edaravone (Radicava®/Radicava ORS®)|"Participants will be followed from enrollment up to 24 weeks after treatment initiation (6 treatment cycles - 28 days per cycle, corresponding to a treatment period of approximately 24 weeks) or premature study discontinuation.~Biomarker testing and clinical assessments will be performed at baseline (at enrollment or before the start of cycle 1), and at cycles 1, 3, and 6. Dosing is 60 mg daily by intravenous infusion for 14 days for the initial treatment cycle, followed by daily dosing on 10 out of 14 days in subsequent treatment cycles."
45481468|NCT03770039|Drug|Oral PF-06700841 containing 14C microtracer|Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period
45481469|NCT03770039|Drug|Oral unlabeled PF-06700841|60 mg unlabeled PF-06700841 oral dose in 2nd period
45689912|NCT03019666|Biological|Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells|"Cyclophosphamide 40 mg/kg x 1 day on Day -5~Fludarabine 25 mg/m^2 x 3 days (Day -5, Day -4, day-3)"
45689913|NCT03569878|Behavioral|Peer-Integrated Multidisciplinary Collaborative Care|Case management, behavioral intervention elements, psychopharmacologic medication recommendations and 24/7 cell phone coverage for 6 months post-injury.
45363664|NCT04082507|Diagnostic Test|Serum alpha-fetoproteine|Midtrimesteric serum alpha-fetoprotein mesurment with 2D US and 3D power Doppler with MS US scan .
45363665|NCT01015378|Procedure|laparoscopid sigmoid resection|A second episode of diverticulitis will be treated with IV antibiotics and documented with CT scan and blood tests
45689914|NCT03569878|Behavioral|Trauma surgery team notification|Trauma surgery team notification of patient emotional distress, with plan for mental health inpatient consultation will be the comparator condition.
45689915|NCT00500578|Drug|Ribavirin|Arm 1 = 6 Grams Over 18 hours Every 24 Hours
45689916|NCT00500578|Drug|Ribavirin|Arm 2 = 2 Grams Over 3 Hours Every 8 Hours.
45689917|NCT01430559|Drug|Meloxicam|7.5mg x2 once a day for 12 weeks
45689918|NCT01430559|Drug|Placebo|Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.
45752164|NCT04110431|Procedure|Left bundle branch pacing|Successful LBBP was defined as (1) LBBP lead is located at 1.5-2cm from His-bundle towards right ventricular apex; (2) Paced QRS morphology of right bundle branch delay(CRBBD) in lead V1; (3) Stimulus to the peak of R wave in V5 and V6 QRS wave, which represents left ventricular activation time(Stim-LVAT), is less than 100ms and constant at high and low output pacing; (4) Unipolar pacing threshold<1.5V/0.5ms; (5) Recording P potential when narrow QRS escape rhythm or CRBBB escape rhythm(not essential).
45363666|NCT04848389|Procedure|Skin Adhesive procedure|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable 3/0 vicryl-type thread, the cutaneous plane is closed by applying skin adhesive. A drying time of 25 seconds is necessary to obtain a satisfactory seal.
45363667|NCT04848389|Procedure|Standard suture procedure|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable thread of the 3/0 Vicryl-type, the cutaneous plane is closed with the same thread with an subcutaneous stitch.
45481470|NCT03770039|Drug|IV 14C-labeled PF-06700841|30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period
45481471|NCT01321385|Other|laboratory biomarker analysis|
45363668|NCT01015456|Drug|mycophenolate sodium|per oral, twice daily, for 12 months
45363669|NCT01015456|Drug|cyclophosphamide|intravenous, monthly, for 6 months
45363670|NCT00919841|Other|Ultrasound examination|Sequential three-dimension sonographic examination for the uterine size after vaginal delivery. The examination will be performed once a week, until the completion of 7 weeks after delivery.
45363671|NCT02589041|Procedure|intraneural sciatic nerve injection|"A popliteal intraneural sciatic nerve block will be performed under ultrasound guidance. Minimal effective volume will be evaluated performing a randomization based on the Up-and-down methodology.~A baseline and postoperative electrophysiological study will assess the presence of any neurological complication."
45363672|NCT02589041|Drug|Ropivacaine 1%|
45363673|NCT00919139|Other|biologic sample preservation procedure|Blood and 3-4 cc bone marrow aspirate collected at same time (in association with treatment protocols on which patient is registered)
45481472|NCT01321385|Other|study of socioeconomic and demographic variables|
45363674|NCT00492232|Drug|Ramelteon and zolpidem|Ramelteon 8 mg, tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
45481473|NCT03782363|Biological|Autologous CIK Dose level 1|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 22
45847795|NCT02956122|Biological|Albumin|The control vials contain human albumin 20% in 50 mL normal saline solution in glass vials (for non-United States (US) Countries), or Flexbumin 25% in 50 mL in normal saline solution in plastic IV bags (for US).
45481474|NCT03782363|Biological|Autologous CIK Dose level 2|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 22
45481475|NCT03782363|Biological|Autologous CIK Dose level 3|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 15
45481476|NCT03782363|Biological|Autologous CIK Dose level 4|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 15
45481477|NCT05693168|Device|ANNE Limb Sensor|Pulse Oximeter
45481478|NCT01321775|Drug|Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet|"Neo-adjuvant doses (12 weeks):~Bevacizumab: 15mg/Kg every 3 weeks Trastuzumab: 4 mg/Kg (First dose) - 2mg/Kg every week. Paclitaxel: 80mg/m2 every week.~Adjuvant doses:~Trastuzumab: 8mg/Kg(first dose)- 6mg/Kg every 3 weeks (At least 9 months) Cyclophosphamide: 600mg/m2 every 3 weeks (9 months) Doxorubicin Liposomal: 50mg/m2 every 3 weeks (3 months)"
45363675|NCT00492232|Drug|Placebo and zolpidem|Ramelteon placebo-matching tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
45363676|NCT02587871|Drug|Cytarabine|Given IV
45363677|NCT02587871|Other|Laboratory Biomarker Analysis|Correlative studies
45363678|NCT02587871|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo microtransplant
45689919|NCT01410357|Behavioral|Targeted Training in Illness Management (TTIM)|This intervention blends psychoeducation, problem identification/goal-setting, behavioral modeling and reinforcement via use of Peer Educators, and health care linkage, has been adapted to the primary care setting and targeted for SMI-DM participants. Generalizability is enhanced with relatively brief in-person participation requirements and by utilizing professional staff typically found in primary care. TTIM will stress information sharing that is accessible to participants, and through a collaborative process, foster motivation for SMI-DM self-management.
45689920|NCT00500656|Drug|Icatibant|Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.
45689921|NCT00500656|Drug|Tranexamic Acid|over encapsulated film tablet an anti-fibrinolytic agent,is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE.
45689922|NCT00500656|Drug|Oral Placebo|hard capsule matched to tranexamic acid
45689923|NCT00500656|Drug|S.C. Placebo|solution for injection, matched to icatibant for injection
45689924|NCT01409811|Drug|zoledronic acid|Given IV
46050264|NCT00610272|Radiation|Radiotherapy|4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
46050265|NCT00610272|Radiation|Radiotherapy|8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
45689925|NCT01409811|Other|laboratory biomarker analysis|Correlative studies
45363679|NCT02587871|Biological|Therapeutic Allogeneic Lymphocytes|Undergo microtransplant
45363680|NCT02587871|Biological|G-CSF mobilized peripheral blood cells|microtransplantation
45363681|NCT05683379|Diagnostic Test|AAV8 DetectCDx|An in vitro diagnostic assay to detect antibodies to AAV8 in human serum specimens.
45363682|NCT02587793|Other|not interventional study|
45363683|NCT04082273|Device|Femtosecond Laser for Cataract Surgery|Cataract Surgery on study eye according to conventional procedure, with the exception of three steps (Capsulotomy, Lens Fragmentation and Clear Corneal Incisions) which are performed with a Femtosecond Laser in the laser treatment group. Equipment uesd for measurements is the same for both groups and in line with the normal equipment used for the conventional cataract treatment
45363684|NCT04082273|Other|Conventional Cataract Surgery|Cataract surgery will be performed conventionally, this means the clear corneal incisions will be performed manually by a blade, the capsulorhexis will be performed manually by a hook, and the lens extraction will be done by phacoemulsification
45363685|NCT00919919|Drug|progesterone|Daily use of 100 mg progesterone vaginal tablet, and Estrofem; estradiol 1 mg administrated orally. for 6 month
45363686|NCT00919919|Drug|activella|Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
45363687|NCT04082195|Other|Fooya mobile game|An application that incorporates the science and technology of immersive gaming, neuropsychology and cognitive behavior therapy in a mobile health game to target early childhood nutrition literacy and health promotion in a fun and exciting way.
45363688|NCT04082195|Other|Uno board game|A popular board game which is not a mobile app.
45363689|NCT04807595|Other|None (Observational study)|The data source for this project will be HER2 IHC historical scores, local lab rescoring of historical HER2 fixed tissue slides, independent central retesting or local lab retesting (under special occasions) of HER2 IHC status for enrolled patients who have available tissue, other biomarker testing results based on historical testing and/or testing of archived tissue samples when available, and curated patient-level data. Real-world data sources include electronic health records/electronic medical records (EHR/EMR) and biobank registries. Data from EHR/EMR sources will be curated. Biobank tissue for enrolled patients who have multiple samples available will be selected consecutively when possible and will start with the latest available samples then move backward in time.
45363690|NCT02587091|Behavioral|Portable obstetric ultrasound|This intervention was advertised at the cluster level
45689926|NCT01409811|Procedure|therapeutic conventional surgery|Undergo definitive lumpectomy or mastectomy
45689927|NCT01445847|Drug|Lidocaine|1 mg/kg or 1 mL/10 kg prior to extubation period. Injection of Lidocaine will be immediately when inhalational agent (Desflurane) is discontinued.
45481479|NCT03764657|Procedure|"In hot group 16 patients were treated by diathermy in Cold"|"In all interventions, the patients were placed in prone position on operating table with the gluteal line opened wide by adhesive patches; after skin disinfection, dimension and extension of cystic disease was studied by injection of hydrogen peroxide through superficial skin orifice. The same procedure was performed: an elliptical incision on midline around the sinus was made and the sinus was excided laterally and in depth on healthy tissue, down till the pre-sacral fascia: this common approach was made both using scalpel and electrosurgery in the two groups. During dissection and excision, in each group were measured and recorded the temperatures developing, both on the section surface using an infrared thermometer and thermal imaging camera, and deeper until 1 cm from the section frontline using a immersion thermometer sealed by a steri-drape to guarantee the sterility on surgical field. In this group excision was carried out with diatermocoagulation"
45481480|NCT03764657|Procedure|"in Cold group 13 patients were treated by scalpel."|"the position and preparation of the patient on the operating table were the same as in the hot group, while the excision procedure performed with knife"
45481481|NCT03764579|Behavioral|sleep and diet intervention vs diet intervention|lifestyle healthy food and use Harvard plate and reduce use electronic device prior sleep.
45481482|NCT05514509|Drug|APRETUDE|Available as intramuscular injection.
45481483|NCT05514509|Drug|Cabotegravir tablet|Available as marketed orally administered tablets.
45481484|NCT03764423|Dietary Supplement|Salmon fishmeal|Salmon fishmeal with high protein content
45481485|NCT03764423|Dietary Supplement|Microcrystalline cellulose|Microcrystalline cellulose contain no energy and is less fermented in the gut than other dietary fibers.
45481486|NCT03764345|Drug|Sofosbovir/Lepipasvir (200/45mg) tablet (Heterosofir)|Patients receive oral daily dose of Sofosbovir/Ledipasvir (200/45mg) daily for 8 weeks
45689928|NCT01445847|Other|Placebo|1 mL/10 kg prior to extubation period. Injection of placebo will be immediately when inhalational agent (Desflurane) is discontinued.
45689929|NCT00501592|Drug|INT-747|25 mg by mouth once daily, 50 mg by mouth once daily
45689930|NCT00501592|Drug|Placebo|Placebo
45689931|NCT03364660|Device|Epidural Stimulation|Eligible participants will be implanted with 16-electrode epidural array and epidural stimulator in the spinal cord.
45689932|NCT03364660|Biological|Stand Training|Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame.
45363691|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
45363692|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
45689933|NCT03191266|Device|Active rTMS|Active rTMS will receive an intermittent rTMS stimulation protocol.
45689934|NCT03191266|Device|Sham rTMS|Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
45752165|NCT04110431|Procedure|Biventricular pacing|Implantation of a LV pacing lead is attempted using the standard-of-care technique first.
45363693|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
45363694|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
45363695|NCT00491764|Drug|Terbinafine|Terbinafine 250 mg QD for 12 weeks.
45363696|NCT00491764|Drug|Placebo|Placebo for 24 weeks.
45363697|NCT04082039|Other|convetional PCA method unsing only 1-channel|Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline); Ch-2 (flow 2ml/h): 100ml normal saline only (for blinding)
45363698|NCT04082039|Other|utilizing 2-channel|Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg (total volume 100 ml with normal saline; Ch-2 (flow 2ml/h fixed): ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
45363699|NCT02586311|Drug|CKD-330 16/5mg|Once a day, 8 weeks
45363700|NCT02586311|Drug|Amlodipine 5mg Placebo|Once a day, 8 weeks
45363701|NCT02586311|Drug|CKD-330 16/5mg Placebo|Once a day, 8 weeks
45363702|NCT02586311|Drug|Amlodipine 5mg|Once a day, 8 weeks
45363703|NCT02586467|Behavioral|Gain-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.)
45363704|NCT02586467|Behavioral|Loss-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium).
45363705|NCT02586467|Behavioral|Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Self-Regulatory Efficacy message condition will receive information pertaining to how to include milk and milk products within their diet. This information will come in the form of recipes, meal planning, food combining etc.
45363706|NCT02586467|Behavioral|Gain-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.) and information pertaining to how to include milk and milk products within their diet.
45481487|NCT03769961|Other|No intervention|No interventions - Observational study
45481488|NCT03769883|Behavioral|Exercise and diet|The participants will undergo diet or combined diet and exercise. The exercise will be provided at different volumes
45481489|NCT03769883|Behavioral|Diet|Dietary intervention
45689935|NCT01445769|Drug|Ruxolitinib|Ruxolitinib was provided as 5 mg tablets. Dose increases were only permitted at wks 12 & 18 for lack of efficacy. Increases were restricted to patients who didn't meet criteria for a dose hold over the prior 6 wks, had a platelet count ≥ 100 x 10^9/L at wk 12 or ≥ 150 x 10^9/L at wk 18, and had a self-reported PGIC score of 3 (minimally improved) to 7 (very much worse) OR the subject's palpable spleen length below the costal margin was reduced by less than 40% relative to Baseline. Dose increases were elective and not required. Subjects were permitted a dose increase of 5 mg BID to 15 mg BID at wk 12 and to a maximum of 20 mg BID at wk 18. The protocol required dose decreases for thrombocytopenia (platelets <100 x 10^9/L) or protocol-defined anemia (decline in hemoglobin of at least 2 g/dL to a level < 8 g/dL, development of transfusion dependence, or a 50% increase in transfusion requirements for transfusion dependent subjects).
45689936|NCT00502216|Drug|Naltrexone|Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day
45481490|NCT04223531|Drug|Normal Saline 0.9% Infusion Solution Bag|Participants will receive a normal saline infusion at a rate of 10ml per unit of body surface area per minute for 120 minutes.
45689937|NCT00502216|Drug|Varenicline|Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day; Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
46050266|NCT00610272|Radiation|Radiotherapy|8 Gy in a single fraction; retreatments > 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);
45481491|NCT03769805|Drug|Anlotinib|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week.
46050267|NCT00610272|Radiation|Radiotherapy|12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments > 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;
46050268|NCT00858208|Drug|pegaptanib sodium|pegaptanib sodium intravitreal injection every 6 weeks for 2 years
46050269|NCT00610350|Drug|levosimendan|24 μg/kg administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
45363707|NCT02586467|Behavioral|Loss-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium) and information pertaining to how to include milk and milk products within their diet.
45363708|NCT05578547|Other|combined Kendell and McKenzie cervical posture correction exercises, ultrasound, hot packs, cervical extensors stretching and strengthening exercise.|"• The combined exercise will be done as follow:~1) slowly pull the subject's neck to the head, thereby attaching the chin to the neck.~(2) the subject's eyes should be looking directly forward. (3) hold both hands on the back of the subject's head. (4) ask the subject to push his/her head backwards against the hands. (5) ask for the hands to be spread as wide as possible in order to stretch the pectoralis major.~Therapeutic ultrasound:~Moist heat packs:~Stretching Exercises:~Posture correction exercises training for forward head posture includes stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles, sternocleidomastoid Stretching exercises of pectoralis major, levator scapulae, upper fibres of trapezius, suboccipital muscles, sternocleidomastoid Strengthening Exercises Chin Tucks exercise Neck isometric exercises"
46050270|NCT00610350|Drug|Placebo|an identical-appearing placebo prepared and labelled by the pharmacy was administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
45481492|NCT03764267|Drug|Remifentanil|"Five minutes before infiltration of the local anesthestic by the surgeon, patients received an initial maintenance infusion of remifentanil 0.1 µg/kg/min and ketofol mixture 0.3 ml/kg (propofol 25 µg /kg/min and ketamine 10 µg/kg/min). ketofol mixture was prepared in a ratio of 1:2.5 (100 mg ketamine 2 mL (100 mg), propofol 1% 25 mL (250 mg), and glucose 5% 23 ml, total volume of 50 ml, each ml contain 2 mg ketamine + 5 mg propofol).~Throughout the surgery, titration of the infusion rate of the remifentanil and ketofol were indicated by vital signs and expression of pain"
46050271|NCT01071200|Drug|Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)|One r-hFSH and one r-hLH injection subcutaneously (s.c.) once daily during the treatment phase from Day 8 of stimulation until injection of human chorionic gonadotropin (hCG) or cancellation of the treatment cycle.
46050272|NCT01071200|Drug|r-hFSH|One r-hFSH injection s.c. once daily during the treatment phase from Day 8 of stimulation until injection of hCG or cancellation of the treatment cycle.
46050273|NCT04255836|Drug|Durvalumab|Durvalumab 1500mg q3w combined with chemotherapy for 4 cycles, then 1500mg q4w combined with SBRT, then 1500mg q4w for PD or up to 24 months
45363709|NCT05578547|Other|ultrasound, hot packs, cervical extensors stretching and strengthening exercise.|"Therapeutic ultrasound:~Moist heat packs:~Stretching Exercises:~Posture correction exercises training for forward head posture includes stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles, sternocleidomastoid Stretching exercises of pectoralis major, levator scapulae, upper fibres of trapezius, suboccipital muscles, sternocleidomastoid Strengthening Exercises Chin Tucks exercise Neck isometric exercises"
45363710|NCT00491608|Biological|rThrombin|1000 U/mL applied directly or in combination with absorbable gelatin sponge or powder
45363711|NCT01018888|Device|Auro KPro (Keratoprosthesis)|Front plate with optical cylinder, a back plate and a titanium ring to hold the complex together
46050274|NCT04255836|Drug|the first line chemotherapy for metastatic NSCLC|paclitaxel+carboplatin or pemetrexed+cisplatin
45481493|NCT03764267|Drug|general anesthetic|general anesthetic was induced with a bolus dose of remifentanil (1 ug/kg over 30 second) and propofol (2 mg/kg) followed by insertion of a laryngeal mask airway (LMA). After the induction of anaesthesia and securing the airway, patient' lungs were ventilated with volume controlled ventilation, 50% oxygen/air mixtures in a circle system. .Anesthesia was maintained with remifentanil (0.5 ug/ kg/ min) and propofol (5 mg/kg/h). Remifentanil and propofol titrated to keep heart rate and the blood pressure within 20% of the baseline values and maintain BIS between 40 and 60, respectively. Patient movements were treated with additional i.v. bolus doses of remifentanil 0.5 ug/kg
45481494|NCT03758885|Drug|Nolasiban|Nolasiban single oral administration
45481495|NCT03758885|Drug|Placebo|Placebo single oral administration
45481496|NCT01321931|Drug|Nicotine|6 mg experimental Nicotine Replacement Therapy (NRT)
45481497|NCT01321931|Drug|Nicotine|4 mg marketed Nicotine Fruit Gum (NFG)
46050275|NCT04255836|Radiation|stereotactic body radiotherapy (SBRT)|SBRT total doses of 50-60Gy/≤10F
46050276|NCT04257786|Procedure|1ry cyto-reductive surgery|1ry surgery then chemotherapy
45481498|NCT01321931|Drug|Nicotine|4 mg marketed nicotine mint lozenge (NIQ)
45363712|NCT04678583|Procedure|Resection of colorectal liver metastases|Comparison of two liver surgery methods
45363713|NCT03996928|Other|Exercise|
45481499|NCT03764189|Procedure|microosteoperforation|small holes made using large round bur
45689938|NCT00545662|Drug|Placebo|Drug Placebo Inactive twice a day given orally or enterally. The first dose is given within 24 hours of injury and treatment continues until 90 days or until the 90-day outcome assessment.
45689939|NCT00545662|Drug|citicoline|1000 mg twice a day orally or enterally. The first dose is within 24 hours of injury and treatment continues for 90-days or until the 90-day outcome assessment.
45363714|NCT04677647|Other|OurChild mHealth Digital Platform|The intervention being created and tested in this study is OurChild an integrated mHealth/EHR app, initially designed for the Chinese American community in Sunset Park, Brooklyn. All participants will be assigned to either beta versions undergoing development, or to version 1.0.
45363715|NCT04675775|Other|Medically-tailored meals (MTM)|After the run-in baseline period participants will be expected to consume the meals and protein supplements meals between approximately Weeks 4 - 11 of the study. Additionally, participants will complete surveys before, during and after the meals.
45481500|NCT02400203|Other|Control|
45481501|NCT02400203|Other|Hemp foods|
45481502|NCT02224469|Device|ECoG (electrocorticography) sensing|Implant electrodes and sensing device and use for control of Assistive Technology
45481503|NCT03764111|Device|Large Mobile Ultrasound System|30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the large mobile ultrasound system.
45689940|NCT00545974|Drug|memantine|memantine 10mg BID
45689941|NCT00545974|Drug|Placebo pill|Placebo pill BID
46050277|NCT04257786|Combination Product|Neoadjuvant chemotherapy followed by surgery|chemotherapy then surgery
46050278|NCT00699478|Drug|mecobalamin|Methycobal Tab 0.5mg (contains 0.5 mg mecobalamin) for 3 times a day (Q8hrs) for three months
46050279|NCT04919148|Behavioral|Heat risk and pro-environment behavior message|Eligible participants will be randomized to either a control condition to receive a standardized heat health warning or an intervention condition to receive a heat health warning plus figures depicting heat risk and pro-environment behavior via their preferred and accessible channel (WhatsApp, WeChat or the text message) each time when a Very Hot Weather Warning is issued by the Hong Kong Observatory.
45481504|NCT03764111|Device|Handheld Ultrasound Machine|30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the handheld device.
45481505|NCT04305197|Drug|ICP-022|Tablet, 50mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
46050280|NCT04119232|Behavioral|Social incentives-based program|Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment. Participants will be placed on a team of 3 randomly assigned participants and receive the social incentives intervention.
46050281|NCT02615002|Drug|Piromelatine|
46050282|NCT02615002|Drug|Placebo|
45363716|NCT04675775|Dietary Supplement|Protein supplements|"A daytime and nighttime protein supplement will be provided after the baseline visit and should be consumed daily at home during the same study days as MTM. The daytime protein supplement is a protein bar (ZonePerfect or Perfect Bar). The nighttime supplement is a protein powder or liquid that can be dissolved in either water or milk.~This is provided to participants with ProCel Vanilla Whey Protein powder which provides 15 grams of protein per serving or the ProCel LiquaCel liquid protein supplement mango, grape, watermelon and/or lemon flavors which provides 16g of protein per serving."
45363717|NCT04675775|Behavioral|Nutrition education handout|A standardized nutrition education handout containing instructions on following a high-protein and sodium restricted diet (depending on the presence of ascites) will be given as part of Standard of Care.
45363718|NCT05557721|Procedure|Sub-tenon lidocaine|See arm description.
45363719|NCT05557721|Procedure|Topical lidocaine|See arm description.
45363720|NCT05557721|Procedure|MP-TLT|"Micro pulse transscleral laser treatment will be performed with the Iridex CycloG6 laser with the revised P3 probe, according to the recent consensus recommendations.~In brief, this includes MP-TLT with 2500 mW, 31.3% duty cycle, four 20 second sweeps per hemisphere, avoiding the 3 and 9 o'clock meridians and sectors with scleral thinning."
45363721|NCT02586545|Other|Shared care|
45363722|NCT04932785|Other|Regular diet|Regular diet
45363723|NCT04932785|Other|Clear Liquid Diet|Clear Liquid Diet
45363724|NCT02587715|Biological|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
45689942|NCT02928718|Procedure|ERCP|Two expert endoscopists will perform ERCP. Patients will be sedated with midazolam(2-5mg) and pethidine(25-50mg) with careful monitoring. Duodenoscope (TJF-240 or TJF-260; Olympus Corp., Tokyo, Japan) will be used. Cholangiography or pancreatography will be gathered after selective bile duct or pancreatic duct cannulation. Therapy such as endoscopic sphincterotomy, stent insertion, and etc., will be done.
45845675|NCT05720286|Device|Arthroscopic rotator cuff repair|Arthroscopic transosseous reinsertion of the rotator cuff is the most widely used arthroscopic technique. The tendons are repositioned on the greater and lesser tuberosities of the humerus with specific anchors. These anchors, placed in the humeral bone, are attached to sutures which are in turn tied to the tendon.
45363725|NCT02587715|Other|Liberation therapy|
45363726|NCT04777721|Biological|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
45689943|NCT00507208|Device|Dynasplint Trismus System|The Dynasplint System will be used for 6 months.
45845676|NCT05720208|Device|SCiP|Noninvasive Spinal Cord Neuromodulator
45845677|NCT05720052|Drug|MS-553|MS-553 oral tablet BID x 28-days
45363727|NCT00615836|Drug|Desmopressin Melt|An orally disintegrating tablet of desmopressin administered under the tongue (sublingually), without water.
45689944|NCT00507208|Other|Tongue Depressors|Tongue depressors to be used for 3 months at which time mouth opening will be measured. If there is no change then the patient will crossover to the Dynasplint Trismus System for another 3 months.
45363728|NCT05139212|Procedure|Optimum time for intravenous cannulation in children premedicated with dexmedetomidine|The optimum time for intravenous cannulation after the induction of anesthesia with sevoflurane, oxygen, and nitrous oxide in children with intranasal dexmedetomidine premedication will be searched in children undergoing elective surgery.
45363729|NCT04040270|Behavioral|Live drama+DVD+Worksheets|"Interactive live drama was proposed to enhance memories of the audience of health promotion programmes.~The interactive live drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
45689945|NCT00548470|Drug|Varenicline|Varenicline 1-2 mg/day
45689946|NCT02732704|Device|JenaValve Pericardial TAVR System|TAVR with JenaValve Pericardial Valve and Delivery System
45689947|NCT02675452|Drug|AMG 176|Study Drug
45689948|NCT02675452|Drug|Azacitidine|Non-investigational product
45689949|NCT02675452|Drug|Itraconazole|Non-investigational product
45689950|NCT00548860|Drug|Ferric Carboxymaltose|
45845678|NCT05719974|Other|rehabilitation protocol|Current conventional protocols were based mainly on biological tissue healing time frames. These protocols emphasize pain reduction, full passive knee extension, quadriceps strength training, immediate motion, immediate par¬tial weight bearing (only if there is a correct gait pattern without any complications), and functional exercises The criterion-based rehabilitation protocol is relatively new. It was developed and recommended in 2016 by the Royal Dutch Society for Physical Therapy (KNGF), aiming to assure a more patient-tailored rehabilitation and to maximize the speed of a patient's progress. It's a three phases protocol with a criterion-based progression.
45845679|NCT05719896|Drug|DT01 tablets|Each subject was given orally 3 DT01 tablets/day for 8 weeks
45845680|NCT05719896|Drug|Placebo tablets|Each subject was given orally 3 DT01 tablets/day for 8 weeks
45363730|NCT04040270|Behavioral|DVD+Worksheets|"The DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
45363731|NCT00872924|Drug|sumatriptan 100mg|
45481506|NCT04305197|Drug|ICP-022|Tablet, 80mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
45481507|NCT04305197|Drug|ICP-022|Tablet, 100mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
45363732|NCT00867776|Behavioral|AAHC Exercise Program Support Group|6-week community-based, culturally tailored support group program, focusing on exercise and healthy lifestyle habits. Groups will also include basic psychoeducation about depression and depression care. Groups will have up to 20 participants and will meet weekly for 2 hours. By the end of the program, participants will be encouraged to create a personalized action plan focusing on exercise and other healthy lifestyle choices.
45363733|NCT04672733|Biological|Hizentra|Solution for injection for subcutaneous use
45363734|NCT00878540|Drug|mirtazapine|30 mg mirtazapine once daily for 7 days
45363735|NCT04039334|Other|Conventional Chest Physiotherapy|Conventional chest physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), teaching of respiratory control, relaxing and coughing techniques.
45363736|NCT04039334|Other|Creative Dance Based Exercise Training|Creative dance based exercise training will be given under the supervision of a physiotherapist who takes creative dance instructor training 2 days and 60 minutes per week.
45481508|NCT04305197|Drug|Placebos|Tablet, matched to ICP-022, once a day, oral, will be administered for 12 weeks in double-blind treatment period
45481509|NCT03763409|Drug|Losartan Potassium|active drug
45481510|NCT03763409|Other|placebo|placebo
45845681|NCT05719896|Drug|DT01-Placebo tablets|Each subject was given orally 2 DT01 tablets and 1 Placebo tablet, three times per day for 8 weeks
45845682|NCT05719818|Drug|biphosphonates|Initiation of bisphosphonate therapy
45481511|NCT03763253|Combination Product|Standard of Care|Androgen deprivation with or without docetaxel chemotherapy, Abiraterone, Enzalutamide or any other proven agent) treatment as determined by treating physician (positive control).
45689951|NCT00548860|Drug|Standard Medical Care (SMC)|
45689952|NCT00508300|Procedure|Epidural analgesia|Thoracic epidural analgesia until day 2
45689953|NCT00508300|Procedure|Patient controlled analgesia|Patient controlled analgesia (morphine-based)
45752166|NCT00554385|Drug|ABT-089|Up to 4 capsules will be taken once daily for 12 months. Dosage forms include 1 mg, 5 mg, 10 mg capsules and 40 mg tablets. Highest dose allowed is 80 mg per day.
45752167|NCT00365209|Other|laboratory biomarker analysis|Correlative studies
45752168|NCT00365209|Other|pharmacological study|Correlative studies
45752169|NCT00365209|Drug|curcumin|Given orally
45363737|NCT04018274|Drug|PF-06651600|50 mg by mouth (PO) once daily (QD)
45363738|NCT04018274|Drug|Ethinyl estradiol (EE) and levonorgestrel(LN)|Oral tablet containing 30 ug EE and 150 ug of LN
45481512|NCT03763253|Procedure|Minimally Invasive Ablative Therapy (MIAT)|"MIAT includes High intensity focused ultrasound (HIFU) or Cryotherapy to the prostate.~Metastatic Directed Therapy available for use."
45845683|NCT05719818|Procedure|Dental care|Surgical dental care
45845684|NCT05719740|Diagnostic Test|osteocrin|laboratory routine test
45845685|NCT05719662|Other|Weight bearing exercises|Weight bearing exercises
45845686|NCT05719662|Other|Jaffrey's core stability exercises|Jaffrey's core stability exercises
45845687|NCT05719584|Other|hypopressive exercises|patients will receive pelvic floor muscle training with hypopressive exercises at outpatient department. Treatment will continue for 12 weeks 3 days per week. They will receive information about the localization and function of the PFM and transversus abdominis (TrA) muscles. Next, lying in a supine position with flexed knees and hips, they will localize their own pelvic floor with the help of touching their perineum. Then they will be instructed how to contract the PFM correctly, then they will directed to contract PFMs and in the end participants will be taught how to voluntarily contract the PFM simultaneously with diaphragmatic Aspiration(8-10 repetitions daily
45847796|NCT02956746|Biological|SYN023|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
45847797|NCT02956746|Biological|Imovax|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
45481513|NCT03763253|Procedure|Radical Therapy (Prostatectomy or Radiotherapy)|"Radical therapy includes: Prostatectomy (any surgical approach) or External beam radiotherapy (High dose).~Metastatic Directed Therapy available for use."
45481514|NCT01322477|Other|F18-FDG PET/CT|
45845688|NCT05719584|Other|pelvic floor muscle training|patients will receive only pelvic floor muscle training exercises(pelvic floor muscle contractions) at the outpatient department and treatment will continue for 12 weeks 3 days per week. PFMT will be performed in the lying, sitting and standing positions. The patients will be instructed to perform three sets of 8-12 maximum voluntary contractions held for 6 sec, with 12 sec of rest between each contraction, followed by three fast contractions in a row
45481515|NCT03763097|Diagnostic Test|Pelvic floor ultrasound|Pelvic floor ultrasound will include transperineal and introital ultrasound
45481516|NCT01321853|Other|MD2 machine and nurse care coordination|MD2 machine filled at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
45689954|NCT02476396|Procedure|Carotid Endarterectomy or Stenting|"Carotid endarterectomy is a procedure to treat carotid artery disease. This disease occurs when fatty, waxy deposits build up in one of the carotid arteries. The carotid arteries are blood vessels located on each side of your neck (carotid arteries).~This buildup of plaques (atherosclerosis) may restrict blood flow to your brain. Removing plaques causing the narrowing in the artery can improve blood flow in your carotid artery and reduce your risk of stroke.~In carotid endarterectomy, you an anesthetic. Your surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging your artery. Your surgeon then repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).~Source: Mayo Clinic~Carotid stenting uses a expandable metal coil to prevent the artery from narrowing."
45689955|NCT00509002|Drug|Gefitinib|250 mg by mouth once a day, every day, at about same time in morning.
45689956|NCT02231008|Drug|tasimelteon|
45689957|NCT02231008|Drug|placebo|
45845689|NCT05719506|Other|normal saline without drug|nebulizer session with normal saline only preoperative
45845690|NCT05719506|Drug|Dexmedetomidine|nebulizer session with dexmedetomidine preoperative
45845691|NCT05719506|Drug|Ketamine|nebulizer session with ketamine preoperative
45845692|NCT05719428|Other|DRUID AI Program|Patients will begin single agent therapy within 4 weeks of enrolment and continue until disease progression, maximum safe cumulative dose reached (where applicable, per standard institution practice) or unacceptable toxicity as per physician's discretion.
46050283|NCT02207569|Device|CoreValve Evolut R TAVR system|
45689958|NCT00509392|Device|Seg. RF Ablation & ClosureFAST catheter|Seg. RF Ablation & ClosureFAST catheter
45845693|NCT05717322|Behavioral|TENS|apply TENS after orthognathic surgery
45481517|NCT01321853|Other|Medplanner and Nurse Care Coordination|Medications are dispensed via a medplanner filled by a nurse at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
45481518|NCT05411705|Drug|rhTPO|rhTPO 300U/kg/d QD, subcutaneous injection applied for 5 days per cycle, total 3 cycles. If the patient's platelet count showed a trend of continuous decline and/or was accompanied by the risk of bleeding during the treatment or after the completion of 5 doses of rhTPO, the investigator judged that rhTPO should be continued for treatment, and rhTPO could be administered subcutaneously at 300U/kg/ day for a maximum of 14 doses per cycle. Discontinue when the absolute platelet count increases by ≥50×10^9/L or when the platelet count rises to ≥250×10^9/L.
45481519|NCT05411705|Drug|Control|Non-rhTPO treatment
45481520|NCT03763955|Behavioral|MIRT|"4 week MIRT provide:~front to front treatment (1 hour/day for 5 days/week)~treatment with robotic devices (1 hour/day for 5 days/week)~occupational therapy (1 hour/day for 5 days/week)"
45689959|NCT00509392|Device|Endovenous Laser|laser catheter
45845694|NCT05717322|Behavioral|sham TENS|apply non active TENS after orthognathic surgery
45845695|NCT05717166|Radiation|Palliative Radiotherapy|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
45845696|NCT05717166|Drug|Chemotherapy|Pre-specified based on the standard of care approach for that patient.
45845697|NCT05717166|Drug|Hormone therapy|Pre-specified based on the standard of care approach for that patient.
45481521|NCT03763019|Procedure|Conventional rehabilitation|Static and dynamic control of position, balance skills, weight shift, and activities of daily living.
45845698|NCT05717166|Drug|Immunotherapy|Pre-specified based on the standard of care approach for that patient.
45845699|NCT05717166|Drug|Targeted Systemic Therapy|Pre-specified based on the standard of care approach for that patient.
45845700|NCT05717166|Other|Observation|Pre-specified based on the standard of care approach for that patient.
46050284|NCT02619058|Biological|NKT cells|autologous natural killer T cell
46050285|NCT01070888|Drug|Budesonide/Formoterol|Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks
46050286|NCT01070888|Drug|Budesonide|Budesonide 180mcg, 2 puffs twice daily for 2 weeks
46050287|NCT04114513|Dietary Supplement|Maltodextrin|NOVAPRODUKT, white powder 5 weeks intervention
46050288|NCT04114513|Dietary Supplement|Inulin|BENEO-Orafti, white powder 5 weeks intervention
46050289|NCT04114513|Dietary Supplement|Pectin|BANG & BONSOMER GROUP OY, white powder 5 weeks intervention
46050290|NCT04114513|Dietary Supplement|Beta-glucan|Tate & Lyle, white powder 5 weeks intervention
46050291|NCT04114513|Dietary Supplement|Galactooligosaccharides|FrieslandCampina, white powder 5 weeks intervention
45481522|NCT03763019|Procedure|Respiratory rehabilitation|Forced expiration, forced inspiration (thoracal expansion exercise), coughing exercise, incentive spirometric trainer, diaphragmatic respiration exercise, autogenic drainage, percussion.
45481523|NCT01772771|Procedure|Biospecimen Collection|Undergo collection of blood, saliva/buccal swab samples
45481524|NCT01772771|Other|Genetic Testing|Correlative studies
45481525|NCT01772771|Other|Medical Chart Review|Review of medical records
45481526|NCT03762863|Device|Tourniquet application skill retention|Tourniquet application following the procedure as learned in the Stop the Bleed curriculum.
45481527|NCT03758807|Other|Manual Therapy with Traditional Biomechanical Explanation|Patients will lie prone and receive lumbar Posterior to Anterior (AP) Pressure with a traditional biomechanical or anatomic explanation of the technique..
45481528|NCT03758807|Other|Manual Therapy with Neuroplastiicity Explanation|Patients will lie prone and receive lumbar Posterior to Anterior (PA) Pressure with a neuroplastic explanation of the technique.
45481529|NCT03762785|Drug|nebulized Dexmedetomidine|inhalation of dexmedetomidine by nebulizer. the study drug will be prepared in 3 ml of 0.9% saline and will be administered by standard hospital jet nebulizer via face-mask with continuous flow of 100%oxygen at 6 l/m for 10 to 15 min
45481530|NCT03763487|Diagnostic Test|venous blood sampling|Venous blood samples to determine memory B lymphocytes.
45481531|NCT03763487|Procedure|spleen volumetry|Ultrasound examination of spleen to scaled the size.
45481532|NCT03756701|Behavioral|Mind body skills|"2 hour skill sessions that focus on mindfulness: The topics for each session is based upon the Centers for Mind Body Medicine model. Both groups will follow this same weekly topic schedule.~Introduction and Drawings~Autogenic Training and Biofeedback~Guided Imagery~Meditation~Mobilizing, Transforming, and Celebrating Emotion~Genograms part 1~Genograms part 2~Mindful Eating and Healthy Nutrition~Spirituality~Closing Drawings and Ritual"
45689960|NCT01797172|Procedure|Percutaneous Cervical Nucleoplasty|Cervical nucleoplasty is a method of percutaneous disc decompression using a 19 Gauge Trocar 3 inch spine needle (ArthroCare Co., Sunnyvale, CA, USA) which is brought to the annulus fibrosis of the herniated disc. If in the correct position, the stylet is withdrawn and the Perc DC SpineWand (ArthroCare Co., Sunnyvale, CA, USA) is introduced. The procedure relies on so-called Coblation technology which involves removing a portion of the nucleus tissue by using radio frequency energy. More specific, it results in ablation of a portion of nucleus tissue, not with heat, but with a low-temperature (typically 40-70° C) plasma field of ionized particles.
45752170|NCT01792895|Procedure|Manipulation|The Cervical Spine Manipulation is a manual therapy technique directed at the hypomobile and painful vertebral level. The subject was supine with the cervical spine in a neutral position. The index finger of the therapist applies contact over the posterolateral aspect of the zygapophyseal joint of the hypomobile vertebra. The therapist performs the technique taking account the most limited movement; lateral or rotational. A maximum of 2 attempts will performed on each subject regardless audible cavitation.
45845701|NCT05717166|Radiation|Stereotactic Ablative Radiotherapy|"The primary tumor may be treated with SABR or with other local modalities at the discretion of the treating team and/or the local multidisciplinary tumor board.~Preferred doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every second day), and 35 Gy in 5 fractions (daily)."
45845702|NCT05717166|Procedure|Surgery|"Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.~The primary tumor may be treated with SABR or with other local modalities at the discretion of the treating team and/or the local multidisciplinary tumor board. Because of the convenience in using SABR for all lesions, non-SABR modalities should only be used if they are likely to provide a benefit over SABR."
45481533|NCT03762629|Behavioral|Exercise|Subjects were provided with energy-restricted diets of 1300-2200 kcal/day based on weight. The energy percentages provided by protein, fat and carbohydrate were 20%, 20% and 60%, respectively, while energy distributions at breakfast, lunch and dinner were 30%, 40% and 30%, respectively. Subjects performed a series of endurance exercise such as bicycling, walking, running, dancing and ball games for 5 hour/day, supplemented with resistance exercise. Training interventions were performed 5-6 day/week for 6 weeks. The exercise program was designed to result in an energy expenditure of 1500-2500 kcal/day.
45481534|NCT03762551|Other|skin biopsy|Two (4 mm) punch skin biopsies were taken from the 20 patients; one prior to the initiation of phototherapy and the other after the last session (from the same site). One skin biopsy was taken from the skin of each of the 10 control healthy participants. Skin biopsy specimens were preserved in Radio-Immunoprecipitation Assay (RIBA) buffer.
45481535|NCT04664855|Other|Trauma-Informed Yoga|8 weeks of twice weekly trauma-informed yoga for 45 minutes per session
45481536|NCT03758729|Drug|Nivolumab|Nivolumab 3mg/kg + NS 100mL MIV over 1hr every 2 weeks
45481537|NCT03758729|Radiation|Radiation Therapy|Radiation Therapy
45481538|NCT03756623|Drug|Metformin powder|0.5g of Metformin powder administered three times a day orally before meal
45481539|NCT03756623|Drug|Probiotics powder|0.5g of Probiotics powder administered three times a day orally before meal
45481540|NCT03756623|Other|Placebo powder|0.5g of Placebo powder administered three times a day orally before meal
45481541|NCT04664153|Drug|PF-07038124 ointment|PF-07038124 ointment at 0.01% with QD dosing for 6 weeks
45481542|NCT04664153|Drug|Vehicle ointment|Vehicle ointment with QD dosing for 6 weeks
45481543|NCT03756467|Behavioral|Girl Empower Program|Girl Empower (GE) encourages adolescent girls living in rural areas of Nimba County, Liberia to partake in weekly mentored community-based workshops on life skills, selfcare, and financial literacy.
45363739|NCT00873002|Drug|panobinostat|Dose escalation: 7.5 mg/m2 day 1 and day 8 of 21 days cycle 10 mg/m2 day 1 and day 8 of 21 days cycle 15 mg/m2 day 1 and day 8 of 21 days cycle 20 mg/m2 day 1 and day 8 of 21 days cycle 30 mg/m2 day 1 and day 8 of 21 days cycle
45481544|NCT04663295|Device|MiniMed™ 670G system|Hybrid closed loop insulin pump with associated CGM and blood glucose meter
45481545|NCT03758495|Other|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, and healthy controls.
45481546|NCT03762239|Other|Purifying the air with a Pure Airbox device (Zonair 3D)|Purifying the air of the classroom where the experiment is conducted using a Pure Airbox device (Zonair 3D)
45481547|NCT03762239|Other|Using a sham air purifier (same device without filters)|Use the air purifier (Pure Airbox, Zonair 3D) without filters in the classroom where the experiment is conducted
45481548|NCT05108831|Device|ePOCT+|ePOCT+ is an electronic clinical decision support algorithm
45481549|NCT03762083|Device|pHyph, Gedea pessary|pHyph is a vaginal tablet for the treatment of BV.
46050292|NCT05683639|Other|warming of the follicular aspiration needle|the follicular aspiration needle will be heated overnight before the ovarian aspiration procedure.
46050293|NCT05683249|Drug|NRCT-101-SR|NRCT-101SR is a sustained release formulation. Subjects ≥ 50 kg LBM receive a total of four 500 mg tablets/day and subjects < 50kg LBM receive a total of four 375 mg tablets per day.
46050294|NCT05683249|Drug|Placebo|Matching placebo
46050295|NCT00914329|Drug|Gelsemium Sempervirens|5CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
46050296|NCT00914329|Drug|Gelsemium Sempervirens|15CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
45481550|NCT03762005|Other|CRT guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), according to capillary refill time (CRT)
45481551|NCT03762005|Other|Lactate guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), according to lactate levels
45481552|NCT03761927|Device|Hearing Aid without NR enabled|Each participant will be fitted with noise reduction disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
45481553|NCT03761927|Device|Hearing Aid with NR(1)|Each participant will be fitted with the noise reduction program on the same hearing aid. The principle of the noise reduction algorithm is to remove noise from a speech signal with the aim of improving the speech intelligibility and comfort.
45481554|NCT03761927|Device|Hearing Aid with NR(2)|Each participant will be fitted with a second noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1).
45481555|NCT04228445|Drug|3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
45481556|NCT04228445|Drug|Saline spray|Placebo
45481557|NCT03599453|Procedure|Biopsy|Undergo Biopsy
46050297|NCT00914329|Drug|Placebo|placebo, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
46050298|NCT00857896|Drug|Fesoterodine|4 mg once daily for Weeks 1-4 and 8 mg once daily for Weeks 5-8
46050299|NCT05652673|Drug|nivolumab|Early discontinuation of nivolumab maintenance therapy in patients with irresectable stage III or metastatic melanoma
46050300|NCT04112485|Procedure|Microdiscectomy|
46050301|NCT00857818|Drug|Aripiprazole|Aripiprazole administered orally as tablets, 5 mg once daily (QD) in Week 1; 10 mg QD in Week 2. Flexible dosing allowed after Week 2, adjusted in 5-mg increments every 7 days within a range of 10 to 30 mg daily, for 16 weeks
45363740|NCT00873002|Drug|sorafenib tosylate|400 mg PO BID
45363741|NCT00491530|Drug|ABT-335|Oral coadministration of ABT-335 (135 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
45363742|NCT00491530|Drug|rosuvastatin calcium|Oral coadministration of rosuvastatin calcium (20 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
45363743|NCT00491530|Drug|simvastatin|Oral coadministration of simvastatin (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
45481558|NCT03599453|Procedure|Chemokine Modulation Therapy|Undergo chemokine modulation therapy
46050302|NCT00857818|Drug|Oanzapine, risperidone, or quetiapine|Oanzapine, risperidone, or quetiapine administered orally as tablets at prior dosage for 16 weeks
45481559|NCT03599453|Drug|Celecoxib|Given by mouth
45481560|NCT03599453|Biological|Recombinant Interferon Alfa-2b|Given intravenously
45481561|NCT03599453|Drug|Rintatolimod|Given intravenously
45481562|NCT03599453|Biological|Pembrolizumab|Given intravenously
45481563|NCT03761771|Device|colonoscopy withdrawal with the ADS monitoring|During the testing of trained ADS, when the system doubts colonic lesions from the input data of the test images, a rectangular frame was displayed in the endoscopic image to surround the lesion. If the system confirmed it as the colonic lesions, a sound of reminder will be played and the types of lesions (non-adenomatous polyps, adenomatous polyps and colorectal cancers) will be classified by the system. We adopted several standards to define the identification and classification of colonic lesions: 1) when the system identified and confirmed any lesion in the images of no polyps or cancers, the results were judged to be false-positive. 2) when the system both confirmed and correctly localized the lesions in images (IoU > 0.3), the results were judged to be true-positive. 3) when the system did not confirm or correctly localize the lesions, the results were judged as false-negative. 4) when system confirmed no lesions in the normal images, the results were judged to be true-negative.
45481564|NCT05460923|Other|Proprioceptive Neuromuscular Facilitation|including trunk twists, supine to sit, knee to chest, crawling, and bridges. Every session will be 45 minutes. Patients will be given 5 sessions per week and the study will last for 12 months
45481565|NCT05460923|Other|Swiss Ball Exercises|trunk twists, supine to sit, knee to chest, crawling, and bridges. Every session will be 45 minutes. Patients will be given 5 sessions per week and the study will last for 12 months
45481566|NCT03756233|Drug|Remifentanil|Remifentanil is a potent, short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anesthetic.
45481567|NCT04641299|Drug|AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
45481568|NCT04641299|Drug|Placebo|Placebo solution
45481569|NCT05280899|Other|Weight-bearing As Tolerated|The WBAT group will be instructed to bear weight as tolerated immediately following their surgical procedure. The rehabilitation protocols provided will be identical beyond the initial weightbearing recommendations. Following the initial protection phase (three weeks), whereby the two weightbearing interventions will be provided, patients will progress through standardized phases including mobility and neuromuscular retraining, muscle balance and strengthening, functional training, and finally, advanced training for return to work and sport.
45481570|NCT05280899|Other|Partial Weight-bearing|"The PWB group will be instructed to bear weight to a maximum of 20 lbs of bodyweight on the operative limb for the initial three weeks (termed toe touch), with graduated return to full weightbearing thereafter."
45481571|NCT03761693|Other|Fasting test|"The included infants will be fasted according to local standardized procedures at the University Medical Centre Groningen. Fasting will take place under hourly blood glucose monitoring and bedside supervision by an experienced, dedicated pediatric nurse, in collaboration with a metabolic pediatrician, who will be available to attend the patient instantly. Furthermore, on request of parent(s) or guardian(s), a continuous blood glucose monitoring device can be used during the study visits.~During study visit 1, at two months of life, fasting will be continued for maximally eight hours.~During study visit 2, at six months of life, fasting will be continued for maximally twelve hours.~Fasting will be ended prematurely in the following events:~blood glucose concentration drops < 3.6 mmol/L;~the child shows symptoms/signs of a low blood glucose concentration;~patients parent(s) or guardian(s) request end of fast."
45481572|NCT03758339|Drug|tucatinib|Single dose of 300 mg of [¹⁴C]-tucatinib containing approximately 150 μCi of [¹⁴C] radioactivity
45481573|NCT03698591|Device|Transcranial magnetic stimulation task|Experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates. Experimenters have defined the target coordinates for stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task.
45481574|NCT03698591|Device|Sham transcranial magnetic stimulation task|A sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject.
45481575|NCT03755921|Other|bried and intensive therapy|Speech Therapy Exercises
45689961|NCT01797172|Procedure|Pulsed Radio Frequency|Pulsed Radio Frequency involves placement of a needle close to the to-be-treated nerve or dorsal root ganglion (DRG). The position is checked radiographically and by motor and sensory nerve stimulation. When the needle has been placed correctly an electrode is introduced, which conducts short bursts of radio frequency energy to nervous tissue. It is known as a non- or minimally neurodestructive technique, alternative to radio frequency heat lesions using so-called thermocoagulation. No nerve damage takes places as the temperature of the tip of the needle does not exceed 42°C. This is achieved by relatively long pauses between pulses which allow generated heat to dissipate and prevent the development of any thermal lesion.
45845703|NCT05717166|Other|Radiofrequency Therapy (RFA)|Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.
45845704|NCT05717166|Radiation|Fractionated Radiation|"Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.~Tumors in the esophagus, stomach, small intestine or colon should be treated with either fractionated radiation or a lower SABR dose (e.g. 25 Gy in 5 fractions) to minimize the risk of perforation."
45363744|NCT00491530|Drug|atorvastatin calcium|Oral coadministration of atorvastatin calcium (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
45363745|NCT04040660|Drug|NexoBrid|NexoBrid is presented as lyophilized powder and gel vehicle for preparation of a gel for cutaneous use. The API is a concentrate of proteolytic enzymes enriched in Bromelain extracted from the stem of Ananas comosus (pineapple plant)
45363746|NCT04313062|Behavioral|Educational Intervention|"An educational intervention based on the PM ACTIVAS' model and a  Falling Prevention Kit , both in a home visit by the trainees. Also, a telephone follow-up and a last house call 12 months after recruiting to assess the changes implemented by the person and their family, to conduct the final survey and to ask for the  Falls and Events Calendar  ."
45363747|NCT00867854|Other|Blood draw|This sub-study does not involve additional treatment of any ATN 061 or ATN 071 study subjects. The only intervention involved is the requirement for whole blood collection (40 ml and 60 ml) to be drawn at the same time as four ATN 061 study visits (36, 48, 56, and 80 weeks) for subjects co-enrolled into ATN 061. When these time points coincide with ATN 061 Central Laboratory samples, the 60 ml blood sample will not be collected. For subjects co-enrolled into ATN 071, there are also two samples of whole blood collection (40 ml and 60 ml) required to be drawn at four time points but at weeks 36, 48, 56, and 80 after the initiation of HAART.
45845705|NCT05717010|Device|Near infrared spectroscopy|The Near Infrared Spectroscopy (NIRS) is the method used for monitorize the risk of the development of cerebral ischaemia while providing information about brain tissue oxygenation.
45363748|NCT00873158|Device|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
45689962|NCT00550654|Other|questionnaire administration|Patients complete a pain assessment questionnaire, Brief Pain Inventory at baseline and at 1 and 3 months after treatment.
45363749|NCT00919685|Biological|blood sample|from rest of blood sample collected for other measurements
45363750|NCT04670549|Other|Implementation of treatment guidelines|To improve knowledge of OA treatment recommendations among people with hip and knee OA, a lay language summary will be emailed all OA patient participants. A second summary of the treatment recommendations, targeting general practitioners (GPs) will also be emailed the OA patient participants. The patients will be encouraged to print and bring this summary to their GP at the next visit (user-initiated implementation). Barriers and facilitators for providing evidence-based OA care among primary care physiotherapists will be mapped through interviews. Thereafter, a tool-kit of strategies and practical aids intended to help overcome these barriers will be developed and made available for the physiotherapists.
45689963|NCT00550654|Radiation|3-dimensional conformal radiation therapy|Conformal radiation therapy improves the ability to spare normal tissues.
45689964|NCT00550654|Radiation|hypofractionated radiation therapy|Hypofractionated radiation therapy is delivered to maximize pain relief while minimizing patient impact if life expectancy is short.
45689965|NCT00550654|Radiation|image-guided radiation therapy|Image guided radiation therapy targets the specific site of disease.
45689966|NCT00550654|Radiation|tomotherapy|Tomotherapy is a delivery method which provides megavoltage computed tomography (CT) localization and may provide superior conformality and localization compared to other dynamic intensity modulated radiation therapy techniques.
45689967|NCT00887380|Drug|Pre-radiotherapy commencement of anastrozole|Anastrozole: 1mg per day will be prescribed for 12 weeks. Commencing within 1 week of randomisation, to be administered from a min of 1 week before and a max of 4 weeks before commencement of radiotherapy and continued throughout radiotherapy. After 12 weeks administration of anastrozole according to trial regimen, anastrozole can be continued at the treating clinician's discretion and in accordance with the preference selected at the time of randomisation and stratification. The alternative options to long-term anastrozole are tamoxifen or cessation of anti-oestrogen therapy.
45845706|NCT05716932|Procedure|Dual focal laser and intravitreal Ranibizumab injection|Direct and perilesional focal laser followed by a single intravitreal 0.5 mg ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA, USA) injection
45845707|NCT05716776|Diagnostic Test|Optical coherence tomography (OCT)|Measurement of retinal nerve fibre layer (RNFL) thickness using optical coherence tomography
45845708|NCT05716698|Dietary Supplement|Pleurotus citrinopileatus after bio-optics (10 ug group)|The participants took D2 10ug per day for a total of 4 weeks.
45845709|NCT05716698|Dietary Supplement|Pleurotus citrinopileatus after bio-optics (100 ug group)|The participants took D2 100ug per day for a total of 4 weeks.
45845710|NCT05716620|Diagnostic Test|MRI|USG and MRI will be performed on the same day. US will be performed prior to MRI. There will be two rounds of screening 6 months apart using paired US and non-enhanced AMRI.
45847798|NCT02956746|Biological|RabAvert|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
45481576|NCT03761303|Device|active rTMS|The rTMS coil is applied tangentially to the head surface above the left DLPF (corresponding to position F3 of the international 10-20 system). For the stimulation intensity, the motor rest threshold of the patient is determined. The motor rest threshold is defined as the minimum intensity that triggers an EMG response with an amplitude> 50 μV in the first right interosseus dorsalis muscle in at least 5 out of 10 cases. The stimulation intensity within the rTMS therapy is 80 percent of the motor rest threshold. In one session, 1,000 pulses are applied in 10 trains at a frequency of 10 Hz (1 train = 100 pulses in 10 s). Between the individual trains there is an inter-train interval of 28 seconds. The total duration of a session is 5:52 minutes. In total, the patient recieve 20 sessions.
45363751|NCT00617240|Drug|metformin|500mg tablets, 250mg to 2000mg/day, po, BID to TID, 26 weeks
45481577|NCT03761303|Device|sham rTMS|Patients in the intervetion group (active rTMS stimulation) receive active 10 Hz rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
45481578|NCT05089799|Behavioral|Exposure and interaction with a socially assistive robot|"Description of scenarios involving robot and users~welcoming patients and family members l: the robot explains its own functionalities and answers persons 'questions.~providing a reminder about sanitary gestures (prevention of virus transmission). In addition, it could mediate a conversation between two or more people so that they keep the appropriate physical distance between them.~providing patients with an assistance to prepare the medical consultations : the robot helps patients to fill in paper forms for professionals. The robot also provides information on the course of consultations and the users 'rights in the hospital.~providing orientation and guidance to the consultation rooms and the available services : the robot helps people to find their way around the hospital.~Providing entertainment to patients and families during the waiting time: the robot offers activities to patients and caregivers"
45481579|NCT03565913|Drug|EffCaMgCit|Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.
45481580|NCT03565913|Other|CaAcS|CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate), three times daily for 2 years
45689968|NCT00887380|Radiation|Radiotherapy|Radiotherapy must commence within 1 month of randomisation. Radiotherapy planning and treatment is as per the protocol.
45689969|NCT00887380|Drug|Post radiotherapy commencement of anastrozole|Anastrozole 1mg per day will be prescribed for 12 weeks after radiotherapy is completed. Anastrozole should commence within 1 week of the last fraction of radiotherapy and be continued for a total of 12 weeks. After 12 weeks administration according to the trial regimen, any subsequent hormone therapy is as for the concurrent arm.
45689970|NCT01445613|Device|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
45847799|NCT02956746|Biological|HyperRAB ST (human rabies immune globulin)|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
46050303|NCT02618668|Drug|Ketamine / Propofol Admixture|propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+4 ml saline in a 20-ml syringe which resulted in0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol
45363752|NCT00617240|Drug|placebo|500/0mg tablets, 250-2000mg/day divided BID to TID, po, 26 weeks
46050304|NCT02618668|Drug|Propofol|2 mg/kg I.V
45363753|NCT04775927|Other|education|premarital education
46050305|NCT02618434|Drug|SPN-810|
46050306|NCT02618434|Drug|Placebo|
46050307|NCT01074944|Drug|Eliglustat tartrate|Oral Capsule in 50 mg or 100 mg dosages
46050308|NCT02613520|Biological|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
46050309|NCT02613520|Other|Normal Saline|0.9% Sodium chloride
46050310|NCT02613520|Biological|PfSPZ Challenge (for CHMI)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
45363754|NCT04918355|Other|Clinical Decision Support (CDS) alerts|CDS alerts are pop-up boxes integrated into the EHR. Each alert provides patient specific information, a link to the PDMP, instructions on how to dismiss the alert, a link to study-specific educational website, and a comment field.
45363755|NCT04039490|Device|SCENERGY|Use of the SCENERGY guidance device in conjunction with ultrasound to guide needles for pediatric vessel cannulations
45363756|NCT05676593|Device|Freestyle Libre 2|The FSL will be placed on patient for 28 days to measure interstitial glucose
45363757|NCT05676593|Other|Therapeutic education|Therapeutic education
46050311|NCT00802945|Drug|NKTR-102|NKTR-102 given on a q14 day schedule
45363758|NCT00878618|Drug|AZD0837|Extended-release tablets, test formulation. 2 tablets given in the morning for 6 days
45481581|NCT04606199|Behavioral|Mindfulness-based intervention, up to 5 minutes 0-3 times/day|The intervention consist of mindfulness and compassion-based practices that are selected to maximize their effect on stress targets. Interventions include, for example, practices that focus on the breath/body (e.g., 3 minute breathing space; compassionate body scan; five senses mediation), on increasing participants' inner resources (e.g., imaging a safe person or safe place), on reducing negative affect (e.g., self-compassion and acceptance-based practices), or on increasing positive emotions (e.g., gratitude practice; metta practices).
45481582|NCT05085665|Drug|Ivermectin|single dose, 150 ug/kg
45481583|NCT05460767|Biological|IBI363|a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
45481584|NCT05017493|Combination Product|Xagrotin|A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care
45481585|NCT04599803|Device|Verily Sleep Apnea (VSA) Program/App|The VSA program/app, is an Obstructive Sleep Apnea (OSA) management platform.
45689971|NCT00551200|Drug|HPN-100|Subjects will be taking prescribed dose of Buphenyl® TID (not to exceed 20g/day) at least two weeks prior to enrollment. Subjects will take prescribed dose of Buphenyl® TID for first week of study, and then switch over to HPN-100 TID during a dose-escalation phase. The dose of HPN-100 will be increased and the dose of Buphenyl® will be decreased each week by 50 mg/kg until entire daily dose of phenylbutyrate is HPN-100. Target HPN-100 dose will contain the same amount of phenylbutyrate as the subject's prescribed daily dose of Buphenyl®. Subject will take HPN-100 alone for one week and then switch back to previous dose of Buphenyl for the last week of the study.
45689972|NCT00551200|Drug|BUPHENYL®|BUPHENYL® (sodium phenylbutyrate) tablets and powder have been approved for marketing in the United States since 1996 as an adjunctive therapy in the long-term management of patients with UCDs involving deficiencies of CPS, OTC, or ASS.
46050312|NCT00802945|Drug|NKTR-102|NKTR-102 given on a q21 day schedule
46050313|NCT02618746|Other|Telerehabilitation|
46050314|NCT02618746|Other|Hospital based Rehabilitation|
45363759|NCT00878618|Drug|AZD0837|Extended-release tablets, reference formulation. 2 tablets given in the morning for 6 days
45481586|NCT01322087|Dietary Supplement|Nutritional intervention|"The study was a 12 weeks intervention trial with inclusion of 40 patients at nutritional risk, according to the NRS-2002 system.~All included patients received nutritional counseling and information about the new food concept by a clinical dietician.~Recording of the dietary intake was carried out on a daily basis over a period of 3 to 7 days, with nutritional registration forms filled in by the nurse and/or the patient."
46050315|NCT04012801|Diagnostic Test|C13 breath test|C13 breath test for patients of acute myocardial infarction who need dual- antiplatelet after PCI.
45363760|NCT05676281|Behavioral|Healthy Together (Control)|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~6 Sessions with a Wellness Coach~4-8 sessions with a Dietician~4-8 sessions of Physical Theraphy~1 session during month 1 or 2 Streetwyze Training~Safety Net Referrals"
45481587|NCT05004077|Drug|AMIODARONE|Assess the effectiveness of different dosing strategies of amiodarone.
45363761|NCT05676281|Behavioral|Healthy Together + Promotora Support|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~6 Sessions with a Wellness Coach~4-8 sessions with a Dietician~4-8 sessions of Physical Theraphy~1 session during month 1 or 2 Streetwyze Training~Safety Net Referrals~16-20 Promotora (in home case management) Sessions (weekly first 2 months, afterwards at least bi-weekly)"
45363762|NCT05676281|Behavioral|Healthy Together + Parenting Training|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~6 Sessions with a Wellness Coach~4-8 sessions with a Dietician~4-8 sessions of Physical Theraphy~1 session during month 1 or 2 Streetwyze Training~Safety Net Referrals~6-10 Parenting Sessions with a Family Health Centers Mental Health Provider using the Incredible Years Curriculum"
45363763|NCT05676281|Behavioral|Healthy Togethers + Parenting Training + Promotora support|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~6 Sessions with a Wellness Coach~4-8 sessions with a Dietician~4-8 sessions of Physical Theraphy~1 session during month 1 or 2 Streetwyze Training~Safety Net Referrals~16-20 Promotora (in home case management) Sessions (weekly first 2 months, afterwards at least bi-weekly)~8-10 Parenting Sessions with a Family Health Centers Mental Health Provider using the Incredible Years Curriculum"
45363764|NCT05102942|Behavioral|Attentional Control Training Program|The 317 patients fulfilling the eligibility criteria will be randomized to one of the three groups: Group A: AACTP delivered via a smartphone application + treatment as usual (TAU; n = 106), Group B: ACTP sham training delivered via a smartphone application + TAU (n = 106), or Group C: TAU only (n = 106). Patients in Group A will receive seven sessions of AACTP (one session per week for seven weeks). Patients in Group B will receive seven sessions of sham training (one session per week for seven weeks). Patients in Group C will receive only the primary treatment for AUD.
45363765|NCT02587559|Procedure|physical therapy|application of manual therapy techniques to upper extremity along with therapeutic exercise procedures to the axioscapular and rotator cuff musculature
45363766|NCT00615290|Drug|tipranavir|
45363767|NCT02587169|Drug|Nilotinib-adriamycin|The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
45363768|NCT00873236|Biological|bevacizumab|Given IV
45363769|NCT00873236|Biological|recombinant interferon alpha-2a|Given SC
45363770|NCT04039724|Drug|HCP0605 + HGP0816|
45363771|NCT04039724|Drug|HCP1305|
45481588|NCT03755843|Diagnostic Test|PASSIVE LEG RISING|"Pasive Leg Rising: In the supine method, the legs are lifted passively from the horizontal position to a 30° to 45° elevation while the head of the bed is flat.~Fluid Challenge: Fluid responsiveness is generally defined as an increase in SV or CO of 10% to 15% in response to a 250 mL crystalloid fluid bolus"
45363772|NCT00878696|Procedure|TMS transcranial magnetic stimulation|"200 pulses of tonic TMS (see Graph 1) were administered with an intensity at 50% of the maximal TMS device output (50%DO).~The frequency of the tonic pulses was randomly chosen between 1Hz, 5Hz, 10Hz or 20Hz.~Burst stimulation was delivered at a burst frequency of 5, 10 or 20Hz. Each burst consisted of 3, 5 or 10 pulses. The individual pulse rate within a burst was 50 or 100Hz."
45481589|NCT05002985|Behavioral|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
45481590|NCT04988555|Drug|DSP-5336|DSP-5336 orally
45689973|NCT00557284|Drug|Montelukast|4 mg oral granules for ages 12 - 23 months; 4 mg chewable tablet for 2 - 5 years of age; or 5 mg chewable tablet for 6 - 8 years of of age
45689974|NCT00557284|Drug|Placebo|Oral granules or chewable tablet, PO QD (given oral daily)
45689975|NCT00551746|Dietary Supplement|Purple Grape Juice|Grape Juice
45481591|NCT03758183|Procedure|total knee arthroplasty|
45481592|NCT03760757|Dietary Supplement|ESPO-572®|ESPO-572® is the same as PCSO-524®, except it has krill oil added to it.
45481593|NCT03760757|Dietary Supplement|PCSO-524®|PCSO-524® (Lyprinol®/Omega XL®) is a nutritional supplement containing a patented extract of highly condensed form of stabilized marine lipids from the New Zealand green lipped mussel (Perna canaliculus) that is combined with olive oil and vitamin E. This marine oil lipid and omega-3 polyunsaturated fatty acid (PUFA) blend is a diverse mixture of sterol esters, sterols, polar lipids, triglycerides, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (split between the triacylglycerol and polar lipid classes), and free fatty acids.
45689976|NCT00552448|Device|High Frequency Chest Compression VEST|every 6 hours for 20 minutes
45689977|NCT00557362|Drug|Natamycin 5%|One drop of medication will be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake
45689978|NCT00557362|Drug|Voriconazole|"Voriconazole (VFEND® I.V., Pfizer, New York, NY) will be prepared as a 1% solution.~One drop of medication should be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake"
45363773|NCT00878774|Biological|ToleroMune Ragweed|ToleroMune Ragweed dose 1x4 administrations 2 weeks apart
45481594|NCT03755609|Drug|Oxycodone|0.1 mg/kg intravenously
45363774|NCT00878774|Biological|Placebo|Placebo comparator, 1x4 administrations 2 weeks apart
45363775|NCT00868010|Drug|donepezil|5 mg or 10 mg, titrated per drug insert. Participants may remain in the study at 5 mg if unable to tolerate 10 mg.
45481595|NCT03755609|Drug|fentanyl|1ug/kg intravenously
45481596|NCT04580303|Drug|collagenase clostridium histolyticum|Delivered via uniform grid injection techniques.
45481597|NCT04577183|Device|RD1 System|The RD1 is created by drawing the patient's blood with the use of citrate anticoagulant. The anticoagulant allows the clot to form later in a controlled fashion-citrate is a widely used anticoagulant. The blood is then placed in the clotting tray (within few minutes) and the coagulation is facilitated by adding calcium and kaolin (insoluble aluminum silicate). The forming clot assumes the shape of the tray containing it, and can then be applied to the wound, and then covered with primary and secondary dressings.
45481598|NCT03760445|Drug|HDM201|2.5 mg and 10mg capsules, given orally
45481599|NCT03760445|Drug|cytarabine|20mg or 1000 mg or other strengths as locally available given intravenously
45481600|NCT03760445|Drug|anthracycline|20mg or other strength as locally available given intravenously
45481601|NCT03760445|Drug|midostaurin|25mg capsules given orally
46050316|NCT04119310|Other|Lumbar-thrust mobilization|The intervention group will receive passive spinal rotational grade V thrust-mobilization, based on Maitland's approach. The intervention will be performed with the subject in right sidelying and left sidelying. The operator's palpating hand is placed over the L2-3 intervertebral space, and the other hand bends both legs of the participant up to the range at which the L2-3 midposition is found. The participant is then asked to straighten the lower leg and hook the upper leg over it with the upper leg's knee positioned over the side of the plinth. While the lower component is kept still, the participant's trunk is rotated until the hip starts to lift off from the plinth. The bottom hand and uppermost hand rest under a pillow and the chest wall, respectively. With the starting position settled, the operator stands behind the participant, takes up the slack within the spine and then provides a grade V thrust- mobilization while stabilizing the uppermost shoulder.
45689979|NCT00557362|Procedure|Corneal de-epithelialization|Corneal de-epithelialization at 1 week and 2 weeks from enrollment to increase epithelial penetration of antifungal medications.
45363776|NCT00868010|Drug|placebo|Participants will receive a placebo pill for 12 weeks if randomized to this treatment.
45363777|NCT05683301|Drug|Amlodipine + Perindopril|Single pill combination of dual antihypertensive agent
45363778|NCT05683301|Drug|Perindopril + Indapamide|Single pill combination of dual antihypertensive agent
45363779|NCT05683301|Drug|Amlodipine + Indapamide|Single pill combination of dual antihypertensive agent
45481602|NCT03760445|Drug|liposomal cytarabine/daunorubicin|100mg/44mg or other strength as locally available given intravenously
45481603|NCT03760445|Drug|posaconazole|100mg delayed release tablet or other strength as locally available given orally
45481604|NCT03760445|Drug|midazolam|2mg/mL oral solution or in other strength as locally available
45481605|NCT03704051|Behavioral|Mode of Feeding (breastfeeding versus bottle-feeding)|Infants will be breastfed during one lab visit and bottle-fed (with expressed breast-milk) during the other.
45481606|NCT05460377|Biological|Full dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS|The Sabin antigen content is 30, 32 and 45 D-antigen units (DU) for types 1, 2 and 3, respectively and will be delivered intramuscularly by needle and syringe.
45481607|NCT05460377|Biological|Fractional (1/5) Dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS|The Sabin antigen content is 30, 32 and 45 D-antigen units (DU) for types 1, 2 and 3, respectively and will be delivered intradermally by needle and syringe.
45481608|NCT05460377|Biological|Full dose Sabin Inactivated Poliovirus Vaccine produced by BIBP|The Sabin antigen content is 15 DU, 45 DU, 45 DU for types 1, 2, and 3, respectively and will be delivered intramuscularly by needle and syringe
45481609|NCT05460377|Biological|Fractional (1/5) dose Sabin Inactivated Poliovirus Vaccine produced by BIBP|The Sabin antigen content is 15 DU, 45 DU, 45 DU for types 1, 2, and 3, respectively and will be delivered intradermally by needle and syringe
45481610|NCT04956575|Biological|mRNA-1010|Sterile liquid for injection
45481611|NCT04956575|Biological|Placebo|0.9% sodium chloride solution for injection
45481612|NCT04956575|Biological|Active Comparator|0.5 milliliter (mL) intramuscular (IM) injection
45481613|NCT05693012|Diagnostic Test|cfDNA methylation assessment|An exploratory study to establish the early detection and prognosis models of multiple myeloma patients in China based on plasma cf DNA methylation assessment
45481614|NCT03626558|Other|ultrasound measures|It is three diaphragmatic ultrasounds measures of a duration of twenty minutes each approximately. The diaphragmatic ultrasound is practised by trans-thoracic way and is non-invasive, completely painless and does not require the exposure of patients to radiation.
45481615|NCT04345562|Procedure|Skin preparation patterns with ChloraPrep 2 x 26 mL single|2 different patterns of skin preparation
45481616|NCT03626324|Device|C2P|The C2P is a fully internal, urethral indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g. due to spinal cord injury). The C2P is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.
45689980|NCT00558844|Drug|Arikayce™ 560 mg|"Arikayce™ at 560 mg~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
45689981|NCT00558844|Drug|Placebo for 560 mg|"Matching placebo~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
46050317|NCT04119310|Other|Sham thrust-mobilization|Subjects are positioned in right sidelying. The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension passive range of motion without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
46050318|NCT01619917|Device|Fractional Vascular Laser|laser energy will be applied to one of 2 sites (proximal or distal) depending on randomization result
45363780|NCT05081648|Procedure|CT MuST|Multiple Single Cannulation Technique (MuST): Experimental technique
45363781|NCT05081648|Procedure|Rope-ladder cannulation technique|Standard cannulation technique( Rope-ladder)
45363782|NCT04770623|Drug|Docetaxel|patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival
45363783|NCT04770623|Drug|Irinotecan|patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival
45363784|NCT05068856|Drug|HRS2543|"Dose-escalation part For the dose-escalation study, five dose cohorts (25 mg , 75 mg , 150 mg , 300 mg , and 450 mg ) of HRS2543 are initially set.~Dose-expansion part After the completion of dose-escalation study, the dose-expansion study will be carried out at the recommended dose level by the SMC."
45363785|NCT04770467|Drug|BRII-196 and BRII-198|BRII-196 and BRII-198 given by intravenous administration
45363786|NCT04770467|Drug|Placebo|Placebo given by intravenous administration
45363787|NCT00873314|Behavioral|Bed rest|The woman assigned to the bed rest group, will be instructed to keep in bed for the study period of four days and will be allowed to go to the toilet
45363788|NCT00873314|Behavioral|Activity restriction|Women assigned to activity restriction group will do the restriction of activities during four days.During the activity restriction phase the women will be allowed to ambulate at home, work at home (home office), child care, household tasks, meal preparation or any forceless activities.
45363789|NCT00878852|Behavioral|Standard treatment|Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy
45363790|NCT00878852|Behavioral|Standard Treatment Plus Contingency Management Program|Participants assigned to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy (10 sessions). This treatment protocol will be supplemented with a contingency management intervention. Intervention will consist in a voucher program: negative urine-screens will be rewarded with vouchers. Voucher will have an increasing value. At the end of the program, vouchers can be changed by gifts. Potential gifts will be selected by the therapists and will be related to pro-social activities, aiming to change preexisting risk behaviours.
45481617|NCT04339634|Other|Simulation of Repurposed Drugs for COVID-19|This study is a simulation of adding repurposed drugs for COVID-19. We are using drug claims, and will not intervene with patient care.
45481618|NCT05692856|Drug|Clenbuterol|Participants ingest 80 micrograms clenbuterol daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.
45481619|NCT05692856|Drug|Placebo|Participants ingest placebo tablets daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.
45481620|NCT04574999|Drug|Estriol|Gel for vaginal application
45845711|NCT05716464|Behavioral|Lifestyle medicine intervention|The lifestyle medicine intervention includes six weekly sessions (i.e., participants will receive the intervention once per week) that are related to the following topics: (a) lifestyle psychoeducation, (b) physical activity, (c) dietary recommendation, (d) stress management, (e) sleep management and (f) motivation and goal-setting techniques. Each topic will be delivered during each face-to-face session and the duration of each session will be around 120 minutes.
46050319|NCT01074554|Drug|Antibiotic Regimen|Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD All four drugs are given concomitanly
45481621|NCT04574999|Other|Placebo|Gel for vaginal application
45481622|NCT04300556|Drug|Farletuzumab ecteribulin|Farletuzumab ecteribulin intravenous infusion.
45481623|NCT03758027|Behavioral|CARESS|"The goals of each component are as follows:~Communicate alternatively - a method to bring the brain back and remove the individual from his/her limbic system;~Release endorphins - a release for the internal stress created by the emotion; and~Self-soothe - a method of quelling and containing."
46050320|NCT01074554|Drug|Placebo Regimen|lactose control tablets; one for each antibiotic with equivalent pills
45481624|NCT03758027|Behavioral|Isometric Exercise|5-minute protocol for cravings management and affect regulation
45481625|NCT04565249|Drug|PLN-74809|PLN-74809
45481626|NCT04565249|Drug|Placebo|Placebo
46050321|NCT00857584|Drug|Extended release quetiapine (quetiapine XR)|"Flexible dose from 300 to 600 mg/d (combination of tablets of 50mg, 200mg and 300mg) oral, daily, 8 weeks length.~Quetiapine XR was initiated at 50 mg/day and titrated to 100 mg on day 2, 200 mg on day 3, 300 mg on day 4, and flexible doses of 300 to 600 mg/d from day 5 to the end of the study."
45481627|NCT03760367|Other|Blue covarine toothpaste|2 min toothbrushing with 1 g of Pepsodent White Now Gold
45481628|NCT03760367|Other|Control toothpaste|2 min toothbrushing with 1 g of Colgate Advanced Whitening
45481629|NCT04942925|Device|Verofilcon A contact lenses|Commercially available silicone hydrogel contact lenses for daily disposable wear
45481630|NCT04942925|Device|Kalifilcon A contact lenses|Commercially available silicone hydrogel contact lenses for daily disposable wear
45481631|NCT01322243|Other|Dietary manipulation|Participants are maintained in a fasted (only noncaloric beverages) or fed (isocaloric weight-maintenance diet) state for two days.
45481632|NCT03755531|Drug|Carbetocin|"Heat stable Carbetocin, a clear colourless solution. Oxytocic activity: approximately 50 IU of oxytocin/vial. One ml of Carbitocin (100 mcg), was given as a bolus intravenous injection, slowly over 1 minute after labor of the baby at once. It was used once and no further doses were given.~Drug was kept in cold storage (2 to 8°C)."
45481633|NCT03755531|Drug|Oxytocin|"Oxytocin, a clear colourless solution. One ml of oxytocin (10 IU), was given as a bolus intravenous injection over 1 minute, after labor of the baby at once. Further doses can be given accordingly.~Drug was kept in cold storage (2 to 8°C)."
45363791|NCT05226806|Other|Measurement of cardiorespiratory performance in 3 different settings|"The study is divided into three examinations days, which extend over a maximum of 2 weeks:~Day 1: Inclusion examination, time required: 1.5 hours Taking anamnesis, medical examination and blood drawing, determination of PROCAM score, Framingham score, ESC score, anthropometric measurements, questionnaires (IPAQ-physical activity, health status / quality of life (SF 36)), pulmonary function test, resting ECG, echocardiography, heart rate variability measurement (VO2max determination), spiroergometry (modified Bruce protocol) on the treadmill incl. inquiries about the BORG scale~Day 2: 1 km test trail, Time required: 1 hour: Completion of a 1 km cardio test path including mobile spiroergometry~Day 3: 8 km hike, time required approx. 3.5 hours: Participation in a guided cardio hike over 8 km, if applicable, including spiroergometry Afterwards (In Austria only): Logging of physical activity, physical motivation and accompanying circumstances over a period of 3 weeks"
45363792|NCT05226806|Other|GENERAL CARDIO HIKES AS PART OF GENERAL TOURIST OFFER OF MUNICIPALITIES|General cardio hikes (WITHOUT spirometric breathing gas analysis) on the selected hiking trails. Measurement of the heart rate as well as the route, time and walking speed using GPS geotracking using an anonymized user profile. User survey regarding the user-friendliness of the application.
45363793|NCT00868088|Procedure|PDT prior to Mohs surgery|"Day 1: Screening and consent for this study. If eligible, a scouting biopsy will be obtained at 1 cm from the clinical border of the SCC for confirmation of AC.~7-14 Days after consultation: PDT to all subjects in the study. If during treatment a subject requests to discontinue due to pain the treatment will be terminated.~3-5 weeks after consultation: return for assessment. At this visit, the assigned treatment may be repeated if the treatment site is adequately healed. Re-treatment will only occur if there is persistent actinic damage.~6-8 weeks after consultation: Mohs surgery will be performed as per routine. Following tumor removal a scouting biopsy will be taken at a site 1 cm from the wound site created by SCC removal. The current waiting time for non-urgent surgery is 8 weeks. Standard care is not being altered for subjects in the study, other then their receiving the PDT intervention.~Photographs may be taken at each subject visit."
45481634|NCT04917653|Device|Heart rhythm monitoring with wearable device|"The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.~Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.~Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.~Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel."
45481635|NCT04917653|Other|Blood samples and biomarkers|"Several blood samples will be collected during the study protocol in pre-defined times before and after the cardioversion intervention.~Atrial peptides and cardiac troponins will be analyzed and kinetics estimated to predict the duration of early-onset AF period."
45481636|NCT03755453|Device|Hearing aid: Phonak Audéo B90-Direct|Hearing aids will be fitted to the participants individual hearing loss.
46050322|NCT00857584|Drug|Sertraline|"Flexible dose from 50 to 200 mg/d (combination of tablets of 50mg and 100mg) oral, daily, 8 weeks length.~Sertraline titration: 50 mg on day 1-3, 100 mg on day 4, and flexible doses of 50 to 200 mg/d from day 5 to the end of the study."
45363794|NCT05653661|Procedure|Biopsy|Undergo tissue biopsies
45363795|NCT05653661|Procedure|Biospecimen Collection|Undergo collection of blood samples
45481637|NCT04913363|Other|Green space|Green space in which activities take place
46050323|NCT00857584|Drug|adequate mood stabilizer|An adequate mood stabilizer treatment with lithium or valproate(defined as a serum concentration of 0.5-1.2 mEq/L or 50-100 microg/ml, respectively).
46050324|NCT02876120|Other|Implementation|Multifaceted implementation strategy to implement evidence based international osteoarthritis treatment recommendations among GPs and PTs in private practice, template for PT discharge reports to GP, patient osteoarthritis education programs, and facilitate multidisciplinary collaboration between the PTs and GPs.
45363796|NCT05653661|Procedure|Computed Tomography|Undergo CT scans
45363797|NCT05653661|Procedure|Magnetic Resonance Imaging|Undergo MRI scans
45845712|NCT05716464|Behavioral|Cognitive-behavioral therapy for depression (CBT-D)|The group-based CBT-D therapy includes six weekly sessions (i.e., participants will attend one 120-minute, face-to-face group therapy per week, and will be asked to practice taught-skills every day, for 42 days) that are related to the following topics: (a) psychoeducation, (b) cognitive restructuring, (c) behavioral activation, (d) self-care and relapse prevention.
45363798|NCT05653661|Drug|Nab-paclitaxel/Danburstotug Complex AP160|Given IV
46050325|NCT04132024|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
45481638|NCT04902053|Diagnostic Test|Subjects previously implanted with INSPIRIS RESILIA Model 11500A and are undergoing planned valve-in-valve treatment.|Designed to capture Adverse Event information and valve measurement data from dysfunctional INSPIRIS RESILIA aortic valves before and after Valve-in-valve (ViV) treatment.
45481639|NCT03760133|Drug|Duolac|Participants included in this group will be taken probiotics for 1 month after bowel preparation for colonoscopy.
45845713|NCT05716308|Behavioral|A continuous nursing intervention group was established.|Intervention group: Continuous nursing intervention was performed on the basis of the control group: ①A continuous nursing intervention group was established. The group members included chief physician, attending physician, head nurse, specialist nurse and nutritionist. ②The establishment of patient records, patients admitted to hospital by the primary nurse to record the basic situation of patients, including name, age, history of diabetes, DR staging, vision and blood glucose before treatment and other information. ③Personalized nursing intervention was given during hospitalization. Systematic health education was carried out for patients on admission. Targeted psychological counseling was given to some patients. ④After discharge to give continuous care, organize patients to join the WeChat group, group to share knowledge of DR-related diseases, to understand the patient 's medication, diet, vision, the patient 's questions and problems to guide and improve.
45363799|NCT00873392|Drug|Transdermal nicotine|Steps of 5 mg until 20 mg Then steps of 10 mg until the dose of 90mg or the maximal tolerated dose One stable dose phase, (90 mg or maximal tolerated dose) during 28 weeks
46050326|NCT00798967|Drug|teduglutide|0.05 mg/kg/day sc injection for 24 weeks
46050327|NCT00798967|Drug|placebo|Matching daily subcutaneous dose of placebo to teduglutide for 24 weeks
45363800|NCT00873392|Other|Usual drug treatment of Parkinson's disease|Usual drug treatment of Parkinson's disease
46050328|NCT02876198|Device|Gonioscopy|Study of the trabecular structure by gonioscopy
46050329|NCT04132102|Drug|Afatinib|Afatinib is a member of the second generation TKIs, which binds irreversibly to the erbB family of receptors. Afatinib will be administrated orally with the starting dose of 40 mg tablets, once per day. If patients can't tolerate drug related AEs with 40mg, patients can receive 30mg once per day after AEs recovered to Grade 0-1.
46050330|NCT02618356|Drug|Raltitrexed and S-1|"Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.~BSA (body surface area) S-1 dosage <1.25 m2 80 mg/d~1.25m2 - <1.5 m2 100 mg/d~1.5 m2 120 mg/d"
46050331|NCT00697996|Drug|Rituximab for transplant rejection|
45363801|NCT04039256|Device|percutaneous ventricular restoration using heartech® device|Patients who are confirmed suitability by imaging analysis, receive heartech® left ventricular partitioning device implantation.
45845714|NCT05716230|Other|bowel function score questionnaire survey|Bowel function score(BFS, total 20 points) was approved by Rintala in 1995, and patients with a score ≥ 17 were considered to have normal bowel habits. 7 items were in BFS, including the ability to hold back defecation, feeling/reporting the urge to defecate, frequency of defecation, soiling, accidents, constipation. In December 2022, BFS questionnaire surveys were conducted on children with ARM who underwent surgical repair between January 2017 and December 2019 at Children's Hospital of Nanjing Medical University.
46050332|NCT04112251|Dietary Supplement|Cocoa Flavonols Supplement|Whose total capsule content of 500 mg of cocoa flavonoids, 50 mg correspond to (-) - epicatechin per capsule, with a total dose of this compound being 100 mg/day.
46050333|NCT04118842|Drug|Savolitinib|Patients will receive a single dose on Study Day 1 and Study Day 20. Savolitinib will be administrated after a high fat, high calorie breakfast to reduce the risk of adverse events.
46050334|NCT04118842|Drug|Rifampicin|Patients will receive Rifampicin once daily on Study Day 15, 16, 17, 18, 19, 20 and 21. Rifampicin will be administered 1 hour before breakfast.
46050335|NCT00699634|Drug|Nabilone|Nabilone 0.5 mg at hs for 1 week, then 0.5 mg BID for 1 week. After a reassessment of the outcome measures, the dose is increased to 0.5 mg in the morning and 1 mg at hs for 1 week, followed by an increase to 1 mg BID in the last week of the study.
45363802|NCT02587013|Procedure|Type A of uterine repair: In situ|The uterine incision is closed with the uterus within the abdominal cavity
45481640|NCT03760055|Device|nGoggle|The nGoggle is a portable visual evoked potential system that uses an EEG to acquire visual evoked potentials in response to visual stimuli presented on a virtual reality goggle. The investigators will assess the ability of the nGoggle to detect visual field loss in patients with glaucoma, as well as to discriminate among the different stages of the disease, its repeatability and reliability for patient self-testing and patient satisfaction compared to standard automated perimetry (SAP), optical coherence tomography (OCT) metrics and Diopsys NOVA (Diopsys, Inc.). In addition, patients with other diseases affecting the visual system will also be tested in order to assess whether the nGoggle can differentiate glaucoma from them.
45363803|NCT02587013|Procedure|Type B of uterine repair: Exteriorization|The uterine incision is repaired with the exteriorization of the uterus
45363804|NCT04040036|Behavioral|Children watch applications by wearing the virtual headset during the blood draw.|wearing the virtual headset
45363805|NCT03933371|Device|Colon Capsule Endoscopy|The capsule endoscopy will be ingested by the participant. This device captures images along the large bowel. This images are stored in an external memory and afterwards they are downloaded in a computer
46050336|NCT02618278|Other|Physiotherapy|The aims of physiotherapy are to promote physical and psychological health for the patient, and in doing so promote and improve function. In light of the evidence to suggest spontaneous resorption of the disc fragment occurs, physiotherapy provides support and guidance for the patient to manage their symptoms whilst resorption takes place. The physiotherapy regimen will be tailored to the individuals' requirements. It will be goal orientated, and assessed using a biopsychosocial approach based on 7 different elements; neurological dysfunction, motor control of movement of the lumbar spine and pelvis, movement restriction in the lumbar spine and pelvis, psychological barriers to recovery, advice and education, functional-based exercise and pain.
45363806|NCT00879008|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information
45481641|NCT03759977|Other|Adapted Physical Activity|The sessions of Adapted Physical Activity will be focus around the theme of balance, with a small part of resistance training.
45481642|NCT04854707|Drug|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH or agonist of GnRH.
45481643|NCT04854707|Drug|Follicle Stimulating Hormone/Luteinizing Hormone|Subcutaneous injection of follitropin alpha biosimilar, with daily dose 100-300 IU for at least 5 days, than added another gonadotropin for a maximum of 10 days, using antagonists of GnRH or agonist of GnRH.
46050337|NCT00698074|Device|Cardiac Resynchronisation Therapy|Biventricular Pacemaker Implant
46050338|NCT02618200|Device|3D prostate ultrasound|
46050339|NCT04131868|Behavioral|Typical sleep opportunity|Typical sleep opportunity with consistent sleep timing for 1 week
46050340|NCT04131868|Behavioral|Extended sleep opportunity|Extended sleep opportunity by 90 min per night with consistent sleep timing for 1 week
46050341|NCT04131790|Behavioral|Tele-Behavioral Activation|Five 1-hour sessions of BA delivered by a trained interventionist via video-conferencing
45363807|NCT04081181|Procedure|Microwave ablation|CT_guided Microwave ablation is a minimally invasive technique that kill the insitu lung cancer cells, produce large volumes of cellular necrosis with reduced procedure time .According to the preoperative CT image of the patient , we will determine the focal position of the lesion ,it's size and it's relationship with adjacent organs to choose the optimal puncture point , puncture path and proper microwave antenna and to set the power and time of ablation.Then under the guidance of CT , the tip of antenna will be sent into the focus by puncture with ablation power of 60_80 W .according to tumor size , the ablation time will be determined.Needle track coagulation will be done to prevent seeding of malignant cells. After ablation a CT scan will be done immediately to observe the size ,shape and relation to nearby organ of the lesion and to determine if there is pneumothorax
45481644|NCT04854707|Drug|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH only for suppression.
45363808|NCT04658147|Drug|Nivolumab|Nivolumab 480mg will be administered as a 30 minute IV infusion (-/+15min) at cycle 1 day 1 and at cycle 2 day 1 (28 days) then every month for up to 12 months. Intravenous administration of Nivolumab (480 mg) will occur on Cycle 1 and 2 of the study then every 28 days up to a year. Nivolumab will be administered on Day 1 of each cycle for 10 doses/ months (whichever occurs first) for adjuvant.
45481645|NCT04854707|Drug|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using agonists of GnRH only for suppression.
45481646|NCT04854707|Drug|Follicle Stimulating Hormone/Luteinizing Hormone|Overall ovarian stimulation protocols with follitropin alpha biosimilar for at least 5 days+other recombinant and menotropins and short (antagonists of GnRH) or long protocol (agonist of GnRH).
45363809|NCT04658147|Drug|Relatlimab|Patients will receive 480 mg Relatlimab intravenously (-/+15min) on cycle 1 day 1 and at cycle 2 day 1 (every 28 days) for up to 1 year co-administered with Nivolumab.
45481647|NCT03215069|Drug|Empagliflozin 10 MG|Empagliflozin 10 mg PO daily
45363810|NCT00873470|Procedure|esophagal stimulation|ECG (rest) esophagal stimulation (rest and during effort)
45363811|NCT00873548|Device|PFNA-Asia|"The operation is performed under regional or general anesthesia and involves the following main steps:~Positioning of the patient~Definition of the CCD-angle~Fracture reduction~Determination of the nail diameter~Incision~Insertion of the device"
45363812|NCT02586935|Drug|Tideglusib|Administered orally after dispersion in approximately 100 ml of water at dose levels of 400 to 1000 mg
45481648|NCT03215069|Drug|Placebo oral capsule|Placebo PO daily
45481649|NCT03759821|Behavioral|Nutrition, mothers|Nutrition-related social and behavior change (SBC) messages and activities for mothers focused on infant and young child feeding (IYCF), dietary diversity, water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
45481650|NCT03759821|Behavioral|Nutrition, mothers and fathers|Nutrition-related social and behavior change (SBC) messages and activities for mothers and fathers focused on infant and young child feeding (IYCF), dietary diversity, water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
45481651|NCT03759821|Behavioral|Nutrition+parenting, mothers|Nutrition- and parenting-related social and behavior change (SBC) messages and activities for mothers focused on infant and young child feeding (IYCF), dietary diversity, responsive caregiving and child stimulation (play and communication), water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
45481652|NCT03759821|Behavioral|Nutrition+parenting, mothers and fathers|Nutrition- and parenting-related social and behavior change (SBC) messages and activities for mothers and fathers focused on infant and young child feeding (IYCF), dietary diversity, responsive caregiving and child stimulation (play and communication), water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
45481653|NCT03759743|Dietary Supplement|LMT1-48|capsules containing Probiotics
45481654|NCT03759743|Dietary Supplement|Placebo|capsules that did not contain any probiotics
45481655|NCT01322321|Drug|ACZ885|
45481656|NCT01322321|Drug|Placebo|
45363813|NCT02586935|Other|Placebo|Administered orally after dispersion in approximately 100 ml of water
45363814|NCT00868400|Dietary Supplement|commercially available high-carbohydrate beverage|800 ml before the day of surgery, and additional 400 ml two hours prior to surgery
45481657|NCT04557371|Other|Serum|Participants will topically apply the serum to the face as per normal home use application in place of their current facial serum product.
45481658|NCT04557371|Other|Lotion|Participants will topically apply lotion to the face as per normal home use application in place of their current facial lotion product.
45363815|NCT00868400|Dietary Supplement|flavored water|will be given in doses equal to those of high-carbohydrate beverage
45481659|NCT04557371|Other|Cream|Participants will topically apply cream to the face as per normal home use application in place of their current facial cream product.
45481660|NCT03755141|Drug|Herzuma|Herzuma + Treatment of Physician's Choice
45481661|NCT04555655|Dietary Supplement|Chicken extract supplement|70ml of chicken extract supplement to be consumed daily in the morning before meals for 2 years.
45363816|NCT00868478|Drug|Milatuzumab|Milatuzumab will be given at a starting dose of 120 mg/m2, and then if no response or significant toxicity is seen after a total of 12 weeks, the dose will be gradually increased, by 120 mg/ m2 every four weeks, for a total of another 12 weeks.
45363817|NCT04079699|Diagnostic Test|Liquid Biopsy|Measuring biomarkers in blood and urine samples
45363818|NCT04079699|Diagnostic Test|Standard biopsy|Histological examination of tissue biopsies
45481662|NCT04555655|Dietary Supplement|Peptide Supplement|70ml of Peptide Supplement (670mg) to be consumed daily in the morning before meals for 2 years.
45481663|NCT04555655|Other|Placebo|70ml of placebo (caesinate) to be consumed daily in the morning before meals for 2 years.
45481664|NCT03757871|Device|Laser stimulation|an acupuncture or placebo session will be performed 30 minutes before the fundus examination. This session will last 5 minutes.
45363819|NCT00879164|Drug|bupivacaine hydrochloride|
45363820|NCT00879164|Other|questionnaire administration|
45363821|NCT00919997|Genetic|DNA analysis|Anal pap smear, penile pap smear, blood collection, and saliva collection at a single study visit for HPV DNA analysis.
45363822|NCT00919997|Genetic|polymerase chain reaction|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
45363823|NCT00919997|Other|fluorescence activated cell sorting|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
45363824|NCT00919997|Other|questionnaire administration|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
46050342|NCT04131790|Behavioral|Tele-Friendly Visiting|Five 1-hour FV sessions delivered by a trained interventionist via video-conferencing
46050343|NCT04131634|Radiation|Stereotactic Ablative Radiation|A stereotactic relocalization system that relies upon stereoscopic radiographs, implanted fiducials, or near real-time CT based verification will be used.Investigators will have the discretion to choose from biologically equivalent dose levels using 1, 3 or 5 fractions. All active lesions need to be addressed by local therapy
45481665|NCT04848233|Dietary Supplement|Drinks containing 5AA+CrPic and Placebo|Same diet will be repeated for 3 days in a row and the beverage switched every day. 3 periods of 3 days are included in the study.
45481666|NCT05460065|Drug|single E4 30 mg|Administration of a single intravenous (i.v.) infusion of estetrol (E4) 30 mg (n=6)
45481667|NCT05460065|Drug|single E4 100 mg|Administration of a single i.v. infusion of E4 100 mg (n=6)
45481668|NCT05460065|Drug|multiple E4 100 mg|Administration of an i.v. infusion of E4 100 mg (or lower dose, depending on single dose results) once a day for 5 consecutive days (n=8)
45481669|NCT05460065|Drug|Placebo|"Cohort A: Single dose of placebo (n=2);~Cohort B: Single dose of placebo (n=2);~Cohort C: multiple dose of placebo (n=4)"
46050344|NCT00798889|Drug|Sunitinib|Sunitinib dose varies according to the doses allowed in previous protocol. It is given once a day, orally with various schedules depending on the parent protocol
45363825|NCT00919997|Other|study of socioeconomic and demographic variables|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
45363826|NCT00919997|Procedure|study of high risk factors|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
45363827|NCT02586779|Other|whatsApp|whatsApp application will be used for consultations.
45363828|NCT02586779|Other|without whatsApp|whatsApp application will be not used for consultations.
45363829|NCT04079777|Drug|Clinical treatment|Liquid Resuscitation, Anti-infection
45363830|NCT04079543|Other|NPO past midnight|NPO after midnight (solids and liquids), except for a sip of water with medication.
45363831|NCT04079543|Other|NPO|No solids after midnight. Clear liquids up to 2 hours prior to procedure. Patients can take medications with a sip of water.
45363832|NCT04593251|Biological|CALY-002|1-hour intravenous infusion
45363833|NCT04593251|Biological|Placebo|1-hour intravenous infusion
45363834|NCT02585687|Device|liver Perfusion MRI|
45363835|NCT00920543|Drug|Placebo|Twice daily dosing
45363836|NCT00920543|Drug|FP 100mcg|Twice daily dosing
45363837|NCT00920543|Drug|FP 500mcg|Twice daily dosing
45481670|NCT03759509|Behavioral|aerobic exercise|the experimental group, in which aerobic exercise training is given three times a week, a total of twenty-four times in eight weeks
45481671|NCT04834271|Other|Side-lying external rotation exercise with a dumbbell|Side-lying external rotation exercise with a dumbbell (20-30% 1RM). 2 times per week during 4 weeks.
45363838|NCT00920543|Drug|FP 250mcg|Twice daily dosing
45363839|NCT00920543|Drug|FSC 100/50mcg|Twice daily dosing
45845715|NCT05716152|Diagnostic Test|Morning blood sample and skin punch biopsy of 4 mm diameter.|"Morning blood sample (8:00-10:00 am) will be obtained for assessment of Total Testosterone (TT), Free Testosterone (fT), Luteinizing hormone (LH), Follicle stimulating hormone (FSH), and Estradiol (E2).~Skin biopsy:~Skin punch biopsy of 4 mm diameter will be obtained from both psoriasis patients (from the lesional and non-lesional sites), and the control group (normal skin). Tissue specimens will be used for formation of Paraffin embedded blocks. Slides will be stained by routine Hematoxylin and Eosin stain. The expression of AR will be measured by immune and histochemical staining by the use of a mouse monoclonal antibody"
46050345|NCT04113889|Drug|Metformin (1000 mg daily), Pioglitazone (30 mg daily), Acetyl-L-carnitine (3 gm daily)|72 patients with PCOS receiving metformin, pioglitazone and Acetyl L-Carnitine 500 mg, 15 mg and 1.5 gm BD daily respectively.
45363840|NCT00920543|Drug|FSC 250/50mcg|Twice daily dosing
45481672|NCT04834271|Other|Side-lying external rotation exercise with a dumbbell with 40% arterial occlusion pressure blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 40% arterial occlusion pressure blood flow restriction. 2 times per week during 4 weeks.
45481673|NCT04834271|Other|Side-lying external rotation exercise with a dumbbell with 80% arterial occlusion pressure blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 80% arterial occlusion pressure blood flow restriction. 2 times per week during 4 weeks.
45481674|NCT03759353|Diagnostic Test|Baseline ferritin level|At enrollment, baseline serum ferritin level will be assessed to quantify iron deficiency.
46050346|NCT04113889|Drug|Metformin, pioglitazone and placebo|72 patients with PCOS receiving metformin, pioglitazone and placebo 500 mg, 15 mg and placebo BD daily respectively.
46050347|NCT00796861|Drug|Sunitinib|Patients will be given Sunitinib 50 mg orally daily for four weeks, followed by a two week holiday. For patients tolerating treatment, three cycles of treatment will be given (18 weeks total).
46050348|NCT04112017|Device|YVOIRE Y-Solution 360|Hyaluronic acid
45363841|NCT00920543|Drug|FSC 500/50mcg|Twice daily dosing
45363842|NCT04731155|Drug|PCSK9 inhibitor （Alirocumab）plus standard medications|PCSK9 inhibitor（Alirocumab） was giving to subjects before PPCI and continued twice a month until 3 month after AMI
45363843|NCT04731155|Drug|standard medications|standard medications was giving to subjects according guidelines
45363844|NCT04080011|Device|NP-PWD|Application of NP-PWD device.
45363845|NCT02584439|Drug|ivabradine|It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
45363846|NCT02584439|Drug|lactose capsule (placebo)|It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
46050349|NCT02605057|Drug|LEO 80185 gel|
46050350|NCT02605057|Drug|Dovobet(r) Ointment|
45363847|NCT04729049|Procedure|Erector Spinae plane Block|Ultrasound-guided interfascial technique, aiming to block the anterior and posterior branches of the spinal nerves for multi-dermatomal analgesia. Injection of local anesthetic in the plane deep to the erector spinae muscles and superficial to the transverse processes, to achieve a craniocaudal distribution along several vertebral levels.
45481675|NCT03759353|Drug|Lactoferrin|lactoferrin 100 mg one sachet twice daily for 30 days to be dissolved in 1/4 glass of water before meals (Pravotin, Hygint pharmaceuticals).
45481676|NCT03759353|Drug|Ferrous Sulfate|200 mg of dried ferrous sulphate tablet once daily for 30 days on empty stomach but may be taken with meals to avoid stomach upset.
45481677|NCT03759353|Diagnostic Test|Follow up ferritin level|Four weeks after treatment, serum ferritin level will be assessed to quantify effect if treatment on iron status.
45689982|NCT00558844|Drug|Arikayce™ 70 mg|Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
45689983|NCT00558844|Drug|Arikayce™ 140 mg|Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
45689984|NCT00558844|Drug|Placebo for 70 mg / 140 mg|"Matching placebo~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
45689985|NCT00512278|Drug|Infliximab|Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
45689986|NCT00512278|Drug|Placebo|Placebo
45689987|NCT01445535|Biological|Rituximab|Rituximab will be given with siplizumab and etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin every 21 days
45689988|NCT01445535|Drug|Etoposide|Etoposide will be given with siplizumab and prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
45689989|NCT01445535|Biological|Siplizumab|Siplizumab will be given with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
46050351|NCT05638945|Behavioral|ED Delirium Screening and Detection Program (ED-DDP)|The intervention arm will have standardized delirium screening by nurses using the brief confusion assessment method (bCAM) in the EHR and will receive the ED-DDP. The ED-DDP will consist of: 1) a multicomponent 1-day delirium champion workshop; 2) real-time direct observation/training via telehealth (tele-training); and 3) training of nurses by champions. Champions will participate in a 1-day workshop, consisting of patient testimonials, small group discussions, delirium and screening tool use (didactics), and role-playing. Following the workshop, champions will receive 3 tele-training sessions; 2 to provide direct observation/feedback while the champion performs a bedside delirium screen, and 1 to provide direct observation/feedback of the champion providing training to the nurse. Once delirium champions complete training, they will provide bedside delirium training for all ED nurses.
45363848|NCT04729049|Drug|Patient controlled analgesia with intravenous morphine|Patient-controlled intermittent boluses of morphine 1 mg (maximum once every 15 minutes).
45481678|NCT05393375|Other|No intervention|No intervention
45689990|NCT01445535|Drug|Prednisone|Prednisone will be given with siplizumab and etoposide, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
45689991|NCT01445535|Drug|Vincristine|Vincristine will be given with siplizumab and etoposide, prednisone, cyclophosphamide, doxorubicin and rituximab every 21 days
45689992|NCT01445535|Drug|Cyclophosphamide|Cyclophosphamide will be given with siplizumab and etoposide, prednisone, vincristine, doxorubicin and rituximab every 21 days
45689993|NCT01445535|Drug|Doxorubicin|Doxorubicin will be given with siplizumab and etoposide, prednisone, cyclophosphamide and rituximab every 21 days
45689994|NCT01445301|Drug|GSK2585823(CLDM 1%-BPO 3% gel)|Topical gel in 1 g containing clindamycin 10 mg and benzoyl peroxide 30 mg
45689995|NCT01445301|Drug|CLDM 1% gel twice daily|Topical gel containing clindamycin 10 mg/1 g gel
45845716|NCT05716074|Other|Supervised exercise|The supervised group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks.
45481679|NCT03754985|Device|Hyperbaric oxygen therapy|"The study included participants 18 years or older, scheduled for 60 HBOT sessions for any indication.~After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session.~After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session."
45481680|NCT04825379|Device|bioactive composite|Cention N
45481681|NCT04825379|Device|posterior composite|G-ænial Posterior
45481682|NCT05280977|Other|POST ISOMETRIC RELAXATION|Group A (Post Isometric Relaxation + Conventional Physiotherapy): This group will receive Muscle Energy Technique in addition to conventional physiotherapy for the treatment of erector spinae tightness. The treatment will be given on alternate days for four weeks with 8 - 10 repetitions of METs per session.
45481683|NCT05280977|Other|POST FACILITATION STRETCHING|"Group B (Post Facilitation Stretching + Conventional Physiotherapy):~This group will receive Post Facilitation Stretching Technique in addition to conventional physiotherapy for the treatment of erector spinae tightness. The treatment will be given on alternate days for four weeks with 8 - 10 repetitions of METs per session."
45481684|NCT03757559|Drug|Cebranopadol 100 micrograms|Tablets were taken under fasted conditions with non-carbonated water.
45481685|NCT03757559|Drug|Cebranopadol 400 micrograms|Tablets were taken under fasted conditions with non-carbonated water.
45481686|NCT03757559|Drug|Hydromorphone hydrochloride 4 milligrams|Over-encapsulated immediate-release tablets were taken under fasted conditions with non-carbonated water.
45481687|NCT03757559|Drug|Placebo matching hydromorphone|Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.
45481688|NCT03757559|Drug|Placebo matching cebranopadol|Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.
45481689|NCT05459987|Behavioral|Lifestyle changes|"Nutritional advice to progressively integrate a moderate-carbohydrate Mediterranean diet with intermittent fasting 16:8 (5 times/week for 12 weeks).~Personalized exercise prescription and training (3 times per week)~Personalized education and motivational interviewing"
45481690|NCT03754907|Procedure|Endocutter stapler|Endocutter ETS 35, ETS Flex 45 stapler, and the Echelon Flex Powered ENDOPATH Stapler with 2.5- or 3.5-mm staples (Johnson & Johnson K.K., Tokyo, Japan)
45689996|NCT01409031|Drug|Intravenous Sildenafil|0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
45845717|NCT05716074|Other|Home exercise|The home group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks in the home.
45481691|NCT03754907|Procedure|suture material|absorbable suture material is used to perform hand-sewn anastomosis in an end-to-end manner.
45481692|NCT05668949|Drug|TTI-101|Given by PO
45689997|NCT01409031|Other|Placebo|An equivalent volume of placebo (D5W)infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
45689998|NCT01430403|Biological|Omalizumab|Participants received active omalizumab (Xolair(R)) injections and a placebo inhaler. Each participant received omalizumab (Xolair(R)) subcutaneous injections at minimum dose of 0.016 mg/kg/IgE (immunoglobulin E) [IU/mL] every 2 or 4 weeks during the 4-5 months treatment period. All participants received standardized specialist asthma care.
45689999|NCT01430403|Drug|Inhaled Corticosteroid Boost Therapy (ICS)|Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone. All participants will receive standardized specialist asthma care.
45690000|NCT01430403|Biological|Placebo omalizumab|Placebo was administered subcutaneously every 2 or 4 weeks over a period of 4 to 5 months. Doses (mg) and dosing frequency were determined by serum total immunoglobulin E (IgE) level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP, 2007) guidelines, under the management of an asthma specialist health care provider.
45845718|NCT05715996|Device|mixed reality guided localization|In this study, MR was utilized to assist in the localization of pulmonary nodule during sublobectomy lung resection in patient to assess the accuracy of the technique.
45845719|NCT05715840|Drug|SG001 injection|360 mg，Q3W，IV infusion
45845720|NCT05715840|Drug|Paclitaxel|175 mg/m^2，Q3W，IV infusion
45845721|NCT05715840|Drug|Cisplatin|50 mg/m^2，Q3W，IV infusion
45481693|NCT05668949|Drug|Pembrolizumab|Given by IV (vein)
45690001|NCT01430403|Biological|Placebo fluticasone|Self-administered placebo fluticasone (placebo Flovent ® Diskus®) inhalers identical in dose and guidance as active fluticasone. All participants will receive standardized specialist asthma care.
45690002|NCT01429623|Drug|ladostigil hemitartrate|10mg ladostigil base administered once daily as hard gelatin capsule
45690003|NCT01429623|Drug|Placebo|Placebo comparator
45845722|NCT05715840|Drug|Carboplatin|AUC=5，Q3W，IV infusion
45845723|NCT05715840|Drug|Bevacizumab injection|15 mg/kg，Q3W，IV infusion
45845724|NCT05715840|Drug|SG001 placebo|Q3W，IV infusion
45845725|NCT05715762|Behavioral|prone postion|ventilation at prone positioning
45845726|NCT05715762|Drug|NO inhalation|NO inhalation at 20 ppm
45363849|NCT04723823|Other|Motor or sensory imagery|Brain activity will be measured using fMRI while participants imagine different movements or sensations in order to assess the organization of sensorimotor cortical activity after injury
45363850|NCT04722107|Drug|rAAV2/8-hCYP4V2|rAAV2/8-hCYP4V2 is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene
45481694|NCT03759119|Behavioral|Tummy time and parent education|Participants will receive tummy time positioning while awake for 10 minutes two times a day. Physiological monitoring will be maintained throughout the entire intervention and the intervention will be adjusted if needed to maintain stability. Participants will also receive parent education on tummy time prior to the tummy time intervention. The primary investigator will perform the tummy time intervention. Participants will be encouraged to continue performing tummy time on their own and record their adherence via the PT Pal application.
45481695|NCT03759119|Behavioral|Parent education only|"Participants will receive the same tummy time education as those in the intervention group and will be asked to continue the intervention on their own and record their adherence via the PT Pal application.~Steps of the intervention for group 2 (standard care).~Complete educational session with primary investigator.~Adherence during the four-week intervention period will be measured remotely through the PT Pal® application."
45481696|NCT02909777|Drug|CUDC-907|
45481697|NCT01322399|Procedure|Structural Integration|"Structural Integration (SI) is an alternative method of manual therapy and somato-sensory training that purports to improve biomechanical functioning of the body as a whole rather than to focus on the treatment of specific symptoms. SI therapists employ both manipulation and somatosensory education. SI is delivered in a series of ten treatments, referred to as the Ten Series, each of approximately one hour in duration. The Ten Series protocol includes manipulation of all major joints and anatomical segments. Each of the ten sessions aims to achieve a different set of biomechanical changes, which are regarded as contributing to the progressive approximation of specific ideals of posture and movement."
45481698|NCT01322399|Procedure|Usual care|Usual care in this study consists of the treatment regimen provided for chronic low back pain at Spaulding Medford Rehabilitation clinic, which may include pain medication, exercise and physical therapy. Frequency of treatment averages twice weekly, duration ranges from 3 to 7 weeks
45481699|NCT05415917|Drug|Gemcitabine and Capecitabine|"A chemotherapy cycle will constitute 28 days of treatment:~Gemcitabine: 1000 mg/m2 IV on days 1, 8, and 15 of each 28-day cycle~Capecitabine: 1660 mg/m2 per day orally on days 1 through 21 of each 28-day cycle."
45481700|NCT02658929|Biological|bb2121|bb2121
45481701|NCT02652923|Drug|Sonazoid; Perflubutane for Injection|subdermal injection into the breast of Sonazoid (1 or 2 ml) divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock)
45481702|NCT03754829|Behavioral|Her Sey Kontrol Altinda (HSKA)|HSKA consists of 5 sessions over 5 weeks and is based on Problem-Solving therapy. Participants receive feedback on their homework assignments in brief weekly online messages from a clinical psychologist.
45596508|NCT02375529|Procedure|Single Incision Laparoscopic Cholecystectomy (SILC)|A 2.5-cm incision is made through the everted umbilicus down to the midline fascia, and through the fascia and the peritoneum. The multichannel port (Olympus) is introduced. Carbon dioxide is insufflated (12 mmHg) and a 30 degree 10-mm laparoscope is introduced. The operating table is put in the reverse Trendelenburg position (20 degrees), left side down. A pre-curved grasper and the monopolar electrocautery are introduced through the other 2 ports of the trocar and the dissection of the gallbladder starts in a retrograde manner. The triangle of Calot is exposed, the cystic duct and artery are separately dissected and ligated with 5 mm clips. The monopolar electrocautery is used to remove the gallbladder from the liver bed. The gallbladder is removed along with the port system from the abdominal cavity. The fascia at the port site is closed and the umbilicus is inverted.
45690004|NCT01408641|Drug|Topiramate|Topiramate titrated over 6 weeks to 400mg or highest tolerated dose.
45690005|NCT01408641|Drug|Placebo|Placebo capsules without topiramate
45690006|NCT01429077|Drug|levodopa/carbidopa|The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
45690007|NCT01429077|Drug|Placebo comparator|The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
45690008|NCT01428453|Drug|250mg rilapladib|Experimental Drug
45690009|NCT01428453|Drug|placebo|Placebo comparator
45690010|NCT01408563|Drug|Fludarabine|30 mg/m2/day IV x 6 days
45690011|NCT01408563|Drug|Melphalan|100 mg/m2/day IV x 1 day
45690012|NCT01408563|Radiation|Total Body Radiation|200 cGy on Day 0
45690013|NCT01408563|Biological|Cord Blood|2 cord blood units IV
45690014|NCT01442493|Other|Patient-Centered Methadone Treatment|Unlike in treatment as usual, counseling will be encouraged but not required and counselors will be responsible for enforcing the clinic's rules. The rules will be enforced by the Clinical Director. Clinic rules will be modified such that involuntary discharge from treatment will be a rare event.
45363851|NCT02585765|Drug|Pioglitazone|8 weeks of daily pioglitazone (30 mg/d).
45363852|NCT02585765|Drug|Placebo|8 weeks of daily placebo capsules.
45363853|NCT02584361|Procedure|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA).
45363854|NCT02584361|Procedure|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
45363855|NCT02584283|Procedure|Dual hypothermic oxygenated perfusion|Dual hypothermic oxygenated perfusion using the Liver Assist
45363856|NCT02584283|Device|Liver Assist®|The Liver Assist® is the device used to give the intervention dual hypothermic perfusion.
45363857|NCT02584283|Procedure|Perfusion fluid|The perfusion fluid is Belzer machine perfusion solution University of Wisconsin (Bridge-to-Life, Ltd., Northbrook, IL).
46050352|NCT00914563|Device|LIDCO Lithium Dilution Cardiac Output|Lithium Dilution Cardiac Output (LIDCO) Plus permits through analysis of the arterial blood pressure trace to acquire items about CO, SVR and DO2.
45363858|NCT02584283|Drug|Glutathione|Glutathione in a dosage of 3 mmol/ is added to the perfusion fluid according to the intention of use of the perfusion fluid.
45690015|NCT01442493|Other|Methadone Treatment as usual|Counseling will be required and counselors will enforce the usual clinic rules. Involuntary discharge may occur for ongoing drug use or rule infractions as usually occurs in the clinic.
45690016|NCT04069923|Other|Magnesium-based Bone Void Filler|Given intraoperatively
45690017|NCT01442181|Procedure|Minimally Invasive Surgery|Small thumb sized incisions are made on each side of the chest wall where instruments are inserted for the purpose of completing the surgery.
45690018|NCT01442181|Other|Medical therapy|Patients are treated with rhythm and rate control medications.
45690019|NCT04407975|Other|Betamethasone|A single injection will be administered to the patient at least 24 hours before undergoing C-section. This injection will be prepared in the hospital's pharmacy to contain betamethasone
45690020|NCT04407975|Other|Placebo|A single injection will be administered to the patient. This injection will be prepared in the hospital's pharmacy to contain normal saline.
45847800|NCT02961894|Device|Revolution™ Peripheral Atherectomy System|The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.
46050353|NCT00914563|Other|Standard Care|We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. The control group will be composed of the patients supervised in a standard way, volume resuscitated according to the Brooke or Parkland formulas.
46050354|NCT00802867|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)|0.5 mL, Intramuscular
45363859|NCT04080401|Device|Game-based rehabilitation exercise|4 games (exercises) on operated limb, for 3 sessions daily, until outpatient physiotherapy review visit.
45363860|NCT04080401|Other|Conventional brochures of rehabilitation exercise|4 exercises on operated limb, 30 reps each, for 3 sessions daily, until outpatient physiotherapy review visit.
45363861|NCT04634669|Drug|AXS-05 (dextromethorphan-bupropion)|- AXS-05 tablet, taken daily (up to 15 months)
45363862|NCT04575311|Drug|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor
45596509|NCT02375529|Procedure|Four Ports Laparoscopic Cholecystectomy (4PLC)|"An 11-mm periumbilical port, a 10-mm left upper quadrant port , 5mm subxyphoid port, and 5-mm right lower quadrant port were used in 4-port LC. We adopted the single surgeon technique in the 4-port LC using 30-degree operating telescopes that was inserted into the umbilical port. Retraction of the gallbladder was done by the long grasping forceps through the 5-mm right lower quadrant port, whereas dissection was accomplished through the 10-mm left upper quadrant port. The cystic duct and cystic artery were clipped by a 5-mm multiple clip applicator. The gallbladder was retrieved through the umbilical port after the position of the operating telescope was changed.~Nontransparent surgical adhesive tape was applied to the standard 4-port sites at the end of the operation ."
46050355|NCT04113967|Other|Biodanza program|Biodanza is a form of intervention aimed at promoting health and well-being through the promotion of self-expression and self-regulation through interaction through music and dance. The music accompanied by the movement of the body induces some experiences that present the ability to modify the organism itself both at an organic level, as affective-motor and existential. This intervention constitutes a means for the correct development of human qualities, whose purpose is to integrate the potentials of bond, health and harmony, as well as to develop new alternatives for the life of each individual.
45363863|NCT04575311|Other|Placebo|Matching Placebo
45363864|NCT02585531|Drug|Hypertonic Saline 3%|"The treatment will be administered in the following order :~First day: 3 treatments of nebulized HS 3% 3ml of treatment with interval 20 minutes Second to fourth day: One treatment of nebulized HS 3% 3ml every 24 hours ."
45363865|NCT02585531|Drug|Epinephrine and Dexamethasone|"The treatment will be administered in the following order :~First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes Second to fourth day: One treatment of nebulized dexamethasone 4 mg (1ml of dexamethasone 8mg/2ml) + 3ml Normal saline 0.9%, every 24 hours."
45847801|NCT02963376|Drug|0.05 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.05 mL/kg based on patient body weight in kilograms (kg).
46050356|NCT00914797|Drug|inhaled and oral terbutaline|"Inhalation of 2 mg terbutaline as powder as a single dosage. Oral terbutaline 10 mg as a single dosage.~Inhaled: Bricanyl Turbohaler 0.5 mg/dose, MA no. 41076.~Oral: Tablet Bricanyl Retard 5 mg, MA no. 10954."
46050357|NCT02604901|Behavioral|Screening and Brief Intervention (BI)|Rite Aid® pharmacists screened patients at the time of the initial fill with the Adherence Estimator™ and using the screening results, provided the behavioral intervention, Brief Intervention using motivational interviewing principles based on POLAR*S (BI). BI was considered an active intervention method.
45363866|NCT04691297|Other|Escape|The ESCAPE intervention consists of five components:1) behavioral counseling, 2) the use of NRT, 3) digital SNC 4) decision aid about LDCT screening, and 5) a letter and educational materials sent to the primary care provider.
45363867|NCT04691297|Other|Standard Care|Participants in the standard care arm (brief advice and referral to quit line), will be referred to the MA Quitline which provides free NRT by the study team and will receive an educational brochure related to lung cancer screening.
45363868|NCT04572893|Drug|danicamtiv|Myosin activator
45363869|NCT04572503|Procedure|Barbed Suture Modified Anterior Palatoplasty|Barbed Suture Modified Anterior Palatoplasty using single resorbable polydioxanone barbed bidirectional size 0 monofilament suture
45363870|NCT00920153|Biological|bleomycin sulfate|Given IV
45363871|NCT00920153|Drug|ABVD regimen|Given IV
45363872|NCT00920153|Drug|carmustine|Given IV
45363873|NCT00920153|Drug|cisplatin|Given IV
45363874|NCT00920153|Drug|cytarabine|Given IV
45363875|NCT00920153|Drug|dacarbazine|Given IV
45363876|NCT00920153|Drug|dexamethasone|Given orally
45363877|NCT00920153|Drug|doxorubicin hydrochloride|Given IV
45363878|NCT00920153|Drug|etoposide|Given IV
45363879|NCT00920153|Drug|gemcitabine hydrochloride|Given IV
45363880|NCT00920153|Drug|ifosfamide|Given IV
45363881|NCT00920153|Drug|melphalan|Given IV
45363882|NCT00920153|Drug|methylprednisolone|Given IV
45363883|NCT00920153|Drug|mitoguazone|Given IV
45363884|NCT00920153|Drug|vincristine sulfate|Given IV
45363885|NCT00920153|Drug|vindesine|Given IV
45481703|NCT03754751|Procedure|Laparoscopic cholecystectomy with the implementation of modified ERAS program|"Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1) Patient informing and brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~Low-pressure pneumoperitoneum (8-9 mmHg)~Trocar wound and intraabdominal anesthesia with 0.25% ropivacaine~PONV prophylaxis in patients of risk~Postoperative care~Early mobilization (2 h after surgery)~Early fluid intake (2 h after surgery)~Early liquid food (6 h after surgery) Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery"
45481704|NCT03754751|Procedure|Laparoscopic cholecystectomy with standard perioperative treatment|"Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1) Patient oral informing. No brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~Standard CO2 pressure (12-14 mmHg)~No additional anesthesia~Postoperative care~Mobilization in 4-6 h after surgery~Fluid intake in 6 hours~Liquid food intake in 12 hours Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery"
45481705|NCT04539275|Drug|Convalescent Plasma|Convalescent plasma from persons recovered from SARS-CoV-2 is being used to treat hospitalized individuals with complicated COVID-19 infection.
45481706|NCT04539275|Other|Masked Saline Placebo|0.9% saline solution will be used as the Masked Saline Placebo
45481707|NCT04784897|Drug|Brilacidin|Brilacidin IV infusion
45481708|NCT04784897|Drug|Placebo|Placebo IV infusion
45481709|NCT04784897|Drug|Standard of Care (SoC)|SoC therapies for COVID-19
45481710|NCT02651597|Other|Oatmeal|
45481711|NCT03757325|Drug|DNL747|DNL747
45481712|NCT03757325|Drug|Placebo|Placebo
45363886|NCT00920153|Drug|vinorelbine tartrate|Given IV
46050358|NCT02604901|Behavioral|Pill Box (PB)|Rite Aid® pharmacists provided patients with a Pill Box (PB) and information about their medications. However, pharmacists did not use motivational interviewing principles for engaging patients in direct interventions to modify behavior. PB was considered a passive intervention method.
45596510|NCT05724589|Drug|Epidermal Growth Factor|Daily application of EGF for facial skin
45596511|NCT02198495|Drug|Supplementation of ferric carboxymaltose|
45596512|NCT02198495|Drug|Supplementation of iron sucrose|
45596513|NCT05724511|Drug|MIYAIRI 588|In the 3 months intervention, each subjects take 1g/package with meal, and 3 packages/day.
45845727|NCT05715294|Other|Music Application|A music CD was prepared within the scope of passive music listening practice. To determine the music, the researcher advice and literature knowledge of Turkish Music A music CD was prepared within the scope of passive music listening practice. To determine the music, the researcher advice and literature knowledge of Turkish Music Research and Promotion Society (TUMATA) was used. In the music application, the selecting instrumental music (ussak maqam which is Turkish Music Maqam) was used. The prepared Music CD will be played on the phones of patients with android processor phones. Patients will be told that they should listen to the music lying down and in a comfortable position, and that they should not use headphones while listening to music. Before going to bed, the patients will be listened to music composed in Ussak maqam for 50 minutes every day for 7 days.
45363887|NCT00920153|Procedure|allogeneic hematopoietic stem cell transplantation|Patients undergo allogeneic stem cell transplantation
45596514|NCT02368509|Other|Perform sensory tests|
45596515|NCT02201849|Drug|Study Drug|
45596516|NCT02201849|Drug|Active Control|
45845728|NCT05713734|Diagnostic Test|Thrombin generation|Measurement of thrombin generation by ST Genesia
45596517|NCT02201849|Drug|Placebo|
45845729|NCT05713734|Diagnostic Test|Fibrinolysis|Measurement of fibrinolysis by Lysis Timer
45845730|NCT05713734|Diagnostic Test|Fibrin clot structure|Measurement of fibrin polymerisation and permeability
46050359|NCT04114045|Dietary Supplement|Experimental:Whey protein|Each participant in the protein group received 2 protein drinks immediately following exercise. The supplement was given using a relative quantity of whey protein isolate (0.3g/kg) and was chocolate flavoured.
45363888|NCT00920153|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
45363889|NCT04080713|Drug|Budesonide|Budesonide 9 mg prolonged release tablet
45363890|NCT04080557|Other|Surgery|All patients treated electively for an abdominal aortic aneurysm (AAA) by open repair and patients undergoing emergency treatment for a ruptured AAA between 2013 and 2018.
45363891|NCT02585453|Device|Thealoz Duo Gel|Manufacturer: Laboratoires Thea, France
45363892|NCT02585453|Device|Hylo-Gel|Manufacturer: Ursapharm, Saarbrücken, Germany
45845731|NCT05713734|Diagnostic Test|Coated platelets|Measurement of coated platelets by flow cytometry
46050360|NCT04114045|Dietary Supplement|Active Comparator: Isoenergetic control - Carbohydrate|Each participant in the carbohydrate group received 2 drinks immediately following exercise. The supplement was given using a relative quantity of maltodextrin (0.3g/kg), non-caloric chocolate flavouring was added to mask the drinks contents.
45363893|NCT02585453|Device|Systane Gel Drops|Manufacturer: Alcon Pharma GmbH, Fort Worth, TX, USA
45481713|NCT03758963|Device|R:GEN Selective Retina Therapy|Selective Retina Therapy (SRT) is the treatment method using innovative laser technology with the wavelength absorbed by melanosomes such as laser photocoagulation, but due to short pulse width (1.7 µs) with 100 Hz repetition rate, Retinal Pigment Epithelium (RPE) cells may be destroyed only through the generation of microbubble around melanosomes (photomechanical action), and no thermal damage of normal cells or tissues may occur in the surrounding tissues. SRT influences the RPE wound healing, including migration and proliferation of RPE cells, which treats CSC in the mechanism of recovering RPE. Once RPE is recovered, the sub-retinal fluid may be pumped out and retinal function again recovered. Moreover, previous studies showed that SRT may stimulate a moderate increase of activated metalloproteinase (MMP), leading to the improvement of Bruch's membrane's transport property.
45481714|NCT05459831|Device|QDot Micro Catheter|Atrial fibrillation radiofrequency ablation with 90W or 50W energy setting.
45690021|NCT01442103|Device|Normlgel Ag|Normlgel Ag dressing will be changed together with planned investigation visits. Dressing changes between visits will be performed at home on Day 3 or 4 of each week by subject or caregiver and documented in a dressing log.
45690022|NCT04069767|Procedure|ICoreDIST|"The intervention consists of exercises that demand enhancement of dynamic trunk stability and functional movements, combined with the following:~Optimised alignment and adaptation to the base of support and often using an unstable reference point for the trunk (therapeutic ball) or the distal body parts.~Enhanced somatosensory integration of hands, feet and face, including reduced influence of vision to enhance somatosensory integration.~Proximal stability prior to selective task-oriented movement of limbs, head, eyes.~Inclusion of dual tasks (motor/motor and motor/cognitive) in exercises and activities such as walking indoors, out-doors and climbing stairs.~Specific hands-on interactions or other adaptations to optimise alignment and neuromuscular recruitment.~Exercises combining core activation and moderate increase in heart rate: in lying, sitting, standing and walking."
45690023|NCT04069767|Procedure|Standard Care|According to national guidelines for stroke care, every patient in Norway will receive in-patient rehabilitation, home-based and out-patient based physiotherapy.
45690024|NCT01428219|Drug|Cabozantinib|Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
45690025|NCT01428063|Drug|Daclatasvir|
45363894|NCT05598827|Other|Tik Tok|The enrolled patients were encouraged to watch Tik Tok without limit starting 24 days before chemotherapy and continuing until the seventh day after chemotherapy.
45363895|NCT02586701|Other|Prehabilitation Plus|Supervised exercise program and home-based exercise program.
45363896|NCT04081805|Procedure|LASER|The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
45363897|NCT04081805|Procedure|Micro Ablative Radiofrequency|Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured
45363898|NCT04081805|Drug|Promestriene|The patient will perform self application of this vaginal promestriene daily for 2 weeks and after that the applications will occur twice a week.
45363899|NCT04079309|Behavioral|Lavender/Orange|A diffuser containing 120 ml water and 0.3 ml lavender oil / 0.3 ml orange oil will be set into the parents' perioperative waiting rooms to mist at least 1 hour before the parent arrive.
45363900|NCT02583503|Radiation|Hindfoot alignment view x ray|Diagnostic x rays used to measure leg alignment.
45363901|NCT05546723|Biological|Autologous CAR-T cell therapy expressing the BAFF-ligand.|LMY-920
45690026|NCT01428063|Drug|Asunaprevir|
45690027|NCT01428063|Drug|Pegylated interferon alfa-2a|
45690028|NCT01428063|Drug|Ribavirin|
45690029|NCT00513292|Drug|Cyclophosphamide|Given IV
45690030|NCT00513292|Drug|Epirubicin Hydrochloride|Given IV
45363902|NCT02584205|Device|Powerbreathe|"In this intervention we will use an equipment called powerbreathe classic light. It provides us to choose resistance levels with an adjustable load setting range: 1 to 9 and it's ideal for beginners. In this research we will use it on the intervention group to improve the strength of inspiratory muscle training and evaluate the results in the functional capacity of the subjects with obstructive sleep apnea."
45363903|NCT04550039|Device|Body-weight-supported treadmill|Gait training performed on treadmill with overhead harness providing necessary body-weight-support with assistance from trained physical therapist
45363904|NCT04550039|Device|Ekso Bionics EksoNR exoskeleton|Gait training performed overground in EksoNR exoskeleton with assistance from trained physical therapist
45363905|NCT02584049|Other|Osteopathy|3 sessions of osteopathy during 60 minutes each
45363906|NCT02584049|Other|Sham osteopathy|3 sessions of sham osteopathy during 60 minutes each
45363907|NCT02585297|Other|no intervention|
45845732|NCT05713656|Other|Physiotherapy care|Physiotherapy care including a bike fit, education and exercises provided by a physiotherapist with a BikePT bronze to gold certification.
45481715|NCT04092257|Procedure|VIA and thermocoagulation|Participants will self-collect a vaginal brush for hr-HPV testing. HPV-positive women and every 10th consecutive HPV-negative woman will complete same-day VIA with colposcopically-directed cervical biopsy and ECC (if lesion seen), and thermocoagulation if ablation-eligible by colposcopy. If no lesion is seen on colposcopy, the woman will have a cervical pap smear and ECC collected, and no thermocoagulation will be performed. Finally, women who are suspicious for cancer at VIA will undergo colposcopically-directed cervical biopsies.
45845733|NCT05713344|Other|Clinical history|Detailed clinical history including demographic details, pain details (character, pattern, location, change in character, involvement of new areas), duration of disease, co-morbidities, family history, adverse life events, sleep details, details of stress/anxiety.
46050361|NCT04114045|Other|Placebo|Each participant in the water group received 2 drinks immediately following exercise. The water was provided in a similar volume using the same non-caloric chocolate flavouring as the other drinks.
45690031|NCT00513292|Other|Laboratory Biomarker Analysis|Correlative studies
46050362|NCT00798655|Drug|Panitumumab|"Panitumumab, starting dose, 2.5mg/kg will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation and chemotherapy for 6 weeks; treatment takes about an hour.~The panitumumab dose will be calculated based on the subject's actual weekly body weight"
46050363|NCT00798655|Drug|Cisplatin|Cisplatin, 30 mg/m2 will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation therapy and after panitumumab for 6 weeks; treatment takes about an hour
45363908|NCT02584127|Behavioral|high reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with high reinforcement.
45363909|NCT02584127|Behavioral|low reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with low reinforcement.
45363910|NCT00501046|Drug|Placebo|9g /day (3 times a day)
45363911|NCT00501046|Drug|AST-120|9g /day (3 times a day)
45363912|NCT01018966|Drug|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, At least 1 cycle, (21 days)
45363913|NCT01019044|Procedure|Rectal mucosa biopsy|Collection of a maximum of 15 rectal mucosa samples in the high portion of the rectum near the rectosigmoidal junction
45363914|NCT04546061|Behavioral|Project Uplift|Substance use and mental health treatment for young sexual and gender minorities in Durham and Charlotte, NC in conjunction with intensive wraparound services that address factors that influence substance use and mental health among this population.
45481716|NCT02780804|Drug|Entinostat|Given PO
45363915|NCT04078685|Procedure|Standard catheter ablation|Radiofrequency catheter ablation using a standard ablation catheters: not equipped with contact-force sensing
45363916|NCT04078685|Procedure|Contact Force-sensing-based catheter ablation|Radiofrequency catheter ablation using a Contact-Force-sensing ablation catheter
45481717|NCT02780804|Other|Laboratory Biomarker Analysis|Correlative studies
45481718|NCT02780804|Other|Pharmacological Study|Correlative studies
45481719|NCT05525000|Device|Validation|"The validation protocol consists of the following activities:~Activities of daily living, Exercise test on the treadmill, Exercise test on the cycle ergometer, Free-living session"
45481720|NCT05692778|Other|Patients being foot examined by using an eHealth tool|Patients being foot examined by using an eHealth tool that has been developed, will be tested with the intention to implement the eHealth tool
45481721|NCT05692778|Other|Patients being foot examined in traditional manner|Patient are being foot examined in the way as health care professionals usually make the foot examination in patients with diabetes
45481722|NCT05692700|Other|aromatherapy|essential oil application by inhalation
45690032|NCT00513292|Drug|Paclitaxel|Given IV
45690033|NCT00513292|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45690034|NCT00513292|Biological|Trastuzumab|Given IV
45690035|NCT00513370|Biological|Humira (adalimumab)|Study drug will be provided as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). Loading dose of 80 mg of adalimumab subcutaneously (sc) at Baseline, and 40 mg of adalimumab sc at Week 1, followed by 40 mg of adalimumab sc every other week (eow) for 24 weeks.
45690036|NCT00559468|Drug|Sugammadex|Single dose 4.0 mg/kg sugammadex, administered at T1 3-10% after continuous infusion of rocuronium
45363917|NCT03928223|Other|exploratory survey on Itch modification by color viewing|"Patients relate their itch to a color of the Manchester Color Wheel (MCW) and choose a color of the MCW aimed at counteracting their itch. They complete the ItchyQoL (German version), which is a standard tool to assess itch-related quality of life. Then patients look at their antipruritic monochrome color for five minutes on a lap-top screen. Itch intensity (0-10 NRS) will be assessed at baseline and again after the patients looked at this color for 5 minutes."
45363918|NCT05519189|Drug|Ropivacaine|Peri-anal infiltration of Ropivacaine
45363919|NCT05519189|Other|Failure to perform peri-anal ropivacaine infiltration|Failure to perform peri-anal ropivacaine infiltration
45481723|NCT05692700|Other|Placebo|Placebo essential oil
45481724|NCT04537949|Biological|BNT162b3|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost (P/B) regimen).
45481725|NCT01322711|Drug|Atorvastatin|Atorvastatin 40 mg day
45481726|NCT01322711|Drug|Placebo|Diet
45481727|NCT04532099|Device|Lehfilcon A contact lenses|Investigational soft contact lenses for daily wear worn in Part A of the study
45481728|NCT04532099|Device|Senofilcon A contact lenses|Commercially available soft contact lenses for daily wear worn in Part A of the study
45481729|NCT04532099|Device|Comfilcon A contact lenses|Commercially available soft contact lenses for daily wear worn in Part B of the study
45481730|NCT04532099|Device|Hydrogen peroxide-based cleaning and disinfecting solution|For nightly cleaning and disinfecting of contact lenses in Part A and Part B of the study
45481731|NCT03041792|Drug|Liraglutide|Liraglutide
45481732|NCT03041792|Other|Placebo|Placebo
45690037|NCT00559468|Drug|Rocuronium|Single bolus dose 0.6 mg/kg rocuronium and continuous infusion rocuronium
45690038|NCT00559468|Drug|Sevoflurane|Sevoflurane IV administered for induction and maintenance of anesthesia, based on randomization.
45690039|NCT00559468|Drug|Propofol|Propofol IV administered for induction and maintenance of anesthesia, based on randomization.
45690040|NCT00513526|Biological|Gardasil|week 0, 8, 24, 128
45690041|NCT00560560|Biological|CP-751, 871|Human IgG2 Monoclonal Antibody. 20mg/kg or 30 mg/kg every 3 weeks for 17 cycles, until progression or unacceptable toxicity develops.
45690042|NCT00561418|Drug|vorinostat|Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles.
45363920|NCT04080323|Drug|Dinoprostone 3 mg|1 vaginal tablet of 3mg dinoprostone 60 minutes before surgery
45363921|NCT04080323|Drug|placebo|1 vaginal tablet of placebo 60 minutes before surgery
45363922|NCT03930017|Biological|Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine (quadrivalent, split virion, inactivated)|Influenza virus (quadrivalent, split virion, inactivated) of the strains that comply with the World Health Organization (WHO) recommendations (Northern Hemisphere) and European Union (EU) decision for the 2018/2019 season. The quadrivalent vaccine is propagated in fertilised hens' eggs from healthy chicken flocks.
45363923|NCT00533949|Biological|Cetuximab|Loading dose: 400 mg/m2, IV, one week prior to start of radiation therapy (RT). Then, beginning day 1 of RT, 250 mg/m2, IV, weekly; for 60 Gy arm for 15 weeks, for 74 Gy arm for 16 weeks.
45363924|NCT00533949|Drug|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy; for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, AUC=6, IV, days 1 and 22."
45363925|NCT00533949|Drug|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy (RT); for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
45363926|NCT00533949|Radiation|60 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 30 fractions over the course of 6 weeks.
45481733|NCT05384093|Device|High Intensity Stretch Device|High Intensity Stretch and Physical Therapy are used either together or alone to treat study arm.
45481734|NCT03753581|Device|Care protocol plus microcurrents|"CARE NURSING PROTOCOL: postural treatment every 4 hours more standardized cure according to the guide of recommendations based on evidence in prevention and treatment of pressure ulcers in adults of Osakidetza health service.~MICROCURRENTS: the electrodes will be placed on the edge of the dressing on the sides of the ulcer's longer length during 12 hours a day until the ulcer is completely healed or for a maximum of 25 days.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.5 s and pause of 300 ms, voltage 21 mV and intensity 42μA with a current density of 4.2 μA."
45481735|NCT03753581|Device|Care protocol plus placebo microcurrents|The same nursing care protocol described for the experimental group will be applied more 12 hours per day of 2 electrodes of microcurrents around the ulcer, which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
45481736|NCT04051424|Device|ConMed bite block|Investigator will fit ConMed bite block in patient's mouth and bronchoscopist will try to visualize the vocal cords.
45596518|NCT02375217|Drug|Sugammadex|half dose
45596519|NCT02375217|Drug|Sugammadex|full dose
45596520|NCT02375217|Drug|Neostigmine|IV = 50mcg/kg
45596521|NCT02375217|Drug|glycopyrrolate|
45596522|NCT05724433|Other|Virtual HF Care|Patients will receive virtual visits for 3 months following hospitalization / emergency department (ED) visit for HF. Physiologic measures will be monitored remotely and therapies will be optimized.
45596523|NCT05724433|Other|Routine HF Care|Care as determined by the treating physician
45596524|NCT02368587|Biological|WJMSCs Vs. placebo|WJMSCs Vs. placebo
45845734|NCT05713344|Other|Clinical examination|Thorough clinical examination, anthropometric measurement, assessment of pain (Izbicki score, Visual analog scale, modified brief pain inventory, pain catastrophising score, painDetect)
45363927|NCT00533949|Radiation|74 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 37 fractions over the course of 7.5 weeks.
45363928|NCT00485134|Biological|240 µg Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
45363929|NCT00485134|Biological|480 µg Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
45363930|NCT00485134|Biological|690 Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
45363931|NCT00485134|Other|Shigella challenge strain|300 colony forming units (CFU) of Shigella challenge strain, Shigella flexneri 2a strain 2457T
45363932|NCT05472077|Diagnostic Test|Lollipop Swab|"The lollipop swab is a typical swab that would be used to obtain routine pharyngeal samples. Participants are instructed to suck on the swab for 20 second, as they would suck on a lollipop."
45363933|NCT05514353|Drug|PBI-100 Topical Cream|PBI-100 Topical Cream in 1 of 3 dose levels
45363934|NCT05514353|Drug|Vehicle Cream|The Vehicle Cream formulation contains the same excipients as the active cream
45363935|NCT02585141|Device|MEDIPLAST® (aspiration)|The aspiration drainage will be with a large caliber needle (MEDIPLAST® 13 G, 2,5 x 110 mm) and a syringe of 20 ml. The cavity must be emptied for pus and irrigated by repeated injection and aspiration of saline until clear fluid is obtained.
45481737|NCT04051424|Device|McKay airway|Investigator will fit McKay airway in patient's mouth and bronchoscopist will try to visualize the vocal cords.
45481738|NCT04051424|Device|Williams Airway|Investigator will fit Williams Airway in patient's mouth and bronchoscopist will try to visualize the vocal cords.
45481739|NCT03753503|Behavioral|exercise|exercised three times a week in the 8-week HIIT program
45481740|NCT03753503|Behavioral|conventional physical therapy|
45481741|NCT03625856|Dietary Supplement|Chlorella Vulgaris|Chlorella capsules 1500 mg/day
45481742|NCT03625856|Dietary Supplement|Placebo|Starch 1500 mg
45481743|NCT05375123|Device|Ultrasound image acquisition|"Echocardiography: left ventricular systolic function of all participants were measured by tissue motion tracking of mitral annular displacement using PHILIPS.~Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of six echocardiographic examinations will be performed in the first trimester (11-14 weeks of gestation), the second trimester (20-24 weeks of gestation), the third trimester (29-32 weeks of gestation), prenatal term (37-41 weeks of gestation), 6 weeks and 3-6 months after delivery.~Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester (20 to 24 weeks of gestation)."
45481744|NCT03757169|Other|Hand grip isometric contraction|The patients at the Hand Grip group will perform 12 weeks of hand grip exercises, three times/week for 16 minutes with time to rest.
45481745|NCT03757169|Other|Control|The patients will receive verbal orientations about the OSA and the arterial hypertension.
45481746|NCT05366270|Device|WBH|Hyperthermia exposure using Heckel Hyperthermia Device
45481747|NCT05366270|Device|Sham|Sham (mild heating) using Heckel Hyperthermia Device
45481748|NCT04507763|Drug|Etanercept|Patients with ankylosing spondylitis as provided in real world practice
45481749|NCT03045302|Drug|BIM23B065|Subcutaneous twice a day or three times a day administration of BIM23B065. Dose will be 0.4, 0.6, 0.8 or 1 mg (twice a day or three times a day).
45481750|NCT05365100|Drug|BN102|oral tablets: BN102, BID
45481751|NCT03754595|Procedure|3D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 3D Laparoscopic pancreatoduodenectomy
45481752|NCT03754595|Procedure|2D Laparoscopic pancreatoduodenectomy|2D Laparoscopic pancreatoduodenectomy
45481753|NCT05459675|Other|Very low-calorie diet|Meal replacement (800 kcal/day, protein 90 g/day)
45481754|NCT05459675|Procedure|Bariatric surgery|Bariatric surgery will be performed by single surgeon at Ramathibodi Hospital Mahidol University, Thailand. Postoperative diet progression according to the current guideline will be prescribed from early post-op period to 1 year after surgery
45690043|NCT00561418|Other|Correlative studies|Laboratory as well as quality of life correlative studies will be obtained at days +26 to +38 (at approximately 1 month post HSCT),days +56 to +66 (≈2 mos), and at Cycle 2 Day 1 (≈3 mos.), Cycle 3 Day 1 (≈4 mos.), Cycle 5 Day 1 (≈6 mos.),Cycle 7 Day 1 (≈8 mos.), and off study (ideally at ≈12 mos.)
45845735|NCT05713344|Other|Evaluation of quality of life|Use of the EORTC QLQ c30 with PAN 28 to evaluate quality of life
45363936|NCT02585141|Procedure|incision|Incision drainage will be undertaken as standardized de-roofing of the abscess and debridement. Wound packing and dressing will not be used, just sitz bath or ordinary hygiene until wound healing.
45481755|NCT00705484|Biological|infliximab|The treating physician will determine the treatment regimen and dose of Remicade.
45363937|NCT02585141|Drug|Clindamycin|Postoperative broad spectrum oral antibiotics covering both aerobes and anaerobes bacteria will be given for seven days of Clindamycin 300 mg tablets x 3 a day
45363938|NCT04443101|Other|different types of intracular lens|different types of intracular lens
45363939|NCT02583347|Device|Vivia Home Hemodialysis System|The cohort of interest is those patients performing nocturnal home hemodialysis using the Vivia Home Hemodialysis System for 8 hours, 5 nights per week
45363940|NCT04079231|Drug|Brolucizumab|Intravitreal Injection
45363941|NCT04079231|Drug|Aflibercept|Intravitreal injection
45481756|NCT00705484|Drug|Standard Therapy|The standard therapy group will consist of participants receiving a treatment regimen that does not include Remicade. The treatment of each standard therapy participant will be left to the discretion of the treating physician and may change during the course of a participant's participation in the registry.
45481757|NCT03754517|Diagnostic Test|RPR Titer|RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing
45481758|NCT03754439|Behavioral|Physiological changes to noise and vibration exposure|Physiological parameters (HR, RR, Sats, NIRS) will be observed during a period of stay on the neonatal unit (Inborn group) or during ambulance transportation (Transported group) whilst simultaneous measurement of noise and vibration exposure. Urine will be collected during the first 24, 48 and 72 hours post exposure for biochemical markers of brain injury (S100B) and stress (Cortisol)
45481759|NCT03754361|Procedure|automated peritoneal dialysis|peritoneal dialysis administered by a cycler
45481760|NCT03754361|Procedure|IHD|HD 4hour 2-3times per week
45363942|NCT00994695|Biological|Mencevax ACW Vaccine|Mencevax ACW polysaccharide vaccine subcutaneously in the left arm at 50 μg in 0.5ml(reconstituted).
45363943|NCT05350293|Other|Molded abutment|"The waxed plastic abutment will dismantle, wedged, and poured using a Ni-Cr mixture then it will be trimmed to make it ready to make the permanent restoration over it.~The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner."
45363944|NCT05350293|Other|3D printed abutment|A marker or Scan body appropriate for the type of implant will be placed on the laboratory implant substitute, a digital scan of the marker will be done in the lab, and the scanned image will be transferred to a computer design software where the prosthesis is designed, In the printing phase, the final prosthesis will be manufactured using a stepwise metal powder supply and a laser fusion process. Making the abutment ready to make the permanent restoration over it. The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner.
45363945|NCT05349123|Behavioral|Mindful Breathing|Subject will be expected to do 12 weeks of home-based rehabilitation, 6 days a week in their home. The proposed project explores the addition of a mindful breathing module, which involves daily guided breathing practice with feedback to encourage mindful breathing.
45481761|NCT02471872|Behavioral|Air Pollution Education|Students are presented with a one-hour interactive session on air pollution.
45363946|NCT05349123|Behavioral|Home-Based Pulmonary Rehabilitation|Subject will be asked to complete exercise guided by a video six days a week and to complete mindful walking six days per week. They will receive weekly health coaching calls.
45363947|NCT02584985|Procedure|ETAP|Primary transanal endoscopic approach, secondary transabdominal laparoscopic approach
45481762|NCT02471872|Other|Non-Air Pollution Education|Students are presented with a one-hour interactive session on vaccines.
45481763|NCT05459597|Drug|antiepileptic drugs|phenytoin, carbamazepine, lamotrigine, levetiracetam, perampanel, etc. as part of routine treatment.
45481764|NCT05358626|Diagnostic Test|SARS-CoV-2 IgG Antibody testing|IgG Antibody testing for previous exposure to SARS-CoV-2
45481765|NCT03754283|Device|Indirect bonding|Indirect bonding is the technique where orthodontic appliances are first placed on a model of the patient and then transferred to the patient using some kinf of trays
45481766|NCT03753425|Procedure|Low volume bowel preparation in inflammatory bowel diseases|Low volume bowel preparation in inflammatory bowel diseases
45481767|NCT05692310|Other|placing a standard central venous line|Patients will benefit from the technique of central venous line placement by conventional ultrasound.
45481768|NCT05692310|Other|placement of a central venous line using an ultraportable ultrasound device|Patients will have a central venous line placed using an ultraportable ultrasound device
45481769|NCT03753269|Drug|Fasudil Hydrochloride|2.5mg fasudil hydrochloride (diulted to 15ml by 0.9% saline )will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
45690044|NCT00514852|Drug|Carboxymethylcellulose and Glycerin based artificial tear|1 to 2 drops into each eye as needed but at least twice daily
45363948|NCT02584985|Procedure|Standard Transabdominal Laparoscopic Proctectomy|Primary transabdominal laparoscopic approach
45481770|NCT03753269|Drug|Placebo saline|15ml 0.9% saline will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
45481771|NCT03753191|Device|transcranial direct current stimulation|Each subject will undergo one tDCS stimulation session lasting for 20 minutes. A constant current of 2 mA will be applied with a linear fade in, fade out of 10 seconds to prevent electrical transients.
45596525|NCT02368587|Biological|Placebo|WJMSCs Vs. placebo
45363949|NCT04521803|Drug|high dose Rifampicin (RIF)|Simulations were performed to determine the dose of RIF required to achieve the most equitable drug exposures across the weight range, 30 to 100 kg. Demographic data of a reference cohort of TB patients (n = 1225), with or without HIV-1 coinfection, recruited in clinical trials conducted in West Africa and South Africa were used for the simulations35-38. An additional 12 250 virtual patients were generated using the weight and height distributions of the 1225 patients to increase the number of patients with a weight close to the boundaries of the weight range. Parameter estimates of the population PK model for RIF were used to simulate (100 replicates) RIF exposures22. Four dosing scenarios were evaluated using the weight-band based dosing with 4-drug FDC tablets and extra RIF tablets with each tablet containing 150 mg or 600 mg RIF. The FDC tablets were assumed to have 20% reduced bioavailability based on data from a clinical trial where the same formulation was used
45363950|NCT00920465|Drug|mifegyne and cytotec|One day dosage versus two days dosage
45481772|NCT05692076|Device|High Velocity Nasal Insufflation|High-flow humidified oxygen with flow rates from 30 to100 L/min with high fraction of inspired oxygen( FiO2) is able to be delivered.
45481773|NCT01322789|Biological|Intravenous Mesenchymal stem cell infusion|Four consecutive intravenous infusions 1 week apart followed by 4 consecutive infusions 1 month apart
45481774|NCT05691998|Other|Prosthetic foot questionnaire|Prosthetic foot related questions will be asked to the patients
45481775|NCT03754205|Device|Microablative Fractional CO2 laser|3 therapies intravaginally administered will be applied at monthly intervals
45690045|NCT00514852|Drug|Carboxymethylcellulose|1 to 2 drops into each eye as needed but at least twice daily
45690046|NCT00555880|Drug|Midodrine hydrochloride|one dose, 10-30mg, given orally
45363951|NCT03890367|Biological|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine|Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular
45363952|NCT03890367|Biological|Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine|Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Intramuscular
45690047|NCT00555880|Drug|Placebo|Placebo
46050364|NCT00798655|Radiation|Radiation Therapy|"Radiation Therapy 60-66 Gy/200 cGy/daily, five days a week, Monday through Friday, except on weekends and holidays, for six weeks; treatments take about 20 minutes.~Radiation will be administered either prior to chemo treatment or after chemo treatment as long as radiation is given on the same day."
45363953|NCT03890367|Biological|Meningococcal group C polysaccharide Conjugate vaccine adsorbed|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
45363954|NCT04078919|Dietary Supplement|Nut consumption|daily consumption of 20 percent of daily calories intake from nuts (pistachio, almond and peanuts)
45363955|NCT04078919|Other|Low calorie diet|Low calorie diet
45363956|NCT02583035|Other|Nurse telephone contact|Nurse will contact patient 3 days before consultation
45363957|NCT00994773|Drug|Simvastatin|daily doses for 14 days
45481776|NCT02285816|Biological|MG1MA3|MG1MA3: Boosting component of Oncolytic Vaccine
45481777|NCT02285816|Biological|AdMA3|AdMA3: Priming component of Oncolytic Vaccine
45845736|NCT05713344|Other|Evaluation of mental state|Use of Beck depression inventory and Hospital Anxiety Depression score to evaluate depression and anxiety
45596526|NCT03527875|Procedure|PTBD group|Percutaneous Transhepatic Biliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
45596527|NCT03527875|Procedure|ENBD group|Endoscopic Nasobiliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
45596528|NCT03527875|Procedure|EBS group|Endoscopic Biliary Stenting, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
45596529|NCT02206295|Drug|selexipag|
46050365|NCT04111783|Device|POU protocol ultrasound|The evaluation method performed a preoperative examination of the patient within 10 minutes by a heart scan and a standard scan of the face, a large vascular scan under the xiphoid, a body cavity scan, and a standard scan of the face and a lung scan. Preparation, providing anesthesia and surgeons with a fast, comprehensive and accurate preoperative judgment with important clinical and social significance.
46050366|NCT01166893|Device|Modulated Imaging and Laser Speckle Imaging|wound healing
45596530|NCT02375139|Drug|DA-1229_01|complex single administration
45596531|NCT02375139|Drug|E+M|co-administration of 2 drugs
45596532|NCT04468945|Other|mirror box therapy|"Patients in Task-specific mirror box therapy group will receive therapy for 30 min/day, 3 times/week for 6 weeks.~The patient is seated close to a table a mirror (33*35 cm) was placed vertically. The involved hand was placed behind the mirror and uninvolved in front of the mirror.~The subject is asked to transfer small cubes from the middle position to the lateral side, placing pegs in holes and taking them out, turning over paper cards, placing steel needles in holes, stacking blocks, and putting glass on a shelf.~During the sessions, subjects will be asked to try and do the activity on the unaffected side and asked to do some movement with the paretic hand simultaneously."
45690048|NCT00563290|Drug|dasatinib|Given PO
45690049|NCT00563290|Other|laboratory biomarker analysis|Correlative studies
45690050|NCT00556504|Drug|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
45690051|NCT00556504|Drug|Peginterferon alfa-2a|conventional treatment of Hepatitis C
45690052|NCT00556504|Drug|Ribavirin|conventional treatment of Hepatitis C
45690053|NCT00556504|Drug|Placebo|Placebo, without acting ingredient.
45363958|NCT00994773|Drug|Tenofovir|
45363959|NCT00994773|Drug|Entecavir|Entecavir
45690054|NCT05560828|Other|Zio XT service|There will be no intervention. Standard of care at participating NHS organizations will not be affected.
45363960|NCT05405543|Drug|MYK-224|Specified dose on specified days
45363961|NCT05405543|Other|Placebo|Specified dose on specified days
45363962|NCT00995631|Procedure|Femoral lipectomy|Standard (non-experimental) suction assisted liposuction surgery
46050367|NCT00773773|Other|serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.|Patients referred for prostate biopsy as part of their routine care are to be recruited. Patients will undergo standard medical evaluation/care by undergoing a prostate biopsy because of an elevated PSA blood test and/or an abnormal digital rectal prostate examination. The protocol involves obtaining the research blood sample at the time of routine pre-biopsy blood draw. As such, an extra five (40 mL) tubes of blood will be drawn. The serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
45363965|NCT00995787|Drug|AZD1656|Dose titration of oral suspension of AZD165 during 3 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 6 days
45363966|NCT00995787|Drug|Placebo|Dose titration of oral suspension of placebo during 3 days given twice daily. Subjects will thereafter be for another 6 days
45363967|NCT04079153|Device|Mandibular advancement Appliance|Advances the mandible at desired range at a fixed vertical dimension
45363968|NCT00994851|Drug|SENNA+CASSIA|Pharmaceutical form: capsule Route of administration: oral Dose regimen: once a day
45363969|NCT00994851|Drug|placebo|Pharmaceutical form: Capsule Route of administration: oral Dose regimen: once a day
45363970|NCT04411745|Other|No intervention, observational study|
45363971|NCT04001127|Other|High Intensity Functional Training|"The exercise intervention for this study will be HIFT, defined as a style of training that incorporates functional, multimodal movements, performed at relatively high intensity, and designed to improve parameters of general physical fitness and performance. The program design and template will be based on the principles of the HIFT program called CrossFit®. CrossFit is described as a strength and conditioning program that focuses on constantly varying functional movements, performed at a relatively high intensity. CrossFit training includes a variety of elements from gymnastics (e.g., floor, bar and ring exercises), weightlifting exercises (e.g., squats, cleans, snatches and presses with a barbell, dumbbell or kettlebell), and cardiovascular activities (e.g., running or rowing)."
45363972|NCT04078607|Behavioral|Rapid Visual Information Processing task|A series of numbers appeared on a computer screen at a rate of one per minute. Each participant was required to identify any series of three consecutive odd or even numbers by hitting the space bar on the keyboard. The task lasted 15 minutes and included a 1-minute practice session before food being served. Participants were instructed to eat at will while completing the computer task.
45363973|NCT04078607|Behavioral|None or Control condition|Participant were instructed to eat at will during a 15-minute duration.
45363974|NCT05198505|Drug|TQB2868 Injection|TQB2868 protein is a bi-functional fusion protein targeting PD-1 and TGF-β
45363975|NCT04078841|Dietary Supplement|ReaLife+ (RLP)|RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids.
45363976|NCT04078841|Other|Inert Brown powder|Brown powder Inert brown powder to look similar to RLP
45363977|NCT03742869|Combination Product|A multi-omics analysis|A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics.
45363978|NCT02583191|Drug|Rivaroxaban|Rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily over a period of 3 months
45363979|NCT02583191|Drug|low-molecular heparine|"LMWH in therapeutic dosage (1-2× daily s.c.) according to standards of the individual study center, using licensed dosages, e.g.~Enoxaparin 1 mg/kg BW twice daily~Tinzaparin 175 I.E./kg BW once daily~Dalteparin 200 I.E./kg BW once daily"
45363980|NCT04000893|Other|Resistance exercise session|Acute isometric exercise session performed with handgrip Jamar about 20 minutes monitored.
45363981|NCT04078217|Device|Jintronix|Participants will perform an exercise program at home through a telerehabilitation platform called Jintronix.
45363982|NCT04078217|Other|Booklet|Home-based exercise program using a paper booklet (not the technology).
45690055|NCT02127892|Biological|unrelated BM with T cell depletion|Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).
45690056|NCT02127892|Biological|unrelated cord blood|Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.
45690057|NCT02127892|Biological|haplo BM with T cell depletion|haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.
45690058|NCT02127892|Device|unrelated PBSC with T cell depletion|peripheral blood stem cell will be processed for CD34+ cell isolation.
45690059|NCT02128828|Drug|cenicriviroc|cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc
45690060|NCT00520234|Drug|Caspofungin|50 mg IV daily
45690061|NCT00520234|Drug|Normal Saline|100 cc IV daily
45481778|NCT05459441|Biological|Autologous progenitor expansion -T|After the completion of RAK cell culture, RAK cells were slowly injected into the tumor cavity through Ommaya capsule for no less than 10 minutes, each time about 1.0-4.0 108/4 mL, once a week,3 times as a course of treatment. Il-2 (500,000 units/capsule) was injected into the tumor cavity through Ommaya reservoir every other day after the injection of RAK cells In other words, the day of RAK cell injection was the first day, and the third and fifth days were respectively injected. Then, about LML of sac fluid was pumped back before each injection to observe the growth of RAK cells in the tumor cavity. Il-2 was dissolved with LML normal saline, and the fluid storage sac was pressed 3-5 times after injection to make the sac fluid and IL-2 fully mixed.
45481779|NCT05459441|Drug|pemetrexed|For patients with brain metastasis from solid tumor that met the inclusion conditions, the Ommaya capsule was placed 2 days later, and the maximum tolerated dose of pemetrexed intrathecal chemotherapy was injected intravaginally at 10mg according to the general situation of the patients and the results of the previous study.
45481780|NCT05691842|Other|HIIT intervention|Patients will perform a muscle strength training circuit interspersed with resistance training circuit. The strength training circuit will consist of 10 strength exercises and resistance training circuit will consist of walking, jogging and running exercises. Each exercise will be performed for one minute, trying to reach maximum intensities adapted to each individual's condition.
45481781|NCT05691842|Other|Dual task intervention|Dual task training will consist of the progressive and specific assignment of primary motor tasks and secondary motor or cognitive tasks focused on: i) Primary tasks: static, dynamic balance and gait exercises; ii) Secondary tasks (motor or cognitive): verbal fluency, mathematical calculation, memory, visual-spatial planning, auditory discrimination, fine motor task, motor transport task.
45481782|NCT04523831|Drug|Ivermectin and Doxycycline|Ivermectin 6 mg, 2 tab stat and Doxycycline 100 mg twice daily for 5 days
45481783|NCT04523831|Drug|Standard of care|Paracetamol, Vitamin D, Oxygen if indicated, Low molecular weight heparin, dexamethasone if indicated
45481784|NCT05691764|Drug|Cyclosporin|Cyclosporin was administered intravenously with the dose of 3 mg/ kg body weight
45690062|NCT05560672|Other|Human Umbilical Cord blood mononuclear cells|Intravenous infusion of cord blood mononuclear cells
45690063|NCT00520468|Drug|Erythropoietin|40,000 units injected under the skin (SQ) weekly
45690064|NCT00520468|Drug|Cyclosporin A|300 mg (tablets) by mouth daily for 6 months
45690065|NCT00520468|Drug|G-CSF|300 mcg injected under the skin (SQ) two times per week
45690066|NCT00520468|Drug|Prednisone|60 mg per day for 7 days, taper over 1 month
45690067|NCT01908712|Drug|Lamazym|ERT, i.v. infusions weekly
45845737|NCT05713344|Diagnostic Test|Pancreatic quantitative sensory testing|Pancreatic quantitative sensory testing will be performed to evaluate temporal summation, pain detection threshold, pain tolerance threshold, and conditioned pain modulation.
45845738|NCT05709288|Drug|BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of an hyper active human factor IX mutant(FIX Padua) transgene in liver. The dose of BBM-H901 is 5x10'12 vg/Kg.
46050368|NCT00593983|Behavioral|Peer-driven intervention|Consists of four structured intervention sessions lasting 6 hours in total, three peer education/recruitment experiences, and brief liaison contacts by an intervention facilitator during AIDS clinical trial screening
46050369|NCT00593983|Behavioral|Time-matched health education|Health education and standard of care treatment
46050370|NCT04113655|Biological|Pertagen (aP BioNet)|"Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202."
45481785|NCT05691764|Procedure|remote ischemic preconditioning|Performed by inflating pressure cuff on the extremity 30 mmHg higher than systolic blood pressure of the patient for 5x5 minutes with 5 minutes reperfusion interval
45481786|NCT05691764|Drug|Placebo|Intravenous placebo
46050371|NCT04113655|Biological|Boostagen (TdaP BioNet)|"Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202."
45481787|NCT04707664|Drug|Sargramostim|All patients randomized to the sargramostim treatment arm will be treated with 250 mcg inhaled sargramostim administered via a vibrating mesh nebulizer once daily for 5 days.
45481788|NCT04707664|Drug|Placebo|All patients in the control arm will receive an equivalent volume of inhaled placebo diluent administered via a vibrating mesh nebulizer once daily for 5 days.
45481789|NCT03752879|Procedure|Fundal Pressure|Fundal Pressure to assist the vaginal delivery to shorten the second stage of labor
45481790|NCT01316276|Drug|Liposomal amikacin for inhalation|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~Administration time is approximately 13 minutes.~Liposomal amikacin for inhalation will be administered in two consecutive extension periods, each consisting of 6 cycles for a total of 12 cycles. Each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
45481791|NCT03756857|Procedure|Afterload Transfer|"Embryo transfer is done by using afterload transfer method"
45481792|NCT03756857|Procedure|Trial followed by transfer|"Embryo transfer is done by using afterload transfer method"
45363983|NCT02582723|Other|High protein/high fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
45363984|NCT02582723|Other|High protein/low fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
45481793|NCT04700566|Biological|Renuva Allograft Adipose Matrix|Injection of Renuva Allograft adipose Matrix in the vocal fold for vocal fold medialization and treatment of glottal insufficiency
45481794|NCT02474290|Drug|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
45690068|NCT05560516|Drug|Qutenza|Capsaicine patch: Qutenza 8% patch will be applied to the skin according to the instruction of the manufacturer. After application of local anesthetics on the skin, a Qutenza 8% patch will be placed. 1-4 patches will be placed and can be adjusted to the right size, depending on the surface of the CIPN. The patch(es) will be removed after 30-60 minutes. The effect will last about 12 weeks.
45690069|NCT05560516|Drug|Duloxetine|Duloxetine tablets: In week 1 patients will receive 30 mg duloxetine one time per day. In week 2 the dose will be increased to 60 mg one time per day. In case of inacceptable adverse events the patient is allowed to reduce the dose to 30 mg one time per day after consultation with the researcher or physician.
45690070|NCT05622526|Drug|Group 1 or Experimental group|Capsules of fecal microbiota transplantation
45690071|NCT05622526|Other|Group 2 or Control group|capsules of placebo
45690072|NCT05560438|Device|Tyromotion Amadeo and Armeo Senso|Robot assisted rehabilitation for arm- and hand function with Tyromotion Amadeo and Armeo Senso
45363985|NCT02582723|Other|Low protein/high fat creme cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
45363986|NCT05347329|Dietary Supplement|Tongkat Ali Maca Plus|Tongkat Ali and Maca (Tongkat Ali: powdered extract 200 mg (from roots of Eurycoma longifolia Jack) + Maca: powdered extract 100 mg (from dried tuberous root of Lepidium meyenii).
45481795|NCT05691608|Biological|Solid tumor and CT DNA|Biopsy and blood sample
45481796|NCT03753971|Other|Sound stimulation|Short sound stimulations will be emitted through a head band during sleep apneas
45481797|NCT02474212|Drug|Enoxaparin|
45481798|NCT04111601|Device|Blue light imaging|Advanced virtual chromoendoscopy
45481799|NCT05227118|Drug|MK-8189|MK-8189 administered orally once a day (QD) at a titration via tablet in 4 mg and 12 mg dose strengths
45481800|NCT05227118|Drug|Placebo|MK-8189 matching placebo administered orally QD
45481801|NCT03756779|Other|Dietary intervention|Dietary intervention with dietary modification of fat intake.
45481802|NCT05200286|Drug|Olorofim|Single oral dose
45481803|NCT03753815|Device|19G FNA needle|Puncture of AIP under Endoscopic Ultrasonography, with a 19-gauge FNA needle
45481804|NCT03753815|Device|20G FNB needle|Puncture of AIP under Endoscopic Ultrasonography, with a 20-gauge FNB needle
45481805|NCT02474446|Dietary Supplement|Vitamin D|150,000 IU of Vitamin D3 Oral solution
45481806|NCT05199818|Drug|Palonosetron HCl Buccal Film 0.5 mg|Palonosetron HCl Buccal Film and IV palonosetron placebo, both administered on Day 1
45481807|NCT05199818|Drug|IV Palonosetron 0.25 mg|IV Palonosetron and Palonosetron HCl Buccal Film placebo, both administered on Day 1
45481808|NCT03753737|Other|Questionnaires and semi-structured interview|"Questionnaires : PDQ-4+ (personality disorders), HAD (Anxiety and Depression), AUDIT-c (Alcohol consumption), CTQ-SF (Childhood Trauma Questionnaire).~Semi-structured interview : Evaluation of socio-demographic characteristics, psychiatric and addiction comorbidities, sexually transmitted infections, sexual practices, sexual dysfunction, hypersexual disorder."
45481809|NCT03752645|Device|Transverse Many Channels Laser Instrument|The device consists of a control box and 4 sets of two light-emitting nasal probes. Prior to treatment, each patient put on a pair of black tinted glasses, and had the nasal probes gently placed into both nostrils. A turn-on switch on the control box activated the probe and the timer was set at 15 minutes during which time 36 J of light energy was delivered to each nostril.
45481810|NCT02474134|Drug|Interferon beta-1b (PF530, Betaferon)|Single subcutaneous administration
45481811|NCT04668989|Device|stenfilcon A - (Test lens)|Subjects will be randomized to wear test lenses for one week.
45481812|NCT04668989|Device|kalifilcon A - (Control Lens)|Subjects will be randomized to wear control lenses for one week.
45481813|NCT03752489|Diagnostic Test|Treatment-specific InSight|The InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis, and in this study will be customized to differentiate between clusters of patients who respond similarly to fluids treatment according to the nature of their disease progression.
45481814|NCT03752489|Diagnostic Test|InSight|The non-customized InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis.
45481815|NCT02473900|Drug|HIP1403|Oseltamivir 75mg
45690073|NCT05622448|Other|RPD with PEEK framework|removable partial denture with CAD designed PEEK framework
45690074|NCT05622448|Other|RPD with metallic framework|removable partial denture with cobalt chromium framework
45690075|NCT05559268|Drug|Denosumab 60 MG/ML Injectable Solution [Prolia]|1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after TKA
45690076|NCT05559268|Drug|Placebo|1 ml (60 mg) subcutaneous injection Saline give in the posterior part of the upper arm after TKA
45690077|NCT02338960|Drug|Bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
45690078|NCT02338960|Drug|Placebo|Placebo
45690079|NCT05622214|Dietary Supplement|Else nutrition formula|Plant based nutrition from almond and buckwheat
45845739|NCT05698758|Drug|Dextrometropine and 0.9% sodium chloride solution|Intranasal dexmedetomidine or 0.9% sodium chloride solution as a sedative premedication for patients undergoing cataract surgery
45481816|NCT02473900|Drug|HGP0919|Oseltamivir phosphate 75mg
45481817|NCT04513691|Diagnostic Test|EOS Calculator|Neonatal Early-Onset Sepsis Risk Calculator which is a tool that determines the risk of EOS for a particular newborn by looking at maternal risk factors and the newborn's clinical picture as opposed to just laboratory tests alone
45481818|NCT02471638|Device|PQ Bypass System for Femoropopliteal Bypass|To access, deliver guidewires and implant stent grafts for a percutaneous fem-pop bypass.
45481819|NCT04689178|Other|Invitation letter + GP reminder|40-65 year-old women who did not perform a PAP test over the last 3 years will receive an invitation to consult a health professional to perform a screening test, AND GPs will receive the list of their 40-65 year-old patients who did not perform a PAP test over the last 3 years
45481820|NCT04689178|Other|Invitation letter|40-65 year-old women who did not perform a PAP test over the last 3 years will receive an invitation to consult a health professional to perform a screening test. GPs will NOT receive any list of their non-adherent patients.
45481821|NCT03700385|Device|IOWA Approach Endocardial Ablation System|Endocardial ablation using the IOWA Approach Endocardial Ablation System
45481822|NCT02471950|Procedure|2.5 % Isoflurane administration|Anaesthesia maintained during cardiopulmonary bypass with 2.5% isoflurane administered via the oxygenator of the bypass circuit.
45481823|NCT05454995|Other|Vessel Restoration System (VRS)|Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA)
45481824|NCT02471794|Behavioral|Personalized Health Planning Shared Medical Appointment|The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum
45481825|NCT01322867|Drug|alprazolam tablet|0,25 mg oral tablets given once
45481826|NCT01322867|Drug|alprazolam oral solution|0,75 mg/ml Oral Solution (Drops) given once
45481827|NCT04512287|Drug|Autologous Platelet Rich Plasma|2 sessions of Autologous PRP will be administered 15 days apart. Each injection will be 0.5 mL of PRP injected into the Peyronie's disease penile plaque.
45481828|NCT04512287|Other|Saline Solution|2 sessions of saline injection will be administered 15 days apart. Each injection will be 0.5 mL of normal saline injected into the Peyronie's disease penile plaque.
45481829|NCT04624828|Procedure|Radiotherapy|"RT treatment Schedule as for clinical practice: Stereotactic body radiation treatment (SBRT) will be delivered with image guidance (image-guided radiation therapy or IGRT) and in the form of volumetric modulated arc therapy (VMAT).~RT treatment Schedule: SBRT will be delivered in 1 to 6 fractions on bone or lymph node metastases. The dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints."
45481830|NCT04624828|Drug|androgen deprivation therapy (ADT)|"ADT as for clinical practice:~for oligorecurrent patients, ADT will be started at time of polimetastatic progression after SBRT;~for oligoprogressive patients, ADT will be continued during SBRT and untill polimetastatic progression"
45481831|NCT04624828|Biological|immune evaluation|We will use the flow cytometer FACSymphony, to analyse multiple immune populations from a limited sample of blood. We will monitor the dynamics of most innate (monocytic and granulocytic cells, Natural killer cells) and adaptive (T cells, B cells) immune subsets in the peripheral blood of PC patients before and after RT. We will deeply characterize CD4+ and CD8+ T cell subpopulations circulating in the patients enrolled in the study. In this attempt our panel will include markers of T cell differentiation and activation, including CD25, CD39, PD-1, CTL4, KLRG1, TIM3. We will analyse neutrophils subpopulations and investigate the functional profile of granulocytes in enrolled patients. Markers such as CD66b, CD24, CD16, MHC-II, LOX1, CD36 and CD62L will be included in our analysis. In conclusion our experimental strategy will result in a comprehensive profiling of the immune landscape in PC patients at single cell level.
45690080|NCT05621980|Device|Actuated Virtual Keyboard (AVK) system|"The participant controls an avatar hand by the movement of their own digits. Each avatar digit corresponds to a given virtual key. Sufficient digit flexion results in playing of that key, with visual and auditory feedback of key strike. Participants will wear a soft exoskeleton, the PneuGlove, with embedded bend sensors to provide real-time measurement of digit flexion. Pneumatic resistance to flexion can be applied to each digit independently, along with extension assistance, through air chambers running through the glove. The FES is intended to assist finger flexion by activating extrinsic finger flexor muscles. A high-density 2×8 stimulation electrode grid will be placed over the median and ulnar nerves at the medial side of the upper arm. The stimulator can deliver electrical stimulation to any pair of electrodes. At the beginning of each session, the investigators will identify the electrode pairs which best produce flexion of each digit with minimal discomfort."
45690081|NCT05621980|Behavioral|Occupational Therapy|Traditional occupational therapy training sessions.
46050372|NCT04113655|Biological|Adacel|"Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202"
46050373|NCT00914641|Drug|Apixaban IR|immediate release tablet, 10 mg, single dose
46050374|NCT00914641|Drug|Apixaban MR1|modified release tablet 1, 10 mg, single dose
45481832|NCT03977753|Drug|2LVERU® or 2LVERU® JUNIOR|"The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day."
45481833|NCT03977753|Drug|Placebo|"The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day."
45481834|NCT02473978|Device|INVOS Cerebral Oximetry|Participants will be connected to INVOS Cerebral Oximetry Cerebral Oximetry preoperativly and intraoperativly to ascess there cerebral perfusion throughout cesarean sections.
45481835|NCT02477722|Other|EFP-NF|
46050375|NCT00914641|Drug|Apixaban MR2|modified release tablet 2, 10 mg, single dose
46050376|NCT00914641|Drug|Apixaban MR3|modified release tablet 3, 10 mg, single dose
45363987|NCT02582567|Other|Exercise intervention|The exercise intervention will be performed in two groups so that each group will have 12-13 participants.The groups will train 3 days/week (60min per session) from the 16th week of gestation until delivery. The exercise intervention group will go through different phases of training: a) Learning phase: which will involve the intervention plan, the goals we want to work, and how we will perform it; b) Movement Learning phase: theoretical and practical sessions with the explanation of movements and ergonomic basic patterns; and c) Physical Fitness Training phase: with training sessions aimed at improving fitness and weight loss, and training sessions focused on a correct pelvic mobilization for the delivery.The intensity will be adapted during the exercise program based on the week of gestation and each pregnant heart rate. The sessions will consist of a mixed work, composed of circuits where both muscular and cardiovascular conditioning will be implemented.
45363988|NCT05347017|Procedure|Alveolar ridge preservation using autogenous demineralized dentin block graft|Atraumatic extraction of non restorable tooth, then the extracted tooth will be prepared and demineralized by HCL acid and inserted as demineralized dentin block graft in the socket
45363989|NCT05347017|Procedure|Alveolar ridge preservation using autogenous bone block graft|Atraumatic extraction of non restorable tooth, then the autogenous bone block graft will be harvested from the maxillary tuberosity and reshaped and inserted into the socket
45363990|NCT04403009|Other|no intervention|no intervention
45481836|NCT02477722|Other|Sham|
45481837|NCT05461079|Diagnostic Test|obtention of up to three semen samples|sorting of spermatozoa with flow cytometry. In the presence of insufficient numbers of spermatozoa after sorting (<15 mill), up to three semen samples will be collected.
45481838|NCT04491760|Other|Inspiratory Muscle Training|The inspiratory muscle training (IMT) will be carried out with a load of 30% of maximal inspiratory pressure (MIP) using a threshold inspiratory muscle trainer (c-type, Shengchang medical equipment factory, Yuyao city, China) at the beginning. During the hospital period, the resistance will increase incrementally, based on the rate of perceived exertion scored on the Borg scale (Borg, 1982). If the rate of perceived exertion less than 5, the resistance of the inspiratory threshold trainer will then be increase incrementally by 5%. The load for home-based IMT training will be set as the highest training load in the hospital. All patients will be required in sitting position during training, wearing nose-clips.
45481839|NCT03750929|Other|Combined acute physical exercises (strength and aerobic)|Patients will be submmitted to combined acute physical exercises (strength and aerobic)
45690082|NCT05621902|Other|Weekly symptom monitoring|Patients randomized to the intervention arm will be invited to respond to a web-based weekly 11-item signs- and symptoms questionnaire
45690083|NCT02121418|Drug|Cytarabine|Given IV
45690084|NCT02121418|Drug|Decitabine|Given IV
45690085|NCT02121418|Other|Laboratory Biomarker Analysis|Correlative studies
45690086|NCT01441635|Drug|Elagolix|Elagolix tablets
45690087|NCT01441635|Drug|Placebo|Matching placebo tablets
45690088|NCT01441635|Drug|Estradiol/Norethindrone acetate (E2/NETA)|A continuous once-daily oral tablet containing estrogen and progestin; the low-dose strength contains estradiol 0.5 mg and norethindrone acetate 0.1 mg.
45690089|NCT01441635|Drug|Estradiol|1.0 mg micronized estradiol tablets administered once a day
45690090|NCT01441635|Drug|Progesterone|Progesterone 200 mg administered during the last 12 days of the 28-day menstrual cycle
45690091|NCT01408485|Device|Therapy™ Cool Flex™ Irrigated Ablation System|"The investigational components of the Therapy™ Cool Flex™ Irrigated Ablation System consist of:~Therapy™ Cool Flex™ 4mm Irrigated Ablation Catheter~IBI 1500T9 V1.43 RF Generator"
46050377|NCT05632393|Drug|Daridorexant|Daridorexant will be available as film-coated tablets for oral administration formulated at a strength of 50 mg.
46050378|NCT00796549|Drug|BiBW 2992|BIBW 2992 in EGFR FISH positive NSCLC patients
46050379|NCT00856492|Biological|bevacizumab|Given IV
46050380|NCT00856492|Biological|pegfilgrastim|Given subcutaneously
46050381|NCT00856492|Drug|cyclophosphamide|Given IV
46050382|NCT00856492|Drug|doxorubicin hydrochloride|Given IV
45363991|NCT00998907|Device|PDS plus|triclosan-coated polydiaxanon 910 suture materials with antiseptic activity (PDS plus®, Ethicon GmbH, Norderstedt, Germany)
45363992|NCT00998907|Device|PDS II|polyglactin 910 suture material for abdominal wall closure
45363993|NCT04621643|Behavioral|digital cognitive behavioral therapy (dCBT-I)|dCBT-I during 9 weeks. Multicomponent intervention that includes the following: psychoeducation about sleep, sleep hygiene, sleep restriction therapy, stimulus control and challenging beliefs and perception about sleep. The digital CBT-I that will be utilized in this study is named Sleep Healthy Using The internet (SHUTi). The intervention is fully automated with no contact with health care personnel, it is interactive and adapts to input from the users. It comprises of the same elements included in face-to-face CBT-I, but the user gains access to a new educational, behavioral or cognitive module each week only after completion of digital sleep diaries. dCBT-I can be accessed on computers or hand-held devices
45363994|NCT04621643|Behavioral|Digital patient education about insomnia (PE)|Control condition PE during 9 weeks. A digital patient education program that can be accessed on computers or hand-held devices. The information overlaps with that included in the dCBT-I intervention but it does not include any of the interactive features of the dCBT-I intervention and all the information is available from the moment the PE site is opened.
45363995|NCT03084237|Biological|HLX02|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
45363996|NCT03084237|Biological|Herceptin®|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles
45363997|NCT03084237|Drug|docetaxel|75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle
45363998|NCT02584907|Other|High Fat Enteral Nutrition|Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
45363999|NCT04615715|Behavioral|CMV Risk-Reduction Intervention|CMV Risk-Reduction Intervention
45364000|NCT04615715|Behavioral|Stress Reduction Messaging|Stress Reduction Messaging
45364001|NCT00996021|Drug|GSK1349572 250 mg|This is an experimental HIV medication in the integrase inhibitor class.
45364002|NCT00996021|Drug|Placebo Suspension|Placebo is a liquid with no drug in it.
45364003|NCT00996021|Drug|Moxifloxacin 400 mg|This is an FDA approved antibiotic in the fluoroquinolone class.
45364004|NCT04614779|Drug|CN128 Tablets|Iron chelator, oral tablets
45364005|NCT00996099|Device|Continuous glucose monitoring system combined with enhanced model predictive control algorithm for intensive insulin treatment|Glucose measured with a real-time continuous glucose monitoring system served as an input for the enhanced model predictive control algorithm adjusting insulin infusion every 15 minutes for the first 24 hours after elective cardiac surgery
45481840|NCT04585594|Behavioral|Mi Propio Camino (MPC)|The Mi Propio Camino (MPC) intervention will be comprised of four sessions. Session 1 will encompass: the facts about high blood pressure (BP), understanding blood pressure readings, provide an overview of changes one can make to manage their BP, introduce MPC personal experience monitoring, and usage the mHealth kit. Subsequently, sessions 2-4 will emphasize the benefits of personal experience monitoring through 1) personal insight (finding what works for them) and 2) empowerment to work with their providers. Session 2 will reinforce this by introducing: synergy between medication and lifestyle, principles of heart-healthy eating and physical activity. Session 3 will incorporate discussion of negative beliefs about medication and patient directed lifestyle learning-rotating stations. Lastly, session 4 will introduce the continuation of personal experience monitoring on their own through the use of behavioral strategies for adherence and provider communication strategies.
45690092|NCT01427907|Drug|Calcium acetate oral solution (COS)|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
45690093|NCT01427907|Drug|Sevelamer carbonate|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
45690094|NCT03026595|Other|no intervention|no intervention
45364006|NCT00996099|Other|Intensive insulin therapy using standard protocol|Insulin dosage according to the standard protocol for intensive insulin delivery used at Department of Cardiothoracic Surgery, General University Hospital, Prague.
45364007|NCT02582645|Procedure|open window technique|palatally impacted canine will be exposed and left without traction for a maximum of 9 months
45364008|NCT02582645|Procedure|closed window technique|palatally impacted canine will be exposed, an attachment will be bonded, and then the canine will be covered with palatal tissue; traction of the canine will be initiated within 2 weeks following surgery
45364009|NCT05345301|Diagnostic Test|Event related desynchronization measurement|Individuals will spend one hour and receive cues to open or close their hand while wearing a EEG cap and EMG sensors on their forearm.
45364010|NCT04515329|Drug|Cyclosporine|Eye drops taken twice daily.
45690095|NCT02985333|Drug|Paclitaxel|Paclitaxel 170 mg/m(2) IV over 3 h d1
45690096|NCT02985333|Drug|Cyclophosphamide|Cyclophosphamide 200mgmg/m(2) IV d1,3,5
45690097|NCT02985333|Drug|Dexamethasone|Dexamethasone 20mg iv d1-4
45690098|NCT01427751|Drug|dexamethasone intravitreal implant|Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
45690099|NCT01427751|Biological|ranibizumab|Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
45481841|NCT04585594|Behavioral|Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control)|The HCP intervention will be comprised of four sessions and introduce seven lifestyle strategies (LS) subdivided per these sessions. Session 1 will encompass the facts about high blood pressure (BP), understanding blood pressure readings, provide an overview of changes one can make to manage their BP, present specific health threats from high BP, and incorporate LS1: taking control of your medication. Subsequently, sessions 2-4 will reinforce the benefits of taking medications through presenting 1) reduced risk for complications and 2) strategies to remember to take medications. Session 2 will present LS2: eating a well-balanced, low-salt diet and LS3: enjoying regular physical activity. Session 3 will follow with introducing LS4: maintaining a healthy weight and LS5: shaking the salt habit while eating out. Session 4 will present LS6: managing stress and LS7: working together with their doctor followed by a review of strategies they can continue on their own.
45481842|NCT04498403|Drug|Crisaborole 2%|Crisaborole 2% ointment
45690100|NCT01920061|Drug|PF-05212384 (gedatolisib)|PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
45481843|NCT02471560|Drug|dimethyl fumarate|As per the prevailing local label.
45481844|NCT02471560|Drug|injectable MS DMT|As described above.
45481845|NCT02477488|Drug|Allopurinol|Administration of allopurinol is changed to bedtime (hs) for each patient, at the same dosage as was previously prescribed.
45481846|NCT03750851|Other|Placebo|In this group, a water soluble gel without addition any desensitizing agent (K-Y®, Johnson & Johnson, Brazil) was applied to hypersensitive dentin. The GPlacebo volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) was used to scrub the placebo gel for 20 seconds on each tooth.
45481847|NCT03750851|Other|CPPACPF|In this group, a toothpaste MI Paste Plus™ (Recaldent™, GC América, USA) was applied to hypersensitive dentin. The GCPPACPF volunteers were submitted to the application of the paste dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) were used to scrub the desensitizing gel for 20 seconds on each tooth.
45690101|NCT01920061|Drug|Docetaxel|Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m^2
45690102|NCT01920061|Drug|Cisplatin|Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m^2
45690103|NCT01920061|Drug|Dacomitinib|Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg
45690104|NCT01426425|Device|Freezor Xtra Cryoablation Catheter|Freezor® Xtra Cardiac CryoAblation applied for cryoablation of the conducting tissues of the heart in the treatment of patients with atrioventricular nodal reentrant tachycardia using an endocardial approach.
46050383|NCT00856492|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
46050384|NCT04113265|Device|SUNEKOS ® Body|SUNEKOS ® Body is a medical device (class III). The study product was injected at level of the inner thighs, knees and arms by needle (29 G) using the interstitial fluid technique (IFT)
46050385|NCT04113577|Other|usability survey|usability survey composed of subpart: System Usability Scale, questions about global ergonomics of the app, questions about eronomics of the exerecices, question about global satisfaction.
46050386|NCT04113343|Drug|Remimazolam|Remimazolam via oral administration
46050387|NCT04113343|Other|Alcohol|Alcohol
46050388|NCT04111471|Drug|Prebiotics|Enrolled patients will receive 10 grams of inulin daily for 21 days
46050389|NCT04111471|Drug|Placebos|Enrolled patients will receive 5.6 grams of placebo powder daily for 21 days
46050390|NCT04111393|Procedure|transoral specimen extraction|transoral specimen extraction during laparoscopic gastric resection
45364011|NCT04515329|Drug|Artificial tear|Preservative-free artificial tear drops 4 times a day.
45364012|NCT02953977|Behavioral|Diabetes Prevention Program|An adapted version of the Diabetes Prevention Program will be delivered to intervention participants.
45364013|NCT02584751|Drug|Omeprazole|Omeprazole is a commonly prescribed anti-reflux medication. If a SCI patient has GERD, they will be prescribed with 40mg omeprazole twice daily for two months
45364014|NCT02584751|Device|24 Hour pH Monitor|Monitors the acidity and levels of pH in the esophagus for 24hours and helps diagnose people with GERD
45364015|NCT02584751|Procedure|Pulmonary Function Examination|Assess pulmonary function such as lung volumes, spirometry, and max inspiration/expiration pressures.
45364016|NCT02584751|Procedure|Exhaled Nitric Oxide|Used to measure inflammation markers for airway resistance.
45364017|NCT02584751|Procedure|Exhaled Breath Concentrate (EBC)|EBC will be used to measure airway inflammation via specific markers, such as 8-isoprostane. This marker, if elevated, has been identified as an indicator for asthma inflammation.
45364018|NCT02584751|Procedure|Bernstein's Acid Clearance Test|Bernstein test is a clinical test for the diagnosis of chest pain in association with gastric acid exposure
45364019|NCT02584751|Procedure|Esophageal Motility|Esophageal Motility will be used to measure a subject's ability to swallow a bolus (i.e. saline solution) and record pressure changes throughout the esophagus during the swallow. This will also be used to identify anatomical landmarks, such as lower esophageal sphincter, which are necessary for proper placement of 24hr pH catheter.
45364020|NCT00999219|Drug|FK199B|oral
45364021|NCT00999219|Drug|Zolpidem|oral
45364022|NCT00996177|Drug|IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem|40 µg fentanyl on-demand (240µg/hr) or a maximum of 80 doses (3.2 mg) per day
45364023|NCT00996177|Drug|IV Morphine Patient-Controlled Analgesia (IV PCA)|20mg/2hr (240 mg during 24 hours)
45364024|NCT04079933|Other|Oral tobacco-derived nicotine product (OTDN)|
45364025|NCT02584595|Device|ICD/CRT-D with NIPS or EP Study|ICD/CRT-D implanted patients are tested for inducible MMVT during electrophysiology (EP) Study or Non-Invasive Programmed Stimulation (NIPS) Study
45481848|NCT03750851|Other|Laser|In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda, Brazil) was applied in hypersensitive dentin. GLaser received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 3 sessions with a time interval of 24 hours between them.
45481849|NCT03750851|Other|LaserCPPACPF|In this group the laser + CPP-ACPF was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, Brazil) and a toothpaste containing CPP-ACPF MI Paste Plus™ (Recaldent™, GC América, USA) was applied in hypersensitive dentin. GLaserCPPacpf first named a toothpaste application and them the laser application, according to the manufacturer's recommendations.
45481850|NCT05163106|Drug|Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet|Patients will be given letrozole 2.5mg and ribociclib 600mg daily, per oral for a period of 21 days followed by 7 days of letrozole only.
45481851|NCT05163106|Drug|Goserelin|Premenopausal women will be given goserelin 3.6 mg (subcutaneous) every 4 weeks in concert with their Letrozole and Ribociclib treatment.
45364026|NCT00996255|Drug|PHA-793887|Escalating doses of PHA-793887 administered weekly by IV infusion for 3 consecutive weeks in 4-week cycles.
45364027|NCT04080089|Combination Product|Surgical treatment, drug therapy, remote cognitive training|"Surgical treatment：Children with OSAHS who had surgical indications and informed consent from the parents underwent tonsillectomy and adenoidectomy.~drug therapy：For children whose parents only agree to receive medical treatment, montelukast sodium tablets are given for 6 months to reduce the inflammatory response of adenoids, tonsils, etc.~remote cognitive training:For children whose parents did not agree to undergo surgery or medication, the cognitive function was evaluated at the time of enrollment, and cognitive training was performed. Individualized training programs were developed according to the cognitive assessment system, and cognitive function was evaluated again after one course of treatment."
45481852|NCT02477410|Dietary Supplement|Hydrolysed porcine protein from blood|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
45481853|NCT02477410|Dietary Supplement|Hydrolysed porcine protein from muscle|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
46050391|NCT04113031|Behavioral|Flywheel squats versus free weight high load squats for explosive actions in football|Over the course of the interventions, all players in all three groups will be instructed to adhere to their two-three weekly football practices and preseason matches of their team (~one weekly match). The flywheel group performes squat resistance exercise in using a flywheel device, and the barbell free weight group performes squat resistance exercise using an Olympic barbell and weights.
45481854|NCT02477410|Dietary Supplement|Hydrolysed whey protein|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
45596533|NCT04468945|Other|Repetitive Facilitation Exercise|"The patients in the control group will receive Repetitive Facilitation Exercise for 30 min/day, 3 times/week for 6 weeks.~Repetitive facilitative techniques were used to elicit movement of the shoulder, elbow, wrist, and fingers in a manner designed to minimize synergistic movements.~Participants were directed to concentrate on generating movement on the joint being treated while avoiding contraction of non-targeted muscles.~Therapists provided verbal directions with commands such as bend/straighten or one, two, three.~Participant efforts were supplemented as necessary to achieve a full range of motion (ROM)"
45690105|NCT02074995|Biological|BVS857|Group 1A&1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
45690106|NCT02074995|Other|placebo|Group 1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
46050392|NCT04111159|Drug|HSK3486|Subjects < 65 years old:Initial dose of 0.4 mg/kg followed by 0.15 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects < 65 years old.
46050393|NCT04111159|Drug|Propofol|Subjects < 65 years old:Initial dose of 2 mg/kg followed by 0.75 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects < 65 years old.
46050394|NCT04111081|Other|Auricular pressure|Select related auricular points: Shenmen(TF4), sympathetic(AH6a), rectum(HX2), anus(HX5), stomach(CO4), subcortical(AT4). The auricle skin of the patient was disinfected 24 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
45364028|NCT00999297|Other|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
45596534|NCT02199119|Behavioral|Exercise|30 min of moderate exercise on a treadmill
45690107|NCT01426347|Drug|Placebo sugar pill|Intervention includes 1 sugar pill once a week for 16 weeks dispensed as a capsule.
45690108|NCT01426347|Drug|Ergocalciferol|Ergocalciferol 50,000 IU per week for 16 weeks
45690109|NCT01882465|Device|etafilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
45690110|NCT01882465|Device|2-HEMA, EGDMA Non-ionic|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
45690111|NCT01882465|Device|hefilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
45690112|NCT04612309|Drug|Immunotherapy|patient treated with at least 1 immunotherapy administration
45690113|NCT04415983|Drug|Nitazoxanide|Nitazoxanide twice daily
45690114|NCT04415983|Drug|Clarithromycin|Klacid twice daily
45690115|NCT04415983|Drug|Metronidazole|Metronidazole twice daily
45364029|NCT00999297|Other|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
45481855|NCT05594524|Behavioral|Body Confident Athletes|The Body Confident Athletes program is a three-session in-person program designed to be delivered by coaches to their athletes. Groups should be of approximately 10-20 girls. The sports organizations will work with the community partner and researchers on how to schedule the intervention over a three-week period. These sessions can replace a regular sport practice each week or an additional session can be organized by the sports organization. Each session will take approximately 60 minutes and will consist of four phases, including The Game Plan (5 mins), The Knowledge (20 mins), The Skills (20 mins), and The Final Score (15 mins). A variety of activity modalities will be utilized to convey learning outcomes, including group and individual activities and discussion-, writing-, and movement-based activities.
45481856|NCT02471248|Device|Ankle Robot with Power Assistance|"Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 * 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote gait recovery and physical fitness.~They will wear the Ankle Robot during the gait training. The motor will synchronise with the paretic-side gait pattern to provide dorsiflexion moment during swing phase, and free the ankle joint when the sole is loaded."
45596535|NCT02199119|Behavioral|TV viewing|watching TV (animated children's programming) for 30 min
45596536|NCT02199119|Behavioral|Sitting quietly|Sitting quietly for 30 min
45596537|NCT02375061|Behavioral|e-BPS|
45596538|NCT02375061|Behavioral|Daily Activities|
45690116|NCT04415983|Drug|Proton pump inhibitor|Omeprazoe twice daily
45364030|NCT00999297|Other|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
45364031|NCT02582801|Drug|18F-Alfatide Ⅱ PET/CT|Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min
45364032|NCT05388695|Biological|Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells|Single or sequential injection of CD19, CD20 and CD22 CAR T cells.
45364033|NCT04078451|Procedure|preserve the main cystic artery|The experimental group preserve the main cystic artery, and the control group cut off the main cystic artery
45364034|NCT00583115|Drug|Gleevec|260 mg/M2/day, given once daily by mouth
45596539|NCT04468867|Diagnostic Test|Automated whole breast ultrasound|This will be performed by a band 6 radiographer and will be done at baseline, post 2 cycles of chemotherapy and end of treatment chemotherapy
45596540|NCT04468867|Diagnostic Test|Breast MRI|This will be performed by band 6 or 7 radiographer with MRI training
46050395|NCT04111081|Other|Shame auricular pressure|Select unrelated auricular points: eye(LO5), occipital(AT3), tonsil(LO7,8,9), lower auricular root(R3), dorsum auricular kidney(P5) and dorsum auricular lung(P2). The auricle skin of the patient was disinfected 24 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
45364035|NCT05371223|Drug|Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine|"Each combined course is constituted by two consecutive 28-day cycles of systemic chemotherapy (three adminstrations per cycle: days 1,8 and 15) and one cycle of PIPAC administered within 10-13 days from the last administration of systemic chemotherapy. Between each combined course a 7-10 days pause is observed.~The recommended dose of Nabpaclitaxel in combination with Gemcitabine is 125 mg/m2 administered endovenous over 30 minutes on Days 1, 8 and 15 of each 28-day cycle. The concurrent recommended dose of Gemcitabine is 1000 mg/m2 administered intravenously over 30 minutes immediately after the completion of Nabpaclitaxel administration on Days 1, 8 and 15 of each 28-day cycle.~A pressurized aerosol containing Nabpaclitaxel at the dose of 112,5 mg/m2 diluted in a total volume of 200 ml of NaCl 0.9% is applied through the nebulizer inside the abdominal cavity during laparoscopy."
45364036|NCT04079075|Other|Cognitive training|"This comprises training using using the cogweb software, both in person and remotely:~i) in person training: 30-minute sessions, supervised by a trained nurse, twice weekly .~ii) remote training: unsupervised 30-minute sessions, to be performed at home at the participants will."
45364037|NCT04079075|Behavioral|Physical activity|This is based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, directed by a physical education teacher and supervised by a nurse, twice weekly.
45364038|NCT04079075|Behavioral|Nutrition education|"This is based on monthly 180-minute sessions, directed by a nutritionist, comprising:~i) Presentation and discussion of healthy and easy to cook recipes by the nutritionist; ii) Preparation of healthy meals by the participants, followed by a period of social interaction between the participants while consuming the meals prepared."
45364039|NCT04079075|Behavioral|Adaption to memory loss|This is based on monthly 30-minute sessions, directed by a psychologist or a nurse, who will provide strategies that participants may use in their daily life to cope with memory loss.
45364040|NCT04079075|Diagnostic Test|Diagnosis of hearing impairment|Before implementing the sessions of cognitive training, physical activity, nutrition education and adaption to memory loss, an audiologist will perform an audiogram to all participants. Those with auditive performance inferior to the reference values will be referred for a medical appointment with an otolaryngologist.
45364041|NCT05370443|Behavioral|Life Skills education program|"The World Health Organization (WHO), describes life skills as abilities for adaptive and positive behaviour that enables individuals to deal effectively with the demands and challenges of everyday life. Life Skills Education includes activities that support critical and creative thinking, coping with emotions and stress, self-awareness and empathy, decision-making and problem-solving, communication skills, and interpersonal relations."
45364042|NCT02582411|Device|Laser Speckle Flowgraphy|A commercially available LSFG (Softcare, Fukutsu, Japan) system will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device. NB, the relative velocity of blood flow, is derived from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. Images are acquired continuously at the rate of 30 frames per seconds in a 4-second time period and stored on a personal computer. Heartbeat map of the optic nerve head and the retina/choroid is generated
45364043|NCT02582411|Device|Doppler Optical Coherence Tomography|"A dual-beam bidirectional Doppler OCT system comprises a broadband superluminescent diode (SLD) with a central wavelength of 840 (spectral bandwidth 54 nm) and two CCD cameras with a maximum readout rate of 20 kHz. The system provides a resolution (in tissue) of about 6 and 18 μm in axial and lateral direction, respectively. The sample, i.e. the retinal vessel under study, is illuminated by two probe beams separated by their polarization properties. Light back scattered and backreflected from the sample is spectrally detected by two identical spectrometers and postprocessing, i.e.~calculation the phase shift due moving scatterers within the sample, is carried out by a personal computer with software written in National Instruments LabView. The power of both probe beams incident on the cornea is 650 μW, which is below the ANSI (American National Standard Institute) limits for small source ocular exposure to a laser beam within the measuring time."
45364044|NCT00532779|Drug|Naltrexone SR 16 mg/Bupropion SR 360 mg /day|
45364045|NCT00532779|Drug|Naltrexone SR 32 mg/Bupropion SR 360 mg /day|
45364046|NCT00532779|Drug|Placebo|
45364047|NCT00532779|Behavioral|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
45364048|NCT02583737|Procedure|freeze bone allograft|sinus lifting filling procedure employing freeze bone allograft from tissue bone bank.
45364049|NCT02583737|Procedure|lyophilized bone allograft|sinus lifting filling procedure employing lyophilized bone allograft from tissue bone bank.
45364050|NCT04489355|Procedure|coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR) and mitral repair (MR)|
45364051|NCT04078997|Other|nasopharyngeal swab|A nasopharyngeal swab will be collected from consenting individuals by inserting a commercially-available dacron swab to the nasopharynx, gently rotating before removing.
45596541|NCT02201927|Device|galvanic vestibular stimulation|
45596542|NCT02202005|Drug|Nevirapine|Nevirapine 400mg PR tablet
45596543|NCT02202005|Drug|Viramune®|Viramune® 400 mg Retardtabletten
45690117|NCT01426269|Drug|Doxycycline|During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release & 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release & 10 mg delayed release beads), oral, one capsule daily in the morning
45690118|NCT01426269|Drug|Metronidazole|During Phase 1: MetroGel 1% (metronidazole 1% gel), topical, apply a thin layer once daily to the affected area
45481857|NCT02471248|Device|Sham|"Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 * 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote physical fitness.~They will wear the Ankle Robot during the gait training. The robot will synchronise with the paretic-side gait pattern to the Ankle Robot provides very low assistance which can be barely perceived by the stroke patient but does not suffice to support the ankle dorsiflexion."
45481858|NCT02477254|Biological|Vaccination|A quadrivalent HPV vaccine
45481859|NCT04362137|Drug|Ruxolitinib|Ruxolitinib 5 mg tablets
45481860|NCT04362137|Drug|Placebo|Matching-image placebo
45690119|NCT01426269|Drug|Placebo|During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning
46050396|NCT02605291|Other|Diet with a different macronutrient content A|A diet with altered macronutrient content will be provided to participants on days 4-6 of experimental arm 1.
46050397|NCT02605291|Other|Diet with a different macronutrient content B|A diet with a different macronutrient content compared to arm 1 will be provided to participants on days 4-6 of experimental arm 2.
46050398|NCT02605291|Other|Diet with a different macronutrient content C|A diet with a different macronutrient content compared to arms 1 and 2 will be provided to participants on days 4-6 of experimental arm 3.
46050399|NCT02605291|Other|Interval treadmill running exercise|Participants will perform interval treadmill running exercise on days 4 and 5 of all experimental arms.
45364052|NCT04078763|Behavioral|Rehabilitation protocol with visual-auditory feedback|The rehabilitation protocol with visual-auditory feedback is based on 8 sessions, over a period of 1 month, with 2 sessions per week. Each session lasts 45 minutes. During a session, the participant has to localize a sound around him, at hand. For this, he has to direct his head (which acts as a pointer) to the place where he seems to get the sound. Then, he validates his answer using the joystick placed in his hand. Regardless of the answer given (exact or incorrect), the subject will always have a visual-auditory feedback
45481861|NCT04491916|Drug|irone sucrose|drug ingredient: Ferric Hydroxide in complex with sucrose drug dosage form: 270injection/100mg/5ml/Amp
45364053|NCT04078763|Behavioral|Rehabilitation protocol with visual feedback|The rehabilitation protocol with visual feedback is based on 8 sessions, over a period of 1 month, with 2 sessions per week. Each session lasts 45 minutes. During a session, the participant has to localize a sound around him, at hand. For this, he has to direct his head (which acts as a pointer) to the place where he seems to get the sound. Then, he validates his answer using the joystick placed in his hand. Regardless of the answer given (exact or incorrect), the subject will only have a visual feedback.
45481862|NCT02473588|Device|Retia Medical Long Time Interval Analysis|"Retia Medical Long Time Interval Analysis will be used to analyze the blood pressure tracing of patients having surgery who have an arterial catheter"
45481863|NCT02477098|Drug|preoperative 0.5% ropivacaine hydrochloride preoperative|Before surgery (Pre RSB) , a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.
45481864|NCT02477098|Drug|postoperative 0.5% Ropivacaine hydrochloride|Before surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.
45481865|NCT03790553|Radiation|Radiotherapy|Different total radiotherapy dose between two arms.
45481866|NCT03752255|Other|Anxiety measurement method|Two different techniques (video or verbal information) will be examined about impacted third molar surgery.
45481867|NCT05099380|Device|senofilcon A C3|TEST Lens
45481868|NCT05099380|Device|senofilcon A|CONTROL Lens
45481869|NCT03108742|Device|INSORB|dermal stapler for skin closure
45481870|NCT03108742|Procedure|classic intradermal suture|intradermal suture for skin closure
45481871|NCT04518046|Drug|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
45481872|NCT04518046|Drug|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
45481873|NCT04518046|Drug|Ipilimumab|Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody
45481874|NCT02473744|Other|subcutaneous drainage|After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.
45481875|NCT02723734|Other|Decipher® Testing|Decipher® Prostate Cancer Classifier (Post-Op and Biopsy), a Genomic Classifier (GC) test. Biopsy and prostatectomy specimens will be collected for GC testing.
45481876|NCT02476942|Drug|Bypassing Agents|Episodic or prophylactic treatment with the use of bypassing agents must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
45481877|NCT02476942|Drug|FVIII Replacement|Episodic or prophylactic treatment with the use of FVIII replacement must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
46050400|NCT02605291|Other|Steady state treadmill running exercise|Participants will perform steady state treadmill running exercise on day 7 of all experimental arms.
45481878|NCT05571670|Drug|Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor|Participants will be treated with PI3K/AKT/mTOR inhibitors by their treating oncologist based on standard of care. This study will prospectively monitor bile acids and parameters of insulin resistance before and during treatment with these drugs.
46050401|NCT05297227|Procedure|Non surgical periodontal Therapy|Non-surgical periodontal therapy comprising oral hygiene instruction and motivation, professional mechanical plaque removal, and subgingival instrumentation will be performed. It consists in the use of an ultrasuond (piezoeletric device) and manual curettes.
46050402|NCT00697372|Device|Sirolimus eluting stent|Implantation of Sirolimus eluting stent
46050403|NCT00697372|Device|Everolimus eluting stent|Implantation of Everolimus eluting stent
45481879|NCT02473432|Procedure|RMT + usual care|Respiratory muscle training is performed with the Orygen Dual valve (inspiratory and espiratory trainer)
45481880|NCT02473432|Procedure|NMES|Neuromuscular electrical stimulation is performed with the Vital Stim ® device (approved by the FDA for dysphagia treatment). It consists in the placement of two electrodes located in suprahyoid muscles as above described.
45481881|NCT02473432|Procedure|Usual care|Standard swallow therapy consists of physiotherapy, occupational therapy and speech therapy targeting specific swallow impairments. In the case of dysphagia, the standard pattern includes measures to protect the airway and compensatory techniques.
45364054|NCT04078763|Behavioral|SPHERE protocol|"Data from spatial sound perception will be recorded in three dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D, hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure. This lasts 10 minutes and the result is expressed by the 3d-D value"
45364055|NCT04078763|Behavioral|French Matrix Test|This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value. This test lasts 10 minutes.
45364056|NCT04078763|Behavioral|Speech Spatial and Qualities of Hearing Scale (SSQ15) questionnaire|15 items questionnaire (each answer to questions is quoted between 0 and 10) resulting in a global SSQ 15 score. It takes 10 minutes to fill the questionnaire.
45364057|NCT04001673|Behavioral|Pharmacist's intervention|Information about bDMARDs management.
45481882|NCT02473354|Drug|Remifentanil|The opioid used for this study is Remifentanil and is commonly used in the operating room. Remifentanil will be given under normoxic (breathing room air [21% Oxygen]) and hyperoxic (breathing 50% oxygen) conditions to determine if the measurement of the specific respiratory parameters will predict the OIRD response.
45481883|NCT02473354|Drug|Oxygen|Remifentanil will be administered under normal oxygen (normoxia) and increased oxygen (hyperemic) conditions.
45481884|NCT02473354|Drug|Carbon dioxide|Carbon dioxide is used as part of the hypercapnia ventilatory response measurement (HCVR)
45481885|NCT04382638|Combination Product|RCO group|Patients in the experimental group will receive RCO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
45481886|NCT04382638|Device|TLSO group|Patients in the experimental group will receive TLSO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
45481887|NCT02470936|Behavioral|Lifestyle intervention|Patients will have access to the lifestyle website and an activity monitor (e.g., Fitbit), receive texts, and be provided with individualized lifestyle recommendations.
45481888|NCT03628612|Biological|AUTO CAR T cell therapy|No study drug is administered in this study. Patients previously treated with AUTO CAR T cell therapy will be monitored for safety following the first infusion.
45481889|NCT02470858|Drug|LDV/SOF+ASV|Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed-dose combination (FDC) tablet; administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
45481890|NCT02470858|Drug|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
45481891|NCT02470858|Drug|SOF+DCV+ASV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
45481892|NCT02473198|Drug|Exparel|Prior to cementing of the prosthesis (minimum 20 minutes later), injection with mixture of 40 mL normal saline solution and 20mL 1.3% Exparel.
45481893|NCT02473198|Drug|Femoral Nerve Block Bupivacaine|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
46050404|NCT04118686|Other|CoRe software training plus non-invasive brain stimulation techniques (anodical tDCS / rTMS)|CT program with Computerized cognitive training (CoRe) plus stimulation that modulates cortical activities by delivering strong magnetic pulses to the cortex through the scalp (rTMS) and weak electrical currents to the scalp to modulate neuronal transmembrane potential towards hyperpolarization or depolarization (tDCS).
46050405|NCT04118686|Other|CoRe software training plus sham non-invasive brain stimulation (sham tDCS/ sham rTMS)|CT program with Computerized cognitive training (CoRe) plus sham stimulation
46050406|NCT04111003|Procedure|local anesthesia|administering local anesthesia in the region of the planned restorative procedure
46050407|NCT04111003|Procedure|Tooth restored using SFRC filling|Restoration of an endodontivally treated molar using a shor-fiber base filling and veneering composite
45364058|NCT00500266|Biological|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|
45364059|NCT00996411|Drug|Salvinorin A|This is an initial dose ranging study
45364060|NCT00996567|Drug|Cetuximab (Erbitux)|Patients will be treated with standard chemotherapy (4-6 cycles), combined with weekly administration of Cetuximab (Erbitux) until disease progression.
45364061|NCT02583581|Device|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
45364062|NCT02583581|Device|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
45364063|NCT04120805|Device|Hemostatic Agent|Patients undergoing robotic-assisted laparoscopic partial nephrectomy with the use of hemostatic agents by a surgeon
46050408|NCT04111003|Procedure|Tooth restored using Ceramic indirect endocrown|Restoration of an endodontically treated molar using a ceramic indirect restoration
46050409|NCT04118530|Other|HSCT Patients|Prospective, observational review of incidence of AF/AFL through Carelink remote monitoring and safety of implantation of device in this population of patients through review of standard of care follow up visits post HSCT implant
46050410|NCT04110847|Drug|JING CEIH SHERN YUAN EXTRACT PILL|Oral use, 3#BID
45364064|NCT04120805|Other|No Hemostatic Agent|Patients undergoing robotic-assisted laparoscopic partial nephrectomy without the use of hemostatic agents by a surgeon
45364065|NCT02852655|Drug|MK-3475|
45364066|NCT00500110|Drug|Docetaxel|30 mg/m^2 by vein (IV) Weekly Over 60 Minutes on Days 1, 8, 15, and 22. This will be followed by 2 weeks with no docetaxel.
45364067|NCT00500110|Drug|Imatinib Mesylate|600 mg by mouth (PO) Daily x 42 Days.
45364068|NCT00500110|Drug|Leuprolide|Hormone injections given every other month or every 3 months, as determined by the doctor.
45364069|NCT00500110|Drug|Goserelin Acetate|Hormone injections given every other month or every 3 months, as determined by the doctor.
45364070|NCT02582333|Other|Observation for clinical and virological changes|Only observation after stopping nucleos(t)ide analogue
45364071|NCT05335551|Diagnostic Test|Patients monitored with TruGraf and TRAC Liver testing|This is an observational study there are no protocol mandated interventions. TruGraf and TRAC Liver results will be utilized in conjunction with standard of care assessments to determine patient management in the study arm.
45364072|NCT04358237|Drug|Lurbinectedin|"Lurbinectedin will be presented as a lyophilized powder for concentrate for solution for infusion in 4-mg vials. Before use, the 4-mg vial will be reconstituted with 8 mL of sterile water for injection, to give a solution containing 0.5 mg/mL of PM01183. For administration to patients as IV infusion, reconstituted vials will be diluted with glucose 50 mg/mL (5%) or sodium chloride 9 mg/mL (0.9%) solution for infusion.~PM01183 will be administered as a 1 hour IV infusion Q3W, in a minimum volume of 100 mL of solution for infusion (either 5% glucose or 0.9% sodium chloride), or a minimum volume of 250 mL if through a peripheral line, always at a fixed rate and through a pump device."
45364073|NCT04358237|Drug|Pembrolizumab|Pembrolizumab will be supplied as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
45364074|NCT04358159|Device|Ventralex|Repair of the hernia by a Ventralex patch in sublay position
45364075|NCT04358159|Device|Progrip|Repair of the hernia by a Progrip mesh in onlay position
45364076|NCT03925649|Biological|HB-adMSCs|single infusion of HB-adMSCs
45364077|NCT05312801|Drug|BAFF CAR-T|Autologous CAR-T cell therapy expressing the BAFF-ligand.
45364078|NCT05304533|Drug|MYK-224|Specified dose on specified days
45364079|NCT05304533|Drug|Itraconazole|Specified dose on specified days
45364080|NCT05304533|Drug|Verapamil|Specified dose on specified days
45364081|NCT00534495|Biological|Rilonacept|2.2 mg/kg subcutaneously
45364082|NCT04077827|Drug|Propofol|Patients will be divided into 2 groups. The TIVA group (N = 23) will be administrated intravenous anesthesia (propofol-remifentanil), while to the DES group (N = 23) volatile anesthetics (desflurane-remifentanil)
45364083|NCT00999375|Behavioral|Education|
45481894|NCT02473198|Drug|Toradol|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
45481895|NCT02473198|Drug|Morphine Sulfate|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
46050411|NCT00699712|Drug|CD-NP (Chimeric natriuretic peptide)|Infusion of CDNP at two of four doses
46050412|NCT02605135|Device|Continued Pessary Use|Pessary Fitting
46050413|NCT05628727|Other|Time Restricted Feeding|This group will use the 16:8 method every day, eating only during an 8-hour period that will commence at wake-up time.
45364084|NCT00999375|Behavioral|Problem Solving|
45364085|NCT00999375|Behavioral|Social Learning|
45364086|NCT00999375|Behavioral|Behavior Modification|
45364087|NCT00996645|Other|Worksheet to facilitate goal-setting and action plans|Developed based on goal-setting theory and implementation intentions, the worksheet will be mailed out with the feedback reports and is expected to facilitate improved quality of care in response to feedback reports.
45364088|NCT00996723|Drug|vandetanib and dasatinib|Two oral investigational agents (vandetanib [VEGFR2, RET, and EGFR inhibitor] and dasatinib [bcr-abl, PDGFRA and B, src, lck, yes, and c-kit inhibitor] will be administered during and after local RT, which is the only standard therapy for children with DIPG.
45364089|NCT00999453|Other|LDL-cholesterol|This is a 2-arm, open label, multi-center, randomized trial comparing aggressive to standard treatment of LDL-cholesterol. After screening, randomization, participants will be seen every 3 months during the follow-up period. An LDL-cholesterol 100 mg/dL is the goal for the standard group and the target for the aggressive group is 70 mg/dL. A lipid lowering algorithm has been developed based on the NCEP-ATP III recommendation which is used as a general guideline, allowing alterations based on the individual participants needs.
45364090|NCT01019122|Radiation|Dexa Scan|Dexa scan of left and right distal femur, then lumbar spine, and whole body when possible
45364091|NCT05332587|Drug|Rituximab|The therapeutical schema is rituximab 100-200 mg/week for a total of 2-4 times
45364092|NCT04078529|Other|5 day falls prevention training|Intensive training on balance, gait re-education, functional activities, backwards chaining and postural control, completed at 0 and 12 weeks.
45364093|NCT04078529|Other|Home exercise programme|A modified version of the Falls Management Exercise programme (FaME) provided in written or audio format and completed over 12 weeks.
45364094|NCT04078529|Other|Environmental Assessment|Use of the Homefast assessment tool to reduce risk of falls at home.
45364095|NCT00996879|Drug|Midazolam|Syrup, Oral, 5 mg, Single dose, 2 days
45364096|NCT00996879|Drug|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 8 days
45364097|NCT02581397|Drug|Transpulmin suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
45364098|NCT02581397|Drug|Guaiacol suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
45364099|NCT02581397|Drug|Transpulmin syrup|7,5ml every 4 hours, orally, for 03 or 07 days
45364100|NCT02582177|Drug|Candicort®|Apply on the affected area and around it twice a day
45364101|NCT02582177|Drug|Nizoral®|Apply on the affected area and around it twice a day
46050414|NCT05628727|Other|5:2 Fasting|This group will use the 5:2 method and fast for two non-consecutive days of the week.
46050415|NCT00856180|Drug|Bevacizumab|
46050416|NCT00856180|Drug|Cyclophosphamide|
46050417|NCT02605213|Drug|Vancomycin|Vancomycin for treatment of primary sclerosing cholangitis
45690120|NCT01426113|Drug|bimatoprost ophthalmic solution formulation A|1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning for 6 weeks.
45364102|NCT02582177|Drug|Baycuten N®|Apply on the affected area and around it twice a day
45481896|NCT03614728|Drug|GSK3326595|GSK3326595 will be administered.
46050418|NCT02605213|Drug|Placebo|Placebo for control Group of primary sclerosing vhlangitis
46050419|NCT04112563|Procedure|exploration in white light (WLI)|Exploration of the right colon done in white light (WLI)
46050420|NCT04112563|Procedure|Exploration in LCI|Exploration of the right colon in linked color imaging (LCI)
46050421|NCT04131478|Genetic|Pharmacogenetic testing|Pharmacogenetic testing for TNF alfa
46050422|NCT00900627|Drug|AZD8931|Tablet Oral bid
46050423|NCT00900627|Drug|Paclitaxel|IV once weekly for 3 weeks followed by a week off (repeated cycles)
46050424|NCT00900627|Drug|Placebo|Oral bid (twice daily)
46050425|NCT04010773|Other|collective and psycho-social intervention|The intervention duration is 1 year. It combine (1) In each unit, working groups aimed at improving QWL, (2) counseling and training of directors and frontline managers, and (3) in each unit, concertation meeting between workers, front-line managers and directors.
46050426|NCT00866320|Drug|sorafenib tosylate|Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor targeting both tumor cells and the tumor vasculature. Patients with metastatic RCC meeting eligibility criteria will receive 400 mg BID of sorafenib in a single-arm phase II study. Treatment will be administered on an outpatient basis.
46050427|NCT04115449|Drug|Dexmedetomidine|Injection dexmedetomidine 1 mcg /kg will be infused over a period of ten minutes
45364103|NCT02582177|Drug|Canesten®|Apply on the affected area and around it twice a day
45364104|NCT00999531|Drug|GS-9411|Inhaled GS-9411 dissolved in sterile saline
45364105|NCT00999531|Drug|Placebo|Inhaled Placebo, sterile saline
45364106|NCT00996957|Biological|ACE-041|Subcutaneous dose of ACE-041 approximately once every 3 weeks for a total of 4 doses. If disease stays the same or gets better, additional study drug may be offered.
45364107|NCT02626715|Drug|Reduced-Intensity Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Droxia (hydroxyurea) - drug class: antimetabolite Fludara (fludarabine) - drug class: antimetabolite Alkeran (melphalan) - drug class: alkylating agent Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent
45364108|NCT02626715|Drug|Myeloablative Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent Fludara (fludarabine) - drug class: antimetabolite Busulfex (busulfan) - drug class: alkylating agent
45481897|NCT03614728|Drug|5-Azacitidine|5-Azacitidine will be administered.
45364109|NCT05325177|Drug|Standard Dose Ibuprofen|(10-5-5 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
45364110|NCT05325177|Drug|High Dose Ibuprofen|(20-10-10 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
46050428|NCT04115449|Drug|normal saline|Normal Saline as a placebo will be infused over a period of ten minutes
45364111|NCT04099667|Drug|Phase 2; Low Dose MYOBLOC|Intramuscular injections on Day 1
45364112|NCT04099667|Drug|Phase 2; High Dose MYOBLOC|Intramuscular injections on Day 1
45481898|NCT03154086|Drug|GSK3352589|It will be available in the dose of 1, 5, 25 and 100 mg tablet for oral administration.
45481899|NCT03154086|Drug|Matching Placebo|It will be available across all strengths to match active drug in the form of tablet for oral administration.
45481900|NCT05069974|Drug|Linezolid|After randomized to the experimental arm, the patient will take 1 tablet of Linezolid every 12hours during 10 days.
45481901|NCT05069974|Drug|Benzathine Penicilllin G|After randomized to the control arm, the patient will receive a single dose of intramuscular BPG.
45481902|NCT02471482|Other|Mozart music lullaby|Recorded Mozart Lullaby will be played. The noise level will be kept below 45db as recommended by American Academy of Pediatrics and will be monitored by sound monitor placed in incubator during the study period. Enrolled babies will have hearing screening performed prior to discharge from hospital.
46050429|NCT04133974|Behavioral|methadone induced memory retrieval-extinction procedure|Drug memory is not invariably stable and can be induced transiently labile again by drug-related cues or drug itself, which is termed as 'reconsolidation'. Previously we and other groups have demonstrated that extinction coincided with reconsolidation weakened the drug memory and decreased drug craving and relapse. In the present study, we tried to interfere the methadone-induced heroin addiction memory reconsolidation by extinction given at different times following methadone administration.
45364113|NCT04099667|Drug|Phase 2; Placebo|Intramuscular injections on Day 1
45364114|NCT04099667|Drug|Phase 3; MYOBLOC|Intramuscular injections on Day 1
45364115|NCT04099667|Drug|Phase 3; Placebo|Intramuscular injections on Day 1
45364116|NCT00997191|Procedure|Laser photocoagulation|Focal / grid photocoagulation for diabetic macular edema according to ETDRS guidelines
45364117|NCT00997191|Drug|Intravitreal triamcinolone|Intravitreal preservative-free triamcinolone (4mg) associated to focal photocoagulation for diabetic macular edema on baseline; Re-treatment at weeks 20 and 40 if CMT>275um
46050430|NCT04110925|Genetic|Genetic Mutations|DNA sequencing for mutations to be obtained by bloodwork within 6 months of diagnosis, or by accessing diagnostic bone marrow aspirate slides.
45481905|NCT05336266|Drug|Ketorolac Tromethamine|Trial treatment of ketorolac 10mg orally four times a day for 5 consecutive days
45481906|NCT05691374|Procedure|Ultrasound (US) examination|"Shear-Wave Elastography (SWE) measurements of operated shoulder (quality, elasticity of repaired tendon) compared to healthy contralateral side. Parameters documented by regular US: Diameter of repaired tendon/ tendon thickness (mm), Rotator cuff muscle fatty infiltration (Grade 0-4), Signs of suture cut-through (yes | no), Signs of anchor displacement and location (lateral|medial row), Location of defect (at the foot print|medial cuff failure), Status of long biceps tendon (intact|in continuity|defect). Tissue elasticity measured by SWE in longitudinal orientation (in passive state and with active tension): Trapezius and Deltoid muscle: uninjured superficial muscle for individual patient muscle quality, SSP muscle and tendon: anterior and posterior part, SSC muscle and tendon: cranial and caudal part, ISP muscle and tendon, Biceps muscle and tendon: native (intraarticular) or subpectoral tenodesis (extraarticular)"
45364118|NCT00997191|Drug|Intravitreal bevacizumab|Intravitreal bevacizumab (1.5mg) associated to focal photocoagulation for diabetic macular edema at baseline; Re-treatment at weeks 20 and 40 if CMT>275um
45364119|NCT02581319|Procedure|Periodontal treatment|Periodontal treatment will consist of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects were made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
45364120|NCT05315739|Device|Non-invasive transcutaneous vagus nerve stimulation (tVNS)|tVNS delivers an electrical current to the cervical branch of the vagus nerve. Four minutes of bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2) are performed. The two periods are separated by a 2 weeks wash-out period.
45481907|NCT05691374|Procedure|Clinical examination|Clinical examination for shoulder range of motion and strength measurement
45481908|NCT02470780|Drug|Rifaximin|Rifaximin is an antibiotic used to treat SIBO. It is a 7-day course of treatment followed by three or six months of follow-up. This is a placebo-controlled study designed so that all participants will receive the active drug at least once during the study.
45481909|NCT02470780|Drug|Placebo|Placebo matching Rifaximin treatment.
45481910|NCT05691296|Behavioral|Home training|Letter Chart Accomodative Rock Training for 2 minutes each time
45481911|NCT05691296|Behavioral|School training|Letter Chart Accomodative Rock Training for 2 minutes each time
45481912|NCT02473120|Biological|Determination of ESR1 mutations|Blood sample prelevement. Plasma issued from patient with metastatic breast cancer will be analysed at progression by Digital PCR to detect ESR1 mutations
46050431|NCT04110925|Other|Inflammatory and lipid markers|Bloodwork to be done for lipid profile, c-reactive protein (CRP), and multiplex chemokine/cytokine analysis.
45364121|NCT05315739|Device|Sham vagus nerve stimulation|"The sham device produces a slight vibrating sound, but does not produce an electical current and hence, does not activate the vagus nerve.~Four minutes of bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period."
45481913|NCT02472808|Other|cTBNA without ROSE|Patients will undergo conventional TBNA and endobronchial biopsy and transbronchial lung biopsy
45481914|NCT02472808|Other|cTBNA with ROSE|Patients will undergo conventional TBNA with rapid on site evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
45481915|NCT02472808|Other|EBUS-TBNA without ROSE|Patients will undergo EBUS-TBNA and endobronchial biopsy and transbronchial lung biopsy
45364122|NCT05294081|Behavioral|Exposure therapy|10 sessions based on an individualized pain hierarchy
45364123|NCT05294081|Behavioral|Cognitive behavioral therapy|10 sessions with graded activity, relaxations techniques and cognitive interventions
45481916|NCT02472808|Other|EBUS-TBNA with ROSE|Patients will undergo EBUS-TBNA with rapid onsite evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
45481917|NCT05687942|Device|REBUILD|3.1.1. REBUILD is an investigational medical device provided as a sterile, single use set containing 10 suture Anchors and two non-implantable Carriers, with reusable stainless-steel instruments for deployment supplied separately.
45481918|NCT05180292|Drug|Carvedilol 12.5 MG|Carvedilol 12.5 mg
45481919|NCT01315938|Drug|Abatacept Active Treatment|Participants will be treated with abatacept by intravenous infusions a total of seven times at week(s) 0, 2, 4, 8, 12, 16 and 20 weeks.
45481920|NCT01315938|Drug|Abatacept Delayed-Onset Treatment|Participants will be treated with abatacept for 6 months and received a total of seven intravenous infusions at weeks 12, 14, 16, 20, 24, 28 and 32.
45481921|NCT03108430|Other|Risk factors and incidence of IP after inhalation|Calculate the annual incidence of PI, the incidence of PI in inhaled patients (in each subgroup), and analyze the risk factors by logistic regression, based on the number of patients hospitalized during the study period.
45481922|NCT04800354|Behavioral|Nurse-led Mindfulness Based Intervention|Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then have them listen to a very brief (1 minute 30 second) guided mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time they experience intense pain or take pain medication before and after surgery.
46050432|NCT04110925|Other|Computed Tomography (CT) of the heart|Sunnybrook Patients with no history of cardiovascular disease [ex: past/present coronary artery disease (CAD), peripheral vascular disease (PVD), angina, myocardial infarction (MI), stroke, transient ischemic attack (TIA), or stents], not pregnant, and able to undergo CT will receive a CT of the heart to look for and quantify any occult coronary artery disease.
45364125|NCT00997269|Dietary Supplement|Co-enzyme Q-10|Patients will be supplemented with 300 mg of CoQ-10 1 time daily for one month
45364126|NCT00997269|Dietary Supplement|Placebo|Patients will be supplemented with CoQ-10 placebo 1 time daily for one month
45364127|NCT02582099|Drug|Gentamicin nasal irrigation|Nasal wash with gentamicin solution
45364128|NCT02582099|Drug|Normal saline nasal irrigation|Nasal wash with normal saline solution
45364129|NCT00997347|Drug|Mifepristone and misoprostol|"200 mg oral mifepristone~800 mcg buccal misoprostol or 400 mcg sublingual misoprostol 24-48 hours after mifepristone"
45364130|NCT00997581|Drug|apremilast|apremilast 20 mg taken twice daily by mouth
45364131|NCT00997581|Drug|indomethacin SR|indomethacin SR 75 mg taken twice daily by mouth
45364132|NCT04345601|Biological|Mesenchymal Stromal Cells|Patients will be given the cell product by intravenous injection (into the vein through an IV line). Dose:1 x 10^8 MSCs.
45364133|NCT04345601|Other|Supportive Care|Patients will receive supportive care per their treating physician
46050433|NCT02841735|Device|Smartphone breathalyzer device/app use|Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.
45364134|NCT04001439|Drug|Experimental drug|All patients will recive 30 microbiota capsules intake preceded by bowel lavage by 4 liters macrogol solution. the capsules are developed by the services of JC Lagier.
45364135|NCT02582021|Procedure|Coronary Angiography|"A coronary angiogram is a procedure that uses x-ray imaging to see the heart's blood vessels; it is a part of Heart (cardiac) catheterization procedure. During a coronary angiogram, a type of dye that's visible by an x-ray machine is injected into the blood vessels of the heart. The x-ray machine rapidly takes a series of images (angiograms).~The Coronary Reactivity test (CRT), heart pressure (Millar) evaluation, and Millar stress testing are performed during the coronary angiography."
45364136|NCT02582021|Procedure|Coronary Reactivity Testing|An angiography procedure specifically designed to examine the blood vessels in the heart and how they respond to different medications.
45364137|NCT02582021|Procedure|Cardiac Magnetic Resonance Imaging|"Noninvasive high resolution imaging test; Optimized magnetic resonance imaging technique for use in the cardiovascular system - use of ECG gating and rapid imaging sequences.~Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. The CMRA is performed as part of the CMRI."
45364138|NCT02582021|Procedure|Cardiac Magnetic Resonance Angiography|Test for validation purposes against gold-standard Angiography. CMRA is a part of the CMRI test. The residual contrast (gadolinium) circulating in the blood stream (following the CMRI prior images) is sufficient for CMRA evaluation.
45364139|NCT02582021|Procedure|Computed Coronary Tomographic Angiography|Noninvasive, imaging method that uses a computed tomography (CT) scanner to look at the structures and blood vessels of the heart.
45364140|NCT02582021|Procedure|Rest-Stress Millar Testing|"Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. They are designed to test how your heart muscle is functioning.~Rest-stress Millar testing is performed during the coronary angiography and Cardiac Magnetic Resonance Imaging."
46050434|NCT02841735|Device|BAC estimator app use|Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.
46050435|NCT02841735|Device|Text messaging procedure|Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
46050436|NCT04133896|Diagnostic Test|IL-6, Clusterin, Irisin Level|Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
46050437|NCT04112875|Dietary Supplement|L-arginine|Handled powdered supplement to be mixed with water, has orange flavor for oral use.
46050438|NCT04112875|Dietary Supplement|Maltodextrin|hydrolysis of cornstarch or starch as a white powder to be mixed with water, has orange flavor for oral use.
45364141|NCT02582021|Procedure|Aortic vasorelaxation tests|Non-invasive clinical test. Repeat blood pressure and heart rate per minute will be read for three times; Your pulse wave velocity, pulse wave analysis and central pressure measurements will be recorded.
45364142|NCT02044497|Drug|oral oxycodone|
45364143|NCT05301153|Diagnostic Test|real time PCR , ELISA|Real-time RT PCR will be performed on complementary DNA produced from 250 ng total RNA using the following primers Interleukin 37, F: 59-CAGTGAGGTCAGCGATTAGGAA-39 R: 59-TTAGTGAGCAGGTTTGGTGTTTT-39 b-actin, F: 59-CACCATTGGCAATGAGCGGTTC-39 R 59-AGGTCTTTGCGGATGTCCACGT-39. Detection of autoantibodies to muscle specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4) serum levels by ELISA
45364144|NCT05183139|Drug|Ixazomib|Ixazomib capsules
45364145|NCT05183139|Drug|Pomalidomide|Pomalidomide capsules
45364146|NCT05183139|Drug|Lenalidomide|Lenalidomide capsules
46050439|NCT03679611|Drug|Sugammadex Sodium|Sugammadex is a FDA approved newer NMBD reversal agent. But does not use in standard of care in most of institutions This study is designed to compare the impact of reversal of neuromuscular blockade with sugammadex vs. neostigmine on discharge time from the operating room in obese patients with OSA undergoing bariatric surgery
45364147|NCT05183139|Drug|Dexamethasone|Dexamethasone tablets
45690121|NCT01426113|Drug|timolol ophthalmic solution|1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
46050440|NCT03679611|Drug|Neostigmine|neostigmine is a FDA approved NMBD reversal drug, uses as standard care drug in most of the institutions. neostigmine use as active comparator to compare with investigational drug Sugammadex in the study.
46050441|NCT04131244|Procedure|In vitro activation of primordial follicles by PTEN inhibitor and AKT stimulator|After laparoscopic unilateral oophorectomy, ovarian medulla would be dissected from cortex. After fragmentation of 2 cm square ovarian cortex into smaller pieces they would be incubated PTEN inhibitor and AKT stimulator for 48 hours. Finally we will auto graft these fragments beneath to the fallopian tube peritoneal surface.
45364148|NCT00999843|Drug|Sorafenib|Sorafenib is administered only to the patients with non-progression disease (CR, PR and SD) 4 weeks after the completion of radiotherapy. The dose is 400 mg, p.o., twice a day. Sorafenib is continuously given for 12 months unless intolerable toxicities and/or tumor progression.
45481923|NCT04800354|Behavioral|Nurse-led Pain Psychoeducation|Nurses will provide psychoeducation about pain along with common pain coping strategies, such as rest, ice, and elevation, for use any time they experience intense pain or take pain medication before and after surgery.
45481924|NCT05684432|Other|No intervention|No intervention
45690122|NCT01426113|Drug|bimatoprost vehicle|1 drop of bimatoprost vehicle in the affected eye(s) in the morning for 6 weeks, followed by 1 drop of bimatoprost vehicle in the affected eye(s) in the evening for 6 weeks.
46050442|NCT04112719|Other|supine position|The patient will be placed in a supine position. Changes in cardiac output will be measured.
46050443|NCT04112719|Other|15 degrees lateral tilt|The patient will be placed in 15 degrees lateral tilt position. Changes in cardiac output will be measured.
46050444|NCT04112719|Other|30 degrees lateral tilt|The patient will be placed in 30 degrees lateral tilt position. Changes in cardiac output will be measured.
46050445|NCT02841891|Device|Sylys® Surgical Sealant|Standard Stapled Anastomosis Colectomy Procedure with the addition of Sylys® Surgical Sealant
46050446|NCT02841891|Procedure|Stapled Anastomosis Colectomy Procedure|Standard Stapled Anastomosis Colectomy Procedure without the addition of Sylys® Surgical Sealant
46050447|NCT00699868|Other|Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings|Sampling of blood
45364149|NCT03830567|Other|Pharmacist prescription|Pharmacist prescribed hormonal contraception (initiation or continuation).
45364150|NCT03830567|Other|Clinician prescription|Clinician prescribed hormonal contraception (initiation or continuation).
45364151|NCT00997659|Dietary Supplement|chromium picolinate|1000 mg per day
45481925|NCT02470624|Other|treatment following current guideline|
45690123|NCT01864603|Other|Universal ART in a streamlined care model|immediate ART start for all HIV+ in community with streamlined care
45690124|NCT01864603|Other|Annual Community Health Campaigns|HIV and multi-disease testing for all community members
46050448|NCT00699868|Other|Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings|Sampling of blood
46050449|NCT02604667|Other|Blood tests|"Study participants will undergo a single, peripheral blood draw. Blood specimens will be used to perform hematological biomarker testing and leukocyte RNA gene expression analysis.~Hematological biomarker testing will be performed to better elucidate the mechanisms of ischemic stroke in cancer patients and will include markers of coagulation, platelet function, and endothelial integrity. This analysis will occur at MSKCC.~Leukocyte RNA gene expression analysis will be performed to evaluate whether patients with cancer and stroke more often have cardioembolic mechanisms than patients with stroke and no cancer. This analysis will occur at the University of California, Davis where investigators have previously shown that differential RNA expression patterns can predict stroke subtypes."
45364154|NCT00997737|Device|DB, VI and FI|Two modalities of respiratory exercises based on deep and slow inspirations will be used: DB and IS. During DB, the researcher will place one hand slightly below the lower ribs in the abdominal region of the subject and the subject will be instructed to perform inspirations up to the maximum level of volume avoiding rib cage displacement; this recommendation will also be valid for exercises using incentive spirometers. IS will be executed using two different devices: Triflo II and Voldyne.
45364155|NCT05300919|Other|Measurement based care|Measurement-based care based on arm.
45364156|NCT03827213|Drug|Exparel|A shot of long acting local anesthetic for post operative pain management
45364157|NCT03827213|Device|Indwelling Interscalene Catheter|ropivacaine, given through a catheter inserted between the shoulders
45364158|NCT00999999|Procedure|Craniotomy supra- or infratentorial, dural closure|After dural closure with a water-tight suture, randomization is performed. Depending on the randomization outcome, the study drug Tachosil is applied on the dural suture or omitted.
45364159|NCT00997815|Drug|Botulinum toxin A|Concentration at 2 units per 0.1 of normal saline dilution
45364160|NCT00997815|Drug|Normal saline injection|Using normal saline 2.5 ml injected in control side
45364161|NCT04078139|Drug|The MP/RP group|Miscible liquid of methylprednisolone and ropivacaine in this study will be peri-incisional scalp infiltration with 40mg methylprednisolone, 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
45364162|NCT04078139|Drug|The RP group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
45364163|NCT04077983|Drug|combined therapy using nab-paclitaxel and gemcitabine chemotherapy|"Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2~Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2~Three weeks is a course of treatment with a total of 4 courses."
45364164|NCT00997971|Other|Modilac Rose 1|Infant formula used for non-breastfed children
45364165|NCT03823469|Behavioral|CCTP|Twelve weekly one-on-one 30-minute tele-sessions through video conference. At the first session, subjects identify their vision regarding home cooking and 3-month goals. During each subsequent meeting, subjects will review their progress towards reaching the prior week's culinary goals and identify goals for the coming week, using a self-discovery process. When patients detect a new culinary skill that is necessary for their progress, s/he will either be taught through discussions or referred to active learning from a Culinary Resource Center.
45364166|NCT03823469|Behavioral|Nutritional counseling|Two 30-minute nutritional counseling sessions
45364167|NCT04000191|Procedure|MAC|Monitored anesthesia care (MAC) administered by anesthesiology and Injection of local anesthesia mixture of 1% lidocaine with epinephrine and 0.25% Marcaine by the operating surgeon.
45690125|NCT01864603|Other|Targeted PrEP and Targeted testing interventions|
46050450|NCT02604667|Other|Transcranial Doppler Microemboli Detection Study|Study participants will undergo a single Transcranial Doppler Microemboli Detection Study at NYPH/WCMC or MSKCC within two weeks of enrollment. Both middle cerebral arteries will be insonated for 30 minutes by a trained technician or stroke neurologist certified in neurosonology using a fixed headset to assess for the rate and laterality of microemboli.
45364168|NCT04000191|Other|Perianal ice application|Application of ice to the perianal area after the area is prepared with betadine, prior to injection of local anesthesia by the surgeon.
45690126|NCT01864603|Other|Baseline community-based HIV and multi-disease testing|HIV and multi-disease testing for all community members at baseline only
45690127|NCT01892293|Drug|Treatment with NY-ESO-1c259-modified T cells|"An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to < 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.~For patients whose disease progresses and whose tumor still expresses tumor antigen and HLA-A201, a second infusion of up to 5e10 cells may be given."
45690128|NCT04415593|Dietary Supplement|High dose of peanuts|Patients will receive a high dose of ground peanuts (300 mg) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
46050451|NCT00914953|Drug|oxytocin (Pitocin)|40 IU OT intranasally (IN) once-daily for 10 consecutive days
46050452|NCT00869518|Drug|rifabutin plus trimethoprim sulfamethoxazole|rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
46050453|NCT00869518|Drug|placebo plus trimethoprim-sulfamethoxazole|placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
45481926|NCT01339884|Drug|Resveratrol|Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks
46050454|NCT00794781|Drug|E6201|E6201 Part A (Dose Escalation): Intravenous (IV) infusion administered over 30 minutes once weekly for 3 weeks (Days 1, 8, and 15). The first 3 to 6 subjects of the first cohort will receive 20 mg/m^2/week for a cycle of 3 weeks followed by a 1-week rest period. Subsequent dose escalations may increase at increments of 100% until two Grade 2 toxicities or 1 dose-limiting toxicity (DLT) are observed in a dose group. Thereafter, doses will be increased in increments of 50% or less until the maximum tolerated dose (MTD) is determined. Part B (MTD Expansion): After the MTD is determined in Part A, 15 additional subjects will continue to receive cycles at the MTD.
45481927|NCT05112614|Procedure|Biospecimen Collection|Undergo collection of blood and stool samples
46050455|NCT04112329|Behavioral|Exergaming|will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks.
45481928|NCT05112614|Other|Electronic Health Record Review|Review of medical records
45481929|NCT04260646|Device|Enuresis Alarm Rodger and Timer watch (Rodger)|Nocturnal enuresis fluid sensitive alarm and Timer watch (Rodger) vibrating or sounding alarm for remembering timed voiding intervals
45481930|NCT04260646|Device|Timer watch (Rodger)|Timer watch (Rodger) vibrating or sounding alarm for remembering timed voiding intervals
45481931|NCT04736394|Drug|APL-1202|APL-1202 single-agent oral treatment
45481932|NCT04736394|Drug|Epirubicin Hydrochloride|Epirubicin hydrochloride
45481933|NCT04257370|Device|Kerecis™ Omega3 Wound|Kerecis™ Omega3 Wound is decellularised, intact fish skin from North Atlantic cod fish. Kerecis™ Omega3 Wound is FDA approved and EU cleared for the treatment of diabetic ulcers, chronic vascular ulcers, venous ulcers, trauma wounds (including abrasions, lacerations, and skin tears), acute surgical wounds (including debridement, amputation, and donor sites), surgical wounds (dehiscence or failed healing after surgery), imminent failure of STSG, and post-injection necrosis.
45364169|NCT03822845|Drug|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
45364170|NCT01000233|Dietary Supplement|Phytine (phytate)|300 mg tid * 24 months
45364171|NCT01000233|Dietary Supplement|Placebo|Phytine (Phytate)
45364172|NCT04075955|Drug|Zyprexa® (OLANZapine 5MG)|"Olanzapine 5mg orally at bedtime for 4 days (starting the day before the chemotherapy)~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally twice a day for 6 doses (starting on the morning of day 2)"
45364173|NCT04075955|Drug|Emend® (Aprepitant)|"Aprepitant 125mg orally pre-chemotherapy on day 1, then 80mg orally once daily on days 2 and 3~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally once daily for 3 doses (starting on the morning of day 2)"
45364174|NCT04076033|Other|functional compressive bandage|"The functional compressive bandage is being performed with the volunteer sitting with the upper limb homolateral to the surgery supported by a support. After hydration of the limb, a cotton mesh is being used to prevent friction of the 1 cm density foam band being wrapped around the limb. No therapeutic procedure is being performed prior to functional compressive bandage.~The bandage of the limb is being performed with 5 cm, 10 cm, 15 cm elastic cotton bandages from the fingers to the axillary region in four layers."
45364175|NCT03814187|Drug|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
45364176|NCT00484198|Drug|Pioglitazone|45 mg over-encapsulated tablet administered orally, once daily
45364177|NCT00484198|Drug|Placebo|Rivoglitazone-matching placebo administered as a tablet orally, once daily or a pioglitazone-matching placebo administered as an over-encapsulated tablet orally, once daily capsule
45364178|NCT00484198|Drug|Rivoglitazone|1.0 mg tablet administered orally, once daily
45364179|NCT00484198|Drug|Rivoglitazone|1.5 mg tablet administered orally, once daily
45364180|NCT04077905|Drug|Pegylated liposomal doxorubicin|35mg/m² ivgtt on day 1
45364181|NCT04077905|Drug|Etoposide|100mg/m² ivgtt on day 1
45364182|NCT04077905|Drug|Methylprednisolone|2 mg/kg ivgtt or PO days 1 to 3, 0.75 mg/kg ivgtt or PO days 4 to 7, 0.25 mg/kg ivgtt or PO days 8 to 10, 0. 1 mg/kg ivgtt or PO days 11 to 14,
45364183|NCT04076501|Procedure|Oxygen application|Oxygen application Supplemental oxygen via mask
45364184|NCT04076501|Procedure|Sham room air|Room air applied via mask
45364185|NCT04077749|Biological|Femdophilus probiotic|Lactobacillus rhamnosus (GR-1®) and reuteri (RC-14®) species, which is offered as an over the counter probiotic capsule sold under the brand name of Femdophilus dissolved in 50 mL normal saline at room temperature.
45364186|NCT04077749|Other|Normal Saline|50 mL normal saline at room temperature
45364187|NCT04282187|Drug|Decitabine|Given IV
45364188|NCT04282187|Drug|Ruxolitinib|Given PO
45481934|NCT04257370|Other|Standard of care|Standard of care wound treatment as defined by the local site, including debridement of the wound, standard wound dressing, and proper offloading of the wound site.
45481935|NCT01339962|Other|Non-interventional|Non-interventional (retrospective chart reviews)
45481936|NCT01341834|Drug|LBH589 and RAD001|Dose escalation of LBH589 tablets (5 and 10 mg) and RAD001 tablets (2.5, 5 mg and 10mg)
45481937|NCT01340040|Drug|MEDI-573|MEDI-573 will be administrated once 7 days in Cohort 1 and 2, and once every 21 days in Cohort 3 as a IV infusion as part of a 21-day treatment cycle.
45596544|NCT02364921|Device|Two multilayer compression bandage|"Usual clinical practice in venous ulcer in wound care in assessing, cleaning, desinfection, debridement and topical treatment.~Compression therapy: a multilayer compression bandage with two layers, suitable for the treatment of venous leg ulcers and to reduce edema chronic venous be used. Apply one two seven days"
45596545|NCT02364921|Device|Crepe bandage|Crepe bandage: Usual clinical practice in venous ulcer in wound care. crepe bandage apply one to seven days
45596546|NCT02741245|Drug|Ezetimibe 10 mg|
45364189|NCT04282187|Drug|Fedratinib|Given PO
45364190|NCT04282187|Other|Questionnaire Administration|Ancillary studies
45364191|NCT01015846|Other|Exercise|Redcord (sling exercise) and traditional exercise
45364192|NCT01015846|Other|Core stability exercise|Traditional core stability exercise
45364193|NCT04471246|Drug|Cephalexin|1000 mg PO QID for 7 days
45364194|NCT04471246|Drug|Cephalexin|500 mg PO QID plus oral placebo for 7 days
45364195|NCT04278521|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
45364196|NCT04276259|Drug|Buprenorphine|Buprenorphine is a μ-opioid partial agonist and kappa-opioid antagonist that is used to treat moderate to severe pain and opioid dependence. The intramuscular administered opioid agonist which will be used to modulate reward learning signals to understand placebo effects in patients with depression. In the buprenorphine condition, participants will receive one IM injection of 0.3mg/1ML buprenorphine hydrochloride (Buprenex®. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; 2006) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~6 hours) and an oral placebo tablet.
45364197|NCT04276259|Drug|Naltrexone|Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate reward learning signals to understand placebo effects in participants with depression. In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~24 hours) and a saline IM injection.
45364198|NCT04276259|Drug|Oral Placebo|Oral placebo: to match the oral naltrexone.
45364199|NCT04276259|Drug|IM Placebo|IM saline placebo: to match the i.v. buprenorphine.
45364200|NCT04276259|Device|Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.|Participants will receive two blocks of each TBS form. During the first block, stimulation intensity will be gradually escalated in 5% increments (from 80% to 110% rMT) in order to enhance tolerability. In all conditions, the investigators will apply 600 pulses of theta burst at 110% RMT. Each block of iTBS will consist of 20 trains, each lasting 2s with intertrain intervals of 8s, for a total of 192s. Each block of cTBS will consist of one continuous train of 40s. The sTBS will make use of two surface electrodes placed on the scalp.
45481938|NCT02723344|Dietary Supplement|of Lactobacillus reuteri (L. reuteri; DSM 17938)|Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.
45481939|NCT02723344|Other|Sunflower and medium chain triglyceride oils|Placebo
45481940|NCT01340118|Drug|Budesonide|once daily inhalation with 400 µg budesonide (dry powder)during 6 weeks
45481941|NCT03401398|Drug|Hydrocortisone, sodium succinate|Patients randomized to the hydrocortisone treatment arm will receive an initial bolus of 2 mg/kg IV hydrocortisone, followed by 1 mg/kg (maximum 50 mg) of hydrocortisone dosed every six hours for a maximum of seven days or until all vasoactive infusions have been discontinued for at least 12 hours, whichever comes first. When the hydrocortisone course is completed, the medication will be discontinued.
45481942|NCT03401398|Drug|Normal saline|Patients randomized to the placebo treatment arm will receive an equivalent volume of normal saline, with the identical dosing schedule to the intervention (hydrocortisone) arm.
45596547|NCT02741245|Drug|Rosuvastatin 2.5 mg|
46050456|NCT00797563|Device|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with capillary blood; healthcare professionals use the new blood glucose monitoring system with subject capillary and venous blood. All results are compared to a laboratory glucose method - Yellow Springs Instrument (YSI).
46050457|NCT00869440|Drug|CNS 7056|Administered as a single intravenous injection by a syringe driver over 1 minute
46050458|NCT00869440|Drug|Midazolam|Administered as a single intravenous injection by a syringe driver over 1 minute
46050459|NCT00895947|Drug|interferon-alpha|a lozenge for oral dissolution containing 150 international units of human interferon-alpha taken once daily for 16 weeks
46050460|NCT00895947|Other|placebo|placebo lozenges for oral dissolution taken once daily for 16 weeks
45481943|NCT01340274|Behavioral|CRAFT treatment|Clients will receive 12 sessions of CRAFT delivered over a 12 week period. There will be 1 session per week.
45364201|NCT03797651|Drug|Standard DAPT|Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.
45364202|NCT03797651|Drug|Very-short DAPT less than 1 month after PCI|Patient will stop aspirin (ticagrelor monotherapy) after discharge or within 1 month. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).
45364203|NCT05062109|Behavioral|Multimodal geriatric prehabilitation|"Multimodal prehabilitation will be carried out over a period of 6 weeks in a day admission (once a week) and at home, and will include:~Muscle rehabilitation developed with a physiotherapist or physical activity monitor~Nutritional support (dietitian at the 1st, 3rd, and 6th day admission (DA))~Cognitive and physical stimulation Exergame~Psychological support by a psychologist~Information in the form of videos on the main risks and important points to know and prepare before and after surgery~Assessment of patient satisfaction, any limitations encountered, the possible performance of exercises at home and the occurrence of any adverse effects.~One session of adapted physical activity at home of one hour per week by a physical trainer from the Siel Bleu association"
45364204|NCT00499486|Drug|sirolimus|Treatment with rapamycin will begin on Day 1 at a single flat dose level of 5 mg/day. Rapamycin will be administered continuously without interruption through all cycles in an outpatient setting. Each cycle will last 28 days.
45364205|NCT03794375|Other|Telehealth|After 45 days after the estimated date of the consultation (6 months after discharge), the Telehealth staff will contact the patient to check if the consultation was actually performed. When individuals report difficulty accessing the unit, contact will be made to the primary care teams and the Telehealth staff will schedule the appointment. A new contact will be made in 12 months to verify if the consultation was actually performed.
45364206|NCT03794375|Other|Usual care|The patients will remain in care at the HCPA thyroid disease outpatient clinic during the study period. This follow-up will be done by endocrinologists, and the patients will undergo clinical, biochemical (TSH, thyroglobulin, and antithyroglobulin) and radiological (cervical ultrasound) tests to seek disease recurrence. The patient's consultation will be done one or twice a year.
46050461|NCT02604823|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered at a dose of 180 mcg subcutaneously once weekly for 48 weeks.
46050462|NCT00869362|Other|Diabetes management team|MD evaluation followed by NP education and and medication titration
46050463|NCT00915187|Drug|CCS/C|Adjuvant to influenza vaccine
45364207|NCT01019278|Radiation|proton beam radiation therapy|Undergo external proton beam radiation
45481944|NCT01340274|Behavioral|Treatment as Usual|Clients will receive Treatment as Usual delivered over 12 session. There will be 1 session per week.
46050464|NCT00915187|Biological|Influenza Vaccine|Influenza vaccine
46050465|NCT04131400|Diagnostic Test|Visual Acuity Testing and Retinal Imaging|All clinical and para- clinical tests including visual acuity assessment, perimetry, optical coherence tomography (OCT), enhanced depth- OCT, OCT angiography, color fundus, autofluorescence and infrared fundus photography will be performed
45364208|NCT01019278|Radiation|radiation therapy treatment planning/simulation|
45364209|NCT01019278|Drug|cisplatin|Given IV
45364210|NCT02581241|Device|tilt table|"Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
45481945|NCT02470702|Drug|Oritavancin|
45481946|NCT02470702|Drug|Placebo (D5W)|
45481947|NCT05162508|Other|Nasopharyngeal swab|Nasopharyngeal swab available in Standard Of Care (SOC) will be analysed (Full-length SARS-CoV-2 RNA sequencing and Transcriptomic analyses)
45481948|NCT02469766|Procedure|SWL|Patients in this arm will undergo SWL
45481949|NCT02469766|Procedure|Semirigid URS|Patients in this arm will undergo semirigid URS
46050466|NCT02841579|Drug|Osimertinib|The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose.
46050467|NCT00588445|Drug|Gefitinib|"Patients will receive gefitinib 250 mg po daily for at least 21 days preoperatively (depending on the timing of the surgery). Treatment with gefitinib will be stopped 2 days before the date of surgery.~Patients who have had at least a minor response to gefitinib therapy preoperatively (> 25% reduction in tumor measured bidimensionally) and / or have mutations in the protein-tyrosine kinase domain of the EGF receptor gene identified will continue on the study and will resume gefitinib treatment after at least 7 days from surgery providing adequate wound healing has occurred.~Patients who are determined to be candidates for adjuvant chemotherapy and/or radiation therapy by their treating physician may receive treatment with adjuvant chemotherapy and/or radiation therapy. The post-operative gefitinib will be started after completion of the chemotherapy and/or radiation therapy."
46050468|NCT04118218|Other|Rhizolysis pain analysis|"Definition of the subgroup of good clinical outcome after rhizolysis (called effective rhizolysis) by lumbar VAS or lower extremity pain VAS or Oswestry index decreased at 6 weeks after rhizolysis.~The efficiency criterion based on the decrease in the dolorimeter or the Oswestry index corresponds to a decrease of at least 50% [1, 2, 3, 4]."
46050469|NCT00092781|Drug|MK0663, etoricoxib|
45690129|NCT04415593|Dietary Supplement|Low dose of peanuts|Patients will receive a low dose of ground peanuts (150 mg) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
45690130|NCT01393899|Drug|Placebo|oral tablets twice daily
46050470|NCT00092781|Drug|Comparator: celecoxib|
46050471|NCT04118296|Drug|Anti-Acne Preparations for Topical Use|Combination of anti acne cream that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%
45364211|NCT01014520|Drug|Gabapentin , Amitriptyline|"Capsule, 300 mg, oral, single dose 2 hours before surgery~Capsule,300 mg containing 25 mg Amitriptyline, oral, single dose 2 hours before surgery"
45364212|NCT04040699|Biological|KN026 combined with KN046|KN026 and KN046 are given at 20mg/Kg and 3mg/Kg intravenously on day 1of each 2 weeks cycle at the beginning respectively.The dosage will be escalated if adverse events are tolerated according to the scheme.
45690131|NCT01393899|Drug|CP-690,550|oral tablets twice daily
45690132|NCT01393899|Drug|CP-690,550|oral tablets twice daily
45690133|NCT01393743|Drug|Perampanel|
45690134|NCT01393743|Drug|Placebo comparator|
45690135|NCT02078193|Drug|Belatacept|Patients will be converted from their MMF to Belatacept
45690136|NCT01405911|Drug|Placebo for Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
46050472|NCT00092703|Drug|MK0663, etoricoxib|
46050473|NCT00092703|Drug|Comparator: Diclofenac sodium|
45481950|NCT02469766|Procedure|Flexible URS|Patients in this arm will undergo Flexible URS
45481951|NCT03635658|Procedure|titanium mesh|the non resorbable titanium mesh is used to fix the 1:1 mixture of autograft and xenograft particulate bone on the severely atrophies maxillary ridge.
46050474|NCT00699946|Drug|olanzapine|5 mg preoperative and 5mg postoperative prior to discharge to inpatient nursing floor
46050475|NCT00699946|Drug|placebo|placebo administered preoperatively and postoperatively prior to discharge to inpatient nursing floor
45364213|NCT01015924|Procedure|plate osteosynthesis|Patients are operated upon within 3 w of the fracture
45364214|NCT01015924|Procedure|ESIN|Elastiv stable intramedullary nailing
45481952|NCT03635658|Procedure|collagen membrane (Sausage technique)|the resorbable collagen membrane is used to fix the 1:1 mixture of autograft and xenograft particulate bone on the severely atrophies maxillary ridge.
46050476|NCT00796315|Drug|Doxylamine Succinate USP|One dose of liquid, dosing range 3.125mg/7.5mL - 12.5mg/30mL
45481953|NCT02723188|Device|Sham stimulation (1.5 milliampere,30 seconds)|
45481954|NCT02723188|Device|DC stimulation (1.5 milliampere, 20 minutes)|
45481955|NCT02723188|Device|AC stimulation (1.5 milliampere,1.5 Hertz frequency)|
45481956|NCT04422366|Biological|9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
46050477|NCT00855166|Drug|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 102 weeks
45481957|NCT04422366|Biological|GARDASIL®|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule
45481958|NCT01375582|Drug|B & L Soothe Lubricant Eye Drops|Eye Drop
45481959|NCT01375582|Drug|Liposic EDO|Eye Drop
46050478|NCT00855166|Drug|Metformin|Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks
46050479|NCT00855166|Drug|Sitagliptin|Tablet oral 100 mg total daily dose once daily rescue medication
46050480|NCT00855166|Drug|Placebo|Matching placebo for dapagliflozin, tablet, oral, once daily, 102 weeks
45481960|NCT01375582|Drug|OcuFresh Eye Wash|Saline drop
45481961|NCT03311074|Biological|Strimvelis|Strimvelis is a gene therapy that aims to restore ADA function in hematopoietic cell lineages and prevent the immunological manifestations. Strimvelis is a cluster of differentiation (CD) 34+ cell enriched dispersion of human bone marrow derived hematopoietic stem cells for infusion which have been transduced with a retroviral vector containing the human ADA gene.
45481962|NCT04409964|Drug|Dexmedetomidine Hydrochloride|dexmedetomidine iv bolus followed by the infusion of 0.1-1 ug/kg/hr during general anesthesia
45481963|NCT04409964|Drug|Lidocaine Hydrochloride|lidocaine iv bolus followed by the infusion of 1.5 mg/kg/hr during general anesthesia
46050481|NCT05336019|Behavioral|Diabetes self-management Coaching|A 12-week Diabetes self-management coaching program
46050482|NCT05336019|Other|Usual care|Assigned to 12 weeks of usual care which includes a physical examination, history taking,, medication refill, lab investigation, and health education
46050483|NCT00587587|Device|Apligraf|Application at Day 0, potential re-application at Week 4
46050484|NCT00587587|Other|Standard dressing regimen|A primary nonadherent dressing, dry gauze dressing and bolster gauze dressing if necessary
45481964|NCT04409964|Drug|Remifentanil Hydrochloride|remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
45481965|NCT03220282|Other|Donor milk|For late preterm newborns who are breastfeeding and whose mothers are not making enough breast milk yet to meet their nutritional needs, the study will compare the intervention of banked donor breast milk with the control of preterm infant formula.
46050485|NCT02843841|Other|Blood and fecal sample.|Blood (28 ml) and fecal sample at day 0, 4 days, 3 months and one year after transplantation
46050486|NCT04117828|Dietary Supplement|Dates|Phoenix dactylifera, commonly known as date or date palm is a flowering plant species in the palm family, Arecaceae. Dates are the fruit of the date palm tree, which is grown in many tropical regions of the world. Dates provide a wide range of essential nutrients, and has certain protective effects on health of individuals.
46050487|NCT04107259|Diagnostic Test|Blood sample|Ten ml of venous blood was collected from all participants in the early morning after an overnight 12 hour fast by venipuncture of the antecubital vein into sterile tubes. Plasma and sera were separated immediately and were stored at -70 C until biochemical analyses.
45364215|NCT04267367|Behavioral|Dietitian-led dietary approach to management of diabetes|In the intervention phase, the educational and diet plan package will be developed. All the intervention packages will be approved by a multi-disciplinary expert team comprising an endocrinologist and dietitian prior to the intervention. Patients in the usual care arm will receive routine care as to how he/she is practicing in their daily life. Routine care includes general knowledge on diabetes disease process, blood glucose monitoring, a healthy lifestyle, preventing treating diabetes complications and developing personalized strategies for the decision-making process[27]. The intervention package will include mainly two-phase, nutritional counseling emphasis on lifestyle modification of diabetes patients and individual basis diet plan for each T2DM patients for intervention arm. The nutrition education and counseling and individual diet plan will be applied by trained dietitians.
45481966|NCT03220282|Other|Preterm infant formula|Preterm formula determined by clinical practice
45596548|NCT02741245|Drug|Placebo for Ezetimibe|
45596549|NCT02741245|Drug|Placebo for Rosuvastatin|
46050488|NCT02841501|Genetic|Analysis of genetic polymorphisms|An analysis of the SNPs (single nucleotide polymorphism) of 25 candidate genes will be performed. This analysis will be completed by a genome wide association study.
45596550|NCT02202083|Other|Cook Balloon|"There are two groups. Acoording to the bishop score, one group uses the oxytocin , and the other uses the cook balloon.~This group is term gestaion,with bishop score less than 6."
46050489|NCT00854620|Drug|Sorafenib|Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID)
45364216|NCT04266574|Device|Near Infrared Spectroscopy (NIRS)|"The anesthesiologist will apply optodes before induction of anesthesia and before preoxygenation, to detect baseline NIRS level, NIRS will be monitored continuously up to post-anaesthesia care unit (PACU) discharge, or up to three the investigator's after ICU admission.~When a decrease in NIRS value over 10% is detected, or if NIRS value is below 60%, patients will start hemodynamic optimization, to reverse the reduction in NIRS and return to baseline values, according to a predefined protocol."
45690137|NCT01405911|Drug|Placebo for Sitagliptin 50 mg|1 tablet orally once daily before breakfast for 8 weeks
46050490|NCT02178657|Drug|Autologous bone marrow mononuclear cell intra-arterial injection|
45364217|NCT04266574|Device|Standard Care|Controls will be treated according to standard of care, maintaining a MAP≥65 and an adequate cardiac output according to the hemodynamic monitoring chosen by the anesthesiologist (invasive blood pressure monitoring or pulse contour monitors). NIRS will be recorded also in controls, but caring anesthesiologists will be blinded to NIRS.
45690138|NCT01405911|Drug|Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
45690139|NCT01405911|Drug|Sitagliptin 50 mg|1 tablet orally once daily before breakfast for 8 weeks
45690140|NCT01425801|Drug|LAS100977 0.313 μg|Dry powder inhalation, once-daily, single-dose
45690141|NCT01425801|Drug|LAS100977 0.625 μg|Dry powder inhalation, once-daily, single-dose
46050491|NCT00793585|Drug|allopurinol|Patients will receive the lifestyle modification and treatment of allopurinol (300 mg /d) and lifestyle modification for 4 weeks; when the UA level < 6mg/dl , the dosage changed to 200mg/d.
45481967|NCT04328376|Diagnostic Test|ECG coupled to phonocardiography|"A standard ECG is recorded along with a phonocardiographic recording. The phonocardiographic recording is obtained by using a specific electronic stethoscope plugged into the auxiliary port of the ECG machine. The recording takes less than 30 seconds. The two recording methods are concomitant.~QT interval is measured on the ECG recording, EMW is measured with ECG coupled to phonocardiography."
45596551|NCT02368353|Other|Cognitive behavioral therapy|
45596552|NCT02368353|Other|Supportive therapy|
45690142|NCT01425801|Drug|LAS100977 1.25 μg|Dry powder inhalation, once-daily, single-dose
45690143|NCT01425801|Drug|LAS100977 2.5 μg|Dry powder inhalation, once-daily, single-dose
45690144|NCT01425801|Drug|Salbutamol 400 μg|Pressurized inhalation suspension, once-daily, single-dose
46050492|NCT00793585|Other|continue their usual therapy|Patients will receive lifestyle modification and continue their usual therapy.
46050493|NCT02013141|Drug|Telavancin|
46050494|NCT04107103|Drug|Combination Product: Nivolumab with Pemetrexed|Nivolumab 3 mg/kg IV q.2 weekly in combination with pemetrexed 500mg/m2 q.6weekly. Treatment with nivolumab will continue every 14-days, and pemetrexed treatment will continue every 42-days. Treatment continues until disease progression or toxicity resulting in treatment discontinuation or until 2 years of treatment.
46050495|NCT04133818|Behavioral|Multidisciplinary education and exercise therapy program|"Multidisciplinary program: one and a half day of education and exercise therapy about low back pain :~Lectures and explanations about low back pain~Physical activity~Relaxation"
46050496|NCT02841423|Procedure|neuropsychological test battery|
45481968|NCT03310996|Other|Transcranial direct current stimulation|tDCS is an established research tool for non-invasive modulation of neuroplasticity. It has shown promise as a neurorehabilitation tool and demonstrated positive effects in various clinical conditions such as Alzheimer's, stroke, childhood psychosis, epilepsy and dystonias. tDCS uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential.
45481969|NCT01342146|Drug|pegylated Somatropin|0.1 mg/kg/wk once a week for 25 weeks
45481970|NCT01342146|Drug|pegylated Somatropin|0.2 mg/kg/wk once a week for 25 weeks
45481971|NCT01342146|Drug|Jintropin AQ|0.25 mg/kg/wk, once a day for 25 weeks
45481972|NCT02471092|Other|Skim milk products|Milk treatments will be served with 58g of breakfast cereal.
45481973|NCT05184270|Device|Acoustic stimulation|"In this project, the intervention is a presentation of low-volume non-arousing auditory stimuli during deep NREM sleep via attached headphones. Stimuli will be applied targeting the up-phase of slow waves to enhance sleep slow-wave activity.~Previous studies showed that this procedure does not lead to reduced sleep quality nor result in changed sleep architecture. Therefore, no negative consequences as a result of our intervention are to be expected. In fact, it is currently applied in several other studies including children, adults, and the elderly. Importantly, stimulation is not arousing, as the sounds presented during deep sleep are brief (50 ms) and at low volume (around 50 dB). In case of arousal during sleep (detected using the surface EEG signal), the volume will be adjusted."
45481974|NCT03212716|Drug|Oseltamivir|150 mg twice a day during 10 days (ANSM guidelines for severe flu).
45690145|NCT01425801|Drug|Salbutamol placebo|Pressurized inhalation, once-daily
46050497|NCT04109287|Device|REVITIVE® device|The REVITIVE® device applies neuromuscular electrical stimulation to the soles of the feet, causing the muscles of the leg to contract and relax, thus improving blood circulation through the legs.
46050498|NCT02841345|Other|behavioral and fMRI|"The experience will include 3 sessions. Each session will consist of the presentation of a pseudo-random sequence of 24 black and white images of negative emotional natural scenes, 24 positive emotional situations and 24 neutral emotional situations.~In the first session, participants will carry out an emotional assessment task: it will show at the end of each test his emotional feeling - pleasant, unpleasant or nothing - using a joystick.~In a second session, the participant will perform a motor task decision: it will show at the end of each test the tendency to action he would handle the situation actually using 3 buttons également- approach withdrawal or neither one nor the other.~In the third session, the participant will perform a simple visual perception task. To be comparable to the engine plane with the other sessions, a non-categorical motor task will be requested from participants."
45481975|NCT03212716|Drug|Diltiazem|60 mgx3 per day during 10 days.
45690146|NCT01425801|Drug|LAS100977 placebo|Dry powder inhalation, once-daily
45690147|NCT03025503|Other|nipple stimulation|
45690148|NCT02335125|Behavioral|Motivational Interviewing|
45690149|NCT02335125|Behavioral|Cognitive Behavioral Therapy Elements|
45690150|NCT02335125|Drug|Psychotropic Drugs|
45690151|NCT02335125|Other|Care Management|
46050499|NCT02617810|Drug|JNJ-42847922|Participants will receive JNJ-42847922 20 milligram (mg) tablet orally once daily from Day 1 to Day 9.
46050500|NCT02617810|Drug|Midazolam|Participants will receive midazolam 4 milligram (mg) syrup orally once on Day 1 during treatment A and on Day 7 during treatment B.
45690152|NCT01425723|Biological|rFIXFc|Administered as specified in the treatment arm.
46050501|NCT02617810|Drug|Warfarin|Participants will receive warfarin 25 milligram (mg) tablet orally once on Day 3 during treatment A and on Day 9 during treatment B.
46050502|NCT04111237|Behavioral|Two Finger technique|two finger method for chest compression provuision
46050503|NCT04111237|Behavioral|Two Thumb Technique|Two thumb technique
46050504|NCT00898443|Other|Epidural anesthetic|Use of the existing continuous labor epidural for surgical anesthetic for postpartum tubal ligation
46050505|NCT00898443|Other|Spinal anesthetic|This group was assigned to receive spinal anesthetic for postpartum tubal ligation.
46050506|NCT02614612|Drug|Itacitinib (200 mg)|
45481976|NCT03212716|Drug|Placebos|Placebo of diltiazem
46050507|NCT02614612|Drug|Itacitinib (300 mg)|
46050508|NCT02614612|Drug|prednisone or methylprednisolone (corticosteroids)|All subjects will receive prednisone 2.5 mg/kg per day PO (or methylprednisolone 2 mg/kg IV daily) on Days 1 through 5. Subjects will be tapered as tolerated beginning on Day 6 to no less than 0.25 mg/kg per day PO (or methylprednisolone 0.2 mg/kg per day) by Day 28. After Day 28, corticosteroids should be tapered according to institutional guidelines to attain ≤ prednisone 0.2 mg/kg per day (or ≤ methylprednisolone 0.16 mg/kg per day) by Day 56.
46050509|NCT00900159|Drug|eszopiclone|3mg eszopiclone prior to daytime sleep for 3 days (at home) and 1 day (in lab)
45481977|NCT03310840|Other|others|others
46050510|NCT00900159|Drug|matching placebo|matching placebo prior to daytime sleep for 3 days (at home) and 1 day (in lab)
45481978|NCT05184114|Diagnostic Test|Cardiac Magnetic Resonance, Blood Tests|Imaging, blood investigations (white cell count, C-reactive protein, NT-proBNP, lactate dehydrogenase and high sensitivity troponin)
45481979|NCT02469922|Device|Positron emission tomography|
45481980|NCT02469922|Radiation|radiochemotherapy|Every patients will be treated with radiochemotherapy as a standard of care
45481981|NCT04762836|Drug|D-cycloserine|Antibiotic medication that augments the function of NMDA-receptors
45481982|NCT04762836|Behavioral|Conditioning|During nocebo acquisition trials, the conditioned stimulus (i.e., activation of a sham electrode that can increase pain sensitivity, is paired to unconditioned high-pain stimuli (nocebo trials). During control trials of the acquisition phase, moderate-pain stimuli are paired to no sham electrode activation.
45481983|NCT04762836|Behavioral|Extinction|During nocebo extinction, moderate pain stimulations are administered both after the administration of the conditioned stimulus (i.e., activation of the sham electrode) and the control stimulus (no activation of the sham electrode), in order to evoke nocebo responses to the sham hyperalgesic procedure.
45847802|NCT02963376|Drug|0.05 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.05 mL/kg is based on patient body weight in kilograms (kg).
45847803|NCT02963376|Drug|0.10 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.10 mL/kg based on patient body weight in kilograms (kg).
45364218|NCT01016002|Drug|Temoporfin|"Drug treatment: Temoporfin 0.15 mg/kg body weight, intravenous injection within at least 6 min.~Laser Treatment: 652nm wavelength; 30 Joules/cm diffusor length ( 200 sec at 150mW/cm diffusor length), within 96 h after Foscan"
45364219|NCT01016080|Drug|glutathione|250 mg capsules, twice daily, orally
45364220|NCT01016080|Drug|placebo|250 mg capsules, twice daily, orally
45364221|NCT01019434|Drug|temozolomide|TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
45364222|NCT01019434|Drug|temsirolimus|CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
45364223|NCT01016158|Drug|Umbilical cord serum eyedrops|20% umbilical cord serum eye drops 3 to 4 times a day
45481984|NCT04762836|Other|fMRI|In both arms of the study, BOLD response data will be collected with fMRI during the acquisition and extinction of nocebo effects on pain.
45364224|NCT04024631|Other|75g glucose beverage (Glucola, Trutol, or similar brand)|Subjects will present fasting to the study day and ingest the glucose beverage during the oral glucose tolerance test.
45481985|NCT04762836|Drug|Placebo|Placebo control in oral form
45364225|NCT04024631|Other|DXA, whole body|Subjects will undergo a whole body DXA scan for assessment of adiposity index and body fat distribution.
45364226|NCT05325671|Procedure|transarticular multimodal drug infiltration|as described previously
45364227|NCT00499252|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|
45364228|NCT00499174|Procedure|conventional surgery|Radical prostatectomy
45481986|NCT04755660|Behavioral|Exercise behavior change for resistance exercise|The intervention includes motivational interviews and self-efficacy theory-based exercise behavior and home-based resistance exercise intervention (by Elastic Band or non- Elastic Band ), and 3 follow-up telephone calls. The usual care group will receive exercise counseling.
45481987|NCT00705406|Drug|Peramivir|600 mg peramivir administered as bilateral 2-mL intramuscular injection
45481988|NCT00705406|Drug|Placebo|Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
45481989|NCT04318314|Diagnostic Test|COPAN swabbing and blood sample collection|COPAN swabbing of nostrils and/or oropharynx and blood sample collection
45690153|NCT02076243|Drug|nab-paclitaxel|nab-paclitaxel (abraxane) administered weekly (days 1,8, and 15 of 28 day cycle) to patients with unresectable locoregional or distantly metastatic cutaneous squamous cell carcinoma (SCC).
45690154|NCT01424397|Drug|SB-705498|12mg intranasal
45847804|NCT02963376|Drug|0.10 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.10 mL/kg is based on patient body weight in kilograms (kg).
45690155|NCT01424397|Drug|FP|200ug intranasal
45690156|NCT01424397|Drug|placebo|placebo intranasal
45690157|NCT01392963|Drug|botulinum toxin type A neurotoxin complex|29-40 U injection
45690158|NCT01392963|Drug|Placebo|29-40 U 0.9% NaCl injection
45364229|NCT00499174|Radiation|brachytherapy|high dose rate temporary seed implant; permanent seed implant.
45364230|NCT00499174|Radiation|external beam radiation therapy|3D conformal radiation therapy; intensity modulated radiation therapy.
45364231|NCT00499174|Procedure|Biopsies|Periodic repeat biopsies
45364232|NCT01019512|Other|questionnaire administration|Ancillary studies
45364233|NCT01019512|Other|lymphedema management|
45364234|NCT01019590|Drug|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
45364235|NCT01019590|Drug|Benicar HCT ® Tablets 40 mg/25 mg|
45364236|NCT03775421|Drug|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
45364237|NCT04130620|Diagnostic Test|Applied Kinesiology|An Applied Kinesiology muscle test will be supplemented by a single blood draw for validation.
45364238|NCT01016314|Device|Aspen Spinous Process System|Aspen Spinous Process System is an interspinous process fixation device
45364239|NCT01016314|Device|Pedicle Screw Fixation|Pedicle Screws are used for the fixation of the spine
45364240|NCT01014676|Dietary Supplement|Probiotic|
45364241|NCT01014676|Other|Placebo|
45364242|NCT05325437|Procedure|Laparoscopic splenectomy and azygoportal disconnection|The laparoscopic splenectomy and azygoportal disconnection was performed by the same surgical team.
45364243|NCT00532155|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|6 mg/kg Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
45481990|NCT01342224|Biological|tadalafil and vaccination|Participants receive a 4-week course of vaccination with telomerase vaccine and GM-CSF by injection, along with a cycle of gemcitabine chemotherapy (IV). This is followed by radiation and gemcitabine given twice weekly then by another dose of vaccine. Four weeks after completion of chemotherapy and radiation, participants able to have surgical treatment will have surgery followed by vaccination and chemotherapy. Participants with stable or responsive disease that cannot be treated by surgery will have vaccination and chemotherapy with 2 cycles of telomerase vaccine with GM-CSF along with gemcitabine. Participants with unresectable and progressive disease after administration of vaccine, chemotherapy and radiation treatment may transition to vaccination and chemotherapy treatment.
45481991|NCT01342302|Behavioral|Psychosocial Intervention for Couples|Intervention delivered on line
45847805|NCT02963376|Drug|0.17 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.17 mL/kg based on patient body weight in kilograms (kg).
46050511|NCT02843997|Genetic|Endophenotype and sequencing|Draw an endophenotype and genetic study
45364244|NCT00532155|Drug|Placebo|Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
45364245|NCT00532155|Drug|Docetaxel (Taxotere®)|75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.
45364246|NCT00532155|Drug|Dexamethasone (pre- and post-medication for docetaxel)|As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).
45364247|NCT01019668|Drug|Verteporfin PDT, half-dose|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
45364248|NCT01019668|Drug|verteporfin PDT, half-fluence|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
45364249|NCT04076345|Diagnostic Test|Prespesin assay on PATHFAST analyser|"Collection of parental non-opposition by the doctor taking care of the child. Addition of an additional 500μl tube to the usual blood sampling as part of the protocol for the management of children under 3 months of age with fever. This blood test contains CRP, PCT, NFS, Hemoculture.~There is no additional venipuncture. This blood sample is taken by the nurse after parental non-opposition. Transfer of the sample to the laboratory. In the laboratory, centrifugation of the sample, taking the plasma alone which will be frozen.~Delayed assay of presepsin, in series, after thawing of samples. Collection of data and analyzes by the principal investigator in collaboration with the statistician methodologist.~The immunoassay of presepsin with PATHFAST is based on chemiluminescence."
45364250|NCT01019746|Drug|propofol|propofol administration
45364251|NCT03764033|Behavioral|Impact of Killing (IOK)|Participants in this arm will receive 10 sessions (60-90 minutes) of a cognitive-behavioral moral injury treatment called IOK .
45364252|NCT03764033|Behavioral|Present Centered Therapy|Participants in this arm will receive 10 sessions (60-90 minutes) of a PTSD treatment that does not focus on trauma or cognitive restructuring, but rather the functional impact of trauma called Present Center Therapy (PCT)
45364253|NCT00205777|Drug|Bazedoxifene Acetate|BZA 20mg, daily, oral
45364254|NCT00205777|Other|Placebo|Placebo, daily, oral
45364255|NCT03762395|Drug|CXA-10|6 weeks of treatment with 150 mg/day of orally administered CXA-10
46050512|NCT05334693|Biological|Expanded haploidentical NK cells|Two doses of expanded haploidentical NK cells (30-100 x 10^6 cells /kg).
46050513|NCT02840955|Device|Staphefekt SA.100|
46050514|NCT02840955|Other|Placebo|
46050515|NCT01689909|Drug|Zolpidem-CR|Zolpidem 6.25 mg or 12.5 mg in tablet form at nighttime 15 minutes before bed for 8 weeks
46050516|NCT01689909|Drug|Placebo|Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks
46050517|NCT00854308|Drug|Erlotinib HCl|Erlotinib 150 mg oral dose once daily.
46050518|NCT00854308|Drug|MetMAb|MetMab (a monovalent antagonist antibody to the receptor MET) 15 mg/kg in 250 CC 0.9% saline intravenous infusion every 3 weeks.
46050519|NCT00854308|Drug|placebo (0.9 % saline)|Placebo Intravenous infusion every 3 weeks.
45364256|NCT03762395|Drug|Matching Placebo|6 weeks of treatment with orally administered matching placebo (to 150 mg/day of CXA-10)
45364257|NCT01000389|Device|Grindcare® (Biofeedback)|Active treatment with functional electrical stimulation
45364258|NCT05674097|Other|no intervention|no intervention
45364259|NCT01004055|Device|Procellera™ Antimicrobial Wound Dressing|Dressing indicated for partial and full-thickness wounds. Dressing changes every 2-3 days, more frequently if needed
45364260|NCT01004055|Drug|ACTICOAT™ Antimicrobial Barrier Dressing|Dressing changes every 2-3 days, more frequently if needed
45364261|NCT01004055|Drug|Mepilex® Ag Silver Foam Dressing|Dressing changes every 2-3 days, more frequently if needed
45364262|NCT03748511|Other|fibroscan and stool sample|patients undergo ultrasaound (fibroscan) in order to stage the liver disease.
45364263|NCT00483652|Drug|Fampridine-SR|Tablets, 10 mg, twice daily, 9 weeks
45364264|NCT00483652|Drug|Placebo|placebo (sugar pill)
45364265|NCT04000425|Combination Product|AVENIO ctDNA surveillance kit|AVENIO circulating tumor DNA (ctDNA) Analysis Kits is a portfolio of three next-generation sequencing (NGS) liquid biopsy assay kits for oncology research: the AVENIO ctDNA Targeted Kit, Expanded Kit and Surveillance Kit.
45364266|NCT03742791|Drug|TS-134|5 mg to 80 mg oral solution
45481992|NCT03186508|Behavioral|Optimize Sleep (OS)|"All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact."
45481993|NCT03186508|Behavioral|Optimize Sleep-Plus (OS-Plus)|"All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact."
45481994|NCT03155178|Drug|3M CHG/IPA Prep|Apply topically to intact dry skin (abdominal site) for 30 seconds or moist skin (inguinal site) for 2 minutes.
45481995|NCT03155178|Drug|ChloraPrep|Apply topically to intact dry skin (abdominal site) for 30 seconds or moist skin (inguinal site) for 2 minutes.
45847806|NCT02963376|Drug|0.17 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.17 mL/kg is based on patient body weight in kilograms (kg).
45847807|NCT02967354|Radiation|Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan|Estimation of islet mass by PET using the tracer [11C]5-hydroxy-tryptophan
45364267|NCT03742791|Drug|Placebo|Matched Placebo oral solution
45364268|NCT04245683|Procedure|Bowel/rectal resection|surgical removal of the portion of the rectum where the tumor was originally identified
45364269|NCT04245683|Other|non-operative follow up|patients who choose the non-operative option will be required to adhere to a very intensive follow up protocol, including endoscopy and CT imaging
45364270|NCT00998283|Drug|HM10460A 5μg/kg|Subcutaneously administrate at 0 hour on Day 1
45364271|NCT00998283|Drug|HM10460A 15μg/kg|Subcutaneously administrate at 0 hour on Day 1
45364272|NCT00998283|Drug|HM10460A 45μg/kg|Subcutaneously administrate at 0 hour on Day 1
45364273|NCT00998283|Drug|HM10460A 135μg/kg|Subcutaneously administrate at 0 hour on Day 1
45364274|NCT00998283|Drug|HM10460A 350μg/kg|Subcutaneously administrate at 0 hour on Day 1
45364275|NCT00998283|Drug|Placebo|Subcutaneously administrate at 0 hour on Day 1
45364276|NCT01014832|Drug|Intensive insulin therapy|Intensive insulin therapy
45364277|NCT03996473|Drug|Radium-223 dichloride (Xofigo, BAY 88-8223)|Intravenous (IV) injection, every 6 weeks for up to 6 administrations
45364278|NCT03996473|Drug|Pembrolizumab|IV infusion, every 3 weeks for a maximum of up to 35 administrations
45364279|NCT04075565|Behavioral|Terrestrial altitude|Terrestrial altitude: The volunteers are in an SAC hut at an altitude of 3000 m. By means of this exposure the psychophysiological effect under hypobaric and hypoxic conditions is determined. The subjects spend the night in this SAC hut and the measurements are repeated the next day.
45364280|NCT04075565|Behavioral|Cloud 9|"Cloud 9 is a solid, certified product that complies with European Directives on Electromagnetic Compatibility, Machine Directive, Air Pressure Equipment and Low Voltage Equipment (89/336 / EEC, 91/368 / CEE, 93/68 / CEE, 97/23 / EC, EN61010-1 All directives are in writing in the Supplements to this Ethics Application.~Simulated height: The subjects are in the laboratory of our institution and are connected to the Cloud 9 by means of a mask. Subjects are exposed to a simulated altitude of 3530m under normobaric conditions. By means of this intervention the psychophysiological effect under normobaric and hypoxic conditions is determined."
45364281|NCT01004211|Procedure|Narrow band imaging transurethral resection|Transurethral resection of bladder lesion by mean of narrow band imaging
45364282|NCT01004211|Procedure|Standard transurethral resection|Transurethral resection of bladder lesion by mean of standard white light
45364283|NCT02580461|Behavioral|A 24 week center-based structured exercise and education program|The intervention will consist of a strength and aerobic exercise program. The exercise program will include twice weekly group resistance exercises classes, twice monthly group education classes, and individual activities to achieve 150 weekly minutes of aerobic activity. The resistance exercise and education classes will be run at a gym space at the University of Calgary. The wait-list control participants will be told not to change their activity levels throughout the 12 weeks of the trial. The wait list control participants will be enrolled into the exercise and education intervention once they have completed 12 weeks of wait-list control. A 12 week maintenance exercise program will be offered to all participants who finish the 12 week exercise and education program. The maintenance exercise program will consist of once weekly resistance group based exercise classes and individual activities to achieve 150 weekly minutes of aerobic physical activity.
45364284|NCT01004289|Procedure|Postconditioning|Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion
46050520|NCT02617498|Device|harmonic scalpel|parenchymal liver transection was performed either by harmonic scalpel after demarcation of line of transection by intraoperative US and doppler.
45364285|NCT01004289|Procedure|Primary angioplasty and stenting without additional intervention|Primary angioplasty and stenting without additional intervention.
45364286|NCT03745079|Other|Esophagus temperature monitoring|Measuring core temperature by esophageal stethoscope
45364287|NCT03745079|Other|Spoton Temporal|Mesuring temperature on skin near to temporal artery using Spoton
45364288|NCT03745079|Other|Spoton Carotid|Mesuring temperature on skin near to carotidl artery using Spoton
45481996|NCT02470546|Drug|Metformin|Metformin 1000mg twice a day
45481997|NCT02470546|Drug|Placebo|Placebo 1000mg twice a day
45481998|NCT01315626|Other|Primary Care Educational event|The purpose of this study is to assess the accuracy of primary care physicians in diagnosing BE and evaluate the impact of an educational intervention targeting those primary care physicians and providing instruction in the recognition and treatment of BE. The hope is that a better understanding of the disease will result in more accurate diagnoses and ultimately in more appropriate care for these patients. In addition to better care for patients, earlier recognition of bronchiectasis may result in a decrease in health care costs.
45481999|NCT03310762|Other|Alma Sana Bracelet|Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
45482000|NCT03310762|Other|Simple Silicon Bracelet|Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
45482001|NCT05158920|Behavioral|Mindfulness-Based Cognitive Therapy for Suicidal individuals (MBCT-S)|MBCT-S is a group intervention of 8 weekly sessions of 2 hours combining techniques of mindfulness with important elements of cognitive therapy (e.g. safety plan and homework).
45482002|NCT03310606|Other|Dosage of serum and peritoneal of the B lactam used for antibiotic treatment|Dosage of serum and peritoneal of the B lactam used B lactam concerning are : CEFTRIAXONE, CEFOTAXIME, PIPERACILLINE/TAZOBACTAM, IMIPENEM
45482003|NCT01315704|Drug|Drug intervention|before-after interventional (anti-dementia drugs and/or vitamin D) study
45482004|NCT03107884|Drug|Metformin (Bed Rest)|A clinical oral dose of Metformin will be given to participant daily during bed rest
45482005|NCT03107884|Drug|Placebo (Bed Rest)|Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin treatment group
45482006|NCT03107884|Drug|Metformin (2 week run-in only)|A clinical oral dose of Metformin will be given to participant daily during a two week run-in period only.
45482007|NCT03107884|Drug|Placebo (2 week run-in only)|Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin 2 week run-in treatment group.
45847808|NCT02967510|Drug|Estriol|
45847809|NCT02967510|Drug|Placebo|
45847810|NCT02968134|Drug|Posaconazole|A single dose of 300mg intravenous posaconazole will be administered and blood samples will be taken prior to start of infusion, at 15,45,75minutes, 3,5,8,12,18,24,30,36 and 48 hours.
45847811|NCT02968368|Drug|Ferric maltol|
46050521|NCT02617498|Device|spray mode diathermy|parenchymal liver transection was performed either by spray mode diathermy after demarcation of line of transection by intraoperative US and doppler.
46050522|NCT04201587|Other|Henna application|Henna application was performed to the patients in the intervention group. The patient was instructed to apply henna before going to bed at night, and after waking up in the morning (for an average of 8-10 hours) was instructed to wash with only water. The patient was asked to do this application at home after the second and third chemotherapy cycles. Thus, the patient applied henna twice in total (fifteen days apart).
45364289|NCT01000545|Drug|Sulodexide|SLX 500 LRU, SLX 1000 LRU, SLX 2000 LRU per day to be taken orally for 12 months.
45364290|NCT01000545|Drug|placebo capsules|8 soft-gel capsules per day to be taken orally for 12 months
45364291|NCT03992729|Drug|Pregnant women exposed to tildrakizumab|Subjects exposure to tildrakizumab for the treatment of an approved indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy
45847812|NCT02968368|Other|Placebo|
45364292|NCT03992729|Drug|Pregnant women not exposed to tildrakizumab|Subjects diagnosed with a tildrakizumab-approved indication; frequency matched to the exposed group by disease indication, with the indication validated by medical records when possible, and Subjects with no exposure to tildrakizumab at any time in the current pregnancy; may or may not have taken another medication for their disease in the current pregnancy
45845740|NCT05696184|Diagnostic Test|Concurrent manometry/impedance/pH with video pharyngo-laryngoscopy|"Combined manometric/impedance/pH recording: we will use combined solid-state high-resolution manometry and impedance catheter with 36 circumferential pressure sensors, spaced 1 cm apart, 18 impedance sensor couplets spaced 2 cm apart, 3 pH sensors spaced 7 and 10 cm respectively. The catheter will be introduced trans-nasally.~Concurrent video-pharyngo-laryngoscopy: to monitor concurrently the pharynx and larynx for entry of simulated refluxate we will use a laryngo-pharyngo-scope passed through the other nostril and positioned within the pharynx such that the UES inlet, vocal cords and pyriform sinuses are visualized. The laryngo-pharyngo-scope images will be synchronized with manometric/impedance/pH recordings by importing and superimposing the endoscopic images onto high resolution manometric recordings. A specially designed timer will be superimposed on the video images for durational analyses of endoscopic images."
45845741|NCT05696184|Diagnostic Test|Slow and rapid intra-esophageal infusion|A 3 mm outer diameter injection tube will be placed through the nose in a fashion that the injection port will be located 5-7cm above the manometrically determined upper border of lower esophageal sphincter (LES). With this arrangement gastroesophageal reflux events will be simulated by intra-esophageal injection of body temperature1/2 normal saline (its ionic nature helps impedance recording and identification of intra-esophageal distribution), 0.1 N HCl. Infused liquid will be colored green using food dye for ease of recognition of pharyngeal reflux. Esophageal clearance will be verified by the presence of an effective peristalsis and return of intra-esophageal impedance and pressure to baseline. Endoscopic views of pharynx will be watched carefully during infusions. At the first sign of reflux, perfusion will be stopped, and participants will be instructed to swallow to avoid any potential airway compromise.
45482008|NCT05184036|Diagnostic Test|Low Vision|"The application of a questionnaire evaluating the functionality and quality of life and records several of the daily life of Greek LV patients.~The evaluation of the basic parameters of visual function included in the LIFE4LV platform in order to evaluate the effectiveness of this platform in correlation with the routine ophthalmologic exams.~The evaluation of existing digital supportive tools for LV and record of the patient's feedback"
45845742|NCT05694156|Other|Music-based cognitive training|8-week music-based cognitive training
45364293|NCT00483574|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, IM at age 9 and 12 months
45364294|NCT00483574|Biological|Measles-mumps-rubella-varicella vaccine|0.5 mL, intramuscular at 12 months of age
45364295|NCT00483574|Biological|Routine paediatric vaccine - Pneumococcal conjugate (PCV)|0.5 mL, Intramuscular at age 12 months
45482009|NCT05158608|Drug|Post-transplantation Cyclophosphamide at dose 25 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 25 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
45690159|NCT01392573|Drug|insulin degludec/liraglutide|IDeg/Lira treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDegLira is injected subcutaneously (under the skin) once daily.
45482010|NCT05158608|Drug|Post-transplantation Cyclophosphamide at dose 50 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 50 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
45690160|NCT01392573|Drug|insulin degludec|IDeg treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDeg is injected subcutaneously (under the skin) once daily.
45690161|NCT01392495|Drug|Imatinib|200 mg or 400 mg qd
45845743|NCT05683392|Device|t:slim X2 insulin pump with Control-IQ technology 2.0|t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor.
45690162|NCT01405053|Drug|Rufinamide|Rufinamide up to 45 mg/kg/day, in 2 divided doses, administered as oral suspension (40 mg/mL) as an add-on to the subject's existing regimen of 1-3 antiepileptic drugs (AEDs)
45690163|NCT01405053|Drug|Any other approved Antiepileptic Drug|Any other approved AED: any other approved AED of the investigator's choice as an add-on to the subject's existing regimen of 1-3 anti-epileptic drugs (AEDs)
45690164|NCT01403805|Biological|Pneumococcal vaccination (Pneumovax NP, 21800AMY10131000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
45690165|NCT01403805|Biological|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
45364296|NCT00483574|Biological|Routine paediatric vaccine - Hepatitis A|0.5 mL, Intramuscular at age 12 months
45364297|NCT01000623|Drug|venlafaxine|Given orally
45364298|NCT01000623|Drug|placebo|Given orally
45364299|NCT01000623|Procedure|hypnotherapy|Practice hypnosis
45364300|NCT01000623|Procedure|mind-body intervention procedure|Practice focused attention
45364301|NCT00998361|Procedure|Allogeneic hemopoietic stem cell transplant|administration of 15 mg/kg of thiotepa + 140 mg/sqm of melphalan followed by infusion of allogeneic hemopoietic stem cell
45364302|NCT00483184|Biological|Veldona,|Very low dose oral natural human interferon alpha lozenges
45690166|NCT01403805|Biological|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
45482011|NCT01342536|Behavioral|Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)|"The OHDC is a culturally adapted, cognitive behavioral group counseling intervention. The OHDC is theoretically grounded in social learning theory and an Afrocentric paradigm (Nguzo Saba). It uses a social support group and psychoeducation format so participants learn skills to help them in coping and reducing symptoms of depression. The OHDC is offered over 13 weeks with 2-hour sessions in a clinical setting.~The CWD, an evidence-based cognitive behavioral depression intervention. The CWD is offered over 8 weeks with 2-hour sessions in a clinical.~Arms: lifestyle counseling (OHDC), lifestyle counseling (CWD)"
45845744|NCT05680116|Device|MYOVOLT (MyovoltTM, Myovolt Limited, Christchurch, New Zealand ) wearable vibration therapy device|Patients will wear Myovolt shoulder device twice a week and each session will continue 30minutes. This therapy will apply during the radiotherapy process. The device will be applied on the bare skin of the shoulder area. The first 10 minutes of the 30 minutes will be intermittent vibration, the other 20 minutes will be done in the sinusoidal vibration program. Both programs will be in the range of 20-100 Hz.
45482012|NCT04702776|Drug|Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%|Application of one drop of Humylub Ofteno® PF (Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%) QID in both eyes (OU) during 30 days.
45364303|NCT00998439|Device|SeQuent® Please|"6 F, 7 F, or 8 F guiding catheters have to be used~after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~ISR must be predilated with uncoated balloon~balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~inflation time has to be ≥ 30 sec~select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~each Paclitaxel-eluting balloon catheter is allowed for single use only~additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
45482013|NCT04702776|Drug|Sodium hyaluronate 0.15%|Application of one drop of Hyabak® PF (Sodium hyaluronate 0.15%) QID in OU during 30 days.
45482014|NCT04702776|Drug|Sodium hyaluronate 0.4%|Application of one drop of Lagricel Ofteno® PF (Sodium Hyaluronate 0.4%) QID in OU during 30 days.
46050523|NCT05334537|Other|Aromatherapy|Ninety-six patients aged between 18 and 45 years, with a height of ≥156 centimeters (cm), and a gestational age of >37 weeks, in the ASA II risk group, who were scheduled for elective CS under spinal anesthesia, were included in the study. Patients who were to undergo lavender aromatherapy with an oxygen mask after the birth of the baby were randomly divided into two groups: aromatherapy (A) (n=48) and control (C) (n=48), who inhaled odorless essential oil. Participants were admitted to the preoperative preparation room 20 min before the operation, and their age, height, weight, and ASA risk scores were recorded after their informed consent was obtained. They were monitored and sent to the operating room after their baseline anxiety levels were measured and recorded using the Visual Analog Scale (VAS) for pain and State-Trait Anxiety Inventory (STAI-I).
45364304|NCT00998439|Device|SeQuent® II|"6 F, 7 F, or 8 F guiding catheters have to be used~after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~ISR must be predilated with uncoated balloon~balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~inflation time has to be ≥ 30 sec~select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~each Paclitaxel-eluting balloon catheter is allowed for single use only~additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
45364305|NCT03996772|Drug|Apixaban Oral Tablet|Factor Xa Inhibitor
45364306|NCT03996772|Drug|Dabigatran|Direct Thrombin Inhibitor
45364307|NCT03996772|Drug|Edoxaban Tablets|Factor Xa Inhibitor
45364308|NCT03996772|Drug|Rivaroxaban|Factor Xa Inhibitor
45364309|NCT01000779|Drug|Propranolol|upto 320mg/day maximum
45364310|NCT01000779|Device|multi band ligator for esophageal varices|to obliterate esophageal varices
45482015|NCT03310372|Radiation|Ultrafractionated brain irradiation|0.75 Gy a day, 5 times a week, for 6 weeks (total dose: 67.5 Gy)
45364311|NCT04228367|Device|JuggerStitch Meniscal Repair Device|Treatment of torn meniscus with JuggerStitch.
45364312|NCT00998595|Other|Promotora|The Promotora will deliver education regarding postpartum follow-up and steps to take to decrease the risk for developing type 2 diabetes. The Promotora will clarify misperceptions and answer questions related to risk of developing diabetes and contraception. If the subject has barriers to accessing care with transportation or childcare, she will help the subjects to access existing resources. The Promotora will give the subject her contact information and will also contact the subject to remind her of her appointments and reschedule if she missed an appointment.
45364313|NCT04075643|Drug|Reference drug|D935 Cap. 1 Cap., single oral administration under fasting condition
45364314|NCT04075643|Drug|Test drug|CKD-385 Tab. 1 Tab., single oral administration under fasting condition
45752171|NCT01792895|Procedure|Mobilization|The mobilization is a passive oscillatory technique, applied over cervical region in the hypomobile cervical level, the patient will be in prone and the therapist standing at the head of the patients with his thumbs in opposition placed at the level of the facet of the hypomobile cervical vertebra. A posteroanterior(PA) oscillatory pressure is applied, through the thumbs, over the process of the hypomobile vertebra. This oscillatory mobilization, is performed at a frequency of 2Hz (with metronome control/steps) for 2 minutes and repeated 3 times. The rest time between each mobilization was 1 minute.
45364315|NCT01000857|Drug|Paroxetine CR and Paroxetine IR|Randomized, 2-period crossover repeat dosing of Paroxetine CR at 25 mg/day for 14 days and Paroxetine IR at 20 mg/day for 14 days in Japanese healthy male volunteers
45482016|NCT03310372|Drug|Temozolomide|75 mg/m2/day, 7 times a week, for 6 weeks (total 42 days)
45364316|NCT01004445|Drug|Amikacin (BAY41-6551)|Single daily dose of 400 mg aerosolized amikacin and a single dose of aerosolized placebo on a rotating every 12hr schedule
45364317|NCT01004445|Drug|Amikacin (BAY41-6551)|Daily dose of 800 mg aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment every 12hr
45364318|NCT01004445|Drug|Placebo|Two aerosol treatments per day (one treatment every 12hr)
45364319|NCT03739931|Biological|mRNA-2752|Solution for intratumoral injection
45482017|NCT01340508|Radiation|Intensity Modulated Radiotherapy|Intensity modulated radiotherapy to a dose of 55Gy in 25 fractions
45845745|NCT05680116|Other|Home based exercise|Patients will do home based exercise during the radiotherapy process. 5 days a week. 2 sessions a day, each exercise will be 10x2 repetitions
45364320|NCT03739931|Biological|Durvalumab|Solution for infusion after dilution
45364321|NCT02580695|Biological|umbilical-cord mesenchymal stromal cells|Intra-articular knee injection of UC-MSC 20x10e6 at 0 and 6 months
45364322|NCT02580695|Drug|Hyaluronic Acid|Intra-articular knee injection of Hyaluronic Acid (3ml) at 0 and 6 months
45364323|NCT04075019|Behavioral|The Raising Healthy Children intervention, including teacher training, child skill development, and parent training|
45364324|NCT03672929|Device|RSA|Roentgen Stereometric Analysis (RSA) is a very accurate measurement technique used to obtain micromotion of the implants relative to bone, by means of inserted tantalum markers in the surrounding acetabulum and femur. RSA provides data on the in-vivo stability of the Cup System within 2 years.
45364325|NCT02581553|Drug|lesinurad/allopurinol 200/300 FDC tablets|
45364326|NCT02581553|Drug|lesinurad 200 mg|
45364327|NCT02581553|Drug|allopurinol 300 mg|
45364328|NCT02581553|Drug|lesinurad/allopurinol 200/200 FDC tablets|
45364329|NCT02581553|Drug|allopurinol 200 mg|
45364330|NCT04077203|Behavioral|Biofeedback / No biofeedback|Biofeedback / No biofeedback
45364331|NCT03666065|Drug|Aspart insulin|Standard insulin
45364332|NCT03944915|Drug|Carboplatin|Carboplatin will be given through IV infusions for 30-60 minutes on day 1 of each cycle. Each cycle will last 21 days. There will be 3 cycles.
45364333|NCT03944915|Drug|Paclitaxel|"During Induction Therapy Paclitaxel (100 mg) will be given through IV infusions on days 1, 8 and 15 of each 21 day cycle. There will be 3 cycles.~During Radiotherapy, paclitaxel will be given after a dose of radiation by IV infusion for 60 minutes after day 1 of radiotherapy."
45364334|NCT03944915|Drug|Nivolumab|Nivolumab will be given through IV infusions at 360 mg on day 1 every 21 days for 3 cycles.
45364335|NCT03944915|Radiation|Radiation|Patients will receive 4.5-5 cycles of radiation depending on response. Those with a positive response will receive radiation for 4.5 cycles with a total radiation dose of 66 Gy. Patients with a moderate or no response will receive 5 cycles with a total radiation dose of 70-75 Gy. 2 times a day for days 1-5 followed by a rest period for days 6-13
45364336|NCT03944915|Drug|Hydroxyurea Pill|One dose of hydroxyurea pill by mouth at start of 5-FU infusion during radiotherapy cycle
45845746|NCT05678322|Drug|18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent|Under development for the diagnosis of prostate cancer by Blue Earth Diagnostics. rhPSMA-7.3 (18F) will be administered intravenously as a single-dose injection. The molecular structure of the drug substance comprises a prostate-specific membrane antigen (PSMA) binding motif, a peptide spacer, an 18F-radiolabeled silicon fluoride acceptor moiety and a gallium chelator complex.
45845747|NCT05678322|Device|PET MRI Imaging|rhPSMA-7.3 (18F) PET MRI imaging will be conducted once at baseline and a second time within one year of the initial scan.
45364337|NCT03944915|Drug|5-fluorouracil|5-FU will be given by IV infusion continuously for 5 days during radiotherapy cycles
45364338|NCT03944915|Drug|Filgrastim Injection|Filgrastim shot will be given if patient has certain side effects during radiotherapy cycle on days 6-12.
45364339|NCT03944915|Drug|Cisplatin|Radiotherapy may also be given with a different chemotherapy agent called cisplatin. This is the traditional standard of care chemotherapy regimen. In this case, the radiotherapy will be given once daily for 5 days per week. Cisplatin will be administered via IV once every 21 days for 2 or 3 cycles.
45364340|NCT05674019|Other|MRI exam|Brain MRI Morphometric exam
45364341|NCT00482170|Device|Enbrel (etanercept)|Arm 1 = Enbrel 50 mg Prefilled Syringe twice weekly
45482020|NCT04702308|Other|Clinical Decision Rule Alerts|The
45845748|NCT05665062|Drug|SYNCAR-001|SYNCAR-001 is an autologous CD19-targeted CAR-T with co-expression of hoRb
45364342|NCT00482170|Device|Etanercept|Arm 2 = Enbrel 50 mg Autoinjector twice weekly
45364343|NCT05228249|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood ASCT
45364344|NCT05228249|Drug|Carmustine|Given IV
45364345|NCT05228249|Drug|Cytarabine|Given IV
45364346|NCT05228249|Drug|Etoposide|Given IV
45482021|NCT05310604|Procedure|Blood withdrawal|Single blood withdrawal for determination of immunoglobulin levels
45482022|NCT02980276|Drug|Metformin Hydrochloride|Women randomised to the metformin group will receive metformin 500mg once daily, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of 2500mg Metformin daily (5 tablets) or maximum tolerated dose, in addition to usual care (exercise and MNT), and taken until delivery.
45845749|NCT05665062|Drug|STK-009|STK-009 is a human orthogonal IL-2 cytokine selective for SYNCAR-001 CAR-T cells expressing hoRb
45482023|NCT02980276|Other|Placebo|Women randomised to the placebo group will receive 1 placebo tablet once daily, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of five placebo tablets daily, in addition to usual care (exercise and MNT), and taken until delivery.
45690167|NCT01403805|Other|Specific frequency of oral care|1 dentist and 2 dental hygienists visited the nursing home once a week. After the residents agreed our receive oral care, the dentist/dental hygienist spent 15 minutes with brushing of teeth, scaling, oral wiping, gargling and cleaning of dentures, to reduce dental plaque which is oral bacteria mechanically by using cleaning tools, including toothbrush, interdental brush, dental scaler, tongue brush, and sponge brush to treatment of periodontal disease at the washstand in their private room primary care physicians. At the same time, they taught and recorded to the nursing care workers the methods of administering responsible oral care to dye for dental plaque by using plaque disclosing agent material.
45482024|NCT05183958|Radiation|Radiotherapy group|Stereotactic body radiotherapy (SBRT, 8Gy/time, 3 -5 times, if other segmentation schemes are used, recommend BED10 >60Gy) or conventional fractional radiotherapy (parts that are not suitable for SBRT, the total dose is more than 30Gy); the primary lesion should be treated with conventional fractional radiotherapy with a dose of 4000cGy or more;
45482025|NCT05183958|Drug|Camrelizumab|4 cycles for combined therapy. Camrelizumab maintenance.
45690168|NCT01423617|Dietary Supplement|Zenoctil|3 tablets 2 times daily
45845750|NCT05665062|Drug|Cyclophosphamide|lymphodepletion
45364347|NCT05228249|Biological|Loncastuximab Tesirine|Given IV
45364348|NCT05228249|Drug|Melphalan|Given IV
45845751|NCT05665062|Drug|Fludarabine|lymphodepletion
45845752|NCT05661864|Behavioral|Multi-Tiered Systems of Support for Teacher Training|In tier 1 of the intervention, all participants will complete online modules on the target practice and self-monitoring. They will then self-monitor the target practice for approximately three weeks. Non-responders will receive intensified intervention (tier 2) in which they will complete an online module on self-management. They will then self-manage their use of the target practice for approximately 3 weeks. Continued non-responders will receive peer coaching on the target practice (tier 3). Responders to tiers 2-3 will move down a tier after 3 weeks of response.
45364349|NCT02580383|Procedure|Radiofrequency neurotomy of lumbar medial branch|In above L5, The RF needle was placed to contact with bone as close as possible to the course of the target nerve in parallel. For L5 dorsal rami ablation, the needle was positioned in the groove between the S1 articular process and sacral ala. At each level, the electrodes were adjusted to optimize sensory stimulation at a frequency of 50 Hz and maximize multifidus contraction at 2 Hz. A 75 second 80°C lesion was made using an RF generator.
45364350|NCT02580227|Drug|Tranexamic Acid|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
45364351|NCT02580227|Other|Placebo|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
45364352|NCT04076267|Other|Tool assessing symptoms validation|Comparison between 2 tools evaluating the symptoms of patients with advanced cancer: the ESAS12-F and the EORTC QLQ C30 to assess if the ESAS12-F well evaluates the symptoms and if it is easy to complete. The objective is to validate the ESAS12-F, which is easier and shorter than the well validated EORTC QLQ C30
45364353|NCT03883113|Biological|MVA-NP+M1|Trial Vaccine
45364354|NCT03883113|Biological|Saline|Sodium Chloride Placebo
45364355|NCT03883113|Biological|H3N2 (A/Belgium/2417/2015)|Challenge Agent
45364356|NCT04218695|Drug|Ceftriaxone|Antibiotic
45364357|NCT04218695|Drug|Normal saline|50cc intravenous once daily
45482026|NCT05183958|Drug|Chemotherapy|4 cycles for combined therapy.
45482027|NCT03108664|Drug|SYL1001 ophthalmic solution|1 drop in the affected eye
45482028|NCT03108664|Drug|Vehicle opthalmic solution|1 drop in the affected eye
45482029|NCT04848012|Device|Auto-titrating non-invasive ventilation|A non-invasive ventilator designed to auto-adjust the expiratory positive airway pressure according to expiratory flow limitation, measured using the forced oscillation technique.
45482030|NCT01342614|Drug|Fosinopril|Fosinopril group received fosinopril, 10mg, once per day.
45690169|NCT01423617|Other|Placebo|3 tablets 2 times daily
45690170|NCT01392183|Drug|Pazopanib|800 mg by mouth daily in 4 week study cycle.
45847813|NCT02968758|Device|Comparison between GenePOC PCR and Reference Method|Stool specimen will be tested with the GenePOC CDiff test on the GenePOC Instrument. The results will be compared to Reference Method defined as direct and enriched culture method for observation of a toxigenic Clostridium difficile strain.
45364358|NCT01000935|Other|Platelet Rich Plasma|Patient's blood will be drawn prior to the start of the procedure. The processing disposable (PD) size of 60ml will be used to yield 7 ml of Platelet concentrate volume. Using the lateral portal, the applicator for the PRP will be positioned in between the bone and the repaired rotator cuff without a cannula. The inflow will then be closed and the arthroscopic fluid will be aspirated via the outflow cannula. All other cannulae will be removed, producing a dry subacromial space. The PRP and autologous thrombin will then be transferred to the sterile field and drawn up into a dedicated spray applicator kit (Smartjet) and applied to the site of repair. A dry arthroscopic check will be performed to evaluate the clot formation of the applied solution.
45364359|NCT03967639|Procedure|Elective cardiac surgery|Elective cardiac surgery
45364360|NCT05674331|Procedure|Extraction site development technique|The technique is described by Molnar et al. in 2019. The aim is to reconstruct the buccal bony wall with a xenogenic membrane with a slow absorption rate properties. This technique aims to stabilizate and enlarge the blood clot .
45364361|NCT05674331|Device|autogenous tooth bone graft|ATB was invented by Kim et al. in 2011. The extracted tooth is grinded and goes throw a sterilization procedure by the manufacturer's recommendation. The graft material can be used immediately for ARP.
45482031|NCT01342614|Drug|Metformin|Metformin group was treated with metformin hydrochloride, 500mg, three times per day
45482032|NCT03310294|Dietary Supplement|Placebo|one bottle of placebo (minidrink fermented with low-fat milk but without Lactobacillus rhamnosus and without FOS, and without viable bacteria 90 grams)per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
45482033|NCT03310294|Dietary Supplement|Prebiotics and Probiotics|one bottle of the study product (minidrink with fermented low-fat milk added with Lactobacillus rhamnosus (Lactobacillus rhamnosus) and fructooligosaccharides (FOS),per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
45482034|NCT03108508|Dietary Supplement|Prod1|60 mL of product (water, silicic acid, Equisetum Arvense, Rosmarinus officinalis) (Silicic acid) equivalent to 21.6 mg of elemental silicon.
45482035|NCT03108508|Dietary Supplement|Prod2|1.4 g of product (Orthosalicic acid) equivalent to 21.6 mg of elemental silicon
45482036|NCT03108508|Dietary Supplement|Prod3|120 mL of product (Aloe barbadensis Miller, organic silicon, potassium sorbate, cítric acid) (Organic silicon) equivalent to 21.6 mg of elemental silicon
45482037|NCT01342692|Drug|Azacitidine|6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks The first course will be started on day 1 regardless of the blood count. Subsequent courses will be scheduled every 4 weeks
45482038|NCT01342692|Drug|Azacitidine associated with Valproic acid|"6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Valproic Acid (Depakine-Chrono®) (VPA) will be administered concomitantly for a minimum of 6 cycles.~- In patients aged 60 years or less: VPA (25 mg/kg twice a day i.e. 50 mg/kg/d) administered orally, daily for 7 days (days 1-7)~- In patients older than 60 years: VPA (17.5 mg/kg twice a day i.e. 35 mg/Kg/d) administered orally daily for 7 days (days 1-7)"
45482039|NCT01342692|Drug|Azacitidine associated with Lenalidomide|"6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Lenalidomide (Revlimid®) will be administered once daily orally as continuous schedule started on day 1 of Azacitidine.~Patients will receive Lenalidomide 10 mg/d, during 14 days (D1 to D14)"
45482040|NCT01342692|Drug|Azacitidine associated with Idarubicine|Azacitidine (Vidaza®) will be administered similarly to group 1 exposed above. Idarubicin (Zavedos®) as the reconstituted solution, will be administered slowly by the intravenous route over 60 minutes at 10 mg/m²of body-surface area on day 8 of Azacitidine or day 10 if azacitidine was administered according to (5-2-2 regimen)
45690171|NCT01392183|Drug|Temsirolimus|25 mg by vein infused over 30-60 minutes every week in 4 week study cycle.
45690172|NCT01392183|Behavioral|Quality of Life Assessment|Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
45690173|NCT01392183|Drug|Benadryl|25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus.
45690174|NCT02985489|Dietary Supplement|Olimel Parenteral Nutrition|Olimel 5.7% with electrolytes
45690175|NCT01751906|Device|Absorb BVS|"Scaffold diameters: 2.5, 3.0 and 3.5 mm~Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
45845753|NCT05642520|Procedure|Oval section abutment of 2.9 mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 5.9 and 6.3 mm, a 2.9 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
45847814|NCT02968914|Biological|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
45847815|NCT02968914|Biological|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
45364362|NCT05674331|Procedure|Socket seal technique|After tooth removal neither graft nor any membrane material is inserted to the extraction socket. A soft tissue pounch is harvested from the hard palate and it is fixed above the extraction socket with single interrupted sutures.
45364363|NCT00998673|Device|Silica Gel Fiber|Silica Gel Fiber (SGF) applications as required
45482041|NCT02853214|Genetic|Genetic analysis of peripheral blood samples|M.D investigators report the identified families with all the information: description of the familial area (for example: 2 cases father and son), last medical report for the case with the type of dysglobulinemia, monoclonal component isotype, medical background and contact information for one of the patients or cases with Name/surname/Date of Birth/address and phone. They contact the patient to explain the study and establish the family pedigree. They collect the information on all the family members and send to the patient a mail: an information note on the study, a prescription for the blood sample and the informed consents. They proceed in the same way for the relatives with the additional prescription: EIP. They organize the logistic in the medical lab or hospital chosen by the person. They receive 4 Heparin and 1 serum tubes for each and with this, they obtain a large amount of biological material for the genetic analysis thanks to the establishment of lymphoblastoid cell lines
45482042|NCT04043208|Behavioral|Biofeedback|Three sessions of biofeedback will be performed during the first 3 weeks of the intervention period. Biofeedback sessions will be performed 30 min after ingestion of the offending meal: patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; specifically, they will be instructed to reduce the abdominal perimeter (girth). Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
45690176|NCT01751906|Device|XIENCE|"Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm~Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition~For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
45690177|NCT01402947|Drug|Ciprofloxacin XR + MMX Placebo|MMX Mesalazine/mesalamine placebo dosed once-a-day (QD) orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose of MMX Mesalazine/mesalamine placebo on day 4
45364364|NCT00998673|Device|Standard-of-Care|Standard-of-Care with dressing changes twice per week using Mepitel and Mepilex wound dressings
45364365|NCT03967561|Other|Progressive water-based aerobic training|The intervention will comprise walking/running in shallow pool with progression in the training variables. The training will have 12 weeks of duration with 3 weekly sessions (of 50 minutes each).
45364366|NCT03967561|Other|Non-progressive aerobic training|The intervention will comprise walking/running in shallow pool without progression in the training variables. The training will have 12 weeks of duration with 3 weekly sessions (of 50 minutes each).
45364367|NCT01001013|Drug|LC15-0444, Pioglitazone|LC15-0444 200 mg (100 mg x 2) qd (12 days once daily) Pioglitazone 30 mg (15 mg x 2) qd (12 days once daily) LC15-0444 200 mg (100 mg x 2) qd + pioglitazone 30 mg (15 mg x 2) qd (12 days once daily)
45364368|NCT01004523|Genetic|fluorescence in situ hybridization|
45364369|NCT01004523|Genetic|loss of heterozygosity analysis|
45364370|NCT01004523|Genetic|polymerase chain reaction|
45364371|NCT01004523|Other|flow cytometry|
45364372|NCT01004523|Other|immunohistochemistry staining method|
45364373|NCT00490282|Radiation|Intensity Modulated Radiation Therapy|IMRT Treatment Over 6-7 Weeks
45364374|NCT00490282|Radiation|Adaptive Radiotherapy|ART Treatment Over 6-7 Weeks
45364375|NCT03646877|Drug|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
45364376|NCT03646877|Other|Filtered Air|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing filtered air.
45364377|NCT00998751|Drug|oral masitinib|7.5 mg/kg/day
45364378|NCT02580929|Radiation|radiotherapy|radiotherapy before surgery
45364379|NCT01016470|Dietary Supplement|VIUSID/ALZER|VIUSID/ALZER, 3 per day, oral, one year
45364380|NCT01016470|Dietary Supplement|Placebo|Placebo Viusid and Placebo Alzer, 3 per day, oral, one year
45364381|NCT01004601|Drug|docetaxel|patients at one university-affiliated hospital received low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)following failure of previous treatment stage IIIb/IV NSCLC.
45364382|NCT01004601|Drug|pemetrexed|patients at one university-affiliated hospital received pemetrexed (500 mg/m2 every 3 weeks) following failure of previous treatment stage IIIb/IV NSCLC.
45364383|NCT03640793|Device|Implantation|Implantation of 6 PPIS implants
45364384|NCT00998829|Other|questionnaire|There is no therapeutic intervention in this study. However PASE (Psoriatic Arthritis Screening and Evaluation) and other patient questionnaires will be completed by participants.
45364385|NCT01001247|Drug|TMC278; Omeprazole|
45364386|NCT03923543|Diagnostic Test|Neutrophil to lymphosit ratio|
45364387|NCT04205357|Drug|Sulfasalazine|Sulfasalazine combined with stereotactic radiosurgery
45364388|NCT01004757|Other|LOGI diet|diet based on 25% low glycemic index carbohydrates, 30% protein and 45% fat combined with heart rate controlled aerobic exercise for three weeks
45364389|NCT01004757|Other|Low Fat diet|traditional low fat diet based on 55% mixed glycemic index carbohydrates, 20% protein and 25% fat for three weeks followed by LOGI diet for two weeks, always combined with heart rate controlled aerobic exercise
45364390|NCT02580773|Drug|Prophylactic anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a prophylactic dose (4500 UI/day)
45364391|NCT02580773|Drug|Curative anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a curative dose (175 UI/kg/day for 7 days)
45364392|NCT05032937|Drug|domestic polysaccharide superparamagnetic iron oxide nanoparticle|Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
45364393|NCT01008813|Biological|adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 [A/California/7/2009 (H1N1)v] (3,8 microgram) adjuvanted with AS 03A
45364394|NCT01008813|Biological|non-adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 [A/California/7/2009 (H1N1)v] (15 microgram)
45364395|NCT05089695|Device|Noninvasive respiratory support|Treatment of acute hypoxemic respiratory failure
45364396|NCT05674565|Drug|Magnesium sulfate loading with maintenance dose|4 gm MgSo4 loading over 20 minutes followed by 1 gm per hour maintenance till delivery
45364397|NCT05674565|Drug|Magnesium sulfate loading dose only|4 gm MgSo4 loading over 20 minutes within one hour before delivery
45482043|NCT04043208|Dietary Supplement|Placebo|Three sessions will be performed during the first 3 weeks of the intervention period. Each session will be performed 30 min after ingestion of the offending meal: abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
45482044|NCT05155488|Other|No Intervention|This is a non-interventional study.
45482045|NCT03310216|Procedure|Order I of visual inspection|Participants in group I are provided AI visual inspection system first and EDTRS later.
45482046|NCT03310216|Procedure|Order II of visual inspection|The participants in Group II are provided EDTRS first and AI visual inspection system later.
45482047|NCT01340742|Procedure|Remote Ischemic Pre-conditioning|Cuff placed on arm. Three 5- minute cycles of blood pressure cuff inflation: cuff is inflated to 200 mm Hg for 5 minutes followed by a 5-minute deflation (reperfusion.)
45364398|NCT01001481|Other|Risk status for medication adherence|Examination of risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia
45482048|NCT01340742|Procedure|Control|Cuff placed on arm uninflated for 30 minutes.
45690178|NCT01402947|Drug|MMX Mesalazine/mesalamine + Ciprofloxacin XR|MMX Mesalazine/mesalamine 4.8 g QD orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose 4.8 g of MMX Mesalazine/mesalamine on day 4
46050524|NCT05334537|Other|Placebo oil (odorless baby oil- jojoba and almond oil)|Ninety-six patients aged between 18 and 45 years, with a height of ≥156 centimeters (cm), and a gestational age of >37 weeks, in the ASA II risk group, who were scheduled for elective CS under spinal anesthesia, were included in the study. Patients who were to undergo lavender aromatherapy with an oxygen mask after the birth of the baby were randomly divided into two groups: aromatherapy (A) (n=48) and control (C) (n=48), who inhaled odorless essential oil. Participants were admitted to the preoperative preparation room 20 min before the operation, and their age, height, weight, and ASA risk scores were recorded after their informed consent was obtained. They were monitored and sent to the operating room after their baseline anxiety levels were measured and recorded using the Visual Analog Scale (VAS) for pain and State-Trait Anxiety Inventory (STAI-I).
46050525|NCT00592852|Drug|fluoxetine|capsules, dose range of 10mgQD - 60mgQD, given daily for 12 weeks
45482049|NCT02469688|Drug|ASP4070|intramuscular or intradermal
45364399|NCT03999645|Procedure|Early laparoscopic cholecystectomy|within 72h from symptom onset
45364400|NCT03999645|Procedure|Late laparoscopic cholecystectomy|after 72h up to seven days from symptom onset
45364401|NCT05195801|Device|USG|Optic Nerve Diameter will be measured in the intraoperative period and postoperative 1st month by ultrasonography method.
45364402|NCT01001637|Dietary Supplement|Curcumin Formulation|2000mg or 3000mg daily BID
45364403|NCT01001637|Dietary Supplement|Placebo|Placebo
45364404|NCT01005069|Drug|DLBS-32|DLBS-32 50 mg once daily and lifestyle modification
45364405|NCT01005069|Drug|DLBS-32|DLBS-32 100 mg once daily and lifestyle modification
45482050|NCT02469688|Drug|Placebo|intramuscular or intradermal
45482051|NCT05153772|Drug|AlphaMedix|212Pb-DOTAMTATE is a radiolabeled derivative of octreotide targeting somatostatin positive neuroendocrine tumors
45482052|NCT03310138|Device|Real Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a figure-8 coil (lasting only microseconds) is able to focally stimulate the cortex by depolarizing superficial neurons, which induces electrical currents in the brain. TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS). In this study TMS is being delivered with the MagVenture MagPro B60 coil.
45482053|NCT03310138|Device|Sham Transcranial Magnetic Stimulation|The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
45690179|NCT03025893|Drug|Sunitinib|Sunitinib, 300 mg administered orally in a weekly schedule.
45847816|NCT02968992|Drug|rhLactoferrin|Eligible participants will be provided with Recombinant Human lactoferrin (rhLF) in 250 mg capsules along with detailed instructions for taking the study drug and they will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
46050526|NCT04117906|Behavioral|STAGE training for anxiety|STAGE is a brief, online, self-help course designed to target anxiety through providing training in perspective broadening and self-distancing.
45364406|NCT01005069|Drug|DLBS-32|DLBS-32 200 mg once daily and lifestyle modification
45364407|NCT01005069|Drug|DLBS-32|DLBS-32 300 mg once daily and lifestyle modification
45364408|NCT01005069|Drug|Placebo capsule|Placebo capsules once daily and lifestyle modification
45364409|NCT01009125|Other|$2 cash|$2 cash incentive will be included in the mailed survey
45364410|NCT01009125|Other|$5 cash|$5 cash incentive will be included in the mailed survey
45364411|NCT02580851|Other|diagnostic test - cardiac magnetic resonance imaging|
45364412|NCT02580851|Other|diagnostic test - coronary angiography|
45364413|NCT01005147|Drug|tranexamic acid|1 gm every 6 hours for 4 days via IV for non-renal impaired subjects. Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)
45364414|NCT01005147|Other|Placebo|Will receive placebo treatment as per the tranexamic acid schedule
45482054|NCT03998046|Behavioral|Outreach Support for Weight Loss Goal Setting and Self-Weighing|Patients will receive a MyChart activation message assessing weight loss interest that invites them to complete a MyChart Survey encouraging a weight loss goal using principles adapted from Brief Action Planning. Patients will then receive a cellular network-enabled electronic body weight scale, and weighing data transmitted by the scale will be received and integrated into the electronic health record for access by the patient's primary care team.
45364415|NCT01001793|Device|Levacor Ventricular Assist Device|Surgical procedure
45482055|NCT03998046|Behavioral|Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions|"Patients will receive via MyChart information and decision support designed to encourage linkages to and participation in intensive lifestyle programs available in the community. Patients who request information or clinical referrals will also receive them. Refreshes of community linkage information will be sent by MyChart every 1 to 4 weeks."
45364416|NCT01009359|Drug|F-18 DPA-714 (BAY85-8102)|Alzheimer Disease patients: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
45482056|NCT03998046|Behavioral|Adaptive Tailoring of Information Delivery and Intensity of Primary Care Outreach Support|Data received into the electronic health record from the cellular network-enabled electronic scale will categorize each patient based on their daily self-weighing behaviors and rate of progress towards their weight loss goal. Patients who are not engaged in daily self-weighing or are not making progress towards their goal will receive more intensive outreach support in the form of automated weekly MyChart problem solving messages, more frequent encouragement to access a broader array of community resources, and telephonic support from a nurse care coordinator who is an existing member of the primary care team. Support from this nurse care coordinator will be facilitated by the incorporation of each patient's self-weighing data into an EpicCare patient dashboard accessible to the nurse coordinator and other members of the care team
45690180|NCT03025893|Drug|Lomustine|Lomustine 110 mg/m2, taken orally on day 1 every 6 weeks.
45364417|NCT01009359|Drug|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for brain imaging: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
45364418|NCT01009359|Drug|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for whole body imaging: Single intervenous bolus injection of 150 MBq BAY85-8102, whole body PET/CT for evaluation of effective dose, kinetics of BAY85-8102 in blood
45690181|NCT01402869|Drug|4% prilocaine plain|5mg/kg via infiltration into multiple sites of the buccal mucosa of mouth 1 time prior to start of restorative dental treatment
46050527|NCT00895245|Drug|fosaprepitant dimeglumine|Given IV
45364419|NCT03603899|Drug|Hp 129Xenon|129 Xenon is a noble gas with no taste or smell. It will be made slightly magnetic (also called hyperpolarizing) and then inhaled into the lungs to provide better pictures of the lungs during MRI.
45364420|NCT01001871|Dietary Supplement|Sprinkles®|powdered vitamin/mineral fortificant WITH iron sprinkled onto food once a day for 5 months
45364421|NCT01001871|Dietary Supplement|vitamin/mineral fortificant without iron|powdered vitamin/mineral fortificant WITHOUT iron sprinkled onto food once a day for 5 months
46050528|NCT00895245|Drug|cisplatin|Given IV
46050529|NCT00895245|Drug|palonosetron hydrochloride|Given IV
46050530|NCT00895245|Drug|dexamethasone|Given IV and orally
46050531|NCT00895245|Other|Functional Living Index-Emesis Questionnaire|Ancillary studies
46050532|NCT00895245|Behavioral|Emesis Diary|Ancillary studies
46050533|NCT00895245|Radiation|Radiotherapy|Undergo radiotherapy
46050534|NCT02617732|Drug|Tianqi capsule|"The patients with type 2 diabetes are divided into two groups, one is experimental group, and the other is placebo group.~The experimental group patients are treated with Tianqi capsule by oral, 5 pills three times a day"
45364422|NCT02580071|Dietary Supplement|Sheng-Yu-Tang|"Granulated formula will be prescribed by KO DA Pharmaceutical co., LTD (科達) composition of formula is as follows: Radix Rehmanniae Praeparata 4g Radix Paeoniae Alba 4g Radix Astragali 4g Radix Ginseng 4g Radix Angelice Sinensis 2g Rhizoma Chuanxiong 2g (for preperation method and concentration ratio's please refer to manufacturers information)~patients will be required to take 4.2gr, t.i.d (total of 12.6gr per day)"
45482057|NCT03310060|Drug|Tisseel|Tisseel® (Fibrin Sealant, 4ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 4 mL vial containing the active product was used
45482058|NCT03310060|Drug|Tranexamic Acid|Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg in 100 ml normal saline before surgical incision and 3 hours after surgery
45482059|NCT02520778|Drug|Navitoclax|Given PO
45482060|NCT02520778|Drug|Osimertinib|Given PO
45482061|NCT02470000|Device|Intravascular laser irradiation of blood (ILIB)|continuous-wave ILIB is performed using a 632.8nm (red light) laser beam from a He-Ne laser machine (Y-J ILIB-5, Bio Human Energy Cooperation, New Taipei City, Taiwan, R.O.C.).The participants sit on a sofa with their arms relax and supported on the table. A 24-gauge catheter is inserted to a superficial vein in upper extremity under sterile preparation, and an optic fiber channel is connected to the catheter for blood irradiation.
45482062|NCT02470000|Device|Transcutaneous electrical nerve stimulation|TENS over neck for 15 minutes.
45482063|NCT02470000|Other|Stretching exercise|stretching exercise to the involved muscle for 15 minutes.
45364423|NCT05673941|Other|Creative physical training|The intervention will be performed as a group activity twice a week during a 12-week period. Each group will include 4-6 participants under the guidance of two instructors, and a related party if needed or wanted from the participant. The exercise is partly accompanied with calm music and recorded nature sounds and partly made in silence listening to one's own bodily rhythm. The exercise consists of tasks related to cardio and strength training, balance, conscious breathing, body awareness, mental imagery (nature visualizations), flexibility, emotional expression, and movement anticipation together with the facilitator and fellow participants. All the tasks are practiced during a flow of 45- to 60-minute exercise without any major breaks. Complexity and physical intensity of the tasks will gradually increase over the 12-week intervention period.
45364424|NCT01001949|Dietary Supplement|Wheat Bran Extract|soft drink comprising WBE and natural flavor and coloring agent, ingestion after breakfast and after dinner
45364425|NCT01001949|Dietary Supplement|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and dinner
45364426|NCT01002027|Behavioral|CBT-Counselling|Intervention entailed six sessions of counselling-CBT delivered either by a trained Nurse, or by a Psychologist. Sessions focussed on: psycho-education about PND, main issues of concern, assessment of symptom severity, problem solving. Behavioural interventions (pleasant activities, anxiety management, relaxation, relationship communication) were used together with cognitive interventions (understanding links between thoughts and feelings, increasing positive thoughts, challenging negative self-talk and unhelpful beliefs).
45364427|NCT01005303|Drug|Placebo|1 Tablet Daily
45482064|NCT03740958|Drug|rt-PA|Intravenous throbolysis with 0.9mg/kg rtPA
45482065|NCT03740958|Drug|Argatroban|100 ug/kg bolus over 3 to 5 minutes was administered intravenously, followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)
45482066|NCT01340820|Drug|AERAS-422|rBCG
45482067|NCT01340820|Drug|BCG Tice|1-8 x 10^5 CFU
45482068|NCT05290246|Behavioral|Time restricted eating|Limiting daily eating time to an 8 hour window
45364428|NCT01005303|Drug|Forceval plus 50 micrograms Vitamin D3|Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily
45364429|NCT01005381|Dietary Supplement|Small Particle Size Calcium Carbonate Supplement|Small Particle Size Calcium Carbonate - tablet, 325 mg/tablet. Given once or twice daily depending on study arm.
45364430|NCT01005381|Dietary Supplement|Large Particle Size Calcium Carbonate Supplement|Large Particle Size Calcium Carbonate Supplement - tablet, 325 mg/tablet. Given twice daily.
45364431|NCT01005381|Dietary Supplement|Vitamin D|Vitamin D - capsule, cholecalciferol, 1000 IU/tablet. Given once daily.
45482069|NCT05290246|Behavioral|Caloric reduction|Cut caloric intake by 15%
45482070|NCT03685188|Drug|Oxycodone Hydrochloride|Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 0.4 mg/ml of oxycodone for postoperative analgesia.
45482071|NCT03685188|Drug|Sufentanil Citrate|Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 2 μg/ml of sufentanil for postoperative analgesia.
45482072|NCT02305654|Procedure|ILND - Inguinal Lymph Node Dissection|Surgery to remove the lymph nodes in the groin near to where the cancer first appeared.
45482073|NCT02305654|Drug|Paclitaxel|Dose 175mg/m2 as part of TIP regimen.
45482074|NCT02305654|Drug|Ifosfamide|Dose 900mg/m2 as part of TIP regimen.
45482075|NCT02305654|Drug|Cisplatin|Dose 15mg/m2 as part of TIP regimen (neoadjuvant chemotherapy arm) Dose 40mg/m2 for use concurrently with raditotherapy (chemoradiotherapy arm)
45482076|NCT02305654|Radiation|Intensity modulated radiation treatment (IMRT)|Treatment with very high energy X-rays (radiotherapy).
45482077|NCT02305654|Procedure|Prophylactic PLND - pelvic lymph node dissection|Surgery to remove the lymph nodes deeper in the pelvis, further away from where the cancer first appeared, that are at high risk of harbouring cancer.
45482078|NCT05251584|Drug|Mupirocin|Apply mupirocin ointments for prevention of peritoneal dialysis-related infection between 1 January 2021 to 31 December 2021
45482079|NCT05251584|Drug|Gentamicin|Apply gentamicin creams for prevention of peritoneal dialysis-related infection for 1 year start after 1 January 2022
45364432|NCT01005381|Dietary Supplement|Calcium Placebo|"Placebo tablets identical to the large and small particle size calcium carbonate tablets.~Given twice daily."
45364433|NCT05080335|Other|Short videos|"As an educational RCT, the didactic content will be the same across the four arms, but its deliver will vary by:~TRANS- vs CIS-gender female instructors~With or without short videos of transgender youth embedded into the didactic [TV or CV]; for the group with no embedded videos [NV], the same videos will be shown AFTER completion of the post measures)~No-intervention control, in which TV will be delivered *after* collection of pre/post measures."
45364434|NCT01002183|Drug|Fosmidomycin|450 mg capsules, every 12 hrs for 3 days
45364435|NCT05734209|Behavioral|Virtual food|Virtual food eaten using immersive virtual reality equipment
45482080|NCT05251506|Device|laser lancing device or lancet for blood glucose level measurement|Subjects measure blood glucose level using laser lancing device (LMT-1000) and lancet for 2 months each.
45364436|NCT05734209|Behavioral|Real food|Real food eaten using regular utensils
45364437|NCT05154279|Drug|Terlipressin|intramyometrial terlipressin vs carbitocin vs saline as placebo
45364438|NCT05734131|Other|Bio-psychosocial assessment|Kinematic parameters were analyzed by two functional tests, the 10-Meter Walking Test (10MWT) and the Time Up&Go test (TUG).
45364439|NCT05734053|Other|Nilotinib|There is no treatment allocation. Patients administered Nilotinib by prescription can be enrolled.
45482081|NCT03309982|Dietary Supplement|Plant polyphenol blend|A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
45482082|NCT03309982|Other|Placebo|A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
45482083|NCT05183568|Behavioral|Mindful Self-Compassion|Self-guided bibliotherapy (specific chapters to read each week) and daily use of a meditation app for 45 minutes
46050535|NCT02617732|Drug|placebo|"The patients with type 2 diabetes are divided into two groups, one is experimental group, the other is placebo group.~The placebo group patients are treated with placebo by oral, 5 pills three times a day"
46050536|NCT03172377|Other|Lengthening adalimumab dosing interval|Lengthening adalimumab dosing interval from 2 weeks to 3 weeks and -later- to 4 weeks.
45364440|NCT01005537|Biological|aldesleukin|Given IV and orally
45364441|NCT01005537|Biological|therapeutic autologous lymphocytes|Given IV
45364442|NCT01005537|Drug|cyclophosphamide|Given IV
45364443|NCT01005693|Other|questionnaire administration|
45364444|NCT01005693|Procedure|cognitive assessment|
45364445|NCT01005693|Procedure|examination|
45482084|NCT03309904|Other|Knee Control training program|10-minute training program to be performed at all team training sessions during the season.
45482085|NCT04406142|Device|VISUAL|thin catheter insertion between vocal cords under direct specially adapted videolaryngoscopy
45690182|NCT01402869|Drug|2% Lidocaine with 1:100,000 epinephrine|2.5mg/kg via infiltration into multiple sites of buccal mucosa of mouth 1 time prior to restorative dental treatment
45364446|NCT01005693|Procedure|management of therapy complications|
45364447|NCT01002417|Drug|MCS-2 15 mg/day|One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.
45364448|NCT01002417|Drug|MCS-2 30 mg/day|Two MCS-2 soft-gel capsules, oral daily for 12 weeks.
45364449|NCT01002417|Drug|Placebo|Two matching placebo soft-gel capsules, oral daily for 12 weeks.
45364450|NCT01002495|Biological|VM202|Endocardial injections on Day 0.
45364451|NCT01005771|Drug|GF-001001-00|GF-001001-00 2%, 1% and 0.25% twice daily for 7 days
45690183|NCT01391793|Drug|Placebo|Twice daily for 3 days
46050537|NCT00865306|Behavioral|"Being Brave: A Program for Coping with Anxiety for Young Children and Their Parents."|"This is a cognitive-behavioral intervention modeled loosely after Kendall's Coping Cat, which includes 7 parent-only sessions and 8-13 child-only sessions. It focuses on helping parents learn strategies for coaching their child in coping with anxiety, and on teaching the child coping skills and carrying out exposure exercises in session and in parent-child homework assignments."
46050538|NCT02843919|Other|Electroencephalography and Electrocardiography|
45364452|NCT01005771|Drug|Placebo|Matching placebo
45364453|NCT01005849|Dietary Supplement|Protecflor|1 Capsule to be taken once a day during the entire study period
45364454|NCT01005849|Dietary Supplement|Placebo|1 Capsule to be taken once a day during the entire study period
45364455|NCT01005927|Dietary Supplement|Fructooligosaccharide|Zero or 3 g of a fructooligosaccharide will be administered in a beverage containing 300 mg total calcium as well as 15 mg 44Ca (calcium carbonate). Participants will be given one of the above beverages in addition to intravenously receiving 5 mg 43Ca (calcium chloride)in 10 ml saline.
45364456|NCT03742713|Drug|CPC634 (CriPec® docetaxel)|Docetaxel containing CriPec® nanoparticles
45364457|NCT01002651|Dietary Supplement|wheat bran extract|soft drink comprising high WBE dose and natural flavor and coloring agent, ingestion after breakfast and after dinner
45364458|NCT01002651|Dietary Supplement|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and after dinner
45364459|NCT05733429|Other|eye cervical re-education|patients will receive eye-cervical re-education in the form of 10 exercises at three phases; the first phase will include stimulation of ocular mobility, the second phase will consist of Cervical mobility exercise with restricted eye movement and the third phase will include stimulation of eye and neck movement co-ordination
45364460|NCT05733429|Other|motor imagery therapy|the patients will receive motor imagery therapy for four weeks; the first week will receive kinesthetic imagery, the second week will receive visual imagery, the third week will receive action observation exercises with motor imagery and the fourth week will receive motor control exercises in front of a mirror.
45364461|NCT05733429|Other|conventional physical therapy|the patients will receive conventional physical therapy programs in the form of hot packs, therapeutic massage, cervical isometric strengthening exercises, and scapular stabilization exercises.
45364462|NCT01002729|Other|Patients with a BMI < 30 given Oseltamivir|Patients with a BMI < 30 given Oseltamivir
45364463|NCT01002729|Other|Patients with a BMI > 40 given Oseltamivir|Patients with a BMI > 40 given Oseltamivir
45364464|NCT01002807|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Single Dose
45364465|NCT01002807|Drug|Metformin XR|Tablets, Oral, 1000 mg, Single Dose
45364466|NCT01002807|Drug|Glucophage|Tablets, Oral, 1000 mg, Single Dose
45364467|NCT05215197|Drug|intracochlear platelet rich fibrin administration|intracochlear platelet rich fibrin administration during routine cochlear implantation surgery
45690184|NCT01391793|Drug|Dexamethasone|0.15 mg/kg/dose twice daily for 3 days
45690185|NCT01422915|Drug|Colestipol|2 grams morning and bedtime for 90 days.
46050539|NCT02617654|Drug|Liraglutide|Treatment with liraglutide for 52 weeks
46050540|NCT02617654|Drug|Placebo for liraglutide|Placebo for liraglutide. Treatment once daily for 52 weeks
45690186|NCT04037943|Dietary Supplement|Walnuts 30 grams|Roasted walnuts without salt or sugar.
45847817|NCT02968992|Other|Placebo|Eligible participant will be provided with placebo in capsules of 250 mg along with detailed instructions for taking the placebo. Participants will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
45364468|NCT05057637|Device|Optical coherence tomography measurements|Optical coherence tomography measurements in femoropopliteal tract
45364469|NCT01002963|Drug|PF-04418948|solution, 30 mg, single
45364470|NCT01002963|Drug|PF-04418948|solution, 100 mg, single
45364471|NCT01002963|Drug|PF-04418948|solution, 300 mg, single
45364472|NCT01002963|Drug|PF-04418948|solution, 1000 mg, single
45364473|NCT01002963|Drug|PF-04418948|solution, 3000 mg, single
45364474|NCT01002963|Drug|PF-04418948|solution, 4500 mg, single
45364475|NCT01002963|Drug|PF-04418948|solution, 6000 mg, single
45364476|NCT01006161|Drug|SCH 527123|Low dose
45364477|NCT01006161|Drug|SCH 527123|Medium dose
45364478|NCT01006161|Drug|SCH 527123|High dose
45364479|NCT01006161|Drug|SCH 527123|Placebo to match SCH 527123
45364480|NCT05733195|Other|OGTT test|The OGTT test (75g glucose) was performed between 24 and 28 weeks of gestation. GDM will be diagnosed using the criteria of the IADPSG.
45364481|NCT05733117|Drug|Vitamin D|cholecalciferol
45364482|NCT01003119|Behavioral|Addiction CHESS|Smartphone with ACHESS application loaded onto the phone.
45690187|NCT04037943|Dietary Supplement|Walnuts 60 grams|Roasted walnuts without salt or sugar.
45364483|NCT01006239|Other|No study intervention|The is no study related intervention.
45364484|NCT01006317|Behavioral|clinical skills training|In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.
45364485|NCT01006317|Behavioral|health education|In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).
45364486|NCT01006317|Other|financial|In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
45690188|NCT01727024|Drug|Tiotropium|Tiotropium via Respimat® device once a day
46050541|NCT00700024|Drug|Testim|50 mg/dose7day
45364487|NCT05732961|Drug|Luspatercept|Participants will be treated with Luspatercept, with a starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
45364488|NCT01006395|Drug|Zoledronic acid|yearly infusion
45364489|NCT01006395|Drug|Placebo|yearly infusion
45690189|NCT01727024|Drug|Indacaterol|Indacaterol via Breezhaler® device once a day
45690190|NCT04558736|Drug|Anti-Thymocyte Globulin (Rabbit)|Given intravenously (IV)
45690191|NCT04558736|Drug|Fludarabine|Given intravenously (IV)
46050542|NCT00700024|Behavioral|Strength training|three times a week
46050543|NCT00700024|Drug|placebo|placebo
46050544|NCT03033771|Device|Implantation with the Multilayer Flow Modulator (MFM)|Endovascular implantation with the MFM
46050545|NCT00697450|Drug|insulin detemir|Start dose, frequency of dosing, dose titration to be prescribed by the physician as a result of a normal clinical evaluation
46050546|NCT00896649|Other|questionnaire administration|Questionnaire regarding patient satisfaction with mammogram experience and with positron emission mammography experience.
45364490|NCT03999801|Genetic|RGX-314|AAV8 vector containing a transgene for anti-VEGF Fab
45364491|NCT03999957|Other|Telehealth web conferencing|Pediatric patient specific case discussions for enrolled pediatric patients at hospice staff interdisciplinary team meeting every 15 days for 60 min sessions via telehealth
45364492|NCT01003353|Behavioral|Maximal strength training|Training will be carried out 3 times a week for 8 weeks. Each session will include a warm up, strength training and warm down. The total time will be approximately 1 hour. The training will consist 2 exercises (leg press and plantarflexion). Participants will train each leg individually with 4 sets of 4 repetitions at 90% of the 1 repetition maximum.
45364493|NCT05732805|Biological|BCD-217|Subject recieves BCD-217 0.2 mL/kg, which is equivalent to 1 mg/kg nurulimab + 3 mg/kg prolgolimab, as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
45690192|NCT04558736|Drug|Cyclophosphamide|Given intravenously (IV)
45690193|NCT04558736|Drug|Mesna|Given intravenously (IV)
45690194|NCT04558736|Drug|G-CSF|Filgrastim is a human granulocyte colony-stimulating factor (G-CSF), produced by recombinant DNA technology. Dosage and Route of Administration: 5mcg/kg subcutaneous or intravenous daily until ANC >2000 for 2 consecutive days, or as clinically indicated
46050547|NCT00896649|Procedure|digital mammography|standard screening mammogram
46050548|NCT00896649|Procedure|positron emission mammography|one-time positron emission mammography to compare recall rates with that of standard mammogram
46050549|NCT00796003|Drug|JNJ-30979754 15 mg/m2|JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1.
45364494|NCT05732805|Biological|BCD-100|Subject recieves prolgolimab 3 mg/kg as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
45364495|NCT05732805|Biological|Placebo|Placebo
45364496|NCT00615056|Drug|Bevacizumab (avastin)|Bevacizumab intravenous [IV] infusion 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
45364497|NCT00615056|Drug|FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion [IV] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) intravenous [IV] and a subsequent 5-FU infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
45364498|NCT00615056|Drug|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily [BID] continuous dosing until disease progression, intolerance or withdrawal of consent.
45364499|NCT00615056|Drug|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) intravenous infusion [IV] over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
45364500|NCT00615056|Drug|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily [BID] continuous dosing until disease progression, intolerance or withdrawal of consent.
45364501|NCT00615056|Drug|FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion [IV] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) IV and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
45482086|NCT02470078|Device|Phagenyx-Catheter, Phagenesis Limited, UK.|Pharyngeal electrical stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual patients. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
45482087|NCT02470078|Device|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for pharyngeal electrical stimulation is placed. In the sham group the optimisation procedure was imitated as closely as possible to mitigate any bias or effect of time spent interacting with the patient during PES, but no current was applied. After this procedure 10 min of sham stimulation were delivered.
45482088|NCT02470156|Behavioral|High Intensity Arm (Intervention)|The high intensity intervention involves monthly wellness coaching, personalized goal setting, and progress tracking in addition to monthly group activities and social support.
45482089|NCT02470156|Behavioral|Low Intensity Arm (Comparison)|The low intensity intervention involves wellness coaching, personalized goal setting, and progress tracking at baseline, 4 months, 8 months, and 12 months.
45482090|NCT05251350|Procedure|surgery|our study is observational and we use secondary data
45482091|NCT03309826|Device|Positive Airway Pressure|Auto-PAP titration followed by fixed PAP treatment
45482092|NCT03309826|Device|Nasal Dilator Strip|Nightly use of nasal dilator strip
45482093|NCT05147532|Procedure|PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714|PET-MRI: 2 at baseline visits (V0 and V1) and 1 at M6
45847818|NCT02970006|Device|neurovisual stimulation|a new system of multisensory stimulation based on virtual and enhanced reality (i.e., neuro-visual stimulation)
45847819|NCT02970162|Drug|Amifampridine Phosphate|
46050550|NCT00796003|Drug|JNJ-30979754 20 mg/m2|Phase I: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1. Phase II: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles until the decitabine was expected to be effective in participants.
45482094|NCT05139888|Device|Single wavelength light (red) only|Clinicians should confirm a diagnosis of distal subungual onychomycosis (DSO). Clinician should assign an OSI score to each nail using the Onychomycosis Severity Index (OSI). The ToeFX system is intended for use in any room in which standard foot care treatments are routinely administered. Debridement should not be carried out more proximally than the most proximal margin of the dystrophic nail, as this can interfere with assessment of clear nail area attributable to the device intervention. The clinician should debride the nail, apply formula, and position the affected foot directly under the ToeFX ClearToe Therapy red light (640-660 nm). For safety, the light has a built-in timer and automatically switches off after 15 minutes. The process should be repeated every 2 weeks for 6 months.
45690195|NCT04558736|Radiation|Total Lymphoid Irradiation (TLI)|TLI will be given at 800 cGy total dose in 4 fractions.
45690196|NCT04558736|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
45690197|NCT04558736|Biological|HPC, A Infusion|Given intravenously Day 0-HPC, A Infusion (TCR αβ+/CD19+-depleted graft)
45690198|NCT04558736|Biological|CD45RA-depleted DLI|CD45RA-depleted DLI will be given at least ONE week after engraftment
45690199|NCT01422213|Drug|Placebo|capsules; daily; orally
46050551|NCT04110379|Behavioral|Virtual Reality (VR)|All the dental procedures that will be done will be explained to the child using tell-show-do technique. VR glasses will be introduced to the child using tell-show-do technique and he will be given a choice of cartoon episodes to select from according to his own interest and age appropriate to view during the dental treatment. The child will be given five minutes to get familiar with the VR glasses before starting the dental treatment.
46050552|NCT04110379|Behavioral|Conventional Behavior Management Techniques|Conventional behavior management techniques will be done to relieve the child's dental anxiety during the dental treatment such as : tell-show-do technique, distraction, and positive reinforcement, according to the child's behavior.
46050553|NCT04110535|Drug|Remimazolam|IV administration over 1 minute
46050554|NCT04110535|Drug|Midazolam|IV administration over 1 minute
45482095|NCT05139888|Device|Dual wavelength light (red/blue)|Clinicians should confirm a diagnosis of distal subungual onychomycosis (DSO). Clinician should assign an OSI score to each nail using the Onychomycosis Severity Index (OSI). The ToeFX system is intended for use in any room in which standard foot care treatments are routinely administered. Debridement should not be carried out more proximally than the most proximal margin of the dystrophic nail, as this can interfere with assessment of clear nail area attributable to the device intervention. The clinician should debride the nail, apply formula, and position the affected foot directly under the ToeFX ClearToe Therapy dual wavelength light (640-660 nm and 405-450 nm). For safety, the light has a built-in timer and automatically switches off after 15 minutes. The process should be repeated every 2 weeks for 6 months..
45482096|NCT03309748|Procedure|Dental prophylaxis|American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110
45364502|NCT00615056|Drug|Bevacizumab (avastin)|Bevacizumab intravenous infusion [IV] 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
45482097|NCT03309748|Device|Dental prophylaxis + antimicrobial photodynamic therapy|Dental prophylaxis using American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110 followed by two 8-minute irradiation cycles using GLO Brilliant home use whitening device (GLO ™ Science LLC, New York, USA).
45482098|NCT03309670|Other|Psychiatric future|Former young psychiatric patients are contacted to determine their psychiatric outcome.
45482099|NCT01316016|Dietary Supplement|Rose hip|40 g of rose hip powder daily for 6 weeks.
45482100|NCT03152682|Dietary Supplement|GoodIdea|Active product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
45482101|NCT03152682|Other|Placebo|Non-active placebo product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
45482102|NCT02108860|Drug|Abatacept|Those randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 6 will have the option of entering an open-label trial period whereby they would receive open-label abatacept. .
45690200|NCT01422213|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
45690201|NCT01422213|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
45845754|NCT05642520|Procedure|Circular section abutment of 3.3 mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 6.4 and 7.1 mm, a 3.3 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
45482103|NCT02108860|Drug|placebo|Those randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week.
45482104|NCT03169998|Device|EV1000 platform|a continuous arterial pressure monitoring was performed via EV1000/ FloTrac (Edwards Lifesciences, Irvine, CA, USA) (Fig 1) with the continuous monitoring of cardiac index (CI), stroke volume index (SVI) and stroke volume (SV).
45482105|NCT01341132|Procedure|MRI Scan of the Liver enhanced with Eovist|10mL of gadoxetate disodium administered intravenously while being scanned via the MRI. Images will be attained on a 5, 10 and 20 minute delay. Expected scan time is 45 minutes total
45482106|NCT00705250|Drug|bendamustine hcl|Patients will receive bendamustine 120mg/m^2, administered as a 30-minute infusion, for two consecutive days. Cycles will be repeated every four weeks and a total of 6 cycles will be planned. Patients will receive pegfilgrastim with each cycle. Treatment will be delayed until the absolute neutrophil count is > 1000/ul and the platelet count is > 75,000/ul.
45482107|NCT03309592|Drug|Ambrisentan Pill|Will be administered as stated in Arm/Group Descriptions
45690202|NCT01390857|Drug|Valaciclovir|
45690203|NCT01725386|Drug|Capecitabine|Oral tablet(s) administered according to prescribing information
45690204|NCT01402011|Procedure|25% dextrose in shoulder entheses|injections of 1 mL of 25% dextrose and .1% lidocaine solution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
45690205|NCT01402011|Procedure|.1% lidocaine in shoulder entheses|injections of 1 mL of .1% lidocaine 'ssolution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
45847820|NCT02970162|Drug|Placebo Oral Tablet|
45364503|NCT00615056|Drug|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
45364504|NCT01003431|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|[Intervention name: RotaTeq™ administered concomitantly with Tritanrix™ HepB (DTwP)] Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration.
45482108|NCT03309592|Drug|Tadalafil Pill|Will be administered as stated in Arm/Group Descriptions
45364505|NCT01003431|Biological|Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP)|Two 1.0 mL oral doses of Rotarix™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration (the second administration will be Tritanrix™ HepB only).
45364506|NCT01003431|Biological|Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)|Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of INFANRIX™ will be given at the same time with about 1 month between each administration.
45690206|NCT01402011|Procedure|.1% lidocaine subcu. above shouldr enth.|injections of 1 mL of .1% lidocaine solution subcutaneously, above the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic, above the insertion of the teres minor and the triceps on the scapula.
45364507|NCT01006473|Other|Exercise training|
45364508|NCT01006551|Drug|Ziprasidone|20mg pills, dosing will be flexible, ranging from 10 to 160 mg divided BID or TID for the duration of the 52 week trial. In very rare cases, if the subject has shown some benefit and no side effects at a dose of 160mg and the treating clinician feels a further dose increase is necessary, the case would need to be presented to all of the other Principal Investigators for special consideration of further dose increases in 20 mg increments to an absolute maximal dose of 220mg.
45364509|NCT05732727|Drug|Antihypertensive algorithm|Antihypertensive algorithm based on diuretics agents
45364510|NCT05732727|Drug|Standard of care|standard of care management for antihypertensive therapy intensification
45364511|NCT00873626|Drug|levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)|Levofloxacin 500mg : 1/j Ofloxacin : 200mgX2/j Ciprofloxacin 500mg X2/j
45364512|NCT01003509|Procedure|modified shouldice and double|one arm modified shouldice, other one is double repair
45364513|NCT00879242|Drug|Deferasirox|Dispersible tables of 125, 250 and 500 mg at the dose of 30 mg/kg/day, oral administration.
45364514|NCT05732493|Drug|Serplulimab|Serplulimab 300mg, d1, q3w
45364515|NCT05732493|Radiation|short-term radiotherapy|radiation: 25Gy/5Fx
45364516|NCT05732493|Drug|Oxaliplatin|130mg/m2 d1 q3w
45364517|NCT05732493|Drug|Capecitabine|1000mg/m2 d1-14 q3w
45364518|NCT00873704|Other|supplemental postoperative oxygen|
45364519|NCT01003587|Behavioral|District health information package|"The intervention package consists of:~A report on disease burden, disease control priorities and health system performance in India~Condensed fact sheet based on the report~District health report cards (DRCs) comparing performance on key health indicators with other districts, information on causes of death in each district, and actionable messages to reduce deaths in the district~Customized speech for district level officials detailing key actions to reduce deaths~Reminder materials including poster version of the DRCs and video on key points and actionable messages"
45482109|NCT03143322|Radiation|SBRT|SBRT will be added to systemic (standard) treatment of bone metastases.
45482110|NCT04641312|Drug|LY3457263|Administered SC
45482111|NCT04641312|Drug|Dulaglutide|Administered SC
45482112|NCT04641312|Drug|Placebo|Administered SC
45482113|NCT05173870|Device|Wearable device|The wearable devices has a biosensor able to daily collect,in a remote way, many biometric measurements such as: blood pressure, blood oxygenation, heart and respiratory rate
45482114|NCT04640220|Procedure|Intra-articular steroid injection|Ultrasound-guided Gleno-humeral joint steroid (Triamcinolone 40mg with 0.5% lidocaine ) injection
45482115|NCT03078192|Drug|GE-141, Hyperpolarized 129Xenon gas|XeMRI scans will provide 3D images of ventilation and gas exchange. Subjects will inhale HP 129Xe from the dose delivery bags. Then the subject will be moved into the scanner and they will undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will under-go several MRI scans after inhalation of HPXe
45482116|NCT03078192|Device|MRI|Perform MRI scans with administration of GE-141, Hyperpolarized 129Xenon
45690207|NCT01421667|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
45482117|NCT00703846|Drug|Ketoconazole|Foam, 2%, Extina will be applied twice daily (morning and evening) to all seborrheic dermatitis lesions on the face, scalp, ears, neck, and chest. Study product should be applied at the first sign of a seborrheic dermatitis flare, and twice daily applications should continue until the area(s) has cleared. All symptom flares should be treated throughout the 12-month study period.
45482118|NCT03309514|Biological|Intracerebral microinjections|Stereotactic delivery of cell suspension into basal ganglia structures
45482119|NCT01341288|Device|EUCLIDIAN Robot|EUCLIDIAN (Endo-Uro Computed Lattice for Intratumoral Delivery, Implantation, Ablation with Nanosensing) system for placement of radioactive seeds in the prostate
45364520|NCT00868634|Drug|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
45364521|NCT00868634|Drug|bevacizumab|15 mg/kg i.v., day 1 Cycles are repeated every three weeks.
45482120|NCT03309436|Drug|Clomiphene Citrate protocol|Take CC 100mg/d at the same time with Gn until hCG injection.
45482121|NCT03309436|Procedure|Procedure|When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection.
45482122|NCT05183334|Drug|Sildenafil 50 mg|PD5I
45482123|NCT05183334|Drug|Placebo|placebo
45482124|NCT05183334|Drug|Tramadol Hydrochloride 100 MG|opiod
45690208|NCT01421667|Drug|rituximab|375 mg/m2 every 3 weeks by IV infusion
45482125|NCT05232526|Other|Mental imagery (MI) and exercise program|Mental imagery and exercise program will be used to improve balance, functional status, cognitive ability, depression and quality of life of the sample
45482126|NCT05232526|Device|Mental Imagery and Exercise program|Questionnaires and functional tests are going to be used to evaluate balance, functional status, cognitive ability, depression and quality of life of the sample.
45482127|NCT05250882|Other|Enhanced perioperative care protocol|See arm/group description
45482128|NCT03304990|Other|Patients with CA or suspected risk of CA or a family Hx|Patients with Family History of Cancer, (ii) Patients with Clinical and Environmental Risk Factors for Cancer, (iii) Patients with a Suspected or Confirmed Diagnosis of Cancer.
45690209|NCT01390779|Device|SENSIMED Triggerfish|Contact lens-based device intended to continuously record the timing of relative changes in IOP for up to 24 hours
45690210|NCT01891669|Drug|PF-06263507|Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined.
45482129|NCT05129592|Behavioral|Coherent corrective messages|Participants will be randomized to one of four message conditions: condition 1 will not contain either component of the coherence; condition 2 will contain one element of coherence (a causal explanation for why the corrective information is accurate); condition 3 will contain the other element of coherence (an explanation for why the misinformation came to be believed); condition 4 will include both elements of coherence.
45482130|NCT03304912|Behavioral|PrEP Education and option to accept a PrEP prescription|Participants will receive educational information about PrEP, be offered a PrEP prescription, and those who choose to initiated PrEP will be monitored for side-effects and adherence at their follow-up visit. There is no group assignment within this study and WWID do not have to choose to initiate PrEP. Rather, the goal of this study is to understand factors that impact PrEP initiation (and engagement in the PrEP care continuum).
45482131|NCT05119530|Diagnostic Test|AcuVid COVID-19 Rapid Antigen Saliva Test|The AcuVid COVID-19 Rapid Antigen Saliva Test is a lateral flow immunoassay to detect SARS-CoV-2 nucleocapsid antigens in human saliva specimens
45482132|NCT03304834|Device|ECHOPULSE|Patient are treated with the HIFU device and the physician is doing a compressive bandage.
45482133|NCT01341366|Other|Fast-track perioperative program|Preoperative counseling, no preoperative fasting, short-acting anesthetics, continuous infiltration of wound with local anesthetic agent, non-opioid pain management, the use of chewing gum, and early postoperative feeding and mobilization
45690211|NCT01891669|Drug|PF-06263507|Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
45690212|NCT01421511|Drug|TR-701 FA|"TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion~TR-701 FA Tablets, 200 mg, orally once daily"
45690213|NCT01421511|Drug|Linezolid|"Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion~Linezolid Tablets, 600 mg, orally every 12 hours"
45847821|NCT02970552|Drug|Vaginal Progesterone|200 mg micronized vaginal progesterone suppository
45847822|NCT02970552|Drug|Placebo|Indistinguishable placebo vaginal suppository
46050555|NCT04110535|Other|Saline|IV administration over 1 minute
45364522|NCT00868634|Drug|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
45364523|NCT00868634|Drug|bevacizumab|15 mg/kg i.v., day 1. Cycles are repeated every three weeks.
45364524|NCT00868634|Drug|vinorelbine|25 mg/m2 i.v., days 1+8. Cycles are repeated every three weeks.
45482134|NCT01341366|Other|Traditional perioperative program|Preoperative fasting, standard anesthetic management with no intraoperative fluid restriction, opioid pain management, no chewing gum, feeding/mobilization according to attending surgeon
45482135|NCT03304756|Drug|CAP|cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
45482136|NCT01315860|Other|Postural Analysis|Measure the subject's weight, sway rate and shift of center of gravity on a postural scale for 15 seconds. Measure lumbosacral angle with an inclinometer.
45482137|NCT03309358|Drug|Inhaled SNSP113|A single ascending dose of inhaled SNSP113 will be administered to healthy subjects and subjects with stable cystic fibrosis.
45482138|NCT03309358|Drug|Inhaled Placebo|A single dose of inhaled placebo control will be administered to healthy subjects and subjects with stable cystic fibrosis.
45482139|NCT03309280|Other|Duration of intubation|Time between intubation in the operating room and exhumation in the Intensive Care Unit.
46050556|NCT05562895|Device|Ion Endoluminal System and Cios Spin|Integrated version of the Ion Endoluminal System and Cios Spin
45364525|NCT05232357|Drug|Sodium thiosulfate and Methylene blue solution|Take a methylene blue injection (2ml:20mg), add 18ml distilled water and mix well. Add NaS2O3.5H2O800mg to the methylene blue solution 10ml, add 4 drops of dilute hydrochloric acid, heat the water bath until the dark blue fades, the solution is milky and turbid, adjust the PH to about 3.5. Put the prepared solution into a glass bottle with a rubber stopper, which is wrapped in tin foil, sealed and protected from light, and stored in a refrigerator at-20 ℃. It can be used after high-pressure sterilization before operation. Sodium thiosulfate-Methylene blue (DMB) staining solution was used as nerve staining agent. During gastroenteroscopy, DMB staining solution was locally sprayed on the surface of gastrointestinal lesion mucosa or injected into the lesion mucosa.
45364526|NCT05020275|Diagnostic Test|Blood Samples|"Samples for ctDNA blood concentration and osimertinib plasma concentration~Sample for genetic polymorphisms"
45364527|NCT00879476|Drug|Ramipril 10mg capsules|
45364528|NCT01003743|Device|endolumenal tissue approximation|
45364529|NCT05732337|Device|Poxclin Coolmousse|cooling mousse for application in the skin
45364530|NCT05732259|Other|Percussion therapy|Participant lying in prone position on the couch will receive percussion therapy with Theragun PRO using standard ball head at speed of 1750 rpm, for total of 90 seconds, split into 3 sets of 30 seconds with 10 seconds rest.
45482140|NCT03309280|Diagnostic Test|Evolution of the renal function|Evolution of the renal function in the next two days
45690214|NCT04612231|Behavioral|TEACCH School Transition to Employment and Postsecondary Education (T-STEP)|The T-STEP Program is a 12-week transition intervention targeting specific challenges that young adults with ASD experience in executive function, social communication, and emotion regulation including group intervention, internship, and counseling services
45364531|NCT05732259|Other|Manual Myofascial Release technique|Manual myofascial release technique for 90 sec continuous.
45364532|NCT04925102|Other|Standardized treatment protocol for cerebral palsy|Passive and active range of motion (ROM) exercises of all joints, prone positioning, slow prolonged manual stretching (30 minutes daily), standing frame for children with GMFCS IV-V, supported sitting, supported walking, lower limb serial casting (if needed), active strength training, progressive resistance training, functional exercises, sensory integration: therapeutic activities to organize sensation from the body and environment, bimanual training: repetitive task training in the use of two hands together, context-focused therapy: changing the task or the environment, the occupational therapy, cognitive behaviour therapy and home programmes.
45364533|NCT00879554|Biological|CVX-045|Weekly, intravenous dose
45482141|NCT04391556|Drug|Firmagon|120 mg subcutaneous Injection of Firmagon after a TEP-PSMA
45482142|NCT03314194|Other|Plant Based Diet|Plant Based Diet for 4 Days Compared to Habitual Diet
45690215|NCT04612231|Behavioral|Counseling Services Alone|The Counseling Services Alone Intervention will receive 12 hours of individual counseling focused on job exploration/career counseling, academic counseling, and self-advocacy counseling.
45690216|NCT01864525|Drug|Octanoic acid|
45690217|NCT01864525|Drug|Inactive capsule|
45690218|NCT01421277|Drug|Statin Therapy|Investigator's choice of any statin.
45482143|NCT05066490|Other|Endurance exercise|Treadmill training at moderate intensity.
45482144|NCT05066490|Other|Resistance exersises.|Resistance exercises using the 10 repetition maximum.
45482145|NCT03304444|Drug|Bupivacaine|bupivacaine hydrochloride used in TAP block
45482146|NCT03304444|Drug|liposomal bupivacaine|liposomal bupivacaine used in TAP block
45482147|NCT03314116|Other|Guidance on auditory protection|by video or medic
45482148|NCT03304366|Diagnostic Test|Pentacam (scheimpflug imaging)|Corneal changes including thickness, elevations....etc
45690219|NCT01891357|Procedure|Biopsy before and after three weeks of study treatment|Core biopsies for histological analyses, to be analysed by the central pathology
45690220|NCT01891357|Drug|paclitaxel|
45690221|NCT01891357|Drug|lapatinib|
45364534|NCT00868946|Drug|Virazole (Ribavirin)|"Duration of Subject Participation:7-day course of treatment with follow-up 28 - 60 days after first dose of IV ribavirin Route of Administration and Regimen:The drug is administered IV in a volume of 50-100 mL of normal saline to be infused over 30-40 minutes.~Ribavirin Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses)."
45364535|NCT00874016|Device|Airtraq|Intubation using Airtraq
45364536|NCT00874016|Device|Direct Laryngoscopy|Intubation using direct laryngoscopy
45364537|NCT00482014|Drug|pemetrexed|"Phase 1 - 500 milligram/meter squared (mg/m²), administered intravenously, every 21 days for 3 cycles~Phase 2 - 500 mg/m², administered intravenously, every 21 days for 3 cycles~Consolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation therapy for each phase"
45364538|NCT00482014|Drug|cisplatin|"Phase 1 - 30 mg/m² and 75 mg/m², administered intravenously, Days 1, 8, 22, 29 and 43~Phase 2 - 75 mg/m², administered intravenously, every 21 days for 3 cycles"
45364539|NCT00482014|Drug|carboplatin|"Phase 1 - dosed at area under the curve (AUC) 2 milligram/milliliter*minute (mg/mL*min), administered intravenously, Days 1, 8, 22, 29 and 43~Phase 2 - dosed at AUC 5 mg/mL*min, administered intravenously, every 21 days for 3 cycles"
45364540|NCT00482014|Radiation|radiation therapy|"Phase 1 - 2 Gray, daily, 5 days a week for Days 1-51~Phase 2 - 2 Gray, daily, 5 days a week for Days 1-45"
45364541|NCT00879788|Drug|Ramipril 10mg capsules|
45364542|NCT03595553|Drug|Ridinilazole|ridinilazole (200 mg bid)
45364543|NCT03595553|Drug|Vancomycin|vancomycin (125 mg qid)
45364544|NCT00874172|Drug|Rapid optimized analgesic strategy|"Oral treatment :~1 gr Acetaminophen 20 mg of nefopam delivered on a lump sugar Nitrous oxide inhalation with initial output of 9 L/min subsequently Intravenous morphine bolus of 3 mg Nitrous oxide interruption after 5 minutes of the initial morphine bolus"
45364545|NCT00874172|Drug|current analgesic strategy|"paracetamol 1 g per os nasal oxygen therapy~1 amp of morphine 10 mg / 10 cc of glucose 5 %, by repeated bolus administration"
45364546|NCT04119154|Diagnostic Test|Contrast Microhalography (CEM)|Fine needle aspirates evaluated by CEM device
45364547|NCT00614822|Drug|Carboplatin, Pemetrexed and Bevacizumab|Carboplatin AUC 5 IV day 1 over 30-60 minutes Pemetrexed 500 mg/M2 IV day 1 over 10 minutes Bevacizumab 15 mg /kg IV day over 90 minutes dose 1, 60 minutes dose 2, 30 minutes subsequent doses. Repeat every 3 weeks for total of 6 cycles
45364548|NCT04861298|Drug|standard of care for COVID-19 as per the hospital guidelines|Hospital standard of care treatment for COVID-19
46050557|NCT05335785|Device|High-intensity lazer therapy|Patients in the laser group will be given hiltherapy (high-intensity laser) with the HIRO 3 device every other day. One session of laser therapy application consists of 3 phases: the beginning, the middle and the ending phase. The initial phases are fast scanning and the ending phase is slow scanning. A total of 2000 J will be applied to the rotatorcuff muscles, the upper part of the trapezius muscle, the deltoid muscle and the pectoralis major muscle, 1000 J in the rapid scan phase and 1000 J in the finishing phase. In the middle phase, 50 J will be applied for the trigger point (hard intramuscular points that cause referred pain) in each muscle and a maximum of 500 J in total. The total dose prescribed for patients in one session will be 2500 J. Each phase will be 15 minutes on average and the session will last for 45 minutes in total. The laser probe will be applied with 90 degrees. During the application, the practitioner and the patient will have protective glasses.
45364549|NCT04861298|Dietary Supplement|Quercetin Phytosome (QP)|Daily dose of 600 mg of Quercetin for 1st week and then 400 mg for the 2nd week
45364550|NCT04860986|Device|EarliPoint|EarliPoint is a non-invasive diagnostic device for ASD
45364551|NCT00869102|Drug|GLP-1|intravenous, 124,5 pmol/kg body weight
45364552|NCT03582917|Drug|Alphacalcidol|Alphacalcidol 0,5mg tablet
45364553|NCT05226728|Drug|pembrolizumab|Eligible patients received pembrolizumab 200mg every 3 weeks with or without chemotherapy for four cycles, then for patients without progressive disease, pembrolizumab was administrated in new dose-intervals according to steady state plasma-concentration (Css) of pembrolizumab until disease progression
45364554|NCT00869180|Drug|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
45482149|NCT03304288|Drug|Rituximab|Low-dose rituximab was used in combination with ATRA or as the monotherapy
46050558|NCT05335785|Other|Exercises|Exercise program including Codman, Range of motion and streightening exercises three times in a week.
45690222|NCT01891357|Drug|trastuzumab|
45364555|NCT00869180|Drug|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
45364556|NCT00874328|Drug|Irinotecan|Irinotecan iv D1 q 3 weeks until maximum 6 cycles
45364557|NCT00874328|Drug|Cisplatin|cisplatin 60mg/m2 iv D1 q 3weeks until maximum 6 cycles
45364558|NCT00874328|Drug|TS-1 (S-1)|TS-1 po D1~D14 q 3 weeks until maximum 6 cycles
45364559|NCT00879866|Biological|EMD 521873|After local irradiation (5 x 4 Gy) given over 5 consecutive days and 2 treatment free days cohorts of 3-6 subjects will receive EMD 521873 (as a 1h-infusion) on 3 consecutive days in 3-week cycles at dose levels of 0.15, 0.30, and 0.45 mg/kg, respectively.
45482150|NCT03304288|Drug|All-trans retinoic acid|ATRA was used in combination with low-dose rituximab
45364560|NCT00879944|Other|Blood pressure|Blood pressure will be measured once while patient is seated
45690223|NCT04035447|Behavioral|Behavioral Symptom Management for Young Adult Cancer Survivors|The intervention includes group sessions held over Zoom along with an integrated mobile application to provide participants with instruction in cognitive and behavioral strategies for managing symptoms (i.e., pain, fatigue, distress). The developed intervention includes 8 face-to-face group sessions (12 therapy hours). Sessions are delivered using a faded contact approach (i.e., sessions 1-6: weekly, sessions 7-8: biweekly). Participants receive secure access to a study-specific mobile application that includes: 1) audio and video files and brief text-based educational content reviewing strategies discussed during the groups; 2) the ability to self-monitor symptom severity; 3) the ability to connect with group members via a social networking platform; and 4) activity tracking synchronization.
45690224|NCT01420965|Drug|CT-011 (Anti-PD1 Antibody)|Immune Enhancer
45364561|NCT00879944|Other|Height|Height will be measured in centimeters at the time of enrollment
45364562|NCT00879944|Other|Weight|Weight will be measured in kilograms at enrollment
45364563|NCT00879944|Other|BMI|Body Mass Index (BMI) will be calculated from a subject's height and weight
45364564|NCT00879944|Other|Waist Circumference|Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
45364565|NCT00874406|Drug|tac + folfox4|tac: oxaliplatin 100mg + fudr 1g + mmc 10mg 7 days later： operation within 28 days after operation: folfox4
45364566|NCT00874406|Drug|folfox4|folfox4 will be done within 28 days after liver resection
45364567|NCT04840628|Other|Resistance of the respiratory system|increase the resistance of the respiratory system of the chronic obstructive pulmonary disease patients
45364568|NCT00880178|Drug|Simvastatin and Extended-Release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
45482151|NCT03309124|Other|White bread|Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.
45482152|NCT03309124|Other|Baked potato with skin|Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).
46050559|NCT04025203|Other|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
45364569|NCT00880178|Drug|Simvastatin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
45364570|NCT04038866|Other|rehabilitation gait with dual task|
45364571|NCT04038866|Other|rehabilitation gait without dual task|
45364572|NCT00529659|Drug|Comparator: MK-0773|MK-0773 50 mg tablets twice daily, 6 month treatment period
46050560|NCT04025203|Drug|Ibuprofen Arginine|Oral tablets
46050561|NCT04025203|Drug|Gabapentin|oral capsules
46050562|NCT02843607|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
45364573|NCT00529659|Drug|Comparator: Placebo|Placebo tablets twice daily, 6 month treatment period
45364574|NCT03569891|Genetic|AAV5-hFIXco-Padua|Single intravenous infusion of AAV5-hFIXco-Padua (AMT-061)
45690225|NCT01420965|Other|Sipuleucel-T (Provenge)|Vaccine
46050563|NCT02843607|Biological|NK immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
46050564|NCT02843685|Drug|Drotrecogin alfa activated|
46050565|NCT04106947|Other|Questionnaires|Questionnaires
46050566|NCT00915577|Drug|Interferon beta-1a|30mcg, IM once-a-week
45364575|NCT03569891|Biological|Factor IX (FIX)|During the lead-in phase, which lasted for a minimum of 26 weeks (i.e., ≥6 months), subjects recorded their use of FIX replacement therapy and bleeding episodes in their dedicated e-diary.
45364576|NCT05726565|Other|multidisciplinary cardiac rehabilitation|A heart failure disease management program was delivered to all patients before discharge, including an HF specialist nurse education program, dietitian consultation, physiatrist consultation, and psychologist consultation and assessment. Participants were advised to receive phase II CR after the CPET within one month. Moderate continuous aerobic exercise training was prescribed individually according to the CPET result.4 The training intensity was within 10 beats of the anaerobic threshold or 40-60% of peak VO2. The training intensity was gradually increased fortnightly as tolerated (Borg's scale of 12-14). Phase II CR consisted of 12 weeks of 36 sessions in the entire course. Patients who received at least one exercise session were considered as receiving CR. Other patients were considered non-receiving CR.
45364577|NCT03547739|Behavioral|Home visits|If a couple has been randomized to the home visit intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the couple about optimal times for a home visit. As described above, the intervention arm will consist of five home visits conducted by one female and one male lay health worker, including two home visits during pregnancy, one at six weeks after the birth, and two booster sessions, one at six months after the birth and one at 12 months after the birth. Home visits are designed for all pregnant couples (regardless of woman's initial HIV test result at the antenatal clinic) and include topics important for maternal, paternal, and child health during pregnancy and postpartum.
45364578|NCT03547739|Behavioral|HIV Self-testing|Women in this study group will receive oral-fluid-based rapid HIV test kits for themselves and their male partner at up to 4 time points (twice during pregnancy and twice postpartum). Each test will be accompanied with a self-testing instruction sheet describing step-by-step procedures in multiple languages. Study staff will also conduct a brief demonstration on how to use the tests. Participants will be encouraged to offer a test kit to their male partner or to undertake couples testing. They will also be counseled on how to talk to their partners and the possibility of adverse partner reactions. Participants will be instructed to seek clinic-based confirmatory testing if a reactive self-test result is obtained.
45364579|NCT04076969|Behavioral|Integrated educational session|The educational session aimed to correct the pregnant women diatery habits and enhance the degree of compliance to the iron treatment and follow up instruction.
46050567|NCT00915577|Device|Single-use autoinjector|Single-use autoinjector with Avonex 30mcg pre-filled syringe
45364580|NCT04077125|Drug|Rifaximin|to investigate changes in cerebral, splanchnic hemodynamics and endothelial function in cirrhotic patients with MHE after 15 days of rifaximin therapy (1200 mg/d)
45364581|NCT05716893|Behavioral|Adaptive Aerobic Training/AT Dosing|o In Phase A (~32 weeks), AT will consist of supervised walking delivered up to 7 days per week using an adaptive dosing schedule that starts at 90 min/wk and is escalated 30 min/wk every 2 weeks to a maximal dose of 300 mins/wk. In Phase B (~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ<3.50 ml O2 .kg-1.min-1 from baseline to ~32 weeks, or unsupervised AT in patients with a CRF Δ>3.50 ml O2 .kg-1.min-1 from baseline to ~32 weeks. Supervised AT will be monitored using TeleEx.
45482153|NCT03309124|Other|Mashed potatoes|Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.
45482154|NCT03309124|Other|Fried French fries|Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.
45482155|NCT03309124|Other|Meal skipping|No food given
46050568|NCT00895011|Drug|Placebo|One dose 30 minutes prior to initiation of sexual activity
46050569|NCT00895011|Drug|Avanafil|One dose 30 minutes prior to initiation of sexual activity
46050570|NCT00895011|Drug|Avanafil|One dose 30 minutes prior to initiation of sexual activity
46050571|NCT02604355|Other|Matching Placebo|Oral dosing with placebo capsules to match RO7020322.
46050572|NCT02604355|Drug|RO7020322|Adaptive oral dosing with RO7020322 capsules, starting at 1 mg daily, with ascending or adjusted dosing based on the results of previous dosing.
46050573|NCT00899847|Procedure|Autologous peripheral blood stem cells (auto-PBSC) transplantation|"Auto-PBSC ≥ 2 to 3 x 10e6 CD34+ cells/kg are intravenously (IV) infused as part of the combination stem cell therapy.~and allogeneic stem cells are administered intravenous (IV) infusion to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective"
46050574|NCT00899847|Procedure|Allogeneic peripheral blood stem cells (allo-PBSC) transplantation|Allo-PBSC (target collection ≥ 5 x 10e6 CD34+ cells/kg) are intravenously (IV) infused as part of the combination stem cell therapy.
46050575|NCT00899847|Drug|Filgrastim|"Filgrastim is administered subcutaneously (SC) at 10 µg/kg/day for auto-PBSC mobilization starting day 2 of mobilization until the last day of apheresis.~Filgrastim is administered SC at 5 µg/kg/day from Day 6 after auto-PBSC infusion to hematologic recovery.~Filgrastim is administered SC at 16 µg/kg/day for donor allo-PBSC mobilization at from Day - 4 to Day 0, prior to allo-PBSC collection."
46050576|NCT00899847|Drug|Cyclophosphamide|Cyclophosphamide is administered intravenously (IV) at 4 g/m2 on Day 1 of the auto-PBSC mobilization regimen.
45364582|NCT05716893|Behavioral|Standard (fixed) Aerobic Training/AT dosing|In Phase A (~32 weeks), AT will consist of supervised walking delivered up to 7 days per week to achieve a cumulative total duration of: 90 min/wk (standard fixed dosing). In Phase B (~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ<3.50 ml O2 .kg-1.min-1 from baseline to ~32 weeks, or unsupervised AT in patients with a CRF Δ>3.50 ml O2 .kg-1.min-1 from baseline to ~32 weeks. Supervised AT will be monitored using TeleEx.
45364583|NCT04194203|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
45364584|NCT04194203|Drug|Placebo|Placebo matching to atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
45364585|NCT04194203|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
45364586|NCT04194203|Drug|Paclitaxel|Paclitaxel will be administered by IV infusion at a dose of 175 mg/m2.
45364587|NCT04194203|Drug|Pemetrexed|Pemetrexed will be administered by IV infusion at a dose of 500 mg/m2.
45364588|NCT04194203|Drug|Carboplatin|Carboplatin will be administered by IV infusion to achieve an initial target AUC of 6 mg/mL/min.
45364589|NCT04076891|Drug|RZL-012|The dosing regimen will be a single dose treatment injection of RZL-012 in multiple sites.
45364590|NCT05707689|Behavioral|Entertainment gaming|If needed, gaming schedule will be tailored based on the participants' individual needs (working, studying, family issues) as long as the total gaming hours will be achieved. Participants are encouraged not to play video games during the study period. Participants' gaming interventions will be monitored carefully and recorded after each gaming session in specific gaming diary.
45364591|NCT05172401|Device|Oxulumis® suprachoroidal microcatheterization administration of Triesence®|Suprachoroidally administered Triamcinolone acetonide (Triesence) 2.4mg/60µl
45364592|NCT05167877|Other|No intervention will be given to the participants|This is an observational feasibility study with no intervention.
45364593|NCT01006785|Drug|DLBS1425|3 X 150 mg daily for 12 - 16 weeks of treatment
45364594|NCT01006785|Drug|DLBS1425|3 X 300 mg daily for 12 - 16 weeks of treatment
45364595|NCT00143455|Drug|Etoposide + cisplatin|etoposide 100 mg/m2 days 1, 2 and 3 cisplatin 80 mg/m2 day 1 3 week cycle
45364596|NCT00143455|Drug|Irinotecan + cisplatin|irinotecan 65 mg/m2 day 1 and 8 cisplatin 80mg/m2 day 1 3 week cycle
45364597|NCT02580617|Biological|ALLO-ASC|Infusion for Crohn's disease
45364598|NCT05016765|Device|Active, self-directed electrical stimulation of the median nerve|Electrical stimulation of the median nerve (12 Hz, pulse width 200µs), initially at the threshold needed to see movement of the right thumb with stimulation. After initial training with the device and education in the rationale for suprathreshold stimulation, participants will choose timing and intensity of stimulation based on their momentary symptom severity and their experience with the treatment since the beginning of the study. Participant can choose right or left median nerve (we will suggest their nondominant hand to minimize interference with daily activities).
45364599|NCT05166551|Procedure|Acupressure|"This study will be conducted in a randomized placebo-controlled research design to investigate the effect of acupressure, to be applied to the Gall Bladder (GB) 31 Fengshi acupuncture point before the vaccinations, on interventional pain in infants (0-1 years) caused by the vaccine."
45364600|NCT05166551|Procedure|Placebo Acupressure|Placebo Acupressure
45364601|NCT01006863|Drug|Ephedrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution [group 1 (n=30)], ephedrine 0.7 mg/mL [group 2 (n=30)], ephedrine 1 mg/mL [group 3 (n=30)] or ephedrine 1.5 mg/mL [group 4 (n=30)]or phenylephrine 15 mcg/mL [group 5 (n=30)]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
45482156|NCT03309046|Other|REACH Individual Session|Individual telephone session with parent
45482157|NCT03309046|Other|Education Webinar|Videos with information on caregiving
45690226|NCT01420965|Drug|Cyclophosphamide|Low dose- Immune Enhancer
45847823|NCT02971488|Other|Screening for HCV in PWID and Linkage-To-Care|"Screening, diagnosis and treatment of HCV in PWID, will be part of a harm reduction strategy.~Treatment of HCV infected PWID will be delivered in a multidisciplinary care setting with services to reduce the risk of reinfection and for management of the common social and psychiatric comorbidities in this population."
46050577|NCT00899847|Drug|Melphalan|Melphalan is administered after CSP at 200 mg/m2 intravenously (IV) on Day -2 before auto-PBSC infusion.
46050578|NCT00899847|Drug|Cyclosporine|Cyclosporine is administered by mouth (PO) for allo-PBSC graft vs host disease (GvHD) prophylaxis at 5 mg/kg from Day -3 through Bay +56. Tacrolimus may substituted.
46050579|NCT00899847|Radiation|Total lymphoid irradiation|Total lymphoid irradiation is administered at 80 centigrey (cGy) on Day -11 to -7; and Day -4 to -2 before alllo-PBSC infusion. TLI is also administered at 80 centigrey (cGy) x 2 on Day -1 before alllo-PBSC infusion.
45482158|NCT02469454|Drug|early insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum.
45690227|NCT04033575|Drug|Colgate Total SF|1100 ppm F Colgate Total Clean Mint White Paste Toothpaste is a test treatment
45690228|NCT04033575|Drug|Colgate Cavity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
45690229|NCT04767009|Drug|PD-1 Blockade|Patients will receive PD-1 blockade for up to 2 years or until confirmed progression or unacceptable toxicity. PD-1 blockade will be administrated as an intravenous(IV) infusion.
45482159|NCT02469454|Drug|conventional insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 6 week of delivery.
45482160|NCT03304210|Drug|PIPAC with Abraxane|Albumin bound nanoparticle paclitaxel (Abraxane) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 35 to 140 mg/m². PIPAC will be performed every 4 weeks for 3 cycles.
45482161|NCT03313960|Drug|"Afrezza plus One Drop | Premium"|"Participants in this group will receive insulin inhalation, prescribed by their physician, and will also receive One Drop | Premium (i.e., One Drop | Experts in-app coaching from a Certified Diabetes Educator (CDE) along with One Drop | Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop | Mobile app and 150 test strips per month for three months)."
46050580|NCT00899847|Biological|Rabbit anti-thymocyte globulin|ATG 1.5 mg/kg is administered intravenously (IV) on Day -11 to -7 before allo-PBSC infusion.
45364602|NCT01006863|Drug|Placebo|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution [group 1 (n=30)], ephedrine 0.7 mg/mL [group 2 (n=30)], ephedrine 1 mg/mL [group 3 (n=30)] or ephedrine 1.5 mg/mL [group 4 (n=30)]or phenylephrine 15 mcg/mL [group 5 (n=30)]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
45364603|NCT01006863|Drug|Phenylephrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/ml of phenylephrine [group 5 (n=30)] All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo, the ephedrine, and the phenylephrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
45364604|NCT03535727|Drug|Nab-paclitaxel|IV over 30 minutes; Days 1 and 15
45364605|NCT03535727|Drug|Gemcitabine|IV over 30 minutes; Days 1 and 15
45482162|NCT03313960|Other|"One Drop | Premium"|"Participants in this group will receive One Drop | Premium (i.e., One Drop | Experts in-app CDE coaching with the One Drop | Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop | Mobile app and 150 test strips per month for three months)."
45482163|NCT03308890|Drug|0.5mg Baraclude(entecavir)|0.5mg Baraclude (entecavir) QD for 6 months after cessation of TDF.
46050581|NCT00899847|Drug|Mycophenolate Mofetil 250mg|MMF is administered at 15 mg/kg 3x/day by mouth (PO) after allo-PBSC through Day 40, followed by 10% dose reduction weekly (dose taper) through day 96, and adjusted if there is evidence of MMF-related GI toxicity or excessive myelosuppression
45482164|NCT03308890|Drug|0.5mg Baraclude(entecavir)|0.5mg Baraclude (entecavir) QD for 12 month after cessation of TDF.
45482165|NCT03313726|Drug|GnRH antagonist|Administration of GnRh antagonist after baseline PSMA-PET at day 0 and then repeated PSMA-PET scans at day 7, day 14 and day 28 to define the timeframe of the SUV-max.
45482166|NCT03313726|Drug|GnRH antagonist|Administration of GnRh-antagonist after baseline PSMA-PET at day 0 and then repeated scan at day in which SUV-max was observed in the Arm A (day 7, day 14 or day 28). Then robot assisted radical prostatectomy and lymphadenectomy are performed to verify the finding.
46050582|NCT00899847|Drug|Solumedrol|Solumedrol 1 mg/kg is administered intravenously (IV) on Day -11 to -7 as a premedication for ATG and allo-PBSC infusion
46050583|NCT00899847|Drug|Diphenhydramine|Diphenhydramine 25 to 50 mg is administered as a premedication for the ATG; allo-PBSC; and DLI infusions.
45364606|NCT03535727|Drug|Capecitabine|PO twice daily (BID); Days 1-7, 15-21
45364607|NCT03535727|Drug|Cisplatin|IV over 60 minutes; Days 1 and 15
45364608|NCT03535727|Drug|Irinotecan|IV over 30 minutes; Days 1 and 15
45364609|NCT03535727|Drug|Nab-paclitaxel|IV over 30 minutes; Days 4 and 11
46050584|NCT00899847|Drug|Acetaminophen|Acetaminophen 650 mg is administered as a premedication for the ATG and allo-PBSC infusions.
46050585|NCT00899847|Drug|Hydrocortisone|Hydrocortisone 100 mg is administered intravenously (IV) is a premedication for the allo-PBSC and DLI infusions.
46050586|NCT04106479|Device|NIRS evaluation|NIRS will be used for measurement of cerebral and renal saturation.
46050587|NCT05558605|Diagnostic Test|AI-guided echo|AI-guided echocardiography
46050588|NCT05558605|Diagnostic Test|Standard echo|Standard echocardiography
46050589|NCT04106791|Device|closed-loop system for vasopressor administration|The closed-loop system' goal is to keep MAP within 5 mmHg of the predefined target MAP.
46050590|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 21 days
46050591|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (300 mg/day) for 21 days
46050592|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 28 days
45845755|NCT05612802|Diagnostic Test|IGF-1|We need to diagnose acute kidney injury in the early postoperative period. The markers examined so far do not provide enough information to diagnose acute kidney injury early. For this reason, many different biomarkers are used in the early diagnosis of acute kidney injury in many parts of the world. Thanks to our research, we can recognise the development of acute kidney injury at an early stage and determine whether a previously unused biomarker (IGF-1) is effective in the early diagnosis of acute kidney injury.
45364610|NCT03535727|Drug|Gemcitabine|IV over 30 minutes; Days 4 and 11
45364611|NCT03535727|Drug|Capecitabine|PO BID; Days 1- 14
46050593|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (200 mg/day) for 28 days
46050594|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (250 mg/day) for 28 days
46050595|NCT00529113|Drug|Bardoxolone methyl|Bardoxlone methyl capsules (300 mg/day) x 28 days
45364612|NCT03535727|Drug|Cisplatin|IV over 60 minutes; Days 4 and 11
45364613|NCT03535727|Drug|Irinotecan|IV over 30 minutes; Days 4 and 11
45482167|NCT03308812|Behavioral|Health360x|Participants will view an orientation video which will include information on how to access the program from home and other internet access sites, how to use their activity monitor and sphygmomanometers, introduction to the curriculum, quizzes and discussion boards. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the application will be available 24 hours by phone.
45482168|NCT03308812|Behavioral|Health Coach|Participants will be contacted by the health coach in the first week of the study to review their initial self-management behavioral goals and approaches. Follow up calls will occur each week for the first month, biweekly for the second and third months, and then once per month for the remainder of the study (months 4-6).
45482169|NCT03308734|Behavioral|Reduced-Exertion High-Intensity Interval Training|The 6-week REHIT protocol will involve 3 training sessions a week. Each session will include 10 minutes of unloaded pedalling using a cycle ergometer. Volunteers will be asked to increase to their maximal pedal frequency possible for 1-2 seconds prior to applying a resistance of 5 % of pre-training body weight for the Wingate sprint. The sprints will take place at 2 minutes and at 6 minutes. Sprint duration will be increased from 10 seconds in the first week to 15 seconds in the second and third weeks and finally 20 seconds in the remaining weeks. Patients will receive strong verbal encouragement during the sprints after which the resistance will be removed.
45482170|NCT03308656|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
45482171|NCT03304132|Other|Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach|The sequence-based approach is selected because it classifies samples by considering the entire difference (genetic distance) in 16S rRNA gene sequences among samples analyzed, unbiased by artificial details such as taxonomies, sequence length, or even quality scores.
45482172|NCT03304132|Other|Classification of Oral Microbiome Using taxonomic approach|The taxonomic approach is a complement to the sequence-based approach in that it will further identify specific taxonomic groups or species that can explain the difference found by overall analyses.
45482173|NCT03303976|Biological|Bioconjugate pneumococcal vaccine|Bioconjuagte vaccine against bacterial pneumococcal infection
45690230|NCT04767009|Radiation|SBRT|Patients with oligoprogressive NSCLC after treatment with PD-1 inhibitors will be treated with curative-intent SBRT of progressing lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist. PD-1 blockade will be withheld one day before the treatment and resumed within 2 weeks after completion of SBRT.
46050596|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (350 mg/day) x 28 days
46050597|NCT00529113|Drug|Gemcitabine|1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
46050598|NCT00529113|Drug|Placebo|Placebo capsules x 28 days
46050599|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
46050600|NCT00853762|Drug|Atacicept 25 mg|Subjects who received atacicept 25 milligram (mg) subcutaneously (SC) as loading dose twice weekly for first 4 weeks, followed by atacicept 25 mg SC for 32 weeks, in 28063 study will continue with atacicept 25 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
46050601|NCT00853762|Drug|Atacicept 75 mg|Subjects who received atacicept 75 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 75 mg SC for 32 weeks, in 28063 study will continued with atacicept 75 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
45690231|NCT04767087|Drug|Honey|0.5 gm/Kg/day honey
45690232|NCT04767087|Drug|Nigella sativa seed|40 mg/Kg/day
45690233|NCT04767087|Other|Placebo|empty capsule with sugar water
46050602|NCT00853762|Drug|Atacicept 150 mg|Subjects who received atacicept 150 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 150 mg SC for 32 weeks, in 28063 study will continue with atacicept 150 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
46050603|NCT00853762|Drug|Atacicept 150 mg|Subjects who received placebo SC twice weekly for first 4 weeks, followed by placebo SC for 32 weeks, in 28063 study will continue with atacicept 150 mg (without loading dose) SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
46050604|NCT00789529|Device|Opti-Free® RepleniSH® MPDS|soft contact lens disinfecting solution
46050605|NCT00789529|Device|ReNu MultiPlus®|soft contact lens disinfecting solution
46050606|NCT02840565|Drug|BIA 5-453|Presented as blue hard gelatine capsules (size 2) of 1 mg, 10 mg and 50 mg for oral administration
46050607|NCT02840565|Drug|Placebo|The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient.
45364614|NCT05688189|Device|different starting temperature setting of HFNC|The humidification temperature will be set based on the enrollment arm (37°C vs 34-37°C vs 31-34-37°C)
45364615|NCT03967093|Drug|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion over a minimum of six 28-day cycles.
45364616|NCT01006941|Biological|Trichuris suis ova|2500 ova per dose, orally, every second week, during 12 weeks
45364617|NCT03534167|Behavioral|TODAY! App and Coaching|"The TODAY! app uses the skill building structure of Cognitive Behavior Therapy (CBT). The intervention will be divided into modules, each devoted to a particular skill. Skills addressed within the intervention include increasing social support, engaging in goal-driven behaviors and reducing mood-driven (i.e., avoidance) behaviors, seeking out positive activities, replacing cognitive distortions with more adaptive thinking styles, improving problem-solving skills, reducing avoidance patterns, and increasing alternate coping strategies. The intervention will be supplemented with brief human contact in the form of a motivational coach. The Coach will be trained on the Motivational Interviewing principles upon which the coaching protocol is based."
45364618|NCT02531347|Behavioral|Telemedical home blood pressure measurements|
45364619|NCT02531347|Behavioral|Conventional blood pressure monitoring|
45364620|NCT04075175|Drug|S315|Human monoclonal antibody against Diphtheria Toxin
45364621|NCT04075175|Drug|0.9% Sodium Chloride (NaCl)|Placebo 0.9% Sodium Chloride (NaCl)
45364622|NCT05550051|Procedure|Awake nasal fiberoptic intubation|Lignocaine nebulization for upper airway block during awake nasal fiberoptic intubation
45364623|NCT03967015|Other|Maternal Administered Malnutrition Monitoring System (MAMMS)|Participants randomized to the MAMMS arm will be provided with two insertion MUAC tapes that are UNICEF color coded and numbered to 1 mm gradations to take home with them. Participants will receive a weekly SMS asking them to measure and send their child's MUAC via SMS. SMS messages will provide actionable reminders to measure and send the child's MUAC. Both the SMS sent to the participant and SMS responses sent by the participant to the MAMMS system will be free of charge. Study staff will screen all SMS measurements returned to the MUAC system for identification of malnutrition.
45690234|NCT03842085|Drug|Recombinant Humanized Bispecific Monoclonal Antibody MBS301|The patients confirming to the eligibility criteria will be assigned to the 8 dose groups based on the sequence of inclusion. MBS301 will be administered intravenousely on day 1 of each 21-day cycle for each patient.The first intravenous infusion for each patient will be last for 90 minutes.It could be changed to 60 minutes for the subsequent infusions if the drug is well tolerated.
46050608|NCT04106557|Drug|Gaboxadol|OV101 versus placebo once daily at bedtime for 12 weeks
46050609|NCT04106557|Drug|Placebo|Matching placebo capsules to OV101 capsules.
46050610|NCT04117750|Dietary Supplement|cholecalciferol (vit D3)|42,000 IU oral vitamin D per week and 500 mg calcium carbonate
46050611|NCT02603653|Device|Virtual radial task in 3D|The virtual radial task is a labyrinth in 3D with twelve ways. The primary aim of our study is the evaluation of persistent cognitive impairments (hippocampal memory) according to the responses of participants after instructions to choose the right way in the labyrinth.
45364624|NCT05012007|Other|Reminder Phone|Standard reminder via phone (audiocare)
45364625|NCT05012007|Other|Reminder Text|reminder via text (VEText)
45364626|NCT03741439|Device|Treatment|Low intensity shockwave treatment in patients with mild/moderate ED using a electromagnetic emitter
45364627|NCT03741439|Device|Sham|Sham treatment
45364628|NCT03529955|Drug|Apremilast 30mg|Patients with refractory cutaneous dermatomyositis will be started on apremilast 30 mg twice a day in addition to a stable dose of their treatment regimen (including steroids and steroid sparing agents).
45364629|NCT00142909|Drug|Lofexidine|Participants will receive lofexidine. The dosing will be initiation at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject.
45364630|NCT00142909|Drug|Placebo|Lofexidine Placebo
45364631|NCT03885245|Drug|L-ctirulline|7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
45364632|NCT03885245|Drug|Matching Placebo|7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
45364633|NCT01007019|Drug|YH4808 30mg|YH4808 30mg (single dose)
46050612|NCT00894933|Device|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
45690235|NCT01390389|Drug|Coenzyme Q10|"Single pill consists of 400 mg and is delivered PO.~CoQ10 dosing guidelines:~Visit 1 (baseline) start at 400mg once a day for two weeks~Visit 2 (within 7 days of baseline visit) increase to 800 mg once a day for two weeks~The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above."
46050613|NCT02614846|Drug|Hetrombopag Olamine|
46050614|NCT04131322|Drug|Amgevita 40Mg Solution for Injection|Adalimumab 40Mg Solution for Injection
46050615|NCT04131322|Drug|HUMIRA 40Mg Solution for Injection|Adalimumab 40Mg Solution for Injection
46050616|NCT02843373|Device|TMS|
46050617|NCT04581759|Device|RIPC device (IPC-906X)|Patients in the RIPC group will have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm twice a day after Mechanical Thrombectomy.
46050618|NCT04581759|Drug|foundational treatment|foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel ) and lipid-lowering (statins) drugs
45364634|NCT01007019|Drug|YH4808 50mg|YH4808 50mg (single dose)
45364635|NCT01007019|Drug|YH4808 100mg|YH4808 100mg (single dose)
45364636|NCT01007019|Drug|YH4808 200mg|YH4808 200mg (single dose)
45364637|NCT01007019|Drug|YH4808|YH4808 400mg (single dose)
45364638|NCT01007019|Drug|YH4808 100mg (repeat dose)|YH4808 100mg (repeat dose)
45364639|NCT01007019|Drug|YH4808 200mg (repeat dose)|YH4808 200mg (repeat dose)
45364640|NCT01007019|Drug|YH4808 600mg|YH4808 600mg
46050619|NCT04133740|Drug|Oxygen|Liberal versus conservative oxygen therapy.
46050620|NCT00792805|Drug|Indacaterol 150 µg|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
46050621|NCT00792805|Drug|Indacaterol 300 μg|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
46050622|NCT00792805|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
45482174|NCT03303976|Biological|Multivalent plain polysaccharide vaccine|Multivalent plain polysaccharide vaccine against bacterial pneumococcal infection
45482175|NCT03313648|Procedure|Laparoscopic Hepatectomy|180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
45690236|NCT03835533|Drug|NKTR-214 (Cohort A)|NKTR-214 will be administered intravenously every 3 weeks for up to 2 years
45690237|NCT03835533|Drug|Nivolumab (Cohort A, B and C)|Nivolumab will be administered intravenously every 3 weeks for up to 2 years to cohort A, every 4 weeks for up to 2 years for cohort B and C.
45690238|NCT03835533|Radiation|Stereotactic body radiation therapy (SBRT) (Cohort B)|Radiation therapy will be administered at 30 - 50 Gy in 1 - 5 doses, starting on Day 1 or 2 of Cycle 1
46050623|NCT02840175|Drug|etanercept|will be tapered from every week to every 2 weeks for 12 weeks then to every 3 weeks for 12 weeks
46050624|NCT02840175|Drug|adalimumab|will be tapered from every 2 weeks to every 3 weeks for 12 weeks and to every 4 weeks for 12 weeks
45364641|NCT01007019|Drug|YH4808 800mg (single dose)|YH4808 800mg (single dose)
45364642|NCT01007019|Drug|YH4808 400 mg (repeat doses)|YH4808 400 mg (repeat doses)
45482176|NCT03313648|Procedure|Radiofrequency Ablation|180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
45482177|NCT04490668|Biological|Human albumin|Patients received intravenous human albumin after gastric cancer surgery. Overall quantity of human albumin were recorded.
45482178|NCT03313414|Drug|Sofosbuvir/Velpatasvir Treatment for 14 days|14 day therapy with Sofosbuvir/Velpatasvir
45482179|NCT04441684|Diagnostic Test|Blood sample for serological test|"Serology tests:~By LFA-ICT: BIOSYNEX COVID-19 BSS reference SW40005, BIOSYNEX SWISS SA, Fribourg, Switzerland~ELISA: EDI™ Novel Coronavirus COVID-19 ELISA IgG Kit, Epitope Diagnostics, Inc., San Diego, USA~Confirmation test by seroneutralization tests developed at the Strasbourg Virology laboratory on whole virus (analyzes performed in a biosafety level 3 laboratory) and by the viral pseudoparticles system, will be performed."
45482180|NCT02468518|Drug|Vitamin E capsule|Capsules will be distributed to each participant free of cost
45690239|NCT03835533|Drug|CDX-301 (Cohort B and C)|CDX-301 will be subcutaneously once a day for 5 days for cohort B. CDX-301 will be subcutaneously once a day for 10 days of immune-priming lead-in for cohort C.
45690240|NCT03835533|Drug|Poly-ICLC (Cohort B)|Poly-ICLC will be administered intramuscularly twice weekly for 3 weeks starting on Day 1 of Cycle 1
45690241|NCT03835533|Drug|INO-5151 (Cohort C)|INO-5151 will be administered intramuscularly on Day 8 of the Immune-priming Lead-in, and on day 1 of Cycle 1, 2 and 3, then every 12 weeks thereafter
45690242|NCT03835533|Device|Cellectra 2000|Electroporation device
46050625|NCT02840175|Drug|Abatacept|will be tapered from every 4 weeks to every 6 weeks for 24 weeks
45364643|NCT01007019|Drug|Placebo|10 volunteers will be administered matched placebo.
45364644|NCT01007019|Drug|Esomeprazole 40mg|24 volunteers will be administered Esomeprazole 40mg
46050626|NCT02840175|Drug|Tocilizumab|will be tapered from every 4 weeks to every 6 weeks for 24 weeks
46050627|NCT04133662|Behavioral|Sleep Manipulation Protocol|A structured sleep duration intervention will be taught to patients
46050628|NCT04031092|Device|Wearable tech with feedback|An armwrist device measuring physical activity level. The user will receive information about their physical activity level through their smartphone.
45482181|NCT03308500|Behavioral|High-intensity intermittent games|The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In HIIG children took part in 5 games per session; 2 velocity games and 3 small-sided games (such 3 vs 3 and 4 vs 4). This session included 4 minutes games and 2 minutes recovery. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
45482182|NCT03308500|Behavioral|Moderate intensity games|The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
45845756|NCT05598918|Procedure|early active mobilization|In the active rehabilitation group, active extension and passive flexion of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints were performed with kleinert splint at angles suitable for active mobilization group.Then, the patients were asked to passively flex the injured side with their healthy hand and hold it in the flexion position for 3-5 seconds.
46050629|NCT04031092|Device|Wearable tech without feedback|An armwrist device measuring physical activity level, no reporting back to the user.
45364645|NCT05673863|Behavioral|Psychological Resilience Program|The psychological resilience program was applied to the children in the intervention group twice a week for a total of 5 weeks. Each session consisted of 90 minutes of structured practice. The application is carried out using narrative therapy, cognitive behavioral therapy, psychodrama and analogy techniques, self-assessment and didactic teaching techniques. In addition, participants were engaged in self-regulation exercises and positive imagery activities. Each session includes practices on empathy, stress management, resilience, realistic and unrealistic thinking, optimism and pessimism, autonomy and humor related to resilience.
45364646|NCT02579993|Procedure|Pannus and conjunctival dissection|A complete conjunctival peritomy is performed and the fibrovascular pannus and conjunctiva invading the cornea is dissected from the cornea and limbus.
45364647|NCT02579993|Procedure|Human cultivated limbal stem cell transplantation|The amniotic membrane graft cultured with the human limbal stem cell transplantation is placed in the limbic and corneal surface and fixed with fibrin glue. The amniotic membrane is placed with the stroma in contact with the graft and it is sutured.
45364648|NCT05633979|Drug|Trastuzumab deruxtecan|Given by IV (vein)
45364649|NCT05633979|Drug|Valemetostat|Given by PO
45364650|NCT04075097|Behavioral|Aerobic exercise|1 session
45364651|NCT04075097|Behavioral|Iyengar yoga|1 session
45482183|NCT03308422|Behavioral|parental representations|parental representations of the impact of the use of screens on their preschool children health and development
46050630|NCT04031092|Behavioral|Rehabilitation program|traditional inpatient rehabilitation program.
46050631|NCT05334225|Other|Training Program|An in-person urethral catheterization training program that utilizes training videos (demonstrating procedures, providing examples of ordinary and difficult cases, utilizing animation techniques as well)
46050632|NCT04106635|Procedure|Paratracheal pressure|To apply paratracheal pressure, the thumb was placed over the left side of the trachea cephalad to the clavicle and medial to the sternocleidomastoid muscle.
45482184|NCT03308344|Behavioral|Mindfulness training|The present MT program includes topics related to mindfulness, emotion regulation, and connection. It will be delivered in short, weekly sessions.
45482185|NCT03313336|Drug|EMLA test patch|EMLA® Test Patch containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc. The source of cellulose for the cellulose disc will be provided from a new supplier in this test patch.
45482186|NCT03313336|Drug|EMLA current reference patch|EMLA current Reference Patch, containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc.
45482187|NCT03313336|Drug|Placebo Patch|Placebo Patch, based on the EMLA Test Patch (incorporating the absorbent cellulose disc with cellulose from the current supplier), where the absorbent disc will be saturated with a placebo oil-in-water emulsion, where the eutectic mixture of lidocaine and prilocaine is replaced with fractionated coconut oil and chlorhexidine digluconate 20%, with identical appearance to the active EMLA patches.
45482188|NCT03308266|Diagnostic Test|electromyography|
46050633|NCT04106635|Procedure|Cricoid pressure|To apply cricoid pressure, the cricoid cartilage is compressed by 30N force with a single-handed three finger maneuvre towards the vertebral bodies.
46050634|NCT02747589|Procedure|Surgical device implant in brain|Neuropace RNS implant ove visual cortex
46050635|NCT02603497|Drug|ASP015K|oral
46050636|NCT04250961|Other|postoperative early shower|The shower group showered in 48-72 hours after median sternotomy with tap water.
46050637|NCT04518891|Behavioral|Cognitive Functional Therapy (CFT)|Cognitive functional therapy (CFT) is an intervention that deals with potentially modifiable multidimensional aspects of pain (e.g. provocative cognitive, movement and lifestyle behaviours). Treatment with CFT will be individualised, the physiotherapist will listen to the complete patient pain history and the intervention will be focused on individual needs. A detailed examination will be crucial in identifying the modifiable multidimensional mediators of pain and disability (provocative cognitive, pain, movement and lifestyle behaviors) of each participant.
46050638|NCT04518891|Device|Sham intervention|Due to the impossibility of applying placebo exercise, the control intervention in this study will be based on successful reports of placebo intervention in patients with chronic low back pain in the literature (Placebo photobiomodulation + neutral talking control)
45482189|NCT05285332|Procedure|surgical treatment 1|Mastectomy OR Breast conserving surgery
45482190|NCT05285332|Procedure|surgical treatment 2|Resection of metastasis
45690243|NCT04016415|Behavioral|Mindfulness Based Stress Reduction|Subjects randomized to Mindfulness-Based Stress Reduction (MBSR) will receive the 8-week University of Massachusetts Authorized MBSR curriculum followed by monthly mindfulness boosters in Months 3 to 6. The University of Massachusetts MBSR curriculum was selected for the intervention, as it is the most standardized and researched mindfulness program that has been shown to reduce psychological distress in various patient populations.
45364652|NCT01007175|Biological|ATN-103 10 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
45364653|NCT01007175|Biological|ATN-103 30 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.3 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
45482191|NCT05285332|Drug|Systemic therapy|Endocrine therapy or chemotherapy or targeted therapy
45845757|NCT05598918|Procedure|early passive mobilization|In the passive rehabilitation group, active extension and passive flexion of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints were performed with kleinert splint at angles suitable for passive mobilization group.
46050639|NCT02840487|Biological|VRC-ZKADNA085-00-VP|VRC-ZKADNA085-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
46050640|NCT00915265|Other|Multilobed catheter (group CPA)|- CPA group: continuous preperitoneal administration of 0.2% ropivacaine using a multilobed catheter positioned between the previously closed parietal peritoneum and the underside of the transversalis fascia
46050641|NCT00915265|Other|Multilobed catheter (group EA)|EA group : thoracic epidural infusion of 0.2 % ropivacaine
45364654|NCT01007175|Biological|ATN-103 80 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
45482192|NCT05262322|Drug|Edoxaban|This was a non-interventional, observational study. No drug was administered in this study.
45482193|NCT05262322|Drug|Apixaban|This was a non-interventional, observational study. No drug was administered in this study.
45482194|NCT05262322|Drug|Rivaroxaban|This was a non-interventional, observational study. No drug was administered in this study.
45482195|NCT05153434|Drug|ARD-101|Twice Daily, Oral Administration
45482196|NCT03313258|Device|Standard of Care Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is blinded to the care team but not to the research personnel.
45482197|NCT03313258|Device|Active Warming Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is un-blinded to everyone so healthcare practitioners will be able to visually detect continuous temperature readings from the ZHF monitor.
45482198|NCT03308110|Drug|PF-06650833|Two formulations of PF-006650833
45482199|NCT03308032|Behavioral|Intervention|SDL intervention employs a comprehensive engagement design that includes seven innovative strategies: 1) customization of content of the training curriculum to fit individual learner's needs; 2) tailoring the length of trainings by using short video clips to allow caregivers flexibility in completing the curriculum; 3) using an instructional format (SCHOLAR) designed to maximize active learning during each training lesson; 4) progress tracking to help the learner stay focused and motivated; 5) a recommendation algorithm that facilitates the learner's transition from one training topic to the next; 6) behavioral economics-based messages, to re-engage the learner if he/she stops participating
45482200|NCT03308032|Behavioral|Control|Participants in the control group will be invited to a comparable online training course consisting of all of our training video clips, without the interactive engagement design features. These represent standard video training based on evidence-based content.
45482201|NCT03303586|Other|Compression Stockings|We will use knee length, ready-made compression stockings at a pressure of 20-30mmHg at the ankle and if a good fit cannot be obtained, custom-made stockings will be ordered. Patients will be measured for compression stockings by a certified fitter.
45482202|NCT03303586|Other|Control|Participants will not wearing compression stockings for two weeks.
45482203|NCT03303508|Diagnostic Test|anti-ds DNA|venous blood samples
45482204|NCT02469376|Drug|[18F]-GP1|Radiopharmaceutical Product (Tracer) to visualize with Positron Emission Tomography a thrombus in humans.
45482205|NCT02469532|Device|Balloon Angioplasty|Device: Balloon Angioplasty Selection is driven by preference of the operator
45482206|NCT02469532|Device|Atherectomy System|Device: Orbital or Directional or Laser Atherectomy Systems Atherectomy selection is driven by preference of the operator
46050642|NCT02843217|Behavioral|Lifestyle, screening|
46050643|NCT02840331|Drug|St. John's Wort|Single oral doses (900 milligram) 2-4 hours before laparoscopy
45690244|NCT04016415|Behavioral|Stress Management Education|Subjects randomized to Stress Management Education (SME) will receive health education on nutrition (adapted for the type 2 diabetes population), exercise as gentle stretching to match yoga in MBSR, and other general health topics that may be relevant to the type 2 diabetes population such as sleep, time management, etc. Stress Management Education does not have any mindfulness in it. Stress Management Education was specifically created as a control condition for MBSR studies so it matches MBSR for time, social support, homework, etc.
45690245|NCT03025347|Other|Control|Participants complete a resting control condition instead of a run.
46050644|NCT02840331|Device|Photodynamic diagnostic and therapy|Intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes
45364655|NCT01007175|Biological|ATN-103 10 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
45364656|NCT01007175|Biological|ATN-103 80 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
45364657|NCT04076189|Procedure|Endotracheal suctioning|Procedure includes: Endotracheal intubation-Suctioning-Endotracheal intubation again and initiation of positive pressure ventilation
45364658|NCT04076189|Procedure|No endotracheal suctioning|Procedure includes: immediate initiation of positive pressure ventilation without intubation and tracheal suctioning
45364659|NCT03508739|Drug|Sacubitril/Valsartan 200mg (blinded)|study day 2 for AB and study day 3 for BA
45364660|NCT03508739|Drug|Valsartan 160mg (blinded)|study day 3 for AB and study day 2 for BA
45364661|NCT03882437|Biological|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single IV infusion.
45364662|NCT00205699|Drug|risperidone|randomized to begin 12 week trial of risperidone
45364663|NCT00205699|Drug|olanzapine|randomized to begin 12 week trial of olanzapine
45364664|NCT00205699|Drug|aripiprazole|randomized to 12 week trial of aripiprazole
45364665|NCT03503513|Drug|Gentamicin Sulfate|Gentamicin will be compounded by the Michigan Medicine Research Pharmacy in a concentration of 480 milligrams of the active product to 1000 milliliters of normal saline. Participants will do daily instillations of 30 milliliters of solution
45364666|NCT03498521|Drug|Alectinib|Alectinib will be administered orally at the label-recommended dose (600 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
45364667|NCT03498521|Drug|Vismodegib|Vismodegib will be administered orally at the label-recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
45364668|NCT03498521|Drug|Ipatasertib|Ipatasertib will be administered orally at the label-recommended dose (400 mg) once daily on Days 1-21 of each 28-day Cycle in combination with paclitaxel, and as monotherapy after the final administration of paclitaxel, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
45364669|NCT03498521|Drug|Olaparib|Olaparib will be administered orally at the label-recommended dose (400 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
45364670|NCT03498521|Drug|Erlotinib|Erlotinib will be administered orally in combination with Bevacizumab at the label recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
45364671|NCT03498521|Drug|Bevacizumab|Bevacizumab will be administered intravenously at 15mg/kg every 3 weeks in combination with Erlotinib until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
45482207|NCT03303430|Diagnostic Test|MRI|Diffusion weighted imaging 24 hours after revascularisation
45482208|NCT02469142|Procedure|ADM tension-free hernia reparation|Use ADM as opposed to nothing to repair incarcerated inguinal hernia
46050645|NCT02840409|Drug|Vinblastine|
46050646|NCT02840409|Drug|Bevacizumab|
46050647|NCT02839941|Drug|Iguratimod|Subjects will receive iguratimod orally, twice a day, for consecutive 52 weeks
46050648|NCT02839941|Drug|Mycophenolate mofetil|All subjects will receive mycophenolate mofetil for consecutive 52 weeks
46050649|NCT02839941|Drug|Tacrolimus|All subjects will receive tacrolimus for consecutive 52 weeks
45364672|NCT03498521|Drug|Vemurafenib|Vemurafenib will be administered orally, 960 mg twice daily, in combination with Cobimetinib, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
45482209|NCT03303352|Procedure|EUS FNA|Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will be randomly allocated to receive EUS FNA (endoscopic ultrasound fine needle aspiration).
45482210|NCT04490980|Drug|butorphanol|Observed group:Intravenous drip of Butorphanol in patients after cesarean section;control group: intravenous drip of saline in patients after cesarean section
46050650|NCT02839941|Drug|Glucocorticoids|All subjects will receive glucocorticoids for consecutive 52 weeks
46050651|NCT02842983|Drug|Esmolol|conventional management plus esmolol infusion
45364673|NCT03498521|Drug|Cobimetinib|Cobimetinib will be administered orally, 60mg once daily, in combination with Vemurafenib, on Days 1-21 of each 28-day Cycle, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
45364674|NCT03498521|Drug|Trastuzumab Subcutaneous (SC)|Trastuzumab will be administered subcutaneously, 600 mg every 3 weeks, in combination with Pertuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
45364675|NCT03498521|Drug|Pertuzumab|Pertuzumab will be initially be administered intravenously, 840 mg, followed by 420 mg every 3 weeks, in combination with Trastuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
45364676|NCT03498521|Drug|Atezolizumab|Atezolizumab will be administered intravenously at the label-recommended dose (1200 mg), alone or in combination with chemotherapy, every 3 weeks until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
45364677|NCT03498521|Drug|Carboplatin|Carboplatin will be administered intravenously at the area under the curve (AUC) dose once every 3 weeks for up to 9 Cycles (Cycle = 21 days) in some combination with the following: Paclitaxel, Gemcitabine, Atezolizumab, Pertuzumab, and Trastuzumab SC.
45364678|NCT03498521|Drug|Paclitaxel|Paclitaxel will be administered intravenously, 175 mg/m^2, once every 3 weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Carboplatin, Ipatasertib, Atezolizumab, Pertuzumab, and Trastuzumab SC
45482211|NCT03303274|Procedure|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally.
45482212|NCT03307954|Device|Ekso Therapy (Exoskeleton Suit)|
45690246|NCT03025347|Other|Exercise|Participants complete a 60 minute run at 70% of their maximal oxygen uptake
46050652|NCT02839785|Drug|Ibuprofen|the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
46050653|NCT02839785|Drug|Placebo|the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
46050654|NCT02843295|Other|blood samples|
46050655|NCT02843061|Drug|Rituximab|
45482213|NCT03307954|Other|Usual Physiotherapy|
45482214|NCT03307876|Other|autologous PPP injection|autologous platelet poor plasma (PPP) injection taken from the participants own blood is injected in to all patients.
45690247|NCT01401465|Drug|ciclesonide|74 mcg ciclesonide nasal aerosol once daily
45690248|NCT01401465|Drug|mometasone|200 mcg mometasone aqueous nasal spray once daily
45690249|NCT01401153|Other|Skipping lunch|Just water.
46050656|NCT02843061|Biological|NK immunotherapy|Each time 10 billion cells, 4 times in all,i.v.
46050657|NCT02838147|Device|FreeStyle sensors.|Patients with normal OGTT (4 normal values) - will be allocated to 2-week period to FreeStyle sensors.
45482215|NCT02468284|Drug|degarelix|
45482216|NCT03313102|Biological|blood samples|sample of 16 blood tubes
45482217|NCT03307720|Drug|Gonadotropin Releasing Hormone Agonists (GNRH-A)|Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.
45482218|NCT03307720|Drug|Human chorionic gonadotropin|Administration of Human chorionic gonadotropin (HCG) 250 IU subcutaneously , 36 hours before ovum pick-up in IVF treatments.
46050658|NCT02838147|Device|Glucometer|Patients with pathological OGTT - 1 abnormal value Patients with pathological OGTT - 2 abnormal value
45482219|NCT03303118|Other|Hypoxia|No drug or product will be used in this study. No medication will be give to the participants. No arm will be used for product administration.
45482220|NCT03312946|Device|Modellata|treatment such as the Modellata electromedical device (Ibramed), in the abdomen, flanks, thigh posterior, inner thigh and buttocks.
45690250|NCT01890967|Drug|LY3015014|Administered SC
45690251|NCT01890967|Drug|Placebo|Administered SC
45690252|NCT01890967|Drug|Statin|Administered orally
45690253|NCT01890967|Drug|Ezetimibe|Administered orally
46050659|NCT02839473|Device|Castalie water spray|
45364679|NCT03498521|Drug|Cisplatin|Cisplatin will be administered intravenously, 60-75 mg/m^2, once every three weeks, for up to 9 cycles (Cycle = 21 days) in some combination with the following: Gemcitabine, Paclitaxel, Atezolizumab, Pertuzumab, and Trastuzumab SC.
45364680|NCT03498521|Drug|Gemcitabine|Gemcitabine will be administered intravenously, 1000 mg/m^2, twice every three weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Cisplatin, Carboplatin, Atezolizumab, Pertuzumab, and Trastuzumab SC.
45364681|NCT03498521|Drug|Entrectinib|Entrectinib will be administered orally at the label-recommended dose (600 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
46050660|NCT02839473|Device|Hydrogel Hydrosorb®|
45364682|NCT03498521|Drug|Ivosidenib|Ivosidenib will be administered orally at the label-recommended dose (500mg) once daily across a 28-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
45364683|NCT03498521|Drug|Pemigatinib|Pemigatinib will be administered orally at the label-recommended dose (13.5mg) once daily across a 21-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
45364684|NCT03882801|Drug|Gefapixant|In Periods 1 and 2 (7 days each) participants receive 4 tablets (180 mg) of gefapixant (MK-7264) QHS.
45364685|NCT03882801|Drug|Placebo|In Periods 1 and 2 (7 days each) participants receive 4 tablets of placebo QHS.
45364686|NCT01073917|Other|Spontaneous Breathing|
45364687|NCT01073917|Other|Pressure Controlled Ventilation|
45364688|NCT01073917|Other|Pressure Support Ventilation|
45364689|NCT01582399|Drug|ASKP1240|intravenous(IV) infusion and subcutaneous (SC)
45364690|NCT03971539|Drug|BI 894416|Tablet
46050661|NCT02613741|Other|Lifestyle-based physical activity|Obese subjects will undergo a randomized physical activity-based weight reduction program (12 weeks). The lifestyle intervention will be determined based on an initial evaluation of each subjects' energy expenditure (by indirect calorimetry). Caloric intake will be set to elicit the loss of 1 to 1.5 lbs/week. The subjects and the family will meet with a dietitian once/week for 12 weeks. The intervention group will undergo an aerobic exercise program 3 times/week. The duration of exercise will be progressively increased from 20 to 45 minutes/session. The subjects will keep daily record of exercise activity and food intake. Interventions will be monitored during the subjects' weekly visit with the research group and they will be given counseling to stick to the intervention program.
46050662|NCT02608203|Drug|[68Ga]-DOTANOC PET/CT|
45690254|NCT01400919|Device|Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System.|Implantation of one or more study devices in the common and/or external iliac artery.
46050663|NCT02839239|Dietary Supplement|Drops with lactobacilli and vitamin D3|Oil suspension with lactobacilli and vitamin D3
46050664|NCT02839239|Dietary Supplement|Drops with vitamin D3|Oil suspension with vitamin D3
45364691|NCT03971539|Drug|Placebo|Tablet
45364692|NCT03880227|Device|Active anodal tDCS|active anodal tDCS with behavioral tasks to assess visual attention
45364693|NCT03880227|Device|Sham tDCS|sham tDCS with behavioral tasks to assess visual attention
45364694|NCT04000113|Device|laser acupuncture|low level laser emission on specific acupuncture points
45364695|NCT04000113|Device|Sham laser|Sham laser
45690255|NCT01864291|Device|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
46050665|NCT05334069|Other|Questionnaire Administration|Complete questionnaire
45690256|NCT01400841|Device|HAART 300 Annuloplasty Device|Implantation of device for aortic valve repair
45690257|NCT01863667|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
45690258|NCT01863667|Drug|Glimepiride|Glimepiride tablet 1 mg and/or 2 mg (uptitrated to a maximum dose 6 mg/day) administered orally once daily with breakfast or the first main meal
45690259|NCT01863667|Drug|Omarigliptin Placebo|Matching placebo to omarigliptin capsule administered orally once weekly
45690260|NCT01863667|Drug|Glimepiride Placebo|Matching placebo to glimepiride tablet administered orally once daily with breakfast or the first main meal
45690261|NCT01614769|Drug|Placebo|Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.
46050666|NCT05334069|Procedure|Biospecimen Collection|Undergo collection of tissue and blood samples
45364696|NCT03999567|Other|Pen and Paper Digit Symbol Substitution Test (DSST)|The DSST is a paper-and-pencil cognitive test presented on a single sheet of paper that requires a subject to match symbols to numbers according to a key located on the top of the page. The subject copies the symbol into spaces below a row of numbers. The number of correct symbols within the allowed time, usually 90 to 120 seconds, constitutes the score.
45364697|NCT03999567|Other|Electronic Digit Symbol Substitution Test (DSST)- (a.k.a. Codebreaker)|Code breaker is the mobile/electronic version of the pen and paper DSST which is capable of identifying deficits in the domains of executive function, processing speed and attention/concentration, and takes 2 minutes to complete. Six symbols are numbered consecutively. Users are presented with a series of numbers that they must then match with the correct corresponding symbol as quickly as possible. Users are scored on speed and accuracy.
46050667|NCT02837835|Drug|ceftazidime|20 mg/kg of body weight followed by 60 mg/kg/day
45364700|NCT02580149|Drug|Ticagrelor|"Subjects will receive an oral loading dose of 180 mg ticagrelor on study day~1 followed by a maintenance dose of 90 mg twice daily for 14 days (until study day 15)."
46050668|NCT02837835|Drug|ceftazidime|20 mg/kg over 30 min every 8 h
45364701|NCT02580149|Drug|Clopidogrel|Subjects will receive a loading dose of 600 mg clopidogrel on the first study day followed by a maintenance dose of 75 mg once daily for 14 days
45364702|NCT05618925|Drug|N803|nogapendekin alfa inbakicept (also known as ALT-803; recombinant human superagonist interleukin-15 (IL-15) complex [also known as IL 15N72D:IL-15RαSu/IgG1 Fc complex])
45364703|NCT05618925|Biological|CD19t-haNK suspension|Derived from the parental NK-92 (aNK) cell line, CD19 t-haNK is a human, allogeneic, NK cell line that has been engineered to express a CAR targeting CD19. Similar to the haNK cell line, CD19 t haNK has also been engineered to produce endoplasmic reticulum-retained IL 2 and the high-affinity (158V) variant of the Fcγ receptor (FcγRIIIa/CD16a), and thereby has enhanced CD16-targeted ADCC capabilities. CD19 t-haNK is similar to PD L1 t-haNK, differing only in the CAR that is expressed (CD19 vs PD-L1).
45364704|NCT05618925|Drug|Cyclophosphamide|Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards. The chemical name for cyclophosphamide is 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate and has the molecular formula C7H15Cl2N2O2P•H2O and a molecular weight of 279.1.
45364705|NCT05618925|Drug|Fludarabine|Fludarabine phosphate is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-β-D-arabinofuranosyladenine (ara-A) that is relatively resistant to deamination by adenosine deaminase. The chemical name for fludarabine phosphate is 9H-Purin-6-amine, 2-fluoro-9-(5-0-phosphono β-D-arabino-furanosyl) (2-fluoro-ara-AMP). The molecular formula of fludarabine phosphate is C10H13FN5O7P and it has a molecular weight of 365.2.
45482221|NCT03302962|Behavioral|Intensive Asthma Education|"One half (54) of the identified cases were randomized to receive the previously established BREATHE study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted."
45482222|NCT03312790|Device|Tasks|Augmented reality device Real condition
45482223|NCT03302884|Other|biological sampling|Tumor and blood samples
45482224|NCT03307642|Other|Text message notification|Three text messages will be sent to 50% of the parents, scheduled around the standard methods of communication
45690262|NCT01614769|Drug|Glimepiride 2 mg|One placebo tablet and one 2-mg glimepiride tablet taken on Day -1 and Day 1 of the three treatment periods.
45690263|NCT01614769|Drug|Glimepiride 4 mg|Two 2-mg glimepiride tablets taken on Day -1 and Day 1 of the three treatment periods.
45690264|NCT01614769|Procedure|Hypoglycemic Clamp|On Day 1 of the three treatment periods, 180 minutes after drug treatment, a fixed-rate insulin infusion is combined with a variable-rate dextrose infusion to maintain plasma glucose concentrations at close to 50 mg/dL for 30 minutes.
46050669|NCT02839161|Biological|Na-GST-1/Alhydrogel|
46050670|NCT02839161|Biological|Na-APR-1 (M74)/Alhydrogel|
46050671|NCT02839161|Biological|Hepatitis B Vaccine|
46050672|NCT02837991|Drug|CDX-014|
46050673|NCT00925002|Drug|Tafamidis|20 mg oral Fx-1006A daily
46050674|NCT02842905|Other|Fitting Audiologist completion|Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the fitting Audiologist
46050675|NCT02842905|Other|Participant's Physician completion|Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the Participant's Physician
46050676|NCT02839395|Other|No intervention- base line|the subject will sited in a dim light room. No screen light illumination.
46050677|NCT02839395|Other|Acute|The subject will be sited in front of computer screen light illumination for 2 hours.
46050678|NCT02839395|Other|Chronic|The subject will be sited in front of computer screen light illumination for 2 hours for 5 consecutive days.
45364706|NCT05618925|Drug|Rituximab|Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kD and has a binding affinity for the CD20 antigen of approximately 8.0 nM.
45364707|NCT01007331|Behavioral|Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07|10^10 colony forming units pr day of probiotics
45364708|NCT04996017|Drug|Atezolizumab 1200 mg in 20 ML Injection|Atezolizumab will be supplied as sterile liquid in 20-mL glass vials. The vial is designed to deliver 20 mL (1200 mg) of atezolizumab solution but may contain more than the stated volume to enable delivery of the entire 20 mL volume. For information on the formulation and handling of atezolizumab, refer to the Atezolizumab Investigator's Brochure.
45364709|NCT04996017|Drug|Placebo|Placebo will be supplied as sterile liquid in 20ml vials. the vial is designed
46050679|NCT02842671|Other|Assigned Ambassador|If assigned to the intervention group, participants will be contacted by the assigned medical student ambassador at least 1 day prior to the procedure. A brief discussion will take place to review the child's history and survey results. The family will be met by the Ambassador at the hospital and stay with the family until the patient is in the post anesthesia recovery unit. The ambassador is expected to make accommodations for the child as determined by the accommodations survey results. The family will be required to allow the Ambassador to stay through check-in and the procedure.
46050680|NCT04206033|Other|Observational study|Observational study
45364710|NCT03483935|Other|Microwave treatment|Microwave energy delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for dermatology applications.
45364711|NCT00530439|Other|Lifestyle intervention|Dietician counselling and physical training
45364712|NCT00530439|Other|Control|Repeated measuring of maternal weight gain, blood samples and ultrasound
45690265|NCT01614457|Drug|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
45364713|NCT00530439|Behavioral|Physical activity, dietetic counselling|"The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.~Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week."
45690266|NCT01614457|Drug|Placebo|Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
45690267|NCT01863433|Biological|Trivalent Influenza Vaccine|
45690268|NCT01862029|Drug|Roflumilast|Selective phosphodiesterase 4 (PDE4) inhibitor
45690269|NCT01835431|Drug|insulin degludec/insulin aspart|Administered subcutaneously (s.c., under the skin) once daily with a main meal. Dose individually adjusted.
45690270|NCT01835431|Drug|insulin aspart|Administered s.c. with the remaining meals. Dose individually adjusted.
45690271|NCT01835431|Drug|insulin detemir|Administered s.c. once or twice daily. Dose individually adjusted. Subjects will continue with their pre-trial dosing scheme (once (OD) or twice daily (BID)) and will be allowed to switch from OD to BID dosing.
45364714|NCT01007409|Drug|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast Period 2: administration of fimasartan 240mg at 9:00am, without the breakfast
45364715|NCT01007409|Drug|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, without the breakfast Period 2: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast
45364716|NCT04994223|Drug|Rivaroxaban 10 MG Oral Tablet [Xarelto]|rivaroxaban has shown improved results after revascularization for PAD in terms of limb survival
45364717|NCT04962633|Other|Probiotic Pasta|Subjects will consume for 4 weeks 80 g per day of probiotic durum wheat pasta. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
45364718|NCT04962633|Other|Control Pasta|Subjects will consume for 4 weeks 80 g per day of conventional durum wheat pasta without probiotics. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
45690272|NCT01835431|Drug|insulin aspart|Administered s.c. at meal-times. Dose individually adjusted.
45690273|NCT01880593|Drug|Lithium|Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study.
45690274|NCT01880593|Drug|Ketamine|
45690275|NCT01880593|Drug|Placebo|Subjects in this arm take placebo pills at night for duration of the study.
45690276|NCT01400451|Drug|Ipilimumab (BMS-734016)|Injection, intravenous (i.v.), cohort 1: 3 mg/kg, Escalate to cohort 2: 10 mg/kg, Escalate to cohort 3: at Recommended Phase 2 Dose (RP2D), De-escalate cohort 1A: 3 mg/kg, De-escalate cohort -1B: 10 mg/kg, (every three week) Q3wk, upto 2 yrs
46050681|NCT04249713|Drug|Brodalumab|Interleukin 17 Receptor A Antagonist
46050682|NCT04249869|Drug|VGH-AD1|VGH-AD1 includes Yi-gan-san 3.0g, Huan-shao-dan 1.0g, Danshen(Radix et Rhizoma Salviae Miltiorrhizae) 0.75g, Tian-ma(Rhizoma Gastrodiae) 0.75g, Gou-teng(Ramulus Uncariae Cum Uneis) 0.375g, and Ba-ji-tian(Radix Morindae Officinalis) 0.375g, two times per day, each serving a small packet of 7.5 grams of concentrated granules.
46050683|NCT00610506|Drug|Escitalopram|Escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability.
45364719|NCT01007565|Procedure|periarticular anesthetics injection|Members in the PI group received intra-operative periarticular injections and additional sensory nerve blocks just before skin closure . For the periarticular injections and additional sensory block, local analgesic solution was injected into the wrist joint, joint capsule, periosteum, subcutaneous tissue, skin, and around the anterior and posterior interosseous nerves and the superficial radial nerve. A volume of 2ml was injected into the joint capsule and periosteum, and of 3ml into the wrist joint, subcutaneous tissue, skin and into each nerve.
46050684|NCT04250649|Procedure|subcutaneous tissue disinfection|"Skin and subcutaneous incision (up to the muscular fascia) with superficial blade scalpel, disinfection of the subcutaneous tissue with 3cc of Betadine solution, placement of the retractors, dissection and development of the delto-pectoral interval with deep blade scalpel.~When the joint is opened, bacteriological smears are taken from 5 sites in the two groups. 1) exposed subcutaneous tissue, 2) surgeon's gloves (distal end of fingers), 3) superficial blade, 4) deep blade, 5) retractors.~The rest of the shoulder surgery procedure does not differ from what is commonly performed.~The samples are sent to bacteriology for bacterial culture. Anaerobic research is done specifically for P. acnes. The results are considered negative after 10 days."
45482225|NCT03312712|Radiation|PET/CT scan|"PET/CT will be performed at Cambridge University Hospital's PET-CT unit, Cambridge.~Participants in Part A of the study (sarcoidosis and HVs) will receive one PET/CT scan. A Cine-CT scan will be performed immediately prior to the 18F-FDG PET/CT scan. Settings for the CT scans will be determined by clinical protocols, radiation dose will be kept as low as reasonably practicable (ALARP) consistent with UK legislation.~After 6 hours of fasting and if blood glucose concentration is ≤11mmol/L participants will proceed to undergo an 18FDG PET/CT scan.~18F-FDG will be administered intravenously at a dose of approximately 200 MBq.~Positron emission scanning will involve a 60-minute dynamic acquisition from the lungs."
45364720|NCT00497146|Drug|paricalcitol|2 µg capsule
45364721|NCT00497146|Drug|placebo|placebo capsule
45364722|NCT05229003|Drug|Anlotinib|Anlotinib 8mg or 10mg, d1-9，q2w
45364723|NCT05229003|Drug|Penpulimab|Penpulimab 200mg, d6, q2w
45364724|NCT05229003|Drug|Irinotecan|Irinotecan 180mg/m2, d6, q2w
45364725|NCT01016548|Biological|AS03-adjuvanted H1N1 pandemic influenza vaccine|One dose constitutes 0.5mL of suspended vaccine via the intramuscular route.
45364726|NCT01019824|Drug|Ralfinamide|Ralfinamide Oral Tablets, 160 or 320 mg per day
45364727|NCT01016626|Drug|CKD-4101 tablet|"CKD-4101 tablet 1000 mg~500mg/tablet, PO, 2 tablet once daily for D1 and D8(crossover)"
45364728|NCT01016626|Drug|Mycophenolate Mofetil capsule|"Mycophenolate Mofetil capsule 1000 mg~250mg/capsule, PO, 4 capsule once daily for D1 and D8(crossover)"
45364729|NCT01016704|Behavioral|Incentive|Participants assigned to the experimental condition are reinforced via monetary incentives for demonstrating superior delivery of an evidence treatment to clients
45364730|NCT04935879|Drug|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
45364731|NCT04935879|Drug|Placebo|Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug
45364732|NCT00489970|Procedure|Taking of blood samples|No treatment is planned to be given in this study. Blood samples will be collected at the following time points: 1 year, 3 years, 5 years and 9 years after the dose of vaccination.
45364733|NCT00489970|Biological|Boostrix|A single dose of Boostrix was administered in the primary study (NCT00346073). No treatment was given in this study.
45364734|NCT00489970|Biological|Adacel|A single dose of Adacel was administered in the primary study (NCT00346073). No treatment was given in this study.
45364735|NCT01020058|Procedure|Mesh repair for primary inguinal hernia|Open Lichtenstein repair in local anesthesia using a polypropylene mesh compared to totally extra-peritoneal laparoscopic repair using a polypropylene mesh
45364736|NCT02798471|Drug|Edoxaban|15 or 30 mg tablets for participants 12 years of age to <18, and 60 mg edoxaban suspension for oral administration to participants under 12 years of age
45364737|NCT02798471|Drug|Standard of Care|Standard of care could include low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors.
45364738|NCT03443765|Diagnostic Test|Detection of Plasma levels of 25(OH) vitamin D by ELISA technique|Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. Plasma levels of 25(OH) vitamin D will be detected by enzyme-linked immunosorbent assay (ELISA) technique.
45364739|NCT03443765|Diagnostic Test|Detection of Total serum immunoglobulin E by ELISA technique|Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. Total serum immunoglobulin E will be detected by enzyme-linked immunosorbent assay (ELISA) technique.
45364740|NCT03441893|Diagnostic Test|parasitological diagnostics (coproscopy)|Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.
45364741|NCT03441893|Drug|Nitazoxanide 500Mg Oral Tablet|Tab. nitazoxanide by a 1.0 g/day (two pills) twice over orally for 14 consecutive days
45364742|NCT03441893|Drug|Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet|Tab. nitazoxanide by a 1.0 g/day (one pill - 500 mg) twice over orally and mesalazine 1.5 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
45364743|NCT03441893|Drug|Mesalazine 250Mg|Tab. mesalazine ≥3 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
45364744|NCT03441893|Drug|Placebo tabletes|Tab. Placebo (shugar pills) will be given to the participants
45364745|NCT03848663|Behavioral|Traditional Remapping|Shifting text outside of scotoma
45364746|NCT03848663|Behavioral|Personalized Remapping|Shifting text based on individual letter-based perimetry
45364747|NCT03440177|Drug|Ramipril|Patients are tested for their normal prescription ramipril medication
45364748|NCT00489736|Drug|dronedarone (SR33589)|oral administration
45364749|NCT00489736|Drug|amiodarone|oral administration
45690277|NCT01400451|Drug|Vemurafenib|tablets, oral, cohort 1: 960 mg Twice daily (BID) x 28 days after date, cohort 2: 960 mg BID x 28 days after date, cohort 3: at Recommended Phase 2 Dose (RP2D) x 14 days after date, De-escalate cohort 1A: 720 mg BID x 28 days after date, De-escalate cohort -1B: 720 mg BID x 28 days after date , Up to 2 yrs
45690278|NCT01400139|Drug|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
45690279|NCT01399905|Drug|carbidopa|75 mg of carbidopa per day versus 450 mg of carbidopa per day
45690280|NCT01725308|Drug|FK949E|Taken by mouth (orally).
46050685|NCT04914078|Drug|Mepolizumab 100 MG|The patients will treated with subcutaneous Mepolizumab at 100 mg every 30 days. Patients will be recruited among those eligible to Mepolizumab treatment according to the Italian Medicine Agency (AIFA; Agenzia Italiana del Farmaco) guidelines who will accept to participate to the study. In particular inclusion criteria will be: severe (Step 4 and 5 GINA) asthma with at least blood eosinophilic count above 300 cells/mcl at least once in the previous year and ≥150 cells/mcl in the absence of systemic corticosteroid treatment before biological treatment initiation. In addition, one of the following conditions will be required: 1) ≥2 exacerbations in the previous year despite appropriate inhaled treatments or 2) the need for systemic corticosteroids on top of inhaled treatment for at least 6 months in the previous year.
46050686|NCT02837601|Device|AirSeal® Insufflation System (AIS)|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® iFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal. Specifically, the AirSeal® System creates a pressure barrier within the proximal housing of the cannula which acts as an invisible seal to maintain pneumoperitoneum during the course of surgery. It utilizes a re-circulation and filtration control unit (AirSeal® iFS) designed specifically for the AirSeal® Access Port to create and maintain the pressure barrier.
45364750|NCT02774759|Device|Accelerometer|Participant wears an accelerometer for 7 days before baseline visit to record activity levels, and again before their 6 month visit.
45364751|NCT02774759|Behavioral|Questionnaires|"Questionnaires completed at baseline regarding quality of life and diet.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
45364752|NCT02774759|Behavioral|Fitness Test|Fitness test given covering various physical activities at baseline and at 6 month visit.
45364753|NCT02774759|Behavioral|Resistance Training|Physical activity guidelines workbook distributed along with activity monitor. Participants receive resistance bands to perform resistance exercises. Exercise handouts and an iPad mini with training videos used to video chat with a research team member. Information from wireless scale and Fitbit sent to Fitbit website to monitor levels.
45364754|NCT02774759|Behavioral|Aerobic Exercise|Participants placed into an exercise plan focused on physical activity only. Physical activity guidelines workbook distributed along with activity monitor.
45364755|NCT02774759|Behavioral|Telephone Coaching/Phone Calls|Participants called 4 times during the first month, 2 times during the second month, and 1 time per month for the rest of the study. Participants also receive a follow-up call at the end of the study.
45364756|NCT02774759|Behavioral|Video Chat Sessions|Video chatting between the research team and participants occurs 2 times per month during the first and third months, when new exercises are introduced. Video chatting offered monthly as needed by participants during months 2, 4, 5, and 6.
45690281|NCT01725308|Drug|Placebo|Taken by mouth (orally).
45690282|NCT01724528|Drug|Febuxostat|Standard dose PO (per os) from Day 1 to Day 7 (can be continued up to DAY 9 at investigator's discretion)
45364757|NCT00617084|Device|Medtronic Endeavor Resolute|Medtronic Endeavor Resolute
45364758|NCT00617084|Device|Abbott Xience V|Abbott Xience V
45364759|NCT02758847|Device|Angiogram, Medtronic DCB (paclitaxel)/stent|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. Each participant will receive angiogram with DCB (drug coated balloon)/stenting with wound debridement. 50% of subjects will receive an Angiogram, Medtronic DCB (paclitaxel)/stent. Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
45364760|NCT02758847|Device|Angiogram, Bard DCB (paclitaxel)/stent|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. 50% of subjects will receive 'Angiogram, Bard DCB (paclitaxel)/stent' . Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
45364761|NCT01016860|Drug|OSI-906|OSI-906 will be given orally in tablets for one dose starting on Cycle 1 Day-3 then on Cycle 1 Day 2-4, 8-10 and 15-17. Cycle is 21 days. Subsequent cycles, dosing will start be Day 1-3, 8-10 and 15-17
46050687|NCT04257708|Diagnostic Test|ultrasound|Transvaginal us to assess the cavity
45364762|NCT01016860|Drug|irinotecan|Irinotecan will be administered IV over 90 minutes on Day 1 and 8 of a 21-day cycle
45364763|NCT04075877|Behavioral|FOCUS|See prior section.
45482226|NCT03312712|Other|LPS Challenge|In Part B, eight healthy volunteers will undergo an LPS challenge whereby each participant is injected with the challenge agent, Lipopolysaccharide (LPS), to invoke temporary mild lung inflammation. Each participant will have a PET/CT scan before and after the administration of LPS and the images will be assessed to determine whether these methods are able to detect true lung inflammation.
45364764|NCT00874484|Drug|Clexane (enoxaparin)|One arm receives enoxoparin, second arm receives saline
45364765|NCT03414905|Device|Aspira Catheter|"15.5Fr catheter~Standard of care"
45482227|NCT03312712|Other|Saline Challenge|In Part B, four healthy volunteers will undergo a saline challenge as outlined above for the LPS challenge. Pre- and post-challenge scans will provide control data for the study.
45482228|NCT03312712|Diagnostic Test|Blood and urine sampling|For women whose post-menopausal status and/or pregnancy status is uncertain at screening, a blood sample will be collected to test for pregnancy and menopausal status (hormone profiling) before enrolling them on to the study. If pregnancy status is still uncertain at study visits, participants will have a urine pregnancy test before undergoing any PET/CT scans to ensure it is safe for them to continue in the study.
45482229|NCT03302806|Other|Non interventional Study|
45482230|NCT04608786|Drug|ZKAB001 5mg/kg|ZKAB001 D1 IV 5mg/kg every three weeks,up to 16 cycles or 1 year
45482231|NCT04608786|Drug|Capecitabine|Capecitabine po 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses
45482232|NCT01314872|Drug|Vibegron|Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.
45482233|NCT01314872|Drug|Tolterodine ER|Participants received one tolterodine ER 4 mg capsule, taken orally once a day.
45482234|NCT01314872|Drug|Placebo matching vibegron|Participants received placebo matching vibegron tablets, taken orally each morning.
46050688|NCT02837679|Other|Geriatric Follow up|
45364766|NCT03414905|Procedure|Ultrasound|Standard of care
45364767|NCT00869492|Drug|benzoyl peroxide|benzoyl peroxide %5 solution once dailly
45482235|NCT01314872|Drug|Placebo matching tolterodine ER|Participants received placebo matching tolterodine ER capsule, taken orally each morning.
45690283|NCT01724528|Drug|Allopurinol|Standard dose, low dose or high dose (as per investigator's judgement at the time of randomization) from DAY 1 to DAY 7 (can be continued up to DAY 9 at investigator's discretion)
45690284|NCT01779440|Behavioral|Electronic Decision Support System|
45482236|NCT04602312|Other|Meditation (1 x 20-minute guided audio training)|Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.
45482237|NCT01343628|Drug|Placebo Comparator|16 NET SNP rs 11648486 CC and CT individuals will receive placebo and then after one week washout period, receive atomoxetine. Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5
45364768|NCT00869492|Drug|nadifloxacine|Nadifloxacine 1% cream twice dailly
45690285|NCT01750346|Drug|Topical acetyl hexapeptide-8|
45690286|NCT01750346|Drug|Placebo|
45690287|NCT01750268|Behavioral|Medical Management Counseling|Brief alcohol and medication counseling
45690288|NCT01750268|Drug|Topiramate|Experimental medication
45690289|NCT01750268|Drug|Placebo|Placebo comparator
45364769|NCT00489424|Drug|Placebo|
45364770|NCT00489424|Drug|Acetaminophen|
45364771|NCT00489424|Drug|Fluvastatin|
46050689|NCT05329974|Other|Computer guided buccal cortical plate separation|Computer guided buccal cortical plate separation for removal of calcified benign odontogenic tumors
46050690|NCT02837055|Device|VivaSight intubation|patients are intubated with an endotracheal tube with an integrated camera
46050691|NCT02837055|Device|conventional intubation|patients are intubated with a conventional endotracheal tube
46050692|NCT04255758|Other|Cycle Ergometer Exercise|25 minutes, 70% VO2max steady state cycle ergometry exercise
45482238|NCT01343628|Drug|Active Comparator: Atomoxetine, Placebo|16 NET SNP rs 11648486 CC and CT individuals will receive atomoxetine and then after one week washout period, receive placebo.Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5.
45364772|NCT05325359|Behavioral|L test|"It is an expanded version of the TUG and is designed to assess advanced functional ambulation with more detail available elsewhere. It is recorded when the participant gets up from the chair, walks 3 m to a cone, turns 90° to the right, continues to walk 7 m to the next cone, turns 180° left around the cone, then returns to the chair the same way. The test time is recorded, starting with the word go and ending with the participant's back touching the back of the chair."
45364773|NCT00869570|Drug|capecitabine|Phase II: 2 x 825 mg/m2 per day (during 5 weeks)
45482239|NCT00703924|Drug|WR 279,396|A topical cream containing 15% paromomycin and 0.5% gentamicin. Approximately 0.0005 mL per mm2 of skin lesion
45482240|NCT00703924|Drug|Placebo|Topical cream vehicle. Approximately 0.0005 mL per mm2 of skin lesion
45364774|NCT00869570|Drug|sorafenib tosylate|Phase II: 1 x 400 mg per day (during 5 weeks)
45482241|NCT03152526|Device|Interventions|CliniMACS® CD3 and CD19 Reagent System
45482242|NCT03302650|Drug|Angiotensin II|Patients will receive angiotensin-II at a starting dose of 20 ng/Kg/min.
45482243|NCT03302650|Drug|Normal saline|Patients will receive normal saline.
45690290|NCT01880437|Drug|cytarabine|Cohort 2: 20 mg sc daily for 10 days starting Day 1, with a possible further cycle of 20 mg sc daily for 5 days starting no earlier than Day 29
45690291|NCT01880437|Drug|vismodegib|Cohorts 1 and 2: 150 mg orally daily
45690292|NCT01861717|Drug|lanreotide|Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses
45690293|NCT01834729|Drug|Alfuzosin|oral alfuzosin immediate release (IR) 2.5 mg (Part A) or oral alfuzosin extended release (ER) 10 mg (Part B)
45690294|NCT01834729|Other|Placebo|placebo capsule identical to the study drug
46050693|NCT02837133|Behavioral|integrated yoga program|the program as a one-time session for 3 hours as a component of a Stress Management Education program
46050694|NCT02837289|Other|Therapy taping|Therapy taping follows an anatomical pattern from the femur until tibia for correction of dynamic valgus with therapy taping.
46050695|NCT02837289|Other|Placebo taping|Placebo taping follows a different anatomical path without tension, eliminating all therapeutic process elements
45690295|NCT01860703|Drug|Deferiprone|Ferriprox 500 mg tablets
46050696|NCT04260828|Drug|Aspirin 100mg|Daily active drug administered orally for 3 months.
46050697|NCT04260828|Other|Placebo|Sugar pill administered orally for 3 months.
46050698|NCT00928746|Device|Ipratropium bromide|
46050699|NCT02834871|Device|Electromyogram|
46050700|NCT02834715|Dietary Supplement|Stevia rebaudiana liquid extract|Sweetener made of liquid stevia self administered daily for 30 days
46050701|NCT04468815|Drug|BMS-986278 Tablet|Specified dose on specified days
46050702|NCT04468815|Drug|Esomeprazole|Specified dose on specified days
45364775|NCT00869570|Radiation|radiation therapy|Phase II: 1.8 Gy per day in 25 fractions (during 5 weeks)
45364776|NCT05072795|Behavioral|Trier Social Stress Task (TSST)|The TSST is a standardized psychological stress challenge which provokes a stress response in a laboratory setting. During the task, saliva samples will be collected for hormone testing along with physiological and subjective measures.
45482244|NCT03302650|Drug|Norepinephrine|patients will receive norepinephrine infusion adjusted according to blood pressure
45482245|NCT01343706|Drug|Placebo|Solution for oral administration
45482246|NCT01343706|Drug|Placebo .|Immediate release solid oral dosage
45690296|NCT01860703|Drug|deferiprone matching placebo tablets|deferiprone matching placebo tablets
45690297|NCT01860703|Drug|moxifloxacin|Active control
45690298|NCT01860703|Drug|placebo|moxifloxacin-matching placebo
45690299|NCT01399593|Drug|Eculizumab|
45690300|NCT01833169|Drug|BKM120|BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28-day cycle
46050703|NCT04468815|Drug|BMS-986278 suspension|Specified dose on specified days
46050704|NCT00610584|Procedure|acupuncture|arm 1: verum acupuncture group: 12 interventions (semi-standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
46050705|NCT00610584|Procedure|minimal (sham)acupuncture|arm 2: minimal (sham) acupuncture group: 12 interventions (standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
46050706|NCT00610584|Drug|cetirizine dihydrochloride (rescue medication)|arm 3: rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily)) alone
45364777|NCT05127304|Device|Trelegy Ellipta|Trelegy Ellipta with Furoate/Umeclidinium/Vilanterol
45364778|NCT05127304|Device|Stiolto Respimat|Stiolto Respimat with Tiotropium Bromide/Olodaterol
45364779|NCT05127304|Drug|Furoate/Umeclidinium/Vilanterol|Furoate/Umeclidinium/Vilanterol
45364780|NCT05127304|Drug|Tiotropium Bromide/Olodaterol|Tiotropium Bromide/Olodaterol
45364781|NCT00880412|Drug|EHT 0202 etazolate|In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
45364782|NCT00880412|Drug|Placebo|In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
45364783|NCT05673707|Diagnostic Test|Thyromental Height|its measure between thyroid and mentum
45364784|NCT01020136|Drug|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
46050707|NCT02834481|Device|ANI/NIPE|ANI/NIPE monitors is a continuous noninvasive measurement of the parasympathetic tone, as a component of the autonomous nervous system. It uses the tiny variations of heart rate induced by each respiratory cycle (natural or induced) to quantify parasympathetic tone (respiratory sinus arrhythmia).
46050708|NCT00894543|Drug|Escitalopram|10 mg (1 pill) escitalopram daily for the first four weeks. Dose increased to 20 mg (2 pills) escitalopram daily if relief from hot flashes has not occurred during the first four weeks of the daily 10 mg dose.
46050709|NCT00894543|Other|Placebo|Inactive pill (1 pill or 2 pills) daily for the 8-11 weeks of the trial.
45364785|NCT01020136|Drug|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
45364786|NCT03412643|Drug|Doxorubicin|60 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
45364787|NCT03412643|Drug|Cyclophosphamide|600 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
45364788|NCT03412643|Drug|Weekly Paclitaxel|80 mg/m2 IV weekly for 12 doses
45364789|NCT03412643|Drug|Trastuzumab|loading dose of 8 mg/kg IV; then 6 mg/kg IV every 3 weeks for Cycles 2-4
45364790|NCT03412643|Drug|Pertuzumab|loading dose of 840 mg IV; then 420 mg IV every 3 weeks for Cycles 2-4
46050710|NCT02838849|Dietary Supplement|Fiber|Fiber composed of wheat bran, pectin and green banana flour (total daily amount of 13 g for women and 20 g for men), keeping the usual liquid intake
46050711|NCT02838849|Dietary Supplement|Fiber and Water|Fiber composed of wheat bran, pectin and green banana flour (total daily amount of 13 g for women and 20 g for men) plus 2 liter of water/day
46050712|NCT02834325|Procedure|mechanical ventilation|
46050713|NCT04249791|Procedure|Transplantation of the uterus from live donor.|Laparoscopic-robotic hysterectomy for uterine transplantation in live-donor patient.
46050714|NCT04249635|Dietary Supplement|DHA|Women received supplementation of Based on Schizochytrium oil, 100% DHA (DSM) from 14 weeks of pregnancy until delivery.
45364791|NCT03412643|Diagnostic Test|Celcuity CELx HSF|Prior to drug interventions 3, 4,and 5, the Celcuity CELx HSF diagnostic test will be conducted to assess HER2 signaling activity
45364792|NCT05125744|Diagnostic Test|Assisted Ventilation|patients will be invasively ventilated in assisted mode. In all enrolled patients ventilated in assisted mode. Diaphragmatic activity will be evaluated through ultrasound (primary end point) and electrical activity of the diaphragm (optional) at stepwise decreasing of PEEP level. Also, the activity of remaining respiratory muscles will be assessed through sonography at the same levels of PEEP (secondary end point).
45364793|NCT00614744|Procedure|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
45364794|NCT00614744|Procedure|Normothermic Control|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
45364795|NCT01017094|Drug|silversulfadiazine|apply once a day
46050715|NCT02838771|Other|Water drinking test|Patient takes a sip of water about 60-70 ml. We assess: coughing, choking, voice changes.
45364796|NCT04074239|Other|Video triage|The operator at the Medical Helpline will offer the parent who's calling regarding the sick child to assess the child on video, as compared to the routine way; on the telephone.
45364797|NCT01020214|Drug|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
45364798|NCT01020214|Drug|Benicar HCT® Tablets 40 mg/25 mg|
45364799|NCT02733029|Drug|Sonazoid|Sonazoid (GE Healthcare) is a contrast agent that is a lipid-stabilized suspension of perfluorobutane microbubbles
45364800|NCT02733029|Device|contrast enhanced ultrasonography|Injection of intravenous ultrasound contrast
45364801|NCT01017172|Other|serologic testing|Serologic testing will be performed baseline, day 21 and day 42
45690301|NCT03814083|Device|Active-tDCS|Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
45364802|NCT02715323|Other|Cross-sectional study|
45364803|NCT02578433|Behavioral|Mindful Self Compassion|Mindful Self Compassion (MSC) training has its primary focus on developing a friendly relationship with oneself by meditation,conversation with the group and the trainer, informal practice and homework assignments. These relationship is founded on mindfulness; therefore the participants will learn a way concentrate on the present moment. The orginal MSC training by Neff and Germer is well established, this intervention will be a shortened form of the original version and will last for the whole visit of the clinical patients in rehabilitation
45364804|NCT02578433|Behavioral|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a well known relaxation technique where participants learn to recognize the difference between tension and relaxation by tensing and subsequently relaxing the muscles. The trainingw ill last the wohole stay and the control group will also do homework assignments.
46050716|NCT02838771|Other|Dysphagia screening questionnaire|Lithuanian version of the questionnaire consists of 16 questions. Interpretation of dysphagia screening questionnaire: advanced symptom - 2 points, moderate intensity symptom - 1 point, no symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points.
45364805|NCT04919993|Behavioral|Cognitive Behavioral Therapy-Insomnia|Group presentation
45364806|NCT00565812|Drug|SD-6010|200 mg tablets once a day for 2 years
45364807|NCT00565812|Drug|SD-6010|50 mg tablets once a day for 2 years
45364808|NCT00565812|Drug|Placebo|Placebo tablets once a day for 2 years
45482247|NCT01343706|Drug|BI 409306|Immediate release solid oral dosage medium
45482248|NCT03312478|Drug|Blood draw for insulin auto-anti body tests*|"Pharmaceutical form: N/A~Route of administration: N/A"
45482249|NCT03619694|Device|MRI Spectroscopy|Patient with brain SOL underwent MRI Spectroscopy to be compared with later pathology
45482250|NCT05658536|Behavioral|6-Week Self-Management Group|The goal of the 6-session group-based intervention for patients with Post-COVID is to teach patients behavioral strategies known to be helpful in managing several common Post-COVID symptoms, including fatigue, memory and attention issues, poor sleep, breathlessness, coping with anxiety and uncertainty, and stress management. It is currently available to patients who are seen in the Post-COVID-19 Rehabilitation and Recovery Clinic at UW and the Post-COVID-19 Clinic in VAPSHCS Rehabilitation Care Services.
45690302|NCT03814083|Device|Sham-tDCS|Sham-tDCS stimulation over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive sham-tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
45482251|NCT05059938|Behavioral|MyFitnessPal user|Patients will be counseled on how to use the MyFitnessPal application to help with the patient's weight loss goals. The physician will monitor the patient's weight, blood pressure, and waist circumference over up to a six month period with visits at 1, 3, and 6 months. Patients will be asked about the patient's use of the application at the end of the study.
45364809|NCT03974334|Behavioral|OWL-Hypertension 8 Wk Trial|Our Whole Lives - Hypertension is an innovative online community and self-management program that provides access to stress reduction, mind-body techniques, nutrition, exercise, and peer support. OWL-H provides educational materials including videos of clinician-led talks (stress reactivity, nutrition, movement, etc.). OWL-H also provides subjects a facilitated community blog, private journal, peer support, and an extensive resource library. It will be tested by 26 patients with hypertension, to refine the platform based on patient feedback and outcomes.
45364810|NCT03970824|Biological|CT-P17|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
45364811|NCT03970824|Biological|US-licensed Humira|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
45482252|NCT03307408|Other|blood collection|Standard routine practice clinico-biological data will be collected
45690303|NCT03814083|Other|Wait-list|No intervention
45845758|NCT05582226|Procedure|ACL reconstruction|"Orthopedic surgical operation in which a ruptured anterior cruciate ligament is repaired and reattached to the muscle connection points with a graft, a fashioned ligament that is meant to serve as a replacement for the ruptured muscle tissue."
45845759|NCT05582226|Procedure|Mesenchymal stem cell implantation|Stem cells are to be extracted from tissue at the stump of the ACL attachment point and inserted on the graft in the hopes of improving healing response
46050717|NCT02837211|Behavioral|Tapered Low Calorie Diet|"All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Tapered Diet Arm will undergo the following 24 week feeding study intervention.~The difference between a participant's run-in period energy intake and low-calorie prescribed energy intake (1000 kcal for women; 1200kcal for men) will be divided by six. At weekly intervals from weeks 1-6, daily caloric intake will be decreased by this fixed amount, reaching the final daily caloric goal (1000 kcals for women and 1200 kcals for men) by the end of the 6th week. Participants will present twice per week during weeks 1-6 to receive food that sums to that week's prescribed calorie level.~From weeks 7-24, these participants will then follow a traditional low-calorie diet, still presenting for food pickups twice per week at a stable caloric level during this period."
45482253|NCT05058222|Other|Deep Breathing Exercise after every 3hrs, each session consists of 10 deep breaths Exercise|• The control program will consist of Deep Breathing Exercises (from Morning to night every three hours; each session consisting of 10 deep breaths with a few seconds pause between each set, for 3 days) in addition with progressive Exercises.
45690304|NCT01860079|Procedure|early discharge|In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
45690305|NCT04407819|Radiation|WHOLE BODY DXA|Muscle mass was estimated by using the whole body DXA (Hologic Horizon W)
45845760|NCT05578560|Procedure|Prehabituation|chemical labyrinthectomy with intratympanically installed gentamicin
46050718|NCT02837211|Behavioral|Traditional Low-Calorie Diet|"All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Traditional Diet Arm will undergo the following 24 week feeding study intervention.~Immediately following run-in, these participants will start a low-calorie diet (1000 kcal per day for women; 1200kcal for men) Participants will present twice per week during weeks 1-24 to receive food that sums to that week's prescribed calorie level."
46050719|NCT02837367|Dietary Supplement|Administration of supplements containing methyl-donors|Administration of supplements containing methyl-donors: betaine, 5-MTHF (L-5-methyltetrahydrofolate), Vitamin B12, choline bitartrate, ALA (alfa-linolenic acid), EPA (eicosapentaenoic acid), DHA(docosahexaenoic acid)
46050720|NCT00922272|Drug|SPD489 (lisdexamfetamine dimesylate)|oral, 20, 30, 40, 50, 60, or 70 mg once daily
46050721|NCT00922272|Drug|Placebo matching SPD489 (lisdexamfetamine dimesylate)|oral, once daily
46050722|NCT00853372|Drug|Sunitinib|Sunitinib will be administered 50 mg QD and is considered to be the background therapy as it is licensed for treatment of reneal cell cancer (RCC) and will be administered to all participants.
45364812|NCT03970824|Biological|EU-approved Humira|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
45364813|NCT00933894|Drug|Telaprevir; Escitalopram|
45364814|NCT00933972|Drug|RO4998452|20mg po single dose
45364815|NCT00564486|Drug|IV Placebo|IV, every 6 hours for 24 hours (4 doses total)
45364816|NCT00564486|Drug|IV Placebo|IV, every 4 hours for 24 hours (6 doses total)
45364817|NCT00564486|Drug|IV Acetaminophen|IV, every 6 hours for 24 hours (4 doses total)
45364818|NCT00564486|Drug|IV Acetaminophen|IV, every 4 hours for 24 hours (6 doses total)
45364819|NCT00481078|Drug|vorinostat|Given PO
45845761|NCT05578560|Procedure|3D optokinetic stimulation in virtual reality space|3D optokinetic stimulation via virtual reality goggles with the software designed by Pro-Zeta comp.
45364820|NCT00481078|Drug|paclitaxel|Given IV
45364821|NCT00481078|Drug|carboplatin|Given IV
45364822|NCT00481078|Other|placebo|Given PO
45364823|NCT00481078|Other|laboratory biomarker analysis|Correlative studies
45364824|NCT00934206|Behavioral|Endurance training|running / walking at 60 % heart rate reserve 4 times per week for 4 weeks
45364825|NCT00934284|Other|Lumbar injection|Patients are instructed to resume normal activity as tolerated.
45364826|NCT00934284|Other|Rehabilitation following lumbar injection|Participants are referred to an average of four weeks of physical therapy after receiving a lumbar injection. Physical therapy designed to include end-range directional preference exercises and/or mechanical traction to reduce lower extremity symptoms and progress activity tolerance.
45364827|NCT00938808|Dietary Supplement|day formula diet|The Cambridge Programme. Formula diet
45364828|NCT00480532|Drug|Lybrel|All women enrolled in the study will take the same daily low dose oral contraceptive (20-mcg EE/90 mcg LNG) dosed in a continuous fashion.
45364829|NCT00480532|Drug|Doxycycline|100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline.
45364830|NCT00480532|Drug|Oracea|40-mg tablet daily for 84 days
45364831|NCT00480532|Drug|Placebo|Placebo pill orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of placebo
45364832|NCT00480532|Drug|Doxycycline 100bid x5 days at the time of bleeding|Doxycycline 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline
46050723|NCT00853372|Drug|Trebananib|Administered until a participant develops disease progression, clinical progression, unacceptable toxicity, withdraws consent, or death.
46050724|NCT02836977|Drug|tegafur-uracil|Eligible patients will receive tegafur-uracil orally at a dose of 400mg/day (100mg/Cap., 2 capsules each time, twice a day) and folinic acid 30mg/day (15mg/Tab., 1 tablet each time, twice a day) for one year.
45364833|NCT00480532|Drug|Subantimicrobial doxycycline daily|Subantimicrobial dose doxycycline 40mg daily for the first 84 days of the study
45690306|NCT01388985|Biological|Human Diploid Cell Vaccine (HDCV) rabies vaccine|Human Diploid Cell Vaccine (HDCV) rabies Merieux 1 ml vaccine for rabies, provided by Sanofi-Pasteur, administered zvia ID route at two sites
46050725|NCT00913042|Other|sample blood|"Early culture~Bacterial DNA tests in blood"
46050726|NCT04988256|Drug|Cyclosporine|"Patients randomized to cyclosporine will be treated as mentioned under Arm/Group Description"
46050727|NCT04988256|Drug|Methylprednisolone and Prednisone|All patients randomized to steroids will initially be treated with IV methylprednisolone and eventually started on an oral prednisone taper.
46050728|NCT00848536|Drug|Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
45364834|NCT00480532|Drug|placebo daily|Placebo daily for the first 84 days of the study
45364835|NCT04013880|Drug|CDA Inhibitor E7727/Decitabine Combination Agent ASTX727|Given by mouth
45364836|NCT04013880|Drug|IDH-1 Inhibitor FT-2102|Given by mouth
45364837|NCT00934518|Radiation|Radiation|Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week
45364838|NCT00934518|Drug|Cetuximab|"Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation"
45364839|NCT00496366|Drug|Capecitabine|The dose of capecitabine is 1000 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2000 mg/m2).
45364840|NCT00496366|Drug|Lapatinib|The daily dose of lapatinib is 1250 mg (5 tablets of 250 mg each) to be taken at approximately the same time each day, continuously. Lapatinib is taken even during the week that capecitabine is not taken.
45364841|NCT00934674|Drug|SKI-606 (Bosutinib)|"Arm 1 - Commercial Tablet manufactured by Excella~Arm 2 - Clinical Tablet manufactured by Wyeth Montreal"
45364842|NCT00934752|Device|Lutonix Paclitaxel-Coated Balloon|Percutaneous transluminal coronary angioplasty (PCTA)
45364843|NCT01020292|Drug|Nelfinavir|
45364844|NCT01017406|Device|PSU heel cushion and plantar fascia specific stretching exercise|"Wear heel cushion during daily activity~Plantar fascia stretching exercise 3 times per day"
45364845|NCT04014426|Other|Blood sample|"Exposed group:~15 to 30 minutes before the start of the procedure: 1 EDTA tube of 6 ml for blood (T0)~2hours after the end of the procedure: 1 EDTA tube of 6 ml (T1)~Non-exposed group:~- During the morning (8 to 10 a.m): 1 EDTA tube of 6 ml (T0)"
45364846|NCT04014426|Other|Urinary sample|"Exposed group:~15 to 30 min before the PIPAC procedure (T0)~2hours after the end of the procedure (T1)~The next morning after the procedure (T2)~Non-exposed group:~- During the morning (8 to 10 a.m) (T0)"
45364847|NCT03117582|Other|Stool specimen|"The following stool specimen will be collected for this study:~4, 3mL stool specimen from patient~1, 25mL stool aliquot from donor"
46050729|NCT00848536|Drug|Travoprost 0.004% (BAK-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
46050730|NCT00922116|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose of 100, 120, 150 or 200 micrograms based on previous ESA therapy)
45482254|NCT05058222|Other|Deep Breathing Exercise after every 3hrs, each session consist of 30 deep breaths Exercise|• The intervention group will perform additional Deep breathing Exercises (from Morning to night every three hours; each session consisting of 30 deep breaths with a few seconds pause between each set, for 3 days).
45364848|NCT00488644|Drug|Levothyroxine|75 mcg by mouth (PO) Daily for 8 Weeks
45482255|NCT03302572|Other|Brief information group|Patients will be given oral brief information about the existence of advance directives after resolving the reason for the visit for which they had come. This information will not last more than 3 minutes and will not be repeated on successive visits within the recruitment period. Also, an informative triptych will be given to the patient so that he can read it at home. These leaflets have been made by the regional Department of Health. They will be advised that we can extend the information or help them to do the document in the near future if they want, we will inform that we would wait for the answer 3 months. In case of interest, they can leave their information in the User Service by specifying name, telephone number and reference doctor or ask for an appointment again.
45482256|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added unripe banana flour|Ready-to-eat frozen soups added unripe banana flour (18 portions; 3 times/week)
45482257|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added maltodextrin|Ready-to-eat frozen soups added maltodextrin (18 portions; 3 times/week)
45482258|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added inulin|Ready-to-eat frozen soups added inulin (18 portions; 3 times/week)
45482259|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added nisin|Ready-to-eat frozen soups added nisin (18 portions; 3 times/week)
45364849|NCT00488644|Drug|Liothyronine|15 mcg PO Daily for 8 Weeks
45482260|NCT05051982|Device|Sedline EEG in View|EEG monitor (Sedline) will be in full view of the Anesthesiologist during surgery.
45690307|NCT01388907|Other|Ringer lactate solution|Ringer lactate solution was applied directly onto the uterine surgical sites at the end of the myomectomy surgery, to prevent post-surgical adhesion formation.
45690308|NCT01388907|Device|Prevadh film|Prevadh film was applied directly onto the uterine surgical sites at the end of the myomectomy surgery to prevent post-surgical adhesion formation.
45845762|NCT05578560|Procedure|Vestibular training|vestibular training program adopted for patients with acute vestibular loss under the supervision of a physical therapist. The program includes gaze stability exercises, smooth pursuit, and saccadic eye movements, and postural exercises to improve balance control and gait stability. Each session lasts around 30 minutes and happened daily for the 7 postoperative days.
45364850|NCT00934830|Drug|Antibiotic (Amoxicillin)|500 mg, 3 times per day for 10 days
45364851|NCT00934830|Other|Therapeutic ultrasound|1.0 W/cm2 in continuous mode for 10 minutes once a day for 4 consecutive days.
45364852|NCT00934908|Dietary Supplement|Green Tea|Green tea capsules taken twice a day.
45364853|NCT00934908|Other|Placebo|"Non-active sugar pill."
45364854|NCT02575404|Drug|GR-MD-02|Patients will receive five doses of GR-MD-02 intravenously over 85 Days.
45364855|NCT02575404|Drug|Pembrolizumab|Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.
45364856|NCT00564018|Drug|Insulin detemir|Dosage adjusted to meet age-specific glycemic goals throughout course of study.
45364857|NCT00564018|Drug|Glargine|Dosage to be adjusted to meet age-specific glycemic goals throughout course of study.
45482261|NCT03312322|Other|High-frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 100Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm < 60 during more than 10s."
45482262|NCT03312322|Other|Low-frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 4Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm < 60 during more than 10s."
45690309|NCT01388361|Drug|insulin degludec|Injected s.c. (under the skin) once daily. The doses will be individually adjusted
45690310|NCT01388361|Drug|insulin aspart|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
45690311|NCT01388361|Drug|liraglutide|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
45690312|NCT04028895|Diagnostic Test|Dosage of IRAP during OGTT|Visit 1: oral glucose tolerance test. visit 2: hyperinsulinemic euglycemic clamp
45690313|NCT05368935|Drug|Nitazoxanide|500 mg Twice Daily for 7 days
45690314|NCT01399125|Drug|Rivastigmine Patch|Once-daily target patch size 10 cm²
45690315|NCT01399125|Drug|Rivastigmine Capsules|Twice-daily target dose of 6 mg oral capsule
45364858|NCT00564018|Drug|NPH|Dosage to be adjusted to meet age specific glycemic goals throughout course of study.
45690316|NCT01399125|Drug|Placebo to Rivastigmine patch|Matching placebo to Rivastigmine patch
46050731|NCT04117282|Other|gait training|training for improving the quality of gait through adjusting gait cycle phases time and improving the functional level and independence during gait
45364859|NCT04013724|Behavioral|Group tobacco cessation interventions|"Group Session Week 1 Participants were introduced to the specific components of the group behavioral intervention. Participants shared their expectations and experiences in their goal of tobacco cessation.~Group Sessions Weeks 2-11 Participants set their anticipated quit date on the 2nd week. During weeks 2 through 11, before the start of the session, feelings of participants were explored, the previous week's self-reported tobacco consumption or cessation attempt was recorded. The topic of each week was explored first by lecture to explain the topic, and then group members took turns sharing their experiences on the topic.~Group Sessions Weeks 14-26 Behavioral group sessions weeks 14-26 were conducted once a month. Each session began with a round of discussion on how participants were feeling about their cessation attempts, including any challenges they had experienced. The self-reported amount of tobacco used and quit attempts were documented."
45364860|NCT00934986|Other|Surface expression of functional biomarkers of the NK cell|"An extra blood sample of 40 ml is required :~Stage A patient who does not require a treatment: one sample the day of enrollment.~Stage B or C patient who require RFC treatment: sample at D0 of the 1st and 4th cure of RFC, and 3 months after the end of the treatment."
45364861|NCT00935142|Drug|[18F]VM4-037|Bolus IV injection of [18F]VM4-037
45482263|NCT03312322|Other|Sham transcutaneous electrical nerve stimulation|The procedure is the same as high-frequency transcutaneous electrical stimulation but intensity is progressively setted back to 1mA (over a 45sec period) after every increment so that constant workload testing is performed with 1mA.
45482264|NCT04543344|Drug|Recifercept|recifercept powder for solution for injection
45690317|NCT01399125|Drug|Placebo to Rivastigmine capsules|matching Placebo to Rivastigmine capsules
46050732|NCT04255524|Device|Optic coherence tomography angiography (OCTA)|Using non-invasive, repeatable, mature device OCTA to obtain choroidal angio-map
45482265|NCT04543344|Other|Placebo|solution for injection
45482266|NCT03302338|Drug|SAFE group|simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
45482267|NCT03302338|Drug|placebo group|distilled water 20 ml/kg/day for maximum of 7 days.
45482268|NCT01343784|Other|Urinary voiding assessment after midurethral sling|Both groups will undergo voiding trial in the similar manner. The decision to discharge based on an objective measure (voided amount) versus based on the subjective measure (force of stream self assessment).
46050733|NCT04260516|Drug|N-acetyl cysteine|Mucolytic and antioxidant drug
46050734|NCT00921024|Drug|CXA-101|intravenous
46050735|NCT00921024|Drug|Ceftazidime|intravenous
46050736|NCT04260594|Drug|Arbidol|Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days
45690318|NCT04015791|Other|NOCISCAN-LS Disc MR Spectroscopy|The investigational Nociscan Suite is a software suite that works with existing high field MR systems and MRS pulse sequence via and optimized protocol to conduct MRS exam of lumbar discs. The software suite post-processes the NOCISCAN-LS disc MRS exam data to calculate ratios of spectroscopic signals at regions along the MRS frequency spectrum associated with certain chemicals that change with degeneration and pain
45690319|NCT04026633|Behavioral|CAA|Participants will write about the use of PBS and alcohol use.
45690320|NCT04026633|Behavioral|Control|Participants will write about eating and exercise.
46050737|NCT04260594|Other|basic treatment|basic treatment
45482269|NCT03307096|Procedure|Microperc surgery|Parents are treated by Microperc Percutaneous Nephrolithotomy
45690321|NCT01399047|Drug|Mycophenolate mofetil|The liquid dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (Omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
45845763|NCT05557812|Drug|non-eugenol based ZOE base material with Ferric Sulfate in primary molar pulpotomies|non-eugenol based ZOE base material placed over ferric sulphate, during vital pulp therapy (pulpotomy) in primary molars
45845764|NCT05557812|Drug|eugenol based zinc oxide and Ferric Sulfate|eugenol based zinc oxide base material placed over Ferric Sulfate medicament, during vital pulp therapy (pulpotomy) in primary molars
46050738|NCT04203888|Other|Swedish Massage|60-minute Swedish Massage delivered in-home by a licensed massage therapist, 2 times per week with at least 48-hours between massage interventions.
46050739|NCT04203888|Other|Yoga|"60-minute yoga session delivered in-home by a certified yoga instructor, 2 times per week with at least 48-hours between yoga interventions.Yoga sessions will be based on the yoga postures available in the appendix of the December 2005 Annals of Internal Medicine article, Comparing Yoga, Exercise, and a Self-Care Book for Chronic Low Back Pain (Sherman KJ et al., 2005)."
46050740|NCT04260438|Drug|CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T|single oral administration under fed condition
46050741|NCT04260438|Drug|CKD-393 0.5/100/1000mg formulation 1 Tab. 1T|single oral administration under fed condition
46050742|NCT04260438|Drug|CKD-393 0.5/100/1000mg formulation 2 Tab. 1T|single oral administration under fed condition
45364862|NCT04013412|Dietary Supplement|Protein-Calorie Restriction|Four day dietary intervention immediately before surgery of ScandiShake [any of 4 flavors] mixed with almond milk, calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on body weight and activity level.
45364863|NCT00935298|Drug|Tacrolimus|The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation. After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5*1/*1 type and CYP3A5*1/*3 type administer 0.15mg/kg/d，CYP3A5*3/*3 type administer 0.08mg/kg/d).
45847824|NCT02973438|Device|Intermittent Hypoxia (IH)|Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute hypoxic intervals (FIO2 = 0.09-0.12) with 3-minute normoxic intervals (FIO2 = 0.21). During hypoxic intervals, oxygen concentration may be adjusted to maintain participants SpO2 levels between 75-90%.
46050743|NCT00928668|Drug|Placebo|Placebo device for comparison
46050744|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
45482270|NCT03307096|Procedure|FURS|Parents are treated by FURS
45364864|NCT04014192|Drug|Dapagliflozin|Treated with dapagliflozin 10mg/d for one week.
45364865|NCT04014192|Drug|Empagliflozin|Treated with empagliflozin 10mg/d for one week.
45364866|NCT04014192|Drug|Canagliflozin|Treated with canagliflozin 100mg/d for one week.
45482271|NCT05250492|Procedure|Prosthetic hip surgery|"Total hip prosthesis performed by an anterior approach with intra-articular infiltration of an anesthetic product intraoperatively.~OR~- Total hip prosthesis performed by an anterior approach with infiltration of the same anesthetic product by ultrasound-guided PENG block intraoperatively."
45364867|NCT00935376|Behavioral|Sleep Education Program|Treatment as usual.
45364868|NCT00935376|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
45364869|NCT00935376|Behavioral|Mindfulness Meditation Program|Mindfulness Meditation Program is based on Mindfulness-Based Stress Reduction, which teaches participants awareness and mindfulness skills using techniques that include a basic meditation practice and yoga.
45364870|NCT00935454|Procedure|Hepatocyte matrix implantation|"First operation:~Removal of liver tissue and biopsy of pancreas~Second operation:~Implantation of hepatocyte matrix implant into small bowel mesentery"
45364871|NCT00935610|Dietary Supplement|Immunocal|20 grams per day of Immunocal for 135 days.
45364872|NCT00935610|Dietary Supplement|Casein|20 grams per day for 135 days
45364873|NCT04013646|Drug|Umbilical cord blood infusion|The umbilical cord blood is donated umbilical cord blood which is stored in the cord blood bank donated by Cha Hospital. The total number of nuclear cells should be at least 2 x 10 7 / kg, and at least three out of six of the six human leukocyte antigens (HLA-A, B, DR) should be selected. The cord blood that matches ABO and Rh blood type is preferentially used. Umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
45482272|NCT04355364|Drug|Dornase Alfa Inhalation Solution [Pulmozyme]|Administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days
45482273|NCT04355364|Procedure|standard procedure|Patients will receive the usual care in accordance with good practice.
45482274|NCT03312244|Drug|Pyridostigmine Bromide|Pyridostigmine 180mg/day p.o.
45482275|NCT03312244|Drug|Placebo|Placebo
45690322|NCT01399047|Drug|Liquid Placebo|The dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
46050745|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
46050746|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
46050747|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
46050748|NCT05057754|Behavioral|Cooling|Participants' dominant hand and wrist will be immersed in cool water (20°C) for five minutes. The cool water will be kept to around 20°C (19 - 21°C) by frequently checking the temperature and corrected when it rises to 20.5°C
46050749|NCT05057754|Behavioral|Heating|A heat pack wrapped in a towel will be applied to participants' dominant hand for five minutes.
46050750|NCT05057754|Behavioral|Exercising|Participants will be asked to participate in moderate-intensity physical activities to induce an increase in blood pressure. The physical activity will be two sets of 30 jumping jacks, followed by 15 squats. Participants are allowed to rest for 20 seconds between the two sets.
45482276|NCT05250336|Other|Observational Study|Assessment of Prognostic and Predictive value of Tumor-Infiltrating Lymphocytes and Programmed cell Death - Ligand 1 in Breast cancer
45482277|NCT03306940|Drug|Botulinum Toxin Type A|patients were injected to the normal side with dose of 1.25 units/per site
45482278|NCT03302260|Behavioral|CardioPrevent® Program|This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context.
45690323|NCT05369169|Behavioral|Resonance breathing|Participants will synchronize their breathing with a visual pacer (E-Z Air, Thought Technology, Ltd., Plattsburgh, NY) that moves up (inhale) and down (exhale) at the rate of 0.1 Hz (6 breaths per min)
46050751|NCT05057754|Behavioral|Typing|All participants will be asked to perform a typing task with a standard wired keyboard. All subjects will be asked to type for five minutes.
46050752|NCT05057754|Behavioral|Using a mouse|"Participants will be asked to draw as many lower-case alphabet characters from a to z as possible using a standardized scroll mouse for five minutes in the Windows Microsoft Paint software."
45364874|NCT04013646|Drug|Erythropoietin injection|Recombinant human erythropoietin is used and is administered intravenously at a maximum of 5 times at a rate of 500 IU / kg 2 times/week after cord blood peripheral blood infusion, calculated as the dose per body weight. Or subcutaneous administration if intravenous administration is not possible. Store in a sealed container at 2-8 °C in the refrigerator before dosing. Erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
45364875|NCT04013646|Drug|Placebo umbilical cord blood infusion|Placebo umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
45482279|NCT03149328|Other|Educational Support|In the intervention group, clinicians will be provided with PRO feedback for use in their clinical practice. They will also receive educational support on how to use PRO data at point of care.
45482280|NCT03312166|Device|Compression device|"interventions on patient are :~surgical excision of ear lobe keloid~application of compression device on sutured skin"
45364876|NCT04013646|Drug|Placebo erythropoietin injection|Placebo erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
45482281|NCT03312088|Device|Freedom Knee PCK Components|Total Knee Revision
45364877|NCT04013646|Procedure|Active rehabilitation|Physical therapy and occupational therapy are performed daily.
45482282|NCT00739050|Drug|simvastatin|simvastatin 20mg daily at nights for 12 weeks. Tablets
45690324|NCT05369169|Behavioral|Low demand cognitive task|Different colored rectangles are presented for 10 sec each, and participants are instructed to silently count the number of blue rectangles
45364878|NCT03381287|Drug|HTD1801 Tablets, 500 mg|500 mg/day (250 mg BID)
45364879|NCT03381287|Drug|HTD1801 Tablets, 1000 mg|1000 mg/day (500 mg BID)
45364880|NCT03381287|Drug|HTD1801 Tablets, 2000 mg|2000 mg/day (1000 mg BID)
45364881|NCT03381287|Drug|Placebo to match 500 mg HTD1801|2 tablets/day (1 tablet BID)
45482283|NCT00739050|Drug|Comparator: Placebo|placebo daily at nights for 12 weeks. Tablets
45482284|NCT03302182|Drug|Ritonavir for cycle1 and NORVIR for cycle 2|During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg in cycle 1 and NORVIR tablet 100mg in cycle 2 .
45482285|NCT03302182|Drug|NORVIR for cycle 1 and Ritonavir for cycle 2|During the study session, healthy subjects will be administered a single dose of NORVIR Tablet 100mg in cycle 1 and Ritonavir tablet 100mg in cycle 2 .
45482286|NCT03306784|Other|questionnaires|questionnaires, including RAPID3 and pain catastrophizing scales
45482287|NCT01343862|Drug|D-cycloserine|single dose of D-cycloserine given 48-72 hours after moderate traumatic brain injury
45482288|NCT01343862|Drug|placebo|A sugar pill will be given to those patients randomized to the control group at 48-72 hours after moderate brain injury
45482289|NCT03311932|Drug|Infacort®|Immediate release multiparticulate formulation (granules) of hydrocortisone
45482290|NCT03311932|Drug|Cortef®|Immediate release hydrocortisone tablets
45482291|NCT02467738|Radiation|Brachytherapy|Undergo brachytherapy with Cesium-131
45482292|NCT02467738|Drug|Cesium-131|Undergo brachytherapy with Cesium-131
45690325|NCT01387737|Drug|TA-7284-Low|TA-7284-Low
45690326|NCT01387737|Drug|TA-7284-High|TA-7284-High
45690327|NCT05367141|Other|"CDSS (MedicBK)"|"Clinical decision support system (MedicBK) is a computer-based program that analyzes published evidence and provides prompts and reminders to assist health care providers in implementing clinical guidelines and science-based medicine at the point of care."
45364882|NCT03381287|Drug|Placebo to match 1000 mg HTD1801|4 tablets/day (2 tablet BID)
45364883|NCT03381287|Drug|Placebo to match 2000 mg HTD1801|8 tablets/day (4 tablet BID)
45364884|NCT04074473|Drug|propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
45482293|NCT02467738|Procedure|Conventional surgery|Undergo surgical resection
45364885|NCT04074473|Procedure|Esophageal varice ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
45364886|NCT04074473|Other|DC propranolol|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
45364887|NCT03356483|Drug|Psilocybin (0.25mg/kg)|Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic.
45364888|NCT03356483|Drug|Niacin (250mg)|A medication used to treat high cholesterol, triglyceride levels, and niacin deficiency.
45364889|NCT03093480|Biological|rFVIIIFc|rFVIIIFc 200 IU/kg/day in ITI Period, 50 or 100 IU/kg (adjusted according to Investigator judgement) in tapering Period, and prophylactic regimen in Follow-Up period as powder for injection administered intravenously.
45364890|NCT00616928|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Two intramuscular injections at Days 0 and 21.
45364891|NCT00616928|Biological|Placebo|Two intramuscular injections at Days 0 and 21.
45482294|NCT03311698|Behavioral|Nutrition-sensitive intervention|Nutrition-sensitive intervention using behavior change communication on home gardening, diet, nutrition, WASH, and women's empowerment.
45364892|NCT03345563|Behavioral|Body Mind Training (BMT)|"Participants will practice BMT under the instruction of a BMT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Each session will include both light physical exercise and mind training.~Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period."
45482295|NCT00604812|Drug|rizatriptan benzoate (5 mg)|A single dose of rizatriptan 5 mg administered on Day 1.
45482296|NCT00604812|Drug|rizatriptan benzoate (10 mg)|A single dose of rizatriptan 10 mg administered on Day 1.
45482297|NCT00604812|Drug|Rizatriptan 5 mg Placebo|A single dose of rizatriptan 5 mg placebo administered on Day 1.
45482298|NCT00604812|Drug|Rizatriptan 10 mg Placebo|A single dose of rizatriptan 10 mg placebo administered on Day 1.
45690328|NCT01387347|Drug|Thymosin beta 4|A preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
45690329|NCT01387347|Drug|Placebo|A preservative-free, sterile eye drop solution containing 0.0% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
45364893|NCT03345563|Behavioral|Body Training (BT):|Participants will practice BT under the instruction of a BT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period.
45364894|NCT03345563|Behavioral|Usual Care (UC)|Participants in the usual care arm will receive care as normal and will not attend classes but will complete the same assessments as participants in the BMT and BT classes.
45364895|NCT00939042|Procedure|Percutaneous Coronary Intervention|common Percutaneous Coronary Intervention
45364896|NCT00939042|Procedure|BMNC therapy|Injection of BMNC after common PCI
45364897|NCT02578511|Drug|Ixazomib|Patients who have been on stable doses of 6 - MP, vincristine, and methotrexate for a minimum of eight weeks and have at least six months remaining of maintenance are eligible to receive Ixazomib, which will be administered on days 1, 8 and 15.
45364898|NCT00935688|Other|Rapid diagnostic test|Dual species test for P. vivax and P. falciparum malaria
45847825|NCT02973438|Device|SHAM|Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute normoxic intervals (FIO2 = 0.21) with 3-minute normoxic intervals (FIO2 = 0.21).
46050753|NCT05057754|Behavioral|Cooking|Participants will be asked to participate in a cooking trial following a prespecified cooking recipe of Rice Krispy Treat. he participant will be asked to follow the procedures as follows: (1) cut and put wax paper in the pan; (2) cut butter into 4 pieces; (3) place butter in a pot over a portable stove and stir until the butter is completely melted; (4) add four oz of marshmallows and stir until melted; (5) add cereal and the rest of marshmallows and stir until all ingredients are combined (6) transfer the ingredients to the pan and use a silicone spatula to pat the ingredients evenly into pan.
46050754|NCT05056428|Behavioral|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
46050755|NCT05305482|Device|Drug-coated stent|The polymer-free drug-coated stent (BioFreedom Ultra stent) will be implanted for the DCS group.
45364899|NCT00869648|Procedure|Extension|After anaesthesia induction the head is placed in extension
45364900|NCT00869648|Procedure|Neutral head position|After anaesthesia induction the head is placed in neutral position
45482299|NCT03302026|Behavioral|Realtime biofeedback using fMRI|Real-time fMRI (rt-fMRI) allows for rapid analysis of brain activation while an individual is actively performing a task, and can be used to provide real-time neurofeedback to individuals during fMRI scanning. Using neurofeedback, individuals can learn to modulate activity in specific regions of the brain. We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. Participants will complete four sessions: an intake session and 3 scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm.
46050756|NCT05305482|Device|Drug-eluting stent|The Biodegradable polymer drug-eluting stent (Ultimaster stent) will be implanted for the DES group.
45364901|NCT00869648|Procedure|Anaesthesiologist's position|after anaesthesia induction the head is placed in a position deemed optimal by the anaesthesiologist
45364902|NCT03325985|Behavioral|Nurse-led telephonic case management|Telephonic meetings with a palliative care nurse. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
45482300|NCT03301948|Other|Overfeed|Participants consume energy intakes that are 50% higher than their estimated requirements instead of consuming energy intakes equal to their estimated requirements
45364903|NCT03325985|Behavioral|Facilitated,outpatient specialty palliative care|In-person palliative care visits with a palliative care provider. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
45482301|NCT03301948|Other|Energy Balance|Participants consume energy intakes equal to their estimated requirements instead of consuming intakes that are 50% higher than their estimated requirements
45482302|NCT04347408|Diagnostic Test|Covid-19 Antibody testing (IgG and IgM)|Antibody testing for previous exposure to Covid-19
45364904|NCT00563784|Drug|Erlotinib|150 mg by mouth daily for 7 Weeks
45482303|NCT04347408|Other|Blood Storage|Storage of blood for multi-omics analysis
45482304|NCT03301870|Drug|ATx201 Gel 2%|2% active gel
45482305|NCT03301870|Drug|ATx201 Gel 4%|4% active gel
45482306|NCT03301870|Drug|Positive Control|Sodium Lauryl Sulfate 0.05% (w/v), USP in sterile, distilled Water for Injection, USP
45482307|NCT03301870|Drug|Negative Control|Water for Injection, USP
45482308|NCT03301870|Drug|ATx201 Placebo|matching placebo gel
45482309|NCT03306628|Other|CO2 Laser Administration|The CO2 fractional laser system will be applied at a pulse energy setting of 50 millijoules and a density of 100 spots/cm2 on one of the breast incisions (either one week after surgery or six weeks after surgery, depending on the randomization group).
45482310|NCT01343940|Behavioral|Project dulce|"Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a Dulce family partner) supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services. Specialist meets with family during all routine well-child visits scheduled in primary care between birth and 6 months (1-mo, 2-mo, 4-mo, 6-mo). Parent may meet with specialist before or after scheduled appointment, and may request a home visit. Specialist will be available by phone for consultation."
45482311|NCT01343940|Behavioral|Safety intervention|Participating family is assigned a safety specialist. Meeting with the safety specialist will occur before or after a routine well-child visit or at a separately agreed upon time. The specialist will discuss infant injury risks associated with transportation and sleep. The specialist will provide safety equipment (car seat and pack-and-play) and instruct the parent in their proper use.
45482312|NCT03306550|Drug|salvianolate injection|The main ingredient of salvianolate injection is salvianolic acid B(SAB) which is extracted from the root of red salvia. Red salvia is used in traditional Chinese Medicine. It could promote blood circulation to removing blood stasis,which is clinically effective in treatment for cardiovascular disease.
45364905|NCT00563784|Drug|Carboplatin|2 AUC by vein weekly for 7 Weeks
45482313|NCT03306550|Drug|Aspirin Tablet|Anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascular disease.
45482314|NCT05250024|Device|Cranioplasty|patient specific cranial implant
45482315|NCT03306472|Drug|Megestrol Acetate 40 MG|Progesterone Agonist
45482316|NCT03306472|Drug|Megestrol Acetate 160 MG|Progesterone Agonist
45482317|NCT03306472|Drug|Letrozole|Aromatase Inhibitor
45482318|NCT03311620|Procedure|Endobronchial ultrasound (EBUS) transbronchial needle aspirate (TBNA)|Biopsy samples will be collected from patients scheduled to undergo EBUS TBNA using 19g and 22g needles
45482319|NCT03311542|Biological|pembrolizumab|Each participant will receive pembrolizumab every 21 days for up to 12 month or until confirmed disease progression on MRI or CT, unacceptable toxicity, confirmed.positive pregnancy test or withdrawal of consent.
45482320|NCT02468362|Procedure|laparoscopic intersphincteric resection|laparoscopic intersphincteric resection for low rectal cancer
45482321|NCT02468362|Procedure|open intersphincteric resection|
45482322|NCT04507152|Other|Blood flow restriction resistance training|The participants will carry weights and perform certain resistance exercises, such as step-up, sit-to-stand, and tip-toe-standing. The experimental group will execute the training with blood flow restriction.
45482323|NCT04507152|Other|Resistance training|The participants will carry weights and perform certain resistance exercises, such as step-up, sit-to-stand, and tip-toe-standing. The control group will execute the training without blood flow restriction.
45847826|NCT02973516|Drug|P03277 at 0.1 mmol/kg|P03277 will be administered at 0.1 mmol/kg BW (corresponding to 0.2 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
46050757|NCT05329818|Device|high definition transcranial direct current stimulation|"Non-invasive brain stimulation neuromodulation using HD (3,14cm^2) gel based round electrodes. Scalp electrode locations will be positioned based on a optimized biophysical solution targeting ipsilesional dlPFC and the contralesional anterior cerebellum.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 1.73mA. Patients in the cerebellar stimulation group will receive 20 min of HD-tDCS with 2.0mA.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 3.73 mA.~Patients in the sham stimulation group will receive 20 min of sham HD-tDCS, with 30 seconds ramp-up and 30 seconds ramp-down."
46050758|NCT00592774|Drug|E2007 (perampanel)|2 mg titrated up to 8 mg maximum; taken once daily.
46050759|NCT00592774|Drug|Placebo|2 mg titrated up to 8 mg maximum; taken once daily.
45364906|NCT00563784|Drug|Paclitaxel|45 mg/m^2 by vein weekly for 7 Weeks
45364907|NCT00563784|Radiation|Radiation Therapy|63 GY/35 fractions for 7 weeks (+/- 5 days)
45482324|NCT02467660|Behavioral|Mindfulness Meditation|Using study-provided iPod device to listen to guided meditations daily
45482325|NCT02467660|Behavioral|Health & Wellness Education|Using study-provided iPod device to listen to educational podcasts daily
45482326|NCT03311464|Drug|adalimumab|Study drug will be administered subcutaneously.
45364908|NCT00869804|Behavioral|Aerobic/ Resistance Exercise Intervention|The intervention will consist of a tailored home-based program of both aerobic (walking, using pedometer) and strength training exercises for upper and lower extremities using resistance power bands.
45364909|NCT00869804|Behavioral|Attention control|
45364910|NCT00869882|Procedure|Circumferential arthrodesis|"Patients are carefully positioned in the proned position and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs which can be performed at surgeon's demand during the whole surgery time.~The preceding procedure is performed. In case of foraminal stenosis, decompression is performed at the same time as discal approach via the narrowest foramen.~In addition to this, before preparation of bed for bone grafting, nerve roots are retracted and the disc nucleus is removed entirely, then endplate decortication is performed. The disc space is distracted. The most anterior part of the disc space is packed with cancellous bone. A cage packed with bone is inserted into the anterior portion of the interspace. According to cage location, bone graft could be inserted in the posterior portion of the interspace. Cage placement is radiologically checked.~The end of the procedure is the same as for GPLI."
45364911|NCT00869882|Procedure|Posterolateral fusion with instrumentation|"Patients are carefully positioned in pronation and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs performed at surgeon's demand during the whole surgery time.~Pedicle screw instrumentation is performed, followed by posterior neural decompression depending on the type of stenosis:~Central stenosis: decompression is performed including medial facectomy, laminectomy;~Foraminal stenosis: foraminotomy is performed, while preserving a graft bed as large as possible;~Pure foraminal stenosis: spinal duct is not opened. Local bone is harvested from the lamina and the spinous process and carefully fragmented for autologous graft.~Subperiosteal dissection is performed between the transverse processes and lateral aspects of the facet joints.~Two rods are placed and locked on screws in maximum compression to optimize segmental lordosis.~Bone autograft is placed into this bed."
45364912|NCT03291509|Behavioral|Video Conference Meetings|Individual video conferencing with a health educator using an iPad.
45482327|NCT05013840|Behavioral|Filling in an online survey|Physicians are asked to fill in an online survey regarding 1) goals to treat patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.
45482328|NCT02468440|Other|ESPAIR|ESPAIR is an educational therapy's program with 6 group session,and if patients ask for it, individual session are possible
45690330|NCT04040439|Drug|Dexmedetomidine Hydrochloride|"[Sedation during and after mechanical ventilation in the intensive care setting] For pediatric patients ages of 6 years and over, dexmedetomidine is usually administrated by continuous intravenous (IV) infusion of at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.0 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition.~For pediatric patients with corrected gestational ages (gestational age + postnatal age) of 45 weeks to under 6 years, dexmedetomidine is usually administrated by continuous IV infusion at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.4 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition. The dosing rate could be decreased according to the patient's condition as appropriate."
45364913|NCT03291509|Behavioral|In-person Meetings|Individual face-to-face (FTF) meetings with a health educator.
45482329|NCT03306238|Procedure|Open approach to port insertion|This involves the peritoneum being cut down, followed by the insertion of a blunt trocar under direct visualisation, gas insufflation, and insertion of the laparoscope
45482330|NCT03306238|Procedure|Closed approach to port insertion|This involves the insertion of a Veress needle (a needle equipped with a spring-loaded obturator) into the peritoneal cavity, followed by gas insufflation (act of blowing) and insertion of a trocar (a sharp, pointed instrument with a cannula used to enter the body cavity).
45482331|NCT05217030|Other|Animal assisted therapy|Patients in AAT group had handler place dog on bed and patient's hand was placed on dog. Bedside RN measured GCS, RLAS, LoCmds before and after intervention
45482332|NCT03306160|Other|48-hour blood pressure ambulatory monitoring|at first-time dialysis after enrollment, each patient will receive brachial and central blood pressure monitoring for 48 hours using a validate and commercially available device Mobil-O-Graph (IEM, Germany).
45482333|NCT05214066|Drug|Rabbit ATG|ATG (Thymoglobuline, rabbit) was used as 1 mg/kg/d from day -5 to day -3 and 2 mg/kg/d on day -2.
45690331|NCT04012827|Drug|Apatinib Mesylate, doxorubicin, ifosfamide|Doxorubicin 50mg/m2 d1 , Ifosfamide 2.5g/m2 d1-3 , Apatinib mesylate 375mg qd
45690332|NCT01859923|Drug|Delamanid|Participants received adult formulation delamanid as per regimen specified in the arm description. Morning dose of the delamanid BID regimen was given within 30 minutes after the start of a standard breakfast meal. The evening dose of the BID dose regimen was given 10 hours post morning dose and within 30 minutes after the start of a standard dinner meal.
45690333|NCT01859923|Drug|Delamanid Pediatric Formulation (DPF)|Participants received delamanid as an extemporaneous suspension using the delamanid pediatric dispersible tablet formulation. Morning dose of the delamanid BID/once daily (QD) regimen was given within 30 minutes after the start of a standard breakfast meal. The evening dose of the BID dose regimen was given 10 hours post morning dose and within 30 minutes after the start of a standard meal.
45364914|NCT03291509|Behavioral|Enhanced Stop Light Diet|Diet composed of healthy, pre-packaged meals, balance of fruits, vegetables, and low calories snacks, and shakes. Participants and study partners will be trained to use a color coded chart which categorize foods based on the Stop Light system (green, yellow, red) to assist in meal planning, grocery shopping, decisions regarding snack foods, and compliance with the diet in special situations such as eating away from home (restaurants, parties, etc.).
45690334|NCT01859923|Drug|Optimized Background Regimen (OBR)|"Selection and administration of the treatment medications (i.e. OBRs) was based on Search Results Web result with site links~World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study Investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results."
45845765|NCT05554302|Drug|18F-Fluciclovine|Patients will receive 5-mCi dose (+/- 20%) of 18F-Fluciclovine intravenously as a bolus injection. They will be required to fast for at least four hours prior to 18F-Fluciclovine injection. Patients will be positioned for PET/CT brain imaging and will be injected with 18F-Fluciclovine immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
45364915|NCT03291509|Behavioral|Physical Activity|Participants will be asked to complete a set amount of time of moderate-to-vigorous physical activity each week. Participants in the Computer group will be asked to attend remote exercise sessions 2 times a week.
45364916|NCT00203047|Drug|Glatiramer Acetate|20mg glatiramer acetate (GA) administered by daily subcutaneous injections
45364917|NCT00203047|Drug|Placebo|Placebo for prednisone given daily
45364918|NCT00203047|Drug|Prednisone|Prednisone 1250 mg taken daily
45364919|NCT00870038|Device|Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent|Predilatation with paclitaxel-eluting balloon, then stenting of the lesion with Genous stent
45364920|NCT00870038|Device|Percutaneous coronary intervention: Uncoated balloon + Genous stent|Predilatation with uncoated balloon, the stenting with Genous stent.
45482334|NCT03306004|Other|Questionare|
45482335|NCT02468206|Procedure|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
45364921|NCT00870038|Device|Percutaneous coronary intervention: Drug eluting stent (Taxus stent)|Predilatation with uncoated balloon, the placement of a Taxus stent.
45364922|NCT04074551|Drug|HCP1701|HCP1701
45482336|NCT02468206|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
45482337|NCT02468206|Drug|N-butyl-2-cyanoacrylate|
45482338|NCT02468206|Drug|Lauromacrogol|
45482339|NCT03233854|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given CD19/CD22 CAR T cells IV
45482340|NCT03233854|Drug|Cyclophosphamide|Given IV
45482341|NCT03233854|Drug|Fludarabine Phosphate|Given IV
45482342|NCT03233854|Other|Laboratory Biomarker Analysis|Correlative studies
45482343|NCT03233854|Other|Questionnaire Administration|Ancillary studies
45482344|NCT03233854|Drug|NKTR-255|Given IV
45482345|NCT04502472|Biological|Convalescent plasma transfusion|Transfusion of COVID-19 convalescent plasma to participants currently hospitalized with COVID-19 infection with severe or life-threatening clinical syndrome.
45482346|NCT03301402|Device|Air purifier|Air purifier with filter at automatic mode on all time
45482347|NCT04969068|Drug|Remimazolam|Interventions:The dose of remimazolam for each patient was determined by the response of the previously tested patients using the modified Dixon's up-and-down method.The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size). Duodenoscopy insertion was conducted when MOAA/S≤1.The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement).' Movement was defined as duodenoscopy insertion a failure was as gross purposeful muscular movement, coughing or vomiting occurring during or within 2 minutes of insertion of duodenoscopy. No movement was depicted when the reactions mentioned earlier were absent. If BIS>75 and MOAA/S > 1 when 3 min after the intravenous injection of remimazolam, it was considered a failure, and the patient received rescue sedation.
45482348|NCT03301324|Device|Intubation Assist Dashboard|The ZOLL X Series Intubation Assist Dashboard feature guides the operator through a three-step auscultation process to verify the proper placement of an endotracheal tube.
45482349|NCT01344174|Drug|5 days dexamethasone therapy|dexamethasone 10mg, intravenously, po daily for the first 5 days
45482350|NCT03301246|Device|Artimes Pro Low Profile Dilatation Catheter|Pre-dilation catheter for the purpose of preparing the vessel to deliver the final therapy.
45482351|NCT05162274|Drug|Lazertinib(G001)|Current formulation
45482352|NCT05162274|Drug|Lazertinib(G002)|New formulation
45482353|NCT03023566|Drug|Dotarem|Dotarem at dose of 0.1 mmol/kg of body weight (routine/standard of care)
45482354|NCT04345302|Behavioral|Brief motivational treatment|"The treatment will be delivered by general psychologists with at least three years of experience in primary care. They will receive training and then will demonstrate proficiency in a simulated client session.~During recruitment, therapy sessions will be recorded, and ten percent of them will be reviewed using a proficiency scale. Then, a feedback report will be issued and discussed with each therapist."
45482355|NCT04345302|Behavioral|Enhanced Usual Care|During the trial, participants will continue to receive regular medical and social care at their health centre. These services may include prescriptions for mental health issues and alcohol (Disulfiram, anti-craving, anti-depressants, and other medications), social assistance, and the full spectrum of primary health care. Nevertheless, they will not receive other psychosocial interventions for alcohol use disorder in the health centre.
45690335|NCT01832155|Behavioral|Hatha yoga|Hatha yoga poses that were specifically designed by a group of yoga experts for older adults with knee osteoarthritis. Program included physical poses and sequence that focus on strengthening the lower extremities, and relaxation techniques.
45847827|NCT02973516|Drug|P03277 at 0.05 mmol/kg|P03277 will be administered at 0.05 mmol/kg BW (corresponding to 0.1 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
45364923|NCT04074551|Drug|Losartan|Losartan
45482356|NCT03301090|Other|Placebo|Placebo
45482357|NCT03301090|Biological|REGN3048|REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.
45482358|NCT03301090|Biological|REGN3051|REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.
45690336|NCT01832155|Behavioral|Hatha Yoga|The same intervention was provided to the wait-list control group at the end of 8 weeks when the intervention completed their intervention classes.
45364924|NCT04074551|Drug|Amlodipine|Amlodipine
45364925|NCT04074551|Drug|Rosuvastatin and Ezetimibe|Rosuvastatin and Ezetimibe
45364926|NCT00870116|Radiation|SBRT by cyberknife|treatment = 2x15 Gy during 2 weeks
45364927|NCT00870116|Radiation|SBRT by linear accelerator|treatment = 2x15 Gy during 2 weeks
45364928|NCT00870116|Radiation|Conformational radiotherapy|treatment = 5x2 Gy during 7 weeks (free breathing or breath holding)
45364929|NCT02608385|Radiation|Stereotactic body radiotherapy (SBRT)|Patients will receive 3 or 5 doses of SBRT to the chosen metastases.
45364930|NCT02608385|Drug|Pembrolizumab|Pembrolizumab (200 mg) given every 3 weeks.
45364931|NCT00142519|Drug|Methadone|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 2 mg
45482359|NCT04342962|Drug|tagraxofusp|Tagraxofusp is provided as an intravenous (IV) injectable and administered as a 15-minute IV infusion. Cycle 1 will include a 2-day dosing period for the first 3 enrolled patients (Days 1-2), a 2-day plus an optional 3rd day for patients 4-6 (Days 1-2 + Day 3 if patient meets criteria for continued dosing) and a 3-day dosing period for patients 7 and beyond (Days 1-3). Cycle 2 and beyond will include a 5-day dosing period for all patients (Days 1-5). In all cycles and schedules, dose delays up to Day 10 of each cycle will be allowed for resolution of toxicities.
46050760|NCT04131010|Device|single operator video cholangioscopy|The technique provides digital imaging with a higher resolution and improved maneuverability compared to the legacy fiberoptic system. In addition, the working channel was enlarged to a diameter of 1.3 mm. Retrospective data showed an overall technical success rate for single-operator video pancreatoscopy (SOVP) guided treatment of pancreatic stones of 95%
45482360|NCT03300934|Device|closed loop glucose control system|Cross over between Closed loop glucose system with DANA pump, Navigator II CGM and Cambridge AP algorithm FD2A, versus usual CSII pump treatment
45482361|NCT04321044|Genetic|Genetic based analysis of identifying predictors of blood pressure in patients after renal denervation|We attempt to idendtify predictors of blood pressure response to renal denervation by using a GWAS (Genome wide association study) approch.
45690337|NCT05364333|Procedure|Remote ischemic preconditioning|For each cycle of RIPC, a blood pressure cuff will be inflated to the non-dominant arm at 200mmHg for 5 minutes (or at least 50mmHg above the systolic arterial blood pressure) followed by 5 minutes of reperfusion time
45690338|NCT01879579|Other|Mobile Insulin Titration Intervention|Patients send their fasting blood glucose levels to the clinic diabetes nurses via text message each weekday. The diabetes nurses call each patient once a week to give insulin titration instructions to replace in-person clinic visits for insulin titration.
45690339|NCT01386645|Other|low glycemic index (LGI) diet|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index <35) for 4 weeks with all food provided by the Human Nutrition Lab
45364932|NCT00142519|Drug|methadone and morphine|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 1 mg and methadone 1 mg
45364933|NCT03714776|Drug|Placebo|Placebo matching solution administered as SC injection.
45690340|NCT01386645|Other|high glycemic index (HGI) diet plus placebo (PLAC)|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index >70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
45845766|NCT05549466|Drug|Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|"Gemcitabine, iv, 1000 mg/m^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m^2, D1, Q3W.~Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W."
45845767|NCT05549466|Drug|Apatinib, Camrelizumab|Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W.
45364934|NCT03714776|Drug|ISIS 757456|Administered as SC injection.
45364935|NCT03713294|Drug|Dexamethasone|Given IV and PO
45364936|NCT03713294|Biological|Elotuzumab|Given IV
45364937|NCT03713294|Drug|Pomalidomide|Given PO
45364938|NCT00141817|Drug|pantoprazole for approximately 9 weeks.|
45364939|NCT00573170|Drug|TREXIMET®|Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate [equivalent to sumatriptan 85mg] and naproxen sodium 500mg)
45364940|NCT00573170|Drug|Butalbital-containing Combination Medications (BCM)|butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) [currently marketed as Fioricet]
45364941|NCT00573170|Drug|placebo|placebo
45364942|NCT03967171|Other|before uterine incision oxytocin|blood loss during elective cesarean section
45364943|NCT03967171|Other|after clamping the umbilical cord oxytocin|blood loss during elective cesarean section
45364944|NCT03971383|Drug|Aolanti Weipang Tablets|3 tablets one time, 3 times a day(tid)
45364945|NCT03971383|Drug|Placebo|3 tablets one time, 3 times a day(tid)
45364946|NCT01077349|Procedure|high volume hemofiltration|(80 ml/kg/h or a maximum of 8L/h) for 48 hours following heart surgery. Hemofiltration will be stopped after 48h if diuresis >1500 ml without diuretics and if IV infusion of catecholamines is less than 0.1 microg/kg/min of epinephrine, 0.2 microg/kg/min of norepinephrine or the sum of epinephrine + nor epinephrine/2 is less than 0.1 microg/kg/min. In other cases, hemodiafiltration (CVVHDF) will be initiated until the above objectives are reached, with equal flow rate of dialysate and reinfusion fluid, the sum of which being <35 ml/kg/h (or a maximum of 3500 ml/h).
45482362|NCT03300778|Behavioral|aerobic exercise|Running at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 3 months
45364947|NCT01077349|Procedure|standard care|"extra-renal replacement therapy (CVVHDF mode, total effluent <35 ml/kg/h or a maximum of 3500 ml/h) will be initiated only if the following criteria are met:~Serum creatinine > 350 micromol/L or increase x3.0 from pre-operative value OR~Diuresis < 0.3 ml/kg/h for 24 hours despite adequate fluid resuscitation OR~Or serum urea > 36 mmol/l OR~Or life threatening hyperkalemia"
45364948|NCT03966937|Other|Dry needling|"Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.~Then after wearing gloves and appropriate personal protective measures, a thin filiform needle will be inserted which will penetrate into the skin and stimulate underlying myofascial trigger points."
45845768|NCT05549466|Drug|Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|"Gemcitabine, iv, 1000 mg/m^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m^2, D1, Q3W.~Camrelizumab, iv, 200mg, D1, Q3W."
45845769|NCT05549466|Drug|Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|Gemcitabine, iv, 1000 mg/m^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m^2, D1, Q3W.
45364949|NCT03966937|Other|Control|Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.
45364950|NCT00880646|Dietary Supplement|Oolong tea containing L-arabinose and indigestible dextrin|
45364951|NCT00880646|Dietary Supplement|Oolong tea (Placebo)|
45364952|NCT00880724|Device|IBV Valve|Placement of IBV Valve in the airways of treatment subjects. Bronchoscopic procedure in control group.
45364953|NCT03967327|Drug|Buprenorphine transdermal patches|It should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest. The skin should be relatively hairless. If none are available, the hair at the site should be clipped, not shaven.
45364954|NCT03967327|Drug|Morphine Sulfate Sustained-Release Tablet|It will be administered orally twice (q12h) daily.
45364955|NCT01075945|Drug|Dihydroartemisinin- piperaquine|three tablets per day
45364956|NCT01075945|Drug|artemether- lumefantrine|twenty tablet in eight doses
45364957|NCT00882752|Procedure|molecular analysis|bowel disease
45364958|NCT00874562|Drug|Corticosteroid|Initial dose of corticosteroid given intravenously. After the first dose, corticosteroid will be taken orally every 8 hours for the duration of the five-day period
45364959|NCT00874562|Drug|Rapamycin|Taken orally mixed with water or orange juice
45845770|NCT05544318|Other|Diatary advices|Advice regarding energy, protein and nutrient intake during cancer treatment
45847828|NCT02974296|Device|transcranial magnetic stimulation|non invasive brain stimulation approach
45364960|NCT00874640|Biological|Gadobutrol (Gadovist, BAY86-4875)|Patients with indication for a MRT or MR-Angiography and for whom the radiologist has decided to use the contrast medium gadobutrol
45482363|NCT03300778|Behavioral|Placebo controlled group|6 sections of group activities: 3 sections of general psychological education; one section of group game, one section of group poetry reading activity, group singing entertainment.
45482364|NCT05117190|Procedure|Facial Allotransplantation|
45482365|NCT04490746|Other|with no intervention, Collect samples|only with observation,there is no need to intervene
45690341|NCT01386645|Drug|high glycemic index diet plus N-acetylcysteine|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index >70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
45364961|NCT00882830|Procedure|EMS|EMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously.
45364962|NCT00874718|Behavioral|educational program|6-week educational program for prevention of occupational musculoskeletal diseases.
45364963|NCT00874718|Behavioral|General education|Non-specific educational program for general health.
45364964|NCT00201643|Drug|Betamethasone or Dexamethasone (2nd course of ACS)|Course of Betamethasone or Dexamethasone
45364965|NCT00201643|Drug|Placebo|Course of Placebo (NS)
45364966|NCT03798314|Biological|Nivolumab|Given IV
45482366|NCT03635268|Other|Data collection|Sociodemographic, medical and hospital, on ambulatory care consumption data.
45690342|NCT01387269|Drug|Anamorelin HCl|Anamorelin HCl will be orally administered daily at least one hour before meal
45690343|NCT01387269|Drug|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour before meal
45690344|NCT01859143|Biological|Trivalent Influenza Vaccine|A single dose of 10^(7.0 ± 0.5) FFU of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
45690345|NCT01859143|Other|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
45690346|NCT01878253|Device|Sidus Stem-Free Total Shoulder Arthroplasty System|
45847829|NCT02978508|Drug|Permethrin Cream, 5%|Subjects on Test product will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
45364967|NCT03798314|Drug|Pomalidomide|Given PO
45482367|NCT03311386|Drug|Actilyse|thrombolytic therapy
45482368|NCT03620448|Device|bCPAP Arm|bCPAP (Rice 360◦c low cost bCPAP device)
45364968|NCT01077427|Device|Gemcitabine + Cisplatin + regional hyperthermia|"Gemcitabine: 1000 mg/m² as iv-infusion on days 1 and 15 of each course (Total dose: 12 g/m²)~Cisplatin: 25 mg/m² as iv-infusion on days 2, 3* and 16, 17* of each course (Total dose: 600 mg/m²)~Regional hyperthermia: 60 minutes on days 2, 3*, and 16, 17* of each course~* as an exception for medical or logistic reasons RHT and cisplatin can be applied day 4 instead of 3 and day 18 instead of 17"
45364969|NCT01077427|Drug|Gemcitabine + Capecitabine|"Gemcitabine: 1000 mg/m² as iv-infusion on days 1, 8 and 15 of each course (Total dose: 18 g/m²)~Capecitabine: daily dose of 1660 mg/m²; administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles"
45364970|NCT05204654|Other|In-office fabricated appliance|A 0.022 Slot MBT™ second molar mini tube that has been modified to have a 2 mm length will be placed on the maxillary first molar and a 0.018 slot MBT™ maxillary canine bracket will be placed on the maxillary canine, with a 0.016x0.022 stainless-steel wire spanning from the maxillary first molar to the maxillary canine. A bayonet bend will be placed mesial to the molar tube. A curve will be bent into the wire, so that the wire is able to passively rest on the buccal surface of the maxillary canine. A stainless-steel closed coil will span the molar to canine and lay flush to the mesial portion of the molar tube and the distal portion of the canine bracket. The wire will be cinched mesial to the maxillary canine tie-wing and also 2-3 mm distal to the maxillary first molar to ensure that the molar can rotate during treatment, if needed. A stainless-steel tie will be used to secure the wire into the canine bracket. AP correction will be completed following CMA protocol
45364971|NCT05204654|Device|Carriere Motion Appliance|A bar spanning from the maxillary first molar to canine with a ball and socket joint at the molar and a canine pad at the canine. A slight bend is present between the molar and canine bracket. The ball and socket is designed to allow the molar to rotate to -15 degrees along it's longitudinal axis. The appliance claims that it allows for Class II correction with minimal secondary tooth movements when used with mandibular anchorage.
45364972|NCT00883064|Drug|Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)|
45364973|NCT00883064|Drug|Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)|
45364974|NCT01077505|Biological|albiglutide|albiglutide 50mg weekly subcutaneous injection
45482369|NCT03620448|Other|Oxygen Arm|Oxygen therapy from oxygen cylinders
45364975|NCT01077505|Drug|Oral contraceptive (Brevicon)|Oral contraceptive (Brevicon)
45364976|NCT01073995|Drug|Kenalog and Sensorcaine|Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
45364977|NCT01074073|Drug|Lurasidone HCl|"lurasidone HCl 40 mg tablets administered orally as three tablets (120 mg) once a day (QD).~Lithium 300 mg capsules administered orally as two capsules (600 mg) twice a day (BID).~On dosing days, breakfast will be served 30 minutes prior to the planned dosing time. Patients must consume the breakfast within 30 minutes or less. Dosing will take place 30 minutes after the start of breakfast."
45364978|NCT00883220|Behavioral|Self-management of urinary catheter|Awareness, self-monitoring, and self-management of urine flow are taught. Focus is on attaining adequate and consistent levels of fluid intake and preventing catheter dislodgement.
45364979|NCT00874874|Drug|sorafenib tosylate|
45364980|NCT01076257|Behavioral|Modified Constraint-induced Movement Therapy|"Home based CIT~Restriction of the less affected limb~Intensive practice using affected limb~Positive experience~Functional task (task)"
45364981|NCT01076413|Behavioral|skill based exercise|2 times per week for 12 weeks Pre gait and gait activities
45364982|NCT01076413|Behavioral|aerobic conditioning|2 times per week for 12 weeks. aerobic conditioning exercise consisting of treadmill walking
45690347|NCT01878175|Behavioral|Functional Movement Retraining|15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
45690348|NCT01878097|Behavioral|Green Dot Bystander Intevention|Intervention allocated at the school level
45690349|NCT01878097|Behavioral|Control|Awareness Education
45690350|NCT01750190|Drug|Roxadustat|Oral tablets
46050761|NCT05603260|Behavioral|Imagery intervention for voice hearing (meta-cognitive imagery rescripting)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of meta-cognitive imagery rescripting.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
45364983|NCT05204264|Behavioral|Acceptance and Commitment Therapy (ACT)|This intervention uses techniques based on mindfulness, metaphors and exposition exercises both in imagination and in real contexts.
45364984|NCT05204264|Behavioral|Mindfulness-based Emotional Regulation (MER)|This intervention includes both formal practices of body scan meditation, standing / sitting Hatha yoga, meditations focused on the breath or other objects of attention, exercises of benevolence or kindness with affection (loving-kindness); as well as informal mindfulness practices in activities of daily living.
45364985|NCT04017884|Combination Product|Remin Pro Forte|a combination of chemicals with natural products cream .
45364986|NCT04017884|Combination Product|Remin Pro|a combination of chemicals
45364987|NCT00880880|Other|e-PAQ-PF|Participants will fill out the e-PAQ-PF prior to their clinic visit. The e-PAQ-PF has 4 dimensions (urinary, bowel, vaginal, sexual) and asks about symptoms severity, bother of symptoms, and impact on quality of life. A copy of the results will be given to their clinician and the participant.
45364988|NCT00880958|Dietary Supplement|Mixture of various probiotics and fermentation products|
45364989|NCT00880958|Dietary Supplement|Placebo|
45482370|NCT01343238|Behavioral|Diet|12 week diet behavior modification
45482371|NCT01343238|Behavioral|Exercise|12 week exercise behavioral intervention
45690351|NCT01750190|Drug|Placebo|Oral tablets
45690352|NCT01831765|Drug|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Meal time dosing is defined as injecting 0-2 minutes before the meal.
45364990|NCT04489628|Drug|Vitamin D3 or Placebo|): Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
45364991|NCT04489628|Device|Doctella telehealth monitoring|Doctella device will be give to participants by the Emergency department as part of usual care to monitor heart rate, respiratory rate, oxygen saturation, and perfusion index vitals continuously for approximately 10 days. The study team will receive the vitals signs data (heart rate, respiratory rate, oxygen saturation, perfusion index, and temperature) retrospectively and will not be able to monitor patients in real time.
45364992|NCT00130039|Drug|clopidogrel|Clopidogrel 75mg once a day plus placebo of cilostazol twice a day
45364993|NCT00130039|Drug|Cilostazol|Cilostazol 100mg twice a day plus placebo of clopidogrel once a day
45364994|NCT00875030|Drug|artesunate sachets|single dose 50 mg (2 X 25 mg) artesunate sachets
45364995|NCT00875030|Drug|Arsuamoon|single dose 50 mg arsuamoon tablet
45364996|NCT00883298|Drug|temozolomide and bevacizumab|oral temozolomide 100 mg/m2 days 1-5 & 15-19 every 28-day cycle plus intravenous bevacizumab 10 mg/kg days 1 & 5 every 28-day cycle
45690353|NCT01831765|Drug|insulin detemir|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Administrated once or twice daily.
45690354|NCT01831765|Drug|insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted.
45690355|NCT01831765|Drug|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Post meal time dosing is defined as injecting 20 minutes after the start of the meal.
45690356|NCT01749800|Device|GVS|A small current is delivered to the vestibular system via electrodes placed over the subject's mastoid processes.
45690357|NCT01749800|Device|Sham GVS|Electrodes are placed over the subject's mastoid processes and connected to the device, but the device is not active.
45364997|NCT03969277|Other|Graded Motor Imagery|"The first stage of GMI includes laterality reconstruction. Patients will view and determine if the various images of body parts to image portrays the right or left side. The second stage targets activation of the primary motor cortex by imagine moving the involved body part. The final stage involves that the patient watches the unaffected body part moving in a mirror to trick the brain into thinking the affected body part is actually moving in a pain-free way. This will be applied for 6 weeks."
45364998|NCT03969277|Other|Standard Rehabilitation|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extension, and wrist flexion and extension stretching exercises. Elbow and wrist strengthening exercises. Grip strengthening exercises. This will be applied for 6 weeks.
45364999|NCT03969277|Other|Home Exercise Program|Proprioception exercises for the elbow. Scapulothoracic strengthening exercises. This will be applied for 6 weeks.
45482372|NCT01343238|Behavioral|Diet and Exercise|12 week diet and exercise behavioral modification intervention
45690358|NCT01749800|Device|Armeo Spring|A robotic system supports the weak arm of the subject to make it easier to perform therapeutic exercises.
45690359|NCT04556396|Diagnostic Test|Cone beam CT|On-table CT scan in the operating room to determine residual kidney stone burden at end of procedure
45690360|NCT04414891|Device|Non invasive ventilation|"Non invasive ventilation will be delivered using an oro-facial interface in both arms. NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks.~ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland)."
45690361|NCT01830595|Drug|Recombinant Lactoferrin|
45690362|NCT01830595|Drug|Placebo|
45690363|NCT01748552|Drug|Placebo|Administered orally as capsules
45847830|NCT02978508|Drug|Elimite|Subjects on RLD will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
45847831|NCT02979054|Device|T4020|
45847832|NCT02979054|Device|Placebo|
45690364|NCT01748552|Drug|LY2922083|Administered orally as capsules
45365000|NCT03969277|Other|Cold Application|Cold application around the elbow joint for 15 minutes in every session.
45365001|NCT04038788|Device|HD hf-tRNS|See detail in arm/group descriptions regarding the intervention.
45365002|NCT00881114|Drug|Cisplatin|Intensity modulated radiation therapy with concurrent chemotherapy. Cisplatin will be administered at a dose of 100 mg/m2 during weeks 1, 4, and 7 of radiation therapy. Post treatment neck dissection will be performed if clinically indicated.
45365003|NCT00881114|Drug|Cetuximab|Intensity modulated Radiation Therapy with concurrent chemotherapy. Cetuximab will be administered beginning at a dose of 400 mg/m2 the week before radiation commences, then at a dose of 250 mg/m2 weekly during weeks 1 to 7. Post treatment neck dissection will be performed if clinically indicated.
45365004|NCT00875186|Other|aerobic endurance training|participants exercises 2 times weekly for 1 hour (aerobic endurance training)
45482373|NCT04343040|Dietary Supplement|carbohydrate supplement (Preload™)|carbohydrate supplement (Preload™) will be administered 4-hours prior to bariatric surgery (experimental treatment) Preload™ is a neutral-tasting carbohydrate loading drink mix specifically designed for use before elective surgery. Preload is presented in 50g pre-measured sachets which when added to water (400ml) produces a solution with low osmolality.
45482374|NCT04343040|Procedure|6 hours of preoperative fasting|Standard of care. In this group, patients continue the standard of care treatment before surgery with fasting recommended 6 hours before surgery.
45482375|NCT03305692|Diagnostic Test|Optimization of CRT Device|Use a body surface mapping system to quantify electrical dyssynchrony or echocardiography to quantify diastolic blood flow characteristics. Program the pacemaker to maximize the benefit of the modality the subject is randomized to.
45482376|NCT01343316|Device|Transpyloric feeding tubes (Nasogastric Tube (NG tube), Tiger2, Syncro BlueTube)|To determine the benefits of utilizing one type of transpyloric tube over another.
45482377|NCT02468908|Drug|Molgramostim|
45482378|NCT02468908|Drug|Placebo|
45482379|NCT01344408|Procedure|Computer-training|"The computer-training program Move IT To Improve IT is a exercise program which is installed and used on a Apple Imac in the patients home to support vestibular rehabilitation"
45482380|NCT02468128|Drug|Sebacoyl Dinalbuphine Ester|Intramuscular injection 2mL/vial (75mg/mL)
45482381|NCT02468128|Drug|Placebo|Sebacoyl Dinalbuphine Ester injection placebo, 2mL/vial
45482382|NCT01343394|Biological|Autologous Human Umbilical Cord Blood|6 million cells/kg will be administered intravenously at one treatment time point.
45482383|NCT03305536|Dietary Supplement|Vitamin K2 (Menaquinone 7) + Vitamin D3|Vitamin K2 + Vitamin D3 arm will be compared with Vitamin D3 arm to slow of reverse the progression of the disease
45365005|NCT00875186|Other|aerobic endurance training|participants exercised 1 time weekly for 1 hour (aerobic endurance training)
45365006|NCT04687436|Device|mechanical cervical ripening|mechanical cervical ripening with a foley catheter or double-balloon catheter or Cook cervical ripening balloon
45365007|NCT00475852|Drug|Nesiritide|0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
45365008|NCT00475852|Drug|Placebo|matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
45365009|NCT00875264|Drug|CEP-11981 (kinase inhibitor)|Patients will be treated with oral CEP-11981 once daily for 28 days, followed by a treatment-free period of 14 days. This 42-day (6-week) period will constitute 1 cycle. The starting dose for the study will be 3 mg/m2. Dose escalation from this starting dose follows a modified Fibonacci sequence.
45482384|NCT01344486|Procedure|full conditioning|addition of 4% oxygen + 10% nitrous oxide to the pneumoperitoneum + humidification + temperature regulation at 32°C
45482385|NCT01344486|Procedure|standard pneumoperitoneum|100% carbon dioxide used for the pneumoperitoenum
45482386|NCT03210688|Drug|Prednisolone|Tablet prednisolone
45482387|NCT03210688|Drug|Alfacalcidol|Capsule alfacalcidol 0,5 microgram/day
45690365|NCT01748162|Drug|Fluticasone|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
45690366|NCT01748162|Drug|Prednisolone IF needed|
45690367|NCT01724216|Device|pulse sequences|Collect in vivo human data to demonstrate neurological Magnetic Resonance Imaging of subjects using a pulse sequence
45690368|NCT01723904|Drug|Rotigotine|Application of Rotigotine up to 8 mg/24 h patches for 24 hours.
45690369|NCT01747772|Device|Shear Wave Sonoelastography|Shear Wave sonoelastography (SWE) as an ultrasound technique to measure liver fibrosis was performed on patients scheduled for non-focal liver biopsy. Results were compared with pathological score from liver biopsy.
45690370|NCT01830127|Drug|Ribavirin|24 Weeks
45690371|NCT01830127|Drug|BI 207127 high dose|24 Weeks
45365010|NCT01017484|Other|DASH, Control|controlled feeding of either the DASH dietary pattern or a typical American diet at isocaloric level.
45365011|NCT00141271|Drug|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-6, then flexible dosing starting on day 7 between 20-40mg bid (20mg bid or 40mg bid) for the remainder of the 6 week trial
45690372|NCT01830127|Drug|Faldaprevir|24 Weeks
45365012|NCT00141271|Drug|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-2, then 40mg bid days 3-4, them 60mg bid for days 5-6 then flexible dosing starting on day 7 between 60-80mg bid (60 mg bid or 80mg bid) for the remainder of the 6 week trial
45482388|NCT01343472|Behavioral|WISP supervision|WISP entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). WISP includes regular random drug testing.
45690373|NCT01830127|Drug|Ribavirin|24 Weeks
45690374|NCT01830127|Drug|BI 207127 low dose|24 Weeks
45365013|NCT00141271|Drug|Placebo|Subjects will start on placebo and remain on placebo for the remainder of the 6 week trial
45365014|NCT01017640|Other|Laboratory Biomarker Analysis|Correlative studies
45365015|NCT01017640|Drug|Mitomycin|Given IV
45365016|NCT01017640|Drug|Veliparib|Given PO
45690375|NCT01830127|Drug|Faldaprevir|24 Weeks
45365017|NCT00614120|Drug|liraglutide|0.6 mg/day, s.c. (under the skin) injection
45365018|NCT00614120|Drug|placebo|Glimepiride placebo, capsules
45365019|NCT00614120|Drug|liraglutide|1.2 mg/day, s.c. (under the skin) injection
45482389|NCT01343472|Behavioral|Parole-as-usual|Parolees are supervised under standard parole supervision practice in Washington State.
45690376|NCT04611295|Procedure|Teleneurological evaluation and support|The study is aimed at developing a remote neurological consultancy system (teleconsultation) for patients with acute neurological symptoms in charge of hospital facilities without 24-hour availability of neurologist consultant.
45690377|NCT01614067|Drug|Ganirelix acetate|Subjects will receive 7 days of pre-treatment with the GnRH antagonist
45752172|NCT01792895|Procedure|Mobilization with movement|"This is a manual therapy technique that consist of applied a sustain pressure over cervical hypomobile symptomatic level and request to patient a pain free movement.~For performs it, the therapist placed his thumbs on the articular process of that level. The patient sitting. Then, the subject had to perform actively the painful motion while the therapist guides the movement of that vertebra and resists it while returning to neutral. The strength applied was parallel to the plane of the joint, and the procedure was performed in 3 sets of 10 repetitions."
45752173|NCT05183919|Other|Digital Treatment|"AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task."
45752174|NCT02109497|Drug|PBT2|PBT2 250 mg administered
45365020|NCT00614120|Drug|liraglutide|1.8 mg/day, s.c. (under the skin) injection
45365021|NCT00614120|Drug|glimepiride|Capsules, 4.0 mg/day
45365022|NCT00614120|Drug|metformin|Tablets, 1.5-2.0 g/day
45482390|NCT02467816|Behavioral|SmartMeal application|The SmartMeal application is a smartphone application that will allow students to pre-order school meals, receive nutrition information about school meals, and provide feedback about school meals to Student Nutrition Services.
45365023|NCT00614120|Drug|placebo|Liraglutide placebo, s.c. (under the skin) injection
45365024|NCT00496054|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|Pentavalent vaccine 9G1, G2, G3, G4 & P1) given 3 times. Dose 1 will be administered at study entry; Dose 2 will be administered 4 to 10 weeks (28 to 70 days) after Dose 1; and Dose 3 will be administered 4 to 10 weeks (28 to 70 days) after Dose 2.
45365025|NCT00881192|Procedure|IABP|preoperative IABP placement
45365026|NCT00495820|Drug|Methylphenidate|Subject will receive 5mg twice a day for two weeks then 10mg twice a day until week 12 of the study.
45365027|NCT00495820|Other|Placebo|Standard inactive pill.
45365028|NCT04387240|Drug|Artemisinin / Artesunate|testing the drug capabilities in reducing the shedding and causing the testing for covid 19 to become negative
45365029|NCT04387240|Other|placebo|placebo or sham drug will be given to the second arm
46050762|NCT05603260|Behavioral|Imagery intervention for voice hearing (Imagery rescripting)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of imagery rescripting.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
45365030|NCT05203328|Device|Vapotherm|Monitored anesthesia care with oxygen supplementation through a high-flow nasal cannula
45365031|NCT05203328|Device|Regular nasal canula|Monitored anesthesia care with oxygen supplementation through a regular nasal cannula
45365032|NCT00495586|Drug|Placebo|One pill to be taken every eight hours for 8 days
45365033|NCT00495586|Drug|Amoxicillin and clavulanic acid|500-125 mg to be taken every eight hours for 8 days
45365034|NCT00881270|Drug|LACTIC ACID(ND)|Dermacyd Infantile (LACTIC ACID)
45365035|NCT00881348|Drug|LACTIC ACID(ND)|Dermacyd infantile (Lactic Acid)
45365036|NCT00613730|Drug|Gemcitabine|Intravenous administration
45365037|NCT00613730|Drug|panitumumab|Intravenous administration
45365038|NCT05200754|Other|Convalescent/Vaccine-boosted Plasma (CP/PVP)|"Plasma from apheresis obtained from donors, who have recovered from SARS-CoV-2 infection or received a successful vaccination against SARS-CoV-2.~CP/PVP infusion is administered on two following days. Each CP/PVP bag contains approx. 238 - 337 ml anti-SARS-Cov-2 CP/PVP for infusion."
45365039|NCT00613574|Drug|tiotropium-bromide|Spiriva® inhaled capsule 18 mcg once daily administered via HandiHaler® on the top of usual care
45365040|NCT00881426|Drug|Cefprozil 500 mg Tablets (Sandoz GmbH)|
45365041|NCT00881426|Drug|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)|
45365042|NCT00883532|Drug|budesonide|budesonide, 0.25 mg/Kg/dose every 8 hours until the infant requires FIO2 < 30% or is extubated
46050763|NCT05603260|Behavioral|Imagery intervention for voice hearing (promoting positive imagery de novo)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of promoting positive imagery de novo.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
45365043|NCT00883532|Drug|surfactant and air (placebo)|receive surfactant and air as control through endotracheal route
45365044|NCT00875498|Procedure|active iTBS|"Intermittent Theta Burst Stimulation (iTBS) over Left dorsolateral prefrontal cortex.~80% MT, 20 sessions of 6 minutes, 2 per day"
45365045|NCT00875498|Procedure|sham iTBS|iTBS placebo (placebo coil)
45365046|NCT00883766|Other|Controlled ovarian hyperstimulation for IVF with a long agonist protocol|"Day 1 of 1st menstruation: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI>30, HOMA >3.8, G/I ratio <4.5~Day 18-24 of cycle: Leuprorelin (Procrin ®) 0.1 s.c. for 14-21 days~Day 1 of 2nd menstruation (=Day 1 COH cycle): Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst >10 mm~Day 2of COH cycle: rFSH (Gonal F ®) 150 IU/day for 4 days; Leuprorelin (Procrin ®) 0.1 s.c. (and following days)~Day 7 of COH (and following): Measure FSH, LH, E2, Pg + Ultrasound~Day before HCG: stop rFSH~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive~(OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
45365047|NCT00883766|Other|Controlled ovarian hyperstimulation for IVF with an antagonist protocol|"Day 1 of pre COH-cycle: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI>30, HOMA >3.8, G/I ratio <4.5~Day 3 of free-pill interval: Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst >10 mm~Day 5 of free-pill interval (=Day 1 COH cycle): Cetrorelix acetate (Cetrotide®) 0.25 mg s.c. + rFSH (Gonal F ®) 150 IU/day (and following days)~Day 3-4-10 of COH cycle: measure FSH, LH, E2, Pg + ECO~Day before HCG: stop rFSH + cetrorelix~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive (OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
45365048|NCT04262258|Dietary Supplement|Blueberry enriched diet|The blueberry intervention will consist of participants ingesting two servings of 19 g freeze dried blueberry powder (equivalent to 250 g whole blueberries) daily for six weeks. Subjects will ingest the freeze dried blueberries orally. Freeze dried blueberry powder will be mixed with 8-10 ounces of water and consumed. Subjects will be asked to rinse the cup to wash any remaining blueberries off of the cup and consume the rinse water. Subjects will be given a two week supply at baseline (week 0) and a four week supply when they return for their blood draw at week 2. Subjects will be asked to return empty packets and check-off daily records as a measure of compliance.
45365049|NCT00881582|Drug|Pegylated interferon alfa-2a plus ribavarin|PEG-interferon alfa-2a and ribavirin. Pegylated interferon alfa-2a - standard dose; plus ribavirin - standard dose (determined by creatinine clearance); for 24 to 48 weeks (genotypes 1 & 4: 48 weeks; genotypes 2 & 3: 24 weeks)
45365050|NCT00875654|Genetic|Autologous mesenchymal stem cells|Intravenous injection of Mesenchymal Stem Cells in a mixing of physiological salt solution/albumin 4% (volume<100ml) less than 6 weeks after stroke
45690378|NCT01777490|Behavioral|Helping Invested Families Improve Veterans Experiences - Control|Usual care will be the Veteran patient care and caregiver support that are normally offered once the Geriatrics and Extended Care (GEC) referral process has occurred. This process entails the patient and caregiver work with the social worker assigned to the patient to obtain home and community based care (HCBC) services. The patients in the usual care group will be free to seek medical, psychological, social support, and social services that are available through VAMCs or any other source. In addition to this, caregivers in the usual care arm will be told about the caregiver support programs in the VHA and the caregiver will receive the national VA caregiver hotline phone number. The information provided mirrors efforts to support caregivers in the VA nationally and new standards of care for VA caregivers. This will be the only contact with the usual care subjects besides the scheduled data collection assessments.
45690379|NCT01777490|Behavioral|Helping Invested Families Improve Veterans Experiences - HI FIVES|In addition to the usual care activities outline in the Control arm, Caregivers in the HI-FIVES group will receive three individual calls with a nurse educator to address topics he/she identified as being the highest priority learning areas. The calls will be tailored to the individual needs of Veteran-caregiver dyad. After the phone calls, caregivers will participate in four evidence-based group sessions aimed to improve clinical care skills, psychological care skills, and support-seeking skills. The curriculum will be delivered by a trained nurse educator and the PI and VA Caregiver Support Staff. The sessions will be targeted to address common needs of Veterans and their caregivers. After the final group session, there will be two optional booster calls at one and three months. Four assessments in all will be collected, baseline (in person), and at 3, 9, and 15 months (by phone).
46050764|NCT05603260|Behavioral|Imagery intervention for voice hearing (visuospatial working memory tasks)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of visuospatial working memory tasks.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
45690380|NCT01397409|Drug|AGN-150998|AGN-150998 Intravitreal injection.
45690381|NCT01397409|Drug|ranibizumab|Ranibizumab 0.5 mg given by intravitreal injection.
45690382|NCT01397409|Other|Sham Injection|Stage 3: Sham injection at Weeks 12 and 16.
45690383|NCT04407429|Diagnostic Test|Laboratory Analyses|Storage of serum for SARS-CoV-2-antibodies and biomarkers
46050765|NCT00700960|Drug|insulin detemir|initiation of an long acting insulin treatment in association with OAD at the discretion of the physician/diabetologist
45690384|NCT01397253|Other|Automated communication tools|"Automated communication tools will include:~PCP notification of patient admission and location~Data on medications begun on admission~Automated alerts on changes in patient status and location while the patient is hospitalized~Links to the EMR and to hospital physician contact information on all email alerts~Real-time delivery of discharge information (medications, instructions, and follow-up) to the PCP~Automatic reporting to PCPs of test results pending at discharge~Electronic delivery of final discharge summaries"
46050766|NCT00700492|Drug|progesterone|vaginal capsules 3X200mg daily
45365051|NCT00881738|Drug|Clarithromycin 250 mg Tablets (Geneva, USA)|
45365052|NCT00881738|Drug|Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)|
45482391|NCT02467816|Behavioral|Distributed points of sale|To increase points of sale for school meals (outside the cafeteria), school meals will be sold at hot and cold mobile food carts and vending machines throughout the school.
45482392|NCT02467816|Behavioral|Staff wellness curriculum|A wellness curriculum will be implemented that encourages teachers and staff members to eat school meals and promote them to students.
45482393|NCT01316406|Drug|ATH008|The subject will be incorporated in the study and randomised to ATH008 cream 3% or 8% or ATH008 cream placebo
45690385|NCT04766775|Device|Silver Diamine Fluoride|Silver Diamine Fluoride (Riva Star) which contains silver, fluoride, ammonia and water.
45690386|NCT01777334|Drug|Umeclidinium/Vilanterol 62.5/25 mcg|Inhalation Powder
45690387|NCT01777334|Drug|Tiotropium 18 mcg|Inhalation Powder
45365053|NCT00613106|Drug|HZT-501|Ibuprofen 800mg/famotidine 26.6 mg administered orally 3 times daily for 2 weeks
45365054|NCT00613106|Drug|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for at least 28 weeks
45365055|NCT00883844|Drug|Nucleos(t)ide analogue treatment with a peginterferon add-on strategy|peginterferon 1.5 microgram/kg once a week Treatment with one of the approved nucleos(t)ide analogues
45365056|NCT00883844|Drug|Nucleos(t)ide analogue treatment|Treatment with one of the approved nucleos(t)ide analogues
45365057|NCT00875732|Device|Bi Ventricular Pacing|
45690388|NCT03024879|Drug|Erythromycin|
45690389|NCT03024879|Drug|Saline|
45690390|NCT01383993|Drug|Voriconazole|"Study Days 1: IV voriconazole 9 mg/kg q12h. Study Days 2 to 7: IV voriconazole 8 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 9 mg/kg q12h with a maximum of 350 mg q12 h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
46050767|NCT04116190|Behavioral|Telerehabilitation|Short inpatient multidisciplinary rehabilitation followed by home-based telerehabilitation and a short evaluation period at the end of it.
46050768|NCT04116190|Behavioral|Conventional inpatient rehabilitation|Multidisciplinary inpatient rehabilitation, no adjustments due to the study.
46050769|NCT00700648|Drug|insulin aspart|Intravenous NovoRapid dose & frequency as decided by treating physician
46050770|NCT00703300|Drug|bortezomib|Given IV
45365058|NCT00875732|Device|Right Ventricular Pacing|
45365059|NCT00881816|Drug|Liposomal paclitaxel plus capecitabine|All Patients will receive liposomal paclitaxel (with a dose of 60mg/m2,3h,ivgtt,at d1,8,15) and capecitabine (with a dose of 1600mg/m2,bid,po.,at d1-14),each cycle for 4 cycles.
45365060|NCT03712904|Radiation|Stereotactic Body Radiation Therapy|Undergo radiation
45365061|NCT03712904|Biological|Ziv-Aflibercept|Given IV
45365062|NCT00875888|Device|continuous venovenous hemodialysis|dialysate flow rate 35 ml/h/kg. Blood flow rate should be aimed at 200 ml/min, but not less than 150 ml/min. Bicarbonate- or lactate-buffered solutions will be used as dialysis fluids. Study dialyzers will be changed routinely every 24 h or earlier if the filter is obstructed by clotting.
45365063|NCT00881972|Behavioral|Exercise|walking/running/cycling
45482394|NCT02467426|Drug|Chemotherapy|intraarterial infusion of cisplatin and mithoxantrone
45482395|NCT03300388|Dietary Supplement|Omega-3 (DHA-rich dietary supplement)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
45482396|NCT03300388|Dietary Supplement|Placebo (olive oil)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
45482397|NCT03300388|Other|Resistance training|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
45482398|NCT02467348|Drug|Albumin|Intravenous albumin 8 gms/L of ascitic fluid
45482399|NCT02467348|Drug|Ascitic fluid|
46050771|NCT00703300|Drug|decitabine|Given IV
46050772|NCT00703300|Other|pharmacological study|Correlative studies
46050773|NCT00703300|Other|laboratory biomarker analysis|Optional correlative studies
45690391|NCT01383993|Drug|Voriconazole|"Study Days 1: IV voriconazole 6 mg/kg q12h. Study Days 2 to 7: IV voriconazole 4 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
45690392|NCT05369637|Behavioral|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
45752175|NCT04350411|Device|Conventional diathermy|Abdominal free flap raise performed with conventional diathermy. Settings: cutting 40 Watt, coagulation 40 Watt.
46050774|NCT04116034|Device|alfapump DSR system|Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis, sodium and ultrafiltrate will be evacuated to the bladder by the alfapump
45365064|NCT04038554|Diagnostic Test|Feces and saliva analysis|Qualitative and quantitative analysis of the microbiota in the feces and saliva by mRNA sequencing.
45365065|NCT00875966|Drug|Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC|
45365066|NCT00875966|Drug|Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer|Subjects randomized to Zithromax received a single oral dose of Zithromax 600mg (15mL), administered with 240mL of water under fed conditions
45365067|NCT04142294|Dietary Supplement|Histidine|ingestion of encapsulated high quality histidine for four continuous weeks followed by a washout period of 3 weeks
45365068|NCT00141037|Drug|Daclizumab|"Steroid-Based Immunosuppression(Prednisone) arm: 1 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, and 8 (e.g., standard dose of daclizumab induction until the second month post-transplant)~Steroid-Free Immunosuppression (Extended daclizumab induction) arm: 2 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, 8, 11, and months 4, 5, and 6 (e.g., extended daclizumab induction until the sixth month post-transplant)"
45365069|NCT00141037|Drug|Mycophenolate mofetil (MMF)|Intravenous MMF was dosed at 1200 mg/m^2/day in two divided doses preoperatively and for the first 48 hours postoperatively. Oral MMF was dosed at 600 to 900 mg/m^2/day in two divided doses; the dose range allowed for dose titration according to tolerability and side effects of MMF. This regimen was used in both arms.
45365070|NCT00141037|Drug|Prednisone|Administered as 10 mg/kg peri-operatively followed by 2 mg/kg/day in subjects weighing <40 kg and 1.5 mg/kg/day in subjects weighing >40 kg. The prednisone dosing was tapered as follows: by the end of wks 1, 2, 4,6,12 and 16, dosages were 0.5, 0.4, 0.3, 0.2, 0.15 and 0.1 mg/kg/day, respectively. The prednisone dose of 0.1 mg/kg was achieved by no later than 6 months post-transplant.
46050775|NCT00703378|Drug|Docetaxel (Taxotere®)|Phase 1 Cycle 1 and 2 Patients in group 1 receive 40mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 2 receive 30mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 3 receive 20mg/m2/week of docetaxel in a 1-hour infusion.
46050776|NCT00703456|Behavioral|Balance Training|balance training three days per week for 4 weeks during single limb standing
46050777|NCT00852202|Drug|cariprazine|Drug: cariprazine (0.25 - 0.75 mg/day)
45690393|NCT05369637|Behavioral|Physical exercise|"This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:~i. In-person group training (monthly); ii. In-person group training or remote synchronous training or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic."
46050778|NCT00852202|Drug|cariprazine|Drug: cariprazine (1.5 - 3.0 mg/day)
46050779|NCT00852202|Drug|placebo|placebo capsules, oral administration, once daily dosing
46050780|NCT01074008|Drug|ABT-450|50 mg capsules co-administered with ritonavir
46050781|NCT01074008|Drug|ABT-072|50 mg tablet
46050782|NCT01074008|Drug|ABT-333|400 mg tablet
45482400|NCT04296942|Biological|Brachyury-TRICOM|Every three weeks, until cycle 9, then every 12 weeks: *Recombinant MVA-Bavarian Nordic (BN)-Brachyury recommended phase 2 dose (R2PD): 4 injections of vaccines with 1 given subcutaneous (SC) in each extremity on Day 1 of Cycles 1 and 2. Each injection of MVA-BN-Brachyury consists of 2.0 x 10^8 infectious units (Inf.U). *Recombinant fowlpox virus (FPV)-BN-Brachyury: 1 injection given SC in one extremity on Day 1 of Cycles 3 and beyond. Each injection of FPV-BN-Brachyury consists of 1.0 x 10^9 Inf.U.
46050783|NCT01074008|Drug|Ritonavir|100 mg capsules co-administered with ABT-450
46050784|NCT01074008|Drug|Peginterferon alpha-2a|Syringe, 180 µg/0.5 mL for subcutaneous injections
46050785|NCT01074008|Drug|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
45365071|NCT00141037|Drug|Tacrolimus|Taken orally from immediately preoperatively to those>age 5 yrs. (starting dose= 0.1 mg/kg/dose twice daily (BID) for living donor recipients; 0.1 mg/kg/dose daily for deceased donor recipients).Subjects <age 5 yrs. received drug from immediately preoperatively at 0.15 mg/kg/dose BID (two preoperative doses) for living donor recipients and 0.15 mg/kg/dose daily (one preoperative dose) for deceased donor recipients. Postoperatively: 0.07 mg/kg/dose BID w/adjustment to achieve target levels of 12-14 ng/mL (days 0-7), 10-12 ng/mL (wks. 2-8), 7-10 ng/mL (wks. 9-12) &5-7 ng/mL >= 12 wks. Evidence of drug toxicity on any protocol biopsy resulted in a further lowering of the drug target level to 4-6 ng/mL before yr 1 & 3-5 ng/mL after yr 1 post-transplant. This regimen was used in both arms.
45690394|NCT05369637|Behavioral|Behavioral: Nutrition education|"This component will be based on the following activities:~i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly)."
46050786|NCT01074008|Other|Placebo|Matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level
46050787|NCT04117048|Device|LabPad® point-of-care|All at home INR measurements will be performed by the nurse using the LabPad® point-of-care
46050788|NCT04117204|Other|Fruits and Vegetables|Fruits and Vegetable delivery, once a week for 12 weeks.
46050789|NCT02613052|Drug|normal saline|10 mL of normal saline agitated prior to IV administration
46050790|NCT02613052|Drug|human albumin|10 mL of 5% albumin agitated prior to IV administration
46050791|NCT02613052|Drug|human albumin and propofol|7 mL of 5% albumin mixed with 3 mL of propofol (10 mg/mL) agitated together prior to IV administration
46050792|NCT01073930|Drug|PicoPrep|PICOPREP (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PICOPREP pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. The first pouch was taken between 5:00 PM and 9:00 PM the evening prior to the colonoscopy procedure. Subjects were to consume five (5) 8-ounce glasses of clear liquids over the next few hours. The second pouch was taken approximately 5 hours before but no more than 9 hours prior to the colonoscopy procedure. Subjects were to consume three (3) 8-ounce glasses of clear liquids.
46050793|NCT01073930|Drug|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
45482401|NCT04296942|Drug|Entinostat|5mg by mouth weekly (RP2D) administered by patient on Days 1, 8 and 15 of each cycle.
45482402|NCT04296942|Biological|M7824|1800mg via intravenous (IV) infusion every (q)3 weeks on Day 1 of each cycle.
45365072|NCT00141037|Drug|Ganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
45365073|NCT00141037|Drug|Valganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
45482403|NCT04296942|Biological|Ado-trastuzumab emtansine|3.6mg/kg via intravenous (IV) infusion every (q)3 weeks on Day 1 of each cycle.
45482404|NCT02468050|Behavioral|Moderate intensity exercise training|6 weeks of moderate intensity exercise training (50 - 75% of heart rate reserve). Sessions are facility and home based and include cardiovascular warm-up, cardiovascular training, muscular conditioning, and flexibility exercises.
45482405|NCT02468050|Behavioral|Self Management of exercise|In addition to the 6 week exercise program (refer to Exercise Treatment Group), participants randomly assigned to the Self Management Group will learn strategies for the self management of exercise.
45482406|NCT04442620|Other|Physical activity and Mediterranean Diet (PA-MD)|Physical Activity plus caloric restricted Mediterranean diet
45482407|NCT04442620|Other|High meal frequency of Mediterranean Diet (HMF-MD)|High meal frequency of unaltered Mediterranean diet
45482408|NCT04442620|Other|Control diet (CD)|Control Diet
45482409|NCT01343550|Other|creativity group|This is a creativity group intervention. There will be 4 groups. Each group has one session per week. Each session is a duration of two hours.
45482410|NCT03305380|Other|No interventions|As this is a patient registry, there are no interventions.
45365074|NCT00141037|Drug|Trimethoprim and sulfamethoxazole|Pneumocystis pneumonia (PCP)/Urinary Tract Infection (UTI) Prophylaxis: Trimethoprim/sulfamethoxazole (Septra®) 2 mg/kg by mouth will be administered daily at bedtime for a minimum period of the first 6 months post-transplant. If unable to tolerate Septra®, inhaled pentamidine (8 mg/kg to a maximum dose of 300 mg monthly) or Dapsone (2 mg/kg PO to a maximum dose of 100 mg/day) may be substituted for a minimum of the first 6 months post-transplant. For UTI prophylaxis, if Septra® is not tolerated, nitrofurantoin (Macrodantin®), 2.5 mg/kg/day, may be given at bedtime up to a maximum dose of 100 mg/day.
45482411|NCT01344564|Drug|Degarelix acetate, Leuprolide acetate|Degarelix acetate, 1 mo depot for 3 months Leuprolide acetate, 3 mo depot once
45482412|NCT03300310|Other|nursing visit|nursing visit at patient home
45365075|NCT04612946|Behavioral|Referral to Telemedicine LCS Counseling Visit|Patients in the intervention arm will be invited to complete a telemedicine LCS counseling visit, and asked for permission to be referred directly to the LCS navigator to help schedule an appointment. They will also be given the option to directly contact the LCS navigator. Telemedicine counseling visits will be conducted using established clinical procedures for virtual or telephone visits at Penn Medicine. In accordance with reimbursement policies for lung cancer screening, these visits will be conducted by a physician or nurse practitioner within the Lung Cancer Screening Program at Penn Medicine. Counseling visits are covered without co-pay as standalone visits according to USPSTF guidelines and costs will not be covered by the study. LCS is an evidence-based practice and considered standard of care for those who are eligible and desire to be screened. Clinicians retain full control on how to conduct LCS counseling or LDCT in this trial.
45482413|NCT03300310|Other|no nursing visit|the patient take his treatment without nursing visit
45482414|NCT04894812|Other|Neurodevelopmental technique|"st month: postural maintenance; exercises with weight on forearms and hands, in sitting, crawling, semi-kneeling and standing positions with support from therapist.~nd month: balance and corrective reactions; using CP ball and tilt board.~rd month: ambulation training; appropriate to motor development level (crawling, creeping, walking in a semi-kneeling position and walking between parallel bars)."
45482415|NCT01344720|Drug|etoricoxib|"At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 1 non-responders will receive an increase in monotherapy from etoricoxib 30mg to eterocoxib 60mg/die."
45482416|NCT01344720|Drug|oxycodone|"At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 2 non-responders will receive in addition to etoricoxib 30mg/day a dose of oxycodone CR 5mg q12hr (dose of 5mg tablet is available in Italy)."
45690395|NCT05369637|Behavioral|Psychoeducation|This component will be based on in-person group sessions (monthly; 60-minute) supervised by a psychologist, aiming to promote the acquisition of important knowledge about secondary prevention and support people understanding, exploring, and self-managing their emotions and impairments.
45690396|NCT05369637|Other|Diagnosis and correction of hearing impairment|This component will be based on a evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and include an otoscopy and an audiogram.
45690397|NCT05368545|Drug|High intensity lipid lowering|Two different regimens of drugs with different effects on LDL lowering
46050794|NCT01073930|Drug|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
46050795|NCT01073618|Drug|voriconazole IV|6 mg/kg iv q 12 hours (loading) then maintenance
46050796|NCT02875964|Device|electroencephalogram|Implanting electrode to measure brain activity
46050797|NCT02875964|Device|magnetoencephalogram|Implanting electrode to measure brain activity
45482417|NCT04442230|Biological|NasoVAX|NasoVAX consists of replication-deficient adenovirus vectors in suspension
45482418|NCT04442230|Other|Placebo|Normal saline
45482419|NCT04921098|Procedure|Diode Laser Cyclophotocoagulation|A handpiece (G probe) is used to deliver the diode laser energy with a wavelength of 810 nm.
45482420|NCT03305302|Procedure|Sample of cancerous epithelium from the tongue|Harvesting and culture of cancerous epithelium from the surgical piece
45482421|NCT04402008|Drug|Poziotinib Once Daily Dosing|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
46050798|NCT00789373|Drug|Pemetrexed|Induction therapy: 500 mg/m^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles
45482422|NCT04402008|Drug|Poziotinib Twice Daily Dosing|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
46050799|NCT00789373|Drug|Cisplatin|Induction therapy: Cisplatin: 75 mg/m^2, IV, on Day 1 of each 21-day cycle for 4 cycles
45482423|NCT04402008|Drug|Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
45482424|NCT04442542|Other|Respiratory muscle training 1 (Experimental Group)|"The participant must perform a series of exercises that will be the same for the two groups in this investigation. In addition to the exercises, this group will use the incentive inspirometer device with a new method created by the main author called the Method JaPer.~For the method JaPer, the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale normally until you run out of air. And after that, inhale slowly as much as possible. This maximum value will be taken as an indicative parameter of its maximum inspiratory capacity and 50 and 80% for 1 set of 10 repetitions at 50% of their maximum value, 2 sets of 10 repetitions at 60% of its maximum capacity and ends with 1 series at 80% of its maximum capacity. It is highlighted that in each series before finishing and without stopping to rest, the participant must do 5 repetitions at 100% maximum capacity"
45482425|NCT04442542|Other|Respiratory muscle training 2 (Control Group)|Training of respiratory muscles under the protocol of conventional use. Which is that the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. Repeat 10 times and use these indications for 3 sets. In addition, participants must perform the same breathing exercises that are identical for experimental group.
45482426|NCT04246788|Other|Intensive robotic rehabilitation|5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks
45690398|NCT01396395|Drug|Nicorandil|The subjects will receive Nicorandil 5 mg tablet orally three times daily for a period of 12 weeks along with the standard treatment.
45690399|NCT01396395|Drug|Standard Treatment|The subjects will receive one of the standard anti-anginal therapies which included but not limited to aspirin, ACEI, lipid lowering statins and beta blockers according to the recommendation of guidelines. If the subject's condition permitted, they should take all these medicines. However, the dose, route, frequency and duration were determined by investigators according to subject's specific condition.
45482427|NCT04246788|Other|classical physiotherapy|3 sessions per week of 30 minutes of classical physiotherapy during two weeks
45482428|NCT05727982|Diagnostic Test|Venous blood samples, Biological samples analysis, Cardiology visit.|These interventions are important to study all patients recruited
45690400|NCT01396317|Drug|Tocilizumab|Tocilizumab is a humanized anti-interleukin-6 receptor antibody that has been FDA approved for the treatment of rheumatoid arthritis (RA). This molecule binds to the IL-6 binding site of human IL-6 receptor, and competitively inhibits IL-6 signaling.
45690401|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
45690402|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
46050800|NCT00789373|Drug|Placebo|Maintenance therapy: Normal saline (0.9% sodium chloride) administered IV on Day 1 every 21-day cycle until progressive disease or treatment discontinuation
45482429|NCT04491058|Diagnostic Test|SSCT thickness measurement|Thickness measurement with ultrasound
45482430|NCT03220854|Radiation|Stereotactic radiotherapy|Treatment will be planned to deliver a total of 18 to 60 Gy to the planning target volume (PTV) in 3 to 5 fractions over 1 to 2 weeks.
46050801|NCT00789373|Drug|Pemetrexed|Maintenance therapy: 500 mg/m^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.
45365076|NCT04612946|Behavioral|Usual Care|Patients in the usual care arm will be provided with contact information for the Penn LCS Program and encouraged to discuss LCS with their providers.
45365077|NCT04602884|Diagnostic Test|Breath biopsy sampling using the ReCIVA Breath Sampler|Breath biopsy sampling using the ReCIVA Breath Sampler
45365078|NCT00140413|Drug|Nutropin AQ|Daily injection. Dosage dependent on weight.
45365079|NCT04039178|Device|BQ|The BQ device (BrainQ Technologies Ltd., Israel), a Brain Computer Interface based stimulation device, uses machine learning tools to identify high resolution spectral patterns associated with motor functions in EEG measurements of healthy/non healthy subjects. These patterns are then translated into a tailored frequency dependent low intensity, non-invasive electro-magnetic treatment protocol.
45365080|NCT04039178|Device|Sham|Sham BQ device
45365081|NCT04038398|Procedure|Non-invasive ventilation with different FiO2 settings|CPAP therapy applied with different order of FiO2 settings.
45365082|NCT01582555|Drug|saline nasal irrigation alone|control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation
45365083|NCT01582555|Drug|dissolved N-Acetylcystine|intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
45365084|NCT03966313|Device|ventricular assist device implantation|"Blood sampling in patients under surgery for ventricular assist device implantation at five time points:~After anesthetic induction~Before starting the device~2h, 6h and 48h after starting the device"
45365085|NCT03741361|Other|anxiety and depression|Female patients who have a previous history of surgery or infertility, or a history of miscarriage or abortion are often susceptible to preoperative anxiety or depression. We will observe the effect of anxiety and depression on the dosage of propofol during induction.
45365086|NCT00884000|Drug|Genotropin|
45365087|NCT00884000|Drug|Zomacton|
45365088|NCT00884078|Other|Culturally adapted manualized problem solving training|The areas covered by the manual include an evaluation of the self-harm attempt, crisis skills, problem solving, and basic cognitive techniques to manage emotions and negative thinking and relapse prevention strategies. The treatment will be structured around patient's current problems with the relevant sections of the manual helping the patient to deal with specific problems leading to the self-harm act. Between the sessions the manual can be used for homework tasks by the patient. We will be able to linguistically match the therapist and the participant in three most common languages spoken and understood in South Asian population i.e. Urdu, Hindi and Punjabi.
45365089|NCT00885716|Behavioral|patient training in shared decision making|
45690403|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
45690404|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule twice daily for 14 days, immediately before breakfast and dinner, in healthy volunteers.
45690405|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once (or twice) daily for 14 days, immediately before breakfast (and dinner), in patients with type 2 diabetes.
45690406|NCT01396083|Drug|Ranibizumab|
46050802|NCT00789373|Other|Best Supportive Care|Best Supportive Care is treatment given with the intent to maximize quality of life. Best Supportive Care excludes any treatment in which the goal is to cure or slow the progression of the study disease. Patients will receive Best Supportive Care as judged by their treating physician. Those therapies considered acceptable include, but are not limited to, palliative radiation to extrathoracic structures, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral).
46050803|NCT00851890|Drug|ABT-333|50 mg capsules
46050804|NCT00851890|Other|Placebo for ABT-333|Capsule
46050805|NCT00851890|Drug|Pegylated interferon|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
46050806|NCT00851890|Drug|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
46050807|NCT00626756|Device|LiDCO technology|non invasive monitoring of cardiac output
46050808|NCT02877368|Other|Computed tomography|
46050809|NCT02877212|Drug|Eltrombopag|Eltrombopag will be given to steroid refractory ITP patients and ITP patients treated with standard Immunosuppressive therapy (IST) will be taken as control.
46050810|NCT04299230|Device|Cortium C3|
45365090|NCT00885716|Behavioral|cognitive training|
46050811|NCT04106713|Behavioral|Individual Psychotherapy|The individual therapy program will differ in orientation according to therapist and session notes will be coded according to the Comparative Psychotherapy Process Scale. Therapy sessions take place approximately once every fortnight, with 8 sessions in total, according to the agreed-upon schedule.
45365091|NCT03948932|Device|Transvaginal sonography|Measurement of cervical length via transvaginal sonography prior to labor induction.
45365092|NCT03948932|Device|Pressure watch|Measurement of inflation pressure in a cervical ripening balloon is PSI units.
45690407|NCT01396083|Drug|Dexamethasone implant and sham injections|
45690408|NCT04345263|Procedure|MTA pulpotomy|Cutting the coronal portion of the pulp to the level of canal orifices and applying the dressing and restoration
45365093|NCT02543684|Other|ready to eat mixed meal 1|wild greens pie providing 50g of carbohydrates
45365094|NCT02543684|Other|ready to eat mixed meal 2|chicken burgers with boiled broccoli and cauliflower providing 50g of carbohydrates
45365095|NCT02543684|Other|ready to eat mixed meal 3|vegetable moussaka providing 50g of carbohydrates
45365096|NCT02543684|Other|oral glucose load|glucose load providing 50g of carbohydrates
45365097|NCT02543762|Procedure|Chromoendoscopy|Chromoendoscopy involves the topical application of stains to improve tissue localization and characterization of lessions during endoscopy . Chromoendoscopy has been used in patients undergoing colonoscopy, including those undergoing surveillance for chronic ulcerative colitis. Using pit pattern classifications, chromoendoscopy has a high sensitivity and specificity for differentiating neoplastic from non-neoplastic lesions
45365098|NCT04562714|Device|FreeStyle Libre Flash Glucose Monitor|The FreeStyle Libre FGM device consists of a skin-worn disposable sensor that automatically measures and continuously stores glucose readings. The sensor is placed by a single-use applicator and is activated by a wireless scan with a handheld reader. It is designed to stay on the body for up to 14 days, and can be worn under clothing. After a 1-hour warm-up period, the sensor takes automatic measurements of glucose every 15 minutes for up to 14 days. The device collects the interstitial glucose values and stores them for subsequent upload at the end of the 14-day wear period. With each scan, users receive their glucose reading; the last eight hours of glucose data; and an arrow illustrating the direction their glucose is heading.
45365099|NCT04562714|Other|Diabetes self-management education|"The DSME curriculum is compromised of:~Review of weekly glucose report (Trend glucose report from Libreview for intervention group; and weekly glucose report in log book format from their glucose monitoring software for control group)~Education modules for both in-person and remote delivery;~Handouts to support the curriculum objectives; and~Blood glucose monitoring challenges to stimulate behaviour change and reinforce learning."
45365100|NCT00923312|Biological|CV9201|CV9201 is a vaccine consisting of five drug product components. Treatment will be administered on 5 timepoints.
45365101|NCT04038710|Drug|Triple combination therapy|Triple combination is compromised of the drugs ivacaftor, tezacaftor and Vertex's next generation modulator.
46050812|NCT04106713|Behavioral|Internet-delivered Cognitive Behavioural Therapy (iCBT)|"The iCBT program (clinician follow-up with the therapist and 4 online modules) will be administered for 8 weeks. The four modules: 1) psychoeducation about emotions, including a functional nature of emotions; 2) alteration of antecedent cognitive misappraisals; 3) prevention of emotional avoidance; and 4) modification of emotion-driven [behaviours] (EDBs), are adapted from The Unified Protocol (UP) for transdiagnostic treatment of emotional disorders. UP is a CBT consisting of four overarching themes- increasing emotional awareness, facilitating flexibility in appraisals, identifying and preventing [behavioural] and emotional awareness, and situational and interoceptive exposure to emotion cues."
45365102|NCT00923390|Genetic|2G-1 TCR Retroviral Vector-Transduced lyn|
45365103|NCT00923390|Drug|Aldesleukin|
45365104|NCT00923390|Drug|Cyclophosphamide|
45365105|NCT00923390|Drug|Fludarabine|
45365106|NCT00923390|Drug|(PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte|
45365107|NCT00882596|Device|Accelerated partial breast irradiation|A total radiation dose of 34 Gy is delivered in 10 fractions bid over 5-7 days with 6 hours between the radiation treatments each day. Each radiation treatment takes 15-30 minutes. There is no radioactivity left behind in the patient.
45482431|NCT03220854|Other|Biological: humanized anti-PD-1 monoclonal antibody|Standard of Care - patient will continue to be given the same PD-1 inhibitor they were receiving prior to study registration
45482432|NCT03220854|Other|Biological: humanized anti-PD-L1 monoclonal antibody|Standard of Care - patient will continue to be given the same PD-L1 inhibitor they were receiving prior to study registration
45690409|NCT01723826|Drug|Crenezumab|Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.
45690410|NCT01721954|Drug|FOLFOX6m|
45690411|NCT01721954|Device|SIR-Spheres microspheres|
45365108|NCT03966781|Procedure|ESWL|ESWL will be conducted under epidural anesthesia. For epidural anesthesia, bupivacaine will be used to block the T6-T12 spinal segments. The patient's eyes will be lightly covered all along the procedure. Once epidural anesthesia is achieved, the patient will be given a light sedation and ESWL will be performed using a Dornier dual focus lithotripsy system providing a maximum of 5000 at the rate of 90 shocks per minute in over 1-2 days.
45365109|NCT03966781|Procedure|ERCP|Once ESWL is over, an endoscopic pancreatic sphincterotomy will be performed and complete stone removal will be attempted with subsequent stenting of the pancreatic duct in the presence of a pancreatic stricture (not detected on MRCP prior to enrolment) or in case of incomplete stone removal
45365110|NCT03966781|Procedure|Sham ESWL|In the sham/control group, patients will be given a transient superficial pin-prick sensation to give the feel of epidural anesthesia. After that the lithotripsy machine the will be switched on, without establishing any form of contact with the patients body.
45365111|NCT03966781|Procedure|Sham ERCP|Following sham ESWL patientswill be subjected to sham ERCP to examine the papillary area, but no pancreatic ductal intervention will be performed.
45365112|NCT00882674|Drug|RG1507|16mg/kg, 9mg/kg, 3mg/kg or 1mg/kg iv on Day 1 in one of 4 cohorts of patients
45365113|NCT00888524|Procedure|GP in Physio|manual therapy, educational advice of health promotion and physical exercises therapy based in a individual assessment
45365114|NCT00888524|Procedure|GP in Physio plus DWR|GP in Physio plus a supplementation of DWR training in high intensive aerobic threshold
45690412|NCT01776554|Biological|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
46050813|NCT04106713|Behavioral|Group Cognitive Behavioural Therapy (group CBT)|The group CBT program (for e.g. PsychUp) will be conducted over 8 weeks, with weekly 2-hour sessions. Each group consists of 4-8 patients and are facilitated by two practicing clinical psychologists and one clinical psychologist in training. Sessions are structured such that each session, except the first, begins with a brief review of previous session material and a collaborative review of homework. This is followed by introduction of new material and completion of any in-session exercises, with sessions concluding with homework assignment. Specific treatment content is similarly adapted from UP. Session 1 begins by covering psychoeducation on the CBT model of pathological depression and anxiety and the role of avoidance in maintenance of symptoms. Sessions 2 to 7 covers goal-setting, cognitive reappraisal and development of adaptive emotional coping strategies through situational emotion-focused exposures. Session 8 ends with a discussion on relapse prevention.
46050814|NCT02875652|Biological|Blood sampling|3 vials of 7,5 ml of peripherical blood will be collected at each blood sample.
46050815|NCT00788827|Biological|Autologous CD34+ stem cells|Up to 5 x 10 log 8 of autologous stem cells on a single occasion
46050816|NCT02875574|Drug|Any treatment regimen|Treatment regimen used to treat patient once isoniazid resistance known (exposure of interest for cohort study)
45365115|NCT04038242|Other|Resilience promotion program|Resilience Promotion Program consists of eight sessions. Except the first orientation session and the last review session, other six sessions focus on cultivating the five internal resiliency factors (physical, behavioral, cognitive, emotional and spiritual). There are two sessions for behavioral factor, including one special to deal with the relationships between parents and children.
45365116|NCT00885794|Drug|Ranibizumab|3 intravitreal injection every 5 weeks
45365117|NCT00888602|Dietary Supplement|3.4 g psyllium|3.4 g psyllium served with meal
45365118|NCT00888602|Dietary Supplement|6.8 g psyllium|6.8 g psyllium served with a meal
45365119|NCT00888602|Dietary Supplement|6.8 g psyllium|6.8 g psyllium
45365120|NCT00888602|Other|Meal|meal
45365121|NCT02543450|Other|Cardiovascular and task-oriented training|
45690413|NCT01776008|Drug|Akt Inhibitor MK2206|Given PO
45690414|NCT01776008|Drug|Anastrozole|Given PO
45690415|NCT01776008|Drug|Goserelin Acetate|Given SC
45690416|NCT01776008|Other|Laboratory Biomarker Analysis|Correlative studies
45690417|NCT01776008|Procedure|Neoadjuvant Therapy|Given before standard-care surgery
45690418|NCT01776008|Other|Pharmacological Study|Correlative studies
45690419|NCT01776008|Procedure|Therapeutic Conventional Surgery|Undergo standard-care surgery
45690420|NCT01746368|Other|The Nurse-Supported Advance Care Planning Intervention|This intervention was a manualized education, support, and guidance session provided by a Registered Nurse that included information about risks, benefits, and alternatives of specific choices. It incorporated an application of the Theory for Enabling Safety.
45482433|NCT02467894|Other|Group-based Care|There will be self-care activities, blood pressure measurements and other vitals, including discussion of specific topics initiated by the participants.
45482434|NCT03305224|Drug|Ra-223 in combination with enzalutamide|Ra-223 (55 kBq/kg i.v.) 6 injections at 4 weeks interval in combination with enzalutamide 160 mg per a day
45690421|NCT01746368|Other|Care-as-Usual|The Care-as-Usual was a session with the social worker who explained what the Advance Directive is, and guided the Veteran regarding the process of completing the Advance Directive document, without providing information about risks, benefits, and alternatives of specific choices.
45365122|NCT02543450|Other|Upper limb strength training program|
45365123|NCT00885872|Drug|Rosuvastatin (Crestor)|at visit 2 each eligible subject will be allocated to rosuvastatin. study medication wil be taken orally with water once daily, as directed by the study physician. subjects who meet the criteria at visit 3, dosage of rosuvastatin will be titrated.
45365124|NCT00888758|Device|biolimus A9|200 patients with STEMI will be treated using Biomatrix stent.
45482435|NCT03305068|Drug|Celecoxib|
45482436|NCT04242810|Device|rTMS|TMS will be applied over task-based target at an intensity up of 130% rMT. The optimal coil placement during stimulation will be guided using the BrainSight neuronavigation system.
45482437|NCT04242810|Device|Sham rTMS|An electrical sham coil that produces the same auditory and somatosensory stimulations, without a significant magnetic field, will be used as an active control.
45482438|NCT04242810|Procedure|MRI scan|Participants will undergo an MRI scan directly after rTMS stimulation that will last less than 120 minutes. During the scan, subjects will encode and retrieve object pictures.
46050817|NCT02875574|Other|Bacterial mutation|Resistance, compensatory or other mutation in the infecting strain of Mycobacterium tuberculosis (exposure of interest for nested case-control study)
46050818|NCT02612974|Biological|Hirudinaria granulosa, qurse mafasil|compare the efficacy of both groups
46050819|NCT04304924|Other|The personalized telephone based intervention|"The personalized telephone based intervention:~Provide Behavioral support to facilitate lifestyle change by a weight loss coach located at a centralized call center. Participants will be paired with an individual coach who will work with the participant through all phases of the 1-year weight loss program. The behavior change program will be based on Social Cognitive Theory, which hypothesizes that the interactions between environmental, personal and behavioral elements determine behavioral change (Bandura 1989);~Utilize a toolbox approach that will allow for tailoring the intervention to the individual participant. Examples of possible Toolbox solutions include: alternative dietary approaches, instructions for strength-training exercises."
45365125|NCT00888758|Device|everolimus|200 patients with STEMI will be treated with PROMUS DES.
45365126|NCT04037150|Diagnostic Test|Circulating tumor DNA|Circulating tumor DNA
45365127|NCT02542436|Other|No intervention|No intervention administered in this study
45365128|NCT00888836|Procedure|Bariatric surgery: Gastric bypass|Gastric bypass (GBP): A subcardial gastric pouch with a 30±10 ml capacity will be created on a naso-gastric 36F calibrating tube by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastroenterostomy.
45365129|NCT00888836|Procedure|Bariatric surgery: Bilio-pancreatic diversion|Biliopancreatic diversion (BPD): A distal two-third gastrectomy will be carried out aiming at leaving an about 400 ml gastric remnant. The gastrointestinal continuity will be re-established by sectioning the small bowel 300 cm proximal to the ileocecal valve, closing the intestinal stumps, and joining the proximal one end-to-side to the distal ileum at 50 cm from the ligament of Treitz. The distal stump of the transacted bowel will be anastomosed to the left corner of the gastric stump, preferably in a totally hand-sewn fashion.
45482439|NCT01317420|Drug|BI 836845|Intravenous infusion once every three weeks
45482440|NCT04490590|Drug|Chidamide+ Etoposide|Patients will receive the treatment of and chidamide and etoposide capsule, and those who have achieved CR（complete response）or PR（partial response）or SD(stable disease)will continue the treatment.
45482441|NCT01344798|Biological|AAV1-gamma-sarcoglycan vector injection|single intramuscular injection into carpi radialis muscle under open procedure
45482442|NCT03300154|Behavioral|Financial incentives|The study nurses will schedule an appointment with the doctor at the health center, within 4 weeks from the participant's inclusion in the study. Participants who attend the first visit at the health center will receive a direct incentive consisting of the payment of a limited amount to be determined (approximately AR $ 150-200) through a shopping voucher for the amount mentioned. Participants attending the follow-up visit at the health center within 3 months from their inclusion in the study will participate in a lottery. The lottery will offer the possibility of winning a new voucher with a probability of 1 in 3. Participants who do not attend the health center will not receive any incentive.
45482443|NCT03300154|Behavioral|Framing (SMS)|After inclusion, participants will receive weekly text messages (SMS) using a specific framing or formulation of the message, highlighting the potential benefits and positive aspects of health care. These messages will promote follow-up visits, adherence to treatment, and benefits to be gained from a follow-up visit with the physician. Messages will be sent with a frequency of two per week during the first 30 days and then 1 per week until the end of the follow-up. These messages will have no cost to participants.
45690422|NCT01381575|Biological|GSK Biologicals' HPV vaccine 580299|Subjects received 2 or 3 doses of HPV vaccine administered intramuscularly.
45690423|NCT01858363|Device|CVI Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|
45690424|NCT01858363|Device|Bare Percutaneous Transluminal Angioplasty Balloon Catheter|
45365130|NCT00888836|Behavioral|anti-diabetic drugs and behavioral suggestions|Medical therapies (oral hypoglycemic agents and insulin) are optimized on an individual basis. Lifestyle modification programs, including reduced energy and fat (<30% total fat and <10% saturated fat, high fibre content) intake and increased physical exercise (suggested at least 30 minutes of brisk walking every day possibly associated with a moderate intensity aerobic activity twice a week), are tailor made by an experienced diabetologist assisted by a dietitian. After the two years, the patients in control group will be offered the choice to undergo one of the two surgical procedures.
45482444|NCT01317498|Other|Standard Care|CD4, liver function and CBC every 6 months
46050820|NCT00592072|Dietary Supplement|Medium chain fatty acid (Octanoic and Decanoic acid)|Octanoic acid(67%) and Decanoic acid (27%); MCFA 50g total at 25 minute intervals with front loading of 20g then 10g for three administrations.
46050821|NCT00592072|Other|Splenda (Placebo Control)|Placebo drink will consist of dietary sweetener Splenda mixed in water at a concentration of 1g/100mL. An unsweetened cherry flavor Koolaid mix will be added at a concentration of 0.3g/100mL of the Splenda drink to enhance flavor.
46050822|NCT02875418|Device|EUM|"STUDY DESIGN~Explanation regarding the study and assessing eligibility criteria.~Signing an informed consent.~Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes."
46050823|NCT02875418|Device|Tocodynamometry|"STUDY DESIGN~Explanation regarding the study and assessing eligibility criteria.~Signing an informed consent.~Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes."
46050824|NCT04742972|Radiation|SABR|SABR is delivered to all sites of oligometastasis with continuation of Enzalutamide. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in SOC Arm.
46050825|NCT04742972|Other|SOC|"Three options:~Continuation of Enzalutamide~Observation~Switch to next line treatment"
46050826|NCT00626288|Drug|Mesalazine|Mesalazine 800mg t.i.d. 12 weeks
46050827|NCT00626288|Drug|Placebo|Placebo cpr, t.i.d. 12 weeks
46050828|NCT00792571|Drug|Beraprost Sodium Modified Release|
46050829|NCT04108975|Procedure|Rectus muscle reapproximation during CS|Reapproximation by 3 interrupted simple sutures or 3 vertical mattress sutures.
46050830|NCT04108975|Procedure|Rectus muscle non reapproximation during CS|During CS rectus muscle non reapproximation will be done.
46050831|NCT01069484|Other|Postpartum pelvic floor muscle training|Beyond a customary leaflet and thorough initial instruction on how to contract the PFM correctly, the training participants will attend one weekly supervised exercise class led by an experienced physiotherapist, and perform daily training at home. The intervention starts 6-8 weeks postpartum and last for 4 months. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum (Bø 1990, Haskell 2007). Emphasis will be on progression in force development. The participants are provided with a DVD of the program (www.corewellness.co.uk). At week 4 during the intervention, the PFM strength will be assessed for each participant. Training adherence at home will be recorded in a training diary, whereas the physical therapist will record group session adherence.
46050832|NCT04110223|Genetic|next generation sequence|targeted NGS of patients' pretreatment tumor biopsy samples using a 474-gene panel, which covers cancer- and radio-sensitivity-related mutations and SNPs.
46050833|NCT04109989|Device|HominisTM Surgical System|Trans-vaginal gynecological procedures
46050834|NCT00794365|Drug|Varenicline|"There are two packs available for Varenicline (Champix™). The titration pack is prescribed initially to subjects with the recommended 1-week titration phase schedule as follows:~Days 1-3 0.5 mg once daily Days 4-7 0.5 mg twice daily Day 8 - End of treatment 1 mg twice daily~Following the titration period, Varenicline (Champix™) dosing is increased to 1mg twice daily for the remainder of the treatment period. Patient should set the target quit date to coincide with the start of 1 mg twice daily dosing. It should be taken after eating and with a full glass of water."
46050835|NCT01067144|Drug|Gabapentin|1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.
46050836|NCT01067144|Drug|Lorazepam (active control)|0.5 mg Lorazepam (active control) given pre-operatively in a single dose.
46050837|NCT01067144|Drug|Placebo (inactive)|2 capsules of inactive placebo given 3-times a day post-operatively for the 72-hour post-surgical period.
46050838|NCT04749758|Biological|SVF treatment|SVF treatment is developed by Cellab Laboratory (Celstem®). It is made following strict manufacturing guidelines and approved by Andorra's Government authorities. An abdominal fat liposuction is required to obtained Celstem®. The preparation of the product is carried out exclusively in a clean laboratory room under the conditions described by the AABB (American Association of Blood Banks) standards. The treatments application is carried out on the same day of the extraction, at some point between the next 6 hours from the end of the extraction. Firstly, ultrasound joint evaluation is performed. Under sterility measures, intraarticular infiltration of SVF treatment is performed at affected knee or knees. Previous synovial fluid aspiration is performed, if required. Once the procedure is completed, rehabilitation recommendations and clinical follow-up information is provided.
46050839|NCT02603185|Drug|Hemay007|
46050840|NCT02603185|Drug|placebo|
46050841|NCT04003129|Other|questionnaire|"Data will be obtained through a written questionnaire for assessing knowledge, practice and attitude of paediatricians regarding early childhood caries.~Data collected will be saved and tabulated on computer and finally statistically analysed."
46050842|NCT05610943|Procedure|ultrasound-guided quadratus lumborum nerve block|The patient was placed in the lateral position with the side to be blocked on top. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed transversely between the iliac crest and the costa edge. After imaging the external-internal oblique and transversus abdominis muscles, the probe was advanced posteriorly. Quadratus lumborum, Psoas Major and Erector Spina muscles were visualized. The needle was advanced towards the middle thoracolumbar fascia between the Quadratus lumborum muscle and the Erector Spina muscle with the in-plane technique, and the location was confirmed by injecting 1 ml of 0.9 saline. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
45365131|NCT00888992|Behavioral|Quitline Service + 10 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 10 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be two calls per a week for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
45365132|NCT00888992|Behavioral|Quitline service + 20 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 20 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be one automated call a day for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
45365133|NCT04038320|Drug|Sofosbuvir/ledipasvir (SOF/LDV)|"SOF/LDV (400mg/90mg) orally once daily with or without food in the morning and will receive treatment for a duration of 12 weeks.~In addition, Ribavirin weight-based (1000 mg for patients <75 kg and 1200 mg for those ≥75 kg) administered orally in two divided doses with food for Genotype 3 patients."
45365134|NCT00563706|Drug|vabicaserin|This study will utilize a randomized, double-blind, placebo-controlled, comparator-referenced, multicenter, parallel-group adaptive design with placebo, risperidone (4 mg/day), and up to 7 treatment arms of vabicaserin (50, 100, 150, 200, 300, 400 and 600 mg/day) over the course of the study
45365135|NCT00563706|Drug|risperidone|
45482445|NCT01317498|Other|Virological Monitoring|Viral Load test every 6 months
45482446|NCT04242654|Procedure|Handheld fetal doppler ultrasound|Handheld fetal doppler ultrasound will be used to assess heart rate in high-risk neonates.
45365136|NCT00563706|Other|placebo|
45482447|NCT03299998|Procedure|Maxillary and mandibular blocks|A Pajunk SonoPlex Stim needle 22G x 55 mm was used. For maxillary nerve block, needle was introduced next to the angle of the orbitae and the zygomatic ridge. The needle was sank until coming into contact of the temporal bone. It was then orientated to the controlateral nostril and sank of 1 cm. For mandibular block, needle was introduced in the pterygoid fossa under and perpendicularly to the zygomatic arch, and sank until the pterygoid process. The needle was then orientated towards controlateral orbitae and sank with neurostimulation. After a motor response at 0.6 milliampere (mA) and the disappearance of contraction at 0.3 mA, local mixture was injected. The mixing of local anesthesia was made of ropivacaine 5 mg/mL and clonidine 30 µg. Five mL were injected in every block for a total of 20 mL.
45690425|NCT01877551|Drug|Tauroursodeoxycholic acid|The intervention group will receive 1.75 grams of tauroursodeoxycholic acid daily for 30 days.
45690426|NCT01877551|Other|Placebo tablet|The placebo group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
45690427|NCT01396005|Drug|boceprevir|boceprevir 800 mg (4 x 200 mg capsules), orally, every 8 hours, Day 2 through Day 7
45690428|NCT01396005|Drug|methadone|methadone, 20-150 mg tablets, liquid, or disket, orally, once per day, Day 1 through Day 8
45690429|NCT01396005|Drug|buprenorphine/naloxone|buprenorphine/naloxone 8/2-24/6 mg, tablets, sublingual, once per day, Day 1 through Day 8
45690430|NCT01877239|Other|non-intervention|observation of Etanercept treatment in moderately active RA patients in Austria. Etanercept treatment according to Austrian SmPC
46050843|NCT05610943|Procedure|ultrasound-guided Ilioinguinal Iliohypogastric Nerve Block|The patient was placed in the supine position. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed on the anterior abdominal wall parallel to the imaginary line between the umbilicus and the anterior superior iliac wing. After imaging the external-internal oblique and transversus abdominis muscles, the ilioinguinal-iliohypogastric nerve was visualized as two small hypoechoic areas between the internal oblique muscle and the transversus abdominis muscle. The location was confirmed by injecting 1 ml of 0.9 saline by advancing the needle with the in-plane technique close to the nerve structures. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
46050844|NCT01078298|Drug|varenicline|varenicline tablets titrated to 1 mg BID during 1st week and then 1 mg BID for 11 weeks
46050845|NCT01078298|Drug|placebo|placebo tablets matched in appearance and dosage to varenicline tablets
46050846|NCT00788593|Drug|Placebo|Placebo matching to EUR-1008 (APT-1008) capsules orally daily for 4 days home treatment and 3 to 5 days hospital treatment in the baseline run-in phase, which will then be randomized to either high dose or low dose of EUR-1008 (APT-1008).
46050847|NCT00788593|Drug|EUR-1008 (APT-1008) High Dose|EUR-1008 (APT-1008) total high dose 140,000 lipase USP Lipase units will be given as 7 capsules containing 20,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
46050848|NCT00788593|Drug|EUR-1008 (APT-1008) Low Dose|EUR-1008 (APT-1008) total low dose 35,000 lipase USP Lipase units will be given as 7 capsules containing 5,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
45690431|NCT03024957|Drug|Morphine Sulfate|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces with injection of morphine sulphate .
45365137|NCT02543606|Drug|Esomelone|powder for injection/ infusion Esomeprazole 40mg
45365138|NCT02543606|Drug|Nexium|powder for injection/ infusion Esomeprazole 40mg
45690432|NCT03024957|Drug|Dexmedetomidine|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
45482448|NCT03299998|Procedure|General anesthesia|Anesthesia was standardized and provided using intravenous administration of propofol and remifentanil. Patients were mechanically ventilated with a mixture of air (50/50), and desflurane or sevoflurane, or Target-controlled infusion (TCI) propofol. One to 5 mg/kg of methyl-prednisolone were administered to reduce inflammatory response.
45482449|NCT04240470|Procedure|Thrombectomy|Participants will receive endovascular treatment (mechanical thrombectomy) alone without using IV rt-PA.
45365139|NCT04038632|Other|Decentralization of Childhood TB Diagnosis|The patient care level TB diagnostic approach consists of systematic TB screening, clinical evaluation, NPA and stool or sputum testing using Xpert Ultra, and optimised CXR reading will be implemented at DH and PHC levels
45365140|NCT00935844|Drug|TAK-901|"This study consists of three sequential parts.~Part 1: Escalating doses of TAK-901 will be administered via IV infusion over a 3-hour period on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 2: Escalating doses of TAK-901 (starting at one-third of the dose identified as the MTD in Part 1) will be administered as a 1-hour infusion on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 3: TAK-901 will be administered to approximately 20 patients using the dose identified as the MTD in the escalation phase. The infusion duration of TAK-901 will be determined after completion of Part 2."
45365141|NCT02543372|Behavioral|Behavioral Couples Therapy (BCT)|BCT integrates cognitive behavioral techniques targeting problem gambling with a large focus on interventions for relationship functioning. The BCT condition requires active participation from both the gambler and the CSO.
45365142|NCT02543372|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT integrates cognitive behavioral techniques targeting problem gambling with some interventions for relationship functioning.The CBT condition requires active participation from the gambler, but not for the CSO.
45365143|NCT00939588|Drug|Aliskiren/ Valsartan|
45365144|NCT00939588|Drug|Telmisartan/ Ramipril|
45482450|NCT02467114|Device|Transcranial magnetic stimulation (TMS)|This method will be applied to measure cortical excitability and as an interference approach; real TMS stimulation will be compared with sham stimulation and no stimulation
45365145|NCT02543138|Device|Trocar|Closed thoracostomy using the new trocar
45365146|NCT00935922|Dietary Supplement|Flaxseed|Flaxseed omega-3 fatty acids and lignans
45365147|NCT00936000|Dietary Supplement|Protandim|The dosage of Protandim will be 1350 mg per day given p.o. in two equally divided doses
45482451|NCT02467114|Device|Sham coil stimulation|Stimulation with a sham coil as a comparison
45482452|NCT02467114|Other|Control without stimulation|
45482453|NCT02467036|Behavioral|Family Based Behavioral Treatment|The intervention for both groups will be a 4-month Family-Based Behavioral Treatment (FBT), which includes dietary changes, physical activity changes, and behavioral therapy. Treatment is provided in separate parent and child groups. Families will learn to reduce caloric consumption and increase caloric expenditure (physical activity). Behavior therapy includes stimulus control, self-monitoring, goal setting and contracting, parenting skills, skills for managing high-risk situations, and maintenance and relapse prevention. Families will self-monitor caloric intake, breakfast consumption, physical activity, and hunger and satiety throughout the day.
45482454|NCT05468632|Drug|Semaglutide|Participants who initiated once weekly (OW) semaglutide in routine clinical practice in were enrolled in the study. The participants were treated according to current clinical practice, applicable local labels, and standard of care as per physicians' discretion.
45690433|NCT03024957|Drug|Bupivacaine|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
45690434|NCT03025113|Drug|ketoprofen and cyclobenzaprine association|The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
45690435|NCT03025113|Drug|Cyclobenzaprine|The patient will take 2 tablets (cyclobenzaprine), oral, per day, each 12h.
45365148|NCT00889148|Drug|Gabapentin|600mg gabapentin given 2 hrs preoperatively and 200mg three times a day after surgery for 3 days
45365149|NCT00889148|Other|Placebo|Half the patients will be randomized to placebo
45690436|NCT01877083|Drug|Lenvatinib|Starting dose of 24 mg orally, once per day
45690437|NCT01380327|Biological|Cockroach Sublingual Immunotherapy (SLIT) - Low Dose|Participants are randomized to receive daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume [w/v] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to three escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
45752176|NCT04350411|Device|PEAK PlasmaBlade™|Abdominal free flap raise performed with PEAK PlasmaBlade™ Settings: cutting 7 (35 Watt), coagulation 7 (35 Watt)
46050849|NCT04305080|Other|Anodic oxidation|Abutments will undergo anodic oxidation process after etching with Hydrofluoric acid & Nitric acid mixture for 10 minutes for debridement in a bath of distilled water with citric acid for 5 minutes to turn the abutment collar into pink color. The stainless steel plate will be connected to the cathode (-) and titanium abutments will be connected to the anode (+) end of the DC Power Supply. After then abutments will be left in distilled water for 10 minutes and sterilized before insertion in patient mouth.
46050850|NCT04305080|Other|Untreated abutment|Abutment will be left untreated with its gray color.
45365150|NCT00936156|Drug|Chemotherapy (carboplatin, etoposide, thiotepa)|Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
45365151|NCT00129961|Drug|sirolimus|
45365152|NCT00129961|Drug|cyclosporine or tacrolimus|
45365153|NCT00528567|Drug|Bevacizumab|Bevacizumab was administered at a dose equivalent of 5 mg/kg/week using 1 of 3 different scheduling options depending on the schedule of the adjuvant chemotherapy regimen selected for an individual patient.
45365154|NCT00528567|Drug|Standard adjuvant chemotherapy|All chemotherapy schedules and doses for each patient were prescribed according to the labeled indication of the country in which the patient was receiving therapy.
45365155|NCT00936234|Drug|Vildagliptin|Vildagliptin, 50 mg twice a days, orally for 30 days followed by placebo
45365156|NCT00886028|Drug|Liposomal doxorubicin|"Liposomal doxorubicin 60 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles."
45365157|NCT00886028|Drug|Cisplatin|"Cisplatin 80 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles."
45365158|NCT00889304|Device|Position HTO system|open wedge high tibial osteotomy
45365159|NCT00936468|Biological|Fluzone® vaccine with JVRS-100 adjuvant or Fluzone alone|One vaccination on Day 0 of Fluzone® vaccine at 45ug mixed with one of three doses (3.75ug, 7.5ug, 25ug) of JVRS-100 adjuvant versus Fluzone® vaccine at 45ug alone.
45365160|NCT02543216|Dietary Supplement|Sunflower oil|Study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. Thus, approximately 16-28 g (6 E%) LA were provided daily on top of the average intake of approximately 10-12 g (4.5 E%).
45365161|NCT00939666|Procedure|Wait&see or TEM with intensive follow-up|Wait&see or TEM with intensive follow-up
45482455|NCT03299920|Other|Standardized instructions|Specific instructions related to peripheral nerve block.
45365162|NCT03835364|Device|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using the Aptus Home, anaemia home monitoring system.
45365163|NCT00936546|Drug|Rituximab|Mabthera, Rituximab 1000 mg I.V.
45365164|NCT00889460|Biological|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 12.5 to 100 µg rBet v 1.
45365165|NCT00889460|Biological|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
45365166|NCT00936624|Drug|SOTB07|SOTB07 100mg
45365167|NCT00936624|Drug|SOTB07|SOTB07 200mg
45365168|NCT00936624|Drug|placebo|placebo
45365169|NCT00936624|Drug|montelukast|montelukast 10mg po, bid, 12week
45365170|NCT00889538|Drug|placebo|50 mL of 1/2 normal saline IV
45365171|NCT00889538|Drug|glutathione|glutathione 600 mg IV
45845771|NCT05540652|Behavioral|Mindfulness-Based Queer Resilience (MBQR)|"Mindfulness-based Queer Resilience (MBQR) is an internet delivered group-based, LGBTQ affirmative mindfulness program designed to address minority stress and promote mental and sexual health among young adult gay, bisexual, and queer men. The intervention group will meet once a week for up to 2.5 hours for nine weeks. Participants will receive free training in meditation, mindful movements, and in directing mindfulness-based skills towards enhancing things like stress recovery, sleep, resilience, cognitive performance and social relationships. MBQR was adapted from the Mindfulness-Based Stress Reduction program. Customization of the curriculum was developed by queer researchers and teachers, with input from the LGBTQ community."
45365172|NCT00889538|Drug|glutathione, vit C and NAC|Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg) Mix above three in 1/2 NS for a total volume of 50 mL
45365173|NCT04012476|Drug|Indocyanine Green|Administration of 5 mg of intravenous indocyanine green after total thyroidectomy for measurement of parathyroid fluorescence under infrared light
45365174|NCT00138151|Biological|recombinant interferon alpha-2b|Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle
45365175|NCT00138151|Drug|isotretinoin|Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle
45365176|NCT00138151|Drug|paclitaxel|Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days
45365177|NCT02543060|Drug|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
45365178|NCT02543060|Drug|cavity protection toothpaste|0.243% sodium fluoride toothpaste
45365179|NCT04012788|Dietary Supplement|Synbiotic mixture|A synbiotic mixture consisting of four probiotic strains and inulin (a prebiotic)
45365180|NCT04012788|Other|Placebo comparator|Placebo powder
45365181|NCT00889616|Drug|BSAM2/Alhydrogel + CPG 7909|
45365182|NCT00138073|Device|Web-based waveform interpretation guide|Use of an educational website.
45365183|NCT04038164|Behavioral|Dog-Assisted Therapy and pharmacological treatment|The investigators used the CTAC Method (Center of Dog Assisted Therapy) (E Domènec 2012).
45365184|NCT04013490|Dietary Supplement|Cassava dietary fiber capsule|Cassava dietary fiber capsule or placebo will be consumed once daily at the recommended doses of each group.
45365185|NCT04037306|Behavioral|Butyrate Feedback|Measure concentrations of stool butyrate by gas chromatography, returned to participants in summary report.
45365186|NCT04037306|Behavioral|Fiber Feedback|Estimated fiber consumption from menu records of weight loss facility.
45365187|NCT02581631|Biological|Nivolumab|
45482456|NCT03299920|Other|Conventional instructions|Usual post-operative instructions.
45482457|NCT02466880|Device|Telemedicine|A diabetes self-management and education program delivered via telemedicine
45482458|NCT02466880|Other|Usual care|A 15-30 minute diabetes self-management session. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
45482459|NCT05727826|Device|Thrive MD-01 .|The experimental group received a 60 Hz vibration stimulation treatment using the SMV method three times per week for two weeks (EG).
45365188|NCT02581631|Drug|Brentuximab Vedotin|
45482460|NCT05619926|Drug|STSP-0601 for Injection|Intravenous Injection
45482461|NCT04763044|Drug|0 ppm F|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
45482462|NCT04763044|Drug|250 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
45482463|NCT04763044|Drug|1100 ppm as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
45482464|NCT04763044|Drug|2800 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
45482465|NCT04763044|Drug|1100 ppm SnF2|Each subject will be assigned to this treatment during the fifth period for this crossover study.
45845772|NCT05520450|Behavioral|Telematic support group|The participation of each patient in the study has been established for 4 months; the first and last months correspond to the evaluation phase, the remaining two months are for the intervention. A total of 7 group sessions of 90 minutes duration and weekly frequency are scheduled, carried out via telematics and conducted by an emotional well-being professional, a nurse and a social worker. In this context, it is guaranteed that patients will receive the care, visits and treatments usually used for people who have presented their clinical situation. The only difference between participating in the intervention and not participating in the intervention is the participation in a telematic support group and some additional assessments, i.e. not routinely carried out, which are part of this project. The intervention will be carried out in a group format, with a maximum of 12 patients per session.
45365189|NCT00884546|Drug|BMS-833923|Capsule, Oral, Once daily, 6 months
45365190|NCT00884546|Drug|Lenalidomide|Capsule, Oral, Once daily, 6 months
45365191|NCT00884546|Drug|Dexamethasone|Capsule, Oral, Once a week, 6 months
45482466|NCT03735420|Drug|Xanthohumol|The xanthohumol supplement will be administered in a capsule. Participants in the experimental arm will consume the capsule once per day, with the first meal. The intervention will extend for 8 weeks.
46050851|NCT04106011|Drug|Gabapentin|Titration of gabapentin will be standardized as 300mg QHS and increased by 300mg every 3 days until taking 1200mg TID or maximum tolerable dose. Subjects will undergo cognitive evaluation prior to initiation of the medication, at 1 week (when titrated to approximately 900mg/day), 3 weeks (when titrated to approximately 2100mg/day), and at 6 weeks (when titrated to 3600mg/day or maximum tolerable dose).
45365192|NCT00884546|Drug|Bortezomib|Powder, IV, On days 1, 4, 8, 11, 6 months
45365193|NCT04970277|Other|drinking water group|Those randomized to drink water group were asked to drink 200 mL colorless water every 10 minutes, starting at the time of capsule ingestion until three times in total.
45365194|NCT04970277|Other|control group|Those randomized to control group were asked not to drink extra water after capsule ingestion.
45365195|NCT02643108|Procedure|Lateral episiotomy|When the woman is randomized to episiotomy, lateral episiotomy is performed with scissors on the left or right side of the vaginal opening. Origin of incision is 1.0 - 3.0 cm from the midline/posterior forchette and is cut 3.0 cm or more towards the ischial tuberosity at an angle of 60 degrees from the midline.
45482467|NCT03735420|Drug|Placebo oral capsule|The placebo (vehicle) will be administered in a capsule. Participants in the placebo arm will consume the capsule once per day, with the first meal.
45482469|NCT03299842|Drug|ZX008 (Fenfluramine Hydrochloride)|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
45482470|NCT03299764|Device|Pursed lip breathing ventilation|A non-invasive ventilation device mimicking the pursed lip breathing in COPD patients will be used.
45482471|NCT03299764|Device|Standard non-invasive ventilation|Standard non-invasive ventilation
45690438|NCT01380327|Other|Placebo|Participants are randomized to receive either daily (low dose) or twice-daily (high dose) placebo treatment placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The placebo was also administered during the preliminary dosing visits, up to three or seven escalating doses, or until the maximum study dose (420 or 840 microliters, 1:20 weight per volume [w/v]) was achieved.
45845773|NCT05519436|Other|Assessment|"Bioelectrical impedance analysis method was used to evaluate the body composition of the cases. Muscle, fat, water ratio was made with Inbody Bioelectrical Impedance Device. Static and dynamic plantar pressure analyzes were evaluated with Sensor Medica pedobarographic measuring device, and postural sway was evaluated with bilateral comparison tests, one of the dynamic balance tests of Biodex Balance System."
45482472|NCT01315028|Other|Cognitive Interpersonal Therapy|Cognitive Interpersonal Therapy in Early Bipolar Disorder: Individuals will receive up to six months of individual CIT-BP. CBT will emphasise assessment, engagement and formulation; normalizing and compassionate understanding; specific cognitive and behavioural strategies; self-management and social rhythm regulation; affect regulation, and staying well (Gumley & Schwannauer, 2006).
45365196|NCT05444049|Device|NEURESCUE device|The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending aorta to redirect blood flow towards the upper body.
45365197|NCT00886106|Drug|Remifentanil|Remifentanil (Ultiva®; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to circa 0.7 µg kg-1 min-1
45482473|NCT01315028|Other|Treatment As Usual|The comparison group is treatment as usual (TAU). This will comprise of the individuals normal psychiatric care and will vary with individual and locality and is therefore not specified.
45752177|NCT04417257|Drug|LAU-7b|LAU-7b will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
45752178|NCT04417257|Drug|Placebo oral capsule|Placebo will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
45845774|NCT05517252|Other|Tele - Yoga|Telehealth interventions with Yoga are called Tele-yoga. Tele-Yoga aims to provide Yoga support to patients at low cost with the same quality and safety as face-to-face
45365198|NCT00886106|Drug|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied intravenously as active placebo at a dose of 15 µg kg-1 min-1 over 5 minutes to mimic typical central nervous side effects of remifentanil
45690439|NCT01380327|Biological|Cockroach Sublingual Immunotherapy (SLIT) - High Dose|Participants are randomized to receive twice-daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume [w/v] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to seven escalating doses, or until the maximum study dose (840 microliters, 1:20 w/v) was achieved.
46050852|NCT04106011|Diagnostic Test|BTACT|Cognition measure: Brief Test of Adult Cognition by Telephone
46050853|NCT04106011|Diagnostic Test|BPI|Pain severity and interference at baseline using the Brief Pain Inventory
46050854|NCT04106011|Diagnostic Test|HADS|Assessment of depression and anxiety with the Hospital Anxiety and Depression Scale
46050855|NCT04106011|Diagnostic Test|SLP9|Assessment of Sleep
45365199|NCT00939978|Drug|rhEPO|recombinant human erythropoietin(rhEPO)
45365200|NCT00889694|Drug|Tripterygium|Tripterygium: 2 capsules per time, 3 times per day for 12 weeks.
45365201|NCT00889694|Drug|Sulfasalazine|Sulfasalazine: 0.75 gram per time, 2 times per day for 12 weeks.
45365202|NCT00889694|Drug|placebo|Placebo: 2 capsules per time, 3 times per day for 12 weeks.
46050856|NCT04106011|Diagnostic Test|NPSI|Assessment of neuropathic components
45365203|NCT04012320|Other|No intervention, observational study|No intervention, observational study
45365204|NCT05278910|Other|Soybean oil + Roasted wheat flour|Assign soybean oil capsule and roasted wheat flour
45365205|NCT05278910|Dietary Supplement|Fish oil + Roasted wheat flour|Assign fish oil and roasted wheat flour
45365206|NCT05278910|Dietary Supplement|Soybean oil + Vegetable and fruit extracts|Assign soybean oil and vegetable and fruit extracts
45365207|NCT05278910|Dietary Supplement|Fish oil + Vegetable and fruit extracts|Assign fish oil and vegetable and fruit extracts
46050857|NCT02877056|Procedure|Endoscopy|Tissue samples taken from tumor and normal colorectal tissue during standard endoscopy before therapy.
46050858|NCT02603029|Other|Placebo cream|Subjects will use placebo cream twice per day for 12 weeks on one half of the face and of the gluteal area.
45690440|NCT01829425|Drug|Anticholinergic medications|The study will use either of two standard, long acting anti-cholinergic medications and dosages. Pharmacotherapy counseling sessions will also be administered over 8 weeks by trained research personnel. Pharmacotherapy counseling sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the medication counselor administers the sessions in a standardized fashion. Pill counts will be performed at the conclusion of the 8 weeks of pharmacotherapy counseling. Subjects will be provided the medication for 1 year.
46050859|NCT02603029|Other|Belinal cream|Subjects will use Belinal cream twice per day for 12 weeks on the other half of the face and of the gluteal area.
46050860|NCT02876744|Other|ophthalmologic examination|ophthalmologic examination including optical coherent tomography with angiography module
46050861|NCT02875886|Drug|Amiloride|Combined with hydrochlorothiazide
46050862|NCT02875886|Drug|Hydrochlorothiazide|Combined with amiloride
46050863|NCT02875886|Other|Low-sodium diet|
45365208|NCT04701203|Combination Product|TransCon PTH|TransCon PTH drug product is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
45365209|NCT04701203|Combination Product|Placebo|Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
45365210|NCT00940212|Drug|AZD2423|oral, single administration
45365211|NCT00940212|Drug|Placebo|oral administration and single dose
45365212|NCT00529035|Drug|Interleukin-2|Dose will vary depending upon when participant enters the trial: Given as a daily injection under the skin for 8 weeks.
45752179|NCT00409825|Drug|17-OHPC|Intra-muscular injection of 250 mg 17-OHPC administered weekly between the second and third trimesters of pregnancy, until time of delivery.
46050864|NCT00793819|Drug|silodosin|α1-adrenergic antagonist
46050865|NCT04109833|Drug|ABT|any antibiotic therapy in the first week of life
46050866|NCT00894387|Drug|Aliskiren|Aliskiren 150 mg and Aliskiren 300 mg
45365213|NCT04421664|Drug|Hydroxychloroquine|200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
45365214|NCT04421664|Drug|Placebo oral tablet|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
45365215|NCT02578043|Drug|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% (Taro Pharmaceuticals Inc.)
46050867|NCT00894387|Drug|Placebo|Placebo
46050868|NCT02839005|Other|Continuous suture with polyglecaprone 25|At the end of surgical procedemento of cesarean delivery , for skin closure continuous suture was performed with polyglecaprone 25
46050869|NCT02839005|Other|Continuous suture with polyamide (nylon)|At the end of surgical procedemento of cesarean delivery , for skin closure continuous suture was performed with polyamide (nylon)
46050870|NCT02836665|Procedure|Telemedicine for dermatological emergency patients|"Study-related photographs of the skin lesion made by a tablet and anamnesis data are uploaded to the hospital information system medico. Those data can directly be processed by the dermatological investigator in charge who enters his diagnosis and his therapy proposal without being on site."
46050871|NCT04249479|Other|CM Temperature (20° C)|CM will be administered at 20° C (room temperature).
45365216|NCT02578043|Drug|Onexton™ Gel|Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) (Valeant Pharmaceuticals LLC)
45365217|NCT02578043|Drug|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
45365218|NCT04037384|Behavioral|Eye yoga|Eye yoga exercises at home given by a trained instructor
45365219|NCT04037384|Behavioral|Passive Reading|Passive reading at home
45482474|NCT02720536|Drug|Deferasirox|Deferasirox FCT will be provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
46050872|NCT04249479|Other|CM Temperature (37° C)|CM will be administered at 37° C (pre-heated).
45365220|NCT00940056|Procedure|Endoscopic ablation of AF|"The procedure is conducted in general anaesthesia. The right chest is entered with three working ports .~After a complete cycle of ablation creating a box lesion in the left atrium, conduction block is tested. A chest tube is placed through the most caudal port and the port incisions are closed. A Reveal loop recorder is then implanted subcutaneously. The patient is extubated and transferred to postoperative care."
45482475|NCT05453032|Device|NeuroConn|A neurostimulation decivse that works be generating weak electric current via Electrodes. These electrodes placed on a specific cerebral location, where the defect assumed to be there) to modulate the neuronal activity. This neuronal modulation does not induce or fire action potential but it facilitate action potentials and cerebral interconnection as well corticolimbic connection)
45690441|NCT01829425|Behavioral|Hypnotherapy|Hypnotherapy will be administered approximately weekly over 8 weeks by certified, trained clinical hypnotherapists. Sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the hypnotherapist administers the hypnotherapy session in a standardized fashion.Subjects will receive or download a digital recording specially prepared for them to for home practice of hypnotherapy sessions.Following the 8 weeks of therapy, subjects will be encouraged to continue to practice self-hypnosis and/or listen to their home practice digital recording and this practice will be tracked for the 1 year duration of the study.
45690442|NCT03796689|Device|Smartphone-linked HBPM and associated app|Participants in the Smartphone-linked arm of the study will receive an Omron 786N Home Blood Pressure Monitor (HBPM) that can be linked to the Omron Connect app via Bluetooth. They will also receive instructions about how to use their device and download the app and will be provided with publicly available guidelines for HBPM. Participants will be instructed to use their device and app to take readings which they can track over time and share with their provider using the app.
46050873|NCT04249479|Other|Weight|The patients' weight is measured prior to scanning by a technician on a weighing scale available in the scanner room.
46050874|NCT02836821|Drug|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
45482476|NCT05727748|Other|Multimodal exercise with augmented reality|The intervention program has a duration of 12 weeks with 3 sessions per week of 60 minutes each. The multimodal group with augmented reality was divided into 4 sub-groups. The session consisted of six stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed). Four stations are the same of the previous group and the other 2 stations are with augmented reality. These 2 stations worked the same cognitive and physical components but through the portable exergame platform for the elderly.
46050875|NCT02836821|Drug|Rifampicin Capsules|rifampicin was administered in the morning 2 hours after breakfast
45690443|NCT03796689|Device|Standard HBPM|Participants in the Standard arm of the study will receive an Omron 785N Home Blood Pressure Monitor (HBPM), instructions about how to use their device and publicly available guidelines for HBPM. They will be instructed to use their device to take readings which they can track over time and share with their provider.
45365221|NCT00940056|Drug|Rate control|Anti-arrhythmic protocol The control group is using a rate-control strategy. All patients keep their anti-arrhythmic/beta-blocker/digoxin medication during the entire follow-up. No attempts are made to rhythm-control the patients, unless subjective symptoms make it necessary.
45365222|NCT00889850|Drug|40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)|40 mg esomeprazole, single dose administration under fasted and fed condition
45365223|NCT00889850|Drug|INexium 40 mg MUPS tablets (AstraZeneca, France)|40 mg esomeprazole, oral single dose administration under fasted and fed condition
45365224|NCT04074317|Drug|PRAM9|SC injection
45365225|NCT04074317|Drug|Regular Insulin + Pramlintide|Separate SC injections
45365226|NCT04074317|Drug|Regular Insulin|SC injection
45690444|NCT05630079|Device|Treatment with Metaneb®|"Every patient of this group receive 3 daily treatments of 20 minutes each, performed at approximately 4-hour intervals.~Each treatment with MetaNeb system consists of four cycles: : 5 minutes of Continuous Positive Expiratory Pressure (CPEP) for lung re-expansion (Cycle I), 5 minutes of Chest High Frequency Oscillation (CHFO) for secretion clearance (Cycle II), 5 min of CPEP (Cycle III), 5 minutes of CHFO (Cycle IV). Treatments are performed by respiratory physiotherapists and the pressure setted was the highest tolerated by the patient. It's associated with the administration of aerosols with 10 ml of saline solution 0.9% and are carried out by connecting the tracheostomy cannula cuffed to the catheter mount."
45845775|NCT05517252|Other|Thoracic Expansion Exercise|Thoracic expansion exercises are deep breathing exercises that focus on inspiration and help to loosen secretions on the lungs. Inspiration is active and usually combined with a three-second, end-inspiratory hold before a passive, relaxed and unforced expiration.
45845776|NCT05508360|Device|PerQdisc Nucleus Replacement System|Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
45845777|NCT05505162|Drug|Zibotentan|Participants will receive two capsules of Zibotentan orally QD from day 6-19.
45365227|NCT00941148|Drug|Insulin Glargin|
45365228|NCT00941148|Drug|NPH insulin|
45365229|NCT00941148|Drug|Insulin detemir|
45365230|NCT00941148|Drug|metformin|metformin (2000 mg/day)
45365231|NCT02541500|Drug|Minocycline|Oral minocycline 200 mg daily will be started on day six of treatment for a period of four months
45845778|NCT05505162|Drug|EE/LNG|Participants will receive two tablets of EE and LNG once on Day 1 and Day 15 as a combined oral dose.
45365232|NCT04073849|Drug|EPOGEN® (epoetin alfa)|Active drug
45365233|NCT04073849|Other|Normal Saline|Placebo
45365234|NCT05280210|Other|PTC drug screening|PTC is an in vitro tumor model, which serves as a structural and functional unit recapitulating the original tumors in genotype, phenotype, and drug response. PTC will be used in drug screening.
45365235|NCT05221203|Behavioral|TR-30|Bodyweight training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
45365236|NCT05221203|Behavioral|TR-45|Bodyweight training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
45365237|NCT03263429|Drug|Glutaminase Inhibitor CB-839|Given by mouth
45365238|NCT03263429|Biological|Panitumumab|Given by vein
46050876|NCT02836587|Behavioral|Balance training|The interventional program will last 8 weeks with the intensity of two 60-minutes lectures a week. Training sessions will be delivered by a physiotherapist to small groups of patients (3-5). Participants will receive individualized exercises which will be focused on main 4 types - stance exercises, gait and transition exercises and strength exercises especially focused on muscle strength of the lower extremities. The difficulty level will be increased progressively after participant's ability to complete each exercise independently (e.g. eyes closed, exercises on balance equipment - wobble board, foam etc., addition of a secondary cognitive task). The training session will consist of a ten-minute warm-up followed by five-minute stretching, 30 minutes of balance training and 15 minutes of stretching and relaxation.
46050877|NCT02834169|Other|Non interventional|Data collection
46050878|NCT00633321|Biological|TA-NIC|TA-NIC vaccine will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
45365239|NCT03263429|Drug|Irinotecan Hydrochloride (phase I only)|Given by vein
45365240|NCT03263429|Other|Laboratory Biomarker Analysis|Correlative studies
45365241|NCT03263429|Other|Pharmacological Study|Correlative studies
45365242|NCT03263429|Device|Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans|During phase II at baseline and day 28 of cycle 1
45365243|NCT00609674|Drug|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray
45365244|NCT00609674|Drug|Placebo|Placebo
45482477|NCT05727748|Other|Multimodal exercise|"The intervention program has a duration of 12 weeks with 3 sessions per week of 60 minutes each. The multimodal group was divided into 2 sub-groups. The session consisted of four stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed).~The session consisted of six stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed)."
45482478|NCT05727748|Other|Control group|The control group continued their daily activities for 12 weeks and did not participate in any new physical activity program during the study.
45845779|NCT05505084|Procedure|Tooth extraction and ridge preservation using different barrier mermbranes|The hopeless and unrestorable teeth are planned for extraction and implant placement.
46050879|NCT00633321|Biological|Placebo|Placebo will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
46050880|NCT02839083|Other|Thoracic Paravertebral group|Thoracic paravertebral block is performed using bupivacaine 0.25% in a total volume of 30 ml
45365245|NCT00940134|Biological|PYY 3-36|0.8 pmol/kg/min x 3 hours
45365246|NCT00940134|Biological|GLP-1|1.0 pmol/kg/min x 3 hours
45365247|NCT00940134|Biological|saline infusion|saline infusion x 3 hours
45365248|NCT00941382|Drug|Sibutramine-Metformin|sibutramine and metformin, 15 mg per day and 850 mg per day, respectively, in a single tablet, for 180 days
45365249|NCT00941382|Drug|Sibutramine|15 mg per day for 180 days
45365250|NCT00941382|Drug|Metformin|Metformin 850 mg per day for 180 days
45365251|NCT03253679|Drug|Adavosertib|Given PO
45365252|NCT00137839|Drug|Erlotinib|
45365253|NCT02542982|Device|tDCS (Endomed 482; Enraf-Nonius B.V.)|non-invasive brain stimulation with pair of electrodes with saline-soaked pads through which the direct current of intensity of 2 mA is delivered
45365254|NCT00941460|Drug|Temozolomide in both arms|initial dose 120 mg/m2 in arm A
45365255|NCT00941460|Drug|Temozolomide in both arms|initial dose 80 mg/m2 in arm B
45482479|NCT03299608|Diagnostic Test|Breath analysis|Spectrometric analysis of exhaled breath as screening for opportunistic respiratory infections
45482480|NCT03299452|Drug|Non Chemotherapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
45482481|NCT03299452|Drug|Chemotherapy and target therapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
45482482|NCT03299452|Drug|Chinese herb medicine|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
45482483|NCT03168438|Drug|Letetresgene autoleucel|Letetresgene autoleucel (GSK3377794) as an IV infusion
45482484|NCT03168438|Drug|Letetresgene autoleucel with pembrolizumab|Letetresgene autoleucel (GSK3377794) as an IV infusion, followed by pembrolizumab every 3 weeks
45482485|NCT03168438|Drug|Fludarabine|Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.
45482486|NCT03168438|Drug|Cyclophosphamide|Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
45482487|NCT03168438|Drug|Pembrolizumab|Pembrolizumab is available as an IV infusion
46050881|NCT02839083|Other|Pecs II group|Ultrasound guided ipsilateral Pecs II block is performed using bupivacaine 0.25% in a total volume of 30 ml
45365257|NCT02542904|Procedure|mesenteric excision|
45365258|NCT04013178|Behavioral|Accentuated eccentric loading + electromyostimulation|An innovative training intervention to optimize muscle strength and muscle mass
45365259|NCT04013178|Behavioral|Conventional resistance training|A conventional approach to resistance training
45365260|NCT00886184|Procedure|Hypothermia.|Induction of pre hospital therapeutic hypothermia.
45482488|NCT03299374|Other|Pilates Intervention|Intervention based on Pilates principles
45482489|NCT03299374|Other|Fall prevention intervention|Intervention based on principles to prevent falls
45482490|NCT03299296|Drug|Rivaroxaban 10 Milligrams|The first group is to be on Rivaroxaban 10 mg with dosage according to the orthopedic approved regimen (10 mg once daily 6-10 hours after the surgery; recommended total duration of therapy: 12 to 14 days; The American College of Chest Physicians (ACCP) recommendation: Minimum of 10 to 14 days; extended duration of up to 35 days suggested.
45482491|NCT03299296|Drug|Enoxaparin 40 Milligrams/0.4 Milliliters Prefilled Syringe|"The other group will be administered the standard of care (SOC) enoxaparin as follows:~Once-daily dosing: 40 mg once daily, with initial dose within 9 to 15 hours before surgery, and daily for at least 10 days (or up to 35 days postoperatively) or until risk of deep venous thrombosis (DVT) has diminished or the patient is adequately anticoagulated on warfarin. The American College of Chest Physicians recommends initiation ≥12 hours preoperatively or ≥12 hours postoperatively; extended duration of up to 35 days suggested."
45482492|NCT02466724|Device|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
45365261|NCT00886184|Procedure|No early hypothermia|Induction of therapeutic hypothermia only once arrived at hospital.
45482493|NCT03137784|Drug|NVA237 (glycopyrronium bromide)|In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
45482494|NCT03137784|Drug|Placebo|In each treatment arm, patient will receive placebo
46050882|NCT02834091|Procedure|Hypnoanalgesia|
46050883|NCT02836743|Drug|Circadin|Slow-release melatonin
46050884|NCT02836743|Drug|Placebo|
46050885|NCT00928512|Drug|Secukinmab|Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
46050886|NCT00928512|Drug|Placebo|Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
46050887|NCT04249089|Behavioral|Relaxation video and pamplet|This group will be asked to watch a video and perform relaxation techniques twice a day following surgery
45482495|NCT02466256|Procedure|Intraocular lens implantation|Intraocular lens implantation
45365262|NCT02542670|Genetic|Whole genome sequencing|At least 50 ng of tumor DNA will be extracted from FFPE samples and/or fresh tissue and used for hybridization capture and NGS using the IlluminaMiSeqDx platform.
45365263|NCT00890240|Drug|JNJ-31001074|
45482496|NCT02466256|Device|Autosert Injector|Motorised injection device for intraocular lens implantation
45482497|NCT02466256|Device|Royale Injector|Manual, plunger type injection device for intraocular lens implantation
45482498|NCT02466256|Device|Monarch III Injector|Manual, screw type injection device for intraocular lens implantation
45482499|NCT01314716|Drug|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
45482500|NCT01314716|Drug|Placebo|Placebo to match AZLI administered via nebulizer three times daily
45365264|NCT00890318|Drug|ABT-072|Powder contents from capsules mixed in an alternative vehicle, for additional information refer to Arm Description.
45365265|NCT00890318|Other|ketoconazole|Tablet, see Arm Description for intervention information.
45365266|NCT00890318|Drug|Placebo|Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.
45365267|NCT00563316|Drug|Panitumumab|The first infusion of panitumumab will occur on Cycle 1 Day 4. On Cycle 2 Day 1, panitumumab will be administered on the same day as irinotecan and every 2 weeks thereafter.
45365268|NCT00563316|Drug|Irinotecan|The first infusion of irinotecan will occur on Cycle 1 Day 1. Irinotecan will be administered on the same day as panitumumab on Cycle 2 Day 1 and every 2 weeks thereafter.
45365269|NCT04037774|Drug|Dexmedetomidine|comparision of different doses of dexmedetomidine used intrathecally
45365270|NCT04037774|Other|placebo|addition of placebo with local anesthetic to create a control group
45365271|NCT00890474|Procedure|Moxibustion of the BL67 acupoint|Moxibustion sessions every day (every other day in hospital, self-administration at home the other day) during a maximum of 14 days. Stopped if cephalic version.
45482501|NCT05727358|Behavioral|Group-based Acceptance and Commitment Therapy|G-ACT treatment in this study comprised 7 sessions of 45-60 minutes and was administered throughout the course of the 4-week long trial.
45482502|NCT03144180|Device|Q-cup|This technology is a different way of collecting umbilical cord blood.
45482503|NCT03299218|Dietary Supplement|SNF (Wawamum)|A monthly ration of 30 sachets of SNF (one 50 gram sachet of Wawamum per child per day) will be provided by LHWs. Each recruited child will receive SNF on a monthly basis for the duration of 18 months during his/her age of 6-24 months.
45482504|NCT03299218|Behavioral|Social and behaviour change communication (SBCC)|SBCC messages will be delivered by LHWs in their monthly routine household visits. Male and female group sessions will be arranged on quarterly basis with the help of health committees.
45482505|NCT03299218|Other|Cash|Cash totaling 1600 rupees per month will be transferred by BISP throughout the study period.
45482506|NCT01344954|Drug|TB-402|Administered intravenously over 10 minutes
46050888|NCT04257318|Other|Vibrating Relaxation Tool|Use of a Vibrating Relaxation Tool in case of pain during pregnancy
45365272|NCT01529736|Procedure|High torque insertion|Osseotite implant placed with high insertion torque forces
45365273|NCT01529736|Procedure|Low torque insertion|Osseotite implant placed with low insertion torque forces
45365274|NCT02542748|Drug|Norepinephrine|norepinephrine injection
45365275|NCT02542748|Drug|Ephedrine|Ephedrine injection
45365276|NCT00941616|Biological|Biostate®|80 IU vWF/kg administered as a bolus intravenous infusion on Day 1 and approximately Day 180
45365277|NCT00941616|Biological|Biostate®|Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
45482507|NCT01344954|Drug|Rivaroxaban|Administered orally as a capsule once a day for 35 days
45482508|NCT01344954|Drug|TB-402|Administered intravenously over 10 minutes
45482509|NCT05728138|Behavioral|CMAP Plus CBT|Culturally Adapted Manual Assisted Problem Solving (CMAP) integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) including 12 sessions delivered over three months. This intervention includes evaluation of the self-harm attempt, psycho-education, crisis skills, problem-solving and simple and thought management
45596553|NCT03529279|Drug|CNG Chemotherapy|"CNG I, IMRT plus oral adjuvant chemotherapy, if EBV-DNA > 0,according to CNG II. CNG II, IMRT + concurrent chemotherapy + oral adjuvant chemotherapy. CNG III, systemic chemotherapy, plus IMRT.~Chemotherapy strategy: Concurrent chemotherapy, 5-Fu + nedaplatin (cisplatin), every 28 days; 5-Fu 500mg/m2. D, civ d1-d5, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1. Systemic chemotherapy, 5-Fu + nedaplatin (cisplatin), every 60 days; 5-Fu (100 - 200 mg/m2. D) civ for 30 days, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1,D28. Aim to achieve CR in imaging.Oral adjuvant chemotherapy, tegafon (400 mg, QID) and Calcium Folinate Tablets (30 mg, QID). Oral 10 days and stop 20 days, 3 months/course. After 6 courses, oral 10 days and stop 50 days, half year/course, 6-7 courses, lasted for 5 years."
46050889|NCT04255368|Other|Water-soluble choline|600 mg choline as choline bitartrate
46050890|NCT04255368|Other|Fat-soluble choline|600 mg choline as phosphatidylcholine
45365278|NCT04037540|Procedure|Operational approach|Operational approach was used to treat the Jones fracture in patients randomized into the respective study arm.
45365279|NCT04037540|Procedure|Conservative approach|Conservative approach was used to treat the Jones fracture in patients randomized into the respective study arm.
45365280|NCT00941694|Behavioral|Self management intervention|Intervention arm will receive 6 group or individual sessions over a 7 week period
45365281|NCT00941694|Behavioral|placebo group|3 phone calls not related to asthma self-management
46050891|NCT04255368|Other|No choline control|No choline
46050892|NCT04257240|Procedure|selective hepatic vascular exclusion|major hepatectomy with vascular control of blood inflow and outflow of the whole liver
45365282|NCT02542592|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
45365283|NCT02542592|Drug|Isotonic Sodium Chloride|Placebo
45365284|NCT00941772|Other|Ultrasonography|Verify nasogastric tube placement with ultrasonography and compare its accuracy with plain radiography
45365285|NCT03178487|Drug|Upadacitinib|Tablet
45690445|NCT05630079|Device|Treatment with IPV®|Each treatment with IPV provides 3 daily treatments of 20 minutes with the high percussion frequency tolerated by the patient. and I/E ratio: 1/1.2. Treatments are performed by respiratory physiotherapists and the pressure setted was the highest tolerated by the patient. It is associated with the administration of aerosols with 10 ml of saline solution 0.9% [-] and are carried out by connecting the tracheostomy cannula cuffed to the catheter mount.
45365286|NCT03178487|Drug|Placebo|Tablet
45365287|NCT02542826|Other|Pulmonary Rehabilitation|Patients will participate in 3 exercise training sessions/wk for a period of 7-12 wks at one of 4 sites in Quebec. Each training session will include 30-45 min of aerobic training (cycling and/or treadmill walking) at a target intensity of 80% of the maximal heart rate achieved during a symptom-limited incremental cycle exercise test performed prior to the pulmonary rehabilitation program; and 20-30 min of strength training exercises.
45365288|NCT04430036|Drug|AGEN1884|A fully human monoclonal Anti-PD-1 Antibody
45365289|NCT04430036|Drug|AGEN2034|A fully human monoclonal Anti-PD-1 Antibody
45365290|NCT04430036|Drug|Cisplatin|Alkylating antineoplastic agent
45365291|NCT04430036|Drug|Gemcitabine|Antimetabolite antineoplastic agent
45365292|NCT00528957|Drug|Tenofovir DF|Tenofovir DF (oral powder or tablet): 300-mg tablets for participants > 37 kg; 8-mg/kg oral powder (up to 300 mg) for participants ≤ 37 kg. During the extension phase, participants whose weight increases to > 37 kg may be switched from the oral powder to the tenofovir DF tablet.
45365293|NCT00528957|Drug|Zidovudine|Zidovudine as prescribed by the investigator prior to study entry (pediatric participants < 30 kg: 1 mg/kg/dose given every 12 hours; pediatric participants ≥ 30 kg: 30 mg twice daily).
45365294|NCT00528957|Drug|Stavudine|Stavudine as prescribed by the investigator prior to study entry (pediatric participants 6 weeks to 12 years of age: 160 mg/m^2 every 8 hours; pediatric participants > 12 years of age: 300 mg twice daily).
45365295|NCT00890630|Procedure|Intracervical Balloon Catheter|Intracervical insertion of an 80cc Double-Balloon Catheter.
45365296|NCT00890630|Drug|Oxytocin|IV Oxytocin infusion, dose dependent on patient response. Start at 2mIU/min, increasing every 30 minutes by 2mIU/min, to max 24mIU/min.
45365297|NCT00890708|Drug|Voriconazole (therapeutic drug monitoring)|dosage adjustment according to trough level of voriconazole in plasma
45365298|NCT00890786|Drug|Temozolomide|"High Grade Glioma Temozolomide during radiotherapy: 90mg/m2/day PO daily (for patients ≤ 18 years of age); 75mg/m2/day PO daily (for patients ≥ 19 years of age); must begin by Day 5 of radiotherapy for a total of 42 days consecutively.~High Grade Glioma Temozolomide during maintenance chemotherapy: 150mg/m2/day PO on Days 1-5."
45365299|NCT00890786|Drug|Bevacizumab|"High Grade Glioma Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Day 22 (± 2 days)and Day 36 (± 2 days) of radiotherapy.~High Grade Glioma Bevacizumab during maintenance chemotherapy:10 mg/kg as a 90 minute infusion on Day 1 (+ 2 days)and Day 15 (± 2 days) of each course.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Days 1 (+ 2 days),15, 29, and 43(±2 days for all 3 doses) of radiotherapy.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during maintenance chemotherapy: 10 mg/kg as a 90 minute infusion on Day 1 (+2 days)and 15 (±2 days)."
45365300|NCT00890786|Drug|Irinotecan|"High Grade Glioma Irinotecan during maintenance chemotherapy:125 mg/m2/day IV over 90 minutes on Days 1 (+ 2 days)and 15 (±2 days) of each course, given no sooner than one hour after temozolomide on Day 1.~Diffuse Intrinsic Pontine Gliomas Irinotecan maintenance chemotherapy: 125 mg/m2/day IV on Day 1 (+2 days)and Day 15 (±2 days)."
45365301|NCT00560508|Drug|Pramipexole Immediate Release|titrated as individually needed (0.25 mg - 4.5 mg daily)
45365302|NCT00560508|Drug|Pramipexole Extended Release|titration as individually needed (0.375 mg -4.5 mg daily)
45690446|NCT01394991|Drug|Epoetin alfa 450 IU/kg once a week|450 IU/kg once a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
45365303|NCT05127759|Drug|HLX208|HLX208 450mg bid po
45365304|NCT00890864|Other|Invitation for breast screening|Invitation for breast screening to women in different age groups
45365305|NCT00890942|Drug|naloxone|naloxone 0.4mg.(1 ml) intramuscular
45365306|NCT00890942|Drug|normal saline|normal saline 1 ml IM
45690447|NCT01394991|Drug|Epoetin alfa 150 IU/kg 3 times a week|150 IU/kg 3 times a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
45365307|NCT05125887|Other|Questionnaire|Patients diagnosed positive for COVID on an outpatient basis will respond to a questionnaire by mail, at 24 month of diagnosis. This questionnaire will make it possible in particular to collect intercurrent events (hospitalization, emergencies, etc.).
45365308|NCT04037852|Device|robotic assisted nipple sparing mastectomy|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM, had been applied in the surgical treatment of early breast cancer or risk reducing mastectomy. R-NSM, which incorporated 3-dimensional (3D) imaging system and flexibility of robotic arm and instruments, was reported to have the potential to overcome the technique difficulty of E-NSM.
46050893|NCT04257240|Procedure|semielective hepatic vascular exclusion|major liver resection by selectively clamping the portal and hepatic vessels only of the lobe harboring the tumor
46050894|NCT00610818|Other|Palifermin|day -14, -13, -12 before transplant and then day 0,1,2 after transplant
46050895|NCT04255290|Other|Leg Squat Lounge|The players assigned to the experimental group will receive an intervention through plyometric and eccentric hamstring exercises
46050896|NCT04255290|Other|Control group|The subjects included in the control group will perform an eccentric work protocol
46050897|NCT04255446|Device|Thora3DiTM|Not international
46050898|NCT04255680|Diagnostic Test|Buccal Swabs and Blood Draws|Buccal Swabs - Frataxin & specific RNA markers Blood Draws - Lipid panel, Uric Acid, Protein Marker Analysis and PAX Gene RNA Analysis
46050899|NCT00787891|Drug|rabeprazole|0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
46050900|NCT00787891|Drug|rabeprazole|1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
46050901|NCT00892437|Drug|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
46050902|NCT00892437|Drug|RTV|Ritonavir (RTV) 100 mg soft gelatin capsule administered orally once daily
45365309|NCT04037852|Procedure|Endoscopic assisted nipple sparing mastectomy|E-NSM, which is performed through small axillary and/or peri-areolar incisions, was reported to be associated with small inconspicuous incision and good cosmetic outcome. Conventional E-NSM was performed with two separate incisions over axilla and peri-areolar regions. E-NSM with areolar incision, just like NSM with areolar related incision (NAC ischemia/necrosis rate: range 7%-81.8%), was associated with increased NAC ischemia/necrosis (reported ranged: 9.1-19%). New technique modifications of E-NSM were emerging focusing on single axillary incision NSM, which spare the peri-areolar incision and thereby decrease the compromise of bloody supply from mastectomy skin flap, was reported to have low NAC necrosis rate (0%).
45365310|NCT04037852|Procedure|Conventional nipple sparing mastectomy|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy, was increasingly performed in breast cancer patients due to better cosmetic outcome, higher patient satisfaction, and maintained oncologic safety.
45482510|NCT05727280|Behavioral|Progressive Relaxation Exercise Practices|The intervention planned within the scope of the research are the Progressive Relaxation Exercise application. Patients in the intervention group undergoing open heart surgery will be given training on progressive relaxation exercise in the patient's room the day before the surgery. Correct breathing techniques will be taught and the relaxation exercises will be performed by using audio recordings. Afterwards, the relaxation exercise will be provided to the patient to practice the progressive relaxation exercise with mp3 accompaniment. After open heart surgery, progressive relaxation exercise will be applied to the patient on the 1st, 2nd and 3rd days of his admission to the service. The patient will be asked to perform the progressive relaxation exercise twice a day, once during the day and once in the evening.
45690448|NCT01394991|Drug|Epoetin alfa 450 IU/kg once a week (QW)|450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
45690449|NCT01394991|Drug|Epoetin alfa 150 IU/kg 3 times a week (TIW)|150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
45690450|NCT04407663|Other|Telemedicine to remote outpatient visit in bariatric patient|Patients that referred for the first time to our bariatric center were investigated for anthropometric, psychological and instrumental data in order to evaluate the eligibility for a future bariatric procedure. In established patients, eligibility for tele-consultation was evaluated by three experienced physicians, consulting the stored patients' data. All included patients provided oral informed consent. Patients approached the virtual visit with their personal smart devices, desktop or laptop computer. Medical counselling was performed using a desktop or laptop computer from the Hospital or home in a smart working modality. The video call was carried out using Skype platform by Microsoft®; any document drawn up by the physician was saved as pdf using the Cute Professional™ PDF software, that allows to add passwords and set security options to protect the patients' data.
45365311|NCT00941850|Procedure|Upgrade to triple ventricular site CRT|Patients in this arm will continue to receive CRT via the original unit, but some will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced).
45365312|NCT04963179|Device|Womed Leaf|"Womed Leaf™ device is composed of a uterine anti-adhesion film pre-loaded inside a flexible inserter.~Womed Leaf™ is inserted in the uterine cavity by the gynecologist surgeon as a film folded into a 5 mm diameter flexible inserter. Once released, the film will unfold and swell into the uterine cavity to keep uterus walls separated during approximately 5 days. It is degraded and discharged naturally through the cervix and vagina in less than 30 days."
45365313|NCT04938986|Diagnostic Test|IMMUNOSCORE®|recommendation for patient care according to the result of the IMMUNOSCORE®
45365314|NCT00942006|Drug|doxycycline|100 mg bid, 14 days
45365315|NCT00942006|Drug|ceftriaxone|2g x 1 iv, 14 days
45365316|NCT00886418|Drug|muscle relaxant|muscle relaxant administration throughout anesthesia
45365317|NCT00886418|Drug|normal saline|no muscle relaxant throughout anesthesia (normal saline infused as a placebo)
45690451|NCT05632653|Procedure|CTO-PCI|Percutaneous coronary intervention (PCI) of a coronary chronic total occlusion (CTO) (CTO-PCI) in patients with systolic heart failure (LVEF <50%).
46050903|NCT00892437|Drug|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
46050904|NCT00892437|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
46050905|NCT00892437|Drug|COBI placebo|Placebo to match COBI administered orally once daily
45365318|NCT00942240|Drug|ACU-4429|administered orally once a day for 14 days
45365319|NCT00942240|Drug|matching placebo tablet|administered orally once a day for 14 days
45365320|NCT05398185|Behavioral|WiseApp|The Intervention group will receive the WiseApp that delivers medication adherence reminders
46050906|NCT00892437|Drug|RTV placebo|Placebo to match RTV administered orally once daily
45365321|NCT02542124|Biological|NM-IL-12 and TSEBT|The LD-TSEBT treatment will start on Day 1 of the study. NM-IL-12 will be administered subcutaneously.
45365322|NCT00942318|Drug|Detemir insulin, Aspart insulin, Metformin|Insulin doses adapted by patients according to self monitoring blood glucose results.
45365323|NCT04037618|Drug|[14C]-EYP001a|Oral drinking suspension
45365324|NCT00942396|Device|Full Field Digital Mammogram (Planmed Sophie Nuance)|Full Field Digital Mammogram
46050907|NCT04108585|Procedure|HFO therapy|HFO therapy from mechanical ventilation
46050908|NCT04108585|Procedure|CPAP therapy|CPAP therapy from mechanical ventilation
46050909|NCT02838537|Drug|Exposure to Triptan|
45365325|NCT00891098|Behavioral|Imaginal exposure|7 individual sessions of imaginal exposure of trauma memories according to the prolonged exposure treatment manual
45365326|NCT00891098|Behavioral|Imagery rescripting|7 individual sessions of imagery rescripting of trauma memories according to the imagery rescripting and reprocessing therapy manual
45365327|NCT04819269|Drug|Tivanisiran sodium ophthalmic solution|1 drop in the affected eye(s) once daily
45365328|NCT04819269|Drug|Vehicle ophthalmic solution|1 drop in the affected eye(s) once daily
46050910|NCT02838537|Drug|Exposure to Ergot|
46050911|NCT04108507|Procedure|posterior branch block of spinal nerve|posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP) operation
45482511|NCT05367076|Behavioral|Web-based Aerobic Exercise Program|"Community based FTTs will use a web-based platform to deliver a 12-week exercise training program (120-minute group sessions of aerobic activity 3 times/week). Each session will include:~Warm-up activities~Aerobic activities and fitness training in a game-like fashion~Organized sports/games~Cool down activity~Snack/reward time"
45365329|NCT00944580|Biological|MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine|A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
45365330|NCT05280054|Drug|AV-101|360 mg capsules
45365331|NCT05280054|Drug|Probenecid|1000 mg oral
45365332|NCT00891254|Device|Implant of a prosthetic mesh|A prosthetic mesh will be implanted either intraperitoneally or in the on-lay (supra-fascial) position depending on the arm of the study
45365333|NCT00942474|Device|Facilitate nerve stimulation lead placement with the nerve access tool|
45365334|NCT03999099|Drug|Suvorexant 20 mg|Suvorexant at a high dose (20 mg)
45365335|NCT03999099|Drug|Suvorexant 10 mg|Suvorexant at a low dose (10 mg)
45482512|NCT05414786|Biological|eOD-GT8 60mer mRNA Vaccine (100µg)|"2 doses eOD-GT8 60mer mRNA Vaccine (100µg), 2 vaccinations, 8 weeks apart~No control group. There is no blinding and no randomization in this open label study"
45482513|NCT05329402|Device|Lung cancer surgery|Only the brand of electric cutting stapler used by different groups was different, and the rest were treated according to routine treatment
45482514|NCT01352832|Other|Interactive DVD|"An interactive DVD (How To Talk To Your Doctor about NSAIDs, HTTTYD-NSAIDs) that presents culturally appropriate stories through which a viewer can learn risk factors for adverse effects related to NSAIDs; and communication behaviors for talking about NSAIDs with their doctor."
46050912|NCT02836509|Drug|Paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes.
46050913|NCT02836509|Drug|Ibuprofen|800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
46050914|NCT00792103|Drug|NP101|NP101 study patch 4 hour application
46050915|NCT02836197|Behavioral|Communication skills training|The general aim of the communication skills training program is to help physicians learn effective communication skills in contexts of high uncertainty. The training will last 30 hours, will be spread over 4 months. The training will be conducted by group of 3 subjects. The training will include mainly role-plays, theoretical information and modeling techniques. A training manual has been developed to increase content standardization and reduce potential group or trainee biases. The role-plays will be based on clinical cases brought up by the participants.
46050916|NCT04108663|Behavioral|Effect of tDCS on cognitive control task performance|Added verum or sham tDCS while working on a cognitive control task.
46050917|NCT05306379|Drug|Simvastatin|Oral dose 40 mg
45365336|NCT03999099|Drug|Placebo oral tablet|Placebo
45365337|NCT03962790|Device|1-DAY ACUVUE® MOIST|etafilcon A contact lenses made with a new manufacturing technology
45365338|NCT03962790|Device|1-DAY ACUVUE® MOIST|etafilcon A contact lenses made with the current manufacturing technology
45365339|NCT05362773|Drug|MGD024|MGD024 is a CD123 x CD3 bispecific DART® molecule designed to target CD123-expressing leukemic cells for elimination by CD3-expressing T lymphocytes.
45365340|NCT05323695|Behavioral|Depression Screening Intervention|All participants will be screened for depression using PHQ-2 and PHQ-9. Those screened positive for PHQ-2 but decline further screening with PHQ-9 will be assisted for further assessment or care. Those with mild to severe symptoms (score of 7 or higher on PHQ-9) will be assisted for further assessment or care with a psychiatrist.
45365341|NCT04013022|Behavioral|Exercise History|The groups will be divided based on their exercise history
45365342|NCT01007799|Dietary Supplement|vitamin D placebo|12 weeks of placebo
45365343|NCT01007799|Dietary Supplement|Vitamin D|12 weeks supplementation based on serum vitamin D levels
45365344|NCT01007877|Other|Red Bull Energy drink|During a 15 minute break, subjects consume 250 ml of Red Bull® Energy Drink or placebo. Before and after the break, a 2 hour driving test is scheduled.
45365345|NCT00609518|Drug|pemetrexed|500 mg/m^2 intravenous infusion on day 1 of each 21-day cycle. Number of Cycles: Until progression or to a maximum of 6 cycles.
45365346|NCT00609518|Dietary Supplement|Folic acid|350-1000 micrograms taken orally for at least 5 daily doses during the 7-day period prior to the first dose of pemetrexed then continues daily throughout treatment until 3 weeks after the last dose of pemetrexed.
45365347|NCT00609518|Dietary Supplement|Folic Acid|350-1000 micrograms taken orally for two consecutive daily doses of folic acid the day before and the day of the first dose of pemetrexed the continues throughout treatment and for 3 weeks after the last dose of pemetrexed.
45365348|NCT00609518|Dietary Supplement|Vitamin B12|1000 micrograms intramuscular injection of vitamin B12 during the week prior to the first dose of pemetrexed then further injections given approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.
45365349|NCT00609518|Drug|dexamethasone|4 mg taken orally [or equivalent] twice per day the day before, the day of, and the day after the first day of pemetrexed. Continue to give dexamethasone twice per day the day before, the day of, and the day after each dose of pemetrexed.
45365350|NCT00609518|Drug|dexamethasone|4 mg taken orally [or equivalent] twice per day on the day of the first dose of pemetrexed. Continue to give dexamethasone twice per day on the day of each dose of pemetrexed.
45482515|NCT01352832|Other|Usual Care|Usual Care
45482516|NCT01347918|Device|19F capsule|Two 19F capsules, one filled with hexafluorobenzene (HFB) and the other filled with perfluoro-15-crown-5-ether (PCE) will be administered orally together with 100 ml of water.
45365351|NCT01008033|Drug|IDP-108|Topical application once a day for 48 weeks
45365352|NCT01008033|Drug|Vehicle|Topical application once a day for 48 weeks
45365353|NCT01008111|Drug|Dermabond|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
45365354|NCT01008111|Drug|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
45482517|NCT01347918|Dietary Supplement|sterculia|7g of sterculia will be ingested over one week together with the normal breakfast.
45690452|NCT01829347|Biological|ELAD|ELAD is an extracorporeal system that draws blood from the subject via a dual-lumen catheter placed in a large vein, and then separates the plasma fluid (ultrafiltrate) from cellular components using a specifically-designed ultrafiltrate generator cartridge. While the cellular components are returned to the subject via the venous access, the ultrafiltrate is circulated at a high flow rate through the four metabolically-active ELAD cartridges which contain cloned, immortalized human hepatoblastoma cells (VTL C3A cells) derived from a subclone of the human hepatoblastoma cell line HepG2.
45482518|NCT05727124|Device|Poul Gjessing|maxillary canine retraction
45690453|NCT01829347|Other|Standard of Care treatment|Standard of care treatment is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
45845780|NCT05504304|Procedure|open reduction and internal fixation plus primary subtalar arthrodesis|they will be scheduled to surgery after resolution of the edema and appearance of wrinkle sign. Lateral position and lateral extensile approach will be used. A 4 mm schanz will be inserted in the calcaneal tuberosity from lateral side to control varus and to restore calcaneal height. Lateral wall of the calcaneus will be lifted keeping it attached inferiorly. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. tricortical iliac bone autograft will be inserted the subtalar joint. A lateral nonlocked plate will be applied to reduce the lateral wall blow out and broadening then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
46050918|NCT05306379|Drug|Voclosporin|Oral dose 23.7 mg twice daily
46050919|NCT05304663|Drug|Onfekafusp alfa|Patients will be treated with 10 µg/kg L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26
46050920|NCT05304663|Drug|Lomustine|"Arm 1: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (60 mg/m2 and 75 mg/m2) on Day 1 and Day 22 (taken in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.~Arm 2: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (90 mg/m2 and 110 mg/m2) on Day 5 (in the evening after infusion of L19TNF) of a 42-day cycle for up to a maximum of 6 cycles."
45365355|NCT00886496|Biological|recombinant human mannose-binding lectin|
45482519|NCT05727124|Device|T loops|T loops
45482520|NCT01347996|Drug|histamine dihydrochloride and IL-2|Ceplene 0.5 mg subcutaneously twice daily and IL-2 1 µg/kg [16,400 IU/kg] body weight twice daily for 10, 21 day cycles
45482521|NCT02421718|Radiation|Radiotherapy|
45482522|NCT05300074|Other|Inspiratory Muscle Training|IMT is performed with an IMT Threshold flute that can be adjusted according to the MIP. The training resistance start at 60% MIP and is calculated weekly and end (if tolerated) at 80 % MIP.
45482523|NCT01345032|Other|Home visit|Patients and their homecare helper will receive visits from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the visits is follow up on the individual diet plan distributed at discharge and supply dietary advice.
45365356|NCT00884858|Drug|Maraviroc|Maraviroc is administered BID according to the other drugs within HAART; dosage ranges from 150 mg to 600 mg bid.
45365357|NCT05272293|Biological|NK cell infusions|Three doses of expanded haploidentical NK cells (30-100 x 10^6 cells /kg).
45365358|NCT00891332|Drug|S-1 plus LV (The combination therapy of S-1 and Leucovorin)|S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
45365359|NCT02541344|Device|Dose 1 of IQP-VV-102|Dose 1 (D1) group will take 2 tablets with active ingredients and 2 placebo tablets.
45365360|NCT02541344|Device|Dose 2 of IQP-VV-102|Dose 2 (D2) group will take 4 tablets with active ingredients.
45365361|NCT02541344|Device|Placebo|"Placebo group will take 4 placebo tablets.~The placebo is designed to be identical to IQP-VV-102."
45365362|NCT00609362|Drug|Rosiglitazone|one tablet of rosiglitazone 8 milligrams per day for 14 weeks
45365363|NCT00609362|Drug|Placebo pill|One encapsulated placebo pill a day for 14 weeks
45482524|NCT01345032|Other|Telephone consultation|Patients and their homecare helper will be contacted on telephone from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the telephone contact is follow up on the individual diet plan distributed at discharge and supply dietary advice.
45365364|NCT02541266|Other|Questionnaire|A short questionnaire (9 questions) will be given to the participants to complete.
45482525|NCT01348074|Drug|Double dose|For each individual the dose on Day 1 and Day 2 will be twice the one normally taken
45482526|NCT01352910|Device|rTMS|120 pulses 0.2 Hz
45365365|NCT04038008|Drug|Fluconazole|Fluconazole is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 200 mg of fluconazole.
45365366|NCT04038008|Drug|Diflucan®|Diflucan® is manufactured by Fareva Amboise, France (MAH: PFIZER PHARMA PFE GmbH, Germany). Each hard capsule contains 200 mg of fluconazole.
45482527|NCT01352910|Device|Sham rTMS|120 pulses 0.2 Hz
45482528|NCT01352988|Drug|Fumaric acid esters|Starting from 1 tablet Fumaderm® initial per day, with titration up to 6 tablets Fumaderm® per day; in case of side effects, the dose will be adapted to the highest tolerable levels
46050921|NCT04109755|Drug|Pembrolizumab|5x5 Gy radiotherapy in 1 week, 4 cycles of Pembrolizumab (200 mg every three week), surgery
46050922|NCT04248387|Drug|Toripalimab|Toripalimab, intravenous drip infusion, a dose of 3 mg / kg once every 2 weeks for a total of two cycles
45365367|NCT05278832|Drug|QLS31905|QLS31905 injection
45365368|NCT00886574|Drug|Cilostazol|Cilostazol 200 mg (50 mg 2T twice per day)
45365369|NCT00886574|Drug|Aspirin|100 mg once a day
45365370|NCT00886652|Other|Aerobic exercise program|Three weekly sessions, with an interval of one day between each, lasting 60 minutes each, and divided into three separate stages: - A 10-minute warm-up (stretching and low intensity aerobic exercises such as slow, gradual walking); - 40 minutes of aerobic exercise on an electric treadmill, with the work intensity maintained at a 60% to 80% of the maximum heart rate; - 10 minutes of winding down and relaxation (stretching exercises, low energy expenditure aerobics and relaxation techniques).
45365371|NCT00891566|Procedure|Immobilization|compared the healing status for 8 weeks of immobilization with the conventional 4 weeks of immobilization after rotator cuff repair
45365372|NCT00885014|Behavioral|CBT|Telephone cognitive-behavioral therapy
45365373|NCT00885014|Behavioral|EAP|Employees Assistance Program
45365374|NCT00611858|Drug|Cetuximab|
45365375|NCT00611858|Drug|5-Fluorouracil|
45365376|NCT00611858|Radiation|Radiation|
45365377|NCT00137449|Drug|SU011248|37.5 mg once daily on a continuous daily dosing schedule. Study medication continued as long as patient was obtaining clinical benefit, or until significant toxicity, or withdrawal of consent, for up to 1 year on study.
45365378|NCT00886730|Behavioral|Simple Card|"Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover."
45365379|NCT00886730|Behavioral|Patient Centered Brochure|"Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email."
45482529|NCT02466802|Drug|Regorafenib|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors. Regorafenib Administration and Treatment Schedule. Regorafenib will be taken orally once daily for the first 21 days of each 28-day cycle. Regorafenib will not be taken on the last 7 days of each cycle. Patients will be instructed as follows: Take regorafenib once daily with a low fat meal that contains less than 30% fat. Take the regorafenib tablets at about the same time each day. Swallow the tablets whole.
45482530|NCT02466802|Drug|Sildenafil Citrate|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors.Sildenafil Administration and Treatment Schedule. Sildenafil will be taken orally once daily at the same time the regorafenib dose is taken for the first 21 days of each 28-day cycle. Sildenafil will not be taken on the last 7 days of each cycle.
45482531|NCT01353066|Drug|Intensive Medical Treatment|
45482532|NCT01353066|Other|IMM+Roux-en-Y Gastric Bypass (RYGBP)|
45690454|NCT01394523|Drug|Bupivacaine|0.25% or 0.5%
46050923|NCT02838693|Procedure|Not applicable. This is an observational study.|Not applicable. This is an observational study.
46050924|NCT04248309|Drug|intramuscular progesterone 20-40mg from D3 until pregnancy test|serum progesterone <7.24ug/L, followed by randomized A1: plus additional treatment（intramuscular progesterone 20-40mg from D3 ）
46050925|NCT00892281|Drug|doxycycline (Oracea®) 40 mg modified release as monotherapy|Take once daily in the morning
46050926|NCT00892281|Drug|doxycycline (Oracea®) 40 mg modified release as add-on therapy|Take once daily in the morning
46050927|NCT02836275|Other|Diffusion/Perfusion-weighted Magnetic Resonance Imaging|
46050928|NCT02836353|Drug|Somatostatin|Single dose of short acting Somatostatin (100mcg) pre Oral glucose tolerance test
46050929|NCT02836353|Drug|Rifaximin|1 week course of 400mg three times daily (TDS) pre Oral glucose tolerance test
45482533|NCT01348230|Other|Urine samples|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
45482534|NCT01348308|Drug|Maraviroc (Celsentri)|"Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Maraviroc at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks."
45482535|NCT01348308|Drug|Placebo|"Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Placebo at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks."
45690455|NCT01857973|Device|Hybrid Closed Loop|The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.
46050930|NCT05333757|Other|Questionnaire|Adults with spinal deformities were asked to complete two questionnaires assessing quality of life
46050931|NCT02836431|Drug|Dexmedetomidine 1mcg/kg Intranasal|DEX 1 mcg/kg Intranasal
46050932|NCT02836431|Drug|Dexmedetomidine 2mcg/kg Intranasal|DEX 2 mcg/kg Intranasal
46050933|NCT02836431|Drug|Dexmedetomidine 1mcg Intravenous|DEX 1 mcg/kg Intravenously
45365380|NCT00886730|Behavioral|Physician's endorsement|Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
45365381|NCT00886808|Drug|iCo-007 Intravitreal Injection|single dose iCo-007 Intravitreal Injection
45482536|NCT04078386|Biological|Placebo|Patients received the test group Placebo weekly administered subcutaneously for 24 times.
45482537|NCT04078386|Biological|RC18 240 mg|Arm Description:Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.
45482538|NCT04078386|Biological|RC18 160 mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.
45482539|NCT04074174|Drug|NNC0174-0833|NNC0174-0833 administered s.c. (subcutaneously, under the skin) once weekly for 12 weeks
45482540|NCT04074174|Drug|Oral contraceptive (OC) tablets|1 tablet daily on days 1-8 and days 79-86
45482541|NCT04074174|Drug|Acetaminophen|Single dose of acetaminophen as part of a standardised meal on day 1 and day 79
45482542|NCT03620370|Drug|Normobaric oxygen therapy|In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should in Pre-hospital or emergency room as early as possible after diagnosed ischemic stroke and uninterrupted during other treatments including mechanical thrombolytic therapy and standard clinical treatment.
45690456|NCT04304469|Other|surveys|delivery of the survey at a domestic violence consultation
45690457|NCT04304469|Other|follow-up|follow-up of women 6 months after their consultation
45752180|NCT00409825|Procedure|Blood Draws|10 cc of blood will be drawn prior to the fifth weekly administration of 17-OHPC during second trimester of pregnancy, and then once daily for seven consecutive days post-dose. 10 cc of blood also will be drawn prior to weekly administration of 17-OHPC from sixth weekly dose in the second trimester until the last scheduled dose in the third trimester. Prior to this last scheduled dose, 10 cc of blood will be drawn, as well as once daily for seven consecutive days post-dose.
45752181|NCT02104427|Drug|TG-0054 combined with G-CSF|
46050934|NCT02833779|Other|Individual exercises|
46050935|NCT02833779|Other|Group exercises|
46050936|NCT02833545|Device|Ozone gas|Injection of ozone gas intra articularly
46050937|NCT02833545|Drug|Steroid injection|Injection of steroids (diprospan) intra articularly
45752182|NCT03832803|Behavioral|Empty bladder|No drinking protocol.
46050938|NCT04250181|Other|RF ablation of atrial fibrillation|Comparison of standard, 40W and 50W RF energy setting for ablation of atrial fibrillation
46050939|NCT05326425|Drug|lazertinib(YH25448)|- lazertinib 240mg(3tablets, 80mg/1tablet), once a day, oral, before disease progression
46050940|NCT02836041|Behavioral|questionnaires|"Pre-hospital sleep questionnaire completed (Brief Infant Sleep Questionnaire (BISQ)7 in children 0-3 years old; Children's Sleep Habits Questionnaire (CSHQ)8 in children 4 years and older). Subsequent Day(s):~In-hospital sleep questionnaire completed between one and three times per subject (Sleep at MSK questionnaire (SAM), adapted from Sleep in a Children's Hospital (SinCH)9 by Dr. Lisa Meltzer). (Patients will be observed for up to 3 consecutive nights in total)."
46050941|NCT02836041|Device|actigraph|This device reliably measures sleep by monitoring the child's motion.
46050942|NCT00784693|Biological|Tanezumab|15 mg IV single dose
46050943|NCT00784693|Drug|Placebo|Placebo IV single dose
46050944|NCT02835885|Device|Digitmer High Voltage Stimulator model DS7A TENS unit|
46050945|NCT00893763|Procedure|Pre-intubation CHX|Oral application of 5 ml CHX gluconate 0.12% solution pre-intubation, and 5 ml CHX gluconate 0.12% solution twice a day following intubation.
46050946|NCT00893763|Procedure|Control|No pre-intubation intervention, 5 ml CHX gluconate 0.12% solution twice a day following intubation
46050947|NCT04105933|Other|CS-CBT|Culturally sensitive Cognitive Behavioural Therapy was delivered individually, focused on potential cultural beliefs and attitudes that might collide with core values of CBT.
46050948|NCT04105933|Other|CBT|CBT was delivered at an individual level, dealing with thoughts, feelings and behaviours in the present. Thoughts are identified and then challenged, to make them more objective and rational.
46050949|NCT00915811|Drug|Fludarabine|Fludarabine 30mg/m2 intravenously daily on days -9 to -5 inclusive of stem cell infusion.
46050950|NCT00915811|Drug|Busulphan|Busulphan 0.8mg/kg intravenously 6 hourly on days -4 and -3 of stem cell infusion.
45482543|NCT04752826|Drug|BI-1808|BI-1808, a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets TNFR2 administered at different dose [Phase I, Part A] and at Recommended Dose for Part B [Phase I, Part B and Phase IIa] by intravenous (IV) infusions every 3 weeks.
45482544|NCT04752826|Drug|Pembrolizumab 25 Mg/mL Solution for Injection|Pembrolizumab a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
45482545|NCT01348386|Drug|Hydroxide Potassium|Treatment will consist of the application of topical 10% or 15% KOH in an aqueous solution for the two treatment groups, compared to a placebo-treated control group. Topical Application.
45690458|NCT05632575|Behavioral|Virtual Promotoras Program|"Participants will receive a unique participant code from the virtual promotoras (i.e., patient educators and navigators), to access the VIP mobile phone app intervention. This will give them access to the three main components of the VIP intervention:~Educational Modules (8 evidence-based educational modules made by the VPs),~Sexual and Reproductive Health Plan (SRHP): Quiz-style instrument to help the participant set goals for her sexual health and develop a set of questions to ask her provider.~Virtual Promotora's (VP) chat room.: Opportunity for participant to ask any questions that she may have about sexual health (SH) or sexual healthcare access (SHCA), refine her SRHP. The VP will also help her make her appointment for her clinical visit with one of the local free clinics which do not require insurance and are youth-friendly, and practice having the conversation that she wants to have with her clinical provider."
45690459|NCT04407273|Drug|observational|observational study
45690460|NCT05632497|Biological|Stool sample|Stool sample
46050951|NCT00915811|Drug|Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme|Thymoglobuline will be given intravenously over a minimum of 6 hours for the first two doses and 4 hours for the subsequent doses. Acute side effects of ATG appear to be reduced if a very low dose is given for the first injection. Thymoglobuline 0.5mg/kg iv on day -4, 1.5mg/kg/day on day -3; and 2mg/kg/day iv on day -2 to -1 inclusive.
46050952|NCT00915811|Procedure|Haematopoietic stem cell infusion|The source of stem cells will be PBSC wherever possible. Patients whose donors decline or are unable to donate PBSC will be transplanted with marrow cells.
46050953|NCT00892047|Drug|venlafaxine XR plus aripiprazole|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
46050954|NCT00892047|Drug|venlafaxine plus placebo|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
46050955|NCT05549011|Other|PENG Block|PENG block for analgesic purposes performed before hip surgery
46050956|NCT05549011|Other|SIFI compartment block|SIFI compartment block for analgesic purposes performed before hip surgery
46050957|NCT05549011|Diagnostic Test|Numeric Rating Scale|Self-reported pain intensity score between 0-10
46050958|NCT05549011|Diagnostic Test|Angle of sitting|Measurement of sitting angle in degrees with a protractor
46050959|NCT02602561|Dietary Supplement|HMB|
46050960|NCT02602561|Dietary Supplement|Placebo|
45482546|NCT01348386|Drug|Placebo|
45482547|NCT03620292|Drug|Bevacizumab-IRDye800CW|Intravenous administration of Bevacizumab-IRDye800CW prior to surgery for hilar cholangiocarcinoma
46050961|NCT02835729|Drug|Idarubicin|Chemotherapy
46050962|NCT02835729|Drug|Cytarabine|Chemotherapy
45482548|NCT03620292|Device|near infrared (NIR) fluorescence imaging|Intraoperative NIR fluorescence imaging of hilar cholangiocarcinoma, lymph nodes, resection margins, resection specimens
45690461|NCT05363553|Dietary Supplement|Infant formula based on whole goat milk|Infant formula based on whole goat milk, nutritionally suitable for infants aged 0-6 months
46050963|NCT02835729|Drug|Indoximod Freebase|IDO pathway inhibitor
46050964|NCT02835729|Drug|Indoximod HCL F1|IDO pathway inhibitor
46050965|NCT02835729|Drug|Indoximod HCL F2|IDO pathway inhibitor
46050966|NCT02835651|Dietary Supplement|Palmitic acid|Experimental products are enriched with C16:0
46050967|NCT02835651|Dietary Supplement|Stearic acid|Experimental products are enriched with C18:0
45482549|NCT01353300|Genetic|DNA analysis|
45482550|NCT01353300|Genetic|cytogenetic analysis|
45690462|NCT05363553|Dietary Supplement|infant formula based on cow milk proteins|Infant formula based on cow milk proteins, nutritionally suitable for infants aged 0-6 months
45690463|NCT05367297|Diagnostic Test|Coronary CT Angiogram|A computerized tomography (CT) coronary angiogram is non-invasive imaging test that looks at the arteries that supply blood to your heart.
45690464|NCT01857583|Drug|15mg DU-176b|
45365382|NCT00891644|Other|Case Management|"Clinical personnel at each AMTU site may work with other personnel from organizations authorized to have access to personal health information to identify clients identified as HIV positive within the past 6 - 18 months.~Initial contact will be made by persons at source organizations who are authorized to have access to personal health information. Persons so authorized will explain the nature of the research study and request permission from the client for subsequent contact by research personnel from the AMTU site. If permission for contact is received, research personnel at each site will attempt calls as specified by the potential participant or at random times (before 12:00 pm; between 12:00 - 4:00 pm; and between 4:00 - 10:00 pm) for no more than 10 attempts."
45365383|NCT00891644|Other|Snowball sampling|"Snowball sampling assumes that social networks of HIV sero-positive persons in treatment may overlap with those of HIV sero-positive persons not in treatment.~When a site is assigned to identify HIV positive adolescents not in care by snowball sampling, all HIV positive persons in care at the site will be invited to refer other adolescents known to them as HIV positive, but not in care, for possible participation in the study.~Printed information containing a brief description of the research in English and in Spanish and contact information of site study personnel will be provided to in-care adolescents at the site for distribution to those known HIV positive adolescents who are not in care."
46050968|NCT02833623|Behavioral|Short-message-based Re-education|
46050969|NCT02833623|Behavioral|conventional education|
46050970|NCT02838303|Other|Organophosphate|Chlorpyrifos 50% plus cypermethrin 5%, WHO Class II: Moderately hazardous
45365384|NCT00891644|Other|Referral Lists|AMTU staff will develop lists of potential participants at their sites who have had an initial HIV-related health care visit but not received additional visits within the 12 mos prior the list (or before protocol screening) or have completed initial and follow up visits but dropped out of care for 12 or more mos. Back-up lists will be made of potential participants who have gone 9-12 mos and 6-9 mos without a visit. Clinical staff at each AMTU may work with staff from other organizations authorized to access personal health information to find potential participants. 1st contact will be made by persons at source organizations who are authorized to access personal health information. Authorized staff will explain the study and ask permission for contact by research staff at the AMTU site. If so, research staff will attempt calls as specified by the potential participant or at random (before 12 pm; between 12-4 pm; and between 4-10 pm) for no more than 10 attempts.
45365385|NCT00886886|Drug|MDMA|125 mg, single dose
46050971|NCT02838303|Other|Placebo|Multineem, WHO Class U: Unlikely to present acute hazard in normal use
46050972|NCT00787267|Drug|Dasatinib|70 mg PO twice daily until progression. Re-assess radiographically every 6 weeks.
46050973|NCT02838615|Procedure|epidural steroid (dexamethasone) injection|spinal injections performed in epidural space to relieve chronic low back pain or leg pain
46050974|NCT04104061|Other|iron profile|blood test
45365386|NCT00886886|Drug|Reboxetine, 8 mg|two doses 12h and 2h before MDMA
45365387|NCT00886886|Drug|Placebo|capsules identical to MDMA or Reboxetine
45482551|NCT01353300|Genetic|gene expression analysis|
45482552|NCT01353300|Genetic|gene rearrangement analysis|
45482553|NCT01353300|Genetic|mutation analysis|
45482554|NCT01353300|Genetic|polymerase chain reaction|
45482555|NCT01353300|Genetic|polymorphism analysis|
45482556|NCT01353300|Other|laboratory biomarker analysis|
45482557|NCT01353300|Other|medical chart review|
45482558|NCT01345266|Procedure|Inhalation Profiling|All subects recieve Inhaltion Profiling there are no interventions.
45690465|NCT01857583|Drug|30mg DU-176b|
45690466|NCT01857583|Drug|Fondaparinux|
45690467|NCT04000347|Drug|2.5% benzoyl peroxide gel|2.5% benzoyl peroxide gel was given to patients for 2 weeks
45690468|NCT04000347|Drug|5% benzoyl peroxide gel|5% benzoyl peroxide gel was given to patients for 2 weeks
45690469|NCT01829191|Device|Soft Contact Test Lens A|FDA-approved, non-marketed daily disposable soft contact lens, conventional design
45690470|NCT01829191|Device|Soft Contact Test Lens C|Daily disposable soft contact lens with new optical design
45690471|NCT05360745|Dietary Supplement|ARACOMPLEX®|ARACOMPLEX® is an authorized food supplement that contains maca extract, vitamin complexes and ions, and that improves the quality of life of the patient.
46050975|NCT05324319|Drug|Ad26COVS1|Heterologous vaccination
46050976|NCT05324319|Drug|ChAdOx1 SARS2 Vaccine|Heterologous vaccination
46050977|NCT05324319|Drug|BNT162B2|Homologous vaccination
46050978|NCT05324319|Drug|mRNA-1273|Homologous vaccination
46050979|NCT02603263|Other|Social Norms Poster|"A poster containing a social norms message: Most people here choose to eat vegetables with their lunch"
46050980|NCT02833701|Dietary Supplement|Ascorbic Acid|Given IV
46050981|NCT02833701|Biological|Bevacizumab|Given intravenously (IV)
46050982|NCT02833701|Other|Laboratory Biomarker Analysis|Correlative studies
46050983|NCT02833701|Other|Quality-of-Life Assessment|Ancillary studies
46050984|NCT04104295|Diagnostic Test|Ultrasound following X-ray|A short (less than 10 minutes) ultrasound (US) scan of the abdomen within 2 hours of the routine X-ray (XR). The performer will be a physician who received a focused training on relevant US views, blinded to the XR image and report.
46050985|NCT02838225|Drug|Docetaxel, Doxorubicin|
45365388|NCT04036760|Behavioral|Research transitional care coordination|Though care coordination was offered to all HCV positive inmates who are approached,the care coordination will still constitute a research intervention that requires informed consent, rather than a new uniform standard of care, to allow maximum autonomy for this incarcerated population.
45365389|NCT04036916|Other|Virtual Reality Sensorimotor Training|Games/activities specifically developed to train the sensorimotor system in headset virtual reality + strengthening of the neck
45365390|NCT00891722|Other|biologic sample preservation procedure|
45365391|NCT00891722|Other|laboratory biomarker analysis|
45365392|NCT00891722|Other|questionnaire administration|
45365393|NCT00891800|Device|Brachytherapy|SIR-Sphere contains radiation of Y-90.
45365394|NCT00891800|Device|SIR-Sphere|Brachytherapy Radiation seeds
45690472|NCT05360745|Dietary Supplement|placebo|Placebo has a composition that makes its weight and organoleptic characteristics are identical to ARACOMPLEX®.
45365395|NCT00886964|Biological|Intradermal HBV 1 course|"Dosage: 2 microgram (mcg), 0.1 ml per dose~Location: left deltoid area x 1 injection~Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months"
45690473|NCT00211185|Drug|Denileukin diftitox|Denileukin diftitox will be administered intravenously (IV) at a dosage of 18 micrograms/kilogram/day (ug/kg/d) on Days 1 and 2 of each 21-Day cycle for a total of 6 cycles, with a maximum of 8 cycles.
45690474|NCT00211185|Drug|Cyclophosphamide|Cyclophosphamide will be administered IV at a dosage of 750 milligrams/meter squared (mg/m^2) on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
45690475|NCT00211185|Drug|Doxorubicin|Doxorubicin will be administered IV at a dosage of 50 mg/m^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
45690476|NCT00211185|Drug|Vincristine|Vincristine will be administered IV at a dosage of 1.4 mg/m^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
46050986|NCT02838225|Drug|Docetaxel, Doxorubicin, Cyclophosphamide|
46050987|NCT04107883|Biological|fresh frozen plasma|perform plasma transfusion in different phases during perioperation
46050988|NCT04107883|Diagnostic Test|blood sample|get blood samples at several specific points in time during perioperation
45365396|NCT00886964|Biological|Intramuscular HBV I course|"Dosage: 2 microgram (mcg), 0.1 ml per dose~Location: left deltoid area x 1 injection~Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months"
45365397|NCT00887042|Drug|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 & -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, & -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, & -6)
45365398|NCT00892112|Drug|Intravenous Immunoglobulins|2 gr/kg body weight of intravenous immunoglobulin product Nanogam® administered as 0.5 gr/kg IV over a period of 6 hours on each of 4 consecutive days
45365399|NCT00892112|Drug|plasma volume expander|10 ml/kg BW will be administrated on four consecutive days.
45365400|NCT00887120|Drug|Lopinavir/ritonavir standard dose According to WHO simplified dosing table|"BW 6-7.9 kg: 1.5 mL oral q 12 hr~BW 8.0-16.9 kg: 2.0 ml oral q 12 hr~BW 17.0-19.9 kg: 2.5 ml oral q 12 hr~BW 20.0 - 24.9 kg: 3.0 ml oral q 12 hr~BW 25.0 - 29.9 kg: 3.5 ml oral q 12 hr~BW 30.0-34.9 kg: 4.0 ml oral q 12 hr~BW > 35 kg: 5.0 ml oral q 12 hr~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)"
45365401|NCT00887120|Drug|Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)|"BW 6-7.9 kg: 1.0 mL oral q 12 hr~BW 8.0-16.9 kg: 1.5 ml oral q 12 hr~BW 17.0-19.9 kg: 1.8 ml oral q 12 hr~BW 20.0 - 24.9 kg: 2.0 ml oral q 12 hr~BW 25.0 - 29.9 kg: 2.5 ml oral q 12 hr~BW 30.0-34.9 kg: 3.0 ml oral q 12 hr~BW > 35 kg: 3.5 ml oral q 12 h~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)"
45365402|NCT00892190|Drug|dasatinib (SPRYCEL)|DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours
45690477|NCT00211185|Drug|Prednisone|Prednisone will be administered orally at a dosage of 100 mg on Days 3 to 7 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
46050989|NCT00928434|Drug|Degarelix|Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.
45690478|NCT00211185|Other|Pegfilgrastim|Pegfilgrastim will be administered at a dosage of 6 mg subcutaneously on Day 4 to help prevent neutropenia. Alternatively, participants received filgrastim 5 ug/kg/d starting on Day 4 and continued until absolute neutrophil count (ANC) was less than 5000/millimeter squared (mm^2) for 2 days post-nadir.
46050990|NCT00928434|Drug|Degarelix|Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).
46050991|NCT00928434|Drug|Leuprolide|Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each)
45365403|NCT00892190|Drug|all trans retinoic acid (VESANOID)|22.5mg/m2 every 12 hours
45365404|NCT00887276|Drug|Moxifloxacin|"intravenous infusion: at least 3 days until to the drug switch (oral use),3 times daily (all 8 hours)~20 ml physiologic saline solution (placebo)(over 30 min) + Moxifloxacin infusion solution(400 mg/250ml) over 60 minutes~20 ml physiologic saline solution (placebo) (over 30 min)~20 ml physiologic saline solution (placebo) (over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~1 capsule Moxifloxacin (400 mg) + 1 capsule Placebo~2 capsules Placebo~2 capsules Placebo~Total time of the therapy:at least 7 days, but at most 10 days"
45365405|NCT00887276|Drug|Ampicillin;Amoxicillin|"intravenous infusion:at least 3 days until to the drug switch (oral use), 3 times daily (all 8 hours)~2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min) + 250 ml physiologic saline solution (placebo) (over 60 min)~2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~2 capsules Amoxicillin (0,5 g)~2 capsules Amoxicillin (0,5 g)~2 capsules Amoxicillin (0,5 g)~Total time of the therapy: at least 7 days, but at most 10 days"
45365406|NCT00528879|Drug|Dapagliflozin|Tablets administered orally as a 2.5-, 5-, or 10-mg dose once daily for up to 102 weeks
45365407|NCT00528879|Drug|Placebo|Dapagliflozin-matching placebo administered as tablets orally once daily for up to 102 weeks
45365408|NCT00528879|Drug|Metformin|Open-label metformin administered as ≥1500 mg per day for up to 102 weeks
45690479|NCT00210639|Drug|No intervention|This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.
45690480|NCT05632185|Behavioral|Equine-assisted Therapy|An equine therapy session typically consists of specific tasks and challenges to overcome, with the aid and guidance of horses. There is no riding involved and no specific skills are necessary to take part in these sessions
45690481|NCT05632029|Device|active laser|32 lupus prediabetic women will receive laser acupuncture (active laser) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
45690482|NCT05632029|Device|sham laser|32 lupus prediabetic women will receive laser acupuncture (sham laser, i.e power of device will be zero watt) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
45690483|NCT05631873|Other|Assistance with implementing Epic Smartlist|A research assistant helps GI providers add a new SmartList in to patient letters in Epic EHR that auto populates the colonoscopy recommendation time interval in patient records
45690484|NCT01829113|Drug|OGX-427|Three loading doses of 600mg OGX-427 will be administered intravenously (IV) during a 9 day period. Then 600mg IV OGX-427 will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive 600 mg IV OGX-427 plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
45752183|NCT03832803|Behavioral|Full bladder|Followed drinking protocol
46050992|NCT02604121|Device|Orcellex® Rovers brush|transepithelial brushing
46050993|NCT02831595|Device|GKS Prime Flex Bioloy by Permedica, a TiNbN coated fixed-bearing cruciate-retaining total knee prosthesis|
46050994|NCT04248699|Dietary Supplement|Lumenato|tomato oleoresin obtained from yellow dry tomato pulp
46050995|NCT00787189|Device|The Hearing Laser|Two 6-minute low level laser light applications to the head/neck/ears region, each one week apart.
46050996|NCT00787189|Device|Placebo Laser|inactive low level laser light therapy with no therapeutic output
46050997|NCT04248621|Drug|Leuprorelin|LHRH agonist
46050998|NCT04248621|Drug|Goserelin|LHRH agonist
46050999|NCT04248621|Drug|Triptorelin|LHRH agonist
46051000|NCT04248621|Drug|Degarelix|LHRH antagonist
46051001|NCT04248621|Drug|Bicalutamide|Antiandrogen
46051002|NCT04248621|Drug|Flutamide|Antiandrogen
46051003|NCT04248621|Drug|Maximum androgen blockade|Combination therapy with LHRH agonist and antiandrogen
46051004|NCT00784459|Drug|abatacept|Treatment with abatacept, 10 mg/kg IV, for 5 doses.
46051005|NCT00784459|Drug|Placebo|Treatment with Placebo, IV
46051006|NCT04257006|Device|oXiris membrane|Open heart surgery patients in early postoperative period with clinical signs of fluid overload undergoing CRRT
46051007|NCT02831517|Drug|BIIB074|Administered as specified in the treatment arm
46051008|NCT02831517|Drug|Placebo|Matched Placebo
45365409|NCT00608894|Drug|LCP-Tacro (tacrolimus)|LCP-Tacro(tacrolimus)tablets starting at 2 mg once daily, then adjusted to achieve and maintain target whole blood tacrolimus levels of 3 - 6 ng/mL, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
45365410|NCT00608894|Drug|Azathioprine|Azathioprine tablets 50 - 100 mg (approximately 1 mg/kg) once daily, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
45365411|NCT00892268|Procedure|acupuncture therapy|Undergo acupuncture
45365412|NCT00892268|Procedure|pain therapy|Receive standard care
45365413|NCT00892346|Procedure|Single ASCT with Thalidomide maintenance|"Single ASCT with Thalidomide maintenance:~Single Autologous Stem Cell Transplantation: conditioning with Melphalan 200mg/m2 (iv)~Thalidomide maintenance: starting from D60 after transplantation at 100-200mg daily (Oral)"
45365414|NCT00892424|Drug|Sorafenib|Sorafenib doses will be 200mg twice daily orally for 28 days in level I, 400 mg in the morning and 200mg in the evening in level II, and 400mg twice daily orally for 28 days in level III . Radiotherapy will be started at day 8, patients will receive a total of 6 fractions over 2 weeks. Patients will be assessed weekly during treatment, 1 month post-tx, then at 3-month intervals for up to a year after tx, and then followed-up at 6-month intervals up to 3 years.
45482559|NCT05252026|Behavioral|PROCARE-I (UP-A for indicated purposes)|This intervention is meant to respond to the heterogeneity inherent in emotional difficulties presentation by extinguishing distress associated with the presentation of heightened negative emotion in general and reduction or elimination of resultant emotionally-driven behaviours, including avoidance, escape, aggression, and controlling behaviours (e.g., reassurance seeking) that reinforce emotional distress intensity over time.
45482560|NCT05252026|Behavioral|Active control condition|Psychoeducation about many different emotions, emphasis on discussing thoughts, feelings, and behavior as parts of emotion, and emphasis on providing support around generally distressing events.
45482561|NCT01353378|Drug|dexmedetomidine|Intravenously injecting 0.125microgram/kg for 10ml IV(in the vein)in group 1, 0.25microgram/kg for 10ml in group 2 within 10 minutes as soon as the operation begin. The control group receives 10mlsaline in 10 minutes.
45482562|NCT05245006|Drug|89Zr-DFO-YS5|3 mCi will be administered intravenously
45482563|NCT05245006|Biological|YS5 antibody|20 or 50 mg administered intravenously
46051009|NCT04256928|Procedure|Preoperative electrical clipping|Body hair in the operative field will be clipped with an electrical clipper by hospital personnel during preparation to planned surgery.
46051010|NCT00786799|Dietary Supplement|Omega-3 Fatty Acids|"Omega-3's are administered in the form of an orange pudding made by Coromega~1 mg of omega-3 fatty acid 2 times per day"
45482564|NCT05245006|Procedure|Positron Emission Tomography (PET)/Computerized tomography (CT)|Imaging which combines a CT scan and a PET scan
45690485|NCT01829113|Drug|Placebo|Three loading doses of placebo will be administered intravenously (IV) during a 9 day period. Then placebo (IV) will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive placebo (IV) plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
45690486|NCT00219297|Drug|Patupilone|
45690487|NCT05631795|Drug|Alpelisib|Film coated tablet for oral use. Participants will be treated with 300 mg of alpelisib once daily starting on Cycle 1 Day 1
45690488|NCT05631795|Drug|Fulvestrant|Injection for intramuscular administration. Participants will be treated with fulvestrant 500 mg on Cycle 1 Day 1 and Day 15, and Day 1 of every cycle thereafter in a 28-day cycle.
46051011|NCT00786799|Dietary Supplement|Omega-3 Fatty Acids|"Omega-3 Fatty Acids in orange pudding form~1 packet two times per day"
46051012|NCT04248777|Other|standardised OCT-guided intervention|The first OCT run (run1) analyse plaque characteristics, identify proximal and distal landing zones (according to previously published criteria) , measure lesion length and reference segments dimensions (diameters and luminal areas). The second run (run2) aims to assess adequate guidewire recrossing point into stent jailed side branch and identify early stent mechanical non-optimal results. The third run (run3) analyse final stent expansion and identify major struts malposition and edge dissection.
45482565|NCT05245006|Procedure|Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)|Imaging which combines an MRI scan and a PET scan
45482566|NCT01465334|Drug|Ofatumumab|
45482567|NCT01465334|Drug|High-Dose Methylprednisolone|
45482568|NCT01465334|Drug|Alemtuzumab|
45482569|NCT01348464|Procedure|single port appendectomy, three port appendectomy|visual analog scale. questionnaire on wound satisfaction
45482570|NCT04019262|Radiation|Radiation Therapy|Radiation
45482571|NCT04019262|Drug|Temozolomide Oral Product|Oral Temozolomide (150mg/m^2 or 75 mg/m^2)
45482572|NCT04718194|Behavioral|ESTEEM iCBT|The online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
45482573|NCT04718194|Behavioral|Self-monitoring control|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
45690489|NCT01857271|Drug|Erlotinib Hydrochloride|Given PO
45690490|NCT01857271|Procedure|Therapeutic Conventional Surgery|Undergo thoracotomy
45690491|NCT01857271|Other|Laboratory Biomarker Analysis|Correlative studies
45690492|NCT00216255|Drug|Pagoclone|
45690493|NCT00216255|Drug|Placebo|
45690494|NCT01745120|Genetic|LentiGlobin BB305 Drug Product|Transplant of autologous hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector.
46051013|NCT02834949|Behavioral|Brief Motivational Intervention (BMI)|This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; an alcohol use decisional balance exercise; personalized alcohol-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students drink and actual student norms, (b) a comparison of the student's alcohol consumption vs. norms, (c) an estimate of the student's peak blood alcohol content in the past month, (d) alcohol-related problems experienced, (e) money spent on alcohol, and (f) calories consumed from alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if he or she indicates interest.
45690495|NCT03024723|Device|nasal mask CPAP|CPAP and ventilation administered via nasal mask
45690496|NCT01828567|Behavioral|Shared decision making with a Prevention Coach|A series of two phone sessions with a prevention coach. The first to engage the veteran to choose a preferred prevention program and link them to Patient Aligned Care Team (PACT), and a follow-up call one month later to assess the progress of the prevention plan.
45482574|NCT03626246|Other|Kidney disease|"Being part of this study you agree to participate in all these interventions:~Genetic:~• Blood sample~Procedure/Surgery:~• Bone and muscle biopsies.~Radiation:~Bone density (DXA)~Thoracic and lumbar spine plain films.~HRpQCT: high-resolution peripheral quantitative computed tomography~Other:~Completing medical history, physical activity level, and dietary questionnaires for calcium and vitamin D.~Measure levels of Advanced Glycation End products (AGEs) in the skin."
45482575|NCT04693624|Other|Hormonal levels|"A total of ten (10) blood samples (2ml/each) will be collected during the study for subsequent analysis of progesterone, hCG, inhibin-A, and 17-OH-progesterone:~Day of triggering (before the injection of hCG, appx. 6 pm) Twelve (12 hours) after hCG injection (appx. at 6 am) Twenty-four (24) hours after hCG injection (appx. at 6 pm) Thirty-six (36) hours after hCG injection (appx. at 8 am, 2 hours after OPU) One (1) day after OPU (60h after hCG) (appx. at 6 am) Two (2) days after OPU (84h after hCG) (appx. at 6 am) Three (3) days after OPU 108h after hCG) (appx. at 6 am) Four (4) days after OPU (132h after hCG) (appx. at 6 am) Five (5) days after OPU (156h after hCG) (appx. at 6 am) Six (6) days after OPU (180h after hCG) (appx. at 6 am)"
45690497|NCT04019535|Device|physiological assessment with Volcano Verrata pressure wire (iFR)|physiological assessment of the coronary lesion will be made with both iFR and dFR. all clinical decisions will be made based on the results of iFR
45690498|NCT03999879|Diagnostic Test|Measure of OxPhos upregulation|OxPhos upregulation [i.e., lower phosphocreatine (PCr)-to-ATP ratio levels] in the PET AG mask. PIB+ NL subjects will show OxPhos downregulation (i.e. increased PCr/ATP ratio that indicate the presence of metabolically inert PCr that cannot be used as ATP) when compared to PIB- NL subjects in the PETAG mask
45690499|NCT03999879|Diagnostic Test|lactate (measured with 1H-MRSI)|PIB+ NL subjects will show increased levels of lactate (measured with 1H-MRSI) when compared to PIB- NL subjects in the PETAG mask.
45845781|NCT05504304|Procedure|conservative management then calcaneoplasty and subtalar arthrodesis.|they will be assessed upon 1st clinic visit. After at least three months patients will be scheduled for subtalar arthrodesis. A new preoperative ankle CT scan will be done. Lateral position and lateral extensile approach will be used. Lateral wall and plantar exostosis will be resected. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. Hind foot deformity (mostly varus) will be corrected through the subtalar joint manually and checked clinically. Loss of calcaneal height will be corrected by tricortical iliac bone autograft to distract the subtalar joint then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
45482576|NCT05015816|Diagnostic Test|Total body photography|3 monthly TBP imaging
45482577|NCT00702208|Device|Delphi Screener|Self-sampling device for cervical vaginal lavage
45482578|NCT02464618|Behavioral|Social contact intervention|The social contact of the patients in this arm will be engaged to improve adherence to out-patient endoscopy
45690500|NCT01721486|Drug|IV acetaminophen|IV acetaminophen 15 mg/kg (up to 1000 mg) over 15 minute infusion after IV placement in OR .
45690501|NCT01721486|Drug|PO acetaminophen|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30minutes) prior to induction of anesthesia in the pre-operative area.
45690502|NCT04610905|Behavioral|Reducing sedentary behaviour|This group needs to download an app on their computer and their smartphone. This app will give a notification every 30 minutes to walk during 2 minutes during working hours. The participants will receive a diary to write down whether they stand up.
45690503|NCT04610905|Behavioral|Increase physical activity|This group will be asked to be more physically active. They need to be active during 150min/week. It can include walking, to ride a bike, jogging, tennis, football,... Additionnaly they need to be active in periods of at least 10 minutes. The participants will receive a diary to write down which activity they did and also for how long.
46051014|NCT02834949|Behavioral|Substance-Free Activity Session (SFAS)|The clinician initiates a discussion of the student's college and career goals. Students discuss the values that motivate them as well as how alcohol use may interfere with their ability to accomplish these goals. Students then receive information on graduation rates and income benefits for those who attend and excel in college. They receive personalized feedback on (a) the requirements for their major and intended career, (b) a list of extracurricular activities tailored to their goals, (c) a graph showing time they allocate to their activities, (d) information on stress and depressive symptoms (if applicable) and possible adaptive coping responses and (e) a list of substance-free recreational activities in which they would like to start or continuing engaging.
46051015|NCT02834949|Behavioral|Relaxation Session|The session includes a clinician-led diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (~30 minutes). At the end of the session, participants will be asked about their reaction to the relaxation techniques and provided with relaxation training handouts.
45365415|NCT02541032|Procedure|Intensive dental treatment|Up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
45365416|NCT02541032|Procedure|Standard dental treatment|Supragingival mechanical scaling and polishing.
45482579|NCT05322746|Device|Focal muscle vibration|Focal muscle vibration (FMV) defined as a technique that applies a vibratory stimulus to a specific muscle or its tendon using a mechanical device. FMV generates the Ia inputs as a consequence of the activation primary ending of the muscle spindle leading to alteration of corticospinal pathways results in activation of Ia inputs by FMV. The vibration of a specific muscle can increase the motor evoked potential, enhance the changes in corticospinal excitability and produces involuntary contraction in the vibrated muscle
46051016|NCT00786565|Device|Advanced Akreos Adapt in one operated eye.|Cataract surgery to implant the assigned IOL according to randomized schedule.
46051017|NCT00786565|Device|Akreos Adapt in fellow operated eye.|Cataract surgery to implant the assigned IOL according to randomized schedule.
46051018|NCT00610974|Behavioral|Body-weight supported treadmill training|BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
46051019|NCT00610974|Behavioral|Body-weight supported treadmill training|BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
45365417|NCT02541032|Drug|Arestin|To better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
45482580|NCT02464774|Procedure|Breast-Conserving Therapy|Patients undergo lumpectomy with surgical axillary staging with all lesions resected to negative margins.
45690504|NCT05631639|Device|PillSense System|The PillSense capsule is a diagnostic capsule equipped with a sensor for in vivo detection of liquid blood and a paired PillSense receiver for result display.
45482581|NCT02464774|Procedure|Mastectomy|Patients undergo mastectomy with surgical axillary staging with all lesions resected to negative margins.
45365418|NCT00557856|Drug|PF-03446962|To determine the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of PF-03446962 administered in patients with advanced solid tumors.
45365419|NCT00892502|Drug|Bismuth tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
45482582|NCT02464774|Drug|Adjuvant Chemotherapy|Patients with stage I and II receive adjuvant chemotherapy using TC and TAC regimen respectively.
45482583|NCT02464774|Radiation|Radiation Therapy|N0: Radiation therapy to whole breast (+boost to tumor bed) or consideration of partial breast irradiation in selected patients; (2) N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes.
45482584|NCT05583578|Device|Home-based mobility testing and active tDCS|"A Soterix Clinical Trials tDCS unit will be used for delivery of stimulation for twenty minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm2 sponges placed over the frontal cortices at F3 and F4 (based on the international 10-20 system of standardized brain electrode placement). 2.0mA was"
45482585|NCT05583578|Device|Sham tDCS|Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2.0mA of direct current stimulation at the beginning of each rehabilitation session. Since participants habituate to the sensation of tDCS within 30-60 seconds of stimulation, this procedure provides the same sensation of active tDCS.
45482586|NCT05549726|Drug|Cabotegravir Injectable Suspension|CAB-LA will be one of the options for the Dynamic Choice Delivery intervention arm. CAB-LA will be a choice for at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Single-dose vial containing 600 mg/3 mL (200 mg/mL) of cabotegravir is a white to light pink, free-flowing, extended-release injectable suspension. CAB-LA administration will occur at health facilities.
45482587|NCT05549726|Other|Dynamic Choice Delivery Model|The Dynamic Choice Delivery Model includes integrated PrEP (including CAB-LA) and PEP services at outpatient clinics, antenatal clinics, and via VHT workers in community households. The procedures for each trial include PrEP/PEP counseling and services, choice of service location, HIV testing options, option for longer PrEP refills, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, assessment of PrEP/PEP barriers and personalized actions, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services.
45482588|NCT05549726|Other|Standard of Care|The standard of care differs according to country but does not routinely offer PEP or PrEP to clients seeking services, does not offer choice of service location, HIV testing option or access to medical provider mobile phone number.
45482589|NCT05536232|Behavioral|Low carbohydrate diet|Low carbohydrate diet under 75 g per day
45482590|NCT00973856|Other|PURELL VF481|One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
45690505|NCT05366517|Device|Dornier Aries 2 device|For 6 weeks, patients will receive 6 sessions with active LiST probe, 2 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7) frequency = 5Hz
45690506|NCT05631483|Device|DAISe|Use of the DAISe Thrombectomy Device
45365420|NCT00892502|Drug|Placebo tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
45690507|NCT01775930|Drug|Carfilzomib|20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
45365421|NCT01008189|Behavioral|Self- study comparison group|Caregivers, children and adolescents each received three books about coping with grief following the death of a loved one plus a syllabus to guide reading
45365422|NCT01008189|Behavioral|Family Bereavement Program|12 session groups for caregivers and bereaved children and adolescents plus two individual sessions
45482591|NCT00973856|Other|Placebo Solution|One (1) pump of product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
45482592|NCT01348620|Device|Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa)|Single port laparoscopic cholecystectomy. SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa)
46051020|NCT02835105|Drug|Surotomycin|A single oral dose of either 0.5, 1, 2 or 4 g surotomycin in hard gelatin capsules
45482593|NCT01348620|Procedure|Four port laparoscopic cholecystectomy surgery|Four port laparoscopic cholecystectomy surgery
45482594|NCT01353456|Drug|Dexmedetomidine|Patient will receive a loading dose of 1μg/kg (0.25ml/kg) intravenous dexmedetomidine over 10 minutes before induction, and then followed by continuous infusion at a rate of 0.5μg/kg/h (0.125ml/kg/h) until wound closure.
45482595|NCT01353456|Drug|Normal Saline|Same volume as dexmedetomidine given
45482596|NCT04010214|Other|No intervention|No intervention
45482597|NCT05506358|Diagnostic Test|High performance liquid chromatography|High performance liquid chromatography (HPLC) using the D10 System by Bio-Rad Laboratories will be used as the gold standard test.
45482598|NCT05506358|Device|Automated sickling test|The standard sickling test using 2% sodium metabisulphite will be augmented using an automated microscope (such as Octopi) and machine learning, and will be used as one of the low-cost tests.
45365423|NCT00885404|Drug|Lower chloride fluids (Hartmann's solution and Plasmalyte®)|Intravenous fluids used during the 6 month intervention period (after). Amount of fluids to be used is based on clinicians' discretion.
45365424|NCT00892580|Drug|STX209|collection of serum for DNA to elucidate a potential biomarker for patients with ASD
45482599|NCT05506358|Diagnostic Test|HbS solubility test|Standard HbS solubility test currently used in Nepal (e.g. Sicklevue) will be used as one of the low-cost tests
45482600|NCT05506358|Device|HemoTypeSC|A point-of-care lateral flow assay, HemoTypeSC (https://www.hemotype.com/), will be used as one of the low-cost tests
45482601|NCT05506358|Device|Sickle SCAN|A point-of-care lateral flow assay, Sickle SCAN (https://www.biomedomics.com/products/hematology/sicklescan/), will be used as one of the low-cost tests
45482602|NCT05506358|Device|Gazelle Hb Variant Test|A portable electrophoresis machine, Gazelle diagnostic device (https://hemexhealth.com/), will be used as one of the low-cost tests
46051021|NCT02835105|Drug|Placebo|A single oral dose of placebo for surotomycin in hard gelatin capsules
46051022|NCT02835027|Procedure|Open versus endovascular surgery|Treatment for acute ischemia
45365425|NCT00191113|Drug|Somatropin|0.05 mg/kg/dose by subcutaneous injection 6 times per week, until Core study completion criteria are met (protocol final height).
45365426|NCT00191113|Drug|Ethinyl estradiol|escalating doses 2.5-20.0 mcg tablets daily after age 13 and at least one year on study, continuing until Core study completion criteria are met.
45365427|NCT00191113|Drug|Medroxyprogesterone acetate|10 mg tablets, ten days monthly, after age 15, continuing until Core study completion criteria are met.
45365428|NCT00608582|Device|Transcranial Magnetic Stimulation, Repetitive|10 rTMS treatments (90% of motor threshold, 20 minutes, at 1 Hz) to specific right hemisphere area of brain cortex; 5 days per week for 2 weeks at the Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; or at the Neurology Department, Hospital of the University of Pennsylvania, Philadelphia, PA.
45482603|NCT04289142|Drug|Dexmedetomidine Hydrochloride Group|Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1.2 ug kg-1 over approximately 20 minutes. This will be followed by an infusion at 0.1-1.2 ug kg-1h-1 in CVICU for up to 24 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier).
45482604|NCT00920972|Drug|Treatment Plan 1: Stratum 1|Day -50 to -21: Hydroxyurea 30mg/kg PO q day Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients <10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on Day 0...
45690508|NCT01856569|Other|no intervention|in real life of drug,dosage,frequency and duration
45482605|NCT00920972|Drug|Treatment Plan 2: Strata 2, 3, or 4|Day -50 to -21: Hydroxyurea 30mg/kg PO q day… Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -4: Thiotepa 8mg/kg IV… Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients <10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
45482606|NCT00920972|Drug|GVHD Regimen A: UCB Recipients|Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +5: Abatacept 10mg/kg IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV
45482607|NCT00920972|Drug|GVHD Regimen B: BM Recipients|Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +1: Methotrexate 7.5mg/m2 IV Day +3: Methotrexate 7.5mg/m2 IV Day +5: Abatacept 10mg/kg IV Day +6: Methotrexate 7.5mg/m2 IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV Day +180: Abatacept 10mg/kg IV Day +270: Abatacept 10mg/kg IV Day +365: Abatacept 10mg/kg IV
45482608|NCT01353534|Biological|A/H5N1 Antigen|A/H5N1 Antigen
46051023|NCT05285514|Diagnostic Test|Comparison of macro- and microcirculatory parameters|"Microcirculation examination using sublingual videomicroscopy, tissue O2 saturation (StO2) by NIRS and transcutaneous CO2 pressure (tcpCO2) monitoring, in conjunction with macrocirculatory parameters measures including cardiac output, arterial pressure and pulsed O2 saturation, in order to establish the relationship between the macrocirculatory changes in blood pressure and cardiac output and the microcirculatory flow and capillary density during vasoactive agent use. . Participants receive interventions as part of routine medical care to restore Cerebral Perfusion pressure (CPP) to appropriate levels (60-70 mmHg)"
45365429|NCT03965052|Drug|PRO 179|"Generic name: Travoprost~Distinctive denomination: Bristrio® (PRO-179)~Active principles: Travoprost 0.004%.~Pharmaceutical form: Ophthalmic solution~Presentation: multi-dose dropper bottle, 2.5 milliliters.~Prepared by: Sophia Laboratories, S.A. of C.V.~Description of the solution: transparent solution, free of visible particles.~Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene."
45365430|NCT03965052|Drug|Travatan 0.004 % Ophthalmic Solution|"Generic name: Travoprost~Distinctive denomination: Travatan®~Active ingredients: Travoprost 0.004%~Pharmaceutical form: Ophthalmic solution.~Presentation: multi-dose dropper bottle, 2.5 milliliters.~Prepared by: Alcon Laboratories Inc.~Description of the solution: transparent solution, free of visible particles.~Consult information to prescribe."
45365431|NCT05265117|Procedure|HIPEC|HIPEC is given after primary or interval debulking surgery.
45365432|NCT03964974|Behavioral|Cognitive Behavioral Therapy for Insomnia in Cannabis Users (CBTi-CB)|Each CBTi-CB therapy session will review the previous week of sleep/wake diaries and summarize key sleep parameters with participants. The treatment will address cannabis use by increasing use of appropriate coping strategies and improving self-efficacy to manage insomnia and next-day consequences. The content includes: (1) Sleep Scheduling Strategies to consolidate sleep using behavioral strategies that increase the drive for sleep and stabilize the circadian timing system; (2) Sleep Hygiene to discuss behaviors, substances, and environmental conditions that can help or hinder sleep; (3) Cognitive Therapy aims to identify and alter dysfunctional beliefs about sleep and functioning that contribute to insomnia; (4) Counter-Arousal Strategies address ruminative thoughts and increased body tension interfering with ability to fall or return to sleep; (5) Relapse Prevention for Insomnia reviews treatment gains and the behavioral and cognitive strategies that were most helpful.
45690509|NCT03999021|Drug|NAC effervescent tablets|After completing the pretreatment visits, all patients will enter into the treatment phase where patients will receive 1800 mg of NAC effervescent tablets twice a day. The patients will be followed up every 3 months for 2 years. Therefore, there will be a total of 9 treatment visits (baseline, months 3, 6, 9, 12, 15, 18, 21 and 24).
45752184|NCT05153499|Biological|CP101|CP101 is an investigational microbiome therapeutic designed to deliver a complete and functional microbiome to durably repair intestinal dysbiosis, which is being evaluated for the prevention of recurrent CDI.
45752185|NCT05153499|Other|Placebo|Placebo
45482609|NCT01353534|Drug|Vaccine Enhancement Patch|Vaccine Enhancement Patch
45482610|NCT01345422|Other|Wii Balance Board|Participant will undergo Nintendo Wii Balance Board training for two months , five days a week for 30 minutes
45482611|NCT05472116|Device|Mobile Health application (CapApp)|Mobile Health application (CapApp) will be used to measure capillary refill time in a healthy pediatric population and compared to two additional manual methods to include both human and computer annotation and mobile health application (Cap App).
45482612|NCT04953962|Drug|CBP501 (16)|16 mg/m2
45365433|NCT03964974|Behavioral|Sleep Hygiene Education (SHE)|The SHE condition will be matched to the CBTi-CB condition in terms of level of attention and the non-specific aspects of receiving social support from a study therapist, without providing individualized recommendations. The current content includes: (1) Insomnia History of the participant, including triggers that initiated the problem, duration, severity, and frequency, premorbid sleep characteristics, and previous sleep treatments; (2) Sleep Education about why we sleep, sleep stages, sleep regulation at night, and sleep changes across lifespan; (3) Substance Use and Sleep and the effects of cannabis and other licit and illicit substances on sleep; (4) Environmental Factors that contribute to a sleep-conducive environment; (5) Lifestyle Factors like the effects of diet, exercise, and napping on sleep; (6) Sleep Maintenance Strategies to review treatment gains from the participant's perspective and emphasize the principles covered to maintain sleep improvements.
45365434|NCT00892658|Drug|Sorafenib|Patients will receive sorafenib alone (following the dose escalation scheme) for one week, followed by 2 weeks of concurrent administration of sorafenib with conformal radiation therapy (6 fractions over two weeks). Sorafenib administration will continue for four weeks following completion of radiation. At three months following radiation, when liver toxicity is assessed, full dose sorafenib (400mg PO BID) will then be initiated and continued until disease progression or serious toxicity occurs, to a maximum time of 12 months.
45365435|NCT00892736|Other|Laboratory Biomarker Analysis|Correlative studies
45365436|NCT00892736|Other|Pharmacological Study|Correlative studies
45365437|NCT00892736|Drug|Veliparib|Given PO
45365438|NCT03966235|Drug|Melatonin 3 mg|Melatonin was taken daily for 6 months.
45365439|NCT03966235|Drug|Placebo|Placebo tablet was taken daily for 6 months.
45365440|NCT00892814|Radiation|Partial breast irradiation|40 Gy/15 fractions, 3 weeks
45365441|NCT00892814|Radiation|Whole breast irradiation|40 Gy/15 fractions, 3 weeks
45365442|NCT03966469|Other|Preoperative support person present|Participants who bring a support person to their preoperative appointment.
45482613|NCT04953962|Drug|CBP501 (25)|25 mg/m2
45482614|NCT04953962|Drug|Cisplatin|60mg/m2
45482615|NCT04953962|Drug|Nivolumab|240 mg
45365443|NCT03966469|Other|Patient Present Only|Patient presents to their preoperative appointment without a support person.
45365444|NCT01077661|Drug|Nebivolol|patients administrated Nebivolol according to the prescribing information
45365445|NCT00606320|Drug|Aripiprazole|oral, 24mg(4 tablets)/day
45482616|NCT01345500|Other|Higher Carbohydrate, Lower Fat Diet|Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower fat, higher carbohydrate diet provides 60% energy from carbohydrate, 20% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.
45482617|NCT01345500|Other|Lower carbohydrate, Higher fat diet|Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower carbohydrate, higher fat diet provides 45% energy from carbohydrate, 35% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.
45482618|NCT01345500|Other|Individualized Counseling|Participants assigned to the usual care group will be provided consultation with a research staff dietetics professional, who will provide publicly available print material that describes dietary and physical activity guidelines to promote weight loss and maintenance, at baseline (after randomization) and again at 6 months.
45482619|NCT04948814|Biological|Fecal microbiota transplantation|FMT utilizing stool from healthy children
45482620|NCT04948814|Drug|Vancomycin|40mg/kg/day
45482621|NCT02718898|Drug|Ixekizumab|Administered SC
45752186|NCT00410059|Drug|Erlotinib|150 mg by mouth daily x 28 days
45752187|NCT04749147|Other|Black and White Printed Survey|This survey will feature black and white text and graphics.
45365446|NCT03966079|Drug|recombinant tissue plasminogen activator|Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter
45365447|NCT02540486|Other|Long-acting insulin glargine titration web tool (LTHome)|The LTHome study arm will receive insulin glargine titration instructions from the LTHome web-based tool
45365448|NCT02540486|Other|Diabetes Education|Individual diabetes education, detailed instructions on the use of the blood glucose monitor and unlimited availability of blood glucose monitoring supplies.
45482622|NCT02718898|Drug|Placebo|Administered SC
45482623|NCT01353690|Biological|AMDC|Cell Treatment
45482624|NCT03619616|Drug|ZSP1603 7.5 mg|ZSP1603 capsule administered orally once daily under fasted condition.
45482625|NCT03619616|Drug|ZSP1603 12.5 mg|ZSP1603 capsule administered orally once daily in the fasting state.
45482626|NCT03619616|Drug|Placebo 12.5mg|Participants will receive placebo matching to ZSP1603 orally once daily under fasted condition.
45752188|NCT04749147|Other|Red Printed Survey|This survey will feature red text and graphics.
45752189|NCT00310427|Drug|LY686017|50 mg administered orally on a daily basis
45482627|NCT03619616|Drug|ZSP1603 25 mg|ZSP1603 capsule administered orally once daily under fasted condition.
45482628|NCT03619616|Drug|Placebo 25mg|Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
45482629|NCT03619616|Drug|ZSP1603 50 mg|ZSP1603 capsule administered orally once daily under fasted state.
45482630|NCT03619616|Drug|Placebo 50mg|Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
45365449|NCT03966859|Drug|Atorvastatin 20mg|oral dose, once daily for 7 days
45365450|NCT03966859|Other|Lactose placebo|oral dose, once daily for 7 days
45365451|NCT00528411|Drug|Ticagrelor Tablets|Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily (BD)
45365452|NCT00528411|Drug|Clopidogrel (over encapsulated) capsule|Oral 75 mg; 600 mg loading dose followed by 75 mg once daily (ODD)
45482631|NCT01317264|Other|no β-glucan|daily consumption of non-β-glucan containing milk drinks together with the 3 main meals for 21 days
45482632|NCT01317264|Other|oat β-glucan|daily consumption of 5g of oat β-glucan in the form of milk drinks with the 3 main meals for 21 days
45482633|NCT01317264|Other|barley β-glucan|"daily consumption of 5g β-glucan extracted from the barley-mutant mother Bomi in the form of milk drinks with the 3 main meals for 21 days"
45752190|NCT00310427|Drug|Placebo|Administered on a daily basis
45845782|NCT05473572|Behavioral|Fluency shaping exercises|Training for prolonged speech, easy onset, light contact and abdominal breathing moving from the level of single words till using short sentences describing pictures
46051024|NCT04257084|Diagnostic Test|chromoendoscopy with target biopsy; NBI with target biopsy|"Chromoendoscopy with target biopsy: 0.03% indigo carmine solution based chromoendoscopy (using high-definition colonoscopy) will be fulfilled and target biopsies will be taken at all abnormal mucosal lesions suspected dysplasia/neoplasia.~NBI with target biopsy: After inserting a high definition colonoscopy up to cecum, endoscopists observe the colon in combination of white light and NBI (white light first and then NBI). Target biopsies will be taken at all abnormal mucosal lesions suspected dysplasia/neoplasia."
45365453|NCT00528411|Drug|Aspirin Tablets|Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.
45365454|NCT00895544|Biological|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose B (Indonesia strain) for booster vaccination (Day 360)
45365455|NCT00895544|Biological|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose A (Indonesia strain) for booster vaccination (Day 360)
45365456|NCT00136357|Behavioral|Mind-Body Skills Groups|12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
45365457|NCT00895700|Behavioral|web-based multifactorial intervention|12-week multi-factorial web-based behavioral intervention comprised of psycho-education, cognitive behavioral therapy (CBT) and relaxation therapy
45365458|NCT00129649|Behavioral|Telephone reminder call|
45482634|NCT01317264|Other|mutant-barley β-glucan|"daily consumption of 5g β-glucan extracted from the high β-glucan barely mutant lys. 5.f in the form of milk drinks with the 3 main meals for 21 days"
45482635|NCT03986580|Device|Annular closure device|Annular closure, following limited discectomy procedure at a single LS level between L4 and S1
45482636|NCT05726812|Behavioral|Plan My Life Together|A group training for adolescents with ADHD in which they learn to plan and organize. The training consists of 8 weekly sessions of 90 minutes for the adolescent and 2 parent sessions of 90 minutes.
45482637|NCT03682614|Drug|HCG|we will use the catheter to pass through the cervix, and after that, the experiment Group will accept 40 μl 500 IU HCG injection into the uterine cavity 2 days before the blastocyst transfer.
45482638|NCT03682614|Other|culture medium|The placebo group will accept 40 μl of culture medium injection into the uterine cavity 2 days before the blastocyst transfer.
45482639|NCT04489654|Biological|deproteinized bovine bone mineral (DBBM) by OneXeno Graft. ( OneGraft, Germany)|deproteinized bovine bone mineral (DBBM) put in the gap between implant and labial shield
45690510|NCT03024645|Behavioral|Be A Mom|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention to prevent postpartum depression, targeting postpartum women. It consists of 5 weekly modules, each module targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
45690511|NCT03024645|Other|Treatment as usually (TAU)|performed in primary care settings
45690512|NCT01721408|Drug|Tigecycline|every 12 hours (an initial intravenous dose of 100 mg followed by 50 mg twice a day approximately every 12 hours) and placebo intravenous doses every 12 hours beginning 6 hours after the initial intravenous dose of tigecycline for at least for 5 days and up to 14 days.
45690513|NCT01721408|Drug|Imipenem/cilastatin|every 6 hours intravenously, and the imipenem/cilastatin will be dosed by 500mg/500mg for the subjects with creatinine clearance equal or above 71ml/min/1.73m2 or dose will be adjusted by Schedule of Study Drug Administration for Subjects with Renal Impairment.
45845783|NCT05467800|Drug|Canakinumab|Canakinumab administered as a subcutaneous injection on day 1 of a 21 day cycle for a core study period of 8 cycles.
45845784|NCT05436678|Drug|PrimeC 748 mg|PrimeC is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
45845785|NCT05436678|Drug|Ciprofloxacin 750 MG|Ciprofloxacin
45845786|NCT05436678|Drug|Celecoxib 200mg|Celecoxib
45365459|NCT00895778|Other|Neuromuscular blockade with rocuronium and reversal with sugammadex|
45482640|NCT03660228|Other|Peri-Transfusion QOL Assessment|Participants will undergo a peri-transfusion quality of life assessment (PTQA) using the Quality of Life in Myelodysplasia Scale (QUALMS)
45845787|NCT05434338|Diagnostic Test|HPV detection test|Samples taken from the squamocolumnar junction using swabs (UTM Copan)
45845788|NCT05433012|Device|Ultrahigh Field MRI at 7T|Assessment of the micro-anatomy of the menisci and cartilage in patients with presumed Isolated Acute Anterior Cruciate Ligament Injury with Ultrahigh Field MRI at 7T
46051025|NCT02835183|Device|iDECIDE|The iDECIDE app will be installed in study participant's smartphone. The app requests from study participants input on food consumed (included food's carbohydrate content), alcohol consumed (included alcohol's carbohydrate content) and exercise plans (including duration and intensity). Based on that input the app suggests insulin bolus dosing.
46051026|NCT02835183|Device|Insulin pump|Study participants will use during the study their own insulin pump and continuous glucose sensor. As inclusion criteria, investigators expect study participants to have been using their insulin pump and continuous glucose sensor for at least one year.
46051027|NCT02602483|Drug|Ibuprofen|
46051028|NCT02602483|Drug|Magnesium|
46051029|NCT02602483|Drug|Ascorbic Acid|
46051030|NCT02602483|Drug|Placebo|
46051031|NCT04245813|Behavioral|Interdisciplinary educational program|Interdisciplinary educational component based on the Clinical Practice Guide for Heart Failure
46051032|NCT04256694|Diagnostic Test|Rapid Antigen Test for Group A Streptococcus|Rapid strep tests will be performed by throat swab of healthy adult volunteers.
46051033|NCT02828943|Behavioral|IMT with High Resistance EMT|
46051034|NCT02828943|Behavioral|IMT with Low Resistance EMT|
45482641|NCT01317888|Drug|MAB-425 radiolabeled with I-125|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
45482642|NCT05726734|Drug|Vonoprazan|potassium-competitive acid blocker
45482643|NCT05726734|Drug|Amoxicillin, Metronidazole|Antibiotics for H. pylori eradication
45482644|NCT05726734|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
45482645|NCT05726734|Drug|Esomeprazole|Proton pump inhibitor
45482646|NCT01317966|Drug|rhIL-11|Recombinant Human Interleukin-11 (rhIL-11) Combinating Low-dose Rituximab
45482647|NCT01345734|Drug|liraglutide|Liraglutide will be prescribed and titrated by the treating physician and will be self-administered by the subject s.c. (under the skin) once daily. Study participants being treated with GLP-1 (Glucagon-Like Peptide 1)agonists or DDP-4-inhibitors (Dipeptidyl-peptidase 4 ) should stop treatment when initiating liraglutide treatment.
45482648|NCT04674670|Drug|Low dose naltrexone|Low dose naltrexone will not be utilized here as therapeutic clinical interventions, but to assess psychobiological mechanisms in pain processing. Participants will receive low dose naltrexone with 4.5 mg p.o. daily over a period of 12 weeks.
45482649|NCT04674670|Drug|Placebo|Placebo will be give daily (p.o.) over a period of 12 weeks.
45482650|NCT04674670|Drug|Bromocriptine Mesylate Capsules|In substudy 2, healthy controls and fibromyalgia patients will be administered a single dose of bromocriptine (1.25mg, p.o.) to investigate the effect of transiently increasing the availability of dopamine on fronto-striatal functional connectivity in relation to emotional-motivational pain processing.
45482651|NCT04674670|Drug|Amisulpride 400 MG|In substudy 2, healthy controls will be administered a single dose of amisulpride (400mg, p.o.) to investigate the effect of transiently decreasing the availability of dopamine on fronto-striatal functional connectivity in relation to emotional-motivational pain processing.
45690514|NCT03998709|Drug|Somatostatin|Somatostatin will be used to inhibit endogenous insulin secretion on either study day in both arms of the study
45690515|NCT03998709|Other|Dextrose|intravenous glucose will be used to raise fasting glucose in people with NFG / NGT
45690516|NCT03998709|Drug|Insulin|insulin will be used to lower fasting FFA and glucose in people with IFG / IGT
45690517|NCT03998709|Other|Intralipid|intravenous intralipid (Fat Emulsion) will be used to raise fasting FFA in people with NFG / NGT
45690518|NCT03025191|Behavioral|Speaker/Listener technique|Couple will learn taking turns as the speaker and as the listener who paraphrases the speaker's point.The couple will then identify an issue they have faced in their relationship and will role-play using the technique to discuss it.
45690519|NCT03025191|Behavioral|Social Support|Identification of and mapping sources of social support and the types of support provided by members of the network. Participants will also identify the strengths and weaknesses of their support network and think through ways to strengthen those networks.
45365460|NCT00895856|Other|Evaluation of the functional capacity|An evaluation (questionnaire) was performed by the Katz Index of individuals in this group, including personal issues (sex and age) and different levels of functional independence for the elderly in their basic activities of daily living (ABVD's) such as: bathe, dress, use the bathroom for withdrawals, transfers perform, has control of the sphincters and the food itself. Subject themselves, if capable of responding to the issues of consistency index, did. The answers were given to the auxiliary nurse responsible for care to residents.
45365461|NCT00896246|Drug|Klean-Prep®|Four litres of solution administered orally as a divided dose.
45365462|NCT00896246|Drug|Moviprep®|Two litres of solution administered orally as a divided dose
45365463|NCT00187135|Drug|Fentanyl|"Fentanyl - 1 mcg/kg in 3 ml normal saline~Fentanyl - 0.5 mcg/kg in 3 ml normal saline"
45365464|NCT00187135|Drug|EMLA|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). EMLA application has to be over at least 60 minutes and not to exceed 5 hours.
45482652|NCT04674670|Drug|Placebo|In substudy 2, healthy controls and fibromyalgia patients will be administered a placebo as for comparison with the effects of bromocriptine (healthy controls and patients) and amisulpride (healthy controls only) on fronto-striatal functional connectivity in relation to emotional-motivational pain processing.
45690520|NCT03025191|Behavioral|Problem-Solving|Couple will be taught steps to systematically analyze a problem and brainstorm solutions through a short video. Steps include identify the trigger/problem; identify the goal for addressing the problem; brainstorm possible solutions for each partner; evaluate the solutions and pick the best; and act on the best solution.
46051035|NCT04256382|Other|dementia pain care education|Participants are educated about dementia pain care.
46051036|NCT04256382|Other|dementia care education|Participants are educated about dementia pain care.
46051037|NCT02833389|Drug|Placebo|UTTR1147A matching placebo will be administered SC.
46051038|NCT02833389|Drug|UTTR1147A|UTTR1147A will be administered SC.
46051039|NCT00784147|Drug|Ibalizumab|Ibalizumab 800 mg IV every 2 weeks
46051040|NCT00784147|Drug|Ibalizumab|Ibalizumab 2000 mg IV every 4 weeks
45482653|NCT01318044|Drug|Propofol and Thiopental|"An initial bolus of 0.5 mg/kg of propofol will be administered over 1 minute. Supplementary boluses of propofol will be added until the UMSS score 3 are achieved.~An initial bolus of 2 mg/kg of thiopental will be administered over 1 minute. Supplementary boluses of thiopental will be added until the UMSS score 3 are achieved"
46051041|NCT04260360|Drug|NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension|NanoDoce is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate docetaxel nanoparticles within a well-characterized particle-size distribution. Prior to administration, the NanoDoce powder in vial is suspended with a sterile solution of Polysorbate 80 (0.0075% - 0.0375% (w/w))/Ethanol (0.06% - 0.3% (w/w)) in 0.9% Sodium Chloride for injection.
46051042|NCT05276505|Other|Lavender Aromatherapy Tablet|Before the breast biopsy, aromatherapy tablets was adhered to the patient's shoulder in the waiting room and were asked to sniff
45365465|NCT00187135|Drug|L.M.X4|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). In order to optimize transdermal anesthesia LMX4 application has to be over at least 30 minutes.
45845789|NCT05426772|Other|exercise and kinesiotaping|"Exercise: Aerobic exercise will be performed on the treadmill for 20 minutes with a maximum heart rate of 55%-65% and a perceived exertion of less than 3. The Moxy muscle oxygen monitor will take measurements over the quadriceps femoris muscle at this time.~Kinesiotaping: After 3 days, the same participants will be called for kinesiotaping application. The application will be applied to the quadriceps femoris muscle with the facilitation technique by a physiotherapist who has a kinesio taping training certificate."
45482654|NCT01353768|Other|retrospective chart review|retrospective chart review
45845790|NCT05425134|Diagnostic Test|PET/CT-based Deep Learning Signature|Deep Learning Signature Based on PET-CT for Predicting Occult Nodal Metastasis of Clinical N0 Non-small Cell Lung Cancer
46051043|NCT04256616|Other|This is an observational study that does not concern a direct intervention on patients and control subjects and does not interfere with the clinical management of patients.|"urine collection: DNA is isolated from urine samples (catheterized, washout, midstream) and the 16S rRNA gene is sequenced.~Specimen collection: Specimens collected during TURBT are selected by a pathologist and trasferred to the laboratory. The tissues are treated ex vivo with MMC."
46051044|NCT04254822|Procedure|Transjugular intrahepatic portosystemic shunt|The TIPS procedures will be performed by experienced interventional radiologists. polytetrafluroethylene-covered stents were used with initial balloon dilatation to 8 mm, aiming for a decrease in portal-venous pressure gradient to less than 12 mm Hg.
45365466|NCT00187135|Drug|Propofol|Propofol - 1 mg/kg increments every 30 seconds-1minute until loss of consciousness is indicated by lack of response to verbal command and loss of eyelid reflex.
45365467|NCT00896324|Behavioral|Cognitive Rehabilitation|The cognitive rehabilitation procedure will involve a curriculum of game-like cognitive exercises designed to facilitate graded practice of EF skills including attention, processing speed, mental flexibility, planning and logic. The exercises will be delivered to participants via a secure, password protected website created specifically for this study by the PI. Subjects will complete a curriculum of cognitive exercises 30 minutes per day, 5 days per week for 6-weeks.
45365468|NCT00896324|Behavioral|Active Neurofeedback Training|Neurofeedback training is a type of biofeedback during which the subjects will be trained to improve cognitive function by implementing certain cognitive strategies while receiving feedback of their own brain activity. This is done using an infrared spectroscopy (NIRS) system. NIRS measurements will be performed using an ETG-4000 NIRS system (Hitachi Medical, Tokyo, Japan), at two wavelengths of near-infrared light (695 and 830 nm). Each participant will have 2 or 3 sessions, each lasting approximately 30 minutes.
45365469|NCT00896324|Behavioral|Neurofeedback Training (placebo / Sham)|Neurofeedback training: 2-3, 30 min training sessions. For the sham placebo group, fabricated real-time data will be provided to the subject as feedback information hence enabling the subject to view information identical to experimental subjects but without accurate data pertaining to their own brain activation. The technician will be blinded to the subject's treatment condition assignment.
45482655|NCT01353846|Other|observation natural cycle|The patients natural reproductive cycle will be observed and compared to the second arm.
45482656|NCT01353846|Drug|Agonist GnRH; estradiol Valerate; progesterone|Medications: Agonist GnRH Acetate Triptoreline and Acetate Triptorelina and Estradiol Valerate and Natural micronized progesterone, 400 mg/12 hours vaginal administration
45690521|NCT03025191|Behavioral|Goal Setting|Couple will be introduced to the concept of short- and long-term goal setting, including components of goal and planning for potential barriers. The couple will then set a goal for themselves that incorporates the skills obtained during the intervention, such as strengthening ties in their social support network. Participants will fill in a worksheet outlining their goal, potential barriers, and solutions to those barriers.
45365470|NCT00528021|Drug|Placebo|Vehicle Only
45482657|NCT05726656|Other|traditional physical therapy session|manual lymph drainage-pneumatic compression and skin care
45482658|NCT05726656|Other|wii console based exercise|execise session using the wii console video games
45690522|NCT01744496|Drug|Rotigotine|Patches will contain 4 mg / 24 h (20 cm^2), 6 mg/ 24 h (30 cm^2), or 8 mg /24 h (40 cm^2) of Rotigotine. Application of study medication starts at the Baseline Visit. Rotigotine will be administered once daily starting at 4 mg / 24 h. Doses will then be up-titrated in weekly increments of 2 mg / 24 h until optimal or maximum dose (16 mg / 24 h) is reached and the Maintenance Period can be started. The duration of the Titration Period will vary from 1 to 7 weeks ± 3 days. The Maintenance Period will last 12 weeks ± 5 days. Thereafter, during the De-escalation Period, the dose of study medication will be decreased by 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
46051045|NCT04254822|Drug|Carvedilol|Carvedilol will be started at least 5 days after the index bleeding, unless a contraindication was present. Carvedilol will be start with 6.25 mg once a day and after 3 days increase to 6.25 mg twice-daily (the maximal dose was 12.5 mg/day). Systolic arterial blood pressure should not decrease <90 mmHg.
45482659|NCT01349010|Drug|Probucol|250mg (1 tablet) bid. p.o for 8 weeks
45845791|NCT05425056|Drug|Sirolimus|SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.
45482660|NCT01349010|Drug|Placebo|1 tablet bid. p.o for 8 weeks
45845792|NCT05405010|Other|Stair climbing and descending for 1 minute|Stair climbing and descending for 1 minute
45845793|NCT05405010|Other|Stair climbing and descending for 3 minutes|Stair climbing and descending for 3 minutes
45845794|NCT05405010|Other|Seated control|Seated control
46051046|NCT04254822|Procedure|Endoscopic variceal ligation|For endoscopic variceal ligation, the first elective session will be carried out within 7 days of randomisation. Then EBL sessions were scheduled every 10-14 days until variceal eradication (disappearance of varices or being too small to be sucked in the banding device).
46051047|NCT00891813|Drug|Zemplar (paricalcitol)|Zemplar (paricalcitol) dose will be calculated mcg=PARATHYROID HORMONE level/100; this will be provided 3 times per week. Dose will be adjusted by 2-4 mcg every 4 weeks according to the parathyroid hormone level.
45365471|NCT00528021|Drug|BGC20-0582|BGC20-0582 is a topical gel formulation of a naturally derived product. Subjects are treated either once (day 1) or twice (day 1 and 7) with either placebo or BGC20-0582 at one of the three concentrations. Following application of the BGC20-0582 lice treatment gel of placebo the product is rinsed from the subjects hair.
45365472|NCT00896402|Drug|Skin antisepsis with chlorhexidine|Chlorhexidine swabs will be used to antiseptically clean the skin, then cultures of the skin and femoral nerve block catheters will be analyzed via standard microbiological techniques
45365473|NCT00896402|Drug|povidone-iodine|Povidone-iodine swabs will be used to antiseptically clean the skin; then cultures of the skin and femoral nerve catheters will be performed by standard microbiologic techniques
45365474|NCT00560352|Drug|Dasatinib|Tablets; oral; approximately 2 years on study, depending on response; 50 mg once daily (QD), 100 mg QD, 140 mg QD
45365475|NCT00560352|Drug|Bortezomib|Powder; intravenous; approximately 2 years on study, depending on response; 1.0 mg/m^2 QD, 1.3 mg/m^2 QD
45482661|NCT05213260|Other|Flipped Teaching method|Before the clinical skill laboratory session, the students will receive the learning materials that they have to read and assimilate before the in-class part which will include interactive, discussion-oriented, and practice-oriented activities.
45482662|NCT01345812|Drug|HP-HMG|100 - 300 IU for stimulation of women in ART treatment
45482663|NCT01345812|Drug|recombinant FSH|100 -300 IU for stimulation of women in ART treatment
45690523|NCT01744496|Drug|Placebo|Placebo patches match the size of active patches 20 cm^2, 30 cm^2, or 40 cm^2 and will contain Placebo. Application of Placebo patches starts at the Baseline Visit. Placebo patches will be administered once daily starting with the equivalent of 4 mg / 24 h. Doses will then be up-titrated in weekly equivalents to 2 mg / 24 h until either optimal dose or maximum dose is reached. The maximum dose is the equivalent to 16 mg / 24 h. The duration of the Titration Period will vary from 1 to 7 weeks. The Maintenance Period will last 12 weeks ± 5 days. During the De-escalation Period, the dose of Placebo will be decreased by the equivalent to 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
45482664|NCT05232370|Drug|Angiotensin converting enzyme inhibitor|Angiotensin-converting enzyme inhibitors after Kidney Transplant
45482665|NCT05232370|Drug|Angiotensin Receptor Blockers|Angiotensin receptor blockers after Kidney Transplant
45482666|NCT01349088|Drug|Ixabepilone|Patients will receive ixabepilone at 40 mg/m2.
45482667|NCT01349088|Drug|Capecitabine|Patients will receive capecitabine at 2000 mg/m2.
45482668|NCT01349088|Drug|Motesanib|Patient will receive motesanib at 100mg or 125mg once daily dependent on outcome of Phase I, which will involve the first 3-6 patients.
45482669|NCT01349166|Behavioral|Behavior: Supervised physical training|protocol designed to evaluate effects of physical activity on cardiometabolic and inflammatory biomarkers according to glucose tolerance
45482670|NCT04490434|Drug|DWP14012|DWP14012 40mg, bid
45482671|NCT04490434|Drug|Celecoxib|Celecoxib 200mg, bid
45482672|NCT04490434|Drug|Naproxen|Naproxen 500mg, bid
45690524|NCT04007055|Diagnostic Test|Point of care screening for HPR|HPR testing using VerifyNow testing system. HPR is defined platelet reactivity units are greater than 234
45690525|NCT04007055|Drug|Ticagrelor 90mg|Participants who test positive for HPR will be prescribed ticagrelor 90mg twice daily instead of standard therapy with clopidogrel 75mg daily
45482673|NCT04490434|Drug|Meloxicam|Meloxicam 15mg, qd
45482674|NCT01353924|Biological|Bet v 1aF1-Alum + Bet v 1aF2-Alum|subcutaneous injection of equimolar mixture (20µg each) of Bet v 1aF1-Alum and Bet v 1aF2-Alum, three times in monthly intervals and a booster injection after one year
45482675|NCT01353924|Biological|Alum-Placebo|subcutaneous injection of Alum-Placebo, three times in monthly intervals and a booster injection after one year
45482676|NCT04643782|Device|ANNE Sleep|ANNE sleep system
45482677|NCT03143166|Drug|Dabigatran Etexilate|Tablet, film coated
45482678|NCT03143166|Drug|Rabeprazol sodium|Tablet
45482679|NCT02466568|Drug|Nivolumab|Participants will receive treatment with nivolumab as a 60-minute +/-5 minutes intravenous (IV) infusion on Day 1 and 15 of each 28-day cycle.
45482680|NCT02466568|Biological|GM.CD40L Vaccine|GM.CD40L will be injected intradermally every 2 weeks for 4 injections, then every month for 4 injections, then every 3 months until the patient is off treatment.
45482681|NCT02466100|Behavioral|goals of care|. Patients in the GoC intervention group, telephone coaching by a research nurse to help patients role-play talking with their HF providers. Both patients and their providers, will be provided with summaries of individualized, patient-centered information about patient preferences for communicating about end-of-life care and patient self-identified barriers to and facilitators of communication about end-of-life care with tips on how to initiate goals of care discussions. Providers of patients in the intervention group will also be provided with patient-specific prognostic information based on the Seattle Heart Failure Model.
45690526|NCT05366205|Dietary Supplement|Oral nutritional supplement|Enteral nutritional emulsion(TPF-T) will be given by oral intake,400ml per day, lasting for 7-10 days.
45690527|NCT05366205|Behavioral|Nutrition consultation|Nutritional treatment advice will be given
45690528|NCT01721330|Drug|Naltrexone|Up to 100mg of Naltrexone once a day for 6 weeks
46051048|NCT05528575|Dietary Supplement|Blueberry, cranberry, green tea extract, cocoa|tablet supplements, available readily.
46051049|NCT05528575|Dietary Supplement|GOS, Inulin, RS2|Prebiotic combination, Inulin, GOS and RS2
45690529|NCT01721330|Drug|Placebo|Placebo twice a day for 6 weeks
45690530|NCT05366127|Other|IGA score|IGA score will be assessed by 2 blinded investigators
45690531|NCT05366127|Other|BULLOUS PEMPHIGOID DISEASE AREA INDEX (BPDAI)|BPDAI will be assessed by 2 by 2 blinded investigators
46051050|NCT05528575|Dietary Supplement|prebiotics and polyphenols|combination of the same prebiotics and polyphenols as above
45482682|NCT02843646|Device|Walk Aide training|
45690532|NCT05631015|Other|AI recongnize disease and generate recommendations|According the endoscopic reports and pathological reports, the decision support system recognise patients' disease types and grades, and generate guidelines based survilliance or treatment recommendations.
46051051|NCT05528575|Dietary Supplement|Maltodextrin|maltodextrin, 10g per day
46051052|NCT04254900|Other|evaluating energy availability|energy availability will be determined by measuring energy intake, exercise energy expenditure and fat-free mass and using the following formula: energy availability = (energy intake - exercise energy expenditure) / fat-free mass
46051053|NCT02833311|Behavioral|Computer Tablet Group|A computer tablet application to set goals,self-monitor healthy behaviors, record condition-related symptom impact, and self-manage a problematic symptom.
46051054|NCT02833311|Behavioral|Paper and Pencil Group|Use of paper and pencil diaries and worksheets to set goals, record condition-related symptom impact, and self-monitor behaviors.
46051055|NCT02833311|Behavioral|Contact Control Group|Participants are prescribed an exercise program and given information on healthy eating.
45690533|NCT03595605|Behavioral|Ambulation|This group will be encouraged twice daily to ambulate
45690534|NCT03595605|Other|Standard of Care|Care as usual at inpatient NYU Langone
45690535|NCT04407195|Other|Exposure to the SARS-CoV-2|This is an observational design. Participants are exposed to the Covid-19 pandemic.
45690536|NCT03592407|Drug|Epacadostat|Given PO
45690537|NCT03592407|Other|Laboratory Biomarker Analysis|Correlative studies
45690538|NCT03592407|Biological|Pembrolizumab|Given IV
45690539|NCT03592407|Other|Pharmacodynamic Study|Correlative studies
45690540|NCT03593187|Drug|Cal-1 (LVsh5/C46) drug product|Autologous CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct
46051056|NCT04255056|Drug|Pyrotinib|"Pyrotinib is administered orally at 400 mg daily from day 1 of the first cycle to day 21 of the fourth cycle or to the day of surgery, within 30 minutes after breakfast.~Epirubicin (90 mg/m2), intravenously, every 21 days. Cyclophosphamide (600 mg/m2), intravenously, every 21 days."
45690541|NCT04258293|Diagnostic Test|Blood sampling|fasting venous glycemia, venous glycemia after sugar loading, glycated hemoglobin and platelet count
45690542|NCT04254159|Other|Superimposed Neuromuscular Electrical Stimulation|NMES will be applied during each strengthening exercise session. A dual channel NMES stimulation device will be used with biphasic symmetric constant current impulses with a pulse width 300ms, a frequency of 50 Hz and a duty cycle of 10s on and 20s off protocol for 3 days a week for eight weeks.
46051057|NCT00783835|Drug|Long-Acting Methylphenidate|Long-Acting Methylphenidate within the range of 18, 36, 54 and 76 milligram will be orally administered once daily up to Day 56.
46051058|NCT04248075|Device|Electroencephalogram|Electroencephalogram is performed before, during, and 1 day after surgery in elderly patients undergoing spinal anesthesia.
45365476|NCT00560352|Drug|Dexamethasone|Tablets; oral; approximately 2 years on study, depending on response; 20 mg QD
45365477|NCT00892892|Drug|Rilmenidine|1 mg Rilmenidine per day versus
45690543|NCT04254159|Other|Quadriceps Strengthening|Quadriceps strength training will be done with resistive elastics bands for 3 days a week for eight weeks.
45690544|NCT04254159|Behavioral|Patient Education Program|The aim of patient education is to increase awareness of patients about COPD and develop skills to better manage their disease. The patient education will be performed at least once via face to face interview. Education topics will be covered basic information about COPD, environmental risk factors, monitoring and managing the signs and symptoms of their disease, energy conservation techniques and relaxation positions to reduce dyspnea and usage of a specific inhaler.
45690545|NCT04254159|Other|Aerobic Exercise Training|Exercise training will be comprised of cardiovascular endurance training with cycle ergometer and lower extremity strength training. The exercises will be done 3 days a week at the clinic under the supervision of physiotherapist. Total duration of exercise training will last for 8 weeks
46051059|NCT05031546|Drug|Difelikefalin|IV Difelikefalin 0.5 mcg/kg administered after each dialysis session (3 times/week)
46051060|NCT04254744|Drug|Sevoflurane|Sevoflurane inhalation for anesthesia
45365478|NCT00892892|Drug|Nitrendipine|20 mg Nitrendipine per day
45365479|NCT04037696|Behavioral|General Health Promotion Approach|"The trained Research assistants will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting."
45365480|NCT04037696|Behavioral|Control|The subjects will be given general brief advice and a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention.
45365481|NCT00944736|Dietary Supplement|VSL#3|1 packet BID
45365482|NCT00944736|Dietary Supplement|Placebo|1 inactive packet BID
45365483|NCT00887900|Procedure|Deep anterior lamellar keratoplasty (DALK)|Deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
45690546|NCT03595371|Drug|dapansutrile|500 mg dapansutrile administered twice daily (with a potential to increase the dosage to 2 g dapansutrile daily) for a duration of up to 14 consecutive days.
45690547|NCT03978585|Device|high tone external muscle stimulation|Participants receive self-administered home based high tone therapy for 8 weeks for 30 minutes daily after device instruction
45365484|NCT00887900|Procedure|Penetrated keratoplasty|Regular corneal transplant using the penetrated keratoplasty technique
45365485|NCT00944814|Dietary Supplement|LNS with zinc|Lipid-based nutrient supplement (LNS) containing 10 mg zinc/20 g LNS dose
45365486|NCT00944814|Dietary Supplement|LNS without zinc|LNS containing no zinc
45365487|NCT00527787|Drug|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
45365488|NCT00527787|Drug|Naproxen|Naproxen (500 mg) dosed twice daily (bid) orally
45365489|NCT00893048|Drug|Prednisone|Prednisone, 60 mg, one time at time of diagnosis
45365490|NCT00893048|Drug|Placebo Oral Tablet|Placebo
45482683|NCT02466178|Device|Serene RF System|The Serene RF System provides percutaneous delivery of radiofrequency (RF) energy to a targeted nerve.
45482684|NCT05264818|Procedure|Glycocheck|Assessment of the sublingual microvascularization
45482685|NCT05264818|Procedure|Ophthalmological examinations|"Description :~Measurement of best corrected distance visual acuity with ETDRS (Early Treatment Diabetic Retinopathy Study) Measurement of intraocular pressure by aplanation and forced air tonometer Central corneal thickness measurement with OCT (Optical Coherence Tomography) Non-mydriatic retinophotography Humphrey 24-2 visual field OCT-RNFL (Optical Coherence Tomography - retinal nerve fiber layer)"
45482686|NCT04742374|Biological|Blood sampling|Blood sampling before and after each type of cycle, Single Plasma Exchange or Double Filtration Plasmapheresis
45482687|NCT02879994|Other|Laboratory Biomarker Analysis|Correlative studies
45690548|NCT03978585|Device|transcutaneous electrical nerve stimulation (TENS) therapy|Participants receive self-administered home based TENS therapy for 8 weeks for 30 minutes daily after device instruction
45365491|NCT00940368|Dietary Supplement|Provision of capsules containing ginger powder or placebo|"The patients(children and adolescents) will be provided with Capsules containing either ginger powder or placebo on the three days when they receive chemotherapy.~For weight category 1(20-40kg),6 capsules are given in three divided doses and the amount of ginger powder administered per day is 1 gram.~For weight category 2(40-60kg), 5 capsules are given in three divided doses and the amount of ginger powder administered per day is 2 gram."
46051061|NCT05274711|Other|Whole body vibration training|The participants will be instructed to stand on the vibration platform bare footed and distribute their weight evenly on both feet (fig 3). Next, they will be asked to do a head and neck retraction while looking forward with their knees at 30 degrees of flexion. In order to prevent fatigue in the subject's cervical area due to holding their head and neck in retraction, they will be asked to hold this position for 15 seconds then rest for 5 seconds. Since each set will last 60 second this allowed the subjects to do 3 retractions in each set. In total each subject will perform 15 retractions during the training. The subjects will experience a vertical vibration at a frequency and amplitude of 30 Hz and 4 mm during the sets (Salami et al., 2018).
45365492|NCT00608426|Behavioral|Proactive Outreach with choice of telephone or in-person smoking cessation services|This group of participants is sent a recruitment letter, then receives a phone call to offer them their choice of smoking cessation services (either telephone care or in-person care).
45365493|NCT00557076|Behavioral|Familiar Auditory Sensory Training|Patient is provided with customized recordings of stories told by people well known to the patient at least 1 year prior to injury. The stories represent specific events experienced by both the patient and the storyteller. Patients received FAST for 10 minutes 4 times per day, with at least 2 hours in between, for 6 week.
45365494|NCT00557076|Behavioral|Sham Auditory Sensory Training|The sham intervention is zero minutes of Familiar Auditory Sensory Training. Each day for 6 weeks 0 minutes of Familiar voice stimulation will be provided in 10 minute daily segments for 6 weeks. Each 10 minute recording is a digital recording of silence.
45365495|NCT00942864|Drug|ranibizumab|ranibizumab 0.5mg (0.05ml volume), intravitreal injection first 3 injection every 4 weeks additional injection (optional) according to the judgement of doctor
45365496|NCT04036448|Drug|REVLIMID®|REVLIMID®
45482688|NCT02879994|Biological|Pembrolizumab|Given IV
45482689|NCT02466022|Drug|Dexmedetomidine|Bolus dose prior to spinal anesthetic
45482690|NCT02466022|Drug|Bupivicaine|Intrathecal hyperbaric bupivicaine 12.75mg
45482691|NCT02466022|Drug|Normal Saline|Bolus 0.1cc/kg Normal Saline over 10 min
45482692|NCT02466022|Drug|Fentanyl|Intrathecal Fentanyl 10ug
45482693|NCT02466022|Drug|Midazolam|0-4mg of IV Midazolam prn for rescue sedation
45482694|NCT03943758|Dietary Supplement|Prepackaged Low-residue diet|Subjects in the prepackaged Low-residue diet group were given 6 packs (60g/pack) pre-packaged formula LRD and asked to use the formula according to individual needs prior to colonoscopy.
45482695|NCT03943758|Dietary Supplement|Self-prepared Low-residue diet|Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy.
45690549|NCT05634057|Drug|Anisodamine hydrobromide|The anisodamine hydrobromide treatment group is on the basis of conventional treatment.
45690550|NCT05634057|Drug|Heparin|The heparin treatment group is on the basis of conventional treatment.
45690551|NCT05634057|Drug|Anisodamine hydrobromide combined with heparin|The anisodamine hydrobromide combined with heparin treatment group is on the basis of conventional treatment.
46051062|NCT05274711|Other|Conventional physical treatment|Posturalcorrectionexercisesintheformofstretchingandstrengthening exercise. Manual stretching exercises as passive stretch to (upper trapezius, levator scapulae, sub occipitalis, scalene, sternocleidomastoid, and pectoralis major muscles), 30 seconds of 3-5 repetitions for each muscle, followed by 30 seconds of rest, as well as isotonic exercises (to strength deep neck flexors and scapular retractor muscles) 3 sets of 12 repetitions each with a 6 second hold in between, with a 1-2-minute rest between sets (Kisner. and Colby 2012).
45365497|NCT00943020|Dietary Supplement|Nutricia PreOp nutritional supplement|nutritional supplement
45365498|NCT00943020|Dietary Supplement|Lipid|Drink
45365499|NCT00943020|Dietary Supplement|Glutamine|Drink
45365500|NCT04017728|Device|Conventional Percutaneous Vertebroplasty|The cement is injected into the bone metastases directly.
45365501|NCT04017728|Device|Percutaneous Vertebroplasty with Rotary Cutter|The rotary cutter is applied before the cement injection. Then, the cement is injected with lower pressure.
45365502|NCT00945048|Device|electrical velocimetry|determination of cardiac output by electrical velocimetry
45365503|NCT00945048|Device|inert gas rebreathing|determination of cardiac output by inert gas rebreathing
45482696|NCT03937596|Drug|D-cycloserine|Daily oral D-cycloserine 100mg during the blinded phase (10 days).
45482697|NCT03937596|Device|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
45482698|NCT03937596|Drug|Placebo oral capsule|Daily oral placebo during the blinded phase (10 days).
45482699|NCT04606264|Drug|Neuraxial Analgesia|This randomized group will receive a neuraxial morphine injection (intrathecal morphine/hydromorphone).
45482700|NCT04606264|Drug|Regional Block 1: Paravertebral|This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
45482701|NCT04606264|Drug|Perphenazine|This randomized group will receive 8 mg of perphenazine orally preoperatively.
45482702|NCT04606264|Drug|Aprepitant|This randomized group will receive 40 mg of aprepitant orally preoperatively.
45482703|NCT04606264|Drug|Dimenhydrinate|This randomized group will receive 25 mg of dimenhydrinate orally preoperatively.
45482704|NCT04606264|Drug|Ondansetron 4 MG|This randomized group will receive 4 mg of ondansetron orally.
46051063|NCT04103827|Other|usability assessment|"Usability of Le Qoos will be assessed using a validated usability questionnaire"
45482705|NCT04606264|Drug|Dexamethasone|This randomized group will receive 4-5 mg of dexamethasone intravenously.
45482706|NCT04606264|Drug|Regional Block 2: QL1|This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
45482707|NCT03578172|Drug|human menopausal gonadotrophin|experimental group:Women will be given HMG 37.5-150IU daily followed by monitoring of the follicular growth (folliculometry) when serum Estradiol (E2)<100pg/ml，progesterone (P)<1ng/ml. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle ≥20mm in diameter followed by luteal phase support (using progesterone supplements) after 24 hours.
45690552|NCT02079987|Behavioral|ED-to-home care transition intervention|The Area Agency on Aging coach's role is to build self-management capabilities for the patient and their caregiver. During each contact, the coach reviews the four components of the Care Transition Intervention: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists patients use the PHR to document and maintain vital information and to communicate with providers.
45690553|NCT02079987|Other|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating ED physician and nurse as is the standard of care.
45690554|NCT04004403|Other|Alternate day fasting|"The diet involves consuming 600 kcal on the fast day and eat ad libitum at home on alternating feed days."
46051064|NCT02831361|Drug|Gemigliptin|
46051065|NCT02831361|Drug|Gemigliptin placebo|
46051066|NCT02831361|Drug|Metformin|For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
46051067|NCT02831361|Procedure|Diet/exercise questionnaire|"doing exercise with about intermediate intensity(50~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regualr diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -week2, week 1 week 7, week 13, week 19, week 25"
46051068|NCT00611052|Behavioral|the Adolescent Coping with Stress|A group cognitive intervention, manualized and highly structured. Includes 8 sessions (á 1.5 hours) and a booster session 6 months after termination of the actual intervention. Groups leaders are specifically trained for this course.
46051069|NCT00611052|Behavioral|Treatment as usual|The usual treatment received by the adolescent with mild to moderate self-reported depressive symptoms in school health care.
46051070|NCT00611052|Other|usual health education|usual health education given by the school nurses, targeted for healthy controls with no depressive symptoms according to the self-report scale
46051071|NCT04103905|Drug|Recombinant Humanized Monoclonal Antibody MIL62 Injection|The patients confirming to the eligibility criteria will be assigned to the 5 dose groups (200mg, 400mg, 800mg, 1000mg, and 1500mg, respectively) based on the sequence of inclusion. Each patient received an intravenous infusion of MIL62 on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
46051072|NCT02828631|Device|Macintosh laryngoscope|
46051073|NCT02828631|Device|McGrath videolaryngoscope|
46051074|NCT02828631|Device|Pentax videolaryngoscope|
45365504|NCT00945048|Device|spirometry|spirometry for testing the ventilatory function
45365505|NCT00945048|Device|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
45365506|NCT00896558|Drug|GSK1322322/placebo|GSK1322322/placebo escalating doses from 500mg to 1500mg
45482708|NCT03578172|Drug|hormone replacement therapy|Women will be given 17 β-estradiol hemihydrate 2 mg and estrogen gel 5 g daily from day 3 of the cycle then the endometrial thickness will be assessed on day 7 by transvaginal sonography (TVS). If the endometrium is ≥ 9 mm, luteal phase support (using progesterone supplements) will be started but if the endometrium is < 9 mm, estradiol will be continued until reaching appropriate endometrial thickness and then the luteal phase support will be started. The cycle will be cancelled If the estradiol administration >60 days.
45365507|NCT00896558|Drug|GSK1322322/placebo and midazolam|GSK1322322/placebo and 5mg midazolam
45690555|NCT04004403|Other|Exercise|The exercise intervention involves supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax.
46051075|NCT02828709|Device|Irreversible Electroporation|Guided by CT and accompanied by an external spacer for fixation, needle electrodes will be placed. The amount of probes and probe placement will be attuned for specific tumour size and location, granting 15mm between the electrodes with an active tip length of 15mm. IRE pulses with pulse intensity of 1500 V/cm will be delivered in 90 consecutive pulses of 90µs.
45365508|NCT00943176|Drug|Modafinil|100 mg tablets of modafinil or matched placebo will be given for a total of 12 weeks. Patients will be instructed to start one capsule once daily (modafinil or placebo), and dose will be titrated according to tolerability and response.
46051076|NCT05036148|Other|Data analysis|MH registry data will be screened for MH positive diagnosis
46051077|NCT05240937|Behavioral|mindfulness-based self-compassion will be applied|A mindfulness-based self-compassion program will be applied to this group of patients who have had breast cancer and have fully completed their treatment.
45365509|NCT00896636|Procedure|Random fine need aspiration (rFNA)|Deep infiltration into the tissue of each breast with up to a 21 gauge needle attached to a syringe with about 4-5 passes at each location (up to 8-10 passes per breast) under local anesthesia (lidocaine).
45365510|NCT00896636|Other|Mammogram|Standard mammography of both breasts to obtain images for breast density measurement.
45365511|NCT00129259|Biological|Anti-CD3 mAb|Daily 14-day dose escalation course at study entry, with possible second course after 12-month interval
45365512|NCT00129259|Other|Diabetes Standard of Care Treatment|Receipt of intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.
45365513|NCT00129259|Dietary Supplement|Iron supplementation|Immediately following randomization, all participants regardless of arm allocation begin iron supplementation with either ferrous sulfate or multivitamin with iron.
45365514|NCT00896714|Device|Closed loop anesthesia|Propofol and Remifentanil are administered automatically using a closed-loop system
45365515|NCT00943254|Other|High-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently watch two 10-minute videos on the metabolic syndrome and on getting started with exercise. They also receive all the paper-based educational material as in arm 2
45482709|NCT05726500|Diagnostic Test|Arterial blood gas analysis|The researches will collect 2 ml of arterial blood using an arterial line already in place for clinical purposes to perform and arterial gas analysis.
45482710|NCT05726500|Diagnostic Test|Venous blood gas analysis|The researches will collect 2 ml of arterial blood using a central venous line already in place for clinical purposes to perform a gas analysis.
45482711|NCT05726500|Diagnostic Test|Esophageal pressure monitoring|The researchers will position an esophageal balloon to evaluate esophageal pressure
46051078|NCT05014620|Other|Semi-directive interview|semi-structured exploratory interview
46051079|NCT02831205|Device|everolimus-eluting bioresorbable vascular (Absorb) scaffold|
46051080|NCT02831205|Device|everolimus-eluting cobalt-chromium (Xience) stent|
46051081|NCT04253340|Diagnostic Test|Bone mineral analyser|high resolution digital radiology (200 µm): D0 + M12 Trabecular Bone Score:D0 + M12 DXA scan:D0 + M12
46051082|NCT04260204|Procedure|Pediatric cardiac surgery|
46051083|NCT02831439|Behavioral|Basic public reporting|The basic intervention will comprise public reporting through the WCHQ website. Individual-level, claims data submitted for billing to third party payers by participating healthsystems will be used to (i) identify cohorts of women with incident breast cancer at the practice-level and (ii) construct the metrics for public reporting and individual benchmarking information. These data are consistent with Medicare and Marketscan claims in both format and content thereby ensuring seamless application of the validated algorithm as well as construction of outcome variables as proposed in Aims 1 and 2 of the study.
46051084|NCT02831439|Behavioral|Enhanced intervention|The enhanced intervention adds an app comprising a decision tool, patient education and communication information that will be delivering concise, readily accessible information about the main components of the intervention. Specifically, physicians in participating practices will be provided a smartphone-based, point-of-care application that will include i) a list of the unproven/ineffective interventions with statements about a) scientifically proven appropriate use; b) proven or suspected downsides to inappropriate use; ii) clinical calculators that allow physician to input individual patients' clinical/tumor characteristics for each test; iii) practice-specific summary of publicly reported results; and iv) printable patient information adapted from the ASCO Choosing Wisely website.
46051085|NCT02831439|Behavioral|Control group - observational|"Comparison states will be used to evaluate the interventions in light of possible secular trends in the region and the nation. The design strategy will enable estimates of the effectiveness of the basic intervention (Aim 1) by comparing (i) the pre-intervention rates to post-intervention rates as well as by comparing (ii) changes between the pre- and post-intervention periods for the treatment state (WI) relative to comparison states, neighboring states and others. A similar approach will be used in Part II to provide estimates of the enhanced intervention's impact relative to the basic intervention and contemporary usual care provided in control states, thereby enabling the cost-savings analyses proposed as part of Aim 3."
46051086|NCT04254432|Device|remote ischemic conditioning|RIC is a physical strategy performed by an electric auto-control device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times# two times per day. The duration of the treatment is 4 weeks.
45482712|NCT05726500|Diagnostic Test|Intrabdominal pressure|The researches will assess intrabdominal pressure using the urinary catheter system already in place for clinical purposes .
45482713|NCT05726500|Diagnostic Test|Electrical impedance tomopgraphy|The researches will evaluate regional ventilation distribution using Electrical impedance tomography at different levels of positive end-expiratory pressure
45690556|NCT03596385|Drug|Beta blocker|long-term maintenance beta-blocker therapy
45690557|NCT03996135|Device|Cannulation with AccuVein AV400|Cannulation using AccuVein AV400 device
45690558|NCT03995511|Procedure|Bilateral Sagittal Split Osteotomy|Surgical correction of lower jaw deformity by performing bilateral intraoral sagittal osteotomy of the mandible under general anesthesia.
45690559|NCT03595137|Device|Sono with Device|In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
46051087|NCT02828553|Other|Aggressive planned ambulation with a mobility aide|A trained mobility aide will provide aggressive ambulation at least 3X per day for all patients on the heart failure unit
45365516|NCT00943254|Other|Low-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently receive paper-based educational material on the metabolic syndrome,pre-diabetes, and hypertension. They also receive pamphlets on dietary management of high cholesterol and triglycerides, and the importance of exercise and weight loss.
45365517|NCT04017572|Procedure|Automated peritoneal dialysis (APD)|Automated peritoneal dialysis (APD) using the Baxter HomeChoice Pro Cycler.
45365518|NCT00896792|Other|counseling intervention|
45365519|NCT00896792|Other|questionnaire administration|
45482714|NCT01345890|Procedure|electrical stimulation|sub motor threshold stimulation of mylohyoid muscles
45482715|NCT01354080|Other|massage based on the tensegrity rule|The massage consist of brushing the skin, stroking of the lower abdominal integuments. Elastic deformation of the thoracolumbar fascia. Then the abdominal integuments were elastically deformed by kneading to normalize the rest tension of the muscles of the abdominal integuments as well as, indirectly, the myofascial apparatus of the pelvic floor and in this way improve venous blood and lymph outflow from the large intestine and the sigmoid colon area. The next treatment stage - performing circular movements within the limits of the skin's mobility at 1/3 of the medial part of the thigh. By stroking movements in the direction of the armpit in accordance with the run of the thoracoepigastric and costalaxillary veins. Then the intercostal muscles were deformed.
45690560|NCT03595137|Device|Sono only|In group S, sono-guided internal jugular vein cannulation was performed after induction of anesthesia
45690561|NCT03594903|Behavioral|video intervention (therapy expectation violation)|The investigators asked experts (psychotherapist and scientists in the area of clinical psychology) about typical therapy expectation violations in therapy and searched the literature for information about typical therapy processes and outcomes. Having these information they designed a script for the experimental video. The patients in the video are played by actors aged from 28 to 58 years (two male and two female actors). Patients are representing common mental disorders (depression, anxiety disorder, alcohol addiction, depression after physical disease). The abbreviated name, age and disorder of the patients is displayed for 3 seconds in the video. The patients are giving information about the mostly positive outcome and the process of their therapy. All participants are watching a video with all patients (7 minutes). The videos (control and experimental group) have been evaluated by 12 experts (psychotherapist and scientists in the area of clinical psychology).
46051088|NCT05331534|Behavioral|Eye-tracking assisted attention control training (ACTo)|"ACT is made of 8 sessions of a Dot-Probe Task (DPT). The DPT is a computerized task in which two visual stimuli (one emotional stimulus and one neutral stimulus) are displayed simultaneously on the left and right side of the screen. AB towards or away from emotional stimuli is respectively inferred by faster or slower responses to detect a probe replacing an emotional stimulus than a probe replacing a neutral stimulus. In the ACT therapy, the probe replaces the negative and neutral stimuli with equal frequency.~ACTo will combine ACT with eye tracking methodology, allowing to directly record eye movements of the participants during the task. At each trial, images will be displayed for 2s and the negative image will be replaced by the neutral image (and vice versa) if the patient continues to explore the negative image beyond the first fixation, in order to block any additional attentional engagement."
46051089|NCT05331534|Behavioral|Attention control training (ACT)|Patients will benefit from the ACT as described above; at each trial, images will remain on screen for 2s.
46051090|NCT00783289|Other|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.
46051091|NCT00783289|Biological|Benralizumab 25 mg|Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
46051092|NCT00783289|Biological|Benralizumab 100 mg|Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
45365520|NCT00896792|Other|survey administration|
45365521|NCT00896792|Procedure|end-of-life treatment/management|
45365522|NCT00896792|Procedure|psychosocial assessment and care|
45365523|NCT00940524|Drug|Dasatinib, Mitoxantrone, Cytarabine|"INDUCTION- Dasatinib† (dose levels 1-3) *continuously Cytarabine 3 g/m2 IV over 3 hours Mitoxantrone 80 mg/m2 IV Myeloid growth factor on day 7 until ANC > 1,000/μl x 2 days Allopurinol 300 mg BID-TID x 7 days (starting 6-12 hours prior to chemotherapy) Dexamethasone 0.1% eye drops q6h while on cytarabine (start prior to the first dose of cytarabine and continuing at least 24 hours after the last dose) IT Methotrexate 12 mg days 2 and 4~CONSOLIDATION A-Dasatinib† (dose levels 1-3) *continuously Vincristine 2 mg IV Dexamethasone 10 mg/m2/d days 2 to 29, then taper over 10 days Sulfamethoxazole/Trimethoprim 1 DS BID three times weekly days 2 to 29, then BID daily days 30 to 45 IT Methotrexate 12 mg days 8, 15, 22 and 29"
45482716|NCT01354080|Other|massage - classical abdominal|The classical abdominal massage consisted of circular movements performed on the abdominal integuments by superficial and deep stroking techniques according to the colonic route (clockwise)
45365524|NCT00186901|Drug|Calcium carbonate (Tums), vitamin D|Calcium carbonate 100mg/day (Tums), vitamin D 800 units/day
45365525|NCT00186901|Other|Placebo|Placebo
45482717|NCT03928158|Drug|LCZ 696|50-100-200 mg tablet
45482718|NCT03928158|Drug|Valsartan|40-80-160 mg tablet
45847833|NCT02979444|Behavioral|Mothers and Babies Groups|"The Mothers and Babies group intervention is comprised of 6, two hour sessions. It is divided into three overall sections, one on each of the following Cognitive Behavioral Theory components; Pleasant Activities, Thoughts, and Contact with Others. In each of these sections, participants are first taught to understand how the component influences her mood. This teaching of the relationships between CBT components and mood is referred to as psychoeducation. In addition to psychoeducation, participants also receive concrete skills in each of the three sections (pleasant activities, thoughts, contact with others). These skills are intended to provide participants with a toolkit of approaches they can use to improve their mood."
46051093|NCT00783289|Biological|Benralizumab 200 mg|Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.
46051094|NCT02828787|Other|MRI|"The study will take place in two phases. The first phase consists of a meeting of inclusion. During this phase, the principal investigator of the study will verify the inclusion criteria for patients using a questionnaire and an interview. Then, the effects of video on each person will be tested to verify that they well induce itch and measure it using visual analogue scales. This phase will also test the benefit of the relief by scraping and cold.~The second phase will be carried out only if the mental induction of pruritus has been possible in the first session. It involves acquiring the corresponding physiological signals fMRI. It will also be achieved during this phase an anatomical image of the brain of each participant and an image in DTI.~The phases will be carried out in this order in each participant. They will be separated at least one night."
45365526|NCT00893126|Procedure|CCTA Scan (Coronary CT Angiogram)|CCTA scan will be performed to study and evaluate the prevalence and severity of coronary artery disease (CAD).
45365527|NCT00945126|Other|Hematopoietic stem cell product from haploidentical or unrelated donor CD3/CD19 depleted with CliniMACS|The aim is to transplant 7x106 CD34+/kg of recipient body weight.
45365528|NCT00888056|Procedure|Bilateral chronic electrical stimulation of the hypothalamus/fornix|Clinical, neuro-psychological, biological and imaging assessment will be performed 3 and one month before and 3, 6, 12 and 24 months after surgery. Bilateral electrodes (Medtronic 3389) will be implanted, under local anesthesia, by MR-guided frame-based stereotaxy, in the hypothalamic part of the fornix, before its entry in the mamillary body (well defined on T2 weighted sequences). Intra-operative stimulation will be used to search adverse effects or acute effects. Electrodes will be connected to the generator (Kinetra, Medtronic) under general anesthesia. Chronic high-frequency stimulation will be delivered immediately after surgery.
45482719|NCT05174884|Drug|22.2 mg Etonogestrel (ENG)|Subdermal insertion of a single Casea S pellet (22.2 mg ENG) in healthy female participants
45482720|NCT05174884|Drug|44.4 mg Etonogestrel (ENG)|Subdermal insertion of a two Casea S pellet (44.4 mg ENG) in healthy female participants
45482721|NCT05174884|Drug|22.2-66.6 mg Etonogestrel (ENG)|Subdermal insertion of 1-3 Casea S pellets (22.2 - 66.6 mg ENG) in healthy female participants
45482722|NCT01354158|Drug|Droxidopa|Dose titration of placebo, 100mg, 200mg, 400mg of Droxidopa will be given to assess the effects of Droxidopa on blood pressure and cerebral blood flow.
45482723|NCT02466490|Drug|Fimasartan|Fimasartan tablets
45482724|NCT02466490|Drug|Fimasartan; Hydrochlorothiazide|Fimasartan plus hydrochlorothiazide fixed dose combination tablets
45482725|NCT03542682|Device|Quick Bolus|"Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via quick bolus of 15 units per minute during a euglycemic clamp."
45482726|NCT03542682|Device|Standard Bolus|"Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via standard bolus of 1.5 units per minute during a euglycemic clamp."
45482727|NCT01345968|Drug|Ferinject 50 mg/ml|iv administration of max. 50 ml (Dilution: 20 ml in 30 ml NaCl 0.9%) in 30 minutes
45482728|NCT01345968|Drug|NaCl 0.9%|iv administration of max. 50 ml in 30 minutes
45482729|NCT04547842|Drug|Mirtazapine 30 MG|mirtazapine is given in arm M to prevent PONV
45482730|NCT04547842|Drug|Dexamethasone|Dexamethasone is given in arm D to prevent PONV
45482731|NCT03928080|Diagnostic Test|Bleeding on brushing|Index tests are bleeding on brushing and aMMP-8 Gold standard: clinical diagnosis performed by specialist
45365529|NCT00943332|Procedure|femur fracture repair|all participants will have undergone surgical intervention to repair a femur fracture, the investigators will simply be collecting data after the procedure; participants will not be consented until after the procedure
45365530|NCT04036370|Procedure|PECS group|Pecs block performed using ultrasound guidance. Standard pain follow up and monitorization will be performed.
45482732|NCT03142932|Device|Individualized carbon monoxide (iCO) monitor|a personal monitor for a breath test for carbon monoxide (CO)
45482733|NCT03142932|Other|COach2Quit smartphone application|This smartphone application works in conjunction with the iCO monitor
45482734|NCT03142932|Behavioral|Cessation counseling|The advice to quit smoking message will follow NCI's 5 A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.
45365531|NCT04036370|Other|Control group|Standard pain follow up and monitorization will be performed.
45365532|NCT00943410|Radiation|external beam radiation therapy|Radiation therapy will consist of 50Gy in 2Gy fractions to the breast/chest wall and regional lymphatics for 5 consecutive days up to 5 weeks for surgical candidates and 7 weeks for non-surgical candidates
45482735|NCT03536676|Other|'Egg-cellent' Breakfast in the Classroom|Includes the additional 2 eggs per day
45482736|NCT03536676|Other|Breakfast in the Classroom|Receives the standard meal for Breakfast in the Classroom
45482737|NCT00702052|Drug|Everolimus|Everolimus tablets
45482738|NCT05725018|Biological|EB-101 Surgical application of RDEB wounds|"EB-101 autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7~Other Names:~• LZRSE-Col7A1 Engineered Autologous Epidermal Sheets [LEAES]"
45482739|NCT04520698|Behavioral|UPLIFT-AD|Access to palliative care needs screening, advance care planning conversations, palliative care consultations
45482740|NCT04499326|Other|Validated quality of life questionnaire (EQ-5D & C-CAP)|Patient quality of life to be assessed at baseline, 1, 2, 3, 4, 6, 9 and 12 months
45482741|NCT03140280|Drug|Freeze-Dried Black Raspberry Powder|25 gm (2x/day) of freeze-dried black raspberry powder taken orally in 8 ounces of water for 12 weeks. If the patient is tolerating BRBs well and is benefiting from therapy, he or she will continue treatment for a total maximum of 48 weeks.
45482742|NCT05157880|Behavioral|Recovering Together|In the skills-based intervention group, sessions focus on developing skills to cope and manage ANI related stressors. The intervention will be tailored consistent with AHA recommendations for ANI skills-based interventions and will include 2 general and 4 specific modules. It is anticipated that the intervention will have 6 sessions with 2 general sessions delivered, in person if possible, within the NICU, or through live video using Zoom if patients leave the hospital before sessions occur, and 4 tailored specific sessions (chosen from by the dyads from 6 available modules) to be delivered via live video using Zoom.
45482743|NCT05157880|Behavioral|Recovering Together|Those in the educational program will receive general health information that mimics the skills-based intervention, but without teaching any of the resiliency or interpersonal communication skills that are hypothesized to be responsible for improvement in emotional distress. There will also be 6 sessions, 2 in-person dyadic visits in the NICU and 4 dyadic virtual visits following discharge. The educational program group will not have the opportunity to specify which modules they would like to take; the modules will be predetermined. All participants will receive medical care as determined by their medical team.
45482744|NCT01354392|Drug|AZD1152|Up to 6 cycles. Each cycle consists of 800 mg. IV infusion over 96 hrs.
45482745|NCT01318200|Procedure|Transarterial Chemoembolization|Transarterial Chemoembolization will be given within 12 weeks and up to 3 staged procedures, depending on the architecture of the tumor vasculature.
45365533|NCT00943410|Drug|Herceptin|Patients who are already receiving weekly Herceptin® will continue weekly Herceptin®, 2mg/kg IV on day 1 of each week of radiotherapy. Patients who have not been receiving weekly Herceptin® as a component of systemic therapy will begin Herceptin® one week prior to beginning radiotherapy with a loading dose of 4mg/kg followed by weekly Herceptin® at 2mg/kg on day 1 of each week of radiotherapy
45365534|NCT00896948|Genetic|Southern blotting|
45690562|NCT03594903|Behavioral|video intervention (symptoms+ expectation)|Participants in the control group are watching a video with the same patients (actors) as in the experimental video. In this video patients are shown before or after the first therapy session. They are giving information about symptoms and their expectation on therapy but NOT about therapy outcome.
45690563|NCT05633589|Biological|Sc610 cell injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell product preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and amplification factor, and cell quantity are amplified. The obtained Sc610 is used for one-time intravenous infusion."
45847834|NCT02881008|Drug|Entecavir|
45365535|NCT00896948|Genetic|TdT-mediated dUTP nick end labeling assay|
45365536|NCT00896948|Genetic|gene expression analysis|
45365537|NCT00896948|Genetic|protein expression analysis|
45365538|NCT00896948|Other|flow cytometry|
45365539|NCT00896948|Other|fluorescent antibody technique|
45365540|NCT00896948|Other|immunoenzyme technique|
45365541|NCT00896948|Other|immunohistochemistry staining method|
45365542|NCT00896948|Other|immunologic technique|
45365543|NCT00186121|Drug|Anastrozole (Arimidex)|Anastrozole is a prescription hormonal treatment that helps fight breast cancer by lowering the amount of estrogen in the body. It is a non-steroidal aromatase inhibitor, which significantly lowers serum estradiol (estrogen) concentrations, without interfering with the formation of adrenal corticosteroids or aldosterone
46051095|NCT04358445|Other|Magnesium-Rich Artificial Cerebrospinal Fluid|The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the operating room in a special container. Finally, it will be used in the operation by the neurosurgeons. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.
46051096|NCT05591053|Device|ActivSight|Use of ActivSight in patients undergoing laparoscopic or robot assisted esophagectomy.
46051097|NCT04245579|Other|Multifactorial Memory Training Program (UMAM method)|
45365544|NCT00186121|Drug|Goserelin (Zoladex)|Goserelin is a palliative treatment of advanced breast cancer in pre- and perimenopausal women
45365545|NCT00897026|Drug|cyclophosphamide|
45365546|NCT00897026|Drug|doxorubicin hydrochloride|
45365547|NCT00897026|Drug|paclitaxel|
45365548|NCT00897026|Genetic|fluorescence in situ hybridization|
45365549|NCT00897026|Other|immunohistochemistry staining method|
45365550|NCT00897182|Genetic|microarray analysis|
45365551|NCT00897182|Genetic|polymerase chain reaction|
45365552|NCT00186043|Drug|Quetiapine/Seroquel|Quetiapine/Seroquel
46051098|NCT05583955|Drug|NOE-105|Escalating dose levels of NOE-105 will be given and maximum tolerated dose will be maintained
45365553|NCT00186043|Drug|Placebo|Placebo
45365554|NCT00897260|Drug|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|"To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.~DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x~Fludarabine 40mg/m2 10:00am (After TBI) over 60 minutes x x x x Umbilical cord blood infusion (minimum of 24hrs after Flu infusion) x~Fludarabine dose adjustment:~70ml/min: decrease dose by Creatinine Clearance 20% Fludarabine dosing will be based on the 40% adjusted ideal body weight.~UCB Infusion"
45847835|NCT02881008|Drug|Myrcludex B|
46051099|NCT05583955|Drug|Placebo|Escalating dose levels of matching Placebo will be given
46051100|NCT05149911|Behavioral|Life Coaching|Sessions with a professional life coach.
46051101|NCT02828319|Drug|Z-213|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
46051102|NCT04025281|Other|Extra Virgin Olive Oil|Participants will consume a meal prepared with 50 mL extra virgin olive oil. The meals will be prepared and provided to the study participants in the cafeteria of Griffin Hospital, where the Prevention Research Center is located. With the exception of the type of olive oil used in the meals, the meal plan will be comparable in all the intervention phases for the same individual.
45365555|NCT00897260|Radiation|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x
45365556|NCT00897260|Procedure|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|
45365557|NCT00897338|Other|flow cytometry|laboratory analysis
45365558|NCT00897338|Other|fluorescence activated cell sorting|laboratory analysis
45365559|NCT00897338|Other|immunohistochemistry staining method|laboratory analysis
45365560|NCT00897338|Other|immunologic technique|laboratory analysis
45365561|NCT00897338|Other|biomarker analysis|laboratory analysis
45365562|NCT00185965|Drug|CPG 7909|6 mg intratumoral injection, administered immediately before 2 Gy radiotherapy (RT) to a designated tumor lesion, about 24 hours later after a 2nd 2 Gy RT dose, then weekly for 8 additional weeks (total of 10 injections).
45365563|NCT00607880|Procedure|vascular access device placement|
45365564|NCT01076491|Drug|mannitol|inhaled mannitol - single doses of either 70 mg or 90 mg
45365565|NCT02541890|Behavioral|Work place intervention|Meeting at the work place including the patient, the employer and the rehabilitation therapist. Aim of meeting is to discuss challenges and possibilities in the patient's return to work process and to make a plan for return to work.
45365566|NCT01076569|Other|laboratory biomarker analysis|Correlative studies
45365567|NCT00893282|Device|BackStop|BackStop in a gel plug that potentially prevents retropulsion during intracorporeal lithotripsy.
45365568|NCT00893282|Device|Intracorporeal lithotripsy without the use of an anti-retropulsion device|
45365569|NCT00127933|Drug|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
45365570|NCT00127933|Drug|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
45365571|NCT00127933|Drug|Herceptin (HER2-neu positive patients only)|4mg/kg iv (loading dose) followed by 2mg/kg iv weekly
45365572|NCT00127933|Drug|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
45365573|NCT00127933|Drug|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
45365574|NCT03875313|Drug|CB-839|CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.
45365575|NCT03875313|Drug|Talazoparib|Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.
46051103|NCT04025281|Other|Refined Olive Oil|Participants will consume a meal prepared with 50 mL refined olive oil in the cafeteria of Griffin Hospital. With the exception of the olive oil used, the meal plan will be comparable in each the intervention phases for the same individual.
45365576|NCT01008345|Drug|ezetimibe|Patients will receive 10 mg/day of ezetimibe for 8 weeks
45365577|NCT04675515|Behavioral|Intensive Tobacco Treatment|Bi-weekly tobacco treatment counseling and regular carbon monoxide monitoring
45365578|NCT03999255|Procedure|combined respiratory support (CRS)|combined respiratory support (CRS) which consisted of reduction of tidal volume to 250-300 ml and respiratory rate to 4-5 per minute with transcatheter high-frequency jet ventilation (HFJV) through an endotracheal tube with a respiratory cycle frequency (RCF) of 300 per minute and maintained during RIRS.
45365579|NCT05239533|Drug|177Lu-labeled-girentuximab|"The initial starting dose/Dose Level 1 of 177Lu-labeled-girentuximab is 1804 MBq/m2. if 0/3 or 1/6 DLTs, participants will be treated at Dose Level 2 177Lu-girentuximab 2405 MBq/m2. >/= 2/6 DLTs, Dose Level -1 is 177Lu-girentuximab 1353 MBq/m2~Once the MTD is established, a Simon two-stage optimal design will commence."
45690564|NCT04003779|Other|Room configuration|Adjust distance, handrails, degrees of turn for participant
45690565|NCT01828021|Biological|Margetuximab|Anti-HER2 monoclonal antibody
45690566|NCT03594669|Other|Intervention|Multi-modal sensorimotor training interventions, including vestibular, oculomotor, neuromotor, and postural control/ balance exercises.
46051104|NCT02828163|Other|Autologous Platelet rich plasma|Intralesional injection of 1 milliliter of autologous Platelet rich plasma in the oral erosions every 2 weeks for 3 months.
45365580|NCT05239533|Drug|Nivolumab|Nivolumab 240mg q2wk
45365581|NCT05239533|Diagnostic Test|89Zr-girentuximab PET/CT|All patients will undergo a 89Zr-girentuximab PET/CT scan prior to every 177Lu-girentuximab administration
45365582|NCT05239533|Diagnostic Test|177Lu whole body (WB) planar and SPECT/CT scans|177Lu whole body (WB) planar and SPECT/CT scans will be performed after each administration of 177Lu-girentuximab
45365583|NCT04828083|Drug|Lidocaine IV|Intravenous lidocaine of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
45365584|NCT04828083|Drug|Saline IV|Intravenous saline of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
45482746|NCT01318200|Radiation|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) or 36 Gy(12 Gy in 3 fractions). Tumors should receive the higher dose unless normal tissue constraints cannot be met.
45482747|NCT01346124|Radiation|High Dose Intensity Modulated Proton Radiation|Radiation given once a day Monday-Friday
45365585|NCT05225961|Drug|Tirofiban|An intravenous bolus of 500 micrograms of Tirofiban will be intravenously administered in five minutes with an infusion pump (infusion rate: 120 milliliters / hour), which is equivalent to 500 micrograms of Tirofiban. After five minutes, a dose reduction will be programmed to 200 micrograms / hour (infusion rate: 4 milliliters / hour for 24 hours (maximum total infused dose of 96 milliliters). Tirofiban infusion started in the neuroradiology room should be maintained until a control brain computerized tomography (CT) scan is performed at 20 hours (+/-2 hours). Once the absence of parenchymal hematoma is demonstrated in control CT, loading doses of acetylsalicylic acid and clopidogrel will be intravenously administered in the Tirofiban group, and the perfusion must be maintained simultaneously of Tirofiban and oral double antiplatelet therapy for four hours, after which the administration of the experimental drug should be discontinued.
45365586|NCT05225961|Drug|Acetylsalicylic acid|A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial. It will not be necessary to maintain aspirin infusion. In the Acetylsalicylic acid group, a head computerized tomography scan will also be performed at 20 (+/- 2 hours) after the endovascular procedure. Once the absence of parenchymal hematoma is demonstrated, a load of clopidogrel and 100 mg of Acetylsalicylic acid will be administered. Oral antiplatelet medication can be administered orally if the patient has a good level of consciousness and is not associated with dysphagia; or by placing a nasogastric tube.
45365587|NCT00556998|Drug|Voriconazole|Voriconazole will be used for prophylaxis purpose. 6 mg/kg IV q12h on the first day (Day 1) and 4 mg/kg IV q12h for at least 5.5 days. The IV treatment is no more than 20 days. Then switch to 300 mg oral tablets q12h for at least 6.5 days. The total treatment duration is no more than 30 days.
45365588|NCT00528801|Behavioral|NP Battery|Neuropsych Battery with 7 different tests that evaluate the patients neurological functioning.
45365589|NCT00528801|Procedure|MRI|The MRI is a standard procedure involving 30 minutes under the machine in order to obtain various images of the patients brain.
45365590|NCT01564563|Drug|standard therapy|Standard treatment of bleeding
45365591|NCT01564563|Drug|placebo|Placebo
45482748|NCT01349400|Other|Watchful waiting|Watchful waiting means the observation of the hernia. The patient is informed about signs of deterioration or incarceration. The hernia is controlled clinically on defined follow-up visits.
45482749|NCT01349400|Procedure|Hernia repair|"Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided.~These are all standard techniques in incisional hernia repair."
45482750|NCT01354470|Drug|Modafinil|600 mg Modafinil capsule
45482751|NCT01354548|Device|TheraBite® Jaw Motion Rehabilitation System™|A portable device which utilizes passive motion and stretching to improve mobility and flexibility of the jaw muscles and associated joints. Patients are given written and verbal information about TheraBite before the commencement of Radiotherapy. Investigators instruct on usage and maintenance of TheraBite. Patients are instructed to start a trainings pass by softening the jaw muscles with a simple exercise. The training programme consists of five stretches performed 5 times per day, each stretch held for 15 seconds, training continually during Radiation Therapy and up to one year after completion of Radiation Therapy.
45482752|NCT04911608|Other|cervical spinal manipulation|High-velocity, mid-range, low amplitude force at the segment of pain and/or segmental restriction. The participant will lay comfortably in a supine position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual thrust at those levels. A maximum of 2 attempts for each side of the cervical spine will be allowed regardless of the having achieved joint cavitation.
45482753|NCT04911608|Other|cervical spinal mobilization|Participant will lay comfortably in a prone position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual forces at those segments.
45482754|NCT01349478|Device|LOKOMAT|Robot-assisted gait training,8 weeks,3 sessions a week,20-45 min each session.
45482755|NCT01349556|Drug|Tretinoin|tretinoin 0.025% cream
45482756|NCT03480126|Other|Herbal Teas|Steeped tea ingested 3 times a day for 3 mos
46051105|NCT02828163|Drug|Triamcinolone Acetonide|10mg/ml of Triamcinolone acetonide will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
45365592|NCT01564563|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
45365593|NCT01564563|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
45482757|NCT05393258|Radiation|temporally-modulated pulsed radiotherapy (TMPRT)|Intensity modulated RT (IMRT) using single or two arc therapy will be used for RT delivery.
45482758|NCT01349634|Other|Iodized salt|salt for human consumption is fortified at the national level with iodine. The experimental group will receive iodized salt early. the comparison group will receive it by market forces. presently there is only enough iodized salt to meet 10% of the countries needs, and is targeted mainly to urban areas.
45482759|NCT01346358|Biological|IMC-CS4|
45482760|NCT03462498|Drug|1-months DAPT|1-month DAPT followed by 59-month monotherapy
45482761|NCT03462498|Drug|12-month DAPT|12-month DAPT followed by 48-month monotherapy
45482762|NCT04282590|Drug|TRK-750/Placebo|Powder for oral solution
45482763|NCT04282590|Drug|Placebo/TRK-750|Powder for oral solution
46051106|NCT04245189|Other|Endoscopic ultrasound for detection of Chronic pancreatitis|Presence of Chronic pancreatitis in alcoholic cirrhosis patients.
46051107|NCT04107805|Drug|BI 1323495|Tablet
46051108|NCT04107805|Drug|Placebo|Tablet
46051109|NCT04107805|Drug|Midazolam|Oral administration
46051110|NCT02828475|Other|CALYPSO|Software platform of machine-learning based predictive models of surgical complication.
46051111|NCT02828475|Behavioral|Standard Care|Previous standard of care based on surgeon judgement alone.
46051112|NCT02833155|Drug|Entinostat|Given PO
46051113|NCT02833155|Drug|Exemestane|Given PO
45482764|NCT01354626|Other|dietary protein|in the low-protein group 13EN% of protein will be provided in the diet; in the high-protein 25EN% of protein will be provided
45482765|NCT01354626|Other|low-protein|The control group will get a diet which is according to healthy eating guidelines.
45482766|NCT03136380|Drug|GSK1325756H|Danirixin will be available as 10 and 50 milligram (mg) white film coated, round and oval tablets intended for oral administration. It will be administered with 240 mL of water.
45365594|NCT00945204|Other|intermediate care clinics (ICCs)|The ICCs will be community based. Their aim is to support primary care, particularly smaller practices that have the most difficulty achieving good control. They will comprise a multidisciplinary team, and be led by specialist nurses who will place an emphasis on education and self management. Medical care will be provided by a diabetologist. The ICC will work closely with hospital based specialist teams and community services including podiatry and dietetics. Team members will work to local guidelines, adapted from national evidence based guidelines. Guidelines for referral to the ICCs will be common across all sites, and will include people with poorly controlled type 2 diabetes and those with poorly controlled cardiovascular risk factors.
45365595|NCT00945360|Drug|Letrozole (aromatase inhibitor)|Letrozole at a dose of 2.5 mg/day for 8 weeks.
45365596|NCT05178927|Device|HoloLens v2|The HoloLens v2 will be used to access the participant's hologram & set the participant up for treatment. Standard of care methods will be utilized to confirm treatment set-up.
45365597|NCT00943566|Drug|Sufentanil|Transdermal Delivery System; Apply up to six 3 cm2 sufentanil TDS patches every 3 days for 12 days of observation. The 12 days of observation begin after a 7 day conversion to sustained release morphine sulfate. If the subject continues on the pharmacokinetic portion of the study, an additional 6 days of intervention will be evaluated (at the same dose as the primary efficacy study).
45365598|NCT00943566|Drug|Sustained Release Morphine Sulfate|Sustained Release Morphine Sulfate tablets every 12 hours; up to 400 mg every day for 19 days (7 days of conversion to sustained release morphine sulfate and 12 days of observation)
45482767|NCT03136380|Drug|Placebo|Subjects will receive visually matching danirixin placebo tablets. It will be administered with 240 mL of water.
45482768|NCT01346436|Procedure|Minimally invasive rectopexy|Use of a minimally invasive approach (robotic or laparoscopy) to perform a rectopexy
45482769|NCT01354704|Drug|Enoxaparin|enoxaparin 4000 IU 1 injection/day in subcutaneous.
45482770|NCT01346670|Drug|LipoCol and Mevacor|To evaluate the relative bioavailability of lovastatin and its ß-hydroxy acid of 600 mg LipoCol Forte® Capsules compared to that of one 20 mg Mevacor® Tablet after single oral administration in healthy subjects using a 2x2 crossover design.
46051114|NCT04105387|Procedure|Early Tracheostomy Change|The treatment group will have the first tracheostomy change on postoperative day 4 by an Otolaryngology physician (attending or fellow) on the study team.
46051115|NCT04247841|Other|Visual Aid|The visual aid will include a graphic display of 100 individuals with number of individuals anticipated to suffer a myocardial injury highlighted by being filled in in red. There will also be a textual discription stating the anticipated risk. For example in a patient with an rCRI score = 2 the text will state 10 out of 100 patients will have a myocardial injury (MINS) and 90 out of 100 patients will have no myocardial injury and 10 of the patients will be shaded red on the visual aid. The patients in this intervention will also received the scripted discussion of perioperative risk of MINS.
46051116|NCT04247841|Other|Scripted Risk Discussion|The patients seen in PSS will have a standardized discussion of perioperative risk of myocardial injury read to them by the anesthesiologist in the PSS clinic.
45365599|NCT00943644|Device|Molecular Breast Imaging (MBI)|To determine the sensitivity of MBI
45365600|NCT00943644|Device|CZT semiconductor detectors|Dual headed CZT semiconductor detectors
45365601|NCT01008657|Procedure|Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
45365602|NCT00940680|Drug|Amlodipine plus Losartan|amlodipine/losartan 5/100mg q.d.
45482771|NCT01354782|Drug|Roflumilast|"Period I: single dose of roflumilast 500 μg orally in the morning.~Period II: repeated dose of roflumilast 500 μg orally in the morning for 14 days."
45482772|NCT03136068|Drug|Digoxin|Trans-abdominal injection
45365603|NCT00940680|Drug|Losartan|losartan 100mg q.d.
45365604|NCT01564641|Device|iDuo G2|single comparator
45365605|NCT00945438|Biological|Influenza virus vaccine 2009-2010 formulation|0.1 mL, Intradermal
45365606|NCT00945438|Biological|Influenza virus vaccine 2009-2010 formulation|0.5 mL, Intradermal
45365607|NCT01564719|Behavioral|Holistic health|The investigators conceptualize this as a holistic health intervention because it has components involving the mind, body, and spirit. The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; $500 small grants to use to promote health; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
45365608|NCT00940758|Drug|PEP02|Dose escalation: 50-100 mg/m2 biweekly
45365609|NCT01792752|Behavioral|Enhanced HIV Care Access and Retention Intervention|Through the Enhanced HIV Care Access and Retention Intervention, the five neighborhoods will receive the 4 components of the intervention: 1) HIV Testing Campaign; 2) Treatment Re-engagement Campaign; 3) Patient Navigator Linkage to Care and Substance Abuse Treatment Team; and 4) Mobile Care Clinic. In addition to these intervention components, study participants will receive screening and access to treatment for other physical and mental co-morbidities, general primary health care, and social/psychosocial services addressing unstable housing, food insecurity, interpersonal violence, legal issues. All HIV-positive IDUs identified either through the HIV Testing Campaign or the Treatment Re-engagement Campaign will be enrolled in the HIV Care Cohort. The HIV Care Cohort will be comprised of the HIV-positive injectors who are receiving direct services in the Mobile Care Clinic. The 4 intervention components are detailed below:
45365610|NCT01792752|Behavioral|HIV Testing Campaign|When the intervention is initiated in a neighborhood, HIV rapid testing will begin and continue in a particular neighborhood from the time that the neighborhood's intervention begins until the end of the study period. Anyone testing HIV positive will be seen and counseled by a member of the Patient Navigator Team.
45365611|NCT01792752|Behavioral|Treatment Re-engagement Campaign|Simultaneously with the introduction of the HIV Testing Campaign, a patient navigator team will approach HIV-positive IDUs identified as not having seen their HIV care provider in the last 6 months. In addition, known HIV-positive IDUs within the designated neighborhoods will be approached for service enrollment and meet with a patient navigator.
45365612|NCT01792752|Behavioral|Patient Navigator Linkage to Care and Substance Abuse Treatment Team|The patient navigator team will provide informational support to the HIV-positive injectors, motivate them to attend HIV care visits and engage in substance abuse treatment, encourage their use of and adherence to antiretroviral therapies, and work with them to overcome any barriers to attendance at HIV care visits and substance abuse treatment. All clients of the patient navigator will become part of the HIV Care Cohort; they will have been identified either in the HIV Testing Campaign or the Treatment Re-Engagement Campaign.
45482773|NCT03136068|Drug|Placebo|Trans-abdominal injection
45482774|NCT01350024|Procedure|Frontal nerve block with 2% lidocaine with 1:100,000 dilution of epinephrine|Frontal Nerve Block 5 cc will be administered preoperatively once.
45482775|NCT01350024|Procedure|Subconjunctival injection of 2% lidocaine with 1:100,000 dilution with epinephrine|Patients will receive a 1.5 cc dose of subconjunctival lidocaine as above
45482776|NCT01346748|Drug|statin|Sinvastatin 80 mg per day - 21 days versus placebo
45482777|NCT01318590|Drug|EUS procedure with drug injection|EUS procedure with injection of 10 ml Bupivacaine 0.5% and 40 mg of Triamcinolone in the celiac plexus after administration of intravenous (IV) antibioprophylaxis
45482778|NCT01318590|Other|EUS procedure|EUS procedure without any drug injection
45482779|NCT01346826|Drug|Standard 2 hours-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 2 hours-infusion group, patients get 5 mg/kg infliximab infusion for 2 hours. Total infusion number after randomization is 7."
45482780|NCT01346826|Drug|Accelerated 1 hour-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 1 hour-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. Total infusion number after randomization is 7."
46051117|NCT02875730|Procedure|Pulse Sequence|Cylindrical Navigator Preparatory Pulse Sequence
46051118|NCT02875730|Procedure|CMRI|Cardiac Magnetic Resonance Imaging
46051119|NCT02876666|Behavioral|SCI Virtual Coach|Participants are given a computer with the SCI Virtual Coach program and are asked to interact with the Coach daily for 2 months.
46051120|NCT04205708|Diagnostic Test|Tuberculosis test|Tuberculosis (TB) test: A blood sample is collected for lab testing to determine if you have tuberculosis (QuantiFeron test). Alternatively, the test is done by injecting a small amount of fluid (called tuberculin) into the skin on the lower part of the arm. A person given the tuberculin skin test must return within 48 to 72 hours to have a trained health care worker look for a reaction on the arm.
46051121|NCT04205708|Diagnostic Test|Chest X-ray|Chest X ray: non-invasive medical test that helps physicians diagnose and treat medical conditions of the lungs and chest. The Chest X-ray will be done to check for abnormalities on the lungs. The test is non-invasive.
46051122|NCT04205708|Diagnostic Test|Pulmonary Function Test|A pulmonary function test (PFT, spirometry) is a breathing test that measures how much air your lungs can hold as well as how hard and fast you can blow air out of your lungs. The test is not invasive and involves blowing into a machine.
46051123|NCT04672460|Drug|TALZENNA capsule|Current commercial talazoparib formulation 1 mg once daily given under fasting condition
46051124|NCT04672460|Drug|Talazoparib soft gel capsule|Proposed talazoparib soft gel capsule formulation 1 mg once daily under fasting condition
46051125|NCT04672460|Drug|Talazoparib soft gel capsule|Proposed talazoparib soft gel capsule formulation 1 mg once daily under fed condition
46051126|NCT02874950|Other|office exercise training|The exercise group, did 6 months office exercise training.
45690567|NCT03994653|Other|Risk Factor Questionnaire|For cases, the study recruiter at the Trust will present this in the clinic. Controls will complete this online or at home when volunteering to participate. The participant questionnaire will be completed by the participant.
45365613|NCT01792752|Behavioral|Mobile Care Clinic|Participants who choose to receive services in the study mobile HIV care clinic will receive an initial appointment and the patient navigator will ensure that the client attends it. At the initial visit, clients will have a medical history taken, be examined and have blood drawn to measure CD4 and viral load. The mobile care clinic doctor will also prescribe medications for the client at the subsequent visit which will be scheduled as soon as lab results are available and interpreted, approximately one week later. The mobile HIV care clinic van will provide health services to the general IDU population within each intervention neighborhood to avoid any stigmatization of the HIV positive clients.
45365614|NCT00945516|Device|Bona stent® (Flared end FCSEMS)|Flared end FCSEMS for benign bile duct stricture will be inserted with ERCP.
46051127|NCT02874950|Other|ergonomic modification|The ergonomic modification group, followed 6 months modified office ergonomic modification.
45365615|NCT00945516|Device|Hanarostent® (Anchoring FCSEMS)|Anchoring FCSEMS for benign bile duct stricture will be inserted with ERCP.
45365616|NCT00527397|Drug|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
45365617|NCT00527397|Drug|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
46051128|NCT02874950|Other|Exercise and ergonomic|The mixture group, did 6 months exercise training and also followed 6 months modified office ergonomic modification.
46051129|NCT02874950|Other|Control|Control group did not do any exercise and did not follow any ergonomic modification.
45365618|NCT00527397|Drug|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose:adjusted based on the results of self-monitoring of blood glucose before each meal.
45365619|NCT00943956|Drug|bicalutamide|
45365620|NCT00943956|Drug|everolimus|
46051130|NCT00847912|Drug|5-fluorouracil|"Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but 5-FU will be stopped."
45845795|NCT05403060|Behavioral|ALIADA: Alimentación, Adolescencia y Ambiente|The objective of the educational nutritional intervention is to promote in adolescents an increase in their consumption of vegetables and fruits and a decrease in their consumption of ultra-processed foods, through the application of the TSC constructs, with the use of education by pairs as the main strategy (peer leaders). It lasts two months, includes three exclusive sessions for peer leaders and five sessions for all participants, where the leaders, together with the researchers, will lead the activities of the sessions, as well as a general event for all high school students. Intervention activities include: electronic presentations, videos, food preparation and label reading workshops, individual and team reflection activities, goal setting and monitoring, board games, contests, among others. In addition, each participant is given a workbook, which contains key messages and activities for each educational session.
45365621|NCT00943956|Drug|leuprolide acetate|
45365622|NCT00943956|Radiation|external beam radiation therapy|
45365623|NCT01564797|Behavioral|Home Health Party|An education-based lay health educator-led intervention designed to educate Hispanic participants with elevated HA1c levels about diabetes, treatment of diabetes, and diet and lifestyle changes.
45365624|NCT00945828|Behavioral|Annual Intervention Group|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP once per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
45482781|NCT01346826|Drug|Accelerated 30 minutes-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 30 minutes-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. If any infusion reactions do not develop during 2 infusions for 1 hour, patients get further 5 mg/kg infliximab infusion for 30 minutes. The total number of 30 minutes-infusion is 5."
45845796|NCT05377320|Other|Clinical Decision Aid|The clinical decision aid tool will be used at the subject's first visit (Week 0), Week 12 and Week 24.
45482782|NCT01354860|Other|Moxibustion treatment plus usual care|"Treatment group received moxibustion treatment three times a week for 4 consecutive weeks, totally 12 sessions of treatment in addition to usual care to manage their knee OA.~Moxibustion points include six local acupuncture points on affected knee joint. Up to two additional tender points will be allowed, if necessary. If participants feel knee pain on both knee joints, study practitioners will provide treatment on both knee.~We will use smokeless indirect moxibustion made of wormwood with a diameter of 1.9 centirmeter and a length of 2.1 centimeter in a cylindrical form for this study (Haitnim Bosung Inc, Korea). Free participant-practitioner interaction will be allowed during the treatment session. Expected total time of each treatment session will be 40 - 60 minutes."
45482783|NCT01354860|Other|Usual care alone group|"Usual care alone group can receive or use any kind of treatment other than moxibustion treatment provided as study intervention, which includes surgery, conventional medication, physical treatment, acupuncture, herbal medicine, over-the-counter drugs and other active treatment. This also applies to the moxibustion treatment group.~Education material of information on knee osteoarthritis and current management option and self-exercise sheet with a yoga-mat to enhance regular exercise will be provided in both groups at baseline."
45482784|NCT03422562|Dietary Supplement|Florababy|Probiotic supplement
45845797|NCT05377320|Other|Standard Care|Cardiology clinic visits will take place at the subjects first visit (Week 0), Week 12 and Week 24.
45482785|NCT03422016|Diagnostic Test|electroretinogram (ERG)|an ERG is a measure of the eyes response to a flash of light
45482786|NCT01355016|Drug|MDT-637|Inhaled doses of MDT-637 over a 24 hour period
45482787|NCT01346982|Drug|Silimarine|darunavir/ritonavir 600/100 mg + silimarine (150 mg every 8 hours)
45482788|NCT02719002|Device|spectral domain optical coherence tomography C-scan and multifocal electroretinogram|
45482789|NCT01355172|Biological|AdimFlu-S|0.25mL per injection 2 injections at 4 weeks apart
45482790|NCT02585232|Behavioral|Counseling (C)|The counseling component incorporates elements of existing manualized interventions that have been tailored for this population and follow a cognitive behavioral therapy framework. Counseling sessions will be completed for 8-10 domains of potential distress (grief, hostility, sexual intimacy, etc.).
45690568|NCT03994653|Other|Clinical Questionnaire|For cases, the study recruiter at the trust will complete this form together with the participant. Controls will not complete this form.
45845798|NCT05371080|Biological|HZ/su vaccine|No study intervention is administered in this extension study. Participants received the HZ/su vaccine administered in the ZOSTER-049 (NCT02723773), ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies. In order to assess the persistence of immune responses, participants provide blood samples at Day 1 and yearly from Month 12 until Month 48 in the current ZOSTER-101 study, according to their study group assignment. In case of a suspected HZ case diagnosis in any of the participants, clinical specimens from HZ lesions (3 replicate samples, collected on the same day, per participant) are collected to confirm the diagnosis of HZ by Polymerase Chain Reaction (PCR)
45845799|NCT05364606|Device|Patient Specific Talus Spacer|Patient Specific Talus Spacer is a solid polished replica of the patient's bone.
45847836|NCT02987868|Drug|Amino acid supplement first day|An orally administered supplement of the proprietary amino acid derivative
45847837|NCT02987868|Drug|Placebo first day|A non-active orally administered supplement of the proprietary amino acid derivative
45482791|NCT02585232|Behavioral|Care Consultation (CC)|"Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment, which then immediately shapes development of concrete action plans."
45482792|NCT01355328|Procedure|laser and radiofrequency|different laser and radiofrequency with different fluences
45482793|NCT02556606|Drug|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg
45365625|NCT00945828|Behavioral|Quarterly Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP four times per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
45365626|NCT01564875|Drug|Simvast CR|Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.
45365627|NCT01564875|Drug|Zocor|Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m.
45365628|NCT00944112|Biological|Restrictive RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70 g/L with a target Hb concentration of 71-90 g/L during the intervention period.
45365629|NCT00944112|Biological|Liberal RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90 g/L with a target Hb concentration of 91-110 g/L during intervention.
45482794|NCT02556606|Drug|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg
45482795|NCT02556606|Drug|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
45482796|NCT02556606|Drug|Midazolam|single 40 min infusion of MID 0.03mg/Kg
45482797|NCT01355562|Drug|Interleukin-2 (IL-2)|Daily for 4 doses every 3 weeks for a total of 12 doses in an outpatient setting
45365630|NCT04012086|Other|Physical therapy|Our physical therapy program included a variety of different exercise modalities (aerobic exercises, treadmill training and exercise intervention program) performed under the supervision of a physiotherapist
45690569|NCT05633199|Other|cytoreductive surgery|Open surgery is conducted by senior doctors in gynecological oncology. The following parameters should be recorded: period of operation, location and number of recurrent lesions, location and number of resected lesions, amount of intraoperative bleeding and blood transfusion, whether R0 is reached, size and distribution of residual lesions, surgical complications, hospital stay, and period to adjuvant chemotherapy. Patients are required to start intravenous chemotherapy within 4W after surgery, at least for 4 cycles.
45690570|NCT03594279|Behavioral|Community Mobilization|Community Mobilization
45690571|NCT03594279|Behavioral|Community Mobilization and Community Incentive|Community Mobilization and Community Incentive
45365631|NCT01529814|Device|Implant with new abutment connection|New abutment connection implant system
45365632|NCT01529814|Device|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
45365633|NCT00944190|Behavioral|Self-management intervention|Brief counseling technique, self-management,
45365634|NCT00944190|Behavioral|Education|Educational information about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
45365635|NCT00945984|Procedure|Radical nephrectomy|Surgical options to treat localized renal cell carcinoma
45365636|NCT00944268|Drug|Passiflora, Crataegus e Salix|Comparison of different pharmaceutics forms of drug
45690572|NCT03784599|Drug|Trastuzumab emtansine|Infusion
45690573|NCT03784599|Drug|Osimertinib|Tablet
45365637|NCT00944346|Drug|Metformin HCl|
45365638|NCT00527319|Drug|VT-122 low dose|VT-122 low dose, dose escalated
45365639|NCT00527319|Drug|VT-122 high dose|VT-122 high dose, dose escalated
45365640|NCT04115319|Drug|SEP363856|SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule
45365641|NCT04115319|Drug|quetiapine XR|quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
45365642|NCT00562302|Device|Bio-Seal Plug|Deployment of the Bio-Seal plug in needle track
45365645|NCT00946062|Other|orientation and mobility training|orientation and mobility training
45365646|NCT04012632|Other|this study was an observational study and no interventions were given to the participants|the participants were recruited and the data as well as blood sample were collected.
45365647|NCT00134719|Biological|MenHibrix (Hib-MenCY-TT)|One intramuscular dose at 2, 4 and 6 months of age ( group A) and one intramuscular dose at 12 to 15 months of age (groups A and B)
45365648|NCT00134719|Biological|Infanrix® Penta|One intramuscular dose at 2, 4 and 6 months of age
45365649|NCT00134719|Biological|Prevenar®|One intramuscular dose at 2, 4 and 6 months of age
45365650|NCT00134719|Biological|ActHIB®|One intramuscular dose at 2, 4 and 6 months of age
45365651|NCT00134719|Biological|Meningitec®|One intramuscular dose at 2, 4 and 6 months of age
45365652|NCT00134719|Biological|M-M-R®II|One subcutaneous dose at 12-15 months of age
45365653|NCT00134719|Biological|Varivax®|One subcutaneous dose at 12 to 15 months of age
45365654|NCT00134719|Biological|PedvaxHIB®|One intramuscular dose at 12 to 15 months of age
45365655|NCT00940836|Drug|Resfenol|Each capsule of the active drug contains 400mg of acetaminophen, 4mg of chlorpheniramine and 4mg of phenylephrine. Patients will receive up to five capsules a day.
45365656|NCT00940836|Drug|Placebo|Patients in this group will receive placebo capsules up to five times a day, with the exact same taste and appearance as the active comparator.
45365657|NCT00940836|Drug|Co interventional acetaminophen|All patients received, along with the assigned intervention, 12 acetaminophen 500mg pills, that they were instructed to take only in case of persisting PAIN or FEVER, up to 4 times a day.
45365658|NCT03999177|Behavioral|Kinect-TOLF Training System|This system will teach patients to perform the lymphatic exercises correctly. Like playing the video games, patients follow the avatar model in the video to perform the lymphatic exercises. The Kinect system can automatically detect whether a user is performing the set of lymphatic exercises correctly in real time and provide instantaneous feedback to the user, thus enhancing patients' self-efficacy to perform the lymphatic exercises correctly. Patients will be asked to conduct two types of usability testing: heuristic evaluation and end-user testing.
45690574|NCT01827943|Drug|Temsirolimus|Temsirolimus
45690575|NCT03594201|Other|semen pretreatment|semen pretreatment
45690576|NCT02985255|Drug|Docetaxel|Neoadjuvant Arm
45690577|NCT02985255|Drug|Cisplatin|Neoadjuvant Arm
45690578|NCT02985255|Drug|5FU|Neoadjuvant Arm
45690579|NCT02985255|Radiation|Radiotherapy|Neoadjuvant Arm
45690580|NCT02985255|Procedure|Glossectomy|Neoadjuvant Arm
45690581|NCT04609813|Diagnostic Test|Sponge cytological test|Esophageal cell specimen were collected with Esoheal 1.0 sponge collection device. A prediction model will be built based on digital cytopathological features of participants.
45847838|NCT02987868|Drug|Amino acid supplement second day|An orally administered supplement of the proprietary amino acid derivative
45847839|NCT02987868|Drug|Placebo second day|A non-active orally administered supplement of the proprietary amino acid derivative
45847840|NCT02988882|Drug|Dexamethasone|
45847841|NCT02988882|Other|Placebo Vehicle|
45847842|NCT02992236|Drug|VAS203|Infusion of NO-Synthase inhibitor VAS203
45847843|NCT02992236|Drug|Saline|Infusion of saline
45847844|NCT02994732|Drug|[14C]-BVD-523|[14C]-BVD-523 administered as a 600-mg (approximately 200 µCi) oral dose to 6 healthy male subjects following a 2-hour fast from food (not including water) that follows breakfast.
45752191|NCT01792999|Device|Contrast-enhanced KBCT|Contrast-enhanced KBCT includes pre-contrast KBCT scan and post-contrast KBCT scan. After the pre contrast scan is completed, a bolus injection of a low osmolar, nonionic, iodinated 300mg of iodine per mL contrast agent, will be injected at a rate of approximately 2.0 mL/s, for a total injection time of approximately 30-60 seconds. 30-60 seconds after the contrast injection, the post-contrast scan will be acquired.
45752192|NCT04749069|Diagnostic Test|Comparison of pain intensity rating scale|Comparison of numerical pain intensity rating scale Comparison of faces pain rating scale Comparison of consumption of total amount of remifentanil
45847845|NCT03001674|Device|Conductance catheterization|CD Leycom Conductance Catheter
45847846|NCT03002454|Drug|99mTc MDP Injection:neutron-bombardment|Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from neutron-activation-produced 99Mo.
46051131|NCT00847912|Drug|Placebo, vehicle control|"Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but vehicle control cream will be stopped."
46051132|NCT04116892|Procedure|the Cover group|The internal limiting membrane around the MH was left to cover the hole
46051133|NCT04116892|Procedure|the Fill group|The internal limiting membrane around the MH was left to fill the hole
45365659|NCT05104827|Other|Complementary Integrative Medicine|30-minute individually tailored integrative medicine care, including acupuncture, acupressure, reflexology, movement therapies like QiGong or Feldenkrais as well as Anthroposophic Medicine and mind-body treatments.
45365660|NCT00940914|Drug|ioflupane 123I (DATSCAN®)|One administration (2,5 ml) of ioflupane 123I 0,07-0,13 µg/ml; 74 MBq/ml; IV (in the vein)
45365661|NCT00944424|Drug|Docetaxel + High dose Vitamin D2|Docetaxel + High dose Vitamin D2
45847847|NCT03004638|Drug|MEDI6012 40 mg|Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.
46051134|NCT04116892|Procedure|the peeling group|the internal limiting membrane was discarded
45365662|NCT00944424|Drug|Docetaxel + Standard dose Vitamin D2|Docetaxel + Standard dose Vitamin D2
45365663|NCT04591353|Drug|PENG Block|The pericapsular nerve group (PENG) block is a novel regional anesthesia technique for providing analgesia after hip fractures and hip arthroplasties.
45365664|NCT04591353|Drug|Lidocaine|2-3 cc of 2% lidocaine and NO bolus of bupivacaine will be injected.
45365665|NCT00944502|Drug|Dexamethasone|"Group A: Vitatonus DEXA injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group B: Vitatonus DEXA tablets:~1 tablet orally every 8 hours for 10 days.~Group C: Dexamethasone Injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group D: Dexamethasone tablets:~1 tablet orally every 8 hours for 10 days."
45365666|NCT04754295|Other|Goal-Directed Therapy|Administration of fluids and vasoactive drugs guided by non-invasive haemodynamic monitoring
45365667|NCT04754295|Other|STANDARD|Administration of fluids and vasoactive drugs guided by standard vital signs monitoring
45365668|NCT00946140|Procedure|DCE-MRI scans|Initially you will be given safety information about MRI scans and a questionnaire to determine your compatibility with the MRI scanner. For each patient, DCE-MRI data sets will be acquired three times - at baseline just prior to the start of the drug therapy, within 24-48 hours of the start of the therapy, and within 6-8 weeks of the start of the therapy.
45365669|NCT04803825|Other|Heavy Slow Exercises|"Load magnitude: A dumbbell as heavy as possible within the given repetitions and sets.~Number of repetitions: week 1: 15 reps, Week 2-3: 12 reps, Week 4-5: 10 reps, Week 6-8: 8 reps, Week 9-12: 6 reps~Number of sets: 3~Rest between sets: 2 - 3 min.~Number of exercise interventions: 2~Duration of experimental period: 12 weeks~Fractional and temporal distribution of the contraction modes per repetition and duration of one repetition: 3s concentric, 2s isometric: while change concentric/eccentric phase, 3s eccentric.~Rest in-between repetitions: No~Range of motion: Full range of motion~Intervention frequency: 3 times a week, with minimum 48 h recovery time in-between."
45365670|NCT04803825|Device|Extracorporeal Shock wave therapy|Two thousand impulses of shock waves are applied to the painful tendon, with a pressure between 1.5 and 3.0 bar (depending on what the patient tolerates). We use a power hand piece that provides energy of 0.01-0.35 mJ/mm2
45365671|NCT04803825|Other|Information and advice|Information and advice are based on assessment and will comprise the standardized oral and written information. Participants will be educated regarding pain during and after activities and encouraged to be physically active. With only one session, there is great reliance on self-management. Thus, information and advice are made available through a handout.
45365672|NCT00949962|Drug|antiandrogen therapy|Given systemically
45365673|NCT00949962|Drug|leuprolide acetate|Given subcutaneously
45365674|NCT00949962|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
45752193|NCT00411463|Behavioral|Interpersonal and Social Rhythm Therapy (IPSRT-BPII)|"IPSRT is comprised of three components: psychoeducation, social rhythm therapy, and standard IPT as developed for unipolar depression.~Psychoeducation focuses on a) the illness and its consequences, b) treatment options and associated side effects, and c) prodromal symptoms/detection of early warning symptoms."
45365675|NCT04115007|Radiation|Stereotactic Body Radiotherapy (SBRT) + Standard of care|"Definition of standard of care (prior to randomization):~Radiotherapy to the prostate in de novo metastatic patients~Radiotherapy to the pelvic lymph nodes in patients with positive pelvic nodes (given as full dose to the positive lymph node and prophylactic dose to the pelvic nodal basin)~Long term ADT +/- intermittent treatment~Additional therapy following tumor board meeting : new generation hormonal therapy (abiraterone, enzalutamide, apalutamide or other approved) or chemotherapy (docetaxel).~SBRT is delivered using the following regimen: 30 Grays (10 Gy x 3 fractions) for axial and appendicular bones and lymph node metastases if present. In case the dose cannot be safely delivered while maintaining a safe dose to the organs at risk, an alternate regimen (35 Gy in 5 fractions of 7 Gy) can be used."
45365676|NCT04115007|Drug|Standard of care|"Definition of standard of care (prior to randomization):~Radiotherapy to the prostate in de novo metastatic patients~Radiotherapy to the pelvic lymph nodes in patients with positive pelvic nodes (given as full dose to the positive lymph node and prophylactic dose to the pelvic nodal basin)~Long term ADT +/- intermittent treatment~Additional therapy following tumor board meeting : new generation hormonal therapy (abiraterone, enzalutamide, apalutamide or other approved) or chemotherapy (docetaxel)."
45365677|NCT04012866|Behavioral|Aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
45365678|NCT04012866|Behavioral|Computerized cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
45365679|NCT04012866|Behavioral|Control training|The Control training will receive an intervention including combinations of non-aerobic physical activities and unstructured mental activities.
45365680|NCT00950040|Behavioral|Brief alcohol intervention|The intervention consists of educational information, aspects of motivational interviewing, feedback concerning alcohol use and measures of glycemic control, alcohol use monitoring, and formulation of a change plan.
45365681|NCT00950040|Behavioral|General health education|The intervention will consist of information about several general health behaviors.
45365682|NCT00946374|Drug|Immunochemotherapy|R-CHOP: Rituximab 375 mg/m²,intravenous ( iv ), day 0 ; Cyclophosphamide 750 mg/m²,iv, day1; Vincristine 1,4 mg/m² but at the maximum 2 mg,iv,d1; Doxorubicin 50 mg/m², iv, d1; Prednisone 100 mg, peroral ( po ), day 1 to day 5
45847848|NCT03004638|Drug|Placebo|Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.
45847849|NCT03004638|Drug|MEDI6012 120 mg|Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.
45690582|NCT03593967|Behavioral|ARTISAN|"In the first four weeks, dyads will engage in museum tours facilitated by a docent from the National Museum, followed by a guided storytelling/art-making session (inspired by the artifacts in the gallery), writing activity and group sharing/debrief. The first three weeks of art making will be pair-work by the seniors and youth, while the fourth week will be a collaborative art piece that is created by all participants in the working group. In the last week, the participants will be involved in a mini-exhibition where they will share their works with the group and members of the public, and engage in guided reflection on each other's artworks.~The main content and discussion point for each session are as follows:~Week 1: Food and Play as our National Heritage~Week 2: Our Voices, Our Singapore: Strengthening Bonds~Week 3: Overcoming Adversities: Stories of Resilience~Week 4: Beholding the Future: Dreams and Aspirations~Week 5: Passing It On: The Stories We Share"
45845800|NCT05352282|Procedure|Serratus Anterior Plane Block|SAPB will be done preoperative before induction of anesthesia under songraphic guidance and aseptic conditions with the patient in the lateral position, with the side of the surgical side up and the upper limb hanging over the patient's head. The ribs will be then counted, and when the 5th rib is identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane. The ribs, pleura, overlying serratus muscle and latissimus dorsi muscle will be identified, and the needle will be advanced cephalic in-plane until the tip reaches the plane between the serratus anterior and latissimus dorsi. Afterward, 2 mL dextrose 5% will be injected; then, 30 mL of bupivacaine 0.25% will be injected in the plane between the serratus anterior and latissimus dorsi.
45690583|NCT05632887|Other|no intervention|no intervention
45845801|NCT05352282|Procedure|Lumbar Intrathecal Fentanyl Injection|Patients will receive 25 microgram intracthecal fentanyl immediately preoperative.
45845802|NCT05343624|Device|continuous glucose monitoring|Use of continuous glucose monitoring in inpatient and ICU settings
45365683|NCT00946374|Drug|High-dose BEAM plus autologous SCT|High-dose BEAM: Carmustine 300mg/m², iv, day -7; Cytarabine 2 x 200 mg/m², iv, day -6 to day -3; Etoposide 2 x 100 mg/m², iv, day -6 to day -3; Melphalan 140 mg/m², iv, day -2 followed by Autologous stem cell transplantation ( > 2,5 x 10e6 CD34 positive autologous stem cells, iv, day 0
45365684|NCT00946374|Other|HLA-identical allogenic SCT|Fludarabine 30 mg/m², iv, day -4 to day -2; Cyclosporin A 2 x 3mg/kg, iv, day -1 to day 0 plus total body irradiation with 2 Gy, day 0 followed by allogenic stem cell transplantation immediately after Radiation.
45365685|NCT04529577|Device|His-bundle pacing|"A standard pacing electrode (Medtronic 4076) will be placed in RV apex (or RV septum as a secondary option) and in the right atrial appendage (if indicated).~A dedicated His-bundle pacemaker electrode (Medtronic 3830) will be placed in the region of His bundle, using a dedicated introducer sheath (Medtronic C304 or Medtronic C315). His-bundle potentials will be identified and His-bundle capture (non-selective or selective) will be ascertained using an electrophysiology recording system. Device programming will focus on providing physiological atrioventricular delay and safety RV pacing as backup."
45365686|NCT00950196|Drug|amantadine sulphate|amantadine 5/mg/kg for 2 month- tapered up during 2 weeks at 1 month possibility to increase dosage to 8 mg/kg or reduce it if there are side effects
45690584|NCT05632731|Procedure|double cleavage-stage or single blastocyst stage embryos transfer|Infertile women requesting in vitro fertilization treatment were randomly assigned to undergo transfer of either two cleavage-stage embryos or a single blastocyst-stage embryo.
45690585|NCT03596541|Device|Heart and Respiratory Auscultation of an open real-time tele-stethoscopy system (EHAS-Fundatel digital stethoscope)|We compare the respiratory and heart auscultation of clinicians using the EHAS-Fundatel digital stethoscope and a conventional stethoscope and we will observe; inter-observer and intra-observer differences by two auscultation methods.
45690586|NCT00214851|Drug|Kineret (anakinra)|Kineret (anakinra 100 mg. s/c daily x 4 weeks
45365687|NCT01565031|Procedure|Step-wise down-titration according to international guidelines.|The medication will be adjusted according to each patient´s level of control. Depending on the state of control of asthma, the dose will be adjusted up or down (step-up therapy and step-down therapy, respectively) in accordance with GINA.
45365688|NCT04012554|Procedure|avoid chest drainage tube placement after video-assisted thoracoscopic wedge resection of lung|Avoiding chest drainage tube placement after VATS of the lung in the experiment group.
45365689|NCT04012554|Procedure|Indewlling chest drainage tube after video-assisted thoracoscopic wedge resection of lung|Indewlling chest drainage tube after VATS of lung in the control group.
45365690|NCT01565109|Drug|Docetaxel - Cisplatine - 5FU|2 cycles of Docetaxel - Cisplatine - 5 FU
45365691|NCT01565109|Radiation|Radiation of 45 Grays on 5 weeks|Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks
45365692|NCT04521699|Device|CalmioGO Stress management device|CalmiGo device is a device of similar size to an inhaler that uses guided breathing, and grounding techniques to regulate breathing to bring users a sense of calm and relaxation.
45690587|NCT00212121|Radiation|high dose boost|high dose boost
45690588|NCT00212121|Procedure|boost|low dose versus high dose
45365693|NCT00526071|Drug|migalastat HCl|
45690589|NCT00217971|Drug|Dronabinol|Dronabinol
45847850|NCT03004638|Drug|MEDI6012 300 mg|Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.
45847851|NCT03004638|Drug|Placebo IV Push|Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.
46051135|NCT00701194|Behavioral|Early Intervention Foster Care (EIFC)|The EIFC/MTFC-P intervention is delivered through a treatment team approach. Foster parents receive preservice training and ongoing consultation from program staff. Children receive individual therapy and attend a therapeutic playgroup. The intervention emphasizes the use of concrete encouragement for prosocial behavior; consistent, nonabusive limit-setting to address disruptive behavior; and close supervision of the child. The EIFC intervention employs a developmental framework in which the challenges of foster preschoolers are viewed from the perspective of delayed maturation and is oriented toward creating optimal environmental conditions to facilitate developmental progress. These conditions include a responsive and consistent caregiver and a predictable daily routine.
46051136|NCT04116424|Other|nurse training of the patient|visit + telephone follow-up
45365694|NCT00525915|Drug|5-Fluorouracil|"Arm A = 250 mg/m^2 IV over 24 hours for 5 days weekly for 5 weeks.~Arm B = 2.2 mg/m^2 IV over 48 hours on days 1 and 15."
45365695|NCT00525915|Drug|Oxaliplatin|"Arm A: 40 mg/m^2 IV daily over 2 hours for 5 weeks~Arm B: 100 mg/m^2 IV on Day 1 and 15"
46051137|NCT04116424|Other|neurologist accompaniement|presentation during consultation by neurologist
46051138|NCT00850564|Drug|Growth Hormone Releasing Hormone (Tesamorelin)|Tesamorelin 2mg subcutaneous daily x 2 weeks
45365696|NCT00525915|Radiation|Radiation Therapy|Radiation treatment every weekday for 5 weeks.
45690590|NCT00217971|Drug|Placebo|placebo
45690591|NCT03976323|Biological|Pembrolizumab|IV infusion
45690592|NCT03976323|Drug|Pemetrexed|IV infusion
45690593|NCT03976323|Drug|Carboplatin|IV infusion
45690594|NCT03976323|Drug|Cisplatin|IV infusion
45690595|NCT03976323|Drug|Olaparib|Tablets
45690596|NCT03593499|Drug|omaveloxolone|
45690597|NCT03593421|Drug|synthetic PreImplantation Factor|peptide
45690598|NCT00217581|Biological|Bevacizumab|Must be administered 1st before Docetaxel & Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes. If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes. If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
45690599|NCT00217581|Drug|Docetaxel|Must be administered 2nd after Bevacizumab and followed by Oxaliplatin.70 mg/m(2), IV over 60 minutes, day 1 of each cycle;
45690600|NCT00217581|Drug|Oxaliplatin|Must be administered 3rd after Bevacizumab and Docetaxel. 75 mg/m(2), IV over 120 minutes, Day 1 of each cycle.
45845803|NCT05333328|Drug|Ovarian function suppression with endocrine treatments|"Ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.~Either goserelin acetate or leuprorelin Acetate is allowed.~These patients are able to choose bilateral salpingo-oophorectomy instead of OFS.~Chemotherapy is omitted in these patients."
45845804|NCT05322330|Drug|Selinexor|40-60mg QW,w-3～d-3,PO
45845805|NCT05322330|Drug|Flu|25-30 mg/m2，d-5 ～d-3，qd，ivgtt
45690601|NCT03991455|Device|Apyx device|The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system.
45690602|NCT03593343|Behavioral|Overnight fasting duration|Subjects will adhere to overnight fasting protocol for 6 days
45690603|NCT03593265|Other|MUNIX|Motor unit number index in 4 muscles: tibialis anterior, abductor digiti mini, abductor pollicis brevis et deltoideus
45690604|NCT01856257|Biological|Anti-thymocyte Globulin (Rabbit)|The target dosage is 6mg/kg total over 3 to 4 days. The recommended route of administration is intravenous infusion using a high-flow vein.
45845806|NCT05322330|Drug|CTX|250-500 mg/m2，d-5 ～d-3，qd，ivgtt
45845807|NCT05322330|Drug|CAR-T|2-5×10^6 CAR-T/kg，ivgtt。
45845808|NCT05320146|Other|MRI-PDFF|Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a MRI-based diagnostic imaging biomarker of the liver.
45845809|NCT05319990|Drug|Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)|PAH (Basic Pharma, Geleen, Netherlands) has been used to measure ERPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.
45845810|NCT05319990|Drug|Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)|Iohexol (Omnipaque 300, GE Healthcare, Chicago, IL) is a nonionic, low osmolar contrast agent with a history of extensive use in Radiology practice (for contrast x-rays) that shares many qualities of an ideal GFR marker, like inulin, such as not being absorbed, metabolized, or secreted by the kidney.
46051139|NCT04030858|Behavioral|Plant-based diet + nutrition education|The intervention group will adopt a nutrient-dense dietary pattern and receive nutrition education sessions specific to that lifestyle. The diet protocol is comprised of minimally-processed plant foods such as fruits, vegetables, legumes, beans, nuts and seeds. No refined sugars, added salt, or oil will be included. Dietary fat intake limited to 20% of total calories or less per day. Animal products will be eliminated. This dietary pattern is expected to improve resilience, mood, inflammation, microbiome, spirituality, and overall general health (as measured by weight, cholesterol, blood pressure). The treatment group will also receive weekly nutrition education sessions to support the diet.
45690605|NCT01856257|Biological|belatacept|Participants will receive belatacept at a dose of 10mg/kg up on day 1, 5, 14, 28, 56 and 84. After 84 days, subjects will receive a maintenance dose of 5 mg/kg every 4 weeks until completion of the trial.
45365697|NCT00525915|Procedure|Surgery|Surgical removal of the primary tumor and lymph nodes following completion of disease status evaluation post chemotherapy and radiation treatments.
45365698|NCT05191329|Diagnostic Test|TPQue Greek version, NEI-VFQ-25 Greek version|Study participants with non surgical presbyopic correction will be evaluated with TPQue regarding their personality traits. Visual acuity will also be assessed. Study participants with pseudophakic presbyopic correction will be evaluated with the TPQue before surgery. They will also be visual acuity evaluation and NEI-VFQ-25 assessment six months after surgery.
45365699|NCT00521079|Device|Therapy ON|Intermittent, programmable, intra-abdominal vagal blocking device that delivers therapy (Therapy ON)
45365700|NCT00521079|Device|Therapy OFF|Active intra-abdominal placebo device that delivers no therapy (Therapy OFF)
45365701|NCT03107117|Behavioral|Computer Counseling|two computer counseling online programs for a teen and a parent
45690606|NCT01856257|Drug|methylprednisolone|Methylprednisolone will be administered at a target dose of 500 mg beginning on the day of transplant, and tapered to 250 mg day 1 post-transplant, 125 mg day 2 post-transplant, 60 mg day 3 post-transplant, 30 mg day 4 post-transplant and day 5 post-transplant 0 mg if therapeutic tacrolimus level achieved for groups 1 and 3.
45845811|NCT05312892|Drug|Amlodipine|Subjects will receive either an antihypertensive (amlodipine or moxonidine) medication or placebo for two weeks, then cross over to the second arm, and then after 2 weeks of the second drug/placebo, will be switched to the third arm.
45365702|NCT03107117|Behavioral|Standard Care|A referral for substance use counseling
45365703|NCT03105713|Other|Patient Safety Checklist|The intervention is developed, validated and to be implemented in seven surgical clusters in two hospitals, in a stepped wedge cluster randomized controlled trial of the PASC for patients to use.
45845812|NCT05312892|Drug|Moxonidine|Moxonidine
45365704|NCT02579837|Device|Optos 200Tx|non-mydriatic ultra-widefield (UWF) retinal imaging device
45365705|NCT02579837|Device|Zeiss Cirrus|optical coherence tomographer (OCT)
45365706|NCT03103139|Procedure|Transpapillary Stent|ERCP with placement of short stent
45365707|NCT03103139|Procedure|Stent across bile leak|ERCP with long stent
45365708|NCT00521001|Drug|everolimus|
45365709|NCT00521001|Drug|temozolomide|
45365710|NCT04887701|Device|Non-hormonal vaginal device therapy|Experimental Active Therapy
45365711|NCT04887701|Device|Sham vaginal device therapy|Sham Comparator
45365712|NCT00134563|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
45365713|NCT00134563|Drug|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
45365714|NCT04019171|Behavioral|exercise training|6 weeks of physical exercise training. 3 sessions per week. Session duration : 40 minutes. Self-regulated exercise intensity using Borg's ratings of perceived exertion (RPE)
45690607|NCT01856257|Biological|basiliximab|Basiliximab will be administered in two doses of 20 mg each.
45365715|NCT03966547|Procedure|Ganglion sphenopalatine block with local anesthetic administered on study GSPB-2018|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL as per GSPB-2018.
45365716|NCT03966547|Procedure|Ganglion sphenopalatine block with placebo administered on study GSPB-2018|Block performed with bilaterally inserted q-tips with isotone NaCl as per GSPB-2018.
45365717|NCT05189379|Other|Non-Alcoholic Odour|A chemical used in fragrances and flavouring with a smell close to a nutty, buttery structure. Used as a 1:100 deionised water dilution.
45365718|NCT05189379|Other|Alcoholic Odour|Alcoholic beverage beer / Alcoholic beverage red wine / Alcoholic beverage brandy / The type of the Alcoholic Odour intervention will be presented in a participant-preference basis.
45482798|NCT01355640|Other|breast-feeding|Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Mothers breast-fed their babies. The study was initiated when the infants were observed to have a large amount of areola in their mouth, with flanged lips and active jaw movements. Then two minutes after the breast-feeding, an experienced technician began to do heel lance, heel lance was given by the same experienced technician.Mothers breast-fed their babies two minutes before, during and eight minutes after the heel lance. Throughout the whole procedure, mothers were encouraged to continue breast-feeding when the babies stopped sucking and/or began to cry.
45365719|NCT05189379|Other|Non-Alcoholic Images|Images of non-alcoholic items, namely; broom, duster, clothing iron, lightbulb, mat, mulch, penlight, rack, rock, kitchen scissors, trough, vent are presented in parallel with the non-alcoholic odour
45365720|NCT05189379|Other|Alcoholic Images|Images of alcoholic items, namely, beer, wine, schnapps are presented in parallel with the alcoholic odour
45365721|NCT01326325|Drug|Ketamine|Drip continues of ketamine in intravenous injection included posology enters 0,5mg/kg /day and 2mg/kg/day during 4 days
45365722|NCT01326325|Drug|NaCl|Drip continues of NaCl 0,9% in intravenous injection during 4 days
45365723|NCT01326403|Drug|Tranexamic acid|"GROUP A - receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.~GROUP B - IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.~Group C - A control group will only receive placebo in the emergency room and in the OR."
45365724|NCT00520845|Drug|celecoxib|600 mg will be taken by mouth twice a day for 6 weeks then 400 mg twice a day for up to a year after chemotherapy is discontinued in the absence of progression.
45365725|NCT00520845|Drug|Docetaxel|75mg/m2 given through a vein over 90 minutes on day 1 of a 3-week cycle
45482799|NCT01355640|Other|non-nutritive sucking|"Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Each mother in this group was given a vacuum pacifier( the brand is Goodbaby) to console her baby. Heel lance was given by the same experienced technician. The study was initiated when the infants can suck the pacifier and hold it by himself without others' help. This generally requires half or one minute. Then two minutes after non-nutritive sucking, an experienced technician began to do heel lance. Babies sucked the pacifier two minutes before, during and eight minutes after heel lance. Throughout the whole procedure, mothers were encouraged to continue non-nutritive sucking when the babies stopped sucking and/or began to cry."
45482800|NCT01350570|Other|acupuncture|acupuncture group1, acupoints ST25 and BL25 will be used in this trial.
45690608|NCT01856257|Drug|mycophenolate mofetil|Mycophenolate Mofetil will be administered at a target dose of 1000 mg orally twice a day. Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
45365726|NCT00520845|Drug|pemetrexed disodium|500 mg/m2 through a vein over 90 minutes on day 1 of a 3 week cycle.
45365727|NCT00520845|Other|laboratory biomarker analysis|Blood collection
45365728|NCT00185731|Drug|Atorvastatin|80 mg orally once daily
45365729|NCT00582491|Drug|Modafinil|Modafinil 400mg orally every day for 16 days
45365730|NCT00582491|Drug|Placebo|Placebo orally everyday for 16 days
45365731|NCT00520767|Drug|bortezomib|Bortezomib 1.3 mg/m2 days 1, 8, 15, 22
45365732|NCT00520767|Drug|dexamethasone|Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23
45482801|NCT01350570|Other|acupuncture group2|Acupoints LI11 and ST37 will be used in this group. LI11 is located at upper limb while ST37 is located at the lower limb.
45845813|NCT05312892|Drug|Placebo|Placebo
45365733|NCT00520767|Drug|melphalan|Melphalan 9 mg/m2/day days 1-4
45690609|NCT01856257|Drug|tacrolimus|The site investigator will identify a starting tacrolimus dose at their discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. The dose will be adjusted to 5-8ng/ml for the active comparator arm (thymoglobulin + tacrolimus + MMF arm) or tapered off in the experimental arm (basiliximab + 20 weeks of tacrolimus + MMF + belatacept).
45845814|NCT05311020|Dietary Supplement|Placebo drink|consume 1 bottle per day
46051140|NCT04030780|Dietary Supplement|spore-forming probiotic|spore-forming probiotic administered as 1 capsule twice daily (2,5 x 109 CFU per capsule) during 8 weeks
46051141|NCT04030780|Other|Placebo|similar capsules administered twice daily
46051142|NCT00703612|Procedure|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
46051143|NCT00837148|Drug|Sorafenib and Dacarbazine|"Treatment will be administered on an outpatient basis. Sorafenib is supplied as 200-mg tablets. The starting dose of sorafenib will be 400 mg PO twice daily (every 12 hours) continuously. There is no planned treatment interruption between cycles.~All patients will receive dacarbazine as an open-label dose of 850 mg/m2 by IV infusion over 60 minutes, starting on Week 1 and repeated every 3 weeks until disease progression or intolerance."
46051144|NCT00703690|Drug|MK0767|MK0767 2.5, 5, and 10 mg/day supplied as tablets
45365734|NCT00520767|Genetic|microarray analysis|≤28 days prior to enrollment
46051145|NCT00703690|Drug|Comparator: fenofibrate|fenofibrate 200 mg supplied as capsules
45365735|NCT00520767|Other|flow cytometry|Day 1 of cycles 6, 12, 18 and at end of study.
45365736|NCT00520767|Other|laboratory biomarker analysis|≤28 days prior to enrollment
45365737|NCT00520767|Procedure|quality-of-life assessment|Start of each cycle
45365738|NCT02390453|Behavioral|Combined Cognitive and Physical|Combined modules provide Cognitive training from Posit Science designed to improve information processing speed, learning, memory, and attention, and Physical training focused on seated aerobic and progressive resistance exercises designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
45482802|NCT01350570|Other|acupuncture group3|All acupoints used in acupuncture group1 and group2 will be used in this group.
45482803|NCT01350570|Drug|Loperamide|Loperamide will be used in this group for a dose of 2mg a time, three time a day.
45482804|NCT01355718|Drug|repaglinide|The dosage and frequency, as well as later changes to either dose, frequency or add-on medication (if applicable), will be determined by the physician, according to the patient's requirements.
45482805|NCT01347138|Other|case management|confirmation of hospital visit date, checking the adverse effect and treatment compliance
45482806|NCT03377790|Combination Product|VP-102 - Cantharidin, Topical Film Forming Solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
45482807|NCT03377790|Combination Product|Placebo -Topical Film Forming Solution without VP-102|Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
45482808|NCT02717494|Biological|PPV-23|PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.
45482809|NCT02717494|Biological|PCV-10|PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.
45482810|NCT02717494|Other|NaCl|NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.
45482811|NCT01347294|Drug|Bleomycin|Intralesional
45482812|NCT01347294|Drug|Fibrovein|Intralesional
45482813|NCT01347294|Drug|Bleomycin + Fibrovein|Intralesional
45482814|NCT03306342|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
45482815|NCT01355874|Drug|Iferanserin|0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 14 days during double blind.
45482816|NCT01355874|Drug|Placebo|Placebo ointment BID for 14 days during double blind.
45482817|NCT01355874|Drug|Iferanserin + Placebo|0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 7 days followed by placebo ointment BID for 7 days during the double blind.
45690610|NCT00215943|Drug|zoledronic acid|Patients were randomized to receive zoledronic acid I.V. on either Day 1 or 15 of each cycle. This schedule continued monthly as long as the patient remained on study. The dose was calculated based on the patients' monthly creatinine clearance.
46051146|NCT00703690|Drug|Comparator: Placebo (unspecified)|matching placebo will be supplied as tablets/capsules.
46051147|NCT05297968|Drug|Oseltamivir Phosphate For Oral Suspension/Tamiflu|the subjects randomly received single oral administration of Oseltamivir Phosphate For Oral Suspension/Tamiflu 75mg (6mg/ml,12.5ml)
45690611|NCT00215943|Drug|dexamethasone|As outlined in VAD Treatment arm and Thalidomide and Dexamethasone Treatment arm
46051148|NCT05297968|Drug|Oseltamivir Phosphate For Oral Suspension|the subjects randomly received single oral administration of Oseltamivir Phosphate For Oral Suspension 75mg (6mg/ml,12.5ml)
46051149|NCT00849940|Device|CAS NIRS FORE-SIGHT oximeter|Comparison of non-invasive tissue oxygen saturation with blood sample-derived (calculated) tissue oxygen saturation.
46051150|NCT02613130|Drug|Stannous fluoride toothpaste|
45365739|NCT02390453|Behavioral|Cognitive|Cognitive modules from Posit Science are designed to improve information processing speed, learning, memory, and attention.
45365740|NCT02390453|Behavioral|Physical|Physical modules are focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
45365741|NCT02390453|Behavioral|Active Control|Control modules provide social contact for group discussion of health and successful aging.
45365742|NCT04074707|Dietary Supplement|Labeled iron solution (60mg and 120mg Ferrous Sulfate)|3 doses of 60mg iron as FeSO4 are given on 3 consecutive days (e.g., days 1-3); 3 doses of 120mg iron as FeSO4 are given on one consecutive and one alternate day (e.g., days 20, 21, 23); 3 doses of 120mg iron as FeSO4 are given on one consecutive and one 3rd day (e.g., days 37, 38, 41). Iron doses are labeled with 4mg of a stable isotope in 100ml deionized water (57Fe, 58Fe or 54Fe). Participants will be randomly assigned to start with daily, alternate-day or every-third day dosing.
45482818|NCT04487548|Other|Remote smoking cessation bundle|"The bundle is a remote version of what has previously been described in prior literature, which includes:~A brief (<5 minutes) advice~Preoperative smoking cessation video prepared by QuitNow~Patients will be provided brochures on smoking cessation~A referral will be faxed (or internet-registered) to the Quitnow.ca Smokers' Helpline~All patients will be requested to participate in the provincial Smoking Cessation program that provides a free 12-week supply of NRT once per year."
45690612|NCT00215943|Drug|thalidomide|As outlined in Thalidomide and Dexamethasone Treatment arm
45690613|NCT00215943|Drug|vincristine|As outlined in VAD Treatment Arm
45690614|NCT00215943|Drug|adriamycin|As outlined in VAD Treatment arm
45690615|NCT03593031|Behavioral|Office Based Vergence and Accommodative Therapy|Exercises that will stimulate disparity vergence or accommodation independently and then combined will be used.
45845815|NCT05311020|Dietary Supplement|Pitaya Ovule Extract Drink|consume 1 bottle per day
46051151|NCT02613130|Drug|Potassium nitrate toothpaste|
46051152|NCT00849472|Drug|doxorubicin + cyclophosphamide|4 cycles of doxorubicin + cyclophosphamide followed by 4 cycles of paclitaxel + pazopanib.
46051153|NCT00849472|Drug|paclitaxel + pazopanib|4 cycles of paclitaxel + pazopanib
46051154|NCT00849472|Procedure|surgery|neoadjuvant surgery for breast cancer
46051155|NCT00849472|Drug|pazopanib monotherapy|6 months of treatment with pazopanib monotherapy
46051156|NCT04116580|Other|RAAP - for Raw Apple in connection with re-contact with the raw apple according to an Ultra-Rush protocol|
45365743|NCT04679051|Behavioral|Sleep duration|Participants will be asked to alter time in bed to achieve specified sleep durations.
45365744|NCT03075917|Other|Self Questionnaire|self questionnaire for allergic rhinitis control
45482819|NCT02422368|Drug|Methylprednisolone + ASTED|"ASTED tablet: Twice daily for 6 months~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups."
45482820|NCT02422368|Drug|Methylprednisolone +Placebo|"Placebo: twice daily~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups."
45482821|NCT01355952|Dietary Supplement|Alpha Lipoic Acid|600mg three times per day (1800mg total) daily for 10 weeks
45482822|NCT01347372|Behavioral|Peer Mentor Training|Peer mentors will complete a training program (up to 20 hours) during which they will be evaluated. This face-to-face training applies an interactive format, with a combination of lectures, question/answer sessions, and experiential learning (e.g. role-playing, simulations) and practice sessions.
45482823|NCT02292108|Behavioral|dietetic counselling|
45482824|NCT02292108|Behavioral|Hypnosis and self-hypnosis|Erickson's hypnosis and self-hypnosis
45482825|NCT05133076|Biological|Lactobacillus gasseri DSM 27123|Active and placebo capsules for oral use
45482826|NCT05133076|Biological|Placebo|Placebo
45482827|NCT01347450|Dietary Supplement|Cocoa powder berverage, dark chocolate bar|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
45365745|NCT03873987|Drug|Current Formulation of Oritavancin|Current formulation of oritavancin (3 hour infusion of 1200 mg in 1000 ml of D5W)
45365746|NCT03873987|Drug|Kimyrsa|New formulation of oritavancin (1 hour infusion of 1200 mg in 250 ml of saline)
45365747|NCT03018587|Device|TruSculpt|All subjects will receive 1 truSculpt radiofrequency treatment
45365748|NCT02359253|Other|Passive stretching|Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot within preset ranges of motion.
45482828|NCT01347450|Dietary Supplement|Placebo|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
46051157|NCT00782509|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
45482829|NCT05720572|Drug|Antazoline|Participants assigned to the antazoline group will be administered antazoline in boluses in boluses of 100 mg diluted to 20 cm3 every 10 minutes up to a total dose of 300 mg diluted to 60 cm3 or conversion of AF to SR. Drug administration will also be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
45690616|NCT04608877|Behavioral|Take 5 and Audio Clip|Parent will receive the 5 discrete safety steps for infant crying and listen to the audio clip of infant crying and public service announcement message
45690617|NCT04608877|Behavioral|Take 5 Only|Parent will only receive the 5 discrete safety steps for infant crying
45690618|NCT03990207|Device|PowerSpiral Enteroscopy System|Motorized spiral enteroscopy system
46051158|NCT00782509|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
46051159|NCT00782509|Drug|Placebo|Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
46051160|NCT04116346|Other|Oral intake allowed|Oral intake (food and fluids) allowed up to the time of the procedure
46051161|NCT05598112|Biological|FMT capsules|FMT capsules containing extensively screened donor stool.
46051162|NCT05598112|Other|Placebo capsules|Placebo capsules that do not contain donor stool or any active drug.
46051163|NCT00701428|Drug|Losartan|Losartan 50 mg daily during 6 + 6 weeks
46051164|NCT00701428|Other|CPAP|CPAP during the second 6 week-period
46051165|NCT00927810|Drug|Canakinumab|
45365749|NCT02359253|Other|Passive movement|Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot only within ranges that produce no to very minimal forces.
45365750|NCT02359253|Other|IntelliArm|During the active training, subjects will be asked to actively move their arm while supported with IntelliArm robot to interact with virtual targets and objects. The IntelliArm may provide resistance or assistance.
45365751|NCT02359253|Other|Hand robot|During the active training, subjects will be asked to actively open and close their hand with the hand robot on while participating in task oriented occupational therapy focused on grasp and release tasks. The hand robot may provide resistance or assistance.
45690619|NCT01827163|Drug|Paclitaxel|
45690620|NCT01827163|Drug|Trastuzumab|The q 3 week trastuzumab may be started at the last dose of paclitaxel infusion or from 1-3 weeks after the last dose of paclitaxel. Trastuzumab may also be administered at a dose of 6mg/kg during the last dose of paclitaxel in the THL phase.
45690621|NCT01827163|Drug|Lapatinib|
45482830|NCT05720572|Drug|Propafenone|Patients assigned to the propafenone group were administered three 20-cm3 boluses every 10 minutes up to 60 cm3 or conversion of AF to SR. Each of the first two boluses included 70 mg propafenone (total dose 140 mg), and the third bolus contained only 20-cm3 0.9% NaCl. Drug administration will be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
46051166|NCT00848926|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous infusion
46051167|NCT02602951|Other|Pilot MRI program|Pilot MRI program
46051168|NCT02602951|Other|MRI with 4D Flow sequence|MRI with 4D Flow sequence
46051169|NCT00847132|Behavioral|Collaborative Care Treatment|Depression education, treatment recommendations, coordination of care
46051170|NCT00847132|Behavioral|Usual Care Treatment|Treatment as usual, providers are notified of diagnoses
45690622|NCT01827163|Drug|Pegfilgrastim|Pegfilgrastim SQ is given on day # 2 of each paclitaxel cycle and may be dropped at the last paclitaxel infusion. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion.
45690623|NCT00215553|Drug|A.1 Lucinactant|3 30 mL aliquots at concentrations of 5, 5, and 10 mg/mL
45365752|NCT04072913|Other|Vaginal samples (biopsies + vaginal smear)|Two types of samples are envisaged: tissue (large biopsies, coin of conization or hysterectomy) to affirm the diagnosis and detect the matrix metalloproteinases and their tissue inhibitors by immunohistochemistry; cell sample (monolayer smear type) to evaluate the expression of oncogenic Human papillomavirus.
45365753|NCT02579213|Other|observational study done only in women candidate for amniocentesis|As a part of routine test in women with obstetrical indication for amniocentesis, we take 30 cc of amniotic fluid. only additional 3 ml of the amniotic fluid are needed for examination by electronic sensors.
45365754|NCT04072679|Drug|Sintilimab+IBI305|It includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then select specific dose of IBI305 +Sintilimab 200mg/kg, expand to 36-39 patients for the further safety and efficacy study.The study treatment lasts up to 24 months.
45365755|NCT04975503|Other|Observing cardiovascular risk factors|Documenting the presence or absence of CVD risk factors in each participant.
45365756|NCT02579291|Other|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
45365757|NCT02579291|Other|Bobath|Patients will receive different neuromodulatory interventions based on the Bobath concept with the aim to decrease spasticity on the lower extremity
45365758|NCT00474760|Drug|CP-751,871|Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity
45482831|NCT01356030|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP) is usually clinically indicated to place a stent (a plastic or metal tube) in the bile duct. The ERCP procedure is an endoscopic exam during which a small catheter or wire is placed into the bile duct from the point at which it connects to the small intestine. During such a procedure a stent can then be placed to help drain the bile across the site of blockage, and thereby treat your jaundice.
45482832|NCT01356030|Procedure|EUS FNA|Endoscopic ultrasound (EUS) is a procedure in which a flexible tube with a tiny camera and ultrasound probe at the tip is placed through the mouth, down the esophagus, and into the stomach and duodenum (first part of the small intestine where bile flows from the bile duct into the intestine). This allows the doctor performing the EUS to get a much closer view of your pancreas and bile duct. If a suspicious mass is seen, a small sample of the mass (biopsy) is taken using fine needle aspiration (FNA). FNA involves the use of a thin hollow needle to extract cells for diagnostic purposes and is considered safer and less invasive than surgical biopsies.
45482833|NCT05111002|Drug|Lefamulin|600mg tablet orally twice daily
45482834|NCT05111002|Drug|Doxycycline|100mg tablet orally twice daily
45482835|NCT01347528|Behavioral|Medication Adherence Support System (MASS)|The intervention consists of the use of an electronic Medication Adherence Monitor for a 6-month period as well as 2 visits to the heart failure outpatient clinic of the TweeSteden hospital (usual care). This monitor (a) dispenses all prescribed medication in the right dosage at the specified time, (b) reminds patients to take their medications through an alarm, sms or voicemail service and records adherence, and (c) sends critical data about non-adherence to the heart failure nurse, via a web application (CarebyWeb). The Medication Adherence Monitor is provided to the patient by the hospital pharmacy, including an instruction how to use the device. After the intervention patients return to usual care only. We expect a training effect, with continued improved adherence in the intervention group.
45482836|NCT02465944|Drug|FFP104|Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)
45482837|NCT02465944|Drug|Placebo|Three intravenous infusions of 0.9% Saline over 15 days (d0, d7 and d14)
45690624|NCT00215553|Other|B.3 SoC|Standard ARDS management and ICU care
46051171|NCT04254510|Other|Myofascial relaxation technique|"Before the intervention, the number of days of the last menstrual cycle of all participants, the number of painful days throughout the cycle, pain intensity values according to the Visual Analogue Scale will be recorded, and the scores will be recorded in the participants.~Technique of direct relaxation of fascia of both psoas muscles to the participants in the myofascial relaxation group since the end of the last cycle, 90-120 sec. It will be applied by the physiotherapist twice a week."
46051172|NCT00706888|Dietary Supplement|Vitamins B6, B9 and B12 and polyphenols|
46051173|NCT00706888|Dietary Supplement|placebo|
45365759|NCT02579681|Drug|dimethyl fumarate|dimethyl fumarate administered as per the arm description
45365760|NCT00528645|Drug|saracatinib|Given orally
45365761|NCT02911103|Procedure|DBS surgery|Unilateral thalamic DBS therapy
45690625|NCT00215553|Drug|A.2 Lucinactant|3 30 mL aliquots at a concentration of 10 mg/mL each
45690626|NCT00215553|Drug|A.3 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL
45690627|NCT00215553|Drug|A.4 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
45690628|NCT00215553|Drug|B.1 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL
45690629|NCT00215553|Drug|B.2 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
45482838|NCT01356108|Device|Transcatheter Pulmonic Valve Replacement (TPVR) (Edwards SAPIEN™ THV)|The Edwards SAPIEN™ THV is a biological heart valve manufactured with treated bovine pericardial tissue that is mounted into a balloon expandable stainless steel open cell stent. The Edwards SAPIEN™ THV is available in two sizes (23 and 26mm) and is designed for transcatheter implantation in patients with regurgitant pulmonary valved conduit with or without stenosis. This device is commercially available and is used according the current IFU.
45482839|NCT04471792|Drug|Creatine monohydrate|Creatine monohydrate will be used in combination with muscle stretching.
45482840|NCT04471792|Dietary Supplement|Cellulose|Cellulose will be used in combination with muscle stretching.
45482841|NCT01356186|Behavioral|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 6 sessions; 60-90 minutes in duration; administered over preferably 3 days of psychiatric hospitalization
45482842|NCT01347684|Behavioral|Behavioral therapy, splint therapy and physical therapy|Includes patient education, use of a mouth guard, jaw muscle exercises and brief cognitive-behavioral intervention.
45482843|NCT01347684|Drug|Standard care using current drugs|Standard Drug therapy
45482844|NCT05716750|Dietary Supplement|Vitamin D|50,000 IU vit D treatment for 8 weeks
45482845|NCT05709886|Device|EUS-LA by LaserPro Diode Laser System|This trial is a prospective, single-arm, multi-center clinical trial. Four hospitals with national medical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive endoscopic ultrasound (EUS)-guided laser ablation (LA) by LaserPro Diode Laser System according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the procedure will be made according to groups.
45482846|NCT01350882|Drug|MabThera|MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
45482847|NCT01350882|Drug|Physiological serum : sodium chloride, sodium citrate|Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
45482848|NCT01357200|Other|enteral formula|Complete feeding of study enteral formula, route and regime prescribed by the physician.
45482849|NCT01357278|Procedure|Rehabilitation and patient education|"Supervised rehabilitation consists of exercises for strength, balance and coordination twice weekly, and a home-training programme once weekly.~Patient education will be offered every eight week."
46051174|NCT05019534|Drug|Vemurafenib Oral Tablet [Zelboraf]|Vemurafenib 960mg qd or 960mg bid (2 cohorts)
45596554|NCT03529279|Drug|NCCN Chemotherapy|"UICC I, IMRT. UICC II-IVA, concurrent chemoradiotherapy ± adjuvant chemotherapy, or induced chemotherapy plus concurrent chemoradiotherapy. UICC IVB, platinum based combined chemotherapy, followed by IMRT or concurrent chemoradiotherapy, or concurrent chemoradiotherapy.~Chemotherapy strategy: Concurrent cisplatin with or without cisplatin plus 5-Fu or carboplatin combined with 5-Fu adjuvant chemotherapy; The combined chemotherapy regimen of IVB stage patients may choose cisplatin or carboplatin plus docetaxel or paclitaxel, cisplatin plus 5-Fu, carboplatin and cetuximab, cisplatin plus gemcitabine, and gemcitabine. The combination of vinorelbine and cisplatin, carboplatin, paclitaxel, docetaxel, 5-Fu, methotrexate, gemcitabine and capecitabine can be used in combination with radiotherapy."
46051175|NCT05019534|Drug|Cetuximab Injection [Erbitux]|Cetuximab 500mg/m2 Q2W
46051176|NCT05019534|Drug|Camrelizumab|Camrelizumab 200mg Q2W
45845816|NCT05310240|Procedure|Hip arthroscopy|Arthroscopic surgery of the hip
45845817|NCT05309616|Drug|Taltz|Participants will receive160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2,4,6,8,10,12 and then 80 mg every 4 weeks
46051177|NCT00707044|Procedure|Control group (usual care)|control group, care as usual, 24 hours intensive care stay
46051178|NCT00707044|Procedure|Short-Stay Intensive Care treatment (SSIC)|Short-Stay Intensive Care treatment (SSIC), 8 hours of Intensive care treatment
46051179|NCT04254120|Behavioral|Cognitive-behavioral therapy|Psychological treatment focusing on changing cognitions and behaviors using information processing theory and learning theory approaches.
45845818|NCT05304936|Drug|HCW9218|Bifunctional TGF-β antagonist/IL-15 protein complex
45365762|NCT04072757|Behavioral|Intervention Group|"Session One: Loving Food That Loves You Back - Food as Fuel~connection nutrition and health Session Two: Myth busting: Fruits and Vegetables - delicious and affordable~seasonal fruits & vegetables in the diet Session Three: No Time to Cook! Making nutritious meals that are fast and easy~quickly make delicious/nutritious meals using minimal ingredients Session Four: Don't Eat Food You Can't Pronounce Except Quinoa; Eat Quinoa~choose healthier foods Session Five: Taste Bud Rehab~reduce foods high in sugar and salt.Mind-body connection Session Six: Batch & One Ingredient Cooking~making large quantities to freeze; one ingredient cooking Session Seven: Sweet Tooth? Healthy Desserts~prepare healthier desserts Session Eight: Family Meal Practices~healthy eating habits in children Session Nine: Snacks as Mini Meals~make nutritious snacks to keep energy up all day Session Ten: Revamp Your Favorite Recipe~healthy up favorite recipes"
45365763|NCT04072757|Behavioral|Control Group|"The control group will not receive vouchers or nutrition education/skill building but will be exposed to any standard Griffin Hospital worksite offerings. A mini program (2 -4 hours) workshop will be offered to participants in the control group, and all intervention materials will be provided."
45365764|NCT00524745|Biological|Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.
45365765|NCT02896751|Device|3D printed NIV mask|use of 3D printed mask
45365766|NCT04073693|Dietary Supplement|Branched chain amino acids (BRCA)|They were with BRCA during the day apart of following the standard recommendations
45365767|NCT01017796|Drug|N-acetylcysteine and ascorbic acid|1200mg acetylcysteine and 2g ascorbic acid in 200 ml 0,9% normal saline at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
45365768|NCT01783535|Drug|vincristine|Given via minibag/gravity flow.
45365769|NCT01783535|Drug|topotecan|Given IV over 30 minutes.
45365770|NCT01783535|Drug|filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until absolute neutrophil count (ANC) is >2,000/µL on one occasion after the expected nadir.
45365771|NCT01783535|Drug|PEG-filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until ANC is >2,000/µL on one occasion after the expected nadir.
45365772|NCT01783535|Drug|carboplatin|Given IV over 60 minutes. Given periocular (subtenon/subconjunctival).
45365773|NCT01783535|Other|focal therapy|Focal treatments will be administered at the discretion of the treating team to strata A, B and D. In select cases of very early stage retinoblastoma (Stratum A), participants may receive focal therapies only and chemotherapy will be held at the discretion of the treating team. If there is any evidence of progression or unsatisfactory results, the participant will begin chemotherapy as per Stratum A. For selected participants an effort will be made to perform sequential chemo-thermotherapy. In these cases, carboplatin will be administered one or two hours prior to thermotherapy.
45365774|NCT01783535|Drug|etoposide|Given IV. Participants who cannot tolerate etoposide may be given etoposide phosphate (Etopophos(R)).
45365775|NCT01783535|Drug|cyclophosphamide|Given IV.
45690630|NCT03592953|Other|Serious game simulation training sessions|"Each participant of the Serious game groups played 3 scenarios of Perinatsims, a screen-based simulation on the management of a post partum hemorrhage. The serious game control group played basic scenarios and the experimental group played specific scenarios."
45690631|NCT00214461|Biological|Vaccine diluent buffer (Placebo)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
45690632|NCT00214461|Biological|C. difficile toxoid vaccine (2 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
45690633|NCT00214461|Biological|C. difficile toxoid vaccine (10 µg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
45690634|NCT00214461|Biological|C. difficile toxoid vaccine (50 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
45690635|NCT03592875|Behavioral|Professional nurses|The nurses will be interviewed by a semi-structured guiding with 16 questions addressing aspects related to Nursing Care Systematization knowledge and practices.
45845819|NCT05301504|Biological|ChAdOx1 biEBOV|ChAdOx1 biEBOV is provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
45845820|NCT05300256|Device|Peripheral Heating|Peripheral heating of the feet
45845821|NCT05300256|Device|Sham|Sham
45365776|NCT01783535|Drug|MESNA|Given IV before CYCLO and at 3, 6 and 9 hours after CYCLO.
45690636|NCT03599583|Behavioral|STOP-HPV prompts intervention|This intervention will be the addition of the prompts intervention (in the presence of communication skills training and continued performance feedback).
45690637|NCT04407351|Device|Green LED light|Investigators arrange 12 weeks green LED light phototherapy.
45690638|NCT04407351|Device|Red LED light (placebo)|Investigators arrange 12 weeks red LED light phototherapy (placebo).
45845822|NCT05286684|Procedure|Consultation|History of the disease, anatomopathological and molecular biological data concerning the initial tumor; Collection of treatments received and/or in progress by the patient for her meningeal tumor (chemotherapy, targeted therapy, radiotherapy, surgery, corticosteroids, antiepileptics); Evaluation of the general condition and neurological status.
45845823|NCT05286684|Procedure|Cerebral and medullary MRI, lumbar puncture, CSF sampling|diagnosis of leptomeningeal involvement
45365777|NCT01783535|Drug|doxorubicin|Given IV on Day 1 of Cycles 2, 4 and 6 in Stratum C high-risk.
45365778|NCT01783535|Procedure|enucleation|Eye removal due to advanced disease in Strata C and D participants.
45365779|NCT01783535|Radiation|external beam radiation or proton beam radiation|EBRT or proton beam radiation will be administered to any eye in which the disease is considered to be not controllable with focal treatments alone, and in participants with enucleated eyes in which high risk of orbital and/or central nervous system disease is documented histologically (high-risk group with disease extension beyond the sclera or cornea, or beyond the cut end of the optic nerve). EBRT will be administered using standard techniques practices with the objective of limiting dose to normal tissues including the hypothalamic-pituitary unit, supratentorial brain, orbit, cochleae and contralateral eye when indicated. Participants will be evaluated on an individual basis to determine whether they might benefit from referral for proton therapy.
45365780|NCT05001646|Device|In-home resonance-based electromagnetic field protection device|Participants will have an in-home EMF protection device
45365781|NCT00495040|Radiation|Proton Radiotherapy|87.5 CGE with 2.5 Gy/fraction for 35 treatments
45596555|NCT03529279|Radiation|CNG Radiation|"IMRT technique. GTV was given to 6810cGy, CTV1 was given to 6000cGy, and CTV2 was given to 4800-5400cGy. 30 fractions, daily, QW1-5.~CT-SIM or MR-CIM was evaluated every 10 fractions. If CR for CNG I and II patients at 10 fractions, radiotherapy were given 25 fractions, that was, GTV was given to 5675cGy, CTV1 was given 5000cGy, and CTV2 was given 4000-4500cGy, 25 fractions, daily, QW1-5.~If tumor reduced less than 50% at 20 fractions, GTV was modified according to tumor size at 20 fractions. The modified GTV was given 300cGy/F×5 after 25 fractions; the original CTV1 and CTV2 were unchanged, that is, GTV was given to 5675cGy/25Fr+1500cGy/5Fr and CTV1 was given to 6000cGy/30Fr, CTV2 was given 4800-5400cGy/30Fr."
45365782|NCT04073537|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
45365783|NCT04073537|Drug|Placebos|Anlotinib blank analog capsule.
45365784|NCT04073537|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 IV on Day 1 of each 21-day cycle.
45365785|NCT04073537|Drug|Carboplatin|Carboplatin area under the concentration curve (AUC) 5 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
45365786|NCT03998631|Procedure|Carbon Dioxide and Saline Flush|The TEVAR or TAVI device will be flushed with approximately 1.2L of medical grade carbon dioxide using a 60mL syringe and connecting tubing. The reservoir will then be flushed with at least 60mL of standard saline prior to deployment to minimize bubbles in the saline.
45365787|NCT03998631|Procedure|Standard Saline Flush|Standard of care flushing of the TEVAR or TAVI device with normal saline.
45365788|NCT01020760|Behavioral|Face down posture|Patients are requested to maintain a strict face down posture for 50 minutes out of every hour for seven days after surgery.
45365789|NCT04085133|Diagnostic Test|Gene Xpert Chest x ray and MSCT chest|Sputum sample for T.B will be done using gene expert device and chest xray and high resolution ct to evaluate bronchectasis
45365790|NCT01020916|Procedure|Target temperature 36°C|In hospital target temperature management to achieve a core body temperature of 36°C for 24 hours
45845824|NCT05286684|Biological|biological test|5 ml of additional CSF after diagnostic lumbar puncture for proteomic analysis, 50-100 µl of breast aspiration fluid (NAF) for patients with an existing breast tumor, for proteomic analysis 10 ml of blood for proteomic analysis
45365791|NCT01020916|Procedure|Target Temperature 33°C|In hospital target temperature management to achieve a core body temperature of 33°C for 24 hours
45365792|NCT02664363|Biological|EGFRvIII CAR T cells|The name of the drug is CAR gene-modified T cells or abbreviated as EGFRvIII CARs. The class of action is a biological and the mechanism of action is cytotoxicity. The drug substance is autologous T cells transduced with a retroviral vector encoding for a chimeric antigen receptor (CAR) directed against the tumor specific antigen, EGFRvIII. EGFRvIII CARs are genetically engineered T cells that have been taken from patients with GBM ex vivo to express a CAR recognizing the GBM tumor-specific antigen EGFRvIII, which is expressed on a subset of GBMs but not in normal human tissues with the aim of mediating regression of their tumors. Patients' CARs will be radiolabeled with 111In for correlative studies in the expanded cohort.
45365793|NCT01020994|Drug|LAS41003|Once daily, topically
45365794|NCT01020994|Drug|LAS189962|Once daily, topically
45365795|NCT01020994|Drug|LAS189961|Once daily, topically
45365796|NCT00494026|Drug|pemetrexed|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 2 cycles then 500 mg/m2, IV, every 21 days x 2 cycles
45365797|NCT00494026|Drug|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 2 cycles then AUC 5, IV, every 21 days x 2 cycles
45690639|NCT00214383|Behavioral|CHESS Internet telehealth|CHESS Internet telehealth
45690640|NCT03599973|Other|Plasmalyte A Viaflo|Fluid therapy to be given according to the principle of 4-2-1 (4 ml of crystalloid fluid for each of the first 10 kg of weight (0-10 kg), 2 ml of crystalloid fluid for each of the second 10 kg of weight (11-20 kg) and 1 ml of crystalloid fluid for each kg of weight over 20.
45845825|NCT05283252|Device|3-D printed Guide|Guided Endodontic micro-surgery
45845826|NCT05283252|Other|Conventional Endodontic Micro-Surgery|Free-hand endodontic micro-surgery
45365798|NCT00494026|Procedure|radiotherapy|2 Gray (Gy) per fraction, 5 fractions per week, begin day 1, cycle 3 x 5 weeks (Monday-Friday)
45365799|NCT01018108|Procedure|Single Photon Emission Computed Tomography|Undergo single photon emission computed tomographt imaging
45365800|NCT01018108|Procedure|Acupuncture Therapy|Undergo acupuncture
45365801|NCT01018108|Other|Questionnaire Administration|Ancillary study
45365802|NCT01018108|Other|Laboratory Biomarker Analysis|Correlative Study
45365803|NCT00524589|Dietary Supplement|calcitriol|IV
45365804|NCT00524589|Drug|dexamethasone|Oral
45365805|NCT00524589|Genetic|protein expression analysis|Correlative Study
45690641|NCT00212355|Drug|NPC-02|zinc acetate
45690642|NCT03599895|Procedure|3D printing model|Combine the 3D printing technique with imaging examination ,making the 3D model of da Vinci robot assisted radical gastrectomy
45845827|NCT05278494|Drug|Dextromethorphan Hydrobromide|PO
45845828|NCT05278494|Drug|Placebo|PO
45845829|NCT05251038|Drug|Sotorasib|Intervention instruction outlined in protocol
45365806|NCT00524589|Other|laboratory biomarker analysis|Correlative Study
45365807|NCT04074837|Drug|NNI-362|NNI-362 small molecule in liquid suspension.
45365808|NCT04074837|Drug|Placebo|Placebo liquid suspension
45365809|NCT01015066|Drug|Buprenorphine/naloxone|Sublingual tablets, 2/0.5mg (ratio buprenorphine:naloxone = 4:1), three times a day for six months (doses may be adjusted based on an individual's response)
45365810|NCT01015066|Drug|Naltrexone|Oral tables, 50 mg/d, once a day for six months
45365811|NCT01021072|Drug|MABp1|0.25 mg/kg,0.75 mg/kg,1.25 mg/kg, 3.75 mg/kg IV (in the vein) on day 1 of each 21 day cycle until progression or unacceptable toxicity develops.
45365812|NCT00472030|Drug|Omalizumab|Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
45365813|NCT00472030|Drug|prednisone|Prednisone, to a maximum dose of 0.5 mg/kg/day.
45365814|NCT00127855|Biological|Hib-MenCY-TT vaccine (MenHibrix)|Three doses were administered intramuscularly (IM) in left thigh at Months 0,2 and 4 respectively
45365815|NCT00127855|Biological|Meningitec®|Three doses were administered IM in right lower thigh at Months 0,2 and 4.
45365816|NCT00127855|Biological|ActHIB®|Three doses were administered IM in left thigh at Months 0,2 and 4.
45365817|NCT00127855|Biological|Infanrix® Penta|Three doses were administered IM in right upper thigh at Months 0,2 and 4 respectively.
45365818|NCT00127855|Biological|Prevenar®|Three doses were administered IM in right lower thigh at Months 0,2 and 4 respectively.
45690643|NCT03599895|Procedure|non 3D printing model|da Vinci robot assisted radical gastrectomy
45845830|NCT05251038|Drug|Liposomal Irinotecan (nal-IRI)|Intervention instruction outlined in protocol
45845831|NCT05251038|Drug|5 Fluorouracil (5FU)|Per standard of care
45845832|NCT05251038|Drug|Leucovorin (LV)|Per standard of care
45845833|NCT05251038|Drug|Gemcitabine (GEM)|Per standard of care
45845834|NCT05251038|Drug|Nab paclitaxel|Per standard of care
45365819|NCT00127855|Biological|Mencevax® ACWY|One fifth of one dose was administered IM in deltoid region of right arm at Month 10 as booster.
45365820|NCT00127855|Biological|PRP (Polyribosyl Ribitol Phosphate)|One dose was administered IM in deltoid region of left arm at Month 10 as booster.
45365821|NCT00493636|Drug|Gemcitabine|Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle
45690644|NCT03592797|Other|Laser acupuncture therapy|Low level laser therapy to stimulate acupuncture points: Total 11 points will be used in the study. 7 points ST4, ST6, ST7, SI18, BL2, GB14, SJ17 located in the effected side of the face and will be stimulated ipsilateral. Two points ST36, LI4 located distally and will be stimulated bilateral.
45690645|NCT03592797|Other|Sham laser acupuncture therapy|Sham procedure of Low level laser therapy to stimulate acupuncture points is identical procedure as the intervention group. The same 11 points which mention above will be used, However, in the sham group the laser device will be deactivated and won't produce any laser beam irradiation.
45845835|NCT05244096|Other|No intervention|Observational study
45690646|NCT03592719|Behavioral|Experimental Intervention (MI-PrEP)|The experimental intervention will consist of two sessions. The first session will involve psycho-education on PrEP and Motivational Interviewing to explore ambivalence about PrEP uptake. The second session will involve Motivational Interviewing and case management to explore barriers to accessing PrEP.
45690647|NCT03592719|Behavioral|Enhanced Treatment as Usual (E-TAU)|Participants assigned to the control condition will receive two sessions, both of which involve psychoeducation on PrEP.
45690648|NCT00211887|Drug|Interferon beta 1-a|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
45690649|NCT00211887|Drug|glatiramer acetate|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
45690650|NCT00211887|Other|placebo|an inactive substance
45690651|NCT04002453|Procedure|Outpatient Parenteral Antibiotic Therapy|Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
45690652|NCT03599817|Behavioral|Healthy lifestyle promotion program|Before implementing the healthy lifestyle program, it will be adapted according to the characteristics of the Yaqui community, their type of food and the activities they carry out, so that the intervention program is culturally accepted by the community. The intervention will consist of two stages, an intensive phase and a maintenance phase. In the intensive phase, 16 weekly group sessions will be given with the aim of achieving a 5% body weight loss and ensuring that the participants do at least 150 minutes of physical activity per week. In the maintenance phase, 6 monthly group sessions will be given in order to maintain the results achieved in the first stage. In the same maintenance phase, but from 12 to 18 months, the lifestyle trainers will make home visits to the participants. Lifestile trainers will record body weight, physical activity and food consumption. In this period there will be no sessions, only monthly visits.
45690653|NCT04002297|Drug|zanubrutinib|Administered as two 80 mg capsules by mouth twice a day
45845836|NCT05240898|Drug|KSQ-4279 Monotherapy (Dose Escalation and Expansion)|Administered orally in capsule
45365822|NCT00493636|Drug|Sorafenib|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
45365823|NCT00493636|Drug|Placebo|Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
45690654|NCT04002297|Drug|bendamustine|Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6
45690655|NCT04002297|Drug|rituximab|Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6
45690656|NCT03592485|Procedure|Erector Spinae Plane blockade|Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
45690657|NCT03592485|Procedure|Pectoral Fascia block|Before the beginning of the procedure, PECS type I and II blocks will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
45690658|NCT03592485|Drug|Oxycodone|Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
45845837|NCT05240898|Drug|KSQ-4279 Combination Therapy (Dose Escalation and Expansion)|KSQ-4279 will be combined in separate cohorts, including combination with an oral PARPi (poly adenosine diphosphate-ribose polymerase inhibitor) and combination with a platinum-based chemotherapy.
45690659|NCT03592485|Procedure|general anesthesia|Each patient will generally anesthetized and endotracheal tube will be inserted
45690660|NCT03592485|Drug|paracetamol|Paracetamol will be given i.v. every 6 hours.
45690661|NCT04199013|Drug|Ropivacaine 0.75% Injectable Solution|Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
45690662|NCT04199013|Drug|Fentanyl Citrate|Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
46051180|NCT04254120|Behavioral|Integrated motivational interviewing and cognitive-behavioral therapy|Motivational interviewing is a psychological treatment approach focusing on increasing motivation by eliciting patient talk favoring behavior change and resolving patient ambivalence about change.
45365824|NCT00493636|Drug|Capecitabine|Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine).
45690663|NCT03592251|Dietary Supplement|Olive Oil Placebo|6 months placebo supplementation
45365825|NCT00524121|Drug|erlotinib hydrochloride|Oral
45365826|NCT00524121|Other|immunohistochemistry staining method|Correlative Study
45365827|NCT00524121|Radiation|radiation therapy|Radiation Treatment
45365828|NCT03996382|Diagnostic Test|DPD Scintigraphy|Confirms/Refutes diagnosis of cardiac amyloidosis.
45690664|NCT03592251|Dietary Supplement|EPA-rich|6 months placebo supplementation
45690665|NCT03592251|Dietary Supplement|DHA-rich|6 months placebo supplementation
45690666|NCT03989895|Biological|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV
45690667|NCT04747665|Other|Patient and endoscopist reported experience|Exploration of patient and endoscopists experiences of colonoscopy.
45845838|NCT05231304|Procedure|Total Talus Replacement (TTR)|Surgical implantation of restor3d's patient-specific custom Total Talus Replacement device.
45365829|NCT01018342|Drug|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|
45365830|NCT01018342|Drug|Macrobid® Capsules 100 mg|
45365831|NCT01074385|Behavioral|Dignity Therapy|Dignity therapy is a psychotherapeutic intervention developed to address psychosocial and existential distress among terminally ill patients. Basically, it invites patients to discuss topics that matter most or how they want to be remembered. This interview is recorded and then edited and returned to the patient to be used for further reflection or for sharing with loved ones.
45365832|NCT03965767|Drug|Tranexamic Acid|comparison of effect of tranexamic acid on control of bleeding when used locally in the nose or systemic use
45365833|NCT00470626|Device|Celect Vena Cava Filter|Effective filtration of inferior vena cava blood to prevent thromboembolism.
45365834|NCT03966001|Other|Transvaginal sonography at six months after cesarean section|In the sixth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
45365835|NCT03966001|Other|Transvaginal sonography at twelve months after cesarean section|In the twelfth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
45365836|NCT01074541|Radiation|UVB|0.375 SED x 4 in a week
45365837|NCT01074541|Radiation|UVB|0.75 SED x 4 in a week
45365838|NCT01074541|Radiation|UVB|1.5 SED x 4 in a week
45365839|NCT01074541|Radiation|UVB|3.0 SED x 4 in a week
45365840|NCT00133705|Drug|Mifepristone|Mifepristone 5mg/day by mouth for 6 months
45365841|NCT00133705|Drug|Inert Capsule|sugar pill
45365842|NCT00132769|Drug|MK-0873|MK-0873 1.25 mg twice daily for 12 weeks
45365843|NCT00132769|Drug|Comparator: Placebo|Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
45365844|NCT00520299|Drug|ADI PEG 20|Intramuscular injections were administered into the deltoid, gluteal, or quadricep muscles once weekly (± 2 days) for 9 weeks during cycle 1 and 8 weeks during subsequent cycles
45365845|NCT02542683|Other|structured physical activity program|a structured modest physical activity program
45365846|NCT02518269|Procedure|Hip Arthroplasty|Hip Arthroplasty comparing 3 different bearings.
45365847|NCT02478255|Drug|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
45365848|NCT02478255|Device|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
45690668|NCT03592095|Device|Dry needling|Real dry needling will be conducted according to Hong description, fast-in and fast-out interventions. The intervention will be applied until a total of four local twitch responses will be elicited
45690669|NCT03592095|Device|Placebo needle|Sham dry needling with be conducted with a sham needle (Steitberger's Park sham device (PSD). This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient.
45482850|NCT05104528|Device|OSYPKA Medical ICONTM Noninvasive CardiometerTM Model C3|Based on its precedent electrical impedance. 4 electrodes are placed on the patient: 2 on the left of the neck and the other 2 on the left lower chest . A low magnitude (2 mA), high frequency (30-100 KHz) alternating electrical current (AC) of constant amplitude is applied through the outer electrodes, and the resulting voltage is received by the inner electrodes. The ratio of the detected voltage to the applied current is the bio-impedance. The principle on which this is based is that during systole, red blood cells flow in a parallel manner, which allows the electrical current to flow easily thereby improving the electrical velocity and decreasing impedance. While during diastole, RBCs are randomly arranged, consequently hindering the electrical current (increased impedance) and decreasing electrical velocimetry. The changes of impedance over time are integrated in a complex algorithm that allows to measure CO and the other parameters.
45482851|NCT05104528|Device|Fujifilm Sonosite M-Turbo C Ultrasound system|A low-frequency phased array transducer (3.5-5 MHz) will be used to assess the IVC, which lies in the retroperitoneum, to the right of aorta. At or near the junction with the hepatic veins, we will measure the IVC diameter. To properly visualise the IVC, the probe will be inserted in the subxiphoid 4-chamber position with the probe marker oriented vertically to find the right ventricle and atrium. We will see the convergence of the IVC with the right atrium as the probe is progressively aimed towards the spine. We will then follow the IVC inferiorly, to detect the meeting of the hepatic veins with the IVC. M-mode Doppler sonography of the IVC will be used to graphically document the absolute size and dynamic changes in the calibre of the vessel during inspiration and expiration. After the visualisation of the IVC, we will freeze the US screen, and using the caliper function on the US machine, maximum and minimum diameters of the IVC will be documented.
45482852|NCT04489966|Behavioral|Aerobic training|The intervention was aerobic rhythmic training under the guidance and supervision of a professional. The aerobic training program required participants to exercise 3 days/week for 60 minutes/session (including 5-10 minutes of warm-up and 50 minutes aerobic training and 5-10 minutes to relax). All patients received an open class, relate to diabetes health education．
45482853|NCT02476084|Other|Musculoskeletal Ultrasound Imaging|B-mode and PD musculoskeletal ultrasound examination of selected joints.
45482854|NCT02476084|Other|Synovial biopsy|US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.
45690670|NCT04198935|Device|Span Health Mobile Application|A 12 week structured diabetes education program for type 2 diabetes delivered through a mobile application. The application also allows for interaction with a registered nutritionist via text messaging.
45690671|NCT01855945|Biological|Swine Influenza|Comparison of different dosages of vaccines
45845839|NCT05231304|Procedure|Total Ankle Total Talus Replacement (TATTR)|Surgical implantation of restor3d's patient-specific custom Total Ankle Total Talus Replacement (TATTR) device.
45365849|NCT00132691|Drug|fluocinolone acetonide intraocular implant|RETISERT™ (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the first month to a steady state between 0.3-0.4 μg/day over approximately 30 months.
45365850|NCT00132691|Drug|oral corticosteroid with immunosuppressive agents as needed|Prednisone
45365851|NCT02390427|Drug|Taselisib|
45365852|NCT02390427|Drug|Trastuzumab emtansine|
45365853|NCT02390427|Drug|Pertuzumab|
45845840|NCT05231304|Procedure|Total Ankle Total Talus Replacement + Subtalar Fusion (TATTR + STJ)|Surgical implantation of restor3d's patient-specific custom Total Ankle Total Talus Replacement (TATTR) device with concurrent subtalar fusion.
45365854|NCT02390427|Drug|Trastuzumab|
45365855|NCT02390427|Drug|Paclitaxel|
45365856|NCT00125359|Drug|erlotinib and bexarotene|Daily Erlotinib 150mg and daily bexarotene oral capsules 400mg.
45365857|NCT00524043|Drug|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
45365858|NCT00524043|Drug|Placebo|Once daily for 6 weeks
45365859|NCT00524043|Drug|Paliperidone ER|6 mg tablet once daily for 6 weeks
45365860|NCT03966703|Behavioral|mixing analysing test|The chewed gum is retrieved scanned and weighted to quantify masticatory efficiency
45365861|NCT01076725|Device|Standard technique group|In the standard technique group (n = 63), the PLMA was inserted by index finger insertion technique.
45365862|NCT01076725|Device|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
45365863|NCT01076803|Drug|Lanreotide (acetate)|Deep subcutaneous injection into the upper external quadrant of the right or the left buttock.
45365864|NCT01076881|Behavioral|exercise training|
45365865|NCT00523419|Drug|Pemetrexed|500 mg/m^2, IV every 21 days until disease progression, unacceptable toxicity, participant or physician's decision.
45365866|NCT03868059|Drug|LPCN 1021|LPCN 1021 is gelatin capsule product provided as 112.5 mg testosterone undecanoate per capsule.
45365867|NCT03998865|Device|Provisional abutment material|The effect of the provisional abutment material on the characteristics of the bacterial microbiota will be assessed by using PEEK (experimental) or Titanium (active comparator) provisional abutments.
45482855|NCT02476084|Other|Biological samples collection|Draw of research blood samples.
45482856|NCT02476084|Other|Questionnaires|Administration of validated patients' questionnaires.
45690672|NCT03592017|Device|Long-wavelength autofluorescence imaging|Long-wavelength autofluorescence imaging will be performed with a prototype confocal scanning laser (cSLO) ophthalmoscope which will be equipped with additional laser sources and a reference for quantification of the signal. The experimental long-wavelength laser sources will be integrated into a custom-modified Spectralis HRA cSLO from Heidelberg Engineering. The additional laser sources will operate with long wavelength which are less energetic compared to the conventional short-wavelength lasers used currently for routine autofluorescence imaging. All safety standards have been considered and the light exposure for all imaging modes is well below the exposure limits for Class 1 and Class1M laser products as defined in the standard IEC 60825-1, edition 3.0, 2014-5.
45845841|NCT05231304|Procedure|Total Talus Replacement + Subtalar Fusion (TTR + STJ)|Surgical implantation of restor3d's patient-specific custom Total Talus Replacement (TTR) device with concurrent subtalar fusion.
45845842|NCT05226780|Drug|NBI-921352|Administered orally
45845843|NCT05225298|Behavioral|Offering SARS-CoV-2 test|A pragmatic cluster (facility-level) randomized clinical trial, comparing test-based screening performed at a static (every two weeks) frequency versus a dynamic frequency (ranging from once a week to once every four weeks) anchored to county COVID-19 case rates
45365868|NCT04028115|Drug|Ixazomib|Scheduled visits: Patients included in the trial will be treated with Ixazomib 4 mg on day 1, 8, and 15 in a 28-day cycle for up to 24 cycles. Patients will be evaluated every 4th week by a medical doctor, prior to initiation of a new cycle of Ixazomib.
45365869|NCT00522951|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (first injection of gadobutrol 0.1 mmol/kg bw, corresponding to a dose of 0.1 mmol/kg bw)
45365870|NCT00522951|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (second injection of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
45365871|NCT00522951|Drug|ProHance|ProHance enhanced MRI (two injections of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
45365872|NCT03865953|Drug|LAT8881|LAT8881 oral capsule
45690673|NCT04198389|Procedure|PARTIAL KNEE REPLACEMENT|PARTIAL KNEE REPLACEMENT
45690674|NCT04766541|Other|no intervention|There is no intervention.
45365873|NCT03865953|Drug|Placebo|Placebo oral capsule
45365874|NCT03865407|Drug|Allopurinol|Allopurinol dosed to target uric acid levels of 3-5 mg/dL.
45365875|NCT00487942|Drug|armodafinil|50 mg/day armodafinil
45365876|NCT00487942|Drug|armodafinil|100 mg/day armodafinil
45365877|NCT00487942|Drug|armodafinil|200 mg/day armodafinil
45365878|NCT00487942|Drug|placebo|placebo
45365879|NCT00132301|Drug|Docetaxel|Chemotherapy agent
45365880|NCT00132301|Drug|Prednisone|steroid in combination with chemotherapy agent
45482857|NCT01844856|Drug|Eravacycline|
45482858|NCT01844856|Drug|Ertapenem|
45482859|NCT01844856|Drug|Placebo|Administered IV to maintain the blind.
45482860|NCT02465788|Device|GentleTouch|Four distinct areas on each selected anatomical area will be treated with different treatment parameters.
46051181|NCT00707122|Other|Albumin and Crystalloids|"From day 2 to day 28 (or until ICU discharge, whichever comes first), fluid will be administered as follows:~1. treated group: albumin will be infused on a daily basis, aimed to maintain its serum concentration equal or above 30 g/l (8). In particular, after the daily determination of its serum level:~if lower than 25 g/l, 300 ml of 20% of albumin solution (total amount of 60 gr) will be infused;~if equal or higher than 25 g/l and below 30 g/l, 200 ml of 20% of albumin solution (total amount of 40 gr) will be infused;~if higher than or equal to 30 g/l, no albumin will be infused. Albumin solutions will be infused over a period of 3 hours. Further infusion of crystalloids will be allowed, when necessary, according to the clinical judgment. No infusion of colloids, other than albumin, will be admitted."
45482861|NCT00618098|Biological|Octaplex (human prothrombin complex concentrate)|INR is determined 15 minutes after the end of each infusion. Each dose (mL/kg body weight) was calculated as = ln(INR/1.4)/0.52. The maximum dose for initial treatment was not to exceed 5500 IU. If the INR is ≥ 1.5 after the initial infusion, additional infusions will be repeated until the INR was < 1.5. Octaplex (500 units, IU) is supplied in vials and was reconstituted with 20 mL of Water for Injection (Ph.Eur.).
45690675|NCT04198467|Biological|Platelet rich plasma|Platelet rich plasma : 100 billion platelets in 10 ml of plasma(PRP) administered intra-articular
46051182|NCT00707122|Other|Crystalloids|"Volume replacement will be performed in both the treated and the control group according to the early-goal directed therapy.~control group: crystalloids infusion will be allowed whenever necessary on a clinical basis. Albumin administration will be restricted to emergency use, as clinically judged and documented according to the standard criteria of each participating unit. No other colloids will be allowed."
45845844|NCT05220306|Device|Monitoring of vital signs|The MouthLab is a hand-held device. The user holds the unit in their left hand with the Mouthpiece between the teeth and lips and breathes normally into the device for 30 seconds.
45847852|NCT03004638|Drug|MEDI6012 IV Push|Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.
46051183|NCT04254042|Drug|Perindopril Arginine|10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
45365881|NCT00522873|Drug|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One capsule [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 13 cycles (28 days per cycle).
45365882|NCT00522873|Drug|0.5mg NETA / 1.0mg E2 (Activella)|One capsule [0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)] per day taken orally for 13 cycles (28 days per cycle).
45365883|NCT03684057|Behavioral|App-Delivered Mindfulness Training (MT)|Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
45365884|NCT03864627|Drug|MOR106|MOR106 liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
45365885|NCT03864627|Drug|Placebo|Placebo liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
45365886|NCT00519831|Biological|cetuximab|400 mg/m² week 1,then 250 mg/m² weekly
45365887|NCT00519831|Drug|vinflunine|Vinflunine 320 mg/m² every 21 days
45365888|NCT04303845|Drug|Erenumab|140 mg of erenumab via subcutaneous injection
45365889|NCT03995667|Other|Questionnaire Administration|Ancillary studies
45365890|NCT03995667|Device|Tumor Treating Fields Therapy|Optune-Tumor Treating Fields (TTFields). Transducer arrays affixed to scalp, worn continuously.
45365891|NCT03964623|Diagnostic Test|OCT-A (Optical Coherence Tomography)|Included patients will have an OCT-A and will be questioned about their nicotine intake, their background and taking an oral conception
45365892|NCT04269915|Biological|female Schistosoma mansoni cercariae|Viable female Schistosoma mansoni cercariae of the Puerto Rican strain
45365893|NCT04187703|Drug|5-azacytidine|5-azacytidine 50 mg/m^2 Day 1 every week ± G-CSF ~5 µg/kg (300µg vs 480µg)
45365894|NCT04187703|Drug|Decitabine|Decitabine 5 mg/m^2 Day 4 every week ± G-CSF ~5 µg/kg (300µg vs 480µg)
45365895|NCT00131911|Drug|sorafenib tosylate|400 mg given orally
45365896|NCT01077037|Other|Decision Aid|Chest pain choice decision aid
45365897|NCT03968887|Other|plasma oxidized low-density lipoprotein levels|Detection of plasma oxidized low-density lipoprotein levels
45365898|NCT01582633|Biological|2012 trivalent influenza vaccine|"2012 trivalent influenza vaccine:~influenza A/California/7/2009 (H1N1)~influenza A/Perth/16/2009 (H3N2)~influenza B/Brisbane/60/2008 Single dose."
45365899|NCT03968575|Device|laser treatment|sub-threshold micro-pulse laser treatment
45847853|NCT03009162|Drug|Lasmiditan|200 mg, single oral tablet
45365900|NCT00184093|Drug|Gemcitabine|Gemcitabine weekly x 6 wks with concurrent external radiation
45365901|NCT01074619|Drug|Memantine|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
45365902|NCT01074619|Drug|Placebo|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
45365903|NCT00183625|Behavioral|Individual Placement and Support (Supported Employment)|
45365904|NCT00183625|Behavioral|Social Skills Training|
45365905|NCT00183625|Drug|Olanzapine|
45365906|NCT00183625|Drug|Risperidone|
45365907|NCT00511875|Drug|doxycycline monohydrate|50mg once daily for 24 months
45365908|NCT00511875|Drug|placebo|placebo taken once daily for 24 months
45365909|NCT02576327|Drug|Tropisetron|Tropisetron Hydrochloride Injection 5mg (Day 1-6)
45690676|NCT04198467|Drug|Hyaluronic Acid|Hyaluronic acid :Four ml of high-molecular-weight hyaluronic acid with a concentration of 22mg/ml injected intra-articular
45690677|NCT04198155|Radiation|stereotactic body radiotherapy (SBRT)|Image-guided stereotactic body radiation therapy
45482862|NCT00618098|Biological|Fresh frozen plasma|INR is determined 15 minutes after the end of each infusion. The initial dose is 10 mL/kg for a participant with an initial INR of < 3 and 15 mL/kg for a participant with an initial INR of ≥ 3. If the INR is ≥ 1.5 after the initial infusion, additional infusions of 5 mL/kg will be repeated until the INR was < 1.5. Fresh frozen plasma is supplied by the blood bank at each study site and will be prepared and handled according to the site's standard practice.
45482863|NCT02464228|Drug|Tipifarnib|oral
45482864|NCT04051736|Biological|Inactivated Polio Vaccine|Inactivated Polio Vaccine at age of 2,3,4 months old, respectively
45482865|NCT05687968|Behavioral|"3D/AR MetaFood  nutrition education, and receive instant feedback from the nutritionists or AI after recording their dietary food image."|"The participants record diet images by using Taiwan FoodAPP and receive instant feedback from the nutritionists or AI after recording their dietary food image. The dietitian will use 3D/AR MetaFood food nutrition education platform to do nutrition education for patients."
45482866|NCT05687968|Behavioral|conventional nutrition education by dietitian|The participants receive conventional health and nutrition education from state registered dietitian.
45482867|NCT01350960|Drug|SPC5001|3 weekly SC injections
45482868|NCT01350960|Drug|Saline 0.9%|3 weekly SC injections
45482869|NCT01350960|Drug|SPC5001|3 weekly SC injections
45482870|NCT01350960|Drug|SPC5001|3 weekly SC injections
45482871|NCT01350960|Drug|SPC5001|3 weekly SC injections
45690678|NCT03024333|Other||Investigators will use the blender to prepare different viscous foods and liquids. Then, a sound detection device will be attached on the participant's neck. The device will record three times of swallowing sounds at three placements (Apleft, Apright, B) separately with participants' head-trunk in neutral position and also record sounds in the neck such as breathing sound, throat clearing and cough sounds. Participants will use 5 ml spoon to intake different viscous foods or liquids. The conversation will also be recorded using a Sony recorder (ICD-SX713) in each data collection session. The voice recording will not be analyzed, which only provides the additional information about which foods or liquids subjects swallow or at which placement sensor records swallowing sounds.
45482872|NCT01350960|Drug|SPC5001|3 weekly SC injections
45690679|NCT03591705|Drug|TACE-HAIC|transcatheter arterial chemo-lipiodolization with EADM 30mg/m2, followed by hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
46051184|NCT04254042|Drug|Zofenopril, Calcium Salt, (1(R*),2Alpha,4Alpha)-isomer|30 mg Zofenopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
46051185|NCT00918138|Drug|Saxagliptin|Tablets, Oral, 5 mg, once daily, 4 weeks
45482873|NCT05345444|Device|IRE & MRgRT|Subjects will undergo Irreversible electroporation(IRE) followed by Magnetic resonance guided radiotherapy (MRgRT)
45690680|NCT03591705|Drug|HAIC|hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
45690681|NCT03599505|Procedure|localization group|Intraoperative ultrasonographic localization will be performed using an ultrasound system (HI VISON Ascendus), which is equipped with a 5-10MHz mechanical probe (EUP-OL531). The accuracy rate of localization will be evaluated using gray scale mode and elastography mode.
45690682|NCT03599427|Drug|systemic lidocaine|Systemic lidocaine is administrated at induction of anesthesia and at the end of surgery (1.5 mg/kg).
46051186|NCT00918138|Drug|Metformin XR|Tablets, Oral, 1500 mg, once daily, 4 weeks
46051187|NCT00918138|Drug|Placebo matching Metformin XR|Tablets, Oral, 0 mg, once daily, 4 weeks
45690683|NCT03599427|Drug|Placebo|Placebo is administrated at induction of anesthesia and at the end of surgery (0.075 ml/kg)
45690684|NCT01855789|Drug|Tocilizumab (TCZ)|TCZ will be administered at a dose of 162 milligrams (mg) via SC injection weekly (if body weight is greater than or equal to [>/=] 100 kilograms [kg]) or every 2 weeks (if body weight was less than [<] 100 kg).
46051188|NCT00918138|Drug|Metformin XR|Tablets, Oral, 500 mg, once daily, 4 weeks
46051189|NCT00918138|Drug|Placebo matching Saxagliptin|Tablets, Oral, 0 mg, once daily, 4 weeks
46051190|NCT04244136|Device|contrast CT|contrast CT abdomen fir measurement of the volume of expected residual normal renal tissue before surgery
45690685|NCT01855789|Drug|Methotrexate (MTX)|MTX will be administered at a stable dose (15 mg to 25 mg per week) orally.
46051191|NCT04253574|Diagnostic Test|Imaging with 18F-FDG PET/CT and/or Ultrasound|All patients were all examined by 18F-FDG PET/CT, 176 patients additionally by US (peripheral lymph nodes (pUS) and/or abdomen (aUS)) in the search of primary tumors or metastases of their malignant melanomas.
46051192|NCT00782275|Drug|bevacizumab|
46051193|NCT00782275|Drug|temsirolimus|
46051194|NCT04107571|Procedure|A type of operation for coranary heart disease patients.|A type of operation for coranary heart disease patients.
45690686|NCT01855789|Drug|Placebo (PBO)|PBO matching to MTX will be administered orally.
46051195|NCT02602873|Other|therapeutic drug monitoring|with therapeutic drug monitoring , dose of tacrolimus can be adjusted by therapeutic drug monitoring.
45482874|NCT01351038|Drug|Epirubicine, Oxaliplatin, Capecitabine, Panitumumab|3 cycles (repeated q 21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Panitumumab 9mg/kg i.v. d1 Capecitabine 500mg/m² bid d1-21
45482875|NCT02465710|Procedure|Pelvic organ prolapse surgery without mesh|retrospective study
45482876|NCT02465710|Procedure|Pelvic organ prolapse surgery with mesh|
45482877|NCT01351116|Radiation|EBR plus HDRIB|EBR of 20 Gy in 5 daily fractions over one week plus HDRIB of 14 Gy in 2 fractions over two weeks
45482878|NCT01351116|Radiation|EBR|EBR of 20 Gy in 5 daily fractions over one week
45482879|NCT05046340|Other|Passive leg raising|We perform the PLR test by adjusting the bed and not by manually raising the patient's legs. Bronchial secretions must be carefully aspirated before PLR. If awake, the patient should be informed of what the test involves. And measure the cardiac output by using certain devices at the bedside. The end-expiratory occlusion consists in interrupting the ventilator at end-expiration for 15-30 s and assessing the resulting changes in cardiac output.
45690687|NCT03591627|Diagnostic Test|Transesophageal echocardiography|Transesophageal echocardiography will be used to exclude the presence of an LA thrombus before AF/AFI ablation or cardioversion.
45690688|NCT04198233|Drug|Diazepam|Diazepam 10 mg compounded suppository
45845845|NCT05219292|Other|Active music therapy|"Active music therapy is not a musical learning process. The restrictive character of classical respiratory rehabilitation will be alleviated by the playful aspect and the pleasure generated by the sessions, which will facilitate the commitment of the patients in their post-transplant respiratory rehabilitation.~The recorder was chosen among other wind instruments for several reasons:~Its use is simple,~It acts as an oscillating exhalation resistance device that generates a positive expiratory pressure (auto-PEP) produced by this wind instrument allows to obtain conditions similar to the treatment performed by a flutter (classical respiratory rehabilitation), a pressure on the expiratory flow with the obtaining of an oscillating effect during the trills, an increase of the respiratory capacities,~The characteristics of the sound it produces (duration, intensity, timbre and frequency) will generate auditory feedback allowing patients to become aware of their breathing patterns."
45847854|NCT03009396|Drug|RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)|For patients on ACTIVE or PLACEBO in the parent study (RHB-104-01), who were not in remission after 26 weeks
46051196|NCT00791557|Drug|Infliximab|IV drug given at weeks 1,2,14,22
46051197|NCT04107337|Other|Vocal work session with straw exercises|"Voice assessment: A questionnaire on the subject's voice biography will be sent to the subject at the moment of inclusion.~Vocal exercises during 10 minutes : (1 minute) Checking the posture ; (1 minute) Control of the management of breath in the straw ; (1 minute) Phonation in the straw ; (2 minutes) Make a siren in the straw ; (4 minutes) Vocalizations in the straw on the arpeggio of Rossini.~This working session will be preceded and followed by the same 10-minutes voice assessment focusing on aerodynamic parameters."
46051198|NCT04107337|Other|Vocal work session with open mouth exercises|"Voice assessment: A questionnaire on the subject's voice biography will be sent to the subject at the moment of inclusion.~Vocal exercises during 10 minutes : (1 minute) Checking the posture ; (1 minute) Control of the management of breath on a [f] with open mouth ; (1 minute) Phonation on the vowel [a] with open mouth ; (2 minutes) Make a siren on the vowel [a] with open mouth ; (4 minutes) Vocalizations on the vowel [a] on the arpeggio of Rossini with open mouth.~This working session will be preceded and followed by the same 10-minutes voice assessment focusing on aerodynamic parameters."
46051199|NCT00920790|Biological|KW-0761|KW-0761 is administered weekly for 8 weeks as an intravenous infusion of 2 hours at a dose of 1.0 mg/kg.
45365910|NCT02576327|Drug|Dexamethasone|Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)
45365911|NCT02576327|Drug|Aprepitant|Aprepitant 125mg （Day1-2）, 80mg (Day 3-6)
45365912|NCT00183391|Drug|Atomoxetine|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
45482880|NCT01356264|Behavioral|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support starting 3-5 weeks before surgery and continuing postoperative for up to 8 weeks
45690689|NCT04198233|Drug|Placebos|Placebo suppository
46051200|NCT04253886|Device|Ovassapian Fibreoptic Intubating Airway|The fibreoptic bronchoscope remains one of the most important methods of intubating patients particularly when there is difficulty with intubation.Facilitating fiberoptic oropharyngeal intubation procedure, specific airways have been devised to push the tongue anteriorly to clear a passage for the fibrescope into the trachea. Of these airways Ovassapian Fibreoptic Intubating Airway (Kendall, Argyle, New York, New York, USA) and Fekry Oral Intubating Airway (Ameco Tech, Cairo, Egypt).
45365913|NCT00183391|Drug|Methylphenidate|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
45365914|NCT00493246|Drug|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
45482881|NCT01356264|Behavioral|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support beginning postoperative and continuing for up to 8 weeks
45690690|NCT04216563|Drug|Asciminib|Given PO
45690691|NCT03968445|Drug|[18F]DPA-714-PET/MRI|[18F]DPA-714-PET/MRI
45365915|NCT00493246|Drug|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
45365916|NCT01021150|Drug|ombrabulin (AVE8062)|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
45365917|NCT01021150|Drug|cisplatin|"Pharmaceutical form: injection solution~Route of administration: intravenous infusion"
45365918|NCT03997006|Drug|IV Aminophylline|IV Aminophylline (100 mg/8h)
45482882|NCT01356342|Biological|AdimFlu-S 2010-2011, inactivated|"The vaccine contains not less than 90 μg haemagglutinin (HA) per mL. Per mL contains the following three strains: A/California/7/2009 (H1N1)30 μg/mL;A/Perth/16/2009 (H3N2)30 μg/mL;B/Brisbane/60/2008 30 μg/mL~6 months~<3 years;0.25 mL per injection2 injections at 4 weeks apart~3~<9 years;0.5 mL per injection2 injections at 4 weeks apart~9~<18 years;0.5 mL per injection1 injections"
45365919|NCT03997006|Drug|IV Neostigmine Methylsulfate + Atropine Sulphate|IV Neostigmine/Atropine mixture (20 μg/kg Neostigmine + 10 μg/kg Atropine)/8h
45482883|NCT01788306|Drug|OOPEN+BBCC|Take-home naloxone is offered as part of a behavioral prevention intervention to reduce the occurrence of future opioid overdose.
45845846|NCT05219292|Other|Questionnaires|"We chose the HAD (Hospital Anxiety and Depression Scale) to assess anxiety and depression. This test is a reference test, often used in studies of transplant patients. The results obtained in previous studies allowed us to create our hypotheses.~To measure pain we chose the visual analogue scale (VAS). This reference test is often used in pain studies. It has the advantage of being simple to perform and easy to understand.~Quality of life will be assessed using the SF-12 (Short Form 12 Health Survey Questionary). We consider it to be simple and easy for patients to understand."
45365920|NCT02281955|Radiation|Intensity Modulated Radiotherapy (IMRT)|All patients will receive Intensity Modulated Radiotherapy Treatments (IMRT). Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day respectively. The PTV-HR will include the gross tumor and the PTV-SR will include areas at risk for harboring subclinical microscopic disease.
45845847|NCT05218980|Dietary Supplement|Olives|Organic olives (provided by Sakellaropoulos Organic Farms; Sparta, Greece)
45845848|NCT05217498|Drug|Istradefylline|Consume 20mg tablet of istradefylline for 28 consecutive days.
46051201|NCT00781963|Behavioral|Manual-based cognitive behavioral therapy for insomnia|Manual-based CBT-I provided in 5 individual or group sessions by a non-clinician sleep coach.
46051202|NCT00781963|Behavioral|Non-directive sleep education|Manual-based non-directive sleep education provided in 5 group sessions by a health educator.
46051203|NCT05176314|Drug|Rosuvastatin|Administered Orally.
46051204|NCT05176314|Drug|Pirtobrutinib|Administered Orally.
46051205|NCT05523973|Other|Lingual Endurance Exercise|Participants will participate in 3 training sessions per day for 8 weeks. Group 1 will complete 3 sessions of lingual endurance exercise. For example, if the participant completed 100 repetitions during the baseline measurement, they would complete 75 repetitions during their exercise session.
45365921|NCT02281955|Drug|Cisplatin (or alternative)|Cisplatin is the preferred mandated first choice chemotherapy, however alternative weekly regimens are permissible. Justification for not using cisplatin must be documented. Chemotherapy will be given intravenously weekly during IMRT. 6 total doses will be given. It is preferred that the doses be administered on days 1, 8, 15, 22, 29, and 36; however, this is not mandatory. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history.
45365922|NCT02281955|Procedure|Assessment for surgical evaluation|Decisions for surgical evaluation will be based on the results of the PET/CT 10 to 16 weeks after CRT and clinical exam (including fiberoptic laryngoscopy) at that time. Other optional imaging studies may be performed. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon, with the goal being to remove any suspected residual tumor with a negative resection margin while maintaining organ preservation. This may include biopsies and/or oncological resections of the primary tumor and lymph node metastases. Patients with a negative PET/CT scan will be observed.
45482884|NCT02464462|Dietary Supplement|vitamin D3 and calcium|1800 IU vitamin D3 plus 720 mg Calcium
45482885|NCT02464462|Other|Placebo|Rice powder pills
45482886|NCT03135210|Other|Open-Chain Leg Exercise|Individuals in the open-chain group will progress through standard mobility progression.
45482887|NCT03135210|Device|Closed-Chain Leg Exercise|Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
45482888|NCT02464150|Dietary Supplement|Gluten challenge|Challenge done in the form of a gluten containing cookie once daily, or up to four slices of regular bread daily.
45482889|NCT02464384|Procedure|Venipuncture, ultrasound, MRI, x-ray|Collection of blood samples and ultrasound / MRI and x-ray examination
45365923|NCT01015144|Drug|Tulip|Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.
45365924|NCT00511797|Drug|SH T04740B|Drospirenone 1mg/EE 20µg (ß-CDC)
45365925|NCT00511797|Drug|SH T00186DF|Drospirenone 3 mg/EE 20µg (ß-CDC)
45365926|NCT00511797|Drug|SH T04740F|Drospirenone 2 mg/EE 20µg (ß-CDC)
45690692|NCT04197375|Behavioral|Thermal stress and performance using a pre-cooling protocol|One hour before a tennis match, participants were wearing a Cooling Cap (WElkins Sideline Cooling System, SCS) for 45 minutes. During the tennis match the following variables were monitored: heart rate, core temperature, skin temperature, thermal sensation and comfort, rating of perceived exertion and hydration status.
45690693|NCT04197375|Biological|Thermal stress and performance without a pre-cooling protocol|During a tennis match the following variables were monitored: heart rate, core temperature, skin temperature, thermal sensation and comfort, rating of perceived exertion and hydration status.
45690694|NCT03987555|Other|Blood draws|Blood draws for serum and peripheral blood mononuclear cell isolation collected throughout treatment course
45845849|NCT05217498|Device|low oxygen therapy|Breath intermittent low oxygen 4 days/week over 2 consecutive weeks. Intermittent low oxygen consists of 15, 90-second episodes of breathing low oxygen at 10% oxygen with 60-second intervals at 21% oxygen.
45365927|NCT00511797|Drug|Placebo|Placebo
45365928|NCT00487552|Device|Cook Magnetic Anastomosis Device (MAD) with Stent|Gastro-jejunal anastomosis
45365929|NCT02272049|Drug|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
45365930|NCT03996538|Drug|Metformin Hydrochloride Extended-Release Tablets|Subjects will ingest 1500mg/day of metformin hydrochloride extended release. Immune responses will be examined prior to treatment, prior to flu vaccination, and after flu vaccination.
45690695|NCT03987555|Other|QLQ-CIPN20 Survey|20-item self-reported survey for participant reported symptoms related to chemotherapy-induced peripheral neuropathy
45845850|NCT05203692|Drug|DS-7011a|Intravenous or subcutaneous administration, single dose
45845851|NCT05203692|Drug|Placebo|Intravenous or subcutaneous administration, single dose
45845852|NCT05195502|Diagnostic Test|Biopsy|Participants included in the study, will have additional biopsies performed during their colonoscopy
45845853|NCT05184894|Behavioral|AKI in Care Transitions (ACT) program|Multicomponent transitional support bundle that includes consultation from nurse educators before discharge to deliver kidney health education and coordination of appointments post-discharge.
45845854|NCT05181072|Behavioral|Enhanced in-person peer-motivation smoking cessation|Tobacco cessation classes will be offered in-person for a total of five sessions delivered weekly for five weeks and will utilize the CEASE Today Tobacco This is a seven-week tobacco cessation program and will be offered in-person weekly for seven weeks and will utilize the CEASE Today Tobacco Cessation Manual.
46051206|NCT05523973|Other|Lingual Endurance + Transference Exercise|"Group 2 will complete lingual endurance exercise for 2 sessions, and for the 3rd training session participants will complete 30 swallows where they are instructed to press their tongue hard on the bulb and swallow their saliva. The TongueometerTM will provide biofeedback on performance and will be instructed to generate more pressure during this effortful swallow than during a natural, saliva swallow."
46051207|NCT04017325|Other|no intervention (post study follow up)|No intervention (post study follow up)
45845855|NCT05181072|Behavioral|Virtual peer-motivation smoking cessation|This is a seven-week tobacco cessation program and will be offered virtually (except first two sessions: orientation and technology set-up) weekly for seven weeks and will utilize a newly developed website with smoking cessation modules that mirrors lessons of the CEASE Today Tobacco Cessation Manual
46051208|NCT00920556|Drug|5.0g SRT501|5.0g SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. SRT501 will be administered orally as a liquid suspension for 20 consecutive days in each 21 day cycle.
46051209|NCT00920556|Drug|Bortezomib|Bortezomib (1.3 mg/m2) will be given as an intravenous solution in a 3-5 second push on Day 1, 4, 8 and 11 in every 21 day cycle.
46051210|NCT00781885|Drug|Beraprost sodium modified release|Tablets 60mcg
45365931|NCT03996538|Biological|Influenza Vaccine|All subjects will be vaccinated with high-dose influenza vaccine at the appropriate time of the year per current CDC and FDA recommendations
45690696|NCT03987555|Other|PR-CTCAE Survey|124-item survey addressing chemotherapy-induced peripheral neuropathy concerning severity of the numbness and tingling and the degree these symptoms interfere with daily activities.
45690697|NCT03986853|Procedure|Blood sampling|Blood sampling under general anesthesia
45365932|NCT02576015|Procedure|peri-operative continuous femoral nerve block with light sedation|this technique will be administered to participants in group L .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher &Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block intra-operatively and post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 50-60 with BIS monitoring
45365933|NCT02576015|Procedure|post-operative continuous femoral nerve block|this technique will be administered to participants in group D .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher &Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 30-40 with BIS monitoring
45845856|NCT05173428|Behavioral|Smoking Cessation Program Based on Transtheoretic Model|Conducting motivational interviews based on the transtheoretic model according to the stages of change that individuals are in.
45365934|NCT02576015|Drug|lidocaine|
45365935|NCT02576015|Device|ultrasound|
45845857|NCT05166018|Diagnostic Test|SuMO Patient|"The current study is interventional insofar as the patient is collecting all of his socio-medical information. The analysis of the data provided by the patient makes it possible to establish a long-term prognosis for the patient but does not in itself constitute a parallel medical approach.~SUMO allows the surgeon to transmit post-operative advice developed by the surgeons themselves."
46051211|NCT04901676|Drug|Leronlimab|Leronlimab 700 mg (first dose) followed by weekly 350 mg
46051212|NCT04901676|Drug|Placebo|Placebo
46051213|NCT04843176|Diagnostic Test|Prototype artificial intelligence algorithm|Developed by the University of Hong Kong
45365936|NCT02576015|Device|insulated needle (Contiplex B Braun, Melsungen, Germany)|
46051214|NCT04843176|Diagnostic Test|LI-RADS|The Liver Imaging Reporting and Data System (LI-RADS) was established to standardize the lexicon, interpretation and communication of radiological findings related to HCC
45482890|NCT01351194|Procedure|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores. The 14 Ga needle was introduced into the center of the tumor; then, 60 W of the radiofrequency energy was delivered by the generator with an 8-minute duration for every single energy application.
45482891|NCT01351194|Procedure|hepatic resection|SR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
45482892|NCT04270864|Drug|Ipilimumab|20mg (4mL) IT
45482893|NCT04270864|Drug|Nivolumab|360mg IV then 480mg IV
45482894|NCT04270864|Drug|Tilsotolimod|8 mg (2mL) IT
46051215|NCT04831086|Drug|Steroid Drug|Steroids doses will be optimized in the intervention group according the risk based on predictive models
46051216|NCT04831086|Drug|Tocolytic Agents|Tocolysis duration will be optimized in the intervention group according the risk based on predictive models
45365937|NCT02576015|Drug|ropivacaine|
45365938|NCT02576015|Drug|saline|
45365939|NCT03998475|Behavioral|Transition preparation intervention|Young adult participants and parents will complete transition preparation sessions that include meeting with a health behavior coach for in-person sessions and review of materials sent electronically between study visits.
45365940|NCT02577965|Procedure|Percutaneous Coronary Intervention|Thrombus aspiration and histopathological analysis ,Optical Coherence Tomography assessment of culprit vessel during primary PCI, Primary PCI and Drug Eluting Stent (DES) - XIENCE PRIME Everolimus Eluting Coronary Stent implantation in culprit lesion, coronary angiography and OCT assessment at 9 months follow-up
45482895|NCT01318668|Biological|vaccination with Nicvax|5 vaccinations of NicVax 400ug (1 ml) over a 18 week period or matching placebo.
45482896|NCT01318746|Procedure|Blood withdrawal|blood withdrawal every 2 hours during 24 hours
45482897|NCT01357434|Behavioral|Fast Food Restaurant|Participants will purchase a meal at Subway and McDonald's, on different days.
45690698|NCT03591471|Drug|Glycosides Of Tripterygium Wilfordii Hook(GTW)|"For severe HSPN GTW is 2mg/kg/d for the first 2 weeks , continued with 1.5mg/kg/d (maximum to 90mg/d) for another 2 weeks; For light HSPN GTW is 1.5mg/kg/d(maximum to 90mg/d) for 4 weeks.~Both the 2 types are continued with 1mg/kg/d of GTW for another 4 weeks . Besides,Sulfotanshinone Sodium Injection,Qingrezhixue graunles,Chinese herbs by syndrome differentiation are plused at the same time"
45690699|NCT03591471|Drug|Sulfotanshinone Sodium Injection|Intravenous drip of Sulfotanshinone Sodium Injection with the dosage of 1mg/kg/d(maximum to 50mg), combined with 100-250ml 5% Glucose Solution (G.S) for 2 weeks in both the light and serious type of TCM group.
46051217|NCT02603965|Radiation|Copper Cu 64 TP3805|Given IV
46051218|NCT02603965|Procedure|Positron Emission Tomography|Undergo Cu-64-TP3805 PET(Positron Emission Tomography)/CT
46051219|NCT02603965|Procedure|Computed Tomography|Undergo Cu-64-TP3805 PET/CT (Computed Tomography)
46051220|NCT02603965|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
45690700|NCT03591471|Drug|Chinese herbs based on syndrome differentiation|"For both the light and serious type of HSPN in TCM group,five traditional Chinese medicine patterns of syndrome are classified on the main pathogenesis Blood Stasis: based on Qingre Zhixue granule,for wind-heat complicated with blood stasis, add Forsythia, Honeysuckle,;for blood-heat complicated with blood stasis,add Buffalo horn,Comfrey; for yin deficiency complicated with blood stasis, add Rhizoma anemarrhenae,Cortex phellodendri;for both qi and yin deficiency complicated with blood stasis,add Astragalus, Heterophylla;for damp-heat complicated with blood stasis,add Scutellaria baicalensis,Lalang Grass Rhizome."
45845858|NCT05151822|Other|Training session with the virtual reality mask|Patients will have a training session with the virtual reality mask, the day before surgery. The training consists in the realization, by the patient, of a series of language or neuropsychological tests and evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated)).
46051221|NCT02603965|Other|Laboratory Biomarker Analysis|Correlative studies
45365941|NCT02577965|Device|XIENCE PRIME Everolimus Eluting Coronary Stent System|Xience Prime Everolimus Eluting Coronary Stent System implantation to treat Acute Myocardial Infarction
45365942|NCT00182689|Drug|sorafenib tosylate|Given orally
45365943|NCT01326247|Other|thermal waters nasal irrigation|"The first group (group 1) has practiced crenotherapy with hyper-mineral chloride sodium water aerosol by nasal adapter for 15 days per month, for three consecutive months, at thermal spa services of Lacco Ameno, while the control group (group 2) was treated, in the same period, daily, by a micronized nasal douche with 0.9% NaCl (isotonic) solution."
45365944|NCT03860259|Device|Auriculotherapy cryopuncture device without nitrogen gas|Auriculotherapy cryopuncture device without nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
45365945|NCT03860259|Device|Auriculotherapy cryopuncture device with nitrogen gas|Auriculotherapy cryopuncture device with nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
45365946|NCT01078051|Procedure|Cypher, xience, Endeavor, Taxus|all species of drug-eluting stent implantation
45845859|NCT05151822|Other|Monitoring of the device|In the operating room : installation and per-operative monitoring of the device. If the device was removed, the list of device side effects or surgery-related adverse events that was required discontinuation of the device will be established.
45845860|NCT05151822|Other|Acceptability of the device|After the surgery: evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated))
45365947|NCT01078051|Drug|optimal medical therapy|optimal medical therapy
45365948|NCT03915977|Behavioral|Post ICU recovery program|Standardized follow up program
45845861|NCT05151822|Other|Patient state of anxiety|Assessing patient's state of anxiety with the State-Trait Anxiety Inventory (STAI) after surgery.
46051222|NCT02602795|Behavioral|Acceptance and Commitment Therapy|The intervention is based on Acceptance and Commitment Therapy and will be tailored to help participants develop target adaptive responses to negative affect and other negative internal stimuli related to opioid detoxification.
46051223|NCT02602795|Behavioral|Information Motivation Behavioral Model|This intervention is based on the Information Motivation Behavior model for HIV/STI risk reduction and is tailored to more directly address HIV/STI risk among opioid dependent patients.
45365949|NCT04071509|Device|Percutaneous Lung Biopsy|Patients will undergo the usual biopsy procedure with a fine needle inserted through a larger guide needle, under CT guidance; at the end of the biopsy, the MIPP-Kit will be introduced through the same guide needle. The guide needle and the MIPP Kit will be retracted together slowly, whilst injecting BioGlue in appropriate amounts along the whole track, from the lesion to the skin.
45365950|NCT00131365|Device|ExAblate 2000|
45365951|NCT02578121|Drug|Ixazomib|4.0 mg will be given on days 1, 8 and 15 of a 28 day cycle
45365952|NCT02578121|Drug|Pomalidomide|4.0 mg will be given on days 1-21 of a 28 day cycle
45365953|NCT02578121|Drug|Dexamethasone|20 mg will be given on days 1, 8, 15 and 22 of a 28 day cycle
45365954|NCT00487240|Drug|Insulin Lispro Protamine Suspension|Patient specific dose, twice daily (BID), within 15 minutes before meals, subcutaneous (SC) injection x 32 weeks.
46051224|NCT04103047|Other|SAD|The patients who have an SAD inserted as part of their normal Anaesthetic plan will be consented prior to their Anaesthetic and then have a questionnaire to fill out post operatively.
46051225|NCT00918684|Drug|Escitalopram|10mg tab daily
46051226|NCT05543707|Drug|PBI-0451 (Pomotrelvir)|2 × 350 mg tablets administered orally twice daily (BID) (1400 mg/day) with food for 5 days (10 total doses)
45365955|NCT00487240|Drug|Insulin Levemir|Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks
45365956|NCT01077115|Procedure|Laparoscopic cholecystectomy|
45365957|NCT01077115|Procedure|Open Surgery|
45365958|NCT02577809|Drug|Morphine100|100mcg added to the spinal anaesthetic
45365959|NCT02577809|Drug|Morphine50|50mcg added to the spinal anaesthetic
46051227|NCT05543707|Drug|Placebo|2 × placebo to match PBI-0451(Pomotrelvir) tablets administered orally BID with food for 5 days (10 total doses)
45365960|NCT02577809|Drug|Fentanyl|25mcg Fentanyl added to the spinal anaesthetic
45365961|NCT02577809|Drug|Hyperbaric Bupivicaine|1.8ml 0.5% spinal bupivicaine with dextrose
45690701|NCT03591471|Drug|Prednisone Acetate Tablets|Prednisone Acetate Tablets are necessary for serious HSPN in controlled group,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）
45365962|NCT02577809|Drug|Indomethacin|100mg Indomethacin suppository
45482898|NCT01351272|Drug|Methylphenidate, non-retard|Medication (methylphenidate, non-retard) will be titrated to optimal response within 6 weeks, with a maximum of 10 mg/day in week 1, 20 mg/day in week 2, 30 mg/day in week 3, 40 mg/day in week 4, 50 mg/day in week 5, and 60 mg/day in week 6, unless adverse effects emerged. After successful adjustment, medication will be maintained until week 6. Dosing will be based on at least two-weekly evaluations by a psychiatrist, including an interview with a review of symptoms and side effects, completion of the Clinical Global Impression (CGI) scale and completion of a standardised Side Effects Rating Scale for psychostimulants (SERS). The maximal daily dosage of MPH is 60 mg. Within this double blind study the same procedure is applied for the placebo condition.
46051228|NCT04105465|Device|PlasmaJet|The PlasmaJet device is used following groin node dissection on the side randomised to receive it as per protocol specifications
45482899|NCT05672992|Other|Spatial-frequency domain imaging (SFDI)|SFDI is a method using near-infrared (NIR) light to generate wide field images (>10 x 10 cm) of tissue optical properties (absorption and scattering coefficients) at sub-surface depths of 1-10 mm. With SFDI the tissue surface (skin) is illuminated by a rapid sequence of sinusoidal light patterns of varying spatial frequency and at different optical wavelengths. Collected camera images are then processed to yield maps of sub-surface optical properties.
45365963|NCT03998085|Drug|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week. Patients with complete remission (CR), partial remission (PR) and stable disease (SD) continued to administer drugs until the disease progressed, intolerable toxicity or withdrawal was required. Patients with progression of illness (PD) discontinued their medication.
45482900|NCT01351428|Drug|Nifedipine|30-60 mg, twice daily
45365964|NCT00579579|Behavioral|Questionaires|Prior to surgery, patients will be asked to complete baseline surveys. In addition, a random subsample of approximately 30 patients will be asked to participate in a short qualitative interview to explore expectations regarding bowel function and quality of life following surgery. Follow-up surveys will be completed at 6, 12 and 24 months after bowel continuity has been restored (defined by their last surgical procedure). Patients with a permanent stoma will receive the Stoma-specific QOL questions in place of the MSKCC Bowel Function Instrument at 6 and 12 months after initial surgery.
45365965|NCT02224391|Behavioral|Computer-Assisted Smoking Cessation Intervention|Receive ABM training via a smartphone
45365966|NCT02224391|Other|Laboratory Biomarker Analysis|Correlative studies
45482901|NCT02193048|Other|This study will evaluate a new clinical scoring system in patients receiving routine treatment|Treatment for Crohn's disease will be performed routinely based on the treating physicians clinical determination and patients' needs.
45482902|NCT05006326|Drug|68Ga-PSMA|Intravenous access is established in advance, intravenous bolus injection, 68Ga-PSMA dose is about 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg). Patients were encouraged to drink water after injection and asked to empty their bladder before PET scan.
45482903|NCT05006326|Device|PET/MR|Each subject undergoes PET/MR imaging within 40-60 minutes after injection.
45365967|NCT02224391|Drug|Nicotine Patch|Given via transdermal patch
45482904|NCT05006326|Device|PET/CT|Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
45482905|NCT05003830|Device|PET/MR|18F-FDG, 11C-PIB and 18F-PM-PBB3 injection are radiopharmaceuticals used for positron emission tomography (PET) imaging. 18F-FDG dose is about 3.7-5.4 MBq/kg (0.1 -0.15 mCi/kg), and used in the assessment of brain glucose metabolism. 11C-PIB dose is about 5-10mCi, and used in the assessment of amyloid deposition. 18F-PM-PBB3 dose is about 5-10mCi, and used in the assessment of tau deposition. Use PET/MR equipment for simultaneous PET and MR collection.
45482906|NCT00701662|Biological|Vivaglobin|
45690702|NCT03591471|Drug|Benazepril Hydrochloride Tablets|In controlled group, Benazepril Hydrochloride Tablets are used for both the light and serious type with the dosage of 5-10mg/d(10mg/d for children with weight above 30kg) ,12 weeks in total.
45365968|NCT02224391|Other|Questionnaire Administration|Ancillary studies
45690703|NCT03591471|Drug|Low Molecular Weight Heparin Calcium Injection|In controlled group,Low Molecular Weight Heparin Calcium Injection are used for both the light and serious type with the dosage of 100u/kg/d by hypodermic injection for 2 weeks
45690704|NCT03591471|Drug|Dipyridamole Tab 25 MG|In controlled group,Dipyridamole Tab 25 MG are used for both the light and serious type of HSPN with the dosage of 3mg/kg/d ,3 times a day,12 weeks in total.
45365969|NCT02224391|Other|Sham Intervention|Undergo sham training
45690705|NCT03591471|Drug|Chinese medicine placebo|In controlled group,take a potential necessary for patients who come to the hospital of TCM to take traditional Chinese medicine in consideration, we add the traditional Chinese medicine placebo in controlled group.
45690706|NCT04407039|Device|PET/CT, H-MRS and MRI|Use imaging methods to get metabolic parameters.
45690707|NCT04406805|Diagnostic Test|Measurement of plasma and urine trimethylamine-N-oxide concentration|Information already included in arm/group descriptions.
45690708|NCT01610791|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, total of 6 infusions
45365970|NCT00487162|Procedure|intensive glycemic control|intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl
45365971|NCT00487162|Drug|conventional glycemic control|Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl
45365972|NCT03998241|Other|No intervention was provided|No intervention given
45365973|NCT02219711|Drug|MGCD516|MGCD516 is a small molecule inhibitor of several closely related receptor tyrosine kinases. MGCD516 capsules will be taken with water.
45365974|NCT01021384|Behavioral|Problem Solving Education|Problem Solving Education (PSE) is an evidenced-based empowerment strategy, targeted to mothers of young children to promote family well-being by decreasing the burden of maternal depressive symptoms and maternal parenting stress and improving social functioning.
45365975|NCT03871959|Drug|Pembrolizumab|200 mg, intravenous (IV), to be administered on Day 1 of every 3-week cycle i.e. Q3W.
45365976|NCT03871959|Drug|DEBIO1143|3 escalating dose level (100 mg, 150 mg, 200 mg) of Debio 1143 administered daily for 14 days over a 21-day cycle period.
45365977|NCT00487084|Drug|Morphine-CP-saline (MCS)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
45690709|NCT03832491|Other|Home based therapy|Airway clearence techniques
45690710|NCT03832491|Other|Game and home based therapy|Game based approach programme and airway clearence techniques
45690711|NCT03591315|Diagnostic Test|resting state fMRI|Define the visual resting state network.
45690712|NCT03591315|Diagnostic Test|visual tasking state fMRI|Using visual task stimulation to identify the activation characteristic of primary visual cortex.
45690713|NCT03591315|Diagnostic Test|diffusion tensor imaging|Define the integrity of white matter fibers in the visual pathway.
45690714|NCT03591315|Diagnostic Test|automated visual field|Identify the existence and type of visual field defect.
45690715|NCT03591315|Diagnostic Test|visual acuity|Assess the visual acuity by using ETDRS scales.
45845862|NCT05151666|Other|Sunny Health & Fitness Magnetic Mini Exercise Pedal Cycle - SF-B020026 Gray|The intervention will be that the patient cycles in a sitting position within the first 2 hours of hemodialysis treatment for 15-60 minutes/as tolerated, either intermittent/continuous duration. - Graded duration will increase every 2 weeks. This will be supervised by a dialysis nurse as per the schedule of study assessments.
45690716|NCT03591081|Other|Intellin smart phone application|This feasibility study will explore if creating an electronic platform Intellin smart phone application can promote and support timely self-referral for individuals with a recently healed DFU. It will explore the software applications acceptance and ease of use for patients.
45482907|NCT01356420|Dietary Supplement|Cholesterol supplementation|Cholesterol supplementation may be achieved with SLOesterol instead of or in combination with egg yolk. SLOesterol is a powder formulation that contains cholesterol and natural emulsifier. It is considered a medical food developed by Solace Nutrition and available by prescription only.
45690717|NCT01876381|Drug|OPC-41061|The maximum number of days of administration will be 8 days (8 doses) in total 4 days each in the dose-escalation period and intermittant administration period. The investigational medicinal product (IMP) will be administered once daily after breakfast
45690718|NCT03591003|Diagnostic Test|Yellow fever neutralizing antibodies measure|Yellow fever neutralizing antibodies measure before vaccination, within the year after vaccination and at any delay after vaccination
45482908|NCT01357590|Device|Thoracic Endovascular Stent Graft System (ThoraflexTM)|Thoracic Endovascular Stent Graft System
45482909|NCT04489576|Procedure|Keratin hair treatment (Keratin Cure ®) versus (QOD Max ®)|Hair will be treated with 2 different types of keratin in groups 1 & 2. All steps of keratin application will be done in group 3 without keratin application as a control group.
46051229|NCT04105309|Behavioral|Implementation Intentions|"Implementation intentions aid in pre-planning and habitualization of behaviors, as they serve to identify the when, where, and how of behaviors leading to goal attainment. Often taking the form of If/when situation x arises, then I will do y!, implementation intentions can be conceptualized in two parts, namely, an environmental or internal retrieval cue and a goal-directed behavioral response. Implementation intentions are effective because they 1) create a strong association between a retrieval cue and a goal-aligned behavior, increasing the likelihood that the goal-aligned behavior will be retrieved and utilized when the cue is encountered, and 2) increase attention for and cognitive accessibility of the retrieval cue, increasing opportunities for goal-aligned action ."
46051230|NCT04105309|Behavioral|Fluency Training|Fluency training is a learning strategy that requires an individual to perform a skill or demonstrate knowledge repeatedly for both accuracy and response rate; the goal is to enhance automaticity of the response and promote endurance and retention of skills and knowledge over time and in the face of distractors. Participants completed 1 minute fluency training protocol 4 times throughout the study.
45482912|NCT02464306|Drug|fidaxomicin|Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days.
45482913|NCT01575990|Behavioral|Making A Decision About CRC Screening|"Targeted by age and gender with 3 components.~Educational component~Values clarification exercise~Individualized decision making worksheet~The intervention or control condition is administered before the index visit with the patient's provider."
45482914|NCT01575990|Behavioral|Drivers 65 Plus|This text booklet is provided as an attention control for those in the control arm and like the intervention is administered prior to the index visit with the patient's provider.
45482915|NCT04489810|Dietary Supplement|Placebo|Maltodextrin capsule manufactured to mimic the Glutalytic® and DE111® capsules
45482916|NCT04489810|Dietary Supplement|Glutalytic®|1 capsule containing 350 mg of Glutalyltic®
45482917|NCT04489810|Dietary Supplement|DE111®|1 capsule containing Bacillus subtilis DE111
45482918|NCT04489810|Other|Meal A|Oatmeal porridge - serving of cooked oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
45482919|NCT04489810|Other|Meal B|Refrigerated oatmeal - serving of refrigerated oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
45482920|NCT01351662|Behavioral|Arthritis Self Management Program|Intervention activities will consist of six weekly sessions of the Arthritis Self-Management Program (ASMP). Sessions will be administered in a group setting with the 15 African American lupus patients randomly assigned to the intervention arm of the study. Fifteen other patients will serve as controls and receive usual care. Patients participating in the stress intervention will receive six weeks of peer led sessions ranging in disease-specific and more general self-help content. The intervention will include homework assignments to practice and record use of session techniques and to complete worksheets regarding session-specific topics and activities. Usual care will include a brief explanation of the disease and relevant literature.
45690719|NCT03984513|Behavioral|Surviving and Thriving in the Real World|The Surviving and Thriving in the Real World intervention consists of 14 weekly concurrent adolescent and parent group sessions. The daily living skills to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning daily living skills and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).
46051231|NCT04105309|Behavioral|Text Messages|SMS reminders sent to phone of implementation intentions 16 times throughout the study.
46051232|NCT04105309|Behavioral|Goal Intentions|Intentions to complete a goal that do not specify a plan about how to do so (compared to implementation intentions, that do)
45482921|NCT01357746|Procedure|Transthoracic pulmonary doppler recording|A 30 min recording of doppler signals from the right chest wall including measurements while the patient performs Valsalva maneuvers
45482922|NCT01351818|Drug|Growth Hormone|
45482923|NCT02463916|Other|Exercise|8 week structured exercise programme
45482924|NCT02463994|Drug|MPDL3280A|Patients will receive 1,200 mg I.V. Q 3 weeks of MPDL3280A until progression.
45482925|NCT02463994|Radiation|Hypofractionated Radiotherapy|Hypofractionated Image-Guided Radiotherapy (HIGRT)
45482926|NCT01356654|Device|Application of Transcranial direct current stimulation (TDCS)|Application of TDCS for 20 minutes, 4 times a week for 4 weeks.
45482927|NCT01356654|Device|Transcranial Direct current stimulation|Application of true TDCS for 20min, 4 times a week for 4 weeks.
45482928|NCT04235686|Drug|Mydayis Extended-Release Capsule|Randomized, parallel - group, double-blind, placebo-controlled, flexible-dose adjunctive trial of MYDAYIS®
45482929|NCT04235686|Drug|Placebo|Matching placebo
45482930|NCT02079948|Drug|Methotrexate + Folic Acid|"Participants in the methotrexate + folic acid condition will have a~Blood draw at each monthly visit~Cognitive performance testing to assess memory performance~Physical function testing to assess walking speed and measure muscle endurance~Pain assessment testing to assess the presence and location of daily pain~Self-reported function and quality of life to measure disability and mobility limitations, and~Depression assessment testing to assess participants' level of depression."
45482931|NCT02079948|Drug|Placebo + Folic Acid|"Participants in the placebo + folic acid condition will have a~Blood draw at each monthly visit~Cognitive performance testing to assess memory performance~Physical function testing to assess walking speed and measure muscle endurance~Pain assessment testing to assess the presence and location of daily pain~Self-reported function and quality of life to measure disability and mobility limitations, and~Depression assessment testing to assess participants' level of depression"
45482932|NCT02079948|Procedure|Functional MRI Experimental Tasks|Participants who are randomly assigned to the fMRI scan wil receive their study drugs at the the Baseline fMRI visit. Participants who are randomly assigned to the fMRI will also attend complete their last visit at the 6 month period.
45482933|NCT02079948|Procedure|Muscle Biopsy|Participants who are randomly assigned to the muscle biopsy assessment of the study will receive their study drugs at the Baseline muscle biopsy visit. Participants who are randomly assigned to the muscle biopsy portion of the study will also complete their last visit at the 6 month period.
45482934|NCT02463838|Other|Care Support Intervention|Case management and care coordination intervention delivered in person to SFHP members who are frequent users of emergency department and inpatient hospital services.
45482935|NCT01357824|Procedure|Application of Sellick´s maneuver.|The patient will be intubated with a flexible fiberscope, Olympus model, under the application of Sellick´s maneuver, with the recommended 30 Newtons pressure, and also, as control, be intubated with a sham Sellick´s maneuver, with 0 Newton. The order of the pressures is randomized, and it is blinded to the intubating physician by a cloth which of the maneuvers that is used. The pressure is measured be a pediatric cuff, which is pressed against the throat.
45482936|NCT04178824|Behavioral|Discount Intervention|15% or 30% discount on fruits and vegetables
45482937|NCT01357902|Drug|Lamotrigine|Lamotrigine is a selective inhibitor of a voltage-sensitive sodium channel, is an anti-epileptic drug of the phenyltriazine class.
45482938|NCT03247764|Other||observational study
45690720|NCT03984513|Behavioral|Program for the Education and Enrichment of Relational Skills|Program for the Education and Enrichment of Relational Skills is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning a get-together with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
45690721|NCT01855399|Behavioral|Peer Coaching|All participants will be assigned to a peer coach, who is a Detroit VA diabetes patient who previously had poor glycemic control but is currently in good control. Participants will receive information on their lab and blood pressure values and will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns, and develop an action plan to address barriers to self-management they have identified. During the next six months, coaches will call their assigned peers once a week to provide support for their action steps.
45847855|NCT03010488|Behavioral|Morning Light Therapy|10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time.
45365978|NCT00487084|Drug|saline-2CP-morphine (SCM)|6ml of saline will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 3mg of preservative free morphine will be administered at skin incision
45847856|NCT03010488|Behavioral|Assigned Sleep Times|Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation.
45365979|NCT00487084|Drug|saline-lidocaine-morphine (SLM)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 2% lidocaine with epinephrine 1:200,000 will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
45847857|NCT03010488|Device|Goggles|Subjects will wear goggles during saliva collection and Bright Light Therapy
46051233|NCT04883424|Behavioral|Diabetes Education Program Based on Health Belief Model|After the application, increase in family support and decrease in blood sugar levels are expected in diabetic patients. Family members' diabetic attitudes are expected to increase.
46051234|NCT00786409|Biological|Gardasil|0.5 ml Gardasil vaccine will be administered to each patient at months 0,2 and 6.
46051235|NCT05150886|Diagnostic Test|rox index|After HFNC during reassessment, the ROX Index can help suggest which patients will fail HFNC and need to progress to intubation for further ventilatory support.
46051236|NCT04583982|Other|T-Detect™ SARS-CoV-2 Assay|T-Detect™ SARS-CoV-2 Assay is an investigational device that is indicated to assess T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19. These results will not be shared with the participant.
45365980|NCT04770675|Diagnostic Test|Bronchoscopy|All subjects who are scheduled for a bronchoscopy may be eligible.
45365981|NCT00466726|Biological|bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine|
45365982|NCT00466726|Biological|sargramostim|
45365983|NCT03998787|Other|Neurophysiological assessment|Kinematic analysis of movement and transcranial magnetic stimulation
45690722|NCT01855399|Behavioral|Decision Aid|The iDecide tool is designed to present key tailored, evidence-based information on diabetes and diabetes treatments. Importantly for a peer support intervention, all content information will be provided through the tool, with the role of the peer mentor being to assist the participant to go through the program and participate in helping the patient formulate questions and concerns to discuss with their health care provider, to set their own behavioral goals and action steps, and to help the participant practice raising the issues they plan to discuss with their health care provider.
45690723|NCT01875991|Drug|Etanercept via Autoinjector A|Autoinjector A is a hand-held, reusable, electromechanical device used with a single-use disposable cassette preassembled with an etanercept 50-mg prefilled syringe.
45690724|NCT01875991|Drug|Etanercept via Autoinjector B|Autoinjector B is a single-use, spring-loaded, self-contained autoinjector preassembled with an etanercept 50-mg prefilled syringe.
45365984|NCT01721291|Drug|SALBUTAMOL|"In the LUNG DEPOSITION STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT SLOW INHLATION AND AGAIN AT FAST INHALTION;DOSAGE- 30 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION.~In the LUNG PHYSIOLOGY STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT TWO DOSAGES OF 30 MICROGRAMS AND AGAIN AT 15 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION. ALL INHALATIONS WIL BE AT SLOW INHALTION IN THIS PART OF THE STUDY."
45690725|NCT04203927|Drug|Empagliflozin 25 MG|SGLT-2 inhibitor
45690726|NCT04196985|Diagnostic Test|PET/MRI|each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
45847858|NCT03010800|Device|With Yoni.Fit|Abbreviated Pad Test with Yoni.Fit first, then without Yoni.Fit.
45365985|NCT01021462|Procedure|Comparator: graded infusion of intravenous glucose|A stepwise graded infusion of glucose (20% dextrose [D20]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12mg/kg/min. Procedure will be identical in Period 1 and Period 2.
45365986|NCT01403350|Device|Malaria Rapid Diagnostic test|Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
45365987|NCT02579369|Other|Allogeneic mesenchymal stem cells|Dressing for Dystrophic Epidermolysis Bullosa wound.
45365988|NCT02579369|Device|Polyurethene Film|Dressing for Dystrophic Epidermolysis Bullosa wound.
45365989|NCT01021540|Drug|Repository corticotrophin|Acthar 80 IU SQ once a week and titrated up to twice a week
45482939|NCT05313776|Other|Magnetic Resonance Imaging|IMR is a non-invasive imaging technology that produces three dimensional detailed anatomical images. It is often used for disease detection, diagnosis, and treatment monitoring. It is based on sophisticated technology that excites and detects the change in the direction of the rotational axis of protons found in the water that makes up living tissues.
45482940|NCT01318824|Procedure|Nasal Intermittent Positive Pressure Ventilation (NIPPV)|The Control group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment
46051237|NCT04881396|Biological|Evaluation of the immunogenicity of the vaccine in haemodialysis patients|The immunogenicity of the vaccine will be evaluated at the peak of vaccine response (Day 7 - Day 14 after the second dose) and 6 and 12 months post vaccination, by the evaluation of humoral IgG anti-spike protein response (seroconversion rate, absolute antibody titers, affinity of antibody) and cellular anti SARS-Cov2 response (number, activation capacity, production of interferon gamma of CD4 and CD8 anti sars cov2 specific T cells)
45482941|NCT01318824|Procedure|Bi-Level Positive Airway Pressure (BIPAP)|BiPAP group receive Bi-Level Positive Airway Pressure (BIPAP) treatment
45482942|NCT02465476|Procedure|telemedicine|treatment pathway organized by telemedicine
45482943|NCT02878590|Device|BONGO DEVICE|A device to be used for the treatment of mild to moderate obstructive sleep apnea
45482944|NCT05634382|Drug|Intravenous thrombolysis agents|Intravenous thrombolysis with recombinant tissue-type plasminogen activator (rt-PA，alteplase) or TNK-tPA (Tenecteplase，Metalyse)
45365990|NCT04840511|Drug|lidocaine group|lidocaine 1.5 mg/kg bolus (infused over 10 min) followed by 2.0 mg/kg/h during operation and 1.0 mg/kg/h during postoperative 24 hours (no more than 120 mg/h)
45365991|NCT04840511|Drug|control group|normal saline 0.15 ml bolus followed by 0.2 ml/kg/hr during operation and 0.1 ml/kg/hr during postoperative 24 hours
45365992|NCT04072133|Behavioral|Meditative Movement|Intervention will be taught by a certified Tai Chi Easy (TCE) group practice leader. The TCE movements will be repeated in differing sequences and time-frames during the course of the study. The variety and combination of the exercises will begin easy and progress to more advanced movements and/or intensities as the study progresses and participants become more experienced and comfortable with the routine. Participants spend one hour in class each week for a total of eight weeks.
45365993|NCT00486226|Device|Vascular Reconstruction Device|CORDIS ENTERPRISE™ VRD
45482945|NCT05634382|Procedure|endovascular thrombectomy|endovascular mechanical thrombectomy with nonspecific device
45845863|NCT05133336|Drug|Saroglitazar Magnesium 1 mg|Subjects randomized to Saroglitazar Magnesium 1 mg arm will receive Saroglitazar Magnesium 1 mg treatment until the optimal dose (1 or 2 mg) is selected at interim analysis, after which these subjects will receive Saroglitazar Magnesium Optimal Dose (1 or 2 mg) up to Week 52. If the selection of optimal dose is inconclusive at the interim analysis, all subjects in this arm will continue to receive Saroglitazar Magnesium 1 mg as per the initial treatment assignment for the entire treatment period up to Week 52.
45482946|NCT01317732|Device|MOTIONPOD (TM) measures|It is a study with a single arm. The MOTIONPOD TM measures are compared with simultaneous estimations obtained with the criteria measure (indirect calorimeter) and with existing activity monitors (heart rate monitor POLAR; different accelerometers - rT3 et Actigraph GT3X-, Actiheart, Sensewear Pro2 Armband) After physical fitness evaluation, different activity monitors are set up and the subjects perform a series of standardised activity tasks of different intensities, and well as a 30-min free activity period. Physical activity energy expenditure is measured at the end of each task using a metabolic gas analyser
45365994|NCT05007275|Biological|1x10^9 vp AZD1222|A single dose of 1x 10^9 vp AZD1222
45365995|NCT05007275|Biological|5x10^9 vp AZD1222|A single dose of 5x 10^9 vp AZD1222
45847859|NCT03010800|Device|Without Yoni.Fit|Abbreviated Pad Test without Yoni.Fit, then with Yoni.Fit.
45365996|NCT05007275|Biological|1x10^10 vp AZD1222|A single dose of 1x10^10 vp AZD1222
45365997|NCT04196062|Device|EndoMASTER EASE Robotic system for ESD|EndoMaster EASE System, is a robotic-assisted endoscopy system indicated for endoscopic visualization and therapeutic access to the adult gastrointestinal (GI) tract for endoscopic surgery
45365998|NCT02199665|Drug|selinexor|Given PO
45365999|NCT02199665|Drug|carfilzomib|Given IV
45366000|NCT02199665|Drug|dexamethasone|Given PO or IV
45366001|NCT01021696|Drug|Paracetamol|Paracetamol Max. dose: 3g/d
45366002|NCT01021696|Drug|Morphine|Morphine ret. Tab. 5mgx2/d; max. dose:10mgx2/d
45366003|NCT01021696|Drug|Buprenorphine plaster|5ųg/h, change each 7.day; max. dose: 10ųg/h
45482947|NCT05625958|Device|Cilioscleral Interposition Device|Surgical placement of SV22 cilioscleral interposition device in the supraciliary space
45482948|NCT04634409|Drug|Bamlanivimab|Administered IV.
45482949|NCT04634409|Drug|Etesevimab|Administered IV.
45482950|NCT04634409|Drug|Placebo|Administered IV.
45482951|NCT04634409|Drug|VIR-7831|Administered IV.
45482952|NCT04634409|Drug|Bebtelovimab|Administered IV.
45482953|NCT01352052|Other|interdisciplinary rehabilitation|A two-weeks non-residential, group-based, psycho-educative, multi-component treatment course conducted by an interdisciplinary team consisting of a rheumatologist, a nurse, occupational therapists, physical therapists, and a psychologist. The rehabilitation Programme comprises of a combination of lectures and group discussions, as well as instructions during physical exercise and task performance. The main focus is on education and adaptations in everyday life. There is a scheduled Programme for every day, with a daily time schedule between four and six hours. There will be a maximum of eight participants in each group.
45482954|NCT04896034|Device|MILTA Device|Patients in MILTA Device group will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.
45482955|NCT04896034|Device|" control 1  fake MILTA device"|Patients in group control 1 will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.
45482956|NCT01352130|Drug|Ondansetron|Intravenous Ondansetron 8 mgs
45482957|NCT01352130|Drug|Granisetron|Intravenous Granisetron 1 mgs
45847860|NCT03012594|Drug|Lanreotide|Dosage: 120mg Dosage form: subcutaneous injection, pre-filled syringe Dosage frequency: 3 injections over 12 weeks, each dose administered 4 weeks apart
46051238|NCT00919854|Drug|Darunavir|Darunavir oral suspension (100 mg/mL) will be administered as 20 mg per kg body weight twice daily for children weighing between 10 and <20 kg before dose adjustment. Darunavir oral suspension will be administered 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg darunavir tablets twice daily if weight more than or equal to 15 kg after dose adjustment.
46051239|NCT00919854|Drug|Ritonavir|Ritonavir oral solution (80 mg/mL) will be administered as 3 mg per kg body weight twice daily before dose adjustment and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
45366004|NCT01021696|Drug|Pregabalin|25mgx1/d; max 300mg/d
45366005|NCT01018498|Behavioral|Restricted FODMAPs diet|Restricted fermentable substrate diet
45366006|NCT04669301|Behavioral|MAAT-G|Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies.
45366007|NCT04669301|Behavioral|Supportive therapy (time and attention control)|"Supportive Therapy (ST) is a behavioral placebo and controls for non-specific psychotherapeutic factors of the clinician-subject relationship, such as empathy and support, but does not provide active cognitive training. ST utilizes reflective listening to help deepen awareness of participants' emotional experience. Timing and duration of ST sessions will mirror the intervention, and will consist of 10 weekly sessions, 30 to 45 minutes each, delivered by trained psychologists via video-conferencing."
45366008|NCT02577575|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
45366009|NCT02577575|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
45482958|NCT02463604|Procedure|Coronary Angiography|Coronary angiography is performed following usual site standards
45482959|NCT05605834|Other|9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray with reservoir|"Patients will be randomly divided into two groups. Alginate impressions of maxillary dental arches of patients will be taken to obtain casts and produce the customized trays.~Reservoirs 1 mm thick will be created on the facial surfaces of anterior teeth, including the first premolars in the arches, applying a light-cured resin on the casts. The resin layer thickness will be standardized using a thickness gauge (1.5 mm thickness). Then, customized trays will be fabricated with 0.9-mm-thick vinyl acetate sheets using the thermoforming process. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the patients' mouth."
45690727|NCT04196985|Diagnostic Test|PET/CT|each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
45690728|NCT04201431|Biological|PvDBPII/Matrix-M1|50ug PvDBPII in 50ug Matrix M1
45690729|NCT01855243|Drug|regular insulin|
45690730|NCT01855243|Drug|70/30 insulin|
45482960|NCT05605834|Other|9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray without reservoir.|Alginate impressions of maxillary dental arches of patients will be taken to obtain casts to produce the customized trays. Then, customized trays will be fabricated with no space for reservoir, with 0.9-mm-thick vinyl acetate sheets using the thermoforming process applying a light-cured resin on the casts. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the participants' mouths.
45366010|NCT02577653|Other|Posturographic evaluation|Subjects will undergo CDP testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol. Subsequently, subjects will be asked to stand first on the right leg and then on the left leg with eyes open. Finally, subjects will be asked to perform 10 repetition of the squatting movement, with the operator pacing them (telling them when to start and when to stop the movements).
45366011|NCT04827407|Device|Efferon LPS hemoperfusion|Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 24h immediately following admission to the intensive care unit
45366012|NCT02578979|Device|Electrocardiogram|Patients will receive electrocardiogram for detecting atrial fibrillation - a 5-day routine ECG.
45366013|NCT02578979|Device|Holter|Patients will receive electrocardiogram for detecting atrial fibrillation - a 24-h Holter.
45366014|NCT00485758|Drug|ER niacin/laropiprant|One tablet of ER niacin/laropiprant (1g); advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study 36 Weeks.
45366015|NCT00485758|Drug|Comparator : placebo (unspecified)|ER niacin/laropiprant Placebo
45366016|NCT04073459|Biological|DTwP-HepB-Sabin IPV-Hib|Intramuscular injection into the anterolateral area of the thigh
45366017|NCT04073459|Biological|Pentavalent vaccine and Salk IPV|Intramuscular injection into anterolateral area of the thigh
45366018|NCT01018576|Other|Delayed cord clamping|Infants will be covered with plastic and placed on a chemical warmer at delivery and then clamping of the umbilical cord will be delayed for 30-60 seconds.
45482961|NCT04272294|Device|Optical Spectroscopy|Using oral spectroscopy device to characterize treatment response in tumors
45690731|NCT01855243|Drug|Glargine|
45690732|NCT01855243|Drug|glulisine|
45366019|NCT02577341|Drug|Nimotuzumab|Patients received weekly nimotuzumab (200mg, IV) concurrent with chemoradiotherapy.
45690733|NCT03590847|Behavioral|Intermittent Fasting|Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks. Participants will be allowed to consume calorie-free beverages, water, tea, black coffee or sugar-free gum during the fasting period. Participants will be asked to record the time of first and final food/drink consumption each day.
45366020|NCT02577341|Drug|docetaxel and cisplatin|Patients received weekly docetaxel and cisplatin, each of 1 day's duration,concurrent with chest radiotherapy
45366021|NCT02577341|Radiation|daily RT to the chest|Patients received daily RT to the chest
45366022|NCT03998800|Dietary Supplement|Dietary Supplement|Dietary Supplement: L-arginine and L-citrulline supplement, L-arginine supplement, or placebo supplement (corn-starch) Subjects will complete 3 individual 10 day supplementation periods, separated by washout periods of approximately 2 weeks.
45366023|NCT03998800|Behavioral|Endurance exercise on a cycle ergometer|On day 10 of each supplementation period, subjects will complete a performance test on a cycle ergometer to investigate their endurance performance.
45366024|NCT02577497|Drug|beclomethasone|
45366025|NCT02577497|Drug|fluticasone|
45366026|NCT01021774|Procedure|Anal fistula treatment|A comparison of collagen plug vs advancement flap surgery
45366027|NCT01602263|Procedure|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS.
45366028|NCT02577419|Other|Target Fortification|
45366029|NCT02577419|Other|Higher Initial Concentration|
45366030|NCT02577419|Other|Portagen Formula|
45482962|NCT00005780|Drug|EPOCH-R|EPOCH-R for 6 cycles
45482963|NCT00005780|Biological|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) monthly with the vaccine for 5 doses
45690734|NCT04196829|Drug|silver diamine fluoride ⁄ potassium Iodide|The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption . Then after SDF application KI will be applied using a separate microbrush which will be saturated by the solution and will be used to paint solution over carious lesion , no rinse will be performed and special instructions will be given following application
45482964|NCT00005780|Biological|Idiotype vaccine|1 injection of vaccine monthly for 5 doses
45482965|NCT01356732|Drug|Sufentanil|From 0 to 0,05 µg/kg to a maximum of 4 µg/kg of sufentanil. 7 minutes before nursing 3 nursing per day during 3 days
45482966|NCT02463682|Device|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump
45482967|NCT02463682|Device|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:~DiAs - a smart-phone medical platform; Dexcom Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)"
45482968|NCT01356810|Other|Environmental Intervention|The environmental intervention consisted of daily reorientation, avoidance of sensorial deprivation, longer visiting hours, the availability of a clock, a calendar and the presence of familiar objects in the room.
45845864|NCT05133336|Drug|Saroglitazar Magnesium 2 mg|Subjects randomized to Saroglitazar Magnesium 2 mg arm will receive Saroglitazar Magnesium 2 mg treatment until the optimal dose (1 or 2 mg) is selected at interim analysis, after which these subjects will receive Saroglitazar Magnesium Optimal Dose (1 or 2 mg) up to Week 52. If the selection of optimal dose is inconclusive at the interim analysis, all subjects in this arm will continue to receive Saroglitazar Magnesium 2 mg as per the initial treatment assignment for the entire treatment period up to Week 52.
45366031|NCT02576171|Behavioral|Group-therapy + ICBT|The group therapy supported ICBT treatment program is a combined web-based and face-to-face intervention that will involve adolescents as well as their parents. The program is founded on and inspired by previously evaluated and evidence-based interventions. Altogether, adolescents go through 12 chapters/sessions, 3 of which are face-to-face group sessions at the research clinic, and 9 of which are web-bases chapters. The program is divided into three different phases, starting with psychoeducation regarding social anxiety and the rationale for a cognitive behavioral intervention. Phase two is the main part of treatment and contains behavioral interventions, mainly exposure and habituation to feared situations and/or stimuli.
45366032|NCT04071665|Procedure|Modified lateral lumbar interbody fusion|Modified lateral lumbar interbody fusion
45482969|NCT01356810|Other|Standard Care|Delirium management by the attending physician's preferences.
45482970|NCT05315648|Procedure|anesthesia approach (general anesthesia or non-general anesthesia)|patients in group GA received general anesthesia followed with FNB. patients in group NGA received CSEA followed with FNB
45482971|NCT05602246|Procedure|Transobturator cystocele repair|Novel transvaginal surgical reconstruction of anterior compartment pelvic organ prolapse.
45482972|NCT05602246|Procedure|Anterior colporrhaphy|The traditional transvaginal surgery for cystocele treatment used as a comparator in the study
45482973|NCT01978938|Drug|Eravacycline|
45366033|NCT02575937|Behavioral|low glycemic diet|nutrition education-based low glycemic diet intervention
46051240|NCT04698720|Behavioral|Muscle Relaxation with Guided Imagery|Relaxation intervention session begins with diaphragmatic breathing, followed by Jacobson's progressive muscle relaxation, which involves the contraction and subsequent relaxation of the 16 muscle groups of the body (forearm, arm, upper forehead, eye, mouth, jaw and throat, neck, shoulder, chest, stomach, thigh, leg and foot).The contraction is performed for 7 seconds while the relaxation lasts for about 40 to 50 seconds.The relaxation of the foot muscle group is only performed on the healthy foot, because dressing and bandages may bandage the foot with the DFU, which together with the typical joint stiffness of the diabetic foot, make it difficult to perform. After muscle relaxation, begins the guided imagery focused on DFU healing. The patient is instructed to think about his/her current state of health and to imagine the DFU as a dark area and the healing relaxation as a light associated to pleasant sensations, which will focus on the foot with DFU to heal it.
45482974|NCT01978938|Drug|Levofloxacin|
45482975|NCT02465554|Procedure|Myocardial contrast echocardiography|Myocardial contrast echocardiography will be performed to further stratify risk as described in the cohort section.
45482976|NCT02465320|Drug|COL-1077|single dose of 150mg lidocaine (10%w/w) administered by intravaginal insertion
45482977|NCT02465320|Drug|Placebo|single dose of bioadhesive gel administered by intravaginal insertion
45482978|NCT02465008|Drug|Levobupivacaine|
45482979|NCT02465008|Drug|Placebo|
45482980|NCT01356888|Device|Percutaneous Coronary Intervention (Abbott Laboratories - Xience Prime DES)|Stenting
45482981|NCT01356888|Device|Percutaneous Coronary Intervention (Orsiro DES)|stenting
45482982|NCT01352208|Drug|ASP9521|oral
45482983|NCT05583292|Other|ASA-PS|The American Society of Anesthesiologists classification of physical status (ASA PS) is a scale consisting of 6 classes showing the preoperative comorbidity of the patient.
45482984|NCT05583292|Other|SORT|Surgical outcome risk tool (SORT) is a scale used to estimate patient preoperative mortality/ morbidity, measured from sortsurgery.com.
45482985|NCT05583292|Other|Sarcopenia|Sarcopenia represents a loss of muscle strength and mass in older individuals and people who have tumors. Sarcopenia score is valuable in predicting preoperative mortality/ morbidity
45482986|NCT01358058|Radiation|Proton radiation|Total dose of 54-59.4 Gy(RBE) at 1.8 Gy(RBE) per daily fraction delivered 5 days per week on weekdays for 6-6.5 weeks.
45482987|NCT04870840|Radiation|Proton Beam Radiation Therapy|Undergo radiation therapy
45482988|NCT04870840|Other|Quality-of-Life Assessment|Ancillary studies
45482989|NCT04870840|Other|Questionnaire Administration|Ancillary studies
45482990|NCT03228186|Drug|Pevonedistat|25mg/m2 days 1, 3, 5
45482991|NCT03228186|Drug|Docetaxel|75mg/m2 day 1
45482992|NCT01330485|Behavioral|Affect Regulation Training|The ART is a transdiagnostic, group-based intervention that has been developed to explicitly target emotion regulation skills (e.g., the abilities to be aware of, understand, accept, tolerate and modify negative emotions).
45482993|NCT01330485|Behavioral|Common Factor Control Condition|The CFC is an active treatment condition designed to control for unspecific effects of psychotherapeutic interventions.
45690735|NCT04196829|Drug|Silver Diamine Fluoride|The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption .
45690736|NCT03023787|Drug|Hepalatide|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
45482994|NCT03041090|Device|Lucerno ID (identification) System|The Lucerno ID is intended to dynamically measure the uptake of radiotracer in a particular organ or body region during the radiotracer uptake period as part of nuclear medicine (NM) procedures. The Lucerno ID is indicated for use as a tool for trained healthcare professionals (technologists, NM physicians, and radiologists) to help assess whether a radiotracer injection has resulted in an infiltration. The LD ID can be used by healthcare professionals including nuclear medical technologists, nuclear medicine physicians, or any other medical staff in a NM facility, once they have received the necessary training into the use of the system.
45482995|NCT04105114|Drug|Buspirone|Oral Buspirone 7.5mg - 10mg daily during the treatment phase.
45482996|NCT04105114|Device|Non-invasive Spinal Cord Stimulation|A non-invasive transcutaneous electrical spinal cord stimulator, which can be used a multiple spinal locations.
45482997|NCT04105114|Device|Ekso Bionics Exoskeleton|This robotic exoskeleton is designed to assist people with neurological injuries for balance, standing, and stepping overground.
45482998|NCT04105114|Device|Gravity Neutral Device|This device is used to train and assess non-weight bearing stepping movements. When using the device, participants will be lying on their side with their legs suspended off the end of a table supported by small slings that are anchored securely to the apparatus.
45690737|NCT03023787|Drug|Placebo|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
45690738|NCT03832725|Other|High Protein (HP) weight loss diet|"Newly diagnosed Type 2 Diabetic (NT2DM) subjects will be placed on a HP diet for 6 months with all food provided for weight loss and remission of NT2DM.~Intervention with the HP diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
45690739|NCT03832725|Other|High carbohydrate (HC) weight loss diet|"Newly diagnosed Type 2 Diabetic (NT2DM) subjects will be placed on a HC diet for 6 months with all food provided for weight loss and remission of NT2DM.~Intervention with the HP diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
45690740|NCT01825837|Drug|BIA 2-093 1800 mg once daily [Group 1 (Part II)]|BIA 2-093 1800 mg taken orally in the evening, for 2 weeks
45690741|NCT01825837|Drug|BIA 2-093 900 mg once daily [Group 2 (Part II)]|BIA 2-093 900 mg taken orally in the evening, for 2 weeks
45690742|NCT01825837|Drug|BIA 2-093 300 mg once daily [Group 3 (Part II)]|BIA 2-093 300 mg taken orally in the evening, for 2 weeks.
46051241|NCT04698720|Behavioral|Hypnosis with Guided Imagery|"In the beginning of the first session we apply the Eye-Roll Test for Hypnotizability of Herbert Spiegel. Each session follows the Hypnotic Protocol with the following steps:Pre-talk/Absortion/Ratification/Aliciation/Dissociation/Awakening.~The four sessions train the participants in visual, auditory and kinesthetic perception on ulcer healing. The protocol also promotes medical treatment acceptance."
46051242|NCT04698720|Behavioral|Neutral Guided Imagery|This placebo consists of neutral guided imagery focused on themes of the patient's daily life before having DFU. Each session has a theme associated with the patient's life - family, work, friends, and leisure. Initially, the patient is asked to think about an event related to the theme of the session of his/her choice, positive or negative, which occurred before patient has the current DFU. Then, the patient is asked about a number of questions regarding the chosen episode in order to promote a more detailed reconstruction of the event. The patient is asked to imagine according to the instructions given by the Psychologist. When the whole episode is remembered, the patient is asked to tell what he or she imagined/remembered regarding each of the questions.
45482999|NCT04105114|Device|Body Weight Supported Treadmill Training|Participants will be supported by a special harness while they are stepping on a treadmill. Trained technicians or therapists will be assist the trunk and legs during stepping as needed.
45483000|NCT04105114|Device|Rolling Walker|A standard rolling walker will be used for balance support and stability during stepping overground.
45690743|NCT01825837|Drug|BIA 2-093 900 mg (Part I)|In Part I, patients received one 900 mg BIA 2-093 tablet once daily, taken orally in the evening, for 2 weeks.
45483001|NCT03222882|Procedure|personal embryo transfer|According to the histological dating and transcriptomic profile of endometrium of hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer . The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on day P＋7 in an HRT cycle. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy outcome of the FET cycle .
45690744|NCT04197063|Behavioral|Sweetened beverage portion size limit|
45690745|NCT03599115|Behavioral|Inhibitory Control Training|Computerized go/no-go task where individuals make responses to certain items (go trials) and withhold responses from certain items (no-go trials, in this case, trials surrounded by a black box). Intervention is designed to target and improve inhibitory control cognitive mechanisms in general (generic arm) or towards high-calorie foods specifically (food arm).
45690746|NCT04196673|Device|Alcon SN60WF|Implantation of an intraocular lens Alcon SN60WF
45690747|NCT04196673|Device|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
45690748|NCT03590379|Drug|CHF 5993 DPI|BDP/FF/GB DPI
45366034|NCT02577263|Other|Quality of life assessment|Quality of life and chemotherapy induced neurotoxicity evaluation
45366035|NCT02575859|Drug|adjuvant HIPEC|Closed-abdomen HIPEC with cisplatin (25 mg/m2/l of perfusate) and mitomycin-C (3•3 mg/m2/l of perfusate) at 42•5°C for 60 minutes. Perfusate volume: 4-6 l.
45366036|NCT02575859|Procedure|surgery|Colon resections for primary tumors were performed according to the oncologic principles of adequate lymph-adenectomy. Complete adhesiolysis, resection of falciform hepatic ligament, greater and lesser omentectomy were performed in all patients to ensure optimal perfusion during the HIPEC. Tumor deposits on visceral and parietal surfaces were surgically removed by formal peritonectomy procedures and/or organ resections, as needed.
45366037|NCT04779827|Behavioral|Online Social Network and Collective Intelligence Intervention|The online network intervention aims to use different configurations of online social networks to optimize the impacts of collective intelligence process to improve individuals' understanding, beliefs, and behavioral choices regarding a variety of health behaviors. Participants will be put into different online networks and respond to health questions while receiving feedback from their network members.
45690749|NCT03590379|Drug|CHF5993 pMDI|BDP/FF/GB pMDI
45690750|NCT03590379|Drug|CHF 1535 pMDI|BDP/FF pMDI
45690751|NCT03590379|Drug|Placebo DPI|CHF 5993 DPI matched placebo
46051243|NCT04678518|Diagnostic Test|Inflammatory makers that will include Interleukins (IL); IL1, IL2, IL6 and TNF|1 hour before decannulation and 3 times after decannulation (1 hours, 12 hours and 24 hours)
45690752|NCT03590379|Drug|Placebo pMDI|CHF 5993 pMDI matched Placebo (direct blinding of active CHF 5993 and CHF 1535 pMDIs)
45690753|NCT03590301|Behavioral|FUNPALs Playgroup|Based on Self-Determination Theory, the FUNPALs Playgroup aims to enable and inspire parents to improve their toddlers dietary intake and physical activity habits through authoritative parenting, structured feeding practices, and a healthy home environment. Playgroups will include open but structured experiential learning activities, free play, and instruction/discussion.
46051244|NCT04669782|Dietary Supplement|Vitamin K (MK7)|MK-7 will be administered at a dose of 375 microg / day
46051245|NCT04669782|Drug|Teriparatide|Teriparatide will be administered as standard of care
45845865|NCT05133336|Drug|Placebo|Subjects randomized to placebo arm will receive placebo treatment for the entire treatment period up to Week 52.
45483002|NCT01352364|Other|physiotherapy intervention|a program of physical therapy intervention can match or improve motor skills in the deaf children
45483003|NCT02071875|Device|Nautilus NeuroWaveTM recording|Nautilus NeuroWaveTM recording 15 minute recording with Nautilus NeuroWave Neurodiagnostic .
45483004|NCT05309330|Other|No Intervention|This is a non-interventional study.
45483005|NCT05573230|Drug|Midazolam|Administered orally.
45483006|NCT05573230|Drug|LY3502970|Administered orally.
45483007|NCT05573230|Drug|Cyclosporine|Administered orally.
45483008|NCT03635034|Device|Insert bladder catheter|Bladder catheter will be inserted according to randomization schema
45483009|NCT03635034|Device|No catheter|Subjects will not receive a bladder catheter during the ablation procedure
45483010|NCT03240627|Drug|LH-8|LH-8 cutaneous solution
45483011|NCT03240627|Drug|Placebo|Placebo cutaneous solution
45483012|NCT01357044|Dietary Supplement|Extracts of Punica granatum and Alpinia galanga|Tablets, two in the morning and two in the evening
45366038|NCT04779827|Behavioral|Independent Control|Independent control aims to test the baseline of population understanding of health behaviors and choices. Participants will respond to health questions independently without getting any feedback from others.
45366039|NCT02576873|Other|Hemodiafiltration|Hemodiafiltration treatments were prescribed to the patients as their long-term renal replacement therapies
45483013|NCT01357044|Dietary Supplement|Placebo|Tablets, two in the morning and two in the evening
45690754|NCT03590301|Behavioral|Healthy Toddler Parent Group|The parent class will serve as our instruction only control group. Parents in this class will receive information about nutrition and activity recommendations regarding their toddler age children and will discuss it in a group with other parents. No experiential learning activities, information about parenting, or children will be involved in this class.
45690755|NCT03599037|Other|ICOUGH Recovery App v2.0|"The app has pre-set auditory, visual reminders, in the form of push notifications, that remind participants to use the incentive spirometer and ambulate around the hospital at time intervals recommended by the ICOUGH protocol. The app benchmarks the level of adherence to that of other subjects involved in the study via the My Summary page, and this visual anonymous comparison further motivates adherence to the ICOUGH protocol."
45483014|NCT02665065|Drug|Iomab-B|
45690756|NCT03598881|Other|Treatment|
45483015|NCT02665065|Drug|Conventional Care|
45483016|NCT02665065|Procedure|HCT|
45483017|NCT04856722|Procedure|mini-PNL|PCNL using miniature nephroscope. The procedure will be performed under general or regional anaesthesia under fluoroscopy guidance.
45483018|NCT04856722|Procedure|RIRS|RIRS using flexible ureteroscope. The procedure will be performed under general or regional anaesthesia under fluoroscopy guidance. Holmium Laser lithotripter will be used for stone fragmentation.
45483019|NCT04856722|Procedure|SWL|SWL using Dornier SII lithotripter. the procedure will be performed under sedoanalgesia, and fluoroscopy will be used for stone localization; for a maximum of 3 SWL session.
45483020|NCT05559190|Other|Pulsed electromagnetic field|Pulsed electromagnetic field therapy was applied directly over the abdominal muscle from a supine position after the removal of metals or things that can be affected by a magnetic field will be assured prior to magnetic field application. The treatment parameters were set as 15 Hz frequency, 20 gauss amplitude with a rectangular waveform for 20 minutes.
45483021|NCT05559190|Other|Graduated abdominal strengthening exercises|Four specific muscle core exercises were performed
45483022|NCT05550142|Biological|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose|50μg/dose
45483023|NCT05550142|Biological|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose|100μg/dose
45483024|NCT05550142|Drug|Placebo|Saline solution
45483025|NCT04047862|Drug|Ociperlimab|Administered as an intravenous (IV) injection
45690757|NCT04196517|Other|Educational Tool, PALS|The Patient Activated Learning System is a free, health education platform.
45366040|NCT03850444|Biological|pembrolizumab|
45366041|NCT03850444|Drug|carboplatin|
45366042|NCT03850444|Drug|paclitaxel|
45366043|NCT03850444|Drug|pemetrexed|
45483026|NCT04047862|Drug|Tislelizumab|Administered as an IV injection
45483027|NCT04047862|Drug|Pemetrexed|Administered in accordance with local guidelines, prescribing information/summary of product
45483028|NCT04047862|Drug|Paclitaxel|Administered in accordance with local guidelines , prescribing information/summary of product
45483029|NCT04047862|Drug|Nab paclitaxel|Administered in accordance with local guidelines , prescribing information/summary of product
45483030|NCT04047862|Drug|Carboplatin|Administered in accordance with local guidelines , prescribing information/summary of product
45483031|NCT04047862|Drug|Cisplatin|Administered in accordance with local guidelines , prescribing information/summary of product
45483032|NCT04047862|Drug|Etoposide|Administered in accordance with local guidelines , prescribing information/summary of product
45483033|NCT04047862|Drug|5fluorouracil|Administered in accordance with local guidelines , prescribing information/summary of product
45483034|NCT04047862|Drug|Oxaliplatin|Administered in accordance with local guidelines , prescribing information/summary of product
45483035|NCT04047862|Drug|Capecitabine|Administered in accordance with local guidelines , prescribing information/summary of product
45483036|NCT04045834|Device|68Ga-DOTA-TATE PET/MR and PET/CT imaging|Intravenous access is established in advance, intravenous bolus injection, 68Ga-DOTA-TATE dose is about 2 MBq/kg body weight (0.054 mCi/kg) up to 200 MBq (5.4 mCi), 18F-FDG dose is about 3.7-5.4 MBq/kg (0.1 -0.15 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
45483037|NCT00116142|Drug|Docetaxel|60 mg/m² q 3 weeks for 3 cycle at the start of treatment followed by weekly Docetaxel at 20 mg/m² per week beginning at week one of radiation therapy and continuing for seven weeks.
45483038|NCT00116142|Drug|Androgen Hormonal Suppression and Radiation|Total Androgen Ablation and external beam radiation therapy
45483039|NCT00116142|Drug|Androgen Suppression Therapy and Radiation Therapy|Total Androgen Ablation and External Beam Radiation Therapy
45690758|NCT04196517|Other|WebMD|WebMD is a widely used educational platform for health information.
45690759|NCT03590223|Procedure|Coronary Bypass Revascularization|analysis of perioperative major cardiovascular events in diabetic patients
45690760|NCT04196361|Diagnostic Test|Ultrasound|Point of care ultrasound as part of routine physical examination
45690761|NCT03590067|Other|Questionnaire|The data will be collected through a questionnaire that will be obtained through an interview between the investigator and the parent or the legal guardian
46051246|NCT04667754|Behavioral|Internet-delivered Cognitive Behavioural Therapy|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend ~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
45366044|NCT00469612|Device|NeuroVision's NVC treatment for Low Myopia|"NeuroVision's NVC vision correction technology is a method in the treatment of low myopia as the technology is directed at specific neuronal interactions at the level of the visual cortex (area responsible for vision in the brain).~The subject will be exposed to a set of visual stimulations (pattern with black and white lines) and visual threshold level will be obtained. The subject will look at these patterns on a computer. The treatment will be applied in successive 30-40 minute sessions, administered 2-3 times a week, for a total of 40 sessions. Every 5 sessions, subject's visual performance (visual acuity and CSF) will be tested in order to continuously monitor a subject's progress."
45366045|NCT00469456|Drug|Memantine|Memantine 20mg (10mg twice daily) oral administration for 12 weeks
45366046|NCT00469456|Drug|placebo|Placebo oral administration twice daily for 12 weeks
45690762|NCT01854697|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
45690763|NCT01854697|Drug|Ribavirin|Tablet
45366047|NCT00581555|Drug|Etanercept|Etanercept 50 mg QW initiated during taper of ciclosporin
45483040|NCT01357122|Device|NCI Insertion|DSAEK surgery will be performed using the NCI to insert the donor tissue.
45690764|NCT01854697|Drug|Telaprevir|Film-coated tablet
45690765|NCT01854697|Drug|Pegylated Interferon alpha 2-a (PegIFN)|Pre-filled syringe
45690766|NCT03594123|Drug|Brexpiprazole|2 mg tablet
45690767|NCT03594123|Drug|Brexpiprazole|3 mg tablet
45690768|NCT03591159|Other|Membran Sweeping|Cervical Membrane Sweeping by digital examination
45366048|NCT00581555|Other|Placebo|Randomized to placebo during taper of ciclosporin
45483041|NCT01357122|Procedure|Standard Forceps Insertion|DSAEK surgery will be performed using forceps to insert the donor tissue. This is our long-established technique for DSAEK, with well-documented excellent results.
45483042|NCT02463214|Other|Engineered Room|"Touchless devices:~Hand sanitizers, faucets, paper towel dispensers, call devices, Ultraviolet C Aseptix™ Disinfection devices above bathroom doors~Copper products:~Room and bathroom entrance door hardware, over bed table and bed side table surfaces, chair metal arms, wardrobe handles and knobs, weigh scale, sinks, grab bars, light switch panels, toilet flush handles, faucets and handles, patient bed rails.~Titanium dioxide paint:~Room walls, head walls, light switches, bathroom wall shelves, toilet tank and bowl, head wall unit fixed equipment, television remote and Bed Control remote"
45483043|NCT05547256|Biological|COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose|50μg/dose
45483044|NCT05547256|Biological|COVID-19 Variant (Omicron BA.5) mRNA Vaccine High dose|100μg/dose
45483045|NCT05547256|Drug|Placebo|Saline solution
45483046|NCT03135522|Drug|Zinc Acetate 50 Mg Oral Capsule|"Day 0 (randomization) to day 3 Zinc acetate 50 mg per day (one capsule)~Day 4 to day 7 If well tolerated: Zinc acetate 100 mg per day (two capsules)~Day 8 to V5 (6 weeks) If well tolerated: Zinc acetate 150 mg per day (three capsules)"
45483047|NCT03135522|Drug|Placebo oral capsule|"Day 0 (randomization) to day 3 Placebo (one capsule per day)~Day 4 to day 7 If well tolerated: placebo (two capsules per day)~Day 8 to V5 (6 weeks) If well tolerated: placebo (three capsules per day)"
45483048|NCT02463292|Other|no intervention|no intervention
45483049|NCT01361334|Drug|Pazopanib|800 mg QD p.o.
45483050|NCT02463370|Other|suprazygomatic maxillary area infiltration|Local anesthetic infiltration in two injections on each side of the face at the maxillary and infra-orbital areas.
45483051|NCT02463370|Other|non-suprazygomatic maxillary area placebo|The remaining injections at supratrochlear area, medial to the medial canthus, nasal still and anterior septum are placebo (saline)
45483052|NCT02463370|Other|non-suprazygomatic maxillary area infiltration|Local anesthetic infiltration in five injections on each side of the face at the infra-orbital area, supratrochlear area, medial to the medial canthus, nasal still and anterior septum.
45483053|NCT02463370|Other|suprazygomatic maxillary area placebo|The remaining maxillary injection is placebo.
45483054|NCT01757782|Drug|Oral Sildenafil|Patients were randomized into two groups. Placebo was prepared with distilled water. In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses, (3) Dose was doubled if the oxygenation index (OI) or SpO2 did not improve (If OI continued to be <10% of previous value and SpO2 was not increasing >5 of previous value) and blood pressure remained stable
45845866|NCT05132478|Other|Emotionally Supportive Video|The video is approximately 6 1/2 minutes in length and portrays an emotionally supportive conversation between a patient and surgeon during which the surgeon discusses: the diagnosis, prognosis, available treatment options, benefits and harms of the options, and need for decision making. The surgeon speaks for the majority of the simulated visit and discusses total and hemi-thyroidectomy with the addition of emotionally supportive statements and gestures.
45366049|NCT00469144|Drug|Busulfan|"Fixed Dose = 130 mg/m^2 IV Daily Over Three Hours x 4 Days.~Adjusted Dose = 32 mg/m^2 IV Over 2 Hours Test Dose x 1 Day.~Proceeding dosage level determined by pharmacokinetic studies to achieve a daily area under curve (AUC) of 6,000 microMol-min ± 10%."
45366050|NCT00469144|Drug|Fludarabine|40 mg/m^2 IV Daily Over 1 Hour x 4 Days
45483055|NCT01757782|Drug|Placebo (distilled water)|Distill water oral
45483056|NCT02023905|Drug|Everolimus|everolimus at 10 mg daily continuously
45847861|NCT03014700|Biological|Fibrinogen Concentrate|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
46051247|NCT04253028|Device|NERv's Inline Device|NERv's Inline Device attaches to existing catheters or peritoneal drains that are currently being used in the medical industry. This allows the device to measure the pH and conductance of intraperitoneal fluids that typically get drained through peritoneal drains.
46051248|NCT04252872|Drug|HCP0605|
46051249|NCT04252872|Drug|HGP1405|
46051250|NCT04252872|Drug|HCP1401|
46051251|NCT04252482|Device|CPAP|CPAP useg 3month
46051252|NCT00891735|Drug|Ranibizumab|Sterile solution for intravitreal injection.
46051253|NCT04252248|Drug|Dacogen|Intravenous (i.v.) infusion of 20 mg/m2 over 1 hour repeated daily for 5 days starting on day 1. Single repetition of cycle on day 29.
45366051|NCT01025050|Procedure|Intrastromal Correction of Presbyopia|On all patients an intrastromal pattern consisting of concentric rings will be applied.
45366052|NCT02576093|Drug|0.1% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
45366053|NCT02576093|Drug|0.3% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
45366054|NCT02576093|Drug|1.0% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
45483057|NCT02023905|Drug|Temozolomide|Temozolomide will be dosed initially at 150 mg/m2/day for 5 days out of a 28-day cycle. TMZ will be stopped after 12 cycles
45483058|NCT01318980|Drug|GSK2190915 100mg milled tablet|Taken orally
45483059|NCT01318980|Drug|[14C] radiolabelled GSK2190915 solution|Microtracer solution
45483060|NCT01318980|Drug|GSK2190915 100mg milled tablet administered to the proximal small bowel.|Ground half of a 200mg tablet. Administered via Enterion capsule.
45483061|NCT01318980|Drug|GSK2190915 100mg milled tablet administered to the distal small bowel.|Ground half of a 200mg tablet. Administered via Enterion capsule.
45483062|NCT01318980|Drug|GSK2190915 100mg enteric-coated tablet.|Taken orally
45483063|NCT02465086|Other|Training of linguistic recursion|Training of recursion comprehension will include cooperative dialogue and feedback on the sentences and small dialogues. The training conditions will be further divided into marking the change of the truth-value.
45483064|NCT01361412|Biological|ToleroMune Ragweed|Intradermal administration 1x8 administrations, 2 weeks apart
45483065|NCT01361412|Biological|Placebo|Intradermal injection 1x8 administrations, 2 weeks apart
45483066|NCT01330563|Drug|CKD-501, Ketoconazole|Subjects received single 0.5mg doses of CKD-501 alone in one period and, in the other period, Ketoconazole 200 mg twice daily for 5 day with the CKD-501 dose also co-administered with Ketoconazole on day 5.
45483067|NCT05495854|Diagnostic Test|PCR test in the stool|"Patients randomized to the new strategy arm will receive a prescription for an Hp serology and a stool self-collection kit . Only the result of the PCR test in the stool will be considered for this arm. A positive test will determine Hp infection and the indication for treatment."
45483068|NCT05099952|Procedure|Biospecimen Collection|Undergo collection of cheek cell and blood samples
45483069|NCT05099952|Other|Counseling|Meet with therapist
45483070|NCT05099952|Other|Educational Intervention|Participate in BBT-CI sessions
45690769|NCT03590535|Diagnostic Test|4th Gen cTnT|"Current Fourth Generation Cardiac Troponin T Enzyme Assay"
45690770|NCT03590535|Diagnostic Test|5th Gen cTnT|"New Fifth Generation (High-sensitivity) Troponin T Enzyme Assay"
45690771|NCT01824979|Device|CPAP mask ( Pilairo)|
45690772|NCT01824979|Procedure|Other CPAP mask|
45690773|NCT03598803|Other|Survey|Urinary Incontinence Survey
45690774|NCT04195971|Diagnostic Test|Liver CT|Liver CT with precontrast, dual arterial phase, portal venous phase, and delayed phase.
45690775|NCT01824823|Drug|afatinib|Given PO
45690776|NCT01824823|Other|placebo|Given PO
45483071|NCT05099952|Other|Electronic Health Record Review|Medical records are reviewed
45483072|NCT05099952|Other|Medical Device Usage and Evaluation|Wear actigraphy watch
45483073|NCT05099952|Other|Questionnaire Administration|Ancillary studies
45483074|NCT01991379|Drug|MEK162|Patients should take the study drug with a glass of water. MEK162 can be taken with or without food.
45483075|NCT01991379|Drug|Imatinib Mesylate (Gleevec®; STI571; NSC #716051)|
45483076|NCT01991379|Other|Blood draws|
45690777|NCT04196205|Biological|Anti-CD19 CAR-T|1 - 2×10^6 Anti-CD19 CAR-T cells/kg body weigh
46051254|NCT04252326|Other|Survey|Doctors, Nurses and Dentists filled survey about adverse drug reractions
46051255|NCT04833192|Diagnostic Test|experimental group|DHEAS.24h-UFC,ACTH and cortisol are measured in the experimental group
45483077|NCT01991379|Procedure|biopsy|Following informed consent, the first 20 mandatory patients, except for patients who have already been treated with imatinib prior to consent, and subsequent voluntary patients enrolled on the phase II portion of the trial will undergo research biopsies. Patients should hold both imatinib and MEK162 doses on the day they undergo a biopsy.
45483078|NCT03636009|Other|concurrent traction and neuromobilization technique|participant will be on a mechanical traction machine with an on:off cycle. During the on cycle, the primary researcher will be performing a neuromobilization technique on the symptomatic arm. Patients will also receive exercise and manual therapy
45483079|NCT03636009|Other|sequential traction and neuromobilization technique|Participants will receive neuromobilzation techniques followed by supine cervical traction
45690778|NCT03598725|Drug|Coagulation Factor VIII|Domastic plasma derived factor FVIII (with intermidiate vWF) 50IU/kg every other day
45690779|NCT03598725|Drug|Prednisone|2mg/kg every day for 4 weeks then typering in 3 months
45690780|NCT03598725|Drug|Rituximab|375mg/Square meter for consecutive 4 months
45690781|NCT04196127|Other|Bite force testing|Maximum bite force examination with a force intra-oral measuring device
45690782|NCT03598569|Other|dyspnea|dyspnea assessment
45690783|NCT03966261|Other|blood sample|we perform blood sample in healthy subject before and after a meal to measure incretins concentration
45847862|NCT03014700|Biological|Cryoprecipitate|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
46051256|NCT04247763|Other|Saturated Fat Meal|
46051257|NCT04247763|Other|Oleic Sunflower Oil Meal|
45483080|NCT03636009|Other|active exercise program|Participants will have 4-5 exercises to perform at each session
45690784|NCT04766307|Drug|Interleukin-2|Interleukin 2 (IL-2) is a pleiotropic cytokine that is produced after antigen activation and plays crucial roles in the immune response. IL-2 secreted by activated T cells is central to the development of an immune response to infection, promoting the differentiation and proliferation of lymphoid cells. This hydrophobic molecule and the various cytokines that it elicits regulates the behavior of T and B lymphocytes, monocytes/macrophages, natural killer (NK) cells, and neutrophils. IL-2 therapy regimens are expected to limit mycobacterial replication. Early clinical trials with IL-2 demonstrated that IL-2 immunotherapy may be useful in controlling infectious disease.
45690785|NCT03024801|Drug|autologous platelet-rich plasma|The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
45690786|NCT03024801|Drug|normal saline|The patients with knee cartilage injury were randomized to the normal saline group.
46051258|NCT04251858|Procedure|Dental Scaling|The individuals will be treated by a single periodontist and the scaling and root planing procedures will be performed on all teeth as follows: local anesthetic infiltrative type of the areas to be treated, dental and root scaling using Grace 5/6 carbon steel curettes, 11/12, 13/14 and MacCall 13/14, 17/18 curettes, according to their therapeutic indications. Polishing the quadrants treated with abrasive paste; oral hygiene instructions including Bass toothbrushing, dental floss and sometimes inter-dental brush.
46051259|NCT04251858|Other|Oral hygiene instruction|Oral hygiene instructions should be given to all study participants. Guidance on the most appropriate toothbrush, toothpaste and interproximal cleaning method.
45366055|NCT02576093|Drug|Placebo of WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
45366056|NCT03987022|Drug|Ketorolac|Use of non-steroidal anti-inflammatory drug for pain control post operatively
45366057|NCT03987022|Drug|Opioids|Use of narcotic for pain control post operatively
45366058|NCT03987022|Other|Ice Packs|Placement of Ice packs on surgical sites post operatively
45483081|NCT03636009|Other|manual therapy to cervical and thoracic spine|Lateral glides to cervical spine and thoracic manipulations
46051260|NCT00891657|Device|SprayShield™|Anti-adhesion barrier
45366059|NCT03987022|Drug|Tylenol|Use of pain medication post operatively
45366060|NCT03987022|Drug|Motrin|Use of non-steroidal anti-inflammatory drug for pain control post operatively
45483082|NCT02464852|Behavioral|Head movements|Participants will be asked to perform a series of movements of exploration of their maximum neck range of motion, including: flexion, extension, right and left lateral flexion, right and left axial rotation.
45483083|NCT02464852|Behavioral|Activities of daily living (drinking, washing hand and eating)|Patients will be asked to perform a series of activities of daily living (drinking, eating and washing hands).
45483084|NCT02464852|Device|Sheffield Support Snood|
45483085|NCT02464852|Device|sEMG|
46051261|NCT04814082|Device|MicroPort Evolution Medial-Pivot Knee System (Cruciate-substituting)|Medial Pivot Knee System
45483086|NCT05191602|Diagnostic Test|drainge fluid|including bilirubin
45483087|NCT01330641|Procedure|Injection of Subacromial Bursa|Injection of steroid and anesthetic to relieve pain
45690787|NCT03591237|Behavioral|Mindfulness-Based Cognitive Therapy|The patients participate in eight weekly group sessions of two hours each and will be asked to do an additional 45 minutes of daily training at home. The participants will be asked to record their home training to allow assessment of their adherence to the intervention. Generally, the program corresponds to the manualized MBCT program, but with adaptations that take into account the special needs of cancer patients, including shorter sessions, shorter yoga exercises and the omission of the all-day session. The sessions include psychoeducation and formalized mindfulness exercises with focus on the participants' here-and-now experience of their pain.
45366061|NCT03987022|Drug|dilaudid|Use of narcotic for pain control post operatively
45483088|NCT01333761|Device|Cardiox FDS|The Cardiox Shunt Detection system consists of a sensor placed in contact with the outer ear, similar to a finger probe used to detect oxygen levels in blood. Through an intravenous line, ICG (indocyanine green) at a dosage of 10 mg (2 mL of 5 mg/mL ICG solution) per test, is administered into the right or left antecubital fossa. The presence of ICG in the veins within the outer ear are detected, and the results are displayed on a monitor. All patients will also be evaluated with TCD and TEE for the presence of RTLS.
45483089|NCT01333839|Other|exercise training|endurance exercise training: 40 min of exercise at 65% of VO2peak, 3 days/week
45483090|NCT02875080|Drug|OPC-34712|
45483091|NCT01315041|Drug|Capsicum frutescens fruits, homeopathic medicine|5 drops, PO, 3 times a day, during 16 weeks
45366062|NCT02575781|Drug|SAR428926|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
45366063|NCT03789838|Other|Sepsis rapid response team|Patients with suspected sepsis is managed by a sepsis rapid response team in a structured manner.
45366064|NCT01025128|Drug|25 OH vitamin D|oral supplementation of 25 OH vitamin D at dose of 2000 units/d for 3 months then 1000 units/d for 3 months
45366065|NCT04073381|Combination Product|Prehabilitation Program|This is a 4 week prehabilitation program which uses both exercise and nutrition. Exercise will be prescribed at least 6 days a week. Three days a week , for 45 mins, participants will be asked to perform body, leg and arm exercises against light resistance while wearing pneumatic blood flow restriction arm and leg bands. minutes. On the alternate days participants will walk approximately 15 minutes while wearing the leg bands that restrict blood flow. Additionally, a nutrition supplement cocktail will be provided and should be taken every day within 1 hour after completing each exercise session. The 4 Week Nutrition (Sports Drink) Supplement Cocktail: will include whey protein (25 g/day), creatine monohydrate (8 g/day), and L-citrulline (5 g/day). The supplement mixture will be provided in daily packages by the investigators (nutrition supplements are not regulated by the FDA)
45366066|NCT00468910|Drug|acetylsalicylic acid|Given orally
45366067|NCT00468910|Drug|placebo|Given orally
45483092|NCT01315041|Drug|Inert alcoholic solution|5 drops, PO, 3 times a day, during 16 weeks
45483093|NCT01358214|Behavioral|Questionnaire on Quality of Life.|The impact of a disease on patient's Quality of Life has meanwhile gained more influences on the choice of treatment alternatives. The benefit of a method is currently not only defined by the objective outcome but also influenced by the Quality of Life. Two questionnaires with 20 respectively 40 Questions should be filled in by the patients.
45483094|NCT04897503|Drug|Riboflavin|Corneal epithelium removed followed by riboflavin drop administration (riboflavin/dextran -vs- riboflavin/methylcellulose) every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive either the riboflavin/dextran solution or the riboflavin/HPMC solution.
45483095|NCT01333917|Drug|Curcumin C3 tablet|4 grams Curcumin C3 tablet daily x30 days
45690788|NCT04190823|Drug|RC98|Participants will be allocated to one of the following dose groups: 0.003, 0.03, 0.3, 2.5, 5.0, 10.0, 15.0 and 20.0 mg/kg, and receive one treatment of RC98 followed by 28 days of dose limited toxicity (DLT) observation period.
45690789|NCT04195191|Other|ANM|communication intervention
45845867|NCT05132478|Other|Standard Video|The video is approximately 5 minutes in length and portrays a standard conversation between a patient and surgeon during which the surgeon discusses: the diagnosis, prognosis, available treatment options, benefits and harms of the options, and need for decision making. The surgeon speaks for the majority of the simulated visit and discusses total and hemi-thyroidectomy.
46051262|NCT04814082|Device|Stryker Triathlon Tritanium Knee System (Condylar Stabilizing)|Single Radius Design Total Knee System
46051263|NCT04252170|Device|Rehabilitation Therapy, Experimental on the BrightArm Compact device|Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). An Occupational Therapist will assist as needed.
46051264|NCT05238129|Other|No intervention - standard care is assessed|No intervention - standard care is assessed
45366068|NCT00468910|Other|laboratory biomarker analysis|Correlative study
45366069|NCT01025206|Biological|BI-505|Anti-ICAM-1 monoclonal antibody given as a i.v infusion every second week for four weeks,
45366070|NCT01412333|Drug|Interferon beta-1a|
45366071|NCT01412333|Drug|Ocrelizumab-matching placebo|
45366072|NCT01412333|Drug|Ocrelizumab|
45366073|NCT01412333|Drug|Interferon beta-1a-matching placebo|
45366074|NCT02577185|Drug|Botulinum Toxin Type A|
45366075|NCT02577185|Drug|Sodium chloride 9 mg/ml|
45366076|NCT00519285|Drug|Aflibercept|"25 mg/ml solution~6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle"
45366077|NCT00519285|Drug|Placebo (for aflibercept)|"Sterile aqueous buffered solution identical to aflibercept~1-hour IV on Day 1 of each 3-Week cycle"
45366078|NCT00519285|Drug|Docetaxel|"Marketed formulation~75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)"
45366079|NCT00519285|Drug|Prednisone or Prednisolone|"Marketed formulation~5 mg twice daily PO from day 1 continuously"
45847863|NCT03017508|Drug|BHV-0223|35mg of sublingual riluzole before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for 3 hours.
45483096|NCT02463526|Other|Mobilization with Movement (MWM) condition/ Sham condition|The treatment condition consists in the application of a posterolateral glide (MWM) in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. One hand will be placed over the scapula posteriorly while the thenar eminence of the other hand will be placed over the humerus head anterior aspect. A posterior glide will be applied to the humeral head. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. Sham condition will replicate treatment condition except for the hand positioning. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed.
45483097|NCT02463526|Other|Sham condition/ Mobilization with Movement (MWM) condition|The Sham condition consists in the application of a simulated anterior glide in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. The treatment condition will replicate treatment condition except for the hand positioning. The therapist will place one hand over the scapula posteriorly while the thenar eminence of the other hand will be placed over the anterior humerus head. A posterior glide will be applied to the humeral head.
45483098|NCT03129360|Drug|Levetiracetam|Levetiracetam is an atypical anticonvulsant that is frequently used in children and adults due to its superior tolerability, ease of use and excellent safety profile.
45483099|NCT03129360|Drug|Placebo|Prepared in capsules to appear identical to levetiracetam.
45483100|NCT01330875|Other|survey|no intervention. Only questionnaire after lumbar infiltration with steroids - effects on pain reduction
45366080|NCT00464620|Drug|Dasatinib|oral agent, continuous dosing, Cycles = 28 days
45366081|NCT05673317|Other|"Breastfeeding at AU Smartphone Application"|This is a free Apple-Based Smartphone Application the participant can download. In the application, there is information and tips for breastfeeding success and continuation, as well as information on additional resources both online and in the community as a whole.
45366082|NCT05212857|Drug|Leuprolide acetate|Given subcutaneously or as an injection
45366083|NCT05212857|Drug|Goserelin acetate|Given subcutaneously or as an injection
45366084|NCT05212857|Drug|Triptorelin acetate|Given subcutaneously or as an injection
45366085|NCT05212857|Drug|Degarelix acetate|Given subcutaneously or as an injection
45483101|NCT05074524|Device|Repetitive Transcranial Magnetic Stimulation|Active rTMS treatment will be delivered at 10 Hz, 100% resting motor threshold, 2000 pulses delivered in five seconds per train with 10-second intra-train pause, delivered once daily five days per week, Monday through Friday for 10 days (10 total treatments). This protocol is adapted from Shen and colleagues (2016), who did not report any adverse events. Liu and colleagues (2020) also used the same protocol and only reported mild side effects of dizziness, headache, and insomnia, which resolved by the 30-day follow-up. However, it is unclear whether these side effects resolved sooner than the 30-day follow-up.
45483102|NCT05074524|Device|Sham Repetitive Transcranial Magnetic Stimulation|The control group will undergo the same seat positioning and comfort measures but will not have a resting motor threshold determination. The coil will be turned 90 degrees counter-clockwise, and the side of the coil will rest on the scalp over the area of the skull corresponding to the motor cortex, so the participant will feel the coil making contact. The same treatment protocol in the active rTMS group will be initiated to mimic the sound of rTMS treatment, though no pulses will be delivered to the participant because of the coil rotation.
45483103|NCT01315275|Drug|Ranibizumab|
45690790|NCT04195191|Other|Placebo|regular assistance in community pharmacies
45366086|NCT05212857|Drug|Abiraterone acetate|Given orally
45366087|NCT05212857|Drug|Apalutamide|Given orally
45366088|NCT05212857|Drug|Enzalutamide|Given orally
45366089|NCT05212857|Procedure|Local treatment for primary lesion|Radical prostatectomy to remove prostate primary lesion
45366090|NCT05212857|Radiation|Radiotherapy for primary lesion|Radical radiotherapy for primary lesion
45366091|NCT05212857|Radiation|Radiotherapy for metastatic lesion|Stereotactic body radiation therapy or proton and heavy ion radiation therapy is preferred, which could treat all the lesions at once or treat different lesions in stages.
45366092|NCT02099123|Drug|Atorvastatin|Atorvastatin 20 mg tablet
45366093|NCT02099123|Drug|Placebo (for Atorvastatin)|Inactive pill manufactured to mimic Atorvastatin 20 mg tablet
45366094|NCT00464542|Drug|Metronidazole|500 mg, taken by mouth, two times a day, 7 days
45366095|NCT00468676|Behavioral|Nurse-led case management|The case management intervention will entail approximately 10 visits with a trained nurse at the clinic or by telephone. Participants in this group will receive educational materials about how to manage diabetes and/or heart disease and stress or depression. Nurses will also provide guidance and support in managing medications, phone calls to check participants' progress, and assistance in setting personal goals and in managing physical health problems and symptoms of depression or stress.
45366096|NCT00468676|Behavioral|Treatment as usual|Participants will attend 10 study visits and receive 4 follow-up phone calls over 24 months. During this time, participants will receive usual care.
45366097|NCT02578823|Device|Arctic Sun®|Core temperature is maintained to 36℃ for 3 days by using the skin attached pad(Arcticgel™) and targeted temperature management(Arctic Sun®).
45366098|NCT02578823|Device|Arcticgel™|
45366099|NCT02578823|Procedure|Conventional antipyretic treatment|Conventional antipyretic treatment for fever includes using of antipyretics, ice packs, circulating fan, and tepid bathing, etc.
45366100|NCT01969643|Drug|ladiratuzumab vedotin|LV will be given into the vein (IV; intravenously)
45366101|NCT01969643|Drug|Trastuzumab|Trastuzumab will be given by IV every 3 weeks at a dose of 6 mg/kg (the first dose will be 8 mg/kg)
45366102|NCT00464308|Drug|Esomeprazole|20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
45366103|NCT00464308|Drug|Rabeprazole|20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
45366104|NCT00464308|Drug|Esomeprazole|40mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
45366105|NCT03919708|Device|Retinal Birefringence Imager|Device is a hand-help object approximately the size of a brick, and is held, by the user, 30cm away from the patient/subject. The subject peers in to an aperture that includes a fixation target that is in the shape of a smiley face. During this time, a ring of LED lights illuminates the eye and captures an image of the retina in approximately 3 seconds. The results instantaneously identify the presence of amblyopia / strabismus.
45366106|NCT00194285|Procedure|FDG-PET Imaging|
45366107|NCT00468286|Drug|Degarelix|"Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 360 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months."
45366108|NCT00468286|Drug|Degarelix|"Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months."
45366109|NCT00463840|Drug|Oxaliplatin|
45366110|NCT00463840|Drug|5FU|
45366111|NCT00463840|Radiation|Radiation|
45366112|NCT00463840|Procedure|Surgery|
45483104|NCT01358292|Procedure|Semi-extended Surgical Technique|Surgical technique with the knee in 10-20 degrees of flexion, to implant the intramedullary tibia nail.
45366113|NCT00463840|Drug|FOLFOX 6|this is an established regimen of Oxaliplatin+infusional 5FU/Leucovorin
45366114|NCT03995758|Device|MOSES|software based modulation of the laser energy delivered from the homium laser source. The software changes the pulsed laser to have two peaks of energy - one to displace water in front of the stone and a second to deliver the laser energy to the stone
45483105|NCT01358292|Procedure|Standard Surgical Technique|Th e Standard surgical techique is implanting the tibia nail with the knee in 90 degrees of flexion.
45483106|NCT02463136|Behavioral|questionnaires|Clinical questionnaires and behavioural computer-based paradigms, such as the Overlap task (Cohen Kadosh et al., 2014)
45366115|NCT00129389|Drug|Fluorouracil|Arm A: FAC Arm B: FAC-wP
45366116|NCT00129389|Drug|Doxorubicin|Arm A: FAC Arm B: FAC-wP
45366117|NCT00129389|Drug|Cyclophosphamide|Arm A: FAC Arm B: FAC-wP
45366118|NCT00129389|Drug|Paclitaxel|Arm B: FAC-wP
45366119|NCT01025362|Behavioral|Lactation counseling|The Baby-Friendly Community Health Service intervention to improve quality of lactation counseling.
45845868|NCT05119764|Procedure|Manual Lymphatic Drainage|"Manual Lymphatic Drainage is a form of physical therapy with the primary goal of accelerating lymphatic drainage.~In this study, the manual lymphatic drainage is applied by experienced physical therapists 5 days in a row for 30 minutes each; after and/or before the surgery."
45366120|NCT01025362|Behavioral|Standard care|Child Health Services offered standard care
45366121|NCT01025440|Device|Continuous Positive Airway Pressure|"Continuous Positive Airway Pressure (CPAP) Dose: A flow (35 L/min) or pressure (btw 4 and 20 cmH20 -individual to each subject) is set on the device.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)~Duration:"
45366122|NCT00468052|Drug|dexmedetomidine|2 micrograms/kilogram as a bolus then 0.7 micrograms/kilogram infusion
45366123|NCT00468052|Drug|fentanyl|1 microgram/kilogram as a bolus
45366124|NCT04712981|Other|Behavioral Intervention|Peer leaders/role models will be trained in HOPE intervention fundamentals and assigned to online community groups with participants.
45483107|NCT02463136|Device|Functional magnetic resonance imaging w neurofeedback|"The general framework of the scanning part of this experiment consists of a localiser task (lasting approximately 8 minutes), 4 neurofeedback runs (each lasting approximately 5 minutes) and an anatomical scan (approximately 10 minutes).~Immediately prior and following the scanning session, participants will also be asked to completed several), as well as an attentional control task with emotional stimuli, such as a behavioural version of the Overlap task (Cohen Kadosh et al., 2014)."
45483108|NCT01361646|Drug|LC350189|Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg
45366125|NCT00453310|Drug|sunitinib malate|
45483109|NCT02462902|Drug|5% albumin Infusion|colloid, 5% albumin (250 ml over 15 to 30 minutes).
45483110|NCT02462902|Drug|0.9% sodium chloride solution|0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minutes)
45483111|NCT03165045|Drug|Spiolto® Respimat®|6 weeks
45690791|NCT01875367|Drug|Trastuzumab Injectable Solution|Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.
45845869|NCT05117970|Other|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
45847864|NCT03017508|Drug|Placebo|a sublingual tablet identical to the active drug will be given before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for three hours.
45847865|NCT03020004|Drug|Danoprevir|Danoprevir (DNV) 100mg tablet administered orally twice daily
45690792|NCT01875367|Drug|Trastuzumab Injectable Product|Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles
45690793|NCT01875367|Drug|Trastuzumab Injection|Powder for concentrate for solution for infusion. 1 cycle
45847866|NCT03020004|Drug|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
45847867|NCT03020004|Drug|peginterferon alfa-2a|PegIFN subcutaneous injection at 180 mcg weekly
45847868|NCT03020004|Drug|Ribavirin (RBV)|Ribavirin (RBV)1000/1200 mg/day (bodyweight<75/≥75 kg)
45847869|NCT03020082|Drug|Danoprevir|Danoprevir (DNV)administered orally 100mg BID for 12 weeks;
45847870|NCT03020082|Drug|Ritonavir|Ritonavir administered orally 100mg BID for 12 weeks;
45366126|NCT04071743|Device|gammaCore Sapphire|non-invasive vagus nerve stimulator
45366127|NCT04071743|Device|sham gammaCore Sapphire|sham gammaCore Sapphire
45366128|NCT02578667|Device|Gorbly Compression Device|The compression device provides a way to displace critical structures along the path from skin to target, retract excess body wall tissue, and provide mechanical stabilization in a repeatable and sustainable fashion.
45366129|NCT00128843|Drug|Exemestane|25mg/day until progression disease
45366130|NCT00128843|Drug|Anastrozole|1mg/day until progression disease
45366131|NCT02575703|Drug|[¹⁴C]-LY3023414|LY3023414 in solution containing approximately 100 microCi [¹⁴C]-LY3023414
45366132|NCT04609553|Behavioral|Usual care including ROR|Usual care which includes ROR.
45366133|NCT04609553|Behavioral|Text messages|3 text messages per week and one interactive text per month.
45366134|NCT04609553|Behavioral|Connection to community resources|Referral to a non-profit that connects families with community resources and provides families with case management.
45366135|NCT04071431|Other|Result masking|"The quality control system randomly shows the RFQ result to the endoscopists and keep 50% of the RFQ results are not known (deliberately showing N/A) by the endoscopists before and during the endoscopy."
45845870|NCT05103540|Behavioral|Comprehensive SEM-Based Program|The SEM theorizes that there are multiple inter-related levels of influences on human behavior, and a successful preventive program should address factors at each stratum. My intervention addresses three levels; individual, interpersonal, and social. Firstly, the research will collaborate with relevant stakeholders to design and obtain a commitment from the schools to a suicidal behavior prevention policy and protocol document. Secondly, the intervention will train staff and students on best practices to improve students' connectedness thereby, creating a positive school environment. Thirdly, the study will identify and train gatekeepers on the proper response to suicidal thoughts and other suicidal behaviors; and serve as the link between the students and a school-linked mental health specialist. We will train the gatekeepers to use school-based screening tools. Lastly, this research will educate all students on suicidal behaviors.
45483112|NCT02462746|Dietary Supplement|L-Cysteine|The trade name is New Root Herbal Inc.
45690794|NCT04194879|Diagnostic Test|multi-target FIT-DNA analysis|ColoClear® is intended for use as an adjunctive screening test for the detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It has the potential of increasing the sensitivity of detecting CRC as compared to FOBT or faecal immunochemical test (FIT), which detects the presence of hemoglobin in stool alone. A positive result may indicate the presence of colorectal cancer or pre-malignant colorectal neoplasia. ColoClear® is not intended as a replacement for diagnostic colonoscopy. A positive result in ColoClear®, as with any screening test, should be followed by colonoscopy. ColoClear® is intended for colorectal cancer screening in average risk individuals: adults of either sex, 40 years or older, who are at high risk for colorectal cancer.
45690795|NCT04197999|Drug|GMI-1359|Injection 10 mg/mL
45845871|NCT05101044|Behavioral|Acceptance-based Behavioral Therapy (ABBT) Intervention|This acceptance-based behavioral therapy (ABBT) intervention intends to enhance retention in HIV care for people who use substances by targeting stigma. ABBT promotes an accepting stance towards life's challenges and encourages participants to thoughtfully disclose the serostatus and/or substance abuse problems as a behavioral step towards challenging stigmatization fears. The central hypothesis is that increased tolerance of stigmatization, facilitated through increased acceptance of HIV status and substance use behaviors, will increase PWH's longitudinal commitment to care.
45845872|NCT05091372|Drug|Belantamab mafodotin|"Belantamab Mafodotin~Belantamab mafodotin dose levels:~Dose level -2 = 1.4 mg/kg IV every 12 weeks Dose level -1 = 1.9 mg/kg IV every 12 weeks Dose level 0 = 1.9 mg/kg IV every 8 weeks~Cycles 1 - 6:~All patients will start at dose level 0.~Cycles 7 and onwards*:~Patients previously on dose level 0 (1.9 mg/kg IV every 8 weeks) will change to dose level -1 (1.9 mg/kg IV every 12 weeks) Patients previously on dose level -1 (1.9 mg/kg IV every 12 weeks) will continue at the same dose level.~Patients previously on dose level -2 (1.4 mg/kg IV every 12 weeks) will continue at the same dose level.~*Reduction to a lower dose level is allowed in case of development of adverse effects or poor tolerance as determined by the treating physician."
45366136|NCT04073927|Dietary Supplement|Sodium butyrate|"Sodium butyrate Class: Fatty acids Ingredients (100 g): Na-butyrate (50 g), acylglycerol (mono- di, -triacylglycerol; 42 g), bee wax (5 g), sodium alginate E401 (2 g), emulsifier (0.5 g).~The capsules contain granulated sodium butyrate and are coated with a sodium alginate membrane."
45366137|NCT00124657|Drug|Erlotinib hydrochloride|This study has 2 components: a Phase I component which estimated the MTD and DLT(s) of erlotinib given once a day during and after conventionally fractionated RT for a period of 8 weeks (DLT-evaluation period), followed by continuous administration of this medication for up to 3 years; and a Phase II component where erlotinib will be given at the MTD during and after RT for 2 years. The recommended dose of erlotinib for the Phase II component of the current study is 120mg/m2 per day (maximum dose of 200mg per day).
45366138|NCT00581945|Drug|Canakinumab|The dose of canakinumab (ACZ885) administered was individualized, based on the subject's weight pre-dose, and was administered via intravenous infusion.
45366139|NCT00581945|Drug|Placebo|Matching placebo to ACZ885 administered via intravenous infusion.
45690796|NCT04191057|Device|Free light chains|Blood samples will be collected and analyzed
45690797|NCT04195659|Procedure|Mastectomy and chest masculinization|A surgical procedure in which the breasts are removed and the chest is given a masculine contour.
45690798|NCT03598335|Device|Ultrasound|Ultrasound imaging of women arriving at clinic for routine care
45483113|NCT02463058|Other|exercise under hot and humid conditions protocol|"acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously~experiment days (3 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (30 deg. centigrade & 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously."
45483114|NCT01361724|Behavioral|Physical therapy|Physical therapy program for people with PD--one on one with a PT
45483115|NCT01361724|Behavioral|Group Exercise Class|The participant will be in an exercise class for 3 days a week for 4 weeks.
45366140|NCT02578589|Procedure|Plica resection vs conservative treatment|Plica resection vs conservative treatment
45483116|NCT01361724|Behavioral|Home Program|The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
45483117|NCT03296956|Dietary Supplement|Motherwell|The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in day-5 postpartum women.
45483118|NCT03296956|Other|Placebo|Matching placebo for appearance, taste
46051265|NCT02831127|Other|short message service group|Each month after stent implantation, the investigator sent a text message by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date to come back to the hospital for stent management. Patients were requested to respond by SMS and were encouraged to contact the investigator if they had any questions about stent management. Besides, patients received conventional reminder:After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
45366141|NCT01079845|Behavioral|Nutrition Education, Dietary Counseling, and Cooking|Monthly clinic visits with a dietitian, Monthly telephone calls with a dietitian, Three cooking workshops with a chef
45366142|NCT02578277|Drug|CYP and transporter probe substrates|Cocktail of CYP (cytochrome P450) and transporter probe substrates
45483119|NCT01358448|Behavioral|growth monitoring|Caretakers will be encouraged to monitor child growth monthly.
45483120|NCT01358448|Behavioral|Growth Monitoring plus Family-based Behavioral Counseling|Caretakers will monitor growth monthly in addition participating in family-based behavioral counseling
45483121|NCT02462668|Procedure|Bag-mask ventilation|The control group receives preoxygenation with bag-mask ventilation
45483122|NCT02462668|Procedure|Noninvasive positive pressure ventilation(NIPPV)|The NIPPV group receives noninvasive positive pressure ventilation during fibreoptic bronchoscopy assisted intubation
45483123|NCT02462668|Procedure|fibreoptic bronchoscopy assisted intubation|All patients will receive fibreoptic bronchoscopy assisted intubation.
45690799|NCT04194957|Drug|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients that are found to be wild type and have a pre-treatment uracil concentration above 16 ng/mL will receive a reduced dosage of capecitabine or 5-fluorouracil (50% reduction). The dose will be titrated after 2 cycles , to achieve maximal safe exposure. Patients that are wildtype with a uracil concentration below 16 ng/mL will receive a normal (full) dose.
45690800|NCT04194957|Drug|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients that are heterozygous carriers of c.1236G>A or c.2846A>T DPYD variant will receive a reduced dosage of capecitabine or 5-FU (50 % reduction). The dose will be titrated after 2 cycles, to achieve maximal safe exposure.
45690801|NCT04194957|Drug|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients with homozygous or compound heterozygous DPYD variants will be treated with a reduced dose of capecitabine or 5-FU based on the DPD enzyme activity measured in peripheral blood mononuclear cells.
45690802|NCT04194645|Drug|BI 474121|Single dose
45690803|NCT04194645|Drug|Placebo|Single dose
45690804|NCT03023943|Other|Instrument Assisted Soft Tissue Mobilization|Intervention will be 10 minutes of GT1 instrument application at anterior thigh using sweep technique.
45366143|NCT02578277|Drug|BMS-955176|BMS-955176
45366144|NCT02578277|Drug|BMS-955176 plus CYP and transporter probe substrates|BMS-955176 plus the cocktail of CYP and transporter probe substrates
45366145|NCT04071197|Device|Gastostomy-biliary tube|gastrostomy followed by ERCP with nasobiliary stent placement in the CBD with its distal end been exit from the previously performed gastrostomy instead of the nostril
45366146|NCT04071197|Device|External biliary diversion, internal biliary diversion and nasobiliary tube|All biliary diversion modalities other than gastrobiliary tube
45366147|NCT00555906|Drug|Bortezomib|Escalating doses of bortezomib will be administered intravenously on Days 8, 11, 15 and 18 of a 28-day cycle (Schedule A) or of a 21-day cycle (Schedule B). The planned doses to be evaluated are 0.7, 1 and 1.3 mg/m2 in combination with PD 0332991 and dexamethasone.
45366148|NCT00555906|Drug|Dexamethasone|20 mg, orally on Days 8, 11, 15 and 18 of a 28 day cycle (Schedule A) or of a 21-day cycle (Schedule B) in combination with PD 0332991 and bortezomib.
45690805|NCT03024021|Device|Near-infrared spectroscopy (NIRS) (INVOS®, Covidien)|As we start the targeted temperature management protocol (24 hours of hypothermia adjusted to 33-36 C and afterwards up to five days of normothermia [36.5 C]) NIRS sensor pads will be placed over the right and left frontal area. Regional cerebral oxygen values will be continuously recorded at the NIRS monitor. Tests to assess neurological outcome will be performed. Patients will be assessed in terms of neurological performance tests and regional cerebral oxygen.
45483124|NCT01333995|Behavioral|Peer counseling on infant feeding|Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
45483125|NCT03620136|Drug|locoregional analgesia by a block on the adductor channel|"The block at the adductor channel will be realized under echo guidance, before the spinal anesthesia, by puncture at the upper 1/3 of the thigh. It will be used echogenic needle adapted to the morphotype of each patient, of varying length from 50mm to 100mm. A single injection of 20mL of ROPIVACAINE 2mg / ml, the efficacy of which should be checked before spinal anesthesia is performed by a cold test.~Knee analgesia will be supplemented by per-operative infiltration of 50mL of ROPIVACAINE 2mg / ml at the posterior capsule, once the surfaces joints prepared to accommodate the prosthesis and by two placebo infiltrations of 50mL each of physiological saline in the medial and lateral ligaments and in the edges of the incision."
45483126|NCT03620136|Drug|locoregional analgesia by periarticular local infiltrations|"A placebo injection to the adductor channel of 20 mL of physiological serum will be performed in the pre-induction room before surgery, according to the same procedures as the patients of the ACB group.~During the surgical procedure, patients in the ILA group will receive a total dose of 300mg of ROPIVACAINE 2mg / ml in the form of 3 periarticular injections. The first injection of 50mL of ROPIVACAINE 2mg / ml will be made once the articular surfaces are prepared to receive the prosthesis, at the level of the posterior capsule. The second injection of 50mL of ROPIVACAINE 2mg / ml will be performed once the total knee prosthesis is installed, in the medial and lateral ligaments. Finally, the last injection will also include 50mL of ROPIVACAINE 2mg / ml and will be made in the edges of the incision at the time of closure."
45483127|NCT02462824|Behavioral|Home-based exercise intervention|The home-based exercise intervention focuses on walking exercise and consists of two phases. Phase I (weeks 1-4) consists of four on-site visits to an exercise facility, where participants will meet the telephone coach, learn to use the Fitbit activity monitor, become familiar with the study website, learn behavioral skills necessary for long-term adherence to home-based exercise, and get started on their exercise program. Phase II (weeks 5-36) is entirely home-based and includes a) use of the Fitbit for self-monitoring; and b) regularly scheduled telephone calls from the study telephone coach to monitor and support participants' home exercise activity' c) use of the study website; d) optional group telephone calls.
45483128|NCT01319448|Drug|Proguanil|Proguanil tablets, 1.5mg/kg/day
45483129|NCT01319448|Drug|mefloquine plus artesunate|This treatment is given once a day for 3 days. Patients weighing 5-8 kg receive one paediatric tablet per day, those weighing 9-17 kg two paediatric tablets, those weighing 18-29 kg one adult tablet and those weighing 30 kg and two adult tablets.
45483130|NCT01319448|Drug|Sulfadoxine-pyrimethamine plus amodiaquine|amodiaquine plus sulfadoxine-pyrimethamine supervised at each bimonthly clinic visit (amodiaquine 10mg/kg per day for three days and sulfadoxine-pyrimethamine (25/1.25 mg/kg) on the first day).
45690806|NCT03598101|Device|TONEFITreha|The newly developed Tonefit Reha is based on the existing fitness device, the TONEFIT belt. Similar to Nordic Walking, the device aims to include upper limb activity in walking exercise to train the shoulder girdle and arm. While Nordic Walking uses poles, the existing TONEFIT belt uses body-worn resistance handles to actively involve the upper body. It is worn around the waist, like a belt. The two independent pull-push elements with non-adjustable resistance on each side allow increased intensity for strengthening and endurance training during walking, particular for upper extremities and trunk stability.
45690807|NCT04194567|Other|Black Ragi|Pancakes made out of the dark ragi
45690808|NCT04194567|Other|White Ragi|Pancakes made out of the white ragi
45690809|NCT04177797|Drug|Toripalimab|Two cycles of Toripalimab(240 mg administered as an intravenous infusion over 30 minutes per 3 weeks), concurrently paclitaxel(135 mg/m2) and carboplatin(AUC 5) administered as an intravenous infusion per 3 weeks.
45690810|NCT04194255|Dietary Supplement|ferrous fumarate|iron (100 mg) supplement in form of ferrous fumarate
45690811|NCT04194255|Dietary Supplement|ferrous fumarate + 15 g GOS|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
45690812|NCT04194255|Dietary Supplement|ferrous fumarate + 15 g FOS|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g FOS)
45690813|NCT04194255|Dietary Supplement|labelled iron as ferrous fumarate + 15 g acacia gum|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g acacia gum)
45690814|NCT03598023|Device|Cytal® Burn Matrix|Cytal® Burn Matrix
45690815|NCT03598023|Device|EZ-Derm® Porcine Xenograft|EZ-Derm® Porcine Xenograft
45690816|NCT03983577|Other|Point of service delivery model|Participants will receive the pre-test survey, followed by the combined provider/telehealth genetic counseling education video for genetic testing. Afterwards, the participants will receive a post-test and patient satisfaction survey.
45690817|NCT04406883|Drug|Extraction + filled with Simvastatin solution impregnated gelatin sponge|All two first premolars were extracted carefully, have used periotome as a means of atraumatic extraction that facilitated the removal of teeth with minimum damage to the surrounding alveolar bone, teeth to be extracted should have minimum periapical changes radiographically; with decreasing soft tissue reflection; the socket was tan gently irrigated with normal saline and hemostasis was achieved. It must be noted that A group (Extraction + filled with Simvastatin (Poursina Pharmaceutical Co. Tehran-Iran) solution impregnated gelatin sponge (Maquira Industry Dental Products S.A. Brazil) and B group (Extraction + without Simvastatin solution impregnated gelatin sponge), was placed in one of the sockets.
45847871|NCT03020082|Drug|peginterferon alfa-2a|PEG-IFN abdominal or thigh subcutaneous injection, 180μg, once a week for 12 weeks;
45483131|NCT04410237|Device|Med-Jet|"One half of each psoriasis plaque will be treated with a Med-Jet device and Triamcinolone acetonide (TAC) while the control half will be untreated.~One side of the body will be treated using a conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score"
45483132|NCT04410237|Other|Traditional Syringe|"One half of each psoriasis plaque will be treated with a traditional syringe and Triamcinolone acetonide (TAC) while the control half will be untreated.~One side of the body will be treated using conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score"
45483133|NCT01319526|Genetic|DNA analysis|
45483134|NCT01319526|Genetic|RNA analysis|
45483135|NCT01319526|Other|laboratory biomarker analysis|
45690818|NCT04199949|Behavioral|Inactivity|On days 1 and 6 of each main trial, the participants will be asked to attend the laboratory after an overnight fast of at least 8 to 12h to undergo brachial and popliteal arteries FMD measurements (30 min apart) using duplex-Doppler ultrasound, followed by assessment of the hand grip strength of their non-dominant hand using a hand dynamometer.
45690819|NCT04194177|Other|mechanical ventilation during robotic surgery|protective ventilation PEEP= 6 cmh2o TV= 6 ml/kg conventional PEEP=2 cmH2O and TV=9 ml/kg
45845873|NCT05091372|Drug|Lenalidomide|"Lenalidomide dose levels:~Dose level 0 (starting dose): Lenalidomide 10 mg/day PO continuously. Dose level -1: Lenalidomide 10 mg/day PO. One week off after every three weeks of treatment.~Dose level -2: Lenalidomide 5 mg/day PO. One week off after every three weeks of treatment."
46051266|NCT02831127|Other|conventional group|After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
46051267|NCT04251624|Behavioral|Goal Management Therapy|A cognitive training program aimed at improving cognitive deficits such as in memory, attention, learning, and executive functioning.
46051268|NCT04251624|Behavioral|Psychosocial Education|A group therapy program focusing on brain function, neuroplasticity, and lifestyle interventions.
46051269|NCT02828397|Drug|REGN2222|
45366149|NCT00555906|Drug|PD 0332991|Escalating doses of PD 0332991 will be administered orally on Days 1-21 of a 28-day cycle for Schedule A and on Days 1-12 of a 21-day cycle for Schedule B. The planned doses to be evaluated are 50, 75, 100 mg and 125 mg once daily in combination with bortezomib and dexamethasone.
45366150|NCT03817879|Procedure|VivaSight double-lumen tube for single-lung ventilation|Procedure using a tube with a camera
45690820|NCT04199559|Drug|Autologous dendritic cells pulsed with antigen|peptide(WT1-H/K-HELP, Survivin-H/K-HELP,MAGE-A4-H ⁄ K-HELP and MUC1-22) . Each dose contains of 10 million activated autologous DCs. Route of Administration: Intradermal
45845874|NCT05071872|Device|Atherectomy/Thrombectomy|Percutaneous transluminal removal of thrombotic occlusion in arteriovenous graft
46051270|NCT04251780|Procedure|Surgical Treatment of Hyperaldosteronism|Surgery of an Aldosterone-producing adenoma
46051271|NCT04251780|Drug|Drug treatment of Hyperaldosteronism|Treatment of Hyperaldosteronism with Spironolactone or Eplerenone.
46051272|NCT04251936|Behavioral|Exercise training|The moderate-intense aerobic exercise training will involve supervised aerobicycle ergometer training for 30 min with 60-80% HRmax three times per week for 12 weeks.
45366151|NCT03817879|Procedure|Conventional double-lument tube for single-lung ventilation|Procedure using a tube without a camera
45366152|NCT04071353|Drug|Interferon|Interferon combined with ribavirin antiviral therapy
45366153|NCT04071353|Drug|ribavirin|Interferon combined with ribavirin antiviral therapy
46051273|NCT04251936|Behavioral|Smoking cessation group program|Participants of both groups will receive a 6-week standard cognitive behavioral therapy-oriented smoking cessation group program (SCP, one 60 min session per week).
46051274|NCT05237505|Device|Bi-Level Positive Airway Pressure|6 months of Bi-Level positive airway pressure therapy starting at 8cmH2O inspiratory pressure/4 cmH2O expiratory pressure titrated until subject until the subject reaches a minimum, stable breathing pattern and blood oxygen saturation of 88%. If stability in blood oxygen content is not met using these parameters, supplemental oxygen may be added.
45366154|NCT04071353|Drug|DAAs|DAAs antiviral treatment
45366155|NCT03968497|Other|Postoperative pain assessment with female investigator|Postoperative pain evaluation by a female investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
45483136|NCT03296878|Other|Own-Price Elasticity|The price of eggs will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
45483137|NCT03296878|Other|Cross-Price Elasticity|The price of eggs will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
45845875|NCT05035602|Other|Physical activity assessment|Physical activity patterns will be obtained from google location history, using an Android phone
45845876|NCT05034978|Other|no intervention|evaluating the performance of a novel point-of-care test
46051275|NCT05237505|Drug|Oxygen gas|6 Months of Oxygen starting a minimum flow of 2 litres per minute, titrated up until the subject reaches a minimum, stable blood oxygen saturation of 88%
45366156|NCT03968497|Other|Postoperative pain assessment with male investigator|Postoperative pain evaluation by a male investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
45366157|NCT01078129|Behavioral|cognitive remediation therapy|program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions)by means REHACOM® software
45366158|NCT01078129|Behavioral|non-CRT|waiting list
45366159|NCT04071899|Other|Scale vaidation|It's just filling a scale in order to validate it in French
45366160|NCT01078285|Behavioral|No Patient Counseling|Patients do not receive any adherence counseling, or other patient support services
45366161|NCT01078285|Behavioral|Adherence Counseling|Patients receive 3-5 minutes of adherence counseling, and other patient support services
45366162|NCT02576561|Biological|TVGV-1|Antigen + Adjuvant
45366163|NCT02576561|Biological|GPI-0100|Adjuvant Alone
45366164|NCT02576561|Biological|Placebo|Placebo
45690821|NCT04199325|Dietary Supplement|Probiotics|Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.
45690822|NCT04199325|Drug|uric-acid-lowering drug|Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.
45845877|NCT05034432|Procedure|Intra-Op Prophylactic VT ablation|For surgical intra-operative ablation, efforts will be made to identify scarred myocardium based on methods such as cardiac magnetic resonance imaging, nuclear scans, and/or echocardiogram. Electrophysiological mapping may be obtained either pre-surgery or intra-operation. Mapping and ablation will be performed with the currently approved and updated mapping and ablation systems available at each center. Voltage mapping of the ventricle(s) to delineate scars will be carried out through electroanatomic mapping
45690823|NCT03952299|Drug|Oxybutynin Transdermal Patch|Transdermal patch of oxybutynin will be used instead of oral oxybutynin.
45690824|NCT03952299|Drug|Oral Oxybutynin|Oral administration of oxybutynin (5mg) every 8 hours in the hospital.
45845878|NCT05034432|Other|Conventional Management|To ensure uniformity in control arm, a standardized AAD regimen is recommended among subjects randomized to the medical management control arm. Subjects who are already on a stable AAD regimen, such as amiodarone, sotalol or dofetilide, these should be continued
45845879|NCT05027646|Drug|Sancuso - Part 1|Part 1 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
45845880|NCT05027646|Drug|Sancuso - Part 2|Part 2 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
46051276|NCT05137353|Behavioral|Music Training (RitMoZ Training)|This training is inspired by intervention concepts followed in SUVAG Polyclinic in Zagreb, Croatia and Kodaly pedagogy in Hungary. RitMoZ Training programme consists of 6 main activities: matching activity, nursery rhymes, rhythmic stimulations, music shapes, music writing and music reading. The training focuses on the perceptual overlap between language and music, embodiment and entrainment. The aim of the training is to improve characteristic features of reading disorders such as phonological awareness, perception of rhythm, phonological working memory and perception of speech sounds.
45845881|NCT05006976|Other|NSAC health only|"NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health only, clinicians are provided survey information on potential health problems only."
46051277|NCT05137353|Behavioral|Spelling Training|This training consists of activities which focus on practicing spelling words in a computer task; the aim is to train orthographic processing which is suggested to improve phonological awareness and phonological working memory.
46051278|NCT04251468|Device|GEPII|Saliva probes (K+Sa) will be measured using genetically encoded potassium ion indicators (GEPIIs)
46051279|NCT04251468|Device|Ion-selective electrodes|Plasma potassium levels (K+Pl) will be measured using standard ion-selective electrodes.
45366165|NCT04071275|Device|transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive technique that allow the administration of low currents directly to the scalp. The currents affect the cortex, and result in changes to the membrane potential of neurons in the stimulated area. This in turn affects the tendency of those neurons to generate action potentials.
45366166|NCT04071275|Other|Mirror therapy|Mirror therapy is a behavioral technique that proven useful for the treatment of phantom pain, yet the analgesic effects are unfortunately moderate and not long lasting. The assumed underlying mechanism of mirror therapy treatment is the induction of neuronal plasticity in the opposite direction than the abnormal reorganization of the cortex (due to the amputation), and by that relive pain.
45366167|NCT00709475|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
45366168|NCT04071041|Drug|Albumin Human|Administration of albumin 20%, 20g in 100ml (Albutein Instituto Grifols, S.A. Can Guasch 2, Parets del Vallès, 08015 Barcelona, Spain) intravenously every 12 hours for 4 days or until death, discharge or clinical stability if occurring before.
45366169|NCT02575625|Device|Fibroscan|Three series oh independent measures Measure done with Fibroscan will be preceded by tracking ultrasonography.
45366170|NCT02575625|Biological|Blood test for biological assessment of liver function|Blood test for biological assessment of liver function
45366171|NCT02575625|Device|MRI|Liver MRI
45483138|NCT04385121|Other|Questionnary|Family member's will answer the questionnaires by phone
45690825|NCT03597867|Other|Placebo|Artificial tears for 3 days preoperatively
45690826|NCT03597867|Drug|Dicloftil|Dosing of drug 3 days prior to surgery
45690827|NCT03597867|Drug|Nevanac|Dosing of drug 3 days prior to surgery
45690828|NCT03597867|Drug|Indom|Dosing of drug 3 days prior to surgery
45690829|NCT03597867|Drug|Yellox|Dosing of drug 3 days prior to surgery
45483139|NCT01365780|Procedure|Hyperbaric Oxygen Therapy|The patients receive 10 sessions of HBOT in two weeks, starting on the day after the surgical treatment of their radius fracture. Each session lasts about one hour.
45690830|NCT03597555|Drug|Sodium Oxybate Oral Solution 500 MG/ML|"First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal"
45366172|NCT00555672|Drug|5-fluorouracil|5- fluorouracil is given as 4000 mg/m^2 total dose over 96 hr continuous infusion of a 21 day chemotherapy cycle. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
45483140|NCT03949660|Device|Stimulation for blood pressure without stand|Consists of 80 daily training sessions using epidural stimulation optimized for blood pressure for up to 6 hours of stimulation a day.
45483141|NCT03949660|Device|Stimulation for blood pressure with stand|Consists of 80 daily sessions similar to the 1st intervention (without stand) plus 2 hours of epidural stimulation optimized for stand training.
45690831|NCT03597555|Drug|Placebos|Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
45366173|NCT00555672|Drug|cisplatin|Cisplatin is given 80 mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
45366174|NCT00555672|Drug|sunitinib malate|sunitinib is given orally 37.5mg /day for 14 days followed by 7 days of drug free period. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
45366175|NCT02575547|Drug|cisplatin and docetaxel|"NC：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two courses.~CCRT: intensity modulation radiation therapy(IMRT) and cisplatin (100mg/m2 on day 1) every three weeks for three\three cycles during radiation therapy(RT).~Dietary supplement: enteral nutrition and parenteral nutrition"
45366176|NCT01037387|Drug|Control|Current treatment according to the ATS/ERS guidelines
45366177|NCT01037387|Device|NIMV group|Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).
45366178|NCT02574533|Biological|Vigil|Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens)
45366179|NCT02574533|Drug|Pembrolizumab|Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter
45690832|NCT03597477|Drug|Dexmedetomidine|participants were randomly allocated to receive sedation with oral midazolam(0.3 mg/kg) combined with 4 doses of intranasal dexmedetomidine(1.0, 1.5, 2.0, 2.5)
45690833|NCT04199715|Biological|Heplisav-B|This is an FDA-approved vaccine for Hepatitis B that is made by Dynavax Technologies.
45690834|NCT04193319|Drug|Fluzoparib|PARP inhibitor
45690835|NCT04193319|Drug|Fluconazole|inhibitor
45690836|NCT03962985|Other|Guided tour at the Montreal Museum of Fine Arts|"The duration of the participation -3 months~The duration of the guided tour-45 minutes, each week~All participants will be asked to fill out some specific online questionnaires during their participations in the study"
45690837|NCT04192851|Procedure|Tent Pole Technique|"All patients were operated under local or general anaesthesia according to the case and patient tolerability.~The oral cavity was prepared by 0.12% chlorhexidine mouthrinses solution* for thirty seconds.~Full thickness incision down to the bone with blade no.15.~A periosteal elevator was used to perform mucoperiosteal flap.~Gentle elevation of the flap~Fixation of the screws over the alveolar ridge with about 5 mm of the screw threads will be exposed~Bone graft was mixed with the patient blood and placed to cover the screws completely.~PRF membrane was be placed over the grafted sites.~Repositioning of the flap and suturing with 3/0 black silk suture material"
45690838|NCT03957135|Procedure|Laparoscopic distal pancreatectomy|Laparoscopic resection of the diseased portion of the pancreas for treatment of pancreatic cancer
45366180|NCT04652375|Other|Albumin Solution|Participants will receive Albumin solution for fluid resuscitation post-surgery.
45366181|NCT04652375|Other|Lactated Ringer's Solution|Participants will receive Lactated Ringer's solution for fluid resuscitation post-surgery.
45366182|NCT00709553|Drug|midazolam|
45366183|NCT00709553|Drug|ZD4054|ZD4054 10 mg od
45366184|NCT02575391|Dietary Supplement|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
45366185|NCT03958656|Drug|Cyclophosphamide|300 mg/m^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
45690839|NCT03957135|Procedure|open distal pancreatectomy|Open resection of the diseased portion of the pancreas for treatment of pancreatic cancer
45366186|NCT03958656|Drug|Fludarabine|30 mg/m^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
45366187|NCT03958656|Drug|Rimiducid|0.4 mg/kg of Rimiducid intravenous (IV) over 2 hours. (A maximum of 2 doses separated by at least 48 hours) Note: Rimiducid may be administered as needed based on the patient condition at the discretion of the Principal Investigator.
45483142|NCT03949660|Device|Stimulation for trunk and core without stand|Consists of 80 daily training sessions using epidural stimulation optimized for trunk/core/voluntary function for up to 6 hours of stimulation a day.
45483143|NCT03949660|Device|Stimulation for trunk or core with stand|Consists of 80 daily sessions similar to the 1st intervention (without stand) plus 2 hours of epidural stimulation optimized for stand training.
45483144|NCT04360551|Drug|Telmisartan 40mg|Angiotensin Receptor Blocker (ARB)
45483145|NCT04360551|Drug|Placebo|Placebo once daily
45483146|NCT01319604|Device|SENSIMED Triggerfish|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
45483147|NCT01319604|Device|Tonometer|Tonometric assessment of IOP
45690840|NCT03956979|Drug|JM-010 group A|JM-010 fixed combination drug (Group A) + Placebo 2
45483148|NCT02462434|Behavioral|Early palliative care team consultation|The palliative care team will evaluate the patient and family with the following core palliative care goals in mind: evaluating maternal understanding of their child's diagnosis and eliciting maternal concerns regarding their child's physical symptoms, identifying maternal social support systems and additional life stressors, identifying maternal expectations and hopes for their child's medical care, and assessing maternal fears surrounding their child's diagnosis and medical treatments. Palliative care team support and resources will then be provided in areas of necessity identified for the family. Palliative care team follow up will then be determined based on the level of need identified for each individual study participant.
45483149|NCT01334073|Drug|Axitinib plus everolimus|Patients will take both drugs orally, every day, without planned rest period (AX bid and EV once a day). By convention one cycle is 28 days. At the first cycle patients will take one week of AX single agent before starting EV. Patients will be treated at increasing dose levels (DLs) in successive cohorts of 3-6 patients according to the number of patients with dose limiting toxicities (DLT) until the maximum tolerated dose
45483150|NCT05189574|Procedure|Endoscopic negative pressure therapy|Endoscopic placement of a sponge in/at staple line leaks under negative pressure.
45483151|NCT03296722|Behavioral|The Transtheoretical Model|Intervention with the Transtheoretical Model, through group and individual sessions with topics of healthy eating habits taught by a dietician, physical activity and exercise manual taught by a physical therapist, preparation of healthy food with menu taught by graduates in gastronomy, confrontation of barriers given by a psychologist. This group had a monthly monitoring during 3 months. The food plan that was prescribed to the intervention group was with the characteristics of the DASH diet, according to the most recent international guides of the ACC and AHA, for the reduction of cardiovascular risk.
45483152|NCT01358604|Genetic|polymerase chain reaction|
45483153|NCT01358604|Genetic|protein expression analysis|
45690841|NCT03956979|Drug|JM-010 group B|JM-010 fixed combination drug (Group B) + Placebo 1
45690842|NCT03956979|Drug|Placebos|Placebo 1 + Placebo 2
45690843|NCT04190901|Behavioral|Simulated Black Male Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
45690844|NCT04190901|Behavioral|Simulated Black Female Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
45690845|NCT04190901|Behavioral|Simulated White Male Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
45690846|NCT04190901|Behavioral|Simulated White Female Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
45366188|NCT03958656|Biological|Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells|0.3x10^6- 12.0x10^6 CAR+ T cells per kg of recipient bodyweight one-time dose on day 0
45366189|NCT00950274|Drug|CD133+ autologous bone marrow stem cell|Intramyocardial injection of 5 mL CD133+ cells (0.5-5x10e6 cells) suspended in physiological saline + 10% autologous serum intramyocardially during CABG surgery
45366190|NCT00950274|Drug|Placebo|Intramyocardial injection of 5 mL of physiological saline + 10% autologous serum intramyocardially during CABG surgery
45483154|NCT01358604|Genetic|western blotting|
45483155|NCT01358604|Other|flow cytometry|
45483156|NCT01358604|Other|immunohistochemistry staining method|
45483157|NCT01358604|Other|laboratory biomarker analysis|
45483158|NCT02462590|Drug|L. rhamnosus GG - Probiotic|Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
45483159|NCT02462590|Drug|Placebo - Microcrystalline Cellulose|Microcrystalline Cellulose
45847872|NCT03020082|Drug|RBV|RBV administered orally 500mg (5 tablets)( body weight <75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg, for 12 weeks.
45847873|NCT03020472|Biological|2008-2009 FluMist LAIV (Intranasal)|2008-2009 FluMist vaccine delivered intranasally
45366191|NCT03777306|Other|ARM A EARLY INTERVENTION GROUP|"Post randomization, all patients will take baseline survey to assess their level of stress prior to starting the educational program During the educational interventions they will receive~1 video/picture/worksheet per week covering the topic to be covered.~1 phone/week by the Health Advisor, to discuss the topic for the week s/as their disease, stress and anxiety management, life organization, adherence skills, healthy eating and sleeping). Participant and the health advisor will also set up a Tiny Step to serve as a goal for the week .~3 emails/texts through the week, to remind about the topic covered, or to encourage them on their Tiny Step goal.~After 12 weeks on the program participants will re-take the surveys to assess the level of stress."
45483160|NCT01361880|Behavioral|Reduce Infant Mortality|The study's long term goal is to disseminate a new easily implemented and reproducible intervention that based on our previous research is culturally competent and provides a rationale for changing infant sleep position and sleep environment. This intervention if successful will quickly be disseminated and will be an important change to the system of newborn care; the resultant change in parental behavior would ultimately result in a reduction in sleep-related infant mortality rates thereby promoting healthy development.After written consent has been obtained, a brief survey about knowledge of and attitudes toward safe sleep position recommendations, current intent with regards to safe sleep recommendations, and demographics will be completed. Contact information will be obtained from participants to facilitate study follow-up at two weeks of infants birth 2-3 months and 5-6 months.
45483161|NCT01928199|Drug|Sitagliptin|
45366192|NCT03777306|Other|ARM B DELAYED INTERVENTION GROUP|The educational intervention is similar as in ARM A except that the participants will receive standard of care for the first 12 weeks post randomization and then begin the educational intervention
45366193|NCT00561912|Drug|Decitabine|15 mg/m^2 IV Daily over one hour for 5 days
45483162|NCT01928199|Drug|Placebo|
45483163|NCT03713866|Diagnostic Test|EP Imaging and Testing|"Magnetic Resonance Imaging: pre-procedure imaging is standard care prior to catheter ablation procedures for VT to document anatomy of the heart.~120-Lead Body Surface Mapping: a 120-lead ECG will be recorded using a standardized mapping protocol. 120 disposable radiolucent silver chloride (Ag/AgCl) surface electrodes will be placed on the torso in 18 strips and connected via cables to an advanced acquisition system.~Noninvasive programmed stimulation (NIPS) study will be performed using the patient's implanted defibrillator, and is part of standard practice during a VT catheter ablation."
45483164|NCT03128892|Device|Oxygen Reserve Index - RD Lite Sensors|
45483165|NCT03296644|Device|Class II correction using PowerScope2|
45483166|NCT03296644|Device|Class II correction using Forsus|
45483167|NCT01845441|Drug|Dexmedetomidine|Precedex will be given to randomized subjects in thi study to evaluate its efficacy in maintaining optimal sedation and preserving neurological exam.
45483168|NCT01845441|Drug|Fentanyl|Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
45690847|NCT03597321|Biological|prophylactic donor lymphocyte infusion (DLI)|DLI will be collected from the donor by leukapheresis according to local standard procedures of each center. Cell product could be collected in one time or more, and administered fresh or after a frozen storage, according to each center's guidelines. A sufficient amount of T-cell dose should be collected to theoretically perform 3 DLI. DLI procedure will be performed according to local guidelines of each center.
45690848|NCT03597243|Other|Cash Transfer|Girls enrolled receive a quarterly direct cash transfer of a total of 70,000 Tshs (30 USD) quarterly through mobile phone based cash transfer over a period of two years, for which they will receive mobile phones and SIM cards form the program.
45690849|NCT04193007|Drug|molecular targeted therapies|if EGFR mutation is positive, (gefitinib, ecotinib, erlotinib）or ALK/ROS-1 positive（Crizotinib）
45690850|NCT04193007|Radiation|Brain Radiotherapy|SRS was used for 1-3 intracranial lesions, and simultaneous modulated accelerated radiation therapy for Brain(SMART-Brain)was used for more than 3 intracranial lesions
45690851|NCT04190355|Other|Irrigant type|The success of endodontic treatment is directly related to infection control. In successful endodontic treatment, it is necessary to perform an ideal irrigation both in order to gain a better understanding of the complex anatomical structure of the root canals and to increase the efficiency of the instruments and methods used during the canal preparation. Sodium hypochlorite (NaOCl) solution is the standard irrigation agent for cleaning and disinfection of root canal. In this study, the effect of NaOCI on postoperative pain using different uniforms will be evaluated.
45690852|NCT04190355|Drug|5.25% NaOCl|5.25% NaOCl solution
45483169|NCT01845441|Drug|Midazolam|Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
45483170|NCT03296488|Drug|Nalbuphine Sebacate|intramuscular single dose of NALDEBAIN 24±12 hours before surgery.
45690853|NCT04190355|Drug|5.25% Cloraxid gel/ distilled water|5.25% Cloraxid gel/ distilled water
45847874|NCT03026556|Drug|Dabigatran vs. Rivaroxaban|observed for 6 years
45847875|NCT03026556|Drug|Dabigatran vs. Apixaban|Observed for 6 years
45366194|NCT00561912|Drug|Interferon Alfa-2b|0.5 million Units Subcutaneously Twice Daily Continuously. Interferon Alfa-2b will be added on cycle three, day one.
45366195|NCT00561678|Drug|Precedex (Dexmedetomidine)|0.5/ug/kg/hr Dexmedetomidine infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
45366196|NCT00561678|Drug|Placebo|0.5/ug/kg/hr Placebo infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
45483171|NCT03296488|Drug|Fentanyl Citrate|Intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.
45483172|NCT01365858|Other|Rehabilitation|"The experimental group patients receive rehabilitation by training Virtual Action Planning - Supermarket on a computer 45 minutes 5 times a week during a 2-week period. The control group will receive similar duration cognitive rehabilitation (no extra computer training) during this period (problem solving and occupational therapy)."
45483173|NCT01365936|Drug|HMG|In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
45483174|NCT01365936|Drug|rFSH|Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
45483175|NCT02462356|Procedure|Uniportal VATS|Uniportal VATS lobectomy and lymph node dissection will be performed in this group
45366197|NCT00946608|Drug|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)|
45366198|NCT00946608|Drug|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)|
45366199|NCT00946608|Drug|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)|
45483176|NCT02462356|Procedure|Conventional VATS|Conventional VATS lobectomy and lymph node dissection will be performed in this group
45483177|NCT01331343|Device|Guardian RT Telemetered Glucose Monitoring System|
45483178|NCT01358838|Device|ablative 10600 nm fractional laser therapy|"Half of the scar, or one of two comparable scars, will be treated with the ablative 10600 nm fractional laser. There wil be 3 treatments, with 8 weeks apart.~Half of the scar, or one of two comparable scars, will receive no treatment at all."
45366200|NCT00463684|Biological|Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine|Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right brachium.
45483179|NCT01334151|Drug|Insulin LISPRO|Single doses of: 0.15 U/kg
45483180|NCT01334151|Drug|recombinant human insulin|Single doses of: 0.15 U/kg
45483181|NCT03748342|Device|Second-Generation Laryngeal Mask Airway|A second-generation LMA will be used for airway management (instead of ETT).
45366201|NCT00463684|Biological|Live, attenuated measles vaccine|Manufactured by Serum Institute of India, Ltd, Pune, India; batch EU3244. Administered subcutaneously in the left brachium.
45483182|NCT01361958|Drug|NOMAC|
45483183|NCT04216017|Drug|kenalog|Cortisone injection into shoulder
45366202|NCT00463606|Drug|ABT-335 and rosuvastatin calcium|ABT-335 135 mg in combination with rosuvastatin calcium 5 mg administered orally, once daily for 12 weeks
45483184|NCT04216017|Drug|Lidocaine|Lidocaine injection into shoulder
45483185|NCT03039686|Drug|RO7239361|Take RO7239361 subcutaneously on specified days over a 48 week blinded period
45483186|NCT03039686|Drug|Placebo for RO7239361|Take placebo subcutaneously on specified days over a 48 week blinded period
45483187|NCT03296410|Biological|EV71 and two measles attenuated live vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month). And meanwhile, they routine vaccined with two measles attenuated live vaccine at 8 months old.
45483188|NCT03296410|Biological|EV71 and attenuated Japanese encephalitis vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month). And meanwhile, they routine vaccined with attenuated Japanese encephalitis vaccine at 8 months old.
45690854|NCT04193163|Device|Hip prosthesis - ESOP 2 cementless femoral stem|ESOP 2 femoral stems are intended to be implanted in the femoral region during total hip arthroplasty in order to restore joint function.
45690855|NCT03023475|Device|LigaSure endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the LigaSure system.
45847876|NCT03028974|Biological|Fluzone®|Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine
45847877|NCT03028974|Biological|FluMist®|FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray
45847878|NCT03029988|Drug|Tilmanocept (Technetium Tc 99m tilmanocept Injection)|Drug: Technetium Tc 99m tilmanocept
45366203|NCT00463606|Drug|ABT-335|ABT-335 135 mg monotherapy administered orally, once daily for 12 weeks
45366204|NCT00463606|Drug|rosuvastatin calcium|Rosuvastatin calcium 5 mg monotherapy administered orally, once daily for 12 weeks
45366205|NCT03996070|Procedure|Laser therapy|Erbium YAG laser
45366206|NCT03961308|Drug|Vedolizumab SC|Vedolizumab SC liquid.
45366207|NCT00956436|Drug|BIIB022|IV Q3W
45690856|NCT03023475|Device|TLS2 endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the TLS2 system.
45366208|NCT00956436|Drug|Sorafenib|Standard dosing of Sorafenib
45483189|NCT03296410|Biological|two measles attenuated live vaccine|infants vaccined with one dose two measles attenuated live vaccine at 8 months old.
45483190|NCT03296410|Biological|live attenuated Japanese encephalitis vaccine|infants vaccined with one dose attenuated Japanese encephalitis vaccine at 8 months old.
45483191|NCT03296410|Biological|EV71 vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month).
45483192|NCT05189184|Drug|Camrelizumab+Apatinib mesylate+Albumin-bound paclitaxel+cisplatin|Camrelizumab in Combination With Apatinib mesylate Plus Albumin-bound paclitaxel and cisplatin as the First Line Treatment of Recurrent or Metastatic , UnresectableHead and Neck Squamous Cell Carcinoma (HNSCC)
45483193|NCT04639089|Drug|platlet rich plasma on sternal healing post median sternotomy|"Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA~Intraoperative :~We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure.~post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery"
45483194|NCT03290872|Device|Carpentier Edwards Physio 2 Complete flexible mitral ring|Mitral valve Annuloplasty Ring repair using a Carpentier Edwards Physio 2 Complete flexible mitral ring
45483195|NCT03290872|Device|Simplici T Partial flexible mitral annuloplasty ring|Mitral valve Annuloplasty Ring repair using a Simplici T Partial flexible mitral annuloplasty ring
45483196|NCT01362036|Drug|TXA127|Cohorts in this study will receive 300, 600, or 900 ug/kg daily by subcutaneous injection
45483197|NCT04623099|Drug|Escitalopram|Escitalopram is FDA-approved for the treatment of major depressive disorder (MDD) in adolescents (12-17 years of age) and is commonly prescribed for adolescents with anxiety disorders.
45690857|NCT03596931|Drug|Statins (Cardiovascular Agents)|Prescribed with statins
45690858|NCT03596853|Other|Progressive mobilization|"Will be applied once a day, 5x/ week, performed into 4 levels: N1 (bridge and rolling for both sides); N2 (transfer training from lying down to sitting on both sides); N3 (sit and stand up from a chair); N4 (running training). According to their functional level, patients will perform, once a day, 8 sets of each movement, alternating 20 seconds of execution with 10 seconds of rest. Patients will be stimulated constantly to perform the movements with the highest possible speed.~If the patient performs adequately within of your level functional level, can will progress in level, if can not progress, there will be an increase in training volume within the level itself. Adequate performance within the functional level means that the patient is able to complete more than eight sets of exercise and does not present increased sensation of pain, present sensation of perceived exertion within the safety limit of the protocol (Borg ≤ 6)."
45690859|NCT03596853|Other|Usual Care|This group will receive standard usual, which will be monitored, but not protocolised.
45690860|NCT04192617|Drug|SM03|SM03: 600 mg intravenous (IV)
45690861|NCT04192617|Drug|Placebo|Placebo: 600 mg intravenous (IV)
45366209|NCT00956514|Device|Transcranial Magnetic Stimulation|Neurophysiologic Predictors of Outcome with rTMS Treatment of Major Depressive Disorder
45366210|NCT00950508|Procedure|High volume plasma exchange|3 high volume plasma exchanges over 3 days
45366211|NCT00950508|Procedure|Standard medical treatment|Standard medical treatment
45366212|NCT00950586|Drug|GSK1043702|Oral dose in liquid or tablet formulation
45366213|NCT00950586|Drug|Dextromethorphan|30mg Oral dose
45366214|NCT00950586|Drug|Placebo|To match GSK1034702
45366215|NCT00174187|Drug|Somatropin|liquid, daily, until final height Dosage: 0,46 mg/kg/week . The maximum dose should not exceed 50 µg/Kg/day
45366216|NCT01011335|Biological|Monovalent rAT|10, 25, 50 or 100 μg
45366217|NCT01011335|Biological|Monovalent rLukS-PV|10, 25, 50 or 100 μg
45366218|NCT01011335|Biological|Bivalent rLukS-PV / rAT|10, 25 or 50 μg
45366219|NCT01011335|Biological|Placebo with adjuvant|Placebo with adjuvant
45483198|NCT03589300|Device|Persona TM Tibia|Trabecular Metal tibia used in primary cementless total knee arthroplasty
45483199|NCT01366170|Genetic|microarray analysis|
45483200|NCT01366170|Genetic|protein expression analysis|
45690862|NCT04192617|Drug|Methotrexate|methotrexate: 7.5-20 mg/week oral
45847879|NCT03029988|Procedure|SPECT/CT Imaging|4-6 hours post-injection SPECT/CT will be obtained in the abdominal region.
45483201|NCT01366170|Genetic|western blotting|
45690863|NCT04026009|Biological|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A)|"Subjects in CDIFF Ag 18 - 45 Years and CDIFF Ag 50 - 70 Years Groups will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose."
45366220|NCT01011335|Biological|Placebo|Placebo saline
45690864|NCT04026009|Biological|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A) adjuvanted with AS01B|"Subjects in CDIFF Ag + AS01B 50 - 70 Years Group will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag + AS01B vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose."
45690865|NCT04026009|Drug|Placebo|Subjects will receive 2 doses (0.5 mL each) of Placebo, administered intramuscularly in the deltoid, at a 0, 1-month dose interval.
45690866|NCT04192539|Diagnostic Test|Taurine|Serum taurine was determined by High Performance Liquid Chromatography (HPLC) according to the pre-column extraction and derivatization methodology of McMahon et al. In the present work, we use Shimadzu HPLC model LC-10AT
45847880|NCT03033108|Drug|Emixustat|Once daily, tablet for oral administration
45366221|NCT00467896|Drug|Iloprost PD-6|Period I: Patients received iloprost administered using PD-6 for the 37 days prior to the first dosing of iloprost using PD-15. Iloprost inhalation solution was delivered using the I-neb® AAD System. Patients were required to use their own I-neb®.
45366222|NCT00467896|Drug|Iloprost PD-15|Period II: Iloprost inhalation solution was delivered using the investigational product PD-15 with I-neb® AAD System for 37 days. Patients were required to use their own I-neb®.
45366223|NCT00946686|Drug|Leflunomide 20 mg Tablets (Geneva Pharmaceutical)|
45366224|NCT00946686|Drug|Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)|
45366225|NCT00579059|Device|Maxim® Knee System with Removable Molded Polyethylene Tibia|Used for total knee replacements
45366226|NCT00579059|Device|Regular Maxim® Knee System|Used for total knee replacements
45483202|NCT01366170|Other|flow cytometry|
45483203|NCT01366170|Other|immunohistochemistry staining method|
45366227|NCT02531737|Drug|vargatef®|Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle
45483204|NCT01366170|Other|laboratory biomarker analysis|
45483205|NCT01366170|Other|mass spectrometry|
45483206|NCT04613661|Other|Australian Spasticity Assessment Scale|Australian Spasticity Assessment Scale is a clinical measure to assess the severity of spasticity
45366228|NCT02531737|Drug|Docetaxel|Patients will be treated to IV docetaxel 75 mg/m² on day 1 of evry 3-week cycle
45366229|NCT00467818|Drug|Omega 3 fatty acids|The study will start with low doses and based on the weight of the individual the dosage will be increased biweekly.
45366230|NCT00467818|Other|Placebo|Same dosage as that of omega 3 fatty acids
45483207|NCT01358916|Other|Mailing of antibiotic therapy guidelines to the sentinel physicians|Mailing of antibiotic therapy guidelines to the sentinel physicians and regular feedback on antibiotic prescription
45483208|NCT05288504|Drug|AVTX-002|Dose of 600 mg administered subcutaneously three times during the study.
45483209|NCT05288504|Drug|Placebo|Placebo sourced as normal saline administered subcutaneously three times during the study.
45483210|NCT03484702|Drug|JCAR017|Specified dose on specified days
45483211|NCT05177042|Drug|ARV-110 in Combination with Abiraterone|ARV-110 oral tablets in combination with abiraterone and a corticosteroid administered daily in 28 day cycles
45483212|NCT01362114|Drug|SIHOGAYONGGOLMORYU TANG EXTRACT GRAN|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks
45483213|NCT01362114|Other|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
45483214|NCT03296254|Behavioral|Sitting Mindfulness Exercises.|5 weekly sessions of 2,5 hours/session of Sitting Mindfulness Meditation
45483215|NCT03296254|Behavioral|Body Mindfulness Exercises|5 weekly sessions of 2,5 hours/session of Body Scan and Mindful Movements
45483216|NCT03735290|Biological|ilixadencel|Intra-tumoral injection
45483217|NCT03735290|Drug|Pembrolizumab|Administered intravenously over 30 minutes, every 3 weeks, at a dose of 200 mg
45483218|NCT01359072|Other|Self administered coping intervention|The self administered coping intervention (i.e. NUCARE workbook) aims to teach individuals how to cope with their cancer. The intervention embraces two major areas: (i) the enhancement of a sense of personal control; and (ii) the learning of emotional and instrumental coping responses. The approach emphasizes training in problem-solving, relaxation techniques, cognitive coping skills, goal setting, communication, social support and lifestyle factors. The didactic material of the Nucare program is comprised of a workbook containing 12 chapters addressing the above mentioned aspects.
45483219|NCT03290716|Other|SS|Replace regular salt with market available potassium-enriched salt substitute in kitchens of nursing homes.
45483220|NCT03290716|Other|SSSC|A stepwise approach to reduce salt used in the kitchen of nursing homes by controlling the supply of salt.
45483221|NCT04702152|Behavioral|Targeted memory reactivation (sounds)|I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be non-congruently related to the scenes in the previous learning task. This manipulation is within-subject - all participants will get it, but different specific sounds will be presented for each individual participant.
45483222|NCT05173454|Behavioral|Breastfeeding Education and Support|The trained village health workers will provide breastfeeding education and support for male partners and mothers in intervention group for the six month period. During intervention trained village health workers will cover antenatal breastfeeding education to raise knowledge, awareness, support, and counseling on benefits of optimal breastfeeding practices and involvement in supporting breastfeeding mothers once at third trimester pregnancy period; Specific take-home print materials will be developed that support optimal breastfeeding practices and will be given for both partners during third trimester pregnancy; Telephone call counselling will be held to the male partners on optimal breastfeeding practices and involvement in supporting breastfeeding mothers at second week and third month postpartum and there will be three home visits during 6th week, 3.5 month and 5th month.
45483223|NCT04669704|Other|Experimental: Tablet application|"A protocol of exercises based on the current scientific evidence will be provided through a tablet application. A follow-up of the use of the application will be carried out. A minimum of 4-week home exercise intervention will be performed, which will have to be carried out daily by the patient autonomously at home for at least 5 days per week, starting after baseline measurement.~The exercise program will be individualized according to each pathology."
45483224|NCT04669704|Other|Comparator: Conventional treatment|In the control condition, participants will receive a home exercise program on paper. The exercise program will be the conventionally prescribed one by the Andalusian Public Health Service. Participants will be told to perform exercises during a minimum of 4 week at home for at least 5 days per week, starting after baseline measurement.
45483225|NCT03296176|Biological|blood sample|blood sample for metabolome analyse
45483226|NCT03619538|Drug|Nefopam|The nefopam group received 120 mg nefopam (Acupan, Pharmbio, France) by continuous iv infusion over the study period (48h)
45690867|NCT04192383|Radiation|Cyberknife stereotactic radiosurgery|Hypofractionated stereotactic radiosurgery
45690868|NCT01874665|Drug|Ponatinib|Ponatinib 45 mg, tablets, orally, once-daily.
45690869|NCT04192305|Procedure|LPV|LPV means tidal volume of 6 ml/kg, inspiratory-expiratory (I/E) ratio of 1/1, positive end expiratory pressure (PEEP) minimum 5 cmH20 and higher during laparoscopy in obese patients, Inspiratory oxygen concentration (FIO2) 40 % during maintenance and extubation while also giving CPAP. Lung recruitment maneuver (LRM) when lung compliance decreases below 40 ml/cmH2O.
45690870|NCT04192305|Procedure|routine LV|Give volume en frequency as required by end tidal carbon dioxide, PEEP and LRM only when saturation drops intra operative, no requirement to use low FIO2 and CPAP during extubation.
45366231|NCT01326559|Drug|Docetaxel, Cisplatin, 5-FU and Cetuximab|"Induction phase (Weeks 1-9):~Drug Docetaxel Docetaxel 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Cisplatin Cisplatin 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Fluorouracil Fluorouracil 750 mg/m2 IV, D1-4 every 3 weeks for 3 cycles~Concurrent phase (weeks 10-16):~Drug Docetaxel Docetaxel 15 mg/m2 IV, D1 weekly for 7 weeks (Weeks 10-16)~Drug Cetuximab Cetuximab 400 mg m2 IV, D1 initial dose, then 250 mg/m2 weekly for 7 week (Weeks 10-16)~IMRT (60 Gy to GTV or biological dose equivalent): 2 Gy/fraction/day, D1-5 per week, for 6 weeks (Weeks 11-16)"
45366232|NCT02575313|Dietary Supplement|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
45366233|NCT00709709|Procedure|multislice coronary scan|multislice coronary scan
45366234|NCT00709787|Other|Usual Care|Normal care for hypertensive patients with risk factors for CHD
45366235|NCT04069949|Drug|sorafenib; toripalimab|Stage I: cohort A: sorafenib 400 mg qd+ toripalimab 240 mg d1; q3w cohort B: sorafenib 400 mg bid, toripalimab 240 mg d1; q3w Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39.
45366236|NCT00714467|Behavioral|Expert System Only|expert system intervention only to the smoker participants which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters receive assessments only and no intervention.
45366237|NCT00714467|Behavioral|Family Assisted|The smoker participants received an expert system intervention (same intervention for those in the Expert system intervention) which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters will receive a a self-help booklet based on the Transtheoretical Model of Change (TTM) that will aim at teaching the supporters how to use the stages of change framework to apply different strategies that best match with smokers' readiness to quit smoking.
45366238|NCT02574767|Behavioral|Lifestyle counseling|Obese pregnant women from PHCC randomized to this group will receive Home-based Diet & Physical activity (PA) counseling. Home-based intervention will consider 2 home visits of one hour of duration. During this session dietary educational and behavioral will be discussed with the participants and their families tailoring the contents based on the specific contexts.
45366239|NCT02574767|Dietary Supplement|PUFA Supplementation|Obese pregnant women from PHCC randomized to this group will receive n3LC-PUFAs oral supplementation based on Schizochytrium oil (S-oil) containing 800 mg docosahexaenoic (DHA) acid/day, which will be administered as capsular preparations containing 200 mg DHA/capsule (4 capsules/day).
45366240|NCT02574767|Behavioral|Routine diet & PA|Obese pregnant women from PHCC randomized to this group will receive will receive routine diet & PA counseling (i.e. they will receive the standard education sessions included in the prenatal controls at PHCC but no home-based counseling sessions).
45366241|NCT02574767|Dietary Supplement|PUFA placebo|Obese pregnant women from PHCC randomized to this group will receive capsular preparations containing 50 mg DHA/capsule (4 capsules/day), given that evidence suggests that it would be unethical not to provide DHA during pregnancy. Placebo will be delivered in the same way that the n3LC-PUFA supplementation.
45690871|NCT04192149|Other|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
45690872|NCT03596619|Device|PBN|The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation [SD] of 10 nm; 100-200 J/cm2). The ALA-PDT group received ALA cream and irradiation only.
45690873|NCT04191525|Dietary Supplement|BPL-1 Probiotic capsules|BPL-1 Probiotic 1 capsule/day
45690874|NCT04191525|Dietary Supplement|Placebo|Placebo masked with the same presentation as the experimental product 1 capsule/day
45690875|NCT03954171|Other|Patients treated with platinum based-chemotherapy|"Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):~before treatment initiation (blood sample),~during hospitalisation for surgery (blood sample),~during follow-up consultations (blood sample).~If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study."
45366242|NCT02575235|Drug|Cetylpyridinium Chloride (CPC)|Two study groups take CPC of 1.5mg and 4.5mg daily for four weeks.
45366243|NCT02575235|Drug|placebo|Control group takes the placebo for the same period.
45366244|NCT00467740|Drug|BI 1744 CL|
45366245|NCT02575157|Other|No intervention|No intervention
45483227|NCT03619538|Other|saline solution|The Control group received 120 mg placebo infusion (saline solution) by continuous iv infusion over the study period (48h).
45483228|NCT03290638|Procedure|Guided Bone Regeneration (GBR)|Teeth Extraction With Bone Grafting and Membrane
45847881|NCT03035760|Drug|Oxfendazole|methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic. It is the sulphoxide metabolite of fenbendazole.
45483229|NCT05188950|Device|depression screening test App|The participants' use of the depression screening test App of 6 modules for 12 weeks, at least once a week, 20 minutes per once.
45483230|NCT03296098|Drug|Ulipristal acetate|Ulipristal aceteate 5 mg oral tablets to take two tablets daily.
45483231|NCT01366326|Drug|Methylnaltrexone bromide|Subcutaneous MNTX
45483232|NCT01822275|Drug|Chemotherapy with Temodar.|Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
45483233|NCT01822275|Radiation|Radiation therapy|
45483234|NCT05036018|Device|ACURATE neo2|The ACURATE neo2 valve will be implanted using a two-step mechanism during transfemoral transcatheter aortic valve implantation (TAVI). Balloon predilatation will be recommended in the ACURATE neo 2 valve group.
45483235|NCT05036018|Procedure|minimalist approach|Isolated local anesthesia. Central venous lines, additional arterial lines for blood pressure monitoring, and urinary catheters will be avoided. Insertion of temporary pacemakers is optional and should be avoided whenever possible, and peri-procedural pacing can then be performed on the left ventricular wire. Presence of an anesthesiologist is optional. Patients will be directly transferred to the cardiology ward after the procedure, which can be postponed in case of complications.
45483236|NCT05036018|Device|CoreValve Evolut Pro and Pro+|The Evolut Pro or Pro+ valve is positioned in a controlled manner either without pacing or under 'slow-rapid' pacing with allowance for limited repositioning and is anchored to the annulus and ascending aorta.
45483237|NCT05036018|Procedure|Standard of care|Sedation should be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -2 according to local standard of care.The use of EEG monitoring (i.e. BIS, Sedline) can be applied. Continuous CO2-monitoring via face mask should be established during sedation. All patients will receive supplemental oxygen by face mask to maintain an oxygen saturation of approximately 95%. Presence of an anesthesiologist is obligatory. The use of central venous catheters, additional arterial lines for blood pressure monitoring, and urinary catheters can be implemented according to local institutional standards.
45483238|NCT03296020|Other|HONEY|100% Natural pure Honey, produced by EIN HAROD CO-OPERATIVE, ISRAEL
45483239|NCT03295942|Drug|OMP-336B11|OMP-336B11 is an engineered human protein that was designed to bind to the GITR receptor on T cells and activate the immune system to recognize and eliminate cancer cells.
45483240|NCT04011189|Procedure|Videotaping|Before the videotaping, patients will be asked on their baseline pain scores. Their face and body pose from a frontal view will be videotaped via a mobile phone with no internet access. The collected videos will be further processed to extract key points, which will be the primary input for modelling algorithms and will further ensure anonymity of the patients in the video sequences.
45483241|NCT04011189|Other|Questionnaires|"Patients will be asked to fill in 1-2 questionnaires before surgery/procedure/consultation (Hospital Anxiety and Depression Scale (HADS) and/or EQ-5D-3L). After surgery/procedure/consultation, patients will be again asked to fill in HADS questionnaire (optional).~For pediatrics patient, only Child Pain Anxiety Symptoms Scale (CPASS) will be administered before the surgery."
45483242|NCT04011189|Device|Empatica E4 wristband|A medical grade wearable device, Empatica E4 wristband, will be used in phase 3 for pediatrics patients to monitor real-time physiological data on heart rate and body temperature.
45483243|NCT04631796|Device|Lehfilcon A contact lenses|Silicone hydrogel contact lenses with investigational coating
45483244|NCT04631796|Device|Multipurpose disinfection solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
45483245|NCT05655026|Device|NIV, HFNO|Arterial blood pressure and saturation will be measured. Arterial blood gases will be collected to qualify patients to one of the three groups. After qualification, patient will be randomly assigned to a given respiratory support method during FB.
45483246|NCT03290482|Diagnostic Test|Barium Esophagram|Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.
45483247|NCT03290482|Device|EsophaCap|Subjects will swallow the EsophaCap, which has a string attached, 10 minutes later it has devolved in the stomach. The PI will pull the string to remove the EsophaCap. We will send the sponge for cytology assessing the histologic results of eosinophils per high power field (phf)
45690876|NCT04029987|Procedure|Bilateral Ultrasound-Guided Transmuscular Quadratus Lumborum Block.|A 22 G echogenic needle will be inserted in plane from the posterior (medial) end of the probe and directed for the fascial plane between the Quadratus Lumborum and the Psoa Major muscles through the Quadratus Lumborum muscle. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
45690877|NCT04029987|Procedure|Bilateral Ultrasound-Guided intra smuscular Quadratus Lumborum Block.|A 22 G echogenic needle will be inserted in plane from ventral (lateral) edge of the probe and advanced until penetration of QL muscle fascia is observed. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
45483248|NCT03290482|Diagnostic Test|Physical Examination and Questionnaires|Complete the modified Mayo dysphagia Questionnaire (MDQ) and the Eosinophilic Esophagitis Activity Index (EEsAI) at time of physical exam visit with PI.
45483249|NCT01331421|Drug|exemestane|25 mg tablet
45483250|NCT04625478|Other|Patients having had an osteo-articular infection with Stahylococcus|Immunostaining targeting staphylococci and components will be performed on tissue samples collected from patients with osteo-articular infection
45366246|NCT04070963|Other|HbA1C|To take additional blood test of HbA1C once patient consented to the study
45366247|NCT00710099|Drug|sildenafil|systemic absorption of sildenafil
45366248|NCT00710099|Drug|nitroprussiate iontophoresis|nitroprussiate iontophoresis
45483251|NCT01656434|Drug|NOMAC-E2|NOMAC-E2 film-coated oral tablets containing 2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol.
45483252|NCT01656434|Drug|NETA-EE|NETA-EE film-coated oral tablets containing 1 mg norethisterone acetate and 10 μg ethinylestradiol.
45483253|NCT01656434|Other|Placebo|tablet
45483254|NCT01656434|Drug|ethinylestradiol (EE)|EE 10 μg tablet
45483255|NCT01656434|Drug|ferrous fumarate|ferrous fumarate 75 mg tablet
45483256|NCT01319214|Drug|Inderal|Inderal vs. placebo will be administered with or without cocaine cues
45366249|NCT02574689|Behavioral|HIPP|The physical activity intervention is based on the Social Cognitive Theory and Transtheoretical Model and includes motivation-matched physical activity manuals and individually-tailored computer expert system feedback reports. Tailored reports are based on participants' monthly update survey data and cover: 1) current stage of change; 2) self-efficacy; 3) decisional balance; 4) social support; 5) outcome expectations; 6) enjoyment; 7) progress feedback; 8) normative feedback; 9) self regulation. The computer expert system draws from a bank of 330 messages addressing different levels of psychosocial and environmental factors affecting physical activity.
45366250|NCT02574689|Behavioral|Wellness contact control|"Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the American Cancer Society website (www.cancer.org) are mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials."
45366251|NCT00714545|Radiation|Intracoronary brachytherapy|Beta irradiation with a 40-mm strontium/lytrium-90 source
45366252|NCT03944044|Other|Paracetamol route in palliative-care patients: intravenous versus subcutaneous route Pharmacokinetics study protocol|Compare the pharmacokinetic (PK) of SC and intravenous (IV) routes in the same patient in a palliative care situation, to determine if there is a PK equivalence between these two modes of administration of Paracetamol.
45366253|NCT00714623|Device|Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)|Indications for use: The CYPHER™ Sirolimus-eluting Coronary Stent is indicated for improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions of length less than or equal to 30 mm in native coronary arteries with a reference vessel diameter between 2.5 and 3.5 mm. Long-term outcome (beyond 12 months) for this permanent implant is unknown at present.
45366254|NCT00553254|Drug|PF-00299804|Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent
45366255|NCT01022476|Drug|Raltegravir potassium|one pill of raltegravir 400 mg twice a day
45483257|NCT01331499|Device|Bipolar Sealer (Aquamantys)|Standard of care blood sparing techniques along with the use of bipolar sealer
45483258|NCT01331499|Procedure|Standard of Care|Standard of care blood sparing techniques without the useof bipolar sealer
45366256|NCT05673239|Drug|Levocarnitine Injection|The patients in the test group were injected with 1-2g (10-20mg/kg) levocarnitine on each dialysis day
45483259|NCT01359228|Drug|Rifaximin (XIFAXAN)|Rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days
45483260|NCT01359228|Drug|Placebo|Placebo 1 tablet three times a day for 14 days.
45366257|NCT01025518|Other|Resistance training|12 weeks of resistance training in combination with protein and creatine or placebo ingestion
45366258|NCT01025518|Dietary Supplement|Protein and creatine|30 g of protein with each training session, 5 g of creatine pr day
45366259|NCT01025518|Dietary Supplement|Placebo|Maltodextrine
45483261|NCT01334307|Device|Lung Volume Reduction Coil (LVRC) (PneumRx)|Lung Volume Reduction Coil (LVRC)
45483262|NCT01334307|Device|Control|Standard of Care
45483263|NCT02931396|Device|FES|
45690878|NCT04029987|Procedure|Control|Conventional analgesia
45483264|NCT03607058|Other|Kinect + Exercise Training|Kinect + Exercise Training : Patients will play Xbox Kinect games for 40 minutes and take the treatment for 20 minutes, 3 days in a week for 8 weeks. After 10 weeks washout period, patients will take the treatment 1-hour, 3 days in a week for 8 weeks.
45483265|NCT03607058|Other|Exercise Training|Exercise Training: Patients will take the treatment 1-hour, 3 days in a week for 8 weeks. After 10 weeks washout period, patients will play Xbox Kinect games for 40 minutes and take the treatment for 20 minutes, 3 days in a week for 8 weeks.
45483266|NCT03734055|Behavioral|Peer Mentoring|Manualized peer mentorship program designed to provide modeling and reinforcement by peers (mentors) to other African American women with SLE (mentees) to encourage them to engage in activities that promote disease self-management.
45483267|NCT03734055|Behavioral|Social Support Group|Social support controls will participate in a lupus support group created for this project, on the same schedule as peer mentoring sessions.
45366260|NCT02575001|Behavioral|Psychological background determinations|"For the psychological background determinations a structured interview and questionnaires will be administered:~Child Attachment Interview (CAI)~General/sociodemographic questionnaire with the questions on diabetes management, current health status and the child's development in the infancy~Parenting Stress Index with the 19-item Life Stress Scale (PSI)~Achenbach System of Empirically Based Assessment (CBCL, YSR)~Holmes and Rahe Social readjustment rating scale~Lifetime Incidence of Traumatic Events (LITE) - parent and child reports of child's trauma/loss history (LITE- S/ P)~Experiences in Close Relationships - Relationship Structures questionnaire (ECR-RS)"
45483268|NCT01366482|Device|Cotavance Drug-Eluting Balloon|Treatment with a paclitaxel-coated angioplasty balloon (without preceding plaque excision)
45366261|NCT02575001|Genetic|Genetic susceptibility determination|DNA will be isolated from the patients' blood samples and form the control subjects buccal swabs. The genes with expected influence to stress reactivity and mental disorders will be tested.
45366262|NCT02575001|Procedure|Cortisol release test|Synacthen test - will be used with the group of patients with type 1 diabetes to measure HPA axis reactivity
45366263|NCT02575001|Procedure|Saliva cortisol measurement|Saliva cortisol measurement - will be used with the patients before and after the Synacthen test and with the Hashimoto thyroiditis and the healthy control group before and after the Child Attachment Interview
45366264|NCT01021930|Device|Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Polymer-based sirolimus-eluting stent( Cypher, Cordis ) and Polymer-free paclitaxel-eluting stent (YinYi ),randomly implanted in two vessels of one patients
45366265|NCT00946764|Drug|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)|
45366266|NCT00946764|Drug|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)|
45366267|NCT01022008|Device|Osteodistraction techniques|Treatment based on craniofacial osteotomies and osteodistraction techniques.
45366268|NCT00950820|Drug|Oxaliplatin, Capecitabine, Panitumumab|"Panitumumab at a dose of 9 mg/kg BW every three weeks will be administered on day 1 of each cycle just prior to administration of chemotherapy.~The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15."
45366269|NCT00950820|Drug|Oxaliplatin, Capecitabine|The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
45483269|NCT01366482|Device|TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon|Plaque excision with a SilverHawk or TurboHawk plaque excision device followed by treatment with a paclitaxel-coated angioplasty balloon
45752194|NCT00411463|Drug|Seroquel|"Subjects will be started at 100 mg/day titrated to a maximum of 800 mg /day~Day 1-BID doses totaling 100 mg/day, increased to 400 mg/day on Day 4 in increments of up to 100 mg/day in BID divided doses, by Day 6 begin titration up to a maximum dose of 800 mg/day in increments no greater than 200 mg/day.~This titration schedule may be adjusted based on the subject's response and ability to tolerate Seroquel.~Subjects who are unable to tolerate the study medications, or for whom the study medications are an inappropriate clinical choice, will be treated openly by a clinic physician according to the standard of care guidelines designated by the American Psychiatric Association (2002) for the treatment of bipolar disorder."
45483270|NCT01366482|Device|TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon|Plaque excision followed by treatment with a paclitaxel-coated angioplasty balloon
45483271|NCT05032742|Behavioral|mHealth parenting stress app|mHealth parenting stress app intervention to reduce parenting stress and improving youth community-based treatment engagement.
45483272|NCT01366560|Drug|Active|GSK962040 125mg
45483273|NCT01366560|Drug|Placebo|Matching Placebo
45483274|NCT05172128|Dietary Supplement|lyophilized blueberry supplement|lyophilized blueberry supplement bid
45483275|NCT02461030|Drug|In-office and at home Colgate sensitive pro-relief - CSPR|Prophylaxis with rubber cup using In-office Colgate sensitive pro-relief (CSPR), after non-surgical periodontal therapy, and tooth brushing with at home CSPR toothpaste.
45483276|NCT02461030|Drug|In-office Villevie® prophy paste + Colgate Toothpaste|Prophylaxis with rubber cup using In-office Villevie® (fluoride-free) prophy paste + Colgate Toothpaste, after non-surgical periodontal therapy.
45483277|NCT02461030|Procedure|Non-surgical periodontal treatment|Full-mouth debridment, scaling and root planing with ultrasonic/hand instruments
45483278|NCT05168618|Biological|Atezolizumab|Given IV
45483279|NCT05168618|Drug|Cabozantinib S-malate|Given PO
45483280|NCT03295864|Diagnostic Test|Multifrequency tympanometry at Inclusion|Multifrequency tympanometry measurement and particularly width of conductance tympanograms at 2 kHz will be performed for both group at inclusion
45483281|NCT03295864|Diagnostic Test|Multifrequency tympanometry 6 month after surgery|Multifrequency tympanometry measurement and particularly width of conductance tympanograms at 2 kHz will be performed 6 months after surgery for Chiari type I malformation patient
45366270|NCT02574923|Biological|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
45366271|NCT00950898|Other|decaff|2 mugs of decaffeinated coffee
45366272|NCT00950898|Other|caffcoff|2 mugs of caffeinated coffee
45366273|NCT00950898|Other|caffeine|2 mugs of hot water containing caffeine
45366274|NCT00950898|Other|placebo|2 mugs of hot water
45366275|NCT00168805|Drug|enoxaparin|40 mg once daily
45366276|NCT00168805|Drug|dabigatran etexilate|150 mg once daily
45366277|NCT00168805|Drug|dabigatran etexilate|220 mg once daily
45366278|NCT00950976|Other|citrulline|TID for 5 days
45366279|NCT00950976|Other|Lemonade|TID for 5 days
45690879|NCT04191837|Other|Self-administered acupressure treatment group|Subjects in the self-administered acupressure exercise group will receive two training sessions (2 hours each, 1-week apart). The self-administered acupressure treatment protocol was developed based on Chinese medicine meridian theory by previous studies and modified. The acupoints are indicated for knee pain and have been commonly used and tested for feasibility in pilot study. The training will be conducted in a group format with 4-6 subjects per group. Each subject will then receive a handout and an acupressure log. They will be told to perform the self-acupressure twice per day for 12 weeks.The capability of participants for self-administered acupressure will be inspected by the instructor with a competency checklist in each session. And a demonstration video will be sent to the participants via WhatsApp for their reference at home.
46051280|NCT04247373|Drug|Ropivacaine|According to previous patient's response, the investigators will allocate the concentration of ropivacaine of next patient during Co2 insufflation. And, for this allocation of concentration of ropivacaine the investigators use biased coin design up-and-down method.
46051281|NCT02828007|Device|NIV Group|Each patient will be using Non Invasive Ventilation (NIV) and will use it on each possible ventilation mode in a random order with a 10 minutes washout period between modes.
46051282|NCT04251234|Other|Light intensity, ~30 lux|~30 lux compared to very dim light baseline condition <1 lux
45366280|NCT00467584|Drug|High Dose Aspirin (1300 mg/day)|1300 milligrams per day (the equivalent of 4 regular aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
45690880|NCT04191837|Other|Knee health education control group|Subjects in the health education control group will receive knowledge related to knee OA symptom management. The health education will be conducted in a talk format for 2 hours for two sessions. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR and reviewed. Subjects in knee health education group will be told to follow the knee health instruction for 12 weeks.
45752195|NCT03239015|Drug|Gefitinib|Gefitinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
46051283|NCT04251234|Other|Baseline light intensity, <1 lux|Very dim light condition
46051284|NCT04795596|Procedure|secondary cytoreductive surgery|resection of isolated recurrent ovarian carcinoma in platinum resistant disease
46051285|NCT04795596|Drug|Chemotherapy|second line chemotherapy according to investigator's choice
46051286|NCT04245267|Behavioral|DIABEMPIC|Patients are attended by 9 diabetes health-care professionals every 2 weeks for 5 months in a shared medical appointment scheme, including individual and group sessions. Patients will be evaluated at the end of the program and 1 year after.
45366281|NCT00467584|Drug|Low Dose Aspirin (162 mg/day)|162 milligrams per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
45366282|NCT00467584|Drug|Placebo|Placebo tablets matching the active aspirin tablets in appearance, taken as two tablets, twice per day for 8 weeks
45366283|NCT04521725|Device|Respiratory Function Monitor (RFM)|Use of respiratory function monitor to detect tidal volume and expired CO2 to guide mask ventilation during neonatal resuscitation.
45366284|NCT04521725|Device|Cerebral Near-Infrared Spectroscopy (NIRS)|Use of cerebral NIRS to determine cerebral oxygenation to guide oxygen titration during neonatal resuscitation.
45366285|NCT00956670|Other|Quality-of-Life Assessment|Ancillary studies
45366286|NCT00956670|Other|Questionnaire Administration|Ancillary studies
45366287|NCT00956670|Procedure|Study of High Risk Factors|Undergo lymphedema assessment
45366288|NCT00956670|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45366289|NCT00956670|Procedure|Therapeutic Laparoscopic Surgery|Undergo surgery
45366290|NCT00956670|Procedure|Therapeutic Lymphadenectomy|Undergo lymphadenectomy
45366291|NCT02574611|Drug|Neostigmine|
45366292|NCT02574611|Drug|Glycopyrrolate|
45366293|NCT02574611|Other|Saline (Placebo)|
45366294|NCT02574611|Device|High Resolution Colonic Manometry|
45366295|NCT01025596|Drug|Interleukin-7|4dose levels: 3, 10, 20 and 30µg/kg. 4 administrations, 1 per week
45366296|NCT00710255|Procedure|Hyperpnea challenge|5 minutes of dry air hyperpnea to induce bronchospasm
45752196|NCT03239015|Drug|Erlotinib|Erlotinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
46051287|NCT04250766|Procedure|Echo-guided uterine biopsy|"Echo-guided uterine biopsy will be performed by a specialized radiologist by transvaginal and exclusive transuterine approach. 4 to 5 samples will be made.~Local anesthesia will be performed. A pain assessment will be performed during the biopsy (visual or verbal scale)."
45366297|NCT01025674|Behavioral|Positive Action program|Components of the Positive Action program (6 units) use research-supported educational strategies/methods that include active learning, positive classroom management, teacher training, detailed curriculum with almost daily lessons, school-wide climate-change program, and family program of parent support/involvement.
45483282|NCT01599494|Drug|MK-8962|"MK-8962 is supplied in a ready-to-use prefilled syringe containing~100 microgram (μg) or 150 μg corifollitropin alfa per 0.5 mL. Participants are randomized to receive a single subcutaneous (SC) injection of MK-8962 in the abdominal wall on Cycle Day 2 or Cycle Day 3. Dose of administered MK-8962 is weight-based. Participants who weigh 60 kilograms (kg) or less will be given 100 μg MK-8962 and those who weigh more than 60 kg will be given 150 μg MK-8962."
45366298|NCT00714779|Drug|Fluoxetine|20-40 mg / day orally
45366299|NCT00714779|Behavioral|Short-term psychodynamic psychotherapy|1 session / week for 16 weeks
45366300|NCT03912467|Other|Pressure Ulcer Evaluation|Patient was evaluated according to presence of pressur ulcer or not
45483283|NCT01599494|Drug|recFSH|Recombinant Follicle Stimulating Hormone (recFSH) will be supplied as a ready-to-use solution in a 600 IU cartridge for SC injection via the recFSH Pen. Starting on Day 2 or 3 of the menstrual cycle (Stimulation Day 1), recFSH will be administered daily, each morning, via injections in the abdominal wall. A starting dose of between 150 - 300 IU will be administered and is fixed for the first week of stimulation. After 6 days, and based on each participant's individual response, the Investigator may decide to reduce the fixed dose for the remainder of the study. The maximum duration of stimulation is 19 days; recFSH will not be administered on the Day of hCG Administration.
46051288|NCT02832921|Behavioral|cognitive training by virtual reality|
45366301|NCT03839212|Behavioral|HOLA Component 1|At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
45366302|NCT03839212|Behavioral|HOLA Component 2|A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
46051289|NCT02832921|Behavioral|watching a scientific TV documentary|
45366303|NCT03839212|Behavioral|HOLA Component 3|A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
45366304|NCT03839212|Behavioral|HOLA Component 4|One booster walking session twice a month for three months post intervention for reinforcement.
45366305|NCT00946842|Drug|Treatment A|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
45366306|NCT00946842|Drug|Treatment B|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
45366307|NCT00946842|Drug|Treatment C|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
45752197|NCT03239015|Drug|Afatinib|Afatinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
46051290|NCT02832921|Device|treadmill|"VR cognitive training will be augmented by walking on a treadmill, since it is well established that dual tasking-i.e. performing the VR-based cognitive effort together with a motor task, even as simple as walking on a treadmill-places greater demand on cognitive resources than a single task."
45483284|NCT01599494|Drug|Ganirelix|0.25 mg/day SC injection in the upper leg, administered on Stimulation Day 5 up to and including Day of hCG Administration
45483285|NCT01599494|Drug|human Chorionic Gonadotropin (hCG)|Single dose of 10,000 or 5,000 IU hCG, administered via SC injection on Day of hCG Administration.
45483286|NCT01599494|Drug|Progesterone|Crinone 8% (90 mg) gel administered intravaginally via a single-use, one piece polyethylene vaginal applicator once-daily on Day of Oocyte Pick-up or 1 day later and continued for at least 6 weeks or either up to menses or up to a negative pregnancy test performed at least 18 days after Day of Oocyte Pick-up.
45483287|NCT03295786|Drug|Cerebral Dopamine Neurotrophic Factor|Repeated intracerebral infusions
45483288|NCT03295786|Device|Renishaw Drug Delivery System|Stereotactically implanted device
45483289|NCT05268302|Biological|Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose|Low dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 0.
45483290|NCT05268302|Biological|Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Medium Dose|Medium dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 0.
45366308|NCT00946842|Drug|Treatment D|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
46051291|NCT00917124|Device|INVOS|"Monitoring cerebral oxygenation (rSO2) with INVOS. When rSO2 decline occur it can be responded with simple interventions to prevent a brain injury including: repositioning of the head or perfusion cannulae to avoid mechanical obstruction of cerebral blood flow, increasing arterial carbon dioxide tension within normal referent values, increasing oxygen inspiration concentration to maintain adequate tissue oxygen saturation, increasing arterial blood pressure, pump flow rate and cardiac index, temperature decreasing and increasing of anesthetic depth to reduce cerebral oxygen consumption and blood transfusion if hematocrit decreases below 22%.~None of the interventions are outside the range of good clinical practice."
46051292|NCT02832765|Radiation|A|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions of the involved spinal bone metastases
45366309|NCT00946842|Drug|Treatment E|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
45366310|NCT00946842|Drug|Treatment F|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58
45366311|NCT00168103|Biological|C1 Esterase Inhibitor|Single application of C1-INH administered intravenously by slow injection or infusion at a recommended rate of 4mL/min.
45366312|NCT00168103|Biological|Placebo|Single application of physiological saline solution equivalent to the volume calculated for subjects in the C1-INH 20 U/kg bw arm.
46051293|NCT02832765|Radiation|B|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions with an SIB with 40 Gy in 10 fractions to the metastasis of the involved spinal bone metastases
46051294|NCT02832765|Radiation|C|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions of the involved spinal bone metastases
46051295|NCT02832765|Radiation|D|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions with an SIB with 30 Gy in 5 fractions to the metastasis of the involved spinal bone metastases
45366313|NCT04011228|Diagnostic Test|Blood sampling|After a fasting period over night blood samples will be taken.
45483291|NCT05268302|Biological|Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - High Dose|High dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 0.
45483292|NCT02462278|Device|TempuRing|
45483293|NCT03198052|Biological|CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR|CAR-T cells injection: (1-10×10e6/kg CAR-T for each treatment; 3 or more cycles.
45483294|NCT03194932|Drug|Venetoclax|Venetoclax will be given as oral tablets, which are intended to be swallowed intact and may not to be crushed or otherwise altered for administration, or as an oral suspension for patients who cannot swallow tablets.
45483295|NCT03194932|Drug|Cytarabine|Given intravenously (IV) or intrathecally (IT).
45483296|NCT03194932|Drug|Idarubicin|Given IV.
45483297|NCT03194932|Drug|Intrathecal Triple Therapy|Given IT.
45483298|NCT03194932|Drug|Azacitidine|Given IV.
46051296|NCT02832999|Drug|sub cutaneous liraglutide|Liraglutide 1.2mg/day
46051297|NCT02832999|Drug|Oral Vildagliptin|Vildagliptin 50mg/day
45483299|NCT03144388|Procedure|Variable Stepping Training|Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
45483300|NCT03144388|Procedure|Variable Non-specific Training|Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
45483301|NCT03290170|Procedure|Measured Resection|Bony landmarks are used to set femoral component rotation.
45483302|NCT03290170|Procedure|Gap Balancing|Relies on ligament releases prior to bone cuts.
45483303|NCT03037580|Drug|Oral treprostinil|Sustained-release oral tablets for TID administration
45483304|NCT03037580|Drug|Placebo|Placebo (sugar pill) for TID oral administration
45483305|NCT03290092|Drug|Taselisib (GDC0032)|The first six participants cohort receive a starting dose of 1mg once daily of taselisib during four weeks.
45483306|NCT03290092|Drug|Taselisib (GDC0032)|The starting dose of the second cohort of 24 patients is 2 mg once daily. This dose may be adjusted down according to the pharmacokinetic data or tolerability data derived from the first cohort.
45483307|NCT03290014|Diagnostic Test|polysomnography|Monitoring of brain activity and respiratory variables during sleep
45366314|NCT04011228|Diagnostic Test|Saliva and blood samples|After a fasting period over night blood and saliva samples will be taken for the investigation of epigenetics based modifications.
45366315|NCT04011228|Diagnostic Test|Magnet Resonance Spectroscopy|The amount of ectopic lipids in the liver, heart and the skeletal muscle will be measured using 1H-magnetic resonance spectroscopy.
45366316|NCT00463060|Drug|sunitinib malate (Sutent)|Sutent administered PO QD from days 1 to 28 Two weeks after completion of any chemotherapy, maintenance Sutent in 6 week cycles (consisting of Sutent 50 mg PO QD weeks 1-4 followed by no treatment weeks 5-6) until progression or death If no chemotherapy is planned, maintenance Sutent (as described above) will start on day 43.
45690881|NCT04191759|Diagnostic Test|Test-Retest reproducibility|Protocol is the same for extended or flexed knee. The testing apparatus was set up as described in the constructor owner's manual and subjects were positioned in the supine lying position. The After a 5 min rest period, the participant's ankle is passively stretched through slow loading cycles from 15° of ankle flexion to 35° of ankle extension. Oral instruction is given to the participants to stay relaxed and avoid any muscle contraction and movement of the leg throughout the passive stretching. To familiarize, participant have 3 repetitions of passive ankle flexion-extension at 5°.s-1, and after 2min rest, data are collected from one repetitions at 5°.s-1 in passive mode. The measurements are also performed at an angular rate of 90°.s-1, according to the same protocol. Data for maximal voluntary isokinetic contraction are collected from 3 maximal repetitions at 60°.s-1 in concentric mode and participant are encouraged by constant verbal stimulation.
45483308|NCT03290014|Diagnostic Test|Actigraphy|monitoring daily physical activity for 7 days
45483309|NCT03290014|Diagnostic Test|Osler test|Evaluation of subjects´ ability to remain awake
45483310|NCT03295708|Dietary Supplement|fish oil capsule|N-3 PUFAs is a kind of essential fatty acid,however the formation is too slow. Studies show that intakes of N-3 PUFAs is associated with MDD.It have to be got from food like deep-sea fishes. EPA and DHA are crucial for the body.Although studies have shown that reduced N-3 PUFAs were correlated with MDD, and patients with an elevated rate of N-6 PUFAs /N-3 PUFAs or a low level of DHA may be at higher odds for suicide. Trials on whether N-3 PUFAs is effective in the treatment of MDD is still controversial, which might be affected by several factors, such as dose, duration etc.. Now there is no large-scale randomized controlled clinical trial in determining the effects of N-3 PUFAs add-on in treatment of MDD.
45483311|NCT03295708|Dietary Supplement|soybean oil capsule|placebo capsule
45483312|NCT05155826|Device|Virtual Reality Headset|The patient will benefit from the placement of Cook's balloon (standard care) with the placement of the virtual reality headset on the examination table with the launch of the software before the beginning of the procedure. The virtual reality helmet will be removed at the end of the procedure.
45483313|NCT05154734|Drug|Belimumab|Belimumab will be intravenously administered with a dose of 10mg/kg on Days 0,14 and28, then every 28 days until week 48, with a final evaluation at week 52.
45483314|NCT03289624|Behavioral|SHARE-CC|"Each of the 6 SHARE-CC sessions are structured similarly, starting with the dyad reviewing goals of the session, the CG & PWCC meeting jointly or separately with the SHARE-CC Counselor around session-specific material, & ending with a review of material, addressing questions, & previewing the next session. Sessions titles are: Communication & Health Education; Care Values; Care Preferences; Family, Friends, & Community Resources; Taking care of yourself-taking care of each other; & Take Action Now.~The SHARE plan will be developed throughout the sessions and reflects the consensus achieved because of participating in SHARE-CC. It is intended to ensure that the PWCC's values & preferences are supported when decisions have to be in the future."
45690882|NCT03596463|Other|Breast cancer treatment|Multidisciplinary approach for breast cancer treatment is more beneficial for the patients
46051298|NCT05230095|Behavioral|social cognition tests|"The evaluation of social cognition will be carried out using questionnaires and a point lights computer test. During the computer test, participants have to watch several short sequences of interactions between two silhouettes and give an interpretation of the scene.~Patients will be evaluated twice: one time before the surgery and a second time 1 year after surgery.~Healthy volunteers will be evaluated only one time."
46051299|NCT05230095|Behavioral|Quality of life self-questionnaire|Quality of life will be assessed using a self-administered questionnaire in the patients group only.
46051300|NCT04245033|Drug|Dihydroartemisinin-Piperaquine (DP)|Dihydroartemisinin-Piperaquine (DP) for intermittent preventive treatment of malaria in school children (IPTsc).
45366317|NCT00463060|Procedure|radiotherapy|Radiation is to be delivered to each site over 10 fractions separated by at least 16 hours. Up to 5 sites may be treated
45690883|NCT04191603|Device|MONOPOLAR HOOC|COLPOTOMY WITH MONOPOLAR HOOC
45690884|NCT04191603|Device|PLASMAKINETIC BIPOLAR SPATULA|COLPOTOMY WITH BIPOLAR SPATULA
45366318|NCT03964753|Drug|Nab-paclitaxel and Cisplatin|Nab-paclitaxel,125mg/m(2), d1,d8, Cisplatin,75mg/m(2), d1, 3 week, 2 cycles.
45690885|NCT04029909|Drug|Gimatecan 0.6mg/m2/d|0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan
46051301|NCT02830971|Procedure|Doing Different ICU techniques and skills|
46051302|NCT04244799|Behavioral|Behavioral nudges|"Behavioral nudges include the following:~Colorful pathway overlaid with footprints leading from the toilet to the handwashing station~Rotating posters in toilet areas with messages targeting behavioral motivators for handwashing (disgust, social affiliation)~Sticker of a pair of eyes placed above the handwashing station~Soap dish with an arrow beside it on the sink or counter to remind children to wash their hands with soap"
45366319|NCT03964753|Procedure|surgery|surgery
45366320|NCT00956748|Drug|Ciprodex|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
45366321|NCT00956748|Drug|Ciprodex and 2% NAC|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
45366322|NCT00710333|Drug|Avotermin|10 patients undergoing surgical revision of bilateral keloids will be dosed with 500ng Juvista/100µL per cm of wound margin to one ear lobe and placebo to the other and followed up for three months after dosing to assess the local and systemic tolerability.
45483315|NCT05253482|Procedure|wet cupping therapy|Vacuum cups will used on different acupuncture points to perform WCT: The one on the posterior median line, in the depression below the processus spinosus of the 7th cervical vertebra was DU 14 (Dazhui) point; the ones on the back, 3.0 cm lateral to the lower border of the spinous process of the 3rd thoracic vertebra interscapulum region were UB 42 (Pohu) bilateral points; and the ones on the back, 3.0 cm lateral to the lower border of the spinous process of the 7th thoracic vertebra were UB 46 (Geguan) bilateral points and additionally the patient's trigger points which we detect during the examination. There will be 5-7 points in total. The technique used will be triple S (Sucking, Scarification, Sucking) in all sessions.
45483316|NCT01183520|Dietary Supplement|Omega-3 fish oil provided by salmon|Eating 3 different amounts of provided salmon twice a week for four weeks
45483317|NCT02978404|Drug|Nivolumab|Nivolumab is administered to patients to a maximum of 2 year.
45483318|NCT02978404|Radiation|Radiosurgery|Up to 10 cubic centimeter of brain metastases will be treated with radiosurgery. The dose of radiosurgery depends on the size of individual metastases.
45483319|NCT03601286|Drug|Lentiviral vector transduced CD34+ cells|Gene therapy for X-linked Severe Combined Immunodeficiency will be performed by introduction a normal copy of the IL2RG gene into the blood forming stem cells (CD34+ cells) of the patient's bone marrow by using a type of gene delivery system (in this trial called a lentiviral vector). The gene corrected cells are then transplanted back into the patient.
45483320|NCT04489186|Device|Wearable device|Multimodal electrocardiography (ECG), bioimpedance (bioZ) and tri-axial accelerometry (ACC) monitoring with a single wearable device (Byteflies Sensor Dot) to derive heart rate, respiratory rate and actigraphy.
45483321|NCT04441918|Combination Product|JS016 (anti-SARS-CoV-2 monoclonal antibody)|JS016 (anti-SARS-CoV-2 monoclonal antibody)
45483322|NCT01755195|Drug|Cabozantinib|Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2).
45483323|NCT05248646|Drug|Sibeprenlimab 400 mg|Sibeprenlimab 400 mg s.c. q 4 weeks
45483324|NCT05248646|Drug|Placebo|Placebo s.c. q 4 weeks
45483325|NCT03289546|Behavioral|Mindfulness training|"The mindfulness training protocol will include the following basic components of traditional mindfulness-based stress reduction training: 1) training in awareness of sensations (body scan); 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life, and in recognizing when the attention is no longer focused on a specific object of attention; and 4) training in 'open awareness'."
45483326|NCT03289546|Behavioral|Aerobic training|Exercise sessions will be led by CPR- and exercise-certified YMCA instructors and supervised by the senior research assistant. Sessions will consist of 10 minutes of warm-up, 40 minutes of aerobic exercise (walking on a treadmill), 10 minutes of cool down and stretching. Participants will receive heart monitors at the beginning of the study and will be trained by the senior research assistant to exercise targeting heart rates at 65-75% of the age predicted max heart rate or at an intensity of 12-13 in the Borg scale of the rate of perceived exertion.
45366323|NCT00710333|Drug|placebo|placebo
45366324|NCT01079923|Dietary Supplement|Single High Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 150,000 international units orally once (Bio-tech Pharmacal 50,000 IU capsule, Fayetteville, AR).
45483327|NCT01331577|Behavioral|Cognitive Behavioural Training|Two day seminar
45483328|NCT01331577|Behavioral|Integrative Kinesiology Intervention|Two day seminar
45483329|NCT04735718|Device|Cerviron|"Cerviron® ovules is a class IIb medical device used as adjuvant treatment in cervical lesions of mechanical origin. It favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.~Moreover, it provides a strong hemostatic effect, as shown in multiple studies. Moreover, it contains collagen with nutritive, hydrating, healing and trophic effect. Collagen is structurally and functionally a key protein of the extracellular matrix which is also involved in forming the scars during the healing of conjunctive tissues, due to its chemotactic role. Many collagen bandages were developed to improve the repair of the wound, especially of non-infected, chronic, idle cutaneous ulcerations."
45366325|NCT01079923|Dietary Supplement|Daily Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 5,000 IU capsule, Fayetteville, AR).
45483330|NCT03289468|Diagnostic Test|Voluson E8 (GE Medical Systems, USA), Minimally Invasive Endometrium Sampler|The endometrial thickness, basic characteristics information and endometrial blood flow energy index, endometrial vascularization index, blood flow index are detected by color power Doppler and the energy histogram of endometrium is obtained using a Voluson E8 (GE Medical Systems, USA) ultrasound system. The specimen of uterine cytology and endometrial tissue are obtained through minimally invasive endometrium sampler, which are diagnosed by pathology.
45483331|NCT04441606|Radiation|68Ga-FAPI-04 PET/CT|"Patients will undergo two scans: first a routine FDG PET scan and a FAPI PET scan, within 10 days.~Scans will be interpreted by board certified Nuclear medicine physicians and board certified radiologists.~Immunohistochemical analysis with specific staining for FAP will be performed in removed malignant tissues, either at surgery or from biopsy, to assess a possible correlation between the intensity of uptake and the level of FAP expression."
46051303|NCT04244799|Behavioral|National WASH policy|"The Philippines' Department of Education National WASH in Schools (WinS) policy promotes correct hygiene and sanitation practices among school children and a clean environment in and around schools and includes initiatives related to infrastructure, knowledge, and behavior change, but does not include other programs with an explicit focus on handwashing promotion."
46051304|NCT02830737|Procedure|Traditional RFA|Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the lesion center
46051305|NCT02830737|Procedure|No-touch RFA|Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the tumor-free zone (within 5mm along the edge of the tumor)
45366326|NCT00951054|Drug|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m^2 (or 18 mg/m^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
45366327|NCT00947076|Drug|Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)|
45845882|NCT05006976|Other|NSAC health + MBW|"NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health + MBW clinicians are provided survey information on potential health problems as well as information on motivation for work, barriers for return to work and work environment factors."
46051306|NCT04244643|Other|data collection|"Data collected from patient records~Demographic data: date of birth, sex, city of birth~Contact lenses: laboratory, brand, model, wearing time before the exam, opening date of the blister, solution of contact lenses, material, renewal time~Refraction~Dry eye disease: Ocular Surface Disease Index (OSDI) score~LACRYDIAG data: Non-Invasive Break-Up Time (NIBUT), interferometry and tears meniscus height"
46051307|NCT00889863|Drug|canakinumab|Canakinumab 4 mg/kg dose subcutaneous injection supplied as 6 mL glass vials each containing 150 mg canakinumab as a lyophilized cake.
45366328|NCT00947076|Drug|Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)|
45366329|NCT00462982|Drug|sunitinib malate|
45366330|NCT02573597|Drug|Bupivacaine|Continuous or bolus administration
45690886|NCT04029909|Drug|0.8mg/m2/d|0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan
45366331|NCT02573597|Drug|Sufentanil|Continuous or bolus administration
45366332|NCT05300958|Drug|Deferoxamine Plus Chemotherapy|Deferoxamine：50mg/kg+500ml normal saline (NS)
45366333|NCT00951210|Biological|PLX-PAD|IM injection
45366334|NCT04070729|Other|Placebo gel|Localized subgingival application
46051308|NCT00889863|Drug|placebo|Placebo powder matching canakinumab supplied as 6 mL glass vials containing a lyophilized cake for subcutaneous injection every 4 weeks in Part II.
46051309|NCT02832453|Behavioral|Lifestyle|The counselling program consists of 6 group meetings of 1 hour and 3 individual consultations of at least 15 minutes each. Sessions will be set up with the aim to enhance knowledge and empowerment related to physical activity, sedentary conducts, dietary habits, as well as strategies for behaviour change will be given. Individual consultations will focus on establishing realistic objectives and to involve the participants in taking decisions.
45366335|NCT04070729|Drug|Hyaluronic acid gel|Localized subgingival application
45483332|NCT03532191|Other|PrEP Optimization Intervention (PrEP-OI)|PrEP-Rx + PrEP Coordinator
45366336|NCT04070729|Biological|Platelet rich fibrin|Localized subgingival application
45366337|NCT00951288|Dietary Supplement|Saffron|Saffron 20 mg/day supplementation
45366338|NCT00951288|Dietary Supplement|Placebo|Placebo
45366339|NCT00462904|Drug|BPI|BPI will be give IV with an initial bolus given over 30 minutes and then a continuous infusion for the next 47.5 hours
45366340|NCT00956826|Device|Agit Vacuum|With an electrode and a regular vacuum device
45366341|NCT00709397|Other|blood drawing|Subjects will have been prescribed raltegravir (400 mg BID) by their primary physicians. Such subjects will have frequent blood sampling in this study to monitor the virologic response to raltegravir therapy.
45366342|NCT00467272|Drug|Daptomycin|6 mg/kg IV every 24 hours for at least 7-14 days, depending on the type of bacteria. Treatment expected to be at least 14 days for SA and at least 7 days for enterococci and CNS, Corynebacterium, and Propionibacterium.
45483333|NCT01331655|Drug|EE20/DRSP (BAY86-5300)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP (1 tablet/day); up to 120-day treatment period followed by a 4-day tablet-free interval
45690887|NCT04029909|Drug|0.4mg/m2/d|0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan
45690888|NCT04190979|Device|Medyria TrackCath System|The TrackCath System is a non-implantable device and consists of the TrackCath Catheter and the TrackCath Equipment. It is designed to support the successful positioning of third-party guidewires and catheters in the arterial vasculature to detect and cannulate side branches during endovascular aneurysm repair procedures through the measurement of real-time blood flow velocity changes.
45690889|NCT03596307|Dietary Supplement|Ashwagandha extract|Shoden 180 mg capsule.
45690890|NCT03596307|Dietary Supplement|Placebo|Placebo 180 mg (Sucrose) capsule.
45690891|NCT03746535|Drug|Elagolix|Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.
45845883|NCT05002140|Drug|XRD-0394|Single ascending dose
45845884|NCT05002140|Radiation|Palliative radiotherapy|4 Gy × 5 daily fractions
45845885|NCT04988646|Drug|Acyclovir 200 MG|Administered with 240 mL of water
45366343|NCT00956904|Device|3-D TRUS navigation software during T-RALP|A new solution for guiding the surgeon in RALP is image-guided navigation using transrectal ultrasound (TRUS). A TRUS-guided intraoperative navigation system using a robotic ultrasound probe manipulator (TRUS Robot) has been developed. The research is a pilot clinical trial of the TRUS Robot and three-dimensional (3-D) navigation software to test its image-guidance ability of helping the surgeon during RALP. This is a dual robot approach, a Tandem-RALP (T-RALP). The TRUS Robot allows a steady holding as well as remote manipulation of the TRUS probe. In addition, the TRUS Robot can track the accurate position of TRUS probe which allows 3-D reconstruction of the images.
45366344|NCT00956982|Drug|Pegylated interferon alpha-2b plus ribavirin|All patients were treated with a weight-based, 1.5 μg/kg weekly dose of subcutaneous PEG-IFN alpha-2b (PegIntron A, Schering-Plough, Osaka, Japan), in combination with PEG-IFN alpha-2b, RBV (Rebetol; Schering-Plough), which was given orally at a daily dose of 600-1000mg based on bodyweight (600 mg for patients weighing < 60 kg, 800 mg for those weighing 60-80 kg, and 1000 mg for those weighing 80 kg). The length of treatment was 48 weeks for patients with HCV of genotype 1and 24 weeks for patients with genotypes 2, respectively
45366345|NCT00714857|Drug|Dexmedetomidine|The patients are given a normal loading dose (10 min infusion at a rate of 3-6 μg/kg/h) of dexmedetomidine followed by continuous infusion of 0.1 - 2.5 μg/kg/h for the period of time the responsible physician finds reasonable.
45483334|NCT01331655|Drug|EE20/DRSP/L-5-MTHF (BAY98-7071)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium (1 tablet/day) up to 120-day treatment period followed by a 4-day tablet-free interval
45483335|NCT01331655|Drug|EE20/DRSP/L-5-MTHF (BAY98-7071) + L-5-MTHF (BAY86-7660)|Day 1-24: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium per tablet (1 tablet/day) Day 25-28: tablets with 0.451 mg levomefolate calcium (1 tablet/day)
45483336|NCT03295474|Other|Rehabilitation using telehealth technology|"Consecutive patients with chronic respiratory disease referred for pulmonary rehabilitation are offered to participate in the protocol.~Patients are taught to use the system during the first session of aerobic training.~During 2 to 5 sessions of aerobic training (depending on the number of sessions needed to be autonomous), they are monitored in the pulmonary rehabilitation center with an oximeter device (Nonin 3150).~At the end of every session, patients are asked to answer to 3 questions on a Likert scale (see outcome session).~The therapist also ascertains wether the telemonitoring gateway successfully provided informations regarding the session.~The study takes off on the session during which the patients are autonomous in using the telehealthcare system.~If patients are not autonomous on the fifth session, the study also takes off."
45483337|NCT01331733|Drug|hMG-HP|
45483338|NCT01331733|Drug|hMG + GnRH antagonist|
45366346|NCT00957060|Drug|GLIMEPIRIDE (HOE490)|Pharmaceutical form: 2 mg and 4 mg tablets Route of administration: oral
45483339|NCT01085578|Drug|CG400549/placebo|Period 1: a single oral dose of 80 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 320 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1280 mg CG400549 or placebo on Day 1
45483340|NCT01085578|Drug|CG400549/placebo|Period 1: a single oral dose of 160 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 640 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1920 mg CG400549 or placebo on Day 1
45483341|NCT01085578|Drug|CG400549|Period 1: a single oral dose of 640 mg CG400549 on Day 1 in the fasted state Period 2: a single oral dose of 640 mg CG400549 on Day 1 in the fed state
45845886|NCT04988646|Drug|Acyclovir 400 MG|Administered with 240 mL of water
45366347|NCT00957060|Drug|SITAGLIPTIN|Pharmaceutical form: 100 mg tablets Route of administration: oral
46051310|NCT02832453|Behavioral|Aerobic interval training|The supervised aerobic interval training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of 4 series of 4 minutes of cycling at a heart rate of 80% of the VO2peak interspersed with active pauses of 2 minutes at 60% of the VO2peak .
45483342|NCT03289390|Drug|Acetaminophen|Acetaminophen given at discretion of medical team for PDA treatment. Research team to evaluate pre and post laboratory values and echocardiograms.
45483343|NCT04488796|Behavioral|Assigned Strategies: Opt-in|Participants will be assigned two behavioural strategies with the opt-in choice structure
45483344|NCT04488796|Behavioral|Assigned Strategies: Active Choice|Participants will be assigned two behavioural strategies with the Active choice structure
45483345|NCT04488796|Behavioral|Assigned Strategies: Enhanced Active Choice|Participants will be assigned two behavioural strategies with the Enhanced Active choice structure
45845887|NCT04988646|Drug|Zovirax 200 MG Tablet|Administered with 240 mL of water
45845888|NCT04988646|Drug|Zovirax 400 MG Tablet|Administered with 240 mL of water
45845889|NCT04983420|Other|non-alcoholic Pilsner|intake of 1 L non-alcoholic Pilsner per day for 2 weeks
45845890|NCT04983420|Other|non-alcoholic wheat beer|intake of 1 L non-alcoholic wheat beer per day for 2 weeks
46051311|NCT02832453|Behavioral|Traditional continous training|The supervised traditional continous training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of activities such as walking, cycling, or tonification exercises always at an intensity of 60% of the VO2peak.
45366348|NCT02573519|Radiation|11C Donepezil PET/CT scan|Donepezil binds with high affinity to acetylcholine esterase in the cholinergic synapses. The quantity of density of acetylcholine esterase in the abdominal organs including the intestinal wall are demonstrated by 11C Donepezil PET/CT scan. The PET-signal are measured as Standard-uptake values (SUV) in the internal organs. After 6 hours of fast CT- and PET-scans are performed after injection of iv. contrast and about 500MBq (megabecquerel) [11C]donepezil. The CT scan is used for anatomical location of the internal organs. The scan-field includes the heart and the abdominal organs. Total scan time is about 60 minutes.
45483346|NCT04488796|Behavioral|Choice of Assignment: Opt-in|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Opt-in choice structure
45483347|NCT04488796|Behavioral|Choice of Assignment: Active Choice|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Active choice structure
45483348|NCT04488796|Behavioral|Choice of Assignment: Enhanced Active Choice|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Enhanced Active choice structure
45483349|NCT03382977|Biological|VBI-1901|The vaccine is formulated with GM-CSF adjuvant and administered intradermally (ID) or with AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.
45483350|NCT03382977|Drug|Carmustine|Treatment with carmustine intravenously at a dose of 150 mg/m² on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.
45483351|NCT03382977|Drug|Lomustine|Treatment with lomustine given orally at a dose of 110 mg/m² (up to a maximum dose of 200 mg) on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.
45483352|NCT00897104|Drug|rizatriptan benzoate (MK0462)|single dose 5 mg rizatriptan p.o.
45483353|NCT00897104|Drug|Comparator: sumatriptan|single dose 50 mg sumatriptan p.o.
45483354|NCT00897104|Drug|Comparator: Placebo|Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally
45483355|NCT03289156|Behavioral|Arousal Reappraisal|Brief readings educating about the stress response and usefulness of arousal reappraisal.
45483356|NCT03289156|Behavioral|Exercise|Three 5-minute bouts of exercise at increasing intensities (65%, 75%, and 85%) with 5-15 minute breaks in-between for recovery.
45483357|NCT03289078|Other|Spa Treatment|The spa treatments will be realised daily 6 days a week and during 18 days. The care will be provided is : Swimming pool of mobilization by physical therapist (20 minutes daily, Cataplasms (10 minutes daily), Shower in the jet (10 minutes daily), Shower under affusion (10 minutes daily)
45483358|NCT03289000|Device|iTotal Posterior Stabilized (PS) Knee Replacement System|Patient-specific posterior stabilized total knee replacement and patient specific surgical jigs
45483359|NCT00792506|Drug|ITF2357|Treatment was to be administered on an inpatient basis from week 1 to week 13 and on an outpatient basis from week 14 to anticipated end of treatment (week 18). The patients had to be hospitalized on day 1 every week. The Investigator had to administer ITF 2357 in one single dose (two or three 200 mg capsules at one time) under his/her direct control.
45690892|NCT04406337|Device|Low intensity pulsed ultrasound|Low intensity pulsed ultrasound therapy will use ultrasound with frequency of 1.5 MHz, power intensity of 30 mW/cm^2 (0.03 W/cm^2 ) and 20% duty cycle.
46051312|NCT00915018|Drug|Neratinib|Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
46051313|NCT00915018|Drug|Trastuzumab|Trastuzumab - 4 mg/kg IV initial loading dose followed by subsequent once weekly doses of 2mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
46051314|NCT00915018|Drug|Paclitaxel|Paclitaxel - 80 mg/m² IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
46051315|NCT02830425|Other|No intervention|
46051316|NCT04247295|Device|Traditional Cast|Application of a traditional cast
45752198|NCT03239015|Drug|Trastuzumab|Trastuzumab is an FDA/CFDA approved targeted drugs used for Her2 amplification based on NGS results.
46051317|NCT04247295|Device|Woodcast|Application of a woodcast
45483360|NCT03288922|Procedure|Limited BF OL-HDF with SHF|"The new modality Limited BF OL-HDF with SHF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 300 ml/min and the total dialysis fluid flow rate was 800 ml/min which included pre-filter substitution rate of 150 ml/min. The super high-flux dialyzer was PES-17Dα from Nipro Corporation, Japan which contains 1.7 m2 hollow fiber polyethersulfone membrane (ultrafiltration coefficient 80 ml/h/mmHg; urea clearance 267 ml/min, Qb 300 ml/min and Qd 500ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm."
45483361|NCT03288922|Procedure|High-efficiency OL-HDF|"The controlled modality High-efficiency OL-HDF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 400 ml/min and the total dialysis fluid flow rate was 800 ml/min which included post-filter substitution rate of 100 ml/min. The standard high-flux dialyzer that was used was HF80s from Fresenius Medical Care, Germany contains 1.8 m2 hollow fiber polysulfone membrane (ultrafiltration coefficient 55 ml/h/mmHg; urea clearance 248 ml/min, Qb 300ml/min and Qd 500 ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm."
45483362|NCT04416932|Procedure|Ultasound|Evaluation of post-operative patients who have had total shoulder arthroplasty and will assess the integrity of the rotator cuff using ultrasound.
45366349|NCT02573519|Device|3D-Transit|"3D-Transit: 3D-Transit for minimal invasive and ambulant describing of regional transit times and contractions pattern of the bowel. The motility and the passage time is measured by 3D-Transit The description of location and rotation of the capsule is dynamic and very precise. It permits precise detailed description of the gastrointestinal contraction pattern and regional passage time. 3D-transit consist of three different parts:~A wireless electromagnetic capsule to be swallowed by the subject~A portable detector plate comprising four sensors worn in a belt around the waist~Specific software for visualizing and analyzing data"
45483363|NCT02462200|Procedure|Breast-conserving surgery (BCS)|
45483364|NCT02462200|Procedure|Cavity shave margins (CSM)|
45483365|NCT02462200|Behavioral|BREAST-Q Questionnaire|
45483366|NCT02462200|Device|3-D breast imaging|Using a 3-D breast imaging camera Vectra 3-D XT
45483367|NCT02462200|Other|Indocyanine green|
45483368|NCT02462200|Device|Intraoperative imaging device|The goggle device is wearable, compact, and battery-operated, and it allows for hands-free operation by the wearer. The goggles provide functional information via a NIR light-emitting diode (LED) integrated within one of the eyepieces, which causes NIR fluorescence excitation of the molecular probes within the surgical field
45483369|NCT02462200|Procedure|Peripheral blood draw|-Time of surgery if coordinator is available
45690893|NCT04406337|Device|High intensity continuous ultrasound|High intensity continuous ultrasound therapy will use ultrasound with frequency of 1 MHz, power intensity of 3 W/cm^2 and 100% duty cycle.
45690894|NCT04029441|Other|the eradication Hp|the eradication of Hp based on antimicrobial susceptibility test
45690895|NCT04766151|Drug|Transdermal glyceryl trinitrate 10mg patches|Transdermal patches applied to skin 30 minutes before cardiac catheterization
45845891|NCT04983420|Other|apple spritzer|intake of 1 L apple spritzer per day for 2 weeks
45845892|NCT04983420|Other|lemonade|intake of 1 L lemonade per day for 2 weeks
45483370|NCT04488718|Other|EnergieShake® Junior Powder Complete|Oral Nutritional Supplement
45483371|NCT03295162|Drug|Melatonin 10 mg|Melatonin will be given at a total dose of 20 mg dissolved in 4 ml of distilled water via enteral route in two doses of 10 mg each(2 ml ), with a 1-hour interval. to one group together with conventional treatment
45690896|NCT04766151|Drug|Placebo patches|Transdermal placebo patches applied to skin 30 minutes before cardiac catheterization
45690897|NCT04029207|Procedure|Cesarean section|Abdominal, operative delivery of the fetus
45690898|NCT04191213|Dietary Supplement|Acacia Senegal extract|Oral Digestion of Gum Arabic to be consumed early morning in daily basis for 12 weeks
45690899|NCT04191213|Dietary Supplement|Pectin|Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks
45690900|NCT04029129|Other|Air filtration and building envelop modifications|Air filters and closing and sealing of windows and doors was used to reduce infiltration of air pollution from outdoors in rooms next to major highways at rush hour.
45845893|NCT04972110|Drug|RP-3500 (camonsertib)|RP-3500 (camonsertib, ATR inhibitor) in combination with Niraparib or Olaparib (PARP inhibitors)
45845894|NCT04947462|Device|Chronically Implanted Neural and Muscular Interface|Participants will be chronically implanted with neural and muscular interfaces to characterize proprioceptive sensations using Functional Electrical Stimulation (FES).
45690901|NCT03024177|Drug|Vapendavir|Vapendavir Tablets, 264 mg
45690902|NCT03024177|Drug|Placebo Oral Tablet|Vapendavir 264 mg matching tablets
45690903|NCT01874431|Drug|Finerenone (BAY94-8862)|
45690904|NCT01874431|Drug|Placebo|
45845895|NCT04926948|Other|Immunotherapy|Immunotherapy
45845896|NCT04926948|Other|Quality-of-Life Assessment|Ancillary studies
45845897|NCT04926948|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
46051318|NCT04246905|Drug|sulforaphane|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
46051319|NCT04246905|Other|placedo|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
46051320|NCT04246905|Drug|selective 5 - HT reuptake inhibitors (SSRI)|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
46051321|NCT02830503|Procedure|Feeding tube daily replacement|Feeding tubes replaced once a day in the first week of life.
46051322|NCT05251740|Device|Altimate Medical EasyStand Bantam|The child will stand in the device for 60 min per day, 5 days per week for 2 months.
46051323|NCT02832219|Dietary Supplement|Molecular hydrogen|
46051324|NCT02832219|Dietary Supplement|Placebo|
46051325|NCT02827695|Behavioral|SMASK|Medication adherence and BP monitoring
45690905|NCT04028817|Device|photobiomodulation|the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied sublingual laser in a single point, with wavelength of 808 nm, diameter of 0.4 cm, with irradiance of 0.8 w / cm2, for 360 s, the laser applied will be of continuous wave with energy of 36J.
45690906|NCT04028817|Device|placebo photobiomodulation|the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied a placebo sublingual laser for 360 s.
45366350|NCT02573519|Drug|3D-Transit during treatment with Pyridostigmine|3D-Transit and Pyridostigmine: The motility and the passage time is measured by 3D-Transit (as mentioned above) in diabetic patients during administration of Pyridostigmine 60 mg administrated 4 times with 4 hours between each administration. Pyridostigmine is increasing the amount of cholinergic neurotransmitter and is suggested to have a reversible effect on the cholinergic denervation. The mechanism of action of Pyridostigmine in the human body is well-known and the drug is used as a tool to determine if the disturbance in the guts are reversible in diabetic patients.
45483372|NCT03295162|Combination Product|Conventional treatment of neonatal sepsis|Conventional treatment of neonatal sepsis including antibiotics,IV fluids, Total Parenteral Nutrition,etc...
45483373|NCT05237492|Drug|Tramadol|Blood samples will be drawn from 15 patients. Tramadol will be added to all this samples in-vitro and its influence on platelets´ function will be measured.
45483374|NCT05230238|Device|Pituitary gland stimulation|Pituitary gland stimulation via an surface electrode connected to an external neurostimulator
45366351|NCT02573519|Device|3D-Transit after Malone appendicostomy|3D-Transit (as earlier described) is performed after Malone appendicostomy. The patients are suppose use the antegrade edema technic during the 3D-transit examination.
45366352|NCT00947232|Behavioral|Motivational interviewing|Motivational interviewing, a proven counseling method that centers on individual goals and motivations, to increase exercise and decrease depression.
45483375|NCT04586842|Behavioral|Community-based Occupational Therapy|Domiciliary and Community-based Occupational Therapy on mental health and ABI intervention, developed on the basis of the Model Of Human Occupation.
45483376|NCT04586842|Behavioral|Standard community-based intervention|Interventions received at the community, public or private level (e.g. community nursing, social education and/or psychology).
45483377|NCT05226026|Behavioral|NiteCAPP HELPS|4 weeks of NiteCAPP (a digital version of CBT-I recently developed at Mizzou)
45366353|NCT00947232|Behavioral|Education|Educational intervention about the benefits of physical activity to decrease depression for people aging with multiple sclerosis or spinal cord injury.
45366354|NCT02572661|Radiation|radiation in Squamous Head and Neck Cancer|
45366355|NCT02572583|Drug|Liugan Shuangjie Heji|
45366356|NCT02572583|Drug|Shufeng Jiedu Capsule|
45483378|NCT05226026|Other|Tapered Withdrawal|Gradual tapered withdrawal following CDC guidelines, with additional check-ins and motivational interviewing with a therapist.
45366357|NCT02572583|Drug|Oseltamivir Phosphate Capsule|
45366358|NCT04011306|Device|Lumina24 BLU|Lumina24 BLU is the technology used to deliver continuous low-irradiance phototherapy for the treatment of acute burns
45366359|NCT00714935|Behavioral|Decision Counseling Program (DCP)|An individual decisional counseling program (DCP) to help them comprehend the information, adjust this information to their personal illness history and elicit their preferences for cardiac risk fctor modification behavior in light of this personalized information
45483379|NCT03295084|Drug|Irinotecan|Dose Escalation
45483380|NCT03295084|Drug|Capecitabine|Dose Escalation
45483381|NCT03718364|Procedure|catheter-based ablation of atrial fibrillation (pulmonary vein isolation)|catheter-based ablation of atrial fibrillation (pulmonary vein isolation)
45483382|NCT04710134|Biological|Reslizumab|Reslizumab 3,4, or 5 mg/kg IV q4 weeks
45483383|NCT01339689|Drug|Ganaxolone|200-600 mg bid, capsules, up to 12 weeks
45483384|NCT01339689|Drug|Placebo|capsules, bid, up to 12 weeks
45483385|NCT03038126|Other|CCHT|Veterans Administration (VA) CCHT program available to veterans with difficult to manage chronic conditions and employing an established guideline-based CKD DMP, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC).
45690907|NCT04190511|Dietary Supplement|Prebiotic-containing dairy|The trained dietitian gives guidance on diet, exercise, and weight gain during pregnancy based on the Maternal Dietary Guidelines and Dietary Pagoda recommendations developed by the Chinese Institute of Maternal and Child Nutrition. On this basis, intervention was carried out using prebiotic-containing dairy products (200g/day).
45483386|NCT03038126|Other|Usual care|Standard clinical care
45483387|NCT00702806|Drug|Org 36286|Intra-abdominal injection of Org 36286
45483388|NCT00702806|Drug|Puregon®|Subcutaneous Puregon® 150 IU
45483389|NCT00702806|Drug|Orgalutran®|Subcutaneous Orgalutran® 0.25 mg
45483390|NCT00702806|Drug|Pregnyl®|Subcutaneous Pregnyl® 10,000 IU
45690908|NCT04190511|Dietary Supplement|Dietary intervention|The trained dietitian gives guidance on diet, exercise, and weight gain during pregnancy based on the Maternal Dietary Guidelines and Dietary Pagoda recommendations developed by the Chinese Institute of Maternal and Child Nutrition.
45690909|NCT04028739|Dietary Supplement|curmin|curcumin 90mg/day cross-over
45366360|NCT00714935|Behavioral|Coronary Artery Disease Decision Aid|"Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing."
45690910|NCT04028661|Device|3D printed Modified Twin Block Appliance|It is a functional appliance for mandibular advancement designed digitally on virtual models.
45690911|NCT04028583|Other|PIM-Check|In the PIM-Check group, a medication review will be conducted using PIM-Check within 72 hours of patient's admittance to the unit. The physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
45690912|NCT04028583|Other|STOPP/START|In the STOPP/START group, medication lists will be analyzed within 72 hours of patient's admittance and optimized according to STOPP/START criteria. The second physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
45690913|NCT04028505|Drug|Terlipressin Injectable Product|"Intravenous terlipressin will be obtained from Clinical Trials Unit, AKUH pharmacy in standard IV infusion form.~Participants who are randomized to the intervention arm will be administered a continuous infusion of Terlipressin at a rate of 0.5mg/hour for the first 24 hours. Participants randomized into the control group will be administered a bolus form of Terlipressin at a rate of 2mg every six hourly for the first 24 hours respectively. In case of weekends/public holidays intravenous terlipressin will be obtained from the main pharmacy of AKUH."
45690914|NCT01824355|Device|Ninja 3 PLUS Investigational BG Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Ninja 3 PLUS Investigational BG Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to a reference laboratory glucose method.
45690915|NCT04042623|Drug|AVB-S6-500|AVB-S6-500 is experimental drug
45690916|NCT04190745|Drug|Toripalimab+Apatinib mesylate|Toripalimab 240mg, ivgtt, Q3w Apatinib mesylate 250mg PO. QD
45366361|NCT00951444|Biological|dalotuzumab|Given IV
45366362|NCT00951444|Drug|carboplatin|Given IV
45366363|NCT00951444|Drug|gemcitabine hydrochloride|Given IV
45366364|NCT00462826|Biological|ziv-aflibercept|
45366365|NCT00718601|Drug|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
45690917|NCT04190745|Drug|paclitaxel|paclitaxel 80mg/m2, q3w
45752199|NCT03239015|Drug|Oxazolidine|Oxazolidine is an FDA/CFDA approved targeted drugs used for ALK or ROS-1 or MET fusion based on NGS results.
46051326|NCT02827695|Behavioral|EnhancedSC|Standard care without med reminder functions with healthy lifestyle texts
46051327|NCT04528446|Radiation|Dual-energy X-ray absorptiometry|DXA whole body, hip, spine, and radius at baseline, and 12-month visit.
45366366|NCT00951522|Drug|GS-9411|Inhaled GS-9411 dissolved in sterile saline
45366367|NCT00951522|Drug|Placebo|Inhaled placebo in sterile saline
45366368|NCT00718679|Drug|IVN201|Intralymphativ injection of the study drug
45366369|NCT00718679|Drug|Placebo|
46051328|NCT04528446|Radiation|High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT)|HR-pQCT of the radius and tibia at baseline, and 12-month visit.
45366370|NCT00947388|Drug|Bendamustine Hydrochloride|Bendamustine 70 mg/m2 IV Day 8 and 9 every 28 days for 6 courses of therapy
45366371|NCT00947388|Biological|Alemtuzumab|Given subcutaneously (SC)on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26.
45366372|NCT00710645|Device|Lido Workset|The intervention will consist of spasticity testing on the Lido Workset device. The servo-controlled torque motor system will analyze resistance to passive movement of the knee.
45366373|NCT00951600|Drug|oxcarbazepine 300 mg/5mL oral suspension|
45366374|NCT00710723|Procedure|vitrification|Vitrification using Hemi-straw carrier system.
45366375|NCT04323839|Other|Pregnant women under investigation for Coronavirus or diagnosed with COVID-19|This is an observational study with no intervention
45366376|NCT04323839|Other|Postpartum women under investigation for Coronavirus or diagnosed with COVID-19|This is an observational study with no intervention
45366377|NCT00951678|Other|Observational ultrasonography of venous anatomy|The patient will have ultrasound images obtained of the right and left internal jugular veins as a function of the degree of head rotation and of the right and left femoral veins. Our study is an observational study
45366378|NCT03910985|Drug|Duovent HFA|bronchodilation
45366379|NCT05300880|Other|Training program|A multi-component intervention based on health coaching. The strategies of this program consisted in five 16-hour sessions using case studies to find out whether nurses were able to empower chronic cardiac patients and debriefing and a 4-hour booster session seven months later.
45366380|NCT00957216|Drug|Placebo (sugar pill)|placebo: 2 wafers 4 times a day
45366381|NCT00957216|Drug|Coenzyme Q10|300mg wafers; 2 wafers 4 times a day
45366382|NCT00718757|Drug|Dexamethasone|5 doses given on Days 6-10
46051329|NCT04528446|Other|Blood draw and Urine collection|The blood draw can be completed +/- 3 weeks from baseline or 12-month visit.
46051330|NCT04528446|Other|Questionnaires|Questionnaires regarding fracture history, physical activity and dietary intake at baseline, and 12-month visit.
45366383|NCT00718757|Drug|Irinotecan|20 mg/m2/day IV, 10 doses given on Days 1-5, 8-12
45366384|NCT00718757|Drug|Vincristine|"1.5 mg/m2/day IV (max 2 mg), 2 doses given on Days 1,8~* Patients < 1 year of age or < 10kg in weight: Vincristine 0.05 mg/kg"
45366385|NCT00947466|Drug|Buprenorphine|Transdermal patch
45366386|NCT00957606|Procedure|blood sampling, DXA-scan, bone scintigraphy|Blood sampling 5 times DXA-scan 5 times Bone scintigraphy 3 times
45366387|NCT04069013|Procedure|PCNL|Patients receive standard of care treatment for their urolithiasis using one of two surgical procedures, either standard PCNL or Mini-PCNL
45366388|NCT00951756|Other|High fat diet|High fat diet and low fat diet are composed of the same food, but the portion sizes are varied.
45366389|NCT00718835|Behavioral|incentive-based contingency management|Direct comparison of Contingent versus Noncontingent incentives in promoting abstinence from smoking among opioid-treatment patients. The biochemical measures of breath carbon monoxide levels and urinary cotinine are used to confirm smoking status. Participants receive voucher-based incentives either contingent upon demonstrating abstinence from recent smoking (Contingent condition) or independent of smoking status (Noncontingent control condition).
45366390|NCT00951834|Drug|Epigallocatechin-Gallate|"Epigallocatechin-Gallate (EGCG) - Sunphenon EGCg:~Months 1-3: 200 mg EGCG/die (200-0-0 mg)~Months 4-6: 400 mg EGCG/die (200-0-200 mg)~Months 7-9: 600 mg EGCG/die (400-0-200 mg)~Months 10-18: 800 mg EGCG/die (400-0-400 mg)"
45366391|NCT00951834|Drug|Placebo|Placebo
45366392|NCT00715013|Drug|Patupilone|Patupilone
45366393|NCT00715091|Drug|diclophenac|continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily
45366394|NCT00715091|Drug|diclophenac|treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg daily
45366395|NCT00947622|Device|Transcranial direct current stimulation|Transcranial Direct current stimulation
45366396|NCT00957762|Other|Body composition|Day 1 testing will incorporate underwater weighing, Bod Pod, DXA, BIA and anthropometrics. Day 2 will include RMR, MRI, and testing at GCRC
45366397|NCT00718913|Drug|Docetaxel|Docetaxel will be given at 60 mg/m2, as a 60-minute infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Docetaxel 60 mg/m2.
45366398|NCT00718913|Drug|Cisplatin|Cisplatin will be given at 60 mg/m2, as 2-hour infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Cisplatin at 60 mg/m2.
45366399|NCT00718913|Drug|Capecitabine|Capecitabine will be given orally at 1800 mg/m2 days 1 through 14 divided in two daily doses before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Capecitabine at 1800 mg/m2 days 1 through 14 (divided in two daily doses).
45366400|NCT00718913|Radiation|Radiation|At the end of the second cycle of chemotherapy and one week of rest (day 27), a total of 45 Gy (1.8 Gy fx/d) of radiotherapy will be given.
45366401|NCT00718913|Drug|Capecitabine|Capecitabine will be administered orally during radiotherapy for radiosensitization(1650 mg/m2 per day divided in two daily doses, 5 days/week, on Monday through Friday).
45366402|NCT04011930|Drug|cholecalciferol|80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
45366403|NCT04011930|Drug|Placebo oral capsule|80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
45366404|NCT04068857|Device|rTMS|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008 and has become commonly used in clinical practice. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS enables investigators to manipulate brain activity in a targeted cortical region as well as downstream connectivity within an associated neuronal circuit. High frequency (HF) rTMS leads to facilitatory effects on brain excitability. Previous studies have demonstrated that administration of as little as a single train or a small number of trains are able to produce an immediate increase in cortical excitability.
45366405|NCT00957840|Procedure|NIRS, aEEG, and CSF concentration of biomarkers|NIRS and aEEg will be done twice weekly, and CSF will be analyzed with each reservoir tap
45366406|NCT00715169|Drug|MLN1202|10 mg/kg dose of MLN1202 administered via IV infusion administered approximately 30 minutes to an hour
45366407|NCT00715169|Other|Placebo|Placebo consist of 0.9% saline solution administered as a 10 mg/kg dose via IV infusion administered approximately 30 minutes to an hour
45366408|NCT00951990|Behavioral|Ergometer Cycling|Ergometer Cycling under the guidance of a physical therapist after the second postoperative week. These training sessions were scheduled to be performed three times a week for a time period of at least three weeks. The resistance of the ergometer was set to a minimum (for example 30 Watts). Physical therapists were informed to pay special attention, that the height of the saddle is set so that the forefoot reaches the pedal with the knee in extension.
45366409|NCT00951990|Behavioral|No ergometer cycling|Patients of the no ergometer cycling group did not receive any ergometer cycling after surgery
45690918|NCT01823341|Device|Pump suspension algorithm|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia.
45752200|NCT03239015|Drug|Olaparib|Olaparib is an FDA/CFDA approved targeted drugs used for BRCA1/2 mutation based on NGS results.
46051331|NCT02830347|Drug|Amoxicillin|Extraction
46051332|NCT02830347|Procedure|Extraction|Extraction of third molars
46051333|NCT05253456|Procedure|Derma -Dartos Flap for second layer closure|usage of Derma -Dartos Flap for second layer closure of a distal penile hypospadias in circumcised patients
46051334|NCT04246749|Drug|[14C]-CRN00808|Investigational drug
46051335|NCT04246749|Drug|CRN00808|Investigational drug
45596556|NCT03529279|Radiation|NCCN Radiation|"IMRT technique. When IMRT alone, GTV were given (1) 66Gy (2.2Gy/Fr) to 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 6-7 weeks; (2) 69.96 Gy (2.12 Gy/Fr), 6-7 weeks; CTV1-2 were given 44-50 (2.0 Gy/Fr) to 54-63 (1.8 Gy/Fr).~When combined with chemotherapy, GTV were given 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 7 weeks; CTV1-2 were given 44-50 Gy (2 Gy/Fr) to 54-63 Gy (1.8 Gy/Fr).~When palliative radiotherapy, 50Gy/20Fr; 37.5 Gy/15Fr (if tolerable, increases 5 fractions to 50Gy); 30Gy/10Fr, 30Gy/5Fr, 2 fractions per week, interval more than 3 days; 44.4Gy/12Fr was divided into 3 cycles, 2 fractions a day, 6 hours of interval, 2 consecutive days and 3-4 weeks between two cycles. After second cycles, the treatment plan must completely avoid the irradiation of the spinal cord."
45366410|NCT00718991|Device|Spectranetics Turbo elite™ excimer laser catheter|The Spectranetics Turbo elite™ excimer laser catheters are percutaneous intravascular devices constructed of multiple optical fibers around a guidewire lumen. The laser catheters transmit ultraviolet energy from the Spectranetics CVX-300® Excimer Laser System to the obstruction in the artery. The ultraviolet energy is delivered to the tip of the laser catheter to photo-ablate fibrous, calcific and atheromatous lesions, thus recanalizing diseased vessels.
45366411|NCT00947700|Behavioral|Assessment, Monitoring & Intervention|Assessment and monitoring at 6, 12, 18 and 24 months; Parent delivered intervention provided between 6 and 12 months.
45845898|NCT05600322|Drug|Hexaminolevulinate Hydrochloride|Enrolled patients will be instilled with 50 mL hexaminolevulinate hydrochloride as intravesical solution (Hexvix) in the bladder for one hour at Visit 2. After bladder evacuation, the cystoscopic examinations will be performed in both white and blue light.
46051336|NCT05253300|Other|Positioning the patient|"The patients' vital signs, pain and analgesic drug use were recorded in the Pain Follow-up Form at the time they came to the clinic, at the 6th and 12th hours after the surgery, by recording from the end-of-operation file. In case the patient had pain, the time when the pain started was recorded, the experimental group was given the semi-recumbent position with analgesic drug and the patient was asked to maintain this position for 2 hours. If the patient has pain again, this position is given again. Patient Satisfaction Evaluation Form was filled in at the 12th hour after the surgery for the patients in the experimental group."
45366412|NCT02574377|Drug|A: myDC vaccination|
45366413|NCT02574377|Drug|B: pDC vaccination|
45366414|NCT02574377|Drug|C: combined myDC/pDC vaccination|
45366415|NCT00551616|Drug|CDB-2914|Single dose
45366416|NCT00551616|Drug|Levonorgestrel|Single dose
45366417|NCT00715325|Device|Protectiscop CS|Patients who are indicated for screening colonoscopy will be recruited into the trial. The ProtectiScope CS sleeve is assembled on the colonoscope.standard colonoscopy is performed. Subjects will be followed for 1-month post procedure.
45366418|NCT02574221|Drug|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
45366419|NCT02574221|Drug|cavity protection toothpaste|0.243% sodium fluoride toothpaste
45366420|NCT00719147|Procedure|MRI|Not performed for study purposes, MRI will be done as part of routine clinical visit. Findings will be used for study.
45366421|NCT00719147|Other|Functional Status and Symptom Questionnaire|Questionnaire
45366422|NCT02572349|Drug|IW-1701|
45366423|NCT02572349|Drug|Matching Placebo|
45366424|NCT00719303|Behavioral|Behavioral Dietary Intervention|Receive dietary intervention
45366425|NCT00719303|Behavioral|Compliance Monitoring|Complete daily fat gram and step diaries
45845899|NCT05600322|Device|Richard Wolf Photodynamic Diagnostic Equipment (PDD) system|Cystoscopy in White and Blue light will be done using the Richard Wolf PDD system.
45845900|NCT05404854|Other|Physical Activity|wearing an accelerometer for 7 days before and after the rehabilitation program
45845901|NCT05404854|Other|sedentarity|wearing an accelerometer for 7 days before and after the rehabilitation program
46051337|NCT02830269|Device|Transcranial Doppler ultrasonography measurements|Third ventricle diameter measurements with standard method (CT) and Transcranial Doppler ultrasonography
46051338|NCT05253222|Diagnostic Test|retrograde image by colonic TET|"Delivery of contrast fluid by colonic TET Each participant will receive one delivery of 200 ml contrast fluid by colonic TET to the distal portion of the lesion.~One group will be taken CT investigation, another group will be taken X-ray fluoroscopy.~Imaging parameters will be collected and evaluated."
46051339|NCT02832609|Other|Supine|measurements after 30 minutes in complete supine position
46051340|NCT04201899|Dietary Supplement|No intervention - pure observation|Phosphate administration (yes or no)
45366426|NCT00719303|Other|Counseling|Undergo face-to-face and telephone counseling
45483391|NCT01331811|Other|Development of a diagnosis algorithm|"At entry in the study, HIV infected children with suspected tuberculosis will undergo a complete evaluation including:~interview on anamnesis~clinical examination~evaluation of HIV infection stage~hematology and biochemistry tests~CD4 count~HIV viral load~IGRA~chest radiograph~Abdominal ultrasonograph to detect abdominal lymphadenopathy~Tuberculin skin test~gastric aspirates, sputum and string tests according to the age of children~nasopharyngeal aspirate~stool sample~lymph node fine needle aspirate or other specimen collection if applicable~Diagnosis and treatment of all participating children will be done according to national guidelines. The children will be followed-up for 6 months until the end of their anti-TB treatment. For the analysis of data and the validation of the algorithm, children will be randomized into 2 groups. Data from Group I will be used to develop the algorithm; data from Group II will be used to validate it."
45690919|NCT04028427|Behavioral|Values-plus-goals intervention|The VGI is a four-week intervention, adapted from an existing online value-affirmation and goals intervention (Kingston & Ellett, 2014) and an existing 'Living Well with Physical Health Conditions' programme handbook. Participants are first introduced to the concept of values as understood in Acceptance and Commitment Therapy. They are then asked to complete a card-sort task, which involves organising ten life domains according to their perceived level of importance. Participants will be asked to choose one values that is the most important and meaningful to them and to write for up to 10 minutes about it, thinking about why it is meaningful to them. Following this, participants will be given information on how to set value-based 'SMART' goals and asked to choose one to focus on over the next month. Participants will be sent a reminder e-mail every week over the 4 weeks, asking them to review their progress towards the SMART goal they set themselves.
45847882|NCT03036384|Drug|HB Prilocaine 2% (varying dose)|Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
45366427|NCT00719303|Other|Educational Intervention|Receive educational materials
45366428|NCT00719303|Behavioral|Exercise Intervention|Undergo physical activity intervention
45366429|NCT00719303|Other|Laboratory Biomarker Analysis|Correlative studies
45366430|NCT00719303|Other|Quality-of-Life Assessment|Ancillary studies
45366431|NCT00719303|Other|Questionnaire Administration|Ancillary studies
45366432|NCT00452530|Drug|Enoxaparin|40 mg, administered once daily by subcutaneous injection, for 12 days
45366433|NCT00452530|Drug|Apixaban|2.5 mg, administered twice daily as tablets, for 12 days
45366434|NCT00452530|Drug|Enoxaparin-matching placebo|Administered once daily by subcutaneous injection
45366435|NCT00452530|Drug|Apixaban-matching placebo|Oral tablet administered twice daily
45366436|NCT00549198|Drug|Abacavir/lamivudine and efavirenz|
45366437|NCT00549198|Drug|Tenofovir/Emtricitabine and efavirenz|
45752201|NCT03239015|Drug|Everolimus|Everolimus is an FDA/CFDA approved targeted drugs used for mTOR or PI3KCA mutation based on NGS results.
45483392|NCT04441281|Procedure|Traction of the cervix for IUD insertion|Limited mobility of the uterine cervix and alignment with the vaginal canal is often required during insertion of an intrauterine contraceptive device (IUD).
45366438|NCT00607724|Drug|GDC-0449|
45366439|NCT00506415|Drug|Rivastigmine 5 cm^2|5 cm^2 transdermal patch
45366440|NCT00506415|Drug|Rivastigmine 10 cm^2|10 cm^2 transdermal patch.
45366441|NCT00506415|Drug|Rivastigmine 15 cm^2|15 cm^2 transdermal patch.
45366442|NCT00506415|Drug|Placebo to 15 cm^2 patch|Placebo of rivastigmine transdermal patch 15 cm^2.
45366443|NCT00506415|Drug|Placebo to 10 cm^2 patch|Placebo of rivastigmine transdermal patch 10 cm^2.
45366444|NCT04036526|Biological|Vaccine GamLPV|live intranasal vaccine for whooping cough prevention
45366445|NCT04036526|Other|Placebo|Placebo
45366446|NCT00893360|Biological|Autologous stem cell infusion|Subjects will receive 12.5 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
45483393|NCT01336803|Drug|Feraheme|5 mg/kg by intravenous (IV) administration
45483394|NCT01336803|Procedure|Magnetic Resonance Imaging (MRI) scan|Standard of Care magnetic resonance imaging (MRI) scans using GE 1.5T and 3T MRI scanners/
45483395|NCT03635931|Procedure|Concentrated Growth Factor|surgical treatment with CGF for papilla regeneration
45483396|NCT01331967|Drug|Pioglitazone|Pioglitazone 15-30mg, once daily for 9 months
45847883|NCT03036384|Drug|HB Prilocaine 2%|The dose of 45mg of hyperbaric (HB) prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
45847884|NCT03036384|Drug|Sufentanil|2.5µg sufentanyl
45752202|NCT03239015|Drug|Cabozantinib|Cabozantinib is an FDA/CFDA approved targeted drugs used for RET mutation based on NGS results.
45847885|NCT03036384|Drug|Morphine|100 µg Morphine
45366447|NCT00893360|Biological|Autologous stem cell infusion|Subjects will receive 25 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
45366448|NCT02573441|Behavioral|Jump Math|Jump Math is a workbook based program aimed at improving math skills
45366449|NCT02573441|Behavioral|Cogmed|Cogmed is an online computer program aimed at improving working memory skills
45366450|NCT02573441|Behavioral|Liaison Services|Liaison Services will include working closely with schools to help explain the strengths and weaknesses of a child based on cognitive testing and to help with the implementation of recommendations
45366451|NCT04036604|Other|Exercise|"Pelvic floor exercise programme include repetition of pelvic floor muscle contraction during twice a week for 8 weeks performed by an expert pelvic health physiotherapist.~Pelvic floor education programme include pelvic floor anatomy, information about pelvic floor dysfunction and behavioral changes."
45366452|NCT00947778|Other|3 sessions of evaluation tests|3 sessions of evaluation tests, each session during 15 days
45366453|NCT00947778|Other|1 training session|20 sessions of 30 minutes by week during 24 semaines
45366454|NCT02572115|Behavioral|Akutknappen - used|A caller chooses to bypass the telephone waiting line by pressing the emergency access button
45366455|NCT02572115|Behavioral|Akutknappen - not used|A caller chooses NOT to bypass the telephone waiting line.
45366456|NCT00893438|Behavioral|FitNet treatment|web-based cognitive behavioural treatment for adolescents with CFS
45366457|NCT00893438|Other|Usual care|Usual care treatment for adolescents with CFS
45366458|NCT00952146|Procedure|Transgastric peritoneoscopy (NOTES)|Under general anesthesia an endoscope will be passed through the gastric wall into the peritoneal cavity to examine the peritoneal cavity. At the withdrawal of the endoscope, the gastric access in the stomach wall will be closed with T-tags.
45366459|NCT00452452|Biological|13-valent Pneumococcal Conjugate Vaccine|
45847886|NCT03040362|Drug|[14C]-lasmiditan|[14C]-lasmiditan as a 200 mg (approximately 100 µCi) oral solution
45847887|NCT03041298|Procedure|MR mammography with Dotarem|
45847888|NCT03042702|Drug|Kevetrin|Kevetrin dose to associated cohort
45366460|NCT01009437|Drug|ritonavir|"Phase I: Dose escalation will be used with 3 levels of ritonavir given - 200 mg twice a day (bid), 400 mg bid, and 600 mg bid.~Phase II: Dose will be maximum tolerated dose from Phase I."
45366461|NCT01009437|Procedure|therapeutic conventional surgery|Tissue collection is from all patients, including the control, phase I and phase II patients.
45366462|NCT04322435|Other|Continuous blood glucose measurement|Continuous blood glucose measurement with Abbott Freestyle Pro for 14 days, repeated twice at 6 months intervals.
45366463|NCT04322435|Other|Measurement of capillary blood glucose|"Measurement of capillary blood glucose :~In the morning on an empty stomach, every first week of each month for 12 months.~In case of suspicion of hypoglycaemia (parental assessment). Abbott's Freestyle optium neo reader, used with the Accu-Chek FastClix lancing device and the Accu-Chek Performa strips."
45366464|NCT00947934|Device|Deep brain stimulation|Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation
45483397|NCT00696878|Drug|Corifollitropin alfa|Corifollitropin alfa 150 µg administered as a single subcutaneous dose.
45483398|NCT00696878|Biological|FSH|FSH administerd subcutaneously at a dose not to exceed 225 IU/day.
45847889|NCT03042702|Drug|Kevetrin|Kevetrin dose to associated cohort
45366465|NCT00719381|Drug|Pioglitazone|Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
45366466|NCT00897416|Other|laboratory biomarker analysis|
45366467|NCT01022086|Procedure|Cardiac MRI|Cardiac magnetic resonance (CMR) imaging, otherwise called a cardiac (heart) MRI is a safe and standard clinical test that creates detailed images of your heart. It uses a computer to create images of your heart as it is beating, producing both still and moving pictures of your heart and major blood vessels. This test will allow the health professionals to obtain images of your beating heart and to look at the structure and function. Cardiac MRIs can help diagnose and evaluate a number of diseases conditions (such as heart failure, and heart valve disease) and will help doctors decide how to treat or manage patients who have heart problems.
45483399|NCT00696878|Biological|GnRH antagonist|GnRH antagonist administered subcutaneously at a dose of 0.25 mg/day.
45483400|NCT00696878|Biological|(rec)hCG|(rec)hCG administered subcutaneously at a dose of 5,000-10,000 IU/250 µg.
45847890|NCT03044028|Device|CyMedica Orthopedics QB1 e-vive™ system|a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES), for improving quadriceps strength and improving functional outcomes accelerating functional recovery in patients managed with total knee arthroplasty (TKA).
45366468|NCT01022086|Biological|Biomarker Testing|"In addition to undergoing CMR imaging, patients will also have blood tests for two proteins, which serve as markers of heart injury and heart failure. These are called BNP and Troponin. These blood tests are currently used in clinical practice, but their precise role in monitoring heart function in cancer patients has not been well studied. Since the precise cause of Trastuzumab-induced heart damage is currently unknown, it is hoped that these two blood markers will provide valuable insights into how this happens.~Peripheral venous blood samples will also be drawn at each CMR time-point. TGF β1, amino terminal propeptide of procollagen type I (PINP) and type III (PIIINP) and the carboxy-terminal telopeptide of collagen type 1 (CITP) will be measured by radioimmunoassay."
45366469|NCT05673161|Other|iron|iron treatment
45366470|NCT00897494|Genetic|protein expression analysis|Venous blood collection
45366471|NCT00897494|Other|laboratory biomarker analysis|Venous blood collection
45483401|NCT00696878|Drug|Progesterone|Progesterone administered vaginally at a dose of at least 600 mg/day.
45483402|NCT01231971|Drug|Florbetapir|Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
45483403|NCT01231971|Drug|Flortaucipir|Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
45483404|NCT01150929|Device|P.F.C. Sigma knee arthroplasty|Randomization to either rotating platform or fixed bearing tibial plateau and polyethylene
45483405|NCT03288688|Other|Exercise program and education|"The exercise program comprises warm-ups, exercises and cool-downs and aims to improve recruitment, strength and endurance of postural muscle groups that are key to the work of a musician. Basic activation exercises progress to dynamic and resisted exercises as well as functional musical movements. There is a series of six exercises of increasing difficulty for each of the following bodily regions: hips, back, neck, shoulders and abdominals.~Topics to be discussed in the educational presentation and e-mails include healthy practice habits, activity dosage, the importance of physical activity, how the body adapts to workload and physical stressors, and instructions pertaining to the exercise program."
45483406|NCT04493151|Drug|Imipenem, Cilastatin and Relebactam|After receipt of imipenem-cilastatin-relebactam, ten blood samples will be collected to determine the pharmacokinetics of imipenem and relebactam.
45483407|NCT03295006|Device|TheraSphere|Patients who had received TheraSphere
45483408|NCT00731757|Drug|Humira|80 mg at week 0, then 40 mg weekly from week 1-week 23.
45483409|NCT03625622|Drug|AR1001|AR1001 Active Oral Tablet
45483410|NCT03625622|Drug|Placebo|Placebo Oral Tablet
45483411|NCT03108274|Drug|Danicopan|Oral tablet.
45483412|NCT03108274|Drug|Midazolam|Oral syrup.
45845902|NCT05404854|Other|Measurement of explicit motivation|Explicit motivation will be assessed using self-report questionnaires. Explicit attitudes using a 7-point bipolar response scale, participants will be asked to indicate for each of the 4 pairs of positive and negative adjectives used how much they associate them with regular PA and sedentary behaviors, respectively. Perceived behavioral control using a 7-point bipolar response scale, patients will be asked to indicate how well they felt they were able to engage in regular PA, and limit their sedentary behaviors, respectively, based on two items. Intentions using a 7-point bipolar response scale, patients will be asked to indicate how much they intend to adopt regular physical activity, and limit their sedentary behaviors, respectively, according to two items. Fears and beliefs related to physical activity and work will be measured by the FABQ in its French version
45847891|NCT03044418|Other|Application of ET laser tube in propofol anesthesia|The special ET laser tube covered by aluminum tape is used during anesthesia of endolaryngeal laser surgery.
46051341|NCT00916578|Radiation|Radiation Therapy|50-57 Gy per faction once or twice a day, 5 days a week, for about 5 -7 weeks, about 15-30 minutes each time.
45366472|NCT00897494|Other|mass spectrometry|Venous blood collection
45366473|NCT00897494|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|Venous blood collection
45366474|NCT00952224|Other|magnetic resonance imaging|magnetic resonance imaging is used for prognosis assessment
45366475|NCT00510783|Drug|Keppra|The patient will receive 1 gram of Keppra added to 100ml diluent and will be infused over 15 minutes.
45366476|NCT00510783|Drug|Fosphenytoin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals.
45366477|NCT00510783|Drug|Dilantin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals.
45366478|NCT02540252|Other|Nutritional status among patients with lower limb amputation|Patients nutritional status, inflammatory and metabolic pathway are observed during their hospitalization.
45366479|NCT00952302|Drug|Iron sucrose|Single intravenous infusion of iron 200 mg
45366480|NCT00952302|Drug|Normal saline|Single intravenous infusion of normal 0.9% saline 100 mls (as placebo)
45366481|NCT00952302|Procedure|Venesection|Isolvolaemic venesection of total 2 litres of blood - 500 mls each day for 4 days, replaced with normal saline.
45366482|NCT00952302|Drug|Iron sucrose|Two intravenous infusions, each of 200 mg of iron, separated by one day.
45483413|NCT03108274|Drug|Fexofenadine|Oral tablet.
45483414|NCT03108274|Drug|Mycophenolate Mofetil|Oral tablet.
45483415|NCT01334541|Behavioral|SAFE VET|"All SAFE VET EDs provide a standardized intervention that is specifically adapted for use in the ED to mitigate suicide risk. Given that the SAFE VET intervention was developed for use in a busy ED setting, the length of the intervention is approximately 45 minutes. The SAFE VET intervention is administered by a clinical provider who has been specifically trained and consists of:~Risk Assessment~Safety Planning Intervention: Developed by Stanley and Brown (2008), Safety Planning Intervention consists of a hierarchically-arranged list of coping strategies identified for use during a subsequent suicidal crisis.~Clinical Follow-Up Protocol"
45596557|NCT02368119|Biological|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp)
45596558|NCT02368119|Biological|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp)
45366483|NCT00952302|Drug|Normal saline|Two intravenous infusions of normal 0.9% saline 100 mls (as placebo), separated by one day.
45483416|NCT04296357|Diagnostic Test|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages & Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
45483417|NCT04296357|Other|Physical development and General Health|Physical development and General health examination
45483418|NCT04296357|Diagnostic Test|Developmental Red flags|Developmental Red flags Questionnaires
45483419|NCT02332564|Other|Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index|Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index
45366484|NCT00897650|Genetic|DNA/RNA sequencing and expression levels|Lung tumor tissue will be collected.
45366485|NCT00897650|Genetic|Protein expression analysis|Lung tumor tissue will be collected.
45483420|NCT01332045|Procedure|continuous saphenous nerve block|Postoperative intermittent boluses of 15 Ml Ropivacaine 7,5 mg/Ml every 12 hours for three days
45483421|NCT01332045|Procedure|Saline boluses in nerve catheter|A nerve catheter will be placed in the adductor canal using saline instead of Ropivacaine for intermittent boluses.
45483422|NCT03294928|Other|progressive increasing of PEEP level.|"four-step measurements of central artery blood pressure evaluating contour wave analysis during a progressive increasing of PEEP level First step (Baseline) Subjects spontaneously breathe in air at atmospheric pressure during applanation tonometry.~Second step (PEEP=5 cm H2O) Applanation tonometry was performed during the application of PEEP = 5 cmH2O (Oxygen flow = 8lt.- Air flow = 10 lt.).~Third step (PEEP= 10 cm H2O) Applanation tonometry was performed during the application of PEEP = 10 cmH2O (Oxygen flow = 15lt.- Air flow = 20 lt.).~Fourth step (Recovery) Subjects spontaneously rebreathe air at atmospheric pressure during applanation tonometry."
45690920|NCT04028427|Behavioral|Mindfulness-based intervention|The MBI is a four-week intervention, where participants are introduced to the concept of mindfulness and acceptance as understood in ACT (Hayes et al., 1999). They will be asked to complete a 10-minute health-focused mindfulness meditation exercise by listening to a recording of a script focusing on cultivating mindful awareness of internal experiences, particularly in relation to diabetes, and practising making room for any difficult internal experiences. This will be followed by some prompts to promote reflections related to their diabetes following the exercise. They will be asked to practise this exercise 3-4 times a week over a four-week period. As a manipulation check, participants will be sent a reminder e-mail every week over the four weeks to record how many times they practised the exercise over the past week.
45483423|NCT02278588|Drug|Rasagiline|
45483424|NCT02262832|Drug|Metreleptin|administered subcutaneously 1-2 times/day
45483425|NCT03288610|Diagnostic Test|Preoperative copeptin level|Measure of plasmatic copeptin from preoperative samples retained in a biorepository. Physicians are blinded to the result.
45690921|NCT04190121|Dietary Supplement|prosure|The study group will receive the dietary supplement preoperatively and for three months after the operation
45690922|NCT04028349|Drug|Ad26.ZEBOV/MVA-BN-Filo|Candidate Ebola Vaccine
45690923|NCT01853137|Device|Fixed Lingual Mandibular Growth Modificator (FLMGM)|Novel Class II functional appliance, a fixed version of double-plate appliance
45690924|NCT04028271|Device|Comfort-in injection system|local anesthesia during dental treatment
45690925|NCT04028271|Other|conventional injection with dental needle|for local anesthesia during dental treatment
45690926|NCT03595839|Procedure|Fistulotomy|The fistula track is laid open after complete probing till the internal opening
45690927|NCT03595839|Procedure|Marsupialization|The laid open track will be marsupialized using interrupted absorbable sutures
45690928|NCT01823107|Device|Meso BioMatrix Device|
46051342|NCT00916578|Drug|Capecitabine|During 5-7 weeks of radiation therapy, 825 mg/m2 (pills) by mouth, 2 times a day, about 12 hours apart, 30 minutes after eating food and about 2 hours before radiation therapy.
45690929|NCT04190277|Device|Open-loop condition|Patient's standard insulin pump setting combined with continuous glucose monitoring sensor
46051343|NCT02832297|Other|Vectra DA|
45366486|NCT00897650|Procedure|Lung tumor biopsy|Tissue will be collected by percutaneous fine needle aspiration, a percutaneous core biopsy, or during a medically indicated procedure during which lung tumor tissue will be removed
45366487|NCT00897650|Procedure|Blood sample|Patients will be asked for a venous blood sample
45690930|NCT04190277|Device|Closed-loop condition|Closed-loop algorithm system paired with continuous glucose monitoring sensor
46051344|NCT02832297|Other|Usual Care|
46051345|NCT05253144|Radiation|Radiotherapy|Radiotherapy
46051346|NCT05253144|Procedure|Surgery|Surgery
46051347|NCT04801056|Drug|TB006|TB006 monoclonal antibody
46051348|NCT04801056|Other|Placebo|Placebo i.v. infusion
46051349|NCT04503174|Device|t:slim X2 pump with Control-IQ technology|Real-world use
46051350|NCT02830113|Procedure|non-surgical periodontal treatment|One session of complete scaling, polishing, root planning, and the irrigation of periodontal pockets with a 10% povidone iodine solution
46051351|NCT04457154|Device|Inspire Upper Airway Stimulation System|Implant of the Inspire Upper Airway Stimulation System
45483426|NCT00696800|Drug|Corifollitropin alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
45366488|NCT05300646|Behavioral|Prenatal mindfulness-based stress reduction|An adapted mindfulness-based stress reduction (MBSR) program with a particular focus on pregnancy and early motherhood.
45366489|NCT00897728|Other|laboratory biomarker analysis|
45483427|NCT00696800|Biological|RecFSH / Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
45483428|NCT00696800|Drug|Placebo Corifollitropin alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
45483429|NCT00696800|Drug|Placebo RecFSH / follitropin beta|Identical ready-for-use solution, but without the active ingedient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
45483430|NCT00696800|Biological|RecFSH / Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
45483431|NCT00696800|Drug|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
45483432|NCT00696800|Biological|hCG|When 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
45483433|NCT00696800|Biological|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
46051352|NCT02830035|Procedure|Real-time Ultrasound-guided|Real-time ultrasound guided paramedian spinal anesthesia
46051353|NCT02830035|Procedure|Anatomical Landmark Technique|Conventional anatomical landmark technique for paramedian spinal anesthesia
46051354|NCT04247529|Other|Exposure to conflicting health information|At 2 time points across a ~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants in the conflict (experimental) group will have conflicting information added to these news and social media posts.
45366490|NCT00518973|Drug|Quetiapine|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of Quetiapine (or placebo) will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
45366491|NCT00518973|Drug|Placebo|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of placebo will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
45366492|NCT05300334|Diagnostic Test|adenosine deaminase test|adenosine deaminase deficiency test
45366493|NCT00897806|Genetic|Microarray analysis|
45483434|NCT03294772|Other|hand sanitizer|DCCs received alcohol-based hand sanitizer and a program educational.
45483435|NCT03294772|Other|liquid soap|DCCs received liquid soap and a program educational.
45483436|NCT03288532|Drug|Durvalumab|controlled infusion via an infusion pump into a peripheral or central vein
45483437|NCT03288532|Drug|Tremelimumab|controlled infusion via an infusion pump into a peripheral or central vein
45483438|NCT00598208|Drug|corifollitropin alfa|On Cycle Day 2, a single injection of 60 μg, 120 μg, or 180 μg Org 36286 was administered. One week later (Treatment Day 8), treatment was continued with a fixed daily subcutaneous (SC) dose of 150 IU Puregon® up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and up to and including the Day of hCG. The maximum total treatment duration was 19 days.
45596559|NCT02368119|Biological|MVA-EbolaZ|IM injection of MVA-EbolaZ vaccine
45596560|NCT02368119|Other|Placebo|IM injection injection of Phosphate Buffered Saline
45690931|NCT01874275|Device|VECTTOR|"The VT-200, or VECTTOR system, delivers electrical stimulation via electrodes on the acupuncture points of a patient's feet/legs and hands/arms to provide symptomatic relief of chronic intractable pain and/or management of post-surgical pain.~Once these electrodes are placed, the machine determines the appropriate choice of stimulation by automatically measuring body temperatures through the use of thermistors placed on the fingers during a testing sequence."
45483439|NCT00598208|Drug|Follitropin beta injection|Starting on Cycle Day 2, a fixed daily dose of 150 IU Puregon® SC was administered for the entire stimulation period up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and given up to and including the day of hCG. The maximum total treatment duration was 19 days.
45690932|NCT04198623|Drug|Montelukast 10 Mg Oral Tablet|Montelukast(Singulair) 10mg to be taken at least 2 hours prior to initiation of monoclonal antibody infusion addition to institutional protocol premedication regiment
45690933|NCT01873729|Drug|Naltrexone|Adults with ADHD
45752203|NCT03239015|Drug|Vemurafenib|Vemurafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
46051355|NCT04247529|Other|No exposure to conflicting health information|At 2 time points across a ~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants in the no conflict (comparator) group will have no conflicting information included in these news and social media posts.
45366494|NCT00897806|Other|Laboratory biomarker analysis|
45366495|NCT03905525|Drug|CFZ533|Biological
45366496|NCT03905525|Other|Placebo|liquid placebo for injections
45366497|NCT00958152|Drug|VCH-222|Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37
45366498|NCT00958152|Drug|VCH-222|Capsules, Oral, 750 mg, q12h, Days 1-10 and Days 28-37
45366499|NCT00958152|Drug|VCH-222|Capsules, Oral, 1000 mg, q12h, Days 1-10 and Days 28-37
45366500|NCT00958152|Drug|telaprevir|Tablet, Oral, 1125 mg, q12h, Days 18-37
45845903|NCT05404854|Other|Measurement of implicit attitudes|Implicit attitudes will be assessed by administering an Implicit Association Test on physical and sedentary activities. Sitting in front of a computer, participants will see a series of words appear in the middle of the screen referring to 4 conceptual categories - located at the top of the screen. Two represent the targeted behaviours (here, physical activity versus sedentary lifestyle) while the remaining two represent attributes (here, positive versus negative adjectives). The adjectives used will be the same as those used to measure explicit attitudes. The instructions given to the participant are to classify the words as quickly as possible, according to the semantic category to which they belong
45845904|NCT04924062|Biological|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
45845905|NCT04924062|Drug|Gemcitabine|Gemcitabine by IV infusion
45845906|NCT04924062|Drug|Cisplatin|Cisplatin by IV infusion
45845907|NCT04924062|Drug|Placebo|Placebo to pembrolizumab
45366501|NCT00897884|Drug|Metformin|500 mg tablet, taken 3 times a day for 2-3 weeks
45366502|NCT00958230|Device|dCell Vascular Patch|Implantation of a dCell Vascular Patch as part of an Endarterectomy
45366503|NCT01022164|Procedure|fibrin glue|
45483440|NCT00537914|Drug|Somatropin|Infant, Small for Gestational Age, Omnitrope®/Somatropin, rhGH,
45483441|NCT00480662|Drug|alendronate|Duration of Treatment : 6 Months
45483442|NCT00398606|Drug|MK0217, alendronate sodium / Duration of Treatment : 2 Years|
45483443|NCT00398606|Drug|Comparator : calcium carbonate /Duration of Treatment : 2 Years|
45483444|NCT02085772|Other|Blood samples at 37-38 Weeks of amenorrhea|
45483445|NCT02085772|Other|Blood samples at 41 Weeks of amenorrhea if prolonged pregnancy|
45483446|NCT02085772|Other|Blood samples at the time of delivery|
45483447|NCT00395408|Drug|MK0476, montelukast sodium / Duration of Treatment : 56 Weeks|
45845908|NCT04912674|Device|Symphony OCT System|Surgical intervention will be patient specified by treating surgeon.
45845909|NCT04894500|Diagnostic Test|Flow fluorescence cytometry|Level of inflammatory markers in body fluid samples
45845910|NCT04888104|Procedure|Index or revision spine surgery for complex adult spinal deformity|Adult patients receiving minimum 5 level posterior spinal fusion with pedicle screw fixation supplemented at the proximal aspect of the construct with the VersaTie System.
45845911|NCT04876638|Drug|Minocyclin|10mg/kg minocycline up to 700mg for 4 days following aneurysmal subarachnoid hemorrhage
45845912|NCT04854798|Device|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care
45845913|NCT04844190|Diagnostic Test|EndoFLIP|During pre-G-POEM upper endoscopy, an EndoLIP catheter will be inserted through the patient's mouth into the stomach and across the pylorus. Once results of EndoFLIP are obtained, the catheter will be removed (5 minutes).
46051356|NCT02827539|Device|LessRay|A software device has been developed that combines the benefits of reduced radiation associated with low-dose and/or pulse settings while preserving and possibly offering enhanced resolution. LessRay is a software device that is viewed on a separate monitor next to the fluro screen of the C-arm.
46051357|NCT02827539|Device|Standard Fluoroscopy|For control arm, patients will receive the standard fluoroscopy for imaging.
46051358|NCT04675866|Other|Camrelizumab, Albumin-bound paclitaxel, S-1|Camrelizumab: 200mg, iv, Q3W, d1; Albumin-bound paclitaxel: 125mg/m2, iv, d1, 8, Q3W; S-1: According to the patient's body surface area, the dosage is set to 40, 50, 60 mg/time, bid, po, taking 2 weeks, and stopping the drug for 1 week as a cycle.
45366504|NCT01012401|Other|CHESS website for lung cancer patient + internet access if needed|The Comprehensive Health Enhancement Support System (CHESS), a non-commercial, home-based system created by clinical, communication, and decision scientists at the University of Wisconsin, is distinguished by its quality, depth, and ease of use. It employs data on user health status to help users monitor their condition, guide them to tailored information and social support, make and implement important health decisions, and learn coping skills. Our tests and clinical trials demonstrate that an ICCS such as CHESS can be widely accepted and used, improve quality of life, information competence, and in some cases lead to more efficient use of health services. An Internet-based system, CHESS-LC integrates over 14 services to provide tailored cancer information, support, interactive tools, and communication with the clinical team.
45845914|NCT04844190|Diagnostic Test|Antroduodenal Manometry|Following removal the EndoFLIP catheter, a manometry catheter will then be placed through the nose and advanced across the pylorus. Once catheter positioning is confirmed on endoscopy, the endoscope will be withdrawn. The manometry catheter will be taped to the nose and sedation stopped. The patient will be brought to the recovery area where they will wake-up with the catheter in place. In a private recovery room, the patient will have the catheter in place (no positioning or movement restrictions). When pyloric spasms are documented (0.5-4 hours), they will be given a standard small meal (water, toast/bread). Once motility is assessed with eating, the manometry catheter will be removed.
45845915|NCT04827810|Drug|Gamitrinib|This is a first-in-human, phase I, open-label, non-randomized dose-escalation and dose-expansion study with the primary objective to determine the safety profile of small molecule, mitochondrial-targeted Hsp90 inhibitor, gamitrinib, including identification of dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) in patients with advanced cancers. A secondary objective of the study is to determine the recommended dose and regimen(s) for a phase II study. This study is based on preclinical data demonstrating the anticancer activity, unique mechanism of action and preliminary safety of gamitrinib.
45845916|NCT04789746|Behavioral|adapted Chicago Run running program|The intervention being piloted is a 6-8 week running program modified from a running curriculum designed for school-aged children. The children will use a RaceRunner device to facilitate their participation, but this device is not explicitly evaluated in this study. Depending on transportation, they may be given access to the device in their home or school between sessions after it has been fit for them. If given access, guardians will be instructed on care and usage.
46051359|NCT04635930|Other|Taping plus Traditional exercises|The children will be taped 6 days per week for a total a period of 08 weeks. The tape will be used and keep the scapula in position for 3 days and the region will then be left to rest for 24 hours. Kinesio Taping will then be re-applied by the same experienced research assistants for another 3 days.
46051360|NCT00889707|Drug|PRX302|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
46051361|NCT00889707|Drug|Placebo|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
45366505|NCT00897962|Other|Healthy Controls|One blood draw (2 teaspoons)
45366506|NCT00897962|Other|Metastatic Breast Cancer|Blood samples will be drawn every 3 months, for up to 18 months.
45366507|NCT00897962|Other|Non-cancer medical illness|One blood draw (2 teaspoons)
46051362|NCT04662996|Biological|Blood sample|one blood sample is done before beginning a first treatment line for a metastatic castration resistant prostate cancer
46051363|NCT04751760|Biological|collection of blood and urine|blood and urine will be collected during a blood test scheduled for the follow-up of the patient
45366508|NCT05300178|Procedure|coronary artery bypass grafting surgery|Strategies of Complete Arterial Revascularization THE COMPOSITE TECHNIQUE When the distal RIMA bifurcation cannot loosely reach the LAD, we use the RIMA as a free graft, and a T-shaped , or if more suitable, a Y-shaped anastomosis at the level of the main pulmonary artery, is prepared before connection to cardiopulmonary bypass (CPB) THE CROSS TECHNIQUE The cross arrangement is based on the assumption that patency rates of the right internal mammary artery (RIMA) on the left anterior descending coronary artery (LAD) is similar to that of the left internal mammary artery (LIMA) on the LAD. To improve late survival, every effort should be made to use both IMA grafts for the left system THE IN SITU SEQUENCE When a graft to the posterior wall of the heart is not necessary (the circumflex region), the LIMA is grafted to the left anterior descending and the RIMA to the right coronary artery or its posterior de
45483448|NCT00395408|Drug|Comparator : beclomethasone dipropionate / Duration of Treatment : 56 Weeks|
45483449|NCT02462044|Drug|240 mg Iodine|
45483450|NCT02462044|Drug|300 mg Iodine|
45483451|NCT02462044|Drug|370 mg Iodine|
45483452|NCT03294616|Device|transcutaneous electroacupuncture|Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions
45483453|NCT00289874|Drug|montelukast sodium|montelukast 5 mg chewable tablet once daily. Up to 3 weeks of treatment.
45483454|NCT00289874|Drug|Comparator: Placebo|Placebo. Up to 3 weeks of treatment
45483455|NCT02461732|Behavioral|Treatment for Integrated Posttraumatic Stress and Substance Use (TIPSS)|"Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities; education on PTSD and trauma/PTSD/substance use associations; discussion and written statement of impact of trauma on beliefs about self, others, world; written account of trauma memory and in-session review and discussion; cognitive exercises and cognitive restructuring regarding trauma-related thoughts; review of any between-session trauma-relevant substance use and cravings"
45483456|NCT02461732|Behavioral|Cognitive-Behavioral Therapy for Substance Dependence|"Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities"
45483457|NCT02039830|Behavioral|Group physiotherapy|Multimodal Group physiotherapy 12 weeks of weekly Group physiotherapy treatments including education and pelvic floor muscle exercises
45483458|NCT02039830|Behavioral|Individual one-on-one physiotherapy|Multimodal Individual physiotherapy 12 weeks of weekly Individual physiotherapy treatments including education and pelvic floor muscle exercises
45483459|NCT00245570|Drug|Comparator: Montelukast|1 dose montelukast 10 mg tablet given orally in one of three treatment periods
45483460|NCT00245570|Drug|Comparator: Salmeterol|1 dose of 50 ug salmeterol given by inhalation in one of three treatment periods
45483461|NCT00245570|Drug|Comparator: Placebo (montelukast)|1 dose matching-image placebo to montelukast tablet in two of three treatment periods
45483462|NCT00245570|Drug|Comparator: Placebo (salmeterol)|1 dose matching-image placebo of salmeterol 50 ug inhalation in two of three treatment periods
45483463|NCT02461888|Drug|Ixazomib|Chemotherapy
46051364|NCT02829801|Behavioral|AAT and cognitive stimulation and rehabilitation of social tie.|"There are 8 workshops, one workshop per week. The workshops will begin with a 15 minute introductory activity allowing the establishment of the relationship with the dog and between the participants. Activities with the dog will be offered: games, caresses, brushing.~Then, a 40 minute cognitive stimulation will be offered. Finally, 5 minutes will be devoted to the closing of the session and to say goodbye to participants and the dog (pet him, play with him ...)."
46051365|NCT02829801|Behavioral|Cognitive stimulation and rehabilitation of social tie.|"There are 8 workshops, one workshop per week. The workshops will begin with an introductory activity of 15 minutes that will establish the relationship between the participants. Different topics will be proposed to foster communication and exchange.~Then, the same cognitive stimulation in the AAT arm will be offered."
46051366|NCT02827383|Behavioral|Stair Climbing Frequency|Includes 1 sedentary day prior to completing crossover phases.
45366509|NCT01012479|Drug|Candesartan cilexetil and hydrochlorothiazide|Candesartan cilexetil 16 mg, tablets, orally, once daily for 1 week; increased to candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg combination tablet, orally once daily for 2 weeks; then increased to candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for up to 6 weeks
45366510|NCT04317287|Dietary Supplement|Cardio formulation|Tomato-based formulation with dietary supplement softgels
45366511|NCT04317287|Dietary Supplement|Placebo|Placebo softgels
45366512|NCT02541734|Drug|Gelofusine|Infusion of gelofusine
45366513|NCT02541734|Radiation|111In-exendin 4 SPECT/CT|111In-exendin 4 SPECT/CT
45366514|NCT02541734|Drug|Placebo|
45366515|NCT00952458|Device|BIS monitoring|Neuromonitoring of depth of sedation with Bispectral Index
45366516|NCT00898040|Genetic|polymorphism analysis|
45366517|NCT00462670|Drug|OPC-41061(Tolvaptan)|0, 15mg of OPC-41061 per day for 7days p.o. administration
45366518|NCT01009593|Drug|ABT-869|Tablets, Oral, 17.5 mg, Once Daily, Until disease progression or unacceptable toxicity
45483464|NCT02461888|Drug|Cyclophosphamide|Chemotherapy
45483465|NCT02461888|Drug|Dexamethasone|Chemotherapy
45483466|NCT00229970|Drug|montelukast sodium|7 mg or 14 mg single injection
45483467|NCT00229970|Drug|Comparator: Placebo|Placebo single injection
45483468|NCT02460796|Other|Hippotherapy|The sessions began with a 5 minutes warm up that involved stretching and body awareness exercises. Then, the training was conducted for 20 minutes with arms and torso exercises, changes of direction called serpentine movements; up and down hip movements with feet on stirrups, and forced expiration. In the final 5 minutes, exercises for relaxation were conducted with the horse which involved moving the hand on the horse's neck, laying forward on the head and stroking the horse. The horses walking speed was between 5.8 and 6.4 Km/h.
45483469|NCT00111722|Drug|MK0462, rizatriptan benzoate / Duration of Treatment -1day|
45483470|NCT00111722|Drug|Comparator: placebo / Duration of Treatment - 1 day|
45483471|NCT03288064|Dietary Supplement|Corinthian currant|Supplementation of 1.5 g CHO/kg BW in the form of Corinthian currant prior to exercise
46051367|NCT02829879|Drug|8% arginine/1450ppm sodium monofluorophosphate dentifrice|
46051368|NCT02829879|Drug|5% potassium nitrate/2500ppm sodium fluoride dentifrice|
45483472|NCT03288064|Dietary Supplement|Glucose drink|Supplementation of 1.5 g CHO/kg BW in the form of glucose drink prior to exercise
45483473|NCT03288064|Dietary Supplement|Water ingestion|Supplementation of 7ml/kg BW prior to exercise
45483474|NCT04626596|Drug|Radiopaque Etonogestrel (ENG) Implant|68 mg subdermal implant
45690934|NCT01873495|Drug|Omacetaxine|"Omacetaxine 1.25 mg/m² sub-cutaneously twice daily for 5 consecutive days every 28 (± 8) days for 3 cycles.~Patients in continuous remission after 3 cycles of consolidation will receive maintenance omacetaxine 1.25 mg/m² twice daily for 3 days, every 28 days for up to 6 cycles"
45483475|NCT02461810|Device|Vertebral fracture surgery SpineJack®|Vertebral augmentation for one osteoporotic vertebral compression fracture
45483476|NCT02461810|Procedure|Balloon Kyphoplasty|
45483477|NCT01953640|Other|Laboratory Biomarker Analysis|Correlative studies
46051369|NCT04441008|Device|Accelerated Intermittent Theta Burst (aiTBS)|High-dose intermittent theta burst administered at a treatment frequency 10x per day, with each treatment session duration 3x standard TMS (1800 pulses). Delivering 50 sessions in 5 days.
46051370|NCT04441008|Device|Electroconvulsive therapy (ECT)|ECT as per standard clinical care and management.
46051371|NCT04652934|Other|Neurodynamic|The Upper Limb Neurodynamic Test (ULNT1) technique described by Butler will be performed on the affected limb. This technique consists of performing shoulder depression, 90º shoulder abduction, hand, wrist and forearm in a neutral position, external rotation of the shoulder and extension of the elbow. After positioning the limb in this position, wrist flexion-extension movements will be performed smoothly and rhythmically of 20 movements every minute, for 3 minutes, three times per session with 1 minute of rest between each series.
45366519|NCT01009593|Drug|Sorafenib|Tablets, Oral, 400 mg, Twice Daily, Until disease progression or unacceptable toxicity.
45366520|NCT00719459|Drug|Iron Sucrose|Venofer 20 mg/mL
45366521|NCT00719459|Drug|Iron Sucrose|Iron sucrose 20 mg/mL
45483478|NCT01953640|Other|Quality-of-Life Assessment|Ancillary studies
45483479|NCT01882036|Procedure|Gastric Bypass w/ matched hypocaloric diet|Roux en Y Gastric Bypass with Hypocaloric liquid diet for 10 days
45483480|NCT01882036|Other|Hypocaloric diet|Hypocaloric liquid diet for 10 days
45483481|NCT03619460|Procedure|piezoelectric extraction|Only Piezoelectric device will be used for surgical wisdom teeth extraction
45483482|NCT03619460|Procedure|conventional extraction|Only manual instruments and burs on straight handpick will be used for wisdom teeth extraction
45483483|NCT05235100|Drug|Apatinib Mesylate|Apatinib Mesylate 500mg QD, begin from 2 weeks prior to IMRT, to 1 month after end of IMRT
45483484|NCT04225442|Other|Fatty meal to challenge the physiological chronobiome in healthy young and old|The intervention consists of a fatty meal
45752204|NCT03239015|Drug|Dabrafenib|Dabrafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
45752205|NCT03239015|Drug|Palbociclib|Palbociclib is an FDA/CFDA approved targeted drugs used for CDK4/6 mutation or amplification based on NGS results.
46051372|NCT04652934|Other|Mimic group|The protocol used by Beneciuk et al. Will be used. This intervention consists of imitating NM without stressing the nervous system. It will be carried out as follow: a neutral cervical position will be maintained (0º of cervical inclination), 45º of shoulder abduction without depression, 45º of external rotation of the shoulder combined with 45º of elbow flexion with the forearm in pronation. Afterwards, 10 wrist flexion-extension movements will be performed at a rate of 6 seconds per cycle (3 seconds of flexion and 3 seconds of extension). The resistance that you will feel will stabilize when you change motion. Once the 10 cycles of movements have been carried out, a wrist flexion will be maintained for 10 seconds.
46051373|NCT05249283|Other|Questionnaire Measures|Patients will complete the following questionnaires: CDS questionnaire, Niigata PPPD questionnaire, HAD (Hospital Anxiety and Depression) scale and DHI (Dizziness Handicap Inventory)
46051374|NCT05246007|Drug|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 0.02 ml/kg/h (0.025 μg/kg/h) during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
45366522|NCT00898118|Genetic|polymerase chain reaction|
45366523|NCT00898118|Other|flow cytometry|
45366524|NCT00898118|Other|laboratory biomarker analysis|
45366525|NCT00898118|Procedure|allogeneic hematopoietic stem cell transplantation|
45366526|NCT00952536|Dietary Supplement|Daily Juice Plus+ with vegetable & fruit & berry capsule|Daily Juice Plus+ with 2 vegetable & 2 fruit & 2 berry capsule
45366527|NCT00952536|Dietary Supplement|Daily Juice Plus+ vegetable & fruit & placebo capsule|Daily Juice Plus+ with vegetable & fruit & placebo capsule
45366528|NCT00952536|Dietary Supplement|Placebo in the form of 6 capsules|Daily Placebo in the form of 6 capsules (control group)
45366529|NCT01022320|Procedure|Lateral Pharyngoplasty|surgery lateral pharyngoplasty: consists on the section and rotation of the superior constrictor pharyngeal muscle associated with the ressection of the palatopharyngeus preserving the palatoglossus and mucosa of posterior and anterior tonsilar pillar , bilaterally.
45483485|NCT03287986|Other|MRI|Structural and functional sequences
45483486|NCT04612010|Device|WAVES (Wobble-oscillator Auditory/Visual Excitatory Stimulation)|An app-based stimulation program administered that provides desynchronizing visual and auditory stimulation. The frequency of the stimulation oscillates around the baseline frequency determined by EEG.
45483487|NCT03294382|Drug|Botulinum toxin type A|5U botulinum toxin in 0.1 mL normal saline, injected in two points at one side, 2.5U per point, local injection
45483488|NCT03294382|Drug|Placebo|0.1 mL normal saline, injected in two points at one side, 0.05 mL per point, local injection
45483489|NCT05206370|Drug|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
45483490|NCT05206370|Drug|Placebo|film-coated oral tablets containing matched placebo
45483491|NCT05206370|Behavioral|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
45483492|NCT05205434|Other|Synchronous telerehabilitation programme|Exercise program and educational program
45483493|NCT05205434|Other|Asynchronous telerehabilitation programme|Exercise program educational program
45752206|NCT03239015|Drug|PD-1/L1 inhibitor plus anti-angiogenic agent|PD-1/L1 inhibitor plus anti-angiogenic agent is a regimen used for refractory tumor without druggable target
45752207|NCT00356993|Drug|Nicotine Replacement Therapy|transdermal nicotine patch, nicotine gum, nicotine inhaler, nicotine lozenge
45366530|NCT00711503|Drug|anakinra|The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection
45366531|NCT00711503|Drug|saline|The patients are instructed to administer placebo (saline) once daily by subcutaneous injection
45366532|NCT00948168|Drug|exenatide (Byetta)|all patients receive 5 then 10 µg exenatide subcutaneously BID for 6 months
45483494|NCT00092066|Drug|MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks|
46051375|NCT05246007|Drug|Normal Saline|Placebo (normal saline) will be infused at a rate of 0.02 ml/kg/h during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
46051376|NCT00914940|Drug|Fludarabine Phosphate|Fludarabine will be administered in a dose of 25 mg/m2/day IV over approximately 30 minutes for 5 consecutive days (day -6 to -2). The total dose of fludarabine will be 125 mg/m2.
45483495|NCT01466686|Radiation|Low Dose Fractionated Radiation Therapy (LDFRT)|All patients will receive 0.5 Gy of radiation therapy twice daily. This study will include a safety run-in component. If > 33% of patients in the initial cohort of 6 experience grade 3 or greater hematologic toxicity according to the NCI Common Toxicity Criteria version 4, then a dose reduction will occur following the schedule listed below.
45483496|NCT01466686|Drug|Temozolomide|All patients will receive temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle) for a total of 1 year or until the time of disease progression.
45483497|NCT03294226|Device|AuraGain|After anesthetic induction without neuromuscular blocking agent, AuraGain is inserted.
45483498|NCT03294226|Device|I-gel|After anesthetic induction without neuromuscular blocking agent, I-gel is inserted.
45483499|NCT01239082|Procedure|Colonoscopy|One time screening Colonoscopy to screen for colorectal cancer
45483500|NCT01239082|Procedure|FIT|Annual FIT testing
45483501|NCT05225636|Procedure|thrombectomy|Extraction of intracranial thrombus in an acute large vessel occlusion
45483502|NCT03287518|Dietary Supplement|WAK2017|WAK2017 is a solution with following active ingredients: Aged Garlic Extract. One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
45483503|NCT03287518|Dietary Supplement|Placebo|One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
45483504|NCT05225246|Other|Data collection on reasons for unplanned readmission to the University Hospital Basel within 30 days of leaving the hospital|Descriptive analysis of the reasons for unplanned readmissions after cardiac surgery and predictive factors for unplanned readmissions and validation of risk scores
45752208|NCT00356993|Behavioral|behavioural intervention|Smoking cessation counselling, relapse prevention strategies
45752209|NCT01793077|Drug|Depo-Eligard®|Subcutaneous
46051377|NCT00914940|Drug|Tacrolimus|"Tacrolimus will be administered beginning on day -1 at a dose of 0.03 mg/kg/day by continuous IV infusion.~For the first cohort of 35 patients, if there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus should then be tapered at the rate of approximately 5% of the day 50 dose each week for liquid, and 20% of the day 50 dose per month for capsules.~In the second cohort of 25 patients if there is no evidence of grade II GVHD on or prior to day 30, tacrolimus should then be tapered at the rate of approximately 8% of the day 30 dose each week for liquid, and 33% of the day 30 dose per month for capsules."
46051378|NCT00914940|Drug|Thiotepa|Thiotepa will be administered in a dose of 5 mg/kg/day (adjusted body weight) IV over approximately 4 hours for 2 consecutive days (day -6 and day -5).
45366533|NCT00888212|Procedure|Bronchoscopy|Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
45483505|NCT03287440|Behavioral|COPD Wellness|This is low-intensity pulmonary rehabilitation that incorporates exercise, nutrition, patient education, and a support group class.
45483506|NCT03287440|Behavioral|Health Advocate|The Zuckerberg San Francisco General (ZSFG) Hospital Health Advocates program links social needs screening with a tiered referral and linkage process to appropriate resources
45483507|NCT05654792|Device|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation in cases of severe aortic stenosis
45483508|NCT03287362|Behavioral|schema therapy|The intervention consists of a seven-week program of schema therapy, which is a further development of cognitive behavioral therapy, designed in a three-phase combined group and single session concept
45483509|NCT03287362|Behavioral|cognitive behavioral therapy|The intervention consists of a seven-week program of cognitive behavioral therapy, which is the current gold standard of treatment
45483510|NCT03287362|Behavioral|individualized supportive therapy|The intervention consists of a seven-week program of individualized supportive therapy, including different therapeutic offers from the clinic and a high frequency of physician contacts.
45483511|NCT05224934|Radiation|ultra-hypofractionated radiotherapy|stereotactic ablative radiotherapy with 25 to 50Gy in five fractions given preoperatively
45483512|NCT04091750|Drug|Nivolumab|"Induction: 3mg/kg IV every 3 weeks x 4 cycles~Maintenance: 480mg IV every 4 weeks for up to 92 weeks"
45483513|NCT04091750|Drug|Ipilimumab|Induction: 1mg/kg IV every 3 weeks x 4 cycles
45483514|NCT04091750|Drug|Cabozantinib|Induction and Maintenance: 40mg PO daily
45752210|NCT00555477|Drug|anastrozole|1 mg tablet by mouth once a day
45752211|NCT04019249|Behavioral|Healthy Weight Coaching|Healthy Weight Coaching is a 52 week long web-based weight loss program consisting of weekly modules, exercises, peer support, and one-on-one coaching. It encompasses themes such as diet, physical activity, coping with stress, sleep, and general health.
45483515|NCT04051034|Dietary Supplement|Omega 3|"Active: 1.25 g capsules/420 35-count bottles [1.25 g capsule contains min. 750 mg EPA + 250 mg DHA] and heat therapy, increase internal body temperature 1.2 C above baseline.~Placebo: 14,700 1.25 g capsules/420 35-count bottles [1.25-gram high oleic safflower oil capsule]"
45483516|NCT04051034|Other|Placebo|Active: 1.25 g capsules [1.25-gram high oleic safflower oil capsule] and heat therapy, increase internal body temperature 1.2 C above baseline.
45483517|NCT03287284|Device|Active Low Level Laser Therapy|Active application of Low Level Laser Therapy with a dose of 240 Joules
45483518|NCT03287284|Behavioral|Resistance Training|Resistance Training
46051379|NCT00914940|Radiation|Total-Body Irradiation (TBI)|TBI will be given as 165 cGy fractions twice per day x 4 days - total dose 1320cGy (days -10 to -7).
45483519|NCT03287284|Device|Placebo Low Level Laser Therapy|Placebo application of Low Level Laser Therapy
45483520|NCT05126888|Drug|SCI-110|SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg. Maximum dose 20mg Dronabinol and 800mg PEA a day.
45483521|NCT05126888|Other|Placebo|Pill that matches in taste, odour and appearance to SCI-110 active pills
46051380|NCT00914940|Other|Magnetic Affinity Cell Sorting|Device
45366534|NCT00958386|Drug|Panitumumab+irinotecan|"Panitumumab will be administered as a 60 minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. A cycle of Panitumumab is defined as 14 days.~Irinotecan chemotherapy (180 mg/m2 in 90 min on day 1 of each cycle) will be administered after the administration of Panitumumab.~Each treatment cycle will have a duration of 14 days."
46051381|NCT00914940|Procedure|Peripheral Blood Stem Cell Transplantation|Patient will undergo a PBSC transplantation
45366535|NCT00711581|Device|Gallbladder retraction|The gallbladder will be retracted using the Endograb retractor
45483522|NCT01334619|Procedure|appropriate volume of 0.5% ropivacaine|initial concentration: 30 ml, subsequently varied at a ratio of 1: 1.2 for each consecutive patient according to the response of the previous patient, until 5 up-and-down cycles completed.
45366536|NCT04035512|Other|Expressive writing|"The procedure for the writing group will be as follow:~on day 1 the researcher will call the participant at designed time and will provide a brief introduction to the writing task. Participant will be asked to go in a quiet place in their house where they would have no interruptions but can still be close to the phone. Next, participants were given standardized instructions. Then participants will ask to start writing immediately after hanging up the phone and to write for 20 minutes. The researcher will call the participants after 20 minutes. The procedure for the second and third writing days will be identical.~The above method was previously tested by Zakowski et al., 2004."
45483523|NCT03287206|Biological|blood samples from children|CGH array, Fragile-X syndrome screening, DI459 panel, WES
45483524|NCT03287206|Biological|blood samples from parents|secondary controls for children's analyses
45483525|NCT05223764|Other|Follow up survey|phone call follow-up to investigate women's decision not to return for embryo transfer after cancer treatment.
45483526|NCT03223623|Device|TMS|Single pulse TMS, IPL-M1 Interaction, IPL-M1 Interaction, Inhibitory Theta Burst Protocol (cTBS)
45483527|NCT03223623|Device|MRI|High-resolution MRI for anatomical reference; fMRI scan as per research fMRI protocol will be conducted under 3 conditions. 1. Rest 2. Voluntary activity 3. Motor imagery task.
45483528|NCT03223623|Device|VASO Imaging|The voluntary activity condition will involve 4 tasks: a. individual tapping of two fingers (index and little), b. individual tapping of four fingers (index, middle, ring, and little; no thumb) interspaced with rest periods, c. individual tapping of all five fingers (index, middle, ring, little, and thumb) interspaced with rest periods and d. Alternating grasping or retraction of a rubber ball interspaced with rest periods.
45483529|NCT03287128|Drug|Gemtuzumab Ozogamicin (GO)|patients included in a compassionate patient named program with GO
45483530|NCT05223686|Drug|Human CD19-CD22 Targeted T Cells Injection|One time single predetermined dose level CAR-positive T cells will be utilized based on the NMPA approved product label.
46051382|NCT00914940|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Patients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation
45483531|NCT00457275|Drug|MK0653, ezetimibe / Duration of Treatment: 4 Weeks|
45596561|NCT02202239|Drug|midazolam|Before induction, midazolam 0.05mg/kg will be injected intravenously.
45596562|NCT02202239|Drug|Penehyclidine Hydrochloride Injection|Penehyclidine Hydrochloride 0.01mg/kg will be injected intravenously after midazolam is injected.
45596563|NCT02202239|Drug|Etomidate|Induction dose: 0.3 mg/kg. Maintenance dose: 10 μg•kg-1•min-1.
45596564|NCT02202239|Drug|Propofol|Induction dose: 2.0 mg/kg. Maintenance dose: 4 to 6 mg/kg/h.
46051383|NCT00914940|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Patients who are eligible will receive a T Cell-Depleted Hematopoietic Stem Cell Transplantation
46051384|NCT02829567|Behavioral|Motivational interviewing|
46051385|NCT04244721|Other|Preschool Autism Communication Therapy (PACT)|Professionals guide parents in the PACT therapy by videoconference. Sessions between parent and professionals are every 15 days for 6 months. Each session lasts one hour. At the end of the 12 sessions, additional booster sessions (one session per month over 6 months) will allow parents to maintain their skills. Parents will use therapy with their children in daily home practice. The aims of PACT therapy is to improve synchrony in the communication between the child and the parents. Improvement of the synchrony will mediate the decrease of autism symptoms of the child.
45366537|NCT05352438|Other|Manual Therapy Group|"Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Manual Therapy group received a manual therapy program applied as 2 sessions of 45 mins each week for 4 weeks (total 8 sessions) by an investigator. Soft tissue and joint mobilizations were applied to the TMJ and surrounding structures and to cervical segments, trigger point treatment was applied to trigger points, and myofascial loosening was performed. Patients were instructed to perform the exercises learned in the home exercise program in 3 sets of 10 repetitions every day."
45483532|NCT04496804|Behavioral|Behavioral Intervention for Physical Activity in MS (BIPAMS)|A behavioral intervention that involves an Internet website and one-on-one video coaching calls for increasing physical activity in people with MS.
45483533|NCT04496804|Behavioral|Wellness for MS (WellMS)|A behavioral intervention that involves an Internet website and one-on-one video coaching calls for increasing wellness in people with MS.
45483534|NCT03294070|Combination Product|Fimasartan plus amlodipine besylate|Fimasartan 60 mg plus amlodipine besylate 5 mg or Fimasartan plus 12.5 mg HCTZ plus one 5 mg amlodipine besylate
45596565|NCT02202239|Drug|Fentanyl|During induction, after injection of etomidate, fentanyl 3 μg/kg will be given intravenously.
46051386|NCT04244721|Other|Treatment As Usual (TAU)|Children will receive therapies available in the community as speech language therapist or occupational therapist.
46051387|NCT00631800|Drug|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14
45596566|NCT02202239|Drug|Cisatracurium Besilate|"Cisatracurium Besilate 0.14 mg/kg will be used after fentanyl is injected for induction.~During maintenance, intermittent bolus of cisatracurium will be used for maintain muscle relaxation."
45690935|NCT04028037|Procedure|FTPGT|A primary full thickness incision was given at 90 degrees to the long axis of the tooth and directly to the bone, A secondary split thickness incision was performed at 90 degrees to the long axis of the tooth but not directly to the bone, to circumscribe an area that has the same size of the gingival recession you want to cover .in a part of the first incision in order to preserve the area of tissue between them. A partial thickness flap is raised. Then two vertical incisions to the bone on the mesial and distal ends of the graft and one horizontal medial incision is made (under the partial thickness flap), to release it from the surrounding tissue incision were made, inserting the blade as much as possible parallel to the long axis of the teeth, the connective tissue was elevated from the underlying bone with a periosteal elevator.
46051388|NCT00835978|Drug|axitinib|axitinib 5mg BID (open-label) + axitinib dose titration (blinded)
45690936|NCT04028037|Procedure|SCTG|A primary full thickness incision was given at 90 degrees to the long axis of the tooth and directly to the bone, a falp was elevated, three inner incision eas performed and the connective tissue graft was harvested
46051389|NCT00835978|Drug|axitinib|axitinib 5mg BID (open-label) + placebo dose titration (blinded)
46051390|NCT00835978|Drug|axitinib|axitinib 5mg BID (open-label)
46051391|NCT02831907|Procedure|Cardiac surgery|All cardiac surgery procedures with the use of cardiopulmonary bypass
46051392|NCT02832141|Procedure|Mobilization anterior|Participant in prone position. Central thoracic mobilization from posterior-to-anterior.
45596567|NCT02202239|Drug|Remifentanil|Remifentanil will be injected continuously during maintenance of anesthesia.
45596568|NCT02202239|Drug|Sevoflurane|Sevoflurane of 1% to 2% will be administered via inhalation to keep bispectral index（BIS) between 50 to 55.
45596569|NCT05370001|Other|Entotracheal tube size|Compare the levels of carbon dioxide and if it is related to ETT size when using size 9 (routine) or size 8 (intervention).
46051393|NCT02832141|Procedure|Mobilization posterior|Participant in sitting position. Central thoracic mobilization from anteriors-to-posterior.
46051394|NCT04247685|Device|12-lead ECG monitoring device (MiRTLE Medical)|12-lead ECG monitoring device produced by a Massachusetts-based medical device company MiRTLE Medical is the experimental device;
45596570|NCT02368197|Drug|paclitaxel (Cardionovum Legflow drug eluting balloon)|Elution of paclitaxel from inflated balloon catheter into vessel wall
45690937|NCT04027959|Dietary Supplement|Vitamin B12|Diffusion of Vitamin B12 through the skin over 20 minutes under the effect of low amount of direct electric current
45690938|NCT04195503|Procedure|Liver Transplantation|Surgical removal of liver containing tumor(s) and transplantation of new healthy liver graft
45690939|NCT04027569|Other|Patient Specific Functional Scale|A validated patient reported outcome measure that asks patients to write down activities and score them 0 to 10.
45690940|NCT04027569|Other|PROMIS PF|A computer adaptive, validated patient reported outcome measure that measures physical function on a 1 to 100.
45690941|NCT01852825|Biological|MK-8237|A single tablet of MK-8237 with 12 DU, administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
45483535|NCT04075370|Other|Neuropsychological Testing|Measure cognition function and cognitive reserve in patients before, during and after radiation therapy using cumulative scores of Hollingshead Index, North American Adult Reading Test, HVLT-R, TMT A&B and COWA over time.
45690942|NCT01852825|Other|Placebo|A single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
45690943|NCT01852825|Biological|NAC|0.1 mL fixed volume of 10,000 BU/mL of HDM extract is delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1; and in Part 2 on Days -14, 56 and 84
45690944|NCT04027413|Dietary Supplement|fortisip compact protein|(24% protein; 41% carbohydrate; 35% fat)
45845917|NCT04782336|Other|Sample Collection|"Sample Collection - Adult Population:~Two (2) Nasal AND/OR~Two (2) Throat Swabs AND/OR~One (1) Saliva Sample~Sample Collection - Paediatric Population:~Two (2) Nasal OR~Two (2) Throat Swabs AND/OR~One (1) Saliva Sample"
46051395|NCT04247685|Device|3-lead ECG gating system|3-lead ECG gating system is the placebo/standard of care
46051396|NCT02829645|Other|Clinical assessment|Clinical assessment with questionnaires
46051397|NCT00701506|Device|Patterned Electrical Neuromuscular Stimulation|"20-minute session, to each affected knee, 3 times per week for 12 weeks.~PENS for 20 minutes:~Tri-phasic Lower Extremity stimulation pattern based on activation timing of the quadriceps and hamstrings for strength training (50 Hz impulses for 200 ms every 1500 ms).~Minimal twitch for 5 minutes.~Moderate to strong, but well-tolerated twitch contractions for 15 minutes.~Electrodes placed on quadriceps and hamstrings"
46051398|NCT00701506|Device|Placebo PENS|"20-minute session, to each affected knee, 3 times per week for 12 weeks.~Placebo PENS for 20 minutes:~Electrodes placed on quadriceps and hamstrings."
45366538|NCT05352438|Other|Splint Therapy Group|"Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Splint Therapy group was given a static occlusal splint, and adjustments were made as necessary. All the patients in this group were instructed to use the splint when sleeping for a period of one month."
45366539|NCT04069871|Device|trans-cutaneous electrical nerve stimulation.|• Patients assigned to the EMS group received daily EMS sessions of both lower extremities starting from the second day for 5days.
45366540|NCT04069871|Device|Sham TENS|Patients in the control group will receive sham TENS.
45483536|NCT03953703|Drug|Levocarnitine|Levocarnitine 1000 mg twice per day for 6 weeks
45483537|NCT03953703|Drug|Placebo|Placebo 1000 mg twice per day for 6 weeks
45483538|NCT03299140|Behavioral|Family Focused Therapy|
45483539|NCT04479566|Drug|Lithium Carbonate 250 MG|Patients undergoing video assisted thoracic surgery during the morning will take 250mg lithium carbonate 6 hours after surgery.
46051399|NCT04246827|Behavioral|Enhanced Lifestyle Weight Management|The Enhanced Lifestyle Weight Management program was a 12-week protocol in which training in coping skills to increase self-efficacy and decrease the impact of RA pain on behavioral (e.g., activity, eating) and psychosocial (e.g., mood, relationships) weight loss factors were integrated into a lifestyle behavioral weight loss intervention.
46051400|NCT00704002|Procedure|antegrade intramedullary splinting|antegrade intramedullary splinting with 2 to 3 small K-wires
46051401|NCT00704002|Procedure|conservative treatment|conservative treatment with 2-finger splint for one week
45690945|NCT04027413|Dietary Supplement|preOp|(100% carbohydrate).
45690946|NCT04344951|Drug|UNIKINON (Chloroquine phosphate) 200mg tablets|Two and a half tablets (500mg) twice daily for seven days.
45690947|NCT01822561|Drug|Eplerenone 50mg|All patients will receive the same dose of eplerenone.
45690948|NCT02080455|Drug|lomitapide|20 mg dose
45690949|NCT02080455|Drug|Atorvastatin|80 mg
45690950|NCT01852591|Biological|PCV 13|
45845918|NCT04764318|Behavioral|Remote patient monitoring for hypertension|The intervention involves making available remote physiologic monitoring services for hypertension patients allowable under Medicare for blood pressure (and weight if desired) when ordered by a patient's clinician.
46051402|NCT02831829|Other|water-based exercise training|Water-based training will be performed in upright position, in waist to xyphoid process deep thermo-neutral water at temperature of 32,8 C. The immersed exercise will include two session of aerobic and calisthenic exercise per day, six days of a week, both lasting 30 minutes
46051403|NCT02831829|Other|land-based exercise training|Land-based training will include two aerobic and calisthenic exercise session per day, six days of a week, both lasting 30 minutes
45366541|NCT04035746|Other|Observation of microcirculation and plasticity of the brain|Assessment of microcirculation, brain plasticity and clinical function
45366542|NCT00948324|Drug|CSII,ALA,MET,RSG|CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.
45366543|NCT01012635|Other|Hypnosis|Hypnosis Training: Verbal suggestions from an audio recording (via headphones).
45366544|NCT01012635|Other|Meditation|"Meditation: focus on a single word (one) for the entire session."
45483540|NCT04479566|Drug|Calcium Carbonate 500 MG|Patients undergoing video assisted thoracic surgery during the morning will take calcium carbonate 500mg 6 hours after surgery.
45690951|NCT04027491|Behavioral|Virtual Reality|"The selected commercial games are aimed mostly to improve upper limb functions. The games will be randomly administered during each session. Each game will be played for approximately 10 minutes, with 5 minutes break between each game session.~The intervention treatment consists of 12 sessions in 4-week period."
45366545|NCT01012635|Other|Neurofeedback training|Neurofeedback Training: Two electrodes will be placed on your scalp, and one electrode clipped on your head. There is no risk of electrical shock.
45690952|NCT04596241|Device|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
45690953|NCT04406493|Diagnostic Test|Lung impedance technique|"COVID 19 patients are admitted to the Infectious Diseases Unit; they will undergo examination using a lung impedance device. The first value that has been measured will be set as BASAL.~During the hospitalization, each patient will undergo this examination twice a day until discharge.~Changes in impedance values during admission will be evaluated as POSITIVE AND NEGATIVE PREDICTIVE values for clinical deterioration and improvement of COVID 19 patients and as a factor which predicts mechanical ventilation.~The time between lung impedance started to decrease (expression of the lung fluids accumulation), and the need for mechanical ventilation will be measured."
45690954|NCT04021251|Device|P0.2|Investigational Medical Device collecting spectral raman data from tissue.
45690955|NCT03961581|Behavioral|Using electric car|Child will use little electric cars to go to the reception of operating theatre to operating room.
45690956|NCT04021407|Device|LMA group|patients were ventilated with LMA
45690957|NCT04021407|Device|AirQ group|patients were ventilated with AirQ airway
45366546|NCT01012635|Other|Two different levels of tDCS|Direct stimulation of the brain by using a weak electrical current. There is no risk of electrical shock.
46051404|NCT02829411|Behavioral|Workforce Readiness Program|job readiness workshops, organized into ten daily sessions over two weeks.
46051405|NCT02829411|Behavioral|Relationship education|"25-hours of Within My Reach curriculum and relationship skills education sessions"
45366547|NCT04068701|Other|MaNMT Biofeedback|neuromuscular training intervention that incorporates biofeedback training
45483541|NCT02460718|Behavioral|ENCOURAGE Study|This intervention tested the effects of a peer coaching program plus brief diabetes education versus brief diabetes education alone on diabetes outcomes.
45483542|NCT03635853|Drug|drug containing extract from cock's comb|a container containing 25 mg of ointment having extract from cock's comb as active ingredient two times daily for 3 months
45483543|NCT03293992|Drug|0.01% RO7058584|Once daily morning administration for 7 days
45483544|NCT03293992|Drug|0.1% RO7058584|Once daily morning administration for 7 days
45366548|NCT05352360|Diagnostic Test|Pilates Exercises|Exercises with Kinesio Taping
45366549|NCT05352360|Diagnostic Test|Muscle Energy Technique|Exercises with Kinesio Taping
45366550|NCT02573285|Procedure|Simple Aspiration|Aspiration of pneumothorax with a small-bore catheter
45690958|NCT04021173|Drug|Anfibatide|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
45690959|NCT04021173|Drug|Placebos|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
46051406|NCT00914628|Genetic|HSV-Tk|Infusion of approximately 1±0.2 x 10^7 HSV-Tk genetically modified CD3+ cells/Kg between day +21 and day +49 after haploidentical HCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
45366551|NCT02573285|Procedure|Surgeon Preference|Any standard treatment option may be utilized for the treatment of the pneumothorax, including simple aspiration, chest tube placement, or an operation (VATS).
45483545|NCT03293992|Drug|1% RO7058584|Once daily morning administration for 7 days
45483546|NCT03293992|Drug|Matching Placebo|Once daily morning administration for 7 days
46051407|NCT00914628|Other|T-cell depleted or T-cell replete strategies|Haploidentical HCT with the infusion of CD34+ cells plus a fixed dose of T cells (1 x 10^4/Kg) or unmanipulated haploidentical stem cell transplantation followed by high-dose cyclophosphamide as part of GvHD prophylaxis
45366552|NCT01009671|Drug|ART 44|
45366553|NCT01009671|Drug|ART 50|
46051408|NCT00922792|Drug|activated recombinant human factor VII, long acting|Single dose of 0,2 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration
45483547|NCT03293992|Drug|Latanoprost 0.005%|Once daily morning or evening dosing
45366554|NCT04199988|Diagnostic Test|Posterior Shoulder Endurance Test|"Isometric posterior shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction, and the time for maintaining this position will be recorded.~Isotonic shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction and asked to perform horizontal adduction-abduction, and the athlete will horizontally abducted-adducted his/her arm to 90 degrees at a cadence of 30 beats per minute. The number of repetitions will be recorded."
45366555|NCT01009749|Behavioral|Motivational Enhancement System for Adherence (MESA)|MESA is designed to increase motivation for adherence to Highly Active Antiretroviral Therapy (HAART) among youth newly recommended to begin medications.
45366556|NCT01009749|Behavioral|Motivational Enhancement System for Health (MESH)|Motivational Enhancement System for Health (MESH) is an attentional control providing information on nutrition and exercise.
45483548|NCT01332201|Drug|Advagraf|oral
45366557|NCT00719693|Drug|ABT-143 ( rosuvastatin calcium and fenofibric acid )|one dose under low-fat meal condition
45366558|NCT00719693|Drug|ABT-143 (rosuvastatin calcium and fenofibric acid )|one dose under fasting meal condition
45483549|NCT01332201|Drug|Prograf|oral
45483550|NCT05223452|Device|UltraSound|we use prob that admit some of radiation to patient to see the organs inside the abdomen
45483551|NCT03293914|Behavioral|Lifestyle Redesign|Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive approximately 8 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the intervention protocol.
45483552|NCT01332279|Drug|everolimus|Given PO
46051409|NCT00922792|Drug|activated recombinant human factor VII, long acting|Multiple doses of 100 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration every 48 hours
45483553|NCT01332279|Drug|erlotinib hydrochloride|Given PO
45483554|NCT01332279|Procedure|biopsy|Correlative studies
45483555|NCT01332279|Other|laboratory biomarker analysis|Correlative studies
45483556|NCT01332279|Other|immunohistochemistry staining method|Correlative studies
45483557|NCT01332279|Genetic|polyacrylamide gel electrophoresis|Correlative studies
45483558|NCT01332279|Other|pharmacological study|Correlative studies
45483559|NCT01332279|Radiation|external beam radiation therapy|Undergo EBRT
45483560|NCT01332279|Genetic|microarray analysis|Correlative studies
45366559|NCT00952770|Procedure|transradial coronary intervention|percutaneous coronary intervention with transradial approach
45366560|NCT01009827|Other|Observation|Participants will have biomedical information extracted from their medical chart, will complete the ACASI questionnaire and have a face-to-face post-ACASI debriefing interview administered. Participants who do not have a documented HIV-1 viral load and/or CD4+ T-cells count from within the previous six months will also have venipuncture performed to obtain a blood sample for these tests to be performed.
45690960|NCT04027881|Behavioral|Sit Together and REad|STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
45690961|NCT04027335|Device|leva|Vaginal device used for pelvic floor muscle exercises
45690962|NCT04027725|Behavioral|Neurofeedback|Neurofeedback experiment will consist of 20 sessions of neurofeedback training, twice or three times a week during seven weeks. Each session will last for 40 minutes. The experimental group will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-trianing (T1) and 1 month follow-up (T2). Electroencephalography will be recorded by a technician in EEG for each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T1 and T2.
45690963|NCT01852045|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall on Day 1.
45690964|NCT04027257|Behavioral|Sit Together and Read (STAR)|STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
45690965|NCT03960957|Biological|AbobotulinumtoxinA|Treatment of glabellar facial lines with 50 U AbobotulinumtoxinA
45690966|NCT03960957|Other|Placebo|Treatment of glabellar facial lines with placebo
45690967|NCT03960645|Drug|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
45366561|NCT00719771|Device|Global® AP™ Total shoulder arthroplasty|Total shoulder arthroplasty
45366562|NCT00948402|Drug|Metformin|metformin 1250 mg three times daily
45366563|NCT00948402|Drug|oral contraceptive|30 µg ethinylestradiol plus 30 mg drospirenone 21 day/month.
45366564|NCT04068467|Other|Smartphone App|The application consists of content areas focused on mental health.
45366565|NCT04068467|Other|Waitlist Control|Waitlist control
45366566|NCT05352126|Other|Biocide|The product being researched, which is a biocide solution in a spray for atmospheric use without a propellant, will be sprayed in the bedroom of each patient at a rate of 2 sprays per day in the evening (half an hour before going to bed).
45366567|NCT00719927|Behavioral|Comadres Weight Loss Pilot Program|The first condition will consist of women participating with a female friend (comadre), while the second condition will consist of women participating without a support partner.
45690968|NCT04020939|Device|SPY imaging|Use of the SPY Pinpoint imaging device to evaluate intraoperative intestinal perfusion in children.
45690969|NCT04020939|Drug|Indocyanine Green|Intravenous injection of indocyanine green to evaluate the intestinal perfusion.
45366568|NCT00948480|Biological|Autologous tumor cells plus dendritic cells|A series of 8 vaccinations are administered over 6 months
45366569|NCT00948480|Drug|GM-CSF|500 mcg
45483561|NCT03298906|Drug|Esketamine|Participants will self-administer one intranasal spray of 14 mg esketamine at Time 0 and again 5 minutes later on Day 1, a total dose of 56 mg in Treatment Period 1 and 2.
45483562|NCT03298906|Drug|Ticlopidine|Participants will receive 250 mg ticlopidine tablets orally twice daily on Day -9 through Day 1 in Treatment Period 2.
45690970|NCT04027179|Drug|0.12% chlorhexidine digluconate mouthwash|0.12% chlorhexidine digluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
45690971|NCT04027179|Procedure|Periodontal instrumentation|Full-mouth scaling and root planing with manual curettes within 24 hours in two sections 1 hour each.
45690972|NCT04027179|Drug|Placebo mouthwash|placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
45690973|NCT04199169|Biological|HeV-sG-V|A Hendra virus soluble glycoprotein vaccine formulated in phosphate buffer and adjuvanted with aluminum hydroxide. Placebo is normal saline.
45690974|NCT04199169|Biological|Normal Saline Placebo|0.9% Saline
45690975|NCT04021095|Device|Head protection prototype device|The proposed experimental HPPD uses biocompatible material using FDMÔNylon which has high fatigue resistance, chemical resistance with impact resistance and toughness which is free of powders. It is HSA unclassified as yet and the FDMONylon is not FDA approved yet.
45752212|NCT02109731|Other|Negative airway pressure delivery|Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
45483563|NCT03298828|Biological|CD19 CAR and PD-1 knock out engineered T-cells|A single dose of 1 x 10^6/kg CD19 CAR transduced and PD-1 knock out engineered T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
45483564|NCT03298828|Biological|CD19 CAR T-cells|A single dose of 1 x 10^6/kg CD19 CAR transduced T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
45483565|NCT02461576|Device|Xpert HIV-1 VL Assay|in vitro diagnostic test to quantify HIV-1 RNA
45690976|NCT04026789|Other|Same-day-start|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing
45690977|NCT04026789|Other|Delay-for-diagnosis|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion
45690978|NCT04191291|Behavioral|Lunch period length|We are randomly allocating a 10 minute or 20 period of seated lunch time.
45690979|NCT04199871|Other|dichoptic 3D movies|dichoptic movies presented on a Nintendo 3DS
46051410|NCT05493904|Procedure|OCT-guided PCI|"For patients randomly allocated to this arm, PCI for complex lesions will be performed using OCT.~OCT Reference site: Most normal looking segment, No Lipidic plaque. Operator can decide 1 of 2 methods for stent sizing.~By measuring vessel diameter at the distal reference sites (in case of ≥180° of the external elastic membrane [EEL] can be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25mm (Ex> mean external elastic membrane reference diameter 3.35mm, 3.25mm stent diameter will be chosen).~By measuring lumen diameter at the distal reference sites (in case of ≥180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25mm (Ex> mean distal reference lumen diameter 2.55mm, 2.75mm stent diameter will be chosen)."
46051411|NCT05493904|Procedure|Angiography-guided PCI|"For patients randomly allocated to this arm, PCI for complex lesions will be performed using angiography only.~The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 30% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended."
46051412|NCT05493904|Device|Drug-eluting stent|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent.
46051413|NCT01077518|Drug|Ofatumumab|Ofatumumab was a liquid concentrate solution for infusion presented in glass vials containing 50 mL of solution at a concentration of 20 mg/mL to provide 1000 mg per vial. The ofatumumab infusions were prepared in 1000 mL sterile, pyrogen-free 0.9% NaCl to yield a 1 mg/mL ofatumumab concentration infusion.
46051414|NCT01077518|Drug|Bendamustine infusion|Bendamustine 100 mg/vial, injection
46051415|NCT01077518|Drug|Ofatumumab and Bendamustine infusions (Arm A)|Up to 8 cycles of Bendamustine (90 mg/m2 Days 1 and 2, every 21 days) given in combination with 12 doses of ofatumumab (1000 mg). Ofatumumab will be given on day 1 of each cycle of bendamustine as long as patients in Arm A receive bendamustine. Once patients in Arm A complete bendamustine therapy, the remaining doses of ofatumumab will be given monthly until all 12 doses are completed.
46051416|NCT01077518|Drug|Bendamustine infusion (Arm B)|Bendamustine (120 mg/m2 Days 1 and 2, every 21 days, up to 8 cycles).
46051417|NCT04203186|Drug|atovaquone-proguanil|Malaria standard treatment regimen
45366570|NCT05351970|Procedure|Barbed|Efficacy of barbed and monofilament closure regarding incisional hernia
45366571|NCT05351814|Other|Exercise|While the patients will be exercised with a physiotherapist 1 day a week, the treatment will be followed as a home exercise program 2 days a week.
45366572|NCT03753555|Drug|Atorvastatin Calcium|20mg Qd for 12 months
45366573|NCT03753555|Drug|Atorvastatin Calcium|40-80mg Qd for 6 months
45366574|NCT03753555|Drug|Probucol|0.5g Bid for 6 months
45366575|NCT03753555|Drug|PCSK9 inhibitor|Evolocumab 140mg subcutaneously injected, twice each month
45366576|NCT00606086|Drug|GI-5005|40YU, subcutaneous
45366577|NCT00606086|Drug|Pegylated Interferon and Ribavirin|Pegylated interefron is an injection and ribavirin is an oral tablet
45690980|NCT04026555|Other|MEWS++ Monitoring|Patient's electronic medical record data will undergo processing by a machine learning algorithm (MEWS++).
45690981|NCT04026555|Other|Predictor Score|A score predicting the likelihood that the patient will experience a deterioration in their clinical condition within six hours will be generated. If the prediction score exceeds a predetermined threshold, an alert will be sent to the provider. The alerting protocol is tiered, with both a low and high threshold. If the score is above the low threshold, nursing will be notified. If the score is above the high threshold, RRT will be notified.
45690982|NCT03952377|Drug|SX600|Transforaminal Epidural Injection
46051418|NCT00835120|Drug|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
46051419|NCT00914316|Drug|Ranolazine|Ranolazine, 1000 mg, capsule, twice daily, by mouth.
46051420|NCT00914316|Drug|Placebo|twice daily
46051421|NCT00701740|Drug|oral isotretinoin and Mexoryl SX / XL|20mg, 3/week,continuously for three months
45366578|NCT02573363|Drug|Cytarabine|Given per standard of care
45366579|NCT02573363|Drug|Mitoxantrone Hydrochloride|Given per standard of care
45366580|NCT02573363|Drug|Selinexor|Given PO
45366581|NCT03727113|Procedure|Optimization cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.
45483566|NCT02461342|Other|not intervention|This is a cross-sectional study, no intervention was performed.
45483567|NCT03878277|Drug|Starbucks® Cold brew - 325ml bottle|Starbucks® Cold brew 325ml bottles daily [205mg caffeine] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit
45845919|NCT04764318|Behavioral|Remote patient monitoring with care management|The intervention involves making available remote physiologic monitoring services for hypertension patients allowable under Medicare for blood pressure (and weight if desired) when ordered by a patient's clinician and providing care management services to support the enrollment and active use of this service.
46051422|NCT00701740|Drug|Mexoryl XL / SX|11 subjects used only the same moisturizer and SPF 60 sunscreen
45483568|NCT03286972|Device|PET/MRI|Participants will be placed in standard non-ferrous head and neck immobilization devices during PET/MRI (to simulate their anticipated positioning during subsequent CT simulation and treatment). A head/neck PET/MRI (standard bore size, 60 cm) will be performed
45483569|NCT03697629|Drug|Daratumumab|"Patients will receive daratumumab, in the following schedule:~Daratumumab 8mg/kg in 500 mL over 4 hours Cycle 1 Day 1, Daratumumab 16mg/kg in 500 mL over 90 minutes (20% of dose given in first 30 minutes and remaining 80% of dose given over 60 minutes) Cycle 1 Days 8, 15 and 22; Cycle 2 Days 1, 8, 15, and 22, and on Days 1 and 15 for Cycles 3-6."
45366582|NCT03727113|Procedure|Control cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
45366583|NCT00715637|Drug|Daunorubicin and Cytarabine|Daunorubicin: 45 mg/m2 over 30 minutes daily on days 1-3 (up to max. of 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on days 1-7 (up to max. of 2 courses)
45366584|NCT00715637|Drug|Amonafide and Cytarabine|Amonafide: 600 mg/m2 IV over 4 hours daily on Days 1-5 (up to max. 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on Days 1-7 (up to max. 2 courses)
45366585|NCT01012791|Other|Zumba exercise|Subjects with do Zumba exercise for approximately 60 minutes twice a week for 6 months.
45366586|NCT00953004|Dietary Supplement|fiber drink and fiber bread|fiber drink or fiber bread three times daily
45366587|NCT00953316|Other|Measure infant's jaw, record all information about car seat testing, and administer questionnaires.|Collect information about car seat testing of infants (until he/she transitions to a car seat), measure the infant's jaw during the first visit using a tape measure 18 different ways by Dr. Rhein or a trained research assistant, and complete a parent questionnaire about car bed use, previous testing of the infant in his/her car seat and information about the infant's home environment such as cigarette smoking, number of other children and daycare arrangements for the infant during the infant's first visit to the clinic. This short questionnaire asks information about car bed use, previous testing of your infant in his/her car seat and information about your home environment such as cigarette smoking, number of other children at your home and daycare arrangements for your infant.
45483570|NCT03286816|Drug|SodiumChloride|
45483571|NCT03286816|Drug|Sodium Lactate|
45483572|NCT01334697|Drug|recombinant human cardiotrophin-1|Single dose intravenous administration
45483573|NCT01334697|Other|Placebo|Single dose intravenous administration
45483574|NCT02460094|Drug|BIIB092|See Arm Descriptions for dosing information.
45483575|NCT02460094|Drug|Placebo|See Arm Descriptions for dosing information. (0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available)
45845920|NCT04754334|Drug|ORMD-0801|Oral Insulin
45845921|NCT04754334|Other|Placebo|Fish Oil
45847892|NCT03046212|Device|Transcutaneous electrical nerve stimulation|TENS: it was applied in the conventional mode, through four self-adhesive electrodes of size 5x9cm positioned about five centimeters from the edges of the surgical scar, with frequency of 100 Hz and pulse duration of 100μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was it increased during the application time with their permission.
46051423|NCT05560750|Procedure|Frenotomy|Releasing the tongue-tie with scissors
46051424|NCT05560750|Procedure|Oral physiotherapy|Gentle parental activation of the mouth area and the tongue for 1 month
46051425|NCT04938882|Drug|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
46051426|NCT04938882|Drug|Ropivacaine|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
46051427|NCT04938882|Drug|Compound lidocaine at low concentration|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
45483576|NCT01315119|Procedure|SPY Intra-Operative Angiography|Calculated per patient
45690983|NCT03952377|Drug|Placebo|Transforaminal Epidural Injection
45690984|NCT04026321|Drug|SQ001 125mL/day|SQ001 125mL/day will be administered by intravenous route at a rate of 3 mL/minute
45366588|NCT00898274|Other|immunoenzyme technique|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances [TBARS] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
45366589|NCT00898274|Other|laboratory biomarker analysis|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances [TBARS] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
45366590|NCT02541656|Procedure|Study of preload dependence indices after volume expansion in laparoscopy with Saldinger technique.|The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
45596571|NCT02368197|Device|Balloon angioplasty (Bard Dorado)|Dilatation of cephalic arch venous stenosis by radial force applied by a balloon catheter
45596572|NCT03533153|Biological|WJ-MSC cells implantation|Laboratory of Stem Cell of Drum Tower Hospital, Nanjing University Medical School, is able to provide types of Good Manufacture Practice (GMP) level stem cells and stem cell-based medicinal products. Clinical-grade WJ-MSC primary cells are cultured to 4~ 8 passages, and the surface markers (CD90+, CD105+, CD45-, CD31-, CD117-) are identified by flow cytometry. WJ-MSC cells are trypsinized and resuspended in the wash buffer of CTSTMD PBS (+Ca2+, +Mg2+). Within 2 hours after enzyme digestion, WJ-MSC cells are shipped to coronary care unit (CCU) and injected into the body.
45690985|NCT04026321|Drug|SQ001 250mL/day|SQ001 250mL/day will be administered by intravenous route at a rate of 3 mL/minute
45366591|NCT00898352|Procedure|regional lymph node dissection|
45366592|NCT00898352|Radiation|radiation therapy|
45596573|NCT03533153|Drug|CTSTMD PBS without WJ-MSC|For Case-control study only.
45690986|NCT04026321|Drug|SQ001 500mL/day|SQ001 500mL/day will be administered by intravenous route at a rate of 3 mL/minute
45690987|NCT04026321|Drug|SQ001 625mL/day|SQ001 625mL/day will be administered by intravenous route at a rate of 3 mL/minute
45690988|NCT04026321|Drug|Saline 0.9%|Saline 0.9% will be administered by intravenous route at a rate of 3 mL/minute
45690989|NCT04026243|Procedure|QL block|U/S guided Transmuscular Quadratus Lumborum Block
45690990|NCT04026243|Procedure|TF block|U/S guided Transversalis Fascia Plane Block
45690991|NCT01821937|Drug|faldaprevir(high dose)|faldaprevir(high dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to high dose treatment in random order
45690992|NCT01821937|Drug|Faldaprevir(low dose)|faldaprevir(low dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to low dose treatment in random order
45690993|NCT03832335|Diagnostic Test|Measurement of aniseikonia tolerance|Adding sizeglasses of different percent before right and left eye and measure the impact on stereopsis
45690994|NCT03820089|Diagnostic Test|Ultrasonography TP|TP us will be made to the included women
46051428|NCT04938882|Drug|Compound lidocaine at high concentration|Before the induction of anesthesia, 0.6% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
46051429|NCT00704080|Drug|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; continuous daily dosing
45366593|NCT05300490|Drug|Prednisolone|In this routine care study, all patients will receive a joint injection of prednisolone at a dose left to the discretion of the physician. The urinary excretion kinetics of this product and its metabolites will then be followed at different times. An association with metabolic genetic profile will be done.
45366594|NCT00720005|Device|Aspheric Acrysof ReSTOR intraocular lens|Bilateral implantation of Aspheric Acrysof ReSTOR
45366595|NCT00898430|Genetic|DNA Microarray analysis|Tumors will be assayed on Affymetrix Human Genome U133 GeneChip
45483577|NCT03642951|Device|Active Treatment|The study patients will be randomly assigned to two groups, each consisting of 10 patients: Group A - patients stimulated by devices marked A; Group B - patients stimulated by devices marked B. Since the devices used for actual and sham stimulation (placebo control) are similar in all respects including external appearance and the sound produced while activated, the technician(s), investigators and the patients will be completely blind to whether actual or sham stimuli are being delivered, i.e. whether Group A or Group B patients are receiving the actual stimuli. Indeed, both devices marked A&B could be used to deliver either type of stimuli. Only the person who constructed the devices will know which is which. Therefore, this study will be a truly randomized double-blinded placebo-controlled clinical trial. In case of emergency, un-blinding of the device will be available to the study team via a sealed envelope, stored with the study documents, separate from the subjects study files.
45483578|NCT03642951|Device|Sham Treatment|The study patients will be randomly assigned to two groups, each consisting of 10 patients: Group A - patients stimulated by devices marked A; Group B - patients stimulated by devices marked B. Since the devices used for actual and sham stimulation (placebo control) are similar in all respects including external appearance and the sound produced while activated, the technician(s), investigators and the patients will be completely blind to whether actual or sham stimuli are being delivered, i.e. whether Group A or Group B patients are receiving the actual stimuli. Indeed, both devices marked A&B could be used to deliver either type of stimuli. Only the person who constructed the devices will know which is which. Therefore, this study will be a truly randomized double-blinded placebo-controlled clinical trial. In case of emergency, un-blinding of the device will be available to the study team via a sealed envelope, stored with the study documents, separate from the subjects study files.
45483579|NCT04485663|Drug|ALG-010133|Single or multiple doses of ALG-010133
45483580|NCT04485663|Drug|Placebo|Single or multiple doses of Placebo
46051430|NCT00704080|Drug|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
45690995|NCT01821625|Drug|Eltrombopag|Study patients will be provided eltrombopag to raise platelet levels before anti-hepatitis C drugs are initiated, and will continue eltrombopag throughout the study.
45690996|NCT03022929|Behavioral|Enhanced Antimicrobial Stewardship Commitment and Feedback|Goes beyond the GetSmart recommendations to discern whether these recommendations can be improved upon.
45690997|NCT03022695|Device|High Intensity Focused Ultrasound|
45690998|NCT04406571|Other|Data record|Data record
45690999|NCT04020783|Other|NO Intervention|NO Intervention
45691000|NCT01821391|Drug|NDL-PDT|Metvix natural daylight photodynamic therapy
45691001|NCT01821391|Drug|c-PDT|Metvix conventional photodynamic therapy
45847893|NCT03046212|Other|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, flexion and extension of the knees and adduction and abduction of the hips, in both lower limbs. All exercises were performed with the patient in the supine position in the bed, in 10 repetitions.
46051431|NCT05253066|Drug|Chidamide combined with exemestane (+/- goserelin)|Chidamide combined with exemestane (+/- goserelin)
46051432|NCT05253066|Drug|Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)|Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
46051433|NCT05483530|Biological|HLX60 combined with HLX10|five various doses of HLX60 combined with flat dose of HLX10
46051434|NCT04797858|Behavioral|COVID-19 self-test|5 COVID-19 self-test kits will be given to participants after they have been tested for COVID-19. Participants will be instructed to give test kits to others in their social networks who are symptomatic, exposed to COVID-19, or otherwise at high risk of COVID-19.
45691002|NCT01821391|Drug|placebo c-PDT|Metvix placebo conventional photodynamic therapy
45847894|NCT03048006|Procedure|MRI with Dotarem|
45847895|NCT03051672|Drug|Pembrolizumab|Pembrolizumab (formerly MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD1 and its ligands, PD-L1 and PD-L2.
45847896|NCT03051672|Radiation|Palliative radiotherapy|Palliative radiotherapy aims to shrink cancer, slow down its growth or control symptoms.
45847897|NCT03052530|Device|Sapphire II PRO|To pre-dilate coronary arteries or bypass grafts during the subject's index procedure with Sapphire II PRO 1.0 and 1.25 PTCA dilatation catheters.
45691003|NCT04020393|Procedure|SPGB|SPGB was performed by the operating surgeon using a transnasal endoscopic approach before septorhinoplasty in the Block group. The prepared solution (4 cc % 4 lidocaine and 1 cc 8 mg dexamethasone) was delivered by a Mucosal Atomization device (LMA MADgic™ Laryngo-Tracheal Mucosal Atomization Device, US). 2,5 cc of the prepared solution was given to each side of the nose.
45691004|NCT04020705|Device|Citicoline eye drops (OMK1)|(OMK1) will be prescribed in the dosage of 1 drop 3 times a day
45691005|NCT04020705|Other|Placebo Comparator: hypromellose based ocular lubricant|will be prescribed in the dosage of 1 drop 3 times a day
45691006|NCT04020627|Other|BiPAP Group|"BIPAP~- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/Positive Expiratory Pressure(PEP) device"
46051435|NCT04797858|Behavioral|COVID-19 test referral|5 test referral cards and text messages on how to obtain COVID-19 testing will be given to participants after they have been tested for COVID-19. These cards and text messages will have information on how to obtain free COVID-19 tests at local testing sites. Participants will be instructed to give out referral cards and text messages to others in their social networks to obtain testing.
45366596|NCT00898430|Genetic|MALDI-TOF mass spectrometry|Supervised analysis techniques will be employed to identify patterns of protein peaks useful for treatment response and survival prediction. Hierarchical clustering analyses will be used to visualize data.
45366597|NCT00898430|Genetic|DNA microarray and MALDI-TOF mass spectrometry|Tumors from the specific Aim 1/2 and from preliminary data, previously analyzed, will be examined for HPV 16 infection.
45366598|NCT00893594|Drug|sumatriptan with naprosyn|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
46051436|NCT04303442|Procedure|TEP|Total extraperitoneal laparoendoscopic hernia repair with one or three skin incisions.
45366599|NCT00893594|Drug|placebo|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
46051437|NCT04796766|Diagnostic Test|High frequency stimulation (HFS)|Electrical stimuli via circular electrode array. The electrode array serves as cathode placed above the eyebrow. A surface electrode (anode) will be placed on the temple. Electrical stimuli will be applied via a constant current stimulator. The stimulus intensity for the electrophysiological protocol is adjusted to the 10-fold of the detection threshold. A number of 5 electrical pulses (2 ms, 100 Hertz (Hz)), 10 second intervals.
46051438|NCT04796766|Diagnostic Test|Low-frequency sinusoidal transcutaneous stimulation (sLFS)|Stimulation of C-nociceptors with constant current stimulator. Electrodes (placed on the proband's forehead. Stimulation by sine wave pulses of 250 ms duration (4 Hz), intensities inducing a pain intensity of 50/100 on a visual analogue scale from 0-100.
45691007|NCT04020627|Other|CPAP Group|"CPAP~- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/PEP device"
45691008|NCT01873417|Drug|BG00012 (DMF)|
45691009|NCT04025697|Other|Complete Denture|A conventional CD will be constructed
45691010|NCT04025697|Other|Rapid prototyped denture|A 3d printed complete denture will be constructed
45691011|NCT03934827|Drug|MRx0518 Capsules|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery.
45691012|NCT03934827|Drug|MRx0518/placebo Capsules|MRx0518/placebo product consist of a lyophilised formulation of either a proprietary strain of bacterium or placebo.The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery. Placebo capsules are manufactured to mimic MRx0518 capsules and contain the same excipients as the active biotherapeutic product.
45691013|NCT03950427|Behavioral|Videogame-based physical activity|videogame-based physical activity
45691014|NCT03950427|Behavioral|sedentary videogame|sedentary videogame
45691015|NCT03950427|Drug|Bupropion|Bupropion
45483581|NCT03286738|Drug|FOLFIRI, target agent|"Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Bevacizumab~Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Cetuximab"
45483582|NCT01332513|Drug|Investigational Medicinal Product (MR1)|Ezogabine MR1 at a dose strength of 300 mg will be orally administered with approximately 250 milliliter (mL) of water to group A subjects during the bioavailability phase. For the food effect phase subjects in group G will be orally administered MR1 tablets at a dose strength of 600 mg.
45483583|NCT01332513|Drug|Investigational Medicinal Product (MR2)|Ezogabine MR2 at a dose strength of 300 mg will be orally administered to group B subjects with approximately 250 mL of water during the bioavailability phase. For the food effect phase subjects in group H will be orally administered MR2 tablets at a dose strength of 600 mg.
45366600|NCT00715715|Drug|Prednisone Priming|For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.
45366601|NCT00953394|Drug|continuous 5 fluouracil infusion plus long-acting octreotide|long-acting octreotide acetate at a dose of 20 mg was administered intramuscularly every 4 weeks. 5fluorouracil was given as a protracted continuous infusion without interruption at a daily dose of 200 mg/m2 of body-surface area through an elastomeric pump connected to a central venous access.
45366602|NCT00720161|Drug|Metformin|daily 850 mg
45366603|NCT00720161|Drug|placebo|placebo
45366604|NCT00888368|Procedure|Transpatellar Approach|The transpateller approach for the injection of the dye will be used.
45366605|NCT00888368|Procedure|Suprapatellar|The suprapatellar approach will be used for the injection of the dye.
45366606|NCT04068077|Device|ApolloVue™ S100 image system, Viper1-S003|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
45366607|NCT04010916|Other|Group Preoperatively Adductor Canal Block|The ACB will be performed preoperatively before inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
45483584|NCT01332513|Drug|Investigational Medicinal Product (MR3)|Ezogabine MR3 will be orally administered with approximately 250 mL of water to group C subjects during the bioavailability phase. For the food effect phase subjects in group I will be orally administered MR3 tablets at a dose strength of 600 mg.
45483585|NCT01332513|Drug|Investigational Medicinal Product (MR4)|Ezogabine MR4 will be orally administered with approximately 250 mL of water to group D subjects during the bioavailability phase. For the food effect phase subjects in group J will be orally administered MR4 tablets at a dose strength of 600 mg.
45483586|NCT01332513|Drug|Investigational Medicinal Product (MR5)|Ezogabine MR5 will be orally administered with approximately 250 mL of water to group E subjects during the bioavailability phase. For the food effect phase subjects in group K will be orally administered MR5 tablets at a dose strength of 600 mg.
45483587|NCT01332513|Drug|Investigational Medicinal Product (IR)|Ezogabine IR at dose strengths of 50 mg and 200 mg will be orally administered with approximately 250 mL of water.
45483588|NCT03293836|Procedure|Radiofrequency ablation|Radiofrequency ablation of insufficient saphenous and perforating veins using Closure Fast and Closure Stylet catheters (medtronic)
45691016|NCT03950427|Behavioral|Counseling|Counseling for smoking cessation
46051439|NCT00827632|Drug|Low dose formulation|"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet."
46051440|NCT00827632|Drug|High dose formulation|"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 30 ug of ethinyl estradiol (EE) and 150 ug of levonorgestrel (LN) per tablet."
46051441|NCT02874638|Dietary Supplement|BASE egg protein|0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
45691017|NCT01872715|Drug|Oracea|
45691018|NCT04025385|Other|High Intensity Interval Training|Training for 25 min with four 1 minute intervals when participants exercise up to 80% of their individual limits.
45691019|NCT01871545|Device|Magnetic Resonance Imaging|Magnetic Resonance Imaging is a radiation free non invasive technique using magnetic radiofrequency waves to image the body. In this study, the research team would like to investigate the possibility of providing functional information on aggressiveness, vascularity and oxygen uptake in liver cancer tumors.
45691020|NCT04020315|Procedure|Non-surgically performed scaling and root planing|Non-surgically performed scaling and root planing
45691021|NCT04020549|Behavioral|Growth, Gratitude, & Positive Activities|Reading and writing activities based on growth (designed to instill the belief that people can change), gratitude (noticing and appreciating good things in life), and behavioral activation (identifying and scheduling positive activities).
46051442|NCT02874638|Dietary Supplement|BCAA-enriched egg protein|BCAA-enriched egg protein provided as crystalline amino acid.
46051443|NCT02874638|Dietary Supplement|small amount of essential amino acids|essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of essential amino acid in BASE egg protein
45366608|NCT04010916|Other|Group Preoperatively Tourniquet Adductor Canal Block|The ACB will be performed preoperatively after inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
45691022|NCT04020549|Behavioral|Study Skills Control|Reading and writing activities designed to teach evidence-based study strategies.
45691023|NCT03933657|Device|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.
45366609|NCT04010916|Other|Group Postoperatively Adductor Canal Block|The ACB will be performed postoperatively. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
45366610|NCT00948714|Behavioral|Peer Coach Phone Calls|Subjects will receive 3 phone calls from a trained peer coach over 6 months.
45366611|NCT00948714|Behavioral|Health Educator Visits|Subjects will meet 2 times with a trained health educator in the practice
45366612|NCT00948714|Other|written materials|Subjects will receive written material and brochures and a cookbook from the American Heart Association addressing healthy lifestyle
46051444|NCT02874638|Dietary Supplement|large amount of essential amino acids|essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of amino acid in BCAA-enriched egg protein
45366613|NCT00898508|Genetic|gene expression analysis|
45366614|NCT00898508|Genetic|mutation analysis|
45366615|NCT00898508|Genetic|proteomic profiling|
45845922|NCT04749732|Behavioral|WalkingPad plus Psychological Intervention - PsyWPad Group|The 24-week walking program will be monitored by the WalkingPAD application that will accompany the patient on their walks and record their adherence to the previously defined individual program. Motivational support for a behavioral intervention will include two face-to-face sessions and the following contacts will be made over the phone. The behavioral motivational intervention will follow the principles of 1) motivational interview, will be based on 2) Theory of self-determination, taking into account 3) components of the Transtheoretical Model of Change and the Theory of Planned Behavior.
46051445|NCT04303598|Drug|FNC|3mg, 1 tablet，QD
46051446|NCT04303598|Drug|3TC|300mg, 1 tablet，QD
45366616|NCT00898508|Genetic|reverse transcriptase-polymerase chain reaction|
45366617|NCT00898508|Other|fluorescent antibody technique|
45366618|NCT00898508|Other|immunohistochemistry staining method|
45366619|NCT00898508|Other|laboratory biomarker analysis|
45366620|NCT00898508|Other|liquid chromatography|
45366621|NCT00898508|Other|mass spectrometry|
45366622|NCT00898508|Other|medical chart review|
45366623|NCT00898508|Procedure|quality-of-life assessment|
45366624|NCT00711893|Device|Cognis 100-D, Teligen DR and VR 100 HE|Teligen is an implantable defibrillator for detection and termination of life threatening arrhythmias. Cognis includes in addition to these capabilities cardiac resynchronization therapy for patients having heart failure.
45366625|NCT00720239|Other|Taliderm wound healing dressing|"Taliderm wound healing dressing will be applied to the wound site as follows depending on assignment to group:~Control group receives no intervention. Experimental Group 1 (n = 10) will receive TalidermR only one time at the beginning of the treatment phase.~Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.~Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase."
46051447|NCT04303598|Drug|TDF|300mg, 1 tablet，QD
46051448|NCT04303598|Drug|EFV|200mg, 1 tablet，QD
45483589|NCT03293836|Procedure|Multilayer Compressive Bandage|Individual receive multilayer compressive bandage once a week
45691024|NCT04020237|Behavioral|Education about particulate matter practice score|"For the intervention group, specific guidance is given to the patient who might be exposure in environment with higher particulate matter concentration.~1) Start air purifier~2) Do not go out and make it to the minimum when absolutely necessary~3) It is recommended to wear a mask when going out.~4) The investigators recommend a lot of water, fresh fruit and vegetables.~5) Prepare an inhaler and use it when symptoms get worse."
45847898|NCT03055650|Device|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
45847899|NCT03057132|Device|Cavilon Advanced Skin Protectant|Cavilon Advanced Skin Protectant
46051449|NCT04303598|Drug|FNC placebo|1 tablet，QD
46051450|NCT04303598|Drug|3TC placebo|1 tablet，QD
46051451|NCT04607460|Device|JOGO Digital Therapeutics EMG Biofeedback for Lower Back Pain|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 8 weeks with specific exercises to target low back pain.
45366626|NCT00609986|Drug|insulin|"The intravenous regular insulin infusion will be delivered continuously during the transplant surgery and after surgery for a total of three days. While receiving the insulin infusion, the dose will be calculated to keep the blood sugar levels between 70-110 mg/dL.~After the regular insulin infusion is discontinued, the blood sugar levels will be measured by a finger stick blood glucose up to 5-6 times per day and the blood sugar levels will be corrected by a subcutaneous basal-bolus insulin injection for a blood sugar goal 70-110 mg/dL.~Upon discharge from the hospital, the patient will be placed on a basal-bolus regimen consisting of 3-4 insulin injections to maintain a blood sugar between 70-140."
45366627|NCT00609986|Drug|NPH Insulin or glargine insulin and aspartame insulin|"The NPH or glargine and aspartame insulin will be given subcutaneously using a small-short needle to administer the insulin.~The blood sugar level will be checked every 1 hour while in the operating room and treated with rapid-acting insulin as needed to keep the blood sugar levels 70-180 mg/dL. The blood sugar level will be checked every 4 hours when in the recovery room and on the 6 East transplant unit. Once the patient is able to eat, the blood sugar will be checked five times a day (before meals, at bedtime, and at 3:00 am). Long-acting and rapid-acting insulin will be used to maintain the target blood sugar level.~Upon discharge from the hospital, the patient will be placed on a minimum of one to two insulin injections to maintain a blood sugar between 90-180 mg/dL"
45366628|NCT00715871|Drug|Nicotine|"Subjects received an amount of liquid nicotine cigarettes (containing 1.5mg of nicotine each) based on the amount of nicotine the subjects had been receiving from cigarettes. The number of liquid nicotine cigarettes received by each subject was reviewed, and adjusted (if necessary), every two weeks for the duration of the 12-week study."
45366629|NCT00715871|Device|Smoke-Break nicotine delivery device|"The Smoke-Break nicotine delivery device is a liquid nicotine cigarette designed to mimic the act of smoking. It is an NRT (nicotine replacement therapy) similar in concept to the nicotine patch, gum, and lozenge, except the nicotine is delivered in a way designed to duplicate the cigarette smoking experience. The Smoke-Break nicotine delivery device is non-invasive."
45366630|NCT00898664|Genetic|cytogenetic analysis|
45366631|NCT00898664|Genetic|gene expression analysis|
45845923|NCT04749732|Behavioral|WalkingPad plus Virtual Assistant - CyberWPad Group|The 24-week walking program will be monitored by the WalkingPAD application, which will accompany the patient on their walks and record their adherence to the previously defined individual program. Motivational support will be provided by a virtual assistant through daily and on-the-spot interactions and through support and motivational messages.
45845924|NCT04749732|Behavioral|WalkingPad group - Paper WPad Group|The 24-week walking program will be supported by a printed prescription of an individualized HbET previously defined on the WalkingPAD platform. However, this group of patients will not have the support of an application to monitor and record adherence to the program. Motivational support for a behavioral intervention will include two face-to-face sessions and the following contacts will be made over the phone. The behavioral motivational intervention will follow the principles of 1) motivational interview, will be based on 2) Theory of self-determination, taking into account 3) components of the Trans-Theoretical Model of Change and the Theory of Planned Behavior.
45845925|NCT04748796|Other|echocardiography|Full echocardiography will be performed at baseline and during the follow-up at H1, H3, H6 and H12.
45366632|NCT00898664|Genetic|mutation analysis|
45366633|NCT00898664|Genetic|polymerase chain reaction|
45366634|NCT00898664|Other|immunohistochemistry staining method|
45366635|NCT00898664|Other|laboratory biomarker analysis|
45366636|NCT02572193|Procedure|POEM|To determine the feasibility of same-day discharge following a POEM procedure
45691025|NCT04025307|Drug|bacTRL-IL-12|bacTRL-IL-12 is a live, genetically modified Bifidobacterium longum (B longum), for administration via IV infusion. The probiotic bacteria selectively colonize solid tumour tissues and are engineered to deliver genetic material encoding the pro-inflammatory transgene Interleukin-12 (IL-12). Plasmid DNA encoding the IL-12 transgene is delivered to the patient's cells within the tumor microenvironment, whereupon IL-12 is expressed to stimulate local and systemic anti-tumour immune responses.
45691026|NCT01613599|Drug|Rituximab|Participants received rituximab at the discretion of their treating physicians.
45845926|NCT04748796|Drug|Landiolol|Patients randomized to the experimental group will be treated according to the standard of care plus for 2 days with landiolol IV started at a dose of 1 microgram/kg/min and progressively increased every 10 minutes to a maximum of 40 micrograms/kg/min.
45366637|NCT00888446|Biological|tgAAC09|
45366638|NCT00888446|Biological|tgAAC09|
45366639|NCT00888446|Biological|tgAAC09|
45366640|NCT00888446|Other|Formulation buffer|Sterile isotonic buffered salt solution
45366641|NCT02540174|Procedure|integrated addiction treatment program|"At the inclusion, a 45 min interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I), the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million using the CO tester.~At 3, 6, and 12 months : a 20 min interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption.~The first addiction consultation will be carried out directly in the cancer treatment unit and integrated to the overall cancer treatment program."
45483590|NCT03286660|Diagnostic Test|Chair Rise Tests and short questionnaire|"Exercises consist on a Chair Rise Tests and short questionnaire It is a functional test evaluating the number of chair rise over a given time and / or frequency.~This test is combined with a questionnaire to collect quantitative and qualitative information:~dyspnea and muscular fatigue at rest before the start of the test and at the end of the exercise~Saturation at rest, and at the end of the exercise~the number of total a chair rise"
45483591|NCT03549585|Other|Criteria for Screening and Triaging to Appropriate aLternative care|CriSTAL Tool (Criteria for Screening and Treatment of Appropriate Long-Term Care) is a multidimensional geriatric tool that lists 18 elements of the literature, under construction and validation by an Australian retrospective study. This tool is a practical questionnaire and easy to use in current care, with items adapted to the geriatric dimension. The investigators chose to target hospitalized geriatric patients through emergencies.
45483592|NCT03625778|Drug|MEDI0382|MEDI0382 will be administered subcutaneously daily according to the MEDI0382 cohorts.
45483593|NCT03625778|Drug|Placebo|Placebo will be administered subcutaneously daily according to the Placebo cohorts.
45483594|NCT04269538|Drug|PF-06480605|PF-06480605 150 mg and 450 mg SC dosing
45483595|NCT04269538|Drug|Placebo|Placebo SC dosing
45483596|NCT03298750|Procedure|Resection of ovarian tissue and mechanical stimulation|"he women will undergo a surgical laparoscopy during which one of the two technique will ensue.~One of the ovaries will be scratched ( 2 mm depth) with a knife. Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory.~A piece of one ovary will be resected (up to one third of the ovary's volume, without harming the other ovary.~The resected ovarian tissue will be transferred immediately to the laboratory where the cortex will be divided from the medulla and sliced to small pieces of 1-2 square millimeters.~These pieces will be transferred back to the operation room in order for them to be transplanted under the serosa layer of the remaining ovary.~Any bleeding would be stopped using a stiches or hemostatic mesh (diathermy will not be used).~Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory."
45483597|NCT03619382|Radiation|Cone Beam Computed Tomography|Computer tomography (CT) of the foot/ankle for determination of motion and morphology
45483598|NCT03619382|Radiation|Radiographs|Standard radiographs of the foot/ankle as part of the screening criteria
45483599|NCT00398541|Drug|losartan potassium (+) hydrochlorothiazide|losartan potassium (+) hydrochlorothiazide combination will be titrated upwards according to the following scheme: losartan potassium 50/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 25
45483600|NCT03625700|Drug|Oxygen gas|Supplementary oxygen supplied via nasal catheter or oxygen mask during hospital admission.
45483601|NCT03293602|Device|F-MISO PET imaging|F-MISO PET imaging will be added to the preoperative staging explorations of a patient with high risk prostate cancer candidate to radical prostatectomy. Patient will be selected during multidisciplinary meeting and urology consultation of Bordeaux and Toulouse university hospitals. Functional MRI imaging should be available before surgery. If patient consent to participate in the study, F-MISO PET imaging will be planed before prostatectomy. Results of this exam will not be considered for patient therapeutic management.
45483602|NCT03650036|Drug|Pulp Therapy CTZ Paste|CTZ paste is composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline and 125 mg of zinc oxide and manipulated with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use.
45483603|NCT03650036|Drug|Pulp Therapy ZOE Paste|The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use.
45483604|NCT03298672|Drug|NDX-1017|Solution of NDX-1017 for subcutaneous injection
45483605|NCT03298672|Drug|Placebo|Placebo solution for subcutaneous injection
45483606|NCT04049162|Dietary Supplement|Blueberry Plus Exercise (BB-EX)|Pre-packaged blueberry powders are from U.S. Highbush Blueberry Council and are packaged in sealed single-serving packets (18 g/packet) to prevent exposure to light and moisture. All supplement packets are stored under refrigeration until distribution to study participants. Participants will be asked to increase physical activity through a weekly supervised exercise class and increasing baseline daily step counts gradually over the course of the intervention.
45483607|NCT04049162|Dietary Supplement|Blueberry Placebo Plus Exercise (P-EX)|Pre-packaged placebo powders are from U.S. Highbush Blueberry Council and are packaged in sealed single-serving packets (18 g/packet) to prevent exposure to light and moisture. All supplement packets are stored under refrigeration until distribution to study participants. Participants will be asked to increase physical activity through a weekly supervised exercise class and increasing baseline daily step counts gradually over the course of the intervention.
46051452|NCT04607460|Device|JOGO Digital Therapeutics EMG Biofeedback for Persistent Post Mastectomy Pain|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 4 weeks with specific exercises to mitigate persistent post mastectomy pain ahead of the surgery.
45483608|NCT04489264|Drug|Transplant, Autologous|high dose chemotherapy followed by autologous stem cell transplantation
45483609|NCT03298594|Diagnostic Test|specific cervicograph|
45847900|NCT03057366|Drug|Pevonedistat|Pevonedistat intravenous infusion.
46051453|NCT04607460|Device|JOGO Digital Therapeutics EMG Biofeedback for Migraine|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 6 weeks with specific exercises to target migraine pain.
45366642|NCT02540174|Procedure|standard of care|"The following actions will be performed by a nurse or by the study coordinator on site who have been trained in tobaccology and addictology :~At the inclusion, a 45 minutes interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I) , the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million (ppm) using the CO tester.~At 3, 6, and 12 months: a 20 minutes interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption"
45366643|NCT02572271|Procedure|Rubins Mastopexy|The surgical technique described by Rubin is performed. No other intervention.
45366644|NCT02572271|Procedure|LOPOSAM|The surgical technique LOPOSAM is performed. No other intervention.
45483610|NCT05223374|Device|Canvas Dx|Canvas Dx is intended for use by healthcare providers as an aid in the diagnosis of autism spectrum disorder (ASD) for patients ages 18 months through 72 months who are at risk for developmental delay based on concerns of a parent, caregiver, or healthcare provider. The device is not intended for use as a stand-alone diagnostic device but as an adjunct to the diagnostic process. The device is for prescription use only (Rx only)
45483611|NCT03286582|Drug|AC-203 1% Topical Ointment|AC-203 1% ointment BID (twice daily)
45483612|NCT03286582|Drug|Clobetasol 0.05% Topical Ointment|Clobetasol 0.05% Topical Ointment BID
45483613|NCT05202002|Behavioral|Video clip|"After obtaining written informed consent, participants received a sealed envelope containing a preprinted paper referral to an online website, with a unique identifier.~After entering the online website, participants will be asked to enter the unique identifier they have received into a text box. Only those whose identifiers were predetermined to be associated with the intervention group will receive the intervention.~The intervention is twenty minutes long educational video clip, in which a brief discussion was presented, by an obstetrician, pediatrician, dietitian, and a breastfeeding consultant, each presenting the benefits of breastfeeding for mother and newborn."
45483614|NCT05202002|Behavioral|No video clip|Participants in this group will receive a unique identifier that belongs to the control group, thus no video clip will be displayed.
45483615|NCT02460640|Procedure|Tap block|intravenous patient-controlled analgesia with morphine and tap block with subcostal and posterior approach with ropivacaine 0,5% 15ml+15ml
45483616|NCT02460640|Procedure|intravenous Patient controlled analgesia|intravenous patient-controlled analgesia with morphine
45483617|NCT02460640|Drug|Morphine|
45483618|NCT02460640|Drug|Ropivacaine|
45483619|NCT05196074|Other|Acute hypoxemic respiratory failure patients on VV-ECMO|To describe the prevalence of complete airway closure in patients with acute hypoxemic respiratory failure on VV-ECMO and its association with outcome.
45483620|NCT03568760|Behavioral|Semantic feature analysis|Confrontation naming training and training in doing circumlocutions
45483621|NCT03568760|Behavioral|Comprehension training|Reading and hearing comprehension
45483622|NCT03298516|Drug|DCLL9718S|DCLL9718S will be administered as per the schedule specified in the respective arm.
45483623|NCT03298516|Drug|Azacitidine|Azacitidine will be administered as per the schedule specified in the respective arm.
45847901|NCT03057366|Drug|[14C]-Pevonedistat|[14C]-Pevonedistat intravenous infusion.
45366645|NCT04035824|Drug|Gastrodia and Uncaria granule|Patients allocated to the intervention group take 10g of Gastrodia and Uncaria granule each time, twice per day, and for two months.
45366646|NCT04035824|Drug|Placebo of Gastrodia and Uncaria granule|Patients allocated to the control group take 10g of placebo of Gastrodia and Uncaria granule each time, twice per day, and for two months. The placebo has similar appearance and smell to genuine drug but has no effective anti-hypertensive agents.
45847902|NCT03057366|Drug|Docetaxel|Docetaxel intravenous infusion.
45847903|NCT03057366|Drug|Carboplatin|Carboplatin intravenous infusion.
45847904|NCT03057366|Drug|Paclitaxel|Paclitaxel intravenous infusion.
46051454|NCT02874716|Other|Tuberculosis Program (PPIA)|The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free sputum microscopy, free digital chest X-ray, free or subsidized drug-susceptibility testing (DST), free first line anti-TB treatment), (2) training or certified medical education sessions for the providers from the PPIA, and (3) financial incentives to engaged providers for patient registration, diagnostic testing, treatment initiation, and treatment adherence. Meanwhile, health camps, advertising, and other advocacy efforts are aimed to raise awareness in the communities.
45366647|NCT00893750|Behavioral|NET Truth Education|Individual Narrative Exposure and Truth Education in Groups
45847905|NCT03060486|Device|HYBENX®|"The mixture was then introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement.~Finally, the canal was rinsed with sterile saline water using a syringe with a side-vented 30 G needle."
45366648|NCT00893750|Behavioral|Conflict Resolution and Social Competence Skills|Conflict Resolution and Social Competence Skills in Groups
46051455|NCT04727528|Drug|Sodium zirconium cyclosilicate|Investigational medicinal product
46051456|NCT04727528|Drug|Placebo|Plabeco comparator
45366649|NCT00893750|Behavioral|Traditional Ways of Coping|Methods Collected by Local Teachers to Help Vulnerable Children and Youths in Northern Uganda
45366650|NCT00712049|Drug|simvastatin|simvastatin 40 mg
46051457|NCT00704236|Drug|Coptis Chinensis, Astragalus mambranesceus, Lonicera Japonica (Traditional Chinese Treatment)|50 mg of Coptis Chinensis, 30 mg of Astragalus mambranesceus and 120 mg of Lonicera Japonica
45366651|NCT00712049|Drug|Nicotinic Acid|daily dose starting with 500 mg, up to 2000mg
45366652|NCT00712127|Other|Diet and Exercise|The participants in this intervention will receive 12 months of weight loss through diet and exercise
45366653|NCT00712127|Other|Diet and Exercise-Delayed|Participants in this intervention will receive six months of weight loss through diet followed by six months of diet and exercise
45366654|NCT00898742|Genetic|DNA and tissue microarray analysis|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
45366655|NCT00898742|Genetic|reverse transcriptase-polymerase chain reaction|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
45366656|NCT00898742|Other|mass spectrometry|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
45366657|NCT00716027|Behavioral|Standard behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
45366658|NCT00716027|Behavioral|Modified behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
45847906|NCT03061812|Drug|Rovalpituzumab tesirine|Powder for solution for infusion in vials.
46051458|NCT00704236|Drug|Placebo|
46051459|NCT04748718|Other|Exercise-based injury prevention program|~10-minute, 4+ times/week exercise-based injury prevention program. Includes flexibility, strengthening, balance, agility and plyometric exercises.
45366659|NCT00898820|Genetic|gene expression analysis|
45366660|NCT00898820|Genetic|polymorphism analysis|
45483624|NCT03293446|Diagnostic Test|Urinary acidification test|Urinary acidification by administration of ammonium chloride (100 mg/kg body weight, given orally) during a single-day hospital admission.
45483625|NCT04973228|Drug|ARQ-154 - Active|ARQ-154 Foam 0.3% - Active
45483626|NCT04973228|Drug|ARQ-154 Vehicle|ARQ-154 Foam - Vehicle
45483627|NCT03288298|Drug|luteolin|flavonoid natural extract
45483628|NCT03288298|Drug|nano-luteolin|nanoparticles of luteolin
45483629|NCT03298360|Other|Blood sample|167mL of blood in EDTA tube will be obtained on a research visit, after signature of written informed consent
45483630|NCT03298282|Other|OCT (Optical Coherence Tomography)|Coronary images by OCT and selective CTA and FFR values will be registered.
45483631|NCT03298282|Other|Coronary CTA|Coronary images by OCT and Coronary CTA and FFR values will be registered.
45483632|NCT03298282|Other|FFR|Coronary images by OCT and selective CTA and FFR values will be registered.
45483633|NCT05120960|Drug|tepotinib|Given by PO
45483634|NCT05120960|Drug|tepotinib plus osimertinib|Given by PO
45483635|NCT05170802|Other|NanoKnife procedure|clinical data regarding use of the NanoKnife system intraoperatively (via laparotomy) to ablate the pancreatic tumors per the treating physicians discretion will be collected.
45483636|NCT03298126|Procedure|TR BAND removal protocol|To assess radial artery patency after specific protocol used as already described in previous section.
45483637|NCT05169866|Drug|Nifekalant|Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to nifekalant arm will receive a bolus of 0.3mg/kg IV in the first 5 minutes and a maintenance dose of 0.2-0.4mg/kg/h for 24 hours.
45366661|NCT00898820|Genetic|protein expression analysis|
45366662|NCT00712205|Drug|Placebo|once daily 1mcg Placebo for 28days followed by crossover treatment
45366663|NCT00712205|Drug|Calcitriol|once daily 1mcg Calcitriol / Placebo for 28days followed by crossover treatment
45366664|NCT02574299|Other|E-learning|Management of auditory processing disorders with serious game (E-learning)
45366665|NCT02574299|Device|Hearing aids fitting|Symmetrical hearing loss which are fitted with binaural hearing aids for the first time
45366666|NCT00720551|Other|alcohol|alcohol 0.05%, 0.08% or 0.11% or placebo
45366667|NCT00451906|Drug|Platinum-based chemotherapy|As prescribed
45845927|NCT04744194|Other|Nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 - 3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps.
45483638|NCT05169866|Drug|Amiodarone|Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to amiodarone arm will receive a bolus of 150mg IV in the first 10 minutes and a maintenance dose of 0.5-1mg/min for 24 hours.
45483639|NCT05160740|Drug|Indocyanine green for injection|ICG will be injected to participants preoperatively for molecular fluorescence image
45483640|NCT03286192|Behavioral|compassion cultivation training|Eight 2-hour group sessions that provide a structured and systematic way of cultivating daily-life skills needed to strengthen qualities of compassion, empathy, and kindness for oneself and others.
45483641|NCT05073614|Genetic|immunohistochemical detection of Heparanase in chronic gastritis|immunohistochemical detection of Heparanase in chronic gastritis specimens.
45483642|NCT03286036|Other|biomarkers|This is an observational study, there is no intervention
45483643|NCT03843008|Dietary Supplement|Melatonin|Participants in the Melatonin Group will receive 3mg of melatonin each evening for up to seven days for a maximum total of 21mg of melatonin.
45845928|NCT04744194|Other|Assisted nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 - 3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps.
45366668|NCT00451906|Drug|Bevacizumab [Avastin]|15 mg/kg IV on Day 1 of each 3 week cycle
45845929|NCT04725084|Other|Use of High Flow Nasal Cannula alone|Use of high flow nasal cannula oxygen therapy alone
45366669|NCT04162691|Diagnostic Test|Tissue|Four 4-5 mm tissues of the thymoma
45366670|NCT00712283|Drug|Neramexane mesylate|tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days
45366671|NCT04070495|Drug|KW-6356|A single oral dose will be administered at Day 1 and 15
45366672|NCT04070495|Drug|Clarithromycin|400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28
45483644|NCT03285802|Drug|Letrozole|Letrozole 2.5mg will be taken daily q 30 days
45845930|NCT04725084|Other|Use of Non-invasive Ventilation|Use of non-invasive ventilation combined or not with high flow nasal cannula oxygen therapy
45845931|NCT04725084|Other|Use of Continuous Positive Airway Pressure|Use of continuous positive airway pressure combined or not with high flow nasal cannula oxygen therapy
46051460|NCT04745520|Device|Rib fixation|"Rib fixation is performed by a senior surgeon. The patient is under general anesthesia. A thoracotomy focused on the fracture is performed to optimize access to the rib to be repaired. Video-assisted thoracic surgery (VATS) can be performed to better localize rib fractures. Significant muscle division is avoided. Removal of the periosteum is not required. The broken rib segments are approximated with forceps and the medical devices are used to fix the fracture. The medical devices are implemented according to the manufacturers' recommendations. The goal is to stabilize the chest wall. It is not useful to fix all fractures to stabilize the wall. A chest tube can be placed at the end of the operation.~Medical devices~The following medical devices can be used:~MatrixRIB™, De Puy Synthes Companies, Zuchwill, Switzerland~STRATOS™, MedXpert GmbH, Heitersheim, Germany~NiTi Fixing PlatesTM, IAWAI, Yandzhou, China"
45845932|NCT04715958|Procedure|Contrast-Enhanced Ultrasound|Undergo CEUS
45845933|NCT04715958|Drug|Perflutren Lipid Microspheres|Given IV
45483645|NCT03285802|Drug|Everolimus|Everolimus 10mg daily q 28 days
45691027|NCT03771261|Behavioral|Weight Loss|Participants will be prescribed hypo-caloric diet by a registered dietitian and attend weekly social support/nutrition education meetings.
46051461|NCT04745520|Drug|Analgesia|Epidural analgesia is continuing for 24 to 72 hours post-randomization to maximize outcome benefits. Afterwards, paracetamol, NSAID and/or opioid treatment are used according to pain severity. In case of opioid use, morphine treatment is preferred. However, other opioid drugs or doses can be considered to better customize the treatment.
45847907|NCT03061812|Drug|Topotecan|Powder or solution for infusion in vials. Topotecan is commercially available as both a powder and solution for infusion. Availability will vary by region.
46051462|NCT04636086|Drug|Cholecalciferol|Vitamin D supplementation
45366673|NCT04070495|Drug|Rifampicin|600mg, oral tablet (4 x 150mg), once daily (QD), Day 8-21
45691028|NCT03771261|Dietary Supplement|Egg Protein|Participants will be provided pre-packaged hard-boiled eggs (3/day, medium) and egg white protein powder.
45691029|NCT04025619|Device|tape|Sports tape
45691030|NCT01850641|Drug|PA21|
45752213|NCT00365599|Drug|suberoylanilide hydroxamic acid (SAHA, Vorinostat)|Vorinostat will be used to potentiate the effects of tamoxifen or overcome tamoxifen resistance. All patients will receive vorinostat at 400 mg by mouth (po) daily for 3 out of 4 weeks. Responses will be assessed after 2 cycles (8 weeks + 4 days).
45483646|NCT03293290|Drug|PrEP|Subjects on PrEP will be followed for 1 year with quarterly assessments by trained research assistants. Study visits will take place at in New Haven and Hartford. At every scheduled visit, participants will receive a comprehensive package of preventive services, including a prescription for the next 30-day supply of TDF/FTC (with 2 refills), a symptom screen for acute HIV, risk-reduction counseling, PrEP adherence support, bleach for cleaning injection equipment, and condoms. HIV rapid testing with Orasure® will be performed quarterly; participants testing newly positive for HIV (representing seroconversions) will be followed with confirmatory testing and referred to care as needed.
45483647|NCT03929822|Diagnostic Test|Contrast-Enhanced Spectral Mammography|A standard dose of contrast material for other contrast mammography examinations and for body CT scanning, 1.5 ml/kg of Iohexol350 will be injected intravenously (IV) using a power injection (3-4 ml/s) with a maximum does of 150 ml. The IV injection is performed while the patient is in a sitting position. The mammogram will be performed in a standing position.
45483648|NCT04969796|Other|REACH Hope|REACH VA (Resources for Enhancing All Caregivers Health in Department of Veterans Affairs) and the DoD's Virtual Hope Box. For REACH Hope, as the caregiver and interventionist work on strategies one-on-one, these will be integrated into the Hope Box for the caregiver to use between and after sessions.
45366674|NCT00712361|Device|Non Invasive peripheral blood screening (Cnoga Medical Ltd.,SofTouch,OnlyTouch, CM-CL-R-007, CMC 07015922,HT 4502, HTA 4502)|Non Invasive screening of various independent peripheral blood parameters: Glucose, hemoglobin, Hematocrit, blood pressure, pulse, SpO2, CO2, pH.
45483649|NCT02461264|Drug|Single red blood packed cells Transfusion|
45483650|NCT02461264|Drug|Two packed red blood cells Transfusion|
45483651|NCT03770780|Drug|SAGE-718|SAGE-718 in combination with Ketamine
46051463|NCT04636086|Other|Placebo|Placebo comparator
45366675|NCT00720707|Procedure|CAF+ADM+EMD|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
45366676|NCT00720707|Procedure|CAF+ADM|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) without enamel matrix derivatives (EMD) for root coverage procedures.
45366677|NCT00716105|Other|Standard infant formula|From 3 to 12 months of age. As per standard requirement
45366678|NCT00716105|Other|Infant formula with different level of proteins|From 3 to 12 months of age. As per standard requirement
45483652|NCT03770780|Drug|Placebo|Placebo in combination with Ketamine
45483653|NCT05130086|Drug|Islatravir|60 mg Islatravir taken orally in tablet form once monthly for up to 24 weeks
45847908|NCT03061812|Drug|Dexamethasone|Oral tablet.
46051464|NCT04336410|Drug|INO-4800|INO-4800 will be administered ID on Day 0, Week 4 and at the optional Booster Dose Visit.
46051465|NCT04336410|Device|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0, Week 4 and at the optional Booster Dose Visit.
46051466|NCT00827242|Drug|Placebo|Following a 4-week placebo lead-in period, subjects received placebo tablet by mouth once daily over a 12-week period.
46051467|NCT00827242|Drug|tadalafil|Following a 4-week placebo lead-in period, subjects received tadalafil 5 mg tablet by mouth once daily over a 12-week period.
46051468|NCT01077362|Drug|placebo|SC injections
46051469|NCT01077362|Drug|ustekinumab 45 mg|SC injections
46051470|NCT01077362|Drug|ustekinumab 90 mg|SC injections
46051471|NCT00846586|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
46051472|NCT00846586|Drug|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®).
46051473|NCT00846586|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
46051474|NCT00785785|Drug|Nilotinib (AMN107)|
46051475|NCT00785785|Drug|imatinib (STI571)|
46051476|NCT02612818|Device|Coelioscopy|
46051477|NCT00707278|Radiation|Radiation Therapy|Radiation therapy will be delivered concurrently with capecitabine and oxaliplatin chemotherapy Radiation therapy dose will be 50.4 Gy (1.8 Gy per day, 5 days per week, for 28 treatments).
46051478|NCT00707278|Drug|Capecitabine|Capecitabine Dose (given twice daily concurrent with radiation therapy) Dose level 1: 400 mg/m2 Dose level 2:600 mg/m2 Dose level 3:600 mg/m2
45483654|NCT05111210|Other|Blood sample|Blood will be collected in tubes heparinés BD (Vacutainer), homogenised, and immediately transported at room temperature to Institut Pasteur to be further processed
45366679|NCT02573129|Other|Red Meat Restricted|restrict intake of red meat while a Mediterranean diet
46051479|NCT00707278|Drug|Oxaliplatin|Oxaliplatin Dose (given weekly concurrent with radiation therapy) Dose level 1: 50 mg/m2 Dose level 2: 50 mg/m2 Dose level 3: 60 mg/m2
46051480|NCT01077284|Drug|Febuxostat|Febuxostat capsules
45847909|NCT03063294|Other|Online Toolkit|The online toolkit provides a set of tools that clinics can use to improve their care coordination processes.
46051481|NCT01077284|Drug|Allopurinol|Allopurinol capsules
45691031|NCT04020081|Other|Yoga breathing exercises and Meditation|"8 Breathing exercises.The first set of 6 exercises is of the Upper Lobe breathing (Upper and Middle Lobe of the Lungs) while 7th exercise is abdominal breathing,8th exercise is yogic breathing.~6-steps Nirmal Dhyan (meditation).Step 1: Breath awareness,Step 2: Body awareness,Step 3: Thought awareness,Step 4: Refreshing awareness,Step 5: Gap awareness,Step 6: Expanding awareness."
45691032|NCT01850563|Device|Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO|
46051482|NCT01077284|Drug|Placebo|Placebo-matching capsules
45366680|NCT02573129|Other|Red Meat Rich|Mediterranean diet rich in red meat
45366681|NCT00712439|Drug|Gabapentin Extended Release tablets|
45691033|NCT03931473|Other|Bed nets|Next-generation bed nets combining insecticides with different modes of action or a standard pyrethroid bed net
46051483|NCT00704314|Drug|Simvastatin|80 mg Simvastatin daily for 8 weeks
46051484|NCT00704314|Drug|Placebo|The placebo was identical in appearance and was provided by the same manufacturer
46051485|NCT04103437|Diagnostic Test|Maximal incremental running test|"Maximal incremental running test with measures of metabolic, spatio-temporal parameters and video recording with camera in the frontal plane.~video recording of frontal view, metabolic and spatio-temporal measures of three (self-selected speed, + and - 20 percentage of self-selected speed) 6 minutes running test monthly (12 months) follow-up questionnaire"
45366682|NCT00712439|Drug|Placebo|
45366683|NCT00451282|Behavioral|stepped preventive care|2 targeted assessments (T1: in hospital within a few days of injury; T2: two weeks post-discharge) are administered by nurse or social worker, and determine need for additional assistance modules. Additional modules include case management, care coordination, assistance with child and family coping with injury/distress, and trauma-focused Cognitive Behavior Therapy (CBT) beginning at 4-6 weeks post-injury if needed.
45366684|NCT00716183|Biological|Lactobacillus salivarius HN6|9 log colony-forming units, capsules, daily, four weeks
45366685|NCT00716183|Biological|Lactobacillus reuteri CR20|9 log colony-forming units, capsules, daily, four weeks
45366686|NCT00716183|Biological|Lactobacillus fermentum LC40|9 log colony-forming units, capsules, daily, four weeks
45366687|NCT00716183|Drug|Beta-lactam antibiotic|Use of amoxicillin, cloxacillin or amoxicillin/clavulanic acid(500-750 mg), orally, every 8-12 h, for 2-3 weeks (as prescribed by the physician responsible for the clinical diagnosis of lactational mastitis)
45366688|NCT03995446|Device|low-level laser|low level laser emission on specific acupuncture points
45483655|NCT05111210|Other|Data collection|collection of socio-demographic, clinical and biological data.
45483656|NCT05111210|Other|skin biopsies|skin biopsies of 4 mm in diameter. These samples will not be taken on the face or in an area of skin folds
45483657|NCT03285334|Device|XP-endo Shaper|mechanical preparation in a 3D manner using Xp-endo Shaper
45366689|NCT03995446|Device|Sham laser|Sham laser
45483658|NCT03285334|Device|iRace files|rotary mechanical preparation
45596574|NCT03533153|Drug|Conventional drug therapy|All patients undergo guideline-recommended treatment for STEMI, including aspirin (loading dose of 300mg before maintenance dose of 100 mg/d), clopidogrel (loading dose of 300mg before maintenance dose of 75 mg/d) or Ticagrelor (loading dose of 300mg before maintenance dose of 90 mg/d), angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), β-receptor blockers, statins and nitrate esters.
45596575|NCT03527797|Other|Titration of support level|Increasing support in case diaphragm activity is too high. Decreasing support in case diaphragm activity is too low.
45596576|NCT02364765|Drug|Remifentanil|Elective bimaxillary orthognathic surgery consisting of a unsegmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of mean remifentanil administration of 0.3 mg/kg/hour
45691034|NCT03930771|Drug|Capecitabine|1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.
45691035|NCT03930771|Drug|Temozolomide|150 to 200 mg/m2 orally on days 10 through 14.
45847910|NCT03063294|Other|Distance-based coaching|The distance-based coach supports included clinics in carrying out a quality improvement project focused on care coordination, either using the online toolkit or other resources determined by the clinic.
46051486|NCT04103437|Diagnostic Test|Metabolic and movement analysis of running|Running analysis of three six minutes running test (self-selected speed, + and - 20% of the self-selected speed) by video recording with camera in the frontal plane, and acquisition of the metabolic and spatio-temporal parameters
46051487|NCT04103437|Other|Questionnaires|Monthly follow-up questionnaire (12 months) about training habits and injuries
46051488|NCT00704392|Drug|XL647|Tablets supplied at 50-mg strength administered orally daily
45483659|NCT03285256|Behavioral|Experimental memory training|The experimental memory training will be implemented as a computer program that uses state-of-the-art immersive technology to simulate prospective memory in everyday life in which one must remember to carry out tasks throughout the day, while engaging in current ongoing activity. Participants are asked to imagine they have a work-at-home job (ongoing activity), which is an independent program (CogMed QM) designed to train working memory, but that they also need to remember to carry out a number of tasks throughout the day. Using a touch screen, participants will need to touch objects in the simulated environment to appropriately interact with these stimuli according to their pre-assigned tasks.
45366690|NCT04069559|Other|To develop nursing students' attitudes towards refugees program which based on contact hypothesis.|In the first three weeks, education were given to the intervention group about refugees. Students watched a film on the theme of migration. After than the students contacted refugees in three different centers ( an immigrant health center, a school and a civil Society Organization) each of them for a total of nine weeks and two days a week.
45366691|NCT04070417|Behavioral|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and socialisation
45483660|NCT03285256|Behavioral|Comparator memory training 1|The first comparator memory training intervention will utilize the same overall structure and immersive computer environment as the experimental memory intervention, but will not challenge the same aspects of cognition.
45483661|NCT03285256|Behavioral|Comparator memory training 2|The second comparator memory training intervention will utilize the same overall structure and immersive computer environment as the experimental memory intervention, but will not challenge the same aspects of cognition.
45483662|NCT03297814|Biological|Platelet lysate|Intramuscular injection of platelet lysate
45483663|NCT03297814|Biological|Placebo|intramuscular injection of normal saline
45691036|NCT04027101|Drug|Baricitinib|patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
45691037|NCT04027101|Drug|Placebos|patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
45366692|NCT03996226|Drug|E7386|E7386 oral tablets.
45847911|NCT03064152|Device|Rotational Thromboelastometry|ROTEM is a point-of-care coagulation assay.
45366693|NCT00712517|Drug|propofol|propofol anesthesia 3-5mg/kg
45366694|NCT00712517|Drug|sevoflurane|sevoflurane anesthesia
45483664|NCT03297736|Device|3D CAD/CAM autograft prosthesis|Surgical ossicular reconstruction with the experimental autograft prosthesis created using 3D subtraction CAD/CAM.
45483665|NCT03297736|Device|Control device|Surgical ossicular reconstruction with the standard available middle ear prosthesis.
45847912|NCT03066102|Other|muscle fatigue|"Modified push-up plus exercise:~the participants first supported by both knees and the single elbow, and then performed sustained scapular protraction for three minutes with ten repetitions in males and two minutes with five repetitions in females with forty-five seconds rest between."
45366695|NCT04070339|Other|transfontanelle ultrasound|cerebral blood flow investigation using transfontanelle ultrasound
45483666|NCT05110274|Procedure|Overnight Metabolic Flexibility|Participants will spend 13 hours (overnight) in a metabolic chamber where they will be fed a single high-fat supper meal. Energy expenditure, respiratory exchange ratio (RER), and 12-h oxidation of CHO, fat, and protein will be calculated and used to determine metabolic flexibility, i.e. change in RER from baseline.
45483667|NCT05110274|Procedure|Clamp Metabolic Flexibility|Metabolic flexibility with be assessed during a 2-step hyperinsulinemic-euglycemic clamp procedure. The clamp will be performed for four hours, two hours at an insulin dose of 10 mU/m^2/min and two hours at an insulin dose of 80 mU/m^2/min. Resting metabolic rate will be determined via hood indirect calorimetry at baseline, before insulin onset, and during the final 30 min of each step of the clamp. Metabolic flexibility will be determined by comparing the resting metabolic rate during baseline and during the final 30 min of each step of the clamp.
45483668|NCT02461186|Drug|Arterolane maleate-piperaquine phosphate (Synriam)|
45483669|NCT02461186|Drug|Dihydroartemisinin-piperaquine phosphate (Duocotexin)|
45483670|NCT04921670|Diagnostic Test|Infliximab Assay|Participants will be assigned to standard of care or proactive drug monitoring, which is measuring infliximab levels/antibodies before every infusion
45483671|NCT03297658|Device|electro-acupuncture (EA)|stimulation of acupuncture points related to congenital heart surgery for comfort heart and renal health
45483672|NCT03297658|Device|sham|Micro electrodes will be placed but there will be no stimulation
45483673|NCT05108558|Drug|CCH administration|Patients will be randomized 3:1 into the CCH administration arm. After undergoing baseline assessments, this arm will receive up to 8 CCH injections, followed by final assessments 6 weeks later.
45483674|NCT05108558|Drug|Control - Crossover to CCH|Patients will be randomized 1:3 into the control arm. After undergoing baseline assessments, control men will not undergo treatments for 6 months. They will then have repeat assessments and receive up to 8 CCH injections. They will then have final assessments performed 6 weeks after treatment.
45483675|NCT05108558|Device|RestoreX|Both treatment arms will incorporate the use of RestoreX for 30-60 minutes daily during CCH administration and continued until 6 weeks after final injection administration.
45691038|NCT04024683|Procedure|Serratus block with ropivacaine 2mg/ml|The serratus block was made using a 50 mm needle with ultrasound guidance. It was performed supine, the ultrasound probe identifying the 3, 4 or 5th intercostal space and then the needle was introduced under ultrasound control
45691039|NCT04024527|Drug|Esomeprazole|Proton pump inhibitor
45691040|NCT04024527|Drug|Amoxicillin|Antibiotic for H. pylori eradication
45366696|NCT03838198|Behavioral|MI-Enhanced Safety Plan at Hospitalization (1st Component)|"The MI-enhanced safety plan intervention component is delivered during hospitalization and includes an individual and family meetings. The goal of the individual meeting with the adolescent is to develop an individualized safety plan for use during a suicidal crisis. This best practices approach of safety planning is augmented with Motivational Interviewing (MI) as a core strategy to explicitly elicit adolescents' motivation and commitment to behavior change (i.e. use safety plan; adaptive coping), address barriers or ambivalence, and strengthen self-efficacy. The focus of the family meeting, which is similarly guided by MI, is to prepare parents/guardians, with input from the adolescent, for how they may support the adolescent in implementing the individualized safety plan after discharge and on strengthening parents' commitment and self-efficacy."
45483676|NCT03285100|Diagnostic Test|Venipuncture|"Approximately 6 months after discontinuation of VKAs one additional venipuncture will be performed for determination of dp-ucMGP and desmosine.~At baseline two additional blood collection tubes will be drawn for determination of dp-ucMGP, desmosine and VKORC1 polymorphisms. Since this is during one of the last regular International Normalized Ratio (INR) testing at the anticoagulation clinic, no additional venipuncture has to be performed at this moment."
45366697|NCT03838198|Behavioral|MI-Enhanced Text Boosters (2nd Component)|For participants randomized to receive text boosters, booster text messages will be sent daily for 4 weeks. The messages will be tailored to encourage use of individualized coping strategies identified as part of safety planning at hospitalization and will include additional adaptive coping tools and resources. The text message content and tone will be consistent with principles of MI.
45483677|NCT04915352|Drug|Nasal provocation test - 725 Dermatophagoides Pteronyssinus|"3 different concentrations of Nasal Provocation Test are administered to patients:~Nasal spray at 50 SBE/ml for 36 months~Nasal spray at 500 SBE/ml for 36 months~Nasal spray at 5000 SBE/ml for 36 months"
45483678|NCT04915352|Other|Negative control|Negative control using only solvent is applied in order to consider a non-specific nasal hyper reactivity.
45691041|NCT04024527|Drug|Metronidazole|Antibiotic for H. pylori eradication
45483679|NCT03285022|Procedure|Partial caries removel techniques|Removel of all superfacial dentin and leaving the inner affectted dentin
45845934|NCT04707846|Device|Bright Blue Light Commercial AYO Light Therapy Device|"AYO light therapy glasses are a commercially available device which have 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and typical irradiance (100% intensity) of approximately 250 µW/cm². AYO bright light glasses are classified as exempt for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471)."
45483680|NCT03292978|Dietary Supplement|probiotics intervention|The probiotics intention is provided with 4 strains of probiotics as a 2g sachet powder, dried with corn starch for 4 weeks.
45691042|NCT04024215|Device|intravascular ultrasound|IVUS creates axial images perpendicular to the long axis of the catheter by transmitting sound waves covering 360 degrees around the tip of the catheter, which is delivered into the lumen of the vessel over a guidewire.
45691043|NCT01819129|Drug|Faster-acting insulin aspart|Mealtime FIAsp administered subcutaneously (s.c., under the skin). Dose individually adjusted.
46051489|NCT00704392|Drug|XL147|Gelatin capsules supplied at 25-mg and 100-mg strengths administered orally daily
45691044|NCT01819129|Drug|Insulin aspart|Mealtime insulin aspart administered subcutaneously (s.c., under the skin). Dose individually adjusted.
45691045|NCT01819129|Drug|Insulin glargine|Administered s.c. once daily at subjects' pre-trial dose. Subjects will continue their metformin treatment without changing the frequency or dose throughout the trial.
45691046|NCT04147065|Drug|Duration of eradication regimen|14 day eradication regimen
46051490|NCT00704470|Other|Medical simulator training|Contains seminars on airway management, general anesthesia, peri-arrest arrhythmias, and advanced life support. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss management of the critical incidents using videotapes of the scenarios.
46051491|NCT00704470|Other|Simulator based crew resource management course|Contains seminars on human error and non-technical skills. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss usage of non-technical skills as well as behaviour of the participants using videotapes of the scenarios.
46051492|NCT04103125|Device|Janesse® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation.|The subjects will receive at baseline the first IMD by the Investigator in accordance with the CIP
46051493|NCT04103203|Diagnostic Test|PathoRobot/ Patho-Doc Test result|Test results of the new diagnostics will be available to the treating physician.
46051494|NCT00826618|Drug|ranibizumab|This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.
45691047|NCT04024137|Drug|ZSP1273 200 mg|1 X 200-mg tablet taken orally
45691048|NCT04024137|Drug|Placebo|2 tablets taken orally
45691049|NCT04024137|Drug|ZSP1273-400 mg|2 X 200-mg tablet taken orally
45483681|NCT03292978|Dietary Supplement|non-probiotic control|The placebo is corn starch alone provided and the shape, color, flavor and taste are same with the powder of probiotics intervention.
45483682|NCT04488640|Procedure|Thyroid biopsy with ultrasound|Patients with thyroid nodules who underwent ultrasound-guided core needle biopsy with a 20 gauge core needle biopsy apparatus were included in the study.
45483683|NCT03512210|Drug|Sofosbuvir/Velpatasvir (SOF/VEL)|400/100 mg fixed-dose combination (FDC) tablet administered orally once daily with or without food.
45366698|NCT03838198|Behavioral|MI-Enhanced Booster Call (3rd Component)|The focus of the post-discharge booster phone call with adolescent and with parent, each conducted separately, will be to to further adjust the safety plan to better meet post-discharge needs, to further enhance adolescents' motivation and commitment to use coping strategies, and to further support adolescents' and parents' self-efficacy to manage suicidal crises.
45483684|NCT03512210|Other|Minimal Monitoring (MINMON) Strategy|"MINMON Strategy:~No pre-treatment HCV genotyping~Entire treatment course (84) tablets of SOF/VEL administered to participants at study entry~No scheduled on-treatment laboratory monitoring or clinic visits~Remote contact with participants at week 4 and week 22"
45483685|NCT03284944|Device|Small-Volume|"Small-volume (2 - 3 mL soft-draw Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes."
45483686|NCT03284944|Device|Standard-Volume|Standard-volume (4 - 6 mL Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes.
45366699|NCT00712595|Drug|Mifepristone|Oral administration of Mifepristone 10 mg daily for three months
45483687|NCT03284788|Behavioral|ABT Weight Loss Intervention|This includes 15 sessions that are each 90 minutes in length. Intervention sessions will be weekly for the first 2 months, bi-weekly for the next 2 months, and monthly for the last 2 months.
45483688|NCT03422276|Other|Rehabilitation Discharge Plan|"CARF standards for discharge following an inpatient rehabilitation stay for a traumatic brain injury. This approach may include the following:~patient and family education about TBI, both general and individualized to each person's symptoms and level of function, as well as education on medications and symptoms to monitor following discharge;~written discharge care instructions, including recommended appointments with primary care, rehabilitation medicine and outpatient therapies, and medication list which are reviewed with the patient and family prior to discharge; and~a phone call from an inpatient care provider within a few days of discharge to address any immediate problems and ensure that equipment has arrived, medications are being taken, etc."
45483689|NCT03422276|Other|Rehabilitation Transition Plan|"Participants and their caregivers (if applicable) randomized to the Rehabilitation Transition Plan group will receive up to 12 scheduled contacts 6 months post-discharge from a TBI care manager familiar with the care and resource networks at the respective sites. The contacts will at minimum be by telephone, although a HIPAA-compliant video conferencing option will also be available.~The content of these contacts will include:~Particularly in the first few calls, review of discharge plans and assistance and/or directive problem-solving around any obstacles to following discharge plans;~Assessment of unmet needs, developed into a standard checklist of areas of need that are relevant to TBI, culled from literature on need fulfillment in this population."
45483690|NCT02461108|Behavioral|Subsidy|Frame the price difference as a 10% subsidy on nutritious food items.
45483691|NCT02461108|Behavioral|Tax|Frame the price difference as a 10% tax on less nutritious food items.
45483692|NCT02461108|Behavioral|Tax and subsidy|Frame the price difference as a 5% tax on less nutritious food items and a 5% subsidy on nutritious food items, creating a 10% relative price difference between the types of foods.
45483693|NCT00383721|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
45483694|NCT00383721|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
45483695|NCT00383721|Drug|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
45483696|NCT00383721|Drug|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
45483697|NCT00383721|Drug|Placebo|Placebo MDI twice a day for 26 weeks
45366700|NCT00712595|Drug|Mifepristone|Oral administration of Mifepristone 5 mg, daily for three months
45483698|NCT03292822|Dietary Supplement|Licochalcone A|Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties in vitro.
45691050|NCT04024137|Drug|Placebo|1 tablet taken orally
45691051|NCT04024137|Drug|ZSP1273-600 mg|3 X 200-mg tablet taken orally
45691052|NCT04024137|Drug|Placebo|3 tablets taken orally
45691053|NCT04024137|Drug|Placebo|Subjects will receive matching placebo of ZSP1273
45691054|NCT04146831|Drug|Sintilimab|Sintilimab: intravenous, 200mg, every 3 week. Course of treatment: Stop the treatment until clinical or radiographic progression occurs.
45691055|NCT04025775|Device|CamAPS HX Closed-loop|"The CamAPS HX closed-loop system comprises~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump~Glooko/Diasend cloud upload system to monitor CGM/insulin data."
45691056|NCT04025775|Other|Multiple Daily Insulin Injections (Control)|Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
45847913|NCT03067506|Other|No intervention|No intervention
45366701|NCT00115765|Drug|Oxaliplatin Based Chemotherapy|Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
45847914|NCT03070470|Drug|Ranolazine|Ranolazine 1500 mg orally two times per day for 2.5 days
45366702|NCT00115765|Drug|Panitumumab|PanitumumabPanitumumab is a high affinity (Kd = 5 x 10-11 M) fully human IgG2 monoclonal antibody that is directed against the human EGFr. Panitumumab will be administered by a 30-60 minute IV infusion at a dose of 6 mg/kg once every 2 weeks on the same day of the oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.
45366703|NCT00115765|Drug|Irinotecan Based Chemotherapy|Irinotecan-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) - Irinotecan, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
45366704|NCT00115765|Drug|Bevacizumab|Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .
45366705|NCT00606008|Drug|Sunitinib Malate|Initially, patients were started on sunitinib at a dose of 50 mg daily. If 50 mg daily resulted in unacceptable toxicity, 2 dose modifications were allowed (to 37.5 and to 25 mg daily, if necessary). Study patients who could not tolerate 25 mg daily of sunitinib were taken off study.
45366706|NCT00721019|Other|5-hour bedtime|10 days with sleep restricted only to a 5-hour bedtime period at night
45366707|NCT00721019|Other|8.5-hour bedtimes|10 days with sleep allowed only during a 8.5-hour period at night
45366708|NCT03837184|Biological|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). Onasemnogene abeparvovec-xioi will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
45366709|NCT00716261|Device|McROB Hybrid node 3-axes accelerometers and 3-axes gyroscopes|Training with the Audio-feedback device for about 30 minutes, 3 times per week for 6 weeks
45483699|NCT03292822|Drug|Paclitaxel|chemotherapeutic drug
45366710|NCT00898898|Other|diagnostic laboratory biomarker analysis|Correlative studies
45366711|NCT04068233|Other|Pacemaker stimulation mode|Echocardiographic indices are measured during AV asynchronous and AV synchronous pacemaker stimulation.
45366712|NCT04035122|Other|Robotic Treatment|The Lokomat is a robotic device, consisting of a powered gait orthosis with integrated computer-controlled linear actuators at each hip and knee joint, a body weight support, and a treadmill. During the Lokomat training, the patients completed at least 30 min of treatment session.
45483700|NCT03395288|Drug|D-Mannose|A total of 2 g D-mannose daily
45483701|NCT03297502|Drug|pimecrolimus cream 1%|
46051495|NCT05579197|Device|Lower-limb robotic intervention|"The intervention proposed in this study involves the use of an exosuit for lower limbs, the Myosuit. The selection of the tasks has been done in order to replicate typical activities of daily living in a structured environment, i.e. a rehabilitation hospital.~Specifically, the tasks involve walking, sit to stand, balance and stair climbing.~During the phases of assessment (session 2 and session 10), other devices are be used. Specifically:~The Optogait system; for a markerless gait analysis;~The Gyko sensor; an inertial sensor that will be used at the beginning of the training for the synchronisation of the signals recorded by the Myosuit and the signal recorded by the Optogait.~Finally, during all the sessions, the Polar heart rate sensor is used to constantly monitor the cardiac frequency of the patients."
45483702|NCT03297502|Drug|Elidel (pimecrolimus) cream 1%|
45483703|NCT03297502|Drug|placebo|
45366713|NCT04035122|Other|Conventional Treatment|The standard physical treatment program consisted of general conditioning exercises, including warming up (e.g. calf, shoulder, and hand passive range of motion exercises), lower and upper extremity strengthening, postural control exercises. During the conventional training, the patients completed at least 30 min of treatment session.
45366714|NCT00461812|Drug|Mometasone|
45366715|NCT00461812|Drug|Advair|
45483704|NCT05067452|Other|Food support|Diabetes-tailored food support. Project Open Hand will provide intervention participants twelve weeks of supplemental food support. Food support will consist of a mix of meals tailored for T2DM, and T2DM-healthy groceries, consistent with American Diabetes Association (ADA) guidelines for diabetes healthy diets under the responsibility of a registered dietitian. All food support will be home delivered.
45752214|NCT00365599|Drug|tamoxifen citrate (Tamoxifen)|Tamoxifen will be given once daily at 20 mg. Tamoxifen will be given continuously. Responses will be assessed after 2 cycles (8 weeks + 4 days).
45366716|NCT00721097|Other|spirometry, and blood taken|each month during one year
45366717|NCT02539862|Other|cognitive behavioral therapy online|The cognitive behavioral therapy online program is delivered through an accessible web application on a web browser with a personal password
45596577|NCT02206529|Behavioral|Social Network Engagement+Std Treatment|
45596578|NCT02206529|Behavioral|Standard Treatment|Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)
45596579|NCT03529201|Procedure|QLB|On the side of the surgery, QLB with 0.375% ropivacaine (0.2 mL/kg)
45596580|NCT03529201|Device|PCA|Patient-controlled analgesia
45483705|NCT05067452|Other|Case-management|"Project Open Hand client services staff will conduct three case management sessions with the participant. The first session will initiate food services and ensure orientation to the intervention and set up delivery; the second session will support the participant with any issues related to the intervention (logistical or nutrition-related, with referral to the POH registered dietitian as needed); the third session will provide transition from the intervention, connect the participant with local food resources, and ensure a warm hand-off to nutrition"
45483706|NCT01334775|Procedure|Open anterior inguinal hernia repair|Placement of a surgical mesh in open anterior inguinal hernia repair.
45483707|NCT03292744|Drug|Alfacalcidol|alfacalcidol 0,5 mcg
45596581|NCT03529201|Procedure|GA|General anesthesia
45845935|NCT04707846|Device|Dim Blue Light Commercial AYO Light Therapy Device|"AYO light therapy glasses were made available to the research team by the vendor. The device has 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and reduced irradiance (1% intensity) of approximately 250 µW/cm². AYO dim light glasses are classified as exempt for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471)."
45845936|NCT04704258|Procedure|TAVI (Transcatheter Aortic Valve Implant)|Placement of a filter to capture and remove emboli or debris detached during any transcatheter heart procedures
45845937|NCT04704258|Device|FLOWer Embolic Protection System|FLOWer Embolic Protection System
46051496|NCT02876822|Dietary Supplement|Vitamin D|
46051497|NCT04304222|Device|3D Printed Denture Framework|The Denture Framework is 3D printed from the digital image obtained from the denture mold.
46051498|NCT04030624|Device|Remote Electronic Patient Monitoring|The Remote Patient Monitoring intervention is a remote monitoring system intended for use by healthcare professionals for the collection of physiological data in home and healthcare settings. Patient information is displayed on a computer located at the medical institution. Throughout the day, patient data from the remote monitoring system are presented on the clinician user interface (e.g., temperature, blood pressure, heart rate, respiration rate). Data are transmitted from sensors to the patient's smart phone.
46051499|NCT00627146|Drug|ChAgly CD3|6 days treatment 8mg/d intravenous
46051500|NCT00627146|Drug|Placebo|6 days
45366718|NCT02539862|Other|psychoeducation|the psychoeducation is delivered by a doctor
45366719|NCT00721331|Drug|nortriptyline HCl + loratadine|Topical
45366720|NCT00721331|Drug|nortriptyline HCl + loratadine|Topical
45366721|NCT00721331|Drug|nortriptyline HCl|Topical
45366722|NCT00721331|Drug|mometasone furoate|Topical
45366723|NCT00721331|Drug|Active ingredient free vehicle cream of CRx-197|Topical
45366724|NCT01025908|Behavioral|Psychotherapy|Cognitive Behavioral Therapy
45366725|NCT01025908|Behavioral|Supportative psychotherapy|Supportative psychotherapy
45596582|NCT03529201|Drug|Oxycodone|administered by PCA
46051501|NCT02874872|Behavioral|OASIS Collaborative|OASIS (Optimizing Antibiotic Stewardship in Skilled Nursing Facilities) is a system redesign of skilled nursing facility work systems
46051502|NCT00826540|Drug|sorafenib tosylate|Given orally
45366726|NCT02540096|Other|Mental practice|"The sessions will be individualized and carried out in a peaceful setting.The aim of the mental practice protocol was to promote motor imagery of the following activities: get up from a chair and walk and sit, which enrolls the basic and instrumental activities of daily living. The sessions will consist of six steps: (1) Physical Practice (2) Familiarization (3) Memory (4) Relaxation (5) Repeat and (6) post-practice mental relaxation. After the mental practice session, participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups)."
45366727|NCT02540096|Other|Cognitive training and Relaxation|Cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions. The sessions will consist of calculations, memorization, imagination and body relaxation exercises. These sessions will not have any motor imagery. After the cognitive training and relaxation session, participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes with muscle strengthening and stretching exercises.
45366728|NCT00123955|Drug|Spironolactone|25mg tablet daily for 9 months
45691057|NCT03926481|Behavioral|Evaluate Healthy Lifestyle Program on cognitive outcomes|The healthy lifestyle program will be delivered once a week for 17 weeks as part as regular clinical care. It will include an group classes taught by health coaches and dieticians. These classes will focus on diet, exercise, and behavior modification. We plan 2 cohorts of 15 subjects (n=30). In-person research assistant-led assessments will occur at baseline and 17 weeks.
45691058|NCT04028193|Dietary Supplement|Calogen|Polyunsaturated liquid fat supplement
45691059|NCT04028193|Dietary Supplement|Resource Energy|Carbohydrate Supplement
46051503|NCT00826540|Biological|bevacizumab|Given IV
46051504|NCT01077050|Device|SciBase III Electrical Impedance Spectrometer|SciBase III Electrical Impedance Spectrometer is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Enrolled subject will undergo skin measurements with SciBase III Electrical Impedance Spectrometer. The relevant skin lesion(s) will be excised and diagnosed as per routine treatment.
45366729|NCT00123955|Drug|Placebo|Placebo tablet daily for 9 months
45366730|NCT04372121|Drug|75 mg linzagolix tablet|For oral administration once daily
45366731|NCT04372121|Drug|200 mg linzagolix tablet|For oral administration once daily
45596583|NCT03529201|Drug|Sevoflurane|Inhalational anesthetic during GA
45596584|NCT03529201|Drug|Fentanyl|painkiller during GA
45596585|NCT03529201|Drug|Rocuronium|muscle relaxant during GA
45596586|NCT04547049|Drug|Cytarabine|4 mg/m2/day administered IV day -10 through -9.
45596587|NCT04547049|Drug|Busulfan|3.2 mg/kg/day administered IV day -8 through -6.
45596588|NCT04547049|Drug|Cyclophosphamide|1.8 g/m2/day administered IV day -5 through -4.
45596589|NCT04547049|Drug|Me-CCNU|250mg/m2 once administered orally on day -3.
45596590|NCT04547049|Drug|Rabbit antithymocyte globulin|1.5mg/kg/day administered IV day -5 through -2.
45596591|NCT04547049|Procedure|Allogeneic HSCT|Day 0
46051505|NCT04303052|Device|Angiodynamic Bioflo Picc IR-KIT (145 cm guidewire) or|Before Power-PICC-line catheter implantation, the patients undergo an examination of the planned intervention site and ultrasound check, and analysis of the blood tests. An informed consent discussion and the patient's signature on the informed consent are obligatory. The length of the catheter and the optimal position of the catheter tip are verified by fluoroscopy. After catheter implantation, the tip location is verified by a final chest x-ray. The follow-up visit and the control of the puncture site until removal of the catheter are performed during hospitalization or subsequently by the treating family doctor.
45483708|NCT01329861|Behavioral|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
45483709|NCT04189978|Diagnostic Test|Clinical evaluation|The assessment is based on a comprehensive questionnaire, a simple clinical examination, an spirometry test, allergic skin tests, measurement of the exhaled fraction of NO (FeNO) and blood serum analysis.
45483710|NCT03035942|Drug|Dexamethasone|Dexamethasone 8 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
45483711|NCT03035942|Drug|Ondansetron|Ondansetron 4 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
45483712|NCT03035942|Drug|Saline|Normal saline (5 mL total volume) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
45483713|NCT04189354|Device|Transcranial direct current stimulation (t-DCS) device|t-DCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes, in order to modify the cerebral activity of the stimulated zones. The investigators use the Soterix Medical t-DCS devices of the mini-CT 1x1 type.
45483714|NCT01334853|Other|No drug will be used|Biomarker
45845938|NCT04673994|Behavioral|Single, acute bout of high intensity interval exercise|Individuals will perform a single bout of high intensity interval exercise on a seated recumbent stepper. Participants will perform the pattern of high intensity interval exercise by switching between 1-minute high intensity stepping followed by 1-minute light, active recovery stepping for a total of 10 minutes.
45366732|NCT04372121|Drug|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
45366733|NCT04372121|Drug|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
45366734|NCT04372121|Drug|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
45366735|NCT04372121|Drug|Placebo capsule to match Add-back capsule|For oral administration once daily
45483715|NCT01334853|Other|No drug will be used|Biomarker
45483716|NCT03386708|Procedure|intrauterine injection|intrauterine injection with umbilical cord mesenchymal stem cell (SCLnow 19#); one time/one menstrual cycle, total 2 times
45845939|NCT04628442|Procedure|Sinonasal Debridement Procedure|This is a medical procedure prescribed by the participant's physician that has been deemed necessary for patient care in order to address their chronic rhinosinusitis.
45845940|NCT04628442|Procedure|Nasal Polyp Removal|This is a surgical procedure prescribed by the participant's physician that has been deemed necessary for patient care in order to address their chronic rhinosinusitis.
45845941|NCT04628442|Procedure|Biopsy|A biopsy is optional and will remove a sample of inferior turbinate tissue from the nasal passage. It will be performed during a nasal polyp removal surgery already scheduled for patient care.
45483717|NCT03386708|Biological|human umbilical cord mesenchymal stem cell|2 * 10^7 cells (2ml)
45483718|NCT03297346|Other|Cardiac imaging and circulating biomarkers|Automated 2D-speckle-tracking echocardiography (ECHO-ST); Computed tomography coronary angiography (CT); Cardiac magnetic resonance imaging (MRI); Blood samples for circulating biomarkers measurements (BLOOD)
45483719|NCT02820519|Drug|Loxapine|Loxapine dose escalation according to tolerability and analgesic efficacy
45483720|NCT01334931|Radiation|Large field of view arm|Patients will be allocated in the large field of view arm. Coronary angiography will be performed with large field of view lens (25 cm)
45483721|NCT01334931|Radiation|Medium field of view|Patients will be allocated in the medium field of view arm. Coronary angiography will be performed with medium field of view lens (20 cm)
45483722|NCT02460250|Procedure|Fibroscan|All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked.
45483723|NCT01332591|Procedure|Percutaneous coronary intervention|"PCI of significant stenoses of non-infarct coronary arteries"
45366736|NCT03837028|Other|FSFI|Sexual dysfunction was assessed via the self-administered Female Sexual Function Index Questionnaire which was adapted to the Turkish population. This is a 19-item questionnaire that covers six domains: desire; arousal, lubrication, orgasm, satisfaction, and pain. The full score is obtained by adding the six domain scores. FSFI scores range from 2.0 to 36.0, with higher scores indicating better sexual functioning.
45366737|NCT02539784|Device|"Kit for Spinal Cord Stimulator System  SCS Systems  : PRECISION® System"|3 frequencies of SCS are tested for each patient : 50, 100 and 130 Hz
45366738|NCT04069481|Other|Dance|One-hour class, twice a week. Classes include dance warm up exercises, various dance movements and choreography that include coordinated whole body movements through space synchronized to music.
45366739|NCT04069481|Other|Mindfulness meditation and Exercise|One hour class, twice a week. Classes include upper and lower extremity stretching and resistance exercises and mindfulness meditation, that includes body scan technique and breathing exercises.
45366740|NCT00898976|Other|immunohistochemistry staining method|
45366741|NCT00898976|Other|laboratory biomarker analysis|
45366742|NCT01027546|Drug|Tranexamic Acid|Administer 15 mg/kg body weight of tranexamic Acid mixed in 100 mL saline intravenously over 15 min before the skin incision
45366743|NCT00901082|Behavioral|Relaxation and information session|Relaxation and information session before the medial branch block
45366744|NCT05667545|Drug|Peptide|it is about synthetic protein acting on tooth structure help information apatite crystals
45366745|NCT00115063|Behavioral|group sessions|group sessions lead by a trained primary care clinic employee
45366746|NCT00115063|Drug|sibutramine, orlistat, diethylpropion|dosage modified according to package insert instructions at discretion of primary care physicians
45366747|NCT00115063|Behavioral|Low Calorie Diet, Health One|liquid diet for 8-12 weeks to induce weight loss
45366748|NCT00115063|Other|Intensive Medical Combination Therapy for Obesity|"Very Low Calorie Liquid diet, Group Behavioral Therapy, Meal Replacement Therapy, Obesity Pharmacotherapy and a Treatment Toolbox."
45691060|NCT04406181|Behavioral|HADS|Hospital Anxiety and Depression Scale
45691061|NCT04406181|Behavioral|a survey|made up specifically for issues concerning the medical/psychological/access aspects during the COVID-19 outbreak
45366749|NCT00115063|Other|Control Condition|Access to the Mayo Clinic weight management website and usual care from the primary care physician
45366750|NCT01026064|Other|Cantharidin|Cantharone topical liquid containing 0.7% cantharidin (blistering agent) is applied as 25 µL of 0.1% cantharone solution in acetone
45483724|NCT03292510|Other|GO-OUT Group|Following a baseline assessment, eligible participants will be stratified by site, and randomly assigned to receive the 1-day educational workshop and 3-month outdoor mobility program (GO-OUT intervention). Follow-up evaluations will occur at 3, 5.5 and 12 months from baseline.
45483725|NCT03292510|Other|Workshop Group|the 1-day workshop plus reminders. Follow-up evaluations will occur at 3, 5.5 and 12 months from baseline
45691062|NCT04026477|Behavioral|Immediate Universal Trauma-Informed Care and Cultural Humility Training|Instructional video and workshop
45845942|NCT04625946|Drug|Metformin|"Metformin immediate release will be initiated at 250 milligrams (mg) daily (orally), and increased as tolerated to 2000 mg daily over a four week period. If a patient is unable to tolerate a dose increase they will return to their last tolerated dose after omitting one days dosing. 0 to Six weeks after the initiation of drug the patient will undergo (standard of care) ablation with the intent of achieving rhythm control.~Participants will stay on the metformin 12 months after the ablation. In addition, all participants will receive education on lifestyle changes and exercise which are standard of care as well as have a discussion with their treating electrophysiologist and receive a handout."
45847915|NCT03070470|Drug|Verapamil|Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)
45366751|NCT01026064|Drug|Azithromycin|Zithromax (250 mg oral capsule).
45366752|NCT01026064|Drug|Placebo|Matching placebo
45366753|NCT00899054|Drug|P276-00|P276-00 will be administered at different dose levels: level 1: 100 mg/m2/day dose level 2: 140 mg/m2/day dose level 3: 185 mg/m2/day to be given from day 1 to day 5 every 21 days for 2 cycle. P276-00 will be administered as intravenous infusion in 200 ml 5% Dextrose over 30 min from days 1 to 5 per 21 day cycle for two cycles.
45691063|NCT04026477|Behavioral|Waitlisted Universal Trauma-Informed Care and Cultural Humility Training|Instructional video and workshop following waitlist period
45752215|NCT00358007|Device|PTV Reduction|The margin around the area to be treated with radiation is decreased due the image guidance of the cone beam CT
46051506|NCT04303052|Device|Angiodynamic Bioflo Picc MST-KIT (70 cm guidewire)|Before Power-PICC-line catheter implantation, the patients undergo an examination of the planned intervention site and ultrasound check, and analysis of the blood tests. An informed consent discussion and the patient's signature on the informed consent are obligatory. The length of the catheter and the optimal position of the catheter tip are verified by fluoroscopy. After catheter implantation, the tip location is verified by a final chest x-ray. The follow-up visit and the control of the puncture site until removal of the catheter are performed during hospitalization or subsequently by the treating family doctor.
45366754|NCT00899054|Radiation|External beam radiotherapy (EBRT)|All subjects will receive external beam radiotherapy (EBRT)by using standard conventional fractionation i.e. 2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 6 weeks followed by upto 10 additional Gy if required.
45366755|NCT05659745|Other|VM-02|VM-02 is a personal care product for vaginal health.
45366756|NCT05659745|Dietary Supplement|Commercial Oral Probiotic Competitor|Commercial Oral Vaginal Probiotic Competitor is a personal care product for vaginal health.
45366757|NCT05659745|Other|VM-02 Placebo|VM-02 Placebo is a personal care product placebo for vaginal health.
45366758|NCT00899132|Genetic|in situ hybridization|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
45366759|NCT00899132|Genetic|protein expression analysis|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
45366760|NCT00899132|Other|immunologic technique|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
45366761|NCT02571959|Drug|amoxicillin and clavulanic acid|Day 1 : a dose of amoxicillin and clavulanic acid 1g / 200mg will be intravenously administered
45366762|NCT02571959|Drug|amoxicillin and clavulanic acid|Day 2 : a dose of amoxicillin and clavulanic acid 1g / 125mg will be administered by oral route
45366763|NCT00461500|Drug|Salmeterol xinafoate/fluticasone propionate combination|SFC 100
45366764|NCT00461500|Drug|Fluticasone propionate|FP 100
45366765|NCT00893906|Biological|seasonal trivalent inactivated influenza vaccine|vaccine to be used according to marketed dosage and frequency
45366766|NCT00893906|Biological|inactivated polio vaccine|vaccine to be used according to marketed dosage and frequency
45366767|NCT00721487|Drug|Fluconazole|Patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy
45366768|NCT00167245|Drug|Topiramate|300mg/day for 13 weeks
45366769|NCT00167245|Drug|placebo|placebo pills
45366770|NCT00901160|Procedure|blood test|Blood will be taken from patients shortly after surgery in the recovery room in order to perform Thromboelastography® and Platelet Mapping Assay™ tests.
45366771|NCT00716339|Behavioral|motivation|
45366772|NCT00894062|Device|Zotarolimus eluting stent (Endeavor resoulte - ZES resolute)|Zotarolimus eluting stent (ZES)
45366773|NCT00894062|Device|Everolimus eluting stent (Xience - EES)|Everolimus eluting stent (EES)
45366774|NCT00721565|Behavioral|Exercise Behavior Change|attend 12 supervised exercise sessions, attend 6 group sessions with psychologist, attend 3 counseling sessions with exercise specialist
45366775|NCT00894140|Device|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
45366776|NCT00443560|Other|Case controlled analysis of epidural labor analgesia patterns|A retrospective study utilizing the Obstetric Anesthesiology Database to identify parturients who received neuraxial labor analgesia initiated with a combined spinal epidural (CSE) technique and maintained with a continuous epidural infusion with patient controlled epidural analgesia boluses
45366777|NCT04098341|Diagnostic Test|IGRA blood test used as a tool for opt-out screening for latent Tuberculsis infection|All eligible pregnant migrants will be offered an opt-out screening IGRA blood test for latent Tuberculosis infection
45366778|NCT00922454|Procedure|Endovascular Repair of the abdominal aorta|"Patients will undergo or have undergone endovascular aneurysm repair which is minimally invasive approach using endoluminal placement of a stent graft.~EVAR, CTA imaging, 1, 6 12 months post treatment."
45366779|NCT00922454|Device|Cook Zenith Stent-Graft|Cook Zenith AAA Endovascular Graft
45366780|NCT00922454|Device|Talent Stent-Graft|Talent AAA Abdominal Stent Graft System
45366781|NCT00721643|Dietary Supplement|angel's plant (Angelica keiskei)|Healthy control, one time dose of 5g dry power of Angelica keiskei
45366782|NCT00721643|Dietary Supplement|Angel's plant (Angelica keiskei)|Metaboic syndrome subjects, one time dose of 5g dry powder of angel's plant (Angelica keiskei)
45366783|NCT00899210|Other|laboratory biomarker analysis|
45366784|NCT00899210|Procedure|cryosurgery|
45366785|NCT00899210|Procedure|radiofrequency ablation|
45366786|NCT00899210|Procedure|therapeutic conventional surgery|
45366787|NCT00721721|Behavioral|Low Sodium Diet|3 grams of salt or 51.3 mmol of sodium per day
45366788|NCT00721721|Behavioral|High Sodium Diet|18 grams of salt or 307.8 mmol of sodium per day
45483726|NCT02616146|Drug|ENG-E2 125 μg/300 μg vaginal ring|Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
45483727|NCT02616146|Drug|LNG-EE 150 μg/30 μg COC|Up to 13 cycles of LNG-EE 150 μg/30 μg administered orally, each cycle consisting of one tablet per day for 21 days, followed a 7-day tablet-free interval.
45366789|NCT00721721|Dietary Supplement|Potassium Supplementation|60 mmol potassium supplement
45483728|NCT01332669|Procedure|DebDox TACE|HCC patients will receive chemoembolization (TACE) using DC beads containing Doxorubicin. The objective is to give 2 vials of DC Bead (2ml per vial) loaded with 70-75mg of Doxorubicin per vial (Each vial contain 2ml of DC Bead, thus doxorubicin concentration will be of 35-37.5mg per ml of DC Beads)
45483729|NCT03297268|Other|Intervention with Home-Based Caregivers|We will assess whether real-time notifications of potential agitation via a wearable wrist device improves caregiver self-efficacy.
45483730|NCT03107806|Device|OptiScanner®|"Glucose monitoring by OptiScanner® for 48 h~Glucose lowering intervention (insulin) guided by OptiScanner®"
45845943|NCT04625946|Behavioral|Recommendations for lifestyle modification.|All subjects will receive education on lifestyle changes and exercise which are standard of care. This will include discussion with their treating electrophysiologist and a handout.
45845944|NCT04625946|Device|AliveCor|Device will be used in order to record an electrocardiogram during symptoms perceived to be AF. All patients will be instructed to transmit at least once per week.
45845945|NCT04625244|Other|Video assisted home therapy|Subjects will follow along with prerecorded therapy videos.
46051507|NCT04303130|Drug|Camrelizumab|"Carelizumab: PD-1 antibody SHR-1210: SHR-1210 is administered by intravenous infusion, a fixed dose of 200 mg, and intravenous infusion over 30 minutes (the overall infusion time including the flushing time is not shorter than 20 minutes, not longer than 60 minutes), once every 3 weeks, continued medication until the disease progresses intolerable toxicity and receive immunotherapy for a maximum of 2 years (35 cycles); Endo: once a day, 7.5 mg / m2 intravenous infusion, continuous administration for 14 days, rest for a week (or the corresponding dose using a micro-micropump), continued medication until disease progression toxicity intolerance.~The combination regimen is a medication cycle every three weeks (21 days)."
46051508|NCT00626600|Drug|Oxycodone Hydrochloride|
46051509|NCT00707356|Drug|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/Kg,4 mg/Kg or 6 mg/kg, using 753 nm laser light at a fixed power (150mW/cm) and energy (200 J/cm) delivered through transperineal interstitial optical fibers. If deemed necessary and in consideration of the results of the patients treated with 200 J/cm, alternate power (200mW/cm) and alternate energy (300 J/cm) might be applied.The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The number of fibers and the total light energy will be adapted to each patient, taking into account the tumor localization and the volume of the prostate.
46051510|NCT04304456|Other|Treatment|Antimicrobial and other treatment modalities such as source control, vasoactive medications, dialysis
46051511|NCT02612740|Biological|Deproteinized bovine bone|cyst removal followed by heterologous bone grafting
45366790|NCT01022632|Dietary Supplement|Curcumin|Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
45366791|NCT01022632|Drug|Fluoxetine|Fluoxetine ; 20 mg Once a day in morning after taking food for 6 weeks
45366792|NCT01022632|Dietary Supplement|Curcumin and Fluoxetine|Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
45366793|NCT00899288|Procedure|spectroscopy|Nails will be chemically characterized using Raman spectroscopy.
45366794|NCT03716999|Other|Starlight Therapy|Starlight Projector will be placed in patients' rooms and project starlight on the ceilings and walls in an effort to reduce unpleasant symptoms
45366795|NCT00899366|Genetic|microarray analysis|
45366796|NCT00899366|Genetic|mutation analysis|
45366797|NCT00899366|Other|immunologic technique|
45366798|NCT01026298|Other|FDA-Approved Treatment|8 weeks of treatment with Continuous Positive Airway Pressure (CPAP)
45366799|NCT03683381|Behavioral|Sleep Health|Participants in the intervention group will be provided with an application containing weekly instructions to improve sleep
45483731|NCT04050800|Drug|Carbon 11 Butanol|Two sequential administrations of a PET tracer
45483732|NCT01332747|Drug|safoof e muhazzil|"drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~to be given in a dosage of 5 gms twice daily"
45845946|NCT04624698|Device|iStent Inject Implantation|Subjects will be implanted with the iStent Injection Micro-Bypass device
45847916|NCT03070470|Drug|Lopinavir / Ritonavir|Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days
45483733|NCT01332747|Drug|compressed tablet of safoof e muhazzil|"drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~compressed into tablets of 1 gm each+ binders qs. dose is 5 tablets twice daily"
45483734|NCT01332747|Drug|Atorvastatin|atorvastatin 10 mgs once daily
45483735|NCT05098652|Behavioral|CuRB-IT|9 1-hour coaching sessions delivered over a videoconferencing platform (Zoom); 6 delivered weekly, 3 delivered biweekly
45483736|NCT03472833|Drug|High-dose|Patients will receive a high dose - 180.000 I.U. (1 drop equals 400 I.U.) of Vitamin D3 orally on day 1, and then 4000 I.U. for 60 days
45483737|NCT03472833|Drug|Standard dose|Patients will receive a standard dose - 800 I.U. (equals 2 drops) of Vitamin D3 orally for 60 days
45366800|NCT03683381|Other|Patient education|Participants in the Patient education group will receive weekly information on insomnia symptoms
45483738|NCT03284554|Dietary Supplement|Encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria
45483739|NCT03284554|Dietary Supplement|Non-encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria
45483740|NCT03284554|Dietary Supplement|Placebo|Nutrient not expected to stimulate release of GLP-1 and PYY
45483741|NCT03785288|Radiation|HDR vaginal brachytherapy|HDR vaginal brachytherapy 7 Gy in 3 fractions or HDR vaginal brachytherapy 4 Gy in 6 fractions
45483742|NCT03442413|Drug|2-[18F]-FA PET/CT|2-[18F]FA is a highly specific radiotracer which has been used successfully to image nicotinic acetylcholine receptors in the human brain to characterize the effects of nicotine exposure (via smoking) on these receptors.
45483743|NCT03442413|Drug|I.V. Nicotine|Subjects in our study will receive intravenous nicotine at the adaptation session and each of the PET scans, close to the amount of nicotine absorbed from smoking 1/10 cigarette.
45691064|NCT04765917|Other|Selected physical Therapy program|"-Facilitation of balance reactions from standing position including: Standing on one leg, weight shifting from standing position, stoop and recover from standing, squat from standing, standing on balance board and pushing the child in different directions.~Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands.~Strengthening exercises for weakened muscles in upper and lower limbs muscle.~Strengthening exercises for back and abdominal muscles.~Stretching exercises for tight muscles in upper and lower limbs.~Gait training activities for correction of gait pattern including: walking on balance beam, walking on balance board, walking on uneven surface, walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs.~Jumping in place and jumping a board."
45691065|NCT04765917|Other|Motor imagery training program|"As a preparation each child will be shown a video of 5 minutes of normal movements.~They will be positioned in a comfortable position. The screen is in the child's visual field. Children will be asked to close their eyes and imagine they will perform the physically practiced task for 10 minutes, similar to one shown in the video. Sequence of the task will be verbally explained to the child for better recalling of sensations in muscles during the movements. During the entire exercise schedule child's attention will be focused on the position, and movement of their body, on proprioceptive inputs coming from the leg muscles and on the tactile sensations of foot floor contact.~Thereafter, the child will be asked to perform the sequence of tasks, rehearsed mentally for 20 minutes."
45691066|NCT04023903|Drug|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
45691067|NCT04023903|Drug|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
45845947|NCT04609722|Other|Solution-Focused Support Program|All participants will be given a program of 4 sessions for 4 weeks. Each session is planned to last approximately 50 minutes.
45845948|NCT04599816|Drug|levosimendan at a dose of 3 mcg/kg|levosimendan will be administered intravenously at a dose of 3 mcg/kg after anesthesia induction
46051512|NCT02612740|Device|granules of deproteinized bovine bone (Bio-Oss)|
46051513|NCT04799990|Drug|Risankizumab|Subcutaneous Injection
46051514|NCT04799990|Biological|Comparator 1|Subcutaneous or Intravenous Injection
45366801|NCT00899522|Other|biologic sample preservation procedure|Once the pathologist has taken the material needed to establish diagnosis of cancer, the anonymized snap-frozen and fresh samples will be either shipped to our laboratory for analysis or will be picked up by a member of the principal investigator's lab team. Samples will be stored indefinitely.
45366802|NCT00899522|Procedure|biopsy|Once the pathologist has taken the material needed to establish diagnosis of cancer, 1-10 grams of the remaining tissue should be placed in phosphate buffered saline and shipped to the Bagby Lab.
46051515|NCT04799990|Drug|Comparator 2|Oral, Opthalmic, Subcutaneous or Intravenous Injection
46051516|NCT00707512|Drug|natalizumab|Administered as specified in the TOUCH Prescribing Program
46051517|NCT02611726|Other|Acupuncture|Acupuncture
45483744|NCT03292354|Other|Contrast media administration|All patients will receive contrast media with a concentration of 300 mg I/mL (Iopromide 300). The flowrate and volume will be calculated with help of the different formulas belonging to the three different arms.
45845949|NCT04599816|Drug|levosimendan at a dose of 6 mcg/kg|levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
46051518|NCT00704548|Drug|Simvastatin 40mg|Simvastatin once daily, orally in the morning period, during eigth weeks
46051519|NCT00704548|Drug|Placebo|Placebo once daily, orally in the morning period, during eigth weeks
45845950|NCT04599816|Drug|levosimendan at a dose of 12 mcg/kg|levosimendan will be administered intravenously at a dose of 12 mcg/kg after anesthesia induction
45845951|NCT04572204|Other|Surgical|Minimal: Such as PCN insertion Endosopic: Such as DJ insertion Surgical: Repair, Partial or total nephrectomy Angioembolization
45845952|NCT04571970|Genetic|RGX-121|Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette
46051520|NCT00592384|Drug|venlafaxine XR|Once daily oral dose of venlafaxine XR ranging from 37.5 mg up to 300 mg
45366803|NCT01026376|Drug|decitabine|Cycles of 15mg/m2 infusion during 3h, 3 times a day, per 3 days
45366804|NCT01026376|Drug|decitabine|Cycles of 20mg/m2 infusion during 1h, once a day, per 5 days
45366805|NCT00712829|Drug|123-I-MIP-1072|10 mCi intravenous injection given one time during the study
45366806|NCT00712829|Drug|123-I-MIP-1095|10 mCi intravenous injection given one time during the study
46051521|NCT00592384|Drug|placebo|Once daily oral dose of placebo ranging from 37.5 mg up to 300 mg
46051522|NCT00707590|Drug|BMS-767778 or Placebo|
45366807|NCT00899756|Genetic|molecular diagnostic method|
46051523|NCT05473468|Drug|Famitinib|a single oral dose of [14C]famitinib (25 mg/150 uCi suspension)
45366808|NCT00899756|Genetic|mutation analysis|
45366809|NCT00712907|Dietary Supplement|vitamin C (Mayrhofer) 24mg/min i.v. for 64 min|Substance: Ascorbic acid (Mayrhofer) Manufacturer: Mayrhofer, Linz, Austria Dosage form: i.v. Dosage: 24mg/min over 64 min Dosage reference: Ting HH 1996
45366810|NCT00712907|Dietary Supplement|Placebo|Substance: Physiologic saline solution 0.9% (placebo) Dosage form: i.v. Dosage: 24ml/min over 64 min
45366811|NCT00712907|Other|100% O2 (AGA) two times for 12 min|"Substance: 100% oxygen (AGA, Vienna, Austria, gases for human use) Manufacturer: AGA, Vienna, Austria, gases for human use Dosage form: Inhalation through an oxygenmask over a period of 12 minutes two times per study day.~Dosage reference: Strenn K 1997"
45366812|NCT00901238|Procedure|Intra-arterial Chemotherapy|selective catheterization of the ophthalmic artery and injection of melphalan and topotecan
45366813|NCT03734224|Procedure|Adhesix mesh|Adhesix mesh
45366814|NCT03734224|Procedure|Progrip mesh|Progrip mesh
45366815|NCT05003141|Drug|PSB202|PSB202 is an antibody combination product comprised of two full-length monoclonal antibodies, PSB102 and PSB 107, respectively targeting CD20 and CD37. PSB202 is manufactured to work as a single product.
45366816|NCT00716495|Biological|AGI-101H Vaccine|Each patient will receive one dose of AGI - 101H containing 5 x 107 viable cells, administered s.c. for up to 26 weeks.
45366817|NCT00899912|Genetic|microarray analysis|
45366818|NCT00899912|Other|diagnostic laboratory biomarker analysis|
45366819|NCT00716573|Drug|everolimus|0,75 mg bid, 24 months
45366820|NCT02539706|Drug|Rocuronium 0,6mg/kg|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous was applied
45845953|NCT04566276|Biological|ChulaCov19 vaccine|SARS-Cov2 Wild-type S-spike mRNA/ lipid nanoparticle (LNP) vaccine
45366821|NCT02539706|Drug|Rocuronium 0,6mg/kg|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied
45366822|NCT00900068|Other|immunoenzyme technique|
45366823|NCT00900068|Other|laboratory biomarker analysis|
45366824|NCT00900068|Other|medical chart review|
45366825|NCT00451204|Drug|Estriol|Estriol 8 mg capsule, once per day, duration of treatment is 2 years
45366826|NCT00451204|Drug|Placebo|Placebo capsule, once a day, treatment duration is 2 years
45366827|NCT00451204|Drug|Copaxone|Injection, once a day, all subjects
45366828|NCT04067999|Drug|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
45483745|NCT01332825|Other|saline nasal irrigation|subjects irrigate with nasal saline daily for one week
45596592|NCT04547049|Drug|Cyclosporin A|2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.
45596593|NCT04547049|Drug|Mycophenolate Mofetil|500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.
45596594|NCT04547049|Drug|MTX|15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.
45596595|NCT02202395|Drug|LTS 0.25mg|use LTS 0.25mg/d
45596596|NCT02202395|Drug|LTS 0.5mg|use LTS 0.5mg/d
45596597|NCT02202395|Drug|LTS 1.0mg|use LTS 1.0mg/d
45596598|NCT02202395|Drug|Placebo|use placebo once daily
45845954|NCT04566276|Other|Placebo|Saline
45847917|NCT03070470|Drug|Chloroquine|Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)
45847918|NCT03070470|Drug|Placebo|Placebo (administered orally)
46051524|NCT00846040|Other|Reduced fat diet|RF (selective reduction of 85% of baseline fat calories per day)
46051525|NCT00846040|Other|Reduced carbohydrate diet|RC (selective reduction of 60% of baseline carbohydrate calories per day)
45366829|NCT00900302|Genetic|protein expression analysis|The first ten cases will be reviewed to assess the spectrum of OX-40 expression and to devise a semiquantitative scoring system. Each slide will be scanned in its entirety and then scored according to representative views with the greatest expression of immunostaining. Two independent viewers, who will be blinded to clinical data and outcome at the time of scoring, will review all slides. Scores from these independent readings will be compared, and differences were resolved upon mutual review of given cases. We will estimate the distribution of OX-40 IHC score by tumor type and tumor stage. OX-40 IHC score will be correlated with the IHC scores of other markers using Spearman's correlation coefficient. Kruskal-Wallis test will be used to test whether OX-40 IHC score is comparable between tumor type and tumor stage
45366830|NCT00900302|Other|immunohistochemistry staining method|5-micron sections will be cut, mounted on capillary gap slides and dried in a 60°C oven. The slides will then be then deparaffinized in xylene baths and gradually hydrated in graded alcohol. For epitope retrieval, the slides are placed in baths of 0.5 M Tris buffer at pH 10 and subjected to microwave irradiation for at least 19 minutes. The slides will be cooled and washed with deionized water and 0.05% TWEEN. They are then placed in a blocking solution of 0.3% bovine serum albumin, drained, and placed in wells of their primary antibody in a humidity chamber at room temperature overnight. Primary mouse antihuman antibodies will include anti-OX-40, anti-CD4, and anti-HLA class II. Anti-rat CD45 will be used as a negative control for each section. The slides will then be then washed and placed in their appropriate biotinylated anti-mouse secondary antibody for 24 minutes. Endogenous peroxidase in the samples is blocked using a solution of 3% hydrogen peroxide.
46051526|NCT00846040|Drug|Drug: f-18 fallypride|Dopamine D2 receptor availability is measured by positron emission tomography (PET) using the positron emitting compound [18F] fallypride which binds competitively with dopamine to the D2 receptor.
46051527|NCT00846040|Device|fMRI|Functional MRI (fMRI) will be used to measure the effects of diet and weight loss on regional brain activity
46051528|NCT00846040|Device|PET|Positron emission tomography (PET) will be used to assess whether To assess whether brain activity and reward pathways are altered
46051529|NCT02611336|Drug|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 3 months
45366831|NCT00900302|Other|laboratory biomarker analysis|Lymphocytes will be collected from fresh tissue and peripheral blood (PBLs) for use in marker analysis and in vitro assays of immune function. Tissues will be dissociated to obtain lymphocytes
45596599|NCT03533075|Behavioral|Teachable Moment Brief Intervention|Behavioral intervention informed by Collaborative Assessment and Management of Suicidality and Dialectical Behavior Therapy/Cognitive Behavior Therapy to assist in positive recovery trajectory following a suicide attempt
46051530|NCT04115722|Other|IBD ACTIVIT|Effect of IBD disease and activity of disease on coagulation parameters
46051531|NCT00704704|Drug|5-aza-cytidine and Thalidomide|5-AZA-Cytidine 75mg/m2 5 days a month. 12 months. Thalidomide 50mg orally daily for 6 months.
46051532|NCT00707824|Drug|nalbuphine|nalbuphine 5 mg epidural
46051533|NCT00707824|Drug|nalbuphine|nalbuphine 10 mg epidural
46051534|NCT00707824|Other|NSS|NSS
46051535|NCT00826228|Drug|teriparatide|teriparatide 20ug daily sc for 6 months
46051536|NCT00826228|Other|weight-bearing|device assisted walking
45366832|NCT00900302|Procedure|biopsy|De-identified tissue samples will be obtained from the OHSU Pathology Department. Tissues will consist of paraffin blocks collected either prospectively for previous cases, or fresh tissue collected prospectively for patients enrolled in the study. For either case, tissue will be collected only after tissue necessary for the adequate rendering of the pathologic diagnosis has been collected by the pathology Department. Thus, the collection of tissue will not compromise patient diagnosis/care.
45366833|NCT00721877|Drug|resveratrol|Given orally
45483746|NCT03625232|Device|CompuFlo® Epidural Computer Controlled System|"The CompuFlo® Epidural Instrument allows the objective identification of the epidural space by pressure measurement at the needle tip and consequently enables the HCP to perform epidural anesthesia and epidural injections using standard methods. Currently, HCPs rely on their subjective perception to feel a loss of resistance when inserting an epidural needle to identify the epidural space. The CompuFlo® Epidural Computer Controlled Anesthesia System has received a CE mark in the European Union and it received 510(k) clearance from the FDA in June 2017."
45483747|NCT03284476|Other|Collection of medical data from ICU patients|Medical data collected on a electronic secured data base
46051537|NCT00825994|Drug|Omega-3 Fatty Acids|2 g omega-3 fatty acids (docosahexaenoic acid [DHA] + eicosapentaenoic acid [EPA]), PO [by mouth], qd [every day]
46051538|NCT00825916|Drug|AZX100 Drug Product|Subjects were administered AZX100 3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
45483748|NCT01332903|Drug|[14C] AZD5069|Single 120 mg oral dose administered on Day 1
46051539|NCT00825916|Drug|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
45691068|NCT04023981|Device|Parafricta bootees|Parafricta bootees are a medical device designed to eliminate skin damage due to friction and shear. The basis of Parafricta bootees is a low friction material and bi-layer construction to make the material of the bootee slide on itself when movement of the foot would otherwise bring friction and shear to bear on the skin.
45691069|NCT04146675|Device|TRICOT JERSEY VANISE DOUBLE FACE|"Short sleeve t-shirt : TRICOT JERSEY VANISE DOUBLE FACE  THERMOLACTYL EVOLUTION  with ceramic fibers.~A Tinetti test will be performed while wearing the T-shirt, as well as an evaluation of the equilibration on posturography platform under static conditions and an assessment of dynamic equilibrium and locomotion in motion analysis."
45691070|NCT04146675|Device|TRICOT JERSEY SIMPLE|Short sleeve t-shirt : TRICOT JERSEY SIMPLE The comparator T-shirt has the same weight, the same appearance, and will be used by patients in the same way and under the same conditions as the T-shirt with ceramic fibers.
45691071|NCT03022149|Device|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
46051540|NCT00825916|Drug|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
45366834|NCT00721877|Other|pharmacological study|Correlative studies
45366835|NCT00721877|Other|laboratory biomarker analysis|Correlative studies
45366836|NCT03742570|Behavioral|CBBDQ|a questionnaire for childood bladder and bowel dysfunctions
45366837|NCT00716651|Drug|mepolizumab|750 mg mepolizumab iv q4wk until week 32
45366838|NCT00900380|Other|flow cytometry|
45366839|NCT00900380|Other|immunological diagnostic method|
45366840|NCT00900380|Other|laboratory biomarker analysis|
45483749|NCT03292276|Device|Amadeo Training|"To understand the cortical modifications related to movement preparation and execution after robot-assisted training we will study the EEG modifications of cortical activity using time-frequency event-related EEG and task-related coherence (TRCoh).~Friedman ANOVA with post-hoc t-test (corrected for multiple comparisons) will be used to assess the significance of training-induced changes in the two groups."
45483750|NCT01335087|Other|Standard care|Patients with conservative treatment: (Group 2). This group will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counselling.
46051541|NCT00791479|Drug|LY2189265 and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
45483751|NCT01335087|Device|continuous positive airway pressure|Patients with CPAP treatment (Group 1): CPAP pressure titration will be performed by automated equipment before discharge. It will follow the methodology described by our group (Mass et al. Alternative Methods of titrating continuous positive airway pressure: a large multicentre study. American Journal of Respiratory and Critical Care Medicine (2004) vol. 170 (11) pp. 1218-1224). This group will also be instructed in hygienic-dietary measures recommended for all patients, standard care of cardiovascular risk factors and sleep hygiene counselling.
45483752|NCT03292120|Other|measure of the SOFA score|The Sequential Organ Failure Assessment (SOFA) Score predicts ICU mortality based on lab results and clinical data.
45691072|NCT03022149|Device|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
45691073|NCT04194333|Procedure|Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy to guide Electromagnetic Navigational Bronchoscopy instead of Standard Fluroscopic guidance using the C-Arm|Instead of the standard fluoroscopy using the C-arm, the intervention will undergo electromagnetic navigation guided bronchoscopy while using Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy.
45366841|NCT01026532|Biological|Segmental Allergen Challenge|Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
45366842|NCT01022788|Behavioral|Home-based counselling|
46051542|NCT00791479|Drug|Placebo solution and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
46051543|NCT00890097|Drug|AL-8309B Ophthalmic Solution|
45483753|NCT01337427|Drug|BIIB017|BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.
45483754|NCT03283228|Diagnostic Test|Cd11b and Cd56 markers|The expression of CD11b and CD56 in newly diadnosed cases of AML
45691074|NCT04023279|Other|TENS|100 Hz and 100 usec for 20 minutes
45691075|NCT04023279|Other|Myofascial therapy|Seven to fifteen transverse sliding repetitions and three repetitions of longitudinal sliding of myofascial release therapy
45691076|NCT04023123|Other|Ophthalmic imaging|Optical coherence tomography Topography Ocular Response Analyzer Optical Biometry Slit lamp photos
45847919|NCT03070470|Drug|Dofetilide and Diltiazem|"In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.~In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10."
46051544|NCT00890097|Drug|AL-8309B Vehicle|Inactive ingredients used as placebo comparator
46051545|NCT02831751|Biological|30 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
46051546|NCT02831751|Biological|60 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
46051547|NCT02831751|Biological|FluLaval® Tetra (15 µg/strain)|Single dose of a licensed quadrivalent vaccine
46051548|NCT02831751|Biological|Fluzone® High-Dose (60 µg/strain)|Single dose of a licensed trivalent vaccine
46051549|NCT00913458|Drug|etanercept|
45366843|NCT00900458|Behavioral|Aerobic Exercise training|aerobic exercise training (cycling)
45366844|NCT02571803|Behavioral|Dietary And Lifestyle Counseling|The DASH (Dietary Approaches to Stop Hypertension) diet is a dietary pattern of proven effect on arterial blood pressure reduction. It is rich in fruits, vegetables, whole grains, and low-fat dairy foods; includes meat, fish, poultry, nuts, and beans; and is limited in sugar-sweetened foods and beverages, red meat, and added fats. Dietary counseling will be provided during each of 7 control visits within the 12-month time of observation.
45847920|NCT03070548|Drug|Talazoparib|1 mg of talazoparib containing100 μCi of 14C-radiolabeled talazoparib
46051550|NCT05208333|Drug|Albenza 200Mg Tablet|"Distributing albedazol (Zentel) 200mg at school to parents or guardians, dose 15mg/kg divided into 2 times/day, instructions to take the medicine in full dose, at the right time after meals, for 5 days.~Limiting reinfection: Advice on preventing reinfection"
46051551|NCT04201041|Procedure|pudendal nerve pulsed radiofrequency|received pudendal nerve pulsed radiofrequency through trans-vaginal approach or trans-gluteal approach
46051552|NCT04309773|Drug|Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy|Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy Treatment duration : 24 months Bezafibrate/AUDC : daily oral dose
45366845|NCT02571803|Other|Optimal Medical Treatment|Optimal Medical Treatment as per 2013 ESC Guidelines on the Management of Stable Coronary Artery Disease.
45366846|NCT03537586|Drug|Bivalirudin|After diagnostic catheterization, intravenous bivalirudin (Angiomax) will be administered as part of the research procedure, and a 6F-guiding catheter without side holes will be used to engage the ostium of the coronary artery.
45366847|NCT03537586|Drug|Adenosine|An intravenous infusion of adenosine (140 μg/kg/min) will be administered via a large peripheral or central vein to induce steady-state maximal hyperemia.
45366848|NCT03537586|Drug|Heparin|Heparin may be used as an alternative to bivalirudin at the discretion of the interventional cardiologist.
45366849|NCT03537586|Device|Pressure-Temperature Sensor Guidewire|Abbott's Pressure Wire X will be used to measure fractional flow reserve (FFR), cardiac magnetic resonance (CMR) and Index of Microcirculatory Resistance (IMR) in the Left Anterior Descending (LAD) Artery and major epicardial coronary vessels associated with myocardial ischemia.
45366850|NCT03537586|Device|Guiding Catheter|Medtronic's 6F Launcher Guide Catheter will be used to engage the left main coronary artery.
45366851|NCT00894218|Procedure|Arthroplasty|Hip or knee arthroplasty
45366852|NCT00722033|Drug|3 protocols of Indomethacin administration|Indomethacin will consecutive be infused in 30, 60 and 120 minutes in each patient who requires it.
45366853|NCT00894374|Drug|Artesunate (Test)|Oral tablet, single dose, 1 x 100 mg
45366854|NCT00894374|Drug|Artesunate (Comparator)|Oral tablet, single dose, 2 x 50 mg
45366855|NCT04920149|Drug|Mesalamine|The IMP will be supplied as sachets with slow-releasing granules.
45366856|NCT04920149|Drug|Placebo|The IMP will be supplied as sachets with slow-releasing granules.
45366857|NCT01026610|Drug|LB80380 90 mg|LB80380 90 mg + placebo tablets, once daily, for 48 weeks
45366858|NCT01026610|Drug|LB80380 150 mg|LB80380 60 mg + 90 mg tablets, once daily, for 48 weeks
45366859|NCT01026610|Drug|entecavir 0.5 mg|entecavir 0.5 mg tablet, once daily, for 48 weeks
45366860|NCT00900536|Genetic|mutation analysis|
45366861|NCT00900536|Genetic|polymorphism analysis|
45366862|NCT00900536|Genetic|protein expression analysis|
45366863|NCT00900536|Other|immunohistochemistry staining method|
45366864|NCT00900536|Other|laboratory biomarker analysis|
45366865|NCT00713063|Behavioral|aerobic exercise|12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
45366866|NCT00713063|Behavioral|Health Education Control|12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
45366867|NCT03530254|Diagnostic Test|PGT-A|PGT-A will be carried out following the usual clinical practice. Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
45483755|NCT01335165|Drug|ALXN1102|Single Ascending Dose IV
45483756|NCT01335165|Drug|ALXN1103|Single Ascending Dose IV or SC
45483757|NCT02459938|Drug|Glucagon (ZP-Glucagon)|chemically synthesized glucagon as delivered via transdermal microneedle patch system for 30 minutes
45483758|NCT02459938|Drug|Glucagon (GlucaGen)|recombinant glucagon administered via subcutaneous injection
45483759|NCT04850313|Device|ProProKera Plus®|ProKera® is a sutureless form of CryoTek amniotic membrane that is clipped into a dual polycarbonate ring system with the epithelial side up when in contact with the ocular surface.
45483760|NCT03284164|Drug|Tenofovir Exalidex (TXL)|Drug: Tenofovir Exalidex (TXL)
45483761|NCT03035864|Drug|rhNGF|Eye Drop 20 μg/mL
45483762|NCT03035864|Other|Vehicle|Vehicle Eye Drop
45483763|NCT01335243|Procedure|The Transforaminal Lumbar Interbody Fusion (TLIF) surgery|The TLIF surgery use a per-operating artificial substitute specific biomaterial: autologous osteoblasts punctured on iliac crest and put on a collagen support waxed with tri-calcium phosphate (which is osteoconductive) to perform a intervertebral body fusion.
45483764|NCT03107728|Device|Advanced orthotic brace|Participants will use an advanced exoskeletal orthosis.
45483765|NCT03107728|Device|Conventional orthotic brace|Participants will use the standard of care orthosis
45483766|NCT01337583|Other|Dapivirine|Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months
45483767|NCT01337583|Other|Placebo|Vaginal Ring containing no drug substance
45483768|NCT01337583|Drug|Dapivirine|
45483769|NCT03107962|Drug|Pembrolizumab (PD-1 Blocking Antibody)|pembrolizumab 2mg/kg, ivgtt (intravenously guttae), d1. Every three weeks for one cycle and two cycles are required at least. Efficacy and safety were evaluated every two cycles.
45483770|NCT05094050|Drug|ABBV-951|Continuous Subcutaneous Infusion (CSCI)
45483771|NCT03200457|Device|1,5 Tesla abdominal MRI|Measurement of the fat and iron
45483772|NCT03200457|Device|3 Tesla abdominal MRI|Measurement of the fat and iron
45483773|NCT02460406|Other|traditional physiotherapy|We are applying routine traditional physiotherapy consisted of neurodevelopmental treatment (stretching, weight bearing, functional reaching & walking so on).
45483774|NCT02460406|Other|progressive functional strength training|"Participants allocated to the experimental group completed three times a week, 12-week progressive resistance training protocol. This protocol consisted of functional squat system with virtual reality in leg press, plyometric exercises, exercises with Bosu ball & heel-rise exercises. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly."
45483775|NCT04891172|Biological|Anti COVID 19 Intravenous Immunoglobulin (C-IVIG)|"Intervention arm will receive single dose of 0.15g/kg C-IVIG. This will be infused within period of 16 hours intravenously. Additionally, all participants will receive same standard care.~Standard Care as per hospital protocol, which may include:~Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics, anti coagulant"
45483776|NCT03284086|Diagnostic Test|upper-body double-poling|An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the upper-body double-poling mode.
45483777|NCT03284086|Diagnostic Test|arm crank ergometry|An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the arm crank ergometry mode.
45483778|NCT03189303|Device|Primary Uncemented Total Hip Arthroplasty|The study devices are the Pinnacle Hip System acetabular cup with a Summit, Actis, or Corail femoral stem
45483779|NCT03284008|Other|Manual manoeuver + stretching|Patients in experimental group will receive, after AWS diagnose, a manual manoeuver to snap the cord, follow by a demonstration and education of the exercise to be made at home.
45483780|NCT03284008|Other|stretching exercise|Patients in control group will receive, after AWS diagnose, just a demonstration and education of the exercise to be made at home.
45483781|NCT03283072|Device|Hypoxicator|Repeated bouts of hypoxia/normoxia
45483782|NCT03135249|Drug|Alemtuzumab|Alemtuzumab is a humanized monoclonal therapeutic antibody that rapidly depletes cluster of differentiation 52 (CD52)+ cells.
45483783|NCT03292042|Behavioral|Physical health promotion program|"The program has 24 sessions. Each session has two parts:~first part: half an hour of theoretical content, about the Metabolic syndrome, the effect of unhealthy lifestyle, toxic habits such as smoking or drinking alcohol, dietary habits or physical activity.~Second part: 1 hour of physical activity (walk)"
45483784|NCT03282994|Device|Dermal Cooling System|Cryotherapy
45691077|NCT03021915|Other|OvaPrime Treatment|The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.
45691078|NCT04146519|Biological|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
45691079|NCT04146519|Other|Placebo|Saline solution
45691080|NCT04022811|Drug|0.1% bromfenac|the patients received the use of the Ponacore 3 days before and 7 days after the operation. Local eye drops, 2 times a day.
45483785|NCT01335321|Drug|Hylan GF-20 alone|A intraarticular injection of 6ml of Hylan GF-20 (Synvisc)
45483786|NCT01335321|Drug|Triamcinolone|A Intraarticular injection of 6ml of Hylan GF-20 (Synvisc) + 1ml of triamcinolone (Triancil)
45483787|NCT03291964|Diagnostic Test|Rapid Brain MRI|Children undergoing head CT for evaluation of acute head injury will also undergo rapid brain MRI with GRE sequence that is specific for blood. Their clinical care will not change at all based on the MRI.
45847921|NCT03072186|Device|near-infrared light nasal endoscope used with ICG|Using the near-infrared light nasal endoscope with ICG will identify anatomical landmarks and and tumor characteristics to provide a clear demonstration of the blood supply.
45847922|NCT03072732|Device|u-Cor System|Monitoring System
45847923|NCT03072732|Device|ZOE Fluid Status Monitor|Monitoring System
46051553|NCT04309773|Drug|Placebo of Bezafibrate in addition to standard UDCA therapy|Placebo of Bezafibrate (400mg) in addition to standard 15-20 mg/kg/Day UDCA therapy Treatment duration : 24 months Placebo/AUDC : daily oral dose
45845955|NCT04563390|Behavioral|Projection-based augmented reality exposure therapy (P-ARET).|"The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
45483788|NCT03635697|Behavioral|Mindfulness Auditory Intervention|This intervention is a short audio clip that focuses on the practices and principles of mindfulness. The goal of mindfulness is to bring awareness to a person's physical body as well as their thoughts and feelings.
45691081|NCT04022889|Device|INTERCEPT Treated Platelets|Apheresis platelet components in 100% plasma collected using the Trima separator, prepared with the INTERCEPT Blood System for Platelets (Test Platelets) and stored for 7days at 20-24°C with continuous agitation. Samples from the Test component will be processed with either the BEST or the Variant 1 procedure prior to radiolabeling. The radiolabeled autologous Test and Control platelets (approximately 10-30 mL) will be simultaneously administered intravenously into the subject.
45691082|NCT04146129|Drug|CDX-0159|Single dose of one of four dosages of CDX-0159
45691083|NCT04146129|Drug|Normal saline|Single infusion of normal saline
46051554|NCT02827305|Drug|Gotukola|10 ml of mouthwash to be rinsed for duration of 60 seconds
45483789|NCT03283774|Other|current clinical practice|quality management (data registration, drug prescription, diagnostic and clinical tests ...), in primary care of patients with diabetes mellitus
46051555|NCT02827305|Procedure|Scaling|Ultrasonic scaling was performed in one visit on both upper and lower arches.
46051556|NCT02827227|Biological|lymphocytes immunophenotyping|"The lymphocytes immunophenotyping were performed from fresh EDTA-anticoagulated blood harvested during a routine follow-up of patients in HIV Lyon centers.~HIV patients with a known history of PHI and a minimum of 2 years of effective cART (< 200 copies/mL) without interruption or virological failure were included in 2 centers in Lyon (Croix-Rousse and Edouard Herriot hospital).~Baseline factors at the time of PHI, delay, type and duration of first and duration of total cART, CMV status, nadir CD4 cells count and level of activation markers on CD4 and CD8 cells (CD38 and HLA-DR) at the time of the study were assessed.~Patients with hepatitis C or B virus co-infection or with a history of neoplasia or immunosuppressive therapy after the date of PIH were excluded."
45691084|NCT04022655|Other|ICU Care|No intervention
45691085|NCT04022577|Behavioral|Adherence Therapy|Motivational interviewing-based AT in this study was based on Gray et al.'s eight-session AT using the motivational interviewing technique (and principles of cognitive behavioral therapy).
45691086|NCT04022577|Behavioral|control group|The control group received routine care
45366868|NCT03530254|Diagnostic Test|ERA Test|The ERA test requires an endometrial biopsy and will determine if the endometrium is receptive or not by analysing the expression levels of 236 genes involved in endometrial receptivity, to assess the optimal time to place an embryo into the uterus and promote a successful implantation and pregnancy.
45366869|NCT00901550|Drug|Methotrexate|All participants received oral Methotrexate(MTX), starting at 7.5 mg/week. In patients with persistent tender or swollen joints, the dose was escalated in a graduated manner (2.5 mg/week every 1-2 weeks) to 15 mg/week by week 4 or 20 mg/week by week 8
45691087|NCT04145583|Drug|HSK3486|Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
45366870|NCT00901550|Drug|Infliximab|Patients in combination group receive infliximab 3mg/kg at weeks 0, 2, and 6 and every 8 week thereafter.
45691088|NCT04145583|Drug|voriconazole +HSK3486|Sequence 2: voriconazole：Day 1,400mg，BID；Day 2--Day 6,200mg，BID；200 mg of voriconazole were taken orally in the morning on an empty stomach of Day 7; followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
45691089|NCT04022421|Drug|Hydroxychloroquine|the drug will be taken by one group of the patients daily at a dose of 400mg
45691090|NCT04022031|Drug|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
45691091|NCT03947151|Drug|Degarelix injection(s)|1 or 2 degarelix injection(s)
45691092|NCT04145505|Procedure|COLORECTAL CANCER SURGERY|SENTINEL NODE DETECTION
45691093|NCT04023045|Device|Assist-Knee|Assist-Knee is an experimental lower limb knee prosthesis.
45366871|NCT02573051|Drug|Misoprostol|800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries)
45366872|NCT02573051|Drug|Isosorbide mononitrate|40 mg isosorbide mononitrate (Effox 40 mg Minipharma Company)
45366873|NCT02573051|Other|placebo|
45366874|NCT02539940|Device|Angioplasty Paclitaxel-eluted balloon catheter ELUTAX SV|Angioplasty for revascularization in below-the-knee arteries
45366875|NCT01028092|Drug|Anti R-IL2 + Cyclosporine|"anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~cyclosporine A (Neoral ®) started from 6 to 8 mg/kg adjusted to C2~corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
45483790|NCT03041805|Procedure|EVLT|Endovenous laser treatment of great saphenous vein, small saphenous vein, accessorial saphenous vein with different laser wavelength and any bare type
45691094|NCT04023045|Device|Habitual Prosthesis|Habitual baseline prosthesis prescribed by participant's clinician.
45691095|NCT04022109|Device|Breath sampling for VOC detection|Breath sampling will be performed by using a special sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Pepsinogen testing will be used in a subgroup to identify serological increased risk for atrophy
45691096|NCT04022109|Procedure|Surgery material collection for VOC headspace analysis|Only for gastric cancer patients undergoing surgery (Group 1)
45691097|NCT04022109|Diagnostic Test|Upper endoscopy|Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)
45691098|NCT04022109|Diagnostic Test|Microbiota testing|Faecal and gastric contents and biopsy samples for microbiota testing
45847924|NCT03074682|Device|Lifeflow|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
45483791|NCT03041805|Procedure|RFA|Radiofrequency ablation of great saphenous vein, small saphenous vein, accessorial saphenous vein with ClosureFast technique
45483792|NCT03041805|Procedure|USFS|Ultrasound guided foam sclerotherapy of great saphenous vein, small saphenous vein, accessorial saphenous vein with polidocanol or tetradecyl sulphate of any concentration
45483793|NCT03041805|Procedure|HL/stripping|High ligation and stripping of great saphenous vein, small saphenous vein, accessorial saphenous vein
45483794|NCT03041805|Procedure|Miniphlebectomy|Miniphlebectomy of any varicose veins under local, regional or general anaesthesia
45483795|NCT03041805|Procedure|Sclerotherapy|Foam or liquid sclerotherapy of any varicose veins with polidocanol or tetradecyl sulphate of any concentration
45483796|NCT03041805|Device|GCS|Graduated compression stockings may be used after procedure by the decision of the doctor
45483797|NCT03041805|Drug|LMWH|Low-molecular-weight heparin may be used after procedure by the decision of the doctor
45483798|NCT03291730|Behavioral|Breathing and journaling exercise|May help reduce anxiety of receiving chemotherapy
45483799|NCT03291730|Other|Art-therapy|May help reduce anxiety of receiving chemotherapy
45483800|NCT01333137|Drug|Gemcitabine and Carboplatin|Gemcitabine 1000 mg/m2/day on Days 1 & 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.
45366876|NCT01028092|Drug|Thymoglobulin + Everolimus|"Thymoglobulin ® induction started at 1.5mg/kg/j then adjusted to CD2 or total lymphocytes count, for 5 days~Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~everolimus (Certican ®): 4 to 6 mg/day started at D5, adjusted to achieve a residual level between 6 et 10 ng/ml~corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
45366877|NCT01028092|Drug|Anti R-IL2 + Cyclosporine then Everolimus|"anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~Mycophenolate Mofetil (Cellcept ®) 3 g/d beginning at D0~cyclosporine A (Neoral ®) beginning at 6 to 8 mg/kg adjusted to C2, then switch to everolimus (Certican ®) between at W6, started at 3 mg/d, then adjusted to achieve a residual level between 6 et 10 ng/ml~corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
45366878|NCT00900614|Drug|APR-246|Intravenous infusion. Dose escalating. Dosing will be conducted with three patients at each dose level.
46051557|NCT02827929|Behavioral|Education|3 times systemic education program will be provided to patients were diagnosed as asthma or COPD by their physicians.
46051558|NCT02827851|Procedure|Liposuction|
45483801|NCT01333137|Drug|P276-00 along with Gemcitabine and carboplatin|In phase I run in period, P276 00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 & 8 every 21 days. In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
45483802|NCT03283618|Behavioral|Video Conferencing Group|
46051559|NCT02827851|Other|SVF isolation|SVF will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 5 ml of Hartmann's solution.
45483803|NCT02459704|Procedure|Semilunar coronally positioned flap|Semilunar coronally positioned flap with enamel matrix derivative (Emdogain) or alone.
45483804|NCT02459704|Device|Enamel matrix derivative (Emdogain)|Enamel matrix derivative associated to semilunar coronally positioned flap (SCPF + EMD - test group)
45483805|NCT03041727|Other|Fascial Manipulation|Fascial Manipulation is a manual therapy that focused on deep muscular fascial.
46051560|NCT02827851|Other|Intraarticular administration of autologous SVF|
45483806|NCT03041727|Other|Standard exercises protocol|Stretching and strengthening exercises
45483807|NCT02459626|Other|Diagnostic P-V-loops and MRI|Invasive assessment of P-V-loops during catheterization for suspected CAD Magnetic resonance Imaging for assessment of myocardial fibrosis and biventricular function
45483808|NCT01337817|Other|Ariva Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
45483809|NCT01337817|Other|Ariva Wintergreen|Comparator product, a compressed dissolvable smokeless tobacco lozenge containing 2 mg nicotine administered orally as a single dose.
45483810|NCT03282838|Drug|DFN-15 (fasted)|DFN-15 administered to fasted subjects
45483811|NCT03282838|Drug|DFN-15 (fed)|DFN-15 administered to fed subjects
45483812|NCT03282838|Drug|Comparator Celebrex® (fed)|Comparator (Celebrex®) administered to fed subjects
45483813|NCT01333293|Drug|injections|subcutaneous injections
45483814|NCT03291574|Procedure|Electroacupuncture|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
45483815|NCT03291574|Procedure|Sham electroacupuncture|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
46051561|NCT02829333|Other|general anesthesia and patient controlled intravenous analgesia|Patients receive general anesthesia intraoperative period and continuous intravenous analgesia postoperation
46051562|NCT02829333|Other|spinal anesthesia and continuous postoperative epidural analgesia|Patients receive spinal anesthesia intraoperative period and continuous epidural analgesia postoperation
46051563|NCT05251662|Drug|Sintilimab|200mg IV d1 Q3W
46051564|NCT05251662|Drug|IBI305|7.5mg/kg IV d1 Q3W
46051565|NCT05251662|Drug|GEMOX|Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W
45483816|NCT03282760|Biological|Human Neural Stem Cells|Allogenic human Neural Stem Cells (hNSCs) in four different dosages (5, 10, 16 or 24 millions). hNSCs are produced by the Laboratorio Cellule Staminali of Terni according to GMP guidelines and are obtained from brain specimens of several fetal human donors from spontaneous miscarriages occurred after the 8th week after conception.
45483817|NCT04535440|Other|No intervention|No intervention
45483818|NCT04431466|Drug|Ivermectin|SOC plus different dosing regimens of Ivermectin
45483819|NCT04431466|Other|Standard of Care|Standard treatment for COVID-19
45483820|NCT03291418|Drug|ATB-346 OR Placebo|Comparison of gastrointestinal effects
45483821|NCT03291418|Drug|Naproxen sodium|Comparison of gastrointestinal effects
45483822|NCT03291262|Other|Follow up for death and recurrence|Patients are followed up to determine the specific date of diagnosis, recurrence and death.
45483823|NCT03282526|Diagnostic Test|Whole body plethysmography|Whole body plethysmography : measure lung volumes Spirometry : to assess severity of chronic obstructive pulmonary disease also reversibility testing
45483824|NCT02885181|Drug|GS-9876|One tablet administered orally once daily
45691099|NCT04145739|Other|Rehabilitation protocol|The rehabilitation treatment was performer in single session, lasted 60 minutes for session, 2 times a week, carried-out a 6-week exercises program for a total of 12 sessions, by a physiotherapist trained in oncologic rehabilitation, who started with a first phase of at least 15-20 min of low-impact aerobics warm-up. The second phase consisted in diaphragmatic breathing and postural exercises for the midline alignment in a supine position. Finally the patient continued in front of the mirror with exercises for the recovery of shoulder joint, isometric reinforcement exercises for the recovery of strength of shoulder stabilizer muscles. In the presence of lymphedema an additional weekly lymph drainage session was performed for a total of 10 sessions.
45691100|NCT04145661|Device|Hearing aids programmed conventionally.|All participants will wear their hearing aids programmed in this way for around six weeks.
45691101|NCT04145661|Device|Hearing aids programmed with compression activated.|All participants will wear their hearing aids programmed in this way for around six weeks.
46051566|NCT02829177|Drug|Allopurinol|
45366879|NCT00900692|Device|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
45366880|NCT02571647|Other|Non interventional study|"Patients agreeing to participate in the study will have a cognitive assessment and geriatric assessment, carried out according to usual practices and grids clinical gerontology cluster.~They will benefit in addition to a noninvasive screening and risk-free ophthalmic (visual acuity, intraocular pressure, examination of the eyelids and fundus)."
45483825|NCT02885181|Drug|Filgotinib|Two tablets administered orally once daily
45691102|NCT03923673|Procedure|Pericardiotomy|The minimally invasive procedure that creates a small opening in the sac that surrounds the heart.
45845956|NCT04563390|Behavioral|In vivo exposure therapy|"The intervention will be based on traditional in vivo exposure therapy to real cockroaches. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
45483826|NCT02885181|Drug|GS-9876 placebo|One tablet administered orally once daily
45847925|NCT03074682|Device|Push/Pull|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
46051567|NCT02829177|Drug|Placebo|
46051568|NCT00631878|Drug|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.
45483827|NCT02885181|Drug|Filgotinib placebo|Two tablets administered orally once daily
45483828|NCT02885181|Drug|Methotrexate|Background therapy with methotrexate administered orally or parenterally once weekly
45483829|NCT03291184|Device|peripheral neuromuscular monitor|Residual paralysis can only be measured by neuromuscular transmission monitoring of a peripheral nerve, typically the ulnar nerve innervating the adductor pollicis muscle.
45483830|NCT03291106|Diagnostic Test|immunohistochemical staining|immunohistochemical staining for MLH1, MSH2, MSH6 and PMS2
45483831|NCT03291106|Diagnostic Test|tests of microsatellite instability|microsatellite instability in tissues of endometrial cancer
45483832|NCT03291106|Diagnostic Test|clinical criteria of Lynch syndromes|Amsterdam I or II criteria and Bethesda criteria
45483833|NCT03291106|Diagnostic Test|sequencing for mismatch repair genes|next-generation sequencing, Sanger method or qPCR for mismatch repair genes (MLH1, MSH2, MSH6, PMS2, and EPCAM)
45483834|NCT02459782|Procedure|Ultrasound guided Dual Quadrant Peribulbar Anaesthesia|Landmark Guided single injection vs Ultrasound guided dual quadrant injection
45483835|NCT02884089|Drug|Abemaciclib|Administered orally
45483836|NCT02884089|Drug|Metformin|Administered orally
45483837|NCT02884089|Drug|Iohexol|Administered intravenously (IV)
46051569|NCT05112081|Drug|Botulinum toxin type A|The group will receive a solution of 100 units BTX with 10 ml sterile saline close to the superficial inguinal ring.
46051570|NCT05112081|Other|Sterile saline|The group will receive a solution of 10 ml sterile saline close to the superficial inguinal ring.
46051571|NCT00913380|Radiation|Diagnostic CT|2 mSv in an average patient (Low-dose (1/4 to 1/5 of standard-dose))
46051572|NCT00913380|Radiation|Diagnostic CT|8 mSv in an average patient (Standard-dose CT)
45366881|NCT00901706|Other|Comprehensive Geriatric Assessment and APS Usual Care|Comprehensive Geriatric Assessment coupled with APS usual care which collectively will consist standardized cognitive, functional, affective, social, and legal interventions.
45366882|NCT00901706|Other|APS usual care|APS usual care consists of social, medical, and legal assistance.
45366883|NCT00605306|Drug|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 250/400 μg, 2 puffs once daily delivered via the Twisthaler device.
45366884|NCT00605306|Drug|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
45483838|NCT02884089|Drug|Placebo|Administered orally
45483839|NCT04150354|Behavioral|Cogito Companion|During the course of the study, the research application (Cogito Companion) will be installed on participants' mobile phone. The application on the participants' phone will be recording data about their behavior. Participants will also be asked to complete bi-weekly surveys via the app.
45483840|NCT01315431|Drug|Tesetaxel plus capecitabine|"Study medication, which will include tesetaxel capsules and capecitabine tablets, will be administered orally for two 21-day cycles. In each cycle, tesetaxel will be administered at a dose of 27 mg/m2 on Day 1, and capecitabine will be administered in Cohort 1 at a dose of 2000 mg/m2/day and in Cohort 2 at a dose of 1750 mg/m2/day (in 2 equally divided doses) on Day 1 through Day 14.~At the conclusion of Cycle 2, patients who, in the opinion of the investigator, appear to have benefitted from protocol therapy may receive up to 6 additional cycles under a separate protocol."
45483841|NCT03265054|Biological|Analysis of plasma samples|Measuring microparticles (MPs) in Human Plasma Samples
45366885|NCT00905918|Dietary Supplement|vitamin E|Given orally
45366886|NCT00905918|Other|laboratory biomarker analysis|All patients undergo biomarker analyses
45366887|NCT00894608|Drug|letrozole + gonadotropins|patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
45366888|NCT00894608|Drug|GnRHa + gonadotropins|patients in long GnRHa protocol for ovarian stimulation with GnRHa and gonadotropins
45366889|NCT00901784|Drug|Topiramate|25mg Tablets
45483842|NCT03874546|Other|Questionnaire|"Two clinicians will complete a questionnaire that analyses their perception of the patient's prognosis at Day1 and Day7.~At 6 months, another clinician will establish the patient prognosis using Glasgow Outcome Scale and Glasgow outcome scale extended. This clinician must not know the patient's IMPACT score and prognosis established at Day 1 and Day 7. His evaluation will be compare to the patient's prognosis established previously (Day1 and Day7)."
45483843|NCT03282448|Behavioral|family therapy|The family-based intervention is informed by Dialectical Behavior Therapy Skills Training for Adolescents (Rathus & Miller, 2014).
46051573|NCT04244097|Drug|Bupivacaine Hydrochloride|after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
46051574|NCT04244097|Drug|Neostigmine|after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
45366890|NCT00607022|Device|dental implant|Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.
45366891|NCT00722345|Behavioral|"review of Canada's Physical Activity Guide for Youth"|"The contents of the exercise booklet was reviewed with each participant of the control group by the research fellow. Health Canada's Canada's Physical Activity Guide for Youth was used for the exercise booklet"
45366892|NCT00722345|Behavioral|Exercise consultation|The exercise consultation consisted of a one-to-one discussion designed to educate the participant, strengthen his/her motivation and develop realistic goals and strategies to promote physical activity based on the patient's stage of change. The consultation was based upon the standardized protocol previously published by Loughlan and Mutrie. The Consultation Guidelines describe the 5 steps involved in an exercise consultation, including: 1) discussing current & past activities; 2) reviewing the pros & cons of exercising; 3) discussing the barriers to exercising and strategies for overcoming them; 4) determining the social support available to the patient; and finally, 5) setting realistic, attainable short term and long term goals to enhance physical activity.
45366893|NCT00905996|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection in gastric varix
45366894|NCT00905996|Drug|Beta-blocker (propranolol)|
45366895|NCT02574065|Drug|L. reuteri DSM 17938|Effects on crying time in colicky infants with the supplementation of Lactobacillus reuteri DSM 17938
45366896|NCT02574065|Other|The placebo consists of an identical formulation without L. reuteri DSM 17938|
45366897|NCT02539628|Drug|ropivacaine 0.2%|Adductor canal block. Placed immediately postoperative. Intervention stops on POD2 12PM
45366898|NCT00713297|Behavioral|satisfaction questionnaire|Satisfaction questionnaire
45366899|NCT00901862|Device|Pulsed magnetic fields (Quantum MH-2MR bracelet)|Pulsed magnetic fields
45691103|NCT04021953|Behavioral|People Like Us Online Video Series Intervention|"People Like Us miniseries incorporates key sexual health messages to:~Increase viewers' knowledge and perceptions of HIV and other STI risk;~Address homophobia and sexual orientation disclosure;~Increase safer-sex negotiation self-efficacy;~Promote positive attitudes towards condom use and other safe sex behaviors;~Build skills and self-efficacy for practicing safer sex;~Provide information on HIV and other STI testing and its benefits;~Provide information on resources for HIV/STI testing and other mental health services;~Model appropriate behaviors around practicing safer sex.~Each video in the six-part series ends with an educational video segment featuring the managers of Action for AIDS and Gayhealth.sg, who provide a brief synopsis of the episode and cover key points relevant to mental and sexual health for GBQ men."
45691104|NCT04021953|Behavioral|Sexual Health Pamphlet (Standard of Care)|The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
45366900|NCT00901862|Device|Sham pulsed magnetic fields (Quantum MH-2MR bracelet)|Hybrid circuits crucial for the generation of the electromagnetic field had been removed.
45366901|NCT02573987|Drug|Oxygen/nitrous oxide equimolar mix|an experimental strategy inhalation by means of a breathing mask diffusing MEOPA
45845957|NCT04546230|Procedure|Low-Thoracic Epidural Anesthesia|"Under aseptic conditions and local anesthesia, an epidural catheter will be inserted using the Prefix Epidural Anesthesia Tray with an 18 G Tuohy needle & a 20 G catheter at the T7-8 or T8-9 intervertebral space. The epidural catheter will be threaded leaving 3 cm within the epidural space and tapped in place.~Using a mixed preparation of isobaric Bupivacaine 0.5% with Fentanyl 2 μg per ml volume, a bolus dose of 5-10 ml will then be given via the epidural catheter, followed by 5-10 ml/hr as a continuous infusion to be started 1 hour later & continued throughout the procedure."
45845958|NCT04546230|Procedure|General Anesthesia|General anaesthesia will be induced with intra-venous administration of Fentanyl (2 μg/kg), Propofol (2 mg/kg), Atracurium (0.5 mg/kg) and Lidocaine (1 mg/kg). After tracheal intubation, balanced anaesthesia will be maintained with isoflurane in oxygen & infusion of atracurium at a rate of 0.5 mg/kg/hr; and mechanical ventilation will be provided.
46051575|NCT02827773|Other|Talking Pill Bottle|Made by Talking Rx
46051576|NCT04681872|Procedure|Destruction of Marshall bundles|Destruction of Marshall bundles by ethanol 96% infusion (2 separate injections of 5ml on 1 minute each) followed by ablation of the distal coronary sinus bundles, the ridge and the saddle.
46051577|NCT04681872|Procedure|Pulmonary veins isolation|Achievement of a wide disconnection of the right and left pulmonary veins.
46051578|NCT04681872|Procedure|Linear ablation in the left and right atria|Ablation of the mitral, the roof, and the cavo-tricuspid isthmus
45366902|NCT02573987|Drug|Lidocaine|standard strategy by local injection anesthesia of lidocaine
45366903|NCT00901940|Biological|Meningococcal (Groups A, C, Y and W-135) Conjugate|2 x 0.5 mL dose
45366904|NCT00901940|Biological|Meningococcal polysaccharide A, C, Y and W135 and Menveo|1 x 0.5 mL dose of ACWY Vax, 1 x 0.5 mL dose of Menveo
45366905|NCT00906308|Drug|MF101 5 g/day|PO (orally) 5 g/day (administered twice a day, BID) for up to 12 weeks
45691105|NCT02979717|Dietary Supplement|High protein, high fiber dietary supplement|
45366906|NCT00906308|Drug|Placebo|PO (orally) matched placebo (administered twice a day, BID) for up to 12 weeks
45366907|NCT00906308|Drug|MF101 10 g/day|PO (orally) 10 g/day (administered twice a day, BID) for up to 12 weeks
45366908|NCT00906386|Drug|Varenicline|oral, 1 mg twice daily, 12 weeks
45366909|NCT00906386|Drug|placebo|oral, 1 mg twice daily, 12 weeks
45845959|NCT04535310|Device|Precision1® Daily Disposable Contact Lens|Soft, spherical contact lens used to correct distance vision.
45366910|NCT00722501|Drug|ERB-257|
45366911|NCT00722501|Other|placebo|
45366912|NCT00722579|Device|PRESILLION cobalt chromium stent|PTCA with bare-metal stent
45366913|NCT04067687|Other|Palliative home visit|a 3-month home visit, providing two-way communication between a trained health worker and patients with or without their parents were conducted as the intervention (report by proxy or self-report). Interventions were given in 6 sessions (1 session every 2 weeks) focusing on problems solving education, symptoms management, self-care, communication, decision making, and long-term care plan assistance.
45366914|NCT04035902|Drug|Ferric carboxymaltose|Ferric carboxymaltose is administered during surgery
45366915|NCT04035902|Drug|control|Ferric carboxymaltose is not administered
45366916|NCT00894842|Drug|Pregnenolone|Pregnenolone 50 mg BID x 14 days, followed by Pregnenolone 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Pregnenolone 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
45366917|NCT00894842|Drug|Placebo|Placebo 50 mg BID x 14 days, followed by Placebo 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Placebo 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
45366918|NCT02571569|Drug|BAY1093884|Single escalating dose with a starting dose of 0.3 mg/kg for the first cohort. Drug will be administered via IV infusion over 1 hour and SC injection. Based on safety, PK and PD results the doses for the other cohorts will be determined.
45366919|NCT02571569|Drug|BAY1093884|Multiple dose cohort with a single 150-mg SC injection once a week for 6 weeks.
45366920|NCT00906620|Other|QPR: question, persuade and refer (SEYLE)|"The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies."
45366921|NCT02539472|Other|Blood sampling|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
45366922|NCT00902252|Device|Usual|All subjects will wear their usual pouching system for the first 21 days of the study.
45483844|NCT01335711|Drug|ChronVac-C + SOC|"IMP: I.m. administration of 500 μg plasmid DNA vaccine CHRONVAC-C (solution for injection) administered i.m. in combination with electroporation using MedPulser® DDS on 2 occasions with 4 weeks in between followed by standard of care (SOC) initiation after 14 - 42 days.~SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of < 75 kg and 1200 mg/day for subjects with a BW of > 75 kg)"
45691106|NCT02979717|Other|Low protein, low fiber comparator|
45366923|NCT00902252|Device|Natura®|All subjects will wear the Natura® Flexible Skin Barrier with Flange (Stomahesive® or Durahesive®) in the US and Natura® Stomahesive® Flexible Skin Barrier with Flange in Europe for 14 days.
45366924|NCT00902252|Device|Vitala™|"After the successful completion of Stages 1 and 2, subjects will enter the ramp up schedule to allow the subject to adjust to the device. This consists of weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 36 to 42), followed by 6 hours of daily wear time per week (Day 43 to 49), followed by 8 hours of daily wear time (Days 50 to 56) and progressing to 12 hours of daily wear per week (Day 57 to 215)."
45366925|NCT00902408|Dietary Supplement|Lutein enriched eggs|1 year of daily enriched lutein eggs or placebo
45366926|NCT00713687|Drug|Gemcitabine, Oxaliplatin, Photodynamic therapy (Photosan®)|"Photodynamic therapy (PDT) after successful drainage:~Photosan® 2 mg/kg i.v. 48 hrs before laser activation~9 cycles of GemOx chemotherapy (start 4 weeks after PDT):~Gemcitabine 1000 mg/m² 100 min infusion on day 1 of chemotherapy~Oxaliplatin 100 mg/m² 2h infusion on day 2 of chemotherapy~iteration every 14 days~afterwards 4 weeks intermission~Iteration of 1. and 2. in case of good compatibility"
45366927|NCT02539550|Drug|Placebo|Placebo
45366928|NCT02539550|Drug|PF-06266047|PF-06266047
45366929|NCT00717431|Procedure|Hippocampal Electrical Stimulation|Surgical Implantation of electrode and stimulator
45366930|NCT02540876|Drug|Ilorasertib|Given PO
45366931|NCT02540876|Other|Laboratory Biomarker Analysis|Correlative studies
45366932|NCT04353791|Drug|OST-122|Active dose
45366933|NCT04353791|Drug|Placebo|Placebo
45366934|NCT00894920|Dietary Supplement|biotin|capsule approximately 30 mcg daily 21 days
45366935|NCT00894920|Dietary Supplement|biotin|capsule 300 mcg daily 21 days
45691107|NCT04145193|Drug|Standard of Care - mFOLFOX6|Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).
45366936|NCT00722735|Drug|Finafloxacin|Finafloxacin tablets, 300 mg b.i.d., oral administration; Ciprofloxacin placebo capsule, 1 capsule b.i.d.,oral administration; duration: 3 days
45366937|NCT00722735|Drug|Ciprofloxacin|Finafloxacin placebo, 6 tablets b.i.d., oral administration; Ciprofloxacin capsule, 250 mg b.i.d., oral administration; duration: 3 days
45366938|NCT00902642|Behavioral|an eight day university training course designed to integrating psychosocial factors in clinical practice on a patient level|an eight day university training course on psychosocial factors for physical therapists
45366939|NCT00722813|Other|Survey|To determine patient preference for the two tests CT angiography (CTA) and catheter coronary angiography (CCA).
45691108|NCT04145193|Drug|E1 - mFOLFOX and durvalumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)"
45845960|NCT04534218|Drug|Regorafenib|"For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle."
45845961|NCT04534218|Drug|Cyclophosphamide|50 mg per os, daily, for 6 months
45366940|NCT04067531|Drug|treatment of BV with first Deqularum and then direkt after with vaginal clindamycin|All patients will get the same treatment
45845962|NCT04534218|Drug|Capecitabine|625mg/m²/orally twice daily continuously for 6 months
45845963|NCT04534218|Drug|Aspirin|75 mg orally and daily until progression
45845964|NCT04531878|Drug|4-Phenylbutyrate|4-phenylbutyrate therapy will be started at a daily dose of 200 mg kg/d divided in 2 oral doses of sodium phenylbutyrate (AMMONAPS, Swedish Orphan Inter AB). In order to get the best effect, the dose will be increased up to a maximum of 500 mg kg/d.
45366941|NCT00606632|Drug|124-Iodine-cG250 (124I-cG250)|i.v. and PET/CT scan 4+/-2 days after administration
45366942|NCT00606632|Procedure|CT|contrast enhanced CT scan
45366943|NCT00713765|Drug|AZD3480|18 total doses of 40 mg, on days 1-18
45366944|NCT00713765|Drug|Donepezil|One single dose of mg on day 5
45366945|NCT00717587|Drug|motexafin gadolinium|
45366946|NCT00717587|Drug|sunitinib malate|
45366947|NCT00717587|Genetic|comparative genomic hybridization|
45366948|NCT00717587|Genetic|gene expression analysis|
45366949|NCT00717587|Genetic|mutation analysis|
45366950|NCT00717587|Genetic|polymorphism analysis|
45366951|NCT00717587|Other|immunohistochemistry staining method|
45366952|NCT00717587|Other|iodine I-124 girentuximab|
45366953|NCT00717587|Other|laboratory biomarker analysis|
45366954|NCT00717587|Other|pharmacological study|
45366955|NCT00717587|Procedure|adjuvant therapy|
45483845|NCT01335711|Drug|SOC|SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of < 75 kg and 1200 mg/day for subjects with a BW of > 75 kg)
45691109|NCT04145193|Drug|E2 - mFOLFOX6, durvalumab and oleclumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Oleclumab 3,000 mg IV Q2W x5 then Q4W (Day 1 of every 14-day cycle through cycle 4 then Day 1 of every other 14-day cycle)"
45691110|NCT04145193|Drug|E3 - mFOLFOX6, durvalumab and monalizumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Monalizumab 750 mg IV, Q2W (Day 1 of every 14-day cycle)"
45483846|NCT00092625|Drug|MK0653, ezetimibe|
45691111|NCT04021563|Drug|SR419|Ascending single and multiple doses of SR419 orally
45483847|NCT00092625|Drug|Comparator: ezetimibe, placebo|
45691112|NCT04021563|Drug|Placebo|Ascending single and multiple doses of placebo orally
46051579|NCT02826993|Device|CCE in incomplete Colonoscopies|When the initial colonoscopy has failed, participants are invited to ingest a CCE on the day prior to their subsequent CT colonography. Thus, the CCE and CT will be compared within subjects for their ability to identify and estimate sizes of polyps
45483848|NCT04135846|Drug|Doxazosin|16 mg or maximum tolerated dose (MTD)
45483849|NCT04135846|Drug|Placebo|Matching placebo
45483850|NCT04477863|Other|Follow-up Interview|Non Applicable
45483851|NCT01333371|Procedure|Surgical Repair of Distal Radius Fracture|2 surgical methods to treat Distal Radius Fracture
46051580|NCT02829255|Other|altitude exposure|altitude exposure
45483852|NCT01333449|Drug|Decitabine|20mg/m^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
45366956|NCT00717587|Procedure|neoadjuvant therapy|
45366957|NCT00717587|Procedure|therapeutic conventional surgery|
45483853|NCT02809677|Other|Non-Interventional|This is a 52 week non-placebo controlled and non-randomized clinical research study to see whether treating Major Depressive Disorder (MDD) in caregivers of children with asthma will improve asthma outcomes in children. Caregivers may choose to receive an antidepressant medication that is considered standard medical care for MDD, or may opt out of antidepressant treatment. No treatment is withheld from participants and no placebos are used, thus there is no active intervention in this study.
45691113|NCT03021837|Other|antenatal corticosteroid|Will look at maternal glucose level after corticosteroids
45691114|NCT04765839|Other|Educational, culturally appropriate COVID-19 messages|Educational, culturally appropriate COVID-19 messages will be developed and shared by RHCP.
45845965|NCT04509414|Drug|Dexmedetomidine|For dexmedetomidine group after ramdomization, an intranasal dose of 2ug/kg dexmedetomidine will be administrated.
45845966|NCT04509414|Drug|Midazolam|For midazolam group after ramdomization, an intranasal dose of 0.2mg/kg midazolam will be administrated.
45845967|NCT04480554|Drug|Methadone|Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone syrup (MET), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
46051581|NCT04244331|Diagnostic Test|CCO|Determination of COO in tumor biopsies from patients with GBDD using the Lymph2Cx assay using NanoString tectology
46051582|NCT02829021|Device|FLIR ThermaCAM P-65|Women recalled for assessment after positive screening mammography were offered dynamic infrared thermography before clinical mammography and further tests.
45366958|NCT00902720|Other|Tissue sample storage|The tissue sample is frozen and held at -140 degrees at the in vitro fertilization lab at the Center for Health and Healing at OHSU.
45366959|NCT00713843|Other|Manual Therapy Utrecht|Manual Therapy (6 weeks).
45366960|NCT00713843|Other|Physical Therapy|Physical Therapy (six weeks).
46051583|NCT00785629|Drug|Calcium acetate|
46051584|NCT00785629|Drug|Lanthanum Carbonate|
46051585|NCT00785629|Drug|Sevelamer Carbonate|
46051586|NCT00785629|Drug|Placebo|
46051587|NCT05097183|Procedure|Accurate Commissural Alignment (ACA)|Software based, computed tomography analysis that allows planification of accurate commissural alignment of TAVR by inserting the delivery system in a patient-specific degree of rotation.
45366961|NCT00894998|Biological|heparin sodium - Cristália|Heparin sodium 5000UI - Cristália
45366962|NCT00894998|Biological|Heparin sodium APP|Heparin Sodium 5.000 USP - APP
46051588|NCT00916344|Device|EVIA Pacemaker|patient has standard indication for pacemaker therapy
46051589|NCT00915733|Drug|cilostazol|100 mg twice daily for at least 1 month
46051590|NCT00915733|Drug|clopidogrel (Plavix)|150 mg once daily (high maintenance dose group arm), 75 mg once daily (triple group arm)
46051591|NCT00915733|Genetic|CYP2C19|CYP2C19 polymorphism study: Two CYP2C19 polymorphisms, CYP2C19*2 (rs4244285, c. 681G>A, p.P227P), and CYP2C19*3 (rs4986893, c. 636G>A, p. W212X), are investigated using the ABI SNaPshot reaction and the ABI 3100 automated genetic analyzer.
46051592|NCT00915733|Drug|aspirin (Acetylsalicylic acid)|aspirin 100 mg qd
45691115|NCT04145271|Device|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) is a minimally invasive damage control procedure for life-threatening abdominal and/or pelvic haemorrhage. It involves temporary occlusion of the aorta with an endovascular balloon, providing proximal control to the site of vascular injury whilst supporting cerebral and myocardial perfusion
46051593|NCT04245969|Device|Experimental: 448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus|448kilohertz capacitive resistive monopolar radiofrequency will be applied on the shoulder and thoracic area
46051594|NCT04245969|Other|Sham comparator|A simulation of 448kilohertz capacitive resistive monopolar radiofrequency will be carried out to make believe the patient to be treated through this equipment.
46051595|NCT04245969|Other|No intervention|These participants will be assessed at the same time than the rest of participants. They will not receive any kind of treatment.
45366963|NCT02572895|Dietary Supplement|Cranberry extract|The aim of this clinical trial is to assess efficacy of an optimal dose of cranberry extract compared to a control dose on mean number of new UTIs for a 6-month period follow-up in women. Participants will be randomly assigned to the optimal dose or control dose treatment at their first visit at the Institute of Nutrition and Functional Foods. This intervention includes three visits at 0, 12 and 24 weeks. At the first visit, women will have to complete questionnaires to provide sociodemographic, medication and natural health products, health antecedents and quality of life information and to document risk factors related to UTIs. A 24-hour recall questionnaire about consumption of PACs will also be completed. A urinary sample analysis and culture as well as a pregnant test will also be performed. Compliance regarding capsules' intake and potential side effects will be documented. The completion of questionnaires and urinary measurements will be repeated at weeks 12 and 24.
45366964|NCT00717665|Device|Home blood pressure tele-management system.|Scheduled blood pressure monitoring with transmission of information to a central server for processing and disbursement.
45366965|NCT00717665|Other|Usual care.|Patient self-monitoring of blood pressure with results taken by patient to the doctor at scheduled visits.
45483854|NCT02789007|Other|Assess the impact of parabolic flight|"MRI testing will be performed using a 3T MRI facility in Bordeaux close to Novespace (CHU Pellegrin).~Spatial cognition will be assessed using a battery of in-house virtual paradigms General cognitive performance testing will include a wide range of cognitive functions, and particularly executive control using the Cognition Battery Mental status will be assessed on a tablet computer using a visual analogue scale Vigilant attention will be determined using the 3-min Psychomotor Vigilance Test (PVT) Blood samples (5 mL per collection) will be collected prior to neuroimaging by venepuncture"
45483855|NCT01333605|Drug|IGEV|Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles.
45483856|NCT05182671|Other|Scales and measurements for bladder and bowel dysfunction, pelvic angle, proximal hip strength, femoral hip anteversion|"Assessments Children whose physical examination has been completed and diagnosed with BBD will be evaluated with following assessments.~Demographic Data Form Questionnaire Forms Dysfunctional Voiding and Incontinence Scoring System Bladder Diary Bowel Diary EMG-uroflowmetry Ultrasonography~Post Voiding Residual Measurement:~Bladder wall thickness~Pelvic Floor Muscle Activation Measurement:~Pelvic Floor Muscle Strength Assessment:~Hip agonist-antagonist muscle ratios Pelvic angle measurement Femoral anteversiyon angle measurement~Femoral internal and external rotation angle:"
45483857|NCT05186103|Other|observation|The assessment combined a parent-reported questionnaire (the Participation in Childhood Occupation; PICO) alongside the Pediatric Evaluation of Disability Inventory (PEDI self-care) and a Performance-based task, the Washing Hands Structured Observation (WashHO).
45596600|NCT05647291|Device|extracorporeal Shock wave therapy|Two thousand pulses with a frequency of 6 Hz and a pressure of 3 bar were applied to patients with an Auto Wave 695 (Mettler electronics, USA) brand device. Patients underwent two sessions of ESWT per week, for two weeks, adding up to a total of 4 sessions.
45596601|NCT05647291|Drug|Corticosteroid injection|40mg/1ml methylprednisolone, two sessions once a week
45691116|NCT04144569|Drug|PD-1 Combined With Pyrotinib|PD-1 Combined With Pyrotinib
45691117|NCT04141215|Biological|BIOBank bone paste|BIOBank bone paste (PPT322)
46051596|NCT02828865|Device|Irreversible Electroporation (IRE) System|
46051597|NCT02604043|Other|pH monitoring|After endotracheal intubation, the impedence/pH probe will be placed under indirect visualization using a McGrath MAC video laryngoscope directly above the vocal cords. The sensor will remain in place for the duration of the surgery or for 24 hours in ICU patients. At that time, the device will be manually removed by a member of the study staff.
46051598|NCT02604043|Other|accelerometer monitoring|Patient position will be continuously monitored with the accelerometer for the duration of the pH monitoring period.
45366966|NCT00713921|Drug|Fesoterodine Oral Product|After urological and neurological evaluation, those patients who meet he US approved indications for prescribing will be placed on a regimen of Toviaz 4 mg/day taken once daily with liquids and swallowed whole. The Toviaz dose may be increased to 8 mg/day if there is not therapeutic response on the 4 mg/day.
45483858|NCT05182515|Drug|Therapeutic plasma exchange|"Plasma exchange techniques reported in COVID-19 vary from study to study. No consensus exists on the use of a specific technique.~The use of a central venous catheter will be left to the discretion of investigators. If so, central venous catheter will be inserted through the internal jugular or femoral route under ultrasound control by a trained operator. After radiographic control of the position of the catheter and the absence of complications in the placement of the catheter, plasma exchanges will be carried out.~Three plasma exchanges of 1.5 plasma volume will be carried out every 48 hours on D1, D3 and D5. Plasma volume will be assessed by this equation VP = (1-Hct)x70xweight Body(measured). The substitution volume will be 5% albumin as first intervention. The use of a hemofiltration or centrifugation technique will be left to the discretion of each center."
45483859|NCT05182437|Radiation|LINAC-based Stereotactic Radiotherapy|Target definition: the target volume is defined as the epileptogenic zone (EZ) on all (non) invasive examinations (e.g. 3, 7 Tesla MRI or Stereo-EEG) of the presurgical path. Planning target volume (PTV) = GTV. A single fraction SRT with a prescribed isotoxic dose of 24 Gy to the 100% surrounding isodose. Dose is depending on the proximity and maximum tolerable dose to the radiosensitive organs at risk and EZ volume resulting in a V12<= 10 cc reducing the risk on radionecrosis.
45691118|NCT04141215|Biological|BIOBank cortico-cancellous bone powder|BIOBank cortico-cancellous bone powder (PPT6)
45691119|NCT04141059|Dietary Supplement|Oligopin|Oligopin capsules composition is :100 mg Oligopin®, 150 mg Maltodextrin, 1.5 mg Mg stearate.
45691120|NCT04141059|Dietary Supplement|Placebo|Placebo capsules composition is: 250 mg Maltodextrin and 1.5 mg Mg stearate
45691121|NCT04146909|Diagnostic Test|Hyperinsulinemic-euglycemic clamp|After an overnight fast and an equilibration period lasting 2 hours, the 2-step euglycemic-hyperinsulinemic clamp study will be performed. A primed-continuous infusion of regular insulin will be given at 8 mU/(m2 × min) during the first 2 hours, and increased to 40 mU/(m2 × min) for the subsequent 2 hours. Plasma glucose levels will be measured every 5 min, and a variable glucose infusion will be initiated to maintain levels at ∼90 mg/dl. Plasma samples will be drawn at baseline and throughout the infusion period for measurement of isotope enrichment, insulin, NEFA, glycerol turnover, and additional hormones which may be altered with lactation. Approximately 160 mL of blood will be drawn at this visit.
45691122|NCT04142697|Behavioral|Heading direction adaptation|Will adapt subject's perceived heading direction using exposure to visual environments that include rotation and situations where visual and inertial heading direction are systematically offset.
46051599|NCT05660655|Drug|Baricitinib 4 MG|baricitinib 4 mg once daily
46051600|NCT05660655|Drug|Baricitinib 2 MG|baricitinib 2mg once daily in group A
45366967|NCT04067453|Other|Fatiguing contractions|10 sustained external anal sphincter contractions with maximal voluntary contraction of 20 seconds followed by 10 seconds of resting.
45366968|NCT05658263|Dietary Supplement|Standard Diet|Participants receiving only standard of care (SOC) nutrition advice, which is SOC Dietary Instructions, as provided by routine surgical consults and one protein shake per day for 4 weeks prior to surgery (SOC).
45366969|NCT05658263|Dietary Supplement|BIG MACS Diet|Participants will be instructed to consume the study diet, referred to as the 'BIG MACS Diet' and one protein shake per day for 4 weeks prior to surgery (SOC). Following surgery, participants will continue to follow the BIG MACS Diet for an additional four weeks, with solid food reintroduction after surgery as early as tolerated.
45483860|NCT02881047|Device|CO2 Laser|Perform ablative fractional resurfacing using a 10,600nm carbon dioxide (CO2) laser targeted to thickened, sclerotic plaques causing range of motion limitation and contracture across joints.
45483861|NCT02881047|Radiation|Ultrasound|Patients will undergo ultrasound of the planned treatment site to measure skin thickness and blood flow via Doppler ultrasound.
45483862|NCT02881047|Diagnostic Test|Skin Biopsy|standard 4mm punch biopsy of the skin at the planned treatment site for histologic assessment of skin thickness and sclerosis.
45483863|NCT05182281|Device|Whole Body Vibration and Infrared Therapy|Patients in the whole body vibration and infrared group received vibration therapy with a frequency of 60 Hz and amplitude of 0.5-2 mm and infrared therapy at a wavelength of 550-950 nm. Whole body vibration and infrared treatment were applied with the Power Andullator (HHP, CE0197, Germany) device.
46051601|NCT00913770|Behavioral|Brief Negotiation Interview (BNI)|Brief Negotiation Interview (BNI) is a manual-guided therapy that is designed to be feasible in the ED setting. The purpose of the BNI is to assist patients in recognizing and changing their drug use and HIV risk behaviors. It combines techniques based on motivational interviewing and a stage-model of change. The main goal of the interview is to decrease the subject's ambivalence about signing up for a formal drug treatment program.
46051602|NCT00913770|Drug|Buprenorphine Initiation|
46051603|NCT02602639|Device|Functional electrical stimulation rowing (Odstock 4 channel neuromuscular stimulator with Concept 2 Rower)|Participants will strengthen their quadriceps and hamstrings using electrical stimulation for up to 12 weeks (using an Odstock 4 channel neuromuscular stimulator). Then participants will use a seated rower (Concept 2 Rower, fitted with a backrest that allows those with spinal cord injury to engage in rowing) in conjunction with the electrical stimulation for 12-24 weeks.
46051604|NCT04617366|Other|Individualized rTMS strategy|It will adjust the rTMS parameters based on the results of fNIRS.
45483864|NCT05182281|Device|Infrared Therapy|Patients in infrared therapy group received infrared therapy at a wavelength of 550-950 nm.Infrared treatment were applied with the Power Andullator (HHP, CE0197, Germany) device.
45483865|NCT05182281|Other|Classical Treatment|1000 mg Ca and 880 IU vitamin D treatment were given
45691123|NCT03022227|Other|telemedicine|telemedicine applied to adult cochlear implant users' follow-up
45483866|NCT04853199|Drug|Quercetin|Each patient should receive one tablet twice a day 30 minutes before the meal
45483867|NCT04853199|Drug|Placebo|Each placebo capsule contains 150 mg of microcrystalline cellulose and 1.5 mg of magnesium stearate.
45483868|NCT01337895|Other|Low dairy|No more than 1 serving per day
45483869|NCT01337895|Other|High dairy|4 or more servings per day
45483870|NCT01341717|Drug|Sitagliptin|100 mg once daily for 6 months
45483871|NCT01341717|Drug|Glimepiride|1 mg/2 mg/3 mg once daily
45483872|NCT01341717|Drug|Metformin|>=1000 mg twice daily
45691124|NCT04747743|Other|a self structured questionnaire|A self structured questionnaire to assess knowledge of skeletal muscle use in dental practice
45845968|NCT04480554|Drug|Buprenorphine/naloxone|Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone tablets (Suboxone(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
46051605|NCT04617366|Other|Traditional rTMS strategy|The patients will always be given low-frequency rTMS to contralesional M1.
46051606|NCT00780559|Behavioral|Tailored Diet and Physical Activity|Subjects will receive an individually tailored diet and physical activity enhancement program
46051607|NCT00780559|Behavioral|Standard of Care|Subjects will be told to reduce their baseline weight by 7% and exercise for 150 minutes/week. There is no tailored, directed program.
46051608|NCT02826291|Device|RD-100i, OSNA|quantitative reverse transcription polymerase chain reaction (qRT-PCR) cytokeratin-19 detection in specimen (sentinel lymph node)
45483873|NCT01341717|Drug|Insulin|TDD > 10 IU once/twice daily
45483874|NCT03157089|Drug|Afatinib|Film-coated tablet
45483875|NCT03157089|Drug|pembrolizumab|Solution for infusion
45691125|NCT04144335|Biological|N-803 and bNAbs|Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle) and bNAbs will be given every 9 weeks.
46051609|NCT02826057|Other|Targeted temperature management (33 degree Celsius)|
46051610|NCT02602249|Biological|MUC1-gene-DC-CTL|MUC1-gene-DC-CTL will be used against tumor cells.
46051611|NCT02602249|Biological|MUC1-peptide-DC-CTL|MUC1-peptide-DC-CTL will be used against tumor cells.
46051612|NCT00912912|Drug|Sunitinib Malate|50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.
45845969|NCT04480554|Drug|XR-Naltrexone|Participants will receive a 48-week integrated treatment program for opiate use disorder with monthly extended-release naltrexone (Vivitrol(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
45366970|NCT02571335|Behavioral|Intensive Training|"Week 1: Ratio of continuous and interval training of 2:1. Entry point at day one with 20 min of continuous, physiologically defined heart rate controlled cycling at 50-60 rounds per minutes at 75% of HRpeak.~Resistance training is performed with 70% of the subjective-felt 1-round maximum with three sets and 10-12 repetitions and three exercises for the upper and lower extremities.~Week 2 Progression of endurance training: 4x5 minutes with 2 Minutes between each interval performed at 80% of HRmax Progression resistance training: 75% of the subjective-felt 1-round maximum with three sets and 8-10 repetitions and three exercises for the upper and lower extremities.~Week 3 Same as week 2."
45366971|NCT02571335|Behavioral|Normal Training|The control intervention is the normal rehabilitation program of the Valens clinic.
45845970|NCT04475250|Device|Tetragraph (TM) NMT Monitor|TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
45845971|NCT04456998|Drug|GB002 (seralutinib)|Capsule containing GB002 (seralutinib)
45845972|NCT04456998|Drug|Placebo|Matching capsule containing placebo
46051613|NCT00889005|Other|Telephone Based Cognitive Behavioral Therapy|Five biweekly sessions of telephone based, trauma focused cognitive behavioral therapy with homework assignment
45845973|NCT04456998|Device|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 (seralutinib) or placebo delivery
46051614|NCT04104997|Drug|5% GLH8NDE|5% GLH8NDE as eye drops
46051615|NCT04104997|Drug|Placebos|Placebo as eye drops
45483876|NCT03635541|Other|observational group of NAFLD|there's no intervention for patients for it is a observational study
45366972|NCT04067375|Other|Clinical data collection.|The following clinical data will be collected; maternal baseline characteristics, delivery related data, neonatal outcome, neonatal bleeding signs.
45366973|NCT02571413|Other|score before teaching|score the check-point of correct INCS usage before teaching
45845974|NCT04430400|Diagnostic Test|integrated diagnostic algorithm|"Diagnostic management was as follows. An acute aortic syndrome will be considered to be ruled out without advanced aortic imaging, in clinically stable patients at low clinical pre-test probability (defined by ADD score ≤1) and a D-dimer level <500 ng/mL FEU. The other patients will be subjected to advanced aortic imaging for conclusive diagnosis.~Attending physicians will be allowed to derogate from protocol indications based on the clinical scenario and clinal gestalt, irrespective of patient's participation to the present study."
46051616|NCT04600596|Behavioral|Recording of food intake.|The food intake is recorded with a photographic food recognition mobile application. The total energy expenditure is recorded with the DLW method.
46051617|NCT05178537|Other|AAS users|no intervention
46051618|NCT02824653|Biological|Mesenchymal Stem Cells|Allogenic Human Bone Marrow Mesenchymal Stem Cells (ex-vivo expanded in pooled human platelet lysate)
46051619|NCT04714944|Dietary Supplement|Placebo|Supplementation period 12 weeks
46051620|NCT04714944|Dietary Supplement|Whole fiber product|Supplementation period 12 weeks
45483877|NCT03158727|Biological|Cx611|Two intravenous infusions, one on day 1 and another one on day 3.
45483878|NCT03158727|Other|Placebo|Two intravenous infusions, one on day 1 and another one on day 3.
45366974|NCT02571413|Other|score immediately after teaching|score the check-point of correct INCS usage immediately after teaching
45483879|NCT01338051|Biological|Gardasil|"Gardasil will be administered to 10-13 year old daughters and granddaughters of study participants according to manufacturers recommended schedule of administration. Gardasil is supplied as 0.5-mL suspension for intramuscular injection at the following schedule: 0, 2 months, 6 months.~DOSAGE FORMS AND STRENGTHS • 0.5-mL suspension for injection as a single-dose vial and prefilled syringe."
45483880|NCT01338129|Dietary Supplement|vitamin c|1000 mg of vitamin c for 45 days
45483881|NCT01338129|Drug|placebo|placebo pills
45366975|NCT02571413|Other|score 3 months after teaching|score the check-point of correct INCS usage 3 months after teaching
45483882|NCT05181969|Device|Dextran sulfate absorption (LIPOSORBER® D - Kaneka Pharma Europe NV)|Lipoprotein apheresis Method I
45366976|NCT00713999|Drug|Treatment with anti-STI and anti-schistosoma regimens|Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and breastfeeding women) Anti-schistosoma regimen: Praziquantel 40mg/kg
45845975|NCT04417764|Procedure|Transcatheter arterial chemoembolization|The patients are plan to operated by Transcatheter arterial chemoembolization(TACE).
46051621|NCT00779857|Device|AtriCure LAA Exclusion System|Exclusion of the left atrial appendage using the AtriCure LAA Exclusion System
45366977|NCT04072601|Drug|Placebo oral tablet|Lactose monohydrate 50 mg, potato starch 45 mg, Gelatine 1,2 mg, Magnesium stearate 0,5, Talc 4,5 mg
45845976|NCT04417764|Biological|PD-1 knockout engineered T cells|The PD-1 knockout engineered T cells are prepared from autologous origin using CRISPR Cas9 technology. The patients are plan to receive 3 or more cycles of PD-1 knockout engineered T cells infusion by percutaneous fine needle liver puncture with a 4-weeks interval. A total of 1 to 3× 10^9 PD-1 edited T cells will be infused each cycle. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT or they withdrew consent.
45845977|NCT04398966|Device|Prostatic Artery Embolization (HydroPearl® compressible microspheres)|Embolic material
45845978|NCT04358406|Drug|Recombinant human plasma gelsolin (Rhu-pGSN)|Intravenous administration of rhu-pGSN at 12 mg/kg, 3 doses
45366978|NCT04072601|Drug|Atorvastatin 10mg|Tablet, can be adjusted to 2 tablets if tolerated
45845979|NCT04358406|Other|Placebo|Normal saline in matched volume to treatment arm. Undistinguishable in syringe.
45845980|NCT04320342|Drug|Beclomethasone Dipropionate|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
45845981|NCT04320342|Drug|Glycopyrronium Bromide|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg
45845982|NCT04320342|Drug|Formoterol Fumarate|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
45845983|NCT04307862|Drug|ZEP-3Na 0.1%|The Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase
45366979|NCT00717821|Drug|Methoxy Polyethylene Glycol-epoetin Beta|Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will receive monthly injections of methoxy polyethylene glycol-epoetin beta, with the starting dose of 120 or 200 micrograms calculated from the last weekly dose of epoetin beta or darbepoetin alfa previously administered, using the same route of administration (SC or IV). Thereafter, when the hemoglobin concentration will increase or decrease in a clinically significant amount, a dose adjustment will be performed according to specific provided guidance. Total duration of treatment will be up to 48 weeks.
45483883|NCT05181969|Device|Lipid filtration (Octo Nova®, Diamed Medizintechnik)|Lipoprotein apheresis Method II
46051622|NCT02825901|Dietary Supplement|Placebo|
46051623|NCT02825901|Dietary Supplement|Djulis-Buckwheat|
46051624|NCT02825901|Dietary Supplement|Buckwheat|
46051625|NCT04104919|Drug|Brivoligide Injection 660 mg/6 mL|Single preoperative intrathecal injection
46051626|NCT04104919|Drug|Placebo 6 mL|Single preoperative intrathecal injection
45366980|NCT00717821|Drug|Epoetin Beta|Participants who are receiving SC or IV epoetin beta will continue to receive the treatment at the same dose, same administration intervals, and the same route of administration. When necessary, dose adjustments will be performed according to SmPC. Total duration of treatment will be up to 48 weeks.
46051627|NCT04102891|Other|Microbiota modulation diet|The Collect&Go shopping carts of the 400 participants will be adapted by replacing food products by healthier alternative ones based on the Flemish food-based dietary guidelines and the microbiota modulation diet guidelines for the control and study arm respectively. Based on these guidelines, and the habitual dietary pattern and level of food literacy of the participant, personalized dietary advice will be provided. A dietitian helpline will be available for further nutritional issues as well.
45691126|NCT04144335|Biological|haNK™ Cells|Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle), bNAbs will be given every 9 weeks, and haNK cells administered on the same day as each infusion of N-803.
46051628|NCT04241913|Behavioral|Mom Power Intervention|Mom Power is a 10-week therapeutic intervention for at-risk families that incorporates elements of several evidence based practices. It combines didactic material with mindbody self-care skills and in vivo practice to improve the quality of attachment between parent and child, and to reduce the psychopathology of at-risk parents. The child team component provides each child with one-on-one care focusing on meeting the child's social-emotional needs and providing attachment-related experiences within a developmental framework.
45366981|NCT00717821|Drug|Darbepoetin Alfa|Participants who are receiving SC or IV darbepoetin alfa will continue to receive the treatment at the same dose, same administration intervals, and the same route of administration. When necessary, dose adjustments will be performed according to SmPC. Total duration of treatment will be up to 48 weeks.
45366982|NCT00722891|Device|Purevision Lenses with ReNu Multiplus|Purevision lenses using ReNu Multiplus lens solution for 28 days
45366983|NCT00722891|Device|Purevision Lenses with Optifree RepleniSH|Purevision lenses using Optifree RepleniSH lens solution for 28 days
46051629|NCT04201275|Drug|HEC74647PA capsule|Capsule administered orally once daily
46051630|NCT04201275|Drug|placebo|HEC74647PA capsule matching placebo administered orally once daily
45366984|NCT03476369|Drug|Fentanyl|Premedicated with Fentanyl (at least 25mcg by IV)
45691127|NCT02707497|Drug|rhTPO|Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
45691128|NCT02707497|Drug|Placebo|The control group will not use any platelet-increased drugs.
45691129|NCT02704377|Other|Undergo HRV and wear accelerometer to assess therapy complications|Wear accelerometer undergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week
45366985|NCT03476369|Drug|Ticagrelor 90Mg Tablet|Ticagrelor administered crushed vs non-crushed
45366986|NCT00717899|Device|Spirometry (Pony spirometer)|Spirometry at rest
45366987|NCT02571257|Drug|Gemcabene|1-300 mg tablet, QD, 56 days
45366988|NCT02571257|Drug|Gemcabene|3-300 mg tablets, QD, 56 days
45366989|NCT02571257|Drug|Placebo|
45691130|NCT02704377|Procedure|Dual X-ray Absorptiometry|Undergo iDXA
45691131|NCT02704377|Other|Laboratory Biomarker Analysis|Correlative studies
45691132|NCT02704377|Other|Quality-of-Life Assessment|Ancillary studies
45366990|NCT04067297|Other|Lipid management toolbox|The intervention toolbox will include: 1) community-level report cards on lipid management (developed using an updated version of the 2016 CANHEART 'big data' registry of ~10.9 million adults created through linkage of 19+ population health databases) to distribute to family physicians, 2) printed and electronic patient education materials on cholesterol screening and management, 3) a new online clinical decision aid to facilitate shared decision-making between patients and their family physicians regarding statin utilization, 3) patient educational videos, and 4) physician educational videos and material.
45366991|NCT00714155|Other|Questionnaires, Physical Examination|Questionnaires, Physical Examination
45483884|NCT05181969|Device|Direct absorption of lipoproteins (DALI®; ADS 4008, Fresenius)|Lipoprotein apheresis Method III
45483885|NCT05181969|Device|Therasorb (TheraSorb® - LDL adsorbers, Miltenyi Biotec)|Lipoprotein apheresis Method IV
45483886|NCT05174481|Other|Early warning system for emergency department overcrowding|In this study, no interventions are performed.
45691133|NCT02704377|Other|Questionnaire Administration|Ancillary studies
45691134|NCT02702895|Behavioral|In-depth Interview (IDIs) or Focus Group Discussion (FGD)|
45691135|NCT04144257|Drug|[F-18]PBR06|PET radiopharmaceutical. Subjects will undergo [F-18]PBR06-PET (microglial activation).
45691136|NCT04144257|Drug|[C-11]Methylreboxetine|PET radiopharmaceutical. Subjects will undergo [C-11]MRB-PET (norepinephrine transporter binding).
45691137|NCT04147845|Other|Fractional Carbon Dioxide Laser|"The ablative fractional CO2 laser is delivered to the patients' scalp. The fractional ablative method is applied immediately before the topcial medication.~Laser treatment will be given to the affected area, and immediately after the treatment, the treatment solution will be dropped on the treated area and spread evenly"
45366992|NCT02572973|Other|Acoustic Neuromodulation (ANM)|The purpose of this study is test the safety of the Acoustic Neuromodulation (ANM) treatment and see what effects it has on your child's anxiety symptoms. Observation and anecdotal evidence suggest that this is an effective intervention for anxiety disorders. This is the first research study to test this theory, and could lead to more robust studies in the future. This study intends to assess the efficacy of this type of intervention for children with an anxiety disorder. As this is only a pilot study, the results will also inform the design and execution of future research on this treatment. We hope to add to the growing literature supporting novel treatment approaches for affected individuals.
45483887|NCT01315977|Dietary Supplement|Green tea|Each subject will take either green tea (2%w/v), or water, twice a day for twelve weeks, then wash out for twelve weeks and swap onto the other treatment (either green tea of water) for another twelve weeks in addition to their normal food and beverage intake
45483888|NCT00092157|Drug|MK0733, simvastatin|
45483889|NCT00092157|Drug|Comparator: simvastatin|
45366993|NCT00722969|Drug|sorafenib + erlotinib|sorafenib 400mg b.i.d oral Erlotinib 150 mg o.i.d oral
45366994|NCT04069325|Drug|simiaowan|pills, 6g twice daily (BID), oral, 12 weeks
45366995|NCT04069325|Drug|placebo|pills, 6g twice daily (BID), oral, 12 weeks
45366996|NCT04069325|Drug|febuxostat|tablets, 40 mg once daily (QD), oral, 12 weeks
45366997|NCT00723047|Procedure|Fibrin glue injection in fistula|
45366998|NCT03444779|Device|Tibial Tuberoplasty|Kyphoplasty ballon
45366999|NCT03444779|Device|Open technique|Cutaneous incision with submeniscal arthrotomy under guidance of a fluoroscope.
45367000|NCT00726791|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|Patients receive high frequency rTMS applied to the motor cortex (M1 area). The treatment protocol consists of 10 sessions of rTMS. At each session, patients receive 30 stimulation trains (10 Hz, 4 sec, 100% motor threshold) with 26 sec inter-train interval, resulting in a total of 1200 pulses per session.
45367001|NCT05374031|Other|descriptive study|descriptive study
45367002|NCT04069403|Other|Automated Reports on prescription patterns for their patients|de-identified aggregate reports
45367003|NCT05373797|Behavioral|Procedures performed on the experimental and control groups|Intervention Group:26 Control Group (n=26):
45367004|NCT05373641|Other|educational feedback|Educational feedback one week after based on pain documentation audit results.
45483890|NCT00089895|Drug|Eptifibatide (Integrilin)|intravenous; 180 mcg/kg bolus followed by infusion of 2 mcg/kg/min for 12 to 96 hours (or longer if necessary to complete the 18- to 24-hour post-PCI infusion period, or up to 120 hours in patients who proceed to CABG [coronary artery bypass graft]); second bolus of 180 mcg/kg administered 10 minutes after first bolus.
45483891|NCT00089895|Drug|Placebo|intravenous; delivery to match eptifibatide to maintain blind
45483892|NCT01335945|Procedure|Cryoablation|All subjects will receive cryoablation of the celiac plexus with Galil Medical cryoablation systems and needles under imaging guidance.
45483893|NCT05166681|Procedure|surgical wound suturing|single layer surgical wound suturing in comparison with the traditional multi-layer wound suturing
45483894|NCT05166291|Device|Comfort-in injection system|local anesthesia applyed with comfort-in injection system
45483895|NCT05166291|Other|traditional anesthesia|local anesthesia applyed with dental syringe
45845984|NCT04307862|Drug|ZEP-3Na 1%|The Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase, with optional 2 weeks of open label with ZEP-3Na 1%.
45845985|NCT04307862|Drug|Placebo Vehicle only|he Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase
45845986|NCT04307550|Drug|Isopropyl alcohol|10 inhalations of an isopropyl alcohol pad
45845987|NCT04307550|Other|Placebo|10 inhalations of a sterile saline pad
45498128|NCT03681444|Other|Low residue diet|"The Low Residue Diet is the same as the soft diet with the added limitation of milk to one pint. It provides foods that are easily digestible. It is often used as a transition diet from liquids to the general diet. Indigestible fiber is reduced by using tender cooked vegetables and ripe, canned or cooked fruits from which the tough skins and seeds have been removed. Tender meat or meat made tender in the cooking process is used, thus reducing the amount of connective tissue.~Adequacy: By following the recommended guidelines, the diet will be adequate according to the Recommended Daily Allowance.~Note: For patients with dentures this diet can be modified by the substitution of ground meat for whole meat and excluding all raw vegetables. Personal tolerances determine food choices; avoid foods that cause GI (gastrointestinal) distress prior to the admission even though that food may be on the foods included list."
45845988|NCT04299594|Other|Questionnaire|For each subject recruited, will be collected for the study a questionnaire looking for a history of low energy fracture, and the origins of the patient (or relatives), as well as medical history, lifestyle (alcohol and tobacco consumption), weight and height. This data will be used for the secondary outcomes.
45367005|NCT05373641|Other|Pain documentation audit|Monthly pain documentation audit
45483896|NCT05166213|Other|focus group discussions (FGD)|FGD to explore patients' attitudes/ concerns towards OLP implementation into clinical practice by means of assessment of qualitative information: 1) Patients' attitudes towards clinical usage of OLPs 2) Personal acceptance of OLP intervention 3) Perceived ideas, concerns regarding OLP implementation. Core questions: 1) Attitudes: After all that I told you about placebos, i.e. that there is a concept that patients are openly elucidated that they receive placebos: What does this elicit in you/What is your opinion on this? How do you like the idea? 2) Context of Acceptance: Under which conditions would you personally take placebos knowing that they are placebos? 3) Concerns: Why would you not take openly administered placebos? 4) Ideas for clinical implication: How could an open placebo intervention look like in the hospital? Where could it be possible to receive placebos and how could a placebo intervention in the best manner take place? What would be important from your point of view?
45847926|NCT03074682|Device|Pressure Bag|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
46051631|NCT00913692|Drug|Glutamine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
45483897|NCT01341873|Other|educational intervention|Undergo APN FCI
45483898|NCT01341873|Other|psychosocial support for caregiver|Undergo APN FCI
45483899|NCT01341873|Procedure|quality-of-life assessment|Ancillary studies
45483900|NCT01341873|Other|questionnaire administration|Ancillary studies
46051632|NCT00913692|Drug|Glycine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
45483901|NCT01338441|Drug|Erythromycin|4mg/Kg, IV during 20 min once
45483902|NCT01338441|Drug|Placebo|4mg/Kg, IV during 20 min once
45483903|NCT01341951|Drug|Granulocyte colony stimulating factor|300 I.U twice daily for 5 days
45483904|NCT01336101|Device|EPIC™ Self-Expanding Nitinol Vascular Stent|SFA/Popliteal Artery stenting
45483905|NCT01338597|Procedure|endoscopic thyroidectomy|endoscopic thyroidectomy via the breast approach. the difference between two arms is in the subcutaneous dissection area.
45483906|NCT01336179|Procedure|Salvadora persica|twice daily use, two minutes interval
45483907|NCT01336179|Procedure|Toothbrush|Twice daily use two minutes interval
45483908|NCT01342185|Device|medical ozone therapy with tianyi|Medical ozone therapy with instrument made in China Patients in this arm will receive autohemotherapy. First month: ozone concentration: 20µg ~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
45483909|NCT01342185|Device|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment, regime as ArmⅠ.
45691138|NCT04147845|Other|Microneedling using dermapen|"Microneedling is performed using Dermapen. This creates pin point bleeding or mild erythema which will be considered as the end point.~The treatment solution will be applied on each lesion twice, before and after performing microneedling."
45691139|NCT04147845|Other|Triamcinolone Acetonide|triamcinolone solution (10 mg/ml) will be dropped on the treated area and spread evenly
45691140|NCT04147845|Other|Platelet-rich plasma|The applied PRP will be spread over the whole affected area
46051633|NCT04710108|Other|Health Communication|Spoken word poem set to video images performed by author. Comic book was transformed from the video that was equivalent in content to the video.
46051634|NCT04242303|Procedure|Total knee replacement|"Total knee arthroplasty using standard anterior approach. In the EM group, inertial sensor will be used to perform femoral bone cuts.~In the IM group, conventional intramedullary nail will be used as reference to perform femoral bone cuts."
45483910|NCT01342185|Drug|Diammonium glycyrrhizinate Capsules|Drug: Diammonium glycyrrhizinate Capsules Patients in this group will receive oral Diammonium glycyrrhizinate Capsules 150mg, three times a day for 12 weeks.
45367006|NCT05373251|Diagnostic Test|Whole genomic DNA/RNA tumour sequencing|"All participants will undergo pre-radiotherapy fresh core biopsies of the tumour. DNA libraries will be created and stored for future analysis.~Participants with recurrence will have biopsy and subsequently will undergo rapid sequencing of RNA and DNA followed by bioinformatic analysis to identify somatic mutations or other abnormalities that might be drivers of an individual's cancer or predict response to therapies. These data will be compared to the literature and to a comprehensive database of drugs with the aim of identifying drugs most likely to target individual tumors based on the presence of mutated or abnormally expressed genes in the tumor. Any palliative systemic therapy treatment would be closely monitored for tolerability and response, as part of the general clinical care of someone on systemic therapy. The choice of systemic therapy will be up to the treating medical oncologist and the patient."
45367007|NCT05373173|Behavioral|Tele-assessment + In-person assessment|All consented families will complete an initial home-based tele-assessment visit via Zoom that includes the TAP-Preschool and a brief symptom-focused developmental interview with a consented clinician. The initial tele-assessment session includes interviewing and developmental assessment to mimic real-world use of TAP-Preschool. After the session, the examiner will record the clinical diagnosis issued (ASD, other developmental concerns, or typical development) and complete two diagnostic certainty ratings. All initial TAP-Preschool administrations will be recorded via Zoom, and 50% of administrations (randomly selected) will be co-scored by a blinded examiner, unaware of prior assessment results and diagnostic decision, to evaluate inter-rater reliability. Within 7 days of the remote assessment, families will participate in an in-person diagnostic assessment including common comprehensive measures of ASD, cognitive skills, and adaptive behavior.
45691141|NCT03920709|Other|Blood sample and Nasal swabs (right an left) samples|"Nasal swabs (right and left) will be performed (FLOQSwabTM)~Blood samples of 20 mL EDTA will be taken in addition to the current care report"
45483911|NCT02714218|Biological|Nivolumab 3 mg/kg IV|Followed by Nivolumab monotherapy
45483912|NCT02714218|Biological|Ipilimumab 1 mg/kg IV|Followed by Nivolumab monotherapy
45483913|NCT02714218|Biological|Nivolumab 1 mg/kg IV|
45483914|NCT02714218|Biological|Ipilimumab 3 mg/kg IV|
45691142|NCT01849783|Drug|dexamethasone|Given PO
45483915|NCT02714218|Biological|Nivolumab 6 mg/kg IV|A dose of 240mg is identical to a dose of 3mg/kg, therefore 6mg/kg is approximately equal to ~ 480mg.
45498129|NCT03681444|Diagnostic Test|Colonoscopy|Colonoscopy will be performed under conscious sedation with intravenous midazolam and pethidine titrated as required
45498130|NCT05489679|Drug|AC682|Participants will receive AC682 by mouth daily in 28-day cycles.
45691143|NCT01849783|Drug|cisplatin|Given IV
45691144|NCT01849783|Drug|doxorubicin|Given IV
45691145|NCT01849783|Drug|cyclophosphamide|Given IV or PO
45691146|NCT01849783|Drug|etoposide|Given IV
45691147|NCT01849783|Drug|bortezomib|Given IV
45691148|NCT01849783|Drug|thalidomide|Given PO
45691149|NCT01849783|Drug|melphalan|Given IV
45691150|NCT01849783|Procedure|autologous stem cell transplant|
45691151|NCT01611883|Drug|Ezetimibe|10 mg oral dose once daily for 24 weeks
45691152|NCT01611883|Drug|Placebo|Placebo to match ezetimibe orally once daily for 24 weeks.
45691153|NCT04170517|Diagnostic Test|Measurement of serum progesterone on the day of FET|Measurement of serum progesterone on the day of FET
45847927|NCT03078504|Device|continuous renal replacement therapy using System One (TM) setup (Nxstage)|Participants who have been prescribed continuous renal replacement therapy will have hemodynamic parameters measured at various blood flow rates
45845989|NCT04297488|Dietary Supplement|Bifidobacteria and Lactobacilli triple viable capsules|Bifidobacteria and Lactobacilli triple viable capsules (provided by Shenzhen Wan he Pharmaceutical Co., Ltd., China) are bilayer mini pellets and are resistant to gastric acid. So Bifidobacterium billion Lactobacillus can only be released in intestine. Participants will take 1.27g (contain 3 billion Bifidobacterium and 1 billion Lactobacillus) once daily.
45845990|NCT04294446|Device|Biodesign Hernia Graft|The Biodesign Hernia Graft is comprised of 8 layers of decellularized porcine small intestinal submucosa (SIS) that has been pressed-lyophilized (i.e., freeze-dried under vacuum pressure) to laminate the component sheets (i.e., layers) together. In addition, it is perforated and sewn with 4-0 Trisorb suture (polyglycolic acid (PGA); Samyang Corporation, Seoul, South Korea). The suture is distributed in a diamond pattern across the graft and along the periphery and is intended to mitigate delamination of the layers upon rehydration and/or manipulation during implantation. Being a completely biologic device, the Biodesign Hernia Graft is considered MR safe.
45367008|NCT04066985|Behavioral|Growth Mindset Online Single-Session Program|30minute self-administered program for youths
45367009|NCT04066985|Behavioral|Self-Kindness Online Single-Session Program|30minute self-administered program for youths
45367010|NCT04066985|Behavioral|Supportive Therapy Online Single-Session Program (Control)|30minute self-administered active comparator program for youths
45367011|NCT00723359|Drug|BT062|biologic
46051635|NCT04810026|Behavioral|Education|Healthy-lifestyle and diabetes-related virtual education (text and videos)
45367012|NCT00450814|Drug|Cyclophosphamide|Given IV
45367013|NCT00450814|Other|Laboratory Biomarker Analysis|Correlative studies
45367014|NCT00450814|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IV
45367015|NCT00450814|Other|Pharmacological Study|Correlative studies
45367016|NCT02571491|Drug|Ketamine Hydrochloride|50 mg/ml, IV (in the vein) during surgery operation, followed by IV ketamine hydrocloride perfusion 2mcg/Kg/min before and until 72 hours after operation Number of Cycles: until progression or unacceptable toxicity develops.
46051636|NCT04810026|Behavioral|Meal delivery|breakfast, lunch, and dinner adhering to the longevity diet macro-nutrient profiles
45367017|NCT02571491|Other|Placebo|50 mg/ml, IV (in the vein) during surgery operation, followed by IV placebo perfusion 2mcg/Kg/min before and until 72 hours after operation
45367018|NCT02571491|Drug|Remifentanil|at doses of 0.3 mcg / kg / min during and until the end of the surgical operation
45367019|NCT02571491|Drug|Morphine hydrochloride|at the dose of 150 mcg / kg, 60 minutes before the extubation procedure and until 72 hours after operation by intravenous infusion
45367020|NCT00723437|Drug|acitretin|Acitretin at the dosage of 0.2 to 0.3 mg/Kg/day for 6 months.
46051637|NCT04810026|Behavioral|Lifestyle coaching|calls with coach and/or nutritionist, access to Facebook community support group
46051638|NCT04787328|Drug|HA121-28 tablets|HA121-28 450 mg, po, QD×21 days, every 4 weeks (28 days)
46051639|NCT00784927|Biological|rituximab|
46051640|NCT00784927|Drug|cyclophosphamide|
46051641|NCT00784927|Drug|dexamethasone|
46051642|NCT00784927|Drug|lenalidomide|
46051643|NCT00637884|Drug|Fexofenadine HCl|
46051644|NCT00915421|Procedure|Induction of therapeutic mild hypothermia|Rapid administration of 4°C cold normal saline to the peripheral vein, dose 5 - 30 ml/kg, to decrease body core temperature below 34°C
46051645|NCT04785378|Device|Medical mask|Participants will carry out field tests one day wearing a medical mask and the other day without a mask.
46051646|NCT04785378|Other|Field tests|Participants will perform 6 MWT and ISWT tests to determine their exercise capacity, and a 30-second sit and stand test to determine lower extremity endurance.
46051647|NCT00779779|Biological|Rotarix™|Two oral doses, with at least 4 weeks interval in-between
46051648|NCT04203342|Drug|Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.)|Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
45367021|NCT01026688|Other|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
45367022|NCT01026688|Other|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed to Control arm physicians with the May 2010 issue of the newsletter.
45367023|NCT02571023|Procedure|microscope surgery|
45367024|NCT02571023|Procedure|neuroendoscope surgery|
45367025|NCT00723515|Drug|sodium fluoride|sodium fluoride 5%
45367026|NCT00723515|Drug|sodium fluoride calcium fluoride|sodium fluoride 5% + calcium fluoride
45367027|NCT01022944|Procedure|With chronic middle ear effusion|Children with chronic middle ear effusion having adenoidectomy.
45367028|NCT01022944|Procedure|Without chronic middle ear effusion|Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
45367029|NCT01028170|Drug|furosemide and hypertonic saline solution|250-500 mg furosemide (30 min IV Q 12 hours) with 150 mL of 2.4% NaCl
45367030|NCT01028170|Drug|furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
45367031|NCT00723671|Procedure|MRI|
45483916|NCT01342263|Behavioral|iCDM|The iCDM intervention will be managed by a nurse with experience in chronic disease management who will review patient data, communicate with the patients, implement the Treatment Algorithms and interact with the patients' PCP. Patients will also be able to interact with a dietitian and exercise specialist to support them in their disease management. These personnel will have formal training in principles of the Transtheoretical Model of Change and Social Cognitive Theory.
45483917|NCT05185869|Drug|SHR6390|SHR6390, Oral Administration
45483918|NCT05185869|Drug|Nab-paclitaxel|Paclitaxel-albumin, Intravenous Injection
45483919|NCT05185869|Drug|Gemcitabine|Gemcitabine, Intravenous Injection
45483920|NCT03154047|Drug|NEOD001|humanized monoclonal antibody
45691154|NCT01848457|Drug|Pantoprazole|0.3 mg/kg IV over 15 min immediately prior to cisplatin as a loading dose on days 1 & 2 followed by 1.3 mg/kg IV infused over 4 h concurrent with the 4 h cisplatin infusion on days 1 & 2 of treatment Cycles 1 & 2 (Treatment Arms 1, 3) OR Cycles 3 & 4 (Treatment Arms 2, 4)
45691155|NCT01848457|Drug|High-dose methotrexate infusion duration|High-dose methotrexate (12 g/sq m, maximum dose 20 g) will be infused over 4 hours or 12 hours
46051649|NCT04203342|Drug|Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA)|Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
46051650|NCT04203342|Drug|Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)|Topical placebo to treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
45367032|NCT00518115|Drug|Albiglutide (GSK716155) or exenatide|Albiglutide weekly subcutaneous injection or exenatide twice daily injection
45367033|NCT04067219|Procedure|DXA (dual-energy x-ray absorptiometric) measurement|DXA, evaluation of muscular function and muscle strength; neurocognitive tests; non invasive analysis of mechanical skin properties; food frequency questionnaire; laboratory assessment (25 hydroxy vitamin D, calcium/phosphate metabolism, bone remodelling markers, T cell activation).
45367034|NCT00723983|Drug|Sumatriptan succinate|Sumatriptan succinate 50 mg taken orally
45691156|NCT01817959|Drug|Reparixin|Continuous i.v. infusion into a central vein for 7 days, starting approximately 12 hrs (6-18 hrs) before each pancreatic islet infusion.The Investigational Product (IP) were to be administered as an add-on treatment for the immunosuppressant regimen.
45691157|NCT01817959|Drug|Placebo|Continuous infusion at a volume/rate matching active treatment.The placebo was to be administered as well as an add-on treatment for the immunosuppressant regimen.
45691158|NCT01817725|Biological|HBV vaccine (Engerix B)|Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) is administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months. The dosage will be 20μg in those <= 20 years old and 40μg in those > 20 years old.
45691159|NCT01870999|Drug|aripiprazole IM depot|Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.
45691160|NCT01870999|Drug|aripiprazole tablets|Aripiprazole tablets 10 mg once daily in the morning for 14 days.
45691161|NCT01870921|Drug|Ticagrelor|90mg/tablet, 1 tablet bid
45691162|NCT04594291|Procedure|MRI scans|This study does not involve any intervention or new treatment. We will conduct MRI scans of the kidneys, muscles, abdomen and heart at baseline, 12 and 24 months after hospital discharge. The MRI scan will take 60-70 minutes in total.
45367035|NCT00723983|Drug|NP101 Study Patch|NP101 study patch 4 hour application
45691163|NCT00526474|Drug|Vorapaxar|2.5-mg tablet daily for at least 1 year
46051651|NCT00915889|Behavioral|telephone-based intervention|Either 6 or 8 telephone educational sessions
45367036|NCT00450658|Drug|HZT-501|HZT-501: Ibuprofen 800mg/famotidine 26.6mg orally 3 times daily for 24 weeks
45367037|NCT00450658|Drug|Ibuprofen|Ibuprofen 800mg orally 3 times daily for 24 weeks
45367038|NCT02572505|Drug|Truvada|Female patient will take Truvada and use condoms for each act of intercourse except once at the optimal time for fertility.
45483921|NCT02457676|Behavioral|Alert Program for Self-Regulation|"Children attend 12 1.5 hour weekly sessions. Alert uses the analogy of a car engine to help children identify their own self-regulatory behavior. Children learn strategies to regulate their own engine speed in different situations."
45483922|NCT01338675|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
45691164|NCT00526474|Drug|Placebo|matching tablet daily for at least 1 year
45845991|NCT04240314|Biological|scAAV9.U7.ACCA|A single dose of scAAV9.U7.ACCA will be systemically delivered via a peripheral vein injection.
45845992|NCT04208412|Drug|KVD900|KVD900 tablet 600 mg
45845993|NCT04208412|Other|Placebo|KVD900-matched Placebo Tablet
46051652|NCT00915889|Other|counseling intervention|counseling and communications studies
46051653|NCT00915889|Other|questionnaire administration|Ancillary studies
45367039|NCT03720574|Drug|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 48 weeks
45367040|NCT03720574|Drug|Matching Placebo BID|Matching Placebo tablet each morning and evening for a duration of 48 weeks
45483923|NCT03852862|Drug|Serratus plane block and paravertebral block|Single Administration of 20 mL of ropivacaine for Serratus plane block (Intra-muscular injection) followed by a single administration of 20 ml ropivacaine for paravertebral block (T4 inter-vertebral injection)
45483924|NCT03852862|Drug|paravertebral block|Single Administration of 20 ml of ropivacaine for paravertebral block (T4 inter-vertebral injection)
45845994|NCT04200300|Diagnostic Test|Online questionnaire|Online questionnaire via SoSciSurvey
45845995|NCT04194996|Procedure|Surgical intervention|Surgical interventions will be patient specified by treating surgeon.
45845996|NCT04191486|Drug|T-817MA|224mg T-817MA orally once daily for first 4 weeks, and then 448mg T-817MA orally once daily for the following weeks.
46051654|NCT00915889|Other|study of socioeconomic and demographic variables|Ancillary Studies
46051655|NCT00915889|Procedure|psychosocial assessment and care|6 weeks or 8 weeks of psychoeducational telephone sessions
46051656|NCT04104841|Behavioral|Behaviorally Enhancing Adolescents' Mood in Schools|8-session modified behavioral activation intervention
46051657|NCT04104841|Behavioral|Usual Care|Referral to school mental health provider, social worker, or community care.
46051658|NCT04572438|Procedure|Tracheostomy|Tracheostomy is a procedure that creates a surgical airway in the windpipe to improve oxygenation of the lungs.
45367041|NCT00724139|Device|: APOS biomechanical gait system, Apos - Sports and Medical Technologies Ltd. Hertzlia, Israel|training program utilizing a novel biomechanical system comprising four modular elements attached onto foot-worn platforms which conveys perturbation throughout the gait cycle
45367042|NCT00718133|Device|Spirometry (Pony spirometer)|Spirometry at rest
45367043|NCT03720418|Drug|OXB-102|Neurosurgical delivery of OXB-102 (gene therapy) to the putamen
45367044|NCT03720418|Other|Imitation Surgical Procedure (ISP)|Participants randomized to the control group in Part B will receive an ISP
45483925|NCT01338753|Other|Bevacizumab, docetaxel and doxorubicin followed by surgery|"The dosage form is Parenteral Injection (I/V) for all study drugs. Bevacizumab 15mg/kg in a single dose on day 1. Then 3 weeks later begin the cycles. On the day 1 of the cycle the patient receives Bevacizumab 15mg/kg, docetaxel 60mg/m2 and doxorubicin 50mg/m2.~The cycles have a frequency of one every three weeks, and the protocol defines 4 cycles in total.~The surgical procedure will be done 4-6 weeks after completion of chemotherapy."
45483926|NCT04102774|Device|Over-night treatment with myAIRVO2|"Gas flow will be set between 20 and 30 l/min, according to patient's comfort, and administrated via nasal canula.~Temperature will be set at 37°C. If the patient was already in nocturnal oxygen therapy FiO2 will be set according to the prescription."
45483927|NCT01336257|Other|SEBASTIAN Clinical Decision Support System (CDSS)|SEBASTIAN is an example of a clinical decision support technology that supports the latest, service-based architectural approach to CDSS implementation. Developed at Duke University, SEBASTIAN is a clinical decision support Web service whose interface is now the basis of the HL7 Decision Support Service draft standard SEBASTIAN places a standardized interface in front of clinical decision support knowledge modules and makes only limited demands on how relevant patient data are collected or on how decision support inferences are communicated to end-users
45483928|NCT03107650|Procedure|Transanal total mesorectal excision of rectal cancer|To perform a total mesorectal excision through a transanal approach
45845997|NCT04191486|Drug|Placebo|Placebo once daily
45845998|NCT04164732|Drug|LCZ696|LCZ696 at doses of 50mg, 100mg and 200mg b.i.d oral
46051659|NCT05539729|Drug|Vancomycin|A marketed antibiotic (Study Drug) supplied by Amerisource Bergen, by the Mount Sinai Investigational Drug Services (IDS), and encapsulated in red coating to match the placebo.
46051660|NCT05539729|Drug|Placebo|Placebo created by the IDS and encapsulated in red coating to match the Study Drug.
46051661|NCT04102969|Behavioral|Benson Relaxation Technique|Benson relaxation technique will be performed two times a day for 10 minutes during the study period ( two months) for the intervention group.
46051662|NCT04102969|Other|Nutrition Package Session|A nutrition package session will be given to the control group.
46051663|NCT04203108|Drug|ATG|In ATG group, ATG will be intravenously infused via a central venous catheter in day -1 at a dose of 2.5mg/kg.
46051664|NCT04203108|Drug|CsA|In both groups, CsA will be intravenously infused from day -9 and the dose was adjusted based on the concentration.
45483929|NCT05185791|Other|Pre-ERAS® phase (current clinical practice)|Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
45367045|NCT00517881|Drug|Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)|Subcutaneous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 mcg every 4 weeks for 20 weeks. Further dose adjustments will be performed during the study depending on the participant's blood hemoglobin levels.
45483930|NCT05185791|Other|Post-ERAS® implementation phase|Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
45691165|NCT01848145|Drug|Ofatumumab|The first dose of ofatumumab administered on Day 1 will be 300 mg to minimize infusion reactions. If the initial 300 mg dose of ofatumumab is well-tolerated, without occurrence of any infusion-associated AEs of >= grade 3, on Day 3 ofatumumab will increase to 1000 mg IV. If the Day 3 dose was well-tolerated (i.e., no infusion-associated AE >= grade 3), on Day 8 the ofatumumab dose will escalate to 2000 mg IV. To achieve the primary endpoint for this study, 20% of the 2000 mg ofatumumab dose only will be administered over the first 30 minutes and if tolerated the remaining 80% of the dose will be infused over the remaining 1.5/hours of each treatment. Ofatumumab doses, weeks 3-8, will remain at 2000 mg IV with no further dose escalations. If the Day 8 (Week 2) dose is tolerated all subsequent doses may be infused in the same manner.
45691166|NCT01847755|Drug|Oxygen at 1.5 ATA (atmospheres absolute).|Each patient will undergo 5 times-a-week Hyperbaric treatments to 1.5 ATA (atmospheres absolute) for up to 120 treatments. Treatment in hyperbaric chamber will be approximately 60 minutes. At specified intervals 40,80,120, patient will be assessed by Spect scan and cognitive assessments to provide outcome measure data. Pt will have a 3 month post treatment follow up assessment.
45691167|NCT00527566|Biological|Mepolizumab|IV mepolizumab, 750 mg
45367046|NCT02572739|Device|PICCO|measurements based on thermodilution
45367047|NCT02572739|Device|NICCOMO|measurements based on impedance
45691168|NCT00527644|Device|5mm spring clip|Microline Pentax 5mm Visu-Loc Clip Applier
45845999|NCT04164732|Drug|Placebo|placebo
46051665|NCT04203108|Drug|MTX|In both groups, MTX will be intravenously on days +1(15mg), +3(10mg) and +6(10mg).
46051666|NCT04203108|Drug|MMF|In both groups, MMF will be administrated at a dose of 1.0g/d.
46051667|NCT04102657|Other|Intermittent Fasting|Participants will be instructed to limit their daily food consumption to an 8-hour period in the day of their choosing. For the 16-hour fasting period, subjects are to eliminate caloric intake.
46051668|NCT04102657|Other|Free-Living Diet|Participants will maintain their current daily food consumption with no caloric restriction. Patient must not have participated in a specialized diet or weight loss program within 2 weeks of enrollment.
46051669|NCT04102657|Other|Left Arm Exercise|Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the left arm. In the middle of the study, participants will switch to the right arm to complete their unilateral arm exercises.
45367048|NCT01009905|Drug|somatropin|Safety and effectiveness data collection in connection with the use of Norditropin® (somatropin) in daily clinical practice
46051670|NCT04102657|Other|Right Arm Exercise|Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the right arm. In the middle of the study, participants will switch to the left arm to complete their unilateral arm exercises.
46051671|NCT04834206|Drug|Docetaxel, nedaplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
46051672|NCT04834206|Radiation|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
46051673|NCT04834206|Drug|Nedaplatin|Concurrent chemotherapy. nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
45367049|NCT05372081|Other|Digital platform|Patients will be randomized (1:1) in the way they will receive or not any assistance from the digital platform.
45367050|NCT01565577|Biological|MenbVac|Blood test
45367051|NCT00724217|Other|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based supplements.
45367052|NCT00724217|Other|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based
45483931|NCT02457286|Drug|Metformin|Although metformin is FDA approved to treat type 2 diabetes, it is not FDA approved for the treatment of NAFLD and is considered investigational for the purpose of this study.
45483932|NCT02457286|Behavioral|Lifestyle modifications|Recommendations for lifestyle modification will be based on the Diabetes Prevention Program 2002 (26) and will include recommendations for greater than 150 minutes of physical activity weekly, referrals to group and/or individualized sessions with nutritionists and/or lifestyle coaches as well as educational materials
45367053|NCT01010139|Drug|Codeine Sulfate|15 mg, 30 mg and 60 mg Tablet
45367054|NCT00724295|Drug|peginterferon alfa-2b|PegIntron powder (reconstituted) administered in accordance with approved labeling; Subcutaneous injection of 1.5 ug/kg once weekly for 48 weeks.
45367055|NCT00724295|Drug|ribavirin|Rebetol capsule administered orally twice daily in accordance with approved labeling (weight based dosing). Dosing duration 48 weeks.
46051674|NCT02602717|Other|lymph nodes cyto-punction|
46051675|NCT04442802|Procedure|Percutaneous transluminal angioplasty|Under local anesthesia the percutaneous arterial access will be created. Digital subtraction angiography of the whole limb will be performed. Occlusive-stenotic lesion of the superficial femoral and / or popliteal artery will be crossed with a guidewire. The plain old (non drug-eluting) will be positioned in the affected arterial segment and inflated up to nominal pressure. After balloon deflation and extraction the completion angiography will be performed. Presence (yes/no) and severity (grades A-B or C-F according to NHLBI classification) of dissection will be assessed independently by 3 study investigators basing on DSA images in 2 directions. Decision to classify the dissection as severe (grade C-F) and to perform the bailout stenting will be done by the agreement between at least 2 from 3 investigators.
45691169|NCT00527722|Device|Bio-Seal Track Plug|The lung plug will be inserted into the left track when the biopsy needle is removed. The smaller sampling needle is removed, and the lung plug is inserted through the larger needle using a delivery tool that has a plunger to push the plug in place. The lung plug remains in the track left when the larger needle is removed.
46051676|NCT04107415|Other|yoga|A total of 12 yoga sessions, 2 sessions a week for 6 weeks, was applied to the patients in the experimental group.
45367056|NCT00718289|Other|Citrate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate [3.0 mmol/L in A and 0.3 in C], citrate [0 mmol/L in A and 0.8 in C]
45367057|NCT00718289|Other|Acetate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate [3.0 mmol/L in A and 0.3 in C], citrate [0 mmol/L in A and 0.8 in C]
46051677|NCT04440540|Behavioral|Dietitian led life style modification intervention|lifestyle changes supervised by dietitians
46051678|NCT04440540|Behavioral|Conventional care (control)|receive routine care
45847928|NCT03080142|Drug|Exparel|Patients will receive an injection of 30ml of volume to each abdominal side with a total of 60 ml for bilateral TAP blocks.
46051679|NCT05227248|Dietary Supplement|Dark chocolate|Patients were administered 20 grams of dark chocolate
45367058|NCT02571101|Drug|CDFR0812-15/25mg|Contains chlomipramine HCl 15mg and sildenafil citrate 25mg.
45367059|NCT02571101|Drug|CDFR0812-15/50mg|Contains chlomipramine HCl 15mg and sildenafil citrate 50mg.
45367060|NCT02571101|Drug|Condencia|Contains chlomipramine HCl 15mg.
45367061|NCT02571101|Drug|CDFR0812-Placebo|Placebo tablet of CDFR0812.
45367062|NCT02571101|Drug|Condencia-Placebo|Placebo tablet of Condencia
45367063|NCT03525886|Drug|NBI-74788|Capsule, administered daily.
45498131|NCT05475717|Drug|Alprostadil liposome injection|Alprostadil liposome injection, iv drip, QD×4 days (1 to 3 hours before surgery and 3 days after surgery)
45691170|NCT00527722|Other|No lung plug|Standard lung biopsy without placement of the plug.
45691171|NCT01847443|Drug|Nicotine (2 mg)|2 mg nicotine gum in two formulations
45691172|NCT01847443|Drug|Nicotine (4 mg)|4 mg nicotine gum in two formulations
45691173|NCT00527878|Drug|Ranitidine|Double blinded, randomized placebo controlled crossover study. Patients received 12 months of placebo and 12 months of treatment medication (ranitidine).
45691174|NCT00527878|Drug|Placebo|
45691175|NCT01847209|Procedure|Video-Assisted Thoracic Surgery (VATS) wedge resection|
45691176|NCT05558878|Drug|Ambroxol Oral Product|"Drug: Ambroxol (75 mg capsule)~Ambroxol is a mucolytic and expectorant drug. Ambroxol has been approved as lozenges for topical analgesia of sore throat in pharyngitis owing to its local anesthetic properties. Anti-inflammatory properties of ambroxol were confirmed by numerous studies. Ambroxol affect neuronal transduction by blocking (TTX)-resistant Na+ channels (Nav1.8) in small (pain-sensing) dorsal root ganglion neurons more potently than TTX-sensitive channels."
46051680|NCT05227248|Dietary Supplement|Milk Chocolate|Patients were administered 7.5 grams of milk chocolate
45367064|NCT00517413|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc or iv monthly, starting dose
45367065|NCT00724529|Biological|Infliximab|Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.
45691177|NCT01846741|Device|M106 VNS Therapy System|
46051681|NCT00631722|Drug|Quatiapine Fumarate|600-750mg/day
46051682|NCT00631722|Drug|Haloperidol|12-20mg/day
46051683|NCT00845728|Drug|Indacaterol 150 µg|Indacaterol 150 µg o.d. delivered via SDDPI
45367066|NCT03714178|Device|FARAPULSE Endocardial Ablation System|Endocardial ablation using the FARAPULSE Endocardial Ablation System.
45367067|NCT01012869|Device|everolimus-eluting stent|everolimus-eluting stent (Xience, Abbott Vascular) or Promus (Boston Scientific)
45367068|NCT03690999|Dietary Supplement|Placebo|Placebo product
45367069|NCT03690999|Dietary Supplement|Prebiotic supplement|Prebiotic supplement
45367070|NCT05361785|Biological|FMT|FMT from healthy donor or placebo
45367071|NCT03709342|Drug|CM4620-IE|single IV infusion on Day 1 over 4 hours
45367072|NCT01010295|Drug|doxycycline (tetracycline)|doxycycline 100 mg twice daily for 3 weeks
45367073|NCT03632291|Biological|UB-221|UB-221 (75 mg/ml)
45367074|NCT01010373|Drug|AS101|3 mg/m2 AS101 will be given intravenously (IV) three times per week.
45691178|NCT05621590|Drug|MLC 901|MLC901, also known as NeuroAiDII, is a capsule form of drug which should be taken orally and combines nine herbal components
45691179|NCT05621590|Drug|Placebo|placebo capsules filled with stevia sweetened powder
46051684|NCT00845728|Drug|Tiotropium|Tiotropium 18 µg o.d. delivered via handihaler®
46051685|NCT00779467|Drug|Neostigmine|utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
46051686|NCT00779467|Drug|Bupivacaine|
46051687|NCT00779467|Drug|fentanyl|fentanyl 2 mcg/ml
45367075|NCT02570945|Procedure|Pharmacist-physician intervention to reduce high-risk medication use by elderly inpatients|
45367076|NCT01010451|Procedure|Antimicrobial pulpotomy|Pulpotomy of inflamed or necrotic pulp using an antimicrobial paste (chloramphenicol, tetracycline, zinc oxide/eugenol)as medication.
45367077|NCT01010451|Procedure|Calcium hydroxide pulpectomy|Pulpectomy of inflamed or necrotic pulp using a calcium hydroxide paste as medication
45367078|NCT02570789|Drug|patients with sunitinib or pazopanib|The treatment with sunitinib or pazopanib should comply with the recommendations written in the Belgian product information and the reimbursement criteria
45367079|NCT00604214|Drug|Drotrecogin alfa (activated)|24 microgram/kilogram/hour, intravenous, 96 hours (hr)
45483933|NCT02457286|Device|Fibroscan device (Echosens)|This study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity.
45483934|NCT01342497|Drug|isoniazide|Tablets, dosing 3 times daily, 12 weeks
45483935|NCT01342497|Drug|placebo|tablets, dosing 3 times daily, 12 weeks
45483936|NCT03264976|Diagnostic Test|hematological examination, ophthalmic examination|Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP)；Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
45483937|NCT03282370|Biological|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
45483938|NCT03282370|Biological|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
45483939|NCT01342575|Procedure|Intra-operative exposure maneuvers|"Feet compression maneuver: Taking feet from the ankles, gentle pressure will be applied toward the cranium and maintained for 1 minute. X-rays and IONM will be performed~Arm traction maneuver: Holding two strips around the wrists and using a dynamometer adjusted to 8 kg per side, sustained traction will be maintained for 1 minute. X-rays and IONM will be performed.~Shoulder taping maneuver: Both shoulders will be pulled caudally with adhesive tape adjusted for a tension of 8 kg on each side. X-rays and IONM will be performed~Arm traction plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed~Shoulder taping plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed"
45483940|NCT03282292|Procedure|Internal jugular vein CVC insertion|Double lumen CVC insertion in the internal jugular vein
45483941|NCT01338831|Drug|LFA102|
45483942|NCT03282214|Behavioral|Self-management energy conservation|"The experimental group will receive four sessions approximately every three weeks with the PI. These sessions will correspond to the cycles of chemotherapy they will receive, with the first two sessions being during cycle 1, and sessions 3 and 4 being during cycles 2 and 3 of chemotherapy, respectively. The women will be instructed on how to assess their activity patterns by making a list prioritizing their usual activities. The journal and priority list (a to do list) provide the basis for the second session. In this session, the participant will learn to create a plan for managing valued activities to minimize the amount of energy used, to report the fatigue experienced during and after an activity done in the journal and will learn strategies to manage fatigue and optimize activity. In the third session, the participant will evaluate and revise their individualized plan. In addition, the participant will be instructed to wear a pedometer to record objective physical activity."
45483943|NCT05185635|Diagnostic Test|Neuropsychological testing|potential participants will complete the following: Mini-Mental State Examination (MMSE), Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder 7- item (GAD-7) as part of the screening process. Additionally to the pre-screening instruments, participants will complete the following neuropsychological tests: Bi-dimensional Acculturation Scale, Bilingual Dominance Scale, Verbal Fluency Tests, Boston Naming Test, Symbol Digit Modalities Test, Brief Test of Attention, Who-UCLA Auditory Verbal Learning Test, Rey-Osterrieth Complex Figure, Modified Wisconsin Card Sorting Test, Stroop Color and Word Test, Trail Making Test, Word Accentuation Test, Clock Drawing Task, Bells Test, Test of Memory Malingering, and the Five Point Test.
45483944|NCT01336335|Device|CPAP|CPAP
45483945|NCT03590002|Device|Electronic ICU Medical Transfer Tool|Patient transfers of care from the ICU to inpatient wards prepared using the electronic ICU medical transfer tool within the health zone's clinical information system, Sunrise Clinical Manager.
45367080|NCT00604214|Drug|Placebo|0.9% sodium chloride, intravenous, 96 hours
45367081|NCT01010529|Other|occupational therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
45367082|NCT04066439|Other|specimen|Immunohistochemistry analysis
45367083|NCT05325203|Biological|Ongericimab|Administered by subcutaneous injection
45367084|NCT05325203|Drug|Placebo|Administered by subcutaneous injection
45483946|NCT01338909|Drug|Prasugrel|Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5
45483947|NCT01338909|Drug|Clopidogrel|Clopidogrel 150mg/d starting from Day 1
45483948|NCT03264742|Other|Ghrelin|The patients are assigned within the scope of the admission according to emergency to the treatment and clarification on the Stroke Unit of the KSW. There the patients are enclosed in the study and are examined according to the draught on the Stroke Unit within the scope of the complex treatment. The inclusion of the patients occurs after clarification and in the consent of the patients. In the morning after the admission day the decrease of the first blood test occurs within the scope of the blood sample as a matter of routine to be carried out for the Ghrelinbestimmung. Also 48 H occurs after the first withdrawal and 3 months after the stroke a blood sample to the regulation of Ghrelin.
45483949|NCT01342653|Other|Intraperitoneal and systemic chemotherapy plus maximum cytoreduction plus HIPEC|see Design
45483950|NCT02458456|Other|Isometric resistance training|Isometric exercise using a hand dynamometer.
45483951|NCT03264820|Device|Laser Doppler|- Laser measurements at the level of each finger at 47 °C and at ambient temperature
45367085|NCT00450580|Drug|fosamprenavir/ritonavir|Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent
45367086|NCT00724685|Drug|Naropeine (Ropivacaine)|
45483952|NCT03264820|Device|Laser speckle|- Laser measurements at the forearm
45483953|NCT03264820|Behavioral|pain evaluation|Visual scale assesment pain
45483954|NCT03264820|Other|Blood pressure and heart rate|Measurement of blood pressure and heart rate
45483955|NCT03282136|Drug|Incretin Effect|The patients will receive incretins therapy.
45483956|NCT03282136|Device|Cardiac Resynchronization therapy defibrillator device|The patients will receive a Cardiac Resynchronization therapy defibrillator device
45483957|NCT03156621|Drug|Alirocumab|Alirocumab SC Q2W
45483958|NCT03156621|Drug|Placebo|Matching placebo SC Q2W
45483959|NCT03282058|Device|Silastic Stent|The silastic stent is a splint made of silicone.
45483960|NCT03264898|Device|Fecal immunochemical test (FIT)|FIT is a type of fecal occult blood test that uses antibodies to hemoglobin to detect blood in stool.
45483961|NCT03281980|Other|Psychosocial stimulation (PS)|"i) Unconditional Cash Transfer(UCT)/ Maternity Allowance: MoWCA, GoB provides maternity allowance of taka 500 ($6.25) for each mother up to two years in each month.~ii) Health Education Awareness Program: All mothers receive health education training by designated LNGOs/CBOs~iii) Psychosocial stimulation: The participants will receive fortnightly sessions at home."
45483962|NCT03281980|Other|Government Intervention (UCT+HE)|fgbfgjhgykghilk
45498132|NCT03689322|Other|WBV + IMT|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.
45498133|NCT03689322|Other|WBV + IMTsham|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.
45367087|NCT00724685|Drug|Placebo|saline
45367088|NCT00123487|Drug|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
45367089|NCT00123487|Drug|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
45367090|NCT00509925|Drug|insulin detemir|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
45367091|NCT00509925|Drug|insulin NPH|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
45367092|NCT00509925|Drug|insulin aspart|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
45367093|NCT00724763|Device|acupuncture|to Liv 3 and PE 9.
45367094|NCT00724763|Device|sham needle treatment|needle not in meridian area
45367095|NCT03884296|Biological|FluMist|Quadrivalent, live, attenuated influenza vaccine, intranasal spray
46051688|NCT04203030|Behavioral|Physical Activity|Participants will meet in a weekly group session to discuss a topic related to physical activity and physical function and participate in group-based physical activity. Participants will also have instructions to participate in physical activity outside of the weekly sessions, incrementally increasing their total physical activity over the intervention period.
46051689|NCT04273230|Other|Microalbuminuria detection|Detection of microalbumin in urine
45483963|NCT03156543|Device|Jumpstart Dressing|"JumpStart™ is a wireless, advanced microcurrent generating, dressing used for the management of surgical incision sites. Microcell batteries made of silver and zinc, generate an electrical current when activated by conductive fluids, such as saline, hydrogel or wound exudate. These microcells create low voltage electrical fields to stimulate the surrounding area and to provide antimicrobial protection to assist with wound healing. JumpStart has demonstrated superior broad spectrum bactericidal activity of a wound dressing against antibiotic-resistant strains of wound isolates within 24 hours.~It will be applied pre-op in all patients and post operatively in group B"
45483964|NCT03156543|Other|Standard Dressing|This is a standard of care bandage that will be placed on participants in group A post operatively
45483965|NCT03264586|Drug|Lidocaine-prilocaine cream|"5gm dose of cream applied to the intact surface of the perineum and area covered with an occlusive dressing to facilitate penetration~- EMLA cream was applied, 1 hour before the expected time of birth."
45483966|NCT03264586|Drug|mepivacaine infiltration group|"10 ml of 1% mepivacaine solution was injected slowly when the fetal head was crowned with frequent aspiration to avoid intravascular injection.~In the mepivacaine group, if an episiotomy was indicated, it was performed after infiltration of perineal tissue with 10 ml of 1% mepivacaine solution.~The suture procedure was delayed 10 minutes after the injection of the aneathetic"
45483967|NCT03264586|Procedure|mediolateral episiotomy|"Episiotomy repair a loose, continous, non locking suture to close the vaginal mucosa and the muscular layer of the perineum using vicryl Number zero (0).~At the end of the vaginal mucosal repair care is taken to align the edges of the episiotomy wound~At the point where perineal skin begins; the suture is then passed beneath the vaginal mucosa, and repair of perineal muscle begins. The deep layer of muscles is closed first, ensuring no dead space one left behind~The skin was closed with the same continuous suture to approximate the subcutinuous tissue."
45483968|NCT01342731|Drug|Tigecycline|100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 days.
45483969|NCT03271996|Procedure|Primary closure|Asymmetric skin incision and total excision of the lesion with monopolar scalpel. Accurate hemostasis, creation of a cutaneous-subcutaneous flap, primary closure with non-absorbable sutures, optional aspiration drainage.
45483970|NCT03271996|Procedure|Fistulectomy|Evaluation of the cavity using a 0.5-1 mm metal probe which will be inserted into the skin orifice. Excision of the skin around the orifice and debridement/excision of the cavity by monopolar scalpel or Trephines
46051690|NCT04559100|Radiation|chest radiography|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
46051691|NCT04559100|Radiation|thoracic computed tomography scan|6 and 12 months after hospital discharge, if the patient had a CT scan upon admission to the hospital. If the study is normal at 6 months it will not be repeated at 12 months.
46051692|NCT04559100|Diagnostic Test|spirometry|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
46051693|NCT04559100|Diagnostic Test|Diffusing capacity of carbon monoxide|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
45367096|NCT05277974|Drug|inj bupivicain|In goup B 30ml of inj. bupivicaine only will be given in Erector Spinae Plane Block and In Group D inj Bupivicain plus inj dexamethasone will be given
45367097|NCT00504777|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
45846000|NCT04156854|Diagnostic Test|Quantitated Blood Volume Analysis|Measurement of total blood volume, composed of red blood cell mass (RBCM) and plasma volume (PV) by administering low dose iodinated I-131 labeled albumin intravenously then taking blood samples at timed increments.
46051694|NCT04559100|Diagnostic Test|6 minute walk test|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
45367098|NCT00504777|Drug|Methotrexate|10-25mg/week po or parenteral
45367099|NCT00902798|Behavioral|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
45367100|NCT00902798|Behavioral|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
45691180|NCT05554042|Diagnostic Test|Kintsugi Voice Device|The Kintsugi Voice Device is an API with an underlying machine learning algorithm that drives the Device outputs. Depression and Anxiety are separate algorithms. The Device is designed to be adjunct to clinical assessment and estimate the presence of vocal characteristics consistent with a significant depressive episode and/or a clinically significant anxiety state, which are a necessary condition for the diagnosis of lifetime mood disorders, such as major depressive disorder and/or generalized anxiety disorder. Kintsugi Voice Device is not to be used in-lieu of full patient evaluation or relied upon to make or confirm diagnosis.
45846001|NCT04151550|Device|Bilateral Laser Scleral Microporation procedure|"Device: Laser Scleral Microporation~Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern."
45847929|NCT03080142|Drug|Ropivacaine|Patients will receive 30ml of ropivicaine. Peripheral nerve catheters will be placed approximately 3-5cm into the TAP space and secured to the skin with tegaderm tape. Infusions will be ordered with CADD pumps and will be initiated at a rate of 8ml/hr of 0.2% ropivicaine on the inpatient floor.
46051695|NCT04559100|Diagnostic Test|saint george respiratory questionnaire|6 and 12 months after hospital discharge.
45847930|NCT03085836|Drug|TAK-438|TAK-438 tablets.
46051696|NCT00778921|Drug|Amlodipine 10 mg|Amlodipine 10 mg
46051697|NCT00778921|Drug|Aliskiren 150|Aliskiren/Amlodipine 150/10 mg
45367101|NCT03968263|Device|Hycon device(Routine protocol)|Hycon device will be activated half a turn every 3 days.
45367102|NCT03968263|Device|Hycon device(Modified protocol)|The activation period of the hycon device will be modified.
45367103|NCT03968263|Device|Hycon device(Routine protocol) and Vibration(Acceledent)|Hycon device will be activated half a turn every 3 days. Vibration will be applied 2 times 10 minutes per day.
45367104|NCT03968263|Device|Hycon device(Modified protocol) and Vibration(Acceledent)|The activation period of the hycon device will be modified. Vibration will be applied 2 times 10 minutes per day.
46051698|NCT00778921|Drug|Amlodipine 300|Aliskiren/Amlodipine 300/10 mg
45367105|NCT00895076|Drug|dexamethasone|iontophoretic patch and injection
46051699|NCT04173312|Combination Product|Bupivacaine infusion|Local systemic Infusion of anesthetic
46051700|NCT04173312|Combination Product|Saline|Local systemic infusion of saline
46051701|NCT00915876|Drug|Paricalcitol|paricalcitol 1 mcg QD x 8 weeks
46051702|NCT00915876|Drug|Placebo|Placebo for Paricalcitol 1 mcg QD x 8 weeks
45367106|NCT01078519|Drug|Combined epidural and spinal anesthesia|Obstetrics patients will relieve spinal anesthesia with local anesthesics and opioids associated with epidural anesthesia with local anesthetics in low concentrations with opioids
45367107|NCT02539316|Drug|Smoflipid|
45367108|NCT02539316|Drug|Médialipides|
45367109|NCT00724997|Biological|GHB01L1|Study medication administered as a single intranasal aerosol (520ul) at doses of 6.4 log10, 6.7 log10, 7.0 log10, 7.4 log10 and 7.7 log10 TCID50/volunteer
45367110|NCT03968185|Other|Interfascial infiltration|"Injection of L-bupivacaine (50 mg) and dexamethasone (4 mg) in the interfascial space under ultrasound guidance.~Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
45483971|NCT01342809|Behavioral|Follow up|Follow up, consultations with general practitioner, written guidelines, supervision.
45691181|NCT05621434|Drug|Inetetamab, pyrotinib, chemotherapy|"Inetetamab: was administered as an intravenous (IV) loading dose of 8mg/kg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 6mg/kg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~pyrotinib: 400 mg once daily orally within 30 minutes after a meal at the same time each day.~chemotherapy:Taxanes (paclitaxel, docetaxel, liposomal paclitaxel, nabpaclitaxel), vinorelbine, capecitabine, eribulin, and other chemotherapeutic agents indicated in advanced breast cancer are permitted. Refer to the appropriate package insert for dosage and administration recommendations."
45847931|NCT03088800|Drug|Ibuprofen|Oral Ibuprofen at 10 mg/kg dose
45367111|NCT03968185|Other|Standard medical treatment|"Standard medical treatment include acetaminophen, NSAIDs and muscle relaxant as first line pharmacological treatment and escalation to analgesics level II or morphine if required, as needed for low back pain, in agreement with national guidelines Route of administration (orally or iv) was let at the discretion of the attending emergency physician.~Patients were kept under surveillance for one hour before discharge. Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
45367112|NCT00509769|Drug|Trastuzumab emtansine [Kadcyla]|Trastuzumab emtansine was provided in either a liquid or a lyophilized formulation.
45367113|NCT05206877|Drug|Insulin, 4 units|Topical insulin 100 U/ml, 1 drop per day
45367114|NCT05206877|Drug|Insulin, 20 units|Topical insulin 500 U/ml, 1 drop per day
45847932|NCT03088800|Drug|APAP|Oral APAP at 15mg/kg dose
46051703|NCT04079244|Behavioral|Video game|"Children receive a tablet with a video game at their arrival on the unit until the introduction of the anesthesia mask.~The video game used is Le Héros C'est Toi, a game specially developed for the unit. The game recreates the hospital environment and includes mini-games geared to children."
45483972|NCT02459860|Behavioral|Problem Solving Treatment|Individual, face-to-face PST sessions over a span of 8 weeks will be held at PACE sites. The first session will last one hour while subsequent sessions will last 45 minutes. After the last PST session, each subject will have 3 monthly booster sessions (about 15 minutes). The PST protocol is intended to be highly structured, time-limited, and manual-driven; sessions include PST hand outs and homework as well as social and behavioral activation strategies, i.e., pleasant activities scheduling. All interventionists will document attendance and provide a post-session fidelity summary. 10% of the individual sessions will be videotaped with patient consent to assess fidelity and training needs.
45847933|NCT03092934|Drug|LY3295668|Oral capsules
46051704|NCT04079244|Behavioral|Animated cartoon|"Children receive a tablet with an animated cartoon at their arrival on the unit until the introduction of the anesthesia mask.~The cartoon used is L'âge de glace, an animated cartoon geared to children."
46051705|NCT00587431|Drug|GnRh (Leuprolide)|Leuprolide LUPRON
45367115|NCT02531503|Other|Clinical asthma remission|Clinical asthma remission was defined as having no asthma symptoms and no use of medication during the past 12 months.
46051706|NCT00587431|Drug|Testosterone Gel|Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)
46051707|NCT00587431|Drug|Docetaxel|70 mg/m2 given on day o1 of each 3 week cycle
45367116|NCT00902876|Device|Mucograft|Collagen Matrix for soft tissue regeneration
45846002|NCT04134000|Drug|Atezolizumab|1200 mg IV q3w until recurrence of disease, disease progression (e.g., muscle-invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
45367117|NCT00902876|Procedure|Coronally advanced flap (CAF)|
45367118|NCT02977715|Biological|IMVAMUNE (Liquid Formulation)|Two doses of attenuated live virus smallpox vaccine (IMVAMUNE liquid formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 108 Tissue Culture Infectious Dose 50 [TCID50] per 0.5 mL). A subset of participants will receive a booster dose.
45367119|NCT02977715|Biological|IMVAMUNE (Lyophilized Formulation)|Two doses of attenuated live virus smallpox vaccine (IMVAMUNE lyophilized formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 108 Tissue Culture Infectious Dose 50 [TCID50] per 0.5 mL). A subset of participants will receive a booster dose.
45483973|NCT02459860|Behavioral|Enhanced Usual Care|EUC patients will receive psychoeducational materials on depression and depression treatment of older persons. EUC patients will continue to receive the full complement of PACE services (medical, rehabilitation, social) including referrals to specialty mental health services, if indicated.
45483974|NCT01339065|Drug|Ketamine|determining the effect of low dose sub anesthetic doze of ketamine and placaebo on post operative patients
45483975|NCT02460016|Drug|AK0529|AK0529 pellets for oral administration
45483976|NCT03281746|Procedure|Dental Procedure|Undergo dental examination
45691182|NCT05621356|Other|A nasal fluid Basophil Activation Test (BAT)|a BAT technique for monitoring the inhibitory effect of nasal fluid on basophil activation.
45691183|NCT04415203|Device|Transcutaneous acupoint electrical stimulation (TAES)|Patients in TAES group will receive TAES and usual care. TAES will be performed on Neiguan (PC6), Shenmen (HT7), Erzhong and Xin (Auricular Acupuncture Point) for 6 weeks by using the Huato type SDZ-V stimulator; Usual Care: usual medicine treatment for PVCs.
46051708|NCT04550988|Other|feasibility study|The aim of this study is to evaluate the possibility of establishing a patient-based ultrasound monitoring of the knee (representing a target joint accessible with any hand) with a handheld device.
46051709|NCT00776659|Other|Aromasin|Non-Interventional study design.
46051710|NCT04235712|Other|Harmonized Depression Outcome Measures|This is an observational study where outcome measures will be extracted from patients' medical records and from questionnaires to provide information back to the clinician.
45367120|NCT01074697|Drug|Fosaprepitant dimeglumine|Addition of fosaprepitant dimeglumine 150 mg IV single dose weekly (before chemotherapy) to dexamethasone and palonosetron.
45367121|NCT01074697|Drug|Placebo|Saline water
45367122|NCT05124275|Drug|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
45367123|NCT05124275|Drug|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
45367124|NCT05124275|Drug|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
45367125|NCT05124275|Drug|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
45483977|NCT03281746|Other|Educational Intervention (prevention education)|Receive prevention education
45483978|NCT03281746|Other|Interview|Ancillary studies
45483979|NCT03281746|Other|Survey Administration|Ancillary studies
45367126|NCT02539082|Device|Regenseal|Regenseal, collagen, injection in the defect area
45367127|NCT02539082|Drug|normal saline|placebo, normal saline, injection in the defect area
45483980|NCT03281746|Other|Educational Intervention (one-on one education)|Receive one-on-one education
45483981|NCT05187507|Other|Evaluation of the effectiveness of low- fluoridated toothpaste.|"Children will be given low- fluoridated toothpaste, plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
45483982|NCT05187507|Other|Evaluation of the effectiveness of fluoridated toothpaste.|"Children will be given e fluoridated toothpaste, plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
45483983|NCT05187507|Other|Evaluation of the effectiveness of theobromine toothpaste (2%) toothpaste.|"Children will be given theobromine toothpaste(2%),plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
45846003|NCT04134000|Drug|BCG|1 or 1/2 instillation per week until recurrence of disease, disease progression (e.g., muscle-invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
45846004|NCT04099290|Other|Blood and tumor samples|Blood samples to be obtained at consent, post-operatively, post-adjuvant treatment, and at follow-up or recurrence. Tumor samples to be obtained at surgery and at time of recurrence or post-treatment biopsy, if applicable.
45367128|NCT03997695|Other|Core stabilization exercise group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
45367129|NCT03997695|Other|Core stabilization exercise plus kinesio taping group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
45367130|NCT01074775|Biological|Gut infection challenge with M bovis|Oral delivery of 100mg viable M bovis (approximately 10,000,000 viable bacilli) in 5mL 1.5% sodium glutamate solution on three occasions on days 0, 28 and 49
45846005|NCT04095858|Drug|Efprezimod alfa|IV infusion: 480 mg at Day -1, 240 mg at Day 14, 240 mg at Day 28.
45846006|NCT04095858|Drug|Placebo|IV infusion, 100 ml at Day -1, Day 14, and Day 28.
45483984|NCT05187507|Other|Evaluation of the effectiveness of theobromine toothpaste(4%) toothpaste.|"Children will be given theobromine toothpaste(4%),plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
45691184|NCT04415203|Device|Sham Transcutaneous acupoint electrical stimulation (Sham-TAES)|Patients in sham-TAES group will receive sham-TAES and usual care. Sham-TAES will be also performed on Neiguan (PC6), Shenmen (HT7), Erzhong and Xin (Auricular Acupuncture Point) for 6 weeks by using a special Huato type SDZ-V stimulator. We cut the inner electric wire of the stimulator; therefore, there is no current output. Usual Care: usual medicine treatment for PVCs.
45691185|NCT04741204|Drug|Metformin Extended Release Oral Tablet|initial dose of metformin of 750 mg Q.D. (with dinner) for 3-4 weeks. They then will be increased to the final dose of 750 mg BID (breakfast and dinner) until the end of the study.
45691186|NCT01870843|Drug|Escitalopram|Escitalopram will be administered as oral tablets 10 mg per day and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
45691187|NCT01797952|Drug|Lactobacillus CD 2|2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
46051711|NCT00825682|Other|Reflexology treatment.|Reflexology treatments (45 min. each) will be initiated at the beginning of radiation therapy, once a week, for 10 weeks.The treatment includes manual pressure on specific points of foot soles and massage of the calf area, adapted individually to each patient.
45691188|NCT01797952|Other|Placebo|The placebo is a mix of sugars and salts used as excipients in the active formulation
45483985|NCT01339143|Drug|Galvus (vildagliptin)|50mg BID, PO, for 16 weeks
46051712|NCT00632268|Drug|RAD001; Cisplatin; 5-FU; Leucovorin|RAD001: oral 10mg/day on Day 1,8,15 Cisplatin:infusion 35mg/m2/day on Day 1,8 5-FU:infusion 2000mg/m2/day on Day 1,8,15
45483986|NCT01339143|Drug|pioglitazone|15mg, QD, PO, 16 weeks
45483987|NCT03281434|Dietary Supplement|Collagen peptide|Low leucine content protein supplement to be consumed twice daily
45483988|NCT03281434|Dietary Supplement|Whey protein isolate|High quality protein (DIAAS score), high leucine supplement, to be consumed twice daily
45691189|NCT04725838|Device|Medtronic Intellis™ and Vanta™|Differential Target Multiplexed (DTM®) programming using Medtronic's Intellis™ or Vanta™ Spinal Cord Stimulation systems
45846007|NCT04095858|Drug|Methotrexate|IV, 15 mg/m^2/dose at Day 1, then 10 mg/m2/dose at Day 3, 6, 11.
45846008|NCT04095858|Drug|Tacrolimus|Begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted
45846009|NCT04092348|Other|complete blood count|"total RNA is isolated from fresh blood samples~RNA is converted into complementary DNA c.DNA~cDNA is then analysed by quantitatine Real Time PCR(qRT-PCR) to evaluate the relative expression levels of FoxO3a, PU.1 genes and TATA-binding protein (TBP) ,as an endogenous control gene."
45846010|NCT04073862|Other|Stepped-Care TF-CBT|SC-TF-CBT will be administered to children meeting the inclusion criteria of the study. The treatment aims to improve daily function for trauma-exposed children and their families by way of stress-mastery exercises, coping skills and gradual exposure.
45846011|NCT04057716|Behavioral|Sleep restriction|Participants will be asked to restrict their time in bed to 8 hours each night for one week.
46051713|NCT05469568|Other|Circuit training followed by telerehabilitation|Patients participate in an ambulatory rehabilitation program (12 weeks) and then gain access to mobile application to record their movement activities. This application will aslo inlude a library with exercise vidoes from the ambulatory program. These videos should inspire patients to do the exercises at home.
46051714|NCT05469568|Other|Usual care|Patients have usual information about importance of regular movement activities and recommendation of proper exercises
46051715|NCT04145076|Drug|Placebo|Two oral doses of placebo.
45367131|NCT01080079|Drug|Terbinafine Hydrochloride|4% w/w Terbinafine Hydrochloride Gel
45367132|NCT01080079|Other|Purified Water|Purified Water
45367133|NCT02538536|Drug|PBI4050|
45367134|NCT00725231|Biological|alemtuzumab|Addition of 30 mg Alemtuzumab by subcutaneous application for the first 4 cycles
45367135|NCT00725231|Drug|chemotherapy|dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
45367136|NCT02539238|Other|Longitudinal practice and real-time feedback|Brief CPR practice distributed during working hours with real-time feedback
45367137|NCT03381521|Procedure|Ultrasound-guided nerve hydrodissection|Ultrasound-guided nerve hydrodissection with 10cc normal saline between carpal tunnel and median nerve.
45367138|NCT03381521|Procedure|Ultrasound-guided nerve hydrodissection|Ultrasound-guided nerve hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
45846012|NCT04057716|Behavioral|Sleep extension|Participants will be asked to extend their time in bed to 11 hours each night for one week.
46051716|NCT04145076|Drug|Citalopram|Single oral dose of citalopram (20mg) and single oral dose of placebo.
46051717|NCT04145076|Drug|Tianeptine|Single oral dose of tianeptine (12.5mg) and single oral dose of placebo.
46051718|NCT00707902|Drug|chlorhexidine/lidocaine|
46051719|NCT00707902|Drug|echinacea/sage|
46051720|NCT04107025|Other|HELP|Individual counseling were given to each intervention group participant. They were assisted with safety, emotional and mental support and referrals for health and financial assistance. Participants were also given handout to manage anxiety and panic situations during the legal procedures.
46051721|NCT00704860|Other|Open label pharmacotherapy|"Dosage and drug types change based on patients need and response.~doxepin, clomipramine, amoxapine, amitriptyline, maprotiline, desipramine, nortriptyline, trimipramine, imipramine, protriptyline, isocarboxazid, phenelzine, tranylcypromine, moclobemide, fluvoxamine, paroxetine, fluoxetine, sertraline, citalopram, escitalopram, venlafaxine, atomoxetine, pramipexole, bromocriptine, quetiapine, clozapine, olanzapine, ziprasidone, aripiprazole, paliperidone, Risperidone, bupropion, mirtazapine, pindolol, topiramate, trazodone, Lithium,"
45367139|NCT03381521|Device|Ultrasound|The ultrasound was used to measure cross-sectional area and injection guidance
45367140|NCT03381521|Drug|Normal saline|The normal saline was used for injection solution
45367141|NCT00114127|Drug|Duloxetine|60 mg duloxetine 1x per day
45367142|NCT00114127|Drug|Duloxetine|60 mg duloxetine 1x per day + 60mg duloxetine 1x per day
45367143|NCT00114127|Drug|Placebo|60mg placebo 1x per day
45367144|NCT05158179|Device|Sensation testing|Sensation testing tactile aesthesiometer.
45367145|NCT00902954|Drug|anastrozole|anastrozole 1 mg qd
45367146|NCT00902954|Drug|letrozole|letrozole 2.5 mg qd
45367147|NCT00902954|Drug|exemestane|exemestane 25 mg qd
45367148|NCT02570009|Behavioral|TEAMS (Talking about Eating, Activity, Mutual Support)|
45367149|NCT02570009|Behavioral|Need Support Training|
45367150|NCT04034966|Device|Claria telemedicine device|Use of Claria telemedicine module, which stores patient information in the cloud.
45367151|NCT05077553|Dietary Supplement|TCI999 probiotic sachet|Testing product
45367152|NCT05077553|Dietary Supplement|Placebo sachet|Blank
45846013|NCT04025580|Biological|Flucelvax|Seasonal influenza vaccine
45846014|NCT04025580|Biological|Fluvirin|Seasonal influenza vaccine
45846015|NCT04025580|Biological|Fluzone High Dose|Seasonal influenza vaccine for adults ages 65 and older
45483989|NCT05185245|Procedure|Liver Transplantation|Liver Transplantation for Non-Resectable Colorectal Liver Metastasis
45691190|NCT01816477|Device|ON-Q soaker catheter system|"ON-Q soaker catheter system with Ropivicaine at 7 cc per hour placed by a single surgeon in the operating room. 7.5 catheters will be tunneled subcutaneously in the anterior axilla bilateral and secured with steri-strips and dressing. ON-Q systems will be primed with 750 cc and refilled accordingly to provide for 6 days of analgesia. Catheters will be removed by the surgeon in the hospital or clinic on the 6th post operative day. Patients may request removal of the catheter prior to the 6th day and this will not be considered a withdrawal from the study or complication and will be included in overall analysis, but noted accordingly."
45691191|NCT01816477|Drug|Epidural (ropivicaine 0.25%)|Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
45691192|NCT01846507|Drug|Tranexamic Acid|Subjects will be instructed to take 2 tablets (1300) mg of Lysteda three times daily (3900 mg/daily) for five days during monthly menstruation.
45846016|NCT04008108|Other|Activity sensor|Activity sensor worn on the wrist during 7 days, 24h/24 to evaluate physical activity of patient (measured by the number of step per day) before and after Artificial Urinary Sphincter Implantation.
45846017|NCT03958266|Device|MyIBD Care|Novel mobile phone application
45846018|NCT03937986|Drug|Suvorexant|The pharmacodynamic effects of suvorexant maintenance will be determined.
45846019|NCT03937986|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and suvorexant.
45846020|NCT03937986|Drug|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined.
46051722|NCT05511337|Other|Caloric restriction and control oxalate and citrate foods|Restriction of 500 kilocalories from the usual diet plus a decrease in oxalate-rich foods (< 40 mg per day) and an increase in citrate-rich foods (> 40 mEq per day) for 28 days. The treatment will be given through an individualized meal plan.
46051723|NCT05511337|Other|Caloric restriction|Restriction of 500 kilocalories from the usual diet for 28 days. The treatment will be given through an individualized meal plan
46051724|NCT05511337|Other|Real-life intervention with control oxalate and citrate foods|Decrease in oxalate-rich foods (< 40 mg per day) and an increase in citrate-rich foods (> 40 mEq per day) without restriction in kilocalories from the usual diet for 28 days. Treatment will be given only through dietary counseling.
46051725|NCT03360942|Device|SCC DBS|Deep Brain Stimulator
45691193|NCT05615038|Procedure|Contact aspiration Thrombectomy|Contant aspiration is an approach that utilizes the advantages of large-bore aspiration catheters that can be easily tracked and introduced into the cerebral circulation to directly remove the thrombus via negative pressure aspiration.
45691194|NCT05615038|Procedure|Stent retriever thrombectomy|Stent retriever thrombetomy is an approach that utilize sself-expandable stent for thrombectomy. The stent retriever is expanded to capture the thrombus, which immediately may restore blood flow.
45846021|NCT03911856|Other|Echocardiography|We hypothesize that non-invasive indices of RV (echocardiograph-derived strain and strain rate) and pulmonary (gas exchange-derived lung diffusion and surface area) function during light exercise will successfully identify and discern patients with known RV dysfunction (PAH/HFpEF with RV failure) from those with known pulmonary dysfunction (PAH/HFpEF with pulmonary fibrosis). Additionally, we hypothesize that our assessment techniques will identify subtle derangements in RV and pulmonary function in newly diagnosed PAH and HFpEF patients, and that this may guide early and targeted therapeutic intervention.
46051726|NCT04533672|Diagnostic Test|MRI Sequences|New multiparametric MRI techniques
46051727|NCT00833794|Drug|Tramadol Once a day|
46051728|NCT00833794|Drug|Placebo|
46051729|NCT00912288|Drug|Dimebon 20 mg po TID|Dimebon 10 mg po TID for 1 week followed by Dimebon 20 mg TID for 25 weeks
46051730|NCT00912288|Drug|Placebo po TID|Placebo (matched to Dimebon) po for 26 weeks
46051731|NCT00778375|Drug|Clofarabine|20 mg/m^2 by vein as a 1- to 2-hour intravenous infusion daily for 5 days.
45483990|NCT03271684|Other|self-management|one session of up to one-hour per week over a six-week period in addition to their usual rehabilitation. During each session strategies will be used to promote specific behaviors that exemplify the hallmarks of self-management. These behaviors include enabling patients to work out ways of taking control of their daily lives by setting small targets, recording their progress and problem-solving. The content of the sessions is determined by the patient and their personal goals rather than being professionally directed
45483991|NCT03271684|Other|Control|Participants will receive usual rehabilitation treatment, they will also be given a booklet with education program and exercises they can perform at home.
45483992|NCT05130411|Dietary Supplement|DLM - Test product|The group will receive 60 gummies each (to take two gummies per day) across a four-week period. Each participant shall take two gummies per day
46051732|NCT00778375|Drug|Cytarabine|20 mg subcutaneously twice daily for 10 days, administered 3 to 6 hours following the start of the clofarabine infusions.
45367153|NCT00572624|Behavioral|Diet|Participants attended 20 group behavioral modification sessions led by a behaviorist, a registered dietician, and a physical therapist. The meal plans ranged from 1200 to 1500 kilocalories per day, depending on subject sex and BMI, and were designed to achieve ≤1% body weight loss/week. Participants completed daily food records, and were taught a variety of weight management skills. The exercise component included strength, flexibility, balance, and endurance instruction, gradually increasing to 30 minutes of exercise 5 days/week.
45367154|NCT00572624|Procedure|Gastric bypass surgery|The same surgeon performed all bypass procedures using standard techniques. A small (~20 ml) proximal gastric pouch was created by stapling the stomach, and a 75-cm Roux-en-Y limb was constructed by transecting the jejunum distal to the ligament of Treitz, and creating a jejunojejunostomy 75 cm distal to the transection.
45367155|NCT02540720|Drug|Dexamethasone|
45367156|NCT02540720|Drug|Gamma globulin|
45367157|NCT02540720|Procedure|Hemoperfusion|
45367158|NCT02540642|Dietary Supplement|METHYLCOBALAMIN 500 micrograms|Tab Methycobalamin 500 ug will be given with other regular antidiabetic drugs
45367159|NCT00122317|Drug|eculizumab|
45483993|NCT03264430|Drug|Ketamine|an antagonist of the NMDA receptor
45483994|NCT03264430|Drug|bupivacaine|local anaesthetic
45691195|NCT05613790|Device|Active High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|Portable multi-channel tES stimulation (Starstim 8, Neuroelectric, Barcelona, Spain) will be used.
45483995|NCT01339221|Procedure|Stool samples|Stool samples collected and checked for the presence of rotavirus
45483996|NCT03269890|Procedure|Capsule and cutaneous blocks|7.5 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml for both blocks once before surgery per side
45483997|NCT03269890|Procedure|US-intermediate cervical plexus block|15 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml once before surgery per side.
45483998|NCT03269812|Procedure|laparoscopic assisted pull-through oeration|Under general anesthesia and insertion of ports for laparoscopic instruments, laparoscopic assisted mobilization of sigmoid colon and dissection till pelvis and removal of a ganglionic segment of colon and laparoscopic assisted pull through of colon then colo-anal anastomosis will be done,
45483999|NCT01336725|Behavioral|Teaching life style changes|Single group: Teaching, group sessions, physical activity
45484000|NCT01336725|Other|Active participation|Obesity group attend 10 group sessions,are informed about and discuss needed life style changes such as weight loss and participate in physical activity and cooking.
45691196|NCT05613790|Device|Sham High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|Portable multi-channel tES stimulation (Starstim 8, Neuroelectric, Barcelona, Spain) will be used.
45367160|NCT00895388|Behavioral|Structured Rehabilitation program|Questionnaire send by post at 3, 6, 12, 18 and 24 months after operation
45367161|NCT00895466|Biological|PEP-223/CoVaccine HT|
45484001|NCT01336725|Other|Teaching|Morbid obesity group attend 40 hours of group sessions
45484002|NCT03270124|Behavioral|Daily Activity Goal|Patients are given a tailored daily activity goal in terms of steps per day for which to aim.
45484003|NCT03270124|Behavioral|Resistance Exercises|Patients will instructed to perform 3 different resistance exercises targeting muscles pertinent to activities of daily living on 6 out of 7 days a week.
45691197|NCT01846039|Device|Crosslinked hyaluronic acid gel|Up to 3 mL administered by intradermal injection
45367162|NCT03964675|Device|SenseGuard|A single invitational visit with a respiratory rate measurement duration of 30 minutes.
45367163|NCT03870555|Drug|TAK-954|TAK-954 infusion administered intravenously.
45367164|NCT03870555|Drug|TAK-954 Placebo|TAK-954 placebo-matching infusion intravenous.
45367165|NCT02569931|Other|Gait analysis|Participants will be asked to walk on an instrumented treadmill. The study group will undergo gait analysis before surgery and 6 months after surgery. The control group will undergo gait analysis at one visit only.
45367166|NCT02569931|Other|Electromyography|Participants in the study group will undergo electromyography before and 6 months after surgery. Participants in the control group will undergo electromyography at one visit only
45484004|NCT03270124|Behavioral|Daily Activity Recording|A Fitbit will be worn by all participants to record daily activity.
45484005|NCT01339377|Device|AO-1000|Mixture of 2 weight% ozone in 98 weight% oxygen injected into the nucleus pulposus of a contained herniated disc.
46051733|NCT00778375|Drug|Decitabine|20 mg/m^2 as a 1- to 2-hour infusion daily for 5 days.
46051734|NCT04102267|Drug|Bupivacaine liposome injectable suspension|Liposomal bupivacaine 266 mg via injection
46051735|NCT04102267|Drug|Bupivacaine HCl without epinephrine via continuous infusion|Bupivacaine HCl 300 mg via continuous infusion
46051736|NCT02602171|Other|Oldenburger sentence test, localization test|
46051737|NCT04202718|Diagnostic Test|VitalPatch Device|The VitalPatch® is an IRB (791130) and FDA approved wearable device that allows for the constant monitoring of biometric measurements and may have utility in the health management of individuals at high-risk for poor health outcomes and in the detection or prevention of adverse events within settings where more traditional telemetry monitoring devices are not currently in use.
46051738|NCT04498104|Other|Psychological assessment|Psychological assessment with the repertory grid technique (RGT) in order to quantify cognitive conflicts.
46051739|NCT00777829|Drug|zolpidem|Participants will receive one dose of 10 mg before each nap.
46051740|NCT00777829|Drug|Placebo|Participants will receive a dose of placebo before each nap.
45367167|NCT02569931|Procedure|Intra-operative tracking and pressure measurements|Participants in the study group will undergo intra-operative tracking and pressure measurements to see if corrective surgery to stabilise the patella improves tracking and pressure measurements
45367168|NCT00908336|Drug|Docetaxel and Erlotinib|Docetaxel (Taxotere®) 75 mg/m2 iv first day of each 21-day cycle. Erlotinib (Tarceva®) 150 mg po days 2-16 of each 21-day cycle. Total: 4 cycles in the absence of disease progression
45367169|NCT00908336|Drug|Erlotinib|150 mg/day po daily
45367170|NCT03964519|Other|Acute changes|In a crossover design, participants will be randomized to perform on Day 1, 3 sets of repetitions (depending on each treatment group) at 70% or 1RM in the full squat exercise. 48-h later, same will be performed but in the contrary crossover arm.
45367171|NCT03964519|Other|Chronic changes|In a randomized control trial, participants will train during 6 weeks the full squat exercise, 2 days in the week (minimum between-days rest of 48h). Intensity will vary from 70% to 85 of 1RM, and training volume from 3 to 6 sets.
45367172|NCT03964519|Other|Familiarization|Prior to any intervention, all participants will perform a familiarization of the exercise session, together with a progressive resistance test to estimate the 1 RM
45367173|NCT00908414|Drug|TMC589337 40 mg|Participants will receive TMC589337 40 mg in Session Ia of Panel 1.
45367174|NCT00908414|Drug|TMC589337 100 mg|Participants will receive TMC589337 100 mg in Session IIa of Panel 1.
45367175|NCT00908414|Drug|TMC589337 200 mg|Participants will receive TMC589337 200 mg in Session IIIa of Panel 1.
45367176|NCT00908414|Drug|TMC589337 400 mg|Participants will receive TMC589337 400 mg in Session IVa of Panel 1.
45367177|NCT00908414|Drug|TMC589354 40 mg|Participants will receive TMC589354 40 mg in Session Ib of Panel 2.
45367178|NCT00908414|Drug|TMC589354 100 mg|Participants will receive TMC589354 100 mg in Session IIb of Panel 2.
45484006|NCT03281356|Behavioral|Intervention Group|Participants will receive a total of 8 text messages during a 4 week period.
45484007|NCT05250999|Other|Skin stretch sensory stimuli|Skin stretch sensory stimuli will be exerted by a piece of kinesio tape that as applied above right and left lateral malleolus on posterior leg and on both side of spinous process of second thoracic vertebrae till 15cm below for 24 hours a day, 5 days/ week for 6 weeks along with conventional physiotherapy.
45484008|NCT05250999|Other|Transcutaneous Electrical nerve stimulation|TENS will be applied to patient while in sitting position for 30 minutes, twice a week, and for 6 weeks (12 treatment sessions along with conventional physiotherapy). A maximum of 25 m amp electrical stimulation with a biphasic square-wave pattern and a pulse width of 0.5ms in a continuous duty cycle will be used. The intensity of the electrical stimulation will be regulated to the high tolerable level without initiating muscle contractions.
45484009|NCT05250999|Other|Control Group|This program include balance exercises performed twice a week for 6 weeks, which consists of balance, progressive strength, and functional mobility training. Static exercise consists of heel and toe raises, one-legged stance for each limb, weight shifting forward, backward, sideward and diagonally, and turning the head to the left and then to the right keeping the feet together. This exercise comprises two 10-min sessions each, with eyes opened and eyes closed, respectively. Dynamic exercise comprises of walking, step-ups, and bipedal jumps for 10 min. Progressive balance exercises comprises of narrow walking, walking backward, walking sideward, stepping over obstacles, passing, throwing and catching a ball.
45484010|NCT03281278|Other|standard treatment|standard medical treatment
45484011|NCT05250921|Procedure|Corticision|Corticision will be performed to enhance teeth alignment.
45484012|NCT05250921|Device|Conventional fixed appliance|No surgical intervention is going to be applied to the patients in this group.
45367179|NCT00908414|Drug|TMC589354 200 mg|Participants will receive TMC589354 200 mg in Session IIIb of Panel 2.
45367180|NCT00908414|Drug|TMC589354 400 mg|Participants will receive TMC589354 400 mg in Session IVb of Panel 2.
45367181|NCT00908414|Drug|TMC589337 AA mg|Participants will receive TMC589337 AA mg on Days 1 to 7 in Session Va of Panel 3.
45367182|NCT00908414|Drug|TMC589354 BB mg|Participants will receive TMC589354 BB mg on Days 1 to 7 in Session Vb of Panel 4.
45367183|NCT00908414|Drug|TMC589337 CC mg|Participants will receive TMC589337 CC mg on Days 1 to 7 in Session VIa of Panel 5.
45367184|NCT00908414|Drug|TMC589354 DD mg|Participants will receive TMC589354 DD mg on Days 1 to 7 in Session VIb of Panel 6.
45367185|NCT00908414|Drug|TMC589337 EE mg|Participants will receive TMC589337 EE mg on Days 1 to 7 in Session VII of Panel 7.
45367186|NCT00908414|Drug|TMC589354 YY mg|Participants will receive TMC589354 YY mg on Days 1 to 7 in Session VII of Panel 7.
45367187|NCT00908414|Drug|TMC310911 300 mg|Participants will receive TMC310911 300 mg in Panel 3, 4, 5, 6 and 7.
45367188|NCT00908414|Drug|TMC310911 600 mg|Participants will receive TMC310911 600 mg in Panel 7.
45367189|NCT00908414|Drug|Placebo|Participants will receive matching placebo to TMC589337 or TMC589354 in Panel 1 and 2.
45367190|NCT01074853|Drug|propranolol|10mg twice daily escalated to 80mg once daily
45367191|NCT01074853|Drug|placebo|Matched placebo
45367192|NCT03870477|Device|THP Hip Fracture Plating System with telescoping lag screws|The fracture plates are contoured plates used in conjunction with telescoping lag screws that are 7.5mm in diameter with lengths ranging from 70mm to 130mm in 5mm increments.
45367193|NCT02570633|Other|Extract of ginger|Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.
45367194|NCT02570633|Other|Cellulose|Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.
45367195|NCT00908492|Behavioral|Education Control|Caregiver participants are provided with information about caregiver stress and discuss it individually with an interventionist who visits the home. The control intervention involves 5 visits over 6 months.
45367196|NCT00908492|Behavioral|Environmental Skill Building|The ESP intervention addresses home modifications and training in their use, instruction in strategies of problem-solving, energy conservation, safe task performance, fall recovery techniques, and balance and muscle strength training. Intervention is individualized for target areas identified in the initial client assessment and caregiver interview. The intervention involves using a problem solving approach and client-centred focus and the intervention assessment tools are individualized measures which determine the goals identified by the caregiver. It involves 5 visits over 6 months.
45484013|NCT03281122|Drug|Placebo|Specified dose on specified days
45484014|NCT03281122|Drug|BMS-986224|Specified dose on specified days
45484015|NCT03635463|Device|twin block appliance|a functional appliance that enhances mandibular growth in growing patients made from vaccum sheets (esthetic)
45484016|NCT03635463|Device|modified twin block appliance|a convetional twin block functional appliance that enhances mandibular growth in growing patients
45484017|NCT02713594|Behavioral|Counseling from WTQL|Counseling from the Wisconsin Tobacco Quit Line (WTQL) consisted of 5 proactive calls to the participant to help them successfully quit tobacco use, plus ad hoc calls at the participant's initiation; also, WTQL coaches encouraged participants to see their health care provider to obtain Medicaid-approved smoking cessation medications to help them quit smoking.
45484018|NCT02713594|Other|Financial incentive to participate|Participants in the Incentive condition received $30 per call for up to five WTQL calls taken; in addition, Incentive condition participants received $40 for producing biochemical evidence of abstinence at the 6-month follow-up visit. (Note that participants in both the Control condition and the Incentive condition received $40 for completing the baseline biochemical smoking status assessment visit and $40 for completing the 6-month follow-up biochemical smoking status assessment visit.) Compensation was in the form of prepaid Visa gift cards mailed approximately 2-4 weeks after the point of contact.
45484019|NCT01339455|Procedure|AHSCT|"AHSCT Procedure:~Mobilization and Harvesting:~Cyclophosphamide~Rituximab~GSCF~Dexamethasone~Apheresis~Conditioning and Infusion (3-4 weeks after Mobilization and Harvesting):~Cyclophosphamide~MESNA~Rabbit ATG~Rituximab~Methylprednisolone~Stem Cell infusion~GSCF"
45484020|NCT01339533|Device|Mechanical Ventilation|Patients who experience problems breathing and require assistance in breathing are placed on a machine that delivers air to the lungs through a tube through the vocal cords. This study is testing 3 protocols for that machine.
45484021|NCT03281044|Drug|Fecal microbiota capsules|Patients will receive FMT capsules DE containing the fecal microbiota drug substance within a gelatin capsule shell. The drug substance is fecal microbiota from a single donor.
45484022|NCT03281044|Drug|Placebo oral capsule|The control condition is a placebo FMT capsule. The FMT placebo capsule is identical in appearance to active capsules, but does not contain human feces, the active pharmaceutical ingredient. Placebo capsules will contain an autoclaved solution of glycerol and saline, contained in an identical gelatin capsule as the active product, including the same enteric polymer coating
45484023|NCT05250843|Procedure|TACE/HAIC|Within 1-3 days of lenvatinib and sintilimab, start Transarterial chemobolization treatment or FOLFOX-based chemotherapy infusion,after three months,patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection.
45484024|NCT05250843|Drug|Lenvatinib|Participants received lenvatinib capsules 8mg for patients weight <60kg, or 12mg for patients weight more than 60Kg.
45484025|NCT05250843|Drug|Sintilimab|Sintilimab Injection will be administered every three weeks (200mg) until surgery or disease progression.
45484026|NCT05250843|Procedure|liver resection|liver resection is feasible after evaluation by the liver cancer surgery expert group
45484027|NCT01336881|Genetic|RNA analysis|
45484028|NCT01336881|Genetic|gene expression analysis|
45484029|NCT01336881|Genetic|microarray analysis|
45484030|NCT01336881|Genetic|nucleic acid sequencing|
45367197|NCT04880291|Drug|GFB-024|Peripherally acting Cannabinoid-1 receptor inverse agonist monoclonal antibody
45367198|NCT04880291|Drug|Placebo|Matched placebo
45484031|NCT01336881|Other|diagnostic laboratory biomarker analysis|
45484032|NCT02458612|Other|control group|We will apply traditional physiotherapy including upper limb exercises in three times a week for 12 week.
45484033|NCT02458612|Other|intervention group|"Participants allocated to the experimental group completed three times a week, 12-week mirror therapy combined with progressive strength training. This protocol consisted of mirror therapy with a mirror box, strength training with Thera-band and exercises for scapular dyskinesis. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly."
45484034|NCT03264274|Drug|Aflibercept|Antiangiogenic
45484035|NCT03264274|Procedure|Dynamic Contrast Enhanced Ultrasound|DCE-US (a technique using differential liver blood flow assessments using microbubble) will be performed at baseline, Week 2 and 8 of treatment.
46051741|NCT00632190|Other|fluorophotometry|
46051742|NCT00632190|Procedure|colposcopic biopsy|
46051743|NCT00632190|Procedure|colposcopy|
46051744|NCT00632190|Procedure|light-scattering spectroscopy|
46051745|NCT00916045|Drug|Thiotepa|
45367199|NCT00908570|Drug|estriol|4 ml vaginal cream (1.0 mg estriol/1 ml cream), 3 days/week for approximately 2 months.
45367200|NCT00908570|Drug|Placebo|Placebo cream
46051746|NCT00916045|Drug|Fludarabine|
46051747|NCT00916045|Drug|Intravenous busulphan|
46051748|NCT00916045|Drug|Thymoglobulin|
46051749|NCT00916045|Drug|Ciclosporin|
46051750|NCT00916045|Drug|Mycophenolate mofetil (MMF)|
46051751|NCT00916045|Drug|Fludarabine|
46051752|NCT00916045|Drug|Cyclophosphamide|
46051753|NCT00916045|Radiation|Radiotherapy|
46051754|NCT00916045|Drug|Thymoglobulin|
46051755|NCT00916045|Drug|Ciclosporin|
46051756|NCT00916045|Drug|Mycophenolate mofetil (MMF)|
45367201|NCT01010607|Device|Vibration and Mirror|10 treatments of 30 minutes in which vibration of 50-100 Hz will be administrated to the elbow and wrist muscles together with the use of a mirror. The patient moves his healthy hand in a certain repetitive pattern and watches its reflection on a mirror. Meanwhile he receives vibration in his affected hand in a timing that induces the illusion of movements similar to the movements of his healthy hand, thereby inducing a strong illusion of movement of his affected hand.
45367202|NCT01010607|Device|Mirror therapy|10 sessions of mirror therapy: moving the healthy hand while watching its reflection on a mirror. Meanwhile sham vibration over bone in the affected handwill be given to resemble the conditions of the experimental arm.
45367203|NCT01010607|Device|no mirror, sham vibration|10 sessions in which patient moves his healthy hand and tries to move his affected hand, which is hidden by an opaque board instead of a mirror. Sham vibration is applied to bone instead of muscle, no illusion is generated.
46051757|NCT00916045|Drug|Fludarabine|
46051758|NCT00916045|Drug|Melphalan|
46051759|NCT00916045|Drug|Thymoglobulin|
46051760|NCT00916045|Drug|Ciclosporin|
46051761|NCT00916045|Drug|Mycophenolate mofetil (MMF)|
46051762|NCT04298970|Dietary Supplement|Intervention|Freeze-dried Brassica oleracea var. acephala
46051763|NCT04298970|Dietary Supplement|Placebo|Placebo product
46051764|NCT00916123|Drug|Docetaxel|75 mg/m2 by intravenous infusion over one hour on day 1 of a 21 day cycle.
46051765|NCT00916123|Drug|Prednisone|10 mg per day starting on cycle 1, day 1
46051766|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 20 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
45484036|NCT01339611|Behavioral|Educational program|Individual orientation (slides) during hospitalization period and telephone follow-up after discharge
45484037|NCT02457208|Drug|Isoniazid (H)|
45484038|NCT02457208|Drug|Rifampicin (R)|
45484039|NCT02457208|Drug|Pyrazinamide (Z)|
45484040|NCT02457208|Drug|Ethambutol (E)|
45367204|NCT00725777|Drug|artemether-lumefantrine|Standard artemether-lumefantrine treatment
45367205|NCT00165841|Drug|Rabeprazole 20 mg|rabeprazole sodium tablet 20 mg once daily
45367206|NCT00907166|Drug|CPI-613|IV infusion of CPI-613 given on Days 1,4, 8, 11, 15, 18, of 28 day cycle in cancer patients.
45367207|NCT00907166|Drug|CPI-613|IV infusion of CPI-613 given on Days 1, 4, 8, 11, 15, 18, of 28 day cycle in patients with pancreatic carcinoma.
45367208|NCT00907166|Drug|Gemcitabine|IV infusion of 1000 mg/m^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
45367209|NCT00907166|Drug|Gemcitabine|IV infusion of 1000 mg/m^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in cancer patients.
45367210|NCT00907166|Drug|Gemcitabine|IV infusion of 1000 mg/m^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
45367211|NCT00725855|Drug|MEM 3454|1 mg dose
45484041|NCT01337037|Device|VATS lobectomy using modified equipments|"the procedure of this group is the same with standard VATS lobectomy group.the VATS surgical equipments used in the group are designed according to the experience of chinese lobectomy surgery. All the patent applications of the surgical equipments are granted. proprietor of the patents is Jun Wang, head of Department of Thoracic surgery of people's hospital, peking university.~Details of the modified equipments: Lobectomy Equipments Pack (Manufacturer B.J.ZH.F.Panther Medical Equipment Co.,Ltd.) consists of 8 basic surgical equipments, which are crafoord dissecting and ligature forcep, Yankauer suction tube, mixter dissecting and ligature forceps(long),mixter dissecting and ligature forceps(short), atraumatic-grip aorta-aneurysma clamp with toothing De Bakey, De Bakey atraumatic-grip vascular forcep, Bozemann tite grip needle holder, Winter placenta and ovum forcep."
45484042|NCT01337037|Procedure|VATS lobectomy using less staples|VATS lobectomy with at most 4 staples used, aimed at reduced hospital cost.This procedure is similar with the standard VATS lobectomy procedure without staples limits. The lobar vessels and bronchus are stapled. However, the interlobar fissures should be deal with electronic cautery, harmonic scalpel,or suturing.
45484043|NCT01337037|Procedure|Standard VATS lobectomy|VATS lobectomy without new equipments and limitation of staples, same with the current procedure of VATS lobectomy performed in thoracic departments of Peking university people's hospital and the Collaborators. All procedures were conducted under general anesthesia with double lumen intubation. The thoracoscope was introduced through 7th or 8th intercostals space on the mid-axillaries line. The 4 cm long utility incision was made on the 4th or 5th intercostals space anterior axillary's line without rib-spreading. A third retraction incision located on the 7th or 8th intercostals space sub-scapular line. The surgeon stands on the ventral side of patient using an electrocautery hook and a suction device through the utility incision. Anatomic lobectomy was performed with systemic mediastinal lymph node dissection for lung cancer patients.
45484044|NCT01337037|Procedure|Open lobectomy|standard lobectomy procedure by thoracotomy approach
46051767|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 25 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
46051768|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 30 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
45367212|NCT00725855|Drug|MEM 3454|5 mg dose
45367213|NCT00725855|Drug|MEM 3454|15 mg dose
45367214|NCT00725855|Drug|MEM 3454|50 mg dose
45367215|NCT00725855|Drug|Placebo for MEM 3454|Placebo dose
45367216|NCT01326637|Other|Patient Overview Document|"The Intervention has two components:~Pre-visit care coordination:~5-7 days prior to a study patient's appointment with the doctor, the doctor's nurse/MA will call the study patient and collect pertinent clinical information using a data collection form we call a Patient Overview Document or POD. The purpose of the POD is to comprehensively inform the doctor about the patient before the doctor enters the exam room.~The nurse/MA will ensure that lab results, consultant reports, ER reports, imaging studies, etc., needed by the physician during the patient's visit, are available to the doctor in their usual place.~Team Meeting:~On the day of the patient's appointment, prior to the beginning of the clinic session, the nurse/MA and doctor will jointly review the POD."
45691198|NCT01610167|Device|NUPRO Classic Prophy Paste|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
46051769|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 35 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
46051770|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 40 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
46051771|NCT00775021|Device|etafilcon A|Contact Lens
46051772|NCT00775021|Device|nelfilcon A|Contact Lens
45846022|NCT03911856|Other|Pulmonary Gas Exchange|We hypothesize that breathing hyperoxia will increase exercise capacity by reversing RV and pulmonary derangements, and that the mechanisms of action will be related to the underlying dysfunction (e.g., reducing PVR, increasing RV functional reserve, increasing gas diffusion).
45367217|NCT02538458|Drug|3 % hypertonic saline up to 72H|Treatment by inhalation of 3 % hypertonic saline, up to 72H. Test group.
45367218|NCT02538458|Drug|3 % hypertonic saline up to 24H|"Treatment by inhalation of 3 % hypertonic saline, up to 24H.~followed by 48h of placebo : isotonic saline inhalation. Placebo control group."
45367219|NCT00509223|Device|Positive Airway Pressure therapy|Positive Airway Pressure (PAP) therapy initiated at Randomization and continued through the entire study duration (6 months), with instructions for use on a daily basis, during periods of sleep.
45484045|NCT01339845|Biological|ShanChol|Each dose of the vaccine contains whole cell Killed inactivated V.cholerae O1 and O139 strains.Vaccine is packaged as liquid formulations in 1.5-ml doses. The vaccine is given two doses separated by a two week interval and administered orally.
45484046|NCT01339845|Behavioral|Vaccine and behaviour|Together with vaccination the community health worker will offer a hand washing station and water treatment facilities that include both hardware and a software component. The idea of the handwashing station is to bring together with soap and water that people need for handwashing, especially for handwashing after defecation. The hardware for water treatment is a chlorine dispenser that is a reservoir which holds sodium hypochlorite and dispenses a measured dose of the dilute sodium hypochlorite into a 15 liter water tank. Community residents can collect water directly from the 15 L water tanks into their own personal water storage vessels. The community health worker will negotiate with compound residents for the development of a water treatment system.
45484047|NCT02457130|Drug|Ticagrelor|
45484048|NCT02457130|Drug|Clopidogrel|
45484049|NCT01337193|Other|Pelvic floor exercises with biofeedback|Exercises will be performed with assistance of biofeedback cueing
45484050|NCT01337193|Other|Pelvic floor muscle exercises|Exercises will b performed with verbal cueing of investigator.
45484051|NCT03280810|Other|Movement group|Experimental group : patients with schizophrenia who realise psycho-corporal training once a week, during 1 hour and a half for a period of two months
45484052|NCT02457052|Device|DATP|Medical device allowing a custom sitting to help patients with swallowing disorders
45367220|NCT00509223|Behavioral|Lifestyle counseling|Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.
45691199|NCT01610167|Device|NUPRO Sensodyne Prophy Paste with Novamin with fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
45367221|NCT01582867|Device|ARTIS hemodialysis system|"Software versions:~Control Product: 8.06.01KA. Study Product: 8.06.01B_HC01"
45484053|NCT05250531|Behavioral|multicomponent therapy|patient education,Exercise training,Private Psychotherapy,relaxation
45484054|NCT01340001|Procedure|Electrical stimulation of the nucleus basalis of Meynert|Differents parameters will be assessed.
45498134|NCT03689322|Other|WBVsham + IMTsham|Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
45691200|NCT01610167|Device|NUPRO Sensodyne Prophy Paste with Novamin without fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
45691201|NCT04478500|Drug|Minocycline|"Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo.~Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase."
45846023|NCT03873402|Biological|Nivolumab|Specified dose on specified days
45846024|NCT03873402|Biological|Ipilimumab|Specified dose on specified days
45846025|NCT03873402|Other|Ipilimumab placebo|Specified dose on specified days
45846026|NCT03851796|Behavioral|TEENS+Parents as Coaches|Parents as Coaches teaches parenting strategies to facilitate healthy weight loss in adolescent children; adolescents are in a group based behavioral weight management treatment.
45846027|NCT03851796|Behavioral|TEENS+Parent Weight Loss|Parent Weight loss teaches core behavioral weight loss strategies and techniques for parent weight loss; adolescents are in a group based behavioral weight management treatment.
45367222|NCT04984811|Drug|efineptakin alfa|1200 μg/kg NT-I7 administered intramuscularly (IM) once every 6 weeks (Q6W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
45367223|NCT04984811|Drug|Atezolizumab|1200 mg atezolizumab administered intravenously (IV) once every 3 weeks (Q3W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
45367224|NCT02538380|Procedure|EUS-B-FNA followed by EUS-FNA for LAG analysis|
45484055|NCT03269266|Diagnostic Test|Scrub Typhus RDT Test|"A transfer pipette or loop will be used to transfer 10 µL of whole blood from a finger prick to the sample pad area on the scrub typhus test strip and the test will be performed on site according to the manufacturer's instructions. Tests will be read by two independent readers and results recorded as positive, negative or invalid.~In patients with a skin eschar a sterile surgical blade will be used to gently scrape the surface of the eschar. Scrapings will be stored in a cryotube containing 95% ethanol and stored at -80°C for future analysis (PCR genotyping ± whole genome sequencing) to confirm the presence of Orientia tsutsugamushi."
45484056|NCT03263884|Device|Repetitive trancranial magnetic stimulation (rTMS) group|Repetitive trancranial magnetic stimulation is applied on the dorsolateral prefrontal cortex. The protocol consists on 20 minutes of 10Hz stimulation, 5 seconds on, 10 seconds off, at 110% RMT, for a total of 4000 pulses.
45484057|NCT03263884|Device|Sham group|A sham coil is used to mimic the clicking sound of the trancranial magnetic coil and skin stimulation.
45484058|NCT01337271|Procedure|SBT- PSV|An Spontaneous breathing trial for 30 minutes on pressure support ventilation, which is a commonly used strategy to evaluate readiness for extubation
45484059|NCT01337271|Procedure|SBT - NAVA|An spontaneous breathing trial (SBT) on the ventilatory mode NAVA, with ventilatory support titrated to be similar to the support provided during an SBT on pressure support mode (PSV). NAVA captures the electrical activity of the diaphragm with an esophageal-gastric catheter, and uses the electrical signal to deliver inspiratory pressure proportional to the intensity of patient effort, as well as to trigger and cycle assisted mechanical breaths.
45484060|NCT03268798|Device|Unilateral wrist extension training|Participants will join a five-week training protocol with 3 sessions per week. During each session, 5 sets 5 maximal wrist extension training will be performed on participants less affected side.
45484061|NCT01340079|Behavioral|virtual world|health education using virtual world Second Life
45484062|NCT01340079|Behavioral|face to face|health education delivered in face to face groups
45484063|NCT03268720|Other|FODMAP low diet|2 week FODMAP low diet
45484064|NCT03268720|Other|gluten-free diet|2 week gluten-free diet
45484065|NCT05250297|Other|no intervention|standard prenatal care
45484066|NCT03280654|Other|overactive bladder|Association between groups and over active bladder symptoms
45484067|NCT05184621|Other|Eyesing Redlight Instrument|Eyesing Instrument developed by Suzhou Industrial Park Zoguan Medical Equipment Co. and conventional optometry.
45484068|NCT03280498|Procedure|Intubation|elective surgeries under general anesthesia with endotracheal entubation formula or USG asisted
45484069|NCT01340157|Drug|Fexinidazole|Single oral dose of 1200mg fexinidazole consisting of 2 tablets dosed at 600mg per tablet.
45484070|NCT02459470|Procedure|Fluid loading|fluid loading was performed by using 7ml/kg of 6% hydroxyethyl starch within 10 min to all patients
45691202|NCT01816243|Drug|TTS-Fentanyl|Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. The study duration will be 30 days after first patch application.
45691203|NCT01816243|Drug|Morphine|Participants will be allowed the use of oral morphine syrup for the duration of TTS-fentanyl treatment to enable appropriate dose titration. It is expected that most of the participants will be titrated to an appropriate dose of TTS-fentanyl within 1 week.
45691204|NCT05607784|Behavioral|Formative Research- Content Translation|"This formative research includes brainstorming translation of content and reviewing wireframe prototypes generated from this process. It also includes attending to cultural, developmental, and gender considerations.~The design development cycles will begin with advisory focus group feedback about how the existing activities convey the content (i.e., what and how they are learning). They will advise on activity design for the remaining content (sexual health and content connecting this with ER) to ensure these are engaging, appropriate, and informative. They will also provide perspectives about design, structure, navigability, and approach"
45846028|NCT03836196|Radiation|LDR Brachytherapy and External Beam Radiation Therapy|Low Dose Rate Brachytherapy (LDR-PB) and External Beam Radiation Therapy (EBRT)
45846029|NCT03835884|Drug|AR-13503 Implant 10.6 Dose|AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye
45846030|NCT03835884|Drug|AR-13503 Implant 21.2 Dose|AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye
45846031|NCT03835884|Drug|AR-13503 42.4 Dose|AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye
45846032|NCT03835884|Drug|AR-13503 63.6 Dose|AR-13503 Implant 63.6 Dose (63.6 µg) administered as intravitreal implants into a single eye
45484071|NCT01340235|Drug|Oral erythromycin|Severe Dowling Meara EBS patients from 6 months to 8 years old
45484072|NCT02459548|Other|Follow up in Sleep Unit Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
45484073|NCT02459548|Other|Follow up in Primary Care Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
45484074|NCT05243979|Radiation|DEXA scan|bone study
45484075|NCT03263962|Drug|Canrenone|Evaluation of canrenone therapy in patients with CHF
45484076|NCT02459314|Dietary Supplement|plant sterol and soluble fiber-enriched soymilk|Sterols compete with LDL-C for absorption in GI tract. A meta-analysis of 41 trials indicated that an intake of 2 g sterols/stanols reduces the LDL-C level by 10%. Additive effects occur when sterols are combined with statins; the combination being more efficacious than a 2 times up-dosing of statins alone. Soluble dietary fibers also have significant cholesterol lowering effects. In a meta-analysis, Brown et al estimate that a daily soluble fiber intake ranging from 9-30 g/d, were associated with 10.6% reduction in LDL-C levels.
45484077|NCT02459314|Dietary Supplement|soymilk|Soy protein is another LDL-C and total cholesterol lowering food. A meta-analysis by Reynolds K et al. discovered that volunteers receiving 20 to more than 61 g of soy protein had reductions in total cholesterol by 5.26 mg/dL (95% CI -7.14 to -3.38), and LDL-C by 4.25 mg/dL (95% CI -6.00 to -2.50), with an increase of HDL-C by 0.77 mg/dL (95% CI 0.20 to 1.34). Reductions in LDL cholesterol were larger in hypercholesterolemic than in normocholesterolemic subjects.
45484078|NCT03280420|Procedure|Early catheter removal|"Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 3 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy."
45484079|NCT03280420|Procedure|Late catheter removal|"Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 7 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy."
45484080|NCT05186649|Other|WARFARIN|5 mg of daily dosage
45484081|NCT02458534|Other|Mcgrath Mac videolaryngoscope|Participants perform three intubation attempts using Mcgrath Mac videolaryngoscope in the manikin with the normal airway and difficult airway settings.
45484082|NCT02458534|Other|C-MAC videolaryngoscope|Participants perform three intubation attempts using C-MAC videolaryngoscope in the manikin with the normal airway and difficult airway settings.
45484083|NCT02458534|Other|macintosh laryngoscope|Participants perform three intubation attempts using macintosh laryngoscope in the manikin with the normal airway and difficult airway settings.
45484084|NCT05184465|Procedure|spinal anesthesia|"The anesthesiologist, who was not involved in the study, prepared the anesthetic solution immediately before the injection.~Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table. Then the patient was placed on his back."
45484085|NCT03263728|Diagnostic Test|Cardiac Magnetic Resonance|Screening of asymptomatic of high risk type 2 diabetic mellitus patients with stress cardiac magnetic resonance
45484086|NCT03263338|Behavioral|Mobile Sleep and Growth Study|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
45484087|NCT03152019|Drug|Protopic® (Tacrolimus) 0.1% ointment|About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
45691205|NCT05607784|Behavioral|Formative Research- Content Feedback and Acceptability|"This formative research includes providing feedback on the proposed content and ensure contextual acceptability in schools.~The design development cycles will begin with advisory focus group feedback about how the existing activities convey the content (i.e., what and how they are learning). They will advise on activity design for the remaining content (sexual health and content connecting this with ER) to ensure these are engaging, appropriate, and informative. They will also provide perspectives about design, structure, navigability, and approach"
45484088|NCT03152019|Drug|Placebo|About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
45484089|NCT05007639|Other|Public Health intervention programme|The public health intervention programme combined 3 actions : a simple dissemination of information via the regional Unions of private practice physicians and the local correspondents of the regional networks (action 1), an action in the form of oral communication during regional meetings of professionals (action 2) and an action focused on each surgeon for whom the pathologist has diagnosed soft tissue sarcoma (action 3).
45484090|NCT05007639|Other|No public Health intervention programme|
45691206|NCT04604899|Biological|human retinal progenitor cells|single intravitreal injection of 6.0 million human retinal progenitor cells (hRPC)
45846033|NCT03813030|Procedure|Intravenous infusion of lidocaine|Lidocaine is intravenously administered in clearance visit and blood samples are taken to calculate individual clearance of each participant.
45846034|NCT03813030|Drug|"Lidocaine 2.5% and Prilocaine 2.5% cream, USP (2.5% lidocaine, 2.5% prilocaine, Actavis Pharma incorporated, USA)"|Topical application in dermal-sampling visit
45484091|NCT05198115|Behavioral|aerobic exercise|aerobic training for 8 weeks, 3 times a week, and 60 min each time
45484092|NCT04813107|Drug|APL-1202 in combination with tislelizumab|For those assigned to this group (1), each patient will receive 3 cycles of treatment prior to RC and each cycle is 3 weeks. On day 1 of each cycle, a single dose of 200 mg tislelizumab will be administered intravenously. APL-1202 will be administered orally TID daily for 3 weeks at the RP2D defined from Phase I.
45484093|NCT04813107|Drug|Tislelizumab alone|For patients assigned to this group (2), each patient will receive 3 cycles of treatments with a single dose of 200 mg tislelizumab administered on day 1 of each cycle, followed by RC.
45367225|NCT05277662|Diagnostic Test|cell and molecular diagnostics in accordance with functional test results|"Procedure: Anorectal manometry (ARM) Studies are performed in the left lateral position with the hips and knees of the subject flexed. Manometric sensor records circumferential pressure. The base of the rectal balloon attached to the ARM catheter is sited 3-5 cm above the upper border of the anal canal, to prevent the balloon impinging upon the anal canal during inflation. The most distal recording sensor is external to anal verge. If any pain or discomfort is experienced, the probe is immediately withdrawn.~Procedure: Rectal sensory test (RST) The test is also performed in the left lateral position with hips and knees flexed. Studies are conducted with either an integrated balloon on the manometric probe or with a separate system. Balloon capacity is no less than 400 mls and all components are latex-free. Insufflation is always performed with air. For ramp distension, the rate should be between 1 and 5 mL/s, and for phasic distension, inflation rate should be set at 10 mL/s (C1)."
45367226|NCT04067063|Other|Self-administered evaluation questionnaire|Smartphone app with MeMind questionnaires
45367227|NCT00460798|Other|Sutent: observational study|SUNIKA - A Non-Interventional Study With SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
45484094|NCT01340391|Device|Omnicast|dorsal splint 2-5 weeks
45484095|NCT02714062|Drug|Placebo|po once daily
45484096|NCT02714062|Drug|VI-0521 Mid Dose|po once daily
45484097|NCT02714062|Drug|VI-0521 Top Dose|po once daily
46051773|NCT00916201|Drug|URB597|10 mg / d for 5 days, orally
46051774|NCT00916201|Drug|intranasal Insulin|160 IU / d for 5 days, intranasal
45367228|NCT03965455|Device|Diode laser|In the laser-assisted frenectomy, a diode laser device (GIGA Cheese II®, China) (λ= 810 nm) with a 400 µm diameter, plain-ended optical ﬁber tip was used for the procedure maintaining contact with oral mucosa at 2,5 W, 70 Hz frequency with a short pulse (140 microseconds) duration.
45484098|NCT01315587|Device|repetitive Transcranial Magnetic Stimulation (Magstim rapid2 )|"3 pulses at 50Hz repeated each 200 ms for 2 seconds~80% MT~20 days treatment"
45484099|NCT01315587|Device|repetitive Transcranial Magnetic Stimulation (Magstim rapid2)|LDLPFC 110% MT 15 Hz 20 days
45484100|NCT01315587|Device|repetitive Transcranial Magnetic Stimulation(Magstim rapid2)|Placebo treatment: Sham coil
45484101|NCT04782063|Other|Calibration of infant breast milk and formula milk intake|We will calibrate (reduce) the pumped breast milk or formula intake of infants of overweight and obese mothers who exceed 75%ile of WHO BMI, in order to prevent infant obesity and subsequent childhood obesity.
45484102|NCT03268564|Behavioral|HIVST-online promotion|"Health promotion for those who are not users of previous HIVST-online services (i.e. not re-testers):~Viewing a promotion video and a demonstration video~Brief motivational interviewing through telephone~Visiting the HIVST-online webpage~Receiving a free self-testing kit and follow-up reminders~Health promotion for re-testers:~Viewing a promotion video and a demonstration video~Visiting the HIVST-online webpage~Receiving a free self-testing kit and follow-up reminders"
45484103|NCT03280342|Drug|IR-TPM (Topamax)|XR-TPM (Trokendi XR)
45484104|NCT03280342|Drug|XR-TPM (Trokendi XR)|XR-TPM (Trokendi XR)
45484105|NCT04966689|Behavioral|combined speech and music therapy|he telerehabilitation intervention that include both speech therapy and music therapy at the same time
46051775|NCT00916201|Drug|Cannabidiol CR|320 mg / d for 5 days, orally
46051776|NCT02601781|Procedure|Primary percutaneous coronary intervention (PPCI)|Primary percutaneous coronary intervention (PPCI) aims to recanalize an occluded coronary artery causing ST-elevation myocardial infarction (STEMI).
46051777|NCT02601781|Device|Bioresorbable Vascular Scaffold (BVS ABSORB)|BVS Use during Primary PCI following a pre-specified implantation strategy (eventual thrombectomy, intravascular imaging, lesion pre-dilatation, BVS implantation and BVS post-dilatation).
45484106|NCT04966689|Behavioral|speech therapy|A behavioural speech therapy program including breathing exercises, loudness, pitch, and intelligibility which are adapted from Lee Silverman Voice Treatment (LSVT) and voice exercises Which is delivered through telerehabilitation
45484107|NCT04966689|Behavioral|music therapy|music exercises Will be designed based on the music therapy protocols of previous studies Which is delivered through telerehabilitation
45484108|NCT03280186|Procedure|surgery|The minimally invasive surgical treatment methods and new techniques will be adopted such as spinal superselective angiography, preoperative embolization, intraoperative electrophysiological monitoring, intraoperative angiography, etc.
45484109|NCT01315743|Behavioral|Team COOL|1) a classroom-based experiential curriculum that incorporated school, family and community-linked activities to promote physical activity, healthy eating and limited television viewing, 2) environmental modifications of food and beverage offerings and physical activity opportunities at school and 3) a teacher-guided, youth-directed health advisory council to promote and support physical activity, healthy eating and limited television viewing.
45484110|NCT04965519|Drug|RC48-ADC|2.0mg/kg IV every 2 weeks
45484111|NCT05155839|Drug|MRG001|Administrated intravenously
45484112|NCT03279796|Biological|Autologous adipose-derived MSCs|The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 ^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
45484113|NCT03279796|Drug|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
45367229|NCT03965455|Procedure|Conventional|In the conventional frenectomy, the incisions were applied using a scalpel blade no.15 on the upper and lower surface of the haemostat until the frenum was excised.
45367230|NCT04034342|Other|RaceRunning|RaceRunning (www.racerunning.org) is a growing disability sport that provides an opportunity for people with moderate-to-severe CP to participate in exercise in the community. It allows those who are unable to walk independently, to propel themselves using a RaceRunning bike, which has a breastplate for support but no pedals. Participants sit on the saddle and use their legs to propel themselves forward.
45367231|NCT02570399|Radiation|Oligometastatic patients with abdominal-pelvic lymph nodes|Hypofractionated ablative radiation therapy for oligometastatic patients with lymph node metastases
45484114|NCT03263494|Device|Continuous Glucose Monitor (CGM)|Participants randomized to the CGM Group will receive a Dexcom CGM device and be instructed on how to utilize the CGM data in real time for diabetes management.
45484115|NCT03151395|Other|Sputum and blood sampling|Evaluation of the occurrence of potential bacterial and viral pathogens in the sputum of stable COPD patients and at the time of AECOPD.
45484116|NCT03279172|Procedure|direct laryngoscope|procedure entubatıon
45484117|NCT03279172|Procedure|videolaryngoscope|
45367232|NCT01075165|Other|silicone spray|application of silicone spray to predefined area qd 12 weeks
45367233|NCT01075165|Other|saline spray|application of saline spray to predefined area qd 12 weeks
45367234|NCT00725933|Drug|BIIB028|IV infusion administered twice weekly until disease progression or unacceptable toxicity
45367235|NCT03513406|Drug|Sugammadex|Sugammadex is indicated for the reversal of neuromuscular blockade.
45484118|NCT03278392|Behavioral|Trier Social Stress Test|Task instructions provided to subject (5mins), subject prepares speech on their strengths and weaknesses (5 mins), subject delivers speech before a stern evaluative committee while being video-taped (5 mins), subject completes a mental arithmetic challenge task before the evaluative committee with critiques if errors are made (5mins).
45484119|NCT03278392|Behavioral|Placebo Non-stress task|Subject engages in a friendly conversation about a neutral or happy topic (e.g. recent holiday, favorite past-times) for 15 minutes with a familiar research staff member.
45484120|NCT01340469|Biological|probiotics|Daily enteral probiotic supplementation (live Lactobacillus acidophilus and Bifidobacterium infantis) at a dose of 2.5 x 108 CFU of each strain once a day.The supplementation was started on the first day of enteral feeding and continued for at least 28 days or until discharge. The study drug was in liquid form and mixed with breast milk or formula before given to the infants. The preparation was made on a daily basis by one person who was not involved in the care of the infants.
45484121|NCT02713828|Drug|Phase I: Glembatumumab Vedotin|"Escalation Phase: Three to 6 patients will be enrolled in each dose cohort based on a standard Phase I dose escalation scheme. For the dose-escalation, the starting dose of glembatumumab vedotin will be 1.9 mg/kg q3w (Cohort 1). In the event of ≥ 2 DLTs, the dose will de-escalate to Cohort -1 (1.3 mg/kg).~Dose escalation from Cohort 1 to Cohort 2 (2.2 mg/kg) may proceed if three patients in Cohort 1 complete the DLT observation period with 0 DLTs, or if six patients in Cohort 1 complete the DLT observation period with 0 or 1 DLTs."
45846035|NCT03813030|Drug|"Lidocorit 2%-Ampullen (Gebro Pharma Gesellschaft mit beschränkter Haftung, Austria)"|Intravenous infusion in clearance visit
45367236|NCT03513406|Drug|Neostigmine|Neostigmine is indicated for the reversal of neuromuscular blockade.
45367237|NCT03513406|Drug|Glycopyrrolate|Glycopyrrolate is used in conjunction with neostigmine to prevent neostigmine's muscarinic effects.
45367238|NCT00726869|Drug|Elotuzumab (HuLuc63)|Cohort 1 - 2.5 mg/kg elotuzumab IV with bortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8; Cohort 2 - 5.0 mg/kg elotuzumab IV with bortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8; Cohort 3 - 10.0 mg/kg elotuzumab IV withbortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8; and Cohort 4 - 20.0 mg/kg elotuzumab IV with bortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8.
45367239|NCT01028248|Drug|Ranibizumab (Lucentis)|0.5mg and 2.0mg dose of Ranibizumab 0.05ml administered intravitreally
45484122|NCT02713828|Drug|Phase II: Glembatumumab Vedotin|In Stage 1, approximately 20 eligible, treated patients will be enrolled. If ≥ 2 patients achieve a tumor response (Partial Response [PR] or Complete Response [CR]), an additional 15 eligible, treated patients will be enrolled in Stage 2, for a maximum total of 35 eligible, treated patients.
45484123|NCT05183997|Diagnostic Test|complete blood count|laboratory test
45484124|NCT05183997|Diagnostic Test|prothrombin time|laboratory test
45484125|NCT05183997|Diagnostic Test|prothrombin concentration|laboratory test
45484126|NCT05183997|Drug|Verapamil|drug will be add to prolong the effect of regional block
45484127|NCT05119101|Drug|Dexamedotomidine added to Magnesium sulfate|we will give dexamedotomidine and mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
45484128|NCT05119101|Drug|Magnesium sulfate|we will give mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
45484129|NCT05110443|Other|D-WB PET/CT|"Instead of the usual procedure of having the injection of the radiotracer in the waiting room and having to wait 60 minutes before being moved to the scanner room for imaging, the study participants will be injected with the radiotracer already laying on the scanner bed and the scan will commence immediately.~Therefore, in this study the patients are still only being scanned once, but we are gathering PET information in a different way."
45484130|NCT01340547|Drug|palifosfamide-tris|palifosfamide-tris IV infusion of 150 mg/m2 on Days 1, 2 and 3 every three weeks (21 day cycle)
45484131|NCT01340547|Drug|Normal Saline|0.9% Normal Saline 250 ml IV infusion on Cycle 1 Day -1
45484132|NCT03268408|Behavioral|Baby Newsletter|eight newsletters sent home to newborns' parents with advices and recommendations on child care and development
45691207|NCT05484778|Procedure|Dual tasking paradigm|The dual task methodology is a testing model that requires one person to perform two tasks at the same time. The dual task is divided into two as motor-motor or motor-cognitive. Dual tasks provide an opportunity to examine the attention demands of both tasks and allow possible interference to be observed. The idea behind this design is that central processing capacity has a limit and must be distributed among concurrent tasks.
45367240|NCT00726011|Biological|Tetrodotoxin|30 µg twice daily for 4 days; repeated every two weeks as long as there is a meaningful analgesic response
45484133|NCT01340703|Procedure|vitrectomy without laser or gas tamponade|vitrectomy without laser or gas tamponade
45596362|NCT04181879|Behavioral|Intervention|"GPs allocated to the intervention will be given access to the intervention package and asked to perform medication reviews with approximately 10 patients on two occasions (initial and 6-months follow-up).~The intervention package consists of two components: (a) an online video demonstrating how GPs can improve appropriate polypharmacy during typical consultations with older patients; (b) a patient recall process (appointment with the GP for a medication review).~GPs will be asked to schedule appointments with consenting patients (telephone or online consultations where a face-to-face consultation is not possible). During these appointments, GPs will undertake medication reviews ('a structured, critical examination of a person's medicines with the objective of reaching an agreement with the person about treatment, optimising the impact of medicines, minimising the number of medication-related problems and reducing waste')."
45367241|NCT01028326|Biological|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 60 and a 0.5 mL intramuscular dose of DTaP on day 180.
45367242|NCT01028326|Biological|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 180 and a 0.5 mL dose of DTaP on day 60.
45367243|NCT01028326|Biological|hepatitis A vaccine, DTaP, PCV10|A nurse will administer a 0.5mL intramuscular dose of hepatitis A vaccine on day 0 and day 180; a 0.5 mL intramuscular dose of DTaP on day 60; and a 0.5 mL dose of PCV10 on day 180.
45367244|NCT04880837|Other|Educational Intervention|Attend educational session
45367245|NCT04880837|Other|Informational Intervention|Receive handouts
45367246|NCT04880837|Other|Survey Administration|Complete surveys
45367247|NCT00603980|Drug|Inhaled placebo + oral placebo|Inhaled Staccato placebo + oral placebo
45367248|NCT00603980|Drug|Inhaled alprazolam 0.5 mg|Inhaled Staccato alprazolam 0.5 mg + oral placebo
45367249|NCT00603980|Drug|Inhaled alprazolam 1 mg|Inhaled Staccato alprazolam 1 mg + oral placebo
45691208|NCT05576896|Drug|Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab|"Prior to starting therapy, patients will have a pretreatment cross-sectional scan. Patients will then begin with encorafenib 300 mg daily starting with Cycle 1 day 1; then patients will receive IV cetuximab weekly, with 400 mg/m2 on C1D1 as a loading dose and 250 mg/m2 on all other days.~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
45367250|NCT00603980|Drug|Inhaled alprazolam 2 mg|Inhaled Staccato alprazolam 2 mg + oral placebo
45367251|NCT00603980|Drug|Oral alprazolam 1 mg|Oral alprazolam 1 mg + Inhaled placebo
45367252|NCT00603980|Drug|Oral alprazolam 2 mg|Oral alprazolam 2 mg + Inhaled placebo
45367253|NCT00603980|Drug|Oral alprazolam 4 m|Oral alprazolam 4 mg + Inhaled placebo
45691209|NCT01845805|Drug|oral azacitidine|
45691210|NCT01845805|Other|Observation|
45691211|NCT05575804|Drug|GQ1001+pyrotinib|GQ1001 infusions on day 1 of each 21-day cycle combinate with pyrotinib 320mg orally once daily until disease progression or unacceptable toxicity. I.
45691212|NCT05575804|Drug|pyrotinib+capecitabine|pyrotinib 400mg orally once daily in combination with capecitabine 1000mg/m2 twice daily, day1-14, every three weeks until disease progression or unacceptable toxicity.
45846036|NCT03813030|Device|Dermal open flow microperfusion|"Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose"
45367254|NCT00603980|Drug|Oral alprazolam 2 mg qualifying session|Qualifying session (2 mg oral alprazolam)
45367255|NCT00603980|Drug|Oral placebo qualifying session|Qualifying control session (oral placebo)
45367256|NCT04880603|Device|Restrata Graft|Restrata will be meshed in a 1:2 fashion to allow for egress of serous fluid and minimize risk of fluid collection. Restrata will be applied to the entire wound bed not amenable to primary closure and will be underlaid beneath the surrounding skin edges. A split-thickness skin graft is harvested from patient's thigh at 15:1000 inches and placed on top of the Restrata to cover the entire wound bed. The graft is sutured in place using suture choice of surgeon's preference.
45367257|NCT04880603|Procedure|Standard of Care Skin Graft|Standard of Care Skin Graft
45367258|NCT01028404|Drug|NN1952|Subjects will be randomised to receive a single dose of NN1952, at escalating dose levels. Progression to next dose will be based on safety evaluation.
45367259|NCT01028404|Drug|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at all dose levels.
45367260|NCT01028404|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952, at all dose levels.
45367261|NCT01028404|Drug|NN1952|Subjects will be randomised to receive a single dose of NN1952 with or without a meal, on two of four separate study visits. The dose will be selected based on the results of part 1.
45367262|NCT01028404|Drug|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit.
45484134|NCT03263182|Behavioral|Introduction of the Safe Childbirth Checklist|"Adaptation of the SCC tool to Zambia: In order to produce a tool that is fully relevant to the Zambian context, a team of clinical experts from the MOH adapted the language of the SCC.~Training of trainers on the SCC by international experts: Ariadne Labs has designed a training-of-trainers (TOT) for coach training to support quality improvement initiatives, including the implementation of the WHO SCC. Members of the district mentorship team for Nchelenge District will receive this type of TOT training.~Following the TOT session, the district mentorship team will conduct facility-level training for health workers on using the SCC. Within target facilities, all public sector health workers will be invited to participate in the training.~Mentorship and support to facility-level health workers on using the SCC: The district mentorship team will carry out coaching and support visits to health facilities following the initial SCC training."
45484135|NCT05002881|Other|Moringa oleifera (E-HS-01)|One capsule to be taken stat
45691213|NCT04415125|Diagnostic Test|Applying on-ice and off-ice performance tests|The subjects were given a written description of study procedures and potential risks.The athletes'history of injury including previous injury site, type, number, date, surgical status, time to return to the field after the injury and the mechanism of injury were recorded. The subjects completed off-ice performance measures followed by on-ice testing with time allotted for warm-up before both the off-ice and on-ice testing.
45367263|NCT01028404|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952 at one study visit.
45367264|NCT00726947|Procedure|Ultrasound|Ultrasound imaging of Acute DVT
45367265|NCT00726947|Procedure|Ultrasound|Ultrasound imaging of Chronic DVT
45367266|NCT00450190|Device|Saizen® E-Device|Saizen® (recombinant human growth hormone [r-hGH]) injection 8 milligram (mg) per 137 milliliter (mL) will be administered using an electronic auto-injector (E-Device) subcutaneously (SC) in the evening as per local Summary of Product Characteristics (SmPC) for 60 days.
45367267|NCT00727103|Drug|Varenicline|Varenicline will be dispensed in 0.5 mg and 1 mg tablets taken orally. During the first 3 days of medication, participants will take one 0.5 mg tablet of varenicline daily. If the medication is well-tolerated, the dose will be increased to 0.5 mg po twice daily for 4 days. On day 8, the dose will be increased again to the standard dosing schedule of 1 mg (1 tablet) po twice daily. At the end of the 8th week, varenicline will be discontinued.
45691214|NCT04371094|Device|a device to facilitate endotracheal intubation|a device to facilitate endotracheal intubation
45691215|NCT04343716|Behavioral|Low-carbohydrate diet|A diet low in daily carbohydrates (<40 grams/day) provided as prepared meals.
45691216|NCT01845025|Drug|Formoterol 12 mcg|Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler
45691217|NCT01845025|Drug|Fluticasone propionate 100 mcg|Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler
45691218|NCT01845025|Drug|Fluticasone propionate 250 mcg|Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler
45846037|NCT03813030|Device|Dermal Microdialysis|"Dermal microdialysis will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose"
45846038|NCT03813030|Procedure|Blood sampling in dermal sampling visit|1 sample is taken pre-dose and 12 samples are taken post-dose.
45846039|NCT03813030|Procedure|Blood sampling in clearance visit|1 sample is taken pre-dose, 3 samples during intravenous infusion and 13 samples post-dose.
45367268|NCT00727103|Drug|Placebo|Placebo will be dispensed in color-coded capsules. Blue capsules will contain 0.5 mg glucose (placebo), red capsules will contain 1 mg glucose (placebo).
45846040|NCT03778944|Procedure|Mannitol infusion|Infusion of Mannitol 20% at a dose of 0.5 mg/kg to the renal graft donor after induction of anesthesia over 15 minutes.
45484136|NCT05002881|Other|Placebo|One capsule to be taken stat
45484137|NCT02458300|Other|Nebulization of hypertonic saline|application of hypertonic saline serum through a mask fogging or a box fogging
45367269|NCT01028482|Drug|Sertraline|"group A- sertraline 50-100 mg/day and weekly psychotherapy for 3 months~group B- weekly psychotherapy- for 3 months~group C- sertraline 50-100 mg/day-for 3 months"
45367270|NCT01028482|Drug|placebo|placebo
45367271|NCT01028482|Other|psychotherapy|psychotherapy
45367272|NCT00726167|Device|Procalcitonin Level|Procalcitonin concentrations will be determined every day and will be compared with the clinical diagnosis based upon standard clinical practice. All subjects enrolled will be followed until the patient is either extubated or discharged from the SICU.
45367273|NCT00907322|Drug|Dimebon|Oral tablet; 20 mg Dimebon, single dose
45367274|NCT00907322|Drug|Dimebon|Oral tablet; 40 mg Dimebon, single dose
45484138|NCT02458300|Other|Prolonged slow expiration technique (PSE)|Passive expiratory aid implemented baby. the child is placed supine on a hard surface. Thoracoabdominal slow manual pressure that begins at the end of a spontaneous and continuous exhalation to residual volume is exercised. Oppose reaches 2 or 3 breaths. Vibrations can accompany the art. The goal is to achieve a greater expiratory volume.
45484139|NCT02458300|Other|Patient coughing Provocation (TP)|Tp is based on the mechanism reflects cough induced by stimulation of the buttons on the wall of the trachea extrathoracic mechanoreceptors. The child is placed supine. A short pressure is done with the thumb on the tracheal conduit (in the sternal notch) at the end of inspiration, or at the beginning of expiration. With the other hand holding the abdominal region we prevent the dissipation of energy and make the explosion tussive more effective. It is done after the PSE.
45367275|NCT00907322|Drug|Dimebon|Oral tablet; 60 mg Dimebon, single dose
45367276|NCT00907322|Drug|Dimebon|Oral tablet; placebo, single dose
46051778|NCT00777205|Behavioral|Telephone-based peer support|Patients received a) a peer-support manual that outlines self-management and recovery principles and provides peer discussion topics and b) access to a specialized telephone platform that permits free calls to their partners, ready access to mental health staff for back-up and advice on being effective partners, and recorded tips on depression management. They were asked to call their peer partner at least once a week for 24 weeks.
45367277|NCT00903188|Drug|cyclosporine|"Cyclosporine (Group 1):~basiliximab dose: 1x20 mg IV on Day 0 and 1x20 mg IV on Day 4~Cyclosporine: 8 mg/kg PO given before surgery, followed by 2x4 mg/kg/d. C-0h levels: month 1: 150-250 ng/ml; month 2: 100-200 ng/ml; month 3: withdrawal steroids: 100-150 ng/ml.~C-2h levels: month 1: 900-1100 ng/ml; month 2: 800-1000 ng/ml; month 3: withdrawal steroids: maintain level of 750 ng/ml~Enteric-coated mycophenolate(MPA):720mg PO pre-operatively followed by 1.44 g/day.~Steroids: pre-operatively: 250mg methylprednisolone IV; day 1:125mg IV.~Methylprednisolone:day 2-30:PO 12mg/d; day 31-60:tapered to 8mg/d ,day 61-90 :4mg/d; Month 3:stop"
45484140|NCT02458300|Other|inspiratory maneuver to rhinopharyngeal cleaning DRR|After the inspiratory reflection following the PSE, the TP or crying. At the end of expiratory time the child's mouth is closed with the back of his hand just finished his chest support, raising the jaw and forcing the child to an inspiration with the nose
45846041|NCT03778944|Procedure|Dopamine infusion|Infusion of Dopamine at a dose of 4 microg/kg/min to the renal graft donor after induction of anesthesia till ligation of the renal artery.
45846042|NCT03778944|Procedure|Adequate hydration|Infusion of Ringer Acetate at a rate of 15 ml/kg/hr to the renal graft donor after induction of anesthesia till ligation of the renal artery.
45846043|NCT03738150|Biological|Sotatercept|Sotatercept injection
45846044|NCT03738150|Other|SOC|SOC therapy refers to combination therapy consisting of drugs from two or more of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
45846045|NCT03718728|Behavioral|Mind&Life|Acceptance and mindfulness-based group intervention program.
45846046|NCT03718728|Behavioral|Standard|Personalized diet and physical exercise recommendations.
46051779|NCT00777205|Behavioral|Enhanced Usual Care|Patients received their usual mental health care plus a copy of the Depression Helpbook by Wayne Katon and bi-weekly study mailings with depression management tips.
46051780|NCT00833638|Drug|Placebo|One tablet orally daily
46051781|NCT00833638|Drug|Tadalafil|Orally once daily
45367278|NCT00903188|Drug|Everolimus|"Everolimus (Group 2):~Basiliximab dose: idem as in group 1~Cyclosporine: first three months idem group 1; month 3: decreased dose by 50%, simultaneously initiate everolimus at a starting dose of 0.75 mg bid.~Once the everolimus blood levels range 6 - 12 ng/ml, cyclosporine will be stopped.~Enteric-coated mycophenolate (MPA) dosing idem as group 1.~Everolimus starting dose: 0.75 mg bid, trough levels: 6-12 ng/ml.~Steroid dosing: idem group 1, but maintained at 4 mg methylprednisolone after day 60."
45367279|NCT00726245|Biological|PRGF|3-6mg IM (to area of muscle tear)
45367280|NCT00726245|Biological|Placebo|3cc IM of physiological saline
45484141|NCT02458300|Other|Aspiration of secretions|Suctioning with a probe by a vacuum system installed on the wall.
45484142|NCT01316601|Drug|QAX567|
45846047|NCT03683940|Diagnostic Test|Screening|Subjects will undergo a low dose non contrast CT chest for lung cancer screening. The test will be performed by the UCH Radiology Department and read by board-certified chest radiologists using Lung-RADS criteria.
46051782|NCT01041404|Drug|Trastuzumab|Initial loading dose 8 mg/kg i.v. infusion on Day 1 of cycle, followed by 6 mg/kg i.v. infusion every 3 weeks until disease progression
46051783|NCT01041404|Drug|Fluorouracil|800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles
45484143|NCT05183841|Drug|Bronchodilator (Ipratropium and Fenoterol)|8 puffs of Ipratropium (20mcg) and Fenoterol (50mcg) via an inhaler device with a spacer (30 seconds interval between puffs) in 5 tidal volume breaths each puff.
45484144|NCT05183841|Other|Placebo|8 puffs of placebo via an inhaler device with a spacer (30 seconds interval between puffs) in 5 tidal volume breaths each puff.
45484145|NCT03268174|Other|AO+Mist|"Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.~Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.~RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days."
45484146|NCT03268174|Other|Placebo|"Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.~Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.~RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days."
45484147|NCT01340781|Procedure|Polysomnogram|An attended polysomnogram will be conducted in the subjects room during an in patient hospital stay
45484148|NCT03277222|Biological|IN insulin|IN insulin twice daily taken after breakfast and again after dinner using the nasal delivery device.
46051784|NCT01041404|Drug|Cisplatin|80 mg/m2 i.v. infusion on Day 1 of cycle every 3 weeks for 6 cycles
46051785|NCT01041404|Drug|Capecitabine|1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles
46051786|NCT00777049|Drug|Panobinostat|Hard gelatine capsule - 5mg and 20mg
45367281|NCT00450112|Device|Gel-200|Single Intra-articular Injection
45367282|NCT00727181|Device|Trifecta aortic heart valve|Replacement of a diseased, damaged, or malfunctioning aortic heart valve
45367283|NCT00908726|Drug|propofol|Each subject received both propofol formulations in a crossover fashion separated by a 7-day washout period, and the order of the drug administration was randomized. Subjects received both propofol formulations (Lipid emulsion propofol: Diprivan® and Microemulsion propofol: AquafolTM) during 60 min. The infusion rate was assigned according to a nonblinded, randomized design to 1.5, 3, 6, or 12 mg/kg/hr.
45367284|NCT02948309|Drug|Mistletoe extract (Iscador Qu)|1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg
45367285|NCT02948309|Drug|Placebo|1ml subcutaneous injection 3 times/week
45367286|NCT00726401|Drug|COLD-fX|200mg BID for 4 weeks
45367287|NCT00726401|Drug|Placebo|200mg BID for 4 weeks
45484149|NCT03277222|Biological|Sterile Saline placebo|Sterile Saline placebo twice daily taken after breakfast and again after dinner using the nasal delivery device.
45484150|NCT03277144|Device|TST-TriStaple(3lines stapler)Technology|Duodenal stump closed using a Tristaple ( three-lines linear stapler) device
45484151|NCT03277144|Other|other conventional techniques|Duodenal stump closed using other conventional techniques entailing manual suture or mechanical devices with only two lines of sutures.
45691219|NCT01845025|Drug|Fluticasone propionate 500 mcg|Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler
45691220|NCT01845025|Drug|Placebo|Placebo to match formoterol one inhalation twice daily via dry powder inhaler
45691221|NCT03830632|Other|Plyometric Training|
45367288|NCT00903266|Behavioral|Melodic Intonation Therapy|MIT emphasizes the prosody of speech through the use of slow, pitched vocalization (singing).
46051787|NCT00774787|Drug|imiquimod 5% cream|1 packet (250 mg cream) 3 times per week for 4 weeks
45367289|NCT00903266|Behavioral|Speech-Repetition-Therapy|Speech-Reception-Therapy is an equally intensive, alternative verbal treatment method developed for this study.
45367290|NCT02569775|Biological|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
45367291|NCT00449956|Drug|dorzolamide hydrochloride (+) timolol maleate|Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week
45367292|NCT00449956|Drug|Comparator: timolol maleate|timolol maleate 0.5%, 8-week
45367293|NCT00449956|Drug|Comparator: dorzolamide hydrochloride|dorzolamide hydrochloride 1%, 8-week
45367294|NCT00908804|Procedure|open appendectomy|
45367295|NCT00908804|Procedure|laparoscopic appendectomy|
45367296|NCT00726479|Drug|BIBW 2948 BS|7.5 mg b.i.d, 15mg q.d, 15mg b.i.d
45367297|NCT00903422|Drug|eltrombopag olamine|thrombopoietin receptor agonist
45367298|NCT00903422|Other|Placebo|Placebo tablets with no active pharmaceutical ingredient
45367299|NCT01323088|Other|Control|Standard care control (no exercise)
45367300|NCT01323088|Other|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
45367301|NCT01323088|Other|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
45367302|NCT03906461|Device|Radiofrequency Ablation|The Tacticath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) is designed to facilitate electrophysiological mapping of the heart chambers and to transmit radiofrequency (RF) current to the catheter tip electrode for intracardiac ablation purposes.
45846048|NCT03654690|Diagnostic Test|HIV self-test|Home delivery of HIV self-test kits (OraSure OraQuick Rapid HIV test)
46051788|NCT00888927|Biological|KW-0761|The starting dose will be 0.1 mg/kg administered i.v. once every week for four weeks, followed by a 2-week observation period in the first treatment course. Succeeding dose levels will include 0.3 and 1 mg/kg. If a subject has demonstrated an overall CR, may continue on study for up to an additional four infusions beyond CR on an every other week infusion schedule. If a subject experiences a PR or SD, the subject may continue therapy on an every other week infusion schedule until disease progression occurs or other withdrawal criteria are met.
46051789|NCT01040780|Drug|Icotinib|125 mg three times daily (375 mg per day) by mouth
46051790|NCT01040780|Drug|Gefitinib|250 mg every 24 hours by mouth
45367303|NCT00907400|Drug|PN400|oral tablet
45367304|NCT00907400|Drug|Naproxen|oral tablet
45367305|NCT00726635|Behavioral|Cognitive intervention|The intervention will last one hour and will include cognitive technique (self-talk). The technique will be demonstrated to the woman, practiced with her, and taped so as to encourage further practice at home.
45367306|NCT00726635|Other|Control group|A one hour conversation with a nurse
45367307|NCT00726635|Other|psycho-physiological intervention|The intervention will last an hour and will include a psycho-physiological intervention (relaxation and guided imagery). The technique will be demonstrated to the woman, practiced with her, and taped so as to assure further practice at home
45367308|NCT04034732|Behavioral|Mindfulness-based Relapses Prevention (MBRP)|"Manualized MBRP program is used with a central theme in each session, with meditation practices and relapse prevention exercises and discussions. Themes include the concept of automatic pilot and its relationship to addiction relapse, recognizing thoughts and emotions in relation to triggers of relapse, integrating mindfulness practices into daily activities, practicing mindfulness in high risk situations and the role of thoughts and emotions in relapse. Include daily homework exercises that consist of awareness exercises directed at increasing non-judgmental awareness of bodily sensations, thoughts and feelings, together with exercises designed to integrate awareness skills into daily life. Include training in mindfulness through body scan, sitting meditation, and mindful stretching exercises, to cultivate awareness during simple stretching movement."
45367309|NCT04034732|Behavioral|Usual Care Control|Participants in the UCCG condition will remain in their standard outpatient aftercare provided by the treatment agency with an aim to maintain their abstinence with the help from social workers or other healthcare professionals through different activities, such as topics on life training skills such as rational thinking skills, grief and loss, assertiveness, self esteem, goal setting, effects of drugs on interpersonal relationships and experience. Frequency of their visits to / contacts with healthcare professionals will be recorded.
45367310|NCT03995602|Dietary Supplement|Dragon fruit juice drink|Dragon fruit drink containing 24 g of freeze-dried dragon fruit powder dissolved in low nitrate water.
45367311|NCT03995602|Dietary Supplement|Placebo|Drink with macro- and micro-nutrient matched against the intervention drink.
45367312|NCT05277506|Device|18 inch slot MBT orthodontic brackets bonded using smile arc protection bonding strategy|female patients with mild crowding will recieve orthodontic brackets bonding using smile arc protection bonding strategy
45367313|NCT05277506|Device|18 inch slot MBT orthodontic brackets boned using MBT placement guide|female patients with mild crowding will recieve orthodontic brackets bonding using MBT placement guide bonding strategy
45846049|NCT03654690|Behavioral|Counseling|Post-Test HIV Risk ReductionCounseling
45846050|NCT03653052|Drug|Durvalumab|Durvalumab will be administered via an infusion in the arm, over a duration of up to 1 hour.
46051791|NCT00888849|Procedure|Advant 55 Linear Cutter/Stapler|Advant 55 Linear Cutter/Stapler
46051792|NCT00888849|Procedure|Suturing|Suturing
45484152|NCT05387902|Device|Extracorporeal Membrane Oxygenation|Patients with high-risk PCI receive mechanical circulatory support with ECMO.
45367314|NCT00727493|Drug|alendronate once weekly 70mg|alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily for 12 months, dental implant
45367315|NCT00727493|Drug|placebo|placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant
45484153|NCT04931667|Drug|Lorecivivint|Healthcare professional-administered intra-articular (IA) injection into one or both knees as clinically indicated. Bilateral injections of 0.07 mg of LOR are allowed. IA injection performed on Day 1. Additional IA injections of LOR to same knee (with at least a 6 month separation) between Day 1 and Month 33.
45484154|NCT03262948|Drug|nab-paclitaxel|albumin-bound paclitaxel is 260 mg/m2 intravenously over 30 minutes on Days 1 of each 21-day cycle cycle immediately after albumin-bound paclitaxel
45484155|NCT03262948|Drug|Paclitaxel|paclitaxel is 175 mg/m2 intravenously over 3 hours on Days 1 of each 21-day cycle cycle immediately after paclitaxel
45484156|NCT03262948|Drug|Carboplatin|carboplatin is administered on Day 1 of each 21-day，followed by paclitaxel or nab-paclitaxel
45367316|NCT03878914|Drug|Corticosteroids|Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.
45367317|NCT00727727|Drug|Piribedil|
45367318|NCT00907712|Other|cardiac echo examination|cardiac echo examination - before and after the surgery
45367319|NCT04720079|Procedure|Subcutaneous infiltration of intercostobrachial nerve|Preoperative subcutaneous infiltration of intercostobrachial nerve with 10ml of 0.5% ropivacaine
45367320|NCT04720079|Procedure|T2 paravertebral nerve block|Preoperative ultrasound guided T2 paravertebral nerve block with 10ml of 0.5% ropivacaine
45484157|NCT03635619|Other|No intervention|No intervention
45484158|NCT02876328|Biological|Ad26.ZEBOV|0.5 mL at a dose of 5x10^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
45484159|NCT02876328|Biological|MVA-BN-Filo|0.5 mL at a dose of 1x10^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
45367321|NCT00909116|Procedure|Stapled Transanal Rectal Resection with Contour Transtar|Transanal Stapling procedure - Stapled Transanal Rectal Resection
45367322|NCT00729989|Procedure|Gastric suctioning|The stomach will be suctioned shortly following birth with an orogastric tube
45367323|NCT00903656|Drug|doxorubicinhydrochloride, Lapatinib|Lapatinib 1250mg/d p.o. Caelyx 40 mg/m² i.v. q4w for a maximum of 6 cycles
45367324|NCT00730067|Drug|sildenafil|Sildenafil 50 mg three times daily
45367325|NCT00730067|Drug|placebo|tablet with Laetose mono hydrat, talc,Potato tarch, Gelatin, Magnesium stearate.
45367326|NCT00909194|Behavioral|Psychoeducational Seminar and Relaxation Technique|Psychoeducational seminar on Juvenile Primary Fibromyalgia (pain management, diet, exercise and sleep hygiene) followed by a total body relaxation technique
45367327|NCT00509145|Drug|Laquinimod|Laquinimod 0.6 mg capsule, oral, once daily
45367328|NCT00509145|Other|Placebo|oral, once daily, capsule
45484160|NCT02876328|Biological|rVSVΔG-ZEBOV-GP|1 mL at a nominal dose of 2x10^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
45484161|NCT02876328|Biological|Placebo|0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
45484162|NCT02876328|Biological|rVSV boost|1 mL at a nominal dose of 2x10^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
45484163|NCT03276598|Drug|Amlodipine|Treatment for four weeks. Dose: 5 mg o.d.
45484164|NCT03276598|Drug|Bisoprolol|Treatment for four weeks. Dose: 5 mg o.d.
45846051|NCT03640728|Drug|Tenofovir Alafenamide|Tenofovir alafenamide 25 mg/day orally
45846052|NCT03640728|Drug|Entecavir|Entecavir 0.5 mg/day orally
45846053|NCT03640728|Drug|Tenofovir disoproxil fumarate|Tenofovir Disoproxil Fumarate 300 mg/day orally
46051793|NCT04303832|Other|eye exercises|Eye exercises for correcting eye deviation
46051794|NCT04303832|Device|eye glasses|Eye glasses for correcting eye deviation
46051795|NCT04241991|Radiation|Active laser|Participants will receive laser irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the irradiation on eight points distributed over the muscle belly, using a gallium arsenide aluminum (Ga-As-Al) laser (λ: 808 nm) equipment. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.
45367329|NCT00907790|Behavioral|Usual Care (Control Group)|
45367330|NCT00907790|Behavioral|Comprehensive Self-Management (CSM)|Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS
45484165|NCT03276598|Drug|Hydrochlorothiazide|Treatment for four weeks. Dose: 25 mg o.d.
45484166|NCT03276598|Drug|Losartan|Treatment for four weeks. Dose: 50 mg o.d.
45484167|NCT03276598|Drug|Placebo|Treatment for four weeks. Dose: 1 tablet per day.
45484168|NCT03263104|Dietary Supplement|Lactobacillus plantarum ECGC 13110402|Lactobacillus plantarum ECGC 13110402
45484169|NCT03263104|Dietary Supplement|Maltodextrin|
45484170|NCT03275896|Other|Descemet Membrane Transplantation|The diseased host Descemet membrane will first be stripped, as per a standard Descemet Stripping Automated Endothelial Keratoplasty surgery. A cadaveric, acellular Descemet membrane graft will then be harvested and transplanted onto the host.
45484171|NCT03275272|Diagnostic Test|level of IGF-1 in infants|Measurment of blood level of IGF-1 in infants
45846054|NCT03607500|Behavioral|caloric intake reduction|The caloric intake reduction arm will been seen by the kidney disease dietitian at all clinical visits for the first 3 months (weekly for month 1, every other week for months 2 and 3).
45846055|NCT03606174|Drug|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
45846056|NCT03606174|Drug|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
45367331|NCT00832325|Behavioral|interview|The doctor and/or one of her trained research study staff will ask the patient about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take (approximately 1-1 ½ hours)to complete. Interviews will be audiotaped and transcribed by a professional transcription service.
45846057|NCT03606174|Drug|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
45484172|NCT02875860|Device|GoldBal2 detachable balloon|Placement of the balloon using the plug/unplug method.
45484173|NCT02875860|Device|Baltaccidbpe100 Delivery Catheter|The catheter assists with implanting the balloon in the plug/unplug method.
45484174|NCT02875860|Other|Standardized postnatal care|After birth, the babies will receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website. For detailed description on this please visit https://www.karger.com/Article/Abstract/320622
45367332|NCT00832325|Behavioral|Focus groups|The patient will participate with 6-8 other adolescent/young adult cancer survivors. The doctor and/or her trained research study staff will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take about one-and-a-half hour to complete. Focus groups will be audio taped and transcribed by a professional transcription service.
45367333|NCT00832325|Behavioral|Questionnaire|The patient will be asked to participate in three 60-90 minute telephone interviews conducted by the doctor and/or her trained research study staff scheduled at the patient's convenience, the second interview approximately 6-8 months after the first and the last interview approximately 12-16 months after the first. The questionnaire will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life.
45367334|NCT02538224|Drug|2.5%ketoprofen gel + 3 % doxycycline|"GroupA:(0.05cc, mixed gel) be put into the periodontal pocket using an insulin syringe.~Intervention category Treatment: drugs"
45484175|NCT03267706|Other|Palliative Care Comprehensive Tool|Clinicians assigned to the newly developed Palliative Care Comprehensive Tool will be trained during a 1 hour period on the application of the tool; Including rationale for tool development, objective of the tool and demonstration of the tool in action
45367335|NCT02538224|Drug|:2.5%ketoprofen gel|GroupB:2.5%ketoprofen gel which be inserted into the periodontal pocket using an insulin syringe .
45367336|NCT04018781|Other|medication reconciliation|"During hospitalization, the hospital pharmacist will carry out a pharmaceutical analysis for all patients included in the study, each time the prescription is changed and within a maximum of 24 hours (working days).~If necessary, in consultation with the doctor in charge of the patient, the pharmacist may also propose a pharmaceutical interview to the patient at any time during his hospitalisation (e.g. proposal for the de-prescription of benzodiazepines, Proton Pump Inhibitors, etc., according to the recommendations in force)."
45367337|NCT02538302|Drug|Minirin|Minirin 5 to 10 mg daily for 6 months
45484176|NCT03262792|Dietary Supplement|Placebo|Microcrystalline cellulose
45484177|NCT03262792|Dietary Supplement|Andrographis Paniculata|Andrographis Paniculata 150 mg
45484178|NCT03262792|Dietary Supplement|Andrographis Paniculata|Andrographis Paniculata 300 mg
45484179|NCT01359462|Drug|tolvaptan|"Drug: tolvaptan~tablet, 15mg, Qd, for 7 days."
45484180|NCT02457988|Device|Vivify Kit|home telemonitoring devices with vital sign capturing capabilities, i.e. blood pressure, weight, pulse, and specific questionnaires targeted to the cirrhosis diagnosis.
45484181|NCT02875392|Other|275mg Oligo Fucoidan + 275mg HS Fucoxanthin|Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness.The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.
45484182|NCT02875392|Other|placebo pills|taking placebo pills as if patients are under treatment.
45484183|NCT03262636|Drug|Indocyanine Green|Indocyanine Green
45691222|NCT03830632|Other|Traditional Training|
45846058|NCT03606174|Drug|Enfortumab vedotin|Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
45691223|NCT04257760|Behavioral|Palliative Care consultation outside standard of care|The ALS patients and their caregivers will receive a consultation with a palliative care physician. This will take approximately one hour and occur in their location of choice (ie. often the patient's home). Subsequent palliative care consultations will occur at the discretion of the ALS patient and the palliative care physician.
45691224|NCT04242940|Device|Fitting of Ponto 4|Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting one/two bone-anchored sound processors (Ponto 4) to patients that are already implanted with abutments.
45846059|NCT03567174|Other|Integrated care van (ICV)|Structural service delivery intervention
45367338|NCT02538302|Drug|Oxybutynin|Oxybutynin 5 to 10 mg daily for 6 months
45367339|NCT00903734|Drug|Erlotinib Hydrochloride (Tarceva)|Dose of 150 mg daily by mouth.
45367340|NCT04603079|Behavioral|Intervention for COVID-19 preventive protocols|The intervention will comprise (A) digital communication of written material and (B) monthly online training and discussion through skype and zoom, to allow for physical demonstrations, Q&A and sharing of challenges. The five specific areas covered in the intervention for COVID-19 preventive protocols will include: (1) PPE fitting, (2) PPE removal, (3) hand hygiene, (4) cleaning, disinfection and sterilization, and (5) nurse uniform sterilization.
45367341|NCT00903812|Other|No intervention|No intervention as observational study
45367342|NCT00907946|Procedure|NT 1 day before PCNL|"A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one day prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:~Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.~If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol."
45367343|NCT02569619|Behavioral|Activity Intervention|
45367344|NCT02569619|Behavioral|Healthy Diet Intervention|
45367345|NCT00909272|Procedure|Lumbar medial branch block|The ultrasound probe will be placed perpendicular to skin along the midline of lumbar spinous process on longitudinal view first to count the lumbar level. The midpoint of each lumbar level will be marked on the longitudinal view and then will be rotated ninety degrees counter clockwise to axial view to locate the facet joint and the transverse process of lumbar spine. A #22 gauge 10cm long Quincke spinal needle will be inserted to the target area using in plane approach on the axial view. Then the probe will be rotated ninety degrees clockwise to longitudinal view to ensure needle tip is placed on the cephalad aspect of the transverse process. It will then be immediately confirmed by C-arm fluoroscopy on oblique view.
45367346|NCT00909272|Procedure|Ultrasound landmarks|The target point is the superior medial aspect of transverse process of lumbar spine from L3 to S1. A #22 gauge 10cm long Quincke spinal needle will be use for needle placement. Needle placement will be visualized with ultrasound. Practice on cadavers with 3 different operators and see if results are reproducible. Verify with fluoroscopy.
45691225|NCT04233424|Drug|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
45846060|NCT03562572|Procedure|Ischemia driven revascularization|In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting during the index intervention
45367347|NCT00509067|Drug|Galantamine|Galantamine will be titrated to 24 mg/day over 2 weeks. Participants will receive 8 mg/day in two divided doses for 1 week, 16 mg/day in two divided doses for 1 week, and 24 mg/day in two divided doses beginning in Week 3. They will be maintained on 24 mg/day for the remainder of the study.
45367348|NCT00509067|Drug|CDP-choline|CDP-choline will serve as the dietary source of choline. CDP-choline will be titrated to 2000 mg/day over 1 week. Subjects will receive 500 mg/day for 3 days; Thereafter, the dose of CDP-choline will be increased to 1,000 mg/day in two divided doses for 4 days. At the beginning of Week 2, participants will receive the maximum fixed dose of 2000 mg/day in two divided doses, which will be held constant through the end of Week 16.
45484184|NCT03267862|Other|there was no intervention|patients were observed during routine care on separate times when their eye pressure was different on one day from another.
45367349|NCT00509067|Drug|Placebo|The schedule of dose titration of placebo galantamine and placebo CDP-choline will follow the schedule of active medication condition using matching placebos for each agent.
45367350|NCT00509067|Drug|risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole|All participants will continue to take their regular regimen of risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole throughout the trial in addition to their assigned treatment.
45367351|NCT04504487|Other|Drain Removal|Abdominal drain placed during surgery removal
45367352|NCT02538146|Dietary Supplement|acetyl-L-carnitine 1000mg 2X per day for 3 months|non-essential dietary amino acid
45484185|NCT03267784|Biological|allo-APZ2-DFU|Suspension of ABCB5-positive mesenchymal stem cells
45367353|NCT00504309|Drug|4/day of 4g P-OM3 capsules|4/day of 4g P-OM3 capsules for 8 weeks
45367354|NCT00504309|Drug|4/day of 1g P-OM3 capsules|4/day of 1g P-OM3 capsules for 8 weeks
45367355|NCT00504309|Drug|Corn Oil Placebo, 4 capsules/day for 8 weeks|4 capsules per day of corn oil placebo for 8 weeks
45367356|NCT04034654|Other|Questionaire|Child behavior checklist is a questionaire, designed to evaluate 1.5-5 years old child's behavior. The checklist is filled out by parents/caregivers.
45367357|NCT00730145|Drug|PD-0332334|A single, 50 mg oral dose (2 capsules) of PD-0332334 will be administered to each hemodialysis subject
45691226|NCT04233424|Other|Standard of Care (SoC)|prophylactic, pre-operation per institution guidelines
45691227|NCT04211740|Drug|OCH-NCNP1|OCH-NCNP1 3mg is supplied as granules and take orally once a week.
45367358|NCT00908024|Drug|BMS-754807|Tablets, Oral, doses vary during dose escalation, once daily, varies - treatment is continued to disease progression or MD/subject/sponsor decision
45367359|NCT00908024|Drug|cetuximab (Erbitux®)|IV infusion, IV, 400 mg/m² loading dose, then 250 mg/m², weekly, varies - treatment is continued to disease progression or MD/subject/sponsor decision
45367360|NCT00730223|Drug|Nevirapine and Efavirenz|single oral dose 200mg of nevirapine and single oral dose 600 mg of efavirenz
45367361|NCT02539394|Drug|Methylprednisolone Acetate|Methylprednisolone Acetate is a corticosteroid known to reduce swelling and inflammation.
45484186|NCT01366794|Other|Macronutrients|Glucose 330 kcal Protein 110 kcal Fat emulsion 110 kcal Mixed meal 550 kcal
45484187|NCT01359540|Device|OMNI Apex Modular™ Hip Device|
45484188|NCT01359540|Device|OMNI Apex ARC™ Hip Device|
45691228|NCT04211740|Drug|Placebo|Placebo is supplied as granules and take orally once a week.
45484189|NCT03262480|Other|stroke volume optimization|"Hemodynamic variables including stroke volume (SV), stroke volume variation (SVV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), systolic time ratio (STR), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be measured by Cardiac output non-invasive monitor (ICONTM, OSYPKA medical cardiotronic GMBH, Elixir, Germany). Heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP) and arterial oxygen saturation (Sao2) will be measured using HP monitor.~If mean arterial blood pressure(MAP) drops below 65 mmHg despite achievement of SVopt and CVPmax in both groups, a bolus dose of 5 mg ephedrine will be given and repeated as needed .Norepinephrine will be given for persistent hypotension.Dobutamine 5 mic/kg/min will be started if cardiac index less than 2.5 l/m2."
45484190|NCT01359618|Drug|TC-5214|Single dose, oral tablets
45367362|NCT02539394|Other|Hemostatic Matrix Kit|Hemostatic Matrix Kits help prevent uncontrollable bleeding in a operative site during a procedure.
45367363|NCT00508755|Device|Gait Robot|gait training with the use of a gait robot
45367364|NCT00508755|Device|Functional Neuromuscular stimulation with intramuscular electrodes|gait training with use of functional electrical stimulation
45367365|NCT04065815|Other|Resistance Training|"Conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a resistance training program consisting of five exercises: exercises (chest, upper/lower back, abdominals, legs)~1 set per exercise~time-effort per session: ~20 min~2 training sessions per week"
45367366|NCT04065815|Other|WB-EMS|"Whole-Body Electromyostimulation (WB-EMS):~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with WB-EMS training:~Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; patients perform simple exercises during the stimulation period following a video tutorial~time-effort per session: ~20 min~2 training sessions per week"
46051796|NCT04241991|Radiation|Placebo laser|Participants will receive placebo irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the placebo irradiation on eight points distributed over the muscle belly. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.
46051797|NCT04243317|Behavioral|Lifestyle & diet|The control group will receive lifestyle and dietary advice accompanied by meal replacements and dietary plans.
45367367|NCT04065815|Other|High-intensity interval training (HIIT)|"HIIT:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with high-intensity interval training (HIIT):~supervised cycle-ergometer training at at 80-95% HRmax~time-effort per session: ~15 min~2 training sessions per week"
45367368|NCT04065815|Other|Combined HIIT and Resistance Training (Combi)|"HIIT combined with conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a combined HIIT and resistance training program:~HIIT:~supervised cycle-ergometer training at at 80-95% HRmax~time-effort per session: ~15 min~1 training session per week~Resistance Training:~five exercises: exercises (chest, upper/lower back, abdominals, legs)~1 set per exercise~time-effort per session: ~20 min~1 training session per week"
45367369|NCT00908102|Other|Moderate|A two level active intervention with a control group was executed for patients suffering from non-acute, moderate LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
45484191|NCT01359618|Other|Placebo comparator|Single dose, oral tablets
45484192|NCT01359618|Drug|Moxifloxacin|Single dose, oral encapsulated tablet
45691229|NCT04185610|Other|Qi Gong|Guided Qi Gong class
45691230|NCT04164004|Other|Kansas City Cardiomyopathy Questionnaire-12|Health status assessment will be completed using the well-validated Kansas City Cardiomyopathy Questionnaire-12 prior to or at the time of heart failure clinic visits.
46051798|NCT04243317|Behavioral|Lifestyle, diet & sleep|The control group will receive lifestyle and dietary advice accompanied by meal replacements and dietary plans. The experimental group will additionally receive a sleep improvement program based on CBTi.
45367370|NCT00908102|Other|Mild|A one level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
45484193|NCT01359618|Other|Moxifloxacin placebo comparator|Single dose, oral encapsulated tablet
45367371|NCT00908102|Other|Mild vs. NC|A two level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Intervention arms were compared to NC - no intervention group.
45367372|NCT00908102|Other|Moderate vs. NC|A three level intervention with two control groups was executed for patients suffering from non-acute, moderate LBP in occupational health. RCT intervention groups were compared to NC group - i.e. no intervention.
45367373|NCT00730301|Procedure|Bronchoscopic Lung Volume Reduction (BLVR)|Procedure under general anesthesia.
45367374|NCT03870243|Device|Bubble CPAP|To see the effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) in children with severe pneumonia
45367375|NCT03870243|Device|Low flow oxygen|To see the effectiveness of low flow oxygen in children with severe pneumonia
45367376|NCT00903890|Other|Survey|Survey asking questions regarding the subjects cardiac and general health.
45367377|NCT00908180|Biological|alemtuzumab|
45367378|NCT00908180|Biological|donor lymphocytes|
45367379|NCT00908180|Drug|carmustine|
45367380|NCT00908180|Drug|cyclosporine|
45367381|NCT00908180|Drug|cytarabine|
45367382|NCT00908180|Drug|etoposide|
45367383|NCT00908180|Drug|melphalan|
45484194|NCT03267550|Device|SceneRay wireless and remote DBS system|Implement therapeutic programming in patients with network coverage at home
45484195|NCT03267628|Procedure|Intrathecal morphine as well as local anaesthetic in Blocks|A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle. 150mcg morphine will be added to the spinal anaesthetic.
46051799|NCT04303988|Drug|Pyrotinib|PO
46051800|NCT04303988|Drug|Temozolomide Injection|IV
45367384|NCT00908180|Procedure|allogeneic hematopoietic stem cell transplantation|
45367385|NCT04480463|Drug|SCD411|IVT (intravitreal) injection
45367386|NCT04480463|Drug|Aflibercept|IVT injection
45367387|NCT02538068|Behavioral|Daily Surveys|Participants complete 28 daily surveys of daily meaning, mood, and physical activities.
45367388|NCT02538068|Behavioral|Random Surveys (8)|Participants complete 8 random surveys of activities over the past 24 hours during the first 4 weeks.
45367389|NCT00904124|Dietary Supplement|cellulose, alginate, guar gum|6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.
45367390|NCT00504231|Biological|Fluzone Influenza Vaccine (2007-2008)|Manufactured by Sanofi Pasteur
45484196|NCT03267628|Procedure|Intrathecal morphine as well as saline in Block|150mcg morphine will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
45484197|NCT03267628|Procedure|Saline intrathecal as well as saline in Blocks|0.3 ml saline will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
45484198|NCT03267628|Procedure|Saline intrathecal as well as local anaesthetic in Blocks|0.3 ml saline will be added to the spinal anaesthetic. A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle.
46051801|NCT04303988|Drug|SHR-1316|IV
46051802|NCT04303988|Drug|Bevacizumab|IV
46051803|NCT04303988|Drug|Cisplatin/Carboplatin|IV
46051804|NCT04991493|Drug|Tramadol hydrochloride|"pre-tramadol group: 1mg/kg of tramadol will be intravenously injected 15 minutes before anesthesia.~post-tramadol group: 1mg/kg of tramadol will be intravenously injected when the incision was washed and sutured."
46051805|NCT04991493|Other|Normal Saline|"pre-tramadol group: Normal Saline will be injected intravenously when the incision was washed and sutured.~post-tramadol group: Normal Saline will be injected intravenously 15 minutes before anesthesia."
45367391|NCT00909506|Drug|Placebo|"Control: Receive placebo pill once every evening on 1~2 weeks.~Receive placebo pill in every morning and evening on 3~24 weeks (twice a day)."
45367392|NCT00909506|Drug|Metformin|"Metformin 500 mg/d: Receive oral metformin 500 mg dose once daily on 1~2 weeks.~Receive placebo pill in every morning and oral metformin 500 mg in every evening on 3~24 weeks."
45691231|NCT05534932|Device|Remote Patient Monitoring|Subjects in this group will receive RPM therapy through the University of Chicago Heart Failure program. This therapy consist of a bluetooth tablet, blood pressure cuff and a health scale for subjects to bring home and take thier measurements on a daily bases up to their 3 month clinic visit. This data will then be transmitted to EPIC where the study team will retrieve the data.
46051806|NCT04682600|Device|Liver Incytes System|The Liver Incytes System uses the Shear Wave Absolute Vibro-Elastrography (S-WAVE) method. The imaging procedure of the Liver Incytes system is similar to a traditional ultrasound scanning procedure or FibroScan, in which the patient is asked to lie supine on an examination bed, with the operator seated next to them. A vibration source is placed under the patient, between the patient and the bed to induce shear waves in the liver. Ultrasound imaging through the patient ribs is used to track the displacements of these waves. Through tracking of the displacements, the shear wave velocity and tissue stiffness can be calculated. The use of volumetric multi-frequency imaging increases the amount of liver scanned
46051807|NCT01059812|Drug|insulin degludec/insulin aspart|Injected subcutaneously twice daily. Dose was individually adjusted.
46051808|NCT01059812|Drug|biphasic insulin aspart 30|Injected subcutaneously twice daily. Dose was individually adjusted.
46051809|NCT00888615|Drug|Elesclomol Sodium|Given IV
46051810|NCT00888615|Drug|Paclitaxel|Given IV
46051811|NCT02824497|Other|No intervention. It's a description study|
46051812|NCT04241601|Drug|Interleukin-2 [IL-2]|Active Comparator: IL-2 plays a key role in Treg cell development, expansion, survival and suppressive function
45367393|NCT00909506|Drug|Metformin|"Metformin 1000 mg/d : Receive oral metformin 500 mg dose once daily on 1~2 weeks. (Dose-escalate)~Receive oral metformin 500 mg in every morning and evening on 3~24 weeks (metformin 500 mg * twice a day = 1000 mg per day)."
45691232|NCT05367856|Drug|Chidamide combined with BEAM|Chidamide: 30mg po D-7,D-4,D-1 and D+3 Carmustine: 300mg/m2 ivgtt D-7 Etoposide: 100mg/m2/d ivgtt q12h D-6-D-3 Cytarabine: 200mg/m2/d ivgtt q12h D-6-D-3 Melphalan: 140mg/m2 ivgtt D-2
45691233|NCT02124304|Device|Neck exercises using both manual and Thera-Band elasatic resistance|Exercises will include cervical flexion and extension, and cervical right and left side-bending, and rotation. All 6 exercises will be done with both manual and elastic (Thera-Band) resistance.Manual Resistance is applied by the subject placing their own hand on their head and pushing in to it. Thera-Band bands will be used to provide elastic resistance
45691234|NCT01881334|Biological|CliniMACS CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich CD34+ cells from heterogeneous hematologic cell populations for transplantation in cases where this is clinically indicated.
46051813|NCT04241601|Other|Placebo Dextrose 5% solution|Placebo Comparator: Dextrose 5% solution
46051814|NCT00845650|Biological|AIGIV 3.5 mg/kg|AIGIV containing 3.5 mg/kg anti-PA IgG as a single intravenous infusion.
46051815|NCT00845650|Biological|Gamunex 90 mg/kg|Gamunex 90 mg/kg total IgG as a single intravenous infusion.
46051816|NCT00845650|Biological|AIGIV 7.0 mg/kg|AIGIV containing 7.0 mg/kg anti-PA IgG as a single intravenous infusion.
45367394|NCT03997539|Drug|Pyrotinib|Pyrotinib Maleate combine with vinorelbine as the second-line treatment to HER2-positive Metastatic Breast Cancer
45367395|NCT03997539|Drug|Treatment of physician's choice|The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for second-line HER2-positive metastatic breast cancer treatment after receipt of trastuzumab-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone [LHRH] agonist) hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
45367396|NCT03997539|Drug|vinorelbine|vinorelbine
45367397|NCT04422899|Drug|AIV007|intravitreal
46051817|NCT00845650|Biological|Gamunex 180 mg/kg|Gamunex 180 mg/kg total IgG as a single intravenous infusion.
46051818|NCT00845650|Biological|AIGIV 14.0 mg/kg|AIGIV containing 14.0 mg/kg anti-PA IgG as a single intravenous infusion.
46051819|NCT00845650|Biological|Gamunex 360 mg/kg|Gamunex 360 mg/kg total IgG as a single intravenous infusion.
46051820|NCT05086809|Device|Device A|Participant wear Device A and evaluate the performance of the device.
46051821|NCT05086809|Device|Device B|Participant wear Device B and evaluate the performance of the device.
46051822|NCT00888381|Biological|Inactivated Influenza Vaccine (2009 / 2010 formulation)|A single 0.5mL intramuscular injection into the deltoid region of the arm on Day 0.
45367398|NCT04034108|Procedure|Surgical intervention combined with weight-supported ambulation training|"Surgeries were performed between 12 hours to 30 days after trauma. Internal fixation was implemented once instability of the injured spinal column was confirmed by radiology and exploration during operation. At 15 days after surgery, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers. The training program was named Kunming Locomotor Training Program (KLTP)formulated by actively walking for a duration of 6 hours per day, 6 days per week for a minimum of 6 months."
45367399|NCT01013025|Procedure|Ultrasound or CT or MRI to locate implant|Scanning methods (eg, ultrasound, CT, or MRI) were used to locate the implant.
45367400|NCT00728117|Other|feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
45367401|NCT00728117|Other|fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
45367402|NCT00909584|Drug|Ezatiostat Hydrochloride|Starting Dose 2000 mg orally per day in two divided doses with dose to increase or decrease to achieve target median ANC (Range 1,500-10,000 cells/uL)
45367403|NCT00927134|Genetic|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo transduced (SF71-gp91phox)CD34+ cells
45367404|NCT02570243|Drug|High dose of Unfractionated Heparin|Unfractionated Heparin 100IU/Kg
45367405|NCT02570243|Drug|Standard dose of Unfractionated heparin|Unfractionated heparin 50IU/Kg
45367406|NCT00927212|Drug|AS101 ointment|Twice daily topical application
45367407|NCT00730379|Drug|Comparator: ridaforolimus + dalotuzumab|Starting dose of oral ridaforolimus is 10 mg/day, QD, for five days. Dose rising up to 40 mg/day, QD for five days. Dose range for intravenous dalotuzumab is 7.5 mg/kg/week, 10 mg/kg/week or 7.5 mg/kg/every 14 days. Dalotuzumab will be given as an IV infusion over 1 or 2 hour(s).
45367408|NCT00730457|Biological|VAX125|Single intramuscular dose
45367409|NCT00927290|Drug|Pioglitazone|Pioglitazone, 45 mg QD (30 mg QD the first month)
45367410|NCT00927290|Drug|Placebo|Placebo 45 mg QD (30 mg QD the first month)
45367411|NCT00728195|Drug|JNJ-37822681|Participants will receive JNJ-37822681 capsule 10 mg orally twice a day for 12 consecutive weeks.
46051823|NCT00887913|Device|Fractional RF treatment with Matrix RF applicator|3 treatments, single pass, 2-50J
46051824|NCT02825745|Dietary Supplement|Betashot|Betashot is a Food for Special Medical Purposes (FSMP). Suitable for use from 3 years of age.
46051825|NCT02826135|Procedure|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension in pediatric patients with single ventricle, decreased urine output or decreased central venous pressure, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
46051826|NCT02825823|Dietary Supplement|Ketone Salt|
45367412|NCT00728195|Drug|JNJ-37822681|Participants will receive JNJ-37822681 capsule 20 mg orally twice a day for 12 consecutive weeks.
45367413|NCT00728195|Drug|JNJ-37822681|Participants will receive JNJ-37822681 capsule 30 mg orally twice a day for 12 consecutive weeks.
45367414|NCT00728195|Drug|Olanzapine|Participants will receive olanzapine 10 mg capsule alone or in combination with olanzapine 5 mg capsule orally for 6 or 12 weeks.
45367415|NCT00728195|Drug|Placebo|Participants will receive matching placebo capsules orally for 12 weeks.
45367416|NCT00927446|Procedure|Endoscopy screening with narrow band imaging|Narrow Band Imaging (NBI) system, an optical technology that enhances the visualization of superficial vascular network, may be superior to the conventional white light endoscopy for the detection of neoplastic lesions.
45367417|NCT00927524|Drug|Insulin glulisine|Dose injection of insulin glargine (Lantus®) given subcutaneously in the abdomen 1 hour prior to breakfast and a dose of insulin glulisine (Apidra®) at a dose based upon your (body wt.) carbohydrate intake for each of the three meals (breakfast, lunch and dinner).
45367418|NCT00927524|Drug|Insulin|Dose based on carbohydrate intake given subcutaneously in the abdomen prior to breakfast and dinner.
45691235|NCT02124460|Behavioral|Health Coaching|"Parent/child duos enrolled in the intervention group will participate in a total of six visits with a trained health coach. During these visits, the health coach will coach the parent/child duos on improving obesity-related behaviors .~The health coach will also help the family identify supports to assist with behavior change; discuss family health habits and the home environment; and review and encourage use of materials related to both specific target behaviors and available resources in the community.~Following the first call with the health coach, parents will receive semi-weekly text messages designed by the study team. The messages will alternate in structure between 2 types of messages; 1) skills training messages will deliver tips and motivational messages to help their child practice the study's goals and 2) self monitoring messages will ask parents to respond to the message and track health behaviors important to this study."
45691236|NCT04148872|Other|Neuromuscular Retraining Therapy (4 months)|Neuromuscular retraining is an intervention where facial therapists utilize voluntary input to access improved movement patterns in patients with synkinesis.
45691237|NCT04148872|Drug|Chemodenervation (4 months)|A neurotoxin that temporarily reduces muscle activity and minimizes the effects of uncoordinated muscle.
45691238|NCT04148872|Other|Neuromuscular Retraining + Chemodenervation|Participants will receive both interventions for the last 4 months of their time on study.
45367419|NCT00728273|Dietary Supplement|worm treatment and multiple micronutrient fortified biscuits|"A single dose of intestinal anthelminthic treatment as orange-flavored chewable tablets containing 400 mg Albendazole (Vidoca, Thephaco, Vietnam) was given. Deworming was repeated with Albendazole for all children at the end of the study (after 4 months).~The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35µg iodine, 300 µg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 µg vitamin B12, 120 µg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 µg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 µg vitamin E, 10 µg vitamin K and 18 µg biotin."
45367420|NCT00927602|Drug|fondaparinux|once daily sc injection, 1,5 mg, max 14 days
45367421|NCT04286867|Other|Alcohol Moderation Mobile Application|This group will receive a link and in-person instructions on how to use the alcohol moderation application described. Individuals in this group will define their drinking limits within the application. The application will provide time points to aid the individual in maintaining their predefined drinking limits throughout the course of the drinking occasion. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
45367422|NCT04286867|Behavioral|Alcohol Moderation Drink Tracker|This group will receive the NIAAA tracking card and in-person instructions on how to use the drink tracker card (described at https://www.rethinkingdrinking.niaaa.nih.gov/Thinking-about-a-change/Strategies-for-cutting-down/Tips-To-Try.aspx). Individuals in this group will define their drinking limits, and record their alcohol consumption on the drink tracking card. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
45367423|NCT00909662|Procedure|assessment of therapy complications|"Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen~Cognitive Task (2 timed 2-minute tests) with Concomitant EEG~Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS~Borg 15-Category Scale"
45367424|NCT00909662|Procedure|cognitive assessment|Cognitive Task (2 timed 2-minute tests) with Concomitant EEG
45367425|NCT00909662|Procedure|fatigue assessment and management|"Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen~Cognitive Task (2 timed 2-minute tests) with Concomitant EEG~Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS~Borg 15-Category Scale"
46051827|NCT02825823|Dietary Supplement|Placebo|
46051828|NCT04949295|Device|ocular surface analyzer|Using ocular surface analyzer for Inspection
46051829|NCT00833560|Drug|Cyclophosphamide|In Part 1, cyclophosphamide with dose ranging from 900 to 1500 mg will be administered intravenously on Day 1 of each 21 day cycle for 3 cycles to determine optimal dose. In Part 2, optimal dose determined in Part 1 will be administered on Day 1 of each 21 day cycle for 3 cycles.
46051830|NCT00833560|Drug|Bortezomib|Bortezomib 1.3 mg/m2 will be administered intravenously on Days 1,4,8, and 11 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
46051831|NCT00833560|Drug|Dexamethasone|Participants will receive dexamethasone 40 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
46051832|NCT04242927|Drug|Nicotinic acid +Routine care|Nicotinic acid is administered orally at 50 mg (grade 2) or 100 mg (grade 3) three times daily with routine care.
45367426|NCT00730535|Drug|Tolterodine|Extended release tolterodine tartrate 4 mg, once daily, for 1 months
45484199|NCT05189886|Procedure|Double Balloon Valvuloplasty in TAVR|The prospective phase will enroll patients planning to undergo TAVR, at the discretion of Drs. Wan and Fatemi, and if they meet all of the inclusion criteria and none of the exclusion criteria. All patients who provide consent will undergo the TAVR procedure where the valve will be double inflated. Echocardiogram results and procedure details will be collected as data. At the patient's 30-day follow-up clinic visit, as per standard of care, they will be re-evaluated with an echocardiogram. Details from that follow-up visit and the echocardiogram results will be collected as data. Prospective enrollment will begin upon IRB approval and we plan to continue enrollment until December 31, 2023, or once 200 participants are reached, whichever comes first.
45484200|NCT01359696|Drug|GDC-0425|Oral escalating dose
45484201|NCT01359696|Drug|gemcitabine|Intravenous repeating dose
45484202|NCT03268018|Device|Laser induced pressure wave calcium modification|A calcium atherectomy and modification solution in patients with balloon resistant calcified lesions in infrainguinal disease. The intent is to both debulk and modify the vessel to restore blood flow, improve vessel compliance and drive better outcomes
45484203|NCT04323904|Other|Retrospective data collection|Retrospective data collection from patients with hantavirus infection and matching control group patients.
45691239|NCT04129294|Drug|NS-089/NCNP-02|"NS-089/NCNP-02 for Infusion is packaged as 50 mg/mL with 3 mL per vial. Study dosages will be infused over a 1 hour period at the following dose levels.~[Part 1] NS-089/NCNP-02 is administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2.~Dose level 1: 1.62 mg/kg once weekly for 2 weeks; Dose level 2: 10 mg/kg once weekly for 2 weeks; Dose level 3: 40 mg/kg once weekly for 2 weeks; Dose level 4: 80 mg/kg once weekly for 2 weeks [Part 2] Based on the results from Part 1, two dosages are selected as study dosages in Part 2. Each selected dose are administered once a week for 24 weeks."
45691240|NCT05328856|Device|Hansgrohe prototype|Start of the shower with warm comfort temperature and usual body cleansing. Then the Vital shower is carried out with a mixing function for a total of 3-5 minutes, followed optionally by another warm shower with 30 seconds or direct transition to a classic cold shower for 30- 60 seconds
45691241|NCT05310994|Dietary Supplement|Placebo drink|consume 1 bottle per day
45367427|NCT00730535|Drug|Tolterodine|Extended release tolterodine tartrate 4 mg, once daily, for 3 months
45691242|NCT05310994|Dietary Supplement|Wasabi Leaf Extract Drink|consume 1 bottle per day
45691243|NCT05272306|Other|Number of attempts for successful transesophageal echocardiography|Transesophageal echocardiography probe will be inserted after induction of anesthesia. Number of attempts for successful transesophageal echocardiography will be recorded.
46051833|NCT04242927|Drug|Routine care|Routinely apply urea ointment and provide best supportive care.
45691244|NCT05272306|Diagnostic Test|A questionnaire for cardiologist satisfaction|A questionnaire for cardiologist satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).
45691245|NCT05272306|Diagnostic Test|A questionnaire for patient satisfaction|A questionnaire for patient satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).
46051834|NCT00708136|Behavioral|water based training program to improve balance|
46051835|NCT04948047|Diagnostic Test|Pathological examinations as the golden diagnosis criteria|Pathological diagnosis, as the golden standard for diagnosing pulmonary nodules, is achieved by two experienced pathologists and validated by the third senior pathologist.
46051836|NCT04948047|Diagnostic Test|Breath test combined with computed tomography|"Exhaled breath of each participant will be collected with Tedlar bags. The volatile organic compounds will be detected by a high-resolution high-pressure photon ionization time-of-ﬂight mass spectrometry (HPPI-TOFMS).~The Imaging markers of pulmonary nodules, including the size, three-dimensional shape, and appearance characteristics, are derived from the chest computed tomography within 2 weeks before surgery resection."
45367428|NCT00730535|Drug|Tolterodine 6|Extended release tolterodine tartrate 4 mg, once daily, for 6 months
45367429|NCT00909818|Radiation|standard fractionated radiotherapy|standard fractionated radiotherapy 50 Gy/25 fractions
45367430|NCT00909818|Radiation|hypofractionated radiotherapy|hypofractionated radiotherapy 40 Gy/15 fractions
45367431|NCT03743558|Behavioral|smartphone homemade video|value of a video recording of the child sleep on smartphone made by the parents
45367432|NCT00728429|Behavioral|exercise intervention|24 week program of exercise
45367433|NCT00904202|Drug|Placebo Capsules + Placebo Patch|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
45367434|NCT00904202|Drug|Placebo capsules + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
45691246|NCT05072236|Procedure|bronchoscopic insertion|After intravenous anesthesia is stabilized with BIS levels between 50-70, Intravenous lidocaine 1.5 mg/kg, or alfentanil 10 ug/kg, or 5 mL normal saline will be injected. Bronchoscopic insertion will be started 1 minute later. After seeing the vocal cords, local spraying of 2% will be initiated from vocal cords, trachea, and bilateral bronchial trees.
46051837|NCT02824419|Drug|Methionine|Subject undergoes imaging studies with FDG and with methionine.
45367435|NCT00904202|Drug|Gabapentin + Placebo|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
45367436|NCT00904202|Drug|Gabapentin + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
45367437|NCT00904202|Drug|Gabapentin 300 mg capsules 1800 mg/day + placebo patch|Gabapentin 300 mg capsules 1800 mg/day + placebo patch
45691247|NCT04997668|Device|SOLTIVE Thulium Fiber Laser|Patients randomized to Arm A will undergo surgery to remove their kidney stone with FDA approved SOLTIVE Thulium Fiber Laser.
45691248|NCT04997668|Device|Ho:YAG Laser|Patients randomized to Arm B will undergo surgery to remove their kidney stone with FDA approved Ho:YAG laser.
45691249|NCT05246488|Diagnostic Test|American Orthopedic Foot and Ankle Association Midfoot Scale, Foot and Ankle Ability Measure/FAAM, SF-12 Quality of Life Scale, Visual Analog Scale (VAS)|All participants will receive two assessments, 7 days apart. After the demographic data of the patients are recorded with the form prepared by us, they will be evaluated with the AOFAS Midfoot Scale, Foot and Ankle Ability Measure/FAAM, SF-12 Quality of Life Scale, Visual Analogue Scale (VAS).
45691250|NCT04907188|Biological|HB-adMSCs|The subject will receive 6 autologous HB-adMSCs intravenous infusion of 200 million (2 x 10^8 cells) cells approximately every 28 days.
45691251|NCT04847440|Drug|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth. Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
45691252|NCT04847440|Drug|Viread|Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
45691253|NCT04847440|Drug|AB-729|AB-729 is a potent, selective, subcutaneously administered, N-acetylgalactosamine (Ga1NAc)-conjugated small interfering ribonucleic acid (siRNA) inhibitor of HBV
45691254|NCT04812106|Other|No Intervention|No Intervention
46051838|NCT02824419|Drug|DOTANOC|Subject undergoes imaging studies with FDG and with DOTANOC.
46051839|NCT05660343|Drug|Ozonized Olive Oil Solutions|(0.03PPM ozone + 6-6.5 PH olive oil, viscosity at 25°C 55mPas, relative density gr/ml (20°C) 0.98 pycnometer, 100 ml bottle.
46051840|NCT05660343|Device|Low Level Laser LLL Therapy|(0.03PPM ozone + 6-6.5 PH olive oil, viscosity at 25°C 55mPas, relative density gr/ml (20°C) 0.98 pycnometer, Ozonated olive oil, 100 ml bottle, and 810 nm diode laser, 3.4 j/cm2 energy density, 0.5w power, CHEESE DEN7A/DEN4A 810, 2 min for each side
45367438|NCT00904202|Drug|Gabapentin 1800 mg/day + Lidoderm patch|
45367439|NCT04066595|Drug|Cabozantinib|60 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
45367440|NCT00927836|Biological|Filgrastim|135 μg/kg body weight total dose Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
46051841|NCT02825667|Other|Physiotherapy sessions|Physiotherapy by techniques myofascial therapy, in patients with ankle hemophilic arthropathy
46051842|NCT00887679|Drug|Escitalopram|10-20 mg/day oral of Escitalopram for 6-weeks. Escitalopram flexible dose (10-20 mg/day). A forced escalation schedule of escitalopram was used to titrate it to the maximum tolerated dose. Drug was discontinued at the end of the study.
45367441|NCT00927836|Drug|Sodium chloride solution|Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
45367442|NCT04066517|Procedure|SBRT|Multimodal-imaging guided SBRT for VT ablation.
45367443|NCT02570321|Procedure|Bacterial ulcer cross-linking|For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis.
45367444|NCT02570321|Procedure|Bacterial ulcer control|For those bacterial ulcer subjects randomized to the control group, they will receive the standard of care topical treatment for bacterial ulcers. This group will have their eyes irrigated with a balanced salt solution.
45367445|NCT02570321|Procedure|Fungal ulcer cross-linking|"Prior to receiving cross-linking, topical amphotericin B or topical natamycin antifungal therapy will be started as per routine at the hospital; a loading dose of amphotericin B or natamycin every 5 minutes x 6 will be followed by dosing every 30 minutes. Amphotericin B and natamycin are routinely used therapies for fungal keratitis at Aravind Eye Hospital.~For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis."
45367446|NCT02570321|Procedure|Fungal ulcer control|"Prior to receiving sham cross-linking, topical amphotericin B or topical natamycin antifungal therapy will be started as per routine at the hospital; a loading dose of amphotericin B or natamycin every 5 minutes x 6 will be followed by dosing every 30 minutes. Amphotericin B and natamycin are routinely used therapies for fungal keratitis at Aravind Eye Hospital.~For those fungal ulcer subjects randomized to the control group, they will receive the standard of care topical treatment for fungal ulcers. This group will have their eyes irrigated with a balanced salt solution."
45367447|NCT00904280|Drug|Oxymorphone ER|Open label
45367448|NCT04015310|Device|Quantitative Multi parametric MRI and enhanced MRCP|Patients will have quantitative MRI and enhanced MRCP on addition to their standard of care
45484204|NCT03262714|Other|Dance|Participants randomized to the dance group will take part in a dance intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. Dance classes will be performed in group in a dance studio, including a variety of rhythms such as salsa, jazz and aerobics. The dance session wil include a warm up of 15 min (posture, join mobility and dance technique), a main part of 40 min (learning of specific choreographies and practice of moves across the floor), and a cool down of 5 min (muscle stretching and relaxation).
45691255|NCT04807660|Other|middle ear fluid sample|middle ear fluid sample for each enrrolled children
45484205|NCT03262714|Other|Walking|Participants randomized to the walking group will take part in a walking intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. The walking session will include a warm up of 10 min (posture and join mobility), a main part of 40 min (walking on a treadmill with a heart rate corresponding to 60% of VO2peak), and a cool down of 10 min (muscle stretching and relaxation).
45484206|NCT03262714|Other|Stretching|Participants randomized to the control group will take part in stretching classes, once a week, each lasting 60 min, also for 8 weeks. Stretching exercises for large muscle groups will be performed standing or in a match, holding the positions for a maximum of 10 s. There will be no music playing during the session.
45484207|NCT03127644|Drug|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally three times daily for 48 hours.
45691256|NCT03692572|Dietary Supplement|Nitrate supplementation|Subjects will drink 70 ml of beet root juice twice a day for 2 weeks.
45691257|NCT03692572|Dietary Supplement|placebo|Subjects will drink 70 ml of nitrate depleted placebo juice twice a day for 2 weeks.
45691258|NCT03667846|Drug|Topiramate|Generic topiramate, FDA-approve for clinical use, will be purchased in 25mg, 50mg, and 100mg strengths, and encapsulated.
45691259|NCT03667846|Other|Placebo|Placebo tablets will be encapsulated in identical capsules.
46051843|NCT04241523|Drug|Lenvatinib 4 mg Oral|"Planned doses of 8 mg of lenvatinib per day for patients with body weight <60 kg, and 12 mg for those with body weight ≥60 kg.~In case of treatment-related adverse effects, interruption or reduction is allowed."
46051844|NCT04242459|Radiation|Adaptive Radiotherapy|Determining the radiotherapy dose delivered to organs at risk (OAR) or to the target volume (dependent on what arm the participant is assigned to) through adaptive radiotherapy volume adaption planning
46051845|NCT02824185|Device|PET/MRI system (SIEMENS AG, Munich, Germany; distributed in France by SIEMENS S.A.S, Saint-Denis, France)|A PET/MRI examination will be performed once for all included patients, using injected fluorocholine, with a dose of 3MBq/kg, up to 2 months before HCC treatment.
46051846|NCT02825589|Device|BIA|BIA or bioelectrical impedance analysis using electric current through body tissues to estimate body composition particularly body fat and total body water calculating to target body weight.
45367449|NCT00924092|Biological|GI-6207 [Recombinant Saccharomyces Cerevisia|
45367450|NCT00924092|Drug|(Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])|
45367451|NCT04236479|Biological|BM-MSC|Allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery through cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life.
45367452|NCT00904358|Diagnostic Test|cross sectional area|
45367453|NCT00730613|Biological|therapeutic autologous lymphocytes|Cycles of escalating cell dose infusions up to the target cell dose of 10(8)
45484208|NCT03127644|Drug|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times daily for 48 hours.
45484209|NCT03127644|Drug|Placebo|Placebo suspension administered orally placebo three times daily for 48 hours.
45484210|NCT01366950|Behavioral|Intelligent physical activity|30 minutes of moderate activity 6 days a week and 45 minutes of high intensity training 1 day a week. Moderate activity is monitored in diaries and high intensity training is monitored by a trainer.
45484211|NCT01362426|Drug|paliperidone palmitate|Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.
46051847|NCT00833482|Drug|Voriconazole|Treatment A: Participants with functional CYP2C19 alleles (EM) received oral tablets of voriconazole, 400 mg, twice daily (BID), on Day 1, then 200 mg BID on Days 2 and 3. Voriconazole dose was given at least 1 hour after a light meal. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
46051848|NCT00833482|Drug|Atazanavir|Treatment B in EM participants: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Treatment B in participants who were poor metabolizers of CYP2C19 (PMs): PM participants received oral tablets of atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
45367454|NCT00730613|Genetic|gene expression analysis|At the time of excess pathology samples documenting response/relapse
45367455|NCT00730613|Other|laboratory biomarker analysis|CSF generated at the time of each T-cell dose
45367456|NCT00928148|Drug|SPD465|50 or 75 mg once daily for 7 days
45484212|NCT01367028|Drug|Trastuzumab, Docetaxel|"6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion"
45484213|NCT01367028|Drug|Trastuzumab, Docetaxel, Bevacizumab|"6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion Bevacizumab 15 mg/kg"
45484214|NCT01367028|Drug|Trastuzumab+Docetaxel+NPLD|"6 cycles - Day1 (Day22=Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min IV infusion NPLD 50 mg/m2 by 60 min i.v. infusion"
45484215|NCT01367028|Drug|Trastuzumab+Docetaxel+NPLD+Bevacizumab|"6 cycles - Day1 (Day22= Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min i.v. infusion NPLD: 50 mg/m2 by 60 min i.v. infusion; Bevacizumab 15 mg/kg"
45484216|NCT03965962|Biological|VRVg-2|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
45484217|NCT03965962|Biological|Purified Inactivated Rabies Vaccine|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
45484218|NCT03965962|Biological|Human Diploid Cell Vaccine (HDCV)|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
45484219|NCT03965962|Biological|Rabies immune globulin (human)|"Pharmaceutical form: Solution for injection;~Route of administration: IM"
45484220|NCT03262402|Procedure|Basic periodontal treatment|Basic periodontal treatment consists of scaling and root planing performed with manual curettes or ultrasonic instruments.
45691260|NCT03519412|Drug|temozolomide (induction),|temozolomide is administered to MGMT promoter methylation-positive MMRp patients orally, once daily, at the dose of 150-200 mg/m2/day for 5 consecutive days of each treatment cycle A treatment cycle will comprise 5 days of temozolomide administration (Day 1 to 5) followed by 23 days of rest for a total of 28 days (4 weeks) period (dose-schedule: 150 mg/m2 day 1-5 q28),until disease progression or unacceptable toxicity whichever comes first.
45367457|NCT00928148|Drug|Immediate Release Amphetamine Salt|25 mg once daily for 7 days
45367458|NCT00928148|Drug|Placebo|Once daily for 7 days
45367459|NCT02430077|Drug|Obeticholic Acid|Capsules of obeticholic acid (OCA) or an identical placebo in the dose of 25 mg/day for a period of 4 months .
45367460|NCT02430077|Drug|Placebo|Identical to Obeticholic Acid - placebo drug
45367461|NCT00904436|Drug|ipratropium (Atrovent)|Bronchodilator Treatment: Subjects will inhale 1 unit dose vial of aerosolized ipratropium (500 mcg of ipratropium (Atrovent) mixed in 2.5 ml of saline).
45367462|NCT00728585|Drug|Palifermin|Given IV
45367463|NCT00728585|Other|Placebo|Given IV
45367464|NCT02422433|Device|OFDI Capsule Marking|Marking and imaging of the esophagus using the OFDI Capsule and system.
45367465|NCT00730769|Drug|Single arm (ganciclovir and valganciclovir)|Patients received a short induction of IV ganciclovir at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir at 900 mg bid (after meals) for 16 days up to complet 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockroft-Gault equation)
45691261|NCT03519412|Biological|pembrolizumab (treatment)|pembrolizumab is administered to MGMT-IHC-negative, MGMT promoter methylation-positive MMRp patients with TMB>20 Mut/Mb after Temozolomide treatment, and to MMRd. Patients receive pembrolizumab IV , 200 mg Q3W, Day 1 of each 3 week cycle for maximum 35 cycles, until disease progression or unacceptable toxicity whichever comes first.
45691262|NCT05180110|Diagnostic Test|Venepuncture|Venous blood draw
45367466|NCT04200287|Behavioral|Online decision aid tool|The decision aid intervention will be presented via a website
45367467|NCT00728663|Biological|cetuximab|"Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
45691263|NCT05180110|Diagnostic Test|Fingerstick|Capillary blood draw
45691264|NCT03516760|Drug|GEM333|infusion of GEM333; administered intravenously and continuously over 10 days
45691265|NCT01870297|Drug|LY3025876|Administered SQ
45691266|NCT01870297|Drug|Placebo|Administered SQ
45691267|NCT01870297|Drug|Liraglutide|Administered SQ
45846061|NCT03562572|Other|Usual care group|In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.
46051849|NCT00833482|Drug|Ritonavir|"Treatment B: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal.~Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose.Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30. Treatment B in PM participants: PM participants received atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal."
45367468|NCT00728663|Drug|docetaxel|"75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
45367469|NCT00728897|Drug|GSK598809 new formulation|GSK598809 new formulation will be available as an immediate release capsule with a single dose of 100 milligrams, administered orally with 240 milliliters of water.
45367470|NCT00728897|Drug|GSK598809 old formulation|GSK598809 old formulation will be available as an immediate release capsule with a single dose of 25 milligrams, administered orally with 240 milliliters of water.
45367471|NCT04124705|Drug|Armour® Thyroid|Administered orally once a day. the daily dose could range from 1/4 - 2 grains.
45367472|NCT04124705|Drug|Levothyroxine|Administered orally once a day; the daily dose could range from 25- 200 µg.
45367473|NCT03110861|Device|Pulsta® Transcatheter Pulmonary Valve (TPV) Replacement|Pulsta® Transcatheter Pulmonary Valve Replacement
45367474|NCT00731003|Drug|Oxitriptan|100 mg 5-Hydroxytryptophan will be administered orally.
45367475|NCT00731003|Other|Acute tryptophan depletion|Acute tryptophan depletion employs the oral ingestion of an amino acid mixture devoid of tryptophan, the precursor of serotonin, which results in lowered serotonin levels.
45367476|NCT00731003|Other|Amino acid drink with tryptophan|Amino acid drink with tryptophan, placebo for the ATD procedure
45367477|NCT00731003|Drug|Placebo capsule|Placebo for 5-HTP
45367478|NCT00928226|Radiation|Fractionated Stereotactic Radiosurgery (SRS)|Standard of care
46051850|NCT04196049|Procedure|fragmatome|Patients with massive subretinal hemorrhage from age related macular degeneration and organized subretinal blood clot were managed by inferior retinectomy. The subretinal organized blood clot was dragged to the preretinal space and removed by fragmatome. The retinal was reattached with perfluorocarbon liquid and laser was applied at the margin of retinectomy. Silicon oil was infused at the end of surgery.
46051851|NCT02824107|Biological|blood sample|
45484221|NCT05188794|Procedure|lateral tap block|In the axial plane on the midaxillary line between the subcostal margin and the iliac crest with a linear probe using a 12 cm insulated nerve block needle is advanced in planely from skin, external, and internal oblique muscles to the target of fascial plane between the internal oblique and the transversus abdominis muscles.
45484222|NCT05188794|Procedure|posterior tap block|In the axial plane on the midaxillary line a linear probe using a 12 cm insulated nerve block needle is advanced posteriorly to the most posterior limit of the TAP between the internal oblique and transversus abdominis muscles.
45484223|NCT03273088|Drug|Etanercept|A single dose of etanercept (25mg/0.5ml prefilled syringe) was administered subcutaneously to healthy subjects.
45484224|NCT04235634|Drug|Prostavasin|Minimal invasive Cannulation of the Superior Mesenteric Artery (SMA) and subsequent intra-arterial application of prostaglandin E1 (Initial Bolus 20ug, followed by continuous Infusion of 60-80ug/24hr for 24-72hrs)
45484225|NCT03262090|Drug|0.2ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision
45484226|NCT03262090|Drug|0.4ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision
45484227|NCT03262090|Drug|0.6ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision
45484228|NCT03262090|Drug|0.8ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision
45367479|NCT00928226|Procedure|Surgical resection|Standard of care
45367480|NCT00729131|Drug|Etanercept inhibition of ozone-induced airway hyper-responsiveness.|Single dosage of etanercept(50 mg, subcutaneous) given 2 days prior to a laboratory ozone exposure.
46051852|NCT02824107|Behavioral|questionnaires for psychosocial factors|
45367481|NCT02569385|Other|Spontaneous breathing trial|
45484229|NCT03262090|Drug|1.0ug/kg dexmedetomidine|subjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision
45484230|NCT01359774|Other|31P-MR spectroscopy|Brain energy deficit is quantified using 31P-MR spectroscopy
45484231|NCT01359774|Other|31P-RMN spectroscopy|Brain energy deficit is quantified using 31P-RMN spectroscopy
45484232|NCT03272854|Other|No intervention performed, the study is observational|
46051853|NCT04906239|Procedure|Erector Spinae Plane Block|A high-frequency ultrasound linear probe, covered with a sterile sheath, will be placed approximately 2 cm to the right or left of the T 4-5 spinous process. After showing the T 4-5 transverse process and the erector spinae muscle on top of it, a 22-gauge, 80 mm insulated quincke type needle will be inserted into the skin at an angle of approximately 30 degrees from cranial to caudal, using the in-plane technique. When the transverse process is touched, the needle will be pulled out and after a negative aspiration test with 0.5 mL of normal saline and after the demonstration of a hypo-echogenic image and hydro dissection, a local anesthetic solution will be applied to the fascia beneath the erector spinae muscle. A 20 mL dose of 0.25% bupivacaine, which has been shown to spread both above and below the T 4-5 level, will be injected.
45484233|NCT03151551|Drug|Ixekizumab|Administered SC
45484234|NCT03151551|Drug|Adalimumab|Administered SC
45367482|NCT00731159|Biological|sperm capacitation|sperm capacitation measured at Bar Ilan University
45367483|NCT00731159|Other|biologic|sperm synthesis of G-actine to F-actine
45367484|NCT00731159|Other|sperm capacitation|sperm synthesis of G-actine to F-actine
45367485|NCT04095611|Procedure|SPAIRE|To perform the hip surgery called hemiarthroplasty surgeons need to cut through some muscles to expose the hip joint and perform the partial replacement. Currently this often performed using a technique which involves cutting muscles and tendons from the side of the hip and this is called the lateral approach. SPAIRE is a modified technique that accesses the surgical area through a different route.
45367486|NCT04095611|Procedure|LATERAL|surgery in adults with a displaced intracapsular hip fracture requiring hemiarthroplasty, the standard lateral approach.
45367487|NCT04056455|Drug|Mobocertinib|Mobocertinib capsule.
45367488|NCT00729209|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
45367489|NCT00729209|Drug|Placebo; oral|matching placebo
45484235|NCT01362582|Drug|SMOF Kabiven|SMOFKabiven® will be given over night with a content of 1100 kcal in 986 ml.
45484236|NCT03272776|Device|Protector Laryngeal Mask airway|Evaluate the time of insertion, performance, security and insertion success rate of the Protector Laryngeal Mask in patients under general anasthesia.
45484237|NCT05186376|Procedure|bimaxillair osteotomy with maxillar segmentation|Patients who underwent bimaxillair osteotomy with maxillar segmentation
45484238|NCT01367106|Procedure|Euglycemic hyperinsulinemic clamp|Euglycemic hyperinsulinemic clamp will be performed at day 2
46051854|NCT05659953|Drug|LMT503|Subjects will receive one of several different oral doses of LMT503 once daily
46051855|NCT05659953|Drug|Placebo|Subjects will receive one of several different oral doses of Placebo once daily
46051856|NCT00845182|Drug|Pioglitazone|Pioglitazone 15 mg/day for 1 month and then 45 mg/day for 5 months
46051857|NCT00845182|Drug|Exenatide|Exenatide 5mcg twice daily for 1 month, then 10mcg twice daily for 5 months
46051858|NCT00845182|Drug|Pioglitazone and Exenatide|Pioglitazone 30mg daily for 1 month and then 45mg daily for 5 months and Exenatide 5mcg twice daily for one month then 10mcg twice daily for 5 months
45484239|NCT03267316|Biological|CAN04|A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.
45367490|NCT04026347|Device|Vesair Balloon|Indwelling, intravesical balloon
45484240|NCT03267316|Drug|Cisplatin|Standard of care treatment
45484241|NCT03267316|Drug|Gemcitabine|Standard of care treatment
45484242|NCT03267316|Drug|Nab-paclitaxel|Standard of care treatment
45484243|NCT05169216|Behavioral|Cognitive-Behavioral Therapy|"Each week, a sheet of tasks to be executed and a diary were provided to verify compliance with the guidelines:~Week 0. Familiarization: Information gathering~1st week. Self-knowledge and concentration: To know sports psychology and mental training. Information on beliefs and expectations in sport.~2nd week: To integrate daily mental training.~3rd week. Trust: To consolidate concentration activation. To integrate and build confidence (in oneself and in the team).~4th week. Application to sports tactics: To apply concentration strategies to your sports practice. To know those strategies that provide the best results for each athlete.~5th and 6th weeks: To integrate the content already provided.~7th week. Link with the team: To strengthen the bond between team members.~8th week. Daily routines: To improve the daily routine prior to the competition.~9th and 10th weeks: To integrate the content already provided."
45484244|NCT01359852|Drug|[11C] JNJ-42491293|Part B:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection, have a 90 minute PET scan and have arterial and venous blood sampling.
45367491|NCT04026347|Other|Sham balloon placement|Sham balloon placement procedure
45484245|NCT01359852|Drug|[11C] JNJ-42491293 + JNJ-40411813|Part C:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan
45691268|NCT04717726|Dietary Supplement|Milk Thistle (MT)|Participants in the MT and EX + MT groups will be provided 900 mg of standardized milk thistle extract daily (300 mg three times per day before meals) over the 12-week regimen. We will use the standardized Jarrow Formulas Milk Thistle Veggie Caps containing 30:1 extract that is standardized to contain 80% total Milk Thistle seed flavonoids (polyphenols), including the critical Silymarin fractions isosilybinins A and B, silybinins A and B, silychristin and silydianin that is active against suppressing the UGT1A1 enzyme increasing plasma bilirubin. The capsules are free of wheat, gluten, soybeans, dairy, egg, fish/shellfish, peanuts/tree nuts, and GMOs. Rationale for using this brand: There have been inconsistencies with previous studies that did not use a standardized silymarin extract, which may have contained low levels of the active polyphenolic flavonoids in the milk thistle plant, which varies in the plant's stems, leaves, roots, and flowers.
46051859|NCT04934553|Behavioral|Amplification of Positivity Training|12 90-minute, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
45367492|NCT00731315|Other|Computer-assisted treatment group|This group will receive computer-assisted expedited treatment for uncomplicated UTI or complicated cystitis based on their symptoms and past medical history reported on the computer.
45367493|NCT00731315|Other|Usual care group|This group will receive usual care for an uncomplicated UTI or complicated cystitis in the Emergency Department or Community Health Center.
45847934|NCT03094806|Device|Acapella Vibratory PEP Therapy Device plus usual care|The acapella® Vibratory PEP Therapy System (PEP-FV) device is a handheld device that operates in same principle as standard FV. Unlike standard FV, it is not gravity dependent. It comes in two different devices to accommodate for different flows rates of the patient. It has similar properties of a standard FV and may be better tolerated.
46051860|NCT04934553|Behavioral|Cognitive-behavioral Therapy|12 90-minute, clinician-administered treatment sessions focused on strategies to alter cognitions and behavior related to alcohol use.
46051861|NCT00833248|Drug|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
45367494|NCT00729287|Dietary Supplement|selenium|Given orally
45367495|NCT00729287|Other|placebo|Given orally
45367496|NCT02570087|Procedure|chronic total coronary occlusion percutaneous intervention|Percutaneous intervention of chronic total coronary occlusion with stent implantation
45367497|NCT02569697|Other|HEC Placebo gel|
45367498|NCT02569697|Other|Placebo Intravaginal Ring|
45484246|NCT01359852|Drug|[11C] JNJ-42491293 + JNJ-40411813|"Part D:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.~Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain"
45484247|NCT01359852|Drug|[11C] JNJ-42491293|Part A: [11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.
45484248|NCT05075434|Other|Conventional Treatment|This protocol will be the one prescribed by the health centre. It consists of calf stretching exercises, plantar fascia, proprioceptive exercises, ultrasound, magnetic therapy and gait re-education and proprioceptive exercises for 40-45 minutes. Participants will receive 8 treatment sessions spread over 4 weeks (2 sessions per week).
45484249|NCT05075434|Other|Diacutaneous fibrolysis|"15 minutes of the treatment technique. The FD intervention will be carried out with the same duration and protocol for all participants.~The intervention protocol will be: Start with the point of maximum tension between the two muscle bellies of the calf and hamstring (reverse hook). Then work on the peroneus longus lateralis and soleus. Then the external calf muscle belly and soleus and the internal calf muscle belly and soleus. Then work on the tendon of the flexor hallucis proprio of the big toe and the inner edge of the Achilles tendon and peroneus longus. Then treatment of the peroneus longus with the peroneus brevis. Scraping of the insertion of the Achilles tendon, hooking of the internal and external part of the plantar fascia. Finally, longitudinal friction of the plantar fascia."
45484250|NCT03262168|Other|Exercise Programme|Complete background demographics, Sniff Nasal Inspiratory Pressure (study group one only), grip strength, muscle strength, PHQ-9 and GAD-7 questionnaires.
45484251|NCT01359930|Other|placebo|matching placebo
45484252|NCT01359930|Drug|Naltrexone and Bupropion SR|25mg bid/day (NX) 200mg bid/day (BUP)
45484253|NCT05075512|Drug|anlotinib, fulvestrant|anlotinib: 12 mg once daily on days 1-14, repeated every 21 days; fulvestrant: 500 mg on days 1 and 15 of cycle one, and then on day one of each subsequent 28 days cycle
45484254|NCT01316757|Biological|cetuximab|Given IV
45484255|NCT01316757|Drug|paclitaxel|Given IV
45484256|NCT01316757|Drug|carboplatin|Given IV
45484257|NCT01316757|Drug|erlotinib hydrochloride|Given PO
45484258|NCT01316757|Other|laboratory biomarker analysis|Correlative studies
45484259|NCT01367340|Behavioral|Loaded sit-to-stand resistance exercise|Loaded STS exercise at home, 3 times a week for 6 weeks
46051862|NCT00833248|Drug|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 3. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
45367499|NCT02569697|Other|Placebo Vaginal Film|
45367500|NCT02569697|Other|Placebo Vaginal Insert|
45367501|NCT03095417|Behavioral|Physical Exercise Intervention|In home exercise intervention.
45367502|NCT03095417|Behavioral|Cognitive Training Intervention|Online cognitive training modules.
45367503|NCT03095417|Behavioral|Stretching Control|In home stretching.
45367504|NCT03095417|Behavioral|Cognitive Control|Online control puzzles and games.
45367505|NCT00731393|Biological|Thiomersal free trivalent influenza split vaccine 2003/2004|2 doses, intramuscular injection
45367506|NCT00731393|Biological|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2003/2004|2 doses, intramuscular injection
45367507|NCT00731471|Biological|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from Mycobacterium tuberculosis. Both arms will receive two vaccinations six months apart.
45484260|NCT01367340|Behavioral|Physical activity intervention|The intervention is based on the social cognitive theory and the transtheoretical model. There are two principle components, the individual consultation and the small group PA activities. In the individual consultation, assessment of current stage of readiness for PA will be performed first. Then, individualized, stage-matched feedback will be sent to the participants. Small group PA activities will be held every 2 weeks in order to increase learning opportunity by peer interaction, make exercise fun, and introduce a role model.
45484261|NCT01362660|Other|Unintentional exposure in utero|This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).
45484262|NCT05074966|Drug|Experimental: mXELOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Cetuximab: 500 mg/m2, IV, d1, q2w; Oxaliplatin: 85 mg/m2, IV, d1,q2w; Capecitabine: 850 mg/m2, po, bid, q2w maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Capecitabine: 850 mg/m2, po, bid, d1-10, q2w;"
45596602|NCT05647291|Device|Kinesiotaping|The first strip was adhered along the plantar fascia from the calcaneus to the toes using maximum stretch. The other four strips of tape were attached medially and laterally to support the medial longitudinal arch with a 45° inclination. While maximum stretching was applied to the middle 1/3 of all bands, no stretching was applied to the ends. Once a week, three times
45596603|NCT03105765|Drug|Placebo|Normal saline applied by bolus before operation started, followed by a continuous application of normal saline for 24 hours.
45367508|NCT04390217|Drug|LB1148|LB1148 is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
46051863|NCT00833248|Drug|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
45367509|NCT04390217|Drug|Placebo|Placebo is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
45367510|NCT02569463|Drug|Interleukin-2|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks.
45367511|NCT00729443|Drug|AZD3241|single oral dose
45367512|NCT00729443|Drug|Placebo|
45367513|NCT00731627|Drug|placebo|one tablet a day for up to 21 days
46051864|NCT02612506|Drug|Hepalatide|There are seven cohorts as follows 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. Dose of 0.21mg is a pilot trial with no placebo. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
45484263|NCT05074966|Drug|Active Comparator: FOLFOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Oxaliplatin 85 mg/m2, IV d1; Leucovorin 400 mg/m2 IV d1; 5-FU 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48 hours) IV continuous infusion; q2w maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Leucovorin： 400 mg/m2 IV d1, q2w; 5-FU： 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48hours) IV continuous infusion, q2w （Cetuximab combined with capecitabine can be used according to the patient's wishes and the nursing situation of intravenous catheterization）"
45367514|NCT00731627|Drug|simvastatin|simvastatin 40mg once a day for a maximum of 21 days
45484264|NCT01340859|Behavioral|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 60-90 minutes sessions; 6 sessions over preferably 3 days of inpatient stay
45484265|NCT01362738|Procedure|RFCA of PV and extra-PV triggers|PVAI and isolation of extra PV triggers
45367515|NCT00731705|Procedure|collection of peripheral blood and apheresis samples|Sixty mL of peripheral blood will be collected from consenting eligible donors. Additionally, after the laboratory techniques have been fully evaluated, leukopheresis samples will also be collected.
45367516|NCT03050489|Procedure|On-Pump CABG.|Standard On-Pump CABG.
45367517|NCT03050489|Procedure|Off-Pump CABG.|Standard Off-Pump CABG.
45367518|NCT03050489|Procedure|BH-CABG MSC.|Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation
45367519|NCT00568178|Drug|Losartan Potassium|"Losartan Use During the Double-Blind Treatment Phase:~Losartan potassium was administered orally as tablets; 25 or 50 milligrams (mg); or as a liquid suspension 2.5 mg/mL prepared for participants who weighed less than 25 kilograms (kg) or for those participants unable to swallow tablets. During the double-blind period, participants were initially randomized to either a once-daily weight-dependent dose of approximately 0.7 mg/kg (25 mg tablet; up to 50 mg per day) and at 2-weeks the dose was increased to a once-daily maximum weight-dependent dose of 1.4 mg/kg. The maximum dose of losartan, as specified in the protocol, was 50 mg/day (if the patient weighed <50 kg)~or 100 mg/day (if the patient weighed ≥50 kg).~Losartan Use During the Treatment Extension Phase:~Dose modifications of the drug were left up to the discretion of the Investigators based on each participant's level of tolerance."
45367520|NCT00568178|Other|Comparator: Placebo (Losartan)|Placebo (losartan suspension), administered orally, once daily for 12 weeks
45484266|NCT01362738|Procedure|LAA isolation along with the conventional ablation strategy|PVAI + isolation of extra PV triggers + LAA isolation
45484267|NCT01341015|Other|Ultrasound|Single interventional group - patients agree to an ultrasound of potential ankle fracture, to be compared to standard of care xray.
45596604|NCT03105765|Drug|Ketamine|Application of Ketamine 0,2mg/kg ideal Body weight by Bolus before the Operation started, followed by application of 0,2 mg/kg ideal Body weight for 24 hours.
45596605|NCT03660371|Procedure|PPV/MP|Internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
46051865|NCT02612506|Drug|Placebo|There are six cohorts as follows 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
46051866|NCT05530330|Diagnostic Test|Platelet/Endothelial proteomics|Samples taken will undergo a targeted proteomic investigation examining platelet/endothelial markers and associated extracellular vesicles
45847935|NCT03094806|Device|Sham Acapella Vibratory PEP Device plus usual care|The Sham Acapella Vibratory PEP Device is the same as the Therapy Device, except the flutter valve has been removed from the device.
46051867|NCT02612584|Device|Pinhole Soft Contact Lens apply for presbyopia|
46051868|NCT00833092|Dietary Supplement|Sugar Pill|Sugar pill supplementation for 9 weeks
46051869|NCT00833092|Dietary Supplement|magnesium|300 milligrams daily for 8 weeks
46051870|NCT00708370|Other|COACH|COACH Nurse will provide health tele-counselling to patients randomized to COACH arm fortnightly for 24 weeks.
46051871|NCT00708370|Other|No intervention for placebo|There will be no COACH health tele-counselling to patients randomized to Standard Care arm.
45367521|NCT00568178|Drug|Comparator: amlodipine besylate|Amlodipine besylate (1 mg/mL) liquid suspension, oral administration, titrated to 0.2 mg/kg/day (5 mg maximum dose) per day for 12 Weeks
46051872|NCT00702130|Drug|Pravastatin|pravastatin 40mg per os once daily
45367522|NCT00568178|Other|Comparator: Placebo (amlodipine besylate)|Liquid suspension, 1mg/mL, titrated to 0.2 mg/kg/day (5 mg maximum dose) once daily, for 12 weeks
46051873|NCT02611414|Device|anodal tDCS|tDCS anodal stimulation over M1 area applied for 20 minutes at five consecutive days.
45367523|NCT00568178|Other|Placebo (Losartan)|Normotensive patients randomized to losartan placebo for 12 weeks.
46051874|NCT02611414|Device|Sham tDCS|tDCS sham stimulation over M1 applied for 20 minutes (with current turned off at 30 seconds) at five consecutive days.
46051875|NCT00823264|Drug|Activated Charcoal|50 grams by mouth every 4 hours until serum phenytoin level is less than 25.
46051876|NCT00708604|Procedure|Islet Transplantation|Islet Transplantation
45596606|NCT03660371|Procedure|PPV without MP|No internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
46051877|NCT00708604|Biological|Islet cell transplantation|Islet cell transplantation will occur through the portal vein.
45846062|NCT03544632|Drug|Acellular Adipose Tissue (AAT)|"Participants (n=15) will be administered between 5cc and 20cc of AAT, depending on their assigned treatment group, via sterile subcutaneous injection into the target defect. The injection is intended to be permanent. After the 3-month study follow-up visit, participants will have the option to undergo additional AAT injection (up to 20cc per treatment) in order to fully correct the defect. Total injected AAT volume per patient will not exceed 40cc. Additional injection is dependent upon study- and patient-specific adverse / unanticipated events to date.~Each vial contains a 2 milliliter (mL) dose of the injectable AAT. This volume is similar to other commonly used injectable filler materials intended for soft tissue correction."
45367524|NCT00568178|Drug|Enalapril Maleate|Enalapril 2.5-, 5-, 10-, and 20-mg tablets or enalapril suspension (1 mg/mL), oral administration, once daily for 36 months.
45367525|NCT00924248|Drug|Gadoxetic acid disodium (Primovist, BAY86-4873)|Patients in daily life clinical practice treatment receiving Primovist according to indication on the label.
45691269|NCT04717726|Dietary Supplement|Lactobacillus Gasseri (LAC)|Participants in the LAC and LAC + EX groups will receive two doses of 3 billion CFU of lactobacillus gasseri per day for a total of 6 billion CFU, the recommended upper level for supplementation of probiotic cultures. We will use Swanson brand Lactobacillus gasseri, whose capsules are also free of wheat, gluten, soybeans, dairy, egg, fish/shellfish, peanuts/tree nuts, and GMOs. Importantly, this brand uses acid-resistant designed release capsules to improve the viability of the lactobacillus in the human stomach.
45846063|NCT03535272|Drug|Bismuth subsalicylate|We aim to determine if there is a biologic benefit to an intervention (BSS administration) in the acquisition of travelers diarrhea and the acquisition of antimicrobial resistance genes.
45367526|NCT00904514|Genetic|gene expression analysis|
46051878|NCT00832780|Radiation|Stereotactic Body Radiation|A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the planning target volume. Dose homogeneity +/- 5%.
45846064|NCT03535272|Drug|Placebo Oral Tablet|Placebo manufactured to mimic pepto bismol
45367527|NCT00904514|Genetic|microarray analysis|
45367528|NCT00904514|Genetic|mutation analysis|
45367529|NCT00904514|Genetic|polymerase chain reaction|
45367530|NCT00904514|Other|flow cytometry|
45367531|NCT00904514|Other|immunoenzyme technique|
45367532|NCT00904514|Other|laboratory biomarker analysis|
45367533|NCT00928460|Procedure|Removal of preoperative electrocardiogram|A new preanesthesia evaluation strategy without routine ECG. Initially, all patients in the participating centers are assessed following the regular strategy (with routine ECG). The new strategy (without routine ECG) is rolled out to the participating hospitals sequentially. At the end of the trial all participating centers will use the new preoperative strategy.
45367534|NCT00577889|Drug|gemcitabine hydrochloride|750 mg/m2 Given IV
45367535|NCT00577889|Drug|tanespimycin|154 mg/m2 Given IV
45367536|NCT00928538|Other|Enhanced NFP Care|Usual NFP care plus the enhanced care that includes contraceptive administration and distribution during nurse home visits. Participants will have a choice of combined hormonal contraception (oral, patches or vaginal rings)or progestin-only contraception (oral or depomedroxyprogesterone acetate injections.
46051879|NCT02824341|Device|fMRI|
45367537|NCT00928616|Dietary Supplement|margarine + plant sterol esters|margarine supplemented with plant sterol esters (3g/day) over the time period of 4 weeks
45846065|NCT03529110|Drug|Trastuzumab deruxtecan (T-DXd)|T-DXd is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously.
45367538|NCT00928616|Dietary Supplement|margarine (placebo)|non-sterol ester supplemented margarine
45367539|NCT00460564|Drug|GSK1358820|botulinum toxin type A
45367540|NCT00460564|Drug|Placebo|Placebo
45367541|NCT00729599|Drug|Cetylpyridinium chloride|Cetylpyridinium chloride during 21 consecutive days.
45367542|NCT04015076|Drug|Inzomelid|Active Drug
45846066|NCT03529110|Drug|Ado-trastuzumab emtansine (T-DM1)|The treatment will be in accordance with the approved label.
46051880|NCT04241055|Behavioral|Values affirmation exercise|In the experimental values affirmation condition, participants spend 10-15 minutes completing a guided reflection regarding values that are personally important (see Logel and Cohen, 2012; Brady, Griffiths, & Cohen, in prep).
45367543|NCT04015076|Drug|Placebo|Placebo to Match
45367544|NCT03743480|Other|early palliative care|experimental arm. Patients in this arm will meet with the palliative care team soon after the decision on their last active treatment
45367545|NCT02538926|Drug|Asparaginase|Given IM or IV
45367546|NCT02538926|Drug|Cyclophosphamide|Given IV
45367547|NCT02538926|Drug|Doxorubicin Hydrochloride|Given IV
45367548|NCT02538926|Drug|Etoposide|Given IV
45367549|NCT02538926|Drug|Imatinib Mesylate|Given PO
45596607|NCT03105609|Device|Hyperspectral imaging|Hyperspectral retinal images will be taken at baseline (before treatment with Lucentis) and then at 3 and 9 months after treatment.
45596608|NCT03531307|Other|Data correlation|Correlation between lactate levels and Ki-67 index
45596609|NCT02202473|Drug|Lamivudine|
45596610|NCT02202473|Drug|Lamivudine+Oxymatrine Capsules|
46051881|NCT04241055|Behavioral|Active control exercise|In the active control condition, participants spend 10-15 minutes completing a guided reflection regarding values that are not personally important but could be important to someone else (see Logel and Cohen, 2012; Brady, Griffiths, & Cohen, in prep).
45484268|NCT03267004|Device|Dietary Assessment of Meal A using images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal A in the laboratory~Meal A:~Turkey and Provolone Cheese Sandwich [whole wheat bread 52g(female & male), Turkey 70g(female) & 133g(male), Provolone cheese 23g(female & male), tomato 50g(female & male), lettuce 45g(female & male)]; Chicken and wild rice [chicken 98g(female & male), wild rice 71g(female) & 107g(male)]; chocolate chips cookies [44g(female) & 60.5g(male)]; potato chips [39g(female) & 52g(male)]."
45484269|NCT03267004|Device|Dietary Assessment of Meal B using Images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal B in the laboratory~Meal B:~Ham & Cheddar cheese wrap [Tortilla 45g(female & male), Ham deli 76g(female) & 103g(male), cheddar cheese 21g(female) & 32g(male), Spring Mix 36g(female & male), Fat Free ranch dressing 29g(female & male)]; Pasta with broccoli and Alfredo sauce [Pasta 91g(female) & 121g(male), Broccoli 66g(female & male), Alfredo sauce 38g(female) & 50g(male)]; Chocolate Ice-cream [107g(female), 138g(male)]; Red seedless grapes [365g (female), 471g(male)]."
45484270|NCT01341093|Behavioral|educational program+telephone follow up|Patients will participate in the educational program with telephone follow-up, the education program will initiate in preoperative period and will continue for six months.
45367550|NCT02538926|Other|Laboratory Biomarker Analysis|Correlative studies
45367551|NCT02538926|Drug|Prednisone|Given PO
45367552|NCT02538926|Biological|Rituximab|Given IV
45367553|NCT02538926|Drug|Vincristine Sulfate|Given IV
45367554|NCT01323400|Drug|Pazopanib|Pazopanib is administered orally at 800 mg/day (one dose every morning). A dose modification is possible in case of documented toxicity, according to specific algorithms.
45367555|NCT01323400|Other|Best supportive care|"Best supportive care according to the investigator's judgment (chemotherapy, immunotherapy, hormone therapy are not allowed).~Non-targeted radiation therapy is tolerated, as antalgic strategy. Surgery is tolerated in case of emergency."
45367556|NCT00904592|Drug|Qi ming granula|Qi ming granula Usage:4.5g，po，tid. duration:12 months/ arise Endpoint Event
45367557|NCT00904592|Drug|Placebo Comparator|"Control group: Basic therapy ＆ placebo~Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.~placebo,Usage: 4.5g，po，tid"
45484271|NCT01341093|Behavioral|Usual care|Patients will receive orientations about the surgery and the rehabilitation by health professionals, especially in the discharge. And will have return for evaluation scheduled by health professionals.
46051882|NCT04241211|Drug|Forsteo|Patients were administered 20mcg of TP (Forsteo) subcutaneously once a day from the day between before 3months to after 3months about surgery.
46051883|NCT04241211|Drug|Denosumab Prefilled Syringe [Prolia]|Patients were administered 60mg of denosumab (Prolia) subcutaneously once 6months from the day on before 3months to after 3months about surgery.
46051884|NCT00591838|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
46051885|NCT02611648|Other|Double HLD|Standard high level disinfectant (metricide ortho-phthalaldehyde) with an additional exposure time to disinfect
45484272|NCT03267082|Other|Laparoscopic management of perforated appendicitis|"Insertion of Ports~Exposure of the Appendix~peritoneal toilet and aspiration of pus after abdominal exposure~Isolation of Mesoappendicular Artery~Clipping and Dividing of the Artery~Application of 3 x Endoloops~Division of the Appendix~Retrieval of the Appendix in an Endobag"
45367558|NCT00928850|Procedure|radical prostatectomy with urethral irrigation but no fascial suturing, QOL forms|"Cancer cells can spill during surgery and this can cause cancer to return (recur). Some surgeons believe that irrigating could help stop spilling of cancer cells. Irrigating means washing the surgical area with sterile water and sucking the water back up through a tube. As a result, surgeons vary as to how they irrigate. In this study, we will examine irrigation of the urethra. This is the part of the body that carries urine from the bladder to the penis. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery"
45367559|NCT00928850|Procedure|radical prostatectomy with fascial suturing but no urethral irrigation, QOL forms|"Surgeons believe that what happens to the urethra can affect the risk of incontinence. This is when a patient cannot control urine, and drips or leaks urine. One idea is that additional stitches (sutures) to the connective tissue (fascia) could be helpful, but this is not known for sure. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery"
45367560|NCT00928850|Procedure|radical prostatectomy with both urethral irrigation and fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
45484273|NCT05188482|Device|vibroacoustic therapy|Vibroacoustic respiratory therapy
45484274|NCT03266926|Drug|Bupivacaine|0.25% Bupivacaine with epinephrine will be applied to vaginal packing that is placed post vaginal reconstruction surgery.
45484275|NCT03266926|Drug|Premarin Vaginal cream|A Premarin vaginal cream will be used to coat the vaginal pack, prior to insertion in patients post vaginal reconstruction surgery.
45484276|NCT01343745|Drug|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 4 inhalations bid (total daily dose 800 µg BDP + 48 µg formoterol)
45484277|NCT01343745|Drug|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 1 inhalation bid (total daily dose 200 µg BDP + 12 µg formoterol)
45484278|NCT01343745|Drug|Placebo|pressurised metered dose inhaler
45484279|NCT03267160|Diagnostic Test|Hemodynamic parameters|Pulse contour cardiac output monitored heart contractility, end-diastolic volume parameters, and lung water parameters.
45367561|NCT00928850|Procedure|radical prostatectomy with neither urethral irrigation nor fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
45367562|NCT03745313|Device|Edwards PASCAL Transcatheter Valve Repair System|Repair of the tricuspid valve through a transcatheter approach
45691270|NCT04717726|Behavioral|Exercise (EX)|Participants in the EX, EX + MT, and EX + LAC groups will complete five weekly exercise sessions on their own, expending roughly 600 kcal per session. Participants will be provided a Polar A-300 heart rate monitor programmed for their individual attributes (height, weight, age, training status, gender), which gives a real-time estimate of energy expenditure during exercise. Participants will report to the lab once per week to download the exercise sessions and verify compliance. If participants are not compliant (defined as completing 85% of their assigned exercise sessions per month), they will be disqualified. This intervention has been successfully used by Dr. Flack in multiple studies to produce significant weight loss without dietary intervention in this population with a retention rate of over 90%
45691271|NCT04717726|Dietary Supplement|Control (CON)|Participants in the CON and EX group will receive a placebo (maltodextrin) made to look identical to the MT and LAC capsules.
45367563|NCT00904904|Drug|Indomethacin ophthalmic solution|Indomethacin 0.1% eye drops administered pre-cataract surgery and for 4 weeks post-cataract surgery
45367564|NCT00904904|Drug|Ketorolac Ophthalmic Solution|Ketorolac 0.5% eye drops administered pre-cataract surgery and 4 weeks post-cataract surgery
45484280|NCT01367418|Drug|Patient controlled analgesia (PCA)|Morphine 1 mg/ml
45484281|NCT01367418|Drug|Thoracic Epidural Analgesia (TEA)|Intra-operatively: Bupivacaine 0.5% with adrenaline Post-operatively: Ropivacaine 0.2% + sufentanil 1 ug
45484282|NCT03266692|Biological|ACTR087|Autologous T cell product
45484283|NCT03266692|Biological|SEA-BCMA|B-cell maturation antigen (BCMA)-directed antibody
45484284|NCT03147495|Diagnostic Test|Standing anteroposterior knee radiographs and special proximal tibiofibular joint radiograph.|Standing anteroposterior knee radiographs and special proximal tibiofibular joint radiographs will be taken for the participants in both groups. The standing anteroposterior knee radiographs will be obtained with the knee extended. The proximal tibiofibular joint radiographs will be acquired with the knee of the participants in approximately 45°-60° of internal rotation.
45484285|NCT01360086|Biological|cetuximab|6 cycles of intravenous Cetuximab (500mg/m²),
45484286|NCT01360086|Drug|cisplatin|Cisplatine (50mg/m²)
45484287|NCT01360086|Drug|fluorouracil|LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks
45484288|NCT01360086|Drug|leucovorin calcium|
45484289|NCT01360086|Procedure|adjuvant therapy|
45484290|NCT01360086|Procedure|neoadjuvant therapy|
45484291|NCT01360086|Procedure|quality-of-life assessment|
45484292|NCT01360086|Procedure|therapeutic conventional surgery|Surgery was planned 3-4 weeks after the end of neaodjuvant CT
45484293|NCT03262246|Other|medical report consultation|investigators consult medical report concerning patient identified for cerebral amyloid angiopathy
45484294|NCT04454346|Device|Double Foley Catheter For Ripening The Unfavorable Cervix|New method
45484295|NCT05183451|Procedure|En- masse retraction and LLLT|"Retraction will start on a 0.019x0.025 Stainless steel wire using NiTi closed coils (force applied will be 200 g per side) extending between the crimpable hooks and the TADs. LLLT will be applied on days 0,3,7,14 from extraction then repeated biweekly till the end of retraction."
45484296|NCT05183451|Procedure|En- masse retraction without LLLT|"Retraction will start on a 0.019x0.025 Stainless steel wire using NiTi closed coils (force applied will be 200 g per side) extending between the crimpable hooks and the TADs."
45484297|NCT02458924|Biological|Niacin skin test|Two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate were applied for one minute to the inside of the different forearms of each individual.
45367565|NCT00731861|Drug|Paclitaxel plus PTK787|"Paclitaxel will be given on days 1 and 15 over 28 days in cycle 1 with PTK787 on days 3 to 28. PTK787 WILL BE TAKEN AT NIGHT.~In cycle 2 and beyond, paclitaxel will be given on days 1, 8 and 15 every 28 days . PTK787 will be taken orally NIGHTLY."
45367566|NCT00928928|Procedure|Open colectomy|Open colectomy. Epidural anaesthesia used
45484298|NCT01367496|Drug|SC Methylnaltrexone (MNTX)|Dose 1
45484299|NCT01367496|Drug|SC Methylnaltrexone (MNTX)|Dose 2
45367567|NCT00928928|Procedure|laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
45367568|NCT00729755|Dietary Supplement|Creatine monohydrate|In addition to 10-20mg escitalopram, the subjects will be given total 3 gram of creatine (500mg/capsule) a day in first week and then, 5 gram a day in the rest of the weeks.
45367569|NCT00729755|Dietary Supplement|Placebo|In addition to 10-20mg escitalopram, the subjects will be given total 6 capsules of placebo (equal quantities to those of creatine group) a day in first week and then, 10 capsules a day in the rest of the weeks.
45367570|NCT03903263|Diagnostic Test|survey on sleep disorders|self-administered patient questionnaire regarding the different aspects of sleep disorders in patients with dermatologic diseases
45367571|NCT00567476|Drug|Omalizumab|Omalizumab 150 to 375 mg was administered subcutaneously every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of IgE.
45367572|NCT00567476|Drug|Inhaled corticosteroids (ICS)|Any ICS with proprietary drug and device > 500 mcg of fluticasone or equivalent
45367573|NCT00567476|Drug|Long-acting beta 2-adrenergic agonist (LABA)|Fixed dose of LABA as prescribed prior to study entry
45367574|NCT00567476|Drug|Short-acting beta 2-adrenergic agonist (SABA)|Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.
45484300|NCT01367496|Drug|SC Methylnaltrexone (MNTX)|Dose 3
45484301|NCT01367496|Drug|IV Methylnaltrexone (MNTX)|
45484302|NCT02458846|Other|Crowded HOTV Acuity Test|This is one of the most sensitive tests of acuity for vision screening of young children. The child is asked to recognize a letter (H,O,T,V) that is surrounded by bars to induce the crowding effects typical of amblyopia. Children were tested monocularly and was required to achieve at least 20/32 in each eye to pass. Children already wearing glasses were tested with their glasses on.
45484303|NCT02458846|Other|Preschool Randot Stereoacuity Test|"This is a reliable screening test for stereo depth perception for young children. Children wear polarized stereoglasses and are asked to identify or match shapes that are hiding in the snow, which cannot be perceived if the child has abnormal binocular vision. Children were required to achieve at least 60 arcseconds of disparity to pass. Children already wearing glasses were tested with their glasses worn under the stereo glasses."
45484304|NCT02458846|Device|Plusoptix Autorefractor|Autorefractors are electronic devices that measure refractive errors by focusing a light onto the child's eyes and recording how their reflections from the retina return to the camera. The Plusoptix has been shown to have high sensitivity and specificity in previous research. AAPOS (2013) guidelines were used to determine the referral criteria.
45484305|NCT02458846|Other|Comprehensive Eye Exam|Children who did not pass all three screening tests were referred for full cycloplegic optometry exams, with a parent/guardian present. Optometrists assessed visual history, monocular visual acuity (near & far), strabismus, binocular function, abnormalities of the anterior segment, and cycloplegic refraction. If the optometrist prescribed glasses, frames were chosen at the time of the exam and the glasses were dispensed either at school (with an optician) or at the optometrist's office.
45484306|NCT05183373|Other|Evaluation of inflammation and clotting|Evaluation of inflammation biomarkers (such as 8-isoprostane, Il-6) and fibrin clot properties (such as clot lysis time, clot permeability)
45484307|NCT05188404|Behavioral|Choice of cannabis product|Participants choose and purchase their own cannabis product
45691272|NCT01814761|Drug|Bimatoprost 0.01%|One drop of bimatoprost 0.01% (Lumigan® 0.01%) in the affected eye(s) every evening for 12 weeks.
45691273|NCT05141110|Drug|NVP-1705|NVP-1705
45691274|NCT05141110|Drug|NVP-1705-R|NVP-1705-R
45691275|NCT04616248|Biological|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Given IT
45484308|NCT05074576|Other|Mulligan group|"Ultrasound (8minutes, 1.5 w/cm2, pulsed), conventional transcutaneous electrical nerve stimulation (TENS) (20 minutes, 60-120 Hz frequency) and hot pack application (20 minutes) and interferential current (100 rpm) as electrotherapy agents. In addition to the conventional treatments, Sustained Natural Apophysial Gliding (SNAG) a type of Mulligan mobilization technique is applied. Mobilization is performed by giving 15-20 seconds rest between 3 sets of 4-5 repetations.~Patients were treated in a sitting position. SNAG technique was applied by the physiotherapist at each on spinal level. Active movement with using passive manual force in the direction of translation or rotation was applied to the cervical vertebrae. At the end range of the joint, overpressure was applied by the patient himself"
46051886|NCT02611648|Other|HLD/ETO|Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide
45367575|NCT04065737|Drug|Sintilimab|"Sintilimab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.~other name: IBI308"
45367576|NCT00516321|Drug|eltrombopag|25, 50, 75, 100 mg tablets taken once daily orally
45367577|NCT00516321|Drug|placebo|matched placebo taken once daily orally
45367578|NCT00729911|Procedure|Atrial Fibrillation ablation|Radio-frequency catheter ablation of atrial fibrillation
45367579|NCT00729911|Drug|Amiodarone|Taken orally on a daily basis.
46051887|NCT00702442|Drug|Droperidol|0.625 mg droperidol administrated i.v prior to laparoscopic cholecystectomy
46051888|NCT00702442|Drug|Saline solution|Saline solution administrated i.v 30 min prior surgery
46051889|NCT00705172|Drug|somatropin|Prader-Willi syndrome children treated with at least one dose of Norditropin®
46051890|NCT02612272|Drug|Ketorolac|intra-articular ketorolac
46051891|NCT02612272|Drug|Betamethasone|intra-articular betamethasone
45367580|NCT02735252|Other|Systemic therapy|Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.
45367581|NCT02735252|Device|StrataNGS|CLIA-approved assay that is being performed as part of standard of care genomic profiling of patients tumor biopsies. The product currently covers about 90 cancer genes and is able to pick up all the known mutations and other types of genetic alterations across them, he added
45367582|NCT04018703|Drug|Dexmedetomidine|loading dose 0.5-2.5ug/kg followed by continuous infusion 0.2-0.5ug/kg/h
45367583|NCT04018703|Drug|Midazolam|loading dose 30-50ug/kg followed by continuous infusion 10-30ug/kg/h
45691276|NCT04616248|Drug|Poly ICLC|Given IT
45691277|NCT04616248|Radiation|Radiation Therapy|Undergo radiation therapy
46051892|NCT04040218|Procedure|Dry Needling|Dry needling is utilized by multiple practitioners to address impairments in neuromusculoskeletal function, often related to pain and loss of mobility. Dry needling, according the American Physical Therapy Association (APTA), is defined as a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments
46051893|NCT00832624|Drug|sitagliptin|Sitagliptin, 100 mg, 1 Tablet, once a day, for 18 weeks
46051894|NCT00832078|Device|SpeediCath Compact Male|CH 12 hydrophilic coated intermitten compact catheter
45691278|NCT04616248|Biological|Recombinant Flt3 Ligand|Given IT
45691279|NCT01843933|Device|Capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion
45691280|NCT01798030|Other|Vitamin D|N/A, frozen specimen study
45691281|NCT03329950|Drug|CDX-1140|CDX-1140 will be administered every 4 weeks in Parts 1, 2 and 4, and every 3 weeks in Part 3.
45691282|NCT03329950|Drug|CDX-301|CDX-301 will be injected once a day for five days before Cycles 1 and 2.
46051895|NCT00832078|Device|Speedicath|CH 12 hydrophilic coated intermittent coated catheter
46051896|NCT00913120|Drug|YM150|oral
46051897|NCT00913120|Drug|Placebo|oral
45484309|NCT05074576|Other|Control group|Electroterapy agents are applied in the same conditions with Mulligan Group. Active neck, shoulder and thoracic region exercises for correction postural misalignment are performed in both groups. All exercises were done in 3 sets of 10 repetitions. Stretching exercises of upper part of Trapezius, sternocleidomastoideus and pectoral muscles are done with 10 repetitions and for 15-30 seconds.
45484310|NCT01341249|Drug|Experimental DW224aa|DW224aa tablet, single dose
45484311|NCT01341249|Drug|Experimental DW224a|DW224a capsule, single dose
45484312|NCT03261622|Device|Sacral nerve stimulation at different stimulation amplitudes|Exploring the effect of different stimulation amplitude in a randomized study
45484313|NCT01360164|Biological|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
45846067|NCT03522870|Device|Flash glucose monitoring system|Using flash glucose monitoring system continuously on Week 2-14 and Week 14-26
45846068|NCT03522870|Device|SMBG|Performing SMBG at least three times/day on Week 2-14 and Week 14-26
45484314|NCT02459158|Drug|ME1100 inhalation solution|Low dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
45691283|NCT03329950|Drug|Pembrolizumab|Pembrolizumab will be administered every 3 weeks.
45484315|NCT02459158|Drug|ME1100 inhalation solution|High dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
45484316|NCT03634956|Drug|Group B. Sugammadex sodium-IONM|Group B.the vagal nerve is detected and then 2 mg / kg of sugammadex sodium is administered to remove the muscle relaxant effect
45484317|NCT01344135|Dietary Supplement|Dietary supplementation|"Phase A, Rehabilitation (4 months): 3 nutritional supplements daily~Phase B, Maintenance (8 months): nutritional supplementation on advice (1 supplement daily)~Phase C, Follow-up (3 months): no supplementation"
45484318|NCT01344135|Dietary Supplement|Placebo supplement|"Phase A, Rehabilitation (4 months): 3 placebo nutritional supplements daily~Phase B, Maintenance (8 months): No supplementation~Phase C, Follow-up (3 months): No supplementation"
45484319|NCT01344135|Behavioral|Nutritional counselling|"Phase A, Rehabilitation (4 months): No counselling~Phase B, Maintenance (8 months): Nutritional counselling (4x)~Phase C, Follow-up (3 months): No counselling~Aim:~Optimising dietary intake to physical activity pattern and energy expenditure.~Minimize deterioration of dietary intake during acute exacerbations.~Optimize dietary lipid profile with respect to total fat intake; trans fatty acids and proportion of poly-unsaturated fatty acids to modulate cardiovascular risk and muscle fatty acid metabolism.~Increasing adherence/compliance by addressing issues like taste fatigue, gastro-intestinal symptoms, individual preferences and lifestyle."
45484320|NCT01344135|Behavioral|Feedback on physical activity level|"Phase A, Rehabilitation (4 months): No exercise counselling~Phase B, Maintenance (8 months): Exercise counselling (2x)~Phase C, Follow-up (3 months): No exercise counselling~Aim:~Integration of exercise behaviour into daily routine~Improvement of self-regulation skills (e.g. self-monitoring, goal setting, action planning)~Increasing adherence/compliance by addressing issues like coping with difficult situation, individual preferences and lifestyle"
45484321|NCT03261934|Other|No intervention|No intervention
45367584|NCT04629872|Drug|Fingolimod|Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is more than 3 hour prior to mechanical thrombectomy.
45367585|NCT04065581|Drug|Acarbose/Metformin FDC(BAY81-9783)|Single dose: 50 mg acarbose/500 mg metformin tablet, oral
45367586|NCT04065581|Drug|Glucobay|Single dose: 50 mg tablet, oral
45367587|NCT04065581|Drug|Glucophage|Single dose: 500 mg tablet, oral
45367588|NCT00929084|Other|The Survivor Stories Tablet|The Survivor Stories Tablet is a tablet computer where participants can browse an archive of 1-3 minute videotaped survivor stories told by African American Breast Cancer Survivors. Stories contain five main topics: coping, relationships, experiences with the health care system, follow-up care, and quality of life (QOL) living with breast cancer.
45484322|NCT01367574|Drug|SC MNTX|Dose 1
45484323|NCT01367574|Drug|SC MNTX|Dose 2
45484324|NCT01367574|Drug|SC MNTX|Dose 3
45484325|NCT05074108|Behavioral|Pilot study|Aiming for an interaction 6 week course that will discuss many aspects of health and wellness.
45484326|NCT04693689|Other|RNA vaccine|We elicit subjects' willingness to receive RNA COVID-19 vaccine
45484327|NCT04693689|Other|20% adoption rate|We elicit subjects' willingness to receive the new vaccine if 20% of the country's population has received it
45846069|NCT03502746|Drug|Nivolumab|Nivolumab 240mg, IV over 30 minutes.
45846070|NCT03502746|Drug|Ramucirumab|8mg/kg, IV over 60 minutes.
45846071|NCT04194138|Procedure|Index or spine revision surgery for complex adult spinal deformity|Surgical interventions will be patient specified by treating surgeon.
45367589|NCT05585645|Biological|Stimus (NNG-DEPO)|Nanogen's Darbepoetin alfa 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe
45367590|NCT04572854|Drug|Pegcetacoplan|Complement (C3) Inhibitor
45367591|NCT00732017|Device|Standard physical therapy and HVPC with positive polarity|A high voltage stimulator with positive polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
45367592|NCT00732017|Device|high voltage pulse stimulation with negative polarity|A high voltage stimulator with negative polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
45484328|NCT04693689|Other|40% adoption rate|We elicit subjects' willingness to receive the new vaccine if 40% of the country's population has received it
45484329|NCT04693689|Other|60% adoption rate|We elicit subjects' willingness to receive the new vaccine if 60% of the country's population has received it
45484330|NCT04693689|Other|80% adoption rate|We elicit subjects' willingness to receive the new vaccine if 80% of the country's population has received it
46051898|NCT00913120|Drug|Enoxaparin|injection
45484331|NCT04693689|Other|Conventional vaccine|We elicit subjects' willingness to receive conventional COVID-19 vaccine
45484332|NCT04693689|Other|0% adoption rate|We elicit subjects' willingness to receive the new vaccine if 0% of the country's population has received it
45484333|NCT03266848|Diagnostic Test|Quantitative Magnetic Resonance Imaging|Radiological diagnosis
45484334|NCT03266614|Behavioral|Recovery 4 Us|R4US is a social media program aimed at the enhancement of community participation and overall recovery of individuals with psychiatric disabilities.
45691284|NCT03329950|Drug|Chemotherapy|Gemcitabine and Nab-paclitaxel will be administered on Day 1, Day 8 and Day 15 of each 4 week Cycle.
45691285|NCT01814371|Drug|2% mupirocin ointment|Participants over 1 month of age, apply ointment to the anterior nares twice daily for 5 days.
45691286|NCT01814371|Other|Bleach Bath (dilute)|Participants over 1 month of age, pour 1/4 cup of bleach into a bath tub filled 1/4 full of water. Soak in bath for 15 minutes daily for 5 days.
45691287|NCT01814371|Behavioral|Hygiene Protocol|"Follow key hygiene tips:~Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~Use liquid(pour or pump) soaps instead of bar soaps.~Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~Do not share personal care items such as razors, brushes, or deodorant.~Wash all sheets and towels in hot water. Wash sheets every week.~Use towels and wash cloths only once before washing and do not share."
45691288|NCT05124652|Device|Auto Adjusting Prosthesis|Participants will test the auto adjusting prosthesis. The prosthesis will be able to move up to 3 panels built into the socket walls to expand or tighten the socket's fit. The auto adjustments will take place during periods of sitting, standing, or walking. Manual adjustments will also be possible either via the researcher controlling the prosthesis or via the key fob developed in the first aim.
45367593|NCT00732017|Other|standard physical therapy treatment|"Initial phase: Application of crushed ice on the ankle for 20 minutes. The subject performed isometric and active exercises of the ankle in all freedom degrees, with no weight bearing.~Intermediate phase: Application of cryotherapy continued and once mobility was completed and painless, progressive use of weight and reeducation of the walking pattern were initiated. Then, exercises with manual resistance of muscles of ankle and balance in stable surfaces were done.~Advanced phase: Balance exercises on unstable surfaces as well as strengthening ankle muscles with proprioceptive neuromuscular facilitation techniques and elastic band were performed. At the end, the patient did activities like trotting in S or Z and jumping in all directions."
45846072|NCT03455868|Procedure|Bariatric surgery|Sleeve gastrectomy
45367594|NCT00924794|Procedure|Cancer Registry of Norway (database)|Review of database to identify women with primary conization presenting with high grade lesions/ microinvasive cervical carcinomas. Recurrent cones with high grade lesions/ microinvasive cervical carcinomas or invasive cervical cancer will be identified for all women with primary cones.
45484335|NCT03126786|Drug|IVT aflibercept|IVT aflibercept [2 mg/0.05 mL]
45484336|NCT03126786|Drug|Sham SC|sham SC
45484337|NCT03126786|Drug|SC CLS-TA|CLS-TA [4 mg/100 μL] SC injection
45484338|NCT04593771|Drug|BCG-PPD|BCG-PPD was used for skin test in 40 healthy people, and BCG-PPD was marketed in other 40 healthy people (as control)
45484339|NCT05183061|Drug|Ehedrine Norepineprine|No interventions required considering that this was a retrospective study.
45484340|NCT03266458|Procedure|Primary percutaneous coronary intervention|Urgent percutaneous coronary intervention for ST- elevation myocardial infarction patients.
45691289|NCT03232138|Dietary Supplement|Sulforaphane|Sulforaphane (SF) is a naturally occurring substance (phytochemical) found in cruciferous vegetables.
45691290|NCT03232138|Drug|Placebo|Inactive ingredients
45691291|NCT02131402|Device|ocufilcon D|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (ocufilcon D) in the contra lateral eye.
45691292|NCT02131402|Device|omafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (omafilcon A) in the contra lateral eye.
45691293|NCT02131402|Device|methafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (methafilcon A) in the contra lateral eye.
45691294|NCT01814137|Drug|insulin degludec/insulin aspart|For subcutaneous (s.c., under the skin) administration twice daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
46051899|NCT00913198|Drug|IV CP-4126|1250 mg/m2/d, IV (in the vein) on day 1, 8 and 15 of each 4 week cycle. Number of Cycles: until progression or unacceptable toxicity develops.
46051900|NCT00822172|Dietary Supplement|Levocarnitine tartrate|Capsule form, 1,002 mg (3 capsules) taken by mouth two times per day (morning and evening). L-carnitine will be taken from Day 0 to Day 180.
46051901|NCT00822172|Drug|cilostazol|"Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks.~Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days."
45367595|NCT00733889|Drug|cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil)|"Neoadjuvant chemotherapy plus cetuximab:~3 cycles of chemotherapy (Docetaxel: 75 mg/m2; day1; Cisplatin :75 mg/m2, day 1; 5-FU: 750 mg/m2; 24-hour infusion; day1-5) administered every 3 weeks, plus cetuximab (250 mg/m2; day 1, 8 and 15) Cetuximab will be maintained from the beginning of chemotherapy until the end of radiotherapy.~Radio-chemotherapy plus cetuximab:~The radiotherapy treatment: A dose of 50.4 Gy will be administered in 28 fractions of 1.8 Gy / day, 5 days a week (a total of 5.6 weeks).~Cetuximab:250 mg/m2 and Cisplatin: 40 mg/m2, day 1, 8, 15, 22, 29 and 36"
45367596|NCT03903731|Device|Total knee arthroplasty with Journey II BCS Total Knee System|Journey II BCS Total Knee System
45484341|NCT01360242|Procedure|MIMI procedure (two-step strategy)|A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.
45367597|NCT01010685|Procedure|Recovery of gallbladder via gastrotomy instead of via the skin|The gallbladder is dissected as for a standard laparoscopic cholecystectomy but is then recovered via a hole in the stomach created and closed endoscopically rather than through the skin as in the standard fashion
45367598|NCT05153655|Procedure|Local ischemic post-conditioning|"Direct local ischemic post-conditioning will be applied after successful recanalization of the culprit middle cerebral artery. Local ischemic post-conditioning consists of briefly repeated 4 cycles of occlusion and reperfusion (equal duration) of the initially occluded culprit middle cerebral artery using a balloon. The schedule of advancing duration is 0  1  2  3  4  5 min."
45367599|NCT00929318|Procedure|blood sampling|
45484342|NCT01360242|Procedure|Immediate Stenting (one-step strategy)|The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).
45484343|NCT04581057|Biological|Specific blood sampling|"A 30 ml blood sample (6 EDTA tubes) will be taken at inclusion in the study, in addition to the blood sample taken as part of the routine care.~This sampling is carried out for :~Search for CHIP-associated mutations in circulating leukocytes~Plasma determination of IL-1β, IL-6, IL-10 and TNF-α"
45484344|NCT02456506|Radiation|Hyperfractionated IMRT|
45484345|NCT02456506|Radiation|Conventional Fraction IMRT|
45484346|NCT01367652|Drug|Letrozole|2.5 mg tablet
45484347|NCT01367652|Drug|Letrozole|2.5 mg Tablet
45367600|NCT00929318|Procedure|blood sampling|
45367601|NCT00733967|Drug|Varenicline|Varenicline (oral capsule): 0.5 mg once daily for 3 days; 0.5 mg twice daily for 2 days; 1 mg twice daily for one day; 1 mg once daily for one day.
45367602|NCT00733967|Drug|Placebo|Matching oral placebo capsules as control.
45367603|NCT01010841|Dietary Supplement|UltraMealPlus 360 (Medical food)|Specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED)
45367604|NCT01010841|Other|Low-glycemic-load diet|Modified Mediterranean-style low-glycemic-load diet
45367605|NCT00732095|Behavioral|Promoting Self-Change with Ads|Use of Ads immediate or delayed or no ad
45484348|NCT02456584|Drug|DMPA 150|injectable contraceptive
45691295|NCT01814137|Drug|insulin degludec|For subcutaneous (s.c., under the skin) administration once daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
45691296|NCT01814137|Drug|insulin aspart|For subcutaneous (s.c., under the skin) administration once daily. Dose of IDegAsp and IAsp are individually adjusted.
45691297|NCT01814137|Drug|insulin aspart|For subcutaneous (s.c., under the skin) administration three times a day. Dose of IDeg and IAsp are individually adjusted.
45846073|NCT03445650|Drug|ADX-102 1% Topical Dermal Cream (reproxalap)|ADX-102 1% Topical Dermal Cream administered approximately every 24 hours for 6 months.
45846074|NCT03445650|Drug|Vehicle of ADX-102 Topical Dermal Cream|Vehicle of ADX-102 Topical Dermal Cream administered approximately every 24 hours for 6 months.
45484349|NCT02456584|Drug|DMPA 300|injectable contraceptive
45484350|NCT02456584|Drug|DMPA 104|injectable contraceptive
45484351|NCT01360320|Dietary Supplement|Green tea extract of Camellia Sinensis|"Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG~Run-in period with 150mg EGCG two times daily (p.o) for 4 weeks~150mg EGCG two times daily (p.o.) over the course of three years.~Colonoscopy after 3 years"
45484352|NCT01360320|Dietary Supplement|Green tea extract of Camellia Sinensis followed by placebo|"Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG~Run-in period with 150mg EGCG two times daily (p.o.) for 4 weeks~Placebo two times daily (p.o.) over the course of three years~Colonoscopy after 3 years"
45484353|NCT03146403|Biological|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP4 and glycoprotein D
45484354|NCT03146403|Biological|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
45484355|NCT03146403|Other|0.9% normal saline|Placebo
45367606|NCT00732173|Behavioral|behavioral dietary intervention|Undergo SUCCEED lifestyle intervention
45367607|NCT00732173|Behavioral|exercise intervention|Undergo SUCCEED lifestyle intervention
45367608|NCT00732173|Other|counseling intervention|Undergo SUCCEED lifestyle intervention
45367609|NCT00732173|Other|educational intervention|Receive information
45367610|NCT00732173|Other|survey administration|Undergo SUCCEED lifestyle intervention
45367611|NCT04650243|Drug|ursodeoxycholic acid|The two experimental groups will receive reduced dosage of UDCA at 250mg bid and 250mg qd respectively, while the control group will receive standard dosage of UDCA.The treatment duration will be five years.
45367612|NCT00738569|Drug|Raltegravir|Raltegravir 400 mg PO BID for 12 months
45484356|NCT03261778|Device|Acromion 2.0 Brace|Acromion 2.0 Brace will be worn for 6 weeks instead of the conventional Mitella sling
45367613|NCT04646811|Procedure|Tricuspid valve|Clip for the tricuspid valve implantation on top of best medical therapy
45484357|NCT02458144|Procedure|Total hip arthroplasty|"The minimally invasive anterior approach The patient is in supine position. The femoral neck is exposed in the interval between tensor fasciae latae, glutei medius and minimus muscles laterally, and sartorius and rectus femoris muscles medially. After osteotomy of the neck and extraction of the head the acetabulum is reamed to prepare for cup prosthesis. Following peritrochanteric capsulotomy the externally rotated, adducted and elevated femur is broached.~The MIS anterolateral approach The MIS anterolateral technique is a modified Watson-Jones Approach. The patient is in supine position. This approach uses the intermuscular plane between the gluteus medius and the tensor fascia latae. After the anterior capsule is excised, a disc of the femoral neck is removed."
45691298|NCT04084288|Other|Acupuncture|Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed
45691299|NCT04084288|Device|Peripheral Nerve Stimulator|Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus).
45691300|NCT01813435|Drug|Ticagrelor|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.
45367614|NCT04646811|Other|Best medical treatment|Best medical therapy alone
45691301|NCT01813435|Drug|Acetylsalicylic Acid|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy
45691302|NCT01813435|Drug|Clopidogrel|"Active Comparator: Reference treatment strategy Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy"
45691303|NCT05037526|Device|Dexcom G System|Continuous glucose monitoring system
45846075|NCT03436368|Procedure|Continuous spinal anesthesia|Continuous spinal anesthesia will be performed for patients of the CSA group at the L3-L4 intervertebral space using Spinocath (B. Braun, Melsungen, Germany). After the cerebrospinal fluid is aspirated, 7.5 mg hyperbaric Bupivacaine 0.5% (1.5 ml) together with 25 micrograms Fentanyl (0.5 ml) will be injected intra-thecally. Supplemental injections will be given in aliquots of 5 mg hyperbaric Bupivacaine 0.5% (1 ml) if the sensory block is lower or reseeds, during surgery, below T6 dermatome.
45846076|NCT03436368|Procedure|General anesthesia|Anesthesia will be induced with intra-venous administration of Fentanyl (2 micrograms/kg), Ptopofol (1-2 mg/kg) and Atracurium (0.5 mg/kg). Maintenance will be achieved with 0.8-1.5% Isoflurane in an O2 / air mixture, an Atracurium infusion at 0.5 mg/kg/hr and a Fentanyl infusion at 1 micrograms/kg/hr.
45367615|NCT00732329|Behavioral|Occupational Therapy|"optimized home Based Occupational Therapy including:~diagnostic assessment~patient-centered definition of targets involving the care giver~occupational therapy"
45367616|NCT04644627|Drug|Gentamicin Sulfate|Topical gentamicin ointment on wounds once daily for 6 weeks
45367617|NCT02568761|Procedure|Injection Snoreplasty|Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate.
45367618|NCT02568761|Other|Oropharyngeal Exercises|Myofunctional isometric and isotonic exercises of the soft palate, pharyngeal side walls, face and tongue.
45691304|NCT05037526|Device|Self monitoring blood glucose|Standard Care
46051902|NCT00702598|Behavioral|Telephone-based Cognitive Behaviour Therapy (CBT)|Telephone-based CBT: Eight sessions of telephone-based CBT (Tel-CBT) will be delivered over 8-10 weeks, based on a published manual (Simon et al, 2004). Tel-CBT has been modified to be briefer than traditional CBT (30-40 minutes instead of 60 minutes per session) and will be offered at convenient times (including evening sessions). The initial Tel-CBT session will occur within 2 weeks of randomization, with subsequent sessions occurring every 1-2 weeks depending on scheduling and patient preference. The initial session focuses on motivation enhancement exercises, subsequent sessions emphasize identifying, challenging and distancing from negative thoughts, and the final session focuses on a personal care plan and self-management skills.
46051903|NCT00702598|Behavioral|Telephone reminder calls|Telephone reminder calls: Weekly telephone calls for 8 weeks to inquire on progress and remind patients to take their medications properly
45367619|NCT03492801|Procedure|Biospecimen Collection|Undergo collection of blood samples
45367620|NCT03492801|Other|Laboratory Biomarker Analysis|Correlative studies
45367621|NCT00460408|Drug|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.
45367622|NCT02569151|Device|HBP & CBP measurement using systo 130 mmHg|
45367623|NCT00732407|Drug|aliskiren|Aliskiren will be given in a preliminary dosage of 150 mg per day, after a follow up of two weeks dosage will be increased to 300 mg per day.
45484358|NCT01316991|Dietary Supplement|Chewing Gum|chewing gum will be provided
45484359|NCT01316991|Dietary Supplement|No Gum|no chewing gum will be provided
45484360|NCT03634878|Other|perineal ultrasound|Ultrasound measurement of the size and position of the prostheses.
46051904|NCT00832000|Drug|Mexiletine|200 mg three times a day; in pill form
46051905|NCT00832000|Drug|Placebo|Placebo three times a day; in pill form
45691305|NCT04008160|Device|ProTex|Non invasive measurement of pressure, temperature, humidity, perfusion, and oxygenation
45691306|NCT01798498|Device|Princess® VOLUME|
45691307|NCT02554708|Device|implantation of the pCONus Bifurcation Aneurysm Implant|The device will be introduced through a regular microcatheter. After deployment of the device with the crown positioned in the aneurysm neck the aneurysm will be entered with a microcatheter to perform endovascular coil occlusion. After completion of the coiling procedure the pCONus device will be electrolytically detached from the insertion wire and only the crown and the shaft will remain as a permanent implant.
45691308|NCT01813357|Drug|Rosuvastatin|encapsulated tablet 20mg daily
45846077|NCT03393780|Drug|Follitropin Delta|The Intervention (solution for injection) is delivered with an injection pen. The REKOVELLE® dose will be based on recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the following diagnostic test from ROCHE: ELECSYS AMH Plus immunoassay.
45846078|NCT03367572|Drug|Dexamethasone|Given PO
46051906|NCT00911508|Device|Left atrial ablation|"St. Jude: Livewire TC™ , Therapy™ Dual / Thermocouple, Safire,Therapy Cool Path~Biosense Webster: NAVI-STAR, NAVI-STAR/NAVI-STAR DS, Celsius Braided/Long Tip, NAVI-STAR™ and Celsius™ ThermoCool, NAVI-STAR® RMT, Celsius® RMT, ThermoCool® SF~Medtronic CryoCath LP: Freezor®/Freezor MAX®, Artic Front®, Cardiac Ablation System~Bard: Stinger~Boston Scientific: Blazer II RF/XP, Blazer RPM, Chilli II Cooled, SteeroCath"
45691309|NCT01813357|Other|Placebo|Placebo arm included to maintain blinding
45691310|NCT01812655|Device|Virtual Reality|
45691311|NCT01812655|Other|Passive Distraction|
45846079|NCT03367572|Other|Laboratory Biomarker Analysis|Correlative studies
45367624|NCT00732407|Drug|losartan|Losartan will be given in a preliminary dosage of 50 mg per day and after a two weeks follow up dosage will be increased to 100 mg per day
45367625|NCT00507819|Drug|Sildenafil|One 20 mg capsule of sildenafil will be taken by mouth three times-a-day.
45367626|NCT00507819|Drug|Placebo|One placebo capsule will be taken by mouth three times-a-day.
45367627|NCT00738647|Procedure|Tooth restorations with composite|The cavity is excavated and filled according to the guidelines for composite restorations
45367628|NCT01566058|Device|BB Box available|The BB Box video system is provided to the mother during the hospitalisation of her premature baby.
45846080|NCT03367572|Drug|Netupitant/Palonosetron Hydrochloride|Given PO
45846081|NCT03367572|Drug|Olanzapine|Given PO
46051907|NCT00911508|Drug|Rate or Rhythm Control Therapy|"Rate control: Metoprolol 50-100mg, Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg, Digoxin 0.125-0.25mg~Rhythm control: Propafenone 450-625mg, Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg, Amiodarone 200-400mg, Quinidine 600-900mg, Dronedarone 800mg"
45367629|NCT01566058|Other|No BB Box|The BB Box video system is not provided to the mother during the hospitalisation of her premature baby.
45367630|NCT02569307|Drug|Minocycline|Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
45367631|NCT02569307|Drug|Omega-3 fatty acids|Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2g once daily dose
45367632|NCT02569307|Drug|Placebo|Placebo added to TAU
45367633|NCT02569307|Drug|Minocycline Plus Omega-3 fatty acids|Minocycline will be administered in 200mg once daily dose and Omega-3 fatty acid 1.2g taken as once daily dose
45484361|NCT03266380|Diagnostic Test|observational|All patients do an emergency brain computed tomography scan. Intracranial hypertension is treated with mannitol with or without a craniotomy. A third generation cephalosporin (ceftriaxone) and metronidazole are administered as antibiotic prophylaxis for accompanying wound injuries (skin and soft tissue). VAP preventive strategies that are performed in the ICU include daily interruption of sedation and a readiness to extubate assessment, early facilitation of mobility, elevating the head of the bed to 30- 45 degree, change of the ventilator circuit if visibly soiled or malfunctioning, stress ulcer prophylaxis, residual gastric volume monitoring, early parenteral nutrition, and deep venous thrombosis prophylaxis. An infusion of midazolam and propofol is to be used for sedation.
45846082|NCT03367572|Other|Placebo|Given PO
45846083|NCT03367572|Drug|Prochlorperazine|Given PO
45846084|NCT03367572|Other|Quality-of-Life Assessment|Ancillary studies
45846085|NCT03321630|Drug|Lenvatinib|Lenvatinib 20 mg orally each day on days 1-7
45846086|NCT03321630|Drug|Pembrolizumab|Pembrolizumab 200mg intravenously, to be initiated on day 8, and continued every 3 weeks, in combination with daily lenvatinib 20 mg
46051908|NCT04202796|Procedure|Catheter ablation|Catheter ablation of arrhythmia
46051909|NCT04202952|Drug|HEC110114 Tablet|administered orally once daily
46051910|NCT04202952|Drug|Sofosbuvir Tablet|administered orally once daily
45484362|NCT01317381|Procedure|Observational|Blood draw
45484363|NCT01360476|Dietary Supplement|cholecalciferol (Vitamin D)|50,000 UI, chewable wafer every 2 weeks for 52 weeks (27 total doses)
45484364|NCT01360476|Dietary Supplement|Placebo|chewable wafer every 2 weeks for 52 weeks (27 total doses)
45484365|NCT01317069|Drug|Fluorouracil implant|Before the abdomen was closed, fluorouracil implant 1000mg was sprayed evenly on the surface of tumor resection area, and some of the drugs were put into mesenteric root based on the location
45484366|NCT01367808|Drug|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
45484367|NCT01367808|Drug|vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
45691312|NCT02346526|Procedure|Blood Tests|Blood will be drawn for standard and nonstandard testing on day one, day 4, and weeks 5, 9, 13, 17, 21, 25, 37, and 93.
45367634|NCT03490240|Behavioral|BIPAMS|"The primary content of the website is delivered through interactive video courses. The interactive video courses are released seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention.~Another key part of the website is the Tracker feature. This feature allows for tracking of daily step counts (via Yamax SW-200 pedometer) as well as setting goals and monitoring progress over the program.~The one-on-one video chats are conducted face to face through skype and are semi-scripted. The chats consist of an ongoing review of goal-setting and progress toward goal attainment through Tracker as well as discussion of strategies and facilitators of behavioral change based on SCT and current website content. The chats occur seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention."
45484368|NCT01367808|Drug|posakonazole|The subjects will be given posaconazole 400 mg twice a day for 5 days prior to the study.
45484369|NCT04953286|Other|Measure of visual acuity|ETDRS and Parinaud scale
45484370|NCT04953286|Other|Interferometry|Non-contact exam measuring N.I.B.U.T (Non-invasive break-up time), quantitative and qualitative evaluation of the meibomian glands and quantitative evaluation of the tear meniscus
45691313|NCT02346526|Procedure|CT scan|Standard CT scans will be carried out prior to treatment, week 9, and week 25.
46051911|NCT04276740|Dietary Supplement|MitoQ|"MitoQ in inflammation: In the experimental setting, MitoQ has been extensively studied with clear mode of action on inflammatory mechanisms relevant to IBD:~MitoQ can limit the damage to mitochondria caused by mitochondrial ROS and thereby reducing the leak and oxidisation of mtDNA that are critical to its pro-inflammatory actions within the cell.~MitoQ reduces the inflammatory potential of mitochondrial DNA which have escaped or released from dying inflammatory cells.~MitoQ can influence how the immune cells generate their energy, diverting it away from a more inflammatory type of metabolism (glycolysis)~MitoQ can induce autophagy, a cellular recycling mechanism that removes damaged mitochondria. Defective autophagy is heavily implicated in the pathogenesis of IBD.~Hence collectively, MitoQ acts upstream of several pro-inflammatory mechanisms with the net effect to promote resolution of inflammation and mucosal healing."
46051912|NCT04276740|Other|Placebo|Placebo
46051913|NCT04394286|Genetic|SHP648|Participants will receive a single IV infusion of SHP648 in Cohort 1, 2, 3 on Day 0.
46051914|NCT04378296|Other|Teledermatology|The experimental group will be made up of dermatological patients monitored asynchronously.
45484371|NCT04953286|Other|Samples of basal tears|Collection of basal tears without instillation of anesthetic with a Schirmer strip for 5 minutes and by microcapillary
45484372|NCT04953286|Other|Central corneal sensitivity|Central corneal sensitivity using a Cochet-Bonnet esthesiometer (Luneau©)
45484373|NCT04953286|Other|Slit lamp examination and undilated fundus|Slit lamp examination and undilated fundus
45484374|NCT04953286|Other|Conjunctival impression|Conjunctival impression with anesthetic instillation
45484375|NCT04953286|Other|Evaluation of the corneal innervation|Contact corneal confocal microscopy
45484376|NCT01317225|Drug|17 α hydroxyprogesterone caproate|250mg intramuscular (gluteal muscles) biweekly from enrollment until delivery.
45484377|NCT01317225|Drug|Placebo|250 mg intramuscular (gluteal muscles)biweekly from enrollment until delivery.
45691314|NCT02346526|Procedure|FACBC PET/MRI in a subset of participants|Approximately half of the study patients (n=10) will undergo experimental FACBC PET/MRI testing at 2 time points each: (1) prior to therapy, and (2) week 9.
45691315|NCT02346526|Drug|Radium-223 dichloride|Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 at a dose of 50 kBq/kg body weight by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments.
45691316|NCT02346526|Procedure|bone scan|Standard bone scans will be carried out prior to treatment, week 9, and week 25.
45691317|NCT01812109|Device|Hutchison Technologies Inspectra StO2 SpotCheck Near-Infrared Spectroscopy|Device: Near-Infrared Spectroscopy Transscrotal NIRS is a series of 6 transcutaneous scrotal measurements, 3 on both left/right. Each measurement is completely non-invasive, painless and takes ~15 seconds each. Thus, no sedation or supplemental analgesia is needed for NIRS. The NIRS probe will be placed on the anterior, lateral and posterior scrotum on the left/right sides, immediately overlying and parallel to the long axis of the testis but on the skin to obtain the 6 total measurements. The unaffected testis will serve as the patient's own control. Study coordinators will be performing the ER transscrotal NIRS testing. For uniformity, all will be trained for testicular probe placement methods. NIRS will not delay the gray scale/color Doppler testicular US or surgery.
45484378|NCT01363206|Biological|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)|GM-CSF will be administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on D1 of each 21-day cycle for 8 cycles until month 6. Maintenance therapy will begin at month 6 and will consist 14 days of GM-CSF repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
45484379|NCT01363206|Biological|Ipilimumab|Patients will be treated with 4 courses of ipilimumab administered every 3 weeks intravenously in a dose of 10 mg/kg, with appropriate stopping/de-escalation rules. Maintenance therapy will begin at month 6 and will consist of ipilimumab in the same dose administered at the end of cycle 4 repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
45484380|NCT04962022|Drug|PF-07321332/ritonavir|Administered orally every 12 hours for days for a total of 5 doses from Day 1 through Day 3
45484381|NCT04962022|Drug|Itraconazole|Administered orally once daily for 8 days from Days 1 through 8
45484382|NCT04962022|Drug|PF-07321332/ritonavir|Administered orally BID for 3 day for a total on 5 doses starting on Day 4 through Day 6
46051915|NCT04083456|Behavioral|Walking Biobehavioral Intervention|Each walking biobehavioral training session includes self-monitoring, tailored feedback, identification of barriers and facilitators, problem solving, action planning and encouragement. Self-monitoring of walking behavior will occur with participant use of the FitBit sensor and software, reviewed with the interventionist at each session. Tailored feedback from the FitBit sensor, as well as feedback from the interventionist, will detail progress over time and be compared to baseline data. Barriers and facilitators of reaching activity goals will be discussed with emphasis on problem solving to take advantage of facilitators and minimize/remove participant-specific barriers. Action planning will be based on weekly step goals set collaboratively by the interventionist and participant, based the FitBit data. Finally, encouragement will be provided by the interventionist by putting progress or lack of progress in perspective of the efforts made by the participant.
45367635|NCT03490240|Behavioral|WELLMS|The control condition focuses on self-managing MS through means other than physical activity. The materials are transformations of brochures provided by the NMSS, including Gait or Walking Problems: The Basic Facts; MS and Your Emotions; Pain: The Basic Facts; Solving Cognitive Problems; Taming Stress in MS; Food for Thought: MS and Nutrition; and Vitamins, Minerals, and Herbs: An Introduction. The delivery of the Internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition, and will have a comparable time commitment. The control condition will account for attention and social contact as well as other possible biases such as initial reactivity and time spent on the website and video chats. The participants in the control condition will not be offered the behavioral intervention for increasing physical activity after completion of the study procedures.
45484383|NCT01344213|Drug|Pregabalin|Oral single-dose of pregabalin (150 mg) and placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
45484384|NCT01344213|Drug|Celecoxib|Oral single-dose of celecoxib (400 mg) and placebo(C)1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
45484385|NCT01344213|Drug|Pregabalin with celecoxib|Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
45691318|NCT02016430|Behavioral|MeLT Dietary intervention|Mediterranean diet containing food with low TMAO content.
45691319|NCT02016430|Behavioral|TLC Dietary intervention|Standard American Heart Association (AHA) recommendations for dietary counseling
45691320|NCT02016430|Behavioral|MeLT dietary intervention with TMAO|Mediterranean diet containing food with low TMAO content with TMAO levels provided to the subject for guidance.
45691321|NCT03944902|Drug|Cohort 1: Dose Escalation|The first 3 participants will be enrolled on a fixed dose of Niraparib and CB-839, 600mg. Participants will be evaluated for DLT's, if there are none, they will be enrolled in the next cohort.
45691322|NCT03944902|Drug|Cohort 2: Dose Escalation|If no dose limiting toxicities, 3 additional participants will be enrolled in this cohort. Participants will receive a fixed dose of Niraparib and CB-839, 800mg.
45691323|NCT01811953|Drug|Empagliflozin|medium dose oral administration
45484386|NCT01344213|Drug|Placebo|Oral single dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
45691324|NCT01811953|Drug|Metformin|oral administration
45691325|NCT01811953|Drug|Empagliflozin|low dose of Empagliflozin oral administration
45691326|NCT01811953|Drug|Empagliflozin/Metformin|low dose of Empagliflozin
45691327|NCT01811953|Drug|Metformin|oral administration
45367636|NCT01013103|Drug|Atorvastatin, high vs low dose|In this arm patients with ischemic heart disease will be recruited. In a double-blind crossover design heart failure patients (n=30) naïve to statins treatment will be randomized to receive oral atorvastatin 10mg/day 1x1(n=15) or oral atorvastatin 40mg/day 1x1 (n=15) for 4 weeks. At the end of 4 weeks a 2-week wash out period will follow and then all patients will switch atorvastatin dose and continue treatment for 4 weeks (e.g all patients that were under atorvastatin 10mg/day will be switched to atorvastatin 40mg/day and vice versa).
45367637|NCT01013103|Drug|Atorvastatin vs Placebo|In this arm, patients undergoing cardiac surgery (CABG, valve replacement or aortic surgery) that are not under statins treatment will be recruited. Patients will be randomized in a double-blind fashion to atorvastatin 40mg/day or placebo for 3 days before surgery date.
45367638|NCT00732485|Drug|fenofibrate|Fenofibrate, PO, 5 mg/kg/day from admission to 6 months post burn
45484387|NCT04416048|Drug|Rivaroxaban|Treatment with Rivaroxaban 20 mg (15 mg for subjects with an eGFR ≥30 mL/min/1.73m2 and <50 mL/min/1.73m2) once daily (OD) for at least 7 days. In case of hospitalization for more than 7 days, the therapeutic treatment with rivaroxaban will be continued for the duration of the hospital stay until discharge. After at least 7 days of therapeutic treatment with rivaroxaban or after hospital discharge, the study dose of rivaroxaban will be adjusted as follows. Patients randomized to the rivaroxaban study arm will reduce daily dosage to 10 mg OD, provided that they were not diagnosed with a condition requiring continued therapeutic anticoagulation. Thromboprophylaxis therapy will be given for 28 days up to day 35 post randomization or even longer. If the patient cannot be discharged from the hospital prior to day 35 post randomization, the thromboprophylaxis phase will also start upon hospital discharge, but is then shorter than 28 days, because the study ends at day 60 post randomization.
45367639|NCT00732485|Drug|placebo|Placebo, sugar pill, from admission to 6 months post burn
45367640|NCT01010919|Dietary Supplement|Chicory root extract|
45367641|NCT01566136|Behavioral|Rehabilitation Model of Care|The PCRM-CI model includes the following 5 components: rehabilitation management; dementia management; delirium prevention and management; staff education and support; and family/significant other support and education.
45367642|NCT02569073|Drug|Dronabinol|Dronabinol 5 mg, every other night, orally
45367643|NCT02569073|Drug|Placebo|Placebo--no drug
45367644|NCT03490084|Other|Association of day hospitalization with hospital-at-home|Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
45367645|NCT03490084|Other|Day hospitalization exclusively|Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
45367646|NCT00732563|Drug|chemotherapy|Given IV and Orally
45367647|NCT00732563|Procedure|lymphadenectomy|Removal of lymph nodes
45484388|NCT04416048|Other|Standard Of Care (SOC)|Standard of care treatment
45484389|NCT04766385|Drug|KHK7791|oral administration
45484390|NCT04226664|Procedure|Bariatric surgery|Although there may be slight variation by centre, Gastric Bypass generally involves creation of a 30-50 cc stomach pouch, which is anastamosed with a Roux limb of jejunum 75-100 cm in length and a biliary limb of 20-30 cm in length. The operation creates a small gastric pouch, with nutrients bypassing the duodenum and proximal jejunum. Sleeve Gastrectomy involves decreasing the size of the stomach to approximately 15% of its original size by resecting a large portion of the stomach along the greater curvature.
45367648|NCT00732563|Procedure|neoadjuvant therapy|Tumor reduction
45367649|NCT00732563|Procedure|quality-of-life assessment|Correlative Study
45367650|NCT00732563|Procedure|therapeutic conventional surgery|Treatment for cancer
46051916|NCT04083456|Other|Attention Control|Attention control sessions will include a brief review of the conventional home-exercises, a summary of all healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use). Outpatient therapists will provide home-based exercises to ensure that the participant receives adequate training and demonstrates safe performance prior to home use. The CTL interventionist will assess and discuss the safe performance of each home-based exercise with CTL group participants. Exercises in the CTL group will only be progressed by the outpatient physical therapist and not during the telehealth sessions.
46051917|NCT04054674|Procedure|Abutments with flat occlusal scheme preparation restored by lithium disilicate crowns|Clinical trials lacks information about flat occlusal preparation design in case of endodontically treated teeth. Therefore, this is tested during preparation when compared to planer occlusal preparation while the final restoration in both arms is lithium disilicate (e.max) crowns.
46051918|NCT00774397|Drug|BI 201335 NA 240 mg QD / LI|240mg BI 201335 NA (Faldaprevir) once daily with a 3 days lead-in phase of PegIFN/RB, 24 weeks
46051919|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
45367651|NCT00732563|Procedure|thoracic surgical procedure|removal of tissue
45367652|NCT00732563|Radiation|fludeoxyglucose F 18|given IV
46051920|NCT00774397|Drug|BI 201335 NA 120mg QD / LI|120mg BI 201335 NA (Faldaprevir) once daily, for 24 weeks
45367653|NCT00732563|Radiation|radiation therapy|undergoing radiotherapy
45367654|NCT03449667|Device|Cryoneurolysis|Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
45367655|NCT03449667|Device|Sham Comparator|Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
45367656|NCT00734123|Drug|Simvastatin or Atorvastatin|Simvastatin 10-40 mg or Atorvastatin 20-40 mg will be prescribed according to LDL cholesterol reduction target.
45367657|NCT00734123|Drug|Enalapril|Enalapril 10 mg/day will be prescribed as the initial treatment. Doses and adding drugs will be titrated accordingly
45367658|NCT00734123|Drug|Aspirin or clopidogrel|Aspirin 100 mg or clopidogrel 75 mg/ per day
45367659|NCT00734123|Drug|Rimonabant|"In both arms, we will follow the standard clinical care in terms of treatments, as far as obesity and diabetes mellitus is concerned.~Drugs will be prescribed as the standard clinical care"
45367660|NCT00734201|Drug|V24343|Oral, 1mg, 2 mg, 5 mg or 25 mg, or placebo, once daily for 28 days
45367661|NCT00734279|Drug|Leuprolide Acetate - Early Puberty Leuprolide Visit|Dose of 10 mcg/kg Sub cutaneous once at 0800 on day 2 of the Early Puberty Luprolide Visit
45367662|NCT00734279|Drug|Ganirelix - Early Puberty Ganirelix Visit|Dose of 2.5 mcg/kg Sub-cutaneous once at 17:30 on day 1 of the Early Puberty Ganirelix Visit and once at 08:00 on day 2 of the Early Puberty Ganirelix Visit
45367663|NCT00734279|Drug|Ganirelix - Delayed Puberty Ganirelix Visit|Ganirelix is administered at a dose of 2.5 mcg/kg sub cutaneous at 17:30 on day 1 and once at 08:00 on day 2 of the Ganirelix Delayed Puberty Visit
45484391|NCT01317459|Behavioral|Guided self-determination|Group counselling
45484392|NCT04488406|Other|No Intervention|Not applicable to these subjects. There is no study-related intervention
45691328|NCT01811953|Drug|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
45484393|NCT01363284|Drug|Duloxetine|First week of placebo. then, initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks
45484394|NCT04334889|Other|Visual cues|Participants will be asked to move following cues displayed on a screen in front of them.
45691329|NCT01811953|Drug|Empagliflozin|medium dose oral administration
45691330|NCT01811953|Drug|Metformin|oral administration
46051921|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
46051922|NCT00774397|Drug|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
46051923|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
46051924|NCT00774397|Drug|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
46051925|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
46051926|NCT00774397|Drug|BI 201335 NA 240 mg BID|240mg BI 201335 NA (Faldaprevir) twice, 24 weeks
46051927|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
46051928|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
46051929|NCT00774397|Drug|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
46051930|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
46051931|NCT00774397|Drug|Placebo|Placebo
46051932|NCT03576144|Drug|BI 1265162|Multiple rising inhaled doses
46051933|NCT03576144|Drug|Placebo|Multiple rising inhaled doses
46051934|NCT04454736|Behavioral|"Amateur Group Singing"|45-minute singing session led by a professional choirmaster without a therapeutic background once a week
45367664|NCT00734279|Drug|Leuprolide Acetate- Delayed Puberty Leuprolide Visit|Leuprolide acetate is given at a dose of10 mcg/kg at 0800 on day 2 of the Delayed Puberty Leuprolide Visit
45691331|NCT01811953|Drug|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
45691332|NCT03926728|Biological|CTH522-CAF01 IM|On-site reconstitution of IMPs is performed by mixing 85 microgram CTH522 with CAF01. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 ml polypropylene Luer-Lok™ syringe via 23-25-gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
45691333|NCT03926728|Biological|CTH522-CAF09b IM|On-site reconstitution of IMPs is performed by mixing 85 microgram CTH522 with CAF09b. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 ml polypropylene Luer-Lok™ syringe via 23-25-gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
46051935|NCT04454736|Behavioral|"Professional Group Singing"|120-minute singing session led by a professional choirmaster without a therapeutic background three times a week. Assessments take place twice a week.
45367665|NCT00442936|Drug|Telcagepant potassium 150 mg|Telcagepant 150 mg liquid-filled soft gel capsules
45367666|NCT00442936|Drug|Telcagepant potassium 300 mg|Telcagepant 300 mg liquid-filled soft gel capsules
45367667|NCT00442936|Drug|Zolmitriptan 5 mg|Zolmitriptan 5 mg tablets
45367668|NCT00442936|Drug|Placebo to telcagepant 150 mg|Placebo to match telcagepant 150 mg liquid-filled soft gel capsules
45367669|NCT00442936|Drug|Placebo to tecagepant 300 mg|Placebo to match tecagepant 300 mg liquid-filled soft gel capsules
45367670|NCT00442936|Drug|Placebo to zolmitriptan 5 mg|Placebo to match zolmitriptan 5 mg tablets
45367671|NCT00442936|Drug|Rescue medication|If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.
45367672|NCT03410043|Drug|Osimertinib|Given PO
45367673|NCT03410043|Radiation|Radiation Therapy|Undergo radiation therapy
45367674|NCT03410043|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45367675|NCT00734357|Procedure|Blood work|Prior to having the clinically scheduled CT examination the subject will have blood work drawn. This blood work will give the investigators a baseline value of the basic kidney function of the subject. They will then have blood work done again at 2 days and again at 3 days following the CT examination. Some patients, based on their blood work obtained at 2 and 3 days after the CT examination, will be asked to have blood work performed at 7 days after their CT examination.
45691334|NCT03926728|Biological|CTH522 ID|24 microgram CTH522 given ID is in the non-dominant deltoid muscle. ID with a 1 ml syringe via a 26-28 gauge needle using a NanoPass device or similar. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
46051936|NCT04453020|Device|DBS of the LHA|Deep Brain Stimulation of the Lateral Hypothalamic Area
46051937|NCT00632034|Other|CD34+ haemopoietic stem cells|Expanded subset of CD34+ haemopoietic stem cell. Harvested from pelvic marrow aspiration at Day 0 of study. Undergoes refinement and minimum of 1000 fold expansion over 7 days in a dose escalation regime of a maximum dose of 1,000,000,000 cells in 5 millilitres. Injected at Day 7 via contralateral femoral artery under angiographic guidance. First regime up to 10,000,000 cells, second 100,000,000 cells, final regime maximum of 1,000,000,000 cells.
46051938|NCT05491369|Other|Epilepsy application|Nanacara is an epilepsy application which helps people with epilepsy to self-manage their conditions.
46051939|NCT04166292|Device|Stylage® XL Lidocaïne|"On V1 (D0), a total volume of 8 mL maximum can be used per subject on the whole face.~On V2 (M1), a possible touch-up can be made according to the injector and subject's opinion which cannot exceed 4 ml."
46051940|NCT04099771|Drug|Ketamine|Ketamine infusion
45484395|NCT04327557|Behavioral|MBCP Childbirth Education Course|The MBCP program is a fully manualized childbirth and parenting preparation course. Developed in 1998 in a clinical context, MBCP is an enhanced version of the Mindfulness Based Stress Reduction (MBSR) program tailored for addressing the concerns of pregnancy and early parenting. Through MBCP, pregnant women and their partners learn mindfulness skills for coping with the anxiety and stress of pregnancy and parenting, and the pain and fear of childbirth. They are given explicit instruction in skills for cultivating positive emotion and developing mindful, sensitive parenting. MBCP groups meet weekly for 9 weeks, with a retreat day between weeks 6 and 7.
45484396|NCT04327557|Behavioral|Non-MBCP Childbirth Education Course|TAU control participants will undergo standard (real-world) hospital- or community-based childbirth education that does not have a mindfulness focus. They will be able to choose whichever class they want from the list. If they prefer a class that is not on the list, then study staff will obtain the syllabus for that class to check whether there is a mindfulness component.
45484397|NCT01363362|Procedure|Selective Laser Trabeculoplasty|360° selective laser trabeculoplasty, 100 non-overlapping spots, energy 0,5-1,2 mJ
45484398|NCT03265834|Other|< 10 days of antibiotics|Antibiotic duration
45484399|NCT03265834|Other|28 days of antibiotics|Antibiotic duration
45484400|NCT01344291|Drug|Curcumin|Curcumin is prescribed to new cases of hyperprolactinoma
45484401|NCT03734536|Device|REGENETEN™ Bioinductive Implant|The REGENETEN™ Bioinductive Implant is a bioabsorbable device that provides a layer of collagen over injured tendons.
45484402|NCT03734536|Device|Arthroscopic repair of the high-grade (>50%) partialthickness|Surgical treatment of partial-thickness rotator cuff tears using standard techniques.
45484403|NCT03733353|Drug|EDP1815|EDP1815 is an orally administered monoclonal microbial
45484404|NCT03733353|Drug|Placebo oral capsule|Placebo
45484405|NCT03733353|Drug|Placebo oral tablet|Placebo
45484406|NCT01367964|Drug|adrenocorticotropin hormone|ACTH 16 units intramuscular injection once daily for 2 weeks
45691335|NCT03926728|Biological|CTH522 TO|24 microgram CTH522 (12 microgram in each eye) TO administrations will be performed using a Gilson positive displacement pipette. The identity of vaccine will be known to the clinical site staff dispensing/administrating the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
45691336|NCT03926728|Biological|Placebo (Saline)|Placebo only given as IM, ID and TO
45367676|NCT04065503|Biological|Probiotic Strains|A commercial product containing L. helveticus R0052, L. casei HA-108, B. breve HA-129, and B. longum R0175 and S. thermophilus HA-110 be given to healthy adults across a 10-week open label pilot study.
45367677|NCT00732719|Device|Prototype device (unnamed) worn-no pressure given (placebo) from inflatable cuffs|
45367678|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
45484407|NCT02458222|Other|language game therapy|participants will take part in game therapy
45484408|NCT02458222|Other|standard therapy|usual clinical care
45367679|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
45367680|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
45484409|NCT04386837|Other|Turkish Aphasia Rapid Test|Same
45484410|NCT04779424|Other|POCT|Capillary blood sample antibody point of care test
45484411|NCT04326933|Drug|Tyrosine kinase Inhibitors (Imatinib & Nilotinib)|Administration of tyrosine kinase inhibitors (Imatinib in a dose of 400mg/day & Nilotinib in adose of 600mg/day)
45484412|NCT01347723|Other|scrambler therapy|Undergo scrambler therapy
45484413|NCT01347723|Other|questionnaire administration|Ancillary studies
45367681|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
45367682|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
45367683|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
45367684|NCT01010997|Device|Foresee Home|using the Foresee home device
45484414|NCT01347723|Procedure|management of therapy complications|Undergo scrambler therapy
45484415|NCT03265756|Device|Multimometer|A device for measuring respiration rate, temperature, heart rate and the degree of blood oxygenation of children
45691337|NCT03895762|Drug|Abstral Oral Disintegrating Tablet (ODT)|Opioid(Fentanyl)
45691338|NCT01811563|Device|Zimmer|
45691339|NCT01811563|Device|Stryker|
45691340|NCT01033552|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg/day IV over 2 hours x 1 day, total dose 50 mg/kg will be administered on Day -6.
45484416|NCT01317537|Other|Electronic personal health record|
45484417|NCT05234788|Procedure|Renal Denervation surgery|Renal Denervation surgery using TransRadial Access
45367685|NCT01011231|Procedure|Gamma Knife Radiosurgery|Patient treatments will be planned with the Gamma Plan software. The dose will be prescribed to the isodose surface which encompasses the target volume within a range of 50-60% based on a local maximum of 100%. Radiosurgery dose will be prescribed based on volume within the prescribed isodose surface (not to exceed 18 cc)
45484418|NCT01347801|Drug|GLP-1|GLP-1 1,2pmol/kg/min i.v. infusion for 4 hours
45484419|NCT01347801|Drug|Placebo (Saline)|Normal saline (NaCl 0,9%)
45484420|NCT01347801|Drug|TNF-alfa|1000ng/m2 BSA/hour i.v. infusion for 4-6 hours
45691341|NCT01033552|Drug|Fludarabine|40 mg/m^2/day intravenously on Days -6, -5, -4, -3 and -2.
45846087|NCT03249870|Drug|Inotuzumab ozogamicin (INO)|"INO schedule of administration is as follows:~First induction course: 0.8 mg/m² on day 1, 0.5 mg/m² on day 8, and 0.5 mg/m² on day 15~Second induction course: 0.5 mg/m² on day 1, and 0.5 mg/m² on day 8"
45846088|NCT03212742|Drug|Olaparib|We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously DL1 (starting dose level) : Olaparib 50 mg Q12H Monday to wednesday DL2 : Olaparib 100mg Q12H Monday to wednesday DL3: Olaparib 100mg Q12H Monday to friday DL4 : Olaparib 200mg Q12H Monday to wednesday DL5: Olaparib 200mg Q12H Monday to friday DL6: Olaparib 200mg Q12H, continously
45367686|NCT00738803|Procedure|Total hip replacement|Total hip replacement typically preformed for hip arthritis
45367687|NCT01013259|Drug|Mutaflor|1 capsule contains 2.5 - 25 billion viable bacteria of the strain E. coli Nissle 1917, 1 capsule daily over the first 4 days, 2 capsules daily until the end of treatment
45367688|NCT01013259|Drug|Placebo|1 placebo capsule matching the experimental treatment, according to the experimental arm
45367689|NCT00732953|Device|Genous stent implantation with paclitaxel-eluting balloon dilation|Genous stent implantation with paclitaxel-eluting balloon therapy
45484421|NCT01347801|Other|OGTT|Oral glucose tolerance test with 75 g glucose
45484422|NCT01347801|Other|IVGTT|Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT
45484423|NCT04733560|Procedure|Pudendal nerve block|Vaginally administered pudendal nerve block of 10ml 0.25% Bupivacaine prior to making any surgical incisions.
45484424|NCT04733560|Procedure|Sham Pudendal nerve block|Vaginally administered pudendal nerve block of 10ml Normal Saline prior to making any surgical incisions.
45484425|NCT04733560|Drug|Bupivacaine Injectable Product|Used for pudendal nerve block in the intervention arm
45367690|NCT00732953|Device|Genous stent implantation|Genous stent implantation
45367691|NCT00577655|Drug|Albuterol|Albuterol HFA MDI 180 mcg four times a day (q.i.d) for a total daily albuterol dose of 720 mcg for 21 days.
45484426|NCT01347957|Other|Nitric Oxide (NO) Gel|Nitric Oxide (NO) Gel is created by premixing of contents from 2 separate gel bottles. The first bottle, NO gel, is a solution of sodium nitrite (14.6mM) in distilled water with hydroxyethylcellulose (molecular weight 50,000-1,250,000) added for gel formation. The second bottle, Releasing-stimulator gel, is a solution of maleic acid (14.6mM) and ascorbic acid (14.6mM) in distilled water with hydroxyethylcellulose added for gel formation.
45484427|NCT01347957|Other|Placebo gel|The placebo gel is created by premixing of contents from 2 separate gel bottles. The first bottle is phosphate-buffered saline. The second bottle is the second gel bottle (Releasing-stimulator gel) as described in experimental arm.
45484428|NCT04735965|Drug|Dexmedetomidine|Dexmedetomidine would be intravenously infused at a dose of 1μg/kg over 15 minutes 30 min before the end of surgery
45691342|NCT01033552|Drug|Anti-thymocyte globulin|30 mg/kg on Days -4, -3 and -2.
45691343|NCT01033552|Drug|Cyclosporine A|Days -3 to 100+ to maintain a level of >200 ng/ml; initial dose 2.5 mg/kg over 2 hours every 8-12 hours for children.
45691344|NCT01033552|Drug|Mycophenolate mofetil|15 mg/kg intravenous twice per day on days -3 through 30.
45691345|NCT01033552|Procedure|Mesenchymal stem cell transplantation|infused via intravenous drip on Day 0
45691346|NCT01033552|Radiation|Total body irradiation|300 cGY on Day -1 administered in a single fraction at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
45367692|NCT00577655|Drug|Placebo|Placebo HFA MDI four times a day (q.i.d) for 21 days.
45367693|NCT00577655|Drug|Proventil® HFA|Proventil® HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study. The rescue medication was over-labeled with instructions for emergency use in which subjects were instructed to self-administer up to two puffs every 20 minutes to a maximum of six puffs for any given episode while attempting to seek medical assistance.
46051941|NCT04273620|Behavioral|Optokinetic stimulation and cueing-based reading therapy (OKS-READ)|"Each intervention session starts with an optokinetic stimulation (OKS) of at least 15 minutes duration. A pattern of squares, dots, triangles and stars will coherently and continuously move to the left on a computer screen in front of the patients. Patients are instructed to choose one stimulus and follow it with the eyes until it has reached the left side of the screen, then jump to the right edge of the screen and start again.~The second part of each intervention session is the cueing-based reading therapy (READ), which will also last at least 15 minutes. The task of the patient is to read out loud words or a text presented on a paper in front of them. We will use exogenous (e.g., the therapist highlights words when they were omitted) and endogenous cues (verbal instructions which require intrinsic action by the patient) to facilitate attentional shifts to the left. The intensity of cueing will be matched to the actual severity of neglect (adaptive therapy)."
45484429|NCT04735965|Drug|Meperidine|Meperidine would be intravenously injected at a dose of 0.5mg/kg 30 min before the end of surgery
45484430|NCT04735965|Drug|Placeb|Equal volume of normal saline to dexmedetomidine and meperidine group.
45484431|NCT03265990|Procedure|ligasure haemroidectomy|In ligasure group,After the haemorrhoids are prolapsed out from the anal canal with an artery forceps,Ligasure haemorrhoidectomy will be performed by applying the ligasure forceps close to the edge of each pile.Repeated applications of the device will be performed and excision will be continued into the anal canal,lifting the pile from the internal anal sphincter,to the level of the vascular pedicle,which will be finally divided.
45484432|NCT03265990|Procedure|Conventional haemorrhoidectomy|"According to the Ferguson technique~Manual anal sphincter stretching up to 4 fingers~Delivery of hemorrhoidal masses with artery forceps,one being applied at the base of haemorrhoid,the other at the apex.~skin incision at the base of haemorrhoids and submucosal dissection to lift the haemorrhoid mass off the internal sphincter.~After this the haemorrhoid pedicle will be transfixed and the mucosal edges of the defect will be opposed."
45484433|NCT01344525|Procedure|Laparoscopic gastric sleeve|Laparoscopic gastric sleeve
45484434|NCT01344525|Procedure|Gastric Banding|Gastric Banding
45484435|NCT01344525|Procedure|Multidisciplinary lifstyle intervention|Multidisciplinary lifstyle intervention (OPTIFAST®52-program)
45484436|NCT01344525|Procedure|Roux-en-Y Bypass|Roux-en-Y Bypass
45484437|NCT03265444|Biological|CS10BR05|The single injection of CS10BR05 Inj. in the carotid artery; Step 1 dose : 3.0x105cells/kg; Step 2 dose : 6.0x105cells/kg; Step 3 dose : 9.0x105cells/kg; The duration of follow up study following the single dose of CS10BR05 is 28 days.
46051942|NCT04273620|Behavioral|General neuropsychological treatment|As a control treatment the patients will receive neuropsychological treatment without targeting visuospatial attention. Examples for components implemented are supporting conversations, diagnostic assessments (e.g. memory diagnostics) and training of memory and executive functions.
46051943|NCT03378570|Device|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation will be targeted to a location in the left prefrontal cortex and delivered according to FDA-approved parameters for the treatment of major depressive disorder, specifically high-frequency 10 Hz rTMS for 3000 pulses, 5 days per week for a total number of sessions as deemed clinically appropriate by the patient's clinical TMS treatment team but usually on the order of 20-30 treatments.
45484438|NCT04291599|Drug|Ketorolac|Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia.
46051944|NCT00909870|Device|Dermagraft(R)|Weekly application of Dermagraft(R) with Profore compression as a secondary layer, in combination with systematic surgical wound debridement.
45367694|NCT01013337|Procedure|acupuncture therapy|
45367695|NCT01013337|Procedure|sham intervention|Placebo acupuncture
45484439|NCT04291599|Drug|Opioid|Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia
45691347|NCT01033552|Procedure|Bone marrow or umbilical cord blood (UCG) stem cell transplantation|Bone marrow or UCB products will be infused as soon as the product arrives and within 30 minutes. The product is infused via IV drip.
45484440|NCT02456428|Drug|DPP-4 inhibitors|Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
45484441|NCT02456428|Drug|GLP-1 analogs|Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
45484442|NCT02456428|Drug|Insulins|Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
45484443|NCT02456428|Drug|Biguanides|Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
45484444|NCT02456428|Drug|Sulfonylureas|Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
45484445|NCT02456428|Drug|Thiazolidinediones|Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
45484446|NCT02456428|Drug|Alpha-glucosidase inhibitors|Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
46051945|NCT00909870|Device|Profore|Weekly application of Profore compression dressings, in combination with systematic surgical wound debridement.
46051946|NCT00768469|Drug|Neratinib|Administered orally, continuous, once daily.
46051947|NCT00768469|Drug|Paclitaxel|Administered IV, on days 1, 8, 15 of 28 day cycle.
46051948|NCT00886821|Biological|CVX-096|Subcutaneous administration of CVX-096 with doses ranging from 0.1 mg up to a maximum of 36 mg
46051949|NCT03319368|Other|Targeted gown and glove use|Gown and glove use for high risk care activities in high risk residents
45484447|NCT02456428|Drug|Meglitinides|Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event)day.
45484448|NCT03265522|Behavioral|"ThinkMed resource at baseline"|"The ThinkMed resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline."
45484449|NCT03265522|Behavioral|Standard Care Control|"Participants will continue with the standard care provided by their physician. Participants will receive the ThinkMed resource after their final 6 month study visit (i.e. delayed intervention)."
45484450|NCT03265522|Behavioral|"ThinkMed resource (staged)"|"This group of participants will receive the ThinkMed resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian"
45484451|NCT01348113|Other|Brief Alcohol intervention|Brief intervention consists typically in a brief assessment, giving patients personal feedback, dealing with resistance and ambivalence, establishing a goal of reduced alcohol use, and giving a workbook; reinforcement visits or calls are included.
46051950|NCT02825433|Other|No intervention, only ventilation monitoring|
46051951|NCT02823795|Behavioral|Motivational Interviewing|Patients will get motivational interviewing sessions by a patient activation coach (medical social workers and/or nurses trained in motivational interviewing and in the intervention) in five post hospital discharge sessions (whereof one face-to-face, four by phone) aiming to increase patient motivation to become active in self-management (medication management, care plan/follow-up, symptoms/signs of worsening condition, contacts with health care provider).
45367696|NCT04514679|Behavioral|Healthy Lifestyles Program|Regular group visits with a health coach in addition to routine dietician and clinician visits, reviewing successes and challenges from the previous session as well as data collected through self-monitoring
45367697|NCT04514679|Behavioral|Obesity Medicine Program|A tailored approach to obesity care for patients including individual dietician and health coach visits as appropriate.
45367698|NCT00733031|Drug|AZD6918|liquid suspension, daily, oral dose
45367699|NCT00733031|Drug|gemcitabine|intravenous, doses are on an intermittent schedule
45367700|NCT00733031|Drug|pemetrexed|intravenous, dose administered every 21-days
45367701|NCT00734513|Behavioral|Partner-assisted emotional disclosure|Patients and partners in the partner-assisted emotional disclosure condition will attend four weekly face-to-face sessions with a therapist. The first session will last 75 minutes and will focus on training in skills to facilitate the patient's disclosure. The subsequent 3 sessions will last 45 minutes each. In these sessions, the therapist will briefly review the strategies and provide feedback from the previous session and the patient will spend 30 minutes talking about their cancer-related concerns to the partner.
45367702|NCT00734513|Behavioral|Cancer Education|The cancer education protocol consists of four weekly face-to-face sessions for education about living with GI cancer. The cancer education sessions will be delivered to patients and their partners and use a presentation and discussion format. Handouts and discussion sessions will center on the following topics: Orientation to Duke Cancer Care and the treatment team; suggestions for communicating with health care providers; resources for health information, psychosocial support, and financial concerns; evaluating health information on the internet; the impact of cancer on different domains of quality of life; and suggestions for maintaining quality of life.
45691348|NCT00997906|Drug|carboplatin,|Given IV
45691349|NCT00997906|Drug|cisplatin|Given IV
45691350|NCT00997906|Drug|gemcitabine hydrochloride|Given IV
45691351|NCT00997906|Drug|paclitaxel|Given IV
45691352|NCT00997906|Radiation|intensity-modulated radiation therapy|Given once daily 5 days a week for 6½ weeks.
46051952|NCT04242693|Behavioral|Mobile goal-setting intervention|This intervention applied two constructs from the goal setting theory-self-monitoring and goal setting. Briefly, all participants were asked to take photos of all their meals and upload them with descriptions to an online platform. The participants in the experimental group were taken through two additional processes that represented these two constructs. Self-monitoring was operationalized by asking those in the experimental group to count the number of times they ate red/orange vegetables using a counting checklist. Goal setting was operationalized as asking them to set a goal to eat red/orange vegetables one more time tomorrow.
45691353|NCT01811485|Drug|LMF237 50/250 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily
45691354|NCT01811485|Drug|LMF237 50/500 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily
45691355|NCT01811485|Drug|Placebo|Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily
45691356|NCT05246644|Drug|acetaminophen|we will use IV acetaminophen and an oral placebo or IV placebo and active oral acetaminophen
45691357|NCT03832036|Diagnostic Test|Paraspinal Mapping and Quantitative Sensory Pain Test|Participants will be tested at baseline.
45691358|NCT01798888|Procedure|Implantation of Deep Brain Stimulation|
45367703|NCT01327781|Drug|Endoxifen Hydrochloride|Given PO
45367704|NCT01327781|Other|Laboratory Biomarker Analysis|Correlative studies
45367705|NCT01327781|Other|Pharmacological Study|Correlative studies
45367706|NCT01327781|Other|Questionnaire Administration|Ancillary studies
45367707|NCT00734669|Drug|Glibenclamide|Taking a single dose of 3.5 mg glibenclamide
45367708|NCT00738959|Drug|AZD0328|Oral solution A single dose Day 1 followed by once daily doses on Day 3-7
45367709|NCT00113269|Drug|basiliximab|IV
45691359|NCT01810939|Drug|Patiromer|
45691360|NCT01810939|Drug|Placebo|
45691361|NCT01798576|Drug|Pegylated Interferon alfa-2a|Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
45691362|NCT01798576|Drug|Ribavirin|Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
45691363|NCT00565084|Drug|ibuprofen|Patients will receive 800 mg ibuprofen in one of the three treatment periods.
45691364|NCT00565084|Drug|Placebo|Patients will receive placebo to ibuprofen in two of the three treatment periods.
45691365|NCT01810783|Drug|Brexpiprazole|1 to 4 mg/day, once daily, tablets, orally. The patients received 2 mg/day brexpiprazole on Day 1. If a patient could not tolerate the 2 mg dose on Day 1, the dose was decreased to 1 mg/day at Day 2. The patients received 1 or 2 mg/day from Days 2 to 7, 1, 2, or 3 mg/day from Days 8 to 14, and 1, 2, 3, or 4 mg/day from Day 15 to completion of the Treatment Period (up-titration).
45367710|NCT00113269|Drug|rabbit anti-thymocyte globulin|IV
45367711|NCT00113269|Drug|tacrolimus|oral
45484452|NCT03259516|Drug|Nivolumab|1 mg/kg by vein on Days 1 and 15 of a 28 day cycle
45484453|NCT03259516|Drug|Azacitidine|75 mg/m2 subcutaneously on Days 1-7 of a 28 day cycle
45484454|NCT03259516|Drug|Fludarabine|25 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle. Dose reduction to 15 mg/m2 is permitted in cases of grade 4 hematological toxicity after first cycle.
45484455|NCT03259516|Drug|Cyclophosphamide|300 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle.
45484456|NCT03259516|Drug|Cytarabine|10 mg/m2 subcutaneously two times a day on Days 1-10 of a 28 day cycle
45484457|NCT03259516|Drug|all trans retinoic acid|45 mg/m2 per os daily during the whole course of treatment
45484458|NCT03259516|Drug|Sildenafil|20 mg per os three times a day during the whole course of treatment
45484459|NCT03259516|Drug|Melphalan|2 mg per os daily during the whole course of treatment
45367712|NCT00113269|Drug|alemtuzumab|Intravenous (IV)
45484460|NCT01344681|Drug|Micafungin sodium|"Treatment period (active treatment): an average 14 days~Dosage:~- Study Drug: Micafungin sodium (mycamine ® injections 50mg/vial) 2 vials (100mg / day)~Administration Method:~Study Drug: 3-5 days after fever begins. Infusion one time a day (one hour). Termination of treatment after maintaining fever for three days or the recovery of neutrophils with no fever."
45484461|NCT01344681|Drug|Itraconazole|"Treatment period (active treatment): an average 14 days~Dosage:~- Active Comparator: Itraconazole (Sporanox ® injection) 200 mg 2 times(400mg / day)~Administration Method:~Active Comparator: 200 mg two times(400 mg) a day, total of 4 times for 2 days and then one times (200 mg) a day for 12 days. Termination of treatment after keeping fever for three days or the recovery of neutrophils with no fever."
45484462|NCT01348191|Procedure|Myometrial biopsy|At caesarean section, after birth of the baby but before closure of the uterus, a biopsy from the upper lip of the incision in the lower uterine segment will be taken. This biopsy will measure approximately 2x50mm.
45484463|NCT03259360|Behavioral|POP:|90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to sexual and gender minority young adults
45691366|NCT00565864|Drug|L-thyroxine (L-T4)|L-thyroxine (L-T4) is the intervention for each arm/group. In each arm/group, the dose of L-T4 is adjusted to achieve TSH levels in the randomly assigned arm. L-thyroxine at doses appropriate to attain target TSH levels for the different arms for 24 weeks
45484464|NCT03259360|Behavioral|TSP:|90 days of Facebook messaging, weekly live sessions targeting tobacco use
45484465|NCT01348269|Drug|Aclasta|1 x intravenous non-current drip (infusion)
45691367|NCT01808209|Device|stenfilcon A|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
46051953|NCT04242381|Other|Cold Application|At the beginning of each treatment session, gel ice packs were wrapped in a damp towel and applied to the patients' shoulder joints for 20 minutes.
46051954|NCT04242381|Other|Kinesiotaping Application|KT was applied to the deltoid muscle using the inhibition and mechanical correction technique and to the supraspinatus muscle using the inhibition technique (2 sessions with a 5-day interval)
45484466|NCT01348269|Drug|Placebo|NaCl Solution
45484467|NCT03259594|Procedure|Laparoscopic deroofing|The classic treatment of patients with simple renal cysts is deroofing, which can be performed by open surgery or laparoscopy. Laparoscopic deroofing is an effective minimally invasive approach and has gained popularity.
45484468|NCT03259594|Drug|100 g of amino acids supplementation|intravenous supplementation with 100 g of amino acids 2 day before laparoscopic deroofing.
45484469|NCT03259672|Drug|Sevoflurane|Sevoflurane was used as a maintenance anesthetic agent.
45484470|NCT03259672|Drug|Desflurane|Desflurane was used as a maintenance anesthetic agent.
45691368|NCT01808209|Device|filcon II 3|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
45367713|NCT00113269|Drug|mycophenolate mofetil|oral
45367714|NCT00113269|Drug|steroids|IV and/or oral
45367715|NCT04065269|Drug|AZD6738|ATR inhibitor
45367716|NCT04065269|Drug|Olaparib|PARP inhibitor
45367717|NCT00515619|Drug|Lacosamide|50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing throughout the trial
45367718|NCT00733109|Procedure|Excision of the lesion|Surgery with Large Loop Excision of Transformation Zone (LLETZ)
45367719|NCT00733109|Other|Follow-up for spontaneous regression of the lesion|Follow-up at last 12 months
45367720|NCT00733187|Drug|ABT-869|0.25 mg/kg
45367721|NCT01815359|Procedure|Cytoreductive Surgery|Optimal Surgical Debulking
45367722|NCT01815359|Drug|HIPEC with Mitomycin-C|
45367723|NCT01815359|Drug|EPIC with FUDR and Leucovorin|
45691369|NCT05246332|Device|Grounding|The investigators used a grounding wire and a sham grounding wire to create grounding and sham-grounding groups. Participants sat on a chair barefoot in contact with the grounding mat for 30 minutes. The participants were blinded to the grounding because they did not know which one had a grounding effect according to the exterior of the mat.
45691370|NCT05246254|Diagnostic Test|Frailty index scale|There are clinically common scales for assessing weakness and delirium.
45484471|NCT03547960|Dietary Supplement|Guar gum|Fibre supplement to be taken with each meal
45484472|NCT03547960|Dietary Supplement|Cellulose|Placebo. Fibre supplement to be taken with each meal
45484473|NCT03259438|Behavioral|Qigong|Qigong is a form of gentle mind-body movement that originates in China and has traditionally been used for healing purposes. It has been reported to improve energy levels, as well as strength and endurance and mental clarity and equanimity. This study will assess how a 10-week qigong intervention compares to an exercise-nutrition intervention in improving fatigue and vitality in female cancer survivors. On a secondary level, we will asses changes in underlying brain, heart, and peripheral dynamics that occur as a result of the qigong practice to develop a mechanistic understanding of qigong's efficacy.
45484474|NCT03259438|Behavioral|Healthy Living (CHIP + Pre-Train)|The Healthy Living active comparator intervention includes two components: plant based nutrition counseling via the Comprehensive Health Improvement Program (CHIP) and core strengthening exercises and light aerobic activity via the Pre-Train exercise program.
45484475|NCT03542578|Device|outpatient evaluation of fatty liver|outcome of ultrasound evaluation of liver in clinical outpatient settings
45484476|NCT03537742|Biological|alirocumab|alirocumab 150mg Subcutaneous
45484477|NCT03537742|Biological|placebo|placebo to match alirocumab
45484478|NCT03261388|Behavioral|Activity-Based Locomotor Exercise Program (ABLE)|The ABLE program is an intensive locomotor based intervention that is offered at the Golden Valley Courage Kenny Rehabilitation Institute.
46051955|NCT04242381|Other|Exercise treatment|EX treatment was administered for 10 days with 3 sessions/day. A triphasic exercise program was administered to the patients. Before starting the exercise program, the patients were instructed to not perform the movements exceeding 90° overhead. The exercise program was initiated using codman pendulum, passive joint motion range (with a 1-m stick), and posterior capsule stretching exercise. Shoulder wheel, finger ladder, and shoulder strengthening exercise with theraband were added to the exercise programs of patients with full or near total range of motion and pain relief. Exercise was administered twice a week under supervision; however, the patients were advised to exercise at home on the other days with 20 repetitions of each exercise. The patients were followed up via telephone to make sure they were adhering to their exercise programs.
45484479|NCT03258970|Other|Observational cohort study|taking vitamin supplements
45484480|NCT03259282|Biological|Analysis of gamma globulin|Electrophoresis of proteins
45484481|NCT02456194|Device|Calcium Sulfate + Antibiotics + Internal Fixation|STIMULAN Rapid Cure, mixed with antibiotic, and prepared in bead form. Must be used in conjunction with internal fixation. Choice of antibiotic is left to the surgeon's discretion.
45484482|NCT03265288|Drug|LAU-7b|LAU-7b will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
45484483|NCT03265288|Drug|Placebo oral capsule|Placebo will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
45484484|NCT03261466|Drug|Bifidobacterium breve BR03 and Bifidobacterium breve B632|
45484485|NCT03261466|Drug|Placebos|
45484486|NCT02458066|Other|IRS: bendiocarb|carbamate insecticide
45484487|NCT02458066|Other|IRS: deltamethrin|Pyrethroid insecticide
46051956|NCT04242381|Other|Sham Kinesio taping application|Sham-KT was applied in 10 cm I-shaped stripes on the sagittal plane over the acromioclavicular joint without stretching and on the transverse plane distal to the deltoid area. The kinesiotape was applied twice for five days with 2-day intervals
45367724|NCT00449644|Drug|TMC207|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 or 22 weeks.
45367725|NCT00449644|Drug|Placebo|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 or 22 weeks.
45367726|NCT00449644|Drug|Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.
45367727|NCT00515541|Drug|Lovaza|First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily
45367728|NCT00733265|Drug|AZD6140|single oral dose
45484488|NCT03261310|Drug|Acetaminophen or Placebo|"Study subject will receive either 1000mg of acetaminophen in 100ml own diluent, or 100ml of saline during their intra-operative period and an order will be placed in their chart/Essentris order for No acetaminophen for 6 hours post operatively."
45367729|NCT03462628|Procedure|CPVI plus low-voltage substrate modification|CPVI plus low-voltage substrate modification in the left atrium during SR
45367730|NCT03462628|Procedure|CPVI alone|circumferential pulmonary vein isolation
45367731|NCT00112489|Drug|carboplatin|
45367732|NCT00112489|Drug|paclitaxel|
45367733|NCT03666598|Device|Tourniquet|In the patients randomized to the use of tourniquet, the tourniquet time starts before skin incision and terminates when the wound closure starts. The cuff pressure is set at 300mmHg.
45367734|NCT01023100|Drug|CP 690,550 oral solutions|flavored and unflavored prototype CP-690,550 formulations
45367735|NCT00711971|Drug|EPA-rich fish oil supplement|1060 mg EPA plus 274 mg DHA
45367736|NCT00711971|Drug|DHA-rich fish oil supplement|900 mg DHA plus 180 mg EPA
45367737|NCT00711971|Drug|placebo|control arm
45484489|NCT03259126|Device|SCUT|Two different home made curtains were attached to the angiographic table
45484490|NCT03259048|Diagnostic Test|Abdominal ultrasound|Abdominal ultrasound will be used in the diagnosis of acute abdomen in pediatric group.
45484491|NCT02456272|Device|External hearing aid|The external hearing aid (monaural) with an auditory prosthesis contour type, brand PHONAK type Bolero Q70 will be provided to the patients during a minimum of 2 months.For reasons of standardization and comparability of results, only one type of prosthesis (medium-high range) will be provided. The settings will be performed by audiologists of ENT service during the inclusion visit.
45484492|NCT02456272|Procedure|Otosclerosis surgery|Surgical restoration of the columellar effect consists of the intraoperative verification of the stapedo-vestibular ankylosis which provides diagnostic. Then a stapedotomy (laser or Ototool°) is performed and partial ossicular prosthesis s inserted between stapedotomy and the long process of the incus.
45484493|NCT02456350|Drug|Fludarabine|On days -5 through -3, Fludarabine 30mg/m2 IV will be infused over 30 minutes.
45484494|NCT02456350|Drug|Cyclophosphamide|On days -5 through -3, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.
46051957|NCT04242069|Behavioral|Healthy for my Baby|"Participants will start the preconception intervention by meeting with a health professional for a motivational interview session on healthy lifestyle habits. Following this interview, participants will have access to a mobile phone application that will allow them to track daily lifestyle modification goals. After a month, they will meet the health professional for a second motivational interview and review their progression. Participants will continue to make lifestyle changes through the preconception period by accomplishing smart goals followed daily in the mobile phone application.~If the woman becomes pregnant, the couple will participate in two more in-person motivational interviews, a month apart. The mobile application will be put in pregnancy mode, and participants will adapt their daily lifestyle goals for the pregnancy. Participants will continue to make lifestyle changes throughout pregnancy by accomplishing smart goals followed daily in the mobile phone application."
45367738|NCT01078831|Other|Bronchoscopy|Airway pressures, ventilation changes and blood gas changes are recorded in a group of intubated patients on mechanical ventilation before and after bronchoscope insertion. The registration is done immediately before a therapeutic/diagnostic bronchoscopy requested by a staff physician not involved n the study.
45367739|NCT00515463|Biological|denosumab|60 mg denosumab in 1mL
45367740|NCT00515463|Biological|denosumab|60 mg denosumab in 1mL
45367741|NCT00739037|Drug|Placebo|
45367742|NCT00739037|Drug|PAZ-417|
45367743|NCT01080157|Device|SCOUT DS measurement|Non-invasive 3-5 volar forearm scan
45367744|NCT03902483|Device|renal doppler ultrasound|renal doppler ultrasound measuring renal resistive index
45367745|NCT01080235|Other|ABIM Care of Vulnerable Elderly Practice Improvement Module|The ABIM CoVE PIM is a practice-performance self-evaluation instrument. It is a web-based tool based on nationally recognized guidelines that uses chart abstraction, patient surveys, and a practice system survey in order to generate a performance report focused on a key aspects of care for vulnerable elderly.
45367746|NCT01080235|Other|Geriatric and Quality Improvement toolkit|A resource toolkit about geriatrics and quality improvement was given to both study arms.
45367747|NCT00734825|Other|Omnipaque|oral contrast for CT scan
45484495|NCT02456350|Biological|Anti-CD19-CAR transduced T cells|Modified cells will be infused IV over 30 minutes (2-4 days after the last dose of fludarabine).
45484496|NCT02456038|Drug|Asfotase Alfa (ALXN1215)|
45484497|NCT03258736|Procedure|inguinal hernia surgery|repair of inguinal hernia
45484498|NCT01368120|Device|IV Clear™ Dressing|Polyurethane film, silicone adhesive dressing with chlorhexidine and silver
45484499|NCT01368120|Device|Tegaderm CHG™|Polyurethane film, polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
45484500|NCT01368120|Device|Silicone Vehicle Control Dressing|Polyurethane film with silicone adhesive dressing, without antimicrobials
45846089|NCT03212742|Drug|Temozolomide (TMZ)|TMZ will be given at the dose of 75mg/m²/day during radiotherapy period. TMZ will be re-introduced 4 weeks after the end of radiotherapy at the dose of 150mg/m²/day on days 1 to 5 every 28 days, for a total of 6 cycles.
45367748|NCT01080313|Other|Therapy for head and neck cancer|radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
45367749|NCT00739115|Other|Heliox gas|Heliox gas used in conjunction with nasal CPAP
45367750|NCT01082731|Drug|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
45367751|NCT01082731|Drug|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
45367752|NCT00739193|Drug|amiodarone|
45367753|NCT01011543|Procedure|Diagnostic techniques in pulmonary tuberculosis|Two different methods to obtain a diagnosis of pulmonary tuberculosis in patients with negative classic sputum samples are compared.
45367754|NCT00733577|Drug|SB756050|doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations
45367755|NCT03997461|Device|BPro|BPro and Oscar 2 comparison for 24 hours
46051958|NCT04242069|Other|Usual Care|"Participants in the control group will receive standard advice on healthy lifestyle habits as provided by their usual care provider. They will receive standard medical care in preconception and pregnancy.~To improve compliance with the study follow-up, participants in this group will have access to a simplified version of the mobile application that contains a fertility calendar and a research visit calendar. This version of the application does not include lifestyle goals or any information on healthy lifestyle habits."
45484501|NCT04971486|Behavioral|Motor Sequence Task|"Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear."
45484502|NCT04214652|Drug|IDP-126 Gel|IDP-126 Gel applied topically to the face once daily for 12 weeks.
45484503|NCT04214652|Drug|IDP-126 Vehicle Gel|IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
45484504|NCT04226274|Drug|REN001|Once daily for 12 weeks
45484505|NCT01363674|Device|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
45367756|NCT00739271|Other|Early feeding|
45367757|NCT00739271|Other|late feeding after bowel sounds return|Traditional method
45367758|NCT04513977|Other|Geriatric Oncology Supportive Clinic|Patients will undergo Comprehensive Geriatric Assessment with subsequent tailored intervention based on deficits identified. Comprehensive palliative assessment for any symptom burden and symptommatic treatment will be done as well.
45367759|NCT00735059|Device|treatment with the dialyzer ELISIO 170H|one week of three consecutive dialysis treatments, > 3 hours
45484506|NCT01319370|Drug|Minoxidil|1 g of 5% Minoxidil topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
45484507|NCT01319370|Drug|vehicle of 5% Minoxidil topical foam|1 g of vehicle topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
45484508|NCT01363752|Drug|Advagraf|oral
45484509|NCT01363752|Drug|Mycophenolate Mofetil|oral
45484510|NCT01363752|Drug|Sirolimus|oral
45691371|NCT04585009|Drug|GSK3923868|GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
45691372|NCT04585009|Drug|Matching placebo|Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
45691373|NCT04585009|Device|Monodose RS01|Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
45846090|NCT03212742|Radiation|IMRT (Intensity Modulated Radiation Therapy)|Radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week over 6 weeks, for a total dose of 60 Gy by 3D- Intensity-Modulated RT (IMRT)
46051959|NCT04242615|Other|Prognostic score|
46051960|NCT02825121|Device|Monitoring Neuromuscular Blockade the Flexor Hallucis|
46051961|NCT02825121|Device|Monitoring Neuromuscular Blockade adductor of the thumb.|
46051962|NCT02825199|Dietary Supplement|Caffeine|capsule: 300mg caffeine
45846091|NCT03202758|Drug|Durvalumab, Tremelimumab and ,FOLFOX|"Study will be performed in 2 step:~STEP 1 (phase Ib) will assess the safety of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX during the 2 first cycles of treatment (1 month)~STEP 2 (phase II) will assess the efficacy of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX"
45484511|NCT01363752|Drug|Corticosteroids|i.v. and oral
45484512|NCT01368198|Other|Systane Balance Lubricating Eye Drops|One instillation of the eye drop in each eye
45484513|NCT01368198|Other|OPTIVE™|One instillation of the eye drop in each eye
45367760|NCT00735059|Device|treatment with the dialyzer PES-170DS|one week of three consecutive dialysis treatments, > 3 hours
45367761|NCT00735137|Device|Vaginal pessary (CE0482, MED/CERT ISO 9003 / EN 46003)|Inserted from randomization till 36-37 weeks of gestation
45367762|NCT04064255|Other|Practical Body Image (session 1 - 7)|Practical body image therapy
45367763|NCT04064255|Other|Practical Body Image (session 8 - 14)|Twice weekly mirror exposure plus ending session
45367764|NCT00733733|Drug|ATG Fresenius|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
45484514|NCT01360710|Drug|Moxonidine|0.2mg/day for 2 weeks, 0.4mg/day for 6 months
45367765|NCT00733811|Drug|Deferiprone (DFP) and Deferoxamine (DFO)|Sequential treatment including DFP at 75 mg/kg for four days per week and DFO by subcutaneous infusions (8-12h) at 50mg/kg/day for the remaining three days per week
45367766|NCT00733811|Drug|Deferiprone (DFP)|DFP alone at 75 mg/kg divided into three oral daily doses
45367767|NCT00739505|Biological|Asfotase Alfa|"The initial IV dose to be administered to patients was set at one-tenth the no adverse effect level (NOAEL) as determined by one month toxicology studies in animals in which Asfotase Alfa was administered as a single weekly IV dose. The SC doses to be administered are lower than the IV doses and are thought to be near or at the anticipated daily efficacious dose. Dosing will be as follows:~Cohort 1: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 3 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1 mg/kg SC."
45367768|NCT00739505|Biological|Asfotase Alfa|Cohort 2: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 7 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1.5 mg/kg SC.
45484515|NCT01360710|Drug|Irbesartan|75 mg/day for 2 weeks and then 150 mg/day for 24 weeks.
45846092|NCT03194256|Behavioral|Spectrum Research Cigarettes|Participants will be assigned to either normal nicotine content cigarettes or very low nicotine content cigarettes.
45846093|NCT03186534|Behavioral|2GETHER|Communication skills, coping skills, problem-solving, acceptance, HIV prevention
45484516|NCT01368354|Behavioral|CLTS|CLTS (Community Led Total Sanitation) involves facilitating a process to inspire and empower rural communities to stop open defecation and to build and use latrines, without offering external hardware subsidies. Communities are encouraged to appraise and analyse their own sanitation profile, including the extent of open defecation and the spread of faecal-oral contamination. This approach ignites a sense of disgust and share among the community. The community then collectively realises the impact of its unsanitary practices and this realisation mobilises and initiates collective action to improve the existing sanitation profile.
45484517|NCT01363830|Behavioral|Two-Week Post-Operative Restriction|Surgeon recommends the patient restrict bending, lifting, and twisting for two-weeks following discectomy.
45484518|NCT01363830|Behavioral|Six-Week Post-Operative Restriction|Surgeon recommends patient restrict bending, lifting, and twisting for six-weeks following discectomy.
46051963|NCT02825199|Dietary Supplement|Non caffeine|capsule: placebo (maize starch)
45367769|NCT00920777|Behavioral|CBT|Individual Cognitive Behavior Therapy during 16 weeks
46051964|NCT02824965|Drug|Pembrolizumab|Pembrolizumab is a selective monoclonal antibody that blocks the interaction between PD1 and its ligands PDL1 and PDL2, resulting in infiltration of tumour specific CD8+ T-cells and ultimately leads to tumour rejection.
45484521|NCT01360788|Drug|Combination ipratropium/salbutamol or placebo (nebulization)|The COPD patients were randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. The bronchodilation produced by the medication was given in order to evaluate if bronchodilation was effective in increasing exercise tolerance during an endurance shuttle walking test in patients with GOLD stage I COPD.
46051965|NCT02824965|Biological|CVA21|CAVATAK is an oncolytic Coxsackie virus that specifically infects and kills ICAM overexpressing tumour cells
45367770|NCT00920777|Behavioral|CBT|Individual Cognitive Behavior Therapy during 8 weeks
45367771|NCT00920777|Behavioral|Control group|Waiting 16 weeks and receiving 8 weeks individual CBT after waiting period.
45367772|NCT00507507|Drug|Tenofovir DF|Tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablet taken orally once daily
45367773|NCT00507507|Drug|FTC|Emtricitabine (FTC) 200 mg capsule taken orally once daily
45367774|NCT00507507|Drug|Placebo|Placebo to match FTC taken once daily
45367775|NCT00540761|Device|OFDI imaging|Intervention of OFDI system and Imaging of the culprit lesion using the OFDI system.
45367776|NCT00459706|Device|Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
45367777|NCT00459706|Device|Enbrel 50 mg Autoinjector|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
45367778|NCT00735293|Device|VASER|A small incision will be made in the underarm. A VASER probe will be inserted under the skin to break apart fat and sweat glands under the skin. A small hollow tube will be used to draw out the broken-down skin and the incision will be closed with a stitch.
45367779|NCT02568527|Device|PLGA scaffold|Poly-Lactic-co-Glycolic Acid (50:50) biodegradable, synthetic scaffold
46051966|NCT04919343|Behavioral|BBC Education Tiny Happy People videos|This intervention involves regular texting of BBC Education Tiny Happy People videos to parents
46051967|NCT04919343|Behavioral|Physical health control intervention|This intervention involves regular texting of publicly available videos about supporting infant physical and dental health to parents
45484522|NCT01368510|Behavioral|Intensive Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered daily 5 days/week for 4 weeks
45484523|NCT01368510|Behavioral|Waitlist|Minimal contact waitlist weekly for 4 weeks
45484524|NCT01360944|Drug|LAS41004|once daily, topical, 100 microgram
45484525|NCT01360944|Drug|reference|once daily, 100 microgram
45484526|NCT01364064|Drug|TMZ|Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide
45484527|NCT01361022|Drug|Lendormin tablet|Lendormin tablet 250mc is administrated and compared
45484528|NCT01361022|Drug|Brotizolam tablet|Brotizolam tablet 250mc is administrated and compared
45484529|NCT01364142|Procedure|endobronchial blocker|After intubation of endotracheal tube, the Uniblocker® was inserted into the endotracheal tube and advanced step by step with inflation of the blocker balloon until the peak inspiratory pressure dropped abruptly.
45846094|NCT03186534|Behavioral|Positive Affect Enhancement|coping skills for enhancing positive emotions, mindfulness
45367780|NCT00735527|Drug|Lorazepam|Intra-nasal 0.1 mg/kg (maximum 4 mg) once
45367781|NCT00735527|Drug|Lorazepam|Intra-venous 0.1 mg/kg (maximum 4 mg) once
45484530|NCT01364220|Drug|Rosuvastatin|Rosuvastatin 20mg tablet, once daily, for 14 days
45484531|NCT01364220|Other|Placebo tablet|Placebo tablet, once daily, for 14 days
45484532|NCT01368744|Device|OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (> 2 mm).~Groups: OSNA Breast Cancer System"
45484533|NCT01361100|Device|Oncoral® test|The patient rinses his oral cavity for 2 minutes. Then he screws lid back onto a beaker. The investigator holds the beaker straight so that the end of the aspiration mouth is dipped into the liquid. Then, the investigators takes 2 tubes and pushes them one after the other down on the opening of the beaker. The tubes should fill by themselves. The tubes can't be kept more than eleven days and are send to the Clinident Institute for the analysis.
45484534|NCT01368978|Device|InsuPatch|device which apply local heating at 38.5 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site.
45846095|NCT03183102|Dietary Supplement|Flaxseed|2 months of dietary flaxseed supplementation
45846096|NCT03163368|Radiation|Neoadjuvant stereotactic radiosurgery|Dose escalation of neoadjuvant stereotactic radiosurgery
45846097|NCT03163368|Procedure|Neurosurgical resection|Surgical resection of newly diagnosed brain metastases
45691374|NCT05246176|Device|nephrostomy set|insertion of the nephrostomy set through the skin to obtaining good external drainage of bile in case of malignant obstructive jaundice.
45691375|NCT04170283|Drug|Zanubrutinib|Participants will receive zanubrutinib at a dose of 160 mg twice daily (for a total daily dose of 320 mg), or the last dose level received in the BeiGene parent study.
45691376|NCT04170283|Drug|Tislelizumab|Patients in Australia who participated in a parent study that involved combination therapy of zanubrutinib and tislelizumab will receive tislelizumab at a dose of 200mg every 3 weeks..
46051968|NCT04242537|Device|High flow nasal cannula oxygen delivery|It includes the delivery of oxygen through a high flow nasal cannula with head side elevation to 30 degrees to prevent desaturation and improve first pass success rate of endotracheal intubation
46051969|NCT04242537|Device|Low flow nasal cannula oxygen delivery|It includes the delivery of oxygen through a low flow nasal cannula coupled with head side elevation to 30 degrees to prevent desaturation and improve first pass success rate of endotracheal intubation
46051970|NCT00886743|Drug|oprelvekin|injection, 50 mg/kg, once daily
45367782|NCT00735605|Other|BFD|The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip
45367783|NCT00735605|Procedure|PDPR|A 2-3 cm curved incision is made on either side of the anal canal along its posterolateral aspect, each about 2.5 cm distance from the anal verge Fig(2). After that dissection in ischiorectal fossa was done till reaching the puborectalis sling from outside i.e. extrasphincteric approach . Using a right angle forceps the puborectalis sling is lifted up, guided by the contralateral index finger in the anal canal Fig(3). Nearly the inner half of puborectalis sling was divided on each side by using a scalpel NO. 11 Fig(4). Complete haemostasis was followed by skin closure without drain
45691377|NCT03698032|Dietary Supplement|Water|Participants will consume water only
45691378|NCT03698032|Dietary Supplement|1.5 oz Pistachios|Participants will consume water plus 1.5 oz of pistachios as the intervention
45691379|NCT03698032|Dietary Supplement|3.0 oz Pistachios|Participants will consume water plus 3.0 oz of pistachios as the intervention
46051971|NCT02826915|Device|Near Infra Red Spectroscopy (NIRS)|
46051972|NCT02826915|Device|Electroencephalogram (EEG)|
46051973|NCT00886587|Device|F# 11054-010|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
45367784|NCT00735605|Other|BTX A|A vial of Dysport, 500 u, (Dysport, Ipsen, United Kingdom) is dissolved in 2.5 ml isotonic saline Fig(1). A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient
45367785|NCT05741255|Behavioral|Acceptance and Commitment Therapy|type of mindful psychotherapy that helps you stay focused on the present moment and accept thoughts and feelings without judgment. It aims to help you move forward through difficult emotions so you can put your energy into healing instead of dwelling on the negative.
45367786|NCT05741177|Diagnostic Test|lung ultrasound|lung ultrasound score
45367787|NCT05741099|Biological|Umbilical cord mesenchymal stem cells implantation|Patient in Mscs group will receive MSCs implantation by intravenous injection.
45367788|NCT05741099|Other|Comparator|Patients in comparator group will receive placebo treatment
45367789|NCT04063475|Drug|cyanoacrylate tissue adhesive beside sutures|using cyanoacrylate tissue adhesive for FGG fixation
45367790|NCT03459820|Diagnostic Test|18F-DCFPyL PET/CT|18F-DCFPyL Positron Emission Tomography/Computed Tomography Scan
45691380|NCT05246020|Procedure|HIPEC|Docetaxel (60-75mg/m2) perfusion solution will be infused into the peritoneal cavity through the tubes within 24 hours after the laparoscopic evaluation. Then, perfusate containing cisplatin (75 mg/m2) will be infused 24 hours later. NHIPEC will be administered at 43°C for a duration of 60min. Saline solution (3000mL) will be used to dissolve the drug, and it will be heated and circulated at a flow rate of 300-500 mL/min.
45691381|NCT05246020|Procedure|intravenous chemotherapy|Patients in the control group will receive three cycles of intravenous NACT. The regimen of intravenous NACT is docetaxel 60-75mg/m2 followed by carboplatin AUC 5 for a 21-day cycle.
46051974|NCT00886587|Device|F# 10495-053|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
46051975|NCT00886119|Device|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
46051976|NCT00886119|Device|Omafilcon A multifocal contact lens|Hydrogel, soft, multifocal contact lens for daily wear use
45691382|NCT03681262|Device|High frequency spinal cord stimulation|We will use Senza® (Nevro Corp., Palo Alto, CA) trial and implant systems to deliver high frequency spinal cord stimulation. A trial system includes two trial leads, an external pulse generator, and a remote control. The permanent implant system includes two leads, an internal pulse generator, a remote control, and a charging device for internal pulse generator. We will use our routine process of trial and implant. High frequency waveform will be delivered with following parameters: frequency of 10,000 hertz, pulse width of 20 microseconds, and amplitude of 0-15 milliamperes.
45691383|NCT03681262|Device|Burst spinal cord stimulation|We will use BusrtDRTM (Abbott Saint Jude Medical, St. Paul, MN) trial and implant systems to deliver burst spinal cord stimulation. A trial system includes two trial leads, an external pulse generator, and a remote control. The permanent implant system includes two leads, an internal pulse generator, a remote control, and a charging device for internal pulse generator. We will use our routine process of trial and implant. The parameters of the stimulation are as below: each burst includes 5 pulses of electrical stimulation at intra-burst frequency of 500 hertz without time for discharge in between pulses. These bursts will be repeated at inter-burst frequency of 40-60 hertz. The amplitude will range between 0 and 15 milliamperes.
45691384|NCT01807117|Procedure|positron emission tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
45846098|NCT03132948|Behavioral|Physical Activity|Nintendo WII fit console, Xbox console, sport activities (soccer, basketball, yoga, walking and other physical games)
45846099|NCT03122262|Drug|Dolutegravir|DTG 50mg Oral Tablet once daily
45846100|NCT03122262|Drug|Tenofovir Alafenamide|TAF/FTC 25/200mg Oral Tablet once daily
45846101|NCT03122262|Drug|Truvada|
45367791|NCT00735683|Drug|ATHX-105 phosphate|includes diet, physical activity, and lifestyle modification
45367792|NCT00735683|Drug|Placebo|includes diet, physical activity, and lifestyle modification
45367793|NCT03663322|Procedure|OMT Protocol|Selected hands-on OMT techniques intended to improve pancreatic function will be administered during the treatment sessions
45367794|NCT03663322|Procedure|OMT-Sham Protocol|Selected hands-on Sham-OMT techniques that are not intended to affect pancreatic function will be administered during the treatment sessions
45846102|NCT03122262|Drug|Atripla|
45846103|NCT03055416|Other|Mobile Men App Prototype|Testing of app functionality
45846104|NCT03051282|Drug|Enalapril|Study participants in both arms will be treated with 10 mg enalapril orally once daily for seven consecutive days
45846105|NCT03042546|Drug|Calcium Sulfate|Calcium Sulfate with abx will be used in the defect
45846106|NCT03042546|Drug|PMMA|PMMA with abx will be used in the defect
45846107|NCT03042546|Other|No treatment|The defect will not be treated
46051977|NCT02823873|Device|Pulsewave oscillometric wrist cuff blood pressure monitor|Blood pressure monitor utilizing wrist cuff administered and measured using mobile technology.
46051978|NCT02826759|Other|diabetes|the exposure of interests are obesity, diabetes and insulin-resistance
46051979|NCT02824887|Other|Electro-acupuncture|Electro acupuncture deep needling protrusion of lumbar intervertebral disc the five acupoints
46051980|NCT02824887|Other|Conventional treatment of Western Medicine|Routine non operative treatment of Western Medicine
46051981|NCT02823951|Drug|Rebif|
45367795|NCT00735761|Drug|ME-609|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
45484535|NCT03719040|Device|Physiologic pacing device implant|An alternative and potentially more effective pacing strategy for patients with electrical conduction abnormalities is physiologic pacing. Physiologic pacing is achieved by delivering a pacing stimulus to a cardiac conduction structure, such as the bundle of His or left bundle branch (LBB) of the His-Purkinje system, with a permanent lead. Physiologic pacing activates the heart through the native His-Purkinje conduction system, thus offering the most physiologic pacing approach to correct electrical dyssynchrony. Physiologic pacing has emerged as a feasible and safe alternative to pacemaker therapy and CRT with clinical and electrophysiological advantages.
45484536|NCT01361256|Device|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
45484537|NCT01361256|Device|WA-NG Telescope Prothesis|The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
46051982|NCT02823951|Drug|Tecfidera|
45484540|NCT02713204|Drug|REGN910-3|
45484541|NCT02713204|Drug|Intravitreal Aflibercept Injection (IAI)|
45484542|NCT03695172|Drug|Ropivacaine|Patients will be randomly assigned to receive one three blocks (TAP, QL, ESP)after delivery of baby with ropivicaine
45484543|NCT03695172|Procedure|TAP block|Patient will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
45484544|NCT03695172|Biological|QL block|Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
45367796|NCT00735761|Drug|Acyclovir in ME-609 vehicle (5% acyclovir)|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
45367797|NCT03454438|Procedure|Referral strategies|Two referral strategies will be compared to usual care, i.e. the control group. Patients will be followed for one year.
45367798|NCT00740285|Drug|Lidocaine 2% without vessel constrictor|"first 5 days: 20ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours~next 5 days: 30ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days"
45691385|NCT01807117|Procedure|computed tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
45367799|NCT00740285|Other|Placebo - physiological solution 0,9%|first 5 days: 20ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours next 5 days: 30ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days
45367800|NCT00507429|Drug|CA4P|CA4P 60mg/m squared for Days 1, 8, 15 for 6 cycles
45484545|NCT03695172|Procedure|ESP block|Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% of ropivacaine with epinephrine 1:400,000 per side.
45484546|NCT03721107|Biological|Blautix|Blautix is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen was two capsules two times per day for the duration of the treatment period.
45484547|NCT03721107|Other|Placebo|Placebo control
45691386|NCT01807117|Procedure|magnetic resonance imaging|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
45691387|NCT01807117|Radiation|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
45691388|NCT02804854|Drug|Neutrophil Activation Probe (NAP)|Delivery of NAP by direct pulmonary administration followed by fibreoptic confocal microendoscopy. A total of 240 mcg (±25%) in three divided doses of 80 mcg (±25%).
45846108|NCT02948244|Dietary Supplement|Creatine Monohydrate|Synthetically produced dietary supplement Creatine Monohydrate will be used in powder form reconstituted to a drink. The dosage will be 100mg/kg/day up to a maximum of 10 grams daily.
45846109|NCT02948244|Dietary Supplement|Placebo|Placebo
45846110|NCT02748564|Biological|Aldesleukin|Given IV
45846111|NCT02748564|Other|Laboratory Biomarker Analysis|Correlative studies
45367801|NCT00507429|Drug|paclitaxel|200mg/m squared on Day 1
45846112|NCT02748564|Biological|Pembrolizumab|Given IV
45846113|NCT02734602|Drug|Ketamine|Ketamine will be administered after the initial PET scan for subjects participating in the ketamine aim.
45846114|NCT02734134|Procedure|One-stage exchange joint replacement surgery|
45846115|NCT02734134|Procedure|Two-stage exchange joint replacement surgery|
45846116|NCT02663622|Drug|Efprezimod alfa|Acute GVHD prophylaxis
45367802|NCT00507429|Drug|carboplatin|6 AUC on Day 1 following paclitaxel
45367803|NCT01011621|Drug|0.5% prednisolone acetate cream|Small amount applied over the lesion twice a day for 14 days.
45367804|NCT01011621|Drug|0.1% betamethasone valerate cream|Small amount applied over the lesion twice a day for 14 days.
45367805|NCT00449176|Drug|tapentadol (CG5503) ER|50, 100, 150, 200, 250 mg twice daily for 15 weeks
45367806|NCT00449176|Drug|oxycodone CR|10, 20, 30, 40, 50 mg twice daily for 15 weeks
45367807|NCT00449176|Drug|placebo|matching placebo twice daily for 15 weeks
45846117|NCT02663622|Drug|Methotrexate|Acute GVHD prophylaxis
45367808|NCT00515073|Drug|Paclitaxel|50 mg/m^2 IV over one hour on Day 1, 8, 15, 22, and 29 during radiation therapy followed by 4 additional courses at 135 mg/m^2 IV over 3 hours every 21 days, 4-6 weeks after pelvic radiation is completed.
45367809|NCT00515073|Radiation|Pelvic Radiation|Radiation therapy to the pelvis daily for 25 treatments. Beginning Day 1 or 2 and given for 5 days for 5 weeks, giving a total dose of 45 Gy with external beam radiation to the pelvis. The vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for an additional 3 days depending on patient preference. No chemotherapy given with vaginal apex boost.
45484548|NCT01364376|Drug|S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium|"FOLFOX:~oxaliplatin 130mg/m2 on day 1, CF 400mg/m2 on day 1, 5-Fu 400mg/m2 on day 1; 5-FU 2400 mg/m2 46hr civ regimen repeated every 3 weeks Pre-operative chemotherapy: 2-4 cycles and peri-operative chemotherapy consist of 6 cycles~SOX:~oxaliplatin 130mg/m2 on day 1, S-1 for 14 days regimen repeated every 3 weeks Pre-chemotherapy: 2-4 cycles, totally 6 cycles of perioperative chemotherapy"
45484549|NCT01344837|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
45484550|NCT01344837|Other|Immunohistochemistry Staining Method|Correlative studies
45484551|NCT01344837|Other|Medical Chart Review|Correlative studies
45484552|NCT01344837|Genetic|Microarray Analysis|Correlative studies
45484553|NCT01344837|Other|Study of Socioeconomic and Demographic Variables|Correlative studies
45484554|NCT01344837|Genetic|Western Blotting|Correlative studies
45484555|NCT01369056|Behavioral|Advanced Adherence Counseling (AdvAdh)|AdvAdh consists of 3 individual sessions (study months 0, 3, 6) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using Next Step Counseling (NSC) approach. The intervention targets: 1) accurate information about antiretroviral treatment (ART) (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; 2) promotion of perceived sense of ease and efficacy in working ART regimen into the context of one's daily life and present life circumstances that may challenge drug use persistence; 3) identification, refinement of skills promoting ease of adhering to one's ART regimen across the diverse and challenges contexts.
45367810|NCT00515073|Drug|Dexamethasone|20 mg IV given 30 minutes prior to chemotherapy
45367811|NCT00515073|Drug|Cimetidine|300 mg IV given 30 minutes prior to chemotherapy
45367812|NCT00515073|Drug|Diphenhydramine|50 mg IV given 30 minutes prior to chemotherapy
45367813|NCT00710021|Drug|Vitamin D3|8% vitamin D3 powder, 84% microcrystalline cellulose, 8% fumed silica by weight
45484556|NCT01348503|Drug|Lenalidomide|Escalating doses starting at 15 mg by mouth per day.
45484557|NCT01348503|Drug|Sorafenib|Fixed dose of 400 mg by mouth twice a day.
45484558|NCT03260998|Diagnostic Test|electrocardiogram|measurment of QT dispersion and corrected QT and other electrocardiogram changes
45484559|NCT01369134|Device|Adper Easy Bond Self-etch dental adhesive|Bonding composite to restore Class I or Class II cavities
45484560|NCT01344915|Procedure|Locked knee brace|
45484561|NCT01344915|Procedure|Locked knee brace|
45484562|NCT01369290|Drug|Venlafaxine|75 to 375 mg/day for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
45484563|NCT01369290|Drug|bupropion|150 to 300 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
45484564|NCT01369290|Drug|escitalopram|10 to 30 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
45846118|NCT02663622|Drug|Tacrolimus|Acute GVHD prophylaxis
45846119|NCT02663622|Drug|Placebo|100 ml saline IV infusion.
45846120|NCT02632422|Other|Daily acute intermittent hypoxia (dAIH)|Each participant will be exposed to 10 sessions of daily acute intermittent hypoxia (dAIH) via air generators. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02). Participants will receive 5 consecutive days of daily acute intermittent hypoxia (dAIH).
45367814|NCT00710021|Drug|Vitamin D3 placebo|86% microcrystalline cellulose, 14% fumed silica by weight
45484565|NCT01369290|Other|Psychotherapy|Once weekly CBT psychotherapy session for 12 weeks. If no response at 12 weeks, reassignment to one of the other treatment groups for a further 6 weeks in phase II.
45367815|NCT00504153|Drug|dasatinib|
45484566|NCT01369290|Drug|Duloxetine|30 to 60 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
45691389|NCT05245630|Procedure|Robotic arm assisted PET/CT guided biopsy|"After preparing the participant for the procedure, the participant was positioned on the PET/CT table with the immobilizer.~An automated robotic arm (MAXIO-EX, Perfint healthcare Pvt Ltd, Chennai, India) was used to guide the needle for biopsy.~Co-axial 18 G biopsy needle (BARD Biopsy disposable coaxial biopsy needle pack, Bard Peripheral Vascular, Inc., Arizona, USA) was inserted according to the orientation planned by the robotic biopsy device.~After the location is ensured, the trocar stylet is removed from the coaxial cannula and specimens were retrieved using a semiautomated biopsy gun.~A repeat CT chest was acquired two hours after the procedure to rule out post-procedural complications.~Complications during the procedure were noted, and immediate management was done."
45691390|NCT05245630|Procedure|PET fused CT-Fluoroscopy guided biopsy|CT fluoroscopy was used to place the biopsy needle to the FDG avid lung lesion
45691391|NCT05363410|Dietary Supplement|MagnéVie B6®|micronutrient supplement
45691392|NCT05363410|Other|Placebo|placebo supplement
45691393|NCT01613131|Drug|Mirena|Mirena (levonorgestrel-releasing intrauterine system), 52 mg (20 mcg/day), 5 year duration (study duration 6 months).
45691394|NCT01613131|Drug|Estradiol|Topical, .06%, Applied once daily for 50 days.
45691395|NCT01613131|Drug|Placebo Gel|Topical Gel, Applied once daily for 50 days, Placebo comparator.
45691396|NCT01798342|Dietary Supplement|Maltodextrin|The volunteers underwent MRI after the ingestion of the dietary supplement in a crossover fashion aiming at measuring the gastric residual volume
45691397|NCT01798342|Dietary Supplement|Glutamine|The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of GLN before MRI
45367816|NCT00504153|Other|laboratory biomarker analysis|Correlative studies
45367817|NCT05740787|Other|No intervention|Observation only
45367818|NCT00739895|Procedure|Cardiac magnetic Resonance study|follow-up studies
45367819|NCT00739895|Procedure|Blood testing|Blood sample tested for myocardial biomarkers
45691398|NCT04410835|Diagnostic Test|Online Survey|Psychological questionnaires
45691399|NCT05363098|Other|Mechanically ventilated neurosurgical patients|Observational study where respiratory variables and intracranial pressure will be measured during assisted mechanical ventilation. No intervention is planned.
45367820|NCT00735995|Behavioral|Cognitive behavioral therapy (individual)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
45367821|NCT00735995|Behavioral|Cognitive behavioral therapy (group)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
45367822|NCT04064177|Device|NICAS cardiac output monitor|Non-invasive continuous cardiac output monitoring device using total body bioimpedance.
45367823|NCT05740631|Drug|Ocaliva|Assignment of treatment obeticholic acid will be started (randomized) after the study visit and administered orally in a single-blind fashion for 21 days.
45367824|NCT05740631|Drug|Placebo|Assignment of treatment placebo will be started (randomized) after the study visit and placebo will be administered orally in a single-blind fashion for 21 days.
45367825|NCT00740363|Drug|sitagliptin|Once daily sitagliptin. If GFR>50 ml/min/1.73m2: 100 mg/day. If GFR from 25 to 49 ml/min/1.3m2: 50 mg/day
45367826|NCT00740363|Drug|placebo|No active sitagliptin treatment for 4 weeks
45846121|NCT02632422|Other|dSHAM|Each participant will be exposed to 10 sessions of daily room air (dSHAM) via air generators. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes of 1.5 minute normoxia (FIO2=0.21±0.02). Participants will receive 5 consecutive days of daily room air (dSHAM).
45846122|NCT02632422|Other|Walking|"Participants will participate in 10 days of walking practice sessions. Walking practice sessions will immediately follow (within 60 minutes) the breathing intervention during training visits and will last for 60 minutes.~Walking practice will incorporate 5 walking-related tasks:~walking balance (e.g., walking with turns)~skilled walking tasks (e.g., negotiating obstacles)~walking with secondary task (e.g., walking and talking)~endurance~speed"
45367827|NCT04065035|Other|Topical Body Firming Moisturizer|Moisturizer composed of a patent-pending blend of botanical extracts, bioavailable peptides, antioxidants, and a prebiotic innovation
45846123|NCT02566668|Other|1 year Observational Follow-up|Approximately 12 months after research bronchoscopy, subjects will return for follow-up visit.
46051983|NCT02826837|Drug|LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab|"The subjects will be administered FOLFOX + Bevacizumab/Cetuximab by intravenous infusion.~Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.~A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day~Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)"
46051984|NCT02826525|Drug|AZD4076|Investigational product
45691400|NCT05362942|Drug|Venetoclax, Decitabine, Azacytidine, Cytarabine|Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days (n=3) or azacytidine (n=8) was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician. Cytarabine was given at a dose of 10 mg/m2 twice daily for 7 days.
45691401|NCT01868893|Drug|Obinutuzumab|
45691402|NCT01868893|Drug|Chlorambucil|
45691403|NCT03481972|Drug|Doxycycline and tauroursodeoxycholic acid|doxycicline and tauroursodeoxycholic acid
45691404|NCT03481972|Drug|Standard of care|Standard of care
45691405|NCT03459898|Device|AlignRT system (VisionRT Ltd., London, UK)|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
46051985|NCT02826525|Drug|Placebo|Control
45367828|NCT04065035|Other|Body Cleanser|Body cleanser to be used by study participants
45367829|NCT04065035|Other|Sunscreen|Sunscreen to be applied after application of moisturizer
46051986|NCT04243083|Drug|TLL018 tablet, placebo|Oral QD
45367830|NCT04065035|Other|Placebo Moisturizer|Placebo moisturizer is the vehicle control of the topical body firming moisturizer
45367831|NCT00442702|Drug|Mircera|Starting dose of 120, 200 and 360 micrograms administered by subcutaneous injection once a month.
45367832|NCT00442702|Drug|Darbepoetin alfa|As prescribed, subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling specifications.
45367833|NCT04065191|Other|High-intensity interval training|Heart rate based high-intensity interval training
45367834|NCT04649177|Device|Ocular surface optical coherence tomography|EYEdeal Scanning technology enables rapid measurement of the corneal and scleral topography which provides data for an automated sequence to fit PROSE devices
45691406|NCT01868503|Drug|lapatinib ditosylate|Given PO
45691407|NCT01868503|Radiation|radiation therapy|Undergo radiation therapy
45691408|NCT01868503|Other|laboratory biomarker analysis|Correlative studies
45367835|NCT03444844|Drug|Ga-68 P16-093 PET/CT scan|IV injection followed by PET/CT scanning
45367836|NCT00740441|Drug|AS1411|AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles
45691409|NCT05362708|Device|Clinical - Hypnosis with VR (VRH)|The VRH intervention will use the Aqua video session developed by Oncomfort during a port-a-cath procedure.
45484567|NCT04173975|Device|With knee exoskeleton|BELK is a wearable system that assists when and where the patient needs it intelligently through proper control of the system and optimized gait assistance techniques. Assisted-as-needed control allows to create a force field along a desired trajectory, proportionally applying torque only when patient deviates from the pre-programmed correct pattern. This force field control, by assisting only the segments that the patient need, produces a natural gait pattern, improving the rehabilitation process.
45484568|NCT03533452|Drug|Ropivacaine|Local anesthetic injection
45367837|NCT00740519|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
45484569|NCT03533452|Drug|Normal saline|Sham injection
45484570|NCT04321005|Procedure|arthroscopic rotator cuff reconstruction|arthroscopic rotator cuff reconstruction and assessment with evaluation and prediction of core outcomes
45484571|NCT03258346|Other|Inertial Load Cycling Training|Each session of training will require a total of 15 min with the total time actually exercising of only 60-120 sec. The first week will consist of performing 15 'sprints' on the ILE, beginning each sprint with 56 sec of rest. During week 2-5, subjects will rest 41 sec between sprints, completing 20 bouts. Finally, during weeks 6-10, subjects will take 26 s rest between sprints and complete 30 bouts).
45484572|NCT03258346|Dietary Supplement|Pomegranate Juice|Subjects will consume 8oz of pomegranate juice daily for duration of study.
45484573|NCT03258346|Dietary Supplement|Placebo|Subjects will consume 8oz of pomegranate juice daily, that has had the polyphenols removed.
45484574|NCT03488082|Behavioral|fMRI|saccadic adaptation (target presentations, with or without target jump) during fMRI exam
45484575|NCT04138797|Procedure|Electrophysiological exploration|Electrophysiological exploration is performed, as part of the routine care, after the Biosemi high density ECG, the same day or maximum 4 days later. It is performed in interventional rhythmology room, under fluoroscopic control. After local anesthesia, one or more introducers are placed in the femoral vein allowing the introduction of catheters. These catheters allow recording of the HV interval
45484576|NCT04138797|Device|ECG Biosemi|Non invasive ECG monitoring for HV measurement using high density Biosemi device. This device use 256 skin electrodes. At the same time and with the same system, a chest pressure sensor can record the patient's breathing movements.
45484577|NCT03258502|Drug|RV521|RV521 drug in capsules
46051987|NCT04877847|Device|Low-frequency therapeutic ultrasound (LOTUS)|Participants will wear low-frequency therapeutic ultrasound system for procedure. Device will be turned on per normal operating instructions.
46051988|NCT04877847|Device|LOTUS System with Ultrasound Disabled|Participants will wear low-frequency therapeutic ultrasound system for procedure. Device will be turned on and set to Control Setting.
45367838|NCT03397342|Device|CPAP machine|Use of CPAP machine during MRI
45484578|NCT03258502|Drug|Placebo|Placebo in capsules
45484579|NCT04359147|Drug|"Yohimbine"|Effects on neural correlates of decision-making under risk and selective attention to threat
45484580|NCT04359147|Drug|"Hydrocortisone"|Effects on neural correlates of decision-making under risk and selective attention to threat
45691410|NCT04602169|Procedure|PVI|PV re-isolation will be conducted according to the CLOSE-protocol. Point-by-point radiofrequency (RF) delivery will be performed aiming for a contiguous circle enclosing all PVs. RF will be delivered in a power-controlled mode (without ramping) using 35-40 Watt. The irrigation rate will be set at 30 ml/min. RF will be delivered until an ablation index (AI) of ≥400 is reached at the posterior wall and ≥550 at the anterior wall. In case of dislocation, a new RF application reaching the AI target will be applied. Maximal intertag distance between two neighboring lesions is 6 mm. In case of intra-esophageal temperature (T°) rise >38.5°C during posterior LA wall ablation, RF delivery will stopped at an AI of 300. In the absence of first pass isolation, touch-up ablation was applied until PVI. In case of reconnection during the waiting time or during the adenosine test, the site of reconnection will be located and treated with touch-up ablation until adenosine proof PVI is reached.
45846124|NCT02561754|Dietary Supplement|Enhanced Stop Light Diet (eSLD)|eSDL includes reduced energy portion controlled meals for 6 months, encouraged consumption of lower energy shakes and 35 fruits and vegetables per week.
45846125|NCT02561754|Dietary Supplement|Conventional Diet (CD)|CD is a nutritionally balanced, reduced energy, high volume, lower fat ( fat=20-30% energy) diet.
45484581|NCT04359147|Drug|"Yohimbine + Hydrocortisone"|Effects on neural correlates of decision-making under risk and selective attention to threat
46051989|NCT02825277|Device|Doppler|acquisition of 3D power Doppler of uteroplacental vascularization unit in 72h before delivery and morphological analysis for placenta
46051990|NCT02823639|Procedure|Transcranial direct current stimulation|
45484582|NCT04359147|Drug|"Placebo"|Effects on neural correlates of decision-making under risk and selective attention to threat
45484583|NCT03260764|Device|short term Multifocal Contact Lenses|wearing Multifocal Contact Lenses for one week
45484584|NCT03260764|Device|short term Bifocal Spectacles|wearing Bifocal Spectacles for one week
45484585|NCT03260764|Device|long term Multifocal Contact Lenses|wearing Multifocal Contact Lenses for one year
45484586|NCT03260764|Device|long term Bifocal Spectacles|wearing Bifocal Spectacles for one year
45484587|NCT01364454|Other|Eligible patients' paper-based reminder|Providing to the general practitioners every four months a list of their patients who are eligible for colorectal cancer screening but did not proceed yet and were not excluded for medical reason
45367839|NCT00740675|Other|Outpatient Medication Reconciliation|"The post-discharge medication reconciliation module has the following features:~Presents the (preadmission) ambulatory medication list and the hospital discharge medication list side-by-side, sorted by class, with all identical medications lined up next to each other and all differences in the two regimens highlighted.~Allows users to update the ambulatory medication list with a few keystrokes (i.e., to accept individual changes made during the hospitalization).~Allows reconciliation to be performed in full (e.g., for PCPs who are responsible for the entire medication list) or in part (e.g., for specialists)."
45484588|NCT03260374|Device|Electric compound action potential|The electrically evoked compound action potentials, which are closely related to the electrically evoked brainstem responses, would also show a similar correlation with the behavioral threshold. Determining threshold levels requires subjective responses to a series of sophisticated psychophysical percepts. This is often difficult for cochlear implant patients. However, the neural response telemetry system renders possible the measurement of the compound action potential threshold .
45484589|NCT03260374|Device|electric stapedial reflex threshold|electric stapedial reflex threshold measurements are performed using the same software platform and electrical stimulus utilized for fitting the cochlear implant . Thus, stimulus parameters, including pulse duration and repetition rate, can be identical to those used to obtain behavioral judgments for psychophysical levels
45691411|NCT04602169|Procedure|PVI + SVC|Patients in this group receive PVI according to the CLOSE protocol. In addition, they will receive an SVC isolation. The circular mapping catheter will be introduced in the superior vena cava to determine baseline electrical activity and to confirm definite entrance and exit block after ablation. Ablation will be performed proximally to the SVC/right atrial junction with the contact force-catheter using circular point-by-point radiofrequency delivery with a power setting of 35W, targeting an AI ≥400. High output (25 mA) pacing will be applied before each RF application to check for phrenic nerve stimulation. In areas of phrenic nerve capture ablation will be avoided even in case of incomplete isolation.
45846126|NCT02561754|Behavioral|Face-to-face (FTF)|FTF will meet with a health educator in person and will track progress using pen and paper records for both physical activity and diet.
46051991|NCT04240977|Behavioral|"HOBSCOTCH: Home-Based Self-Management and Cognitive Training Changes Lives"|Home-Based Self-Management and Cognitive Training Changes Lives (HOBSCOTCH) is a novel phone-based intervention that is enables acquisition of cognitive skills in line with problem solving therapy (PST), and is well suited for PWRE who have failed all other treatment alternatives. Sessions #2 through #7 focus on building patient's awareness for their own day-to-day memory problems, brainstorming, implementing and reviewing the outcomes of potential solutions they generate themselves using the PST framework. In each of these sessions, providers will assist patients in generating alternative solutions, in thinking through what the implementation of each strategy would entail, and in helping them review outcomes for adopted strategies to refine their approach for optimized adoption and generalization.
45367840|NCT03385486|Biological|TBX-3400|Autologous transfusion
45367841|NCT00736151|Drug|Ralfinamide|Oral tablets administered at rising doses of 80 - 320 mg/day
45367842|NCT00514917|Drug|Docetaxel|75 mg/m^2 intravenous infusion over 1 hour every 3 weeks up to 10 cycles.
45367843|NCT00514917|Drug|Leuprolide|22.5 mg injection subcutaneously every 12 weeks up to 18 months.
45367844|NCT00514917|Drug|Bicalutamide|50 mg tablet orally once daily for first 4 weeks of treatment.
45367845|NCT00711425|Device|OsseoSpeed™|OsseoSpeed™, all dimensions
45691412|NCT05204368|Drug|Combination of Imipenem/Cilastatin and XNW4107|Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for injection
45691413|NCT05204368|Drug|Meropenem|Meropenem 1g for injection
45691414|NCT03394846|Behavioral|Test of Existing MI Products|Three widely available MI products (GoNoodle, Take10, ABC for Fitness) will be tested by teachers in their classrooms. Teachers will participate in the study for four weeks (one baseline week, one week for each product).
45846127|NCT02561754|Behavioral|Technology (TECH)|TECH groups will receive the intervention using an iPad with the FaceTimeTM application for video meetings with a health educator and will track progress using the Lose it! application for both physical activity and diet.
45846128|NCT02561754|Other|iPad with FaceTime|TECH groups will receive the intervention using an iPad with the FaceTimeTM to the intervention field.
45846129|NCT02545998|Other|Telehealthcare|Telephone consultation plus e-mail with attached PAAP and video link
45846130|NCT02524938|Dietary Supplement|Chlorogenic Acid (CGA) enriched coffee|"Chlorogenic Acid (CGA) enriched coffee Phase I: CGA-enriched coffee provided with a CGA content of 70-90 mg/100g. Daily CGA intake of 400mg.~Phase II: recommendation for achieving a CGA-rich diet of at least 400mg/day (total polyphenol intake of at least 1g/day)"
45846131|NCT02524938|Dietary Supplement|Conventional coffee|Phase I: conventional coffee provided (low in CGA) Phase II: standard dietary advice
45846132|NCT02524626|Procedure|Sham stimulation|Sham stimulation
45846133|NCT02524626|Procedure|Vagus stimulation|Vagus stimulation
45691415|NCT05362240|Procedure|Four corner fusion|First , we inspected the radiocarpal joint for any arthritis before starting the technique , if there was no arthritis , we go on for the procedure . After scaphoid excision , we denuded the articulating surfaces between lunate , capitate , hamate and triquetrum . Then ,any lunate extension deformity was corrected . Then we use k.wires as a fixation method between the above mentioned carpal bones
45691416|NCT05362240|Procedure|three corner fusion without triquetrum excision|First , we inspected the radiocarpal joint for any arthritis before starting the technique , if there was no arthritis , we go on for the procedure . After scaphoid excision , we denude the articulating surfaces between lunate , capitate , hamate and don not include triquetrum. Then ,any lunate extension deformity was corrected . Then we use k.wires as a fixation method between the above mentioned carpal bones.
45691417|NCT02132572|Device|BIOCELL™ Textured 410 Implant|Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
45846134|NCT02481414|Biological|PepCan|50 μg peptide + 0.3 mL Candin® per dose administered intradermally in the extremities
45367846|NCT05740397|Other|Management of mean arterial pressure during cardiopulmonary by-pass in cardiac surgery interventions. The MAP will be mantained in the range of values of each study arm|"The patients enrolled to elective cardiac surgeries will be evaluated during a pre-operative outpatient visit and widely informed about the chance to participate in the study. When patients undergo to the elective surgery general anaesthesia is administered and CPB is installed. The nominal flow for each patient will be 2,4 l/min/m2.~To keep the MAP values around those corresponding to the randomized group, vasodilator (if MAP overcomes the assigned MAP value) or vasoconstrictor drugs will be used (if MAP value is lower than the assigned group). The following drugs will be used: nitroglicerine at incremental dose of 0,01 mcg/kg/min for a vasodilator effect and norepinephrine at incremental dose of 0,01 mcg/kg/min for a vasoconstrictor effect"
46051992|NCT04875507|Behavioral|Positive Psychology|This intervention aim to examine the effectiveness of PPI in reducing depressive symptoms, enhancing self-esteem, and promoting quality of life among Chinese children who are living in poverty. Participants in the experimental group will receive a 1.5 hour workshop on 4 positive psychology techniques, including (1) gratitude visit/letters, (2) 3 good things, (3) you at your best, and (4) using signature strengths. A booster intervention will be given at 1-week follow-up.
45367847|NCT01011699|Drug|nicotinamide|"Titration phase of nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks with stable dose of calcic carbonate;~Increase of nicotinamide dose of Nicobion 500mg (nicotinamide 500mg), up to 4 tablets daily, as follows:~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week)."
45367848|NCT01011699|Drug|sevelamer|"Titration phase with sevelamer (Renagel) with the aim of phosphatemia control before 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of sevelamer dose up to 12 tablets, as follows:~0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week)."
45846135|NCT02481414|Biological|Candin®|0.3 mL Candin® per dose administered intradermally in the extremities
45367849|NCT01011699|Drug|cinacalcet|"After 6 months of treatment, patient screening on PTH level:~For patients with PTH > 300pg/ml, introduction of cinacalcet by level of 30 mg every 3 weeks, up to 180mg daily (administered during the meal and before next dialysis) Cinacalcet increase will be stopped once PTH < 250 pg/ml. Calcic carbonate dose will be increase once calcemia will be < 2.25 mmol/l. If maximum tolerated dose is not sufficient to prevent hypocalcemia < 2.10 mmol/l calcium of dialysis bath wille be increased up to 1.75 mmol/l and calcic carbonate will be decreased.~A dose adjustment is possible with nicotinamide to obtain a phosphatemia between 1.10 and 1.60 mmol/l."
45367850|NCT00740909|Behavioral|Cognitive Behavioral Therapy|A therapy designed to help patients with response prevention skills.
45846136|NCT02420652|Drug|Aspirin|Given PO
45846137|NCT02420652|Other|Laboratory Biomarker Analysis|Correlative studies
45367851|NCT05740319|Other|FMT|FMT refers to transplanting healthy donor-derived microbiota to participants via oral capsule or injection of fecal suspension via nasojejunal tube.
45846138|NCT02420652|Drug|Metformin Hydrochloride|Given PO
45846139|NCT02420652|Other|Placebo|Given metformin hydrochloride placebo PO
45846140|NCT02420652|Other|Placebo|Given aspirin placebo PO
45846141|NCT02257242|Drug|Rituximab|375 mg/m2 I.V. on Day 1 of each cycle
45367852|NCT01011777|Drug|MDC|After the biopsy the MDC expansion process takes approximately 21 days after which cells are harvested and cryopreserved for future injection. The MDC product is stored in single use vials, with each vial containing approximately 2.6 x 10^7 total cells. The volume of each vial will be 1.3ml. This study uses a single dose of approximately 2.0 x 10^7 cells administered endoscopically into the external urethral sphincter in 12 injections of 0.1ml each. Six months post-initial MDC injection, group 1 participants with persistent bladder capacity less than 100cc and group 2 participants with persistent urinary incontinence as defined in eligibility criteria may undergo repeat injections of MDC at 6 month intervals for up to a total of 4 injections.
45367853|NCT00740987|Device|Intermittent pneumatic compression of the lower limbs|No Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
45484590|NCT03260374|Device|electric auditory brain stem response|For most implant recipients , even the first introduction of electric stimulation from a cochlear implant evokes activity in the auditory brainstem , which can be measured as clear electric auditory brain stem response waveforms . Therefore the electric auditory brain stem response test can be used in the functional evaluation of the auditory system between the time of initial implant activation and after chronic cochlear implant use
45484591|NCT04188093|Other|PACU discharge criteria and continuous monitoring on the ward|"PACU discharge criteria (modified aldrete score).~Continous monitoring of vital signs 96 postoperative hours"
45484592|NCT01369368|Drug|Combined use of azacitidine, valproic acid, hydroxurea and eventually donor leukocyte infusions.|Azacitidine 100 mg day 1-3 in each cycle Valproic acid, continuous therapy from day 1 All-trans retinoic acid 22.5 mg/m2 twice daily day 1-14 in each cycle Hydroxurea 500 mg initially eventually increased to 1 g daily. Eventually donor leukocyte infusions on day 10 from the second cycle.
45484593|NCT03258424|Drug|PTI-428|PTI-428 or placebo will be given QD for 14 days.
45846142|NCT02257242|Drug|Bendamustine|90 mg/m2 I.V. on Day 1 and 2 of each cycle
45367854|NCT04064645|Device|Measurement of respiratory rate with DUT and comparison with reference|"The subject will follow the paced breathing app, once a stable Respiration Rate at the natural rate (without the breathing app) is captured. The breathing pattern on the app will be set to begin near the normal Respiration Rate of the subject and continue to go down by five intervals until reaching the Respiration Rate of 5 bpm. After that, we will pick back up at the rate above the subject's normal Respiration Rate and continue upwards until reaching 50 bpm or as high as the subject can tolerate up to 50 bpm.~The respiratory rate will be monitored simultaneously with an EtCo2 (Reference) and the BORA BAND™ wristband monitoring system, Device Under Test. These data will be continuously recorded electronically. Additional study notes that describe conditions of the test as well as deviations, device issues and any adverse events will be recorded in written documentation."
45367855|NCT00736307|Procedure|Cultured limbal stem cells Transplantation|Transplantation of cultivated limbal epithelium on amniotic membrane
45484594|NCT03258424|Drug|Placebo|PTI-428 or placebo will be given QD for 14 days.
45484595|NCT01348581|Device|Marigen Wound Dressing|The dressing is changed at least twice a week, with no more than five days between dressing changes. It is extremely important that the dressings are changed sufficiently often. On highly exuding ulcers the three or four dressing changes per week may be necessary. Duration is four weeks.
45484596|NCT04103619|Device|AccuTite|Subjects will undergo treatment with AccuTite
45484597|NCT04103619|Device|AccuTite + Morpheus 8|Subjects will undergo treatment with AccuTite and Morpheus 8
45484598|NCT01369446|Device|Eeva System Study|The Eeva System will image embryos through cleavage and/or blastocyst stage.
45484599|NCT03258268|Device|Standard of Care with EASY DSS|"The EASY DSS is a software tool designed to process and analyze data to facilitate individualized treatment suggestions for type 2 diabetes patients.~Patients will receive standard of care with a board certified physician with EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
45846143|NCT02257242|Drug|Vincristine sulfate liposome injection|Dose per dose escalation protocol, I.V. on Day 2 of each cycle
45846144|NCT02176902|Behavioral|behavioral dietary intervention|Receive dietary counseling
45846145|NCT02176902|Behavioral|behavioral dietary intervention|Receive guidelines for low-fat diet
45846146|NCT02176902|Dietary Supplement|omega-3 fatty acid|Given PO
45846147|NCT02176902|Other|laboratory biomarker analysis|Correlative studies
45846148|NCT02037048|Drug|oxaliplatin|Given IV
45367856|NCT00504075|Biological|Gammaplex, intravenous immunoglobulin|"Dosage form: Gammaplex® is a sterile liquid of 5 % w/v normal immunoglobulin. Gammaplex® contains 5 g/100 mL of human normal immunoglobulin (i.e. 50 g/L, of which virtually 100% is IgG).~The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days. If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX."
45367857|NCT00741065|Procedure|Direct Epicardial Shock Wave Therapy|performed in adjunct to a standard coronary artery bypass grafting procedure Prior to aortic cross clamping direct epicardial shock wave therapy - applied directly to the myocardium
45367858|NCT00503997|Drug|oxaliplatin|"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."
45367859|NCT00503997|Drug|pemetrexed disodium|"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."
45367860|NCT00741143|Other|Fortification of wheat flour with NaFeEdta|NaFeEdta Fortified Wheat Flour (100g)provided as a lunch meal. Fortification level of 6mg Fe/100g/day/child for 7 months
45367861|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
45367862|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
45367863|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
45367864|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
45367865|NCT01011855|Device|GEHC IWS 4400 & Giraffe warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
45367866|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
45367867|NCT04063319|Other|High-fidelity simulation|The set up in the high-fidelity simulation intervention is a deteriorating patient scenario.
45367868|NCT00736463|Drug|Simvastatin|One arm of randomized crossover
45846149|NCT02037048|Drug|leucovorin calcium|Given IV
45846150|NCT02037048|Drug|fluorouracil|Given IV
45846151|NCT02037048|Procedure|therapeutic conventional surgery|Undergo therapeutic conventional surgery
45846152|NCT02037048|Radiation|radiation therapy|Undergo radiation therapy
45846153|NCT02037048|Drug|carboplatin|Given IV
45846154|NCT02037048|Drug|paclitaxel|Given IV
45846155|NCT02034630|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
45484600|NCT03258268|Other|Standard of Care without EASY DSS|"Patients will receive standard of care with a board certified physician without EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
45484601|NCT04098315|Other|REGISTER CREATION|Build a national registry of patients with HIV-1 infection and documented resistance to the 4 classes of antiretroviral drugs.
45846156|NCT02025036|Drug|Capecitabine(Aibin)|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total
45484602|NCT03257956|Device|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
45484603|NCT03257956|Device|reference group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
45691418|NCT01868035|Drug|tositumomab and iodine I-131 tositumomab|"Subjects received the following treatments of TST/I-131 TST by intravenous (IV) infusion:~Dosimetric Dose: 450 mg of TST infused over 1 hour immediately followed by 35 mg of TST labeled with 5 milliCuries (mCi) of I 131 infused over 30 minutes.~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 60 minutes, immediately followed by 35 mg of TST labeled with the subject-specific mCi activity of I 131 needed to deliver a total body dose of 75 centiGrays (cGy), infused over 30 minutes for subjects with a platelet count of 150,000/mm3. Subjects with platelet counts of 100,000 to 149,999/mm3 received 65 cGy, and obese subjects were dosed based upon 137% of their calculated lean body mass."
45691419|NCT05162482|Biological|BIBP (CNBG, Sinopharm) WIV|BIBP (CNBG, Sinopharm) WIV (Whole Inactivated Virus in a single dose, prefilled syringe with a storage temperature of 2-8°C)
45691420|NCT05162482|Biological|CanSinoBIO|CanSinoBIO (Viral Vector in a single dose, prefilled syringe with a storage temperature of 2-8°C)
45691421|NCT05162482|Biological|AstraZeneca ChAdOx|AstraZeneca ChAdOx (Viral Vector in a multi-dose vial consisting of 10 doses with a storage temperature of 2-8°C)
45367869|NCT00736463|Drug|Atorvastatin 80 mg|Second arm of randomized crossover
45367870|NCT00736541|Drug|N-acetylcysteine|The patients in the NAC group will receive a loading dose of 140 mg/kg IV of NAC over one hour at the start of the surgery. Thereafter, NAC will be repeated every 4 hours at a dose of 70 mg/kg IV, for a total of 13 doses
45367871|NCT00096265|Radiation|3-Dimensional Conformal Radiation Therapy|Patients undergo radiation therapy once daily for approximately 3 weeks
45367872|NCT00096265|Drug|Erlotinib Hydrochloride|Given orally
45484604|NCT01348659|Drug|7.2% NaCl/hydroxyethylstarch|250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) will be given into the venous reservoir of the cardiopulmonary bypass circuit after aortic declamping.
45367873|NCT00096265|Radiation|Stereotactic Radiosurgery|Patients undergo surgery after radiation therapy
45484605|NCT01348659|Drug|NaCl 0.9%|250 ml of NaCl 0.9% will be given into the venous reservoir of the CPB circuit after aortic declamping.
45846157|NCT02025036|Drug|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.
45846158|NCT02025036|Radiation|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
45846159|NCT02002572|Other|Magnetic Resonance Imaging (MRI), Surface scan, Motion capture, Digital Image Correlation|
45846160|NCT01943916|Device|Imagio OA/US (US and OA/US)|opto-acoustic plus gray scale ultrasound
45367874|NCT00096265|Drug|Temozolomide|Given orally
45484606|NCT01370070|Drug|MK-2206|200mg weekly repeated q 28 days
45484607|NCT03252574|Other|A|AIR+ Smart Mask Only
45846161|NCT01943916|Device|Imagio gray scale ultrasound|gray scale ultrasound alone
45846162|NCT01921686|Other|Sample collection and Questionnaire|This is an observational biospecimen collection and questionnaire study. The subjects will be asked to complete a symptom questionnaire at screening visit. In addition, 3 esophageal biopsy samples will be taken to conduct laboratory analyses.
45484608|NCT03252574|Other|B|AIR+ Smart Mask with micro-ventilator
45846163|NCT01825356|Procedure|Dorsal Cheilectomy without Amniotic Membrane Tissue Implantation|
45846164|NCT01825356|Procedure|Dorsal Cheilectomy with Amniotic Membrane Tissue Implantation|
45846165|NCT01768338|Drug|Ofatumumab combined with SB-485232|Ofatumumab with escalating doses of SB-485232
45846166|NCT01659606|Biological|alemtuzumab|Conditioning: alemtuzumab 0.2 mg/kg/dose IV/SC x 5 doses
45367875|NCT01082809|Drug|Sunitinib|Sunitinib 37.5 mg orally once daily continuously, comprising a 4-week cycle
45691422|NCT04414969|Drug|Anti-PD-1 antibody+Peg-Asparaginase+Chidamide|Anti-PD-1 antibody 200mg ivdrip d1, PEG-ASP 2500U/m2 im d1, Chidamide, 30mg, po, on d1，d5，d8，d12，d15，d19. The regimen was repeated every 3 weeks for 4 cycles followed by involved-field radiotherapy after got CR and PR (patients with efficacy of SD and PD withdrew from the study). Intensity-modulated radiation treatment was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 54-56 Gy. During the radiotherapy, the anti-PD-1 antibody is administrated (200mg ivdrip, every 3 weeks) for 2 cycles. After the completion of radiotherapy, the subsequent 2 cycles of anti-PD-1 antibody + Peg-Asparaginase + Chidamide are administrated. After the end of all the above induction treatments , anti-PD-1 antibody (200mg ivdrip, every 3 weeks for up to 9 cycles) is given as maintenance therapy for 6 months (the total cycles of anti-PD-1 antibody is 17）.
45846167|NCT01659606|Drug|Fludarabine|fludarabine 30 mg/m2/dose IV x 6 doses
45846168|NCT01659606|Drug|Cyclosporins|
45846169|NCT01659606|Drug|Mycophenolate mofetil|
45367876|NCT01078987|Procedure|Plasmapheresis|A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses
45367877|NCT01080469|Drug|Tacrolimus 1 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
45484609|NCT04847310|Other|Group brief transdiagnostic cognitive-behavioral therapy|An adaptation of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) (Barlow et al., 2015) and the IAPT programme (Clark, 2018). It has been developed by Cano-Vindel (González-Blanch et al., 2018) and consists in seven 90-minute sessions, provided by a non-assessor clinical psychologist in 12-16 weeks, with 8-10 participants per group. Sessions are weekly or biweekly, reducing their frequency as the intervention advances. The activities and homework proposed are supported with materials such as theory documents, a CD for progressive muscle relaxation, self-recording sheets, and a therapy web (www.desordenesemocionales.es).
45846170|NCT01659606|Drug|Tacrolimus|
45846171|NCT01564368|Procedure|diffusion-weighted magnetic resonance imaging|diffusion-weighted magnetic resonance imaging examination and subsequent radiologist interpretation
45846172|NCT01345344|Behavioral|Cognitive Behavioral Therapy|Practicing certain cognitive and behavioral pain self-management strategies such as relaxation and changing negative thoughts about pain.
45846173|NCT01345344|Behavioral|Disease Education|Providing information about fibromyalgia, including its potential causes and management approaches.
45846174|NCT00819546|Drug|RAD001|Participants will receive RAD001 on day 1 at the dose specified then again on days 8-28 for the first cycle. For all subsequent cycles RAD001 will be taken once daily.
45367878|NCT01079065|Drug|Famotidine|Tablets
45367879|NCT01079221|Behavioral|High intensity knee-extensor training|High intensity aerobic knee-extensor exercise training, 4x 3 minutes interval training at < 90 % of peak power, 3 days/week for 6 weeks
45367880|NCT00711191|Biological|monoclonal antibody|CP-870,893 intravenous administration [IV] on day 3 of 4-week cycles
45367881|NCT00711191|Drug|chemotherapy|gemcitabine 1000 mg/m^2 intravenous administration [IV] q week [wk]x3 of 4-week cycles
45846175|NCT00819546|Drug|PKC412|50mg orally twice a day on days 2-28 for the first cycle. For all subsequent cycles 50mg of PKC412 will be taken orally twice daily.
45846176|NCT00596154|Other|Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide|"The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1.~On day 2 you will be admitted to the hospital and will receive 3 other drugs:~Methotrexate will be given by vein over 2 to 3 hours only on day 2. Vincristine will be given as a single injection over a few minutes only on day 2.~Procarbazine is a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine is only given every other cycle."
45846177|NCT00281658|Drug|Lapatinib (GW572016) oral tablets|1500 mg oral daily continuously
45367882|NCT00741221|Drug|Pemetrexed|Pemetrexed (IV) 500 mg/m2 on day 1 every 3 weeks for 6 cycles
45367883|NCT00741221|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles After the end of the 6 cycles Bevacizumab will be administered alone at the dose of 15 mgr/Kgr (IV) every 3 weeks until disease progression
45367884|NCT00736619|Other|Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®)|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity-modulated radiation therapy) administered concurrently with cetuximab (400 mg/m2 intravenous loading dose one week prior to radiation therapy, followed by 250 mg/m2 weekly intravenous infusions). To explore different dose levels of nanoparticle albumin-bound paclitaxel (Abraxane®) given intravenously weekly with the standard regimen of weekly cetuximab + daily radiation therapy.~The total number of planned cetuximab infusions is 8 (loading dose, plus 7 weekly infusions concurrent with radiation therapy). The total number of planned albumin-bound paclitaxel infusions is 7 (all concurrent with radiotherapy). Five dose levels of weekly intravenous (IV) albumin-bound paclitaxel will be explored."
45846178|NCT00281658|Drug|Paclitaxel infusion|Paclitaxel 80 mg/m2 every 3 weeks, 4th week rest for minimum 6 months
45846179|NCT00281658|Drug|Placebo|Paclitaxel Matching Placebo
45367885|NCT04557761|Device|microMend®|microMend® is a novel wound closure device that consists of arrays of tiny staples, known as Microstaples, which are attached to a backing material that is the size and shape of a butterfly closure. The Microstaples enable secure attachment of the device to the skin, allowing for the safe closure of wounds associated with surgery and traumatic injuries, such as lacerations. microMend is listed with the FDA and is available for sale in the United States.
45846180|NCT02417376|Device|piezoelectric ultrasonic scaler (frequency of 28-36 KHz)|Periodontal treatment in the form of scaling and root planing (SRP) is provided to the patients assigned to the experimental group, after baseline examination. Scaling is performed using piezoelectric ultrasonic scaler (frequency of 28-36 KHz) and root planing is performed using area specific Gracey curettes (set of 7 instruments number #1-14). SRP is completed in two appointments of 45 min to 1 hour, within 24 hours period.
45846181|NCT02417376|Device|Gracey curettes|set of 7 instruments number #1-14
45367886|NCT04557761|Device|Closure with Sutures|The Subject's laceration will be closed with sutures per regular institutional policies and procedures.
45367887|NCT00741377|Drug|BHQ880|
45367888|NCT00741377|Drug|Zoledronic acid|
45367889|NCT05742269|Diagnostic Test|89Zr-atezolizumab PET/CT|All patients undergo a 89Zr-atezolizumab PET/CT. Allocation to chemotherapy + atezolizumab in case of a PD-L1 positive tumor (on IHC and/or PET)
45367890|NCT02567903|Device|Thigh Tourniquet|Knee arthroscopy with the use of a thigh tourniquet that is inflated to 100-150 mmHg above systolic blood pressure.
45846182|NCT02417532|Device|Rehabilitation using REX|Exercises of wheelchair dependent subjects using REX
45846183|NCT02417844|Drug|tamsulosin (Astellas)|
45846184|NCT02417844|Drug|Tamsulosin HCL|
45846185|NCT02418234|Other|mutation detection|
45846186|NCT02418234|Other|ARMS and ddPCR|
45846187|NCT02418234|Genetic|ctDNA analysis|
46051993|NCT04243161|Other|Experimental|"The study variables PIM, PEM, FVC, PEF and EQ-5D quality of life questionnaire will be measured on the first day when patient incorporated into the seating position in the patient's bed. Reassessments will be performed every two week till patient discharge from hospital. After that patient will be assessed after 4 month and 1 year after the SCI.~SCIM III will be administered at discharge, 4 month later and 1 year after the injury.~Common clinical practice (pulmonary expansion exercises,drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 50% load after MIP measurement.~The intensity of the treatment will be 50% of the PIM and PEM value (increasing the load in 2 cmH2O weekly). Three sets of 10 reps will be performed, with one total of 30 repetitions, resting 1 minute between each series.~The sessions will be held once per day, from monday to friday, during the entire hospital admission."
45367891|NCT02567903|Procedure|Knee arthroscopy|Knee arthroscopy
45367892|NCT00706511|Device|CPAP|CPAP (continuous positive airway pressure) treatment at home for 6 weeks
45367893|NCT00448864|Drug|Ecallantide|
45367894|NCT00448864|Drug|Placebo|
45367895|NCT00567398|Drug|Dianeal|Dianeal 1.5% Dextrose (1.38% Glucose), 2.5% Dextrose (2.27% Glucose), 4.25% Dextrose (3.86% Glucose)
45367896|NCT00567398|Drug|Physioneal|Physioneal 40 or Physioneal 35
45367897|NCT00567398|Drug|Extraneal|Extraneal - 7.5% Icodextrin
45367898|NCT00567398|Drug|Nutrineal|Nutrineal - 1.1% Amino Acids
45846188|NCT02418312|Drug|histamine-2 receptor antagonist|famotidine 40 mg qd plus thienopyridine
45846189|NCT02418312|Drug|Placebo|placebo plus thienopyridine
45846190|NCT02418546|Behavioral|In-Person Nutritional Counseling by a Registered Dietitian|
45846191|NCT02418546|Behavioral|Nutritional counseling using an e-Health Application|
45846192|NCT02421354|Other|Laboratory Biomarker Analysis|Correlative studies
45846193|NCT02421354|Biological|Nivolumab|Given IV
45846194|NCT02421354|Other|Quality-of-Life Assessment|Ancillary studies
45846195|NCT02422290|Drug|Ketamine|Single infusion of IV Ketamine, 0.5mg/kg
45846196|NCT02425956|Device|GE Optima/Discovery® MRI data of the liver|GE Optima 1.5T®/Discovery 3.0T® MRI data scanning data of the liver and surrounding tissues will be acquired using both field strengths for GE IDEAL IQ® and single field strength with FerriScan® (Resondence Health) Specialized Reconstruction Service, according instructions provided by manufacturer
45846197|NCT02427672|Device|Transcranial direct current stimulation|
45367899|NCT02538848|Drug|HTD4010|injectable solution
45846198|NCT02427672|Device|Sham transcranial direct current stimulation|
45367900|NCT00448708|Device|Vascular Wrap Paclitaxel-Eluting Mesh|0.9 µg/mm^2 paclitaxel
45846199|NCT02427750|Biological|Aggripal®|TIV
45846200|NCT02430090|Drug|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
45846201|NCT02430090|Drug|Fentanyl|this used in intratechal area and for spinal anesthesia in ceserean section
45846202|NCT02430090|Drug|Sufentanil|this used in intratechal area and for spinal anesthesia in ceserean section
45846203|NCT02430090|Drug|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
45846204|NCT02430090|Drug|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
45484610|NCT04847310|Other|Individual brief transdiagnostic cognitive-behavioral therapy|An adaption of the group therapy, with the same phases. However, since it is an individual intervention, it is more flexible than group one and its contents and duration can be personalized. This intervention consists of a minimum of 6 and a maximum of 8 sessions of 30-60 minutes, provided by a clinical psychologist not involved in the assessments.
45846205|NCT02431572|Other|PBR PET|
45846206|NCT02431572|Biological|Cancer Immunotherapy|Subjects who are to be treated with immunotherapy for glioblastoma or melanoma brain metastases will be eligible for 2 of the 3 arms.
45691423|NCT04817098|Behavioral|Journey of Life|The concept underlying the JoL intervention is that caregivers and community members can support each other and their children through reflection, dialogue, and action. JoL addresses children's and adolescents' ecologies by working with caregivers, educators, and community members to understand the importance of their support in protecting children.
45691424|NCT01609933|Drug|ABT-450/r|ABT-450 (tablets) dosed with ritonavir (capsules or tablets)
45846207|NCT02431572|Radiation|Radiation and chemotherapy|Subjects with glioblastoma will receive or will have received treatment with chemotherapy and radiation per the standard of care.
45367901|NCT00448708|Device|Lifespan® ePTFE Vascular Graft|vascular graft
45367902|NCT00448708|Device|Lifespan® ePTFE Vascular Graft|vascular graft
45846208|NCT02431650|Drug|OZ439|
45846209|NCT02431650|Drug|Primaquine|
45846210|NCT02435706|Procedure|Flapless immediate implant placement|Experimental group: No elevation of flap prior to immediate implant placement
45846211|NCT02435706|Procedure|Flap assisted immediate implant placement|Control group: Flap will be elevated prior to immediate implant placement
45846212|NCT02435706|Device|Implant and temporary crown|Both groups receive this intervention
45846213|NCT02437344|Drug|CI-581aa|92 minute infusion of CI-581aa
45367903|NCT00929396|Biological|50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)|o,5 mL suspension for injection x 2 with 2 months interval
45367904|NCT00929396|Biological|50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)|o,5 mL suspension for injection x 2 with 2 months interval
45367905|NCT00929552|Dietary Supplement|Dietary oils (fish, vegetable oil)|6g pr day.
45367906|NCT00924872|Other|wheelchair skills training|Five 30-minute training sessions, at a target frequency of 3-5 sessions per week, aimed at improving their power wheelchair skills.
45691425|NCT01609933|Drug|ABT-267|ABT-267 (tablets)
45691426|NCT01609933|Drug|pegylated interferon alpha-2a (pegIFN)|pegIFN alpha-2a (syringe)
45846214|NCT02437344|Drug|Naltrexone titration and XR-NTX initiation|participants will be provided a titration of naltrexone that culminates in the injection of XR-NTX
45846215|NCT02440308|Drug|68Ga-DOTA-Bombesin|"68Ga-DOTA-Bombesin is a gallium-68-labeled gastrin-releasing peptide receptor (GRPr) antagonist. DOTA is [4,7,10-Tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]-acetyl.~68Ga-DOTA-Bombesin is administered intravenously (IV)"
45846216|NCT02440308|Procedure|Magnetic Resonance Imaging (MRI) scan|
45691427|NCT01609933|Drug|Ribavirin (RBV)|Ribavirin (tablets)
45691428|NCT03255928|Diagnostic Test|PAS assay, TGT|Evaluation of platelet function
45846217|NCT02440308|Procedure|Positron Emission Tomography (PET) scan|
45846218|NCT02444988|Other|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
45846219|NCT02444988|Other|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
45846220|NCT02446314|Dietary Supplement|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
45846221|NCT02446314|Dietary Supplement|Wild Blueberry Powder - 450mg|Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine @ 2.5 mg L-Glutathione 250 mg placebo powder, once daily, in a 2-hard capsule regimen
45846222|NCT02446314|Dietary Supplement|Wild Blueberry Powder - 900 mg|Formulation containing 450 mg wild blueberry powder = 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
45846223|NCT02446314|Dietary Supplement|Wild Blueberry extract 100mg|Formulation containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
45846224|NCT02448654|Drug|Tolcapone|Tolcapone will be compared to sugar pill
45846225|NCT02448654|Drug|Sugar Pill|The sugar pill (placebo) will be compared to tolcapone
45846226|NCT02449356|Device|prone position endotracheal tube(PPT)|some special kind of endotracheal tube,including traditional air tube ,fixed device, fixed rope, and two through holes
45846227|NCT02451150|Drug|Azilsartan|Azilsartan tablets
45846228|NCT02452866|Drug|SYM-1219|Administered with 4 ounces of unsweetened applesauce, and 8 ounces of water
45846229|NCT02452944|Device|nerve stimulator (stimuplex HNS12)|whether using the nerve stimulator or not when the investigators do the ultrasound-guided obturator nerve block
45367907|NCT00925028|Drug|Warfarin|Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. In the second office visit patients will be told to which group they were randomized and if they are in group A they will then be instructed on how to use the warfarin adjustment nomograms provided. After four months the groups will switch to the alternate management strategy. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
45846230|NCT02452944|Device|ultrasound|we did obturator nerve block with ultrasound guided method for searching the fascias where the anterior and posterior branches of obturator nerve run.
45846231|NCT02460666|Behavioral|Tai-Chi-Chih (TCC)|
45846232|NCT02460666|Behavioral|Health Education and Wellness Classes (HEW)|
45846233|NCT02461992|Drug|Intravenous infusions of Xyntha|A single dose 50IU/kg dose of Xyntha administered by intravenous infusion within 10 minutes on Day 1
45691429|NCT03241420|Device|lung clearance index (LCI)|Determine the utility and sensitivity of the lung clearance index (LCI) technique as a marker of lung injury/small airways disease in adults with chronic lung conditions compared to health adults, adjusting for age, sex, and smoking status.
45691430|NCT01843777|Behavioral|Standard-of-Care|the standard of care in audiologic practice
45691431|NCT01843777|Behavioral|Treatment|motivational interviewing
45691432|NCT03166384|Device|electrosurgical bipolar sealing devices|Electrosurgical bipolar sealing devices use the body's own collagen and elastin to create a permanent fusion zone through a combination of pressure and energy. Previous studies suggested that surgery using these devices lead to significant decrease of seroma formation, however their advantages are not well established in case of mastectomy for breast cancer.
45846234|NCT02462070|Drug|IDP-118 Lotion|Lotion
45846235|NCT02462070|Drug|IDP-118 Vehicle Lotion|Lotion
45846236|NCT02462148|Drug|Dexamethasone|Used in nerve block mixture
45846237|NCT02462148|Drug|Bupivacaine|Used in nerve block mixture
45846238|NCT02462148|Drug|Epinephrine|Used in nerve block mixture
45367908|NCT00925028|Drug|Warfarin|Patients of group B will continue to be managed by their physician. This time those in group B will be instructed on how to use the nomograms during an office visit. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
45367909|NCT00905138|Drug|GLPG0259|single ascending doses, oral solution
45691433|NCT03166384|Procedure|conventional suture and tie|the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.
45691434|NCT05361772|Drug|colchicine|colchicine 0.5mg per day for 24 months
45691435|NCT05361772|Drug|Placebo|placebo 0.5mg per day for 24 months
45691436|NCT05360368|Drug|HLX07|A Recombinant Humanized Anti-EGFR Monoclonal Antibody, HLX07 will be administered as a single intravenous (IV) infusion on Day 1 in each 3-week cycle
45691437|NCT05355376|Procedure|Bundle of measures to decreased SSI|
45691438|NCT04810702|Other|no intervention|no intervention
45691439|NCT01842607|Biological|Mepolizumab|Mepolizumab (a fully humanised IgG antibody) 100 mg injected SC once every 4 weeks for 12 months. Mepolizumab will be provided as a lyophilised cake in sterile vials
45846239|NCT02462148|Procedure|Saphenous Peripheral Nerve Block|Peripheral nerve block.
45846240|NCT02462382|Procedure|Arthroscopic Rotator Cuff Repair|During arthroscopic rotator cuff surgery, the surgeon inserts a small camera, called an arthroscope, into your shoulder joint. The camera displays pictures on a television screen, and your surgeon uses these images to guide miniature surgical instruments to repair the torn ligament.
45846241|NCT02462382|Drug|Ropivacaine|The study group will receive a pump with study drug attached to a catheter placed into the shoulder area by the anesthesiologist.
45846242|NCT02462382|Drug|Saline|The control group will receive a pump with saine attached to a catheter placed into the shoulder area by the anesthesiologist.
45691440|NCT03031210|Drug|Amoxicillin|(90 mg/kg/day) twice daily
45847936|NCT03095976|Procedure|Amnion-Chorion allograft membrane on the root surface of periodontally diseased site.|Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects
45847937|NCT03096444|Drug|Ketamine Hydrochloride|2g of topical 10% Ketamine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
45847938|NCT03096444|Drug|Amitriptyline Hydrochloride|2g of topical 5% Amitriptyline will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
45846243|NCT02464176|Drug|Dexamethasone|A lumbar plexus nerve block will be performed for patients undergoing hip arthroplasty. A total of 25cc's of 0.25% bupivacaine with 1:400,000 epinephrine will be administered for postoperative analgesia. Surgical anesthesia will be provided either by an intrathecal spinal block or general anesthesia. Successful blockade will be assumed if the patient has a decrease or loss of pinprick sensation in the femoral nerve distribution, which innervates the anterior thigh. If no evidence of blockade is present, testing will occur again at 30 minutes post block. Testing will be performed with a 25 gauge Whitacre needle and once present the area of testing will be marked with a surgical marking pen so that repeat sensory testing can be undertaken at that same site over the course of the study. The subjects will then receive dexamethasone (4 or 8 mg) or placebo (saline) based on arm placement.
45367910|NCT00905138|Drug|placebo|single dose, oral solution
45367911|NCT00905138|Drug|GLPG0259|multiple dose, oral solution, 5 days
45484611|NCT04847310|Other|Treatment as usual|Participants in this group will be provided the common primary care treatment by the GP, in a face-to-face consultation that seldom exceeds 10 minutes. TAU usually consists in pharmacological treatment prescribed by the GP, however, it might also consist in practical advice or even non-treatment (Watts et al., 2015). The first consultation will count as part of the recruitment process and, if the patient accepts to participate in the trial, no therapeutic help will be provided to them until they are allocated. Once in the TAU intervention, if the practitioner recommended any psychological treatment as part of it (e.g., referral to specialized care), the participant would be excluded to avoid contamination between clusters. TAU has not a specific amount of sessions; it will finish when the GP considers the patient is recovered.
45484612|NCT03260530|Other|Locomotor evaluation|collection of parameters associated with walking and balance in patients with their usual prosthesis and then equipped with the new prosthesis
45484613|NCT03260530|Other|Questionnaires|Houghton's scale, PPA-LCI, ABC, QEP, SF-12, SAT-PRO, ESAT
45846244|NCT02464176|Drug|Bupivacaine|Bupivacaine will be used in lumbar plexus nerve block mixture.
45484614|NCT01348737|Drug|AZD3839|Single Oral Dose
45846245|NCT02464176|Drug|Epinephrine|Epinephrine will be used in lumbar plexus nerve block mixture.
45691441|NCT04794478|Device|Dexcom Continuous Glucose Monitoring System|Dexcom Continuous Glucose Monitoring System
45484615|NCT01348737|Drug|AZD3839 Placebo|Single Oral Dose
45484616|NCT02455570|Other|No intervention|No intervention
45846246|NCT02464176|Procedure|Lumbar Plexus Nerve Block|This is the procedure that will be performed.
45484617|NCT04074759|Biological|FPT155|A soluble CD80 fusion protein
45484618|NCT04074759|Biological|pembrolizumab|An anti-PD1 antibody
45484619|NCT01369602|Drug|PF-04991532|single dose 300-mg
45367912|NCT00905138|Drug|placebo|oral solution, 5 days
45484620|NCT01369602|Drug|PF-04991532|single dose 300-mg
45484621|NCT01369602|Drug|PF-04991532|single dose 300-mg
45691442|NCT04760938|Behavioral|Outdoor Behavioral Healthcare (OBH)|Participants in this intervention will participate in one of 7 programs that have been accredited by the Outdoor Behavioral Healthcare Council that specializes in 13-17 year old adolescents experiencing behavioral healthcare issues. Each program works in a unique wilderness setting in various United States National Forests and Parks (e.g., Washington, Oregon, New Mexico, Wisconsin, Utah). The average length of stay in an OBH wilderness program is 90 days, which is a total standard care time of 1,056 hours. All of the OBH programs have been accredited by the Association for Experiential Education Accreditation for Outdoor Behavioral Healthcare programs.
45846247|NCT02464176|Drug|Saline|Patients randomized to the placebo group will receive normal saline intravenously.
45367913|NCT00905216|Drug|heparin sodium - Bergamo|5.000 UI/mL
45367914|NCT00905216|Drug|heparin sodium - APP|5.000 USP
45367915|NCT00929630|Procedure|transsphincteric Seton positioning|A cutting seton is applied into the fistula tract
45367916|NCT00929630|Procedure|glue (Tissucol) treatment|After preparation of the fistula, a quantity of biological glue (Tissucol) is injected into the fistula tract
45367917|NCT00929630|Procedure|Fistula closing with biological glue|After cleaning and disinfection of the fistula tract, abot 1-2 ml of Tissucol (biological Glue) is inserted into the fistula tract to close it
45367918|NCT00929630|Procedure|Seton positioning into the fistula tract|Under spinal anesthesia a Seton is positioned into the fistula tract.
45367919|NCT00905294|Other|Blood draws|Observational: blood draws only
45484622|NCT01369602|Drug|PF-04991532|single dose 300-mg
45484623|NCT02455492|Other|stroke or myocardial infarction or pneumonia|There are three main exposure groups with exposure defined as a binary variable (yes/no): Stroke in the six months prior to surgery; Myocardial infarction in the six months prior to surgery; Pneumonia in the six months prior to surgery
45484624|NCT01364532|Procedure|Transulnar arterial access|Transulnar arterial access in coronary angiography, ad-hoc or elective PCI
45367920|NCT00925106|Drug|Celebrex capsule|Single dose 200 mg commercial Celebrex capsule
45367921|NCT00925106|Drug|Test formulation D1|Single dose 150 mg celecoxib as formulation D1
45367922|NCT00925106|Drug|Test formulation D2|Single dose 150 mg celecoxib as formulation D2
45367923|NCT00925106|Drug|Test formulation D3|Single dose 150 mg celecoxib as formulation D3
45367924|NCT02538692|Drug|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang is a traditional Chinese formula. It is used for diarrhea management.
45367925|NCT02538692|Drug|Placebo|The placebo is the same as Tong-Xie-Yao-Fang in appearance.
45367926|NCT00706355|Drug|PF-04217903|Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
45367927|NCT00905528|Drug|Telmisartan 80 mg/d|
45846248|NCT02466126|Behavioral|bCBT|"The bCBT intervention uses 6 active-treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to solidify changes. All participants receive an initial (core) session. In this session, participants work with their study clinician to set goals that are not restricted to emotional health (e.g., depression) but may also address physical health concerns (e.g., diet, exercise, managing a chronic condition). Following the core session, clinicians provide participants with a series of module choices, from which they select skills that match their most pressing needs. Each module focuses on a CBT technique (e.g., behavioral activation, changing thoughts), introduced and customized to the patient's immediate goals, regardless of the focus (physical or mental health)."
45846249|NCT02467842|Biological|NBP607-QIV|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria
45484625|NCT01364532|Procedure|Transradial arterial access|Transradial arterial access for coronary angiography,ad-hoc or elective PCI
45846250|NCT02467842|Biological|NBP607-Y|Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata
45484626|NCT03260608|Behavioral|Telesupport|In the intervention will be carried out eight weekly phone calls of psychoeducation and support on the disease of the relatives approaching different themes.
45691443|NCT04760938|Behavioral|Cognitive Behavioral Therapy (CBT)|The 12-week treatment period will consist of 15 90-minute sessions that will be administered individually. Homework (including reading assignments) are given to encourage your child to practice the techniques learned during the weekly sessions. The total standard of care time for CBT is 22.5 hours of direct treatment hours not including time spent on homework over these twelve weeks. Those therapists that are selected to deliver treatment for the CBT group will be certified by a nationally recognized CBT organization and licensed to work as a therapist in the state where they are providing treatment. Therapy will be delivered in an outpatient setting or through Telehealth.
45691444|NCT01803607|Drug|odanacatib|odanacatib 50 mg oral tablet
45484627|NCT01345149|Behavioral|Diet + Exercise|"Diet: Intensive counselling about calorie restriction to reduce weight gain by dietician.~Exercise: Individual counselling"
45484628|NCT03252496|Procedure|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
45691445|NCT01803607|Other|placebo to odanacatib|dose-matched placebo to odanacatib, oral tablet
45846251|NCT02467842|Biological|NBP607-V|Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria
45367928|NCT00905528|Drug|Ramipril 10 mg/d|
45367929|NCT00925262|Behavioral|Cognitive Processing Therapy|an adaptation of cognitive behavioral therapy used to address mental health effects of trauma exposure
45367930|NCT00925262|Behavioral|Behavioral Activation|form of counseling intervention to promote positive behaviors and reduce negative behaviors as a means of reducing depression symptomatology and severity
45367931|NCT00925262|Behavioral|nonspecific counseling|nonspecific counseling interventions useful for a broad range of mental health and psychosocial problems.
45367932|NCT04063553|Other|Volunteers Service|"Subjects in the intervention group will receive standard physiotherapy care and an additional volunteers session once a day for at least 3 times during their stay in the hospital. The volunteer will set up the TKR exercise video for the subjects, then supervise or guide the subjects with the exercises.~All volunteers are recruited from TTSH volunteers pool managed by Center of Health Activation (CHA). TKR volunteers are trained by the study team, including a formal classroom session and a practical and role play session. After the training, volunteers need to pass 3 assessment by the physiotherapists in order to attend to patients independently by themselves. Volunteers who are bilingual will attend to the subject alone, or else those who can only converse in Chinese/ English will pair up with another volunteer who knows another language to make sure there is no communication barrier between volunteers and patients."
45367933|NCT04063553|Other|Exercise brochure|. The control group subjects will receive only standard physiotherapy care and they will be instructed to perform 1 set of exercises daily following a brochure given. The exercises in the brochure and exercises taught by the volunteers are the same. The video and brochure are available in both English and Chinese version.
45484629|NCT03252496|Drug|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
45484630|NCT03252496|Drug|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
45484631|NCT03252496|Procedure|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
45484632|NCT03252496|Radiation|Ultrasound Assessment of the Inferior Vena Cava|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region
45484633|NCT03252496|Drug|250 mL Colloid over 5 minutes|6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
45484634|NCT03252496|Drug|250 mL Crystalloid over 5 minutes|Ringer acetate 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
45484635|NCT03252496|Drug|500 mL Crystalloid over 55 minutes|Ringer acetate 500 mL will be administered over 55 minutes following colloid or crystalloid administration
45691446|NCT02958514|Device|intense pulsed light|Intense pulse light (IPL) has been used in dermatology practices for several years as a treatment for rosacea and acne.IPL uses Xenon flashlamp to emit wavelengths of light from 400 to 1200nm. When placed on the light, a filter restricts the wavelength to the visible light range of *500nm.In 2007-2008, an IPL treatment technology-the Diamond Q4 by DermaMed Solutions-was specifically configured to our specifications with the goal of stimulating secretion of normal meibum via skin treatment effects on the meibomian glands. It was discovered that dry eye patients are better positioned for gland expression, as IPL seems to liquefy the abnormal viscous meibum and dilate the glands.
45691447|NCT02958514|Drug|Tobramycin and Dexamethasone Ophthalmic Ointment|
45691448|NCT04388722|Device|Pulse CO-Oximeter Sensor|Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb) and pleth variability index (PVi).
46051994|NCT04243161|Other|Control|"The study variables PIM, PEM, FVC, PEF and EQ-5D quality of life questionnaire will be measured on the first day when patient incorporated into the seating position in the patient's bed. Reassessments will be performed every two week till patient discharge from hospital. After that patient will be assessed after 4 month and 1 year after the SCI.~SCIM III will be administered at discharge, 4 month later and 1 year after the injury.~Common clinical practice (pulmonary expansion exercises,drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 30% load after MIP measurement.~The intensity of the treatment will be 30% of the PIM value (increasing the load in 2 cmH2O weekly). Three sets of 10 reps will be performed, with one total of 30 repetitions, resting 1 minute between each series.~The sessions will be held once per day, from monday to friday, during the entire hospital admission."
45367934|NCT00925340|Behavioral|Family Check Up|The Family Check-Up provides a thorough assessment of individual family strengths and weaknesses and utilizes principles of motivational interviewing to encourage families to change.
45367935|NCT00925340|Behavioral|Psychoeducation|Psychoeducation regarding teen alcohol and drug use in general, along with ways parents can help their children stay safe from using alcohol or drugs.
45367936|NCT00736697|Drug|moxidectin|
45484636|NCT03252496|Drug|250 mL Colloid over 60 minutes|After 60 minutes of intrathecal injection, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 60 minutes
45484637|NCT03252496|Drug|250 mL Crystalloid over 60 minutes|After 60 minutes of intrathecal injection, Ringer acetate 250 mL will be administered over 60 minutes
45484638|NCT03252496|Drug|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
45484639|NCT03252496|Drug|Intravenous Syntocinon|Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution
45484640|NCT01345227|Procedure|Intra bone marrow islet infusion|A needle for bone marrow aspiration (14 G) will be inserted into the superior-posterior iliac crest and islet suspension (1:2.5; tissue:Ringer's Lactate solution) will be infused. The entire intraBM-injection procedure last 8-15 min from the beginning of anaesthesia (short propofol sedation).
45691449|NCT04667260|Procedure|Maxillary sinus membrane elevation|Maxillary sinus membrane elevation with blood coagulum
45691450|NCT04667260|Procedure|Maxillary sinus floor augmentation|Maxillary sinus floor augmentation with 1:1 autogenous bone graft and deprotinized porcine bone mineral
45367937|NCT00929942|Device|SX-ELLA Stent Degradable DV Bronchial (DV Stent)|"Intervention SX-ELLA Stent Degradable DV Bronchial (DV Stent) will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented."
45367938|NCT00711113|Device|OsseoSpeed™|OsseoSpeed™, all dimensions
45367939|NCT03796598|Drug|Fecal Microbial transplant Capsules|Oral capsules of FMT
45367940|NCT03796598|Drug|Fecal Microbial Transplant Enema|FMT enema
45367941|NCT03796598|Other|Placebo|Placebo
45367942|NCT02568995|Drug|ropivacaine + ketorolac + adrenaline|A combination of drugs injected locally for postoperative pain management
45484641|NCT03237234|Other|Motor Skill Training|Motor skill training will consist of activities that will be performed while standing to promote upright control (the toe-tapping activity will be performed while seated). Participants will perform each of the 6 different activities for one minute each, until 4 cycles of the circuit have been completed (approximately 25 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). Toe tapping will provide the opportunity for scheduled rest. During MT, all participants will wear a heart rate monitor to ensure that the optimal HR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
45367943|NCT03784898|Other|Blood draw for future biomarker analysis|Each participant was required to undergo blood draw for future genetic testing and biomarker analysis as mentioned in the informed consent form (ICF).
45484642|NCT03237234|Device|Transcranial direct current stimulation (tDCS)|The tDCS electrode placement is based on procedures shown to improve gait and balance in a single session when used in combination with gait training activities. tDCS electrodes can simultaneously activate the bilateral leg motor areas when placed at the midline of the scalp slightly anterior to the vertex (anode) and at the inion (cathode), with a current intensity of 2mA. The tDCS device is lightweight, and can be worn in a backpack during the MT activities. As reported previously, participants in the MT-only group will receive sham tDCS to maintain analogous study procedures.
45484643|NCT03688425|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > intermediate > near
45367944|NCT05727137|Procedure|Single shot adductor canal block|Single shot adductor canal block on the the first and second postoperative day.
45691451|NCT05290168|Diagnostic Test|abdominal Doppler|"Inferior vena cava diameter and distensibility~Hepatic vein Doppler~Portal vein Doppler~Splenic artery and vein Doppler~Renal artery and vein Doppler"
45691452|NCT01867021|Biological|Fluvirin(TIVf)|
45691453|NCT01867021|Biological|Agriflu (TIV)|
45691454|NCT02785042|Device|Heidelberg Spectralis OCT|OCT imaging
45691455|NCT01866709|Drug|Sodium polystyrene sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
45846252|NCT02468154|Device|custom made splint|Splints have been made by wrapping synthetic bandages around a leg-foot manufactured splint padded at the heel to off-load the heel. When the desired shape has been obtained, the splint is opened and the manufactured device is removed, thus obtaining a device that is used under the casts of lower limbs.
46051995|NCT02822547|Drug|Peginterferon alfa-2a|Patients will receive Peginterferon alfa-2a according to the standard medical practice
45367945|NCT05727137|Procedure|Continuous adductor canal block|A catheter will be placed in the adductor canal and connected to a continuous patient-controlled analgesia pump.
45367946|NCT00930020|Drug|Minocycline (Borymycin)|oral dose, 200 mg once a day for 5 days
45367947|NCT00930020|Drug|Matched placebo|matched placebo (cornstarch) once a day for 5 days
45367948|NCT00710879|Device|Bausch & Lomb Multi-Purpose Solution|Daily care for contact lenses.
45367949|NCT00930098|Drug|clofarabine|
45367950|NCT00905684|Drug|EE30/DRSP (Yasmin, BAY86-5131)|Patients under regular daily life treatment receiving Yasmin according to local drug information
45367951|NCT00905684|Drug|Any other OC|Patients under regular daily life treatment receiving any other OC according to local drug information
45367952|NCT00736775|Drug|anti-Abeta|Intravenous single and multiple doses
45367953|NCT00736775|Drug|placebo|Intravenous single and multiple doses
45367954|NCT00925418|Procedure|Frozen Glove|Using frozen glove during chemotherapy with Taxotere®
45367955|NCT05742191|Other|Daylight Savings time transitions|Daylight Savings time transitions.
45691456|NCT01866709|Drug|Silicified microcrystalline cellulose|Oral suspension in water of placebo administered three times (tid) daily for 48 hours.
45691457|NCT04621630|Drug|PN-235|Active Drug
45691458|NCT04621630|Drug|Placebo|Matching Placebo
45846253|NCT02468154|Other|standard off-load plaster cast|To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
45846254|NCT02468700|Drug|Dexamethasone|
45846255|NCT02468700|Other|Placebo Vehicle|
45846256|NCT02469714|Behavioral|Peer Navigator Intervention|Peer navigators will be Hispanics/Latinos with a mental illness in recovery who will complete and meet certification for the peer navigator training program that will be evolved out of the mixed methods process. Investigators propose the peer navigators will enhance patient engagement in integrated care which will, in turn, improve physical and mental health and wellness of patients in this group
45367956|NCT03979274|Drug|Reference Eutirox®|Participants received single oral dose of Reference Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment period 1 or 2.
45484644|NCT03688425|Device|IOL implantation active comparator|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > near > intermediate
45367957|NCT03979274|Drug|Test Eutirox®|Participants received single oral dose of Test Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment 1 or 2.
45367958|NCT00930254|Procedure|IV puncture guided by ultrasound|Comparisons between traditional and ultrasound group
45484645|NCT03252418|Drug|Ascorbic Acid 500 MG|ascorbic acid is vitamin that can cause gingival depigmentation
45484646|NCT03252418|Device|diode laser|diode laser is soft tissue laser case photothermolysis of melanoctes
45367959|NCT05706623|Drug|Apraglutide|Single dose of apraglutide 5mg.
45484647|NCT01348893|Behavioral|Yoga|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
45484648|NCT03260452|Procedure|Abdominal subcutaneous biopsies and Blood test|Abdominal subcutaneous biopsies and blood test for each volunteer.
45484649|NCT01364610|Device|Bravo|Bravo pH Monitoring System sited manometrically.
45484650|NCT01364610|Device|Standard Care|Nasally passed pH catheter sited by manometry, accompanied by battery powered data logger. Participant activated event marker in response to symptoms, meals and body position changes.
45484651|NCT03687567|Procedure|Preimplantation genetic diagnosis|
45484652|NCT01364688|Drug|oral alfacalcidol|Oral alfacalcidol 0.5 microgram per day
45484653|NCT01364688|Drug|no drug|no drug
45484654|NCT03260686|Other|experimental|video guide for upper limb exercise
45484655|NCT03252106|Procedure|Contour augmentation with implant placement|Contour augmentation with implant placement
45484656|NCT01370148|Drug|conivaptan hydrochloride|Intravenous
45484657|NCT03260296|Other|self-administered structured questionnaire|"Data will be collected by self-administered structured questionnaire. The aim of the study and the way of filling the questionnaire will be explained to the students, and then he/she fills the questionnaire by him/her self.~The questionnaire will assess smartphones addiction and some of its associated factors and its health consequences"
45484658|NCT01370226|Behavioral|CBI|"The multimedia, interactive Computer Brief Intervention (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The 30-minute interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
45484659|NCT01370226|Behavioral|TBI|"Participants receive a 30-minute intervention session with a Master's-level clinician. The interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
45367960|NCT00905762|Drug|Gatifloxacin|Gatifloxacin 0.3% one drop instilled into study eye at visit 2.
45484660|NCT01348971|Dietary Supplement|Sodium nitrate|Preoperative oral administration of sodium nitrate. 700 mg the night before surgery and 700 mg three hours before surgery
45484661|NCT01348971|Other|Sodium chloride|Preoperative oral administration of sodium chloride the night before surgery and three hours before surgery
45484662|NCT03260062|Behavioral|Parent-Child Early Approaches to Raising Language Skills|The PEARLS intervention will teach parents evidence-based language strategies and sensitive parenting (e.g., warmth, respect for autonomy, linguistic stimulation) to promote language development in young deaf children with cochlear implants (CI).
45484663|NCT03260062|Other|Standard Care Speech therapy|Families will participate in auditory-verbal therapy, which is the standard speech therapy with children with hearing loss.
45484664|NCT04684953|Procedure|Throid autotransplantation|Operative
46051996|NCT05040009|Behavioral|integrated foot care program|"Regular foot care and examination by an adequately trained professional: -~Structured education:~Educational modality will be provided to patients in a structured way. This will take many forms: one-to-one verbal education session last around 30 min motivational interviewing, video education, booklets, pictorial education via animated drawing or descriptive images structured foot care education consists of information on:~Foot ulcers and their consequences~Preventative foot self-care behaviors~Wearing adequately protective footwear~Undergoing regular foot checks~Practicing proper foot hygiene~Seeking professional help in a timely manner after identifying a foot problem~3-Adequate footwear 4-Foot-related exercises and weight-bearing activity 5-Foot examination and screening 6- Instructions about foot self-management"
45367961|NCT00905762|Drug|Moxifloxacin|Moxifloxacin 0.5% one drop instilled into study eye at visit 2.
45367962|NCT00905762|Drug|Besifloxacin|Besifloxacin 0.6% one drop instilled into study eye at visit 2.
45367963|NCT02568137|Behavioral|Smart-phone based technology|
45484665|NCT04684953|Drug|Hormone|thyroid hormone replacement therapy
45484666|NCT01345383|Procedure|bronchoscopy|Routine bronchoscopy under local anesthesia (lidocain). Duration: +/- 10 min
45484667|NCT03252184|Device|Low level laser therapy - 1|In the phase 1, the low level laser therapy will be performed with the Fluence device (HTM, Brasil) and the probe from the same manufacturer. For the interventions in groups G1, G2 and G3 (photobiomodulation) will be used, respectively, the energy doses of 18J, 36J and 54J. A 658nm wavelength with an output power of 10mW will be used. Group 4 intervention (placebo photobiomodulation) will be performed with the application of the device turned off. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
45484668|NCT03252184|Device|Low level laser therapy - 2|In the phase 2, the low level laser therapy will be performed with the Thor DD2 (London, UK) and the cluster probe from the same manufacturer. For the interventions in groups G1 and G2 (photobiomodulation) will be used, respectively, the energy doses of 30J and 60J. A 810nm wavelength and an output power of 200mW will be used. Group 3 intervention (placebo photobiomodulation) will be performed with the application of the device turned off. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
45484669|NCT03252184|Device|Low level laser therapy - 3|In the phase 3, the low level laser therapy will be performed with the Thor DD2 (London, UK) and the cluster probe from the same manufacturer. For the interventions in groups G1 and G2 (photobiomodulation) will be used, respectively, the energy doses of 30J and 60J. A 810nm wavelength and an output power of 200mW will be used. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
45484670|NCT03052920|Device|Cochlear implant|Participants who have failed a BiCROS or bilateral hearing aid trial and otherwise meet inclusion criteria will receive a cochlear implant at the poor hearing ear. Post-implant, participants will continue use of a hearing aid at the better ear and the cochlear implant at the poor ear.
45484671|NCT01345461|Device|transcutaneous electrical muscle stimulation, (model DS7A, Digitimer, Welwyn, Garden City, Hertfordshire, UK)|two constant current high voltage stimulators delivered ten single stimuli twitches with biphasic square pulses at widths of 300 μs. A train generator was then switched on, triggering the delivery a 35 Hz current in bouts of 3 seconds periods separated by 1-second pause for a total of 40 tetanic contractions. In immediate succession to the tetanic contractions a second series of ten single twitch stimuli ended the protocol.
45484672|NCT03252262|Other|Vitalize 360|A comprehensive geriatric assessment system and wellness coaching program.
45484673|NCT01349127|Dietary Supplement|20µg Vitamin D3|20µg (800IU) of vitamin D3/day for 12-weeks while lactating, commencing 10-14 days post-partum.
45484674|NCT01349127|Dietary Supplement|20µg Vitamin D3 + 500 mg Calcium|20µg (800IU) of vitamin D3 + 500mg calcium carbonate/day for 12-weeks while lactating, commencing 10-14 days post-partum.
45484675|NCT01349127|Dietary Supplement|Placebo|One gelatin placebo capsule containing zero vitamin D3 taken for 12-weeks while lactating, commencing 10-14 days post-partum.
45484676|NCT03486964|Drug|DPP-4 inhibitors|Patients will be retrospectively evaluated after the addition of a DPP-4 inhibitor to previously taken anti-diabetic therapy
45484677|NCT01364844|Drug|DS-7423|oral capsule 1mg, 8mg, 48mg, and 80mg strengths administered once daily
45484678|NCT04005027|Other|Intermittent graded exercise test|Participants will run on a treadmill until volitional exhaustion. The speed of the treadmill belt will increase incrementally every 3 minutes. Within each 3 minute stage the speed will vary between the target speed and a complete pause (e.g target speed = 8 km/hr)
45484679|NCT03259906|Other|DASH score|Questionnaire asking about Disability of Arm, Shoulder and Hand
45484680|NCT03259906|Procedure|X-ray|postoperative x-rays at 6 weeks, 3, 6 and 12 months
45484681|NCT03259906|Procedure|posterior osteosynthesis|Osteosynthesis using a posterior plate
46051997|NCT05660889|Other|Blood sampling.|Blood samples from both study groups, taken during an adrenal vein sampling, will be compared across the groups.
45484682|NCT03259906|Procedure|Anterior osteosynthesis|Osteosynthesis using an anterior plate
45484683|NCT01369836|Drug|Tafamidis meglumin|A single oral dose of 20 mg capsule
45484684|NCT01369836|Drug|Tafamidis meglumin|A single oral dose of 40 mg capsule.
45484685|NCT01369836|Drug|Placebo|A single oral dose of matched placebo.
45846257|NCT02469870|Behavioral|Autism Parent Trainer (APT)|Experimental condition
45846258|NCT02469870|Behavioral|Teaching Routines (Control)|Content comparison group.
45846259|NCT02470494|Device|Sound amplification provided via the EarLens CHD|Subjects with mild to severe hearing impairment receiving sound amplification treatment with EarLens CHD.
45846260|NCT02472522|Drug|Ropivacaine + Dexmedetomidine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine and 1 micrograms/kg dexmedetomidine (combination drug) diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
46051998|NCT02823483|Other|Sunscreen Lotion (BAY987521)|50 μl/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.Formulation A: Y49-103, Formulation B: Y71-150.
46051999|NCT02823483|Other|Untreated Skin|This site is patched without treatment as irradiated control
46052000|NCT04848597|Drug|Recombinant humanized anti-PD-1 monoclonal antibody injection|200mg , once every 3 weeks
45484686|NCT01317303|Procedure|cTBS-PAS25|40 seconds of continuous Theta-burst stimulation, followed by PAS25 which refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after
45484687|NCT01317303|Procedure|cTBS-iTBS|40 seconds of continuous Theta-burst stimulation, followed by 190 seconds of intermittent Theta-burst stimulation
45484688|NCT01317303|Procedure|PAS25|PAS25 refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
45484689|NCT01317303|Procedure|iTBS|190 seconds of intermittent theta-burst stimulation
45367964|NCT00930332|Drug|methadone hydrochloride|"Level 1: 1 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA** per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 3: 3mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~OR~Level 1: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)"
45484690|NCT03251950|Behavioral|healthy eating and gardening|15 week healthy eating and gardening intervention for children aged 3-5 years; 15 week online parenting intervention to promote healthy eating; Menu change in early childhood center to promote healthy eating
45484691|NCT01349205|Drug|Caffeine and sodium Benzoate 10 mg/kg IV|IV, 10mg/kg, IVP, 1 time
45484692|NCT01349205|Drug|Caffeine and Sodium Benzoate 20 mg/kg IV|IV, 20 mg/kg, IVP, 1 time
45484693|NCT01349205|Drug|0.9 NS Saline|IV, 0-10 ml, IVP, 1 time
45484694|NCT04785690|Device|CureSight|Subjects assigned to the binocular treatment group will be prescribed the CureSight treatment to watch for 90 minutes per day, 5 days a week for 16 weeks for the total of 120 hours. Parents of subjects will be instructed that the 90 minutes of daily treatment should be completed in a single 90-minute session, but if this is not possible for whatever reason, the treatment may be divided into two shorter sessions totaling 90 minutes per day
45484695|NCT04785690|Device|Patching|"Subjects assigned to the patching group will wear an adhesive patch over the dominant eye for 2 hours per day, 7 days per week for 16 weeks. Parents of subjects will be instructed that the 2 hours of daily patching should be completed in a single 2-hour session, but if this is not possible for whatever reason, the treatment may be divided into shorter sessions totaling 2 hours.~Parents will be asked to complete a usage diary by manually recording the patch usage time on daily basis."
45484696|NCT03251794|Diagnostic Test|three dimensional ultrasound|evaluation of the suprarenal glands
45484697|NCT03251794|Diagnostic Test|color Doppler|Doppler evaluation of the suprarenal artery
45484698|NCT01370304|Other|active rTMS and active Venlafaxine|"rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks"
45846261|NCT02472522|Other|Ropivacaine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
45846262|NCT02476032|Device|Prof applied oxalate|Crest Sensi-Stop strips (Procter & Gamble™) with the active ingredient will be placed on the qualifying teeth by a dental professional.
46052001|NCT04240041|Diagnostic Test|Transcerebellar diamater|Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, trans-cerebellar diameter is identified by obtaining an oblique view through posterior fossa that included visualization of midline thalamus, cerebellar hemispheres and cisterna magna.
46052002|NCT04240041|Diagnostic Test|Placental thickness|Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, placental thickness will be measured at the level of the umbilical cord insertion excluding the myometrium and sub-placental veins
45367965|NCT00930332|Other|questionnaire administration|within 48 hours of registration
45367966|NCT00930332|Procedure|management of therapy complications|if required
45367967|NCT02568059|Drug|Sahastara remedy alcoholic extract|comparison of different dose of drug
45367968|NCT00459316|Biological|Quadrivalent meningococcal conjugate vaccine|MCV4 vaccine (4 µg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 µg of diphtheria toxoid protein carrier ) was given by injection intramuscularly at least once and no more than three times for each participant, depending on adverse reactions.
45484699|NCT01370304|Other|active rTMS and sham Venlafaxine|rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s. 5 sessions per week for 4-6 weeks
45484700|NCT01370304|Other|sham rTMS and active Venlafaxine|"rTMS parameters :same coil, same number of pulses but using an angled coil(90 degree)over the frontotemporal region~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks"
45484701|NCT01349283|Biological|HepavaxGene (thiomersal free)|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
45484702|NCT01349283|Biological|Engerix B|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
45484703|NCT03259828|Radiation|Adjuvant image-guided radiotherapy|Image-guided adjuvant radiotherapy to the sigmoid colon surgical tumor bed and pelvic regional lymph nodes: 45-50.4 Gy in 1.8 Gy/fraction
45484704|NCT03982485|Drug|Apatinib|Apatinib 250mg, Oral, day 2,3,4,5,6,7, every week
45484705|NCT03982485|Drug|Paclitaxel|Paclitaxel 80mg/m2, Intravenous, day 1, 8, 15, 22, every 28 days for a cycle
45484706|NCT03982485|Drug|Cisplatin|Cisplatin 25mg/m2, Intravenous, day 1, 8, 15, every 28 days for a cycle
45484707|NCT03982485|Procedure|Surgery|Surgery
45484708|NCT03259750|Other|Foot and Ankle Ability Measure Turkish version (FAAM-T) questionnaire|Self reported outcome instrument
45484709|NCT03246490|Other|All Participants|all participants will participate in the same protocol involving drinking alcohol to a .08 g% blood alcohol level
45484710|NCT03966339|Drug|Growth hormone|GH has been considered as a cogonadotropin, which plays an important role in the synthesis of ovarian steroid hormone and follicular development as a paracrine hormone.GH can regulate the growth hormone receptor and strengthen the function of mitochondria to improve the quality of the female oocyte.
45484711|NCT03251716|Drug|berberine|berberine 300mg TID add-on for berberine adjunctive group
45484712|NCT03251872|Drug|Olaparib|Olaparib tablets
45484713|NCT02455258|Other|Dance/Movement Therapy (DMT)|Each DMT session follows a similar structure of Opening, Warm up, Development, Cool Down and Closure. Various themes dedicated to an aging population are addressed by the supervising dance/movement therapist through movement activities and using support material (i.e., props, music). This group is provided in a group setting of maximum 10 participants at a time and occurs 3 times per week for 1 hour each session over the course of 12 weeks.
45484714|NCT02455258|Other|Aerobics Exercise (AE)|The aerobics exercise program is composed of warm up exercises followed by cardiovascular training on a recumbent bicycle. The intensity is set and progressively increased using each participants' individualized maximal aerobic power obtained in the baseline VO2 evaluation. This program respects the recommendations made by the American College of Sports Medicine and their adaptations for aging populations. Each session is supervised by a kinesiologist with 2 participants at a time. The training occurs 3 times per week for 1 hour each session over the course of 12 weeks.
45367969|NCT00925574|Drug|CNTO 1959; Placebo|
45484715|NCT03251404|Other|Injury prevention exercise programs|The two intervention programs contain exercises aiming to increase lower extremity strength, core stability, balance and neuromuscular function.
45484716|NCT02930226|Biological|Autologous Freeze Dried Plasma (FDP)|Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers
45484717|NCT02930226|Biological|Fresh Frozen Plasma (FFP)|Controlled FFP in cohort 3 only
45484718|NCT03251560|Drug|Fuke Qianjin capsule|Fuke Qianjin capsule 0.8g pills by mouth, three times daily
45484719|NCT03251560|Drug|Placebo oral capsule|Placebo oral capsule 0.8g pill by mouth, three times daily
45484720|NCT03160521|Drug|Risperidone ISM 75 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
45691459|NCT04572022|Other|Step wise post-procedure mobile health shared rehabilitation teaching video instructions modules (as per fracture type)|Intervention group receive proximal humerus fracture standard care with additional mobile health shared step-wise rehabilitation teaching video instructions modules (as per fracture type). Classic Blue tooth technology will be utilized for teaching information sharing from doctor to the patient.
45691460|NCT01841593|Drug|Raltegravir|Isentress 400mg tablet taken twice daily
45691461|NCT01841593|Drug|Amlodipine|generic amlodipine 5mg tablets (Accord healthcare Limited, UK)
45691462|NCT05238298|Device|repetitive Transcranial Magnetic Stimulation|A technique that involves the use of electrical coils on the head to generate a brief magnetic field which reaches the cerebral cortex.
45367970|NCT02568839|Drug|docetaxel + trastuzumab sc + pertuzumab|docetaxel 75-100 mg IV + trastuzumab sc 5 ml (600 mg) SC + pertuzumab 840 mg IV starting dose, subsequently 420 mg IV, repeated every 3 weeks, 6 courses
45367971|NCT02568839|Drug|trastuzumab emtansin|trastuzumab emtansine 3.6 mg/kg IV, repeated every 3 weeks, 6 courses
45367972|NCT00930410|Procedure|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|Utilisation of the Intra-ductal confocal endomicroscopy to obtain any exploitable image for the anatomopathology.
45367973|NCT02538770|Other|Rapid diagnostics using Anyplex TMII RV16 Detection|Rapid diagnostics using Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR as soon as they are available
45367974|NCT02538770|Other|Delayed diagnostics Anyplex TMII RV16 Detection|Delayed diagnostics Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR after one week delay unless specifically solicited
45484721|NCT03160521|Drug|Risperidone ISM 100 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
45484722|NCT03160521|Drug|Placebo of Risperidone ISM|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
45484723|NCT02722434|Other|Laboratory Biomarker Analysis|Correlative studies
45484724|NCT02722434|Other|MC5-A Scrambler Therapy|Undergo Scrambler therapy
45484725|NCT02722434|Other|Questionnaire Administration|Ancillary studies
45484726|NCT02722434|Other|Transcutaneous Electrical Nerve Stimulation|Undergo TENS
45484727|NCT03251248|Drug|MSB11455|Subjects will receive MSB11455 either on Period 1 Day 1 or Period 2 Day 1.
45484728|NCT03251248|Drug|Neulasta|Subjects will receive Neulasta either on Period 1 Day 1 or Period 2 Day 1.
45484729|NCT03246256|Other|Group 1|
45484730|NCT04438590|Dietary Supplement|Kelulut Honey|The Substance being tested to be used as an alternative
45691463|NCT05236894|Behavioral|Cigarette Smoking|Smoke preferred brand of cigarette
45691464|NCT05236894|Drug|Nicotine Oral Pouch|Given lower dose nicotine pouch
45484731|NCT04438590|Dietary Supplement|Carborie|The commercially available substance
45484732|NCT03246178|Other|MSD-HSCT|"Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 30mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;~Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;~Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 150-250 ng/ml. The oral MMF dose was 20 mg/kg/day from day -1 and was tapered off after 1 months if no aGVHD was observed."
45484733|NCT03246178|Other|HFD-HSCT|"Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 35mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;~Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;~Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 200-300 ng/ml. The oral MMF dose was 20 mg/kg/day from day -3 and was tapered off after 2 months if no aGVHD was observed."
45484734|NCT03954015|Diagnostic Test|Contrast Enhanced imaging|Contrast Enhanced Ultrasound (CEUS) with US Microvessel Imaging, Contrast Enhanced Dual Energy Mammography (CEDM) and Contrast Enhanced Breast MR (CEMR): Comparison of Three Methods for Early Detection of Breast Cancer.
45691465|NCT05236894|Drug|Nicotine Oral Pouch|Given higher dose nicotine pouch
45367975|NCT05742035|Procedure|Venipuncture|Bloodletting of 450 mL, followed by separation of the whole blood in 2 blood components: 1 red blood cell concentrate and 1 plasma. Measurement of the outcomes in the red blood cell concentrate.
45691466|NCT05236894|Other|Questionnaire Administration|Ancillary studies
45691467|NCT05236894|Drug|Nicotine Oral Pouch|Given 3mg nicotine pouch (Aim 2)
45691468|NCT05236894|Drug|Nicotine Oral Pouch|Given 3mg nicotine pouch (Aim 2)
45367976|NCT00931424|Procedure|valve reconstruction|reconstruct valve at the same time of superficial vein surgery
45846263|NCT02476032|Device|Self applied oxalate|Subjects will apply the strips (Procter & Gamble™), that contain the active ingredient, by themselves following the manufacturer's instructions.
45691469|NCT05236894|Drug|Nicotine Oral Pouch|Given 3mg nicotine pouch (Aim 2)
46052003|NCT02822313|Drug|Coppertone (BAY987518)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-76_V27-006)
45367977|NCT05701319|Procedure|PCI|percutaneous coronary intervention
45367978|NCT00930488|Drug|Avelox (Moxifloxacin, BAY12-8039)|Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin
45367979|NCT04063943|Device|Sidus Stem-Free Shoulder|Device: Sidus Stem-Free Total Shoulder Arthroplasty System
45367980|NCT00736931|Drug|Brivaracetam|Brivaracetam 10 mg tablets
45691470|NCT05231824|Behavioral|Standard Behavioral Weight Loss Treatment|Behavioral weight loss treatment is the current gold standard treatment for obesity.
45846264|NCT02476032|Device|Prof applied placebo|Crest Sensi-Stop strips (Procter & Gamble™) without the active ingredient will be placed on the qualifying teeth by a dental professional.
45846265|NCT02476890|Drug|Gefapixant 100 mg|Gefapixant 100 mg (2 x 50 mg tablets), administered orally as a single dose in treatment Period 1 or treatment Period 2
45846266|NCT02476890|Drug|Placebo|Placebo (two tablets matching gefapixant 50 mg), administered orally as a single dose in treatment Period 1 or treatment Period 2
46052004|NCT04239495|Other|Observational study: range of clinical and lifestyle factors|Medical conditions and medications. Educational and occupational history. Lifestyle exposures, assessed using reduced Food Frequency Questionnaire, Rapid Assessment of Physical Activity questionnaire and objectively-measured physical activity levels over 7 days using a GeneActiv wrist-worn accelerometer (Activinsights, Cambridge, UK).
45367981|NCT00736931|Drug|levetiracetam|500mg tablets
45367982|NCT00736931|Drug|lorazepam|lorazepam 2 mg over encapsulated tablets
45367983|NCT00736931|Other|placebo|placebo capsules
45367984|NCT00737087|Device|Delta Xtend Reverse Total Shoulder|Orthopaedic implant for total shoulder replacement
45484735|NCT03954015|Drug|Lumason|FDA approved and used routinely for ultrasound exams of the heart and liver as well as the urinary tract in children. It contains microbubbles that are small enough to pass through the blood stream.
45484736|NCT03251092|Drug|PTI-808|Active
45484737|NCT03251092|Drug|Placebo|Placebo
45484738|NCT03251092|Drug|PTI-428|Active
45484739|NCT03251092|Drug|PTI-801|Active
45484740|NCT01365000|Drug|NKTR118 Formulation 1|Oral dose, 25 mg
45484741|NCT01365000|Drug|NKTR118 Formulation 2|Oral dose, 25 mg
45484742|NCT01365000|Drug|NKTR118 Formulation 3|Oral dose, 25 mg
45484743|NCT01365000|Drug|NKTR118 Formulation 1a|Oral dose, 25 mg
45484744|NCT01365000|Drug|NKTR118 Formulation 3a|Oral dose, 25 mg
45484745|NCT01349361|Procedure|Daylight mediated photodynamic therapy|
45484746|NCT01345773|Procedure|Gastric surgery|Patients receiving gastric cancer surgery will be prospectively observed for the development of venous thromboembolism
45367985|NCT04064099|Device|Custom-fitted sports mouthguard|Pressure dual laminated technique will be used to fabricate the mouthguards. Ethylene-vinyl acetate (EVA) thermoplastic sheets of 3 mm in thickness with 125 mm diameter (Dentsply International Raintree Essix, Court East Sarasota, USA) will be used. Two 3 mm sheets pressure-laminated together should form an even thickness of 4 mm mouthguard. The design of the mouthguards takes into consideration of the following limits: (i) the labial borders of the mouthguard were extended to within 2 mm of the vestibular reflection, (ii) the palatal margins were trimmed to the cervical area of the palatal surface of the upper teeth, (iii) enclosing the maxillary teeth to the distal surface of the first molars.
45367986|NCT05741879|Behavioral|Gamified exercise training|"Participants will complete a 2-days-a-week online training routine with their families: Each session will include a Warm-Up/Activation phase (3 minutes: light intensity continuous training), a Training phase (10-26 minutes: 6-12 repetitions, 20-40 of work, 10-20 recovery), and a Cool Down phase (3 minutes: static and dynamic exercises). The exercises will be different each week and will increase in length and intensity accordingly. The sessions will be supervised by the participants parent(s) and/or guardian(s)."
45484747|NCT03246100|Behavioral|Reminders|Reminders are sent either through autodial or postcards reminding patients to get flu vaccine.
45484748|NCT03147040|Drug|Carboplatin|Chemotherapy treatment with carboplatin and atezolizumab
45484749|NCT03147040|Drug|Atezolizumab|Chemotherapy treatment with carboplatin and atezolizumab
45484750|NCT03245944|Procedure|early Angioplasty|Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Early means pt will get the procedure at 6 weeks from time of initiation of AVFs
45484751|NCT03245944|Procedure|late Angioplasty|Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Late means the angioplasty is done at 3 months from time of AVF creation if still immature at that time.
45484752|NCT03251170|Drug|Ketamine|Patients will receive :1 mg/Kg ketamine for induction of anesthesia
45484753|NCT03251170|Drug|Fentanyl|Patients will receive :2.5 mcg/Kg fentanyl for induction of anesthesia
45484754|NCT03251170|Drug|Midazolam|Patients will receive 0.05 mg/Kg midazolam
45484755|NCT03539601|Drug|Crisaborole ointment, 2%|Applied twice a day (BID)
45484756|NCT03539601|Drug|Hydrocortisone butyrate cream, 0.1%|Applied BID
45484757|NCT03539601|Drug|Pimecrolimus cream, 1%|Applied BID
45484758|NCT03539601|Drug|Crisaborole Vehicle|Applied BID
45484759|NCT03245788|Other|Lay Navigation|Patients who are assigned to intervention will be contacted by a navigator who will explain and offer their services to the patient. Navigators focus efforts on supporting patients in self-management and in supporting non-medical needs.
45484760|NCT03245710|Other|Placebos|starch
45484761|NCT03245710|Dietary Supplement|Zhibai Dihuang powder|the Traditional Chinese Medicine Formula Powder Product
45484762|NCT03250858|Behavioral|Personalised advice|Provision of online personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
45484763|NCT03250858|Behavioral|Non-personalised advice|Provision of online non-personalised advice on dietary intake, weight and physical activity levels. Non-personalized dietary advice for improved food choice based on standard population health guidelines.
45484764|NCT04652583|Device|Earstim - Active Stimulation|Intramuscular stimulation
45484765|NCT04652583|Device|Earstim - Sham Stimulation|Sham stimulation
45484766|NCT02455180|Drug|Ascorbic Acid|Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.
45846267|NCT02480166|Drug|8 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
45846268|NCT02480166|Drug|12 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are not treatment naïve or have cirrhosis will be assigned to 12 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
45846269|NCT02481258|Drug|Ataciguat (HMR1766)|
45846270|NCT02481258|Other|Placebo Comparator: Matching Placebo|
45846271|NCT02483676|Device|Treadmill plus anklebot|This intervention employs the use of the adaptive anklebot control system to complement treadmill exercise training over a 6-week intervention period.
45367987|NCT05741879|Behavioral|Standard Care|This group will be allocated to standard care and therefore no gamified online exercise training will be provided. They will continue to perform their daily routine/activities including their basic motor skills classes at school and their extracurricular sports and/or cultural activities.
45367988|NCT00567164|Drug|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
45367989|NCT00567164|Drug|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
45367990|NCT00567164|Drug|EE20/DRSP (YAZ, BAY86-5300)|Fixed package per cycle containing combination tablets containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone (24 per cycle) + tablets without active substance (4 per cycle)
45367991|NCT00920933|Biological|AIN457|
45367992|NCT00920933|Other|Placebo|
45367993|NCT00920933|Drug|prednisolone|
45367994|NCT00930566|Drug|methoxsalen|"UVADEX® is supplied in a 10 mL single-use vial. Each mL of solution contains 20 mcg of UVADEX®.~In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button. The dose of UVADEX used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, usinge the following formula :~Treatment Volume in mL x 0.017 = Dose of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
45846272|NCT02483676|Behavioral|Treadmill only|This intervention employs the use of a treadmill for gait exercise training over a 6-week intervention period
45846273|NCT02484222|Drug|Fentanyl|Before the end of the procedure, spontaneous respiratory was recovered. All the patients were given 1 mcg/kg fentanyl i.v. after the end of the procedure.
45846274|NCT02486016|Drug|Duragesic reference fentanyl TDS|25 µg/hour
45846275|NCT02486016|Drug|Apotex generic fentanyl TDS|25 µg/hour
46052005|NCT04803669|Procedure|Intrument-assisted soft tissue mobilization technique|This technique; It is applied with the help of a tool made of stainless steel. The instrument is rubbed on the skin at an angle of about 30 degrees, creating a massage-like effect on the soft tissue (2 sessions per week and 5 minutes per session, 8 sessions in total for 4 weeks).
46052006|NCT04803669|Procedure|Conventional Treatment|Hotpack, TENS, Ultrasound and Exercise will be applied as conventional treatment methods.
46052007|NCT05037045|Drug|GLP-1 receptor agonist|GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM
45367995|NCT00930566|Procedure|Extracoporal Photopheresis (ECP)|"In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporeal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
45484767|NCT03514719|Diagnostic Test|89Zr-avelumab PET|89Zr-avelumab injection followed by 89Zr-Avelumab PET scan
45484768|NCT03514719|Drug|Avelumab|"Early stage disease (stage Ia (≥T1b tumor)-IIIa: neo-adjuvant avelumab treatment (10mg/kg iv q2w) for a maximum duration of 2 cycles after PET-imaging, followed by surgical resection of the tumor with curative intent~Stage IIIb-IV disease: systemic treatment with avelumab 10mg/kg iv q2w after PET-imaging"
45484769|NCT03251014|Other|YSS|Intervention providing steamed whole YSS (~265 g/day, 3 days/week) for eight weeks
45484770|NCT03251014|Other|Salmon|Intervention providing steamed salmon fillet (~246 g/day, 3 days/week) for eight weeks
45484771|NCT01349439|Drug|Propranolol|1mg per Kg (participant weight)
45367996|NCT00737165|Behavioral|Multimodal suicide prevention program|"A community intervention of multimodal suicide prevention program includes following components:~Building support networks for suicide prevention and mental health promotion in public health system~Primary prevention of suicide and suicide related behaviors~Secondary prevention of suicide and suicide related behaviors~Tertiary prevention; after care for suicide survivors~Suicide prevention targeting for people with substance/alcohol- related disorders , schizophrenia and other mental health disorders~Suicide prevention targeting for people with work-related problems"
45367997|NCT00737165|Behavioral|Suicide prevention program as usual|Usual suicide prevention program
45367998|NCT00925730|Drug|Pimecrolimus|
45367999|NCT00925808|Behavioral|Questionnaires|Survey tools and VTE Symptom Follow-up Questionnaire
45484772|NCT01349439|Drug|Short acting + long acting propranolol + memory reactivation|After completing the double-blind phase of the study, participants will receive short acting propranolol 1mg/kg (patient weight) + long acting propranolol (1 or 1.5 mg/kg) followed by memory reactivation. Dose level for the long-acting propranolol will be randomly assigned across participants.
45484773|NCT03620331|Procedure|Surgery with a previous non-surgical approach|Non-surgical phase done prior to the surgical treatment of peri-implantitis
45484774|NCT03620331|Procedure|Surgery without a previous non-surgical approach|Non-surgical phase not done prior to the surgical treatment of peri-implantitis
45484775|NCT03245554|Drug|Propranolol|0 or 1 were generated by using Random software. The patient entered the placebo group if number was 0; if the random number generated was 1, then entered the propranolol group.
45484776|NCT01346007|Biological|7-valent pneumococcal conjugate vaccine|A 0,5 ml dose of 7-valent pneumococcal conjugate vaccine in both arms A 0,5 ml anamnestic dose of 7-valent pneumococcal conjugate vaccine in subjects with idiopathic nephrotic syndrome 12 months after priming
45484777|NCT02455102|Other|Electronic warning alert|A newly-installed warning system for stroke prevention in atrial fibrillation.
45484778|NCT01349517|Procedure|MIE|The patients in this group would perform minimal invasive three-incision subtotal esophagectomy (thoracoscopic and/or laparoscopic)
45484779|NCT01349517|Procedure|Three-incision thoracotomy|The patients in this group would perform three-incision subtotal esophagectomy (thoracotomy and laparotomy)
45484780|NCT01349517|Procedure|Ivor-Lewis esophagectomy|The patients in this group would underwent Ivor-Lewis esophagectomy
45484781|NCT01349517|Procedure|Sweet esophagectomy|The patients in this group would underwent Sweet esophagectomy.
45484782|NCT03245476|Other|Physical therapy focus on manual therapy and home-exercises|corticoid injection + physiotherapy with a focus on manual therapy and home-exercises
45691471|NCT05231824|Behavioral|AI-optimized Behavioral Weight Loss Treatment|AI-optimized Behavioral Weight Loss Treatment will continuously vary intensity (automated text message, videoconference group, individual coaching call) and coach type (paraprofessional or MS-level expert) based on continuously-monitored participant digital data.
45846276|NCT02486016|Drug|Mylan generic fentanyl TDS|25 µg/hour
46052008|NCT04239729|Behavioral|ACT Website and Coaching|The ACT website includes sixteen sessions and is designed to teach a series of skills from ACT applied to hoarding. The intervention also includes brief supportive coaching (an initial phone call and weekly support over email).
46052009|NCT02826369|Other|3.0 Tesla in Magnetic Resonance Imaging|"Eligible patient will have a standard MRI. The images taken before 4min30 and after 6min after to the injection of gadolimium contrast medium will be carried out with the standard image acquisition.~The images taken between 4min30 and 6min after the injection of gadolimium contrast medium will be carried out with the compressed sensing image acquisition."
45368000|NCT00925886|Procedure|Acrysof Toric one-piece intraocular lens|Cataract Surgery with a intraocular lens implantation
45484783|NCT03245476|Other|Physical therapy focus on education and supported home exercises|corticosteroid injection + physiotherapy with focus on education and supported home exercises
45484784|NCT03250780|Procedure|indigo-carmine 0.2% using a spray catheter|
45484785|NCT03250780|Procedure|0.03% using a foot pump|
45484786|NCT01349751|Drug|isobaric levobupivacaine|0.42% either isobaric levobupivacaine 3 ml spinal injection once
45484787|NCT01349751|Drug|hyperbaric levobupivacaine|0.42% hyperbaric levobupivacaine 3 ml spinal injection once
45484788|NCT03245632|Other|Carbapenem-Resistant Klebsiella pneumoniae|no intervention, this is an obervational study.
45484789|NCT01346163|Drug|PF 03654746|All participants will receive 3 weeks of PF-03654746 and 3 weeks of placebo. PF-03654746 and placebo will be administered in a flexible titration regimen, beginning with 0.5 mg/d. If 0.5 mg/d is well tolerated, the dose will be increased to 1.0 mg/d after 5 days. If 1.0 mg/d is not well tolerated, the dose will be decreased to 0.5 mg/d, with the goal of achieving a stable dose of PF-03654746 within the first two weeks of dosing and avoiding further dose changes during the final week of dosing.
45484790|NCT01346163|Other|Placebo|Placebo will be used as a comparator to the active arm.
45691472|NCT04507204|Drug|Adhansia XR|Methylphenidate extended-release capsules taken once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, and 85 mg)
45691473|NCT04507204|Drug|Concerta|An osmotic-controlled oral release delivery system (OROS) of methylphenidate HCl (MPH) extended-release tablets taken once daily (18 mg, 27 mg, 36 mg, and 54 mg)
45691474|NCT02520544|Device|Accolade stem|Total hip replacement
45691475|NCT02520544|Device|Accolade II stem|Total hip replacement
45691476|NCT02520544|Device|Trident/Tritanium cup|Total hip replacement
45846277|NCT02486328|Drug|Midazolam|Dosage adjustment
45846278|NCT02486328|Drug|Meperidine|Dosage adjustment
45484791|NCT01346241|Behavioral|Intensive Panic Control Treatment (IPCT)|A manualized treatment that consists of psychoeducation about panic disorder
45846279|NCT02486328|Drug|Remifentanil|Dosage adjustment
45368001|NCT00713219|Radiation|IMRT, cetuximab, docetaxel|IMRT will be administered in once daily fractions (2 Gy/day, Monday through Friday) over approximately 7 weeks to a goal of approximately 70 Gy. The chemotherapy regimen will begin with a loading dose of intravenous cetuximab (400 mg/m2) one week prior to the initiation of radiation therapy, followed by weekly administration of intravenous docetaxel (15 mg/m2) and intravenous cetuximab (250 mg/m2) for approximately 7 weeks concurrently with radiation. Patients will be evaluated weekly prior to their chemotherapy. All patients will be evaluated on an intention-to-treat basis.
45484792|NCT03245164|Other|Physiotherapy group exercises|Physiotherapy exercises had aerobic, balance, strength exercises with music.
45484793|NCT03245164|Other|Basketball program|Basketball education presented the techniques about playing basketball and basketball games were played.
45484794|NCT03004131|Drug|Azelastine hydrochloride + fluticasone propionate nasal spray|
45484795|NCT03004131|Drug|Placebos|
45484796|NCT03004131|Drug|fluticasone propionate nasal spray + loratadine|
45484797|NCT03245086|Device|Transanal hemorrhoid dearterialization|The hemorrhoids are operated in their natural position and not distorted by eversion The proctoscope is fully introduced transanally to reach the lower rectum. Under Doppler guidance, six arterial signals are found circumferentially above the dentate line. The approach to make the 'dearterialization' involves the transfixation of the rectal mucosa and submucosa to entrap the artery using a suture. Mucopexy is performed after the artery ligation with the same suture used for the dearterialization. Finally, the suture is tied to fix the mucopexy.
45484798|NCT03245086|Procedure|Ferguson hemorrhoidectomy|The hemorrhoids are operated in their natural position and not distorted by eversion. A Ferguson-Hill retractor is used to expose the hemorrhoids. Dissection with scissors is directed up to the dentate line where the fibers of the sphincter muscles are exposed and only a mucosal pedicle remains attached. A Buie-Smith crushing clamp is applied to this pedicle and the hemorrhoidal mass is excised at the superior level of the clamp. The pedicle is then ligated and the crushing clamp is removed. After dissection of the intermuscular septum is complete, the margins of the wound are drawn upward into the anal canal with stitches and are secured to the pedicle by the same suture. The remainder of the wound is closed with a stitch tied at the outer extremity of the wound using the same suture.
45484799|NCT01349985|Other|AGATE|AGATE is a web-based adherence-enhancement intervention accessible via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
45484800|NCT01349985|Other|SASED|Participants will receive SASED, a web-based alcohol and side-effects diary via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
46052010|NCT05660811|Drug|short postimplantation dual antiplatelet therapy|continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer Amulet
46052011|NCT05660811|Drug|extended postimplantation dual antiplatelet therapy|stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer Amulet and continuing single antiplatelet agent up until 6 months
46052012|NCT05660811|Drug|long-term treatment with a single antiplatelet agent|continuing long-term treatment with single antiplatelet agent
45484801|NCT03250546|Procedure|transplant from a haplo-identical donor|The transplant procedures will be similar in the 2 groups beside the origin of cells
45484802|NCT03250546|Procedure|transplant from a non related donor|The transplant procedures will be similar in the 2 groups beside the origin of cells
45484803|NCT01350063|Drug|Sodium dichloroisocyanurate (NaDCC) tablet (Aquatab)|One tablet should be added to 10L container, resulting in a free chlorine dose of 2 mg/L.
45484804|NCT01350063|Device|Water storage container (Jerry can)|Shallow tubewell water should be stored in 10L container.
45484805|NCT01350063|Other|No intervention|
45484806|NCT00700804|Behavioral|High Protein Diet|High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
45484807|NCT00700804|Behavioral|Low Protein Diet|High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
45484808|NCT03635307|Other|End Tidal Carbon Dioxide measure|End Tidal Carbon Dioxide measures before and after a volume expansion of 250ml of crystalloid in the operating room.
45484809|NCT02928094|Biological|Ad5FGF-4|Ad5FGF-4 administered via intracoronary infusion using standard balloon catheter, and under conditions of transient ischemia.
45484810|NCT02928094|Biological|Placebo|Placebo buffer administered via intracoronary infusion using standard balloon catheter, without transient ischemia.
45484811|NCT03421041|Drug|Dexamethasone Oral Tablet|Dexamethasone Oral Tablet，0.75mg/tablet
45846280|NCT02486328|Drug|Propofol|Dosage adjustment
46052013|NCT05660811|Drug|6 months treatment with a single antiplatelet agent|continuing single antiplatelet agent up until 6 months
46052014|NCT02823561|Dietary Supplement|Garcinia mangostana|
46052015|NCT02823561|Behavioral|Control group|
46052016|NCT02823405|Drug|X4P-001|X4P-001 100 mg capsules, administered orally, continuous daily dosing
46052017|NCT02823405|Drug|Pembrolizumab|Pembrolizumab 2 mg/kg, administered by IV infusion every 3 weeks
46052018|NCT02823249|Dietary Supplement|1.56 g L-Tryptophan|
45484812|NCT03244774|Drug|Apatinib|"Apatinib 250mg p.o. qd in first cohort (3 subjects). 375mg p.o. qd in second cohort (3 subjects). 500mg p.o. qd in third cohort (3 subjects). 625mg p.o. qd in forth cohort (3 subjects); 750mg p.o. qd in fifth cohort (3 subjects).~Other Name:"
45368002|NCT03699644|Device|Spectral-Domain Optical Coherence Tomography (SD-OCT)|Each participant in this study will undergo Optical coherence tomography (OCT), a non-invasive imaging test of the eye, one time. OCT uses light waves to take cross-section pictures of the retina, which are generated using scattered light waves.
45484813|NCT03244774|Drug|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
45484814|NCT01346553|Device|ESVV device|wearing the ESVV device for 6 hours
45484815|NCT02911090|Other|Data Registry|Data Registry
45484816|NCT01350219|Device|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 ~ 9 hrs.
45484817|NCT03250468|Behavioral|CBT-I|Each weekly session will focus on several psychological and behavioural techniques that include sleep restriction, relaxation strategies, cognitive therapy, stimulus control therapy, and education about proper sleep hygiene.
45484818|NCT01346631|Other|paleolithic diet|The diet consists of unlimited quantities of meat and fish, fruits and vegetables, eggs, nuts and water. Foods to be avoided include grains, wheat products, legumes, soy, potatoes and corn, rice, legumes, processed meats, soft drinks, dairy products and sugar. Allowed in moderation include coffee, alcohol,cooking oil, honey, salt, dried fruit.
45484819|NCT02903823|Drug|Baclofen bolus injection|A baclofen bolus injection (50 micrograms) will be administered daily after the patient returns from radiology to position catheter injection location. The injection may be given at C4, T4, T10 or L2 spinal locations depending on the catheter tip location.
45484820|NCT03244930|Drug|Plerixafor 0.12 mg/kg|Subcutaneously G-CSF 10 mg/kg for 4 days. At day four SC plerixafor 0.12 mg/kg as a single dose 11 hours prior to initiation of aphaeresis.
45484821|NCT03250312|Other|The Osteopathic Manipulation|The types of OMT techniques used will include muscle energy, articular, or high velocity-low amplitude (HVLA) as indicated by the physical findings and will be at the discretion of the treating physician. Additional techniques such as still, counter strain, facilitated positional release, balanced ligamentous tension, and cranial techniques may also be used at the discretion of the treating physician. The treatment will conclude with 2 minutes of pedal lymphatic pumping
45484822|NCT01350297|Procedure|reinnervation|anastomosis between right inferior laryngeal nerve and right phrenic nerve
45484823|NCT01350375|Drug|Botox|
45484824|NCT01350375|Drug|Saline|
45484825|NCT02855697|Drug|Olaparib|300 mg taken twice daily, equivalent to a total daily dose of 600 mg
45368003|NCT03699644|Device|Magnetic Resonance Imaging (MRI)|Each participant in this study will undergo a single Magnetic resonance imaging (MRI) scan, a scanning technique for creating detailed images of the human body. The scan uses a magnetic field and radio waves to generate images of the brain.
45484826|NCT02855697|Drug|Cediranib|20mg dose of cediranib was selected for this study
45484827|NCT02855697|Drug|Platinum-based Chemotherapy|1 or 2 two courses of platinum-based chemotherapy administered depending on trial entry point.
45484828|NCT03250156|Behavioral|MBAT with proctored practice|The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion. Participants will have proctored practice and complete the assigned, out-of-class mindfulness exercises during the duty day as party of their physical training.
45484829|NCT03250156|Behavioral|MBAT with non-proctored practice|The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion.Participants will not have proctored practice and will complete the assigned, out-of-class mindfulness exercises on their own.
45484830|NCT03249766|Other|Observational|Observational study
45691477|NCT02454322|Drug|Magnesium Sulfate|Standard of care Magnesium Sulfate given to women with a diagnosis of a hypertensive disorder of pregnancy.
45691478|NCT04505566|Drug|Ketorolac 0.45% ophthalmic solution|Ketorolac 0.45% ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
45846281|NCT02491788|Drug|Suvorexant|
45484831|NCT03894501|Behavioral|Mindfulness Oriented Recovery Enhancement|MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
45484832|NCT03894501|Behavioral|Methadone program behavioral treatment as usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
45484833|NCT03249922|Device|Spinal Cord Stimulation|Implantation of a spinal cord stimulator for the control of axial back or neuropathic pain.
45368004|NCT03699644|Device|Positron Emission Tomography (PET)|Each participant in this study will undergo a single Positron emission tomography (PET) scan of the brain. PET is a nuclear medicine functional imaging technique that is used to observe metabolic processes in the brain as an aid to the diagnosis of disease using the combination of a radioactive tracer, camera, and a computer.
45484834|NCT03244228|Drug|HTL0016878|Oral solution
45484835|NCT03244228|Drug|Placebo - Concentrate|Matching placebo
45484836|NCT01350531|Behavioral|Skills training|This component includes skills most proximal to adhering to the eating and weight loss plan (e.g., calorie counting, making healthy food choices, measuring food portions, scheduling snacks and meals, meal planning, completing food logs daily, following an exercise plan).
45484837|NCT01350531|Behavioral|Contingency Management|Contingency management uses behavioral principles to counteract the reinforcing mechanisms of food and inactivity.
45484838|NCT02454010|Biological|FF21101|(90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)
45484839|NCT03249688|Other|Regular health advice|Routine healthy lifestyle counseling
45484840|NCT03249688|Behavioral|Multidomain lifestyle|Nutritional guidance, exercise, cognitive training, vascular risk monitoring
45484841|NCT03249688|Dietary Supplement|Medical food|Medical food product (Fortasyn Connect)
45691479|NCT04505566|Drug|Placebo - Preservative-free artificial tears|Preservative free artificial tears ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
45691480|NCT04505566|Other|Aqueous PGE2 and inflammatory cytokines measurements|After topical anesthetic, antibiotic and 5% povidone-iodine application, a 30 gauge needle on a 1 ml tuberculin syringe will be inserted into the anterior chamber and used to collect 0.1 ml of aqueous fluid from each eye. Aqueous PGE2 and Inflammatory cytokines will be measured
45691481|NCT04387864|Device|Whole-body Vibration Device|Power Plate® (pro5TM; Power Plate North America, Inc., Northbrook, IL, USA)
46052019|NCT02823249|Dietary Supplement|1.56 g L-Leucine|
46052020|NCT02823249|Dietary Supplement|50 g Xylitol|
45368005|NCT03699644|Diagnostic Test|Comprehensive Ophthalmic Examination|Each participant in this study will receive one comprehensive eye examination which will be performed by a licensed ophthalmologist at the University of Michigan. This examination will include the assessment of the participant's visual acuity, a slit lamp examination which will look at the anterior and posterior tissues of the eye including the retina using various lights and lenses, and intraocular pressures.
45484842|NCT01346865|Drug|Cilostazol|Cilostazol 100mg bid
45484843|NCT01346865|Drug|Placebo|Placebo 1tablet bid
45484844|NCT03244462|Drug|BAY1834845|Single oral dose (IR [immediate release] tablets)
45691482|NCT02132650|Behavioral|ACC training|Rehabilitation of walking using accurate (ACC) walking tasks, such as stepping on targets, over obstacles, etc.
45691483|NCT02132650|Behavioral|SS training|Rehabilitation of walking using typical steady state (SS) walking. Conducted overground and on treadmill. 36 sessions of training conducted over the course of 12 weeks. Each session lasts about 1 hour.
45846282|NCT02491788|Drug|Placebo|
46052021|NCT02823249|Dietary Supplement|75 g Erythritol|
46052022|NCT02823249|Dietary Supplement|75 g Glucose|
46052023|NCT02823249|Dietary Supplement|Tap water|
46052024|NCT02823249|Dietary Supplement|Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)|
46052025|NCT02823249|Device|Nasogastric Tube|
46052026|NCT04240743|Device|cephalomedullary nail|For patients in the cephalomedullary nail group, an incision was made in the gluteal area from the tip of the greater trochanter in proximal orientation. A guidewire was placed into the medullary canal from slightly medial to the exact tip of the greater trochanter. The entry point of the greater trochanter and proximal medullary canal were reamed. The cephalomedullary nail was then inserted and fixed to the femoral head with a double screw. The cephalomedullary nail was then locked distally using a guide arm. These cephalomedullary nails were not locked proximally to maintain dynamization and to allow compression across the basicervical fracture line.
46052027|NCT04240743|Device|sliding hip screw|For patients in the sliding hip screw group, a lateral incision was made over the lateral proximal aspect of the femur. Under fluoroscopic guidance, the lag screw was placed centrally in the femoral head over the guidewire. A side plate with three holes was then attached to the hip screw.
45484845|NCT03244462|Drug|BAY1834845|I.v. infusion of [13C6]-labeled BAY1834845
45484846|NCT03244462|Drug|Methotrexate|Single dose of commercially available MTX
45484847|NCT01346943|Device|Altura Medical Abdominal Aortic Aneurysm Stent-Graft|Altura Medical AAA Stent Graft System
45484848|NCT01347021|Procedure|sacrospinous colpopexy versus high uterosacral colpopexy|Women with uterine prolapse grade III or IV were randomly allocated to the sacrospinous colpopexy or high uterosacral colpopexy with vaginal hysterectomy.Before the surgery P-Qol questionnaire were completed and urogynecological examination include de POP-Q system was done. All patients underwent clinical check-ups 1, 6 and 12 months postoperatively. Each check-up included clinical examination and questionnaire.
45484849|NCT03244540|Procedure|TAP (transversus abdominis plane block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain
45484850|NCT03244540|Procedure|QLB (quadratus lumborum block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain
45484851|NCT03244540|Device|Stimuplex Ultra 360 needle|ultrasound-guided needle will be used for QLB and TAP and regional blocks
45484852|NCT03244540|Drug|Ropivacaine|0.375 % ropivacaine will be administered for both QLB and TAP (0.2 mL per kg on both sides)
45484853|NCT03244540|Drug|Paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
45484854|NCT03244540|Procedure|subarachnoid anesthesia|subarachnoid anesthesia for each patients participating in the study with pencil point needle
45484855|NCT03244540|Procedure|PCA (patient controlled analgesia)|All patients will receive PCA pump with morphine (1 mg/mL, 5 minute interval, no loading dose) after transfer to PACU (post-anesthesia care unit)
45368006|NCT03699644|Device|Fundus Photography|Each participant in this study will undergo fundus photography of each eye. Fundus photography involves the use of a retinal camera coupled with a low power microscope to capture photographs of the retina.
45484856|NCT03244540|Drug|Metamizol|Intravenous metamizol will be used (1.0 gram), up to 4 grams per day
45484857|NCT03244540|Drug|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
45484858|NCT03244540|Drug|Bupivacaine|Subarachnoid anesthesia with spinal bupivacaine (MARCAINE SPINAL 0.5% HEAVY)
45484859|NCT01347099|Behavioral|Internet-based cognitive behavior therapy|Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks
45484860|NCT01347099|Behavioral|Support therapy on Internet|Internet-delivered support therapy. Contact with therapist thru an e-mail system. 10 weeks
45484861|NCT03243916|Radiation|TACE plus Cyber knife|Patients with histologically confirmed MHCC(Massive Hepatocellular Carcinoma) will receive TACE therapy,after 1 or 2 week's recovery from hepatic insufficiency ,the targeted and staged cyber knife will be given
45484862|NCT03893799|Drug|RBT-1|intravenous administration
45484863|NCT03249610|Behavioral|Lifestyle intervention|Intervention Trial with Multi-Component Lifestyle Intervention for reduction of body weight and cardio-metabolic risk factors
45691484|NCT01583920|Radiation|focal salvage HDR prostate brachytherapy|Treatment will be delivered using 192-Ir HDR afterloading. Dose prescription is 2 fractions of 13.5 Gy each, delivered 1 week apart.
45691485|NCT05122936|Combination Product|SRXPY-based Obesity Wellness Intervention(SOWI)|It is an integrated obesity wellness intervention, composing of lifestyle invention and Chinese herbal therapy (XRXP granule, twice daily, oral administration). XRXPY is made in accordance with standard procedures. Participants will be instructed by TCM practitioner and educated by nutritionist. They will perform diet self-report by WeChat, recording daytime physical active steps and all-day sleeping time by electric bracelet. All the participants will be followed every 2-4 weeks by means of out-patient clinic, phone call or WeChat.
45691486|NCT05076292|Drug|GlucaGen|150 ug or 75*2 ug glucagon will be administered subcutaneously to the participants before and after exercise.
45691487|NCT05076292|Drug|Saline|Saline will be used as placebo before and after exercise.
45691488|NCT04959994|Device|Novel Motorized Spiral Enteroscopy|All the patients with suspected small bowel disease and an indication to undergo total enteroscopy and satisfying inclusion criteria will undergo novel motorized spiral enteroscopy
45368007|NCT00931580|Dietary Supplement|Vitamin D3|vitamin D3 supplementation at 400 IU vs 1,000 IU vs 2,000 IU vs 4,000 IU vs placebo for 12-weeks
45368008|NCT00930800|Other|Exercise|Using a video game so-called Dance Dance Revolution (DDR)
45368009|NCT05661461|Drug|nab-sirolimus|This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
45368010|NCT00930878|Device|Cardiac Stenting|Drug Eluting stent
45484864|NCT02389803|Dietary Supplement|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended DRI for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
45484865|NCT02389803|Dietary Supplement|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and minerals
45484866|NCT02454790|Radiation|Radiotherapy|
45484867|NCT03341715|Drug|Mavoglurant (AFQ056)|2-100mg tablets of Mavoglurant will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
45484868|NCT03341715|Other|Placebo|Two matching tablets of placebo will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
45484869|NCT03249298|Drug|Sterofundin (Bolus of crystalloids)|Bolus of 250 ml crystaloids infused regarding the measures
45484870|NCT03249298|Drug|Voluven (Bolus of colloids)|Bolus of 250 ml colloids infused regarding the measures
45484871|NCT04541979|Drug|aerosolized DNase|DNase
45484872|NCT04541979|Drug|NaCl|NaCl 0.9%, isotonic saline
45484873|NCT02454166|Other|Ischemic stroke TCM syndromes Diagnostic Scale|A scale for Chinese medical differentiation
45484874|NCT02454166|Other|Meridian Energy Analysis Device|A Device to assess involving meridian in certain diseases
45484875|NCT03243994|Diagnostic Test|Absorption test with D-xylose and zink|Absorption of D-xylose (25 g) and zinc (132 mg), administered as a single dose. The concentration of D-xylose and zinc was measured in peripheral blood one, two and three hours after ingestion and used as markers of absorption. Furthermore, urine was collected for five hours to determine the amount of excreted D-xylose.
45484876|NCT03312309|Procedure|personal embryo transfer|"According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .~pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles."
45484877|NCT02454868|Drug|Remifentanil|Remifentanil for intubation without neuromuscular blockade
45484878|NCT03243760|Drug|CCI15106 7.5 mg capsule|Orange capsule containing a white to off-white powder, 21.4 mg of CCI15106: Trehalose:Trileucine 35/55/10 weight by weight (w/w)
45484879|NCT03243760|Drug|Placebo|Orange capsule containing a white to off-white powder, 21.4 mg of Trehalose:Trileucine 85/15 w/w
45484880|NCT03243760|Drug|Placebo-2|Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.
45484881|NCT02454400|Other|Pre-surgery physiotherapy|"Physiotherapy guided intervention twice a week for nine weeks. The program includes:~Active physiotherapy according to a treatment based classification:~Specific exercises and mobilization~Motor control exercises~Traction~Tailor-made general supervised exercise program~Behavioral approach to reduce fear avoidance and increase activity level.~Standardized information about:~the surgery~post-surgery rehabilitation~to stay active"
46052028|NCT02821845|Behavioral|Untrained and Trained SCI Hip or Knee|Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of hip control or knee control, members of this group will be trained at slow to moderate gait speeds,
46052029|NCT02823171|Drug|Treatment A: 400 mg Pacritinib P3CT|400-mg oral dose of pacritinib P3CT (reference) formulation capsules
46052030|NCT02823171|Drug|Treatment B: 400 mg of pacritinib FMI|400-mg oral dose of pacritinib FMI (test) formulation capsules
46052031|NCT04240431|Diagnostic Test|Probing /irrigation of lacrimal passages|Probing of the lacrimal passage was done using #00 Bowman's lacrimal probe which can reveal any narrowing (resistance) or obstruction (soft stop) of the canaliculi during its advancement from punctum towards the lacrimal sac.
45368011|NCT00931736|Drug|Isoniazid|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
45368012|NCT00931736|Drug|Rifampin|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and < 50 kg, otherwise 300 mg for those weighing < 36 kg. Total duration of treatment is for 4 months.
45368013|NCT05651555|Behavioral|Psycho-educational program EHPAD caregivers / Pact & Pad for caregivers with a parent in an institution|Psycho-educational program EHPAD caregivers / Pact & Pad for caregivers with a parent in an institution
45368014|NCT00930956|Dietary Supplement|Resistant Starch|30 g of carbohydrate per Arm
45484882|NCT02454400|Other|Waiting-list|"Standardized information about:~the surgery~post-surgery rehabilitation~to stay active"
45484883|NCT03753087|Drug|Empagliflozin|10 mg tablet
45484884|NCT03753087|Other|Standard care|Standard care with no SGLT-2 inhibitors
45484885|NCT02454712|Drug|PF614|PF614 is an oxycodone prodrug
45484886|NCT02454712|Drug|Oxycodone extended-release|Oxycodone extended-release is the comparator drug
45484887|NCT02454712|Drug|Naltrexone Hydrochloride|Naltrexone HCl tablets, 50 mg, will be used to block high dose opioid effects in healthy volunteers
45484888|NCT03249064|Diagnostic Test|CD 91 levels|
45484889|NCT03249064|Diagnostic Test|Tregs|
45484890|NCT00832455|Drug|montelukast sodium|Montelukast 4-5 mg for 12 weeks, oral tablet
45484891|NCT03248986|Other|Dry needling|Dry needling of the spastic muscles of the affected arm through DNHS®.
45484892|NCT01350765|Behavioral|Intervention|The LHWs of the selected intervention areas would receive additional training on ENC for identification, management and referral for birth asphyxia, lbw and neonatal sepsis.
45484893|NCT01350765|Behavioral|Control|The LHWs in the control areas would perform their routine tasks as assigned to them by their program
45484894|NCT01350843|Dietary Supplement|Orange Juice|250ml of orange juice or a sugars matched orange drink daily
45484895|NCT03248830|Device|radical-7 pulse co-oximeter|Radical-7 pulse co-oximter will be applied to the patient through a special probe attached the the patient digit to measure blood hemoglobin
45484896|NCT03248752|Behavioral|Fitbit use and reports|Participants will receive a Fitbit device to be used for the duration of the study. Participants will engage with the Fitbit and application and receive Weekly Progress Reports from Fitbit.
46052032|NCT00633711|Device|Automatic (variable, automatically controlled) pressure CPAP|"CPAP at a variable level according to instantaneous patients' needs for treatment of sleep respiratory disorders, as evaluated by machine's software.~Home nocturnal usage. Two-month treatment."
46052033|NCT00633711|Device|fixed continuous positive airway pressure (CPAP)|"CPAP at a constant level, whose efficacy on respiratory disorders has been determined by nocturnal titration.~Home nocturnal usage. Two-month treatment."
46052034|NCT00768079|Other|Placebo|A single dose of placebo matched to benralizumab (MEDI-563) intravenous infusion over at least 30 minutes on Day 0.
45484897|NCT03248752|Behavioral|Partner engagement|Participants will be connected with their partner in the Fitbit app and therefore have the ability to access their partner's progress. Participants' Weekly Progress Reports will be automatically forwarded to their partner. Participants will engage in a weekly discussion on the topic of their Weekly Progress Reports.
45484898|NCT00687531|Drug|Mometasone Furoate|Mometasone Furoate 400 mcg once daily, in the evening through 12 weeks.
46052035|NCT00768079|Biological|Benralizumab|A single dose of benralizumab (MEDI-563) 0.3 or 1 mg/kg of body weight intravenous infusion over at least 30 minutes on Day 0.
46052036|NCT02820675|Other|structured case analysis|implementation of a structured analysis of cases coded as sepsis, severe sepsis, or septic shock after risk adjustment for low-risk-fatalities, high-risk-survivors, and coding errors for preventable deaths, best practice, quality improvement and improvement in coding precision.
45368015|NCT04063787|Device|Fist Assist|"The Fist Assist device works by applying pressure to the subject's arm in the area where their arteriovenous fistula will eventually be created. The device is mobile and battery powered.~The Fist Assist device will be assigned to each enrolled subject by randomization code. All subjects will be asked to use their assigned device twice daily, for two 2-hour sessions, once in the morning and once in the evening. Patients will apply the device to the non-dominant arm above the level of the elbow, and to keep a written log to record use, complications and any problems. They will be asked to do this for 3 months, and will come in to be evaluated via study visits at Months 3, 6, 9 and 12."
45368016|NCT00931034|Behavioral|South Beach Diet with South Beach Diet Products|
45484901|NCT01347411|Procedure|CPAP|Treatment with CPAP
45484902|NCT03243526|Other|fluid therapy|fluid resuscitation guided by CVP or PPV
45484903|NCT01347567|Other|Interventions with heart failure medications|Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
45368017|NCT00931034|Behavioral|American Diabetes Association Diabetes Meal Plan|
45368018|NCT02567981|Dietary Supplement|21 micronutrient-fortified supplement|21 micronutrient fortified supplement: Dose: 18.75g/day. Contains the following daily amounts per dose: Zinc 9 mg, Copper 300mcg, Iron 12mg, Vitamin D 5 mcg, Folic Acid 160mcg, Vitamin E 5mg, Iodine 90mcg, Calcium 200mg, Vitamin A 250mg, Phosphorus 150 mg, Vitamin C 40mg, Magnesium 40mg, Vitamin B12 0.9mcg, Selenium 17mcg, Thiamine 0.5mg, Manganese 0.17mg, Niacin 6mg, Biotin 8mg, Riboflavin 0.5mg, Vitamin B5 1.8mg, Vitamin B6 0.5 mg. Formula (percentage by weight): Maize 64.08%, Soy Beans 30%, Vitamins and Minerals 5.92%, BHA 0.006%. Energy: 73kcal, Protein 4g, Fat 1g, Dietary Fiber 2g, Carbohydrates 12g.
45484904|NCT04487002|Procedure|surgical resection|
45484905|NCT01350921|Drug|Ticagrelor|90 mg oral immediate release tablets, single dose on days 1 and 9
45484906|NCT01350921|Drug|Venlaflaxin|37.5 mg oral immediate release tablets, administered twice daily on days 4-8
45484907|NCT03248518|Behavioral|Usual Care|Information booklet on fatigue which represents usual care in almost all UK rheumatology centres
45484908|NCT03248518|Behavioral|Cognitive behavioural approach|A talking therapy which explicitly aims to replace unhelpful beliefs and behaviours through the application of patient-centred strategies and behavioural activities
45484909|NCT03248518|Behavioral|Personalised Exercise Programme|PEP is a graded exposure behaviour therapy which aims to gradually optimise patients levels of physical activity with view to modifying their altered perception of effort and ultimately reduce the severity and impact of fatigue.
45484910|NCT00423579|Drug|Ezetimibe/Simvastatin 10/20 mg|1 tablet containing 10 mg of ezetimibe and 20 mg of simvastatin per day for 6 weeks
45484911|NCT00423579|Drug|simvastatin 40 mg|1 tablet containing 40 mg of simvastatin per day for 6 weeks
45484912|NCT03243682|Procedure|Bidirectional Shock Wave Lithotripsy|the alternating bidirectional (under and over table) approach during SWL for renal and upper lumbar ureteric stones
45484913|NCT03243682|Procedure|Standard Shock Wave Lithotripsy|the standard unidirectional approach during SWL for renal and upper lumbar ureteric stones
45846283|NCT02491944|Drug|AZD9291|Single oral dose of 80 mg AZD9291 tablet on Day 1 administered orally with 240 mL water following an overnight fast.
45846284|NCT02491944|Drug|[14C]AZD9291|Each healthy male subject will also receive a single, radiolabeled, 100 μg dose of [14C] AZD9291 administered as an IV microdose infusion starting at 5 hours and 45 minutes after receiving the oral dose.
45846285|NCT02492802|Drug|posaconazole|collection plasma samples for measuring posaconazole drug concentration
45846286|NCT02493036|Drug|SYN-010|
45846287|NCT02494518|Behavioral|Forced Exercise & Upper Extremity Repetitive Task Practice|
45846288|NCT02494518|Behavioral|Voluntary Exercise & Upper Extremity Repetitive Task Practice|
45846289|NCT02494518|Behavioral|Stroke Education & Upper Extremity Repetitive Task Practice|
45846290|NCT02495454|Drug|Ga101|
45846291|NCT02500368|Device|silicone hydrogel lens (test)|contact lens
45484914|NCT04533945|Device|FreeStyle Libre|The Freestyle Libre is a device worn on the back of the arm to measure glucose levels in the interstitial fluid. The device is applied by the patient and can be worn for 14 days, at which time it is replaced with a new device. The device does not require calibration with blood glucose testing. A scan with the receiver or a cell phone can be used to obtain glucose levels. The device does not alarm, so scanning is the only way for a patient to know if they are hypo or hyperglycemic. Studies have shown that the use of this technology can improve glycemic control as measured by Hemoglobin A1c and glucose variability in some patients. In addition, use of this technology in the outpatient setting has been associated with both improved patient satisfaction and increased glucose monitoring
45484915|NCT03248362|Device|Transcutaneous posterior tibial nerve stimulation|12 session programme (a total of 6 hours) is delivered in 30 minute sessions twice weekly over a 6 week period of tibial nerve stimulation
45484916|NCT03248362|Device|Sham stimulation|12 session programme (a total of 6 hours) is delivered in 30 minute sessions twice weekly over a 6 week period of of the lateral sub-malleolar area
45484917|NCT03243604|Drug|L02 (sex hormones used in treatment of neoplastic diseases) and G03 (sex hormones)|Androgen-deprivation therapies including L02 (sex hormones used in treatment of neoplastic diseases), and G03 (sex hormones)
45368019|NCT02567981|Dietary Supplement|Cereal Fortificado (Fortified Cereal)|"Cereal Fortificado Dose: 45g/day. Contains the following daily amounts per dose: Vitamin A 226.6mcg, Thiamine 0.058mg, Riboflavin 0.202mg, Niacin 2.16mg, Panthotenic acid 3.015mg, Vitamin B6 0.765mg, Folate 27mcg, Vitamin B12 0.9mg, Vitamin C 45mg, Vitamin D 1.8mcg, Vitamin E 3.735mg, Vitamin K 45mcg, iron 3.6mg, Zinc 1.8mg, Iodine 18mcg, potassium 180mg, phosphorus 90 mg, calcium 58.50mg. Percentage weight: 58% corn, 20% soy, Skim dry milk 8%, Sugar 9%, Soy Oil 3%, Vitamins and Minerals 0.2%, calcium phosphate 1.23%, Potassium chloride 0.27%. Energy 184.5 kcal, protein 7.2%, Fat 4.1%, Fiber 1.4%, Ash 4.6%."
45484918|NCT01351155|Device|Skin protective dressing device|Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury
45484919|NCT03248284|Procedure|Tendon biopsy procedure|Two tendon biopsy specimens will be obtained from one Achilles tendon with enthesitis.
45368020|NCT02567981|Dietary Supplement|Ferrous sulphate|"Ferrous sulfate drops children <12 months: 12,5mg elemental iron/day (continuous). Children from 12-23.9months: elemental iron 25mg/day (continuous).~Chidlren from 24 to 59 months: 1ml/day for two months, every 6 months."
45484920|NCT04296123|Behavioral|Step training|A 12-week step training consisting of two 30-minute training session per week. The participants will be instructed to stand upright and step on different targets on a plastic mat repeatedly.
45484921|NCT02454556|Drug|FOLITIME®|
45484922|NCT02454556|Drug|Gonal-F®|
45484923|NCT01352481|Other|Early parent-based speech intervention program|Seven 1h sessions during a three-month period.
45484924|NCT03248050|Behavioral|Pharmacy encouraged to promote call centre use to clients|The details of the intervention will be finalised following an intervention design workshop. The main components will be: Provision of materials with the MSZ call centre number on for pharmacy workers to give women buying MA medications to call the number for free, confidential advice on how to use the pills before they take them; incentives; monthly monitoring visits.
45484925|NCT01352559|Drug|responders|Antidepressants administration for 6 weeks under therapeutic dose
45484926|NCT01352559|Drug|non-responders|Antidepressants administration for 6 weeks under therapeutic dose
45484927|NCT03247972|Drug|Evolocumab|Sixty subjects will be treated with high dose statins for 8 weeks followed by 8 weeks of high dose statin + evolocumab (420mg/4 wk) therapy.
45484928|NCT01351233|Procedure|Cataract Surgery|Take the operation of phacoemulsification and implant the AcrySof Toric intraocular lens into the capsular bag in high myopic subjects.
45484929|NCT03243292|Other|Bronchial Thermoplasty|patients had radio frequency ablation of the smooth muscle for asthma
45484930|NCT03126513|Procedure|G-POEM|After confirmation of refractory gastroparesis, participants will undergo to gastric POEM. Participants will be admitted to hospital 24hrs before procedure and IV antibiotics will be given and then the procedure will be done. Technique consist of 4 steps: First: a submucosa injection of saline solution with methylene blue at 3-4cms from pylorus. Second: a submucosa incision and tunnel creation up to pyloric area. Third: Myotomy of the circular and longitudinal muscular layers of the pylorus and the antrum. Fourth: closure of the mucosal incision with hemoclips. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic and scintigraphic studies up to 1 year after procedure.
45484931|NCT03247894|Other|Data search|Patients data were searched for the patients with MS, who laboured in tertiary perinatology center in the study period
45484932|NCT04502823|Procedure|Management based on sFlt-1/PlGF values|"In women allocated to the intervention group, the sFlt-1/PlGF result will be revealed to the investigators that will act according to the results of sFlt/PlGF:~Fetuses with sFlt-1/PlGF ≥38, elective delivery will be recommended immediately (within 24h) at ≥37 weeks.~Fetuses with sFlt-1/PlGF <38 weekly follow up will be recommended and delivery at ≥40 weeks."
45484933|NCT03243214|Device|TMS|Real or Sham TMS will be given to the PD-MCI patient
45691489|NCT04815070|Procedure|Ultrasonic measurement of antral area|"Ultrasound exam is done before the induction of spinal anesthesia. Three consecutive measurements of the anteroposterior (AP) and cranio-caudal (CC) diameters are performed.~The cross-sectional area (CSA) of antrum is shown by the following formula: CSA = AP x CC x ㅠ/4.~Antral area will correspond to the average of the three measures."
45691490|NCT04789330|Drug|Norepinephrine|Norepinephrine administered during anesthesia
45691491|NCT04789330|Drug|Phenylephrine|Phenylephrine administered during anesthesia
45484934|NCT03243214|Device|Sham-TMS|Real or Sham TMS will be given to the PD-MCI patient
45484935|NCT01346319|Drug|ABT-SLV361|For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
45484936|NCT01346319|Drug|placebo|For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
45368021|NCT02567981|Dietary Supplement|Vitamin A|Vitamin A Capsules: children <12 months: 100.000 IU/6 months. Children 12-59 months: 200.000 IU/6 months.
45368022|NCT00931814|Other|exercise training|A progressive and structured, small-group exercise training 3 times a week, 30-40 min a session at intensity of 12-14 in rate of perceived exertion (RPE) for 8 weeks
45484937|NCT01350609|Drug|Nifedipine/Candesartan (BAY 98-7106)|Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period)
45484938|NCT01350609|Drug|Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)|Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) .
45484939|NCT01351311|Other|Exercise|Resistance Training exercise with swiss ball
45484940|NCT01351311|Other|Drug treatment|Drug treatment
45484941|NCT03269409|Other|Lactated Ringers|Approximately 5 mls of lactated ringers will be injected after decompression into the hip that does not receive adipose derived regenerative cells.
46052037|NCT02820675|Other|"strucured screening every patient, every shift"|implementation of a strutured screening and rescue algorithm on regular wards, emergency departements, and intermediate and intensive care units by checking every patient in every shifts for clinical signs of deterioration and apllying a rescue algorithm including consiliary help and/or the help of outreach teams
46052038|NCT04753047|Other|No intervention|No intervention
46052039|NCT02603575|Drug|caspofungin|70mg ivdrip the first day, then 50mg ivdrip qd
46052040|NCT02603575|Drug|corticosteroids|40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days
45368023|NCT05741567|Procedure|correction of anterior prolapse|percentage of failed prolapse correction
45368024|NCT00931112|Other|individualized exercise training|Lower extremities resistance exercise and bicycle training
45368025|NCT05741489|Device|Continuous glucose monitoring (CGM)|The Dexcom G6 CGM system is a compact, light-weight glucose testing device that measures glucose every 5 minutes. Participants will wear the CGM with the display off for 10 days while continuing their routine dialysis sessions.
45368026|NCT00926120|Dietary Supplement|Mogroside sweetener (PureLo)|Mogroside sweetener administered at a dosage level of 5g every 6 hours for 14 days
45368027|NCT00737555|Drug|CHR-2797|Oral once daily administration of capsules of CHR-2797, to determine safety and tolerability in patients being treated with paclitaxel infusion every 3 weeks for up to 18 weeks.
45368028|NCT00932048|Drug|Atorvastatin|Atorvastatin 10mg once daily for 12 weeks
45368029|NCT04015778|Biological|Nivolumab|240mg Q2W or 360mg Q3W
45484942|NCT03269409|Device|The Celution 800/GP System (Cytori Therapeutics)|The Celution 800/GP System will be used for the preparation of adipose derived regenerative cells from lipoaspirate. The adipose derived regenerative cells will then be transplanted into the hip, post decompression.
45484943|NCT03269409|Biological|Adipose Derived Regenerative Cells (ADRC)|Subjects in this arm will have Adipose Derived Regenerative Cells (ADRC)harvested through autologous liposuction and processed outside the body using The Celution 800/GP System (Cytori Therapeutics) before having approximately 5 mls. of ADRCs transplanted into the femoral head after standard of care hip decompression.
45484944|NCT03248206|Behavioral|lifestyle changes|Providing a home-based exercise program supervised by therapists can be an acceptable strategy with the characteristics of convenience and inexpensiveness to promote neuromuscular and functional component for the patients with diabetes mellitus.
46052041|NCT02603575|Drug|Sulfanilamides|1.92g q8h
46052042|NCT02601859|Drug|Lithium Carbonate|
45368030|NCT04015778|Drug|carboplatin|AUC 5, d1 every three weeks
45368031|NCT04015778|Drug|nab-paclitaxel|135 mg/m2, d1, 8
45368032|NCT02568293|Other|SBCV|SBCV is a single use, sterile product that acts as a localized physical barrier at the vascular wall.
45368033|NCT02568293|Other|Saline|Saline is used as a control.
45368034|NCT05546099|Behavioral|Self-management of BP medications|Patients will be educated on how to manage their home BP based on a pre-determined protocol. They will then monitor home BP and adjust meds accordingly and under the guidance of the clinical pharmacist.
45368035|NCT05546099|Behavioral|Self-monitoring of home BP|Patients will be educated on how to monitor home BP and will be educated to contact their primary care provider/CKD provider if the BP is above the goal.
45484945|NCT01351389|Behavioral|Brief Motivational Intervention (BMI)|The BMI incorporates open-ended exploration, personalized feedback, and discussion about patients' alcohol use and sexual behaviors and the consequences of these behaviors. Using the central principles described by Miller and Rollnick (2002), the goal of the session, conducted in the hospital as soon as possible, is to explore the patient's alcohol use and sexual behaviors and to help patients consider what they might want to change. Also included is a presentation of personalized feedback, and for patients who are interested in change, a focus on establishing goals for reduced drinking and sexual risk abstinence. Collaboratively the counselor and patient develop a plan for the future, identify goals for behavior change, explore barriers to changes, and provide strategic advice.
45368036|NCT00926276|Procedure|Fundoplication|Fundoplication
45484946|NCT01351389|Behavioral|Brief Advice|Patients in the Brief Advice (BA) condition will receive intervention consistent with standard medical practice when alcohol problems or sex-risk behaviors are indicated. Project staff will offer BA about level of alcohol/drug and sexual behaviors and drug problems risk, and will provide a list of treatment resources (including options for HIV testing) in the local area. Patients will be told they show signs of risk associated with alcohol use in that they scored above a cut-score for our alcohol screen, and that they reported recently engaging in sexually risky behaviors. The staff person will advise patients that reducing their alcohol use, and illicit drug use when relevant, and using condoms is advised. BA will take approximately 5 minutes.
45484947|NCT03243136|Other|Exposure of interest is food insecurity|Households were considered food insecure if any of the following conditions were met in the past 12 months: 1) a member of the household worried that there would not be enough food to eat because of a lack of money, 2) a member's food intake was reduced as a result of there not being enough food to eat, or 3) the desired variety or quality of foods was not eaten because of a lack of money. This exposure variable was operationalized as a binary variable with levels of food secure vs. food insecure.
45484948|NCT04343313|Device|Half Moon TMVr System|The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.
45484949|NCT03242902|Device|Light therapy intensity 1|Exposure to white light (10.000 lux) in the morning
45484950|NCT03242902|Device|Light therapy intensity 2|Exposure to white light (10-20 lux) in the morning
45484951|NCT02454634|Drug|IDH1 peptide vaccine|
45484952|NCT03247660|Other|PFM training|See information included in arm/group descriptions.
45484953|NCT03247660|Other|HE|See information included in arm/group descriptions.
45368037|NCT05540873|Drug|YYB-103|Biological: IL13Rα2 CAR-T cells Administration method: intravenous infusion YYB-103 is manufactured according to the subject's assigned dose group and body weight.
45484954|NCT03247660|Behavioral|Educational strategy|See information included in arm/group descriptions.
45484955|NCT04487158|Behavioral|Small Changes|The Small Changes program is an evidence-based 6-month weight-management program. The program runs weekly for 3 months followed by by-weekly contact for 3-months (1x in-person group and 1x phone call). This program uses behaviour change strategies to help with weight loss. The Small Changes approach is different from traditional dieting programs because it encourages modest changes to diet and physical activity which are not overly taxing to maintain. Participants are asked to reduce their nutritional intake by 200-400 calories per day. You will also be asked to increase their daily step count by 2000-3000 steps. Weekly intervention topics include: Monitoring, Nutrition, Physical Activity, Breaking the Chain, External Cues, Mindful Eating, Body Image, Stress, Sleep, Social Support, Social Eating, and the Stoplight Guide.
45691492|NCT02339038|Drug|Ledipasvir 90 mg and Sofosbuvir 400 mg|Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination as per standard of care treatment guidelines
45691493|NCT04497298|Biological|Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - Low dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)
45368038|NCT00926354|Drug|AS101|intravenous infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen during the following 4 chemotherapy courses.
45368039|NCT00926432|Device|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
45368040|NCT00926432|Device|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
45368041|NCT00712985|Drug|Zometa|Zometa (Zoledronic Acid) 5 mg IV over 15 minutes in a one time dose
45368042|NCT00926510|Behavioral|Language toolkit|Simple toolkit of interactive things to stimulate language.
45368043|NCT00926510|Behavioral|Safety counseling|Smoke detector and general safety counseling
45368044|NCT05741411|Other|mHealth assisted specialist access|Concussed subjects will be prompted to report current symptoms twice a day via a digital health platform. A nurse navigator will have access to the symptom data and will facilitate scheduling an in person or telehealth specialist visit as indicated by the symptom data. Symptoms will continue to be monitored through the acute study period with additional clinical visits occurring according to clinical need.
45368045|NCT05518877|Drug|Ketamine|Administration of Ketamine
45368046|NCT00737789|Drug|Mesalazine slow-release granules|Mesalazine 2g Sachet prolonged release granules, administered orally.
45368047|NCT00737789|Drug|Mesalazine liquid enema|1g mesalazine liquid enema, administered topically once a day in the evening.
45484956|NCT04487158|Behavioral|INSPIRE|The INSPIRE program is a modification to the Small Changes program. It combines elements of positive psychology and behaviour change to help with weight loss. The first four weeks of the program are oriented towards improving well-being and include topics such as values, self-compassion/mindfulness, character strengths, and gratitude. The remaining 8 weeks mirrors the Small Changes program in making modest changes to diet and physical activity to achieve weight loss. Participants are asked to reduce their nutritional intake by 200-400 calories per day. Participants will also be asked to increase their daily step count by 2000-3000 steps.
45484957|NCT03247426|Other|Evaluation individuals|Sleep quality of the individuals, job satisfaction, quality of life, occupational burnout level will be evaluated.
45484958|NCT03242980|Behavioral|Structured adherence counseling|"Patients will undergo one standardized enhanced adherence counselling session. Counselling guidelines and a brochure were specifically developed to guide the adherence counselling for individuals with unsuppressed VL. All nurses at the health centres will be trained on the counselling prior to the cross-over to the intervention. The brochure was developed by culturally adapted by social scientists and contains only 3 key messages. The brochure will be given to the patient to take home.~Four weeks after the adherence counselling session, a SMS will be sent to the patient reminding them to take their ART. The content of the text message will be anonymous to protect disclosure and discussed/agreed upon with the patient during the adherence counselling."
45691494|NCT04497298|Biological|Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - High dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)
45691495|NCT04497298|Biological|One COVID-19 vaccine candidate (TMV-083/V-591) administration - High dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2) and placebo
45691496|NCT04497298|Other|Placebo|Physiological saline solution (0.9% NaCl)
45691497|NCT04387786|Drug|Dornase Alfa|nebulized in-line endotracheal dornase alfa co-administered with albuterol
45368048|NCT05612789|Behavioral|Exercise Program (Cohort A Prehab)|Pre-frail and frail potential HCT recipients 60 years and older will participate in a supervised exercise program from the time of enrollment up until HCT admission. Exercise compliance will be measured in part through physical activity trackers.from time of discharge from HCT until day +100 post-HCT. All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
45368049|NCT05612789|Behavioral|Exercise Program (Cohort B Rehab)|All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
45691498|NCT02136004|Device|Closer VSS|At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.
45691499|NCT00569530|Drug|Infasurf (ONY Inc.)|Infasurf 3ml/kg will be given to infants on study days 0, 3, 7, 10, and 14, if remains intubated.
45691500|NCT00569530|Drug|Sham|Sham instillation (no treatment) will be given to study infants on days 0, 3, 7, 10, and 14, if remains intubated.
45691501|NCT04509622|Drug|Venetoclax|Tablet; Oral
45691502|NCT04509622|Drug|Cytarabine|Subcutaneous Injection
45368050|NCT05611619|Radiation|Tyre noise - continuous flow|Tyre noise from continuous traffic, throughout the night
45368051|NCT05611619|Radiation|Tyre noise - discrete events|Tyre noise from few, discrete traffic events, occurring throughout the night
45368052|NCT05611619|Radiation|High noise level|Tyre noise corresponding up to 65 dB LAEq,24h
45368053|NCT05611619|Radiation|Moderate noise level|Tyre noise corresponding up to 60 dB LAEq,24h
45691503|NCT02136238|Device|Hosmer 5XA voluntary opening hook|"Voluntary opening prosthetic terminal device (hand)"
45846292|NCT02500368|Device|enfilcon A lens (control)|contact lens
45368054|NCT05611619|Radiation|Low noise level|Tyre noise corresponding up to 55 dB LAEq,24h
45368055|NCT05611619|Radiation|Air-filled tyres|Tyre noise from traditional, air-filled tyres
45368056|NCT05611619|Radiation|Composite tyres|Tyre noise from newly designed, airless composite tyres
45368057|NCT00700115|Drug|Kaletra + Isentress|Kaletra 400/100 mg + Isentress 400 mg BID
45368058|NCT00700115|Drug|Pre-study antiretroviral regimen|Standard doses of pre-study antiretroviral regimen
45368059|NCT04062929|Behavioral|4-day physical activity program with behavioral intervention|Each program included 8-12 patients. During the four days, the participants had 4 collective sessions of educational information on PA and heart disease and 2 one-to-one sessions for promoting personal advice and experience on PA behavior. The participants had 6 sessions of PA and 2 food-counseling sessions.
45368060|NCT05556473|Drug|1-(2-[18F]FLUOROETHYL)-L-Tryptophan|Radioactive tracer 1-(2-[18F]FLUOROETHYL)-L-Tryptophan 0.14mCi/kg/5MBq/kg injection given one time prior to PET Scan.
45691504|NCT02136238|Device|TRS Grip 3 voluntary closing hook|"Voluntary closing prosthetic terminal device (hand)"
45368061|NCT04062773|Behavioral|TRF|time restricted feeding group
45368062|NCT04062773|Behavioral|Normal timing of food intake|no time restricted feeding
45368063|NCT02568917|Procedure|Atraumatic Restorative Treatment - Ketac Molar Easy Mix|Occlusal and occlusal-proximal ART restorations in primary and permanent molars using the high viscosity GIC Ketac Molar Easy mix will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
45368064|NCT02568917|Procedure|Conventional Restoration - Composite Resin (Bulk Fill)|Occlusal and occlusal-proximal composite resin restorations in primary and permanent molars using the Scotchbond Multi-purpose adhesive system and the Filtek Bulk Fill composite resin wil be performed. Local anesthesia can be used if necessary. Access to caries lesion will be done using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked.
45368065|NCT00566852|Drug|Memantine|Patients began taking memantine(by mouth) while receiving radiation therapy. Patients continued taking memantine for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
45368066|NCT00566852|Other|Placebo|Patients began taking placebo(by mouth) while receiving radiation therapy. Patients continued taking placebo for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
45368067|NCT00566852|Radiation|Whole brain radiation therapy|Whole brain radiation therapy (WBRT) once a day (2.5Gy), five days a week (Monday to Friday) for three weeks, for total fifteen treatments and 37.5 Gy
45368068|NCT00931346|Drug|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
45368069|NCT00931346|Drug|Placebo|Placebo
45368070|NCT00936650|Drug|placebo|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
45368071|NCT00936650|Drug|cinacalcet|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
45368072|NCT00442546|Drug|pregabalin|150 milligram (mg)/ day (double blind)
45484959|NCT03242668|Procedure|VATS|General anesthesia was induced with 2.0 mg/kg of propofol, 2.0 mg/kg of fentanyl, and 1.0 mg kg/1 of rocuronium and maintained with continuous infusion 6-12mg/kg/h of propofol,injected 2.0 mg/kg of fentanyl and 0.15 mg/ kg of rocuronium every 30 minutes . All patients were intubated with a double-lumen endobronchial tube for one-lung ventilation.The VATS (Video-Assisted Thoracic Surgery) was performed.
45484960|NCT03242668|Procedure|PVB using PVC|At the end of the surgery, the upper edge of the spinous process of the thoracic vertebral body was recognized. With an epidural needle (Tuohy 22 G; Braun, Melsungen, Germany), the injection point was punctured 2 cm lateral to the midline. The paravertebral space was entered by advancing the Tuohy needle over the superior border of the transverse process. Once in the right place, the PVC was placed through the needle, checking the tip remained placed when removing the needle. The advance of the needle and the entering of the catheter into the paravertebral space were verified all the time by the surgeon using the camera. The PVC (Paravertebral Catheter ) was inserted at this point preversed at this area.
45691505|NCT04388098|Other|Diagnosis of caries experience and periodontal health|
45368073|NCT00442546|Drug|pregabalin|300 mg/day (double blind)
45368074|NCT00442546|Drug|Placebo|Placebo
45691506|NCT00570700|Drug|Dasatinib|150mg (3 pills) orally daily for as long as the drug benefits
45691507|NCT00571324|Drug|Exendin-(9-39)|A short term intravenous infusion of the study drug, exendin-(9-39), will be given over 6 hours.
45691508|NCT00571324|Other|Vehicle|A short term intravenous infusion of normal saline, or the vehicle, will be given over 6 hours.
45846293|NCT02500602|Drug|doxazosin|active medication
45484961|NCT03242668|Drug|PCA|PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA (Perfusor space pump,Germany)with background rate 3ml/h, bolus dose 2ml was infused through PVC.
45484962|NCT03247192|Dietary Supplement|Whey protein-placebo|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
45484963|NCT03247192|Dietary Supplement|Placebo-whey protein|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
45484964|NCT03247192|Dietary Supplement|Placebo-placebo|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
45368075|NCT03545594|Other|Patient-centered in home rehabilitation|Eight contacts (six in-home visits of 1-2 hours duration each and two telephone contacts before the Corona pandemic and eight sessions with up to six of them video delivered if necessary during the Corona pandemic ) delivered over a 4-month period in three phases
45368076|NCT03545594|Other|Control|Usual follow-up in the municipality
45368077|NCT00936962|Biological|NeisVac C vaccine (12mth)|NeisVac C Meningococcal C Conjugate vaccine given IM 0.5mL in the deltoid muscle at 12 mths of age
45368078|NCT00514683|Drug|low dose BIBF1120 once daily|low dose BIBF1120 once daily
45368079|NCT00514683|Drug|low dose BIBF 1120 twice daily|low dose BIBF 1120 twice daily
45368080|NCT00514683|Drug|intermediate dose BIBF 1120 twice daily|intermediate dose BIBF 1120 twice daily
45368081|NCT00514683|Drug|high dose BIBF 1120 twice daily|high dose BIBF 1120 twice daily
45368082|NCT00514683|Drug|placebo|placebo
45368083|NCT00566696|Device|CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
45368084|NCT00566696|Procedure|Stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
45368085|NCT00566696|Drug|Fludarabine|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
45368086|NCT00566696|Drug|Thioplex®|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
45368087|NCT00566696|Drug|L-phenylalanine mustard|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
45368088|NCT00566696|Drug|Mycophenolate mofetil|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
45368089|NCT00566696|Drug|Rituxan™|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
45484965|NCT03242512|Biological|TK006|Subcutaneous injection
45484966|NCT03247270|Behavioral|Intervention I|Low intensive physical exercise
45484967|NCT03247270|Behavioral|Intervention II|High intensive physical exercise
45368090|NCT00566696|Drug|Alemtuzumab|After January 2010, due to the unavailability of muromonab, transplant recipients received a conditioning regimen consisting of systemic chemotherapy and antibodies, including alemtuzumab.
45368091|NCT00566696|Drug|Cyclophosphamide|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
45368092|NCT00566696|Drug|Anti-thymocyte globulin (Rabbit)|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
45368093|NCT00566696|Drug|G-CSF|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
45368094|NCT00566696|Drug|Muromonab|Prior to January 2010, transplant participants received a conditioning regimen consisting of systemic chemotherapy and antibodies, including muromonab. Muromonab became unavailable from the manufacturer at that time and was replaced by alemtuzumab.
45846294|NCT02500602|Drug|placebo|placebo pill
45368095|NCT00937196|Drug|Placebo globuli|placebo globuli administered together with verbal suggestions of a hypotensive drug effect
45368096|NCT00937196|Drug|Histaminum hydrochloricum globuli|
45368097|NCT00937274|Other|T4 phage cocktail test|T4 phages 106 PFU/ ml up to 5 days
45368098|NCT00937274|Other|Commercial T4 phage cocktail|Treatment as recommended by the manufacturer (Microgen phages)
45368099|NCT00937274|Other|standard oral rehydration solution (ORS)|Standard hospital treatment with ORS
45368100|NCT00926666|Drug|Levobupivacaine|Dose finding study for levobupivacaine in fractured neck of femur patients. Ultrasound guided anterior psoas compartment nerve block to determine EC50 using up/Down methodology in patient before surgery to fix broken hip.
45368101|NCT00926744|Behavioral|physical activity|The targets of amount of physical activity are 3.3METs•h/day (MVPA) and 10,000 step counts/day.
45368102|NCT00932204|Device|repetitive transcranial magnetic stimulation (Magstim rapid magnetic stimulator)|"For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d).~For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area."
45484968|NCT03247348|Behavioral|ReSeT-FM intervention|The ReSeT-FM intervention focuses on behavior changes strategies aimed at reducing sedentary time and includes: education, goal setting, self-monitoring of behavior and behavioral prompts to move via an activity tracker and phone app, and feedback on behavior via weekly meetings with study coaches.
45691509|NCT04338646|Other|Clinical tests|Questionnaire about urinary symptoms, gait difficulties, fear of falling. Clinical test: Time to be Ready to Void
45691510|NCT00573508|Drug|Placebo|Oral Administration
45691511|NCT00573508|Drug|Solifenacin Succinate|Oral Administration
45484969|NCT03242356|Other|Questionnaire to assess of the application of the current French guidelines as to fasting during labor.|"Questionnaire focuses on :~oral intake of clear fluid during the labor~oral intake of solid meal during the labor~fasting duration for solid and liquids~instruction received as to fasting during labor, nature of these instructions, and who given the instruction (midwife, nurse anesthetist, …)~discomfort related to thirst during labor~discomfort related to hunger during labor~We will also record several medical data as to the course of pregnancy and delivery, analgesia technique, history and characteristics of the parturient."
45484971|NCT03246802|Radiation|HDR partial prostate brachytherapy|temporary radioactive implant
45484972|NCT03778372|Drug|Methadone|see desc above
45484973|NCT03242200|Other|Mobile Health App|Mobile Health is a multi-featured app designed to enable participants to self-record and track their health and wellness. Participations will set up a profile and complete questionnaires. The app also records the amount of time and features of programs accessed.
45484974|NCT04486846|Other|eVisit|electronic surveillance program in lieu of in-person clinic visit
45484975|NCT03247114|Other|Water|Water, 300 ml at room temperature
45484976|NCT03247114|Other|Glucose|Glucose, 50 grams in 300 ml water at room temperature
45484977|NCT03247114|Other|Fructose|Fructose, 50 grams in 300 ml water at room temperature
45484978|NCT03247114|Other|Sucrose|Sucrose, 50 grams in 300 ml water at room temperature
45484979|NCT03247114|Other|Sucralose|Sucralose, 0.33 grams in 300 ml water at room temperature
45484980|NCT03246880|Drug|Tamsulosin 0.2mg|per oral for 12weeks after 2~4weeks run-in period
45484981|NCT03246880|Drug|Tadalafil 5mg|per oral for 12weeks after 2~4weeks run-in period
45368103|NCT04014686|Other|No exercise intervention group|no exercise intervention
45368104|NCT04014686|Behavioral|Resistance band exercise intervention group|Resistance band exercise training intervention (12 weeks, 3x per week, for 60 minutes per day)
45368105|NCT00926900|Drug|D-cycloserine|50 mg at approximately 1.5 hours prior to cue-exposure training sessions
45368106|NCT00926900|Drug|Placebo|Placebo
45691512|NCT04364308|Other|Fetal Echography|Fetal ultrasound and its parameters
45691513|NCT00574834|Drug|Ramipril|Ramipril 20 mg once daily for 6 months
45691514|NCT00574834|Drug|HCTZ-hydrochlorothiazide|HCTZ 25 mg once daily for 6 months
45691515|NCT00574834|Drug|Ramipril+HCTZ|Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months
45691516|NCT00575146|Dietary Supplement|TAVARLIN|ketogenic diet, dietary supplementary products provided by TAVARLIN
45846295|NCT02500836|Drug|Cocaine HCl 4% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
45368107|NCT00937430|Other|Bowel preparation (Fleets enema)|Use of Bowel preparation (Fleets enema)
45368108|NCT00503841|Drug|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
45691517|NCT04095520|Procedure|Laser Etching|Before the restorations, cavities will be etched Er:Cr YSGG laser with 4W output power, water pressure 95% and air pressure 60% with MGG6 tip with the spot size of 600 µm will be used.
45691518|NCT04095520|Procedure|Phosphoric acid etching|Before the restorations, cavities will be etched with %37 phosphoric acid for 15 seconds.
45691519|NCT04288414|Diagnostic Test|functional near-infrared spectroscopy|Functional near-infrared spectroscopy (fNIRS) is a non-invasive method that can evaluate the brain function by measuring the change in brain metabolic activity and hemodynamics during a given task with near-infrared spectroscopy.
45484982|NCT03242044|Procedure|Congenital diaphragmatic hernia resuscitation with an intact umbilical cord|10 infants with left or right sided congenital diaphragmatic hernia will be intubated and ventilation initiated while still attached to the placental circulation through the umbilical cord. In addition, at the same time, a nasogastric tube will be placed in the stomach to drain entrained air and secretions. After 5 minutes of resuscitation with the umbilical cord intact, the umbilical cord will be cut, infants separated from the placenta and resuscitation performed per routine neonatal resuscitation protocols. Feasibility, the optimal approach and maternal and infant tolerance to the procedure will be assessed as part of the study.
45484983|NCT02711644|Behavioral|Supportive Lifestyle Counselling|Each participant will meet with the intervention Registered Dietitian twice in pregnancy and have two follow-up phone calls. Participants in this group will have on-going, supportive discussions with the intervention Registered Dietitian about healthy lifestyles in pregnancy. Discussion topics with the intervention Registered Dietitian at each visit will be participant-centered, allowing the participant to guide the conversation. These conversations will be reinforced at every future contact made throughout pregnancy.
45484984|NCT02711644|Behavioral|Standard Lifestyle Counselling|Each participant will meet in person with their respective Registered Dietitian twice in pregnancy and have two follow-up phone calls. At these visits, each participant will complete questionnaires and have anthropometric assessments (height/weight). From home, each participant will also complete online questionnaires at week 26, and week 34. Postpartum,each participant will complete an online questionnaire. Optional postpartum participation includes a focus group in the postpartum period and the option to meet with a Registered Dietitian postpartum.
45484985|NCT02690584|Behavioral|Metacognitive therapy|
45484986|NCT03242122|Other|CHO Control 1 and 2 Glucose|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
45484987|NCT03242122|Other|CHO Experimental 1 Slowly Digested|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
45484988|NCT03242122|Other|CHO Experimental 2 Digestion Resistant|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
45484989|NCT03242122|Other|CHO Experimental 3 Low Sugar|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
45484990|NCT03242122|Other|CHO Experimental 4 Maltodextrin|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
45484991|NCT03246412|Diagnostic Test|Nevus doctor clinical decision support|The computer program analyzes dermatoscopic images. The output is an estimate of the risk of the skin lesion representing skin cancer. The decision support tool helps the doctor to assess the significance of the computer output by taking into account clinical information.
45484992|NCT03258034|Drug|SPA|S1/Paclitaxel chemotherapy plus Apatinib S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:425mg once daily
45484993|NCT03258190|Drug|Lime Powder Regimen|LPR and placebo were randomly given to subjects for 6 months
45484994|NCT03258112|Procedure|Radiofrequency cardiac catheter ablation|procedure used for ablation of ventricular arrhythmia using catheters introduced to target sites percutaneously through venous or arterial systems using radiofrequency power
45484995|NCT03257722|Drug|Pembrolizumab|Anti PD-1 immunotherapeutic agent, which blocks a protective mechanism on cancer cells to allow the immune system to destroy cancer cells. Administered intravenously (IV).
45368109|NCT00503841|Other|immunohistochemistry staining method|Assessed at the time of the initial biopsy and at the time of surgery.
45484996|NCT03257722|Drug|Idelalisib|Phosphatidylinositol 3-kinase (PI3K) inhibitor which promotes anti-tumor immune response. Administered orally (PO).
45484997|NCT03268005|Drug|Faster-acting insulin aspart|Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
45484998|NCT03268005|Drug|Insulin aspart|Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
45484999|NCT03268005|Drug|Insulin degludec|Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
45485000|NCT03268005|Drug|Metformin|Only participants who took metformin before the study should take metformin tablets, same dose as before the study
45485001|NCT03239314|Drug|Saline Solution|Injected in the adductor canal
45485002|NCT03239314|Drug|Dexamethasone|Injected in the adductor canal
45596363|NCT02288923|Procedure|Femoral nerve block|"Supine position~If using peripheral nerve stimulator for localisation of the femoral nerve:~50 mm insulated needle Peripheral nerve stimulator set at 2 Hz with pulse width 100μs When quadriceps muscle twitch is present with a stimulated current between 0.2 and 0.5mA, inject 20ml 0.375% (3.75mg/ml) Levo- bupivacaine~If using ultrasound for localisation of the femoral nerve:~High frequency linear array probe Short bevelled nerve-block needle, using in or out of plane technique Inject 20ml 0.375% (3.75mg/ml) Levo-bupivacaine underneath fascia iliaca ensuring adequate spread of local anaesthetic"
45368110|NCT00503841|Other|laboratory biomarker analysis|Correlative studies
45368111|NCT00503841|Procedure|biopsy|14 days prior to surgery
45368112|NCT00503841|Procedure|conventional surgery|14 days after taking study drug erlotinib hydrochloride.
45368113|NCT00503841|Procedure|neoadjuvant therapy|14 days after taking study drug erlotinib hydrochloride.
45368114|NCT00937508|Behavioral|Smoking counseling|Preoperative and postoperative counseling sessions provided by a trained smoking counselor along with placebo.
45368115|NCT00937508|Drug|varenicline|varenicline (an approved medication for smoking cessation)
45368116|NCT00937508|Drug|placebo|sugar pill without any active medication
45368117|NCT00937664|Drug|AZD7762|solution, intravenous, weekly
45368118|NCT00937664|Drug|gemcitabine|intravenous, weekly
45368119|NCT00937742|Dietary Supplement|Tomato products|Specified amounts of tomato products (i.e. tomato juice, ketchup, salsa, tomato soup, spaghetti sauce) to be consumed daily during a 6 week intervention phase.
45368120|NCT03743324|Procedure|Immediate Breast reconstruction|Immediate Autologous/prosthetic-based breast reconstruction is performed after mastectomy on the breast that is diagnosed with breast cancer
45368121|NCT03743324|Procedure|Delayed Breast Reconstruction|Delayed Autologous/prosthetic-based breast reconstruction is performed after mastectomy on the breast that is diagnosed with breast cancer
45368122|NCT03743324|Radiation|Radiation|Radiation is performed to the surgical site and complies with the ASCO guidelines on post-mastectomy radiotherapy
45485003|NCT02454244|Behavioral|ART with Mindfulness|"Introduction of ART with Mindfulness. Visualization of 100% recovery~Developing Fibromyalgia and CFS. How stress triggers the central nervous system. The benefits of Mindfulness in chronic stress. Mindfulness Practice. Breathing meditation~The ART. Breaking the negative thoughts related to the illness. Walking meditation~Mindfulness and the Body Scan. Breaking the cycle of stress. Body-scan meditation~Mindfulness and self-compassion. Kindly awareness meditation~The accelerator of ART. Behaviors related to CFS and Fibromyalgia. Metta meditation~Aware of negative thoughts related to stress stimulus. Mindfulness in daily activities~Limiting beliefs, identity patterns. Motivation and sense of life. Meditation on values~The recovery, cycles and stages. Fear of fail about recovery. Positive Visualization of future self~Return to regular life. Mindfulness practice"
45485004|NCT02454244|Behavioral|Mindfulness Compassion|"Introduction.Definition of Compassion~Self-Esteemed and Compassion~Cultivate the understanding of the nature of inner experience. Working positive and negative thoughts.Connecting with difficult emotions~Identifying the causes of suffering.How participants contribute to their own suffering. Attachments.Practice of Vulnerability~Love,affection and self-compassion.How participants connect with the suffering of others~Equanimity~Forgiveness~Interdependence. Gratitude.Affection to unknown people~Developing affection and empathy.Empathy and burn out~Review of the practices and meditations"
45485005|NCT02454244|Behavioral|Relaxation|10 sessions based on relaxation techniques as active comparator intervention
45485006|NCT03257644|Drug|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.
45485007|NCT03257878|Other|validated Korean version of the SF36 and EQ-5D|"This is an observational prospective study. SF36 consists of 36 questions that measure patient's HRQoL in 8 domains: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH) that represent the physical HRQoL, vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH) that represent the mental HRQoL. Each domain is scored from 0 (worst health status) to 100 (best health status). The scores of these domains are summarized into the physical component score (PCS) and mental component score (MCS).~The EQ-5D questionnaire is made up for 2 components; health state description and evaluation. In description part, health status is measured in terms of 5 dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS)."
45485008|NCT03241888|Drug|Megestrol Acetate|At a dosage of 160 mg/day
45485009|NCT03241888|Device|Levonorgestrel-releasing Intrauterine System(LNG-IUS)|Active ingredient: levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
45485010|NCT02454088|Other|Calcium Hydroxylapatite and Triamcinolone acetate|Combination Therapy Triamcinolone acetate and Calcium Hydroxylapatite
45485011|NCT02454088|Device|Calcium Hydroxylapatite and Placebo|Calcium Hydroxylapatite and Placebo
45485012|NCT02456116|Device|acupuncture/PCA/NSAID|"standard program with defined points:~Ear acupuncture needles bitten once (day 0-5)~Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released"
45368123|NCT00937820|Drug|YM150|oral
45368124|NCT00932516|Behavioral|South Beach Diet™ with South Beach Diet™ Products|
45846296|NCT02500836|Drug|Cocaine HCl 10% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
45846297|NCT02500836|Drug|Placebo Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
45846298|NCT02501538|Device|Transcutaneous O2 device|A portable device that delivers continuous diffusion of oxygen.
45368125|NCT00932516|Behavioral|South Beach Diet™|
45368126|NCT00932516|Behavioral|Calorie restricted diet with South Beach Diet™ Products|
45368127|NCT00932516|Behavioral|Calorie Restricted Diet|
45368128|NCT03376126|Other|Minimal-invasive isolated limb perfusion|Minimal-invasive isolated limb perfusion
45368129|NCT00937898|Dietary Supplement|BOLD+ Diet|Comparison of lean beef based, high protein diet to DASH diet and Average American diet on cardiovascular disease risk factors
45368130|NCT00937898|Dietary Supplement|BOLD diet|Comparison of lean beef based diet to DASH diet and Average American diet on risk factors of cardiovascular disease
45368131|NCT00442468|Other|Non-interventional study.|This is a non-interventional (no drug treatment administered), prevalence (observational) study.
45368132|NCT00937976|Procedure|Periodontal Scaling and Root Planing|Participants will take antibiotics prior to dental treatment. Periodontal treatment or a deep cleaning (with local anesthesia or numbing) will be performed to remove plaque and tartar around the teeth and gums. A small amount of antibiotics (minocycline) will be placed around the gums to help fight bacteria and inflammation.
45485013|NCT02456116|Device|sham acupuncture/PCA/NSAID|"standard program with defined points:~Ear acupuncture needles bitten once (day 0-5)~Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5"
45485014|NCT02456116|Other|PCA/NSAID|standard boli of morphine by pressing a button of PCA
45485015|NCT04481607|Drug|TQB3454|TQB3454 tablets is a small molecule oral drug.
45485016|NCT01352871|Behavioral|Concentration / meditation|from 30 minutes before endotoxin administration to 1,5 hrs after endotoxin administration the subject is concentrating / meditating with the goal to influence the innate immune response
45846299|NCT02503410|Behavioral|Usual care|Subjects receive standard physical therapy, including outpatient visits as prescribed by the treating clinician and home-based exercises based on recommendations by the physical therapist.
45485017|NCT01352871|Drug|lipopolysaccharide|lipopolysaccharide 2ng/kg intravenously
45485018|NCT03239236|Procedure|Rapid sequence induction t-RSI|Preoxygenation via face mask, no ventilation with no PEEP until intubation
45485019|NCT03239236|Procedure|Rapid sequence induction m-RSI-PEEP|Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.
45485020|NCT03239236|Procedure|Rapid sequence induction m-RSI-vent|Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
45485021|NCT03239236|Procedure|m-RSI-vent-cric|Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
45485022|NCT03239236|Procedure|Cricoid Pressure|Cricoid Pressure will be applied during RSI until laryngoscopy
45691520|NCT04259398|Drug|Propofol|propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia
45846300|NCT02503410|Behavioral|Interactive gaming|Subjects receive a combination of standard physical therapy in the clinic and home-based exercises that they perform using the Valedo system.
45846301|NCT02507388|Drug|Brolucizumab 3 mg/50 μL|Administered as an intravitreal injection
45485023|NCT03239236|Drug|Anesthetics|Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).
45485024|NCT03239236|Diagnostic Test|Aspiration of gastric air via nasogastric tube|A nasogastric tube will be inserted at the beginning of laparoscopy and the air from the stomach will be aspirated with a syringe. The amount of air will be measured in ml.
45485025|NCT03239236|Diagnostic Test|Impression of gastric inflation at laparoscopy.|The impression of gastric inflation at laparoscopy. At the beginning of laparoscopy, images of the stomach will be recorded.
45485026|NCT03239236|Diagnostic Test|Arterial blood gas|Arterial blood gases will we drawn at different time points to investigate oxygenation during the procedure. Blood gases will be taken before pre-oxygenation, before anesthesia induction, before laryngoscopy, immediately after intubation when the cuff of the tracheal tube is inflated.
45485027|NCT01353027|Drug|Placebo|Normal saline
45485028|NCT01353027|Drug|AVI-6002|Single intravenous administration
45485029|NCT01343121|Other|sample collection|Blood samples will be collected on days 1, 8, 15 and 22. They will be taken 30 minutes and 2 hours post Gemcitabine infusion.
45485030|NCT01343121|Other|sample collection|Urine will be collected on days 1, 8, 15 and 22. They will be taken pre gemcitabine and 2 hours post Gemcitabine
45485031|NCT01343121|Other|Sample Collection|Quality of Life (QOL) questionnaires given to the patient at each visit
45485032|NCT03239392|Drug|BNZ132-1-40|Injectable PEGylated peptide antagonist that binds to the common gamma chain (γc) signaling receptor for the cytokines interleukin (IL)-2, IL-9, and IL-15
45485033|NCT01353105|Procedure|Ex vivo lung transplantation|Evaluation and reconditioning of lungs following lung transplantation
45485034|NCT03239158|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
45485035|NCT03239158|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
45691521|NCT04259398|Drug|Sevoflurane|sevoflurane is administered for induction and maintenance of anesthesia
45691522|NCT04251520|Diagnostic Test|Pharmacogenomics testing|Participants will undergo pharmacogenomics testing and will be asked to provide a one-time buccal scraping. These results will be utilized for clinical treatment decisions.
45846302|NCT02507388|Drug|Brolucizumab 6 mg/50 μL|Administered as an intravitreal injection
45847939|NCT03096444|Drug|Lidocaine Hydrochloride|2g of topical 5% Lidocaine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
45847940|NCT03096444|Combination Product|Ketamine hydrochloride, Amitriptyline hydrochloride, and Lidocaine hydrochloride|2g of topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
45485036|NCT01353183|Procedure|colonoscopy or rectosigmoidoscopy|Usual procedure
45485037|NCT03257800|Drug|Ketamine|Ketamine 0,5mg.kg-¹was injected intravenously one minute prior propofol 3mg.kg-¹ and one minute before LMA insertion in Ketamine-propofol group
45485038|NCT03257800|Drug|placebo|The control group which received intravenously the same volume with normal saline one minute prior propofol 3mg.kg-¹ and 1 min before LMA insertion in propofol group
45485039|NCT01351857|Other|Transition Coordinator|The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
45485040|NCT03241654|Procedure|flow trigger|The flow trigger will be adjust during the pressure assist ventilation.
45368133|NCT00926978|Radiation|Radioactive Iodine 124|"After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.~Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is < 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131."
45368134|NCT00506883|Drug|High Dose Colchicine (4.8 mg total dose)|At randomization, patients were given an identical looking blister pack containing (8) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules. Patients were instructed to take 2 capsules initially (1.2 mg) followed by an additional capsule (0.6 mg) every hour for a total of six additional doses (total colchicine dose 4.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
45485041|NCT01351935|Drug|AVL-292|125 mg to 625 mg orally, once a day, for 28 days (28 days equals 1 cycle). Number of cycles: until progression or unacceptable toxicity develops
45485042|NCT01352013|Dietary Supplement|Omega-3 (oil)|5ml daily with breakfast for 56 days.
45485043|NCT01352013|Dietary Supplement|Fatty Acids (placebo)|5ml daily with breakfast for 56 days.
45485044|NCT03241576|Behavioral|Small portion size provision|The intervention is the small meal size participants are provided with during a lunchtime session in the laboratory.
45485045|NCT03241576|Behavioral|Large portion size provision|The intervention is the large meal size participants are provided with during a lunchtime session in the laboratory.
45485046|NCT01353339|Drug|Levofloxacin|500mg, PO, once daily for 3 months
45485047|NCT03241498|Other|Medicines optimisation|
45485048|NCT03239080|Drug|Denosumab|Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
45485049|NCT03239080|Other|Placebo|Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
45485050|NCT03149055|Drug|Isavuconazole|Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose.
45485051|NCT03257488|Device|type IV portable monitoring (Somnocheck micro Weinmann)|Somnocheck micro Weinmann: a screening device for sleep disorders assessment. Somnocheck 2 Weinmann: a diagnostic device for obstructive sleep apnea.
45485052|NCT01317693|Device|Low intensity shock waves|1500 shocks, Energy Density - 0.09 mJ/mm2
45485053|NCT03241264|Drug|ND-L02-s0201|Specified dose on specified day
45485054|NCT01353417|Other|In this observational study no study specific intervention is planned|Patients with stable kidney function who already receive Tacrolimus Sandoz© capsules before being included in this non-interventional study, are being observed for 6 months by their attending physicians. Routine medical treatment is provided.
45485055|NCT03257332|Procedure|Low Anterior Resection for Rectum Cancer|Subjects should have received curative surgery for rectal cancer (low anterior resection) with/with-out adjuvant (radiation/chemo) therapy.
45485056|NCT01317771|Procedure|Open proximal biceps tendon tenodesis with an EndoButton|Surgical fixation for bicipital pathology
45485057|NCT03257176|Behavioral|Stepping Stones and Creating Futures|21 session intervention, comprising of 10 Stepping Stones sessions focused on gender, relationships and communication. 11 Creating Futures sessions focused on livelihoods.
45485058|NCT01352091|Drug|Zoladex+AI|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
45485059|NCT01352091|Drug|TAM|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
45485060|NCT03257098|Biological|allo-APZ2-CVU|Suspension of ABCB5-positive mesenchymal stem cells
45691523|NCT04251520|Other|Pharmacist review|Participants will have their medical information, including patient demographics, problem list, medication list, allergies, and relevant lab work reviewed by a One Point pharmacist. The pharmacist will work with the Palliative Medicine team to make medication related recommendations to improve individual patient care. The pharmacist will call the patient roughly 48 hours following their outpatient consultation or hospital discharge to review the medication list and address any medication-related questions. The pharmacy will send refill reminders to the patients.
45691524|NCT01592110|Drug|risperidone-SABER|25 mg of risperidone-SABER administered as a subcutaneous (SC) injection of 0.25 mL
45485061|NCT01353573|Radiation|Fixed Gantry Radiosurgery|Single fraction radiosurgery will be prescribed using a fixed gantry radiosurgery delivery system
45485062|NCT01353573|Radiation|Robotic Radiosurgery|Single fraction radiosurgery will be prescribed using a robotic radiosurgery system
45485063|NCT03257020|Diagnostic Test|SD-OCT|SD-OCT was performed to all subjects to measure BMO-MRW and RNFL thickness by trained glaucoma specialist. It takes about 5 to 10 minutes. The foveal location was manually detected with a live B-scan, followed by defining BMO center. A radial pattern containing 24 angular, equidistant, high-resolution 15° B-scans centered on the BMO was used to compute the neuroretinal rim parameters. The BMO points and ILM were identified and marked in each B-scan with automated software (Glaucoma Module Premium Edition, version 6.0; Heidelberg Engineering). After radial scan completed, 3 consecutive circumpapillary B-scans were followed to measure RNFL thickness at diameter of 3.5, 4.1 and 4.7mm. BMO-MRW and RNFL thickness was automatically computed globally and sectorally.
45485064|NCT02964897|Behavioral|Peer-support plus usual care from the Health Care for Reentry Veterans program|a peer mentor who is also a veteran will establish a relationship with each subject and provide instrumental and emotional support to the subject during the first 6 months of the subject's release from incarceration. This is in addition to the usual reentry support provided by the Health Care for Reentry Veterans program.
45485065|NCT02964897|Behavioral|Usual care from the Health Care for Reentry Veterans program|Health Care for Reentry Veterans program provides reentry planning while the veteran is incarcerated. An outreach worker visits the veteran in the incarceration facility to conduct a needs assessment and help create a reentry plan to cover issues such as where they will be housed, what health care appointments they will need in the first 30 days, whether they need legal assistance, etc.
45485066|NCT03256942|Device|Etermis 4®|Etermis 4® is a sterile non-pyrogenic physiological gel made of reticulated hyaluronic acid (HA) of non-animal origin.
45485067|NCT03238846|Other|Three month dispensing of ART in CARGs|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 3 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
45485068|NCT03238846|Other|Six month dispensing of ART in CARGs|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 6 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
45485069|NCT02954523|Drug|Dasatinib|oral every day
45485070|NCT02954523|Drug|Osimertinib|oral every day
45691525|NCT01592110|Other|ZX003:risperidone-SABER and the DosePro System|50 mg risperidone-SABER administered as 0.5 mL via the DosePro Needle-Free Injection System
45691526|NCT01592110|Drug|risperidone-SABER|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL
45691527|NCT01592110|Drug|Risperidone-SABER|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL
45691528|NCT03843580|Device|optiflow|we use Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (thrive-optiflow) during general anesthesia for suspension laryngoscopy
45691529|NCT00604552|Device|AneuRx Stent Graft|Abdominal Aortic Aneurysm Repair
45691530|NCT00605644|Drug|MOA-728|Oral Capsules
45691531|NCT00605644|Drug|Placebo|Placebo
45691532|NCT00578734|Drug|Lucinactant|Slow intra-tracheal instillation
45691533|NCT00578734|Other|Sham Comparator|Slow intra-tracheal instillation
45368135|NCT00506883|Drug|Low Dose Colchicine (1.8mg total dose)|At randomization, patients were given an identical looking blister pack containing (3) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules and five placebo capsules. Patients were instructed to take 2 capsules initially (0.6 mg x 2) followed by an additional capsule every hour for a total of six additional doses (one active (0.6 mg) and 5 placebo capsules), a total colchicine dose = 1.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center
45485071|NCT01343355|Drug|Tamibarotene|Oral administration of tamibarotene 2 mg daily over a period of 12 weeks, then 4mg daily for another 12 weeks.
45485072|NCT03238768|Other|Enhanced Intravenous Nutrition|Increased macronutrients for first 7 days
45485073|NCT03238768|Other|Standard Intravenous Nutrition|Standard macronutrients for first 7 days
45485074|NCT01352247|Procedure|Unicompartmental Knee Replacement|A partial knee replacement or UKR involves only the diseased area of the joint being replaced. The healthy compartment of the knee is retained and artificial implants are inserted in place of the diseased area. This is done via a minimally invasive surgical procedure.
45485075|NCT01352247|Procedure|Total Knee Replacement|A total knee replacement involves all surfaces of the knee being replaced. The procedure involves excising both diseased and normal femoral condyles, the tibial plateau and often the patella. This is done through a large skin incision which provides easy access to the knee joint. Each component will be replaced with an artificial implant, which may be cemented in position.
45485076|NCT04486612|Other|spinal anesthesia|prospective observational study
45485077|NCT03241108|Drug|NI-0101|Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody targeting TLR4
45485078|NCT03241108|Other|Placebo|Placebo
45691534|NCT00578968|Drug|Tiotropium|Participants received once daily Spiriva capsules for oral inhalation: 18 mcg tiotropium powder, for use with HandiHaler device.
46052043|NCT04097587|Behavioral|experimental group|This program was carried out for 50 min/week over 8 weeks to empower parents with knowledge and self-efficacy about children's screen use, and motivate them to monitor and change their children's screen behaviors. Teaching strategies included lectures, group discussions, reflection, role playing, and peer sharing (Table 1). Topics included 1) parents' and children's screen use, 2) the relationship between network equipment and children's internet use, 3) the positive and negative effects of excessive screen use on children's physical and psychological development, 4) limiting screen use at mealtimes and bedtime, 5) strategies for screen-related devices, 6) alternative activities to screen use, such as board games and outdoor activities, 7) setting a target of appropriate screen times, and 8) encouraging the signing of a contract between parents and children to limit screen time. We also provided parents with a handbook of the course content.
45691535|NCT00578968|Drug|Placebo|Participants randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose, using the HandiHaler device.
45691536|NCT00579280|Drug|quetiapine SR|flexible dosing, 50 mg up to a maximum of 300 mg per day for 8 weeks
45368136|NCT00506883|Other|Placebo Control|At randomization, patients were given an identical looking blister pack containing (8) placebo capsules identical in appearance to the study drug. Patients were instructed to take 2 capsules initially followed by an additional capsule every hour for a total of six additional doses beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
45368137|NCT00932594|Procedure|Adjust the TMJ Pressure to Normal Value|Adjust the TMJ Pressure by the Operation Only Once for Each Patient
45368138|NCT00932594|Other|Do not adjust the pressure of TMJ|Do the treatments normally without additional treatment
45485079|NCT01353651|Device|Endovascular treatment using self expandable nitinol STENTS|A direct stenting will be performed.
45485080|NCT01353651|Device|Open repair treatment|The surgeon will perform its usual technique to revascularize the common femoral artery
45368139|NCT01028638|Other|89Zr-bevacizumab PET scan|"A tracer dose of 89Zr-bevacizumab (37 MBq, 5 mg protein dose) is given intravenously at day -3, day 11 and day 39.~PET scans are made on day 1, day 15 and day 43."
45485081|NCT01343511|Biological|human cord blood mononuclear cells|Participants will be given rehabilitation therapy plus hCB-MNCs transplantation.
45485082|NCT01343511|Biological|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given rehabilitation therapy plus and hCB-MNCs and hUC-MSCs transplantation.
45485083|NCT03240718|Procedure|Laser treatment|CORE fractional CO2 laser treatment
45485084|NCT01352325|Behavioral|system constellations seminar|individual-centered intervention in a group setting, duration 3 days
45485085|NCT01352325|Behavioral|system constellations seminar|individual-centered intervention in a group setting, duration 3 days
45691537|NCT00579280|Drug|divalproex sodium ER|Flexible dosing, 500 mg up to a maximum of 3000 mg per day for 8 weeks
45368140|NCT00938132|Drug|fimasartan, warfarin|Warfarin(1d) Fimasartan(8d-16d) Fimasartan + Warfarin(11d)
45691538|NCT00579280|Drug|placebo|placebo
45691539|NCT00579436|Drug|omega-3 fatty acid|4g of omega-3 fatty acid daily by mouth for 12 weeks.
45691540|NCT00579436|Drug|placebo|4 inert capsules daily by mouth for 12 weeks.
45691541|NCT03573466|Procedure|Muscle biopsy|A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
45691542|NCT03109210|Behavioral|Online Cognitive Behavioral Therapy (OCBT)|Cognitive behavioral therapy delivered via commercial online software.
45368141|NCT01023334|Procedure|MSICS under topical anesthesia with intracameral lidocaine|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral lidocaine
45485086|NCT03238456|Behavioral|Motivating Pacifika Against Cigarettes and Tobacco|"Participants received one encouraging text message per day prior to their quit date. During the intervention, they received daily text messages with decreasing frequency per week. Participants were also able to craft personal text messages. On-demand text messages were optional and could be requested by texting key words to the program hotline.~The online MPACT program allowed participants to access eight educational modules and a forum where they could communicate with other participants. The modules focused on different aspects of quitting smoking, such as how to deal with withdrawal symptoms, triggers of tobacco use, and stress. Participants were limited to one module per day in order to increase the duration of exposure to the program. Upon completion, participants no longer received text messages but they were still able to access the educational modules, forum, and on-demand text messages."
45485087|NCT01353729|Drug|600 mg zanamivir + moxifloxacin placebo|zanamivir 600 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
45485088|NCT01353729|Drug|1200 mg zanamivir + moxifloxacin placebo|zanamivir 1200 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
45691543|NCT03109210|Behavioral|Therapist-directed Cognitive Behavioral Therapy (TCBT)|Cognitive Behavioral Therapy delivered via traditional, in-person interaction with a licensed mental health professional.
45691544|NCT00580294|Drug|Oxymorphone|IV PO
45691545|NCT00580372|Drug|VAD|3 Cycles (3rd cycle optional): Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20
45691546|NCT00580372|Drug|High-Dose cyclophosphamide|"Approximately 5-6 weeks after VAD 2 or 3:~Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1"
45691547|NCT00580372|Procedure|Hemopoietic stem cell procurement|Collection target = 10 x 10^6 cells/kg
46052044|NCT04097587|Other|control group|received standard school classes and usual activities offered at the kindergarten. Briefly, kindergarten activities included daily learning activities, outdoor activities, breakfast, lunch, snacks, and nap time.
46052045|NCT02822703|Device|rTMS Active 20Hz|Active stimulation will be delivered with 70mm Double Air Film Coils. Participants will attend eight 20Hz sessions within two weeks of the scheduled quit date. Participants will receive 20Hz at 110% of the MT for 1 second, less than the limits indicated in the guidelines. These stimulation parameters have been utilized with no serious adverse events in previous studies to decrease delay discounting among smokers and non-smokers. These parameters are similar to or less intense than those utilized in other smoking cessation studies. All participants will receive rTMS over the same area of the DLPFC (6cm anterior to the MT area) while reading relapse prevention booklets supervised by the study coordinator.
46052046|NCT02822703|Device|rTMS Sham|The sham stimulation uses a similar 70mm Double Air Film Coil to look and sound like the active coil, but the magnetic field produced by the sham coil is markedly attenuated (only 5% of stimulator output setting: that is 2.25% of the maximum stimulator output (5% of 45% = 2.25%) and biologically inactive. Participants in this condition will attend eight sham sessions within two weeks of their scheduled quit date. During these sessions, they will also read relapse prevention booklets supervised by the study coordinator. The sham coil is not intended to and does not produce a stimulation effect so there is no proposed biologic mechanism of action.
46052047|NCT02601079|Device|Endodrill Biopsy|Testing a new device for taking tissue biopsies in the GI tract. The investigators will use the Endodrill instrument in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the Endodrill instrument can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
46052048|NCT02601079|Device|Conventional Biopsy forceps|Using a conventional biopsy forceps for taking tissue biopsies in the GI tract. The investigators will use conventional biopsy forceps in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the conventional biopsy forceps can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
45368142|NCT01023334|Procedure|MSICS under topical anesthesia with intracameral balanced salt solution.|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral balanced salt solution.
45485089|NCT01353729|Drug|zanamivir placebo + moxifloxacin placebo|zanamivir placebo IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
45691548|NCT00580372|Drug|EDAP|Approximately 5-6 weeks after high-dose cyclophosphamide Etoposide 100 mg/m2/d d 1 - 4 CI Cisplatin 25 mg/m2/d d 1 - 4 CI Ara C l g/m2 d 5 Dexamethasone 40 mg d 1-5
45485090|NCT01353729|Drug|zanamivir placebo + 400 mg moxifloxacin|moxifloxacin 400 mg administered orally x 1 dose + zanamivir placebo IV over 30 min x 1 dose
45485091|NCT03238378|Radiation|Brachytherapy|Brachytherapy d 1-5(6)
45485092|NCT03238378|Other|Hyperthermia|Hyperthermia d 2 + 5
45691549|NCT00580372|Procedure|Autologous Hemopoietic Stem Cell Transplant 1|4-6 weeks after EDAP: Melphalan 100 mg/m2 days -1 and -2
45691550|NCT00580372|Procedure|Autologous Hemopoietic Stem Cell Transplant 2|4-6 months after Transplant 1: Melphalan 100 mg/m2 days -1 and -2
45847941|NCT03096444|Drug|Lipoderm Cream|2g of topical vehicle (Lipoderm) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
45368143|NCT04015388|Device|iPro Continuous Glucose Monitoring|iPro device is a continuous glucose monitoring (CGM) FDA approved device. This CGM device consists of a small recorder which reports glucose values every five minutes. This recorder is connected directly to a glucose sensor. The glucose-oxidase based sensor measures extracellular fluid in the subcutaneous tissue. The tiny and flexible sensors are typically inserted just beneath the skin, usually in the abdominal area, but can also be placed in the buttock, or anterior or lateral thigh.
45691551|NCT00580372|Drug|Maintenance|3 months after Transplant 2: Intron A 3 X 10^6 units /m2 M-W-F subcutaneously until relapse
45691552|NCT00581230|Device|Laryngoscopy with RAMP|inflatable positioning ramp
45691553|NCT00581230|Device|Laryngoscopy without RAMP|Laryngoscopy without RAMP
45691554|NCT00581386|Device|LTS-D|supra-glottic airway device
45691555|NCT00581386|Device|ProSeal Laryngeal Mask Airway|pre-existing double-lumen supra-glottic device
45368144|NCT00932672|Behavioral|Atkins Diet|Patients are given an outline of the Atkins diet and are asked to follow it for 6 months
45368145|NCT00927056|Procedure|Microdiscectomy|Minimally invasive microdiscectomy versus conventional open microdiscectomy
45368146|NCT00938210|Procedure|Laparoscopic colonic surgery|Laparoscopic removal of colonic cancer
45368147|NCT00932750|Dietary Supplement|Coffee mannooligosaccharide|2 beverages daily providing either 4 g of coffee mannooligosaccharide or placebo.
45368148|NCT00932750|Dietary Supplement|Coffee mannooligosaccharides|Subjects consume 2 beverages daily providing 4 g of coffee mannooligosaccharides or placebo
45485093|NCT02453854|Behavioral|Group motivational interviewing|Monthly group meetings were held for two hour sessions each month and verifiable (treatment fidelity checked) motivational interviewing employed in helping clients make health behaviour changes.
45485094|NCT01357317|Other|Diet counseling|If serum phosphorus level exceeds 4.6 mg/dl in the lanthanum carbonate arm in spite of consecutive up-titration of the medical dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).
45485095|NCT01357317|Other|Diet counseling|If serum phosphorus level exceeds 4.6 mg/dl in spite of consecutive up-titration of the medication dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).
45485096|NCT01357317|Drug|Phosphorus binder|If serum phosphorus level exceeds 4.6 mg/dl after 3 months of concerted efforts, the patient will be considered a treatment failure and treatment with a phosphorus binder of the treating physician's choice will be allowed.
45485097|NCT03238612|Drug|FFA, clarithromycin, oseltamivir|2-day course of triple combination of clarithromycin 500mg, flufenamic acid 200mg and oseltamivir 75mg twice daily followed by oseltamivir 75mg twice daily for 3 days
45485098|NCT03238612|Drug|Oseltamivir alone|2-day course of oseltamivir 75mg plus placebo capsules twice daily followed by oseltamivir 75mg twice daily for 3 days as control
45485099|NCT03137121|Drug|Olanzapine|Olanzapine is used as an anti-emetic.
45691556|NCT00581386|Device|Esophageal Tracheal Combitube (ETC)|disposable double-lumen tube
45485100|NCT03137121|Other|Placebo|The placebo is a non-anti-emetic.
45485101|NCT02453776|Drug|PRECISION dosing Infliximab|Patients in the PRECISION dosing arm will recieve model based dosing, whereas proactive adjustments in treatment can be made by measuring the Infliximab concentration.
45691557|NCT02134210|Drug|Etanercept|Head-to-head comparison
45691558|NCT02134210|Drug|CHS-0214|
45847942|NCT03100500|Drug|QMF149|QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler
45368149|NCT00938288|Drug|KW-3357|50IU/mL, IV single dose
45368150|NCT00932906|Other|Different self-training methods|Self training with MiniAnne Training Kit
45847943|NCT03100968|Procedure|Palpation|Traditional epidural methods used for the identification of the midline using palpation prior to procedure
45847944|NCT03100968|Device|Ultrasound|Lumbar spinal ultrasound performed for identification of the midline prior to procedure.
45368151|NCT00932906|Other|Standard training|Instructor-based training meeting ERC directions
45368152|NCT00938522|Drug|Cilostazol|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the cilostazol group received 200 mg of cilostazol (loading dose) 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
45368153|NCT00938522|Drug|Placebo|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the placebo group received 200 mg of placebo 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
45691559|NCT02134522|Device|Continuous positive airway pressure (CPAP).|Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
45691560|NCT02134756|Drug|NutraStem Active|
45691561|NCT02134756|Drug|NutraStem Placebo|
45691562|NCT01798732|Procedure|Selective Laser Trabeculoplasty (Tango Laser, Ellex)|One session of selective laser trabeculoplasty with the following parameters (inferior half-circumference, 50 shots, 0.8 to 1.3 mJ)
45691563|NCT00607126|Device|Lokomat|locomotor training using body weight support on a treadmill
45691564|NCT00607126|Procedure|resistive training|resistive training using theraband and/or weights
45691565|NCT00607594|Drug|saracatinib|Patients receive AZD0530 (saracatinib) PO QD in the absence of disease progression or unacceptable toxicity.
45485102|NCT02915679|Other|Blood sample for genetic purpose, psychiatric assessment and pain investigation|"All the participant will performed the same evaluation and blood analysis:~A clinical assessment by psychiatrics assessing psychiatric disorder and suicidal behavior~Thermal stimulation for pain assessment~Computer game named Cyberball: test of social exclusion~Self report questionnaire for the assessment of reject sensitivity, relationship style, impulsivity, childhood trauma.~Routine blood sampling"
45485103|NCT03256864|Drug|Tacrolimus and Everolimus|"In the TAC and EVR BID arm, everolimus will be initiated at a dose of 1.0 mg BID within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.15 mg/kg BID and then taper to 0.10 mg/kg BID to maintain trough (C0) concentration in the range 2.5-5 ng/mL.~In the TAC and EVR QD arm, everolimus will be initiated at a dose of 2.0 mg QD within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.1-0.2 mg/kg/day QD to maintain trough (C0) concentration in the range 2.5-5 ng/mL."
45485104|NCT01317849|Drug|Folic Acid|0.8mg
45485105|NCT01317849|Drug|Vitamin B6|10mg
45485106|NCT01317849|Drug|Vitamin B12|500ug
45485107|NCT01317849|Drug|placebo|0.8 mg
45485108|NCT01317849|Drug|placebo|10mg
45485109|NCT01317849|Drug|placebo|500ug
45485110|NCT03754036|Behavioral|Sleep manipulation|Participants will sleep their typical amount at home for 1 week and will then be randomized to either increase or decrease their time in bed by 1.5 hours per night for 1 week, completing the alternate schedule on the fourth week (washout period of 1 week between sleep conditions). This procedure will result in a targeted 3-hour time in bed difference between conditions. Sleep will be objectively measured using actigraphy (Actiwatch) and sleep schedule adherence will be promoted by providing fixed bedtimes and wake times during the experimental weeks, and will be monitored through phone calls to the research center.
45485111|NCT01317927|Drug|Belinostat, Warfarin|1000 mg/m2 injection infusion given in a 30 min period plus Warfarin 5mg PO
45485112|NCT03256786|Behavioral|Prewarming using forced air warmer, warmed intravenous fluid|Combined modality active warming consisting of preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid in active warming group
45485113|NCT03256708|Dietary Supplement|Prolardii|Prolardii: 2 capsules per day for 12 to 15 days
45485114|NCT03256708|Dietary Supplement|Placebo|Inactive ingredients
45485115|NCT03240796|Procedure|minimal invasive surgery and secondary IOL implantation|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter and moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities. Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus.
45485116|NCT03240796|Procedure|traditional cataract surgery and secondary IOL implantation|"traditional cataract surgery: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + Anti-vit).~Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus."
45846303|NCT02508480|Behavioral|Photovoice|"The 10-session, peer-led Photovoice program, designed to empower individuals with SMI to confront public prejudice and discrimination and reduce personal stigma (self-stigma and perceived stigma), was developed and pilot tested at our Center, with primary contributions from staff with a lived experience of mental illness.~In the Photovoice sessions, participants will be given a workbook titled Combating Prejudice and Discrimination through Photovoice Empowerment. Peer leaders will facilitate discussions based on topics in the workbook. Participants will be given cameras and guidance on taking pictures and writing narratives descriptions about the pictures, specifically the ways in which the pictures relate to experiences of prejudice and discrimination."
45847945|NCT03104322|Other|patientMpower platform|electronic health journal for patient to record compliance, spirometry, impact on daily life and symptoms
45847946|NCT03104322|Other|usual care|usual care
45847947|NCT03107754|Drug|Lidocaine|Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
45847948|NCT03107754|Drug|Lidocaine-Sodium Bicarbonate|Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
45847949|NCT03118596|Device|I-gel|Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.
45368154|NCT00938600|Dietary Supplement|Vitamin D3|Vitamin D3 oral liquid 70,000 IU once
45368155|NCT00938600|Dietary Supplement|Vitamin D3|Vitamin D3 oral liquid 70,000 IU as loading dose, then 35,000 IU weekly thereafter for 10 weeks (non-pregnant) or until delivery (pregnant)
45368156|NCT00938600|Dietary Supplement|Vitamin D3|Vitamin D3 14,000 IU per week by mouth, starting at 27-30 weeks gestation and continued until delivery.
45368157|NCT00932984|Drug|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative during 5 weeks (treatment period).
45368158|NCT00938678|Drug|Pegfilgrastim Hospira|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
45368159|NCT00938678|Drug|Neulasta (Amgen)|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
45485117|NCT03256474|Other|Multimodal Therapy|Drugs, external applications like chest wraps, inhalations
45485118|NCT04461483|Drug|TAK-935|TAK-935 Tablets
45485119|NCT04461483|Drug|Placebo|TAK-935 placebo-matching tablets
45485120|NCT03256084|Procedure|Blood and tumor samples|Blood and tumor samples
45485121|NCT04251585|Drug|Regular Novolin R|Intranasal insulin
45485122|NCT04251585|Drug|Placebo|Intranasal placebo (0.9% saline)
45485123|NCT04486300|Procedure|Pneumatic reduction and Laparotomy|Pneumatic reduction is the main intervention for suitable cases and If failed a laparotomy exploration and surgical reduction is done to save life
45485124|NCT04418427|Biological|6E11 vg/eye of ADVM-022|ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
45485125|NCT04418427|Biological|2E11 vg/eye of ADVM-022|ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
45485126|NCT04418427|Biological|Aflibercept|Commercially available Active Comparator
45485127|NCT04486534|Other|Musculoskeletal ultrasound|Subjects' talar cartilage, tibialis anterior and gastrocnemius muscle thickness measurements will be performed using musculoskeletal ultrasound.
45485128|NCT03240484|Diagnostic Test|X-Ray Imaging|X-Ray imaging in the following positions: Lateral standing, lateral seated, standard standing AP pelvis and AP pelvis lying down.
45485129|NCT03240484|Other|Gait Analysis|Certain patients may be asked to participate in a motion analysis procedure at the Human Movement Laboratory at the University of Ottawa. This procedure takes approximately 1.5 hours and you will only be asked to participate in the motion analysis procedure once. Participants will change into a custom-designed tight body suit, which has reflective markers on its surface for infrared video capture. Participants will then have pairs of surface electromyography (EMG) electrodes placed on certain areas of the skin on the legs and on the back. Wearing the EMG electrodes and marker suit, participants will perform 5 trials of walking on a level walkway, walking up and down a 3-step staircase, sitting from a standing position, and standing from a seated position.
45485130|NCT01353807|Dietary Supplement|Fish oil|4 1-g gelatine capsules per day providing 2,7 grams long chain n-3 fatty acids
45485131|NCT01353807|Dietary Supplement|Olive oil|4 1-g gelatine capsules with virgin olive oil
45485132|NCT03238066|Radiation|Brachytherapy|HDR/PDR brachytherapy
45485133|NCT03238066|Other|Hyperthermia|Interstitial hyperthermia
45485134|NCT02901483|Drug|PEP503|PEP503 will be administered by intratumoral route as slow injection
45485135|NCT02901483|Drug|Cisplatin|The concurrent chemoradiotherapy. Weekly cisplatin 40 mg/m2 or tri-weekly 100 mg/m2, depending on which dose level patients are in, with a minimum of accumulated 200 mg/m2 during the 7~8 weeks' radiation period.
45485136|NCT02901483|Radiation|Radiotherapy|Patients will receive 70-72 Gy, 2-2.12 Gy/fraction over 7~8 weeks.
45485137|NCT03256396|Procedure|PEEP setting based on esophageal pressure measured|PEEP is set on the basis of esophageal pressure measurement with the aim to maintain transpulmonary pressure during expiration between 0 and 5 cmH2O
45485138|NCT03256318|Other|No intervention|No intervention; surveys/questionnaires only
45485139|NCT02874651|Drug|Apatinib|Patients will take oral apatinib. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
45846304|NCT02508480|Behavioral|Enhanced Control|The control SAU condition will be enhanced with a 60-minute peer-led manualized educational group session (Leaders' Guidelines and Handout for Participants are attached). It will provide participants with information about the nature of stigma and the laws in the U.S. that protect people with disabilities from discrimination. Participants will be engaged in a discussion about their use of different strategies for proactive coping with psychiatric stigma. This session will be co-led by the same peers who will be delivering the Photovoice program to the experimental group at relevant wave and study sites. Participants randomized to the enhanced Services as Usual control condition will be invited to join a Photovoice group once they complete the final 6-month follow-up assessment.
45846305|NCT02508636|Drug|Enzalutamide|Given orally
45846306|NCT02508636|Drug|Leuprolide|Given via intramuscular injection
45368160|NCT03743168|Other|Intermittent stretching protocol|Intermittent stretching protocol of five sets of 1 minute and15 second rest
45368161|NCT03743168|Other|Continuous stretch|2 minutes continuous stretch
45368162|NCT00933062|Drug|SRT2104|2.0 g of SRT2104 will be supplied in hard gelatin capsules each containing 250 mg SRT2104. SRT2104 will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of SRT2104 will be orally-administered with approximately 200 mL water.
45485140|NCT02874651|Drug|Placebo|Patients will take oral placebo. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
45485141|NCT03256006|Other|Blood sample|Blood sample to study per and post effort evolution markers of systemic inflammation
45485142|NCT01343589|Dietary Supplement|milk fat|39 g milk fat per day in 12 weeks
45485143|NCT02453932|Drug|Tianzhi granule and placebo identified to donepezil|1 pack Tianzhi granule (5g), 3 times per day and placebo identified to donepezil, 1 pill per day for 24 weeks
45485144|NCT02453932|Drug|Donepezil and placebo identified to Tianzhi granule|donepezil 5mg per day and placebo identified to Tianzhi granule (5g, 3 times per day) for 24 weeks
45485145|NCT02453932|Drug|Placebo|placebo identified to Tianzhi granule (5g, 3 times per day) and placebo identified to donepezil ,1 pills per day for 24 weeks
45485146|NCT04387851|Behavioral|Placebo induction|The placebo interventions of interest are experimental learning methods (e.g. verbal suggestion, conditioning), used to induce placebo effects on somatosensory sensations.
45368163|NCT00933062|Drug|Placebo|Placebo will be supplied in hard gelatine capsules containing an appropriate amount of placebo. Placebo will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of placebo will be orally-administered with approximately 200 mL water.
45485147|NCT04387851|Behavioral|Control|Placebo and nocebo effects should be measured relative to a control group (between-subjects design). In the case of within-subjects designs, these will be included to the extent possible (in a separate analysis or descriptively depending on the number of results).
45485148|NCT04387851|Behavioral|Nocebo|The nocebo interventions of interest are experimental learning methods (e.g. verbal suggestion, conditioning), used to induce nocebo effects on somatosensory sensations.
45485149|NCT04385433|Drug|EXPERIMENTAL ARM|"Patients in the experimental arm will receive:~Daily pravastatin (40mg/d) during 12 months (pravastatin initiation: first day of radiotherapy).~Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)."
45485150|NCT04385433|Other|CONTROL GROUP|"Patients in the standard arm will receive:~Daily placebo during 12 months (placebo initiation: first day of radiotherapy)~Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)."
45846307|NCT02508636|Radiation|Intensity-Modulated Radiation Therapy|A total dose of 45 Gy in 25 fractions of 1.8 Gy each.
45485151|NCT04385433|Radiation|Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)|Radiotherapy will last 5 weeks during treatment by Pravastatine or Placebo
45485152|NCT00700570|Drug|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle.
45846308|NCT02512224|Device|Parenteral nutrition|Participants are retrospectively selected with propensity score matching
45368164|NCT00938756|Other|diagnostic laboratory biomarker analysis|
45368165|NCT00938756|Other|immunoenzyme technique|
45368166|NCT00938756|Procedure|magnetic resonance imaging|
45368167|NCT00503685|Biological|IMC-A12|10 milligrams/kilogram (mg/kg) intravenous infusion every 2 weeks.
45485153|NCT00700570|Drug|capecitabine [Xeloda]|1000mg/m2 iv on days 1-5 and 8-12 of each 2 week cycle
45485154|NCT00700570|Drug|oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
45846309|NCT02512224|Device|Enteral nutrition|Participants are retrospectively selected with propensity score matching
45485155|NCT02453698|Drug|Methylphenidate|oral dose of methylphenidate. The MPH dose was selected based on previous studies in healthy adults (Mehta et al., 2000; Volkow, Fowler, Wang, Ding, & Gatley, 2002) and adults with ADHD (Aron et al., 2003). MPH reaches its peak plasma concentration 1-3 hours after an oral dose, and has a plasma half-life of 1.5-2.5 hours.
45485156|NCT02453698|Other|Placebo|Lactose Placebo
45691566|NCT01866319|Biological|Pembrolizumab|10 mg/kg IV, administered Q2W or Q3W based upon randomization.
45691567|NCT01866319|Biological|Ipilimumab|3 mg/kg IV Q3W.
45691568|NCT00607672|Drug|Placebo|Placebo
45691569|NCT00607672|Drug|Ramipril|Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter
45691570|NCT00607672|Drug|Candesartan|Candesartan 16mg/d
45691571|NCT01802515|Drug|Atomoxetine, low dose|The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.
45691572|NCT01802515|Drug|Atomoxetine, high dose|The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.
45691573|NCT01802515|Drug|Placebo|The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.
45485157|NCT01744041|Behavioral|Dyadic Interpersonal Psychotherapy|This intervention consists of a brief psychotherapeutic intervention, Interpersonal Psychotherapy, during pregnancy. Interpersonal Psychotherapy focuses on improving social relationships and interpersonal communication to improve mood. The postpartum phase also utilizes developmentally appropriate strategies to improve the mother-infant relationship.
45485158|NCT01744041|Other|Enhanced Treatment as Usual|This intervention consists of personalized referrals to specialty mental health providers, spiritual counselors, or other needed social services. It includes some non-specific supportive techniques delivered primarily via telephone.
45485159|NCT03255694|Drug|PEG-somatropin|After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
45485160|NCT02840643|Behavioral|Bimanual hand therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive bimanual hand therapy, which involves actively using both hands in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
45485161|NCT02840643|Behavioral|Constraint therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive constraint therapy, which involves actively using the impaired hand in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
45368168|NCT00503685|Biological|cetuximab|Participants will receive cetuximab 500 milligrams/square meter (mg/m²) intravenous over 2 hours every 2 weeks.
46052049|NCT04240275|Device|Reliability of the G-Walk device in children with Cerebral Palsy|"The purpose of this study was to confirm the test-retest reliability of a commercially available body-worn sensor-G-Walk® sensor system-for spatiotemporal gait parameters in children with CP.~The children will be assessed with the G-Walk on two separate occasions.For the reliability analysis, the second measurement tests will be repeated 3 days after the first assessment.~The device is placed on an elastic belt and worn on the waist of the person being evaluated, with the center of the device at the fifth lumbar vertebrae. To ensure correct placement of the device, the L4-L5 intervertebral space will be palpated via the posterior superior iliac spines (SIPS).~After the accelerometer is placed, the children are asked to walk calmly at normal speed, on a 10 m track, whose boundaries will be determined with colored lines and to return to the starting position."
45368169|NCT00712673|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
45368170|NCT00712673|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
46052050|NCT02822157|Drug|Olaparib|
45368171|NCT00712673|Device|Pen auto-injector|
45368172|NCT00712673|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
45485162|NCT03238144|Other|MRF scan|MRF with or without dynamic contrast-enhanced MRI scans.
45485163|NCT01354041|Behavioral|Acceptance and Commitment Therapy|Seven weekly sessions of Acceptance and Commitment Therapy (ACT) intervention
45485164|NCT03238222|Behavioral|MOSAIC|MOSAIC comprises 2 x 60-minute individual face-to-face consultations (weeks 1 & 2) and 2 x 20-minute follow-up telephone calls (weeks 6 & 12) delivered at a convenient time and location of participant's choice (local NHS Trust or participant's home). All sessions are delivered by a trained Band 6/7 physiotherapist. All participants randomized to receive MOSAIC will be provided with a pedometer and a patient manual which will include information on intermittent claudication, risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.
45485165|NCT01354119|Procedure|Aortic stent-graft|Early intervention with aortic stent-graft
45368173|NCT01562990|Drug|Rituximab, CMC544, Gemcitabine and Oxaliplatine|"2 cycles of induction of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43.~2 cycles of consolidation of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43."
45368174|NCT00939380|Behavioral|Behavioral intervention sessions|Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns.
45368175|NCT00939380|Other|CD-ROM|Participants receive a laptop computer and a CD-ROM after the first session of behavioral intervention.
45368176|NCT00939380|Other|DVD and pamphlet|"Participants receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD."
45368177|NCT00939380|Other|Respite care|Participants receive 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks.
45368178|NCT00933218|Dietary Supplement|polyphenols (non-alcoholic beer)|1.0 - 1.5 l non-alcoholic beer per day; 3 weeks before and during a marathon run
45368179|NCT00933218|Dietary Supplement|beverage without polyphenols|1.0 - 1.5 l of beverage without polyphenols (otherwise the same composition as non-alcoholic beer) per day; 3 weeks before and during a marathon run
45368180|NCT00737867|Drug|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
45368181|NCT00737867|Drug|Gemcitabine|Day 1: Gemcitabine infusion 1000 mg/m2 Day 8: Gemcitabine infusion 1000 mg/m2
45368182|NCT00737867|Drug|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
45485166|NCT03240562|Procedure|serratus anterior plane block|before surgery :ultrasound-guided serratus anterior plane block
45485167|NCT03240562|Drug|patient controlled analgesia|two groups have same intravenous patient controlled analgesia
45485168|NCT01354275|Other|To compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle|150 IU FSH dose and OCP plus GnRH Agonist (long luteal) IVF/ICSI cycle and 150 IU FSH dose and OCP plus GnRH Antagonist (Fixed protocol) IVF/ICSI Cycle
45485169|NCT01354275|Other|GnRH Antagonist|GnRH Antagonist cycle; 150 IU FSH and sixth day Antagonist will be administered
46052051|NCT02822157|Drug|carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly|physician's choice chemotherapy
45368183|NCT00737867|Drug|Carboplatin|Day 1: Carboplatin infusion AUC = 5 (Calvert's formula)
45485170|NCT01318161|Drug|Ropivacaine + opioid epidurally|Epidural analgesia with local anesthetic + opioid
45485171|NCT01318161|Drug|Morphine|Morphine via PCA pump
45485172|NCT03255538|Other|DFM: Mean pressure|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment.
45485173|NCT03255538|Other|DFM: Mean pressure - 25%|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment decremented by 25%.
45485174|NCT03255538|Other|DFM: Mean pressure + 25%|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment incremented by 25%.
45485175|NCT03255226|Drug|Tolvaptan|Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
45368184|NCT03976466|Device|Antibiotic local prophylaxis with medicated calcium sulfate beads|Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
45846310|NCT02513940|Drug|Testosterone|Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days
45846311|NCT02513940|Drug|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
45846312|NCT02513940|Drug|Placebo|Subjects will receive placebo transdermal gel and placebo (lactose) capsules
45846313|NCT02513940|Drug|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval
46052052|NCT00767455|Device|HP828-101|21 day patches
46052053|NCT02822781|Other|No intervention|There is no intervention. The patients will receive common questionnaire usually used by doctors (SNOT 22). Some Data to describe the population are collected then.
46052054|NCT04099615|Procedure|Somatosensory Evoked Potentials|We stimulate both median nerves at wrist by means of surface adhesive electrodes. We apply square wave electrical pulses of 0.2 ms duration at a frequency of 5.7Hz. SEPs are recorded in a referential fashion from the C3' and C4' positions and from a reference electrode at Fpz or Cz' electrodes(international 10-20 system) with needle electrodes. The target signal is the presence of N20 response ipsilateral to the stroke site and, if present, measure amplitude and latency comparing with the contralateral if present. SEPs are registered during the whole procedure.
45368185|NCT03976466|Procedure|Classical parenteral antibiotic prophylaxis|Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
45368186|NCT02536755|Drug|Eliglustat, GZ385660|"Pharmaceutical form: capsule~Route of administration: oral"
45368187|NCT02567279|Drug|Denosumab subcutaneous injections|Subcutaneous injection of Denosumab 60 mg, one injection at baseline and another injection at 6 months
45368188|NCT02567279|Drug|Placebo subcutaneous injections|Subcutaneous injection of Placebo, one injection at baseline and another injection at 6 months
45368189|NCT00938834|Other|CFQ Qigong|CFQ Qigong training session training will consist of three half days of training in the technique. Following the training sessions, participants will return to the study site on a weekly basis for the first 8 weeks.
45485176|NCT03237988|Drug|CPI-444 Capsules|100mg Capsule
45485177|NCT03237988|Drug|CPI-444 Tablets|100mg Tablets
45485178|NCT03237832|Drug|ARN-6039|Ascending doses per Cohort
45485179|NCT03237832|Other|Placebo|Placebo to match ARN-6039
45485180|NCT03237676|Other|Structured cognitive rehabilitation therapy|A computer-based cognitive rehabilitation therapy Therapy frequency is one hour session per week for three months.
45846314|NCT02515656|Drug|POLYGYNAX®|
45485181|NCT03237676|Other|Patient-centred cognitive therapy|"Application of existing cognitive therapy at University Malaya Medical Centre, Malaysia. It is a patient-centred therapy approach over a period of three months, which include therapy session on symptoms management and coping strategies.~Clinical and treatment review are provided as part of routine outpatient rehabilitation clinic review."
45485182|NCT03240250|Procedure|VATS uni-portal lobectomy and lymphoadenectomy|VATS uni-portal lobectomy and lymphoadenectomy
45485183|NCT03240250|Procedure|VATS three-portal lobectomy and lymphoadenectomy|VATS three-portal lobectomy and lymphoadenectomy, Copenhagen approach
45485184|NCT03237598|Other||
45485185|NCT03239782|Behavioral|Calorie restriction|Calorie restriction with behavioral modification and provision of one catered, reduced calorie meal a day
45691574|NCT01802437|Drug|Fluoxetine|If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increase in therapy (4 extra therapy sessions) or fluoxetine therapy. Adolescents who receive pharmacotherapy will be prescribed fluoxetine for 12 weeks. The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and every other week thereafter. If no treatment response was observed by the sixth week, the dosage could be increased to 40 mg per day.
45691575|NCT01802437|Behavioral|Increased Dose of Interpersonal Psychotherapy|If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increased dose of interpersonal psychotherapy (4 extra therapy sessions) or fluoxetine.
45691576|NCT01802437|Behavioral|Continue to Receive Initial Dose of Interpersonal Psychotherapy|If Hamilton Rating Scale for Depression scores meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be assigned to continue initial dose of interpersonal psychotherapy.
45846315|NCT02515656|Drug|GYNODAKTARIN®|
45846316|NCT02515656|Drug|Placebo|
45846317|NCT02515890|Drug|Dexmedetomidine|Selected subjects received this drug during a portion of the study
45846318|NCT02515890|Drug|Midazolam|Selected subjects received this drug during a portion of the study
46052055|NCT02822937|Drug|Methylphenidate|Methylphenidate is a central nervous system stimulant. It affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control. Methylphenidate is used to treat attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and narcolepsy.
46052056|NCT02822937|Drug|Triazolam|Triazolam is a benzodiazepine similar to Valium. Triazolam affects chemicals in the brain that may become unbalanced and cause sleep problems (insomnia). Triazolam is used to treat insomnia (trouble falling or staying asleep).
46052057|NCT02822937|Other|Project: EVO|Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
46052058|NCT02822937|Drug|Placebo|Sugar pill
45368190|NCT05460689|Other|M-HEALTH APP|The intervention group will have in use a mHealth App for education and support of caregivers of children undergoing tonsillectomy and/or adenoidectomy in the perioperative process. An out-patient nurse will be in charge of instructing intervention group participants to mHealth App use and content options. The mHealth App will be available for intervention group families from the day of pre-admission visits to the 7th day post surgery or follow up visit.
45368191|NCT05460689|Other|Standard Care|The control group will receive information and education provided by nurses and physician in the preoperative visits and during hospitalization. Information and education will be provided orally or through printed booklets.
45368192|NCT04013594|Dietary Supplement|carbohydrate group|Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery.
45368193|NCT00933374|Drug|paclitaxel|Paclitaxel (175 mg/m3)will be administered as a 3 hour continuous IV infusion after standard premedication every 3 weeks
45368194|NCT00933374|Drug|RAD001|10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
45368195|NCT03303105|Drug|TEV-48125|TEV-48125 will be administered subcutaneously once every 4 weeks.
45368196|NCT03303105|Drug|TEV-48125|TEV-48125 will be administered subcutaneously once every 12 weeks.
45368197|NCT00933452|Drug|duloxetine|30mg, oral administer; step 1: single dose; step 2: multiple dose, 7 days
45368198|NCT00933452|Drug|duloxetine|15mg, oral administer
45485186|NCT02455726|Dietary Supplement|Magnesium oxide|Oral magnesium oxide 300 mg twice a day
45485187|NCT02455726|Dietary Supplement|Fructose|Oral fructose 10 g twice a day
45485188|NCT02455726|Drug|Oxycodone|Oxycodone hydrochloride 5 mg at 8 am
45485189|NCT02455726|Drug|Pregabalin|Pregabalin 25 mg at 8 pm
45485190|NCT04488328|Other|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks(3 sessions/ week)
45485191|NCT04488172|Dietary Supplement|Multi-vitamin supplementation|Vitamin B6:100 mg/day Vitamin B9: 5 mg/day Vitamin D: 1000 IU/day Vitamin E: 400 IU/day Co-Q10: 100 mg/day
45691577|NCT00608062|Drug|GnRHant - Ganirelix acetate|1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
45485192|NCT03237520|Other|Virtual Reality Therapy|VRT software and device is developed in collaboration with IIT Delhi using Kinect system. Kinect- motion sensor and computer set up is required. VRT (CIMT in a virtual environment)will be provided for 2 hours at every visit(twice weekly for first 4 weeks, once a week for next 4 weeks). VRT will be provided only during scheduled visits with the same principle as mCIMT. Functional activities like repetition of the tasks and shaping will be performed with the affected hand using VRT and CIMT while the unaffected arm is restrained
45485193|NCT03237520|Other|mCIMT|Modified constraint induced movement therapy will be provided to all children according to predefined protocol.
45485194|NCT03237754|Device|tDCS device from neuroConn|weak electrical direct current stimulation
45485195|NCT03237442|Biological|human umbilical cord mesenchymal stem cells|human UC-MSCs: 0.2ml(about 2*10^6 cells) subconjunctival injection
45485196|NCT03237442|Biological|placebo|Saline injection
45368199|NCT00933452|Drug|duloxetine|60mg, oral administer; step 1: generic duloxetine; step 2: Innovator duloxetine
45368200|NCT03263325|Other|Discarded urine sample|Collection of discarded urine during surgery and following surgery
45368201|NCT00933530|Drug|SRT2104|SRT2104 (0.03, 0.1, 0.25, 0.5, 1.0, 2.0, or 3.0 g/day) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. The dosing vehicle is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
45485197|NCT04488016|Drug|Treatment A- Part 1|Subjects will receive 100 mg acalabrutinib capsule, fasted state;
45485198|NCT04488016|Drug|Treatment B- Part 1|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
45485199|NCT04488016|Drug|Treatment C - Part 1|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state
45485200|NCT04488016|Drug|Treatment D- Part 1|Subjects will receive Rabeprazole 20 mg QD (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1) and following prior administration of rabeprazole 20 mg Twice per day (BID) (with meals) on Days -3, -2 and -1.
45368202|NCT00933530|Drug|Placebo|Placebo (at the matched dosage as SRT2104) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. Placebo will consist of titanium dioxide USP and prepared for oral administration identically to the SRT2104 investigational product. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. The subjects enrolled will be blinded to treatment assignment. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
45485201|NCT04488016|Drug|Treatment A-Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
45485202|NCT04488016|Drug|Treatment B - Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 2), fasted state
45485203|NCT04488016|Drug|Treatment C - Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 3), fasted state
45368203|NCT00447694|Drug|Deferasirox|Oral deferasirox 30mg/kg/day once per day for 77 weeks.
45485204|NCT04488016|Drug|Treatment D - Part 2|Subjects will receive 100 mg acalabrutinib solution, (Variant 4), fasted state
45485205|NCT03239704|Behavioral|Telemedicine Follow-Up|Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-urgent care clinic appointment; to monitor the health status of patients with respect to their IBD.
45485206|NCT03239704|Other|Telemedicine Monitoring|Patients will be provided access to a smartphone application entitled: 'Health Promise'. The application will generate short questionnaires every 3 days, where patients can self-report their Crohn's disease activity as measured by the PRO-2 score or Ulcerative Colitis activity as measured by the 6-Point Mayo score, and medication adherence as measured by the MMAS-8 scale. The survey responses will be monitored by an IBD advanced practice nurse, to arrange for additional telemedicine follow-up sessions or to triage patients for an expedited appointment with a gastroenterologist.
45368204|NCT03371602|Procedure|surgery|a diaphragmatic biopsy (100 microgram) and a parietal biopsy will be performed by the surgeon during surgery.
45485207|NCT03239704|Behavioral|30 Day Comprehensive Questionnaire|Patients will complete a web-based questionnaire at 30 days following the urgent care clinic visit when they were enrolled in the study. The questionnaire will query the following: Patient Demographics; Patient Satisfaction as measured by the CACHE Questionnaire; IBD related Quality of Life as measured by the IBDQ questionnaire; and Crohn's Disease activity as measured by the PRO-2 score or Ulcerative Colitis Activity as measured by the 6-Point Mayo score.
45485208|NCT03239860|Drug|GNbAC1 Monoclonal Antibody|Monthly IV
45485209|NCT04486690|Drug|Ketofol (propofol to ketamine ratio 1:1)|"Ketofol 25-150 mic/kg/min with propofol to ketamine ratio 1:1.~Fentanyl infusion, 1-2 mcg/kg/h.~Atracurium infusion, 3-12 mic/kg/min"
45485210|NCT04486690|Drug|propofol|"Propofol infusion, 25-150 mcg/kg/min.~Fentanyl infusion, 1-2 mcg/kg/h.~Atracurium infusion, 3-12 mic/kg/min."
45485211|NCT03237364|Diagnostic Test|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, < 1 hour
45368205|NCT03371602|Procedure|multi-organ sampling|a diaphragmatic biopsy (100 microgram) will be performed by the surgeon during surgery.
45691578|NCT00608062|Drug|Transdermal estradiol patch|0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
45691579|NCT00608062|Drug|Transdermal placebo patch|Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
45691580|NCT02138578|Radiation|SBRT|
45691581|NCT02138578|Radiation|RFA|
45485212|NCT03240094|Other|Nutritional telemonitoring|Participants receive a weighing scale, pedometer and television channel in order to perform self measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
45485213|NCT03255304|Behavioral|health mindest|groups be confronted with health aspects of food items
45485214|NCT03255304|Behavioral|palatability mindset|groups be confronted with palatability aspects of food items
45485215|NCT03255148|Drug|Oxytocin|Syntocinon nasal spray
45485216|NCT03255148|Drug|Placebo|Placebo nasal spray
45485217|NCT04487626|Device|AI|After taking standard bowel preparation regimen, patients receive colonoscopy under the AI system device. During the withdrawal phase, bowel preparation quality is assessed by AI-associated scoring system. The withdrawal time is targeted at least 6min. Every detected polyp will be removed and obtained for pathological assessment.
45485218|NCT03234946|Behavioral|CAIPaDi|Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement
45368206|NCT00564278|Drug|Standard antidepressant therapy (SADT)|Treatment with medication will follow the Texas Medication Algorithm (TMA) for Depression. Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR), bupropion SR (Wellbutrin SR), duloxetine (Cymbalta), nortriptyline (Pamelor), and mirtazapine (Remeron).
45485219|NCT03254914|Procedure|Home Blood Pressure|Measure Home Blood Pressure
45485220|NCT03237130|Procedure|preoperative enhanced chest CT examination|Each patient will receive preoperative enhanced chest CT examination, and their CT images will be used for analysis
45485221|NCT03234868|Device|Impression procedure|Each patient will go through both type of impression during single appointment: first the digital impression and then the conventional one (to avoid residual impression materials for the optical impressions). The time necessary for each procedure will be recorded.
45485222|NCT03234868|Device|Crown manufacturing procedures|Test and control implant crowns will be screw-retained on a multi-unit abutment. The conventional crown will be made of a Zirconia framework veneered with cosmetic ceramics directly screwed on the multi-unit platform (no titanium base). The experimental crown will be made in full zirconia and designed in the TRIOS software.
45485223|NCT03237052|Other|model|a model that has been established in advance.
45485224|NCT03237052|Other|non-model|real-world psychiatrist decision
45485225|NCT03237208|Device|TENS|Transcutaneous electrical nerve stimulation (TENS) treatment will be activated.
45485226|NCT03237208|Device|placebo group|Transcutaneous electrical nerve stimulation treatment will not be activated.
45485227|NCT04487938|Other|No intervention utilised|No intervention utilised
45485228|NCT03234712|Drug|ABBV-321|Intravenous infusion
45485229|NCT04876794|Device|ABLE Exoskeleton|Participants with SCI will undergo a training programme with the ABLE Exoskeleton device three times a week for four to six weeks for a total of 12 sessions.
45485230|NCT02455960|Dietary Supplement|L-arginine|Comparison of the efficacy of L-arginine 3 grams for days versus placebo in contrast induced AKI prevention
45485231|NCT02455960|Dietary Supplement|Placebo|
45485232|NCT03236818|Drug|ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)|Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
45485233|NCT04809246|Other|'One-stop-shop' hepatitis clinic|Establishment of a 'one-stop-shop' hepatitis clinic, integrating point-of-care HCV RNA testing, followed by clinical assessment, non-invasive liver fibrosis assessment by fibro-elastography (Fibroscan), and early DAA prescription (for those with chronic HCV) followed by linkage to ongoing hepatitis care, all in the same 60-minute visit.
45846319|NCT02515890|Device|Peripheral nerve stimulation|Experimental acute pain stimulus was delivered using a nerve stimulator. These painful shocks were paired randomly with some of the auditory experimental cues.
45368207|NCT00564278|Behavioral|Motivational antidepressant therapy (MADT)|The same medication treatment for depression will be offered and supplemented with techniques from motivational interviewing.
45368208|NCT04013906|Diagnostic Test|Rotational atherectomy|Rotational atherectomy
45368209|NCT00933842|Drug|LACTIC ACID(ND)|Treatment duration: 5 weeks
45368210|NCT00565604|Device|Short Catheter Delivery|For treating incompetent perforator veins of the lower extremities
45368211|NCT00933920|Drug|Aliskiren|
45368212|NCT00933920|Drug|Aliskiren|
45846320|NCT02515890|Drug|Ketamine|Selected subjects received this drug during a portion of the study
45368213|NCT00447382|Drug|insulin detemir|NN304 injected s.c. (under the skin). Given as basal insulin.
45368214|NCT00447382|Drug|insulin aspart|Injected s.c. (under the skin). Given as bolus insulin.
45368215|NCT00447382|Drug|insulin detemir|NN729 injected s.c. (under the skin). Given as basal insulin
45368216|NCT00938990|Drug|Etomidate|
45368217|NCT00938990|Drug|Midazolam|
45485234|NCT04486144|Other|Proprietary extract of Nerium oleander|This is a proprietary extract of Nerium oleander that is 6.25 ug per 0.5 ml of suspension. It is administered sublingually every six hours for 5 days. The daily dose is 25 ug and the 5 day dose is 125 ug.
45485235|NCT04760808|Diagnostic Test|Baseline Clinical Examination|Evaluations of Postural control; Subjective postural vertical; Subjective visual vertical; Verticality perception
45485236|NCT04760808|Radiation|Initial 3T MRI of the Brain and Spine|Non-injected CSF flow MRI
45485237|NCT04760808|Diagnostic Test|6-month Follow-up Clinical Examination|Evaluations of Postural control; Subjective postural vertical; Subjective visual vertical; Verticality perception
45485238|NCT04760808|Radiation|6-month Follow-up 3T MRI of the Brain and Spine|Non-injected CSF flow MRI
45485239|NCT03236896|Behavioral|Exercise|Strength training exercises for older adults. All subjects will complete questionnaire (MENQOL Scale),hot flash diary and wear the fitbit flex for duration of study.
45485240|NCT03236896|Behavioral|No exercise|All subjects will complete questionnaire (MENQOL Scale),hot flash diary and wear the fitbit flex for duration of study.
45485241|NCT03236974|Drug|Standard Arm - Fulvestrant|500 mg Fulvestrant administered as two consecutive 5 ml intramuscular injections on Day 1, one in each buttock
45485242|NCT03236974|Drug|AZD9496|Administered at 250 mg bd orally for 5-14 days commencing on Day 1, and continuing up to the day of biopsy
45485243|NCT03748043|Drug|Lactoferrin|lactoferrin 100 mg per day plus ferric hydroxide polymaltose 6 mg /kilogram of Elemental iron
45485244|NCT03748043|Drug|Ferric Hydroxide Polymaltose|group 2 will receive ferric hydroxide polymaltose 6 mg /kilogram of elemental iron
45485245|NCT03254992|Device|ASD - Abstract task|Experimental group using Kinect with more virtual activity.
45485246|NCT03254992|Device|ASD - Tangible task|Experimental group using Keyboard with more real activity.
45485247|NCT03254992|Device|TD - Abstract task|Control group using Kinect with more virtual activity.
45485248|NCT03254992|Device|TD - Tangible task|Control group using Keyboard with more real activity.
45485249|NCT03750773|Drug|Gabapentin 600mg|Subject is given Gabapentin 600mg every 8 hours x 48 hours postoperatively for pain control.
45485250|NCT03750773|Drug|Placebo oral capsule|Subject is given a Placebo capsule every 8 hours x 48 hours postoperatively for pain control.
45368218|NCT00933998|Other|Metanx® (Oral L-methylfolate, Methylcobalamin and Pyridoxal 5'-phosphate)|One pill twice a day for 2 weeks. Then one pill a day until 12 month study is up.
45368219|NCT00447226|Drug|Oral lapatinib tablets or placebo tablets|Subjects administered open label lapatinib, 1500 mg to be taken orally once a day, for 12 weeks. After 12 weeks, subjects with a partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST) will continue to receive open label lapatinib (1500 mg/day orally) until disease progression. Subjects who maintain stable disease will be randomized in a 1:1 ratio to enter stage 2 of the study and receive double blind therapy of either lapatinib 1500 mg/day orally or placebo. Subjects who progress on placebo will have the option to receive lapatinib 1500 mg/day orally until further progression. Those who progress on lapatinib will be withdrawn from the study.
45485251|NCT02874924|Drug|Rapamycin|treatment
45485252|NCT02874924|Drug|Placebo|control
45485253|NCT02874924|Drug|Rapamycin|No placebo control in this substudy group
45485254|NCT03254836|Other|Standard of care|Elective radical surgery for adenocarcinoma.
45485255|NCT04425863|Drug|Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets|24 mg oral Ivermectin on days 0 and 7 and 1 Aspirin tablet daily for 30 days. Outpatient treatment.
45485256|NCT04425863|Other|Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets|36 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, 1 Aspirin tablet daily for 30 days. Inpatient treatment in ward care, including Low flow washed oxygen or oxygen concentrator
45485257|NCT04425863|Other|Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.|48 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, Enoxaparin 100 IU/kg (ca. 1 mg/kg) daily until transfer to ward care. Then continue with inpatient treatment in ward care.
45485258|NCT01370772|Drug|Rituximab|"Cycle 1 Rituximab : 375 mg/m² i.v on day 1~Cycle 2-6 Rituximab:500 mg/m² i.v on day 1, repeated every 28 days"
45485259|NCT01370772|Drug|Rituximab|"Prephase: Rituximab:500 mg on day 0, 2000 mg on days 1, 8, and D15~Cycle 1-6 cycle 1 beginning at D22: Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days"
45368220|NCT03360916|Drug|Lipitor 20Mg Tablet|One tablet by mouth every day for 12 weeks.
45368221|NCT03360916|Drug|Lipitor 80Mg Tablet|One tablet by mouth every day for 12 weeks.
45368222|NCT03360916|Drug|Placebo|One matching placebo tablet by mouth every day for 12 weeks.
45485260|NCT01370772|Drug|Cyclophosphamide|•FCR Cycle 1-6: Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days
45846321|NCT02516046|Drug|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
45846322|NCT02516046|Procedure|PET Scan|positron emission tomography (PET) scan
45847950|NCT03118596|Device|LMA Protector|Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.
46052059|NCT04200885|Drug|Dexketoprofen Trometamol|Patients were instructed to record the number of drugs they used until the second and seventh postoperative days.
45485261|NCT01370772|Drug|Fludarabine|FCR Cycle 1-6: Fludarabine :40 mg/m² per os, days 2-4, repeated every 28 days
46052060|NCT04200885|Drug|Dexamethasone 21-Phosphate|Injections were administered in the immediate preoperative period as a single shot.
46052061|NCT04200885|Device|Therapeutic Elastic Bandage|The bands' lengths were individually measured and divided into five equal parts up to 2/3 of their lengths to obtain fan-type shape.
45485262|NCT02455804|Device|Stenting procedure|All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
45847951|NCT03124368|Drug|Danicopan|Participants received study drug for 14 days (Treatment Period), followed by a taper over the next 7 days (Taper Period).
45847952|NCT03124602|Device|Red Diamond Disposable Pulse Oximeter Sensor|Noninvasive Pulse Oximeter Sensor
46052062|NCT05659251|Combination Product|Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy|Serplulimab 4.5mg/kg, IV, Day 1; Albumin paclitaxel 260mg/m2, Day 1; carboplatin AUC=5, Day 1; Preoperative neoadjuvant therapy for 2-4 cycles, one cycle every 21 days.
46052063|NCT05659251|Procedure|Esophagectomy|Laparoscopy combined with thoracoscope radical resection of esophageal carcinoma
45485263|NCT03254524|Other|Statewide Planning and Research Cooperative System Database|The Statewide Planning and Research Cooperative System (SPARCS) is a comprehensive data reporting system created to collect information on discharges from hospitals. SPARCS currently collects patient level detail on patient characteristics, diagnoses and treatments, services, and charges for every hospital discharge, ambulatory surgery patient, and emergency department admission in New York State.
45485264|NCT03747965|Biological|Mesothelin-directed CAR-T cells|Cells will be infused one day after the completion of conditioning regimen of paclitaxel and cyclophosphamide
45485265|NCT03254446|Drug|TRC150094|TRC150094 Tablet 45 mg
45485266|NCT03254446|Drug|Placebo|Matching Placebo Tablet
45485267|NCT01842282|Drug|Amlexanox|
45485268|NCT01365078|Dietary Supplement|Echium oil (SDA-rich oil)|The echium oil will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the experimental period twice a day, i.e. one sachet at lunch and one sachet at dinner
45485269|NCT01365078|Dietary Supplement|high-oleic acid sunflower oil (HOSO) (low in SDA)|The HOSO will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the control period twice a day, i.e. one sachet at lunch and one sachet at dinner
45847953|NCT03124758|Device|Hemoglobin Sensor ((Rainbow Reusable DCI, DCIP))|Measurement of Noninvasive Hemoglobin (SpHb)
45368223|NCT03360916|Behavioral|Exercise Program|Exercise program of brisk walking and/or slow jogging on a treadmill for 90 minutes of exercise spread over 3 days during week 1, 150 minutes of exercise spread over 5 days during week 2, 225 minutes of exercise over 5 days during week 3 and for the rest of the study.
45368224|NCT00446992|Drug|Olanzapine|16-week open trial of olanzapine. The patients were started on a dose of 15 mg/d by mouth, which could be adjusted to as low as 10 mg/d or as high as 40 mg/d, based on clinical response. The trial began while they were hospitalized and continued after discharge.
45368225|NCT01028794|Biological|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)
45368226|NCT01028794|Biological|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)
45368227|NCT00503139|Drug|Enbrel (etanercept)|Enbrel 10 to 25 mg twice a week subcutaneous injection
45368228|NCT00577031|Drug|bevacizumab [Avastin]|7.5mg iv on day 1 of each 3 week cycle
45368229|NCT00577031|Drug|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
45368230|NCT00577031|Drug|Xeloda|1000mg/m2 po bid on days 1-14 of each 3 week cycle
45368231|NCT00565448|Drug|docetaxel|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
45368232|NCT00565448|Drug|cisplatin|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
45368233|NCT00565448|Drug|5-fluorouracil|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
45368234|NCT01012011|Drug|Sorafenib (Nexavar, BAY43-9006)|Daily dose, dosage frequency and duration will be decided by physicians.
45485270|NCT03234634|Procedure|endovascular thrombectomy|"Intervention description : Group 1: patients with good collateral, Group 2: patient with poor collateral~Group 1 patients (good collateral group) will receive endovascular thrombectomy using stent retriever, aspiration catheter, or both, if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.~Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well."
45485271|NCT01370928|Device|Olympus PCF-Y0014-L|Screening colonoscopy with a prototype colonoscope
45485272|NCT01370928|Device|Standard colonoscope|Screening colonoscopy
45485273|NCT03234244|Drug|Bazedoxifene 20 mg|To estimate the drug-drug interaction between Bazedoxifene and combination of Bazedoxifene and Cholecalciferol, Subject will take Bazedoxifene 20mg 1 tablet one time.
45485274|NCT03234244|Drug|Cholecalciferol|To estimate the drug-drug interaction between Cholecalciferol and combination of Bazedoxifene and Cholecalciferol, Subject will take Cholecalciferol 2 tablets one time.
45485275|NCT03234244|Drug|Bazedoxifene 20mg and Cholecalciferol|For estimate the Drug-Drug Interaction, Subject will take Bazedoxifene 1 tablet and Cholecalciferol 2 tablets at once.
45847954|NCT03124836|Device|Pulse Oximeter Sensor|
45368235|NCT00934076|Drug|Tarceva plus AT-101|"150 mg of Tarceva taken once daily in a continuous regimen expressed in 3 week cycles.~Oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis."
45485276|NCT03254680|Dietary Supplement|Turmeric|Twenty patients will be enrolled and treated with a stable dose of orally administered turmeric oil daily for 3 months.
45485277|NCT03234400|Combination Product|Dapivirine Vaginal Ring, 25 mg|Vaginal Ring containing 25 mg dapivirine
45485278|NCT03234400|Combination Product|Dapivirine Vaginal Ring, 100 mg|Vaginal Ring containing 100 mg dapivirine
45485279|NCT03234400|Combination Product|Dapivirine Vaginal Ring, 200 mg|Vaginal Ring containing 200 mg dapivirine
45485280|NCT04360187|Drug|Crisaborole Ointment|Crisaborole ointment 2%
45485281|NCT04360187|Drug|Crisaborole Placebo Vehicle|Placebo for crisaborole ointment
45485282|NCT03234322|Other|external validated risk prediction model|The risk prediction model will be integrated into a routine health check. The diabetes risk prediction model contains modifiable non-invasive risk factors and consists of eleven questions on age, height, waist circumference, hypertension, physical activity, smoking status, intake of whole-grain bread, intake of red meat, coffee consumption, and family history of diabetes (parents and siblings) to predict the five-year diabetes risk. The filled diabetes risk score will be used in the counseling interview with the PCP at the end of the health check as a practical guide to discuss individual tailored preventive strategies.
45485283|NCT03254290|Biological|NeoMTA|A new formulation of MTA was developed in which bismuth oxide was omitted.
45485284|NCT03254290|Biological|Formocresol|Control group
45847955|NCT03125226|Device|Polyethylene Glycol Hydrogel|Given TracelT hydrogel via injection
45847956|NCT03127956|Drug|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
45485285|NCT03254368|Drug|ZGN-1061|ZGN-1061 is a methionine aminopeptidase 2 inhibitor
45485286|NCT03254368|Drug|Placebo|Placebo has the same excipients and appearance as ZGN-1061
45485287|NCT04498169|Drug|Netarsudil Ophthalmic|Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
45485288|NCT04498169|Drug|Netarsudil Ophthalmic|Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
45485289|NCT03236740|Drug|Ethinyl Estradiol-cyprosterone acetate|Ethinyl Estradiol-cyprosterone acetate in the form of OCPs will be taken cyclically by the participants.
45485290|NCT03236740|Drug|Metformin Hydrochloride|Metformin Hydrochoride in the form of 500 mg tablets will be taken twice daily by participants.
45485291|NCT02453464|Drug|Sevacizumab|escalating doses of Sevacizumab : 3mg/kg，4mg/kg，5mg/kg
45485292|NCT02453464|Drug|Irinotecan|Irinotecan: IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
45485293|NCT02453464|Drug|5-FU|5-FU: IV solution, IV bolus over 2-4 minutes, 400 mg/m²; IV infusion over 46 hours, 2400 mg/m²; Every 14 days, Until disease progression/toxicity
45485294|NCT02453464|Drug|Leucovorin|Leucovorin: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
45368236|NCT04495803|Other|Cognitive Behavioural Group Therapy for Perinatal Anxiety|The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population. Additional strategies for COVID-19 specific worry content have been included.
45368237|NCT02567123|Behavioral|Experimental|
45368238|NCT00934154|Drug|Thalidomide|100 mg/day continuously for 12 months
45368239|NCT00934154|Drug|Melphalan+Prednisolone|Melphalan 2 mg, Prednisolone 16 mg
45368240|NCT00446446|Drug|Panitumumab|Panitumumab was administered over a 1 hour intraveneous (IV) infusion at a dose of 9 mg/kg every 21 days.
45368241|NCT05078255|Drug|Semaglutide 1.34 MG/ML [Ozempic]|Semaglutide 1.34 mg/ml
45368242|NCT05078255|Drug|Glucose-dependent insulinotropic polypeptide (GIP)|GIP
45368243|NCT05078255|Other|Semaglutide 1.34 mg/ml placebo|Saline
45368244|NCT05078255|Other|GIP placebo|Saline
45485295|NCT03695393|Behavioral|ACT Therapy|The ACT intervention will consist of three 2-hour group sessions of culturally adapted ACT (intervention) to reduce stigma and related manifestations.Participants are recruited from a civil society organization and all other study procedures take place at a rehabilitation center. The ACT sessions will be scheduled to take place at the rehabilitation center following randomization.The First St. Petersburg Pavlov State Medical University is an alternative location where sessions can be conducted. Sessions will be planned to occur in weekly succession, with a goal of 3 sessions within the first month of study participation.
45485296|NCT03233932|Drug|LeuplinⓡInj|Investigational drug(=LeuplinⓡInj)is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
45485297|NCT03233932|Drug|CKD-841|Investigational drug(=CDK-841) is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
45485298|NCT03236584|Drug|lamivudine plus adefovir combination|continuing lamivudine plus adefovir
45368245|NCT00939458|Drug|Lamotrigine|
45368246|NCT05077943|Behavioral|Breathing and chest mobilization exercises|Patients walk regularly 5 times per week and increase the distance day by day according to their improved ability. Patients also do breathing and chest mobilization exercise 3 times per week. It is a recorded moderated exercise for 30 minutes duration. Patients can access the video as a home-based activity through an online videos platform and will be supervised.
45368247|NCT05077943|Behavioral|Second phase cardiac rehabilitation|Independently, patients walk regularly 5 times per week and increase the distance day by day according to their improved ability without breathing and chest mobilization exercise.
45368248|NCT04014608|Other|Standard Practice to Prevent Hospital Onset CDI|Bleach cleaning of rooms, use of required soap/water hand hygiene for CDI patients, hand hygiene monitoring, portable ultraviolet (UV) light room disinfection, and monitoring of room cleaning.
45368249|NCT00506493|Device|Cardioblate Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
45485299|NCT03236584|Drug|Tenofovir Disoproxil Fumarate|switching to tenofovir
45485300|NCT01562093|Drug|corticosteroid nasal spray|fluticasone furoate 55 µg (formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, purified water) once daily in each nostril for 3 months
45485301|NCT01562093|Drug|placebo nasal spray|formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, and purified water, once daily in each nostril for 3 months
45485302|NCT03254056|Procedure|Conventional technique|Conventional technique: In this group; S-retractors will be used to visualize the fascia and a single interrupted stitch will be placed using 0-vicryl suture.
45485303|NCT03254056|Procedure|Berci technique|Berci group: In this group; the fascial incision will be closed with the fascial closure device, (Berci Fascial Closure instrument) using 1 interrupted stitch with 0-vicryl suture.
45485304|NCT03694925|Diagnostic Test|Calprotectin test|Calprotectin will be measured both by ELISA and point of care test.
45485305|NCT03234088|Behavioral|Daily weight measured by digital scale and symptom reporting|All subjects will be provided the intervention.
45485306|NCT03233776|Drug|Anakinra|Subjects will be treated with a daily dose of anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT). Predefined doses are 100 mg , 200 mg and 300 mg.
45368250|NCT00506493|Procedure|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
45368251|NCT02566967|Drug|tofacitinib|oral tofacitinib will be taken 2 times daily
45485307|NCT03253588|Procedure|laparoscopic salpingotomy or salpingostomy|A 3-port technique (2 x 5-mm and 1 x 10-mm trocars) was implemented. A diluted solution of vasopressin (20IU in 100 mL saline solution) was initially injected into the mesosalpinx of the affected tube, followed by a linear incision which allowed the removal of the gestational tissue. In case of a ruptured tubal pregnancy, the ectopic mass was evacuated directly from the ruptured site using a combination of forceps and suction device. The tubal lumen was either closed with a single-layer of continuous absorbable suture (salpingotomy) or left to heal by secondary intention (salpingostomy).
45485308|NCT05321615|Device|Palpator|Palpator for tumor localization
45485309|NCT05321615|Device|Grasper|Atraumatic lung grasper
45485310|NCT05321615|Device|Ultrasound|VATS ultrasound
45485311|NCT05321615|Other|Finger palpation|Palpation of the lung/tumour using the surgeon's finger
45485312|NCT03253900|Device|Stable rowing simulator|a standard stable/fixed rowing simulator
45368252|NCT00939068|Drug|Telbivudine|Subjects start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continued to one month after delivery.
45368253|NCT00939068|Biological|engineered HB vaccine|All the newborns in control group are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20 ug respectively at age of 0, 1 and 6 months.
45485313|NCT03253900|Device|Slides based rowing simulator|a slides based rowing simulator, i.e. horizontal plane unstable
45485314|NCT03253900|Device|Tilt board based rowing simulator|a tilt board based rowing simulator; i.e. frontal plane unstable
45485315|NCT04614168|Procedure|Stepped hyperinsulinaemic-hypoglycaemic clamp study|Participants will commence on a primed insulin infusion at a constant rate of 60mU/m2/min along with a variable rate 20% glucose infusion. Participants will have their blood glucose monitored every 5 minutes. The glucose infusion will be altered to achieve the desired blood glucose plateaus of: 5mmol/l, 3mmol/l and 2.5mmol/l. Each plateau will be held for 40 minutes. During each plateau blood samples will be taken on three occasions for: glucagon, cortisol, adrenaline, noradrenaline, D2 glucose and D5 glycerol. On two occasions during each plateau participants will complete the Edinburgh hypoglycaemia scale and the following cognitive tests: trail making test, digit span test, digit symbol substitution test and four choice reaction time test. At the end of the clamp study the insulin infusion will be discontinued and the blood glucose will be allowed to rise to the normal range. Participants will consume lunch before leaving the clinical research facility.
45368254|NCT00939146|Other|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
45847957|NCT03132246|Diagnostic Test|Blood draws|The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.
45847958|NCT03138330|Other|this study is observational, it is not an intervention|
46052064|NCT00766831|Drug|Hydromorphone|Participants will receive hydromorphone OROS (8 milligram [mg] to greater than or equal to 32 mg) once daily for 2 weeks, in a dose adjusted according to previously administered strong oral opioid analgesic (dose with equivalent analgesic effect; hydromorphone OROS dose: oral morphine dose=1:5) hydromorphone OROS will be continued as per Investigator's discretion for additional 84 days of extension phase.
45368255|NCT00939146|Other|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
45368256|NCT00934232|Drug|Busulfan|Busulfan (Bu) is a bifunctional alkylating agent currently used almost exclusively as a component of conditioning regimens for both autologous and allogeneic stem-cell transplants.
45368257|NCT01013571|Drug|insulin glargine|pre-filled disposable pen, in package of 5.
45368258|NCT01013571|Drug|Apidra (insulin glulisine)|pre-filled disposable pen, in package of 5
45368259|NCT04061837|Device|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial chordae or ege-to-ege repair using MitralStitch Mitral Valve Repair System
45485316|NCT04614168|Device|Insulin pump|Insulin pump with a built-in algorithm that allows it to work with a CGM device to adjust insulin delivery based on CGM readings.
45485317|NCT04614168|Device|Continuous glucose monitor|Continuous glucose monitoring device that sends data to the insulin pump to allow the algorithm to adjust insulin delivery. Participants are able to see the glucose data from the device when it is used in open mode.
45485318|NCT04614168|Other|Low carbohydrate diet|30-40g of carbohydrate per main meal portion.
46052065|NCT02821689|Drug|Pirfenidone|Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. The maximum dose was maintained throughout the study in patients who tolerated it.
46052066|NCT02822859|Device|Wright nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
46052067|NCT02822859|Device|Bennett-Twin nebulizer|Puritan Bennett Corp., Carlsbad, CA, USA
46052068|NCT02822859|Device|Aeroneb Solo|Aerogen Ltd., Galway, Ireland
45485319|NCT04614168|Device|Blinded continuous glucose monitor|Allows data on blood glucose to be collected without values altering the behaviour of the participant. Participants have to continue to monitor their own blood glucose while wearing the device in the blinded mode.
45485320|NCT04614168|Procedure|Stable isotope studies- D2 Glucose and D5 Glycerol|These studies will take place at the same time as the hyperinsulinaemic hypoglycaemic clamp studies. Participants will receive a priming dose of each stable isotope followed by a continuous infusion for the remainder of the clamp study.
45485321|NCT04495829|Device|Phorcides Analytical Engine|Surgery planning using the Phorcides analytical engine.
45485322|NCT02453230|Behavioral|Lights on|Determine if ambient room light stimulation changes the amount of time required to perform the fetal biophysical profile.
45368260|NCT03128385|Other|Intensive CIT Model Program|"Day Camp Model:~The treatment was delivered in group-based design, 6 hours a day for 6 days (36 hours in total)~constraint of the unaffected hand to encourage the use of the affected hand~massed and repetitive practice of the affected hand during the period of constraint~use of behavioral techniques termed shaping to train the affected hand"
45485323|NCT02453152|Other|History and physical|Subjects will undergo a physical exam and medical history review, including review of genetic test results.
45485324|NCT02453152|Other|Tidal breathing|Subjects' breathing patterns will be evaluated at rest and at reduced/eliminated ventilator support.
45691582|NCT00608140|Procedure|Surgical mitral valvuloplasty with placement of annular ring (SMVR)|Participants will undergo open heart surgery to mechanically reduce mitral regurgitation (MR). A complete rigid or semi-rigid annular ring will be placed unless specifically contraindicated by intraoperative findings. The ring size will be between 24 mm and 27 mm in the anteroposterior diameter. Annular ring sutures will be placed circumferentially approximately 1 mm off the hinge point between the leaflet and the atrial tissue. The total number of sutures will vary between 4 and 7 sutures anteriorly, while 8 to 12 sutures will be utilized for the posterior segment of the annulus. Additional repair of the mitral apparatus itself will be based on intraoperative findings. Leaflet repair will be performed for significant prolapse. Submitral apparatus repair will be performed for ruptured or significantly elongated chordae as well as significant chordal tethering.
45368261|NCT03128385|Other|Distributed CIT Model Program|"Home-Based Model:~The participants will receive individualized interventions, 2.25 hours a day, two times a week for 8 weeks (36 hours in total).~constraint of the unaffected hand to encourage the use of the affected hand~massed and repetitive practice of the affected hand during the period of constraint~use of behavioral techniques termed shaping to train the affected hand"
45485325|NCT02453152|Other|Maximal respiratory pressures|Subjects' strongest inspiratory and expiratory pressures will be measured.
45691583|NCT00608140|Drug|Optimal medical therapy (OMT)|Optimal medical therapy can include, but is not limited to, any of the following treatment regimens: combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy.
45691584|NCT02135146|Drug|Plasmalyte 3ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 3 ml/kg/hr. and a nexfin monitor placed on them
45691585|NCT02135146|Drug|Plasmalyte 6ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 6 ml/kg/hr. and a Nexfix Monitor placed on them
45847959|NCT03138798|Device|Laboraide TM dental support device|Patients will give consent in the first stage of labor. Subsequently a randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group A will received a sealed Laboraide TM package. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment. Following delivery, patients assigned to Group A will complete a patient satisfaction survey.
45847960|NCT03138876|Device|EEG Cap|Patient will be fitted with an EEG cap by the on-call neurology resident to assess for NCSE.
45485326|NCT02453152|Other|Peak cough flow|Subjects' strongest coughs will be measured.
46052069|NCT02821533|Procedure|TACE|TACE is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.
46052070|NCT02821533|Drug|Cisplatin|Cisplatin will be mixed with a mixture of Lipiodol and ethanol (LEM), which consists of 33% ethanol by volume in Lipiodol, in a ratio of 2mg cisplatin per mL of LEM, and delivered through catheters or microcatheters to the tumors until there is flow reduction at the tumor feeders. The total dose of cisplatin given in each treatment session is limited to 100mg (50mL LEM) in each treatment session. The usual volume of LEM delivered will be 20 - 30 mL.
46052071|NCT05659407|Drug|Belimumab in SLE patients / Rituximab in RA patients|Belimumab and Rituximab are the the investigated treatments, respectively in the SLE and RA group. They are administrated according to the approved indications and in compliance with the current recommendations and the good clinical practice, independently to the aim of the present observational study.
45485327|NCT02453152|Other|Pediatric Evaluation of Disability Inventory|Assesses the functional capabilities of children with disabilities.
45485328|NCT02453152|Other|PedsQL Multidimensional Fatigue Scale|Assesses general fatigue, sleep/rest fatigue, and cognitive fatigue.
45485329|NCT02453152|Other|Review of ventilation requirements|Subjects's use of mechanical ventilation reviewed by the study team.
45485330|NCT01372488|Procedure|Suture self removal|Suture self removal
45485331|NCT01372488|Procedure|Suture removal by family doctor or clinic|As above
45485332|NCT03234010|Other|FT21092|An electronic cigarette
45485333|NCT03234010|Other|FT21093|An electronic cigarette
45368262|NCT04062071|Other|no intervention|no intervention
45485334|NCT03234010|Other|FT21096|An electronic cigarette
45368263|NCT00514449|Drug|Valacyclovir|1 g PO BID x 2 weeks after 2 weeks it goes up to 1.5 g PO BID x 16 weeks along with antipsychotic
45485335|NCT03234010|Other|FT21097|An electronic cigarette
45368264|NCT00514449|Drug|Placebo|2 pills twice a day x 2 weeks, after 2 weeks 3 pills twice a day x 16 weeks along with antipsychotic
45485336|NCT01365234|Device|Pacing Lead|Implant and follow up of Model 20066 lead
45485337|NCT02453308|Drug|ACT|"Artemether-lumefantrine for 3 days~Dihydroartemisinin-piperaquine for 3 days.~Artesunate-mefloquine for 3 days"
45485338|NCT02453308|Drug|TACT|"Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days.~Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days.~Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days."
45485339|NCT04258020|Device|BiPAP|Bilevel Positive Airway Pressure (BiPAP) oxygen administration
45847961|NCT03138876|Drug|Anti-seizure medication|Patients may be treated for NCSE or seizures based on EEG cap findings, if the findings are clear to an attending EEG reviewer. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
45368265|NCT04061759|Other|Effectiveness of four physical therapy approaches (soft tissue manual therapy, Kinesio® Taping techniques, stabilization exercises and reflex therapy) for treating lumbar disc pathologies.|Visual analog scale (VAS) scores for pain intensity, goniometric measurements for the range of motion and hamstring flexibility, the sit and reach test for flexibility, an isokinetic evaluation for strength at 60°/sec, and a side-plank position test for trunk stabilization were measured. The functional status was evaluated with the Oswestry Disability Index. All groups were assessed at the beginning, after a four-week treatment and four weeks of follow-up.
45368266|NCT00565136|Device|TOPAS|A mesh sling permanently implanted to increase pelvic floor support
45485340|NCT04258020|Device|HFNC|Heated High Flow Nasal Cannula oxygen administration
45485341|NCT03236350|Device|Active autoRIC® (CRIC Treatment)|The active autoRIC® Device is programmed to go through a preset protocol of inflation and deflation cycles every session. The sessions will be repeated daily for 28 days.
46052072|NCT04240353|Other|COPD digital support service|Use of COPD digital services to record patient symptoms, integrate physiology monitoring, communicate with the clinical team and track interaction
46052073|NCT00766675|Drug|Tramadol hydrochloride|Tramadol hydrochloride oral tablet will be administered at a dose of 37.5 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
46052074|NCT00766675|Drug|Acetaminophen|Acetaminophen oral tablet will be administered at a dose of 325 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
46052075|NCT04101799|Behavioral|For Our Children's Sake|Parental support with the aim to support positive parenting and promote healthy child development. Conducted in group-format with weekly 2.hour sessions conducted by trained group leaders according to a programme manual.
45368267|NCT00738179|Device|Continuous Positive Airway Pressure (CPAP)|CPAP worn nightly
45485342|NCT03236350|Device|Sham Control autoRIC® (Sham Control)|The Sham Control autoRIC® Device is visually identical to the active autoRIC® Device but the simulated protocol applied comprises of vibrations of the device but no inflation of the cuff every session. The sham device provides the same sound and vibration as that of the pump inflating and the same LED indicators on the Active Unit. The sessions will be repeated daily for 28 days.
45485343|NCT01365312|Drug|Ethanol lock|Placement of 0.5 cc 70% ethanol, every 72 hours, for 15 minutes, into PICC lines randomized to ethanol intervention
45485344|NCT01365312|Drug|Heparinized saline|0.5 cc heparinized saline to be placed once every 72 hours for 15 minutes, in PICC lines randomized to placebo
45485345|NCT04495283|Drug|Pregabalin|Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
45485346|NCT04495283|Drug|Acetaminophen|Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
45485347|NCT04495283|Other|Placebo 1|Placebo for APAP
45485348|NCT04495283|Other|Placebo 2|Placebo for combination
45485349|NCT03253822|Other|Decision aid|The DA is an online tool. The web-based design opens up possibilities to feature more advanced functions, e.g. questions for the participant during the process, and a summary of answers at the end. The DA is tailored to lower educational attainment citizens, and is designed to embrace different information needs in the target population, ranging from a desire to receive a clear recommendation and a minimum of information to the desire to receive full information and make a personalized choice.
45847962|NCT03138876|Procedure|Standard EEG|An electroencephalogram (EEG) is a test used to find problems related to electrical activity of the brain. An EEG tracks and records brain wave patterns. Small metal discs with thin wires (electrodes) are placed on the scalp, and then send signals to a computer to record the results.
45485350|NCT01365390|Other|Data collection (Retrospective)|For the retrospective part of the study, the parent(s)/ legally acceptable representative(s) of the subjects will be interviewed to collect information on factors potentially related to risk for middle ear diseases. The medical records of the subjects will also be reviewed and all acute otitis media related problems that occurred during the last year prior to enrolment (for subjects aged 1 to < 6 years) or since birth (for subjects aged < 1 year) will be recorded in the electronic case report form.
45485351|NCT01365390|Other|Data collection (Prospective)|For the prospective part of the study, the enrolled subjects will be followed up for a period of 1 year starting from the consent date, during which the parent(s)/ legally acceptable representative(s) will be asked to bring the subject for a visit each time they notice symptoms of acute otitis media or respiratory tract infection in the subject. In case AOM is diagnosed by the investigator, detailed information on the signs, symptoms, severity, course and treatment will be recorded. The parent(s)/ legally acceptable representative(s) of the subjects will also be required to fill up a parental quality of life questionnaire and an Otitis Media-6 children's quality of life questionnaire.
45368268|NCT00738179|Other|Standard care|Standard care of cardiovascular risk factors
45368269|NCT00492921|Drug|Cyclophosphamide|
45368270|NCT00738257|Drug|Pamidronate|
45368271|NCT00738335|Drug|erlotinib hydrochloride|
45368272|NCT00738335|Other|immunoenzyme technique|
45368273|NCT00738335|Other|laboratory biomarker analysis|
45485352|NCT03253510|Other|Poly-amide|New denture base material that exhibit high flexibility, physical strength, heat and chemical resistance and the exceedingly rare allergy response
45485353|NCT03253510|Other|Poly-methyl methacrylate|Gold standard denture base material
45485354|NCT03744845|Other|Virtual Reality Distraction|This RCT will utilize an Oculus Go VR headset that delivers VR images and sound. Users will wear the VR headset. A research coordinator will familiarize patients with hardware before use. The VR will be used preoperatively and intraoperatively to distracts patients, and aid with the treatment of pain and anxiety.
45485355|NCT03634020|Device|DynamX Sirolimus-eluting Coronary Bioadaptor System|de novo native coronary artery lesions
45485356|NCT03253666|Other|Nutrient Intake|Dietary nutrient intake (such as folate) and supplemental nutrient intake (such as folic acid)
45485357|NCT03253432|Other|Genetic testing|Targeted next-generation sequencing for familial hypercholesterolemia causative mutations
45485358|NCT04466592|Behavioral|Promotion of competences of participant involved in the management of the post operative period|The research psychologist will be in touch with the participants for 9 months after the surgery (weekly, biweekly or monthly) in order to help them recovering social and work activities, and dealing with the consequences of the surgery. Specifically, four competences will be promoted (future forethought; context evaluation; consequences of own actions forethought; use of available resources), each relevant to four areas (clinical; familiar; working; daily-activities).
45485359|NCT03233620|Other|Knee arthroplasty|Effectiveness of knee arthroplasty surgery.
45485360|NCT04445220|Biological|SBI-101|SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.
45485361|NCT03253276|Drug|Obeticholic acid|Placebo-controlled
45485362|NCT03253276|Drug|Placebos|
45485363|NCT01372644|Drug|SOM 230 / Pasireotide|
46052076|NCT04101799|Other|Active control|Participating in everyday activities that may include parenting activities in the control prisons
46052077|NCT02821611|Behavioral|Meditation Group|twice daily 20 minute mantra-based meditation practice for 8 weeks
45368274|NCT00738335|Other|liquid chromatography|
45368275|NCT00738335|Other|mass spectrometry|
45368276|NCT00738335|Other|pharmacological study|
45368277|NCT00738335|Radiation|stereotactic radiosurgery|
45368278|NCT00502671|Drug|capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 of each 3 week cycle
45368279|NCT00738413|Drug|Deferoxamine|Deferoxamine will be administered subcutaneously over 8 hours for 6 days at a dose of 40 mg/kg.
45368280|NCT00738413|Drug|Deferasirox|Deferasirox will be orally administered at a dose of 30 mg/kg once daily for 6 days.
46052078|NCT04722939|Diagnostic Test|Cerebral oxygenation|Cerebral oxygenation will be monitored with the FORESIGHT Elite cerebral oximeter during the first 72h of critical illness, and during subsequent hemodialysis sessions
46052079|NCT00766597|Drug|Vicriviroc|Administered orally in either tablet or liquid form at a dosage of approximately 0.8/mg/kg every 24 hours, with a ritonavir boosted protease inhibitor containing background regimen
45847963|NCT03139032|Drug|APD334|APD334 active treatment for 12 weeks.
45847964|NCT03139578|Device|Test 8.5BC|senofilcon A contact lenses with 8.5 base curve
45847965|NCT03139578|Device|Test 9.0BC|senofilcon A contact lenses with 9.0 base curve
45847966|NCT03139578|Device|Control 8.5BC|narafilcon A contact lenses with 8.5 base curve
45847967|NCT03139578|Device|Control 9.0BC|narafilcon A contact lenses with 9.0 base curve
46052080|NCT02820441|Drug|Zopiclone|
46052081|NCT02820441|Drug|Placebo|
46052082|NCT04097431|Behavioral|Response Blocking|Physically preventing the response (i.e., precursor) from occurring.
45485364|NCT01371084|Behavioral|Pedal@Work Worksite Wellness|Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.
45485365|NCT01371084|Behavioral|Pedal@Work|Worksite wellness program.
45485366|NCT03233386|Behavioral|Mantente REAL|substance abuse prevention curriculum for adolescents
45368283|NCT00697463|Drug|Teriparatide (PTH 1-34)|20 micrograms subcutaneous injection daily
45485367|NCT02455648|Procedure|ESD/EMR plus Cell Sheet|"Patients receive ESD/EMR plus CellSheet:~Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane (Cell Sheet) that are inserted 2 weeks later on the occasion of the ESD or EMR"
45485368|NCT02455648|Procedure|ESD/EMR|"only ESD/EMR: Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane (Cell Sheet) but NOT used for insertion in the patient during/after ESD/EMR two weeks later"
45485369|NCT04237116|Biological|Investigational Arm - secukinumab|secukinumab 300mg s.c. weekly in first 4 weeks, followed by q4w up to Week 20; and placebo 300mg s.c. at weeks 13, 14 and 15 to maintain the blind
45485370|NCT04237116|Biological|Control Arm - placebo|placebo 300 mg s.c. weekly in first 4 weeks, followed by q4w up to Week 8; and secukinumab 300 mg s.c. weekly for 4 weeks starting at Week 12, followed by q4w up to Week 20
45485371|NCT03253198|Drug|Saline|A preoperative interscalene brachial plexus single-shot block using 25 ml of 0.5% Ropivicaine plus saline injection postoperative
45485372|NCT03253198|Drug|Bupivacaine liposome|an interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
45485373|NCT03253042|Other|WBV exercise program|The intervention will consist of a 8-week whole-body vibration exercise program with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
45485374|NCT03253042|Other|Sham WBV exercise program|The intervention will consist of a 8-week exercise program, but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
45485375|NCT03252730|Other|WO 4260 Cosmetic Product for Topical Use|Application on the hair scalp at least once a day over four weeks
45485376|NCT03252886|Procedure|Endotracheal Intubation|Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation
45485377|NCT03117738|Drug|AstroStem|Autologous adipose tissue derived mesenchymal stem cells (AdMSC)
46052083|NCT04817943|Other|Non applicable|When the patient enters the operating room, oxygen saturation, blood pressure, and electrocardiogram are monitored, and general anesthesia is induced using 1-2 mg/kg of 1% propofol. 0.8 mg/kg of rocuronium, a neuromuscular blocker, is injected intravenously, and a human endotracheal tube is intubated. A thermometer is attached to the inside of the double-layered endotracheal tube cuff, which measures the temperature in the trachea. After the endotracheal intubation is performed, the esophageal thermometer is inserted, and from this point, the temperature measured by the esophageal thermometer and the thermometer of the endotracheal tube are recorded. The temperature immediately after insertion of the esophageal thermometer is set as Tbaseline, and the temperature of the esophagus and trachea, the temperature of the operating room, and the temperature of breathing circuit with heated wire humidifier are recorded every 5 minutes from thereafter until the end of the operation.
45368284|NCT04409795|Drug|Metformin Extended Release Oral Tablet|Initial oral hypoglycemic agent added to existing insulin treatment
45368285|NCT04409795|Drug|Sitagliptin|Secondary oral hypoglycemic agent added to existing insulin treatment (for those who are intolerant to or unable to achieve glycemic targets with metformin)
45368286|NCT00492531|Drug|Sildenafil|Oral Sildenafil 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
45485378|NCT03117738|Other|Placebo-Control|Saline with 30% auto-serum
45485379|NCT03252652|Radiation|vascular duplex ultrasound imaging|Duplex ultrasound is a non-invasive evaluation of blood flow through cranial arteries and veins.
45368287|NCT00492531|Drug|Placebo|Placebo 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
45368288|NCT04334603|Other|Exercise Training Program|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital or at home.
45368289|NCT04334655|Other|Physical Therapy|Patients with primary complaints of neck pain will receive routine physical therapy care including modalities, manual therapy including neck mobilization and manipulation, stretching and strengthening exercises, and patient education.
45368290|NCT00111475|Drug|Romiplostim|Administered by subcutaneous injection
45368291|NCT00111475|Drug|Placebo|Administered by subcutaneous injection
45485380|NCT03229330|Procedure|Low-level Light Therapy|Low-level Light Therapy 660nm (red laser), 1 to 3 Joules, irradiation time and number of points varied.
45485381|NCT03229330|Combination Product|Conventional treatment|Topical treatment: essential fatty oil, hydrogel, papain gel, petrolatum gauze, calcium or silver alginate, zinc oxide and barrier cream; and high compression bandage SurePress
45485382|NCT02855268|Drug|lademirsen (SAR339375)|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection
45485383|NCT02855268|Drug|Placebo|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection
45485384|NCT03236038|Diagnostic Test|Labeled triolein urea breath test|"The diagnosis of EPI will be made through the combination of two diagnostic tests.~The labeled triolein breath test will use criteria established by the manufacturer of the product (Pancreo-Kit®) Isomed pharma.~The fecal elastase test will be performed at our own center (Bioserv Diagnostics (BS-86-01 Elastase Pancreatic ELISA) distributed by Palex Medical.) In those cases where both results are negative, it will be considered that there is no EPI. In cases where both results are positive, the diagnosis of EPI will be performed. If the results are discordant, a Sobel test or feces quantification test will be performed."
46052084|NCT00910962|Drug|GW856553|7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
45485385|NCT04292106|Dietary Supplement|Red Spinach Extract (RSE)|Oral capsules containing 2g of Red Spinach Extract will be consumed daily for 7 days
45485386|NCT04292106|Dietary Supplement|Placebo|Oral placebo capsules will be taken consisting of maltodrextrin daily for 7 days
45485387|NCT03235882|Diagnostic Test|LS-ratio|Accurately predict RDS using Lecithin/Sphingomyelin ratio (L/S ratio determined by a rapid FTIR test on fresh gastric aspirates) using retrospective analysis
45485388|NCT04285086|Biological|Ropeginterferon alfa-2b|Ropeginterferon alfa-2b (P1101) dosage: from 250 mcg to 500 mcg
45485389|NCT04285086|Drug|Anagrelide|Anagrelide dosage: 0.5 mg per capsule, according to label and physician's judgement
45485390|NCT03236116|Other|Almonds|Participants will consume almonds everyday for 6 months.
45485391|NCT03236116|Other|Control (no nuts)|Participants will not be permited to consume any nuts for 6 months.
45485392|NCT04485988|Drug|Beta blocker|Duration of medication
45485393|NCT04163484|Other|Iodinated contrast|Intra-arterial injection of iodinated contrast media during percutaneous coronary intervention
45485394|NCT03235960|Device|glass-ionomer fissure sealant|The encapsulated glass-ionomer cement for fissure protection was applied onto the selected permanent molar according to the manufacturer's instruction
45485395|NCT04234464|Combination Product|Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol single dose
45485396|NCT04234464|Combination Product|Placebo metered-dose inhaler|Placebo inhalation aerosol single dose
45485397|NCT04485910|Other|Single step media|Usage of single step media in embryo culture
45485398|NCT04485910|Other|Sequential media|Usage of sequential media in embryo culture
45485399|NCT03235570|Drug|Pemigatinib|Pemigatinib at the protocol-defined dose administered once daily.
45485400|NCT01371162|Drug|RO5428029|Multiple ascending doses
45485401|NCT01371162|Drug|placebo|multiple doses
46052085|NCT00910962|Drug|GW856553|15 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
46052086|NCT00910962|Drug|Placebo|Placebo
45485402|NCT04485832|Device|Telehealth care|Patients in the intervention group daily answer 6 questions, which are focused on the recognition of AECOPD, using the electronic healthcare platform Evita by Swisscom, which has been and continuously is developed by the study team and Swisscom. The study team daily analyses all patients online and reacts according to a pre-specified action plan.
45485403|NCT04485832|Diagnostic Test|Weekly CAT measurement|
45485404|NCT03233152|Drug|Ipilimumab (YervoyTM, 50 mg/10 mL solution)|"Ipilimumab will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (: 2 ml of YervoyTM, 50 mg/10mL vial).~Injections will be performed manually using a 100 μ-liter dispensing syringe. Twenty needle tracks will dispense the ipilimumab solution within the brain tissue lining the resection cavity. The region suspect on preoperative MRI of the brain to be invaded by glioblastoma cells but not amenable to safe resection will be targeted by adjacent needle tracks through which up to 2 cm of depth a volume of 100 μl per needle track will be injected (: in total 20 needle tracks will be performed). This methodology has been applied previously within the context of phase III clinical trials with sitimagene ceradenovec."
45485405|NCT03233152|Drug|Nivolumab (OpdivoTM, 40 mg/4mL solution)|First administration of 10 mg of nivolumab by the intravenous route should be administered within 24 hours prior to the planned neurosurgical resection. Administrations of 10 mg nivolumab (OpdivoTM, 40 mg/4mL solution) will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary).
45485406|NCT03235648|Procedure|cardiophrenic lymph nodes resection|surgical resection
45485407|NCT03229096|Drug|Apatinib plus XELOX|"three weeks is one cycle, 4 cycles followed by radical gastrectomy. Apatinib: 250 mg, p.o., qd, every 3 weeks for the first two cycles. if no level 3 or severer AEs happened, change apatinib to 500mg, p.o.,qd, otherwise keep 250mg in the third cycle. no apatinib in the fourth cycle.~Capecitabine: 1000mg/m2, p.o., bid, D1-14, every 3 weeks (treatment for 2 weeks and rest 1 week).~Oxaliplatin: 130mg/m2, i.v. over 2h, D1, every 3 weeks."
45485408|NCT03232996|Other|Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease|All the participants will take part in an 8 week (twice per week) computer game based exercise program for dual task balance and dual task walk training. Participants will be standing in front of LED monitor. They will be asked to wear a head band which will be instrumented with motion sense mouse. Thus, hands-free head rotations will be used to interact with the computer games selected for the DT rehabilitation program. Participants will play few interactive computer games during - Normal standing (fixed surface), Standing on a compliant sponge pad and then while walking on a treadmill.
45485409|NCT03123588|Drug|Ruxolitinib|Ruxolitinib administered orally twice daily (BID) at the protocol-defined starting dose.
45485410|NCT03123588|Drug|Anagrelide|Anagrelide administered orally at a starting dose of 1 mg BID.
45485411|NCT03123588|Drug|Placebo|Anagrelide-placebo administered orally BID
45485412|NCT03123588|Drug|Placebo|Ruxolitinib-placebo administered orally BID.
45485413|NCT02453074|Other|Online survey - Follow up for Better Care|
46052087|NCT02822391|Other|observation|
46052088|NCT02690571|Other|Bronchoscopy|The bronchoscopy procedure was performed six hours after completion of the exposure session, with sampling of endobronchial mucosal biopsies, bronchial wash and bronchoalveolar lavage performed under topical anaesthesia.
46052089|NCT04200807|Device|Ultrasound Cardiac Output Monitor (USCOM 1A)|doplerometry with USCOM and echocardiograph is made for assessing central blood flow and spectroscopy with NONIN- for the blood flow in individual peripheral organs (brain and kidney)
45485414|NCT04114812|Other|Blended learning|In the intervention group, students will be given access to an e-learning platform that contains five e-learning modules. They will attend individual small group tutoring sessions, with a maximum of 4 students per group. They will be able to book these sessions at a dedicated web platform. They will have 16 weeks in which to complete the 5 e-learning modules and 16 hours of practical training. Progress will be monitored and supported by regular follow-up messages and calls by the study team. Students must hand in the logbook with tutors' signatures when they enter the exam. All students within the blended learning group that completed 5 hours of e-learning as well as 16 hours of peer-tutoring and passed a predefined total score in the test directly after the intervention will receive a course certificate. Students not fulfilling all of these criteria will have the possibility to complete the program and/or re-do the test after the end of the study.
45485415|NCT04114812|Other|Standard course|In the standard course or control group, students will participate in a 2.5-day course in abdominal ultrasound, comprising 5 hours of lectures and 16 hours of ultrasound training in small groups, with a maximum of 4 students per group. The course will be held in an ultrasound training centre in Bern. All students within the standard course group that participated in the whole 2.5 day course and passed a predefined total score in the test directly after the intervention will receive a course certificate. Students not fulfilling all of these criteria will have the possibility to complete the program and/or re-do the test after the end of the study.
45485416|NCT03232762|Dietary Supplement|Refined Grains|In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
45485417|NCT03232762|Dietary Supplement|Whole Grains|In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
45485418|NCT01372722|Device|DBS Activa PC systems Medtronic|130Hz, 90us pulsewidth, 4V Amplitude
45485419|NCT01372722|Device|DBS, Activa PC systems Medtronic|30Hz, 90us pulsewidth, 4V Amplitude
45485420|NCT02452918|Drug|Oritavancin|a single 1200 mg IV dose of Orbactiv (oritavancin)
45485421|NCT02821026|Procedure|Omental Islet transplant|The intervention is transplanting the islets into an omental pouch instead of into the liver. The omentum is a large apron-like fold of membrane inside the abdomen that drapes over the intestines. This study will test to see if omental islet transplantation is safe and effective. Standard immunosuppressive medicines (anti-thymocyte globulin, tacrolimus, mycophenolic acid, sirolimus, etanercept) will be used in this study to prevent rejection of the islets.
45485422|NCT02821026|Drug|Anti-Thymocyte Globulin|
45485423|NCT02821026|Drug|Mycophenolate mofetil|
45485424|NCT02821026|Drug|Tacrolimus|
45485425|NCT02821026|Drug|Etanercept|
45485426|NCT02821026|Drug|Sirolimus|Sirolimus will be used in case of tacrolimus or/and mycophenolate mofetil intolerance.
46052090|NCT05659095|Other|autologous hair follicle derived mesenchymal stem cell suspension|Healthy hair follicles were extracted from the occipital area and treated to obtain hair follicle mesenchymal stem cells suspensions. The recipient sites were divided into two groups. Nine points were injected in a 1 cm2 area, and 100 μl of solution containing either 1 × 105 cells or normal saline was injected at each point. The follow-up duration was 9 months.
46052091|NCT02821065|Device|Remote Patient Monitoring|
45596364|NCT02288923|Procedure|Local Infiltration Analgesia|"Local infiltration analgesia to be administered by surgeon towards the end of operation:~40ml of bupivacaine 0.25% with adrenaline 1:200 000, diluted to 150ml with saline 0.9%. This is then divided into thirds; 50ml into the posterior capsule before cementing, 50ml into the medial and lateral capsules and 50ml into subcutaneous tissues and in and around the vastus medialis and sartorius muscles (where it may block the saphenous nerve)."
45596365|NCT02288923|Procedure|Sub arachnoid analgesia|Patients in both arms of the trial will be given sub arachnoid anasthesia of 2.5-3.0ml of plain bupivacaine 0.5% using a 25G Whitacre needle. Patients may have 0-4mg midazolam and/or 0-1mcg/kg fentanyl and/or 0-4mcg/ml propofol sedation using the Marsh protocol if required for this procedure as deemed appropriate by the anaesthetist.
45691586|NCT02829268|Drug|dantrolene sodium|"The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions.~There is a screening period up to 56 days, a 6-month treatment period with an optional extension phase up to 24 months, and a 4-week safety follow-up period. Study assessments include medical & medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires."
46052092|NCT02820285|Other|Evaluation of the staging of fibrosis liver|The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies
46052093|NCT02820285|Other|Determine the expression level of semaphorin|The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,
46052094|NCT02820285|Other|Determination of the composition of immunity cells|"The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting~)"
45485427|NCT03107494|Device|Gala Airway Treatment System|The Gala Airway Treatment system is a device-based, energy delivery system that delivers high frequency short duration energy to the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope. In this study, 2 treatment sessions will be delivered 1 month apart. The right lung is treated at the first treatment session and the left lung is treated at the second treatment session. A third bronchoscopy will be performed 3 months following the second treatment session where treatment is not delivered but a cryo-biopsy will be taken from the airway sites that have been treated during the two previous bronchoscopic treatment session to evaluate the effect of the treatment on the airways producing excessive mucous. Subjects will be required to submit to several tests during the study including two CT scans (lung), respiratory function tests, exercise testing.
45485428|NCT03123354|Device|O3 regional oximeter sensor|Noninvasive sensor that is placed on the forehead for measurement of oxygenation in the area under the sensor
45485429|NCT03235102|Other|No treatment given|Completion of a survey
45485430|NCT02452996|Drug|GNbAC1|Single dose of IMP, IV infusion
45485431|NCT04421027|Drug|Baricitinib|Given orally
45368292|NCT02566655|Biological|Fucosylated MSC for Osteoporosis|"Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).~Mononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access."
45368293|NCT01015209|Device|Chitosan- N- Acetylcysteine eye drops|Cohort 1: 1 drop once Cohort 2: 2 drops daily for 5 days
45368294|NCT04948463|Drug|Piperacillin and Tazobactam for Injection|Given if patient has no known allergies, until ANC recovery at 100mg/kg (max 4g) 6 hourly.
45368295|NCT04948463|Drug|Cefepime Injection|Given if patient has non life-threatening hypersensitivity (preferred option), until ANC recovery at 50mg/kg (max 2g) 8 hourly.
45368296|NCT04948463|Drug|Ceftazidime Injection|If non life-threatening hypersensitivity (second option), given until ANC recovery at 50mg/kg (max 2g) 8 hourly
45485432|NCT04421027|Drug|Placebo|Given orally
45485433|NCT03228940|Drug|RVX000222|oral, BID
45485434|NCT03228784|Procedure|LASIK|
46052095|NCT04239807|Device|Group 1 GALILEO WBV|3 month home based WBV training
46052096|NCT04239807|Other|Group 2 Control|Training on the floor without WBV
46052097|NCT04807881|Drug|Keynatinib|All subjects shall be treated with Keynatinib twice a day (once every 12 hours), 20 mg each time, fasting within 2 hours before and 1 hour after taking the drug, and taking warm water when taking the drug. It is recommended to take the drug at the same time every day. In case of missed administration, the subjects should be instructed to take it as soon as possible when they think of it on the same day. If it is within 3 hours later than the scheduled administration, the study drug should be taken as soon as possible; if the interval is > 3 hours, skip this time and take the next dose at the normal scheduled time. Do not take double dose at one time. Every 28 days is a treatment cycle until the specified interview completed, PD, intolerable toxicity, death occurs or withdraw from the study (including withdrawal of informed consent by the subject or termination of the study when the investigator judges that the risk is greater than the benefit), whichever occurs first.
46052098|NCT00773461|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
46052099|NCT00773461|Drug|Placebo|iv every 4 weeks for 24 weeks
45368297|NCT04948463|Drug|Vancomycin Injection|If life-threatening hypersensitivity given with ciprofloxacin, given until ANC recovery at 15mg/kg (max 500mg) 6 hourly
45368298|NCT04948463|Drug|Amikacin Injection|Given until ANC recovery at 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s.
45485435|NCT03228628|Drug|Fixed 50:50 mixture of nitrous oxide and oxygen|Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
45485436|NCT03228628|Other|Placebo|inhale medical air (22% O2 - 78% N2)
45485437|NCT03228550|Dietary Supplement|Efamol Active 50+|1000 mg docosahexaenoic acid, 160 mg eicosapentaenoic acid, 20 µg B12, 1 mg folic acid, 124 mg phosphatidylserine, 240 mg ginkgo biloba standardized leaf extract and 20 mg vitamin E
45485438|NCT03228550|Behavioral|Aerobic exercise|Static exercise cycle
45485439|NCT03228550|Dietary Supplement|Placebo multinutrient|Placebo multinutrient supplement
45596366|NCT02288923|Procedure|Sedation or general anaesthesia|After insertion of the sub arachnoid anaesthesia the patient may choose to be fully asleep or sedated. If they choose to be fully asleep, they may have up to 2mcg/kg fentanyl in total (including any given at time of subarachnoid injection), muscle relaxation as indicated for facilitation of intubation where needed, airway control using LMA or tracheal tube where needed, and general anaesthesia maintained using inspired oxygen concentration of 0.3-0.7 with propofol up to 5mcg/kg (Marsh protocol) or isoflurane or sevoflurane. If the patient chooses to have sedation they may have additional midazolam up to a total dose of 4mg and/or a propofol infusion (Marsh protocol) of 0-4mcg/ml.
45485440|NCT03228706|Behavioral|Know Your Medicine - Take It For Health (KYM-TIFH)|The KYM-TIFH employed psychosocial, educational and behavioral approach. It was designed based on the application of multiple behavior change theories and persuasion theory as recommended by Slater (1999). The cross-theoretical framework for the message design of intervention as recommended by Slater (1999) involved theories such as Transtheoretical Model (TTM) (Prochaska & Velicer 1997), Theory of Reasoned Action (TRA) (Ajzen & Fishbein 1980), Protection Motivation Theory (PMT) (Rogers 1975), Elaboration-Likelihood Model (ELM) (Petty and Cacioppo 1986) and Social Cognitive Theory (SCT) (Bandura 1992) as in Table 2. Nonetheless, the intervention embraces the philosophy of patients' empowerment, which had found to be effective in engaging patients to produce behavioral change among diabetes patients (Anderson 1995; Anderson et al 1995). Hence, the facilitators are trained to employ a non-didactic approach in facilitating the and eliciting the learning among the group members.
45485441|NCT03232684|Diagnostic Test|Rapid on-site evaluation|On-site (endoscopy suite) evaluation, by a pathologist or a pulmonologist, of specimens retrieved from intrathoracic lymph nodes during EBUS-TBNA
45485442|NCT04419311|Device|Vanguard® Knee System|Posterior cruciate ligament retention versus sacrificing is one of the main debates in total knee arthroplasty (TKA) and retention or sacrificing depends on the individual preference of the surgeon during the surgery. Whenever the surgeon decides to sacrifice the posterior cruciate ligament (PCL), another controversial question arises regarding the tibial insert type. While the posterior cruciate ligament-stabilized (PS) insert is widely used as the tibial insert in PCL-sacrificing TKA, it has some disadvantages such as increased polyethylene wear, additional bone resection, breakage of the post and patellar clunk syndrome. The ultra-congruent (UC) insert was designed to prevent bone loss in particular, and the other mentioned disadvantages of the conventional PS insert. However, patients with postoperative hyperextension have been seen to be associated with inferior clinical outcomes and knees become gradually more extended until two years after TKA using the UC insert.
45485443|NCT03232528|Other|Herb-partitioned moxibustion|Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
45485444|NCT03232528|Other|Sham herb-partitioned moxibustion|Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
45485445|NCT03232450|Drug|Aspirin|Subjects will receive 81 mg enteric coated aspirin
45485446|NCT03232450|Device|Cardiovascular Implantable Device (CIED)|All subjects will receive either a pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT).
45485447|NCT03232450|Device|Gore Cardioform Septal Occluder|The Gore Cardioform Septal Occluder closes the patent foramen ovale (PFO).
45485448|NCT03228316|Procedure|superior hypogastric plexus block|nerve plexus block
45485449|NCT03228316|Radiation|pulsed radiofrequency|pulsed radiofrequency on sacral nerve roots 2,3 and 4
45485450|NCT04411667|Drug|Octagam|Standard of Care plus Octagam infusion for 3 days.
45485451|NCT03232372|Device|External-Connection non-submerged Imp|Through a surgical procedure, we will implant implant whit external connection and non submerged to patients.
45485452|NCT03232372|Device|Internal Connection Submerged implants|Through a surgical procedure, we will implant implant whit internal connection and submerged to patients.
45485453|NCT03232372|Device|Internal Connection non-Submerged Impl|Through a surgical procedure, we will implant implant whit internal connection and non-submerged to patients.
45485454|NCT03750617|Diagnostic Test|pre-endoscopic screening risk assessment|pre-endoscopic screening risk assessment
45485455|NCT03222622|Drug|Icotinib hydrochloride cream|Apply topically twice daily for 12 consecutive weeks
45485456|NCT03222622|Drug|Placebo cream|Apply topically twice daily for 12 consecutive weeks
45485457|NCT03752021|Procedure|Myometrial Sampling|"A myometrial sample will be obtained at the time of cesarean delivery. Sample will be obtained from the superior edge of the existing lower uterine segment incision and will be 2 inches in length and 0.5 inches in width. The uterine incision will be repaired in a standard two-layer closure. If a classical cesarean (vertical) uterine incision is deemed necessary and is performed by the surgical team, a sample of the same size will be taken parallel to the incision at the existing edge. The classical uterine incision will be closed utilizing the standard layered technique.~Placenta and gestational membrane tissue will be obtained after placental delivery. The entire placenta and attached gestational membranes will be collected if not being sent for pathologic review"
45485458|NCT03750539|Radiation|Standard radiotherapy|External Bean Pelvic Radiation: 50 Gy in 15 fractions, with weekly cisplatin.
45485459|NCT03750539|Radiation|hypofractionated radiotherapy|External Bean Pelvic Radiation: 37.5 Gy in 15 fractions, with weekly cisplatin.
46052100|NCT02821377|Drug|intravenous furosemide|treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) plus small volumes of HSS (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
46052101|NCT02821377|Drug|Hypertonic saline solutions|Intravenous small volumes of HSS (150mL 1.4-4.6% NaCl), plus treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
46052102|NCT02821377|Procedure|Seriated paracentesis|repeated paracentesis from the first day after admission until 3 days before discharge
45485460|NCT03750539|Procedure|Radical hysterectomy|Radical hysterectomy and pelvic and paraaortic lymph node resection
45485461|NCT03751943|Device|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)within one posterolateral gutter
45485462|NCT04948697|Drug|Ociperlimab|900 mg intravenously once every 3 weeks (dosed in 21-day cycles)
45485463|NCT04948697|Drug|Tislelizumab|200 mg intravenously once every 3 weeks (dosed in 21-day cycles)
45485464|NCT04948697|Drug|BAT1706|15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)
46052103|NCT02820987|Drug|MEROPENEM|Administration of MEROPENEM according to a protocol of extended infusion defining dose and duration of infusion.
46052104|NCT02820987|Drug|PIPERACILLIN-TAZOBACTAM|Administration of PIPERACILLIN-TAZOBACTAM according to a protocol of continuous infusion defining dose and duration of infusion.
46052105|NCT02820987|Drug|CEFEPIME|Administration of CEFEPIME according to a protocol of continuous infusion defining dose and duration of infusion.
45368299|NCT04948463|Drug|Ciprofloxacin|If life-threatening hypersensitivity given with vancomycin, given until ANC recovery at 10 mg/kg (max 400 mg) 12 hourly
45485465|NCT04358549|Drug|Favipiravir|Favipiravir to be administered as an oral tablet or made into a slurry for subjects who cannot swallow tablets
45485466|NCT04358549|Other|Standard of Care|Standard of Care for individual study site as determined by each hospital's protocol
45485467|NCT01562483|Drug|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
45485468|NCT01562483|Drug|Placebo|Identical to the Namisol arm.
45485469|NCT00700180|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
45485470|NCT00700180|Drug|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
45485471|NCT00700180|Drug|Carboplatin-based chemotherapy|As prescribed
45485472|NCT03222544|Combination Product|methylene blue|Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand
45485473|NCT03222544|Combination Product|Photon therapy instrument|Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand
45691587|NCT00581854|Drug|modified Hyper-CVAD|rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
45368300|NCT04948463|Drug|Piperacillin and Tazobactam for Injection|Given if patient has no known allergies at 100mg/kg (max 4g) 6 hourly, stopping 48 hours post-fever resolution.
45368301|NCT04948463|Drug|Cefepime Injection|If non life-threatening hypersensitivity (preferred option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution
45368302|NCT04948463|Drug|Ceftazidime Injection|If non life-threatening hypersensitivity (second option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution
45368303|NCT04948463|Drug|Vancomycin Injection|If life-threatening hypersensitivity given with ciprofloxacin at 15mg/kg (max 500mg) 6 hourly, stopping 48 hours post-fever resolution
45368304|NCT04948463|Drug|Amikacin Injection|At 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s, stopping 48 hours post-fever resolution
45368305|NCT04948463|Drug|Ciprofloxacin|If life-threatening hypersensitivity given with vancomycin at 10 mg/kg (max 400 mg) 12 hourly, stopping 48 hours post-fever resolution
45368306|NCT04945421|Drug|Sintilimab|(IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
45368307|NCT04945421|Drug|IBI310|(IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
45691588|NCT00610480|Drug|1st visit Optive, then 2nd visit Systane|"First visit: Instillation of Optive followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Systane followed by evaporometry assessment after 30 minutes."
45691589|NCT00610480|Drug|1st visit Systane, then 2nd visit Optive|"First visit: Instillation of Systane followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Optive followed by evaporometry assessment after 30 minutes."
45847968|NCT03141372|Device|Void Trial using Foley catheter|A void trial is a test to ensure that a subject does not have urinary retention after a surgical procedure. In an autofill void trial, the subject is allowed to void after surgery and the amount of resulting urine and the amount of urine still remaining in the bladder are measured. In a backfill void trial, water is instilled into the bladder, the foley is removed, and the subject is then allowed to urinate. Again, the amount of urine resulting and the amount of urine still in the bladder are measured.
45847969|NCT03141528|Other|Self-learning|Training without supervision
45368308|NCT01080547|Procedure|Laparoscopic Surgery for Colorectal Cancer|Laparoscopic surgery for colorectal cancer using STORZ laparoscope
45368309|NCT01080547|Drug|XELOX Chemotherapy|XELOX chemotherapy
45368310|NCT01080547|Drug|mFolfox6 chemotherapy|Conventional (mFolfox6) chemotherapy
45368311|NCT01080547|Other|Fast Track Perioperative Treatment|Fast track treatment during perioperation period
45485474|NCT03228862|Drug|Ergocalciferol|Ergocalciferol 40000, 60000 and 80000 once weekly
45485475|NCT03228238|Drug|Vitamin C and Vitamin E|Ascorbic acid Tablet 1g and Tocopherol Capsule 400IU
45485476|NCT03228238|Drug|Statin|Atorvastatin calcium 10mg
45485477|NCT03228238|Drug|Standard medication for variant angina|Calcium Channel blocker or NG
45485478|NCT03232216|Dietary Supplement|Vitamin D3.|Vitamin D3 50.000 UI in each packet of powder for oral solution.
45691590|NCT02202772|Drug|Cabazitaxel|Intravesical instillation of the Cabazitaxel for 2 hours
45691591|NCT02202772|Drug|Gemcitabine|Intravesical instillation of Gemcitabine for 2 hours
45691592|NCT02202772|Drug|Cisplatin|Intravesical installation of Cisplatin for 2hours
45368312|NCT01080547|Other|Conventional Perioperative Treatment|Conventional treatment during perioperation period
45485479|NCT03232216|Dietary Supplement|Placebo|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution.
45485480|NCT03228082|Device|Home Blood Pressure Monitoring (HBPM)|Home blood pressure monitoring using the Withings Wireless BP monitor. Patients will be asked to measure their blood pressure twice daily for 7 consecutive days. This will be repeated for every month for 1 year.
45485481|NCT03222700|Procedure|surgical procedure|In robotic thyroidectomy group, patients are received surgery using robotic system. In open thyroidectomy group, patients are received conventional open surgery.
45485482|NCT03222934|Device|multislice computed tomography|radiological diagnosis of the status and variations in the sphenoid sinus
45485483|NCT03231982|Drug|Group I|Machkhan Tab. 8/5 mg + Atacan Tab. 8 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks or Machkhan Tab. 16/5 mg + Atacan Tab. 16 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks
45368313|NCT01080547|Procedure|Open Surgery for Colorectal Cancer|Open surgery for colorectal cancer using conventional methods
45368314|NCT04930991|Drug|Omeprazole|Treatment will consist of Omeprazole 2 weeks prior to surgical therapy of pancreatectomy.
45691593|NCT00582400|Drug|arsenic trioxide|"Trisenox will be diluted with 100 to 250 mL 0.9% Sodium Chloride injection, USP, using proper aseptic technique, immediately after withdrawal from the ampule. The Trisenox ampule is single-use and does not contain any preservatives. Unused portions of each ampule should be discarded properly. Trisenox is not to be mixed with other medications.~The loading dose of Trisenox will be administered intravenously over 2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. The drug will be administered IV through a functional peripheral or central venous line. Trisenox is not a vesicant, and may be a mild irritant if administered into the skin without dilution."
45691594|NCT00582946|Device|Hearing Aid|Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss.
45691595|NCT00583414|Device|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
46052106|NCT04052490|Other|Abutment with flat occlusal reduction with feather edge finish|Non vital teeth require a full coverage restoration to withstand the functional stresses and prevent any further destruction of tooth/crown complex. The zirconia all-ceramic crowns yield a high flexure strength and are used as an esthetic alternative to ceramo-metallic crowns. Several studies linked the effect of preparation designs to the survival of the restoration. Others, studied the effect of the finish line geometries as deep chamfer and shoulder on the marginal integrity of restorations. The feather edge finish line is used with zirconia crowns with limited data regarding its success. However, there is no presented research dealing with the effect of finishing line designs in combination with different occlusal reduction schemes on the marginal fit of full contour zirconia crowns.
45368315|NCT02566811|Procedure|Abdominal surgery|Hysterectomy defined as an extrafascial hysterectomy whereby the cervix is removed completely but no radical dissection of the parametria is required
45368316|NCT02566811|Procedure|Lymphadenectomy|Bilateral pelvic and para-aortic lymph node dissection
45368317|NCT00111241|Drug|aromatase inhibitors (letrozole, anastrozole)|Women prescribed an aromatase inhibitor by their clinician were compared with healthy controls in the community who had been recruited to a prior study
45485484|NCT03231982|Drug|Group II|Atacan Tab. 8 mg + Norvasc Tab. 5 mg + Machkhan Tab.8/5 mg placebo for 8 weeks or Atacan Tab. 16 mg + Norvasc Tab. 5 mg + Machkhan Tab.16/5 mg placebo for 8 weeks
45368318|NCT02567747|Other|Data collection|Data will be collected retrospectively for cases identified through RIPS*/ DANE** from 2008 until 2014 and through PAI*** from 2009 until 2014. *Registro Individual de Prestación de Servicios de Salud (RIPS) database (Health Service Provider Individual Registration Database), Columbia. **Departamento Administrativo Nacional de Estadística (DANE) database (The National Administrative Department of Statistics database), Columbia. ***Programa Ampliado de Immunizaciones (PAI) database (National Immunization Program database), Columbia.
45368319|NCT00492297|Drug|Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)|Dacarbazine 1000 mg/m^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
45368320|NCT02567513|Behavioral|Supplement Intervention|Supplements given twice/day, 5 days/week, for 24 weeks by research staff.
45368321|NCT02567513|Behavioral|Snack Intervention|Snacks given twice/day, 5 days/week for 24 weeks by research staff.
45485485|NCT03222466|Other|Co-created PEM|A co-created PEM has been designed in collaboration with patients.
45485486|NCT03222154|Device|Experimental - Shock wave therapy|Shock wave therapy was performed with the Master Plus 200® Storz Medical equipment, radial emission 2000 pulses, frequency 15 Hz and pressure 1 Bar.
45485487|NCT03222154|Device|Placebo - Shock wave therapy|Simulation of shock wave therapy
45485488|NCT03222388|Other|Questionnaire - IIEF 5/15|International Index of Erectile Function
45485489|NCT03227848|Device|Automated Heart Murmur Detection AI|Automated AI algorithm-based analysis of digital heart sound recordings to detect and classify heart murmurs. Heart sound recordings were fully blinded before undergoing one-time automated analysis. AI algorithm results for each recording include: AHA classification (Class I (pathologic heart murmur) versus class III (innocent heart murmur or no heart murmur), murmur timing, murmur grade, heart rate and S1/S2 identification.
45485490|NCT03231904|Diagnostic Test|Blood test|blood samples will be taken for maternal and fetal levels of ACTH and LIF
45368322|NCT04608435|Other|Video-Assisted Thoracoscopic Surgery|patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
45485491|NCT03120130|Biological|Amblyomin-X|Intravenous drug administration, with different doses in each cohort
45485492|NCT03231670|Procedure|Blood sampling|5ml blood will be taken in addition to standard sampling
45485493|NCT03119974|Drug|Tpo-RA discontinuation|a standardized strategy of dosage reduction will be implemented according to a predetermined scheme on persistent and/or chronic ITP patients who have previously achieved a stable and prolonged (> 2 months) complete response (platelets counts > 100 x 109/L) period on Tpo-RA treatment.
45485494|NCT03119896|Other|The Navigator Tool Intervention|The intervention consists of two parts; a training session on self-management of chronic conditions for the healthcare professionals, and a paper-based tool for the patients. Both parts aim to inform and prepare the two parties as to what self-management entails in order to facilitate a constrictive consultation.
45485495|NCT03231592|Other|CSA Group|Already included in the arm descriptions.
45485496|NCT03231592|Other|Enhanced Usual Care Group|Already included in the arm descriptions.
45485497|NCT03228004|Behavioral|Glooko MeterSync|The participant and caregiver will receive a reminder via text or email to upload glucose data via Glooko on a biweekly basis.
45485498|NCT03222310|Drug|Ipatasertib|Ipatasertib 100 mg tablet orally once daily.
45485499|NCT03222310|Drug|Itraconazole|Itraconazole 100 mg capsules orally once daily.
45485500|NCT03222232|Behavioral|catheter salvage|In each case of catheter-related bloodstream infection the management of the central venous catheter was registred to evaluate the future risk of new infections
45485501|NCT04485520|Other|CARICA PAPAYA MOUTHWASH|Each application was 10 ml. applied for 1 minute, once a day for 8 days
45485502|NCT04485520|Other|CHLORHEXIDINE MOUTHWASH|Each application was 10 ml. applied for 1 minute, once a day for 8 days
45691596|NCT00583492|Biological|Ad5-yCD/mutTKSR39rep-ADP|Ad5-yCD/mutTKSR39rep-ADP (1 x 10^12 vp) on day 1 Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy
45691597|NCT00583492|Radiation|IMRT|40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
45691598|NCT04583527|Device|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
45847970|NCT03141528|Other|Instructor-led learning|Supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
45485503|NCT03231514|Dietary Supplement|Carbohydrate Supplement (Carb10)|2 of 4 arms will be supplemented with carbohydrate pre-workout (Carb10, Compound Solutions, Carlsbad, CA)
45847971|NCT03145818|Other|VD-HCBS|Like the participant-directed programs developed for Medicaid programs,VD-HCBS maximizes Veteran-centered care and independence. VD-HCBS provides Veterans with a monthly financial allotment based on an assessment of the extent of their need for assistance with personal care due to injury or the impact of disease
46052107|NCT04041258|Procedure|pseudoarthrosis of clavicle|Pseudoarthrosis represents a complication following a fracture, resulting in persistent symptoms and functional limitation, which prolongs the recovery time for the patient and necessitates new surgery. The purpose of surgery for pseudoarthrosis is to re-establish the length and alignment of the clavicle in an environment favorable to the union of bone fragments.
46052108|NCT02820363|Device|"CERAMENT|G"|"Surgical repair of tibia fracture, CERAMENT™|G applied to bony voids."
46052109|NCT02820363|Procedure|SOC treatment|surgical repair of tibial fracture
46052110|NCT03652272|Behavioral|EMC2|"Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks~Patients will receive a Medication Guide + Summary with their After Visit Summary~Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study)~Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols."
46052111|NCT04202640|Procedure|Mechanical Stimulation|The technique of mechanical stimulation alternates between compression and decompression of the treated area. It aims to reestablish a good blood circulation and lymphatic drainage.
45485504|NCT03231514|Other|Diet|2 groups will be on a carbohydrate-based diet (% energy from carbohydrate:fat:protein, 53:24:23) and 2 groups will be on a ketogenic diet (72:5:23)
45485505|NCT03231514|Other|Exercise|All groups will participate in a standardized exercise intervention.
45485506|NCT03231436|Drug|Fixed dose of 12.5mg bupivacaine|Spinal anesthesia performed with 12,5mg of bupivacaine with 25mcg fentanyl for cesarean section
45485507|NCT03231436|Drug|Height-adjusted dose of bupivacaine|Spinal anesthesia performed with height-adjusted dose of bupivacaine with 25mcg fentanyl for cesarean section
45485508|NCT02452450|Drug|Ibuprofen Acid|
45485509|NCT02452450|Drug|Ibuprofen Lysine|
45485510|NCT02452450|Drug|Ibuprofen Sodium|
45485511|NCT02452450|Drug|Ibuprofen Liquid Capsules|
45485512|NCT02452450|Drug|Paracetamol|
45485513|NCT01293214|Procedure|Limb transplantation|
45485514|NCT02452372|Drug|givosiran (ALN-AS1)|Single or multiple doses of ALN-AS1 by subcutaneous (sc) injection
45485515|NCT02452372|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
45485516|NCT03221920|Other|Very Low Carbohydrate Diet|1 : 4 ratio of carbohydrate to fat of the total daily calories intake
45485517|NCT01204684|Biological|autologous tumor lysate-pulsed DC vaccination|
45368323|NCT03997227|Procedure|Erector spinae Block|After anesthesia and surgical procedures, a bilateral ESP block with ultrasound guidance will be applied from the T10 level at the middle line 3 cm lateral. Prior to the block, with povidone iodine, the T10 transverse protrusion will be determined by using linear ultrasound probe. The local anesthetic will be applied between the transverse projection and the erector spina muscle with the help of an isolated needle designed for peripheral block operations. Without local anesthesia, the location of the needle with saline will be confirmed by hydrodissection. After confirming the location of the needle, 20 ml of LA and saline mixture will be applied and the same procedure will be repeated in the control. A total of 40 ml of LA, 20 ml of bupivacaine 0.5%, 10 ml of lidocaine 2%, 10 ml of saline will be composed of saline.
45485518|NCT01204684|Biological|Tumor lysate-pulsed DC vaccination+0.2% resiquimod|
45485519|NCT01204684|Biological|Tumor-lysate pulsed DC vaccination +adjuvant polyICLC|
45485520|NCT03227302|Procedure|attending obstetrician|Attending obstetrician can do the caesarean operation without pregnant complications.
45485521|NCT03227302|Procedure|associate obstetrician|Associate chief Obstetrician can do the caesarean operation without or mild or middle pregnant complications.
45485522|NCT03227302|Procedure|chief obstetrician|Chief obstetrician can do all caesarean operation without limitations.
45485523|NCT00594334|Drug|Risedronate|Weekly Risedronate
45485524|NCT03227380|Other|thoracic densitometry with contrast|injected CT scan at 3 or 6 months after segmentectomy VATS
45485525|NCT03229018|Diagnostic Test|Voxel size|200 μm and 300 μm Voxel Sizes
45691599|NCT04583215|Device|Paired Associative Stimulation (PAS)|On each of the 10 days of the intervention, participants will receive PAS (or PAS-C) to the left DLPFC by delivering peripheral nerve stimulation (PNS) to the right median nerve and TMS to the left DLPFC, followed immediately by PAS (or PAS-C) to the right DLPFC by delivering PNS to the left median nerve and TMS to the right DLPFC. PAS-C differs from PAS only by including an interstimulus interval of 100 ms between PNS and TMS to the DLPFC, compared to 25 ms in the active PAS condition. Using 100 ms interval, we have previously demonstrated that PAS-C does not induce PAS-LTP in the DLPFC. If a participant cannot attend one or more of the 10 consecutive PAS or PAS-C treatment sessions, we will allow up to four extra treatment days to make up for missed sessions.
45691600|NCT01801735|Drug|Meloxicam Test Capsules|
46052112|NCT04202640|Procedure|Massages|"Massages will be carried out according to a specific regime as specified in the study protocol. The massages will be done in 15 sessions of 30 minutes each, done twice a week and will consist of:~One part muscle exercise~One part skin work (drainage)"
46052113|NCT02820909|Procedure|venous and arterial catheter set-up using ultrasound guidance|The insertion of the venous and arterial catheter will be done using ultrasound guidance. Vein and artery will be identified in cross section. In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than > 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit.
45368324|NCT00565058|Biological|GTI-2040|GTI-2040 will be administered one day after HiDAC in the pilot PD study and one day before HiDAC in the Phase II study for a cycle. Those who achieve a complete remission (CR) will be permitted to receive one cycle of consolidation of GTI-2040 and HiDAC
45368325|NCT04061681|Behavioral|Behavioral Intervention (BIPAMS)|This 16-week behavioral intervention teaches people the skills, techniques, and strategies based on Social Cognitive Theory of behavior change for modifying and self-regulating health behaviors, including physical activity. The behavioral intervention consists of two primary components, namely a dedicated Internet website and one-on-one video chats with a behavioral coach via SkypeTM.
45368326|NCT00934388|Procedure|Pre peritoneal mesh placement|
45847972|NCT03147690|Drug|Lumason|Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.
45368327|NCT00934388|Procedure|Laparoscopy|
45368328|NCT00939224|Device|Model 7600 Regional Oximeter System|Non-invasive regional oxygen saturation measurements
45485526|NCT00238420|Drug|Paclitaxel|Given IV
45485527|NCT00238420|Radiation|Radiation Therapy|Undergo radiation therapy
45485528|NCT00238420|Biological|Trastuzumab|Given IV
45485529|NCT03221998|Drug|IV paracetamol|100 gram paracetamol infusion for moderate pain management
45485530|NCT03221998|Drug|IV saline (NaCl 0.9 %)|100 ml of Normal Saline (IV NaCl 0.9 %) as placebo
45485531|NCT03221686|Dietary Supplement|Intervention|The patients in the intervention group are given 55 mg zinc, 1251 mg vitamin C, and 15 g arginine once daily 14 days pre-operatively and post-operatively together with a high quality protein supplement.
45485532|NCT03221686|Dietary Supplement|Control|High quality protein supplement 14 days pre-operatively and post-operatively.
45485533|NCT03231280|Device|SB-061|delivered via intra-articular injection
45847973|NCT03148236|Drug|Vitamin C|200mg/kg/day split into 4 doses infused every six hours over 30 minutes in 50ml D5W
45847974|NCT03148236|Other|Placebo|50mL infused over 30 minutes
45847975|NCT03148470|Device|Sham iTBS|Placebo stimulation for the iTBS group
45847976|NCT03148470|Device|Sham cTBS|Placebo stimulation for the cTBS group
45847977|NCT03148470|Device|intermittent theta burst stimulation (iTBS)|Excitatory theta burst stimulation
45847978|NCT03148470|Device|continuous theta burst stimulation (cTBS)|inhibitory theta burst stimulation
45368329|NCT00564902|Drug|3R 3'R Zeaxanthin|8 mg per day during 12 months
45368330|NCT00564902|Dietary Supplement|Lutein|9 mg of Lutein during 12 months
45368331|NCT00564902|Dietary Supplement|Lutein and Zeaxanthin|8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months
45368332|NCT04013516|Behavioral|Cash Incentive|During the phone call, New Incentives' team member promised a greater cash payment from New Incentives' staff members at primary health care facilities when infants enrolled in the program and received their measles vaccination.
45485534|NCT03231280|Other|Placebo|Placebo delivered via intra-articular injection
45485535|NCT03231202|Procedure|Embolization|"The intervention arm will perform SAE as a central embolization of the splenic artery.~Additional peripheral embolization is left to the discretion of the interventional radiologist."
45485536|NCT03221530|Behavioral|Early Intervention for Suicide Risk Among Immigrant Youth|The EISR-I intervention includes family treatment engagement, shared problem definition, and sessions designed to address family cohesion, communication, and conflict resolution.
45485537|NCT03221530|Behavioral|Enhanced usual care|This intervention includes a session with the family to engage in safety planning and provide feedback on their baseline assessment data.
45485538|NCT02452294|Drug|Buparlisib|Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events
45368333|NCT04013516|Behavioral|Call|A New Incentives' team member reminded caregivers of their child's measles immunization date and the total amount of incentive they would receive once their child was vaccinated. If the caregiver could not be reached on the first attempt, the team made additional attempts at different times of the day on five different days across two weeks (up to 10 attempts were made per caregiver).
45368334|NCT04014452|Procedure|Microwave ablation|Use of microwave energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
45485539|NCT03221608|Procedure|Surgery and HIPEC with Lobaplatin|The combination of surgery and HIPEC with Lobaplatin are performed in patients with colorectal cancer (T4N0-2M0).
45485540|NCT03221608|Procedure|Surgery without HIPEC|The patients with colorectal cancer (T4N0-2M0) are undergone a curative resection by laparoscopy or open approach.
45691602|NCT00612430|Drug|Bevacizumab and Etoposide|32 pts w recurrent WHO grade III MG & 27 pts w recurrent WHO grade IV MG will be enrolled in this study. Estimated rate of accrual is 10 pts per month. The estimated date of study completion is 6-9 months from study initiation. Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If pt tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day. The Duke investigators will review all la data & order treatment. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent.
46052114|NCT02820909|Procedure|Anatomical guidance.|"In the anatomical group, catheter will be inserted using, as it is currently done in intensive care unit, anatomic landmarks. If catheterization according to the anatomic method is considered too difficult (> 3 punctures), a conversion to ultrasound guidance will be done.~In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than > 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit."
45368335|NCT04014452|Procedure|Radiofrequency ablation|Use of radiofrequency energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
45368336|NCT04013750|Other|Modified Constraint Induced Movement Therapy|constraint-induced movement therapy (CIMT) is characterized by the restraint of the less effected upper limb accompanied by the shaping and repetitive task-oriented training of more affected upper extremity.
45847979|NCT03149172|Device|Equimatrix®|Ridge preservation bone grafting after tooth extraction
45847980|NCT03149172|Device|Bio-Oss®|Ridge preservation bone grafting after tooth extraction
45847981|NCT03149172|Device|Endobon®|Ridge preservation bone grafting after tooth extraction
45368337|NCT00446134|Drug|Taribavirin|Oral (200 mg) Tablet: 20mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
45368338|NCT00446134|Drug|Taribavirin|Oral (200 mg) Tablet: 25mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
45368339|NCT00446134|Drug|Taribavirin|Oral (200mg)Tablet: 30mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
45485541|NCT04492475|Drug|Interferon beta-1a|Rebif (R) is a purified 166 amino acid human interferon beta glycoprotein with an amino acid sequence identical to natural fibroblast derived human interferon beta. Each 0.5 mL prefilled syringe contains 44 mcg of interferon beta-1a, 4 mg human albumin, USP; 27.3 mg mannitol, USP; 0.4 mg sodium acetate; and water for injection, USP.
45485542|NCT04492475|Other|Placebo|The interferon beta-1a placebo contains either 0.5 mL 0.9% normal saline or 0.5 mL sterile water for injection.
45485543|NCT04492475|Drug|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
45485544|NCT03231124|Drug|LEO 32731|LEO 32731 is being developed by LEO Pharma.
45485545|NCT03231124|Drug|Placebo|Placebo contains the same excipients in the same concentration, only lacking LEO 32731
45847982|NCT03150108|Drug|rhPTH(1-84)|25 mcg rhPTH(1-84) SC injection
45847983|NCT03150108|Drug|rhPTH(1-84)|50 mcg rhPTH(1-84) SC injection
45847984|NCT03150108|Drug|rhPTH(1-84)|100 mcg rhPTH(1-84) SC injection
45485546|NCT03227068|Other|PEDSS - symptom management|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - symptom management will be delivered prior to the initial hospital discharge. The nurse will review the symptom management worksheet verbally with the parent, then distribute the written worksheet to the parent.
45847985|NCT03154710|Device|MOOVCARE|web-mediated follow up
45368340|NCT00446134|Drug|Ribavirin|Oral (200mg)Tablet: 800 mg/day, 1000 mg/day, 1200 mg/day, or 1400 mg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
45847986|NCT03160170|Device|SISTER device|Use of the Suction-Integrated Surgical Tissue Elevator & Retractor (SISTER) device during surgery
46052115|NCT04148118|Biological|BW-1010: 50 µg - sprayer - IN|"20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart."
46052116|NCT04148118|Biological|BW-1010: 50 µg - pipette - IN|"20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
46052117|NCT04148118|Biological|BW-1010: 100 µg - sprayer - IN|"20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL)~Two doses administered 4 weeks apart"
46052118|NCT04148118|Biological|BW-1010: 100 µg - pipette - IN|"20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
46052119|NCT04148118|Biological|Saline (Placebo) - sprayer - IN|"Saline (negative control) administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart."
45368341|NCT00934466|Drug|MK2637|Single dose of 120 mg MK2637 capsules in one of five treatment periods.
45368342|NCT00934466|Drug|Comparator: MK2637|Single dose of 50 mg MK2637 capsules in one of five treatment periods.
45368343|NCT00934466|Drug|Comparator: Placebo|Single dose of placebo only in one of five treatment periods.
45368344|NCT00934466|Drug|Comparator: Dextromethorphan|Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.
45368345|NCT00934466|Drug|Comparator: Dextromethorphan|Single dose of 110 mg dextromethorphan capsules in one of five treatment periods.
46052120|NCT04148118|Biological|Saline (Placebo) - pipette - IN|"Saline (negative control) administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
46052121|NCT04148118|Biological|BioThrax (positive control) - SC|"BioThrax licensed vaccine administered subcutaneously (500µL).~Three doses administered 2 weeks apart."
46052122|NCT04595721|Behavioral|Hidden object|Participant will be instructed to look at the hidden object image on the overhead light to look for a number of objects and observe the image.
45368346|NCT00921245|Drug|Darifenacin (Emselex, BAY79-4998)|Patients in daily clinical treatment receiving Emselex according to local drug information
45485547|NCT03227068|Other|PEDSS - support for the caregiver|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - support for the caregiver will be delivered prior to the initial hospital discharge. The nurse will review the worksheet verbally with the parent, then distribute the written worksheet to the parent.
45485548|NCT03231046|Device|CBCT-US Fusion Arm|Use of Clear Guide SCENERGY for CBCT-US fusion guidance
45485549|NCT03231046|Procedure|Hepatic Biopsy or Ablation|Standard of Care
45485550|NCT03230812|Drug|Carnitene (L-Carnitine or Levocarnitine)|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
45485551|NCT03226990|Other|impression technique|impression technique with and without wax spacer
45485552|NCT03221452|Behavioral|Memory, Attention, and Problem Solving Skills for Diabetes|Classes will include: (1) information on diabetes self-management including glucose self-monitoring and medication management; (2) assessment of cognitive problems; (3) resources and barriers to self-management; and (4) lifestyle changes to maximize cognitive health. Participants will also practice those skills with online computer games.
45485553|NCT04936763|Device|Janesse 20 (Cross-linked Hyaluronic Acid)|Janesse 20 will be administered at baseline (visit 2, day 0) and, if the Investigator will evaluate necessary, also at day 30 (visit 3). The Investigational device will be injected with retrograde technique (moving backward) with homogeneous amount on the length of each side of Labia Majora. The Janesse 20 dosage administered will be 1 ml in left labia and 1 ml in right labia for each session.
45847987|NCT03162354|Other|Application of a validated Clinical Decision Rule (CDR) as an AHT screening tool|"The Clinical Decision Rule (CDR) for AHT reads as follows:~Every acutely head-injured infant or young child hospitalized for intensive care presenting with any one or more of these four variables should be considered high risk and thoroughly evaluated for abuse: (1) any clinically significant respiratory compromise at the scene of injury, during transport, in the Emergency Department, or prior to admission; (2) Any bruising involving the child's ear(s), neck, or torso; (3) Any subdural hemorrhage(s) or fluid collection(s) that are bilateral OR involve the interhemispheric space; (4) Any skull fracture(s) other than an isolated, nondiastatic, linear, parietal, skull fracture."
46052123|NCT04595721|Behavioral|Stress ball|Participants will be handed a single-use, squeezable stress ball and instructed to squeeze the stress ball.
46052124|NCT04146636|Diagnostic Test|e-LIFT|Diagnostic procedure: elastography devices, blood tests (e-LIFT), liver biopsy if necessary (elstometry ≥ 8 kPa and < 15 kPa)
45368347|NCT00563186|Other|Admission to a novel hospital ward|Hospital admission to a ward with novel infection control design features (e.g., abundance of sinks, predominance (80%) of private rooms, absence of shared bathrooms, absence of curtains)
45368348|NCT00699413|Drug|nutrition education plus active supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste. Active supplements will contain 2,700 mgs/day of Super CitriMax (hydroxycitrate)and 400 µg per day of ChromeMate (niacin-bound Chromium). Supplements will be in powder and tablet form, and should be taken 30 minutes prior to each meal."
45368349|NCT00699413|Drug|nutrition education plus inactive supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste."
45368350|NCT01028872|Device|Intraocular lens|
45368351|NCT01028872|Device|Intraocular lens|
45368352|NCT01028872|Device|Intraocular lens|
45368353|NCT04061525|Procedure|Percutaneous coronary intervention with FFR measurement and intracoronary ECG registration|Measurement of fractional flow reserve (FFR), registration of intracoronary ECG and radioscopic registration of wire tip movement in the main and in the side branch in the beginning, at the end and during every step of coronary bifurcation percutaneous intervention.
45368354|NCT04808609|Device|Lumme mobile phone application|Lumme mobile phone app provides smoking cessation support and tracks smoking behaviors
46052125|NCT02820129|Device|Medication Wallet Card|A medication wallet card will be given to the intervention group. This will be personalized for each patient and will include the patient's medications, dosages, and medical conditions. It will be personally given to a patient after a medical appointment with their family physician.
45485554|NCT03221296|Behavioral|Vestibular Training (Intervention Group)|Exercises three times daily, for up to approximately 20 minutes. Changes in functional status and physical status shall be measured at study onset and follow up.
45485555|NCT03230656|Other|Early cognitive-communication therapy|
45485556|NCT03751865|Behavioral|CBT|A total of 8 CBT sessions will be provided to the participants, each session lasts for approximately 1.5 hour.
45485557|NCT03751865|Behavioral|Psychoeducation|A total of 8 psychoeducation sessions will be provided to the participants, each session lasts for approximately 1.5 hour.
45485558|NCT03221062|Device|Laser en Bloc Resection|Procedure: Laser en Bloc Resection of bladder tumor Procedure: Hydroknife transurethral resection of bladder tumor Procedure: conventional transurethral resection
45485559|NCT04486235|Behavioral|Brief waiting room pamphlet|An experiential pamphlet including brief assessment questions and recommended questions for the participant to ask their physician based on their responses. Areas covered in the pamphlet include patients' knowledge of weight status and implications of weight, confidence in physicians' abilities to treat weight, stage of change for weight-related behaviors, and comfort in discussing their weight.
45485560|NCT03747653|Drug|ADVATE|Patients will be administered a single dose of ADVATE.
45485561|NCT03747653|Drug|FRSW107|Patients will be administered a single dose of FRSW107 for Injection.
45485562|NCT03226834|Device|MUSIC CARE|Musicotherapy session using one of the U musical sequences of MUSIC CARE among the preselected music styles
45485563|NCT03226834|Other|PERSONAL PLAY-LIST|Musicotherapy session using the patient's play-list composed by the patient with her favourite songs
45485564|NCT03230968|Behavioral|Integral Action Program for Respiration|
45485565|NCT03230578|Other|Pharmacists & women's perspectives on pharmacist prescribed hormonal contraception|The goal of this study is to identify the thoughts and perceptions of pharmacy access to hormonal contraception among rural women and pharmacists. This will be key in order to address concerns or perceived barriers in order to inform the implementation of this program.
45485566|NCT03226600|Device|OrACELL|OrACELL is human dermis that undergoes the MATRACELL process. MATRACELL is a patented and validated process that renders allograft tissue acellular, without compromising the biomechanical or desired biochemical properties of an allograft bio-implant for its intended surgical application.
45847988|NCT03163134|Device|Lumbar Drain|
46052126|NCT02820129|Device|Reminder Card|"A reminder card will be given to this group. The card will not be personal and will be mailed to patients. It will state, Remember to keep an up-to-date listing of your medications and bring your medications to your doctor's appointments."
46052127|NCT00773383|Drug|RG1507|iv 9mg/kg weekly
46052128|NCT00773383|Drug|erlotinib [Tarceva]|150mg oral daily
46052129|NCT04239417|Other|Graduated abdominal strengthening exercises|"Exercise mat and inflatable Swiss ball~Wall bar, wedges, elastic tubing"
46052130|NCT04239417|Device|The Russian current stimulation|The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation.
46052131|NCT04239417|Combination Product|Graduated abdominal strengthening exercises and the Russian current stimulation|Combination between The Russian current and abdominal exercises
45368355|NCT04808609|Behavioral|Standard of Care|Smoking cessation counseling and nicotine replacement therapy
45368356|NCT00940160|Drug|QAX576|
45368357|NCT00940160|Drug|QAX576|
45368358|NCT00940160|Drug|QAX576|
45368359|NCT00940160|Drug|Placebo|
45368360|NCT00940238|Drug|Citalopram Hydrobromide|
45368361|NCT02565875|Behavioral|SLL Presentation|Educational presentation on the use of a standardized lexicon for communication between surgeon and assistant during laparoscopy
46052132|NCT04101409|Other|Decision aids|Shared decision making with decision aids
45368362|NCT02565875|Behavioral|Control Presentation|Educational presentation on relevant anatomy related to laparoscopy performed by a gynecologic surgeon.
45368363|NCT02565875|Other|Simulated laparoscopic task|Using a low-fidelity pelvis simulator and laparoscopic instruments, pairs of each arm will be asked to perform a laparoscopic task (maneuver a ball into a nylon surgical bag). Use of SLL will be tabulated and task will be timed.
46052133|NCT02818881|Other|High-speed yoga|
46052134|NCT02818881|Other|Low-speed yoga|
45485567|NCT03226600|Device|Connective Tissue Graft|A measured layer of dermis is surgically removed from the palate for use as a graft to cover gingival recession
45485568|NCT03227614|Behavioral|Support Person Intervention|The patient participant will have a support person of her choice accompany her during her abortion procedure.
45485569|NCT03220984|Biological|Immuncell-LC intravenous infusion using a CIK cell agent|Patients with metastatic colorectal cancer, which is refractory to the 3rd-line chemotherapy are enrolled in this study. Enrolled patients receive a total of 12 times of Immuncell-LC therapy: 8 times in every 1 week and the next 4 times in every 2 weeks. The treatment responses of immuncell-LC are evaluated by radiologic findings (Abdomin-pelvic CT and Chest CT), immune-markers and a selorogic tumor marker (Carcinoembryologic antigen (CEA)) at the 8th week and 17th week. The safety of Immuncell-LC is evaluated by the results of serologic tests, vital signs, ECOG-PS and adverse events. The follow-up period is the 1 year after the enrolled date.
45485570|NCT03220594|Procedure|hypogastric artery ligation|hypogastric artery ligation is the ligation of the internal iliac artery to stop bleeding related to obstetrics obstetric hemorrhage Hysterectomy is the removal of the uterus if bleeding can't stop by hypogastric artery ligation
45485571|NCT03220828|Behavioral|Technology Based Distractions|Technology based distractions (VR headsets)
45485572|NCT03220906|Other|Blood pressure measurement|Blood pressure will be measured in both upper and lower extremities.
45485573|NCT03226444|Drug|0.005% Lacripep|One drop (approximately 50 microliters) of 0.005% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
45485574|NCT03226444|Drug|0.01% Lacripep|One drop (approximately 50 microliters) of 0.01% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
45485575|NCT03226444|Drug|Placebo|One drop (approximately 50 microliters) of placebo solution will be administered three times a day (TID) to both eyes for four weeks.
45485576|NCT04358081|Drug|HCQ|Hydroxychloroquine Monotherapy
45485577|NCT04358081|Drug|HCQ+AZT|Hydroxychloroquine with azithromycin
45485578|NCT04358081|Drug|Placebo|Placebo
45485579|NCT03220672|Behavioral|Tailored assessment and educational|Intervention will consist of 45 minutes of anatomy education, pelvic floor assessment and neuromuscular re-education. Women will be given an explanation of how the pelvis is composed, including the viscera and pelvic floor function and anatomy, through a simple explanatory sheet. They will be also informed of the causes of pelvic floor deterioration as well as its consequences.. Neuromuscular re-education will continued by teaching them how to perform slow contractions, fast contractions and lifting contraction. They will be also shown vaginal cones and advised on possible treatment methods if they were needed. After that, women will be given a tip sheet to improve pelvic floor function. Those recommendations will included: Tips to take into account during habits like urination, doing sport, gymnastics or any efforts, pelvic floor muscles exercises and how to use vaginal cones adequately.
45485580|NCT03230500|Procedure|Computer guided implant placement|Implant will be placed immediately using computer aided surgical guide
45485581|NCT03934931|Other|Streamlined weekly DOT visits|Streamlined, weekly DOT clinic visits to have health worker observe medication ingestion and screen for side effects
45485582|NCT03934931|Other|Weekly DOT visit reminders|Weekly SMS or interactive voice response (IVR) phone call reminder for DOT clinic visits
45485583|NCT03934931|Other|Cost reimbursement DOT|Reimbursement of costs associated with weekly clinic visits (15,000 Ush/visit in Weeks 2-12)
45485584|NCT03934931|Other|99DOTS|99DOTS-based digital adherence technology to monitor and promote adherence
45485585|NCT03934931|Other|Weekly SAT dosing reminders/check-ins|Weekly SMS or IVR phone call dosing reminder/check-in for side effects
45485586|NCT03934931|Other|Cost reimbursement SAT|Reimbursement of costs associated with streamlined refill and end-of treatment clinic visits (15,000 Ush/visit in Weeks 6 and 12)
45485587|NCT02452138|Other|Severe sepsis management|
45485588|NCT03230344|Procedure|open flap debridement|open flap debridement simultaneously with root canal treatment
46052135|NCT04097665|Device|indocyanine green angiography|All patients treated with expanded flaps will be assessed by surgeons, and the possible area of necrosis will be marked based on clinical experience. This area will be further divided into perfusion units (1*1 square centimeter for each), and the center of each perfusion unit will be marked. Then all patients will receive ICGA after the complete transfer of flap to the recipient site. For ICGA, a 2ml bolus of indocyanine green (2.5mg/ml) was injected through the patient's intravenous line. The detector/camera of the SPY imaging system should place over the flap at approximately 30cm for fluorescence image acquisition. The fluorescence value will be recorded afterwards.
45485589|NCT03230344|Procedure|open flap debridement|open flap debridement and delayed root canal treatment
45485590|NCT03230422|Device|normal airway|The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
45485591|NCT03230422|Device|difficult airway|The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
45485592|NCT04355663|Behavioral|Motor program activating therapy|Pacients underwent two months' therapy consisted of 16 face-to-face sessions (1 hour, twice a week for two months).
45485593|NCT04355663|Behavioral|Vojta's reflex locomotion|Pacients underwent two months' therapy consisted of 16 face-to-face sessions (1 hour, twice a week for two months).
45485594|NCT04355663|Behavioral|Functional electric stimulation|Pacients uderwent two months' therapy. They used the whole time Functional electric stimulation during activities of daily living and underwent 2 individual sessions of Motor program activating therapy.
45485595|NCT03226522|Drug|AXS-05|AXS-05
45485596|NCT03226522|Drug|Bupropion|Bupropion
45485597|NCT03226522|Drug|Placebo|Placebo
45485598|NCT03220360|Procedure|indirect pulp capping|Sixty children with deep caries of deciduous teeth underwent indirect pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
45485599|NCT03220360|Procedure|direct pulp capping|Sixty children with deep caries of deciduous teeth underwent direct pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
45485600|NCT03220360|Procedure|vital pulpotomy|Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
46052136|NCT04097509|Biological|AFG application on palatinal wound healing|9 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. In the protocol, venous blood collected in the tube was centrifuged for 2 minutes at 2700 rpm (approximately 692 g) in a special centrifuge (Medifuge, Silfradent, Italy) to obtain two layers: the lower layer of red blood cells and the upper layer of AFG. The AFG at the top of the tube was collected by means of an injector and transferred to the metal godet. It was held for 15-20 minutes for polymerization. After polymerization occurred, the polymerized AFG in the metal gum was applied to the wound surface in the donor site . No suture or tissue glue was used. Adhesive properties of AFG were utilized.
46052137|NCT04097509|Biological|i-PRF application on palatinal wound healing|10 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. Based on G force, collected venous blood were centrifuged at 2300 rpm (about 241 g) in a centrifuge (PC-O2, Process for PRF, Nice, France) for 3 minutes to obtain two layers: The two layers are the lower layer of red blood cells and the upper layer of i-PRF. The i-PRF at the top of the tube was collected with a syringe and transferred to the metal godet. It was held for 20-25 minutes for polymerization. After the polymerization, the polymerized i-PRF was applied to the wound surface in the donor site. No suture or tissue glue was used. Adhesive properties of AFG were utilized.
45368364|NCT04013438|Drug|Strogen|The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
45485601|NCT03752333|Drug|Pembrolizumab|"Pembrolizumab has high affinity and potent receptor blocking activity for PD-1, based on preclinical in vitro data. Pembrolizumab has an acceptable preclinical and clinical safety profile and is in clinical development as an IV immunotherapy for advanced malignancies.~The PD-1 pathway represents a major immune control switch, which may be engaged by tumour cells to overcome active T-cell immune surveillance. Pembrolizumab is a potent and highly selective humanized mAb of the Immunoglobulin (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection."
45691603|NCT01571128|Other|Male-Specific Intervention Package|Combination HIV Prevention: Male-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
45691604|NCT01571128|Other|Female-Specific Intervention Package|Combination HIV Prevention: Female-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
45691605|NCT01571128|Drug|Pre-Exposure Prophylaxis (Females)|Females 18-24 who are out of school.
45691606|NCT01571128|Behavioral|Cash Transfer Cohort (Females)|Cash transfer for females (and their parents) who are aged 15-24 and enrolled in school.
45691607|NCT00614458|Drug|Raltegravir; valproic acid|raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
45691608|NCT01429168|Drug|Etoricoxib|One 60-mg tablet orally daily
45691609|NCT01429168|Drug|Placebo for etoricoxib|One 60-mg tablet orally daily
45485602|NCT03230188|Other|functional Magnetic Resonance Imaging (research grade)|Subjects will undergo a simulated and actual functional Magnetic Resonance Imaging scan.
45485603|NCT03230188|Other|Cognitive Function Testing (non-diagnostic)|Subjects will take non-diagnostic cognitive function tests
45485604|NCT03230188|Other|Asthma and Psychological Questionnaires (non-diagnostic)|Subjects will fill out asthma and psychological questionnaires (non-diagnostic)
45485605|NCT03751787|Other|cranial osteopathy|two sessions at three weeks intervals
45485606|NCT03751787|Other|comfort massage|manipulation, comfort massage, standardized and not affecting the skull
45485607|NCT03220438|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
45485608|NCT03750383|Drug|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and Day 5 (Part 1)
45368365|NCT04013438|Drug|Strogen|The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
45485609|NCT03750383|Drug|EDP-938|Subjects will receive one dose of EDP-938 on Day 1 and Day 8 (Part 2)
45485610|NCT03750383|Drug|Cyclosporine|Subjects will receive one dose of cyclosporine on Day 5
46052138|NCT04097509|Other|control|no application
46052139|NCT02818803|Other|Propolis|
46052140|NCT02818803|Drug|Miconazole|
45368366|NCT02565719|Drug|REP 2139-Mg|REP 2139-Mg = magnesium chelate complex of REP 2139
45368367|NCT02565719|Drug|Pegasys|immunotherapy
45368368|NCT02565719|Drug|Viread|HBV RT polymerase inhibitor
45368369|NCT02565719|Drug|REP 2165-Mg|REP 2165-Mg = magnesium chelate complex of REP 2165
45368370|NCT00934778|Procedure|Confocal microscopy and endocytoscopy|2 probe based imaging systems for use via the working channel of the bronchoscope. 0.5ml of methylene blue injected into airways for endocytoscopy. Each procedure takes about 2-3 minutes.
45368371|NCT00111007|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg po (per os), 2 tablets (200 mg each) bid Study Days 2-19
45485611|NCT03750383|Drug|Prednisone|Subjects will receive prednisone once daily from Day 5 to Day 14
45485612|NCT03220516|Procedure|single use digital ureteroscope|All participants in this arm will undergo RIRS using a single use digital ureteroscope.
45485613|NCT03220516|Procedure|reusable fiberoptic ureteroscope|All participants under this arm will undergo RIRS using a reusable fiberoptic ureteroscope
45485614|NCT03220516|Procedure|reusable digital flexible ureteroscope|All participants under this arm will undergo RIRS using reusable digital flexible ureteroscope
45485615|NCT04901273|Procedure|Homologous PRP injections|Patients will be treated with a single injection of Homologous PRP (5 ml) in the knee joint affected by osteoarthritis.
45485616|NCT04901273|Procedure|Placebo injection (saline solution)|Patients will be treated with a single injections of saline solution (5 ml) in the knee joint affected by osteoarthritis
45485617|NCT03226210|Drug|aspart insulin or lipro insulin|After completing OGTTS, enrolled subjects (new diagnosed T2DM) were randomly assigned into two groups: NovoRapid group (group Asp, Novo Nordisk, Bagsvaerd, Denmark) and Prandilin group (group Lis, Gan & Lee pharmaceuticals, Beijing, China) in CSII, combined with metformin (Bristol-Myers Squibb, USA) therapy. During insulin intensive therapy, every patient general use 1.5g metformin per day. If the patient is unable to tolerate the side effects of metformin, such as diarrhea, nausea, vomiting, allergies, etc., the daily dose of metformin is reduced to 1.0g. If the patients are still unable to tolerate the daily 1.0g of metformin, exit from this study.
45485618|NCT03750305|Other|imagery-focused Cognitive Therapy|"In depth identification phase: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus.~Imagery interventions: The imagery intervention consists of metacognitive imagery rescripting or promoting positive imagery or competing tasks (or a combination of these).~Consolidation: Consist of fine tuning the strategies, relapse prevention using a video diary."
45485619|NCT03750305|Other|TAU|Psycho-education is offered in groups, using the format described by Honig (Postma, Honig, & van Gent, 2008).
45485620|NCT03226054|Behavioral|Lifestyle Modifications|Lifestyle Modifications to wean off of a Proton Pump Inhibitor, i.e. avoiding dietary triggers, waiting 3 hours to lie flat, and elevating the head of the bed
45485621|NCT03750149|Device|EyeTracker|Patients with various ophthalmologic diseases (ERM, glaucoma, AMD, diabetic retinopathy) will undergo reading analysis using the EyeTracker
45691610|NCT00771160|Drug|montelukast sodium|Arm 1: montelukast tablet 5 mg, QD. Treatment period is 12-weeks. Arm 2: montelukast tablet 10 mg, QD. Treatment period is 12-weeks.
46052141|NCT04238403|Behavioral|Behavioral Parent Training (MATCH Protocol)|BPT. Behavioral Parent Training (BPT) is a well-established psychosocial intervention for the treatment for ADHD and related behavioral difficulties (e.g., oppositional problems). BPT is based on social learning and operant conditioning principles in which parents are instructed to utilize methods (e.g., praise, effective communication, reward systems, time-out from positive reinforcement) to facilitate positive behaviors in their child (e.g., compliance) and reduce challenging behaviors (e.g., opposition). BPT comes in several manualized, commercially available manuals. The version of BPT that we will be utilizing is from the MATCH protocol (Chorpita and Weisz, 2009), which consists of 10 components, delivered with individual families, typically over the course of 10-16 weekly individual meetings (total meetings depends upon parent availability and acquisition of BPT skills).
45485622|NCT03225976|Device|Light-Emitting Diode Device|"The therapy will be applied on the second, third and fourth day of collection using a 25x40 cm2 LED blanket, with an equidistant distribution, with total energy per area of 180 J bilaterally on the quadriceps femoris muscle.~All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
45485623|NCT03225976|Device|Sham Light-Emitting Diode Device|The Sham Light-Emitting Diode Device will be applied on the second, third and fourth day of collection using a 25x40 cm2 LED blanket, with an equidistant distribution, with total energy per area of 0 J bilaterally on the quadriceps femoris muscle. At the time of application the device will not be activated
45485624|NCT03225898|Other|Resistance Exercise with Blood Flow Restriction|A cuff will be used to restrict blood flow to the extremities.
46052142|NCT04350060|Other|Retro-fitted room with technological enhancements|Reconstructing and retrofitting a currently existing memory care room at Samaritan Bethany Arbor Terrace Senior Living with integrated technologies specifically to accommodate the needs of persons with dementia to enhance sensory stimulation in sight, sound and sleep.
46052143|NCT00757003|Device|Endovascular Stent-graft repair of descending thoracic aorta|A TAG device will be used to repair the pathology in the thoracic aorta
45485625|NCT03225898|Other|High-intensity Resistance Exercise|Participants will follow a conventional resistance exercise regime.
45485626|NCT03229954|Drug|iron isomaltoside (Monofer) intravenous infusion|"The investigational drug is a newest formulation of intravenous iron. The drug, iron isomaltoside (Monofer), will be infused one single high dose with infusion time more than 30 minutes (< 1,000 mg) or 60 minutes (≥ 1,000 mg). The dosage is determined using the Ganzoni formula and divided when the calculated dose exceeds 20 mg/kg.~If the calculated dose exceeds 1,500 mg, the patient will be excluded from trial for patient safety."
45368372|NCT00111007|Drug|Carboplatin/Paclitaxel|Paclitaxel (225 mg/m^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1
45485627|NCT03229954|Drug|Ferrous sulfate(Feroba-YOU) per oral|160 mg/day of ferrous sulfate (Feroba-YOU) will be taken per oral for 12 weeks.
45485628|NCT03230110|Diagnostic Test|WP200U home sleep study device|WP200U, is a Type III, wrist-worn, FDA-approved home sleep testing device that utilizes finger plethysmography (peripheral arterial tone, oxyhemoglobin saturation and heart rate), actigraphy (movement), acoustic decibel detection (snoring volume), and accelerometry (body position) to help diagnose sleep-related breathing disorders (including snoring), and to give information about sleep stages and position during actual sleep time.
45485629|NCT03226132|Behavioral|Brief Behavioral Therapy for Insomnia|Brief Behavioral Therapy for Insomnia
46052144|NCT02817009|Behavioral|Social Support|The social worker for the parent support group addresses culturally specific questions and adopts culturally acceptable strategies for setting limits and promoting healthy behaviors, engaging the group as a whole and building peer support.
45485630|NCT03226132|Behavioral|Repeated Contact|Repeated Contact
45368373|NCT00111007|Drug|Placebo|Placebo, 2 tablets bid Study Days 2-19
45368374|NCT03975920|Device|The Restful Jaw Device|The Restful Jaw Device is used to support the jaw during dental procedures including surgical removal of 3rd molars (wisdom teeth) with sedation. The device is designed to counter the downward forces placed on the mandible by clinicians during dental procedures and prevent jaw hyperextension (opening too wide) while providing a secure, stable jaw position. When 3rd molar teeth are surgically removed with sedation, a dental assistant stands behind the dental chair and supports the patient's jaw with both hands under the patient's jaw. This device replicates the dental assistant in holding the jaw during dental procedures.
45485631|NCT03220126|Biological|LY3074828|Administered IV
45691611|NCT00756418|Drug|montelukast|montelukast 5 mg QD 4-weeks.
45691612|NCT00756418|Drug|Theophylline|Theophylline 100 to 200 mg BID 4-weeks.
45691613|NCT00615472|Drug|Isoflurane|Group 1 Inhaled anesthesia Patients will be maintained on 50% oxygen in air and isoflurane 0 to 4%, titrated as needed to maintain a standard blood pressure (standard practice). If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
45368375|NCT00699335|Drug|Fentanyl|Fentanyl transdermal patch. This was an observational study - therefore, the physician decided about dosage according to individual needs
45691614|NCT00615472|Drug|Remifentanil|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
45847989|NCT03163758|Device|real Repetitive Transcranial Magnetic Stimulation|The rTMS treatments were performed using a Medtronic MagPro type magnetic stimulation device (Medtronic, Minneapolis, MN, USA) and a figure-of-eight coil (MC-B70, Medtronic). Coils were placed tangent to the scalp. The stimulation protocol involved 50 trains of 20 pulses applied over the ipsilesional M1 at a frequency of 5 HZ, with the stimulus intensity set at 120% of the resting motor threshold of the unaffected extremity.
45368376|NCT01082887|Other|TIL-Ad-INFg|After verification of inclusion and non-inclusion criteria and after obtaining informed consent from the patients, a tumor sample will be taken for sterile production of TIL. Patients will receive intra-tumoral injections of Ad-INFg every 15 days from J-15 to M2, then every month from M3 to M11 or until disease progression. The Ad-INFg will be administered by intra-tumoral injection at a dose of 5x1010 vp (viral particles) per lesion. A maximum of 6 lesions will be treated simultaneously. They will also receive two infusion of TIL at M0 (Cycle 1) and M1 (Cycle 2) by intravenous infusion lasting 30 to 65 minutes followed by subcutaneous injections of IL2 from J1 to J5 and from J8 to J12 of each cycle.An evaluation of injected and not injected tumoral lesions including photographs will be realised at the pre-inclusion visit, J-15, M0 and every month until M12.
45368377|NCT00939614|Drug|Lamotrigine|
45368378|NCT03963037|Other|Blood draw|Draw venous blood for baseline blood parameters and plasma samples for lipoprotein fractionation.
45368379|NCT00935168|Drug|6% Hydroxy-ethyl starch (130/0.4)|Maximum dose of 50ml/kg/day of 6% hydroxy-ethyl starch (130/0.4) for intravascular volume fluid resuscitation
45368380|NCT00935168|Drug|Saline|Maximum dose of 50ml/kg/day of saline for intravascular volume fluid resuscitation
45368381|NCT03962881|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
45368382|NCT03962881|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 20 µg per dose
45368383|NCT03962881|Biological|60 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 60 µg per dose
45368384|NCT00940394|Behavioral|mutual support group|bi-weekly, 12-session, family-led mutual support group
45368385|NCT00940394|Behavioral|psychoeducation group|bi-weekly, 12-session, family psychoeducation group
45368386|NCT00940394|Other|Standard care|Routine mental health care services provided by the outpatient clinic and related agencies for families of people with schizophrenia
46052145|NCT02817009|Behavioral|Nutrition Session|Nutrition sessions will focus on how to make traditional Latin American foods healthier, including the sharing of recipes and learning what foods to buy in local supermarkets. Home visits by the nutritionist assists with family-centric strategies for healthier eating in their urban Latino households, including those with large extended families.
46052146|NCT02817009|Behavioral|Physical Activity Session|45 minutes physical activity session to promote healthy behaviors
45368387|NCT00935246|Drug|Escitalopram|Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose
45368388|NCT04013360|Other|Breath Stacking|The patients will perform the maneuver through successive inspiratory efforts for 20 s. Subsequently, the expiratory branch will be unobstructed to allow expiration. This maneuver will be repeated 5 times in each series, with intervals of 30 seconds between them. The technique will be performed with the trunk inclined 30º in relation to the horizontal plane, in 3 series, with interval of 2 min completing 15 min of therapy.
45368389|NCT04013360|Other|Expiratory Positive Airway Pressure|Patients will perform exhalation of air through a facial mask containing an extrinsic positive expiratory pressure valve with a defined load of 10 cmH2O for 5 min. During the application of the technique the patients will have a trunk inclined 30º and will be stimulated to breathe normally, without effort or deep and fast breaths.
45368390|NCT02793284|Radiation|18F-DCFPyL PET/CT scan|PET/CT scan using the radioactive agent 18F-DCFPyL
45368391|NCT00935402|Behavioral|Sleep|Subjects are randomly assigned to one of 2 arms sequence: short followed by regular or regular followed by short. Each arm is 6 days in length and separated by a 2-4 week washout period.
45368392|NCT02667002|Procedure|Bilateral Abdominal Sacral Hysteropexy|The mesh will be fixed right and left side of sacrum.
45368393|NCT02667002|Procedure|Conventional abdominal Sacral Hysteropexy|The mesh will be fixed only right side of sacrum
45368394|NCT02667002|Other|Nulliparous women with no uterovaginal prolapsed|This will be control group which consistent patients with no uterovaginal prolapse.
45368395|NCT00935480|Drug|Isentress®|P.O, 1 tablet containing 400 mg every 12 hours
45368396|NCT00935480|Drug|Celsentri®|p.o.: 1 tablet containing 150 mg morning and evening (due to combination with PI/r) or containing 300 mg if fosamprenavir/r is used as the PI (MA)
45368397|NCT00939848|Drug|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
45368398|NCT00939848|Drug|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
45368399|NCT00939848|Drug|Placebo|20mg od (continuous dosing) until evidence of disease progression has been confirmed
45485632|NCT03220126|Biological|LY900021|Administered SC
45485633|NCT02452684|Drug|Eszopiclone|The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
45485634|NCT03119428|Drug|OMP-313M32|OMP-313M32 is a monoclonal antibody which binds to the human TIGIT receptor on T cells.
45368400|NCT00939848|Drug|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
45368401|NCT00939848|Drug|cediranib|cediranib 20mg oral daily (continuous dosing)until evidence of disease progression has been confirmed
45485635|NCT03119428|Drug|Nivolumab|Human IgG4 anti-PD-1 monoclonal antibody
45485636|NCT03119818|Device|Phosphorus (31P) magnetic resonance spectroscopy|Phosphorus MR spectroscopy realized using a 3-Tesla MR imaging system. A twenty-cm circular surface coil will be set to the 31P resonance frequency and placed over the leg muscle region to obtain spectroscopy acquisitions. 31P MR spectra will be acquired before, during (every 160 seconds), and 30 minutes after dialysis. 31P MR system data will be analyzed using jMRUI Software. Five different peaks will be analyzed: inorganic phosphate, phosphocreatine, α-, β-, and γ-ATP.
45485637|NCT03119818|Other|Hemodialysis|Hemodialysis realized using a 5008 generator, a portable plant, a FX80 Dialyzer, a dialyzing solution with a standard electrolytes composition. The dialysis generator will be placed outside of the MRI examination room. The dialysis lines will pass through a wave guide to connect patients positioned on the bed of the MRI. A suitably trained nurse will proceed to the cannulation of the fistula, the connection of the catheter, and the monitoring of the clinical tolerance of the session.
46052147|NCT04203264|Diagnostic Test|Real-time artificial intelligence identification system|The patients swallowed the MCE with a small amount of water in the left lateral decubitus position. Once the capsule reached the stomach after investigating the esophagus, it was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. The magnetic steering time for passing through the pylorus was not allowed more than 15 min. The real-time auxiliary system implemented real-time processing for the output image of MCE system. Professional operators guarantee the integrity of the examination and the diagnostic results of professional endoscopist was used as the gold standard. The system diagnosis results was recorded at the same time. The sensitivity, delay time, specificity of lesions and anatomical landmarks will be analyzed.
45691615|NCT00615472|Drug|Propofol|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
45691616|NCT00615784|Drug|Bexarotene|Bexarotene given orally at a dose of 300mg/m2 until disease progression or unacceptable toxicities experienced by patient
45691617|NCT00755794|Drug|montelukast sodium|Montelukast Tablet, 10 mg, 8 weeks, daily
45691618|NCT00652444|Drug|ezetimibe|ezetimibe 10mg. Blood samples were collected again at the end of study treatment, week 6.
45691619|NCT00652444|Drug|simvastatin|simvastatin 20mg . Blood samples were collected again at the end of study treatment, week 6.
45691620|NCT00652444|Drug|Placebo (Unspecified)|Matching ezetimibe placebo
45691621|NCT00585910|Drug|Atomoxetine and OROS Methylphenidate|Subjects must have at least attempted to tolerate a dose of 1.2 mg/kg of atomoxetine. If tolerated, they must remain on this dose for at least two weeks. OROS methylphenidate will be target dosed and titrated to a maximum dose of 54 mg.
46052148|NCT05658705|Procedure|15-min supine time|The length of preoperative supine time before AVS was 15 minutes.
45368402|NCT00939848|Drug|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
45691622|NCT00489346|Drug|MK0476, montelukast sodium / Duration of Treatment: 1 Year|
45368403|NCT04013048|Drug|[14C]-Fluzoparib|Patients will receive single dose of orally [14C]- Fluzoparib on Day 1.
45691623|NCT00489346|Drug|Comparator : fluticasone propionate / Duration of Treatment: 1 Year|
45691624|NCT00617188|Drug|Fulvestrant|Fulvestrant, 500 milligrams (mg) intramuscularly (IM) on Day 1, 250 mg IM on Day 15, and 250 mg IM on Day 29 and every 28 days thereafter until either intolerance or disease progression.
45691625|NCT00618436|Drug|Levetiracetam|Levetiracetam group will receive a loading dose of 20 mg/kg IV(rounded to nearest 250mg) to a maximum of 2000mg, then started on maintenance dose (1000 mg,IV q 12h) as prophylaxis for seven days.
45368404|NCT04014218|Drug|Inhalation Sedation|Inhalation Sedation by Administration of Sevoflurane
45368405|NCT04014218|Drug|Intravenous Sedation|Intravenous Sedation by Administration of Propofol
45485638|NCT03229642|Device|Active rTMS|The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
46052149|NCT05658705|Procedure|2-hour supine time|The length of preoperative supine time before AVS was 2 hours.
45485639|NCT03229642|Device|Sham rTMS|The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
45485640|NCT03119506|Behavioral|Recess|Recess timing and duration effects on lunch intake
45485641|NCT03219814|Other|The Body Project|The Body Project is a dissonance-based body-acceptance program designed to help high school girls and college-age women resist cultural pressures to conform to the appearance ideal standard of female beauty and reduce their pursuit of unrealistic bodies. The Body Project is supported by more research than any other body image program and has been found to reduce onset of eating disorders.
45485642|NCT03219814|Other|Mediapsychoeducation|Mediapsychoeducation is used to educate individuals on psychological issues through the use of various medias, in this study mediapsychoeducation is being used to educate individuals on eating disorders and the thin ideal.
45485643|NCT04345367|Drug|Abrocitinib 200 mg|Abrocitinib 200 mg administered as two 100 mg tablets to be taken orally once daily for 26 weeks. Placebo injections will be administered every other week for 24 weeks.
45485644|NCT04345367|Combination Product|Dupilumab 300 mg|Dupilumab 300 mg administered as a single subcutaneous injection every other week for 24 weeks (2 injections on day 1). Placebo tablets will be administered daily.
45485645|NCT03229720|Device|Nibiru 3D Virtual Reality Headset|This device is a kind of head glass that obstructs the vision with a wide screen showing movies or photos. Earphones are extended from it and inserted in ears. so it obstructs the vision and audio of the surroundings.
45368406|NCT00935558|Biological|DC vaccine|DC vaccination regime consist of primary 10 intradermal injections of 1-2 weeks interval. At the time of each vaccine 6 MIU/m² IL-2 will be administered sc. Zadaxin 1.6 mg is injected sc twice a week. and tablet Aromatase inhibitor is administered ; Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
45485646|NCT03225742|Diagnostic Test|to measure the residual volume after catheterization|after first micturition to measure the residual volume in bladder
45485647|NCT02452606|Drug|Stalevo®|"Sleep disorders in Parkinson's disease~Analysis by Parkinson's Disease Sleep Scale(PDSS) scores.~If the PDSS score is improving at least 15 percent than the baseline score, It can be determined to be effective."
45485648|NCT03225352|Drug|500 mg acetylsalicylic acid (Aspirin, BAYE4465)|Single intake of 1 tablet, 500mg
45485649|NCT03225352|Drug|1000 mg acetylsalicylic acid (Aspirin, BAYE4465)|Single intake of 1 tablet, 1000mg
46052150|NCT02818647|Procedure|Tonsillectomy|Tonsillectomy is the name of the surgery where tonsils are removed via capsullary dissection. There are various techniques and its basically removing the tonsil from its tonsillary fossa and conducting hemostasis with various equipments.
45485650|NCT03225352|Drug|400 mg ibuprofen(Nurofen)|Single intake of 1 tablet, 400mg
45485651|NCT03225352|Drug|400 mg ibuprofen (Dolormin Extra)|Single intake of 1 tablet, 400mg
45691626|NCT00618436|Drug|Phenytoin|The group will receive a loading dose of fosphenytoin 20 mg/kg IV to a maximum of 2000 mg, then started on maintenance dose of 5mg/kg/day, rounded to nearest 100mg dose, IV, q 12h for seven days.
46052151|NCT04203420|Other|screening and confirmatory tests|screening test is a blood test of the ratio of plasma aldosterone concentration(PAC) and direct renin concentration(DRC), confirmatory test is Captopril Challenge test
45368407|NCT00935558|Drug|aromatase inhibitor|Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
45368408|NCT05280236|Drug|Propofol TIVA|Patients will receive propofol-based TIVA with propofol and remifentanil TCI (target controlled infusion)
45368409|NCT05280236|Drug|Remimazolam TIVA|Patients will receive remimazolam-based TIVA with remimazolam infusion and remifentanil TCI
45485652|NCT03225508|Diagnostic Test|Linear Ultrasound to Measure Diaphragmatic Movement|A linear 10-12 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the zone of apposition. Diaphragmatic excursion will be measured from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken. The distance between the two external skin markings, one at the end of full expiration and one at the end of full inspiration will indicate the excursion of the diaphragm.
45485653|NCT03225508|Diagnostic Test|Curvilinear Ultrasound to Measure Diaphragmatic Movement|A curvilinear 2-5 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the dome of the diaphragm. M-mode will be used to image the motion of the diaphragm from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken.
45485654|NCT03225508|Diagnostic Test|Pulmonary function tests|Bedside pulmonary function tests to measure forced vital capacity (FVC). The FVC measures the maximal volume of gas that can be expired as forcefully and rapidly as possible after a maximal inspiration to total lung capacity. This measurement will help determine if the patient has any obstructive or restrictive diseases of the airways. Three measurements will be taken.
45485655|NCT03217240|Procedure|Cardiac Magnetic Resonance - MRI|All participants will have to undergo CMR which uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images. Participants will be asked to lie on a narrow bed placed inside of a large magnet for about 1 hour. Several sets of images are needed. Participants are required to stay very still and follow the instruction of the MRI technologist who operates the machine from a room next door.
45485656|NCT03217240|Other|Cardiopulmonary Exercise Test|Participants will be asked to undergo a cardiopulmonary exercise test (CPET). Participants will need to wear a mask. Several electrodes will be placed on the chest to record heart activity during exercise. Participants will need to pedal for at least 8-12 minutes. Pedalling will be instructed to report any symptoms such as chest discomfort, shortness of breath, leg fatigue or dizziness. A small probe will be placed on participant's finger during the test to measure the oxygen content in the blood. Immediately after exercising, participants will rest for 5-10 minutes while the blood pressure and electrocardiogram are monitored. The results will be read by a cardiologist.
45485657|NCT03217240|Other|Blood Sampling for all participants|Serum samples will be obtained before CMR. The sample will be stored at -80 degree until assay. Investigators will perform various tests related to participants heart function
45485658|NCT02451280|Procedure|Unilateral Hybrid Intervention|For the unilateral RT training, participants will practice with their affected arms following a unilateral training protocol of BMT for 45 minutes (Yang, et al., 2012). For the UAT training, participants will receive training of the affected UL in functional tasks with behavioral shaping for 45 minutes (Lin, Wu, et al., 2009).
45485659|NCT02451280|Procedure|Bilateral Hybrid Intervention|For the bilateral RT training, patients will focus on training involving both arms using the BMT robot for 45 minutes. During the 45 minutes BAT training, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs.
45846323|NCT02517996|Drug|Lidocaine|Total 20cc (10cc bilateral) of 1% Lidocaine: Lidocaine is a commonly used anesthetic agent suitable for infiltration, block and surface anesthesia. It is characterized by a rapid onset of action, intermediate duration of efficacy, and its elimination half-life is 90-120 minutes. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anesthetic effect by not merely preventing pain signals from propagating to the brain but by stopping them before they begin. Adverse drug reactions are rare when lidocaine is used as a local anesthetic and when administered correctly.
45846324|NCT02517996|Drug|Placebo|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
45846325|NCT02518230|Device|Neurally Adjusted Ventilatory Assist|The subject will be crossed over from the baseline ventilator mode to Neurally Adjusted Ventilatory Assist
45846326|NCT02518230|Device|Synchronized Interm. Mandatory Assist|The subject will be crossed over from the baseline ventilator mode to Synchronized Intermittent Mandatory Assist with Pressure Support
45368410|NCT00940472|Drug|DMMET-01|90 days: 15 days daily dose 1050.6 mg (before dinner)+75 days dose twice a day 1050.6 mg (before breakfast) 1050.6 mg (before dinner).
45368411|NCT00940472|Drug|Metformin Hydrochloride|90 days: 15 days daily dose 850 mg (before dinner)+ 75 days dose twice a day 850 mg (before breakfast) 850 mg (before dinner)
45368412|NCT04013204|Other|Endothelial function guided therapy|To evaluate the effect of integration of non invasive endothelial function test (EFT) as a routine test in increasing appropriate treatment to reduce cardiovascular risk including prescription of lipid, blood pressure and glucose lowering medications by physicians at the clinic for patients with non-obstructive coronary artery disease (NOCAD) and the effect of introducing EFT as a routine test in reducing clinical endpoint (major adverse cardiovascular events) among patients with non-obstructive coronary artery disease(NOCAD).
45368413|NCT00939926|Drug|Risperidone|
45368414|NCT00940550|Drug|Prolonged-release melatonin|2 mg tablet, once.
45368415|NCT00940550|Drug|Temazepam|20 mg capsule, once
45368416|NCT00940550|Drug|Zolpidem|10 mg capsule, once
45485660|NCT02451280|Procedure|Robot-Assisted Training|The RT intervention will be matched in duration and intensity with the hybrid interventions. Participants in the RT group will practice on the BMT with bilateral protocols for 90 minutes. The tasks will be tailored according to the level
45485661|NCT03120208|Behavioral|• The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.|The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.
45485662|NCT03120208|Behavioral|The GAD-7 with a discrimination threshold ≥10.|The GAD-7 with a discrimination threshold ≥10.
45485663|NCT03120208|Behavioral|• Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46|Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46
45368417|NCT00940550|Drug|Placebo to match melatonin, zolpidem and temazepam|Placebo to match melatonin: tablet, once. Placebo to match zolpidem: capsule, once. Placebo to match temazepam: capsule, once.
45485664|NCT03120208|Behavioral|The IES-R, validated in French, with a discrimination threshold ≥ 30.|The IES-R, validated in French, with a discrimination threshold ≥ 30.
45485665|NCT03120208|Behavioral|EPDS, MINI, STAI-A and B, IES-R and QEVA (experience)|For the partners
45485666|NCT03225040|Drug|Pegvisomant|Subjects receiving pegvisomant as part of their clinical care for acromegaly will be studied.
45485667|NCT04404725|Device|comfilcon A|Subjects will be randomized to wear comfilcon A for one month.
45485668|NCT04404725|Device|Samfilcon A|Subjects will be randomized to wear samfilcon A for one month.
45485669|NCT03208348|Other|Pilot Virtual Reality|Exposure to a virtual reality vignette with anxiety rating to support exposure therapy
45485670|NCT03208270|Drug|Antithrombin supplementation|antithrombin concentrate will be supplemented to maintain a functional antithrombin level between 80%-120%
45485671|NCT03208270|Drug|No antithrombin supplementation|"supplementation of antithrombin will not be provided unless heparin resistance occurs"
45485672|NCT04343261|Biological|Convalescent Plasma|treatment with 2 Units of convalescent plasma
45485673|NCT03208426|Drug|Esomeprazole (S14)|Nexium, esomeprazole 40mg bid, 14 days
45485674|NCT03208426|Drug|Esomeprazole (BQ10)|Nexium, esomeprazole, 40mg bid for 10 days
45485675|NCT03208426|Drug|Amoxicillin (ST14)|Day 1-7 amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid for 7 days
45485676|NCT03208426|Drug|Clarithromycin (ST14)|Klaricid-XL, clarithromycin, 500mg, bid, for 7 days, (day 8-14)
45368418|NCT00935714|Other|Exercise|
45368419|NCT00935714|Other|Exercise|
45368420|NCT00935870|Device|Bioactive glass and/or autogenous bone|No intervention in the current study (10-year follow-up study)
45368421|NCT00935948|Drug|Imescard compound water smartweed ointment|Patients in this arm were instructed to apply the ointment after waking up, after evacuations and before bedtime, for 5 days.
45368422|NCT00935948|Drug|Placebo|Patients in this arm received placebo, with the exact same appearance of the Imescard ointment, and were instructed to apply it at the same intervals and period.
45368423|NCT00936026|Drug|Neramexane|Drug-Drug Interaction Study
45368424|NCT00940628|Behavioral|Diet and Exercise|mildly hypocaloric diet and physical exercise
45368425|NCT00940628|Drug|orlistat [Xenical]|120mg po tid
45485677|NCT03208426|Drug|Metronidazole (ST14)|Flagyl, metronidazole, 500mg bid, for 7 days (day 8-14)
45485678|NCT03208426|Drug|dibismuth trioxide 120mg (BQ10)|KCB F.C. TABLETS, dibismuth trioxide 120mg qid for 10 days
45485679|NCT03208426|Drug|Metronidazole (BQ10)|Flagyl, metronidazole 500mg tid for 10 days
45485680|NCT03208426|Drug|tetracycline (BQ10)|Tetracycline (Brand name: Tetracycline Capsule ) 500mg qid for 10 days
45485681|NCT04336475|Other|orofacial exercise program|combined stretching&strengthening exercise regimen
45485682|NCT03224962|Device|fluorescence camera|drug - diagnostic test
45485683|NCT03216070|Drug|Dasatinib 50 MG|50mg of dasatinib orally daily
45485684|NCT04335929|Behavioral|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
45485685|NCT03215602|Other|NEMEX and education + strength training|Optimizing sensorimotor control and achieving functional stability. Increasing knee extensor muscle strength. Teaching everyday disease management.
45485686|NCT03215602|Other|NEMEX and education|Optimizing sensorimotor control and achieving functional stability. Teaching everyday disease management.
45485687|NCT03207646|Other|BrightHeart®|BrightHeart® has two components: smartphone mobile based application and a human coach. It is a combined approach of medication adherence, exercise, diet, sleep and stress reduction.
45691627|NCT04345900|Drug|Plinabulin|a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
45485688|NCT05115383|Other|VO2 Max test|The participant will be equipped with a vo2 mask or mouthpiece. They will get on the bike and begin with a 5 minute warmup ranging from 30-100 watts. After the warm up there will be a 15-30 watt increase every minute in the cadence that the participant is required to maintain. Once the participant has decided to stop pedalling, the participants mask will be removed to ensure they are feeling well. They will allowed to continue pedaling at their own pace for a cool down for up to two minutes.
45485689|NCT02450968|Drug|Dexamethasone|
45485690|NCT02450968|Drug|Placebo|
45485691|NCT03749993|Other|Screening|Use of bpMRI for opportunistic prostate cancer screening.
45485692|NCT03749915|Device|Pain Ease Cold Spray|Pain Ease is a spray containing 1,1,1,3,3-Pentafluoropropane (HFC-245fa) and 1,1,1,2-Tetrafluoroethane (HFC-134a). It is a vapocoolant for use as a topical anesthetic.
45485693|NCT03749915|Drug|Ametop|Tetracaine Hydrochloride Gel 4%
45485694|NCT03207724|Drug|Xilonix plus Onivyde and 5FU|Xilonix by IV
45485695|NCT05064371|Drug|Eptinezumab|Concentrate for solution for IV infusion
45485696|NCT03225274|Other|Breathing Exercises as Therapeutic Play|"On day 1, pre- intervention assessment of respiratory status was done before administration of breathing exercises as therapeutic play and after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and then after 5 minutes 1st post-intervention assessment was done on same day.~On 2nd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day.~On 3rd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day."
45485697|NCT05050409|Behavioral|Brief mindfulness|A 15-minute guided mindfulness practice that includes focused attention on breath and body sensations and open monitoring and acceptance of thoughts, emotions, and pain.
45485698|NCT05050409|Behavioral|Mindfulness-Oriented Recovery Enhancement (MORE)|An 8-session intervention. Sessions involve: 1) mindfulness training to reduce pain and increase self-regulation over opioid use, 2) cognitive reappraisal to decrease psychological distress, and 3) savoring to augment natural reward processing, positive emotion, and esprit de corps.
45485699|NCT05050409|Other|Standard care|Preoperative Standard Care. Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. Postoperative standard care includes (1) pain medications to minimize opioid use, including acetaminophen, lyrica, meloxicam/naproxen and celebrex, and (2) anticoagulants for 3-6 weeks postoperatively, as well as (3) ambulatory care with assistive devices 1-6 weeks after surgery. Patients see their surgeon postoperatively 2-6 weeks after surgery, 3-6 months, and yearly.
45485700|NCT03207880|Device|Multi-level pregnancy test|Study participants will be instructed to perform a baseline MLPT immediately prior to administering the first dose of abortion medication and a second MLPT one week later to ascertain the follow-up hCG range. Any woman who obtains a stable or increasing hCG result, when comparing the baseline test result with the follow-up test result, will be instructed to contact safe2choose. Any woman who obtains a decrease in her hCG range, when comparing the baseline test result with the follow-up test result, will be informed that her abortion was a success and she is no longer pregnant.
45846327|NCT02519244|Device|Ekso® (Wearable lower limb exoskeleton)|The wearable lower limb exoskeleton is a powered, robotic lower limb exoskeleton with actuated hips and knees. A control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
46052152|NCT05659017|Genetic|Genetic analysis|The DNA will then be analyzed with a custom panel designed ad hoc to study the candidate gene by Next Generation Sequencing according to the protocols of the supplier of the kit.
45368426|NCT00921323|Behavioral|Goal-setting group|This intervention group will be advised to increase their daily steps by at least 20% gradually over 3 months
45368427|NCT00921323|Behavioral|Control|The control group will be advised to continue to be physically active and record daily steps
45368428|NCT00940004|Biological|autologous dendritic cell vaccination|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
45368429|NCT05294471|Device|Non-contrast MRI with novel MRI software|The investigational software being used in automatic prescription of the imaging is an application of an AI algorithm. This software prescribes where the MRI system will take images by finding the liver within a set of localizer scans. The software gives coordinates to the scanner.
45368430|NCT02565797|Device|DabirAIR alternating pressure overlay|DabirAIR alternating pressure overlay is a dynamic support surface that is placed on top a mattress. The DabirAIR overlay provides periodic pressure relief through the alternate inflation and deflation of air cells.
45368431|NCT00936182|Drug|Fluconazole|Fluconazole daily for 30 days
45368432|NCT00936260|Drug|alendronate|several duration of treatment
45485701|NCT03214822|Dietary Supplement|H2MF|As described in the Experimental Arm description.
45485702|NCT04333199|Behavioral|Timely|Email
45485703|NCT04333199|Behavioral|Transparency|Email
45485704|NCT04333199|Behavioral|Foot-in-the-door|Email
46052153|NCT04339452|Device|Impella 5.0 and Impella 5.5 with SmartAssist Supported OPCABG|Subjects will undergo insertion of an axillary or ascending aortic Impella 5.0 Device or Impella 5.5 with SmartAssist, followed by Impella supported OPCABG using a sternotomy approach with shunting of the coronary arteries to achieve myocardial protection.
46052154|NCT05658939|Other|Phone/Internet survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone/internet for patients.
45485705|NCT03119116|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Oral direct factor Xa inhibitors, 15mg and 20mg tablets QD
45485706|NCT03119116|Drug|Dabigatran|Oral direct thrombin inhibitors, 75mg and 150mg capsules BID
45485707|NCT03119116|Drug|Apixaban|Oral direct factor Xa inhibitors, 2.5mg and 5 mg tablets BID
45485708|NCT03207802|Device|Discontinuation of using device|Subject will be instructed to discontinuation of use of device
45485709|NCT04332419|Device|PET/CT|Standard Imaging
45368433|NCT00445978|Drug|Sapropterin Dihydrochloride|Subjects will receive oral, once-daily (for 2.5, 5, 10mg/kg/day doses) or twice-daily (for the 20 mg/kg/day dose) sapropterin dihydrochloride during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks as follows: 2.5, 5, 10, and 20 mg/kg/day. Dosing was with 100 mg tablets and rounded to the nearest whole tablet. Each dose was taken within 1 hour after the morning meal. Subjects may continue in an optional extension phase at the highest tolerated dose for up to a total of 2 years.
45485710|NCT04332419|Device|PET/MR|Additional Imaging
45368434|NCT02566733|Drug|Remiva|Target controlled infusion of remifentanil (generic drug, Remiva™)
45485711|NCT04332419|Radiation|SIRT with Y-90|SIRT with Y-90 for palliative treatment of the liver malignancy.
45485712|NCT02450734|Procedure|Ultrasound-guided intermediate cervical plexus block|
45368435|NCT02566733|Drug|Ultiva|Target controlled infusion of remifentanil (brand-named drug, Ultiva™)
45485713|NCT03224806|Other|Wholegrain bread|156.8g wholegrain bread
45485714|NCT03224806|Other|White bread|122.6g white bread
45485715|NCT03224806|Other|15% fiber-rich bread|139.2g bread made with 15% added wheat bran
45485716|NCT03224806|Other|30% fiber-rich bread|166.5g bread made with 30% added wheat bran
45485717|NCT03207568|Device|Thoracic Endovascular Aortic Repair (TEVAR)|thoracic endovascular repair (TEVAR) with a thoracic stent-graft
45485718|NCT03224884|Procedure|Interscalene block|Ultrasound guided brachial plexus block injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in the interscalene groove, under the prevertebral fascia.
45485719|NCT03224884|Procedure|Supraclavicular block|"Ultrasound guided brachial plexus injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL (3 mL in the corner pocket followed by 17 mL posterolateral to the brachial plexus)."
46052155|NCT04116372|Behavioral|Digital Health Online Platform|"The website has 10 lessons that the participant will gain access to on a weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity"
45485720|NCT04329923|Drug|Hydroxychloroquine Sulfate 400 mg twice a day|Antimalarial compound
45485721|NCT04329923|Drug|Hydroxychloroquine Sulfate 600 mg twice a day|Antimalarial compound
45485722|NCT04329923|Drug|Hydroxychloroquine Sulfate 600 mg once a day|Antimalarial compound
45485723|NCT04329923|Drug|Placebo oral tablet|Placebo
45368436|NCT00936338|Behavioral|splint and joint mobilization self exercise|
45368437|NCT05281991|Device|Doppler ultrasonography|color flow Doppler ultrasonography
45368438|NCT05281991|Device|Tsui test|The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
45368439|NCT00936416|Procedure|Inulin and PAH clearance and MRI|"GFR and renal blood flow estimation by Inulin and PAH clearance will be performed in the Renal Physiology Lab for approximately 2.5 hours;~The MRI test will be performed afterwards at Medical Imaging department and last about 45 minutes."
45368440|NCT02566421|Other|Laboratory Biomarker Analysis|Correlative studies
45368441|NCT02566421|Other|Quality-of-Life Assessment|Ancillary studies
45368442|NCT02566421|Other|Targeted Therapy|Receive treatment based on genomic sequencing
45485724|NCT03207178|Biological|Mixed CD19/CD20 CAR-T Transfer|Autologous CD19 CAR-T cells and CD20 CAR-T cells with average 1-5*10^6 cells/kg body weight,separately.
45368443|NCT00940706|Device|TreadMill|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes~TreadMill training: During each session the subject will first exercise with basic stretching and muscle strengthening and then walk on the treadmill. According to the subject's rate of improvement, a therapist will determine the rate of increase in the velocity and slope. The treating therapist will make a written report after each session."
45485725|NCT03213496|Behavioral|Walk prescription|30-40 minutes daily, for five days at the week, all weeks up to surgery.
45485726|NCT03213496|Other|Conventional care|Patient do not walk before surgery
45485727|NCT03224728|Device|intraocular lens|
45485728|NCT03207412|Biological|hAECs|human amniotic epithelial cells
45485729|NCT03207412|Procedure|Minimally invasive implantation|Minimally invasive implantation with ultrasound guidance
45485730|NCT04403399|Drug|Varenicline|Initial 0.25 mg oral dose of varenicline administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final 0.5 mg BID oral varenicline administered for the remaining 3 weeks.
45485731|NCT04403399|Drug|Placebo|Initial placebo oral dose administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final placebo BID dosing administered orally for the remaining 3 weeks.
45485732|NCT03224572|Drug|high-dose vitamin C 30gm|High-dose vitamin C 30 gm in 500 ml normal saline, once per week, and total 4-week treatment.
45485733|NCT03224572|Other|normal saline|500ml normal saline, once per week, and total 4-week treatment
45485734|NCT02452216|Drug|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
45846328|NCT02520414|Device|Symphion® Bipolar Hysteroscopic Tissue Resection System|
46052156|NCT02818725|Drug|Chemotherapy|METHOTREXATE: 30 mg/m² on day 1 VINBLASTINE: 3 mg/m² on day 2 DOXORUBICIN: 30 mg/m² on day 2 CISPLATIN: 70 mg/m² on day 2
46052157|NCT02818725|Drug|Panitumumab|PANITUMUMAB: 6 mg/kg on day 2
45485735|NCT02452216|Other|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
45485736|NCT02452216|Procedure|Magnetic Resonance Imaging|All subjects in the experimental arm who undergo ferumoxytol infusion will subsequently have MRI.
45485737|NCT03749759|Procedure|Cataract surgery|A biofeedback measurement will be carried out during cataract surgery of both eyes
45485738|NCT03207334|Drug|Midostaurin|"Induction Phase: 50 mg orally twice daily beginning on day 7 and ending 48 hours prior to beginning the consolidation phase~Consolidation Phase: 50 mg orally twice daily beginning on Day 6 and ending 48 hours prior to either the start of the next cycle or beginning conditioning therapy for allogenic stem cell transplant."
45485739|NCT03207334|Drug|Cytarabine|"Induction Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients > 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1-6.~Consolidation Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients > 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1, 3, and 5 of each cycle."
45368444|NCT00940706|Other|Physical activity in groups|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes.~Activity Focus Training: this involves performing gross motor activities at exercise stations that involve repetitive, reciprocal and coordinated movements to facilitate strength and endurance conducted by physical therapists and instructing parents or other caregivers to be involved in the program. These activities are performed in a group, having a minimum of 6 children at one time."
45368445|NCT00940706|Behavioral|Monitoring physical activity|Activity monitoring with accelerometers
45368446|NCT01023412|Dietary Supplement|Immunonutrition|Oral Nutritional Supplement containing the amino acid arginine, omega-3 fatty acids, and nucleotides (RNA).
45368447|NCT02566499|Device|Breast Microwave Imaging|A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
45368448|NCT00936494|Procedure|Cold ablation inferior turbinate reduction|The procedure usually takes 30 minutes and involves the surgeon inserting the coblation inferior turbinate reduction wand into the inferior turbinates and allowing for the radiofrequency cold ablation to ablate soft tissues, with a resultant thermal lesion allowing for additional soft tissue attenuation and contracture with time.
45485740|NCT03751475|Other|Nutritional Strategy - OptiMA|"All children with a MUAC<125mm or oedema will be treated with the same RUTF, according to a new dosage table based on the evolution of MUAC and weight during recovery (RUTF dosage prescribed is gradually reduced as weight and MUAC increase).~All children will be followed-up for 6 months following randomization. They will have weekly outpatient visit in the health facility until they meet discharge criteria, and then a bimonthly community-based follow-up in their villages (vital & anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated)."
45485741|NCT03751475|Other|Effective nutritional standard strategy|"Children presenting with MUAC<115 or WHZ<-3 or nutritional oedema, will be treated with RUTF, according to the usual dosage table based on weight at each visit.~All children (whether eligible for RUTF or not) will be followed-up for 6 months following randomization. Children eligible for RUTF at randomization will have a weekly outpatient visit in the health facility until they meet discharge criteria, and then a bi-monthly community-based follow-up in their villages (vital & anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated). Children not eligible for RUTF at randomization will benefit from this same monthly community-based follow-up."
45485742|NCT03212950|Drug|Fast-CL|After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
45485743|NCT03212950|Drug|Regular-CL|After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
45847990|NCT03163758|Device|sham Repetitive Transcranial Magnetic Stimulation|The sham rTMS was performed on the same site as the rTMS treatment group but without any true stimulations. Coils were placed perpendicular to the scalp.
46052158|NCT02817165|Dietary Supplement|Probiotic (BioK+)|Probiotic (BioK+) with 3 stains of Lactobacillus
46052159|NCT02817165|Other|Placebo|Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.
46052160|NCT02820051|Device|Transcutaneous CO2 monitor|Measurement and surveillance of transcutaneous CO2 pressure (PtcCO2) to determine PtcCO2 behavior for each sedation group.
46052161|NCT02820051|Drug|Midazolam|The initial dose was 0.05 mg/kg. Additional doses of 2 mg of midazolam were allowed to reach a score level of three to four in the Observer´s assessment of alertness/ sedation scale.
45368449|NCT01028950|Drug|YM150|oral
45368450|NCT05265923|Drug|CM310|IL-4Rα monoclonal antibody
45368451|NCT05265923|Other|Placebo|Placebo
45368452|NCT00940784|Drug|Clopidogrel (Plavix)|Clopidogrel, aspirin plus hydroxyurea 75mg qd (Plavix) + 81 - 100 mg qd (aspirin) + hydroxyurea
45368453|NCT00940784|Drug|Placebo|Placebo, aspirin (81-100 mg qd) plus hydroxyurea
45368454|NCT00940784|Drug|Aspirin|81-100 mg qd
45368455|NCT01023490|Drug|Vitamin D|34,5000 IU vitamin D per week
45368456|NCT01023490|Drug|Placebo|Placebo
45485744|NCT03207490|Device|AMADEO|"Robot therapy: 1-Degrees-Of-Freedom (1DOFs) robot training for flexion and extention movements of the hand.~Standard rehabilitation therapy includes speech, physical, occupational therapies and group activities"
45485745|NCT03212248|Diagnostic Test|Thoracic Ultrasound (TUS)|
45485746|NCT03207100|Combination Product|Analgesia-first minimal sedation|Remifentanil will be administered by IV infusion and maintained at a dose of 0.025 μg/kg/min in non-mechanically ventilated patients and a dose of 0.05 μg/kg/min in mechanically ventilated patients. BP will be measured after 10 min of continuous infusion.If systolic BP is still ≥ 140 mmHg, then dexmedetomidine will be applied using an infusion pump at a dose of 0.2 μg/kg/h. BP will be measured again after 15 min of continuous infusion of dexmedetomidine. If systolic BP is still ≥ 140 mmHg, the dose of dexmedetomidine can be increased 0.1 μg/kg/h to the maximum of 0.6 μg/kg/h.If the maximum dose of dexmedetomidine does not lower blood pressure, use routine blood pressure reduction programs in each center to reduce blood pressure to the target range. Mechanically ventilated patients will be given a rapid remifentanil (0.5 μg/kg) infusion to reduce procedure-related pain.
45485747|NCT03207100|Combination Product|Antihypertensive treatment|Routine antihypertensive treatment will be performed in accordance with the protocol of each respective research center. Urapidil, nicardipine, and labetalol will be used in this group. Urapidil will be used as follows: a slow IV injection of 10-15 mg and then IV pumping for maintenance at an initial rate of 2 mg/min, adjusted according to BP to a maximum of 9 mg/min. Nicardipine will be used as follows: IV pumping at 0.5μg/kg/min adjusted according to BP to a maximum of 6μg/kg/min. Labetalol will be used as follows: IV infusion for maintenance at 1-4 mg/min until the aim is reached.The mechanically ventilated patients in the control group will be administered a rapid physiological saline infusion as a controlled pretreatment.
45368457|NCT00566228|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
45485748|NCT03212092|Dietary Supplement|Multivitamin, mineral & n-3 FA|The 2 multi vitamin capsules with the two multi vitamin softgel capsules will be handed out once a day during a meal by the staff of the care organization. The compliance will be registered
45485749|NCT03212092|Dietary Supplement|Placebo|The placebo of the multi vitamin capsules and the two multi vitamin softgel capsules will be handed out once a day during a meal by the staff of the care organization. The compliance will be registered
45485750|NCT03211390|Diagnostic Test|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
45485751|NCT03211390|Diagnostic Test|Teleneurological Examination|A Vanderbilt neurologist will examine all consented residents using a telemedicine platform, with the assistance of a nurse at the subject's bedside. The neurologist will guide the nurse to perform elements of a physical examination to determine if a referral to a movement disorders neurologist is required for a spasticity consultation.
46052162|NCT02820051|Drug|Propofol|The initial dose was 0.1 mg /kg. Additional doses of 10 mg of propofol were allowed to reach a score level of three to four in the Observer´s assessment of alertness/ sedation scale.
46052163|NCT02820051|Drug|Nalbuphine|The starting dose was 2 mg with additional doses of 1 mg if it was necessary.
46052164|NCT02820051|Drug|Lidocaine|Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.
46052165|NCT02819817|Drug|Aloe Vera Gel|The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
46052166|NCT02819817|Other|Ultrasound gel|The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
46052167|NCT02817243|Drug|SP2086|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
45368458|NCT00566228|Procedure|leukapheresis|Stem cells collected
45368459|NCT00698009|Drug|Fludarabine|25 mg/m^2 By Vein Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2.
45368460|NCT00698009|Drug|Cyclophosphamide|60 mg/kg By Vein Daily Over 2 Hours On Days -5 and -4
45368461|NCT00698009|Biological|Natural Killer Cell Infusion|Natural Killer Cell Infusion on Day 0.
45368462|NCT00698009|Drug|Mesna|12 mg/kg By Vein, Over about 15 minutes, Five Times Per Day on Days -5 and -4.
45368463|NCT00698009|Drug|Interleukin-2|"Received under skin three times weekly for 9 total doses following NK Cell Infusion:~For patients weighing 45 kg or more, dose administered is 10 Million units three times weekly for 9 total doses. For patients less than 45 kg, dose administered is 5 Million units/m2 (max dose 10 Million units) three times weekly for 9 total doses."
45368464|NCT01027156|Behavioral|High Intensity Exercise|In this study, participants will be instructed to sprint maximally for a period of 30 seconds. Following 30s rest, the participants will be instructed to repeat this procedure a further 3 times. This equates to 2 minutes of maximal effort sprinting interspersed with 2 minutes recovery. Participants will be requested to perform this protocol 3 times weekly. Training progression will be implemented by increasing the number of repeats from four repetitions during weeks 1 and 2, to five repetitions during weeks 3 and 4, to six repetitions during weeks 5 and 6. Finally, during week 7 participants will still perform six repetitions but interspersed by only 20 s recovery.
45368465|NCT01029106|Procedure|Gynecare TVT Secur|Implant of the Gynecare TVT Secur
45485752|NCT01561937|Drug|warfarin|After a baseline punch biopsy (B0), warfarin is administered over a period of approximately 7-14 days. Dose is adjusted individually to achieve INR target. Once a stable INR is achieved, a second biopsy (B1) will be performed
45485753|NCT01561937|Drug|eptacog alfa (activated)|If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
45485754|NCT01561937|Drug|placebo|If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
45485755|NCT03210766|Drug|Nabilone|
45485756|NCT03210766|Drug|THC/CBD|
45485757|NCT03747341|Drug|Buprenorphine Injectable Solution - Part A|"Buprenorphine intravenous (IV) injection given as a primed-continuous infusion.~Low Dose: initial bolus (0.05 mg/70 kg) administered over 15 minutes and infusion continued (0.02 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 0.2 ng/ml.~High Dose: initial bolus (0.125 mg/70 kg) administered over 15 minutes and infusion continued (0.05 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 0.5 ng/ml.~Administration of buprenorphine was flexible and infusion rates were selected to target approximately 25 to 50% respiratory depression."
45485758|NCT03747341|Drug|Placebo - Parts A + B|0.9% normal saline for IV administration was used as placebo matching the buprenorphine formulation and administration.
45485759|NCT03747341|Drug|Fentanyl - Part A|Participant received up to four fentanyl doses: 0.075, 0.15, 0.25, and 0.35 mg/70 kg in Periods 1 and 2. Fentanyl boluses were administered over 90 seconds by dose escalation +2hr, +3hr, +4hr and +5hr after starting administration of buprenorphine/ placebo. Administration of fentanyl was flexible and bolus doses were selected to elicit moderate to more severe respiratory depression with apnoea ≥20 seconds.
45485760|NCT03747341|Drug|Ondansetron - Parts A + B|A non-investigational intervention administered as an infusion prior to investigation intervention. 4 mg of ondansetron was administered to manage the expected gastrointestinal side effect (nausea, vomiting) to buprenorphine.
45485761|NCT03747341|Drug|Buprenorphine Injectable Solution - Part B|"Buprenorphine intravenous (IV) injection given as a primed-continuous infusion.~Low Dose: initial bolus (0.25 mg/70 kg) administered over 15 minutes and infusion continued (0.1 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 1 ng/ml.~Mid Dose: initial bolus (0.5 mg/70 kg) administered over 15 minutes and infusion continued (0.2 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 2 ng/ml.~High Dose: initial bolus (1.25 mg/70 kg) administered over 15 minutes and infusion continued (0.5 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 5 ng/ml."
45485762|NCT03747341|Drug|Fentanyl - Part B|"Participant received up to four fentanyl doses: 0.25, 0.35, 0.5, and 0.7 mg/70 kg in Periods 1 and 2.~Fentanyl boluses were administered over 90 seconds by dose escalation +2hr, +3hr, +4hr and +5hr after starting administration of buprenorphine/ placebo."
46052168|NCT02817243|Drug|Simvastatin|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
46052169|NCT00766363|Drug|EVP-6124 (0.1 mg/day)|EVP-6124 was administered as one 0.1 mg capsule per day for 28 days.
45368466|NCT05264831|Procedure|Pulmonary Vein Isolation (PVI) alone|PVI procedures correspond to point-by-point 50W AI-guided RF applications (400 posterior LA wall, and 550 elsewhere). The PVI will be validated by the absence of any activity recorded inside the PV encirclement by a multipolar catheter (either a Lasso catheter or a Pentaray catheter) (entrance block) and by the non-capture of the LA despite pacing maneuvers from inside the encirclement (exit block). The bidirectional block will be validated again after a 15-minutes waiting period.
45368467|NCT05264831|Procedure|PVI procedure associated with substrate modulation|PVI procedure associated with substrate modulation
45368468|NCT00936572|Procedure|Probiotics (La1, BB536)|
45368469|NCT00936572|Biological|probiotics (La1, BB536)|
45368470|NCT00936572|Biological|placebo|Maltodoxtrin
45368471|NCT04648631|Device|antibiofilm surfactant wound gel (ABWG)|ABWG is a hydro-gel applied topically using a tongue depressor
45368472|NCT04012658|Other|No intervention|No intervention
46052170|NCT00766363|Drug|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule every day for 28 days.
46052171|NCT00766363|Drug|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule every day for 28 days.
45368473|NCT03894605|Device|thalassemia|thalassemic patient use chelator and thaladssemic patient with frequent blood transfusion
45368474|NCT00944606|Dietary Supplement|Vitamin D|2000-3000 IU Vitamin D daily x 6 weeks
45368475|NCT00944606|Other|Placebo candy|candy gum drops
45368476|NCT05257655|Procedure|MRI after ganglionic local opioid analgesia (GLOA)|MRI after Ganglionic Local Opioid Analgesia at the Ganglion Cervicale Superius
45368477|NCT00941018|Drug|RX-10001|RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.
46052172|NCT00766363|Drug|Comparator: Placebo|Matching placebo was administered as one capsule per day for 28 days.
46052173|NCT00766363|Drug|Donepezil|Concomitant therapy with donepezil at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
46052174|NCT00766363|Drug|Rivastigmine|Concomitant therapy with rivastigmine at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
45485763|NCT03747341|Drug|Oxycodone - Part B|All opioid-tolerant participants in Part B were transitioned to oral oxycodone at least 48 hours before Period 1 to ensure washout of the participants' regular opioids and a stable dose of oxycodone with an adequate bridging schedule reached. Oxycodone is a non-investigational intervention.
45485764|NCT03210298|Combination Product|PIPAC|A chemotherapeutic solution is aerosolized into the expanded abdominal cavity during laparoscopy, under pressure. This allows a relatively homogeneous repartition of the drug and an effective tissue penetration.
45485765|NCT04401293|Drug|Enoxaparin|Full Dose LMWH anticoagulation therapy
45485766|NCT04401293|Drug|Prophylactic/Intermediate Dose Enoxaparin|Prophylactic/Intermediate Dose LMWH or UFH therapy
45368478|NCT04060901|Behavioral|CCSH Intervention for Teams|"CCSH Interventions for Teams will be a six session intervention. The groups meet once per week for 60 minutes for 4 weeks, coupled with 2 booster sessions over the following 2 months. Participants will receive the CCSH interventional approach, adapted for a group setting, which follows four stages: 1) Preparing the care responder; 2) Attuning to the Relationship; 3) Accessing Compassion, and 4) Entrusting the Careseeker.~The CCSH approach will be used to assess group dynamics, individual member sources of distress, as well as existing resources for resilience and compassion. Through the intervention, resources will then be identified and accessed in order to respond to team (and individual) sources of distress with greater resilience and increased compassion toward self and others. CCSH clinicians will utilize group process skills to encourage team communication about work-related challenges, enhance team cohesion, and enable interpersonal support among members of the team."
45485767|NCT03209830|Drug|OSU 6162|All patients will receive a dose of OSU6162 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
45485768|NCT03209830|Drug|Placebo Oral Tablet|All patients will receive a dose of placebo 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
45485769|NCT03209986|Procedure|mesenchymal stem cell transplantation via peripheral vein|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8
45485770|NCT03209986|Other|mesenchymal stem cell|mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China
45485771|NCT03209908|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
45485772|NCT03209440|Behavioral|Dignity Therapy - Nurse Led|The nurse-led intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
45485773|NCT03209440|Behavioral|Usual care|Palliative care nurses usually see patients each clinic visit to assess vital signs, function, symptoms, and to provide patient and family education. They document findings and interventions in the electronic health record (EHR). Whereas usual care for palliative care chaplaincy in the outpatient setting varies by site, chaplaincy care for usual care patients in this study will follow the usual practice for inpatient palliative care chaplaincy, which is to visit all new referrals to the clinic and assess their spiritual and religious needs. This assessment is then memorialized in a spiritual treatment plan documented in the EHR.
45485774|NCT03209440|Behavioral|Dignity Therapy - Chaplain Led|The chaplain-led DT intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
45846329|NCT02521974|Biological|SABIN monovalent OPV2|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2
45846330|NCT02522442|Device|CPAP|Continuous positive airway pressure
46052175|NCT02636946|Drug|Bimatoprost SR|Up to three Bimatoprost SR 15 micrograms (μg) administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR 15 μg administrations at Day 4 and Week 16 (Stage 2).
45485775|NCT04484740|Drug|Gepotidacin|Single oral dose of 1500 mg gepotidacin
46052176|NCT02636946|Drug|Sham Bimatoprost SR|Up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).
46052177|NCT02636946|Procedure|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty administered on Day 1.
45485776|NCT03224494|Device|Rapid Barostat Bag|Both healthy controls (n= 100) and IBS patients (n=100) will undergo anorectal studies using a Rapid barostat bag catheter.
45485777|NCT03224494|Other|IBS severity scoring system questionnaire (IBS-SSS)|We will correlate the changes to IBS symptoms using the IBS severity scoring system questionnaire (IBS-SSS). The questionnaire will be administered twice for IBS patients who have consented to return for a second study visit, at each of the two RBB studies.
45485778|NCT03224494|Other|HAD scale questionnaire|It is a validated anxiety and depression questionnaire
45485779|NCT04319159|Combination Product|BF-200 ALA and red light LED lamp|Combination Product: Photodynamic therapy (PDT) using BF-RhodoLED® (ALA-PDT, Ameluz®-PDT).
45846331|NCT02522442|Device|Auto BiLevel|Auto Bilevel positive airway pressure with Flex
45846332|NCT02523690|Drug|Lorcaserin|10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later
45846333|NCT02523690|Drug|Placebo|Oral or enteral, single dose. Oral or enteral, single dose two days later
46052178|NCT02636946|Procedure|Sham Selective Laser Trabeculoplasty|Sham Selective Laser Trabeculoplasty administered on Day 1.
46052179|NCT04617717|Procedure|Invasive cardiac electrophysiological study and ablation therapy|Invasive cardiac electrophysiological study with cathecholamine provocation and pacing procedures, as well as standard 3D mapping and PVC ablation
46052180|NCT04617717|Diagnostic Test|Cardiopulmonary exercise testing|Standard ergometer bicycle test
46052181|NCT04617717|Diagnostic Test|Cardiac MRI|Cardiac MRI with cine-imaging and late-gadolinium enhancement
46052182|NCT04617717|Diagnostic Test|Holter monitoring|24h 5 lead or 12 lead ECG recording
46052183|NCT04617717|Diagnostic Test|Transthoracic echocardiography|2D echocardiography
45368479|NCT00944684|Drug|High ribavirin dose|Ribavirin dose started according to kidney function (usually 1,800mg) and adapted according to plasma level during follow-up
46052184|NCT04617717|Diagnostic Test|Coronary angiography|Conventional invasive coronary angiography or CT angiography as indicated
45368480|NCT00944684|Drug|Standard ribavirin dose|Ribavirin dose started at 1,000mg (body weight <65kg) or 1,200mg (body weight equal or >65kg)
45368481|NCT04061057|Drug|Lidocaine|"Drug: 1. Lidocaine Intravenous lidocaine bolus of 1.5mg/kg immediately after anesthesia induction followed by infusion at 2.0mg/kg/hr up to 1 hr after end of surgery.~2. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min."
45368482|NCT04061057|Drug|Normal saline|"Drug: 1. Normal saline Intravenous normal saline bolus of immediately after anesthesia induction followed by infusion up to 1 hr after end of surgery. Volume of normal saline is equal to lidocaine.~2. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min."
45368483|NCT04635059|Drug|Pacritinib|Pacritinib is an oral drug which will be taken daily on a 28-day cycle at a dose of 200 mg twice a day (BID).
45368484|NCT00921167|Drug|Bevacizumab/Irinotecan|Bevacizumab 10mg/kg D1 Irinotecan 125mg/m2 D1 (without enzyme-inducing antiepileptic drugs [EIAEDs] or 340mg/m2 for patients on EIAEDs) every 2 weeks
45368485|NCT04061447|Drug|susceptibility-guided therapy|rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.
45368486|NCT04061447|Drug|empirical clarithromycin-based triple therapy|The eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.
45368487|NCT03968978|Biological|Tezepelumab (APFS)|Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
45368488|NCT03968978|Biological|Tezepelumab (AI)|Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
45368489|NCT05472779|Drug|Periurethral application of estradiol cream|The experimental group will apply estradiol cream in a different location (periurethral) and at a smaller dose (0.5 gram) compared to the control group.
45368490|NCT05472779|Drug|Intravaginal application of estradiol cream|The control group will apply 1 gram estradiol cream intravaginally using an applicator.
45368491|NCT02567591|Other|Physical activity|walk (three times per week) and muscle building twice per week with the use of elastic bands. They will include 5 strengthening exercises mobilizing large muscle groups of the lower limbs (abs (if possible for the patient), hamstrings, quadriceps, triceps sural and gluteus maximus).
45368492|NCT02565953|Device|Paclitaxel-releasing PTA balloon catheter|
45368493|NCT02565953|Device|PTA balloon catheter|
45368494|NCT05462951|Radiation|Standard|Radiation then brachytherapy
45368495|NCT00562718|Drug|capecitabine|
45368496|NCT00562718|Procedure|adjuvant therapy|
45368497|NCT00562718|Radiation|radiation therapy|
45368498|NCT05222165|Drug|Infigratinib|Hard gelatin capsules for oral use
45485780|NCT02451904|Other|Observation|
45846334|NCT02523924|Drug|18F-DCFPyL|18F-DCFPyL PET/CT
45846335|NCT02525718|Drug|Saline|If randomized to this arm, subjects will receive an intraoperative injection of saline. (2.5 mg/ml)
46052185|NCT02819895|Other|A customized windows® software application|A customized windows® software application with the ability to send automated voice call, SMS and email reminder about due dates for childhood routine immunizations.
45485781|NCT03224338|Drug|Dolutegravir 50 mg|Dolutegravir will be used in combination with 2 nucleoside reverse transcriptase inhibitors (NRTIs). The NRTIs used in combination with DTG will be abacavir (ABC) plus lamivudine (3TC) or tenofovir (TDF) plus emtricitabine (FTC), which is in line with the current standard of care. The combination ABC/3TC/DTG will be preferential except in case of hepatitis B co-infection or in case the subject has a positive HLA-B*5701 allele screening assessment.
45485782|NCT03224260|Drug|BMS-986177|Oral Suspension
45485783|NCT03224260|Other|Matched Placebo|Oral Suspension
45691628|NCT04345900|Drug|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
45846336|NCT02525718|Drug|0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone|"If randomized to this arm, subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine.~(2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively."
45846337|NCT02526654|Diagnostic Test|Heidelberg Edge Perimeter|HEP measures peripheral vision
45846338|NCT02526654|Diagnostic Test|Octopus Visual Field|OVF measures peripheral vision
45846339|NCT02526654|Diagnostic Test|Optical Coherence Tomography|OCT measures retinal nerve fiber layer thickness
45846340|NCT02527512|Drug|Povidone-Iodine|Chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine
45368499|NCT02567357|Behavioral|Visual Scheduling|Caregivers will present a visual schedule with pictorial representations of activities/events expected to occur each day will be presented to children at set times of day (tailored for individual's schedules). Ultimately caregivers will aim to ensure that activities occur as per the schedule as far as possible - thus decreasing the child's level of exposure to unexpected changes in routines or plans.
45368500|NCT02567357|Behavioral|signalling change|Caregivers will present a distinct visual-verbal cue card whenever they become aware that a change to the child's routine or plan is about to occur. Thus, the intervention uses a stimulus control approach so that the child learns that presentation of the cue reliably predicts the subsequent occurrence of a change to routine/plan, and the change is therefore more predictable and easier for the child to deal with.
45368501|NCT04555811|Drug|FT596|FT596 is given 2-3 days after rituximab; however, it may be delayed for up to 7 days until all rituximab infusion related toxicities resolve to ≤Grade 1.
45368502|NCT04555811|Drug|Rituximab|Rituximab 375 mg/m^2 is administered as an IV infusion per institutional standard of care and package insert on 2-3 days (48 to 72 hours) prior to the FT596 infusion
45485784|NCT04318535|Drug|Griseofulvin 500 mg|Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.
45485785|NCT04318535|Drug|Griseofulvin 250 mg|Griseofulvin 250 mg will be administered as an oral tablet once in each treatment period under fed condition.
45485786|NCT04318535|Drug|Reference Griseofulvin 500 mg|Reference Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.
45485787|NCT02451826|Drug|Ulipristal acetate|CVR delivering Ulipristal acetate and one tablet levonorgestrel.
45485788|NCT03224416|Other|Alcohol Administration|In the alcohol condition (target BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in his presence.
45485789|NCT03224416|Other|Placebo Alcohol Administration|"In the placebo condition (target BrAC = 0.000g%), the participant will be told he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from a vodka bottle) and tonic water, with a minimal amount of vodka floated on the surface (using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and mint, all mixed in his presence and served in glasses with vodka-soaked rims."
45485790|NCT03224416|Other|No Alcohol Administration|In the true control (or nonalcohol) condition, the participant will be told he is receiving no alcohol and will be given water (poured in his presence) in a volume comparable to the other conditions.
45485791|NCT04400903|Device|Activity Monitor|Undergo HRV monitoring via WHOOP device
45485792|NCT04400903|Other|Quality-of-Life Assessment|Ancillary studies
45485793|NCT04400903|Other|Questionnaire Administration|Complete questionnaires
45691629|NCT00619060|Drug|Topical Myristyl Nicotinate Cream|Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.
45846341|NCT02527512|Other|Normal Saline|Solution of 0.90% w/v of NaCl, 308 mOsm/L or 9.0 g per liter
45691630|NCT00619060|Drug|Placebo|Participants apply topical placebo to one forearm once daily for 4 weeks.
45691631|NCT05247424|Drug|Unfractionated heparin|Unfractionated heparin at dose of 100 IU /kg body weight
45691632|NCT00092716|Drug|MK0653, ezetimibe / Duration of Treatment: 28 weeks|
45368503|NCT04546217|Combination Product|Treadmill training + transfer package (TT+TP)|Participants will walk in different speeds, step over obstacles, and keep their balance during perturbations in the robotic treadmill. In combination with the gait training, participants will also receive a group of behavioral strategies (Transfer Package). Participants will sign the behavioral contract to achieve safety while engaging in activities, increase use of the paretic leg in daily activities, and increase coordination of both legs. A list of activities to be performed outside the clinical setting, the Home Skill Assignment, will be developed for each day of the week during the treatment period and given to the participants at the end of the session. The Home Practice after treatment aims to assure continued progress with LE use after the intervention program is completed. The LE-MAL Log will be administered in all sessions to assess quality of movement of the affected leg, level of assistance needed to perform daily activities, and level of confidence.
45485794|NCT03223948|Device|'Optiflow'|High flow nasal oxygen delivery device 'Optiflow'
45485795|NCT03223870|Diagnostic Test|Diagnostic|Diagnostic
45691633|NCT00092716|Drug|Comparator: atorvastatin / Duration of Treatment: 28 weeks|
45691634|NCT00619684|Drug|lenalidomide|Given PO
45691635|NCT00619762|Device|LTM - a porcine-based surgical mesh|Use of LTM to support weak and/or absent soft tissue to facilitate immediate breast reconstruction postmastectomy
45691636|NCT01799122|Device|Mini Arc Precise Pro and Trans vaginal obturator sling (TVT-0)|
46052186|NCT00766051|Other|The intervention group: Neurophysiologically Based Occupational Therapy Intervention (NBOTI)|This study included a pre-feeding, feeding, and postural-respiratory protocol, given per the attending physician's order. The interventions were given daily when possible, and the infants FiO2 and heart rate, along with stress behaviors, were monitored prior to, during, and after the NBOTI. The intervention included parent education for feeding, handling, and interaction with their infant, along with nursing training during the feeding session. The occupational therapy investigator partnered with the parents and when the parents were not available, she partnered with the nursing staff.
45368504|NCT04546217|Device|Treadmill training (TT)|Participants in this group will walk in different speeds, step over obstacles, and keep their balance during perturbations in the robotic treadmill. The treadmill training will be identical to the experimental group, but no element of the TP will be delivered.
45368505|NCT00697619|Drug|Zometa (zoledronic acid)|Zometa 4 mg IV infusion every 4 weeks for 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
45485796|NCT03223792|Other|Control|Routine cow's milk-based infant formula
45485797|NCT03223792|Other|Investigational|Partially-hydrolyzed cow's milk protein infant formula
45691637|NCT05246956|Other|Intradialytic exercise|Intradialytic exercise group
45691638|NCT05246800|Other|Structured 8-week mHealth mindfulness program|The mindfulness application was developed by Minddistrict The content of the app was developed by professionals in the field of mental healthcare and based on the principles of MBSR and MBCT The app consisted of a structured program, with chapters on psycho-education on mindfulness and the importance of practicing; acting on auto-pilot, conscious attention; non-judgmental attention, awareness; doing versus being-modus; attention for breath and body, conscious response; acceptance; a mindful attitude towards thoughts; applying mindfulness in daily life and staying mindful.
45691639|NCT00588406|Drug|Budesonide|2mg/dose by nebulizer, four doses over 3 hours
45691640|NCT00588406|Drug|albuterol|2.5mg/dose by nebulizer, 7 doses over 6 hours
45691641|NCT00588406|Drug|Ipratropium bromide|2.5 mg, one dose
45691642|NCT00588406|Drug|Prednisone|60mg PO
46052187|NCT00909792|Device|Lotrafilcon B|Silicone hydrogel, soft, multifocal contact lens
46052188|NCT00909792|Device|Senofilcon A|Silicone hydrogel, soft, multifocal contact lens
46052189|NCT02819739|Drug|medical oxygen|
45368506|NCT02566187|Drug|Fimasartan/Atorvastatin Combination Tablet|
45691643|NCT00668434|Drug|Prednisone|For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.
45691644|NCT00668434|Drug|Placebo|Placebo capsules will look the same as the study medication but will not contain active medicine.
45691645|NCT00668902|Drug|[13C]Pantoprazole|[13C]Pantoprazole was administered to EM, IM and PM of CYP2C19 and enzyme activity was measured through breath test and compared among the genotypes
45691646|NCT00669214|Drug|efalizumab|All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
45368507|NCT02566187|Drug|Fimasartan|
45368508|NCT02566187|Drug|Atorvastatin|
45368509|NCT05324891|Drug|Dexmedetomidine|Infants received dexmedetomidine IV loading dose: 0.5 mcg/kg given over 20 minutes followed by maintenance dose 0.3 µg/kg/hour by infusion over 24 hours.Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
45368510|NCT05324891|Drug|Fentanyl|Infants received Fentanyl IV continuous infusion: 1µg/ kg /hour. Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
45368511|NCT04482803|Drug|Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes|Before NST, one of the clinically assesed positive lymph nodes will be subjected to ultrasound-guided CNB or FNA, and a locating clip (Ultraclip, BARD) will be placed. Meanwhile, a small amount of Kanarine (carbon nanoparticles suspension injection, 0.5ml:25mg, H20073246) will be injected into or around the cortex of the locating lymph node and other clinically assessed positive lymph nodes. Preoperative FNA will be performed again for locating clip labelled node.
45368512|NCT05451329|Drug|VVN539 Ophthalmic Solution 0.02%|Once a day [q.d.] in the morning, q.d. in the evening and twice a day [b.i.d.]) will be tested for 7-9 days
45368513|NCT05451329|Drug|VVN539 Ophthalmic Solution 0.04%|Once a day [q.d.] in the morning, q.d. in the evening and twice a day [b.i.d.]) will be tested for 7-9 days
45368514|NCT05451329|Drug|VVN539 Ophthalmic Solution Vehicle|Once a day [q.d.] in the morning, q.d. in the evening and twice a day [b.i.d.]) will be tested for 7-9 days
45368515|NCT00445432|Biological|adalimumab|Subcutaneous injection of 40 mg adalimumab (0.8 mL/injection) every other week (eow)
45368516|NCT00445432|Other|Placebo|Subcutaneous injection of placebo (0.8 mL/injection) every other week (eow)
45368517|NCT03370133|Drug|Bimekizumab|Bimekizumab will be provided at pre-specified time intervals.
45368518|NCT03370133|Drug|Ustekinumab|Ustekinumab will be provided as dose 1 for subjects weighing <=100 kg and as dose 2 for subjects weighing >100 kg at pre-specified time intervals.
45368519|NCT03370133|Other|Placebo|Subjects will receive Placebo at pre-specified time points.
45368520|NCT00696137|Drug|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, and 1200 mcg fentanyl; up to 4 times daily
45368521|NCT02565641|Drug|Capecitabine|Capecitabine will be administered orally at 830 mg/m^2 BID (equivalent to a total daily dose of 1660 mg/m^2) as intermittent treatment (given days 1 to 21 q4w).
45691647|NCT00669214|Drug|placebo|All patients received a conditioning dose of placebo equivalent SC on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).
45691648|NCT00589888|Drug|Intralipid 20% @ 20cc/hour|In this arm subjects received Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting
45368522|NCT02565641|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 1000 mg/m^2 once weekly via IV infusion as intermittent treatment (repeated 4-week cycles of 3 weeks treatment and 1 week rest).
45368523|NCT04036721|Drug|Prolonged glucocorticosteroid (prednisone) regimen|Prolongation of maintenance therapy with prednisone of patients with pneumonitis inducted by anyi-PD-1/anti-PD-L1 antibodies.
45368524|NCT04036721|Drug|Short glucocorticosteroid (prednisone) regimen|Prednison regimen based upon American Society of Clinical Oncology and European Society for Medical Oncology Clinical Practice Guidelines on pneumonitis treatment in patients receiving immunotherapy agents
45368525|NCT00441142|Drug|ZD6474|Taken orally once a day (at 100 mg/day is the phase II dose; the MTD determined by the phase I portion of the trial) until disease gets worse or participants experience unacceptable side effects
45485798|NCT03747263|Procedure|Catheter ablation|Electrophysiology studies are performed during conscious sedation using boluses of midazolam and fentanyl and a continuous infusion of propofol. Vital parameters are continuously monitored. One 7F standard diagnostic catheter is positioned inside the coronary sinus (CS) via the femoral vein. One 8,5-F sheath is advanced to the left atrium (LA). After transseptal catheterization, intravenous heparin is administered to target an activated clotting time of ≥300 seconds. PV angiographies are obtained for each PV and PV recordings are registered at baseline in SR. The 8.5F transseptal sheath (TS) is changed over the wire for a 12F steerable TS.
45485799|NCT01562561|Drug|repaglinide|2 mg at each main meal
45485800|NCT01562561|Drug|insulin NPH|Administrated subcutaneously (s.c., under the skin) either at bedtime or twice daily at breakfast and before dinner.
45485801|NCT03206944|Drug|acetylsalicylic acid|Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg in the morning
45485802|NCT03206944|Drug|Tomato Fruit Extract|Group 2 (STE) included 32 patients receiving standardized tomato extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally in the morning
45368526|NCT00441142|Drug|temozolomide|"During the 'Induction' phase: 75/mg/m2/day temozolomide will be given orally daily for 6 weeks (42 days) during radiation therapy, beginning either the night before or on the first day of the first fraction of radiation, including weekends and holidays. This is followed by a 4-6 week break.~During the 'Maintenance' phase: The first post-radiation temozolomide cycle will be administered at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle. If 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given. This is given for 12 cycles."
45485803|NCT03209596|Dietary Supplement|Orange juice (1L/d)|The players (n=17) drank 1 liter per day of orange juice. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
45485804|NCT03209596|Dietary Supplement|Control drink (1L/d)|The players (n=13) drank 1 liter per day of the control drink during a 60-day period. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
45485805|NCT04454567|Drug|ABI-H0731|Participants will receive ABI-H0731 tablets orally once daily
45485806|NCT04454567|Drug|Placebo|Participants will receive placebo to ABI-H0731 tablets orally once daily
45485807|NCT04454567|Drug|NrtI|Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert
45485808|NCT03206632|Drug|BI 690517|single dose
45485809|NCT03206632|Drug|Placebo|single dose
45846342|NCT02528370|Device|telEPOC|The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
45368527|NCT00441142|Radiation|Radiation Therapy|Radiotherapy must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy.
45485810|NCT03206554|Drug|Ropivacaine|Large volume local anaesthetic intraarticularly
45485811|NCT03206554|Other|Saline|sham injection
45485812|NCT03751319|Other|CGA|Comprehensive Geriatric Assessment
45485813|NCT03209284|Procedure|transcrestal sinus floor elevation|augmentation procedure with xenograft
45485814|NCT03209206|Drug|Docetaxel|Intravesical Instillation of Docetaxel (Docetaxel 75 mg diluted in 100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
45485815|NCT03209206|Drug|Placebo Normal saline|Intravesical Instillation of Normal saline (100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
45368528|NCT05208281|Drug|GNR-055 1.0-2.0-3.0 mg/kg|Weekly IV infusion (lyophilized powder) 1.0-2.0-3.0 mg/kg
45368529|NCT05208281|Drug|GNR-055 2.0 mg/kg|Weekly IV infusion (lyophilized powder) 2.0 mg/kg
45485816|NCT04449341|Device|Oculus Go headset with Ocean Rift application|Information already included in arm description
45485817|NCT03223636|Device|TMS|We will use TMS with paired-pulse technique to activate corticospinal neurons in the primary motor cortex and motorneurons in the brainstem, respectively (Hallett 2007; Ugawa et al. 1991; Ugawa et al.1994). Two stimulations will be separated with various interstimulus intervals to produce collision on nerve fibers with different conduction velocity in the corticospinal tract. The conduction time on nerve fibers in the corticospinal tract with different conduction velocity will be identified and the distribution of these fibers will be calculated.
45485818|NCT03223636|Device|MRI|MRI exams will consist of several sessions including calibration, anatomic, and diffusion MRI scanning (Avram et al. 2013; Avram et al. 2016; Pierpaoli et al. 1996). Data in each exam will be acquired in the left or right forearm (PNS).
45485819|NCT03749603|Device|TIBAY Meter|fluorescence probe will be applied for 3-5 minutes onto the wet vermillion of the lower lip.
45485820|NCT03223558|Behavioral|timing of initiation of cardiac rehabilitation|earlier timing of cardiac rehabilitation
45368530|NCT05208281|Drug|GNR-055 3.0 mg/kg|Weekly IV infusion (lyophilized powder) 3.0 mg/kg
45485821|NCT04638647|Biological|Secukinumab s.c. injection|Secukinumab pre-filled syringes (PFS) for s.c. injection
45368531|NCT00921401|Behavioral|Asthma Feedback|All participants will log in to the study Web site at least once a month and before all doctor visits. They will answer a series of questions and receive individualized feedback about the types of questions they should ask their doctor.
45368532|NCT01029184|Other|commercialized complete cereals|complete cereals suitable for the weaning period
45368533|NCT01029184|Other|commercialized complete cereals with additional ingredient|complete cereals suitable for weaning period
45368534|NCT03896555|Device|ExacTrac position verification|Repeated measurement of patient head position with ExacTrac X-ray Monitoring
45485822|NCT03223402|Other|Nevirapine plus lamivudine|In this Pilot study, the efficacy of a bi-therapy consisting of NVP+3TC instead of NVP+2NRTI should be evaluated before a large multicenter study evaluating this combination is started.
45485823|NCT03208972|Drug|low dose hCG|
45691649|NCT00589888|Drug|Intralipid 20%@ 40cc/hour|In this arm subjects received Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours. In this arm subjects will receive Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting.
45846343|NCT02529072|Drug|nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes. Binding of PD-1 to its ligands, programmed death-ligands 1 and 2, results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T cell responses to both foreign antigens as well as self-antigens. Nivolumab is expressed in Chinese hamster ovary cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies. The clinical study product is a sterile solution for parenteral administration.
46052190|NCT03104868|Behavioral|TAKE IT Strategy|"The TAKE IT Strategy includes:~Programming the electronic health record (EHR) to organize/simplify daily regimen schedules and generate electronic, tangible, print, low literacy medication education materials at every clinical encounter.~SMS text-messaging to remind patients when to take all their medicine.~A web-based patient portal that requests patients to periodically report upon their medication use, providing a continuous link between the transplant center and patient beyond routine in-person visits.~EHR notifications directed to the transplant center nurse coordinator if an adherence-related problem is identified by the web-based portal assessment, who then can activate appropriate staff to respond."
45691650|NCT00589888|Drug|Normal Saline|In this arm subjects received 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours.
45368535|NCT04025021|Dietary Supplement|Targeted Fortification|The TPN and SMOF lipids will be optimized to provide a goal of 4 g/kg/day of protein, and 100-130kcal/kg/day. At 100 ml/kg/day of enteral feeds additional liquid protein and/or microlipids will be added to the breast milk to provide goal of 4 g/kg/day of protein and 100-130 kcal/kg/day. This will be determined by analysis of the milk and reported composition. They will continue targeted fortification for 4 weeks after achieving full feeds of 150 ml/kg/day.
45485824|NCT03208972|Drug|hp-FSH|
45485825|NCT03208972|Drug|Corifollitropin Alfa|"Corifollitropin Alfa (Elonva) dosage depending on weight, once administered first day of ovarian stimulation for all subjects, and on day 7 they proceed with the treatment of the allocated group.~<60 kg: Elonva 100 MCG > 60 kg: Elonva 150 MCG"
45485826|NCT03206866|Diagnostic Test|serum regucalcin antibody|serum regucalcin antibody
45691651|NCT00589888|Dietary Supplement|32-gram oral fat load|In this arm subjects received oral liquid fat load prepared by the General Clinical Research Center (GCRC) at baseline and every 2 hours for 6 hours. Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
46052191|NCT02819661|Device|SOMNOTOUCH RESP|Ventilatory effort recorder
46052192|NCT02819661|Procedure|Caesarean section|Cesarean delivery is defined as the delivery of a fetus through surgical incisions made through the abdominal wall (laparotomy) and the uterine wall (hysterotomy).
45596367|NCT02288923|Drug|Pre-medication|All patients will receive 1g paracetamol pre-operatively. Those on non steroidal anti inflammatory drugs may continue to take them. Apart from these, no other pain relieving pre-medications are to be used. Patients may be given anxiolysis using temazepam 10-20mg or diazepam 2-5mg by mouth if required. Antacid premedication is permitted using ranitidine, metoclopramide or proton pump inhibitors.
45691652|NCT00589888|Dietary Supplement|64-gram oral fat load|In this arm subjects received 60-gram oral fat load intake at baseline and every 2 hours for 6 hours prepared by the General Clinical Research Center (GCRC). Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
45691653|NCT00669682|Other|Congestive heart failure|Spontaneous occurrence of fluid overload.
45846344|NCT02529072|Biological|DC|DCs are potent immunostimulatory cells that continuously sample the antigenic environment of the host and specifically activate cluster of differentiation 4 positive (CD4+) and cluster of differentiation 8 positive (CD8+) T-cells and B-cells. They are at the crossroads of many of the elegant networks of the immune system, and DCs represent the most promising contemporary biologic entity for realizing the promise of immunotherapy. Potent immune responses and encouraging clinical results have been seen in Phase I and II human clinical trials in systemic cancers. Numerous animal studies and the investigator's institution's humans studies have demonstrated potent antitumor responses using DC-based immunotherapy against MGs.
45846345|NCT02530476|Drug|Selinexor|"Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
45846346|NCT02530476|Drug|Sorafenib|"Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I."
45846347|NCT02530554|Drug|CHG|Single application
45846348|NCT02531022|Behavioral|Financial incentive|A daily financial incentive framed as a loss of $2 each day goal is not acheived
45368536|NCT04025021|Device|The Miris Human Milk Analyzer|The Miris human milk analyzer is a mid infrared that reports the amount of energy absorbed at each wavelength. The amount of fat (grams), lactose (grams), total protein (grams), true protein (grams), and energy (kcal) per 100 ml will be reported.
45368537|NCT03848416|Biological|Ixekizumab|Administered SC
45368538|NCT01029418|Drug|AZD6244 and sorafenib|dose escalation of AZD6244; sorafenib 400mg bd
45368539|NCT04060979|Drug|Nitric Oxide|Nitric Oxide given intermittently via inhalation
45368540|NCT04060979|Other|Standard Supportive treatment|Standard Supportive treatment (including oxygen)
46052193|NCT02819661|Drug|Spinal anesthesia with intrathecal morphine|is a form of regional anaesthesia involving injection of a local anaesthetic into the subarachnoid space
45368541|NCT00458302|Drug|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
45368542|NCT00458302|Drug|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
45368543|NCT03851146|Biological|LeY CAR T cells|Autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector (LeY CAR T cells)
45368544|NCT01023646|Other|Carbohydrate + Protein|Light Tuna Packed in water.
45368545|NCT01023646|Other|Carbohydrate + Fat|Butter
45368546|NCT01023646|Other|Fiber|Unrefined Carbohydrate
45368547|NCT01023646|Other|Carbohydrate load|Carbohydrate
45368548|NCT03847480|Radiation|FDG-PET guided dose painting|The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
45368549|NCT00444106|Drug|Artesunate-mefloquine|
45691654|NCT00669916|Biological|AIN457|single infusion of 3 mg/kg
45691655|NCT00669916|Drug|Placebo|single infusion of placebo
45691656|NCT00621946|Drug|Placebo|Placebo Matching Escitalopram
46052194|NCT02816541|Other|Pelvis Retroverted|Pilates-based therapeutic exercises with the pelvis retroverted - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).
45368550|NCT00444106|Drug|Atovaquone-proguanil|
45368551|NCT00444106|Drug|Artemether-lumefantrine|
45368552|NCT00561470|Drug|Placebo|4 mg/kg of sterile aqueous buffered vehicle (pH 6.0) was administered intra venously (IV) over 1 hour on Day 1, every 2 weeks
45368553|NCT00561470|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg of Aflibercept was administered IV over 1 hour on Day 1, every 2 weeks.
45691657|NCT00621946|Drug|Escitalopram|Active Escitalopram
45691658|NCT00591760|Drug|Somatotropin|Subcutaneous Somatotropin (recombinant human Growth Hormone) 0.012 mg/kg every second day for 6 months
45691659|NCT00623506|Drug|Pregnenolone|"Placebo for two weeks (during placebo lead-in), then:~Pregnenolone 100 mg in divided doses (50 mg, PO, BID) Pregnenolone 300 mg in divided doses (150 mg, PO, BID) Pregnenolone 500 mg in divided doses (250 mg, PO, BID)"
45846349|NCT02531022|Behavioral|Daily feedback|Daily feedback from an activity tracking device worn on the wrist to track step counts and sleep patterns
45846350|NCT02532036|Biological|Aerosol inhaled MVA85A|
45846351|NCT02532036|Biological|Intramuscular MVA85A|
45846352|NCT02532036|Biological|Intramuscular Saline placebo|
45846353|NCT02532036|Biological|Aerosol inhaled Saline placebo|
45846354|NCT02536248|Drug|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
45846355|NCT02536248|Drug|Placebo|Placebo for 6 weeks
46052195|NCT02816541|Other|Pelvis in Neutral Position|Pilates-based therapeutic exercises with the pelvis in neutral position - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).
46052196|NCT02816541|Other|Aerobic exercise|Aerobic exercises (walking) performed on a treadmill.
46052197|NCT00765817|Drug|placebo|subcutaneous injection, twice a day
46052198|NCT00765817|Drug|exenatide|subcutaneous injection, twice a day, 10mcg
45368554|NCT00561470|Drug|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|"The FOLFIRI regimen was initiated immediately after Placebo administration on Day 1~The FOLFIRI regimen included:~180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~5-FU 2400 mg/m² continuous IV infusion over 46-hours"
46052199|NCT02818491|Drug|Placebo|Normal saline 0.9% in 2 mls
45368555|NCT00561470|Drug|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|"The FOLFIRI regimen was initiated immediately after Aflibercept administration on Day 1~The FOLFIRI regimen included:~180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~5-FU 2400 mg/m² continuous IV infusion over 46-hours"
46052200|NCT02818491|Drug|Dexamethasone 1 mg|Dexamethasone 1 mg in 2 mls
45368556|NCT00443872|Drug|orally disintegrating selegiline (Zelapar)|1.25 mg once daily orally disintegrating selegiline for 6 weeks with an increase to 2.5 mg once daily orally disintegrating selegiline for remaining 6 weeks if tolerated
45368557|NCT01323166|Procedure|Excision of the levator muscle|Cylindrical perineal excision including the levator muscle
46052201|NCT02818491|Drug|Dexamethasone 2 mg|Dexamethasone 2 mg in 2 mls
46052202|NCT02818491|Drug|Dexamethasone 3 mg|Dexamethasone 3 mg in 2 mls
46052203|NCT02818491|Drug|Dexamethasone 4 mg|Dexamethasone 4 mg in 2 mls
45368558|NCT03620266|Dietary Supplement|Bilberry|The dietary intervention will be initiated within five days post PCI and will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture as both oat and bilberry), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
45368559|NCT03620266|Dietary Supplement|Placebo|The dietary intervention will be initiated within five days post PCI and will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
45368560|NCT03620266|Dietary Supplement|Bioprocessed oat bran|The dietary intervention will be initiated within five days post PCI and will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
45368561|NCT03620266|Dietary Supplement|Combination bilberry/oats|The dietary intervention will be initiated within five days post PCI and will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
45368562|NCT01323244|Drug|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use, once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
45691660|NCT00623506|Drug|Placebo|"Placebo for two weeks (placebo lead in), then:~Placebo equivalent to Pregnenolone arm: 100 mg in divided doses (50 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 300 mg in divided doses (150 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 500 mg in divided doses (250 mg, PO, BID)"
45846356|NCT02537730|Device|Bioclean MPS VII|PHMB (Polyhexamethylene biguanide) base Disinfecting and Cleaning system
45846357|NCT02537730|Device|Aosept Clearcare|Hydrogen Peroxide Disinfecting and Cleaning system
45846358|NCT02537730|Device|comfilcon A|contact lens
46052204|NCT02818491|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% 20 mls
46052205|NCT02818179|Radiation|THERMOGRAPHY IMAGING|
46052206|NCT02816853|Drug|Domperidone|Domperidone 10 mg or 20 mg tablets will be administered.
46052207|NCT02816853|Drug|Placebo|Matching placebo will be administered.
46052208|NCT02816853|Drug|Moxifloxacin|Moxifloxacin 400 mg tablet will be administered.
46052209|NCT04101097|Other||
46052210|NCT02818257|Other|Strip A|Adhesive strip A
46052211|NCT02818257|Other|Strip B|Adhesive strip B
46052212|NCT02818257|Other|Strip C|Adhesive strip C
46052213|NCT02818335|Drug|LY3023414 Reference Fasted|Administered Orally
46052214|NCT02818335|Drug|LY3023414 Test Fasted|Administered Orally
46052215|NCT02818335|Drug|LY3023414 Test Fed|Administered Orally
46052216|NCT02818413|Other|Biospecimen collection and questionnaires|Biospecimen collection and questionnaires
46052217|NCT02819583|Biological|PCAR-019 (anti-CD19 CAR-T cells)|
46052218|NCT02819349|Behavioral|Texting for Relapse Prevention (T4RP)|T4RP is a relapse prevention mHealth program text messaging to people who have schizophrenia/SAD. Content is guided by components of the Assertive Community Treatment (ACT) and focuses on facilitating improved patient-provider communication, promoting medication adherence, helping people self-monitor their early warning signs, and promoting self-management of symptoms.
46052219|NCT00772603|Drug|Placebo|Non-active tablet identical to study drug tablets
45368563|NCT01027234|Drug|AZD8418|Single oral dose
45368564|NCT01027234|Drug|Placebo|single oral dose
45368565|NCT01029496|Procedure|different time of umbilical cord clamping|"for normal birth(apgar score over 7),include:term ,preterm,normal birth or cesarean section : experimental group1: waiting until the ceased of the umbilical cord pulsing, then cut the cord.before cutting the cord, the baby is keeping warm and put over mother's abdomen.~control group 1-1: clamping and cut the cord within 10 second after birth. control group1-2: clamping and cut the cord 90 second after birth.~for in case of asphyxia(regardless term or preterm,normal birth or cesarean section born):~experimental group2: resuscitate on bed site with the cord unclamped until the umbilical cord ceased pulsing.~control group 2-1 clamping and cut the cord within 10 second. and resuscitate the baby after transfer to the Irradiation table."
45485827|NCT02450500|Behavioral|Lifestyle counselling|This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging. Participants will be issued with a pedometer and instructed to wear this daily. Participants will access web-based material on prediabetes through the lifestyle app. Contact between the dietitian and participants will consist of weekly messaging to facilitate changes in diet and activity behaviour through motivational and cognitive behavioural strategies. Changes in diet and activity levels will be recorded as personalised goals which will be monitored and reviewed by both the participants and dietitian. In addition participants will be encouraged to complete a food diary to self-monitor their progress against dietary recommendations.
45485828|NCT03223324|Device|abdominal fetal/maternal monitor|A single passive patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
45485829|NCT03206398|Device|anti-gravity treadmill|anti-gravity treadmill for a total of 40 days in addition to physiotherapy
45485830|NCT02451748|Other|Lab Work|Lab work to measure IL-7 and IL-7R
45485831|NCT02451748|Drug|Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)|"Certolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection."
45485832|NCT02451748|Drug|Certolizumab pegol (CDP870, tradename Cimzia)|"rtolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection."
45485833|NCT02451748|Drug|Hydroxychloroquine|some patients are on 400mg/day of hydroxychloroquine.
46052220|NCT00772603|Drug|2400mg SPN-804|tablets containing 600mg OXC XR, identical to non-active tablets
45485834|NCT02451748|Drug|Sulfasalazine|some patients are on 300 mg/day and some patients are on 1000 mg/day dose of sulfasalazine
45485835|NCT02451748|Drug|Medrol|some patients are on 8mg/day of medrol
45485836|NCT02451748|Drug|Prednisone|some patients are on 10mg /day, some patients are on 20 mg/day, some patients are on 2.5 mg/day, some patients are on 30 mg/day, and some patients are on 5 mg/day of prednisone
45368566|NCT01027390|Behavioral|physical training exercise|physical exercise training at the work site during work time
46052221|NCT00772603|Drug|1200mg SPN-804|two active tablets and two non-active tablets, all identical
46052222|NCT02819427|Device|Near Infra Red Spectroscopy (NIRS)|
45368567|NCT03034642|Procedure|Bronchoscopy with bilateral bronchoalveolar lavages|Bronchoscopy with bilateral bronchoalveolar lavages
45368568|NCT03840226|Drug|Placebo Oral Tablet|Placebo tablets
45368569|NCT03840226|Drug|Magnesium Oxide|Magnesium tablets
45368570|NCT04839562|Drug|Solriamfetol 75 MG|Daily oral consumption
45368571|NCT04839562|Drug|Solriamfetol 150 MG|Daily oral consumption
45368572|NCT04839562|Other|Placebo|Placebo
45368573|NCT04888624|Device|DrySee® dressing with moisture detection|DrySee® is a waterproof bandage designed to protect surgical incisions. It contains an indicator at the perimeter of the dressing, and at the wound site that turns blue when it comes into contact with liquid (figure 1). The indicator identifies a break in the integrity of the postoperative dressing. Changing the dressing at this point prevents bacteria from reaching the incision reducing the risk of infection. In addition, the waterproof dressing allows patients to shower or bath following surgery.
45485837|NCT02451748|Drug|Triamcinolone|some patients are on Triamcinolone 40-80mg IM monthly (received 40mg dose 1 week before blood draw, off enbrel 50mg weekly and SSZ 1000mg bid for ~ 3 months) some patients are on Triamcinolone 40mg IM monthly
45485838|NCT02451748|Drug|Naproxen|some patients are on 1000 mg/day of naproxen
45485839|NCT02451748|Drug|Leflunomide|some patients are on 20mg/day of leflunomide
45485840|NCT02451748|Drug|Methotrexate|some patients are on 20mg weekly, some patients are on 25mg weekly, some patients are on 17.5 mg, some patients are on 15 mg weekly, some patients are on 7.5 mg weekly, and some patients are on 15 mg weekly dose of methotrexate
45485841|NCT02451748|Drug|humira|some patients are on Humira 40mg q2weeks
45485842|NCT03223168|Device|Hayek RTX ventilator|Participants will receive Noninvasive negative pressure from the Hayek RTX ventilator for 30 minutes during diagnostic catheterization procedure.
45485843|NCT03208894|Drug|Furosemide Injection|efficacy of salbutamol and furosemide in TTN
45485844|NCT02450656|Drug|Afatinib|Tablet
45485845|NCT02450656|Drug|Selumetinib|Capsule
45485846|NCT02450656|Drug|Docetaxel|
45485847|NCT03208816|Behavioral|symptom management program for chemotherapy patients|Nurses will call study participants two times a week, to proactively assess and manage symptoms they might be experiencing during chemotherapy.
45485848|NCT03206242|Other|Physiotherapy|Interventions of physical therapy will be implemented after reconstructive surgery including edema control, scar management, pain management, respiration training, oral function training, neck and shoulder function training, donor site mobility training.
45485849|NCT03206320|Drug|Lidocaine Topical|Comparison of lidocaine topical gel with lidocaine infiltration and with no local anesthesia in reducing needle insertion and injection pain
45485850|NCT04448561|Drug|ASP8082|oral
45485851|NCT04448561|Drug|morphine|oral
46052223|NCT02819427|Device|Electroencephalography (EEG)|Electroencephalography (EEG) in a simultaneous High-Resolution (HR) recording.
46052224|NCT02819505|Dietary Supplement|beta-alanine|
46052225|NCT02819505|Dietary Supplement|Placebo|
45368574|NCT04888624|Device|Tegaderm® + Pad transparent film dressing|Tegaderm® is a transparent adhesive dressing commonly used as a postoperative dressing. The dressing has been shown to be superior to gauze in reducing SSIs. Tegaderm®, like DrySee,® is waterproof; however, it lacks technology that identifies a breach in dressing integrity.
45368575|NCT01030978|Behavioral|Bright Bodies Healthy Lifestyle Program|Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
45368576|NCT01030978|Behavioral|Control|Subjects will be given basic instruction by clinical provider and goals will be followed up every 3 months.
45368577|NCT01029574|Other|Platelet rich plasma|Ultra-centrifuged PRP, 40ml, in the liquid way, after portal closure.
45368578|NCT03316222|Drug|GNS561|Escalating doses to be administered 3 times a week.
45368579|NCT01031056|Procedure|Blood Draw|
45368580|NCT01031056|Procedure|Frozen Tumor Specimens|
45368581|NCT03742492|Dietary Supplement|Meal containing canned tuna + fish oil (5 g EPA + DHA)|Meal containing canned tuna + fish oil (5 g EPA + DHA)
45368582|NCT03742492|Dietary Supplement|Meal containing canned tuna + soybean oil|Meal containing canned tuna + soybean oil
45368583|NCT03315754|Drug|TOOKAD Soluble 4 mg/kg|Vascular targeted photodynamic therapy using TOOKAD Soluble
45368584|NCT04773652|Diagnostic Test|speckle tracking echo|Two-dimensional and 3D Speckle tracking echocardiography and feature tracking CMR will be performed twice: within 48 hours of admission and 3 months following the index event.
45368585|NCT00441064|Drug|Aliskiren|
45368586|NCT03962738|Drug|Lasmiditan|Administered orally
45368587|NCT03962738|Drug|Placebo|Administered orally
45368588|NCT05280002|Biological|Adipose Tissue derived Total-Stromal-Cells (TOST)|Single dose autologous aAdipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cell was injected in each knee of the participants having knee osteoarthritis.
45368589|NCT00561392|Drug|Rivastigmine 5 and 10 cm^2 patch|
45485852|NCT04448561|Drug|Placebo|oral
45485853|NCT03208660|Drug|Fycompa|Oral suspension
45485854|NCT03208738|Behavioral|VetChange|VetChange is a self-management mobile application designed to to concurrently reduce both alcohol misuse and PTSD symptoms.
46052226|NCT05658861|Other|Milk containing A1 and A2 beta-casein|Single dose of commercial milk
46052227|NCT05658861|Other|Milk containing only A2 beta-casein|Single dose of A2 milk
46052228|NCT04237779|Biological|PRP injection into at least one testis|Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols. PRP injection will be performed under local anesthesia. Sperm analysis, testicular volumes (using orchiometer), serum FSH and testosterone measurements will be re-evaluated at 8 weeks post-procedure. On the third month after the procedure, presence of spermatozoa will be reassessed in micro testicular sperm extraction (TESE) material.
46052229|NCT04239105|Device|Microfluidic and Raman spectrum|Detection of Circulating Tumor Cells
46052230|NCT02819271|Drug|CXL-1427 Ascending Dose|
46052231|NCT02819271|Other|Placebo|
46052232|NCT02819271|Drug|CXL-1427 Descending Dose|
45368590|NCT00694109|Drug|Mipomersen Sodium|Subcutaneous injection as a single injection directly into the abdomen, thigh, or outer area of the upper arm.
45368591|NCT03137693|Other|Standard of Care Schedule Variation: SABR|SABR will be delivered over 3 days, prior to surgery.
45368592|NCT03137693|Procedure|Breast-conserving Surgery|Breast-conserving surgery will be scheduled for 6-8 weeks after SABR and will be conducted by a Moffitt breast surgeon.
45368593|NCT03078491|Other|eCGM (enhanced CGM)|Glucose (CGM and Bluetooth BG meter), insulin (pump or Bluetooth insulin pen) and activity data will be automatically uploaded via the subjects' tablet computers, and analyzed by the CDS. The CDS will, if indicated generate adjustable insulin dosing recommendations that will compensate for different insulin requirements following high vs low activity days. The recommendations of the CDS will be used by the clinical team in their therapeutic decision-making about insulin dosing adjustments at the scheduled study follow up visits and the remote visits between these in-person visits. In addition, study staff will provide recommendations regarding hypoglycemic warning symptoms, causes, and appropriateness of treatment.
45368594|NCT00562484|Biological|CSL Limited Influenza Vaccine|A single 0.5 mL, intramuscular Injection in the deltoid region of the arm on day 0.
45368595|NCT00562484|Biological|Placebo|Placebo
45368596|NCT00944762|Behavioral|Ecosystem Focused Therapy (EFT)|12 therapist-led sessions over 25 weeks, in which a participant will learn problem-solving skills, the participant's physical environment will be modified, and the family or caregiver will facilitate the participant's adaptation. Active participation in treatment and rehabilitation for stroke will also be targeted by EFT's problem-solving approach, creating synergy among treatments.
45368597|NCT00944762|Behavioral|Education in stroke and depression|Information and resources on living with stroke and depression will be provided in 12 sessions over 25 weeks.
46052233|NCT02816463|Device|Ambu AuraGain|
45368598|NCT04012892|Combination Product|CD19 CART|CD19 CART
45368599|NCT03070301|Drug|LEE011|LEE011 200 mg daily
45368600|NCT03070301|Drug|everolimus|everolimus 5 mg daily or 2.5mg daily
45368601|NCT00940862|Biological|adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)
46052234|NCT02816463|Device|LMA Supreme|
46052235|NCT02818101|Behavioral|Hypnosis session|
46052236|NCT02816619|Behavioral|Personalized Physical Activity coaching program|
45485855|NCT03208738|Behavioral|web-based drinking assessment and feedback tool (AFT)|Program will administer a comprehensive assessment of drinking and consequences of drinking, and will provide normative feedback and highlight negative consequences of drinking.
45485856|NCT03751241|Device|EyeTracker|The EyeTracker is used to determine reading quality of patients with different intraocular lens types (EROV, monofocal, minimonovision)
45485857|NCT03206008|Drug|Magnesium Sulfate|
45485858|NCT03206008|Drug|Normal saline|Placebo
46052237|NCT02816619|Behavioral|Free practice of physical activity|
46052238|NCT00772447|Drug|Daptomycin|4mg/kg IV ; Q 24 hr (once every 24 hours)
46052239|NCT00772447|Drug|Vancomycin|"Vancomycin - 1g per 12 hrs, for 7-14 days~Or switch to~Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin:~- 1 g every 6 hours or 2 g every 8 hours"
46052240|NCT00765037|Device|Encore Reverse Shoulder Prosthesis|rotator cuff deficiency and glenohumeral arthritis
45368602|NCT00940862|Device|UVB Phototherapy|This intervention can be applied alone or in combination with topical treatment. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening.
45368603|NCT00940862|Other|Topical treatment|"This intervention can be applied alone or in combination with UVB phototherapy. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening. The investigator will prescribe to patients randomized in this arm a select topical product from the list:~Calcipotriol, Calcipotriene, Dovonex, Tazorac, Tazarotene Anthralin, Corticosteroids."
45368604|NCT03068741|Drug|Comparison 1: Prehospital Ceftriaxone|Paramedics will administer 1g of intramuscular ceftriaxone.
45368605|NCT03068741|Drug|Comparison 1: Placebo|Paramedics will administer an identical volume of reconstituted intramuscular placebo.
45485859|NCT04978259|Drug|Remdesivir|Intravenous remdesivir during hospital stay up to 10 days in addition to standard care.
45485860|NCT03201874|Behavioral|Pain self-management|The program is designed to enhance self-efficacy. The app will guide youth in setting structured and personalized goals aimed at improving their pain and functioning. The pain self-management skills will include personalized CBT-based coping skills including deep breathing, relaxation, and cognitive skills (e.g., staying positive). The app will provide in-the-moment access to pain coping strategies to promote positive changes in mood, behavior, and pain.
45485861|NCT03201874|Behavioral|Education|Education about sickle cell disease to increase disease knowledge
45485862|NCT03747185|Other|Lumbopelvic stiffening technique|"Participants will stretch the hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense the back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
45485863|NCT03747185|Other|Lumbopelvic relaxing technique|"Participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax the back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
46052241|NCT02817867|Device|tDCS|Transcranial direct current stimulation (tDCS)
46052242|NCT02817867|Device|TMS|Transcranial magnetic stimulation
45368606|NCT03068741|Drug|Comparison 2: Liberal fluids|Paramedics will administer up to 2 litres of intravenous saline (0.9%) to all patients regardless of systolic blood pressure, and reassessing this infusion after each 250ml are infused.
45485864|NCT03208582|Drug|Risedronate Sodium|Participants will be initially tested on the response to mechanical stimulation as a baseline and then tested again after 6 weeks treatment with Risedronate
46052243|NCT02817867|Device|tDCS + TMS|Association between tDCS and TMS.
46052244|NCT04238169|Drug|Bevacizumab|7.5mg/kg once every three weeks
46052245|NCT04238169|Drug|Toripalimab|240 mg once every three weeks
46052246|NCT04238169|Radiation|SBRT|30-50Gy/5F（2-4 lesions）
46052247|NCT04687371|Other|Proprioceptive vestibular exercise|To assess effects of proprioceptive vestibular exercises training in patients with peripheral vestibular hypofunctions
45485865|NCT03208582|Dietary Supplement|Calcichew tablets|Participants will take calcichew tablets during the 6 week period of risedronate treatment
45485866|NCT03205930|Biological|Neo-MASCT|The end product of Neo - MASCT technology is DC and CTL cells.DC injection,in each treatment cycle day 8, axillary, inguinal lymph node with subcutaneous injection. CTL cells， in every treatment cycle 21-28 days.
45485867|NCT04308239|Behavioral|Reactive balance training|Participants were exposed to simulated trips and slips under safe, controlled conditions in order to practice their reactive response to these common balance perturbations.
45485868|NCT04308239|Behavioral|Otago Balance Training|Balance exercises and strength exercises using ankle weights, and were progressively increased as performance improved by increasing ankle weights or the difficulty of the balance exercises (e.g., not holding onto a wall or support).
45485869|NCT03201328|Other|Audio-vestibular examination|Vestibular tests (videonystagmoscopy and head video impulse test), the tonal and vocal audiogram and the localigramme to the cochlear implanted subjects. Tonal audiometry and localigramme to the healthy subjects.
45485870|NCT03201328|Other|Videonystagmoscopic study|Rotating sound stimulation on a rotatory armchair and a laborer of Fukuda with sound stimulation and questionary before and after examination.
45485871|NCT03201328|Other|Posturographies study|(stabilometry, sensory preferences, indications of energy consumption) with stereophonic stimulation and questionnaire before and after the examination.
46052248|NCT04687371|Other|Standard vestibular rehabilitation exercises|To assess effects of standard vestibular rehabilitation exercises in patients with peripheral vestibular hypofunctions
45368607|NCT03068741|Drug|Comparison 2: Conservative fluids|Paramedics will administer intravenous saline (0.9%) according to the Medical Directive, which allows for infusion of fluids if systolic blood pressure is <90mmHg and continued until systolic blood pressure is >=100mmHg.
45368608|NCT04012580|Behavioral|Therapist-assisted ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students will provide support by email once a week.
45368609|NCT03937661|Biological|PRP|Autologous PRP intra ovarian infusion
45368610|NCT03937661|Biological|Placebo|Autologous PFP intra ovarian infusion
45368611|NCT04012502|Other|Toxicities reduced treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
45368612|NCT04012502|Other|conventional treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
45485872|NCT03205774|Behavioral|6 hours fasting and free oral intake of water|Ultrasound examination of the gastric antrum are performed in volunteers after prolonged fasting and 10 min after oral intake of water. Volunteer should be lying on his/her back, right lateral decubitus position and left lateral decubitus position with randomization of the order.
45485873|NCT03201172|Device|Primary Unicompartmental Knee Arthroplasty|Primary implantation of an unicompartmental knee implant
45485874|NCT03208114|Other|Receiving written information on breast milk substitute|Receiving written information on breast milk substitute
45485875|NCT04302545|Procedure|Cystoinflation|Bladder retrofill with 300cc saline to distend the bladder to recognize bladder outline
45485876|NCT04484896|Other|Gain-framed SMS message|Emergency recruitment cell phone short messages that emphasizing donating blood can save patients' lives were sent to donors in this group.
45485877|NCT04484896|Other|Loss-framed SMS message|Emergency recruitment cell phone short messages emphasizing that donating blood can prevent patients from death were sent to donors in this group.
46052249|NCT04687371|Other|Controlled|First and last measurement will be taken. There will be no intervention. study will include 9 patients.
46052250|NCT04200573|Drug|Ampreloxetine|The study drug will be administered orally as a single Dose A tablet
46052251|NCT00831844|Biological|cixutumumab|Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.
46052252|NCT00831844|Other|laboratory biomarker analysis|Correlative studies
46052253|NCT02816073|Device|Pan-retinal photocoagulation using pattern scanning laser|Patients receive the designated number of laser shots of pan-retinal photocoagulation with pattern scanning laser in a single session
46052254|NCT02816229|Device|Insertion of endobronchial valve|One or more endobronchial one- way valves will be inserted into the appropriate lung regions
45485878|NCT04484896|Other|Information SMS message|Emergency recruitment cell phone short messages that only mentioning the low Rh-negative blood stockpile were sent to donors in this group.
45485879|NCT03205852|Other|questionnaire|fulfillment of questionnaire
45485880|NCT03200938|Device|formocresol and zinc oxide.|Removal of the coronary pulp from primary molar teeth, use of formocresol and zinc oxide
45485881|NCT03200938|Device|PBS CIMMO cement.|Removal of the coronary pulp from primary molar teeth, use of PBS cement
45485882|NCT04297241|Drug|Isosorbide Dinitrate|All patients will be given a 6 week titration regimen of study medication. Patients will begin at a 5mg dosage and titrate up to 30mg three times per day if each subsequent dose is tolerated.
45485883|NCT03205618|Other|Non-Interventional|Non-Interventional
45485884|NCT03749525|Drug|shenfu injection|we hypothesis that shenfu injection could improve patients' arterial vascular reactivity with septic shock
45485885|NCT03201016|Diagnostic Test|Bone densitometry|Procollagen Type I Propeptides, alkaline phosphatase, Crosslinked Telopeptides of Type I Collagen
45485886|NCT04578665|Behavioral|Behavioral Interaction Conditions|The participants will be single-blinded and complete a tracking task as either: solo task, collaboration task (both participants work on a common task synchronously to achieve a goal; this is a summative effort to achieve the goal), competition task (each participant has to achieve a goal at the expense of his or her partner, therefore maximizing effort or error of the partner in reaching the goal), or cooperation task (an asymmetric partnership with an active partner and a passive partner working towards a goal).
45485887|NCT04578665|Device|Haptic Impedance Level|The subjects will complete their task at 3 impedance levels: high (a virtual stiffness 160-200 N/m and damping 0~10 Nm/s; this will be a stiff connection in which the subjects feel like they are connected via rigid links and each subject will perceive the other partner's movement directly), medium (a virtual stiffness 100-140 N/m and damping 0~10 Nm/s; this will be a spring like-connection in which the subjects feel like they are connected with a spring and each subject will perceive the other partner with a force that is proportional to the trajectory difference of the two participants), and soft (a virtual stiffness 40-80 N/m and damping 0~10 Nm/s; this will be a spring like connection in which the subjects feel like they are connected with a loose spring and each subject will perceive the other partner with a force that is proportional to the trajectory difference of the two subjects, however, this force will be smaller than that of the medium impedance).
45596611|NCT02364531|Other|Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry|Participants will not receive any intervention in this study. The chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who, on failing conventional androgen deprivation therapy (ADT), are prescribed to initiate Abiraterone Acetate (ZYTIGA) therapy as part of their physician's treatment approach for their asymptomatic or mildly symptomatic disease, will be observed in this study. Participants will receive standard of care therapy.
45691661|NCT02139358|Drug|Gemcitabine|The Phase I trial will start at the recommended phase II dose (RP2D) for gemcitabine but will have a de-escalation dose levels in the event that an unacceptable toxicity requires dose reduction. Dose level 0 = gemcitabine (1200 mg/m2) IV D1,8 q21 days; Dose level -1 = gemcitabine (1000 mg/m^2) IV D1,8 q21 days; Dose level -2 = gemcitabine (850 mg/m^2) IV D1,8 q21 days. The RP2D will be the dose level where 0-1 dose limiting toxicities (DLTs) in six patients occur.
45691662|NCT02139358|Drug|Trastuzumab|Trastuzumab will be given using an 8 mg/kg loading dose on cycle one, day one (C1D1), followed by 6 mg/kg IV on subsequent cycles every (q) 21 days.
45691663|NCT02139358|Drug|Pertuzumab|Pertuzumab will be given using an 840 mg IV loading dose on C1D1, followed by 420 mg IV on subsequent cycles q 21 days.
46052255|NCT00764881|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated SH T00658ID for 28 days per cycle, for 6 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo, encapsulated for blinding purpose
46052256|NCT00764881|Drug|Microgynon|Days 1 to 21: daily oral administration of one encapsulated Microgynon tablet; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Six 28-day treatment cycles.
46052257|NCT00764881|Drug|Placebo|Days 22 to 28: daily oral administration of one encapsulated placebo tablet. Six 28-day treatment cycles.
46052258|NCT02816385|Procedure|Antegrade cardioplegia|Injection of the cardioplegia in the coronary arteries
46052259|NCT02816385|Procedure|Retrograde cardioplegia|Injection of the cardioplegia in the venous system
45368613|NCT04062149|Other|single leg stance treatment|SLS treatment following the neurodevelopmental treatment (NDT). SLS is the ability of one limb to support the body's weight in a standing position. In gait it is the foot being in contact with the ground whilst the body passes over it and this stance phase of gait accounts for 60% of the gait cycle. The treatment approach of NDT has been chosen as this is the most common physiotherapy treatment option in the UK and is the most common option in the studies above. NDT is a problem-solving approach to the assessment and treatment of individuals with disturbances of function, movement and postural control due to a lesion of the central nervous system and provides an outline of the treatment required to achieve SLS which will form the basis of the intervention of this study.
45368614|NCT04062149|Other|Usual physiotherapy|Individualised physiotherapy treatment approach, as per standard protocol, but it will not work specifically on SLS. Will be based on the neuro-developmental technique.
46052260|NCT04044196|Procedure|Rotator cuff repair|Rotator cuff repair performed arthroscopically
46052261|NCT02819193|Other|raw mother's own milk|Infants receive mother's own milk before day 7.
45485888|NCT04578665|Behavioral|Skill Level of Partner|There will be two skill levels: novice (a participant who has no prior experience with the trajectory tracking experiment; in testing with the clinical populations, the investigators will assign this condition to the clinical participant) and expert (a participant who is experienced with the trajectory tracking experiment and who can achieve a tracking error [difference of the desired trajectory and actual trajectory] below a certain threshold; in testing with the clinical population, the investigators will assign this condition to the therapist). Participants will start experimentation paired as novice-novice, and at the end of the session may be invited to continue additional sessions to be paired as the expert in a novice-expert dyad.
45485889|NCT04578665|Device|Robot Controller Showcase|The subjects will complete 10 training sessions per assistive robot for the researchers to observe motor learning and functional outcomes.
45485890|NCT03205540|Procedure|Continuous epidural block|Continuous epidural block at level L2-3 or L3-4 with 0.0625% bupivacaine + fentanyl 2 mcg/ml infusion epidurally 5 ml/hr for 48 hours postoperatively.
45485891|NCT03205540|Procedure|Bilateral single-shot bilateral adductor canal blocks|Bilateral single-shot adductor canal blocks, ultrasound guidance, with 0.33% bupivacaine 15 ml on each side.
45691664|NCT02140372|Drug|Colchicine|Colchicine 1.2 mg followed by 0.6 mg one hour later
45691665|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.125 mg/kg/h followed by 1 hour at 0.0625 mg/kg/h
45846359|NCT02538042|Drug|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d if smoking ≥10 cigs/d or 14 mg/d if smoking <10 cigs/d) to wear for 3 weeks prior to the quit date. After the quit date, both groups will wear the nicotine patch for 10 weeks. Participants that smoked ≥10 cigs/d will wear a 21 mg/d patch for 6 weeks, a 14 mg/d patch for 2 weeks, and a 7 mg/d patch for 2 weeks. Participants that smoked <10 cigs/d will wear a 14 mg/d patch for 6 weeks, then step down to a 7 mg/d patch for 4 weeks.
45846360|NCT02538042|Drug|SPECTRUM Nicotine Research Cigarettes (0.07 mg)|For 3 weeks prior to their quit day, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
45691666|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h
45691667|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h
45691668|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.75 mg/kg/h followed by 1 hour at 0.375 mg/kg/h
45846361|NCT02538042|Behavioral|MCE+|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes.
45368615|NCT02565563|Other|Eye Movement Desensitisation Reprocessing|The purpose of this study is not to assess the device itself. The new device will seek to measure heart rate variabilty during the administration of the treatment EMDR. It will measure the patients sympathetic nervous systems (anxiety arousal). Previous reseach studies have used Electrocardiography (ECG) and the purpose of this study is to determine whether or not this device will obtain similar findings as ECG has done.
45368616|NCT02565563|Device|HeartMath measuring Heart Rate Variability (HRV)|This small device will be attached to the patients finger to allow their heart rate variability to be measured.
45368617|NCT00561080|Biological|Zostavax|
45691669|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h
45691670|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h followed by 22 hours at 0.025 mg/kg/h
45691671|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h followed by 22 hours at 0.05 mg/kg/h
45691672|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h followed by 22 hours at 0.1 mg/kg/h
45691673|NCT00624442|Drug|Placebo|IV infusion for 2 hours
45691674|NCT00624442|Drug|Placebo|IV infusion for 24 hours
45846362|NCT02538042|Behavioral|MCE-|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes.
45846363|NCT02538354|Dietary Supplement|Riboflavin supplementation|Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks
45846364|NCT02539992|Device|Triathlon® CR/Kinematic Alignment|Total knee replacement using patient-specific cutting guides
45846365|NCT02539992|Device|Triathlon® CR/Neutral Overall Limb Alignment|Total knee replacement using patient-specific cutting guides
45846366|NCT02539992|Device|Triathlon® CR/Conventional Limb Alignment|Total knee replacement using traditional instrumentation
45368618|NCT01307306|Drug|Humulin R|Humulin R (U-100) will be given i.v. The dose given will be adjusted in order to achieve a blood glucose level of 130-140 mg/dl.
45368619|NCT01307306|Drug|Metformin|Metformin 850 mg q. 8 hours will be given to decrease blood glucose to 130-140 mg/dl.
45691675|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
45846367|NCT02540226|Drug|Intravenous tranexamic acid|
45368620|NCT00941096|Drug|Bimatoprost and Bimatoprost/Timolol fixed combination.|Following an appropriate wash-out period, participants were given a 5-week long treatment with Bimatoprost 0.03% once daily in the evening followed by a further 5-week long treatment with the Bimatoprost 0.03%/Timolol 0.5% fixed combination administered in the evening.
45368621|NCT04012424|Drug|curcumin group:Curcumin is an ancient coloring spice . Interestingly, it has various pharmacological activities including analgesic, anti-inf|"effect of taking 400mg curcumin one hour before endodontic ttt on post endodontic pain immediatelly and after 8,12,24,48 hours after endodontic treatment.Curcumin is an ancient coloring spice of Asia which is powerful antioxidant , it has hepatoprotective effect and traditionally used for many remedies . Interestingly, it has various pharmacological activities including analgesic, anti-inflammatory , It is even reported to have antimicrobial effect .~Medical clinical trials reported on the analgesic effect of curcuminoids in reducing postsurgical pain osteoarthritis and rheumatoid arthritis .~other name : curcum, tumeric"
45368622|NCT04012424|Dietary Supplement|400mg starch|patints taking(400mg) starch in tabelts in same shape and color of control group before endodontic treatment by one hour and post endodontic pain immediately and after 8,12,24,48 hours after treatment completion
45368623|NCT00562094|Drug|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
45368624|NCT03817853|Drug|Obinutuzumab|Obinutuzumab 1000 mg IV infusion, administered on Day 1, 8 and 15 during Cycle 1, and on Day 1 of subsequent cycles, for 6-8 cycles. Each cycle is 21 or 28 days long depending on the chemotherapy regimen allocated. Maintenance obinutuzumab monotherapy in patients who achieve at least a partial response, after induction therapy will be administered a dose of 1000 mg once every 8 weeks for 2 years or until disease progression (whichever occurs first).
45485892|NCT02449876|Other|Neuroscience Education|"The following topics will be discussed in the education~Basic structure of the nervous system~Basic physiology of the nervous system~The function and importance of pain~Strategies to lessen the impact of pain~The instruction will be delivered in an interactive manner so that questions are addressed immediately. At the conclusion of the session each subject will receive the book: Why Do I Hurt by Adriaan Louw to reinforce the information discussed in the session. Subjects will be asked to read the 50 page book prior to the second session.~Session 2:~The session will begin with a review of the topics discussed in Session 1 and contained in the book. Subject will be encouraged to ask questions and get clarification on any of the topics that are unclear."
45485893|NCT04292171|Drug|Gabapentin|Preoperative treatment with Gabapentin
45691676|NCT00624442|Drug|Placebo|IV infusion for 72 hours
45691677|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.75 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
45691678|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 23 hours at 0.025 mg/kg/h
45691679|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 23 hours at 0.05 mg/kg/h
45691680|NCT00624442|Drug|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 23 hours at 0.1 mg/kg/h
45846368|NCT02540226|Drug|Topical tranexamic acid|
45846369|NCT02540226|Drug|Intravenous saline|
45846370|NCT02540226|Drug|Topical saline|
46052262|NCT00705328|Behavioral|Primary Health Care Model (PRMHLTH)|Primary health care service delivery
46052263|NCT00705328|Behavioral|Recreation Coordination Model (REC)|Recreation coordination service delivery
46052264|NCT00705328|Behavioral|Comprehensive Model (COMP)|a comprehensive service delivery model consisting of PRMHLTH plus REC.
46052265|NCT00922870|Device|Cascade|Cascade treatment over 48h
46052266|NCT00922870|Other|Standard treatment|Standard therapy
46052267|NCT00702676|Drug|Quetiapine Fumarate|Tablet, Oral, once daily
46052268|NCT00702676|Drug|Quetiapine Fumarate|Tablet, Oral, once daily
46052269|NCT04609215|Other|ALECSAT|"Patients will receive concurrent chemotherapy with carboplatin/gemcitabine with cycles repeated every 3 weeks.~During the loading phase, patients will receive ALECSAT at 28 days intervals at weeks 5, 9, and 13. Hereafter (the maintenance phase), ALECSAT will be administered every 12 weeks until disease progression, death, unacceptable toxicity, investigator/patient decision or EOT visit at 18 months."
46052270|NCT05384548|Behavioral|Problematic smart phone use course|A 6 session, online, group-based, psychological course targetting problematic smart phone use.
45368625|NCT03817853|Drug|Bendamustine|Bendamustine will be administered on Days 1 and 2 for Cycles 1-6 at a dose of 90 mg/m2/day, for six 28-day cycles.
45368626|NCT03817853|Drug|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m^2), administered intravenously (IV) on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
45368627|NCT03817853|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 IV, administered on Day 1 of each 21-day cycle, for six cycles.
45368628|NCT03817853|Drug|Prednisone/Prednisolone/Methylprednisolone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
45368629|NCT03817853|Drug|Vincristine|Vincristine 1.4 mg/m^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
45368630|NCT02565251|Device|Flotrac/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with Flotrac/Ev1000 device in the first two hours
45368631|NCT02565251|Device|Standard ICU monitorisation|Hemodynamic resusucitation guided by the data obtained from ICU standard hemodynamic monitoring (BP, CVP) in the first 2 hours
45368632|NCT02565251|Device|VolumeView/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with VolumeView/Ev1000 device in the next four hours
45368633|NCT02565095|Procedure|Stimulation of the carotid baroreceptors with a pressure system|In each decubitus, trains of stimuli 8 (-80, -60, -40, -20, 0, 10, 20 and 40 Torr), with a duration of 500 milliseconds each, will be applied using a positive and negative pressure system placed around the neck of the subject.
45368634|NCT02567045|Procedure|annual FIT and colonoscopy in case of a positive test|FIT and colonoscopy in case of a positive test. Annual interval (2 rounds), without diet restriction, 1 stool sample. Positive cut-off 10 mcg Hemoglobin/g feces.
45368635|NCT02567045|Procedure|colonoscopy with sedation|One-time Colonoscopy with sedation.
45368636|NCT00944840|Drug|SP plus amodiaquine|SP plus amodiaquine or placebo at monthly interval during September, October and November
45368637|NCT00944840|Drug|SP placebo plus amodiaquine placebo|monthly treatment with amodiaquine and SP or placebo during September, October and November
45368638|NCT00439270|Drug|Dasatinib|Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression
45368639|NCT00439270|Drug|Docetaxel|Infusion, 60 or 75 mg/m^2, administered every 3 weeks.
45368640|NCT00944918|Drug|fulvestrant|Intramuscular injection on days 1, 15, and 29 and then once monthly until disease progression.
45368641|NCT00944918|Drug|anastrozole|Tablet, oral, once daily until disease progression.
45368642|NCT00944918|Drug|exemestane|Tablet, oral, once daily until disease progression.
45691681|NCT00670462|Behavioral|Standard Behavioral Treatment (SBT)|SBT is state-of-the-art behavioral weight loss treatment, comprised of 6 months of weekly treatment meetings followed by 6 months of biweekly meetings and 6 months of monthly meetings. Topical coverage and behavioral assignments include typical combination of energy balance information and self-control skills training. MTT has the same number of treatment contacts, but the contacts are distributed in distinct 8-week segments, each of which have a unique topic and unique behavioral assignments. Between each segment, participants are left on their own for 4 weeks with instructions to continue regular weighing but otherwise to make their own choices about what to do for weight control.
45691682|NCT00670462|Behavioral|Maintenance-Tailored Treatment (MTT)|
46052271|NCT02817477|Drug|Ketamine Hydrochloride|Delivered intranasally using an atomizer
46052272|NCT02817477|Drug|Morphine|Delivered either as an IM injection or a slow IV bolus
45368643|NCT04012268|Device|RIC|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
45368644|NCT04012268|Drug|Aspirin|patients will accept medication guided by neurologists
45368645|NCT03995134|Combination Product|Propofol and Remifentanil administered by TCI pump|Propofol, Remifentanil, Alaris PK (pharmacokinetic) infusion pump with TCI
45368646|NCT00553280|Drug|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
45368647|NCT01024192|Drug|ZOLPIDEM SL800750|"Pharmaceutical form: Zopidem 12.5 mg tablets~Route of administration: Oral~Dose regimen:One tablet at bed time and as needed (the patients choose which night they take the tablet without limit of number of nights)"
45368648|NCT01024270|Drug|Misoprostol|
45368649|NCT00944996|Drug|SSRI; SNRI; TCA|Tablets or Pills, 1 or 2 per day, more than 2 month
45368650|NCT03266536|Behavioral|Western diet|Western diet for 7 days: the meals in this Western diet will be provided by the Clinical Research and Trials Unit (CRTU) after participants meet with the nutrition staff (to discuss food preferences, how to obtain the meals). The meals will reflect a typical Western diet: a low fiber, high sugar diet with weight maintenance calories with < 10 grams fiber per day, and a typical US macronutrient calorie distribution of 50% carbs, 35% fat and 15% protein, with no alcohol. At least 50% of carbohydrates will be provided as simple sugars.
46052273|NCT00844558|Other|Gait Training|Gait training with a physical therapist 2/week for the first 3 months followed by 1/week for the following 3 months
46052274|NCT00844558|Other|Control|There is no intervention associated with this arm of the study
46052275|NCT02819115|Biological|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Butantan Fragmented Inactivated Trivalent Influenza Vaccine
45485894|NCT04292171|Drug|Placebos|Preoperative treatment with Placebo
45485895|NCT03200782|Drug|Empagliflozin|Glucose lowering effect of empagliflozin for reducing the counter-regulatory glucose-lowering response
45368651|NCT00950066|Drug|IRBESARTAN (SR47436)|Oral administration of Irbesartan 150mg or 300mg once a day
45368652|NCT00950066|Drug|Amlodipine|Oral administration of Amlodipine 5mg once a day
45485896|NCT03200782|Drug|Anakinra|IL-1Beta blockage effect on insulin secretion and thereby influencing postprandial glucose level
45485897|NCT03200782|Other|oral placebo (winthrop tablet)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
45485898|NCT03200782|Other|subcutaneous placebo (0.67 ml of 0.9% sodium chloride)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) will be administered in arm 'Placebo-Placebo' and arm 'drug: Empagliflozin'
45485899|NCT02449954|Drug|Intravenous morphine sulphate|Group I:received IV 0.1mg/kg morphine sulphate.
45485900|NCT02449954|Drug|Intravenous tramadol HCL|Group II:received IV 2 mg/kg tramadol HCL.
45485901|NCT02449954|Drug|Intravenous ketorolac tromethamine|Group III: received IV 30 mg ketorolac tromethamine
45485902|NCT02448160|Device|alfapump|Implantation of alfapump
45485903|NCT02448160|Drug|salt-poor Human Albumin solution|Patients implanted with an alfapump will receive intermittent salt-poor human albumin solution
45485904|NCT04393493|Drug|Furosemide intravenous solution|Administrated as an 80 mg intravenous bolus every 24 hours in both arms and then as a continuous infusion dosed according to the experimental arm.
45691683|NCT00670774|Drug|Eculizumab|"Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery.~Patients will be given 900 mg of eculizumab on Day 1 post-transplant.~Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant~At week 4, patients will be assessed for B cell flow cytometry cross match (FCXM). Patients with B cell FCXM less than 200 will stop eculizumab treatment. Patients with B cell FCXM greater than or equal to 200 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly. Similar discontinuation assessments will be performed at week 9, 26, 39 and 52.~In addition, eculizumab 600 mg will be administered immediately after each plasmapheresis (PP) and immediately after any fresh frozen plasma (FFP) that is given post-transplant during the treatment period"
45691684|NCT00672100|Drug|Ropivacaine|Initial Bolus 5 ml Ropivacaine via interscalene injection
46052276|NCT02818959|Device|JenaValve Pericardial TAVR System|The JenaValve Pericardial TAVI system is intended for use in subjects with symptomatic severe aortic stenosis who are at high risk for surgical aortic valve replacement.
46052277|NCT04101175|Procedure|Evaluation of the procedure of abortion|Observational study using questionnaires
46052278|NCT02815839|Drug|SHR4640|
46052279|NCT02815839|Drug|Placebo|
46052280|NCT04099069|Procedure|anesthesia|patient was insert trachial intubation or rigid bronchoscopy with ventilation under general anesthesia
45368653|NCT00950066|Drug|Irbesartan / Amlodipine|Oral administration of Irbesartan 150 mg / Amlodipine 5mg or Irbesartan 300mg / Amlodipine 5mg once a day
45368654|NCT00950066|Drug|Placebo|Oral administration of a placebo once a day
45368655|NCT01031212|Drug|ASA404|Administered intravenously over 20 minutes weekly after chemotherapy
45368656|NCT01031212|Drug|Cetuximab|Administered at 400mg/m2 over 120 minutes on day -7 and then 250mg/m2 over 60 minutes weekly thereafter
45485905|NCT04393493|Drug|Chlortalidone|One 50 mg pill administrated every 24 hours in group B
45485906|NCT04393493|Drug|Spironolactone|One 50 mg pill administrated every 24 hours in group B
45485907|NCT02448238|Other|VSL#3® probiotic|"Other: VSL#3® probiotic VSL#3® DS (Sigma-Tau Pharmaceuticals) is a well characterized water soluble, live (9 × 1011 bacteria/sachet), lyophilized preparation of 8 probiotic bacterium that have been detailed previously. Subjects will take 1 sachet of powder orally daily for 12 weeks. As many Malian homes lack refrigeration, subjects will be issued a special canari, a commonly used earthenware water container also containing sand that works on the principal of trans-evaporation to keep contents at room temperature (~24°C) even in warmer climates. We have verified this in country. Probiotics will be placed in a sealed plastic bag within a sealed jar in the sand of the canari. At the research site, probiotics will be kept refrigerated (4-8°C) in a study provided refrigerator"
45485908|NCT02448082|Other|Shampoo (inactive)|Shampoo which is made to look and feel the same as the experimental shampoo but does not contain the active ingredient of sodium shale oil sulponate 1%.
45485909|NCT02448082|Other|Sodium shale oil sulponate 1% shampoo|Shampoo containing the active ingredient of sodium shale oil sulponate 1%.
45368657|NCT01031212|Drug|Carboplatin|Administered at fixed dose of AUC 6 intravenously on day 1 of each 3-week cycle
45368658|NCT01031212|Drug|Paclitaxel|Administered over 3 hours at a fixed dose of 175mg/m2 intravenously on day 1 of each 3-week cycle
45368659|NCT00950144|Other|medical chart review|
45485910|NCT03205228|Drug|Omeprazole|A capsule of Omeprazole 20 mg & 1 capsule of placebo will be given in individual subject, once daily for 4 weeks. Both drugs will be presented in the same appearance (white capsule).
46052281|NCT00709072|Behavioral|SMS (Short Message Service) reminders|SMS reminders sent every 2 weeks
46052282|NCT04097197|Behavioral|Brief educational intervention|same as before
46052283|NCT00821236|Device|Excimer Laser|WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment
45485911|NCT03205228|Behavioral|psychoeducation|Psychoeducation will be given by psychologists at the Day 1 and Day 15 of the study period.One white capsule of placebo will be given once daily for 4 weeks of the study period.
45368660|NCT00950144|Other|questionnaire administration|
45485912|NCT03205228|Drug|Flupentixol +Melitracen|A capsule containing of a tablet of melitracen 10 mg + flupentixol 0.5 mg & a capsule of placebo will be given once daily, for 4 weeks. Both would be presented in the same appearance (white capsule)
45485913|NCT04568681|Device|Deep brain stimulation (DBS)|Deep brain stimulation is an FDA approved therapy that involves surgical implantation of electrodes in deep brain targets and an implantable pulse generator delivers electrical pulses.
45485914|NCT03195946|Drug|Lu AF35700|tablets for oral use, 10 mg/day
45485915|NCT03195946|Drug|Midazolam|syrup for oral use, 4mg/day
45485916|NCT03195946|Drug|Cocktail of CYP450 substrates|Caffeine tablets for oral use, 200 mg/day. Omeprazole tablets for oral use, 40 mg/day. Dextromethorphan tablets for oral use, 30 mg/day. Midazolam IV solution for Intravenous use, 0.025 mg/kg/day
46052284|NCT00821236|Device|AMO/VISX CustomVue™|Excimer Laser
46052285|NCT00821236|Device|LADARVision 4000 excimer laser|Excimer Laser
45691685|NCT00672100|Drug|Ropivacaine|Initial Bolus 10 ml Ropivacaine via interscalene injection
45691686|NCT00672100|Drug|Ropivacaine|Initial Bolus 20 ml Ropivacaine via interscalene injection
46052286|NCT02816151|Drug|full dose at 16 UI/kg for Dysport or 6,5 UA/kg for Botox|Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
45368661|NCT00950144|Other|study of socioeconomic and demographic variables|
45368662|NCT00950144|Procedure|quality-of-life assessment|
45368663|NCT01024348|Drug|extended-release tramadol|30 minutes prior vto surgery and 24 hours afterwards, patients will take a tablet of 100 mg TRAMADEX-OD
45368664|NCT01024348|Drug|paracetamol|in the control group, postoperative pain will managed with 1 gr paracetamol (per os) as needed (up to 4 times a day)
45368665|NCT00945074|Other|Standard Acupuncture/Moxibustion (fixed protocol)|Acupuncture/Moxibustion
45368666|NCT00945074|Other|Individualized Acupuncture/Moxibustion|Individualized Tailored Acupuncture/Moxibustion Protocol based on TCM Diagnosis
45368667|NCT00945074|Other|Sham/Placebo Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion Protocol: Not-Active
45368668|NCT03994744|Drug|PD-1 inhibitor|Intravenous administration of Sintilimab (1200mg/3weeks)
45368669|NCT03994744|Drug|Metformin|"Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).~To reduce GI toxicity, participants start Metformin at 1000 mg daily (500mg am, 500 mg pm) for 1 week."
45368670|NCT00950222|Drug|Imipenem/Amikacin|patients will received as empirical therapy for VAP imipenem associated with amikacin.
45368671|NCT01031290|Device|Repetitive Transcranial Magnetic Stimulation|daily sessions for 5 days
45485917|NCT03205462|Drug|Fluorothyazinone 300 mg|Fluorothyazinone in a dosage of 300 mg (1 tablet)
45485918|NCT03205462|Drug|Fluorothyazinone 600 mg|Fluorothyazinone in a dosage of 600 mg (2 tablets) is received per os (oral administration) as a single dose
45691687|NCT00593866|Radiation|INTENSITY MODULATED RADIOTHERAPY|Five fractions weekly, fraction size determined by dose level
45691688|NCT00593866|Drug|Gemcitabine|1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment
46052287|NCT02816151|Drug|half dose at 8 UI/kg for Dysport or 3,25 UA/kg for Botox|Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
46052288|NCT00756457|Device|Bracing|Participants will wear a brace that includes ankle stirrup support and medial longitudinal arch support. The brace will be worn during weight-bearing tasks throughout the 12-week study.
45485919|NCT03205462|Drug|Fluorothyazinone 3900 mg|The total dose of Fluorothyazinone per treatment course is 3900 mg.
45485920|NCT02448004|Drug|JNJ-63623872|Participants will receive a single 600-mg dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
45485921|NCT02450422|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
45485922|NCT02450422|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
45485923|NCT03747029|Other|No intervention is provided|No intervention is provided
46052289|NCT00756457|Other|Strengthening exercises|"Participants performed strengthening exercises progressively longer each time for up to 3 sets of 30 repetitions twice daily by the third visit. Exercises included bilateral heel raises, foot adduction/rear foot inversion with thera-tubing, and unilateral heel raises. Participants increased resistance by using thera-bands with higher levels of resistance over the 12 week period. The amount of resistance was progressed according to patient tolerance at each visit. Strengthening exercises were preceded by the control stretching exercises which constituted a warm up."
45368672|NCT05301530|Drug|Faceptor|NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
45368673|NCT05301530|Drug|Herceptin|Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.
45368674|NCT05301530|Drug|Docetaxel|The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.
45368675|NCT03228160|Other|Linearly Polarized Near-Infrared light Irradiation|The SGI was carried out with the use of a linear-polarized near-infrared irradiation device, Minato Alphabeam Infrared Ray Therapy Unit (Minato Medical Science Co., Ltd., Hyogo, Japan), by a senior physical therapist. The maximum output was 3000 mW/cm² at wavelengths of 0.7 to 1.6 m-⁶, including a combination of red and near-infrared radiation. All patients in the experimental group received SGI under the conditions as follows: output, 90%; irradiation circle 1:2 (irradiation 3 seconds followed by 7-seconds pause); duration of irradiation, 10 min; and total irradiation energy density, 194.8 J/cm². The instrument in the control group with shame irradiation was the same as that in the experimental group with the exception that emitted radiation from device was inactive.
45485924|NCT02447770|Dietary Supplement|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 500 mg of cocoa flavanols per capsule: 1000 mg of cocoa flavanols consumed daily during week 1 and 2, 1500 mg of cocoa flavanols consumed daily during week 3 and 4, and 2000 mg of cocoa flavanols consumed daily during week 5 and 6, and no capsule consumed (washout) during week 7 and 8.
45485925|NCT03118882|Behavioral|Diet group|A meeting where an expert illustrates the scientific basis of a proper diet. Moreover, clear and practical indications for dietary habits improvement and for suggested food purchase are provided. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module:hree theoretical and practical cooking meetings (total of 10 hours) held by cooks with an expertise in natural cuisine and by trained dieticians.
45485926|NCT03118882|Behavioral|Physical activity group|A meeting where an expert illustrates the benefits of a constant PA. Moreover, indications are given on sport opportunities and walking groups in the city organised by public authorities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: three theoretical and practical lessons (total of 10 hours) held by expert physical trainers.
45691689|NCT00624910|Drug|Bupivacaine Collagen Sponge (CollaRx®)|The bupivacaine sponge contains 70 mg Type I collagen and 50 mg bupivacaine hydrochloride. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
45691690|NCT00624910|Drug|placebo|The placebo sponge contains 70 mg Type I collagen. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
45691691|NCT00594022|Device|"Electric stimulation of the Vestibular Nerve - VirtuSom"|This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. A small electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes.
46052290|NCT00756457|Other|Stretching exercises|Subjects were provided with written descriptions and pictures demonstrating 2 range-of-motion exercises which included a wall calf stretch, and a supine ankle active range-of-motion exercise. Subjects were instructed to perform 3 sets of the stretching exercises, 2 times a day, similar to the intervention group. Each stretching exercise was performed twice and held for 30 seconds.
46052291|NCT02814123|Other|24-hour inpatient intervention|Subjects will be admitted at the research facility at 7:30. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. Each 24-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (21:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The insulin and pramlintide pumps' infusion rates will then be changed manually based on the computer generated recommendation, while still maintaining the ratio. The computer generated recommendations are based on a predictive algorithm.
45368676|NCT00941174|Drug|13C5-Calcium-L-Leucovorin|This drug will be used in a clinical trial the objective of which is to determine whether, and to what extent, a physiological concentration of natural folate is absorbed across the large intestine with an intact microflora.
45485927|NCT03118882|Behavioral|Physical activity and diet group|A meeting where the indications given to the previous groups are presented simultaneously. Particular attention is paid to the interaction between the two activities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: four theoretical and practical meetings (total of 12 hours), two lessons focus on diet and two on PA.
46052292|NCT00709150|Behavioral|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are socio-culturally adaptated for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
45368677|NCT00950456|Biological|H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)|It is anticipated that subjects will receive two intramuscular injections approximately 3 weeks apart. The vaccine will be provided in two doses, one for adults, the other for children.
45368678|NCT00440518|Drug|Lacosamide|Lacosamide 100mg immediate-release film-coated tablet (white,oval) oral administration twice daily 12 hours apart
45368679|NCT00440518|Other|Placebo|Immediate-release film coated tablet (white, oval), oral administration twice daily 12 hours apart
45368680|NCT00440518|Drug|Lacosamide|Lacosamide 300mg, immediate-release film coated tablet (white,oval), oral administration twice daily 12 hours apart.
45368681|NCT00945230|Procedure|Re-section of a large left anterior cranial fossa meningioma|Neurosurgical re-section of an incidental large left anterior cranial fossa meningioma
45368682|NCT00950534|Drug|INSULIN GLARGINE (HOE901)|The dose of insulin glargine will be titrated toward a fasting plasma glucose (FPG) target of 5.5 mmol/L. Treatment with oral antidiabetic drugs (OADs) prescribed before study entry may continue (except Sitagliptin, Acarbose, Rosiglitazone)
45368683|NCT00950534|Drug|Oral Anti Diabetics (OAD)|Patients treated with the usual standard of care (OAD dose titration, addition of a second or third OAD or referral to an endocrinologist) until optimal doses are reached to maintain a FPG of 5.5 mmol/L
45368684|NCT01029964|Behavioral|Individually and in groups|During three year in a clinical setting.
45368685|NCT00941252|Drug|Topical imiquimod therapy|therapy consists of treatment with topical vaginal suppositories for 16 weeks, each vaginal suppository contains 6.25mg of imiquimod, frequency (one time a week in treatment week 1+2, two times a week in treatment week 3+4, three times a week in treatment week 5-16)
45368686|NCT01031368|Drug|cytarabine|Given IV
45368687|NCT01031368|Drug|clofarabine|Given IV
45368688|NCT01031368|Drug|filgrastim|Given SC
46052293|NCT00709150|Behavioral|Enhanced usual care|Participants will receive educational pamphlets on depression and a list of mental health resources in the community. Participants' primary care doctors will be free to prescribe antidepressant medication or provide other usual care.
45368689|NCT01031368|Biological|Ex-vivo expanded cord blood progenitor cell infusion|Undergo ex vivo-expanded cord blood progenitor cell infusion
45368690|NCT01031368|Other|laboratory biomarker analysis|Correlative studies
45368691|NCT00945308|Drug|Eptifibatide|Intracoronary injection of Eptifibatide injected in two consecutive bolus of 180 mcg/kg each, followed immediately by continuous infusion of 2 mcg/kg/min for 12 hs.
45368692|NCT00945308|Drug|Eptifibatide|Intravenous injection of Eptifibatide in two consecutive boluses of 180 mcg/kg followed by continuous intravenous injection dosing 2 mcg/kg/min for 12 hours
45368693|NCT00950768|Procedure|Autologous transplantation|Tandem autologous transplantation Melphalan 100 mg/m2 versus Melphalan 200 mg/m2
45368694|NCT03172936|Drug|MIW815|MIW 815 (ADU-S100) is a STING agonist
45368695|NCT03172936|Biological|PDR001|PDR001 is an anti-PD-1 antibody
45368696|NCT00950924|Device|Simultaneous Vision Bifocal Soft Contact Lenses|Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
45485928|NCT03205384|Procedure|surgery|
45485929|NCT03204994|Drug|Indocyanine Green|Fluorescence guided lymphatic mapping using indocyanine green.
45368697|NCT00950924|Device|Single Vision Soft Contact Lenses|Single vision soft contact lenses will be prescribed to properly correct the distance vision as measured by manifest subjective refraction.
45485930|NCT03118648|Diagnostic Test|Scale Action Research Arm Test (ARAT)|Measuring the functional recovery of the paretic upper limb rehabilitation outing with the scale ARAT
45485931|NCT03204760|Drug|Dexamethasone 8Mg Solution for Injection|Effect single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg) in the treatment of mild to moderate acute asthma exacerbations in children
45485932|NCT03204760|Drug|Prednisolone Oral, Per 5 Mg|Effect of prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses in the treatment of mild to moderate acute asthma exacerbations in children.
45485933|NCT03200470|Other|No intervention: sample collection study|Sample collection and collection of laboratory values
45485934|NCT03200392|Device|laser root surface conditioning & laser DGG harvesting|laser root surface bio-modification (single application) and placement of harvested de-epithelialized gingival graft (DGG) followed by coronal repositioned flap for gingival recession Miller's I, II defect coverage
45485935|NCT03200392|Device|laser root surface conditioning & blade DGG harvesting|laser root surface bio-modification (single application) and scalpel blade harvesting of de-epithelialized palatal graft (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession Miller's I, II defect coverage
45485936|NCT03200392|Procedure|blade DGG harvesting|De-epithelialized palatal graft harvested using scalpel blade (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession defect coverage
46052294|NCT04101019|Drug|Lidocaine|Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of 5% lidocaine will be dripped into one or two nostrils.
46052295|NCT04101019|Drug|Saline Solution|Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of saline will be dripped into one or two nostrils.
46052296|NCT02817321|Procedure|single-injection TPVB + continuous TPVB|Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.
46052297|NCT02817321|Device|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning
46052298|NCT02817321|Device|PAJUNK Contiplex S Catheter|
46052299|NCT02817321|Drug|single dose ropivacaine|"2mg/kg ropivacaine in saline with 1:200,000 adrenaline, 25ml in total~given immediately after the correct position of the tip of the needle has been confirmed"
46052300|NCT02817321|Drug|continuously infusion of ropivacaine|"0.2% ropivacaine, pulse dosadge: 0.125ml/kg/pulse, 1pulse/h at a rate of 6ml/minutes~given through the catheter inserted in the T8 paravertebral space following the single dose"
45368698|NCT01024426|Procedure|Enhanced health facility-based care|The intervention is designed to address barriers to delivering quality care at health centers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs.
45368699|NCT01024426|Other|Standard care|In the clusters randomized to standard care, standard care will include services typically provided by government-run facilities; we will not provide any additional support to these facilities. Health care will be provided to patients attending these facilities according to the usual standards; in-charges will continue to manage the facilities using their standard approach, no additional training will be provided to the health workers stationed at these facilities; and no support for staffing or supplies will be provided beyond what is supplied by the district and MoH.
45368700|NCT00951002|Procedure|acellular dermal matrix plug|anal fistula treated with human acellular dermal matrix plug
45368701|NCT01030042|Drug|FOLFOX-4|Day 1: OXA will be administered as a 85 mg/m2 iv infusion over 2 hours; Leucovorin as a 100 mg/m2 infusion over 2 hours, 5-FU will be given as a 400 mg/m2 bolus injection, and then as a 600 mg/m2 continuous infusion over 22 hours after the first infusion Day 2: Leucovorin 100 mg/m2 (alone), followed by 5-FU 400 mg/m2 bolus injection, and 5-FU 600 mg/m2 continuous infusion after the first infusion Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest. Cycles are to be repeated every second week for a total of either 6 (12 weeks) or 12 cycles (24 weeks).
45485937|NCT03204838|Genetic|IDH mutation test performed at diagnosis|Observation of the test result
45485938|NCT03204682|Device|Repetitive transcranial magnetic stimulation|Realization of a brain and medullary MRI to allow neuronavigation. Realization of 5 sessions of rTMS in 5 days during the first week then evaluation (physical examination, questionnaires) in consultation on post-stimulation. Then followed for 28 days in total through self-assessment of pain that will be filled daily on REDCap and last consultation on D28 for further evaluation
45485939|NCT04484662|Other|Potted Mint Plants|We will measure 2 indoor environments (living room and bedroom) for placing potted plants.
45485940|NCT03195556|Device|Ultrasound|Ultrasound exposure of Definity microbubbles infused over 10 min. Ultrasound administered at 1.3 MHz, mechanical index of 1.3, and pulsing interval of 10 s.
45485941|NCT03204604|Dietary Supplement|Challenge A - low calorie Ensure®|Challenge A will include a low calorie Ensure shake for the participant to drink with no ketone esters (KE).
45485942|NCT03204604|Dietary Supplement|Challenge B - Ensure® plus ketone esters (KE)|Challenge B will include an Ensure shake for the participant to drink with deltaG ketone ester, which has generally recognized as safe (GRAS) supplement status .
46052301|NCT02817321|Drug|Morphine given as IPCA|bolus: 2mg, lock time: 10min, 1h limitation: 8mg
46052302|NCT00844480|Drug|zoledronic acid|zoledronic acid, 5mg, iv
46052303|NCT00844480|Drug|placebo|iv
45485943|NCT03204604|Procedure|PET Scan|Subject will drink the shake. Immediate recall memory testing. Subject will be placed in the scanner. Prior to PET acquisition, a low dose CT scan of the head will be obtained for attenuation correction. Patients will be injected with an intravenous bolus of up to 5-10mCi (370 MBq) (+/- 10%) of [11C]AcAc (over 2 minutes). This is the standard dose used in published clinical studies using [11C]AcAc. The PET acquisition will begin immediately after the tracer injection and last for a total of 30 minutes. 2 ml of blood will be sampled from the forearm vein at 3, 6, 8, 12, 20, and 28 minutes post [11C]AcAc tracer injection. This will be used for quantification of radiation estimates throughout the scan-period
45485944|NCT03204604|Behavioral|Cognitive Testing - FCSRT|The Free and Cued Selective Reminding Test (FCSRT) measures verbal memory through multiple trials of a list learning task. A list of 16 items is visually presented to the participants, who then recall as many items as possible. On subsequent trials, participants are told only those items they omitted on the previous trial. The procedure continues until the participant recalls all items on two subsequent trials. After approximately 30-minute delay, participants are asked to recall as many items as possible. The number of items recalled after the delay is then summed.
45485945|NCT03204604|Behavioral|Story Recall|Story Recall: This test is a modification of the episodic memory measure from the Wechsler Memory Scale-Revised (WMS-R). In this modified version, free recall of one short story that consists of 44 bits of information will be elicited immediately after it is read aloud to the participant and again after a thirty-minute delay. The total bits of information from the story that are recalled immediately (maximum score = 44) and after the delay interval (maximum score = 44) are recorded. Six comparable versions of this task have been validated in prior studies with older adults.
45485946|NCT03204604|Behavioral|BVRT|Benton Visual Retention Test (BVRT): The BVRT is a multiple-choice visual recognition task. Participants view a visual pattern and are then asked to select the target from an array of four patterns, three of which are distractors. It assesses visuospatial working memory. This recognition format has the advantage assessing visual memory while eliminating the influence of visuomotor and manual dexterity difficulties.
45485947|NCT03204604|Behavioral|CogState One Card Learning|The One Card Learning Test involves a visual learning task sensitive to early-stage cognitive impairment. It is one of several computerized assessments developed by CogState that assess executive function and working memory.
45485948|NCT03204370|Drug|Elosulfase Alfa 1 MG/ML Intravenous Solution [VIMIZIM]|A subgroup of MPS4A patients will be treated by VIMIZIM drug, prescribed in usual care
45368702|NCT01030042|Drug|Irinotecan/Cetuximab|"CET 400 mg/m2 intravenously via infusion pump given over a 120 min time and weekly CET infusions at a maintenance dose of 250 mg/m2 given over a 60 min time.~IRI 180 mg/m2 iv infusion over 30-90 min. Cycle length is 2 weeks and it is to be repeated until disease progression."
45368703|NCT00941408|Procedure|Diagnostic tumor core biopsy|
45368704|NCT01024504|Drug|Oxaliplatin|Oxaliplatin at the dose of 85 mg/m2 over a 4 hour intravenous infusion at day 1 every 2 weeks for a maximum of 12 consecutive cycles
45485949|NCT03200158|Other|Endoscopy biopsy and blood|Medical operation
45485950|NCT03204448|Device|BioCLIA Ro60|BioCLIA Ro60 is a Chemiluminescent Immuno Assay (CLIA) as a fully automated testing process, reporting with arbitrary units, RU/mL
45485951|NCT03200080|Drug|Tozadenant|2, 4, 6 or 8 Tozadenant 60 mg tablets
45485952|NCT03200080|Drug|Placebo oral tablet|2, 4, 6 or 8 Tozadenant matching placebo tablets
45485953|NCT03200080|Drug|d-amphetamine|2 or 4 capsules, each containing 2 over-encapsulated d-amphetamine 5 mg tablets
45691692|NCT00594022|Device|"Electric stim of the Vestibular Nerve - VirtuSom - SHAM"|This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. For the Sham Group, NO electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes. This is a sham / placebo device only.
45691693|NCT00626626|Drug|Clofar, Cyclophos, Alemtuzumab|Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 500 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion.
46052304|NCT00771901|Drug|tauroursodeoxycholic acid|1750 mg/day for four weeks. Seven pills daily, 2 with breakfast, 2 with lunch, and 3 with dinner.
46052305|NCT00771901|Other|placebo|7 pills daily for 4 weeks
46052306|NCT00771901|Drug|sodium phenylbutyrate|20g/day for four weeks.
45485954|NCT03200080|Drug|Placebo oral capsule|2 or 4 capsules, each containing d-amphetamine matching over-encapsulated PLACEBO 200 mg lactose tablet
46052307|NCT05349682|Diagnostic Test|dynamic contrast enhanced MRI|An MRI study of the knee will be done to check the degree of osteoarthritis and blood flow to the affected knee. This scan will take about 1-2 hour(s).
45368705|NCT01024504|Drug|Capecitabine|Capecitabine at the dose of 1500 mg/m2 per os at days 1 to 7 every 2 weeks for a maximum of 12 consecutive cycles
45368706|NCT01024504|Drug|Bevacizumab|Bevacizumab at the dose of 5 mg/Kgr (intravenous infusion) at day 1, every 2 weeks for a maximum of 12 consecutive cycles
45485955|NCT03200236|Behavioral|Intensive Telephone Counseling (8 sessions) with nicotine replacement|Participants are provided up to 8 counseling sessions lasting approximately 20 minutes each and access to 8-weeks of free nicotine replacement patches. A counselor-initiated discussion of screening results will also be included throughout the counseling sessions.
45485956|NCT03200236|Behavioral|Usual Care: Telephone counseling (3 sessions) with nicotine replacement|Participants are provided up to 3 counseling sessions lasting approximately 20 minutes each and access to 2-weeks of free nicotine replacement patches.
45485957|NCT03200314|Other|Measurment of blood recirculation|Ultrasound based measurments of blood recirculating through the vvECMO circuit.
45485958|NCT03200002|Drug|Cyclophosphamide|Cyclophosphamide injection was administered in the dose of 0.5 to 1 gram per m2 of body surface area. The medicine, which is available in the strength of 1 gram in powder form, was first dissolved in 20 ml of normal saline. Only15 ml of this preparation was mixed in 100 ml of normal saline and was infused over a period of one hour. CYC was not given to those patients who had total leukocyte counts (TLC) less than 2500/mm3. Those patients were re-evaluated after one week and intravenous pulse CYC was reinstituted if the TLC exceeds 2500/mm3. Pulse CYC was administered every month for a total of six infusions.
45485959|NCT03200002|Drug|Mycophenolate Mofetil|Participants in the MMF group were administered tablet mycophenolate mofetil at a starting dose of 500 mg twice daily if the weight of the patient was less than 50 kilograms and 750 mg twice daily if the weight was more than 50 kilograms. After one month, the dose of MMF was increased to 750 mg twice daily. The clinical response was monitored in terms of reduction in serum creatinine and proteinuria. MMF dose was decreased or interrupted in patients experiencing an absolute neutrophil count <1300/mm3 at any study visit; MMF treatment was discontinued if a patient experienced an absolute neutrophil count <1000/mm3.
45485960|NCT03195166|Diagnostic Test|FloTrac sensor/Vigileo|blood pressure (systolic, diastolic and mean), stroke volume cardiac output ephedrine consumption after bupivacaine continuous spinal anesthesia
45485961|NCT02447536|Biological|BCG-Denmark 1331 (Statens Serum Institute)|See above
45485962|NCT02447536|Biological|BCG-Russia-I (Serum Institute of India)|See above
45485963|NCT03203980|Other|Triple antithrombotic therapy|patients who are prescribed double antiplatelets agents and oral anticoagulation (except VKA)
45485964|NCT02447380|Drug|AZD6094|AZD6094 600MG qd
45485965|NCT02447380|Drug|Docetaxel|Docetaxel 60 mg/m2
45485966|NCT02447224|Drug|1 gm IV ertapenem at enrollment|
45846371|NCT02540772|Behavioral|Neuropsychological treatment|Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
45368707|NCT00945464|Other|Blood/saliva samples, historic breast imaging|Subjects are required only to provide a blood or saliva sample, relevant personal and family history (if available), and 5 years of historic breast imaging reports.
45368708|NCT01030120|Drug|etanercept|etanercept 50mg BIW S.Q.
45368709|NCT01030120|Drug|placebo|placebo
45368710|NCT04012112|Device|thoracolumbar brace (Flexpine brace)|Patient's would wear the FLEXpine brace over 18 hours a day for the 6 month
45485967|NCT02447224|Drug|1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days|
45485968|NCT02447224|Procedure|Appendectomy|
45485969|NCT03199690|Drug|Dolutegravir|Antiviral (integrase inhibitor)
45368711|NCT01024582|Procedure|biopsy|before treatment a biopsy will be taken to confirm breast cancer type
45485970|NCT03199690|Drug|Rifampicin|Antibiotic
45485971|NCT03203902|Other|Psychoeducation and Therapeutic Touch|6-week, 1-hour psychoeducation group followed by 30-minute therapeutic touch
45485972|NCT03204058|Drug|Placebos|Oral prophylaxis followed by placement of placebo gel
45485973|NCT03204058|Drug|Rosuvastatin|Oral prophylaxis followed by placement of rosuvastatin gel
45485974|NCT03204058|Drug|Metformin|Oral prophylaxis followed by placement of metformin gel
45368712|NCT01024582|Procedure|fine-needle aspiration|at FNA tumor material will be collected and fresh frozen for micro-analyses; parafin embedded tissue will bestored for tissue-array analysis
45368713|NCT01024582|Radiation|accelerated partial breast irradiation|
45368714|NCT01024582|Radiation|image-guided radiation therapy|
45368715|NCT00941564|Other|Infant Formula milk based|Consume ad lib
45485975|NCT03199846|Other|Non-Interventional|Non-Interventional
45485976|NCT03203824|Dietary Supplement|dark chocolate|Participants will be provided Parliament dark chocolate (70% cocoa) from Redlands, CA. The Parliament chocolate is made with cacao and cane sugar. Each participant will be given half a piece (1.4 g) of dark chocolate to consume for this experiment over three minutes.
45485977|NCT03203824|Other|non dark chocolate|No dark chocolate will be given to this group during the procedures.
45485978|NCT03118414|Other|Physical Exercise|"Participants were trained by exercise program based on their initial muscle strength and balance condition.~They received a 30-minute exercise for 3sessions per week for 8 weeks in this study."
45485979|NCT03118414|Other|Virtual Reality|"Participants were trained with the guidance of VR system.The participants will be asked to choose 6 games from the list before each 30-minute session, and were asked to choose the games to include the upper limbs, lower limbs, and also for both strength and balance challenges instead of choosing the games that need to use only upper limbs or lower limbs, and only for strength or balance gain.~They received a 30-minute exercise for 3sessions per week for 8 weeks in this study."
45485980|NCT03118414|Other|Brain Exercise|Brain Exercise (BE) BE stimulates the executive function, planning, concentration, visual memory and eye-hand co-ordination of the participants throughout the training.For the brain exercise, participants needed to play cognitive stimulating games; Chinese Checker, Janga and Memory Matched pair game; in the sitting position. The participants needed to paly 10 minutes for each gamed and total duration of all 3 games was about 30 minutes in each session for 3sessions per week for 8 weeks in this study.
45485981|NCT03203746|Drug|Lycopene + SRP|
45368716|NCT00941564|Other|Infant formula milk based|consume ad lib
45368717|NCT00951158|Dietary Supplement|Conjugated Linoleic Acid|"This is a open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. The dose a participant receives is dependent upon the cohort to with the patient is assigned.~CLA will be given as oral soft gels, once daily, with pharmacokinetic sampling and biopsies (pretreatment and on day 15). Doses will be escalated by patient cohorts, using an accelerated titration design (single-patient cohorts) with expansion to conventional cohort sizes (3-6 patients) once either inhibition of S14 expression or clinical toxicity is observed. Subjects with stable or responsive disease and who tolerate treatment may continue on CLA until the time of disease progression."
45485982|NCT03203746|Procedure|SRP only|
45485983|NCT02447068|Device|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
45485984|NCT02447068|Device|Luma Light|NBUVB light
45485985|NCT02447068|Device|Occlusive Dressing|Off-the-shelf occlusive dressing
45485986|NCT02447146|Other|Resistance Training|The TG performed the RT program using weight machines. Before the training period, participants underwent three weeks with eight familiarization sessions to ensure proper technique execution. The protocol aimed to workout major muscle groups and involved the following exercises: chest press, knee extension, hamstrings curl, leg press, and seated row. Training sessions lasted approximately 50-60 minutes with 2 sets of 10-12 repetitions until fatigue.
45691694|NCT00626626|Drug|Clofar, Cyclophos,Alemtuzumab(Ph II)|Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 1000 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion (patients 4-9)
45691695|NCT00673114|Biological|haplo/cord transplant|T-cell depleted haplo-matched cells from related donor and unrelated umbilical cord blood
45846372|NCT02541864|Drug|Bismuth quadruple therapy|pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
45485987|NCT02447146|Other|Lectures on the disease|The control group attended an orientation program with lectures on health, quality of life and scientific update on disease.
45485988|NCT03199456|Device|Zip surgical skin closure device|Zip surgical skin closure device manufactured by ZipLine Medical, Inc. is a CE-marked, non-invasive, single use device that is designated to provide closure of the skin layer for lacerations or surgical incisions.
45485989|NCT03199456|Device|Standard of Care sutures|Standard of Care sutures according to the hospitals current clinical praxis.
45485990|NCT03203668|Radiation|18F-choline PET/CT|18F-choline PET/CT imaging (neck, mediastinum)
45485991|NCT02446678|Device|PillCam ESO2|Capsule endoscopy
45485992|NCT03203434|Diagnostic Test|Urinary volatile organic compound analysis|
45485993|NCT02446756|Other|acupuncture|
45485994|NCT02446756|Other|physiotherapy|
45691696|NCT00626782|Drug|Ranibizumab|Ranibizumab 0.5mg (0.05mL)one injection in sub-tenon's at the conclusion of glaucoma surgery
45691697|NCT00626782|Drug|Mitomycin (MMC)|Mitomycin (MMC) C 0.4 mg/ml applied with soaked pledget inserted in the sub-tenon's space during glaucoma surgery.
45485995|NCT03199534|Drug|Botulinum toxin A 50u|Subject will receive injection of 50u Botulinum toxin A with local sedation as an office procedure.
45485996|NCT03199534|Drug|Botulinum toxin A 100u|Subject will receive injection of 100u Botulinum toxin A in either the office or while anesthetized.
45485997|NCT03199534|Drug|Botulinum toxin A 150u|Subject will receive injection of 150u Botulinum toxin A while anesthetized.
45485998|NCT03203356|Drug|growth hormone|Children with a diagnosis of GHD will practice GH replacement therapy in line with normal clinical practice and international guidelines. Controls will be evaluated just at baseline.
45485999|NCT04280705|Other|Placebo|The supplied placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients. Alternatively, a placebo of normal saline of equal volume may be given if there are limitations on matching placebo supplies.
45846373|NCT02541864|Drug|Hybrid therapy|(pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
45486000|NCT04280705|Drug|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
45368718|NCT00951158|Drug|Conjugated Linoleic Acid|Phase I Dose Escalation Study
45368719|NCT00951236|Drug|One cortisone injection|Patients in this arm will receive one cortisone injection for the treatment of his/her symptoms
45368720|NCT00951236|Drug|Two cortisone Injections|Subjects randomized to this treatment will receive two cortisone injections, 4-6 weeks apart
45368721|NCT00945542|Other|Massive transfusion protocol|"Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. As discussed previously, this would correspond to an FFP:RBC transfusion ratio of 1:1.~Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians."
45486001|NCT03199378|Other|Neuropsychological Testing|Each group will be administered a battery of neuropsychological tests
45486002|NCT03199222|Device|Prosthetic smart socket technology with patient prompting|The smart socket technology will send feedback to the user's smartphone with suggestions including the removal or application of prosthetic socks over the residual limb or other volume management strategies to improve fit and comfort.
45486003|NCT03203590|Drug|Oral Navelbine + Carboplatin|The patient will be given Navelbine 60 mg/m2, p.o. day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v. day 1 of every cycle.After 2 cycle we will evaluate their clinical response.Then operable patients will have surgery.
45486004|NCT03203590|Drug|Gefitinib|The patient will be given Gefitinib 250mg,p.o.,q.d. for 8 weeks.After 8 weeks we evaluate their clinical response.Then operable patients will have surgery.
45846374|NCT02541942|Other|No treatment given|For patient convenience, genetic material will be collected in the form of saliva samples.
45846375|NCT02542410|Drug|Cabergoline|
45846376|NCT02542410|Drug|Norethindrone acetate|
45846377|NCT02544984|Drug|Azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
45846378|NCT02544984|Drug|placebo|Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
45486005|NCT02446522|Procedure|Open vein harvesting|Open vein harvesting was performed as a continuous incision under vision control. The GSV was identified two fingers proximal to the medial malleolus according to the standard practice. The vein was harvested using Metzenbaum scissors, and a continuous incision was made along the route of the vein. Care was taken not to traumatize the nerve, vein or its branches. Vein branches were ligated with titanium clips. The wound was closed in layers with continuous 2-0 Polysorb sutures and 3-0 skin sutures.
46052308|NCT05349682|Procedure|geniculate artery embolization|The physician will perform a diagnostic angiography, where they will take pictures of vessels near the knee that will be treated. Once the artery to be treated is identified, the doctor will guide a thin wire called a microwire, and a plastic tube called a microcatheter to the targeted artery, and more pictures of vessels at the knee will be taken. This picture will be used to see if there are any abnormal vessels at the knee, such as abnormal blood flow, abnormal vessel connections (between the veins and arteries), or new blood vessel growth. Once the targeted artery at the knee is confirmed, the doctor will inject enough particle embolic (Embozene) to slow or stop the blood flow in the geniculate artery. Once all vessels are treated, a final angiogram (pictures of blood vessels) will be performed to ensure that the blood flow has slowed.
46052309|NCT04099147|Other|This is an observational study.|This is an observational study. No intervention is planned outside of usual clinical practice.
46052310|NCT00705562|Other|milk protein formulas, varying carbohydrate/protein sources|ad lib for 0-8 days of age until 28 days of age
45486006|NCT02446522|Procedure|Endoscopic vein harvesting|Endoscopic vein harvesting was performed through minimal incisions with use of Vasoview 6 system (Maquet Medical Systems, Wayne, NJ, USA.) The vein was identified through a 3 cm incision below the knee. The incision site was sealed using a balloon port to create a tunnel inside the leg. A second unit with cautery was inserted via the port to cut and seal the tributary branches. A 1 cm skin incision was made near the groin to ligate the distal end of the GSV and remove the vein, which was checked for leakage. The wound was closed with 3-0 skin sutures
45486007|NCT03203278|Behavioral|Web-based exercise programme|Aerobic, resistance and balance exercises
45486008|NCT02450344|Behavioral|Interactive health promotion|An Internet quiz game competition utilising quiz questions related to alcohol
45486009|NCT02450344|Behavioral|Passive health promotion|An electronic package of information related to alcohol
45486010|NCT04362449|Combination Product|Shortened hydration time and dispensary of Akynzeo|Hydration is reduced to 1 hour and 40 minutes and Akynzeo is administered as an oral drug instead of Ondansetron being given as an IV before chemotherapy.
45486011|NCT04362449|Combination Product|Standard of care|Hydration remains at around 6 hours and 30 minutes due to no oral fluids being consumed prior to treatment and normal saline being administered for 90 minutes before cisplatin and then for 2 hours after cisplatin and before gemcitabine administration
45486012|NCT02446210|Device|Magstim 200|Transcranial Magnetic Stimulation
45486013|NCT02446210|Device|Digitimer electrical stimulator|Transcranial Magnetic Stimulation paired with Electrical Peripheral Nerve Stimulation
45486014|NCT02077166|Drug|Ibrutinib|
45486015|NCT02077166|Drug|Lenalidomide|
45486016|NCT02077166|Drug|Rituximab|
45486017|NCT05186350|Procedure|ERCP+ SpyGlass|SpyGlass direct Vision guided laser lithotripsy
45486018|NCT05186350|Procedure|ESWL+ ERCP|ESWL + Stone removal through ERCP
45486019|NCT03198832|Procedure|Non-surgical periodontal treatment|Debridement in a single session in which patients will be anesthetized and receive scaling and root planing with ultrasound equipment .
45486020|NCT04273217|Drug|AV-1|Single dose, administered by IV infusion (volume: 250 mL)
45486021|NCT04273217|Drug|Placebo|0.9% sterile saline. Administered by IV infusion (volume: 250 mL)
45486022|NCT05234086|Combination Product|InbioDerm + C plus advanced healing|For patients who are assigned to experimental treatment with InbioDerm+C plus advanced healing a section of skin tissue and peripheral venous blood will be taken. From the skin section, through an enzymatic process and cell proliferation for a period of approximately fourteen days, the cells that are integrated in the InbioDerm+C will be obtained and used to treat the foot ulcer.
45486023|NCT05234086|Procedure|Advanced healing|Patients who are assigned to active comparator correspond to the control treatment, which will be received advanced healing.
45846379|NCT02546388|Drug|Indium-111 Pentreotide|
45846380|NCT02546388|Drug|Gallium-68 DOTATATE|
45368722|NCT00945542|Other|Standard of care|Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
45368723|NCT00438256|Procedure|Proton Beam Radiation|Given over different schedules and duration
45486024|NCT02450188|Drug|Vardenafil|"In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. We choose this kind of tablets because of their easy way of assumption that can also have a minor psychological impact on patients.~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
45486025|NCT02450188|Behavioral|CBST|"The CBST cognitive intervention, in according with Beck (1976), includes to help patients and their partners to gain a commonsense understanding and reframe their problems.~On the other side, the CBST behaviour intervention, how described by Meichenbaum (1993), is a method to teach patients to practice different behaviours that allows the replacement of the compromised behaviour with a functional one.~CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
45486026|NCT03198676|Drug|PrEP-001 6.4 mg|6.4 mg as 4 sprays per nostril (ie total of 8 sprays for a single dose) using Aptar unit dose strength powder (UDSP) device
45486027|NCT03198676|Drug|PrEP-001 6.4 mg|6.4 mg as 2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
45486028|NCT03198676|Drug|PrEP-001 3.2 mg|3.2 mg as 1 spray per nostril (ie total of 2 sprays for a single dose) using Aptar UDSP device
45486029|NCT03198676|Drug|Placebo|2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
45486030|NCT03749369|Drug|Salvadora Persica Root|Salvadora Persica Gel
45752423|NCT00428077|Genetic|reverse transcriptase-polymerase chain reaction|"A baseline reverse transcriptase-polymerase chain reaction(RT-PCR) transcript level of BCR-ABL will be determined after enrollment on study. This baseline will be used to measure response to the vaccine. Patients will have 3 quantitative RT-PCR tests for BCR-ABL transcript levels performed on their peripheral blood in the first month after enrolling on study. Peripheral blood samples will be drawn at approximately 1-month prior (about day -30), 2 weeks prior (about day -14), and the day of the first vaccination (day 0). Samples will be analyzed at a central lab and the three values will be averaged to determine a baseline circulating transcript level. During this one-month period, a peripheral blood sample will be analyzed to determine whether patients have a B3A2 or B2A2 junction."
45368724|NCT00438256|Drug|Capecitabine|Given orally starting on day one of radiation therapy for 2 weeks
45368725|NCT00951392|Drug|euglycemic hyperinsulinemic clamp|"Insulin perfusion at 1 mU.kg-1.min-1~Glucose perfusion to maintain euglycemia at 5,0 ± 0,5 mmol/l~Blood tests"
45368726|NCT00951392|Procedure|muscle biopsy|"Gene expression in muscle tissue will be studied with two approaches :~Candidate gene approach by quantitative RT-PCR : genes involved in the carbohydrates and lipids metabolism including lipid oxidation in muscle (lipid carriers, PPARs), expression of 7 sirtuins isoforms as well as some of their target genes (NFkB, PGC1a)~Global transcriptome analysis by DNA Chip"
45368727|NCT00951392|Device|indirect calorimetry|energy expenditure measurement
45368728|NCT00941642|Drug|Lovaza|Approximately 50% of study subjects will be randomized to the active treatment arm -Lovaza. Subjects will be dosed with 4g of Lovaza gel capsules daily for a minimum of 48 weeks duration.
45368729|NCT00941642|Drug|placebo control|Approximately 50% of study subjects will be randomized to the placebo arm of this study. Placebo arm subjects will receive 4g of placebo gel caps daily for a minimum of 48 weeks duration.
45368730|NCT01031524|Biological|PfCS102|Antigen of the sporozoite protein
45368731|NCT01031524|Biological|Montanide ISA 720|adjuvant alone
45486031|NCT03749369|Procedure|Scaling and root planing|Thorough scaling and root planing (SRP) will be performed by a single clinician. The SRP procedure will be carried out in two sittings, comprising of ultrasonic scaling in the first, and manual instrumentation and root debridement in the second.
45368732|NCT00945620|Drug|ropivicaine|30mL containing 300mg ropivicaine 1% with addition of 1:300,000 epinepherine
45368733|NCT00945620|Drug|placebo|Placebo
45486032|NCT03202966|Other|Rehabilitation therapy|Rehabilitation therapy will be provided by a trained community rehabilitation worker (CRW) and specialist (i.e., physical therapist, occupational therapist, special educator and/or speech therapist) with a focus on the one or more domains where delays are identified (i.e. speech, motor, cognition). Therapy will be tailored based on the needs of the individual child and will follow current evidence-based practice.
45486033|NCT04264949|Other|Education in the use of smartphone app (Mon coach dos)|In addition to conventional care and the therapeutic education program, GA will benefit from three education sessions (one per week) on the use of the smartphone app mon coach dos
45486034|NCT04264949|Other|conventional care|conventional care and the therapeutic education program
45486035|NCT04484506|Drug|pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone|Cyclophosphamide 750 mg/m2 intravenously on day 1, vincristine 1.4 mg/m2 intravenously on day1, etoposide 60mg/m2 intravenously on days 1-3; pegaspargase 2500IU/m2 intramuscularly on day 2, prednisone 100mg orally on days 1-5.
45486036|NCT04332653|Drug|NT-I7|Administered by intramuscular (IM) injection
45486037|NCT04332653|Drug|Pembrolizumab|Administered by intravenous (IV) injection
45486038|NCT02449564|Drug|sirolimus|sirolimus 1mg daily
45486039|NCT05668871|Drug|Danning Tablet|3 times each day, 5 tablets each time, take orally after meals.
45486040|NCT02449720|Drug|Ropivacaine|Intraperitoneal instillation and infusion
45486041|NCT02449720|Drug|0.9% Saline|Intraperitoneal instillation and infusion
45486042|NCT03194620|Other|Thearubigins|Single oral intake of 94.9 mg of therubigins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink
45486043|NCT03194620|Other|Theaflavins|Single oral intake of 120 µmol of an equimolar mixture of theaflavins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink. The theaflavin mix includes theaflavin, theaflavin-3-gallate and theaflavin-3,3'-gallate
45486044|NCT03194620|Other|Procyanidin Dimer B2 (DB2)|Single oral intake of 120 µmol of Procyanidin Dimer B2 (DB2) (isolated from Theobroma cacao) in a flavanol-free, fruit flavored, non-dairy drink.
45486045|NCT03194620|Other|(-)-Epigallocatechin-3-O-gallate (EGCG)|Single oral intake of 120 µmol of (-)-Epigallocatechin-3-O-gallate (EGCG)(isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
45486046|NCT03194620|Other|(-)-Epicatechin-3-O-gallate (ECG)|Single oral intake of 120 µmol of (-)-Epicatechin-3-O-gallate (ECG) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
45486047|NCT03194620|Other|(-)-Epicatechin (EC)|Single oral intake of 120 µmol of (-)-Epicatechin (EC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
45486048|NCT03194620|Other|(-)-Epigallocatechin (EGC)|Single oral intake of 120 µmol of (-)-Epigallocatechin (EGC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
45486049|NCT03194620|Other|Control|Single oral intake of a flavanol-free, fruit flavored, non-dairy drink.
45486050|NCT03203122|Other|IPL laser|IPL laser monthly. Vertical and horizontal treatment, one pass over. Settings according to fitzpatrick skin type
46052311|NCT02814201|Behavioral|SRT|"simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase worst -off at the Parkinson's patient )"
46052312|NCT04098991|Drug|Levothyroxine|All participants will be treated for their hypothyroidism according to the standard of care as reflected in recent guidelines from the American Thyroid Association.
46052313|NCT00843856|Drug|tacrolimus|tacrolimus 2mgs bd adjusted to obtain levels of 5-12ng/ml
46052314|NCT00843856|Drug|tacrolimus and mycophenolate mofetil|tacrolimus 2mg bd adjusted to achieve levels of 5-12ng/L mycophenolate mofetil 500mgs bd adjusted to achieve levels of 1.5-3mg/L
46052315|NCT04480125|Drug|Azacitidine|100mg D1-7
46052316|NCT04480125|Drug|Chidamide|30mg BIW PO
46052317|NCT00764491|Device|Structural Allograft Spacer|Following disc space preparation the spacer is placed in accordance with cleared labeling and supplemental instrumentation is provided as an adjunct to fixation.
45368734|NCT01030276|Other|Bright light therapy|Bright light therapy
45368735|NCT01030276|Other|"Inactive placebo-light"|In this arm, patients will not get any bright-light therapy in a double-blind setting
45368736|NCT03814252|Device|MRI-TULSA|"The technology is developed to ablate targeted prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.~TULSA-PRO (Profound Medical Inc, Toronto, Canada): PAD-105, integrated into a 3 Tesla MR-system (Ingenia 3.0 Tesla, Philips Healthcare, Best, Netherlands)"
45368737|NCT02037620|Device|5-6-5 Specify electrode|
45368738|NCT02037620|Device|Restore Advance Pulse Generator|
45368739|NCT01030354|Dietary Supplement|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass
45368740|NCT01030354|Dietary Supplement|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass.
45368741|NCT00951470|Other|Follow -Up Visits|If CDT is declined, participants will have follow-up visits at 1, 3, and 6 months after study interview.
45486051|NCT03203122|Other|No sham treatment|The treatment is slightly painful, and noisy. Sham treatment impossible
45486052|NCT04384523|Drug|OsrHSA 20 mg/kg IV|A single dose of OsrHSA 20 mg/kg IV infusion at a rate lower than 2 ml/min
45486053|NCT04384523|Drug|OsrHSA 40 mg/kg IV|A single dose of OsrHSA 40 mg/kg IV infusion at a rate lower than 2 ml/min
45486054|NCT04384523|Drug|OsrHSA 80 mg/kg IV|A single dose of OsrHSA 80 mg/kg IV infusion at a rate lower than 2 ml/min
45486055|NCT04384523|Drug|OsrHSA 140 mg/kg IV|A single dose of OsrHSA 140 mg/kg IV infusion at a rate lower than 2 ml/min
45486056|NCT04384523|Drug|OsrHSA 200 mg/kg IV|A single dose of OsrHSA 200 mg/kg IV infusion at a rate lower than 2 ml/min
45486057|NCT04384523|Other|Placebo|Normal Saline (0.9% Sodium Chloride)
45486058|NCT02446054|Dietary Supplement|Musashino T2DM diet|provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
45486059|NCT03202888|Behavioral|Intervention|QuesGen-created mobile responsive website tool, Family Input for Quality and Safety.
45486060|NCT02446288|Device|TMJ Next Generation|
45486061|NCT02446288|Device|DSG Relaxer|
45752424|NCT01795729|Device|Stent|Coronary revascularization
45752425|NCT01795729|Drug|optimal medical therapy|Dual antiplatelet therapy: aspirin and a P2Y12 inhibitor as indicated
45752426|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
45752427|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
45368742|NCT00951470|Other|Full CDT|"Monday through Friday visits to the clinic for 2 weeks of intensive outpatient therapy. The CDT will be done by the lymphedema therapist. Each session will last about 1 hour.~During the last 2 treatment visits (Visits 9 and 10), the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months."
45752428|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
45752429|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16
45846381|NCT02547012|Drug|esomeprazole+amox+levo+tetra|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
45486062|NCT02445976|Drug|Seviteronel: given orally once daily in 28-day cycles|Oral Seviteronel given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
45486063|NCT03198442|Procedure|F-18 FDG breast PET scan|
45486064|NCT03198364|Behavioral|Safety and Recovery Therapy|4 session individualized psychoeducation tailored to people with bipolar disorder or schizophrenia targeting coping skills for suicidal thoughts and their determinants.
45486065|NCT03198364|Behavioral|Mobile Augmentation|Though a smartphone device, participants receive 12 weeks of personalized prompts derived from content produced in individual START sessions to increase transfer of skills to day to day life
45486066|NCT03198208|Drug|Fentanyl dose administration|
45486067|NCT01044056|Drug|Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets|LNG/EE oral contraceptive tablets (Microgynon® 30), 21 in total, containing 0.150 mg LNG and 0.030 mg EE per tablet administered once daily orally for 21 consecutive days.
45486068|NCT01044056|Drug|norelgestrominum and ethinylestradiol patch oral contraceptive patch|A contraceptive patch (EVRA ™), one patch for 7 days for three consecutive weeks, 3 patches in total, applied on the lower abdomen. Dose: per patch 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
45486069|NCT01044056|Drug|Nuvaring ™ (etonorgestrel/ethinylestradiol)|NuvaRing ™ , one ring for a period of 21 days, inserted vaginally. Dose: per ring 11.7 mg etonogestrel and 2.7 mg EE releasing a daily average amount of 0.120 mg etonogestrel and 0.015 mg EE.
45486070|NCT03198286|Other|Informational Intervention|Receive treatment summary and survivor care plan
45486071|NCT03203044|Other|Soylent and water diet|A diet of five servings of Soylent 2.0 liquid meal-replacement drink per day and water as needed.
45486072|NCT01005056|Drug|Ethinylestradiol + Desogestrel|All participants receive Marvelon® according to the approved dosage and administration method.
45486073|NCT04796714|Drug|Double antiplatelet therapy|One sachet of aspirin 160 mg and one tablet of clopidogrel 75 mg per day.during 3 months
45486074|NCT04796714|Drug|Aspirin|One sachet of aspirin 160 mg per day during 3 months
45846382|NCT02547012|Drug|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.,
45368743|NCT00951470|Other|Modified CDT Program|The participant will come to the clinic for 1-2 training sessions taught by the lymphedema therapist. Each training session will last about 1 hour, and the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months.
45486075|NCT04796714|Device|Brain MRI|Two cerebral Magnetic Resonance Imaging (MRI) examinations will be carried out (D0 and D90).
46052318|NCT00764491|Device|OptiMesh 1500S|Following disc space preparation the OptiMesh is deployed and filled in accordance with study surgical technique and supplemental instrumentation is provided as an adjunct to fixation.
45368744|NCT01565746|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
45486076|NCT04796714|Other|Neurological tests|Neurological assessment with the implementation of the modified rankin, National Institute of Health Stroke Score (NIHSS), and Montreal Cognitive Assessment (MoCA) tests (D1 and M3)
45486077|NCT04382651|Drug|MAS825|MAS825 liquid solution for intravenous infusion
45486078|NCT04382651|Other|Placebo|Placebo liquid solution for intravenous infusion
45486079|NCT04382651|Drug|Standard of Care (SoC)|SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
45486080|NCT02445898|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
45486081|NCT02445898|Drug|Isotonic Sodium Chloride|Placebo
45691698|NCT00594256|Drug|Sodium Oxybate|Patients will undergo a one-week evaluation period, which will include a taper and discontinuation of any currently prescribed sedative/hypnotics, as well as baseline diagnostic, psychopathology, neurocognitive and polysomnographic measurements (see below for details). Hypnotic taper may be extended or abbreviated, depending on clinical judgment. Patients will then begin a 4-week trial of adjunctive Xyrem (sodium oxybate). Patients will begin at 4.5 g/night (in divided doses of 2.25 g, with 1st dose at bedtime and then 2nd dose four hours later). Dosage will increase by 1.5 g/day every week, until a dose of 9 g nightly is reached, or a patient cannot tolerate further dose escalations. Medication will be administered in divided dosage for the duration of the study. A three-week taper (by 3 g/day weekly) of sodium oxybate will follow the four-week trial of sodium oxybate.
45691699|NCT00627406|Drug|Buserelin and Pregnyl|Subcutaneous injection 0.5 mg and 1500 IU
45691700|NCT00627406|Drug|Pregnyl|Subcutaneous injection 5000 IU
46052319|NCT00705640|Biological|incomplete Freund's adjuvant|Given subcutaneously and intradermally
45368745|NCT01565746|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 100 kBq/kg
45368746|NCT01565746|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Expansion arm: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
45368747|NCT00951548|Dietary Supplement|VSL#3|Probiotic blend of 8 different strains of lactobacilli and bifidobacteria, dosed at 900 billion bacteria/sachet). Dosage regimen is 2 sachets b.i.d. for 8 weeks
45368748|NCT00951548|Dietary Supplement|Placebo|Corn Starch. Dosage regimen is 2 sachets b.i.d. for 8 weeks
45486082|NCT03202576|Device|Nasal Bridle|Nasal bridle placement and securement of the tube. Instead of taping the tube to the patient's face, nose or upper lip the bridle is a device whereby a magnetic retrieval system is attached to 1/8 inch umbilical tape which is inserted via the nares, looping around the nasal septum and vomer bone and ending with both ends of the bridle (umbilical tape) secured together and to the feeding tube just outside the nose.
45486083|NCT03749291|Other|Obemat2.0 therapy|"Lifestyle (diet & physical activity) structured recommendations through a motivational interview.~Duration: 12(+3) months Description: 1 visit/month & 3 Workshops in primary care centers Providers: pediatricians and nurses trained to perform motivational interview The interviews are structured as follows: First, checking the accomplishment of objectives to motivate the participant. Second, a specific topic per visit is explained to the participant. Third, a task related to the topic (i.e. to plan a weekly menu for the family) is given to be brought back at the next visit. 4th. Objectives about diet, weight & physical activity are defined to be accomplished until the next visit."
45691701|NCT00627406|Drug|Buserelin and Pregnyl|Subcutaneous injection 0,5 mg and 1500 IU + 1500 IU after 7 days
45691702|NCT00627406|Drug|Pregnyl|Subcutaneous injection 5000 IU
45846383|NCT02547714|Drug|Secukinumab (AIN457)|Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.
46052320|NCT00705640|Biological|multi-epitope melanoma peptide vaccine|Given subcutaneously and intradermally
46052321|NCT00705640|Biological|tetanus toxoid helper peptide|Given subcutaneously and intradermally
46052322|NCT00705640|Procedure|biopsy|Patients undergo surgical biopsy at replicate vaccine site
46052323|NCT02813733|Procedure|Thyroid surgery|Thyroidectomies performed by all surgeons in 5 academic hospitals in France.
46052324|NCT00705796|Drug|MPP10, testosterone|Testosterone intranasal, 7.6 mg, twice daily to be taken immediately after waking up and washing/showering (approx. 7:00-8:00 AM) and at lunch time (approx. 12:00 AM).
46052325|NCT00705796|Drug|Testosterone|AndroGel® 50 mg, once daily in the morning after washing/showering.
45691703|NCT00673738|Drug|Cetuximab|"Cetuximab dose: based on patient's actual weight. Loading phase dose of cetuximab is 400 mg/m2 IV administered over 120 minutes, on day 1 followed by; Concurrent phase, weekly infusion dose at 250 mg/m2 IV over 60 minutes, on days 8, 15, 22, 29, 36, 43, 50.~Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week complete blood counts (CBCs), differentials, and blood urea nitrogen (BUN) plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted."
45486084|NCT03749291|Other|Usual Clinical Practice|Lifestyle (diet and physical activity) Duration: 12 (+3) months Description: 1visit/month to the primary care centers. Providers: pediatricians & nurses. Children assigned to the control group receive the usual treatment conducted in primary care centers based on the Clinical Practice Guidelines on the Prevention and Treatment of Child and Adolescent Obesity [Spanish Ministry of Science and Innovation], 2009). At visits, the family receive recommendations to carry out a balanced diet, to provide a moderate energy reduction from the previous intake. An increase in physical activity, both in terms of leisure activity, as sports is advised.
45486085|NCT02445820|Drug|HES|2500 mL of balanced HES 130/0.4
45486086|NCT02445820|Drug|Crystalloid|2500 mL of balanced crystalloid.
45486087|NCT04673630|Biological|Tezepelumab|Single dose subcutaneous injection
45486088|NCT03749213|Drug|Icotinib|Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks as neoadjuvant therapy before surgery and for 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
45486089|NCT04484116|Diagnostic Test|Intraoperative Paratohormone|Three IOPTH determinations were withdrawn: at anesthetic induction (PTH0), 15 minutes (PTH15), and 30 minutes (PTH30) after completion gland resection. Another sample was taken 24 hours after the procedure (PTH24), values <150pg/mL defined a successful surgery and patients were assigned to the successful or unsuccessful group. IOPTH drop was analyzed to predict successful surgery with drops of 70% and 90% at 15 and 30 minutes.
45486090|NCT04614428|Behavioral|RESILIENCE Program|"In addition to the standard care participants would normally receive (including exposure to any standard hospital avoidance programs), the 150 participants assigned to the RESILIENCE Program group will receive a combination of strategies designed to promote seasonal resilience.~This includes profiling of seasonal vulnerability; a 60-80 minute home visit by the RESILIENCE Nurse to assess physiological status, behavioural adaptations, environment, and modulating factors; a dedicated RESILIENCE Clinic with a dedicated RESILIENCE physician to develop a long-term plan to help promote/maintain seasonal resilience and; a structured follow-up over the next 12 months to monitor and adjust the participant's status and management from a seasonal perspective."
45486091|NCT03198130|Drug|REGN2810|Intravenous (IV) use
46052326|NCT02811081|Procedure|Passive Deflation|In the control group, residual carbon dioxide gas was evacuated by the routine method using passive exsufflation through the port site at the end of surgery.
46052327|NCT02811081|Procedure|Normal Saline Instillation|In the normal saline instillation group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), isotonic normal saline (20 ml/kg of body weight) was infused in the sub-diaphragmatic region at the end of surgery.
46052328|NCT02811081|Procedure|Normal Saline Instillation + Pulmonary Recruitment|In the combined intervention group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), and a pulmonary recruitment maneuver was performed after instillation of isotonic normal saline (20 ml/kg of body weight) in the sub-diaphragmatic region at the end of surgery.
46052329|NCT04021693|Other|Handheld Ultrasound Devices|Interns in the handheld ultrasound device arm shall carry a personal handheld ultrasound device to be used for self-directed learning
45846384|NCT02548728|Drug|Intranasal Oxytocin Spray|10 insufflations (40IU of oxytocin total) given three times on day of enrollment and then twice daily for 4 days
45486092|NCT04611854|Behavioral|Guidance|Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
45486093|NCT04611854|Behavioral|ICBT for alcohol misuse|The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 8 lessons distributed across 8 weeks.
45486094|NCT03202654|Other|Corn Oil|4 tablespoons/day of corn oil for 4-week treatment period.
46052330|NCT02813967|Radiation|Radiotherapy 54 Gy|Radiotherapy was administered in 1.8 Gy fractions 5 times weekly to a total dose of 54 Gy.
46052331|NCT02813967|Radiation|Radiotherapy 60 Gy|Radiotherapy was administered in 2 Gy fractions 5 times weekly to a total dose of 60Gy.
45486095|NCT03202654|Other|Coconut Oil|4 tablespoons/day of coconut oil for 4-week treatment period.
45486096|NCT04238780|Procedure|Erector Spinae Plane Block|The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine needle was inserted in cranial-caudal direction towards the transvers process using in plane technique until the needle cross all the muscles then interfascial injection of 20ml local anesthetics is done after ensuring negative aspiration, the procedure was repeated following the same steps on the other side of the back.
45486097|NCT04238780|Procedure|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
45486098|NCT03197974|Behavioral|Mindfulness for Bipolar|Brief online self-management program with email coaching support
45486099|NCT03197974|Behavioral|Psychoeducation for Bipolar|Brief online self-management program with email coaching support
45486100|NCT00944216|Drug|Salkera Emollient Foam|application of the Salkera emollient foam twice a day during the 12 week study period.
45486101|NCT04238663|Drug|MB02 (Bevacizumab Biosimilar)|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
45486102|NCT04238663|Drug|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
45486103|NCT04238663|Drug|US licenced Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
45846385|NCT02548728|Drug|Placebo|10 insufflations (40IU of placebo, same solution as active treatment minus oxytocin) given three times on day of enrollment and then twice daily for 4 day
45846386|NCT02549040|Drug|Treatment A: Doravirine 100 mg film coated tablet|Single doravirine 100 mg film coated tablet administered orally at the start of Period 2
46052332|NCT02813967|Drug|S-1|S-1 70mg/m2 was administered on days 1-14 and 29-42.
46052333|NCT00913432|Drug|masitinib|3 mg/kg/day oral route
45368749|NCT01031602|Behavioral|Surveys|Surveys -- Female Sexual Function Index (FSFI), the Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire completed at time of clinic appointment, taking about 20 minutes.
45368750|NCT00951626|Behavioral|exercise intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
46052334|NCT00913432|Drug|masitinib|masitinib 6 mg/kg/day oral route
46052335|NCT02600689|Behavioral|Physical exercise training|
45368751|NCT00951626|Behavioral|telephone-based intervention|"Those on the Standard Nursing Intervention Program will receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.~For those on the Usual Care plus Attention Control program, the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant."
45486104|NCT03202732|Other|DiabetesFlex|"DiabetesFlex consist of one mandatory and two optional consultations. Before the consultations patients receive the AmbuFlex Diabetes questionnaire.~The AmbuFlex Diabetes questionnaire is based on both validated questionnaires and clinical consensus. The AmbuFlex Diabetes questionnaire consists of: SF36 well-being question, WHO-5 Well-being Index. Questions concerning: HgA1c, home-based blood pressure monitoring, incidents of hypoglycemia, diabetes complications, regular eye check, regular food check, erectile dysfunction and peripheral neuropathy, The PAID scale, Topics patients may want to talk with the health care professional about, the patient's evaluation of the need for diabetes care. View the AmbuFlex Diabetes questionnaire at the homepage: www.diabetesflex.auh.dk."
45486105|NCT00878462|Drug|Asenapine WHITE raspberry flavor (Treatment A)|Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets
45486106|NCT00878462|Drug|Asenapine RED raspberry flavor (Treatment B)|Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets
45486107|NCT00878462|Drug|Asenapine WHITE UNFLAVORED (Treatment C)|Asenapine (Org 5222), 5 mg WHITE UNflavored as fast dissolving tablets
45486108|NCT03197818|Drug|CHF 5993 100/6/12.5 µg|Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose
46052336|NCT02600689|Behavioral|Cognitive exercise training|
46052337|NCT02811315|Other|Observational. Non interventional study|Observational. Non interventional study
46052338|NCT00702832|Behavioral|Vestibular rehabilitation|Daily home training (4-6 specific exercises) 2-3 times per day. Group training led by a physiotherapist twice per week during the first 10 weeks and once per week from 10 weeks to 12 months or to symptoms are cured.
45486109|NCT03197818|Drug|160 µg budesonide + 4.5 µg formoterol fumarate|Fixed combination of budesonide 160 µg plus formoterol fumarate 4.5 µg
45486110|NCT00754520|Device|Ceramic On Metal|Ceramic on Metal articulation using M2a-38™ mm cup
45486111|NCT00754520|Device|Metal on Metal|Metal on Metal articulation using M2a-38™ mm cup
45486112|NCT01562249|Other|orofacial myofunctional treatment protocol|Once a week for six weeks, the experimental group received a forty minutes session of orofacial myofunctional treatment. A home exercise program was prescribed during each session. The protocol implies in continuous and daily practices - participants were asked to perform exercises at least three times a day. After the first six weeks, the experimental group underwent four sessions for maintenance purposes (two sessions twice a month and two sessions once a month). The total treatment duration was of five months.
45486113|NCT01562249|Other|counseling|The instruction group underwent two supervised forty minutes therapy sessions along the six weeks following surgery. These sessions involved the perception of the stomatognathic system, especially in terms of adequate performance during mastication. Specific exercises were not given and patients were instructed to try to reproduce the adequate pattern of mastication at all meals (i.e. alternated bilateral, with lip closure; with coordination activity of the tongue and mandible).
45486114|NCT01562249|Other|Control Group|As the sEMG test-retest is a critical issue, participants of CG were also tested in two distinct moments (testing occurred with 1 year interval) in order to verify possible changes in the sEMG measurements as a result of retesting.
45486115|NCT03197896|Other|Educational Intervention|Review prostate cancer information
45486116|NCT03442088|Drug|Apremilast|Apremilast will be given as approved by the FDA for the treatment of moderate to severe plaque psoriasis. An initial dosage titration from Day 1 (10mg) to Day 5 (30mg). Following the titration, the recommended maintenance dosage of 30 mg twice daily taken orally starting on Day 6 will be dispensed, as per labeled indication.
46052339|NCT00702832|Other|standard treatment|treatment as usual
45486117|NCT03202420|Other|TOPS|Take Off Pounds Sensibly (TOPS) is a national, nonprofit, peer-led, group-based, weight loss program that offers a comprehensive program on diet and physical activity with group support for weight management.
45486118|NCT03746795|Device|Spirometric examinations realized using the EIT|Spirometric examinations will be realized using the EIT alone.
45486119|NCT03746795|Device|Simultaneous measurement by spirometer and EIT|Spirometric examinations will be realized using the simultaneous measurement by spirometer and EIT
45486120|NCT03202498|Device|4g Yaq-001|Study patients will be dosed daily with 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
45486121|NCT03202498|Other|4g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
45486122|NCT03202498|Device|8g Yaq-001|Study patients will be dosed daily with 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
45486123|NCT03202498|Other|8g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
45846387|NCT02549040|Drug|Treatment B: Doravirine 150 mg tablet (40% drug loaded granule)|Single doravirine NF Type 1 dose (150 mg tablet [40% drug loaded granule]) administered orally at the start of Period 1
46052340|NCT02811237|Other|HESTIA|"Management based on the HESTIA rule:~If the rule is negative, meaning that patient meet none of the exclusion criteria of the rule, the proposed management will be outpatient care.~In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF."
46052341|NCT02811237|Other|sPESI|"Management based on the simplified PESI score:~If the sPESI score =0, the proposed management will be outpatient care.~In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF."
46052342|NCT04257123|Device|Gelesis100|Participants will administer Gelesis100 before lunch and dinner meals.
46052343|NCT04257123|Other|Placebo|Participants will administer a placebo before lunch and dinner meals.
45486124|NCT01562405|Drug|ACE-011|Injection every 28 days, dose escalation levels from 15-45 mg
45486125|NCT01562405|Drug|Lenalidomide|15 to 25 mg days 1-21, given orally
45486126|NCT01562405|Drug|Dexamethasone|40 mg days 1,8,15,22; given orally
45486127|NCT01562405|Drug|Pomalidomide|Pomalidomide 4 mg daily on days 1-21
45486128|NCT03194386|Other|Reassurance|At the end of cares, before ED discharge, a trained psychologist will conduct a session in order to reassure patients about their future after ED visit.
45486129|NCT03194386|Other|Eye-Movement Desensitization and Reprocessing (EMDR)|At the end of cares, before ED discharge, a trained psychologist will conduct a single EMDR session. Each session may last about 60 minutes
45486130|NCT03748745|Drug|SH229|tablet, oral, 600 mg once daily for day 1 to day 14
45486131|NCT03748745|Drug|SH229|tablet, oral, 600 mg once daily for day 8 to day 14
45486132|NCT03748745|Drug|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 8 to day 14
45486133|NCT03748745|Drug|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 1 to day 14
45486134|NCT03298334|Biological|Vaginal Seeding|A gauze containing the Mother's vaginal flora will be swabbed over the face and body of the neonate shortly after cesarean delivery.
45486135|NCT03298334|Other|No Vaginal Seeding|A gauze carrying sterile saline will be swabbed over the face and body of the neonate shortly after cesarean delivery.
45486136|NCT03194230|Other|With cervical dilatator|Induction of labour by cervical placement of hygroscopic dilators (Dilapan-S Hygroscopic cervical dilator )
45486137|NCT03746717|Device|occlusive wound closure|skin closure with a commercially available wound closure product consisting of a synthetic adhesive mesh and cyanoacrylate based skin glue
45486138|NCT03746717|Device|conventional wound closure|wound closure with surgical staples
45486139|NCT03119194|Drug|[14C]-BIA 9-1067|1 × 100 mg capsule, Oral
45486140|NCT03748667|Diagnostic Test|White light endoscopy (WLE)|Subjective endoscopic assessment of deep submucosal invasion based on the presence of gross morphological malignant features, morphology and size.
45486141|NCT03748667|Diagnostic Test|NBI/BLI +/- chromoendoscopy (NBIBLI +/- CE)|Endoscopic assessment of deep submucosal invasion with NBI and dual focus/magnification or BLI and magnification. In the case of demarcated areas or JNET 2B, Kudo pit pattern assessment with crystal violet will be performed.
45486142|NCT05582564|Other|abstract vs concrete texts|The main experiment involved two groups of participants and two different articles about vaccine-related thrombosis taken from two Italian newspapers. One article used a more abstract descriptive style and language, while the other used a more anecdotical style and concrete language: each group read only one of these articles. Both articles are the same length and describe an episode of vaccine-related thrombosis. The abstract text uses a more formal and impersonal language, reporting more scientific considerations; the concrete text uses a more familiar and emotional style and provides a more anecdotical description of the case. Texts were also weighted according to a concreteness semantic vocabulary. French received translated versions.Two other groups were assigned categorization tasks; one was asked to complete a concrete categorization task and the other an abstract categorization task.
45486143|NCT03194152|Dietary Supplement|Peanut|Dietary Supplement: Peanut
45486144|NCT03194152|Dietary Supplement|Control|Dietary Supplement: High carbohydrate snacks
45486145|NCT03107338|Drug|DEXKETOPROFEN TROMETAMOL|Patients who were administered a single dose of 25 mg of DKT 15 minutes before surgery
45486146|NCT03107338|Other|Placebo|Patients who were administered a single dose of 500 mg of Vitamin C 15 minutes before surgery
45846388|NCT02549040|Drug|Treatment C: Doravirine 150 mg tablet (30% drug loaded granule)|Single doravirine NF Type 2 dose (150 mg tablet [30% drug loaded granule])administered orally at the start of Period 3
45846389|NCT02549040|Drug|Treatment D: Doravirine 150 mg tablet (50% drug loaded granule)|Single doravirine NF Type 3 dose (150 mg tablet [50% drug loaded granule])administered orally at the start of Period 4
45846390|NCT02549040|Drug|Treatment E: Doravirine 100 mg tablet (30% drug loaded granule)|Single doravirine NF Type 4 dose (100 mg tablet [30% drug loaded granule]) administered orally at the start of Period 5
45368752|NCT00951626|Dietary Supplement|dietary intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
45368753|NCT00951626|Other|educational intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
45368754|NCT00951626|Other|questionnaire administration|For both groups of participants, administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
45486147|NCT05581940|Combination Product|Group A Caudal Epidural Anesthesia with bupivacaine 0.25% and group B with opioid intervenors|(CEB) in group A using drugs bupivacaine 0.25% commonly used in children including neonates in group A In infraumbilical operations, it is used as a supplement to GA and to control postoperative pain It is a safe, easy, and effective type of central neuraxial block.[ The patient will be intubated and the caudal block will be performed under GA after securing the airway. The patient's position will be turned onto the lateral decubitus then a landmark-based, blind technique will be used. In children, the success rate with the blind technique is above 96% but the occurrence of side effects is reported. Group B uses general anesthesia (GA) alone for intraoperative and perioperative pain control used the opioid intervious without caudal block .
45486148|NCT04223687|Other|Sugar-Sweetened Beverage Warning Label|Labels with a pictorial warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research.
45486149|NCT04223687|Other|Neutral label|Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
45486150|NCT05579132|Drug|CN201|During the treatment period, subjects will receive an intravenous (IV) infusion of CN201 once a week (QW) in a 4-week treatment cycle.
45486151|NCT05549648|Behavioral|Home oral excrise|The training program will utilize certain technologies and behavioral activities to train the oral and facial muscles.
45486152|NCT02445742|Drug|Bosutinib|500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
45368755|NCT00951626|Procedure|allogeneic bone marrow transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic bone marrow transplant.
45486153|NCT03748589|Device|laryngeal mask airway|i-gel laryngeal mask airway is a supraglottic airway device made from a medical grade thermoplastic elastomer , is a non-inflatable device to create anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures and avoid compression trauma.
45486154|NCT03942770|Behavioral|Contingency Management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
45486155|NCT03942770|Behavioral|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
45486156|NCT02445508|Drug|Sevelamer|
45486157|NCT02445508|Drug|Cholecystokinin|
45486158|NCT02445508|Drug|Sevelamer placebo|
45486159|NCT02445508|Drug|Isotonic saline|
45486160|NCT03746639|Other|physiotherapy modalities|"The physiotherapy modalities will be applied for five sessions a week for 3 weeks.~The all patients will be treated with superficial heating (the moist heat pack will be applied to the patient's lower back for 20 minutes) , transcutaneous electrical nerve stimulation(frequency of 100 Hz, pulse duration of 100 μs, sensory-level amplitude was applied for 25 minutes) , exercise therapy (consisting of flexion, extension, stretching, mobilisation, and postural exercises performed for approximately 25 minutes ) .~In addition to these therapies, continuous therapeutic ultrasound treatment will be applied to patients in first group for 10 minutes; frequency of 1 megahertz, intensity of 1.5 W/cm2, effective irradiation area of the transducer head 5 cm2 ."
45486161|NCT03197584|Biological|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
46052344|NCT02810847|Device|I-Bit plus|The study will treat amblyopia (lazy eye) using 3-D computer technology and active shutter glasses. Computer games and DVD's are viewed through the active shutter glasses and are specially prepared to preferentially stimulate the lazy eye; the child can only play the game accurately if they are using their lazy eye.
45368756|NCT00951626|Procedure|allogeneic hematopoietic stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
45368757|NCT00951626|Procedure|assessment of therapy complications|Collected throughout the 12 month study period
45486162|NCT03197584|Biological|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
45486163|NCT03197584|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
45486164|NCT03197584|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
45486165|NCT03197584|Drug|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
45486166|NCT03197584|Drug|Fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
45846391|NCT02549508|Device|AutoCPAP with SensAwake On|The comfort feature 'SensAwake' will be turned on
46052345|NCT00843778|Biological|Certolizumab Pegol|"200 mg every two weeks~Certolizuimab Pegol 200 mg every two weeks Subjects who flared at Week 48 or Week 52 of feeder study C87076 [NCT00674362], will receive respectively once 400 mg Certolizumab Pegol or three times 400 mg Certolizumab Pegol at two weeks interval as part of an induction phase in the C87080 study. Thereafter the subject enters the C87080 study and will be further treated with 200 mg Certolizumab Pegol every two weeks."
46052346|NCT04432935|Dietary Supplement|Bovine Lactoferrin|Lactoferrin is a nutritional supplement which was first discovered in bovine milk which was later isolated in human milk as the second most abundant protein; with high levels found in colostrum. The use of bovine Lactoferrin in children is generally recognized as safe by the US Food and Drug Administration.
46052347|NCT04432935|Other|Placebo Glucon D|This group will be given 100mg Glucon-D (99.4% glucose) which will be similar in shape, color to the bLF.
45486167|NCT03197584|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
45486168|NCT03197584|Drug|Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
45486169|NCT03197584|Drug|omega-3 acid ethyl esters|omega-3 acid ethyl esters
45486170|NCT03197584|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
45486171|NCT03197584|Radiation|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy (SBRT)
45486172|NCT03197584|Biological|ALT-803|Recombinant human super agonist IL-15 complex
45486173|NCT03197584|Biological|ETBX-021|Ad5 [E1-, E2b-]-HER2 vaccine
45486174|NCT03197584|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
45486175|NCT03197584|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1 vaccine
45486176|NCT03197584|Biological|GI-4000|Heat-killed S. cerevisiae yeast expressing the mutated RAS oncoproteins
45486177|NCT03197584|Biological|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
45486178|NCT03197584|Biological|haNK®|NK-92 [CD16.158V, ER IL-2]
45486179|NCT03722576|Drug|Vidofludimus calcium|During the 6-month treatment period, subjects will receive 30 mg VC orally once daily. This will be preceded by a lead-in dosing period where subjects will receive 15 mg VC once daily for 1 week.
45486180|NCT02445664|Behavioral|Educational video|Video: Information on osteoporosis and alendronate treatment.
45486181|NCT04221815|Device|Eagle Eye Platinum digital IVUS catheter with optional SyncVision|IVUS catheter
45486182|NCT04221815|Device|Resolute Onyx Drug Eluting Stent|Stent
45486183|NCT03416348|Drug|Aluminum Chloride 20% (deodorant)|Aluminum Chloride (deodorant)
45486184|NCT03416348|Drug|Alcohol|Placebo
45486185|NCT03202342|Other|Water|Water, 300 ml, at room temperature
45486186|NCT03202342|Other|Glucose|Water containing 50 g glucose, 300 ml, at room temperature
45368758|NCT00951626|Procedure|peripheral blood stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
45368759|NCT00951626|Procedure|psychosocial assessment and care|Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge. They will also receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.
45486187|NCT03202342|Other|Ethyl butyrate|Water containing ethyl butyrate (pineapple flavour) 300 ml, at room temperature
45486188|NCT03202342|Other|Glucose + ethyl butyrate|Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at room temperature
45486189|NCT03202342|Other|Glucose + ethyl butyrate 0 C|Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade
45486190|NCT03236012|Drug|Botulinum Toxin Type A (Botox)|Maximum dose up to 400 units given one time
45486191|NCT03187340|Behavioral|Sleep education and relaxation 1|Sleep hygiene and relaxation training; Sleep education and relaxation 1
45486192|NCT03187340|Behavioral|Sleep education and relaxation 2|Modified sleep hygiene and relaxation training; Sleep education and relaxation 2
45486193|NCT02449486|Drug|Ropivacaine|
45486194|NCT03625154|Procedure|ankle open reduction internal fixation|Open Reduction and Internal Fixation with plates and screws
45486195|NCT03625154|Other|non operative management|closed reduction and splinting followed by progressive weight bearing
45486196|NCT03202186|Drug|Progesterone oral capsule|Oral capsule treatment
45846392|NCT02549508|Device|AutoCPAP with SensAwake Off|The comfort feature 'SensAwake' will be turned off
45368760|NCT00951626|Procedure|quality-of-life assessment|For both groups of participants, questionnaires administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
45486197|NCT03202186|Drug|Placebo oral capsule|Oral capsule treatment
45486198|NCT03625076|Drug|Intra-articular Lidocaine|20 mL of 1% Lidocaine will be injected into the joint of the dislocated shoulder. Afterwards, the physician will attempt to reduce the shoulder using a technique of his or her choice.
45486199|NCT03625076|Drug|Procedural Sedation with etomidate or propofol|Procedural sedation using etomidate or propofol (physician's choice) will be performed. The dose of the drugs will also be left the treating physician. The physician will then attempt to reduce the shoulder using a technique of his or her choice.
45486200|NCT03202108|Dietary Supplement|Krio|"Krio is a ready to eat, chocolate-flavoured, solid bar containing 20g fat per 28g bar. It contains protein and carbohydrate with added sweetener and flavourings. It does not contain any added micronutrients. Krio is not for use as a sole source of nutrition.~It has a fat to protein and carbohydrate ratio of 3 to 1, making it suitable for use in all versions of the ketogenic diet.~This product is to be consumed daily under the direction of a dietitian."
45486201|NCT03197272|Procedure|PiXL|Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of mild myopia.
45486202|NCT02445352|Drug|Rosuvastatin 5mg|
45486203|NCT02445352|Drug|DP-R207 5/10mg|
45486204|NCT02445352|Drug|Rosuvastatin 10mg|
45486205|NCT02445352|Drug|DP-R207 10/10mg|
45486206|NCT02445352|Drug|Rosuvastatin 20mg|
45486207|NCT02445352|Drug|DP-R207 20/10mg|
45486208|NCT02445352|Drug|Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)|
45486209|NCT02445352|Drug|Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)|
45486210|NCT02445352|Drug|Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)|
45486211|NCT03693989|Drug|Difluprednate 0.05%|Dosage: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.
45486212|NCT03693989|Drug|Prednefrin|"1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.~- Route of administration: topical ophthalmic"
45486213|NCT02786186|Drug|Secikinumab|
45486214|NCT02445274|Procedure|Anterior lens capsule was reserved|The anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.
45486215|NCT03746561|Diagnostic Test|deep learning|detect and classify spinal stenosis by deep learning
45486216|NCT02445118|Other|Adipose Allograft Matrix (AAM) injection|Adipose Allograft Matrix (AAM) injection, Non-dominant wrist
46052348|NCT04251507|Device|Oculus Go Virtual Reality Goggles|Oculus Go is a standalone portable Virtual Reality device that enables the user to immerse in different virtual environments.Non pharmacological technique to reduce pain and anxiety during a procedure.
46052349|NCT02813343|Device|BlueStar app|BlueStar is a smart-phone enabled application that is designed to serve as a virtual coach for patients. The app sends daily evidence-based, real-time messages as well as longitudinal feedback on how to improve diabetes management. The Bluestar app has been shown to be effective at teaching patients about dietary impacts on their blood glucose levels, encouraging patients to generate higher-quality blood glucose data for enhanced self-monitoring, and to improve overall management of diabetes as represented by reductions in levels of HgbA1c. Benefits have been demonstrated in time periods as brief as three months. One US based study showed a decrease in hospitalizations and emergency department visits among participants who use the application.
45486217|NCT04944212|Diagnostic Test|Measuring vitamin D serum level using ELIZA|Venous blood will be obtained from pregnant women at the time of admission and from the umbilical cord veins of the newborns immediately after their delivery. The quantitative measurement of 25OHD in serum will be performed using ELIZA.
45486218|NCT05234242|Procedure|inguinal hernia repair|inguinal hernia repair performed either in stationary/inpatient or ambulatory/outpatient setting
45486219|NCT04206293|Device|Juvederm® VOLITE|1 mL of Juvéderm® VOLITE contains hyaluronic acid gel 12.0 milligram (mg), lidocaine hydrochloride 3.0 mg in a phosphate buffer pH 7.2 q.s. 1 mL (or gram).
45486220|NCT05520476|Device|Neuroliten MVP system|The Neuroliten MVP system will be an App that gets uploaded to the patients iPhone from the App Store.
45486221|NCT03197350|Diagnostic Test|cMR|cardiac MRI done to complete the diagnosis
45486222|NCT03197350|Biological|biomarker|Biomarker correlation with cMR parameters Prognostic information
45486223|NCT04939532|Behavioral|Text-Messaging (TM)|"Patients in the TM condition will receive HIPAA-compliant bidirectional text messages. Texts will include a brief message regarding COVID-19 risk and will screen the participants for COVID testing needs. Participants who reply yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. Patients who reply no will receive a text with the clinic phone number and a note to call if anything changes."
45486224|NCT04939532|Behavioral|Patient Navigation (PN)|"Patients in the PN condition, who respond yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. In addition they will receive a notice via text message that a Community Health Worker will contact them for patient navigation. At this time, patients will will have the option to opt-out of the phone call from the patient navigator. The Patient Navigation includes advice from navigators to address practical barriers to COVID testing such as logistics, transportation, and expenses as well as behavioral barriers such as hesitancy, fear, and uncertainty."
45486225|NCT03197740|Drug|Donepezil patch|Treatment
45486226|NCT03197740|Drug|aricept Tab|Comparator
46052350|NCT00591370|Drug|Temozolomide (TMZ)|One group treatment study
46052351|NCT02815371|Procedure|Needle Acupuncture|See above
45486227|NCT03197428|Other|Platelet-rich plasma|Platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament
45486228|NCT03197428|Other|Control|Whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament
45486229|NCT04050878|Device|Facial scanner (Bellus3D) to assess perioral alterations|Use of a digital caliper for conventional measurements and a facial scanner (Bellus3D) to analyse the modifications induced by the use of implant supported dental prostheses in the lip support
45486230|NCT02450266|Device|Systematic transrectal ultrasound-guided prostate biopsy|12-18 systematic biopsy cores
45486231|NCT02450266|Device|MRI/ultrasound fusion-guided prostate biopsy|2 targeted biopsy cores from each prostate lesion
45486232|NCT03197116|Other|Telephone reminder|Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
45486233|NCT03197116|Other|No other|No additional reminder will be offered
45486234|NCT02444962|Device|HAVD-implant|hydroxy-apatite coated, acid etched implant for extra oral use to reconstruct craniofacial defects with an episthesis
45486235|NCT04200989|Biological|Peanut allergen|Intralymphatic immunotherapy injections.
45486236|NCT02450110|Device|Spinal cord stimulation|
45486237|NCT03748355|Genetic|Pharmacogentic Analysis|Participant will complete a buccal swab and it will be sent off to OneOme for analysis. When the results are available, the study investigators will review the medications for potential drug-drug and drug-genotype interactions. The risk for interactions will be classified as low, medium or high. The investigators will then communicate to the clinical team taking care of the patient these results and whether medication changes are recommended to minimize the drug-drug and drug-genotype interactions.
45486238|NCT02444884|Drug|MLN8237|
45486239|NCT02450032|Biological|G17DT|
46052352|NCT02815371|Procedure|Laser Acupuncture|See above
46052353|NCT02815371|Procedure|Sham Laser Acupuncture|See above
46052354|NCT02810769|Dietary Supplement|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
45486240|NCT03201796|Drug|Prulifloxacin 600 mg|Oral administration of one tablet once daily for 28 days of prulifloxacin 600 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
45486241|NCT03201796|Drug|Levofloxacin 500mg|Oral administration of one tablet once daily for 28 days of levofloxacin 500 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
45486242|NCT03107260|Other|To evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in emergency surgery in elderly patients|Evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in non-cardiac, thoracic and vascular emergency surgery in patients 65 years of age and older. The occurrence of POCD will be defined by the MMSE decrease of at least 4 points at 24, 48 or 72 hours
45486243|NCT02727998|Drug|Ketamine|Prolonged exposure therapy combined with a single infusion of 0.50 mg/kg/hour for 40 min on day 2.
45486244|NCT02727998|Drug|Midazolam|Prolonged exposure therapy combined with a single infusion of 0.045 mg/kg/hour for 40 min on day 2.
46052355|NCT02810769|Dietary Supplement|Control|Sugar matched control containing berry flavouring and no phytochemicals
46052356|NCT02810769|Dietary Supplement|Powdered berry drink|Berry drink made from a powder concentrate standardised to contain 500mg of polyphenols
45486245|NCT02444806|Other|Full polysomnography|Full sleep and respiratory monitoring with EEG
46052357|NCT02810691|Dietary Supplement|Soluble fiber supplementation|Two different doses of psyllium powder will be diluted in 250 ml of orange-flavored water and drink in 5 minutes before breakfast.
46052358|NCT02810691|Dietary Supplement|Placebo (for fiber supplementation)|Placebo will consist of 250 ml of orange-flavored water to be drink in 5 minutes before breakfast.
46052359|NCT00910728|Drug|AZD1480|Oral capsule 2.5 mg, 10 mg and 40 mg
45486246|NCT02444806|Other|Oximetry-capnography|Limited monitoring with nurse observation and continuous oximetry-capnography overnight for NIV titration.
45486247|NCT02636270|Drug|Increlex|Treat PAPP-A2 deficient patients with Increlex
45486248|NCT04366349|Biological|melrilimab (GSK3772847) 70 milligram (mg)|melrilimab (GSK3772837) will be available at a dose strength of 70 milligram per milliliter (mg/mL) in a 3 milliliter (mL) glass vial.
45486249|NCT04366349|Biological|melrilimab (GSK3772847) 140 milligram (mg)|Two doses of melrilimab (GSK3772837) 70 milligram per milliliter (mg/mL) will be administered to achieve a dose strength of 140 milligram per milliliter (mg/mL)
45486250|NCT04366349|Other|Placebo|Placebo to match melrilimab (GSK3772847) will be available in the form of solution for injection in a 3 milliliter (mL) glass vial.
45486251|NCT02108990|Drug|Acetaminophen|
45486252|NCT01996046|Other|FDG PET/CT scan|[18F] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
45486253|NCT01766648|Device|Far Cortical locking screw fixation|Standard screw fixation
45486254|NCT01766648|Device|Standard screw fixation|
45486255|NCT03194074|Drug|Propofol|In propofol/remifentanil group, propofol at a rate 75~150 µg/kg/min and remifentanil at 0.1-0.3 µg/kg/min are maintained throughout surgery.
45486256|NCT03194074|Drug|Desflurane|In desflurane/remifentanil group, desflurane at end tidal concentration at 0.7~1.0 minimum alveolar concentration (MAC) and remifentanil 0.1-0.3 ug/kg/min are used.
45486257|NCT03748277|Procedure|Decompression|Bilateral decompression
45486258|NCT03748277|Procedure|PLIF|Traditional open surgery
45486259|NCT03748277|Procedure|MIS TLIF|On the one side - Wiltse approach, on the other side - percutaneous
45486260|NCT03748277|Procedure|Screw Fixation|Transpedicular Screw Fixation
45486261|NCT01163864|Behavioral|affect regulation training|8 sessions of a 1-hour long treatment intended to help women deal more effectively with negative affect; cognitive-behavioral smoking cessation intervention
45486262|NCT01163864|Behavioral|health and lifestyle|8 sessions of a 1-hour long treatment designed to help women improve their overall health; cognitive-behavioral smoking cessation intervention
45486263|NCT03201952|Drug|Ursodeoxycholic Acid|Ileostomy administration of 300mg UDCA once
45486264|NCT03201952|Drug|Placebos|Ileostomy administration of 5cc saline placebo once
46052360|NCT04235517|Other|Temporary hemi-epiphysiodesis or epiphysiodesis|Tension band plate (eight-plate, pedi plate), staple or locking plate
45486265|NCT04179461|Drug|Cholecalciferol|Oral administration
45486266|NCT04179461|Drug|antihistamine|Oral administration
45486267|NCT04179461|Drug|Azithromycin|Oral administration
45486268|NCT04179461|Drug|emollient cream|Topical
45486269|NCT04179461|Drug|Fluticasone Propionate|Nasal spray
45486270|NCT04179461|Drug|Asthma Controller Medication|Study participants asthma controller medication may be increased based off of their asthma control and the recommendation of the personalized plan.
45486271|NCT03193840|Procedure|posterior wall osteotomy|posterior wall osteotomy is conducted through Kocher-Langenbeck approach.
45486272|NCT03748199|Drug|POL6014|"DL1 80 mg cohorts 1A and 1B (80 mg QD and 40 mg BID) DL2 160 mg cohorts 2A and 2B (160 mg QD and 80 mg BID) DL3 40 mg QD cohort C~DL = dose Level QD= quaque die (once daily) BID= bis in die (twice daily)"
45486273|NCT03748199|Drug|Placebo|Placebo will be administered orally at a dose and frequency matched to POL6014
45486274|NCT03201484|Other|FACE-Q questionnaire, 3D photography|FACE-Q questionnaire, 3D photography
45486275|NCT04017611|Device|INVSENSOR00038|Noninvasive regional oximeter
45486276|NCT03119350|Other|Physical Training|"Intervention with concurrent physical training: strength and aerobic exercises in the same session.~Duration: 2 weeks of adaptation to physical exercise, 8 weeks of training. Frequency: 3 times a week. Time: 55 minutes each session. Intensity: 75 to 90% of maximum heart rate."
45486277|NCT04844528|Drug|Nicotinamide|oral nicotinamide 500 mg twice daily (BID)
45486278|NCT04844528|Drug|Placebo|oral placebo twice daily for first year. Cross over to oral nicotinamide 500 mg twice daily (BID) for year two.
45486279|NCT03117296|Other|Post procedure daily PT and OT|PT evaluation and treatment on post procedure day zero: Nurses mobility patient using egress testing one time
45486280|NCT03117296|Other|PT post procedure|post procedure day one: PT and OT assessment, education and intervention.
45486281|NCT03117296|Other|OT post procedure|PT and OT Daily until goals met or patient discharge.
45486282|NCT03117296|Other|Routine PT or OT|Routine PT or OT consulted by physician when identified discharge disposition of home
45486283|NCT03196882|Drug|40mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution. The doses of 40 mg per day of elemental iron correspond to 300 mg ferrimanitol ovoalbumin
45486284|NCT03196882|Drug|20mg/day of iron|Ferrimanitol ovalbumin granulated Powder for oral solution. The doses of 20 mg per day of elemental iron correspond to 150 mg ferrimanitol ovoalbumin
45486285|NCT03196882|Drug|80mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution The doses of 80 mg per day of elemental iron correspond to 600 mg ferrimanitol ovoalbumin.
45486286|NCT04172831|Drug|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
45486287|NCT04172831|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
45486288|NCT03196804|Drug|LC28-0126|LC28-0126
45486289|NCT03196804|Drug|Placebo|Placebo
45486290|NCT04839770|Device|Axonpen system|"The Axonpen™ system, containing the Axonpen and the Axonmonitor, has been cleared for the illumination and visualization of intracranial tissue and fluids and the controlled aspiration of tissue and/or fluid during surgery of the ventricular system or cerebrum.~The Axonpen is a neuroendoscope integrated with suction (sourced from hospital vacuum) and irrigation (sourced from third-party saline infusion bag) functions. The Axonmonitor is used for view and storage of the endoscopic image. The Axonpen™ system is intended to optimize the procedure of minimally invasive neurosurgery for early ICH evacuation."
45486291|NCT02444650|Device|Pulse wave velocity measurement Photoplethysmogram|Correlation of pulse wave velocity measurement.
45486292|NCT02444650|Device|tonometer|
45486293|NCT03118960|Device|Freedom Bed|This is an automatic rotational system in a bed designed to disburse capillary pressure
45486294|NCT03118960|Device|Group II Low Air Loss/Alternating Pressure Mattress|Subjects placed on the Group II Low Air Loss/Alternating Pressure Mattresses will require manual repositioning every 2 hours
45486295|NCT01562717|Drug|Ibuprofen|3 times a day
45486296|NCT01562717|Drug|Placebo|3 times a day
45486297|NCT03196648|Other|Gingival health formulation in an accelerating device|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used with the GLO Science Device
45486298|NCT03196648|Other|Gingival health formulation on a toothbrush|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used on a toothbrush together with toothpaste.
45486299|NCT03196648|Other|OTC fluoride toothpaste|OTC anti-cavity toothpaste containing fluoride and sodium monofluorophosphate.
45486300|NCT03111914|Diagnostic Test|Dual Energy Computed Tomography|"The subject's diagnostic scan will be preceded by a not clinically indicated non enhanced dual energy scan. The overall radiation dose to the patient for the first and second acquisition will be twice the radiation dose of a conventional CT of the chest, abdomen and pelvis. The non enhanced dual energy scan will be repeated during a clinical follow-up after the subject's first three months of enrollment and at a clinical follow-up after six months of enrollment.~The clinically-indicated, contrast-enhanced diagnostic scan will be performed according to standard of care."
45486301|NCT03744923|Procedure|transmuscular QL block|"Ultrasound device will be used; The probe is placed in the mid-axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall. Then, scan dorsally keeping the transverse orientation until observing that the transversusabdominus muscle becomes aponeurotic, and this aponeurosis is followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle.~The view of the psoas major muscle (PM) anteriorly, the erector spinae muscle (ESM) posteriorly and the QL muscle adherent to the apex of the transverse process result in a well recognizable pattern of a Shamrock with three leaves (trifoliate)."
45486302|NCT03744923|Procedure|Transversus Abdominus Plane block|"Posterior TAP block will be performed on the same side of surgery (unilateral) under ultrasonographic guidance with a with broadband (7-13MHz) linear probe covered with a sterile plastic sheath. Probe will positioned transversely midway between the iliac crest and the costal margin at level of mid axillary line.~Once the external oblique muscle (EOM), internal oblique muscle (IOM) and transversus abdominis muscle (TAM) are visualized at the level of the mid axillary line between the 12th rib and the iliac crest, the puncture area and the ultrasound probe were prepared in a sterile manner. After identification of the neuro-facial plane between IOM and TAM, block was performed with 20G spinal needle. The needle will be directed to approach the TAP with in-plane USG-guided technique. Once the tip of the needle placed in the space between the IOM and TAM, Inject a 1 ml test dose of lidocaine 2% for hydrovisualization of needle-tip position and confirming its correct postioning."
45486303|NCT03193138|Drug|Hormonal therapies: G03, H01C and L02 in the ATC classification|Hormonal therapies including all therapies classified G03, H01C and L02 in the ATC classification
45486304|NCT03625310|Drug|Sodium Fluoride|
46052361|NCT04103580|Behavioral|Photo elicitation|Caregivers are taught to use photos to illustrate various feelings and meanings
46052362|NCT02813499|Other|CARE Rule|Evaluation of the clinical suspicion of myocardial infarction, calculation of CARE rule and troponin assay performed by the practitioner.
46052363|NCT02332200|Other|Physical Therapy|Physical therapy will consist of standard physical therapy care for spondylolysis or spondylolisthesis.
46052364|NCT05631249|Drug|Sotorasib 120Mg Tab|Daily sotorasib treatment until progression, unacceptable toxicity, death, or lost to follow-up
46052365|NCT02810925|Procedure|PENS T6|Patients undergo percutaneous electrical stimulation of dermatome T6, weekly, during 12 weeks.
45486305|NCT03625310|Drug|Sodium Fluoride with TCP|
45486306|NCT03625310|Drug|Sodium Fluoride with CXP|
45486307|NCT03625310|Drug|Sodium Fluoride with CPP-ACP|
45486308|NCT03192982|Device|A-V impulse 6000 Series|foot pad and pump
45486309|NCT03192982|Device|Standard treatment (compression)|Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg
45486310|NCT05058404|Drug|Immunochemotherapy regimen: Rituximab-bendamustine (Arm A)|"Arm A (Standard arm):~4 cycles of Rituximab-bendamustine Q28 (28-days cycles); Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of R-bendamustine Q28 + 2 cycles Q28 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
45486311|NCT05058404|Drug|Immunochemotherapy regimen: Rituximab-bendamustine (Arm B)|"Arm B (Experimental arm):~4 cycles of Rituximab-bendamustine Q28 (28-days cycles);~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~if in CR: patients will receive no more chemotherapy but will complete induction with the MoAb only, in this case: 4 cycles of rituximab;~if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of R-bendamustine Q28 + 2 cycles Q28 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
45691704|NCT00673738|Radiation|Conformal Thoracic Radiotherapy (CTRT)|"Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week CBCs, differentials, and BUN plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted.~Radiation therapy will begin on day 8 (with window of ± 3 days). Adequate hematologic profile (ANC >1,000 and platelets >75,000) required. Patient may be delayed for a max. of 2 weeks. If > 2 week delay occurs, patient will come off study."
45368761|NCT00951626|Procedure|standard follow-up care|Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge. Also the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant.
45368762|NCT03994666|Biological|allogeneic umbilical cord-derived mesenchymal stem cells|Injection of mesenchymal stem cells
45486312|NCT05058404|Drug|Immunochemotherapy regimen: R-CHOP (Arm A)|"Arm A (Standard arm):~4 cycles of R-CHOP Q21 (21-days cycles); R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of R-CHOP Q21 + 2 cycles Q21 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion: these patients will be included in the analysis planned by the study."
45486313|NCT05058404|Drug|Immunochemotherapy regimen: R-CHOP (Arm B)|"Arm B (Experimental arm):~4 cycles of R-CHOP Q21 (21-days cycles); R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~After cycle 4 patients will undergo an early restaging: induction therapy shall be completed based on the response achieved and on the treatment chosen:~if in CR: patients will receive no more chemotherapy but will complete induction with the MoAb only, in this case: 4 cycles of rituximab;~if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of R-CHOP Q21+ 2 cycles Q21of rituximab~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the EOI shall be considered for salvage therapy at clinician discretion: these patients will be included in the analysis."
45486314|NCT05058404|Drug|Immunochemotherapy regimen: G-bendamustine (Arm A)|"Arm A (Standard arm):~4 cycles of G-bendamustine Q28 (28-days cycles); G-Bendamustine = Obinutuzumab and Bendamustine~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of G-bendamustine Q28 (28-days cycles);~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in Stable Disease SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
45486315|NCT05058404|Drug|Immunochemotherapy regimen: G-bendamustine (Arm B)|"Arm B (Experimental arm):~4 cycles of G-bendamustine Q28 (28-days cycles); G-Bendamustine = Obinutuzumab and Bendamustine~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case 2 cycles of obinutuzumab;~if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of G-bendamustine Q28;~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
46052366|NCT02810925|Procedure|TENS T11/T12|Patients undergo transcutaneous electrical stimulation of dermatomes T11-T12, weekly, during 12 weeks.
46052367|NCT02810925|Dietary Supplement|Hypocaloric 1200 Kcal/day diet|Patients follow a Hypocaloric 1200 Kcal/day diet during 12 weeks.
45691705|NCT00674206|Drug|Gemcitabine|Gemcitabine 1000mg/m^2 on day 1 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
45691706|NCT00674206|Drug|Oxaliplatin|Oxaliplatin 100mg/m^2 on day 2 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
45691707|NCT00595270|Biological|IC51|
46052368|NCT02810925|Dietary Supplement|Normocaloric 2000 Kcal/day diet|Patients follow a Normocaloric 2000 Kcal/day diet during 12 weeks.
46052369|NCT04774224|Drug|Baricitinib|Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. Two-thirds of participants will receive Baricitinib.
46052370|NCT04774224|Drug|Placebo|Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. One-third of participants will receive Placebo.
46052371|NCT04248894|Other|Exercise training of High Intensity|High intensity
46052372|NCT04248894|Other|Exercise training of Moderate Intensity|Moderate intensity
46052373|NCT04248894|Other|Untraining|Sedentary
45368763|NCT03994666|Biological|Placebo (NaCl)|Placebo injection
45368764|NCT03994588|Procedure|Intraperitoneal Mesh hernia repair|The mesh will be inserted intraperitoneally for complex ventral hernia repair and fixed according the previously described ADMIR technique.
45368765|NCT00951782|Device|High frequency TMS|deep TMS HADD coil
45368766|NCT00951782|Device|Sham TMS|sham deep TMS HADD coil
45368767|NCT00951782|Device|Low frequency TMS|Deep TMS - HADD coil
45486316|NCT05058404|Drug|Immunochemotherapy regimen: G-CHOP (Arm A)|"Arm A (Standard arm):~4 cycles of G-CHOP Q21 (21-days cycles) G-CHOP = Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of G-CHOP Q21 + 2 cycles Q21 of obinutuzumab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
45486317|NCT05058404|Drug|Immunochemotherapy regimen: G-CHOP (Arm B)|"4 cycles of G-CHOP Q21 (21-days cycles) G-CHOP = Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case: 4 cycles of obinutuzumab;~if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of G-CHOP Q21 + 2 cycles Q21 of obinutuzumab;~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the EOI shall be considered for salvage therapy at clinician discretion."
45486318|NCT05058404|Drug|Immunochemotherapy regimen: G-CVP (Arm A)|"Arm A (Standard arm):~4 cycles of G-CVP Q21 (21-days cycles) G-CVP = Obinutuzumab, Cyclophosphamide, Vincristine, Prednisone.~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 4 cycles of G-CVP Q21;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
45486319|NCT05058404|Drug|Immunochemotherapy regimen: G-CVP (Arm B)|"Arm B (Experimental arm):~4 cycles of G-CVP Q21 (21-days cycles) G-CVP = Obinutuzumab, Cyclophosphamide, Vincristine, Prednisone.~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case: 4 cycles of obinutuzumab;~if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 4 cycles of G-CVP Q21~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
45486320|NCT03118336|Drug|Empagliflozin 10Mg Tab|1 tablet of 10 milligrams per bone 1 time a day during 12 weeks
45486321|NCT02444572|Drug|Enoxaparin 4000 IU|
45486322|NCT03196726|Behavioral|Brief Cognitive Behavioral Therapy|Week 1: Understanding postnatal depression Week 2: Relaxation techniques and tips to reduce stress Week 3: Positive thinking style and Self-Esteem Week 4: Relationship with partner Week 5: Relationship with infant Week 6: Relapse prevention
45486323|NCT03196726|Behavioral|standard management based on Clinical Practice Guideline|Mild depression: behavioral therapy; moderate depression: behavioral therapy and consider anti-depressant if required
45486324|NCT04165031|Drug|LY3499446|Administered orally
45486325|NCT04165031|Drug|Abemaciclib|Administered orally
45486326|NCT04165031|Drug|Cetuximab|Administered IV
46052374|NCT02813187|Biological|cellular and tissue based therapy|
46052375|NCT02813187|Procedure|debridement|
46052376|NCT02813187|Procedure|advanced wound therapy|
46052377|NCT02813187|Dietary Supplement|Nutritional screening|
46052378|NCT04419207|Diagnostic Test|Breath test|Exhaled breath of each participant will be collected with air bags and directly detected by a high-resolution high-pressure photon ionization time-of-ﬂight mass spectrometry (HPPI-TOFMS).
45368768|NCT02939638|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
46052379|NCT02815527|Other|Fresubin intensive|Enteral nutrition containing a high protein concentration
46052380|NCT02810379|Procedure|written informed consent|
46052381|NCT02810379|Procedure|video+written informed consent|
46052382|NCT05629923|Drug|tixagevimab-cilgavimab(AZD7442, AstraZeneca)|In the case of antibody level <100 IU/ml, patients were invited to prophylaxis with tixagevimab-cilgavimab(AZD7442, AstraZeneca).
45368769|NCT02939638|Other|Control Diet|Participants will be asked to continue their usual diets for the 16-week study period.
45368770|NCT00945698|Dietary Supplement|Lipid-based nutrient supplement, 10gM|"140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
45368771|NCT00945698|Dietary Supplement|Lipid-based nutrient supplement, 20gM|"280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
45368772|NCT00945698|Dietary Supplement|Lipid-based Nutrient Supplement, 20gNoM|"280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
45486327|NCT04165031|Drug|Erlotinib|Administered orally
45368773|NCT00945698|Dietary Supplement|Lipid-based nutrient supplement, 40gM|"560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
45486328|NCT04165031|Drug|Docetaxel|Administered IV
45486329|NCT03118258|Behavioral|'Pap smear' arm|"Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by direct patient referral for Pap smear testing in a partner health facility."
45486330|NCT03118258|Behavioral|'Self-collected vaginal swab for HPV testing + pap smear triage' arm|"Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive.~A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason."
45486331|NCT05480930|Other|paper-based clinical decision support (dCDS) tool|The paper based clinical decision support tools currently employed at the TMDS that are used to triage, assess and generate treatment plans for pediatric patients.
45691708|NCT00628498|Drug|Defibrotide|"Defibrotide is a single-stranded polydeoxyribonucleotide derived from porcine intestinal mucosa by controlled depolymerisation. Defibrotide has a complex mechanism of action with antithrombotic, anti-ischemic, anti-inflammatory, anti-adhesive and thrombolytic properties but no significant systemic anti-coagulant effects.~Defibrotide is dose intravenously as a 2-hour infusion every 6 hours at a dose of 25 mg/kg/day. Recommended duration of therapy is 21 days."
45691709|NCT00628498|Drug|Defibrotide|
46052383|NCT05629065|Other|Clinician Nudge Email|"-Clinician nudge email encouraging discussion to initiate discussion on SIC at next visit"
46052384|NCT05629065|Other|Patient Nudge Letter and Share questionaire|"Involves patient nudge consists of a letter and SHARE questionnaire~- patient nudge is a letter and a SHARE questionnaire encourages the participant to complete the SHARE questionnaire, which asks questions about the participants goals and preferences around cancer care, and discuss the questionnaire with their oncology clinician at the next visit."
46052385|NCT02810535|Other|Observation|"Visit 1:~Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~Completion of a Health Questionnaire~Lung function testing with spirometry~Skin prick test~Visit 2:~Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~Measurement of nitric oxide in expired air (FeNO)~Taking nasal secretion samples with a cotton carrier for 15 min~Nasal provocation test with dust mite~Blood sample collection to define blood count, IgE and specific IgE"
46052386|NCT02810223|Biological|CART-19|2 to 5 x 10(6) autologous CART-19 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
45368774|NCT00945698|Dietary Supplement|Lipid-based Nutrient Supplement, 40gNoM|"560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
45368775|NCT00945698|Dietary Supplement|Maize-soy flour|"No food supplement during the primary trial period (6 to 18 months of age)~1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
45368776|NCT01565824|Other|web-based support|
45486332|NCT05480930|Other|digital clinical decision support (dCDS) tool|The intervention is a digitized version of the paper based clinical decision support tools currently employed at the TMDS that are used to triage, assess and generate treatment plans for pediatric patients.
45486333|NCT05480150|Drug|Escitalopram Oxalate Tablets|Starting at 5mg qn, the treatment dose was titrated to 10-20mg qn within 1 week and maintained for 4 weeks
45486334|NCT05480150|Drug|Quetiapine Fumarate Tablets|Starting at 50mg qn, the treatment dose was titrated to 300-400mg qn within 10 days, and maintained the treatment for 4 weeks.
45486335|NCT05480150|Drug|Lurasidone|Starting at 20mg qn, the treatment dose was titrated to 40mg qn within 6 days,and maintained the treatment for 4 weeks.
45691710|NCT00629122|Drug|Tacrolimus (Arm B)|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
45486336|NCT03196570|Behavioral|Physical Activity Intervention|After randomization into the intervention arm, participants will be instructed on how to use the Spanish language study website. During the six month intervention, they will complete online questionnaires to determine their stage of change towards increasing physical activity. A manual of information will be automatically generated based on their responses. Participants can read this information online, along with tip sheets related to increasing physical activity. On the website they can also set weekly goals and log their weekly PA. It will also include short videos with demonstrations for PA they can do at home and around their neighborhood. Information will also include community resources (community centers, public events, parks) where they can be physically active. Participants will also receive prompts and encouragement via text-message to encourage them to log into the website and continue to track their progress.
45486337|NCT03196570|Behavioral|Wellness Contact Control|Participants in the control arm will attend the same baseline orientation sessions and measurements as the intervention arm. After randomization into the control group, participants will complete an introductory in-person session to introduce them to a website, similar in design, with information on health topics other than physical activity, including diet and other factors associated with CVD risk. It will include information from NHLBI heart health materials for Latinos. Topics include healthy eating, increasing fruit and vegetable consumption, reducing fat and salt intake, learning about cholesterol, stress management. Participants will log onto a separate website unique to the control group and complete monthly surveys on the wellness topics and their progress. Participants will also receive prompts and encouragement text-messages to encourage them to log onto the website.
45486338|NCT05464628|Drug|Atorvastatin|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
45486339|NCT05464628|Drug|ASC42|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
45486340|NCT03196492|Other|No intervention|No intervention
45486341|NCT04829630|Biological|rabies vaccine|"day 0 : questionnaire, blood sampling and vaccine booster (a single session of two intradermal doses of 0.1 mL)~day 7 : questionnaire and blood sampling"
45486342|NCT02712424|Biological|DAR-901|
45486343|NCT02712424|Biological|Sterile saline placebo|
45486344|NCT03196414|Biological|CART-138/BCMA/19/more|Cyclophosphamide，Fludarabine，CART-138/BCMA /19/more cells Cyclophosphamide: 300 mg/m2 IV over 30 minutes on days -5 , -4,and -3; Fludarabine: 30 mg/m2 IV over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3 Biological: Anti-CD138/BCMA/CD19/more total CART cells 5x106- 100x106 CAR+ T cells per kg of recipient bodyweight
45486345|NCT02449408|Other|Measurement of leptin and adiponectin obtained through blood sampling via venipuncture or finger/heelstick using novel screening tool|
45486346|NCT02449330|Drug|Teneligliptin|
45486347|NCT03653884|Diagnostic Test|Ultrasound monitoring|Ultrasound monitoring is recommended during the third trimester in search of an increase in dilation and especially the appearance of a thrombus. A particular clinical form, related to abnormal umbilical vein involvement in the infra-hepatic portal system, must be individualized because of a high risk of thrombosis. It justifies the realization of an abdominal ultrasound in the first days of life. This is an aneurysm of the umbilical vein when the umbilical vein has a diameter greater than 9 mm, or a diameter of the subhepatic segment of the umbilical vein greater than 50% of the diameter of its intrahepatic segment.
45486348|NCT03648814|Procedure|Intracameral injection|A/C injection of 1.25 mg/0.05 mL bevacizumab
45368777|NCT04222634|Other|Radiotherapy (SBRT) and/or surgery (metastasectomy)|Metastasis-directed therapy (surgery and/or radiotherapy) as treatment for oligoprogressive lesions
45368778|NCT01030510|Drug|the order of drug administration|In group R, remifentanil was infused first before administrating propofol and rocuronium and in group P, it was administered last after the rocuronium injection. In other words, the order of drug infusion in each group is remifentanil-propofol-rocuronium in group R and propofol-rocuronium-remifentanil in group P, respectively.
45368779|NCT00941876|Behavioral|Facilitated Referral|Seven key steps carried out by CTC and FP staff to encourage completion of FP referral by CTC.
45368780|NCT04813822|Drug|Miconazole Nitrate 2% + Domiphen Bromide Low Dose|Dosage 1
45368781|NCT04813822|Drug|Miconazole Nitrate 2% + Domiphen Bromide High Dose|Dosage 2
45368782|NCT04813822|Drug|Miconazole Nitrate 2%|Active Comparator
45486349|NCT03648814|Procedure|Intravitreal injection|Vitreous injection of 1.25 mg/0.05 mL bevacizumab
45486350|NCT02968004|Drug|MOD-4023|Once weekly subcutaneous injection using pre-filled pen device.
45486351|NCT02968004|Drug|Somatropin|Once daily subcutaneous injection of Genotropin using pre-filled pen device.
45486352|NCT03192592|Other|Body moisturizer|Daily body moisturizer application for skin protection and barrier.
45368783|NCT00951860|Other|Autonomic Nervous System activity|Autonomic activity measured at birth and at 6, 12, 18 and 24 months is represented by time-domain indices (SDNN index, SDANN, pNN50) and frequency- domain indices(PTOT, VLF, LF, HF, ratio LF / HF, LFnu, HFnu), which reflect the short-term variability (parasympathetic branch) and medium term (ortho and parasympathetic branch) of the vegetative balance. This subtle technical assessment of autonomic functioning has been validated in the literature for two decades
45486353|NCT05234164|Device|EXIST 6F NiTi Stent System FLEX|Subjects requiring treatment of the P1 segment of the proximal popliteal artery will be treated with the Exist 6F NiTi Stent FLEX type. Subjects requiring treatment of the SFA will undergo an additional calcification review based on the Fanelli classification. Subjects graded with Fanelli 1 or 2 will be treated with the Exist 6F NiTi Stent FLEX type.
45486354|NCT05234164|Device|EXIST 6F NiTi Stent System PULL|Subjects requiring treatment of the SFA will undergo a calcification review based on the Fanelli classification. Subjects graded with Fanelli grade 3 and 4 will be treated with the Exist 6F NiTi Stent PULL type.
45486355|NCT03705260|Other|Usual Care|Usual care from Primary Care Physician and dietitian.
45486356|NCT03705260|Behavioral|Intensive Behavioral Intervention|The intensive behavioral intervention which will incorporate lower carbohydrate diet, diet coaching, and more intensive glucose monitoring.
45486357|NCT03705260|Other|Monthly Screening for Risk|Monthly screening of HbA1C to identify patents who have become poorly controlled in the interval.
45486358|NCT03118180|Biological|CD19 targeted chimeric antigen receptor T cells|CD19 targeted chimeric antigen receptor T cells for refractory and relapsed B cell lymphoma
45486359|NCT03705182|Device|Fluorescence visualization (feedback)|UVA-light will illuminate the skin of head, neck, arms and hands and the fluorescent areas will be recorded and quantified by a computer vision system each time the participant leaves a production area. The intervention group will be shown the fluorescent areas on their skin, the control group will not have this opportunity
45486360|NCT03193762|Other|Anxiety VAS|Anxiety will be measure with a 10-points visual analogic scale (VAS)
45486361|NCT05461352|Drug|TS-142 5 mg|Participants received repeated doses of 5 mg of TS-142 (oral tablet)
45486362|NCT05461352|Drug|TS-142 10 mg|Participants received repeated doses of 10 mg of TS-142 (oral tablet)
45486363|NCT05455502|Drug|VX-548|Tablet for oral administration.
45486364|NCT03193918|Drug|Crenolanib|Crenolanib continuously on Days 1-28 at 1 of 3 BID doses - 60 mg, 80 mg or 100 mg
45486365|NCT03193918|Drug|Ramucirumab|Ramucirumab IV 8 mg/kg on Days 1 and 15 q28 days
45486366|NCT03193918|Drug|Paclitaxel|Paclitaxel IV 80 mg/m2 on Days 1, 8 and 15 q28 days
45486367|NCT05427812|Drug|ISB 1442 SC injection escalating doses|Participants will receive escalating SC doses of ISB 1442
45486368|NCT05427812|Drug|ISB 1442 SC injection at RP2D|ISB 1442 SC injection dose regimen at RP2D until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met
45486369|NCT02449096|Device|Arthroscope|AORIF - arthroscopically assisted open reduction and internal fixation of acute ankle fractures
45486370|NCT02449096|Other|No arthroscope|ORIF - open reduction and internal fixation of acute ankle fractures
45486371|NCT02912312|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RNI
45486372|NCT02912312|Other|Laboratory Biomarker Analysis|Correlative studies
45486373|NCT02912312|Other|Quality-of-Life Assessment|Ancillary studies
45486374|NCT02912312|Other|Questionnaire Administration|Ancillary studies
45486375|NCT02912312|Radiation|Radiation Therapy|Undergo standard RNI
45486376|NCT03117790|Drug|Dexmedetomidine|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
45486377|NCT03117790|Drug|Placebo|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
45368784|NCT00945776|Behavioral|Weekly phone calls|Calling weekly to answer questions regarding CPAP usage.
45368785|NCT00945776|Behavioral|Frequently asked questions|Answers to frequently asked questions in pre-printed form.
45368786|NCT00945776|Behavioral|Usual care|Answers will be provided by the renter of the equipment, and the sleep center if asked in addition to explanations by the sleep specialist.
45486378|NCT03117712|Diagnostic Test|Delirium Scores|"Confusion Assessment method for the ICU (CAM-ICU) and~The Intensive Care Delirium Screening Checklist (ICDSC)~Delirium Scores will be measured at the following timepoints:~Postoperative day (POD) 1~POD 2~POD 5"
45486379|NCT03117712|Diagnostic Test|Carotis duplex sonography|"Carotis duplex sonography for perfusion flow will be evaluated at the following timepoints:~Before induction of anaesthesia~Before going on cardiopulmonary bypass (CBP)~During CPB, 5 min after aortic cross clamping~After CPB~24 hours after CPB"
45486380|NCT03117712|Diagnostic Test|TCD for detection of HITS|"Transcranial Doppler ultrasound (TCD) for detection and differentiation of high-intensity transient signals (HITS) in both middle cerebral arteries (MCAs) into artefacts, solid, and gaseous cerebral microemboli (CME) will be performed at the following timepoints:~During cannulation of the ascending aorta~After aortic cross-clamp~After opening of the aortic cross-clamp~During decannulation"
45486381|NCT05387720|Procedure|Manual diaphragmatic facilitation (PNF) technique|"Diaphragmatic PNF is a facilitator technique used to improve chest expansion, increase epigastric excursion, promote breathing frequency and depth, by applying external proprioceptive tactile stimuli over diaphragm. The therapist places the thumbs toward the xiphoid process and the fingers along the costal margins of the lower ribs and pushing deep to stimulate the diaphragm During inspiration, the patient will be instructed take a deep breath breathe in and the therapist assists the movement to promote the subject's respiratory pattern in downward movement. At the maximum inspiration, therapist will say hold your breath for 5 seconds. The therapist gives mild resistance to the inferior movement of the contracting diaphragm during inspiration while pushing diaphragm superiorly. During expiration, therapist says breathe out and pushed under lower ribs on both sides upward to assist the discharge of air remaining in the lungs."
45486382|NCT05387720|Procedure|Trigger sensitivity adjustment on mechanical ventilation|The pressure trigger sensitivity will be adjusted to 20% of the first recorded MIP at the start of training by decreasing trigger sensitivity towards negative pressure. In the first session, inspiratory muscle training (IMT) will be limited to 5 min; afterwards the duration will be increased by 5 min at every session until it reaches 30 min. If a patient tolerates 30 min of IMT, The next session will be performed with increasing negative pressure of the trigger sensitivity by 10% of the initial MIP. The maximal acceptable intensity is 40% of MIP, Patients who can't tolerate IMT with 20% of MIP for 5 min will be trained with 10% of MIP
45486383|NCT05387720|Procedure|concurrent trigger sensitivity adjustment and manual diaphragmatic facilitation (PNF) technique|Diaphragmatic PNF technique will be applied synchronously in the same time, on each breath with trigger sensitivity adjustment on mechanical ventilation in same manner as discussed before
45486384|NCT03193372|Drug|Azelaic Acid (Finacea Foam, BAY39-6251)|Finacea Foam, Active substance Azelaic acid
45368787|NCT02917564|Drug|Triamcinolone Acetonide 1 ml of 40 mg/mL suspension|After preparation, Triamcinolone Acetonide 1 ml of 40 mg/mL suspension is injected through the superotemporal conjunctival fornix using a 25 Gauge needle, 5/8 inch length on a 3 ml syringe, following the contour of the globe with the needle, external to sclera for the full length of the needle such that the needle tip is ultimately positioned immediately posterior to the macula with the bevel down.
45486385|NCT03034772|Drug|Dorzolamide-timolol|Topical eye drop (active comparator) used twice daily for study duration
45486386|NCT03034772|Other|Artificial tears|Topical eye drop (placebo comparator) used twice daily for study duration
45486387|NCT03196336|Other|Pharmacotherapy follow-up care|The pharmacotherapy follow-up care consists of five pharmaceutical consultations (every up to 2-3 months) aimed to identify, prevent and solve the drug related problems regarding the indication, effectiveness and safety of the use of medicines.
45486388|NCT03196258|Behavioral|Cognitive behavioural therapy|Participants who are randomized to the CBT intervention are required to start CBT within 8 weeks of their fracture surgery. The CBT intervention will consist of 6 weekly one-on-one, 1-hour sessions that will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses on the SPOC questionnaire. All other aspects of post-operative care will be at the discretion of participant's surgeon
45486389|NCT03704870|Diagnostic Test|Chest Xray|Daily chest xray
45486390|NCT03704870|Diagnostic Test|No daily chest xray|Chest xray will be done post chest tube removal only
45691711|NCT00629122|Drug|Clotrimazole Troche|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
46052387|NCT02810301|Other|Probiotic ES1|B. longum ES1 is formulated for oral use as Glutagest. Each capsule contains 1 billion CFU of B. longum. The capsules are off-white in color and cylindrical in shape with approximate dimensions of 19 mm x 6.63 mm and a weight of 500 mg. Non-medicinal ingredients consist of the common excipients filler rice maltodextrin, lubricant stearic acid, and encapsulating agent vegetable cellulose.
46052388|NCT02810301|Other|Placebo|The placebo is composed of the same non-medicinal ingredients as the investigational product (IP) (i.e. rice maltodextrin, stearic acid, and vegetable cellulose) but it does not contain the active ingredient B. longum ES1. The placebo is designed to resemble the IP in terms of physical appearance.
46052389|NCT00820222|Drug|capecitabine|oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle
45368788|NCT02917564|Other|Sham - Participants will not recieve the Triamcinolone Acetonide|Patients will be given a sham.
45368789|NCT00941954|Behavioral|Structured Education|The intervention group will be offered a group-based structured educational programme aimed at promoting increased ambulatory activity by targeting perceptions and knowledge of diabetes risk, physical activity self-efficacy, barriers to physical activity and self-regulatory skills based on pedometer use. The programme will employ a person-centred approach to patient education that is based on self-management programmes for individuals with type 2 diabetes and prediabetes that have been developed and tested by our research group. The programme will be designed to be delivered to 5-10 participants by two trained educators and is 3.5 hours long. Brief follow-up counselling will be offered once every 6 months.
46052390|NCT00820222|Drug|lapatinib|oral medication; daily dose taken once a day
45486391|NCT03196102|Behavioral|BTI|Brief Tobacco Intervention (BTI). The group intervention was designed to include the components of effective tobacco control programs for military personnel, and specifically tailored to the Technical Training environment. The intervention is approximately 40 minutes and delivered in a group format (e.g., groups of 50 Airmen). The format of the BTI is meant to be interactive, utilizing the Socratic teaching style and eliciting participation through the principles of motivational interviewing. A series of open-ended questions, reflections, and decisional balance, were used to increases motivation to remain tobacco free.
45486392|NCT03196102|Behavioral|Cigarette smoking military tailored pamphlet|The Airmen's Guide is 5×7 inches, 46 pages, with text and color illustration. The text covers the advantages of remaining tobacco-free after Basic Military Training, and the opportunity the ban provides to begin a lifetime without tobacco, focusing on cigarettes and smokeless tobacco. Information is included about challenges and coping suggestions for the times that Airmen are at particular risk of smoking. The text is supplemented by images created specifically for Airmen and designed to reinforce the messages that smoking: 1) is responsible for more fatalities than combat; 2) conveys a negative image to civilians; and 3) impedes military readiness and promotion through the ranks.
45486393|NCT03196102|Behavioral|Standard smoking cessation intervention|This booklet is a 36-page, comprehensive guide for quitting smoking with 7 pages dedicated to relapse-prevention.
45486394|NCT04794218|Drug|rVSV∆G-LASV-GPC|2 × 10^4 pfu delivered intramuscularly
45486395|NCT04794218|Drug|rVSV∆G-LASV-GPC|2 × 10^5 pfu delivered intramuscularly
45486396|NCT04794218|Drug|rVSV∆G-LASV-GPC|2 × 10^6 pfu delivered intramuscularly
45486397|NCT04794218|Drug|rVSV∆G-LASV-GPC|2 × 10^7 pfu delivered intramuscularly
45486398|NCT04794218|Other|Placebo/Diluent|N/A delivered intramuscularly
45486399|NCT03192514|Other|Electronic Deprescribing tool|"Each GP of the intervention group will have exclusive access to an electronic tool that will guide them on deprescribing. The innovative electronic tool created by the researchers provide the rationale on indications for prescribing or deprescribing Benzodiazepines or/and Non-benzodiazepine hypnotics and also provides an interactive tapering suggestion integrated on a calendar.~The tool emphasizes that any decision to continue or discontinue a drug remains a shared decision between GP and the patient.~The electronic Deprescribing tool is designed to support clinical decisions"
45486400|NCT05374460|Behavioral|Explanatory diagram|Participant is told there will be a mismatch between their target finger and the visual indicator of target finger position. They will be shown a diagram explaining this.
45486401|NCT05374460|Behavioral|Direct vision|Foamboard under mirror removed, making the mirror see-through and the hand directly visible. Mismatch between target hand and visual indicator will be directly visible.
45486402|NCT05374460|Behavioral|Movement feedback, target hand|After the participant points at each target, a cursor indicating final pointing position will be displayed briefly. The visual indicator of the target hand will be displaced.
45486403|NCT05374460|Behavioral|Movement feedback, pointing hand|After the participant points at each target, a cursor indicating final pointing position will be displayed briefly. The visual indicator of the target hand will not change, but the cursor indicating pointing hand position will change.
46052391|NCT00820222|Drug|trastuzumab|infusion therapy; loading dose of 8mg/kg, followed by 6mg/kg given every 3 weeks
46052392|NCT04181151|Other|Electromyographic device|An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.
46052393|NCT02810067|Procedure|Tunnel + AlloDerm|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm).
46052394|NCT02810067|Procedure|Tunnel + Novomatrix|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (Novomatrix).
45486404|NCT05374460|Behavioral|No movement feedback|The visual indicator of the target hand will be displaced, but there will be no cursor to indicate the pointing hand's position.
45486405|NCT05374460|Behavioral|Attend to the targets|Participants will not be told anything about the visuo-proprioceptive mismatch. Instead, they will be asked simply to attend to the target positions.
45486406|NCT02448940|Dietary Supplement|Species of Lactobacillus|2 capsule a day Lactofem probiotics containing Species of Lactobacillus
45486407|NCT02448940|Dietary Supplement|lactose|2 capsule a day containing lactose
45486408|NCT02644460|Drug|Abemaciclib|
45486409|NCT03193294|Diagnostic Test|Stratified medicine involving a diagnostic intervention|Adjunctive tests of coronary artery function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with no-obstructive coronary artery disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results). Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013)).
45486410|NCT03193450|Behavioral|telephone-based re-education|Patients will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
45486411|NCT03193450|Behavioral|First education at the clinic|Patients will receive an instruction card about the drug administration at the clinic by doctors.
45486412|NCT05302154|Behavioral|Distraction by dentist|Basic behavior orientation techniques (tell-show-do) is applied by the dentist during the treatment.
45846393|NCT02550132|Procedure|Spinal manipulation|Participants will lie down during the 45-minute experimental session. Vertebral displacements (cm) and muscle response amplitude (RMS value) will be recorded through kinematic markers (on T6, T7 and T8 spinous processes) and surface electromyography electrodes (on the left and right erector spinae at T6 and T8 vertebra level). Each SMT (4 per participant) will be delivered at T7 transverse processes by an apparatus. Responses during the thrust phase (duration equal to twice the time to peak force) and after the thrust (1,5s duration) will be compared between SMTs.
45846394|NCT02550132|Device|Apparatus used to deliver spinal manipulations|An apparatus using a servo-controlled linear actuator motor (Linear Motor Series P01-48x360, LinMot Inc., Switzerland) will be used to deliver spinal manipulations.
45368790|NCT00941954|Behavioral|Written Information|Control subjects will receive a booklet detailing information on risk factors for type 2 diabetes (T2DM) and cardiovascular disease (CVD) and how physical activity can be used to prevent T2DM and CVD.
45486413|NCT05302154|Behavioral|Distraction by cartoon movie|Children watch cartoons on a screen mounted dental unit during the treatment.
45486414|NCT05302154|Behavioral|Distraction by virtual reality glasses|During the treatment visual and auditory stimuli provide information about treatment to the patient with the help of avatars (characters) and environmental elements placed within the VRG application. In a vivid dentist room, the explanatory introduction part takes place while the movies are watched in a fairy world or a futuristic world to separate the user from the actual location and context. The application was designed to function in such a way as not to require outside intervention. From start to finish, the application interacts with the user through gaze selection and head tracking mechanisms. The avatar characters provide information related to the dental treatment in a joyful manner. Gamification elements such as gaining stars and collecting rewards have been used to keep the patient engaged. Motion blur feature ensures the patient to keep head still as sudden movements are dangerous and undesired by the dentist during the treatment.
46052395|NCT02815449|Other|Meals prepared with iron fortified cube with Low stabilizer level|Meals prepared with iron fortified cube with Low stabilizer level
46052396|NCT02815449|Other|Meals prepared with iron fortified cube with Medium stabilizer level|Meals prepared with iron fortified cube with Medium stabilizer level
45486415|NCT03193606|Other|nano silver fluoride solution|prepared Nano-silver fluoride could have the capability to arrest caries. As its Nano silver particles have an antimicrobial activity against Mutans Streptococci and Lactobacilli; the main pathogens involved in the development of carious lesions. In addition, its fluoride component is well known to enhance remineralization and inhibit bacterial activity. So, Nano silver fluoride could be a promising solution to combat residual bacteria in tooth cavity with effective remineralization potential on remaining carious dentin
45691712|NCT00629122|Drug|Tacrolimus (Arm A)|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
46052397|NCT02815449|Other|Meals prepared with iron fortified cube with High stabilizer level|Meals prepared with iron fortified cube with High stabilizer level
46052398|NCT02815215|Procedure|Minimally Invasive Carroll's Technique|Patient will be treated with minimally invasive Carroll's technique by 3 small incisions in the heel, in the medial side of the foot and in the planta pedis, respectively. Long-leg plaster cast fixation was applied for 6-8 weeks
46052399|NCT02815215|Procedure|Ponseti method|As a control, Patient will be treated with classical Ponseti method, including multiple steps: manipulative correction, continuous plaster, achilles tendon cutting, fixation.
45368791|NCT03079414|Procedure|Invasive Electrophysiology Study|Invasive electrophysiology studies will be performed using four catheters placed in the right ventricular apex, the coronary sinus, the His bundle region, and the high right atrium. Standard induction protocols for supraventricular and ventricular arrhythmias will be utilized in the absence and presence of isoproterenol. Long-short ventricular extra-stimuli will also be delivered to screen for bundle branch reentrant ventricular tachycardia. The study is considered observational as the participating sites perform electrophysiology studies in this patient population as part of standard clinical care.
45368792|NCT00945932|Drug|GW870086X|Investigational product
45368793|NCT00945932|Drug|Placebo|Placebo control
45368794|NCT01031758|Other|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
45368795|NCT05300828|Drug|Genexl PM|Every three weeks, after intravenous infusion of 260 mg/m2 for 3 hours, followed by carboplatin AUC 5 for 3 hours.
46052400|NCT02814825|Other|ViviGen|ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 127 1.3(d).
45368796|NCT05300750|Other|Oral fluids|Starting amount of oral fluid after 2 hours post C/s should be 5cm and then increase gradually to be 45-50 cm of oral fluid at 4 hours post C/s and 100 cm each hours later.
46052401|NCT01039688|Drug|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 24 months
46052402|NCT01039688|Drug|CP-690,550|Oral tablets administered at a dose of 10 mg BID for 24 months
45368797|NCT05300750|Other|Chewing gum|Chewed free sugar gum for 15 minutes
45368798|NCT00952016|Drug|Methotrexate|study subjects will receive methotrexate intravenously on day 1 and day 8 of a 3 weekly cycle.
45368799|NCT00952094|Drug|KRN1493|KRN1493 25mg tablet 2,3 or 4 tablets single oral administration
45368800|NCT00942110|Device|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
45368801|NCT00942344|Drug|Amlodipine plus Losartan|amlodipine/losartan 5/50mg, 5/100mg, 10/50mg, 10/100mg
45486416|NCT03032198|Device|Imagio OA/US|Diagnostic opto-acoustic gray-scale ultrasound
45486417|NCT02448784|Drug|Donepezil Hydrochloride|Initial dose for oral use is 3 mg once daily. The dose is increased to 5 mg after 1-2 weeks. Following at least 4 weeks of dosing at 5 mg, the dose is increased to 10 mg. The dose may be decreased to 5 mg depending on the symptoms of the participant.
45486418|NCT04050488|Drug|Zinc Sulfate|At the age of 3 days or priming> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing zinc (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
45486419|NCT04050488|Drug|Placebos|At the age of 3 days or priming> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing placebo (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
45486420|NCT02444338|Device|MitraClip|Implantation of the MitraClip System for patients with chronic heart failure.
45486421|NCT02444338|Other|standard of care|
45486422|NCT02448628|Drug|CS-3150|
45846395|NCT02550210|Device|Breast Cancer Locator (BCL)|This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
45846396|NCT02551224|Other|Patient preference questionnaire|The primary variable will be the mean score of questions 1(a) to 1(c) from the preference questionnaire completed at the end of study.
45846397|NCT02551770|Procedure|Scaling and root planing|Using minimally invasive surgical procedure (scaling and root planing) with Emdogain application to treat one contra-lateral quadrant in subject's jaw.
46052403|NCT01039688|Drug|Disease-modifying antirheumatic drug|Oral capsules,administered as 10 mg per week for 4 weeks titrated to 15 mg per week for 4 weeks, then titrated to 20 mg week for 24 months
46052404|NCT02815137|Other|Digital Polymerase Chain Reaction|Determination of mutation of XPO1 E571K by digital PCR in blod sample of patient with classical hodgkin lymphoma
45368802|NCT00942344|Drug|Amlodipine|amlodipine 5mg, 10mg
45486423|NCT02449252|Radiation|Consolidation involved-site radiotherapy (ISRT)|"six cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~Involved-site radiotherapy (ISRT) is given in 24Gy~30Gy in 12~15 fractions of 2 Gy 5 days per week."
45486424|NCT02449252|Radiation|Consolidation involved-field radiotherapy (IFRT)|"six cycles modern CHOP chemotherapy. Radiotherapy field of involved-field radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.~Involved-field RT (IFRT) is given in 24Gy~30Gy in 12~15 fractions of 2 Gy 5 days per week."
45486425|NCT02449252|Drug|cyclophosphamide|patients in both arms will be given cyclophosphamide chemotherapy.
45486426|NCT02449252|Drug|doxorubicin|patients in both arms will be given cyclophosphamide chemotherapy.
45486427|NCT02449252|Drug|vincristine|patients in both arms will be given cyclophosphamide chemotherapy.
45846398|NCT02551770|Procedure|Scaling and root planing without Emdogain|Using minimally invasive surgical procedure (scaling and root planing) without Emdogain application to treat one contra-lateral quadrant in subject's jaw.
46052405|NCT02237508|Drug|Z7200 without oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).
46052406|NCT02237508|Drug|Symbicort Turbohaler without oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).
46052407|NCT02237508|Drug|Z7200 with oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).
46052408|NCT02237508|Drug|Symbicort Turbohaler with oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).
45368803|NCT00942344|Drug|Losartan|Losartan 50mg, 100mg
45368804|NCT00952172|Behavioral|stair stepping exercise|Stair stepping exercise performed at home daily for eight weeks
45368805|NCT00952250|Behavioral|Targeted Feedback Reports|Sites randomized to this arm will receive specialized feedback summarizing their adherence to the guidelines and suggestions on ways to improve performance.
45368806|NCT00952250|Behavioral|Targeted Feedback Report|Report designed to target areas for local hospital-specific improvement
45368807|NCT00952328|Dietary Supplement|Nutramigen infant formula|Investigators will advise mothers to supplement with 10 cc of elemental formula immediately following each breastfeeding and to discontinue formula once mature milk production begins.
45368808|NCT00952406|Other|Survey|This is a study to develop a survey for sexual health in women with pelvic floor dysfunction
45486428|NCT02449252|Drug|prednisone|patients in both arms will be given cyclophosphamide chemotherapy.
45486429|NCT04779554|Drug|Mitomycin C, flat dose 40 mg|Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two flat doses. Dose 1 will be 30mg at minute 0 and dose 2 will be 10 mg at minute 60.
45486430|NCT04779554|Drug|Mitomycin C, weight-based dose 12.5 mg/m2|Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two weight-based doses of 9 mg/m2 at minute 0 and 3 mg/m2 at minute 60.
45486431|NCT02444260|Drug|Midazolam|Midazolam will administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg. Additional sedation will be given to achieve and maintain a score of 2-3 on the Ramsay sedation scale during the procedure, up to the maximum dose of 10mg.
45486432|NCT02444260|Drug|Intravenous Normal Saline|Intravenous normal saline will be infused by non-blinded anaesthetist
45486433|NCT02444260|Drug|Bupivocaine|Bupivcaine 0.25% solution administered by wound infiltration to a maximum dose of 2 mg/kg
45486434|NCT02444260|Drug|Lignocaine HCl|Lignocaine !% solution administered by wound infiltration to a maximum dose of 4.5mg/kg
45486435|NCT03010930|Other|Supplementation of diet with MSG|Subjects eat normal diet and consume 8 ounces of vegetable broth with added MSG one time per day for 1 month
45486436|NCT03010930|Other|No supplementation of diet with MSG|Subjects eat normal diet and consume 8 ounces of low glutamate vegetable broth without MSG (sodium-matched with NaCl) one time per day for 1 month
45486437|NCT02448472|Other|Observational study, none intervention|
45486438|NCT03195634|Drug|Carvedilol|an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate >55 beats per minute, or up to 12.5 mg/day
45486439|NCT02448394|Other|Community Support Worker|At each of the intervention sites, all newly enrolled participants will have an HIV community support worker (CSW) assigned them. CSW responsibilities include: education on HIV treatment and health promoting behaviors, social support/counseling, facilitated communication with the HIV clinic, referrals as needed for other support needs.
45486440|NCT02448550|Drug|Bivalirudin|
45486441|NCT02448550|Drug|Unfractionated heparin|
45486442|NCT02431364|Drug|Verdinexor|Participants received verdinexor; Dosage form: coated, immediate release Tablet; Route of administration: oral
45486443|NCT02431364|Other|Placebo|Participants received placebo matched to verdinexor; Dosage form: coated, immediate release Tablet; Route of administration: oral
45486444|NCT03701750|Drug|Low Molecular Weight Heparin (enoxaparin sodium)|enoxaparin sodium 40mg/day subcutaneously after oocyte collection, and routine luteal phase support after embryo transfer until clinical pregnancy confirmed by ultrasound
45486445|NCT03704402|Other|Alcohol policy|Introduction of new mutual alcohol policy
46052409|NCT04175847|Drug|RC88|"Phase I:Participants will be allocated to one of the following dose groups: 0.1, 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC88-ADC followed by 21 days of dose limited toxicity (DLT) observation period.~Phase IIa indication exploration"
46052410|NCT02813031|Other|Functional meat products|
46052411|NCT02813031|Other|Traditional meat products|
46052412|NCT05626569|Drug|PD-1 combined with SBRT|Anti-PD1 monoclonal antibody combined with SBRT. The SBRT defined as the radiation prescription with single dose equal or over 4Gy and the fractions less or equal to 10 fractions. BED equal or over 50Gy is required.
45486446|NCT03704246|Drug|Anti-PD-1 monoclonal antibody|HX008 is a monoclonal antibody drug which is intravenous drip at a dose of 200mg.
45486447|NCT05273684|Other|High intensity interval training|Participants will undergo 4x4 and 1x10 minutes of interval training on two separate days.
45486448|NCT05260892|Device|Narrow GM implants|Rehabilitation of superior lateral incisors or inferior central and lateral incisors with narrow implants supporting single unit or partial prostheses
45486449|NCT05239910|Drug|Tenalisib|Tenalisib will be administered orally twice daily in a 21-day cycle for 26 cycles (from cycle 1 to cycle 26), CHOP will be administered for 6 cycles (from Cycle 4 to Cycle 9) on Days 1 to 5 of each cycle.
45486450|NCT03701672|Other|Opioid Analgesic Treatment|Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
46052413|NCT02812875|Drug|CA-170|"Dose escalation stage (Phase 1a) accelerated titration and standard 3+3 dose escalation in patients with advanced solid tumor or lymphoma.~Dose expansion stage (Phase 1b) in patients with tumors that are shown to be responsive to anti-PD-1 or anti-PD-L1 checkpoint inhibitors and/or in tumor types known to express PD-L1 or VISTA, including but not limited to: mesothelioma, melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, triple negative breast cancer, head and neck cancer, colorectal cancer, gastric cancer, bladder cancer, and ovarian cancer."
45486451|NCT03624998|Other|Cognitive and physiatric testing|Neuropsychological test battery and physiatric tests
45486452|NCT03704090|Behavioral|Occupational therapy intervention|Prevention of postoperative delirium by occupational therapy intervention
45486453|NCT03704090|Behavioral|Standard non-pharmacological prevention intervention|Prevention of postoperative delirium using standard non-pharmacological prevention measures
45486454|NCT03704012|Behavioral|Protocol of massage therapy and kinesiotherapy|Infants received massage and kinesiotherapy, applied by parents, twice a day; 15 minutes each.
45486455|NCT03034460|Drug|CD5024 1% cream|500 µL on half-face, five days a week during 6 weeks
45486456|NCT03034460|Drug|CD5024 cream placebo|500 µL on half-face, five days a week during 6 weeks
45486457|NCT03034460|Drug|CD0271/CD1579 gel|500 µL on half-face, five days a week during 6 weeks
46052414|NCT00909090|Dietary Supplement|12 mg Lutein + Zeaxanthin|10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin, taken once daily for one year
45486458|NCT03034460|Drug|CD0271/CD1579 gel placebo|500 µL on half-face, five days a week during 6 weeks
45486459|NCT04162769|Drug|Etrasimod 1 mg|Etrasimod 1 mg tablet taken by mouth, once daily
45486460|NCT04162769|Drug|Etrasimod 2 mg|Etrasimod 2 mg tablet taken by mouth, once daily.
45486461|NCT04162769|Drug|Etrasimod matching placebo|Etrasimod matching placebo tablet by mouth, once daily.
45486462|NCT04593602|Behavioral|Early Mobilization|Nurse-driven early mobilization activities twice daily
45486463|NCT04593602|Behavioral|Usual Mobility Care|Usual mobility care involves following physician orders for mobilization (i.e., bedrest, mobilization to chair with meals, physiotherapy consultation and care) as per local practice.
45486464|NCT04589468|Other|Exercise|Exercise therapy in both phases will consist of individualized walking delivered 3 to 6 times weekly (over a 7-day period). Exercise treatment will be delivered for up to 18 months, or until progression of disease or withdrawal of consent, whichever comes first. The phase 1a trial will assess five doses of exercise therapy (i.e., 90, 150, 225, 300, and 375 mins/wk) delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule. The phase 1b trial will only test one dose of exercise therapy - the RP2D identified in the phase 1a trial.
45486465|NCT04161131|Behavioral|ONBOARD|Session 1: Overview; Overcoming Physical Barriers (experiential wear) Session 2: Managing CGM data (cognitive restructuring) Session 3: Social barriers (problem solving) Session 4: Trust in CGM (motivational interviewing, review of prior sessions)
45486466|NCT03703700|Drug|Zishen Yutai Pill|Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
45486467|NCT03703700|Drug|Placebo|Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
45486468|NCT04743518|Other|Aortic pulse wave velocity|Aortic pulse wave velocity (aPWV) is a measure of aortic stiffness
45486469|NCT04743518|Other|carotid intima media thickness (CIMT)|carotid intima media thickness (CIMT)
45486470|NCT04155047|Combination Product|Glyocopyrrolate Inhalation Solution administered by Magnair|glycopyrrolate Inhalation Solution 25mcg, single dose
45486471|NCT04155047|Drug|Placebo administered by Magnair|Placebo Inhalation Solution
45486472|NCT03624530|Drug|Tyrosine kinase inhibitor (TKIs)|TKI was selected according to the mutation results of ABL kinase region. Imatinib was initiated at a dose of 200mg/d, dasatinib at a dose of 50mg/d, and ponatinib at a dose of 30mg/d. Then increase the dosage of TKI gradually and increase to therapeutic dose within one month. The duration of TKI was 180 days.
45846399|NCT02551770|Device|Emdogain application|Using minimally invasive surgical procedure (scaling and root planing) with Emdogain application to treat one contra-lateral quadrant in subject's jaw
46052415|NCT00909090|Dietary Supplement|Visually identical placebo|Visually identical placebo, taken once daily for one year
46052416|NCT04243746|Behavioral|Time Restricted Feeding|Subjects practise TRF (2-3 meals) as an adjunct to the QQH healthy plate diet. Subjects of the intervention group can eat during the pre-determined 8-12 hours eating window, but they are only allowed to drink water and calorie-free drinks for the remaining 12-16 hours. Subjects are allowed to decide the time of their first and the last meal of the day as long as they eat within the 8-12 hour window period. However, skipping breakfast and having late dinner are discouraged.
45368809|NCT00946010|Biological|blood sampling and abdominal sonography|10cc blood sampling and abdominal sonography
45368810|NCT00436852|Drug|ABT-751|Given orally
45368811|NCT00436852|Procedure|quality-of-life assessment|Ancillary studies
45368812|NCT00946166|Drug|simvastatin|40 mg daily in the evening for a maximum of 14 days
45368813|NCT00946166|Drug|Placebo|Simvastatin-like placebo administered daily in the evening for a maximum of 14 days
45368814|NCT00952562|Dietary Supplement|cholecalciferol|Capsule cholecalciferol 1000 IU, 3 capsules per day for 16 weeks
45368815|NCT00952562|Dietary Supplement|placebo|Empty capsules, 3 capsules per day for 16 weeks
45368816|NCT00952640|Dietary Supplement|vitamin A|high dose vitamin A, 200.000 IU
45486473|NCT03624452|Other|rIPC + Exercise|The interventions consist of exercise training on a static bike three times per week and/or three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes cuff deflation repeated 4 times.
45486474|NCT03624452|Other|rIPC only|Three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes deflation repeated 4 times.
45486475|NCT03746327|Drug|Sivextro 200 milligrams Oral Tablet|200 mg milligram per day during 4 weeks
45486476|NCT03746249|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
45486477|NCT03746249|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
45486478|NCT03624686|Other|peripheral blood|draw peripheral blood
45486479|NCT04152083|Drug|Eptinezumab|Injection for IV administration
45486480|NCT04152083|Drug|Placebo|Injection for IV administration
45486481|NCT03698474|Drug|Natrium picosulfate / Magnesium citrate|bowel preparation formula
45486482|NCT03698474|Drug|Polyethylene glycol / Ascorbic acid|bowel preparation formula
46052417|NCT04243746|Behavioral|Standard Care|Subjects practice the QQH healthy plate diet as per guidelines set by the Health Ministry the guidelines.QQH refers to a normal food plate (23cm in diameter), divided into a quarter of rice (carbohydrates), a quarter of meat (protein) and a half plate of vegetables and fruits. Additionally, no calories specification is required and snacks are discouraged.
46052418|NCT04220034|Biological|Blood sample|Blood sample will be collected to determine development or increase level frequencies of different types of autoantibodies in patients receiving ICI for the first time
46052419|NCT04237935|Drug|Ticagrelor 90mg|Ticagrelor 90 mg dispensing claim is used as the exposure group
46052420|NCT04237935|Drug|Clopidogrel 75mg|Clopidogrel 75 mg dispensing claim is used as the reference group
46052421|NCT05579574|Drug|BMS-986322|Specified dose on specified days
46052422|NCT05579574|Drug|Loestrin|Specified dose on specified days
46052423|NCT05624931|Behavioral|Brief CBT-Based Intervention|"Aims 1 (n=30) and 2 (n=18) will inform the Aim 3 intervention. We anticipate that the intervention will be comprised of four treatment sessions. These sessions will likely target two pathways to PrEP adherence and persistence: (1) decreased withdrawal and avoidance and (2) behavioral skill building to increase self-care/health behaviors. To decrease withdrawal and avoidance, we will likely include CBT-based exercises that improve distress tolerance and coping. To help participants build new behavioral skills, we will likely incorporate behavioral activation and problem-solving. Behavioral activation is a CBT strategy that promotes scheduling activities that align with an individual's values, which will also break maladaptive patterns of withdrawal and avoidance. Problem-solving is an empirically-supported treatment for depression; training patients to problem-solve adaptively will help them approach PrEP use by navigating barriers."
46052424|NCT05624931|Other|Enhanced Treatment as Usual|This is the control intervention. Participants will receive antenatal care as usual, which is monthly visits to the MOU, information about using PrEP during pregnancy (information sheet or pamphlet), and a psychological services referral.
46052425|NCT03955302|Behavioral|Exercise|There will be an intervention for 12 weeks. For exercises in the water, there will be an expert physiotherapist in the field of hydrotherapy that will guide the exercises in controlled sessions of approximately 45 minutes. Exercises of joint mobility, balance, strength and coordination with / without aquatic material will be included. At all times, qualified health personnel will monitor any symptom or sign that advises the removal of the subject of the study.
46052426|NCT02809755|Drug|4% Lidocaine|
45368817|NCT00942500|Procedure|Post-conditioning|Coronary angiogram is performed to allow identification of the culprit coronary artery and to check no reperfusion before PCI (TIMI grade <2). Restoration of coronary blood flow can be achieved by thrombus aspiration, balloon angioplasty, direct stenting or together.In the postconditioning group, immediately after restoration (TIMI grade ≥2) of coronary flow (without regard to method of achieving restoration), angioplasty balloon will be positioned at the culprit lesion or stented segment and inflated 4 times for 1 minute with low-pressure (4 to 6 atm) inflations, each separated by 1 minute of reflow. When restoration of coronary flow is achieved by thrombus aspiration or balloon angioplasty and residual stenosis is remained ≥30%, stent will be deployed.
45368818|NCT00952796|Drug|moxifloxacin|moxifloxacin 400mg once daily (IV form, 60minutes)
45368819|NCT00952796|Drug|ampicillin/sulbactam|ampicillin/sulbactam 1.5g 4 times daily (IV form, administered 60minutes)
45368820|NCT00952952|Drug|Mesalamine|
45486483|NCT03698474|Drug|Natrium/ Kalium/ Magnesium sulfate|bowel preparation formula
45486484|NCT02711956|Drug|ZEN003694|
45486485|NCT02711956|Drug|Enzalutamide|
46052427|NCT02809755|Other|Saline|
45368821|NCT00953030|Behavioral|COACH|
45486486|NCT03698396|Biological|Allogenic Islet Cell Transplantation|Transplantation of allogenic islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
45486487|NCT03703622|Behavioral|Video-debriefing with standard HBB training compared with standard HBB training only|"We will use the AAP training curriculum for the HBB 2nd edition through out the training and course assessments pre-and post- training and during follow-up period.~Both intervention arms will a 2 days training consisting of: lectures, neonatal resuscitation demonstrations using NeoNatali mannequin, and practical skills s sessions. Pre- and post-tests knowledge (MCQs) and skills (bag mask ventilation, OSCE A, & OSCE B) will be given to all participants.~In the intervention arm, in addition to standard training, participants will work in teams of three (birth attendant, mother, and an assistant) to perform different HBB case scenarios. These will be filmed and used for subsequent debriefing after each case scenarios. After all participants in the intervention have had the opportunity to participate in the debriefing, then a post test is done to assess performance.~Analysis is done to compare the intervention and control arms performances."
45486488|NCT04149353|Diagnostic Test|PET/MR|Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant chemotherapy per the direction of the medical oncologist. Within four weeks after completion of chemotherapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery if they are still surgical candidates.
45486489|NCT02711800|Drug|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by the study Co-PI, Dr. Seed. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The treatment duration is 30 days.
45486490|NCT03701594|Other|Yoga-based physical therapy group|All yoga-based sessions will be led by the same therapist to maximize between-session consistency. A trained researcher will also be present to provide additional cueing to subjects when required. The basic elements of the postures are similar to that of traditional physical therapy balance exercises. Cues will be provided throughout to pair appropriate breath cycles with appropriate postures consistent with a standard, able-bodied yoga program. The session will close with a 4-5 minute savasana performed in a supine or seated position pending patient physical abilities, which consists of progressive relaxation, guided meditation, and guided motor imagery.
45846400|NCT02553798|Drug|Glycopyrronium Topical Wipes|Glycopyrronium Topical Wipes
45846401|NCT02557698|Other|Balneum oil bath|
45368822|NCT00953030|Behavioral|RealAge|
45368823|NCT00953108|Drug|quetiapine|300 mg per day
45368824|NCT00953108|Drug|escitalopram|escitalopram 10 mg per day
45368825|NCT00953186|Device|hyperbaric air|air at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
45846402|NCT02560038|Drug|Gemcitabine|1000 mg/m2 will be administered as an IV infusion over 10 mg/minute on Days 1 and 8 of each cycle (each cycle is 21 days).
46052428|NCT02812719|Drug|Glycolic acid peel alone|"One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.~This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals"
46052429|NCT02812719|Drug|Glycolic and salicylic acid peel|"The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.~This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals."
45368826|NCT00953186|Device|HBOT|100 % oxygen at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
45368827|NCT00953264|Behavioral|lifestyle|lifestyle intervention, including diet, physical activity and behavioral changes
45368828|NCT00953342|Behavioral|Aerobic exercise|12 weeks of supervised exercise, 3 x week, 1 hour sessions
45368829|NCT00953342|Behavioral|Usual care|Standard medical care
45368830|NCT00953498|Drug|pioglitazone|After randomization, patients will be treated by pioglitazone or rosiglitazone
45368831|NCT00953498|Drug|rosiglitazone|treatment with rosiglitazone at a dose between 4mg and 8 mg/day
45368832|NCT00942656|Other|PHVO|base diet plus 3.0% energy mixed isomers of trans fatty acids from partially hydrogenated vegetable oil
45368833|NCT00942656|Other|CLA|base diet plus 1.0% energy added from cis-9, trans-11 conjugated linoleic acid
45368834|NCT00942656|Other|VA|base diet plus 3.0% energy added from vaccenic acid
45368835|NCT00942656|Other|base|base diet containing approximately 0.1% energy of mixed trans fatty acid isomers
45368836|NCT00942812|Other|Diarrhea Pack|Low osmolality ORS, Zinc tablets, water purification tablets and pictorial chart
45368837|NCT00942812|Other|ORS|ORS has been supplied to diarrheal cases as standard care through the LHW program at community level
45368838|NCT00943046|Device|Pacemaker therapy|Implantation of the SIELLO pacemaker leads
45368839|NCT04012034|Device|Radiofrequency A|Application of radiofrequency for 30 minutes per week during 8 weeks
45486491|NCT03701594|Other|Seated Rest|Subjects will engage in 1 hour of seated rest in a relaxing environment in a group of approximately 2-5 individuals. This session will occur in the same enclosed, quiet space as condition A to minimize outside noise or distraction and to reproduce environment of condition A. The lights will be dimmed, and the same light, instrumental, calming music will be played throughout to contribute to a relaxing ambiance. Subjects will be instructed to rest quietly.
45368840|NCT04012034|Device|Radiofrequency B|Application of radiofrequency without energy for 30 minutes per week during 8 weeks
45486492|NCT03701594|Other|Conventional Physical Therapy|"Subjects will engage in 1 hour of a conventional PT session (or treatment as usual) led by a different physical therapist than who is leading the yoga-based session to minimize bias. There will be no restrictions on what can and cannot occur during conventional PT sessions in order to accurately represent and preserve the wide range of treatments that may occur during a physical therapy session in the inpatient setting. Examples of what may occur include, but are not limited to: gait, standing balance, functional mobility, or therapeutic exercise."
45486493|NCT02091154|Behavioral|USDA Regulations|"Implement new USDA regulations assigned school cafeterias.~Fruit or vegetable on every tray~Meet requirements for vegetable varieties~50% of all grains must be whole grain~Milk must be 1% or skim; flavored milk must be skim"
45486494|NCT02091154|Behavioral|Marketing Kit|"This marketing tool kit is designed to encourage purchasing of school lunches. The marketing tool kit included the following components:~56''x72'' vinyl sign with the words [school mascot] Cafe~8.5''x11'' signs describing the foods offered on a specific day~2''x4'' signs used to name all foods. These were to be placed in a visible location near the corresponding food.~Magnetic board displaying a tray onto which magnets shaped as food can be placed to show what foods were being offered during a specific lunch shift."
45486495|NCT02091154|Behavioral|Smarter Lunchrooms Makeover (SLM)|"Implement three basic Smarter Lunchrooms techniques. It consists of the following components:~Place fruit in an attractive bowl or serving dish and set on two places on the line. One of the places should be at or near the register.~Give all vegetables descriptive names and write or type them on a 2''x4'' card. These cards should be visible and placed near the corresponding food.~Make white milk the most prominent milk in the milk coolers by making it the most available milk and easiest to take."
45486497|NCT02444026|Behavioral|iCBT for Insomnia|Internet-delivered Cognitive Behavioural Therapy for Insomnia
45486498|NCT04709276|Drug|Nivolumab|360 mg intravenously every 3 weeks
45486499|NCT04709276|Drug|Ipilimumab|1 mg/kg intravenously every 6 weeks
45486500|NCT04709276|Drug|Carboplatin|"AUC 4 mg/ml per minute intravenously every 3 weeks for up to 10 cycles.~Subjects will also receive granulocyte-colony stimulating factor (G-CSF) therapy while receiving carboplatin."
45486501|NCT04709276|Drug|Cabazitaxel|"20 or 25 mg/m2 intravenously every 3 weeks for up to 10 cycles.~Subjects will also take prednisone by mouth at a dose of 10 mg daily and receive granulocyte-colony stimulating factor (G-CSF) therapy while receiving cabazitaxel."
45486502|NCT01526668|Behavioral|Follow-up strategy|Comparison of different follow-up strategies
45368841|NCT00946400|Other|Scoring 4Ts and Chong scale|Two physicians will independently score both the 4Ts and the Chong scale on all patients enrolled in this study.
45486503|NCT01526668|Behavioral|No contact after discharge|
45368842|NCT00946400|Other|Blood draw|Patient serum will be collected to perform Serotonin Release Assay testing to verify the presence of HIT.
45368843|NCT05301296|Diagnostic Test|Clinical examination of the breast for early detection of Cancer|Participants were invited for 3 rounds of clinical breast examination, conducted 3-years apart. Screening was conducted by health workers trained to perform clinical breast examination for early detection of cancer. Women with abnormal referable lesions underwent CBE by a trained clinician and those women with a confirmed breast lump or any other breast abnormality warranting further investigations were evaluated by triple-testing involving expert physical examination, diagnostic mammography with or without ultrasonography and fine needle aspiration cytology (FNAC) or core biopsy or excision biopsy. Those with confirmed breast cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.
45368844|NCT00943358|Biological|MF59 H1N1 vaccine|3.75-7.5ug dose
45368845|NCT00943358|Biological|Plain H1N1 vaccine|7.5-15ug
45368846|NCT00120289|Drug|Extended release niacin|2,000 mg/day or 1,500 mg/day if higher dose not tolerated
45486504|NCT04706624|Behavioral|High intensity contingency management|Participants receive 12 weeks of contingency management.
45486505|NCT04706624|Behavioral|Low intensity contingency management|Participants receive 6 weeks of contingency management and 6 weeks of group education.
45368847|NCT00120289|Drug|Simvastatin|Dose adjusted to achieve LDL-C 40 mg/dL - 80 mg/dL, adding ezetimibe (10 mg/day) if needed to achieve LDL-C target
45368848|NCT00946556|Drug|Valacyclovir|1g po od for 2 months
45368849|NCT00946556|Drug|Placebo|Placebo po od for 2 months
45368850|NCT00946634|Drug|Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. After a last foaming with ozone gas (Philozon, Santa Catarina, Brazil) at 40mg/L concentration.
45846403|NCT02560038|Drug|Paclitaxel|175 mg/m2 will be administered as an IVPB over 3 hours on Day 2 of each cycle (each cycle is 21 days).
46052430|NCT04236765|Other|TB infection-screening benefiting group|The children who participate in the study will be recruited during a programmed visit to a traveler health clinic or a primary care center. During the first visit the parents or legal guardian will be interviewed, a questionnaire will be completed with sociodemographic, epidemiologic and clinical data and a tuberculin skin test (TST) will be performed and read at 48-72 hours. At 8-12 weeks after returning from the travel abroad the child will have a new visit. A new interview will be carried out with the parents or legal guardian and a questionnaire will be completed with epidemiological and clinical data. The child will undergo a new TST and QFT-Plus test.
45368851|NCT00946634|Drug|Control (no last irrigation)|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes.
46052431|NCT02876978|Genetic|CAR-GPC3 T Cells|Intravenous infusion of CAR-GPC3 T cells is conducted 1 - 2 days following lymphodepletion.
45368852|NCT00946634|Drug|Aqueous Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. A last irrigation with 10mL of ozonated water at 40mg/mL concentration
45846404|NCT02560038|Drug|Cisplatin|70 mg/m2 will be administered as an IVPB over 2 hours on Day 2 of each cycle (each cycle is 21 days).
45486506|NCT04706624|Behavioral|SMS reminders|Participants receive two daily SMS reminders plus one weekly self-monitoring assessment.
45846405|NCT02560584|Drug|Hexaminolevulinate hydrochloride|Instillation in bladder
46052432|NCT02876978|Drug|Fludarabine|30 mg/m^2/day x 4 days
46052433|NCT02876978|Drug|Cyclophosphamide|500 mg/m^2/day x 2 days
46052434|NCT05621187|Device|Pamira ICD lead family|Implantation, measurements and follow-up schedule
46052435|NCT04782596|Procedure|Posterium nasal septum resection|Posterium nasal septum resection is required to ensure approach during transnasal endoscopic pituitary surgery in patients with pituitary adenoma.
45486507|NCT04706624|Behavioral|Matrix only|Participants attend 12 weekly Matrix group counseling sessions.
45486508|NCT04706624|Behavioral|Matrix + Contingency management|Participants attend 12 weekly Matrix group counseling sessions plus 12 weeks of contingency management.
45486509|NCT01194622|Drug|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
45486510|NCT01194622|Drug|Fluticasone mono|REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
45486511|NCT01194622|Drug|Fluticasone|COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
45486512|NCT02448316|Procedure|endoscopic surgery|"Through 2 portals profound for the fascia plantaris (deep-fascial) lateral and medial a heel-spur will be resected and the medial half of the fascia is released from its attachment to the calcaneus.~A mikroskopic X-ray sensitive pearle (Tantalum-pearle) will be inserted in the fascia in the proximal end of the distal part of the remaining fascia for measuring distance (resorbtion).~Three weeks after operation, the patients are instructed to start a specific training program. Training is supervised every third week by a physiotherapist (week 3,6,9,12 after operation), and daily training is carried out at home. Sutures are removed after 10 days,"
45486513|NCT02448316|Drug|methylprednisolon|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
45486514|NCT02448316|Drug|lidokaine|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
45486515|NCT02448316|Behavioral|Training|the patient is instructed in reduction in impact. strength training 3 times weekly and stretching exercises daily are recommended.
45486516|NCT03698318|Dietary Supplement|Tested product n°1|1 capsule (26% of gingerol/shogaol in 100 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
45486517|NCT03698318|Dietary Supplement|Tested product n°2|1 capsule (38.6% of gingerol/shogaol in 74.9 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
45486518|NCT03698318|Dietary Supplement|Tested product n°3|2 capsules (6.8% of gingerol/shogaol in 424.3 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
45486519|NCT03698318|Dietary Supplement|Tested product n°4|1 capsule (27% of gingerol/shogaol in 104.9 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
45486520|NCT03698318|Dietary Supplement|Tested product n°5|6 capsules (1.6% of gingerol/shogaol in 1806.25 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
45486521|NCT03698240|Behavioral|Mindfulness-based program|The program includes 9 mindfulness-based sessions for children and their parents.
45486522|NCT05200858|Device|Electrical Stimulation - Active|Subjects will receive an active electrical stimulation device (delivers 100% of the dose) to wear for 1 hour daily for up to 4 weeks.
45486523|NCT05200858|Device|Electrical Stimulation - Placebo|Subjects will receive a placebo electrical stimulation device (delivers 10% of the dose) to wear for 1 hour daily for up to 4 weeks.
45486524|NCT04564898|Drug|Capecitabine|"Part 1 • Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days~Part 2~• Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days"
45486525|NCT04564898|Drug|Bevacizumab|"Part 1 • Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days~Part 2~• Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days"
45486526|NCT04564898|Drug|Trifluridine/Tipiracil|"Part 1 • Trifluridine/tipiracil, dose escalation from 25 mg/sqm to 35 mg/sqm orally twice daily on days 15-19 (and days 22-26) each 28 days~Part 2~• Trifluridine/tipiracil, at the recommanded dose established during part 1 orally twice daily on days 15-19 (and days 22-26) each 28 days"
45486527|NCT05178238|Other|Fecal sample|Fecal sample taken to investigate intestinal microbiota
45486528|NCT03697928|Other|Exercise metabolism|Participants will perform a series of exercises inside and outside the MRS/MRI scanner.
45486529|NCT03703388|Dietary Supplement|Arctigenin|Arctigenin capsule
45486530|NCT02443714|Device|Needle-free jet injection with insulin lispro|Subjects injected by jet injectors which deliver insulin lispro
45486531|NCT02443714|Device|Conventional pen injection with insulin lispro|Subjects injected by conventional insulin pens which deliver insulin lispro
45486532|NCT03703310|Drug|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
45486533|NCT03703310|Drug|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
45486534|NCT03190408|Other|Fluids|Fluids Administered in Shock
45486535|NCT03703232|Device|Investigational prosthetic foot|Individuals will complete 2-4 weeks of community walking with the investigational foot and compare to their regular prosthetic foot.
45486536|NCT04483570|Procedure|Redo-tethering operation|
45486537|NCT03703154|Drug|Envarsus|Patients will then be randomized in the ratio of 2:1 with 20 being in the study arm and 10 in the control arm. Envarsus will be prescribed by the transplant team per conversion guidelines. The transplant team will monitor drug levels, per the dosing guidelines.
45486538|NCT03703154|Drug|Tacrolimus|The patient's physician will prescribe drug according to standard practice.
45486539|NCT03188380|Diagnostic Test|Plain abdominal radiography|After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
45486540|NCT03188380|Diagnostic Test|Abdominal ultrasound|If the AR is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
45486541|NCT04561232|Behavioral|Prone and Upright Locomotor Training|"During the movement observation phase, infants will wear a wireless movement sensor at each ankle for two days. Research staff will show the caregivers how to place the sensors in the morning and charge them overnight.~The training protocol for the prone training will consist of: 1) Warm-up. 2) Assisted movement of the arms and legs. 3) Calibration of the infant's arm and leg positions. 4) Self-initiated mobility for up to five minutes.~For upright training, the environment will be arranged to encourage active motor exploration and variability in walking activities.The therapist will assist the child as needed to encourage upright locomotor activities, but only the minimum amount needed to perform the task. Weight assistance will be gradually reduced as postural control and coordination improve."
45486542|NCT02443558|Other|Brain-Computer Interface control of robotic arms.|The patients will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement).
45486543|NCT02443558|Device|MERCURY v2.0 robotic arms|MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics Lab.
45486544|NCT04701164|Drug|ANX005|Solution for intravenous infusion
45486545|NCT04701164|Drug|Placebo|Solution for intravenous infusion
45486546|NCT03192670|Device|Low-level light therapy device|Peak wavelength:610nm, Power intensity: 1.7mW/cm2, Energy density: 2.0J/cm2, Skin-adhesive light-emitting probes: spot size, 1cm diameter
45486547|NCT03703544|Other|High glycemic index|Wheat yellow noodle, glutinous rice, tea with sucrose, biscuits, jelly made with sucrose and teriyaki chicken rice.The foods provided have been tested as high glycemic index. Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
45486548|NCT03703544|Other|Low glycemic index|Beta-glucan yellow noodle, basmati rice, tea with isomaltulose, biscuits, jelly made with isomaltulose and mung bean noodles.The foods provided have been tested as low glycemic index.Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
45486549|NCT02434276|Biological|VAX2012Q|Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages
45486550|NCT02434276|Biological|Fluzone Quadrivalent|Fluzone Quadrivalent (Influenza Vaccine)
45486551|NCT03624842|Drug|Trappsol (R) Cyclo (TM)|
45846406|NCT02560584|Device|KARL STORZ D-Light C PDD Flexible Videoscope System|Cystoscopy procedure
45368853|NCT00953732|Drug|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
45486552|NCT03697694|Dietary Supplement|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
45486553|NCT03697694|Other|Placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
45486554|NCT03190642|Drug|Methylprednisolone|Administration of 1000mg vs 125mg methylprednisolone preoperatively in orthognathic surgery.
45846407|NCT02561130|Drug|insulin glargine|Dose is titrated to achieve fasting normoglycemia
45846408|NCT02561130|Drug|metformin|Dose is titrated to 1 g bid or maximal tolerated dose
45846409|NCT02561130|Drug|Forxiga|Dose is titrated to 10 mg po daily or maximal tolerated dose
45846410|NCT02561130|Behavioral|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
45846411|NCT02562066|Drug|amifampridine phosphate|Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
45846412|NCT02562066|Drug|Placebo|A placebo equivalent will be provided as tablets indistinguishable from the amifampridine phosphate tablets. The placebo will be administered consistent with the dose regimen of amifampridine phosphate.
45846413|NCT02562924|Device|MEDIHONEY®|MEDIHONEY® is a seminatural product with antibacterial and anti-inflammatory properties
45846414|NCT02562924|Drug|Budesonide|Topical steroid
45846415|NCT02562924|Drug|Normal saline sinus rinse|8 oz or 4 oz of normal saline with NeilMed sinus rinse bottle
45368854|NCT04011488|Other|Shared Decision Making Tool|"We've used the framework from this model and adapted it to the patient perspective to create a Patient Shared Decision Making Tool. The model is interactive so it can be customized to a specific patient. It has adjustments built in for gender, race/ethnicity, age, and select comorbidities (obesity, hypertension and diabetes).~The strongest, underlying message is that any treatment choice is better than not seeking treatment. To illustrate this, a Do Nothing pathway is included for comparison purposes."
45368855|NCT01083277|Device|variable ventilation|In variable ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be randomly varied by 40% on a breath-by-breath basis around a pre-set mean, using the variable ventilation software developed by Dr. Bela Suki and Dr. Arnab Majumdar. In conventional ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be set to equal the mean tidal volume used in variable ventilation and does not vary.
45368856|NCT01083277|Other|Conventional ventilation|tidal volume will be set as the patient's baseline tidal volume prior to study entry and will not vary.
45368857|NCT00943748|Drug|deferiprone|A standard dose-escalation phase will be initiated, with a 3 ml of the deferiprone oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of deferiprone oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
45368858|NCT00943748|Drug|placebo|A standard dose-escalation phase will first be initiated, with a 3 ml of the placebo oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of placebo oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
45368859|NCT01326793|Other|Skype Consultation|One-hour Skype consultation with MA-licensed psychiatrist and a written summary of findings.
45486555|NCT03697616|Device|Ridge augmentation with sticky bone and GBR|"Autogenous particulate bone will be harvested and a mixture of autogenous particulate and anorganic bovine bone mineral will be prepared at a ratio of 1:1~Venous blood will be drawn from patients' forearm and centrifuged at 2500 RPM/3 minutes and 4000 RPM/15 minutes to produce autologous fibrin glue and concentrated growth factors membrane, respectively~Sticky bone will be prepared by adding autologous fibrin glue to the particulate mixture, placed onto the defect and covered by the prepared concentrated growth factors membrane~For guided bone regeneration the particulate mixture will be placed onto the defect and covered by resorbable collagen membrane~Periosteal releasing incision will be done to provide flap advancement for tension free closure~Closure will be done using horizontal mattress and interrupted 4/0 polypropylene sutures"
45486556|NCT02439892|Behavioral|Exercise and nutrition during radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements. The exercise sessions will be conducted twice a week for 30 minutes each time during the RT treatment period, and include a main part of progressive resistance training (PRT). The PRT will be conducted by conventional upper and lower body exercises at a load of 60 - 80 % of 1 repetition maximum (RM) in 3-4 sets of 6-12 repetitions. The patients will receive nutritional information and dietary advice, and up to 2 energy dense oral nutritional supplements (ONS) daily. A nutrition interview will be conducted at study baseline and individual goals and targets will be set during the first counselling and monitored during the intervention period.
45486557|NCT02439892|Behavioral|Multidimensional rehabilitation after radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements and patient education. The exercise sessions will be conducted 3 times a week for 45 minutes each time during the 3 week rehabilitation programme, and include a main part of progressive resistance training (PRT). PRT will be conducted as described in the intervention during treatment. The nutritional intervention will be carried out as described in the intervention during treatment. Patient education will be run as 45-60 minutes lecture/group discussion on relevant topics, lead by health professionals.
45486558|NCT03702686|Device|FEEDBACK System|Smart Nipple Shield and Monitor Unit
45691713|NCT00629122|Drug|Nystatin Suspension|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
45368860|NCT00953810|Other|Educational training regarding heart failure|Like control plus one education training regarding heart failure aspects and management
45691714|NCT00596440|Drug|Transdermal nicotine patch|8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg.
45691715|NCT00631852|Drug|American Ginseng root|four, 250mg tablets daily 5-14 days prior to surgery
45368861|NCT00946790|Drug|Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)|
45368862|NCT00946790|Drug|Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)|
45368863|NCT00953888|Drug|AZD5069|Single dose of oral solution.
45368864|NCT00953888|Drug|Placebo|Single dose of oral solution.
45368865|NCT00953966|Other|Genetically modified potatoes|Starch from genetically modified potatoes
45368866|NCT00954044|Behavioral|Randomized Exercise Intervention|"The Exercising Together training group will participate in 6 months of supervised, progressive partnered resistance exercise.~Couples will participate in 2 exercise sessions a week for 6 months."
45846416|NCT02562924|Drug|Prednisone|Post-operatively, 40 mg daily for 7 days
45486559|NCT03701438|Biological|Influenza Vaccine|Administered per standard of care using a vaccine licensed and recommended in the site's country
45486560|NCT02440048|Device|Bond Apatite synthetic bone substitute|Synthetic bone grafts had been successful for ridge preservation. Calcium sulfate is the oldest material, being in use in dentistry for more than 30 years ago, and in orthopedics for more than 100 years ago. Calcium sulfate is completely absorbed and constitutes a matrix on wich bone is able to grow (osteoconductive). It does not induce inflammation and does not alter calcium levels in the blood flow.Previous studies has shown that calcium sulfate is completely replaced by bone. On the other hand, fast absorption of calcium sulfates can alter the dimensional stability of the graft. Adding Hydroxy Apatite may improve stability during bone remodeling.
45486561|NCT02440048|Device|BioOss bovine bone substitute|To assess efficiency of ridge preservation (in vertical and horizontal dimensions) after tooth extraction using Calcium Sulfate with HA (®Bond-apatite) compared to the use of bovine bone substitute (BioOss®) and to extraction only as negative control.
45368867|NCT00954044|Behavioral|Randomized Exercise Intervention|Couples will continue doing their usual daily activities for 6 months
45486562|NCT04050332|Behavioral|Stair Walking|Walking up and down stairs for four minutes at a comfortable pace
45486563|NCT03188458|Other|Blood sample|Blood samples will be collected from infants prior to their first routine primary pertussis vaccination (At Visit 2 [approximately 4-8 weeks of age]).
45486564|NCT03702530|Biological|3x 50 L3 larvae immunisation with albendazole treatment|Immunisation with 50 Necator americanus L3 larvae at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
45846417|NCT02562924|Procedure|Endoscopic sinus surgery|Endoscopic sinus surgery to debride polyps and establish adequate sinus drainage
45846418|NCT02562924|Drug|nasal saline spray|saline nasal mist every hour while awake
45486565|NCT03702530|Other|3x placebo immunisation with albendazole treatment|Mock immunisation with water at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
45486566|NCT03702530|Biological|2x 50 L3 larvae infection|After (mock) immunisation, infection with 50 Necator americanus larvae at week 13 and 15
45486567|NCT02443246|Drug|Vitamin D3 B.O.N. Injection (cholecalciferol 200,000IU)|
45486568|NCT02443246|Drug|Placebo|
45486569|NCT03702452|Other|functional rehabilitation nursing program|According to the modified Barthel index score, the patients' function was divided into four parts Level,each level has different kinds of rehabilitation nursing.
45486570|NCT03702452|Other|control group|The rehabilitation were given by the rehabilitation therapist based on the patient's condition, such as, bridge movement,limb passive motion, limb active motion,turn over,sit upw,walk, and so on.
45486571|NCT03188302|Other|Collection of stool samples|The subjects collect stool samples to be used for validation of a new direct measurement of stool consistency. Every stool sample produced during 2 collection periods of approximately 60 hours each have to be collected using the Commode Specimen Collection System (Medline Industries, Inc.). Each collection period starts preferably in the evening (20h00) and ends 3 days later in the morning (08h00). The collected samples must be stored at subject's home in a refrigerator provided by the sponsor until handover to the site staff.
45486572|NCT02443168|Drug|AG-221|Part 1: oral solution containing 100 mg [14C]-AG-221
45486573|NCT02443168|Radiation|14C AG-221|5 mL of 100 micrograms [14C] AG-221 given intravenously 4 hours after swallowing the formulated tablet.
45486574|NCT02443948|Other|Vena puncture for blood collection|Cf-DNA blood samples will be collected in EDTA tubes (20 ml) during the routine blood test
45486575|NCT02439580|Dietary Supplement|Annona muricata extract|ethanol-soluble fraction of water extract
45846419|NCT02563860|Drug|Lovastatin|dose escallating
45846420|NCT02564016|Drug|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
45846421|NCT02564016|Other|Capped Epidural|epidural will be capped with no saline infusion.
45846422|NCT02566044|Other|Placebo|Placebo
45368868|NCT00954200|Drug|ibuprofen|ibuprofen 10mg/kg syrup, single dose vs placebo
45368869|NCT00954200|Drug|ibuprofen|10mg/kg syrup - single dose
45368870|NCT00954278|Drug|sorafenib|sorafenib (400mg or 600mg or 800mg) by mouth twice daily, for 28 days
45368871|NCT00550446|Drug|Adalimumab|40mg subcutaneous injections every other week for 6 injections during week 0-10 with oral placebo BID. Subjects switched to CP-690,550 at week 12.
45368872|NCT00550446|Drug|CP-690-550|15 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
45368873|NCT00550446|Drug|CP-690-550|10 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
45486576|NCT02439580|Dietary Supplement|Placebo|maltose
45486577|NCT03192202|Drug|AFM13|AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
45368874|NCT00550446|Drug|CP-690-550|5 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
45368875|NCT00550446|Drug|CP-690,550|3 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
45368876|NCT00550446|Drug|CP-690,550|1 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
45368877|NCT00550446|Drug|Placebo|Placebo by mouth plus 6 placebo subcutaneous injections (week 0-10)
45368878|NCT00953472|Drug|brain natriuretic peptide|start 10 mcg/kg (2 participants), 7 mcg/kg (2 participants), 5 mcg/kg (2 participants) and 2 mcg/kg (2 participants)
45846423|NCT02566044|Drug|QBW276|0.3 mg and 1.5 mg strengths
45846424|NCT02566590|Device|NMES|device is used to stimulate muscle contraction in the legs of the patient. The intervention will be used 3 times a day during bed rest.
45846425|NCT02566590|Dietary Supplement|Protein|supplement will used to enhance muscle anabolism. The intervention will be provided 3 times a day during bed rest.
45846426|NCT02566590|Dietary Supplement|non-protein placebo supplement|supplement will be used as a placebo to control participants. The supplement will be provided 3x a day during bed rest.
45368879|NCT00953472|Other|no-added salt diet|instruction to reduce salt for one week prior to study
45368880|NCT05279820|Procedure|Partial pulpotomy|Partial pulp tissue amputation
45368881|NCT05279820|Procedure|Full Pulpotomy|Full Pulpotomy
45368882|NCT00953550|Drug|Rocuronium-Sugammadex|Rocuronium 1,0 mg/kg is administered iv initially. Upon intubation Sugammadex is administered 16 mg/kg iv.
45486578|NCT03031496|Drug|GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets)|"GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets) are cream-colored, circular, flat faced uncoated tablets with beveled edges having break line on one side and BD embossed on the other side."
45486579|NCT03031496|Drug|Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets)|"Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets) tablets are peach-colored, half scored, diamond shaped tablets marked MSD917."
45691716|NCT00632632|Drug|D-Cycloserine|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality with D-Cycloserine -100 mg on days when receiving exposure with virtual reality (approximately 10-12 times)
45846427|NCT02568852|Procedure|Combined anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
45846428|NCT02568852|Procedure|General anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
46052436|NCT00909480|Drug|insulin detemir|"Treat-to-target (individually adjusted dose) titration according to titration algorithm.~S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued"
45368883|NCT00953550|Drug|Succinylcholine|1 mg/kg
45368884|NCT00948870|Drug|Shugan decoction|Decoction ,two times a day,one bag of decoction one time
45368885|NCT05351034|Device|Anorectal manometry|Anorectal manometry in diagnosis of Functional anorectal disorders
45368886|NCT05350956|Drug|TPO-RA (Herombopag)|During the correction period, subjects will receive a dose of Herombopag starting at 5-7.5mg once daily, orally for 14 days, subject to dosing adjustment (or discontinuation) depending on their platelet response or at the investigator's discretion. In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
45846429|NCT02569086|Other|Blood draw|
46052437|NCT00909480|Drug|insulin glargine|"Treat-to-target (individually adjusted dose) titration according to titration algorithm.~S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued"
46052438|NCT05642715|Behavioral|EX+|All participants, regardless of study arm, will be offered: BecomeAnEX, an online tobacco treatment with support community PLUS Positively Smoke Free on the Web (an intervention targeting people with HIV who smoke) integrated into the BecomeAnEX site.
46052439|NCT05642715|Drug|Varenicline|All participants, regardless of study arm, will be offered: A 12-week course of varenicline dosed according to product label.
45486580|NCT03190486|Other|functional Magnetic Resonance Imaging (fMRI)|During fMRI, healthy volunteers will listen 80 baby's cry.
45486581|NCT03187990|Drug|[68Ga]PSMA-11|PET/MRI with [68Ga]PSMA will be compared to mpMRI for biopsy guidance.
45486582|NCT03187990|Drug|[18F]PSMA-1007|18F-PSMA-1007 PET/CT for biopsy guidance and intraoperative target verification.
45486583|NCT03697382|Behavioral|Very Low Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Very Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
45486584|NCT03697382|Behavioral|Low Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
45691717|NCT00632632|Other|Placebo|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality. Placebo given on days when receiving exposure with virtual reality (approximately 10-12 times).
45691718|NCT00633256|Drug|Cycloserine|50 mg Cycloserine given in two separate experimental sessions separated by approximately one week.
45691719|NCT00633256|Drug|Placebo|Matched placebo for subjects randomized to placebo arm. Given in two experimental sessions separated by approximately one week.
45486585|NCT03697382|Behavioral|Moderate Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Moderate Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
45486586|NCT03187912|Drug|Riboflavin|Riboflavin with 20% Dextran or HPMC will be admininstered every 2 minutes for overall 30 minuts (Dextran) or 10 minutes (HPMC), respectively
45486587|NCT03701204|Behavioral|DynamiCare Rewards|"Participants assigned to the DynamiCare Rewards group will receive the following:~App on their smartphone~Substance Testing Devices: BACTrack Mobile Pro - submits BAC results directly to smartphone via Bluetooth and Saliva Test Kits.~Next Step debit card to receive financial incentives~Participant will be prompted via the app to conduct breathalyzer/saliva tests, using the devices camera to take selfie photo/videos to prevent cheating.~Negative tests result in participant receiving electronic virtual coins, which can be transferred from reserve account (reserve account inaccessible to participant) to the spendable Next Step debit card.~The amount of coins and funds are available on a progressive variable reward schedule."
45486588|NCT03188224|Other|MyTransition app|MyTransition app is designed to support youth moving from pediatric to adult healthcare.
45486589|NCT03697226|Drug|Topical ABI-1968|Multiple Doses of Topical ABI-1968 Cream with 4 once weekly doses administered in up to 5 Cohorts
45368887|NCT05350956|Drug|TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin)|During the correction period, subjects will receive a combination of Herombopag and rhTPO, Herombopag starting at a recommended dose of 5mg once daily for 14 days. The recombinant human thrombopoietin dose is 300U/kg. bw/day or 15000U/day per person, once daily, for 14 consecutive days (or as determined by the investigator). In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
45486590|NCT03189940|Behavioral|Life style modification by using and app with a wrist-worn activity tracker|The mobile app was designed to collect daily lifestyle data by wearing a wrist activity tracker and reporting dietary intake. At the visit after 2 weeks of use, a summary of the lifestyle was displayed on the hospital EMR and reviewed by both physicians and app users. Further lifestyle modification was encouraged on the basis of the electronically collected data.
45486591|NCT03189940|Behavioral|Conventional Life style modification|Physician's usual consultation for life style modification at 0 week, and 2 weeks of enrollment
45846430|NCT02569632|Biological|Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)|All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.
45846431|NCT02570022|Drug|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
46052440|NCT05642715|Behavioral|HR|Participants allocated to the EX+/HR arm will be offered: 30-minute video urging smokers who cannot or will not quit to cut down on cigarettes, and also to control their risk for lung cancer and cardio or cerebrovascular disease by undergoing low-dose CT screening for lung cancer (for those meeting prespecified criteria), and referral to Cardiometabolic Clinic (for those meeting prespecified criteria).
46052441|NCT05642715|Behavioral|TAU|Participants allocated to the EX+/TAU arm will be offered: Medical treatment as usual from their regular providers after completing Stage 1 of the study
46052442|NCT02874170|Other|Spectroscopy magnetic resonance of phosphorus 31|
46052443|NCT04368039|Device|Normobaric Oxygen|40% FiO2 for 4 weeks
46052444|NCT04368039|Device|Placebo|21% FiO2 for 4 weeks
46052445|NCT02874326|Drug|Octreotide LAR|
46052446|NCT00627302|Drug|PEG-400|Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
46052447|NCT00627302|Drug|Systane|Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
46052448|NCT02812641|Drug|BPF-CCRT (run-in)|Six patients will be enrolled in run-in phase. If <= 1 patient developed dose-limiting toxicity, the trial will be continued to randomized phase. If > 1 patients developed dose-limiting toxicities, the protocol will be discontinued.
45368888|NCT00948948|Device|Silicone Gel-Filled Mammary Prostheses|"Mentor Gel-Filled Mammary Prostheses are comprised of a shell made of medical grade silicone elastomer. Gel-filled implant devices manufactured by Mentor will be used in this study:~Gel-filled device which is available in smooth surface and textured surface (Siltex®)~Becker Expander/Mammary Prosthesis which is available in both the smooth and the textured (Siltex) version~Both of these devices were originally indicated for both augmentation and reconstruction mammaplasty procedures, however for purposes of this study, indications are for reconstruction only."
45368889|NCT00953628|Drug|10000 IU urinary HCG|bolus 10000 units for ovulation triggering
45368890|NCT00953628|Drug|250 mcg recombinant HCG|bolus 250 mcg for ovulation triggering in IVF patients
45368891|NCT00949026|Drug|Temsirolimus (Torisel)|Dose de-escalation dependent on microdialysis results
45368892|NCT00953784|Procedure|standard operating management|As previously described
45368893|NCT00949104|Drug|Sucrose|1 ml of 24% sucrose was administered 2 minutes prior to the procedure
45368894|NCT00949104|Drug|Double distilled water|1 ml of double distilled water (Placebo) was administered 2 minutes prior to the procedure
45368895|NCT00953940|Drug|Isotonic saline|Isotonic saline administrated i.v at 1.5 ml/Kg/h , 8 to 12 h before surgery
45486592|NCT04681742|Behavioral|CO-OP Group|CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods, such as asking a series of probing questions, to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the GPDC process. First, participants identify a specific goal (Goal). Then, participants consider a detailed plan (Plan) for accomplishing the goal. By carrying out the plan (Do) and critically analyzing the results (Check), participants determine how the plan worked. The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
45486593|NCT03192124|Device|Bactisure|"Level 1 Panel is a quantitative real-time PCR test to detect 12 microbial organisms that may be present in patient specimen (bacteria and fungi) and includes test for resistance factors to vancomycin and methicillin.~Microbial DNA in each sample will be sequenced using the Ion Torrent PGM sequencer in order to establish what type of bacterial and fungal species are present."
45486594|NCT03190252|Other|Exposure to oxygen partial pressure of 130 kPa|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
45486595|NCT03190252|Other|Exposure to ambient pressure of maximum 11 ATA|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
45368896|NCT00436618|Drug|Everolimus|Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
45486596|NCT03702296|Other|Ear plugs and eye masks|Patients in the intervention arm will be provided with ear plugs and eye masks and instructed on the use of these during sleep
45486597|NCT03192280|Drug|Leukotriene B4|Leukotriene B4 (LTB4)
45486598|NCT03192280|Device|FLIR One|Thermal imaging attachment to iPhone
45486599|NCT03192280|Device|SCIO|Handheld near-IR molecular spectroscopy device
45486600|NCT03192280|Device|MS Band 2|"Wearable watch-like device with multiple sensors"
45486601|NCT03192280|Device|AGE reader|Portable bench top device for in-clinic near UV assessment
45486602|NCT03192280|Device|HSI prototype (PARC) hyper-spectral camera|Portable bench top device for in-clinic multispectral imaging
46052449|NCT02812641|Drug|BPF-CCRT (randomized)|Twenty-two patients will be planned to assign to the experimental arm
45691720|NCT00634270|Drug|Sirolimus|This phase II study will evaluate children and adults with neurofibromatosis type-1 (NF1) and plexiform neurofibromas treated with sirolimus. It is divided in two strata. The first stratum will evaluate time to progression (TTP) in children and adults with NF1 and progressive plexiform neurofibromas with the potential to cause significant morbidity treated with sirolimus. The second stratum will evaluate objective radiographic response to sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas with the potential to cause significant morbidity that do not have documented progression of the PN at time of trial entry.
45691721|NCT00635128|Biological|Boostrix-Polio|A single booster dose of dTpa-IPV vaccine will be administered to all subjects. IM administration in the deltoid muscle of the non-dominant arm.
45691722|NCT00676780|Drug|Polyphenon E (EGCG)|4 capsules daily with a meal for the duration of the study
46052450|NCT02812641|Drug|PF-CCRT (randomized)|Twenty-two patients will be planned to assign to the active control arm
46052451|NCT02812563|Other|genetic|Galilee exam - Corn analysis with Optiwave Refractive Analysis
46052452|NCT02809365|Device|FreeStyle Libre|Addition of FreeStyle Libre system for 10 weeks to the treatment of uncontrolled Type 2 diabetic patients currently on multiple daily injections
46052453|NCT02809365|Device|personal glucometer|Subjects in the Control Group will measure blood glucose levels by personal glucometer (SMBG = self monitoring blood glucose)
46052454|NCT01058096|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine.
45368897|NCT03995836|Device|CPAP|Decision of CPAP treatment is according to clinical guidelines
46052455|NCT01058096|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo.
46052456|NCT05581134|Device|Virtual Reality intervention|Virtual reality (VR) is a powerful tool to create an illusory state in which the user can feel that they have been transported to a new location (place illusion), that events happening are real (plausibility illusion), and even that bodies have been substituted by an avatar (embodiment illusion). VR illusions are driven by the same neurological mechanisms of everyday perception of the body in the world and induce realistic responses to VR.
45368898|NCT03995836|Procedure|Bariatric Surgery|All patients.
45368899|NCT01024660|Drug|Donepezil|5 mg capsule, orally, once daily, first 14 days of treatment
45368900|NCT01024660|Drug|Donepezil|10 mg, orally, once daily, for remaining 70 days of treatment
45368901|NCT01024660|Drug|Placebo to match Aricept|Placebo capsule, orally, 84 days of treatment
45368902|NCT01751126|Drug|NOVA22007 ''Ciclosporin''|Sterile, ophthalmic cationic oil-in-water emulsion containing 1 mg/ml Ciclosporin.
45486603|NCT03192280|Device|iPhone 7|Smart phone
45486604|NCT03190018|Device|lCarry Life System Peritoneal Dialysis (CLS PD)|The assigned intervention is with the CLS PD device in patients currently receiving peritoneal dialysis for the duration of one study session. A temporary Pigtail catheter is inserted on the same morning as the study session and removed after the session on the same day.
45486605|NCT02443012|Drug|Topical Gutt Nepafenac 0.1%|Topical Nepafenac as an adjunct to focal/grid laser
45486606|NCT02443012|Procedure|Laser|Grid/Focal Laser Photocoagulation
45486607|NCT04670432|Drug|Hydroxyethylrutoside|500 mg film-coated tablet
45486608|NCT02443090|Drug|fispemifene|
45486609|NCT02443090|Other|Placebo|
46052457|NCT05581134|Behavioral|Control Group intervention|Treatment will follow general treatment principles in physiotherapy for FMDs: (1) education; (2) exploration of how symptoms affect movement and posture; (3) retraining movement using strategies based on redirection of attention; and (4) development of a self-management plan.
45486610|NCT03624764|Procedure|Laparostopic promontofixation using surgical glue|The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by the surgical glue (cyanoacrylate biocompatible adhesive)
45486611|NCT03624764|Procedure|Laparostopic promontofixation using threads|The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by sutures with threads
45486612|NCT03701126|Procedure|Transversus Abdominis Plane Block|ultrasound (US) guided TAP block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
45486613|NCT03701126|Procedure|Caudal Block|ultrasound (US) guided caudal block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
45486614|NCT03701126|Drug|Bupivacaine 0.25% Injectable Solution|Dose 1ml /kg of patient body weight
45368903|NCT01751126|Drug|Placebo|Sterile, drug-free, cationic ophthalmic oil-in-water emulsion containing 0 mg/ml Ciclosporin.
45368904|NCT00943982|Drug|Interferon Gamma 1-b|
45486615|NCT03701126|Device|Ultra-sound guidance|using superficial high frequency probe to guide regional anesthesia
45486616|NCT02439736|Other|Blood draw within 12 hours of head injury|
45486617|NCT02442934|Other|Administration of the IPREA3 questionnaire|On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
45486618|NCT02442934|Other|Immediate feedback through electronic reminder messages|After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
45368905|NCT01570010|Other|Norwegian food based dietary guidelines|several means will be applied to guide participarts to cohere to the dietary guidelines including access to clinical nutritionists, free food, food discounts, cooking courses, cookbook/recipies, study website, organized physical activity, etc
45486619|NCT02442934|Other|Targeted interventions in each ICU to reduce discomforts|"These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures."
45486620|NCT04668326|Device|Manual Standing Wheelchair|Mobile in seated position; Not mobile in standing position
45486621|NCT04668326|Device|Mobile Manual Standing Wheelchair|Mobile in BOTH seated and standing positions
45486622|NCT02439502|Device|Fuse® system|Fuse® system will be used to perform gastro and endoscopic diagnostic procedures for upper and lower GI tract.
45486623|NCT03701048|Procedure|Cesarean Section|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed.
45486624|NCT03187600|Procedure|Mucosa/submucosa Pharyngeal Flap|Included in study arm description
45486625|NCT03187600|Procedure|Standard of Care Pharyngeal Flap|Included in study arm description
45486626|NCT03696836|Device|Trammpolin® meniscus prosthesis|Trammpolin® meniscus prosthesis is an anatomically shaped, synthetic medial meniscus replacement
45486627|NCT02442544|Dietary Supplement|Prebiotic|1:1 oligofructose: inulin 8 g orally /day
45486628|NCT02442544|Dietary Supplement|Placebo|maltodextrin 3.3g orally/day
45486629|NCT03187522|Device|TREO Stent-Graft System|The TREO® Stent-Graft is designed for use in the management of patients with AAAs and is composed of self-expanding nitinol stents sutured to polyester vascular graft fabric.
46052458|NCT02809287|Procedure|Jackknife posture|patients with left lateral position plus jackknife position when perform laparoscopic hepatectomy
46052459|NCT00626990|Drug|temozolomide|Patients randomized to concomitant temozolomide will receive temozolomide continuously at a daily dose of 75 mg/m² during radiotherapy.
46052460|NCT00626990|Genetic|DNA methylation analysis|MGMT methylation status is used for stratification at randomization.
46052461|NCT00626990|Other|laboratory biomarker analysis|Prognostic factor analyses
46052462|NCT00626990|Procedure|adjuvant therapy|Patients randomized to adjuvant temozolomide will start adjuvant temozolomide after a 4 week resting period after the end of radiotherapy.
46052463|NCT00626990|Procedure|quality-of-life assessment|Quality of Life analysis will also be used to assess neurological deterioration free progression
46052464|NCT00626990|Radiation|radiation therapy|Radiotherapy will consist of a conventionally fractionated regimen for 6.5 weeks in a once daily schedule
45368906|NCT00944060|Other|lifestyle intervention|
45486630|NCT03702140|Drug|"Teriparatide, Forteo® or Teribon"|To examine the effects of terimaratide less than 6 months in osteoporosis
45486631|NCT02433886|Procedure|Gamma Ventral Capsulotomy|
45486632|NCT03700814|Drug|Co-amoxiclav|Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which was injected 30 minutes prior to the incision during surgery.
45486633|NCT02433964|Other|Grupo LED|
45486634|NCT02433964|Other|Placebo|ledterapia off + price
45486635|NCT02433808|Drug|Neostigmine Group|Neostigmine will be used to reverse neuromuscular block at the conclusion of the surgical procedure. The effect on muscle strength will be determined using the TOF-Watch-SX and clinical examination
45486636|NCT02433808|Other|No Neostigmine group|Saline will be administered to patients at the end of the surgical procedure when neuromuscular function has recovered
45486637|NCT02434042|Dietary Supplement|BB536|Intervention consists of daily administration of 1g probiotic Bifidobacterium longum BB536, administer daily for five days a week at a fixed dosage of 9 log CFU/day for BB536 and continue for 10 months.
45486638|NCT02434042|Other|Placebo|Intervention consists of daily administration of 1g of 100% dextrin, administer daily for five days a week and continue for 10 months.
45486639|NCT02439346|Drug|BAY1143269 tablet|BAY 1143269 5 mg or 25 mg tablet. Each treatment cycle will last 21 days.
45486640|NCT03702062|Diagnostic Test|6 Minute Walk Test Smart phone Application|The intervention requests participants to user the smart phone application at prescribed frequencies during the follow-up period.
45486641|NCT02439424|Device|Reactive ATP|"Reactive ATP turned to on"
45486642|NCT03701984|Drug|Lidocaine|The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
45486643|NCT03701984|Drug|Tramadol|an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.
45486644|NCT03701984|Drug|placebo|a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
45486645|NCT03190096|Procedure|SVC isolation|After PVI ablation SVC will be performed. The CB will be retrieved to the right atrium and the achieve catheter will be advanced in the SVC. The CB will be inflated in the right atrium and advanced towards the ostium of the SVC to occlude the vessel
45486646|NCT04651400|Drug|Antithrombin III|Antithrombin III
45486647|NCT02439190|Drug|BMS-986120|
45486648|NCT02439190|Drug|Aspirin|
45486649|NCT02439190|Drug|Clopidogrel|
45486650|NCT02442466|Drug|Endothelin Receptor B inhibitor BQ788|
45486651|NCT02442466|Drug|PBS|
45486652|NCT04336982|Drug|CC-90009|Injection
45486653|NCT04336982|Drug|Venetoclax|Tablet
45486654|NCT04336982|Drug|Azacitidine|Injection
46052465|NCT04219839|Behavioral|SOC + Educational Videos Designed Especially for post-transplant patients|Patient focused videos (3-5 minutes each) with topics that will include: What to Expect After Transplant, What is the Kidney, Understanding your Labs, Transplant Medications, General Medical Care Post-Transplant, When to Call your Coordinator, and Self-Management/Sick Day protocols. Video curriculum will be offered in two ways. First, tablet computers with active links to each video will be available in kidney transplant clinic. At provider/coordinator discretion, study participants may also view videos while waiting for other appointments. In addition, for patients with smartphones who consent to this, a desktop link will be provided to the transplant video curriculum webpage (mobile friendly view).
45486655|NCT04336982|Drug|Gilteritinib|Tablet
45486656|NCT02439034|Drug|Paracetamol|Paracetamol 1 g IV then 1 g 3 times a day IV or oral (PO)
45486657|NCT02439034|Drug|Ketoprofen|Ketoprofen* 100 mg (IV then PO) : Ketoprofen 100 mg IV 2 times a day or Ketoprofen LP 100 mg PO 2 times a day.
45486658|NCT03700580|Drug|Hydrogel treatment|Hydrogel dressing containing water, carboxymethyl cellulose and sodium alginate in non-specified proportions, purchased in bulk amounts was sterile dispensed in smaller amounts (200 g) for frequent use.
45486659|NCT03700580|Drug|P1G10|P1G10 containing dressing composed by 8% Polawax, 6% liquid vaseline, 0.06% butylated hydroxytoluene, 0.15% Nipagin, 5% propyleneglycol, 0.1% Nipazol, 0.1% ethylenediaminetetraacetate disodium salt, 0.03% methyl-aminopropanol-95, 0.3% Imidazolidinyl urea, 2% Cyclomethicone, 78.2% distilled water. A single batch of the formulation was made and used throughout the intervention. A sample of this preparation was used to assess the extended stability of the formulation. The formulation was dispensed into 100 g dispensers for weekly use.
45486660|NCT02439112|Other|Exercise|"8 supervised in-hospital training sessions in a period of 10 weeks. On a general level, the intervention will follow the Danish physical activity guidelines for elderly >65 years (Sundhedsstyrelsen 2011, see link) and consist of strength exercise, aerobic exercise and physical activity.~Bone involvement will taken into consideration in all parts of the exercise program by excluding and including specific exercises and mode of exercise according to location and extent of bone involvement (Galvão 2011; Cormie 2013)"
45486661|NCT03696602|Diagnostic Test|bronchial provocation test|
45691723|NCT00678418|Drug|VIVITROL® 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for 24 weeks during Part A, followed by once every 4 weeks for 52 weeks in Part B.
46052466|NCT02814747|Other|quantitive study: 500 patients likely to be candidates for HTS|
46052467|NCT02814747|Other|qualitative study: 30 patients who have benefited from HTS|
45486662|NCT03701906|Dietary Supplement|Lactobacillus PS11603 & Bifidobacterium PS10402|Approximately 8 weeks intervention study: Participants with 0-5 days of age will start a period of 8 weeks of intervention. During this time the participants will intake one daily dose of the product that contains 1*10E9 CFU of L.salivarius PS11603 and 1*10E8 CFU of B.longum PS10402.
45368907|NCT00548808|Drug|Insulin lispro low mixture|Dose depending on patient's need; subcutaneous injection before meal; start with once-daily injection before evening meal for 48 weeks, may add second injection before breakfast at any time during the treatment period if required, and may further add third injection before lunch at any time in the remainder of the treatment period if required.
45486663|NCT03701906|Dietary Supplement|Placebo|8 weeks intervention study: A 8 weeks intervention period. During the 8 weeks of intervention the participants will intake one daily dose of placebo supplement.
45486664|NCT02438956|Dietary Supplement|Setria glutathione supplement|500 mg/day capsule taken in the morning for 120 days.
45486665|NCT02438956|Dietary Supplement|Crystalline Cellulose|500 mg/day capsule taken in the morning for 120 days.
45368908|NCT00548808|Drug|Insulin glargine|Dose depending on patient's need; one daily subcutaneous injection before bedtime for 48 weeks
45368909|NCT00548808|Drug|Insulin lispro|Dose depending on patient's need; subcutaneous injection before meal; may start once-daily injection before meal (e.g. lunch if the highest blood glucose value is measured before dinner) on top of insulin glargine at any time of the treatment period if required, and may further add second or even third injection in the remainder of the treatment period if required.
45368910|NCT00944138|Behavioral|Relaxation methods|Relaxation methods will include mindful meditation techniques for the intervention and listening to music for the control arm
45368911|NCT00954434|Dietary Supplement|red wine|intake of red wine on a daily basis
45368912|NCT04011878|Procedure|Combined trabeculotomy trabeculectomy with mitomycin C|Combined trabeculotomy trabeculectomy with mitomycin C with histopathological examination of the peripheral iris tissue specimen of all cases
45368913|NCT00954096|Drug|transdermal nicotine patch (7mg)|A 7mg transdermal nicotine patch will be applied to the subject's arm for an 8 hour period.
45368914|NCT00949338|Procedure|pre-procedural preparation|Patients empty their bladders and consume 6 cups or 3 cups of water 30 minutes before undergoing radiotherapy.
46052468|NCT02812017|Behavioral|Thirty Million Words- Well Baby|Through evidence-based strategies, the TMW-WB curriculum teaches parents how to harness the power of their words to build their child's brain and impact their child's learning trajectory.
45368915|NCT00954252|Drug|CHF 5074|1x, oral capsule, single dose
45486666|NCT02438800|Behavioral|LARC First Video|LARC First is an evidence-based, 12-minute video developed by the CHOICE project that features women of all racial and ethnic backgrounds describing LARC methods of contraception in simple, understandable language with summary text when appropriate.
45368916|NCT00954252|Drug|placebo|placebo, oral capsule, single dose
45368917|NCT00954252|Drug|CHF 5074|2x, oral capsule, single dose
45368918|NCT00954252|Drug|CHF 5074|4x, oral capsule, single dose
45368919|NCT00954252|Drug|CHF 5074|8x, oral capsule, single dose
45368920|NCT00954252|Drug|CHF 5074|16x, oral capsule, single dose
45368921|NCT00954252|Drug|CHF 5074|24x, oral capsule, single dose
45368922|NCT01563042|Drug|Intravenous (IV) single dose|GSK2434735 administered as a single intervenous dose at the beginning of the study
45368923|NCT01563042|Drug|Subcutaneous (SC) single dose|GSK2434735 administered as a single subcutaneous dose at the beginning of the study
45368924|NCT00110617|Drug|Deferasirox (ICL670)|Deferasirox was provided in 125 mg, 250 mg, and 500 mg dispersible tablets and was administered orally at an initial dose of 20 mg/kg/day.
45486667|NCT03692858|Drug|Adductor Canal Block plus IPACK Block|Adductor Canal Block plus IPACK Block using Ropivacaine
45486668|NCT03692858|Drug|Adductor Canal Block|Adductor Canal Block using Ropivacaine
45486669|NCT03692780|Drug|Careseng 1370|4,000mg granules in sachet
46052469|NCT02812017|Other|Safety Starts at Home|A portion of the Safety Stars at Home set is shown. Demonstrating proven childproofing techniques and accident-prevention strategies, which unifies safety guidelines and shows caregivers how to take proactive measures at home. Many no- or low-cost safety alternatives are offered.
46052470|NCT01057862|Drug|Naltrexone|Targeted dosage of 50mg PO daily
46052471|NCT01057862|Other|Placebo|Sugar pills daily PO
46052472|NCT02812251|Drug|JNJ-61393215|JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.
45486670|NCT03692780|Drug|Placebo|4,000mg granules in sachet
45486671|NCT04483492|Drug|Caffeine citrate|diaphragm contractility after administration
45486672|NCT02442154|Procedure|Tracheostomy|It is a surgical procedure which involves making an incision on the anterior aspect of the neck and opening a direct airway through an incision in the trachea with stitching the trachea to the skin and placement of a tube
45486673|NCT04483336|Other|Virtual Reality Distraction|Virtual reality goggles are commercially available wearable devices that are used to view view videos and play video games three dimensionally.
45368925|NCT00110617|Drug|Deferoxamine (DFO)|Deferoxamine was supplied in vials of 500 mg and 2000 mg administered subcutaneously for a weekly dose of 175 mg/kg.
45486674|NCT04483336|Other|TV Screen Distraction|A cartoon video was played on a regular TV screen.
45368926|NCT00954330|Procedure|lateral ligament surgery|. The disrupted FTA or/and FC and superficial retinacular structures were repaired by using absorbable sutures. In case of avulsion from the bone, the ligament was reapproximated with the use of sutures that were passed through 2.0 millimeter drill-holes in the bone.
45486675|NCT02438878|Behavioral|Baby Behavior|
45486676|NCT03186976|Behavioral|Aggressive Risk Factor Control|"1.) Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.~2) Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (>5 drinks at one setting).~3) Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.~4) An OMRON BP monitor will be supplied to each patient. A target SBP of <140/80 mm/Hg will be targeted.~5) Smoking cessation - through local resources already established at each site 6) Management of diabetes to achieve HgA1c<6.5%"
45486677|NCT03186976|Other|Standard of Care|Recommendations based on current guidelines
45486678|NCT02442388|Procedure|Instrumentation technique with hand file|type of instrumentation technique for root canal treatment
45486679|NCT02442388|Procedure|Instrumentation technique with ProTaper|type of instrumentation technique for root canal treatment
45486680|NCT02442388|Procedure|Instrumentation technique with WaveOne|type of instrumentation technique for root canal treatment
45486681|NCT03186742|Drug|Eplerenone 50 mg Tab|Eplerenone 50 mg Tab once a day
45368927|NCT00954330|Device|functional treatment|Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle.
45486682|NCT02441998|Other|Education intervention: Training in Narrow Band Imaging|Two hour training session in interpretation and application of narrow band imaging technology
45486683|NCT03186664|Device|Lokomat training|The neurorobotic treatment will be performed by using the Lokomat (Lokomat, Hocoma, Volketswil, Switzerland) device. The work load will be progressively adjusted based on the improvement of motor performances. Training parameters (weight support, etc) will be individually adapted. During the first Lokomat session, support will be set at 50% of the body weight and will be adapted on observation of the gait. The Lokomat motor guidance system will be first set at 100%, corresponding to a passive walk.
45486684|NCT03186664|Drug|Sativex|"Patients in treatment with Sativex will receive cannabis-based medicine extract presented in a pump action sublingual spray. Sativex is composed of whole cannabis plant extract, containing THC (27 mg/mL) and CBD (25 mg/mL), in ethanol/propylene glycol (50:50) excipient.~Each actuation delivers 100 KL of spray, containing THC 2.7 mg and CBD 2.5 mg. The number and frequency of dosing (sprays) with Sativex will vary from individual to individual and it may take a number of weeks to find the correct dose of Sativex for the individual patient."
45486685|NCT03189784|Other|mobilization with movement techniques|patient will receive an anteroposterior stimuli in the talus in order to restore the range of motion
45486686|NCT02441842|Drug|atenolol|administered 60 minutes pre procedure
45486687|NCT02441842|Drug|lisinopril|administered 60 minutes pre procedure
46052473|NCT02812251|Drug|Placebo|Matching placebo will be administered.
46052474|NCT01038128|Drug|Memantine|Drug: Memantine, 10-40 mg daily
46052475|NCT02812329|Behavioral|HIV prevention videogame|Assess acceptability and efficacy of a HIV prevention videogame
46052476|NCT04303520|Biological|anti-CD19/CD22 CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs
46052477|NCT04303520|Drug|Fludarabine|30mg/m2/d
45368928|NCT00949494|Device|Synvisc|intra-articular, 3 weekly injections
45486688|NCT02441842|Other|glucose|administered 60 minutes pre procedure
46052478|NCT04303520|Drug|Cyclophosphamide|500mg/m2/d
46052479|NCT02812095|Procedure|Refeeding|when amount of feeding reach to 120mL/kg a day,
46052480|NCT02812407|Device|Mucosal Impedance|"During the clinical endoscopy, the 2.13 mm catheter will be passed through the channel of the standard endoscope this is called an Intraluminal Impedance. The Intraluminal impedance (made by Sandhill Scientific) has not been approved by the Food and Drug Administration (FDA) but it is considered to be minimal risk related to using it. The catheter gives the investigators a reading at each level.~The catheter will be placed on the esophageal mucosa 5 cm above the gastroesophageal junction (where the stomach and esophagus meet) for 5 second~At 10 cm above the gastroesophageal junction the catheter will be placed for 5 seconds~And at 20 cm"
45486689|NCT02438566|Drug|Tranexamic Acid (Oral)|OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
45486690|NCT02438566|Drug|Tranexamic Acid (Intravenous)|IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
45486691|NCT02433652|Biological|Recombinant live attenuated trivalent dengue vaccine|Contains 10^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10^3.3 PFU/mL of rDEN3Δ30/31-7164 and 10^3.3 PFU/mL of rDEN4Δ30. It is administered in 0.5 mL containing 10^3.0 PFU of each component.
45486692|NCT02433652|Biological|Placebo|
45486693|NCT02433652|Biological|rDEN2Δ30-7169 vaccine|Live recombinant attenuated DENV-2 candidate vaccine virus; will be administered at a dose of 10^3 PFU
45486694|NCT03186586|Drug|Ulipristal acetate|5mg/day/five days
45486695|NCT03186586|Drug|Placebo|Placebo one pill a day for 5 days at the bleeding episode
46052481|NCT02809599|Behavioral|DIZZTINCT|The intervention, DIZZTINCT, is a multi-faceted educational and care-process based intervention designed to improve the guideline-concordant care of patients with BPPV in the emergency department. The intervention includes six main components: the recruitment and training of local champions who will serve as colleague experts in the community; interactive hands-on educational sessions that address BPPV mechanisms, evidence and practice; a high-yield decision-aid web application for self study and point of care use; development of a referral network for follow up care; follow-up educational sessions to review successes and barriers amongst the intervention group; and other resources developed locally in partnership with the community medical providers.
46052482|NCT02562378|Drug|Trastuzumab and non-pegylated liposomal doxorubicin|"3 Cohorts (3+3 design):~Cohort 1- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (45 mg/m2) IV~Cohort 2- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (50 mg/m2) IV~Cohort 3- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (60 mg/m2) IV"
45368929|NCT04011462|Device|prewarming 20 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 20 minutes.
45486696|NCT02441608|Device|KL029 Intimate Lubricant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
45486697|NCT02433574|Radiation|Neoadjuvant Stereotactic body radiation (SBRT)|"Dose escalation of neo-adjuvant SBRT in operable patients with locally advanced non-small cell lung cancer.~The first cohort will be treated with a dose of 35 Gy in 10 fractions, the second cohort will be treated with a dose of 40 Gy in 10 fractions, the third cohort will be treated with a dose of 45 Gy in 10 fractions, the fourth cohort will be treated with a dose of 50 Gy in 10 fractions. The SBRT doses will be escalated only once all patients in the previous cohort will have completed safely their treatments."
45486698|NCT02438176|Procedure|single trans-septal puncture|The investigators will compare bilateral groin puncture AF ablation and single groin puncture AF ablation with 1:2 randomization.
45486699|NCT02438176|Procedure|conventional bilateral groin puncture|Bilateral groin puncture AF ablation is control procedure exactly same to routine AF ablation with double trans-septal puncture.
45486700|NCT02438332|Device|Smooth NATRELLE® INSPIRA® TruForrm® 1 Breast Implants|Surgical implant
45486701|NCT02438332|Device|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
45486702|NCT02438332|Device|Smooth NATRELLE® INSPIRA® TruForrm® 2 Breast Implants|surgical implant
45368930|NCT04011462|Device|prewarming 30 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 30 minutes.
45368931|NCT00954486|Drug|Epoetin alfa|Epoetin alfa will be administered at 10,000 units/week
45368932|NCT03956862|Drug|GB001|film-coated oral tablet
45368933|NCT03956862|Drug|Placebo|film-coated oral tablet
45368934|NCT00550238|Drug|Pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
45368935|NCT02903680|Drug|Dexamethasone group|The intervention of interest was the administration of dexamethasone 0.6 mg/kg IV (max 15 mg) before departure from the ED. The control group received a similar looking placebo (NaCl 0,9% IV) with the same volume.
45368936|NCT02903680|Drug|Placebo group|Normal Saline 0,9% same volume
45486703|NCT02438332|Device|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
45486704|NCT02433418|Procedure|Tubal flushing by Urografin®|Women will have tubal flushing through HSG using water soluble media (Urographin ®)
45486705|NCT02433418|Drug|Diclofenac|Women will receive oral diclofenac 50 mg (voltaren ®) 1 hour before hysterosalpingography
45368937|NCT00946946|Drug|Azathioprine|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
45368938|NCT00946946|Drug|Mesalazine|4g Mesalazine tablets/day AND azathioprine placebo tablets
45368939|NCT00946946|Drug|Azathioprine placebo|4g Mesalazine tablets/day AND azathioprine placebo tablets
45486706|NCT04484038|Radiation|hypofractionated postoperative radiation therapy|The patients included in the study will undergo intensity-modulated radiotherapy, of any modality, and image-guided (IGRT) with an emphasis on tissue preservation and administration precision through the use of devices that guarantee the stability and reproducibility of the same.
45486707|NCT02433730|Drug|Testosterone|intramuscular injection
45486708|NCT02433730|Drug|placebo|intramuscular injection
45486709|NCT02438098|Drug|Rivaroxaban 10 mg|Patients receive the day before the surgical intervention the first dose of Rivaroxaban (10 mg) p.o. The second tablet Rivaroxaban is administered on the third postoperative day.
45486710|NCT02433262|Other|WHO (World Health Organisation)|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using WHO criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
45368940|NCT00946946|Drug|Mesalazine placebo|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
45486711|NCT02433262|Other|IADPSG|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using IADPSG criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
45846432|NCT02570022|Procedure|Inter-scalene nerve block|Pre-operative inter-scalene nerve block
46052483|NCT05610267|Device|Retrospective chart review|The retrospective chart review will include the full consecutive series of patients between 22 years and 80 years old who underwent abdominal wall reconstruction for achart hernia with Integra Gentrix® Surgical Matrix during the time period between November 1, 2017, and present (90 days prior to the start of data collection).
45368941|NCT03956550|Drug|REGN5069|Intravenous (IV) Dose every 4 weeks (Q4W)
45486712|NCT02441530|Dietary Supplement|Vitamin D|
45368942|NCT03956550|Drug|Matching Placebo|Intravenous (IV) Dose every 4 weeks (QW4)
45368943|NCT03037294|Dietary Supplement|Preoperative protein supplementation|Daily 40 g of pre-sleep protein supplementation during 2-week preoperative period.
45486713|NCT02441530|Dietary Supplement|Vitamin E|
45486714|NCT02441530|Drug|Ibuprofen|
45486715|NCT02433184|Drug|Etanercept|Etanercept will be administered subcutaneously at a dose of 50 mg weekly and will be discontinued at the primary endpoint (48 weeks).
45486716|NCT02433184|Drug|Methotrexate|Methotrexate will be administered orally at a starting dose of 15 mg and will be increased to 25mg weekly at 2 weeks.
45486717|NCT02433184|Drug|Sulfasalazine|Sulfasalazine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered orally at a dose of 1g twice daily. Will be discontinued if starting etanercept at 24 weeks.
45486718|NCT02433184|Drug|Hydroxychloroquine|Hydroxychloroquine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered at a dose of 200mg daily. Will be discontinued if starting etanercept at 24 weeks.
46052484|NCT04141137|Device|TricValve® System|The TricValve® Delivery System (catheter) with already pre-mounted biological heart valve is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is released at the implantation site and positions itself as per the anatomy - self expanding frame.
45486719|NCT02433184|Drug|Etanercept|Etanercept will be added at 24 weeks, if a subject fails to achieve clinical remission,at a dose of 50 mg weekly and will be discontinued at 48 weeks with the exception of those patients who are eligible to continue according to local prescribing guidelines (NICE guidelines)
45486720|NCT02433184|Drug|Methotrexate|Methotrexate will be administered orally at a starting dose of 15 mg weekly, increasing to 20mg and 25mg weekly at weeks 4 and 8 respectively.
45486721|NCT02433106|Other|GAA 15|Neuromuscular injury prevention training
45486722|NCT02433106|Other|Control|Usual training
45486723|NCT02438020|Drug|Metformin|One tablet of 500 mg will be ingested before the main meal
45846433|NCT02570022|Drug|Ropivacaine|Ropivicaine was used for the inter-scalene nerve block.
45846434|NCT02572752|Drug|Nintedanib|1 soft gelatine capsule, single dose, oral
45846435|NCT02572752|Drug|Nintedanib|Nintedanib, 2 soft gelatine capsules, single dose, oral
45846436|NCT02572752|Drug|Nintedanib|
45846437|NCT02574858|Drug|QRH-882260|The investigational agent to be used in this study is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached to Cy5.
45846438|NCT02577042|Drug|Raltegravir|Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.
45368944|NCT00954668|Procedure|immediate angiography and revascularization|immediate angiography < 2 hours after randomization
45368945|NCT00954668|Procedure|early invasive angiography|early invasive angiography 12-72 h after randomization
46052485|NCT00842530|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous
45368946|NCT00947024|Drug|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.|
45368947|NCT00947024|Drug|10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.|
45368948|NCT00947024|Drug|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.|
45368949|NCT01033708|Behavioral|narrative exposure therapy|Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
45486724|NCT02438020|Other|Placebo|A placebo tablet will be ingested daily before main meal.
45486725|NCT02437942|Other|Biomechanics led physical therapy rehabilitation|Rehabilitation intervention will consist of movement control (3 days per week), whole body strength and power (2 days per week), linear running mechanics (3 days per week), multi-directional mechanics (3 days per week), conditioning sessions (2 days per week). Rehabilitation will continue until physical therapist deems the athlete ready to return to sport.
46052486|NCT00842530|Biological|Inactivated rabies virus vaccine|0.5 mL, Subcutaneous
46052487|NCT00842530|Biological|Placebo|Sodium chloride 0.9%
46052488|NCT04190238|Other|Super inductive system (high frequency electromagnetic field)|Super inductive system (high frequency electromagnetic field)
46052489|NCT04190238|Other|Physical therapy|specific for spasticity
46052490|NCT04236921|Drug|DopaSnap®|immediate release CD/LD 25/100mg; Riverside Pharmaceuticals Corporation, USA
45368950|NCT00949572|Biological|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 intramuscular dose (0.5 ml) on month 0, 1 and 4 containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
45368951|NCT00949572|Biological|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 sublingual application on month 0, 1 and 4 of 0.5 ml containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
45368952|NCT01031992|Drug|Tranexamic acid first, than placebo|For 3 months Tranexamic acid 3 times daily 1 g taken orally, followed by placebo for 3 months.
45368953|NCT01031992|Drug|First placebo, than Tranexamic acid.|First placebo for 3 months, than tranexamic acid 3 times daily 1 g for 3 months.
45368954|NCT00954564|Other|aromatase inhibition therapy - OBSERVATIONAL ONLY|Observational only - as prescribed
45368955|NCT00954564|Other|medical chart review|Observational only
45368956|NCT00954564|Other|questionnaire administration|Observational only
45368957|NCT00954564|Procedure|assessment of therapy complications|Observational only
45368958|NCT04012346|Device|Transcranial magnetic stimulation|Transcranial magnetic stimulation device will be used. Short protocol iTBS will be applied.
45368959|NCT01323556|Behavioral|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure with interoceptive exposure during in vivo exposure
45368960|NCT01323556|Behavioral|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure without additional fear augmenting strategies
46052491|NCT04236921|Drug|RDL of CD-LD|(immediate release CD/LD 25/100mg; Merck Sharp & Dohme Corp., USA),
46052492|NCT05580510|Drug|Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID|"This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Sacubitril/Valsartan as an active comparator."
45368961|NCT00949728|Procedure|Conjunctival autograft using fibrin glue|Conjunctival autograft using fibrin glue in pterygium surgery
45368962|NCT00947102|Other|Observation|
45486726|NCT02441452|Other|Early rehabilitation|The physical exercises and breathing exercises are started as soon as after the Nuss procedure
45691724|NCT00678418|Drug|Placebo|Administered via IM injection once every 4 weeks for 24 weeks during Part A, followed by VIVITROL® 380 mg via IM injection once every 4 weeks for 52 weeks in Part B.
46052493|NCT05580510|Drug|Empagliflozin 10 MG OD|"This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Empagliflozin as an experimental drug."
45486727|NCT02441140|Procedure|Culdocentesis|A sterile speculum will be placed in the vagina and the cervix identified. The cervix will be elevated using a tenaculum and a spinal needle inserted through the posterior vaginal fornix. Fluid from the posterior cul de sac will be collected
45486728|NCT02441140|Procedure|Vaginal Swab|. A sterile speculum will be placed in the vagina and a Pap smear spatula will be used to swab the posterior fornix of the vagina. This swab will then be rinsed in a tube of saline.
45486729|NCT02441140|Procedure|Chromopertubation|Chromopertubation is a common gynecologic technique used to test the patency of fallopian tubes during infertility evaluations. Fluid is flushed through the cervix and uterus and out the fallopian tubes.
45486730|NCT02441140|Procedure|Blood collection|Intravenous blood collection will be drawn from an IV
45486731|NCT02441140|Procedure|Tissue collection|As part of the standard surgical procedure for presumed ovarian cancer, the primary tumor will be resected and a sample obtained for evaluation
45486732|NCT02437786|Drug|GRAZAX|GRAZAX
45486733|NCT02437552|Device|ergometer cycle exercise|
45486734|NCT02437552|Other|routine physiotherapy|routine physiotherapy
45486735|NCT02441296|Other|Formula with lactose|
45368963|NCT05229666|Other|Cognitive Challenge|Cognitive challenge delivered via computer.
45368964|NCT00954902|Dietary Supplement|High Antioxidant Spice Blend|14.5 g spice blend incorporated into a delivery meal including: cloves, cinnamon, oregano, rosemary, ginger, black pepper, paprika, garlic powder, and turmeric.
45368965|NCT00954902|Behavioral|Trier Psychological Stressor|This is a psychological stressor that is used to invoked stress responses in human subjects. Subjects are told they are taped and evaluated and deliver the speech in front of a trained panel of judges.
45368966|NCT00954902|Other|Placebo antioxidant concentrate|Placebo capsules
45486736|NCT02441296|Other|Formula with maltodextrins|
45486737|NCT03189628|Biological|stromal vascular fraction|The adipose tissue(no less than 40ml) in abdomen will be harvested and digested at 37 °C for (45-60) min with (0.125-1.5)mg/ml collagenase . After filtration and centrifugation at the speed of (700-1500)g, mature adipocytes are separated from the cell pellet. The pellet then is treated with saline twice to remove cell fragment and rudimental collagenase . The harvested pellet is stromal vascular fraction (SVF) The SVF was resuspended in 1 ml saline and transplanted for 3 area including the forehead、palpebra inferior and crow's-feet.
45486738|NCT03189628|Drug|Saline|1 ml saline was injected for 3 area including the forehead、palpebra inferior and crow's-feet.
45486739|NCT03186820|Other|Susceptibility Weighted Imaging as 3D SWAN sequence|Susceptibility Weighted Imaging as 3D SWAN sequence
45486740|NCT02441374|Device|Tubular mesh.|Rehabilitation in upper limb during and after applying of FUT (through the tubular mesh) post stroke.
45846439|NCT02577042|Drug|PI-based regimen|Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.
45846440|NCT02577042|Drug|Atorvastatin|Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks
46052494|NCT02811627|Drug|Memantine|Namenda (pill and the liquid) will be started at 5 mg/day doses to be titrated up 20 mg/day based on response and tolerability, as per the package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks. Namenda XR will be started at 7 mg/day to be titrated up to 28mg/day based on response and tolerability, as per package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks.
45368967|NCT01034020|Drug|Nicotine|
45486741|NCT02441374|Other|Classical kinesiotherapy.|Applying classical kinesiotherapy in upper limb post stroke.
45846441|NCT02577510|Drug|Nerve Injection- Nerve Stimulator|For the neurostimulation nerve injection technique, the initial puncture site will be located medial to the anterosuperior iliac spine, just caudal to the inguinal ligament [7]. The 22-gauge insulated needle will be connected to a stimulator set at a current of 1.5 mA, a pulse width of 300 ms and a frequency of 2 Hz. A paresthesia referred to the lateral aspect of the thigh at a minimal stimulatory threshold of 0.6 mA (0.3ms) will be sought prior to the injection of local anesthetic [7]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
46052495|NCT02811627|Device|Magnetic Resonance Imaging|The subjects will undergo an MRI assessment after baseline behavioral assessment. The session will involve a structural MRI scan, single voxel spectroscopy scans and resting state functional MRI. The subjects will be started on memantine post the imaging session. The imaging will be carried out on a research dedicated 3 Tesla (3T) Siemens Trio Scanner at the University of Missouri Brain Imaging Center by trained personnel.
46052496|NCT00634413|Drug|Theophylline - ADC4022|Inhaled theophylline (ADC4022) administered twice daily for 28 days
46052497|NCT00634413|Drug|Placebo|Inhaled matching placebo administered twice daily for 28 days
46052498|NCT00634413|Drug|Budesonide|Inhaled budesonide twice daily for 28 days
46052499|NCT02683824|Diagnostic Test|Computed Tomography|Undergo CT scan
46052500|NCT02683824|Other|Laboratory Biomarker Analysis|Correlative studies
46052501|NCT02683824|Diagnostic Test|PET/MRI scan|Undergo PET/MRI scan
45486742|NCT03186274|Behavioral|Facilitated Group Session|Participants will review the SPIKES model with a facilitator and then participate in a guided and supported simulated patient encounter utilizing aspects of the SPIKES model, with feedback at the end of the session.
45486743|NCT03186274|Behavioral|CELA Session|Participants will review the SPIKES model on their own and then participate in a simulated patient encounter utilizing the SPIKES model. They will receive feedback following the encounter.
45486744|NCT02437474|Behavioral|Omnivorous diet|Adopting or continuing the selected diet for 6 months (omnivorous)
45486745|NCT02437474|Behavioral|Lacto-ovo-vegetarian diet|Adopting or continuing the selected diet for 6 months (lacto-ovo-vegetarian)
45486746|NCT02437474|Behavioral|Vegan diet|Adopting or continuing the selected diet for 6 months (vegan)
45691725|NCT00678496|Other|CBT Software|"Beating the Blues is a CBT-based software package for patients with anxiety and/or depression. The CBT strategies used include: identifying thinking errors, challenging automatic negative thoughts, modifying attributional style and identifying core beliefs. The behavioural techniques used include graded exposure, sleep management, problem solving, task breakdown and activity scheduling. The programme consists of a 15 minute Introduction to Therapy video plus eight computer-interactive sessions of approximately 50 minutes each in duration. Each session consists of a mix of cognitive and behavioural strategies, which are customised to the patient's individual problems. The eight computer sessions are designed to be taken weekly, or thereabouts, and each session builds on the previous one."
45691726|NCT00678496|Other|Treatment as usual|Participants in the usual care arm are asked to refrain from accessing psychological services during their participation in the study, but may be prescribed anti-depressants or referred to a counsellor by their general practitioner.
45368968|NCT05204940|Behavioral|Mechanisms of Late life depression (LLD)-dementia through functional Magnetic Resonance Imaging (fMRI)|Analyzing mechanisms of the LLD-dementia relationship through fMRI acquisitions and analyses, to capture the specific brain networks implicated in executive function and episodic memory decline.
45368969|NCT05204940|Behavioral|Neuropsychological Data|Neuropsychological Data, including Montreal Cognitive Assessment (MoCA), Wide Range Achievement Test-4 (WRAT-4) Reading subtest, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and Delis-Kaplan Executive Function System (D-KEFS) (Color Word Interference, Trail Making and Verbal Fluency).
45368970|NCT05204940|Behavioral|Clinical Scales|Clinical scales, including the Everyday Cognition Scale (E-Cog), Global Clinical Dementia Rating (CDR), Performance Assessment of Selfcare Skills (PASS)--CIADL (Cognitive Instrumental Activities of Daily Living) Short version, Patient Health Questionnaire (PHQ-9), and Suicide Risk Assessments (Suicide Questions, Baseline Suicidal Ideation, Suicide Intent Scale, Beck Lethality Scale, Decision Outcome Inventory, Columbia-Suicide Severity Rating Scale, and High Suicide Risk Protocol).
45368971|NCT00944372|Drug|Indium In-111 pentetreotide|Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide
45368972|NCT01032148|Drug|LBH589|LBH589 will be administered orally as once daily dose of 20 mg po q M, W, F on a q28 day cycle.
45486747|NCT02437708|Procedure|REP with L-PRF|
45486748|NCT02437708|Procedure|REP|
45486749|NCT02437708|Biological|stem and progenitor cells|
45486750|NCT03186430|Behavioral|Comprehensive Vaccine Promotion Package|"Practice-level components: Periodic feedback on adolescent immunization coverage. Assistance with implementing and utilizing standing orders for adolescent vaccine administration in the practice, utilizing standardized materials as provided by the Centers for Disease Control and Prevention and the Immunization Action Coalition. Identification of an immunization champion to facilitate immunization activities in the practice. Linkage to peer-to-peer training on adolescent vaccination through the Georgia Educating Providers In their Communities (EPIC) program.~Provider-level components: Providers will receive standardized talking points, vaccine promotion scripts and answers to frequently asked questions, with training on how best to discuss, recommend and answer questions about vaccines.~Patient/Parent-level components: An iPad tablet-based educational presentation will be provided for parents while they are waiting with their adolescent child in the examination room."
45691727|NCT00599248|Biological|TissueGene-C|TissueGene-C at 3x10e6, 1x10e7 or 3x10e7 cells/joint to be administered by intra-articular injection
45691728|NCT00599248|Biological|Placebo|Placebo control (DMEM)
45691729|NCT00599872|Biological|Standardized Ragweed Allergenic Extract|Standardized Ragweed Allergenic Extract, sublingual oral
45691730|NCT00599872|Biological|Placebo|Placebo, sublingual oral
45691731|NCT00600340|Biological|Bevacizumab and Paclitaxel|A: Bevacizumab 10 mg/kg i.v., days 1 and 15, every 4 weeks Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks
45691732|NCT00600340|Biological|Bevacizumab and Capecitabine|B:Bevacizumab 15 mg/kg i.v., day 1, every 3 weeks Capecitabine twice-daily 1000 mg/m², day 1 to 14, every 3 weeks
45691733|NCT01799356|Drug|Moxifloxacin|daily 400 mg moksifloksasin
46052502|NCT02683824|Drug|[18F]FP-R01-MG-F2|radioactive tracer
46052503|NCT05758792|Other|Muscle Quality Index|Evaluations are applied to older adults to compare the results of muscle quality.
46052504|NCT02815059|Drug|Ibrutinib|Ibrutinib 420mg PO daily (dose level 0) or 560mg PO daily (dose level +1) administered Day 15 through day 90.
46052505|NCT02815059|Drug|Dasatinib|Dasatinib 100mg PO daily (Day 1 through Day 90). Dasatinib dose will be increased to 140mg daily in patients tolerating dasatinib 100mg who have not achieved a complete bone marrow response (less than 5% blasts) by Day 22 or who have not achieved major molecular response by Day 43.
46052506|NCT02815059|Drug|Prednisone|Prednisone 60mg/m2 PO daily (Day 1 through Day 32)
46052507|NCT05638269|Other|no intervention|Observational studies, no intervention
45486751|NCT02440984|Procedure|Colonic biopsies during endoscopy|eligible patients will have physical examination, colonic biopsies during endoscopy and anal manometry with barostat. these investigations are part of the usual healthcare. Colonic biopsies will be used to study intestinal permeability, colonic inflammation and enteric nervous system.
45486752|NCT02432794|Procedure|delay phenomenon by arteriographic approach|we improve the microvascularization of the gastric fundus occluding the right and left gastric artery, and splenic artery two weeks before surgery by arteriography
45486753|NCT02440906|Behavioral|Patient-Directed Wellness Account|The intervention group (n=629) continue to receive usual care and receive a financial incentive to use in meeting their health goals.
45486754|NCT02440906|Behavioral|Health Navigator|The intervention group (n=629) will work with a health navigator on a monthly basis to develop and refine patient-centered health goals. Motivational interviewing techniques are used to establish the wellness goals.
45486755|NCT02437630|Procedure|Oesophageal balloon to measure intra-thoracic pressure|An oesophageal balloon will be inserted via a nostril after instillation of local anaesthetic and swallowed until the tip is in the lower third of the oesophagus. This will allow the intrathoracic pressure to be monitored via a pressure sensor attached to the oesophageal balloon catheter and placed next to the subject. This will allow us to observe the changes in oesophageal pressure during quiet breathing under a variety of applied positive pressure conditions.
45486756|NCT02437630|Procedure|Fibre-optic laryngoscopy|A fibre-optic laryngoscope will be inserted through the opposite nostril to that used for the oesophageal balloon and placed with its tip abve the larynx where the laryngeal movement can be observed This will allow us to observe the changes in laryngeal aperture under a variety of applied positive pressure conditions.
45486757|NCT02437630|Other|standard lung function tests|These will be carried out in any subject who has not had lung function testing in the previous 6 weeks and will be carried out by a lung function physiologist from the institution in accordance with standard procedures for lung function testing
45486758|NCT02437630|Procedure|face mask CPAP|The subjects will wear a facemask with apertures for the oesophageal balloon and fibre-optic devices to cover the mouth and nose. airflow and volume will be recorded with a pneumotachograph and there will be tubing to connect to a positive pressure source (CPAP) to allow mouth pressures to be altered between 0-15cm H20.( 1cm H20 is the pressure produced by a column of water of 1centimetre in depth)
45691734|NCT01799356|Drug|Ofloxacin|daily 800 mg oflaksasin plus 1000 mg metronidazol treatment
45691735|NCT01799356|Drug|Metronidazole|daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID
46052508|NCT03735732|Behavioral|prime|groups be confronted with health or palatability aspects of food items
45691736|NCT00602290|Drug|Citalopram|Citalopram dosage will be 20 to 60 mg a day prior to FDA warning limiting it to 20-40 mg in 2011. Participants will begin taking one 20-mg capsule once per day for 4 weeks, and this dosage may be increased or decreased depending on the participant's response to the medication or side-effect profile. Participants will continue on their assigned dosage of citalopram that will be titrated up after week 4 if clinical global impressions (CGI) scores were > 2 until treatment completion.
46052509|NCT03919968|Behavioral|Martial Arts|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of fight simulation and / or play activities. The activities will be carried out in a way adapted for the elderly. Will be used kickers, gauntlets, thorax and head protectors, shin guards, gloves, and other devices.
45486759|NCT02437630|Procedure|variation of mouth pressure with CPAP|Once the other procedures are completed the subject will have his mouth pressure varied via application of positive pressure via a commercial CPAP device as used for treatment of obstructive sleep apnoea. The pressure will be varied randomly between 0-15cm H2O (water)for periods of 5 minutes both sitting and lying. Oesophageal balloon recording of intra-thoracic pressure and laryngeal movement and mouth airflow and volume will be recorded simultaneously and at the end of each 5 minute period the subject will be requested to take as big a breath in as possible to allow measurement of functional residual capacity and inspiratory capacity. This will allow us to observe the effect of changing mouth pressure with CPAP on laryngeal aperture and oesophageal pressures and airflow.
45486760|NCT02437630|Other|facemask pneumotachograph|The facemask will incorporate a pneumotachograph to allow measurement of airflow and volumes throughout the respiratory cycle. This will allow us to observe the pattern of airflow with varying applied CPAP
45486761|NCT02440750|Procedure|operative hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
45486762|NCT02440750|Drug|Dienogest|21 days administration of dienogest 2 mg/die
45691737|NCT00602290|Drug|Methylphenidate (MPH)|MPH dosage will be 5 to 40 mg a day. Participants will initially take 1 capsule (2.5 mg) twice per day, which will be increased to a maximum up to 8 x 2.5 mg capsules twice per day. After Visit 11, MPH dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
45691738|NCT00602290|Drug|Placebo|Placebo pills will be taken in combination with the active pills. Participants will initially take 1 capsule twice per day, which will be increased to a maximum of 16 capsules twice per day matching methylphenidate, and 1-3 capsules matching citalopram. After Visit 11, placebo dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
45691739|NCT00637780|Drug|Sulfasalazine|Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 7 days. Blood sampling for Pharmacokinetic assessment to be performed on Day 7
45846442|NCT02577510|Drug|Nerve Injection - Ultrasound|For the ultrasound nerve injection group, after skin disinfection, the inguinal region of patients will be scanned using a high-frequency (6 to 13 MHz) linear array transducer covered with a sterile plastic cover. An ultrasound image showing the inguinal ligament and anterior superior iliac spine (ASIS) will be obtained. Using an out-of-plane technique, a 22-gauge nerve block needle will be inserted 1-2 cm medial to ASIS. The needle will be advanced until its tip rests under the inguinal ligament, immediately ventral to the iliopsoas muscle [6]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
45846443|NCT02577822|Device|Taperloc standard length stem|
45846444|NCT02577822|Device|Taperloc short length stem|
46052510|NCT03919968|Behavioral|Functional Training|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of play activities. The activities will be carried out in a way adapted for the elderly. Will be carried out neuromotor control / coordination, balance, flexibility and static and dynamic stabilization. They will also have acceleration and deceleration activities, rotation and counter-rotation, extension and counter-extension, flexion and counter-flexion.
46052511|NCT03918720|Behavioral|Trekkers Family Health Empowerment Programme|Health Assessment, Health Enablement and Health Literacy provided to empower participants awareness towards a healthier life style
46052512|NCT02811393|Other|Assess muscle function|Assess muscle function with hand grip test and sit and stand test
45486763|NCT02440750|Drug|Ulipristal acetate|21 days administration of ulipristal acetate 5 mg/die
46052513|NCT00819910|Drug|Rosiglitazone|Rosiglitazone 8mg daily for 12 weeks
45486764|NCT03186196|Dietary Supplement|Diet containing Folate|
45486765|NCT03186352|Procedure|photoactivated disinfection|"After manual preparation of the cavity with an excavator and taking a sample for a microbial analysis with a rose bur on micro motor (size 014) the cavity undergoes the procedure of photodynamic disinfection:~application of photosensitizer 'Fotosan' Agent (CMS Dental, Denmark) for 5 minutes, radiation with low power laser, wavelength 635 nm power 200mW 120 s. ('Lasotronix', DiodeLX model SMART) rinsing with water and drying"
45486766|NCT02432872|Drug|Daunorubicin|defferent doses of daunorubicin,that is 60mg/m2 for 3 doses compared with 45mg/m2 for 3 doses
45486767|NCT02432872|Drug|Cytarabine|medium dosage cytarabine（1 g/m2 q12h for 3 days) compared with standard dosage cytarabine(100mg/m2 per day for 6 days)combinated with aclacinomycin（20mg per day for 6 days）for consolidation therapy.
45691740|NCT00638014|Device|Rapid Sternal Closure System|Sternal talons will be used and supplemented with wires
45368973|NCT00949806|Drug|BNT (intradermal injection)|"Patients with severe RLS will receive a one-time intradermal administration of BNT into the most symptomatic areas of both legs.~Injections will be distributed in a grid distribution pattern covering a total of 20 equidistant sites per symptomatic area. Each symptomatic area will receive a maximum 250 units of BNT (12.5 units per injection). The total BNT injected units should not exceed 1000 units per patient."
45368974|NCT00947180|Behavioral|Biofeedback|Electromyographic (EMG) activity was recorded from sensors placed in the anal canal, averaged, and displayed to patients to help them learn to relax the pelvic floor muscles during straining.
45368975|NCT00947180|Other|Electrogalvanic stimulation|Electrical stimulation was applied to pelvic floor muscles through an anal plug. Frequency was 80 pulses per sec, and voltage was slowly increased from 0 to 150-350 volts as tolerated.
45846445|NCT02577900|Device|Acticoat absorbent|Apply Acticoat absorbent daily onto diabetic foot ulcer in 12-week study interval
45486768|NCT05145478|Device|Shockwave Intravascular Lithotripsy (IVL)|Eligible patients with atherosclerotic lesions in the femoral artery who either have claudication or critical limb ischemia will receive endovascular treatment in addition to be treated with Shockwave Intravascular Lithotripsy (IVL) technology.
45486769|NCT02432248|Drug|Dehydroepiandrosterone|75mg/day, PO for 90 days
45486770|NCT02432248|Other|placebo(medical starch)|75mg/day, PO for 90 days
45486771|NCT03189472|Device|Active tDCS|low amplitude direct currents to induce changes in cortical excitability. tDCS produces current intensities in the brain orders of magnitude below other stimulation techniques such as transcranial magnetic stimulation (TMS) or electroconvulsive therapy (ECT)
45486772|NCT03189472|Device|Sham tDCS|The device will be programmed to deliver either active or sham tDCS (all study personnel and participants will be blinded), and operated with unlock codes provided by the study technician daily to release one session
45486773|NCT03189550|Procedure|ERAS perioperative care|Standard of care implementation of multi-modal evidence-based care pathway, including standardized preoperative preparation (medical and diet), perioperative goal-directed fluid therapy, multi-modal perioperative pain management, postoperative nausea and vomiting prevention, surgical care and bowel isolation, and surgical site infection prevention
45486774|NCT03189550|Procedure|Standard perioperative care|Standard perioperative care prior to implementation of ERAS care pathway
45486775|NCT03189550|Procedure|Noninvasive hemodynamic monitoring|Standard of care perioperative noninvasive hemodynamic monitoring with the ClearSight System (Edwards LifeSciences)
45486776|NCT03189394|Behavioral|PRIDE|A couples curriculum that is relationship-focused and in-person, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
45486777|NCT03189394|Behavioral|ePRIDE|A couples curriculum that is relationship-focused and online, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
45486778|NCT03189394|Behavioral|Men's Health|A men's health curriculum that is individualized and in-person, aimed at helping participants to focus on gay men's health.
45486779|NCT02437006|Other|exercise|cycle ergometry
45486780|NCT02437240|Behavioral|Pilates-based CPT|To emphasize the self-perception of breathing and body core control during in-patient cardiopulmonary physical therapy following cardiac surgery
45486781|NCT02437240|Behavioral|Traditional CPT|A traditional in-patient cardiopulmonary physical therapy following cardiac surgery including airway clearance, breathing exercises, chest mobility and reconditioning exercises and so on
45691741|NCT00638014|Device|Conventional wire closure|Conventional wire closure of sternum
45691742|NCT00680524|Other|Phone-based outreach|Nurse care managers will use a phone call outreach intervention with structured templated notes to help deliver evidence-based care for PTSD
45691743|NCT01799902|Drug|Solifenacin|Oral
45846446|NCT02577900|Device|Honey gel sheet|Apply Honey gel sheet daily onto diabetic foot ulcer in 12-week study interval
45368976|NCT00947180|Behavioral|Digital massage|Using a gloved finger, the therapist pressed on the levator ani as firmly as tolerated and moved the finger from side to side 3-4 times.
45368977|NCT01032304|Drug|Erdosteine|One 300 mg capsule twice a day
45368978|NCT01032304|Drug|Placebo|One capsule twice a day
45368979|NCT05190510|Other|Data collection|Collection of data from preoperative imaging examinations (routine examination prescribed before the operation)
45486782|NCT02436850|Procedure|Thoracentesis|An invasive procedure to remove fluid or air from the pleural space for diagnostic or therapeutic purposes.
45486783|NCT02436928|Biological|AT-501 High Dose vaccine|Comparison of each dose of vaccine
45486784|NCT02436928|Biological|AT-501 High Dose vaccine with Adjuvant|Comparison of each dose of vaccine
45486785|NCT02436928|Biological|AT-501 Low Dose vaccine|Comparison of each dose of vaccine
45486786|NCT02436928|Biological|AT-501 Low Dose vaccine with Adjuvant|Comparison of each dose of vaccine
45486787|NCT02436538|Other|Anti Mullerian hormone level; Mullerian duct anomaly type|Diagnosis of Mullerian duct anomaly type Clinically or by Imaging Anti-Müllerian Hormone levels
45486788|NCT02432014|Behavioral|PMTO-PTC Group clinic-based|
45691744|NCT00602446|Drug|deferasirox|20 mg/kg once daily orally for 6 months
45691745|NCT00635830|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|HPV 6,11,16,18 VLP, 0.5 mL 1 dose injection.
45691746|NCT00638716|Drug|CJC-1134-PC|1.5 or 2.0 mg CJC-1134-PC
45691747|NCT00638716|Drug|Placebo|Placebo
45846447|NCT02577900|Device|Jelonet|Apply Jelonet daily onto diabetic foot ulcer in 12-week study interval
45368980|NCT05190510|Procedure|collection of the carotid plaque (surgical specimen)|collection of the carotid plaque
45368981|NCT05190510|Other|anatomopathological, histological, cellular and molecular biology examinations (metabolomics and transcriptomics) on surgical specimens|anatomopathological, histological, cellular and molecular biology examinations (metabolomics and transcriptomics) on surgical specimens
45486789|NCT02432014|Behavioral|PMTO Individual home-based|
45486790|NCT02432014|Behavioral|PMTO Individual clinic-based|
45486791|NCT02432014|Behavioral|Services as Usual|
45486792|NCT03191968|Behavioral|Supervised Physical Activity Plus Behavioral Counseling|In addition to supervised physical activity, behavioral counseling sessions will be delivered with a PA specialist based on the Multi-process Action Control (M-PAC) framework and include behavior change techniques addressing information regarding the consequences, social support, goal setting, self-monitoring, cues and prompts, barrier identification, intention formation, planning, and habit and identity formation
45691748|NCT00602836|Biological|Rituximab|Cycle 1: 100 mg by IV on day 1, 375 mg/m^2 by IV on day 2 Cycle 2-6: 375 mg/m^2 by IV on day 1 (every 21 days)
45691749|NCT00602836|Drug|Cyclophosphamide|600 mg/m^2 by IV on day 1 of cycles 1-6 (every 21 days)
45691750|NCT00602836|Drug|Lenalidomide|Cycle 7: 5 mg orally daily on days 1-28 Cycle 8: 10 mg orally daily on days 1-28 as tolerability permits Cycle 9 and beyond: 10 mg orally daily on days 1-28
45691751|NCT00602836|Drug|Pentostatin|2 mg/m^2 by IV on day 1 of cycles 1-6 (every 21 days)
45846448|NCT02580318|Device|breathalyzer|
45846449|NCT02582970|Drug|5-Fluorouracil|Intravenous 5-fluorouracil based chemotherapy will be administered until disease progression or until termination of the study. The chemotherapy regimen will be at the discretion of the prescriber and will not be provided by the sponsor.
45846450|NCT02582970|Drug|Bevacizumab|Bevacizumab will be administered IV 5 mg/kg every 2 weeks until disease progression or until termination of the study.
45846451|NCT02582970|Drug|Irinotecan|Irinotecan will be administered at the discretion of the prescriber until disease progression or until termination of the study.
45368982|NCT00954642|Drug|bevacizumab|Intravenous repeating dose
45368983|NCT00954642|Drug|MNRP1685A|Escalating intravenous dose
45368984|NCT00954642|Drug|paclitaxel|Intravenous repeating dose
45368985|NCT00955058|Drug|OCP|Daily For 3 months
45486793|NCT03191968|Behavioral|Supervised Physical Activity Plus Exercise Counseling|In addition to the supervised exercise sessions, standard exercise counseling will be delivered by a PA specialist to teach proper PA and resistance training techniques, how to monitor intensity, and to progress PA safely and effectively to achieve the public health PA guideline.
45486794|NCT02436694|Drug|Local Anesthetic ropivacaíne|Femoral and sciatic nerve block with ropivacaíne
45486795|NCT02436694|Drug|Perineural Dexamethasone|Addition of perineural dexamethasone to local anesthetic for femoral and sciatic nerve block
45368986|NCT01024816|Behavioral|Restorative yoga|"Group yoga sessions: Participants will attend 90 minute yoga group classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. We plan a progressive series of classes, with a subset of poses for each class and then selecting individual poses to focus on in each class.~Home yoga practice: Participants will be given a video disk (DVD) of the yoga postures at the start of the yoga intervention practice. We will also provide the yoga participants with a written manual with pictures and descriptions of each posture that they will be taught in the group sessions. The participants will be asked to practice the postures taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given a set of yoga props for their use at home. We will ask all participants to keep a log of their home practice sessions"
45368987|NCT01024816|Behavioral|Stretching|"Group classes: Participants will attend 90 minute group stretching classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. The stretches will address all body parts, including cervical, upper extremity, thoracic, lumbar, pelvic, and lower extremity musculature.~Home stretching practice: Each participant will receive a written manual with pictures and descriptions of each stretch that they will be learning in group sessions and a DVD with instruction on each of the stretches. The participants will be asked to practice the stretches taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given stretching supplies. We will ask all participants to keep a log of their home practice sessions."
45368988|NCT00954720|Other|No Intervention|There is no intervention on this trial
45368989|NCT01024894|Drug|Interleukin-7|3 dose levels: 3, 10 & 20 µg/kg. 4 administrations, 1 per week
45368990|NCT00954798|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants); and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
45368991|NCT00954798|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants), and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
45368992|NCT00954798|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21
45368993|NCT00110305|Drug|TMC278 25 mg|TMC278 25 mg tablet will be administered once daily.
45368994|NCT00110305|Drug|TMC278 75 mg|TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.
45752430|NCT03570463|Behavioral|GLA:D Back|The intervention aims at improving the participant's ability to self-manage low back pain (LBP). The content is based on a cognitive behavioural approach aimed at supporting pain self-efficacy. An individual session at the beginning and the end of the group sessions involve goal-setting and physical tests. Key messages of the patient education include that pain is not a sign of danger and back pain is explained using a behavioural model of (im)balance between demands and capacity rather than emphasising tissue damage. The exercises aim at restoring natural variation in movement and provides guidance for patients in exploring movement rather than teaching exercises in only one correct manner.
45846452|NCT02582970|Drug|Oxaliplatin|Oxaliplatin will be administered at the discretion of the prescriber until disease progression or until termination of the study.
45846453|NCT02583360|Diagnostic Test|Combined testing (diagnostic VFSS + research HRM) + Parent Preferred Therapy|Addition of research HRM along with diagnostic VFSS with parental choice of therapy
45368995|NCT00110305|Drug|TMC278 150 mg|TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.
45368996|NCT00110305|Drug|Efavirenz|Efavirenz 600 mg (1 x 600 mg tablet or 3 x 200 mg capsules, depending on formulation locally available) will be administered once daily.
45368997|NCT00110305|Drug|Non-nucleoside reverse transcriptase inhibitor (NRTIs)|Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
45368998|NCT00954954|Device|Standard PS RP-MB (P.F.C Sigma Rotating Platform knee)|Comparison of different types of knee prosthesis
45368999|NCT00954954|Device|High-flexion PS RP-MB (P.F.C Sigma Rotating Platform Flex)|Comparison of different types of knee prosthesis
45846454|NCT02584140|Behavioral|Text Messaging|All participants assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.
45846455|NCT02584140|Behavioral|Adherence Counseling|All participants assigned to the counseling intervention will receive sexual health and medication adherence counseling at each study visit. Participants with suboptimal adherence (TFV-DP levels of <1050 fmol/punch (representing fewer than mean 6-7 daily doses per week)) will trigger a targeted iNSC session. Participants with two TFV-DP levels of <1050 fmol/punch will trigger PrEP Steps, a higher intensity adherence counseling intervention consisting of four 50-minute counseling sessions and 2 booster counseling sessions.
45846456|NCT02584140|Drug|Daily Oral PrEP|All participants will be offered daily oral emtricitabine/tenofovir disoproxil fumarate for Pre-exposure Prophylaxis.
45846457|NCT02584608|Drug|ACTIMMUNE|
45486796|NCT02436616|Device|microEEG|"microEEG is a miniature, wireless, and battery-powered EEG device used to obtain EEG recording in challenging environment. All infants have an initial EEG at study enrollment. Follow up microEEGs will be performed at approximately 2-4 week intervals, depending on the Corrected Gestational Age (CGA).~If ABD events have not resolved at 34 weeks, an 8 hour recording will be performed prior to discharge or at 42 weeks CGA, whichever comes first. EEG will be assessed in 3 hour epochs. The EEG will be reviewed off line by two blinded neurologists and classified as normal or abnormal based on CGA and other findings. Follow up EEGs will be scored similarly, with emphasis on maturation."
45486797|NCT02436460|Biological|AbGn-168H|Humanized monoclonal antibody
45486798|NCT03191422|Behavioral|LSVT BIG|LSVT BIG is a motor learning based intervention 4 hour long sessions per week for 4 weeks following a specific protocol. Each session is composed of exercises and participant specific activities, as well as a homework program.
45486799|NCT03186040|Drug|Lacosamide|Sodium channel blocker
45486800|NCT03191734|Device|AQUABEAM System|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-pressure saline stream to resect and remove prostate tissue.
45369000|NCT00428116|Drug|HAART|Combination first line antiretrovirals as previously described.
45486801|NCT03191500|Device|steerable catheter|peripheral vascular disease
45486802|NCT02432170|Device|Digital Tomosynthesis of Foot and Ankle|Imaging Technique
45486803|NCT02440516|Other|Early treatment group|Physical- and occupational Therapy
45486804|NCT02440516|Other|Late treatment group|Waiting list - then Physical- and occupational Therapy
45486805|NCT02659020|Drug|Olaratumab|Administered IV
45486806|NCT02659020|Drug|Gemcitabine|Administered IV
45486807|NCT02659020|Drug|Docetaxel|Administered IV
45486808|NCT02659020|Drug|Placebo|Administered IV
45486809|NCT02436382|Other|change in temperature|increase in ambient room temperature
45486810|NCT03482011|Drug|Mirikizumab|Administered SC
45486811|NCT03482011|Drug|Placebo|Administered SC
45486812|NCT02436226|Drug|Clomiphene citrate and Human chorionic gonadotropin (HCG)|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle) and HCG (200 IU/day SC from day 7 of cycle)
45486813|NCT02436226|Drug|Clomiphene citrate|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle)
45752431|NCT00367601|Drug|Erlotinib|Erlotinib 150 mg qd days 1-21
45752432|NCT00367601|Drug|Bevacizumab|Bevacizumab 15 mg/kg IV, day 1
46052514|NCT00819910|Drug|Placebo (Rosiglitazone)|Placebo (Rosiglitazone) 8mg daily for 12 weeks
46052515|NCT00819910|Drug|Placebo (Fenofibrate)|Placebo (Fenofibrate) 145 mg daily for 12 weeks
46052516|NCT00819910|Drug|Fenofibrate|Fenofibrate 145 mg daily for 12 weeks
46052517|NCT04197843|Device|NaviCam (ANKON)|The NaviCam (ANKON) is a miniaturised wireless endoscope in a single use capsule. It can be remotely controlled with the patient in a magnetic console. The operator to the magnetic-driven NaviCam sits in a computer workstation and manipulates the capsule suspended in a waterfilled stomach. After careful examination of the stomach, the capsule is then allowed to passed through the pylorus into duodenum and small bowel. The patient wears harness with small bowel imaging capabilities.
46052518|NCT02808117|Dietary Supplement|MNP|"Program that delivered MNP and implemented by an MFI in Haiti during 2011-2012.~One form of micronutrient supplementation proven to effectively combat micronutrient deficiency."
45369001|NCT00560066|Biological|Cell-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
45369002|NCT00560066|Biological|Egg-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
45369003|NCT00549900|Biological|GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)|Intramuscular injection, 3 doses
45369004|NCT00435994|Drug|Inhaled primatene will be given as a breathing treatment|While the research subject is sedated an inhaled mist of primatene mist will be given to the patient.
45369005|NCT00435994|Other|Nasal Washing|1-3 mls of normal saline will be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which will be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence
45486814|NCT02436148|Other|Prosthetic for major lower limb amputation|Prosthetic for major lower limb amputee
45486815|NCT02436070|Behavioral|Targeted text messages|Subjects received text messages specific to post ED asthma follow-up
45486816|NCT02436070|Behavioral|General text messages|Subjects received text messages generalized to children with asthma
45486817|NCT03189238|Biological|Peri-urethral and clitoral injections|Peri-urethral and clitoral injections
45752433|NCT00385801|Drug|Risperidone|
45752434|NCT00385801|Drug|Placebo|
45752435|NCT01759901|Procedure|Pringle|Vascular clamp is applied across hepatoduodenal ligament intermittently in 15 minutes on / 5 minutes off interval
45752436|NCT00429403|Drug|Goserelin|3.6 mg subcutaneous injection 1 week before the start of chemotherapy, then once a month until 3 weeks after the last chemotherapy dose.
45752437|NCT05286931|Drug|Ciprofloxacin 500 mg|Ciprofloxacin 500 MG, taken once orally.
45486818|NCT03189082|Procedure|Microbotox|Microbotox is the injection of multiple microdroplets of diluted botulinum toxin into the dermis of the lower face
45752438|NCT00367679|Drug|Pazopanib|Pazopanib is an oral, potent, multi-target receptor tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit. Subjects were to receive 800 mg oral pazopanib daily for a minimum of 2 weeks to a maximum of 6 weeks.
45846458|NCT02584686|Drug|Botulinum Toxin Type A|The treatment group will be injected intracavernously with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) for colour Doppler assessment, followed next day by 50 units of BTX-A.
45846459|NCT02584686|Drug|Normal Saline|The control group, 12 patients, will be injected with a trimix solution during penile colour Doppler assessment followed next day with a normal saline injection.
45846460|NCT02584998|Other|Mailed-FIT|The FIT is analyzed at the Philadelphia VAMC by an auto-analyzer system that provides quantitative results corresponding to the concentration of hemoglobin in the collected sample. Specimens will be analyzed according to manufacturer's instructions to minimize potential degradation of hemoglobin. Results are provided as positive if the hemoglobin concentration is 100ng/dL. The machine records (but does not report) the quantitative results of the hemoglobin concentration in the sample, which we will seek to obtain from the laboratory for future studies.
45846461|NCT02584998|Other|Screening invitation-reminder|These patients will continue to receive UC. They will in addition receive an invitation letter with all of the information about CRC testing in the mail-FIT arm
46052519|NCT05323240|Other|PM exposure|To determine whether 3-day consecutive exposures to levels of fine particulate matter (PM2.5) that are close to the current 24-hr national standard will cause changes in inflammatory and cardiopulmonary endpoints.
45486819|NCT02431858|Device|E-Catheter (Pajunk)|
45486820|NCT02431858|Device|Sonolong Catheter (Pajunk)|
45486821|NCT01374126|Drug|Artesunate|Artesunate alone
45486822|NCT01374126|Drug|Azithromycin + Artesunate|Combination of azithromycin + artesunate
45486823|NCT02431624|Drug|BTDS|
45486824|NCT02584920|Drug|HLX01|
45752439|NCT00368459|Drug|raloxifene|Raloxifene is a selective estrogen receptor modulator
45752440|NCT00368459|Drug|Placebo|Identical appearing placebo
45846462|NCT02585700|Biological|Influenza vaccine, split inactivated|Seasonal trivalent inactivated influenza vaccine (TIV), inactivated split virion, purified by sucrose gradient ultracentrifugation. The vaccine is produced in hen's eggs, and inactivated with beta-propiolactone.
45846463|NCT02585700|Other|Placebo|0.5 mL of phosphate buffered saline
45846464|NCT05249556|Drug|Ganaxolone|Ganaxolone
45846465|NCT05249556|Drug|Placebo|Placebo (for ganaxolone)
46052520|NCT05323240|Other|Filtered air exposure|To determine whether 3-day consecutive exposures to filtered air will cause changes in inflammatory and cardiopulmonary endpoints.
46052521|NCT04237311|Procedure|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy is performed as following: after greater curvature dissociating, the gastric tube was calibrated over a 36F bougie and transection started approximately 5-6 cm from the pylorus toward the left diaphragmatic crus, using linear cutting stapler of 3.5- or 4.8-mm-high staples, depending on gastric thickness.
45486825|NCT02584920|Drug|Rituximab|
45486826|NCT03185650|Device|tPAD Device|A novel, transnasal aerosol generator
45486827|NCT03185650|Device|PARI LC Star Nebulizer|Standard oral nebulizer
45752441|NCT01402700|Device|Visi-Pro™ Balloon Expandable Stent System|Implantation of one or more study devices in the common and/or external iliac artery.
45752442|NCT00429949|Drug|Dasatinib|
45752443|NCT04767152|Diagnostic Test|MRI|The quantitative assessment of MRI parameters, The macromolecular proton fraction (MPF) (%) in brain tissue. Before the start of therapy - the starting point. Point 2. 36 ± 3 days after the start of the therapy. Point 3. After completing three courses of consolidation chemotherapy. Point 4. After confirmation of remission status, optionally provided.
45486828|NCT01371318|Other|Online Wound Electronic Medical Record|Online Wound Electronic Medical Record is a medical informatics tool that synthesizes data about complex wound problems from multiple sources and is innovative in its capability to performing these critical tasks: i) identification of the information needed to make treatment decisions at the point of care in real time ii) use intelligent search and report features to identify patients who require emergency interventions, and iii) provide evidence-based clinical decision support to clinicians
46052522|NCT04237311|Procedure|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass is performed as following: a gastric pouch of approximately 30mL was obtained using linear cutting stapler, the sum of the length of the alimentary limb and the biliopancreatic limb> 200 cm (can be adjusted according to the incidence of the patient's BMI, type 2 diabetes mellitus and the specific situation).
45369006|NCT00947258|Other|Stretching|Participants were divided into 3 groups. The group was referred to stretching 3 weekly for 4 consecutive weeks. Group B went 4 weeks without any intervention and held only one stretch before the re-test. And the group C performed passive knee mobilization. All participants were assessed for goniometry of the knee in flexion and extension and peak torque and power on the isokinetic dynamometer.
45369007|NCT01563120|Drug|metformin|metformin up to 2550mg per day.
45369008|NCT01563120|Drug|glybenclamide|glybenclamide up to 20mg per day.
45369009|NCT00435370|Drug|Tropisetron|10 mg/day
45369010|NCT00435370|Drug|Placebo|placebo
45369011|NCT00435370|Drug|Risperidone|6mg/day
45369012|NCT05098548|Procedure|angioplasty|using a balloon to stretch open a narrowed or blocked artery. However, most modern angioplasty procedures also involve inserting a short wire-mesh tube, called a stent, into the artery during the procedure. The stent is left in place permanently to allow blood to flow more freely .
45369013|NCT00096031|Biological|cetuximab|1 time Cetuximab 400mg/m2 IV over 120 minutes followed by weekly Cetuximab 250mg/m2 IV over 60 minutes.
45369014|NCT04010526|Combination Product|local co-administration of autologous ADIpose|local co-administration of autologous ADIpose derived stromal vascular fraction and microfat for refractory perianal CROHN's fistulas Each batch of the final product is composed of one 5 mL syringes containing 25,9 +/- 10,7 millions viable cells. Each syringe will be obstructed with a sterile stopper and packaged in an external packaging.
45369015|NCT04010526|Other|placebo|local co-administration of placebo The study placebo will consist of a saline solution for intralesional administration and will follow the same administration schema described for the SFV
45369016|NCT05043324|Drug|AntiCov-220 (1)|The daily maintenance, AntiCov-220 (1) dose is to take 3 times a day, 1 tablet each time.
45369017|NCT05043324|Drug|AntiCov-220 (2)|The daily maintenance, AntiCov-220 (2) dose is to take 3 times a day, 1 tablet each time.
45369018|NCT04303728|Diagnostic Test|Muscle ultrasound|The muscle thickness and muscle quality will be assessed on ultrasound
46052523|NCT02808897|Device|Standard drainage|One (1) chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 French (FR) to 32 FR shall be used for the single anterior mediastinal chest tube.
46052524|NCT02808897|Device|Active Clearance Technology drainage|One (1) PleuraFlow chest tube must be placed in the anterior mediastinum with one (1) standard chest tube. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 FR to 32 FR shall be used for the single anterior mediastinal chest tube.
45369019|NCT00118417|Drug|Clonazepam|Participants will receive clonazepam.
45369020|NCT00118417|Drug|Sertraline|Participants will receive sertraline.
45369021|NCT00118417|Behavioral|Cognitive behavioral therapy|Participants will receive cognitive behavioral therapy
45486829|NCT02431780|Device|ANSeR Software System|ANSeR Software System a stand alone, software medical device for Neonatal seizure decision support tool
45369022|NCT04293744|Device|Colloid priming solution for ECC circuit|Prospective, multi-center, double-blinded, randomized, controlled clinical trial
45369023|NCT04293744|Device|Standard priming solution for ECC circuit|Prospective, multi-center, double-blinded, randomized, controlled clinical trial
45369024|NCT00955188|Other|computer-assisted intervention|
45369025|NCT00955188|Other|educational intervention|
45369026|NCT00955188|Other|medical chart review|
45369027|NCT01080703|Other|Exercise|Lower extremity resistance exercises and aerobic exercises 3 times a week in 10 week pulmonary rehabilitation program prior to lung transplant.
45369028|NCT01079455|Drug|Corticosterone|Hyaluronic acid 40 mg / 2 ml Corticosteroids 80 mg / 2 ml Bupivacaine 0.125% / 2 ml
45369029|NCT04270422|Other|Multidimensional physiotherapy|Multidimensional physiotherapy based on biopsychosocial approach
45369030|NCT04270422|Other|Usual physiotherapy|Usual evidence based physiotherapy
45846466|NCT05249166|Other|ALINFA|Comparing the usual recommendations with the healthy diet designed and developed
45846467|NCT05249166|Other|Control|control group
45846468|NCT05248698|Behavioral|lifestyle change|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, plus Mediterranean Diet for 6 months
45486830|NCT03639103|Procedure|Distal Metatarsal Metaphyseal Osteotomy (DMMO)|The scalpel is advanced at an oblique angle of about 45° until it reaches the dorsal aspect of the distal metatarsal bone to undergo osteotomy. First a bone rasp specific for percutaneous surgery is used to separate the periosteum at the level of the osteotomy site. A Shannon Isham burr is introduced until it reaches the metatarsal neck where the periosteum was previously removed. Fluoroscopy is used to confirm the correct position of the osteotomy site. The lateral cortical surface is cut first, then the plantar, medial, and lastly, the dorsal cortical surface. During the osteotomy process, the incision site is irrigated by normal saline, as the burr can cause excessive heat, causing skin burn and resulting subsequently in fibrosis and pseudoarthrosis at the bone level.
45486831|NCT04036032|Other|Exercise program|Encourage to work out 4 to 5 times a week for 3 months. Patient chooses what exercise they would like to do. At YMCA visit for fitness assessments they provide exercise support
45486832|NCT02431936|Drug|Prazosin|Double blind placebo controlled cross over trial to determine effectiveness of alpha adrenergic blocker in reducing sodium retention during stress.
45486833|NCT02431936|Drug|Placebo|Sugar pill made to look identical to Prazosin intervention.
45486834|NCT03916770|Device|Sham vibrator|The Sham control group will have WBV the same time,in the same position with the same frequency but 99.5% weakened amplitude.
45486835|NCT03916770|Device|Real vibrator|The intervention group will have WBV(frequency:30Hz,amplitude:2,2mm,at upright position
45486836|NCT03185806|Device|Puncture and drainage|The enrolled SAP patients are punctured under guidance of B ultrasound or CT scan, and prolonged drained by 8-F or 10-F pigtail tube
45486837|NCT03481309|Device|anodal tDCS|The participant will receive anodal tDCS with 2 mA for 10 minutes on the left motor cortex.
45369031|NCT00549848|Drug|Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine|See Detailed Description section for details of treatment interventions.
45369032|NCT00549848|Drug|Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib|See Detailed Description section for details of treatment interventions.
45369033|NCT01083589|Drug|Imatinib Mesylate|Oral 400 mg daily
45369034|NCT01083589|Drug|Docetaxel|60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
45369035|NCT05005962|Device|Neurothrombectomy|Neurothrombectomy device will be used to treat patients experiencing the AIS due to large intracranial vessel occlusion within 8 hours of last known well to collect real-world data and to access clinical outcomes associated with the use of these devices.
45369036|NCT01080859|Device|OCT|Optical coherence tomography
45486838|NCT03481309|Device|cathodal tDCS|The participant will receive cathodal tDCS with -2 mA for 10 minutes on the left motor cortex.
45486839|NCT03481309|Device|sham tDCS|The participant will receive sham tDCS with 2 mA for 40 seconds on the left motor cortex which mimics the skin sensations as active tDCS interventions.
45486840|NCT03185884|Other|Control|control carbohydrate blend
45846469|NCT05248698|Other|exercise|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, for 6 months
45846470|NCT05248542|Other|Virtual Reality Usage on Oral Care Knowledge|Virtual Reality Usage on Oral Care Knowledge about independent older adults
45486841|NCT03185884|Other|Experimental|experimental carbohydrate blend
45486842|NCT03185494|Biological|anti-CD19/22-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
45369037|NCT01080859|Device|OCT|Optical coherence tomography
45369038|NCT00955136|Device|Use of intermittent high MI impulses during echocardiogram|Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
45846471|NCT05248152|Combination Product|Paracetamol and Ibuprofen|Patients will receive paracetamol 1g and ibuprofen 400 mg before surgical incision.
46052525|NCT02808039|Other|Platelet reactivity testing|assessment of platelet aggregation using the VerifyNow purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) platelet function assay (Accumetrics, San Diego, California)
46052526|NCT05316610|Behavioral|Body Confident Athletes|The Body Confident Athletes program is a five-session in-person program designed to be delivered by coaches to their athletes. Groups should be of approximately 10 girls. The organizations will work with the community partner and researchers on how to schedule the intervention over a five-week period. These sessions can replace a regular sport practice each week or an additional session can be organized by the sport organizations. Each session will take approximately 60 minutes and will consist of four phases, including The Game Plan (5 mins), The Skills (20 mins), Game Time (20 mins), and The Final Score (15 mins). A variety of activity modalities are utilized to convey learning outcomes, including group and individual activities, and discussion-, writing- and movement-based activities.
46052527|NCT04321395|Drug|Vigabatrin|Vigabatrin - Pill, 500 mg twice daily for 7 days (days 0-6), 1000 mg twice daily for 7 days (days 7-13), 1500 mg twice daily for 10 days (days 14-23), 1000 mg twice daily for 7 days (days 24-30), 500 mg twice daily for 7 days (days 31-37) and will discontinue treatment on day 38.
45846472|NCT05248152|Drug|Pregabalin 150mg|Patients will receive pregabalin 150 mg in the hour before surgery
45486843|NCT03480841|Behavioral|Language ENhancement Assessment/intervention system|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. Researchers will provide an initial feedback session to mothers, which will include reviewing the LENA visual output from the previous recording and how mothers can access the output on their own for future recordings. Mothers will independently use the LENA system and access the output on their own.
45486844|NCT02440828|Drug|tobramycin inhalation|tobramycin inhalation 300 mg twice daily
45369039|NCT01079533|Behavioral|Stepped CRCS Interventions|"In Step 1, we will evaluate a theory-based minimal cue delivered by a letter, telephone call, or automated telephone call. Persons who do not complete CRCS in Step 1 will be randomized to Step 2 using principles of Motivation Interviewing. Step 2 also will determine whether an automated approach, telephone-linked communication (TLC), is as effective as a telephone counselor in promoting initiation of CRCS. Steps 1 and 2 together will address the important issue of the dose needed to encourage completion of CRCS."
45486845|NCT02440828|Drug|placebo|NaCl 0.9% inhalation 4 ml twice daily
45486846|NCT01311037|Other|GnRh Analogue and Aromatase Inhibitor|GnRh Analogue and Aromatase Inhibitor
45486847|NCT02431390|Device|RAPAELⓇ Smart Glove digital treatment system|The RAPAELⓇ Smart Glove digital treatment system is constituted for stroke rehabilitation. For use, stroke patients wear the gloves and play the games or puzzle for rehabilitation of upper limbs. The system provides biofeedback to user.
45486848|NCT02431390|Behavioral|Additional occupational therapy|30 minutes of additional conventional occupational therapy session composed of hand dexteriy training
45486849|NCT02435758|Procedure|Preservation of Denonvilliers Fascia during L-PANP surgery|In this group, the patients accept L-PANP surgery, as well as preservation of Denonvilliers Fascia
45486850|NCT02440438|Biological|Blood sampling|Blood samples of 10 mL will be performed every 2 days from the first symptoms of CDI and until clinical recovery and/or hospital discharge
45369040|NCT01079533|Behavioral|Control|A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
45486851|NCT02431546|Behavioral|Mobile Health Application|"Health coaching is an innovative, holistic approach oriented towards one's full health and wellbeing. Coaches provide mentoring and support regarding many areas of life that impact one's health with a focus on skill-building. Health coaches do not provide medical advice, treat any medical conditions, provide mental health therapy, or provide individualized assessments of nutrient needs. Health coaches will not conduct medication counseling activities that would alter the prescribed regimen nor provide medication information/advice that would be considered the practice of medicine or pharmacy.~A Fitbit activity monitor will be used to track daily physical activity and provide real-time feedback to the participant."
45486852|NCT03191110|Other|No intervention: observational study|
45486853|NCT02431312|Biological|INO-1800|INO-1800 delivered by EP
45846473|NCT05248152|Drug|Placebo|Patients will receive a placebo capsule in the hour before surgery and two intravenous doses of saline before surgical incision.
46052528|NCT02807961|Drug|ELX-02|Synthetic aminoglycoside
46052529|NCT02807961|Drug|Placebo|Placebo comparator
46052530|NCT02814669|Drug|Atezolizumab|Atezolizumab will be given at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or disease progression.
46052531|NCT02814669|Drug|Radium-223 Dichloride|Radium-223 dichloride will be administered at a dose of 55 kilobecquerels per kilogram (kBq/kg) via slow IV bolus on Day 1 of each 28-day cycle for up to 6 cycles.
46052532|NCT04237389|Procedure|Ablation Index Guided endocardial catheter radiofrequency ablation|Ablation Index (AI) guided catheter RF ablation with circumferential ablation around the right and left PVs and 2 additional lines between the lower and upper PVs (endoBox-lesion).
46052533|NCT04237389|Procedure|minimally invasive thoracoscopic surgical epicardial ablation.|"Description: minimally invasive thoracoscopic surgical epicardial ablation using Box-lesion set, which includes isolation of the right and left PVs, roof and posterior wall lines and removal of the LAA."
46052534|NCT02808741|Drug|F901318 SDD|Pharmacokinetics area under curve
46052535|NCT02808741|Drug|F901318 IR|Pharmacokinetics area under curve
45486854|NCT02431312|Biological|INO-9112|INO-9112 delivered by EP
45486855|NCT02431312|Drug|Nucleos(t)ide Analogue Treatment|Continued treatment with nucleos(t)ide analogue
45486856|NCT02431234|Other|serum RANKL|
45486857|NCT03191344|Behavioral|with IPSS|all patient in one group use IPSS to record the parathyroid status. the other group operation as ordinary. record the parathyroid status in verbal description
46052536|NCT02808741|Drug|F901318 IR Fasting|Pharmacokinetics area under curve
46052537|NCT02808741|Drug|F901318 IR Fed|Pharmacokinetics area under curve
45369041|NCT05299788|Other|Active external warming|In this study, methods used routinely in the Intensive Care Unit (ICU) such as cotton blankets and socks were used for the control group. In addition to the cotton blankets and socks, electric blankets were used for the patients in the intervention group. In accordance with the literature, the temperature of the electric blanket was set at 38 °C (Celsius) at the beginning and increased to a maximum of 40-41 °C based on the patient's body temperature .
45369042|NCT05299788|Other|Ice application|In the intervention group, an ice pack was applied to the incision site for pain control in addition to active external warming. Ice packs at 0-5 °C with external dimensions of 160 × 91 × 34 mm and a filled weight of 363 g that were kept in the fridge were used for ice application. To prevent direct contact of the ice pack with the patient's skin, the ice pack was wrapped in a thin cotton sheath.
45369043|NCT00949182|Drug|sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C|After Sorafenib Tosylate has been administered the actual HACE procedure is performed using Doxorubicin Hydrochloride or Mitomycin C
45369044|NCT00949182|Other|laboratory biomarker analysis|
45369045|NCT00955344|Behavioral|eToolbox|Participants randomized to the Web-based intervention will be automatically routed to a URL that will contain the Web-based intervention.
45369046|NCT00955344|Behavioral|no link to eToolbox|Participants randomized to the Practice Improvement Module will not be automatically routed to a URL that will contain the Web-based intervention.
45369047|NCT01083823|Other|Mental health telemetry (MHT)|Use a cell phone equipped with MHT software to complete a self-report mood symptom questionnaire daily at a fixed time of day, as well as additional discretionary questionnaires following any significantly stressful events.
45369048|NCT00549770|Drug|LCZ696|
45369049|NCT00549770|Drug|Valsartan|
45369050|NCT00549770|Drug|AHU377|
45369051|NCT00549770|Drug|Placebo|
45369052|NCT00548184|Drug|Lapatinib|Monoclonal Antibody
45369053|NCT00548184|Drug|Trastuzumab|Monoclonal Antibody
45369054|NCT00548184|Drug|Endocrine|Hormonal Therapy
45369055|NCT00955500|Dietary Supplement|Branched-chain amino acids|30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams) daily
45369056|NCT00955500|Dietary Supplement|Maltodextrin|30 grams of oral maltodextrin daily
45369057|NCT00955578|Procedure|Punch Biopsy|5-6 punch biopsies of affected areas
45369058|NCT00955734|Other|Early motion|One set of patients will begin wrist motion at 1 week after surgery.
46052538|NCT02808663|Biological|fecal calprotectin concentration|
46052539|NCT02808663|Biological|blood collection|
46052540|NCT05571189|Behavioral|Daily Activity Text|Participants will receive a text each day with instructions about the daily activity they should complete for that day.
46052541|NCT05571189|Behavioral|Control Text|"Participants will receive a text each day with no instructions about daily activity. It will have messages like have a nice day."
46052542|NCT02807727|Drug|Intralipid 20%|Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
46052543|NCT02807727|Drug|Modified Ringers Lactate|Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
45369059|NCT00955734|Other|Immobilization|This set of patients will be casted for 6 weeks after surgery.
45369060|NCT00955812|Drug|OPB-31121|50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
45369061|NCT04010994|Procedure|Transorbital electrical stimulation|Transorbital ACS using 8-12 Hz with 0,5-1,5 mA Intensity, during the first two weeks 1/day, after 2/week for 10 weeks, as a home treatment
45369062|NCT05299710|Procedure|Laparoscopic surgery|Surgery used to remove your child's ovary tissue is called laparoscopic surgery. Laparoscopic surgery employs a telescope-like instrument called laparoscope. The laparoscope will be put into your child's belly through a small (about half an inch) cut just below the belly button. Two or three other cuts may be made to allow for other instruments to help remove one of the ovaries. The surgeon will then look at both ovaries before the removal of one. Both of your child's ovaries must appear normal and be free of any masses in order to complete the surgery. The surgeon will choose which ovary will be removed at the time of surgery. This type of surgery is likely to last for 30 to 65 minutes.
45369063|NCT00454636|Drug|Cisplatin|80 mg/m2/day, intravenous (IV), every 3 weeks
46052544|NCT05561907|Procedure|Surgical gastrojejunostomy (SGJ)|Laparoscopic gastrojejunostomy
46052545|NCT05561907|Procedure|Endoscopic gastrojejunostomy (EGJ)|Endoscopic ultrasound (EUS) guided gastrojejunostomy
46052546|NCT02807649|Dietary Supplement|Experimental: Nutrilite® Low dose|Two tablets consume daily with meal.
46052547|NCT02807649|Dietary Supplement|Experimental: Nutrilite® High dose|Two tablets consume daily with meal.
46052548|NCT02807649|Dietary Supplement|Placebo Comparator: Placebo|Two tablets consume daily with meal.
46052549|NCT02814435|Other|Questionnaire|The participants will answer two questionnaires. These are the NEI VFQ-25 and the DLTV (daily living tasks of vision).
46052550|NCT02814435|Other|Computerised contrast sensitivity function test|This test involves the patient identifying whether bars on a screen are horizontal or vertical. It is designed to measure contrast sensitivity.
46052551|NCT02814513|Device|ANDAGO|Feasibility: the researchers will examine technical features as well as patient-related aspects, safety and operability of the device during static (standing) and dynamic (walking) tasks.
46052552|NCT02814513|Device|ANDAGO|Differences in static and dynamic tasks when standing/walking in the ANDAGO or when being supervised by a therapist/walking with regular walking aids.
45369064|NCT00454636|Drug|Capecitabine|1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle
45369065|NCT00454636|Drug|Epirubicin|50 mg/m2/day, IV, every 3 weeks
45486858|NCT02431156|Other|Assessment of visual capacity|"Visual capacity (VC) is variable comprised by three sub-variables: a) (DVC) Visual capacity for activities requiring distant vision, b) (IVC) Visual capacity for activities requiring intermediate vision, and c) (NVC) Visual capacity for activities requiring near vision.~VC will be measured in a scale from 1 to 100 as the sum of the DVC, IVC and NVC"
45486859|NCT02709538|Drug|GSP 301 NS|FDC of olopatadine HCl and mometasone furoate: 2 spray in each nostril twice daily for 52 weeks
45486860|NCT02709538|Drug|GSP 301 Placebo NS pH 3.7|2 spray in each nostril twice daily for 52 weeks
45486861|NCT02709538|Drug|GSP 301 Placebo NS pH 7.0|2 spray in each nostril twice daily for 52 weeks
45486862|NCT03789318|Drug|CA-008 5 mg|5 mg CA-008 reconstituted in saline.
45486863|NCT03789318|Drug|Placebo|Each cohort will use placebo reconstituted in saline.
45486864|NCT03789318|Drug|Bupivacaine Hydrochloride|0.25% administered pre-surgery
45486865|NCT03789318|Drug|Hydromorphone|0.02 mg/kg IV administered intraoperatively
45486866|NCT03789318|Drug|Fentanyl|100 mcg IV administered intraoperatively
45486867|NCT03789318|Drug|Acetaminophen|1000 mg IV administered intraoperatively
45486868|NCT03789318|Drug|Oxycodone|5-10 mg PO administered post-surgery
45486869|NCT03789318|Drug|CA-008 10 mg|10 mg CA-008 reconstituted in saline.
45486870|NCT03789318|Drug|CA-008 15 mg|15 mg CA-008 reconstituted in saline.
45486871|NCT02431078|Procedure|Routine comprehensive treatment|Radical gastrectomy for gastric cancer and postoperative adjuvant chemotherapy
45486872|NCT05226468|Drug|NEI-01|"Part1:~Single dose period: Intravenous single dose of NEI-01 with 4 ascending dose levels.~Multiple dose period: Intravenous weekly dose of NEI-01 for 9 weeks with 4 ascending dose levels.~Part2:~Intravenous weekly dose of NEI-01 at the recommended dose obtained from Part 1"
45486873|NCT02435602|Procedure|NBI endoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy Biopsy at the visually abnormal lesions
45486874|NCT02435602|Procedure|Lugol chromoendoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy Biopsy at the unstained lesions >= 5 mm diameter Pathologic examination of all biopsy tissue specimens
45486875|NCT03773952|Drug|PBF-677|oral small molecule, antagonist of Adenosine A3 receptor (AA3R)
46052553|NCT02814513|Device|ANDAGO|Investigate the handling of the ANDAGO. Patients will have time to practice with the device and the researchers will evaluate improvements in static/dynamic task performance with the ANDAGO.
46052554|NCT02814513|Device|ANDAGO|Determine which patients (characterized by demographics and neurological, cognitive and functional status) can improve their handling with the ANDAGO (i.e. whether patients can improve relatively quickly (i.e. 30 minutes of practice time) in dynamic tasks).
46052555|NCT02814513|Device|ANDAGO|To investigate how well healthy age- and gender matched children can perform the dynamic tasks (obstacle and precision course) and compare these results to those obtained in patients.
45369066|NCT00454636|Drug|Cisplatin|60 mg/m2/day, IV, every 3 weeks
45369067|NCT00454636|Drug|Capecitabine|625 mg/m2, oral, twice daily per 3-week cycle
45369068|NCT00454636|Drug|Oxaliplatin|130 mg/m2/day, IV, every 3 weeks
45369069|NCT00454636|Drug|Docetaxel|60 mg/m2/day, IV, every 3 weeks
45486876|NCT03773952|Drug|Placebo oral capsule|Oral capsules
45486877|NCT02431000|Procedure|Sperm and blood collected for analysis|Sperm Collection and Freezing (Cryopreservation), Blood Collection for analysis
45486878|NCT05212428|Procedure|Biospecimen Collection|Undergo collection of saliva, blood, urine and stool samples
45486879|NCT05212428|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
45486880|NCT05212428|Other|Genetic Counseling|Receive genetic counseling
45486881|NCT05212428|Other|Questionnaire Administration|Complete family history
45486882|NCT05212428|Other|Questionnaire Administration|Ancillary studies
45486883|NCT03191188|Drug|Levothyroxine Sodium|Thyroid hormone supplement
45486884|NCT03191188|Drug|Placebo Oral Tablet|Placebo
45486885|NCT04518410|Biological|bamlanivimab 7000mg|Administered by single IV infusion. Participants are no longer being randomized to this intervention.
45486886|NCT04518410|Biological|BRII-196+BRII-198|1000 mg (BRII-196)/1000 mg (BRII-198) combination therapy. Administered by consecutive IV infusions as single dose. Participants are no longer being randomized to this intervention.
46052556|NCT02814357|Other|Control (market standard)|
45369070|NCT00454636|Drug|Capecitabine|825 mg/m2, oral, twice daily for 2 weeks
45486887|NCT04518410|Biological|AZD7442 (IV)|300 mg AZD7442 (150 mg AZD8895 + 150 mg AZD1061). Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
45486888|NCT04518410|Biological|AZD7442 (IM)|Administered intramuscularly as 2 separate injections sequentially (300 mg AZD8895 then 300 mg AZD1061) for one dose. Injections administered in the side of the thigh, one injection in each thigh. Participants are no longer being randomized to this intervention.
45486889|NCT04518410|Drug|SNG001|1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
45486890|NCT04518410|Drug|Camostat|200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
46052557|NCT02814357|Other|wheat flour|
46052558|NCT02814357|Other|chickpea flour|
46052559|NCT02814357|Other|guar gum|
46052560|NCT02814357|Other|barley|
45369071|NCT04850196|Device|TEAS|TEAS treatment was performed for 30 mins before anesthesia on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints . And TEAS treatment for 30 mins was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints at the end of surgery as well as on the each night before sleeping after surgery until discharged from the hospital
45369072|NCT04850196|Other|control group|Patients in the Control group received electrical stimulation at a non-acupoint which was located 2 cm interior to the bilateral Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints similar to patients in group TEAS
45369073|NCT00427960|Behavioral|Dietary advice|
45486891|NCT04518410|Biological|BMS-986414 + BMS-986413|Administered subcutaneously (SC) as 4 separate injections for one dose (two injections of C135-LS 200mg and two injections of C144-SL 200mg). Participants are no longer being randomized to this intervention.
45486892|NCT04518410|Biological|SAB-185 (3,840 Units/kg)|Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
45486893|NCT04518410|Biological|SAB-185 (10,240 Units/kg)|Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
45486894|NCT04518410|Drug|CASIRIVIMAB + IMDEVIMAB|600 mg casirivimab and 600 mg imdevimab, administered together as single IV infusion as one-time dose at study entry. Participants are no longer being randomized to this intervention.
45486895|NCT04518410|Drug|Placebo for Bamlanivimab 7000mg|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
45369074|NCT00427960|Drug|rosuvastatin|rosuvastatin 5 mg
45369075|NCT00427960|Drug|atorvastatin|atorvastatin 10 mg
45369076|NCT00548340|Drug|VEC-162 20 mg|20 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
45486896|NCT04518410|Drug|Placebo for Bamlanivimab 700mg|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
45369077|NCT00548340|Drug|Placebo|Placebo capsules, PO daily for five weeks
45486897|NCT04518410|Drug|Placebo for BRII-196+BRII-198|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
45486898|NCT04518410|Drug|Placebo for SNG001|Trisodium citrate dihydrate, di-sodium hydrogen-phosphate, sodium dihydrogen-phosphate dihydrate, racemic methionine (DL-methionine) and water. 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
45486899|NCT04518410|Drug|Placebo for Camostat|200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
45486900|NCT04518410|Drug|Placebo for SAB-185 (low dose)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
45486901|NCT04518410|Drug|Placebo for BMS-986414 + BMS-986413|Administered SC as 4 separate injections for one dose. Participants are no longer being randomized to this intervention.
45486902|NCT04518410|Drug|Placebo for AZD7442 (IV)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
46052561|NCT02807337|Drug|Caphosol|
46052562|NCT02807337|Drug|0,9% NaCl|
46052563|NCT02807415|Drug|Lumacaftor plus Ivacaftor|Oral treatment with lumacaftor/ivacaftor tablets according to the prescribing information
46052564|NCT02804841|Dietary Supplement|Cholecalciferol -Vitamin D3|
46052565|NCT02804841|Other|Placebo -gel capsule containing no vitamin D.|
46052566|NCT05529537|Other|manual lymphatic drainage|In addition to conventional treatment for 4 weeks, manual lymph drainage will be applied to the patients.
46052567|NCT05529537|Other|excersize|upper extremity normal joint range of motion exercise, strengthening exercise, tendon gliding exercises
46052568|NCT02808273|Drug|Bemiparine|Bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
46052569|NCT00634491|Drug|sodium bicarbonate|150 meq/l Sodium bicarbonate 3cc/kg/hr before and 1cc/kg/hr after angiography
46052570|NCT00634491|Drug|Acetazolamide|Acetazolamide 250 mg+ 1 cc/kg/hr normal salin before and after angiography
46052571|NCT00634491|Drug|normal salin|1 cc/kg/hr 6 hour before and after angiography
45369078|NCT00548340|Drug|VEC-162 50 mg|50 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
46052572|NCT02807103|Drug|Rituximab|1 g intravenous pulse at day1 and day15
46052573|NCT02807103|Drug|Placebo-rituximab|intravenous pulses at day1 and day15
46052574|NCT02807103|Drug|Cyclophosphamide|intravenous 9 pulses : 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.
46052575|NCT02807103|Drug|Placebo-cyclophosphamide|intravenous 7 pulses : at days 29, 50, 71, 92, 113, 134 and 155.
46052576|NCT02806791|Drug|FILGRASTIM|
45369079|NCT04839588|Other|Usability study|"Participants will first be screened for propensity to simulation sickness and for cognitive state using the MoCA evaluation test. Those who passed the screening will perform 4 usability sessions rating the ease of use and perceived benefit of the experimental system and of a caregiver interface laptop. The 2 healthy volunteers will evaluate first, such that issues may be resolved before testing is done on the impaired participants. Each session will be compensated with a $35 payment. During each session participants will play a series of increasing difficulty simulated tasks, aimed to train primarily the executive functions domain. At the end of each session participants will rate their experience using custom subjective evaluation forms with multiple items. Each item will be scored using a 5-point Likert scale. At the end of the 4th session, participants will also fill the USE standardized usability form.~This usability evaluation will be conducted at the NJ Bioscience Center."
45486903|NCT04518410|Drug|Placebo for AZD7442 (IM)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
45369080|NCT03994198|Dietary Supplement|Alpha-lactalbumin|A protein fraction of whey protein, higher in tryptophan
45846474|NCT05247996|Procedure|Transcatheter arterial chemoembolization|"Treatment regimens have chosen lipiodol-based hepatic arterial chemoembolization, with lipiodol dosage varying from 5-20ml depending on tumor size. The chemotherapy drug is gemcitabine 1.0 combined with 100mg oxaliplatin, combined with 1/3 to 1 dose of solid embolic agent (the dosage is determined by the investigator based on the tumor size). After uniform emulsification, the drug is injected into the supplying blood vessels and stops when the intravascular blood flow is slow. Later, angiography is performed again, and the tumor staining disappears and the supplying artery is occlusions.~CT or MRI scans are performed 4 to 6 weeks postoperatively to assess the presence of active lesions. Repeat TACE if active lesions are still present. The frequency of TACE treatment is determined by the investigator and is given according to the patient's condition, generally 2-4 times. The interval between TACE treatments is 30-45 days, with a maximum of six cycles."
46052577|NCT00830518|Drug|Alisertib|Alisertib capsules
45369081|NCT03994198|Dietary Supplement|Collagen peptides|Collagen peptides from bovine sources
45369082|NCT04142814|Procedure|T-PEP|"First of all, a corrugated tube for ventilation is assembled: in one end with an antibacterial filter for ventilation and then an inflation system (like Auxiliary Manual Breathing Unit - AMBU); in the other end with a connector and then a one-way PEP Valve. The latter holds a junction for the tracheal cannula and a pressure gauge. A Venturi Resistor is placed in the expiratory part of the PEP Valve.~After connection to the tracheal cannula, the disostructive maneuver is manually executed by a respiratory physiotherapist."
45369083|NCT04142814|Procedure|IPV|IPV is delivered via a commercial device that can be set by frequency, duration of inspiratory time, inspiratory-expiratory ratio and positive end-expiratory pressure, based on patients characteristics and clinical needs. It is connected to the patient's tracheal cannula via a Mount catheter. The air supplied is sterile, due to the presence of an antibacterial filter present in the device.
45369084|NCT04010760|Diagnostic Test|Test of biomarkers for PE in EBC|"New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath condensate (EBC).~The EBC will be collected by use of the RTube(R) system which has been used in previous studies of EBC. As the patient breathes through a mouth piece, the exhaled breath is led through a cooling chamber where the vaporous part of the exhaled breath condenses.~We aim at collecting a total minimum of 3.0 mL EBC per study subject in order to have a sufficient amount of protein for the subsequent analysis. We aim at collecting exhaled breath condensate for 2*15 minutes with the possibility to stop the collection after less than 15 minutes if the volume is sufficient."
45369085|NCT04768686|Drug|FLX475|tablet
45369086|NCT04768686|Drug|Pembrolizumab|IV infusion
45369087|NCT00955890|Drug|Dexrazoxane hydrochloride|pink power 250mg/bottle DEX:EPI,10:1 every 3 weeks
45369088|NCT00955890|Drug|Dexrazoxane hydrochloride|pink powder 250mg/bottle DEX:EPI,15:1 every 3 weeks
45486904|NCT04518410|Drug|Placebo for SAB-185 (high dose)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
45486905|NCT04518410|Biological|bamlanivimab 700mg|Administered by single IV infusion. Participants are no longer being randomized to this intervention.
45486906|NCT02435446|Device|Cone-beam computed tomography|Cone-beam computed tomography
46052578|NCT02804685|Other|exercise protocol|The multi-intervention exercise protocol consists in a performance of agility, strength and balance exercises. It has to be fulfilled during 6 weeks (twice a week) before the regular training performance. The exercises should be done for almost 15 minutes approx. There will be 6 exercises in total: squat with toe raise, one-leg squats, single-leg balance (throwing a ball with a partner), vertical jumps, hamstring exercise, quick forwards and backwards sprints.
46052579|NCT00908544|Other|PHI-patients|Treatment initiation with multi drug class (MDC) HAART. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
46052580|NCT00908544|Other|CHI-patients|Treatment intensification of PI-based HAART with Maraviroc and Raltegravir. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
46052581|NCT02804607|Other|questionnaire|
46052582|NCT00830440|Device|EndoBarrier Device|NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp and EndoBarrier Device for 12 weeks
45369089|NCT00956046|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
45369090|NCT00956046|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
45369091|NCT00956046|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21
45369092|NCT00454246|Drug|methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in a 1-mL prefilled syringe containing 0.3 mL or 0.6 mL solution. The methoxy polyethylene glycol-epoetin beta injectable solution was formulated in sodium phosphate, sodium sulfate, mannitol, methionine and poloxamer 188, pH 6.2 and did not contain any preservative. Participants received methoxy polyethylene glycol-epoetin beta subcutaneous once a month.
45369093|NCT00454246|Drug|epoetin alfa|Standard of care as prescribed, per individual participant, subcutaneous once per week. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.
45369094|NCT00454246|Drug|darbepoetin alfa|Standard of care as prescribed, per individual participant, darbepoetin alfa subcutaneous once every two weeks. Subcutaneous injections were to be administered in the same part of the body (ie, thigh,abdomen or arm) throughout the study.
45369095|NCT04717284|Other|Self-compassion intervention (SCI)|All participants will be asked to recall a recent parenting event they feel ashamed of and type it into a text box provided. Participants in the SCI group will then be instructed to reflect on their recalled parenting event and prompted to think about and write about the event in a self-compassionate manner. The prompt is designed to induce on all of the three key elements of self-compassion described by Neff (2003a): self-kindness; common humanity; and mindfulness. The same instructions will be provided for follow-up period.
45486907|NCT03613662|Drug|SP-102|Injection
45486908|NCT02435368|Drug|mycophenolic acid|Monocytes were co-cultured with LPS and/or MPA.After 12 hours, the supernatants were harvested and stored at -80°C for ELISA.
45691752|NCT00683020|Behavioral|ATSM Intervention|"The ATSM system is designed to promote the efficiency of a care manager by having her focus outreach phone calls to patients who, by virtue of their responses to the ATSM system, report a need for further support. The purpose of these call-backs is to have the care manager directly engage patients in setting goals and developing an action plan to improve their overall health. The care manager is trained to perform motivational interviewing, assess and overcome barriers to health communication.~For some patients, the ATSM system as described above is augmented by additional phone communications from care manager to patient, triggered by health IT derived from 2 additional data sources: SFHP pharmacy claims data and CHNSF diabetes registry. The latter combines clinical data (labs and blood pressure). Based on clinical criteria, the ATSM system will alert care manager to make additional calls to patients."
45691753|NCT00683332|Drug|Tigecycline (Tygacil)|This is a non-interventional study; patients are administered Tygacil as prescribed by their doctor as per registered indications stated in product label/insert (50 mg by Intravenous Injection).
46052583|NCT00830440|Behavioral|Diet & Lifestyle Counseling|NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp
46052584|NCT04115865|Device|Endotracheal sonde or laryngeal mask|Healthy subjects ; requiring general anesthesia with endotracheal or endobuccal device
45486909|NCT01698294|Other|Clinical Observation|Participants maintain usual diet and undergo clinical observation
45486910|NCT01698294|Dietary Supplement|Flaxseed|Given PO
45486911|NCT01698294|Other|Laboratory Biomarker Analysis|Correlative studies
45691754|NCT00683410|Biological|Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)|
46052585|NCT00913354|Device|Acupuncture (Carbo®)|The acupuncture points were chosen according to traditional Chinese medicine and included DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.
45486912|NCT01698294|Other|Questionnaire Administration|Ancillary studies
45486913|NCT03191032|Other|Early sensory re-education of the hand with a sensor glove model|Training Group patients were submitted to application of a three-month protocol for early sensory re-education of the hand using the sensor glove model developed by Mendes et al. (2011). Patients also received conventional physical therapy for this type of injury in a specialized hand therapy center in a university hospital. Control Group patients received only conventional physical therapy treatment. No home sensory re-education program was established for any group and the CG patients were not submitted to any protocol for early sensory re-education of the hand.
45486914|NCT03190876|Procedure|Variable drain usage|Influence of drain usage on seroma formation rate
45486915|NCT05160090|Drug|Bupropion HCl MR tablets 300mg|In each study period, a single 300 mg dose of Bupropion will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.
45486916|NCT03190720|Device|Mobile community|A mobile community based on smartphone application (WalkOn) which gives participants to information about their own steps and others'.
45486917|NCT03538002|Device|Blue-light filtering spectacle lenses|This is a single vision spectacle lens for correction of distant refractions and filtering out the blue light by providing anti-blue light coating.
45486918|NCT05144308|Procedure|Images of the operated eye (s)|Through the operating microscope or a slit lamp, dilated pupil. Taken on the day of surgery (D0) and at 1 week, 1 month and 3 months post-op
45486919|NCT03692702|Behavioral|WE PLAY|WE PLAY is an online preschool teacher training that is based in theory and implementation science. It contains six components: (1) online training; (2) video library; (3) game sheets; (4) teacher self-assessment; (5) supervisor support; and (6) activity packs containing low cost physical activity equipment
45486920|NCT03117946|Other|Biological samples|blood and tumor tissue sample
45486921|NCT04516616|Drug|Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)|PD-1 monoclonal antibody （SHR-1210)：200mg，IV infusion，Q3W Cisplatin：75-80 mg/m2, IV infusion, Q3W Albumin-bound paclitaxel: 260 mg/m2，30min，IV infusion, Q3W
45486922|NCT00511134|Drug|Eszopiclone|eszopiclone (lunesta) - 3 mg qd x 6 weeks, oral capsule
45486923|NCT00511134|Drug|Bupropion|bupropion SR in oral capsule will be begun at the beginning of week 1 (150 mg qd x 7 days) with an increase to the full dose (150 mg bid x 6 weeks) at the beginning of week 2.
45486924|NCT02435056|Other|IEPR Approach|"Adoption of Interactive Electronic Patient Record (IEPR) that consists of the following clinically-relevant main components:~Minimum Data Set for supporting the diagnosis~Electronic Diary with associated alerting system for monitoring the patient during the follow-up period~Second opinion system for improving the management"
45486925|NCT02435134|Other|no intervention|
45691755|NCT00639418|Biological|Influenza vaccination|This non-interventional study prospectively captured vaccine coverage and practices of participating physician offices through use of surveys during the influenza vaccination season.
45691756|NCT00640822|Drug|Calcipotriol plus hydrocortisone ointment vehicle|Once daily application for up to 8 weeks
45691757|NCT00640822|Drug|Tacalcitol Ointment|Once daily application for up to 8 weeks
45691758|NCT00640822|Drug|Calcipotriol plus hydrocortisone ointment|Once daily application for up to 8 weeks
45846475|NCT05247996|Drug|Multi-target Drug Therapy|Multi-target drugs (lenvatinib or donafenib) are selected at the patient's preference. Oral multitarget drugs are initiated 3-7 days after initial TACE treatment until tumor progression is assessed. The initial dose of lenvatinib is 8mg/ day (bodyweight < 60 kg) or 12 mg/ day (body weight≥60 kg); Donafenil 0.2g, twice a day, taken orally on an empty stomach. If the medication is missed, there is no need to take a refill and the next dose shall be taken at the usual time.
45486926|NCT03634722|Device|PHENIX4-8-8 PLUS|transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS
45691759|NCT00640978|Drug|RAD001|30 mg orally weekly for 4 weeks
45486927|NCT03118024|Drug|Crystalloid Solutions|crystalloid restrictive anesthesia protocol
45691760|NCT00640978|Drug|Erlotinib|150 mg by mouth daily for 28 Days
45691761|NCT01799434|Other|treadmill run|
45486928|NCT03118024|Drug|Catecholamines|catecholamine restrictive anesthesia protocol
45486929|NCT03117868|Other|Study of mortality at 6 months|The objective is to provide strong arguments for establishing a dynamic of collective care for patients suffering from an EFSF
45486930|NCT03634644|Drug|Omega 3 fatty acid|Omega 3 fatty acid,mainly composed of EPA and DHA.
45486931|NCT03634644|Drug|Placebo oral capsule|mainly composed of corn oil
45486932|NCT05103228|Drug|Follitropin Alfa|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
45486933|NCT05103228|Drug|Follitropin delta|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
45486934|NCT05103228|Drug|human menopausal gonadotropin|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
45486935|NCT01372384|Drug|erlotinib [Tarceva]|150 mg orally daily
45486936|NCT03185416|Other|Palliative Care Training|The intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
45486937|NCT03190798|Drug|Canagliflozin 300mg|"Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by decreasing the amount of sugar the body absorbs, and increasing the amount of sugar that leaves the body in the urine.~Administered in 300mg tablets."
45486938|NCT03190798|Drug|Placebo|Placebo for Canagliflozin
45691762|NCT02998216|Procedure|Bilateral sacrospinous fixation|Bilateral sacrospinous vaginal suspension
45486939|NCT03117478|Other|Magneto-encephalography (MEG)|Magneto-encephalography
45486940|NCT03117478|Other|Electro-encephalography (EEG)|Electro-encephalography
45846476|NCT05247996|Drug|Immunocheckpoint Inhibitor Therapy|Optional types of immune checkpoint inhibitors include Sintilimab injection and Tislelizumab injection. Treatment shall be based on the immune checkpoint inhibitors before enrollment, and it is not recommended to change the immune checkpoint inhibitors; Dosage: 200mg, iv, D1, every 21 days (Q3W), continuous until tumor progression.
45486941|NCT03117478|Other|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging
45486942|NCT03117478|Other|Anatomical Magnetic Resonance Imaging (aMRI)|Anatomical Magnetic Resonance Imaging
45486943|NCT03117478|Other|Meditation|Meditation
45691763|NCT00642694|Drug|Escitalopram|Escitalopram 10 or 20mg qd based on symptoms at patient visit
45691764|NCT00642694|Drug|Ramelteon|Ramelteon 8 mg qd
45691765|NCT00642694|Other|Placebo|Matching placebo qd
45691766|NCT02998294|Device|Respiratory Volume Monitor(RVM)|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
45691767|NCT02998294|Device|artificial respirator|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
45486944|NCT03115476|Drug|ingenol disoxate gel 0.018%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
45486945|NCT03115476|Drug|ingenol disoxate gel 0.037%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
45486946|NCT03115476|Other|Vehicle gel|Vehicle to ingenol disoxate gel with no active ingredient
45486947|NCT03117556|Procedure|Bilateral Thoracoscopic Splanchnicectomy|BTS will be performed on all patients under general endotracheal anesthesia. Patients will be placed in the prone position. A 5 mm trocar should be placed at the inferior scapular apex on the patient's left side. After confirmation of trocar placement with a 30 degree 5 mm thoracoscope, a second trocar will be placed two intercostal spaces below and two cm medial to the first trocar. After the splanchnic nerves are identified inferior and medial to the sympathetic trunk, the pleura will be incised on both sides of each of the nerves. Skin incisions are then closed and the procedure will then be repeated on the patient's right side.
45486948|NCT02435290|Behavioral|determine the incidence , type , and severity of prescribing errors in the oncology department|"patients' files are revised according to BCCA reference protocols to report errors which are categorized according to type,and severity including: BSA calculation, the eligibility of the chemotherapy protocol , the dosage form ,dosage , the modification of doses according to toxicity and laboratory data results ,frequency ,duration of treatment , intention of treatment , the omitted or duplicated medications ,and the drug interactions.~the impact of the risk factors on the incidence , and type of prescribing errors are studied including :The tumor type, Cancer stage , co morbid illness,The number of drugs in the treatment regimen ,The route of administration of chemotherapy ,Dosing Frequency of treatment, The toxicity of chemotherapy experienced by the patient, The number of abnormal lab data,The type of abnormal lab data ,the age of patient.~."
45486949|NCT03911778|Other|Improvement of symptoms|Improvement of symptoms on the Patient Global Impression of Improvement Index (PGI-I) scale (score 1, 2, or 3) at 6 weeks postoperatively
45486950|NCT02434978|Device|Supplementary endoscopy with doppler-guided therapy|Patients randomized to supplementary doppler-guided therapy undergo repeat endoscopy with doppler evaluation within 24 hours from the primary endoscopy. At the control endoscopy the ulcer base is examined using a doppler device. If active doppler flow is demonstrated the ulcer is treated with a thermal probe until a control doppler-scan is negative. All patients are observed for rebleeding at a specialized GI-bleeding unit.
45486951|NCT02434978|Drug|IV. PPI|All patients receive 80mg of Esomeprazole iv as a bolus followed by 8mg Esomeprazole per hour for 72 hours.
45486952|NCT02434978|Other|Endoscopic treatment at primary endoscopy|All patients are initially treated with endoscopic therapy using a minimum of two different treatment modalities. The primary endoscopy is performed wihtin 24 hours from time of admission to hospital
45486953|NCT01371396|Other|Low-fat diet|The subject will consume a diet that is calorically restricted to cause at least a 6% body weight loss over 4 months. Fat will make up less than 30% of dietary energy.
45486954|NCT01371396|Other|Low-carbohydrate diet|The diet will be restricted in energy to cause at least a 6% loss of body weight over a 4 month period. Carbohydrate will provide less than 40% of total dietary energy.
45486955|NCT03696290|Drug|Aztreonam lysine|Nebulised aztreonam lysine 75mg
45486956|NCT03696290|Other|Placebo|Nebulised lactose monohydrate 5mg
45486957|NCT03633942|Device|LMA Supreme|Placement of the LMA Supreme supraglottic airway device for patients undergoing outpatient spine surgery in the prone position.
45486958|NCT02434666|Drug|CPC-201|
45486959|NCT03696212|Drug|grapiprant and pembrolizumab|Participants will be administered 21-day cycles of oral grapiprant in combination with IV pembrolizumab
45486960|NCT05048160|Drug|Intravenous Infusion|Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
45486961|NCT03803280|Procedure|ERAS program|ERAS pathway according to the Spanish Via RICA
45486962|NCT03692624|Behavioral|Biofeedback|Heart Rate Variability Biofeedback
45486963|NCT02430922|Device|iVolution nitinol stent|
45486964|NCT03692546|Drug|Liposomal bupivacaine (LB)|Addition of LB solution to soft tissue surgical field block to a standard interscalene block procedure
45486965|NCT03248388|Device|Argus II Eyeglasses|The Argus II Eyeglasses (retinal prosthesis) can restore rudimentary forms of vision to patients with bare light-perception vision. Using the prosthesis, patients can identify obstacles, handles, switches, eating utensils and demonstrate improved navigation when used in conjunction with other ambulation-assist tools. Current limits in the resolution of the device prevent useful reading or face recognition.
45486966|NCT03248388|Device|ORCAM|ORCAM is a commercially-available eyeglass-mounted visual pattern recognition system capable of converting photographs of text to speech. It is comprised of a camera, a small belt-worn computer, pattern recognition software and a small audio transducer. ORCAM can acquire the image of a sheet of paper and read the text to the user through a small speaker adjacent to the ear. In addition, ORCAM can be trained to recognize faces and speak the name of the individual to the user. ORCAM can also be used to recognize everyday products after being programmed.
45486967|NCT02434588|Device|Bhattacharjee ring|Insertion of a Bhattacharjee ring to stabilise the pupil during cataract surgery
45486968|NCT03480763|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
45486969|NCT03480763|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose
45486970|NCT03480763|Biological|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
45486971|NCT02434432|Behavioral|music therapy selected by mothers|mothers' choice of music
46052586|NCT00913354|Device|Placebo acupuncture (Strietberger®)|"The acupuncture points were the same as in the true acupuncture group, namely DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.~Sham acupuncture needles used were the validated Strietberger® placebo-needle from the company, Asia Med. The needle is not fixed inside the copper handle and its tip is blunt. When the needle touches the skin it moves inside the handle and appears to be shortened. A pricking sensation is felt by the patient, simulating the puncturing of the skin. Developed by dr. Konrad Streitberger."
45486972|NCT02434432|Behavioral|Music therapy recorded lullaby|recorded lullaby
45486973|NCT04223804|Drug|ABBV-181|Intravenous (IV) Infusion
45486974|NCT04223804|Drug|Placebo|Intravenous (IV) infusion
45486975|NCT02434822|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
45486976|NCT02434822|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
45486977|NCT02434822|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
46052587|NCT05523687|Drug|[14C]-PC14586|Single, oral dose of [14C]-PC14586
46052588|NCT00702910|Drug|Placebo|comparator
46052589|NCT00702910|Drug|GW642444|investigational drug or placebo
45486978|NCT03692390|Device|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
45486979|NCT02430766|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Lymph Node Metastases guide with ultrasound or/and CT.
45486980|NCT02430766|Device|NanoKnife|
45486981|NCT03700502|Diagnostic Test|resting-state functional Magnetic Resonance Imaging|The investigators used fraction Amplitude of Low Frequency Fluctuation (fALFF) and Regional Homogeneity (ReHo) of resting-state functional Magnetic Resonance Imaging (rs-fMRI) to explore the brain activity in patients with PDN in order to study the central mechanism. The investigators also evaluated the symptoms, signs and mental conditions of the patients.
45486982|NCT03123120|Drug|Spesolimab|12 weeks treatment
45486983|NCT03123120|Drug|Placebo|12 weeks treatment
45486984|NCT03692234|Dietary Supplement|125 mg L-homoarginine|capsules for oral supplementation
45486985|NCT03692234|Other|placebo|capsules for oral supplementation
45486986|NCT02430688|Procedure|Irreversible electroporation (IRE)|
45486987|NCT02430688|Device|NanoKnife|
45486988|NCT03185338|Behavioral|Active commuting to/from school|Active transport to/from school on foot or by bike will be promoted
45369096|NCT04717284|Other|Control condition|All participants will be asked to recall a recent parenting event they feel ashamed of and type it into a text box provided. Participants in the control group will then be instructed to make notes about factual information of the event (e.g. time of day, who was there, the weather, etc.). During the two-week follow-up period, participants in the control group will not take part in any intervention as part of the trial.
45369097|NCT00434590|Drug|Enteric coated mycophenolate sodium (Myfortic®)|
45369098|NCT04711512|Behavioral|Encouragement/Support|Messages that focus on improving self-efficacy and motivation for physical activity
45369099|NCT04711512|Behavioral|Social Comparison|Messages that provide exposure to another person's physical activity engagement data (for comparison)
45486989|NCT03185338|Behavioral|Active Physical Education lessons|Specific lessons designed for increasing moderate to vigorous physical activity in Physical Education will be applied
45486990|NCT03185338|Behavioral|Active school recess|Teachers will design games and activities and will encourage children for being active
45486991|NCT03185338|Behavioral|Sleep health promotion|This intervention will aim to raise the awareness of the importance of having a good quality sleep at night and to teach healthy sleep behaviours that will contribute to improving sleep hygiene
45486992|NCT03185338|Behavioral|School global intervention|A simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
45486993|NCT03624296|Device|MRI 7T|MRI 7T
45486994|NCT03624296|Other|TEST EDSS|EDSS - Expanded Disability Status Scale
45486995|NCT03624296|Other|TEST MSFC|MSFC - Multiple Sclerosis Functional Composite
45486996|NCT03692832|Procedure|LH|Laparoscopic hysterectomy following AAGL class IV E, vault closed vaginally
45486997|NCT03692832|Procedure|VH|Vaginal hysterectomy following Heaney technique
45486998|NCT03696134|Other|questionnaire|questionnaire
45486999|NCT01371474|Drug|Paroxetine|
45487000|NCT03184948|Device|Brilliance|The intervention is the provision of the Brilliance phototherapy machines to hospitals. This device is to be provided to facilities regardless of the study -- the study's involvement has been to collaborate with the Ministry of Health so that Brilliance is distributed in a randomized staggered method. In that sense, the study may be considered observational, as the study is not driving whether or not a hospital receives Brilliance, only when it receives Brilliance in a short time frame.
45691768|NCT00705874|Drug|CGC-11047 and gemcitabine|Gemcitabine: (Closed to enrollment) 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle. CGC-11047 will only be given on days 1 and 15 of each cycle and will start at dose level -1 (50 mg).
45691769|NCT00705874|Drug|CGC-11047 and docetaxel|Docetaxel: (Closed to enrollment) 75 mg/m2 administered IV over 60 minutes every 21 days. CGC-11047 will be administered only on Day 1 of each 21-day cycle and will start at dose level -1 (50 mg).
45691770|NCT00705874|Drug|CGC-11047 and bevacizumab|Bevacizumab: 5 mg/kg administered IV once every 14 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
45691771|NCT00705874|Drug|CGC-11047 and erlotinib|Erlotinib: 150 mg taken orally every day of each 28-day cycle. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
45369100|NCT04010838|Procedure|spinal cord stimulation|The spinal cord stimulation(SCS) is a type of implantable neuromodulation device (spinal cord stimulator) that is used to send electrical signals to select areas of the spinal cord (C2-C4 in this study) for the treatment of disorders of consciousness.
46052590|NCT00702910|Drug|Magnesium Stearate|Magnesium Stearate
46052591|NCT02806635|Behavioral|OurRelationship|
46052592|NCT02806635|Behavioral|PREP Online|
46052593|NCT00908310|Drug|Omniscan|OMNISCAN will be administered intravenously at the medical discretion of the prescribing physician.
46052594|NCT02804529|Device|Veress needle|
46052595|NCT03896334|Behavioral|Supervised Isometric Handgrip Training|The participants randomized to the experimental group will perform 24 weeks of isometric handgrip exercise training, three times/week for 16 minutes with time to rest.
45487001|NCT03696056|Behavioral|Kirtan Kriya meditation|The program incorporates song with visualization and mudras, and is a multi-faceted, multisensory exercise that appears to engage several areas of the brain implicated in cognitive decline, yet is simple to learn and practice. The meditation includes a repeated Kirtan or song, a mudra or physical/motor component, and a visualization component. The meditation sound file will contain a user friendly introduction to the Kirtan Kriya meditation technique along with detailed instructions and meditation tracks. Three tracks will contain 12 minute guided meditations with the same female voice, and 2 with nature sounds, 2 without any additional sounds. Another 2 tracks will provide only the timing cues (1 with nature sounds, 1 without) so that the participant can conduct the meditation session without guidance if they chose.
45487002|NCT03696056|Behavioral|Music listening program|"The participants will receive audio files and an instruction sheet to facilitate their practice.~The audio tracks are 12 minutes in length and contain relaxing instrumental music from Mozart, Bach, Beethoven, Debussy, and Pachebel. Participants are instructed to sit comfortably with their eyes closed and listen to a track of their choice for 12 min daily, for 8 weeks and to record each session on their practice log."
45369101|NCT04012164|Biological|blood sampling|5ml blood sampling
45369102|NCT04012164|Biological|stool collection|self stool collection (2g)
45369103|NCT04012164|Other|Participatory activity and contact investigation|30 human subjects will self-report daily activities and contacts with selected wild and domesticated animals for five months.
45369104|NCT04012164|Other|Anthropological and historical interviews|Oral interviews on current and past practices and engagements with wild and domesticated animals will be conducted with the 30 human subjects who are recruited to self-report their activities (Participatory activity and contact investigation) and to provide blood and stool samples. Another 30 human subjects will be recruited only to participate in the same type of interviews, addressing past and present activities and relations with wild and domesticated animals.
45369105|NCT04674618|Device|US-assisted nusinersen administration|Ultrasound identification of intervertebral space (L2-L3 or L3-L4)
45369106|NCT00956202|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
45369107|NCT00956202|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
45369108|NCT00956202|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and day 21
45369109|NCT02891837|Drug|L-citrulline|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base;~Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L;~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~9 mg/kg/hr continuous infusion for up to 48 hours."
45369110|NCT02891837|Other|Placebo|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass;~Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass;~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~9 mg/kg/hr continuous infusion for up to 48 hours."
45487003|NCT03185104|Drug|Silver Diamine Fluoride|Silver diamine fluoride solution is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
45487004|NCT03185104|Drug|Distilled Water|Distilled water is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
45691772|NCT00705874|Drug|CGC-11047 and cisplatin|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
45691773|NCT00705874|Drug|CGC-11047 and 5-flurouracil / leucovorin|5-Flurouracil / Leucovorin: Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 wks, repeated every 56 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
45487005|NCT03700424|Drug|Trehalose|"Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products.~In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes."
45487006|NCT03700424|Drug|Normal saline|A solution of 0.90% w/v of sodium chloride (NaCl) in water
45487007|NCT01319994|Drug|Metformin|Metformin 850mg TDS (12 weeks)
45487008|NCT01319994|Drug|Placebo|Placebo 850mg TDS (12 weeks)
45487009|NCT02430298|Drug|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
45487010|NCT02430298|Drug|Matched Placebo|Drug: Melatonin 20 mg/ 10 ml placebo suspension gargle for 2 minutes before radiation 15 minutes and 20 mg placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
45487011|NCT03624218|Behavioral|Prolonged Exposure Therapy|Using a combination of In vivo and Imaginal exposure, Prolonged Exposure therapy aims to treat those with Posttraumatic Stress Disorder.
45487012|NCT03626376|Drug|oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily|Treatment used in standard of care
45487013|NCT03626376|Drug|oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops|Topical steroid medications to be used in this study include Prednisolone acetate 1.0% or Prednisolone sodium phosphate 1%. The choice of formulation will be dependent on physician preference and medication availability. Formulations of other potencies such as Difluprednate emulsion will not be used in this study. Patients in the study arm will be started on topical corticosteroid 1 drop once a day in the affected eye.
45691774|NCT00705874|Drug|CGC-11047 and sunitinib|Sunitinib: 50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle). CGC-11047 will be administered on Days 1 and 8 of a 21 day cycle.
45691775|NCT00646048|Device|TriVascular Stent-Graft System|TriVascular Stent-Graft System
45691776|NCT00647998|Drug|Darbepoetin alfa|Patients will receive one IV injection of Darbepoetin alfa at doses ranging from 1mcg/kg to 6.5 mcg/kg prior to surgery
45691777|NCT00647998|Other|Standard care|
45691778|NCT00649792|Drug|Fampridine-SR|Tablets, 10 mg, BID (twice daily)
45691779|NCT00685516|Dietary Supplement|green tea|6 cups of green tea daily for 2-8 weeks
45369111|NCT03682458|Genetic|Study of Neurodegenerative Diseases Induced Stem Cells|The aim of this study is to generate iPS-induced stem cell lines from patients with neurological and neurodegenerative diseases to differentiate into neurons and glial cells to study the pathological cellular and molecular processes of these diseases. These in vitro cultures will also be used to validate molecules or experimental therapeutic approaches. IPS cells will be generated by the reprogramming of isolated 10-mL cells of peripheral venous blood.
45369112|NCT04009590|Other|Educational Intervention|Read educational booklet
45369113|NCT04009590|Other|Questionnaire Administration|Ancillary studies
45487014|NCT03714139|Procedure|immediate loading|"The participants will be assigned to immediate or delayed functional loading groups. In each participant, edentulous areas with adequate thickness of the alveolar bone crest will be identified and at least two sites will be identified for implant installation. All implant recipient sites will be sub-prepared to allow good stability of the implants. Experimental mini-implants (Sweden & Martina, Due Carrare, Padova, Italy), 3.5 mm in diameter and with an intraosseous portion of 4 mm in length will be installed.~Immediate loading group - A prosthetic component will be applied over the trial implants. Impressions will be taken and a crown / bridge will be provided to patients in one day."
45487015|NCT03714139|Procedure|non implant loading|Control implants will receive a healing screw and will remain unloaded
45487016|NCT02430454|Behavioral|Increased cognitive load|simulated conditions to increase cognitive load: encourage first impression, time-limit, distractions
45487017|NCT03700346|Device|microdialysis|Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained by using muscle microdialysis
45691780|NCT00685516|Dietary Supplement|placebo|6 cups of water daily for 2-8 weeks
45691781|NCT00685516|Dietary Supplement|decaffeinated black tea|6 cups of decaffeinated black tea daily for 2-8 weeks
45691782|NCT00686842|Drug|VEGF inhibitor PTC299|20 mg capsules to be taken by mouth BID. Three dose levels will be evaluated: 40 mg, 80mg, and 100mg BID. Subjects will receive PTC299 in consecutive 28-day cycles for a maximum of 12 cycles.
45691783|NCT00686842|Genetic|gene expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
45691784|NCT00686842|Genetic|polymerase chain reaction|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
45369114|NCT04009590|Behavioral|Smoking Cessation Intervention|Utilize Quit4Health
45369115|NCT00961974|Behavioral|Care Ambassador Intervention|Care Ambassador provides additional monthly outreach (by phone or e-mail) to families between clinic visits.
45369116|NCT00961974|Behavioral|Psychoeducational Intervention|"A psychoeducational intervention module is reviewed with the family by the Care Ambassador at each clinic visit. The intervention focuses on incorporating intensive therapy into the daily routine of the child through positive family support for blood glucose monitoring and healthy eating. The intervention modules review positive family communication, realistic expectations, ways to avoid perfectionism and maintain family involvement, prevention of hypoglycemia, avoidance of diabetes-specific family conflict, and approaches to reducing diabetes burnout."
45369117|NCT00962130|Device|Continuous glucose monitoring system|one or two monitors will be placed in the tissue to be transferred
45369118|NCT00695903|Drug|daptomycin|daptomycin 10 mg/kg IV every 24 hours
45369119|NCT00695903|Drug|vancomycin|Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
45369120|NCT05112731|Diagnostic Test|BAFF and MGO|measurement of BAFF and MGO levels before reperfusion and after 3 months
45369121|NCT02793167|Device|AKI alert|
45487018|NCT01373034|Dietary Supplement|Soy Dietary Fiber|Soy Dietary Fiber, Once a day, before meal, 1 pack(20g), per oral with water 90mL
45487019|NCT01373034|Dietary Supplement|Rice powder|Rice powder, Once a day, before meal, 1 pack(20g), per oral with water 90mL
45487020|NCT03189316|Other|peritoneal fluid and blood sample|Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample or Peritoneal fluid obtained from coelioscopy for exploration of ovarian cysts and blood cell
45487021|NCT05631613|Procedure|cTACE(conventional transarterial chemoembolization)|transarterial chemoembolization with lipiodol-idarubicin emulsion
45487022|NCT03624608|Device|AuryzoN Family of Devices|The AuryzoN family of devices includes a longitudinal cartilage trimmer (DimensioN) and 2D shape carving machine with custom blades (AuryzoN).
45487023|NCT05007522|Drug|Ketotifen/Indomethacin|2 mg tablet, 75 mg SR tablet
45487024|NCT05007522|Drug|Placebo|Matching placebo tablet
45369122|NCT02759861|Drug|harvoni|8 or 12 weeks of harvoni therapy with monthly nursing visiting to monitor alcohol and adherence of harvoni therapy
45487025|NCT02430064|Other|Low PAMP diet|
45487026|NCT03716089|Procedure|Laparoscopic resection|Laparoscopic surgery under general anesthesia
45487027|NCT03692078|Other|OTDN product 1|Oral tobacco-derived nicotine product
45487028|NCT03692078|Other|OTDN product 2|Oral tobacco-derived nicotine product
45369123|NCT00548262|Drug|Anidulafungin|All patients will receive anidulafungin 200 mg IV dose on Day 1. On Day 2 and daily thereafter the patients will receive one daily IV dose of 100 mg of anidulafungin.
45487029|NCT03692078|Other|Tobacco Cessation|Tobacco Cessation
45487030|NCT03189160|Biological|PEG-rhGH low dose|PEG-rhGH Injection 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
45487031|NCT03189160|Biological|PEG-rhGH high dose|PEG-rhGH Injection 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
45487032|NCT03189160|Other|Non-treatment control group|
45487033|NCT03208530|Behavioral|Brief motivational interview intervention|A brief (<7minutes) interview by an emergency department clinician to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
45487034|NCT03695822|Drug|Mirabegron 25mg|The aim of this study is to elucidate the impact of mirabegron on psychological distress, bladder blood flow and c reactive protein.
45487035|NCT03718507|Drug|Fentanyl|atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes)
45487036|NCT03718507|Drug|Sucrose 24% Oral Solution|0.5 ml given orally 2 minutes before LISA procedure
45487037|NCT03700268|Other|Manual intervention to programme Cochlear Implant electrodes|The Clinician test the 22 electrodes so that the patient is able to hear the language
45487038|NCT03188692|Biological|DPT-IPV-Hib (Combined Vaccine)|0.5mL, intramuscular injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
45369124|NCT00548262|Drug|Voriconazole|Patients who complete a minimum of 5 days of IV treatment with anidulafungin may be switched to oral voriconazole 200 mg BID (or 100 mg BID if <40 kg body weight) therapy on Day 5 and thereafter, starting with a loading dose of 400 mg BID (or 200 mg BID if <40 kg body weight).
45369125|NCT00742547|Other|Telephone counseling|Telephone counseling is provided once a month by the medical secretary of the general practitioner's practices
45369126|NCT02757989|Other|transplantation|allogeneic hematopoietic stem cell transplantation in patients with donor
45369127|NCT02565173|Drug|trabodenoson 4.5% BID|Trabodenoson 4.5% administered twice per day in both eyes for 12 weeks.
45487039|NCT03716011|Device|EXCROSSAL|a Second Generation Biodegradable Polymer Sirolimus-Eluting Stent
45487040|NCT03695744|Drug|Daratumumab|Daratumumab
45487041|NCT03695744|Drug|Bortezomib|Bortezomib
45487042|NCT03695744|Drug|Dexamethasone|Dexamethasone
45487043|NCT04940832|Device|pulsed radiofrequency modulation|a percutaneous needle electrode to apply pulsed RF signals that modulate the activity of sensory nerves. The pulsing of the RF signal permits a maximum temperature to be achieved - usually 42 Celsius. This helps prevent collateral damage from occurring during the procedure and should help reduce procedural complications.
45487044|NCT02430610|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Uterine Cervical Neoplasms guide with ultrasound or/and CT.
45487045|NCT02430610|Device|NanoKnife|
45596368|NCT02288923|Drug|Intra-operative medication|If paracetamol has not been given pre-operatively, it will be given intraoperatively 1g IV. Where 2 or more of the following risk factors are present; female, non smoker, previous post operative nausea or vomiting, intra operative opiates, the patients will be given 4mg dexamethasone and or 4mg ondansetron IV. Vasopressor drugs may be given at the anaesthetist's discretion to maintain an appropriate blood pressure. Intraoperative fluid infusion is at the discretion of the anaesthetist. Antibiotic prophylaxis is as per the hospital protocol (currently 6mg/kg Teicoplanin IV and 3mg/kg gentamicin pre induction). Tranexamic acid will be given as per unit protocol, (currently 1g pre-operatively IV and 500mg orally at 8 hours post op. unless contraindicated by a high risk of thrombosis.)
45487046|NCT03714061|Other|Pain Neuroscience Education|"The PNE will be administered following Explaining Pain concepts, initially contextualizing the importance of the program, addressing concepts of neuroscience and pain, incorrect information about what is pain, how the brain responds to nociception in a variety of situations, and how an experience of danger can trigger or aggravate a state of pain, coexistence of several potential protection systems, central sensitization and how to promote behavioral change, abandoning incorrect beliefs, proposing graded activity exposure.~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks."
45487047|NCT03714061|Other|Self-Management Education|"Concepts about pain, musculoskeletal pain, chronic pain and disability will be addressed. Participants will be guided on the process of chronic pain, associated suffering, conceptual model of fear-avoidance and clarified on avoidant and confronting profiles. In a third phase, strategies will be presented on how to deal with chronic pain, with advice on the harmful effects of restricting activities and the use of drug therapy in a careful way (Dupeyron et al, 2011).~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises (reinforcement) and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks."
45596369|NCT02288923|Drug|Post-operative analgesia - morphine|Patients will all be given a morphine pump which will give 1mg every 5 minutes. This is to be discontinued after 48 hours and changed to oral morphine 10-20mg if weight 50-70kg, 20-30mg if weight >70kg 2 hourly.
45596370|NCT02288923|Drug|Post-operative analgesia - ibuprofen and paracetamol|All patients will be given 1g paracetamol 6 hourly and 400mg ibuprofen 8 hourly unless there are contraindications. If patients are on an alternative non-steroidal anti inflammatory drug then this may be substituted for ibuprofen.
45369128|NCT02565173|Drug|trabodenoson 6.0% QD|Trabodenoson 6.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
45369129|NCT02565173|Drug|trabodenoson 3.0% QD|Trabodenoson 3.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
45369130|NCT02565173|Drug|timolol 0.5% BID|Timolol 0.5% administered twice per day in both eyes for 12 weeks.
45369131|NCT02565173|Drug|placebo BID|Placebo administered twice per day in both eyes for 12 weeks.
45369132|NCT02730923|Drug|AZD2014|"Following inclusion, patients will be randomized (2:1) to receive Arm A : AZD2014 + anastrozole Arm B : anastrozole alone~Mode of Action Selective and specific mTOR kinase inhibitor targeting both mTORC1 and mTORC2 complexes.~Route of Administration Oral~Dosage regimen 125mg BID with intermittent schedule (2 days of treatment followed by 5 days off (500mg/week))~Duration of treatment Until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
45369133|NCT02730923|Drug|Anastrozole|"Therapeutic Class Aromatase inhibitor~Mode of Action Potent and highly selective non-steroidal aromatase inhibitor.~Route of Administration Oral~Dosage regimen~1 mg tablet once a day~Duration of treatment Patients may continue treatment with anastrozole until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
45369134|NCT04619082|Drug|Tenofovir alafenamide|Tenofovir alafenamide 25 mg once per day for one year
45369135|NCT02724683|Device|Ascites drainage with vascular catheter.|In case of symptomatic malignant ascites, the procedure of vascular catheter insertion into abdominal cavity will be performed, followed by slow, systematic drainage, on patient's demand.
45369136|NCT02724683|Behavioral|Interview.|Interview with patients will be performed according to attached chart. The aim is to collect data concerning patient's symptoms, co-morbidity, and basic clinical data about the primary malignancy and treatment status.
45369137|NCT02724683|Behavioral|Quality of life.|Quality of life questionnaire (QLQ). Patients will be asked to complete QLQ at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
45369138|NCT02724683|Device|Quality of procedure.|Patients will be asked to complete quality of procedure questionnaire at one time point: one or two weeks after the procedure.
45369139|NCT02724683|Other|Nutritional status|Risk of malnutrition and ability to feed normally will be assessed with specific questionnaire at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
45487048|NCT01373112|Procedure|Static Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
45487049|NCT01373112|Procedure|Articulating Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
45487050|NCT03695666|Other|Clerical policy|Clerical policy introduction
45487051|NCT03188848|Drug|BPI-3016|Single-dose subcutaneous injection of BPI-3016
45487052|NCT03188848|Drug|Placebo|Single-dose subcutaneous injection of placebo to match BPI-3016
45487053|NCT01311271|Device|repetitive transcranial magnetic stimulation (rTMS)|"1 Hz frequency, 15 minutes, intensity of 90% resting motor threshold, with one session a day,~Real: unaffected M1 hotspot~Sham: coil perpendicular to scalp"
45487054|NCT01374282|Drug|Cuprimine (penicillamine)|Dosage determined by the physician based on indication for treatment
45487055|NCT02429986|Device|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation proceeds by continually measuring either minute ventilation or airflow and calculates a target ventilation to be applied as needed.
45369140|NCT04593342|Device|B-Cure Pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
45487056|NCT03691922|Procedure|Erector Spinae Plane (ESP) Block|"Preoperative US guided ESP blockade using 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine, injected in 5-mL aliquots through the needle (maximum of 3 mg/kg)~PAI of 30 mL of saline at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle"
45691785|NCT00686842|Genetic|protein expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
45691786|NCT00686842|Other|immunohistochemistry staining method|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
45691787|NCT00686842|Other|laboratory biomarker analysis|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
45691788|NCT00686842|Other|pharmacological study|To describe the pharmacokinetics of PTC299 in patients with HIV-associated KS. To describe the effects of PTC299 on circulating VEGF, VEGFR and cytokine levels in patients with HIV-associated KS.
45369141|NCT04593342|Device|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
45369142|NCT02717897|Other|No intervention|This study is not interventional
45369143|NCT04060667|Combination Product|Wireless physiologic monitoring|The intervention in this study is the use of a wireless monitor to perform physiologic monitoring of women undergoing emergency cesarean delivery for the first 24 hours after completion of the cesarean and send alerts to responding clinicians should vital signs fall out of a pre-specified range.
45369144|NCT03717623|Drug|Posaconazole pharmacokinetics|Blood samples will be collected on Days 7, 14 and 21 from the onset of Posaconazole prophylactic treatment If significant diarrhoea occurs, additional blood samples will be collected twice weekly until symptoms resolve. All blood samples will be used for Posaconazole pharmacokinetics study.
45369145|NCT00742703|Other|Mineralized water|
45369146|NCT00742703|Other|Low mineralized water|
45369147|NCT00095173|Drug|Abatacept|IV infusions, IV, 10mg/kg body weight, every 4 weeks, 6 months (unless a disease flare discontinued the patient earlier).
45369148|NCT00095173|Drug|Placebo|IV infusions, IV, N/A, every 4 weeks, 6 months.
45369149|NCT00095173|Drug|Abatacept|Solution, intravenous, Approximately 10 mg/kg fixed dose, based on subject's body weight; 500 mg for subjects weighing < 60kg; 750 mg for subjects weighing 60 to 100 kg; and 1 gram for subjects weighing > 100 kg, monthly
45369150|NCT03704753|Drug|Ropivacaine|Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients
45691789|NCT00686842|Procedure|biopsy|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
45691790|NCT00687076|Drug|Ezetimibe|Daily dose of 10 mg of Ezetimibe
45691791|NCT00687076|Drug|Niaspan|Daily dose of 1500 mg of Niaspan
45691792|NCT00687076|Drug|Statin therapy|Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)
45691793|NCT00687076|Behavioral|Standard care|Standard of medical care for PAD
45369151|NCT03704753|Drug|Sodium chloride 0.9%|Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients (placebo).
45487057|NCT03691922|Procedure|Periarticular Infiltration (PAI)|"Preoperative US guided ESP blockade using 30 mL of saline, injected in 5-mL aliquots through the needle~PAI of 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle"
45487058|NCT03453151|Drug|splanchnic nerve anesthesia with a local anesthetic|regional nerve block with a local anesthetic (Lidocaine/Bupivacaine)
45487059|NCT03433248|Drug|EMPA/LINA 10/5 mg QD (n=22)|Once daily treatment with oral empagliflozin (Jardiance) 10 mg Once daily treatment with oral linagliptin (Tradjenta) 5 mg
45487060|NCT03433248|Drug|LINA/EMPA 5/10 mg QD (N=22)|Once daily treatment with oral linagliptin (Tradjenta) 5 mg Once daily treatment with oral empagliflozin (Jardiance) 10 mg
45487061|NCT03433248|Drug|Gliclazide 30 mg QD/BID (N=22)|Once daily or twice daily treatment with oral glicazide MR 30mg
45487062|NCT02430142|Other|Vasoocclusive testing|Forearm vasoocclusive testing with a laser-doppler spectrophotometry system, transpulmonary thermodilution and blood sampling;
45487063|NCT03691766|Other|Photobiomodulation Therapy|Photobiomodulation therapy, a mix of red lights thought to improve mitochondrial function will be applied in and acute and chronic manner to test whether muscle fatigue improves in persons with MS.
45487064|NCT03691766|Other|Placebo|Device with sham light source
45487065|NCT03691688|Drug|Aspirin 100 mg|Aspirin 100mg will be prescribed for antiplatelet therapy at the physician's discretion
45487066|NCT03691688|Drug|Clopidogrel 75mg|Clopidogrel will be prescribed for antiplatelet therapy in case of aspirin intolerance at the physician's discretion
45487067|NCT02887248|Drug|nab-paclitaxel|"Induction: 125 mg/m² by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles to be given with Gemcitabine.~Maintenance: single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment."
45487068|NCT02887248|Drug|Gemcitabine|Induction: 1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles.
45691794|NCT00687076|Drug|Aspirin|Daily dose of 325 mg of aspirin
45487069|NCT03619304|Dietary Supplement|coffee|coffee beverage
45487070|NCT02425462|Drug|Dienogest (Visanne, BAY86-5258)|Dienogest 2mg daily Oral dose
45487071|NCT03700112|Other|JUUL Virginia Tobacco flavored 5.0% ENDS|Virginia Tobacco Flavored 5.0% ENDS product is administered using a controlled method and adlibitum
45487072|NCT03700112|Other|PMI iQOS Heat sticks|PMI IQOS Heat sticks is administered using a controlled method and ad-libitum
45487073|NCT03700112|Other|Reynolds VUSE Solo ENDS - Original|Reynolds VUSE solo ENDS - Original is administered using a controlled method and ad-libitum
45487074|NCT03700112|Other|Imperial MyBlu ENDS - Original|Imperial MyBlu ENDS- original is administered using a controlled method and ad-libitum
45487075|NCT03700112|Other|Altria MarkTen ENDS - Bold Classic|Altria MarkTen ENDS - Bold Classic is administered using a controlled method and ad-libitum
45487076|NCT03700112|Other|MLV PHIX ENDS - Original Tobacco|MLV PHIX ENDS - Original Tobacco is administered using a controlled method and ad-libitum
45487077|NCT03700112|Other|NJOY Daily EXTRA ENDS - Rich Tobacco|NJOY Daily EXTRA ENDS - Rich Tobacco is administered using a controlled method and ad-libitum
45487078|NCT03700112|Other|Altria Marlboro combustible cigarette - Red|Altria Marlboro combustible cigarette - Red is administered using a controlled method and ad-libitum
45487079|NCT04482868|Procedure|Percutaneous screw fixation through K-wire-assisted reduction and maintenance|Percutaneous screw fixation for acute scaphoid fractures through K-wire-assisted reduction and maintenance
45691795|NCT00687076|Drug|Clopidogrel|Daily dose of 75 mg of clopidogrel for 3 months or as recommended by the primary care physician
45487080|NCT03307824|Device|Synthetic glue IfabondTM|Use of the synthetic glue IfabondTM
45487081|NCT03307824|Procedure|Glue-Free Suture Technique|Suture Technique
45487082|NCT03452527|Biological|ICON-1|ICON-1 0.6 mg by intravitreal injection
45487083|NCT03452527|Biological|aflibercept|aflibercept 2 mg by intravitreal injection
45487084|NCT02429908|Device|TM-Ardis Interbody|The TM Ardis implant is a single device manufactured wholly from Trabecular Metal™ (porous tantalum) material, a highly porous, three-dimensional biomaterial designed for biologic fixation. is indicated for use with autogenous bone graft as an intervertebral body fusion device at one or two contiguous levels in the lumbosacral region (L2- S1) in the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s).
45487085|NCT03226470|Biological|T512|T512 suppository contain 500 µg of T512 and suppocire.
45487086|NCT04878510|Drug|Dexmedetomidine|Dexmedetomidine is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and when compared to γ-aminobutyric acid receptor agonists like benzodiazepines, reduces delirium.
45487087|NCT04878510|Other|Placebo|Normal saline placebo will be given as continuous infusion.
45369152|NCT02565017|Behavioral|Focus groups|After the presentation of the of IBM Watson Oncology at the opening of the focus group, participants will be asked to fill out a de-identified brief 15-item questionnaire to assess participants' first impressions of IBM Watson Oncology. The questionnaire will be self administered, and will take approximately 5 minutes to complete. Completed questionnaires will be collected by a member of the study staff, and the focus group will proceed with introductions. The focus group will be audio recorded from the completion of the introductions and notes will be taken. The focus group guide will address the study aims. At the end of the focus group, participants will complete a 7-item questionnaire to capture simple demographic information including education, income, and health literacy. This questionnaire will take 3-5 minutes to complete.
45487088|NCT03188926|Procedure|intramedullary fixation or endoprosthetic reconstruction|Surgical treatment of impending or pathologic fracture in the extremities
45369153|NCT01079689|Other|needle stimulation|stimulation with acupuncture needles
45487089|NCT03718351|Procedure|transanal endoscopic microsurgery|a TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
45487090|NCT03718351|Procedure|endoscopic submucosal dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
45487091|NCT03713827|Device|tooth restoration|restoration of non carious cervical lesions with two different restorative materials
45487092|NCT02429674|Behavioral|TranS-C and IPT-A|The goal of IPT-A is to decrease depressive symptoms by focusing on current interpersonal difficulties and helping the adolescent improve his or her relationships and interpersonal interactions. This is accomplished through psychoeducation about the adolescent's depression and its link to interpersonal relationships, review of the adolescent's significant relationships, identification of interpersonal problem areas on which to focus the treatment, development of interpersonal problem solving and communication skills, and role-playing. The sleep disturbances intervention will include several modules selected because they are successful treatments for insomnia, and/or may help promote adherence to some of the recommendations related to sleep.
45369154|NCT00690443|Drug|Atorvastatin|atorvastatin 20 mg tablets, daily dosing, for 8 weeks.
45487093|NCT03028142|Drug|1.5 mg RPL554 plus tiotropium|
45487094|NCT03028142|Drug|6 mg RPL554 plus tiotropium|
45487095|NCT03028142|Drug|Placebo plus tiotropium|
45487096|NCT03188614|Drug|Fluid resuscitation|The placebo group is resuscitated with normal saline, the experimental group is resuscitated with balanced fluid.
45691796|NCT00687076|Drug|Placebo Niaspan|Daily dose of 1500 mg of placebo Niaspan
45691797|NCT00687076|Drug|Placebo Ezetimibe|Daily dose of 10 mg of placebo Ezetimibe
45369155|NCT00690443|Drug|AEGR-733|2.5 mg AEGR-733 capsules, daily dosing, 4 weeks followed by 5 mg AEGR-733 capsules, daily dosing, 4 weeks
45369156|NCT03954834|Drug|Tirzepatide|Administered SC
45369157|NCT03954834|Drug|Placebo|Administered SC
45369158|NCT02630615|Other|Blood draw|Whole blood will be collected using standard phlebotomy procedures
45487097|NCT02866812|Other|questionnaires assessing the state of fatigue, depression and anxiety|
45487098|NCT03713749|Device|Robot esophagectomy (RE)|Patients in RE group will receive Robotic-assisted surgery in thoracic phase.
45487099|NCT03182842|Device|FreeStyle Libre FGM|Insulin dosing based on FreeStyle Libre FGM system that is indicated for measuring interstitial fluid glucose levels in people (age 4 and older) with diabetes mellitus.
45487100|NCT03182842|Device|SMBG - Blinded Sensor|Insulin dosing based on SMBG
45487101|NCT02800824|Drug|Budesonide|
45487102|NCT02800824|Drug|Uceris|
45487103|NCT03695588|Procedure|Quadratus lumborum block|Ultrasound guided Quadratus Lumborum block using a posterior approach. (QLB 2)
46052596|NCT03896334|Behavioral|Sham comparator - stretching and relaxation exercises|The participants randomized to the control group (active comparator) will perform 24 weeks of stretching and relaxation exercise training, three times/week for 16 minutes with time to rest.
46052597|NCT00830128|Drug|pregabalin (Lyrica)|Dosage: 300-450 mg/day (150-225 mg twice daily), oral administration, Treatment duration: 52 weeks
46052598|NCT03906357|Drug|Pemigatinib|
46052599|NCT04034550|Other|Blood and urine sampling and blood banking|In routine management, blood and urine will be sampled for each patients and specific analyses carried out. Only blood samples will be banked.
45487104|NCT03695588|Procedure|Sham QLB|Sham QLB - Ultrasound identification of QLB followed by skin pressure with blunt needle.
45487105|NCT04806360|Procedure|ACRF surgery|A new surgical procedure that previously proposed by our team.
45487106|NCT04806360|Procedure|conventional anterior surgery|Anterior cervical discectomy and fusion surgery or anterior cervical corpectomy and fusion surgery.
45487107|NCT04806360|Procedure|conventional posterior surgery|Laminectomy and fusion surgery or laminoplasty surgery.
45487108|NCT02429752|Other|Inspiratory muscle training|Subjects that demonstrate unresolved BPD's upon reassessment after PT treatment, will have the option to participate in the second phase of the study. These subjects will be scheduled twice a week to receive IMT using the RT2 device and software program. The IMT protocol uses biofeedback to train at a specific percentage of MIP and SMIP for each inspiratory effort.
45487109|NCT03713359|Biological|Trial arm (MRVAC)|Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
45487110|NCT03713359|Biological|Control arm|Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
45487111|NCT03695432|Biological|Flubio|Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly
45487112|NCT03695432|Dietary Supplement|Lacidofil|Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic The antibiotic will be given 2 times each day for 6 months
45487113|NCT03695432|Other|Placebo Vaccine|Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly
45487114|NCT03695432|Other|Placebo probiotic|Capsul
45487115|NCT03715777|Drug|Clostridium botulinum type A (BoNTA)|"Powder and solution for solution for injection Specify total dose: 80 U~Route of administration:"
45487116|NCT03695354|Device|whole body vibration plus conventional therapy|"Subjects enrolled in whole body vibration training group are exposed to side-to-side alternating vertical sinusoidal vibration. Galileo system(Novotec Medical GmbH, Pforzheim, Germany) is used to training. Frequency of whole body vibration is 12Hz and amplitude is 4mm. After 10 minutes of vibration training, subjects rest 3 minutes. Then, additional 10 minutes of training will be given.~conventional physical therapy is consisted of passive range of motion exercise and walking exercise."
45487117|NCT03695354|Procedure|conventional therapy|conventional physical therapy is consisted of passive range of motion exercise and walking exercise.
45487118|NCT03715699|Drug|Prednisone|Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 7.5mg to 10mg/d to 12 months.
45487119|NCT03715699|Drug|Prednisone and Leflunomide|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Leflunomide: 20mg qd for 6 months and 10mg qd for 6 months."
45487120|NCT02708524|Device|Senofilcon C Contact Lens|
45487121|NCT02708524|Device|Comfilcon A Contact Lens|
45487122|NCT02708524|Device|Lotrafilcon B Contact Lens|
45487123|NCT02708524|Device|Samfilcon A Contact Lens|
45487124|NCT03699800|Other|Graphomotor intervention program|The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
45487125|NCT04776408|Device|Lung recruitment combined inhaled Nitric oxide|Ventilator combined inhaled Nitric oxide and Electrical Impedance Tomography monitor the V/Q mismatch
45691798|NCT00687076|Procedure|Percutaneous transluminal angioplasty (PTA)|Participants who have not had an endovascular intervention in the 3 months before study entry will undergo PTA to mechanically open the artery blockages. This procedure will involve the inflation and deflation of a small balloon to open the blocked artery. Additionally, participants may have a metal mesh tube called a stent placed in the blocked area if deemed necessary by their physicians.
45691799|NCT00687544|Biological|Peginterferon alfa-2b (SCH 054031)|Subjects will be given peginterferon alfa-2b (PEG-IFN) subcutaneously, at a dose of 1.5 ug/kg weekly. Treatment duration will be 48 weeks for subjects with Hepatitis C Virus (HCV) genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline Hepatitis C Virus-ribonucleic acid (HCV-RNA) below 800,000 IU/mL.
45487126|NCT04776408|Device|Lung recruitment|Ventilator and Electrical Impedance Tomography monitor the V/Q mismatch
45487127|NCT03695198|Drug|LY3361237 - SC|LY3361237 administered SC
45487128|NCT03695198|Drug|LY3361237 - IV|LY3361237 administered IV
45487129|NCT03695198|Drug|Placebo - SC|Placebo administered SC
45487130|NCT03695198|Drug|Placebo - IV|Placebo administered IV
45487131|NCT02773524|Drug|Regorafenib|Regorafenib is the experimental intervention in this study. Regorafenib will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
46052600|NCT05580120|Behavioral|Online-supervised exercise group|Participants in the online-supervised exercise group were provided with an online-supervised exercise program by using the video conferencing method three times a week for 6 weeks on the Zoom application. The exercise program was carried out synchronously
45487132|NCT02773524|Other|Placebo|Placebo (matching in appearance to regorafenib) made of microcrystalline cellulose, will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
45487133|NCT02429596|Drug|Experimental|Switch from brand to generic
45487134|NCT03418675|Drug|Rexulti|Atypical antipsychotic
45487135|NCT03418675|Drug|Placebo|Pill that contains no medicine
45487136|NCT03695120|Other|Change of treatment plan|Withholding ACEI/ARBs during initial 72 hours of admission with acute decompensated heart failure may help preserve renal function with a lesser decline in GFR. This treatment modification will also allow the option of aggressive diuresis in volume overloaded CHF patients which should result in a lesser decline of AKI, length of stay, readmission rates, and cost associated with CHF treatment.
45487137|NCT03694964|Drug|ProteoCIT®|30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
45691800|NCT00687544|Drug|Ribavirin (SCH 018908)|Subjects will be given ribavirin 800 mg/day orally(PO) when body weight is <65 kg, 1000 mg/day when body weight is between 65 kg and 85 kg, and 1200 mg/day when body weight is >85 kg. Treatment duration will be 48 weeks for subjects with HCV genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline HCV-RNA below 800,000 IU/mL.
45691801|NCT02998060|Procedure|Pedicle Screw Placement|As a part of the lumbar spinal fusion procedure, posterior pedicle screws will be placed.
45487138|NCT03694964|Drug|Placebo Oral Tablet|30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
45487139|NCT02421406|Behavioral|Internet Behavioral Intervention|A series of 12 multi-media lessons will be accessible to participants on their own computers. The lessons (each of which takes about 15 minutes to complete) are based on the Diabetes Prevention Program (DPP) and Look AHEAD. Participants will be taught to record their weight, the calories and the fat grams in each food item, and their physical activity (in minutes) on a daily basis. At the end of the week, they will submit their self-monitored information to the study website and receive an automated feedback message about their progress to date. The lessons will also present key behavior change strategies such as cognitive restructuring, problem solving and relapse prevention.
45691802|NCT02998060|Device|SpineAssist®/Renaissance® (Mazor Robotics Ltd. Caesarea, Israel)|This robot will be used to guide pedicle screws into their trajectories.
45691803|NCT02998060|Device|3D C-Arm (Ziehm Imaging, Nuremberg, Germany)|This 3D Fluoroscope will be used to navigate pedicle screws into their trajectories.
45846477|NCT05247996|Procedure|Systemic Intravenous Chemotherapy|GEMOX regimen (gemcitabine 1000mg/m2, oxaliplatin 100mg/m2) is given for systemic intravenous chemotherapy after the exclusion of contraindications for chemotherapy, and the presence of active lesions is assessed by laboratory and imaging examinations after every two courses of treatment. If active lesions remain, repeated systemic intravenous chemotherapy may be performed. The frequency of chemotherapy is determined by the investigator and is given according to the needs of the patient, usually 6 times with an interval of 21-28 days.
46052601|NCT05580120|Behavioral|Unsupervised-exercise training group|The unsupervised-exercise training group was informed about how to do the same exercises by another researcher, a nurse academician, on the online platform by using the lecturing method. Each training intervention took approximately 30 minutes.
46052602|NCT05498103|Drug|Methazolamide 25 MG|25 mg tablets
46052603|NCT05498103|Drug|Methazolamide 50 MG|50 mg tablets
46052604|NCT04011852|Device|Electrical Impedance tomography|Monitoring with Electrical impedance tomography during spontaneous breathing trials on T-piece in children
45487140|NCT02421406|Behavioral|Internet Education Intervention|A series of 12 lessons will be accessible to participants on their own computers. Participants will be given information about normal, overweight and obese categories of body mass index, and provided information on the health problems that are associated with being overweight and the benefits of weight loss for treating and preventing such problems. General information about healthy eating will be provided. Participants will be educated about the benefits of increasing their physical activity, and strategies for increasing activity safely.
45487141|NCT02653092|Drug|Insulin|
45487142|NCT02653092|Drug|Intralipid|
45369159|NCT00693017|Drug|Zonisamide|"50-400 mg capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
45487143|NCT02653092|Drug|Dextrose|
45487144|NCT02653092|Drug|Heparin|
45487145|NCT02653092|Drug|GnRH|
45487146|NCT02653092|Procedure|Hyperinsulinemic Euglycemic Clamp|
45487147|NCT03691454|Drug|Docetaxel|Docetaxel 50mg/m2, intravenous drip, D1, combined with Oxaliplatin 85mg/m2，intravenous drip 2h，D1 and S-1 40-60mg bid(BSA<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid)，D1-7；For patients with Her2 positive, add Herceptin 4mg/kg(6mg/kg first cycle) D1; every 14 days for a cycle.
45487148|NCT03691454|Drug|Oxaliplatin|Oxaliplatin 130mg/m2，intravenous drip 2h，D1 combined with S-1 40-60mg bid(BSA<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid)，D1-14；For patients with Her2 positive, add Herceptin 6mg/kg(8mg/kg first cycle) D1; every 21 days for a cycle.
45487149|NCT02421484|Biological|Allogeneic mesenchymal stromal cells|The allogeneic mesenchymal stromal cells will be administered intravenously.
45487150|NCT02736318|Biological|OD-PHOENIX|Decellularized, freeze-dried, irradiated osteochondral allograft
45487151|NCT03182764|Other|No intervention|No intervention
45369160|NCT00693017|Drug|Placebo|"50-400 mg Zonisamide Placebo capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg Zonisamide Placebo daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg Zonisamide Placebo (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
45369161|NCT05299554|Drug|Chronocort|Hydrocortisone modified-release capsule 5 mg and 10 mg
45487152|NCT03691142|Other|Questionnaire|Interview of women with Hereditary Haemorrhagic Telangiectasia (HHT) during a consultation in the Reference Center for HHT or through a phone questionnaire about obstetric history, complications during pregnancy, delivery and neonatal outcomes.
45487153|NCT03699722|Behavioral|Education + Activities|Format:Video; discussion; information handouts; facilitated referral
45487154|NCT03699722|Behavioral|Information|Format: Information handouts
45487155|NCT02425228|Device|Targeted biopsy|conventional/systematic biopsy, targeted fusion biopsy and cognitive biopsy
45369162|NCT03965065|Device|Sutureless aortic bioprosthesis|Patients will receive a sutureless aortic bioprosthesis
45487156|NCT03715543|Procedure|Surgical Resection of the Greater Splanchnic Nerve|"Video-Assisted Thoracoscopic Surgery (VATS) is performed under general anesthesia using existing, CE marked instrumentation. Two or more 5 mm incisions are used to pass a tiny video camera and a single dissecting instrument into the chest. These small ports are advantageous because the chance for infection and wound dehiscence are drastically reduced. This allows for a faster recovery by the patient and a greater chance for the wound to heal.~In the procedure the GSN will be identified visually or through stimulation-induced hemodynamic reflex. The GSN will then be ablated using standard techniques. If there are multiple branches of the GSN, each branch will be systematically identified and ablated."
46052605|NCT00841906|Device|Alice PDx with only written instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
45369163|NCT03965065|Device|Conventional stented sutured aortic prosthesis|Patients will receive a stented sutured aortic prosthesis
45487157|NCT03690908|Other|no intervention (descriptive study)|no intervention (descriptive study)
45487158|NCT03718273|Drug|Ivabradine|"Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.~Patients with 75 or more years of age will receive an initial dose of 2.5 mg / twice a day, which can be increased to 5 mg / twice a day in week 7 and to 7.5 mg in month 1 if the tolerance has been good"
45487159|NCT03718273|Drug|Digoxin|The initial dose will be based on whether there are factors such as age over 80 years, weight less than 60 kg and creatinine clearance <60ml / min, if there is no factor, the oral dose will be 0.25mg / 24h. If there are 2 factors, the dose will be 0.15 mg / 24 h. and if there are 2 or 3 factors, the dose will be 0.10 mg / 24 h.
45487160|NCT03690830|Other|metabolomics analysis|collect blood samples and endometrial cells
45487161|NCT02421640|Drug|Cisplatin+TIL|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy,then TIL infusing following concurrent chemoradiotherapy
45487162|NCT02421640|Drug|Cisplatin|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy only
45487163|NCT01311193|Other|light therapy|early morning exposures to bright light, 8000lux for 40min, daily during 3 weeks
45487164|NCT03417505|Device|Scleral lenses treated with Tangible Hydra-PEG|Scleral lenses treated with Tangible Hydra-PEG, a hydrophilic, PEG-based contact lens coating designed to improve lens wettability, deposit resistance, and tear film breakup time.
45487165|NCT03417505|Device|Untreated scleral lenses|Scleral lenses without the Tangible Hydra-PEG treatment will serve as a control.
45487166|NCT02421562|Procedure|training in hypnoanalgesia|training nurses in hypnoanalgesia techniques to perform painful procedures in children followed in the outpatient hematology oncology clinic
45487167|NCT02421328|Device|CPAP first (Fisher & Paykel Healthcare)|Infants will start on nasal CPAP for 60 minutes and then switched to HHHFNC for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
45487168|NCT02421328|Device|HHHFNC first (Fisher & Paykel Healthcare)|Infants will start on HHHFNC for 60 minutes and then switched to nasal CPAP for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
45487169|NCT02425150|Procedure|Corneal reshaping/crosslinking (CRXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. A flat, rigid contact lens is sutured to the cornea and the cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
45487170|NCT02425150|Procedure|Corneal Crosslinking (CXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. The cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
45487171|NCT03715387|Drug|Tacrolimus Topical 0.1% Topical Ointment|Topical tacrolimus ointment
45487172|NCT03715387|Drug|Polysporin Ointment|Polysporin ointment
45487173|NCT02425072|Device|NovoTTF-100A plus chemotherapy|NovoTTF-100A System with Physician's Choice Chemotherapy
45487174|NCT03715309|Drug|Revlimid|Revlimid 25mg PO d1-10 Plus Rituximab 375 mg/m2 IV d0
45487175|NCT02424994|Other|No intervention|
45487176|NCT02429206|Other|SQIN|Each patient will be asked to self-apply both creams (experimental vs positive control) on the right and left sides of their body (sides will be randomly assigned).
45487177|NCT02429206|Other|standard moisturizing cream (Glaxal Base)|
45487178|NCT03182608|Diagnostic Test|Noninvasive ultrasound assessment|An investigator evaluate the L4-5 interspinous level using anatomic landmarks in turn, then another independent investigator assess the consistency of the landmarks-guided interspinous level with the actual one by noninvasive ultrasound assessment.
45487179|NCT03182530|Device|ulnar artery compression device|a radial compression device will be applied at the access site. another closure device will be used for ipsilateral ulnar artery compression for 1-hour duration in order to increase peak velocity blood flow into the radi¬al artery. neither pulse oxymetry nor duplex ultrasonography will be performed in case of ulnar artery compression. after ulnar artery compression, the initial compression of the radial artery will be reduced by letting up the pressure until bleeding will be seen and then adding minimal pressure whenever needed in order to maintain radial artery patency.
46052606|NCT00841906|Device|Alice PDx with written and verbal instructions|Participants will be provided instruction by a trained sleep professional on the set up of the Alice PDx device. They will then be asked to follow the instructions for the Alice PDx device, if necessary, and undergo a sleep study in their home. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
45487180|NCT03182530|Device|radial artery compression device guided with plysthmography|a radial compression device will be applied at the access site. A pulse oximeter sensor was placed over the index finger. Transient ipsilateral ulnar artery will be occluded manually to evaluate the status of radial artery patency by plethysmography (digital pulse analysis), and if there's lack of signal, the process of deflation and reinflation of the radial artery device's bladder will be repeated over the next 15 min to attempt re-establishment of antegrade radial artery flow without affecting hemostasis
45487181|NCT03182530|Device|radial artery compression device|patients undergo the conventional hemostasis compression by using a radial compression device applied at the access site.
46052607|NCT05557227|Other|1-hour cycling|60 % VO2 max
46052608|NCT00771667|Drug|Placebo (IP)|Induction phase (Week 0-8) (IP) - Placebo IV group
45487182|NCT03179254|Drug|Metformin continue|Oral hypoglycemic agent continue on the day of ambulatory surgery
45487183|NCT03179254|Drug|Metformin discontinue|Oral hypoglycemic agent discontinue on the day of ambulatory surgery
45487184|NCT02953639|Drug|Basmisanil|Participants received either 80 milligrams (mg) or 240 mg of Basmisanil, as per the dosing schedules described above.
45487185|NCT02953639|Drug|Placebo|Participants received matching Placebo to Basmisanil, as per the dosing schedules described above.
45487186|NCT04147715|Drug|S-648414|Tablet for oral administration
45487187|NCT04147715|Drug|Placebo|Tablet for oral administration
45487188|NCT04147715|Drug|Midazolam|Solution for oral administration
45487189|NCT04147715|Drug|Dolutegravir|Tablet for oral administration
46052609|NCT00771667|Drug|Ustekinumab 1mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 1 mg/kg IV group
46052610|NCT00771667|Drug|Ustekinumab 3 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group
46052611|NCT00771667|Drug|Ustekinumab 6 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group
45487190|NCT02420938|Drug|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course.
45487191|NCT02420938|Drug|Urelumab|8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the 12-week course.
45487192|NCT02429440|Biological|peptide vaccine|subcutaneous
45487193|NCT02429440|Drug|Granulocyte Macrophage Colony Stimulating Factor|intradermal
45487194|NCT02429440|Drug|Montanide ISA-51|subcutaneous
45487195|NCT03182452|Other|Alarm Advisor|Providing advice on alarm limits as part of routine medical care
45487196|NCT02429518|Drug|Miltefosine|
45487197|NCT00708526|Other|standard of care for phase one anesthesia care|Patients received intravenous fentanyl at the discretion of the attending anesthesiologist. Anesthesia was induced with a remifentanil infusion, lidocaine, propofol, and rocuronium or succinylcholine at the anesthesiologist's discretion. Maintenance anesthesia was 6% end tidal desflurane with oxygen flows of 2 L/min (though clinicians could deviate from this at their discretion). Clinicians were directed to maintain blood pressure at ±20% of baseline. A baseline remifentanil infusion was used throughout each case, and both remifentanil and fentanyl were titrated at the anesthesiologist's discretion. Ventilation was adjusted to maintain an end tidal carbon dioxide concentration (EtCO2) of 35 mmHg. Ondansetron 4 mg was given prophylactically before the end of surgery.
45487198|NCT00708526|Device|Quick Emergence Device|The Quick Emergence Device is placed between the endotracheal tube and the anesthesia breathing circuit to enable hypercapnia when ventilation is increased. The end-tidal gas sampling line is connected between the device and the endotracheal tube connector. Minute ventilation is doubled and the EtCO2 is elevated to approximately 48 mmHg from the previous maintenance level of 35 mmHg.
45487199|NCT03712735|Drug|Bupivacaine 0.08% - fentanyl 2mcg|In each arm, bupivacaine and fentanyl are being delivered at different intervals and rates for the maintenance of labor analgesia.
45487200|NCT02428816|Other|MRI acquisition|MRI acquisitions
45487201|NCT02428816|Behavioral|behavioral evaluations|Evaluations about motor abilities, sleep, cognition and lifestyle
45487202|NCT03718195|Other|Pediatric Formula|One week intake diary, one week tolerance diary, product intake
45487203|NCT03182218|Drug|Direct oral anticoagulant|Time of direct oral anticoagulant withdrawal Use or not of bridging with low molecular weight heparin
45487204|NCT02452554|Other|Laboratory Biomarker Analysis|Correlative studies
45487205|NCT02452554|Biological|Lorvotuzumab Mertansine|Given IV
45487206|NCT02452554|Other|Pharmacological Study|Correlative studies
45487207|NCT03182296|Radiation|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
45487208|NCT03712501|Behavioral|Exercise|A 60 minute walk at 60% maximal oxygen uptake.
45487209|NCT03182374|Device|nSTRIDE APS|Intra-articular injection
45487210|NCT03182374|Device|Synvisc-One|Intra-articular injection
45487211|NCT01319682|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
46052612|NCT00771667|Drug|Placebo IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
45487212|NCT01319682|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
45487213|NCT03715075|Procedure|Caesarean Section|Caesarean Section
45487214|NCT03182062|Procedure|Alveolar recruitment maneuver|To start the Alveolar Recruitment Maneuver (ARM) the ventilatory mode will be changed to pressure-controlled mode (PCV) with 20 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 5 cmH2O. The PEEP level will be increased in 5 cmH2O steps every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (20 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
45487215|NCT03182062|Procedure|PEEP Titration Trial|The ventilation mode will then switch back to volume controlled ventilation with the same baseline settings but with 20 cmH2O PEEP level. Then PEEP will be reduced in 2 cmH2O steps each maintained for 5 breaths the level of PEEP with the best (higher) dynamic compliance.
45487216|NCT03182062|Procedure|Lung protective ventilation|Ventilatory strategy with a PEEP level of 5 cmH2O but without recruitment maneuvers and PEEP titration trial.
46052613|NCT00771667|Drug|Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 270 mg SC at Week 8 and 90 mg at Week 16
46052614|NCT00771667|Drug|Ustekinumab IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
45369164|NCT00692237|Drug|Sildenafil|100 mg daily (3 capsules/day)
45369165|NCT00692237|Drug|Placebo|Placebo 100 mg (3 capsules/day)
45369166|NCT00110149|Biological|rituximab|
45369167|NCT00110149|Radiation|yttrium Y 90 ibritumomab tiuxetan|
45369168|NCT03890081|Other|Questionnaire|Translate and culturally adapt the original English version of the Coping Strategies Questionnaire into Turkish
45369169|NCT03964285|Other|rumination induction|The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. For example, they will be led, in the rumination condition, to reflect on the causes, meanings and consequences of the amount of tension they feel in their muscles.
45369170|NCT03964285|Other|distraction induction|The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. In the distraction condition they will, for example, imagine a ship crossing the Atlantic.
45487217|NCT02424916|Biological|Melanoma antigens-specific CD8+ T lymphocytes|The intervention uses an autologous somatic cell therapy medicinal product. It consists in the intravenous injection of melanoma antigens (Melan-A and MELOE-1) - specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
45487218|NCT04009577|Drug|LEM 5 mg|LEM tablet.
45487219|NCT04009577|Drug|LEM 10 mg|LEM tablet.
45487220|NCT03714841|Other|CRP|Knowledge of CRP value
45487221|NCT02176668|Drug|YH4808 NF 100|The number of times : multiple-dose Rout : oral administration
45487222|NCT02176668|Drug|YH4808 OF 200|The number of times : multiple-dose Rout : oral administration
45487223|NCT02176668|Drug|YH4808 NF 200|The number of times : multiple-dose Rout : oral administration
46052615|NCT00771667|Drug|Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
46052616|NCT00771667|Drug|Ustekinumab IV - Nonresponder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Placebo SC at Week 8 and Week 16
45487224|NCT02176668|Drug|YH4808 NF 400|The number of times : multiple-dose Rout : oral administration
45487225|NCT02424838|Procedure|EUS-FNA of pancreatic masses|EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.
45487226|NCT02424838|Device|22 gauge needle|
45487227|NCT02424838|Device|25 gauge needle|
45487228|NCT03714763|Drug|Drug treatment|Subjects who show high expression of dopamine D2 receptors in PET-MR imaging will be treated with Cabergoline(CAB) tablets 2mg/week or bromocriptine(BC) tablets 7.5mg/ day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The medication will be stopped if failure to decrease tumor size and the subjects will be advised to surgical therapy.
45487229|NCT03714763|Other|Surgery|Subjects who show low expression of dopamine D2 receptors in PET-MR imaging will be treated with endoscopic transphenoidal pituitary surgery .
45487230|NCT04640532|Drug|KRT-232|KRT-232, administered by mouth
45487231|NCT04640532|Drug|TL-895|TL-895, administered by mouth
45487232|NCT03712423|Drug|Cripec Docetaxel|89 Zirconium Cripec Docetaxel PET
45487233|NCT02424760|Device|Shoulder hemi-arthroplasty|
45691804|NCT00687856|Procedure|Echocardiogram (echo)|Participants will undergo a series of echoes to determine if they are eligible to be weaned from LVAD support. Each echo exam will involve the use of an ultrasound probe on the chest of participants to assess the pumping ability of their hearts.
45691805|NCT02143648|Drug|nalbuphine HCl ER tablets 60 mg BID|nalbuphine HCl ER tablets 60 mg BID administered for 6 weeks
45691806|NCT02143648|Drug|nalbuphine HCl ER tablets 120mg BID|nalbuphine HCl ER tablets 120mg BID administered for 6 weeks
45691807|NCT02143648|Drug|Placebo tablets BID|Placebo tablets BID administered for 8 weeks
45487234|NCT03717805|Other|POAM|The new 5 minutes preparatory information movie on oocyte aspiration (POAM) details what couples can expect to happen on the day of oocyte aspiration. More specifically, it describes the patient journey detailing which procedures will happen when and how, in which room, in the presence of their partner or not, and in the presence of which healthcare professionals.
45487235|NCT02421016|Device|SYNERGY EES|Bioresorbable polymer everolimus-eluting stent
45487236|NCT02421016|Device|ABSORB [BVS]|Everolimus-eluting bioresorbable backbone stent
45487237|NCT04620252|Drug|Inactive supplement|Chewable candy (negative control), chewed for 30 seconds.
45487238|NCT04620252|Drug|Tricalcium phosphate supplement|Chewable tricalcium phosphate supplement, chewed for 30 seconds.
45487239|NCT04620252|Drug|Calcium carbonate supplement|Chewable calcium carbonate supplement, chewed for 30 seconds.
45487240|NCT04620252|Drug|Calcium citrate supplement|Chewable calcium citrate supplement, chewed for 30 seconds.
45487241|NCT04620252|Drug|Inactive supplement and fluoride mouthwash|A chewable candy chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
45487242|NCT04620252|Drug|Calcium carbonate supplement and fluoride mouthwash|A calcium carbonate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
45487243|NCT04620252|Drug|Calcium citrate supplement and fluoride mouthwash|A calcium citrate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
46052617|NCT00771667|Drug|Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
46052618|NCT02801175|Procedure|Pulmonary vein isolation|
46052619|NCT04039360|Combination Product|self-expanding metallic stent placement followed by neoadjuvant chemotherapy|Neoadjuvant chemotherapy was administered 1 week after successful SEMS placement and decompression for patient with obstructing left-sided colonic cancer. Patients received either three cycles of mFOLFOX6 repeated every 2 weeks or two cycles of CAPOX repeated every 3 weeks. Elective surgery was performed 2 weeks after completion of chemotherapy by experienced colorectal surgeons.
45487244|NCT03694886|Drug|Caffeine Anhydrous with small sucrose pill|caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 1 mm sucrose pillule
45487245|NCT03694886|Other|Placebo - large sucrose pill|sucrose pillules of 5 mm diameter will be given to all participants in the large pill groups
45691808|NCT02997982|Drug|Valaciclovir 500Mg Tablet|Valaciclovir treatment (oral, 500 mg tablets). First week: 500 mg three times daily, second to fourth week: 1000 mg three times daily.
45691809|NCT00689260|Device|easypod|Subjects is aware that the device records injection information that can be viewed by user
45691810|NCT00689260|Device|easypod|Subjects is not aware that the device records injection information that can be viewed by user
45691811|NCT00689572|Drug|Ondansetron|4 mg twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
45691812|NCT00689572|Drug|Placebo|twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
45487246|NCT03694886|Drug|Caffeine Anhydrous with large sucrose pill|caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 5 mm sucrose pillule
45487247|NCT03694886|Other|Placebo - small sucrose pill|sucrose pillules of 1 mm diameter will be given to all participants in the small pill groups
45487248|NCT04146467|Device|Renuvion APR Device|The Renuvion APR Handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for soft tissue cutting, coagulation or ablation. The Renuvion APR Handpiece has a non-extendable electrode to generate helium plasma.
45487249|NCT02429128|Other|14 weeks exercise training|
45487250|NCT05602675|Drug|LY3871801|Administered orally.
45487251|NCT05602675|Drug|Methotrexate|Administered orally.
45487252|NCT05602675|Drug|Warfarin|Administered orally.
45487253|NCT05602675|Drug|Dextromethorphan|Administered orally.
45487254|NCT05602675|Drug|Midazolam|Administered orally.
45487255|NCT05602675|Drug|Repaglinide|Administered orally.
45487256|NCT02421250|Device|Radical-7 Noninvasive Hgb Monitor|
45487257|NCT04602468|Drug|Kaftrio|The intervention is the same for both study groups. In addition to all the assessments in the standard arm, the advanced arm subjects will undergo spirometry controlled CT, nasal lavage and sputum sample collection.
45487258|NCT03714685|Drug|Firibastat|Firibastat (QGC001) 500 mg
45487259|NCT03699566|Other|Assessment of Respiratory Muscle Strength|The maximal voluntary inspiratory (PImax) and expiratory (PEmax) pressure measurements of the subjects were performed using Cosmed Pony FX model (Italy 2001) while the subjects were in the sitting position with a nose clip.
45487260|NCT03699566|Other|Spirometer|Spirometric measurements were conducted with Cosmed, Pony FX (descopt spirometer- Italy 2001) spirometer using a nose clips while the subjects were in 90 degree relaxed sitting position.
45487261|NCT03699566|Other|Trunk Muscles Endurance Tests|Trunk muscle endurance of the subjects was measured using four different tests (Side Bridge Test- SBT, Prone Bridge Test- PBT, Flexor Endurance Test- FET, Sorenson Test- ST).
45487262|NCT03714607|Device|Erbium Yttrium Aluminum Garnet (Er:YAG) laser|5 Er:YAG laser therapies vaginally administered at monthly intervals
45487263|NCT03694730|Other|Exercise Treatment|Exercise treatment will consist of squatting and knee extension exercises, designed to progressively load the patellar tendon (Heavy-Slow Resistance protocol). A pain-monitoring model is used to guide exercise loads. As the protocol progresses, exercise load is increased while repetitions are decreased.
45487264|NCT03694730|Other|Pain- Guided Activity Modification|Participants sports participation and physical activity will be guided by the Pain-Monitoring Model. Using the Pain-Monitoring Model, patients may participate in activities that cause patellar tendon pain, as long as pain does not exceed 5/10 on the numeric pain rating scale (NPRS) (0 = No pain, 10 = Worst pain imaginable) during or immediately after activity. Additionally, pain should return to pre-activity levels by the following morning and pain should not increase from week-to-week.
45487265|NCT03444181|Behavioral|Music lessons|Also described as neurocognitive music therapy. Singing lessons will be provided once a week for a period of 12 months by a person with a qualification in music therapy, or by a person with a different relevant qualification (e.g. psychology and music teaching) under the supervision of a music therapist. Additionally, participants will have the opportunity to meet regularly (1-2 times per month) as a choir to sing the song they have learned together in a group.
45487266|NCT03444181|Behavioral|Training intervention|Cognitive training that is comparable in scope and extent to the music lessons, but not using music. Group training sessions will be provided once a week for a period of 12 months by a person with a qualification in physiotherapy or occupational therapy. Group activities may include group tours such as mountain hikes and the like (about 2 times per month) and will follow an established program for the elderly.
45487267|NCT03690752|Device|unweighting using Alter-G Anti-Gravity Treadmill|The unweighted group (experimental) is allowed to self-select a comfortable unweighting using the weight control feature on the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
45596371|NCT02288923|Drug|Regular anti emetics|All patients will receive 4mg ondansetron regularly for 2 days. They will be prescribed 50mg cyclizine as an addition to this if needed.
45691813|NCT01840579|Biological|Pembrolizumab 2 mg/kg|Administered as an intravenous (IV) infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
45691814|NCT01840579|Biological|Pembrolizumab 10 mg/kg|Administered as an IV infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
46052620|NCT05579964|Drug|Dexmedetomidine Hcl 100 Mcg/mL Inj|Priming dose of 0.5 mcg/kg in a 5 ml syringe mixed in priming fluid and 0.25 mcg/kg/hour DEX infusion diluted in 0.9% NaCl 20 ml in a 20 ml syringe administered to the CPB reservoir with an infusion rate of 10 ml/hour
46052621|NCT05579964|Drug|Placebo|Priming dose of NaCl 0.9% in a 5 ml syringe mixed in priming fluid and NaCl 0.9% 20 ml in a 20 ml syringe administered to the CPB reservoir with an infusion rate of 10 ml/hour
46052622|NCT02800395|Procedure|Malnutrition screening and perioperative nutritional support|"Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines~Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)~Implementation of an adapted nutritional support based on ESPEN Guidelines"
45487268|NCT03690752|Device|normal weight using Alter-G Anti-Gravity Treadmill|The weighted (control) group will walk at 100% their body weight using the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
45487269|NCT02705716|Other|0.454% w/w stannous fluoride (1100ppm fluoride)|Dentifrice containing 0.454% w/w stannous fluoride (1100ppm fluoride)
45487270|NCT02705716|Other|0.76% sodium monofluorophosphate (1000ppm fluoride)|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
45487271|NCT01374672|Other|laboratory biomarker analysis|Correlative studies
45487272|NCT03714529|Biological|PD-L1|IO103 is a anti-cancer therapy consisting of a synthetic PD-L1-derived peptide.
45487273|NCT04138043|Drug|Placebo|Placebo is 0.9 percent sodium chloride solution. It will be administered as SC injection to abdomen by study personnel. Three injections will be used to match active doses.
45487274|NCT04138043|Drug|GSK2330811|GSK2330811 will be available as SC injection 150 mg/mL.
45487275|NCT03699488|Behavioral|psychotherapy via asynchronous message|Behavioral psychotherapy delivered by asynchronous message using the Talkspace application
45487276|NCT03116620|Other|Chewing evaluation|Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
45487277|NCT02429050|Drug|sustained release morphine|Patients will receive morphine SR 10mg two to three times daily or placebo. Hard gelatin capsules of size AA in Swedish orange containing one morphine SR tablet 10 mg per capsule will be produced. Morphine SR has a marketing authorisation for pain and will be used according to current Dutch and international guidelines for treatment of dyspnea.
45487278|NCT02429050|Drug|placebo|Patients in the control group will receive placebo, consisting of microcrystalline cellulose (FMC BioPolymer). Hard gelatin capsules of size AA in Swedish orange containing microcrystalline cellulose will be produced.
45487279|NCT04479488|Other|Hospital admission|Usual care.
45487280|NCT04479488|Other|Non-hospitalization procedures|Usual care.
45487281|NCT01311427|Behavioral|8-form Yang-style Tai chi|This study tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in a small group two times weekly for 60 minutes over 12 weeks.
45487282|NCT01311427|Behavioral|Group education|Standard group education was delivered to participants in a small group format twice weekly for 60 minutes over 12 weeks.
45487283|NCT02417142|Drug|Exenatide|Exenatide SQ 2mg/week for 24 weeks.
45487284|NCT02417142|Drug|Placebo|Placebo SQ 1x/week for 24 weeks.
45487285|NCT03179098|Other|Modified Weeks protocol|The modified Weeks group (GWM) will apply the protocol suggested by Flowers (2002), the positioning will be maintained and at rest will be done electromyographic registers, active goniometry and EVA. Soon afterwards the patients will be submitted to the whirlwind for 20 minutes at a temperature of 41 ° C performing active flexion and elbow extension movements. After the swirl the patients will be submitted to a stretching maintained for 10 minutes with load proportional to the force captured during MVIC according to the pain of the patient. The load will be positioned through a leather device 20 cm from the lateral epicondyle of the elbow.
45487286|NCT03179098|Other|CIVM|Patients underwent electromyographic analysis for the determination of maximal voluntary isometric contraction. The force will be collected for 5 seconds during a CIVM, in which a load cell model MM50 (Kratos, Cotia, SP, Brazil) will be positioned between the floor and the forearm of the volunteer, being coupled to a leather device at 20 cm Make the lateral epicondyle of the elbow. The angle between the forearm and the cable containing a load cell with a 90 degree service.
45487287|NCT03179098|Other|GC- Sustained Stretching|The control group will be applied to sustained stretching, patients will be placed in the supine position with abduction of the shoulder of 30 ° in the plane of the scapula and the forearm in neutral throughout the entire test and the elbow will be supported in a towel to avoid discomfort And compression in the region of the olecranon.
45487288|NCT04135937|Drug|Bupropion|Smoking cessation pharmacotherapy prescribed in accordance with package insert.
45487289|NCT04135937|Drug|Varenicline|Smoking cessation pharmacotherapy prescribed in accordance with package insert.
45487290|NCT04135937|Behavioral|Cognitive Behavioral Therapy|Behavioral intervention; modules include identifying reasons for quitting, setting a quit date, breathing relaxation technique, identifying smoking triggers, identifying social support, and education about relapse prevention
45487291|NCT04135937|Drug|Nicotine Replacement Therapy|Participants may be prescribed single-formulation NRT (i.e., nicotine patch) or dual NRT (patch + rescue method such as nicotine gum, inhaler, or lozenges).
45596372|NCT02369445|Behavioral|Moisture Pager Intervention for Toilet Training|
45596373|NCT02369445|Behavioral|Standard of Care|
45596374|NCT02195375|Drug|Flutiform 500/20 µg BID|
45369171|NCT02530957|Device|Non invasive ventilation + High flow nasal cannula oxygen|In the interventional group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% and combined to HNFC (nasal cannula oxygen of Fisher and Paykel) with Flow of 60L/min, FiO2 = 100% is applied.
45487292|NCT04135937|Behavioral|Relapse Prevention Text Messaging|Participants will be invited to utilize SmokefreeVET, a mobile text messaging service for military Veterans trying to quit smoking. The 6- to 8-week program provides 24/7 encouragement, advice, and tips to help smokers quit smoking and stay quit.
45487293|NCT04477928|Diagnostic Test|Sera and whole blood sampling|"Study Entry: Single Nucleotide Polymorphism (SNP)-Based Genetic Risk Score at study entry.~2 years old: T1D autoantibodies, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibodies~5 years old: T1D and celiac autoantibodies~9-16 year old: one-time T1D and celiac autoantibodies~Siblings of people with T1D autoimmunity, ages 6-17 years: one-time T1D and celiac autoantibodies"
45487294|NCT04477928|Diagnostic Test|Differential Gene Expression (DGE)|Opt-in: Differential Gene Expression from cord blood at birth and peripheral blood at 12 months of age
45487295|NCT01374750|Drug|Sirolimus|Sirolimus
45487296|NCT01374750|Drug|m-TOR inhibitor free|calcineurin inhibitors
45487297|NCT03106792|Dietary Supplement|Hairfinity #1|Main Hairfinity formulation
45487298|NCT03106792|Dietary Supplement|Hairfinity #2|Variation to main formulation
45487299|NCT03106792|Dietary Supplement|Hairfinity #3|Variation to main formulation
45487300|NCT03106792|Dietary Supplement|Placebo|No active ingredients
45487301|NCT03443713|Device|Dexcom G6 CGM|Subjects will wear a Dexcom G6 CGM for the 28 days they are on study.
45487302|NCT03106558|Device|Total Knee Arthroplasty using Manual Instrumentation|
45369172|NCT02530957|Device|Non invasive ventilation|In the reference group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) only, with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% is applied.
45369173|NCT01084057|Drug|vorinostat|Given orally
45369174|NCT01084057|Drug|ixabepilone|Given IV
45369175|NCT01084057|Other|laboratory biomarker analysis|Correlative studies
45369176|NCT01084057|Other|pharmacological study|Correlative studies
45487303|NCT03106558|Device|Total Knee Arthroplasty using Robotic Arm|
46052623|NCT04236063|Other|WHODAS 2.0 Questionnaire|36-item WHODAS 2.0 questionnaire will be used for each patient to identify difficulty faced by patient over past 30 days from the day of interview
46052624|NCT02804451|Device|Macintosh laryngoscope|intubation with standard macintosh larygoscope; gold standard
46052625|NCT02804451|Device|TruView EVO2 laryngoscope|A TruView EVO2 laryngoscope with blade size 3 (EVO2; Truphatek Holdings, Ltd., Netanya, Israel),
46052626|NCT02804451|Device|TruView EVO2 PCD laryngoscope|A TruView EVO2 PCD laryngoscope with blade size 3 (PCD; Truphatek Interbational Ltd., Netanya, Israel),
46052627|NCT02804451|Device|ETView SL|An ETView SL (ETView; ETViewLtd, Misgav, Israel) ednotracheal tube
46052628|NCT04008537|Device|Ring gantry kV-CBCT combined with linear accelerator|Each imaging session will be less than one hour, and is expected to take no more than 15 minutes.
46052629|NCT05579808|Procedure|Epidural Analgesia|Using an aseptic technique while the patient is in sitting position, an epidural catheter was placed at the L2-L3 or L3-L4 interspace. Analgesia was established with the epidural administration of a low dose of local anaesthetic, plus a lipid-soluble opioid (ropivacaine 0.1% and sufentanyl 0.5%, 20 mL). Analgesia was maintained with a top-up regimen, using intermittent manual epidural boluses of increasing concentrations of ropivacaine, with up to 0.15% at full dilation, according to specific needs of individual participants.
45369177|NCT03954444|Drug|Oxymetazoline Hydrochloride|Test Comparator
45369178|NCT03954444|Drug|Rhofade Cream, 1%|Reference Comparator
45369179|NCT03954444|Drug|Placebo|Placebo Comparator
45369180|NCT03953820|Drug|Diazepam Buccal Film|Diazepam Buccal Film administered on inner aspect of the cheek at the recommended dose regimen (10 mg to 17.5 mg according to body weight) following ingestion of a moderate fat meal and following ingestion of a high-fat meal.
45487304|NCT03694574|Behavioral|instruction to suppress|"It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, try not to think of the situation that makes you angry, mad or irritated. Please try as much as you cannot to think about the situation, don't think about how you feel or what had happened, and try to suppress your emotions and not to feel them. It's very important to try as much as you cannot to think about the situation that makes you angry, mad or irritated. (Szasz, Szentagothai, & Hoffmann, 2011)"
45487305|NCT03694574|Behavioral|instruction to reappraise|"It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, please try to tell yourself that or would be preferable that the others are nice and/or fair to you, but if they are not, it does not mean that you or they are worthless human beings. It would be preferable that the others be nice and/or fair to you but if they are not, remember that it is only (very) bad), not catastrophic (the worst thing that could happen to you). It would be preferable that others are nice and/or fair to you, but if they are not, you can tolerate it, and go on enjoying life, even if it's more difficult at the beginning. (Szasz et al., 2011)"
45487306|NCT03694574|Behavioral|control|No instruction
45487307|NCT01977144|Other|Comprehensive Chromosomal Screening|
45487308|NCT03717649|Device|Conventional 2-stage venous cannula|venous cannula
45487309|NCT03717649|Device|Conventional 3-stage venous cannula|venous cannula
45487310|NCT03717649|Device|Fenestrated 3-stage venous cannula|venous cannula
45487311|NCT03182140|Drug|Kyleena|Kyleena - intrauterine delivery system containing 19.5 mg LNG
45487312|NCT03694496|Behavioral|peer-led theory-based intervention group|"We plan to select 2-8 peer leaders in S2 students within each school in the intervention group. A total of 25-48 peer leaders will be selected and trained in this study.~An experienced behavioural scientist will train the peer leaders through lectures, workshops, and individual counselling.~A total of 6 hours training (3 hours per day x 2 days) will be conducted during weekends. Peer leaders will practice in groups, and only those who pass the evaluation are allowed to conduct peer-led interventions. We will record the performance and give specific feedback to each peer leader."
45487313|NCT01374828|Drug|Ketolorac|Ketorolac 30 mg in 10 ml saline will be injected at the incision sites at the conclusion of the procedure.
45487314|NCT04133519|Device|Arm 1 - Active behavioral Treatment Arm (Regulora; Gut-Directed Hypnotherapy Software as a Medical Device - SaMD)|The active treatment consists of 7 unique video/audio recordings administered via a mobile application every other week for 12 weeks (SaMD). Since subjects in both the active and comparator treatment arms receive a behavioral treatment, the subjects are blinded to active treatment.
45369181|NCT03953820|Drug|Diastat® Rectal Gel (Valeant Pharmaceuticals USA)|Diastat Rectal Gel administered rectally according to product label administration and dosing instructions (10 mg to 20 mg according to body weight) following ingestion of a moderate-fat meal.
45487315|NCT04133519|Device|Arm 2 - Active Comparator behavioral treatment arm (MR-1; Muscle Relaxation, Software as a Medical Device - SaMD)|The comparator treatment consists of an identical treatment platform, scheduling platform, and reminder platform as the Active Treatment Arm, but in place of Gut-Directed Hypnotherapy there is a comparator relaxation treatment administered on an identical schedule: 7 unique video/audio recordings administered via a mobile application every other week for 12 weeks.
45487316|NCT05567497|Procedure|trigeminal nerve block|ultrasound guided trigeminal nerve block
45487317|NCT03181906|Other|Pre-Consultation Medication Reconciliation|Medication reconciliation service to be done for participants randomised to the intervention group
46052630|NCT05520879|Dietary Supplement|Sharnali 1|"The intervention is food product, made from locally available food ingredients in Bangladesh.~Sharnali 1 made from rice, lentil, dried skimmed milk, sugar, vegetable oils and micronutrient premix."
46052631|NCT05520879|Dietary Supplement|Sharnali 2|Sharnali 2 made from chick peas, dried skimmed milk, sugar, vegetable oils and micronutrient premix.
45369182|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
45369183|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
45487318|NCT03714295|Other|Use of interdental brushes|No intervention they just use interdental brushes as it should be done routinely
45487319|NCT02424682|Other|No intervention|No intervention administered in this study
45487320|NCT01373502|Device|DES Limus Carbostent|DES Limus Carbostent Carbofilm Coated Coronary Stent
45487321|NCT01373502|Device|Taxus Liberté Stent|Taxus Liberté Coronary Stent
45487322|NCT03690362|Drug|VNRX-5133 and VNRX-5022|intravenous infusion
45487323|NCT03714217|Behavioral|Telenutrition Counseling|A registered dietitian nutritionist will contact each participant twice a month for 3 months to provide nutrition counseling via iPad FaceTime.
46052632|NCT03893175|Drug|Ibuprofen|400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
46052633|NCT03893175|Drug|Acetaminophen|500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
46052634|NCT03893175|Drug|Placebo|By mouth
46052635|NCT03893175|Drug|Oxycodone|5 mg by mouth every 6 hours as needed for pain
46052636|NCT04050189|Biological|Natural products: Probiotics|Probiotics intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum
46052637|NCT04050189|Other|Placebo|Placebo intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum
45369184|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
45369185|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
45369186|NCT02611037|Drug|Cisplatin|The recommended dose of cisplatin for transarterial chemoperfusion in this study is 35 mg/m^2 body surface area (BSA). During the lead in phase of the study, 3 patients will be treated with regular doses of cisplatin.
45596375|NCT02195375|Drug|Flutiform 250/10 µg BID|
45596376|NCT02195375|Drug|Seretide Accuhaler 50/500 µg BID|
45691815|NCT01840579|Biological|Pembrolizumab 200 mg|Administered as an IV infusion on Day 1 of each 21-day cycle
45691816|NCT01840579|Drug|Cisplatin 75 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
45691817|NCT01840579|Drug|Pemetrexed 500 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
45691818|NCT01840579|Drug|Carboplatin AUC 5 mg/mL/min|Administered as an IV infusion on Day 1 of each 21-day cycle
45487324|NCT03746171|Diagnostic Test|Colonic polyp characterization by BLI|"All rectosigmoid <5 mm polyps, regardless of the presence of larger polyps, will be characterized by BLI-assisted optical diagnosis by using BASIC criteria (neoplastic vs. non neoplastic) and will be included in polyp-level assessment.~The polyp characterization will be always performed and recorded without zoom magnification. In patients in which colonoscopy will be performed with endoscopes equipped with zoom magnification, the zoom will be eventually systematically applied and the characterization with zoom will be also recorded. The post-polypectomy surveillance intervals based on BLI will be calculated by using histology estimation performed without zoom for all patients. Only polyps characterized with high confidence will be included in the analysis; the high-confidence characterization rate will be calculated."
45487325|NCT03717493|Behavioral|Affect Regulation Training|Following the guidelines for the 6-week intensive ART format, we scheduled one 180-minutes session per week (each consisting of two modules à 90min) for a period of six subsequent weeks. Training groups included four to eight participants. The implementation of ART followed standardized treatment protocols (Berking & Whitley, 2014). ART was delivered by doctoral candidates (DCs) in clinical psychology who had completed or were in advanced stages of their clinical training. All therapists had been intensely trained and received weekly supervision from experienced ART trainers. To control adherence a random sample of 5% of all sessions was be videotaped and will be rated with regard to adherence.
45487326|NCT04477694|Procedure|colonoscopy under sedoanalgesia|Colonoscopy is a widely used method for diagnosing and treating colonic diseasea with a thin, flexible camera.
45487327|NCT03634332|Drug|PEGPH20|PEGPH20 is a PEGylated, neutral-pH-active human hyaluronidase PH20 produced by recombinant DNA technology
45487328|NCT03634332|Biological|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2
45487329|NCT03744767|Drug|Spironolactone 50 MG|oral administration of Spironolactone, 25mg daily for 1 week, then 50mg daily until visit Month 3, followed by 25mg daily from visit Month 3 to visit Month 4
45487330|NCT02428972|Drug|Propofol|Propofol infusion @100-200 mcg/kg/min Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
45487331|NCT02428972|Drug|Sevoflurane|MAC of Sevoflurane will be maintained between 0.8-1.2 Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
45487332|NCT03634254|Other|Satisfaction survey of communication quality:|a conversation from phone call to survey primary caregivers of AAC users in New Taipei City who think the users communication quality
45487333|NCT02428660|Genetic|Pharmacogenetic testing|Genetic testing for 2D6, 2C9, 2C19, 3A4, 3A5 polymorphisms
45487334|NCT02428660|Other|Software-based drug & gene interaction risk analysis|By assessing a patient's medication list along with the frequencies of variant phenotypes in the population, YouScript is able to identify whether a patient might be at risk for an adverse drug event and suggest when testing might be appropriate.
45487335|NCT02428660|Other|MTM|Medication Therapy Management
45487336|NCT03694340|Other|Re-programming of cochlear implant|New MAP based on behavioral T- and C-levels
45487337|NCT03699332|Drug|Indium-111-DOTA-Labetuzumab-IRDye800CW injection|Tracer injection
45369187|NCT02611037|Drug|Methotrexate|The recommended dose of methotrexate for transarterial chemoperfusion in this study is 100 mg/m^2 BSA. During the lead in phase of the study, 3 patients will be treated with 50% reduced dose of methotrexate (50 mg/m^2).
45369188|NCT02611037|Drug|Gemcitabine|The recommended dose of gemcitabine for transarterial chemoperfusion in this study is 1000 mg/m^2 BSA. During the lead in phase of the study, 3 patients will be treated with regular doses of gemcitabine.
45487338|NCT03699332|Radiation|SPECT/CT scan|Abdominal and thoracic SPECT/CT scan.
45691819|NCT01840579|Drug|Carboplatin AUC 6 mg/mL/min|Administered as an IV infusion on Day 1 of each 21-day cycle
45691820|NCT01840579|Drug|Paclitaxel 200 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
45691821|NCT01840579|Drug|Nab-paclitaxel 100 mg/m^2|Administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle
45691822|NCT01840579|Biological|Ipilimumab 1 mg/kg|Administered as an IV infusion on Day 1 of every other 21-day cycle (every 42 days)
45691823|NCT01840579|Drug|Etoposide 100 mg/m^2|Administered as an IV infusion on Days 1, 2, and 3 of each 21-day cycle
45691824|NCT01840579|Drug|G-CSF (pegfilgrastim) 3.6 mg|Administered as a subcutaneous injection on Day 4 of Cycle 1
46052638|NCT05489991|Biological|TmPSMA-02|Intravenous administration of genetically modified autologous T-cells engineered to express a protein capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) with a lentiviral vector to express anti-PSMA scFv, CD2 co-stimulatory domain and dually armored with a dominant negative TGFβ receptor and PD1.CD28 switch, will be infused intravenously on Day 0 as a single flat dose following standard lymphodepleting (LD) regimen.
46052639|NCT02235792|Device|Activa PC+S|The model 37604 Activa PC+S system is a multiprogrammable device that both delivers electrical stimulation and records bioelectric data through one or two leads implanted in the brain.
45369189|NCT02611037|Other|Lung Cancer Symptom Scale for Mesothelioma Questionnaire|Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire.
45369190|NCT03678636|Device|Silver antimicrobial dressing|Silver dressing suitable for exudate level
45369191|NCT03678636|Device|Standard care|Usual care for wound type and condition
45369192|NCT04517994|Behavioral|Active Treatment|See arm description.
45369193|NCT04517994|Behavioral|Supportive Treatment|See arm description.
45369194|NCT04492956|Drug|Ecopipam|Oral tablet
45691825|NCT00690040|Device|Foley catheter|Single balloon catheter
45691826|NCT00690040|Device|Atad catheter|Double balloon catheter
45487339|NCT03699332|Procedure|CRS extended with dual-modality imaging|cytoreductive surgery will be performed extended with the use of dual-modality imaging.
45487340|NCT03179176|Other|High Frequence Ultrasound Doppler (HFUD) utilisation|Utilisation of HFUD will be done during on patients during an operation in waking condition. This procedure extends the usual procedure from 15 to 20 minutes.
45487341|NCT04007159|Other|Serum|Participants will be topically applied serum to the dorsum, under a semi-occlusive patch (0.02 milliliters per centimeters square [mL/cm^2] of serum in an individual cell of patch)
45487342|NCT04007159|Other|Lotion|Participants will be topically applied lotion to the dorsum, under a semi-occlusive patch (0.02mL/cm^2 of lotion in an individual cell of patch)
45487343|NCT04007159|Other|Cream|Participants will be topically applied cream to the dorsum, under a semi-occlusive patch (0.02mL/cm^2 of cream in an individual cell of patch)
45487344|NCT04007159|Other|Normal Saline|Participants will be topically applied normal saline to the dorsum, under a semi-occlusive patch (0.02mL/cm^2 of normal saline in an individual cell of patch)
45487345|NCT04483024|Dietary Supplement|Collagen hydrolysate and chicken extract|One bottle (68mL) of collagen hydrolysate (2g) in chicken extract taken daily in the morning after meal for 24 weeks
45487346|NCT03690128|Behavioral|I-EWS with incorporated clinical assessment (Trigger Tool)|In relation to systematic measurement of vital parameters the nursing staff will perform an individual clinical assessment of the patient and adjust the I-EWS score accordingly.
45487347|NCT03690128|Behavioral|Standard EWS - Control (Trigger Tool)|Standard EWS - Based on principles of National Early Warning Score (NEWS)
45487348|NCT03119688|Other|Test Product|Micellar cleanser (0.09 ml)
45487349|NCT03119688|Other|Positive Control|Bar Soap (rubbed for 6 seconds to generate a lather)
45487350|NCT03119688|Other|Reference Product|Sterile Water (0.09 ml)
45487351|NCT03119688|Other|No Treatment|Unwashed area of the forearm
45487352|NCT03389893|Drug|Dupilumab|Dupilumab, an interleukin (IL)-4 receptor alpha (IL-4Rα) antagonist, is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. (FDA approved on March 28, 2017.)
45487353|NCT03389893|Drug|Placebo|Placebo will contain the identical formulation as the dupilumab formulation without the active mAb and will be given by exactly the same route and schedule through Day 28.
45487354|NCT03178708|Drug|Group A amantadine sulfate|infusion solution for slowly intravenous application 3 hours preoperative
45487355|NCT03178708|Other|Group B ringer lactate|infusion solution for intravenous application 3 hours preoperative
45487356|NCT03694106|Behavioral|TEAM PSYCHOTHERAPY|Patients data will be collected from the first to the final psychotherapy session as performed normally by TEAM trained clinicians. The treatment-as-usual includes therapy sessions of 50 to 110minutes long, typically once or twice per week for an average of 8-12 sessions. Treatment as usual by these clinicians includes the use of psychological symptoms survey immediately before and after each psychotherapy session. Typically patients will fill out these surveys in the clinic's waiting area before and after each session.
45487357|NCT02424292|Other|Physical activity|Physical activity in a personalised program.
45369195|NCT04492956|Drug|Placebo|Oral tablet
45487358|NCT04473872|Other|respiratory rehabilitation|intervention includes respiratory muscle strengthening with diaphragmatic respiration and IMT device, in addition to neurodevelopmental rehabilitation.
45487359|NCT01373658|Device|Yinyi stent|subjects with Yinyi stent implantation
45487360|NCT04128293|Drug|GSK3640254 Tablet|GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
45487361|NCT04128293|Drug|GSK3640254 Capsule|GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
45487362|NCT02428582|Device|Covered stent (Atrium Type V12)|An endovascular treatment that consists of inserting a covered stent into the stenosed vessels.
45487363|NCT02428582|Device|Bare stent (Brand Cordis Type Palmaz Blue)|An endovascular treatment that consists of inserting a stent into the stenosed vessels.
45487364|NCT05197686|Device|Oxygen theraphy with high flow nasal cannule|Oxygen theraphy with high flow nasal cannule
45487365|NCT05197686|Device|Oxygen theraphy with mask with reservoir|Oxygen theraphy with mask with reservoir
45487366|NCT03179020|Other|Checklist use|Management of the potential donor guided by the use of an evidence-based checklist. This checklist is based on main recommendations of the Brazilian guideline for the management of potential multiple organ donors.
45369196|NCT04478136|Diagnostic Test|Blood test of factor levels|Blood draw from central line to check coagulation factors
45369197|NCT00117793|Device|Total Surface Bearing Suction Socket|Current clinical practice
45369198|NCT00117793|Device|Vacuum assisted socket system|Novel socket system
45369199|NCT01084213|Drug|Intermittent screening and treatment of malaria in pregnancy (IST)|Scheduled intermittent screening of study women using rapid diagnostic test and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester with arthemether lumefantrine.
45369200|NCT01084213|Drug|SP-IPTp|Study women will receive at least two doses of Sulfadoxine Pyrimethamine during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
45369201|NCT00695669|Biological|Influenza A (H5N1) Virus Monovalent Vaccine|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
45487367|NCT03179020|Other|Usual care|Management of the potential donor according usual care.
45691827|NCT00690274|Drug|BF2.649|up to 20mg per day
45691828|NCT00690274|Drug|Placebo|up to 20mg per day
45487368|NCT05197608|Other|System Navigator|Participants will be connected to a System Navigator, who is a trained staff embedded within their primary health clinic to support and help navigate biological, psychological and social needs in proactively identified vulnerable patients.
45487369|NCT05197608|Other|Tailored list of resources|Control group will be provided a tailored list of resources
45487370|NCT02428894|Device|LVAD|
45487371|NCT00787176|Drug|Group A Intravenous bolus of 1000 ml lactated ringers solution|An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient was positioned for epidural placement. Oxytocin management continued as per protocol.
45487372|NCT00787176|Drug|Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1/2 current rate|An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
45487373|NCT00787176|Drug|Group C 125 mL/hr of lactated ringers|The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. Oxytocin management continued per protocol.
45487374|NCT00787176|Drug|Group D 125 mL/hr lactated ringers oxytocin decreased to 1/2 current rate|The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
45487375|NCT03711487|Drug|Foeniculum Vulgare Seed Ironing|Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, twice daily on postoperative days 2 to 3. The medicine bag can be heated and reused after it cool down.
45487376|NCT02424370|Procedure|TAVR|Percutaneous aortic valve replacement
45487377|NCT03633864|Biological|Fecal microbiota transplantation|Fecal donors are selected according to the predefined criteria. Fecal microbiota suspension is prepared by using fresh feces from the selected fecal donors. Then, administration of 200 ml fecal microbiota suspension through a transendoscopic enteral tubing or retention enema.
45487378|NCT05560555|Drug|Tafamidis|61 milligrams (mg) as received in studies B3461028 and B3461045
45487379|NCT03744689|Procedure|Erector Spinae Plane block|Erector Spinae plane block will be done according to hernia level using bupivacaine hydrochloride
45487380|NCT03744689|Procedure|Sham block|Sham block will be done with serum physiologic.
45487381|NCT03744689|Drug|Bupivacaine Hydrochloride|20 ml 0,25% Bupivacaine will be used for block performances
45487382|NCT03744689|Device|PCA|Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
45487383|NCT02424214|Other|Artificial Oocyte activation|
45487384|NCT02424214|Drug|Ca Ionophore|
45487385|NCT02424214|Drug|Strontium Chloride|
45487386|NCT05559541|Drug|AK119|AK119 is an anti-CD73 monoclonal antibody.
45487387|NCT05559541|Drug|AK104|AK104 is an anti-PD-1 and CTLA-4 bispecific antibody.
45487388|NCT02428426|Other|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
45487389|NCT03691571|Device|Esophageal Cooling|The EnsoETM is a non-sterile multi-lumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while simultaneously allowing gastric decompression and drainage.
45487390|NCT03691571|Device|Control|Standard of care involves standard temperature probe monitoring.
45487391|NCT03113916|Behavioral|Behavioural Lifestyle Intervention|A culturally tailored behavioral intervention.
45487392|NCT03712111|Drug|Norepinephrine 6 mcg|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
45487393|NCT03712111|Drug|Norepinephrine 10 mcg|An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
45487394|NCT03712111|Drug|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg
45487395|NCT03712111|Drug|Norepinephrine infusion|Prophylactic norepinephrine infusion will be started after subarachnoid block
45487396|NCT02925494|Drug|Estradiol/Norethindrone Acetate|capsules
45487397|NCT02925494|Drug|Elagolix|film-coated tablets
45487398|NCT03711409|Other|Soft tissue biased manual therapy group|It includes hot pack and muscle release technique of pectoralis major, pectoralis minor, teres major, teres minor, infraspinatus and posterior deltoid muscles. Subjects are supine on the bed. The muscle release technique is applied at the end available range and the acceptable intensity. The time of muscle release intervention is about 30 min and hot-pack about 15 min.
45487399|NCT03711409|Other|Conventional physical therapy group|It includes modality (electrotherapy, ultrasound and low-level laser therapy) and GH joint mobilization. GH joint mobilization includes anterior to posterior glide, caudal glide and distraction. The intensity of joint mobilization is grade III to IV. The time of joint mobilization is about 30 min and hot-pack for 15 min.
45487400|NCT02428348|Other|Interview about prototype EEG-cap|
45846478|NCT05247762|Device|Acupuncture|The stainless steel needles are used to insert into the two points of Jingming and the Qiuhou, and der-qi, once a week, once for 20 minutes, for 24 consecutive weeks.
45846479|NCT05247684|Drug|AK112|IV infusion
45846480|NCT05247684|Drug|Carboplatin|IV infusion
45846481|NCT05247684|Drug|Cisplatin|IV infusion
45487401|NCT03744533|Other|head-down position treatment|the head position of subjects is lowered to 20 degrees in a supine position between 8:00-22:00 within 24h post-randomization as long as possible. During the procedure, when subjects feel intolerable, the head position will be elevated to lying flat (0 degree) for 5-10min, and then the above procedure is repeated. After 24h post-randomization, the head down procedures with -20 degrees in a supine position with duration of 1-1.5 hour will be performed three times daily at 9:00-11:00, 15:00-17:00 and 20:00-22:00, respectively.
45487402|NCT03744533|Other|guideline-based treatment|guideline-based treatment
45487403|NCT02420704|Procedure|Embryo transfer|For fresh cycles, embryos were transferred 3-5 days after oocyte retrieval; For frozen thawed cycles, embryos were transferred 3-5 days after starting to use progesterone based on the stage of cryopreservation.
45487404|NCT03717415|Drug|rebastinib|25 mg tablets or 75 mg tablets
45487405|NCT03717415|Drug|Carboplatin|Carboplatin administered by IV infusion at AUC5 or AUC6
45487406|NCT03744455|Biological|Axillary Plexus|Axillary plexus anesthesia technique for hand surgery
45487407|NCT03181672|Procedure|Stellate ganglion block|Stellate ganglion block with 1% lidocaine 10ml
45487408|NCT03181672|Procedure|control group|Deltoid muscle injection with 1% lidocaine 10ml
45487409|NCT05658445|Other|evacuation|after complete evacuation of uterus follow abortion
45487410|NCT03689894|Drug|Ibrutinib|"Subjects will receive oral (PO) Ibrutinib 140 mg once daily with Rituximab 375 mg per meter squared IV weekly x4 (with pre-medications and infusion procedure as per standard protocol) Rituximab Pre-medications:Acetaminophen 650 mg PO; Diphenhydramine 25 mg PO/IV; Dexamethasone 20 mg IV.~If no adverse events >Grade 3+ are noted after 1 week, the Ibrutinib dose schedule will be increased to 280 mg daily. If no adverse events >Gr3+ are noted after an additional 1 week, the Ibrutinib dose will be increased to 420 mg daily."
45369202|NCT03671369|Other|Safety data collection (following routine vaccination) by a continuous surveillance method.|"This study assesses the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine in terms of frequency and intensity of adverse events (AEs) and serious adverse events (SAEs) when administered routinely in male and female subjects aged between 9 and 25 years, according to the approved Prescribing Information in Korea.~All AEs reported during the 30-day post-vaccination follow-up period (Day 1 to Day 30) and all SAEs reported through the study period from dose 1 up to 30 days after the last dose administered during the post-marketing surveillance (PMS) were collected as part of safety data in this PMS."
45487411|NCT03689894|Drug|Rituximab|Subject will receive an intravenous infusion of 375mg per meter squared weekly for 4 weeks, which may be repeated 8 weeks after initial therapy if only a suboptimal response is achieved.
45487412|NCT04006145|Drug|Elobixibat|Elobixibat is a small molecule and a potent inhibitor of the ileal bile acid transporter (iBAT).
45487413|NCT04006145|Drug|Placebo oral tablet|Placebo identical in appearance to active drug
45487414|NCT03717337|Procedure|Single visit pulp regeneration|Access cavity, disinfection, preparing and injecting platelet rich plasma, and restoring the tooth all done in one visit.
45487415|NCT03717337|Procedure|Two visit pulp regeneration|first visit : access, disinfection and placing calcium hydroxide as intracanal medicament second visit: re opening of tooth, preparing and injecting platelet rich plasma and restoring the tooth.
45487416|NCT03689816|Procedure|sleeve gastrectomy|sleeve gastrectomy
45487417|NCT03689816|Procedure|gastric bypass|gastric bypass
45487418|NCT03386773|Behavioral|16-week program|16-week program where patients will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity.
45846482|NCT05247684|Drug|Paclitaxel|IV infusion
45846483|NCT05184348|Radiation|Narrow band Ultraviolet B phototherapy group|3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
45846484|NCT05184348|Drug|Acitretin group|dose of 0.5-1 mg per kg per day orally for 3 month.
45487419|NCT03386773|Behavioral|Patient generated health data|Intervention patients will be asked to track patient generated health data and patient reported outcomes. PGHD elements related to weight management will be collected through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
45487420|NCT04207866|Other|Teleconferencing|Use of video/audio stream to provide auditory training at a remote site.
45487421|NCT04207866|Other|Auditory training services|"Participants will engage in regular visits with a specialist to: 1) facilitate auditory training exercises; 2) work with the family/friends to encourage optimal communication strategies in the home; 3) evaluate and assess achievement of listening goals.~Auditory training assess/reviews skills associated with but not necessarily limited to: 1) developing strategies to repair communication breakdowns; 2) listening in quiet; 3) listening in noise; 4) listening to a degraded signal."
45487422|NCT04126343|Drug|Padsevonil|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Study participants will receive padsevonil in a pre-specified dosing sequence during the Treatment Period"
45487423|NCT04126343|Drug|Moxifloxacin|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Study participants will receive moxifloxacin once during the Treatment Period"
45487424|NCT04126343|Drug|Placebo|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Study participants will receive placebo in a pre-specified sequence during the Treatment Period to match padsevonil and maintain the blinding"
45487425|NCT04207710|Drug|Gebauer Pain Ease Top Aerosol Mist Spray|Topical numbing spray
45487426|NCT04207710|Drug|Gebauer Ethyl Chloride|Topical numbing spray
45369203|NCT04060745|Other|cooling using a water-perfused vest|"BAT is activated by cold exposure. Each participant will have a shivering threshold test performed before entering the cooling arm. Participants will be gradually cooled (decreasing the temperature in the cooling vest by 0.6C every 15 min. until 3.8C) using a perfused cooling vest until they start to shiver. The temperature in which they start to shiver will be noted. If shivering has not occurred at 3.8C after 15 min. they will stay at the temperature for 45 min. in total or until shivering occurs. Shivering is defined by subjective perception of shivering by the participant in a numeric scale (NRS) where 0 refers to I'm not shivering and 10 refers to I'm shivering a lot and visual inspection by the investigator. The temperature used in the cooling arm will be set a few degrees above the shivering threshold test or at 3.8C if shivering did not occur.~During cooling indirect calorimetry and OGTT will be performed and finally the DMI scan will be performed"
45369204|NCT04060745|Other|thermoneutrality|In the thermoneutrality arm participants will rest in thermoneutrality (22C) for one hour. Before the DMI scan indirect calorimetry will be performed
45369205|NCT00742937|Dietary Supplement|vitamin A|second capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E, eight days after delivery.
45369206|NCT00742937|Dietary Supplement|Placebo|second capsule with vitamin E, eight days after delivery.
45369207|NCT00692003|Drug|Zonisamide|"25-400 mg capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) <12 years old: 1 mg/kg; >= 12 years old: 50 mg daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)"
45369208|NCT00692003|Drug|Placebo|"25-400 mg Zonisamide Placebo capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) <12 years old: 1 mg/kg Zonisamide Placebo; >= 12 years old: 50 mg Zonisamide Placebo capsules daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)"
45369209|NCT02564315|Drug|Nicotine Mini-Lozenge for 11 Months|Participants receive up to 11 months of Nicotine Mini-Lozenges as part of this treatment (dosing based on their nicotine dependence as measured when they started the study: 4 mg if they smoked within 30 minutes of waking and 2 mg if they smoked more than 30 minutes after waking, as per the package insert), along with instructions for use.
45487427|NCT02952313|Device|Nasal Implant|
45487428|NCT03119610|Drug|Oxytocin nasal spray|Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)
45487429|NCT03119610|Drug|Placebo nasal spray|Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)
45487430|NCT03689738|Other|Potato (Resistant Starch)|Potato lunch and dinner meals, and an evening snack containing 100 g potatoes and 5 g resistant starch (RS) per meal, providing a total of 300 g/d potatoes, equivalent to roughly two whole potatoes, and 15 g/d RS.
45487431|NCT03689738|Other|CHO-matched (Low-fiber, RS-free)|Isocaloric, CHO-matched, low-fiber, RS-free lunch and dinner meals, and an evening snack.
45487432|NCT04005755|Drug|Maxigesic® IV|acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion
45487433|NCT03699176|Drug|Vilaprisan (BAY1002670)|2 mg, once daily, oral
45487434|NCT03699176|Drug|Placebo|Once daily, oral
45487435|NCT04106544|Procedure|Investigational Procedures|The investigational assessments will be performed
45369210|NCT02564315|Behavioral|Preparation Phase Behavioral Reduction Counseling|Participants randomized to receive this treatment receive manual-based counseling calls and visits over the course of 11 months. The ultimate goal will be smoking that is reduced in amount and location. Case managers and participants will collaboratively identify a set of steps to progressively reduce smoking. The primary vehicles for change are to encourage substitution of the nicotine mini-lozenge for cigarettes and to reduce the contexts in which smoking occurs. Counseling will counter post-lapse demoralization by emphasizing participants' progress, the value of smoking reduction as a transitional goal, and the critical value of ongoing treatment engagement. Evidence of progress in reduction of smoking, and smoking contexts will be used to build self-efficacy.
45369211|NCT02564315|Behavioral|Preparation Phase Recycling Counseling|Participants randomized to receive this treatment condition will be encouraged to commit to a new quit date as soon as they feel ready. In the counseling sessions, participants will be encouraged to discuss reasons for and concerns about quitting as well as barriers to setting a quit date.
45369212|NCT02564315|Behavioral|Preparation Phase Control Treatment|Participants randomly assigned to the Preparation Phase Control Treatment condition will continue to receive the Initial Cessation usual care treatment (8 weeks of nicotine patch; two coaching sessions), but will also be told that they can receive additional treatment at no cost from the Wisconsin Tobacco Quitline (WTQL).
45487436|NCT03442777|Device|Allevyn® brand silicone adhesive multilayer foam dressings|Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith&Nephew (Allevyn® brand).
45487437|NCT03442777|Device|Mepilex® brand silicone adhesive multilayer foam dressings|Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand).
45369213|NCT02564315|Behavioral|Cessation Phase Supportive Counseling|Supportive Counseling will be consistent with the Public Health Service (PHS) Clinical Practice Guideline (Fiore et al., 2008) and will involve encouragement, a focus on short-term goals, discussion of participant values (what the participant feels would be good and healthy for them in the long run) and how these values are congruent with cessation, emphasis on the patient and the counselor being a team, encouragement for the participant to generate a quitting strategy with the message that smokers often have a good sense of what will work for them, and prompts for the participant to explore his/her feelings about quitting and feelings of optimism and concern (i.e., to use the counselor as a sounding board).
45487438|NCT01373736|Drug|123I-meta-iodobenzylguanidine|
45487439|NCT03746093|Dietary Supplement|Water|Participants will consume a bottle of water (330 ml) every day for 12 weeks.
45487440|NCT03746093|Dietary Supplement|Non-alcoholic beer|Participants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
45487441|NCT03689348|Dietary Supplement|Avena sativa|A supplement derived from wild green oat
45487442|NCT03689348|Dietary Supplement|Placebo|Maltodextrin
45487443|NCT03689270|Procedure|Subluxation|One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete.
45487444|NCT03689270|Procedure|Divide and conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
45487445|NCT01375062|Other|analyse and proliferate the cells|"Obtention of excess tissue from testicular biopsies and maintained in 4ºC until procedures.~Digestion of the biopsies through controlled enzymes~Replication of the cells~Selection undifferentiated cells~Expansion of the purification cells population~Characterization of the cell population~Assessment of pluripotent and germinal cell potential.~Possible maturation of the cells."
45487446|NCT03401749|Drug|Chlorhexidine Gluconate 2% Wipe|Patients will be instructed to use CHG wipes after showering the night before surgery and again on the morning of surgery.
45487447|NCT03401749|Other|Theraworx Bath Wipes|Theraworx TM is a cosmetic product that is a non-rinse skin formulation that combines multiple ingredients, including Aloe Concentrate, Allantoin, Tego Betaine F 50, Tego Betaine L-7, Lauryl Glucoside, Abil 8852, Vitamin E, Natural Fragrances, Methyl paraben, Propyl paraben, EDTA, Antimicrobial Preservative, Colloidal Silver, and Beta Glucan, in preoperative disposable bath wipes. The main proposed antimicrobial mechanism of action involves the local reduction in skin pH to around 4.6.
45487448|NCT03689114|Drug|Low dose carbamazepine|Carbamazepine, 300 mg/die
45487449|NCT03689114|Drug|Standard dose carbamazepine|Carbamazepine 600 mg/die
45487450|NCT03689114|Drug|Low dose levetiracetam|Levetiracetam 500 mg/die
45487451|NCT03689114|Drug|Standard dose levetiracetam|Levetiracetam 1000 mg/die
45487452|NCT03689114|Drug|Low dose valproate|Valproate 300 mg/die
45487453|NCT03689114|Drug|Standard dose valproate|Valproate 600 mg/die
45487454|NCT03689114|Drug|Low dose zonisamide|Zonisamide 150 mg/die
45487455|NCT03689114|Drug|Standard dose zonisamide|Zonisamide 300 mg/die
45487456|NCT03689114|Drug|Low dose oxcarbazepine|Oxcarbazepine 600 mg/die
45487457|NCT03689114|Drug|Standard dose oxcarbazepine|Oxcarbazepine 1200 mg/die
45487458|NCT03689114|Drug|Low dose topiramate|Topiramate 100 mg/die
45487459|NCT03689114|Drug|Standard dose topiramate|Topiramate 200 mg/die
45487460|NCT03689114|Drug|Low dose lamotrigine|Lamotrigine 100 mg/die
45487461|NCT03689114|Drug|Standard dose lamotrigine|Lamotrigine 200 mg/die
45487462|NCT03689114|Drug|Low dose gabapentin|Gabapentin 450 mg/die
45487463|NCT03689114|Drug|Standard dose gabapentin|Gabapentin 900 mg/die
45487464|NCT03634176|Diagnostic Test|optical nerve sheet diameter|The ONSD in each eye was measured vertically and horizontally 3 mm behind the optic disc, with the two values averaged. No pressure was applied to the orbit. At each time point, measurements were taken within 5 min. The measurements were made before (T1) and after some of the strategies according to group 30 min (T2), 60 min (T3), and 90 min (T4).
45487465|NCT01311583|Behavioral|Teach Back method of patient discharge teaching|Trained nurses will provide Teach Back to the intervention group. Appendix D lists the four questions that will be used in this study to confirm the patient's understanding. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
45487466|NCT03029624|Device|eCoin|Patients are implanted with active implantable device called eCoin. eCoin is turned ON in order to deliver neuromodulation therapy.
45487467|NCT04040946|Diagnostic Test|MIBI scintigraphy|Performing a MIBI scintigraphy, then, in the case of negativity, a single F18-choline PET
45369214|NCT02564315|Behavioral|Cessation Phase Skill Training Counseling|"Skill training Counseling will: 1) carefully assess smoking cue contexts and opportunities to smoke, to identify problems encountered in the prior quit attempt; 2) develop specific plans for avoiding such contexts and identify skills for coping with them; 3) develop plans for negotiating with others who smoke; 4) develop lifestyle changes to reduce future smoking opportunities and contexts; and 5) assign homework and assess execution of assigned skills. Participants will receive coping menus that provide personalized coping/avoidance options and coping reports that assess coping execution over time and troublesome contexts and cues around which counseling will be focused. There will be praise for any progress and a collaborative determination of barriers to skill execution."
45487468|NCT04040946|Diagnostic Test|F18-choline PET|Realization of a F18-choline PET, then, in case of negativity, a MIBI scintigraphy
45487469|NCT02952001|Drug|4 mg CLS-TA Suprachoriodal Injection|This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
45487470|NCT02952001|Drug|Sham procedure|This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
45487471|NCT05196594|Diagnostic Test|collection of stools for genetic analysis|Intestinal microbiome analysis
45487472|NCT03699098|Diagnostic Test|TSH, T3, T4 and thyroid gland DVH|measuring thyroid functions and DVH parameters of thyroid gland
45487473|NCT04050176|Behavioral|Hypnotic Medication Open-Label Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 10 week open-label tapering period.
45487474|NCT04050176|Behavioral|Hypnotic Medication Blinded Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 10 week blinded tapering period.
45487475|NCT01372020|Other|neuromuscular electrical stimulation|The application technique used will be bipolar, with electrodes of the type metal-tipped pen. The electrodes will be placed at the outer edges of the ulcer, on opposite sides of the same and the estimated time of 1 minute at each point. All the edge of the ulcer will be bypassed, thereby separating the injections every 1 cm, returning to the starting point at the end of the application. To ensure that the entire edge of the ulcer to receive the stimulation, the end points of the application, the application will be made for another minute sliding the pen around the whole edge. Thus the application time will be directly proportional to the ulcer area. The subjects will be received 10 applications, three times a week for a period of 4 weeks.
45487476|NCT03744299|Other|Questionnaire|Patients and caregivers are asked to complete a questionnaire
45487477|NCT01311739|Drug|Cyanocobalamin|
45487478|NCT05196438|Other|Collecting statistics about congenital heart patterns and investigations done and interventions done to them|Collecting statistics about congenital heart patterns and investigations done and treatment given or interventions e.g. catheterization or surgical operations done to them
45487479|NCT03744221|Dietary Supplement|Corn protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
45487480|NCT03744221|Dietary Supplement|Bovine plasma protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
45487481|NCT03744221|Dietary Supplement|Whey protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
45487482|NCT05507359|Other|clove gel|4.7% (Pain Out Dental Gel, Colgate Palmolive India Ltd, Solan, India) clove gel
45487483|NCT05507359|Other|Benzocaine gel|20% Benzocaine gel (Opahl gel)
45487484|NCT05196360|Drug|MAX-10181|"Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
45487485|NCT04123067|Drug|Pioglitazone 45 mg|45mg Pioglitazone daily for three subsequent days, initiated within 12h of stroke symptom onset
45487486|NCT04123067|Drug|Placebo oral tablet|placebo daily for three subsequent days, initiated within 12h of stroke symptom onset
45487487|NCT03703050|Drug|Nivolumab cohort 1|Induction: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) iv Q2W until CR Evaluation of response as defined below, including biopsy in case of residual masses at Week 24 Maintenance: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) Q4W Total duration of treatment (induction + maintenance) = 24 months
45487488|NCT03703050|Drug|Nivolumab cohort 2|Induction: nivolumab 3 mg/kg iv Q2W for 4 doses (Wk0, Wk2, Wk4 and Wk6) Maintenance: nivolumab 3 mg/kg Q4W, for 25 doses, starting at Week 8 (14 days after the last induction dose) Total duration of treatment (induction + maintenance) = 24 months
45487489|NCT05193006|Other|No intervention|No intervention
45487490|NCT03711955|Other|Exercise|Two types of training exercises, AET and IRT, will be used as the interventions in this study. Participants will either be assigned to the AET group or the IRT group, where they will participate in the respective training intervention group for 8 consecutive weeks.
45487491|NCT05192928|Device|Ripple Health Smart Pill Cap|The device is a smart medical device created to allow physicians to have better access to patient compliance data, and intervene on the patient's health through the use of a text message, phone call, or email.
45487492|NCT01375218|Other|Pavlik Brace|Pavlik Brace
45487493|NCT01375218|Other|Plastizote Brace|Plastizote Brace
45487494|NCT05196282|Other|Smoking cessation|Patients are forced to stop smoking
45487495|NCT03688958|Drug|Placebo|Selected patients with early breast cancer (stage II) non-pretreated received colored water solution (placebo) within the time before the hospital assigned them to her surgery (7 to 35 days).
45691829|NCT00650260|Device|Dynatherm Medical vitalHEAT Temperature Management System vH2|The vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical.
45846485|NCT05184348|Combination Product|Acitretin plus Narrow band Ultraviolet B phototherapy group|Acitretin in dose of 0.5-1 mg per kg per day orally plus Narrow band Ultraviolet B phototherapy 3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
46052640|NCT04236453|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally on Day 1 of treatment periods with Treatment A.
45487496|NCT03688958|Drug|iodine|Selected patients with early breast cancer (stage II) non-pretreated received iodine solution (Experimental) within the time before the hospital assigned them to her surgery (7 to 35 days).
45487497|NCT03688958|Drug|FEC/TE Placebo|The selected patients with advanced breast cancer (stage III) non-pretreated received colored water solution (placebo) within the time of oncology designed chemotherapy treatment FEC/TE (4 or 6 cycles/ every 21 days).
46052641|NCT04236453|Drug|Darunavir|Participants will receive a single dose of Darunavir orally on Day 1 of treatment periods with Treatment B.
45369215|NCT02564315|Behavioral|Cessation Phase Brief Information|Participants randomized to receive Brief Information will receive brief (generic) information about the importance of taking the cessation medication, how to use the medication, information about side effects/safety, and what to do in case of problems, and will also be given encouragement to quit smoking.
46052642|NCT04236453|Drug|Emtricitabine/Tenofovir Alafenamide|Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally on Day 1.
46052643|NCT04236453|Drug|Cobicistat|Participant will receive a single dose of Cobicistat tablet orally on Day 1.
45487498|NCT03688958|Drug|FEC/TE iodine|The selected patients with advanced breast cancer (stage III) non-pretreated received iodine solution (experimental) within the time of oncology designed chemotherapy treatment (4 or 6 cycles/ every 21 days).
45369216|NCT02564315|Drug|Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge|All participants will receive 8-weeks of combination NRT (nicotine patch + nicotine mini-lozenge). Nicotine patch dosing will be based on current cigarettes smoked per day, per package insert: for those who currently smoke >10 cigs/day=4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches, along with nicotine mini-lozenges; for those who currently smoke <=10 cigs/day=6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches along with mini-lozenges. Mini-lozenge dosing will be based on how soon participants currently smoke after waking before their initial quit attempt and will be consistent with the package insert (4 mg for participants who smoke within 30 minutes of waking and 2 mg for participants smoke more than 30 minutes after waking).
45487499|NCT05192616|Device|Covered stent implantation|Percutaneous transluminal angioplasty (PTA) with iCover covered stent for the treatment of de novo aorto-iliac occlusive lesions
45487500|NCT03698942|Device|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
45369217|NCT00743015|Drug|BI 44370 TA tablet|
45487501|NCT05196204|Other|Trunk-oriented task training combined with functional electrical stimulation|Training will consist to perform one hour of trunk task-oriented training combined with functional electrical stimulation (FES/T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. FES will be combined with functional and non-functional tasks to work functionality and muscle strengthening. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises.
45487502|NCT05196204|Other|Trunk-oriented task training alone|"The SCI participants who will perform T-TOT training alone will have to perform the same exercises as explained in the previous section (two functional tasks and two non-functional tasks) but they will not receive any functional electrical stimulation.~Training will consist to perform one hour of trunk task-oriented training (T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises."
45487503|NCT03688646|Dietary Supplement|Intensive Nutrition Intervention|
45487504|NCT05196048|Other|No Intervention|No Intervention
45487505|NCT04080050|Drug|Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy|No investigational product will be administered in this study. All participants have previously received a one-time intravenous infusion of RGX-501 in a separate clinical trial
45487506|NCT04117607|Other|Placebo|5% Dextrose Injection, USP, a sterile, nonpyrogenic solution of dextrose in water for injection. The solution has the osmolarity of 252 mOsmol/L, which is slightly hypotonic. This solution contains no bacteriostat, antimicrobial agent or added buffer.
45487507|NCT04117607|Drug|Rezafungin|Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
45369218|NCT02564237|Biological|StreptAnova™ (Group A streptococcal (GAS) vaccine)|StreptAnova™ vaccine - 30-valent plus Spa group A Streptococcal vaccine
45487508|NCT04117607|Drug|Rezafungin|Rezafungin, 200 mg/vial, is a sterile product supplied as a white to pale yellow lyophilized powder in single-dose glass vials for reconstitution with Sterile Water for Injection, United States Pharmacopeia (USP). The reconstituted product is diluted in 0.9% Sodium Chloride Injection, USP for IV infusion. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredients include excipients of mannitol, polysorbate 80, and histidine.
45487509|NCT03657654|Other|No intervention: observational only|No intervention: observational only
45487510|NCT03688568|Drug|Imatinib Mesylate|Imatinib given orally as dose escalation treatment.
45487511|NCT05192304|Drug|TPN-672|single dose of TPN-672 maleate tablet
45369219|NCT02564237|Biological|Hepatitis B vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
45369220|NCT02564237|Biological|Hepatitis A vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
45487512|NCT03693872|Drug|Apomorphine|Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient
45487513|NCT03693872|Drug|Dopaminergic Agonist + Apomorphine|Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient and associated with dopaminergic agonists
45487514|NCT01375296|Device|China-made SES (Firebird 2 and Excel)|patients with coronary 50-70% narrowing treated with China-made SES stent,i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
45487515|NCT01375296|Other|routine medicine|patients with coronary 50-70% narrowing treated with routine medicine
45487516|NCT03527862|Other|Treatment according to lung ultrasonography|Appropriate treatment for atelectasis, pleural effusion, pulmonary edema, pneumothorax or pneumonia which are confirmed by lung ultrasonography
45487517|NCT04430660|Other|13C-MRS procedure/Acetate infusion|Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples.
45487518|NCT04430660|Device|Continuous glucose monitoring|Participants will wear blinded continuous glucose monitoring devices (dexcom, G6) for approximately 4 weeks. Sensors will be replaced every 7-10 days.
45369221|NCT02564237|Biological|Human Papillomavirus vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
45487519|NCT03744143|Procedure|longitudinal suture|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a longitudinal suture
45487520|NCT03744143|Procedure|transverse suture|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a transverse suture
45487521|NCT03744143|Procedure|Removal of vaginal endometriotic nodule|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, or vaginal technique, isolating the nodule through the vagina.
45369222|NCT00434512|Biological|HIV vaccine 732461|
45369223|NCT02564939|Drug|ramelteon|double-blind RCT
45369224|NCT02564939|Drug|Placebo|double-blind RCT
45369225|NCT02564783|Other|No intervention|No intervention
45369226|NCT03605771|Other|Daily Clinical Practice|The assignment of a patient to a specific therapeutic strategy will not be decided in advance by the study protocol, but will be determined by the usual clinical practice of medicine, and the decision to prescribe a specific treatment will be clearly dissociated from the decision to include a patient in the study. No intervention will be applied to patients, either diagnostic or follow-up, other than the usual clinical practice.
45369227|NCT03552965|Other|Robust Radiotherapy planning|Investigator will plan Intensity-Modulated Radiation Therapy (IMRT) using calculations that minimize the dose of radiation to normal tissue
45369228|NCT03552965|Other|Margin-Based Radiotherapy planning|Investigator will plan Intensity-Modulated Radiation Therapy (IMRT) using calculations that introduce a margin to the target area
45487522|NCT05191992|Other|CPR training with e-learning with a handmade mannequin.|The group, who was given theory training with the e learning method, will be taught to make pillows and plastic bottles and cpr mannequins, and they will be asked to practice. Knowledge and skills assessment will be made before, immediately after and 1 month after the training.
45487523|NCT03693638|Drug|Bupivacaine-fentanyl|2,5 ml total anesthetic drug dose were given with 0.2 ml/second rate, and subjects were asked to remain sitted for 90 seconds
45487524|NCT03693638|Drug|Bupivacaine-fentanyl|1,5 ml of total anesthetic drug dose followed by 1 ml remaining dose after 90 s interval were given
45487525|NCT04112303|Drug|SOF/VEL|Tablets administered orally once daily
45487526|NCT01319838|Drug|Isotretinoin|>12 kg: 160 mg/m2/day, given PO, divided BID <=12 kg: 5.33 mg/kg/day, given PO, dividied BID doses given days 1-14 of 28 day cycle for 24 consecutive cycles
45487527|NCT05195580|Device|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
45487528|NCT03693482|Diagnostic Test|the Four Square Step test|A square will be formed by using four 90 cm long canes placed on the ground. The sequence will be explained and demonstrated to the participants. They will be allowed one practice trial and subsequently two trials. Instructions will be given and encouraged to complete the sequence as fast as possible without touching the canes. The sequence of trial was 1,2,3,4,1,4,3,2,1. If a participant touch the canes, or perform the test sequence inaccurately, or both feet of the participant do not make contact with the floor in each square, the trial will be considered as unsuccessful and the test will be repeated. One unsuccessful trial will be allowed. The best time will be taken as the score of FSST which are completed successfully.
45487529|NCT03634566|Drug|N-Acetylecysteine|N-Acetylecysteine 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
45487530|NCT03634566|Drug|Placebo|Ringer acetate continuous infusion at the same rate for 2 days.
45487531|NCT03998189|Other|Breath Collection|Pre-surgery, two 500 ml of exhaled breath volatiles (EBV) in each of 4 collection tubes will be collected in 5-7 min of breathing
45487532|NCT03998189|Other|Saliva Collection|Pre-surgery, 2 ml minimum of saliva will be collected into SalivaBio Passive Drool collection tubes
45487533|NCT03998189|Other|Blood Collection|Pre-surgery, an optional 5 ml blood sample in each redtop and purple top vacutainer blood collection tube
45487534|NCT03998189|Other|Urine Collection|Pre-surgery, 25 ml minimum of urine will be collected in sterile specimen containers
45487535|NCT03998189|Other|Tumor Collection|During surgical tumor removal, a tumor tissue sample will be collected
45487536|NCT03998189|Other|Medical History Data Collection|Medical history will be obtained from the patients charts to identify demographics (age, race, ethnicity, zip code), oncologic history (date of diagnosis and cancer type), and medical history of disease.
45487537|NCT01372098|Behavioral|NFP + IPV intervention|The intervention focuses on helping women stay safe in a relationship. Strategies for overcoming barriers to using and accessing community resources and services, and community agency interventions for women exposed to IPV is built into the intervention.
45487538|NCT03688412|Device|Cook lead extraction devices|The Cook lead extraction devices are mechanical devices that encompass a full variety of devices required for percutaneous removal of CIED leads, indwelling catheters and foreign objects.
45487539|NCT01373892|Procedure|Bariatric surgery|
45487540|NCT04068038|Other|Ventilation protocol|An evidence based ventilation protocol will be implemented at participating sites. This will include limits on peak inspiratory pressure (28cmH2O), driving pressure (16cmH2O), tidal volume (mild 8ml/kg, mod/severe 6ml/kg), positive end expiratory pressure to fraction of inspired oxygen table, permissive hypercarbia (mild allow pH 7.30, mod/severe allow pH 7.20) and permissive hypoxia (mild SpO2 92-97%, mod/severe SpO2 88-92%).
45487541|NCT04103567|Other|Biological collection|Fecal samples collected at different times : during inclusion consultation with surgeon, after neoadjuvant treatment and before surgery.
45369229|NCT02470468|Biological|DCVAC add on to SOC|DCVAC add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
45369230|NCT02470468|Biological|DCVAC and immune enhancers add on to SOC|DCVAC +/- immune enhancers (Interferon-α and Hydroxychloroquine) add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
45369231|NCT02470468|Other|Standard of Care Chemotherapy|SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
45369232|NCT00921635|Procedure|Blood transfusion|Blood transfusion to maintain hemoglobin level above 120 g/L
45369233|NCT00921635|Procedure|Blood transfusion|Blood transfusion to maintain hemoglobin level above 100 g/L
45369234|NCT00427648|Drug|alkalinized xylocaine|30 cc of 1% xylocaine and 10 cc of 0.9% sodium bicarbonate, dosed twice a week for three weeks
45369235|NCT00427648|Drug|placebo|normal saline
45369236|NCT02153177|Procedure|Rotator cuff repair|Arthroscopic procedure
45487542|NCT03355872|Drug|HLX01|Biosimilar of Rituximab
45487543|NCT03744065|Procedure|lumbar plexus block|Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, in the posteromedial quadrant of psoas muscle
45487544|NCT03744065|Procedure|suprainguinal fascia iliaca block|Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, underneath the fascia iliaca at the suprainguinal level
45487545|NCT05191914|Drug|Chidamide+ Fulvestrant|"Drug: Chidamide chidamide 30mg orally，Biw~Drug: Fulvestrant Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1"
45487546|NCT04060394|Drug|Phase I and Phase II: LAE001/prednisone + afuresertib|In the Phase I portion of the study will identify the RPD2 of the combined therapy. In the Phase II will evaluate LAE001/prednisone + afuresertib at the RP2D (Cohort 1) and docetaxel/prednisone + afuresertib (Cohort 2).
45487547|NCT03688334|Drug|Oxygen 40 %|Oxygen supplementation (40%) via Venturi mask
45487548|NCT03688334|Drug|Medical air (sham O2)|Medical air supplementation via Venturi mask
45487549|NCT05191836|Behavioral|Evaluation of the effectiveness of Video Game Distraction in the management of anxious pediatric patients during dental treatment|"The child will be provided dental treatment during watching video game.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
45487550|NCT05191836|Behavioral|Evaluation of the effectiveness of Audio Video Distraction in the management of anxious pediatric patients during dental treatment|"The child will be provided dental treatment during audio video distraction.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~The child will be provided dental treatment during watching video game. All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
45487551|NCT05191836|Other|Evaluation of the anxiety in pediatric patients during dental treatment without using any type of distraction aids|"The child will be provided dental treatment without using any type of distraction aids.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~The child will be provided dental treatment during watching video game. All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
45487552|NCT04099277|Drug|LY3435151|Administered IV
45487553|NCT04099277|Drug|Pembrolizumab|Administered IV
45487554|NCT03698786|Behavioral|Exercise|Participants will be required to complete two, 8-hours trials (exercise & control) in a randomised order, preceded by 2 hours of preliminary testing (baseline) with no more than 14 days between conditions.
45369237|NCT02153177|Drug|Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole|In addition to pain medication after the procedure patients will receive Ibuprofen and Omeprazole. Omeprazole is given to minimize the gastrointestinal side effects of Ibuprofen.
45487555|NCT03311256|Diagnostic Test|Tissue Transit Time|Determination of Tissue Transit Time as a prognostic and diagnostic factor
45487556|NCT03743987|Procedure|control group|a procedure used to prevent or resolves apical periodontitis.
45487557|NCT03743987|Procedure|MTA group|a procedure used to prevent or resolves apical periodontitis.
45487558|NCT03743987|Procedure|PRF group|a procedure that is used for wound healing
45487559|NCT03743987|Procedure|MTA + PRF group|a procedure used to prevent or resolves apical periodontitis in combination with a procedure that is used for wound healing.
45487560|NCT03688256|Device|Obalon Balloon System|6 month Obalon Intragastric Balloons
45691830|NCT00650260|Device|Bair Hugger™ (Arizant Healthcare, Eden Prairie, MN)|The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket.
45691831|NCT04582201|Drug|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
45369238|NCT02153177|Drug|Hydrocodone/Acetaminophen|Hydrocodone/Acetaminophen is given for pain control after the surgery.
45369239|NCT00743327|Drug|Pioglitazone|45mg capsule, once daily for 1 year
45369240|NCT01032460|Device|intubate with the macintosh laryngoscope|intubate with the macintosh laryngoscope
45369241|NCT01032460|Device|intubate with the C-MAC laryngoscope|intubate with the C-MAC laryngoscope
45369242|NCT01032460|Device|intubate with the Airtraq device|intubate with the Airtraq device
45487561|NCT05171322|Device|WARD|"The following monitoring devices are included in the WARD monitoring system (as intervention):~Isansys Life Touch patch: Measures heart rate (HR), respiratory rate (RR) and electrocardiogram (ECG)~Wearable, wireless Pulse Oximeter (Model 3150 WristOx from Nonin): Measures peripheral oxygen saturation of arterial hemoglobin (SpO2) and pulse rate (PR)~Blood pressure monitor (Meditech BlueBP-05): Measures BP every 30 minutes during daytime and every 60 minutes during the night~All included patients are set up with the monitoring devices after surgery when they are back at their ward (with a maximum of 24 hours postoperative). Afterwards they wear the devices for up to 5 days. All measurements are sent through bluetooth to a tablet serving as a gateway which in turn sends data to a central server where the algorithmic processing ensures."
45487562|NCT04053842|Diagnostic Test|PET Scan|PET imaging uses small amounts of a radioactive substance called a tracer to look for disease in the body. The radioactive substance used in this study is [18F]PSMA-1007.
45487563|NCT04053842|Drug|[18F]PSMA-1007 Injection|[18F]PSMA-1007 is given by intravenous (IV) injection into the arm. It travels through the blood stream where it is rapidly taken up by prostate cancer cells and emits tiny, positively charged particles (called positrons) that produce signals into the body. These signals are detected by the PET component of the PET/MRI scanner.
45487564|NCT04053842|Diagnostic Test|Sodium MRI|Sodium MRI uses magnetic waves and a specially-designed rectal probe to measure the sodium concentration (amount of salt) in the prostate. Previous research has shown that higher sodium concentrations in the prostate might be a sign of more aggressive cancer.
45487565|NCT04053842|Diagnostic Test|Multiparametric MRI|MRI is a common medical diagnostic tool that uses magnetic waves and a contrast agent (dye) called Gadovist to take pictures of body tissue.
45487566|NCT03990389|Device|Chatbot Intervention|a chatbot will be used to monitor depression severity
45487567|NCT04044794|Behavioral|Standard Care|Standard care includes standardized educational materials to promote self-management of body weight along with provision of $60 for participants to purchase supplies or equipment to facilitate weight management.
45691832|NCT00651040|Drug|Prednisone|Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms
45691833|NCT00651040|Drug|Methotrexate|MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
45691834|NCT01184950|Other|Trainer Curriculum|
45691835|NCT02997748|Procedure|Remote ischemic preconditioning (RIPC)|3 cycles or more cycles of 5 to 10-min inflation of a blood-pressure cuff to 200 mm HG (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed in arm 6.
45369243|NCT03888599|Behavioral|knowledge questioannaire|", all enrolled undergraduate student received directly on your email the online questionnaire based on the Fluid Survey tool, which was an on line survey tool (https://fluidsurveys.com/)"
45369244|NCT02564861|Drug|DS-1971a|DS 1971a is supplied as a powder or crystals and will be given as an oral suspension
45369245|NCT02564861|Drug|Placebo|Placebo matching DS-1971a suspension
45369246|NCT00416884|Drug|Campath|30 mg on day -8 over 5-6 hours
45369247|NCT00416884|Drug|Fludarabine|Fludarabine 30 mg/m^2 on day -4 through day -2
45369248|NCT00416884|Radiation|Total Body Irradiation (TBI)|Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0
45369249|NCT00416884|Other|T-Cell Deplete|Stem cells will be T cell depleted and given on day 0
45369250|NCT02564627|Procedure|Self-applied patch|An ambulatory self-applied patch will be placed weekly by the patients for PENS of dermatome T6.
45369251|NCT02564627|Procedure|Conventional procedure|PENS of dermatome T6 will be applied by the MD in the Outpatient Clinic.
45369252|NCT02564627|Dietary Supplement|1200 Kcal/day diet|A 1200 Kcal/day diet will be prescribed.
45369253|NCT00743405|Drug|GSK1034702|Oral or liquid
45369254|NCT00743405|Drug|Placebo|To match GSK1034702
45369255|NCT01032616|Other|Threonine Experimental: Study Period 1|Enteral and parenteral infusion of threonine isotope
45369256|NCT01032616|Other|Lysine Experimental: Study Period 2|Both intravenous (iv) and intragastric (ig) Lysine isotopes.
45369257|NCT02564081|Other|Static Stretching lower limb|
45487568|NCT04044794|Behavioral|Daily Self-Weighing|Participants will receive a wireless digital scale and will be asked to keep the scale in their home, weigh daily at the same time, and view their weight trajectory on the scale's digital display.
45487569|NCT03168360|Procedure|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hours on every working day during subacute stroke phase
45487570|NCT04037462|Drug|Dexamthasone|escalating doses of pretreatment dexamethasone in patients who have failed initial immunotherapy to 1. assess changes in FLT PET uptake 2. assess overall response rates of pretreatment dexamethasone (dose from 1) on subsequent immunotherapy re-challenge
45487571|NCT05194878|Drug|neoadjuvant chemotherapyI|mFOLFOXIRI (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV Irinotecan 150 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 48h every 14 days) for 6 cycles followed by colectomy (3 to 6 weeks after) . If PD was observed after 3 cycles, direct colectomy was performed.
45487572|NCT05194878|Procedure|Colectomy|Radical colectomy
45487573|NCT05194878|Drug|adjuvant chemotherapy|mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) . CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) . Oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days. The plan and cycles are determined according to the surgical pathology and physical conditions.
45487574|NCT03693326|Drug|PDR001|PDR001 300 mg (fixed dose) intraveneously every 3 weeks
45487575|NCT01319916|Drug|ATX-101|ATX-101 2mg/cm2
45487576|NCT03988907|Drug|Risdiplam|Part 1: a dose of 5 milligram (mg) risdiplam QD ; Part 2: precise dose will be based on Part 1 results
45487577|NCT03988907|Drug|Midazolam|single dose administration of 2 mg midazolam
45487578|NCT03693248|Drug|Two cycles of neoadjuvant chemotherapy|Two and three cycles of neoadjuvant chemotherapy will be administered in experimental and control groups, respectively
45691836|NCT00654784|Drug|idebenone|idebenone 450 mg/day (150 mg three times a day)
45487579|NCT03987191|Drug|Multiple daily ijnection using Insulin Degludec and Insulin Aspart|Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
45487580|NCT04098809|Device|16 French urinary catheter|16 French urinary catheter
45487581|NCT04098809|Device|20 French urinary catheter|20 French urinary catheter
45487582|NCT03122184|Behavioral|Positive Psychology + Motivational Interviewing|For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
45487583|NCT03122184|Behavioral|Motivational Interviewing Health Education|Each week, participants will learn about a different health behavior topic related to cardiac health. They will also be introduced to motivational interviewing topics in concert with the health behavior education topics. The intervention is divided into five sections, focusing on five different important cardiac health-related topics (recovery from an acute cardiac illness, physical activity, a heart-healthy diet, medication adherence, and stress reduction).
45487584|NCT03745781|Drug|Placebos|placebo pills
45487585|NCT01372176|Other|Early Goal-Directed Nutrition|"Initiation of early supplementary parenteral nutrition (≤ 24 hours of admission).~Measurement of requirements (indirect calorimetry, 24-hour urinary urea) leading to patient-specific, individualised and goal-directed nutritional therapy.~Intervention goal: delivering 100% of patient-specific requirements, measured or calculated throughout entire admission (EN+PN)."
45487586|NCT01372176|Other|ASPEN-guidelines|EN will be the preferred route of nutrition, and will be initiated within the first 24 hours of ICU admission, in accordance with best evidence. The amount is gradually increased over the first days of admission as tolerated by the patient (assessed from gastric aspirates). If EN fails to reach calculated goals at day 7, supplementary PN will be initiated at admission day 8 to reach goals. Protein and energy goals will be calculated as 25 kcal/kg/day and 1.2 g protein/kg/day.
45487587|NCT04396106|Drug|AT-527|One 550 mg tablet of AT-527 administered every ~12 hours (twice a day) for a total of 5 days
45691837|NCT00654784|Drug|placebo|
45487588|NCT04396106|Other|Placebo|One placebo tablet administered every ~12 hours (twice a day) for a total of 5 days
45487589|NCT04396106|Drug|AT-527|Two 550 mg tablets of AT-527 administered every ~12 hours (twice a day) for a total of 5 days
45487590|NCT04396106|Other|Placebo|Two placebo tablets administered every ~12 hours (twice a day) for a total of 5 days
45487591|NCT03743831|Device|orotracheal intubation by direct laryngoscopy|Orotracheal intubation by direct laryngoscopy by metal blade type Macintosch
45487592|NCT03743831|Device|orotracheal intubation by indirect laryngoscopy|orotracheal intubation by indirect laryngoscopy by Airtraq
45487593|NCT01373970|Drug|Placebo|Placebo, one tablet daily for 12 weeks
45487594|NCT01373970|Drug|Pantoprazole + Placebo|Pantoprazole 40 mg, one tablet daily in eight weeks followed by a blinded cross over to placebo, one tablet daily for four weeks
45487595|NCT03743675|Behavioral|Diet-Induced Weight Loss|Diet-Induced Weight Loss: The goal of the diet intervention is to produce a weight loss of approximately 5-10% of body weight over the six-month period, which is consistent with the goals for obesity treatment outlined by the Academy of Nutrition and Dietetics (AND). According to the 2016 AND position paper for obesity-related interventions, this level of weight loss produces clinically significant reductions in biometrics (biochemical and anthropometrics measurements) and associated risk factors for chronic disease. Additionally, obese older adults who achieve weight loss intentionally through lifestyle changes experience improved physical function. This intervention will last for 6-months with bi-weekly face-to-face counseling sessions with a registered dietitian.
45487596|NCT03743675|Behavioral|Aerobic Exercise Training|"Exercise Intervention: Subjects will exercise on a cycle ergometer during the training sessions. Each session will consist of 1) a 5-10 minute warm up at light intensity; 2) a 20 to 30-minute training phase at moderate-to-vigorous intensity; and 3) a 5-minute cool down phase at light. The training will be conducted 3 days per week for 6 months."
45487597|NCT04050098|Drug|gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release|"Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base)."
45487598|NCT04050098|Drug|Gemigliptin tartrate sesquihydrate and metformin|Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
45487599|NCT03117036|Drug|Chemotherapy|Systemic chemotherapy with curative intent
45487600|NCT03745625|Drug|HSK3486|"First-stage:after an initial dose of 1mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: a single loading dose of 0.2 mg/kg given over 1 minute, then a continuous infusion of maintenance dose 0.35 mg/kg/h for a total infusion time of 12h."
45487601|NCT03745625|Drug|Propofol|"First-stage: after an initial dose of 5mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: loading dose of 1mg/kg given over 1 minute, then a continuous infusion of maintenance dose 1.75 mg/kg/h for a total infusion time of 12h."
45487602|NCT04021706|Drug|Anamorelin Hydrochloride|Ghrelin receptor agonist
45487603|NCT04021706|Drug|Placebo|placebo is a inert substance
45487604|NCT05194020|Other|Primary Services|Participants receive 16 hours of Father Factor curricula, 4 hours of The New Playbook curricula, 4 hours of Money Smart curricula over the course of five weeks. Participants also receive on-going job readiness support and post-employment support.
45487605|NCT03698630|Drug|Prednisolone Sodium Phosphate|Prednesol 5mg Tablets (Phoenix Labs Ltd). Pink, circular, flat, bevel-edged scored tablets containing 5 mg of prednisolone as prednisolone sodium phosphate.
45487606|NCT03698630|Drug|Dexamethasone|"Dexamethasone 2 mg tablets (Organon Ireland Ltd). Round, 6 mm, flat, white tablet with the code XC/8 engraved on one surface and Organon* on the other containing 2 mg dexamethasone."
45487607|NCT01375452|Drug|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
45487608|NCT03053466|Drug|APL-501|"Subjects will be assigned to a dose level in the order of study entry. Treatment includes a minimum of four 28-day cycles at three planned dose levels (1, 3, and 10 mg/kg). In the Dose Escalation Segment, each treatment cycle is comprised of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle. In the Cohort Extension, the treatment cycle will consist of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle.~In Dose and Disease Expansion, the treatment cycle will consist of 2 doses of study drug (non-weight based dosing of 400 mg) administered on Days 1 and 15 of a 28-day cycle."
45487609|NCT03687944|Other|Validity and reliability|Test-retest method and concurrent validity
45487610|NCT05131308|Other|leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA|All patients were evaluated and followed with imaging, and per investigators' respective clinical judgement, then proceeded to have an intervention for leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA.
45487611|NCT03624140|Device|blood measurement|Hemoglobin measurement
45487612|NCT03624140|Device|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
45487613|NCT03624140|Device|hemoCue|non invasive method of hemoglobin measurement
45487614|NCT04091087|Drug|crisaborole ointment|crisaborole ointment
45487615|NCT04091087|Other|vehicle ointment|vehicle ointment
45487616|NCT03687866|Genetic|non invasive prenatal testing|
45487617|NCT03046836|Drug|Oxytocin|40 IU oxytocin nasal spray
45487618|NCT03046836|Drug|Placebo|Saline
45691838|NCT02997514|Behavioral|Solution Focused Coaching|SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
45487619|NCT03687788|Behavioral|Laughter Therapy|Laughter therapy program was composed of four steps. The first step, which took 10 minutes, had warm-up exercises including gentle stretching and hand clapping. The second step, which included deep breathing exercises and hand clapping, took 5 minutes. The third step involved children's games and laughter exercises. In this step, the most common laughter exercises were milkshake laughter, bugi bugi laughter techniques, lion laughter, cell phone, hot soup laughter, hug laughter, bird laughter, dialogue with nonsense, speech exercises, laugh at one's own aches and pains exercises, argument laughter, brushing teeth and mouthwash exercises. The sessions included a combination of different laughter exercises. This step took 15 minutes. The last step, which included wishes and resting by breathing, took 10 minutes.
45487620|NCT03400033|Drug|Daprodustat tablets|Round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
45487621|NCT03400033|Drug|Matching placebo tablets|Matching placebo to daprodustat tablets supplied as round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
45487622|NCT03400033|Drug|Epoetin alfa vials|Single-dose, preservative-free vials in unit dose strengths of 2000, 3000, 4000 and 10,000 Units/milliliter administered by the IV route.
45487623|NCT03400033|Drug|Saline vials or bags|0.9% sodium chloride saline vials or bags administered by the IV route.
45487624|NCT02995902|Device|FLT-PET|
45487625|NCT02995902|Device|MRI|
45487626|NCT05123820|Drug|Treatment period A|Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
45487627|NCT05123820|Drug|Treatment period B|ACT-1014-6470 soft capsule for oral administration. Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
46052644|NCT03705078|Procedure|Transjugular Portosytemic Shunt (TIPS)|The TIPS is placed under radiologic guidance. A branch of the intrahepatic portal vein is punctured; afterwards, the splenic vein is catheterized so that a portal venography and pressure measurements can be performed. Then, the parenchymal track is dilated and a stent is placed. A final portography and pressure measurement in the main portal vein and the inferior caval vein are performed.
45691839|NCT02997514|Behavioral|Intensive Solution Focused Coaching|Intensive SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
45691840|NCT01799824|Biological|ANT-1403|
45691841|NCT01799824|Biological|placebo|
46052645|NCT03705078|Procedure|glue obliteration|The standard protocol uses cyanoacrylate and lipiodol in 1:1 ratio injecting with no more than 1 mL at the varix each time. In most cases, cyanoacrylate is usually extruded into the stomach lumen within 1-3 months after injection. The French observational survey observed that a large majority (78%) of practitioners diluted glue with lipiodol and most (68%) proposed a proportion of glue to lipiodol of 1:1 the total volume injected per varix (from 1mL to 20 mL) varied substantially. Regarding the type of glue, although the majority of published data concern Histoacryl®, nearly half of practitioners used Glubran®. This lack of preference for one glue over the other may be explained by the fact that only Glubran® is approved in this indication in Europe.
46052646|NCT02807571|Procedure|Wide Awake Local Anesthesia No Tourniquet|Wide Awake Local Anesthesia No Tourniquet for office based hand surgery.
46052647|NCT02801019|Other|E-poly|comparison of two different polyethylene plastic 0,04 mm at 3 months 0,06 at 2 years
46052648|NCT02801019|Other|ArComXL|comparison of two different polyethylene plastic 0,03 mm at 3 months 0,10 mm at 2 years
46052649|NCT02800473|Device|Strorz (commercial)|
45369258|NCT02564081|Other|Static stretching Cervical|
45369259|NCT01032772|Behavioral|Choices Plus|Participants in this condition will receive two brief, motivational-interviewing-based counseling sessions.
45369260|NCT01032772|Behavioral|Information|Participants are provided with informational materials about healthy lifestyle and local resources.
45369261|NCT03507257|Drug|Flortaucipir|All participants will receive a single bolus intravenous injection of approximately 10 mCi (+/- 10%, 20μg mass dose) of flortaucipir (18F-AV-1451). At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
45369262|NCT03507257|Drug|Florbetaben|All participants will receive a single bolus intravenous injection of approximately 8 mCi +/- .8mCi of florbetaben (AV-45). At approximately 90-minutes (+/- 10 minutes) post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
45369263|NCT03507257|Drug|Fluorodeoxyglucose|All participants will receive a single bolus intravenous injection of approximately 5 mCi (+/- 10%, 0.5 mCi) of fluorodeoxyglucose. At approximately 30 minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
45369264|NCT00434122|Drug|Degarelix mid-luteal, 2.5 mg|Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
46052650|NCT02800473|Device|CyPaM2 (experimental)|
46052651|NCT00770965|Biological|AIN457|
46052652|NCT00770965|Biological|Placebo|
46052653|NCT04096651|Other|gait recordings|gait recordings
45369265|NCT00434122|Drug|Placebo|"Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day."
45369266|NCT00555620|Drug|capecitabine|Capecitabine is given orally at 1000mg/m^2 twice a day for 14 days followed by 7 days of drug free period.
45369267|NCT00555620|Drug|oxaliplatin|Oxaliplatin is given 110mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
45487628|NCT04089761|Device|Nerivio|Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
45487629|NCT03118518|Device|Cryoablation|Pulmonary vein isolation via ablation with cryoballoon catheter
45487630|NCT03118518|Drug|Antiarrhythmic drug|Antiarrhythmic drug initiation
45487631|NCT03984305|Device|Personal KinetiGraph® (PKG®) Watch|"The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~A wrist-worn data logger (PKG Watch) designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~An application to configure the data logger and transfer the acquired data at the end of a recording."
45487632|NCT03984305|Device|Personal KinetiGraph® (PKG®) Report|"The Personal KinetiGraph (PKG®) Movement Recording System was developed by neurologists at the Melbourne-based Florey Institute of Neuroscience and Mental Health. The product is manufactured and marketed by GKC.~The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~• A series of algorithms that analyze the uploaded data, producing a PDF that is delivered to the clinician. The PDF contains objective data distinguishing the movement patterns consistent with tremor, bradykinesia, dyskinesia and immobility."
45487633|NCT03397771|Drug|Litoxetine|oral study medication provided in a dose titration manner
45691842|NCT04387396|Other|Exercise|Exercise specific to knee osteoarthritis.
45691843|NCT01801111|Drug|Erlotinib|Erlotinib will be administered at a dose of 100 mg via tablet, orally, once daily in combination with alectinib to participants who progressed on alectinib alone treatment as per treating physician discretion.
45691844|NCT01801111|Drug|Alectinib|Alectinib will be administered at a dose of 600 milligrams (mg) via capsule, orally, twice daily.
46052654|NCT04096651|Other|brain magnetic resonance imaging|brain magnetic resonance imaging
46052655|NCT04096651|Other|oculomotor movement recordings|oculomotor movement recordings
46052656|NCT02806557|Device|Home finger-prick capillary blood count monitoring|A nurse will visit the participant's home according to the test schedule (up to a maximum frequency of 21 visits in a 21-day cycle) and perform the finger-prick capillary blood test and measure the neutrophil count using the Hemocue® WBC DIFF device.
46052657|NCT05333250|Drug|Modafinil|Modafinil
46052658|NCT05333250|Other|Placebo|Placebo
45369268|NCT00555620|Drug|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
45369269|NCT00555620|Drug|capecitabine|Capecitabine is given orally at 1000mg/m^2 twice a day for 14 days followed by 7 days of drug free period.
45691845|NCT00691600|Drug|oral trimethoprim/sulfamethoxazole|80 mg caps or 8 mg/ml suspension every 12 hours for 10 days
45691846|NCT00691600|Drug|Placebo|Placebo caps or suspension every 12 hours for 10 days
46052659|NCT05461339|Drug|TAB014 Monoclonal Antibody Injection|intravitreal injection at 1.25mg once every 4 weeks
45487634|NCT03397771|Drug|placebo|placebo medication provided in a dose titration manner
45487635|NCT05009160|Device|dreaMS App R2.1|The Healios+Me platform App which contains the dreaMS App will be downloaded by all participants and all participants (PwMS and HC) will follow the same schedule
45487636|NCT03711721|Dietary Supplement|Food basket|
45487637|NCT03711721|Dietary Supplement|Ready-to-Use Therapeutic Food|
45487638|NCT05166954|Procedure|LSG|Laparoscopic sleeve gastrectomy (LSG) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
45487639|NCT05166954|Procedure|RYGB|Roux-en-Y gastric bypass (LRYGB) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
45487640|NCT02876835|Drug|Daprodustat|The initial dose or oral daprodustat for ESA naïve subjects is based on Hgb and for ESA users is based on prior ESA dose. The dose is adjusted thereafter in order to achieve the target range.
45691847|NCT00655642|Drug|Ondansetron|4 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
46052660|NCT05461339|Drug|Ranibizumab Injection [Lucentis]|intravitreal injection at 0.5mg once every 4 weeks
46052661|NCT02806479|Other|Observational: Arrhythmogenic Substrate|
45487641|NCT02876835|Drug|Darbepoetin alfa|The initial dose of darbepoetin alfa to be administered for SC injection for ESA naïve subjects is based in Hgb and weight, and for ESA users is based on converting the prior ESA dose to the nearest available study darbepoetin alfa dose. The dose is adjusted thereafter in order to achieve the target range. IV darbepoetin alfa can be considered for participants transitioning to hemodialysis.
45487642|NCT02876835|Drug|Placebo|Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
45487643|NCT02876835|Drug|Iron Therapy|Participants will receive supplemental iron therapy if ferritin is <=100 ng/mL or TSAT is <=20%. The investigator will choose the route of administration and dose of iron.
45487644|NCT04086641|Device|Crossover foot|A prosthetic foot that features an extended strut (keel) that attaches to the posterior proximal aspect of the prosthetic socket.
45487645|NCT04086641|Device|Energy Storing Foot|A prosthetic foot that features a short strut (keel) that attaches to the distal aspect of the prosthetic socket.
45487646|NCT03503318|Drug|TV-46000|TV-46000 will be administered per dose and schedule specified in the arm.
45487647|NCT03503318|Drug|Placebo|Placebo matching to TV-46000 will be administered per schedule specified in the arm.
45369270|NCT00555620|Drug|cisplatin|Cisplatin is given 80mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
45369271|NCT00555620|Drug|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
45369272|NCT00433966|Drug|Bivalirudin|Bivalirudin bolus of 0.75 mg/kg IV, followed by an infusion of 1.75 mg/kg/h as soon as logistically feasible (ideally in the emergency room).
45369273|NCT00433966|Drug|Unfractionated heparin|60 U/kg of IV heparin, started as soon as possible (ideally in the emergency room).
45487648|NCT03396913|Device|IPL|Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
45487649|NCT03396913|Device|Sham IPL|Sham intense pulsed light (IPL) will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of10-15 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
45487650|NCT03396913|Procedure|MGX|Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps
45487651|NCT01375920|Drug|Metyrapone|500 milligrams to be taken twice a day orally
45487652|NCT01375920|Drug|placebo|a matched placebo will be administered to patients to take twice a day for 3 weeks
45487653|NCT03982433|Behavioral|Motivation and Cognitive Behavioral Management for Alcohol and Pain|Behavioral intervention that includes motivational, cognitive, and behavioral intervention strategies to reduce heavy drinking and chronic pain interference
45487654|NCT03396835|Device|INVSENSOR00009|All subjects who are enrolled into the test group and participate in data collection receive both the INVSENSOR00009 and the control sensor simultaneously on the forehead.
45487655|NCT01375998|Drug|EE20/DRSP(YAZ, BAY86-5300)|Patients in daily life treatment receiving YAZ for dysmenorrhea.
45369274|NCT00433966|Device|Bare metal stent|Uncoated bare metal stent
45369275|NCT00433966|Device|Paclitaxel-eluting stent|slow rate-release paclitaxel-eluting stent
45369276|NCT00743561|Device|Polysomnography|Simultaneous recording of electro-encephalography, tibial and submental electro-myography, electro-oculography, nasal air flow, oxygen saturation, as well as the thoracic and abdominal respiratory effort
45369277|NCT00743561|Device|ambulatory polygraphy|Simultaneous recording of nasal air flow, oxygen saturation, as well as the abdominal and thoracic respiratory effort.
45487656|NCT03743597|Device|SOCKNLEG|"Innovative multilayer leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition understocking (polyamide, cotton, spandex), overstocking (polyamide, spandex)~In each participant all examinations will be performed with both study stockings, one after the other"
45487657|NCT03743597|Device|Sigvaris COTTON|"Standard single leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition one stocking (polyamide, spandex, cotton)~In each participant all examinations will be performed with both study stockings, one after the other"
45487658|NCT03683108|Drug|Resveratrol and Carbossimetyl Beta Glucan|Medical device based on Resveratrol and Carbossimetyl Beta Glucan. 3 drops, 4 times a day for 1 week.
45487659|NCT03683108|Other|Saline Solution|Medical device based on Saline Solution. 3 drops, 4 times a day for 1 week.
45487660|NCT05137860|Drug|Bortezomib|Combination of Bortezomib with Standard Chemotherapy scheme for acute lymphoblastic patients in relapse.
45487661|NCT03682952|Drug|Alprostadil Injection|Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks.
45487662|NCT03682952|Drug|Beraprost sodium tablets|Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks ,then they take beraprost sodium tablets 40ug orally three times perday for 3 months.
45487663|NCT03682718|Device|Transcervical Foley catheter|combined methods of induction of labor Floey Catheter with misoprstol
45487664|NCT03682718|Drug|Misoprostol|Misoprstol inserted vaginally for induction of labor
45487665|NCT03682640|Drug|Azithromycin Monohydrate|Azithromycin Monohydrate tablet (Azithromycin Sandoz) or oral suspension (Azithromax).
45487666|NCT03682640|Drug|Insulin Lispro|Solution for intravenous or subcutaneous use
45487667|NCT03682640|Behavioral|Dietician support|Dietary advice
45487668|NCT03122106|Biological|Personalized neoantigen DNA vaccine|-Personalized polyepitope inserts integrating the prioritized neoantigens and mesothelin epitopes will be designed and then synthesized and cloned into the pING parent vector
45487669|NCT03122106|Device|TDS-IM Electrode Array System|-Ichor Medical Systems
45487670|NCT03122106|Procedure|Peripheral blood draws|-Enrollment, mid adjuvant chemotherapy, end of chemotherapy, week 1, week 5, week 9, week 13, week 17, week 21, week 25, and week 77
45487671|NCT03682562|Diagnostic Test|DNA Integrity Index|"This test will be performed for ALL three groups:~Sample collection:~Patients will be given a sterile cup containing 5mL saline solution with which they will vigorously rinse their mouth while rubbing their tongues against the oral mucosa for 30 seconds, then spit it back into the cup. The solution will then be used for DNA extraction.~DNA integrity analysis:~The DNA integrity will be done through measuring a housekeeping gene using competitive polymerase chain reaction where the isolated DNA will be combined with DNA capture probes for sequence-specific DNA fragments. The DNA integrity index will be calculated as the ratio of the concentration of longer DNA fragments to the ratio of shorter ones."
45487672|NCT04084769|Biological|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: IM
45487673|NCT04084769|Biological|Meningococcal Group B vaccine (Trumenba®)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
45487674|NCT04084769|Biological|Meningococcal group B vaccine (Bexsero®)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
45487675|NCT03687476|Drug|VTS-270|VTS-270 200 mg/mL administered as described in the arm group description.
45487676|NCT01376076|Drug|Cariprazine|Patients meeting all study eligibility criteria will be randomized to receive cariprazine (Group 1) 1.5 to 18 mg once daily, administered orally.
45487677|NCT01376076|Drug|Risperidone/Moxifloxacin|Patients randomized to Group 2A will receive double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35.
45487678|NCT01376076|Drug|Risperidone/Moxifloxacin|Patients randomized to Group 2B will receive double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35.
45487679|NCT03687398|Diagnostic Test|genetic testing with nanoclonal technique|endometrial sampling
46052662|NCT02800629|Dietary Supplement|Modified Citrus Pectin|MCP versus placebo
46052663|NCT02800629|Dietary Supplement|Placebo|
45487680|NCT03121950|Other|Dance|The primary intervention is a dance class
46052664|NCT03854682|Procedure|Radiofrequency microtenotomy|A longitudinal incision of about 3 cm will be made over the most tender part of the foot taking care to avoid the weight bearing part of the sole, and the tissues dissected down to the affected plantar fascia. After initiating sterile isotonic saline flow of 1 drop every 1-2 s from a line connected to the RF system, the TOPAZ tip will be placed onto the fascia and the micro debridements carried out in a grid like pattern on and throughout the symptomatic fascia area. After debridement, the wound will be irrigated with copious amounts of normal saline solution and closed in layers. A local anaesthetic will be injected into the skin and subcutaneous tissues around the wound and standard wound dressings will be applied
45487681|NCT03121950|Other|Music|the secondary intervention is listening to live music
45487682|NCT03395353|Drug|Duloxetine Hydrochloride|Administered orally
45487683|NCT03687242|Drug|SPR001|Open label SPR001
45487684|NCT05760066|Other|Resistance Training Preconditioning|Resistance training prior to disuse-induced atrophy followed by another period of resistance training
45369278|NCT00743639|Procedure|intramyocardial bone marrow stem cells implantation|"Control group: the patients will be monitored with regular medical visits. Echocardiography: baseline,3,6,9 months. Cardiac NMR at baseline, 3 and 9 months.~Interventional group: Bone-marrow was collected from in the anterior-superior iliac crest and mononuclear stem cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5ml), in the anterior, lateral, posterior and apical faces of the LV ((average 9.6±2.6 x 10[7] cells). After the procedure, the patients were kept in the p.o. for a minimum period of 24hrs. They were released from the hospital in a period that varied from 5-7 days."
45487685|NCT05760066|Other|Control|Activities of daily living prior to disuse-induced atrophy followed by a period of resistance training
45487686|NCT03687164|Other|Group Medical Visits|Patients will attend group medical visits in groups of 6 -10. Groups will have a set curriculum and patients will meet with the provider one on one to assess individual needs at each session.
45487687|NCT05074758|Diagnostic Test|alveolar dead-space quantification|measurement of alveolar dead-space based on volumetric capnography
45487688|NCT05074758|Diagnostic Test|Coagulation activation and impaired fibrinolysis explorations|"blood sampling:~Fibrinolytic components~NETs components~Elastase-derived fragments of proteins of interest"
45487689|NCT05074758|Diagnostic Test|Endothelial activation / endothelial senescence|circulating endothelial cells, E-selectin, endoglin, LVEF-A, LVEFR-2, Angiopoietin -1 and -2, cKit and SDF-1 Willebrand factor (activity, antigen, multimeric analysis )
45487690|NCT04082663|Device|Dental Mouthpiece|Participants will complete motor tasks with and without the dental mouthpiece during the in-person baseline visit. They will also be asked to wear the mouthpiece for one month, and complete sleep and quality of life questionnaires before and after wearing the mouthpiece.
45487691|NCT01376154|Drug|Lamivudine|
45487692|NCT01562951|Drug|ADALIMUMAB|Adalimumab at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly.
45487693|NCT01562951|Drug|Placebo|PLACEBO at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly
45487694|NCT01375842|Drug|Atezolizumab|Atezolizumab will be administered as IV infusion at eight dose levels (0.01, 0.03, 0.1, 0.3, 1, 3, 10, 20 mg/kg) in dose escalation cohort and at a dose which result in total drug exposure </= exposures achieved at the MTD or MAD, will be selected for expansion cohort.
45487695|NCT03682367|Drug|Gabapentin|Use of Gabapentin peri- and post-operatively.
45487696|NCT03682367|Drug|Placebo - Concentrate|Use of sugar-free Placebo peri- and post-operatively.
45487697|NCT03677570|Diagnostic Test|postural stability|Postural Stability, vertical jump test, hexagonal obstacle test, trunk flexion test, trunk extension test, side bridge test,prone bridge test
45487698|NCT05170464|Behavioral|Acute Exercise|Brisk walking on a treadmill at ⅔ maximum heart rate as defined by 220-age (in years).
45487699|NCT05170464|Drug|Caffeine Powder|Participants will receive powdered caffeine dissolved in one cup of water (1.2mg/kg)
45487700|NCT03677492|Other|Medium Supplemented with Cytochalasin D|A medium with in-house supplementation of Cytochalasin D to decrease oocyte degeneration after ICSI and improve the survival rate
45487701|NCT03681353|Behavioral|Mobile Contingency Management, active|Participants are provided monetary reinforcement for providing oral fluid test results that suggest they have reduced cannabis use.
45487702|NCT03394885|Drug|Atezolizumab|1200mg IV q3weeks
45369279|NCT03463265|Drug|nab-sirolimus|nab-sirolimus
45369280|NCT03463265|Drug|nab-sirolimus + bevacizumab|bevacizumab
45369281|NCT03463265|Drug|nab-sirolimus + temozolomide|temozolomide
45369282|NCT03463265|Drug|nab-sirolimus + lomustine|lomustine
45369283|NCT03463265|Drug|nab-sirolimus + temozolomide + radiotherapy|temozolomide + radiotherapy
45487703|NCT03394885|Drug|Carboplatin|5-6mg/ML IV q3 weeks
45487704|NCT03394885|Drug|Paclitaxel|70-80 mg/m2 IV q1 week
45487705|NCT03394885|Drug|Bevacizumab|15 mg/kg IV q3 weeks
45487706|NCT03682484|Drug|MA-0211|oral
45487707|NCT03682484|Drug|Placebo|oral
45487708|NCT05168592|Behavioral|Threat conditioning|Day 1: The participant is repeatedly shown two stimulus (CS+,CS-), one at a time. CS+ is paired with an electric shock. CS- acts as a control stimulus. The stimuli consist of photos of two different objects. Stimuli will be counterbalanced between participants.
45487709|NCT05168592|Behavioral|Imaginal extinction|Day 1: Participants are repeatedly instructed to produce mental imagery of the two stimuli used during threat conditioning. Imagery is prompted through different written instructions presented in pseudo-randomized order on a screen. No shocks will be delivered.
45487710|NCT01361373|Drug|L- DOPA|Sinemet up to 10 mg/kg/ day increasing gradually for 2 weeks
45487711|NCT01361373|Drug|placebo|placebo for 2 weeks
45487712|NCT03677336|Drug|Dydrogesterone Oral Tablet|Tablet, oral, 10 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days
45487713|NCT03677336|Drug|Micronized progesterone|Capsule, vaginal, 200 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days
45487714|NCT03677336|Drug|Placebo Dydrogesterone oral tablet|Tablet, indistinguishable from dydrogesterone oral tablet
45691848|NCT00655642|Drug|Metoclopramide|10 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
45691849|NCT00655642|Drug|Promethazine|12.5 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
45487715|NCT03677336|Drug|Placebo Micronized progesterone|Capsule, indistinguishable from micronized vaginal progesterone capsules
45487716|NCT03634995|Drug|BMS-986256|Specified dose on specified days
45487717|NCT03634995|Other|Placebo|Specified dose on specified days
45487718|NCT01559805|Behavioral|Positive Choices|A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.
45487719|NCT01559805|Behavioral|Personalized Cognitive Counseling|A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
45487720|NCT02877927|Drug|Omadacycline|po tablets
45487721|NCT02877927|Drug|Linezolid|po tablets
45487722|NCT02706886|Drug|Lumasiran|Lumasiran will be administered SC once in Part A. In Part B lumasiran will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
45487723|NCT02706886|Drug|Placebo|Matching placebo (sterile saline: 0.9% sodium chloride [NaCl]) will be administered SC once in Part A. In Part B matching placebo will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
45487724|NCT01357707|Genetic|DNA preparation|Taking blood or saliva from the patient to prepare DNA therefrom
45487725|NCT01318239|Procedure|DCE MRI|"MRI and blood test(VEGFR2 signaling assay) will be undergoing at three time points in the patients with Avastin chemotherapy; at baseline (pretreatment), 3 days after Avastin alone treatment, 3 days after Avastin combined chemotherapy (about 10 days after initial Avastin alone treatment).~MRI and blood test(VEGFR2 signaling assay) will be undergoing at two time points in the patients who will get chemotherapy without antiangiogenic agent; at baseline (pretreatment), 3 days after chemotherapy."
45487726|NCT01357785|Procedure|Cell therapy|The use of periodontal ligament stem cells for periodontal regeneration
45487727|NCT03116932|Behavioral|PrEP knowledge and acceptability questionnaire|This questionnaire consists of 187 items and evaluates socio-demographic variables, sex conducts, PrEP knowledge and PrEP acceptability.
45487728|NCT01357863|Drug|Treatment|Patients treated with Lapatinib-capecitabine after Trastuzumab progression
45487729|NCT02809131|Drug|polymixin/bacitracin|Antibacterial irrigation
45487730|NCT02809131|Drug|cephalexin, or levofloxacin, or clindamycin|Post operative oral antibiotics
45846486|NCT05132166|Other|Drug or biologic - anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.|Will vary depending upon Investigator's choice identified prior to randomization. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT. No cross-over to DSC treatment is planned. The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.
45487731|NCT02809131|Drug|Saline|Saline irrigation
45487732|NCT05046054|Device|transcutaneous electrical nerve stimulation|transcutaneous electrical nerve stimulation group received transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection
45487733|NCT05046054|Device|Placebo transcutaneous electrical nerve stimulation|Placebo transcutaneous electrical nerve stimulation group received no transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection
45487734|NCT03633318|Device|electrical impedance myography (EIM)|EIM is a measure of impedance. EIM is a measure of the obstruction of flow of current through the tissue. It is a completely painless assessment of muscle health.
45487735|NCT05032950|Drug|Midazolam|Midazolam administered as a single dose on Day 1
45487736|NCT05032950|Drug|PF-07321332/ritonavir + Midazolam|"PF-07321332/ritonavir:~Administered orally every 12 hours for a total of 9 doses on Days 1-5~Midazolam:~Administered orally as a single dose on Day 5"
45487737|NCT05032950|Drug|Ritonavir + Midazolam|"Ritonavir:~Administered orally every 12 hours for a total of 9 doses on Day1-5.~Midazolam:~Administered orally as a single dose on Day 5"
45691850|NCT00655642|Drug|Normal Saline|Volume matched isotonic sodium chloride solution dose administered over 2 minutes through a peripheral intravenous catheter
45369284|NCT03463265|Drug|nab-sirolimus + marizomib (MRZ)|marizomib (MRZ)
45369285|NCT00947336|Drug|Norfloxacin + Synbiotic|Norfloxacin 400 mg once daily with synbiotic capsules (Streptococcus faecalis JPC 30 million, Clostridium butyricum 2 million, Bacillus mesentericus JPC 1 million, Lactobacillus sporogenes 50 million spores) 2 t.i.d.
45369286|NCT00947336|Drug|Norfloxacin + Placebo|Norfloxacin 400 mg once daily with placebo
45369287|NCT00956384|Procedure|One-stage dermal matrix/implant procedure|One-stage breast reconstruction with dermal matrix and implant
45369288|NCT00956384|Procedure|Two-stage tissue expander/implant procedure|Two-stage breast reconstruction with tissue expander and implant
45369289|NCT00955214|Device|TAXUS Liberté paclitaxel-eluting coronary stent system|diameter is 2.5mm
45369290|NCT00947414|Device|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,25mJ/mm2) plus daily gluteal exercises
45369291|NCT00947414|Device|Sham extracorporeal shock wave plus gluteal strength exercise|Sham extracorporeal shock wave plus gluteal strength exercise
45369292|NCT00955292|Drug|Quarfloxin|Escalating doses of quarfloxin administered intravenously for 24 hours once weekly for three weeks every four weeks
45369293|NCT00956462|Drug|Ketorolac (NSAID) versus Dexamethasone (steroid)|Topical NSAID versus topical steroid after implantation of glaucoma drainage device
45487738|NCT05009628|Procedure|automated oxygenation with a sitting patient position in the ICU|Oxygenation will be done with the Free O2 device via oxygen goggles or a face mask and with an O2 prescription to obtain a SpO2> 94%. The patient's position in the ICU will be a sitting position with the chest raised at an angle greater than 45°.
45487739|NCT05009628|Procedure|Automated oxygenation with the patient lying down in the ICU|Oxygenation will be done with the Free O2 device via oxygen goggles or a face mask and with an O2 prescription to obtain a SpO2> 94%. The patient's position in the ICU will be a recumbent position with the head elevated to a maximum of 10
45487740|NCT05009628|Procedure|Oxygenation is controlled with the patient in a sitting position in the ICU.|ICU. Oxygenation will be done via the same interface in manual mode where the post-interventional monitoring room nurse modifies the flow to maintain oxygen saturation above 94%. The patient's position in the ICU will be a sitting position with the chest raised at an angle greater than 45°.
45487741|NCT02784951|Drug|Red blood cells (0Rh D-neg)|Fresh produced RBC
45487742|NCT02784951|Drug|Whole blood (O Rh D-neg K-neg)|Fresh produced WB
45846487|NCT05132166|Biological|Decidual Stromal Cells|The dose will be 1×106 DSC/kg bodyweight, at least 2 doses at least one week apart. Within the first 28 days, patients meeting criteria of aGvHD disease progression, mixed response or no response, may be given additional weekly doses of DSC until satisfactory response (ie: CR) are reached (max 4 doses in total).
45369294|NCT00947492|Biological|Venous blood sample|Venous blood sample twice a year during 3 years
45369295|NCT05300360|Diagnostic Test|adenosine deaminase test|adenosine deaminase enzyme deficiency test
45487743|NCT02784951|Drug|Freeze dried plasma (LyoPlas)|(LyoPlas N-w (German Red Cross)
45487744|NCT05002062|Device|"RehaCom computer-based cognitive training in addition to Conventional physical therapy program"|"Rehacom procedure: It is a computer-based intensive cognitive rehabilitation test used to assess patient's cognitive functions. It includes 32 assessment tasks for attention, memory , logical reasoning& executive functioning. It composes of regular PC , 1G RAM , DVD drive, 100 GB hard drive with windows XP SP3, 128 MB RAM direct 3D graphic card , Screen at least 19 , regular PC keyboard or Rehacom panel & printer .The Rehacom software version is (patient enpult (1990-1997) EN/ISO-13485-certified). It is characterized by easy handling, close to reality , motivating for patients."
45487745|NCT05002062|Other|Conventional physical therapy program|Conventional physical therapy program for MS patients include aerobic training, resistive training and flexibility program
45487746|NCT01442649|Drug|Oxaliplatin|85mg/m² over 120 mn on D1 every 2 weeks up to progression or toxicity
45487747|NCT01442649|Drug|Folinic Acid|400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 (in the same time that oxaliplatin or irinotecan) every 2 weeks up to progression or toxicity
45369296|NCT00956696|Drug|topiramate|oral, daily dose or twice daily dose, total daily dose 25-200mg per day duration: 16 weeks
45487748|NCT01442649|Drug|5-fluoro-uracil|400mg/m² in bolus on D1, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
45487749|NCT01442649|Drug|Irinotecan|180 mg/m2 over 90 mn IV on D1 every 2 weeks up to progression or toxicity
45487750|NCT01442649|Drug|Bevacizumab|5 mg/kg IV over 90 mn on D1 every 2 weeks up to progression or toxicity
45369297|NCT00955448|Device|SIS mesh (Cook Medical)|Anterior prolapse repair will be reinforced using surgical mesh made from porcine small intestine mucosa (Cook Medical)
45369298|NCT00955448|Procedure|Anterior prolapse repair|Anterior prolapse repair will be conducted without using mesh reinforcement
45487751|NCT01442649|Drug|Cetuximab|500mg/m² on D1 every 2 weeks up to progression or toxicity
45487752|NCT05199792|Diagnostic Test|Dotarem|(Dotarem) (0.4 ml/kg (0.2 mmol/kg))
45487753|NCT01354587|Drug|Hizentra|Subjects transition from Vivaglobin to Hizentra using weekly subcutaneous infusions for 32 weeks.
45846488|NCT04990986|Other|Complex intervention|Will be co-developed during the study.
45846489|NCT04845828|Procedure|Sentinel lymph node mapping|"Laparoscopic or robotic hysterectomy with/without bilateral salpingo-oophorectomy 2. Inject 1.25 mg/ml of ICG and a total of 6ml into the cornual area (0.5-1 cm deep) of the uterus. And then inject 1 ml of mucous membrane (1-3 mm deep) and 1 ml of substrate (1-2 cm deep) into the cervix, and a total of 4 ml in each direction of 3 and 9 o'clock.~3. Sentinel lymph node is excised"
45846490|NCT04845828|Procedure|Routine lymph node dissection|"Laparoscopic or robotic hysterectomy with/without bilateral salpingo-oophorectomy~Lymph node detection is performed."
45487754|NCT04995120|Drug|chemotherapy TP regimen combined with Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.~Response rate of primary tumor is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If overall response rate of primary tumor is complete response or partial response, then chemoradiation is conducted, followed by maintenance therapy of Toripalimab for 8 cycles (6 months). Otherwise, surgery is conducted (laryngeal preservation surgery is preferred), followed by adjuvant radiation/chemoradiation and then maintenance therapy of Toripalimab for 8 cycles."
45487755|NCT03745469|Device|Smartphone|A standard smartphone will be used for browsing the internet for two different durations (10 and 30 minutes)
45487756|NCT03988998|Drug|Radiofrequency ablation with radiotherapy|Radiofrequency ablation with radiotherapy
45487757|NCT03988998|Drug|Radiofrequency ablation alone|Radiofrequency ablation without radiotherapy
45487758|NCT01318785|Other|Compression Armsleeves|"Type: Compression Class II (according to RAL)~The study is designed in a way, that per product after a one weak resting (preparing) cycle a 2 weeks wearing period will follow. Herewith the whole duration of the study is 6 weeks per patient."
45487759|NCT01376232|Drug|GSK1278863|GSk1278863 100mg
45487760|NCT01376232|Drug|GSK1278863 + food|High Fat meal + 100 mg GSK1278863
45487761|NCT01376232|Drug|Gemfibrozil|600 mg Gemfibrozil
45487762|NCT01354665|Biological|Interferon beta-1b (Betaferon, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under routine practice setting.
45487763|NCT01354743|Drug|Dysport|"Patients entering will be based on gender and assessment of procerus and corrugator muscle mass. Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large) by assessment of the procerus/corrugator muscles. Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ Female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region~Subjects will be treated with Dysport™ 20 or 30 units bilaterally to crow's feet.~Subjects will be treated at baseline and if maximum amount of product has not been used at 1 month follow up subject will receive a touch up. No further treatment will be done for the remaining study visits."
45487764|NCT01354743|Device|Perlane L|The subject will be allowed to receive up to 4 mls between the temporal fossa and the glabella area.
45487765|NCT05759910|Dietary Supplement|Brainphyt high dose|Participants will take BrainPhyt capsules during 3 months
45487766|NCT05759910|Dietary Supplement|Placebo|Participants will take placebo capsules during 3 months
45487767|NCT01361529|Drug|FLP,dose escalation,MTD|dosage from 93mg/m2 to 331mg/m2, 7 days' continuous dosing, 21 days for one cycle
45487768|NCT05018403|Drug|Intravenous AON-D21|AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
45487769|NCT05018403|Drug|Intravenous placebo|Isotonic glucose solution identical in appearance to AON-D21.
45487770|NCT04944108|Procedure|LISA approach|Participants will be randomized to administer surfactant in a preterm manikin by using the LISA approach (thin catheter) or the INSURE approach (tracheal tube)
45487771|NCT04944108|Procedure|Insure approach|Participants will be randomized to administer surfactant in a preterm manikin by using the INSURE approach (tracheal tube)
45487772|NCT05008575|Biological|anti-CD33 CAR NK cells|6×10^8, 12×10^8, 18×10^8/KG Treatment follows a lymphodepletion
45487773|NCT05008575|Drug|Fludarabine|recommendation: 30mg/m2 (D-5~D-3),determined by tumor burden at baseline.
45487774|NCT05008575|Drug|Cytoxan|recommendation: 300-500mg/m2 (D-5~D-3),determined by tumor burden at baseline.
45487775|NCT03971994|Behavioral|Facial expression recognition task|We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.
45487776|NCT04069715|Dietary Supplement|Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract)|A product made of highly concentrated pharmaceutical grade notoginseng root extract, and containing high potency bioactive components, notoginsenoside, ginsenoside Rb1, Rg1, Rd, Re and Rb2.
45487777|NCT04069715|Other|Placebo|Turmeric 0.4%, Rice Flour 76.6%, Magnesium stearate 23%, capsule shell (gelatin) 61 mg
45487778|NCT03970512|Device|Apioc-A and Apioc-S Contact Lenses|Appropriately fit, document and dispense a new spherical and toric contact lens design worn for up to 35 days.
45487779|NCT01319487|Drug|2304 Eye Drops High Dose|2304 Eye Drops High Dose self-administered in the study eye during the treatment period
45691851|NCT02997436|Device|Laser speckle flowmetry|"A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by laser speckle flowmetry 10 minutes later.~Measurement of the value of skin blood flow (by laser speckle) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
45846491|NCT04808466|Drug|Paclitaxel|Paclitaxel is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Paclitaxel 75 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
45846492|NCT04808466|Drug|Lobaplatin|Lobaplatin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
45487780|NCT01319487|Drug|2304 Eye Drops Low Dose|2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
45487781|NCT01319487|Drug|Placebo Eye Drops|Placebo Eye Drops self-administered in the study eye during the treatment period
45487782|NCT03681119|Behavioral|Dementia symptom management at home hospice edition|Quality assurance performance improvement program
45487783|NCT03681119|Behavioral|Education and Training|Education and training
45487784|NCT03111108|Drug|EBR/GZR (50 mg/100 mg) FDC|One FDC tablet taken once daily by mouth for 8 or 12 weeks depending upon randomization.
45487785|NCT03677375|Device|INVSENSOR00026|Noninvasive pulse oximeter sensor
45487786|NCT00702520|Drug|Corifollitropin alpha (MK-8962, Org 36286) 100 ug|Subcutaneous administration of corifollitropin alpha at a dose of 100 ug
45487787|NCT00702520|Drug|Corifollitropin alpha (MK-8962, Org 36286) 150 ug|Subcutaneous administration of corifollitropin alpha at a dose of 150 ug
45487788|NCT00702520|Drug|Triptorelin|Daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase).
45487789|NCT00702520|Biological|Recombinant follicle stimulating hormone (recFSH)|From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG.
45487790|NCT00702520|Biological|Human chorionic gonadotprophin (hCG).|HCG was administered as a single subcutaneous injection of 5,000 to 10,000 international units.
45487791|NCT05198856|Drug|Thalidomide Combined With Chemotherapy and Monotherapy|"Combined period：chemotherapy + T ：Thalidomide tablets: 100mg/d~Maintenance period: 100 mg/d, qn, orally. Sustained to disease progression or intolerable adverse reactions."
45487792|NCT04067141|Device|somofilcon A|Contact Lens
45487793|NCT04067141|Device|nelfilcon A|Contact Lens
45487794|NCT03887910|Other|Enhanced Intervention|Participants randomized to the Enhanced Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated and addressed with either referrals with matched community resources or thorough education. In addition, they will be given a set of six developmental toys.
45487795|NCT03887910|Other|Intervention|Participants randomized to the Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated. For each screened domain, the nurse is able to systematically address them, which may result in an immediate intervention; either referrals with matched community resources or thorough education.
45846493|NCT04670640|Device|Vibration|Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. There will be no explicit tasks or direction given in this intervention. Participants will experience smooth slowly varying breath-like vibration on their sternum. They will receive their assigned intervention for approximately 18 minutes.
45846494|NCT04670640|Behavioral|Breath Focus|Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. The participant will be asked to focus on their breathing during this intervention. They will receive their assigned intervention for approximately 18 minutes.
46052665|NCT03854682|Behavioral|Strength training|Non-surgical treatment consists of one-legged heel lift to primarily activate the windlass effect and increase the mechanical stress on the tendon. The exercise is performed on a step, a thick book or the like, so the heel movement finishes below the horizontal level. The exercise is performed every other day with as many sets as possible and as heavy as possible, but not heavier than eight repetitions can be performed per. set. The load progressed from two to one leg +/- backpack. The exercise is performed as 3 s/2 s / 3 s concentric, isometric and eccentric respectively followed by 2 min rest. Patients continue to exercise 4 weeks after patient acceptable symptom state (PASS) has been achieved
45691852|NCT02997280|Drug|Ruxolitinib Oral Tablet|"Dose reduction criteria for acute GVHD: grade 4 neutropenia or grade 4 thrombocytopenia related to ruxolitinib administration based on the decision of attending physician.~Dose reduction criteria for chronic GVHD: grade 3 neutropenia, grade 3 thrombocytopenia or anemia requiring transfusion, related to ruxolitinib administration based on the decision of attending physician.~Reduced dose schedule: 5 mg bid for adults and children with body weight > 40 kg, 0.08 mg/kg bid for children with body weight < 40 kg.~Treatment discontinuation criteria: complete response; absence of response after 28 days or progressive disease after 7 days for acute GVHD; absence of response after 84 days or progressive disease after 28 days for chronic GVHD; life-threatening complications."
45691853|NCT01773967|Drug|LGG|LGG 10^10 cfu PO BID X 5 days
45691854|NCT01773967|Drug|micro-crystalline cellulose|1 capsule PO bid x 5 days
45487796|NCT03184714|Device|NIPPV|BiPAP treatment for 3 years
45487797|NCT02876601|Drug|Defibrotide|6.25mg/kg bodyweight over 2h infusion
45487798|NCT02876601|Drug|Placebo (0.9% sodium chloride)|(0.9% sodium chloride) infusion over 2h infusion
45487799|NCT02876601|Drug|Lipopolysaccharide|bolus infusion of 2ng/kg bodyweight lps
45487800|NCT02876601|Drug|Placebo (0.9% sodium chloride bolus)|(0.9% sodium chloride) bolus infusion
45487801|NCT04059536|Device|Roxwood Anchoring Catheters|Anchoring catheters
45487802|NCT04059536|Drug|Acetylsalicylic Acid|Oral Tablet
45487803|NCT04059536|Drug|Heparin|Intravenous Injection
46052666|NCT02806245|Other|Biventricular pacing|"Randomization into one of 3 study arms for acute phase and for extended phase.~Measurement of baseline variables on arrival to CCU. Acute pacing protocol (order of pacing randomized):~Atrial sensing- right ventricular pacing 10 min.~5 min no pacing (washout).~Atrial sensing - biventricular pacing 10 min.~5 min no pacing (washout).~Intrinsic rhythm~5 min no pacing (washout). Start extended phase pacing according to randomization. Measure hemodynamic variables 10 min after start of pacing.~Measure hemodynamic variables 30 min after start of pacing. Pacing hiatus for 60 minutes at 24 hours with measurement of hemodynamics without pacing and after reinitiating pacing.~Stop pacing at 72 hours or after extubation, whichever comes first. For those patients who are extubated before 72 hours: measurements will be taken before extubation and one hour after extubation. Pacing will then be stopped."
45369299|NCT03952650|Drug|Chloroquine Phosphate|Chloroquine phosphate is approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a blood-stage schizonticide, highly active against replicating forms of blood-stage drug- sensitive parasites. As such, it is routinely employed as first-line prophylaxis against development of patent parasitemia and clinical malaria in non-immune travelers to areas with chloroquine sensitive Pf. In the pilot, chloroquine administration will begin with a loading dose 2 days prior to PfSPZ Challenge and finishing with a maintenance dose 5 days after PfSPZ Challenge. In the main phase, chloroquine will be first administered as a loading dose 2 days prior to PfSPZ Challenge and continuing weekly using a maintenance dose for a total of 10 doses, finishing with a last dose 5 days after the third injection with PfSPZ Challenge.
45369300|NCT03952650|Biological|PfSPZ Challenge|PfSPZ Challenge (NF54) acts as the immunogen in the PfSPZ-CVac approach to vaccinating against malaria. Participants will receive either one (in the pilot phase) or 3 (in the main phase) 400,000 or 300,000 aseptic, purified, cryopreserved, fully infectious PfSPZ injections by DVI (with concurrent administration of antimalarial drugs). Following immunization, participants in the main phase will be followed through the transmission season in order to assess vaccine efficacy.
45369301|NCT03952650|Drug|Pyrimethamine|"Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia.~Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses or a total of 6 doses."
45369302|NCT03952650|Drug|Coartem|Antimalarial (Coartem ) will be administered to all participants twice during the study, approximately 2 weeks prior to the first vaccination in order to clear pre-existing parasitemia that may interfere with immunity development. The second dose will be given approximately 2 weeks prior to the 3rd vaccination in order to clear any parasitemia infection that may have happened naturally during the vaccination period and prior to the follow up period.
45691855|NCT00656656|Drug|Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine|"Protein A Immunoadsorption: performed on 3 consecutive days every 3 weeks~Rituximab: 1000 mg i.v. given twice at a 2-week interval~Dexamethasone pulse therapy: 100 mg i.v. given on 3 consecutive days every 3 weeks~Azathioprine: 2.5 mg/kg body weight daily p.o."
45691856|NCT01773889|Drug|Denileukin Diftitox/SC Pegylated IFNα-2a|
45369303|NCT03952650|Drug|ibuprofen|Ibuprofen likewise is not a part of the investigational product/regimen, but will be provided to participants in the chloroquine arm (Arm 4) if required to mitigate typical symptoms of malaria infection such as headache, myalgia, fever and chills.
45369304|NCT00955526|Drug|Istradefylline|20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
45369305|NCT00955526|Drug|Istradefylline|40mg KW-6002 per day (two 20 mg tablets orally once daily for 12 weeks)
45369306|NCT00955526|Drug|Placebo|Two placebo tablets once daily for 12 weeks
45369307|NCT00955604|Drug|Group R+AD Rasagiline + Antidepressant|Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) at least 14 days
45369308|NCT00955604|Drug|Group R Rasagiline|At least 2 months of rasagiline
45369309|NCT00955604|Drug|Group AD Anti-PD + Antidepressant|An approved dopaminergic medication for PD. (2 months of treatment with an antidepressant medication.
45369310|NCT00947570|Behavioral|Cognitive behavioral therapy for anxiety|10 sessions delivered over the course of 14 weeks and aimed at reducing pathological behaviors and patterns of thought
45369311|NCT03623646|Drug|Chemoradiotherapy arm|Radiation Therapy in combination with Chemotherapy (Cisplatin)
45691857|NCT00656968|Drug|10-day sequential treatment|esomeprazole (40 mg daily) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, metronidazole (500 mg, bid) from day 6 to day 10
45691858|NCT00656968|Drug|10-day concomitant therapy|esomeprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 10, clarithromycin (500 mg, bid) from day 1 to day 10, metronidazole (500 mg, bid) from day 1 to day 10
45691859|NCT00657280|Drug|Sitagliptin|No one is blinded to the treatments.
45691860|NCT00692692|Procedure|DermaMatrix|experimental group with DermaMatrix acellular dermis over tissue expanders in addition to skin/soft tissue and muscle to allow for more natural appearing breast and prevention of complications
45369312|NCT03623646|Drug|Immunotherapy + Radiotherapy arm|Radiation Therapy in combination with Immunotherapy drug (Durvalumab)
45369313|NCT00947648|Other|Raw Fruits & Vegetables|Diet containing fresh fruits and vegetables in addition to cooked food.
45369314|NCT00947648|Other|Cooked Foods|Diet containing only cooked foods.
45369315|NCT00962286|Drug|Furosemide|"Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.Intravenous catheters will be placed in each upper limb for infusion of clearance markers and blood sampling.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered. Thereafter, inulin and p-aminohippuric acid will be infused continuously. A 200-300 ml water load will be given during the first 60-min prime.~Subjects will be started on furosemide p.o. 20 mg every 12 hours, starting on day 1 at 15.00 after the renal function studies. Nine doses will be taken, the last dose on day 4 at 7 am.~In case the blood pressure does not decrease following 20 mg bid furosemide administration, the study will be repeated after 4 weeks using a dose of 40 mg p.o. bid."
45369316|NCT00691301|Drug|cisplatin|Cisplatin as an IV infusion at less than 1 mg/min over less than 4 hours at a dose of
45369317|NCT00691301|Drug|pemetrexed disodium|
45369318|NCT00955760|Drug|Neramexane|Drug-Drug Interaction Study
45369319|NCT04010448|Biological|TV P2-VP8|90 µg of the TV P2-VP8 vaccine IM plus oral placebo administered on study days 1, 29 and 57
45369320|NCT04010448|Biological|Rotarix|Rotarix® PO plus IM placebo administered on study days 1, 29 and 57
45369321|NCT00955838|Other|Rehabilitation technique|12 therapy session
45369322|NCT03554382|Other|system to support self-management of hypertension|The patients are provided with a home BP monitor. Thereafter they will be asked to use the self-management support system and self-report, once daily in the evening, via their own mobile phone during eight weeks. At each occasion, the patients first answer the questions on wellbeing, symptoms, lifestyle, medication intake and side effects and then measure their BP and pulse, and when these data (mean of three readings) are input into the mobile phone, they automatically register in the database. During intervention the paient has regular access to self-reported data via graphs
45369323|NCT00947726|Drug|CeraVe|Using OTC cream on foot twice daily for two weeks.
45369324|NCT03887819|Diagnostic Test|Hystological evaluation|The original tissues samples will be fixed in 10% neutral buffered formalin and embedded in paraffin blocks. Sections (4 μm thick) will be stained with hematoxylin and eosin stain (H&E) for diagnosis. The immunohistochemistry for anti-LCA, anti-CD68, and anti-CD3 will be performed to identify the inflammatory infiltrate.
45369325|NCT00955994|Drug|asimadoline|
45369326|NCT05277480|Drug|Apatinib+IE|apatinib po； ifosfamide ivgtt ; etoposide ivgtt .
45369327|NCT05277480|Drug|IE|ifosfamide ivgtt ; etoposide ivgtt .
45369328|NCT03429335|Behavioral|Teaching session|The cardiology nurse (RN) will have an hour long one-on-one teaching session prior to their pediatric cardiology clinic visit. The RN will go over the youth's cardiac history including the chronic heart disease diagnoses, names and dates of cardiac surgical procedures and cardiac catheterizations, and current cardiac medications and doses. She will also discuss transitioning from pediatric to adult care and healthy lifestyle choices.
45691861|NCT00692692|Procedure|standard of care tissue expander breast reconstruction surgery after mastectomy|standard of care using skin/soft tissue and muscle coverage of tissue expander for breast reconstruction after mastectomy without acellular dermal matrix
45369329|NCT03429335|Behavioral|Just TRAC It!|Just TRAC It! (Transitioning Responsibly to Adult Care) is a mobile health intervention that encourages youth to use existing functions on their personal phones to track their health information. The use of Just TRAC It! allows youth to electronically document all medical information that would previously be printed on their MyHealth Passport, but may offer additional functionality in terms of learning to manage their health.
45369330|NCT03429335|Behavioral|MyHealth Passport|"MyHealth Passport is a customized, wallet-size card that includes the youth's important medical information. The RN will help the youth create a MyHealth Passport online, and print out the card for them.~The same educational intervention will be completed by cardiology nurse using a MyHealth Passport to track their medical information instead of the electronic Just TRAC It!"
45369331|NCT00956072|Drug|imatinib mesylate|Patients receive imatinib mesylate
45369332|NCT00956072|Procedure|therapeutic conventional surgery|Patients undergo surgery
45369333|NCT03518190|Device|Infrared spectroscopy (ODP)|Infrared spectroscopy device will be used to detect non-visible pressure injuries
45369334|NCT02565407|Behavioral|Proprioceptive training|Training includes a virtual balance board and center-out task. Small vibratory motors placed on forearms provide vibro-tactile movement feedback (VTF). During familiarization participants learn to associate VTF with wrist movement and visual feedback. Vision is occluded after this phase. In the virtual balance board task participants use wrist motion to roll a ball to a target on the board. VTF indicates the desired movement direction and ball velocity. The center-out task involves wrist motion to control a cursor to reach a target. The wrist robot delivers an assistive force towards the target. VTF signals magnitude and direction of the cursor deviating away from the desired path.
45369335|NCT02565407|Behavioral|Usual care|Usual care refers to care that participants receive through their healthcare providers. It may range from no treatment to various sessions of occupational and physical therapy received at in- or outpatient rehabilitation clinics or at home.
45369336|NCT00962364|Biological|autologous bone marrow-derived cells|autologous bone marrow-derived cells isolated by density gradient centrifugation from 50 ml bone marrow aspirate obtained under local anesthesia
45369337|NCT02564003|Drug|Oxycodone|oxycodone 0,1 mg/kg iv
45487804|NCT05714982|Other|Label with text health warning|Labels with e-cigarette health warning that include text about health harms of vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
45691862|NCT00693160|Drug|ketorolac|single intrathecal injection of ketorolac 2 mg
45369338|NCT00956150|Procedure|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
45369339|NCT00956150|Drug|Rifaximin|Rifaximin 600 mg three times a day by mouth (TID PO) x 10 days
45369340|NCT00956150|Drug|Placebo|Placebo TID PO x 10 days
45369341|NCT00967824|Other|informational intervention|
45369342|NCT00967824|Other|questionnaire administration|
45369343|NCT00967824|Other|survey administration|
45369344|NCT00947960|Drug|Triheptanoin|1-2 grams triheptanoin (drug)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months.
45691863|NCT00693160|Drug|placebo|subject will receive a placebo (preservative free normal saline) spinal injection
45691864|NCT00693160|Drug|remifentanil|All subjects will receive a remifentanil infusion
45691865|NCT00693160|Drug|Capsaicin|Topical capsaicin pain model utilized for each subject
45691866|NCT00694018|Other|Education and standard care|Educational program for individuals with chronic back pain.
45369345|NCT00947960|Other|Vegetable Oil|1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 g triheptanoin (drug)/kilogram body weight for 6 months.
45369346|NCT00923663|Drug|Lenalidomide|25 mg Lenalidomide p.o. daily for 21 days
45487805|NCT05714982|Other|Label with pictorial health warning|Labels with e-cigarette health warning that include the same text about health harms of vaping and corresponding pictorial images will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
45487806|NCT05714982|Other|Label with neutral statements about vaping|Labels with neutral statements about vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 statements based on their assigned trial arm; at Visit 3, they will get 2 additional statements based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
45487807|NCT03178318|Procedure|ultrasound|ultrasound of the neck to identify the position of upper and lower border of the cricothyroid membrane.
45369347|NCT00956228|Radiation|radioimmuniguided intenstiy modulated radiotherapy|All patients recieved 75.6 Gy in 42 fractions to the prostate and the region of the prostate which enhanced on prostascint scan was simaltaneously boosted to a total dose of 82 Gy
45487808|NCT03745391|Diagnostic Test|MULTIMODAL MAGNETIC RESONANCE (Multimodal MR)|After randomization, a MULTIMODAL MR will be performed to select treatment patient
45487809|NCT03745391|Diagnostic Test|MULTIMODAL COMPUTERIZED TOMOGRAPHY (Multimodal CT)|After randomization, a MULTIMODAL CT will be performed to select treatment patient
45487810|NCT05711628|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
45487811|NCT05711628|Drug|Bendamustine|Given IV
45487812|NCT05711628|Drug|Brentuximab Vedotin|Given IV
45487813|NCT05711628|Drug|Carboplatin|Given IV
45487814|NCT05711628|Procedure|Computed Tomography|Undergo PET/CT and CT
45487815|NCT05711628|Drug|Etoposide|Given IV
45487816|NCT05711628|Drug|Gemcitabine|Given IV
45691867|NCT00694018|Behavioral|Internet mediated enhanced pedometer intervention|Enhanced pedometer for uploading step information and website that provides step goals and feedback, tailored motivational messages and an online community.
45691868|NCT00694564|Drug|S-adenosyl methionine|S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
45369348|NCT03284502|Drug|HM95573, cobimetinib|Regimen: twice daily (BID), continuous dosing for HM95573, once daily (QD) 21 days, 7 days off for cobimetinib
45369349|NCT03284502|Drug|HM95573, cetuximab|Regimen: twice daily (BID), continuous dosing for HM95573
45487817|NCT05711628|Drug|Ifosfamide|Given IV
45487818|NCT05711628|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
45487819|NCT05711628|Biological|Pembrolizumab|Given IV
45691869|NCT00695188|Drug|methotrexate|oral administration Escalating dose (15, 20, 25 mg)
45691870|NCT00695188|Drug|methotrexate|25 mg oral administration
45487820|NCT05711628|Procedure|Positron Emission Tomography|Undergo PET/CT
45487821|NCT05711628|Radiation|Radiation Therapy|Undergo RT
45691871|NCT00658138|Device|3M ESPE Adper Scotchbond SE|To be used per manufacturer's instructions.
45691872|NCT00658138|Device|3M ESPE Adper Scotchbond 1XT|To be used per manufacturer's instructions.
45691873|NCT00706264|Device|Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
45487822|NCT05711628|Other|Transplant Conditioning|Receive standard preparative chemotherapy regimen
45487823|NCT05711628|Drug|Vinorelbine|Given IV
45487824|NCT03178396|Dietary Supplement|melatonin|controlled release, 9 mg taken 30 minutes before bedtime x 6 weeks
45487825|NCT03677258|Device|Collagen for injections 7%|Injection of medical device
45691874|NCT04344964|Other|None - NA|Observational study
45691875|NCT00695500|Drug|Varenicline|Varenicline tablets, 2 mg per day for 3 weeks
45691876|NCT00695500|Drug|Placebo|Placebo tablets, 0 mg per day for 3 weeks
45691877|NCT00695578|Drug|Biafine|Apply to wounds 3 times daily for 4 weeks: ingredients: purified water, liquid paraffin, glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalene, avocado oil, trolamine sodium alginate, cetyl palmitate, methylparaben, sorbic acid, propyl paraben and fragrance.
45487826|NCT03677258|Device|Hyaluronic acid for injections 2%|Injection of medical device
45487827|NCT03682328|Procedure|vertebroplasty|Cement augmentation of the vertebral body
45487828|NCT03682328|Procedure|kyphoplaty|Cement augmentation of the vertebral body
45487829|NCT01361763|Drug|Dabigatran|110 mg twice daily
45487830|NCT01361763|Drug|Antiplatelets|100mg once a day
45487831|NCT02420782|Drug|ASP6282|oral
45487832|NCT02420782|Drug|Itraconazole|oral
45487833|NCT02420782|Drug|Pilocarpine|oral
45369350|NCT03284502|Drug|HM95573, cobimetinib|Regimen: Recommended dose (RD) and schedule selected based on the data of safety, tolerability, pharmacokinetics, and anti-tumor activity tested in Stage 1
45369351|NCT03284502|Drug|HM95573, cetuximab|Regimen: Expansion dose of HM95573 selected based on the data of safety and tolerability tested in Stage 1b
45369352|NCT00743873|Biological|Plasma Rich in Growth Factors (PRGF)|US guided IM injection 3-6mg
45487834|NCT02420782|Drug|Placebo|oral
45487835|NCT02420782|Drug|Midazolam|oral
45487836|NCT03677024|Procedure|SLN arm|Intra-operative SN mapping with indocyanin green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and another 1ml will be injected superficially (2mm-depth). The time between the injection and the search for SLN must be as soon as possible.
45487837|NCT04054193|Drug|Fosaprepitant Dimeglumine|Participants received IV fosaprepitant dimeglumine ≤115 mg on Day 1 and ≤80 mg on Days 2 and 3 (dose adjusted for age).
45487838|NCT04054193|Drug|5-HT3 antagonist|All participants received an oral 5-hydroxytryptamine (serotonin; [5-HT]) 3 receptor antagonist on Day 1 and had the option to take on Days 2-3. The dose was as per product label or standard of care.
45487839|NCT04054193|Drug|Dexamethasone|Participants received optional oral dexamethasone at the investigator's discretion according to product label or standard of care.
45369353|NCT00743873|Drug|placebo|injection of 6 cc of saline into injured area
45369354|NCT04011098|Drug|Epidural Fentanyl Bolus|Fentanyl bolus refers to the provision of a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia (0.08% Bupivicaine with 2 mcg/ml Fentanyl Solution).
45369355|NCT04011098|Drug|Standard Epidural Group|The Control group will receive a 2 ml bolus of standard epidural mix solution (0.08% Bupivicaine with 2 mcg/ml Fentanyl) after epidural placement followed by standard care infusion of the same solution, with a PCEA pump for subsequent analgesia.
45369356|NCT00927563|Drug|Tolcapone|pill, 100-300mg/day for 8 weeks
45369357|NCT00967902|Device|coronary stenting|Balloon dilatation of obstructive coronary artery disease with deployment of a metallic stent to scaffold the dilated lesion; stent incorporating sustained release of anti-proliferative agent to control neointimal proliferation and reocclusion; test device incorporates affinity surface for circulating EPCs
45369358|NCT00956306|Drug|Udenafil|100mg Single Oral Dose of Udenafil
45487840|NCT03394027|Drug|ONC201|625 mg by mouth every 7 days; each cycle = 28 days. Patients will receive ONC201 as long as they derive clinical benefit or toxicity becomes impeditive.
45487841|NCT03682172|Drug|GLP-2 (1pmol/kg/min)|Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min
45487842|NCT03682172|Drug|GLP-2 (10pmol/kg/min)|Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10 pmol/kg/min
45487843|NCT03682172|Drug|Placebo|Four hour intravenous infusion with saline water
45487844|NCT03184480|Drug|Arnuity Ellipta|The active component of Arnuity Ellipta is fluticasone furoate and it is indicated for the treatment of bronchial asthma. Post-marketing investigation of ARNUITY ELLIPTA will be carried out in this analysis.
45487845|NCT03136107|Other|Physiogel Daily Defence Protective Day Cream Light|Investigator controlled, topical application to the epidermis at a dose of 2 milligrams per square centimeter (mg/cm2). Single application.
45487846|NCT03136107|Other|ISO 24444:2010 P3 Standard Sunscreen|Investigator controlled, topical application to the epidermis at a dose of 2 mg/cm2. Single application.
45487847|NCT01376466|Other|CT scanning|CT image of the abdomen included the area between the 3rd. lumber vertebra and the top of acetabulum. A liter of contrast mixed with normal salin will be given by rectal catheter 20 minutes before CT image is taken.
45691878|NCT00695578|Drug|Polysporin|over the counter Polysporin ointment 3 times daily for 4 weeks to wounds
45487848|NCT03686852|Other|same medications but different dosages|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 50IU (Group A), 150IU (Group B) or 250IU (Group C) of recFSH (Puregon®, MSD)
45487849|NCT03184402|Drug|DWJ1252|tablet
45369359|NCT00957164|Behavioral|Brief Prolonged Exposure Protocol|The PTSD treatment used in this study is an adaptation of a brief Prolonged Exposure treatment protocol for PTSD as illustrated in a 2005 paper published by Cigrang, Peterson, and Schobitz 54 in which a 4-session prolonged exposure treatment was used to address PTSD symptoms in three injured soldiers recently exposed to trauma. The authors found a 50+% decrease in PTSD symptoms after these four sessions. The present study will rely upon a similar brief PTSD intervention for treating chronic PTSD among trauma-exposed injured active duty service members. The PTSD intervention will be expanded into five sessions over 5 weeks to include an initial session for assessment and education on the co-morbidity of pain and PTSD. All PTSD treatment will be provided under the direct care or supervision of a Master Trained therapist in Prolonged Exposure.
45487850|NCT03184402|Drug|Gasmotin|tablet
45487851|NCT03184402|Drug|Placebo of Gasmotin|tablet
45487852|NCT03184402|Drug|Placebo of DWJ1252|tablet
45487853|NCT01318395|Drug|Aliskiren|orally 150 mg/d for 1 week, then orally 300 mg/d for 7 weeks
45487854|NCT01318395|Drug|Placebo|orally once per day
45487855|NCT01376544|Device|Treatment protocol designed to evaluate (SLE 5000 ventilator)|Assist control ventilation and pressure support ventilation
45691879|NCT01792102|Drug|Carfilzomib and Dexamethasone|"Phase 1: Carfilzomib will be administered at an escalating dose by cohort as 60-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. On Cycle 1 Days 1 and 2, carfilzomib will be given at 20 mg/m^2. For all subsequent doses, carfilzomib will be administered at the dose assigned to the cohort (56, 70, or 88 mg/m^2). Dexamethasone (8 mg IV or PO) will be administered prior to carfilzomib on Days 1, 2, 8, 9, 15, and 16.~Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: From Cycle 9 onward, carfilzomib and dexamethasone will be administered in the same fashion as during the previous treatment cycle, but only on days 1, 2, 15, and 16."
45846495|NCT04670640|Behavioral|No Distractions|Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. Participants will engage in a period of no-screen time; during this time there will be no outside visual or auditory distractions. There will be no explicit tasks or direction given in this intervention. They will receive their assigned intervention for approximately 18 minutes.
45487856|NCT02329925|Device|Tongue Stabilizing Device (TSD)|Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
45691880|NCT02996734|Procedure|curettage and resection|the investigators analyzed patients with giant cell tumor of bone who underwent curettage or resection with or without denosumab administration
45846496|NCT04597554|Dietary Supplement|Cranberry|Cranberry beverage and gummies supplement
45487857|NCT03686774|Drug|Memantine|"Women provide written informed consent prior to their participation in the study, during their Anesthesiology visit. After baseline assessments (15 days before surgery: Day 0 - 15) of pain intensity, cognitive, quality of life and quality of sleep questionnaires, participants will be randomized in two parallel groups: memantine (n=75) or usual care (n=75). Memantine will be given orally for four weeks starting two weeks before surgery. Endpoints will be assessed 15 days (Day 0 + 15), 3 months (Day 0 + 3 months), 6 months (Day 0 + 6 months) et 12 months (Day 0 + 12 months) post-mastectomy. In order to maintain a good compliance and to verify that women do not develop adverse events, patients will be called once a week by phone. A booklet for monitoring will be completed daily by the patient for 3 months from the day of surgery."
45487858|NCT03686774|Other|no memantine|"Concerning the comparator group, patients will be followed in the same way as those in the memantine group except that they will not receive the study treatment"
45487859|NCT02420392|Drug|Dapagliflozin|8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea
45487860|NCT01318551|Drug|BAY85-3934|single dose, 20 mg
45487861|NCT01318551|Drug|BAY85-3934|single dose, 40 mg (optional)
45487862|NCT01318551|Drug|BAY85-3934|single dose, 80 mg (optional)
45487863|NCT01562795|Drug|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
45487864|NCT01562795|Drug|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
45487865|NCT01562795|Drug|corticosteroids|corticosteroids plus artificial tear substitute
45487866|NCT01562795|Drug|artificial tear substitute|artificial tear substitute alone
45691881|NCT00699010|Drug|Acurox 5/30mg taken first|followed by oxycodone 5mg with 48 hour washout
45691882|NCT00699010|Drug|Oxycodone 5mg taken first|followed by Acurox 5/30mg with 48 hour washout
45691883|NCT02996812|Drug|Exendin (9-39)|
45846497|NCT04597554|Dietary Supplement|Placebo|Placebo beverages and gummies supplement
45846498|NCT04488900|Drug|CKD-508 Capsule|Investigational drug
45846499|NCT04488900|Drug|Placebo Capsule|Placebo
45846500|NCT04488900|Drug|CKD-508 Tablet|Investigational drug
45846501|NCT04488900|Drug|Placebo Tablet|Placebo
45487867|NCT02424448|Procedure|Biopsies, blood and urine samples|"Session 1: Biopsies will be taken from the main study lesion and up to 2 metastatic sites at 1 visit or over 3 visits. Both formalin fixed and snap frozen material will be collected. At the session (i.e. once over the potential maximum of 3 visits in a session) a urine sample, blood samples for circulating tumour cells (CTC) and an exploratory blood sample (processed to plasma) will be taken.~Session 2: 7 days +/-3 following the last biopsy taken from Session 1, repeat biopsies from the same tumour sites will be obtained. In cases where this is not possible, it is acceptable to biopsy alternative lesions. As in Session 1 biopsies may be taken at 1 visit or over 3 visits and urine, CTC blood samples and an exploratory blood sample (processed to plasma) will be taken."
45487868|NCT01311817|Biological|BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)|1mL liquid contained in an adhesive skin patch
45691884|NCT00661570|Device|Provox Vega voice prosthesis (20 Fr)|The current Provox2 voice prosthesis of laryngectomized patients will, when the patient comes in for a change, be replaced with a new, next generation Provox Vega voice prosthesis and insertion system
45369360|NCT00957164|Behavioral|Chronic Pain Management Treatment|Pain treatment will involve five-sessions over 5 weeks of individual treatment protocol based on the existing chronic pain management program through the Clinical Health Psychology Service at Wilford Hall Medical Center. This treatment will involve covering the difference between chronic and acute pain, the role of cognitive, behavioral, and emotional variables in pain progression, and ways to manage these variables to prevent the development of chronic pain.
45369361|NCT00957164|Behavioral|Self-Care|participants randomized to either the Pain-only or PTSD-only groups will receive five sessions of pain- or PTSD-specific treatment followed by five sessions of self-care placebo over 5 weeks. The self-care module will be manualized for reliability and fidelity between providers and will involve 60-minute sessions covering various topics.
45691885|NCT00706810|Drug|Hydroxyurea|Hydroxyurea inhibits DNA synthesis by inhibition of ribonucleotide diphosphate reductase and is a well-known drug used for the treatment of a number of tumor types including head and neck tumors and chronic myelogenous leukemia. It has also been used as an adjuvant for antiretroviral treatment for patients with HIV and as a treatment for polycythemia vera, essential thrombocythemia and sickle cell disease.
45487869|NCT01354821|Procedure|Endovascular aortic repair|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
45369362|NCT05228340|Procedure|Flexor tenotomy|Minimally-invasive percutaneous needle flexor tenotomy of the long digital flexor tendon
45369363|NCT00775229|Drug|Naltrexone|pill, by mouth, 50mg-150mg/day for the duration of the study
45369364|NCT00775229|Drug|Placebo|pill, by mouth, daily
45369365|NCT00962442|Drug|N-Acetylcysteine|300 mg/kg for 14 days, intravenously
45487870|NCT01354821|Procedure|Open surgical repair|Conventional therapy in France with the national database of the M.O.H.
45487871|NCT02424136|Other|Questionnaire|5 minute questionnaire focused on symptoms of allergic disease
45369366|NCT00962442|Drug|placebo|Glucosé 5% perfusion for 14 days, intravenously
45369367|NCT00948038|Dietary Supplement|Milk|Milk-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate adn 350 mg Ca. Three consumed each day.
45487872|NCT02424136|Other|Peanut Skin prick test|Skin prick testing with peanut antigen, according to ASCIA Skin Prick testing manual
45487873|NCT02424136|Other|Fraction of exhaled nitric oxide|Measurement of exhaled nitric oxide, according to American Thoracic Society/ European Thoracic Society (ATS/ERS) standardised procedures (Not required for those age less than 6 years).
45487874|NCT02424136|Other|Spirometry|Measurement of lung flows/volumes, according to ATS/ERS standardised procedures (Not required for those age less than 6 years).
45846502|NCT04003740|Device|Home-based transcranial direct current stimulation|The stimulation protocol will include one daily stimulation during the first 4 weeks, 2 weekly stimulations for the next 4 weeks, and one weekly stimulation over the last 4 weeks.
45846503|NCT03939234|Combination Product|PD-L1, PD-L2 peptides with Montanide ISA51|PD-L1: 19 amino acid sequence from the PD-L1 protein; PD-L2: 21 amino acid sequence from the PD-L2 protein; The peptides are dissolved in dimethyl sulphoxide (DMSO) and mixed with Montanide.
45369368|NCT00948038|Dietary Supplement|Soy|Soy-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate and 30 mg Ca. Three consumed each day for 28 days,
45369369|NCT00967980|Procedure|Femoral Nerve Block vs. Psoas Compartment Nerve Block|Patients, undergoing hip arthroplasty or hip resurfacing will be randomized to one of two groups: femoral nerve block or psoas compartment nerve block. Patients randomized to femoral nerve block will receive this block prior to surgery. Patients randomized to psoas compartment nerve block will receive this block prior to surgery. Both patients will receive Mepivicaine via catheter prior to surgery and following surgery, Ropivicaine via pain pump.
45369370|NCT00743951|Behavioral|1 Patient decision aid|"Patients will receive:~i)patient education booklet ii) a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form is an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referral to the surgeon with a standardized report of their clinical findings plus decisional data (knowledge, values, preference)."
45487875|NCT02424136|Other|Serum Peanut and Ara h2 specific immunoglobulin E|Peanut and Ara h2 specific IgE antibodies
45487876|NCT02424136|Other|Collection of blood biomarker|Correlation of blood biomarker levels in patients with successful or unsuccessful peanut food challenge
45487877|NCT02424136|Other|Peanut food challenge|Open label peanut challenge conducted according to ASCIA's peanut challenge protocol and PRACTALL consensus report
45487878|NCT02916056|Drug|Azeliragon 5mg|
45487879|NCT03857256|Drug|CP105F|Natural Health Product
45487880|NCT03857256|Drug|Placebo|tablet manufactured to mimic the CP105F beta-glucan
45487881|NCT03770676|Dietary Supplement|Selenium-fortified biscuits|Selenium-fortified biscuits, fortified with selenium-enriched yeast (approx. 60 mcg selenium per day, for 14 days). One of three novel flavours.
45487882|NCT03181438|Procedure|TAP Block|It will be performed a ultrasound-guided transverse abdominal plane block with 20 ml of 0.375% of ropivacaine for patients submitted to renal transplantation
45487883|NCT03181438|Procedure|Saline Group|t will be performed a ultrasound-guided transverse abdominal plane block with 2o mL of saline for patients submitted to renal transplantation
45691886|NCT00706810|Drug|Verapamil|Verapamil is another commonly used medication. It is used for the treatment of angina, hypertension, supraventricular arrhythmias, and migraine prophylaxis. Dosing with standard verapamil is 80-120 mg pox three times a day but the sustained release form can be given 120-480mg once or twice each day.
45691887|NCT00661960|Drug|raltegravir|400mg tablet twice daily by mouth for nine months
45691888|NCT00661960|Drug|efavirenz|600mg capsule once daily by mouth without regard to food
45691889|NCT00662818|Drug|Telcagepant|Telcagepant (MK-0974) (300 mg soft gel capsules or 280 mg tablets)
45691890|NCT00662818|Drug|Acetaminophen/Paracetamol|Acetaminophen/Paracetamol (500 mg X 2 dosage units)
45691891|NCT00662818|Drug|Placebo to Telcagepant|Placebo 300 mg soft gel capsules or placebo 280 mg tablet.
45487884|NCT01355133|Biological|Transurethral intrasphincteric autologous myoblast implantation|Patients undergo upper arm muscle biopsy to isolate and cultivate autologous myoblasts. Using the ultrasound-directed transurethral medical device, 15-18 aliquots (50 - 100 µl per depot) of the 2 ml myoblasts/media suspension are directly injected into the urethral rhabdosphincter at two different levels. The procedure is a single-dose injection of a cell count in range of 1x106 -5x107 cells, depending of the size/quality of the biopsy and quality of outgrowing cells in order to identify possible dose related effects. To possibly enhance cell integration following implantation, a course of transvaginal electrical stimulation is undertaken.
45487885|NCT02424058|Device|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
45487886|NCT02424058|Behavioral|Neck pain intensity measurement|The neck pain intensity of the patients was questioned by Visual Analogue Scale
45487887|NCT02420158|Device|Trans-cutaneous vagal nerve electrical stimulation|
45487888|NCT01361841|Drug|Latanoprost, bimatoprost, travoprost|topic drops, once a day at bedtime, for years
45369371|NCT00743951|Behavioral|2 Usual care|"Patient will be given i) education booklet from local hospital which is a standardized teaching booklet given to all patients describing preparation for surgery, recovery after surgery, discharge plans.~ii) Referral to the surgeon with a standardized report of their clinical findings."
45487889|NCT01361841|Drug|travoprost, latanoprost and bimatoprost|one drop once a day for life
45487890|NCT04854642|Drug|Ladarixin|A single oral dose of 400 mg of ladarixin (two 200 mg capsules) was administered to healthy male and female volunteers under fed (Test treatment) and fasting (Reference treatment) conditions in two consecutive study periods, according to a two-way crossover design, with a wash-out interval of at least 14 days between the two administrations.
45487891|NCT02420236|Behavioral|High-intensity resistance training|
45369372|NCT00957320|Drug|Sirolimus|Sirolimus daily po days 1 through 28, Dose level 0: 0.25 mg/m2 po daily Dose level 1: 0.5 mg/m2 po daily Dose level 2: 1 mg/m2 po daily Dose level 3 1.5 mg/m2 po daily Dose level 4 2 mg/m2 po daily
45369373|NCT00957320|Drug|PEG-asparaginase|Subjects will receive PEG-asparaginase at a fixed weekly dose, as per published reports in relapsed childhood ALL.
45369374|NCT00968058|Procedure|Leak Test Recording|Recording of the Leak Pressure by the Leak Test at 0, 5, 10, 15, 20, 30 min timepoints
45369375|NCT00957476|Dietary Supplement|Omega-3 Fish Oil|800mg DHA and 1200mg EPA or the equivalent of a placebo PO (by mouth) once a day from enrollment (prior to 16 weeks gestation) until delivery.
45369376|NCT04316078|Other|patient engagement platform|"Allows patients to receive the action plan as educational videos on demand.~Allows patients to report side effects and quality of life via questionnaires and receive immediate targeted education based on the predefined action plan."
45487892|NCT02420236|Behavioral|General physical activity|
45487893|NCT02420236|Behavioral|Multidisciplinary rehabilitation program|
45487894|NCT02583789|Drug|oral treprostinil|Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
45369377|NCT05277324|Other|Protective facial mask|Participants, students of health related professions, who wear protective facial mask daily during their internship/practice in health institutions.
45487895|NCT02583789|Drug|Placebo|Placebo is a sugar pill manufactured to resemble UT-15C. Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
45487896|NCT01358019|Drug|LY2523355|Days 1, 2, and 3 in a cycle that consists of 21-days
45487897|NCT02428036|Biological|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10^6 TCID50/mL.
45846504|NCT03907176|Drug|HTX-011|300 mg
45369378|NCT00653159|Device|Levonorgestrel-releasing intrauterine device (LNG-IUS)|Teens are randomly assigned to receive the LNG-IUS after completing a screening visit.
45846505|NCT03907176|Device|Luer lock applicator|Applicator for instillation
45846506|NCT03907176|Drug|Ibuprofen|600 mg
45846507|NCT03907176|Drug|Acetaminophen|1 g
45846508|NCT03675672|Drug|Misoprostol Oral Tablet|Misoprostol 200mcg
45846509|NCT03675672|Drug|Placebo Oral Tablet|Placebo Tablet
45846510|NCT02692950|Other|Honor My Decisions Advance Care Planning Video|Honor My Decisions is a commercial computer application which allows a person to record a video of his/her advanced care planning and legacy information.
45846511|NCT02692950|Behavioral|Post-video questionnaire|Questions regarding the video process, changes to previous answers and reaction received by others viewing the video
45487898|NCT02428036|Biological|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10^7 TCID50/mL.
45487899|NCT01355367|Drug|Nifedipine (Adalat, BAYA1040)|BAYA1040 CR 40mg BID
45487900|NCT05759520|Biological|13-valent pneumococcal conjugate vaccine (multivalent conjugate)|the 2-month-old experimental group and the 3-month-old group received the experimental vaccine
45487901|NCT05759520|Biological|Prevenar 13|the 2-month-old control group received the active control vaccine
45487902|NCT02423902|Biological|Ad-RTS-hIL-12|Approximately 1.0x10^12 viral particles (vp) per injection
45487903|NCT02423902|Drug|Veledimex|7 oral doses of veledimex
45487904|NCT02427880|Drug|Acetazolamide and Hydrochlorothiazide Followed by Furosemide|
45487905|NCT02427880|Drug|Furosemide and Hydrochlorothiazide Followed by Furosemide|
45487906|NCT02567643|Radiation|Stereotactic Radiosurgery|
45487907|NCT04789200|Drug|NX9 Oral Contrast Agent|Distension and marking of the bowel lumen will be compared between the 1st and 2nd scan. Ability to see IV contrast enhancement will be assessed on the 3rd scan in relationship to the 2nd scan.
45487908|NCT02423746|Behavioral|Family Check Up Behavioral Parenting Training Program (BPT)|"The Family Check Up is an evidence-based Behavioral Parenting Training (BPT) program focused on harnessing parents' motivation to change and skills training.~Intervention parents receive the initial assessment session followed by 3 Family Check-up Sessions within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
45487909|NCT02423746|Behavioral|Behavioral Placebo|"The Behavioral Placebo sessions will consist of presentations of information about healthy lifestyles.~Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
45487910|NCT01355445|Drug|Vincristine, Irinotecan|"D1 and D8: Vincristine 1.5 mg/m² (max 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~D1 to D5: Irinotecan 50 mg/m²/d, IV~cycle / 21 days"
45487911|NCT01355445|Drug|Vincristine, Irinotecan, Temozolomide|"D1 to D5: Temozolomide 125 mg/m²/d, PO (the dose will be escalated to 150 mg/m²/day at cycle 2 for patients who do not experience > grade 3 toxicity of any kind)~D1 and D8: Vincristine 1.5 mg/m² (maximum 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~D1 to D5: Irinotecan 50 mg/m²/d, IV~cycle / 21 days"
45487912|NCT05759442|Drug|Metformin Hydrochloride (HCL)|Tab Metformin HCL 500mg twice per day aimed at improving glycemic indices in Prediabetics
45846512|NCT02108496|Device|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
45487913|NCT05759442|Dietary Supplement|Apple cider vinegar|Apple cider vinegar aimed at improving glycemic indices in Prediabetics
45487914|NCT02420080|Drug|Brincidofovir|Rates of adenovirus progression and mortality in subjects with adenovirus infection and/or disease. Sites participating in the CMX001-304 study will be asked to participate in the CMX001-305 study retrospective data collection study.
45487915|NCT01355601|Other|Nutritional Beverage|Nutritional Beverage with varying types and levels of carbohydrates
45369379|NCT00653159|Device|Copper T380A intrauterine device (CuT380A)|Teens are randomly assigned to Copper T380 after the screening visit
45369380|NCT03047070|Drug|Lidocaine|IV Lidocaine infusion
45369381|NCT03047070|Drug|Normal saline|IV normal saline infusion
45369382|NCT00948272|Biological|Purified Vero Rabies Vaccine - Serum Free|0.5 mL, Intramuscular
45487916|NCT01355601|Other|Nutritional Beverage|Nutritional beverage with varying types and levels of carbohydrates
45487917|NCT04772118|Other|Carevive PROmpt™|Patient Reported Outcomes Mobile Patient (Carevive PROmpt™), a digital cancer symptom monitoring platform.
45369383|NCT00948272|Biological|Purified inactivated rabies vaccine|0.5 mL, Intramuscular
45369384|NCT00968214|Genetic|polymorphism analysis|
45369385|NCT00968214|Other|laboratory biomarker analysis|
45487918|NCT04483258|Procedure|Sedation with sevoflurane insufflation|Induction with %8sevoflurane after adequate sedation reducing %3
45487919|NCT04483258|Procedure|intravenous sedation|midazolam +ketamine + atropine
45487920|NCT02419768|Other|Physical Exercise|The physical exercise program will include 30 sessions of 60 minutes (twice a week). According to the recent guidelines, the program will include a specific work on balance, posture, gait, fitness, dual tasks and stretching.
45487921|NCT03178474|Other|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: a type of Phase I infant formula for 0-6 month infants, with a trademark of PRO-KIDO™ I-PROTECH®. The formula contains both OPO structured lipid and α+β patented protein (patent number: ZL200810241156.3).It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
45487922|NCT03178474|Other|TOFER Infant formula,TOFER®|TOFER Infant formula,TOFER®: a type of Phase I infant formula for 0-6 month infants, with a trademark of TOFER®. The formula was characterized by (1) Moderate digestible small-molecule protein; and (2) BID® complex probiotics. It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
45487923|NCT03178474|Other|Breast milk|Breast milk: Human breast milk, provided and fed by the corresponding infant's mother
45487924|NCT01355757|Device|Baxter INFUSOR System|Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
45487925|NCT01355757|Drug|Single Injection of Local Anesthetic|Single injection of 20 ml ropivacaine 0.5%
45369386|NCT00957554|Drug|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily
45369387|NCT00957554|Drug|irbesartan|Pharmaceutical form: 150 and 300 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily
45369388|NCT00921713|Other|Oncology Nurse Care Management|
45487926|NCT02507505|Procedure|Regional Anesthesia|Regional anesthesia involves temporarily numbing parts of the body with nerve blocks. Spinal anesthesia is a type of regional anesthesia that uses medications injected into the fluid surrounding the spinal cord to temporarily numb the legs and lower abdomen. Spinal anesthesia is the most widely used type of regional anesthesia for hip fracture surgery. While intravenous sedation is typically used for comfort with spinal anesthesia, invasive airway interventions are not typically required.
45487927|NCT02507505|Procedure|General Anesthesia|General anesthesia uses injected or inhaled medications to keep people unconscious during surgery. Since general anesthesia depresses breathing and impairs protective airway reflexes, invasive airway interventions such as breathing tube placement and mechanical ventilation are usually required.
45487928|NCT03181360|Drug|Tenecteplase|Single dose intravenous injection of recombinant fibrin-specific tissue plasminogen activator (tenecteplase) 0.25 mg (200 IU) per kg body weight up to a maximum of 25 mg (5000 IU), given as a bolus over approx. 10 seconds.
45487929|NCT03181360|Other|Control|Best standard treatment
45487930|NCT04769856|Other|State-Trait Anxiety Inventory (STAI) scale|State-Trait Anxiety Inventory (STAI) scale
45487931|NCT04769856|Other|Satisfaction scale|Satisfaction scale
45487932|NCT04275531|Drug|Anesthesia Agent|various anesthetic agents used in both general and regional anesthesia
45487933|NCT04764864|Procedure|Angioembolization|"Via the femoral route, a non-selective pelvic arteriography with a selective embolization of the arterial branches that show direct or indirect signs of injury will be performed.~In the event of persistent hemodynamic instability after selective embolization, non-selective bilateral embolization of the internal iliac arteries will be evaluated.~The material used will vary depending on the characteristics of the injury and the availability of the materials."
45691892|NCT00662818|Drug|Placebo to Acetaminophen/Paracetamol|Placebo to acetaminophen/paracetamol (500 mg X 2 dosage units)
45369389|NCT00921713|Other|Patient-centered materials|
45369390|NCT00744029|Behavioral|educational material|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
45369391|NCT03024684|Drug|Atorvastatin|Atorvastatin 10mg daily
45369392|NCT03024684|Drug|Placebo Oral Tablet|Placebo one tablet daily
45369393|NCT00746057|Biological|DNA chip|One biopsy is realized before graft, another biopsy is realized one year after graft and a blood sample is collected 3 months after graft to realize DNA chip. Blood samples are also collected at day 0, day 1, month 3, month 6 and month 12 to analyze biochemistry, proteinuria, haematology, creatinine clearance and immunology at day 0, month 3 and month 12.
45369394|NCT00948350|Procedure|awake intubation|two anesthesia techniques
45369395|NCT00968292|Device|Experimental prosthetics foot (K3 Promoter)|The tests will be unblinded randomized studies of the subject's current prosthetic foot and the K3 Promoter on traumatic/congenital amputees and dysvascular/diabetic amputees. Assessments will be made after a 30-day accommodation period with each foot prosthesis. In order to randomize the treatment and factor out habituation to the testing site and the protocol, two cohorts will be used. Half of the volunteers will be randomly assigned to be fitted with the K3 Promoter by their regular prosthetist or will continue wearing their current foot prothesis. Both cohorts will have a 30-day accommodation period. Subjects in either cohort will then visit the CGMA to be tested. Volunteers will then use the other prosthesis for 30 days. After that second 30-day period, height and weight will again be recorded, and the tests will be repeated. Because of anticipated difficulty with scheduling, volunteers will be given a +3 day grace period on the 30 day-accommodation time.
45487934|NCT04764864|Procedure|Preperitoneal Pelvic Packing|"Pfannestiel incision / infraumbilical laparotomy. Dissection of tissues up to and including the transversalis fascia. Inferior to this and anterior to the peritoneum, the preperitoneal cavity is identified.~Inclusion of radiopaque laparotomy gauze in each hemipelvis, from the posterior part (anterior to the sacro-iliac joint) to the most anterior in the retropubic position. Subsequently, the closure is carried out to increase the plugging effect.~A second intervention is required to remove the material in 24-48 hours."
45487935|NCT01355835|Device|deep brain stimulation (ACTIVA PC, Medtronic)|High frequent deep brain stimulation with variable (best individual) stimulation on subthalamic contacts and standard parameters on nigral contacts (125 Hz, 60µs, best individual amplitude)
45487936|NCT03689712|Drug|GC4419 90mg|60 minute IV infusion
45369396|NCT00957710|Behavioral|Errorless learning|Language testing,20 sessions of language therapy, and 2 neuroimaging sessions for participants with progressive aphasia Language testing and 1 imaging session for healthy controls
45487937|NCT03689712|Drug|Placebo|60 minute IV infusion
45487938|NCT04804527|Other|Intensified physiotherapy|Physiotherapy x2
45487939|NCT04804527|Other|Usual care physiotherapy|Physiotherapy x1
45487940|NCT03384745|Drug|M1095 (Sonelokimab)|M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.
45487941|NCT03384745|Drug|Placebo|Placebo contains no active drug.
45487942|NCT03384745|Drug|Secukinumab|Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.
45487943|NCT03180814|Other|Whole Body Vibration|A whole body vibration session will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 04 mm.
45487944|NCT01361997|Biological|chlorhexidine in isopropyl alcohol|When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
45487945|NCT01361997|Biological|Isopropyl alcohol|When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
45487946|NCT03180892|Other|The investigators did not apply any intervention for the participants.|The investigators did not apply any intervention for the participants.
45487947|NCT04750824|Drug|Afatinib|Afatinib
45846513|NCT02108496|Drug|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
45487948|NCT04750824|Drug|other systemic therapy|other systemic therapy
45846514|NCT02108496|Drug|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
45369397|NCT00962910|Other|PFF evidence based pathway|A care pathway, as complex intervention, will be implemented.
45369398|NCT00744107|Device|PCI with the Cobra™ Cobalt Super Alloy Coronary Stent System|stent placement, single-arm study
45369399|NCT00117637|Drug|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor
45369400|NCT00117637|Drug|Interferon|Interferon
45846515|NCT02108496|Drug|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
45369401|NCT00746135|Device|Device Implantation|RV apical pacing lead, RV pacing lead at HIS bundle position, LV pacing lead implantation
45369402|NCT00744185|Drug|propranolol treatment|30 days-propranolol treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
46052667|NCT05562414|Behavioral|HIIT|"Exercise intensity will be regulated and heart rate controlled based on the age-predicted heart rate (HRmax), as calculated by the formula 220 minus age in years.~Participants will perform six high-intensity intervals (95% HRmax) at high pedalling rates of 80-100 rounds per minute (rpm) for 60-90 seconds each. Intervals are interspersed by active breaks of unloaded pedalling (20 watts, 60-80rpm) aimed to return to 60% HRmax (approximately 1.5-2 min). The duration of the HIIT bout is approximately 21 minutes."
45369403|NCT00744185|Drug|placebo treatment|30 days-placebo treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
45369404|NCT02897778|Drug|Entinostat|Single, supratherapeutic dose of entinostat given orally.
45369405|NCT02897778|Drug|Placebo|Single dose of placebo-matching entinostat (containing inactive ingredients matching the appearance of the active product).
45369406|NCT00746291|Other|6 min walk test, Step climbing|walking for 6 minute and climbing steps
45369407|NCT01084291|Biological|Investigational Vaccine for DEN1|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
45369408|NCT01084291|Other|Placebo injection|Subcutaneous injection of placebo
45369409|NCT00741689|Drug|AZD1656|Dose escalation of oral single doses of AZD1656 to achieve maximal tolerated dose
45369410|NCT00963066|Device|PSV - pressure suppot ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Different levels of pressure support ventilator assistance are tested.
45369411|NCT00963066|Device|NAVA - Neurally Adjusted Ventilatory Assist|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Positive pressure, delivered by the machine, is driven using inspiratory flow trigger.
45369412|NCT00963066|Device|NAVA - EMG|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. The machine applies positive pressure throughout inspiration in proportion to the electrical activity of the diaphragm (Eadi). Eadi was obtained trhough a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden).
45369413|NCT01081093|Procedure|additional temporary pacewire|Placement of an additional pacing wire on the left side of the heart after aortic valve replacement in patients with hypertrophic cardiomyopathy
45369414|NCT00744341|Drug|SLV320|1.25mg i.v. bid
45369415|NCT00744341|Drug|SLV320|3.75mg i.v. bid
45369416|NCT00744341|Drug|SLV320|7.5mg i.v. bid
45369417|NCT00744341|Drug|SLV320|15.0mg i.v. bid
45369418|NCT00744341|Drug|Placebo|
45369419|NCT00968370|Other|Day-care clinic|Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.
45691893|NCT00699556|Drug|21mg transdermal nicotine patch (Nicoderm CQ)|21mg transdermal nicotine patch
46052668|NCT05562414|Behavioral|MCT|"Exercise intensity will be regulated and heart rate controlled based on the age-predicted heart rate (HRmax), as calculated by the formula 220 minus age in years.~Participants will continuously train at 60% HRmax and pedal at 60-80 rounds per minute. The duration of the MCT bout is 26 minutes."
46052669|NCT02800707|Other|Sucralose|Sweetner
46052670|NCT02800707|Other|Stevia|Sweetner
46052671|NCT02800239|Dietary Supplement|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
45369420|NCT00968370|Other|Hospital Management|Inj. Ceftriaxone and other micronutrients will be given to children at the hospital from admission till discharge.
45369421|NCT02685384|Other|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
45369422|NCT00968448|Behavioral|Respiratory muscle training|Daily training with a handheld device (Pressure threshold loading). 1x50 breaths with adjustments (gradually increasing levels).
45369423|NCT00968448|Behavioral|Sham training|Sham training with same handheld device. 50 breaths daily on the lowest level
45369424|NCT00741767|Drug|salmeterol-fluticasone|250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily
45369425|NCT00741845|Drug|intravaginal metronidazole|high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg
45369426|NCT02564549|Procedure|TRUS-guided biopsy|Patients on the TRUS biopsy-based arm will undergo annual systematic biopsies without any MRI staging or guidance.
45369427|NCT02564549|Procedure|mpMRI with targeted biopsy|Patients on the mpMRI- based arm will undergo annual mpMRI surveillance imaging, with image-guided targeted biopsies only as indicated by radiographic findings.
45369428|NCT00741923|Other|navy beans added to regular diet|5 cups per week of commercially available white beans for 4-weeks
45369429|NCT00746369|Behavioral|IMARA HIV Prevention Intervention|Three individual sessions- behavioral intervention for incarcerated female adolescents.
45369430|NCT00746447|Drug|mesalamine granules|3.0g mesalamine in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
45369431|NCT00746447|Drug|mesalamine granules|1.5g mesalamine and 1.5g placebo in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
45369432|NCT00746447|Drug|mesalamine granules|0.5g mesalamine and 2.5g placebo in the morning, 0.5g mesalamine at lunch, 0.5g mesalamine in the evening
45691894|NCT00699556|Drug|1mg nicotine nasal spray|two 0.5mg/sprays, one to each nostril (dose = 1mg) The nicotine nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital. It is similar in concentration to Nicotrol.
45691895|NCT00699556|Drug|placebo nasal spray|saline combined with capsaicin to mimic the brief nasal irritation from active nicotine spray The placebo nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital.
45487949|NCT01362075|Procedure|Local infiltration analgesia|150 ml ropivacaine, of which 100 ml is with adrenalin
45487950|NCT01362075|Procedure|Interscalene catheter|7 ml ropivacaine interscalene block via catheter, subsequently given 5 ml/h and possibility of 5 ml bolus for the first 48 hours.
45487951|NCT03180970|Drug|1.2% Lugol's solution|1.2% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
45487952|NCT03180970|Drug|1.0% Lugol's solution|1.0% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
45691896|NCT00700336|Drug|pemetrexed, cisplatin and CBP501|"CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
45487953|NCT03180970|Drug|0.8% Lugol's solution|0.8% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
45487954|NCT03180970|Drug|0.6% Lugol's solution|0.6% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
45487955|NCT03180970|Drug|0.4% Lugol's solution|0.4% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
45487956|NCT05676528|Other|Exercise intervention|The participants will carry out a physiotherapeutic exercise intervention over a period of 6 weeks. The exercise intervention is stored in a smartphone app (PhysiApp) and consists of different neck and shoulder exercises. The investigators will provide the training material to the participants and they may keep it after the end of the study. Participants can choose which and how many exercises they would like to do. However, the investigators ask participants to exercise at least three times a week for 20 minutes each time (a total of one hour per week) and to document the training afterwards in the smartphone app. In the first, third and sixth week, the investigators train together with the participants via a virtual platform (e.g. video call via Microsoft Teams) so that the correct execution of the exercise can be checked and questions can be clarified.
45487957|NCT01319097|Other|Sorbion Sachet S|Dressing is indicated for moderately to heavily exuding wounds.
45487958|NCT03631446|Drug|Sodium Picosulfate, Magnesium Oxide and Citric Acid|Combination powder for oral solution
45487959|NCT03178240|Behavioral|photoaging mirroring intervention|selfies of the students are photoaged showing them the consequences of their UV protection behavior on their own face
45487960|NCT03383887|Drug|Placebo oral capsule|Placebo before sleep
45487961|NCT03383887|Drug|DAW1033D oral capsule|DAW1033D before sleep
45487962|NCT03184168|Drug|[14C]lorlatinib|Extemporaneously compounded oral solution of [14C]lorlatinib (approximately 100 mg/100 µCi)
45487963|NCT04709874|Other|Paravertebral block|Paravertebral block using nerve stimulator guidance will be done at C7-T1
45487964|NCT04709874|Other|Suprascapular block|Paravertebral block using nerve stimulator guidance will be done
45487965|NCT01362153|Drug|Golimumab|SC injection of 100 mg every 4 weeks through Week 20
45487966|NCT01362153|Drug|Golimumab|IV infusions of 2 mg/kg golimumab on Days 1 and 85.
45691897|NCT00700336|Drug|pemetrexed and cisplatin|"Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
45691898|NCT00700336|Drug|pemetrexed, cisplatin and CBP501, dose finding|"Dose level 1: CBP501 16 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Dose level 2: CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
45487967|NCT03184324|Drug|DWP14012|tablet
45487968|NCT03184324|Drug|Esomeprazole|tablet
45487969|NCT03184324|Drug|DWP14012 placebo|tablet
45487970|NCT03184324|Drug|Esomeprazole placebo|tablet
45487971|NCT03711097|Drug|Vanish XT Dental Varnish|Varnish will be applied to the front surface of the intervention upper central and lateral incisors
45487972|NCT02427334|Drug|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
45487973|NCT02427334|Drug|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
45487974|NCT02427334|Drug|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
45487975|NCT03379753|Other|music and positive images|The diad of misic and positive image will be administered to the standard care by adding a Bluetooth capable speaker with selections of music and a soothing nature landscape into the hospital room.
45487976|NCT03620253|Drug|Modafinil|Participants randomized to the modafinil group will receive 100 mg of modafinil capsules for 1 week, followed by 200 mg for 7 weeks (as long as the drug is well tolerated), which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
45487977|NCT03620253|Drug|Placebo|Participants randomized to the placebo group will receive 100 mg placebo capsules for 1 week, followed by 200 mg for 7 weeks, which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
45487978|NCT03177928|Device|Transthorathic echocardiogram|In echocardiography lab and using transthoracic echocardiogram to reveal any cardiac changes in patients.
45487979|NCT01355991|Drug|Tiotropium|18mcg/ capsule inhaled once daily for two weeks.
45487980|NCT01355991|Drug|Salmeterol|50mcg inhalation twice daily for two weeks
45487981|NCT03180658|Procedure|GTR + CGF + bone graft|Guided tissue regeneration (GTR) combined with CGF and bone graft to treat mandibular furcation involvements
45487982|NCT03180658|Procedure|CGF + bone graft|CGF combined with bone graft to treat mandibular furcation involvements
45487983|NCT01356069|Other|SB-APP|"SB-APP, derived from Brief-Adlerian Psychodynamic Psychotherapy (B-APP) is a time-limited (40 weekly sessions) psychodynamic psychotherapy based on Alfred Adler's theory and delivered in sequential and repeatable modules.~SB-APP is focused specifically on four personality functioning levels (PFL). These are assessed by the therapists on the basis of symptoms, quality of interpersonal relationships, overall social behaviors, cognitive and emotional patterns, and defense mechanisms"
45487984|NCT01356069|Other|treatment as usual|This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators.
45487985|NCT03180424|Drug|L Carnitine|L Carnitine liquid, single daily dose of 2g orally.
45487986|NCT03180424|Behavioral|Supervised exercise|Modified Otago exercise programme, 2 times a week with a duration of 45 minutes, to be supervised by a previously qualified and trained instructor. Follow up of the established plan includes an adequate monitoring, evaluating the evolution and the possible adverse effects that may appear.
45487987|NCT03180424|Drug|Placebos|Liquid substance, similar to the one containing L carnitine, in the same presentation
45487988|NCT03180424|Behavioral|Exercise at home|A schedule of exercises will be given in the consultation, which the patient will perform at home, without supervision
45487989|NCT01319175|Other|Hip flexion strength training|
45487990|NCT01358253|Drug|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)(odd courses).
45369433|NCT00744419|Drug|pantoprazole|Intravenous pantoprazole will be administered daiy for 6 (+/- 1 day). The first 6 subjects in each age group will receive low dose [0.4 mg/kg (< 44 wks PMA) or 0.8 mg/kg (44 wks to < 1 yr)] and the last 6 subjects in each age group will receive high dose [0.8 mg/kg(< 44 wks PMA) or 1.6 mg/kg(44 wks to < 1 yr)]
45487991|NCT01358253|Drug|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
45487992|NCT01358253|Drug|Vincristine|Consolidation:1.4 mg/m2 (max 2mg) IV on day 4 and day 11 (odd courses). Maintenance:1.4mg/m2(max 2mg) IV monthly from 1st to 12th month.
45487993|NCT01358253|Drug|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 and days 11-14(odd courses)
45691899|NCT02996422|Behavioral|School-based water campaign|Includes: 1) the installation of filtered water bottle refilling stations, 2) the distribution of reusable water bottles to all students and teachers, and 3) a social marketing campaign to support the increase of water consumption among students.
46052672|NCT03409848|Drug|Nivolumab|Addition of Nivolumab to Standard therapy (chemotherapy and Trastuzumab)
45369434|NCT00742157|Drug|Growth Hormone|dosage = 0.05mg/kg/day, in diluent for injection, once a day, for 23 - 54 days.
45369435|NCT00549302|Drug|tadalafil|20 milligram (mg) tablet, taken by mouth once a day for 52 weeks for the phase 1 portion. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of Pulmonary Arterial Hypertension (PAH).
45487994|NCT01358253|Drug|Cytarabine|2g/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
45487995|NCT01358253|Drug|Methotrexate|Consolidation:1000 mg/m2 IV over 24 hours on day 1 (even courses). Maintenance:25mg/m2 weekly for 24 months.
45487996|NCT01358253|Drug|Rituximab|"Consolidation:375 mg/m2 IV day 1 for the odd courses of therapy (total 4 times).~Maintenance:375 mg/m2 IV in 6th month and 12th month."
45487997|NCT01358253|Drug|6-Mercaptopurine|Maintenance:60mg/m2 daily for 24 months.
45487998|NCT01358253|Drug|Prednisone|Maintenance:40mg/m2 from days 1-7 monthly from 1st to 12th month.
45487999|NCT01358253|Drug|L-asparaginase|Maintenance:6000IU/m2 IV on days 1,3,5 of the 3rd and 9th month.
45691900|NCT02996422|Behavioral|Community cooking classes|Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
46052673|NCT03409848|Drug|Nivolumab|Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
45488000|NCT03548064|Other|Placebo|Placebo
45488001|NCT03548064|Other|Placebo|Placebo
45488002|NCT03548064|Other|Placebo|Placebo
45488003|NCT03548064|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
45691901|NCT01795846|Other|Allergen specific immunotherapy and placebo injections|
46052674|NCT03409848|Drug|Ipilimumab|Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
46052675|NCT02806323|Other|Yoga practice|
45488004|NCT03548064|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
45488005|NCT03548064|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
45488006|NCT03180346|Device|PICO|Single Use Negative Pressure Dressing
45488007|NCT03180346|Device|Aquacel|Occlusive surgical dressing infused with ionized silver
45369436|NCT00549302|Drug|tadalafil|40 mg tablet taken by mouth once a day for 52 weeks in phase 1. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of PAH.
45488008|NCT03180112|Genetic|enzyme linked immunosorbent assay and polymerase chain reaction|Blood samples will be collected and analyzed for herpes simplex viruses (type one and two) antibody by sensitive enzyme-linked immunosorbent assay and quantitative polymerase chain reaction.
45691902|NCT00701896|Drug|Varenicline tartrate|1 mMg tablet form; daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12.
45691903|NCT00701896|Drug|Nicotine Replacement Therapy|Nicotine gum and nicotine patch
45691904|NCT00701896|Other|Biological Control|No treatment intervention only information and procedures.
45369437|NCT00957788|Drug|NST-001|Comparison of different dosages of drug.
45369438|NCT04230278|Behavioral|START-Play Physical Therapy|Physical Therapy focused on movement and cognitive skills at the same time
45488009|NCT01356225|Drug|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution), single dose
45488010|NCT01356225|Drug|Placebo|IN placebo
45488011|NCT03379675|Drug|JNJ-53718678 500 mg|Participants will receive 500 mg dose of JNJ-53718678 oral solution once daily for 7 days.
45488012|NCT03379675|Drug|JNJ-53718678 80 mg|Participants will receive 80 mg dose of JNJ-53718678 oral solution along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
45488013|NCT03379675|Drug|Placebo|In treatment B, participants will receive matching placebo along with JNJ-53718678 to maintain the same total volume as for the 500 mg dose once daily for 7 days. In treatment C, participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
45488014|NCT02427412|Drug|Tranexamic Acid|An anti-fibrinolytic drug injected into the knee joint at the end of surgery, 3 g diluted in 30 ml saline water.
45488015|NCT02427412|Drug|Saline water|30 ml of Saline water injected into the knee capsula at the end of surgery.
45488016|NCT02427412|Drug|Tranexamic Acid|An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.
45488017|NCT01356303|Drug|cisplatin, docetaxel|"All patients met the eligibility criteria will undergo treatment with chemotherapy.~Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of Dextrose 5% in Water or Normal Saline administered as a 1-hour intravenous infusion followed by cisplatin at dose of 75 mg/m2 administered as a 2-hour intravenous infusion every 3 weeks per cycle for totally 4-6 cycles."
45691905|NCT00701896|Behavioral|Motivational Interview|60 minute one-on-one Interview
45691906|NCT01797406|Other|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum
45691907|NCT01797406|Other|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
45369439|NCT04230278|Behavioral|Usual Care Physical Therapy|Physical Therapy focused on movement and reducing impairments
45691908|NCT01839487|Drug|PEGPH20|PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
45691909|NCT01839487|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
45691910|NCT01839487|Drug|Gemcitabine|Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
45691911|NCT01839487|Drug|Dexamethasone|Dexamethasone will be administered as per the dose and schedule specified in the respective arms.
45691912|NCT01839487|Drug|Enoxaparin|Enoxaparin will be administered as per the dose and schedule specified in the respective arms.
45488018|NCT03184012|Device|NuSmile Zirconia crowns by NuSmile company|anterior carious teeth restored with Zirconia crowns
45369440|NCT04225130|Behavioral|Written Exposure Therapy -for Suicide|The first session will consist of the therapist educating the participant about common reactions to trauma and providing information regarding the rationale of WET-S as a treatment for PTSD. The participant will then be given general instructions for completing the trauma narratives, specific instructions for completing the first session, and will then complete the first (30 minutes) narrative writing session. Participants will be instructed to write about the same trauma experience during each session. The importance of delving into their deepest emotions surrounding the trauma event is emphasized. All WET-S sessions will take place in a private room and begin with the therapist reading the specific writing instructions for that session and then leaving the instructions with the participant while 30-minute writing session is completed.
45369441|NCT04225130|Behavioral|Treatment as Usual|The TAU condition consists of daily contact and patient centered care by the acute psychiatric inpatient unit provider team (e.g., psychiatrists, therapists, case managers, behavioral health techs). TAU includes initial stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily.
45369442|NCT05299424|Drug|CM336_group 1|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.04mg on C1D8, 0.04mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
45369443|NCT05299424|Drug|CM336_group 2a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
45369444|NCT05299424|Drug|CM336_group 2b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 0.2mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
45369445|NCT05299424|Drug|CM336_group 3a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 5.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
45488019|NCT03184012|Device|Composite resin strip crowns by 3M company|anterior carious teeth restored with Strip crowns
45691913|NCT00665470|Drug|Aldesleukin|"High-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).~Receive low-dose aldesleukin subcutaneously (SC) once daily 5 days a week for up to 6 weeks"
45488020|NCT02220309|Drug|Pramipexole Oral Tablet|Pramipexole is an oral Dopamine agonist.
45488021|NCT02419534|Drug|Polyethylene glycol|Laxative to treat constipation
45488022|NCT02419534|Drug|Polyethylene glycol with Diltiazem|Laxative and topical calcium channel blocker
45488023|NCT04674852|Device|Research Marker|The research marker is a cylindrical-shaped marker made of an FDA-approved material that can be seen by ultrasound.
45691914|NCT00665704|Behavioral|Tobacco Tactics website|Pilot test the Tobacco Tactics website tailored to the needs of veteran smokers
45691915|NCT00666406|Drug|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM)|Infusion of 50 +/- 5 IU/kg bodyweight
46052676|NCT02804295|Other|Collaborative Care Intervention|All eligible subjects that meet the eligibility requirements for approach and consent and have a positive screen for PDM will complete a baseline survey and will be enrolled into the intervention condition. This is an open trial and thus all consenting eligible subjects will receive the intervention.
46052677|NCT00763555|Drug|CD 2027|Participants applied Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.
46052678|NCT00763555|Drug|Calcitriol Vehicle|Participants applied placebo matched to Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.
46052679|NCT02804373|Drug|Oxytocin (OXT) continuous|Administration of 24 IU of oxytocin daily during 28 days
46052680|NCT02804373|Drug|Placebo|Placebo daily during 28 days
46052681|NCT02804373|Drug|Placebo continuous|Placebo administration the following 2 days after each OXT administration, during 28 days.
46052682|NCT02804373|Drug|Oxytocin|Administration of 24 IU of oxytocin every 3 days during 28 days.
46052683|NCT05514678|Behavioral|Cognitive Stimulation Therapy|CST consists of 14 sessions, each session with different themes. The materials used in therapy will differ according to the characteristics of each theme. For example; In the theme of physical games, one of the individuals will be selected by voting, and each individual will be asked to choose a song suitable for the theme and introduce himself/herself to the music accompaniment. Then, a small table game will be prepared with the rackets and ball used for table tennis, and individuals will be able to play a round of table tennis with the researcher and their groupmates. Sessions 10 min. introductory part, 25 min. activity section and 10 min. 45 minutes in total, including the ending. in progress.
46052684|NCT02806401|Device|landmark|
46052685|NCT02806401|Device|US_Ax|
46052686|NCT02804061|Behavioral|NELIP|
45488024|NCT01362231|Drug|GS-6624|Patients will be treated with GS-6624 (125 or 200 mg) administered IV over 1 hour on specific days during the treatment period.
45369446|NCT05299424|Drug|CM336_group 3b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
45488025|NCT03527316|Drug|MDMA|125 mg MDMA per os, single dose
45488026|NCT03527316|Drug|Placebo|Capsules containing mannitol looking identical to the other drugs.
45488027|NCT03184246|Device|GlideScope|videolaryngoscopy (GlideScope) will be used for intubation
45488028|NCT03184246|Device|Direct laryngoscopy|direct laryngoscopy will be used for intubation
45488029|NCT01358409|Drug|Nebivolol|Day 1 - Patients will start Nebivolol 5 mg PO daily; after one month, if the subject has tolerated 5 mg PO Nebivolol, the dose will be increased to 10 mg PO daily. If the patients is unable to tolerate 5 mg PO Nebivolol, he/she will be discontinued from the study. After six months, medication will be tapered to 5 mg PO daily for two weeks. Medication will then be tapered to 2.5 mg PO daily for two additional weeks.
45488030|NCT02423590|Drug|Apatorsen (OGX-427)|Apatorsen (OGX-427) is a second generation antisense oligonucleotide designed to bind to Hsp27 mRNA
45369447|NCT05299424|Drug|CM336_group 4a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 5.0mg on C1D8, 15.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
45369448|NCT05299424|Drug|CM336_group 4b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 2.0mg on C1D8, 2.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
45369449|NCT05299424|Drug|CM336_group 5|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 8.0mg on C1D8, 24.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
45488031|NCT02423590|Drug|Gemcitabine|"Gemcitabine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Gemcitabine is classified as an antimetabolite"
45691916|NCT00666406|Drug|Recombinant Factor VIII (rAHF)|Infusion of 50 +/- 5 IU/kg bodyweight
45691917|NCT02996344|Other|Didactic training|Six online training modules pertaining to suicide prevention in primary care.
45691918|NCT02996344|Other|Standardized patient interaction|Two standardized patient practice interactions - 1 face-to-face, 1 remote/telehealth.
45488032|NCT02423590|Drug|Carboplatin|"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
46052687|NCT02800083|Drug|Pitolisant (BF2.649)|
46052688|NCT02800083|Drug|Placebo|
46052689|NCT02806167|Other|Clinical algorithm|Patients presenting with suspected acute CES will be assessed in accordance with the algorithm previously outlined.
46052690|NCT00763321|Drug|ABT-712|ABT-712 extended-release tablet
45488033|NCT01362309|Drug|d-cycloserine.|50 mg administered on two occasions.
45488034|NCT05759286|Behavioral|Aromatherapy|Aroma therapy will apply before 5 minutes and during IANB injection in children, aromatherapy will apply through a nasal mask similar to one that uses when applying nitrous oxide after putting a 3d printed perforated box on the mask's circular halo on its surface, in this box cotton bolls impregnated with 3 drops of a 15% lavender-neroli oils blend are placed and then the child will smell the scent of aromatic oil blend from the box's perforated bottom surface which faces child's nose
45488035|NCT05759286|Behavioral|Music|Music will be played from a speaker in the treatment environment and will start 5 minutes before anesthesia and will be played through the whole anesthesia process, the music used will be chosen by the child from his favourite cartoon
45488036|NCT05759286|Behavioral|Control|using a tell-show-do approach and children will put on a nasal mask without the box that contains an aromatic oil blend for the placebo effect
45488037|NCT03710941|Drug|REGN2477+REGN1033|Single, sequential, repeat-dose Intravenous (IV) or matching placebo
45488038|NCT03710941|Drug|Matching placebo|Single, sequential, repeat-dose Intravenous (IV)
45488039|NCT05114356|Device|TIDAL Cervical Interbody Fusion implant|Cervical interbody fusion device
45691919|NCT02999152|Other|blood and urines samples|"For all patients the blood samples must be organized: Before, 4 hours (+/-30 min), 1 day, 2 days, and 3 days after the start of the radiation therapy.~Collections of urine must be organized: Before, 1 day, and 2 days after the radiation therapy."
45691920|NCT02996188|Procedure|routine therapeutic paracentesis|
45691921|NCT02996032|Other|Vascular and Pulmonary Ultrasound|
45691922|NCT02995954|Drug|Perindopril/Amlodipine|Single table containing Perindopril/Amlodipine
45691923|NCT01799941|Drug|Nuedexta (DM 20 mg/Q 10 mg)|Single Arm, Open-Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
45691924|NCT00702364|Drug|atomoxetine|
45691925|NCT00702364|Drug|placebo|
46052691|NCT00763321|Drug|Placebo|Placebo tablet
46052692|NCT02799927|Procedure|Indirect Pulp Treatment with Bioactive Dentin Substitute|The indirect pulp treatment (IPT), with Biodentine is a vital pulp procedure for dep cariously primary teeth without carious exposure, involving the removal of the softened, humid and infected dentin layer, leaving intact intentionally the deepest layer of the dentin-pulp complex, followed by the placement of Biodentine and a hermetic restoration to provide a seal against microleakage, without the necessity to reenter for removing the residual caries.
45691926|NCT00667186|Other|Targeted Screening|Selection method for screening is based on risk
45691927|NCT00667186|Other|Routine Screening|Selection method for screening is not based on risk
45691928|NCT01799239|Device|Test product|The test product consists of an adhesive with a new top film
45369450|NCT05299424|Drug|CM336_group 6a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 10.0mg on C1D8, 40.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
45369451|NCT05299424|Drug|CM336_group 6b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 3.0mg on C1D8, 3.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
45369452|NCT05299424|Drug|CM336_group 7|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 60.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
45369453|NCT05299424|Drug|CM336_group 8a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 75.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
45369454|NCT05299424|Drug|CM336_group 8b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 4.0mg on C1D8, 4.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
45369455|NCT05299424|Drug|CM336_group 9|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 20.0mg on C1D8, 90.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
45369456|NCT05299424|Drug|CM336_RP2D|CM336 will be administered subcutaneously (SC) once a week (QW). Individual subjects may continue study treatment until disease progression/relapse, unacceptable toxicity, withdrawal of consent, receipt of other anti-MM therapies, death, loss to follow-up, or the end of study.
45369457|NCT04277858|Drug|Docetaxel|Subjects will be treated with neoadjuvant docetaxel and cisplatin for 3 cycles. This is followed by transoral robotic surgery (TORS) and neck dissection as definitive treatment, reserving radiotherapy for salvage.
45369458|NCT04186208|Drug|NOVOCART 3D|Autologous Chondrocyte Implantation
45369459|NCT03996824|Other|Peroperative collect of inner ear cells|"After obtaining an informed consent during the preoperative medical visit, and if a non-conservative approach (translabyrinthine or transotic) is decided, the collect of inner ear cells will be performed during surgical approach.~The sample will be collect in a sterile tube, and carried to the laboratory were it will be placed bon cell culture."
45369460|NCT03969914|Procedure|PEEP changes|All patients will be ventilated with a tidal volume of 6 ml/kg before the RRI assessment. Further, three level of PEEP (5, 10 and 15 cmH2O) will be randomly set. For each levels of PEEP, the RRI will be evaluated
45369461|NCT03961724|Device|magnetic resonance image (MRI)|serum metabolomics
45369462|NCT00957866|Drug|Pegylated Interferons (Peg-IFN) and Ribavirin|A anti-viral regimen with a combination of pegylated Interferons (Peg-IFN) and Ribavirin
45369463|NCT00117325|Drug|GW685698X|Aqueous Nasal Spray 100mcg
45369464|NCT00958022|Drug|LBH589 and carboplatin with etoposide|"LBH589 will be given in oral formulation starting at a dose of 10 mg (Dose Level 1) 3x/week (2 days apart, e.g. Mon, Wed, Fri), during 2 weeks out of 3-weekly dosing schedule. After establishing the MTD at a 2 out 3 weeks dosing schedule, a 3 out of 3 weeks dosing schedule will be tested at that dose. This schedule will be adopted in the absence of limiting toxicities. Will be continued weekly after completion of 6 cycles of combo chemotherapy until progression or intolerable toxicities.~Etoposide: Cycles 1-6: 100 mg/m² IV over 60 mins, Days 1-3 every 21 days for 6 cycles Carboplatin: commercially available as a sterile lyophilized powder available in single dose vials containing 50mg, 150mg, or 450mg of carboplatin. Each vial contains equal parts by weight of carboplatin & mannitol. Commercial supplies will be used for this study. It will be administered as an i.v. infusion over 30 minutes. The dose will be calculated based on patient's body weight at each treatment visit."
45369465|NCT00958100|Drug|tenofovir emtricitabine raltegravir|switch from current antiretroviral regimen to raltegravir with tenofovir/emtricitabine as backbone
45369466|NCT00958100|Drug|Lamivudine Abacavir Raltegravir|Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
45488040|NCT05760768|Behavioral|Individualized exercise guidance|Participants accept individualized exercise guidance. They are also managed continuously through WeChat group chat during prenatal clinical interval.
45488041|NCT03710863|Drug|CM082|Subjects will receive CM082 orally twice daily for two weeks followed by two weeks off in four-week cycles. The starting dose of 25mg BID will be increased by 100% to the maximum dose of 50mg BID.The treatment period is tentatively set at 1 year.
45488042|NCT02930889|Device|Prostate Artery Embolization|Prostate Artery Embolization
45488043|NCT02423668|Procedure|50% Partial adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 50% partial adjustment of the PE1.
45488044|NCT02423668|Procedure|No adjustment|IOL power selection for the second eye irrespective of first eye prediction error
45488045|NCT02423668|Procedure|Full adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 100% partial adjustment of the PE1.
45691929|NCT01799239|Device|SenSura|SenSura is the CE-marked and commercially available comparator product
45691930|NCT02995798|Other|Cortical Bone thickness and Hounsfield unit (HU) numbers|Cortical Bone thickness and Hounsfield unit (HU) numbers considering BMD
45691931|NCT02649868|Procedure|TAE|Transarterial embolization
45488046|NCT04604496|Drug|PF-06882961 20MG|PF-06882961 in 20 mg oral tablet will be administered on Day 1
45488047|NCT03178084|Drug|Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
45488048|NCT03178084|Drug|Efavirenz QD + Zidovudine/Lamivudine BID|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
45488049|NCT03178084|Drug|Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
45488050|NCT02875977|Other|Educational video|A 4-minute educational video describing PFPT
45488051|NCT02875977|Other|Educational handout|A 2-page educational handout describing PFPT
45488052|NCT02419222|Behavioral|Prism Adaptation|PAT uses wedged prism lenses to displace the entire visual field horizontally to the left or right (depending on the orientation of the base of the prism). The left-base prism lenses (thicker on the left) shift the entire visual field to the right. The result is a curving reaching trajectory, aiming toward the image location (right to the actual location) and then corrected toward the actual location. After several reaching movement, the coordinates of motor and visual systems are aligned, which in other words, is that the motor output adapts to the visual input, and thus the reaching trajectory is straight ahead to the object. This visually-guided goal-oriented movement is essential in PAT.
45488053|NCT05122572|Biological|Oncolytic Virus Injection (RT-01）|Intravenous injection of RT-01 with or without Nivolumab
45488054|NCT03183934|Biological|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Dystrophic Epidermolysis Bullosa.~This study is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
45488055|NCT03633006|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment.
45488056|NCT03633006|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment if lung cancer has not been confirmed.
45488057|NCT03633006|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
45488058|NCT01356381|Drug|Vildagliptin|Dosage 50mg b.i.d.
46052693|NCT02799927|Procedure|Indirect Pulp treatment with Calcium hydroxide|The indirect pulp treatment (IPT), with Biodentine is a vital pulp procedure for dep cariously primary teeth without carious exposure, involving the removal of the softened, humid and infected dentin layer, leaving intact intentionally the deepest layer of the dentin-pulp complex, followed by the placement of Ultra-Blend plus, and a hermetic restoration to provide a seal against microleakage, without the necessity to reenter for removing the residual caries.
46052694|NCT02800005|Device|AFA group (successive patients)|The abdominal fat area at the umbilical level was measured using a CT scanner(sango Mount Monitor Wireless Panel; Siemens , Munich, Germany) while the examinee was in a supine position and estimated using a Volume software (fat Pointer; Siemens , Munich, Germany). The imaging conditions were 120 kilovolt and 50 milliampere, using a 5-mm-thick slice.The areas covered by visceral fat software calculated from pixels with densities ranging from-190 to -30 hounsfield unit . No contrast agent is needed.
46052695|NCT02800005|Other|BMI group (successive patients)|The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese.
46052696|NCT02804139|Other|Standard care plus physical therapy|Subjects attend 1 to 2 physical therapy sessions per week for 6 weeks beginning 8-10 weeks post-C section. The physical therapy program includes scar management, core retraining, and lumbar and pelvic joint mobilization.
45369467|NCT00958100|Drug|Abacavir free|Patients will receive raltegravir with tenofovir/emtricitabine; data will be added to those of Tenofovir Emtricitabine Raltegravir arm in a separate longitudinal analysis comparing data at baseline and at 48 weeks. In this separate analysis, data will not be compared to those obtained from the Lamivudine Abacavir Raltegravir arm. The number of patients in this arm is not pre-established.
45369468|NCT00948584|Other|Insulin dose titration system using a SMS|We applied 'Insulin dose titration system in diabetic patients using a short messaging service automatically produced by a knowledge matrix' for 12 weeks in the intervention group. In the control group, a conventional insulin titration schedule was used. The insulin used in this study was Lantus (insulin glargine).
45369469|NCT00958178|Drug|Oxygen|Experimental: Low flow Oxygen for 30 seconds then high flow for 3.5 minutes. Active comparator: High flow Oxygen for 4 minutes.
45369470|NCT00948662|Drug|SAM-760|SAM-760 capsule, 0.25, 0.75, 2.25, 5, 10, 15, 20, 25, 35 and 45mg, single dose, 1 day
45488059|NCT01356381|Drug|Placebo|50mg bid
45488060|NCT03117166|Drug|lidocaine|A one time bolus of lidocaine 0.5 mg/kg iv will be administered just prior to IV propofol injection,then successful defibrillation will be ascertained
45691932|NCT02649868|Radiation|RFA|Thermal ablation
45691933|NCT02649868|Device|LC Bead LUMI|LC Bead LUMI has been designed as a radiopaque version of the LC Bead
46052697|NCT02804139|Other|Standard Care|Standard Care after C-section with no additional physical therapy.
45691934|NCT00713284|Drug|sirolimus|Oral tablet(s) taken daily for 6 months; dose will be based on serum trough levels.
45488061|NCT03117166|Drug|Placebo|A control group will get an IV bolus of 0.9% NS just prior to IV bolus of propofol, then successful defibrillation will be ascertained
45488062|NCT01356459|Device|Mepilex Border Dressing|Soft silicone self adherent dressing
45488063|NCT05189613|Biological|Mepolizumab|Subcutaneous Mepolizumab (100 mcg) injection in patients with severe eosinophilic asthma
46052698|NCT02806089|Device|Handheld dynamometer|Evaluation of muscle strength
46052699|NCT02806089|Biological|Creatinine index|Evaluation of muscle mass using plasma creatinine level
46052700|NCT02806089|Device|Electrical bioimpedance analysis|Evaluation of lean body mass
46052701|NCT02806089|Other|"Voorrips score questionnaire"|Evaluation of physical activity
45369471|NCT00948662|Drug|Placebo of SAM-760|SAM-760 matching placebo capsule, single dose, 1 day,
46052702|NCT02806089|Biological|Inflammatory and nutritional status|Evaluation of C reactive protein and albumin
46052703|NCT04099017|Other|Mulligan Joint mobilization|"This study ARM will received Mulligan joint mobilization and concomitant therapies in this group.~The following are the brief detail of therapy~Mulligan joint mobilization in Non-weight bearing (NWB) to weight-bearing (WB) 6 -10 Reps and 3 sets/ session.~Procedural detail:~Joint mobilization will be performed in sagittal, frontal and transverse direction, following glide will be preferred will depend on patient adherence to the joint mobilization. Mobilization will be progress from NWB to WB according to patient compliance 27~Knee strengthening Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~Kinesiotaping:"
45369472|NCT00948662|Drug|ketoconazole|Ketoconazole oral tablets, 200 mg bid, 14 days
45369473|NCT03748472|Procedure|Continuous gavage feeding|Each subject will serve as his or her own control. In this arm infants will receive their feed over 2 hours and the next feed will be given over 30 min and then over 2 hours again.
45369474|NCT03748472|Procedure|Bolus feeding|Each subject will serve as his or her own control. In this arm infants will receive their feed over 30 min and the next feed will be given over 2 hours and then over 30 minutes again.
45369475|NCT03747458|Drug|OPN-375|OPN-375, BID
45488064|NCT03183700|Device|Self sampling device|The investigators will allocate randomly the women to two different self sampling devices differing in having or not a preservative buffer
45488065|NCT03183700|Other|Cervical ThinPrep sampling|Women are inviated with a standard invitation letter to perform cervical ThinPrep sampling at the clinic on a pre-fixed date
45488066|NCT03632928|Other|Ultrasound Elastography|Measuring muscle hardness at the trapezius and neck bilateral
45488067|NCT03632928|Other|Pressure Pain threshold|Measuring Pressure pain threshold at the trapezius and neck bilateral
45488068|NCT01358487|Behavioral|Online self-help course plus live follow-up if needed|In addition to the self-help mood management course and the email reminders to return to the site to complete assessments at 1, 3, and 6 months (and the monetary incentives), this condition will also receive phone reminders if they do not complete assessments online.
45488069|NCT01358487|Behavioral|Online + incentives Follow-up Group|This group tests online email reminders and monetary online incentives to estimate percentage of participants who will complete online assessments at 1, 3, and 6 month follow-ups.
45488070|NCT03302286|Diagnostic Test|Heart-lung machine primining solution which includes Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
45691935|NCT00702754|Biological|Botulinum Toxin Type B|Eligible patients could receive injections of MYOBLOC once every 12 weeks. Total Dose could range from 5,000 Units up to 25,000 Units.
45369476|NCT04010084|Radiation|Low level laser therapy|"The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive irradiation with a DMC-branded laser EC device, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested."
45369477|NCT04010084|Procedure|Placebo group|"The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive placebo (with switched-off) irradiation of the DMC-brand laser therapy EC model, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested."
45488071|NCT03302286|Diagnostic Test|Heart-lung machine primining solution which does not include Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
45488072|NCT02419300|Device|ultrasoungraphy|pelvic ultrasonography and Doppler
45488073|NCT02419144|Behavioral|AMI and campaigns|The intervention we are proposing is a tailored bi-level intervention with two components, an individual level component (component A) with tailored messages based on performance on clinical assessment results, ADLs and cognitive domains in the survey delivered through adapted motivational interviewing with practice to mastery (AMI-PM); , and a building level campaign (component B) for those enrolled in the study (but open to all building residents that includes building tailored messages based on cognitive domains and skills reinforcement through Practice to Mastery.
45488074|NCT01356615|Drug|low molecular weight heparin (enoxaparin sodium)|Enoxaparin sodium (Clexane; 40 mg) was administered 3-4 min before dialysis as a bolus dose, into the arterial line pre-dialyzer.
45488075|NCT01356615|Drug|standard unfractionated heparin|Heparin (sodium heparin 5000 IU/ml) was administered as a bolus dose (50 IU/kg body weight) intravenously into the pre-dialyzer arterial line of the extracorporeal blood circuit, followed by a maintenance dose of 1000 IU sodium heparin per hour.
45488076|NCT03117322|Biological|agave inulin|Duration: four weeks Dosage: powder 4 g/d
45488077|NCT03117322|Biological|Lactobacillus reuteri DSM 17938|Duration: four weeks Dosage: 5 drops/d
45488078|NCT03117322|Other|maltodextrin|Duration: four weeks Dosage: powder 4 g/d
45488079|NCT03117322|Other|Oil mix (medium chain triglycerides and sunflower oil)|Duration: four weeks Dosage: 5 drops/d
45488080|NCT01358565|Drug|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
45488081|NCT01358565|Drug|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
45691936|NCT02995720|Drug|Fimasartan/Amlodipine combination drug, Rosuvastatin|
45691937|NCT02990728|Drug|Metformin|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
45691938|NCT02990728|Device|Mirena®|
45488082|NCT03620175|Drug|TolaSure Topical Gel|TolaSure topical gel is applied to skin punch biopsies daily over the course of 2 weeks.
45488083|NCT03180190|Drug|Hydroxychloroquine Oral Tablet|"slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT)"
45488084|NCT01356693|Drug|Bromelin|Ananas comosus extract (3,3g) on vehicle: methylparaben, propylparaben, honey from Apis mellifera, sodium benzoate, ethilic alcohol, water) 5ml. Given in single dose.
45691939|NCT02995486|Other|Exercise|Otago Exercise Program for falls prevention after discharge due to fall-related injuries.
45691940|NCT02995564|Behavioral|social skills therapy|Sixteen week manual based social skills curriculum targeting social fluency and responsiveness.
45691941|NCT04387006|Other|OMT|OMT techniques were focused on correcting the dysfunctions found during the initial physical examination and included articular and myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field
45488085|NCT01356693|Drug|Placebo|Placebo with mimicking characteristics of experimental drug
45488086|NCT03183856|Device|Morning walk|a end-effector typed gait robot with a saddle
45847991|NCT03164538|Behavioral|Positive Psychology + Motivational Interviewing|Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instructions and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 16 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered stepwise within sessions (rather than intertwined).
45369478|NCT03571022|Behavioral|USE-MI System|"Pilot Phase: 10 subjects will continue with their ART or PrEP medication and begin using the USE-MI system. Subjects will wear a smartwatch every day to monitor their pill taking activity for 1 month and receive weekly phone calls to obtain feedback on the system. During the first call, subjects will respond to 2 questionnaires about how they are taking their daily ART or PrEP pill(s).~Second Phase: Up to 50 subjects will continue with their ART or PrEP medication and begin using the USE-MI system. Subjects will wear a smartwatch every day to monitor their pill taking activity for up to 6 months. During their first month, subjects will receive weekly phone calls to obtain feedback on the system. During the first call, subjects will respond to 2 questionnaires about how they are taking their daily ART or PrEP pill(s). Subjects will then have monthly follow-up visits to complete a brief questionnaire about how they are taking their daily ART or PrEP pill(s)."
45488087|NCT03183856|Other|no Morning walk|ambulation voluntary or with a help of walker
45488088|NCT03179878|Drug|Placebo|Placebo
45691942|NCT04387006|Other|MP|MP treatment was performed by the same osteopaths who performed OMT and was carried out in the same hospital setting. P treatment consisted of a passive touch without joint mobilization in a protocolled order. The osteopaths were standing next to the bed, they touched lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they touched for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest were touched for 5 minutes each. Another researcher on the placebo protocol specifically trained the osteopaths.
45691943|NCT04386772|Procedure|PVE with coils plus TAGM|PVE with TAGM distally and coils proximally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on future liver remnant (FLR) side for patients with pCCA when obstructive jaundice is present.
45691944|NCT04386772|Procedure|PVE with multiple coils|Procedure: PVE with multiple coils PVE with multiple coils proximally and distally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on FLR side for patients with pCCA when obstructive jaundice is present.
45691945|NCT02995330|Procedure|Bone marrow transplantation|Infused with non-T-cell depleted bone marrow from a related female donor on Day 0
45691946|NCT02995330|Drug|Cytoxan|Cytoxan 50mg/kg IV on Days +3 and +4
45488089|NCT03179878|Drug|SYNB1020|Investigational Product
45488090|NCT01362387|Other|Alternative follow-up protocol|Women (n=1000) will be allocated by chance to one of two groups: alternative follow-up using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test, or standard follow-up which consists of an in person visit with an ultrasound or a telephone call and high sensitivity pregnancy test.
45488091|NCT04583592|Drug|Camostat Mesilate|Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
45488092|NCT04583592|Drug|Placebo|Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.
45691947|NCT02995330|Drug|testosterone cypionate|testosterone cypionate 400 mg IM will be administered on Day +60, +90, and +120 (every 30 days x 3 doses)
45691948|NCT02990884|Drug|ketamine|
45488093|NCT01358643|Other|Three home-based diet and exercise programs|"All research activities are outpatient. This pilot study will be a crossover study of two 6-week programs. The participant will be involved for 15 weeks.~Thirty OEF/OIF veterans with BMI > 30 will be recruited to test the diet and exercise programs. Each veteran will test only two of the three programs described above. The participants will use the the programs for six weeks then crossover and use a second program."
45488094|NCT03179722|Behavioral|Medication review|The intervention consists of a medicines use review provided by community pharmacists in Belgium. A medicines use review is a medication review type 2a in which both a patient interview and dispensing data are used as information sources to identify drug-related problems with a specific focus on the medicines use of the patient.
45488095|NCT03179722|Behavioral|Additional data collection: questionnaires|"Pre-post study design.~At three timepoints, data is collected:~before the medication review (T-1week)~during the review (Tweek 3)~after the review (Tweek12) The questionnaire provide data for the outcomes: medication related quality of life, adherence questionnaire, service satisfaction, use of emergency health services, self-management"
45488096|NCT01362465|Procedure|Cardiac Resynchronization Therapy|Implanting device to measure delays between paced chambers in heart failure patients.
45488097|NCT03117088|Other|Checklist ISBAR3|"Checklist ISBAR 3~Use of an online based checklist for handovers with the following items:~Identification Situation Background Assessment Recommendation Read- back Risk~Established Checklist as communication tool"
45488098|NCT03117088|Other|Checklist VICUR|"Checklist Vicur~Use of an online based alternative checklist for handovers with the following items:~Vaccination status Insurance status Contact person Utilisation Rehabilitation Organ donor? Patient decree?~alternative checklist missing communication tool"
45488099|NCT01362543|Other|Cognitive behavioural therapy (stress management)|Following a manual
45488100|NCT01362543|Other|Cognitive Behavioural Therapy (cognitive restructuring)|Following a manual
45488101|NCT02418988|Drug|TACE plus rAd-p53 artery injection|Trans-catheter chemo-embolization (TACE) with rAd-p53 injection will be given every 21 days
45488102|NCT02418988|Drug|TACE|Trans-catheter chemo-embolization (TACE) without rAd-p53 injection will be given every 21 days
45488103|NCT04579146|Other|coronary computed tomographic angiographic (CCTA)|x-ray examination with contrast by a 64-slice CT coronary angiography.
45691949|NCT02990650|Behavioral|Balance Task Training with therapist guarding support|"Nine balance tasks:~long forward step~forward reach~push forward~push backward~step over hurdle~step up on foam surface~step up on solid surface~sit-to-stand~step onto slippery surface The therapist will provide guarding support"
45846516|NCT02056236|Drug|Anti-epileptic drugs|"Recommendations for the treatment of status epilepticus are based on recent international guidelines for treatment of overt status epilepticus.~The objective of treatment with AED is to suppress all epileptiform activity. There is no clear proof that induction of a burst-suppression pattern is of additional value and induction of burst suppression is therefore not obligate. If the electroencephalographic status epilepticus returns after tapering sedative treatment at 24 hours, the procedure will be repeated. If the status returns after 2 x 24 hours, it will be considered refractory.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
45691950|NCT02990650|Behavioral|Balance task training with robotic guarding support|"Nine balance tasks:~long forward step~forward reach~push forward~push backward~step over hurdle~step up on foam surface~step up on solid surface~sit-to-stand~step onto slippery surface The guarding support will be provided by a robot"
45369479|NCT05300126|Behavioral|Hypnosis|Four sessions of 15 minute hypnosis, based on standardised script, focused on symptom management for the patients and of resource development for relatives.
45369480|NCT00948740|Drug|vitamin D (ergocalciferol)|The intervention is oral ergocalciferol 50,000 IU per week for 8 weeks
45369481|NCT00108433|Drug|Cefazolin IV|
45369482|NCT00108433|Drug|Linezolid IV|
45369483|NCT00108433|Drug|Vancomycin (IV)|
45369484|NCT00949052|Genetic|DNA analysis|
45369485|NCT00949052|Genetic|polymorphism analysis|
45369486|NCT00949052|Other|laboratory biomarker analysis|
45369487|NCT00949052|Other|medical chart review|
45369488|NCT00949052|Other|questionnaire administration|
45369489|NCT00949052|Procedure|assessment of therapy complications|
45369490|NCT00949052|Procedure|evaluation of cancer risk factors|
45369491|NCT01084369|Drug|Testosterone|"NEBIDO ampoules containing a solution for injection of 1000mg/4ml of testosterone undecanoate. NEBIDO injection 1000mg/4ml will be given at baseline, 6 weeks, 18 weeks, 30 weeks, 42 and 54 weeks. Levitra will be given to those patients with erectile dysfunction for 2 weeks in addition to Nebido.~Concomitant medication deemed necessary by the investigator as part of the routine clinical management will be permissable."
45369492|NCT05352308|Behavioral|Common Sense Model Guided Narrative Video|The narrative video will address illness risk representations and information on HPV, the HPV vaccine, and HPV-related cancers
45369493|NCT03416738|Behavioral|Semantically focused treatment|"Tasks are as follows:~Semantic feature analysis (SFA): For each pictured stimulus the patient is prompted to name the picture, and then to produce related words that represent features similar to the target word.~Semantic barrier task: The goal is for one participant (e.g., patient) to describe each card so that the other participant (e.g., clinician) can guess the picture on the card. Participants are only allowed to describe the semantic features of the target and the clinician models the kinds of cues that are allowed.~Verb network strengthening treatment (VNeST): This treatment targets lexical retrieval of verbs and their thematic nouns. The objective of VNeST is for the patient to generate verb-noun associates with the purpose of strengthening the connections between the verb and its uses.~These are tasks used in clinical aphasia rehabilitation."
45369494|NCT03416738|Behavioral|Phonologically focused treatment|"Tasks are as follows:~Phonological (sound) components analysis task: Participants are to name a given picture and then to identify the sound features of the target words (e.g., first sound, last sound, and rhyme).~Phonological production task: This tasks asks participants to sort and identify the sounds that make up a word. Various stages include identifying first sounds, last sounds, etc. Participants also work on blending sounds together to form words.~The phonological judgment task: A computerized presentation of verbs and nouns where participants are required to judge whether pairs of words include similar phonological features.~These are tasks used in clinical aphasia rehabilitation."
45369495|NCT04010006|Procedure|4K Laparoscopic Surgery|4K Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
45369496|NCT04010006|Procedure|HD Laparoscopic Surgery|HD Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
45369497|NCT04010162|Other|Mesh debate awareness survey|"A web-based questionnaire with questions about recent discussions of mesh in urogynecology.~10 questions. Average survey completion time: 1 minute"
45369498|NCT03084224|Genetic|neurological and neurodegenerative diseases|NGS on a large scale of Patients with complexes phenotypes
45369499|NCT02994446|Device|Saline-Enhanced Radiofrequency Catheter and Ablation System|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
45369500|NCT00116779|Drug|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Maintenance dose given in twelve 28-day cycles.
45369501|NCT00949130|Drug|NXL103|BID for 7-14 days
45691951|NCT02990650|Behavioral|Challneged balance task training with robotic guarding support|"Nine balance tasks where the subject is challenged to perform at a harder level of difficulty:~long forward step~forward reach~push forward~push backward~step over hurdle~step up on foam surface~step up on solid surface~sit-to-stand~step onto slippery surface The guarding support will be provided by a robot"
45691952|NCT02995018|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z09-174)
45691953|NCT02995018|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
45691954|NCT02992990|Procedure|Bladder tumor biopsy|Bladder tumor biopsy performed at the time of the preoperative office flexible cystoscopic evaluation.
45691955|NCT02997592|Device|SpinCare|The burn wound is treated using the SpinCare Systen
45691956|NCT02990494|Behavioral|STANDARD|Standard Internet-delivered behavioral weight loss
45691957|NCT02990494|Behavioral|PREVENT|enhanced standard Internet-delivered behavioral weight loss program
45691958|NCT02990494|Behavioral|PROMOTE|enhanced standard Internet-delivered behavioral weight loss program
45369502|NCT00949130|Drug|Linezolid|BID for 7-14 days
45369503|NCT02815592|Drug|BMS-986012|
45691959|NCT02990416|Biological|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
45691960|NCT02990416|Biological|Pembrolizumab|A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
45846517|NCT02056236|Other|No anti-epileptic drugs|"The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
45846518|NCT01962246|Drug|Oxaliplatin; Capecitabine|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for eight cycles postoperation
45369504|NCT02815592|Drug|Cisplatin|
45369505|NCT02815592|Drug|Etoposide|
45369506|NCT02815592|Drug|Platinum|
45369507|NCT02815592|Drug|Carboplatin|
45369508|NCT03943290|Drug|ACE-083|Recombinant fusion protein
45369509|NCT04010318|Procedure|Spinal Anesthesia|The patients will receive spinal block at lumbar 3-4 space with hyperbaric bupivacaine 8 mg plus 25 mic fentanyl. After giving anesthesia and positioning for surgery with a left lateral tilt of 15 degrees, supplemental oxygen at rate of 4 liter/minute is applied.
45369510|NCT00108355|Drug|Albumin|Intravenous Albumin at a dose of 8g/liter of ascitic fluid removed
45369511|NCT00108355|Drug|Intravenous Saline Infusion (Albumin placebo)|Intravenous saline Infusion (Albumin placebo)
45369512|NCT00108355|Drug|Midodrine|Midodrine oral tablet at 10 mg three times a day.
45691961|NCT02990416|Radiation|Ionizing Radiation|Electromagnetic or corpuscular radiation capable of producing ions, directly or indirectly, in its passage through matter.
45369513|NCT00108355|Drug|Oral tablet (Midodrine placebo)|Oral tablet (Midodrine placebo) three times a day
45369514|NCT00108355|Drug|Octreotide LAR|Octreotide LAR 20 mg intramuscular injection every 30 days
45369515|NCT00108355|Drug|Saline injection (Octreotide LAR placebo)|Saline intramuscular injection 5 cc every 30 days.
45369516|NCT00108355|Procedure|Large Volume Paracentesis|Procedure to remove large amounts (more than 5 liter) of ascitic fluid via a catheter.
45369517|NCT05351996|Device|Kinesiotape|The participants received kinesiotape application three times with one-week intervals. Y strip tape was used. The interventionist applied the band to the rectus femoris muscle with facilitation technique.
45369518|NCT05351996|Device|Sham-kinesiotape|"The participants received sham-kinesiotape application three times with one-week intervals.~In the sham group, the interventionist adhered KT to the rectus femoris transversely, without stretching."
45691962|NCT02994862|Other|Galla Chinnesis|new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta
45691963|NCT02994862|Other|Conventional Bonding|Normal Bonding Protocol
45691964|NCT02990260|Dietary Supplement|Saccharomyces cerevisiae|Live Saccharomyces cerevisiae
45691965|NCT02990260|Dietary Supplement|Lynside Wall Basic|yeast cell walls
45691966|NCT02990260|Dietary Supplement|Placebo|Maize starch and magnesium stearate
45691967|NCT02994706|Procedure|Home Monitoring|Participants selected to receive home monitoring, in addition to routine CF care, will be given a digital lung function monitor (spirometer) and a modified mobile phone.
45846519|NCT01962246|Other|Oxaliplatin; Capecitabine; concurrent radiotherapy|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for two cycles preoperation , Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation Radiation: radiotherapy 50 Gy in 25 fractions (2Gy /day, 5 days/week,Monday through Friday, ) Other Name: XRT
45846520|NCT02588586|Drug|3BNC117|3BNC117 infusions
45846521|NCT02588586|Other|Antiretroviral Treatment Interruption|Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.
45369519|NCT05351996|Other|Home-based exercise program|Participants were taught exercise program training. The exercise intervention was based on quadriceps and knee flexor muscle group strengthening, and knee joint range of motion exercises, in their home.
45846522|NCT02588976|Device|Sonoclot Analyzer|Blood coagulation test during cardiac surgery: Measurement of activated clotting time during cardiac surgery by Sonoclot Analyzer
45846523|NCT02592486|Biological|Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine and influenza vaccine simultaneously.
45369520|NCT02755220|Device|Cingularbio® Aortic valve replacement|the patients will be replaced by Cingularbio heart valve
45369521|NCT00963222|Drug|vitamin A|1 cap vitamin A 25000 IU/day for 3 month
45369522|NCT00963222|Drug|placebo|1 cap placebo/day for 3 month
45369523|NCT00963300|Procedure|blood-oxygen-level-dependent functional magnetic resonance imaging|
45691968|NCT02994706|Other|Clinical Care|Participants selected for this arm will continue to receive routine clinical care.
45369524|NCT00963300|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
45369525|NCT00963300|Procedure|magnetic resonance spectroscopic imaging|
45369526|NCT00963300|Procedure|tissue-oxygen-level-dependent functional magnetic resonance imaging|
45369527|NCT05297474|Other|MRI|No intervention was performed in this study.
45369528|NCT00968604|Genetic|BikDD Nanoparticle|Starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
45369529|NCT02703584|Drug|Buseralin|
45369530|NCT02703584|Other|Placebo|
45369531|NCT02703584|Drug|pregnyl|
45369532|NCT00968682|Biological|trastuzumab|
45369533|NCT00968682|Other|laboratory biomarker analysis|
45369534|NCT00968682|Procedure|assessment of therapy complications|
45369535|NCT04010292|Behavioral|Patient education card|Patient who are randomized to receive a patient card at the end of the counseling visit will be able to take an index-card sized card with them which will highlight their anticipated surgery.
45369536|NCT02575976|Behavioral|comprehensive CR|In the comprehensive CR arm, 24 sessions education will be offered, of 30 minutes duration beyond the exercises already performed in the cardiac rehabilitation program (The main program is 6 months in duration, with 36 1-hour exercise sessions)
45369537|NCT02575976|Other|exercise-based CR|The main program is 6 months in duration, with 36 1-hour exercise sessions.
45369538|NCT02575976|Other|wait list control|No cardiac rehabilitation.
45369539|NCT00968760|Procedure|Leukapheresis|"Leukapheresis #1 - For Collecting T Cells~Leukapheresis #2 - For Collecting Stem Cells, month following #1~Blood drawn through vein, passed through a machine to collect specific blood cells, then remaining blood returned, about 3 hours to complete."
45369540|NCT00968760|Procedure|Stem Cell Transplant|Stem cell infusion by vein over 30-45 minutes on Day 0
45369541|NCT00968760|Procedure|CD19-specific T Cell Infusion|T Cell Infusion (Gene Transfer) by vein over 15-30 minutes sometime between Day +2 through Day +7.
45369542|NCT00968760|Drug|IL-2|Group 2 or 4, IL-2 dose of 0.3 x 10^6 U/m^2 injected under skin, once a day for up to 14 days; first dose on day of T cell infusion.
45369543|NCT00968760|Drug|Carmustine|300 mg/m^2 IV over 1 hour on Day -6
45369544|NCT00968760|Drug|Etoposide|200 mg/m^2 IV over 3 hours every 12 hours on Days -5 to -2
45369545|NCT00968760|Drug|Cytarabine|200 mg/m^2 by vein over 1 hour every 12 hours on Days -5 to -2.
45369546|NCT00968760|Drug|Melphalan|140 mg/m^2 IV over 30 minutes on Day -1
45369547|NCT04009980|Other|OMK2 group|topical administration of OMk2 ophthalmic solution for 36 months three times/day
45369548|NCT04009980|Other|Placebo group|topical administration of ophthalmic placebo solution for 36 months three times/day
45691969|NCT02999776|Device|Laser microporation alone|The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
45691970|NCT02999776|Drug|Standard of care-daily administration of Daivobet|The other control treatment is Daivobet®, which is applied topically daily for 8 weeks on one pre-selected randomized plaque.
45691971|NCT02999776|Drug|Laser microporation + topical application of Etanercept|Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
45691972|NCT02999698|Other|Observational|Observational
45488104|NCT01356771|Other|Surveys & Mailed Materials|"Phase I: Patients are screened for their level of risk for skin cancer. They will complete a survey and undergo a skin exam administered by the research staff. Moderate- and high-risk persons will be invited to enroll in Phase II.~Phase II: Three sets of materials will be sent in the mail over the course of 6 weeks. Pamphlets will contain information about ways to reduce participant's risk of skin cancer, including sun protection practices, benefits of skin screening practices, and how to do skin self-examinations.~The participant will also complete two surveys for this study, one at baseline and then one at follow up approximately three months later.~Each survey will ask the participant about:~Current and past skin cancer screening practices~Current and past sun protection practices~Attitudes about skin cancer and sun protection~Knowledge of melanoma"
45488105|NCT01358799|Device|APTIMA Assay for Chlamydia trachomatis|APTIMA Assay for Chlamydia trachomatis
45369549|NCT02465138|Drug|Ketorolac|Intravenous ketorolac
45488106|NCT05189301|Diagnostic Test|first pass study|Radionuclide assessment of ventricular performance was performed (Symbia T2, Germany)
45488107|NCT05189301|Diagnostic Test|cardiopulmonary exercise testing|to measured (mL/min, STPD), CO2 output ( ) (mL/min), and minute ventilation ( ) (L/min, BTPS) breath by-breath (MasterScreen CPX™, Germany)
45488108|NCT05005182|Drug|Hydroxyurea|Given PO
45488109|NCT05005182|Biological|Luspatercept|Given SC
45488110|NCT01356927|Drug|DMPA|DMPA 150 mg IM given on the day of mifepristone 200 mg po for medical abortion
45488111|NCT01356927|Drug|Etonogestrel implant|Etonogestrel implant placed at the time of mifepristone 200 mg po for medical abortion
45691973|NCT02990026|Behavioral|Specialty Mental Health Probation|Specialty mental health probation includes the following components: (1) exclusively mentally ill caseload of probationers; (2) reduced caseload of 40-45 probationers; (3) problem-solving supervision orientation; (4) ongoing training and consultation; and (5) greater connection with local mental health services
45691974|NCT02996656|Drug|Cefazolin|Antibiotic that will be give before a Trauma or elective open shoulder surgery
45691975|NCT02996656|Drug|Ceftriaxone|Antibiotic that will be give before a Trauma or elective open shoulder surgery
45691976|NCT02996266|Device|Targeted Temperature Management|Prophylactic normothermia
45691977|NCT02996266|Other|Standard Care|No intervention to control temperature unless fever occurs
45753493|NCT04198688|Behavioral|Intensive Smoking Cessation Intervention|The intervention comprises 5-6 meetings during six weeks, and can be held in group or as an individual intervention. It is based on counselling and a clearly structured manual-based patient education programme taught by specially trained staff, and contains individual counselling on nicotine replacement therapy or other medical support, according to the level of dependence measured by the Fagerström test score. The first two weeks cover teaching sessions on: ambivalence and motivation, pros and cons of continuous smoking versus cessation, and a quit date is set between the 2. and 3. week. The last 3 sessions cover: risk situations, withdrawal symptoms and medical support for withdrawal symptoms, relapse prevention and how to handle a completely smoke-free life.
45846524|NCT02592486|Biological|Sequential administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine.
45846525|NCT02593032|Device|Pre-filled trays|Randomized Control Trial Patients in the research treatment group receive pre-filled, 3x7 disposable trays that separate their medication by dose and time (e.g. morning, afternoon, evening). These pre-filled trays are inserted into a connected, weekly pillbox that detects when pills are removed from its wells.
45846526|NCT05372016|Biological|Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|9vHPV vaccine ,0.5mL, three doses, 0,2,6 months
45369550|NCT02465138|Drug|Placebo|Intravenous saline
45369551|NCT00968916|Drug|ombrabulin (AVE8062)|"Pharmaceutical form: injection solution~Route of administration: intravenous infusion"
45369552|NCT05351528|Other|Questionnaire|Caregiver burden and healthy lifestyle behaviors were evaluated.
45369553|NCT00968994|Device|The exSALT™ SD7 Wound Dressing|The exSALT™ SD7 Wound Dressing is indicated for the management of partial and full thickness wounds, including decubitus ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, grafts and donor sites, or other acute or chronic wounds. The dressing may be used over debrided and grafted wounds.
45369554|NCT00968994|Device|Xeroform® Petrolatum Dressing|Sterile, single use, non-adherent dressing consisting of absorbent gauze impregnated with Xeroform in a petrolatum blend.
45369555|NCT00969072|Drug|GI198745 0.05mg|GI198745 (drug) - benign prostatic hyperplasia
45369556|NCT00969072|Drug|GI198745 0.5mg|GI198745 (drug) - benign prostatic hyperplasia
45369557|NCT00969072|Drug|GI198745 2.5mg|GI198745 (drug) - benign prostatic hyperplasia
45369558|NCT00094861|Drug|Palifermin|
45488112|NCT02703532|Behavioral|CARE-CITE Education Program|"CARE-CITE is an online educational program developed to provide information that may help caregivers understand more about constraint-induced movement therapy (CIMT) and their potential roles in helping the stoke survivor gain as much benefit as possible from CIMT.~If participants do not have access to a computer or tablet, they will be loaned an electronic tablet for the 2-3 week period of the study to access the information.~Participants will be asked to review six educational modules over a period of 2-3 weeks while the stroke survivor receives CIMT.~Participants will attend three in home evaluation visits; one at the beginning of the stroke survivors therapy sessions, one at the end of his/her therapy visit series, and a third evaluation one month later in which they will be asked to complete questionnaires. Evaluation visits will take approximately 1 ½ hours to complete."
45488113|NCT02703532|Behavioral|Traditional Education|Investigators will explain constraint-induced movement therapy (CIMT) to caregivers and stroke survivors during the first home therapy session for the stroke survivor and provide traditional educational information about CIMT during therapy sessions as needed.
45488114|NCT02703532|Behavioral|Constraint-Induced Movement Therapy (CIMT)|"Constraint-Induced Movement Therapy (CIMT) is one type of therapy that helps stroke survivors gain more use of their weaker arm.This therapy involves wearing a soft mitt (like a sock or oven mitt) on the stronger arm to remind the stroke survivor to use their weaker arm for daily activities and also intensive practice of tasks with the supervision of a therapist.~Participants will attend three in home evaluation visits; one at the beginning of your therapy sessions, one at the end of your therapy visit series and a third evaluation one month later. These evaluation sessions will involve an evaluation of arm function and answering three questionnaires about how well the weaker arm works and how the stroke has affected daily activities. The interview questions and assessment will take approximately 1 ½ hours to complete."
45488115|NCT03439670|Drug|Vamorolone|Oral administration of 2.0 mg/kg/day for the duration of the study.
45488116|NCT03439670|Drug|Prednisone|Oral administration of 0.75 mg/kg/day for 24 weeks.
45488117|NCT03439670|Other|Placebo|Oral administration of placebo daily for 24 weeks.
45488118|NCT03439670|Drug|Vamorolone|Oral administration of 6.0 mg/kg/day for the duration of the study.
45488119|NCT03439670|Drug|Prednisone|Oral administration of 0.75 mg/kg/day for 24 weeks.
45488120|NCT03439670|Other|Placebo|Oral administration of placebo daily for 24 weeks.
45488121|NCT03439670|Drug|Vamorolone|Oral administration of 2.0 mg/kg/day for 20 weeks.
45691978|NCT04270162|Device|Respiratory muscle training 1|"For inspirometer, the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. This maximum value will be taken as an indicative parameter of its maximum inspiratory capacity and 50 and 80% of that value will be determined so that the participant performs 1 set of 10 repetitions at 50% of their maximum value, 2 sets of 10 repetitions at 60% of its maximum capacity and ends with 1 series at 80% of its maximum capacity.~It is highlighted that in each series before finishing and without stopping to rest, the participant must do 5 repetitions at 100% maximum capacity.~In addition, the respiratory exercises that will be carried out by the 3 intervention groups."
45846527|NCT05372016|Biological|Active Comparator: GARDASIL ®9|GARDASIL®9 vaccine, 0.5mL, three doses, 0,2,6 months
45369559|NCT00094861|Drug|Placebo|
45369560|NCT00094861|Radiation|Radiotherapy|
45488122|NCT03439670|Drug|Vamorolone|Oral administration of 6.0 mg/kg/day for 20 weeks.
45488123|NCT01357005|Other|No intervention would be provided in this research|No intervention would be provided in this research, but need to draw blood
45488124|NCT02930343|Drug|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic diseases
45488125|NCT02930343|Drug|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
45488126|NCT02930343|Drug|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
45488127|NCT02930343|Drug|Prednisolone|Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop)
45846528|NCT05371938|Procedure|Volar locking plate|Volar locking plate is the intervention
45369561|NCT00094861|Drug|Paclitaxel|
45369562|NCT00094861|Drug|Carboplatin|
45369563|NCT00963534|Drug|lenalidomide, bendamustine, rituximab|"Phase I: Maximally tolerable dose of lenalidomide will be determined, starting with 5 mg per day, and up to maximally 25 mg per day. This treatment is given in combination with bendamustine and rituximab.~Phase II: Determination of progression free survival with treatment with lenalidomide (dosing determined in phase I) in combination with bendamustine and rituximab."
45369564|NCT00963534|Drug|lenalidomide, bendamustine, rituximab|lenalidomide: day 1-21, maximum 13 cycles bendamustine: days 1-2, cycle 1-6 rituximab: day1, cycle 1-6
45369565|NCT00963612|Procedure|BOLD MRI test|Additional MR pulse sequence performed on BOLD MRI is expected to increase the regular scan time by an additional 5-10 minutes. No intravenous contrast is required for BOLD acquisition.
45369566|NCT00963690|Device|CloSys Hemostatic Device (HD)|Deploy CloSys HD to achieve hemostasis
45846529|NCT05371938|Procedure|external fixation|surgery with external fixation
45846530|NCT05371860|Other|Omit breast radiation|Omit breast radiation for 3 years after surgery
45369567|NCT00963690|Procedure|Standard compression|Use standard compression to achieve hemostasis
45369568|NCT01079767|Drug|temsirolimus|
45369569|NCT01151124|Biological|CTX0E03 neural stem cells|Single administration by surgical delivery to the damaged area of the brain
45369570|NCT01084447|Device|inspiratory muscle training|This daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)was initially set at 40% of the maximal inspiratory pressure, obtained in the 2nd post-operative day, being adjusted to every new maximal inspiratory pressure measurement.
45369571|NCT01084447|Device|control group|In placebo muscular training the daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)no load until the 30th post-operative day.
45369572|NCT00969306|Drug|Chloroquine, A-CQ 100|"Administration:~Orally~Timing: Once daily~Tablets of 100 mg~During or after meals~In case of missed dose: intake of the missed dose is still possible up until 12 hours before the next dose.~Patients should always note date and time of intake on the chloroquine monitoring form."
45369573|NCT05260710|Behavioral|Telemedicine Intervention|"Tele-Critical Care: 1) establishing a diagnosis 2) guiding the therapeutic approach and 3) performing clinical follow-up. Physicians will discuss all patients in the unit, bed by bed, evaluating the specific clinical situation of each hospitalized patient, according to the protocol developed by the study.The proposal is to maintain horizontal care (the patient is monitored from the 1st day of hospitalization until discharge) for all patients in the unit.~+~Continuing education activities: video classes and discussions of complex cases."
45369574|NCT00958464|Procedure|MRI|MRI protocol consists of intravenous injection of 0.4 ml/kg dose of gadopentetate dimeglumine 2- [Gd-DTPA2-] contrast agent (Magnevist, Bayer) 90 minutes prior to imaging.
45846531|NCT05371704|Dietary Supplement|Multivitamin Supplementation|Participants will supplement daily with an over-the-counter oral multivitamin pill
45369575|NCT00963768|Drug|JNJ 28431754|A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).
45369576|NCT00963768|Drug|Placebo|A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
45369577|NCT00969384|Behavioral|Active awareness/Lifestyle counseling|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
45369578|NCT00958542|Procedure|Surgical fusion|Surgical intervention for correction of scoliotic or kyphotic curvatures of the spine will include either the posterior approach or the anterior + posterior approach, with either the unit or custom rod, depending on the choice of the surgeon.
45369579|NCT00969462|Drug|Doxorubicin|measurements of serum Doxorubicin levels
45369580|NCT00963846|Drug|placebo|matching pill placebo
45369581|NCT00963846|Drug|huperzine 0.2 mg BID|huperzine rising doses up to 0.2 mg BID
45369582|NCT00963846|Drug|huperzine 0.4 mg BID|huperzine rising doses up to 0.4 mg BID
45369583|NCT00963846|Drug|huperzine 0.8 mg BID|huperzine rising doses up to 0.8 mg BID
45369584|NCT00958620|Procedure|Shock Wave Therapy|Extracorporal shock-wave therapy
45488128|NCT02930343|Drug|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
45488129|NCT02930343|Drug|Sulfasalazine|5-aminosalicylic acid (5-ASA) is the active component of sulfasalazine; the specific mechanism of action of 5-ASA is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF)
45488130|NCT03681938|Procedure|Autograft|Autograft
45488131|NCT02703454|Procedure|FIRM-guided RF ablation|
45488132|NCT02703454|Procedure|Conventional RF ablation|
45488133|NCT03686618|Drug|Secretin|Drug to stimulate pancreatic secretion
45488134|NCT03103542|Biological|Recombinant coagulation factor (rFVIIIFc)|"rFVIIIFc 200 IU/kg/day during ITI Period and thereafter adjusted according to the Investigator's judgement~administered intravenously."
45488135|NCT02426866|Drug|Efavirenz|
45846532|NCT05371704|Other|Dietary Replication|Patients will record their dietary intake in an estimated food diary during the first trial. During the second trial, participants will be asked to replicate their diet from the first trial
45369585|NCT00958698|Other|Communication Intervention|Ancillary studies
45369586|NCT00958698|Other|Educational Intervention|Ancillary studies
45369587|NCT00958698|Other|Internet-Based Intervention|Ancillary studies
45846533|NCT05371236|Other|Questionnaire|Phase I will use a descriptive qualitative approach to understand pediatric cancer patients' opinions related with spiritual issues and experience. The results of the qualitative study will be used to compare with the items of the original scale, and emerging themes will be used to generate new items. Phase Ⅱ will translates the original scale and validates the psychological properties of scale adapted for pediatric cancer patients.
45847992|NCT03164538|Behavioral|Diabetes Education|Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments.
45488136|NCT03686540|Procedure|ExtraCorporeal Membrane Oxygenation (ECMO)|The objective of this study is to determine the average cost of stay of a patient supported by ExtraCorporeal Membrane Oxygenation from the point of view of the hospital facility, during the hospitalization in which the ECMO was implanted.
45691979|NCT04270162|Other|Respiratory muscle training 2|"Training of respiratory muscles under the protocol of conventional use. Which is that the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. Repeat 10 times and use these indications for 3 sets.~In addition, participants must perform different breathing exercises that are identical for the 3 intervention groups."
46052704|NCT04099017|Other|Trunk stabilization group|"This study ARM will received Trunk stabilization exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~Trunk stabilization Area: Trunk Type of exercise: Stabilization exercise Intensity: 6-8 reps Frequency: 3 sets per session and 30 second duration break between sets~Procedural detail:~i. modified supermen extension exercise ii. Back bridge: iii. Unilateral back bridge:~Iv. lateral step up:~Knee strengthening Area: Knee Joint Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~Procedural detail:~i. Isometric quadriceps exercise: ii. Straight leg raising (SLR) exercise:~Kinesiotaping:"
45691980|NCT04270162|Other|Respiratory muscle training 3|The same exercises that apply to the participants of experimental group 1 and 2 will be performed. The only difference is that the participants of this group do not perform exercises with inspirometer.
45369588|NCT00958698|Procedure|Psychosocial Assessment and Care|Ancillary studies
45369589|NCT00958698|Other|Quality-of-Life Assessment|Ancillary studies
45369590|NCT00958698|Other|Questionnaire Administration|Ancillary studies
45369591|NCT00969696|Drug|Placebo|8Mg a day of a sugar pill
45369592|NCT00969696|Drug|Galantamine|8mg of Galantamine
45691981|NCT04387630|Drug|Metformin|Oral hypoglycemic drug. Initial dose 500-850 mg/d. incrementally increased to a maximum daily dose of 2550 mg in three divided doses.
45691982|NCT04387630|Drug|Placebo oral tablet|Simethicone 60 mg three times daily.
45691983|NCT04270318|Other|CH Pulpotomy, physiologic saline|Pulp chamber was cleansed with physiologic saline for 30 s.
45369593|NCT00958854|Drug|cyclophosphamide|
45369594|NCT00958854|Drug|fludarabine phosphate|
45369595|NCT00958854|Drug|thalidomide|
45369596|NCT00958854|Other|laboratory biomarker analysis|
45488137|NCT00706498|Drug|BI 2536|
45488138|NCT01358955|Other|group cognitive intervention|The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
45691984|NCT04270318|Other|CH pulpotomy, NaOCl|Pulp chamber was cleansed with 5 % NaOCl for 30 s.
45691985|NCT04270318|Other|MTA Pulpotomy, physiologic saline|Pulp chamber was cleansed with physiologic saline for 30 s.
45488139|NCT01358955|Other|Home-based cognitive intervention|The participants will do their paper and pencil homework for 30 minutes every business days for 12 weeks.
45488140|NCT04960722|Device|OIF/β-TCP|bone graft implantation
45488141|NCT02418598|Genetic|Cohort1|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 3x10^11 vg/subject.
45488142|NCT02418598|Genetic|Cohort2|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 9x10^11 vg/subject.
45488143|NCT03428828|Behavioral|Amygdala Neurofeedback|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
45691986|NCT04270318|Other|MTA pulpotomy, NaOCl|Pulp chamber was cleansed with 5 % NaOCl for 30 s.
45691987|NCT02998372|Procedure|patellar stabilization|surgery to either alter soft tissues around the patella or reorient the patellar tendon to restore patellar stability
45691988|NCT02994472|Radiation|Gastric emptying scintigraphy using 99mTc-DTPA|
45847993|NCT03169062|Device|Gated Stationary Chest Tomosynthesis|The technologist will comfortably position the patient laying face up on the imaging table. EKG leads will be placed in appropriate positions to derive an EKG signal. The EKG will be used to trigger the image collection. The subject will be asked to hold his or her breath for 25-30 seconds during the scan. Total patient preparation and imaging time should not exceed 20 minutes.
45847994|NCT03170388|Drug|IDP-126 Gel|Gel
45847995|NCT03170388|Drug|IDP-126 Component A|Component A
45847996|NCT03170388|Drug|IDP-126 Component B|Component B
45488144|NCT03428828|Behavioral|Parietal Neurofeedback|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
45488145|NCT04874922|Behavioral|Gestational Diabetes Training Intervention based on Planned Behavior Theory|On the basis of Planned Behavior Theory, an training intervention is planned in three stages for medical nutrition, physical activity and gestational diabetes follow-up.
45691989|NCT02993692|Device|Direct laryngoscopy and fiberoptic bronchoscopy|These devices is used in endotracheal intubation and tonopen for measuring of intraoculer pressure. I want to see whcih is better.
45753494|NCT04198610|Procedure|Non surgical periodontal therapy|Procedure/Surgery: non surgical periodontal therapy and root planing (SRP) was performed in two to four appointments lasting approximately 60 minutes each under local anaesthesia (2% lignocaine hydrochloride with 1:2,00,000 adrenaline) using area specific Gracey periodontal curettes and an ultrasonic device. The treatment was concluded in 3 months. Within the duration of the study, all subjects received supportive therapy, which included professional plaque control and reinstruction of oral hygiene.
45753495|NCT03023852|Drug|JNJ-63623872|Participants will receive JNJ-63623872 600 mg (2*300 mg) oral tablets in Panel 1 and 2 under Fasted conditions.
45847997|NCT03170388|Drug|IDP-126 Component C|Component C
45847998|NCT03170388|Drug|IDP-126 Vehicle Gel|Vehicle Gel
45488146|NCT04874922|Behavioral|Gestational Diabetes Training Intervention based on standart|Standard training for gestational diabetes will be given once at 28 weeks of gestation.
45488147|NCT03686462|Device|Virtual reality-based interactive treadmill training|During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.
45488148|NCT03686462|Device|Treadmill training without VR-based interaction|Treadmill training without VR-based interaction
45488149|NCT02423824|Biological|Liraglutide|Study participants will received the following study intervention in addition to 'standard of care' treatment: Adjunctive liraglutide will be initiated at 0.6 mg for the first 1 week, then increased to 1.2 mg with the option of increasing to 1.8 mg thereafter based on efficacy/tolerability (n=15 in each group). Liraglutide will be adjunctively administered to a conventional antidepressant, antipsychotic and mood stabilizing agent at guideline-concordant therapeutic plasma levels. Subjects will be randomized to receive liraglutide for a 4 week period. No major change in the pharmacological regimen will be permitted during the 4 week trial unless required for medical reasons.
45488150|NCT03425786|Behavioral|Diagnostic training|Training in the Dix-Hallpike maneuver and the supine head roll test to diagnose BPPV.
45488151|NCT03425786|Behavioral|Diagnostic and treatment training|Training in the Dix-Hallpike maneuver and the supine head roll test to diagnose BPPV. Training in the Epley and Barbecue maneuvers to treat BPPV.
45488152|NCT04548570|Procedure|approximation of both rectus muscles|closure of both rectus muscle before closure of rectus sheeth
45488153|NCT02423434|Other|Exposure: Corneal nerve fibre morphology by the CCM Procedure|"CCM is a non-invasive method for direct visualization of corneal nerve fibers. Previous research work has confirmed that corneal nerves status correlates with both small and large fibre damage as assessed by quantitative sensory testing and nerve conduction.~In the current trial subjects will undergo a bilateral examination of the Bowman's layer of the cornea using the Rostock Cornea Module of the Heidelberg Tomograph III (Heidelberg Engineering, Smithfield RI, USA) to determine their corneal nerve fiber length, corneal nerve fiber density, corneal nerve branch density, and the tortuosity coefficient. Topical anaesthetic and a viscous gel medium will be applied to the eye, which will create a visual gel bridge between the cornea and the sterile single-use cap on the microscope objective lens. After the interface between the corneal epithelium and Bowman's layer is identified, batches of images will be taken and the most technically sound images will be identified and analyzed."
45488154|NCT01012167|Drug|Oxytocin|Oxytocin: 24 IU in the morning and 24 IU in the evening given by nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
45488155|NCT01012167|Drug|Galantamine|Galantamine: 4 mg twice a day for 1 week, then 8 mg twice a day for 1 week, then 12 mg twice a day for 4 weeks
45488156|NCT01012167|Other|Placebo-Oxytocin|Saline nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
45488157|NCT01012167|Other|Placebo-Galantamine|Placebo tablets twice a day for 6 weeks
45369597|NCT04009278|Other|Self compression arm|The optimal compression level up will be under the supervision of the radiographer who will interpose the compression when a level is reached beyond which there is no further reduction in thickness (15 daN). If the woman stops at a compression of less than 10 daN and that the radiographer considers not adequate to perform a quality mammogram, the radiographer will perform the compression in conventional mode and record the passage of compression mode.
45488158|NCT04522518|Device|PmP-C App|"The key features of PmP-C App include: About Me (entering child's demographic data e.g. age, gender, family members), My participation (answering frequency and involvement of activities), and My goal (selecting 3 important activities they desire to change and identify things that made them easy or hard to do, i.e. participation goals and environmental supports or barriers). The App is to be manipulated adult interviewers but also can be manipulated by the child if they are able to."
45753496|NCT03023852|Drug|Oseltamivir|Participants will receive Oseltamivir 75 mg (1*75 mg) oral capsule (reference) in Treatment D of Panel 2 and Oseltamivir 75 mg administered as JNJ-63623872/37.5 mg Oseltamivir oral FDC tablet concept formulation (test 3) in Treatment E of Panel 2.
45753497|NCT00214136|Radiation|radiotherapy|prostate radiation to 70Gy; nodal radiation to 56Gy
45369598|NCT00964080|Drug|MBP-426/Leucovorin/5-FU|MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered at a dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
45753498|NCT00213980|Drug|Zoledronate|4 mg IV over 15 minutes administered once every 12 weeks times 4
45847999|NCT03172884|Drug|Copanlisib (ALIQOPA, BAY80-6946)|12mg single dose, intravenous on Day 0
45848000|NCT03174366|Drug|Denosumab|Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.
45848001|NCT03177798|Drug|Icatibant|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, The investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
45848002|NCT03177798|Drug|Placebo|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, the investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
45488159|NCT02426710|Device|Intracardiac echocardiography|Flutter ablation will be done using intracardiac echocardiography.
45488160|NCT05759052|Behavioral|self-administered questionnaire|Patients will answer to a self- administered questionnaire exploring chemotherapy-induced peripheral neuropathy and related comorbidities
45488161|NCT03424850|Radiation|HDR brachytherapy|"Dose constraints for 21 Gy:~Bladder and rectum: V70 < 1 cc~Urethra: V115 < 1 cc~V135: 0%~Dose constraints for 23 Gy:~Bladder and rectum: V65 < 1 cc~Urethra: V105 < 1 cc~V125: 0%~Dose constraints for 25 Gy:~Prostate V100 >90% (>95% preferred)~Bladder and rectum: V70 < 1 cc, Dmax <115%~Urethra: V110 < 1 cc, Dmax <120%"
45488162|NCT05758974|Procedure|dental treatment|Extraction, pulp therapy or both
45488163|NCT02426944|Drug|NOAC|Medical arm, patients will be treated by NOAC.
45488164|NCT02426944|Device|Left atrial appendage closure|The patients will be treated by interventional closure of the left atrial appendage.
45488165|NCT03376321|Drug|Pimodivir 600 mg|Participants will receive pimodivir 600 mg orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
45488166|NCT03376321|Drug|Placebo|Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
45488167|NCT03376321|Other|SOC Treatment|Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either the treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
45488168|NCT02418520|Device|Miswak|Oral hygiene with Miswak chewing sticks and normal tooth brush
45488169|NCT04437732|Device|Apioc-P and Apioc-PT Contact Lens Design|Novel soft contact lens design
45846534|NCT05371158|Behavioral|Online intervention|The first module includes psychoeducation on neuropathic pain and CIPN (Table 1). Participants acquaintance themselves with intervention goals and mindfulness exercises central to ACT. In subsequent modules, participants learn about the aversive effects of pain avoidance, gain insight into their personal values, and work on pain acceptance. Participants exercise to recognize unhelpful thoughts about their pain and learn the difference between the subjective (judging) and objective self, and think about concrete actions to prevent relapse. The intervention primarily consists of text and experiential exercises, complemented with illustrations, metaphors and audio (mp3) files. Additional functionalities may be an outline of experiences by other CIPN patients and/or the ability to keep a diary. Participants in the experimental condition will receive therapist guidance.
46052705|NCT04099017|Other|Knee strengthening group|"This study ARM will received Knee strengthening exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~Knee strengthening Area: Knee Joint Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~Procedural detail:~i. Isometric quadriceps exercise ii. Straight leg raising (SLR) exercise:~Kinesio-taping:~Muscle stretch method will be applied which involves one Y and two I straps: The Y-shaped tape base will be affixed over the top of patella then pulls up his/her knee to its maximum bending capacity then both end of Y strip is placed around the patella ending on the tibial tuberosity. Then reinforcing I-tape will be affixed at the origin and insertion of MCL and LCL. Tape will be change in every session."
46052706|NCT02799849|Other|Sleep and metabolism assessment|
46052707|NCT00770653|Drug|Pioglitazone and Metformin|Pioglitazone 15 mg/metformin 850 mg combination tablets, orally, twice daily and glimepiride placebo-matching tablets, orally, once daily and metformin placebo-matching tablets, orally, twice daily for up to 24 weeks.
46052708|NCT00770653|Drug|Glimepiride and Metformin|Pioglitazone/metformin placebo-matching combination tablets, orally, twice daily and glimepiride 2 mg, tablets, orally, once daily and metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
45848003|NCT03178344|Device|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
45369599|NCT00958932|Behavioral|Speech recognition|The TEAM intervention is a program to increase communication with families, provide feedback to families about their refill adherence, assess asthma symptoms, deliver health communication messages, encourage parents to ask questions of asthma care managers, and facilitate refilling ICS prescription. Speech recognition calls will be tailored to specific situations including new or re-issued ICS prescriptions, failure to fill an initial prescription, failure to refill, or failure to refill following an ED visit, hospitalization, or oral steroid burst resulting from an asthma exacerbation.
45369600|NCT00958932|Behavioral|Speech recognition|Automated, speech recognition telephone calls
45369601|NCT00969852|Drug|Sertraline|Multiple doses of 5, 25, and 50 mg Sertraline for 6 days each period.
45369602|NCT00959010|Dietary Supplement|omega-3 triglycerides|capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA, 60mg/kg/day 3 times a day during 12 months.
45369603|NCT00959010|Dietary Supplement|Placebo|capsules containing middle chain triglycerides
45369604|NCT04009434|Device|Mitral Valve Clipping|Patients receive treatment for mitral regurgitation with mitral valve clipping including standard drug therapy.
45369605|NCT04009434|Device|TAVI|Transfemoral transcatheter aortic valve implantation plus optimal standard of care therapy.
45691990|NCT04386382|Procedure|ridge splitting flapless technique using interchangeable guide followed by implant placement|"An informed consent is taken from all the patients~I. Presurgical phase:~Proper dental and medical history.~Scaling and oral hygiene measurements.~Clinical examination.~Radiographic examination. Clinical bucco-lingual measurements was done using calipers to ensure the patients would meet our initial inclusion criteria prior to further investigations.~III. Fabrication of interchangeable surgical guide stent from primary impression:~Optical scanning of the dental casts was done using Ceramill map 400~surgical stent was designed using Mimics Innovation Suite 19 ™ software.~Series of creating and designing special 3D virtual guide slits and boxes that can accommodate and precisely fit the tools used for the ridge splitting technique.~All patients will be operated under local anesthesia, stent was placed on ridge and adapted well after disinfection osteotomy was done using piezotome splitting tips Implant-insertion was started immediately"
45369606|NCT00426556|Drug|Everolimus|Everolimus (RAD001) was supplied as tablets in 3 different dosage strengths, 2.5, 5, and 10 mg. The drug was packaged in blisters containing 10 tablets per blister. Blisters and packaging labels were compliant with local regulations and were printed in local language.
45691991|NCT02999854|Biological|ATIR101|ATIR101 is a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells using photodynamic treatment; single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT (intravenous infusion)
45488170|NCT03183622|Biological|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.~This tudy is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
45488171|NCT05760534|Drug|Remimazolam|0.075 mg/kg Remimazolam will be loaded over 1 min, then continuously infused at 0.2-1.0 mg/kg/h based on ideal or total body weight
45488172|NCT02418364|Other|Placebo reflexology treatment|Placebo reflexology treatment will be done in the same rate as the reflexology treatment itself, but will be superficial in particular,and will be directed to organs and organ systems which are not relevant to the research topic.
45846535|NCT05370846|Other|Clinical pharmacy antimicrobial stewardship intervention|"A new AMS group will be introduced in Tauernklinikum in Zell am See, based on the S3-AWMF-guideline Strategien zur Sicherung rationale Antibiotika-Anwendung im Krankenhaus on antibiotic use in hospitals. As part of this, a new formulary will be developed and gradually introduced where we determined which AMS guidelines need to be incorporated. Antimicrobial use will be audited after set-up of the local formulary against the data from before implementation (using defined daily dose, DDD, as suggested by the WHO). Data on antimicrobial use will be obtained from a recently purchased and installed AMS programme called HyBase® by epiNET AG. AMS group will be provided with implementation material and toolkits, baseline data for antimicrobial use within hospital will be obtained."
46052709|NCT04185207|Other|no intervention|There is no intervention.
46052710|NCT02799615|Drug|Infliximab|No standard dosing regimen will be used and the dose of infliximab will be determined by the treating physician
45488173|NCT02418364|Other|Reflexology treatment|Reflexology treatment will be done until the eggs implant. If the patient is not pregnant, she will start another reflexology treatment cycle. There will be minimum 4 and up to 6 reflexology treatments in every IVF cycle (maximum three IVF cycles) . Rate treatment will be two or three times a week.
46052711|NCT04079907|Dietary Supplement|Ketone|This intervention will take their respective supplement for 14 days, then will be followed for up to 1 year during routine clinic visits.
46052712|NCT04079907|Dietary Supplement|Placebo|This intervention will take their respective supplement for 14 days, then will be followed for up to 1 year during routine clinic visits.
46052713|NCT04036773|Dietary Supplement|Fruit and vegetable deliveries|Weekly home deliveries of approximately 15 pounds of fresh fruits & vegetables
46052714|NCT00819052|Drug|Nevirapine XR|Nevirapine XR
45488174|NCT01362699|Drug|JNJ-31001074|Type=exact number, unit=mg, number=3, form=tablet, route=oral use. One tablet once daily for 7 days.
45488175|NCT01362699|Drug|Placebo|Form=tablet, route=oral administration. One tablet once daily for 7 days.
45369607|NCT00426556|Drug|Trastuzumab|Commercially-available trastuzumab was used in this study. A 4 mg/kg loading dose was administered, intra-venous (IV), over 90 minutes on Day 1 (if patient was not already receiving trastuzumab); this was followed by weekly trastuzumab 2 mg/kg IV administered over 30 minutes. For patients who continued to receive trastuzumab and everolimus after completion/discontinuation of chemotherapy in the core treatment phase, trastuzumab may have been administered once every 3 weeks at a dose of 6 mg/kg. PT = Paclitaxel & Trastuzumab
45369608|NCT00426556|Drug|Paclitaxel|Commercially-available paclitaxel was used in this study. Paclitaxel infusion was administered on Days 1, 8, and 15 of each 28-day cycle, after administration of trastuzumab. Paclitaxel (80 mg/m2) was administered as a 60-minute continuous IV infusion after standard premedication. Patients received paclitaxel for 6 cycles. At the investigator's discretion, treatment with paclitaxel could continue beyond 6 cycles.
45369609|NCT00107653|Drug|Ribavirin|1000-1200mg po daily for 48 weeks
45369610|NCT00107653|Drug|Peginterferon alfa-2a|180 micrograms sc/week for 48 weeks
45488176|NCT03686072|Procedure|Cataract surgery with endoscopic goniosynechialysis|Phacoemulsification was performed first. Immediately after implantation of the IOL, a 23G ophthalmic endoscope (OE) probe was inserted into the anterior chamber to visualize the PAS through the main incision and side incision. A viscoelastic agent and a blunt iris spatula were used to release the areas where where PAS existed.
45488177|NCT02423278|Procedure|Radical Gastrectomy Plus D2 Lymphadenectomy|"This surgical procedure is performed by the same high-experienced surgical team as the control arm.~All lymph nodes around stomach (station 1&2 LNs) must be removed to achieve a radical lymphadenectomy. Para-aortic lymph nodes should not be dissected even if a suspected lymph node metastasis is diagnosed from radiographic exams."
45488178|NCT02423278|Procedure|Radical Gastrectomy Plus D4 Lymphadenectomy|"This surgical procedure is also performed by the same high-experienced surgical team as the control arm.~Lymph nodes around stomach (station 1&2 LNs) and para-aortic lymph nodes must be removed during the operation."
45488179|NCT02423278|Drug|S-1+Oxaliplatin|"A perioperative chemotherapy, known as SOX regimen, should be performed in each enrolled patient with three-cycle treatments followed after a pathological carcinoma diagnosis. After a radical operation (arm groups), additional five-cycle treatments of adjuvant chemotherapy (SOX regimen) would be performed, followed by follow-up program. The treatment bundles are listed as follows:~S-1: 40~60mg bid，po, Day1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid）~Oxaliplatin: 130mg/m2，iv drip for 2h，Day1"
45488180|NCT01365429|Device|XPS™ with Steen Solution™|The XPS™ System is an integrated cardiac bypass system comprised of various components such as a Maquet CardioHelp centrifugal pump (K102726), the HicoVariotherm Heater/Cooler, the Hamilton C2 ICU (intensive care unit) pressure- controlled ventilator (K092148), the perfusate gas monitors, and the display monitors. The XPS™ System is responsible for housing the organ for preservation, providing the normothermic environment, and perfusing the organ with the STEEN Solution™. Donor lungs that meet inclusion criteria are placed on the XPS™ and rewarmed and perfused with STEEN Solution™ and ventilated for 3-6 hours. If the lungs meet transplant suitability, they are cooled down and transplanted into a consented recipient that meet's trial criteria.
45488181|NCT02423356|Procedure|Echocardiogram|An echocardiogram uses sound waves to produce images of the heart. This commonly used test allows doctors to see how your the heart is beating and pumping blood. Doctors can use the images from an echocardiogram to identify various abnormalities in the heart muscle and valves.
45488182|NCT02950506|Device|transcranial direct current stimulation|The anode will be placed over left DLPFC at F3, according to the 10-20 international system for EEG electrode placement. The cathode will be placed over the contralateral supraorbital area. They will be placed via two saline soaked electrode sponges (3 cm x 4.5 cm).After electrodes have been placed, the participants will be instructed to log into CRT software using a unique patient identifier. The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.)Active tDCS will be applied at a ramp-like fashion from 0 to 2mA over 10 seconds, and will be ramped down for the last 10 seconds of stimulation. Active tDCS will last 20 minutes each session. The sham procedure involves only 30 seconds of stimulation at 2mA.
45691992|NCT02999854|Drug|Cyclophosphamide|High dose post-transplant cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT (powder for intravenous infusion)
45691993|NCT02999854|Procedure|T-cell depleted HSCT from a related, haploidentical donor|T-cell depleted graft prepared from peripheral blood stem cells using the CD34+ cell selection method; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
46052715|NCT00819052|Drug|Nevirapine XR|Nevirapine extended release
46052716|NCT00819052|Drug|Nevirapine IR|Nevirapine Immediate Release
46052717|NCT02799537|Other|Randomized clinical study|Participants will be randomly assigned to one of two advance directives and we will assess which they prefer. This is not a human health intervention
46052718|NCT00763009|Drug|dipyridamole|0.28mg/kg over 4 minutes intravenously x three doses; totalling 0.84mg/kg intravenously
45488183|NCT02950506|Other|Cognitive Remediation Therapy|The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.). Cogmed is a targeted computerized training program that has been shown to improve working memory and attention. (Spencer-Smith 2015).
45488184|NCT03183466|Procedure|arthroscopic repair|
45488185|NCT03183466|Procedure|arthroscopic debridement|
45488186|NCT05189067|Drug|Paclitaxel|i.v. 80mg/m^2
45488187|NCT05189067|Drug|Trastuzumab|i.v. loading dose of 8 mg/kg, followed by 6mg/kg
45488188|NCT05189067|Drug|Docetaxel|i.v. 100mg/m2
45488189|NCT03374995|Other|Best Practice|Receive standard of care
45488190|NCT03374995|Other|Quality-of-Life Assessment|Ancillary studies
45369611|NCT00107653|Drug|Ribavirin|1000-1200mg po daily for 48 weeks
45488191|NCT03374995|Device|Topical Keratin|Given topically
45488192|NCT02418208|Diagnostic Test|Performint EEG tests and BNA analysis|
45488193|NCT02828982|Device|Powered ankle prosthesis|This device is a commercially available powered ankle prosthesis, (BioM, Bionx, Bedford, MA) which was given FDA device exempt status.
45488194|NCT02828982|Device|Dynamic Response Foot|This condition is a sham condition as the participant will wear the prosthesis they were clinically prescribed and usually wear.
45488195|NCT01362777|Behavioral|In-patient rehabilitation|"Individualized exercise training (IET):~Duration : 24 sessions during 4 weeks~IET session (2h) contains:~15' start warming up muscles~30' muscle strengthening exercise for arms and abdominal muscles~45' individualized cycle ergometer endurance training to the ventilatory threshold heart rate measured on the cardiopulmonary exercise test.~15' stretching~15' postural, movement and balance exercises IET session was controlled by a professional instructor using heart rate monitoring. Duration, intensity and attendance were recorded in a logbook.~Educational activities (20h): the 8 themes are comparable to comparator arm. Dietary management: was performed by dietician to ensure that energy intakes are adjusted to energy expenditure. No restrictive diet was prescribe."
45488196|NCT01362777|Behavioral|Educational activities alone|"Educational activities alone contains 10 sessions lasting 1:00 with 8 themes :~Physiological mechanisms of apneas/hypopneas~Effects of apneas/hypopneas on health (vascular morbidity/mortality and sleepiness)~Beneficials effects of CPAP and/or advanced mandibular orthosis~Description of sleep stages and physiological roles of sleep~Known effects of exercise on sleep and metabolism~Importance of good nutritional status and sleep hygiene on quality of life~How to apply theses lessons of rehabilitation in daily life"
45488197|NCT02427022|Other|CTI|CTI is an empirically supported, time-limited case management model designed to prevent homelessness and other adverse outcomes in people with mental illness following discharge from hospitals, shelters, prisons and other institutions. CTI was originally developed and tested by researchers and clinicians at Columbia University and New York State Psychiatric Institute with significant support from the National Institute of Mental Health and the New York State Office of Mental Health.
45488198|NCT03711643|Procedure|Periprostatic nerve block|4 injections of 2 cc of lidocaine for a Periprostatic nerve block
45488199|NCT03711643|Device|hypnosis mask|"The mask HYPNOS pro stimulates the imagination of the user by means of 6 diodes among 3 by eye.~Just before the introduction of ultrasound probe, the patient put the hypnotic mask and choose a session.Twenty minutes after the removal of the probe, an healthworker assess the painful patient with the visual analogue scale VAS, after this the patient fulfill the STATE- TRAIT Anxiety Inventory (STAI) form Y-A."
45488200|NCT02418286|Other|expose to any drugs or procedures based on traditional Korean medicine theory|There are no specific interventions associated with this registry as it is purely observational study of medical utilization.
45488201|NCT03133767|Drug|Lactated Ringer Solution|2 liters of intravenous lactated ringers solution will be administered by peripheral IV
45488202|NCT03133767|Drug|Normal Saline 0.9% Infusion Solution Bag|2 liters of intravenous normal saline solution will be administered by peripheral IV
45488203|NCT02422966|Drug|Paracetamol|
45488204|NCT02422966|Drug|Ibuprofen|
45488205|NCT02422888|Drug|Ticagrelor|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a maintenance dose of ticagrelor 90 mg twice a day for 1 year.
45369612|NCT00107653|Drug|Peginterferon alfa-2a|180 micrograms sc/week for 48 weeks
45369613|NCT03994354|Procedure|J-P drainage and cutaneous penrose drainage insertion|Lots of the stoma wound closure technique have been developed, including subcutaneous antibiotic material implantation, wound irrigation with iodine, closure wound with a drain tube, secondary closure, delayed primary closure and pursestring closure. But there still is in debate about best skin closure test. In Division of Colorectal Surgery Shuang Ho Hospital, two current stoma wound closure methods were subcutaneous Jackson-Pratt drainage and cutaneous penrose drainage insertion.
45369614|NCT03950856|Drug|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
45369615|NCT03950856|Drug|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F in each 0.5. mL dose.
45369616|NCT00970008|Other|Massage 30 min 2x/wk x4 wks then 1x/wk x4 wks|Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
45369617|NCT00970008|Other|Massage 60 min 2x/wk for 4 wks then 1x/wk for 4 wks|Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
45369618|NCT00970008|Other|Massage 30 min sessions 1x/wk for 8 wks|Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
45488206|NCT02422888|Drug|Prasugrel|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a single loading dose of prasugrel 60 mg (1 day after standard loading dose ticagrelor),followed by a maintenance dose of prasugrel 10 mg once a day for 1 year.
45488207|NCT05641350|Behavioral|Barlow's Unified Protocol|Adaptation of the cognitive-behavioral Barlow's Unified Protocol for emotional eating pattern.
45488208|NCT03633552|Drug|Temozolomide|The patients will initially undergo surgery. Within 4 to 6 weeks after surgery, all patients will receive chemoradiation. After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meter body surface per day for the first 5 days of every 28 days). In the control group, the patients will receive 6 cycles of adjuvant Temozolomide (in the same dosage).
45488209|NCT02426632|Drug|Formulation A|Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.
45488210|NCT02426632|Drug|Formulation B|10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.
45488211|NCT02426632|Drug|Formulation C|10 mg/mL oral solution containing 10 mg/mL sucralose.
45488212|NCT02426632|Drug|Formulation D|10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.
45488213|NCT02426632|Drug|Formulation E|10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.
45488214|NCT02426632|Drug|Formulation F|10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.
45488215|NCT02426632|Drug|Formulation M1|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
45488216|NCT02426632|Drug|Formulation M2|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
45488217|NCT02426632|Drug|Formulation M3|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
45488218|NCT02426632|Drug|Formulation N1|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
45488219|NCT02426632|Drug|Formulation N2|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
45488220|NCT02426632|Drug|Formulation N3|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
45488221|NCT03633474|Biological|N. lactamica|Stocks of N. lactamica (strain Y92-1009, sequence type 3493, clonal complex 613) in Frantz medium containing 30% (v/v) glycerol have been previously prepared using the Good Manufacturing Practices pharmaceutical manufacturing facilities at Public Health England (Porton Down, United Kingdom).
45488222|NCT03633474|Other|PBS only|Sterile PBS only containing no bacteria
45369619|NCT00970008|Other|Massage 60 min session 1x/wk for 8 wks|Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
45369620|NCT05281146|Dietary Supplement|Chickpeas and crushed peanuts fortified biscuit|This group received one daily pack of three fortified biscuits as snakes between breakfast and lunch on daily basis for four months. The chickpeas and crushed peanuts fortified biscuit consisted of wheat flour (extract 72%), Chickpea flour, crushed peanuts, wheat germ, Skimmed milk, corn oil, egg, sugar, Cinnamon, baking powder, salt, and vanilla.
45488223|NCT05760456|Drug|DIDALA hard capsules|DIDALA is given orally with a dose of 2 capsules, 3 times per day for 12 weeks
45488224|NCT05760456|Drug|Metformin|Metformin 500mg, 1 tablet twice a day, immediately after breakfast and dinner for 12 weeks
45488225|NCT02418130|Drug|Ursodeoxycholic acid, taurine, ginsenoside, thiamine, inositol|
45488226|NCT02418130|Drug|Placebo|
45488227|NCT02426788|Behavioral|Cognitive behavioural therapy (CBT)|Behavioral: Cognitive behavioural therapy (CBT) The CBT intervention used in the trial has been adapted for people with PPS and it is based on a model of understanding PPS (Deary et al 2007). The therapy aims to help the patient develop an understanding of the relationship between cognitive, physiological and behavioural aspects of their problem; to understand factors that may be maintaining the problem and to learn how to modify their behavioural and cognitive responses in order to improve quality of life. The approach is transdiagnostic in that it targets processes and underlying mechanisms that affect disorders similarly, rather than focusing on how they are diagnostically different. The approach is personalised during therapy following a detailed assessment.
45488228|NCT03179956|Drug|Ribociclib|Treatment with ribociclib [600mg] will be from Days 1-14, with surgical resection on Day 14. Labs (CBC, CMP, coagulation parameters) and an ECG will be checked once in a window defined by days 9-12.
45488229|NCT03391765|Drug|ABBV-8E12|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW >59 kg, 4.7 mL/min or 282 mL/hr.
45488230|NCT03391765|Drug|Placebo solution for IV infusion on Day 15|0.9% NaCl injection/solution for infusion 500 mL; participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW >59 kg, 4.7 mL/min or 282 mL/hr.
45488231|NCT02802228|Drug|Ifetroban|thromboxane prostanoid receptor antagonist delivered as infusion and oral capsule
45488232|NCT02802228|Drug|Placebo|matched placebo delivered as infusion and oral capsule
45488233|NCT02426554|Dietary Supplement|DDU-supplement|DDU: Vitamin D, DHA, Uridine
45488234|NCT02426554|Dietary Supplement|Placebo supplement|
45488235|NCT03179488|Device|Spinal TENS|Spinal TENS stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
45488236|NCT03179488|Device|Sham stimulation|Sham stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
45488237|NCT03130257|Diagnostic Test|Clinic Blood Pressure Measurement|Participants will be asked to check their blood pressure once within the subsequent three weeks.
45488238|NCT03130257|Diagnostic Test|Home Blood Pressure Measurement|Participants will receive a validated upper-arm home blood pressure monitor and asked to two measurements in the morning and two in the evening for at least 5 days over three weeks.
45488239|NCT03130257|Diagnostic Test|Kiosk Blood Pressure Measurement|Participants will be asked to use a validated blood pressure kiosk in their clinic or local pharmacy to measure their blood pressure three times on three separate days over three weeks.
45488240|NCT03130257|Diagnostic Test|24-hour Ambulatory Blood Pressure Monitoring (Reference Standard)|Participants will be asked to wear an arm cuff and ambulatory blood pressure monitor for 24 hours, with measurements taken every 30 minutes during the day and every 60 minutes at night.
46052719|NCT04098757|Dietary Supplement|Migratens|2 sachets/day: 800 mg of α-Lipoic acid, 450 mg of magnesium bisglycinate, 300 mg of L-Tryptophan, 20 mcg of Vitamin D3, 2.4 mg of Vitamin B2, 25 mg of Niacin, 150 mg of Coenzyme Q10. Patients who receive Migratens food supplementation have to take 2 sachets / day for 12 weeks. The supplement will be prescribed as usual and the assumption of the same will be recorded by partecipants in the appropriate daily; if the subject does not continue the indication the data collected up to that moment will be considered.
46052720|NCT02799459|Procedure|General anaesthesia|the patient will receive a general anaesthesia do proceed at her conization
45369621|NCT05281146|Other|Cognitive stimulation for the mothers|"I. Sessions for mothers~Informing mothers about the most common causes of poor school achievement~Clarification of mother's and family roles in improving student's cognitive abilities~Defining cognitive functions needed for learning and school achievement~o Attention, perceptive reasoning, memory, problem solving, proper use of language~Identifying sensory functions necessary for the growth of cognitive functions~Explaining factors that assist in academic excellence"
45369622|NCT05281146|Other|Cognitive stimulation for students|"Activities to improve focus and visual attention~Activities to improve visual memory~Activities to improve vigilance and auditory attention~Explaining types of memory Causes of weak memory Factors helping in improving memory Nutritional elements improving memory~Training on skills of problem-solving"
45369623|NCT00433654|Device|Implantable Pulse Generator (IPG) and Pacing Leads (wires)|Pacer and leads
46052721|NCT02799459|Procedure|Hypnosis in conization|this is the experimental treatment which is allocated to the experimental group
46052722|NCT02803983|Procedure|Pediatric hip plate|Children were treated with pediatric hip plate.
45369624|NCT00433654|Other|Magnetic Resonance Imaging (MRI) scan|One hour MRI scan on the head and lower back.
45369625|NCT00970086|Drug|Bupivacain/levobupivacaine|"Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures by the ultrasound technique, administration of 0.4ml/kg levobupivacaine 0.25%."
45488241|NCT02801448|Drug|sulforaphane|sulforaphane-containing broccoli sprout extracts
45488242|NCT02801448|Drug|Placebo|Maltodextrine-based placebo without sulforaphane
45488243|NCT03179332|Drug|BioChaperone® insulin lispro|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
45488244|NCT03179332|Drug|Fiasp®|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
45488245|NCT03179332|Drug|Novorapid®|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
45488246|NCT03674177|Biological|GSK3888550A RSV Maternal vaccine formulation 1|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
46052723|NCT02803983|Procedure|Cannulated screw|Children were treated with cannulated screw.
46052724|NCT02612350|Genetic|ctDNA Analysis for the Detection of Genetic Mutations|Cell-free DNA (cfDNA) is isolated from a blood plasma sample and tested for the presence of 96 specific well-described mutations in 9 cancer driver genes. The presence of more than 2 copies of a mutation may indicate the presence of a malignancy. Follow up with the subject's physician would be needed for an examination and any additional testing that the physician wants to perform to further assess for the development of cancer.
46052725|NCT02805777|Device|CPAP mask|A new vent CPAP mask system will be used in this trial
46052726|NCT05477589|Drug|busulfan, cyclophosphamide and melphalan, BuCyMel|a three alkylator combination of busulfan, cyclophosphamide and melphalan (BuCyMel, standard arm)
46052727|NCT05477589|Drug|clofarabine, fludarabine and busulfan, CloFluBu|combination of clofarabine, fludarabine and busulfan in which two alkylators are replaced by antimetabolites (CloFluBu, experimental arm)
45488247|NCT03674177|Biological|GSK3888550A RSV Maternal vaccine formulation 2|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
45488248|NCT03674177|Biological|GSK3888550A RSV Maternal vaccine formulation 3|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
45488249|NCT03674177|Drug|Placebo (Normal Saline)|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
45488250|NCT03717259|Procedure|Open nephrectomy|The surgical technique for open nephrectomy consists of placing the donor in the lateral decubitus position and making an incision with or without rib resection that allows retroperitoneal access.
45488251|NCT03717259|Procedure|Hand-assisted laparoscopic nephrectomy|The hand-assisted technique begins with the incision for the introduction port of the hand, the renal artery and vein are divided using endoscopic staples and the graft is manually removed.
45488252|NCT03717259|Procedure|Laparoscopic nephrectomy|In the pure laparoscopic technique the patient is placed in the same position of lateral decubitus and after introducing the trocars in the abdomen, the colon is mobilized and the renal capsule is divided, the kidney is removed after performing the cut of the renal artery and vein through a suprapubic incision.
45488253|NCT02675790|Drug|Moderate Dose Hydroxyurea|Hydroxyurea therapy at 20 mg/kg/day for primary stroke prevention.
45488254|NCT02675790|Drug|Low Dose Hydroxyurea|Hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for primary stroke prevention.
45488255|NCT01359189|Device|ProxiScan (scintigraphic rectal probe)|"ProxiScanTM is a compact, high-resolution gamma camera which has been developed for the detection of cancer and other abnormalities in the body by imaging the distribution of radionuclides in the human body using planar imaging techniques. This camera is capable of high-performance imaging of radiopharmaceuticals distributed within anatomical regions of interest located close to the camera head. The ProxiScan compact scintigraphic detector was approved by the FDA to market the device for the following indication: The ProxiScanTM is indicated for use in imaging the distribution of radionuclides in the human body using planar imaging techniques. ProxiScanTM may also be used intraoperatively, on pathological specimens and for endocavity applications if a protective sheath is used."
45369626|NCT00689351|Biological|13-valent pneumococcal conjugate vaccine|13vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
45369627|NCT00689351|Biological|7-valent pneumococcal conjugate vaccine|7vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
45369628|NCT05448287|Behavioral|Health and family planning|Promotion of health and family planning behaviors
45369629|NCT05448287|Behavioral|Nutrition|Promotion of maternal, infant, and young child feeding behaviors and nutrition
45691994|NCT02999854|Procedure|T-cell replete HSCT from a related, haploidentical donor|T-cell replete (full, non-manipulated) graft prepared from either bone marrow or peripheral blood stem cells; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
45691995|NCT02999542|Other|Music|Children will be randomised to receive either music via headphones or silence via headphones
45691996|NCT02999542|Other|No music|Children will be randomised to receive either music via headphones or silence via headphones
45848004|NCT03178344|Device|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.
45369630|NCT05448287|Behavioral|Agriculture and homestead food production|Promotion of knowledge and practices about homestead food production
45369631|NCT05448287|Behavioral|Water, sanitation, and hygiene|Promotion of behaviors to improve water, sanitation, and hygiene
45488256|NCT02417896|Drug|Spironolactone|Spironolactone is administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3. A total 1 x 100 mg and 3 x 25 mg doses of spironolactone in the intervention group will be given. If the patient has not been extubated, spironolactone is administered nasogastrically. Oral drugs will be delayed by up to 4 hours if extubation has just occurred.
45488257|NCT01365663|Drug|SPC4955|3 Weekly SC injections
45488258|NCT01365663|Drug|SPC4955|3 Weekly SC injections
45488259|NCT01365663|Drug|SPC4955|3 Weekly SC injections
45369632|NCT02563301|Device|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis, laryngoscopy is performed and the patient's trachea is intubated.
45488260|NCT01365663|Drug|SPC4955|3 Weekly SC injections
45691997|NCT02999620|Dietary Supplement|Alpha-cyclodextrin|Alpha-cyclodextrin (α-CD) is a soluble dietary fiber that has a history of use in foods and as a pharmaceutical excipient. Recently the ability of the fiber to bind to dietary fat has led to further investigation of the possible health benefits of dietary supplementation with this fiber.
45369633|NCT03950622|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
45488261|NCT01365663|Drug|SPC4955|3 Weekly SC injections
46052728|NCT05758636|Behavioral|Emotional Freedom Technique|"Before starting the EFT session, the participants were asked to identify the problem that aroused their anxiety. After the common point of the problems was determined, the ORDS level of all participants was determined. Next, the EFT session explained traditional acupressure meridian points on the head, face, neck, chest, and hands. Next, they were asked to repeat the phrase, Even though I have this feeling of stress and anxiety, I accept myself deeply and completely, while gently applying to the acupuncture points with their index and middle fingers. While using this expression, the participants hit each acupuncture area seven times. After the first round of hits accompanied by this phrase, participants were asked to abbreviate this feeling of anxiety, stress with another short phrase. The participants then repeated rounds of this process until they noticed that their anxiety had decreased"
45488262|NCT01365663|Drug|Saline 0.9%|3 Weekly SC injections
45488263|NCT05488483|Diagnostic Test|Multispectral Optoacoustic Tomography Imaging|Each participants will undergo MSOT imaging of the suspicious breast tumor detected with ultrasound imaging and any additional lesion present in either breast before undergoing ultrasound-guided breast biopsy as the standard of care. Melanoma participants with pathologically confirmed ITM will undergo MSOT imaging following physical exam and biopsy. Melanoma patients receiving immunotherapy will undergo MSOT imaging prior to and following immunotherapy.
45488264|NCT03183544|Combination Product|Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit|The patients will receive a single injection of Gallium-68 PSMA-11 to diagnose biochemical relapse of prostate cancer after treatment.
45488265|NCT04380090|Drug|Propylene Glycol|Patients in the propylene glycol arm will receive one standard dose of the drug on postoperative day one prior to discharge with the aim of decreasing rates of postoperative constipation for patients following single total knee replacement surgery
45488266|NCT04380090|Drug|Docusate Sodium|Patients in the docusate sodium arm are receiving the current standard of care for prevention of postoperative constipation following single total knee replacement surgery, docusate sodium one pill twice a day by mouth for 28 days
45488267|NCT05191563|Drug|HCP1904-1|Take it once per period.
45488268|NCT05191563|Drug|RLD2006|Take it once per period.
45488269|NCT05191563|Drug|RLD2001-2|Take it once per period.
45691998|NCT02999620|Dietary Supplement|Placebo|Identical looking placebo tablet to active (Alpha-cyclodextrin)
45691999|NCT04270708|Drug|Dexmedetomidine|Patients with Autism will be treated with intranasal Dexmedetomidine as a sedative for EEG
45692000|NCT04270708|Drug|Triclofos 100 MG/ML|Patients with Autism will be treated with oral Triclofos as a sedative for EEG
45692001|NCT02999464|Other|Qigong|The experimental group will be required to practice a total of 50 minutes of qigong training 3 times per week and for 16 weeks
45369634|NCT03950622|Biological|Prevnar 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in each 0.5 mL dose.
45369635|NCT00746525|Other|Surface functional electrical stimulation (FES)|FES is a technique that electrically stimulates a muscle in a comfortable manner in order to contract the muscle. It uses an electrode placed on the surface of the skin. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
45692002|NCT02999464|Other|Fitness exercise|Active control group will be required to practice a total of 50 minutes of fitness training 3 times per week and for 16 weeks
45488270|NCT03711565|Device|Regular Nasal CPAP using a conventional ventilator|The Nasal CPAP is connected to the patient via prongs in the nose. Pressure adjustments are made to improve lung inflation. The frequency and pressure can be adjusted as needed to improve the patient's oxygen and carbon dioxide levels
45488271|NCT03711565|Device|High Frequency Nasal CPAP|High Frequency Nasal CPAP for management of respiratory distress Patient will be connected to the high frequency device through nasal prongs. The Bronchotron produces a pressure that is variable with an adjustable frequency that is equal or greater than 500 times per minute connecting to prongs in the patient's nose. The pressure, frequency and amplitude of the pulsations will be adjusted as needed to provide acceptable oxygenation and ventilation.
45488272|NCT02418052|Procedure|neck flexion|After the cervical esophagogastric anastomoses is completed and the skin incision is closed, the patient's occiput will be lifted, and then the neck will be maintained in flexing position by an assistant. The underside of the chin will be fixed to the anterior chest wall with two stout nylon sutures by the surgeon. The neck will be fixed in the neutral flexing position for 7 to 10 days after surgery.
45488273|NCT03685916|Other|Control|Plain rice with plain water
45488274|NCT03685916|Other|Cumin Rice|Cumin rice with plain water
45488275|NCT03685916|Other|Cumin Drink|Cumin drink with plain rice
45369636|NCT00746525|Other|Motor learning|Motor learning is an exercise that uses movements needed for everyday tasks such as picking up a glass or opening a book. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
45488276|NCT03685916|Other|Cornsilk Rice (Low dose)|Low dose cornsilk rice with plain water
45488277|NCT03685916|Other|Cornsilk Rice (High dose)|High dose cornsilk rice with plain water
45488278|NCT03685916|Other|Cornsilk Drink (Low dose)|Low dose cornsilk drink with plain rice
45488279|NCT03685916|Other|Cornsilk Drink (High dose)|High dose cornsilk drink with plain rice
45488280|NCT03685916|Other|Tamarind Rice|Tamarind rice with plain water
45488281|NCT03685916|Other|Tamarind Drink|Tamarind drink with plain rice
45488282|NCT03745235|Other|stress reduction program based on mindfulness|a two and a half hour session per week for 8 weeks
46052729|NCT00841672|Drug|Aliskiren/amlodipine 300/10 mg tablet|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
45369637|NCT00746525|Other|Brain computer interface (BCI) training|BCI training uses signals produced by the brain to help individuals with stroke move their weak arm. This study will use BCI, FES and motor learning interventions to address upper extremity motor deficits following stroke.
45369638|NCT02563847|Dietary Supplement|0.52 g L-Tryptophan|
45369639|NCT02563847|Dietary Supplement|1.56 g L-Tryptophan|
45369640|NCT02563847|Dietary Supplement|1.56 g L-Leucine|
45369641|NCT02563847|Dietary Supplement|50 g Xylitol|
45369642|NCT02563847|Dietary Supplement|75 g Erythritol|
45488283|NCT03745235|Biological|venipunctures|1 dry tube of 5 ml and 5 heparinized tubes of 6 ml taken at inclusion, at 3 months and at 12 months
45488284|NCT03745235|Other|psychometric questionnaires|"Cohen PSS' perceived stress scale~Beck's anxiety and depression questionnaires~Watson's affectivity questionnaire, positive affect and negative affect schedule~optimism questionnaire, Life Orientation Test LOT-R by Sheier and Carver~IN-OUT DASQ dispositional affective style questionnaire"
45488285|NCT03116776|Procedure|Walnut Shell Glasses Moxibustion|Participants in experimental group will receive 12 sessions of walnut shell glasses moxibustion, each for 30 minutes,3 times per week, and administered over 4 weeks.
45488286|NCT03116776|Drug|Sodium hyaluronate eye drops|One drop for each eye, four times per day for over 4 weeks.
45488287|NCT02505204|Other|Clonidine|The anesthetic mixture will contain: lidocaine 2% 7 mL, lidocaine 2% 6 mL with epinephrine 5µg.mL-1, bupivacaine 0.5% 5 mL, and clonidine 2 mL.
45488288|NCT02505204|Other|Placebo|the same anesthetic mixture will be administrated however the clonidine will be substituted with 2 mL saline.
45488289|NCT01359267|Drug|99mTc-EC-DG|99mTc-EC-DG will be used before the SPECT/CT scans throughout the study to determine the its effectiveness. 20 mCi of 99mtc-EC-DG will be administered through a vein through a catheter. This will be done before the SPECT/CT scan at 4 weeks and 10 weeks.
45692003|NCT02999308|Other|Observe the patient's condition and then change the regimen|The patients will be assessed every 3 months and the treatment regimen will be modified by the result of assessment.
45369643|NCT02563847|Dietary Supplement|75 g Glucose|
45369644|NCT02563847|Dietary Supplement|300 mL tap water|
45369645|NCT02563847|Other|50 mg 13C-sodium acetate|
45369646|NCT00746681|Drug|Tolterodine & Pregabalin|Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks
45488290|NCT03183232|Procedure|Cryosurgery or IRE surgery|Cryosurgery or IRE surgery will be used in local tumor
45488291|NCT03183232|Biological|γδ T cell|γδ T cells will be used against Lung Cancer
45488292|NCT03183232|Other|γδ T cells/ A Cryosurgery or IRE|Combination γδ T cell and Cryosurgery or IRE surgery will be used in Lung Cancer
45488293|NCT01362933|Procedure|VTE treatment in cancer patient description|proportion of patients treated for evolutive VTE according to international recommendations
45488294|NCT03681626|Procedure|no tracheal suction|No tracheal suctioning during extubation
45488295|NCT03681626|Procedure|tracheal suction|tracheal suctioning during extubation
45488296|NCT05056714|Other|Questionaries|The patient will answer several questionaries
45488297|NCT04351698|Drug|Montelukast|Montelukast is used to treat and prevent asthma. It will decrease the symptoms and the number of acute asthma attacks. However this medicine should not be used to relieve an asthma attack that has already started.
45488298|NCT04351698|Other|Oral Placebo|Inert chewable tablet with no therapeutic value
46052730|NCT00841672|Drug|Amlodipine 10 mg capsule|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
45369647|NCT00746681|Drug|Tolterodine|Tolterodine SR, Oral, 4 mg, once daily for 4 weeks
45369648|NCT00746681|Drug|Placebo|Placebo, Oral, twice daily for 4 weeks
45369649|NCT00746681|Drug|Tolterodine & Pregabalin|Tolterodine SR Oral, 4mg, once daily for 4 weeks Pregabalin, Oral, 150 mg, twice daily for 4 weeks
45369650|NCT00746681|Drug|Pregabalin|Pregabalin, Oral, 150 mg twice daily for 4 weeks
45369651|NCT00746759|Device|Biomarker (not used as an intervention)|This study is an observational study. There is no intervention.
45369652|NCT00959244|Other|high performance liquid chromatography|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
45488299|NCT01359345|Drug|gadollinum|use of on injection gadollinum Iv for imaging
45692004|NCT00704938|Biological|aldesleukin|Intravenous (IV) aldesleukin 720,000 IU/kg every 8 hours for a maximum of 15 doses.
45692005|NCT00704938|Biological|anti-p53 T-cell receptor-transduced peripheral blood lymphocytes|Intravenous (IV) anti-p53 TCR transduced PBL will be administered at a a dose of 1 x 10^8 cells to 5 x 10^10 cells.
45692006|NCT00704938|Biological|autologous dendritic cell-adenovirus p53 vaccine|Ad-p53 DC vaccine, up to 2 x 10^8 ad-p53 DCs per dose will be administered subcutaneously, divided into 4 injections, one into each of the 4 extremities. Ad-p53 DCs will be administered subcutaneously on day 7 (± 2 days), day 14 (between day 14 and day 18), and day 28 (between day 25 and day 42) post T cell infusion.
45692007|NCT00704938|Biological|filgrastim|subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day).
46052731|NCT05549115|Drug|clarithromycin-sensitive(first-line)|esomeprazole (20 mg, twice daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days
45488300|NCT02417584|Device|positive airway pressure (PAP)|Positive Airway Pressure (PAP) is a non-invasive machine providing air pressure f to prevent the collapse of the oropharyngeal walls and the obstruction of airflow during sleep, which occurs in obstructive sleep apnea hypopnea syndrome.
45488301|NCT01359423|Drug|Percutaneous transluminal angioplasty of femoropopliteal artery lesions with primary long|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
45488302|NCT01359423|Drug|short stenting for the primary outcome and use of cilostazol for 12 months for secondary outcome.|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
45488303|NCT04330716|Behavioral|Standard Genetic Counseling|Standard of care genetic counseling
45488304|NCT04330716|Behavioral|Educational Video|Video tutorial about genetic testing
45692008|NCT00704938|Drug|cyclophosphamide|60mg/kg/day (Days-7,-6)
45692009|NCT00704938|Drug|fludarabine phosphate|25mg/m^2 (Days -5, -4, -3, -2, and -1)
46052732|NCT05549115|Drug|clarithromycin-resistant(first-line)|esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily) for 14 days
45369653|NCT00959244|Other|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
45369654|NCT00959244|Other|mass spectrometry|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
45369655|NCT00959244|Other|medical chart review|Information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease, body mass index, age at menarche, menopausal status (pre- or peri- menopausal or postmenopausal), age at menopause if applicable, chemotherapy regimen (if applicable), radiation therapy (if applicable), smoking history, alcohol consumption, pregnancy history including age at each pregnancy, lactation, history of benign breast disease, hysterectomy and disease type.
45488305|NCT03179566|Behavioral|Information Sheet|Patients will receive an informational sheet about how to dispose of leftover opioid medication during discharge. Nurses will provide this information sheet and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
45488306|NCT03179566|Behavioral|Deterra Drug Deactivation System|This system is a pouch that deactivates prescription drugs, rendering them ineffective for misuse and safe for regular garbage disposal. It uses a patented activated carbon technology to deactivate drugs, including pills, liquids, and patches, and has been found to be 99% percent effective in studies funded by the National Institute of Drug Abuse (NIDA). Additionally, the pouches are made from environmentally friendly materials and contain active ingredients that are considered non-toxic and pose minimal risk, according to their MSDS. Nurses will provide the Deterra bag and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
45848005|NCT05364216|Behavioral|Measurement of cognitive function|Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE and MoCA were assessed at one day before surgery, one day after surgery, and three months after surgery
45488307|NCT01363089|Drug|Ketorolac tromethamine|30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
45488308|NCT01363089|Drug|Oxymetazoline hydrochloride|Single intranasal dose of oxymetazoline hydrochloride (Afrazine®) (3 sprays of a 0.05% solution into each nostril) followed 30 minutes later by 30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
46052733|NCT05549115|Drug|empirical therapy group first-line|esomeprazole (20 mg, twice daily), colloidal bismuth pectin (150 mg, four times daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days
46052734|NCT05549115|Drug|levofloxacin-sensitive(rescue treatment)|esomeprazole (20 mg, twice daily), levofloxacin (500 mg, once daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily) for 14 days
46052735|NCT05549115|Drug|levofloxacin-resistant(rescue treatment)|esomeprazole (20 mg, twice daily), furazolidone (100 mg, twice daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily) for 14 days
46052736|NCT05549115|Drug|empirical therapy group rescue treatment|esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily) for 14 days
46052737|NCT02805699|Drug|Baofeikang Granule|To observe the efficacy and safety of Baofeikang granules on Combined Pulmonary Fibrosis and Emphysema Treatment.Baofeikang Granules consist of（Codonopsis 30g, Cordyceps fungi powder 12g, ophiopogon root 10g, Schisandra 10g, angelica 15g, Bulbus Fritillariae thunbergii 10g, Sophora flavescens 10g,Forsythia suspensa 12g，Pinellia 10g, saponins thorn 10g, Radix Peucedani 10g）.1 bags,P.O（Oral）twice of each 3 months cycle.
45369656|NCT00746837|Drug|AZD5672|single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period
45369657|NCT00746837|Drug|AZD5672|50 mg od, 12 days
45369658|NCT00746837|Drug|AZD5672|150mg od, 12 days
45488309|NCT03354637|Drug|ATI-50002 high dose|Topical solution
45488310|NCT03354637|Drug|ATI-50002 low dose|Topical solution
45488311|NCT03354637|Drug|Placebo|Topical solution
45488312|NCT03685838|Other|Compression Stockings|Class II above knee compression stockings
45488313|NCT02422576|Other|cinnamon extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
45488314|NCT02422576|Other|lemon extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
45488315|NCT02422576|Other|lemon extract plus eucalyptus extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
45488316|NCT02422576|Other|Thicken Up clear: TUC|
45488317|NCT04540068|Drug|Transforaminal Epidural Injection|Injections above L3 will contain 1,5 ml lidocaine 1% and 10 mg dexamethasone and injections at L3 or below will contain 1,5 ml lidocaine 2% and 40mg methylprednisolone acetate in accordance with current Dutch anesthesiologic guidelines for usual care.
45846536|NCT05365854|Procedure|Alveolar Recruitment Maneuver (ARM)|"When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order."
45846537|NCT05365620|Device|Mechanical In-Line Inexsufflation|In-line mechanical inexsufflation (IL-MIE) is a new method for performing MIE in intubated patients, which overcomes the drawbacks of MIE for ICU use . IL-MIE devices are integrated in-line with the patient's ventilator circuit, and do not themselves perform insufflations. Rather, the regular inspiration provided by the ventilator serves as the insufflation phase of each simulated cough, and the IL-MIE device performs only exsufflation, timing the onset of each exsufflation to the beginning of passive exhalation. Figure 1 demonstrates the setup and mode of operation of an IL-MIE device. The concept of IL-MIE was first developed by one of the authors (EB) in the Department of Respiratory Rehabilitation of ALYN Hospital in Jerusalem, Israel.
45846538|NCT05365620|Procedure|catheter suction|catheter suction is the standard, routine method for clearing secretions from the airway of a ventilated subject, by means of inserting a catheter into the endotracheal tube.
45846539|NCT05362734|Behavioral|obstetric outcomes after fresh versus cryopreserved embryo transfer|measure of ongoing pregnancy rate, delivery rate, abortion rate, ectopic pregnancy rate, multiple birth rate, ovarian hyperstimulation syndrome incidence
45846540|NCT05346276|Diagnostic Test|68Ga-DOTA-hLAG-3 PET/CT|Each participant receives a single intravenous injection of 68Ga-DOTA-hLAG-3, and undergo PET/CT imaging within the specified time.
45846541|NCT05120856|Behavioral|AAT-App|Participants will receive the active AAT-App on their smartphone, which includes ApBM training, and prompted to engage with the app during the 28-day intervention period.
45846542|NCT05120856|Behavioral|Minimal AAT-App|Participants will receive the minimal version of AAT-App, which does not include ApBM training, on their smartphone and prompted to engage with the app during the 28-day intervention period.
45846543|NCT05091060|Device|Erchonia HLS|56 procedure administrations with the Erchonia® HLS™ administered by the subject at home: daily procedure administrations for 8 weeks.
45692010|NCT02994316|Other|Copeptine dosage in children with diabetic ketoacidosis at diagnosis|Blood collection of 3 mL for copeptin dosage will be taken at different times in the first hours of management of diabetic ketoacodosis in children under the age of 16 years
45692011|NCT02994628|Other|Water|Water only without carbohydrate
45488318|NCT04053023|Drug|GSK2330672 (linerixibat)|GSK2330672 is available as a tablet with unit dose strength of 45 mg.
45488319|NCT04053023|Drug|Obeticholic acid|Obeticholic acid is available as a tablet with a unit dose strength of 10 mg (or 5 mg dependent on evaluation of Part A).
45692012|NCT02994628|Other|Mini banana|Ingest mini banana containing higher phenolics and carbohydrate concentration
45488320|NCT01365741|Other|Upright position|The test person will ingest Efient in an upright position and remain upright for 2 minutes. After 2 minutes, the test person will lie down, and remain supine for 2 hours, the same way as the person did in the control arm
45488321|NCT03361748|Biological|bb2121|: bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA02 CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
45488322|NCT02426320|Other|Sedation Interruption Protocol|
45488323|NCT02426320|Other|Standard Sedation Protocol|
45488324|NCT05191173|Procedure|Cardiac Surgery|No intervention, just observation is performed.
45488325|NCT02422732|Other|Neuropsychological assessments|"IQ (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette, Lobrot, Odedys tests. Visuo-spatial skill (JLO, Thurston, CORSI tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)"
45488326|NCT02422732|Radiation|morphological and functional MRI (fMRI)|"The fMRI will consider on the acquisition of a 3D anatomical sequence in T1 high resolution in axial slices of 1mm with an acquisition time of 10 min and a T2 sequence and a Flair to allow UBO location."
45488327|NCT02422732|Genetic|genetic analysis|Blood collection in 3 tubes (2 PAXgen® and 1 EDTA) and analysis to study the NF1 gene deletion.
45488328|NCT03623906|Procedure|Carbon dioxide insufflation colonoscopy|Carbon dioxide insufflation colonoscopy
45488329|NCT03623906|Procedure|Air insufflation colonoscopy|Room air insufflation colonoscopy
45488330|NCT05416788|Other|cervical manipulation|high-velocity, low-amplitude cervical manipulation
45488331|NCT05416788|Other|Sham intervention|lateral flexion and cervical rotation without manipulation
45692013|NCT02994628|Other|Cavendish banana|Ingest Cavendish banana (common banana)
45692014|NCT02994628|Other|6% sugar beverage|Ingest 6% sugar beverage containing same glucose and fructose profile as banana
45692015|NCT02994004|Other|no intervention|
45369659|NCT00964236|Drug|Sapropterin|Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
45369660|NCT00749099|Drug|pancrelipase|"The test drug (PANCRECARB® [pancrelipase] - Phase II) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
45692016|NCT02995408|Behavioral|Relaxation Response Resiliency Program for Parents of Children with ASD|
45369661|NCT00749099|Drug|placebo|"5 capsules of a placebo drug (Phase I) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
45369662|NCT00959322|Device|LenSx 550 Laser System|Femtosecond laser used to create capsulotomy incision.
45369663|NCT00749177|Other|Traditional Healing options|Dream work, energy healing, healing circles, pipe ceremonies, self care, smudging, sweat lodges and traditional learning.
45369664|NCT00964314|Other|music|"Experimental Group one : Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.~Experimental Group two: Listening western music based on conventional therapy in China.~Control Group: no music therapy will be done."
45369665|NCT04059419|Behavioral|PARQVE Program|Two days of lectures about knee OA, come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved, participate in a group therapy session with the psychologists and sessions with the physical educators.
45369666|NCT04059419|Behavioral|Geriatric Care|Remain under geriatric care as usual
45692017|NCT02994082|Behavioral|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smokeless tobacco cessation combined with supplemental treatment modules based on individual need and preferences.
45692018|NCT02994082|Behavioral|Behavioral activation for elevated depressive symptoms|Participants with elevated depressive symptoms may receive this six session telephone-based behavioral activation intervention.
45692019|NCT02994082|Behavioral|Post-cessation weight gain management|Participants with concerns about gaining weight after quitting smokeless tobacco use may receive this six session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
45846544|NCT04970004|Other|No intervention|No study intervention will be administered as part of this study.
46052738|NCT02805699|Drug|Placebo|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant, cough ， give Chinese medicine placebo,1 bags,P.O（Oral）twice of each 3 months cycle.
45369667|NCT00959400|Drug|Fentanyl Transdermal|Fentanest® 25 mcg/h. Each patch delivers 25 mcg of fentanyl per hour continuously for 72 hours. Therefore paches must be changed every 3 days.
45369668|NCT02563769|Drug|Clavulanic acid|
45369669|NCT02563769|Drug|Intravenous cocaine|
45369670|NCT02563769|Drug|Placebo|
45369671|NCT00970398|Other|Infant formula supplemented with bovine milk Osteopontin|Infant formula supplemented with bovine milk osteopontin at 50% and 100% levels of that of breast milk respectively.
45369672|NCT00970398|Other|Standard infant formula|Infant formula without supplementation of bovine milk Osteopontin
45692020|NCT02994082|Behavioral|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six session telephone-based behavioral intervention for reducing alcohol use.
45692021|NCT02994082|Drug|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be based on individual participant preferences, medical history, and contraindications.
45692022|NCT02994082|Drug|Nicotine replacement therapy - nicotine lozenge|Medication selection will be based on individual participant preferences, medical history, and contraindications.
45846545|NCT04946214|Behavioral|Smart Water Bottle|Patients will be given a smart water bottle and coached on its use. The device is a 24 oz non-bisphenol A acrylic water bottle with the ability to track water consumption from the bottle, alert its users via a smartphone-based notification system, as well as visually remind patients with a light-emitting diode in the device. Participants will be alerted to drink patient-specific volumes of room temperature water 45 minutes prior to daily standard of care radiotherapy.
45846546|NCT04945122|Drug|Pitavastatin|Pitavastatin 4mg Qn
45846547|NCT04945122|Drug|Atorvastatin|Atorvastatin 20mg Qn
45846548|NCT04803630|Other|Quality-of-Life Assessment|Ancillary studies
45846549|NCT04803630|Other|Questionnaire Administration|Ancillary studies
45846550|NCT04803630|Procedure|Thermotherapy|Undergo thermal therapy
46052739|NCT04236219|Drug|ALLN-346|ALLN-346 is novel urate oxidase provided as capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
46052740|NCT04236219|Drug|Placebo|Matching placebo capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
46052741|NCT00908232|Drug|Cyclophosphamide|500 mg, p.o daily, days 1, 8 and 15 for cycles 5 to 8 cycles
46052742|NCT00908232|Drug|Bortezomib|1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8
46052743|NCT00908232|Drug|Dexamethasone|20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8
45488332|NCT01359501|Drug|Chinese medical treatment-LCH1|Start to take the powder of Chinese herb-LCH1 3g*BID just after the 1st chemotherapy, and Stop 2-3 weeks after the final cycle of chemotherapy.
45488333|NCT01359501|Drug|Placebo|Start to take the powder of Placebo 3g*BID just after the 1st chemotherapy, and stop 2-3 weeks after the final chemotherapy.
45488334|NCT02422420|Behavioral|Financial Incentives|Use of financial incentives to promote health behaviors.
45488335|NCT03681548|Drug|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 1 patients will receive either reference or test product, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation
45488336|NCT05626452|Behavioral|PrEP Education|Education for participants regarding PrEP
45488337|NCT05626452|Behavioral|Provider training|Training for medical providers at CHCs about how to identify participants eligible for PrEP, how to perform behavioral risk assessment and discussion of PrEP, and how to prescribe PrEP and monitor PrEP
45488338|NCT05626452|Other|EMR Optimization|EMR modifications to enhance PrEP care continuum outcomes including HIV risk assessment, identification of participants eligible for PrEP, provision of PrEP education, clinical decision support tools for prescription of PrEP, and tracking of PrEP care continuum outcomes using an electronic population health management tool
45488339|NCT05626452|Other|PrEP Navigation|Use of CHC staff members to assist participants with obtaining PrEP and attending PrEP care appointments
45488340|NCT05626452|Other|Provider Audit and Feedback|Audit of provider rates of PrEP prescription and persistence among participants and regular provision of feedback to providers with their performance on these PrEP measures
45488341|NCT02417506|Other|E-OA-07 (Lanconone)|
45488342|NCT02417506|Drug|Ibuprofen|
45488343|NCT05188911|Drug|Abiraterone|Patients would be treated with 1000mg abiraterone qd.
45488344|NCT05188911|Drug|Prednisone|Patients would be treated with 5mg prednisone bid.
45488345|NCT05188911|Drug|Androgen deprivation therapy|Patients would get medical or surgical castration.
45692023|NCT02994082|Drug|Nicotine replacement therapy - nicotine gum|Medication selection will be based on individual participant preferences, medical history, and contraindications.
46052744|NCT00908232|Drug|Lenalidomide|10 mg orally daily, days 1-14 for cycles 5 to 8
45369673|NCT00959478|Behavioral|Educational Tool & Carbon Monoxide Alarm|Based on the recommendations from the expert panel and focus group meetings, Fast Facts about Carbon Monoxide was developed to be an educational tool aimed at helping parents understand the dangers of CO and the need CO alarms in every home. In addition, this tool will help parents select and purchase the correct CO alarm, as well as properly install and maintain the alarm in their home. Each parent assigned to the intervention group will be given a Fast Facts about Carbon Monoxide educational tool and a Kidde Nighthawk Carbon Monoxide Alarm at enrollment.
45369674|NCT03937908|Drug|2g Centella asiatica water extract product|2g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
46052745|NCT05545761|Other|music therapy|Feedback will be received via WhatsApp that the participants have listened to the maqam conveyed to them.Before applying music therapy in the experimental group, they will be asked to fill out the questionnaires.At the end of the music therapy application, the questionnaires made at the beginning will be applied to the experimental group again.No application will be made to the control group, and data collection forms will be applied twice with an interval of 4 weeks.
45488346|NCT03676946|Drug|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
45488347|NCT03676946|Drug|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
45488348|NCT03676946|Drug|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
45692024|NCT02994082|Drug|Bupropion sustained release|Medication selection will be based on individual participant preferences, medical history, and contraindications.
45692025|NCT02994082|Drug|Varenicline|Medication selection will be based on individual participant preferences, medical history, and contraindications.
45488349|NCT02426242|Other|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, ISS, clinical exam at time of extubation, extubation failure, tracheotomy, will be collected during ICU stay.
45488350|NCT03352453|Drug|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
45488351|NCT03352453|Drug|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
45488352|NCT03623438|Behavioral|Self-administered acupressure group|Subjects in the self-administered acupressure group will attend an acupressure training course (2 sessions, 2 hours each) to learn self-administered acupressure, which will then be performed every night for 4 weeks.
45488353|NCT03623438|Behavioral|Sleep hygiene education (SHE) group|Subjects in the comparison group will receive sleep hygiene education (2 sessions, 2 hours each, same as the treatment group) and be reminded to follow the sleep hygiene practice daily for 4 weeks.
45488354|NCT03128931|Device|Pediatric SedLine forehead EEG sensor|Pediatric EEG sensor.
45488355|NCT02417662|Radiation|Radical Radiotherapy (Conventional RT and SABR)|Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases
46052746|NCT00770341|Drug|Daptomycin 4 mg/kg|MK3009 (daptomycin) once daily by intravenous (IV) drip, 4 mg/kg for 7-14 days for skin and soft tissue infections (SSTI)
46052747|NCT00770341|Drug|Comparator: vancomycin|vancomycin 1g, twice daily (b.i.d.) by IV drip, for 7-14 days
45488356|NCT02417662|Other|Non-investigational SACT|There is no intervention in the control group, patients will receive SACT. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.
45369675|NCT03937908|Drug|4g Centella asiatica water extract product|4g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
45488357|NCT03676790|Other|Group I|"Group I In the first month, continuous ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the ultrasound treatment, the following parameters were used: frequency of 1 MHz, intensity of 1.5 W/cm2 (temporal and spatial mean SATA), duty cycle of 100%, with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
45488358|NCT03676790|Other|Group II|"Group II In the first month, pulsed ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
45488359|NCT03676790|Other|Group III|"Group III In the first month, the continuous ultrasound was applied 3 times a week. In the second month, 3 times a week, the continuous ultrasound was applied associated with exercises. The parameters were used: frequency of 1 MHz, intensity of 1.5 w / cm2 (temporal and spatial mean SATA), continuous mode (100%), with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
45488360|NCT03676790|Other|Group IV|"Group IV In the first month, the pulsed ultrasound was applied three times a week. In the second month, three times a week, the pulsed ultrasound associated with exercises was applied. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 Minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
45488361|NCT03676790|Other|Group V|"Group V Patients received only exercise sessions three times a week for two months.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
45488362|NCT01363167|Dietary Supplement|400 IU Cholecalciferol- Vitamin D Daily|Infants who are defined as vitamin D deficient at birth will be randomized to receive either 400 IU vitamin D/day or placebo daily until term age is reached.
45488363|NCT03710707|Drug|DNL201|Oral repeating dose
45488364|NCT03710707|Drug|Placebo|Oral repeating dose
45488365|NCT03107052|Drug|Fremanezumab|Fremanezumab
46052748|NCT00770341|Drug|Daptomycin 6 mg/kg|MK-3009 (daptomycin) once daily by intravenous drip, 6 mg/kg for 14-42 days for septicemia or right-sided infective endocarditis
46052749|NCT03813420|Behavioral|Pittsburgh Sleep Quality Index (PSQI)|"The sleep quality was evaluated through the Turkish version of the PSQI containing 19 self-rated questions searching the sleep quality during the previous month. It has seven components as subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction.~Each component is scored from 0 to 3, and the Global Pittsburgh Quality of Sleep (PQS) score is the sum of the scores of the seven components that is between 0 and 21. The higher Global PQS scores indicate poor sleep quality and the cut off score for poor sleep is 5 and over."
46052750|NCT03813420|Behavioral|International Physical Activity Questionnaire (IPAQ)|The physical activity of the participants was assessed through the Turkish version of the International Physical Activity Questionnaire -Short Form (IPAQ-SF), which includes 6 questions searching the frequency (days per week) and duration (hours) of walking, as well as low, moderate and vigorous physical activity that they engaged in during the last seven days prior to survey. Vigorous physical activity, defined by the questionnaire, referred to intense exercise that resulted in very rapid breathing and an elevated heart rate (e.g. intense weight lifting, aerobics, running, and cycling). Moderate physical activity was defined as less intense exercise that slightly heightened breathing and heart rate (e.g. less exertive cycling, fast walking, and light weight lifting).
45369676|NCT00964470|Device|AWBAT™-D and XEROFORM™ OR GLUCAN II™ dressings|Dressing, donor site dressings
45369677|NCT00689273|Drug|PF-04136309|125 mg capsules. Dose will be 4 capsules BID for 2 weeks for a total of 500 mg for each dosing interval.
45369678|NCT00689273|Drug|Placebo|Placebo will be matched to PF-04136309. Dose, frequency, and duration same as PF-04136309.
45369679|NCT00959556|Other|laboratory biomarker analysis|
45369680|NCT00959634|Drug|ABT-126|Dose administered twice daily on Study Days 1-10
45369681|NCT00959634|Drug|Placebo|Dose administered twice daily on Study Days 1-10
45488366|NCT01359579|Drug|varespladib methyl|Single oral 500 mg dose
45488367|NCT02422654|Drug|eliglustat|"Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion"
45488368|NCT05668793|Diagnostic Test|GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescent PCR Method)|Blood samples from participants in the group were collected and methylation tests were performed according to the kit instructions.
45488369|NCT05188833|Device|Deep Transcranial Magnetic Stimulation|Deep TMS, unlike traditional TMS, is a treatment method that provides stimulation of lower parts of the brain and larger brain volume, in addition to drug treatment and psychotherapy approaches, in addition to localized brain regions magnetic stimulation is a treatment method where disease symptoms are addressed.
45488370|NCT05188833|Drug|Paroxetine|Paroxetine is a type of antidepressant known as an SSRI (selective serotonin reuptake inhibitor). It's often used to treat depression.
45488371|NCT02426164|Drug|Liposomal bupivacaine|Periarticular infiltration of the liposomal bupivacaine with 20cc of normal saline
45488372|NCT02426164|Drug|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone
45488373|NCT03640013|Procedure|Hall Technique PMC|Hall Technique primary fitted crowns to restore carious primary molars
45488374|NCT02417428|Dietary Supplement|Citrulline|Twelve weeks of citrulline oral supplementation will be taken by half of the participants (other are taken a placebo). Citrulline supplementation will be taken orally. Ten grams of citrulline (white powder) will be mixed with a liquid daily. Supplementation will be consumed once at lunch time.
45488375|NCT02417428|Other|Placebo|Twelve weeks of oral placebo will be taken by half of the participants. Ten grams of placebo (maltodextrin white powder) will be mixed with a liquid and will be consumed once daily at lunch time.
45488376|NCT02417428|Behavioral|Exercise|Participants will also take part in twelve weeks of HIIT (30s at 85% and up of maximal heart rate + 1m30sec at 60-75% of maximal heart rate (HR max). 3 times/ week during 30 continuous minutes. Each period are supervised and monitored using borg scale and polar system.
45488377|NCT02417428|Other|without exercise|No exercise program will be assigned to participants.
45488378|NCT02015897|Procedure|Physical TherapyA|"Group A:~Skin care~Manual lymphatic drainage~Bandaging using Coban™2Lite~Guidance on physical activity"
45846551|NCT04725396|Device|Mandibular Reconstruction (MR) with Preoperative Virtual Planning (PVP).|PVP-assisted mandibular reconstruction includes the production of the surgical cutting guides required for mandibular resection and fibula free-flap conformation and of the preformed plates for flap osteosynthesis (for all patients, PVP will be done by the same laboratory).
46052751|NCT03813420|Behavioral|The Short Form 36 Health Survey (SF-36)|The Turkish version of SF-36 was used to understand the health related quality-of -life (HRQOL) of the participants over the past four weeks in eight health concepts: limitations in physical activities because of health problems; limitations in social activities because of physical or emotional problems; limitations in usual role activities because of physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities because of emotional problems; vitality (energy and fatigue); and general health perceptions. Additionally, the psychometric evaluation of the SF-36 generated two summary scores as the Mental Health Component Score and the Physical Health Component Score that the higher scores indicate better HRQOL.
45369683|NCT00970554|Other|Patching|Patching of the sound eye for 30 minutes a day for 17 weeks.
45369684|NCT00970554|Other|Telescopic magnification|Patching of the sound eye plus simultaneous use of a telescopic device by the amblyopic eye for 30 minutes a day for 17 weeks.
45369685|NCT00959790|Dietary Supplement|Vegetables|200 or 50 grams of vegetables daily for four weeks
45369686|NCT00959790|Dietary Supplement|energy restriction|Consume about 1000 kcal less daily, for four weeks, as a positive control to the vegetables interventions.
45488379|NCT02015897|Procedure|Physical TherapyB|"Group B:~Skin care~Bandaging using Coban™2Lite~Guidance on physical activity"
45488380|NCT04249674|Diagnostic Test|Dextrometorphan|Administration of 4 ml=10 mg of Dextrometorphan (Bexine sirup)
45488381|NCT04249674|Genetic|Genotyping by single nulcetoide polymorphism.|Single nucleotide polymorphism determination
45488382|NCT03745157|Drug|Insulin Degludec/Insulin Aspart|Patients will be treated with commercially available Insulin Degludec/Insulin Aspart (Ryzodeg®) in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the treating physician in accordance with the Ryzodeg® label in Japan
45488383|NCT02426008|Other|Growth Factors and Cytokine adding to embryo culture media|
45488384|NCT02426008|Other|No Intervention|Nothing to Add
45846552|NCT04725396|Device|Conventional Mandibular Reconstruction (MR without PVP)|Conventional Mandibular Reconstruction
45846553|NCT04445064|Biological|IO102|100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
45488385|NCT04050371|Drug|200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate|All study participants received daily observed therapy with FTC/TDF.
45488386|NCT04189536|Other|SMS Intervention|Delivery of text messages will use the Rip Road Mobile platform.
45488387|NCT04183764|Drug|MAX-40279-01|"Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
45488388|NCT04447287|Drug|ASP8062|Oral
45488389|NCT04447287|Drug|Placebo ASP8062|Oral
45488390|NCT04447287|Drug|buprenorphine/naloxone|Sublingual
45488391|NCT01879319|Biological|Evolocumab AMD|Evolocumab subcutaneous injection using a single use, disposable AMD containing 3.5 mL deliverable volume.
45488392|NCT01879319|Biological|Evolocumab AI/pen|Evolocumab subcutaneous injection using a handheld mechanical (spring-based) prefilled AI/Pen, each containing 1.0 mL deliverable volume.
45369687|NCT04059575|Other|Kinesio Taping (Performance Plus)|PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
45369688|NCT04059575|Other|Kinesio taping (Gold Tex)|PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
45369689|NCT00964626|Drug|cisplatin|
45369690|NCT00964626|Drug|paclitaxel|
45369691|NCT02562209|Dietary Supplement|PACER Diet|Pacer diet to be followed for 8 weeks
45369692|NCT02562209|Other|Standard weight reducing diet|Standard weight reducing diet to be followed for 8 weeks
45369693|NCT00749333|Drug|AZD8566|solution. Specific dose will be selected by the safety review committee
45369694|NCT00749333|Drug|Placebo|Single 10ml oral solution.
45369695|NCT02562287|Drug|Clozapine|Flexible dosage, with up-titration according to standard schedules employed for schezophrenia
45369696|NCT02562287|Drug|Risperidone|Risperidone, in a flexible dosage
45488393|NCT04165122|Biological|HDIT101|i.v. Infusion
45488394|NCT04165122|Drug|Valaciclovir|oral application of encapsulated Valaciclovir tablets
45488395|NCT04165122|Biological|HDIT101 placebo|i.v. Infusion
45488396|NCT04165122|Drug|Valaciclovir placebo|oral application of encapsulated Valaciclovir placebo tablets
45488397|NCT02417350|Other|Ketogenic diet for four weeks, then a 15 week washout, and finally a NFA recommended diet for four weeks|
45488398|NCT02417350|Other|NFA recommended diet for four weeks, then a 15 week washout, and finally a ketogenic diet for four weeks.|
45488399|NCT02422030|Drug|Lipitor Tab. 40mg|
45488400|NCT02422030|Drug|Trilipix 135mg|
45488401|NCT04159350|Device|Rectal Expulsion Device (RED) - Feasibility|"After a complete physical exam at bedside including a digital rectal exam, the patient is turned on their side and RED is gently inserted into the rectum. The patient is then given one minute to expel RED while remaining on their side. If the patient is unable to pass RED, the patient transfers to a commode and attempts to expel the device. If the device is not expelled, the device can be safely removed at bedside and the patient diagnosed with a biofeedback-responsive evacuation disorder.~The RED device is manufactured by Rose Medical (Grand Rapids, MI) under GMP conditions and final assembly is performed by In2Being (Saline, MI). The device contains accepted technologies that are already in use of humans, namely biomedical grade materials."
45488402|NCT04159350|Device|Rectal Expulsion Device (RED) - Validation|"After a complete physical exam at bedside including a digital rectal exam, the patient is turned on their LEFT side and RED is gently inserted into the rectum. The patient then attempts to expel RED while remaining on their side. If the patient is unable to pass RED, the patient transfers to a commode and attempts to expel the device. If the device is not expelled, the device can be safely removed at bedside and the patient diagnosed with a biofeedback-responsive evacuation disorder.~The RED device is manufactured by Rose Medical (Grand Rapids, MI) under GMP conditions and final assembly is performed by In2Being (Saline, MI). The device contains accepted technologies that are already in use of humans, namely biomedical grade materials."
45369697|NCT02562287|Drug|Olanzapine|Olanzapine, flexible dosage
45369698|NCT02562287|Drug|Quetiapine|Quetiapine, flexible dosage
45369699|NCT02562053|Drug|Fluoxetine|Women will receive oral fluoxetine 20 mg daily.
45369700|NCT02562053|Drug|Combined oral contraceptives|women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation
45369701|NCT02562053|Drug|Placebo 1|Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
45369702|NCT02562053|Drug|Placebo 2|Women will receive a daily oral placebo similar to fluoxetine
45369703|NCT00746915|Device|EpiDetect|During the epidural needle insertion, data will be collected to characterize in real-time the electrical bioimpedance properties of the types of tissue along the path of the needle.
45369704|NCT02563223|Other|Parabolic flight|
45369705|NCT02563223|Device|Subject Loading System|a device that combines a force platform on which the subject jumps and a Subject Loading System (SLS) that pulls the subject downwards.
45369706|NCT00746993|Other|Structured contraceptive counseling|Uniform set of visual information about contraception which a counselor will read out loud with each participant and answer questions.
45369707|NCT04060433|Behavioral|Family Therapy|Swedish version of the evidence based manualized Family Therapy
45369708|NCT04060043|Drug|Goserelin Acetate|The Pepti 10.8mg (goserelin acetate) implant is supplied as a cylindrical rod of biodegradable and biocompatible D, L Lactic and glycolic acids copolymer. Each implant contains goserelin acetate equivalent to 10.8mg of goserelin as well as a blend of high and low molecular weight range of D, L lactic and glycolic acids copolymer to total a weight of approximately 36.0mg per depot. The implant will be injected subcutaneously through the patient's anterior abdominal wall.
45369709|NCT00553358|Drug|Lapatinib|Small molecule receptor tyrosine kinase inhibitor
45369710|NCT00553358|Biological|Trastuzumab|Therapeutic Monoclonal Antibody
45369711|NCT00553358|Drug|Paclitaxel|antimicrotubule agent
45369712|NCT00744809|Drug|TMC278; Moxifloxacin; Efavirenz|
45692026|NCT02994082|Drug|Combination nicotine replacement therapy|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + nicotine lozenge and nicotine patch + nicotine gum.
45692027|NCT02994082|Drug|Combination nicotine replacement therapy + bupropion|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + bupropion, nicotine gum + bupropion, and nicotine lozenge + bupropion.
45369713|NCT00688259|Behavioral|Supportive Therapy (ST)|approximately 20 sessions of manualized psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to recovery
45369714|NCT00688259|Behavioral|Cognitive Behavioral Therapy for Psychosis (CBTp)|approximately 20 sessions of individual manualized psychotherapy in which participants are taught to evaluate the data supporting beliefs that may interfere with recovery
45369715|NCT00749489|Procedure|Femoral Nerve Block|Patients assigned to the intervention group will have a femoral nerve block administered by the attending emergency department physician. Twenty-four hours after the femoral nerve block or at the time of surgery, an anesthesiologist will insert a continuous fascia iliaca block. Both procedures (femoral nerve block and fascia iliaca blocks) are standard anesthetic techniques that are used in orthopedic procedures but their efficacy as compared to standard opioid therapy has not been evaluated in controlled clinical trials in hip fracture. The medications that will be used in each procedure are as follows: 1) femoral nerve block: 0.5% bupivacaine with 1:300,000 epinephrine; 2) fascia iliaca block: 0.2% ropivacaine will be infused at 5ml/hr.
45369716|NCT00744887|Drug|Darunavir|
45369717|NCT04059029|Procedure|Bariatric surgery|During bariatric surgery, all patients would undergo a wedge liver biopsy under laparoscopic guidance.
45369718|NCT02286830|Drug|Zoledronic acid|Zoledronic acid will be given to all participants for two years. Then patients will be randomized to A receive 2 more years of treatment or B stop treatment.
45369719|NCT00688181|Device|The Prefyx PPS™ Pre-pubic Sling System|device designed to treat female stress urinary incontinence (SUI).
45369720|NCT02563535|Device|DEB|angioplasty with Litos drug eluting balloon
45369721|NCT02563535|Device|PTA|angioplasty with conventional balloon
45846554|NCT04445064|Biological|IO103|100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
45846555|NCT04227366|Biological|BCD-089|BCD-089 162 mg SC
45369722|NCT00749567|Drug|Erlotinib|Erlotinib 150mg daily, continuously, until disease progression or the appearance of unacceptable toxicity
45369723|NCT00749567|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression or the appearance of unacceptable toxicity
45369724|NCT04010942|Drug|Vit D|Injection
45369725|NCT04010942|Drug|Metformin|tablets
45692028|NCT02994082|Behavioral|Tobacco quit line|Referral to the Department of Veterans Affairs tobacco telephone quit line.
45369726|NCT04010942|Drug|Clomiphene|Tablet
45369727|NCT00749645|Drug|FANG(30)|Andrographolide formula Oral tablets, 30mg, three times per day, during a total of 105 continuous days.
45369728|NCT00749645|Drug|Placebo|Placebo 30mg tabs, 3/day, 105 days continuously.
45369729|NCT00949364|Drug|Pomalidomide|"Treatment starts with pomalidomide as single agent therapy: 0.5 mg/day. Prednisolone will be started in the absence of PD as randomized either at start of cycle 4 or start of cycle 7 (starting dose: 30 mg/day for 28 days followed by 15 mg/day and 10 mg/day for 28 days), if no response acc. to IWG-MRT (no CR, PR, CI, TI) was achieved.~If PD: treatment is stopped. Otherwise, continuous treatment at least until end of cycle 12 is intended. For patients responding to the combination treatment (pomalidomide/prednisolone) a concom. treatment after cycle 6 or 9 (depending on the randomization result) with prednisolone in doses equal or below 7.5 mg/day are allowed.~If a patient may benefit from treatment with pomalidomide the invest. and the PI will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision (max. duration: 12 cycles)."
45692029|NCT02994082|Behavioral|Educational materials|Information regarding the VA tobacco quit line and associated treatment services, self-help materials for tobacco cessation, and information about tobacco cessation medications available in the VA,
45846556|NCT04227366|Biological|Placebo|Placebo
45846557|NCT04227366|Drug|Methotrexat|15 to 25 mg/week
45846558|NCT04113252|Other|Possible Incentive for Tablet Return|Subjects who return completed diary will have the possibility to receive money for returned opioid tablets.
45369730|NCT01634048|Dietary Supplement|High Protein, low calorie meal replacement|The high protein group will have meal replacements with added protein powder (to achieve 1.34g protein/kg body weight) and the control group will have standard meal replacements (0.8g protein/kg body weight). Meal replacements have been used in hundreds of previous human studies and are generally not found to be linked to any serious adverse effects.
45692030|NCT01270048|Drug|mild-ex-gwarip|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
45692031|NCT01270048|Other|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
45692032|NCT02995096|Procedure|Pre-treatment|Non-transplantation pre-treatments prior to transplantation (e.g. radiofrequency ablation, transcatheter arterial chemoembolization)
45692033|NCT02995096|Drug|Sirolimus based immunosuppression|Immunosuppression regimens containing Sirolimus
45692034|NCT02993848|Other|No intervention|
45692035|NCT01275820|Dietary Supplement|Nutralin|Food product to be taken 15 minutes prior to each of the three main meals of the day.
45692036|NCT02993536|Other|Biospecimen Collection|
45692037|NCT02993770|Procedure|Endoscopic DCR|Endonasal endoscopic technique as described by Wormold et al.
45692038|NCT02993770|Procedure|External DCR|External DCR
45488403|NCT05668715|Other|Transcutaneous tibial nerve stimulation (TTNS)|PTNS has some disadvantages such as it is a minimally invasive method applied by needle, and the need to go to the hospital for this. However, the number of studies on transcutaneous tibial nerve stimulation (TTNS) (non-invasive and can be applied at home) tends to increase in recent years
45488404|NCT04158726|Behavioral|modified Geriatric Assessment (mGA)|The mGA, administered via patient self-report on a touchscreen computer, as well as the real-time use and utility by clinicians and the correlation of mGA results on treatment decision-making.
45488405|NCT02425930|Procedure|gastrectomy plus D2 lymphadenectomy|A classic total or subtotal gastrectomy plus D2 lymph nodes dissection would be performed for all enrolled patients. Patients in both groups would undergo the identical therapeutic approach for gastric cancer, mainly decided by a multidisciplinary treatment group in our center.
45488406|NCT02425930|Drug|S-1+Oxaliplatin|"A postoperative systemic chemotherapy would be performed for some subjects who have advanced gastric cancer. The concrete chemo regimen for adjuvant chemotherapy is also determined by a MDT group. Generally, SOX chemo regimen is the first-line treatment in our center, as following described:~S-1: 40~60mg bid，po, Day1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid）~Oxaliplatin: 130mg/m2，iv drip for 2h，Day1"
45488407|NCT03685682|Biological|recombinant subunit Herpes zoster vaccine|Seronegative Solid Organ Transplant patients will receive two doses of the subunit Herpes zoster vaccine at 0 and 2-6 months
45488408|NCT01365897|Drug|Modafinil|Modafinil 200mg
45488409|NCT02422108|Drug|Denosumab|
45488410|NCT03685604|Drug|CHX disinfection|CHX (Softasept® Chlorhexidine solution 2% coloured, from B. Braun Medical AG) is applied three times on the patient's skin with the use of swabs. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
45488411|NCT03685604|Drug|PI Disinfection|PI (Braunoderm® from B.Braun or Betaseptic® from Mundipharma) is applied prior to surgery on the patient's skin with the use of swabs. The product is applied three times. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
45692039|NCT00709306|Device|UV-Detect Photos|UV-Detect Photos
45692040|NCT00709306|Behavioral|Motivational Interviewing|Motivational Interviewing
45692041|NCT00709306|Behavioral|Education|Education
45846559|NCT04113252|Other|Incentive for Completed Diary|Subjects who return completed diary will receive a gift card.
45846560|NCT04113252|Behavioral|Coaching|Subjects will receive coaching prior to starting pain medication.
45369731|NCT00689117|Drug|CT Gel|Topical gel consisting of clindamycin 1% and tretinoin 0.025%, applied once daily in the evening for 12 weeks
45369732|NCT00689117|Drug|Clindamycin Gel (clindamycin )|Clindamycin 1% gel applied topically once daily in the evening for 12 weeks
45846561|NCT04087122|Device|Esophageal warming device (Attune Medical, Chicago, IL|Prospective, single center pilot stud
45369733|NCT00689117|Drug|Tretinoin Gel (tretinoin)|Tretinoin 0.025% gel applied topically once daily in the evening for 12 weeks
45369734|NCT00689117|Drug|Vehicle Gel|Topical gel without clindamycin or tretinoin applied topically once daily in the evening for 12 weeks
45369735|NCT01266044|Procedure|Acupuncture - Group 1|Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment.
45369736|NCT01266044|Procedure|Acupuncture - Group 2|Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment.
45369737|NCT01266044|Other|Standard Care|Standard oral care recommendations. Participants in all groups will receive the same recommendations.
45369738|NCT01266044|Other|Questionnaire|Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
45692042|NCT01275976|Drug|C1-esterase inhibitor|C1-esterase inhibitor 200 U/kg infusion over 30 minutes, just before the start of the femur or pelvic fixation operation.
45692043|NCT01275976|Other|Saline 0.9%|Infusion, just before the start of the femur or pelvic fixation operation
45692044|NCT00725530|Device|balafilcon A contact lens (PureVision)|Commercially marketed, silicone hydrogel contact lens
45692045|NCT00725530|Device|etafilcon A contact lens (Acuvue2)|Commercially marketed, hydrogel contact lens
45692046|NCT01270360|Device|COLOHYBRITEST OR VALIHYBRITEST|Detection of human colon or rectal tumours by using a simplified molecular test based on either a combination of methylated DNA or protein marker(s) alone or considered together in biological fluids like blood, urine and stools
45369739|NCT00949442|Drug|Insulin Glargine (HOE901) [Lantus]|100 Units/ml solution for injection in a pre-filled pen SoloStar® (3 ml)
45488412|NCT03685526|Device|Cinenses Lung Volume Reduction Reverser System|Lung Volume Reduction Reverser System is show as figure 1-4, consists of lung volume reduction reverser (short as: reverser), conveyor, measuring guide wire and transporting sheath. Matrix of reverser is nickel titanium alloy, its surface is coated by polymer flexible film, at the end of the connection segment is specially designed connector, which is easy for the reverser's transport and recycling. The silica gel part at the far end of reverser makes it softer.
45369740|NCT00949442|Drug|Glimepiride|tablets of 1 and 2 mg
45369741|NCT00949442|Drug|human insulin [NPH]|100 IU/ml suspension for injection in a prefilled pen OptiSet® (3 ml)
45488413|NCT02422342|Device|Pulse Oximeter CMS50FW (Contec Medical)|"The patients will be wearing the pulse oximeter during the test period (20-30 minutes).~The data from the oximeter will be sent by Bluetooth to the mobile application"
45488414|NCT01359657|Biological|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 42 days (cycle 1) 28 days subsequent cycles
45488415|NCT01359657|Biological|Lenalidomide|Tablets, per os (by mouth route of administration) (P.O), 25 mg, daily for 21 days (Day 15-35 in cycle 1; Day 1-21 in subsequent cycles), no dosing in Cycle 1, Cycle 2 +:daily dosing from Day 1-21
45488416|NCT01359657|Biological|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered with Lenalidomide once every 7 days, 42 days (cycle 1) 28 days subsequent cycles
45488417|NCT01359657|Biological|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 35 days (cycle 1) 21 days subsequent cycles
45488418|NCT01359657|Biological|Bortezomib|Intravenous (IV), 1.3 mg/m2, administered on day 15, 18, 22, 25 in cycle 1, then on Day 1, 4, 8, 11 in subsequent cycles, no dosing in Cycle 1, Cycle 2 +:dosing on Day 1, 4, 8, 11
45488419|NCT01359657|Biological|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered on the day of (and the day after) Bortezomib infusion, 35 days (cycle 1) 21 days subsequent cycles
45488420|NCT02417116|Other|Tear supplement|Application as required to improve comfort
45488421|NCT02417116|Other|Tear supplement 2|Application as required to improve comfort
45488422|NCT02417116|Dietary Supplement|Omega 3 nutrition supplement|Taken each day
45488423|NCT02417116|Device|Eye bag|Applied following microwave heating to closed eyelids for 5 minutes each day
46052752|NCT02803905|Biological|Biological: Islet transplantation|This is a single procedure protocol. Only a single islet transplant will be performed in the patient. Islets can be isolated from more than one pancreas donor. The final islet product is a sterile suspension of ≥70% viable, ≥30% pure, allogeneic islets. A minimum of 5000 IEQ/KG will be transplanted. Although this study is a single dose protocol, islet transplant recipients with partial islet graft function will be considered for a second islet transplant (intra-hepatic administration) if they do not achieve primary efficacy endpoint criteria at 1 year
45369742|NCT00749723|Drug|carboplatin|200 mg/m²/d continuously IV on day 1-4 of each 21-28-day-cycle. Number of cycles: until disease progression, maximum 4 cycles
45488424|NCT02417116|Other|Saline|Application as required to improve comfort
45488425|NCT03685370|Procedure|LOS|placement of epidural catheters with LOS technique
45488426|NCT03685370|Procedure|X-ray placement|placement of epidural catheters with x-ray guide
45488427|NCT05416398|Other|Aerobic Exercise, High Intensity Interval Training|Aerobic exercise is a form of exercise done by consuming oxygen in order to give energy to the body. High Intensity Interval Training consists of low-intensity periods of active rest combined with short periods of intense exercise.
45692047|NCT01270438|Drug|FOLFOX regimen|Given IV
45692048|NCT01270438|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
45692049|NCT01270438|Biological|bevacizumab|Given IV
45692050|NCT01270438|Drug|oxaliplatin|Given IV
45692051|NCT01270438|Drug|leucovorin calcium|Given IV
45692052|NCT01270438|Drug|fluorouracil|Given IV
45369743|NCT00749723|Drug|etoposide|100mg/m²/d continuously IV on day 1-4 of each 21-28 day cycle. Number of cycles: until disease progression, maximum 4 cycles
46052753|NCT02601547|Device|PET-FDG brain imaging and NPT|PET-FDG brain imaging and NPT should be performed at T0, at Tf (within 1 month after chemotherapy termination), T+12. Several PET parameters should be calculated: minimal SUV (Standard Uptake Value), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.
46052754|NCT02804217|Other|Genetic: mutation profile|
45369744|NCT00749723|Drug|temozolomide|150mg/m²/d p.o. on day 1-5 of a 21-28-day-cycle. Number of cycles: until progression or maximum up to 2 years
45369745|NCT00749723|Drug|thiotepa, carboplatin, etoposide|high dose chemotherapy followed by to autologous stem cell transplantation
45692053|NCT01270594|Behavioral|COPD Inhaler Counseling|The counseling will be performed via telephone by a pharmacist at the William S Middleton Memorial Veterans Hospital. The counseling will include education about inhaled COPD medication, inhaler technique review, reminder tools, and motivational interviewing.
45488428|NCT03685292|Behavioral|Behavioral Advisory System|Support and training to help increase throughput while promoting upstanding stature and reproducibility in behavioral testing using cutting edge methodologies.
45488429|NCT03685292|Drug|Behavioral Treatment|This study addressed the efficacy of cognitive-behavioral therapy (CBT) treatment.
45488430|NCT03685292|Device|Behavioral Division|This study is relative to minimal contact control (MCC).
45488431|NCT05416164|Radiation|Omission of radiotherapy|Omission of radiotherapy
45488432|NCT03177694|Device|Wireless bed sensor|Remote data collection
45488433|NCT01363245|Behavioral|Telephone Counseling|Telephone counseling: 7 calls over 6 weeks
45488434|NCT01363245|Behavioral|Fax-to-quit|referral to state smoking cessation 'quitline' for counseling - 1 call over 2 weeks
45488435|NCT05416086|Device|cryoablation procedure using the iCLAS Cryoablation System|all subjects will receive a cryoablation procedure using the iCLAS Cryoablation System (catheter, stylets, and console) and warming balloon
45488436|NCT03685214|Drug|0.9% saline|we use 0.9% saline in ICU patients with sepsis for resuscitation fluid.
45488437|NCT03685214|Drug|lactated Ringer's solution|we use balanced balanced crystalloids in ICU patients with sepsis for resuscitation fluid.
45488438|NCT01359813|Drug|Human Albumin|Administration: 1,5 g/kg at Day 1 and 1g/kg at Day 3 In case of a new infection appears in the 3 months, the same doses will be administrated.
45488439|NCT03183310|Drug|Chlorpromazine|an intravenous bolus injection of Chlorpromazine will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of dopamine antagonism on esophageal sensitivity
45488440|NCT03183310|Device|Multimodal stimulation probe|The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
46052755|NCT02691000|Device|LiteBook|Light therapy using a Bright White Light Litebook for 1 hour each morning for 8 weeks. This is the experimental intervention.
45488441|NCT03183310|Drug|Placebo - Concentrate|an intravenous bolus injection of saline (NaCl 0.9%) will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation.
45488442|NCT03685058|Device|Light curable resin modified glass ionomer varnish|Treatment of non-cavitated proximal carious lesions with light curable resin modified glass ionomer varnish at initial and six-months follow-up visits, in addition, the patient will receive standard-of-care preventive measures, at initial, six-months follow-up, and 12-months follow-up visits.
45488443|NCT03685058|Other|standard-of-care preventive measures|Patient will receive standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish, oral hygiene instructions, and dietary counseling at initial, six-months follow-up, and 12-months follow-up visits
45692054|NCT01270594|Behavioral|Usual Pharmacy Care|The usual care arm will receive standard care from the William S Middleton Memorial Veterans Hospital pharmacists.
45692055|NCT01270672|Drug|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
45692056|NCT01270672|Drug|carvedilol|50 mg per os, single dose
45692057|NCT01270672|Drug|placebo|capsules identical to MDMA or carvedilol
45692058|NCT02992834|Biological|IL-2 pre-treated CD19 cells|IL-2 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
46052756|NCT02691000|Device|LiteBook|Light therapy using a Dim Red Light Litebook for 1 hour each morning for 8 weeks. This is the control.
45369746|NCT00749723|Drug|temozolomide, thiotepa|high dose chemotherapy followed by autologous stem cell transplantation
45369747|NCT00749723|Procedure|autologous stem cell transplantation|autologous stem cell transplantation following HD-chemotherapy
45369748|NCT00749723|Drug|intraventricular etoposide|prior to systemic chemotherapy as single agent in patients with neoplastic meningitis, in addition to systemic chemotherapy if proven effective in phase II study, intraventricularly age-dependent daily dose (>3m to <3y 0.7 mg; >3y 1.0 mg) for 5 days every 2 two 4 weeks. Number of cycles: at least 3 courses, maximum up to 2 years
45369749|NCT00749723|Drug|trofosfamide, etoposide|maintenance therapy: trofosfamide and etoposide: 100 mg/m²/d and 25 mg/m²/d, respectively, for 21 days every 4 weeks. Number of cycles: until progression or maximum up to 2 years
45369750|NCT00958490|Other|Walking program|4 week physical activity walking program
45369751|NCT00949520|Other|coronary dual source computed tomography (DSCT)|coronary dual source computed tomography during dipyridamole injection
45846562|NCT03963492|Other|Walking|Participants will undergo training in either the CONT or INT walking interventions 2x/week for 6 weeks for a total plan of 12 training sessions.
45846563|NCT03945162|Combination Product|Ruvidar® (TLD-1433) Bladder infusion and PDT|Ruvidar® (TLD-1433) is infused into the bladder and treatment of bladder wall with light activation.
46052757|NCT04097041|Procedure|Tympanomastoidectomy|Patient undergoes tympanomastoidectomy (approx 2 hour operation on ear and mastoid) where a local soft tissue flap is transferred to cover the sigmoid sinus, a cartilage and perichondrial graft is taken from the tragus to cover the jugular bulb).
45369752|NCT00949520|Other|myocardial single photon emission computed topography (SPECT)|myocardial single photon emission computed topography during dipyridamole injection
45369753|NCT00749801|Drug|Nattokinase|2 capsules in the morning and before bed-time daily
45369754|NCT00958646|Other|Osteopathic Manipulation|Standardized rib raising protocol
45369755|NCT00958646|Other|Placebo|Light touch control procedure
45846564|NCT03917316|Other|Language and neuropsychological tests|Tests related to language, narrative and specific and general cognitive function
46052758|NCT04097041|Procedure|Non-Surgery|"Screening performed at outpatient clinic after consultation for management of venous pulsatile tinnitus. Consent and formal recruitment into study performed at preoperative visit or at audiological visit.~The masking device is a hearing aid that provides sound that is aimed to negate the internal sound from the pulsatile tinnitus. Almost all hearing aid can be converted to a masking device for tinnitus. It is externally worn on the ear and provides sound at a desired volume. The benefits of wearing the masking device are that it may reduce the volume of the pulsatile tinnitus. As it is worn on the external ear and is not invasive there are minimal risks but potential risks could include irritation of the external ear and discomfort from wearing."
46052759|NCT04236687|Device|Holmium laser enucleation of the prostate|Holmium laser will be used to enucleate the prostatic hyperplasia trough the urethra
46052760|NCT04236687|Procedure|Artery embolization of the prostate|A catheter is placed in the prostate artery, a fluid containing thousands of tiny particles (microspheres) is injected through the catheter into these small arteries which nourish the prostate
45369756|NCT02561975|Other|Double pulmonary diffusing|"Measure of double pulmonary diffusing will be done as the single-breath test: the patient will be seated and connected to device by an oral tip. Measure begins by a maximal inhalation of a gas mixture (0.28% of CO, 14% of He, 21% of O2,450 ppm of NO/N2 and 40ppm of NO).After, the patient will maintain an apnea of 4 secondes and will breathe out in oral tip until his residual capacity.~With the expired air, some parameters will be assessed:~Alveolar volume (VA)~Membrane ductance (Dm) and pulmonar capillary volume (values adjusted by Haemoglobin)~Values of TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc"
45369757|NCT00958802|Other|Platelet-rich plasma (PRP)|PRP was extracted from total blood and TGF-b1 was used as indicator
45369758|NCT00958802|Other|Chondrocyte culture with FBS medium|Microtia chondrocyte culture with FBS medium only
45369759|NCT00547248|Biological|Synflorix|Intramuscular injection, 1 dose
45369760|NCT00547248|Biological|Tritanrix-HepB|Intramuscular injection, 1 dose
45369761|NCT00547248|Biological|Hiberix|Reconstituted with Tritanrix-Hep B before injection
45369762|NCT00547248|Biological|Polio Sabin|Oral, 1 dose
45369763|NCT00547248|Biological|Poliorix|Intramuscular injection, 1 dose
45369764|NCT00547248|Biological|Prevenar (Wyeth)|Intramuscular injection, 1 dose
45369765|NCT02562833|Device|Self-Management and exercise|Self-Management and exercise It is a 3 months intervention where the participants were enrolled two times per week, 90 minutes each session, first 30 minutes were allocated for the self-management component and the remaining 60 minutes for the exercise component. Additionally,participants received glucosamine and chondroitin sulfate supplement.
45369766|NCT02562833|Device|Educational|This group received an educational book with information about OA features, treatment modalities and exercise education with illustration. Additionally, a monthly educational session each with one hour and a half duration, in total 3, where joint protections strategies, OA self-management and exercise contents were transmitted. Additionally,participants received glucosamine and chondroitin sulfate supplement.
45369767|NCT05351060|Other|Custom Fabricated Splint|Participants will wear a customized splint on their affected hand(s)during the hours of sleep for the duration of the study.
45369768|NCT05350982|Device|SalivaBio +/- SaliPac|Sterile collection swab (SalivaBio), Modified dummy (SaliPac)
45369769|NCT00688103|Drug|ETN Alone|etanercept (25 mg, twice/week, s.c.)
45369770|NCT00688103|Drug|ETN+MTX|etanercept (25 mg, twice/week, s.c.) combined with methotrexate (6-8 mg/week)
45369771|NCT00949598|Drug|letrozole|Given orally
45369772|NCT00949598|Drug|tamoxifen citrate|Given orally
46052761|NCT02803827|Other|Rapid diagnostics|Participants will have enteric specimens obtained using a flocked rectal swab, which will be transported in 2 mL Cary Blair medium. These will be tested using the BioMerieux BioFire FilmArray GI panel.
45488444|NCT05415930|Other|Psychosocial assistance|Firs evaluation at Acceptess-T locals by a health mediator specialised in transidentity : advice for administrative procedures (health insurance, residency permit, housing, etc.) management of others social issues Orientation to Acceptess-T sexual health space for medical evaluation Orientation to Acceptess-T mental health space if needed : special focus on sexual health and gender related issues
45488445|NCT05415930|Other|Medical care|Sexual health clinics at Acceptess-T health space First STI risk evaluation: HIV, HCV, HBV, syphilis TROD realisation Spanish speaking Infectious Diseases (ID) specialist (from ID Department of Bichat hospital) first evaluation Proposition of PrEP if indicated Orientation for hospital follow-up in dedicate PrEP clinics Prescription and follow-up of a feminazing hormonal therapy if needed
45488446|NCT05415930|Other|Legal-Administrative Assistance|Legal counselling, provided by a sex worker union representative Access to FAST (fond action social trans) which give an economic help to TW in high precarity situations
45488447|NCT05415930|Other|Focus Group|"A group of 10-15 TW, identified through convenience sampling, along with the Acceptess-T Health Space multidisciplinary team will be invited to participate in an Human Centered Design (HCD) project.~The project will be led by a team of anthropologists and sociologists and exchanges will be recorded and fully transcribed and analysed by a person competent in qualitative methodology.~The objective will be to co-create tailored solutions that meet the needs of TW and are viable to implement within the health system, so TW can be better managed The solutions ideated will work synergistically towards improving TW PrEP access and adherence and health system retention.This is an adaptative program : if new solutions to face PrEP barriers are created during the study follow-up, new mesures will be added to the intervention."
45488448|NCT03177850|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
45488449|NCT03177850|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
45488450|NCT03102918|Drug|Cannabidiol|Participants will receive either up to 800 mg Epidiolex over a 6-week treatment period.
45488451|NCT03102918|Drug|Placebo|Participants will receive placebo over a 6-week treatment period.
45488452|NCT03676712|Device|scoliosis brace|Wear at least 18 hours a day
45488453|NCT03684902|Procedure|emergency midline exploratory laparotomy|Once an adequate level of anesthesia has been reached, the initial incision into the skin may be made. A scalpel is first used to cut into the superficial layers of the skin.with the diathermy The incision is then continued through the subcutaneous fat, the abdominal muscles, and finally, the peritoneum. (Morris J ;2017) For all the patients, closure of midline laparotomy wound was en-mass closure done with non-absorbable No. 1 (Polypropylene) or slowly absorbable (PDS) (double loop). sutures in continuous single layer fashion with 1 cm interval. (Morris J ;2017) The operative details were recorded with special consideration to the operative diagnosis, presence and types of adhesions, duration of surgery, the need for diversion and stoma formation, the use of intraperitoneal drain and the suture material to close the rectus sheath.
45488454|NCT03183154|Other|no intervention|no intervention
45692059|NCT02992834|Biological|IL-7/IL-15 pre-treated CD19 cells|IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
45488455|NCT03128307|Device|Zyppah Anti-snoring Appliance|Use of an OTC mouth guard at night to prevent snoring
45488456|NCT03102762|Drug|Botulinum Toxin Type A|Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.
45488457|NCT03102762|Drug|Normal saline|The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.
45488458|NCT03684824|Drug|Long luteal phase GnRH agonist protocol|Pituitary suppression will be done using daily subcutaneous injection of triptorelin acetate ( Decapeptyl 0.1mg, Ferring, Germany). Starting from day 21 of the previous cycle
45488459|NCT03684824|Drug|Gonadotropins|Controlled ovarian hyperstimulation will be done using daily intramuscular injection of highly purified Human Menopausal Gonadotrophins (Merional 75 IU/ml, IBSA, Switzerland), starting from day 2-3 of the stimulated cycle, total dose will be adjusted according to patient response
45488460|NCT02421874|Behavioral|Wraparound Team Monitoring System electronic health record|Wraparound Team Monitoring System (Wrap-TMS) is a web-based, electronic behavioral health information system (EBHIS) for the most widely implemented care coordination model in children's behavioral health, the wraparound process
45692060|NCT01276210|Drug|sorafenib tosylate|Given PO
45692061|NCT01276210|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
45692062|NCT01276210|Other|laboratory biomarker analysis|Correlative studies
45692063|NCT00727636|Biological|Gardasil vaccine|standard 0.5 mL dose of Gardasil vaccine given at Day 0, Month 2, and Month 6
45488461|NCT02421874|Behavioral|Education about fidelity maintenance and monitoring|As an active comparator, we will educate practitioners randomized to the control condition about the importance of maintaining fidelity and monitoring fidelity and progress via a 3 hour training.
45488462|NCT03681002|Behavioral|structured lifestyle program|Intensive Lifestyle counseling during one year
45488463|NCT03177538|Drug|Corifollitropin alfa and menotropin|"Procedure: Ovarian stimulation is performed by the combination of a single Corifollitropin alfa 150 mcg injection on menstrual cycle day 2-3 and daily menotropin administration at the dose of 150 IU from stimulation day 1-7 and at the dose of 300 IU from day 8 to the end of stimulation (maximal dose adjustment to 450 IU).~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle"
45488464|NCT03177538|Drug|Follitropin alfa and lutropin alfa|"Procedure: Ovarian stimulation is performed with daily 300 IU of Follitropin alfa and lutropin alfa starting on menstrual cycle day 2-3. Maximal allowed dose adjustment is 450 IU daily.~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle."
45488465|NCT01363323|Drug|Methylnaltrexone (MNTX)|Dose 1
45488466|NCT01363323|Drug|Methylnaltrexone (MNTX)|Dose 2
45488467|NCT01363323|Drug|Methylnaltrexone (MNTX)|Dose 3
45488468|NCT01363323|Drug|Placebo|
45488469|NCT01363323|Drug|Moxifloxacin|
45488470|NCT03183076|Other|modified adkins diet|Patients were assigned to two groups, one of them received modified adkins diet for treatment of drug-resistant epilepsy. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis
45488471|NCT03183076|Drug|Pharmacotherapy without diet|Patients were assigned to two groups, one of them received conventional treatment with antiepileptic drugs without a special diet
45488472|NCT05609292|Device|observational|Infants will get their temperature measured with the liquid crystal thermometer. We are not providing any interventions as they will be in the care of a healthcare team.
45488473|NCT04388553|Procedure|single shot lumbar Erector Spinae Plane block|unilateral (operative side), performed at L1 level, under ultrasound guidance
46052762|NCT02803827|Biological|Probiotic|The probiotic given will be Lactobacillus reuteri DSM 17938, 5x10e8 cfu/mL x 60 days, suspended in vegetable oil.
46052763|NCT02803827|Other|Placebo|The placebo will be the vegetable oil vehicle and look identical to the probiotic.
45369773|NCT02562911|Procedure|Data collection|"Clinical examination~Complete pelvic ultrasound abdominal ultrasound~Bone age: X-ray~biological examination~Lung function assessed by the Maximum Volume Expired~Brasfield radiological score (if available)"
45369774|NCT00964704|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
45369775|NCT00964704|Drug|capecitabine [Xeloda]|added at time of disease-progression, 1000mg/m2 bid po days 1-14 of every 3-week cycle
45369776|NCT00964704|Drug|docetaxel|background therapy at time of disease progression, 100mg/m2 iv every 3 weeks
45369777|NCT00964704|Drug|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg every 3 weeks
45369778|NCT00747071|Drug|Colostrum|Daily administration of Colostrum derived antibodies against C. difficile.
45369779|NCT05350670|Behavioral|Perineal massage and cold compress|Using perineal massage and cold compress during the second stage of labor to observe the effect
45369780|NCT00970710|Behavioral|Vaasa Childhood Obesity Primary Prevention Study|Intensified counselling concerning healthy diet and suitable physical activity during pregnancy to mothers in the intervention group continuing in child health care clinic visits with the offspring until child's age of 5 year.
45488474|NCT05415852|Device|Laser|Laser
45488475|NCT03117244|Other|Exercise for Foot Strengthening|Stabilization exercises of the longitudinal arch of the foot
45488476|NCT03117244|Other|Exercise for Foot Strengthening and Electrostimulation|Exercise for the Strengthening of the Foot associated with Electrostimulation
45488477|NCT01366287|Drug|PF-03882845|25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition
45488478|NCT01366287|Drug|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fasted condition
45488479|NCT01366287|Drug|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fed condition
45488480|NCT03177382|Radiation|Total neoadjuvant treatment|The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w.
45488481|NCT03177382|Radiation|concurrent chemoradiotherapy|The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
45488482|NCT03177382|Procedure|TME|The TME operation will be given after the end of the neoadjuvant treatment.
45488483|NCT03177382|Drug|Adjuvant chemotherapy|Patients will receive another 6 cycles of CAPOX after TME.
45692064|NCT01270750|Drug|BOSENTAN|TWICE DAILY PERORAL BOSENTAN, 125 MG DAILY DIVIDED IN TWO DOSES DURING THE FIRST MONTH AND 250 MG DAILY DIVIDED IN TWO DOSES SUBSEQUENTLY.
45692065|NCT00709696|Drug|Placebo|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
45692066|NCT00709696|Drug|Varenicline|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
45692067|NCT01270906|Drug|CHIR-258 (TKI258)|
46052764|NCT02799303|Device|Multi-parametric MRI|Non contrast magnetic resonance imaging using T1/T2 weighting, DWI and ADC will be performed. MRI images will be reviewed by a single uro-radiologist and assessed using the PiRADs standards.
46052765|NCT02799303|Other|PSA testing|Serum prostate specific antigen (PSA) testing will be performed using a standardized laboratory assay.
46052766|NCT03793608|Drug|Dupilumab|Dupilumab weight-based dosing will be administered subcutaneously (SC) in a single-use, pre-filled syringe every two weeks (Q2W)
45488484|NCT05190861|Diagnostic Test|droplet digital PCR method|The droplet digital PCR method can detect nucleic acids from the most common pathogens (approximately 90%) responsible for BSIs according to Chinet2020 and takes about 4 hours to perform, reporting within the first 24h of suspected sepsis/septic shock.
45488485|NCT05190861|Diagnostic Test|blood culture|Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling.
45488486|NCT03177304|Other|Web based IPT Training|
45488487|NCT05760222|Other|Acupuncture|Acupuncture for prevention/early treatment of vasomotor symptoms and sleep impairment in LHRHa induced amenorrhea in Breast Cancer patients
45488488|NCT03106948|Drug|Placebo|Subject will undergo endoluminal biopsy prior to angioplasty but will NOT undergo insertion of the ACT drug delivery catheter
45846565|NCT03869970|Behavioral|REST|The REST group will be recommended to return to school and light physical and cognitive activity as soon as tolerated- but no sooner than 48 hrs post-injury per current consensus recommendations. Notifications from the Fitbit app will be turned off, and step goal will be set at 500, to minimize positive feedback and reminders from achievement of activity goals
46052767|NCT02798991|Drug|GSK3179106|It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally
45488489|NCT03106948|Drug|Ascorbic Acid|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
45488490|NCT03106948|Drug|Cuprimine Oral Product|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
45488491|NCT01366365|Drug|methylnaltrexone|
45488492|NCT01366365|Drug|placebo|
45488493|NCT01881048|Dietary Supplement|Omega-3 fatty acid|Given PO
45488494|NCT01881048|Drug|Celecoxib|Given PO
45488495|NCT03177148|Behavioral|Intervention by Clinicians|PCPs deliver 4 sessions of MI in person, and RDs deliver 6 sessions of MI via telephone. PCPs and RDs will receive 2 days of MI training.
45488496|NCT03177148|Behavioral|Usual Care|PCPs provide care as normal
45488497|NCT01363557|Other|whole brain radiotherapy|External beam RT using a total dose of 30 Gy with ten daily fractions of 3.0 Gy given 5 days per week over 2 weeks + Gefitinib 250 mg/day
45488498|NCT01363557|Drug|Gefitinib (IRESSA)|250 mg/day
45488499|NCT02416336|Device|Sentinella Intraoperative imaging protocol|"There is a holding time of 15-20 minutes after the lymph node is removed during which the node is further dissected, examined and prepared for pathological analysis. This occurs before the procedure is completed in case the surgeon determines that further surgical exploration or tissue removal is required.~In this study, the investigators will use this holding time to collect images of the sentinel lymph node area using the Sentinella camera for this study. Therefore, participation in this study will not increase the subject's overall procedure time. However, if the Sentinella camera detects something that the standard imaging techniques have missed, such as an additional sentinel node, the surgeon will do further exploration and tissue removal as needed."
45488500|NCT01360125|Genetic|proteomic profiling|
45488501|NCT01360125|Other|flow cytometry|
45488502|NCT01360125|Other|laboratory biomarker analysis|
45488503|NCT02425540|Device|Pelvic MRI|
45488504|NCT01804296|Device|Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
46052768|NCT02798991|Drug|Matched Placebo|It is uncoated round or oblong placebo tablet prepared to match actives across all strengths. It is White to slightly colored tablet and will be administered orally
45488505|NCT01346475|Drug|valacyclovir|1000 mg orally three times daily for 5 weeks
45488506|NCT01346475|Drug|Valacyclovir|500 mg orally once daily for 5 weeks
45488507|NCT02416414|Device|QuantiFERON Monitor Assay|Assay to measure cell-mediated immune function using QuantiFERON Monitor assay.
45488508|NCT02416414|Device|Existing methodology|Assay to measure cell-mediated immune function using existing methodology.
45369781|NCT00958958|Other|multifaceted strategy|"There are multifaceted Interventions Including~Distribution of educational materials: distribution of published or printed recommendations for clinical care.~Case manager: Use of a trained person who works in the hospital and will be responsible to assure that all interventions were used~Reminders~Practical training"
45369782|NCT00959868|Drug|OGX-427|OGX-427 drug product is in 25mg/mL injection in a mannitol-phosphate buffer solution packaged to deliver at least 8mL volume from a 10mL Type I, clear glass vial (ammonium sulfate treated) with Teflon coated bromobutyl rubber stopper and sealed with an aluminum, red, flip-off over seal. The drug product is aseptically compounded and sterilized via sterile filtration prior to aseptic filling.
45369783|NCT00686855|Drug|Tacrolimus|Tacrolimus elixir taken as an oral rinse four times a day for 4 weeks
45369784|NCT00686855|Drug|Dexamethasone|Dexamethasone elixir taken as an oral rinse 4 times a day for 4 weeks
45369785|NCT00949754|Drug|honeybee venom (Apitoxin (Korea) Apitox (USA))|multiple intradermal injections of 100 ug pure honeybee venom
45488509|NCT05415306|Behavioral|Attention Bias Modification|Attention bias modification (ABM) is a procedure for treatment of depression, with the intention of supplementing cognitive behavioural therapy (CBT) or as a treatment on its own. ABM procedures modify attention biases in emotional disorders, resulting in subjects learning to deploy their attention toward the more positive stimuli (Jonassen et al., 2018). A computerized attention bias modification intervention for depression involves repeatedly redirecting the attention of the subject away from emotionally relevant threat cues, and towards neutral (non-threatening) stimuli (Amir et al., 2009). The location of the probe will replace the relatively positive stimulus in the pair with 100% probability.
45488510|NCT05415306|Behavioral|Deep-breathing training|In most deep breathing studies, participants are required to alter their breathing pattern to a specific frequency for a specific duration of time. In the present study, participants will be required to perform deep-breathing at a rate of 6 breaths per minute for 9 minutes.
45488511|NCT05415306|Behavioral|Sham Training|This condition is identical to the Attention Bias Modification condition with the except of the location of the probe, which replaces the positive, negative, and neutral stimuli with equal probability. This control procedure is not expected to modify any underlying biases present.
45488512|NCT02417038|Device|Capnostream|The Capnostream capnograph (is registered with the FDA) is supplied by Covidien. The Capnostream is a portable CO2 monitor with a pulse oximetry module to measure and record SpO2 (oxygen saturation) and heart rate continuously. The Capnostream provides waveform patterns for respiratory rate and EtCO2 measurement.
45488513|NCT02425384|Behavioral|Intervention Group (motivational website, activity meter)|The activity meter linked to a motivational website is designed to motivate middle school-aged children to increase their rates of physical activity by providing feedback on the amount of activity, and rewards based on the amount and duration of activity.
45488514|NCT02425384|Behavioral|Active Control (active video game, activity meter)|The active video game, Dance Dance Revolution, requires physical movement as part of game play and may motivate users to engage in more activity. The same activity meter used in the Intervention Group is provided to this group to track physical activity but does not link to the motivational website nor does it provide any feedback on levels or duration of activity.
46052769|NCT03787836|Behavioral|Maintained Exercise|"Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing.~Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs).~Duration:~Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week~Week 17: Physiological Testing~Week 18 - 29 Intensity: 4.5 METs Duration: 150 minutes/week~All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity."
46052770|NCT03787836|Behavioral|Increased Intensity|"Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing.~Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs).~Duration:~Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week~Week 17: Physiological Testing~Week 18 - 29 Intensity: 6.0 METs Duration: 150 minutes/week~All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity."
45369786|NCT00960024|Behavioral|Individual Placement and Support-vocational rehabilitation|Individual contact with an employment specialist, who works according to 7 core principles according to SE/IPS. 1) competitive employment as primary goal, 2) rapid job search, 3) eligibility based on client choice, 4) job search based on to client preferences, 5) integration with the mental health care team, 6) availability of time unlimited support at work 7) benefits counseling.
45369787|NCT00960024|Behavioral|Vocational rehabilitation available|The participants are offered vocational rehabilitation available at site
45369788|NCT00745043|Drug|bronchodilator response|
46052771|NCT05472753|Dietary Supplement|Experimental Treatment, DCOOP Product, Hydroxytyrosol extract|Intervention group will receive a nutritional formula from DCOOP (Spain).
46052772|NCT05472753|Dietary Supplement|Experimental Treatment,Indukern product, Curcumin and selenium extract|Intervention group will receive a nutritional formula from Indukern (Spain).
45488515|NCT02425384|Other|Passive Control (activity meter)|Participants are provided the same activity meter used in the other study groups to track physical activity but it does not link to the motivational website nor does it provide any feedback on levels or duration of activity. Participants are asked to go about their normal activities.
45488516|NCT05754060|Other|Saint-Louis Lille Battery (SSLIB)|"Saint-Louis Lille Battery (SSLIB) composed of three tests studying the speed of cognitive processing and proposed to the subjects on a tactile tablet. These three tasks are:~(a) Reaction time tasks specifically developed for this study b) A digital adaptation of the WAIS-IV code subtest c) A digital version of the Trail Making Test (A and B)"
45488517|NCT03177226|Device|Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
45488518|NCT03177226|Device|Non-Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
45488519|NCT02416960|Other|Low Glycemic Index Diet Group|This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, low glycemic index/load diet.
45488520|NCT02416960|Other|Conventional Diet Group|This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, high glycemic index/load diet.
45488521|NCT01338636|Drug|Ambrisentan|5 mg orally every day for 4 weeks. At Week 4, if ambrisentan 5 mg was tolerated, the dose was increased to 10 mg every day for the remainder of the 24-week period.
45488522|NCT02416726|Device|Nextseq500 sequencer|The sequencer will be used to detect the gene mutations of the primary tumor, metastatic LN and peripheral blood samples obtained from patients.
45488523|NCT02416258|Drug|LP0113 aerosol spray|
45488524|NCT02416258|Drug|Aerosol spray vehicle|
45488525|NCT02416258|Drug|LEO 90100 aerosol foam|
45488526|NCT02416258|Drug|Betamethasone dipropionate aerosol spray|
45488527|NCT02416258|Drug|Calcipotriol aerosol spray|
45488528|NCT02416258|Drug|Daivobet® gel|
45488529|NCT02410720|Other|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
45488530|NCT02410720|Other|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
45488531|NCT02410720|Other|Explanation of paper and application instructions|The research fellow will explain instructions to patients
45488532|NCT02410720|Other|Picoprep solution|
45488533|NCT05403996|Behavioral|Activa-Mente|Active break program
45488534|NCT02416570|Drug|Clarithromycin|
45488535|NCT02416570|Drug|Placebo|
45488536|NCT02410642|Procedure|cardiopulmonary bypass|Routine use of cardiopulmonary bypass as needed during cardiac surgery
45488537|NCT03176914|Behavioral|prevention and management of childhood illnesses at community level|provision of critical health education and targeted promotion services to the participants in their locality
46052773|NCT05472753|Other|Control Treatment|Control group will receive a placebo (product loading substance)
46052774|NCT03396276|Drug|Suboxone|8mg of buprenorphine/2mg of naloxone
46052775|NCT03396276|Behavioral|Brief counseling in the ED|"Patients will receive brief counseling from ED physician prior to discharge about the options for outpatient treatment, as well as opioid dependency.Consented patients will be provided with a pamphlet from the Substance Abuse and Mental Health Services Administration called Facts About Buprenorphine, as well as an information packet for study contact information for the opioid recovery network providers."
45488538|NCT03176914|Behavioral|conventional community interventions|community health programs as the sole source of health education
45488539|NCT02416024|Device|SphygmoCor system|Carotid-femoral pulse wave velocity (cfPWV) will be determined by applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery. The time (t) between the feet of simultaneously recorded waves will be determined as the mean of 10 consecutive cardiac cycles. PWV is calculated by the system software from the distance between measurement points (D) and the measured time delay (t) as follows: cfPWV = D/Δt (m/s) where D is distance in meters and t is the time interval in seconds.
45488540|NCT00322218|Drug|Zevalin|"Zevalin study treatment regimen consisted of 2 rituximab i.v. infusions (Day 1 and Day 7-9) and one [90Y]-ibritumomab tiuxetan infusion in connection with the second rituximab infusion.~The core treatment regimen in the Zevalin arm was:~Day 1: Rituximab i.v. infusion 250 mg/m^2~Day 7-to 9: Rituximab i.v. infusion 250 mg/m^2 immediately followed by [90Y]-ibritumomab tiuxetan 14.8 MBq/kg (0.4 mCi/kg) with a maximum dose of 1184 MBq (32 mCi),administered as slow intravenous push over 10 minutes."
45488541|NCT02410564|Behavioral|cognitive behavioral therapy for insomnia (CBTI)|SHUTi program is made up of six, weekly treatment Cores modeled after weekly facetoface(CBTI). Each Core begins by providing a rationale for learning the material, explains main content, homework page with suggestions for improving sleep, and a summarized review of main points. The main content each Core addresses myths about sleep, indepth information about topics, vignettes, and quizzes to evaluate users learning in an interactive. As well as being interactive, SHUTi allows for personalization.Modifications are made to sleep recommendations based in sleep diary data and individually set treatment goals. The cores include Overview, Sleep Behavior Core, Sleep Behavior Core 2, Sleep Education Core, Sleep Thoughts Core, and Problem Prevention Core. Each Core takes approximately 45 to 60 minutes to complete. Cores are presented one at a time; next Core becomes available to users a week after they complete one Core.
45488542|NCT02410564|Behavioral|Waitlist control condition|Phone calls with control participants, no advice regarding sleep will be given and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
46052776|NCT03396276|Behavioral|Referral to outpatient treatment|A referral will be made to one of the affiliated MAT clinics.
46052777|NCT03396276|Behavioral|Follow-up coaching|A designated paramedic with the Houston Fire Department (called the navigator or care coordinator) will work with UTHealth to jointly follow-up on patients both telephonically and in-person. The Houston Fire Department paramedic will provide brief information sharing and assist with coordination in scheduling or registering with MAT clinics or recovery coaching.
46052778|NCT02799147|Procedure|Allogeneic stem cell transplantation|
45369789|NCT00949832|Dietary Supplement|Vitamin D + Calcium|Vitamin D 50,000 IU orally once monthly for 6 months; Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months
45369790|NCT00949832|Dietary Supplement|Calcium|Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months; Vitamin B complex (used as placebo) 1 tablet monthly for 6 months
45488543|NCT05046730|Device|Ileostomy Reversal using Self Forming Magnets (SFM)|The magnets will be manually deployed into the small intestine during open surgery following creation of a mini or full laparotomy as clinically indicated. Once the desired segment of small bowel is resected, the magnet is inserted through the open ends of each bowel section. Once proper magnet position is confirmed and the bowel ends are approximated, the magnets couple to form the anastomosis.
45369791|NCT00949832|Dietary Supplement|Vitamin D2|50,000 IU given orally once
45369792|NCT00949832|Dietary Supplement|Vitamin D3|Vitamin D3 50,000 IU given orally once
45369793|NCT00970788|Behavioral|Video intervention|Video of goals of care
45369794|NCT00745199|Drug|cromolyn sodium|oral cromolyn sodium, capsule 135mg, 1 capsule 3 times daily for 8 weeks
45369795|NCT00745199|Drug|placebo|capsule contains 135 mg lactose, 1 capsule 3 times daily for 8 weeks
45369796|NCT00961844|Biological|Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion|
45369797|NCT00961844|Drug|Temozolomide|
45488544|NCT05200494|Procedure|Recruiting Maneuver|Airway pressure will be increased to 30 cmH2O for 30 seconds at the end of the bronchoscopy
45488545|NCT03176992|Drug|SURGICEL®|insertion of 4 pieces of Surgicel inside the uterine cavity after formal curettage
45488546|NCT05328336|Drug|Tislelizumab Nab paclitaxel|"Drug: Tislelizumab Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles~Other Names:~• BGB-A317 Drug: Nab paclitaxel Nab paclitaxel 200mg will"
45488547|NCT02410408|Device|Apps Root Cause Analysis or patient safety ISO certification|Apps for conducting RCA or PSC
45488548|NCT02410408|Other|information package|Information on PSC and RCA
45692068|NCT01270984|Drug|Luckyvec 400mg film coated tablet|•400mg/tablet, PO, 1 tablet once daily for Period I & II D1(crossover)
46052779|NCT02799147|Drug|Fludarabine monophosphate|
46052780|NCT02799147|Drug|Busulfan|
46052781|NCT02799147|Drug|Bendamustine|
46052782|NCT03394326|Behavioral|family-based obesity prevention lifestyle intervention|A family-based obesity prevention lifestyle intervention is based on the combination of behavioral therapy strategies, a physical activity prescription and a dietary prescription. Both the parent and child will be working to achieve the same behavioral targets.
46052783|NCT02798913|Drug|Short DAPT|acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months
46052784|NCT02798913|Drug|Long DAPT|acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months
46052785|NCT03388476|Diagnostic Test|Capnography|Measuring of the exhaled air, especially endtidal co2, through capnography.
45488549|NCT03176680|Procedure|Fluid therapy optimization|colloid 250 mL bolus to increase stroke volume index (SVI). If the increase of SVI is more than 10% of baseline, repeat the bolus. If the increase of SVI is less than 10% of baseline, stop the bolus.
45488550|NCT02873754|Behavioral|Cognitive Behavioral Counseling|Participants will receive five cognitive-behavioral counseling sessions designed to improve rates of smoking cessation, enhance relapse prevention, and increase physical activity.
45488551|NCT02873754|Behavioral|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. They will also be asked to wear a fitness tracker to monitor physical activity (i.e., steps walked). Participants are provided monetary reward for videos that suggest smoking abstinence, and for fitness tracker readings that suggest increased physical activity.
45488552|NCT02873754|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
45488553|NCT02873754|Drug|Transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
45488554|NCT02873754|Drug|Nicotine polacrilex|Nicotine gum will be initiated at smoking quit date; 4 mg dose administered as needed
45488555|NCT02873754|Drug|Nicotine lozenge|Nicotine lozenge will be initiated at smoking quit date; 4 mg dose administered as needed
45488556|NCT03287414|Drug|VAY736|300 mg VAY736 administered subcutaneously every 4 weeks for 48 weeks
45488557|NCT03287414|Drug|Placebo|Placebo administered subcutaneously every 4 weeks for 48 weeks
45488558|NCT03287414|Drug|Standard of Care (SoC)|Background standard-of-care treatment for IPF: nintedanib, pirfenidone, or no background therapy
45488559|NCT03174886|Drug|AADvac1 40 µg|Active immunotherapy against neurofibrillary pathology.
45488560|NCT03174886|Drug|AADvac1 160 µg|Active immunotherapy against neurofibrillary pathology.
45488561|NCT05348460|Dietary Supplement|Ketone ester drink (DeltaG®, 500 mg/kg body weight)|In a double blind fashion, subjects will receive a ketone ester drink ór a taste-matched, isovolumic placebo drink and will then perform the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time receiving the other treatment.
45488562|NCT05348460|Dietary Supplement|Taste-matched, isovolumic placebo drink|In a double blind fashion, subjects will receive a ketone ester drink ór a taste-matched, isovolumic placebo drink and will then perform the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time receiving the other treatment.
45488563|NCT02415790|Drug|E2027|Part A: E2027 capsules will be administered orally in doses of 10 mg to 1200 mg in Part A and in Part B, C, and D at doses not exceeding the highest dose achieved in Part A.
45488564|NCT02415790|Drug|E2027 matching placebo|E2027 matching placebo capsule will be administered.
45488565|NCT03644160|Behavioral|Physical activity and behaviour change|The intervention group (group A) will receive an 8 week individualised, tailored behaviour change intervention to promote PA and an information booklet about physical activity to include an initial 1:1 session with a physiotherapist with training in behaviour change techniques and motivational interviewing. Using a range of behaviour change and self-regulation techniques (eg goal-setting, self-monitoring), participants will be guided towards physical activity maintenance at the end of the 8 weeks. In addition, participants will be signposted to physical activity classes, facilities and resources in the local community. This group will continue with their routine care for their condition throughout the study period.
45488566|NCT03669614|Drug|Inhaled AR-501|single and multiple ascending doses of inhaled AR-501
45488567|NCT03669614|Drug|Inhaled Placebo|single and multiple ascending doses of inhaled placebo
45846566|NCT03869970|Behavioral|ACTIVITY|ACTIVITY group will be encouraged to engage in light to moderate physical activity with the goal of reaching 10,000 steps a day for one or more days during the first week. Subjects will be encouraged to engage in low-risk activities (e.g. walking). Subjects will be instructed to avoid activities that may increase risk of re-injury (e.g. bike riding, climbing, trampoline, sports). Fitbit notifications will be turned on and step goals will be set at 10,000. The simple goal of reaching 10,000 steps is clear to patients regardless of health literacy level, and real-time feedback provides continuous motivation.
45369798|NCT00959426|Drug|PF-04620110|Multiple oral doses of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned Initial planned doses are 1, 3, 5, 10 and 20 mg but may be modified based on emerging PK and safety data.
45369799|NCT00959426|Drug|Placebo|Subjects will be given placebo or PF-04620110. Anticipated total daily doses for Cohorts A, B, C, D, E, F and G are 1, 3, 5, 10 and 20 mg. In each Cohort 9 subjects will receive active treatment and 3 will receive placebo for 14 days. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses during the study based on ongoing safety, tolerability and PK results, but will not be projected to exceed established PK stopping criteria.
45369800|NCT05328050|Other|Registry|observational, data collection
45488568|NCT02415946|Procedure|Sinus floor augmentation (lateral)|
45488569|NCT02415946|Procedure|Sinus floor augmentation (transcrestal)|
45369801|NCT05297162|Diagnostic Test|PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy|"The prostate profile and ROIs will be drawn on PSMA PET and mpMRI and fused in real time with the TRUS image stack during biopsy. Biopsies, transrectal or transperineal according to lesion site, will be performed with patients in the dorsal lithotomy position, under antibiotic prophylaxis and local anesthesia, using 3D triplane transrectal ultrasound system (BK Medical, Analogic Ultrasound Group, Pro Focus, Transducer 8818, 6/9 MHz).~Biopsy cores will be numbered according to ROI number and topography. Specimens will be processed and evaluated by a genitourinary pathologist. Tumor foci will be quantified and graded according to the ISUP consensus conference on Gleason grading."
46052786|NCT02805543|Device|Color doppler imaging|
45369802|NCT00686777|Biological|Pegylated Interferon alfa-2b|Pegylated Interferon alfa-2b 1.5 ug/kg SC once weekly for 48 weeks
45369803|NCT00686777|Drug|Ribavirin|Ribavirin 400 mg/day orally
45369804|NCT04009772|Drug|Cefepime|Antibiotic prophylaxis
45369805|NCT04009772|Drug|Cefuroxime plus Metronidazole|Antibiotic prophylaxis
45369806|NCT00961922|Other|Neurofeedback|30 sessions of neurofeedback will be given twice a week at the child's home. It will take about 15 weeks to complete the training.
45369807|NCT00961922|Other|Placebo feedback|Feedback based on a random signal generator and muscular tension instead of brain activity. 30 sessions at home, twice a week, total 15 weeks.
45369808|NCT00959582|Procedure|Comparator: 18-F-FDG PET/CT and Volumetric CT|Patients will receive standard-of-care therapy (carboplatin or cisplatin monotherapy, or a two-drug combination where one is platinum). FDG-PET/CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, and if patients are progression-free at the end of Cycle 6. Volumetric CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, after Cycle 3 of chemotherapy (optional), and if patients are progression-free at the end of Cycle 6 and at 40 weeks after Cycle 1 dosing.
45369809|NCT00962156|Drug|6% Hydroxyethyl starch 130/0.4|Infusion for volume expansion in the ICU
45369810|NCT00962156|Drug|Ringers acetate|Infusion for volume expansion in the ICU
45369811|NCT00959738|Procedure|Diverting loop ileostomy with rod|Diverting loop ileostomy with rod
45369812|NCT00959738|Procedure|diverting loop ileostomy without rod|diverting loop ileostomy without rod
45369813|NCT00686699|Drug|Preladenant|capsules
45369814|NCT00686699|Drug|Placebo|capsules
45369815|NCT00959816|Drug|ABT-614|Single dose administered on Study Day 1 in Part 1, daily dose administered on Study Days 1-14 in Part 2.
45369816|NCT01563068|Drug|Calcipotriene 0.005% Foam|Topical application applied twice a day for 15 days
45369817|NCT00747305|Drug|sunitinib malate|
45369818|NCT00747305|Genetic|gene expression analysis|
45369819|NCT00747305|Genetic|reverse transcriptase-polymerase chain reaction|
45369820|NCT00747305|Genetic|western blotting|
45369821|NCT00747305|Other|immunohistochemistry staining method|
45369822|NCT00747305|Other|laboratory biomarker analysis|
45488570|NCT05200260|Procedure|Primary debulking surgery|Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
46052787|NCT03356028|Behavioral|Child and adolescent psychiatry and Epidemiology|psychosocial risk assessment questionnaire, structured diagnostic interview, pedopsychiatric questionnaire
45369823|NCT00747305|Procedure|adjuvant therapy|
45369824|NCT00747305|Procedure|neoadjuvant therapy|
45369825|NCT00747305|Procedure|therapeutic conventional surgery|
45369826|NCT05254106|Device|Lower limb artery revascularization with paclitaxel-eluting device|Lower limb artery revascularization with paclitaxel-eluting stent and/or paclitaxel-coated balloon
45369827|NCT00747383|Drug|Glimepiride|3mg oral tablet.
45369828|NCT00747383|Drug|Sitagliptin|100mg oral tablet.
45692069|NCT01270984|Drug|Glivec 100mg film coated tablet|•100mg/tablet, PO, 4 tablets once daily for Period I & II D1(crossover)
45369829|NCT00106639|Drug|CP-690,550|15 mg twice daily
45369830|NCT00106639|Drug|CP-690,550|30 mg twice daily
45369831|NCT00106639|Drug|tacrolimus|dose adjusted according to level
45369832|NCT00747539|Drug|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV), considered standard care for patients with chronic HCV, will be given to participants.
45369833|NCT00745433|Drug|repaglinide|Start dose and frequency at the discretion of the physician following clinical practice
45369834|NCT00745433|Drug|metformin|Start dose and frequency at the discretion of the physician following clinical practice
45369835|NCT00962234|Other|Blood draws|Up to 4 blood draws will be required, in the amount of about 10 mL each
45692070|NCT01276366|Other|breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
45692071|NCT01276366|Other|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
45692072|NCT01276366|Other|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
45846567|NCT03869970|Behavioral|mHEALTH|mHEALTH group will be instructed to download the SuperBetter© app. In addition to the pre-programmed general resilience goals, research assistants will help the subjects to set personal mental, social, and emotional rehabilitation goals and milestones for acute recovery from mTBI (e.g. return to school for ½ the day, have an improvement in symptoms). These goals/milestones will give the patient an opportunity to celebrate the achievement of improvement from mTBI with the goal of generating a positive contextual frame for recovery.
45488571|NCT05200260|Procedure|Neoadjuvant chemotherapy|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
45488572|NCT05200260|Drug|PARP inhibitor|For patients with CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors. In this trial, Niraparib 200mg po qd is suggested after the front-line therapy.
45488573|NCT02415634|Other|RECAP|"Patients will receive an information pack at ICU discharge called the RECAP. This pack will include~Part 1: A critical care discharge summary (UCCDIP) (Bench and Day, 2012)~Part 2: A rehabilitation goal setting care plan~Part 3: A patient communication forum~Part 4: Useful supports and contact information~Part 5: Tailored exercise programme~The patient will have a consultation with the ICU physiotherapist before ICU discharge once weekly thereafter for 3 weeks . The focus of the session will be to discuss goal attainment and associated challenges.~The ICU therapist will meet once weekly with the patient's primary physiotherapist to provide clinical support if necessary, in determining the patient's needs post critical care."
45488574|NCT02415634|Other|Control|Participants allocated to the control group will receive standard physiotherapy intervention post ICU discharge
45488575|NCT03680768|Other|Health Assessment|The protocol includes measurements of body composition, strength test, functional and fitness test as well as biochemical measurements from blood samples and AGEreader
45846568|NCT03560466|Drug|Dupilumab (SAR231893/REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous (sc)"
45846569|NCT03560466|Drug|Asthma controller therapies (incl. prednisone/prednisolone)|"Pharmaceutical form: powder, or solution, or pill~Route of administration: inhaled, oral or parenteral"
45846570|NCT03560466|Drug|Asthma reliever therapies|"Pharmaceutical form: powder or solution~Route of administration: inhaled"
45846571|NCT03376698|Drug|Colchicine 0.5 mg|oral administration of Colchicine 0.5 mg once daily for 12 weeks
45369836|NCT00962234|Biological|Oral administration of stable isotope (deuterium)|1 mg deuterium-labeled water/kg body water (loading dose), and 0.5 mg/kg body water diluted in 1 L of normal water (maintenance dose) to be consumed over the following 16 hours
45369837|NCT00962234|Procedure|Metabolic rate testing|Metabolic rate testing is a painless, non-invasive test that takes about 1h. A metabolic cart is used, which detects the amount of oxygen and carbon dioxide the body uses. Patients will lie down on a bed for 30 minutes with lights dimmed and soft music to help them relax. After 30 minutes, a canopy will be placed over the patient's head and shoulders for 30 minutes for the analysis of breath samples. This test will be performed only once for this study.
45369838|NCT00747695|Drug|Rabeprazole sodium|
45488576|NCT05579106|Device|Nociception Level Monitor (NOL) by Medasense Biometrics Ltd., Israel|"The NOL monitor measures various parameters via a sensor in a finger probe that is attached to the patient.~These parameters are:~Temperature~Galvanic skin response~Accelerometer~Photoplethysmograph (pulse rate, pulse rate variability, photoplethysmograph amplitude)~All this data is combined in an algorithm which produces a number between 0-100. Between 10-25 indicates adequate analgesia, below 10 too much analgesia, above 25 too little analgesia. No actions are taken based on this measurement."
45488577|NCT05579106|Device|Bispectral index (BIS)|The BIS processes EEG information to provide a direct measurement of the patient's level of consciousness and insight into the effects of anesthesia on the brain.
45488578|NCT05579106|Other|Questionnaire perception of the nurse on pain patient|The investigators developed a questionnaire with 7-questions regarding the perception of the responsible nurse on the pain of the patient. When the investigators measured for 8 hours with the BIS and the NOL they will ask the nurse what his or her perception was of the pain of the patient. Eventually the investigators will compare the answers of this questionnaire with the NOL and BIS values that they observed, whether the information corresponds or not.
45488579|NCT03684746|Other|No Intervention|It is an observational Study with staff
45488580|NCT02416648|Behavioral|Clinician Client Centered (CCC) Counseling|"Counseling sessions were interactive allowing for listening, questions and answers. They were cultural sensitive and also consider issues related to gender and age. Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.~Clinicians evaluated patients' readiness to change risky or maintain safer behaviors. They also assisted the patient to negotiate an individually tailored behavior change or maintenance plan of action."
45692073|NCT00625066|Other|biologic sample preservation procedure|
45692074|NCT00625066|Other|cytology specimen collection procedure|
45692075|NCT00625066|Other|medical chart review|
45692076|NCT00625066|Other|questionnaire administration|
45692077|NCT00625066|Other|survey administration|
45692078|NCT00625066|Procedure|biopsy|
45692079|NCT00625066|Procedure|evaluation of cancer risk factors|
45692080|NCT00625066|Procedure|screening colonoscopy|
45692081|NCT02992678|Drug|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.
45692082|NCT02992678|Drug|Placebo|Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
45692083|NCT01276444|Device|Swan-Ganz catheter|the data s=derived from PAC included pulmonary artery occlusion pressure etc
45692084|NCT01276444|Device|transpulmonary thermodilution + central venous saturation|Described in details above
45692085|NCT01271062|Procedure|gastric bypass surgery|
45692086|NCT01271062|Procedure|abdominal surgery|
45692087|NCT01271062|Behavioral|very low caloric diet|
45692088|NCT02992912|Drug|Anti-PD-L1 antibody atezolizumab|1200 mg every 3 weeks
45692089|NCT02992912|Procedure|SABR|Hypofractionated SABR will be delivered at a dose of 45 Gy in 3 fractions of 15 Gy
45488581|NCT05745168|Diagnostic Test|OraQuick|The intervention is based on respondent-driven sampling approach. Each selected seed from hotspots and on social networks is provided with two types of coupons for HIVST kit at partner pharmacy: electronic coupons (e-coupons) consisting of a pictured unique anonymous QR code and identifier and the address of pharmacies; paper coupons consisting of similar information to e-coupon. The seeds will then distribute coupons to their networks physically, via social media, and smart phone applications. Each recruited participant will bring the coupon to be scanned at the pharmacies to receive a free access HIVST kit. There, trained community worker will do the study visit including information/consent, e-CRF filling and providing link to send the test results. These recruited individuals will be considered as wave 1 and will each receive 10 additional coupons to recruit new members in the networks. The next round of individuals recruited and enrolled will be considered as wave 2, and so on.
45488582|NCT03684668|Behavioral|Psychoeducational intervention|The intervention will be carried out every 24 hours with four participants in four computers and 3D lenses available in the computer labs of the University.
45692090|NCT01276522|Drug|Canakinumab|Monthly subcutaneous injection with 150mg Canakinumab for 6 months
45692091|NCT02992444|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
46052788|NCT03356028|Other|salivary biological collection|Saliva sampling will be done using a specific kit
46052789|NCT03356028|Behavioral|qualitative analysis of the discourse|two semi-structured interviews, the first with the teenager alone, the second with the lone parents
46052790|NCT03356028|Behavioral|Parenthood|Parenting Sense of Competence (PSOC) questionnaires completed online.Two visits will be realized: a first in the month preceding the start of the trial and a second in the month following the end of the trial
46052791|NCT03356028|Behavioral|Cognitive alterations|Episodic memory will be assessed using Grober and Buschke. The evaluation of the cognitive alterations will include two stages: a first in the month preceding the start of the trial and a second in the month following the end of the trial. For child and parents
45369839|NCT00959972|Drug|Varenicline|Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
45369840|NCT00959972|Drug|Transdermal Nicotine Patch|Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
45369841|NCT00747773|Device|CryoSpray Ablation System|"CSA Medical, Inc. (formerly CryMed Technologies, Inc.) received FDA market clearance for the CSA System (CryoSpray AblationTM System, formally Cryo Ablator System) on April 21, 2006. It is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications (K070893). As defined by the FDA, the CSA System is a cryosurgical unit with a liquid nitrogen cooled cryocatheter and accessories used to destroy tissue during surgical procedures by applying extreme cold"
45369842|NCT04059653|Device|Electrical stimulation|Electrical stimulation device
45369843|NCT04059653|Other|Treatment as usual|GP treatment as usual
45488583|NCT03174964|Drug|IVIg|Patients will take a dose of 400mg/kg of IVIg 2 days before ET.
45692092|NCT02992444|Other|Experimental adhesive strip|This is a strip of a newly developed adhesive.
45692093|NCT01271140|Drug|Insulin|Intravenous insulin clamp at a rate of 2 mlu/kg/hr. In adition a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.
45692094|NCT01271218|Other|Diet|Participants followed isoenergetic low fat diets with higher protein (HP) or higher carbohydrate (HC) macronutrient content. Participants consumed 1,200 kcals/d for 1-week (Phase I) and 1,600 kcals/d for 9-weeks (Phase II) during a 10-week weight loss period. Participants in the HC diet consumed a diet containing 55% carbohydrate, 15% protein, and 30% fat. Subjects in the HP group consumed a diet containing 7% carbohydrate, 63% protein, and 30% fat during Phase I of the diet and 15% carbohydrate, 55% protein, and 30% fat during Phase II of the diet. The final 4-weeks of the diet (Phase III) served as a weight maintenance period in which participants consumed 2,600 kcals•d-1 consisting of 55% carbohydrate, 15% protein, and 30% fat and were instructed to follow their respective Phase I diet (1,200 kcals/d) for 2-days only if they gained 1.35 kg (3 lbs).
45753499|NCT04190498|Diagnostic Test|Nocturnal oximetry|Diagnosis of OSA will be based on the 3% Oxygen Desaturation Index (IDO) obtained by home nocturnal oximetry. The oximetry recordings will be centralized in sleep laboratory of the University Hospital of Grenoble Alpes. Oximetry data will be analyzed by a technician from the sleep laboratory of the University Hospital of Grenoble Alpes
45753500|NCT00516217|Biological|galiximab|
45753501|NCT04001504|Biological|Double Dose Quadrivalent Influenza Vaccine|Double Dose QIV (30µg Hemagglutinin)
46052792|NCT03356028|Behavioral|Impact on schooling|collect of several data about the number of absences of the child, the number of exclusions and hours of detention of the child, as well as the school reports of the child
46052793|NCT03356028|Behavioral|Sleep disorders and associated somatizations|Evaluation of sleep disorders and associated somatizations by connected watche and sleep questionnaire
46052794|NCT04016025|Behavioral|Adherence to topical standard therapy assessed|Adherence defined as percentage of patients applying at least aimed daily dose
46052795|NCT03327636|Device|Echopulse|This is a machine to apply high intensity focused ultrasound to ablation the target zone. In this study, we would apply it to the papillary thyroid microcarcinoma.
46052796|NCT05331924|Procedure|IPL therapy|Intense pulsed light therapy (IPL) is a non-coherent large wavelength high-intensity light in the range of 500-1200nm. It has been used by many investigators for the treatment of evaporative dry eye safely and effectively.
46052797|NCT05331924|Procedure|Punctal plugs|Silicone punctal plugs are small pieces of silicone designed to block tear drainage through occluding the lacrimal punctum.
46052798|NCT02805387|Dietary Supplement|Treatment|Bicarbonate was ingested
45369844|NCT04009616|Drug|Aloe Vera mouthwash|rinsing with aloe vera mouthwash for 5 days.
45369845|NCT04009616|Drug|Chlorhexidine mouthwash|rinsing with chlorhexidine mouthwash for 5 days.
45488584|NCT03684434|Behavioral|Online MI plus Online CBT|An online motivational interviewing (MI) lesson will first be delivered to clients. The MI lesson is expected to take one hour to complete. No therapist support will be provided during this component of treatment. An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be then delivered to clients following completion of online MI. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
45488585|NCT03684434|Behavioral|Online CBT|An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be delivered to clients. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
45488586|NCT02416804|Drug|Buprenorphine|Buprenorphine transdermal patch Initial : 5 μg/hr Sequential increasing of dose : 5 μg/hr -> 10 μg/hr -> 15 (5+10) μg/hr -> 20 μg/hr
45488587|NCT02416804|Drug|Tramadol|Tramadol Initial : 150 mg/d Sequential increasing of dose : 150 mg/d -> 200 mg/d -> 250 mg/d -> 300 mg/d
46052799|NCT05333094|Other|Brackets|"Levelling and alignment for the bonded teeth through following the wire sequence: 0.014 NiTi, 16 NiTi, 0.016×0.022 NiTi and 0.017×0.025 StSt. (Wires from American Orthodontics)~• After levelling and aligning is completed the patient will be referred for the uptake of post intervention records; a standardized dental photograph and CBCT after 6- 9 months)"
46052800|NCT00762463|Drug|Celecoxib|capsule, 200 mg QD, 6-12 weeks
46052801|NCT00762463|Drug|Diclofenac SR|tablet, 75 mg QD,6-12 weeks
46052802|NCT05469945|Device|Compressive garments class II|Daily wearing of compressive garments, especially during prolonged standing upright or strenuous activities.
46052803|NCT03326310|Drug|Azacitidine|"Patients will receive azacitidine 75 mg/m2 as a subcutaneous injection on days 1-7. The dose of azacitidine 75 mg/m2 will remain unchanged, unless a dose reduction is required based on toxicities (dose level -1 = selumetinib 50 mg PO twice daily and azacitidine 50 mg/m2).~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression"
46052804|NCT03326310|Drug|Selumetinib|"Patients will receive selumetinib administered by mouth on days 8-21. The starting dose cohort (dose level 1) will receive selumetinib 50 mg PO twice daily on days 8-21. Subsequent planned doses include selumetinib 75 mg PO twice daily (dose level 2) and selumetinib 100 mg PO twice daily (dose level 3). Subsequent dose levels will only be given once the prior dose level has shown acceptable safety.~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression."
45369846|NCT04009616|Drug|Placebo mouthwash|rinsing with placebo mouthwash for 5 days.
45369847|NCT00750035|Procedure|Total abdominal hysterectomy|Total abdominal hysterectomy and Subtotal abdominal hysterectomy
45369848|NCT00750035|Procedure|Subtotal abdominal hysterectomy|
45369849|NCT00106249|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Stimulus train of 30 min duration, 1Hz frequency, and 110% of the motor threshold intensity given once a day, 5 days a week, for 4 weeks by Magstim SuperRapid Magnetic Stimulator.
45488588|NCT04933812|Behavioral|Facebook discussions and Virtual group meetings|Participants must join a study-specific private Facebook group and engage in discussion. Once the discussion is complete, participants have the opportunity to join virtual group sessions via Zoom
45369850|NCT00106249|Device|Sham|Sham rTMS will be administered using the Magstim Sham coil which contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (less than 3%) magnetic field is delivered to the cortex in order to provoke a subjective sensation similar to that obtained with the real stimulation but without inducing significant cortical stimulation.
45488589|NCT03684356|Procedure|socket shield technique|immediate implant placement with buccal part of the root is retained
45488590|NCT03684356|Procedure|xenograft|immediate implant placement with filling the buccal gap with xenograft
45488591|NCT02416882|Other|Aerobic Exercise|Subjects will sample and rate their liking of three cardiovascular machines (treadmill, cycle ergometer, elliptical step ergometer) to determine which one will be used during the test.
45488592|NCT02416882|Other|Resistance Exercise|Subjects will sample and rate their liking of three different resistance training circuits (upper body, lower body, core) to determine which one will be used during the test.
45846572|NCT03376698|Drug|Colchicine 0.25 mg|oral administration of Colchicine 0.25 mg once daily for 12 weeks
45846573|NCT03376698|Drug|Placebo|oral administration of Placebo once daily for 12 weeks
46052805|NCT02805465|Device|CRT Device and Bi-ventricular pacing|Bi-ventricular pacing by a CRT device
46052806|NCT02805465|Device|CRT Device and His-bundle Pacing|His-bundle pacing by a CRT device through the pacing lead at His-bundle region
45488593|NCT02416882|Other|Sedentary Option|Subjects will rate their liking of three sedentary activities (reading magazines, playing puzzles, completing word games) as an alternative to exercise.
45488594|NCT04792320|Dietary Supplement|Active bamboo charcoal|4g particle
45488595|NCT04792320|Dietary Supplement|probiotics|0.8g powder
45488596|NCT03176758|Drug|Spinal Block|Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
45488597|NCT03176758|Drug|General anesthetic|1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
45488598|NCT03176758|Device|Total knee replacement|A total knee arthroplasty surgery, which is not the intervention of interest
45488599|NCT04203537|Drug|CA-008|Local administration during surgery
45488600|NCT04203537|Drug|Placebo|Local administration during surgery
45488601|NCT05565612|Dietary Supplement|Normodigest Classic|Symbiotic composed of 15 probiotic strains and fructooligosaccharides as prebiotic
45488602|NCT05565612|Dietary Supplement|Placebo|Compound based on maltodextrin and other excipients
45488603|NCT03177070|Drug|Methylene Blue|As described above. Intravenous injection with visualisation via fluorescence enabled laparoscope.
45692095|NCT01271218|Other|Exercise|All subjects participated in a supervised exercise program three days per week for 14-weeks. Each circuit-style workout consisted of 14 exercises (e.g. elbow flexion/extension, knee flexion/extension, shoulder press/lat pull, hip abductor/adductor, chest press/seated row, horizontal leg press, squat, abdominal crunch/back extension, pec deck, oblique, shoulder shrug/dip, hip extension, side bends and stepping). Participants performed as many repetitions in a 30-s time period. In a continuous, interval fashion, participants performed floor-based callisthenic (e.g. running/skipping in place, arm circles, etc.) exercises on recovery pads for a 30-s time period after each resistance exercise in an effort to maintain a consistent exercise heart rate that corresponded to 60% to 80% of their maximum heart rate.
45846574|NCT03295734|Behavioral|Aerobic exercise|Twice weekly centered based aerobic exercise + 3/week home-based walking
46052807|NCT03638700|Device|VisiGlide™ angled tip|Arm A: Primary use of VisiGlide™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (straight tip) resp. to VisiGlid2e™ (tip according to the examiner)
46052808|NCT03638700|Device|VisiGlide2™ angled tip|Arm B: Primary use of VisiGlide2™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (straight tip) resp. to VisiGlide™ (tip according to the examiner)
45488604|NCT03174808|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Participants will attend weekly 2.5-hour group sessions (of 10-14 persons) based on the standard MBSR protocol.
45488605|NCT03680690|Procedure|hysteroscopy|office hysteroscopy will be done for all candidates and operative correction of detected lesions will be carried on.
45488606|NCT05190393|Procedure|hemivertebra resection on convex side|Patients were used hemivertebra resection procedure to treat congenital cervical scoliosis.
45488607|NCT05190393|Procedure|concave distraction group|Patients were used distraction and lateral opening procedure to treat congenital cervical scoliosis.
45488608|NCT03101592|Other|Three-month ART dispensing|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART from their provider for the duration of the study.
45692096|NCT01271296|Dietary Supplement|Liquorice|24 gram liquorice eq. to 150 mg glycyrrhizinic acid, taken orally, for three days.
45488609|NCT03101592|Other|Six-month ART dispensing|Patients enrolled in the six-month ART dispensing arm will receive a 180-day supply of ART from their provider for the duration of the study.
45488610|NCT02410174|Radiation|Stereotactic Body Radiotherapy (SBRT)|
45488611|NCT03275402|Biological|131I-omburtamab|Murine IgG1 monoclonal antibody radiolabeled with iodine-131
45692097|NCT01271296|Dietary Supplement|Grapefruit Juice|200 ml pink grapefruit juice three times a day, taken orally, for three days.
45692098|NCT01271374|Drug|amlodipine and olmesartan|Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
45846575|NCT03295734|Drug|Perindopril|4 mg qd titrated to 8 mg qd perindopril
46052809|NCT03638700|Device|VisiGlide™ straight tip|Arm C: Primary use of VisiGlide™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (angled tip) resp. to VisiGlide2™ (tip according to the examiner)
45369851|NCT00960128|Drug|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with adults.
45369852|NCT00960128|Drug|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with children.
45369853|NCT01086943|Device|LT2420|
45369854|NCT00960284|Drug|capecitabine|Given orally
45846576|NCT03295734|Drug|Losartan|50 mg qd titrated to 100 qd losartan
45846577|NCT03295734|Drug|HCTZ|12.5 mg qd titrated to 25 qd HCTZ
45846578|NCT03084666|Device|Zimmer ATS tourniquet system|The tourniquet is the same kind that is used in orthopedic surgeries to limit blood loss in arm or leg surgery. It can be inflated to a set pressure for a set amount of time.
45846579|NCT02928978|Drug|Ruxolitinib|tablet (taken by mouth)
45846580|NCT02928978|Drug|Placebo (for Ruxolitinib)|tablet (taken by mouth)
45369855|NCT00960284|Drug|cisplatin|Given IV
45369856|NCT00960284|Drug|epirubicin hydrochloride|Given IV
45369857|NCT00960284|Drug|fluorouracil|Given IV
45369858|NCT00960284|Drug|gemcitabine hydrochloride|Given IV
45488612|NCT01360203|Other|Structured Telephone / Remote Outpatient Monitoring|During their hospitalization, patients will receive education on their condition and will be taught to use a wireless remote monitoring device that they will use from home on a daily basis for six months following hospital discharge. Patients will receive structured telephone phone calls from a centralized call center nurse at least once a week for the first month post-discharge, and monthly for the remainder of the six month study period. Patients may receive additional calls depending upon the information gathered during the scheduled call center phone calls and/or their health status as ascertained by the data (weight, heart rate, blood pressure, answers to general health and heart failure-related questions) transmitted daily by the wireless remote monitoring device.
45846581|NCT02405208|Device|PyroTITAN HRA|Humeral resurfacing using the PyroTITAN HRA device
45846582|NCT00394758|Procedure|CO2 laser surgery|
45369859|NCT00105469|Drug|AzaSite|AzaSite ophthalmic solution; one topical drop to the infected eye or eyes twice daily (in the morning and at bedtime) on Days 1 and 2 followed by once daily (in the morning between 7 and 10am) on Days 3 through 5.
45369860|NCT00105469|Drug|Tobramycin|Tobramycin ophthalmic solution; one topical drop to the infected eye or eyes four times daily at 4 to 6 hour intervals (first dose in the morning between 7 and 10am) for 5 days.
46052810|NCT03638700|Device|VisiGlide2™ straight tip|Arm D: Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide1™ (tip according to the examiner)
46052811|NCT05511909|Drug|Buspirone|Buspirone administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
45488613|NCT02415478|Other|endoscopic lung volume reduction by valves|"Independent of the study, subject will get a bronchoscopy with chartis measurement in general anaesthesia. chartis measurement is a Balloon angioplasty. Balloon will be well-positioned in lung and filled by air for occlusion of lobe of the lung. System recognizes collateral ventilation of lobe of the lung via calculation of airflow resistance.~Negative result allows the endoscopic placement of selfexpandig endobronchial valves in the subject lung. Inhale airflow will be inhibit an enclosed air and liquids can exhaust."
45692099|NCT01271374|Drug|losartan and HCTZ|Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
45692100|NCT00710944|Device|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™: Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm.
45692101|NCT01271530|Other|Upper Limb Ergometry|Cardiovascular training will be performed using upper limb ergometers at home for 8 weeks. Each subject will receive an individually prescribed programme and will begin exercising for at least ten minutes per day three days per week. If an individual has difficulty exercising for 10 minutes continuously, the 10 minute session may be broken into 2-3 minute bursts of exercise, with one minute rests. Subjects will aim to increase exercise durations to 20 minutes per day five days per week and will exercise at moderate to high intensities.
45692102|NCT01271608|Device|needle exchange|Comparing the pain intensity on a numeric scale (0-10) with intramuscular and subcutaneous injection between a retractable fixed syringe needle and the technique involving needle exchange; Comparing bruise formation following administration of insulin subcutaneous injections between retractable fixed needle and the conventional technique.
45692103|NCT01276834|Drug|everolimus|comparison of everolimus-based and CNI-based immunosuppression
45692104|NCT01276912|Drug|Insulin glargine|Insulin glargine therapy with a dosage adjusted to get FBG ≤ 5.3mmol / L as the goal, accompanied with a lifestyle counseling.
45692105|NCT01276912|Behavioral|Lifestyle counseling|To give lifestyle guidance, specifically including low fat, low saturated fatty acids, rich in dietary fiber, salt restriction, limit alcohol diet plan to reduce the 5% to 10% of body weight, and to ensure a regular moderate physical activity at least 150 minutes per week.
45846583|NCT00394758|Procedure|ultrasonic surgical aspiration|
45846584|NCT02594826|Behavioral|Culturally appropriate intervention|Church-based educational intervention combined with navigation assistance
45846585|NCT02594826|Behavioral|General health education control|General health and cancer education
45846586|NCT02595684|Drug|Tadalafil|Tadalafil capsules: 5 mg, one per day, at night, during 28 days.
45846587|NCT02595684|Drug|Placebo|Calcined magnesia capsules: one per day, at night, during 28 days.
45846588|NCT02599194|Drug|18F-FSPG|Administered intravenously (IV)
45846589|NCT02599194|Drug|18F-FDG|Administered intravenously (IV)
45846590|NCT02604810|Biological|IGIV-C 10%|IGIV-C 10% infusions every 3 to 4 weeks based on previous IgG regimen
45846591|NCT02604810|Biological|IGSC 20%|IGSC 20% weekly infusions with dose calculated based on previous IgG regimen
45846592|NCT02606604|Device|RT 300: Lower Extremity Cycling|Individuals will be randomly assigned to either the FES cycling or cycling only group and will perform lower extremity cycling. Individuals will participate in an interval training cycling program 3 times per week for 8 weeks.
45846593|NCT02606838|Device|Styx Lancing Device|Untrained Persons With Diabetes used the Styx Lancing Device with 28 and 30 Gauge lancets to obtain fingerstick and Alternate Site palm capillary blood. Study Staff tested the capillary blood using Contour NEXT Blood Glucose Meters (BGMs) and recorded the results. Meter results could be numeric, non-numeric (ie, error messages), or not obtained at all.
45488614|NCT03684200|Other|Copenhagen adductor exercise|The active player is supported on one forearm on the floor and the upper arm is resting along their side. The supporting partner places their hands at the ankle and the knee of the upper leg. The active partner raises their body from the floor and adducts both legs in a three second movement until the body reaches a straight line. The body is then lowered to the ground in a three second movement, the foot of the lower leg touches the ground before performing another repetition.
45488615|NCT01366599|Drug|HEC or MEC|Any HEC or MEC, including aprepitant
45488616|NCT05560932|Behavioral|IMB-motivational interviewing (MI) techniques (IMB-MI)|The clinical pharmacist will employ MI in informational, participant-centered discussions in which the clinical pharmacist and participant collaboratively discuss the harms of drinking and polypharmacy (specifically alcohol interactive medications), symptoms associated with alcohol and specific medications, and how to mitigate these harms. Motivational elements include messages highlighting the participant's personal risk of bothersome symptoms from their use of alcohol and level of polypharmacy, attitude change elements to improve attitudes toward the intended behavior change, social normative support for the intended behavior change including identification of people who can support the participant in this process, and a menu of options for referrals for skill building (e.g. Social Work, meeting with the clinical pharmacist at their clinic, follow-up with the HIV clinician, alcohol-reduction programs, based on what is locally available as part of VA-based care).
45488617|NCT03172000|Diagnostic Test|Colonoscopy and biopsy|Colonoscopic biopsy were taken from the rectum, the sigmoid, descending, transverse, ascending colon, and the cecum of each patient.
45488618|NCT03680612|Drug|Cefepime 1G - 2G / AAI101 0.5G - 0.75G|Experimental drug
45488619|NCT03680612|Drug|cefepime 1 g or cefepime 2 g|cefepime monotherapy
45488620|NCT01360281|Other|Neuromuscular Electrical Stimulation|
45488621|NCT01360281|Other|ECR|Resisted exercises
45488622|NCT02410096|Other|Exercise challenge in a cold chamber|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
45488623|NCT02410096|Other|Methacholine challenge|Nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
45488624|NCT02410096|Dietary Supplement|Oil supplementation verum|Patients and subjects will take double blind an oil supplementation with middle-chain and polyunsaturated fatty acids for four weeks
45488625|NCT02410096|Dietary Supplement|Oil supplementation placebo|Patients and subjects will take double blind sunflower oil for four weeks
45488626|NCT03676478|Other|delayed start enteral support @ POD5|instead of caloric suppletion, participants will receive 500mls of water over the jejunostomy feeding tube daily.
45488627|NCT01366677|Behavioral|Yoga Intervention|Three yoga classes per week for 8 weeks.
45488628|NCT03684122|Biological|Injection of Umbilical cord derived MSCs|Allogenic umbilical cord derived MSCs which are to be injected intrathecally and intravenously as a treatment option for consenting PD patients
45488629|NCT05188209|Drug|MRG003|Administered intravenously
45488630|NCT03171922|Behavioral|Internet Diet|ID group have online dietary coach every 2 weeks
45488631|NCT03171922|Behavioral|Clinic Diet|CD group have every 2 weeks visit at clinic
45488632|NCT04046939|Drug|Dexpramipexole|dexpramipexole twice daily oral dosing for up to 12 weeks
45488633|NCT04046939|Drug|Placebo|placebo twice daily oral dosing for up to 12 weeks
46052812|NCT05511909|Drug|Lofexidine|Lofexidine administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
46052813|NCT05511909|Drug|Placebo|Participants administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
46052814|NCT05511597|Behavioral|Split-belt treadmill training|Split-belt walking with various speed ratios between the two legs, applied with random-block practice
46052815|NCT05511597|Behavioral|Complex task practice|Overground gait flexibility training with added cognitive tasks
46052816|NCT05511597|Behavioral|Static balance exercise|Mindfulness and breathing combined with static balance exercises
45488634|NCT03272906|Device|Anodal transcranial direct current stimulation|2 mA of A-tDCS stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 2 mA occurs over 30 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 60-minute treatment session.
45488635|NCT03272906|Device|Sham transcranial direct current stimulation|2 mA of A-tDCS stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 2 mA occurs over 30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition.
45488636|NCT03272906|Behavioral|Speech-language therapy|Therapy tasks will be determined by the clinician on an individualized basis and will not be affected by this research protocol. The only difference between the clinical therapy that is normally provided in the clinic and this research paradigm is the application of tDCS electrodes during therapy. Therapist is blinded to stimulation type.
45488637|NCT05188131|Drug|Intravenous Infusion of Diclofenac Sodium|Intravenous Infusion of Diclofenac Sodium is administered at the dose of 75 mg, diluted in 100 ml of isotonic saline, over 15 minutes.
45488638|NCT05188131|Drug|Intravenous Infusion of Placebo|Intravenous Infusion of Placebo (represented by 100 ml of isotonic saline) is administered over 15 minutes.
45488639|NCT03172156|Genetic|ctDNA detection|To detect ctDNA in Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Using Secondary Gene Sequencing (NGS)
45692106|NCT00728260|Biological|None administered in this study|N/A in this study
46052817|NCT02798601|Other|Hypernatremia|Serum Sodium goal: 150 - 155 milliequivalent/L.
46052818|NCT00762385|Device|galyfilcon A|galyfilcon A
46052819|NCT00762385|Device|comfilcon A|comfilcon A
45488640|NCT01360359|Other|Core Stabilization|"3 Stages: Stage 1: emphasis on neutral spine position, co-contraction of stabilizing muscles with performance feedback through observation and palpation for correct muscle activation; patient education~Stage 2: promotes maintenance of co-contraction while performing movements of the arms/legs and trunk progressing to preformance of these exercises on unstable surfaces; trunk muscle conditioning also emphasized; feedback gradually reduced.~Stage 3: emphasis on maintenance of co-contraction while performing functional activities; stable and unstable surfaces; use of perturbation and random practice to enhance motor learning."
45488641|NCT01360359|Other|Trunk Motion and Fitness|"3 Stages: Stage 1: reducing pain and restoring spine motion and flexibility; patient education~Stage 2: trunk muscle conditioning exercises~Stage 3: trunk muscle conditioning and cardiovascular conditioning exercises"
45488642|NCT02409940|Biological|Mesenchymal Stem Cells|These Mesenchymal stem cells are derived from bone marrow of either renal transplant patients or their donors depending upon the group of study.
45488643|NCT03651206|Drug|Niraparib|PARP Inhibitor
45488644|NCT03651206|Combination Product|Niraparib + TSR-042 (Dostarlimab)|Combination of 2 drugs, a PARP Inhibitor and an Anti-PD-1
45488645|NCT03651206|Drug|Chemotherapy Drugs|Chemotherapies given in standard of care
45488646|NCT01366833|Radiation|Brachytherapy|Patients in arm B will receive a single dose of brachytherapy (10Gy) via a 10 or 13 mm catheter within 10days of stent insertion. Patients on the study will not be given preferential treatment, and will not be prioritized over patients treated with brachytherapy not on the study.
45488647|NCT01366833|Procedure|Stent insertion|After placement of clips to mark the proximal and distal extent of the tumor, an endoscopically placed self-expanding metallic stent (WallFlex™ Partially Covered Esophageal Stent by Boston Scientific) will be inserted within 10 days of recruitment. This will be the only intervention in Arm A patients.
45488648|NCT03171844|Other|Skin to skin|3 sessions of skin to skin will be made on newborn wearing an umbilical venous catheter
45488649|NCT01363791|Other|Dietary fructose|Oral dietary fructose in free (unbound) form in isocaloric exchange for other non-fructose carbohydrate sources (isocaloric trials) or added to a control diet as a source of excess energy (hypercaloric trials).
45488650|NCT02415322|Other|refer to mental health specialists|children who have diagnosed internet and/or smartphone disorder by psychiatrists referred to mental health specialists
45488651|NCT03680534|Procedure|Root canal preparation|Root canals from lower premolars with extraction indicated were prepared previous to being extracted with either the Reciproc Blue, the WaveOne Gold or the XP EndoShaper single-file techniques.
45488652|NCT00704782|Drug|dimebon|
45488653|NCT03676400|Other|conditioned media of umbilical cord blood-derived stem cells|Hair serum with 5% conditioned media of human umbilical cord blood-derived mesenchymal stem cells
45488654|NCT03676400|Other|Placebo|Hair serum without conditioned media of human umbilical cord blood-derived mesenchymal stem cells
45488655|NCT01360437|Drug|Prasugrel|Prasugrel 10mg/day
45488656|NCT01360437|Drug|Ticagrelor|Ticagrelor 90mg twice a day
45488657|NCT04042103|Drug|Tapinarof cream, 1%|Tapinarof cream, 1% applied topically once daily
45692107|NCT01276990|Drug|BI 224436|Oral drinking solution
45488658|NCT03172078|Procedure|advanced endoscopic procedure|The advanced endoscopic procedure include endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP), and other upper gastrointestinal endoscopy.
45488659|NCT01363869|Dietary Supplement|green tea extracts 2 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 2 grams per day."
45488660|NCT01363869|Dietary Supplement|green tea extracts 4 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 4 grams per day."
45692108|NCT01276990|Drug|BI 224436|Oral drinking solution
45846594|NCT02607618|Drug|Iclaprim|Experimental treatment
45488661|NCT01363869|Dietary Supplement|green tea extracts 6 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 6 grams per day."
45488662|NCT03883646|Behavioral|Mindfulness|Mindfulness-based Relapse Prevention. Guided meditation/discussion (Group sessions).
45488663|NCT03883646|Behavioral|Relapse Prevention|Relapse Prevention. Cognitive behavioral principles/strategies (Group sessions).
45846595|NCT02607618|Drug|Vancomycin|Active comparator
45488664|NCT03174730|Behavioral|Growth Mindset|The intervention is aimed at creating more flexible thinking about addiction to tobacco. Participants will be sent tips by email to help foster the belief that people can overcome addiction to smoking.
45488665|NCT03174730|Behavioral|SmartQuit|This is an Acceptance and Commitment Therapy based intervention designed a smoking cessation smartphone application.
45692109|NCT01276990|Drug|BI 224436|Oral drinking solution
45692110|NCT01276990|Drug|BI 224436|Oral drinking solution
45692111|NCT01276990|Drug|BI 224436|Oral drinking solution
45692112|NCT01276990|Drug|BI 224436|Oral drinking solution
45692113|NCT01276990|Drug|BI 224436|Oral drinking solution
45692114|NCT01276990|Drug|BI 224436|Oral drinking solution
45692115|NCT01276990|Drug|BI 224436|Oral drinking solution
45692116|NCT01276990|Drug|Placebo|Oral drinking solution
45692117|NCT01277068|Procedure|Surgical and medical procedures|this study want to compare the differential effect of the 3 bariatric surgery procedures on the production rates of the intestinal TRL: the adjustable gastric banding the sleeve gastrectomy the gastric bypass
45692118|NCT01271764|Other|no drug|The role of G9a protein in patients with endometrial cancer
45692119|NCT01277146|Drug|OMP-59R5|IV infusion
46052820|NCT00906282|Drug|Pemetrexed|500 mg/m2 IV over 10 minutes on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
46052821|NCT00906282|Drug|Carboplatin|AUC 6.0 IV on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
46052822|NCT02798445|Other|TAPIRS|Terminal Axial Perforator Interruption Reflux Source plus Adjustable compression system
46052823|NCT02798445|Other|CONTROL|Multilayer bandages and wound care
46052824|NCT02798757|Drug|Dapagliflozin|Urine samples will be collected for 1HNMR spectroscopies
45488666|NCT03676322|Drug|M5049|Participants will receive single ascending oral dose of M5049 in Part A. Participants will receive multiple ascending oral dose of M5049 once daily for 14 days or twice daily for 13 days followed by a single dose on Day 14 in the morning in Part B. Participants will receive a single oral dose of M5049 under fed conditions in Part C.
45488667|NCT03676322|Drug|Placebo|Participants will receive placebo matched to M5049.
45488668|NCT02409862|Drug|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
45488669|NCT02409862|Drug|Placebo Spray|This group will receive the single dose of 24 IU placebo, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
45488670|NCT05187897|Behavioral|CHV-NEO|CHV-NEO is a two-way SMS platform that supports communication between mothers and community health volunteers between home visits. The platform engages mothers with SMS communication and brings timely information and support - asking critical questions at crucial times in order to assess the needs and health of newborns and assist in care seeking decisions. The CHV-NEO SMS intervention is integrated into the current digital community health toolkit (dCHT) to support CHV workflow.
45488671|NCT02415010|Device|Enterprise 2 Vascular Reconstruction Device|Stenting Assisted coiling procedure
45488672|NCT01366989|Device|Radiographic evaluation of previously implanted patients|Radiographs of the ankle
45488673|NCT02415088|Procedure|Interscalene block|block of the plexus brachialis in the interscalene region with local anaesthetics
45488674|NCT02415088|Procedure|Selective shoulder block|selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
45488675|NCT01360671|Drug|Sildenafil|Loading dose of 0.1 mg/kg for 30 minutes followed by maintenance treatment of 0.03 mg/kg.h for up to 14 days
46052825|NCT04100863|Other|No Intervention|There is no intervention for this study.
46052826|NCT05200806|Other|Non-Narcotic ERAS Post-Operative Pain Management|As described previously.
46052827|NCT02798367|Behavioral|CBT-I plus placebo|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus placebo (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days)
46052828|NCT02798367|Drug|CBT-I plus Melatonin 3 mg|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 3 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
45692120|NCT00711022|Device|ASTRA TECH Implant System, OsseoSpeed™, all dimensions.|
45692121|NCT00728728|Drug|Dietary Supplement: Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial.
46052829|NCT02798367|Drug|CBT-I plus Melatonin 5 mg|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 5 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
46052830|NCT00762229|Drug|Ezetimibe 10 mg|Ezetimibe 10 mg daily for 4 weeks
46052831|NCT00762229|Drug|Ezetimibe 5 mg|"Ezetimibe 5 mg daily for 4 weeks, formulated as a 10 mg tablet split in half"
46052832|NCT00907374|Drug|benazepril|benazepril 10 mg orally once daily
46052833|NCT00907374|Drug|benazepril|40-80 mg benazepril plus 25-100 mg losartan orally once or twice daily
46052834|NCT02805153|Drug|PEG-rhG-CSF|
45369861|NCT05192408|Behavioral|Multi-component intervention|"Individual intervention will comprise:~Cognitive- behavioral therapy (CBT) which includes: - Behavioural activation, cognitive restructuring, promotion of safety, relaxation techniques~Exercise recommendation utilizing current Exercise in older adults Patient Education Materials (PEMs) and videos, tailored based on frailty level and readiness to progress - Components include balance and strength~Use of motivational interviewing (MI) techniques for goal setting~There will be 4 sessions in total. Initial sessions will be carried out face to face or via videoconferencing platform if participant prefers due to ongoing COVID-19 pandemic. Subsequent sessions will be carried out via telephone."
45369862|NCT05192408|Other|Usual Care|Patient Education Materials
45692122|NCT00728728|Dietary Supplement|Placebo|Placebo
46052835|NCT02805153|Drug|rhG-CSF|
45369863|NCT04009694|Other|Pelvic Floor Muscle training|Sixteen weeks of supervised pelvic floor muscle training with a specialist physiotherapist
45369864|NCT00960362|Drug|AGS-009|Single dose in the range of 0.01 to 30 mg/kg administered intravenously (in the vein)
45369865|NCT00960362|Drug|placebo|Single dose of 0 mg/kg administered intravenously (in the vein) cohort 1-6.
45369866|NCT00962312|Drug|capecitabine|
45369867|NCT00962312|Drug|lapatinib ditosylate|
45369868|NCT00962468|Other|COPD evidence based care pathway|A care pathways, as complex intervention, will be implemented.
45369869|NCT00960518|Drug|adefovir|adefovir at 10 mg daily for 48 weeks
46052836|NCT04096339|Other|Colonoscopy followed by EGD|Colonoscopy is done first followed by EGD
46052837|NCT04096339|Other|EGD followed by Colonoscopy|Esophagoduodenoscopy (EGD) is done first followed by Colonoscopy
46052838|NCT04100707|Procedure|Genicular block was applied|This procedure is performed with ultrasound and / or fluoroscopy, sterile staining and covering of painful knee to the middle of thigh and leg, localization of superomedial, superolateral, inferomedial genicular nerves are tested and then conventional radiofrequency is applied to all 3 nerve regions
46052839|NCT02805231|Other|Vitamin D receptor polymorphic analysis|
46052840|NCT02803671|Device|TFU-NIRS|
46052841|NCT02803671|Device|NIRS|
46052842|NCT02803671|Device|EEG|
45488680|NCT03676244|Device|immediate implant in defected anterior maxillary esthetic zone|"Patients indicated for immediate implant placement with presence of partial or complete loss (type 2 sockets) of labial bone plate.~Use of GBR (mix of autogenous bone graft and xenograft in combination to absorbable collagen membrane) and healing abutment at the same time of extraction then place implant palatally engaging the side walls of the socket, leaving a buccal gap.~construct custom two-piece screw retained healing abutment then remove custom healing abutment and fit and place the collagen membrane for GBR , the membrane should cover the defect 2 mm circumferentially and extend to the level of free gingival margin, Place bone graft material buccal to the implant surface ,replace custom healing abutment."
45488681|NCT01363947|Drug|DNIB0600A|Several dose levels will be evaluated for DNIB0600A administered via IV infusion on Day 1 of each 21-day cycle until disease progression.
45488682|NCT02955797|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular
45488683|NCT02955797|Biological|Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine|0.5 mL, Intramuscular
45488684|NCT02955797|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
45488685|NCT02955797|Biological|Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine|0.5 mL, Intramuscular
45488686|NCT05554068|Drug|Shingrix|Shingrix vaccine will be given to all eligible patients at one to three year post allogeneic stem cell transplantation.
45369870|NCT00960518|Procedure|TACE|An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
45369871|NCT00960596|Behavioral|Health promotion and health education for smoking habits|We provide the education to intervention group.
45488687|NCT03680378|Drug|Cefepime 2 gram|Combination of cefepime 2 gram with AAI101 1 gram
45488688|NCT01319331|Drug|Alpha 1-Antitrypsin (AAT, Aralast NP)|Eligible subjects will be treated once a week for 8 weeks (8 total treatments).
45488689|NCT04913298|Device|Cytosorb therapy|Start of Cytosorb therapy is at the discretion of the attending physician
45488690|NCT02406352|Device|Multispectral Digital Colposcope with probe|"Cervical images will be obtained with the Multispectral Digital Colposcope. Spectroscopic data will be obtained with the probe from eligible patients who provided consent to participate in the study.~The standard of care for research participants will not change."
45369872|NCT00960674|Procedure|Tactile massage|Gentle massage given for one hour by specially educated massage therapists, usually registered nurses.
45488691|NCT05418348|Drug|GTX-104|new formulation of nimodipine injection for IV infusion
45488692|NCT05418348|Drug|Nimodipine Capsules|Nimodipine capsules (reference formulation)
45488693|NCT02409628|Device|EktoTherix|The EktoTherix scaffold is applied to the fresh wound resulting from a full thickness excision of non-melanoma skin cancer and then bolstered by the application of a non-adhesive foam dressing (discontinued at the first visit); both scaffold and foam dressing are secured in place using a semi-occlusive film dressing. The EktoTherix-treated wound is assessed weekly as per standard of care.
45488694|NCT03676166|Drug|Cannabis|Inhaled cannabis
45488695|NCT02406118|Procedure|Transanal total mesorectal excision|Subjects will have their rectal cancer removed using a technique combining surgery through the anus and standard laparoscopy. Transanal visualization will be using endoscopy. At the end of the procedure, the rectum will be removed though the anus or ileostomy formation site, the bowel will be re-connected to the anus, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
45488696|NCT03101514|Drug|Kanglaite|Kanglaite injection 200ml is injected intravenous from the first day to the last day of radiotherapy.
45692123|NCT00711490|Drug|Sirolimus|20 μL (440 μg) of sirolimus were injected at baseline, Month 2, and every 2 months thereafter if re-treatment criteria were satisfied.
45692124|NCT04270006|Biological|adipose derived stem cells exosomes|they are small extracellular vesicles
46052843|NCT03278730|Drug|Para-Tyrosine supplementation|Patients will recieve the study drug during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of para-Tyrosine, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
45369873|NCT00960674|Behavioral|Relaxation|Relaxation by a CD with relaxation exercises, at least one hour per week for ten weeks
45488697|NCT03101514|Drug|chemotherapy|Cisplatin 80-100mg/m2 was used every 3 weeks during radiotherapy.
45692125|NCT01271998|Drug|TR-701 FA|200 mg, oral, once daily for 3 days.
45692126|NCT00717418|Drug|cyclosporine ophthalmic emulsion 0.05%, artificial tears|one drop, twice a day in each eye
45692127|NCT00798226|Dietary Supplement|n-3 fatty acid|Oral intake of 4 capsules daily from week 24 of gestation to 1 week after delivery
46052844|NCT03278730|Drug|Placebo solution|Patients will recieveplacebo during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of placebo, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
46052845|NCT02805075|Other|Fructooligosaccharide|Given PO
46052846|NCT02805075|Other|Laboratory Biomarker Analysis|Correlative studies
45369874|NCT04010864|Other|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
45692128|NCT00798226|Dietary Supplement|olive oil|Oral intake of 4 capsules (1 g) daily from 24 weeks of gestation to 1 week after delivery
45692129|NCT00717574|Drug|Sevoflurane group|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
45692130|NCT00717574|Drug|Propofol group|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
46052847|NCT02803515|Biological|peripheral venous blood samples|peripheral venous blood samples measured preoperatively and postoperatively HIPEC (Day 1, day 3 and day 5 postoperative)
46052848|NCT03240978|Behavioral|exercise intervention|A period of 12-week exercise intervention under the supervision of exercise specialists will be conducted.
46052849|NCT05461209|Drug|Talquetamab|Talquetamab will be administered as subcutaneous injection.
45488698|NCT02406040|Other|Energy Restriction|All meals will be provided for the duration of the energy restriction intervention and the energy deficit will be calculated based on estimated energy requirements by indirect calorimetry to provide 60% of energy requirements. In addition, one leg will be assigned to perform resistance exercise for 5 days during the 10 day energy deficit.
45488699|NCT02405884|Other|Kowa HA-2 Perkins applanation tonometer.|Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
45488700|NCT03010176|Drug|Ulevostinag|IT injection
45488701|NCT03010176|Biological|Pembrolizumab|IV infusion
45488702|NCT04040933|Device|Marketed Adhesive Bandage #1|On the randomized wound site, a marketed adhesive bandage will be applied.
45488703|NCT04040933|Device|Marketed Bandage #2|On the randomized wound site, a marketed adhesive bandage will be applied.
45488704|NCT04040933|Device|Non-Marketed Bandage #1|On the randomized wound site, a non-marketed adhesive bandage will be applied.
45692131|NCT00718120|Biological|Fluviral®|One intramuscular injection into the deltoid region of the non-dominant arm
46052850|NCT05461209|Drug|Belantamab Mafodotin|Belantamab Mafodotin will be administered as intravenous infusion.
46052851|NCT03230604|Device|Filtek Bulk Fill Composite and Tetric N Ceram Bulk Fill Composite|Restorative cavities one, two and five with material Filtek Bulk Fill Composite
45753502|NCT04001504|Biological|Standard Dose Quadrivalent Influenza Vaccine|Standard Dose QIV (15µg Hemagglutinin)
45488705|NCT04040933|Device|Non-Marketed Bandage #2|On the randomized wound site, a non-marketed adhesive bandage will be applied.
45488706|NCT04040933|Device|Non-Marketed Adhesive Bandage #3|On the randomized wound site, a non-marketed adhesive bandage will be applied.
45488707|NCT04040933|Device|Non-Marketed Adhesive Bandage #4|On the randomized wound site, a non-marketed adhesive bandage will be applied.
45488708|NCT04040933|Device|Non-Marketed Adhesive Bandage #5|On the randomized wound site, a non-marketed adhesive bandage will be applied.
45488709|NCT02405728|Device|Centrally inserted central catheters (CICCs)|Randomization between two well established clinical routine vascular access devices
45488710|NCT02405728|Device|Peripherally inserted central catheters (PICCs)|Randomization between two well established clinical routine vascular access devices
45488711|NCT04897698|Dietary Supplement|LB001|Probiotics
45488712|NCT02702518|Drug|rhDNase I|rhDNase I, 0.1% eye drops 4 times a day for 8 weeks
45488713|NCT02702518|Drug|Vehicle|Drug vehicle 4 times a day for 8 weeks
45488714|NCT04935060|Behavioral|A guide to inform the process of delivering the outcomes of a dementia assessment|The guide provides information that informs the approach taken to assessing people for dementia. It aims to guide clinicians. patients and their companions to think about how the diagnostic process is carried out, taking into account patient preferences, particularly around how they would like diagnostic decisions to be communicated to them.
45488715|NCT04935060|Behavioral|Usual Care|Clinicians conduct the dementia assessment as per standard protocols
45753503|NCT04198532|Other|Contrast bath|Contrast bath (hot and cold therapy)
46052852|NCT03230604|Device|Z 350 Xt Composite|Restorative cavities one, two and five with material Z 350 XT Composite
46052853|NCT02798055|Drug|Bosentan group|
46052854|NCT03223194|Genetic|AT342|AT342 is an AAV8 vector containing a functional copy of the UGT1A1 gene.
46052855|NCT02804919|Device|Fisher & Paykel Healthcare CPAP Device|Fisher & Paykel Healthcare CPAP Device
45488716|NCT04482946|Diagnostic Test|Assessment of fluid responsiveness|The positive end-expiratory pressure test (PEEP-test) consisted of a transient increase of PEEP from 5 to 20 cm H2O for 120 seconds. The PEEP-test was interrupted if MAP decreased below 55 mm Hg and/or pulse contour cardiac index (PCCI) decreased below 1.5 L/min/m2. Mini-fluid challenge test (mFCT) consisted of rapid infusion of crystalloids 1.5 mL/kg during 120 seconds. Thereafter, all patients received fluid challenge (standard fluid challenge test, sFCT). During the sFCT, patients received 7 mL/kg of crystalloids within 10 minutes. Investigators performed monitoring of mean arterial pressure (MAP), SVV and PPVPiCCO using femoral artery (PiCCO2). Investigators also assessed PVVNK using radial artery and Nihon Kohden patient monitor. HLI (Hamilton G-5, Switzerland) and PVI (Masimo, USA) were assessed non-invasively, using finger probes.
45488717|NCT03683888|Behavioral|HealthSnap|HealthSnap provides personalized lifestyle reports and track progress over time using an electronic lifestyle record (ELR). HealthSnap Assessment is a simple, quick and not invasive tool that uses an algorithm that includes a questionnaire, physical measurements, dietary data and body fat indices
45753504|NCT00564265|Other|Observation|Not applied
45369875|NCT01563146|Other|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2006- May 31st 2007) and analysed for rotavirus, in children aged ≤5 years.
45488718|NCT03683888|Behavioral|dietary counseling|Dietary counseling by RD. Low Calorie and/or Low Carb dietary plans will be discussed and provided to the study participant
45488719|NCT04482478|Dietary Supplement|Extract of Dolichos lablab Linne (EDL)|Investigational product (EDL): once a day, 2 tablets orally intake (Extract of Dolichos lablab Linne 715 mg/day)
45488720|NCT04482478|Other|Placebo oral tablet|Placebo: consumed in the same way as the investigational product
45488721|NCT03683732|Behavioral|Individual semi-structured interviews|Individual semi-structured interviews were conducted using purposeful sampling of 15- to 18-year-olds, until data saturation, and were transcribed and analysed
45488722|NCT03739229|Biological|Placebo|2 intranasal administrations of lyophilized purified allantoic fluid of chicken embryos with stabilizers
45488723|NCT03739229|Biological|H7N9 LAIV|2 intranasal administrations of H7N9 live influenza vaccine
45488724|NCT03683654|Other|Identify Biomarkers of Dietary Intake in Healthy Subjects|Observational study. No intervention.
46052856|NCT05331768|Combination Product|banding ligation plus terlipressin infusion|Subjects were randomly allocated to banding ligation plus terlipressin infusion for 24 hours (24-h group) or banding ligation plus terlipressin infusion for 72 hours (72-h group) using a blocked allocation strategy. The 72-h group received the standard treatment with administration of intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) with an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 72 hours. Terlipressin was administered blinded after endoscopic treatment and infused as a 5 ml bolus in a pre-prepared syringe. The 24-h group received intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) as an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 24 hours.
45369876|NCT05069948|Other|HeadOn|HeadOn is a web application which takes the participant through a 5-stage CBT programme including: (i) understanding post-concussion symptoms; (ii) sleep after a concussion; (iii) lifestyle habits and exercise; (iv) managing negative thought patterns and (v) returning to baseline. The programme is delivered through a combination of weekly tasks (such as completing symptom diary, setting exercise goals and setting up a sleep time routine), audio/video media and reading material.
45369877|NCT00960830|Drug|mirtazapine|mirtazapine 15 mg daily tablets
45369878|NCT00960830|Drug|mirtazapine|15 mg daily
45488725|NCT03680300|Other|Post Facilitation Stretch|"The Post Facilitating Stretch technique is performed as follows:~The hamstring muscle will be placed between a fully stretched and a fully relaxed state. The patient will be asked to contract the agonist using a maximum degree of effort for 5-10 seconds while the therapist resists the patients force. The patient will then be asked to relax and release the effort, whereas the therapist will apply the rapid stretch to a new barrier and will be held for 10 seconds. Then the patient will relaxes for approximately 20 seconds and the procedure will be repeated between three to five times and five times more. Instead of starting from a new barrier, the muscle will be placed between a fully stretched and a fully relaxed state before every repetition."
45488726|NCT03680300|Other|Post Isometric Relaxation|"The Post Isometric Relaxation technique is performed as follows :~The hamstring muscle will be taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle will be performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction the patient will be asked to relax and exhale while doing so. Following this a gentle stretch will be applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times."
45488727|NCT03680300|Other|Friction Massage|Each patient in group C will receive hot pack along with Tens for 20 mins then the patients will receive frictional massage alone for about one months on daily basis. Friction massage on hamstrings will be given for 20 mins by thrive massager by a therapist.
45753505|NCT04198298|Drug|EndoSequence|The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.
45753506|NCT04198298|Drug|ProRoot MTA|The ProRoot® MTA retrograde sealing material was used to provide a biologic seal at the apex.
45753507|NCT04198298|Drug|Biodentine|The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.
45846596|NCT02609100|Procedure|Video Capsule Endoscopy|Video Capsule Endoscopy allows for imaging of the small intestine between the distant duodeno-jejunal junction, which is beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. It is of greatest use in identifying points of bleeding and ulcers.
45369879|NCT00960908|Device|Endeavor Resolute stents|2nd generation ZES
45369880|NCT00960908|Device|Endeavor Sprint stent|1st generation ZES
45369881|NCT00962624|Drug|meningococcal B vaccine & meningococcal ACYW conjugate vaccine|Meningococcal B vaccine will be administered at 0, 2 and 6 months and a single dose of meningococcal ACYW vaccine will be administered at 0 months, concomitantly with the first dose of the meningococcal B vaccine.
45369882|NCT00962702|Device|LAAx TigerPaw System|Exclusion of Left Atrial Appendage
45488728|NCT02414620|Device|Generation II Dental Vibe Unit|. The Dental Vibe emits strong pulsed vibration which is transmitted via a silicone mouth piece to mucosal tissue.
45488729|NCT03680222|Procedure|Reversed Tracking Method|Reversed Tracking Method
45488730|NCT02414542|Device|MINIMA stem|
46052857|NCT04235595|Other|Connective Tissue Manipulation|The application was delivered with the participant in a sitting position, with the entire back and sacral regions left exposed. The treatment was administered to the sacral, lower thoracic and pelvic regions.
45369883|NCT00105235|Drug|Alemtuzumab|T-cell depleting monoclonal antibody; two doses by intravenous infusion on Days 0 and 4
45369884|NCT00105235|Drug|Cyclosporine|Oral immunosuppressant
45488731|NCT03176524|Drug|BioChaperone® glucagon formulation 1|Injection of BioChaperone® glucagon formulation 1 at Day 1: 50 µg and at Day 2: 1 mg
45369885|NCT00105235|Drug|Mycophenolate mofetil|Oral immunosuppressant
45488732|NCT03176524|Drug|BioChaperone® glucagon formulation 2|Injection of BioChaperone® glucagon formulation 2 at Day 1: 50 µg and at Day 2: 1 mg
45488733|NCT03176524|Drug|GlucaGen® HypoKit®|Injection of GlucaGen® HypoKit® at Day 1: 50 µg and at Day 2: 1 mg
45488734|NCT03676088|Procedure|root coverage|recession coverage is treated with modified coronally advanced tunnel with connective tissue graft with recombinant human platelet derived growth factor- BB for Experimental: Test group and without recombinant human platelet derived growth factor- BB for Active Comparator: Control group
45488735|NCT02414464|Other|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP 35% gel was applied to the vestibular faces of these teeth.~In the present study, the Whiteness HP 35% gel was applied without an external auxiliary source. As this is not a self-catalyzed system, the gel was removed after each 15-minute application and reapplied two more times, totaling 45 minutes of contact with the teeth."
45488736|NCT02414464|Other|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 35% gel was applied to the vestibular faces of these teeth for 40 minutes in each session."
45753508|NCT04199936|Device|Electrical Muscle stimulation|Electrical muscle stimulation
45753509|NCT00516919|Drug|Xenical + behavioral intervention|120 mg TID; Behavioral weight loss in Spanish
45753510|NCT00516919|Behavioral|Behavioral intervention + placebo|Behavioral weight loss treatment in Spanish Placebo TID
46052858|NCT04235595|Other|Transcutaneous Electrical Nerve Stimulation|TENS was administered with the participant lying face down with a flat cushion underneath the abdomen. TENS was administered via 2 channels of electrodes placed with the sacral region in the middle. The intensity of the current was increased until the participant felt it.
45846597|NCT02609100|Procedure|Colonoscopy|The colonoscopy helps find ulcers, tumors, and areas of inflammation or bleeding in the large intestine.
45369886|NCT00105235|Drug|Tacrolimus|Oral immunosuppressant
45369887|NCT00105235|Procedure|Liver transplant|Occurs at study entry
45369888|NCT00105235|Procedure|Immunosuppression withdrawal|Beginning no earlier than Year 1
45369889|NCT03962803|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
45369890|NCT03962803|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 20 µg per dose
45369891|NCT03962803|Biological|60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 60 µg per dose
45369892|NCT00547118|Drug|Rimonabant|One 20 mg tablet given 1 time per day for 112 days.
45369893|NCT00547118|Drug|Placebo|One placebo tablet given 1 time per day for 112 days.
45369894|NCT01087021|Drug|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
45369895|NCT01084525|Drug|OTO-104 (steroid) 3 mg|OTO-104 3 mg dose cohort, single intratympanic injection.
45369896|NCT01084525|Drug|Placebo|Placebo arm will be conducted in parallel with each OTO-104 dose cohort.
45692132|NCT04275310|Behavioral|Microeconomic Intervention|The intervention will consist of six sessions on six different days. Sessions will be held at VCU or at one of VCU's community partners. Each session will last for around 2 ½ hours (around 15 hours total). There will be breaks and food will be provided. During the sessions the facilitators will provide education on a variety of topics, including economic services that are available to people living in Richmond, job skills (such as creating a resume and dealing with discrimination at work), personal finance education, gender transition ideas, and HIV prevention. The sessions will occur in a group of about 4-10 transgender women.
45692133|NCT02992054|Other|stimulating activities|
45369897|NCT01084525|Drug|OTO-104 (steroid) 12 mg|Sequential dose cohort escalation to OTO-104 12 mg dose cohort will occur pending the safety evaluation of 28 day follow up safety data for the OTO-104 3 mg dose cohort. OTO-104 12mg dose cohort is also a single intratympanic injection.
45369898|NCT00962936|Drug|CT-011|CT-011
45369899|NCT00502593|Biological|Pandemic Influenza Vaccine (GSK1562902A)|2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.
45369900|NCT00502593|Biological|Fluarix™|2 doses, intramuscular injection on Days 0 and 21.
45369901|NCT01087099|Drug|Albendazole|Treatment with albendazole
45369902|NCT00686543|Drug|Posaconazole|Posaconazole will be used for prophylaxis
45369903|NCT04009538|Other|Rehabilitation program|exercise program twice a week
45369904|NCT02561741|Drug|COV155|COV155 tablets
45369905|NCT04010708|Diagnostic Test|Urinary Iodine Concentration Measurement|UIC
45369906|NCT00750113|Drug|Nifidipine|Tablets 20 Mg daily for 4 weeks then combination therapy
45369907|NCT00750113|Drug|Telmisartan|Tablets 80 Mg daily for 4 weeks then combination therapy
45369908|NCT00750113|Drug|Nifedipine/Telmisartan|2 drugs (20 Mg Nifedipine/80 Mg Telmisartan) Combination therapy since the beginning
45369909|NCT04971590|Other|Participant completed survey|Participants will be required to complete the participant survey.
45369910|NCT04971590|Other|Medical chart review|Data will be collected from medical charts of participants.
45369911|NCT00963092|Genetic|DNA analysis|
45369912|NCT00963092|Genetic|RNA analysis|
45369913|NCT00963092|Genetic|microarray analysis|
45369914|NCT00963092|Genetic|protein analysis|
45369915|NCT00963092|Other|cytology specimen collection procedure|
45369916|NCT00963092|Other|laboratory biomarker analysis|
45369917|NCT00963092|Other|questionnaire administration|
45369918|NCT00745511|Drug|ORA102 and Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)and ORA102
45369919|NCT00745511|Drug|Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)
45369920|NCT00961376|Biological|PBMC re-infusion|Autologous PBMC re-infusion
45369921|NCT00961376|Biological|CD25 depletion|Autologous, CD25-depleted PBMC re-infusion
45369922|NCT00961454|Device|Photobiomodulation with a super-luminous light emitting diode|The treatment will consist of applying PBM in the form of a super-luminous LED with an output of 250 mW/cm2 at a wavelength of 815 nm with a full width half maximum of 40 nm when applied at 4 mm from the skin. The treatment will consist of the exposure to the light for 4 minutes (total delivered fluence per spot of 60 J/cm2) at each of 4 sites on the forehead that correspond to the 10-20 EEG sites, F3, and F4.
45369923|NCT00545688|Drug|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
45369924|NCT00545688|Drug|Docetaxel|75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
45369925|NCT00545688|Drug|Pertuzumab|840mg iv loading dose, followed by 420mg iv 3-weekly
45369926|NCT01563380|Biological|Platelet rich plasma|PRP ready to be injected was supplied in a syringe in a quantity of 8 ml for each knee. The entire procedure was done under complete aseptic precautions. The calcium chloride required for activation was given in a separate syringe in a ratio of 4:1. About 12-16 ml of platelet rich plasma was obtained by this method and it was used for application. To confirm sterility, culture and sensitivity of PRP was performed. Patient's peripheral blood platelet count and the prepared platelet concentrate's platelet count was performed and recorded. Number of tramadol injections given was also noted
45369927|NCT00961610|Behavioral|Internet peer-support group|"The Internet peer-support groups provided a self-guided space for communication, including an Internet discussion forum, a live chat room and a personal message system. No therapeutic content or information services were offered within the groups.~All Internet groups were run in a browser-based software platform with access through the website of the Danish Cancer Society (http://www.cancer.dk). All discussions were protected by a password and communication was encrypted.~The Internet groups in this study were all closed peer-support groups, accessible only by an invitation received by e-mail after registration for the study. The groups were open to access 24 h a day for 13 months from their individual starting date."
45369928|NCT00961766|Drug|BG00010 (Neublastin)|Single dose, weight-based IV administration
45369929|NCT00961766|Drug|Placebo|Single dose IV matched placebo
45692134|NCT01277614|Behavioral|Therapeutic lifestyle|This is a 6-month intervention in which participants with 2r more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
45692135|NCT01277692|Drug|GSK2336805 10mg|single dose once daily
45692136|NCT01277692|Drug|GSK2336805 30mg|single dose once daily
45692137|NCT01277692|Drug|GSK2236805 100mg|single dose once daily
45692138|NCT01277692|Drug|GSK2236805 200mg|single dose once daily
45692139|NCT01277692|Drug|GSK2236805 10mg|repeat dose once daily for 7 days
45846598|NCT02609100|Device|1.0 X 2.5 cm 'pill' containing a camera|
45488737|NCT02414464|Other|20% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 20% gel was applied to the vestibular faces of these teeth 50 minutes in each session."
45488738|NCT02961582|Device|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period. If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF <3 a week), the lead is explanted.~Patients in the intervention group are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
45488739|NCT02961582|Other|Personalized Conservative Treatment|The control group will receive the best and least invasive alternative treatment, which is personalized conservative treatment (PCT). PCT includes, a combination of laxative/medication use and/or colonic irrigation, depending on the preferences of the patient. Use of PCT will be documented.
45488740|NCT03226418|Drug|Cytarabine|Given IV
45488741|NCT03226418|Drug|Decitabine|Given IV
45488742|NCT03226418|Drug|Idarubicin|Given IV
45369930|NCT00502203|Drug|Carboplatin|AUC 5 By Vein Over 1 Hour Every 21 Days for 6 Courses
45488743|NCT03226418|Other|Laboratory Biomarker Analysis|Correlative studies
45488744|NCT03226418|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
45488745|NCT03226418|Other|Quality-of-Life Assessment|Ancillary studies
45369931|NCT00502203|Drug|Paclitaxel|175 mg/m^2 By Vein Over 3 Hours Every 21 Days for 6 Courses
45488746|NCT03226418|Other|Questionnaire Administration|Ancillary studies
45488747|NCT03226418|Drug|Azacitidine|Given by infusion
45488748|NCT03226418|Drug|Venetoclax|oral tablet
45488749|NCT03226418|Drug|glasdegib|oral tablet
45488750|NCT04039503|Drug|Tirzepatide|Administered SC as add-on to the pre-trial background medication.
45488751|NCT04039503|Drug|Placebo|Administered SC as add-on to the pre-trial background medication.
45488752|NCT02414308|Drug|Adipose tissue stem cell injection|Stem cell will be harvested through adipose tissue by liposuction and isolation occurred Injection will distribute through corpora cavernosa and dorsal penile artery
45488753|NCT02943408|Behavioral|person-centered mental health intervention|We anticipate that the PCMHI will be comprised of three, one-hour sessions offered over three to six weeks, scheduled at the participants' preference. Sessions will be one-on-one and the peer support specialist interventionist.
45488754|NCT02943408|Behavioral|health and wellness|The control condition will be an educational health and wellness intervention for stress related disorders that will match the experimental condition for time and attention. The control condition will be three, one hour, individual sessions covering the symptom cycle, managing stress, and identifying social supports.
45488755|NCT02860728|Behavioral|Individualized Resistance Training|Lower body resistance exercises will be prescribed in various combinations over multiple days and individually modified and progressed to achieve advances in both movement pattern, intensity, and exercise volume.
45488756|NCT03679910|Diagnostic Test|CEMIP , CA19-9 ,CEA|CEMIP: Cell migration inducing protein CA19-9: Carbohydrate antigen 19-9 CEA: Carcinoembryonic antigen
45488757|NCT03679910|Diagnostic Test|A) CBC . B) RBG. C)KFT. D) LFT.|A)CBC: Complete blood count. B)RBG: Random blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
45488758|NCT05418114|Drug|Magnesium sulfate|. One group (Group A) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine + 1 ml (500 mg) of 50% Magnesium sulphate. Other group (Group B) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine.
45488759|NCT03683420|Behavioral|Music Therapy|The intervention consists of using an iPod to listen to music for up to 60 minutes while patients are receiving chemo infusion. There are no on components to the study.
46052859|NCT03609762|Behavioral|EQ-5D-5L HRQOL results be available to the attending doctor|all subjects attending the intervention clinics will complete the electronic EQ-5D-5L before seeing the doctor during each follow-up visit for the musculoskeletal problem, a print out of the longitudinal EQ-5D-5L data (Table 1) since recruitment will be given to the patients to show to the attending doctors during the consultation. The doctors will provide the management based on the usual clinical information and the additional EQ-5D-5L HRQOL results. The doctor will complete the clinician-reported follow-up clinical data form (CRF) of each eligible patient at the end of the consultation.
45488760|NCT05528952|Drug|Atezolizumab|1200 mg IV every 3 weeks until disease progression or unacceptable toxicity
45488761|NCT05528952|Drug|Bevacizumab|15 mg/kg IV every 3 weeks until disease progression or unacceptable toxicity
45488762|NCT05528952|Drug|UCPVax|UCPVax vaccine (combined with Montanide ISA51 as adjuvant) at 0.5 mg subcutaneously
46052860|NCT04235439|Drug|Gan & Lee Insulin Lispro Injection|All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area by use of a disposable prefilled pen.
46052861|NCT05119686|Drug|AR882 Dose 1|Solid Oral Capsule
46052862|NCT05119686|Drug|AR882 Dose 2|Solid Oral Capsule
46052863|NCT05119686|Drug|Placebo|Matching Solid Oral Capsule Placebo
45488763|NCT03683264|Other|Ultrasound diagnosis of avulsion of the levator ani muscle|In the multi-view ultrasound images, complete avulsion was defined as an abnormal insertion of LAM in the lower pubic branch identified in all three central slices, i.e. in the plane of minimal hiatal dimensions (PMD) and the 2.5 and 5.0mm slices cranial to this one. Levator hiatus measurements, transverse diameters, anteroposterior diameters and area were also determined in the same plane (PMD).
45488764|NCT01364025|Procedure|uterosacral ligament suspension colpopexy bilateral|Uterosacral ligament suspension colpopexy bilateral
45488765|NCT03225716|Drug|Ulocuplumab|Ulocuplumab is a type of protein called an antibody that attacks CXCR4
45488766|NCT03225716|Drug|Ibrutinib|Ibrutinib small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity
45488767|NCT05189769|Behavioral|CP no REACT|Coping Power no REACT
45488768|NCT05189769|Behavioral|CP+/No REACT|CP+ and no REACT
45488769|NCT05189769|Behavioral|CP and REACT|Coping Power traditional and REACT
45488770|NCT05189769|Behavioral|CP+ and REACT|CP+ and REACT
45369932|NCT04900298|Device|SafeHaven Automated Hand Hygiene Device|Anesthesia providers in the intervention arm will be given a personal hand hygiene device, containing 64% ethyl alcohol, which provides actionable real-time performance feedback. The personalized device will be affixed to the provider's waist and will remain there for use throughout the perioperative period. Performance feedback is given to the anesthesia provider in real time with the number of personal hand hygiene events and an hourly hand hygiene rate, which is displayed on the device. Devices will be handed out to participating providers in the preoperative bay and retrieved in the post-anesthesia care unit upon case completion.
45369933|NCT03049371|Other|No Intervention for both groups|No Intervention for both groups However, computer-administered questionnaire will collect quantitative demographic information and details about surgical history, neovaginal health, neovaginal practices, and sexual behavior including neovaginal intercourse and drug use history from each participant
45488771|NCT03672812|Drug|Liraglutide|liraglutide 3mg 6/6 hours
45488772|NCT05417880|Drug|Oral Hypoglycemic Agents,Oral|Control group with routine current oral hypoglycemic agents for 3-6 months
45488773|NCT05417880|Drug|Voreta|Empagliflozin 10 mg oral tablets Once Daily for 3-6 months
45488774|NCT05417880|Drug|Voreta plus SunnyD PRO|Empagliflozin 10 mg oral tablets + Vitamin D3 ( 2000 IU ) + Vitamin K2 ( 100 mcg) Once Daily for 3-6 months
45488775|NCT05029726|Drug|Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine|Bupivacaine-Epinephrine 0.25%-1:200,000 plus clonidine 50 micrograms in 30cc syringes administered as ESPB
45488776|NCT05029726|Drug|normal saline|normal saline in 30cc syringes administered using ESPB technique
46052864|NCT02798133|Procedure|OLA|PEEP titration trial for best Cdyn after the alveolar recruitment maneuver
46052865|NCT02798133|Procedure|RM-5|Fixed standard PEEP after the alveolar recruitment maneuver
46052866|NCT02797743|Other|Whole blood|"Adults ≥18 yrs of age: up to 50 mL (5 tubes)~Adolescents 12-17 yrs of age: up to 30 mL (3 tubes)~Children 0-11 yrs of age: single tube (1 tube, 10 mL)"
45488777|NCT05186883|Biological|Allogenic parathyroid cells|Allogenic parathyroid cells
45488778|NCT05186883|Other|Standard treatment according to the Clinical protocols|Standard treatment of postoperative hypoparathyroidism according to the Clinical protocols
45488779|NCT05522244|Diagnostic Test|extended CTA|Extending the standard CTA 3 cm below the carina.
46052867|NCT02640222|Drug|VKA|
46052868|NCT02640222|Drug|Apixaban|
46052869|NCT02640222|Drug|dabigatran|
46052870|NCT02640222|Drug|rivaroxaban|
46052871|NCT03868605|Device|EMR and ESD|Endoscopic mucosal resection using a resection snare Endoscopic submucosal dissection using an electrosurgical knife
45369934|NCT00546078|Biological|Cervarix™|Intramuscular injection, one or three doses
45369935|NCT04819256|Other|PACE-It mobile application|Care co-ordination platform
45369936|NCT03035565|Behavioral|Computerized Cognitive Training with Brain HQ|Computerized Cognitive Training Brain HQ activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
45369937|NCT03035565|Behavioral|Computerized Crossword Puzzles|Computerized Crossword Puzzles activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
45369938|NCT00963326|Other|laboratory biomarker analysis|
45369939|NCT00967772|Drug|Naftopidil|25mg/ 50 mg/ 75mg dosage tablets
45369940|NCT00967850|Drug|Intravitreal Injection|Intravitreal injection of 1,25 mg in 0,05 ml
45488780|NCT05007652|Drug|KRN125(pegfilgrastim), PLR001(plerixafor)|7.2 mg of KRN125 in Day 1 Single subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
45692140|NCT01277692|Drug|GSK2236805 dose to be determined up to 100mg|repeat dose once daily for 7 days
46052872|NCT03868605|Device|Over- the- scope full- thickness resection device|Endoscopic resection of neoplastic lesions of the colon using the over- the- scope full- thickness resection device
46052873|NCT02795871|Behavioral|Neuropsychological and cognitive assessment|
46052874|NCT02795715|Device|tDCS|
46052875|NCT02795715|Behavioral|training|
46052876|NCT00818662|Biological|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg|400 mg/kg bodyweight every 2 weeks for 70 weeks
45488781|NCT05007652|Drug|KRN8601(filgrastim), PLR001(plerixafor)|400 ug/m2 of KRN8601 from Day 1 to the end date of the Apheresis Once daily subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
45488782|NCT03675932|Other|Rapid Cadence Cycling on a Solo-Rider Spin Bicycle|Individuals with Parkinson's Disease will participate in 60 minute spin-classes during which they will follow the Pedaling for Parkinson's(TM) Foundation recommended protocol to achieve a cadence of 80-90 during the 40 minute main set.
45488783|NCT01367145|Drug|OMACOR|4 capsules OMACOR 1g per day
45488784|NCT01367145|Drug|Placebo|4 capsules placebo per day
45488785|NCT05521698|Drug|Apalutamide|Given PO
45488786|NCT05521698|Procedure|Biospecimen Collection|Correlative studies
45488787|NCT05521698|Other|Questionnaire Administration|Ancillary studies
45488788|NCT05521698|Procedure|Transurethral Resection of Bladder Tumor|Undergo TURBT
45488789|NCT03679754|Biological|Ad-RTS-hIL-12|"2.0 x 10^11 viral particles (vp) per injection~intratumoral injection of Ad-RTS-hIL-12"
45488790|NCT03679754|Drug|veledimex|"20mg/day~15 oral daily doses of veledimex"
45488791|NCT02405572|Other|infant formula|infant formulas
45488792|NCT01319409|Procedure|Anatomic Double-Bundle ACL Reconstruction|Surgical reconstruction of the posterolateral (PL) and anteromedial (AM) bundles of the ACL using an autograft quadriceps tendon with a bone block that is split into 2 free arms to recreate the AM and PL bundles. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft are be placed in 2 separate tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle is fixed with the knee in full extension and the AM bundle is fixed with the knee at 45 degrees of flexion.
45488793|NCT01319409|Procedure|Anatomic Single-Bundle ACL Reconstruction|Surgical reconstruction of the ACL using a single autograft quadriceps tendon with a bone block. The free end of the graft is not split. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The single free end of the graft is placed in a single tibial tunnel located in the center of the tibial ACL insertion site. The graft is fixed with the knee in 10 to 20 degrees of flexion.
45488794|NCT02405806|Dietary Supplement|low carbohydrate food|low carbohydrate food
45488795|NCT02405806|Dietary Supplement|standard food|standard food
45488796|NCT03632772|Drug|Solifenacin 5Mg|We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
45488797|NCT03632772|Drug|Mirabegron 50 MG|We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
45488798|NCT01360749|Drug|Lambdalina® (Lidocaine 4% cream)|Lambdaline dose: 2 g for 10 cm2.
45488799|NCT01360749|Drug|Placebo|Placebo dose: 2 g for 10 cm2.
45488800|NCT02960516|Device|MRI of 3.0T|Diffusion Tensor Testing for peripheral nerve monitoring
45488801|NCT01367223|Dietary Supplement|solution of amino acids supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
45846599|NCT02610972|Device|Congo Red test GV-005|Congo Red test GV-005 test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
45846600|NCT02612688|Behavioral|ACP Video Program|The ACP Video Program consists of five videos that address ACP decisions: (1) General Goals of Care, (2) Goals of Care for Advanced Dementia, (3) Hospice, (4) Hospitalization, and (5) ACP for Healthy Patients. NH staff will offer videos to patients at these clinical triggers: (1) Within 7 days of admission or readmission; (2) Every 6 months for long-stay patients; (3) When there is a significant change in clinical status; (4) When a treatment decision arises for which there is a specific video; and (5) Special circumstances when goals of care are being considered (e.g., family visiting).
45846601|NCT05732064|Drug|Dexmedetomidine|Dexmedetomidine 0.5 microgram/kg (300 microgram/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
45488802|NCT01367223|Dietary Supplement|amino acids not supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
45488803|NCT03171766|Diagnostic Test|Mini-Mental State Examination (MMSE)|It is simple scored form of the cognitive mental status examination which includes eleven questions and requires only 5 to 10 minutes.
45488804|NCT03171766|Diagnostic Test|Visual Analog Scale (VAS)|Visual Analog Scale (VAS) for pain score (including aphasia, motor disability, major neurocognitive disorder, etc)
45488805|NCT03171766|Diagnostic Test|Mini Cog test|The Mini-Cog© test is another validated and simple tool to screen for dementia and cognitive dysfunction. It measures the cognitive reserve at the time of acute stress with a low degree of interobserver variability.
45692141|NCT01277692|Drug|GSK2236805 5mg|single dose in HCV infected patients
45692142|NCT01277692|Drug|GSK2236805 30mg|single dose in HCV infected patients
45692143|NCT01277692|Drug|GSK2236805 100mg|single dose in HCV infected patients
45692144|NCT00719134|Drug|Maxalt|anti-migraine drug
45692145|NCT00719134|Drug|placebo pill|placebo pills
45692146|NCT00719134|Drug|placebo pills|placebo pills
45692147|NCT04146363|Biological|Lebrikizumab|Subcutaneous injection
45692148|NCT04146363|Other|Placebo|Subcutaneous Injection
45692149|NCT01272154|Other|Transcranial magnetic stimulation|Transcranial magnetic stimulation (PAS and rTMS)
45846602|NCT05732064|Drug|Esketamine|Esketamine 0.2 mg/kg (25 mg/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
45846603|NCT05732064|Drug|Normal saline|Normal saline of same volume is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
46052877|NCT00818662|Biological|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg|200 mg/kg bodyweight every 2 weeks for 70 weeks
45692150|NCT01277770|Drug|Steroid-Free Maintenance Immunosuppression|10 year follow-up of steroid-free maintenance immunosuppression
45369941|NCT00967850|Drug|Photodynamic Therapy (Visudyne)|Photodynamic therapy on day 1 as described in standard clinical guidelines.
45369942|NCT00964938|Device|Quadripolar LV lead (pacing configurations)|Quadripolar LV lead will be used to deliver a combination of pacing configurations
45369943|NCT00965016|Procedure|hypothermia|Core temperature --> 34.9℃ within 30 min --> 33.5℃ within 120min --> 33℃for 24 H Decrease temperature in 0.9℃/hour
45369944|NCT04009928|Device|Active stimulation of the medial forebrain bundle or subcallosal cingulate|Deep brain stimulation of the medial forebrain bundle or subcallosal cingulate
45692151|NCT01277770|Other|Infection After Kidney Transplantation|A cross-sectional study of infection after kidney transplantation (with emphasis on infection in steroid-free recipients).
45692152|NCT01277770|Drug|Evaluation of the DGF nomogram in Thymoglobulin|An evaluation of the DGF nomogram in Thymoglobulin treated recipients at the University of Minnesota
45692153|NCT02992210|Genetic|4SCAR-GD2|
45692154|NCT00721162|Biological|Ramucirumab|Participants will receive ramucirumab at 8 milligrams/kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
46052878|NCT00818662|Biological|Placebo solution: Human Albumin 0.25% - 4 mL/kg|Placebo solution: 0.25% human albumin solution infused at 4 mL/kg/2weeks for 70 weeks
46052879|NCT00818662|Biological|Placebo solution: Human Albumin 0.25% - 2 mL/kg|Placebo solution: 0.25% human albumin solution infused at 2 mL/kg/2weeks for 70 weeks
45369945|NCT04009928|Device|Sham stimulation|Sham stimulation for 2 weeks (Cross-over design)
45369946|NCT00967928|Drug|RAD001|RAD001 will be administered orally as 5 mg qod, 5 mg qd, or 10mg qd continuously from study Day 1 until the end of whole pelvic radiation therapy unless the patient develops progression of disease or unacceptable toxicity prior to that.
45369947|NCT00967928|Drug|Cisplatin|Cisplatin will be administered intravenously once weekly at 40mg/m2 for 6 weeks. The preferred administration day is Monday.
45369948|NCT00967928|Radiation|External Beam Whole Pelvis Radiation Therapy|Patients will receive 180 cGy daily fraction Monday through Friday x 25 days (4500 cGy total) using a four field technique throughout the entire treatment with all fields treated each day.
45369949|NCT00546000|Drug|Fluticasone propionate 0.05% lotion|Daily applications
45369950|NCT00963404|Radiation|Radiation boost|Radiation boost of the bladder-tumor: 10 Gy/5 fractions, 2 Gy per fraction.
45369951|NCT00968006|Drug|Sitagliptin|100 mg once daily for 4 weeks
45369952|NCT00971022|Behavioral|Survey|20 minute survey to determine the relationship between awareness of the discount generic prescription program and utilization of the program.
45369953|NCT00971022|Behavioral|Focus Group|5 - 8 focus groups of 6 - 10 people, lasting approximately 90 minutes
45369954|NCT00963716|Device|Hot biopsy forceps|Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
45369955|NCT00963716|Device|Cold biopsy forceps|Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
45369956|NCT00971100|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen & adjuvant, or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups.
45692155|NCT01838941|Drug|Betaine|"Betaine will be given orally (mixed with food or dissolved in water, juice, milk, or formula) or through gastrostomy tube as follows:~6 g/day in children < 30 kg, in 3 divided doses (2 g at meal time)~12 g/day in children > 30 kg, in 4 divided doses (3 g at meal time and bed time)."
45692156|NCT01773109|Drug|Etirinotecan pegol (NKTR-102)|Eligible patients will receive etirinotecan pegol at a dose of 145 mg/m2 iv every 3 weeks. One cycle will be defined as 3 weeks. Treatment will be administered on an outpatient basis.
45692157|NCT02991976|Procedure|Oxygen concentration|Shunting, raising concentration of O2 because of improving regional cerebral oxygen saturation (rSO2), keeping blood pressure above 120-130 mmHg, positive end expiratory pressure (PEEP)
45692158|NCT01772719|Drug|Simvastatin and zoledronic acid|"Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy.~Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly."
45692159|NCT05582265|Drug|Tislelizumab（neoadjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
45692160|NCT05582265|Drug|Cisplatin （neoadjuvant）|Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
45692161|NCT05582265|Drug|Nab-paclitaxel （neoadjuvant）|Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
45692162|NCT05582265|Procedure|Surgical resection|Standard of care
46052880|NCT02797899|Device|Platelet Rich Fibrin|Native growth factors
46052881|NCT03983031|Drug|Rituximab|Infusion
46052882|NCT03970005|Behavioral|Step-Based Care Model|Care model comprised of psychosocial and pharmacological interventions in which individuals start with low-intensity interventions and progress onto progressively higher-intensity interventions until their reach remission criteria.
46052883|NCT00903786|Drug|perampanel|Patients will receive the same oral dosage (2 mg up to 12 mg once daily before bedtime) as used in the maintenance period of Study 231.
46052884|NCT02795637|Drug|dasotraline|dasotraline 8mg capsule/day
46052885|NCT00703066|Biological|GMZ 2 vaccine (GLURP + MSP 3)|three doses of 30µg of GMZ 2 vaccine,
45488806|NCT03171532|Procedure|Strands of Hamstring Autograft in ACL reconstruction|The femoral and tibial ends will be tubularised and the final graft diameter will be recorded after passing through sizing cylinders graduated in 0.5mm increments. The femoral and tibial tunnels will be drilled as per standard technique for single bundle ACL reconstruction via trans-portal or trans-tibial route and both ends fixed by interference screw with additional post on the tibial end.
45488807|NCT03672656|Device|lasercoagulation by Pascal system|pattern scanning laser system Pascal given in a single-session
45369957|NCT00968162|Drug|fludarabine|Conduct a pilot trial using a transplant protocol, in which the standard busulfan, cyclophosphamide and anti-thymocyte globulin conditioning regimen is modified by adding fludarabine, a highly immunosuppressive agent, in order to determine the feasibility of reducing the total dose of cyclophosphamide from its present standard of 200 mg/kg to 90 mg/kg and of busulfan from its present standard of 12.8 mg/kg (IV) to 6.4 mg/kg, using a four step dose de-escalation schema.
45369958|NCT00968240|Drug|Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB|"This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival of patients with relapsed/refractory GBM/AA.~Day 0: Intraarterial Avastin single dose (starting at 2mg/kg and up to 10mg/kg) after Mannitol to open the blood brain barrier."
45488808|NCT03672656|Device|conventional laser|conventional laser multiple-session treatment
45488809|NCT01367301|Drug|paclitaxel|Given IV
45488810|NCT01367301|Drug|carboplatin|Given IV
45488811|NCT01367301|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
45488812|NCT01367301|Radiation|brachytherapy|Undergo HDR brachytherapy
45488813|NCT01367301|Radiation|intensity-modulated radiation therapy|Undergo IMRT
45488814|NCT01367301|Other|laboratory biomarker analysis|Correlative studies
45488815|NCT03675854|Drug|Cefazolin|3 weeks
45488816|NCT03672578|Other|loss-frame|loss frame label
46052886|NCT00703066|Biological|GMZ 2 vaccine (GLURP + MSP 3)|100 µg of GMZ 2 vaccine
46052887|NCT00703066|Biological|Rabies vaccine|3 doses of Rabies vaccine
45488817|NCT03672578|Other|gain-frame|gain frame label
45692163|NCT05582265|Drug|Cisplatin（adjuvant）|Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
45692164|NCT05582265|Drug|Tislelizumab（adjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
45692165|NCT05582265|Radiation|Radiation|Recommended, standard of care
45369959|NCT05207462|Behavioral|Intensive treatment with prolonged exposure|Intensive treatment with prolonged exposure
45369960|NCT00501969|Drug|Rotigotine|"Rotigotine trans-dermal patches once daily:~20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) 50 cm2 (10 mg/24 hours) 60 cm2 (12 mg/24 hours) 70 cm2 (14 mg/24 hours) 80 cm2 (16 mg/24 hours)"
45488818|NCT03672578|Other|text-only|text-only label
45488819|NCT03672578|Other|icon|label with icon and text
45488820|NCT03672578|Other|attribution|label with attribution
45488821|NCT03672578|Other|no attribution|label with no attribution
45488822|NCT03672578|Other|No label|No label
45488823|NCT02414074|Behavioral|Youth Behavioral Intervention|Teen Intervene is an early intervention program for 12-19 year olds.
45488824|NCT02414074|Behavioral|Parent Education|Everyday Parenting is a parent training curriculum.
45488825|NCT01367379|Procedure|24 hour EKG and blood pressure monitor|All subjects will have non-invasive 24 hour EKG and 24 hour EKG monitoring for 24 hours.
45488826|NCT01367379|Other|Blood and urine sampling|Right before and after the duty loading, all subjects will have blood samplings, including CRP, WBC, IL-6, Fibrinogen, insulin, IL-6, Procalcitonin, TNF-alfa, catecholamine level. Right after the duty loading, all subjects will have urine samplings for cortisol and catecholamine level.(blood : 15CC/time and 2~4 times/month)
45488827|NCT02409472|Other|surveillance program after completion of primary treatment|These are two different surveillance programs for Dukes B2-C colorectal cancer patients who have no evidence of disease at the end of their front line treatment (surgery and adjuvant radio-chemotherapy, if indicated). These programs differ greatly in the frequency of diagnostic imaging. They had similar schedules of physical examinations and carcinoembryonic antigen (CEA) assessments.
45488828|NCT01364103|Other|volume expansion|fluid loading of 10 mL/kg colloid (voluven)
45692166|NCT01798927|Device|Ankle foot orthosis|Participants will receive a Tamarack ankle foot orthosis with a check strap for gait training as well as a home walking program.
45692167|NCT00729430|Drug|Omega-3 Fatty Acids (Fish Oil Supplements)|4 grams of omega-3 fatty acids taken orally once per day for 6 months
45692168|NCT00729430|Drug|Placebo|Placebo tablets taken orally once per day for 6 months
45692169|NCT04144101|Drug|Etoricoxib|Etoricoxib 60 mg QD Oral
45692170|NCT04144101|Drug|Aceclofenac|Aceclofenac 100 mg BID Oral
45692171|NCT01278004|Drug|Ethosuximide|Drug will be dose escalated in order to reach maximum tolerated dose starting with 250mg.
45692172|NCT01278004|Drug|Placebo|Capsule
45692173|NCT02700009|Behavioral|Computer-assisted CBT (CCBT)|Computer-assisted psychotherapy for depression using a computer program plus clinician support
45692174|NCT02700009|Other|Treatment as Usual (TAU)|Ordinary treatment for depression in primary care setting
45692175|NCT01278238|Drug|Phenylephrine|Intravenous infusion Dosage 0,25 microgram/kg bodyweight as bolus, continuous infusion with 0,25 microgram/kg/min
46052888|NCT05307094|Behavioral|Improving Parents as Communication Teachers|A parent-mediated naturalistic developmental behavioral intervention delivered 2-times per week with a primary caregiver and the child.
46052889|NCT02803359|Procedure|Placement of a needle electrode through the thyrohyoid membrane into the submucosal space within the false vocal fold|
46052890|NCT00762073|Drug|budesonide|oral suspension
46052891|NCT00762073|Drug|placebo|oral suspension matching budesonide
45488829|NCT03679520|Other|New programme|"Time for topics related to the time after birth and in reversed chronological order to give an early and joint focus on parenthood for both parents. Involving new parents to share their experiences of early parenthood with expectant parents. Introducing and using evidence-based websites in the sessions A breastfeeding preparation that gives tools to meet common challenges in the initial phase of breastfeeding. Based on principles for adult learning.~Sessions~Introduction, life-change of becoming a parent and co-parenting~Early parenthood~Breastfeeding, caring for the baby and early parenthood~and 5 Labour, birth and postnatal care"
45488830|NCT03679520|Other|Regular programme|"Antenatal parental preparation as usual. As no guidelines exist the number of sessions may vary between 2 and 3 sessions and smaller variations in content may also occur.~Sessions~(or 1 and 2) Labour, birth and postnatal care~or 3 Breastfeeding, caring for the baby and early parenthood"
45488831|NCT02413840|Behavioral|Baduanjin qigong|
45488832|NCT01360827|Drug|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|3-6 subjects per cohort will receive EMD 1201081 as a weekly subcutaneous injection on Days 1, 8, and 15 in 3-week cycles at dose levels of 0.16, 0.32, and 0.48mg/kg, respectively until progression of disease, unacceptable toxicity, or subject refusal to continue in the trial. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
45488833|NCT01360827|Drug|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|Part 2 seeks to enroll 12 subjects at the MTD of EMD 1201081 in combination with 5-FU/cisplatin + cetuximab; furthermore, an additional 3 to 6 subjects for a total of 9 subjects will be accrued at the 0.16 mg/kg low dose level in Part 2a once the Part 1 0.16 mg/kg dose cohort has been accrued and it is deemed safe to proceed to the 0.32 mg/kg dose cohort. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
45488834|NCT03171610|Drug|Sufentanil group|PCA device containing sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
45488835|NCT03171610|Drug|Fentanyl group|PCA device containing fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
45488836|NCT03675698|Other|Nasotracheal Intubation|side of nostril and size of endotracheal tube estimation for nasotracheal intubation will be done based on radiological imaging ( CT/MRI head)
45488837|NCT01364181|Drug|Udenafil|Udenafil 50mg qd po
45488838|NCT02409550|Other|CARATKids Questionnaire|
45369961|NCT03942042|Drug|Ixekizumab|Administered SC
45369962|NCT00968318|Procedure|Excision of strip of deep fascia|operative technique to excise deep fascia.
45488839|NCT03629756|Drug|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
45488840|NCT03629756|Drug|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
45369963|NCT00968396|Procedure|Apheresis|On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation.
45488841|NCT02414230|Drug|Drug: F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
45488842|NCT03679442|Drug|N-acetylcysteine|Non-randomized exposure to N-acetylcysteine (NAC) of healthy individuals corresponding to the clinical treatment guidelines for paracetamol-overdosed patients
46052892|NCT03847857|Biological|Porcine Fibrin Sealant (PFS)|McKeown esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
45488843|NCT01367535|Drug|SC Methylnaltrexone (MNTX)|
45692176|NCT01278238|Device|Lower limb compression|Tight bandaging of lower extremity up to hips with compression bandages
46052893|NCT03847857|Procedure|McKeown esophagectomy|McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
46052894|NCT04030468|Other|Educational intervention addressed to general practitioners|"feedback reports regarding the status of their patients according to the appropriateness indicators determined at baseline and the pooled prevalences for their patients, Local Health Units, and region~Continuous Medical Education (CME) course"
46052895|NCT04030468|Other|Informative intervention addressed to patients|• leaflets and posters distributed in primary care ambulatories and community pharmacies, focusing on correct drug use
46052896|NCT02630628|Drug|Tacrolimus|Dosage: start at 2mg twice a day, then taper as per protocol
45369964|NCT00968396|Procedure|Stem Cell Transplantation|Co-culture Stem Cell Infusion on Day 0.
45369965|NCT00968396|Drug|Melphalan|100 mg/m^2 IV over 30 minutes daily on Days -2 and -1
45692177|NCT01278238|Other|Placebo|Neither phenylephrine nor lower limb bandaging
45692178|NCT02706795|Biological|DaxibotulinumtoxinA|Low, mid, and high dose sequential treatments of daxibotulinumtoxinA in dose-escalation safety and efficacy study
46052897|NCT02630628|Drug|Mycophenolate mofetil|Dosage: start at 1g twice a day, then taper as per protocol
46052898|NCT02795793|Drug|Non-operative management group (NOM)|With intravenous Piperacillin with Tazobactam (Tazocin)
46052899|NCT02795793|Procedure|Appendectomy group (Operative management, OM)|
46052900|NCT00913588|Drug|Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)|
46052901|NCT00913588|Drug|Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)|
46052902|NCT00913588|Drug|Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)|
46052903|NCT02803281|Other|Frailty Assessment|Various physiologic and frailty assessment tests
46052904|NCT02610946|Behavioral|Electronic application|Electronic application (app) based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
45369966|NCT04008732|Drug|MED2005|(Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.
45369967|NCT04008732|Drug|Nitrostat 0.6Mg Sublingual Tablet|Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.
45369968|NCT04008732|Drug|Nitro Pohl|to be dosed intravenously in Part 2 of the study
45369969|NCT01013727|Radiation|SPECT : ECD-Tc99m - Neurolite, Bristol-Myers Squibb Medical Imaging|
45369970|NCT00960180|Drug|MR1817|
46052905|NCT02610946|Behavioral|Paper-based|Paper-based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
46052906|NCT04100785|Behavioral|Internet-delivered Cognitive Behavioural Therapy|The iCBT programme comprised on 6 online modules. Module 1 provided an introduction to the symptoms of depression, its causes and information on CBT. Module 2 covered problem-solving strategies. Module 3 provided information on problematic thought patterns and beliefs in depression. Module 4 entailed identifying problematic thought patterns and using various techniques to counter problematic thoughts. Module 5 covered pleasurable activities scheduling to help increase activity levels.
46052907|NCT02797665|Drug|corticosteroids|prednisone 0.6mg/kg/d
45369971|NCT00960180|Drug|Placebo|
45369972|NCT00963794|Other|Electromagnetic measurement|RC screening was carried out using a Tissue Resonance InterferoMeter probe electromagnetic detector, which consists of a nonlinear oscillator placed in a cylindrical probe about 30 cm long, a radiofrequency spectrum analyzer, and dedicated computer software. Detection of RC is based on the decrease of the electromagnetic signal compared to the mean signal obtained in healthy subjects. The test was performed while the patient stood 120 cm from the receiver. The operator was on the opposite side of the examined pelvis. The detector was kept at close contact to the pelvis surface and was moved through six planes, to obtain a scan of the whole pelvis volume. Based on our previous study, we used the electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U.
45369973|NCT04593290|Device|Oticon Opn S 1 miniRITE hearing aid|Everyone who participates in Part 1 (listening effort testing and cognitive testing) will be invited to participate in Part 2 (hearing aids). It is not a requirement to participate in the administration, 6-week use, and re-testing procedures involved in Part 2 of the study. All cognitively healthy participants will be invited to participate, only MCI patients with a live-in informant will be given this opportunity. After ear measurement and dome and wire length selection, Oticon Opn S 1 miniRITE hearing aid fitting will occur wirelessly using Genie software, followed by hearing aid use instructions. The fitting will use Open domes, the standard NAL-NL2 protocol, and will increase gain seven steps on top of Real Ear Unaided Gain (REUG) from 750 Hz to 6 kHz.
45369974|NCT00971490|Device|Acu-TENS (Transcutaneous electrical nerve stimulation)|Transcutaneous electrical nerve stimulation applied onto acupuncture point
45369975|NCT00971490|Device|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but without electrical stimulation
45369976|NCT00971490|Device|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but applied onto non acupuncture point
45369977|NCT01015365|Procedure|Cementless one-stage surgical revision|A Cementless one-stage surgical revision is to be performed for all included in the cohort.
45369978|NCT05299580|Drug|dabrafenib|Dabrafenib 150 mg bid
45369979|NCT05299580|Drug|Trametinib|Trametinib 2mg qd
45369980|NCT01013805|Radiation|External Beam Radiotherapy|"Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy.~Weeks 8-10: as per Weeks 3-5"
45369981|NCT01013805|Drug|Oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
45488844|NCT01367535|Drug|IV Methylnaltrexone (MNTX)|
45488845|NCT01367535|Drug|Oral Paroxetine|
45488846|NCT01367535|Drug|SC Placebo|
45488847|NCT02414776|Drug|hydroxychloroquine|administration of hydroxychloroquine in combination with the current hormonal therapy
45692179|NCT04279834|Behavioral|PAP Treatment|Motivational enhancement plus remote-monitoring and participant self-monitoring of PAP use.
45488848|NCT03174418|Procedure|Coronary angiography and optical coherence tomography|Coronary angiography and OCT images will be combined to obtain a three-dimensional model of the diseased coronary vessels that will be used to calculate the local blood flow patterns and the arterial time-averaged wall shear stress at the bifurcated lesion level
45488849|NCT02413762|Other|No intervention|No intervention
45692180|NCT04279834|Behavioral|Sleep Education I|Motivational enhancement plus participant self-monitoring of sleep.
46052908|NCT02797665|Procedure|biliary stent|placement of biliary stent during endoscopic retrograde cholangiopancreatography (ERCP)
46052909|NCT05297149|Behavioral|Hippotherapy|The hippotherapy program consisted of 6 weekly sessions that varied in duration between 20 and 30 minutes depending on the weekly program and the participant's condition. Each session started with brief greetings and contact with the horse.
45369982|NCT01013805|Drug|Fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.~Leucovorin 200 mg/m2 Day 1 concurrent with Oxaliplatin over 2 hrs, then 2nd: 5-FU 400 mg/m2 bolus Day 1, then 3rd: 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1"
45369983|NCT01013805|Drug|Leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
45369984|NCT01013805|Procedure|Surgical Resection|Surgery is to be performed according to the standard procedure for locally advanced rectal cancer 4 to 6 weeks after completion of the integrated preoperative radiotherapy with FOLFOX chemotherapy regimen.
45369985|NCT04491045|Other|Workshop Training on Multicomponent Collaborative Care for Depression|Hybrid Workshop Trainings on Stepped collaborative care model for depression that involves using a team-based approach to integrating depression care components (screening, psychoeducation, Behavior Activation therapy, and antidepressant medications) into primary care settings. This integration involves task-shifting mental health tasks from mental health specialist to community providers at the commune health stations.
45692181|NCT00722020|Device|VEST|15 minutes of HFCWO via the Vest 2-3 times daily
45369986|NCT04491045|Other|Supervision|Ongoing supervision and coaching is provided to community health providers by local mental health specialist from the provincial psychiatric hospital for 6-9 months
45692182|NCT04143867|Device|Nolix Device|For temporary management of SUI
45692183|NCT01272310|Biological|Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin|"HCQ will be taken daily as an oral tablet of 200 mg b.i.d. Pegylated Interferon Alpha-2a - (180 µg) will be administered as weekly subcutaneous (s.c.) injections of 0.5 ml.~Ribavirin - will be taken daily based on the patient body weight. If body weight is < 75 kg, the total daily dose of Copegus® is 1000 mg, administered as 400 mg (2 tablets of 200 mg, morning intake) and 600 mg (3 tablets of 200 mg, evening intake). If body weight is >= 75 kg, the total daily dose is 1200 mg administered as twice 600 mg (3 tablets of 200 mg per intake, morning and evening)."
45692184|NCT01272466|Biological|peptides derived from antiapoptotic proteins|8 Vaccinations on day 2 and 9 in every bortezomib treatment series
45488850|NCT05187663|Procedure|Photodynamic (PDT) group|Mucoperiostal buccal and lingual incisions were made using a surgical blade under local anaesthesia. Full-thickness mucoperiosteal flaps were elevated buccally and lingually. In the photodynamic (PDT) group, after careful removal of granulation tissue and mechanical debridement of the implant surface, decontamination of implant surfaces and peri-implant tissues was performed using the photodynamic therapy, PDT (HELBO, Photodynamic Systems GmbH, Wels, Austria). The implant surface and the surrounding tissue were exposed to the laser light by means of fibres (HELBO ® TheraLite Laser HELBO ® 2D Spot Probe; bredent medical GmbH & Co KG) for the 30s/spot, which operates on the wavelength of 660 nm and irradiance of 100 Mw. Bone augmentation and bio-resorbable membrane were applied in peri-implant defects using the bovine bone substitute and collagen membrane (Bio -Oss and Bio Guide, GeistlichPharma; Dembone). The mucoperiosteal flaps were repositioned and sutured.
45692185|NCT04143789|Drug|AP-002|Dose escalation
45692186|NCT01272700|Procedure|volume control|Volume controlled ventilation of tidal volume 10 ml/kg
45692187|NCT01272700|Procedure|pressure control|Pressure controlled ventilation for peak airway pressure to deliver tidal volume 10 ml/kg.
45692188|NCT02991742|Other|contrast media|Compare 2 contrast media
45692189|NCT01278316|Behavioral|Control|Participants will be asked to perform computerized tasks that involve auditory and verbal performance one hour each day, five days per week for 8-10 weeks. Six tasks requiring auditory and verbal information will be presented.
45692190|NCT01278316|Behavioral|Cognitive Training|Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
45692191|NCT02991664|Other|Equia Forte|Glass ionomer restorative system
45692192|NCT02991664|Other|G-aenial Posterior|Micro hybrid composite resin
45692193|NCT04386850|Drug|Oral 25-Hydroxyvitamin D3|Subjects in the case group will receive 25 mcg of 25(OH)D3 once daily at bedtime for 2 months and the control group will receive placebo daily for 2 months.
45692194|NCT01278472|Device|Single Port Cholecystectomy|Using transumbilical single port device: SILS Port
45692195|NCT01278472|Device|4 Port Cholecystectomy|using 4 separate skin incisions and 2 5mm and 2 12 mm conventional ports
45692196|NCT01272778|Drug|Lorazepam|Oral capsule, 0.2 mg, single acute dose
45692197|NCT01272778|Drug|Lorazepam|oral capsule, 0.5 mg, single acute dose
45692198|NCT01272778|Drug|Lorazepam|oral capsule, 1.0 mg, single acute dose
45692199|NCT01272778|Drug|Lorazepam|oral capsule, 2.0 mg, single acute dose
45692200|NCT01272778|Drug|Placebo|oral capsule, single acute dose
45369987|NCT04491045|Other|Community-Engaged Learning Collaborative|The CELC group will receive support for continuous quality improvement using a province-wide learning collaborative that will meet monthly for 3 months, followed by bi-monthly meetings for 12 months.
45369988|NCT00104299|Drug|Rituximab plus cyclophosphamide placebo (rituximab group)|375 mg/m^2 infusions once weekly for 4 week
45369989|NCT00104299|Drug|Cyclophosphamide plus rituximab placebo (control group)|2 mg/kg/day orally for months 1-3
45369990|NCT00104299|Drug|Azathioprine|2 mg/kg/day orally for months 4-6
45369991|NCT00104299|Drug|Methylprednisolone (or other glucocorticoid)|1 g/day intravenously for up to 3 days within 14 days prior to receiving rituximab
45369992|NCT00104299|Drug|Prednisone|During the remission induction phase, all participants will receive oral prednisone daily (1 mg/kg/day, not to exceed 80 mg/day). Prednisone tapering will be completed by the Month 6 study visit.
45369993|NCT03939312|Drug|Atogepant|Atogepant Tablets
45369994|NCT00968552|Procedure|Self-expandable stent placement via endoscopy|Self-expandable stent placement via endoscopy
45369995|NCT00968630|Other|Laboratory Biomarker Analysis|Correlative studies
45369996|NCT00968630|Procedure|Leukapheresis|Undergo leukapheresis
45369997|NCT00963950|Procedure|transvaginal cholecystectomy|Transvaginal approach to gallbladder removal.
45369998|NCT00963950|Procedure|laparoscopic cholecystectomy|laparoscopic cholecystectomy
45369999|NCT05196308|Drug|Investigational product administration Xeomin® (MERZ PHARMACEUTICALS GMBH)|"Administration of the investigational product.~For the double-blind treatment phase, experimental group :~Patients will receive Xeomin® (MERZ PHARMACEUTICALS GMBH), 100 U, a paired intracavernosal injection to be performed by the investigator."
45370000|NCT05196308|Drug|Placebo administration|"For the double-blind treatment phase, control group :~Patients will receive placebo of Xeomin® 100 U, a paired intracavernosal injection is to be performed by the investigator."
45370001|NCT01563432|Drug|Feburic®|80 mg*1 tablet
45370002|NCT01563432|Drug|TMX-67|40 mg*2 tablets
45370003|NCT00968786|Device|Home monitoring|automated measuring devices for patients using at home
45370004|NCT00960258|Drug|Regorafenib (BAY73-4506)|The patients will be treated on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, the patients will be treated with BAY 73-4506 (160 mg once daily orally, 21 days on/ 7 days off schedule). Dose level : 160 mgDose level-1: 120 mgDose level-2: 60 mg
45370005|NCT04566926|Drug|JNJ-64140284|Participant will receive JNJ-64140284 formulation 1 or 2 under fasting or fed condition.
45370006|NCT04566926|Drug|Placebo|Participant will receive matching placebo.
45370007|NCT00082381|Drug|Exenatide (AC2993)|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
45370008|NCT00082381|Drug|Insulin glargine|subcutaneous injection, once daily; forced titration to target blood glucose level
45370009|NCT00964106|Drug|Caffeine|Caffeine dosed at 100 mg as probe for CYP1A2 pathway
45370010|NCT00964106|Drug|Rosiglitazone|Dosed at 4 mg as probe for CYP2C8 pathway
45370011|NCT00964106|Drug|Flurbiprofen|Dosed at 40 mg, probe for CYP2C9 pathway
45370012|NCT00964106|Drug|Omeprazole|Dosed at 20 mg, probe for CYP2C19 pathway
45370013|NCT00964106|Drug|Dextromethorphan|Dosed at 30 mg, probe for CYP2D6 pathway
45370014|NCT00964106|Drug|Midazolam|Dosed at 3 mg for Part 1, Part 2 cohorts B and C and 1 mg for Part 2 Cohort A, probe drug for CYP3A4/5 pathway
45370015|NCT00964106|Drug|Rosuvastatin|Dosed at 10 mg, probe drug for OATP1B1 pathway
45370016|NCT00964106|Drug|Ketoconazole|Dosed at 400 mg once-daily Day 1 through Day 9, inhibitor of CYP3A4
45370017|NCT00964106|Drug|Fluconazole|Dosed at 400 mg x 1 dose on day 1, 200 mg once daily on days 2 through 9, inhibitor of CYP2C9 pathway
45370018|NCT00964106|Drug|Rifampin|Dosed at 600 mg x 1 dose on Day 1 and Day 8, inhibitor of OATP1B1 pathway
45370019|NCT00964106|Drug|Rosiglitazone|Dosed at 15 mg, probe drug for CYP2C8 pathway
45370020|NCT00960336|Drug|pegylated liposomal doxorubicin hydrochloride|
45370021|NCT04557176|Device|CRP, point-of-care assay|CRP is a non-specific marker of inflammation whose levels rise in the setting of interleukin 6 (IL-6)-mediated inflammation, such as active TB. In clinical settings, CRP is used to identify patients with systemic inflammation from infection or non-infectious cases. In settings with high TB prevalence, the investigators hypothesize that CRP can be used to accurately screen individuals for active TB (i.e., distinguish individuals with high likelihood of having active TB from those individuals unlikely to have active TB).
45370022|NCT00971646|Other|Micturition diary|On the micturition diary patients are asked to note every void and drink. With every void they are asked to estimate their bladder volume and grade their degree of desire to void.
45370023|NCT00971646|Other|Hospital Anxiety and Depression scale|This questionnaire is designed to screen for the presence of a mood disorder.
45692201|NCT01272856|Drug|Abatacept|125 mg pre-filled syringe for sub-q injection weekly.
46052910|NCT05297149|Behavioral|Home exrecises|The home exercise program consisted of the following balance training exercises: one leg standing on foam with eyes open and closed, double leg standing on foam with eyes open and closed, walking in tandem with eyes open and closed, balance exercises on an inclined surface, balance exercises in squat, and jumping over an obstacle on the ground. All participants performed the exercises under parental supervision, 3 times per week for 6 weeks. The physiotherapist made video calls to the children and parents to ensure their adherence to the home exercise program.
45692202|NCT01273090|Drug|imetelstat sodium|
45692203|NCT01273090|Other|laboratory biomarker analysis|
45692204|NCT01273090|Other|pharmacological study|
45753511|NCT04199858|Behavioral|Baseline pain stimulations|During baseline pain stimulations, a comparison block will include 6 high- and 2 moderate-pain stimulations.
45488851|NCT05187663|Procedure|Chlorhexidine (CHX) group|Mucoperiostal buccal and lingual incisions were made using a surgical blade under local anaesthesia. Full-thickness mucoperiosteal flaps were elevated buccally and lingually. In the chlorhexidine (CHX) group, after careful removal of granulation tissue and mechanical debridement of the implant surface 1% gel of chlorhexidine (Chlorhexamed® - Direkt) was applied on the implant surface for one minute and irrigated for 1 min by saline. Bone augmentation and bio-resorbable membrane were applied in peri-implant defects using the bovine bone substitute and collagen membrane (Bio -Oss and Bio Guide, GeistlichPharma; Dembone). The mucoperiosteal flaps were repositioned and sutured.
45488852|NCT03672422|Diagnostic Test|Blood sample|Six ml of blood will be collected from patients in an EDTA tube. 2 ml saliva samples in Oragene DNA collection kits
45488853|NCT03672422|Behavioral|Patient questionnaires|Questionnaires will be completed at the baseline and annual follow-up visits to collect data that will define the demographics of the pediatric ARP and CP cohort, describe risk factors, presence of family history of acute and chronic pancreatitis, diabetes and pancreatic cancer and assess disease burden and sequelae.
45488854|NCT03672422|Diagnostic Test|Saliva sample|2 ml saliva samples in Oragene DNA collection kits collected if no blood sample being collected.
45488855|NCT03672422|Diagnostic Test|Urine sample|50 ml of urine in collection container.
45692205|NCT04386694|Device|Active PBMT/sMF|The PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used in the lower thorax will be 31.50 J per site, a total of 6 sites will be irradiated, totalizing a dose of 189J. In addition, the dose used in the neck area (bilaterally) will be 31.50J per site, a total of 1 site (bilaterally) will be irradiated, totalizing a dose of 31.50J (bilaterally). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
45488856|NCT03171376|Procedure|Root canal treatment and coronal restoration|After primary root canal treatment, Glass Ionomer Cement (Ketac™ Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
45488857|NCT03171298|Procedure|Laparoscopic Assisted Transanal Total Mesorectal Excision|"Abdominal approach with laparoscopic mobilization of the left colon~Laparoscopic isolation and transection of inferior mesenteric vessels .~Transabdominal dissection of the upper rectum and mesorectam.~Insertion of transanal platform and the creation of pneumorectum.~Occlusion of rectum 2 cm distal to the rectal lesion via purse string.~Transanal dissection of lower and mid mesorectam~The specimen will be extracted transanally"
45692206|NCT04386694|Device|Placebo PBMT/sMF|The placebo PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used for applications during the treatment will be 0 Joules (J) per site. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
45488858|NCT03675542|Drug|CUDC-305|Dose-selection treatment with HSP90 inhibitor (CUDU-305)
45488859|NCT03671954|Behavioral|Home Strengthening Exercises|The intervention group will perform unsupervised home strengthening exercises for the hip abductors in addition to standard physical therapy, while the control group will receive standard physical therapy alone.
45488860|NCT03671954|Other|Standard Physical Therapy|Physician determined standard of care for individual TKA patients.
45488861|NCT03671954|Other|Preoperative Assessments|"Assessments will include:~TUG (timed up and go test) >12 sec indicates increased fall risk~Tandem balance test < 10 sec indicates increased fall risk~Sit to Stand test (age based norms)~Knee Range Of Motion (ROM)~Quadriceps and hamstring strength (MMT or hand held dynamometer)~Lower Extremity Functional Score (LEFS questionnaire)"
45692207|NCT01273246|Biological|100U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 100U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
46052911|NCT02795091|Other|manual cleaning|manual clean the rag and floor towel
45488862|NCT03171454|Procedure|Delayed Intrauterine Balloon therapy|D-IUB dilatation therapy group will be performed using a (size 12-14fr) Foley catheter and according to the methodology published in the literature. This will be prepared by cutting the catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 5mls of saline will be slowly instilled into the balloon under ultrasound guidance.
45488863|NCT03171454|Procedure|immediate Intrauterine Balloon therapy|At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 4-5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
45692208|NCT01273246|Biological|200U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 200U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
46052912|NCT02795091|Device|machine clean|machine clean the rag and floor towel
46052913|NCT02797587|Drug|Varenicline|1 week starter kit followed by 1mg twice daily for 12 weeks.
46052914|NCT02797587|Drug|Cytisine|Multi-daily dosing, range 3-9 mg daily for 25 days.
46052915|NCT02797587|Drug|Nicotine Replacement Therapy|Mouth spray dosing based on standard recommendations tapered over 8 weeks.
46052916|NCT02797587|Drug|Varenicline Placebo|1 week starter kit followed by 1 pill twice daily for 12 weeks.
46052917|NCT02797587|Drug|Cytisine Placebo|Multi-daily dosing for 25 days.
46052918|NCT02797587|Drug|Nicotine Replacement Therapy Placebo|Mouth spray dosing based on standard recommendations tapered over 8 weeks.
45370024|NCT00971646|Other|EuroQol-5D|This questionnaire grades the health condition of the subject.
45370025|NCT00971646|Other|Self-consciousness questionnaire|The questions tap cognitive, emotional, and physical appearance aspects of directing their attention to the self.
45370026|NCT00965172|Other|Caphosol|Oral rinse of calcium phosphate solution five times daily beginning on day one of chemotherapy.
45370027|NCT00965172|Other|Baking Soda|Oral rinse of baking soda solution as per standard of care five times daily beginning on day one of chemotherapy.
45370028|NCT01084681|Device|Endovascular treatment of intracranial aneurysms|Endovascular treatment with the SILK Artery Reconstruction Device for occluding intracranial aneurysms.
45488864|NCT03679286|Device|PCM and ROTEM|Test of blood sample by both PCM and ROTEM
45488865|NCT04482712|Drug|Rapamycin|Daily administration of a dose of investigational drug for up to 4 weeks while hospitalized
45370029|NCT01084681|Device|Endovascular treatment of intracranial aneurysm with coils|Endovascular treatment with commercially available intracranial coils for occluding intracranial aneurysms.
45370030|NCT04505852|Device|Embrace|Patients wear Embrace2 to help in seizure reporting and patient care.
45488866|NCT04482712|Drug|Placebo|Administration of investigational drug placebo for up to 4 weeks while hospitalized
45370031|NCT00960414|Behavioral|SHINE|Both groups will receive a diet and exercise based intervention aimed at eating a caloric intake that will maintain ideal body weight and increasing exercise. SHINE A will emphasize awareness of hunger and satiety cues, while SHINE B will receive more detained nutritional education.
45370032|NCT00969020|Procedure|remote rehabilitation support|An information technology solution containing RRS. The way it supports,, informs and educates the patient and support person, provides an opportunity for communication between the patient and the surgeons, physiotherapists and nurses at the hospital.
45692209|NCT01273246|Biological|400U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 400U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
45692210|NCT01273246|Biological|Placebo|Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
45692211|NCT00730522|Drug|CPP-109 vigabatrin|tablets, bid for 12 weeks
45692212|NCT00730522|Drug|Matching Placebo|tablets, bid, 12 weeks
46052919|NCT02611128|Other|Phenotype/genotype assessment|The investigators will perform careful phenotyping in addition to hormonal assessments and assessments of DENND1A
46052920|NCT04098601|Behavioral|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
45488867|NCT03679208|Device|Investigational device coded KIO014|Innovative chitosan-based biomaterial intended for intraarticular injection.
45488868|NCT03679208|Device|Durolane(r) as control device|Crosslinked hyaluronic acid-based biomaterial intended for intraarticular injection.
45488869|NCT02409394|Drug|Hetrombopag Olamine|
45488870|NCT02409004|Drug|Ataluren|Powder for oral suspension (supplied in sachets) 1X 125 mg + 1 x 250 mg + 1000 mg (total of 1375 mg)
45488871|NCT02409004|Drug|Rifampin|Capsule 2x3oo mg Oral
45488872|NCT03131895|Drug|30 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
45488873|NCT03131895|Drug|30 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
45488874|NCT03131895|Drug|60 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
45488875|NCT03131895|Drug|60 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
45488876|NCT03671876|Device|Intervention plus therapy|Task oriented exercise plan to improve mobility for stroke patients
45488877|NCT04039919|Drug|Padsevonil|Padsevonil will be administered in predefined dosages.
45488878|NCT04039919|Drug|Placebo (PSL)|Placebo will be provided matching Padsevonil to maintain the blinding.
46052921|NCT02797509|Behavioral|Psychosocial Skills-Based Intervention|Subjects will attend group skills-based sessions once weekly (either in-person or via Vidyo) for 6 weeks and learn skills to cope and manage stroke-related stressors.
45370033|NCT01084837|Drug|velcade|"INDUCTIoN (Cycles 1-4)~Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment~Dexamethasone 40 mg/p.o. days 1-4 and 9-12 cycles 1-4 (Cycles of 21 days)~For patients wich is not planned autotransplantation, add:~Cycles 5-8~Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment~Dexamethasone 40 mg/v.o. days 1-4 (Cycles of 21 days)~EXTENSION TREATMENT(Cycles 9-12)~Bortezomib 1,3 mg/m2 i.v. days 1, 8, 15 and 22~Dexamethasone 40 mg/d v.o. days 1-4 (Every 6 weeks)"
45488879|NCT02405494|Dietary Supplement|Beverage 1|
46052922|NCT04100941|Diagnostic Test|standard suction|After the needle is inserted in the mass, removing the stylet before performing EUS-FNA. Then attach a 10mL syringe to the end of needle. 20 times of for-backward Suction was applied after the lesion was punctured.
46052923|NCT04100941|Diagnostic Test|slow pull|After the needle is inserted in the mass, slowly pull the stylet out while performing EUS-FNA with 20 times for-backward.
45488880|NCT02405494|Dietary Supplement|Beverage 2|
45488881|NCT02405494|Dietary Supplement|Beverage 3|
45488882|NCT02405494|Dietary Supplement|Beverage 4|
45488883|NCT02405494|Dietary Supplement|Beverage 5|
45488884|NCT02405494|Dietary Supplement|Beverage 6|
45488885|NCT02405494|Dietary Supplement|Beverage 7|
45488886|NCT02405494|Dietary Supplement|Beverage 8|
45488887|NCT02405494|Dietary Supplement|Beverage 9|
45488888|NCT02409160|Procedure|Standard Roux-en-Y gastric bypass|
45488889|NCT05171595|Device|Lifetouch single-lead ECG monitoring|The continuous wireless monitoring is a single-lead ECG patch (Isansys Life Touch patch) which consists of two ECG electrodes placed on the left side of the patients' thorax. The patch measures respiratory rate (RR), heart rate (HR), heart rate variability (HRV) and electrocardiogram (ECG)s.
45488890|NCT05171595|Diagnostic Test|high-sensitive TnT measurements|Another monitoring device in the study was the plasma concentration of high-sensitive cardiac troponin T (hsTnT).
45692213|NCT04345276|Drug|Danoprevir+Ritonavir|Danoprevir 100mg , one tablet each time , twice per day, up to 10 days. Ritonavir 100mg, one tablet each time , twice per day, up to 10 days.
45692214|NCT02991352|Device|Image guided needle placement|Stereotactic MRI based image guidance to aid in the placement of percutaneous needles into vascular malformations using a CE marked navigation system (CAS-One IR, CAScination AG)
45692215|NCT01278628|Other|exercise training|exercise class once a year
45370034|NCT03962413|Procedure|Endoscopic Approaches To Maxillary Sinus|"The first group (group A):~The middle meatal antrostomy approach.~The second group (group B):~The endoscopic prelacrimal recess approach~The third group (group c):~The canine fossa approach."
45370035|NCT00545844|Drug|montelukast sodium|montelukast sodium, 10 mg, one tablet once a day for 8 weeks as add on therapy to usual current asthma controller treatment
45370036|NCT01084993|Drug|Bivalirudin|Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
45488891|NCT03174340|Behavioral|Exercise|Once per week, participants will be enrolled in supervised group exercise intervention. They will be encouraged in walking 45 minutes per day
45488892|NCT01367613|Drug|SC Methylnaltrexone|
45488893|NCT03174106|Device|Smartphone-Application|Longterm follow-up after Cardiac rehabilitation With an Smartphone-Application
45488894|NCT03739151|Behavioral|Behavioral Obesity Treatment|"Self-monitoring. Participants will be taught to record their weight, the calories of each food item, and physical activity using a method of their choice (e.g., commercial smartphone app, paper diary). The clinician will review dietary intake and provide personalized feedback at the outset of session.~Diet. Per national guidelines for weight loss, a daily goal of 1200-1800 kcal/day will be prescribed depending on baseline weight. A Mediterranean diet will be prescribed to meet the recommended calorie goal and be consistent with dietary recommendations for CVD patients.~Exercise. Participants will be encouraged to achieve 250 minutes/week of moderate intensity activity in accordance with current national recommendations for physical activity among individuals attempting weight loss. Participants will be encouraged to gradually increase activity level to achieve approximately 50 minutes of activity over five days per week."
45488895|NCT02405182|Other|Magnetic Resonance Imaging|
45488896|NCT03745001|Drug|EHP-101 Liquid single dose|One single oral administration with EHP-101 liquid formulation. The doses will be ascending per cohort from 0.91 mg to 200 mg. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day).
45488897|NCT03745001|Drug|EHP-101 Liquid multiple doses|One single daily administration with EHP-101 liquid formulation during 7 consecutive days. The doses will be ascending per cohort. Each ascending level will not exceed the tested dose levels in the single dose part of the study. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day)
45488898|NCT03745001|Drug|Matching placebo|Oral liquid administration daily
45488899|NCT01367691|Device|CRT reprogramming (Medtronic CRT)|CRT devices will be reprogrammed according to CMR analysis
45488900|NCT02405338|Biological|WT1/PRAME vaccination|
45488901|NCT03738839|Device|Quantitative Light-Induced Fluorescence|White spot lesion on the tooth surfaces detected with Quantitative Light-Induced Fluorescence Orthodontic Bonding.
45488902|NCT03738839|Procedure|Direct bonding|The patients in the direct bonding group received a bonding procedure with a conventional composite adhesive.
45488903|NCT03738839|Procedure|Indirect bonding|For the patients in the indirect bonding group, bonding was performed with a flowable composite adhesive.
45488904|NCT01364337|Other|DASH diet|DASH diet: A diet rich in whole grain, fruit and vegetable, low-fat dairy products, white meat and nuts; and lower of total fat and saturated fat.
45488905|NCT01364337|Other|lower carbohydrate DASH diet|lower carbohydrate DASH diet: A DASH diet with lower carbohydrate percentage
45692216|NCT00731614|Behavioral|Cognitive Behavioral Therapy and Mirror Retraining|Cognitive Behavioral Pain Management treatment administered in 8 weeks of individual treatment, combined with training in use of a mirror device to reduce phantom limb pain.
45692217|NCT00731614|Behavioral|Supportive therapy|Non-directive, emotion focused psychotherapy to facilitate coping with pain, delivered in weekly individual sessions.
46052924|NCT04100941|Diagnostic Test|wet suction|After removing the stylet, the needle was flushed with 5mL of saline solution to replace the column of air with saline. A 10mL syringe was attached to the end of the needle. 20 times of for-backward Suction was applied after the lesion was punctured.
46052925|NCT02795325|Drug|DCR-PH1|IV infusion of DCR-PH1
46052926|NCT02795325|Other|Placebo|
46052927|NCT00761761|Drug|Sensoril|
45692218|NCT00731614|Behavioral|Mirror retraining|Use of a mirror to produce an illusion of the missing limb. By attending to the reflected limb while moving the existing limb, the patient provides visual feedback that helps correct changes in the neural organization of the somatosensory cortex resulting from the amputation and contributing to the phantom limb pain
45370037|NCT01084993|Drug|Heparin|70 U/kg
45370038|NCT00492063|Biological|Cell culture-derived trivalent subunit influenza vaccine (cTIV)|One vaccination (0.5 mL) of cell culture-derived influenza vaccine (cTIV) was administered in the deltoid muscle
45692219|NCT01273324|Device|ADM Cup|ADM Cup
46052928|NCT00761761|Other|Placebo|
46052929|NCT02803047|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation number - SR15-61-Z15-034).
46052930|NCT02795403|Other|blood draw of 150ml, twice|
46052931|NCT04235361|Diagnostic Test|Differential RPA tests|The mobile diagnostic suitcases will be deployed at Ebola Treatment centres in DRC. Samples of patients refered for diagnostic testing will be tested by PCR by existing diagnostic teams, and will be additionally tested by the mobile suitcase laboratory using differential RPA tests for 6 parameters.
45488906|NCT02413606|Other|Reduced follow-up schedule|In the intervention group, the follow-up schedule will be limited to four follow-up visits at 3, 12, 24 and 36 months, under the specific condition that patients have easy and prompt access to care (specialised nurse of gynaecologist) if symptoms or questions occur. The content of the follow-up visits will be similar for both groups.
45488907|NCT05166993|Device|MostCareUp|Pressure transducers have been connected to the MostCareUp and the hemodynamic parameters compared as follows: no filter, electronic filter, no electronic filter plus Accudynamic (our reference system). Invasive pressure values have been then compared with the non-invasive ones.
45488908|NCT02405416|Procedure|Infrahepatic inferior vena cava clamping|Infrahepatic inferior vena cava is clamped in hepatectomy.
45488909|NCT02405416|Procedure|Selective hepatic vascular exclusion|Selected major hepatic vein is clamped in hepatectomy.
45488910|NCT02405416|Procedure|Portal triad clamping|Portal triad are clamped in hepatectomy.
45488911|NCT01361295|Procedure|PVI with PVAC gold|Pulmonary vein isolation using the Medtronic PVAC gold catheter
45488912|NCT01361295|Procedure|PVI with Cooled-RF|Pulmonary vein isolation using the Biosense Webster Navistar Thermocool catheter
45488913|NCT03671720|Biological|personalized DC vaccine|personalized vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous tumor cells, administered intranodally on day 1,8,15, with a combination of oral cyclophosphamide (50mg) every day except the day of vaccine administrations.Cycles are repeated every 21 days. Treatment is continued until disease progression or exhaustion of vaccine supply, whichever comes first.
45488914|NCT02405104|Drug|chlorzoxazone|ATC-code: M03BB03
45488915|NCT02405104|Drug|Placebo|Placebo
45488916|NCT02405104|Procedure|THA|Surgical treatment of osteoarthrosis in the hip, by replacement.
45488917|NCT02405104|Procedure|TKA|Surgical treatment of osteoarthrosis in the knee, by replacement.
45488918|NCT01364415|Drug|Pasireotide LAR|
45488919|NCT03176368|Other|Coconut Oil|Coconut Oil
45488920|NCT03522129|Drug|CT1812|Active Study Drug
45488921|NCT03522129|Drug|Placebo|Non-active study drug
45488922|NCT03176446|Device|Local anesthesia with traditional technique|Puncture with short needle in the region of the apical third of the tooth to be anesthetized Injection of local anesthetic, with speed 1ml / min
45488923|NCT03176446|Device|Local anesthesia with computerized technique|Puncture with short needle in the region of the apical third of the tooth to be anesthetized according to the recommendations of the manufacturer Injection of local anesthetic with computerized anesthesia equipment, with speed 0.5 ml / min
45370039|NCT00492063|Biological|Egg-derived trivalent subunit influenza vaccine (TIV)|One vaccination (0.5 mL) of egg-derived influenza virus vaccine (TIV) was administered in the deltoid muscle
45488924|NCT03176446|Device|Local anesthesia with DentalVibe technique|Use of DentalVibe in the apical region of the tooth to be anesthetized according to the manufacturer's guidelines Puncture with short needle enters the tips of the DentalVibe Injection of local anesthetic with traditional carpule, with speed 1 ml / min
45488925|NCT03176446|Drug|Topic anesthesia|Application of topical anesthetic for 60 seconds with benzocaine
45488926|NCT03176446|Drug|Local anesthetic|2% lidocaine with epinephrine 1: 100000 1.8 mL
45848006|NCT05364216|Procedure|Thoracic paravertebral block|"The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3 cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block"
45488927|NCT03176212|Dietary Supplement|Milk fat globule membrane|
45488928|NCT03176290|Diagnostic Test|Fibro-α score = (1.35 (numeric constant) +AFP (IU ml-1) × 0.009584 + aspartate aminotransferase (AST)/alanine aminotransferase(ALT) × 0.243 - platelet count (×109 l-1) × 0.001624).|Radiological investigations included Abdominal Doppler ultrasound, Magnetic Resonance Elastography(within 3 months of liver biopsy) and fibroscan.
45488929|NCT02408614|Other|Slow-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a slow-pace.
45488930|NCT02408614|Other|Moderate-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a moderate pace.
45488931|NCT02408614|Other|Interval Training|Subjects will complete 40 minutes of walking on the treadmill alternating between a moderate and a fast pace.
45488932|NCT02408614|Device|Treadmill|
45488933|NCT03171142|Drug|Heliox|Heliox (21:79) via nasal cannula 2 litter per minutes
45488934|NCT03171142|Drug|Air|Air 21% via nasal cannula 2 litter per minutes
45488935|NCT04035473|Drug|HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules|"HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules~Oral paclitaxel capsules"
45488936|NCT02408848|Other|Observational|This is an observational study. There is no intervention.
45488937|NCT02413528|Device|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
45488938|NCT02413528|Behavioral|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
45488939|NCT04032977|Device|PN40082|To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
45370040|NCT04008654|Behavioral|ERAS Protocol|"Preoperative measures:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative measures:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Application of midthoracic, epidural anesthesia/analgesia Refraining from use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results"
45370041|NCT04008654|Behavioral|Conventional care|This group of patients will not receive the specific ERAS protocol but will receive conventional care.
45488940|NCT04032977|Device|Restylane Silk|To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
45488941|NCT02408926|Biological|Boostrix|Pregnant women will be vaccinated with an acellular pertussis containing vaccine between 27 and 36 weeks of gestation.
45488942|NCT02408926|Biological|Infanrix hexa|Children from group A will be vaccinated with an acellular pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
45692220|NCT01273480|Drug|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
45848007|NCT05364216|Behavioral|The assessment of cognitive function|Participants were assessed for MMSE and MoCA at the same period as the group C
45370042|NCT01085071|Drug|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-high Potassium (4.5 mmol/L)
45370043|NCT01085071|Drug|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-low Potassium (4.0 mmol/L)
45370044|NCT00960492|Drug|XL184|XL184 will be administered daily as a single oral agent supplied as 25- and 100-mg capsules
45370045|NCT00960492|Drug|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 75 mg/m2/day given daily with concurrent RT for 6 weeks
45370046|NCT00960492|Drug|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 200 mg/m2/day given for 5 consecutive days and repeated every 28 days.
45488943|NCT02408926|Biological|Quinvaxem|Children from group B will be vaccinated with a whole cell pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
45488944|NCT02408926|Biological|OPV|Children from group B will be vaccinated with OPV vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
45488945|NCT04030247|Drug|Plant Sterol|Patients will receive a plant sterol supplement to take twice daily from their cardiologist/dietician in management of their moderate risk of cardiovascular disease.
45488946|NCT00704158|Drug|CR011-vcMMAE|administered as an intravenous infusion on Day 1 of a 21 day cycle.
45488947|NCT04481698|Other|Mesoglycan|Prisma® 30 mg 2 vials i.m./day for the first 5 post-operative days and then Prisma® 50 mg 1 oral tablet twice/day for an additional 30 days
45488948|NCT03738761|Drug|Amlessa®|Fixed-dose combination (FDC) of perindopril/amlodipine, tablets. Strengths: 4mg/5 mg, 8mg/5 mg, 8mg/10 mg.
45488949|NCT03738761|Drug|Co-Amlessa®|Fixed-dose combination (FDC) of perindopril/indapamide/amlodipine, tablets. Strengths: 4mg/1.25 mg/5 mg, 8mg/2.5 mg/5 mg, 8mg/2.5 mg/10 mg.
45488950|NCT02413216|Behavioral|TicHelper|TicHelper.com is an 8-week online program designed to teach tic management skills. Content and activities included in TicHelper.com are based on existing empirically-supported treatments including Habit Reversal Training (HRT) and Comprehensive Behavioral Intervention for Tics (CBIT). TicHelper.com is designed to teach tic management skills including psychoeducation, relaxation training, awareness training, competing response training, and social support. It is also designed to teach patients/parents to recognize and reduce tic-exacerbating reactions and activities.
45488951|NCT02413216|Other|Internet Based Resources|The Internet-Based Resources (IBR) condition is designed to provide patients/parents with access to a wide range of educational materials. These materials contain up-to-date information regarding what is known about tic disorders and their management. Materials covering medical, educational, and behavioral/psychological topics are provided.
45692221|NCT01273480|Drug|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
45692222|NCT01273480|Drug|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
45370047|NCT00960492|Radiation|Radiation Therapy|Subjects will receive RT consisting of fractionated focal irradiation administered using 1.8-2 Gy/fraction, daily for 5 days/week for 6-7 weeks, for a total dose of up to 60 Gy.
45370048|NCT00960492|Drug|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules.
45370049|NCT00971724|Drug|Placebo|Oral administration, once daily, for 15 days
45370050|NCT00971724|Drug|Prednisolone|Oral administration
45370051|NCT04331301|Procedure|Bipolar Vapo-Enucleation of the prostate|group A: Patient will be subjected to bipolar endoscopic enucleation of the prostate by vaporization electrode (vapoenucleation).
45370052|NCT04331301|Procedure|Bipolar Needlescopic Enucleation of the prostate|group B: Patient will be subjected to bipolar endoscopic enucleation of the prostate by hot knife electrode (Needlescopic Enucleation ).
45370053|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 20 mg or Placebo, daily for 10 days.
45488952|NCT03671642|Device|Q-ICG|Quantitative perfusion assessment with indocyanine green on a touch screen tablet
45488953|NCT03671642|Procedure|White light perfusion assessment|Traditional visual perfusion assessment in white light
45488954|NCT03671642|Procedure|Fluorescence angiography|Perfusion assessment with fluorescence angiography - without quantification
45488955|NCT03623282|Drug|Synatura® 15 mL|All subjects will receive Synatura® 15 mL every day three times for 3 months.
45488956|NCT03738605|Device|Microablative Fractional CO2 Laser Therapy|5 laser therapies intravaginally administered will be applied at monthly intervals.
45488957|NCT04482790|Procedure|Conventional celluloid matrix technique in management of black triangle|conventional restorative technique in management of black triangle
45488958|NCT04482790|Procedure|Bioclear cervical matrix with injection molding technique|New restorative technique in management of black triangle restorative papilla regeneration
45488959|NCT03738527|Drug|Tranexamic Acid 100mg/mL, 20mL topical|"Drug: Tranexamic Acid~20 mL TXA (100 mg/mL injection solution, total 2g TXA) applied topically to the mastectomy cavity for 5 minutes before wound closure"
45488960|NCT03738527|Drug|Normal Saline Flush, 0.9%, 20mL topical|"Drug: Normal Saline~20 mL 0.9% NaCl (normal saline) applied topically to the mastectomy cavity for 5 minutes before wound closure"
45488961|NCT03738449|Drug|CKD-387|Test drug
45488962|NCT03738449|Drug|D484|reference drug
45488963|NCT03174262|Behavioral|Ergonomic Computer Workstation Training|Training in proper body alignment and use of computer at computer workstations for people who spend 30% or more of a typical day at a computer. Training consists of learning proper positioning for head, neck, shoulders, arms, hands, and legs; proper arrangement of computer monitor, keyboard, mouse, and accessories.
45488964|NCT02413060|Other|Resistance training|This training consists 4 exercises and every exercises lasts 5 seconds.
45370054|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 60 mg or Placebo, daily for 10 days.
45488965|NCT02413060|Behavioral|Lifestyle counselling|Lifestyle counselling mainly indicates dietary instruction.
45488966|NCT03738371|Other|In situ simulation|Team involved in thrombectomy procedures will be trained by in situ simulation. Simulation will reproduce the initial step of a thrombectomy procedure, i.e from from the installation of the patient to the percutaneous punch by the neuroradiologist. Simulation will be followed by a debriefing focused on the team performance. Three in situ simulation sessions will be realized by each team.
45692223|NCT01273480|Drug|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
46052932|NCT04235283|Device|Primary total knee replacement by pinless navigation (Orthomap Express,Stryker, Michigan)|The varus/valgus, extension/flexion, thickness of distal cut of femur was determined and done by pinless navigation system. After cutting, the instant information of resection level can show on the display screen. If the alignment is satisfying, the anterior/posterior femoral cut, chamfer cut and box resection were done by conventional jig
46052933|NCT04235283|Procedure|Primary total knee replacement by traditional jig and minimally invasive technique|The femoral alignment was determined by intramedullary guide. The femoral alignment jig was set to 5-7 degree valgus dependent on the preoperative radiograph. A bone plug is impacted into the entry hole of femoral medullary canal before prosthesis placement.
46052934|NCT00761605|Drug|Paliperidone|Paliperidone oral tablet will be administered once daily at a dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.
45370055|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 120 mg or Placebo, daily for 10 days.
45692224|NCT02991274|Procedure|genomic testing of T790M mutation|patients will need to have genomic testing of T790M mutation at hospital laboratories and in central laboratory.
46052935|NCT02797431|Drug|Interleukin-7|IM administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR>2.5 or platelet count < 35,000
45692225|NCT02991508|Drug|Placebo|
45370056|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 185 mg or Placebo, daily for 10 days.
45370057|NCT05181813|Procedure|Ginge-Cal|Fill the infected root canal of of primary teeth with Gingerols extract and Calcium Hydroxide (Ginge-Cal)
45370058|NCT05181813|Procedure|Metapex|Fill the infected root canal of of primary teeth with Metapex
45370059|NCT00971880|Other|Clinical medical record summary|Summary of immediate and late adverse effects of blood transfusions
45370060|NCT02976909|Drug|Paclitaxel+Cisplatin+5fluorouracil|Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
45692226|NCT02991508|Drug|Adrecizumab|
45692227|NCT01273558|Drug|Canagliflozin|One 100 mg capsule taken orally (by mouth) on Days Days 1-8
45370061|NCT00960648|Device|Xience/Promus|Active prospective registration of patients receiving everolimus-eluting stent
45370062|NCT00960648|Device|Cypher|Retrospective historical controls that received sirolimus-eluting stent
45370063|NCT02878083|Drug|VEDOLIZUMAB|Infusion at week 0 week 2 week 6 week 14 for all patients Infusion at week 22 for responder patient only
45692228|NCT00733096|Drug|etanercept|Two transforaminal epidural injections of 4 mg, two weeks apart
45692229|NCT00733096|Drug|methylprednisolone|Two transforaminal epidural steroid injections with 60 mg, two weeks apart
45692230|NCT00733096|Drug|normal saline|Two transforaminal epidural saline injections, two weeks apart
45848008|NCT05353920|Other|Cognitive training|cognitive related training bu virtual reality system
45488967|NCT03176056|Dietary Supplement|Low carbohydrate diet|For the LCD group, the daily carbohydrate intake was limited to less than 90g, without any restriction to total energy. The concept of a LCD was introduced and an educational 15 g equivalent carbohydrate food list was provided. The easy conversion method is that 15 g equivalent carbohydrate =1/4 bowel of rice= 1/2 bowel of noodle = 1 slice of toast = 3 soup-spoon of oats = one bowl of fruit =1/2 regular size banana= one glass of milk = 3 dumplings. Less than two equivalent 15g-carbohydrate intakes per meal were advised.
45488968|NCT03176056|Dietary Supplement|Calori restricted diet|For the calori restricted diet group, the target total calorie intake was calculated by multiplying the ideal body weight by 25 kcal/kg for those with a BMI in the range 18.5 to 24, 20 kcal/kg for obese subjects with a BMI > 24 and 30 kcal/day for underweight subjects with a BMI <18.5. The macronutrient percentage was 50-60% for carbohydrate, 1.0-1.2 g/kg for protein and fat ≦30%.
45488969|NCT02915978|Drug|Fentanyl|Fentanyl delivered via sublingual spray
45488970|NCT02915978|Drug|Placebo|Matching placebo delivered via sublingual spray
45692231|NCT02991196|Drug|DS-8273a + nivolumab|Nivolumab will be administered at 240 mg intravenously (IV) once every two weeks (Q2W) over 30 (± 5) minutes (on Days 1 and 15 of each cycle of 28 days). DS-8273a will be administered [90 (± 15) minutes on Day 1 of Cycle 1, and 60 (± 15) minutes in subsequent infusions] after the end of the nivolumab infusion in ascending doses up to 1200 mg IV Q2W. The regimen is adjusted based on injection site reactions or adverse events. Additional dose combinations may be considered based on the assessment of safety, primary pharmacodynamic (PDy) effects, and preliminary anti-tumor activities.
46052936|NCT02797431|Drug|Placebo|IM administration of Placebo (SC administration for patients with INR>2.5 or platelet count < 35,000
45370064|NCT02878083|Drug|ADALIMUMAB|For nonresponder patients only : Injection at week 22 week 24 week 26 and week 28
45370065|NCT00971958|Procedure|Circumcision|Neonatal circumcision using one of three non-experimental, widely available devices.
45370066|NCT00971958|Device|Mogen Clamp|Mogen clamp is a reusable, one-size stainless steel clamp use for neonatal circumcision.
45370067|NCT00971958|Device|Plastibell|The plastibell is a one-time use device for the circumcision of male neonates, infants and children.
45370068|NCT00971958|Device|AccuCirc|AccuCirc is a device used for the circumcision of male infants approved for use by the FDA up to 10 days of life.
45370069|NCT00093145|Drug|Albumin-bound paclitaxel|Administered by intravenous infusion.
45370070|NCT00093145|Drug|Carboplatin|Carboplatin dose was calculated using a modified Calvert formula (creatinine clearance was substituted for GFR): Total dose (mg) = (target AUC) x (creatinine clearance + 25). Note: AUC = 6 was initially targeted, but could be decreased due to toxicity.
45692232|NCT01278706|Procedure|endometrial biopsy/ies|performing office endometrial biopsy with a disposable sterile catheter
45692233|NCT00733330|Device|Either P.F.C. Sigma or L.C.S. Complete knee replacement using the conventional surgical approach and manual surgical technique|Orthopaedic implants for total knee replacement implanted with a standard approach using standard instrumentation
45692234|NCT00733330|Device|Either P.F.C. Sigma or L.C.S. Complete knee replacement using minimally invasive surgical approach and computer navigation|Orthopaedic implants for total knee replacement implanted with a minimally invasive approach and computer navigation
45692235|NCT01278784|Device|0.05% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
46052937|NCT00761527|Drug|Desloratadine Syrup|"Desloratadine (Aerius) Syrup;~Dose selection was based upon the age of the participant, and the timing of dose for each participant was once daily (QD) as described in the Product Insert for 14 days:~Children 6 through 11 years of age, 5 mL (milliliters) of Aerius Syrup (2.5 mg [milligrams] of desloratadine)~Children 1 through 5 years of age, 2.5 mL of Aerius Syrup (1.25 mg of desloratadine)~Children 6 months to 11 months of age, 2 mL of Aerius Syrup (1 mg of desloratadine)"
45370071|NCT00093145|Drug|Herceptin®|Administered by IV infusion
45488971|NCT02412904|Drug|rFSH|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and antral follicle count (AFC). This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
45692236|NCT01278784|Device|0.1% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
45692237|NCT04386226|Dietary Supplement|Ambrotose LIFE|Ambrotose LIFE contains aloe vera extract inner leaf gel, arabinogalactin, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, rice starch, RiFiber (rice bran), and Modified Citrus Pectin with Sodium Alginate.
45692238|NCT04386226|Dietary Supplement|Advanced Ambrotose|Advanced Ambrotose contains aloe vera extract inner leaf gel, arabinogalactan, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, and rice starch
45488972|NCT02412904|Drug|HMG|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and AFC. This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
45488973|NCT02412826|Device|Abstats sensor|The AbStats abdominal biosensor will be applied to the abdomen of patients who are admitted with acute pancreatitis.
45488974|NCT03671564|Drug|Milademetan|Milademetan, an MDM2 inhibitor, is provided in capsules for oral administration
45488975|NCT02404948|Other|Diagnostic algorithm|Validation of a diagnostic algorithm used to detect coronary artery disease and/or myocardial ischemia based on pulse wave analyses.
45370072|NCT02808195|Other|Constraint-induced therapy|
45488976|NCT03675230|Device|Tomotherapy HD|Patients with Medulloblastoma receiving Tomotherapy
45488977|NCT03675230|Device|3DCRT|Patients with Medulloblastoma receiving Three-Dimensional Conformal Radiation Therapy
45488978|NCT02404714|Device|Iontophoresis sweat test|The intervention is iontophoretic sweat testing which includes the stimulation, collection and analysis of sweat. The standard of care sweat testing used at each institution will be compared to a new iontophoresis sweat test called the CF Quantum.
45488979|NCT03671408|Other|clinical measurements|only clinical parameters were recorded
45488980|NCT03174028|Device|laparoscopic pull-through|laparoscopic pull-through
45488981|NCT02701192|Other|Coccygectomy|Patient receiving coccygectomy surgery.
45370073|NCT02808195|Other|kinect-based constraint-induced therapy|
45488982|NCT02404480|Drug|PTC596|PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted
45488983|NCT02412514|Biological|bOPV (three dose)|bOPV administered at 6, 10, and 14 weeks of age.
45488984|NCT02412514|Biological|bOPV (two dose)|bOPV administered at 10 and 14 weeks of age.
45488985|NCT02412514|Biological|IPV|IPV administered at 6 weeks of age
45488986|NCT02408458|Device|MIROMESH®|
45488987|NCT02404558|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: Subcutaneous injection
45488988|NCT02404558|Drug|tocilizumab|Pharmaceutical form:solution Route of administration: Subcutaneous injection
45488989|NCT02404636|Other|Interview|Brief structured interview
45488990|NCT04481854|Procedure|cricoid pressure|cricoid pressure during laryngoscopy
45488991|NCT04481854|Procedure|left paratracheal pressure|left paratracheal pressure during laryngoscopy
45488992|NCT02408302|Drug|Midazolam|comparison between 3 routes of administration of the drug Midazolam used for sedation for minor procedures in pediatric population. the routes are oral intranasal and buccal.
45488993|NCT02404324|Other|Prescription of spectacles|All children are prescribed full optical correction of refractive errors with special attention to astigmatism up to 0.5 Dptr to achieve maximal clear image on the retina of both eyes.If necessary, direct occlusion or penalization are administered to the children.
45488994|NCT03170986|Behavioral|Multisectoral agriculture and Microfinance Intervention|
45370074|NCT00965328|Procedure|CVVH 4 to 2 L/h|CVVH is initiated at 4L/h and is converted to 2L/h after 60 min
45370075|NCT00965328|Procedure|CVVH 2 to 4L/h|CVVH is initiated at 2L/h and is converted to 4L/h after 60 min
45370076|NCT01014039|Procedure|Flexible Sigmoidoscopy Screening arm|sigmoidoscopy screening
45370077|NCT00965406|Drug|GIK and intensive insulin therapy|GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
45370078|NCT00960726|Drug|NOV-002|60 mg delivered daily subcutaneously for up to 12 months.
45488995|NCT02412358|Device|toothbrush|
45488996|NCT02412280|Other|retrospecive observational|
45488997|NCT03173716|Procedure|Definity|Real-Time Myocardial Perfusion Echocardiography (RTMPE) will be performed as opposed to the standard echocardiogram (TTE) of the control arm
45488998|NCT03115372|Other|Educational Intervention|Attend CRC education session
45488999|NCT03115372|Other|Educational Intervention|Attend healthy nutrition session
45489000|NCT03115372|Other|Informational Intervention|Receive CRC screening brochure
45489001|NCT03115372|Other|Survey Administration|Ancillary studies
45489002|NCT03115372|Behavioral|Telephone-Based Intervention|Receive telephone reminder about CRC screening
45489003|NCT03115372|Behavioral|Telephone-Based Intervention|Receive telephone reminder about healthy nutrition
45489004|NCT04481542|Diagnostic Test|MRI|check MRI quality in aorta
45489005|NCT03173872|Procedure|Reiki Protocol Hand Placement Procedures|Ten Reiki hand placement procedures will last 3 minutes each for a total Reiki session lasting 30 minutes long.
45489006|NCT02412202|Other|Monitoring of pulmonary oedema induced by weaning from mechanical ventilation|
45489007|NCT02408146|Procedure|conventional intravenous infusion pump|The first group receives conventional intravenous infusion pump of patient-controlled analgesia (fentanyl citrate 20 mg/mL/kg + ondansetron hydrochloride 16 mg/8 mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
45489008|NCT02408146|Drug|parecoxib|The second group has oral celecoxib before surgery, then receives 40 mg parecoxib sodium intravenously guttae twice a day for three days after surgery.
45489009|NCT02408146|Procedure|intravenous infusion pump of patient-controlled analgesia|The third group has oral celecoxib before surgery, and receives 40 mg parecoxib sodium intravenously guttae immediately after surgery, then uses new intravenous infusion pump of patient-controlled analgesia (parecoxib sodium 1 mg/mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
45489010|NCT02408146|Drug|fentanyl citrate+ ondansetron hydrochloride + normal saline|
45489011|NCT02408146|Drug|celecoxib|
45489012|NCT02412124|Procedure|Supportive Care|Complete W2W mentoring program
45489013|NCT02412124|Other|Quality-of-Life Assessment|Complete the FACT-G
45489014|NCT02412124|Other|Questionnaire Administration|Complete the W2W Patient Survey
45489015|NCT04482010|Other|Local community-based HIV care|"Compared to the classic HIV care, community-based HIV care includes:~Individual interviews with a psychosocial agent;~Support groups conducted by psychosocial agents;~Culinary workshops gathering PLWHIV and healthcare professionals;~Home visits by a community worker;~Emergency relief based on a funding for patients with urgent needs~As in the classic HIV care, ARCAD Santé PLUS provides consultations with doctors, prescriptions and delivery of antiretroviral (ARV) treatment every 3 months, biological analyses for enrolment, and follow-up every 6 months. In addition, psychosocial agents from ARCAD Santé PLUS propose workshops on education and support for adherence to treatment."
45489016|NCT03175900|Drug|Naoan dripping pills|"Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI）"
45489017|NCT03175900|Drug|Placebo|"Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI)"
45489018|NCT03175666|Biological|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
45489019|NCT03175666|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
45489020|NCT03175666|Drug|capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
45489021|NCT03175666|Drug|cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
45489022|NCT03175666|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
45489023|NCT03175666|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
45489024|NCT03175666|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
45489025|NCT03175666|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
45489026|NCT03175666|Drug|Lovaza|omega-3-acid ethyl esters)
45489027|NCT03175666|Radiation|Stereotactic Body Radiation Therapy|(SBRT)
45489028|NCT03175666|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
45489029|NCT03175666|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-CEA (carcinoembryonic antigen)
45489030|NCT03175666|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
45489031|NCT03175666|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 (MUC1)
45489032|NCT03175666|Biological|GI-4000|RAS yeast vaccine
45489033|NCT03175666|Biological|GI-6207|CEA yeast vaccine
45489034|NCT03175666|Biological|GI-6301|Brachyury yeast vaccine
45489035|NCT03175666|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion (haNK™ for Infusion)
45489036|NCT03101358|Drug|SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment|One (1) Finger Tip Unit (FTU), or approximately 0.5 g, of SOR007 ointment will be applied topically to a 50 cm2 treatment area.
45489037|NCT02404246|Behavioral|Peer support program|
45489038|NCT02404090|Radiation|CT-osteoarbsorptiometry|Conventional CT-scan analyzed by means of a specific tool (Analyze, Mayo Clinic).
45489039|NCT05236218|Other|Discrete Choice Experiment (DCE) Patients DCE Questionnaire|Discrete Choice Experiment (DCE) Patients
45489040|NCT05236218|Other|Semi-Structured Interview Patients Interview|First version of questionnaire (readability/comprehension check)
45692239|NCT04386226|Other|Placebo|Maltodextrin
45370079|NCT00972036|Device|SIR-spheres® (Selective Internal Radiation Therapy)|SIR-spheres® will be administered at 70%, 85% and 100% of the calculated individual patient dose (approximately 1 month prior to SIR-spheres® administration).The first cohort will receive SIRSpheres® at 70% of the individually calculated patient dose, the second will receive 85% of the calculated patient dose, and the third will receive 100% of the calculated patient dose.
45370080|NCT00513357|Drug|Melatonin|20 mg by mouth daily for 4 Weeks
45370081|NCT00513357|Drug|Placebo|Capsule by mouth daily for 4 Weeks
45370082|NCT00960882|Drug|DMMET-01|1050.6 mg daily for 30 days
45370083|NCT05163678|Other|monitoring naturalistic of cohort|"Assessment at the start of care in the Relais (T0), at the end (T1) and 6 months later (T6)."
45370084|NCT00972114|Procedure|CABG combined cardiomyoplasty|coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
45370085|NCT00972114|Procedure|CABG combined pedicled omentum graft|Coronary artery bypass graft surgery combined pedicled omentum graft
45370086|NCT00972114|Procedure|CABG alone|Coronary artery bypass graft surgery alone
45370087|NCT01014117|Drug|Placebo|Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
45370088|NCT01014117|Drug|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg of SRT2104.
45370089|NCT00960960|Drug|Bevacizumab|Bevacizumab will be administered IV at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.
45370090|NCT00960960|Drug|Pictilisib|Pictilisib will be administered PO QD on escalating doses.
45370091|NCT00960960|Drug|Letrozole|Letrozole will be administered PO at a dose of 2.5 mg QD for for each 28-day cycle.
45370092|NCT00960960|Drug|Paclitaxel|Paclitaxel will be administered IV at a dose of 90 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle.
45370093|NCT00960960|Drug|Trastuzumab|Trastuzumab will be administered IV at a dose of 2-4 mg/kg on on Days 1, 8, 15, and 22 of each 28-day cycle.
45370094|NCT00972192|Behavioral|Inpatient HIV testing|Participants who were randomized to the intervention group received free HIV testing and their results before they were discharged from the hospital.
45370095|NCT00972192|Behavioral|Outpatient HIV testing|Participants randomised to the control arm received referral for testing post-discharge
45370096|NCT04315857|Other|interstitial glycaemia|Continuous measurement of interstitial blood glucose during the first 15 days of the first two chemotherapy courses.
45370097|NCT01014195|Other|Neurocognitive and behavioral evaluation|The primary neurocognitive outcome will be performance on measures of cognitive flexibility and cognitive fluency. Functional behavior will be evaluated via the child or adult version of the Behavior Rating Inventory of Executive Function, using parent respondent for each version. The presence of ADHD and common comorbid conditions (i.e. depression, anxiety) will be determined with structured diagnostic interviews. Quality of life will be re-assessed with the PedQL.
45370098|NCT00972270|Device|Impella LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5L/min.
45370099|NCT00972270|Device|Intra-Aortic Balloon Pump|The Intra-Aortic Balloon Pump consists of a cylindrical balloon that sits in the aorta and counterpulsates.
45370100|NCT01015521|Drug|Aminoflavone Prodrug|Aminoflavone Prodrug administered D1, D8 of 21-day cycle
45370101|NCT00965640|Drug|Botulinum Toxin - A injections|
45370102|NCT04307277|Drug|Standard of care + chemotherapy|Doxorubicine with Ifosfamide during 4 cycles Q3W Or Doxorubicine with Dacarbazine during 4 cycles Q3W (for patients with Leiomyosarcoma)
45370103|NCT04307277|Other|Standard of care|Surgical excision with external radiotherapy (if applicable)
45370104|NCT00961038|Drug|Ciprofloxacin (PulmoSphere, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
45370105|NCT00961038|Drug|Ciprofloxacin (PulmoSphere, BAYQ3939)|48,75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
45753512|NCT04199858|Behavioral|Conditioning|"During nocebo induction trials, the conditioned stimulus (i.e., a sham medical gel that can increase pain sensitivity, named TDA and contained in either a brown or a blue jar) is paired to unconditioned high-pain stimuli (nocebo trials). Lower 'baseline' pain is paired with no gel application (control trials)."
45489041|NCT03173794|Other|CommunityRx-H|"CommunityRx-H has two components: (1) health-information technology (HIT) e-prescribing, and (2) a Community Resource Specialist (CRS). CommunityRx functions like an e-prescribing system: a HealtheRx prescription is automatically generated at the point of care. The HealtheRx provides referrals to food resources and federal nutrition assistance information tailored to the caregiver's address and proactive social support in the form of SMS-text message nudges from the CRS. Caregivers in the intervention arm are able to request information on resources not limited to food, including employment support, help paying rent or mortgage, etc. Nudges will promote caregiver self- and family management by increasing knowledge of and encouraging activation of community resources."
45370106|NCT00961038|Drug|Placebo|Placebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)
45489042|NCT03171220|Biological|Neoantigen Reactive T Cells(NRTs)|Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
45489043|NCT03171220|Biological|SHR-1210|SHR-1210 200mg will be administered as an intravenous infusion over 60 minutes.
45489044|NCT03171220|Drug|Fludarabine|Fludarabine(FLU) 30mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
45370107|NCT00972348|Other|Online access to a personal health record|Patients in the intervention arm have full access to their online personal health record
45489045|NCT03171220|Drug|Cyclophosphamide|Cyclophosphamide(CTX) 300mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
45489046|NCT03171220|Biological|Interleukin-2|Interleukin-2(IL-2)will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.
45489047|NCT04853004|Diagnostic Test|SARS-CoV2 antibody measurement|Blood samples for serology, collected immediately prior to and five to ten weeks after vaccination against SARS-CoV2, to be analyzed for the presence of SARS-CoV-2 antibodies.
45489048|NCT03170830|Diagnostic Test|the diagnosis value of cUck2 in acute myocardial infarction.|Collect blood at different time points and compare cUck2 in three groups.
45489049|NCT03175822|Behavioral|Visual Arts Training|The art training program has been designed as a drawing program and focuses on basic visual art concepts (the elements [e.g., colour and line] and principles [e.g., proportion and balance] of design). Each week has a different activity and a different focus (one activity per week focusing on one element and principle of design). Each art training program will occur one hour per day, two days per week, for eight weeks. The art training program will take place at the participants' respective dementia care location in an area separate from waitlist control participants and uninvolved clients. All art programs are free for participants.
45489050|NCT05417724|Other|Battlefield Acupuncture|Battlefield Acupuncture
45489051|NCT03173482|Other|questionnaire|asking about details of indication of cesarean section
45489052|NCT04847934|Behavioral|distraction methods|distraction methods
45489053|NCT03116386|Other|run-in period|observational time i.e. baseline situation
45370108|NCT00972348|Other|No access to the PHR|Patients will not be given access to their PHR but will complete online surveys.
45489054|NCT03116386|Device|Control period|neither activation of any lighting environment when the resident gets up from his bed nor alert if the resident did not return to bed after 15 minutes Etolya-F ® devices will only permit detection and recording of the moment of the elderlly will leave his/her bed and recording of the moment the elderly will be found by caregivers
45489055|NCT03116386|Device|Etolya-F ® devices|Etolya-F ® devices will permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
45489056|NCT05200650|Combination Product|TumoCure|TumoCure is a polymer-based gel, loaded with Cisplatin in a dose of 100mg (10% w/w), injected to head and neck tumors locally in a single injection.
45489057|NCT03116542|Device|Diagnostic (18F-FLT PET/CT)|The tracer compound [F-18] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
45489058|NCT03632694|Behavioral|Health Coaching and Tech Support|"Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. Additionally, this arm receives health coaching to provide encouragement and further motivate and help study participants to modify their sedentary behavior."
45692240|NCT04386070|Drug|RESP301|RESP301 is a formulation consisting of three agents already used in clinical practice: mannitol, sodium nitrite and citric acid. Delivered by a vibrating mesh nebuliser three times per day (TID) (at least 4 hours apart), for 7 days. Each dose of RESP301 is a 6ml admixture of 150mM NaNO2, 50mM mannitol and 100mM citric acid, buffered at pH 5.4.
45489059|NCT03632694|Behavioral|Tech Support Only|"Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. However, there is no additional health coaching."
45489060|NCT04814550|Diagnostic Test|FFR|FFR measured by pressure wire, AccuFFRangio computed by coronary angiographic images
45489061|NCT03170674|Other|FT21039|an electronic cigarette product
45489062|NCT03170674|Other|FT21092|an electronic cigarette product
45489063|NCT03170674|Other|FT21018|an electronic cigarette product
45489064|NCT04913142|Other|Fecal and oral samples|oral and rectal swab from patients hospitalized at day 1, each 7 days and at the end of their ICU stay
45489065|NCT03170596|Drug|tazarotene gel 0.1%|Patients will be instructed to apply 0.1% tazarotene gel as a thin film over the affected area once daily in the evening.
45489066|NCT03170596|Device|Microneedling|Microneedling is a method of percutaneous collagen induction
45489067|NCT03170752|Behavioral|Cardiovascular Assessment Screening Program (CASP)|Step 1. Identification of patients; Step 2. Screening utilizing appropriate tools; and Step 3. Actions to follow up on the screening results.
45692241|NCT04386148|Procedure|Obsidian ASG®|As part of the elective laparoscopic colorectal surgery, an autologous fibrin matrix was used as part of anastomotic technique in conjunction with activated thrombocytes (Obsidian ASG®). During anastomosis, this matrix was applied after resection onto the colorectal tissue surfaces with the aim of triggering tissue regeneration and improved wound healing.
45489068|NCT03173404|Procedure|Hysteroscopy|The hysteroscopy is the visualization of the cervical canal and uterine cavity with a camera. Patients randomized to group I underwent hysteroscopy prior to the IVF cycle.
45489069|NCT05194176|Device|Virtual Reality|For all VR exercises a head mounted display (HMD), the PICO G2 4K (Barcelona, Spain) will be used. Together with SyncVRMedical (Utrecht, Netherlands) a VR dashboard has been created from which patients can chose the different exercises.
45489070|NCT03173638|Procedure|intravitreal injection of MSV|A unique intravitreal injection of MSV in acute fase of NAION
46052938|NCT00770029|Drug|IncobotulinumtoxinA (Xeomin) (20 Units)|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.
46052939|NCT00770029|Drug|Placebo|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
46052940|NCT02797353|Other|Maternal Neonatal and Child Health Interventions|Antenatal care, postnatal care, skilled birth attendance, recognition and referral of complicated cases, immunization
45692242|NCT01276288|Drug|BI 10773|multiple oral doses
45489074|NCT03175354|Drug|ALX-101 Gel 1.5% and ALX-101 Gel Vehicle|Bilateral application of ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
45489075|NCT03175354|Drug|ALX-101 Gel 5% and ALX-101 Gel Vehicle|Bilateral application of ALX-101 Gel 5% and ALX-101 Gel Vehicle
45489076|NCT05417412|Behavioral|Brief Behavioral Therapy|8-12 sessions of brief behavioral therapy administered by behavioral health / mental health staff at participating community health centers (CHCs)
45489077|NCT03173326|Procedure|General anesthesia|General anesthesia will be delivered per standard procedure. General anesthesia will include induction with propofol 1-3mg/kg followed by placement of a laryngeal mask airway with maintenance anesthesia of sevoflurane 0.5-1 minimum alveolar concentration (MAC).
45489078|NCT03173326|Procedure|Subarachnoid block|Neuraxial anesthesia will be performed at the L2-3 or L3-4 interspace with a 25-gauge Whitacre needle in the sitting position. After free flow of cerebrospinal fluid (CSF), 40-45mg of 2-chloroprocaine will be injected based on patient's height and discretion of attending anesthesiologist, needle withdrawn and the patient placed supine.
45489079|NCT02411968|Other|111In-Girentuximab DOTA SPECT|
45489080|NCT04481776|Other|Breakfast consumption|Standardised breakfast consumption across seven days
45489081|NCT04481776|Other|Breakfast omission|No breakfast consumed across seven days
45489082|NCT03172858|Device|Intracervical balloon catheter|cervical ripening balloon
45489083|NCT03172858|Drug|Oxytocin|medication used to induce contractions
45489084|NCT02403934|Device|Jaw Elevation Device (JED)|apply JED when End tidal O2 low
45489085|NCT02403856|Drug|Sodium Chloride 0.9%|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
45370109|NCT00961194|Drug|Ketamine|"Initial dosage: 250 mg/5 ml~Three doses of ketamine will be tested:~0.35 mg/kg~0.7 mg/kg~1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
45370110|NCT02665923|Other|Gastric ultrasound|Ultrasound of abdomen to assess antral volume
45489086|NCT02403856|Drug|Methylprednisolone acetate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
45489087|NCT02403856|Procedure|Ultrasound-guided Needling and Lavage|
45489088|NCT03170284|Drug|Bevacizumab|Bevacizumab is prescribed by physicians as per SPC.
45489089|NCT02411734|Behavioral|Rehabilitation|Rehabilitation after hospitalization
45489090|NCT02411890|Procedure|Adductor canal block (active)|adductor canal block: single injection, 0.5% levobupivacaine 15 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
45489091|NCT02411890|Procedure|Femoral nerve block (active)|femoral nerve block: single injection, 0.25% levobupivacaine 30 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
45370111|NCT03933462|Device|InnoSpire Go|Participants will use for 30 days.
45370112|NCT03933462|Device|Jet Nebulizer|Participants will use for 30 days.
45370113|NCT03929562|Behavioral|Brief advice|One 10-minute brief advice session
45489092|NCT02411890|Procedure|Femoral nerve block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the inguinal area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance to create quadriceps contraction before injection
45692243|NCT01276288|Drug|hydrochlorothiazide|multiple oral doses
45692244|NCT01276288|Drug|torasemide|multiple oral doses
45692245|NCT01276288|Drug|BI 10773|multiple oral doses
45692246|NCT01276288|Drug|torasemide|multiple oral doses
45692247|NCT01276288|Drug|BI 10773|multiple oral doses
45692248|NCT01276288|Drug|hydrochlorothiazide|multiple oral doses
45370114|NCT03929562|Behavioral|Health coaching|Two 45-minute health coaching sessions will use a non-confrontation motivational interviewing (MI) style. Intervention delivery will include expressing concern about unhealthy drinking, providing feedback linking alcohol use and health (related to surgery and general health), advising the patient regarding abstinence or alcohol use reduction, and working with the patient to set a drinking goal if he/she is ready to change. We will also include a personalized feedback component to address the links between pre-operative alcohol use and postoperative morbidity/mortality.
45370115|NCT05279586|Drug|lactulose|all interventions are used in secondary prophylaxis in cirrhotic patients
45370116|NCT05279586|Drug|colistin|all interventions are used in secondary prophylaxis in cirrhotic patients
45370117|NCT00965796|Drug|Lidocaine|Lidocaine 2 mg/kg/h- during surgical procedure Saline
45370118|NCT00415636|Drug|IC83/LY2603618|40 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. Dose finding study: dose is escalated after a minimum of 6 participants receive 40 mg/m^2.
45370119|NCT00415636|Drug|IC83/LY2603618|70 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
45489093|NCT02411890|Procedure|Adductor canal block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the midfemoral area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance without muscle contraction
45692249|NCT02702271|Device|WATCHMAN FLX|Left atrial appendage closure with WATCHMAN FLX
45692250|NCT00722566|Drug|VELCADE Administered by subcutaneous injection|Patients will receive a 1.3mg/meters(squared)/dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle
45692251|NCT00722566|Drug|VELCADE Administered by intravenous infusion|Patients will receive a 1.3mg/meters(squared) dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle.
45692252|NCT05582889|Behavioral|Fitbit Intervention|Participants receive a Fitbit activity tracker and the free Fitbit smartphone app. A trained health coach provides technical support to set up and use the Fitbit and app. The health coach also provides motivational counseling to help participants to gradually increase the number of steps per day during the 12-weeks.
45692253|NCT04143633|Other|Low FODMAP diet|The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. The distribution of carbohydrates depends on the content of fodmaps on each food.
45489094|NCT02407912|Drug|cisplatin|ciplatin in distilled water is injected into the chest for 48 h.
45489095|NCT02411500|Drug|TRV734|Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.
45489096|NCT02411422|Device|Conventional endotracheal tube|Conventional endotracheal tube
45489097|NCT02411422|Device|Reinforced endotracheal tube|Reinforced endotracheal tube
45370120|NCT00415636|Drug|IC83/LY2603618|105 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
45489098|NCT03170128|Procedure|Outpatient physical therapy in addition to standard follow-up visits|Patients in Group 1 will be given a prescription for outpatient physical therapy.
45489099|NCT03170128|Behavioral|Home exercises in addition to standard follow-up visits|Patients in Group 2 will be carefully instructed on home exercises for range of motion and strengthening of their affected elbow. All therapy regimens will be prescribed at initial presentation, as is the current practice. All other care will be identical for patients in both groups. This
45489100|NCT03170050|Device|YYD701-2|HA Filler
45692254|NCT04143633|Other|Standard diet|The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. Cruciferous vegetables, fruits and condiments will be eliminated and a normal content of fodmap.
45370121|NCT00415636|Drug|IC83/LY2603618|150 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
45370122|NCT00415636|Drug|IC83/LY2603618|195 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
45489101|NCT03170050|Device|Restylane Perlane Lidocaine|HA Filler
45489102|NCT02407834|Other|S1|Immersion in 0.25% sodium hypochlorite for 20 minutes, during 7 days.
45489103|NCT02407834|Other|S2|Immersion in 0.5% sodium hypochlorite for 20 minutes, during 7 days.
45489104|NCT02407834|Other|S3|Immersion in 10% Ricinus communis for 20 minutes, during 7 days.
45692255|NCT05581563|Procedure|total knee arthroplasty(TKA)|Knee replacement, also called knee arthroplasty or total knee replacement, is a surgical procedure to resurface a knee damaged by arthritis. Metal and plastic parts are used to cap the ends of the bones that form the knee joint, along with the kneecap. This surgery may be considered for someone who has severe arthritis or a severe knee injury.
45370123|NCT00415636|Drug|pemetrexed|pemetrexed 500 mg/m^2, intravenous (IV), Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
45370124|NCT00415636|Drug|pemetrexed|pemetrexed 500 mg/m^2 IV, Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
45370125|NCT00965874|Drug|Magnesium Sulfate high dose|9 g infusion once during 30 minutes
45370126|NCT00965874|Drug|Magnesium Sulfate low dose|4.5 g magnesium sulfate infusion
45370127|NCT00965874|Drug|Placebos|serum salin
45370128|NCT00972426|Drug|carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)|Experimental: Mikelan, 1 drop/daily, for 8 weeks Active Comparator: Timoptol, 1 drop/daily, for 8 weeks
45489105|NCT02407834|Other|S4|Immersion in Saline solution for 20 minutes, during 7 days.
45489106|NCT02407678|Genetic|AAV-mediated REP1 gene replacement|AAV vector carrying human REP1 gene is delivered into the treated eye by subretinal injection
45489107|NCT02411266|Other|ischemic conditioning group|application of a blood pressure cuff around a leg and inflating the cuff to 200mmHg to induce limb ischemia for 10min followed by 5min reperfusion. this will be done for 3 cycles every 24-48hours during the first 14 days after subarachnoid hemorrhage
45489108|NCT02407522|Dietary Supplement|Black rice|They asked to keep their normal life style during intervention
45489109|NCT02407522|Other|follow-up|They asked not to consume any black rice or excess amount of food rich in anthocyanin compared to their normal life style, such as grapes, blueberry, red wine, black bean during intervention.
45489110|NCT02411188|Behavioral|The STEP Program|Intervention: The 12-week STEP Program will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
45489111|NCT03169738|Biological|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
45489112|NCT03169738|Biological|Bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
45489113|NCT03169738|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
45489114|NCT03169738|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
45489115|NCT03169738|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
45489116|NCT03169738|Drug|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
45489117|NCT03169738|Drug|fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
45692256|NCT00722722|Drug|Bortezomib|Velcade given in four-dose cycles intravenously (through a vein).
45370129|NCT00972582|Dietary Supplement|Leucine Increase|Graded stepwise increases in leucine intakes (50, 250, 500, 750, 1000, 1250 and 1500mg/kg/day)
45489118|NCT03169738|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5- formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
45489119|NCT03169738|Drug|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11- en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
45846604|NCT05731830|Other|Data extraction|"The exposure of patients to air pollution compounds in the two years prior to the occurrence of TTS will be analysed. We will investigate: PM10, PM2.5, O3, NO2, C6H6, SO2 e CO. Residential addresses will be obtained from medical records. Annual average 24-h of pollutants levels will be measured matching each individual's home address, and the ArpaLazio website (http://www.arpalazio.net/main/aria/sci/basedati/chimici/chimici.php), which provides the concentration of NO, NO2, NOx, PM10, PM2.5, O3, CO, C6H6, SO2 expressed in micrograms per cubic meter (µg/m3). Hourly data are available for all gaseous pollutants, while the levels of PM10 and PM2.5 are expressed daily. Data will be obtained from the air quality monitor closest to each participant's residence that was active for the entire year, and short-term (daily and weekly) and long-term (annual) air pollution exposure will be quantified as daily, weekly, and annual average 24-h pollutants level of measurements before TTS."
45846605|NCT05731830|Other|Clinical follow-up|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 6, 12, 24, 36, 48 and 60 months from hospital discharge, during which the incidence of MACE, defined as the composite of all-cause mortality, non-fatal MI, transient ischemic attack (TIA)/stroke, and hospitalization for heart failure, and the recurrence of TTA in the past months will be investigated and collected.
45489120|NCT03169738|Biological|nivolumab|Human anti-PD-1 IgG4 kappa monoclonal antibody
45489121|NCT03169738|Drug|Lovaza|Omega-3-acid ethyl esters
45489122|NCT03169738|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
45489123|NCT03169738|Radiation|Stereotactic Body Radiation Therapy|(SRBT)
45692257|NCT04143555|Procedure|endoscopic submucosal injection of indocyanine green before laparoscopic gastrectomy|Indocyanine green was injected under endoscope within 24 hours before operation. Four points(0.5ml/point,1.25mg/ml) were evenly injected in four quadrants at the edge of the tumor. The injection method was direct submucosal injection and 0.5ml saline + 0.5ml indocyanine green solution + 0.5ml saline (sandwich method). The imaging effect was evaluated by indocyanine green fluorescence imaging system during the operation. The effect was divided into grade0 and Grade1. Grade1: The imaging of the tumor and the corresponding lymphatic drainage area in the injection area both were ideal. Grade 0: not up to grade 1, classified into tumor body and drainage area without imaging, only tumor body imaging, and even though tumor body and regional lymph drainage area imaging, the contrast agent in the gastric wall was too diffuse or even overflowing, which seriously interfered with the observation of lymph drainage area imaging.
45692258|NCT03021603|Behavioral|Brief Hope Intervention|"The present Brief Hope Intervention (BHI) is a four-weeks individual intervention:~Hope enhancement strategies included sharing and recalling past successes, hope-based goal mapping exercises, examining possible pathways to reach the targeted goals, hope visualization exercise and positive self-talk.~Purpose: help participants to develop positive thoughts.~The programme consists of four sessions:~Two face-to-face sessions (1-hour) and two telephone follow up (30 mins) Homework: A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets."
45846606|NCT05731752|Drug|HX009|The subjects will receive HX009 treatment via IV infusion once every 2 weeks at different dose escalation cohorts
45846607|NCT05731674|Other|Random selection of excercises|Participants in the intervention group will train using a random selection of excercises and complete the profiency-based traning program.
45846608|NCT05731518|Drug|SC0245|SC0245 Quaque Die(QD) administered with a 3-day on and 4-day off schedule in Day 1 Day8 and Day 15 of each cycle. One cycle is consisted of 28 days.
46052941|NCT02794935|Other|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
45370130|NCT00972660|Biological|Mesenchymal stem cell (MSC)|"Experimental:Mesenchymal stem cell(MSC). Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).~Refractory extensive cGVHD: receive primary treatment (prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate ) and MSC2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally)."
45370131|NCT00972660|Drug|Prednisone and cyclosporine or primary therapies|"Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus~Patients with refractory extensive cGVHD: primary treatment (eg.prednisone 1mg/kg + cyclosporine or tacrolimus,or plus mycophenolate mofetil, or methotrexate.)"
45489124|NCT03169738|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL15N72D:IL-15RαSu/IgG1 Fc complex]
45489125|NCT03169738|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine
45489126|NCT03169738|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
45489127|NCT03169738|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
45489128|NCT03169738|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine
45489129|NCT03169738|Biological|GI-4000|Ras yeast vaccine
45489130|NCT03169738|Biological|GI-6207|CEA yeast vaccine
45489131|NCT03169738|Biological|GI-6301|Brachyury yeast vaccine
45489132|NCT03169738|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion
45489133|NCT02407600|Drug|FOSAPREPITANT (Emend)|Uee of fosprepitant in EITHER first OR 2nd cycle of carboplatin containing combination chemotherapy in patients with advanced NSCLC
45489134|NCT02407600|Drug|Placebo|
45370132|NCT00961506|Procedure|LESS cholecystectomy|LESS cholecystectomy
45489135|NCT02403544|Radiation|IGRT|IGRT: 45 to 54Gy, 1.8-3Gy per fraction.
45489136|NCT02403544|Drug|Capecitabine|Capecitabine: by oral, D1-14, every 21 days, 600mg/m2 bid per day in level 1, and then escalated every another dose level.
45489137|NCT02403544|Drug|Oxaliplatin|Oxaliplatin: intravenously, D1 and D8, every 21 days, 30mg/m2 per day in level 1, and then escalated every another dose level.
45489138|NCT02411032|Behavioral|Reminder|Customer gets mailing that reminds them to take their medication.
45489139|NCT02411032|Behavioral|Fresh start|Customers receive a mailing around a fresh start event: New Year's or birthday
45489140|NCT02411032|Behavioral|Fresh start framing|The fresh start event will be highlighted in the mailings.
45489141|NCT02411344|Drug|Pertuzumab|"Pertuzumab 840 mg loading dose iv on day one, followed by 420 mg iv every 3 weeks for 5 cycles~Trastuzumab 8 mg/kg loading dose iv on day 2, followed by 6 mg/kg iv on day 2 of each subsequent 3 weekly cycle~Letrozole 2.5 mg daily p.o. for five 21-day cycles (to be continued until surgery)."
45489142|NCT02407444|Other|Physiotherapy treatment & leg cycling|"All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will train with stationary leg cycle ergometer for 20 minutes under physical therapist's supervision . Cycling exercise intensity subjectively determined by the patient using RPE Borg scale . Maximal intensity level determined as 14 in Borg scale."
45370133|NCT00961506|Procedure|Laparoscopic cholecystectomy|laparoscopic cholecystectomy
45370134|NCT04008966|Drug|combined oral contaraceptive pills|1 tablet daily between days 5 and 25 of the cycle before stimulation
45370135|NCT04008966|Drug|recombinant FSH|300 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
45370136|NCT04008966|Drug|Urinaru gonadotropin|150 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
45370137|NCT04008966|Drug|GnRH antagonist|0.25 subcutaneously daily from the day in which the leading follicles reached 12 mm till the day of triggering
45489143|NCT02407444|Other|Physiotherapy treatment & music listening|"All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will listen to music with earphone for 20 minutes while sitting under physical therapist supervision.~Overall treatment session will last 50 minutes."
45692259|NCT00723580|Drug|risperidone|Five treatment conditions: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.).
45692260|NCT05581329|Procedure|Acupuncture|Acupuncture is a method of inserting very thin needles into special points on the body which are called acupoints. To conduct this intervention, we will use disposable acupuncture needles the size of 0.30 x 13 mm to acupuncture the control acupoint (Yuji - LU10) in the first session and the research acupoint (Houxi - SI3) in the second session.
45692261|NCT05581251|Behavioral|Food and cooking skills|The researchers collected the study data using the face-to-face interview method through a questionnaire including the Descriptive Information Form, Cooking Skills and Food Skills Scale, and Three-Factor Eating Questionnaire-R21.
45753513|NCT04199858|Behavioral|Evocation|"During nocebo evocation, lower pain stimulations are administered both after the administration of the conditioned stimulus (i.e., a sham medical gel TDA) and the control stimulus (no medical gel), in order to evoke nocebo responses to the sham hyperalgesic medication."
45489144|NCT03657095|Drug|Esuberaprost|Sodium tablets
45489145|NCT03657095|Drug|Placebo|Placebo tablets, which are identical in size and appearance to those containing Esuberaprost.
45489146|NCT03100344|Drug|Nemolizumab|Injection every 4 weeks during 24 weeks (last injection at week 20)
45489147|NCT03100344|Drug|Placebo|Injection every 4 weeks during 24 weeks (last injection at week 20)
45370138|NCT04008966|Drug|Human chorionic gonadotropin|10,000 IU intramuscular when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
45370139|NCT04008966|Drug|GnRH agonist|0.2 mg subcutaneously when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
45370140|NCT04008966|Procedure|Ovum pick up|34 hours after triggering under the guidance of transvaginal ultrasound
45692262|NCT01273948|Drug|Bavituximab|"Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or~Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or"
45489148|NCT02403700|Device|Cone beam computed tomography (CBCT)|Dimensional changes are documented over a healing period of 8-weeks following single tooth extraction. To document these changes over time, two methods will be applied. Firstly, two cone beam computed tomographies (CBCT) will be obtained, one directly after tooth extraction, the other one at 8 weeks of socket healing prior to implant placement. The two CBCT's will be analyzed with a novel software program (InVivo Dental). Secondly, consecutive impressions will be made at day 0 (day of extraction), day 14, 28, 42, and 56 to digitally produce virtual 3D study models. These models can be analyzed with another software program (Geomagic Studi 10) to document the variations of the soft tissue in the extraction site.
45692263|NCT01273948|Drug|Pegylated interferon (PEG-IFN)|Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal 75 kg) divided into twice-daily doses, for 12 weeks
45489149|NCT02407366|Drug|Icotinib|Icotinib (125 mg ,Three times daily)
45489150|NCT02407366|Drug|Pemetrexed|Pemetrexed(500mg/m2)every 21 days
45370141|NCT04008966|Procedure|Embryo transfer|Transabdominal ultrasound guided embryo transfer was done 3 days after oocyte retrieval using Labotect semirigid catheter
45489151|NCT02407366|Drug|Carboplatin|Carboplatin (AUC，5) every 21 days
45489152|NCT02407366|Radiation|Thoracic radiotherapy(TRT)|TRT (total dose 66Gy, 2Gy per time, once a day, five times a week, a total of 33 times)
45489153|NCT03738137|Device|Narotrend|Narcotrend motoring
45692264|NCT00734344|Drug|Raltegravir|Raltegravir 400 mg. BID
45692265|NCT00734344|Drug|Efavirenz|600 mg once daily
45370142|NCT04008966|Drug|natural Progesterone|400 mg twice daily per vagina
45370143|NCT00425854|Drug|BIBW 2992|high dose once daily
45370144|NCT00961740|Behavioral|Cognitive Behavioural Therapy|See summary
45370145|NCT00961740|Other|Waitlist condition|See Summary
45692266|NCT00734344|Drug|Emtricitibine|200mg once daily
45692267|NCT00734344|Drug|Tenofovir disoproxil once daily|300mg once daily
45692268|NCT00734344|Drug|Tenofovir disoproxil twice daily|300mg twice daily
45846609|NCT05731518|Drug|Irinotecan|Irinotecan 80mg/m^2 via IV administered for every 4 weeks (fixed dosing) in Day 1 Day8 and Day 15 of each cycle. One cycle is consisted of 28 days.
45370146|NCT02771938|Other|Radiotherapy before surgery|Radiotherapy followed by mastectomy and DIEP flap reconstruction
45370147|NCT00972972|Dietary Supplement|bilberry (European blueberries) and red grape juice|Intervention juice: 50/50 combination of 300 ml bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.) per day for 9 weeks
45370148|NCT00972972|Dietary Supplement|placebo juice|Placebo juice: 300 ml, similar to the intervention juice as to taste, energy, salt, and carbohydrates
45370149|NCT00425698|Drug|Recombinant erythropoietin alpha (rHuEPO alpha)|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
45692269|NCT04148937|Drug|LY3475070|Administered orally
45692270|NCT04148937|Drug|Pembrolizumab|Administered IV
45692271|NCT03021057|Drug|pembrolizumab|200mg i.v. once every 3 weeks Number of Cycles: until progression or unacceptable toxicity develops
45692272|NCT00734500|Drug|Anidulafungin|Intravenous form. Loading Dose: 3 mg/kg/dose. Maintenance dose: 1.5 mg/kg/dose. Treatment duration: 5 days total.
45370150|NCT00425698|Drug|Placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
45370151|NCT00966030|Drug|MK0974 tablet|MK0974 280 mg tablet in one of two treatment periods
45370152|NCT00966030|Drug|Comparator: MK0974 liquid filled capsule|MK0974 300 mg liquid filled capsule in one of two treatment periods
45370153|NCT01037530|Drug|Ramipril|5 mg/day for 2 weeks then 10 mg/day for 22 weeks
45370154|NCT05238246|Behavioral|Behavioral guidance with tell-show-do|The effect of tell-show-do technique during dental treatment on behavior in pediatric patients was evaluated and compared.
45370155|NCT05238246|Behavioral|Behavioral guidance with robot|The effect of the tell-show-do and distraction technique during dental treatment on behavior in pediatric patients was evaluated and compared.
45489154|NCT03738137|Device|BIS|Bispectral index monitoring
45489155|NCT03738137|Drug|Sufentanil|sufentanil is applied.
45489156|NCT03738137|Drug|Lidocaine|Topical Anesthesia
45489157|NCT03738137|Drug|Midazolam|midazolam is applied.
45489158|NCT02410876|Procedure|Bladder biopsy|Small biopsy of the bladder is taken with cold-cup tongs.
45489159|NCT02410876|Procedure|Urodynamic study|Assessment of bladder function through intravesical and intrabdominal pressure measurements according to International Continence Society standards.
45489160|NCT03737279|Behavioral|Meditation|Routine care + twice daily meditation per schedule, to start on the day of randomization
45370156|NCT00973050|Drug|Bicalutamide|50 mg Tablet
45489161|NCT03737279|Behavioral|Routine Care|"Routine care including ACOG educational pamphlets:~Day 1: Nutrition in Pregnancy~Day 2: Heart Health for Women~Day 3: Exercise after Pregnancy"
45489162|NCT02407210|Drug|azilsartan|
46052942|NCT02794935|Other|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center
45489163|NCT02407210|Drug|Olmesartan medoxomil|
45489164|NCT03737201|Other|ozone|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
45489165|NCT03737201|Other|chlorhexidine digluconate|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
45489166|NCT03737201|Other|Control|without any cavity disinfectant
45370157|NCT00973050|Drug|Casodex®|50 mg Tabelt
45370158|NCT00973128|Drug|GMCSF plus Antimony reduced dose|400 µg, divided in two doses a week apart, antimony (20mg/daily for 10 days)
45370159|NCT00973128|Drug|Meglumine antimoniate|20mg/daily for 20 days
45489167|NCT02951533|Drug|Guselkumab|Participants will receive 100 mg of Guselkumab as 100 mg/mL solution subcutaneously.
45692273|NCT04148391|Drug|Placebo Oral Capsule|Matching placebo capsules.
45692274|NCT04148391|Drug|NYX-458|NYX-458 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
45692275|NCT00734734|Biological|Seasonal Influenza Vaccine|1 single intramuscular dose of influenza vaccine, 2008/2009 NH formulation
45692276|NCT04143321|Drug|Empagliflozin 25 MG|after washout period and EST and SAQ patients gave 25 mg Empagliflozin daily in experimental group
46052943|NCT04095949|Dietary Supplement|Artichokes|Approximately 200 g of cooked artichokes
45370160|NCT00966108|Device|SENSIMED Triggerfish|Ocular Telemetry Sensor for IOP monitoring
45370161|NCT00973908|Drug|VSL#3|Patients will o receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
45370162|NCT00973908|Drug|Placebo|Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
45370163|NCT00966342|Drug|Fluviral 2009/10|single dose given IM .05 mL
45370164|NCT00966420|Device|traction assisted endoscopic mucosa resection|A haemoclip is connected to suture material and will be fixed (next) to a polyp to allow traction and lifting the lesion in order to facilitate its resection with a loop.
45370165|NCT00966498|Procedure|Peripheral Blood Stem Cell Transplant|Peripheral Blood Stem Cell Transplant
45370166|NCT00973986|Drug|Atorvastatin|The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.
45489168|NCT02951533|Drug|Fumaric Acid Esters|Participants will receive Fumaderm initial/ Fumaderm tablets through self-administration.
45489169|NCT03175042|Device|Masimo spot hemoglobin non-invasive monitor|This non-invasive monitor measures hemoglobin using LED light technology. We will be using it to determine if it is as accurate as routine CBC in anemic obstetric patients.
45489170|NCT03738059|Drug|Dexmedetomidine Injection [Precedex]|will receive intravenous Dexmedetomidine
45489171|NCT03738059|Other|normal saline 0.9%|will receive intravenous normal saline 0.9%
45489172|NCT05233462|Other|standardized dose|intrathecal anesthesia with 10 mg of bupivacaine
45489173|NCT05233462|Other|adjusted dose|intrathecal anesthesia with 0.05 mg of bupivacaine par cm of patient's height
45489174|NCT02700412|Drug|Epidiolex|Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
45489175|NCT03115606|Device|C-Mac D Blade|Videolaryngoscope
45489176|NCT03115606|Device|Fastrach LMA|Laryngeal mask airway
45489177|NCT02403466|Behavioral|Resident Handoff Bundle|1) team training, 2) verbal mnemonics, and 3) standardization of written/computerized handoff tools
45489178|NCT02403388|Other|PRisM|A risk management program for each professional of care in multiprofessional primary care offices in France.
45489179|NCT02407288|Device|transcranial dirrect current stimulation|The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
45370167|NCT00979524|Behavioral|Comprehensive Mental Health Services and Supports|"This study uses a quasi-experimental design to test the efficacy of a comprehensive mental health intervention to improve the mental health and employment outcomes of young adults (18-24) enrolling in the Eastside YO Program. Newly enrolling Eastside YO members will receive an array of mental health education and services based on level of need and serve as this study's intervention group. Newly enrolling Westside YO members will receive usual care services delivered by the staff at the Westside YO Program and serve as this study's comparison group."
45370168|NCT00966576|Drug|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|1 drop of study medication into the study eye(s) beginning the evening of Visit 1 and continuing twice daily (morning and evening) for 12 weeks
45370169|NCT00425308|Drug|Everolimus + Cyclosporine|
45489180|NCT02407288|Device|Sham tDCS|
45370170|NCT00425308|Drug|Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)|
45489181|NCT02406898|Device|morcellator uterine system (MH)Karl Storz, Tuttligen- Germany|
45370171|NCT00425308|Drug|Steroids|
45370172|NCT04008888|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Stem Cell Transplant: Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with GCSF mobilization and infused fresh to the recipients.
45489182|NCT02351544|Drug|Botulinum Toxin Type A|
45848009|NCT05304000|Behavioral|Mindfulness Meditation|Participants are informed they should sit down in a chair or, if they preferred, to lie down, and then to set a timer for 5 minutes. Then they are told to close their eyes and to start breathing while focusing their mental attention on their forehead region between their two eyes. They are told that if their focus drifted from that location to re-recenter their attention by focusing back first on their breath and then on the forehead region between their eyes. They are told that as thoughts arise, to recognize that as normal, refocus their attention back to their forehead region and to continue the practice until time has elapsed.
46052944|NCT04096183|Other|Ventilation of healthy volunteers|Ventilation of healthy volunteers in different clinical situations
45489183|NCT02351544|Procedure|Surgery|
45692277|NCT00734968|Drug|Nitrofurantoin|Nitrofurantoin 100mg PO BID for 3 days post operatively following the placement of a sub-urethral sling for the treatment of stress urinary incontinence
45692278|NCT00734968|Other|Placebo|6 tablets to be taken 1 tablet PO BID. These tablets are identical to nitrofurantoin 100mg tablets.
45692279|NCT03753945|Diagnostic Test|MRI of the spine|Perform a clinically indicated MRI of the spine in DBS patients
45692280|NCT03918837|Other|Sham rTMS|Participants will undergo sham rTMS for five days with two daily fifteen minutes rTMS sessions.
45692281|NCT03918837|Other|Active rTMS|Participants will undergo active rTMS for five days with two daily fifteen minutes rTMS sessions.
46052945|NCT04235985|Combination Product|Chlorhexidine Gluconate with HUBS|4% CHG soap will be applied to HUBS following manufacturers recommendation and applied to skin for different application times as dictated by the randomization of the marked sites on the forearm. Followed by a HUBS moistened with water.
46052946|NCT00817414|Drug|LCI699-matching placebo|LCI699-matching placebo oral capsules
46052947|NCT00817414|Drug|LCI699|LCI699 oral capsules
45489184|NCT02351544|Other|Daily headache diary|
45489185|NCT02351544|Other|Migraine Disability Assessment Test (MIDAS)|
45489186|NCT02351544|Other|Migraine Work and Productivity Loss Questionnaire (MWPLQ)|
45489187|NCT02351544|Other|Migraine-Specific Quality of Life Questionnaire (MSQ)|
45489188|NCT02406976|Other|G1 -Exercise|"20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.~Furthermore the similar treatment to G3."
45489189|NCT02406976|Behavioral|G2- Exercise and Lifestyle|"Exercise more techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors and the reduction or elimination of undesirable conduct.~Furthermore the similar treatment to G3."
45692282|NCT04143399|Procedure|holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser (Versa pulse 100W; Lumenis; Germany)
45489190|NCT02406976|Other|G3- Control|Routine treatment in outpatient of bariatric surgery. Consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
45489191|NCT02288832|Other|-self-collected vaginal samples|
45489192|NCT02288832|Drug|zithromax|
45489193|NCT02288832|Other|usual practices|
45489194|NCT03175588|Other|Virtual Rehabilitation|Nintendo Wii program with balance board, which is the most frequently preferred game consoles in rehabilitation will be used
45489195|NCT03173014|Device|EEG|EEG monitoring
45489196|NCT02401906|Other|MRI|
45489197|NCT02401984|Other|Screening|Participants will fill out a short screening questionnaire where different aspects of mental health and behavioral problems will be assessed.
45489198|NCT02403232|Procedure|ASCs injection|"In the infiltration step, adrenalin in a saline solution is infiltrated using a 19-cm specially designed disposable blunt cannula.~The aspiration step is performed by a luer-lock syringe connected to a disposable 19-cm blunt cannula.~The harvested lipoaspirate can be progressively put into the device using multiple 10-cc syringes.~Subsequently, in lithotomy position, a seton will be removed and a fistula tract will be thoroughly curetted and irrigated. After a mucosal flap preparing round the internal opening, cells will be injected in the perianal adipose tissue."
45489199|NCT02403232|Device|ASCs injection|In general anesthesia subcutaneous abdominal adipose tissue will be collected by LIPOGEMS system to prepare ASCS.
45489200|NCT02403232|Device|Closure of fistula tract.|A SALVECOLL-E paste will be injected into the fistula tract.
45489201|NCT02406820|Device|Non-invasive hemodynamic monitoring (CVInsight™ [CVI])|
45489202|NCT03116308|Drug|Opicapone (OPC)|50 mg OPC capsules; oral route
45489203|NCT02402998|Drug|Eltrombopag|Eltrombopag 50 mg/daily.
45489204|NCT03665441|Drug|eryaspase|L-asparaginase encapsulated in erythrocytes (red blood cells)
45489205|NCT03665441|Drug|Gemcitabine plus Abraxane|gemcitabine, Abraxane
45489206|NCT03665441|Drug|Irinotecan plus 5-FU plus leucovorin|irinotecan, 5-FU, leucovorin
45489207|NCT03169660|Drug|Vascular endothelial growth factor trap-eye|Intravitreal injection of vascular endothelial growth factor trap-eye During the first 3 months, 3 monthly injections are performed After 3 serial injections, additional injections are performed once per 2 months until 48 weeks after the initial injection.
45489208|NCT02401828|Drug|Dolutegravir|Switch from combination antiretroviral therapy to dolutegravir monotherapy
45489209|NCT02699866|Device|BLT Implant Ø 2.9 mm|Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.
45489210|NCT03663569|Drug|Spiolto® Respimat®|Drug
45489211|NCT02401438|Other|5D ultrasound|
45846610|NCT05731362|Other|MDCIT Intervention|"The MidWest Multidisciplinary Community Intervention Teams (MDCIT) comprise of specialist, healthcare teams that provide a rapid and integrated response to a patient with an acute episode of illness who requires enhanced services/acute intervention for a defined short period of time. This is provided in the patient's home after an acute hospital admission, thereby facilitating early discharge. The MDCIT intervention is composed of occupational therapy, physiotherapy, and healthcare assistants, with nursing support as required.~The MDCIT therapists aim to make their first visit to patients within 24-48 hours of hospital discharge. Patients receive two-three visits per week, over a period of two to four weeks dependant on the patient's rehabilitation needs. Upon discharge from the MDCIT service, patients can be referred to community services as indicated by therapists."
46052948|NCT03944187|Diagnostic Test|Transvaginal sonography|Transvaginal sonography for measurement of cervical length, fetal head circumference and fetal head to cervix angle .
45846611|NCT05731206|Other|Hydrolyzed protein infant formula|Hydrolyzed protein infant formula
45846612|NCT05731206|Other|commercially available hypoallergenic infant formula|commercially available hypoallergenic infant formula
45370173|NCT04008888|Procedure|Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2|Autologous hematopoietic stem cell transplantation :Stem cell mobilization with granulocyte colony-stimulating factor (GCSF) at a dose of 10 μg/kg/day followed collecting CD34+ peripheral blood stem cells . Day 0 Infusion of autologous stem cells. Patients during 3-6 months after the 1st SCT will undergo a 2nd SCT. Patients who had not enough PBSC will undergo a 1st SCT.
45489212|NCT02401438|Other|2D ultrasound|
45489213|NCT02401516|Device|Reprogramming insoles|1)Answer demographic, lifestyle and health questionnaire; 2)Weight and height evaluation; 3)ABPM (Ambulatory Blood Pressure Monitoring) and diary of activities assessment; 4)Postural Assessment software (SAPO), created by São Paulo's University (USP), which assesses posture through full body images of people with marked bone prominences on the body in all planes of motion. Images are captured by a Sony Cybershot 14 Megapixel camera, supported on a tripod, placed three meters away from the subject and at half its height. 5)Six-Minutes Walk Test in accordance with Britto and Souza25 and American Thoracic Society guidelines43; 6)analog manometer Globalmed® brand to assess respiratory muscle strength; 7)Dynamometer Jamar® brand to measure grip strength; 8)Wells bank to evaluate Flexibility.
45489214|NCT03596762|Drug|Elinzanetant (BAY3427080)|BAY3427080 capsules
45489215|NCT03596762|Drug|Placebo|Placebo capsules
45489216|NCT04481386|Device|Vitargus, BFC-1401|A single intravitreal (IVT) dose of BFC-1401 in participants as a vitreous substitute during vitrectomy surgery.
45489217|NCT02401594|Drug|Rivaroxaban|10 mg once daily of Rivaroxaban active substance (10 mg tablet) plus a placebo syringe of enoxaparin 4000 UI once daily
45489218|NCT02401594|Drug|Enoxaparin|A syringe of enoxaparin active substance 4000 UI once daily plus a placebo tablet of Rivaroxaban 10 mg.
45489219|NCT02406508|Device|Melphalan/HDS|
45489220|NCT02406508|Drug|Sorafenib|
45370174|NCT04008888|Drug|Melphalan Given IV|conditioning regimen: autologous ARM: Day -2 Melphalan 200 mg/m^2/day IV over 30 minutes. allogeneic ARM: Day -4, Day -3 Melphalan 70 mg/m^2/day IV over 30 minutes
45370175|NCT04008888|Drug|Fludarabine Injection|conditioning regimen:Days -6,-5,-4,-3 Fludarabine 30 mg/m^2/day IV
45370176|NCT04008888|Drug|PI and dexamethasone as maintenance therapy|Bortezomib and dexamethasone(VD),Ixazomib and dexamethasone(ID)
45370177|NCT04008888|Drug|PI+IMids+Dexamethasone as Consolidated Chemotherapy|Oral lenalidomide at the starting dose of 25mg on days 1-21 every 28 days or days 1-14 every 21 days. Dexamethasone at 20mg twice weekly on days 1,2,4,5,8,9,11&12 of each 21-day.
45370178|NCT01563588|Behavioral|dietaty education, physical training, physiotherapy and SPA cares|12 days session of daily physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
45489221|NCT02401360|Drug|China Crest® Pro-health 7 Complete Toothpaste|Crest® pro-health manual toothbrush Crest® pro-health gum protection rinse
45489222|NCT02401360|Drug|China Crest® Cavity Protection Toothpaste|Crest® meliliangje manual toothbrush
45489223|NCT02402686|Drug|Tocilizumab|Dosing and treatment duration of tocilizumab collected as part of this non-interventional study are at the discretion of the physician in accordance with local clinical practice and local labeling. Observation period is 24 weeks from first SC tocilizumab administration.
45489224|NCT03736577|Other|Drug reviews with NorGeP-NH|Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH). The nursing home physicians will do the drug review on the participants' drug charts
46052949|NCT00769561|Behavioral|Biofeedback-Based Cognitive Behavioral Treatment|The biofeedback-based cognitive behavioral intervention comprises 8 individual sessions, each containing both cognitive behavioral and biofeedback elements. Treatment elements are education about the disorder, biofeedback training aimed at improving proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients receive portable biofeedback devices for EMG-biofeedback training during day and nighttime in order to reverse diurnal and nocturnal bruxing habits.
45489225|NCT02402608|Dietary Supplement|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture
45489226|NCT02402608|Dietary Supplement|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
45489227|NCT02401282|Behavioral|Attention Bias Modification|This is a modification of the dot-probe task (placebo task) designed to train attention away from threat
45489228|NCT02401282|Behavioral|Dot-probe task|This is the active control placebo condition that simply measures levels of attention to threat
45489229|NCT03663179|Device|Transcranial Magnetic Stimulation (TMS)|A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. TMS will be administered at 10 Hertz (Hz) with an intensity of 120% of patient resting motor threshold. Stimulation will be delivered to the left dorsolateral prefrontal cortex using 20 sec cycles (i.e., 5 sec train with 15 sec inter train interval). Subjects will receive 80 trains per session for a total of 4000 pulses per session (~26 min sessions). Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).
45489230|NCT03663179|Device|Sham Transcranial Magnetic Stimulation (Sham TMS)|A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. For sham stimulation, the sham side of the coil is positioned toward the participant's scalp. The sham coil is designed to mimic the appearance and sound of active TMS stimulation, but is equipped with a magnetic shield that reduces the strength of the field by approximately 80%. This reduction in field strength ensures that no neural stimulation occurs. Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).
46052950|NCT00769561|Device|Dental treatment with occlusal splint (OS)|Maxillary or mandibular occlusal splints are made of hard acrylic after taking impressions of the upper and lower dental arches, face bow registration and recording of centric relation. Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night and during day time for a period of 7 weeks. One week after initial insertion of the splint patients are requested to return for adjustment.
46052951|NCT02797041|Drug|Bortezomib|Re-challenge with bortezomib as second line therapy in myeloma patients relapsed after a previous bortezomib-based treatment
45489231|NCT03662789|Drug|Iron Isomaltoside 1000|Intravenous infusion
45489232|NCT03662789|Other|Placebo: NaCl 0,9%|Intravenous infusion
45489233|NCT03115996|Drug|REGN3918|Intravenous (IV) or Subcutaneous (SC)
45489234|NCT03115996|Drug|Placebo|Matching Placebo
45489235|NCT02401204|Other|Longitudinal surveillance study|"Regular specimens will be routinely collected as standard of practice.~A rectal swab and stool specimen will be collected twice a week since first admission on NICU until discharge from NICU.~If participant is intubated/ventilated, a throat swab will be collected."
45489236|NCT03736421|Procedure|Peripheral Intravenous Analysis (PIVA)|Non-invasive measurement of peripheral intravenous waveform analysis (PIVA) obtained by connecting an Edwards standard transducer to a universal adaptor or stopcock on a peripheral IV
45489237|NCT03736421|Procedure|Non-invasive fluid response measure|To measure the stroke volume and changes in stroke volume in response to a passive leg raise (PLR) maneuver and fluid administration.
45489238|NCT03736421|Diagnostic Test|Passive leg raise (PLR)|Test to predict cardiac output and fluid responsiveness
45489239|NCT02401126|Dietary Supplement|Nitrate supplementation|Nitrate supplementation: concentrated nitrate-rich beetroot juice (2 x 70 ml/day; approximately 10 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days.
45489240|NCT02401126|Dietary Supplement|Placebo|Placebo: nitrate-depleted beetroot juice (2 x 70 ml/day; approximately 0.01 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days. The placebo juice is similar to the concentrated beetroot juice in appearance, texture, smell and taste and is obtained by removing nitrate ions from the latter.
45489241|NCT04896580|Behavioral|Nature based exercise|Participants will engage in three months of moderate intensity PA, consisting of three 50-minute walking sessions per week (5-minute warm-up, 40 minute walk, 5 minute cool-down and stretch) with an exercise physiologist for 12 weeks.
45489242|NCT05668559|Procedure|repetitive transcranial magnetic stimulation|"The rTMS mode consists of a cluster stimulus delivered every 0.2 seconds (5 Hz), with each cluster stimulus consisting of three burst stimuli with a 50 Hz body frequency. The duration of a single stimulus was approximately 40 seconds, for a total of 600 pulses. Stimulation takes place bilaterally in the dorsolateral prefrontal cortex (DLPFC).~All enrolled patient in the rTMS group will receive 1 set simulation per day with an intersession interval (ISI) of over 30 minutes on postoperative day 1 to 5 after the surgery."
45489243|NCT05668559|Procedure|Sham Stimulation|Shaman stimulation uses the same protocol (600 pulses per session, 3 sessions per set, ISI≥30 min, 3 sets) with the coil set at 90 against the skull on postoperative day 1 to 5 after the surgery.
45692283|NCT04143399|Procedure|Bipolar resection of the prostate|cystoscopic transurethral resection of the prostate using bipolar energy
45692284|NCT00735436|Drug|Gliadel/Avastin/CPT-11|
45692285|NCT04143165|Drug|Epidural block with lidocaine and triamcinilone|caudal epidural injections with 1% lidocaine hydrochloride (xylocaine AstraZeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)
45846613|NCT05731050|Drug|NM8074|"NM8074 will be administered as an intravenous infusion. All enrolled subjects will receive a dose of 15 mg/kg NM8074 once every two weeks for a total of 6 doses from Day1 to Day 84.~For Soliris-treated PNH subjects, admission and dosing of NM8074 on Day 1 should be scheduled to coincide with the next scheduled dose of Soliris (i.e., 14 ± 2 days after the last Soliris dose). Soliris should NOT be administered on Day 1 or at any time thereafter during course of the study.~Subjects in the treatment groups will receive a dose of 15 mg/kg of NM8074 on Day 1, which will be administered during the study visit by the site staff. During the remainder of the treatment period, subjects will be given another 15 mg/kg dose every two weeks at approximately the same time. On days of scheduled study visits at the Investigation Site, the dose must be administered after blood work is completed."
45692286|NCT04143087|Drug|withdrawal TKIs or halve TKIs|Stop TKIs or treated by half TKIs
45692287|NCT03917043|Drug|APG-2449|Capsule, multiple dose cohorts, oral administration every day (QD) of a 28-day cycle
45692288|NCT00735670|Drug|Venlafaxine HCl|Starting dose is 37.5 mg and ending dose is 150 mg at 13 weeks. From weeks 13 to 26 subjects no longer will receive the drug
45692289|NCT00735670|Other|Placebo|Subjects received a placebo instead of Venlafaxine HCl until week 13 as did the Venlafaxine group.
45692290|NCT04765605|Device|WeFlow-Tbranch Stent Graft System|The single-embedded branch thoracic aorta stent graft system consists of the thoracic aorta stent graft system and the branch stent system. The main chest embedded stent graft system consists of the main chest embedded stent graft and its system conveyor, and the branch stent system consists of branch stents and its conveyor. The main chest embedded stent graft and the branch stent are pre-installed in the conveyor
45370179|NCT00966732|Behavioral|Yoga of Awareness Program|The 8 week yoga program will meet in groups of about 8-10 persons. Each 2-hour session will include gentle stretching, strengthening, and balance poses; meditation exercises; breathing techniques; study of pertinent topics (eg, mind/body stress reactivity), and group discussions (eg, experiences while practicing yoga). Participants will be asked to practice yoga methods at home, guided by a DVD (or audio recordings). The program will be taught by a certified yoga teacher (RYT) who has extensive experience in teaching yoga to medical patients.
45489244|NCT04481932|Drug|Trastuzumab combined with Pyrotinib and chemotherapy|"Pyrotinib is a small molecule, irreversible tyrosine kinase inhibitor with targets of epidermal growth factor receptor 1 (EGFR/HER1/ErbB1), human epidermal factor receptor 2 (HER2/ErbB2/Neu) and human epidermis Factor Receptor 4 (HER4/ErbB4).~As a new generation of anti-HER2 therapeutic targeted drugs, pirotinib covalently binds to the ATP binding sites of the kinase regions of EGFR, HER2 and HER4 in cells to prevent homogeneity and heterogeneity of EGFR, HER2 and HER4 in tumor cells Dimer formation, inhibiting its own phosphorylation, blocking the activation of downstream signaling pathways, thereby inhibiting tumor cell growth"
45489245|NCT03169582|Drug|Avanafil|Drug administration (Avanafil)
45489246|NCT03169582|Drug|Sildenafil|Drug administration (Sildenafil)
45489247|NCT02406664|Procedure|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
45489248|NCT02402374|Device|Autologous platelet rich plasma gel|PRP gel application to exuding wounds, such as leg ulcers, pressure ulcers, and diabetic foot ulcers and for the management of mechanically- or surgically-debrided wounds
45489249|NCT02402374|Device|Placebo|Placebo control arm will be receiving commercial formulations of pre-prepared saline gel.
45489250|NCT02402140|Other|Pharmaceutical Intervention|Patients allocated to group 1, with pharmaceutical intervention, received instructions on the proper use of immunosuppressants as doses, frequency, importance, schedules on the following days 3, 5, 7, 10, 14, 21, 28, 60 and 90 after kidney transplant. Teaching materials were designed to assist in the pharmaceutical guidelines that understood the importance of immunosuppressive drugs, the risk of rejection, the schedules and the most appropriate way for the administration. In addition to these guidelines, pharmacists helped patients in filling out the patient diary. This diary contains all the medications that the patient administers and encourages them to write down daily doses in order to remind them. This was a standardized pharmacist intervention.
45489251|NCT03655691|Biological|Vehicle|Vehicle Formulation
45489252|NCT03655691|Biological|botulinum toxin, Type A|botulinum toxin, Type A, lower Dose 1, administered once, topically, at Baseline
45846614|NCT05730738|Drug|Dalfampridine ER, 10 Mg Oral Tablet, Extended Release|The only approved treatment for impaired ambulation in MS is Dalfampridine (also known as fampridine, 4-aminopyridine, 4-AP). Fampridine penetrates the blood-brain barrier and improves impaired axonal conduction by selectively blocking potassium channels
46052952|NCT02794779|Drug|Oxytocin|Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.
46052953|NCT00817336|Drug|D Serine|60 mg/kg/day
46052954|NCT00817336|Drug|Placebo|oral
46052955|NCT02802657|Procedure|Treat-and-Extend regimen|For the T&E regimen,investigators recorded patients' data after retreatment by 3 monthly intravitreal injections of Conbercept. Patients were examined 6 weeks after the third injection, with ETDRS visual acuity testing, fundus ophthalmoscopy and photography, and OCT, and treated on the same day. The interval between treatments was extended by 2-week (12-week was a maximum) provided that OCT and fundus examination did not show either exudative manifestations or new macular hemorrhage or active CNV or reduced by 2 weeks (4-week was minimum) in case of such manifestations or hemorrhage. The persistence of pigment epithelium detachment was not considered a condition that justified shortening the interval between injections.
45489253|NCT03655691|Biological|botulinum toxin, Type A|botulinum toxin, Type A, higher Dose 2, administered once, topically, at Baseline
46052956|NCT02802657|Procedure|Pro Re Nata|For the PRN group, investigators recorded patients'data after retreatment by 3 monthly intravitreal injections of Conbercept.Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four to five weeks after the third and last injection, all patients in the PRN group underwent an examination, including ETDRS visual acuity, fundus photography,and OCT. In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of >5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later.
45370182|NCT01033006|Procedure|Active Comparator: Arm 1: catheter injection|
45370183|NCT01033006|Procedure|Active Comparator: Arm 2: transarterial injection|
45370184|NCT01033006|Procedure|Active Comparator: Arm 3: catheter and transarterial injection|
45370185|NCT00974298|Procedure|Total elbow replacement arthroplasty|Total elbow arthroplasty using pressfit technique in which no cement is used.
45370186|NCT01033084|Device|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively and two extra stimulations at week 4 and 6.
45370187|NCT01033084|Drug|Sertraline|Patient will receive sertraline 50mg/day.
45370188|NCT01033084|Other|double placebo|double placebo arm (sham stimulation/placebo pill)
45846615|NCT05730738|Drug|Placebo|placebo similar to Dalfampridine capsule
45846616|NCT05730660|Dietary Supplement|Quercetin group|2 capsules a day of Quercetin Fitosoma® of 250 mg each
45846617|NCT05730660|Dietary Supplement|Placebo group|2 tablets per day, white film-coated having the same appearance as Quercetin Fitosoma ® tablets.
46052957|NCT02802657|Drug|Conbercept|
45489254|NCT03169504|Other|Acupuncture|Feishu (BL13), Dazhui (DU14) and Fengmen (BL12) will be selected as main acupoints. There are four groups of acupoints: Taiyuan (LU9) and Zusanli (ST36) for Qi deficiency of the lung ZHEGN, Taiyuan (LU9), Pishu (BL20) and Zusanli (ST36) for Qi deficiency of the lung and spleen ZHEGN, Taiyuan (LU9), Shenshu (BL23) and Zusanli (ST36) for Qi deficiency of the lung and kidney ZHEGN, and Gaohuang (BL43), Shenshu (BL23), Taixi (KI3) and Guanyuan (RN4) for Qi and Yin deficiency of the lung and kidney ZHEGN. Besides, acupoints for specific symptoms will also be considered. Hwato Sterile Acupuncture Needles For Single Use (Hwato®, Suzhou Hua Tuo Medical Instruments Co., Ltd.) size in 0.30*25 mm, 0.30*40 mm or 0.30*50 mm will be used 3 times weekly for 12 weeks.
45489255|NCT03169504|Drug|Conventional drug|"Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd.), 100 μg/press, 200 press, 100 μg each time (when needed), no more than 8 press daily for 12 weeks.~Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH), 18 μg/capsule, 10 capsule, 18 μg each time, once daily for 12 weeks.~Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline), 50ug/250μg/inhalation, 60 inhalations, 50ug/250μg each time, twice daily for 12 weeks."
45489256|NCT03169504|Other|Acupuncture plus conventional drug|Both acupuncture and conventional drug will be used for 12 weeks treatment.
45489257|NCT03169426|Drug|Beta Blockers Carvedilol Phosphate|Subjects are going to take Beta Blockers Carvedilol Phosphate (12.5mg once) before undergoing remote ischemic conditioning.
45489258|NCT03658811|Device|intense pulsed light|Use of 6 mm SapphireCool light guide to treat upper lid margins from tragus to tragus including the nose
45370189|NCT00979758|Drug|Atorvastatin and mononuclear cells transplantation|Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation
45370190|NCT01672060|Behavioral|Nurse-Family Partnership (NFP)|Trained Public Health Nurses (PHNs) will deliver Nurse-Family Partnership (NFP) using specified pregnancy, infancy and toddler curricula. Following enrollment in the study, NFP PHNs will provide regular home visits to participants throughout the remainder of the participant's pregnancy, continuing through until the child's second birthday. In addition to offering standard care during each visit, PHNs will deliver NFP content using program materials relevant to the following domains: personal health, maternal role, environmental health, family and friends, life course development, and health and human services.
45370191|NCT01672060|Behavioral|Existing services|Participants allocated to the comparison group will receive all the usual perinatal programs and services offered within their Health Authority, including primary care and specialist physician services covered under BC's public healthcare system. These services vary across the province but may include: standard primary healthcare services; public health programs including prenatal classes, pregnancy outreach and home visiting by nurses or paraprofessionals; and a variety of targeted and universal parenting and early child development programs.
45489259|NCT03580928|Drug|Venetoclax|Venetoclax is an oral drug that blocks the function of a protein called BCL-2. CLL cancer cells are thought to depend on the BCL-2 protein for their survival. By blocking BCL-2, venetoclax may kill cancer cells or stop them from growing.
45489260|NCT03580928|Drug|Obinutuzumab|Obinutuzumab is a type of drug called a monoclonal antibody. It targets a protein CD20 on the surface of the CLL cell, causing it to die
45489261|NCT03580928|Drug|Acalabrutinib|Acalabrutinib is a type of drug called a kinase inhibitor. It blocks a type of protein called Bruton Tyrosine Kinase (BTK) that helps CLL cells live and grow
45489262|NCT02406430|Procedure|a combined cataract and ERM surgery|All patients underwent a combined cataract and ERM surgery owing to visual impairment or disabling metamorphopsia. A complete ophthalmological examination was performed before and at 1,6, and 12 months after the surgery, including best corrected visual acuity with Snellen charts converted into the logarithm of the minimum angle of resolution, slit-lamp biomicroscopy, indirect fundus, and macular optical coherence tomography
45370192|NCT00545064|Drug|dorzolamide hydrochloride (+) timolol maleate|dorzolamide hydrochloride (2%)/ timolol maleate (0.5%) Preservative free twice a day (BID), for 8 weeks of treatment
45370193|NCT01034332|Procedure|TP-HDFL,TP-CCRT, Esophagectomy|To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT) in patients with locally advanced esophageal cancer.
45370194|NCT00979836|Drug|Calcium Dobesilate|500 mg/ three times/day for 6 months (capsules)
45370195|NCT01588912|Drug|Telbivudine|If virologic response, which means HBV DNA < 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
45489263|NCT03732521|Other|Educational therapy|educational intervention to the caregiver and individualization according to their family and social context
45846618|NCT05725434|Biological|CT-P47 AI (tocilizumab)|CT-P47 (162 mg/0.9 mL) by subcutaneous (SC) injection via autoinjector (AI) at Week 0 and Week 2
45370196|NCT01588912|Drug|Tenofovir|If virologic response, which means HBV DNA < 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
45489264|NCT03115528|Behavioral|Estimation of Prognosis Questionnaire|Survey will examine two aspects of prognosis estimation: 1.) physician factors, 2.) prognosis estimation and contributing factors to patient prognosis. Survey will take approximately 5 minutes to complete.
45489265|NCT03732443|Diagnostic Test|FAM-CAM|Family Confusion Assessment Method
46052958|NCT04039438|Other|No intervention|No intervention will be provided during the study nor participants will be receiving any intervention anywhere else.
45489266|NCT03573206|Device|Cardiva Mid-Bore Venous Vascular Closure Device (VVCS)|The device will be used to close all femoral venous access sites at the end of the case.
45489267|NCT03169348|Drug|sofosbuvir daclatasvir|oral tablets
45489268|NCT03169348|Drug|Ledipasvir/sofosbuvir|oral tablets
45489269|NCT03172546|Genetic|PK-PD genetic polymorphisms|PK-PD genetic polymorphisms analysis in patients receiving either anti-IIa or anti-Xa treatment
45846619|NCT05725434|Biological|CT-P47 PFS (tocilizumab)|CT-P47 (162 mg/0.9 mL) by SC injection via pre-filled syringe from Week 4 every other week or weekly (based on the clinical response by investigator's discretion) up to Week 10
45846620|NCT05712798|Other|No intervention|No intervention
45489270|NCT03631355|Drug|Tranexamic Acid|One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.
45489271|NCT03571568|Biological|BI-1206|375 mg/m2, as per SmPC
45489272|NCT03169192|Drug|Zoledronic Acid|intravenous injections once every 3 months
45846621|NCT05697276|Drug|Lidocaine|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
45370197|NCT01588912|Drug|Entecavir|Maintain the entecavir through the study period
45370198|NCT00966810|Procedure|Stem cell transplantation|Patients were conditioned with oral busulfan 12mg/kg (days -6 to -4), cyclophosphamide 120mg/kg (days -3,-2), rabbit antithymocytic globulin, (Fresenius, Bad Hamburg, Germany) 25mg/kg (days -5 to -1) and fludarabine 200 mg/kg (days -7 to-3). CD34 cells were positively selected using anti-CD34 antibody conjugated to iron-dextran microbeads using CliniMACS device (Miltenyi Biotech, Bergisch Gladbach, Germany) with an aim to collect > 5.0 x 106 CD34 cells/kg. DLI was administered in escalating dose regimen starting from 3 x 106 cells/kg followed as necessary by 1 x 107 cells/kg, 5 x 107 cells/kg and 1 x 108 cells/kg.
45489273|NCT05000957|Device|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1.5 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
45489274|NCT05000957|Diagnostic Test|Blood analysis|Taking blood from a vein for clinical blood analysis, glucose test, hepatitis B, C viruses, human immunodeficiency viruses and syphilis test, blood clotting tests, blood type and rhesus factor determination (to include the participant in the study).
45489275|NCT05000957|Diagnostic Test|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
45489276|NCT05000957|Diagnostic Test|Electrocardiography|Electrocardiography investigation to determine cardiac abnormalities (to include the participant in the study).
45489277|NCT05000957|Diagnostic Test|Vaginal smear|Vaginal smear for flora investigation, oncocytology (to include the participant in the study).
45489278|NCT05000957|Diagnostic Test|Colposcopy|Colposcopy investigation to determine pre-malignant and malignant lesions of cervix, vagina or vulva (to include the participant in the study).
45489279|NCT05000957|Diagnostic Test|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
45489280|NCT05000957|Diagnostic Test|Doppler ultrasonography|Ultrasound investigation for assessing blood flow in the tissues of vulva region (to evaluate procedure efficiency).
45846622|NCT05697276|Drug|Bupivacain|Bupivacaine: Patients will receive 10 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
46052959|NCT05286892|Other|Diabetes LIVE JustICE|Diabetes LIVE JustICE will be an adaptation of the current Diabetes LIVE persistent multi-user online virtual environment built on the Unreal Engine (Epic Games, Inc., Cary, NC) that allows users to talk to each other in real-time and participate in instructor-led synchronous sessions. Users can access the virtual environment through IOS/Android devices. Instructors can show learning material such as Google Docs and PowerPoint. The LIVE JustICE community will contain a community center, a tranquility center, and a message board. This will be an interactive community where participants will communicate in real-time on their mobile device or, if preferred, using their computer via text or audio chat. Access to LIVE will allow participants to utilize resources and links in the application, leave a message on the message board for the diabetes educators, or engage with other participants. Research team members will add and trial gaming activities to the VE during this feasibility study.
46052960|NCT05286892|Other|Enhanced Education|See control group description above
46052961|NCT00761215|Drug|TR-701 200 mg|oral TR-701 200 mg for 5 to 7 days
46052962|NCT00761215|Drug|TR-701 300 mg|oral TR-701 300 mg for 5 to 7 days
46052963|NCT00761215|Drug|TR-701 400 mg|TR-701 400 mg for 5 to 7 days
46052964|NCT04235751|Behavioral|Professional Coaching|6 individualized professional coaching sessions via phone
45489281|NCT05000957|Diagnostic Test|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
46052965|NCT02794857|Drug|NP001|
46052966|NCT02794857|Drug|Placebo|
45489282|NCT05000957|Diagnostic Test|Biopsy of the vaginal wall|Sampling of the vaginal wall material in the posterior fornix area including the mucous membrane and muscle layer will be performed during colporrhaphy or any pelvic surgical procedure for histological, immunohistochemical studies, and optical coherence tomography (elastography) (to evaluate procedure efficiency)
45489283|NCT05000957|Diagnostic Test|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
45489284|NCT05000957|Diagnostic Test|Pelvic Floor Distress Inventory Questionnaire|Pelvic Floor Distress Inventory Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
45489285|NCT05000957|Diagnostic Test|International Consultation on Incontinence Questionnaire - Short Form|International Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
46052967|NCT04100629|Behavioral|digital support: text messages|In this study, the text messages are intended to be one-directional, from the PI to the participant. Participants are not expected to reply. If participants reply to any of the text messages, the PI will screen the content and only reply if it is a question regarding the study or a request to seek counseling. Additionally, participants will be instructed by the PI to access their Smartphones to read texts while on a break, after their shift, or when not at work; participants will be instructed to not use Smartphones to read texts while working. A series of four text messages will be sent to all study participants (experimental and control groups) by the PI every Monday, Wednesday, Friday, and Saturday (M, W, F, S) at 1pm for six weeks, for a total of 24 different texts for each group.
45489286|NCT05000957|Diagnostic Test|Pelvic Floor Impact Questionnaire|Pelvic Floor Impact Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
45489287|NCT05000957|Procedure|Anterior and/or posterior colporrhaphy|Surgical procedure to repair pelvic organ prolapse followed by biopsy for histological, immunohistochemical studies, and optical coherence tomography (elastography).
45489288|NCT05000957|Procedure|Pelvic surgical procedure|Any pelvic surgical procedure which do not affect condition of vagina, vulva and paraurethral region followed by biopsy for histological, immunohistochemical studies, and optical coherence tomography (elastography).
45489289|NCT05000957|Other|Physical examination|Pelvic examination (to include the participant in the study and observe throughout the study)
46052968|NCT05432817|Behavioral|Cognitive Processing Therapy|CPT: a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
45370199|NCT01589068|Drug|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70 kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
45370200|NCT01589068|Drug|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
45370201|NCT00966888|Procedure|standard follow-up care|No intervention
45370202|NCT00966888|Radiation|radiation therapy|Chest wall radiotherapy
45370203|NCT04008498|Diagnostic Test|AEEG brain monitoring|"Babies will be recorded continuously for the entire duration of their time on the intensive care unit.~Once the child is receiving high dependency or special care, we will record aEEG for 4 hours once a week until the baby is discharged home. If a participant is moved back to intensive care, the aEEG will be started again if the aEEG monitor is not being used on another baby."
45370204|NCT00974454|Drug|Fuzheng 2|Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
45489290|NCT05000957|Other|Сonsultation|Сonsultation of a therapist about the absence of contraindications for surgical treatment (to include the participant in the study)
45489291|NCT05000957|Genetic|Buccal smear|"Buccal smear to performing genetic testing.~The following markers will be analyzed:~ESR1 rs2234693, ESR1 rs2228480, COL3A1 rs1800255, COL14A1 rs4870723, MMP9 rs3918253, MMP10 rs17435959, LOXL1 rs2304719, WNT4 rs3820282, MMP2 rs243865, TIMP2 rs2277698, CD31 / PECAM1 rs1131012, Ki67 rs11016076."
45489292|NCT04482166|Other|Training|20-times training of fiberoptic-guided tracheal intubation through supraglottic airway device to pediatric airway manikin
45489293|NCT04482166|Device|supraglottic airway device|supraglottic airway device
45370205|NCT00974454|Drug|Placebo|Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
45370206|NCT00432562|Drug|Vinorelbine Tartrate|Subjects received one dose each of ANX-530 and NAVELBINE, each providing 30 mg/m2 vinorelbine. Study drugs will be infused into an arm vein over ten minutes.
45370207|NCT00966966|Drug|SAM-531 and gemfibrozil|2 single doses of 5 mg SAM-531 (capsules) a daily dose of 1200 mg Gemfibrozil (one tablet of 600mg at approximately 8 a.m. and one tablet of 600 mg at approximately 6 p.m.) for 14 days
45489294|NCT03679052|Drug|Mirtazapine|Each patient received 30 mg mirtazapine tablet and a placebo tablet for clonidine orally with sips of water 2 h preoperatively.
45489295|NCT03679052|Drug|Clonidine|Each patient received 150 µg clonidine tablet and a placebo tablet for mirtazapine orally with sips of water 2 h preoperatively.
45489296|NCT03679052|Drug|Placebo|Each patient received two placebo tablets for mirtazapine and clonidine orally with sips of water 2 h preoperatively.
45489297|NCT03172312|Procedure|Different range of thyroid surgery|Observe and record parathyroid status during thyroid surgery
45489298|NCT03675074|Device|Neujia|Neujia devices endoscopically deployed for jejunoileal compression anastomosis
46052969|NCT05432817|Behavioral|Therapist-facilitated Support group|Therapist-facilitated Support: group therapy oriented toward providing general support networks and communities of individuals with similar experiences. Sessions will also focus on establishing trust, open communication, and developing therapeutic alliance with group members and the therapist facilitator. Occurs over 12 sessions.
46052970|NCT05805293|Device|High-Velocity Nasal Insufflation Therapy|"Parameter settings for the HVNI apparatus are as follows:~The flow of HVNI will initially be set at 30-40 L/min, and inspiratory flow rate could be increased to 45-60 L/min.~FIO2 will be adjusted to maintain a SaO2 more than 90 % and relative humidity of 30-34%.~Temperature range of 35-37°C."
45370208|NCT00979914|Other|Patient education programme|The intervention consisted of five group sessions, three hours for each session. The focus was on self-efficacy. Eight to ten patients participated in the programme at the same time.
45370209|NCT00974532|Dietary Supplement|High calcium diet 2000 mg/day|High calcium (2000 mg elemental calcium) diet x 9 days
45370210|NCT00974532|Dietary Supplement|Low calcium diet, 800 mg/day|Low calcium (800 mg elemental calcium) diet x 9 days
45370211|NCT00980070|Device|Pediatric Restraint for Lumbar Puncture|Restraint for children 1-90 days of age that allows physician to position pt for optimal lumbar puncture procedure.
45370212|NCT00980070|Device|Lumbar Puncture Device|Lumbar Puncture positioner
45370213|NCT00980070|Other|Standard of Care|Lumbar Puncture positioner
45370214|NCT00432172|Drug|Epirubicin|
46052971|NCT05805293|Device|Non-Invasive Ventilation|Patients will be put on inspiratory/expiratory pressure 10/5 cmH2O (11). The inspiratory and expiratory pressures will be titrated with increments of 2 cmH2O based on improvement of oxygen saturation by continuous pulse oximetry and arterial blood gases values, alleviation of dyspnea and a decrease of respiratory rate and heart rate. The maximum allowed inspiratory pressure was 20 cm H2O. The maximum allowed expiratory pressure was 10 cm H2O.
45370215|NCT00432172|Drug|Cyclophosphamide|
45489299|NCT03172390|Device|4D Cardiac Magnetic Resonance|4D Cardiac Magnetic Resonance for patients with a ascending aorta dilatation without current indication for surgery for measured parameters of ascending aorta
46052972|NCT05805280|Device|intravascular ultrasound-guided group|intravascular ultrasound use
46052973|NCT05805280|Device|angiography-guided group|angiography-guided use
46052974|NCT05805228|Other|Sexual Counseling|Pregnancy and postpartum period-specific sexual counseling was given to pregnant women and their spouses.
45370216|NCT00432172|Drug|Docetaxel|
45370217|NCT00432172|Drug|Exemestane|
45370218|NCT00432172|Drug|Goserelin|
45489300|NCT03678974|Behavioral|Exercise Prescription|The CardioCoach Vo2Max app allows the physician to upload an individual's Vo2 Max and resting metabolic rate results to the app which will allow each subject to view those results in the context of workout zones, goals, and energy balance. The app shows time spent aerobic versus anaerobic, and the actual number of calories burned during a workout and post-workout. It will also show what fuel source (Fats vs Carbs) are being used in real time during your workouts. Subjects can be guided through their workouts utilizing voice coaching to keep you in your customized zones. Additionally, the app accommodates a quick add of calories directly to the app to track calories consumed vs calories burned.
45489301|NCT03540914|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
46052975|NCT05805189|Procedure|pulmonary vein (PV) isolation|The settings used during ablation will be for both groups: 15W, unipolar; 5ml/min baseline irrigation, 35ml/min irrigation during inflation/RF application; 55°C target electrode temperature; RF application time 60s for anterior electrodes, 20s for posterior electrodes. The catheter insertion in Pulmonary vein and ablation workflow will be different for two groups.
46052976|NCT05805163|Behavioral|FABI tailored COVID-19 testing pamphlet|FABI adapted COVID-19 educational pamphlet
45370219|NCT00432172|Drug|Carboplatin|
45370220|NCT01034410|Drug|AS1411|AS1411 40mg/kg/day or AS1411 80mg/kg/day
45370221|NCT01034410|Drug|Cytarabine|Cytarabine 2g/m2 bid Days 4-7
45370222|NCT01034488|Biological|Suine|5000UI /mL
45370223|NCT01034488|Biological|Suine|5000UI/mL
45370224|NCT00415168|Drug|pemetrexed|700 milligrams/meters squared (mg/m2), intravenous (IV), every 21 days x 6 cycles
45370225|NCT00415168|Drug|cisplatin|75 mg/m2, IV, every 21 days x 6 cycles
45370226|NCT01034566|Radiation|Proton Beam Radiation Therapy|
45370227|NCT00424762|Drug|rosiglitazone|6 months of treatment of blinded study drug
45370228|NCT00424762|Drug|placebo|blinded treatment with matching placebo
46052977|NCT05805163|Behavioral|Standard COVID-19 home-based test kit|Standard COVID-19 home-based test kit
46052978|NCT05805124|Diagnostic Test|Preop evaluation|"All preop evaluations prescribed in the preadmission clinic will be recorded, especially:~renal function tests~hematologic tests~coagulation tests~hepatic function tests~ECG~cardiac function tests~pulmonary function tests~endocrine function tests"
46052979|NCT05805098|Drug|Venetoclax|Starting on day 1, venetoclax will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2 and 400 mg on day 3. The patient then continues to take the 400mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day.
45370229|NCT00967122|Procedure|Band adjustment and specimen collection|Clinical evaluation and sample collection before and after band adjustment
45370230|NCT00967200|Other|laboratory biomarker analysis|laboratory biomarker analysis
45370231|NCT00967200|Other|pharmacogenomic studies|pharmacogenomic studies
45370232|NCT00974688|Behavioral|Information Intervention|The information intervention is designed to ensure that the parent(s) and child have a clear understanding of the range of physical activity opportunities that are appropriate and recommended for the child. The information intervention will be comprised of discussions and written information.
45370233|NCT00974688|Behavioral|Demonstration Intervention|The demonstration intervention will be designed to demonstrate to the child and parent(s) specifically what the child is able to do in relation to fitness and motor skill activities. The demonstration intervention will consist of having the child complete a standardized exercise testing protocol on the treadmill, followed by discussions with the child and parent(s) to convey the results of the study testing of fitness and gross motor skill.
45370234|NCT00967356|Drug|AZD5985|Single dose-The starting dose will be 40 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca predefined upper exposure limits
45370235|NCT00967356|Drug|Placebo|Oral suspension
45370236|NCT00980304|Drug|Rituximab|
45489302|NCT03540914|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
45692291|NCT00735826|Drug|Vorinostat|Vorinostat will be administered orally once daily in an open-labeled, unblinded manner to all subjects enrolled in the study. Subjects will receive vorinostat 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection. Vorinostat should be taken with food within 0 to 30 minutes of a meal if possible. Patients should take the medication at approximately the same time each day on an ongoing basis. Missed doses will not be made up.
46052980|NCT05805098|Drug|Homoharringtonine|On day 1, homoharringtonine 1 mg/m2 IV will be given, and will continue for 5 days.
46052981|NCT05805098|Drug|Cytarabine|On day 1, cytarabine 100 mg/m2 IV will be given, and will continue for 5 days.
46052982|NCT05805085|Device|Lens A (Hydrogel Daily Disposable Toric Contact Lens)|15 minutes
46052983|NCT05805085|Device|Lens B (Silicone Hydrogel Daily Disposable Toric Contact Lens)|15 minutes
46052984|NCT05805046|Device|Negative Pressure Wound Therapy System|The study device combines a sterile dressing comprising gelling fibre technology to absorb wound exudate with negative pressure applied to the wound via a vacuum pump.
45370237|NCT00974766|Drug|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 2 weeks; then 0.5 mg/kg/day for alternate days for eight weeks. Then taper by 5 mg every 2 weeks and discontinue
45370238|NCT00974766|Drug|Glucocorticoids|Prednisolone 0.75 mg/kg/day for 6 weeks; then 0.5 mg/kg/day for 6 weeks. Then taper by 5 mg every 6 weeks and discontinue
45489303|NCT02400970|Other|malignant cells|
45489304|NCT03671252|Drug|FOLFOXIRI|Irinotecan165 mg/m2、Oxaliplatin85 mg/m2、Left-calcium leucovorin 200mg/㎡，Intravenous infusion，first day. Then, 5-FU 1600 mg/m2/d×2 continuous intravenous infusion（total 3200 mg/m2，infusion 46 hours）in the next two days. Repeat every 14 days.
45692292|NCT03916341|Other|EC with nicotine|Use an EC with nicotine for up to 30 minutes
45692293|NCT03916341|Other|EC without nicotine|Use an EC without nicotine for up to 30 minutes
45370239|NCT00980382|Drug|S-1, Docetaxel|"Phase I study~S-1 (level 0, 1/2, 3/4, 5: 60, 70, 80, 90 mg/m2/day) q 12 hours po Days 1-14~Docetaxel (level 0/1,2/3, 4/5: 25, 30, 35 mg/m2) iv : Days 1, 8~Phase II study~S-1 (80mg/m2/day) q 12 hours po Days 1-14~Docetaxel (35 mg/m2) iv : Days 1, 8"
45370240|NCT00967434|Drug|Atorvastatin|atorvastatin 80 mg daily for at least 7 preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
45370241|NCT00967434|Drug|Atorvastatin|Daily placebo on the preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
45370242|NCT00967434|Drug|Placebo|Daily placebo in preoperative period Placebo on day of surgery Daily placebo for up to 7 postoperative days
45692294|NCT03916341|Other|control|sham control
45692295|NCT03916341|Other|TC with nicotine (own brand)|smoke a TC
46052985|NCT05805007|Drug|ZVS203e|ZVS203e is a rAAV-mediated gene editing drug that silences RHO mutant protein expression by CRISPR/Cas9 editing system.
46052986|NCT05804994|Device|Elgydium Clinic Sensileave Gel (V063B - DP3003)|Tested product is applied/used only once a day before whitening tray wear.
46052987|NCT05804981|Other|PRO-CS|4 questions about cognitive function added to annual wellness visit protocol
45489305|NCT03671252|Drug|XELOX|XELOX consisting of 130 mg/m2 oxaliplatin administered intravenously on day 1 and 1,000 mg/m2 capecitabine administered orally twice daily on days 1-14 for a 3-week cycle.
45489306|NCT03671252|Other|Chemoradiotherapy|"Chemotherapy: oral capecitabine（1650 mg/m2）twice daily during radiotherapy without weekend breaks.~Radiation: Radiation therapy is administered via intensity-modulated radiation therapy (IMRT) with a linear accelerator, 6MV-X ray. The patients are scheduled to receive a GTV expanding 6mm to form PTV1 and CTV expanding 6mm to form PTV2. The dose of PTV1 is 50Gy/25 times for 35 days and the dose of PTV2 is 45Gy/25 times for 35 days. Patients were treated in consecutive days per week for a total of 5 weeks."
45489307|NCT03671252|Procedure|TME operation|TME operation
45489308|NCT03671252|Procedure|efficacy evaluation|chest/ abdominal CT、pelvic nuclear magnetic resonanceimaging、transrectal ultrasonography
46052988|NCT05804968|Other|Digital HIV Self Disclosure Intervention|This project will develop a digital HIV disclosure intervention, drawing from the HEADSUP manual (Evangeli et al., 2020), which consists of four modules, including a HIV disclosure planning component. A SCED will be used to explore HIV disclosure intention, amongst other variables throughout baseline, intervention and follow up phases. Participants will further be asked to complete a participant experiences questionnaire to explore how they found the digital intervention and assess acceptability. This project will recruit a diverse sample of Sub-Saharan Africa adults living with HIV and residing in the U.K.
46052989|NCT02795559|Other|Glucose|75g glucose dissolved in 300ml water
45370243|NCT00967512|Drug|cenersen|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
45370244|NCT00967512|Drug|placebo|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
45370245|NCT00967512|Drug|idarubicin, cytarabine|idarubicin, cytarabine
45370246|NCT00414544|Device|CosmetaLife|Dermal filler
45370247|NCT00414544|Device|Restylane|Dermal filler
45370248|NCT04082910|Drug|Metoprolol|Metoprolol was given in patients who received CAR T cell therapy for CRS control or CRS precaution.
45370249|NCT04082910|Drug|metoprolol, infliximab, etanercept, tocilizumab and/or other agents|During the term of metoprolol use, antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited to be used under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
45489309|NCT02400892|Other|TTE Bubble Study|Bedside transthoracic echocardiogram bubble study to assess for the presence or absence of a PFO
45692296|NCT03916341|Other|research TC with very low level nicotine|smoke a research TC with very low level nicotine
45692297|NCT04765995|Drug|HZBio1 0.96mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
45692298|NCT04765995|Drug|HZBio1 3mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
45489310|NCT03629249|Drug|Placebo once daily|Placebo to QAW039 once daily (one tablet blinded placebo to QAW039 150 mg and one tablet blinded placebo to QAW039 450 mg).
45489311|NCT03629249|Drug|QAW039 150 mg once daily|QAW039 150 mg once daily (one tablet of blinded QAW039 150 mg to be given together with one tablet blinded placebo to QAW039 450 mg)
45489312|NCT03629249|Drug|QAW039 450 mg once daily|QAW039 450 mg once daily (one tablet of blinded QAW039 450 mg to be given together with one tablet blinded placebo to QAW039 150 mg)
45692299|NCT04765995|Drug|HZBio1 6mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
45692300|NCT04765995|Drug|HZBio1 9mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
46052990|NCT02795559|Other|Inulin|75g glucose plus 24g inulin dissolved in 300ml water
45692301|NCT04765995|Drug|HZBio1 12mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
46052991|NCT02795559|Other|Resistant starch|75g glucose plus 28g resistant starch in 300ml water
46052992|NCT05804942|Behavioral|High glycemic index|Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:>70), 20% fat and 20% protein.
46052993|NCT05804942|Behavioral|Medium glycemic index|Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:55-70), 20% fat and 20% protein.
46052994|NCT05804942|Behavioral|Low glycemic index|Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:<55), 20% fat and 20% protein.
45370250|NCT01618786|Other|SmartCell flooring|SmartCell (SATECH Inc., Chehalis, WA, USA) is a continuous rubber surface layer supported by an array of cylindrical rubber columns 14 mm in diameter, and spaced at 19 mm intervals. It has a surface hardness of 50 durometer. It has been reported to provide approximately 35% peak force attenuation during mechanical tests that simulate falls on the hip. It has also been reported to have minimal effect on balance and mobility of older women during activities of daily living. It will be covered with hospital-grade vinyl and will be inspected regularly for maintenance requirements.
45370251|NCT01618786|Other|Plywood flooring|Plywood flooring covered with the same hospital-grade vinyl as the SmartCell flooring.
46052995|NCT05804929|Other|Observation without intervention|Observation of food intake, body composition, microbiota, genetics, metabolic rate, metabolomics.
45370252|NCT00967590|Drug|RO5036505|380mg iv infusion once weekly for 8 weeks
45370253|NCT00967590|Drug|placebo|iv infusion once weekly for 8 weeks
45370254|NCT00975078|Procedure|adrenal insufficiency testing|"On the day getting the baseline data we will perform a low dose cosyntropin test to asses adrenal axis function.~All participants will then undergo an overnight 0.5mg dexamethasone suppression test. Thereby participants will take 0.5mg of dexamethasone at 11 pm and a fasting blood sample will be collected the next morning at 8 am to measure the serum cortisol level.~Six days later participants will start taking 0.5mg/kg body-weight prednisone each morning for 14 days.~On day 1, 3, 7 and 21 after withdrawal of prednisone the participant will undergo a low dose cosyntropin test. The investigators will take a blood sample before and 30 minutes after i.v. administration of 1ug of cosyntropin for the measurement of cortisol."
45370255|NCT00975078|Drug|prednisone|0.5mg/kg body-weight prednisone each morning for 14 days
45370256|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding
45370257|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
45370258|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding
45370259|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
45370260|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding
45370261|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
45370262|NCT00984516|Drug|Placebo|Intradermal Placebo, 100μl administered once prior to wounding
45692302|NCT04765995|Drug|Placebo|Matching placebo will be administered intramuscularly.
45692303|NCT01276054|Radiation|technetium Tc 99m sulfur colloid|Given intradermally and periareolarly
45692304|NCT01276054|Drug|methylene blue|Given subcutaneously
46052996|NCT05804916|Device|Surface Guided Radiation Therapy (SGRT)|SGRT and DIBH those two devices could be combined together to improve the accuracy in radiation therapy position and heart protection
45692305|NCT01276054|Drug|indocyanine green solution|Given subcutaneously
45692306|NCT01276054|Procedure|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
46052997|NCT05804903|Device|(ALLEGRA Plus Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis|Implantation of the ALLEGRA Plus Transcatheter Heart Valve in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
45692307|NCT01276054|Procedure|axillary lymph node biopsy|Undergo axillary lymph node biopsy
45692308|NCT01276054|Procedure|bioimpedance spectroscopy|Correlative studies
46052998|NCT05804877|Behavioral|mindfulness-based cognitive therapy|Participants in the experimental group would be arranged to attend online mindfulness-based cognitive programs for eight weeks. Each week was divided into 3 parts, which were detailed mindfulness-based skills training with pictures or short videos, techniques application in different scenarios, and concepts consolidation through a web-based assignment.
46052999|NCT05804877|Other|Mental health education|The mental health education was delivered on the platform of LINE to the control group 3 times a week for 8 weeks
46053000|NCT05804864|Drug|KM501|1a: The program evaluated six dose levels, i.e., 0.1, 0.3, 0.6, 1.2, 1.8, 2.4 mg/kg, An accelerated titration was performed in the 0.1 and 0.3 mg/kg dose groups, and then a Bayesian optimal interval design was used to determine MTDS for four subsequent dose levels. Ib: The antitumor activity of KM501 monotherapy in subjects with specific types of tumors that are HER2-positive or express, amplify, or mutate will be evaluated at the RP2D dose level
46053001|NCT05804838|Other|Mindfulness stress reduction program group|Conscious Awareness Based Stress Reduction program will be applied to women in this group, which will last for 8 weeks. Informed Voluntary Consent Form, Descriptive Characteristics Information Form, Psychological Well-Being Scale, Beck Depression Scale, Prenatal Attachment Scale and Conscious Awareness Scale will be administered to the pregnant women who make up the intervention group before the implementation of the Mindfulness-Based Stress Reduction program. The intervention group will receive 1 session per week. Each session will last 80 minutes. After completing the 8-week MBSR program, data collection forms will be re-applied to the pregnant women in the intervention group and posttest-1 measurements will be made. After the posttest-1 measurements, the pregnants in the intervention group will be given posttest-2 measurements of the pregnants in the intervention group, 1 month after the measurements.
45370263|NCT00984516|Drug|Placebo|Intradermal Placebo, 100μl administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
46053002|NCT05804825|Behavioral|Argument inoculation messages|Participants will then be presented with arguments randomly selected by the Qualtrics software algorithm from the full set of messages.
45370264|NCT04007016|Procedure|"a new osteotomy from the inner L shaped iliac osteotomy"|"There were two ostectomies were used in the osteotomy. The first was was a cured and 5mm width and the second one was straight 1.5cm width. All the directions was started from the inner to outer just a bove the triradiate cartilage and its shape likeL"
45370265|NCT00980616|Drug|ropivacaine, physical serum and adrenalin|A: experimental group: 235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin
45370266|NCT00980694|Dietary Supplement|ubiquinol|up to 600 mg per day, oral capsules for 8 weeks
45370267|NCT00980850|Biological|Baxter Novel Influenza A H1N1 Whole Virus Vaccine|Two 0.5 ml doses of vaccine given within 3 weeks interval
45370268|NCT00980850|Biological|GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine|Two 0.25 ml doses of vaccine given within 3 weeks interval
45370269|NCT00414466|Drug|Intraspinal Gabapentin|Surgical implantation of a drug infusion system with intrathecal (spinal) delivery of active drug (1 of 3 possible dose levels) or placebo (saline) for 22 days followed by 7 days of infusion at half dose level. Subjects may then continue in open-label treatment with study drug. Dosage in open-label may be adjusted to meet subject needs.
45370270|NCT00975234|Procedure|Intra-lesion injection of autologous skeletal myoblasts|Intra-lesion injection
45370271|NCT00975234|Procedure|Revascularisation|Revascularisation surgery
45370272|NCT00984750|Drug|acetyl-L-carnitine/statin (simvastatin)|"acetyl-L-carnitine: 4 tablets of 500 mg a day~simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability"
45370273|NCT00984750|Drug|placebo|placebo: 4 tablets of 500 mg a day simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability
45370274|NCT01033162|Behavioral|Enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)|"Half of the participating women will be randomly assigned to use an informative but static website (Basic ICCS), and half will be offered a fully interactive CHESS (Enhanced ICCS + the Basic ICCS). Study outcome data will be gathered from patients, clinicians, and the healthcare system (i.e., from the electronic medical record: EMR) for at least 8 months after study entry. We propose that the Enhanced ICCS relative to the Basic ICCS, will:~Improve patients' sense of cancer information competence (perceived ability to obtain and use relevant information)~Reduce patients' negative affect and increase their emotional well being~Improve patients' sense of social support~Improve patients' health self-efficacy~Improve patients' ratings of experience with cancer specialty care services~Improve patients' health related quality of life (HRQL)~Improve clinicians' ratings of quality of patient contacts~Reduce healthcare utilization and costs (obtained via the EMR)"
45370275|NCT00975312|Drug|Triple combination cream|The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand once daily for up 12 weeks.
45370276|NCT00975312|Drug|Tretinoin 0.05%|Tretinoin 0.05% cream was applied on the whole back of the other hand once daily for up 12 weeks.
45370277|NCT00984906|Other|Empty inhalers|Empty Easyhaler inhalers (type A and type B) and empty Turbohaler inhaler
45370278|NCT00424528|Drug|Arformoterol Tartrate Inhalation Solution|Arformoterol tartrate inhalation solution 15 mcg twice daily and placebo inhalation powder once daily.
45370279|NCT00424528|Drug|Tiotropium|Placebo inhalation solution twice daily and tiotropium inhalation powder 18 mcg once daily.
45370280|NCT00424528|Drug|Arformoterol and Tiotropium|Arformoterol tartrate inhalation solution 15 mcg twice daily and Tiotropium inhalation powder 18 mcg once daily.
45370281|NCT00424528|Drug|Placebo|Placebo inhalation solution and placebo inhalation powder
45370282|NCT04974996|Drug|Loncastuximab tesirine|Intravenous (IV) infusion
45370283|NCT04974996|Drug|Prednisone|Orally via tablet or capsule
45370284|NCT04974996|Drug|Rituximab|Intravenous (IV) infusion
45370285|NCT04974996|Drug|Cyclophosphamide|Intravenous (IV) infusion
45370286|NCT04974996|Drug|Doxorubicin|Intravenous (IV) infusion
45370287|NCT04974996|Drug|Vincristine|Intravenous (IV) infusion
45370288|NCT00981006|Procedure|human cardiac stem cells|Single intramyocardial Injection of autologous hCSCs : 20 cites of infarcted myocardium Implantation of gelatin hydrogel sheet incorporating bFGF: 200 microgram. CABG surgery.
45370289|NCT00975390|Dietary Supplement|Carbohydrate|1.2 g/kg/h
45370290|NCT00975390|Dietary Supplement|Carbohydrate and protein ingestion|1.2 g/kg/h carbohydrate plus 0.4 g/kg/h protein
45370291|NCT00975390|Dietary Supplement|Carbohydrate and caffeine ingestion|1.2 g/kg/h carbohydrate and 1.67 g/kg/h caffeine
45370292|NCT00981240|Drug|SAR103168|"Pharmaceutical form: Concentrate for solution for infusion~Route of administration: Intravenous infusion"
45370293|NCT00981318|Drug|lopinavir/ritonavir plus maraviroc|lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid
45370294|NCT00975468|Other|Pressure Controlled vs. Volume Controlled Ventilation during OLV|Ventilation will be initiated with a tidal volume of 8 ml.kg-1 in Volume-controlled group and with a peak airway pressure that provided a tidal volume of 8 ml.kg-1 in pressure-controlled group. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
45370295|NCT00984984|Drug|methylprednisolone PO|10 capsules Methylprednisolone 100 mg and 50 ml IV NaCl 0,9% (syringe pump 30 mn to 2 h, every day during 3 days
46053003|NCT05804825|Behavioral|Simple forewarning message|Participants will be presented with a simple forewarning message.
45370296|NCT00984984|Drug|methylprednisolone IV|IV Methylprednisolone 1 g in 50 ml NaCl 0,9% (syringe pump 30 mn to 2 h) and 10 capsules of placebo, every day during 3 days
45370297|NCT00975546|Other|Sperm washing and testing for HIV contamination|Semen will undergo specialized washing to reduce viral contamination of sperm. The sperm are first separated from leukocytes and other seminal constituents by centrifugation over a stepwise gradient. Motile sperm will be separated from the resulting pellet by a swim-up step in which washed sperm are overlaid with fresh medium into which sperm migrate. The final sperm suspension will be stored while testing for HIV is performed by reverse transcription polymerase chain reaction (RT-PCR)
45370298|NCT00975546|Procedure|Intrauterine Insemination|Intrauterine Insemination (IUI) will be performed on the HIV-negative wife, following standard clinical practice, using washed sperm from her HIV-positive husband after testing the IUI sample for HIV.
45370299|NCT00985062|Procedure|Mild Ovarian Stimulation Treatment|Administration of a fixed dose of 150 IU/day rFSH s.c. (Puregon® NV Organon, Oss, The Netherlands) from cycle day 5 onwards. As soon as the leading follicle reached a diameter of 14mm, a GnRH-antagonist (Orgalutran®, NV Organon, Oss, The Netherlands) was administered at 0.25 mg/day s.c.. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered.
45370300|NCT00985062|Procedure|Conventional Ovarian Stimulation Treatment|Administration of GnRH agonist Triptorelin (Decapeptyl®, Ferring BV, Hoofddorp, The Netherlands) at 0.1 mg/day s.c., starting on cycle day 21 of the menstrual cycle preceding the actual stimulation cycle. After two weeks of the GnRH regimen, co-treatment with rFSH 225 IU/day s.c. (Puregon®, NV Organon, Oss, The Netherlands) was initiated. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered
45370301|NCT00981552|Radiation|IMRT planning|
45370302|NCT00981552|Radiation|4-Field Radiation Planning|
45370303|NCT00975702|Procedure|RIPC by Inflation of Pneumatic Tourniquet|Pneumatic tourniquets will be placed on both lower extremities in all deceased donor subjects. In the RIPC group the tourniquets will be inflated sequentially for 10 min each followed by deflation, approximately, 30-60 min prior to aortic crossclamping and organ perfusion.
45370304|NCT00985218|Device|SMART System|microfluidic embryo culture system
45370305|NCT00985218|Device|Culture dish|Standard IVF culture dish
45370306|NCT00545532|Drug|oseltamivir|Dose ranging between 30 to 150 mg orally administered as syrup or capsules (depending on participant's age and weight) po twice daily for 10 days
45370307|NCT00545532|Other|placebo|Placebo matched to oseltamivir po twice daily for 10 days
45370308|NCT00544440|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
45370309|NCT00544440|Drug|Prednisone|Prednisone 5 mg tablet taken orally twice daily
45370310|NCT04006860|Drug|SHC014748M Capsules|SHC014748M Capsules: 200mg
45370311|NCT03874104|Dietary Supplement|Extensively Hydrolysed Formula containing Pre- & Probiotics|Extensively Hydrolysed Formula containing Pre- and Probiotics
45370312|NCT00981708|Drug|Lenalidomide, Dexamethasone and Cyclophosphamide|"Lenalidomide capsules on days 1 to 21. the dose starts at 5 mg/day up to 25 mg/day.~Dexamethasone tablets on days 1 to 4. Dose 20 mg per day.~Cyclophosphamide tablets on days 1 to 10. The dose starts at 50 mg per day up to 100 mg per day.~The cycle is to be repeated every 28 days (4 weeks)"
45370313|NCT04007718|Behavioral|Interpretation bias training|Active: 50% positive endings to scenarios, 50% generation of positive endings to ambiguous scenarios Control: 100% ambiguous endings to scenarios with no instructions to imagine positive endings
45370314|NCT03920670|Device|TetraGraph (TG)|TetraGraph device is a neuromuscular transmission monitor capable of estimating the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to percutaneous electrical neurostimulation. Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured.
45370315|NCT03920670|Device|ToFscan (TS)|ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured.
45370316|NCT00430300|Drug|UK-432,097|Formulated as a dry powder, supplied as capsules and administered using an atomizer device. Given as either 150mcg, 450mcg or 1350mcg BID.
45370317|NCT00430300|Drug|Placebo|Capsules containing 100% lactose administered BID using an atomizer device
45370318|NCT00981786|Drug|Brimonidine/timolol fixed combination drops added to travoprost|twice daily administration
45370319|NCT00981786|Drug|Brinzolamide/timolol fixed combination drops added to travoprost|twice daily dosing
45370320|NCT00975858|Procedure|Coronary Revascularization|revascularization of coronary arteries in case of symptomatic obstructive coronary artery disease
45489313|NCT02396524|Behavioral|Hockey FIT Program|Active phase: a) Classroom-based education on successful weight management strategies and instruction on behaviour change techniques/dietary interventions; promote peer and other forms of social support; and b) Physical activity sessions in aerobic/strength/flexibility exercises. Maintenance phase: Participants independently set new lifestyle prescriptions and goals and track their exercise, physical activity, and healthy eating with the support of a suite of free-of-charge health technology support tools
46053004|NCT05804812|Behavioral|laughter therapy|Assigned Interventions Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
46053005|NCT05804799|Diagnostic Test|Contrast-enhanced liver CT scan|"The contrast-enhanced liver CT scans were obtained from all of the participants.~The liver CT images were reconstructed by both low-dose scans with a deep-learning-based denoising program (ClariCT.AI) and standard-dose scans with model-based iterative reconstruction."
45489314|NCT03671174|Drug|Prednisone|10mg once daily orally
45489315|NCT03671174|Drug|Hydroxychloroquine|100mg to 200mg twice daily orally
45489316|NCT03671174|Drug|Aspirin|50mg once daily orally
45489317|NCT03671174|Drug|low molecular weight heparin|Enoxaparin 40mg once daily subcutaneous or dalteparin 5000IU once daily subcutaneous or nadroparin calcium 4100U once daily subcutaneous
45489318|NCT03172234|Other|oral amantadine sulfate|In amantadine group:the patients will receive100 mg oral amantadine sulfate 90 minute prior to the surgery
45489319|NCT03172234|Drug|oral gabapentin|In gabapentin group: the patients will receive oral 800 mg gabapentin 90 minute prior to the surgery
45489320|NCT03172234|Drug|Placebo Oral Tablet|in control group : the patients will receive Placebo Oral Tablet 90 minute prior to the surgery
45489321|NCT02396836|Other|6 step technique|Hand decontamination with alcohol hand rub using the World Health Organizations 6 step technique
45489322|NCT02396836|Other|3 step technique|Hand decontamination with alcohol hand rub using the 3 step technique
45489323|NCT03671096|Other|Intrastromal TCA Inlay|An intrastromal inlay that will be provided to correct the required hyperopic correction
45489324|NCT03623360|Diagnostic Test|Free breathing DCE-MRI|Free breathing DCE-MRI
45489325|NCT03628781|Other|Behavioral tools integrated within mehealth for ADHD software|Integrated functionality within the mehealth for ADHD software allows parents and teachers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.
45489326|NCT03628781|Other|mehealth for ADHD|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
45489327|NCT02717078|Other|Diet Therapy|The intervention for both study groups will be a change in diet.
45489328|NCT03371251|Drug|BOS161721|SC administration
45370321|NCT04007562|Drug|Hydroxychloroquine Sulfate|"The dosage and the route of administration of Hydroxychloroquine Sulfate was the same than in Lupus disease:~Oral administration: administered in soluble form in patients under the age of 6 years old and administered in tablets in patients other the age of 6 years old with Lipin-1 deficiency.~The soluble form was prepared at the Necker Hospital Pharmacy. Dose: 6.5 mg/kg/day (max 400 mg/day). The plasma concentration of the drug during follow-up was made, in order to follow a possible overdose."
45370322|NCT05077722|Device|Garmin|A smartwatch device that measures subjects level of activity, heartrate, respirations and quality of your sleep at night. Artificial intelligence will be applied to analyze all the data over the course of 12 weeks to monitor and attempt to predict the onset of tantrums or disruptive behavior. Subjects are required to wear the watch at least 70% of the day and night each day for 70% of days during 12 weeks of treatment.
45489329|NCT03371251|Drug|Placebo|SC administration
45489330|NCT02700230|Procedure|Computed Tomography|Undergo CT scan
45489331|NCT02700230|Other|Laboratory Biomarker Analysis|Correlative studies
45489332|NCT02700230|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given intratumorally
45489333|NCT02700230|Other|Quality-of-Life Assessment|Ancillary studies
45489334|NCT02700230|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT imaging
45692309|NCT01276054|Procedure|quality-of-life assessment|Ancillary studies
45692310|NCT01276054|Other|lymphedema management|Undergo axillary reverse mapping
45692311|NCT05580627|Other|Livestream Modality (treatment)|For this evaluation, the livestream modality is considered the treatment group.
45692312|NCT05580627|Other|Live Modality (control)|For this evaluation, the live modality is considered the control group.
45692313|NCT01798849|Drug|MK-8892|
45370323|NCT04007484|Device|Hemoperfusion|Hemoperfusion is achieved by blood filtration with a hemoperfusion device. Specifically, the hemoperfusion device composed of multiple parallel resin cartridges is connected in parallel to the oxygenator and blood reservoir and perfused at a rate of 200-250ml/min. The purpose of hemoperfusion is to decrease inflammatory mediators produced during cardiopulmonary bypass through resin cartridges adsorption, such as cytokines, free hemoglobin and other toxins. The ultimate goal of hemoperfusion is to decrease postoperative complications, improve postoperative recovery, and eventually shorten the length of hospital stay.
45370324|NCT00981864|Radiation|Concurrent Boost RT|Patient will receive radiation to the tumour bed concurrently with whole breast radiation instead of receiving this treatment sequentially, that is, whole breast RT first then followed by RT directly to the tumour bed.
45370325|NCT00985374|Drug|RAD001|5mg or 10mg po daily
45370326|NCT00985374|Drug|RG1507|16mg/kg iv every 3 weeks
45370327|NCT05072730|Device|Super High Pressure Balloon (OPN NC)|"Strategy of super high-pressure balloon angioplasty after unsuccessful lesion preparation with conventional NC balloon angioplasty.~Optical coherence tomography (OCT) imaging will be performed after lesion preparation with OPN balloon. Optional additional pre-dilatation with OPN/standard NC balloon is permitted at the operator´s discretion. Following lesion preparation, stenting will be performed in the same setting using a latest-generation everolimus-eluting stent (XIENCE; Abbott Vascular, Chicago, IL, USA). Optional post-dilatation with OPN balloon or standard NC balloon is permitted at the operator´s discretion."
45370328|NCT05072730|Device|Intravascular lithotripsy (IVL)|"Strategy of IVL after unsuccessful lesion preparation with conventional NC balloon angioplasty.~Optical coherence tomography (OCT) imaging will be performed after lesion preparation with IVL balloon. Optional additional pre-dilatation with standard NC balloon is permitted at the operator´s discretion. Following lesion preparation, stenting will be performed in the same setting using a latest-generation everolimus-eluting stent (XIENCE; Abbott Vascular, Chicago, IL, USA). Optional post-dilatation with standard NC balloon is permitted at the operator´s discretion."
45370329|NCT00975936|Drug|[14C]-GSK706769|50µg [14C]-GSK706769 containing 250 nCi
45370330|NCT00975936|Drug|Ketoconazole|200 mg Ketoconazole (Q12)
45370331|NCT00976092|Drug|Prasugrel|60 mg prasugrel as loading dose prior to PPCI
45370332|NCT00976092|Drug|Bivalirudin|IV bolus 0.75 mg/kg of body weight followed by an infusion of 1.75 mg/kg/hour during the PPCI
45370333|NCT00976092|Drug|Clopidogrel|600 mg clopidogrel as loading dose before PPCI
45370334|NCT00976092|Drug|Heparin|i.v. bolus of 70-100 IU/kg body weight
45370335|NCT00985452|Other|GlowCaps Connect system|The GlowCaps Connect system is an electronic medication reminder system, which provides reminders to help people to remember to take their medication.
45370336|NCT00985452|Other|Glow cap system - deactivated|The Glow cap system - deactivated is an electronic medication system, which will track medication adherence.
45370337|NCT00985530|Drug|Tamibarotene|Self-administered tablets BID (approximately one hour after breakfast & dinner) during each 6 week cycle
45370338|NCT00985530|Drug|Arsenic trioxide|Administered intravenously Monday thru Friday at 0.15 mg/kg - 30 doses per cycle.
45370339|NCT04006782|Device|Narrow dental implants|Insertion of narrow dental implants in multiple fixed prosthesis
45370340|NCT04006470|Drug|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
45370341|NCT04006470|Drug|Positive control dentifrice|Positive control dentifrice containing potassium nitrate or arginine.
45370342|NCT04006470|Drug|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
45370343|NCT01323712|Dietary Supplement|Vitamin D Cholecalciferol|Cholecalciferol 100,000 Units 6 doses; 0,4,8,12,24,42 weeks
45370344|NCT04911036|Other|Questionnaires|Perinatal PTSD Questionnaire State Trait Anxiety Inventory-forme Y-B Early Support Questionnaire Socio-demographic questionnaire
45370345|NCT00981942|Drug|Imatinib mesylate (Glivec)|400 mg, one tablet daily for 12 or 24 weeks
45370346|NCT03927846|Behavioral|Nurse-guided Web-based Cognitive Behavioral Therapy|nurse contact is to support and enhance participants' motivation to engage in the web-based CBT program.
45370347|NCT00982098|Procedure|BioFeedback; Functional Electrical Stimulation; Pelvic Floor Muscle training exercises|After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).
45370348|NCT03927144|Drug|AMG334|Subcutaneous Injection
45370349|NCT03927144|Drug|Oral Prophylactic|SOC Oral Tablet/Capsule
45370350|NCT00976170|Drug|GC33(RO5137382)|IV administration at 6 escalating dose levels.
45370351|NCT00976170|Drug|Sorafenib|Oral administration at 400mg twice daily or 400mg once daily
45489335|NCT03370471|Behavioral|Retrieval Practice + Moderate Intensity Exercise|Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)
45692314|NCT01798849|Drug|Placebo for MK-8892|
45489336|NCT03370471|Behavioral|Retrieval Practice + Gentle Stretching|Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)
45489337|NCT03370471|Behavioral|Study Only + Moderate Intensity Exercise|Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)
45489338|NCT03370471|Behavioral|Study Only + Gentle Stretching|Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)
45489339|NCT03709849|Drug|experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo|the same as group description including dosage, frequency and duration
45489340|NCT03709849|Drug|control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo|the same as group description including dosage, frequency and duration
45489341|NCT05343325|Drug|Tislelizumab|Tislelizumab: 200 mg D1, Q3W for two cycles. Albumin-bound paclitaxel: 100mg/m2, D1, D8, D15, Q3W for two cycles. Cisplatin: 25mg/m2, D1, D8, D15, Q3W for two cycles.
45489342|NCT05343325|Radiation|Low-dose radiotherapy|Low-dose radiotherapy: 1GY/1F, D1, D2, D8, D15, Q3W for two cycles. The total radiation dose will be GTV 8Gy/8F, GTVnd 8 Gy/8F.
45489343|NCT03709693|Device|SternaLock Blu|Sternal closure will be accomplished using SternaLock Blu plates and screws in combination with single-wire method of sternal reduction.
45489344|NCT03709615|Behavioral|Internet delivered CBT for social anxiety disorder|"An internet-based CBT for social anxiety based on a protocol from Andersson et al., 2006:~Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomized controlled trial."
45370352|NCT00982176|Other|Brain MRI and cerebral perfusion scintigraphy|"A standard neuropsychological assessment will be performed by a neuropsychologist. The daily life experience study will be performed. Questions will be asked to the patients by a pocket computer (Palm).~MRI will be performed on a 3 Tesla research MRI. Two Tc-99m-HMPAO SPECT studies will be performed The second SPECT study will be performed after intravenous injection of acetazolamide."
45489345|NCT03349645|Biological|4 mL injection of AMPION™|4 mL injection of AMPION™
45489346|NCT03678896|Behavioral|CrewD Program|The CrewD Program - Creative reading and writing in Diabetes Program - is a Diabetes self-management education and support program to help people with Diabetes coping with the disease.
45489347|NCT03678896|Behavioral|Classical structured education|The Classical educational approach consists in an educational method based on the presentation of relevant theoretical information to help people with Diabetes coping with the disease.
45489348|NCT03349333|Drug|pralatrexate|Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.
45489349|NCT03349333|Dietary Supplement|Vitamin B12 and folic acid|The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.
45489350|NCT03349099|Device|Cook Flexor|ureteral access sheath
45489351|NCT03349099|Device|Boston Scientific Navigator|ureteral access sheath
45370353|NCT00982254|Drug|Oral insulin|oral insulin capsule formulation (150 U insulin/200 mg 4-CNAB in one capsule); single dose administration of 300 U insulin (in two capsules) and of 150 U insulin (one capsule) on two separate dosing days.
45489352|NCT03707665|Diagnostic Test|Compression ultrasound testing|Compression ultrasound testing, screening technique for diagnosing deep venous thrombosis
45489353|NCT03348163|Drug|B/FTC/TAF|B/FTC/TAF is bictegravir + tenofovir alafenamide + emtricitabine in one pill (single tablet regimen)
45489354|NCT03348163|Drug|Current ART|Current ART is emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent.
45370354|NCT00982254|Drug|regular human insulin|subcutaneous injection of 15 U regular human insulin; single dose administration on one separate dosing visit.
45370355|NCT00985608|Drug|Group A: NCA 600 mg+antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
45370356|NCT00985608|Drug|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
45370357|NCT00985764|Procedure|cesarean delivery|
45489355|NCT03347695|Procedure|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure(selected patients)|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
45489356|NCT03347695|Procedure|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
45489357|NCT02892019|Drug|Indacaterol acetate 75 μg|Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
45489358|NCT02892019|Drug|Indacaterol acetate 150 μg|Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
45489359|NCT03709537|Behavioral|Mental Health Peer Workforce Support|"Supervisors and peer workers will participate in trainings covering effective peer services, trauma-informed effective peer supervision, and responsibilities of peer workers in a supervising relationship. A monthly Supervisors of Peer Workers meeting will support site change efforts. Sites will create an implementation team to work within their site to implement the training received.~Peer Workers will enroll in a peer mentoring program, where they serve as peer mentors matched with fellow peer mentors. Recovery International and the Los Angeles Department of Mental Health will encourage peer workers to attend Recovery International meetings. Emotional Health Association will refer Peer Workers and their Supervisors in the intervention group to self-help support groups that reduce stress and increase resiliency."
45489360|NCT03710629|Other|Patients with driver genes|Patients with driver genes
45489361|NCT03710551|Other|Experimental Infant Formula|Standard bovine milk-based infant formula with a new fat blend plus L. reuteri, fed ad libitum
45489362|NCT03710551|Other|Standard Infant Formula|Standard bovine milk-based infant formula, fed ad libitum
45489363|NCT03365791|Biological|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-programmed death-1 (PD-1) IgG4 antibody that blocks the binding of Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) to PD-1.
45489364|NCT03365791|Biological|LAG525|LAG525 is a high-affinity, ligand-blocking, humanized anti-LAG-3 IgG4 antibody which blocks the binding of the known LAG-3 ligand MHC class II to LAG-3.
45489365|NCT03365011|Drug|Nitrous oxide gas for inhalation|Nitrous oxide gaseous mixture (50% nitrous oxide and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
45370358|NCT00976326|Drug|insulin degludec|The dose level will be one single dose of 0.4 units per kg body weight injected s.c. (subcutaneously, under the skin)
45370359|NCT00985842|Device|Pe-Lite and sleeve suspension socket|Prosthetic socket worn by the amputee that has a Pe-lite foam liner between the socket and the residual limb. It is suspended from the residual limb using a sleeve at the top of the socket.
45370360|NCT00985842|Device|Total Surface bearing a socket with a sleeve suspension but without suction|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a sleeve at the top of the socket.
45370361|NCT00985842|Device|Total surface bearing suction socket with a pin lock suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a pin that protrudes from the bottom of the liner into the socket that is then locked in place by the amputee.
45370362|NCT00985842|Device|Total surface bearing suction socket with a sleeve suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket using vacuum suction plus a sleeve at the top of the prosthetic socket to enhance the security of the suspension.
45370363|NCT00985842|Device|Vacuum-assisted socket system (Harmony System, Otto Bock)|Prosthetic socket worn by the amputee where the a vacuum pump, in this case a mechanically-activated pump, creates a vacuum between the socket and the limb. This vacuum suspends the prosthetic limb from the amputee's residual limb.
45370364|NCT00982332|Drug|Betamethasone|betamethasone dipropionate 20 mg + betamethasone sodium phosphate 8 md as a single intramuscular injection
45370365|NCT00982332|Drug|isotonic sodium chloride solution (placebo)|4 ml intramuscular
45370366|NCT00976638|Other|Chromogenic surveillance|All admitted patients are screened on admission for MRSA and VRE by chromogenic agar and isolated when positive
45370367|NCT00976638|Other|Molecular surveillance|All patients are screened for MRSA and VRE by PCR; and for ESBL by chromogenic agar on admission. Positive patients are isolated
45370368|NCT04007328|Drug|Methylprednisolone Sodium Succinate|methylprednisolone vial
45370369|NCT04007328|Drug|Placebo|Normal saline manufactured to mimic methylprednisolone vial
45489366|NCT03365011|Drug|Placebo gas for inhalation|Placebo gaseous mixture (50% nitrogen and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
45489367|NCT03627767|Drug|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 40 weeks
45489368|NCT03627767|Drug|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 40 weeks
45489369|NCT03627767|Drug|Placebo|Placebo, administered as two tablets to be taken orally once daily for 40 weeks
45692315|NCT05580471|Device|Use 4DryField|Patients randomly use 4DryField in Colorectal resection combined with temporary stomy before fascia closure. We observed the adhesion severity and adhesion extent when stomy closure.
46053006|NCT05804773|Diagnostic Test|Non-invasive Measurement of cerebral blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) (Mean velocity, Vm, cm/s)|"Measurement of cerebral blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) (Mean velocity, Vm, cm/s) (recorded on Data Warehouse Connect).~For all patients Vm in (cm/s) will be collected during the adjustment of the mean arterial pressure level between 90% and 70% of the baseline value, without ever going below 60 mmHg for the patients at low risk and 80 mmHg for the patients at high cardiovascular risk. For neuro-injured patients with intracranial pressure monitoring (ICP), the lower limit of cerebral perfusion pressure (CPP = MAP - ICP) will be set at 50 mmHg"
45489370|NCT03732365|Combination Product|Ultrasonic Drug Delivery|A maximum dose of 2 grams cefazolin in a solution of 1 gram/100 mL sterile saline will be injected into the affected area, followed by a 3-minute application of external ultrasound delivered at an acoustic intensity equal to 3 watts/square centimeter of surface area.
45489371|NCT03732365|Drug|Standard of Care Antibiotic Treatment|Antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days.
45370370|NCT04007250|Device|FENIX™ Continence Restoration System|"The FENIX™ Continence Restoration System is indicated for use for the treatment of chronic fecal incontinence in patients who have failed or are not candidates for more conservative therapy. The FENIX™ System Implant is placed around the external anal sphincter to augment a weak anal sphincter and restore continence.~The FENIX™ System is comprised of the following components:~FENIX™ System Implant~FENIX™ System Anal Sphincter Sizing Tool The FENIX™ System Implant consists of a series of titanium beads with magnetic cores that are connected with independent titanium wires to form an annular shape. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak anal sphincter closed."
45489372|NCT03627065|Drug|Parsaclisib|Parsaclisib administered orally once daily at the protocol-defined dose.
45489373|NCT05665985|Drug|Moringa Oleifera|Intervention with Dry Extract of Moringa Oleifera (trade name is Keloreena Ⓡ , registered number in National Food and Drug Registry: 193332021) The dose given is 1000 mg bi in day for 30 days.
45489374|NCT03732287|Device|Cooling Anesthesia|Application of cooling anesthesia device prior to intravitreal injection
45489375|NCT03624881|Device|Catheter ablation with EPU|Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation
45489376|NCT05665907|Other|Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)|Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)
45489377|NCT02142738|Drug|Pembrolizumab|Pembrolizumab IV solution
45489378|NCT02142738|Drug|Paclitaxel|Paclitaxel IV solution
45489379|NCT02142738|Drug|Carboplatin|Carboplatin IV solution
45489380|NCT02142738|Drug|Pemetrexed|Pemetrexed Lyophilized Powder for Infusion
45489381|NCT02142738|Drug|Cisplatin|Cisplatin IV solution
45489382|NCT02142738|Drug|Gemcitabine|Gemcitabine Lyophilized Powder for Infusion
45489383|NCT03617861|Drug|Human Secretin|Injected once over one minute
45489384|NCT03617861|Drug|Placebo|Injected once over one minute
45489386|NCT03732053|Other|GPR Intervention Research group|The research intervention consisted in the reappointment of three GPR therapeutic postures.
45753514|NCT04199858|Other|Electroencephalography (EEG)|In the single group of participants, EEG recordings will be conducted during baseline, during a first resting-state of 5-minutes, during induction/evocation of nocebo responses, and during a second resting-state of 5-minutes.
45370371|NCT04007172|Procedure|neural therapy|Intracutaneous quaddle injections were performed using 1% lidocaine preparation as a local anesthetic for local application to painful points with palpation on the back and shoulders and for the segmental application, 2 cm lateral to the midline of the C1-T5 vertebrae and on spinous processes.
45370372|NCT04007172|Device|Physical Therapy|Physical therapy program was consist of transcutaneous electrical nerve stimulation- TENS (30-40 Hz, 20 minutes), hotpack (20 minutes) and continuous ultrasound (1mHz, 1.5w / cm2, 10 minutes) on painful points with palpation on the back and shoulders.
45370373|NCT00985920|Drug|tranexamic acid|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
45846623|NCT05665842|Other|Music Application|The Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be applied. After, the predetermined instrumental music will be shared with the adolescents every evening for 15 days via social media by the researcher and participants will be asked to listen to these music. Participants will listen to the instrumental music sent by the researcher for at least 20 minutes every evening during the music application. This whole process will be reminded to the adolescents with messages every evening and they will be asked to listen the music before the normal bedtime (before 23:00 at night). At the end of the music application (after 15 days), the Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be reapplied. In the music application, the selecting instrumental music will be used. To determine the music, the researcher will be advice received from the TÜMATA and the a music education expert.
45489387|NCT03614975|Biological|Flucelvax inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Flucelvax inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
45489388|NCT03614975|Biological|Fluzone inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Fluzone inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
45489389|NCT04832022|Other|Biological samples|Serum and plasma samples. At baseline, 3, 6 and 12 months
45489390|NCT03613649|Drug|AZD0914|Spiropyrimidinetrione antibacterial drug, which inhibits bacterial DNA synthesis by a novel mechanism. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
45489391|NCT03613649|Drug|Moxifloxacin|Broad-spectrum 8-methoxy fluoroquinolone with activity against both Gram-positive and Gram-negative bacteria, including anaerobes. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride will be administered orally with 120 mL of tap water.
45489392|NCT03613649|Other|Placebo|Composed of 4 g of the same excipients found in zoliflodacin. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of placebo is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
45489393|NCT05417334|Device|Resistive Capicitive Monopolar Radiofrequency|5 Radiofrequency sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home
45489394|NCT04652856|Device|Electrical Brain Stimulation|Electrical Brain Stimulation (EBS) will be used to disrupt local neural activity in inferior temporal regions (ITC), parahippocampal cortex (PHC), the hippocampus, and control regions. The effects of EBS will be examined on attention and eye movement behavior, and all participants will receive both EBS and sham electrical brain stimulation.
45489395|NCT04652856|Device|Sham Electrical Brain Stimulation|Sham electrical brain stimulation (SEBS) will be applied to inferior temporal regions (ITC), parahippocampal cortex (PHC), the hippocampus, and control regions. The effects of SEBS will be examined on attention and eye movement behavior, and all participants will receive both SEBS and EBS.
45489396|NCT03096288|Drug|Evolocumab|Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
45692316|NCT05580393|Diagnostic Test|RFLP analysis of SSU rRNA|"Genomic DNA will be extracted from Blastocystis-positive fecal samples using a specific DNA Stool Mini Kit according to the manufacturer's instructions and will be stored at -20°C until use.~PCR will be used to amplify a region of Blastocystis small subunit ribosomal RNA (SSU rRNA) gene.~The amplified products for the SSU rRNA gene will be digested to determine the strain subtype of Blastocystis spp. using specific restriction enzymes."
45692317|NCT04405947|Procedure|Reverse Shoulder Arthroplasty|implantation of a reversed shoulder prostheses through two different surgical approaches
45489397|NCT03096288|Other|Placebo|Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
45489398|NCT03731975|Procedure|CTZ Paste|Tooth allocated to this group will be treated with CTZ paste, according to the Cappielo's protocol (1964), updated by Moura et al. (2016).
45489399|NCT03731975|Procedure|GP Paste|Tooth allocated to this group will be treated with Guedes-Pinto paste, according to the Guedes-Pinto's protocol (1981), updated by Mello-Moura et al. (2011).
45489400|NCT05417256|Device|Tappa Endobronchial Blocker|After intubation, the Tappa bronchial blocker will be advanced either through the intubation tube or outside the tube using a fiberoptic broncoscope. Once the position of the blocker is confirmed, the cuff of the blocker will be inflated with 1-3 mL of air. Since Tappa blocker has an autoinflation system, the anaesthetist can both inflate the cuff with one hand and operate the fiberoptic broncoscope at the same time.
45692318|NCT00724594|Drug|N-acetylcysteine|NAC (100 mg/kg/dose) was given intravenously to mothers within 4 hours of diagnosis of chorioamnionitis, and every 6 hours until delivery. NAC was given to preterm (12.5 mg/kg/dose) and term infants (25 mg/kg/dose) every 12 hours for 5 doses after birth.
45489401|NCT05417256|Device|Arndt Endobronchial Blocker|After intubation, the endobronchial blocker will be passed through a multiport airway adapter that is placed at the proximal end of the tracheal tube.The fiberoptic broncoscope will be passed through the port and then through the guidewire loop at the end of the blocker. The bronchial blocker and the broncoscope will be advanced as a single unit into the target part of a right or left lung. The broncoscope will be withdrawn into the trachea and the blocker cuff will be inflated and the position of the blocker will be confirmed using the fiberoptic broncoscope. The wire loop will be removed after correct placement of the blocker. Once the guide wire is removed, the blocker can't be replaced.
45489402|NCT05665829|Procedure|Awake transnasal laser-assisted surgery (TNLS)|The experimental intervention would be awake transnasal laser-assisted surgery under local anesthesia, carried out in minor operation theater as a day-case basis in ENT ambulatory center.
45489403|NCT05665829|Procedure|Microlaryngeal surgery (MLS)|For traditional MLS under general anesthesia, laryngeal lesions are visualized and removed with under microscopic or endoscopic approach.
45489404|NCT04609956|Other|Virtual reality|Virtual reality consists of a headphones, a virtual reality headset and a smartphone.
45489405|NCT04609956|Other|Standard|Standard arm is the habitual procedure. They use hydroxyzine and music with headphones
45489406|NCT03731897|Other|5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine.|Plantar fascia will be injected to the places where it adheres to the bone.
45489407|NCT03731897|Other|9 cc salin + 1cc 2% lidocaine.|Plantar fascia will be injected to the places where it adheres to the bone.
45489408|NCT02072148|Procedure|PET/CT|PET scan or CT scan q 4 months for 5 years
45489409|NCT02072148|Radiation|Radiotherapy|Postoperative XRT 5000 cGy
45370374|NCT00985920|Drug|Placebo|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
45489410|NCT02072148|Radiation|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5000 cGy"
45489411|NCT02072148|Radiation|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5600 cGy"
45370375|NCT04780230|Device|tDCS active|An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.
45370376|NCT04780230|Device|tDCS sham|An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.
45489412|NCT01735812|Device|IceSense3 system|The IceSense3™ is a modern cryosurgical device that was designed by IceCure Medical for a variety of applications.
45489413|NCT04456608|Drug|Aspirin|Low and high n-3 PUFA participants will receive 81-mg aspirin once a day, for 6 days.
45489414|NCT05451030|Device|remote ischemic preconditioning|The cuff of a pneumatic electronic auto-control device placed around the bilateral upper limbs was used to deliver the protocol: 5 cycles of cuff inflation (200mmHg for 5 minutes) and deflation (for 5 minutes), for a total procedure time of 50 minutes, twice daily from the first DSA to the day of carotid artery stenting.
45489415|NCT03611075|Other|No Intervention|No interventions are administered in this study
45489416|NCT04450212|Genetic|Phase I, Buccal Swab Collection for DNA Isolation|Buccal swab will be taken from study participants for DNA isolation.
45370377|NCT00976794|Drug|lithium plus carbamazepine|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Carbamazepine : Starting at 200mg daily and getting 600 mg daily at the end of the first week. Dose weekly adjusted according to blood serum level (8 and 12µg/ml), efficacy and tolerability"
45489417|NCT04450212|Dietary Supplement|Phase II, Vitamin K (Vitacost) Supplementation|1-mg/day phylloquinone (Vitacost; Natures Life K-1 Phylloquinone) for 10 consecutive days. Each dose will be taken in the morning (~ 8 am), with one half pint of 2% milk to facilitate absorption. Blood and urine samples collection before and during the vitamin K supplementation period.
45489418|NCT05417022|Device|Diamondback 360TM orbital atherectomy system|Use of the Diamondback 360TM orbital atherectomy system in the preparation of calcified coronary lesions before implantation of a coronary endoprothesis
45489419|NCT05430204|Device|Group 1: one-hour GCT|Group I will be comprised of one-hour 50g glucose challenge participants for diagnosis of GDM..Diagnosis will be based on 1-hour glucose challenge test results: 1-hour result ≤ 130 mg/dL, the participant will have passed the challenge test. 1-hour result ≥ 130 mg/dL will complete a three-hour 100g glucose tolerance test. If two out of three values are elevated per Carpenter Coustan criteria , the participant will be diagnosed with GDM and treated according to the standard of care. This group will also receive the CGM.CGM data will not be observed until completion of study and will not be available to provider. Participants will return transmitter at follow up visit after completion of 7 days.Group I will receive routine prenatal care follow-up depending upon one-hour glucose results as written above.
45692319|NCT00724594|Drug|Control|Saline was given in the same volume, at the same timing as NAC infusions
45692320|NCT04143243|Behavioral|ACT on Life|1 day group workshop of ACT plus ERS
45692321|NCT04143243|Behavioral|Education, Resources, and Support|1 day group workshop of Education, Resources, and Support
45370378|NCT00976794|Drug|lithium plus valproate|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Valproic acid: Starting at 500mg daily, dose weekly adjusted according to blood serum level (50 and 125µg/ml), efficacy and tolerability."
45370379|NCT00985998|Drug|Nimotuzumab and chemotherapy|"The chemotherapy treament：docetaxel( 75mg/m2/d,every21days,for4~6cycles) and cisplatin(total dose 75mg/m2 on day 2,3,4,every21days,for4~6cycles).~the nimotuzumab treatment:3 levels (200mg/w,400mg/w,600mg/w,weekly,for12~18 weeks)."
45489420|NCT05430204|Device|Group 2: CGM placement|"CGM will consist of using the Dexcom G6 Pro device. The device will be placed on the abdomen or the arm.The Dexcom G6/G7 Pro App will be downloaded on the patient's phone. A patient profile will be created on the Dexcom Clarity portal .The patient will receive an email to link their portal to the clinic's portal.The patient will receive a message through Epic electronic medical records to remove the CGM 10 days after placement.The device will be reviewed by the Diabetes team 48 hours after CGM is removed. The recommended range for glucose during pregnancy is defined as 63-140 mg/dL .The time above range has been defined as ≥ 140 mg/dL, greater than 10% of total CGM placement time. The following criteria will currently be used to diagnose gestational diabetes in the CGM group:~Time above range (≥140 mg/dL) ≥ 10% of the time while using CGM or~Average glucose≥130 mg/dL or~Any glucose value ≥200 mg/dL"
45370380|NCT04008186|Drug|Omaveloxolone|50 mg capsules
45370381|NCT04008186|Drug|Midazolam oral solution|2 mg/mL oral solution
45489421|NCT05074290|Drug|Epidiferphane|"During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each taxane regimen (docetaxel or paclitaxel).~All subjects in the phase II portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months."
45489422|NCT05074290|Drug|Taxane Chemotherapy|All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly, nab-paclitaxel given weekly or every 3 weeks or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
45489423|NCT03095508|Drug|Angal S, topical spray [Menthol]|0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
45489424|NCT03095508|Drug|ANTI-ANGIN® FORMULA, topical metered spray|"0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as one to two consecutive presses on the actuator button, up to 6 times per day, , for a maximum 5 days or until full illness resolution"
45489425|NCT05416866|Procedure|Retrolaminar block on the operative side|After the skin near the puncture site was disinfected, 2ml of 1% lidocaine was injected into the puncture site for local infiltration. The needle was inserted beneath the ultrasound probe using an in-plane orientation to contact the lamina of the T8-T11 vertebra. Then we retracted the tip of needle to the lamina about 1 mm and withdrew to make sure that there was no blood or cerebrospinal fluid. Then, 30-40 mL mixture was injected posterior to the lamina of T8-T11.
45489426|NCT05416866|Procedure|Quadratus lumborum block on the operative side|In our study, we applied a transmuscular approach to the QLB. After the patients were placed in the lateral position, the skin near the puncture site was disinfected, a low-frequency (3-5 MHz), curvilinear probe is used and is located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. After the local infiltration for puncture site, the 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the QL muscle is confirmed, 30 ml mixture is injected into the interfascial plane.
45489427|NCT05416866|Procedure|Transversus abdominis plane block on the nonoperative side|After placing the patients in the supine position, the skin was disinfected. A linear probe was placed in the transverse plane at the midaxillary line between the lower costal margin and iliac crest. When the external oblique, internal oblique, and transversus abdominis muscles were observed, 2ml of 1% lidocaine was injected into the puncture site for local infiltration.Then, a 22-gauge, 80-mm needle was advanced using an in-plane technique in an anteromedial to posterolateral direction toward the TAP (the fascial plane between the internal oblique and transversus abdominis muscles). After the correct position of the needle tip was verified, 20 ml mixture was injected into the TAP. The ultrasound showed that the local anesthetic separated the internal oblique and transversus abdominis muscles, confirming the success of the block.
45489428|NCT03632538|Diagnostic Test|"Biomarker (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide)"|Drawing of patients blood for measurement of biomarkers for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours).
45489429|NCT05416242|Device|Traditional braces|MBT 0.022 perception traditional braces will be used without any acceleration method.
45489430|NCT05416242|Device|Self-ligating braces|MBT 0.022 perception Self-ligating braces will be used without any acceleration method.
45489431|NCT05416242|Procedure|Self-ligating braces + piezocision|Flapless corticotomy will be applied for the upper anterior teeth.
45692322|NCT04142931|Combination Product|ImmunicomAIAC|filtration through the ImmunicomAIAC followed by Nivolumab Administrated IV starting C2.
45370382|NCT04008186|Drug|Repaglinide 1 MG|1 mg tablet
45370383|NCT04008186|Drug|MetFORMIN 500 Mg Oral Tablet|500 mg tablet
45370384|NCT04008186|Drug|Rosuvastatin|10 mg tablet
45370385|NCT04008186|Drug|Digoxin tablet|0.25 mg tablet
45370386|NCT04008186|Drug|Gemfibrozil Tablets|600 mg tablet
45370387|NCT04008186|Drug|Itraconazole capsule|100 mg capsule
45370388|NCT04008186|Drug|Verapamil Pill|120 mg tablet
45370389|NCT00982566|Drug|ABT-263|Part 1: Single (oral) dose of 250 mg of Formulation B1 vs. single (oral) dose of 250 mg of Formulation A
45370390|NCT00982566|Drug|ABT-263|Part 1 continued. Single (oral) dose of 250 mg of Formulation B2 vs. single (oral) dose of 250 mg of Formulation A
45370391|NCT00982566|Drug|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
45489432|NCT05407194|Dietary Supplement|Collagen + vitamin C|Participants take the supplement (or placebo) every day for 24 weeks. On three days per week they perform tendon loading exercises.
45489433|NCT00973830|Other|Diabetes Guide and Brief Counseling|If in one of the intervention arms, patients will receive a Diabetes Guide (a patient-friendly guide to help patients make healthy changes to improve their diabetes). The Diabetes Guide includes a brief counseling component, to be conducted with clinic staff (Carve-In) or an outside diabetes educator (Carve-Out).
45489434|NCT03607487|Drug|INCB054707|INCB054707 tablet administered orally once daily at the protocol-defined dose.
45489435|NCT03607487|Drug|Placebo|Placebo tablet administered orally once daily.
45489436|NCT03731741|Drug|Pentoxifylline|a known drug of xanthine derivatives used in intermittent claudication
45489437|NCT03736187|Drug|Cephalexin|Giving cephalexin and metronidazole in one group &cephalexin alone in another group
45489438|NCT03731663|Behavioral|Exposure to pictures of appetizing food (known as Foodporn)|- Participants allocated to the experimental group will watch a 3 minute video presenting a series of pictures of appetizing foods. An audio of a young adult describing herself eating these foods during a trip to London will be played.
45489439|NCT03731663|Behavioral|Exposure to neutral pictures|Participants allocated to the control group will watch a 3 minute video presenting a series of control pictures of tourist attractions in London. An audio of a young adult describing herself visiting these sites during a trip will be played.
45489440|NCT03605693|Behavioral|Written Exposure Therapy|Written exposure therapy is a 5 session treatment in which participants write about their trauma event in a specified manner.
45370392|NCT00982566|Drug|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
45489441|NCT03736109|Genetic|Soluble and genetic biomarkers measurements|Insulin-Like Growth Factor-1 and Coll2-1 gene expression will be measured by real time PCR. In addition, syndecan 4, hyaluronic acid, substance P and nitric oxide will be measured in plasma by ELISA
45489442|NCT03605303|Device|Test/Control|Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Test/Control sequence with a 7 to 9-day washout period in between treatments
45489443|NCT03605303|Device|Control/Test|Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Control/Test sequence with a 7 to 9-day washout period in between treatments
45489444|NCT03735953|Diagnostic Test|Retroflexion in the total colon|retroflexion in the cecum or proximal ascending colon and slow withdrawal to the rectum
45489445|NCT03731507|Device|Assessment of Range of Motion with Kinect Controller|A ROM measurement method called as KinectROM by us has been developed with Kinect Controller
45489446|NCT03604523|Device|Dilation by Balloon|Esophageal dilation by balloon device.
45489447|NCT03604523|Device|Dilation by Semi-rigid Savary|Esophageal dilation by semi-rigid savary device
45489448|NCT03621059|Behavioral|habit reversal training (HRT)|"The intervention group received 4 sessions during 3months of behavior intervention and then, were reassessed at 3 and 6 months following treatment.~Pyridoxine(50mg)"
45489449|NCT03731429|Drug|Lidocaine|prior to extubation
45489450|NCT03731429|Drug|Saline Solution|Prior to extubation
45489451|NCT03735641|Procedure|Expanded Pedicled Deltopectoral Flap|Expanded Pedicled Deltopectoral Flap is a type of surgical flap
45489452|NCT03602339|Drug|Gadoterate (Dotarem/Clariscan)|Patients received a single dose of 0.5 molar gadoterate (0.1 mmol per kg body weight) intravenously.
45489453|NCT03602339|Drug|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|Patients received a single dose of 1.0 molar BAY86-4875 (0.075 mmol per kg body weight) intravenously.
45489454|NCT03735485|Other|Conventional Physiotherapy|"The conventional physiotherapy program consisted of electrotherapy and exercise approaches. The electrotherapy program consisted of infrared (for 15 minutes, from 70 cm distance), conventional Transcutaneous Electrical Nerve Stimulation (TENS) in an encircled region (for 20 minutes; with 4 electrodes, 100 Hz, 100 msec), and therapeutic Ultrasound (for 3 minutes; 1 megahertz (MHz), power: 1,5 W/cm²).~A physiotherapist supervised exercise program was performed following the electrotherapy program. Elastic resistive exercises were added at the week three. While, the first set of wand exercises and elastic resistive exercises was performed under supervision, two sets of the showed exercises were given as the home exercise program."
45489455|NCT03735485|Other|Shoulder Mobilization|In shoulder mobilization technique while the shoulder joint was placed in the traction, anterior, posterior, and inferior gliding and circumduction were applied to the humerus for 2-3 minutes. All mobilization applications were performed in painless range of motion (ROM) limits. The degree of traction and gliding were increased as the relaxing obtained in the tissues.
45489456|NCT03735485|Other|Proprioceptive Neuromuscular Facilitation|"In the Proprioceptive Neuromuscular Facilitation (PNF) program participants received PNF exercises with contract-relax technique, in the patterns of flexion-abduction-external rotation, extension-adduction-internal rotation, flexion-adduction-external rotation and extension-abduction-internal rotation along with the verbal and manual facilitation of the physiotherapist."
45489457|NCT03653429|Drug|Tranexamic Acid|administered prior to surgical incision
45489458|NCT03653429|Drug|Normal saline|administered prior to surgical incision
45489459|NCT03601715|Other|Coplanar|The coplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
45692323|NCT00724750|Device|Gauze suction (G-SUC)|Negative pressure wound therapy
45692324|NCT00724750|Device|Vacuum Assisted Closure Device (VAC)|Negative Pressure Wound Therapy
45370393|NCT00976872|Drug|omega-3|"omega-3: 2 pills of Omega950®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA"
45370394|NCT00976872|Drug|placebo|hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
45370395|NCT00977028|Drug|Tumescent Local Anesthesia (lidocaine, epinephrine)|Tumescent solution of lidocaine (up to 1 gm per liter) and epinephrine (up to 1 mg per liter)with subcutaneous infiltration of up to 45 mg per kilogram
45489460|NCT03601715|Other|Contraplanar|The contraplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
45489461|NCT03601715|Other|Longitudinal|The longitudinal arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
45489462|NCT03735407|Device|C-Scan procedure|"The subjects will be connected to the C-Scan Track and after successful system's activation. The subject will be asked to ingest the C-Scan Capsule with some water, contrast media The subject will be required to ingest daily dose (3 X 15 ml) of contrast media. Capsule procedure is completed upon capsule excretion.~o Collecting procedure related data: Technical performance in normal daily routine, Segmental transit time,Procedure duration, Number of Bowel movements , Similarity between C-Scan results and colonoscopy Etc,"
45489463|NCT03731117|Drug|Furosemide|"Furosemide (FUROSEMIDE®) 20 mg / 2ml, ampoule for injection~1 mg / kg slow intravenous injection 1.5 mg / kg if chronic exposure to diuretics in the week prior to inclusion Measurement of urine output after two and six hours. Compensation of diuresis by same volume of crystalloids over a 6-hour period"
45489464|NCT03735329|Device|Diagnostic test of SPO2|The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.
45489465|NCT03735251|Other|Diuretic，Betaloc，antiplatelet drugs|According to international guidelines,we treated patinets who suffered from different disease
45489466|NCT03735173|Procedure|ReUnion TSA, pegged design|ReUnion total shoulder arthroplasty system, pegged design
45370396|NCT00977028|Procedure|Liposuction|Subcutaneous infiltration of tumescent local anesthesia (large volumes of dilute lidocaine and epinephrine) on at least two different occasions, followed by sequential serum samples every two hours for HPLC determination of serum lidocaine concentration and peak serum lidocaine concentration, initially without subsequent liposuction and finally on the last occasion with liposuction
45370397|NCT04006938|Behavioral|Single Bout ('S')|Each subject will perform a single bout of 30-minutes of moderate-intensity cycling before breakfast
45370398|NCT04006938|Behavioral|Multiple Bout ('M')|Each subject will perform three (3) 10-minute bouts of moderate intensity cycling before breakfast, lunch and dinner
45370399|NCT00982722|Drug|cholecalciferol and calcium carbonate|cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
45370400|NCT00982722|Drug|calcium carbonate|calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
45370401|NCT00982800|Drug|Gabapentin|200mg 3x/day for 3 days (9 doses total)
45370402|NCT00982800|Drug|Placebo Sugar Pill|
45489467|NCT03735173|Procedure|ReUnion TSA, keeled design|ReUnion total shoulder arthroplasty system, keeled design
45489468|NCT05665673|Other|Physical functions test|Participants; sociodemographic and descriptive data will be recorded. The Standardized Mini-Mental Test will be used for the global cognitive assessment of participants, the Brunnstrom staging to assess lower extremity motor recovery and indicate at what motor level, and the Functional Ambulation Classification to classify them according to the basic motor skills required for functional ambulation. Gait and balance assessment will be evaluated with Tinetti Balance and Gait Assessment (POMA), functional exercise capacity will be evaluated with 6 Minute Walking Test (6MWT), and peripheral muscle strength will be evaluated with knee extension strength.
45489469|NCT03731039|Other|Observational study|Pain assessment, Anxiety assessment, Depression assessment
45489470|NCT03594227|Drug|ATI-501 400mg BID (Low dose)|ATI-501 400mg BID oral low dose for oral administration
45489471|NCT03594227|Drug|ATI-501 600mg BID (Mid dose)|ATI-501 600mg BID oral mid dose for oral administration
45489472|NCT03594227|Drug|ATI-501 800mg BID (High dose)|ATI-501 800mg BID high dose for oral administration
45489473|NCT03594227|Drug|Placebo|Placebo - oral administration
45489474|NCT03098550|Biological|Nivolumab|Specified dose on specified days
45489475|NCT03098550|Biological|Daratumumab|Specified dose on specified days
45489476|NCT05039190|Drug|HBM9161 Injection (680mg)|HBM9161 Injection
45489477|NCT05039190|Drug|Placebo|Placebo Injection
45692325|NCT04140825|Device|Resmon PRO FULL|Measurement of lung impedance by the Forced Oscillation Technique
45692326|NCT01797835|Behavioral|CHAT brief MI intervention|CHAT is one 15-20 minute session delivered in a single PC visit and utilizes motivational interviewing with youth to target alcohol and drug use in primary care.
45692327|NCT01797835|Behavioral|usual care|Youth receive a brochure with information on AOD use.
45692328|NCT03945747|Diagnostic Test|Blood draw|Participants will undergo a blood collection for hemoglobin A1c, adiponectin, total cholesterol, LDL, HDL, triglycerides, and c-peptide at baseline and follow up in 3-6 months.
45370403|NCT00986076|Drug|Enoxaparin|Enoxaparin 40 mg / 500 ml in Balanced Salt Solution
45370404|NCT00986076|Drug|Balanced Salt Solution|Intraocular infusion of Balanced Salt solution
45370405|NCT00977262|Other|High saturated fat shake|milkshake containing 95 gram of fat, high percentage of saturated fat
45489478|NCT03095118|Drug|Daratumumab|Intravenously (IV) at a dose of 16 mg/kg once weekly for 8 weeks, followed by once every 2 weeks for eight additional doses
45489479|NCT04228068|Other|Rehabilitation Program|"PT visits (two visits): The first visit will happen within a week of discharge. During this visit, the PT will assess participants, tailor the program to their needs, and coach them in carrying out the exercises at home. The last visit will be 12 weeks after the first. During this visit, the PT will reassess the participants and make adjustments to the program. The participants will be encouraged to continue exercising beyond the 12 weeks.~The PTA will visit the participants' homes with the PT and will conduct additional solo visits every other week (i.e. 7 PTA visits in total, in 1st week and at 2, 4, 6, 8, 10, and 12 weeks). The PTA will facilitate and progress the exercise program as prescribed and directed by the PT and help in delivering the education component of the program."
45370406|NCT00977262|Other|High monounsaturated fat shake|milkshake containing 95 gram of fat, high percentage of monounsaturated fat
45370407|NCT00977262|Other|High polyunsaturated fat shake|milkshake containing 95 gram of fat, high percentage polyunsaturated fat
45370408|NCT00984828|Drug|velcade|velcade 1.3mg/m2 D1, 4, 8 and 11
45370409|NCT00983034|Drug|lansoprazole, amoxicillin, clarithromycin|lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
45370410|NCT00977340|Behavioral|Imagery Rehearsal Treatment|Imagery Rehearsal Therapy
45489480|NCT04228068|Other|Pain self management|In addition to the exercise program, the intervention group will receive a pain self-management support tailored by the PT to the participants' needs.
45489481|NCT04228068|Other|Conventional care|The control group will receive the usual care provided by the healthcare system.
45489482|NCT04224480|Drug|Pembrolizumab|200mg of intravenous infusion every 3 weeks
45489483|NCT03594071|Device|The Q-Fix™ All-Suture Anchor|Observational, post-market, clinical follow-up study
45489484|NCT02696902|Drug|MEDI3902|Participants will receive a single IV dose of MEDI3902 500 mg and 1500 mg in MEDI3902 500 mg arm and MEDI3902 1500 mg arm, respectively.
45370411|NCT00977340|Behavioral|confrontation|Confrontation
45370412|NCT00977340|Behavioral|imagination|Imagination
45489485|NCT02696902|Other|Placebo|Participants will receive a single IV dose of placebo matched to MEDI3902.
46053007|NCT05804760|Diagnostic Test|Measurement of implant parameters|"Examination of the inclusion criteria~Medical history/patient-specific data (smoking, tumour diseases, radiation, gender, number of implants, history of periodontitis).~Recording of implant-specific parameters (measurement depth at six sites per implant(probing depth/PD), bleeding and or pus on probing (BOP) at six measurement sites per implant, condition of the peri-implant mucosa using the modified plaque index(mPI) and the modified ginigiva index (mGI), measurement of the width of the keratinised mucosa(KM), type of denture, approximal plaque index (API), radiographically detectable bone resorption."
45370413|NCT00977418|Behavioral|SMART- Strategic Memory and Reasoning Training|Teach people to filter out un necessary or unimportant details to enhance mental efficiency. This training will be done over 12 weeks for 3 hours each week.
45370414|NCT00977418|Other|Physical Exercise|The group with undergo 1 hour of aerobic exercise (at 50-70 % of the participants max oxygen intake) 3 times a week for 12 weeks.
45370415|NCT00983112|Drug|Human Fibrinogen and human thrombin (Evicel)|Product to be applied intraoperatively. No further administration will take place after this.
45370416|NCT00983112|Drug|Sodium Chlorure (Physiological saline)|Sterile concentration, local use.
45370417|NCT04006704|Drug|D/C/F/TAF FDC placebo|Participants will receive matching placebo tablet (whole and split) of D/C/F/TAF 675/150/200/10 mg FDC on Day 1 as intake period 1 and intake period 2.
45489486|NCT05386758|Drug|Molnupiravir|Four 200 mg capsules administered orally as a single dose
45370418|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
45370419|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|placebo per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
45489487|NCT05013216|Drug|KRAS peptide vaccine|"KRAS peptide vaccine will be administered on Prime week 1, 3, and 5. Boost vaccinations with will be administered at week 13.~Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC"
45489488|NCT03169114|Drug|Amikacin Injection|Participants allocated to Antibiotic Non-operative Management Strategy will be given intravenous Amikacin 15mg/kg/day divided over 3 doses for first 48 hours and followed by oral ciprofloxacin 500mg bd for 7 days
45489489|NCT03169114|Procedure|Appendicectomy|Patients allocated to Surgery Management Strategy will undergo appendicectomy
45489490|NCT05011422|Device|Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus|Once pheresed, the product will be washed to remove platelets and the cell concentration will be adjusted per laboratory and ClinicMACS technology recommendations. It is then labeled using the CliniMACS αβ-TCR Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product
45489491|NCT04064112|Procedure|S-BLR|Surery of slanted bilateral LR recession for CI-IXT patients
45489492|NCT04064112|Procedure|C-BLR|Surery of conventional bilateral lateral rectus recession for CI-IXT patients
45692329|NCT03945747|Diagnostic Test|Urine sample collection|Participants will undergo urine sample collection for urine microalbumin and urine creatinine at baseline and follow up in 3-6 months.
45692330|NCT03945747|Diagnostic Test|DXA scan|Participants will undergo a DXA scan for lean and fat mass measurements at baseline and follow up in 3-6 months.
45692331|NCT04581733|Drug|MT1621|All patients will receive MT1621 up to a target dose of 400 mg/kg/day each dC and dT, as tolerated.
45692332|NCT01275430|Device|Sherlock 3CG|Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
45692333|NCT01275430|Other|Blind Placement|"PICCs will be placed blindly, without the use of any tip location/positioning device."
46053008|NCT05804734|Drug|Vitamin K Antagonist - Drug|"Only clinical data (number and types of severe bleeding events, HAS-BLED score, CHA2DS2-VASc score) are collected during the follow-up:~For cases when they received an anticoagulant treatment and during the 12 months preceding this treatment,~For controls during the same periods of their cross-matched cases when reciving anticoagulant treatment."
46053009|NCT05804721|Drug|Apipe (Aripiprazole10 mg)|Test drug
45370420|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years no supervised training (maintenance of their current level of physical activity)
45370421|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|placebo per day for two years no supervised training (maintenance of their current level of physical activity)
45489493|NCT03169270|Other|Exercise training|All subjects performed a supervised 8-week, 5 days-week of endurance exercise training program in cycle-ergometer Each session included 5 minutes of warm-up and cool-down pedalling at 30% of peak work-rate (WR) and 50 minutes of interval training. The interval training combined 2 minutes of high-intensity pedalling and 3 minutes of active rest. Work-rate progress during the 8-week period was tailored on individual basis, according to subjects' symptoms, to maximize the training effect. During the first 2 weeks, high intensity pedalling interval was at least 70% of peak WR and active rest interval was at least 40% of peak WR. Thereafter, work-rate was increased by approximately 5% every week up to a maximum of 100% of peak WR during the last 2 weeks for the high intensity period and 50% of peak WR for the active rest. The cycling rate during the sessions was maintained at 60-70 rpm.
45370422|NCT00977496|Procedure|Nasal Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the anterior vestibule of both nares and processed for S aureus cultures and for bacterial DNA extraction.
45370423|NCT00983190|Device|Left Ventricular Assist Device (HeartMate II)|The HM II is a high speed, electric, axial flow, rotary blood pump. The pump drains blood from the left ventricular apex via rigid inlet cannulae and ejects into the aortic root via an outflow cannula joined to the aorta with an end to side anastamosis. Power and control of the pump are delivered through a percutaneous cable from pump to the belt-worn System Controller. The System Controller will receive power from the Power Base Unit (PBU), or two battery modules that may be worn in shoulder holsters or on the belt
45489494|NCT04602936|Drug|Solriamfetol|Solriamfetol is a novel DNRI (novel dopamine and norepinephrine reuptake inhibitor) that has recently received regulatory approval for the treatment of excessive daytime sleepiness in individuals with narcolepsy or obstructive sleep apnea.
45489495|NCT04602936|Drug|Placebo|"A placebo is a substance or treatment which is designed to have no therapeutic value (an inactive compound, i.e. inert, often called a sugar pill)."
45489496|NCT02396602|Behavioral|miPlan intervention|miPlan mobile contraceptive counseling waiting room app intervention
45489497|NCT02694562|Device|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg).
45489498|NCT02874534|Behavioral|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions.
45489499|NCT02874534|Behavioral|Mindfulness Treatment|Treatment will consist of 15 weekly 45-minute sessions.
45489500|NCT02396446|Other|Abdominal acoustic measurement|Device meant to listen to the sounds of the gut to determine post op ileus.
45489501|NCT05417178|Other|myStrength Macropersonalization Enginge|An onboarding process that utilizes the PHQ-9, GAD-7, and WHO-5 that leads to a user of the digital program's clinical focus and primary, secondary, and tertiary intervention recommendations.
45489502|NCT03115762|Biological|bevacizumab|recombinant humanized monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells
45489503|NCT03115762|Biological|ASKB1202|
45489504|NCT03168958|Drug|Methadone|Methadone will be provided at induction of anesthesia
45489505|NCT03168958|Drug|Saline|Saline will be administered at induction of anesthesia
45489506|NCT05745844|Other|activity sessions|77 activity sessions ; muscle strengthening, testing or unloading
45489507|NCT02396056|Other|BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration.
45489508|NCT02396056|Other|Modified BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration. This membrane will be perforated to allow the passage of cells and growth factors that can potentially enhanced bone augmentation.
45489509|NCT02396368|Drug|Tasquinimod|Tasquinimod is a quinoline-3-carboxamide analog that has demonstrated significant improvements in progression-free survival and overall survival in men with CRPC in a phase II trial.Tasquinimod will be administered at three dose levels (dose levels 1, 2, and -1). During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day. Dose level -1 will be 0.25mg/day without dose titration.
45692334|NCT05580237|Procedure|Simultaneous right and left heart catheterization|Pressure recordings across the aortic valve with simultaneous flow measurements by right heart catheterization, during rest and during supine exercise.
45692335|NCT04142775|Other|complication versus no complication|development of ICH
45692336|NCT01838551|Drug|Levoketoconazole|Levoketoconazole is the 2S,4R- enantiomer derived from racemic ketoconazole
46053010|NCT05804721|Drug|Abilify (Aripiprazole10 mg)|Reference drug
46053011|NCT05804695|Procedure|Arthroscopic TMJ disc repositioning under GA|a surgical procedure used to treat Tempro- mandibular disc displacement using arthroscope.
46053012|NCT05804682|Procedure|Fascial Neck Dissection|Central and lateral neck dissection with the fascial technique
46053013|NCT05804682|Procedure|Standard Neck Dissection|Central and lateral neck dissection with the standard technique
46053014|NCT05804669|Drug|CRN04894|CRN04894 is an orally active investigational agent which antagonizes the action of ACTH at its receptor administered as oral tablets.
46053015|NCT05804656|Drug|CKDB-501A|Intramuscular injection CKDB-501A
45370424|NCT00545298|Drug|Nitric Oxide - same dose 6 wks|200ppm, 8hrs / day for 6 weeks NO gas in nitrogen delivered to a patch over the wound
45692337|NCT03021369|Device|Pleural drainage system|Pleural drainage system is connected to the chest tubes after surgery.
45692338|NCT04142853|Other|Training intervention + Dance intervention|Training intervention + Dance intervention
45692339|NCT05580081|Behavioral|i-CAN|online support and consultation to providers
45692340|NCT05587413|Procedure|periodontal care|periodontal treatment
45370425|NCT00545298|Drug|Nitric Oxide modified treatment|200ppm, 8hrs/day for 1 week, followed by 25ppm 8hrs/day for 5 weeks Gas is delivered to a patch over the wound
45370426|NCT00977652|Procedure|active stimulation|percutaneous posterior tibial nerve stimulation with following parameters: frequency: 14hz; impulse duration: 210usec;intensity:sensibility threshold during 3 months
45370427|NCT00977652|Procedure|sham stimulation|Same location with the same device than active stimulation but amplitude of stimulation = 0
45370428|NCT00977730|Dietary Supplement|Protandim|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
45370429|NCT00977730|Dietary Supplement|Placebo|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
45489510|NCT02396368|Radiation|Radium 223|Radium Ra 223 dichloride, an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug. Radium 223 is supplied as a clear, colorless, isotonic, and sterile solution to be administered intravenously with pH between 6 and 8. Each milliliter of solution contains 1,000 kBq radium-223 dichloride (27 microcurie), corresponding to 0.53 ng radium-223, at the reference date. Radium is present in the solution as a free divalent cation.Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks).
45489511|NCT03632460|Drug|Dexmedetomidine Injection [Precedex]|epidural administration of dexmedetomidine added to ropivacaine
45489512|NCT02396290|Procedure|fractional carbon dioxide laser with platelet rich plasma|fractional carbon dioxide laser followed by platelet rich plasma injection
45489513|NCT02396290|Procedure|fractional carbon dioxide laser with NS|fractional carbon dioxide laser followed by normal saline injection
45489514|NCT01567956|Drug|Propionyl-L-Carnitine|500 mg modified release tablets, 500 mg bid; treatment duration 8 weeks
45489515|NCT01567956|Drug|Placebo|500 mg inert substances modified release tablets, 500 mg bid; treatment duration 8 weeks
45489516|NCT03168724|Behavioral|GMT intervention|
45489517|NCT03168646|Procedure|wafer procedure|wrist arthroscopy and debridement of Triangular fibrocartilage and shortening of the head ulna by burr
45489518|NCT03168646|Procedure|arthroscopy and ulnar shortening osteotomy|wrist arthroscopy,debride debridement of Triangular fibrocartilage and shortening of the ulna by osteotomy and plate
45489519|NCT03097614|Device|TrueTear|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
45489520|NCT05745766|Other|Panoramic and lateral cephalometric radiography|The 2D-based assessments of the impacted maxillary canine will be achieved using panoramic and lateral cephalometric radiographs.
45489521|NCT05745766|Other|Cone beam computed tomography|The 3D-based assessments of the impacted maxillary canine will be achieved using a cone beam computed tomography (CBCT) image.
46053016|NCT05804656|Drug|Botox®|Intramuscular injection Botox®
45489522|NCT05745766|Other|Surgery|The surgical exposure will be accomplished, and the impacted maxillary canine will be assessed by a direct vision.
45489523|NCT04547712|Device|Adaptive DBS|Subjects for whom both aDBS modes are acceptable will receive Dual and Single Threshold aDBS
45489524|NCT03168802|Procedure|MRgFUS ablation|Focus ultrasound ablation therapy under MRI navigation for facet joint syndrome.
45489525|NCT03168802|Procedure|Radiofrequency ablation|Radiofrequency ablation therapy under C-arm navigation for facet joint syndrome.
45489526|NCT05418660|Drug|Immunotherapy|At least 24 months with Pembrolizumab, Nivolumab or Atezolizumab in any treatment line
45489527|NCT03364309|Drug|Ixekizumab|Administered SC
45489528|NCT03364309|Drug|Placebo|Administered SC
45489529|NCT03168178|Drug|Standard Antibiotic Treatment|"Participants randomized to this intervention will receive standard antibiotic treatment.~The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes"
45489530|NCT03168178|Other|No Antibiotic Treatment|Participant randomized to this arm of the study will not receive antibiotics. The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes
45489531|NCT05166096|Drug|Rho-11|Subjects will be administered 325 mg aspirin by rapid IV push
46053017|NCT05804630|Drug|Different dental anesthetic agents during wisdom tooth surgery (Orabloc®, Octocaine®, and Xylestesin-A®)|As mentioned in arm/group descriptions. The amount of dental anesthetic agents used during the surgery will be tailored for patient according to their response, which will not exceed the recommended dosage described in the instruction of the product. The amount of the drug used during the surgery will be recorded.
46053018|NCT05804617|Procedure|Dome-type (Modified C-incision) manual morcellation|Morcellation performed by surgeon or trainee
45370430|NCT00983268|Drug|capecitabine|1000 mg taken by mouth on the days of radiation only.
45370431|NCT00983268|Drug|vorinostat|"Vorinostat will be given by mouth on the day of radiation and then Monday-Friday for two weeks after radiation in these 4 possible doses:~Vorinostat,at 100 mg~Vorinostat,at 200 mg~Vorinostat, at 300 mg~Vorinostat, at 400 mg"
45370432|NCT00983268|Radiation|Radiotherapy|High-dose hypofractionated radiotherapy consisting of 3000 cGy in 10 fractions, Monday-Friday for 2 weeks.
45489532|NCT05166096|Drug|aspirin 325mg|Subjects will be administered 325 mg aspirin orally
45489533|NCT03168490|Dietary Supplement|Gluten Friendly bread|parallel study
45489534|NCT03168412|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 7, 21 days.
45489535|NCT03168412|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
45489536|NCT05110638|Drug|SKX-16 (Luliconazole 10% Solution)|SKX-16 (Luliconazole 10% Solution) will be applied to each toenail and periungual areas once daily for 29 days such that there is sufficient quantity of solution to treat all toenails. All ten toes will be treated regardless of whether affected. The applications will occur in the clinic and be applied by study personnel. The nails will remain exposed until the applied solution dries.
45489537|NCT03700788|Drug|Chlorhexidine|2% Chorhexidine (intracranial; remains in canal until removal at next visit)
45489538|NCT03700788|Drug|Calcium Hydroxide|Calcium Hydroxide (intracranial; remains in canal until removal at next visit)
45370433|NCT00983268|Procedure|Surgery to remove tumor|Patients will be assessed for resectability within six weeks of the end of chemoradiation, if resectable, surgery will be performed.
45370434|NCT03957252|Diagnostic Test|Blood test: ClarityDX Prostate|Extracellular Vesicle profiling on patients who are suspected to have prostate cancer and will undergo a prostate biopsy. ClarityDX Prostate Risk Score will be compared with biopsy results to assess its predictive accuracy.
45370435|NCT03811236|Other|Cold exposure|Two hours of mild cold exposure using a water-perfused vest
45370436|NCT00977886|Drug|Placebo|Oral, 10 days
45692341|NCT04144413|Drug|Open-label Ikervis|NOVA22007, IKERVIS® is a sterile, ophthalmic cationic oil-in-water emulsion containing 1mg/ml CsA.
45370437|NCT00977886|Drug|ELB353|Oral, 10 days
45370438|NCT00977964|Other|Experimental milk protein infant formula Process A|ad lib for 1-8 days of age until 28 days of age
45370439|NCT00977964|Other|Experimental milk protein infant formula Process B|ad lib from 1-8 days of age until 28 days of age
45370440|NCT00977964|Other|Experimental milk protein infant formula Process C|ad lib from 1-8 days of age to 28 days of age
45370441|NCT00977964|Other|Experimental milk protein infant formula Process D|ad lib from 1-8 days of age until 28 days of age
45692342|NCT04144413|Drug|Masked Ikervis|NOVA22007, IKERVIS® is a sterile, ophthalmic cationic oil-in-water emulsion containing 1mg/ml CsA.
45692343|NCT04144413|Other|Vehicle Comparator: Masked Vehicle|Vehicle of IKERVIS® - sterile, ophthalmic cationic oil-in-water emulsion containing no active substance.
45846624|NCT05665842|Other|Sleep Hygiene Training|"After explaining the purpose of the study and the way it was applied to the adolescents in the music practice group, the Introductory Characteristics Form for Adolescents, the Pediatric Quality of Life Inventory (PedsQL) and Adolescent Insomnia Questionary (AIQ) will be applied.~Adolescents in this group will be trained on Zoom for 4 weeks, 2 times a week, for 8 sessions (1 session 40 min). Sleep hygiene training prepared based on expert opinions and literature (Halal & Nunes, 2014; Dinis & Bragança, 2018; İşsever et al., 2021) will be given by the researcher. A Sleep Hygiene Training Booklet will be prepared for use in education and to give to adolescents after education.The Sleep Hygiene training booklet to be prepared will be prepared by the researcher and submitted for expert opinions. Adolescents who received sleep hygiene training will be reapply 15 days after the training, with the PedsQL and AIQ."
45846625|NCT05629416|Behavioral|Interventions to transform the culture of healthcare systems to achieve excellence in providing culturally safe care for First Nations peoples|"Implement 'Ask the Specialist Plus', a structured program to promote anti-racism within Northern Territory (NT) hospitals by giving healthcare providers training in cultural safety.~Implement strategies to foster 'Clinical champions of cultural safety' through a social media chat platform and face to face meetings to discuss anti-racism practice, cultural safety and practical ways to deliver culturally safe care including interpreter use.~Support simplified and improved strategies for booking an interpreter to increase uptake.~Implement retention strategies to ensure interpreters receive workplace support.~Provide training in health terminology for interpreters.~Integrate interpreter supply and demand through efficiency and effectiveness strategies tailored to participating sites.~Implement continuous quality improvement cycles with senior managers, using findings from qualitative and quantitative data collection and evaluation."
45370442|NCT00977964|Other|Experimental milk protein infant formula Process E|ad lib from 1-8 days of age until 28 days of age
45370443|NCT00977964|Other|Experimental milk protein infant formula Process F|ad lib from 1-8 days of age until 28 days of age
45489539|NCT02395900|Dietary Supplement|Flaxseed|
45692344|NCT04143477|Drug|peficitinib|Oral
45692345|NCT04142463|Other|Care pathway|A care pathway is a complex intervention for the mutual decision-making and organisation of care processes for a well-defined group of patients during a well-defined period. Care pathways can be used to optimise care processes when problems arise on communication, coordination, standardisation and monitoring of care for a specific group of patients. A care pathway for patients treated with OACD, should therefore consist of all relevant sustainable interventions that cover the continuum of the medicines' pathway with the aim to support self-management (e.g. consultations with doctors, contact moments with nurses, telephone follow-up, ...). The role of each stakeholder in the different interventions should be well-described including communication strategies between HCPs from primary and secondary care.
45370444|NCT00983424|Drug|Cyclosporins|dose escalation, administered orally twice a day
45370445|NCT00983424|Drug|nab-paclitaxel|100 mg/m2 IV days 1, 8 and 15
45370446|NCT00978198|Drug|ASP1517|oral
45370447|NCT00978198|Drug|Placebo|oral
45370448|NCT00983658|Drug|huMAb OX40L|Intravenous repeating dose
45370449|NCT00983658|Drug|placebo|Intravenous repeating dose
45489540|NCT02395900|Other|control|
45692346|NCT04144803|Diagnostic Test|Cerebral near-infrared spectroscopy|Nonin H500 one-channel near-infrared spectroscopy monitor on forehead of the patient from before induction of anesthesia to arrival to hospital
45370450|NCT00983736|Drug|Tramadol Hydrochloride|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
45370451|NCT00983736|Drug|Placebo|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
45370452|NCT00983970|Behavioral|Interactive video game cycling|"Participants were required to exercise on a Gamebike® (Cat Eye Electronics Ltd, Boulder Col.) interactive video gaming system that was interfaced with a Sony Play Station 2® (Sony computer Entertainment America Inc. Foster, City, CA) and a 42 flat screen television monitor. The Gamebike® has a handlebar mounted game controller allowing the participant to play most Sony Playstation 2- race-based video games. The Gamebike® reads the participant's speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were told that they could exercise at any intensity and duration they desired. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks. Although participants were required to stay in the lab for 60 minutes, they could take breaks or stop when they wanted, and reading materials were available for those who did not or could not cycle for the full 60 minute session."
45370453|NCT00983970|Behavioral|Cycling to Music|Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device. We incorporated music into the control condition because most youth and young adults exercise to music and this provides a more stringent test of the Gamebike® while improving the ecological validity of the research design. We also wanted to minimize drop-out and felt that expecting overweight/obese adolescents, who often report disliking aerobic exercise, to bike in a lab with no form of distraction would create a less than desirable exercise environment and result in high drop-out rates.
45370454|NCT00986700|Dietary Supplement|late night meal|Three different kinds of late night meal each for 2 days.
45370455|NCT00986778|Drug|Lamivudine|Tablets, Oral, 100mg, once daily, 48-96 weeks depending on response
45370456|NCT00986778|Drug|Entecavir|Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response
45370457|NCT00986778|Drug|Adefovir|Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response
45370458|NCT00429364|Drug|Losartan Potassium|Losartan .3 - 1.4 mg/kg
45370459|NCT00429364|Drug|Atenolol|Atenolol .5 - 4 mg/kg
45370460|NCT04758468|Behavioral|Telerehabilitation-based pelvic floor muscle training|"Telerehabilitation-based pelvic floor muscle training group will individually receive telerehabilitation-based pelvic floor muscle training under the guidance of a physiotherapist 2 sessions per week for 8 weeks. Participants will do their exercises themselves 2 times on the days where sessions are held with a physiotherapist. Participants will continue to exercise 3 times a day in the remaining days.~Both intervention groups will follow the same pelvic floor muscle training protocol for 8 weeks."
45370461|NCT04758468|Behavioral|Home-based pelvic floor muscle training|"The home-based pelvic floor muscle training group will do their individual exercises 3 times a day for 8 weeks.~Both intervention groups will follow the same pelvic floor muscle training protocol for 8 weeks."
45370462|NCT04008342|Other|Multisensory intervention|The intervention group (IG) was submitted to 16 individual multisensory stimulation sessions that followed the protocol. In each session, at least two senses are stimulated in a safe, quiet and confidential environment. The sessions lasted 30 minutes and were conducted twice a week, on the same day and time whenever possible. Nonetheless, the session could be interrupted when the participant wished or if the therapist observed that the patient was uncomfortable. A nondirective approach and one-to-one intervention were adopted.
45370463|NCT00984048|Other|Needle core biopsies of liver metastasis|No investigational products will be administered to subjects as part of this translational research study. A first-line chemotherapy regimen consisting of FOLFOX, XELOX or FOLFIRI +/- bevacizumab will be administered as per the standard of care at each treating institution. Needle core biopsies of liver metastasis will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn monthly and stored in the tissue biobank.
45489541|NCT03167398|Biological|Fecal Microbiota Transplantation|Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
45489542|NCT03334903|Drug|Gabapentin|600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.
45489543|NCT03167008|Diagnostic Test|semen sample|-Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
45489544|NCT03167008|Diagnostic Test|blood sample|blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured
45489545|NCT03679026|Other|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages|Participants' baseline characteristics will be summarized using means and standard deviations or frequencies and percentages, as appropriate.
45489546|NCT05414851|Other|Whole-Food, Plant-Based Diet and Low-Carbohydrate Diet|Participants will consume two weeks of each diet, with a 4-6 week washout period in between. Meals and snacks are provided for convenience to enhance adherence to each dietary pattern, but subjects can add or include their own home-prepared foods as long as they meet dietary guidelines. Each dietary intervention will include an education session via Zoom teleconference, and at least 2 individual contacts by phone to address questions and assess for adverse events.
45489547|NCT03168100|Drug|Elotuzumab|administered via IV infusion
45489548|NCT03168100|Drug|Lenalidomide|taken by mouth
45489549|NCT03168100|Drug|Dexamethasone|taken by mouth
45489550|NCT03168100|Drug|Bortezomib|administered as a subcutaneous injection
45489551|NCT03709381|Drug|Low Dose Cosyntropin (ACTH) stimulation test|Cosyntropin 1 mcg IV given to subjects at t=0
45692347|NCT05586009|Drug|cisplatin with hydration magnesium|Optimal doses of magnesium in prevention cisplatin induced nephrotoxicity
45692348|NCT03020979|Drug|Apatinib|Patients will take 500mg apatinib daily orally.
45370464|NCT00978354|Drug|Furosemide|Continuous intravenous infusion of furosemide titrated to urine output
45370465|NCT00978354|Drug|Normal Saline|Continuous intravenous infusion 0.9% normal saline placebo control
45489552|NCT03709381|Drug|High Dose Cosyntropin (ACTH) stimulation test|Cosyntropin 250 mcg IV given to subjects at t=60
45692349|NCT04142151|Drug|Sanchitongshu|SanchiTongshu capsule produced by Chengdu Huashen Group Co., Ltd.
45692350|NCT04142151|Drug|Aspirin|Aspirin produced by Bayer Co., Ltd.
45370466|NCT00987012|Dietary Supplement|Pomegranate juice|Twice daily ingestion of pomegranate juice over 4-5 days
45370467|NCT00987012|Dietary Supplement|Placebo drink|Twice daily ingestion of placebo drink over 4-5 days
45370468|NCT00984360|Drug|Naltrexone|380mg extended-release, given once by intramuscular gluteal injection
45370469|NCT03808350|Procedure|Families Invited to Be Present at Procedures|Family members will be invited (but not required) to remain in the ICU room during procedures, if patients agree
45370470|NCT03808350|Other|Placebo/Control|Family members will not be invited to remain in the ICU room
45370471|NCT00414388|Drug|Sorafenib|400mg twice daily
45370472|NCT00978588|Drug|6% hydroxyethyl starch 130/0.4 and 5% albumin|Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass
45370473|NCT01037608|Drug|Sativex(Registered Trademark)|
46053019|NCT05804604|Procedure|Surgical treatment of proximal femur fracture and blood sample test|Open reduction of femoral neck or pertrochanteric fracture with hemi/total hip arthroplasty or gamma nail. Analysis of serum concentration of: SHBG, CTX - I, CK-MB
46053020|NCT05804604|Procedure|Blood sample test|Analysis of serum concentration of: SHBG, CTX - I, CK-MB
45370474|NCT01037608|Drug|THC|
45370475|NCT04006080|Biological|Vedolizumab|Intravenously administered selective leukocyte adhesion molecule inhibitor
45370476|NCT00984438|Drug|BCNU Wafer|Implantable during surgical resection into the tumor bed
45370477|NCT00984438|Drug|Irinotecan|IV every 2 weeks for up to one year
45489553|NCT04970082|Diagnostic Test|FFR DWP|FFR will be measured twice in the same lesion : One with the standard method and the other with the DWP method.
45489554|NCT04970082|Diagnostic Test|FFR|FFR will be measured twice in the same lesion : One with the standard method and the other with the DWP method.
45489555|NCT01353664|Drug|Romidepsin|The participants will generally continue at the same dose, infusion time and frequency used for the last dose of romidepsin given in the preceding romidepsin study. If the participant entered this rollover study in the middle of a cycle, then the cycle number and cycle day will be carried over from the preceding romidepsin study.
45692351|NCT04142151|Drug|Clopidogrel|Clopidogrel produced by Shenzhen Salubris Co., Ltd.
45692352|NCT04142151|Drug|placebo of Sanchitongshu|SanchiTongshu palcebo capsule contained dark brown muscovada sugar and the same inactive excipient (starch). Produced by Chengdu Huashen Group Co., Ltd.
45692353|NCT02985099|Drug|SRP plus Rosuvastatin gel|SRP followed by 1.2% Rosuvastatin placement into intrabony defect
45692354|NCT02985099|Drug|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
45370478|NCT00984438|Drug|Bevacizumab|IV every 2 weeks for up to one year
45370479|NCT01037686|Radiation|Injection of 15mCi of Tc-ECD and scanning by SPECT camera|All subjects (PD patients with or without DBS and healthy controls) will be injected with 15mCi of Tc-ECD and afterwards will be scanned by an Irix SPECT camera.
45370480|NCT01037686|Behavioral|Semantic verbal fluency task performance|All Subjects (PD patients with or without DBS and healthy controls) before one of the two scans will perform the semantic verbal fluency task during the Tc-ECD uptake for 9 minutes. Before the other scan subjects will be at rest.
45370481|NCT01037686|Device|Turning off the stimulator|For PD patients treated with DBS, the neurologist will turn off the stimulator after the injection of Tc-ECD for ten minutes and then turn it back on.
45370482|NCT03920280|Device|LID015385 contact lenses|Investigational silicone hydrogel contact lenses
45370483|NCT03920280|Device|Comfilcon A soft contact lenses|Commercially available silicone hydrogel contact lenses
46053021|NCT05804591|Drug|Pregabalin 150mg|Single dose of pregabalin 150mg in a capsule per os 1 hour before start of the operation.
46053022|NCT05804591|Drug|Placebo|1 capsule containing placebo per os 1 hour before start of the operation.
46053023|NCT05804565|Procedure|Bone Saw|The surgeon will use an oscillating microsaw to transect the metatarsal shaft
45370484|NCT03920280|Device|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting system
45370485|NCT00424372|Drug|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
45370486|NCT00987090|Biological|Clinic and neuropsychologic evaluation|evaluation at the inclusion and 18 months after
45370487|NCT00987090|Radiation|MRI|intervention at the inclusion and 18 months after
45489556|NCT04952766|Biological|Biological samples|"Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.~Biological samples :~Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests~Nasopharyngeal samples (not mandatory)~Associated data :~Demographic data~Description of clinical manifestations related to vaccination~Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning~Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)"
45489557|NCT02395744|Other|Paclitaxel administration using the OPC|
45489558|NCT02400502|Behavioral|I-CAT Therapy|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life). Participants meet weekly with a master's level clinician over the course of 20 weeks.
45489559|NCT02400268|Other|7 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
45489560|NCT02400268|Other|14 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
45489561|NCT02400424|Radiation|SBRT|54 Gy in 3 fractions D1-D3-D5. SBRT should be started within 3 to 4 weeks after the end of radiochemotheray (RT-CT).
45489562|NCT03168568|Drug|Valsartan/Sacubitril or placebo|tablet (double dummy)
45489563|NCT03168568|Drug|Valsartan or placebo|tablet (double dummy)
45489564|NCT05745610|Drug|Shen Hai Long Capsule|3 times/day (9 capsules/day) for 12 weeks
45489565|NCT05745610|Drug|Sheng Jing Capsule|3 times/day (12 capsules/day) for 12 weeks
45489566|NCT02395588|Other|Guideline based care|Patient education using guideline based teaching guides
45489567|NCT02395354|Device|Placing a self-expanding metallic stent|"Income on short stay unit (SSU) post-procedure~Light sedation by the endoscopist vs anesthetist by center~Fully covered self-expanding metal stents Tae Woong Medical® type; prosthesis size at the endoscopist discretion~Clips can be placed at the distal end of the prosthesis according to the endoscopist.~Prosthesis removal time in 4 weeks."
45489568|NCT02395354|Device|A balloon dilatation|"Income on short stay unit (SSU) post-procedure~Light sedation by the endoscopist vs anesthetist by center.~Pneumatic ball type CRE Boston cientific®; balloon diameter at the endoscopist discretion~Up to 2 expansion will be made with a minimum interval between 15-30 days between each expansion~It shall be deemed failure to expansion if required> 2 expansions."
45489569|NCT02400112|Drug|Vancomycin|Vancomycin powder administered locally, intraoperatively at site of open fracture
45489570|NCT02694328|Drug|ALKS 3831|Daily dosing
45489571|NCT02694328|Drug|Olanzapine|Daily dosing
45489572|NCT04480996|Drug|Drugs Responsible for Cognitive Side Effects|identification of road traffic accidents associated with drugs responsible for psychomotor side effects
45489573|NCT02399878|Drug|Inspiratory oxygen|
45489574|NCT02395276|Device|Whole body hypothermia|Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
45489575|NCT02395510|Drug|Vortioxetine|Vortioxetine 5-20mg
45370488|NCT00987090|Procedure|PET|18-FDG (18-fluoro-2-deoxyglucose)PET imaging of the brain at the inclusion and 18 months after.
45489576|NCT05745532|Biological|β-globin restored autologous hematopoietic stem cells|β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q
45489577|NCT05745454|Biological|HER2-E-CART cells|E-CAR-T is a novel second-generation CAR-T product targeting HER2 protein
45370489|NCT00987090|Biological|Apolipoprotein E genotyping|genotyping at the inclusion
45370490|NCT00987090|Biological|Study of cerebrospinal fluid|intervention at the inclusion
45370491|NCT04006236|Other|Experimental Infant Formula|Feed Ad Libitum
45370492|NCT04006236|Other|Control Infant Formula|Feed Ad Libitum
45370493|NCT04676178|Drug|PRA023|PRA023
45370494|NCT04676178|Other|Placebo|Placebo
45370495|NCT00988104|Behavioral|Cognitive Behavioral Therapy|CBT (4 sessions): 1) Cognitive therapy targeting key appraisals. 2) Prolonged exposure targeting trauma memories and reminders. 3) Active coping/Anxiety Management training mindfulness-based techniques.
45489578|NCT02395432|Device|orotracheal intubation|
45489579|NCT02394886|Biological|ALLO-ASC-DFU|
45489580|NCT02400034|Other|Voiding trial|1 of 2 tests to assess bladder function after midurethral sling surgery with and without anterior or posterior colporrhaphy
45489581|NCT02399956|Other|Survey|Those who agree to participate will complete a cross-sectional survey on lactation outcomes (LACOUT). Eligible participants who consent to our study will complete the LACOUT questionnaire. The questionnaire uses the same breastfeeding measures as the CDC's Project First surveys and adds 21 items that are specific to the participant's cancer treatment and current health status.
45489582|NCT02399800|Procedure|Celiac Block with triamcinolone and bupivicaine|Endosonography of the pancreas performed following by analgesic injection
45846626|NCT05627388|Other|Dreem 3 System At-Home Monitoring|Patients will be asked to wear the Dreem 3 System and actigraphy devices at home. Research support staff will teach patients how set up the device beforehand. Patients will wear Dreem and actigraph for 5 nights, while keeping the actigraph on during the day, to monitor sleep/wake cycle. Then, for an additional continuous 48hr measurement, patients will wear the Dreem and actigraph. The patient will be given 2 devices, as one device can record up to 24h of data continuously. Patients are not required to stay home during the 48hr testing period. However, patients will be instructed to refrain from participating in activities which may shift or require removal of Dreem. Patients who wish to remain home for the 48hr testing period should have adequate sustenance (i.e., groceries). Any caffeine and sleep medication intake will be logged by the patient in a sleep diary. If needed, patients will be given an off work order from work/school for the 48hr assessment.
45370496|NCT00988104|Behavioral|Supportive Counseling|Supportive counseling (4 sessions): common factors among effective psychotherapies (e.g., empathy, positive regard)
45846627|NCT05600088|Device|CryoTherapy System (CTS)|local cryotherapy of coronary high-risk plaque lesions using the CTS consisting of a semi-compliant balloon and a console controlling the temperature of cryotherapy
45370497|NCT00978900|Dietary Supplement|Artificial sweeteners; Carbohydrate Sugars|sweetening agent dissolved in tap water, administered via intragastric tube
45370498|NCT00978900|Dietary Supplement|Water|
45370499|NCT00988182|Other|dietary intervention|whey protein
45370500|NCT00988182|Other|water control|
45370501|NCT00987168|Drug|Sandostatine LP|Intramuscular injection of Sandostatine LP, once per month Dosage : 10 mg, 20 mg, 30 mg
45370502|NCT00978978|Drug|Propofol VS. midazolam and fentanyl, endoscopies, liver diseases|"Intervention group (Propofol): It will be administered as a monotherapy under direct gastroenterologists'~Control group (Midazolam with or without Fentanyl): Both drugs will be administered by the gastroenterologists"
45370503|NCT00414310|Drug|Decitabine|20 mg/m^2 IV over 1 hour daily for 5 days.
45489583|NCT02399800|Procedure|No Celiac Block|EUS but no celiac block performed
45489584|NCT02399800|Drug|Intra Plexus Triamcinolone and Bupivicaine Injection|Injection of Triamcinolone and Bupivicaine into celiac plexus for pain relief
45489585|NCT02399566|Drug|Erlotinib, Pemetrexed|followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy.
45370504|NCT00414310|Drug|Valproic Acid|50 mg/kg orally daily for 7 days
45370505|NCT00542880|Drug|Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg|
45370506|NCT00542880|Drug|Seretide Diskus (salmeterol/fluticasone) 50/500 μg|
45370507|NCT03726294|Drug|NBM-BMX softgel capsules|Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
45370508|NCT00414076|Drug|Letrozole|2.5 mg Tablet By Mouth Daily for 12 Weeks.
45370509|NCT00987246|Drug|Placebo Gel|Topical
45370510|NCT00987246|Drug|LAS41005|Topical
45370511|NCT00987246|Drug|LAS106521|Topical
45489586|NCT02399644|Behavioral|ACT|ACT is a type of Cognitive behavioral Therapy (CBT) that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
45846628|NCT05555082|Other|Massage|10 times of 30 minutes Swedish classical Massage will be given monthly during one year. The massage will be give by a cerified masseur
45370512|NCT01424098|Behavioral|Balance training program|Training will consist of 30 minute sessions 3 times/week for 6 weeks in keeping with best practice guidelines for older adults. Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
45370513|NCT01033318|Drug|MK1809|single oral doses of MK1809
45370514|NCT01033318|Drug|Comparator: Losartan|single oral doses of 100 mg Losartan
45370515|NCT01033318|Drug|Comparator: Placebo|Placebo to MK1809
45370516|NCT04006158|Device|LED bed|Low risk FDA cleared full body LED bed
45370517|NCT00988338|Biological|Trinity Evolution|Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem and Osteoprogenitor Cells
45370518|NCT01033396|Drug|PF-03654764|PF-03654764 single dose 5 mg
45370519|NCT01033396|Drug|Allegra|Fexofenadine single dose 60 mg
45370520|NCT01033396|Drug|PF-03654764|PF-03654764 single dose 5 mg
45370521|NCT01033396|Drug|Allegra-D|Fexofenadine 60 mg combined with pseudoephedrine 120 mg single dose
45370522|NCT01033396|Drug|Placebo|Placebo single dose
45370523|NCT00988416|Procedure|PET-CT|Pancreas Protocol PET-CT
45370524|NCT00979056|Drug|Rifaximin|400 mg per day, oral use, maximum duration 28 days
45370525|NCT00979056|Drug|Lactose|Coated Tablet, Oral Use
45370526|NCT04006314|Other|Autologous platelet rich plasma and dextrose solution.|"Autologous platelet rich plasma are injected into the knee joint and pes anserinus complex.~Dextrose solutions are injected to the genicular nerves."
45370527|NCT00987324|Device|Taxus stent|Implantation of paclitaxel-eluting stent
45370528|NCT00987324|Device|SeQuent Please|Dilation with SeQuent Please (paclitaxel-eluting balloon)
45370529|NCT00987324|Device|Conventional Balloon Catheter|Ryuijin, Trek
45692355|NCT04142229|Device|iAPS|The AID system (iAPS) is comprised of an insulin pump, a Dexcom G6 continuous glucose monitoring sensor, and a smart phone that contains the algorithm and communicates with the other devices.
45692356|NCT04142229|Other|Sensor-Augmented Pump|Subjects will use their home insulin pump and a Dexcom G6 continuous glucose monitoring sensor.
45692357|NCT04149951|Device|Vestal Device|Vestibular nerve stimulator
45370530|NCT00092677|Drug|ezetimibe (+) simvastatin|Duration of Treatment: 4 years
45370531|NCT00092677|Drug|Comparator: Placebo|matching Placebo
45370532|NCT00988572|Other|Vestibular rehabilitation|The intervention program comprises of vestibular rehabilitation, at group sessions, twice a week for 9 weeks. The program is described in detail in table 1. Vestibular rehabilitation aims to facilitate rearrangement and recruitment of the control capacities of the vestibular system, by letting the patient be exposed to unstable body positions, such as standing on foam and performing head, trunk or eye-movements.
45370533|NCT00979368|Drug|BMS-816336|Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days
45370534|NCT00979368|Drug|BMS-816336|Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days
45370535|NCT00979368|Drug|BMS-816336|Suspension, Oral, 180 mg Active, Once on Day 1 only, 4 days
45370536|NCT00979368|Drug|BMS-816336|Suspension, Oral, 450 mg Active, Once on Day 1 only, 4 days
45370537|NCT00979368|Drug|BMS-816336|Suspension, Oral, 900 mg Active, Once on Day 1 only, 4 days
45370538|NCT00979368|Drug|Placebo|Suspension, Oral, 0 mg, Once on Day 1 only, 4 days
45692358|NCT04149951|Device|Placebo device|Sham nerve stimulator
45692359|NCT04149873|Procedure|MIE|MIE
45692360|NCT05583591|Device|Combined cataract surgery with Hydrus microstent|Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.
45370539|NCT04651920|Genetic|Evaluation of homologous recombination deficiency score|Evaluation of homologous recombination deficiency score which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST)
45370540|NCT00542178|Drug|Hypoglycemic Agents|Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%
45370541|NCT00542178|Drug|Standard glycemia control|A strategy of glycemia drugs for HbA1c 7% - 7.9%
45370542|NCT00542178|Drug|Intensive BP treatment|A strategy of multiple BP agents to reduce SBP less than 120 mm Hg
45370543|NCT00542178|Drug|Standard BP control|A strategy of BP drugs for SBP less than 140 mm Hg
45370544|NCT00542178|Drug|Fenofibrate|Blinded fenofibrate
45846629|NCT05541120|Device|Remote Patient Monitoring|Remote patient monitoring as the intervention is defined as a tablet and Bluetooth-enabled glucometer technology that collects point-of-care (POC) blood glucose data from a patient outside of a traditional clinical setting, and securely transmits this data to Epic for review and potential intervention.
45370545|NCT00542178|Drug|Simvastatin|Simvastatin 20-40 mg/d
45846630|NCT05518656|Behavioral|Experimental intervention|Daily lessons received by email to be completed the same day
45370546|NCT00542178|Drug|Placebo|Placebo
45370547|NCT00987636|Drug|Zoledronic acid|"intravenously at 28 day intervals beginning with cycle 6 of VAC/VAI consolidation chemotherapy for a total period of nine months.~Patients < 18 years will receive 0.05 mg/kg BW by IV infusion 30 min-1 h.~Patients >= 18 years will receive a bodyweight-dependent dose:~Patients >40kg receive 4 mg by IV infusion 30 min-1h Patients 20-40 kg receive 2 mg by IV infusion 30 min-1h"
45846631|NCT05518656|Behavioral|Comparison intervention|Daily lessons receive by email to be completed the same day
45846632|NCT05515458|Drug|Chiglitazar|Oral single dose 48 mg
45846633|NCT05466552|Procedure|PCI procedure|During the PCI procedure, use of ECMO/Impella 5.0 is allowed hemodynamic instability (bail- out).
45370548|NCT00987636|Drug|Busulfan|intravenously, day -6 to d -3 adults: 0.8 mg/kg body weight (BW) children and adolescents: <9 kg= 1mg/kg BW 9 - <16 kg= 1.2 mg/kg BW 16 - 23 kg= 1.1 mg/kg BW >23 - 34 kg= 0.95 mg/kg BW >34 kg = 0.8 mg/kg BW
45370549|NCT00987636|Drug|Treosulfan|12 g/m² d-5 to d-3
45370550|NCT00424294|Drug|CP-195,543|CP-195543 is a potent and specific antagonist of the leukotriene B4 (LTB4) receptor.
45370551|NCT00424294|Drug|celecoxib|Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States [US] as Celeberex) and approved for the relief of signs and symptoms of osteoarthritis.
45370552|NCT00424294|Drug|Methotrexate|Methotrexate is a folate analogue that, based on it efficacy and safety in RA, is commonly used as frontline DMARD treatment in patients with moderate to severe disease who do not respond to NSAIDs alone.
45370553|NCT00979446|Behavioral|Guided|Engaged in a 4 month pilot of a multi-domain lifestyle intervention with a phone coach
45370554|NCT00979446|Behavioral|Self-directed|Received study materials but no phone coaching
45370555|NCT00988650|Other|isocaloric diet|
45370556|NCT00988650|Other|free living conditions|
45846634|NCT05460702|Diagnostic Test|Soluble immune checkpoints|Blood collection from breast cancer patients with stage I-II
45846635|NCT05446272|Device|NIV-NAVA|Infants in the intervention arm will be managed with non-invasive neurally adjusted ventilatory assist (NIV-NAVA) using FDA-approved servos with associated FDA-approved Edi catheter.
45846636|NCT05446272|Device|NS-NIPPV|Infants in the active comparator arm will be treated with non-synchronized non-invasive positive pressure ventilation (NIPPV) through FDA-approved ventilators currently in use at each site.
45846637|NCT05419674|Drug|Vonoprazan|Potassium-competitive acid blocker
45846638|NCT05419674|Drug|Rabeprazole|Proton pump inhibitor
45846639|NCT05419674|Drug|Amoxicillin|Antibiotic for H. pylori eradication
45846640|NCT05419674|Drug|Clarithromycin|Antibiotic for H. pylori eradication
45370557|NCT00988728|Drug|SCH 900435 (Org 25935)|"Oral tablets, containing 8 mg of active substance, two tablets (i.e. 16 mg) to be taken twice daily in the morning after breakfast and in the evening after dinner during 4 weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with SCH 900435 plus 1 capsule with placebo per day)."
45370558|NCT00988728|Drug|Placebo|"Oral capsules and tablets containing excipients only.~Because of the double-dummy design, subjects will be administered one capsule in the evening, plus two tablets in the morning after breakfast and two tablets after dinner."
45370559|NCT00988728|Drug|Olanzapine|"Oral capsules containing 15 mg of active substance, one capsule to be taken once daily after dinner for four weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with placebo plus 1 capsule with olanzapine per day)."
45370560|NCT00988806|Drug|Levosimendan|"Patients included in the intervention group receive optimal drug therapy for heart failure symptoms and also infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment."
45370561|NCT00988806|Drug|Placebo|"Patients included in the placebo group receive optimal drug therapy for heart failure and also infusion of placebo at the same infusion rate as levosimendan doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment."
45846641|NCT05419674|Drug|Colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
45846642|NCT05409300|Biological|BBIBP-CorV|Inactivated COVID19 vaccine, adjuvanted with aluminum hydroxide
45846643|NCT05386524|Drug|sintilimab|sintilimab 200mg, ivgtt，d1
45846644|NCT05386524|Drug|bevacizumab biosimilar|bevacizumab biosimilar 15mg/kg，ivgtt d1
45370562|NCT04005768|Drug|Hydroxychloroquine Sulphate|After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
45370563|NCT04005768|Drug|Placebo|After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
45370564|NCT00987714|Procedure|Protocolized care|Organ Procurement Coordinators will utilize a hemodynamic monitor and algorithm for donor management of cardiac index, pulse pressure variation and mean arterial pressure.
45692361|NCT05583591|Device|Combined cataract surgery with iStent Inject W|Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.
45370565|NCT00987792|Drug|Moxifloxacin (Avelox, BAY12-8039)|Hospitalized patients receiving Avelox according to local drug information
45370566|NCT04459260|Behavioral|Cognitive Behavior Therapy|"A standardized evidence-based treatment manual based on cognitive behavior therapy, developed specifically for targeting perfectionism (Egan et al., 2016). Includes the following components: 1) providing psychoeducation about perfectionism and creating an individualized conceptualization 2) broadening the domains for self-evaluation 3) testing out beliefs and predictions, and 4) addressing personal standards and self-criticism.~Week 1: Understanding your perfectionism.~Week 2: Your own model, values, and motivation.~Week 3: Surveys and experiments.~Week 4: Dealing with perfectionistic behaviors.~Week 5: New ways of thinking.~Week 6: Self-criticism and self-compassion.~Week 7: Self-worth.~Week 8: Maintain and continue positive change."
45692362|NCT03904329|Drug|Oral Anticoagulant|Oral tablets of anti coagulations either warfare or NOACs
45692363|NCT04141995|Drug|Digoxin|Tablet, Oral: Generic: 0.125 mg, 0.25 mg
45846645|NCT05386524|Drug|pegylated liposomal doxorubicin|pegylated liposomal doxorubicin 30mg/m2 d1，q3w
45692364|NCT04141995|Drug|5Fluorouracil|5-FU will be given as a 46 hour continuous IV infusion
45692365|NCT04141995|Drug|Calcium Leucovorin|IV injection over 90 minutes
45692366|NCT04141995|Drug|Irinotecan|IV administration over 90 minutes
45692367|NCT04141995|Drug|Oxaliplatin|IV administration
45692368|NCT05583435|Behavioral|One-on-one professional coaching|One-on-one professional coaching
45692369|NCT05583435|Behavioral|Small-group professional coaching|Small-group professional coaching
45846646|NCT05357664|Device|Total Hip Arthroplasty|Pinnacle acetabular shells used with PINNACLE DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
45489587|NCT02399644|Other|Physical activity|Participants are going to perform a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
46053024|NCT05804565|Procedure|Bone Cutter|The surgeon will use a manual bone cutter to transect the metatarsal shaft
46053025|NCT05804539|Behavioral|Manual therapy|The therapist checks the range of motion of the cervical joints and gives manual treatment to the restricted joints. Throughout the examination, the subject lied in a supine position on a professional rehabilitation bed with the seventh cervical vertebra (C7) on the edge of the bed and the other the body above the C7 were placed off the bed. The therapist held the subject's occipital bone with one hand and the radial aspect of the second metacarpophalangeal joint of the other hand to grip the spinous process of the sixth cervical vertebra and slowly pushed the occiput downward to check the joint mobility of the fifth cervical vertebra and the sixth cervical vertebra. After the examination, the restricted joint was accurately located and treated with targeted manual therapy. For example, stretching was performed with the right side of C4-C5 flexed, closing only the right side of the subject's C4-C5 as much as possible to increase joint mobility on the right side of C4-C5.
45370567|NCT04459260|Behavioral|Unified Protocol|"A standardized evidence-based treatment manual based on cognitive behavior therapy, developed to target the shared emotional factors in depression and anxiety disorders (Ellard et al., 2010). Fundamental to this approach is to register and become more aware of the emotions, cognitions, and physical sensations that occur in difficult situation, and to try out more adaptive ways of coping in these instances.~Week 1: Emotional symptoms.~Week 2: Understanding your emotions.~Week 3: Emotional awareness.~Week 4: Thoughts.~Week 5: Behaviors.~Week 6: Emotional exposure.~Week 7: Continued emotional exposure.~Week 8: Planning ahead."
45370568|NCT00987870|Drug|BFH772|
45370569|NCT00987870|Drug|Placebo|
45370570|NCT00987870|Drug|BFH772|
45489588|NCT03167164|Biological|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
45370571|NCT00987870|Drug|Placebo|
45489589|NCT03167164|Biological|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
45489590|NCT03167164|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
45489591|NCT03167164|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
45489592|NCT03167164|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
45370572|NCT00987870|Drug|calcipotriol/betamethasone|
46053026|NCT05804539|Behavioral|Tai Chi|Based on the characteristics of young people and the need to correct their FHP, the classic Yang's 24 Forms of Tai Chi has been improved. The movements are mostly upper limb movements and the lower limb movements have been simplified to make the movements easy to learn. The modified Tai Chi exercise retains the traditional Tai Chi movements but is simple and easy to learn; at the same time, it increases the movement of the shoulder and neck joints. The subjects performed each exercise session in a group setting at the school gymnasium, with a professional Tai Chi instructor guiding them through a warm-up session, followed by a Tai Chi exercise session.
46053027|NCT05804539|Behavioral|Tai Chi and Manual therapy|Intervention content of MSG included 15-min Tai Chi exercise and 15-min manual therapy, with the order of intervention being Tai Chi exercise first and then manual therapy.
45370573|NCT00988026|Drug|Minocycline vs Lymecycline|Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.
46053028|NCT05804526|Drug|RC88+JS001|JS001 240mg by intravenous (IV) infusion
45370574|NCT00988962|Behavioral|cognitive behavioral training|electronic diaries, compliance checklists, urine screens, individual and group motivational counseling
45370575|NCT05578170|Drug|Pembrolizumab|Participants receive 200 mg pembrolizumab as a neoadjuvant by intravenous (IV) infusion administered on Day 1 of a 21-day cycle for 2 cycles before surgery.
45692370|NCT04149561|Other|communication skill measurement with self report questionnaire|Demographic information form, Communication Function Classification System, Functional Communication Classification System, The Gross Motor Function Classification System and Manual Ability Classification System will be filled in for the patients.
45370576|NCT00989040|Drug|usual treatment: Versatis|"To explore if the cognition is failed in treated patients suffering of neuropathic postzosteria pain.~To see if treated patients with patch (Versatis®) have better cognition than treated patients without patch."
45489593|NCT03167164|Drug|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
45692371|NCT04141683|Diagnostic Test|Stress Echocardiography|Dynamic stress echocardiography using a cycle ergometer on a semi supine exercise table.
45692372|NCT04141683|Diagnostic Test|Pressure volume loop analysis|Pressure volume loop analysis unsing conductance catheter measurements during right heart catheterization.
45692373|NCT04141683|Procedure|Tricuspid valve repair or replacement|Tricuspid valve repair or replacement using a surgical or interventionale approach according to local heart team recommendation and patients' preference.
45692374|NCT04149483|Drug|Atorvastatin|One with the intervention (atorvastatin, 20mg OD), 30 patients for this arm.
45692375|NCT04149483|Drug|Placebos|One with the intervention (Placebo, 20mg OD), 30 patients for this arm.
45692376|NCT04149639|Dietary Supplement|NeuroQ|Supplement includes phosphatidylserine, coffee fruit, curcumin, ginkgo, gotu kola, and propolis active ingredients inside a veggie capsule.
45692377|NCT04141371|Drug|Molar Sodium Lactate|daily 3-hour infusion of sodium molar lactate during the vasospasm period
45370577|NCT00989118|Procedure|Laser treatment of ovarian endometrioma|Laser vaporization of ovarian endometrioma
45370578|NCT00989274|Biological|Vaccine Sanofi A(H1N1) 15 ug & trivalent|Grup 1: day 0: Vaccine trivalent (A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) Vaccine Sanofi A(H1N1) administrated 15 ug. (nonadjuvant); day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant);
45370579|NCT00989274|Biological|Vaccine Sanofi (H1N1) 15 ug.nonadyuvante|Grup 2: Day 0: Vaccine trivalent(A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, y B/Brisbane/60/2008-like virus); Day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant)
45370580|NCT00989274|Biological|Vaccine Sanofi A(H1N1) 7.5 ug|Grup 3: day 0: day 28 Vaccine Sanofi A(H1N1) administrated a 7.5 ug (non adjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 7.5 ug (nonadjuvant).
45370581|NCT04442490|Drug|SAGE-217|SAGE-217 oral capsules.
45370582|NCT04442490|Drug|Placebo|SAGE-217 matched-placebo oral capsules.
45370583|NCT04812522|Behavioral|Clean Cut program|Clean Cut, is an adaptive, multimodal surgical infection prevention program that integrates perioperative process improvement and patient outcomes measurement using process mapping, training and improved management practices, and compliance with critical standards of surgical antisepsis
45370584|NCT03310944|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
45489594|NCT03167164|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
45370585|NCT04804254|Drug|ABBV-623|Oral Tablets
46053029|NCT05804500|Behavioral|Cardiac Telerehabilitation (CTR) via the RecoveryPlus platform|RecoveryPlus has developed an innovative CTR platform for patients with CVD that leverages: (1) video conferencing functionality (Zoom) for synchronous telehealth sessions of CR instruction for patients and licensed exercise physiologists (EPs), (2) a patient-facing mobile application delivering asynchronous exercise videos, and (3) a health care provider web portal for clinicians and EPs. The RecoveryPlus platform includes the ability for EPs and clinicians to monitor patient clinical data (e.g., heart rate) and input (e.g., rating of difficulty for individual exercises) and tailor individual patient regimens regularly for increased safety and optimal outcomes.
46053030|NCT05804487|Device|ABL90 FLEX PLUS analyser running SW3.5 MR2.|The ABL90 FLEX PLUS analyzer is a portable, automated analyzer that measures pH, blood gases, electrolytes, metabolites, and oximetry in whole blood - utilizing 3 measuring modes (syringe, short probe, and capillary mode) to measure samples from a syringe, test tube or a capillary tube. The analyzer provides results for 17 parameters in 35 seconds using 65 μL heparinized whole blood.
45370586|NCT04804254|Drug|ABBV-992|Oral Tablets
45370587|NCT05712642|Drug|Intravitreal Bevacizumab|Serum systemic level of VEGF was measured before and after 1 week and 4 weeks of intravitreal injection of bevacizumab
46053031|NCT05804474|Other|Observational study|Observational study
45370588|NCT00092521|Biological|V501|Final Manufactured Product (FMP) quadrivalent HPV vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
45370589|NCT00092521|Biological|Comparator: Placebo|a 0.5 mL intramuscular placebo injection given at Day 1, Month 2 and Month 6.
45489595|NCT03167164|Drug|nab-Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
45489596|NCT03167164|Drug|omega-3-acid ethyl esters|Omega-3-acid ethyl esters
45489597|NCT03167164|Radiation|Stereotactic Body Radiation Therapy|radiation
45489598|NCT03167164|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
45489599|NCT03167164|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
45489600|NCT03167164|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
45489601|NCT03167164|Biological|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
45370590|NCT00092521|Biological|Human Papillomavirus (HPV) 16 Monovalent|HPV 16 Monovalent vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
45370591|NCT05712564|Other|Questionnaire|Questionnaire for fatigue assessment
45370592|NCT05492682|Drug|PeptiCRAd-1|All patients will receive 6 doses of PeptiCRAd-1.
45370593|NCT05492682|Drug|Cyclophosphamide|All patients will be pre-treated with one single dose of Cyclophosphamide.
45370594|NCT05492682|Drug|Pembrolizumab|All patients will receive 6 doses of Pembrolizumab within the study.
45489602|NCT03167164|Biological|haNK|NK-92 [CD16.158V, ER IL-2] (high-affinity activated Natural Killer cells)
45489603|NCT03167086|Behavioral|"Empowered Relief (ER)"|"Empowered Relief (ER): A single-session skills-based approximately 2-hr group intervention to treat chronic pain.~Format of intervention: Therapist-delivered PowerPoint presentation with experiential exercises. Experienced senior level psychologist and two (2) additional doctoral level psychologists will conduct the ER sessions.~Content of intervention: ER Participants have the 'ER Relaxation Resource' app (guided relaxation audiofile) loaded on their apple or android electronic device."
45692378|NCT04141371|Drug|physiological serum|daily saline infusion over 3 hours during the vasospasm period
45370595|NCT05712408|Behavioral|800g Challenge|The intervention will involve 8 weeks of an online diet program. Outcomes testing will occur at baseline and post-intervention (following 8 week diet program). During the first 4 weeks, participants will receive educaitonal material and log their daily points in an online application and attend a weekly check-in call with members of the research team. During weeks 5-8, participants will log their daily points in the online application.
46053032|NCT05804461|Behavioral|Motivational Interviewing|Upon refinement from Formative Research (Aim 1), a three-session, individual-level intervention to increase PrEP uptake among MSM in Puerto Rico will be implemented. The facilitator will use Motivational Interviewing techniques to guide the sessions. The intervention's design and content will be the same for each study group; the only difference will be the modality of implementation; one group of participants will receive a face-to-face intervention, while another group will receive an online intervention.A total of 170 participants will be randomized in a 1:1 ratio into each of the two intervention modalities (n=85 face-to-face and n=85 online) while a control group will be recruited following a 3:1 ratio of intervention vs. control. In addition to baseline assessment, participants will be asked to complete a post test at the end of the third session (60 days) and a follow-up post-test at the 150-day mark, separately.
45370596|NCT03908970|Drug|1% OPA-15406|Twice daily
45370597|NCT03908970|Drug|Placebos|Twice daily
45692379|NCT04141449|Other|Potlako intervention|Combined provider, patient, and health system intervention to expedite cancer diagnosis and care.
45370598|NCT05487924|Other|SVV-GDHT|GDHT guided by SVV using Flotra/Vigileo monitor
45370599|NCT05487924|Other|O2ER-GDHT|GDHT guided by O2ER
45692380|NCT04141449|Other|Enhanced care|Provider education and limited patient counseling.
45692381|NCT04140981|Device|ultrasounography|in preoperative period, airway ultrasounagraphy for all patients will be made
45370600|NCT05487924|Other|conventional care|conventional fluid therapy without GDHT
45370601|NCT05712330|Other|non invasive ventilation samples|machine samples for bacterial culture will be performed
45370602|NCT05712330|Other|patient samples|Patient samples for sputum culture
45370603|NCT05712330|Other|parent questionnaire|parent questionnaire
45370604|NCT00092443|Biological|RotaTeq™, rotavirus vaccine, live, oral, pentavalent|Three doses of RotaTeq™ administered 28 to 70 days apart.
45370605|NCT00092443|Biological|Comparator: Placebo matching RotaTeq™|Placebo matching RotaTeq™ administered 28 to 70 days apart.
46053033|NCT05804422|Dietary Supplement|Probiotic lysate (postbiotic and metabiotc)|Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
45370606|NCT05712174|Drug|[18]F-PSMA-1007|[18]F-PSMA-1007 is a diagnostic radiopharmaceutical for use with PET/CT or PET/MRI scanning to diagnose prostate cancer.
45370607|NCT04005924|Other|arabinogalactan|Arabinogalactan will be mixed into sugar-free blackberry jam and consumed with the provided bread.
45370608|NCT01085149|Drug|Simvastatin|10 mg simvastatin, slow release in socket of extracted tooth (single application only)
45370609|NCT04691622|Biological|Norovirus -specific T-cell (NST) therapy|"Arm A: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion.~Arm B: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion."
45370610|NCT04005612|Dietary Supplement|vitamin D3|50,000 IU VD3 / week for 8 weeks
45370611|NCT04005612|Dietary Supplement|omega-3 fatty acid|300 mg of omega 3-FA once daily for 8 weeks
45370612|NCT04005612|Dietary Supplement|vitamin D3 and omega-3 fatty acid|50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
45370613|NCT04005612|Other|control|no intervention
45370614|NCT00413920|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|An initial dose of 1080 mg EC-MPS was administered immediately before transplantation. Then, during the first 6 weeks post-transplantation, EC-MPS was administered at a dose of 1080 mg twice a day 12 hours apart. From week 7 until the end of the study (month 6), EC-MPS was administered at standard dose of 720 mg twice a day.
45370615|NCT00413920|Drug|Prednisone|Oral tablets
45370616|NCT03993964|Drug|Pyrotinib combine with SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic breast cancer
46053034|NCT05804422|Dietary Supplement|Placebo|Placebo
45692382|NCT04149093|Diagnostic Test|Calretinin staining|"A paraffin-embedded hematoxylinphloxin-safran sections will be performed on tissue specimens of proximal resection margins to evaluate the presence or absence of ganglion cells.~Immunohistochemistry (IHC) will then be done on paraffin-embedded sections for calretinin staining."
45692383|NCT04149327|Drug|amoxicillin 500 mg + metronidazole 500 mg|500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for 7 days
46053035|NCT05804409|Diagnostic Test|FECAL ELASTASE|screening for pancreatic exocrine insufficiency in MAFLD patients
46053036|NCT05804383|Drug|BMS-984923|Capsules
46053037|NCT05804383|Drug|Placebo|Capsules
46053038|NCT05804370|Drug|Gleolan|Gleolan is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). The oral provision of Gleolan leads to a highly selective accumulation of PpIX in tumor cells. Following excitation with blue light (BL) (wavelength [λ] = 375 - 450 nm), the PpIX, which has accumulated selectively in tumor tissue, emits a red-violet light.
46053039|NCT05804357|Behavioral|Manual Therapy|Mobilization applications are passive movements that do not involve pushing or stimuli, applied within the range of motion or up to the physiological range of motion
46053040|NCT05804357|Behavioral|Exercise|It is an approach that is combined with diaphragmatic breathing, activating the passive-active musculoskeletal and neural systems. In this approach, transversus abdominis and multifudus muscles are activated as deep core muscles.
46053041|NCT05804344|Device|Anodal speech motor tDCS|tDCS montage set for Anode: C5; Cathode: Fp2
46053042|NCT05804344|Device|Cathodal speech motor tDCS|tDCS montage set for Anode: Fp2; Cathode: C5
46053043|NCT05804344|Device|Anodal IFG tDCS|tDCS montage set for Anode: F3; Cathode: Fp2
46053044|NCT05804344|Device|Cathodal IFG tDCS|tDCS montage set for Anode: Fp2; Cathode: F3
45370617|NCT01037764|Procedure|alloHCT|"[ alloHCT arm ] Bu-Cy conditioning; Busulfan (Bu) 3.2 mg/kg*/day iv daily on days -7 and -4. Cyclophosphamide (Cy) 60 mg/kg* in D5W 200 mL iv over 1-2 hours daily on days -3 and -2.~BuFluATG conditioning; Bu 3.2 mg/kg*/day iv daily on days -7 and -6. Fludarabine (Flu) 30 mg/m2/day in D5W 100 ml iv over 30 minutes starting at 4 pm daily on days -7, -6, -5, -4, -3, and -2.~Anti-thymocyte globulin (ATG, Thymoglobulin, Genzyme Transplant, Cambridge, MA, USA) 1.5 mg/kg/day (for HLA-matched sibling HCT) or 3.0 mg/kg/day (for HLA-matched unrelated donor HCT or HLA-mismatched familial donor HCT) in N/S 500-800 ml (less than 4 mg/ml) iv over 4 hours starting at 8 am daily on days , -3, -2 and -1."
45489604|NCT03167086|Behavioral|Cognitive Behavioral Therapy (CBT)|"Format of intervention: 8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total). The group is run weekly for 8 consecutive classes. Each class is 2 hours with a midpoint break (16 hours total intervention time).~Content of intervention: The protocol and materials were developed with funding from NIH/NCCAM R01 AT006226 (Dan Cherkin, PI) [1& 2], and include content from a pain-CBT program developed by Drs. Ehde, Dillworth, and Turner [3].~Participants receive a workbook with homework and a copy of The Pain Survival Guide: How to reclaim your life © 2005 by Turk & Winter [4] for optional reading."
45370618|NCT01033630|Drug|D&G 2g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 2g per Day
45489605|NCT03167086|Behavioral|Health Education (HE)|"Format of intervention: The HE class will be instructor taught and will involve a PowerPoint presentation and handouts. Two additional providers will be identified and trained to conduct the sessions. Selected instructors will have substantial health education experience.~Content of intervention: HE content will include basic information such as nutrition and interacting with the healthcare system; these relatively 'inert' topics are unlikely to impart any specific effects typically found with a true psychobehavioral intervention."
45489606|NCT02399488|Device|Masimo Radical 7|Simultaneous determination of haemoglobin with the continuous haemoglobin monitor, the central lanboratory coulter and a POC:
45489607|NCT03334747|Drug|KAE609|Exploration of different doses of KAE609 to establish safety profile.
45370619|NCT01033630|Drug|D&G 1g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 1g per Day
46053045|NCT05804344|Device|Sham tDCS|tDCS device set in Sham mode
45489608|NCT03334747|Drug|Coartem|Control Arm
45370620|NCT01033630|Drug|Placebo|Image-matched placebo, made with starch.
45489609|NCT02399722|Device|WICVAC|combined wound therapy
45370621|NCT00091819|Drug|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
45370622|NCT00091819|Drug|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 14 days.
45489610|NCT02399722|Device|VAC mono therapy|mono therapy
45489611|NCT02394652|Drug|Metformin|Metformin is an antidiabetic agent given orally.
45489612|NCT02394652|Drug|Cisplatin|Cisplatin is an antineoplastic agent given intravenously.
45489613|NCT02394652|Drug|FAZA|FAZA is an investigational imaging agent for positron emission tomography scans indicated for hypoxia.
45489614|NCT02394496|Drug|Fulvestrant|Fulvestrant 500mg (2 x 5ml) im injections as a loading dose on Day 0, followed by 500mg (2x5ml) on Day 14 (+/- 3 days) , Day 28 (+/- 3 days) and every 28 Days (+/- 3 days) thereafter.
45489615|NCT02394496|Drug|Lapatinib|1500mg (TBD) O.S. qd
45489616|NCT02394496|Drug|Aromatase Inhibitors|as indicated in the Summary Product Characteristic
45489617|NCT02394496|Drug|Placebo Lapatinib|1500mg (TBD) O.S. qd
45489618|NCT03346759|Device|Tampon A|24 Tampax Pearl Regular Tampons for use during a single menstrual period.
45489619|NCT03346759|Device|Tampon B|24 Playtex Gentle Glide 360 Regular Tampons for use during a single menstrual period.
45489620|NCT03710473|Diagnostic Test|Optical sensor, Pulse watch|Continuous blood pressure monitoring obtained by a Pulse watch
45489621|NCT03362671|Device|Implant Supported Mandibular Advancement Oral Appliance|This device is a novel oral appliance that attached to orthodontic mini implants in the jaw and is designed to keep the jaw in an advanced position, opening the upper airway during sleep.
45489622|NCT03362671|Device|Orthodontic Mini Implant|Small titanium devices that are fixed to the bone for the purpose of enhancing anchorage of other orthodontic devices.
45489623|NCT02394418|Drug|Sevoflurane|Treatment of delirium by inhaled sevoflurane
45489624|NCT02394418|Drug|Propofol|Treatment of delirium by propofol i.v. infusion
46053046|NCT05804305|Drug|Misoprostol|Misoprostol is a prostaglandin E1 analogue
46053047|NCT05804305|Drug|Placebo|Placebo contained substance that has no therapeutic value.
46053048|NCT05804292|Other|Questionnaire administration|Questionnaire administration
46053049|NCT05804279|Drug|BPDO-1603|donepezil/mematine
46053050|NCT05804253|Procedure|Maxillary sinus augmentation|Maxillary sinus grafting with 2 different xenogenic materials
46053051|NCT05804240|Diagnostic Test|3D TEE RVEF|With TEE package software, the investigators measure and calculate 3D TEE RVEF using mid esophageal 4 chamber view
45489625|NCT02394418|Drug|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
45489626|NCT03361423|Device|Nerivio Migra-1 active device|"The device is placed on the subject upper arm. when activated, stimulus is applied to influence the subject's perception of a painful stimulus, delivered (or originating) at a different location. Based on diffused noxious inhibitory control mechanism, sometimes referred to as pain inhibits pain principle, conditioned pain modulation evokes an endogenous analgesic mechanism. The modulatory effect is over the whole body, and can be induced anywhere in the body. This approach allows applying the conditioning stimuli away from the painful site."
45370623|NCT01326871|Drug|Cisplatin|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 1 of each course (if given)
45370624|NCT01326871|Drug|Gemcitabine|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course
45489627|NCT03361423|Device|Nerivio Migra-1 Sham device|The device is placed on the subject upper arm. when activated, the stimulus is applied is not sufficient to influence the subject's perception of a painful stimulus.
45370625|NCT01326871|Biological|ALT-801|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course
45370626|NCT01081405|Other|TOTAL LYMPHOID IRRADIATION|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
45489628|NCT02693002|Drug|Estradiol/Norethindrone acetate|Estradiol/Norethindrone acetate 1mg/0.5 mg
45370627|NCT01081483|Drug|ABT-072|See arm description for more information
45370628|NCT01081483|Drug|Placebo|See arm description for more information
45370629|NCT03964129|Procedure|Avance Nerve Graft with Autologous BMAC|The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested. Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained. Of the 7 to 10 ml of final BMAC that is yielded, half (3.5 to 5 ml) of the final concentrate, will be injected on top of the Avance Nerve Graft following coaptation. The second half (3.5 to 5 ml) of the final concentrate will be inserted into a sterile tube containing culture media and shipped overnight to Cleveland Clinic Lerner Research Institute for cell processing and colony assay to confirm that the BMAC indeed contains autologous bone marrow stem cells.
45370630|NCT00540228|Biological|Influenza Vaccine GSK1247446A - 4 different formulations|Single dose, Intramuscular injection
45370631|NCT00540228|Biological|Fluarix™|Single dose, Intramuscular injection
45489629|NCT02693002|Drug|Placebo|inactive ingredient
45489630|NCT04480606|Behavioral|Home exercise program|47 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in home exercise group. A video exercise protocol was created and each exercise session was planned as daily 30 minutes for 6 weeks. Individuals will ask to do their exercises. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The exercise protocol was additionally determined as a combination of aerobic, balance and strengthening exercises. The exercise program consists of 3 levels and individuals will be provided to start at a level appropriate to their level of physical activity.
45489631|NCT05408923|Drug|saline 0.9%|Control group will get normal saline for irrigation throughout the case.
45489632|NCT05408923|Drug|(0.05% chlorhexidine gluconate (CHG) in sterile water)|Intervention group will get Irrisept irrigation (0.05% CHG in sterile water) throughout the case.
46053052|NCT05804175|Device|Linshom Continuous Predictive Respiratory Monitoring|Observational study. Monitoring of Linshom, pulse oximetry and capnography data with comparison to current standard of care.
45370632|NCT01081561|Drug|Riboflavin|Removal of the epithelium, riboflavin drops every 2 minutes for 30 minutes follow by UV light radiation and addition riboflavin drops every 2 minutes for 30 minutes. Some subjects will be randomized to recieve INTACS prior to treatment with riboflavin.
45370633|NCT04620174|Other|Custom-made zirconia crowns|Ten decayed primary molars will be restored with custom-made zirconia crowns.
45370634|NCT04620174|Other|Prefabricated zirconia crowns|Ten decayed primary molars will be restored with prefabricated zirconia crowns.
45370635|NCT04004754|Drug|Miltefosine (administration is not part of study procedures)|Patients who receive miltefosine in the routine setting will be asked to participate in the study to document their outcomes
45370636|NCT05372094|Device|Phonak Hearing Aid|Commercially available hearing aid
45753515|NCT00547105|Drug|Erlotinib|Erlotinib is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
45753516|NCT00547105|Radiation|SBRT|SBRT is a treatment method to deliver a high dose of radiation to the target, utilizing either a single dose or a small number of fractions with a high degree of precision within the body
46053053|NCT05804149|Device|acupuncture|study group take acupuncture Acupuncture was applied with a total duration of 35-45 minutes, 2 sessions per week for 4 months.
46053054|NCT05804149|Drug|Thyroxine|Each woman in both groups (control and study) will receive thyroxine tablets (levothyroxine) (1tablet per day) describe by the physician. Levothyroxine is usually taken 30-60 minutes before breakfast, or four hours after food, as certain substance such as food and calcium can inhabit the absorption of levothyroxine
45370637|NCT04567056|Diagnostic Test|Blood sample|A separate blood sample will be taken for methylation-analyses
45370638|NCT05919914|Other|Exercise with Blood Flow Restriction (BFR)|Wrist extensor exercise (concentric - eccentic) with BFR. BFR involves the reduction of blood flow to working skeletal muscle by applying a flexible cuff to the most proximal portions of a person's arms or legs that results in decreased arterial flow to the exercising muscle and occluded venous return back to the central circulation.
45370639|NCT05919914|Other|Exercice without Blood Flow Restriction (BFR)|Wrist extensor exercise (concentric - eccentic)
45370640|NCT05919901|Other|HPV Vaccine Communication Strategy|The intervention will include health promotions materials and provision of HPV vaccine
45370641|NCT05919888|Drug|Povidone-Iodine|Applied to skin incision.
45370642|NCT05919888|Device|SURGX Wound Gel|Applied to skin incision.
45489633|NCT05744986|Device|SYMPICITY Spyral RENAL DENERVATION (RDN) SYSTEMTM|The second generation SYMPLICITY RDN catheterTM has 4 times electrodes that are arranged in spirally in 90-degree intervals. Theoretically, the newer generation catheter can provide more efficient and extensive denervation in a shorter period of time16. Its efficacy was confirmed in SYMPLICITY HTN ON-MED and OFF-MED trial, which confirmed a consistent and durable BP reduction that lasted into 36 months with or without adjuvant anti-hypertensive drugs
45489634|NCT03707509|Drug|Camrelizumab|Maximum 6 cycles for combined therapy. Camrelizumab maintenance.
45489635|NCT03707509|Drug|Placebos|Maximum 6 cycles for combined therapy.
45489636|NCT03707509|Drug|Gemcitabine|Maximum 6 cycles for combined therapy.
45753517|NCT04198064|Procedure|Bag Squeeze|"Participants will receive a bag squeeze of irrigation fluid (500 ml/~2 cups of % 0.9 saline solution) during the insertion of the cystocopy tube during their cystocopy."
45489637|NCT03707509|Drug|Cisplatin|Maximum 6 cycles for combined therapy.
45489638|NCT03710395|Procedure|Blood and breast milk sampling|At least 15 days after starting treatment with 20 mg slow-release nifedipine every 12 hours. Blood and breast milk will be sampled before first dosing in the morning.
46053055|NCT05804149|Dietary Supplement|low caloric diet|Each woman in both groups will follow a low caloric diet regime consisting of 1200 to 800Kcal/ day for 4 months. The regime will start with 1200 Kcal for the first month and 1100 for the second month then 900 Kcal for the third month until reach 800 Kcal in fourth month.
46053056|NCT05804110|Other|Mindful Caring Education Program|A four-session education plan was prepared under the nature of action research. The Theory of Unitary Caring Science is transferred to practice through Caritas processes. In this context, ten Caritas processes and caring-healing modalities (meditation, reflection, etc.) were used in the study. The pilot study was carried out with six nurses face-to-face. The education program was conducted on an online platform. Each education took approximately 2.30-3 hours. The evaluation process in action research is an essential part of the change.
45489639|NCT03710395|Drug|Nifedipine|Chronic hypertensive breastfeeding women will be treated with slow-release 20 mg nifedipine, twice a day.
45489640|NCT02399098|Behavioral|Attentional focus|The participants will learn the dart throwing task according to specific instructions. Participants in all groups will be given the same technical instructions on how to throw the dart. The technical instructions will be followed by attentional focus instructions that will differ between the groups.
45489641|NCT04889950|Device|Tixel C|Tixel C )Novoxel®, Israel) is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.
45489642|NCT04889950|Device|LipiFlow|LipiFlow
45489643|NCT02394262|Radiation|Coronary CT-angiography|Sequential CCTA after one year follow-up. The first CCTA will be performed in terms of diagnostic work-up (referral outpatient Cardiology department).
45753518|NCT04198064|Procedure|No Bag Squeeze|Participants will receive a standard cystocopy procedure as per standard of care.
45753519|NCT03969368|Device|rPMS device|Pelvic floor muscle contractions will be induced by the rPMS device.
46053057|NCT05804097|Drug|Hyperbaric oxygen|90-120 min sessions of hyperbaric oxygen treatment of 2.2-2.5 ATA
45370643|NCT05919875|Behavioral|Unguided Mindfulness-Based Cognitive Therapy|"The unguided iMBCT intervention is divided into six sessions. The sessions are an online adaptation of the regular MBCT. Subsequent sessions are unlocked gradually, once a week. The training consists of audio/video recordings and a workbook. Materials are recorded by a certified MBCT teacher and represent topics raised during regular courses:~Awareness and automatic pilot~Living in our heads~Being present in the body~Recognizing aversion~Allowing / Letting be~How can I best take care of myself?~The intervention requires daily commitment of about 30-40 minutes."
45489644|NCT02394262|Other|Assesment of biomarkers involved in atherothrombosis|Sequential assesment of atherothrombis biomarkers: baseline and at 1 year follow-up.
45370644|NCT05919875|Behavioral|Guided Mindfulness-Based Cognitive Therapy|"The guided iMBCT intervention consists of six online meetings in groups of maximum 25 participants. The weekly meetings will be led by an experienced and certified MBCT teacher. The course of the meeting will represent thematically the unguided condition according to the agenda:~Introduction to the topic~Guided meditation~Brief inquiry and discussion~Setting tasks for the upcoming week~To reduce the number of differences between the conditions as much as possible and narrow it down to the active participation of the teacher, the meetings will be modified version of MBCT and will last maximum 90 minutes. Between the meetings participants will be ask to practice daily 30-40 minutes mindfulness exercises."
45370645|NCT05919862|Procedure|Robot system|Prosthetically guided Implant placement utilising robotic surgery based on a digital plan
45370646|NCT05919862|Procedure|Freehand surgery|Freehand implant placement by experienced surgeon.
45370647|NCT05919849|Behavioral|Brief online writing intervention|Participants will be instructed to write for 20 minutes across 3 consecutive days. They will be writing based on the prompts given to them.
45370648|NCT05919849|Other|Control condition|Participants will be instructed to write in order to control for time and writing engagement.
45370649|NCT05919836|Procedure|Laparoscopic assisted hernia|Percutaneous assisted laparoscopic hernia
45370650|NCT05919836|Procedure|Laparoscopic hernia by purse string closure|Laparoscopic purse string closure of hernial sac
45370651|NCT05919836|Procedure|Total laparoscopic dissection of hernial sac|Total laparoscopic dissection of hernial sac
46053058|NCT05804071|Drug|Niferex|"Daily iron supplement scheme (QD)：Oral polysaccharide iron complex capsule (Niferex)150mg/300mg daily.~Alternative iron supplement scheme（QOD）：Oral polysaccharide iron complex capsule(Niferex) 150mg/300mg every other day.~Intravenous iron supplement(MonoFer):use as instructions"
45489645|NCT03093870|Drug|Varlitinib|Varlitinib:300mg, oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
45489646|NCT03093870|Drug|Capecitabine|1000mg/m2, oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
45489647|NCT03093870|Drug|Placebo (for Varlitinib)|oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death
45846647|NCT05357664|Device|Revision Total Hip Arthroplasty|Pinnacle acetabular shells used with Pinnacle DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
45846648|NCT05350098|Other|Plant-protein Diets|Participants will consume meals with 70% plant-based protein three times a day. Participants will be prohibited to have meals other than experimental diets and to drink milk and soy milk.
45846649|NCT05350098|Other|Control Diets|Participants will consume meals with 50% plant-based protein three times a day. Participants will be prohibited to have meals other than experimental diets and to drink milk and soy milk.
45846650|NCT05338554|Device|Repetitive transcranial magnetic stimulation|Magnetic stimulation was performed using a figure-eight coil connected to a Magstim Rapid2 system, All patients seat in a comfortable reclining chair and delivered pcTBS protocol using repetitive transcranial magnetic stimulation . The stimulation intensity was set to 80% of the resting motor threshold, which is measured as the minimal intensity of stimulation evoking an electromyographic response ≥50µV on the first dorsal interosseus muscle of the hand contralateral to the stimulated hemisphere in at least 5 out of 10 trials. For this measurement, a figure-of-eight coil is positioned over the hand motor hotspot and oriented perpendicular to the central sulcus (parallel to the hemispheric midline).
46053059|NCT05804058|Procedure|Revision surgery|Patients due to undergo prosthetic revision surgery for any reason (infection or aseptic)
45489648|NCT02394184|Procedure|transcatheter aortic valve replacement|
45489649|NCT05744908|Other|Pentosan Polysulphate|300mg 3 times a day
46053060|NCT05804019|Behavioral|Nutritional and physical interventions|The intervention is developed with a focus on nutritional needs and physical activities. The Plan-Do-Study-Act (PDSA) model is used to redefine issues and relevant actions together with residents, relatives, care staff, and nursing home management. The intervention will be developed based on new knowledge from sub-study 1, previous studies, practical experiences, the participant's experiences and wishes as well as the staff's experiences and wishes. Together they will form an implementation catalog, from here, the intervention nursing homes can select a relevant number of components, which will be tested and implemented in practice. The implementation duration is 6 months and the PDSA model is repeated at two-month intervals to strengthen and qualify the intervention. The PDSA model is known to the city's staff in advance and is additionally used in connection to continuing education. The Usual Care Group will continue the usual care.
45489650|NCT02394106|Drug|Ofatumumab|Ofatumumab 1500 mg/1.73m2 administered once, diluted in 1000 ml of normal saline
45489651|NCT02394106|Other|Placebo|Normal saline, 1000 ml, administered once
45489652|NCT01568346|Other|MRI|Breast MRI
45489653|NCT02393872|Behavioral|Feel4Diabetes-intervention|Community-based intervention.
45370656|NCT05919797|Drug|Naltrexone-Bupropion Combination|Participants receive 28 weeks of naltrexone-bupropion weight loss medication during phase two of this study.
45370657|NCT05919784|Behavioral|Cognitive behavioural therapy|The group therapy program (virtual, synchronous) involves elements based in Cognitive Behavioural Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Dialectical Behaviour Therapy (DBT).
46053061|NCT05804006|Other|Conventional physiotherapy followed by HIIT-REC program|The experimental protocol will be preceded by 30 minutes of conventional physiotherapy followed by 15 min the rest period; then the HIIT-REC procedure will start at 4-min at 30% of the peak workload interspersed with 1-min at 70% of the peak workload at 50 rpm for weeks 1-2 and increased by approximately 5 minutes every two weeks as tolerated to reach 30 minutes from week 5 (4 to 6 repetitions). The training intensity will progress similarly by 5% peak workload two weeks as tolerated to reach 4-min at 40% peak workload interspersed with 1-min 80% peak workload from week-5
45846651|NCT05338554|Device|Repetitive transcranial magnetic stimulation|Magnetic stimulation was performed using a figure-eight coil connected to a Magstim Rapid2 system, All patients seat in a comfortable reclining chair and delivered 10HZ protocol using repetitive transcranial magnetic stimulation . The stimulation intensity was set to 80% of the resting motor threshold, which is measured as the minimal intensity of stimulation evoking an electromyographic response ≥50µV on the first dorsal interosseus muscle of the hand contralateral to the stimulated hemisphere in at least 5 out of 10 trials. For this measurement, a figure-of-eight coil is positioned over the hand motor hotspot and oriented perpendicular to the central sulcus (45° away from the hemispheric midline).
45846652|NCT05318040|Drug|CMS121|CMS121 is a small molecule to be delivered orally in capsule form and is a therapeutic drug candidate for treatment of Alzheimer's Disease
45846653|NCT05318040|Drug|Placebo|Placebo will be provided as visually matching placebo capsules.
46053062|NCT05803993|Procedure|Fecal microbiota transplantation (FMT) Single FMT infusion|Single FMT infusion via colonoscopy
46053063|NCT05803980|Procedure|Fecal microbiota transplantation (FMT)|Single FMT infusion via colonoscopy
46053064|NCT05803967|Behavioral|Baduanjin exercising|baduanjin will be applied 5 times per the week, under supervision, for 12 weeks,
45370662|NCT05919732|Drug|Bupivacaine and epinephrine infusion|"For caudal infusion group: bupivacaine .3% + 1: 200,000 epinephrine (dose 3mg/kg) will be administered via the catheter.~For general anesthesia group: bupivacaine 0.25% + 1:200,000 epinephrine (total dose 2.5mg/kg) prior to start of the surgery."
45370663|NCT05919719|Procedure|Non interventional study (study of diagnostic accuracy with an extra echocardiographic assessment).|"Fluid expansion will be delayed while our index test is performed. After fluid expansion, patient will undergo an echocardiographic assessment of response to fluid expansion (gold-standard).~Our index test is the ΔSVi-AC: indexed percentage of stroke volume variation between baseline and during a standardized abdominal compression. Stroke volume will be assessed by transthoracic echocardiography.~Patient will undergo 3 echocardiographic assessment: At baseline, During abdominal compression, After the 10 to 20ml/kg crystalloid fluid expansion Abdominal compression : a sphygmomanometer will be inflated to a pressure of less than 10 mmHg and will be applied to the center of the patient's abdomen. Then, a gentle compression on the sphygmomanometer will be performed, calibrated at 22 - 26 mmHg according to the sphygmomanometer. The echocardiographic assessments will take place between 10 and 60 seconds after the start of the compression, which will therefore last less than a minute."
45370665|NCT05919693|Drug|EYE103|EYE103 is a humanized antibody formulated for IVT administration
45370666|NCT05919680|Drug|NST-6179 Part A|Once daily (QD) oral administration of 800mg (32 mL solution) of NST-6179 for 4 weeks
45370667|NCT05919680|Drug|NST-6179 Part B|Once daily (QD) oral administration of 1200mg of NST-6179 for 12 weeks
45846654|NCT05224986|Behavioral|Fixed Schedule|Participants will be asked to maintain a fixed schedule for 12 weeks.
45370668|NCT05919680|Other|Matched Placebo|Matched placebo for administration in Part A or Part B
45370669|NCT05919667|Dietary Supplement|Dairy and plant-based dairy beverages and solids|Crossover design: participants received all treatment arms in a randomized order
45489654|NCT02558634|Device|VIM Thalamic Deep Brain Stimulation ON|
45489655|NCT02558634|Device|VIM Thalamic Deep Brain Stimulation OFF|
45370670|NCT05919654|Device|MyoCare|Children assigned to the study group will wear ZEISS MyoCare lenses, while those assigned to the control group will wear conventional ZEISS ClearView single-vision lenses in their spectacles. Both lenses will be made of the same material (MR8) and hard as well as anti-reflection coating (ZEISS DuraVision Platinum) and will have the same surface treatments.
45370671|NCT05919654|Device|ClearView|Children assigned to the study group will wear ZEISS MyoCare lenses, while those assigned to the control group will wear conventional ZEISS ClearView single-vision lenses in their spectacles. Both lenses will be made of the same material (MR8) and hard as well as anti-reflection coating (ZEISS DuraVision Platinum) and will have the same surface treatments.
45370672|NCT05919641|Other|Comprehensive Geriatric Assessment|Comprehensive geriatric assessment (CGA) is defined as a multidisciplinary diagnostic and treatment process that identifies medical, psychosocial, and functional capabilities of an older adult in order to develop a coordinated plan to maximize overall health with aging.
45370673|NCT05919628|Other|ResPsyPark group|Evaluation of the parkinson's disease patient's score over different psychological questionnaires and a therapeutical observance questionnaire
45370674|NCT05919615|Drug|Tranexamic Acid 100 MG/ML|Tranexamic Acid: 100 MG/ML Solution for injection
45370675|NCT05919615|Drug|Normal saline|0.9% sodium chloride normal saline
45370676|NCT05919602|Other|Visualization of an image catalogue|Participants in the intervention group will be shown a catalog consisting of 8 images, each for 8 seconds, 25 minutes before entering the operating room. The images shown will be landscapes and/or objects of nature as an expression of neutrality, with light and soft colors, and will be chosen by over 50% of the research team from a gallery of 20 possible images that meet the aforementioned requirements.
45370677|NCT05919589|Other|Care Integration for Children With Special Health Care Needs|The Evelina London Children's Hospital (ELCH) is planning to integrate care for children with special health care needs (CSHCN) using a package of support, including 1) family support workers to manage care coordination and support parents, and 2) 'navigation' packs outlining key services, for both the services users and providers
45370678|NCT05919576|Device|Near infrared imaging|In the study, all volunteers are recorded with the itero Element 5D by activating the NIRI mode. The recording method does not involve ionizing radiation. 850 nm wavelength beams are used.
45370679|NCT05919563|Diagnostic Test|Magnetic Resonance Imaging (MRI)|Observational study; annual MRI for first 5 years only to monitor changes in the injection site
45370680|NCT05919550|Drug|search for a clozapine intake|search for a clozapine intake
45370681|NCT05919537|Drug|HMBD-001|HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly
45370682|NCT05919537|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV once every 3 weeks
45370683|NCT05919537|Drug|Nab-paclitaxel|Nab-paclitaxel 125 mg/m^2 IV on days 1, 8, 15, every 4 weeks
45370684|NCT05919537|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 IV on days 1, 8, 15, every 4 weeks
45370685|NCT05919524|Radiation|Prostate SBRT (stereotactic body radiation therapy) with focal boost|"Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions of 7.25 Gy to the entire prostate (including seminal vesicles) using VMAT~mpMRI defined DIL was simultaneously boosted up to 50 Gy in 5 sessions to the mpMRI identified DIL.~Additional urethra and bladder trigone sparing constrains~Daily IGRT with cone beam CT and intrafraction gold-seeds fiducial tracking"
45370686|NCT05919511|Other|Non-Interventional|This is an observational study
45370687|NCT05919498|Other|Individual semi-directive interview|"This intervention concerns the trajectories of patients who have completed their participation in FASTRACS-RCT. Participant are : patients in the FASTRACS-RCT intervention arm (Groupe 1) and Trajectory persons (groupe 2).~During the individual interviews, the investigator and the participant will discuss the use of the FASTRACS-RCT tools and the patient's course of care.~The individual interviews will take place at the location chosen by the participant and will last on average one hour."
45370688|NCT05919498|Other|Focus groups|"This second intervention will take place at the end of the last patient followed by the FASTRACS-RCT.~During the focus groups, participants will discuss the use of the FASTRACS-RCT tools.~The focus groups will take place in a meeting room made available for the occasion and will last on average two hours."
45370689|NCT05919485|Procedure|tDCS|"0.06mA/cm2 from each electrode with total density of 0.054/cm2 for 20 minutes for 5 days a week, for 10 days and a total of 10 sessions in 14 days.~Brain area; DLPFC / LPC"
45692384|NCT04149327|Procedure|non-surgical periodontal and peri-implant treatment|"Patients are instructed on how to perform proper oral hygiene measures using an electric toothbrush, interdental brushes (to be used in combination with Corsodyl® gel) and floss (Oral-B® superfloss or Meridol® floss, at implants only).~Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned."
45370690|NCT05919472|Dietary Supplement|Oral iron supplementation (pre-treatment)|Iron supplements as 200 mg oral iron as FeSO4 given on alternate day on days 1-56
45370691|NCT05919472|Biological|COVID-19 vaccine|Johnson & Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants
45370692|NCT05919472|Biological|MenACWY vaccine|MenACWY vaccination given on day 28 to all participants
45370693|NCT05919472|Dietary Supplement|Oral iron supplementation (simultaneous treatment)|Iron supplements as 200 mg oral iron as FeSO4 given on alternate day on days 28-56
45370694|NCT05919459|Behavioral|5-week online synchronous ACT intervention|Parents will meet a trained ACT counsellor to undergo five weekly sessions of ACT group training via Zoom. Specifically, each 120-minute synchronous videoconferencing session will involve the ACT counsellor and 6-8 parents.
45370695|NCT05919459|Behavioral|asynchronous online AIS education|A healthcare educator with a background in nursing, physiotherapy, or occupational therapy will meet with parents in five weekly 120-minute interactive AIS-related education videoconferencing via Zoom. Specifically, each 120-minute synchronous videoconferencing session will involve the ACT counsellor and 6-8 parents.
45370696|NCT05919446|Behavioral|Acceptance and commitment therapy (ACT)|Each session in the ACT group will include the first hour of ACT intervention followed by 1 hour of back exercise class. The ACT group will be led by a trained ACT counsellor and a trained exercise trainer.
45370697|NCT05919446|Behavioral|back exercise|The control group will undergo 1 hour of back exercise class, while the control group will be led by a trained exercise trainer.
45370698|NCT05919407|Drug|Pyridostigmine|Participants will receive pyridostigmine 10 mg tablets.
45370699|NCT05919407|Drug|Amifampridine (base) with modified release|Participants will receive amifampridine (base) with modified release 15 mg or 30 mg tablets.
45370700|NCT05919407|Drug|Placebo|The placebo tablets will be identical apart from the active substance (pyridostigmine)
45370701|NCT05919407|Drug|Placebo|The placebo tablets will be identical apart from the active substance (amifampridine base)
45370702|NCT05919394|Drug|To compare in both treatment arms the percentage of patients controlled at week 52.|Participants will be assigned to receive one of two therapeutic strategies: the same ICS/LABA combination at the higher doses or the same maintenance treatment at medium doses plus a LAMA.
45370703|NCT05919381|Drug|Gentuximab Injection|Gentuximab Injection 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
45370704|NCT05919381|Drug|Gentuximab Injection Placebo|Gentuximab Injection Placebo 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
45370705|NCT05919368|Dietary Supplement|Yam pill|It consists of sweet potato, white art and ginseng
45370706|NCT05919355|Other|Offer to try Komp|The participants are offered services using the communication solution Komp. If they accept, they will receive one unit at home.
45489656|NCT02399176|Behavioral|Yoga|Subjects assume 10 physical postures for 30 seconds each
45753520|NCT03969368|Procedure|Pelvic floor muscle training|Control group will undergo a pelvic floor muscle training
45370707|NCT05919342|Diagnostic Test|NT-proBNP|Patients will undergo an NT-proBNP which will guide their future involvement within the study. Patients with an NT-proBNP of ≥125 pg/mL will undergo transthoracic echocardiogram along with a clinical assessment - any diagnosis of HF will result in patients undergoing referral for initiation of guideline directed medical therapy (for HF).
46053065|NCT05803954|Other|Sustained natural apophyseal glides (SNAGS)|SNAGS will be applied with the patient sitting comfortably on a stool. The therapist stand behind the patient and the medial border of one thumb's distal phalanx is placed on the articular pillar on the chosen side of the suspected site of lesion. The thumb nail slope at approximately 45 degree (in the direction of the eyeball). SNAGS mulligan will be given by active movement followed by passive overpressure based on the movement restricted by frequency of treatment will be three sets of ten repetitions. SNAG the anteroposterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s depending on response. A maximum of 6 repetitions will be given if there is a reduction in headache intensity at the time of the first application. A total of 20 oscillations (1 oscillation/1 second) will be given to each joint with a total duration of 15 minutes
46053066|NCT05803954|Other|Neural mobilization|Neural mobilization will be applied with grade three neural mobilization and traditional therapy: Subjects will be placed in supine position and remained relaxed with the feet uncrossed. The patient will be slightly angled obliquely for easier access to the scapula. The therapist will be depressed the scapula with concomitant upper extremity joint positioning as per median nerve bias i.e., ULTT2 (shoulder abduction, elbow extension with forearm supination, wrist and fingers extended and ulnar deviated and thumb abduction). The wrist will be used as a tension factor and at the point where tension was felt by the therapist and perceived by the subject. Grade 3 oscillations were given rhythmically and slowly to each joint from proximal to distal. A total of 20 oscillations (1 oscillation/1 second) were given to each joint with a total duration of 15 minutes.
45370708|NCT05919329|Drug|Piflufolastat|Given IV
45370709|NCT05919329|Procedure|Positron Emission Tomography/Computed Tomography|Undergo PSMA PET/CT
45370710|NCT05919329|Procedure|Positron Emission Tomography/Magnetic Resonance Imaging|Undergo PET/MRI
45370711|NCT05919329|Procedure|Biospecimen Collection|Undergo collection of blood samples
45370712|NCT05919329|Other|Electronic Health Record Review|Ancillary studies
46053067|NCT05803954|Other|Traditional physical therapy|traditional therapy will be applied in the form of stretching for bilateral upper and middle trapezius muscles and bilateral neck rotators and isometric strengthening exercises for neck rotators, extensors, side bending muscles. Exercise was repeated for ten repetitions per session. In addition to hot pack was placed over the neck and upper part of shoulders musculature. This was being applied for ten min, over middle trapezius trigger Point itself.
46053068|NCT05803915|Drug|Toripalimab|The participants will receive Toripalimab 240mg intravenous infusion every 3 week, and Nimotuzumab 150mg/㎡ every 2 week for 2 cycles
45370715|NCT05919303|Radiation|CT Scan|CT scan study of abdomen
45370716|NCT05919290|Other|MRI|Non-invasive imaging technique that is used to take pictures of organs within the body.
45370717|NCT05919277|Diagnostic Test|Dengue Immunoglobulin G antibodies performed with ELISA|All participants who agree to participate by signing an informed consent form will undergo a finger prick for the determination of Immunoglobulin G antibodies measured by ELISA. In a subgroup of persons who test positive, they will be invited to have blood drawn for neutralization determination in order to study serotypes and the presence of other flaviviruses.
45370718|NCT05919264|Drug|FOG-001|FOG-001 will be administered IV once weekly at assigned doses in continuous cycles of 28 days
45370719|NCT05919264|Drug|FOG-001|FOG-001 will be administered IV once weekly at the RP2D dose in continuous cycles of 28 days
45370720|NCT05919251|Behavioral|Ageless Grace|This unique program attempts to combine multiple aspects that easily fit together including music and a group setting for socialization. The use of music to improve cognition as has been shown in other research studies to improve participation in exercise program. By linking cognitive retraining, low intensity exercise, group activities and music, the researchers of this project can determine if a movement program with these attributes can benefit individuals as a program of wellness once their rehabilitation plans have been completed. The researchers are specifically interested in the effect on balance, activity and incidence of falls in people with chronic stroke. Additionally, the researchers will investigate the differences that this structured program will make on older adults who will act as a comparison group. This will bring insight into some of the additional challenges that people with stroke encounter on a daily basis.
46053069|NCT05803902|Drug|Experimental drug 9MW1911|Experimental drug administered with IV infusion
45370722|NCT05919225|Procedure|Risk stratification before decision-making about patient hospitalization or discharge|Once AHF has been diagnosed at ED, and before decision-making about hospitalize/discharge home is taken, physicians will objectively measure the severity of decompensation, based on risk of 30-day death using MEESSI scale. As result, patient can be allocated to low, intermediate, high or very-high risk. For patients classified as low-risk, the propocol recommendation will be discharge patient to home. For patients classified as increased risk (i.e., intermediate, high or very-high risk categories), the protocol recommendation will be to hospitalize patient. Nonetheless, final decission will be left to emergency physician, and overruling (disposition against recommendation) will be allowed.
45370723|NCT05919212|Diagnostic Test|HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment|We study the circulating changes associated with resistance to T-DXd, including changes in HER2 status,studied through a new approach called HER2-2D that simultaneously assesses HER2 amplification and overexpression in blood
45370724|NCT05919199|Other|No intervention|No intervention
45370725|NCT05919186|Drug|EmbryORP®|EmbryORP® is a novel antioxidant (Cystein 32.9 mM, Glutation 32.6 mM, Ascorbic Acid 22.7 mM)
45370726|NCT05919186|Device|O2 tension 20%|After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2, and 95%
45370727|NCT05919186|Device|O2 tension 5%|After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2 and 95%
45370730|NCT05919160|Device|DBC (Diagnostic Biochips) Deep Array microelectrode; Intan Electrophysiology recording system; Matlab response recording to behavioral task|Devices listed are components of a single intervention that includes: Record neuronal activity (Intan) from electrodes (DBC), record and analyze patient responses (Matlab)
45753521|NCT04388215|Drug|CKD-828|orally, 1 tablet once a day for 8 weeks
45370731|NCT05919147|Drug|Pioglitazone 45 mg|The dose of pioglitazone will not exceed 45 mg once daily. Pioglitazone dose will titrate progressively over the first three weeks.
45370732|NCT05919147|Drug|Placebo|Placebo will have the same appearance as the active drug.
45370733|NCT05919134|Dietary Supplement|Dentoblis|dissolve the tablets in the mouth once a day for 4 weeks
45370734|NCT05919134|Dietary Supplement|Placebo|dissolve the tablets in the mouth once a day for 4 weeks
45370735|NCT05919121|Other|Therapeutic exercise|"Stretching exercise of posterior shoulder capsule~Strengthening exercises: consists of 6 strengthening exercises all of which have been recommended as essential for any shoulder rehabilitation program.~The remaining 2 exercises are the seated press-up and the elbow push up. Both will be performed to fatigue or for a maximum of 25 repetitions. The quality of all repetitions of each exercise will continuously monitored by the investigator of the study"
45370736|NCT05919121|Other|hydrocortisone phonophoresis|In this study, the effective area of radiation (ERA) in the mode continuous (100 percent) is 5 cm2, in 1 MHz and 0.7 W/cm2, with four ERA treated areas. Therapy lasted five minutes (three minutes in the insertion of the supraspinatus and 37 two minutes in the infraspinatus insertion) three times weekly over 6 weeks in addition to therapeutic exercises
45370737|NCT05919121|Other|hydrocortisone iontophoresis|A direct current electrical stimulation unit will be used to apply iontophoresis. The unit has two electrodes; one electrode is for the negative current, and one is for the positive current. The Active (Negative) electrode will be placed on the anterolateral aspect of the shoulder joint. The passive electrode: will be placed on the upper arm region. Intensity of the current: Between the range of 3-5 mA at the point of sensation of patient was set. Treatment duration: Calculated accordingly with intensity of current. Method of application: hydrocortisone gel 10% will be administered by applying on the active rubber electrode for each session three times weekly over 6 weeks in addition to therapeutic exercises.
46053070|NCT05803902|Drug|Placebo|Placebo administered with IV infusion
45370738|NCT05919108|Procedure|Endocrine Therapy|Undergo endocrine therapy
45370739|NCT05919108|Procedure|Biopsy of breast|Undergo breast biopsy
45692385|NCT05582733|Other|Cervical spine manipulation|hot pack for 10 minutes will be applied followed by cervical manipulation (chin hold kaltenborn) once and then stretching
46053071|NCT05803889|Other|Cardiac evaluation|In order to obtain information on the body composition of the patients, a body composition measurement will be performed. A resting cardiac echocardiography will be performed to record myocardial deformations in a non-vulnerable way. A non-invasive evaluation of arterial function will be performed by ultrasound on the femoral artery during a standardized passive movement of the leg. An assessment of myocardial deformations will also be performed under submaximal exercise conditions (at a target heart rate of 120 beats per minute, low to moderate exercise intensity). All of these measurements will be performed during evaluation 1 and reproduced in the same way during the 4 other sessions planned during (evaluation 2, 3 and 4) and after the treatment (evaluation 5).
45370740|NCT05919108|Drug|Neratinib|Taken by mouth
45370741|NCT05919108|Procedure|Biospecimen Collection|Undergo collection of blood samples
45370742|NCT05919108|Procedure|Mammogram|Undergo Mammogram
45370743|NCT05919108|Procedure|Magnetic Resonance Imaging|Undergo breast Magnetic Resonance Imaging
45370744|NCT05919108|Procedure|Breast Surgery|Undergo Breast Surgery
45692386|NCT05582733|Other|traction|Hot pack will be applied followed by sustained pressure or MPR for 90 sec and then stretching.
45692387|NCT05582655|Behavioral|ONLINE|The ONLINE intervention applies the JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation: Kasari et al., 2021) social communication intervention for young children with autism. The JASPER approach has been tested in a caregiver-mediated format where caregivers are taught to use the JASPER strategies with their children during play and home routine (e.g., Kasari et al., 2010; Kasari et al., 2014). The JASPER intervention is being adapted in this study to include online web based materials.
45692388|NCT05582655|Behavioral|COACH|COACH includes live synchronous caregiver coaching in the JASPER intervention model. Coaching follows prior published JASPER caregiver coaching protocols (e.g., Shire, Shih, Barriault, & Kasari, 2022). This implementation strategy has been tested in a pilot study when applied by community early intervention providers (Shire, Baker Worthman, & Arbuckle, 2021).
45692389|NCT05582577|Combination Product|Intravitreal bevacizumab injection with subthreshold micropulse laser|Group A: intravitreal interjection of Bevacizumab and subthreshold micropulse laser
45370745|NCT05919108|Procedure|Ultrasound|Undergo Ultrasound
45370746|NCT05919095|Drug|Carrilizumab plus GEMOX|"PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1intravenous infusion.Three weeks is a course of treatment."
45370747|NCT05919082|Drug|LEO 90100|Subjects will apply LEO 90100 topically; up to 15 g per day (or 105 g per week).
45370748|NCT05919082|Drug|Daivobet® ointment|Subjects will apply Daivobet® ointment topically; up to 15 g per day (or 105 g per week).
45370749|NCT05919069|Drug|AZD2693|Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment
45370750|NCT05919056|Other|Frequent and automatic cardiovascular risk assessment|The 10-year cardiovascular risk scores using the 2019 World Health Organization (WHO) laboratory-based risk charts will be automatically calculated using the latest health information on an EHR-based system per month.
45370751|NCT05919056|Other|Dynamic risk monitoring|High-risk individuals will be reassessed by the Dynamic Risk-based Early wArning and Monitoring (DREAM) system to obtain the short-term risk. The DREAM system will send a text message about advice to the high-risk individual every month. The text message includes information on the health status (e.g., current cardiovascular risk, level of blood pressure and lipid) and real-time warning messages (e.g., high short-term risk).
45489657|NCT02399332|Other|Community pharmacist involvement|Collaborative involvement of the community pharmacists in formulating and following complex care plans
45692390|NCT05582577|Drug|Intravitreal bevacizumab injection alone|Group B: Intravitreal injection of Bevacizumab alone
45370752|NCT05919056|Other|Regular GP visits|"The general practitioners will communicate with the participants based on the information automatically generated from the DREAM system every three months: each participant's cardiovascular risk score, health status (e.g., diabetes mellitus and/or hypertension), and Chinese guidelines-based recommendations (e.g., for the management of dyslipidemia, to provide clear treatment targets for high-risk participants)."
45370753|NCT05919043|Other|Upper limb-based movement priming (UL-priming)|Repetitive upper limb movements administered to the beat of a metronome.
45489658|NCT05744830|Other|Overdenture|15 patients will receive removable complete dentures, then a single implant is placed in the midline of the mandible, then loaded with the denture.
45370754|NCT05919043|Other|Stimulation-based priming (Stim priming)|Noninvasive brain stimulation.
45370755|NCT05919043|Other|Lower limb-based movement priming (LL-priming)|Aerobic exercise using a treadmill or recumbent stepper.
45489659|NCT05744830|Other|Complete Denture|15 patients will only receive removable complete dentures
45370756|NCT05919043|Other|Sham priming|Auditory stimulation.
45370757|NCT05919030|Radiation|Intensity-modulated radiotherapy (IMRT)|Esophageal primary tumor: 39.6Gy/2.2Gy Bone metastasis: 30Gy/3Gy Lung, liver, brain metastases, metastatic lymph nodes: 45Gy/3Gy
45370758|NCT05919030|Drug|Tislelizumab|200 mg IV Q3W
45370759|NCT05919030|Drug|Cisplatin|During concurrent radiation therapy: 25 mg/m² IV QW During consolidation therapy: 75 mg/m² IV Q3W
45370760|NCT05919030|Drug|Nab paclitaxel|During concurrent radiation therapy: 75 mg/m² IV QW During consolidation therapy: 220 mg/m² IV Q3W
45370761|NCT05919017|Drug|Naltrexone implant|Naltrexone implant
45370762|NCT05919017|Drug|Placebo|Placebo
46053072|NCT05803889|Other|Cardiac evaluation|The same measurements as the EC + Tax group will be performed but only once, at the end of the treatment.
45370764|NCT05918991|Behavioral|Daily Report Card|Behavioral consultants will meet with teachers to review daily report card implementation and effective classroom management. The consultant collaborates with the teacher to identify specific behavioral goal targets for the student's DRC based on a review of teacher ratings and teacher description of key problem behaviors. After establishing the initial DRC, the consultant will review procedures with the teacher for scoring the DRC and, importantly, providing the student with effective and consistent performance feedback. The consultant will also make a plan with the teacher to review DRC progress and revise the DRC as needed. Consultants will also meet with parents to develop a plan for reinforcing the DRC at home. The DRC will be implemented for 18 weeks. The behavioral consultants will be available to teachers and parents throughout the duration of the intervention to assist with implementation and adjustment of target behaviors and goals.
45370765|NCT05918991|Other|Language Intervention|The intervention protocol to be provided in each grade level will include 18 weeks of 20-25 minutes of small-group intervention 4 days per week, for a total of 72 lessons. The fifth day per week will be allocated to make-up lessons for students absent earlier in the week to maximize opportunity for each participant to receive the full dosage of lessons. Half of these lessons in each grade will be allocated to Language in Motion implementation and the other half to Dialogic Reading. Dialogic Reading is designed to increase vocabulary knowledge through shared reading of picture books. The content involves reading of 9 children's books with 108 targeted vocabulary words. Language in Motion is designed to increase syntax and grammar knowledge using science manipulatives. Daily lessons are highly scripted to introduce primary syntax targets through narrative text. Manipulation props are used to reinforce syntax targets and basic science topics.
45370766|NCT05918978|Drug|Efgartigimod|Participants will receive efgartigimod IV 10 mg/kg open label, respectively.
45370767|NCT05918965|Device|transcutaneous electrical vagal neurostimulation|daily for 12 weeks
45370768|NCT05918952|Diagnostic Test|Covid-19 Antibody Test|"The investigators propose to use the iHealth® Rapid COVID-19 Antigen Rapid Test. Per the EUA guidance, study participants will complete one test at a study location and receive one test to take home with instructions to complete it within 48 hours.~Each testing site will have a private designated space for customers to self-collect and test themselves privately. The edutainment video will serve as a resource for information on accurate test performance. Test one will be done in a private setting and results entered into REDcap and will also be written on a testing card with contact information for the purpose of follow-up. For test number two the customer will self-collect within 48 hours (per the FDA EUA for this particular test) and results will be entered into RedCap."
45489660|NCT04793646|Drug|N-acetylcysteine syrup|N-acetylcysteine syrup 600 mg (15 mL) twice a day for 3 months
45489661|NCT04793646|Drug|Placebo syrup|Placebo syrup 15 mL twice a day for 3 months
45489662|NCT03106714|Diagnostic Test|RT-PCR|Persistence of detectable Zika virus (by RT-PCR test) in all selected body fluids
45753522|NCT04388215|Drug|CKD-828(placebo)|orally, 1 tablet once a day for 8 weeks
46053073|NCT05803876|Other|Diagnostic test - monitoring|"Continuous measurement of blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) Atys Medical TCD-X®. The probe attachment system on the patient's head looks like a pair of glasses; it is light and comfortable. The orientation of the robotic probe is automatically readjusted to ensure stable recording quality over time. (recorded on Data Warehouse Connect).~For all patients Vm in (cm/s) will be collected during the adjustment of the mean arterial pressure level between 90% and 70% of the baseline value, without ever going below 60 mmHg for the patients at low risk and 80 mmHg for the patients at high cardiovascular risk."
46053074|NCT05803863|Drug|Myatro|myopia control with 0.01% atropine drops
46053075|NCT05803863|Drug|Myatro XL|myopia control with 0.05% atropine drops
46053076|NCT05803850|Drug|HNC1058 Capsules|HNC1058 Capsules/Placebos, single dose, PO, starting dose of 10 mg escalating up to 80 mg；HNC1058 Capsules/Placebos, 50 mg, single dose, FED.
46053077|NCT05803811|Dietary Supplement|Riboflavin|Colon delivered vitamin B2 (Riboflavin) for 12 weeks
45370769|NCT05918952|Other|Short Clip videos|Designed to discuss the testing process, the importance of getting tested and accessing care, and how COVID-19 has disproportionately affected the Black/African-American community.
45370770|NCT05918939|Biological|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|"Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) contains purified S protein of SARSCoV-2 - Dose: 5 µg, aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005%, Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial~(1 ml per vial). The vial should be shaken well before injection."
45370771|NCT05918939|Biological|CoronaVac Biofarma COVID-1 9 Vaccine 3 µg|Control vaccine in this study is existing CoronaVacBioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia.
45370772|NCT05918926|Behavioral|Exercise|Individualised remote exercise intervention
45370773|NCT05918913|Drug|SNDX-5613|SNDX-5613 administered orally every 12 hours.
45370774|NCT05918887|Other|NIDA Standardized Research Electronic Cigarette|"The Standardized Research E-Cigarette (SREC) was developed by NIDA to help researchers assess uncertainties in electronic nicotine delivery devices.~Nicotine pods:~Sealed, pre-filled, non-refillable~1.9 mL e-liquid with 5% w/w nicotine (placebo also available)~Approx 300 (280-330) puffs/pod~Nicotine liquid characteristics:~Volume of liquid per pod 1.9 mL~Active (nicotine USP 5% wt/wt) and placebo (nicotine 0%)~Propylene Glycol USP & Vegetable Glycerin USP - PG/VG Ratio 0.77~Lactic Acid USP~Battery characteristics:~USB Rechargeable~Storage Capacity ~ 400 mAh~Approx 200 (3s) puffs / charge~300 charge cycles to > 80% initial capacity~Time to full charge 75 - 85 min~Voltage / Temperature settings not user adjustable"
45370775|NCT05918874|Other|Descriptive questionnaire|Questionnaires were administered to calculate whether the children were obese or not, to determine their asthma control levels, to determine their physical activity levels and to determine their leisure time activities.
45370776|NCT05918861|Drug|Dalcetrapib|Cholesterol Ester Transfer Protein Inhibitor, 300 mg tablets
45370777|NCT05918861|Drug|Placebo|matching placebo tablets
45370778|NCT05918848|Device|Filme Gyno-V® Vaginal Ovules|Administration of tocopherol (Filme Gyno-V® Vaginal Ovules) for 14 days
45370779|NCT05918835|Device|High-frequency repetitive transcranial magnetic stimulation (active rTMS)|HF-rTMS is applied with a figure-of-8 coil using the Magstim TMS System. Participants receive one administration of HF-rTMS, delivered to the region of the right dorsolateral prefrontal cortex (DLPFC) with greatest resting-state functional connectivity to the dorsal striatum (individualized per participant). HF-rTMS is delivered at a frequency of 10 Hz for approximately 37 minutes (3000 total pulses).
45489663|NCT05336214|Other|Virtual CGM initiation service|Primary care practices will refer patients to an external virtual initiation service staffed by clinical pharmacists, diabetes care and education specialists, and physicians. The initiation service will communicate with eligible patients (referred to the virtual initiation service by their provider) to review device options and provide patient education and support on device use for up to 12 months to help initiate use of the device. The initiation service will communicate with a patient's provider about treatment and follow up, but will not make treatment recommendations directly to patients.
45489664|NCT05336214|Other|Online educational module on CGM|Primary care practices will complete online educational modules, the American Academy of Family Physicians Transformation in Practice Series on CGM. This series includes education on diabetes; glucose monitoring; evidence behind CGM; CGM implementation tools, strategies, and workflows; billing, reimbursement, and insurance authorization of CGM; and tools and strategies to use CGM for quality improvement in diabetes care.
45489665|NCT05336214|Other|Practice facilitation|A practice facilitator will support primary care practices in training team members using the American Academy of Family Physicians Transformation in Practice Series on CGM and in implementation of strategies to support CGM use for patients with diabetes in primary care.
45489666|NCT05232292|Biological|Ultrix Quadri|vaccination by Ultrix Quadri against flu
45489667|NCT03607890|Drug|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
45489668|NCT03607890|Drug|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
45489669|NCT03607890|Drug|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
45692391|NCT04149015|Drug|paclitaxel ,oxaliplatin,fluorouracil|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles.
45370780|NCT05918835|Device|Sham repetitive transcranial magnetic stimulation (sham rTMS)|Sham rTMS is applied with a figure-of-8 sham coil using the Magstim TMS System, which is identical to the active coil, replicates the sounds of HF-rTMS, and is designed to mimic sensations of HF-rTMS. Participants receive one administration of sham rTMS, delivered to the region of the right dorsolateral prefrontal cortex (DLPFC) with greatest resting-state functional connectivity to the dorsal striatum (individualized per participant). Sham rTMS is delivered for approximately 37 minutes (3000 total pulses).
45370781|NCT05918822|Drug|Maribavir Commercial Tablet Formulation|Maribavir commercial tablet.
45370782|NCT05918822|Drug|Maribavir Pediatric Powder-for-oral Suspension Formulation|Maribavir pediatric powder-for-oral suspension.
45370783|NCT05918822|Drug|Rabeprazole|Rabeprazole tablet.
45370784|NCT05918796|Drug|Bupivacaine|18 ml of bupivacaine of 0.25% injected bilaterally in quadratus lumborum block
45370785|NCT05918796|Drug|Dexamethasone|dexamethasone
45370786|NCT05918783|Combination Product|Padeliporfin Vascular Targeted Photodynamic (VTP) therapy|Bronchoscopy will be performed with robotic assisted approach using standard practices using general anaesthesia and placement of the optic fiber intratumorally followed by IV administration of Padeliporfin for 10 min and laser light illumination.
45370787|NCT05918770|Diagnostic Test|systematic screening and early treatment|in case of positive screening, the online app will alert and the patient will be referred to the corresponding area for diagnosis and early treatment (Rehabilitation, Psycho-oncology, Sexual health and Nutrition
45370788|NCT05918757|Other|Protein dose 1.5 g/kg/day|Administration of 1.5 g of protein/kg/day via enteral/parenteral nutrition
45370789|NCT05918757|Other|Protein dose 1.0 g/kg/day|Administration of 1.0 g of protein/kg/day via enteral/parenteral nutrition
45370790|NCT05918744|Behavioral|Sleep Extension|Participants will extend their time in bed by one hour for 2 weeks while being monitored.
45489670|NCT03607890|Drug|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
45489671|NCT03607890|Drug|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
45489672|NCT03607890|Drug|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
45489673|NCT02393638|Other|Simulation and lecture|Endoscopic sphincterotomy on simulator and lecture
45489674|NCT02393638|Other|Lecture|Lecture
45489675|NCT03166852|Other|Home-training|5 weeks of interval training at home. The training consisted of 3 minutes of warm-up. 10 intervals of 1 minute at 90% of maxHR interspersed with one minute of low intensity pedalling. Cool-down period of 2 minutes.
45692392|NCT04149171|Drug|with red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC),administration of Crystalloids and TXA.|The treating physician must have evaluated the patient's eligibility and approved the patient's enrolment in the trial prior to blood samples extraction and RBC, TXA and Fibrinogen Concentrate administration. The experimental and control arms will be determined according to the medical emergency system units with RBC, TXA and Fibrinogen Concentrate administration capacity which will be the H2 helicopter unit ,fast intervention vehicle and G409 ambulance (Advanced Life Support). The medical emergency system units are activated according current protocols based on distance, severity and weather conditions.
45692393|NCT04149171|Drug|conventional treatment|standard treatment based on crystalloid fluid and tranexamic acid (TXA)
45692394|NCT04140591|Drug|Proton-pump inhibitor|PPI: Pariet EC 20mg/QDAC
45753523|NCT04388215|Drug|D326|orally, 1 tablet once a day for 8 weeks
46053078|NCT05803785|Drug|BBC1501|BBC1501 solution for Intravitreal injection
46053079|NCT05803772|Drug|APHD-012|Drug: APHD-012 Distal jejunal-release dextrose beads (Aphaia technology, AT)
46053080|NCT05803772|Drug|APH-012P|Distal jejunal-release placebo beads
46053081|NCT05803746|Drug|18F-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
46053082|NCT05803733|Other|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper limb.
46053083|NCT05803720|Behavioral|Provider Intervention on Addressing Intersectional Stigma and Medical Mistrust in Patients with HIV|The intervention will consist of psychoeducation and skills-building for HIV care providers to gain knowledge and skills needed to address intersectional stigma and medical mistrust with patients. The intervention will be online and conducted in groups.
46053084|NCT05803707|Behavioral|Home-based Adapted Physical Activity|There will be 8 weekly sessions at a time defined in advance for the same group and for the 8 sessions
46053085|NCT05803694|Device|ABL90 FLEX PLUS analyser running SW3.5 MR2.|The ABL90 FLEX PLUS analyzer is a portable, automated analyzer that measures pH, blood gases, electrolytes, metabolites, and oximetry in whole blood - utilizing 3 measuring modes (syringe, short probe, and capillary mode) to measure samples from a syringe, test tube or a capillary tube. The analyzer provides results for 17 parameters in 35 seconds using 65 μL heparinized whole blood.
45692395|NCT04140591|Drug|Propranolol+Proton-pump inhibitor|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure >90mmHg) PPI: Pariet EC 20mg/QDAC
45692396|NCT03909321|Behavioral|Beach tennis training group|Beach Tennis Training Group (BTG) will perform two sessions of 40-60 min of beach tennis during 12 weeks. BT sessions will be composed by a warm up of 5-10 min of BT technical exercises (i.e., serve, volley, forehand and backhand exercises) followed by 3 BT small games of 10-15 min each.
45370791|NCT05918731|Behavioral|Self Management|"A training book was given to this group, which was created for the study. The implementation process followed a five-step approach including sessions once a month for five consecutive months with a coach and follow-up phone calls after the end of the sessions.To inspire and engage patients, the sessions included a variety of educational techniques, including knowledge transfer, discussion, hands-on training, and homework. Additionally, coaches received training in motivational interviewing methods. The self-management program and all the process of data collection is described in detail on the supplementary file."
45370792|NCT05918718|Drug|Letrozole|assessment of the efficacy of Letrozole in treatment of ectopic pregnancy
45370793|NCT05918718|Drug|methotrexate|methotrexate
45489676|NCT02399020|Behavioral|Social Cognition and Interaction Training|manualized group treatment providing training in facial emotion recognition, understanding the role of emotion in social situations, training with videoed vignettes to avoid jumping to conclusions in order to avoid attributional biases, tolerating ambiguity and distinguishing facts from guesses, skill consolidation and generalization to everyday life situations.
45489677|NCT03596736|Procedure|Elbow Hemiarthroplasty|
45489678|NCT03596736|Procedure|Total Elbow Arthroplasty|
45489679|NCT05744752|Other|Lead Acetate|The oral LD50 of lead acetate is 390mg/kg body weight. The experimental group B, C, and D will receive a single dose of 19.5 mg/kg b.w (1/120th of LD50),31 daily dissolved in distilled water and given by oral gavage method for 12 weeks. Lead acetate Pb(CH3COO)2x3H2O, will be purchased from Sigma-Aldrich Chemie (Germany).
45489680|NCT05744752|Dietary Supplement|Moringa oleifera Extract|The method described by Hanaa Elgamily(32) with minor modifications. Fresh Leaves will be washed and dried in dry heat oven. All the preparation will be done in pharmacological department, University of Health Sciences in sterile environment. Dried leaves will be crushed to make fine powder. 1000 g powder of MO will be socked in 5000 ml of 70% ethanol (70% ethanol and 30% distilled water) for 72 hours at room temperature. Then mixture will be magnetically stirred for 24 hours and stored at 4oC for 48 hours to allow extraction of active ingredients. Then the mixture will be filtered twicely by using Whatman No 1 filter paper. The extract will be concentrated by rotary vacuum evaporator at 40 oC to evaporate the solvent. The extract will be freeze, dried and stored at -70 oC for use. Dose of MO extract will be 400 mg per kg.(33) body weight given daily in 1ml of distilled water by oral gavage method for 12 weeks.
45692397|NCT05582109|Drug|Envafolimab, Lenvatinib Combined With TACE|PD-L1 inhibitor
45692398|NCT04140123|Drug|ZSP1601|ZSP1601 tablets be taken orally for 28 days.
45692399|NCT04140123|Drug|ZSP1601 Placebo|Subjects will receive matching placebo of ZSP1601
45692400|NCT03020901|Drug|Teicoplanin for Injection|Use Teicoplanin for Injection
45692401|NCT04140201|Drug|Simvastatin 40mg|Drugs that lower lipid level
46053086|NCT05803681|Device|Capacitive Coupled Electric Fields (CCEF)|In the CCEF Group, patients received, as an adjunct to the clinical study protocol, CCEF stimulation (Osteospine®, IGEA SpA, Carpi, Italy) 8 h/die for sixty days.
45692402|NCT04140201|Drug|Fenofibrate 200mg|Drugs that lower lipid levels
45692403|NCT04140201|Drug|Omega 3 fatty acid|Drugs that lower lipid levels
45692404|NCT05581875|Drug|Belantamab Mafodotin-Blmf|Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes
46053087|NCT05803681|Other|Calssic clinical protocol|(1) bed rest for the first twenty-five days and subsequent mobilization with a three-point hyperextension brace; (2) antiresorptive therapy (75 mg risedronate tablet weekly); (3) supplemental calcium carbonate with 1000 mg of elemental calcium daily if needed based on serum calcium concentration; (4) Vitamin D (≤500 IU daily) if the serum 25-hydroxyvitamin D concentration at the time of screening was below 16 ng/ml). Analgesic therapy with paracetamol 1000mg tablets was assumed for seven days and further depending on pain intensity; patients were required to report on a specific sheet paracetamol assumption.
46053088|NCT05803642|Drug|Olanzapine|intramuscular injection, 10 mg/dose, first dose and an optional second or third dose.
45489681|NCT05744752|Dietary Supplement|Allium sativum Extract|Fresh Allium sativum bulbs will be selected for study. The cloves will be peeled, washed with distilled water and dried under shed. Then it will be chopped into small pieces. 1000g of chopped garlic will be crushed by mortar and passel. The garlic paste will be mixed with 5000 ml of 70% ethanol (70% ethanol and 30% distilled water) for 72 hours at room temperature. Rest the procedure is same as mentioned in moringa extract. Dose of 500 mg per kg(34) body weight garlic extract will be given daily in 1ml of distilled water.
45489682|NCT05744752|Other|Placebo|1ml NaCl 0.9% daily for 12 weeks
45489683|NCT02393404|Other|PT-FMT|Physiotherapeutic functional movement-power training
45489684|NCT02393404|Other|FMT alone|Physiotherapeutic power training
45692405|NCT05581875|Drug|Daratumumab|Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
45370794|NCT05918705|Procedure|Ultrasound optic nerve sheath diameter / eyeball transverse diameter ratio|"Ocular ultrasonography will be performed once daily on patients diagnosed with sepsis associated encephalopathy at the bedside by two experienced examiners, who will be blinded to patients' clinical data, following the CLOSED protocol for ONSD sonography.~ONSD will be measured at 3 mm behind the merging point of the nerve from the papilla optic disc. The maximum external diameter of ONSD will be measured in the transverse plane perpendicular to the optic nerve and the maximum diameter of ETD (parallel lens) on this plane will be measured.~Two measurements will be taken for each eye; horizontal and vertical. The sequence for measurements will be left eye horizontal; left eye vertical; right eye horizontal; right eye vertical.~The ONSD measurements in the transversal and the sagittal plane for each eye measured by the two examiners will be averaged. Then, ETDs measurements will be averaged to obtain averaged ONSD/ETD ratio as a data to record the mean values of ONSD/ETD ratio."
46053089|NCT05803642|Drug|Haloperidol|intramuscular injection, 7.5 mg/dose, first dose and an optional second or third dose.
45370796|NCT05918679|Behavioral|Effects of speech variability on speech motor learning|This intervention will examine whether reducing normal variability of speech could improve error detection and speech motor learning. We will design training tasks to change subjects' speech variability. We will train subjects to decrease/decrease their speech variability. Upon completing the training tasks, subjects will complete a motor learning task.
45370797|NCT05918679|Behavioral|Effects of error-detection training on speech motor learning|This intervention will examine whether improving subjects' ability to detect and estimate auditory perturbation could improve speech motor learning. For this purpose, we will design training tasks to change subjects' estimation of the perturbation magnitude. After completing the training tasks, subjects will complete the motor learning task.
45489685|NCT02393482|Drug|Estroprogestinic therapy (Etinil-estradiol/levonorgestre)|Etinil-estradiol/levonorgestrel (100 mcg/20 mcg)/die
45489686|NCT02393482|Drug|Gonadotropin-releasing hormone agonist (Leuprorelin acetate)|Leuprorelin acetate (3,75 mg/2 ml)/month
45489687|NCT02393482|Drug|Add back therapy 1 (tibolone)|tibolone 5 mg/die
45489688|NCT02393482|Drug|Add back therapy 2 (calcium carbonate/colecalciferol)|calcium carbonate/colecalciferol (500mg/400UI)/die
46053090|NCT05803603|Behavioral|Stipend and Social Work Supports|Same as arm description
45692406|NCT05581875|Drug|Pomalidomide|Pomalidomide will be administered per os.
45692407|NCT05581875|Drug|Dexamethasone|Dexamethasone will be administered intravenously or per os.
46053091|NCT05803590|Drug|Green tea mouthwash|effictive against caries and periodontal diseases
46053092|NCT05803590|Drug|Chlorhexidine mouthwash|the gold standard against which other anti-plaque and gingivitis agents are measured
46053093|NCT05803564|Device|Thoracoabdominal aortic stent system|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with thoracoabdominal aortic stent system.
46053094|NCT05803538|Device|SMS, telephone interview or diary card|SMS, telephone interview or diary card
45489689|NCT03166774|Other|Program of support of the sexual health|Patients included in the study have to answer to a questionnaire
45489690|NCT02393560|Procedure|DECT scan|
45489691|NCT03346057|Drug|Sugammadex 2 mg/kg|Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex 2 mg/kg for reversal of moderate NMB. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.
45692408|NCT03945045|Procedure|Subclavian vein approach|Subclavian vein approach for Ultrasound-guided Implantation of TIVAD
45692409|NCT03945045|Procedure|internal jugular vein approach|internal jugular vein approach for Ultrasound-guided Implantation of TIVAD
46053095|NCT05803525|Other|Intra-canal medication protocol|"Copious gentle irrigation will be provided without canal instrumentation using 20 mL 1.5% NaOCl in a slow flowing rate by a 27-gauge irrigating side vented needle positioned 2 mm from the root end followed by 20 mL saline.~After root canal dryness using paper points , double antibiotic paste (DAP) containing 500 mg of metronidazole and ciprofloxacin mixed with 0.5 mL polypropylene glycol giving a creamy paste will transported into root canal via lentulo spiral filler positioned 2 mm shorter than the WL apically and to level just below the cement-enamel junction (CEJ) coronally. Access cavity will be sealed response to the initial treatment will be assessed after 3 weeks.(21) In the next visit, If the patient is asymptomatic, the DAP will be removed using 10 mL of NaOCl according to the concentrations mentioned in each study group, followed by copious irrigation with 10 mL of 17% EDTA (22) and normal saline then drying the canals with sterile paper points."
46053096|NCT05803499|Behavioral|Targeted Cognitive Behavior Therapy for Insomnia|This intervention consists of six, 50-min. online individual sessions delivered via video conference. Content was developed by tailoring standard cognitive behavioral therapy for insomnia (CBT-I) to the specific needs of people who recently lost spouses/long-term partners, by using qualitative data gathered in focus groups. The intervention incorporates key concepts of CBT-I (sleep restriction; stimulus control) and positive emotion psychology (everyday mindfulness; gratitude and self-compassion). Individualized sleep plans (including weekly sleep windows) will be created for intervention participants, and each weekly session will involve a discussion about participants' progress in improving sleep disturbance. Support and recommended coping skills for loss and bereavement will also be provided.
45370798|NCT05918679|Behavioral|Contributions of error awareness to speech motor learning|This intervention will examine the contributions of error awareness to speech motor learning. Subjects will produce a target word while receiving perturbed auditory feedback with different magnitudes. Subjects will be trained to indicate the magnitude of the error they perceived with or without visual feedback.
45489692|NCT03346057|Drug|Sugammadex 4 mg/kg|Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex 4 mg/kg for reversal of deep NMB. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.
45370799|NCT05918679|Behavioral|Enhancing auditory-to-motor mapping with augmented visual feedback|This intervention will determine the contributions of enhanced auditory-to-motor mappings to speech motor learning. We will design training tasks in which we will use visual feedback to provide feedback regarding subjects' accuracy of auditory-to-motor mapping.
45370800|NCT05918679|Behavioral|Effects of enhanced auditory-motor awareness on speech motor learning|In this intervention, subjects will be trained to control their articulators more accurately and be more aware of their articulators' position and their auditory consequences. After the training tasks, subjects will complete a motor learning task.
45692410|NCT04148469|Procedure|Dry needling|Dry needlin is a manual therapy technique used for miofascuial pain syndrom treatment. The patient will be supine, in a confortable position. The therapist localizes the trapezius trigger point number 2 and then performes the needling until 2 REL are obtenined. The patient will remain supine during 15 minutes.
45370801|NCT05918653|Other|Home Healthcare|No intervention in this study
45370803|NCT05918627|Drug|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
45370804|NCT05918627|Drug|Placebo|Pharmaceutical form: capsule; Route of administration: oral
45692411|NCT04148469|Procedure|Transcutaneous Nerve Stimulation.|Transcutaneous Nerve Stimulation (TENS) is a current used for pain treatment. The needle will be used as the negative pole and a adhesive patch 2 centimeters lateral will be the positive pole. The frecuency selected will have 2 Hz with pulses of 120 microseconds. The currente will be applied for 15 minutes.
45692412|NCT04148469|Procedure|Placebo needling|No active technique is performed with the placebo needling. Patient will be supine and a placebo needle willb be performed. The patient will remain supine for 15 minutes.
45370805|NCT05918614|Drug|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
45370806|NCT05918614|Drug|Placebo|Pharmaceutical form: capsule; Route of administration: oral
45489693|NCT03346057|Drug|Sugammadex 16 mg/kg|Following administration of NMBA (Rocuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex 16 mg/kg for reversal of deep NMB. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.
45692413|NCT04406025|Procedure|participation in Regional Anesthesia Seminar|this group of anesthesiologists attended the Regional Anesthesia Seminar
45692414|NCT04406025|Procedure|no participation in Regional Anesthesia Seminar|this group of anesthesiologists did not attend the Regional Anesthesia Seminar
46053097|NCT05803499|Other|Information-Only Control|The control session (approx. 50-min. in length) will be delivered online in a one-to-one format (participant and facilitator) via videoconference. Educational brochures based on recommendations provided by the American Academy of Sleep Medicine focused on sleep and health and sleep hygiene education will be used. No specific or individualized recommendations will be given to control participants.
45370813|NCT05918588|Drug|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
45370814|NCT05918588|Drug|Placebo|Pharmaceutical form: capsule; Route of administration: oral
45370815|NCT05918562|Dietary Supplement|Low fiber diet|Low fiber diet including cereal, white bread, eggs, meat, dairy
45370816|NCT05918562|Dietary Supplement|Standard clear liquid diet|Standard clear liquid diet including broth, jello, water, juice
45370817|NCT05918549|Device|Motion Analysis in Musculoskeletal Oncology|Noninterventional, prospective, multicenter pilot study of patients with primary and secondary musculoskeletal tumors designed to investigate functional outcomes after therapy using both subjective and quantitative motion detection techniques
45370818|NCT05918536|Diagnostic Test|evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT|Noninterventional, prospective study of patients operated on for musculoskeletal neoplasms designed to evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT
45370819|NCT05918523|Biological|Renal Autologous Cell Therapy (REACT)|No interventions in this trial
45489694|NCT03346057|Drug|Neostigmine + Glycopyrrolate|Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Neostigmine (50 μg/kg; 5 mg maximum) and Glycopyrrolate (10 μg/kg; 1 mg maximum) for reversal of moderate NMB. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.
45489695|NCT03346057|Drug|Rocuronium|To achieve NMB, participants received steroidal NMBA Rocuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.
45489696|NCT03346057|Drug|Vecuronium|To achieve NMB, participants received steroidal NMBA Vecuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.
45489697|NCT02393326|Procedure|partial pulpotomy with biodentine|After caries removal resulted in a pulp exposure, the pulp at the exposed area is amputated to a depth of 2 mm. The wound surface is irrigated and dried. After homeostasis is obtained, biodentine is gently applied to the wound surface, and then covered with reinforced zinc oxide-eugenol
45489698|NCT02393326|Procedure|Formocresol pulpotomy|Following removal of the coronal pulp and achievement of homeostasis, a cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min. The pulp stumps is then covered by IRM.
45489699|NCT03523962|Drug|DuraPrep|The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol. 3M™ DuraPrep™ [3M Health Care, St Paul, MN], will be the commercial product used.
45489700|NCT03523962|Drug|ChloraPrep|The CHG intervention is an antiseptic solution comprised of 2% CHG in 70% isopropyl alcohol. ChloraPrep® [CareFusion Inc., Leawood, KS, USA] will be the product used.
46053098|NCT05803460|Behavioral|Stage 1 Experimental A group: actual natural environment|Participants will go to the park and sit still for 20 minutes.
45370820|NCT05918510|Diagnostic Test|Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx|The prospective observational study involves the collection of tissue, blood and saliva samples from OPSCC and occult T patients for detection of HPV-DNA/RNA, miRNA and mutation profile from DNA with centralized analysis of samples at IRCCS Regina Elena National Cancer Institute.
45370821|NCT05918484|Device|Intermittenly scanned continuous glucose monitoring|"Use of Intermittenly scanned continuous glucose monitoring (FreeStyle Libre) and meeting the glycometric data criteria:~Time in range 70-180 mg/L >70%~Glycemic management index <7%~Coefficient of variation <36%"
45489701|NCT02398708|Other|Questionnaires|Both groups will have questionnaires collected and compared.
45489702|NCT02398708|Other|Blood Sample|Both groups will have a blood sample collected and compared.
45692415|NCT04140045|Other|Water intake|Water intake will be manipulated in both arms to create a hypohydrated state and a euhydrated state, post-exercise
45370822|NCT05918484|Other|MODY genetic diagnostic test|"Those patients fulfilling the glycometric data criteria and with clinical MODY suspicion:~diagnosis before 35 years of age~first-degree family history of diabetes.~negative pancreatic autoimmunity (Ac GAD, IA-2A and Ac ZnT8)~preserved pancreatic beta cell function defined as C-peptide > 0.2 ng/mL in the presence of plasma glycemia >140 mg/dL).~Those patients who meet the previous criteria will proceed to the MODY genetic diagnostic test."
45489703|NCT02398708|Other|Stool Sample|Both groups will have a stool sample collected and compared.
45489704|NCT02398708|Other|Clinical data|Both groups will have clinical data collected and compared.
46053099|NCT05803460|Behavioral|Stage 1 Experimental B group: virtual reality natural environment|Participants will experience the virtual reality natural environment by the researcher for 20 minutes
46053100|NCT05803460|Behavioral|Stage 1 Control group: city environment|Participants will sit still for 20 minutes in a city environment.
46053101|NCT05803460|Behavioral|Stage 2 group|tree element virtual natural environment and tree and water element virtual natural environment experiences
45370823|NCT05918471|Dietary Supplement|Very Low Energy Diet with Liquid Supplementation|"The preoperative VLED protocol will utilize Optifast 900, a commercially available weight loss product sold by Nestlé Health Sciences. Optifast 900 is designed as a high-protein, low-carbohydrate, and low-fat meal replacement with complete micronutrient composition. Instructions for use are as follows:~Consume 4 Optifast 900 packets each day~Take 1 sachet of Optifast 900 once in the morning (AM), once at noon, once in the early evening (PM #1), and once later in the evening (PM #2) for three-weeks.~Mix 1 sachet with at least 300 mL (1 1⁄4 cups) of cold water. Shake well or blend in a blender."
46053102|NCT05803460|Behavioral|Stage 3 Experimental group: virtual reality natural environment|virtual reality natural environment programs for 2 time a week (40 mins/ every week) and 8weeks.
45370825|NCT05918419|Drug|Serplulimab|PD-1 antibody
46053103|NCT05803460|Behavioral|Stage 3 Control group: routine care|Control group received routine care last for 8 weeks.
45370827|NCT05918393|Behavioral|functional communication training|During functional communication training, signaled intervals of reinforcement (i.e., the functional reinforcer is available contingent on communication) and extinction (i.e., the functional reinforcer is unavailable and thus both problem behavior and communication are on extinction) will be alternated within a single session. All communication responses will be reinforced every time they occur during the signaled reinforcement intervals.
45370828|NCT05918380|Behavioral|PAL2|"Low CVD risk participants (CAC < 100) will be followed by their primary care provider accompanied by monthly contact with community health workers provided by ACHIEVE Greater who will screen participants for social determinants of health and implement the PAL2.~PAL2 is defined as a community health worked based intervention to mitigate psychosocial and health equity barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education."
45370829|NCT05918380|Other|CINEMA|High CVD risk participants (CAC ≥ 100) will be followed by specialists in the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) at UHCMC. While they too will be assessed, by the CHW for SDOH and a plan developed to address them, this plan will be addressed by the usual resources available in the CINEMA clinic.
45370830|NCT05918354|Device|Skin Prick Automated Test|Detection of sensitisation to specific allergens via the skin prick automated test.
45370831|NCT05918341|Drug|Piracetam|Subtherapeutic dose of piracetam (once-weekly doses of 7.5 mg, 5 mg, 2.5 mg and 1.25 mg)
45370832|NCT05918328|Drug|Albumin paclitaxel+trastuzumab+pyrrolitinib|Albumin paclitaxel 260mg/m 2+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+pyrrolitinib (400mg, QD), one cycle every 21 days.
45370833|NCT05918328|Drug|Docetaxel+Carboplatin+trastuzumab+Parstuzumab|Docetaxel 75 mg/m2+carboplatin (AUC=6)+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+patuzumab (initial loading dose 840mg, sequential maintenance dose 420 mg), one cycle every 21 days
45370834|NCT05918315|Procedure|Buccal mucosa substitution urethroplasty|Use of buccal mucosa as a substitution for urethroplasty
46053104|NCT05803447|Other|Interview questionnaire|"An Interview questionnaire concerning an assessment of the intensity suicidal behavior, M.I.N.I. 7.0.2 was used.~M.I.N.I. interview was conducted with each patient to verify the intensification of suicidal behaviour."
46053105|NCT05803447|Diagnostic Test|biochemical parameters|"The concentrations of the following parameters were determined from the:~blood serum: vitamin D3, B12, folic acid, sodium, potassium, calcium, magnesium, chlorine, total cholesterol, LDL and HDL fractions, TG~plasma: metabolites of the oxidative stress"
45489705|NCT02398864|Procedure|EBUS with TBNA|endobronchial ultrasound (EBUS) with transbronchial needle aspiration (TBNA)
45489706|NCT03166306|Diagnostic Test|PET-CT Imaging with [89Zr]-bevacizumab|Subjects will receive 1 millicurie of 89Zr and less than 5 mg of bevacizumab, followed by PET-CT imaging.
46053106|NCT05803447|Diagnostic Test|cognitive function|The participants completing cognitive function were assessed using computer CogState Test. The following cognitive functions were assessed: psychomotor drive (DET), metastability of attention (IDN), verbal memory, retrieval of learned material (ISLR) and verbal learning and memory (ISL), visual learning and memory (OCL), processing speed (GMCT), visual memory including deferred retrieval (GMR), executive functions (SETS and GML), working memory (ONB, TWOB).
45370835|NCT05918302|Drug|177Lu-edotreotide|6 cycles of 7.5 ± 0.7 Giga becquerel (GBq) 177Lu-edotreotide
45370836|NCT05918302|Drug|Everolimus|10 mg orally once daily (QD)
45370837|NCT05918289|Behavioral|Blended& integrated happy aging active aging program(BIHAAAP)|12 Weeks intervention devided in to two phases( face to face and home based)
45370838|NCT05918276|Drug|Orelabrutinib and BG|"Drug: Orelabrutinib Orelabrutinib 200mg, po, qd，C2-C7. Twenty-eight days for a cycle.~Drug: BG Bendamustin 70mg/m2, IV, d2&d3 inC1, and then d1&d2 inC2-6.Twenty-eight days for a cycle.~Obintuzumab 100mg IV, d1, 900mg d2, 1000mg d8&d15 in C1, and then 1000mg/m2 IV, d1 in C2-6. Twenty-eight days for a cycle."
45370839|NCT05918263|Behavioral|High-Intensity Interval Training Exercise Program|Home-based, virtually supervised, aerobic exercise program of 48 sessions accessible via internet-enabled tablet (provided to participant if needed). Participants will be supplied with stationary bike, heart rate monitor, and blood pressure monitor.
45489707|NCT03631992|Behavioral|Low Sweet|Children in the experimental group get repeated exposure to lower sweet snacks and mothers get education lessons on dental care, reading food labels, portion size, and nutrition.
45489708|NCT03631992|Behavioral|Regular Sweet|Children in sham comparator get typical snacks and mothers get education lessons on portion size, physical activity, sleep, and screen time.
46053107|NCT05803408|Other|gluten-free oats|Early vs late introduction of gluten free oats
45489709|NCT02398630|Radiation|TC Virtual Hysterosalpingography|Virtual hysterosalpingography: a new multidetector CT technique for evaluating the female reproductive system
46053108|NCT05803369|Behavioral|Regulating Together (RT)|Regulating Together is an intensive outpatient group treatment targeting emotion dysregulation. It engages both caregivers and children and utilizes evidence-based intervention techniques including cognitive behavioral therapy (CBT), visuals, reinforcements, and scaffolding, and newer interventions such as mindfulness and acceptance-based therapy.
46053109|NCT05803369|Behavioral|Achieving Independence and Mastery in School (AIMS)|AIMS is a school-based program developed to help students with social-communication challenges (such as autism spectrum disorder) achieve academic success. It is well-established and has been used with autistic youth, both in schools and in outpatient settings.
46053110|NCT05803343|Behavioral|Regulating Together-Canine|RT-C is an animal assisted, intensive outpatient group intervention for children with autism spectrum disorder and emotion dysregulation. RT-C meets for 1.5 hours, twice weekly for five weeks with concurrent youth and caregiver groups. The children progress through skills including relaxation training, arousal ratings, problem size, mindfulness, problem solving, and cognitive flexibility. The caregivers learn crisis management, reward systems, and coaching strategies for topics taught to the children. Homework is utilized to reinforce use of skills outside the group. The canines are present throughout as both a calming presence and teaching assistant. Children will be able to interact with the dog when practicing relaxation at the beginning of each session and throughout the session. Additionally, the dog will help to emphasize certain curriculum concepts.
46053111|NCT05803343|Behavioral|Regulating Together-Standard|RT-S an established, intensive outpatient group intervention for children with autism spectrum disorder and emotion dysregulation. It engages both caregivers and children and utilizes evidence-based intervention techniques including cognitive behavioral therapy (CBT), visuals, reinforcements, and scaffolding, and newer interventions such as mindfulness and acceptance-based therapy.
45692416|NCT05587881|Biological|COVID-19 vaccine(donor)|Donor received COVID-19 vaccine before stem cells collection.
45370840|NCT05918250|Biological|mRNA-2736|mRNA-2736 will be administered IV.
45370841|NCT05918237|Other|Arctiva|A colloidal oatmeal cream designed to stimulate healing and repair of damaged tissue naturally, working with the body instead of against it.
45370842|NCT05918224|Drug|Streptococcus salivarius K12|The patients in intervention group were treated with Streptococcus salivarius K12 lozenges three times a day after gargling from the first day of radiotherapy up to 1 week after the end of treatment. Streptococcus salivarius K12 is dissolved in the mouth and then swallowed.
45370843|NCT05918224|Drug|Streptococcus salivarius K12 simulants|Patients in control group were treated with Streptococcus salivarius K12 simulants, and its use method and use time are the same as intervention group.
45370844|NCT05918211|Drug|Udenafil|Active drug
45370845|NCT05918211|Drug|Placebo|Matching Placebo
45370846|NCT05918198|Drug|Ven+CAG|"100 mg on the first day, and then gradually increase to the target dose of 400 mg (100 mg d1, 200 mg d2, 400 mg d3) within 3 days; After that, the drug continued to be administered until the 14th day, 400 mg/day. When combined with CYP3A or P-gp inhibitors (mainly voriconazole in this study), adjust the venetoclax dose to 100 mg/day.~Ara-C 10mg/m2, ih, q12h × 14d； Acla 20mg/d × 4d； G-CSF 5ug/kg × 14d (WBC > 30 × 10^9/L pause)"
45370851|NCT05918172|Device|endotracheal cuff pressure manual measurement|The cuff pressure of the tracheal tube will be monitored every 8 hours in the manual group using a portable manometer. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients. Before starting to work, PICU nurses will be given training in recognizing and preventing VAP and using cuff pressure measuring devices. The application period will continue from the day of intubation to extubation or a maximum of 14 days. Study data forms will be filled out by PICU nurses and monitored by physicians. The research group will periodically observe PICU personnel to verify adherence to the protocol. While patients are mechanically ventilated, VIP findings will be routinely screened at each daily visit.
45489710|NCT02398630|Other|MRI Virtual Hysterosalpingography|Magnetic Resonance Imaging Virtual hysterosalpingography
45489711|NCT02398630|Other|Antimullerian Hormone dosing|Blood Draw for Antimullerian Hormone dosing
45489712|NCT02398630|Other|Transvaginal Echography|Transvaginal Echography for evaluating the female reproductive system
45489713|NCT03631914|Procedure|Infraclavicular brachial plexus block|An infraclavicular brachial plexus block is performed using ultrasound guidance.
45489714|NCT02398552|Drug|Sunitinib|altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.
45489715|NCT03402906|Behavioral|Family-Clinician Collaboration Program|Family-mediated treatment activities and collaboration between clinician and family members
45489716|NCT03402906|Behavioral|Standard Care at KIR|Participants will receive the standard care provided at Kessler Institute for Rehabilitation.
46053112|NCT05803330|Drug|Abandonment of intravenous volume expansion during preoperative preparation in patients with pheochromocytoma|Abandonment of intravenous volume expansion with alpha-blockers during preoperative preparation in patients with pheochromocytoma
46053113|NCT05803317|Other|usual care : Evaluation of walking on a baropodometric platform|Pure observationnal study
45489717|NCT03345979|Combination Product|Aripiprazole Lauroxil|Intramuscular injection; study drug provided using a pre-filled syringe
45489718|NCT03345979|Drug|Paliperidone Palmitate|Intramuscular injection
45489719|NCT04680468|Drug|Belantamab mafodotin|2.5 mg/kg IV
45489720|NCT04654338|Radiation|SABR + HDR|One SABR treatment + one HDR brachytherapy treatment
45489721|NCT02696434|Drug|Naltrexone|daily dosing
45489722|NCT02696434|Drug|Placebo|daily dosing
45489723|NCT02696434|Drug|Buprenorphine|daily dosing
45489724|NCT05683093|Other|History of being born to hypertensive or normal pregnancy|"CLARITY is an observational study whereby participants will attend one 4-hr visit the Division of Cardiovascular Medicine, University of Oxford at the John Radcliffe Hospital in Oxford, with the option to split the study visit over two days for convenience.~Participants will be invited by the ALSPAC study team to attend a study visit in Oxford where the investigators will use MRI and other imaging modalities to study the brain, heart, liver, kidneys, and vasculature using standardised protocols. A dataset including information from previous follow-up of these cohorts and the detailed pregnancy data available within ALSPAC will be generated by the study team in Bristol and integrated with available data from the Oxford cohorts."
45692417|NCT05587881|Biological|COVID-19 vaccine(patient)|Patient received COVID-19 vaccine before allo-HSCT.
46053114|NCT05803278|Other|Online enhancement training|"Online enhancement training lasting 3 months, using the InTempo app system (Gea-Metaphonology-Athena-reading/Ermes-writing) three times a week for twenty minutes. The training will include: Metaphonological Enhancement; Reading Enhancement; Writing Enhancement."
45370852|NCT05918172|Device|endotracheal cuff pressure automatic measurement|"The cuff pressure of the tracheal tube will be monitored continuously using a pneumatic device in the automatic group. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients.~Before starting to work, PICU nurses will be given training in recognizing and preventing VAP and using cuff pressure measuring devices.~The application period will continue from the day of intubation to extubation or a maximum of 14 days Study data forms will be filled out by PICU nurses and monitored by physicians. The research group will periodically observe PICU personnel to verify adherence to the protocol. While patients are mechanically ventilated, VIP findings will be routinely screened at each daily visit."
45370853|NCT05918159|Other|Sarcopenia Assessment|The prevalence of sarcopenia in a group of elderly people and its correlation with other health variables was determined.
46053115|NCT05803252|Behavioral|Focused Acceptance and Commitment Therapy|"FACT aims to increase one's psychological flexibility so that one will not generate feelings of distress and suffering when confronted with painful life situations. The intervention of this study will follow the FACT principles laid out by Strosahl, Robinson and Gustavsson to increase parents' psychological flexibility. Three core processes influence one's psychological flexibility: awareness, openness, and engagement.~The key objectives of each core process are:~Awareness: Able to experience the present moment, able to take perspective on self~Openness: Able to detach distressing private experiences and associated rules, able to take a non-judgemental, accepting stance towards painful material~Engagement: Exhibits strong connection with values, able to sustain values-consistent action"
46053116|NCT05803252|Other|Waitlist Control|The waitlist control group participants will commence their FACT intervention immediately after they complete their follow-up assessment.
46053117|NCT05803239|Device|EBUS-TBNA|Participants would undergo EBUS-TBNA(NA-201SX-4022, OLYMPUS MEDICAL SYSTEMS CORP, JAPAN).
45370858|NCT05918120|Device|Home Sleep Apnea Test|Use of a home sleep apnea test that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
45370859|NCT05918120|Device|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
45692418|NCT05586165|Behavioral|Reminder to boost protection against COVID-19|Patients will receive a text message reminding them to enhance their protection against COVID-19 by getting the bivalent booster. The message will contain one link to schedule an appointment at UCLA Health and one link for scheduling an appointment at CVS Pharmacy.
45370864|NCT05918094|Drug|Experimental dose: modified XELOX + sintilimab|The treatment option for the modified XELOX group (study group) is 200 mg of sintilimab IV Drip Q3W, 600 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 78 mg/m2 IV Drip Q3W.
45489725|NCT04615416|Behavioral|Emotion Regulation Training via Telehealth|The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
45489726|NCT03345901|Drug|Pemafibrate|0.2 mg orally BID - twice daily
45489727|NCT03345901|Drug|Placebo|orally BID - twice daily
45692419|NCT05586165|Behavioral|Flu Tag Along|This message will also encourage patients to protect themselves against the flu by asking for their flu vaccine at the booster appointment (at UCLA Health) or adding the flu vaccine to the COVID-19 vaccine booster appointment (at CVS).
45692420|NCT05586165|Behavioral|COVID-19 Booster & Flu Bundle|This message will simultaneously encourage patients to enhance their protection against COVID-19 and the flu and will inform them that, to save time, they can bundle two vaccines at once. Patients will learn that at UCLA Health, they can book an appointment for the booster and then ask for the flu vaccine at their appointment; at CVS Pharmacy, they can book one appointment to get both the bivalent COVID-19 booster and the flu vaccine.
45692421|NCT03944265|Other|Counseling|Participate in treatment decision counseling session
45692422|NCT03944265|Other|Questionnaire Administration|Ancillary studies
45489728|NCT02393092|Behavioral|Brief Violence Awareness|The Brief Violence Awareness (BVA) will consist of a packet of information about violence prevention and local community resources.
45489729|NCT02393092|Behavioral|Brief Violence Prevention|The Brief Violence Prevention (BVP) will be a psycho-educational intervention administered by a case manager that will include an interactive discussion with youth regarding resources for remaining safe and preventing violence. The intervention will address the concerns and questions of youth and youth will be given information on how to access community based resources if needed.
45692423|NCT03944265|Other|Medical Chart Review|Ancillary studies
45692424|NCT04148547|Device|Sooma transcranial direct current stimulation device|This group received brain training through transcranial direct current for 20 minutes.
45692425|NCT04148547|Device|Placebo Sooma transcranial direct current stimulation device|This group received sham brain training through transcranial direct current for 20 minutes. The current is active for 15 seconds and then switches off until the intervention is finished.
45692426|NCT03588897|Dietary Supplement|Nutridrink Multi Fibre|Dietary supplementation of 300 kcal for 14 days
45489730|NCT02393092|Behavioral|Emerging Leaders: East End curriculum|The Emerging Leaders: East End curriculum focuses on positive youth development and education, which includes an emphasis on health careers. The curriculum will be administered at the Boys and Girls Club of Metro Richmond, Martin Luther King Middle School site.
45692427|NCT03941847|Other|music|listening music
45370865|NCT05918094|Drug|Standard dose: standard XELOX + sintilimab|The treatment option for the standard XELOX group (control group) is 200 mg of sintilimab IV Drip Q3W, 1000 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 130 mg/m2 IV Drip Q3W.
45370866|NCT05918081|Other|Multi-Stage 20 m Shuttle Run Test|"The aerobic capacities of the participants will be evaluated with the Multi-Stage 20 m Shuttle Run Test, their agility levels with the Pro Agility Test, their core muscle endurance with the McGill Trunk Extensor and Flexor Endurance test and their peripheral muscle strength with the MicroFET® 2 handheld dynamometer."
45370867|NCT05918068|Drug|Metformin 500 mg/day|Metformin 500 mg/day in addition to non-pharmacological therapy
45489731|NCT04254198|Behavioral|TERTULIAS structured dialogue peer support groups|"TERTULIAS will involve structured dialogue groups using the model developed and tested by the investigators through their preliminary research. Each group will have 10 women and will meet weekly for two hours over a 12-month period. Group meetings will be conducted in Spanish, led by a team of two FMI facilitators. Facilitation will use the structured dialogue approach. In the last two months of each cohort, participants will be invited to write their own stories or recipes, or produce poetry or art representing their experience to share with the group. These contributions will be gathered and reproduced in booklet form and each participant will receive a copy."
45489732|NCT04254198|Behavioral|Modified Attention Placebo Control (MAPC)|MAPC participants will receive a phone call every other month from the project coordinator to document that their contact information is up to date, to remind them that they are in the study and to tell them that the study is continuing. Survey data and hair samples will be gathered from them at baseline and 12 months
45692428|NCT05582421|Drug|Diclofenac Sodium|intracanal medication
45489733|NCT03166462|Other|Evaluation by Sleep Medicine Specialists|Patients randomized to the intervention arm will be referred to the sleep medicine specialists for evaluation. All of their recommendations will be followed if indicated.
45370868|NCT05918068|Combination Product|Metformin 500 mg/day plus vitamin B6 300 mg/day|Metformin 500 mg/day plus vitamin B6 300 mg/day in addition to non-pharmacological therapy
45370869|NCT05918068|Other|non-pharmacological therapy|non-pharmacological therapy (healthy lifestyle modifications)
45692429|NCT05581407|Biological|TETRALITE|LiteVax Adjuvanted Seasonal Influenza Vaccine
45692430|NCT03897933|Procedure|Erector Spinae Plane block ( Group I)|ESP Block was performed preoperative to all patients in ESP block group. Patients in all groups were provided with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
45692431|NCT03897933|Procedure|non- blocked Group (GROUP II)|This group was received no intervetion. Patients in all groups were provided with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
46053118|NCT05803239|Device|EBUS-TBCB|Participants would undergo EBUS-TBCB(20402-401, ERBE Elektromedizin Gmbh, Germany).
46053119|NCT05803226|Behavioral|Slow Art Plus|Slow Art Plus involved a full 90-minute engagement, one that is built upon the existing Slow Art programme with added layers of mindfulness and self-compassion practices, as well as a response art activity that fosters symbolic dialogue and an emotional aesthetic experience between participants and the selected artwork.
45370872|NCT05918029|Drug|Potassium citrate|Oral potassium citrate
45370873|NCT05918029|Drug|Placebo|Placebo capsule identical to active ingredient
45846655|NCT05214456|Other|Dry needling|The method of performing the dry needling technique will be based on the method presented by Dommerholt and Fernandez-de-las-Penas. The length of the needle (Tony, china) for each patient will be selected based on the size of the patient: 1) Multifidus: the patient will be placed in a prone position with a pillow under their belly to accommodate lumbar lordosis. The needles will be inserted into the lumbar multifidus muscles, 1.5 to 2 cm lateral to the spinous process of all lumbar vertebrates, perpendicular to the lamina (after piercing the skin, needles are directed inferomedially). 2) Quadratus lumborum: The patient will be placed in the side lying position with the side to be treated facing up. After identifying the lateral border of the quadratus lumborum muscle, the needle will be aimed straight downward in the direction of the transverse process, followed by slight anterior, posterior, and caudal needling to explore the entire muscle.
46053120|NCT05803213|Other|Virtual Reality 360 interactive video|Clinical scenarios revised and presented with 360 video, and interactive design on the learning platform that is available anytime and anywhere to the medical students
45370874|NCT05918016|Diagnostic Test|Routine cranial ultrasounds|we will use the routine cranial ultrasounds
45370875|NCT05917990|Behavioral|Dyadic Text-Messaging Micro-Intervention|Participants receive text-messages consisting of information and skills relevant to improving couples' communication and relationship functioning.
45370876|NCT05917977|Behavioral|Collective Motivational Interviewing plus Education Materials|The participants in the intervention group will receive IGD educational materials as well as four counseling sessions of CMI intervention.
45370877|NCT05917977|Other|Control group (Education Materials)|The participants in the control group will receive IGD educational materials.
45489734|NCT03166540|Other|cup of espresso coffee|Subjects will consume the assigned treatment for one month. Espresso coffee will be prepared by using coffee capsules. Serving size: approximately 45 mL. The last day of the intervention is the sampling day.
45489735|NCT03166540|Other|cocoa-based products containing coffee|Subjects will consume the assigned treatment (2 products per serving) for one month. Serving size: approximately 37 g. The last day of the intervention is the sampling day.
46053121|NCT05803213|Other|Traditional mini-lecture|Clinical scenario described according to the script as a mini-lecture to the medical students
46053122|NCT05803174|Diagnostic Test|blood sample|"Blood collection Circulating serum concentrations of melatonin and dopamine were determined from fasting blood samples. Participants were required to fast from 10 pm the previous evening. A 5 mL serum blood sample was collected from the antecubital vein between 8.30 am and 10 am.~Tear collection Tear samples were collected using Schirmer's strip without anesthesia between 8:30-10:00am. Tears were extracted in 200 μl of 1 X Phosphate Buffered Saline with 0.1% Tween-20 (PBST).~Saliva collection Saliva samples were collected via the passive drool method with subjects in a seated position. Subjects were asked to rinse their mouth with water 10 minutes prior to saliva collection and to refrain from using lip makeup during the sampling period."
45489736|NCT02950831|Other|Accelerometry|Record of activity levels using a wrist worn accelerometer
45753524|NCT04388215|Drug|D326(placebo)|orally, 1 tablet once a day for 8 weeks
45753525|NCT04388215|Drug|D337|orally, 1 tablet once a day for 8 weeks
45489737|NCT02392936|Procedure|Sternotomy for coronary artery bypass graft, valvuloplasty, aortic surgery or combined procedures, under extracorporeal circulation or not, in emergency or scheduled.|
45489738|NCT03709147|Drug|Metformin Hydrochloride|Metformin 1500 mg/day up to disease progression or unacceptable toxicity Every-21-days, 5-day Fasting-mimicking diet (FMD)
45489739|NCT03709147|Drug|Cisplatin|Intravenous cisplatin, administered at a dosage of 75 mg/mq every three weeks for a maximim of 4 consecutive cycles
45753526|NCT04388215|Drug|D337(placebo)|orally, 1 tablet once a day for 8 weeks
46053123|NCT05803161|Drug|Congrong Runtong oral liquid|"Congrong Runtong oral liquid：component total glycosides of Cistanche extracted and refined from the traditional Chinese medicine Cistanche deserticola"
45370880|NCT05917925|Dietary Supplement|COLLAGEN (COL)|The collagen-based supplement will be ingested every day for 12 weeks at the same time.
45370881|NCT05917925|Dietary Supplement|PLACEBO (PLA)|The placebo will be ingested every day for 12 weeks at the same time.
45370882|NCT05917912|Drug|Amitriptyline Hydrochloride|hydrogel formulation of amitriptyline hydrochloride (AMT HCl) for topical use, containing 15% AMT HCl w/w
45370883|NCT05917912|Drug|Placebo|Placebo
46053124|NCT05803161|Drug|Placental Congrong Runtong oral liquid|Placental Congrong Runtong oral liquid
46053125|NCT05803148|Procedure|Cardioneuroablation|The left atrium model was established under the guidance of three-dimensional mapping. Atrial septum puncture、left atrium mapping and right atrium mapping will be performed according to standard EP lab protocol. The location of GPs will be detected with HAFE potential (duration ≥ 50ms， deflections ≥ 8 times， amplitude ≥ 1.95mV) and high frequency stimulation (HFS; 30 Hz, 20 mV, pulse width 2ms) through positive vasovagal response (transient ventricular asystole, atrioventricular block, or R-R interval increased by 30%) . Saline Irrigated-tip catheter with pressure monitoring will be applied for the procedure, and radiofrequency energy is limited to 40W and 43℃ for at least 30s at each site. The ablation endpoint for each GP is defined as the complete elimination of all targeted HAFE potential and elimination of positive vasovagal response. The endpoint of the procedure was that the heart rate reach 75% of the maximum heart rate in atropine test.
45370884|NCT05917899|Behavioral|Virtual Family-Centered Rounds|The care team will use a computer with a speaker camera, mounted on a stand with wheels to launch telehealth visits using the application ExtendedCare. This platform meets HIPAA security rules and launches from the patient's electronic health record. From within this telehealth visit, a care team member will send a message (via text or email) to the parent(s) that includes a link that can be clicked to open a browser that allows the parent to join the telehealth visit. Parent do not need to download or use an application. The care team will invite the video interpreter to join the visit if a parent is present. Family-centered rounds will then proceed in usual fashion with the care team and [if in attendance] parent(s). Parents can participate in virtual family-centered rounds as much, or as little, as they choose.
45370885|NCT05917886|Other|Auditory beat stimulation: 8Hz monaural beat stimulation|Auditory beat stimulation is a reversible, non-invasive application of sound to the ears.
45370886|NCT05917873|Dietary Supplement|LaKe Ester|Lactate and ketone body ester (one equivalent of S-lactate and one equivalent of 1,3-butanediol / D-β-hydroxybutyrate)
45370887|NCT05917873|Dietary Supplement|Placebo|Taste and appearance matched noncaloric placebo
45370888|NCT05917860|Drug|Degarelix|Degarelix is injected subcutaneously into the fatty tissue of the abdomen. A typical protocol consists of a starting dose of 240 mg with a maintenance dose of 80 mg administered every 28 days. In this study, one starting dose and two maintenance doses of Degarelix will be administered between baseline and TULSA treatment in accordance with the terms of Degarelix marketing authorizations.
45370889|NCT05917860|Device|MRI-guided transurethral ultrasound ablation (TULSA)|MRI-guided transurethral ultrasound ablation (TULSA) (TULSA-PRO, Profound Medical Inc., Toronto, Canada) will be used to deliver whole-prostate gland treatment in accordance with the terms of TULSA marketing authorizations. The treating physicians will contour the entire prostate gland for a whole gland ablation.
45370890|NCT05917847|Other|Awake intubation|Awake videolaryngoscopic intubation with dexmedetomidine for sedation
45370891|NCT05917834|Biological|Nipple sparing mastecomy with different incision placements|Nipple sparing mastectomy was performed using Radial/Peri-areolar incision or imframammary incision
45370892|NCT05917808|Other|Ready-to-eat wholegrain porridge|A ready-to-eat wholegrain porridget will be consumed shortly after a diagnostic OGTT on two consecutive evenings, the OGTT will then be repeated
45370893|NCT05917795|Procedure|Endoscopic Sleeve Gastroplasty (ESG)|ESG will be performed under general anaesthesia with orotracheal intubation. The Endomina® suturing system (EndoTools Therapeutics S.A., Gosselies, Belgium) mounted on a single channel endoscope (GIF-H190/GIF-HQ190; Olympus Medical Systems Corp., Tokyo, Japan) will be used. This system allows to obtain full thickness gastric sutures through the gastric wall of the gastric body, leaving the antrum and the gastric fundus free. The ESG starts with the reduction of the gastric body, suturing from distal to proximal and starting from the notch of the angulus and ending at the level of the fundus. 4-8 full thickness stitches will be placed, with 2 passes per stitch. The final effect of ESG is the creation of a gastric tubule thus reducing the volume of the stomach. After the procedure, the final shape will be evaluated, to examine any gaps that would require additional closure, and to exclude bleedings and/or other complications.
45370894|NCT05917782|Biological|Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)|subcutaneous injection of 2 doses on Day 1
45370895|NCT05917782|Biological|Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL)|subcutaneous injection of 1 dose on Day 1
45370896|NCT05917782|Biological|Reference drug (R): CBP-201 injection (vial, 150 mg/1 mL)|subcutaneous injection of 2 doses on Day 1
45489740|NCT03709147|Drug|Carboplatin|Carboplatin at an area-under-the-curve (AUC) of 5, administered intravenously every-three weeks for a maximum of 4 consecutive cycles
45489741|NCT03709147|Drug|Pemetrexed|Pemetrexed, administered intravenously at the dose of 500 mg/mq every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles
45489742|NCT03709147|Dietary Supplement|Fasting-mimicking diet|5-day fasting-mimicking diet regimen, consisting of 700 KCal on day 1, 300 KCal on days 2-4, and 450 KCal on day 5, to be repeated every three weeks up to a maximum of 4 cycles
45370897|NCT05917769|Other|Rocabdo exercises|"The exercises created by Dr. Rocabado, will be performed by the patient at home, consist of six different exercises and six repetitions of each exercise, performed six times per day.~It consists of Tongue 'Clucking', Controlled TMJ Rotation on Opening, Mandibular Rhythmic Stabilization, Upper Cervical Distraction, Axial Extension of the Cervical Spine and Shoulder Girdle Retraction. This group will only perform Rocabdo exercises."
45370898|NCT05917769|Other|Postural correction exercises|"Posture correction exercises will be performed six times a day for six days.~Patient will be assessed on the first day and then on the last day of the treatment, i.e., on 6th day the patient will be re-assessed after they have performed posture correction exercises.~Posture correction exercises consist of chin tuck in, chest stretch, wall stretch, on your Back chest stretch and face down arm lifts."
45370899|NCT05917756|Other|Mobilization with Movement (MWM) and Tailored Therapeutic Exercise Program|The intervention consists of MWM techniques targeting the cervical and thoracic spine, and the first rib, applied by a certified physiotherapist for 8 weeks, 2 sessions per week, each session lasting 45 minutes. The intervention also includes a tailored therapeutic exercise program for the patients, comprising postural correction, stretching, and strengthening exercises. This intervention will be compared to conventional physiotherapy in the control group.
45489743|NCT03709147|Drug|Pembrolizumab|Pembrolizumab, administered intravenously at the flat dose of 200 mg every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles
45753527|NCT04388215|Drug|D013|orally, 1 tablet once a day for 8 weeks
45753528|NCT04388215|Drug|D013(placebo)|orally, 1 tablet once a day for 8 weeks
45753529|NCT04195100|Drug|Pilocarpine Ophthalmic Solution|"low dose pilocarpine = 3 x 2.0 mg = 3 x 2 drops of pilocarpine 20.0 mg/ml (2%) per day~high dose pilocarpine = 3 x 5.0 mg = 3 x 5 drops of pilocarpine 20.0 mg/ml (2%) per day"
45370900|NCT05917756|Other|Conventional Physiotherapy|Conventional physiotherapy, including manual therapy (soft tissue mobilization, joint mobilization, and nerve gliding techniques) for 8 weeks, 2 sessions per week, each session lasting 45 minutes, combined with a tailored therapeutic exercise program (including postural correction, stretching, and strengthening exercises).
45370901|NCT05917743|Other|Mat Pilates|Duration: 50 minutes per session Repetitions: 8-12 repetitions per exercise Sets: 2-3 sets per exercise Rests: 30-60 seconds rest between sets Frequency: 3 times per week for 4 weeks Exercises: A series of Mat Pilates exercises targeting core strength, flexibility, and muscle control
45370902|NCT05917743|Other|General Exercises|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises of a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. The Back to Fitness Program is based on the principles of exercise prescription and is intended to be a safe and effective way to manage back pain through exercise.
45370903|NCT05917730|Behavioral|Emotional Regulation and Interpersonal Abilities group Therapy (MERITA)|"Therapy sessions Block 1. Recognition and verbalization of emotions: Session 1: Presentation, framing, and beginning of identification and denomination of emotions. Session 2: Recognition and differentiation of emotions. Session 3 and 4: Effects of traumatic experiences.~Block 2. Learning to manage emotions: Session 5: Managing unpleasant emotions, coping Abilities in body, mind, and behavior. Session 6: New coping skills, self-esteem. Session 7: New coping skills, self-care. Session 8: Skills for clear communication. Session 9: Assertiveness and reciprocity. Session 10: Save card and the good relations game/negotiation skills. Session 11: Social skills and confidence recovery. Session 12: Consolidation and farewell."
45489744|NCT02392858|Other|influenza cohort|Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.
46053126|NCT05803148|Drug|Midodrine Oral Tablet|Midodrine will start dosing with 5 mg of the study drug 3 times daily, 4 hours apart, during daylight hours.Dose with be adjusted within a range of 2.5 mg twice daily, 4 hours apart, up to 10 mg, 3 times daily, every 4 hours. The optimal dose ranging be completed within the first 2 weeks. If intolerable symptoms persisted despite dose reductions, the drug will be withdrawn, and the patient was released from the study.
45370905|NCT05917704|Other|Guitar then physical therapy|See arm/group descriptions
45370906|NCT05917704|Other|Physical therapy then guitar|See arm/group descriptions
45370907|NCT05917691|Procedure|Bariatric surgery|Current Procedural Terminology (CPT) codes: 43644, 43645, 43770, 43775, 43842, 43843, 43845, 43846, 43847.
45370908|NCT05917691|Drug|General anesthetic|"Cases were required to have a documented general anesthesia anesthetic technique. Administered drugs were otherwise indeterminate under the current study design (observational study of a deidentified database)."
45370909|NCT05917691|Device|Indeterminate|Devices were indeterminate under the current study design (observational study of a deidentified database).
45370910|NCT05917678|Other|Repositioning Therapy|Caregivers will be instructed how to increase tummy time activities and reshape their infant's heads using at-home methods to direct their attention to the non-preferred side.
45692432|NCT03588663|Device|Baseline Bionic Leg Assessment|The 'Bionic Leg' (BL) [Alter G, Fremont, CA, USA; approved by the Food and Drug Administration (FDA) in 2014], is an externally-wearable, battery-operated robotic device that assists patients and therapists during rehabilitation by providing adjustable and progressive functional mobility training. A patient or therapist can programme the BL to provide motor assistance during sit-to-stand exercises, over-ground walking, and stair climbing, with either more or less robotic-assistance, as desired by the therapist. As the BL increases stability and actively engages the affected leg during functional tasks, it enables patients to undertake more repetitions of specific tasks than when not wearing a BL.
46053127|NCT05803148|Behavioral|patients educaiton|Patient education includes fully informing patients of the benign prognosis of vasovagal syncope, and told patients to avoid triggering factors as much as possible . At the same time, the patient should be taught how to cope with the impending syncope with physical counter-pressure maneuvers and dietary suggestions that emphasize fluid and sodium intake.
45370911|NCT05917678|Device|Cranial Remolding Orthosis|A custom cranial remolding orthosis (FDA Class II device) will be made to fit affected infants. this should be worn 23 hours per day and the Orthotist needs to be seen regularly for adjustments until the head shape is resolved.
45489745|NCT02393170|Other|self-training using video-games|"Individuals will receive a video-game console and will be taught how to play the games.~They will be requested to play 60 minutes a day for 5 weeks."
45489746|NCT02393170|Other|traditional self-training|Individuals will receive a manual and equipment and will be taught how to perform the exercises. They will be requested to perform the exercises 60 minutes a day for 5 weeks.
45489747|NCT03709069|Dietary Supplement|Albumin supplementation|Enteral supplementation by albumin of boiled egg as 2mg per kg body weight.
46053128|NCT05803135|Drug|Iguratimod combined with Tofacitinib;|Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily); Placebo of Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily)
46053129|NCT05803122|Other|Uniform Data Set (UDS) neuropsychological battery|Uniform Data Set (UDS) neuropsychological battery was administered to patients with Mild Cognitive Impairment (MCI) and patients with Alzheimer's Disease
46053130|NCT05803096|Drug|Self-Administered Nitrous Oxide|Nitrous oxide administered at concentrations of mild sedation (20-45%) for the duration of prostate biopsy.
46053131|NCT05803096|Other|Oxygen|Oxygen will be administered at 10 Liters/min for the duration of prostate biopsy.
45489748|NCT02398474|Drug|TFP block ropivacaine|
45489749|NCT02398474|Drug|ropivacaine infiltration of the iliac crest bone|
45489750|NCT02398318|Device|Bilateral Nucleus Accumbens DBS (Suzhou Sceneray)|High frequency stimulation applied using Suzhou Sceneray® DBS hardware (1120 electrode, 1180 (S) battery).
45489751|NCT02398318|Device|Sham Bilateral Nucleus Accumbens DBS|DBS system switched off.
45370912|NCT05917652|Behavioral|Tool kit|The study team will develop and design key elements of the implementation intervention (toolkit) among a small group of burn and non-burn clinician stakeholders (4-6 total). The study team will use in-person interviews with stakeholders and a semi-structured interview guide to elicit feedback and assess face and content validity of the toolkit elements prior to deployment across the study hospitals. For those who consent to participation, the study team will conduct virtual teleconference interviews in-person using a secure videoconferencing platform while the person is not working, at a time convenient for them. Interviews will last between 45 and 60 minutes. The study team anticipates conducting 4-6 interviews to finalize toolkit elements prior to implementation.
45370913|NCT05917639|Device|Vitruvian plot|Visual (magnitude, uncertainty) and written (magnitude) communication tool / interventional decision-making aid tool
45370914|NCT05917639|Device|Kilim plot|Visual (uncertainty) and written (magnitude) communication tool / interventional decision-making aid tool
45370915|NCT05917639|Device|Summary of findings table|Written (magnitude, uncertainty) communication tool / interventional decision-making aid tool
45370916|NCT05917626|Behavioral|Digital SPA|A psychological digital intervention for chronic pain in adolescents, based on evidence-based cognitive-behavioral and Acceptance and Commitment Therapy techniques. The intervention will be co-created with patients in a previous phase of the study, so the exact number or format of sessions and content has not been determined yet.
45370917|NCT05917613|Behavioral|Enhanced Skills Training in Affective and Interpersonal Regulation combined with Modified Prolonged Exposure (ESTAIR/MPE)|Psychotherapeutic manual for the treatment of Complex Post-Traumatic Stress Disorder (CPTSD)
45370918|NCT05917600|Other|APN intervention|"Advanced Practice Nurses (APN) intervention between the ambulatory hospitalization (AH) and the MD consultation~APN intervention is divided into five main steps:~clinical and paraclinical examinations,~appraisal of patient's knowledge,~health education on hypertension and treatments,~setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary~decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
45370919|NCT05917587|Drug|Metformin Hydrochloride|12 weeks: 850mg metformin once daily for first 7 days then twice daily for the remaining 11 weeks.
45370920|NCT05917587|Other|placebo|12 weeks: placebo tablet once daily for the first 7 days then twice daily for the remaining 11 weeks.
45370921|NCT05917574|Other|n/a (non-interventional)|Non-interventional (Realist Evaluation study)
45370922|NCT05917561|Drug|Anifrolumab Infusion Product|Anifrolumab 300mg/month infusion for 36 weeks
45370923|NCT05917561|Drug|Placebo|Placebo once a month, infusion for 36 weeks
45692433|NCT03588663|Other|Baseline Control Condition Assessment|Participants will complete identical tasks as that undertaken with the Bionic Leg, but will complete the tasks without wearing the Bionic Leg.
45370924|NCT05917548|Device|Teledentistry oral health promotion|Educational videos specially designed and validated for elderly (duration 4 to 6 minutes each one)
45370925|NCT05917548|Behavioral|Face-to-Face oral health promotion|Standardized PowerPoint presentation of 15 minutes about the most common or dangerous oral diseases (dental caries, periodontal disease and oral cancer), and toothbrushing and flossing practice in dental models
45370926|NCT05917535|Behavioral|Mentalizing course|6 hour mental health education course about mentalizing.
45370927|NCT05917522|Biological|Abatacept|Injection: 125 mg/mL of a clear to slightly opalescent, colorless to pale-yellow solution in a single-dose prefilled ClickJect autoinjector
46053132|NCT05803083|Dietary Supplement|Hyaluronic acid 75 mg/capsule|Take 2 capsules per day at any time.
46053133|NCT05803083|Dietary Supplement|Hyaluronic acid 50 mg/capsule|Take 2 capsules per day at any time.
46053134|NCT05803083|Dietary Supplement|Placebo|Take 2 capsules per day at any time.
46053135|NCT05803070|Drug|Topical Cetirizine 1 %|topical cetirizine belongs to anti histamines group
46053136|NCT05803070|Drug|Topical betamethasone valerate 0.1%|topical betamethasone valerate belongs to corticosteroids group
46053137|NCT05803031|Drug|Melaleuca Alternifolia Oil|"Tea tree oil 5% gel (Sigma Aldrich® Steinheim, Germany) for local sub gingival application was prepared by the Department of Pharmaceutics, Faculty of Pharmacy.~The gelling agent; Carbopol 940 (1% w/v) was first soaked in distilled water for 2 h then TTO dissolved in an appropriate amount of propylene glycol was added to the Carbopol dispersion. Methyl paraben 0.2% w/v dissolved in preheated water was used as a preservative. The gel mixture was then magnetically stirred for 30 min. Finally, pH was adjusted using 1 N NaOH added dropwise with gentle stirring with a spatula until the desired pH value (6.5-7) was reached. The gel was sterilized by autoclaving at 110 °C for 20 min."
46053138|NCT05803031|Procedure|Non-surgical periodontal debridement|Scaling and root surface debridement
45370928|NCT05917522|Procedure|Standard of Care at US Transplant Centers|Control group, remaining on SOC (Tacrolimus/ Mycophenolic Acid (MPA)/ Prednisone (Pred))
45370929|NCT05917509|Drug|DTG/3TC|DTG/3TC FDC will be administered as an oral once daily tablet.
45370930|NCT05917509|Drug|Cabotegravir (CAB) LA|CAB LA will be administered as an intramuscular injection once every 2 months in combination with RPV LA.
46053139|NCT05803005|Other|inflammatory marker in autism spectrum disorder|Evaluate some Inflammatory markers [IL-6, IL-8, TNF_alpha] in children with autism spectrum disorder
45692434|NCT03588663|Other|Training|Participants will take -part in a 30-minute training session whilst wearing the Bionic Leg. The training programme will ask participants to engage in a variety of walking, balance and stair exercises. The training programme will include a 15-minute rest period after completion of the 30 minutes of exercises. This will take 45 minutes in total.
46053140|NCT05802992|Drug|Colchicine|"The investigational drug colchicine was used at a daily dose of 0.5-1 mg. In every cycle, lenalidomide was administered at 10-25 mg (days 1-21). Dexamethasone 40mg (≤75 years old) or 20mg (>75 years old) per week.If the weekly dose of dexamethasone is 40mg, it should be taken in the first two days of the week, 20mg per day; If the weekly dose is 20mg or take the lower dose on the first day of each week.~If the patient needs to be treated with the investigational drug colchicine on the day of dexamethasone administration, he should take dexamethasone orally within 3 hours before the administration of colchicine."
45370931|NCT05917509|Drug|Rilpivirine (RPV) LA|RPV LA will be administered as an intramuscular injection once every 2 months in combination with CAB LA.
46053141|NCT05802992|Drug|Lenalidomide|In every cycle, lenalidomide was administered at 10-25 mg (days 1-21). Dexamethasone 40mg (≤75 years old) or 20mg (>75 years old) per week.If the weekly dose of dexamethasone is 40mg, it should be taken in the first two days of the week, 20mg per day; If the weekly dose is 20mg or take the lower dose on the first day of each week.
46053142|NCT05802979|Drug|Adjuvants, Anesthesia|testing the effect of adding ketamine versus neostigmine to the analgesic efficacy of serratus anterior plane block in modified radical mastectomy surgeries
45370934|NCT05917093|Behavioral|Culturally tailored HLWD|"Participants receive the culturally tailored HLWD intervention for 6 weeks~Week 0 - Baseline enrollment.~Weeks 1-6 will consist of 6 separate group sessions. Diabetes self-management topics will be covered by 2 Black HLWD Facilitators. Participants will meet once a week, for a 2½-hour session, in community settings such as a community center, or church."
45692435|NCT03588663|Other|Follow-up Assessment|45 minutes after the baseline assessment, immediately following the Training programme, the following tests (PCI, TUG, postural sway, 6-min walk, sit-to-stand) will be completed. These tests will be undertaken whilst not wearing the Bionic Leg. It is anticipated that this session will last approximately 2 hours.
45692436|NCT03580473|Drug|SATURNO II association|opthalmic solution, 4 times a day
45692437|NCT03580473|Drug|Vigadexa®|opthalmic solution, 4 times a day
46053143|NCT05802953|Other|Physical assessments|Physical assessments include the presence of joint sounds (yes/no), Fonseca Anamnestic Questionnaire, tenderness/pressure pain threshold rating, muscle strengths assessments, temporomandibular joint and cervical region range of motion measurements, and pain.
46053144|NCT05802953|Other|Questionnaire|General Health Questionnaire-28 and SF-36 will be apply.
46053145|NCT05802927|Other|DSF|Diabetes-specific formula
46053146|NCT05802927|Other|Breakfast 1|Noodle Soup
46053147|NCT05802927|Other|Breakfast 2|Glutinous rice
46053148|NCT05802914|Device|Back Exosuit|The back exosuit is a soft wearable robotic suit designed to improve a wearer physiology, kinetics, kinematics to reduce the possibility of injury. The back exosuit is primarily composed of textiles that wrap around an individual's shoulder (backpack) and thighs (thigh wrap) to serve as anchor points. An actuating element attaches to those anchor elements to provide assistive forces while the user performs a physical activity. The soft wearable robot integrates sensing components to be able to detect user biomechanics and device function and actuating elements via algorithms that command the actuation based on users' intent. To encourage usability, the device is easy to don and intuitive to use. This back exosuit has demonstrated significant reductions in back (18%), hip (11%) and knee (22%) extensor muscle activity during a 1-hour workplace simulation task when compared to lifting without a suit.
45370935|NCT05916534|Behavioral|WeCAB Intervention|The WeCAB intervention will use a dedicated WeCAB community health worker who will administer a social determinants of health (SDOH) tool and use digital care navigation to monitor closed loop referrals.
45370936|NCT05916417|Device|TMS-fNIRS over the dl-PFC|Transcranial Magnetic Stimulation (TMS) is a non-invasive brain stimulation technology. Functional Near Infrared Spectroscopy (fNIRS) is a brain imaging technology that utilizes light.
45489752|NCT03710317|Drug|carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
45692438|NCT03581721|Device|enFlow® IV fluid warmer and from July 2019 Fluido®Compact IV fluid warmer|"The fluid warmer will be set up by an external co-investigator in every patient included in the study. It will be turned on in patients belonging to the warming group, and turned off in the control group"
45370937|NCT05916144|Behavioral|Interaction-Based Early Education Program|The intervention program will be created based on the ETEÇOM model which is the Turkish adaptation of the Responsive Teaching Program developed in the United States. In this program, by improving the interactive behaviors of experts/educators or parents, the aim is for the child to acquire or develop 15 core behavior. Each session is planned to last between 60-90 minutes on average and will be conducted in a group format, consisting of 5 sessions, and can be conducted face-to-face or online.
45370938|NCT05915910|Diagnostic Test|Specimen Donation|blood donation
45489753|NCT03710317|Drug|Tranexamic Acid|1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min.
45489754|NCT03710317|Drug|misoprostol|Group 2 400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision
45489755|NCT05744596|Other|Incisura biopsy analysis|a pathologist blinded to the other biopsies analyzes the biopsy from the incisura
45489756|NCT05379985|Drug|RMC-6236|Oral Tablets
45489757|NCT02392780|Drug|Cannabidiol|Oral cannabidiol at a dose of 150 mg BID up to 90 days.
45692439|NCT04148859|Procedure|amnioreduction|The amniotic fluid is drained via needle, which is stubbed in the abdomen wall, connected to a tube into a plastic bag. The amniotic fluid pressure will be measured by a water manometer. A T-shape connector will be connected to the tube on one side, and to a short tube on the other side. The height of the fluid within the short tube will indicate the pressure. All the fluid will be drained to the plastic bag. The pressure and the blood flow of the fetuses will be measured during the procedure, depends on the drainage rate.
45846656|NCT05214456|Other|Mobilization|To perform Maitland's mobilization for lumbar spine, the anterior-posterior mobilization technique will be used and it is performed by pushing the heel (pisiform grip) or thumbs (thumb grip) to the vertebrae and can immediately reduce pain and restore motor function. First, the complete physical orthopedic evaluation of manual therapies will be performed using the Maitland evaluation method. Then, based on the findings of the patient evaluation, the severity, rhythm, duration and the degree of the mobilization and the place of force (spine or lamina) will be determined. To apply mobilization, the person will sleep in a prone position and the physiotherapist will use the heel of the hand or the thumbs to apply force to the first to fifth vertebrae of the lumbar spine. In segments that do not have a problem based on evaluation, first grade of the anterior-posterior Maitland's mobilization will be applied to the spinous process of the segment.
45846657|NCT05093400|Other|no intervention|saliva collection
45846658|NCT05044182|Procedure|Decompression and drainage seton|Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
46053149|NCT05802901|Procedure|Spinal manipulation|Spinal manipulation of the lumbar spine only to be performed in the spinal manipulation arm/group.
45489758|NCT02392780|Drug|Methylprednisolone|IV methylprednisolone 2 mg/kg/day
45489759|NCT02392780|Drug|Calcineurin inhibitor|cyclosporine with dose adjusted based on drug trough levels (200-400 ng/ml) or tacrolimus with dose adjusted on drug trough levels (5-15 ng/ml)
45489760|NCT03710239|Device|Dilapan-S|Synthetic osmotic dilator
45489761|NCT03710239|Device|Laminaria|Seaweed-based osmotic dilator
45370939|NCT05915572|Other|Mulligan Mobilization Technique|"The therapist applied passive accessory glide to increase shoulder flexion, abduction, external rotation as the patient moved the arm actively in the desired direction with in a pain free range with dosage: 3 sets for 10 repetitions with 1 minute rest between sets. 3 times a week for 6 weeks.~Traditional physical therapy will include chin tucks, shoulder shrugs, shoulder circle, scapular retraction/adduction and shoulder ROM exercises, including shoulder flexion and abduction to improve glenohumeral & scapulothoracic motion and shoulder extension & adduction with moderate resistance and shoulder internal/external rotation with approximately two sets of 15 repetitions."
45370940|NCT05915572|Other|Traditional Physical Therapy Program|Myofascial release, capsular stretching ex. strengthening ex. and ROM ex. 3 sessions per week for 6 weeks. Traditional physical therapy will include chin tucks, shoulder shrugs, shoulder circle, scapular retraction/adduction and shoulder ROM exercises, including shoulder flexion and abduction to improve glenohumeral & scapulothoracic motion and shoulder extension & adduction with moderate resistance and shoulder internal/external rotation with approximately two sets of 15 repetitions.
45370941|NCT05915455|Other|HCP-facing Portfolio Diet Infographic + Informative Video|Resources to evaluate include the healthcare professional-facing Portfolio Diet infographic (1-page) and 4-minute accompanying video
45370942|NCT05915455|Other|Portfolio Diet Application|Resource to evaluate includes the Portfolio Diet mobile application
45692440|NCT03588507|Combination Product|PPF+NCHA bone graft substitute|nanocrystalline hydroxyapatite bone graft is a a newly developed HA containing about 65% water and 35% nanostructured apatite particles. This gave the nanocrystalline hydroxyapatite bone graft many advantages such as providing a close contact with the surrounding tissues, bioresorbability and extremely high number of nano-sized particles and molecules on the surface .
45692441|NCT03940521|Other|Bioclinical evaluation|50-100ml blood extracted for flow cytometry and qPCR
45370943|NCT05915351|Drug|Enfortumab vedotin|Enfortumab vedotin 1.25 mg/kg on D1, D8, D15 every 28 days
45489762|NCT02393014|Procedure|Simple physical exercises|"The participant must stay out of the bed 3 hours. This pre-required level prevents the occurrence of acute postural mismatch which can occur when elderly patients are bedridden and too long increases the risk of falling.~The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes. Depending on the patient's abilities, the exercise will be done on both feet or one foot.~The participant performs a transfer activity of sitting to standing repeated 5 times (FTSS test). According to the patient's abilities, the exercise will be done with physical assistance or not."
45489763|NCT04053478|Drug|Ephedrine|Ephedrine in solution, at applicable concentrations based on literature
45489764|NCT04053478|Drug|Phenylephrine|Phenylephrine, at applicable concentrations based on literature
45489765|NCT04053478|Drug|Norepinephrine|Norepinephrine, at applicable concentrations based on literature
45489766|NCT04053478|Drug|Vasopressin|Vasopressin, at applicable concentrations based on literature
45489767|NCT04474392|Other|N/A (Observational Study)|Observational study, no intervention will be administered.
45489768|NCT05744518|Other|Response monitoring|Other: Response monitoring (no intervention)
45692442|NCT03897309|Biological|VXA-G1.1-NN|Monovalent GI.1 tableted vaccine
45692443|NCT03897309|Biological|VXA-G2.4-NS|Monovalent GII.4 tableted vaccine
45370944|NCT05915039|Other|Computer Assisted Learning (CAL) Module|The students assigned to Group A will undergo interactive CAL module training by the American Medical Association which outlines how to properly measure blood pressure manually following the American Heart Association guidelines.
45370945|NCT05914766|Behavioral|PATHWAYS|The PATHWAYS intervention is a psychoeducational intervention comprised of three components.
45370946|NCT05914766|Other|Enhanced usual care|The enhanced usual care condition consists of an information resource guide.
45370947|NCT05914649|Other|IV normal saline (1 Litre)|One Liter of IV normal saline will be infused intravenously
45370948|NCT05914636|Biological|analysis of foecal microbiota|"An analysis of foecal microbiota including taxonomic and metabolomic analysis will be performed and compared between ruptured and unruptured patient.~confundens factors as diet, obesity for microbiota and as smoking, hypertension, size for aneurysm ruptured will be sampled and independence will be analyzed."
45370949|NCT05914506|Diagnostic Test|Hyperpolarized xenon-129 MRI|Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level
45489769|NCT02392390|Procedure|Topical Dynamic Phototherapy (TDP)|Metvixia cream is applied to the lesion (about 1mm thickness) and the treated zone is covered with an opaque dression for 3 hours. Any residual cream is removed an and the lesion immediately rinsed with saline solution when uncovering. One session (8 minutes) of phototherapy is then performed using an Altilite lamp in accordance with HAS (haute authorité de santé) recommendations.
45489770|NCT02392390|Drug|Metvixia cream|
45692444|NCT03897309|Biological|Placebo Tablets|Tablets matching in number and appearance to active vaccine doses
45692445|NCT03588429|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
45692446|NCT03588429|Drug|Isoflurane|Anesthesia was maintained with isoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
45846659|NCT05044182|Procedure|Cutting seton|Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
45846660|NCT05024994|Drug|E7820|100mg of E7820 QD
45370950|NCT05914480|Other|PCR for legionella ,blood ,urine cultures and from catheters or source of infection|Investigations to detect cause of sepsis as blood cultures ,urine cultures and from catheters .also PCR for legionella will be done
45370952|NCT05913817|Biological|AVT02 (Alvotech Biosimilar to Adalimumab)|Phase IV Study
45370954|NCT05912764|Other|Patient support|Patients will be supported by nurses before and after intervention and hospital leave
45370955|NCT05912244|Drug|IO102/IO103|IO102/IO103 will be administered subcutaneously on Days 1 and 15 of the first two 28-day cycles, and then on Day 1 only of subsequent cycles for two total years of treatment. Each vaccine contains 85ug.
45370956|NCT05912244|Drug|Nivolumab-Relatlimab|Nivolumab-relatlimab will be administered as a single infusion 160mg relatlimab and nivolumab 480 mg for all participants. Both agents will be combined in a single fixed-dose combination (FDC) as an intravenous 30-minute infusion every four weeks.
45370957|NCT05909683|Diagnostic Test|Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results.|After the patient's blood flask is flagged positive for bloodstream infection, the blood sample will be assessed in the BCID2 diagnostic test in order to identify the underlying pathogens the patient is infected with. After the identification, and in the presence of gram-negative bacteria, the sample will be assessed in the Reveal Rapid AST test to provide information about which antimicrobials the specific pathogens are sensitive to. When both the identification of the pathogen and the sensitivities are available, the central laboratory will inform the attending physicians, who are obliged to change the standard of care antimicrobial therapy administered based on the rule in Box1 of the protocol. Finally, based on the results of the procalcitonin (PCT) on the first day by day 5 when PCT value is less than 80% of the initial value or it remains below 0.5 ng/ml, the attending physicians should discontinue the antimicrobial therapy.
45370958|NCT05909683|Other|Standard of Care|Standard of care practices of the specific study site. Antimicrobials will be administered based on the attending physicians' critical opinion, and discontinuation will be done based on the standard procedures of the study site.
45370959|NCT05909176|Behavioral|GYN Residency Training|The combined care model will be implemented and during months 5-8.
45370960|NCT05909176|Behavioral|Social Media Campaign|The social media campaign will be implemented along with the combined care model in months 9-12.
45846661|NCT05016024|Device|Colilen IBS|Patients will take Colilen IBS in First or Second Period
45846662|NCT05016024|Other|Placebo|Patients will take PlaceboS in First or Second Period
45846663|NCT04986540|Drug|SHR-1906；Placebo|"Drug: SHR-1906 IV, single dose~Drug: Placebo IV, single dose"
45846664|NCT04965714|Biological|Nivolumab|Given IV
45846665|NCT04965714|Biological|Pegargiminase|Given IM
45846666|NCT04965714|Procedure|Resection|Undergo surgical resection
45846667|NCT04939350|Other|questionnaire|patients will complete a vaccination questionnaire
45370961|NCT05907993|Drug|Ibuprofen 800 mg|Intravenous Ibuprofen versus intravenous Ketorolac for postoperative pain relief
46053150|NCT05802901|Procedure|Dry needling|Dry needling of the lumbar erector spinae, multifidus, and gluteus medius on the symptomatic side performed in the dry needling arm/group.
46053151|NCT05802901|Procedure|Spinal manipulation and dry needling|The spinal manipulation and dry needling arm/group receive both spinal manipulation and dry needling as outlined in the other groups.
46053152|NCT05802888|Drug|Tetracycline 500mg tid|Amoxicillin 1000mg bid +Tetracycline 500mg tid +Bismuth+Esomeprazole 40mg bid
46053153|NCT05802888|Drug|Tetracycline 500mg qid|Amoxicillin 1000mg bid +Tetracycline 500mg qid +Bismuth+Esomeprazole 40mg bid
45846668|NCT04787562|Drug|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
45846669|NCT04787562|Drug|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
45370971|NCT05907044|Biological|RQ3013|0.15mL/dose containing mRNA 30μg
45370972|NCT05907044|Biological|RQ3025|0.15mL/dose containing mRNA 30μg
45370973|NCT05907044|Biological|RQ3027|0.15mL/dose containing mRNA 30μg
45370974|NCT05904132|Device|tACS device|you will receive one of four treatment conditions that include active and sham tACS. The four conditions are the following: (1) closed-loop-tACS (peak-locked), (2) closed-loop-tACS (trough-locked), (3) open-loop tACS, and (4) sham tACS. Although each subject will undergo all four treatments in four separate study visits, the order of the treatments will be randomized
45370976|NCT05903573|Behavioral|Cognitive Training|The intervention group will receive cognitive training that provides specific training tasks directed at essential cognitive domains tied to the project's aims and hypotheses (processing speed and working memory) that correspond with the neurocognitive and functional neuroimaging measures to be studied. The specific tasks used will be Hawk eye, Divided Attention, Target Tracker, Double Decision, to do List Training, Memory Grid, Auditory Aces, and Card Shark.
45370977|NCT05903573|Behavioral|Educational training|This group will receive educational training by way of viewing equivalent-length (~40 minute) nature videos with follow-up quizzes.
45370978|NCT05901883|Drug|CEL383|Subjects will receive CEL383
45370979|NCT05901883|Drug|Placebo|Subjects will receive placebo
45370980|NCT05900427|Drug|Liposomal bupivacaine|Subjects randomized to the Liposomal bupivacaine group will receive 10 mL (133 mg) of Liposomal bupivacaine and 20 mL (50 mg) of 0.25% bupivacaine and 6 mL of saline (183 mg).
45692447|NCT03581019|Procedure|uterus transplantation|uterus transplantation from deceased donor
45692448|NCT03580161|Other|18-F FDG PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
45846670|NCT04787562|Drug|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
45846671|NCT04787562|Drug|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose"
45846672|NCT04787562|Drug|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose"
45846673|NCT04780698|Diagnostic Test|SARS-CoV-2 RT-PCR Assay for Detection of COVID-19 Infection|COVID-19 infection and antibody testing
45692449|NCT03580161|Other|Ga-68 PSMA PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
45370981|NCT05900427|Drug|Bupivacaine|Subjects randomized to the Plain Bupivacaine group will receive 36 mL (180 mg) of 0.5% bupivacaine.
46053154|NCT05802875|Behavioral|RASMUS Resilience Training|"RASMUS stands for Resilience through mindfulness, self-compassion and self-care and is a German-language 10-week group resilience program with one training unit per week. The main content of the RASMUS is based on seven resilience factors, i.e. acceptance, optimism, taking responsibility, solution orientation, future orientation, role clarity, and network orientation including the aspects of mindfulness, self-compassion, and self-care.~RASMUS has been tested and certified according to the German Prevention Standard. The Central Prevention Test Center has awarded the seal of approval for the areas of exercise, nutrition, stress management/relaxation, and addictive substance consumption. Accordingly, this training program has been certified as a prevention course that is recognized by the German statutory health insurance companies. Furthermore, RASMUS can and is already offered as a (group) online course."
45370982|NCT05899257|Behavioral|Immersive Training using EYME|Psychological assessment based on the RGT with EYME-Explore Your Meanings, a digital platform to explore the structure and content of personal identity with Virtual Reality.
45498135|NCT04171375|Device|trans-spinal Electrical Stimulation (tsES)|The trans-spinal pulsed-current stimulation utilizes non-invasive russian stimulation using a research grade stimulator and direct-current stimulation utilizes non-invasive constant stimulation using a medical grade stimulator. Both pulsed- and direct-current stimulation will be achieved with cutaneous cathode electrodes attached to the dorsal aspect of the back overlying at and bellow thoracic vertebrae and anode electrodes placed over the iliac crests or lower abdomen. Spinal motor evoked potentials will be induced by trans-spinal pulsed-current stimulation (parameters, 1 Hz with a 1 millisecond pulse width and monophasic waveform) to determine recruitment profiles of proximal and distal motor pools with increasing stimulation intensity ranging from 10-200 milliampere. Stimulation parameters for the therapeutic stimulation will be ranged from 5-50 Hz and 20-200 milliampere. For direct-current stimulation, the stimulation current will be kept constant at 2-2.5 milliampere.
45692450|NCT03580161|Other|68-Ga Dotatate PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
45692451|NCT03580161|Other|99mTc Pertechnetate Thyroid dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
45692452|NCT03580161|Other|99mTc DMSA(III) Renal dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
46053155|NCT05802875|Behavioral|Progressive Muscle Relaxation|"Progressive Muscle Relaxation is a representative relaxation technique used in a wide scope of disorders. Developed by the American physician E.Jacobson in the late 1920s, it is based on the finding that anxiety states are usually accompanied by increased muscle tension, while in resting states the muscles are relaxed. By applying this technique, an individual learns how to relax several muscle groups in the body.~In the context of the current project, PMR is chosen as the active control condition because it is a broadly accepted and easy-to-implement relaxation exercise that can be offered as a (group) online course and does not include specific contents of RASMUS."
46053156|NCT05802862|Drug|Insulin Degludec and Insulin Aspart|administered subcutaneously, once a day
46053157|NCT05802836|Other|no interventions|no intervention, only 3 different patients groups
46053158|NCT05802823|Other|Standardized Simülation Patient|There are preliminary information, information, application and analysis sessions in the research. A rehearsal will be made 10 days before the application and arrangements will be made if necessary. The students will be given the resources 1 week before the application and the scenario 5 minutes before the application and informed consent will be obtained. Just before the application, information about the simulation process and analysis will be given. Students will be divided into 6 groups with the random numbers table and the application will be made on different days and times. The application time is 10-15 minutes and the camera will be recorded during the interview. At the end of the application, standard patient feedback will be given for each student. At the end of the application, analysis sessions will be held with the students as a group and feedback will be given by peers and trainers about their own performances. Analysis sessions will take between 30-45 minutes.
46053159|NCT05802810|Drug|[14C]JT001|Subjects will receive approximately 300 mg/100 µCi of [14C]JT001 orally.
45498136|NCT03685266|Other|Observation|There are no specific interventions in this study; it is observational only. One could argue that the act of observing the participants may change their behavior (the Hawthorne effect).
45498137|NCT05133687|Drug|Bupivacaine Hydrochloride|Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G), (Group 1.2-G) and (Group G).
46053160|NCT05802797|Other|Algae Oil Fortified Soymilk|Flavored soymilk beverage fortified with 0.4% algae oil with both EPA and DHA
45370987|NCT05898386|Behavioral|Behaviour and Lifestyle Changes in Urinary Incontinence|"The women included in the second stage were given a pre-test before the training program. Training program included behavioral and lifestyle changes in coping with urinary incontinence~After the training program, the women applied behavior and lifestyle changes for 3 months.~3 home visits, 3 phone calls and 3 follow-ups were made."
45370988|NCT05897866|Procedure|Sayed Issa's Hybrid Shoulder Arthroscopic-Open Surgical Management|Using Arthroscopy and then Limited Opening by Mini Lateral Shoulder Approach (MLSA) for the shoulder surgery.
45370989|NCT05896644|Other|Eat Well|A program offered by Reinvestment Partners giving clients gift/debit cards that allow the purchase of WIC approved fruits and vegetables.
45370990|NCT05895734|Device|NDS-Powerball®,|Rehabilitation using the Powerball system
45370991|NCT05895734|Other|Conventional treatment|Rehabilitation by conventional treatment
45370992|NCT05893940|Procedure|Low Intensity Vibration Therapy|Undergo LIMS vibration therapy
45370993|NCT05893940|Procedure|Dual X-ray Absorptiometry|Undergo DEXA scan
45370994|NCT05893940|Procedure|Biospecimen Collection|Undergo blood sample collection
45370995|NCT05893940|Other|Survey Administration|Complete Survey
45370996|NCT05890976|Drug|Semaglutide|Participants will receive semaglutide tablets orally once daily for 44 weeks.
45370997|NCT05890976|Drug|Semaglutide Placebo|Participants will receive placebo matched to semaglutide.
45370998|NCT05888831|Drug|BMS-986449|Specified dose on specified days
45370999|NCT05888831|Drug|Nivolumab|Specified dose on specified days
45371000|NCT05888805|Other|DIMS spectacle lens|DIMS spectacle lens is a multifocal spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously.
45498138|NCT03689088|Device|Goldfish|Goldfish will be placed in the eye for 24h monitoring
45498139|NCT03689088|Device|Tonometry|Fellow eye will be measured by tonometry
46053161|NCT05802797|Dietary Supplement|Algae Oil Capsule|Algae oil capsules with EPA and DHA
46053162|NCT05802771|Procedure|surgical resection|surgical resection of the lung cancer
45371001|NCT05888792|Other|Variant of Defocus Incorporated Spectacle lens (DG2)|DG2 is a variant of Defocus Incorporated Spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously
45371002|NCT05887518|Device|Socks Developed with Wearable Technology|This new material will have the ability to prevent hypothermia by rewarming the patient when the body temperature drops below 360C and will reduce the risk of DVT that may develop in patients due to hypothermia. Thus, a single material will be used for two important complications of the surgical process, such as hypothermia and DVT, which negatively affect patient outcomes. This situation suggests that this material developed with an innovative approach will be more cost effective.
46053163|NCT05802758|Behavioral|Psychopathy.comp and training in virtual reality (VR)|Psychopathy.comp is a CFT-based manualized program of 20 sessions a 60 min, on a weekly basis. During the CFT-intervention, partipants try out their new skills in a tailored VR setting (x5)
46053164|NCT05802745|Other|Reintubation|Patients requiring re-intubation for acute respiratory failure.
45371005|NCT05883241|Device|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3-megahertz (MHz) frequency and 0.132 Watts/cm^2 with 2.5% Diclofenac patches.
45371006|NCT05883241|Drug|2.5% Diclofenac Patches|Topical pain relief-gel worn during treatment via SAM patch.
45371007|NCT05882812|Device|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm^2 with 2.5% Diclofenac patches.
45371008|NCT05882812|Device|Sustained Acoustic Device with 0% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.
45371009|NCT05882812|Drug|2.5% Diclofenac Patches|Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
45371010|NCT05882669|Other|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period); the WOMAC questionnaire to measure their functional outcomes before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period).
45489771|NCT03593915|Combination Product|Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine|"PHASE 1b:~Decitabine administered as an intravenous (IV) infusion daily for 5 days at a dose of 20 mg/m2 followed on Day 8 by alvocidib as a loading dose over 30 minutes followed by a 4-hour IV infusion (hybrid dosing) Once the maximum dose of alvocidib administered via hybrid dosing has been determined, 2 cohorts of patients will receive azacitidine followed by alvocidib administered as an IV infusion. Azacitidine may be administered as either an IV bolus over 10 to 40 minutes or as a subcutaneous (SC) injection on either a 7 day or 5-2 2 schedule. Regardless of which azacitidine schedule or route of administration is used, alvocidib will be given on Day 10 as a 30-to-60 minute IVI~PHASE 2:~The Phase 2 study will use the RP2D from the Phase 1b study and follow a Simon 2-stage minimax design using the RP2D of alvocidib administered as a 30-to-60 minute IV infusion determined in the Ph1b study to explore efficacy of alvocidib when administered in sequence after azacitidine."
45371011|NCT05882656|Other|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the WOMAC questionnaire to measure their functional outcomes before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period).
45371012|NCT05880888|Biological|Renuva|Renuva® (MTF Biologics) is an injectable decellularized allograft adipose matrix (AAM) used to increase volume in adipose tissue.
45489772|NCT02392546|Drug|elobixibat|
46053165|NCT05802563|Device|fitness tracker|Study subjects will wear a Fitbit fitness tracker
45489773|NCT02392546|Drug|placebo|
45489774|NCT02392702|Drug|C-10355|
45489775|NCT02392702|Drug|C-10358|
45489776|NCT02392702|Drug|Kalydeco|
45489777|NCT02392468|Drug|BI 409306 matching placebo|placebo
45489778|NCT02392468|Drug|BI 409306 matching placebo|placebo
45692453|NCT03580161|Other|99mTc MAG3 Renal dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
45692454|NCT03580161|Other|99mTc MDP/HDP Bone dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
45692455|NCT03583437|Behavioral|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
46053166|NCT05801406|Device|Tornado (Cook)|Fiducial marker endobronchial positioning under augmented fluoroscopy to mark ground glass opacities.
46053167|NCT05801120|Dietary Supplement|Ketogenic food products|Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
45489779|NCT02392468|Drug|BI 409306|low dose
45489780|NCT02392468|Drug|BI 409306|high dose
45489781|NCT02397928|Device|NovoTTF-100L device|Patients will be treated continuously with the NovoTTF-100L device. NovoTTF-100L treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.
45489782|NCT02397928|Drug|Pemetrexed|Pemetrexed 500 mg/m2 will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on day 1 of a 21-day cycle.
45489783|NCT02397928|Drug|Cisplatin or Carboplatin|Cisplatin 75 mg/m2 or carboplatin AUC 5 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end on the pemetrexed infusion on day 1 of a 21-day cycle.
45489784|NCT03593681|Device|Hysteroscopic cell sampling of the fallopian tube|Hysteroscopic fallopian tube biopsy
45489785|NCT05744440|Drug|allogenic NK cells|The relapsed/refractory AML after allo-HSCT patients will receive allogenic NK cells infusion up to 2 dose levels (1x10^7/kg, 5x10^7/kg) after chemotherapy with azacitidine
45692456|NCT03588351|Drug|chitosan nanoparticles gel|intracanal medicament
45692457|NCT03588351|Drug|chitosan gel|intracanal medicament
45692458|NCT03588351|Drug|chlorhexidine gluconate|intracanal medicament
46053168|NCT05800574|Radiation|Radiation therapy (5 days for 7 weeks)|Mon-Fri (5 days for 7 weeks), total 35 fractions over 35 treatment days of radiation therapy (RT)
45371015|NCT05879107|Biological|RSVPreF3 OA investigational vaccine|One dose of RSVPreF3 OA vaccine given intramuscularly in participant's non-dominant arm on Day 1 (in the Coad group) or Day 31(in the Control group).
45371016|NCT05879107|Biological|PCV20|One dose of the 20-valent pneumococcal conjugate vaccine (PCV20) given intramuscularly in participant's dominant arm (Coad group) or non-dominant arm (Control group) on Day 1
45371017|NCT05876091|Other|Vaping|Undergo vape puffing regimen
45371018|NCT05876091|Procedure|Biospecimen Collection|Undergo collection of saliva samples and oral cell samples
45371019|NCT05876091|Other|Questionnaire Administration|Administer Quesitonnaire
45489786|NCT03734627|Drug|Octreotide Acetate|50mcg octreotide acetate by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
45489787|NCT03734627|Drug|Saline Solution|Equivalent volume of 0.9% saline by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
45489788|NCT03734627|Drug|Paracetamol|Paracetamol 1g by mouth consumed with a 400kcal mixed meal challenge
45489789|NCT03734627|Drug|Sulfasalazine|1g sulfasalazine by mouth consumed with a 400kcal mixed meal challenge
45489790|NCT03734627|Diagnostic Test|Duodenal biopsy|Biopsy from the second part of the duodenum taken at routine endoscopic surveillance, undertaken for another clinical indication.
45489791|NCT02397850|Behavioral|phone calls 30 min|Patients receive either seven 30 minutes phone calls over 6 months (psychotherapy/continuation treatment)
45489792|NCT02397850|Behavioral|phone calls 50 min|Patients receive either seven 50 minutes phone calls over 6 months (psychotherapy/continuation treatment)
45489793|NCT02397772|Drug|albendazole|Single dose of albendazole (400 mg)
45489794|NCT03592745|Device|Transcutaneous Vagus Nerve Stimulation (tVNS)|tVNS is a non-invasive form of vagus nerve stimulation, activating the auricular branch of the vagus nerve transcutaneously through the cymba concha at the pinna of the ear.
45489795|NCT03592745|Device|Sham Transcutaneous Vagus Nerve Stimulation (tVNS)|tVNS is a non-invasive form of vagus nerve stimulation, activating the auricular branch of the vagus nerve transcutaneously through the cymba concha at the pinna of the ear. Sham tVNS means the patient is wearing the device, but it is turned off and not delivering current during the treatment. This is a placebo condition, which is used as a study control.
45692459|NCT03585465|Drug|Vinblastine|"Experimentals Arm A or C (First stage): 2 mg/m2/day IV, weekly per cycle, 28 days cycle~Experimental Arms Metronomic or Metronomic+Nivolumab (second stage): see C"
45692460|NCT03585465|Drug|Cyclophosphamide|"Arm A (First stage): 30 mg/m2/day PO, D1-4// D8-11// D15-18// D22-25 per cycle, 28 days cycle~Arm C (First stage): 30 mg/m2/day PO, D1-D4// D15-D18 per cycle, 28 days cycle~Metronomic or Metronomic+Nivolumab Arm (second stage): see C"
46053169|NCT05800574|Radiation|Radiation therapy (5 days for 6 weeks)|Mon-Fri (5 days for 6 weeks), total 35 fractions over 30 treatment days of RT (two doses 6 hours apart except for the last 6th Friday of the 6 weeks )
46053170|NCT05800574|Drug|Cisplatin|Cisplatin, 40mg/m2 (weekly for 7 weeks)
46053171|NCT05797974|Other|MyChart enabled virtual weight loss coach|MyChart-enabled virtual coach utilized to aid in preoperative weight loss.
46053172|NCT05797974|Other|Standard preoperative weight loss tools|Participants will utilize current standard preoperative weight loss tools.
45489796|NCT02398162|Procedure|Multi Blood Collections|At baseline (the day of presentation to hospital), 2 weeks, 12 weeks and 1 year later.
46053173|NCT05797519|Device|VDyne Transcatheter Tricuspid Valve Replacement System|The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System which consists of a bioprosthetic implantable tricuspid valve, the VDyne Delivery System, Drop Tether, accessories that facilitate the placement of the valve and the VDyne Retrieval System. The VDyne Valve is deployed by transfemoral implantation within the native tricuspid valve and is implanted under fluoroscopic and transesophageal echocardiography (TEE) guidance, while the heart remains beating, without the use of CPB. The valve is repositionable and fully retrievable intraoperatively. Repositioning allows optimization of the valve position following deployment, and retrieval, with the VDyne Retrieval System, allows use of an alternative valve size or removal of the index VDyne Valve in the event of suboptimal valve delivery or other intraoperative complication.
45489797|NCT02398162|Procedure|Single Blood Collection|On the enrollment day
45489798|NCT03165838|Behavioral|Postpartum Visit 3-4 Weeks|This visit will be the same as the standard of care postpartum visit, but it will be scheduled earlier.
45371020|NCT05874245|Drug|oral Dexmedetomidine|will receive 4 micrograms/kg oral Dexmedetomidine diluted in paracetamol [Paracetamol syrup 150 mg/5ml] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
45371021|NCT05874245|Drug|oral ketamine|will receive 6 mg/kg oral ketamine diluted in paracetamol [Paracetamol syrup 150 mg/5ml] at a dose of 15 mg/kg 45 minutes before the induction of anaesthesia
45371022|NCT05874245|Drug|oral Midazolam|will receive 0.3 mg/kg (maximum 20 mg) oral Midazolam diluted in paracetamol [Paracetamol syrup 150 mg/5ml] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
45489799|NCT03165838|Behavioral|Postpartum Visit 6-8 Weeks|This standard of care postpartum visit will be scheduled for the standard time interval.
45371023|NCT05873257|Device|Biatain Fiber Ag applied to participants|Intervention involving a wound gelling fiber dressing with silver
45489800|NCT02398006|Other|a standard arm sling|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
45489801|NCT02398006|Other|a figure-of-eight bandage|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
45489802|NCT03592277|Drug|Vitamin C|Patients will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum).
45489803|NCT03592277|Drug|Vitamin B1|Patients will also receive 200 mg of IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
45498140|NCT01383135|Drug|FPPRGD2|radiopharmaceutical administered for imaging, up to 14 mCi i.v.
45498141|NCT03685032|Drug|Dexamethasone|The 4 mg of dexamethasone in 1 ml intravenous was administrated after patient received general anesthesia
46053174|NCT05796440|Drug|LUM-201|Administered orally once daily
45371024|NCT05872490|Other|Semi-structured interviews|An interview guide was developed for each population. Depending on the population interviewed, this interview guide focuses on the current state of driving, the obstacles and levers to driving, the representations related to driving by the elderly, their opinion concerning the implementation of a potential aptitude test and more generally their opinion on policies related to road safety.
45371025|NCT05872490|Other|Questionnaire|The questionnaire asks people aged 80 and over included in the PROOF cohort about their relationship to driving, their driving status, their societal and personal environment, the circumstances in which they stopped driving, recent accidents and, more generally, their driving habits.
45489804|NCT02398084|Other|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (cashews or walnuts) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
45371026|NCT05870189|Behavioral|Remote CMR|12 weeks of remote CMR is done 3x/week, 45 min/session.
45371027|NCT05870189|Behavioral|Remote Exercise|12 weeks of remote exercise is done 3x/week, 45 min/session.
45371028|NCT05869318|Other|ECIG own|Participants will vape using their own ecig device
45692461|NCT03585465|Drug|Capecitabine|"Arm B (First stage): 400 to 600 mg/m2/day PO, all days per cycle, 28 days cycle~Arm C (First stage): 400 to 600 mg/m2/day PO, D8-D11// D22-D25 per cycle, 28 days cycle~Metronomic or Metronomic+Nivolumab Arm (second stage): see C"
45489805|NCT03167710|Other|Dry Needling, manipulation, stretching|HVLA thrust manipulation to elbow, wrist and spine (C5-C6). Dry needling to wrist extensor muscles on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
45489806|NCT03167710|Other|manual therapy, exercise, ultrasound|Impairment-based manual therapy, exercise and ultrasound targeting the wrist extensors on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
45489807|NCT03730805|Behavioral|ASSIST-linked Brief Intervention|The intervention follows the WHO's ASSIST-linked Brief Intervention (Humenik et al., 2012; Humeniuk et al., 2010), a manualized one-session intervention that can be categorised as belonging to the Screening and Brief Intervention approach. It follows the FRAMES model (Bien et al., 1993) and contains techniques from Motivational Interviewing (Miller & Rollnick, 1991).
45489808|NCT03730805|Behavioral|Induction of Deliberative Mindset|Based on the Mindset Theory of Action Phases (Gollwitzer & Keller, 2016), a brief writing task (writing down pros and cons for an unresolved personal problem of the participant's own choice) is used to induce a specific psychological state in which the individual is cognitively open to process new information.
45498142|NCT03685032|Drug|Ondansetron|The 4 mg of ondansetron in 2 ml intravenous was administrated at the end of the operation.
45692462|NCT03585465|Drug|Nivolumab|"Arm A, B or C (First stage): 3 mg/kg IV, D1 & D15 per cycle, 28 days cycle~Metronomic+Nivolumab Arm (second stage): 3 mg/kg IV, D1 & D15 per cycle, 28 days cycle"
46053175|NCT05796375|Procedure|Cystoscopy|Cystoscopy entails direct inspection of the bladder via a cystoscope that is inserted into a patient's urethra.
46053176|NCT05796375|Diagnostic Test|Bladder EpiCheck urine test|The Bladder EpiCheck is a laboratory-developed test for early-stage non-muscle invasive bladder cancer. The Bladder EpiCheck test is a DNA methylation test that is run on DNA extracted from cell pellet from centrifuged urine according to Standardized Operating Procedures. The test has internal controls and a dedicated software to ensure required quality assurance processes and prompt reporting of results.
46053177|NCT05796375|Diagnostic Test|Xpert Bladder Cancer Monitor urine test|A 4.5 ml sample of voided urine is added to Xpert® Urine Transport Reagent, mixed, and then 4ml of treated urine are transferred to the Sample Chamber of the cartridge. In the cartridge, cells in the urine sample are captured on a filter and lysed by sonication. The released nucleic acid is eluted, mixed with dry RT-PCR reagents, and the solution is transferred to the reaction tube for RT-PCR and detection.
45371029|NCT05869318|Other|ECIG Vuse|Participants will vape a VUSE e-cigarette (GOLD 5%)
45371030|NCT05859178|Other|Exercise group|Along with nerve transfer surgery, individuals in the exercise group will undergo handgrip exercise for 30 minutes a day, 5 days a week for a total of 12 weeks.
45371031|NCT05853380|Device|Informed Vital Core App|All subjects assigned to a single arm, pulse rate measurement will be collected, calculated, and displayed on the web based application. A conventional ECG device will also be used to collect and display the heart rate at the same time. If additional consent is obtained subjects may provide blood pressure and SpO2 measurements for the web based application.
45489809|NCT03730805|Behavioral|Induction of Implemental Mindset|Based on the Mindset Theory of Action Phases (Gollwitzer & Keller, 2016), a brief writing task (writing down steps necessary to implement a personal decision of the participant's choice that has not yet been put into practice) is used to induce a specific psychological state in which the individual is cognitively not open to process new information.
45489810|NCT03167866|Behavioral|motivational SMS|the participant receives a weekly text message that is aimed to increase motivation
45692463|NCT03940209|Behavioral|Basic needs navigation|Navigators will help participants address unmet basic needs for 6 months by telephone. Either party can initiate a call. On every call, navigators will: (1) review unmet needs previously reported (baseline survey for first call) and ask participants to report new needs; (2) jointly prioritize among multiple needs based on severity and resource availability; (3) identify community resources that could help solve the problem; (4) evaluate eligibility for those resources; and (5) prepare participants to interact with service agencies and/or act as an advocate on their behalf. On each subsequent call, navigators will review progress toward resolving those needs, assess emergent needs, and adapt priorities accordingly. Navigators will provide instrumental and emotional social support through regular friendly contact, and will attempt to reduce barriers to needs resolution to improve stability and security for participants longer-term.
46053178|NCT05796063|Diagnostic Test|gastric point of care ultrasound|Patients will receive a gastric point of care ultrasound to evaluate for delayed gastric emptying. Gastric POCUS studies will be obtained using Kosmos, a handheld portable ultrasound that is FDA approved for clinical use. This product has already been validated for use, and this is not a novel application of the technology.
46053179|NCT05795205|Behavioral|Normal dinner|Participants will consume breakfast at 0830-0855 am, lunch at 1230-1255 pm, followed by dinner at 1800-1825 pm. Snacks will be consumed at 2130-2140 pm.
46053180|NCT05795205|Behavioral|Delayed dinner consumption|Participants will consume breakfast at 08:30-08:55 am, lunch at 12:30-12:55 pm, followed by snacks at 18:00-18:10 pm. Dinner will be consumed at 21:30-21:55 pm.
46053181|NCT05795205|Behavioral|Exercise with delayed dinner consumption|Participants will consume breakfast at 08:30-08:55 am, lunch at 12:30-12:55 pm, followed by snacks at 18:00-18:10 pm. Participants will exercise for 45 min at moderate-intensity 45 min prior to the delayed dinner at 21:30-21:55 pm.
46053182|NCT05794295|Other|Acoustic Stimulation (AS)|Acoustic Stimulation will be administered while participants have their sleep monitored during one night in the UC Davis Epilepsy Monitoring Unit (EMU).
45489811|NCT03167866|Behavioral|informational SMS|the participant a weekly text message that is provides information on improving lifestyle
45489812|NCT03734471|Device|Reactor Device|The Reactor is a Class II FDA medical device to facilitate the insertion of chest tubes into the thoracic cavity.
45489813|NCT03734471|Procedure|Tube thoracostomy|Traditional chest tube placement
45489814|NCT03730727|Behavioral|Physical activity|Physical activity will consist of either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises (10 squats, 10 push-ups, 10 lunges, 10 sit-ups).
45489815|NCT03730727|Dietary Supplement|Meal|Liquid meal replacement shake containing 500 kcal, with 55% kcals from carb, 30% from fat, and 15% from protein.
45489816|NCT03115138|Other|Correlation between molecular anomalies of the primary tumor and circulating tumor DNA|The presence of a specific abnormality initially identified on the primary tumor and which can be quantified in the cDNA during the management will allow a better follow-up of the patient.
45692464|NCT03588273|Drug|Amoxil 500 MG Oral Capsule|
45371043|NCT05838911|Other|Study Group chest physiotherapy program combined with neuromuscular electrical stimulation (NMES)|The patients in this group were received the same chest physiotherapy program combined with neuromuscular electrical stimulation of quadriceps and calf muscles performed for 30 min /day for five days a week for three consecutive weeks.
45498143|NCT03685032|Drug|0.9% Sodium Chloride Injection|The 0.9% sodium chloride in 1 ml intravenous was administrated after patient received general anesthesia. At the end of operation, the 0.9% sodium chloride in 2 ml intravenous was administrated.
45692465|NCT03938649|Radiation|Conventional IMRT|"RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).~38 fractions of daily treatment, Monday to Friday.~All patients will be given neoadjuvant and adjuvant androgen deprivation therapy."
46053183|NCT05794295|Other|SHAM Stimulation|No stimulation will be administered while participants have their sleep monitored during one night in the UC Davis Epilepsy Monitoring Unit (EMU).
46053184|NCT05793112|Drug|INF108F probiotic|Oral suspension
46053185|NCT05793112|Drug|Placebo|Oral suspension
45371044|NCT05838911|Other|Control Group Chest physical therapy|The patients in this group were received the chest physiotherapy program for 20 min each day, for five days a week for three consecutive weeks
45371045|NCT05838378|Other|Package image sorting with pictorial warnings|Weekly for six weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories [fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other]. Participants will sort 18 images of cigarillo packages from various brands with pictorial warnings on each pack.
45371046|NCT05838378|Other|Package image sorting with Surgeon General text-only warnings|Weekly for six weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories [fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other]. Participants will sort 18 images of cigarillo packages from various brands with Surgeon General text-only warnings on each pack.
45489817|NCT05665517|Device|Chatbot Little K Nurse|"The CKD chat-based instant messaging support health education system in this study was named Chatbot Little K Nurse and connected to the Line platform to set up a one-to-one line. K stands for kidney. Each group contained three parties: patients with CKD (participants ), Chatbot Little K Nurse (virtual), and an instructor (health teacher) for an enhanced intervention. According to the handbook of CKD health management by the Health Promotion Administration (2018b) and the CKD Clinical Diagnosis and Treatment Guidelines for literature investigation in Taiwan, 350 groups of question-and-answer (Q&A) corpora were formed."
45489818|NCT03106402|Drug|topical bromfenac sodium hydrate|
45371047|NCT05838378|Other|Package image sorting with FDA text-only warnings|Weekly for six weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories [fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other]. Participants will sort 18 images of cigarillo packages from various brands with FDA text-only warnings on each pack.
45489819|NCT03730571|Device|AbsorbaSeal 6Fr Vascular Closure Device|Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device
45489820|NCT03106168|Procedure|Extraction of mandibular molar|Patients who require extraction of mandibular molars will be submitted to surgery
45489821|NCT03734159|Drug|Ropivacaine|Injection of 60 ml of ropivacaine 0.25% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
45489822|NCT03734159|Drug|sodium chloride 0.9%|Injection of 60 ml of sodium chloride 0.9% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
45489823|NCT02397382|Drug|Guselkumab|Guselkumab will be administered as a single dose of 200 milligram (mg) by subcutaneous injection (2*100 mg) on Day 8.
45489824|NCT02397382|Drug|Midazolam|Midazolam will be administered orally as probe cocktail containing 0.03 mg per kilogram (kg) once on Day 1, 15 and 36.
45489825|NCT02397382|Drug|Warfarin|Warfarin will be administered orally as probe cocktail containing 10 mg once on Day 1, 15 and 36.
45489826|NCT02397382|Drug|Omeprazole|Omeprazole will be administered orally as probe cocktail containing 20 mg once on Day 1, 15 and 36.
45692466|NCT03938649|Drug|SBRT|RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.
45692467|NCT04747821|Biological|Adsorbed COVID-19 (Inactivated) Vaccine|Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
46053186|NCT05791812|Device|home-based transcranial direct current stimulation (tDCS)|2mA of tDCS for 20 min every weekday for six weeks
46053187|NCT05791448|Procedure|Biospecimen Collection|Undergo collection of blood samples
46053188|NCT05791448|Procedure|Computed Tomography|Undergo CT scan
46053189|NCT05791448|Procedure|Magnetic Resonance Imaging|Undergo MRI
45371048|NCT05831280|Behavioral|Laughter Yoga|"Warm-up exercises (5 minutes),~Deep breathing exercises (5 minutes),~Childlike playfulness (5 minutes),~Laughter exercises (15 minutes)."
45371049|NCT05829668|Behavioral|ABA-based functional analysis and treatment|Functional analysis to identify environmental variables maintaining child problem behavior and function-based treatment
46053190|NCT05791448|Drug|RNA Transcription Modulator AU-409|Given PO
45371051|NCT05825170|Device|FASY L|Subjects will receive FASY L in lips at level of their scar.
45371052|NCT05824351|Device|Tanzanian beeswax-pine resin|Thin ring of adhesive in the form of a Tanzanian beeswax-pine resin formula.
46053191|NCT05787990|Diagnostic Test|Diabetes Microvascular Complication Tests|Continuous glucose monitoring using Freestyle Libre Pro, Foot examination with monofilament and neurothesiometer, HbA1c and Urine Microalbumin Creatinine Ratio, Corneal confocal microscopy, Fundal photography, Optical coherence tomography, Optical cohere
45371053|NCT05824351|Device|Domestic beeswax-pine resin|Thin ring of adhesive in the form of a domestic beeswax-pine resin formula.
45371054|NCT05824351|Device|Hollister's AdaptTM Barrier Rings|Thin ring of adhesive in the form of Hollister's AdaptTM Barrier Rings.
45371055|NCT05824143|Drug|Darigabat|Oral tablet
45371056|NCT05824143|Drug|Carbamazepine|Oral tablets
45489827|NCT02397382|Drug|Dextromethorphan|Dextromethorphan will be administered orally as probe cocktail containing 30 mg once on Day 1, 15 and 36.
45489828|NCT02397382|Drug|Caffeine|Caffeine will be administered orally as probe cocktail containing 100 mg once on Day 1, 15 and 36.
45489829|NCT02397304|Other|Exercise|Participants will complete two morning exercise sessions. One will be performed in the overnight fasted-state (i.e. no food or drink, except water, from 10pm the evening before) and the other will be performed in the fed-state having received a breakfast by the research team before exercise.
46053192|NCT05787288|Biological|Extracellular Vesicles from Mesenchymal Stem Cells|Umbilical cord mesenchymal stem cell-derived extracellular vesicle preparation; Specification: 5ml, with extracellular vesicle concentration of 1 × 109 particles/ml in the preparation;
46053193|NCT05783999|Device|vibra plus|the device is applied to the patient's lower limbs and generates an active flow of vibrations that may reduce fatigue
46053194|NCT05783583|Device|Remote Digital Slit Lamp|Slit Lamp Examination
46053195|NCT05781412|Device|tDCS|Anodal and Sham cerebellar tDCS will be used in each participant in a counterbalanced order
46053196|NCT05781399|Drug|JNT-517 Suspension|JNT-517 in on-site compounded suspension
46053197|NCT05781399|Drug|Placebo Suspension|On-site compounded placebo suspension
46053198|NCT05781399|Drug|JNT-517 Tablet|JNT-517 tablets, 25 mg and 75 mg
46053199|NCT05781399|Drug|Placebo Tablet|Matching film-coated placebo tablet
46053200|NCT05776875|Drug|Atezolizumab Injection|Atezolizumab is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), hepatocellular carcinoma, and alveolar soft part sarcoma It is a fully humanized, engineered monoclonal antibody of Immunoglobulin G1 (IgG1) isotype against the protein programmed cell death-ligand 1 (PD-L1).
46053201|NCT05776875|Drug|Bevacizumab|Bevacizumab, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).
45371057|NCT05822492|Procedure|Group QLB3|"Patients who applied the QLB3 block before PCNL surgery were included in this group~Multimodal analgesia protocol is applied to all patients undergoing PCNL surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg after induction of general anesthesia and iv paracetamol 1 gr intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv PCA of 0,2mg/ml morphine (the bolus dose is 1mg, the lock-in time of 20 minutes, and the 4-hour limit is adjusted to be 80% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥4), 100 mg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation."
45371058|NCT05822492|Procedure|Group ESPB|"Patients who applied ESP block before PCNL surgery were included in this group~Multimodal analgesia protocol is applied to all patients undergoing PCNL surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg after induction of general anesthesia and iv paracetamol 1 gr intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv PCA of 0,2mg/ml morphine (the bolus dose is 1mg, the lock-in time of 20 minutes, and the 4-hour limit is adjusted to be 80% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥4), 100 mg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation."
45489830|NCT04869826|Device|Pulsewave Health Monitor (PAD-2A) Device|This is an observational, comparison study of blood pressure measurements. The objective of this study is to calibrate the blood pressure measurements of the Pulsewave Health Monitor (PAD-2A) device to be within 5±8 mmHg of the average of the dual-observer auscultatory blood pressure measurements via an aneroid sphygmomanometer (reference device), as per the ISO 81060-2: AMD_2020 universal protocol.
46053202|NCT05776875|Combination Product|Transarterial chemoembolization|Transarterial chemoembolization (TACE) is a local therapy for HCC which induces tumor necrosis.
45489831|NCT03401112|Drug|IMR-687|Oral administration of IMR-687 once daily with or without HU.
45692468|NCT03588195|Other|Educational Program|Educational program consist in 5 consecutive sessions held once a week, with a duration of 60 minutes each class and at the end of the last class, a booklet was delivered for each patient with all the contents of the classes. This group also received Transcutaneous Nerve Electro-Stimulation twice weekly, for 5 weeks for 40 minutes each session
45692469|NCT03588195|Device|Transcutaneous Nerve Electro-Stimulation|Transcutaneous Nerve Electro-Stimulation performed twice weekly, for 5 weeks for 40 minutes each session
45692470|NCT03585621|Radiation|SBRT|Each radiation treatment plan will be customized to the patient and tumour in order to deliver highly conformal, conebeam CT guided SBRT radiotherapy in 4 fractions delivered over 2-4 weeks.
46053203|NCT05776290|Biological|Hyaluronic Acid|This material will be injected into the prepared impact socket prior to inserting the implant. This injection will be done inside the socket as well as on the periphery of the socket.
46053204|NCT05776264|Behavioral|Music Condition|During one of the sessions, participants will listen to music while walking on the treadmill for 10 minutes.
46053205|NCT05776264|Behavioral|Podcast Condition|During one of the sessions, participant will listen to a podcast for 10 minutes while walking on the treadmill.
46053206|NCT05776069|Drug|VGA039|Single doses of VGA039
46053207|NCT05776069|Other|Placebo|Single doses of Placebo
46053208|NCT05774782|Device|Cerebral flow diverter|The surface-modified flow diverter is an intracranial implant designed to be placed in a parent artery so as to divert blood flow away from an aneurysm.
45371059|NCT05822492|Other|Group Control|"Patients who did not use block before PCNL surgery were included in this group.~Multimodal analgesia protocol is applied to all patients undergoing PCNL surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg after induction of general anesthesia and iv paracetamol 1 gr intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv PCA of 0,2mg/ml morphine (the bolus dose is 1mg, the lock-in time of 20 minutes, and the 4-hour limit is adjusted to be 80% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥4), 100 mg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation."
45371060|NCT05822479|Procedure|Bilateral ultrasound guided external oblique intercostal block (EOIB)|"Bilateral ultrasound-guided EOIB (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA~Multimodal analgesia :~Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients. Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis."
45489832|NCT03401112|Drug|Placebo|Oral administration of placebo once daily with or without HU.
45692471|NCT03588819|Radiation|SABR|26 Gy in 2 fractions to the prostate and DIL dose of up to 32 Gy in 2 fractions of MR-guided SABR delivered 1 week apart
45692472|NCT03588117|Behavioral|Physician-supervised nonsurgical weight management program|Participants of a physician-supervised nonsurgical weight management program were observed as they received weekly in-person coaching sessions with licensed clinicians. In-person coaching sessions were focused on educating participants on strategies to manage their weight and adopt a healthy lifestyle. Prescribed diets were individualized based on each participant's behavior, level of physical activity, and total energy expenditure. Supplements, appetite suppressant medications, and compounded injections were used to control appetite and/or boost energy during a period of low-caloric intake. The program was generally divided into three phases: Acute, Short-Term Maintenance, and Wellness.
45692473|NCT03545607|Biological|MultiStem|single intravenous infusion 18-36 hours after stroke
45489833|NCT02697916|Drug|aspirin|81mg of aspirin daily vs. 325mg of aspirin daily
45489834|NCT04866316|Other|There is no active intervention as this is a service evaluation|There is no active intervention as this is a service evaluation
45489835|NCT04762680|Biological|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
45489836|NCT04762680|Biological|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
45489837|NCT04762680|Biological|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
45489838|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
45489839|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
45489840|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
45692474|NCT03545607|Biological|Placebo|single intravenous infusion 18-36 hours after stroke
45371061|NCT05822479|Other|Control|"Patients in this group will not be performed interfacial plane blocks.~Multimodal analgesia :~Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg (IBW) iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients. Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis."
45489841|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
45371062|NCT05819866|Drug|Leriglitazone|Leriglitazone at a strength of 15 mg/ml. Once-daily dosing at an initial volume of 10 ml
45371063|NCT05819866|Drug|Placebo|Placebo will match the study drug visually and by taste
45371064|NCT05813769|Dietary Supplement|Dairy protein|During each visit, research subjects will receive the product dissolved in water, representing a 20g protein load.
45371065|NCT05813769|Dietary Supplement|Plant protein|During each visit, research subjects will receive the product dissolved in water, representing a 20g protein load.
46053209|NCT05772390|Radiation|Partial breast re-irradiation|partial breast re-irradiation
45489842|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
45489843|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
45489844|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
45489845|NCT04762680|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
45489846|NCT03650387|Device|RADIESSE® (+) Lidocaine|RADIESSE® (+) Lidocaine will be injected as per its current approved labelling and investigator's usual practice
45489847|NCT02392312|Drug|ATF-Fresenius S|intravenous
45489848|NCT03115216|Procedure|FLA-CEIOL|Femtosecond laser-assisted cataract extraction and intraocular lens placement
45489849|NCT03115216|Procedure|CEIOL|Manual cataract extraction and intraocular lens placement
45489850|NCT01310153|Procedure|prone positioning|newborn babies in prone positioning
45489851|NCT01310153|Procedure|Supine|newborn babies in supine positioning
45489852|NCT04462536|Drug|Placebo|Vehicle only
45489853|NCT04462536|Drug|Nerinetide|Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
46053210|NCT05770726|Dietary Supplement|Probiotics administration|A total of 10 grams of probiotics was administered in both group, but the routes were different. One group were per colonoscopic spray, and the other was per oral.
46053211|NCT05768711|Drug|Venetoclax|Combination of Azacitidine and Venetoclax
46053212|NCT05766735|Behavioral|Glycemic Excursion Minimization (GEM)|A structured, self-directed, and personalized program that will allow participants with pre-diabetes to improve their metabolic status by illustrating the effects of their routine food and physical activity choices on their blood glucose levels and variability
46053213|NCT05766735|Other|Medication Management (MM)|MM participants will meet with their personal physician to determine the best diabetes medication and proper dose. The participant will be allowed to change medications, or use a combination of medications, that is best suited for their care during the duration of the study. The study team will not influence these decisions.
46053214|NCT05766670|Drug|Vancomycin Hydrochloride|The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
46053215|NCT05766670|Drug|Gentamicin|The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
46053216|NCT05766670|Other|Standard Intramedullary Nail|Standard Intramedullary Nail
46053217|NCT05765227|Device|Lehfilcon A multlifocal contact lenses|Investigational silicone hydrogel multifocal contact lenses
45371070|NCT05794230|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Liquid solution - intramuscular
45489854|NCT02392156|Biological|rFVIIIFc|As described in the treatment arm
45489855|NCT02392156|Biological|rFIXFc|As described in the treatment arm
46053218|NCT05765227|Device|Lotrafilcon B multifocal contact lenses|Commercially available silicone hydrogel multifocal contact lenses
45692475|NCT04148235|Other|No Intervention|There is no intervention for this study
45371071|NCT05794230|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|Liquid solution - intramuscular
46053219|NCT05765227|Device|Hydrogen peroxide-based cleaning and disinfection system|Commercially available cleaning and disinfection system for silicone hydrogel contact lenses
46053220|NCT05761444|Drug|Atozet 10/40 mg or 10/80 mg|Atozet 10/40 mg or 10/80 mg Dosage Formulation: Tablet Dosing Instructions: oral. Take 1 tablet daily
46053221|NCT05761444|Drug|Lipitor 40 mg or 80 mg|Lipitor 40 mg or 80 mg Dosage Formulation: Tablet Dosing Instructions: oral. Take 1 tablet daily
46053222|NCT05758948|Diagnostic Test|NGS in blood and Formalin-Fixed Paraffin-Embedded (FFPE) tissue|In patients with denovo metastatic breast cancer blood and tissue sample will be collected and then further analysed using NGS in order to detect somatic and germline pathogenic variants
46053223|NCT05758194|Other|Standardized RV Management|Standardized parameters for post-operative management (i.e., Rhythm Management, Ventilation Management, RV Ischemia Management, RV Preload, RV Afterload, RV Contractility, and RV Geometry)
45371072|NCT05794230|Biological|Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)|Oral suspension - oral
45371073|NCT05794230|Biological|Pneumoccocal Vaccine|Suspension for injection - intramuscular
45371074|NCT05794230|Biological|Measles, Mumps, and Rubella Vaccine live (MMR) - TRESIVAC®|Lyophilized powder for injection - subcutaneous
45371075|NCT05794230|Biological|DTwP-HepB-Hib-IPV vaccine|Suspension - intramuscular
45371076|NCT05794230|Biological|DTaP-IPV-Hib-HepB vaccine|Liquid solution - intramuscular
45371077|NCT05794230|Biological|Hepatitis A vaccine - HAPIBEV™|Suspension for injection - intramuscular
45371078|NCT05794230|Biological|Rotavirus vaccine|Oral solution - oral
45371079|NCT05794230|Biological|Typhoid conjugate vaccine (TCV)|Suspension for injection - intramuscular
45371080|NCT05794230|Biological|Measles vaccine - MeasBio®|Freeze-dried powder for reconstitution and injection - subcutaneous
45371081|NCT05794230|Biological|Varicella vaccine live - VARIPED®|Sterile powder and diluent for injection - subcutaneous
45371082|NCT05794230|Biological|Varicella vaccine live - Onvara|Lyophilized powder for injection - subcutaneous
45371083|NCT05794230|Biological|Measles, Mumps, and Rubella Vaccine live (MMR) - OMZYTA®|Lyophilized powder for injection - subcutaneous
45371084|NCT05794230|Biological|Hepatitis A vaccine - Avaxim 80 U|Suspension for injection - intramuscular
45371085|NCT05793957|Other|Questionnaire Administration|Ancillary studies
45371086|NCT05793957|Behavioral|Telephone-Based Intervention|Use smartphone
45371087|NCT05793957|Other|Virtual Technology Intervention|Use VR headset
45489856|NCT02392156|Drug|non-Fc FVIII replacement products|Standard plasma-derived (pd) or recombinant (r) FVIII concentrate and other traditional treatment options
45489857|NCT02392156|Drug|non-Fc FIX replacement products|Standard plasma-derived (pd) or recombinant (r) FIX concentrate and other traditional treatment options
45489858|NCT03115060|Drug|intravenous fluid administration WITH NORMAL SALINE, PLASMALYTE A, OR RINGER LACTATE|intravenous fluid to be used for maintainance and replacement during renal transplant surgery will be normal saline, ringer lactate or plasmalyte A depending on the arm of intervention
46053224|NCT05758194|Other|Usual Care RV Management|No standardized parameters for post-operative management (i.e., Rhythm Management, Ventilation Management, RV Ischemia Management, RV Preload, RV Afterload, RV Contractility, and RV Geometry)
46053225|NCT05757791|Drug|Empagliflozin|The full duration of therapy will be six-weeks. The route of administration will be oral. The starting dose of the medication will be 10mg daily for the first 14 days of the study, with a dose escalation to 25mg for the last 28 days of the study.
46053226|NCT05754346|Other|Complete Decongestive Therapy|Complete Decongestive Therapy will include manual lymphedema drainage (self) for 20 min everyday, skin care everyday, wearing compression garment or bandages everyday and upper-extremity exercises twice a day.
45489859|NCT01871220|Device|Concave Transition Profile|An Atlantis abutment is delivered with a concave transition profile.
45489860|NCT01871220|Device|Divergent Transition Profile|An Atlantis abutment is delivered with a linear transition profile
45489861|NCT03359473|Drug|GSK2881078|GSK2881078 will be available as capsules for oral administration. GSK2881078 will be administered once daily by the oral route at a dose of 1 mg and 2mg to post-menopausal female subjects and male subjects, respectively.
45489862|NCT03359473|Drug|Matching Placebo|Subjects will be administered two capsules of GSK2881078 matching placebo once daily by the oral route.
45489863|NCT04831060|Procedure|Periodontal treatment|"For Cases :~Inclusion; Periodontal bacteria, gingival fluid and unstimulated saliva collection; Teaching of oral hygiene techniques.~Non-surgical periodontal treatment~At 3 months = periodontal reevaluation; Periodontal bacteria, gingival fluid and unstimulated saliva collection~If periodontal pockets greater than 5mm and bleeding persist: periodontal surgery and gingival explant sampling~At 3 months post-surgery = periodontal re-evaluation; Periodontal bacteria, gingival fluid and unstimulated saliva collection~Maintenance~For Controls:~Inclusion; Periodontal bacteria, gingival fluid and unstimulated saliva collection, teaching of oral hygiene techniques.~Plastic or pre-prosthetic surgery = gingival explant sampling~Healing control at 15 days"
45489864|NCT03632304|Procedure|Local anesthesia with minimal sedation|The operating surgeon will perform a digital or wrist block to numb the surgical area prior to the surgery, instead of using a brachial plexus block.
45371088|NCT05792046|Device|Visual field|test for detecting loss in visual function
45371089|NCT05789199|Drug|Cefiderocol|Cefiderocol is a novel siderophore cephalosporin developed for the treatment of infections caused by Gram-negative bacteria (GNB), including those resistant to carbapenems.
45371090|NCT05788965|Drug|Semaglutide|glucagon-like peptide 1 (GLP-1) receptor agonist
45371091|NCT05786469|Drug|Veltassa Oral Powder Product|"The recommended starting dose is 8.4 g of patiromer, once daily (equivalent to one packet of the active ingredient, once daily). The daily dose may be adjusted in intervals of one week or longer, based on the serum potassium level and the desired target range. The daily dose may be increased or decreased by 8.4 g as necessary to reach the desired target range, up to a maximum dose of 25.2 g daily. If serum potassium falls below the desired range, the dose should be reduced or discontinued.~Patients are expected to be included during an 18-month recruitment period. The last randomized patient will be maintained on active follow-up for 6 months. All other randomized patients will be maintained on active follow-up until the last randomized patient will have completed the planned 6-month follow-up period. Thus, the follow-up period will be expected to range from a minimum of 6 months for the last randomized patient to a maximum of 24 months for the first randomized patient"
45489865|NCT02397538|Drug|Fimasartan|
45489866|NCT02397538|Drug|Amlodipine|
45489867|NCT02397538|Drug|Rosuvastatin|
45489868|NCT02397616|Other|high resolution esophageal manometry|high resolution esophageal manometry using liquid and solid swallows and a test meal.
45489869|NCT01429038|Biological|Mesenchymal Stem Cells|Third party MSC 1,5-3,010E6/kg. No HLA matching between MSC donor and the recipient or the liver/kidney donor. One infusion at day 3+/-2.
45489870|NCT02396992|Other|Minimal-Massive Intervention|The intervention will consist in basic recommendations based on the evaluations done at admission and discharge: a) diet adaptation (solids and fluids) based on dysphagia clinical evaluation (V-VST) to avoid efficacy or safety alterations; b) nutritional supplements in case of malnutrition (MNA-sf; bioimpedance and blood analysis) to improve nutritional status;and c) oral health and hygiene recommendations (toothbrushing and antiseptic mouthwashes to decline bacterial colonization).
45489871|NCT04418778|Behavioral|BEAR|Building Empowerment and Resilience Therapy group
45489872|NCT03589469|Drug|Loncastuximab tesirine|intravenous infusion
45489873|NCT04800484|Device|Tall Soft|Tall heel wedge made of soft foam
45489874|NCT04800484|Device|Tall Firm|Tall heel wedge made of firm foam
45489875|NCT04800484|Device|Short Soft|Short heel wedge made of soft foam
45489876|NCT04800484|Device|Short Firm|Short heel wedge made of firm foam
46053227|NCT05754346|Other|Upper extremity exercises combined with diaphragmatic breathing exercises|"Upper-extremity exercises component of Complete Decongestive Therapy will be performed combined with diaphragmatic breathing exercises."
46053228|NCT05752734|Drug|Group D|"Patients who received 8 mg dexamethasone before bariatric surgery will be included in this group.~Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation."
46053229|NCT05752734|Drug|Group C|"Patients not administered dexamethasone will be included in this group.~Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation."
45371092|NCT05786469|Other|Placebo|"The recommended starting dose is 8.4 g of patiromer, once daily (equivalent to one packet of the active ingredient, once daily). The daily dose may be adjusted in intervals of one week or longer, based on the serum potassium level and the desired target range. The daily dose may be increased or decreased by 8.4 g as necessary to reach the desired target range, up to a maximum dose of 25.2 g daily. If serum potassium falls below the desired range, the dose should be reduced or discontinued.~Patients are expected to be included during an 18-month recruitment period. The last randomized patient will be maintained on active follow-up for 6 months. All other randomized patients will be maintained on active follow-up until the last randomized patient will have completed the planned 6-month follow-up period. Thus, the follow-up period will be expected to range from a minimum of 6 months for the last randomized patient to a maximum of 24 months for the first randomized patient"
45371093|NCT05784714|Behavioral|NOLA GEM|This is a mobile application that has 6 psychoeducational sessions and related skills, local resources, and a way for participants to track their progress. Further information is in the arm descriptions.
46053230|NCT05745402|Behavioral|Mobility Checkup for older adults|The Mobility Checkup (MC) for older adults is a 45-minute preventative physical therapy visit designed to maintain mobility during aging. It has two parts, measurement (25 minutes) and education (20 minutes). The 5 standardized measures of physical performance in the MC are Walking speed, single leg stance time (balance), Five rep sit to stand (muscular endurance, transitions), 6-meter walk test (general endurance), and Timed up from floor test (transitions). Participants are provided education structured into 4 elements. 1. They are told their performance scores 2. They are shown how their performance scores on each of the measures compare to age and sex-referenced normative values 3. They are provided information about what their performance predicts about their health 4. They are referred to an appropriate provider if there was a health or safety concern during their MC or they are educated to follow the recommendations for physical activity that are recommended by the CDC.
46053231|NCT05739994|Other|Theta burst transcranial magnetic stimulation|Continuous theta burst TMS (cTBS) will be delivered to a location on the head. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.
45371097|NCT05777031|Drug|Collagenase Clostridium Histolyticum (CCH)|Injection of intralesional CCH (0.58mg) to the penile plaque at the point of maximal curvature. Second injection of each cycle will be injected 2-3mm apart from the prior injection.
45371098|NCT05774223|Device|Transcranial magnetic stimulation (TMS)-active|Active intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
45371099|NCT05774223|Device|Transcranial magnetic stimulation (TMS)-sham|Sham intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). The coil will be placed perpendicular to the left DLPFC. A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
45371100|NCT05773274|Procedure|Biospecimen Collection|Undergo collection of blood samples
45371101|NCT05773274|Procedure|Computed Tomography|Undergo CT scan
45371102|NCT05773274|Drug|Everolimus|Given PO
45371103|NCT05773274|Drug|Lutetium Lu 177 Dotatate|Given IV
45371104|NCT05773274|Other|Quality-of-Life Assessment|Ancillary studies
45371105|NCT05773274|Other|Questionnaire Administration|Ancillary studies
45371106|NCT05771974|Device|Compression therapy using surgical gloves|Intervention group wear two-layer of normal-sized surgical gloves on both hands during chemotherapy infusion
45371107|NCT05766501|Drug|DOR/ISL|FDC tablet of 100 mg doravirine (DOR)/0.25 mg islatravir (ISL) taken once daily
45371108|NCT05763823|Drug|Letermovir|Letermovir 240 mg or 480 mg oral tablets or IV once daily dose
45371109|NCT05763459|Drug|ABBV-CLS-7262|Drug: ABBV-CLS-7262 Drug: Digoxin Drug: Rosuvastatin
45489877|NCT03734081|Device|ODC system (type 1 capsule)|ODC (one day capsule) type 1 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
45371110|NCT05761522|Other|transthoracic echocardiography|"Concerning the main judgment criterion and the secondary judgment criteria:~Left ventricular ejection fraction (LVEF) by the Simpson Biplane method,~Cardiac output and cardiac index by continuity equation (measurement of left ventricular outflow chamber (mm) and sub-aortic time-velocity integral (cm/s)).~Tricuspid Annular Systolic Excursion (TAPSE) (mm)~S wave at the tricuspid ring (cm/s)~Other parameters collected systematically:~Surface of the left ventricle (end-systolic and end-diastolic),~Global strain of the left ventricle~Mitral Annular Plane Systolic Excursion (MAPSE) (mm)~Left ventricular filling pressure (LVRP) (at the mitral annulus, E, A, e', S' waves, E/A ratio, E/e');~Maximum tricuspid regurgitation velocity (m/s) to estimate systolic pulmonary arterial pressure (PAPs) (mmHg)"
45371113|NCT05740982|Biological|JYNNEOS|JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus.
45371114|NCT05739435|Drug|ESK-001|Oral tablet
45371115|NCT05737940|Drug|AZD3427|The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.
45371116|NCT05737940|Drug|Placebo|The participants will receive SC injection of placebo single dose every 2 weeks for 24 weeks.
45371117|NCT05737420|Diagnostic Test|Video call|The on-call neurologist can see and communicate with the patient via live stream video-call.
45371118|NCT05730712|Procedure|Biopsy|Undergo biopsy
45371119|NCT05730712|Procedure|Biospecimen Collection|Undergo collection of blood and tissue samples
45371120|NCT05730712|Procedure|Computed Tomography|Undergo CT
45371121|NCT05730712|Procedure|Echocardiography|Undergo ECHO
45371122|NCT05730712|Drug|Enzalutamide|Given PO
45371123|NCT05730712|Drug|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Given SC
45371124|NCT05730712|Procedure|Magnetic Resonance Imaging|Undergo MRI
45371125|NCT05730712|Other|Questionnaire Administration|Ancillary studies
45371126|NCT05727332|Behavioral|Single-Sprint Training|A single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks
45371127|NCT05726864|Drug|ELI-002 7P|ELI-002 Amph-CpG-7909 admixed with ELI-002 Amph-Peptides 7P administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
45371128|NCT05725863|Other|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is a structured group intervention developed by Segal et al. (2002). The intervention consisted of eight weekly 2.5-hr sessions and one 3-hr silent session. First, psycho-education focused on the importance of recognizing personal feelings and the relationship between stress, postpartum blues, mother-infant attachment and breastfeeding symptoms, and stress management, stress, postpartum blues, mother-infant attachment and breastfeeding. Additionally, postpartum mothers' experiences of stress, postpartum blues, mother-infant attachment, and breastfeeding were central during the study and were a recurring topic for the purpose of the study in general. Postpartum mothers were given homework assignments, including audio CDs with formal exercises, and were asked to practice for 30 min per day.
45371129|NCT05725616|Procedure|Coronary angiography|Snuff Box Approach or radial Arterial Approach at wrist for coronary angiography.
45371130|NCT05725603|Other|MRI imaging|Shoulder MRI will be performed at least 3 years after shoulder surgery
45371131|NCT05724875|Device|FLASH RT|For T1 (small) lesions: 22 Gy single dose FLASH RT; For T2 (large) lesions: 5 x 6 Gy fractionated dose FLASH RT
45371132|NCT05724875|Device|Conventional RT|For T1 (small) lesions: 22 Gy single dose conventional RT; For T2 (large) lesions: 5 x 6 Gy fractionated dose conventional RT
45371133|NCT05720702|Dietary Supplement|homocysteine (Hcy) lowering supplements|NAFLD participants will take homocysteine (Hcy) lowering supplements daily for 12 weeks.
45371134|NCT05713981|Procedure|Meibomian gland (MG) expression|The procedure is performed with a sterile cotton tip applicator once in the upper and lower eyelids of the subject's choosing.
45489878|NCT03734081|Device|ODC system (type 2 capsule)|ODC (one day capsule) type 2 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
45489879|NCT03359395|Drug|Alfentanil|Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
45489880|NCT03359395|Drug|Placebos|Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
45489881|NCT03734003|Device|liquid nitrogen|As an active comparator, for patients with cutaneous warts, liquid nitrogen crytherapy is applied
45489882|NCT03734003|Device|controllable infrared bioeffect system|As an experimental arm, for patients with cutaneous warts
45489883|NCT03730493|Behavioral|Teaching subjects regarding self-care of PIVC with Pictorial Flashcard.|In the experimental group researcher explained self-care of PIVC using pictorial flashcard on one to one basis. Patients were explained Do's and Don'ts, they have to keep in mind during self-care or management. Doubts of the patients were also addressed simultaneously. After this a copy of pictorial flashcard was given to the subjects to be used in future (during PIVC in-situ). In control group, standard care was given as per the hospital protocol. After 24 hours/one day, PIVC was observed for presence of any complications such as Phlebitis, Infiltration, Pain, Blockage and Dislodgement using V.I.P. Score, Infusion nurses society infiltration scale, Universal pain assessment tool and PIVC Documentation Tool and need for PIVC removal was also assessed. After 72 hours PIVC removed (whatever applicable) site of PIVC was reassessed, reason for removal was recorded and indwelling time was noted.
45489884|NCT05683015|Procedure|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of tildrakizumab.
45489885|NCT05683015|Procedure|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
45489886|NCT03730415|Procedure|Viscoelastic (VE) Guided Transfusion|A viscoelastic analyzer (ROTEM) will be used to guide the transfusion algorithm during the burn wound excision of subjects enrolled into this arm
45489887|NCT05364307|Other|Prescreener database|Identify and characterize participants with reported memory complaints and/or cognitive impairment to determine the probability of randomization into a therapeutic AD clinical trial.
45489888|NCT03586427|Drug|AGN-241751|AGN-241751 administered orally as a single tablet
46053232|NCT05739994|Other|Sham theta burst transcranial magnetic stimulation|Continuous theta burst TMS (cTBS) will be delivered near the head, while an unplugged TMS coil is held at the vertex. No current will be induced in the head with this procedure.
46053233|NCT05739214|Device|laser therapy|"All patients received 2 sessions of laser therapy / week in two consecutive months of treatment aiming complete wound closure , patients received & infrared laser therapy plus traditional wound care:~(I) Use red & infrared laser therapy device with 4 different wavelengths in a synchronized mode:~980 nm for wound decontamination, improve circulation, lymphatic drainage~915 nm enhances O2 delivery~810 nm increases ATP production~650 nm accelerate surface healing, tissue regeneration plus traditional wound treatment mentioned before"
45371138|NCT05711849|Biological|Bone marrow aspiration and intracoronary infusion of autologous bone marrow-derived cells|Patients who present with symptomatic coronary artery disease of greater than or equal to 90 days of persistent refractory angina CCS Grade III or IV, despite maximal guideline medical therapy. No further PCI or CABG treatment options will be possible but they will have evidence of reversible ischaemia with an ejection fraction greater than or equal to 30%. These participants will have bone marrow aspiration and intracoronary infusion of 10mls of the autologous bone marrow-derived cells into the target vessels.
45371139|NCT05711849|Procedure|Sham bone marrow aspiration and insertion of vascular access sheath|Patients who present with symptomatic coronary artery disease of greater than or equal to 90 days of persistent refractory angina CCS Grade III or IV, despite maximal guideline medical therapy. No further PCI or CABG treatment options will be possible but they will have evidence of reversible ischaemia with an ejection fraction greater than or equal to 30%. These participants will have sham bone marrow aspiration (local anaesthetic and 3mm incision in the skin) and sham intracoronary infusion procedure (local anaesthetic and insertion of radial or femoral sheath).
45489889|NCT03586427|Drug|Placebo|Placebo administered orally as a single tablet
45489890|NCT03733769|Procedure|transmuscular quadratus lumborum block|transmuscular quadratus lumborum block as an alternative to lumbar plexus block for peri-operative analgesia in hip Surgery
45489891|NCT03648983|Procedure|arm circumference measurement|Undergo arm circumference measurement
46053234|NCT05730101|Other|Cognitive-behavioral treatment (CBT)|In the first individual session (CBT1), together with the therapist, participants develop a behavioral and conditional model of their procrastination behavior. In the next 2 group sessions (CBT2 and CBT3), participants receive psychoeducation on procrastination. The focus is on learning the method of starting on time. In the 3 group session (CBT4), participants identify key procrastination-promoting thoughts and are supported to develop alternative thoughts; deepened in the second individual session (CBT5). In the next 2 group sessions (CBT 6 and CBT7), participants are informed about action planning with focus on learning to plan realistically. The last group session is a concluding session: Experiences with the methods learned and an outlook on further steps and goals are discussed. At the end of both individual sessions (CBT1 and CBT5), participants receive a link to an online survey to rate their treatment expectations (treatment expectation 1 and 2).
45371141|NCT05705349|Drug|DOR/ISL|Fixed dose combination tablet containing DOR/ISL 100 mg/0.25 mg taken by mouth.
45371142|NCT05705349|Drug|BIC/FTC/TAF|Fixed dose combination tablet containing BIC/FTC/TAF 50 mg/200 mg/25 mg taken by mouth.
45371143|NCT05705349|Drug|Placebo to DOR/ISL|Placebo tablet matched to DOR/ISL tablet taken by mouth.
45371144|NCT05705349|Drug|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF tablet taken by mouth.
45371146|NCT05703009|Drug|Sacrosidase Oral Solution|Study drug
45489892|NCT03648983|Device|Bioimpedance spectroscopy|bioimpedance spectroscopy
45371147|NCT05703009|Drug|Placebo|Placebo
45371148|NCT05702645|Procedure|Biospecimen Collection|Patients undergo saliva/buccal and blood sample collection
45371149|NCT05702645|Other|Clinical Evaluation|Undergo a clinical assessment
45371150|NCT05702645|Other|Questionnaire Administration|Ancillary studies
45371151|NCT05702645|Other|Survey Administration|Ancillary studies
45371152|NCT05700331|Procedure|Fecal Microbiota Transplantation|"FMT performed at week 0, week-2 and week-4: FMT solution will be prepared using stool from a single donor or mixing of stool from multiple donors. Feces will be diluted with sterile saline (0.9%). This solution will be blended and strained with filter. The resulting supernatant will then be used directly as fresh FMT solution or stored as frozen FMT solution for future FMT.~Procedures for Infusion: 100-200 ml of FMT solution or sterile saline will be infused over 2-3 minutes into the distal duodenum or jejunum via oesophago-gastro-duodenoscopy (OGD). After infusion, subjects will be monitored for 1 hour before discharged.~2 study biopsies in total (from duodenum) will be obtained during FMT infusion via OGD."
45371153|NCT05700331|Procedure|Sigmoidoscopy|Optional sigmoidoscopy will be done at week 0 and week 4, during which 2 study biopsies in total (obtained via sigmoidoscopy) will be obtained from the rectum.
45371154|NCT05696080|Biological|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
45371155|NCT05696080|Drug|Placebo for PCV15 + PPSV23|Saline in each 0.5 mL sterile solution
45371156|NCT05696080|Biological|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
45371157|NCT05696080|Biological|PPSV23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
45489893|NCT05666453|Biological|LIV-GAMMA SN Inj.|LIV-GAMMA SN Inj. is administered at a dose of 0.6 g/kg/day from anhepatic phase to Day 2 post-operative to patients undergoing ABO-incompatible liver transplantation as an experimental group.
45489894|NCT05666453|Other|No intervention|None of investigational drugs are administered to patients.
45489895|NCT03733691|Drug|Ixazomib|3 mg oral capsule, Days 1, 8 and 15 of 28-day cycles
45489896|NCT03733691|Drug|Lenalidomide|Same dose as in the front-line treatment in the last treatment cycle, taken orally, on days 1-28 of a 28-day cycle.
45489897|NCT02695420|Drug|25 mg Omecamtiv Mecarbil|oral tablet
45489898|NCT02695420|Drug|Placebo|oral tablet
45489899|NCT02695420|Drug|37.5 mg Omecamtiv Mecarbil|oral tablet
45489900|NCT02695420|Drug|50 mg Omecamtiv Mecarbil|oral tablet
45489901|NCT03733613|Other|no intervention|no intervention
45489902|NCT03358147|Drug|GP MDI 28.8 μg|GP MDI (PT001)14.4 μg per actuation taken as 2 inhalations BID
45489903|NCT03358147|Drug|GP MDI 14.4 μg|GP MDI (PT001) 7.2 μg per actuation taken as 2 inhalations BID
45489904|NCT03358147|Drug|GP MDI 7.2 μg|GP MDI (PT001) 3.6 μg per actuation taken as 2 inhalations BID
45489905|NCT03358147|Drug|Placebo MDI|Placebo taken as 2 inhalations BID
46053235|NCT05730101|Other|Imaginary pill treatment (IP)|In the first session (IP1), participants will be asked about the nature of their procrastination behavior and receive a procedure to take an imaginary pill following a rationale of 5 steps. In the second IP session (IP2), experiences with taking the IP are discussed and the procedure of taking the IP is adapted according to previous experiences and current needs. The rationale of the second session encompasses the same five steps with small modifications: 1) discussing IP sensitive problem and adapting it if necessary, 2) building trust/belief/reality of the IP, 3) discussing the personally meaningful IP and adapting it if necessary, 4) taking the IP, 5) adapting the procedure for self-administering the IP in real life on daily basis if necessary and building adherence. At the end of both sessions, participants receive a link to an online survey to rate their treatment expectations (treatment expectation 1 and 2).
46053236|NCT05728775|Drug|Remimazolam|Remimazolam is administered intravenously for induction and maintenance of general anesthesia.
46053237|NCT05728775|Drug|Propofol|Propofol is administered intravenously for induction and maintenance of general anesthesia.
45489906|NCT03358147|Drug|Spiriva Respimat 2.5 μg|Spiriva Respimat 2.5 μg QD (open-label)
45489907|NCT03733457|Behavioral|Technology-assisted Stepped-care|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
45489908|NCT05741632|Drug|Moxifloxacin Ophthalmic Solution|Moxifloxacin solution 0.1 cc undiluted, self preserved, injected into intracamera at the end of cataract surgery
45692476|NCT03587649|Drug|[18F]MNI-1126|"Florbetapir PET imaging will be completed in all healthy volunteers and AD subjects as part of the screening procedures.~DaTscan SPECT imaging will be completed in those PDsubjects who have not previously had DaTscan imaging as part of the screening procedures."
45692477|NCT04148313|Other|No Intervention|There is no intervention for this study.
45692478|NCT03589755|Behavioral|Mindfulness meditation|The intervention consist of a weekly session of mindfulness meditation provided by a clinical psychologist trained in this area. She will provide weekly session to a group of 10 patients at a time for a total of 8 weeks. Upon completing the course, the other 10 people will start
45692479|NCT03589599|Other|Flavored tobacco|Effects of flavored tobacco
45371167|NCT05689749|Device|Superb Microvascular Imaging (SMI) (Toshiba)|To determine whether SMI has diagnostic value for detecting the inflammatory state in the lacrimal glands in Sjögren's syndrome and whether it has any superiority compared to Power Doppler and Color Doppler modalities.
45371168|NCT05687136|Procedure|Biopsy|Undergo tissue biopsy
45371169|NCT05687136|Procedure|Biospecimen Collection|Undergo blood sample collection
45371170|NCT05687136|Procedure|Computed Tomography|Undergo CT
45371171|NCT05687136|Procedure|Magnetic Resonance Imaging|Undergo MRI
45371172|NCT05687136|Drug|Peposertib|Given PO
45371173|NCT05687136|Procedure|Positron Emission Tomography|Undergo PET
45371174|NCT05687136|Drug|Tuvusertib|Given PO
45371175|NCT05687110|Procedure|Biopsy|Undergo tumor biopsy
45371176|NCT05687110|Procedure|Biospecimen Collection|Undergo blood sample collection
45489909|NCT05741632|Drug|Levofloxacin Ophthalmic|Levofloxacin solution 0.1 cc undiluted, self preserved, injected into intracamera at the end of cataract surgery
45489910|NCT03093402|Drug|JBT-101|Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
45489911|NCT03093402|Drug|Placebo|Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
45489912|NCT03585959|Device|superDimension™ Navigation System Version 7.2|superDimension™ Navigation System Version 7.2 with Fluoroscopic Navigation Technology in subjects undergoing lung lesion biopsy
45489913|NCT02397070|Procedure|Jaw exercise program|The jaw exercise program will consist of three cycles: 1st CYCLE - simple opening and closing mouth, right and left lateral excursions with mechanisms of proprioceptive neuromuscular facilitation and muscle coordination; 2 ° CYCLE - opening and closing exercises, right and left lateral excursions with a counter-resistance force imposed by the participant, with reciprocal inhibition, stretching, and muscular endurance mechanisms; 3rd CYCLE - specific exercises to disk capture attempt in cases of disk displacement with reduction and acute disk displacement without reduction (mouth opening and closing in protrusion) or chronic disk displacement without reduction (forced mouth opening in order to push the disc), with remodeling articulate mechanisms. The conduct will be individualized according to the need and symptoms of patients, which will be monitored fortnightly. It will be proposed 3 times a day, lasting a minute and a half per turn, in front of the mirror, during three months.
45692480|NCT03589599|Other|Non-flavored tobacco|Effects of non-flavored tobacco
46053238|NCT05728411|Other|Remote foot temperature monitoring system|"Remote temperature monitoring involves a thermometric mat that can detect hot spots on the plantar surface of the foot. The mat has embedded cellular connectivity so that data can be transmitted from the patient's home to the company, where the temperature data can be analyzed. The company has a team of health coaches that work with patients and providers to detect signs of damage early in order to prevent ulceration."
46053239|NCT05728411|Other|Enhanced usual care|"Usual care is based on the VA's amputation prevention program (PAVE - Preventing Amputation in Veterans Everywhere - VHA Directive 1410), which provides a model of care for patients at risk for amputation as well as patients who have already undergone an amputation.~Usual care will be enhanced by providing resources (e.g., information through written newsletters) relevant to a population of Veterans with diabetes, including information on nutrition and cooking, physical activities, and whole health opportunities"
46053240|NCT05722769|Behavioral|CSTOP Now!|Child sex trafficking stops with you. Implement and evaluate the effectiveness of a multi-level bystander-informed program (CSTOP Now!) aimed at Kentucky public middle school staff. Participants will be trained to use the See It To Stop It Indicator Tool (SITSII) by using tiers of concern (clear concern, possible concern, and monitor of emerging concern). The SITSII tool directs the bystander actions to Decide, Directly Intervene, Disrupt, Delegate, and Document.
46053241|NCT05722769|Behavioral|Prevent Child Abuse Kentucky Online Training|The Kentucky State Police, in association with Prevent Child Abuse Kentucky, have developed videos we invite active comparator schools to review which also include how to identify and report child sex trafficking.
46053242|NCT05721209|Device|C-Mill with AR/VR Guidance|Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training. The AR/VR feedback will include computer generated obstacles and objects projected as images on the treadmill. Participants will be asked to use these projections as stepping cues and step on some images of objects while avoiding stepping on the images of obstacles.
46053243|NCT05721209|Device|C-Mill without AR/VR Guidance|Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training.
46053244|NCT05721209|Device|Zeno 3-Layer Walkway|Used to conduct mobility assessments to assess temporal and spatial gait parameters during the 6-minute walk test.
46053245|NCT05721209|Device|Hunova|Used to conduct fall-risk assessment.
45371177|NCT05687110|Procedure|Diagnostic Imaging|Undergo medical imaging scans
45371178|NCT05687110|Biological|Novobiocin Sodium|Given PO
45371179|NCT05687032|Drug|inotuzumab ozogamicin|Given IV
45371183|NCT05681468|Other|Keto-SAT|"Nutrition counselling focused on Keto diet (saturated fat).~10% TE as carbohydrate (mainly from vegetables and whole grain products), protein between 20-30% TE and fat between 60-70%."
45371184|NCT05681468|Other|Keto-CAN|"Nutrition counselling focused on Keto diet (unsaturated fat).~10% TE as carbohydrate (mainly from vegetables and whole grain products), protein between 20-30% TE and fat between 60-70%."
45371185|NCT05681468|Other|LFD|"Nutrition counselling focused on low-fat diet.~30% total energy (TE) as fat, 50% TE as carbohydrates (primarily whole grains) and 17-20% TE protein (mainly lean sources)."
45371186|NCT05678998|Drug|WTX-330|Investigation Product
45371187|NCT05678595|Device|high-intensity laser therapy|HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the hand wrist area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first five sessions consisted of a 100-second intermittent phase analgesic effect at 8 W and 8 J/cm2 for a total energy of 200 J. The following five sessions consisted of a continuous 11 minutes 6 second bio stimulating effect with a dosage of 3 W 80 J/cm2. Over the course of two weeks, ten treatment sessions of HILT will be given.
45371188|NCT05678595|Device|sham high-intensity laser therapy|HILT is administered as a placebo for two weeks, 5 sessions a week, for a total of 10 sessions.
46053246|NCT05717023|Behavioral|Online guided self-help intervention for sexual distress following sexual assault|4 Sessions of guided self-help will be shared with the participants. These will be in the form of handout and video recordings that participant access through Qualtrics. The intervention is based on research on sexual trauma, psychosexual difficulties and materials developed by Bart's NHS Foundation Trust Sexual Wellbeing Service. It has been made in collaboration with clinicians within the service, experts by experience and the chief investigator.Within the document there are scripts for each session which are read out in the video recordings. The handouts depict the visual images for the video and the materials provided to participant.
46053247|NCT05715671|Drug|esketamine|The corresponding esketamine dose for each group was used at the end of anesthesia induction, and esketamine was changed to the corresponding maintenance dose for each group prior to surgical skin incision.
45489914|NCT02397070|Device|Occlusal Splint and counseling|The occlusal splints will be made from obtaining a plaster type IV model of upper arch using alginate and metal stock tray. A 2mm thick polyacetate blade will be adapted to the vacuum device plasticizer, heated and pressed over the previously cut U-shaped plaster model. After cooling, it will be added the self-curing acrylic resin on occlusal surface in order to increase the vertical dimension of occlusion in 2mm (anterior region). After polishing, the splints will be intraorally adjusted using carbon paper and clamp Muller, and installed obtaining maximum tooth contacts in centric relation. The splints will be flat and of full coverage for night use. Patients will be monitored every two weeks for the occlusal adjustment for three months. It will also be done counseling measures through a printed guide in relation to the daily care and the various contributing factors of TMD (diet, stress reduction, elimination of parafunctions and posture correction).
45489915|NCT02397148|Radiation|Computed Tomography|imagery with ionizing radiation
45489916|NCT02397148|Radiation|Cone Beam Computed Tomography|imagery with ionizing radiation
45692481|NCT02984865|Drug|Sulfentanyl|
45692482|NCT02984865|Drug|Nalbuphine|
45692483|NCT02984865|Drug|flubiprofen axetil|
45692484|NCT02984865|Procedure|rectus sheath block|Transversus abdominis plane (TAP) block combined with rectus sheath (RS) block will be applied in Group ESRD
45692485|NCT03696069|Other|Non-Interventional|Non-Interventional
45692486|NCT03589521|Behavioral|ABCT_Military|15 Weekly Couple Therapy Sessions
45692487|NCT03589443|Drug|Multiplexed heptapeptides|Heptapeptides QRH and KSP
45371194|NCT05666713|Device|TELLTALE BASILICA procedure|The TELLTALE BASILICA procedure has five steps: (1) engagement of the target leaflet with a guiding catheter; (2) electrosurgical leaflet traversal with the TELLTALE guidewire, (3) preparation and positioning of the TELLTALE guidewire electrosurgical leaflet laceration surface; (4) electrosurgical leaflet laceration with the TELLTALE guidewire, immediately followed by (5) TAVR. These are all guided by fluoroscopy, with adjunctive echocardiography as needed.
45371197|NCT05664568|Drug|Cephalexin|Participants in intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment
45692488|NCT03589365|Other|Magnetic resonance imaging (MRI)|"Compare the left ventricular mass of a young adult population born prematurely (Prema group) to that of a group of young adults born at term (Witness group~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume"
45692489|NCT03587415|Diagnostic Test|preptin and amylin level|we will take both of group blood samples to compare them serum preptin and amylin
45371198|NCT05664568|Drug|Amoxicillin-Clavulanate 500 Mg-125 Mg Oral Tablet|Participants in the intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment
45371199|NCT05664568|Other|Standard of care treatment of tuberculosis|The control group will be given standard of care treatment of tuberculosis consisting of rifampicin, isoniazid, pyrazinamide and ethambutol
46053248|NCT05714605|Behavioral|THRIVE Intervention|The THRIVE Clinical Pathway is a standardized transitional care clinical pathway that supports Medicaid insured or Medicaid eligible individuals following hospitalization.
45371201|NCT05660486|Other|Aromatherapy|Participants in this group will receive 2-3 drops of 100% pure Lavandula angustifolia essential oil applied to a surgical mask pre-procedure for aromatherapy.
45371202|NCT05660486|Other|Placebo|Participants in this group will receive 2-3 drops of water applied to a surgical mask pre-procedure.
45371203|NCT05659303|Procedure|Laparoscopic hysterectomy|Patient having undergone a hysterectomy, planned as an outpatient during the pre-operative consultation, by laparoscopic route.
46053249|NCT05712538|Drug|ARCT-032|ARCT-032 is messenger RNA (mRNA) coding for cystic fibrosis transmembrane conductance regulator (CFTR) protein, formulated in a lipid nanoparticle (LNP).
45371204|NCT05656768|Other|Constant Routine Protocol|A constant routine protocol is used to directly examine markers of circadian rhythmicity (e.g., melatonin and core body temperature). A constant routine protocol requires an individual to remain in a dimly lit room, in a constant semi-recumbent posture, and remain awake for more than 24 hours. It is one of two gold-standard research protocols for examining circadian rhythms in humans.
45371205|NCT05654220|Behavioral|Text Messaging Intervention|A text messaging intervention will be conducted that includes prompts to call trained BenePhilly enrollment specialists to submit applications for benefits programs. Text message prompts will be sent on days 2, 4, 7, 14, and 21 post-discharge from a Penn Medicine emergency department.
46053250|NCT05712538|Other|Placebo|Normal saline
45489917|NCT03584789|Other|Clinical Decision Support|A clinical decision support system designed to assist dentists in providing optimal pain management for patients without resorting to opioids when a non-opioid alternative would suffice. It provides pertinent clinical information to the dentist, including point-of-care access to the Prescription Drug Monitoring Program.
46053251|NCT05711251|Other|Physical Activity in Health Promotion|During the term, the participants in the study group took lessons on many subjects, from the benefits of physical activity to suggestions to increase physical activity at work and in daily life.
46053252|NCT05707897|Drug|TS-142 10 mg|Single-dose of 10 mg of TS-142
46053253|NCT05705453|Device|Epidural Spinal Cord Stimulation|Stimulation of the spinal cord from the epidural space.
46053254|NCT05705089|Drug|Rivaroxaban 15 MG|Rivaroxaban 15 MG once daily orally + Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))
46053255|NCT05705089|Drug|Warfarin|Warfarin (to reach an INR goal of 2-2.5)+ Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))
46053256|NCT05701917|Device|ClotTriever System|Mechanical thrombectomy
46053257|NCT05701917|Drug|Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.|Anticoagulants are a group of medications that decrease your blood's ability to clot.
46053258|NCT05695560|Other|No Intervention|As this is an observational study, no intervention will be administered.
46053259|NCT05693766|Drug|Capecitabine|2000 mg taken by mouth twice daily for 7 days on, 7 days off
46053260|NCT05693766|Other|Endocrine-therapy|Endocrine therapy administered
45371212|NCT05651022|Drug|Decoy20|Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy.
45371213|NCT05649696|Drug|Recombinant Staphylokinase|Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
46053261|NCT05693766|Other|MammoPrint ® and BluePrint assays|Archival tissue will be analyzed using the MammoPrint ® and BluePrint assays
46053262|NCT05691218|Device|Standard Nebulization|Beta-2 adrenergic agonist administred by standrad nebulization
45489918|NCT03584789|Other|Patient education|Patient education regarding pain management before and after dental extraction, including information about the risks and benefits of various strategies.
45489919|NCT03710005|Procedure|Ascent|Dehydrated Cell and Protein Concentrate injection
45489920|NCT03710005|Procedure|Standard|Standard corticosteroid injection
45489921|NCT05736484|Behavioral|Social Support Gamification|Participants sign a pre-commitment contract agreeing to try their best to achieve their daily step goal. Over the 26-week intervention period, participants are endowed 70 points (10/day) weekly and informed they will lose 10 points each day goal is not met. Points are replenished at start of each week. At the end of each week, if the participant has 40 points or more, they will advance a level, or drop a level if they have less than 40 points. The levels include blue (lowest), bronze, silver, gold, platinum (highest). Participants select a family member or friend as a support partner to receive weekly email on participants' progress (points, game level, and average step count). Participants will also work with a virtual health coach by attending group sessions organized by them with other participants through video calls once a month to discuss ways to motivate participants to increase their physical activity.
45692490|NCT03896763|Other|Either supine or prone positioning and either CMV or HFOV|"Supine positioning: Subjects randomized to supine positioning will remain supine.~Prone positioning: Subjects randomized to prone positioning will be positioned prone ≥16 hours/day for a maximum of 28 days.~CMV strategy: Low tidal volume to obtain exhaled Vt of 5-7 ml/kg (ideal body weight), PIP goal limited to ≤ 28 cm H2O and lung recruitment maneuver to identify best PEEP then maintained per PEEP-FiO2 grid.~HFOV strategy: Frequency at 8-12 Hz, amplitude (delta-P) 60-90 and mPaw recruitment maneuver."
45692491|NCT03020433|Device|rTMS Contralesional M1|1Hz Contalesional M1 repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 90% AMT
45692492|NCT03020433|Device|rTMS Contralesional PMC|5Hz Contralesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
46053263|NCT05691218|Device|A - Vibrating mesh nebulization|Beta-2 adrenergic agonist nebulisation using a vibrating mesh nebuliser device (Aerogen, Galway, Ireland). Nebulisation will take place under medical air at 6L/min or medical O2 at 6L/min depending on the patient's needs and for a SpO2 target between 94-96%
45371214|NCT05649696|Drug|Normal Saline|Intravenous injection of normal saline is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
45371215|NCT05645692|Drug|Atezolizumab|Participants will receive 1200 mg IV atezolizumab Q3W.
45371216|NCT05645692|Drug|RO7247669|Participants will receive 600 mg IV RO7247669 Q3W.
45371217|NCT05645692|Drug|Tiragolumab|Participants will receive 600 mg IV tiragolumab Q3W.
46053264|NCT05691218|Device|B - Vibrating mesh nebulisation and high-flow nasal cannula heated and humidified oxygen|"High-flow nasal cannula heated and humidified oxygen (HFNO) and nebulisation of beta-adrenergic agonist using a vibrating mesh device.~HFNO will be administered using an Airvo2 device and beta-2 adrenergic agonist nebulisation enabled by the use of a dedicated heated humidifier and an adaptable vibrating mesh nebuliser device"
45692493|NCT03020433|Device|rTMS Ipsilesional PMC|5HZ Ipsilesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
46053265|NCT05687721|Drug|copanlisib|intravenous infusion (IV) at 60 mg on Day 1, 8 and 15 of each 4-week treatment cycle for up to 26 cycles
46053266|NCT05687721|Drug|Avelumab|800 mg intravenous infusion on Day 1 and 15 of each 4-week treatment cycle for up to 26 cycles
46053267|NCT05684055|Drug|First-line antihypertensive single-pill combination (SPC)|In intervention villages, participants diagnosed with aHT are offered pharmacological treatment (eHealth supported prescription of first-line antihypertensive single-pill combination (SPC)) and treatment monitoring in the villages by CC-VHWs guided by the ComBaCaL app.
46053268|NCT05684055|Other|Standardized counselling and referral to the closest health facility|In control villages, participants diagnosed with aHT receive a standardized counselling by the CC-VHW and are referred to the closest health facility for initiation or continuation of antihypertensive treatment.
45489922|NCT03733379|Procedure|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
45489923|NCT03733379|Drug|Metronidazole and Amoxicillin placebos|Amoxicillin and metronidazole placebos thrice a day for 14 days (beginning with the first SRP session).
45489924|NCT03733379|Drug|Metronidazole|Metronidazole 400 mg thrice a day for 14 days (beginning with the first SRP session).
46053269|NCT05682495|Drug|ARM A|Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR*2 followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR*2 followed by 7 days washout and then receive treatment HR20031 FDC 10/100/1000 mg.
45489925|NCT03733379|Drug|Amoxicillin|Amoxicillin 500 mg thrice a day for 14 days (beginning with the first SRP session).
45489926|NCT03733379|Dietary Supplement|Probiotic|The probiotic contains 2 different strains of Lactobacillus reuteri: L.reuteri DSM 17938 and L. reuteri ATCC PTA 5289 each at a concentration of 1 x 108 CFU per tablet. It will be used 2 times per day by 90 days.
45692494|NCT03020433|Device|rTMS sham at Ipsilesional M1|1Hz Ipsilesional M1 sham repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 50% MSO)
45692495|NCT01797445|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
45692496|NCT01797445|Drug|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
45692497|NCT01797445|Drug|E/C/F/TDF Placebo|Tablet administered orally once daily
45692498|NCT01797445|Drug|E/C/F/TAF Placebo|Tablet administered orally once daily
45692499|NCT03935451|Drug|Apixaban 2.5 milligram|2.5 milligram daily dosing of Apixaban beginning on the first day of hospital discharge for a total of 30 days
46053270|NCT05682495|Drug|ARM B|Subjects will receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR*2 followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR*2.
45489927|NCT03733379|Dietary Supplement|Probiotic placebo|The placebo is identical to the active but without L. reuteri. The two Study Products are identical in taste, texture and shape. It will be used 2 times per day by 90 days.
45846674|NCT04669236|Behavioral|Intervention to promote healthy sleep behavior|An action group (6 - 8 pupils) was conducted at each school. Brainstorm sessions about effective strategies to change sleeping behavior in this population were held. Strategies, perceived as effective by the target population, will be summarized in an overview. Also feedback of adolescent, who are not part of the action group, will be asked. After feedback, the intervention will be developed by the intervention schools. Thereby, three different intervention strategies will be implemented and tested (one intervention at each school) to meet the individuals needs of each school. The action groups will develop the intervention materials during sessions this year. Afterwards, they will implement the intervention themselves in collaboration with teachers of the school and the researchers.
45846675|NCT04355130|Dietary Supplement|Iron, vitamin B12 and acid folic supplementation|Vitamin and iron supplementation is administered one-two weeks before donation, and consist of iron supplementation (i.v. infusion of 20 mg/Kg ferric carboxymaltose in saline 100 ml), s.c. injection of 1 mg of vitamin B12 and acid folic 5 mg/die per os until day +15 post BM donation. BM collection is carried out by the transplant team and a maximal dose of 20-22 ml/Kg of the donor body weight is collected under general anesthesia (induction with fentanyl 1-3 mcg/Kg, Propofol 2-3 mg/Kg, rocuronium 0,6 mg/Kg and mantenaince with sevoflurane 0,8 MAC). Noninvasive cardiac output, blood pressure and hemoglobin monitoring are carried out during the entire procedure and in in the recovery room using the ClearSight™ system (Edwards Clinical) and the Radical Pulse co oxymeter (Masimo). After discharge from the hospital, donors will be revaluated on day + 7 after BM collection, and blood tests will be repeated in outpatient setting.
45846676|NCT04293198|Device|KODEX-EPD System|The KODEX - EPD system is an open platform that uses any validated EP catheter to create real-time 3D images of the human heart. The KODEX occlusion viewer provides an indication of the occlusion status of the PV during cryoballoon PVI procedure
45846677|NCT04293198|Device|Fluoroscopy with contrast dye|Fluoroscopy with contrast dye is used to determine occlusion status during cryoballoon PVI procedures
45846678|NCT04266912|Drug|Avelumab|Given IV
45846679|NCT04266912|Drug|Berzosertib|Given IV
45846680|NCT04199832|Dietary Supplement|Dietary guidance|Dietary guidance for feeding tube patients with food homogenate，dietary guidance for patients with oral feeding.
45846681|NCT04116996|Device|DEEP BRAIN STIMULATION|NEUROMODULATION
45846682|NCT04114266|Other|Questionnaires on Urinary Incontinence-, Sex Function- and Quality of Life (ICIQ-UI-SF, ICIQ-FLUTSsex, ICIQ-LUTSqol, PGI-I)|"Artificial Urinary Sphincter Surgery (Robot-assisted, Laparoscopic, Open, or other) for Female Stress Urinary Incontinence due to intrinsic sphincter deficiency is according to standard practice. Patients scheduled for this type of surgery will be asked to participate in this Registry.~At baseline and follow-up, the patients will be required to fill in Questionnaires, i.e. ICIQ -Urinary Incontinence - Short Form (ICIQ-UI-SF), ICIQ Female Sexual Matters associated with Lower Urinary Tract Symptoms ( ICIQ-FLUTSsex), ICIQ Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol), Patient Global Impression of Improvement-I (PGI-I) which are commonly used in daily practice to assess urinary incontinence, sexual function and quality of life. During the yearly visits, patients will not be required to come for a clinical visit as the questionnaires and a Follow-up form can be completed by post, e-mail or phone call."
45846683|NCT04107168|Drug|Nivolumab|A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).
45846684|NCT04107168|Drug|Pembrolizumab|A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.
45846685|NCT04107168|Drug|Ipilimumab|A human immunoglobulin G1 (IgG1) monoclonal antibody raised against cytotoxic T lymphocyte antigen-4 (CTLA-4).
45846686|NCT04107168|Drug|Durvalumab|A human immunoglobulin G1-kappa (IgG1-kappa) monoclonal antibody that binds to programmed death ligand 1 (PD-L1).
45846687|NCT04107168|Drug|Tremelimumab|A fully human monoclonal antibody raised to target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
45846688|NCT04107168|Drug|Atezolizumab|A humanised IgG1 monoclonal antibody raised to target programmed death-ligand 1 (PD-L1).
45846689|NCT04107168|Drug|Bevacizumab|A humanised IgG1 monoclonal antibody raised to target vascular endothelial growth factor (VEGF).
45846690|NCT04022850|Behavioral|Intuitive de-implementation|A set of de-implementation strategies targeting automatic cognition to alter the clinical decision making of physicians regarding the CVD primary prevention practice to be performed with hypercholesterolemic patients aged 40-75 years old without ischemic heart disease or diagnosed cardiovascular disease and with low CVD risk (<5%)
45846691|NCT04022850|Behavioral|Reflexive de-implementation|A set of de-implementation strategies targeting reflexive cognition to alter the clinical decision making of physicians regarding the CVD primary prevention practice to be performed with hypercholesterolemic patients aged 40-75 years old without ischemic heart disease or diagnosed cardiovascular disease and with low CVD risk (<5%)
45846692|NCT04022850|Behavioral|Passive dissemination|Usual procedures of dissemination of clinical practice guidelines, focused in the distribution of materials, support tools and training in the reference group.
45846693|NCT03958344|Drug|Prednisolone|Oral Tablet
45846694|NCT03958344|Drug|Triamcinolone + Betamethason|A compound long acting and short acting injectable steroid
45846695|NCT03901950|Drug|XNW7201 tablets|A wnt pathway inhibitor
45489928|NCT03708991|Diagnostic Test|IVF combined with PGT-A|trophectoderm biopsy to test the ploidy state of the IVF embryos
45489929|NCT03708991|Diagnostic Test|ICSI combined with PGT-A|trophectoderm biopsy to test the ploidy state of the ICSI embryos
45489930|NCT05659732|Drug|PEP07|PEP07 is a selective Chk1 inhibitor maleate drug which is supplied as a hard gelatin capsule. PEP07 will be provided as 20 mg and 150 mg strength capsules to be administrated orally. Patients allocated to different dose levels of PEP07 monotherapy will receive either 20 mg or 150 mg oral capsules for 2 consecutive days followed by 5 days treatment off (2-on/5-off) schedule every week, 4 weeks as a treatment cycle.
45846696|NCT03780816|Other|Observation of provider-patient interactions and interviews|Clinical interactions between cancer patients and providers will be observed and hand-written field notes recorded and later transcribed. Semi-structured interviews with providers, patients, caregivers, and other informants will take place following initial observation.
46053271|NCT05682495|Drug|ARM C|Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR*2 followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR*2.
45489931|NCT05733676|Device|Resin infiltration|Base line treatment of white spot lesions in smooth surface with Resin infiltration -Icon + etch, DMG, Germany.
45692500|NCT03935451|Drug|Placebo Oral Tablet|placebo oral tablet that resembles the experimental drug. To be taken with the same frequency and duration
46053272|NCT05682495|Drug|ARM D|Subjects will receive treatment SHR3824 5 mg*2+ SP2086 50 mg*2+ Metformin 500 mg XR*3 followed by 7 days washout ，then receive treatment SHR3824 5 mg*2+ SP2086 50 mg*2+ Metformin 500 mg XR*3 followed by 7 days washout and then receive treatment HR20031 FDC 5/50/750 mg*2.
46053273|NCT05682495|Drug|ARM E|Subjects will receive treatment HR20031 FDC 5/50/750 mg*2 followed by 7 days washout ，then receive treatment SHR3824 5 mg*2+ SP2086 50 mg*2+ Metformin 500 mg XR*3 followed by 7 days washout and then receive treatment SHR3824 5 mg*2+ SP2086 50 mg*2+ Metformin 500 mg XR*3.
45489932|NCT05733676|Device|Casein Phosphopeptide (CPP) - Amorphous Calcium Phosphate (ACP) - Fluoride|Base line treatment of white spot lesions in smooth surface with MI paste plus + etch , GC corporation, Germany, Europe
46053274|NCT05682495|Drug|ARM F|Subjects will receive treatment SHR3824 5 mg*2+ SP2086 50 mg*2+ Metformin 500 mg XR*3 followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg*2 followed by 7 days washout and then receive treatment SHR3824 5 mg*2+ SP2086 50 mg*2+ Metformin 500 mg XR*3.
46053275|NCT05672901|Device|StrataMGT|StrataMGT is a 100% medical grade film-forming silicone gel for the treatment of cutaneous skin lesions and Genitourinary Syndrome of Menopause. StrataMGT is a flexible wound dressing used on compromised skin. It dries to form a thin, flexible wound dressing which hydrates and protects affected areas. StrataMGT is used to relieve low grade inflammatory changes such as dry, itching, flaking, peeling and irritated skin. StrataMGT is designed for partially epithelized skin and is suitable for children and patients with sensitive skin.
46053276|NCT05672901|Drug|Estrace 0.01% Vaginal Cream|Estrace is a prescriptive female hormone indicated in the treatment of moderate to severe symptoms of Genitourinary Syndrome of Menopause.
45371222|NCT05636020|Behavioral|ICARE Treatment|The treatment is 12 teletherapy sessions lasting approximately 60-90 minutes. Of the 12 treatment sessions, 7 of them will focus on training skills to help the participant with TBI better recognize emotions from facial expressions. The remaining 5 sessions will teach skills important for empathizing with others' thoughts and feelings, and how to be emotionally supportive. Role-playing will be a big part of these last 5 sessions. The care-partner will be expected to attend as many of these 5 empathy sessions with the participant with TBI as possible.
45371223|NCT05630755|Drug|DOR/ISL|DOR/ISL 100 mg/0.25 mg oral tablets once daily
46053277|NCT05671822|Drug|SHR-A1811；SHR-1701；capecitabine；oxaliplatin|(Arm 1A) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion; (Arm 1B) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； (Arm 1C) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally； (Arm 1D) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
45371224|NCT05630755|Drug|BIC/FTC/TAF|BIC/FTC/TAF 50 mg/200 mg/25 mg oral tablets once daily
45489933|NCT03343639|Drug|5 mg Serlopitant Tablets|Serlopitant Tablets
45692501|NCT03587181|Procedure|Cryoablation of the pulmonary veins and myocardial biopsy|"Before intervention blood samples will be collected for biobank storage. After left atrial appendage thrombus exclusion, a cardiac biopsy from intraventricular and interatrial septum will be performed. PV isolation will be performed with cryoablation. Successful PV isolation will be confirmed by the confirmation of bi-directional block. Phrenic nerve function will be assessed in a standard fashion during intervention of the right PVs using high output phrenic nerve pacing from the superior vena cava. Loop recorder implantation will be performed during the same procedure.~In patients with recurrent atrial tachyarrhythmias an EP study will be performed to assess the mechanism of recurrence. PV reconnections will be re-isolated and linear lesions performed as required."
45692502|NCT04765683|Other|questionnaire|Survey of views on outpatient consultation format
45692503|NCT03589131|Procedure|Total Operative time|Investigators compare the preparation time of the procedure in the operating room and the actual operative time
45371225|NCT05630755|Drug|Placebo to BIC/FTC/TAF|0 mg oral tablets once daily
45371226|NCT05630755|Drug|Placebo to DOR/ISL|0 mg oral tablets once daily
45371227|NCT05630066|Drug|60 mg QD Alogabat|"Participants aged 15-17 years or above receiving the adult 60 mg of alogabat dose.~I"
45371228|NCT05630066|Drug|40 mg QD Alogabat|Participants aged 10-14 years receiving the equivalent of the adult 60 mg alogabat dose.
45371229|NCT05630066|Drug|7 mg QD Alogabat|Participants aged 5-9 years receiving the equivalent of the adult 20 mg alogabat dose.
45489934|NCT03343639|Drug|Matching Placebo Tablets|Placebo Tablets
45489935|NCT04479748|Drug|Dexamethasone|Treatment of pain and inflammation following ophthalmic surgery
45489936|NCT04479748|Drug|Prednisolone Acetate 1% Oph Susp|Topical steroid
45489937|NCT03647267|Device|Pneumatic Vitreolysis (C3F8 injection)|Pneumatic Vitreolysis will be performed via an intraocular injection of C3F8 gas. Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the vitreous cavity. It was approved by the FDA in February 1993 (P900066) for the use of placing pressure on detached retina.
45692504|NCT03589131|Procedure|Margin assessment|In this intervention investigators measure the proximal, distal and the important circumferential radial margin away from the tumor to determine if this arm is oncologically safe or not.
45371230|NCT05630066|Drug|Part 2 Adult Alogabat High Dose (aged 15-17)|In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
45489938|NCT03647267|Other|Observation|No intervention; sham injection only
45489939|NCT03707353|Biological|ChAd63 ME-TRAP and MVA ME-TRAP vaccination|vaccination with ChAd63 ME-TRAP 5x10^10 vp (intramuscularly and intravenously) vaccination with MVA METRAP 2x10^8 pfu (intramuscularly) and MVA METRAP 2x10^7 pfu (intravenously) Group 5 will be challenged with malaria by mosquito bite.
45489940|NCT05731180|Other|Identify pathological and not pathological lung sounds|First group is the control group (CNT), second group (EXP) who will be exposed to pathological and none pathological lung sounds
46053278|NCT05671822|Drug|SHR-A1811；SHR-1701；capecitabine；oxaliplatin|(Arm 2A) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion; (Arm 2B) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally； (Arm 2C) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
46053279|NCT05671679|Other|SNAQ app|SNAQ is a smartphone food analysis app that estimates the macronutrient content of a meal, based on a single image. The app first determines meal content in terms of food components with input from the user to correct or add further components (e.g. foods, ingredients, sauces, herbs or seasonings). Then, the total macronutrient and energy content of the meal is determined based on the estimated volume and information from a nutritional database. Of note, the application also allows for assessing nutritional content of packaged foods by means of a barcode scanning function. The user can always adapt proposed nutritional contents at their own discretion. Meal macronutrients alongside the food pictures are collected in a detailed log which allows users to review their dietary choices. The product is not conceived by its manufacturer to be used for medical purposes and can thus not be considered a medical device.
45489941|NCT05329129|Device|OssDsign® Catalyst|An osteoconductive, resorbable, porous, 100 % nano synthetic calcium phosphate bone void filler
45371231|NCT05630066|Drug|Alogabat|In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
45371232|NCT05630066|Drug|Alogabat|In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
45489942|NCT03708913|Device|Hypothalamic Deep Brain Stimulation|One-year continuous hypothalamic deep brain stimulation
45489943|NCT03356977|Drug|Crisaborole ointment 2%|Applied BID
45489944|NCT02690974|Drug|LCZ696 (sacubitril/valsartan)|All patients were treated with the LCZ696 (sacubitril and valsartan) tablets
45489945|NCT03093324|Drug|ALKS 8700|Administered as specified in the treatment arm.
45489946|NCT03093324|Drug|Dimethyl Fumarate|Administered as specified in the treatment arm.
45489947|NCT03584009|Drug|Venetoclax|Venetoclax was administered orally, 800-mg tablet beginning on Cycle 1 Day 1 until the 9th October 2020.
45489948|NCT03584009|Drug|Fulvestrant|Fulvestrant was administered orally, 500 mg administered as two 250-mg IM injections on Cycle 1 Days 1 and 15 and on Day 1 of each subsequent 28-day cycle
45692505|NCT03589131|Procedure|Conversion rate to open surgery|In this interversion investigators try to measure how much is this arm feasible to completely perform the procedure whether robotically or laparoscopically without conversion to open surgery
46053280|NCT05671679|Other|Traditional carbohydrate counting|Patients will follow their traditional methods of carbohydrate counting during the control period. In addition to assess sustainability of the intervention, following the control period, the control group will also go an intervention period of 3 weeks using the SNAQ App.
45371233|NCT05630066|Drug|Alogabat|If dose adjustments (e.g., increase or decrease in dose) are required, particularly due to uncertainty of the clearance estimates (e.g., due to high variability) or over-/underprediction of the pediatric clearance versus adult clearance, up to 8 additional participants may be recruited in any of the 3 age-groups in order to confirm the exposure equivalence prior to selecting doses and proceeding to Part 2.
46053281|NCT05666167|Behavioral|Group Telehealth Exercise Sessions with text messaging plus booster sessions|Participants receive 3 months of group telehealth exercise initiation plus text messaging followed by 6 months of text messaging plus monthly group telehealth exercise booster sessions.
46053282|NCT05652153|Other|Single-/paired-pulse transcranial magnetic stimulation|Single-/paired-pulse transcranial magnetic stimulation (sp/ppTMS) is a technique for noninvasive assessment of brain physiology by delivering single or paired magnetic stimuli to the scalp with an electromagnetic coil. This results in transient induction of cortical electrical activity, which can be measured as evoked potentials by electromyography (EMG) and electroencephalography (EEG). Note that sp/ppTMS is used for neurophysiologic measurements; it is distinct from other TMS applications such as repetitive TMS, which can be used as interventions.
46053283|NCT05650515|Other|Co-creation|The development of a technology-based exercise intervention based on ideas of older adults and experts in the field of geriatric rehabilitation/research/medicine
45371235|NCT05619692|Drug|SAGE-718|Softgel lipid capsules.
45371236|NCT05619692|Drug|SAGE-718-matching Placebo|Softgel lipid capsules.
46053284|NCT05649540|Drug|Vonoprazan|Potassium-competitive acid blocker
46053285|NCT05649540|Drug|Amoxicillin|Antibiotic for H. pylori eradication
45371239|NCT05615233|Behavioral|TACAD|"Technology-based information and coaching/support program that is tailored for Asian American midlife women who are family caregivers of PLAD (TACAD). It includes four components in three languages (English, MandarinChinese, and Korean):~2 sub-ethnic specific social media sites;~interactive online educational modules;~online resources; and~a VR component based on A Walk Through Dementia (WTD)"
45371240|NCT05615233|Behavioral|Alzheimer's Association website|The webpage on caregiving includes information on caregiving, care option, financial/legal planning, caregiver health, daily care, stages and behaviors, and safety. The content will be available in the three languages at the project website.
45371241|NCT05614323|Other|Interview and determining taste and smell with taste strips and Sniffin' Sticks|The Patient-Generated Subjective Global Assessment (PG-SGA) Short Form will be filled in by the participants. Next, a semi-structured in-depth interview will be performed in a quiet environment. The interview will take a maximum of one hour and will take place once. Topics that will be discussed are eating-related problems, the taste and smell of the offered hospital food, the choice in hospital food, the ambience during the eating moments, the use of protein-enriched snacks, the difference between eating at home and at the hospital, personal tips- and-tricks to maintain adequate nutritional intake, and how patients' think that food enjoyment can be improved in the hospital. The interview will be recorded. At last, taste and smell will be objectively determined with respectively taste strips and Sniffin' Sticks.
45489949|NCT03709927|Drug|ZTI-01|6g IV fosfomycin
45489950|NCT03709927|Drug|Moxifloxacin 400mg|oral moxifloxacin (Avelox 400 mg) + IV normal saline (Placebo)
45692506|NCT03589131|Procedure|Baseline demographics|These include gender, age, ASA and BMI. All these data are analyzed and compared in both groups
45692507|NCT03589131|Procedure|Preoperative data|"These include distance of the tumor from the anal verge, clinical stage, whether preoperative chemoradiation CRT, presence of residual tumor after CRT. All were analyzed and compared"
45692508|NCT03589131|Procedure|Postoperative data|These include pathological stage, number of harvested lymph nodes and immediate postoperative outcome within one month (days of return of bowel function, days of hospital stay, complications, if any, like anastomotic leakage, ileus,wound problems and others, rate of reoperation, rate of readmission & 30-days mortality. All were analyzed and compared
45692509|NCT03589053|Device|Limb remote ischemic conditioning|The LRIC treatment consisted of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion.
45846697|NCT03734952|Radiation|Neoadjuvant Radiotherapy Program:|Gross tumor volume (GTV) should include the primary tumor and involved regional lymph nodes as identified on pre-treatment diagnostic studies. Clinical target volume (CTV) is defined as the primary tumor plus 3cm expansion superiorly and inferiorly along the length of the esophagus and a 1cm radial expansion.The nodal CTV should be defined by a 0.5cm expansion from the nodal GTV.CTV should also include coverage the nodal region(s) in which the involved lymph node(s). A total dose of 45 Gy in 25 fractions is delivered 5 days per week on workdays with intensity modulated radiotherapy (IMRT).
45489951|NCT03709927|Other|Placebo IV|IV Placebo (0.9% Normal Saline)
45692510|NCT03589053|Device|Control group|Participants in the control group receive both sham LRIC and standard clinical therapy.
45692511|NCT03587103|Behavioral|Protocol initiate with A|The BP-lowering medication adjustment and titration will follow A-AC-ACD or A-AD-ADC for individuals randomized to A or two-drug combination therapy with full dose of A in their initial medication assignment.
45692512|NCT03587103|Behavioral|Protocol initiate with C|The BP-lowering medication adjustment and titration will follow C-CA-CAD or C-CD-CDA for individuals randomized to C or two-drug combination therapy with full dose of C in their initial medication assignment.
45692513|NCT03587103|Behavioral|Protocol initiate with D|The BP-lowering medication adjustment and titration will follow D-DA-DAC or D-DC-DCA for individuals randomized to D or two-drug combination therapy with full dose of D in their initial medication assignment.
45692514|NCT01611259|Drug|Rituximab and Lenalidomide|Rituximab 375 mg/m² i.v. day 1 Lenalidomide 20 mg p.o. daily for 21 days Cycles should be repeated every 28 days. Restaging should be performed after three cycles. In case of at least stable disease, patients should receive another three courses of therapy. Patients with documented CR after 6 courses will stop therapy/study, while patients with PR or SD will be given another two cycles for a maximum of 8 cycles.
45692515|NCT03581331|Diagnostic Test|orthoptic balance|"Measurement of visual acuity by far: Monocular measurement, right eye, left eye and binocular Measurement of visual acuity closely: Monocular measurement, right eye, left eye and binocular Corneal reflection method or Hirschberg: Analysis of the corneal reflection after fixation of a point of fixation of light from a distance, then from near.~Cover-Test: Study of the restitution movement following the fixation of the fixation point"
45692516|NCT04147767|Dietary Supplement|Cholesterol Reducing Strawberry Yogurt Drink (Tesco Ltd)|"Ingredients: Skimmed Milk, Strawberry Juice from Concentrate (5%), Plant Sterols Ester (3.4%)***, Sugar, Maize Starch, Flavourings, Colour (Anthocyanins), Starter Culture including Bifidobacterium (Milk), Thickener (Carob Gum), Sweetener (Sucralose), Milk Proteins.~*** Equivalent to 2% Free Plant Sterols"
45692517|NCT04147767|Dietary Supplement|Low Fat Strawberry Yogurt Drinks (Morrisons Ltd)|Ingredients: Yogurt (Milk), Water, Sugar, Strawberry Purée (1%), Modified Maize Starch, Carrot Concentrate, Flavouring, Acidity Regulator (Citric Acid), Vitamin C, Colour (Paprika Extract), Sweetener (Sucralose), Vitamin D, Vitamin B6.
45692518|NCT03586869|Drug|Aldoxorubicin HCl|Aldoxorubicin Hydrochloride
45692519|NCT03586869|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
45692520|NCT03586869|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
45692521|NCT03586869|Biological|ETBX-021|Ad5 [E1-, E2b-]-HER2
45692522|NCT03586869|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
45692523|NCT03586869|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
45692524|NCT03586869|Biological|GI-4000|RAS yeast
45692525|NCT03586869|Biological|GI-6207|Carcinoembryonic Antigen (CEA) yeast
46053286|NCT05646693|Dietary Supplement|Drusen Mega®|It consists of a dietary supplement composed of Vitamin C 60.0mg, Vitamin E 30.0mg, Zinc 12.5mg, Copper 1.0mg, Astaxanthin 4.0mg, Zeaxanthin 2.0mg, Lutein 10.0mg and Omega 3 Acids 500.0mg. It is suggested to consume one capsule per day, preferably with food. This supplement is indicated for nutritional deficiencies and in patients with ophthalmological pathologies.
45489952|NCT05666375|Procedure|Percutaneous translumbar and transhepatic permcath|For selected ESRD patients who have exhausted all conventional access routes , translumbar and transhepatic insertion of long term hemodialysis catheters provide additional sites for access
45498144|NCT04508049|Device|qMT-MRI to detect fibrosis.|The hypothesis underlying this proposal is that qMT would reliably detect development of renal fibrosis at both 1.5T and 3.0T in subjects with RVD. Patients will be studied with MRI (for fibrosis) and CT (for renal function).
45692526|NCT03586869|Biological|GI-6301|Brachyury yeast
46053287|NCT05646693|Drug|Sertraline|It consists of a drug capsule composed of Sertraline Hydrochloride 50mg. In adults it is suggested to consume one to four capsule(s) per day, administering (preferably) the highest dose in the evening, before going to bed. This drug is indicated in the treatment of depressive states with anxiety or moderate to severe agitation, which are accompanied by tension, excitement, insomnia, obsessive and hypochondriac traits. It is also indicated in obsessive-compulsive disorder, panic attacks, stress disorder, post-traumatic disorder, social anxiety disorder and used to relieve the symptoms of premenstrual dysphoric disorder.
45489953|NCT03707275|Device|Alexa+|Patients will receive the Amazon Echo Dot with Alexa voice technology (Alexa+) and will be asked to interact with the device for 3 months. Alexa+ will ask a series of questions. Based on the answers to these questions, it will either contact a study coordinator or will ask patients to take a specific action (such as weighing themselves). Data from this simple intervention will be merged with data extracted from the patient's health record and analyzed for clinical variables and demographics that are most predictive for success in use of these technologies.
45489954|NCT03707275|Other|Standard of Care Arm|This group will receive standard of care (SOC) HF management, which will entail regular follow up from the HF nurse and data from all hospital or clinic visits will be captured from the EHR.
46053288|NCT05646693|Drug|Placebo|It consists of a placebo capsule composed of Magnesium Oxide 100mg. This component is inert in the dose at which it will be administered.
45371245|NCT05610124|Other|Ad libitum full-fat French fries with beef meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the French fries ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g French fries and about 120 g meatballs (25 g protein), additional plates of freshly cooked French fries (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
46053289|NCT05624463|Behavioral|Modified intubation process|"Refers to the modified intubation process of recurrent laryngeal nerve monitoring tube published by the applicant on Journal of Clinical Anesthesia.~1. Turn on the EMG monitor and connect the EMG monitor to the patient as the patient is anesthetized; 2. View the vocal cords with video laryngoscope and intubate the patient with the EMG endotracheal tube; 3. Check the EMG monitor to confirm the correct contact between the electrodes and vocal cords; 4. Adjust the tube to achieve proper and stable contact between the electrodes and vocal cords; 5. Tape the EMG endotracheal tube at the midline and position the patient."
45489955|NCT03730181|Drug|Rifapentine|Rifapentine. Initial dose will be 25mg/kg. Based on interim analysis, this may be adjusted throughout the study to achieve target exposures. The standalone water-dispersible rifapentine tablet may be used to adjust the rifapentine doses, if needed.
45692527|NCT03586869|Biological|haNK for infusion|NK-92 [CD16.158V, ER IL-2]
45692528|NCT03586869|Biological|bevacizumab|Recombinant human anti-Vascular Endothelial Growth Factor (VEGF) IgG1 monoclonal
45692529|NCT03586869|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
45489956|NCT03730181|Drug|Isoniazid|Isoniazid. 25mg/kg
45489957|NCT04167462|Drug|BMS-986165|Specified dose on Specified Days
45489958|NCT04167462|Other|Placebo|Specified dose on Specified days
45489959|NCT03733223|Drug|Ateptidase|Treatment of ischemic stroke with Ateptidase
45489960|NCT03707197|Behavioral|Meditation|Ten minutes of meditation per day for 8 weeks using a mobile application
45692530|NCT03586869|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
45692531|NCT03586869|Drug|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
45692532|NCT03586869|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
45692533|NCT03586869|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
45371246|NCT05610124|Other|Ad libitum instant mashed potatoes with beef meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the mashed potatoes ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g mashed potatoes and about 120 g meatballs (25 g protein), additional plates of freshly cooked mashed potatoes (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
45846698|NCT03734952|Drug|Neoadjuvant chemotherapy Program|Chemotherapy is delivered concomitantly and composed of two cycles of Docetaxel 60mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 21 days at the intervals of neoadjuvant radiotherapy.
45371247|NCT05610124|Other|Ad libitum macaroni pasta with beef meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the macaroni pasta ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g macaroni pasta and about 120 g meatballs (25 g protein), additional plates of freshly cooked macaroni pasta (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
46053290|NCT05624463|Behavioral|Conventional intubation process|"It means that the recurrent laryngeal nerve monitoring tube is intubated according to the intubation method described in the current guidelines.~1. Intubate the patient with the EMG endotracheal tube and note depth; 2. Position patient and verify the position via Glottic Exam or Respiratory Variation; 3. Fix tube position."
45489961|NCT05680441|Other|Peirodontal clinical measurements and gingival crevicular fluid sampling|The clinical periodontal examination of the healthy and periodontitis subjects consisted of plaque index (PI), probing pocket depth (PPD), clinical attachment level (CAL), and bleeding on probing (BOP) recorded. CAL was calculated by adding GR to the PPD values. Averages for full mouth PPD, CAL, and the percentage of sites with BOP were calculated for each subject. A single calibrated examiner (VO) conducted a full mouth periodontal examination of all participants.
46053291|NCT05624463|Behavioral|Early resumption of oral intake|Drink 30-50ml of normal temperature water after meeting the post-anaesthesia care unit transfer out standard. If the patient swallows successfully and does not cough, after returning to the ward, medical personnel of the ward will guide patient to resume drinking and eating early: patient will resume drinking water within one hour after returning to the ward, a small amount of water for several times until the amount of drinking water reaches 300ml. If the patient does not have discomfort symptoms, the patient will resume eating according to normal drinking and eating habits.
45489962|NCT04160520|Drug|Pramipexole|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
45489963|NCT04160520|Drug|Morphine|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
45489964|NCT04160520|Drug|Placebo oral tablet|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
45489965|NCT03583385|Drug|Glucophage XR (Test drug)|Participants received single oral dose of Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) under fasted conditions.
45489966|NCT03583385|Drug|Glucophage XR (Comparator drug)|Participants received single oral dose of Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) under fasted conditions.
45489967|NCT03632382|Diagnostic Test|3D acquisition of maxillofacial characteristics|A 3D acquisition of maxillofacial characteristics will be performed for each patient in order to validate a predictive model comparable to data obtained by polysomnography
45489968|NCT05288335|Device|Circular cylindrical mirror modulated frame glasses (compact)|Circular cylindrical mirror modulated frame glasses (compact)
45489969|NCT05288335|Device|Circular cylindrical mirror modulated frame glasses (strong defocus)|Circular cylindrical mirror modulated frame glasses (strong defocus)
45489970|NCT05288335|Device|single vision frame glasses|single vision frame glasses
45489971|NCT05282953|Drug|KIO-301|KIO-301 intravitreal injection at ascending doses
45846699|NCT03734952|Procedure|Esophagectomy program:|Patients receive esophagectomy in 4-6 weeks after neoadjuvant neoadjuvant chemotherapy
45846700|NCT03734952|Radiation|Postoperative radiotherapy program|A total dose of 18 Gy in10 fractions is delivered 5 days per week on workdays with IMRT.
45846701|NCT03712410|Behavioral|PISCES|The intervention is based on Problem Solving Therapy and is a coping skills intervention designed for family caregivers of hospice patients.
45846702|NCT03139344|Other|Low-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of low-frequency electrical stimulation.
45371248|NCT05610124|Other|Ad libitum full-fat French fries with vegetarian substitute meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the French fries ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g French fries and about 120 g vegetarian meatballs (25 g protein), additional plates of freshly cooked French fries (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
45371249|NCT05610124|Other|Ad libitum instant mashed potatoes with vegetarian substitute meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the mashed potatoes ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g mashed potatoes and about 120 g vegetarian meatballs (25 g protein), additional plates of freshly cooked mashed potatoes (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
45371250|NCT05610124|Other|Ad libitum macaroni pasta with vegetarian substitute meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the vegetarian meatballs but to eat the macaroni pasta ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g macaroni pasta and about 120 g meatballs (25 g protein), additional plates of freshly cooked macaroni pasta (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
45489972|NCT04350372|Device|MitraClip Procedure|MitraClip procedure with MitraClip NT System
46053292|NCT05624463|Behavioral|Late resumption of oral intake|Drink 30-50ml of normal temperature water after 6h after the operation. A small amount of water can be used several times, and the amount of water can reach 300ml. If the patient does not have any discomfort symptoms, medical personnel can guide the patient to recover diet according to normal drinking and eating habits.
46053293|NCT05624359|Drug|FA plus ropivacaine|Th group will receive 0.17% FA and 0.5% ropivacaine for pre-emptive scalp infiltration at about 30 min before surgical incision. The assigned solution was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder, using a 22-gauge needle introduced throughout the entire thickness of the scalp at a 45° angle.
45489973|NCT03708835|Other|Transitional care model|In this study, the feasibility and impact of a transitional care model from hospital to home for stroke patients and caregivers will be tested.
46053294|NCT05624359|Drug|ropivacaine alone|The ropivacaine alone group will receive 0.5% ropivacaine alone for pre-emptive scalp infiltration at about 30 min before surgical incision. The assigned solution was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder, using a 22-gauge needle introduced throughout the entire thickness of the scalp at a 45° angle.
46053295|NCT05616624|Drug|ADI-PEG 20|-Given 60 minutes (+/- 15 minutes) prior to docetaxel
45371253|NCT05606289|Behavioral|Crisis Intervention Team (CIT) training|Standard 40-hour CIT training given in one week.
45371254|NCT05603897|Other|Mann Assessment of Swallowing Ability (MASA) (dysphagia screening tool)|Upon 1-2 days of admission to inpatient rehabilitation, the MASA will be administered for approximately 20 minutes during initial speech language pathology evaluation. The MASA will be administered at bedside as a cognitive/speech language evaluation as well as oropharyngeal function examination.
45371255|NCT05603897|Other|Non-standardized clinical swallow evaluation|Participants will receive current standard of care for dysphagia screening and treatment.
46053296|NCT05616624|Drug|Gemcitabine|-Given over the course of 90 minutes (+/- 10 minutes)
46053297|NCT05616624|Drug|Docetaxel|-Given over the course of 60 minutes (+/- 10 minutes)
46053298|NCT05609487|Other|As usual|Patients included in the control phase, i.e. without intervention, will be asked not to oppose participation in the research, after having received the presentation of the study and the information notice. The data collection will be similar to the data collection during the intervention period.
45371259|NCT05600894|Procedure|Biospecimen Collection|Undergo collection of blood and buccal samples
45371260|NCT05600894|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
45371261|NCT05600894|Drug|Decitabine and Cedazuridine|Given PO
45371262|NCT05600894|Drug|Venetoclax|Given PO
45371263|NCT05598320|Drug|TransCon CNP|Once-weekly subcutaneous injection of 100 µg/kg TransCon CNP
45371264|NCT05598320|Drug|Placebo for TransCon CNP|Once-weekly subcutaneous injection of 100 µg/kg placebo for TransCon CNP
45371265|NCT05593328|Drug|Onvansertib|Oral capsule
45371266|NCT05593328|Drug|FOLFIRI|FOLFIRI (irinotecan + fluorouracil [5-FU] + leucovorin) as intravenous (IV) infusion
45371267|NCT05593328|Drug|Bevacizumab|IV infusion
45371268|NCT05592379|Drug|Psilocybin and Saline|"The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC).~The IV placebo (saline) will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center."
45371269|NCT05583695|Behavioral|mindfulness-based music therapy|eight weekly sessions with a combination of both mindfulness and music therapy
45371270|NCT05583695|Behavioral|mindfulness-based therapy|eight weekly sessions of mindfulness
45371271|NCT05583695|Behavioral|routine care|eight weekly sessions of routine care
45489974|NCT04792801|Radiation|PET TDM FDG-Choline|Performing an FDG TDM PET and a Choline TDM PET at two different times
45692534|NCT03586869|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
45692535|NCT03586869|Biological|Avelumab|Recombinant human anti-programmed death-ligand 1 (PD-L1) IgG1 monoclonal antibody
45692536|NCT03586869|Procedure|SBRT|Stereotactic Body Radiation Therapy
45692537|NCT04147377|Behavioral|behavioral intervention based on sensory cues|Patients will receive behavior intervention training that includes how to apply visual and auditory cues to freezing of gait in real clinical practice.
45692538|NCT03581253|Other|"Facial disability Index (FDi)"|questionnaires regarding to quality of life
45692539|NCT03581253|Other|"Facial Clinimetric Evaluation (FaCE)"|questionnaires regarding to quality of life
45692540|NCT03581175|Procedure|Colonoscopy|
45692541|NCT03581175|Drug|Bowel cleansing regimen|
45692542|NCT01796197|Drug|Trastuzumab|
45692543|NCT01796197|Drug|Pertuzumab|
45692544|NCT01796197|Drug|Paclitaxel|
45692545|NCT01796197|Drug|Doxorubicin|
45692546|NCT01796197|Drug|Cyclophosphamide|
46053299|NCT05609487|Device|Protection plan|"The intervention consists of making the protection plan in a co-constructed process with the care user. This tool is built in 6 steps, is written and takes 20 to 40 minutes to complete.~These 6 steps allow to identify the first signs of a suicidal crisis and to identify different strategies to face it. They are constructed in an ascending order, with the aim of being used by the care user in an autonomous situation."
46053300|NCT05606367|Device|Non-slip Balloon Catheter of Shanghai MicroPort Rhythm|The principle of Non-slip Balloon Catheter in dilating stenotic lesions is mechanical extrusion of the vessel through the balloon, resulting in irregular rupture of atheromatous plaque and enlargement of the lumen.
46053301|NCT05606367|Device|NSE Coronary Dilatation Catheter|The Lacrosse® NSE is an angioplasty catheter with 3 longitudinal elements attached directly proximal and distal to the balloon that produces 3 endovascular surgical incisions during balloon dilation.
46053302|NCT05601817|Behavioral|Vita|Vita is developed by this study team based on Attention Restoration Theory. The Vita intervention involves viewing 360 degree nature pictures on a virtual reality headset.
45371273|NCT05580562|Drug|ONC201|Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) dosing days; participants < 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments.
45371274|NCT05580562|Drug|ONC201 + Placebo|Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) or matching placebo on dosing days; participants < 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments
45371275|NCT05580562|Other|Placebo|Participants will receive placebo (same number of capsules as the ONC201 dose) on dosing days
45371276|NCT05575011|Drug|BIIB115|Administered as specified in the treatment arm
45371277|NCT05575011|Drug|BIIB115-Matching Placebo|Administered as specified in the treatment arm
45371278|NCT05568004|Behavioral|Combined exercise|aerobic plus resistance exercise
45371279|NCT05568004|Behavioral|Aerobic exercise|Only aerobic exercise
46053303|NCT05601817|Behavioral|Com|Com intervention uses BrainHQ from PositScience that was developed based on the brain neuroplasticity. The com intervention involves doing game-like training on a iPad.
46053304|NCT05601817|Behavioral|Vita+Com|Vita+Com intervention is a combination of both Vita and Com interventions. Participants will be asked to complete Vita first and then Com intervention.
46053305|NCT05597397|Device|RLRL|In addition to SVS with power for correcting distance refraction, RLRL will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.
46053306|NCT05594043|Drug|MK-6598|Oral tablet
46053307|NCT05594043|Biological|Pembrolizumab|Intravenous (IV) infusion
46053308|NCT05590065|Device|ABLE Exoskeleton|The ABLE Exoskeleton is a lower-limb overground robotic exoskeleton intended for SCI patients for rehabilitation in a clinical setting.
46053309|NCT05585372|Other|CT guided opening mobilization of cervical intervertebral foreman|"the patients lies in supine with his head resting comfortably at the position which cause maximum opening of the intervertebral foramen which has been determined by the 3D CT.~cervical lateral glide from right to left for C5, C6 and C7, Grade IV 3 × 6 on each segment.~Passive mobilization techniques were progressed, utilizing unilateral posteroanterior mobilization of the mid and lower cervical spine and lateral gliding movements, in both directions, progressing in duration and intensity to allow a graded exposure of load.~Sustained Natural Apophyseal Glides (SNAGS) were used mainly as self-treatment techniques to maintain the gains that achieved."
45371303|NCT05547542|Drug|CVL-354|Oral solution/capsule
45371304|NCT05547542|Drug|[11C]-LY2795050|IV injection
45371305|NCT05547542|Drug|[11C]-carfentanil|IV injection
45371306|NCT05537896|Drug|Eravacycline|"Eravacycline will be continued until one of the following criteria is met:~neutrophil recovery (ANC >500, post-nadir)~febrile neutropenia~breakthrough infection~any grade 3-4 toxicity related to eravacycline use"
45371307|NCT05536908|Behavioral|Residential Written Exposure Therapy|Residential Written Exposure Therapy (resWET): TAU plus 5-individual WET sessions (40-60 min each; Marx & Sloan, 2019) twice a week for two weeks and once a week for the final session, administered by WET trained psychologists, social workers, or postdoctoral residents. Treatment instructions are read, patients write for 30 minutes, and the writing is briefly processed. No formal written homework is required.
45371308|NCT05536908|Behavioral|Treatment as Usual|Treatment as Usual (DOM SUD): The DOM SUD (TAU) is a 24-bed intensive SUD residential program with a typical 28-day length of stay. The program focuses on evidence-based treatments for SUD such as Cognitive-Behavioral Therapy, Motivational Enhancement Therapy, Medication Assisted Treatment, and Contingency Management therapy. Patients diagnosed with PTSD are typically referred to outpatient PTSD treatment following DOM SUD and often attend Seeking Safety during the program. Most of the programming is group-based though Veterans also have weekly individual case management appointments.
45371309|NCT05528939|Device|EndeavorRx|EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.
45371310|NCT05528939|Other|Control video game|The active control program, used in previous studies of this intervention, was designed to match EndeavorRx on expectancy, engagement, and time on task in the form of a challenging and engaging digital word game, targeting cognitive domains not targeted by EndeavorRx and not primarily associated with attentional difficulties. Users are instructed to find and connect letters on a grid to spell words; points are awarded based on number of words formed, word length, and the use of unusual letters. There is progression in difficulty to maintain engagement and expectation of benefit from patients and their caregivers.
45371311|NCT05525858|Drug|Alectinib|ALK fusion or mutations, Mutations or amplification in any of the following: RET
45489975|NCT03708757|Other|Post isometric relaxation - Group I|Post isometric relaxation (PIR) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
45371312|NCT05525858|Drug|Atezolizumab|"MSI high status by any method Or Any mutation in any of these genes:~MLH1 or MSH2 or MSH6 or PMS2 or EPCAM Or Any of the following mutations in POLE: R150X, P286R, P286H, S297F, Y298fs, F367S, V411, L424V, P436R, S459F, R665W, L698fs, R762W, R1519C, R1826W, D316H, D316G, R409W, L474P Or Any of the following mutations in POLD1: P112fs, A930fs, S478N Or Any mutation in the following: POLE not listed above, POLD1 not listed above, POLD2, POLD3, POLD4, POLQ or PRKDC Or Any loss of function mutations in BRCA1, BRCA2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1, RFC2, RFC3, RFC4, RFC5, PCNA, RPA1, PRA2, PRA3, PRA4, or SSBP1 High tumor mutational burden decided by KOSMOS-II MTB (TMB ≥20/Mb in local NGS or if 10-20/Mb, confirmed by central NGS te sting)"
45371313|NCT05525858|Drug|Erlotinib|"EGFR Exon 19 deletions in the region E746_E759;~Any of the following EGFR mutations:~E709A, E709G, E709K, E884K, G719A, G719C, G719S, L858R, L861Q, L833V, S768I"
45371314|NCT05525858|Drug|Trastuzumab + Pertuzumab|"ERBB2 amplification, or over-expression; or presence of any of the following ERBB2 mutations:~G309A, G309E, S310F, S310Y, R678Q, I655V, D769H, D769Y, L755S, p.L75 5_T759del, I767M, V777L, E321G, R896C; P780ins; delL755-T759 ERBB2 amplification or approved by the KOSMOS Molecular Tumor Board"
45371315|NCT05525858|Drug|Trastuzumab emtansine|"ERBB2 amplification, or over-expression; or presence of any of the following ERBB2 mutations:~G309A, G309E, S310F, S310Y, R678Q, I655V, D769H, D769Y,L755S, p.L75 5_T759del, I767M, V777L, E321G, R896C; P780ins; delL755-T759 ERBB2 oncogenic mutations; G152V, X215_splice, D277Y, G292C, N302K, V308M, G309A, S310F, S310Y, S244C, L651V, V659E, G660D, R678Q, V697L, G727A, T733I, L755A, L755P, L755S, D769H, D769Y, A775_G776insSVMA, A775_G776insYVMA (i.e.,Y772_A775dup,M774_A775insAYVME 770delinsEAYVM), G776_V777 > AVCV, G776_V777 > AVGCV, G776_V777 > VCV, G776_V777insVC, G776C, G776delinsLCT, G776L, G776dleinsVC, G776L777_G778insC, V777L, V777M, G778_Y779insGSP, P780_Y781insGSP (i.e.,G778_P780dup), L786V, N813D, R840W, V842I, T862A, R896G, E1021Q or approved by the KOSMOS Molecular Tumor Board"
45371316|NCT05525858|Drug|Vemurafenib|BRAF_V600E/D/K/R mutations
45371317|NCT05525858|Drug|Bevacizumab + Erlotinib|FH inactivating mutations or approved by the KOSMOS Molecular Tumor Board
45371318|NCT05525858|Drug|Entrectinib|ROS1 gene fusion using either a fluo rescence in situ hybridization (FISH) or next-generation sequencing (NGS) or approved by the KOSMOS Molecular Tumor Board
45371319|NCT05525858|Drug|Pralsetinib|RET fusion or mutations; CCDC6 RET, RET V804L, RET V804M, RET M918T, KIF5B-RET, RET C634W or approved by the KOSMOS Molecular Tumor Board
45371320|NCT05524883|Drug|DYNE-251|Administered by IV infusion, every 4 weeks
45371321|NCT05524883|Drug|Placebo|Administered by IV infusion, every 4 weeks
45371322|NCT05524584|Drug|Fulvestrant|Given intramuscularly
45371323|NCT05524584|Drug|Anastrozole|Given orally
45371324|NCT05524584|Drug|Abemaciclib|Given orally
45489976|NCT03708757|Other|Eccentric Muscle contraction - Group II|and Eccentric muscle energy techniques(EME) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
45489977|NCT03707119|Other|Educational programme|the health professional students were undergone to Student 4 Best Evidence blog, as a specific educational programme to learn EBP competencies.
45371325|NCT05524532|Dietary Supplement|Immulina TM|Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiiating properties.
45371326|NCT05524532|Dietary Supplement|Placebo|Placebo is inert powder in cellulose capsule that appears identical to Immulina TM capsules
45371327|NCT05522296|Drug|Mpox Vaccine|Vaccination with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara)
45371328|NCT05512949|Biological|JYNNEOS|JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus. Each 0.5 mL dose is formulated to contain 0.5 x 10^8 to 3.95 x 10^8 infectious units of MVA-BN live virus in 10 mM Tris (tromethamine), 140 mM sodium chloride at pH 7.7. Subcutaneous is administered in the deltoid region, intradermal is administered in the volar aspect (inner side) of the forearm.
45489978|NCT05682859|Drug|Roflumilast 500 Mcg Oral Tablet|Randomized to either systemic roflumilast or placebo in phase 1. All participating patients will receive roflumilast in phase 2.
45489979|NCT05682859|Drug|Placebo|Placebo tablets
45489980|NCT02949973|Drug|voclosporin|
45489981|NCT05175937|Device|smartphone APP based remote monitoring|smartphone APP to monitor remotely patients implanted with ICD
45489982|NCT05175937|Device|bedside transmitter based remote monitoring|bedside transmitter to monitor remotely patients implanted with ICD
45489983|NCT04152252|Other|Real time feedback|Real-time feedback on chest compression depth, chest compression rate and recoil available to EMS while performing CPR. Feedback is delivered as visual text, numeric and graphical presentations on the defibrillator with audio tones for rate.
45489984|NCT04152252|Behavioral|Post-event debriefing|Structured oral post-event debriefing based on objective performance data from the resuscitation attempt. The debriefing is conducted as hot/immediate self-directed debriefing session with a maximum length of 10 minutes.
45371329|NCT05511363|Drug|KarXT|KarXT 20 mg/2 mg TID KarXT 30 mg/3 mg TID KarXT 40 mg/4 mg TID KarXT 50 mg/5 mg TID KarXT 66.7/6.67 mg TID
45371330|NCT05511363|Drug|Placebo|Placebo Capsules
45371331|NCT05510739|Behavioral|Motor-cognitive home exercise supported by eHealth technology|10-week, individualized and progressive exercise program targeting functional strength, cardiovascular fitness and physical activity levels. Cognitive exercises are incorporated with motor exercises as an adjunct to the intervention.
45371332|NCT05510739|Behavioral|Individualized home exercise program|Individualised home exercise program leaflet involving one initial instruction session. Written instructions involving dose and exercise progression. No support during the 10 week period.
46053310|NCT05568043|Behavioral|COPD Transitions of Care Intervention Bundle: Virtual Interventions|The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. Virtual interventions included in the bundle may consist of: phone or e-consults for medication reconciliation, virtual teach-to-goal [V-TTG] or tele-TTG inhaler education, and post-discharge phone call communication and/or texts/ and/or electronic portal use, among others.
45489985|NCT04394676|Procedure|Pressure applied during RARP|Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 12 mmHg (experimental) or 15mm Hg (standard technique).
45489986|NCT04384146|Radiation|Cyclical Hypofractionated Palliative Radiation (Quad Shot)|3.7 Gy twice daily x 2 days for a total dose of 14.8 Gy per cycle. The next cycle will occur after a 21-28 day break.
45489987|NCT04384146|Behavioral|EORTC QLQ-C30 questionnaire|at baseline, each cycle of Quad Shot, and at 3 weeks, 3 months and 6 months after last cycle of Quad Shot.
45489988|NCT05420922|Drug|Lenvatinib Oral Product|Lenvatinib or Sorafenib
45489989|NCT05420922|Drug|PD-1 inhibitor|Programmed cell death protein-1 (PD-1) or Programmed cell death ligand 1 (PDL-1
45371335|NCT05507541|Procedure|Biospecimen Collection|Undergo correlative studies
45489990|NCT05420922|Procedure|Local treatment|Local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.
45489991|NCT05283096|Other|Questionnaire|A questionnaire about beliefs on food and diet in rheumatic diseases, and if a diet was tried what effect it had on health and rheumatism
45489992|NCT02948959|Drug|Dupilumab|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
45489993|NCT02948959|Drug|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
45489994|NCT02948959|Drug|Asthma Controller Therapies|"Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhaled, oral"
45371336|NCT05507541|Procedure|Computed Tomography|Undergo PET/CT or CT scans of the chest, abdomen, and pelvis
45371337|NCT05507541|Drug|Ontorpacept|Given IV
45371338|NCT05507541|Biological|Pembrolizumab|Given IV
45371339|NCT05507541|Procedure|Positron Emission Tomography|Undergo PET/CT scans
45489995|NCT02948959|Drug|Asthma Reliever Therapies|"Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled"
45489996|NCT03582215|Drug|Part 1: Cream|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
45489997|NCT03582215|Drug|Part 1: Lotion|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
45489998|NCT03582215|Drug|Part 1: Spray 1|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
45371340|NCT05507541|Drug|SIRPa-IgG4-Fc Fusion Protein TTI-622|Given IV
45371341|NCT05498220|Drug|Polatuzumab vedotin (PV)|1.8 mg/kg, intravenous, at day 1, in every 21 days
45371342|NCT05498220|Drug|Rituximab|375 mg/m2 intravenous, at day 1 or day 2, in every 21 days
45371343|NCT05498220|Drug|Hyaluronidase|1,400 mg/23,400 units sub-cutaneous, starts at cycle 2, in every 21 days
45489999|NCT03582215|Drug|Part 1: Spray 2|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
45371344|NCT05498220|Drug|Gemcitabine|1,000 mg/m2 intravenous at day 1 and 8, in every 21 days
45490000|NCT03582215|Drug|Part 2: Lotion|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
45490001|NCT03582215|Drug|Part 2: Aerosol Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
45490002|NCT03582215|Drug|Part 2: Nonaerosol Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
45490003|NCT03582215|Drug|Part 2: Pump Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
45490004|NCT05420766|Behavioral|Shortened Sleep|In this experimental condition, children go to bed 90 minutes later than their typical bedtime during Week 2 of the 4-week protocol.
45490005|NCT05420766|Behavioral|Stabilized sleep|In this control condition, children go to bed at their usual time throughout the 4-week protocol.
45490006|NCT03089580|Device|Intense Pulsed Light Therapy|Intense pulsed light therapy is a non-invasive and non-laser light treatment that was approved in 1995 by the FDA for dermatology. Participants will receive a total of 4 treatments over the course of the study.
45371345|NCT05498220|Drug|Cisplatin|75 mg/m2, intravenous, at day 1, in every 21 days
45490007|NCT03089580|Procedure|Sham Treatment|The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
45490008|NCT05420610|Other|Control group: Patients being admitted when The advancement of transpulmonary thermodilution(TPTD) device was unavailable.|The control group included patients being admitted when TPTD device was unavailable; and relatively stable patients without the need for TPTD. The adequacy of fluid resuscitation in the control group was monitored by traditional monitoring parameters including vital signs and hourly urine output.
45490009|NCT05420610|Other|Study group: TPTD device was implemented for monitoring.|TPTD device was implemented for monitoring; the inclusion criteria included patients suffering from 2nd degree burn greater than 40% TBSA; a combined 2nd to 3rd degree burn greater than 30% TBSA; or patients with inhalation injury despite the burned surface area.
45490010|NCT05420532|Other|Exergaming|A video game-based physical activity training applied using a commercial game console.
45490011|NCT01568580|Drug|GreenGene|Dose : 10 ~ 50IU/kg Administration method : intravenous infusion or bolus
45490012|NCT04107870|Behavioral|Virtual Reality Exposure Therapy sessions|Female adolescents aged 13 to 18 are proposed virtual reality exposure therapy sessions, accompanied by a cognitive and behavioral therapy (CBT) therapist, to work on their body representations
45490013|NCT04107870|Behavioral|Psychomotor therapy sessions|Psychomotor therapy sessions are proposed to female adolescents aged 13 to 18 years, ac-companied by a psychomotor therapist, to work on their body representations.
45692547|NCT01796197|Procedure|Mastectomy|
45692548|NCT01796197|Radiation|Radiation Therapy|
45753530|NCT04199546|Other|Chewing and swallowing rehabilitation|A home based chewing and swallowing training program (CST) will be applied by an experienced physical therapist. The Functional Chewing Training will be used to improve chewing function which has five steps including positioning the child and food, sensory stimulation, chewing training and adjustment of food consistency to improve chewing function. To support hyolaryngeal elevation, laryngeal mobilization will be performed. Hyolaryngeal mobilization will be performed by moving hyolaryngeal complex in right, left and up directions manually.
45371346|NCT05498220|Drug|Dexamethasone|40 mg intravenous at day 1, Per oral days at days 2-4
45371347|NCT05498220|Drug|GCSF|granulocyte-colony stimulating factor (GCSF )
45371348|NCT05496738|Drug|PF-07264660 intravenous single ascending dose|PF-07264660 will be administered intravenously in single ascending doses
45371349|NCT05496738|Drug|PF-07264660 subcutaneous multiple ascending dose|PF-07264660 will be administered subcutaneously in multiple ascending doses
45371350|NCT05496738|Other|Intravenous placebo|Placebo will be administered intravenously in single ascending doses
45371351|NCT05496738|Other|subcutaneous placebo|Placebo will be administered subcutaneously in multiple ascending doses
45371352|NCT05495503|Device|Prototype (814A-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
45371353|NCT05495503|Device|Prototype (814B-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
45371354|NCT05495503|Device|Prototype (814C-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
45371355|NCT05495503|Device|Prototype (814D-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
45371356|NCT05494437|Combination Product|PP-01 High Dose|Cannabinoid-1 (CB1) partial agonist / GABAergic modulator
45371357|NCT05494437|Combination Product|PP-01 Low Dose|CB1 partial agonist / GABAergic modulator
45371358|NCT05494437|Drug|Placebo|Placebo comparator
45371359|NCT05494437|Drug|Nabilone|CB1 receptor
45371360|NCT05494437|Drug|Gabapentin|GABAergic modulator
45371361|NCT05481892|Device|Cellular Home blood pressure (BP) monitoring|Patients receiving intervention will receive cellular home blood pressure (BP) monitoring devices. Some patients will also receive pharmacist support for treatment intervention.
46053311|NCT05568043|Behavioral|COPD Transitions of Care Intervention Bundle: In-Person Interventions|The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. In-person interventions include face-to-face general COPD education, inhaler education, medication reconciliation, post-discharge clinic visits, community health worker home visits, pulmonary rehabilitation, smoking cessation programs, among others.
45371363|NCT05464082|Other|Functional Precision Oncology|Patient derived models (PDMs), comprising patient derived xenografts (PDXs) and organoids (PDO and PDxO),
45371364|NCT05462977|Behavioral|Group exercise program|Participants will be asked to join a music-based group exercise program for 24 weeks (up to 6 days/week, 30 - 45 min/day), which is designed for older adults with functional limitations to safely exercise on a chair or in a supported standing posture for the improvement of aerobic capacity, upper and lower body strength, and balance control at a gradually increasing pace in synchrony with music.
45371365|NCT05462522|Drug|RO7303509|RO7303509 will be administered as SC injection monthly, as specified in each treatment group.
45371366|NCT05462522|Drug|Placebo|RO7303509 matching placebo will be administered as SC injection monthly, during the MAD stage.
45371367|NCT05461053|Drug|LMX 4 Topical Cream|The intervention group will be prescribed a course of LMX4 with application of a non-permeable dressing (Tegaderm, 3M, St Paul, MN) until time of spontaneous drainage, treatment failure, or resolve of pain. LMX4 is a topical anesthetic consisting of 4% lidocaine which is Food and Drug Administration (FDA) approved for topical use in children.
45371368|NCT05458284|Procedure|Real Acupuncture|Real Acupuncture weekly till taxane completion
45371369|NCT05458284|Other|Sham Acupuncture|Sham Acupuncture weekly till taxane completion
46053312|NCT05566886|Device|Continuous measurement of photoplethysmography at the wrist|Patients receive a wristband that uses multi-color LEDs to measure pulsations at the wrist.
46053313|NCT05566873|Behavioral|PA Education plus human and planetary health information|One year of continuing person-level physical activity promotion and health-related information delivered primarily by mail, email, and through online scientific video presentations and exploration of freely available citizen science mobile applications
46053314|NCT05566873|Behavioral|PA Education plus Our Voice citizen science|One year of continuing person-level physical activity promotion and health-related information delivered primarily by mail and email, plus participatory citizen science activities involving neighborhood audits of the walking environment using a mobile app and remote group discussion and problem-solving around physical activity barriers
45371372|NCT05456841|Behavioral|Empathic Communication Skills (ECS) training|"The overall training goal of this 2-hour ECS module is to enhance OCP recognition and responsiveness to lung cancer patients' empathic opportunities by communicating understanding, alleviating stigma and distress, and providing support. The ECS training also provides tools to OCPs to buffer/inoculate patients against stigmatizing attitudes and behaviors by others such that lung cancer patients who currently or formerly smoked can be given small doses of an opposing viewpoint (termed as preparing patients for recurring smoking questions) and suggestions of counterarguments in order to make them resistant to future stigmatizing attacks by others"
45371373|NCT05447663|Drug|Siremadlin|30-40 mg QD siremadlin capsules, orally (1-5 days of 28 or 42 days cycle)
46053315|NCT05566795|Drug|DAY101|Oral pan-RAF inhibitor
46053316|NCT05566795|Drug|Chemotherapeutic Agent|Intravenous solution for injection
45490014|NCT05175703|Device|Passeo-18 Lux Paclitaxel releasing Balloon Catheter|collect short term and long term clinical evaluation data of the Passeo-18 Lux Paclitaxel releasing balloon catheter, subject to patients who visit hospital from arteriosclerosis in the infrainguinal arteries in actual clinical environment.
46053317|NCT05563831|Other|national registry|The investigators will collect demographic, clinical, biological and imaging characteristics of patients with PROS.
46053318|NCT05563038|Device|Scrambler Therapy|"Scrambler Therapy is a non-invasive neuromodulator treatment that focuses on relieving chronic pain through the sending of non-pain signals to the brain through the afferent pain sensory nerves. The signals given off by the scrambler therapy machine are intended to mimic neuronal action potentials through the synthesis of 16 unique waveforms that in combination forms a patient specific cutaneous electrostimulation to reduce pain. These information packets are then carried by the afferent C-fibers, an established system that modulates the sensations received instead of blocking them. The modulated signals are received as nonpainful and endogenous by the central nervous system."
45371377|NCT05444504|Device|Cup|an insertable vaginal cup ('cup')
45371378|NCT05444504|Device|Cup+|the cup attached via rubber tubing to a leg-secured urine collection bag ('cup+') for greater urine holding capacity
45371379|NCT05440708|Drug|TTI-101|Oral tablet
45371380|NCT05440708|Drug|Pembrolizumab|Intravenous (IV) infusion
45371381|NCT05440708|Drug|Atezolizumab|Intravenous (IV) infusion
45371382|NCT05440708|Drug|Bevacizumab|Intravenous (IV) infusion
46053319|NCT05563038|Drug|Standard Medication Management|Medications such as: gabapentin, duloxetine and Lyrica are all FDA approved for treatment of neuropathic pain, particularly that caused by diabetes.
45490015|NCT04102800|Drug|Benralizumab|subcutaneous injection
46053320|NCT05561335|Device|hearing aid -novel program|novel microphone configuration
46053321|NCT05561335|Device|hearing aid - standard program|standard microphone configuration
46053322|NCT05560451|Behavioral|Peer health coach intervention|Eligible participants will be randomly assigned to receive a telehealth delivered peer health coach intervention to promote health outcomes and behavior change among Veterans with multimorbidty.
46053323|NCT05558124|Drug|Vyxeos|Fixed dose of Vyxeos (44 mg/m2 daunorubicin and 100 mg/m2 cytarabine) (Day 1, 3, and 5) in combination with various dose schedules of Gemtuzumab Ozogamicin (GO)
46053324|NCT05558124|Drug|Gemtuzumab Ozogamicin|"Participants will be treated at the following dose levels:~Dose Level 1 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 Dose Level 2 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 and 4 Dose Level 3 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1, 4, 7"
46053325|NCT05557331|Device|PIMPmyHospital (mobile app)|After the implementation of the app, data will be collected prospectively over a 6-month period of use. This will include the times (HH:MM:SS) when the results issued by the central laboratory are made available on caregivers' mobile app and access times (as well as concurrent or preferred access times on the conventional computerized workstations should this occur).
46053326|NCT05557292|Drug|RMC-5552|Given IV
45371386|NCT05429632|Drug|mocravimod|S1PR modulator
45371387|NCT05428488|Drug|Abatacept (W12-W48)|"The experimental strategy will evaluate abatacept 125 mg/week following 12 weeks of anti-TNF prescribed in usual care. Concomitant treatment with stable doses of csDMARD, non-steroidal anti-inflammatory drugs, analgesic agents, glucocorticoids (≤10 mg of prednisone or the equivalent per day), or a combination of these drugs will be permitted.~Patients will continue to take methotrexate or leflunomide for the duration of the study."
45371388|NCT05428488|Drug|TNF Inhibitor (W12-W48)|In the control group, the 88 randomized RA patients will be treated with TNF inhibitor subcutaneous for 36 weeks. In case of insufficient response to a first TNF inhibitor at 24 or 36 weeks, a second TNF inhibitor will be proposed.
45371389|NCT05428488|Drug|TNF Inhibitor (W0-W12)|All included patients will receive TNF inhibitors subcutaneous for 12 weeks.
45490016|NCT03632226|Drug|18F-OGA-1|
46053327|NCT05556850|Behavioral|STABL Virtual Rehabilitation|"STABL is a digital health platform that uses computer-vision technology to facilitate at-home post-op recovery for patients while enabling remote monitoring by their surgeon. The platform is fully HIPAA compliant.~STABL analyzes a patient's biomechanics in real time while they perform their recovery exercises to provide them with cues to ensure the exercises are done correctly and track adherence. They then relay all the data to the patient's clinician to allow them to monitor their recovery remotely, address any adherence barriers, and mitigate readmission risks that arise in a more timely manner."
45490017|NCT05682703|Diagnostic Test|Proteomics technology and liquid biopsy|using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites by collecting residual blood and urine from routine diagnosis and treatment or physical examination
45490018|NCT05664919|Drug|SA58 Nasal Spray|SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
45490019|NCT05175079|Device|Acupressure band|"acupressure band apply to P6 (nei guan) point which located three fingers below the skin wrinkles of the anterior wrist.~Acupressure band wear 3 times daily before breakfast, lunch and dinner for at least 10 minutes"
45490020|NCT05175079|Other|Standard treatment hospital protocol|Intravenous metaclopromide 10mg PRN Intravenous fluids as per protocol
45753531|NCT04199390|Procedure|total hip arthroplasty|each patient is expected to undergo an anterior total hip arthroplasty procedure and some sort of physical therapy postoperatively
45753532|NCT04193774|Diagnostic Test|Conjunctival swab|Swab of the conjunctival fornices of both eyes
46053328|NCT05554926|Drug|AEF0117|2 mg AEF0117 containing approximately 100 μCi of [4-14C]AEF0117
45371390|NCT05425992|Other|Interview|Patient/parent dyads expressing interest will be interviewed by a bilingual Spanish certified provider via televideo with as needed interpreter support. Interviews will be audio recorded for review and translation purposes and then will be destroyed. Interview format will be supportive and information seeking only with reassurance that purpose is for care improvement and that all answers will be evaluated without association to patient name. Interviews will then be translated and reviewed by the PI for themes regarding perceived clinic successes and perceived clinic barriers in communication or care.
45692549|NCT03586791|Procedure|Pupillometry guided anesthesia|"At least 10 min after anesthesia induction by target-controlled infusion of propofol and remifentanil, baseline values for pupillary diameter is recorded before any surgical procedure.~During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60. Remifentanil Ce is adapted every 5 min based on the changes of pupillary diameter. If the pupillary diameter is increased by more than 30% compared to baseline value, remifentanil concentration is increased by 0.5 ng/ml. If the pupillary diameter is maintained between 5 and 30 % change compared with baseline, remifentanil is not modified. In a case of pupillary diameter is decreased less than 5 % change of baseline, remifentanil concentration is decreased by 0.5 ng/ml."
45692550|NCT03586791|Procedure|SPI guided anesthesia|During the operation, SPI value should be maintained between 20 and 50 by changing the infusion rate of remifentanil. Even if the SPI is maintained within the target range, the remifentanil infusion rate is increased by 0.5 ng/ml in a case of the SPI value suddenly arises by more than 10.
45371391|NCT05423600|Procedure|BES + TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
45371392|NCT05423600|Procedure|Experimental: BES+sham TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) sham treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
45371393|NCT05414201|Drug|Adalimumab|Subcutaneous Injection
45371394|NCT05412004|Drug|Tirzepatide|Administered SC
45371395|NCT05412004|Drug|Placebo|Administered SC
45371396|NCT05405751|Drug|Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]|Patients enrolled in the study and accessing the HIV consultation will start treatment with BIKTARVY on the day of enrollment. Medication will be provided by the sponsor and dispensed through the pharmacy service. The drug will be delivered to the patient with a delegated person outside the hospital environment or it will be the patient himself who picks up the medication.
45371397|NCT05405309|Drug|RP-3500 in combination with Olaparib|"During dose escalation, four DLs of combination therapy of RP-3500 and olaparib may be explored. Subjects will be enrolled in cohorts of three starting with DL 1. Enrollment will be placed on hold to allow for all members of a cohort to complete the Dose Limiting Toxicity (DLT) period. Once all subjects in a cohort have completed the defined DLT evaluation period, the assignment of the dose level for the following cohort will be made per the decision algorithm.~Once RP2D is assigned continuous enrollment will begin among the 2 expansion cohorts."
45371398|NCT05403476|Drug|FE 999049|FE 999049 is administered as single daily subcutaneous injections of 12 μg for 6 months.
45371399|NCT05403476|Drug|Placebo|Placebo is administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049 for 6 months.
45692551|NCT03586791|Procedure|Standard management|"During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60.~Remifentanil concentration is controlled by the discretion of the anesthesiologist in charge of the patients."
45692552|NCT01795495|Drug|Methadone hydrochloride|This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia
45371400|NCT05392452|Device|CamAPS HX|Fully automated closed-loop subcutaneous insulin delivery system. A model predictive controller modulates insulin delivery every 10-12 minutes based on interstitial glucose measurements.
45490021|NCT03323346|Drug|Disulfiram|"Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed.~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper."
45371401|NCT05392452|Drug|Standard insulin therapy|Standard insulin therapy according to local clinical practice.
46053329|NCT05550857|Other|eccentric resistance exercise|The subject will lying prone on a treatment table. One end of eccentric resistance band will tie around the mid of the foot of indvidual, the other end of the resistance band will be attach to the table and the band is adjusted so that it will tight and there will be no slack present in it. It will provide a smooth eccentric resistance throughout the dorsiflexion range
45490022|NCT05628571|Combination Product|Zinc toothpaste|Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing amine-based zinc lactate (0.1%) and fluoride (1400 ppm F).
45490023|NCT05628571|Combination Product|Fluoride Toothpaste|Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing fluoride (1450 ppm F).
45692553|NCT01795495|Drug|Magnesium Sulfate|This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).
46053330|NCT05550857|Other|myofascial release|The subject will lye prone on a treatment table. Deep longitudinal massage with the help of both thumbs reinforcing eachother will be given on the subject's calf muscles.
46053331|NCT05543382|Device|Axonics System|The Axonics System will be implanted as standard care
46053332|NCT05541913|Other|Tele nursing|The intervention group in the study will be the parents of children who received routine care in the surgical service and who received tele-nursing service, who had undergone circumcision operation.After the admission of the child in the service, the Beck Anxiety Scale will be applied to measure the anxiety levels of the parents at the first hospitalization. After the routine discharge training in the service, the Beck Anxiety Scale and Health Care Satisfaction Scale will be applied to the parents again. Then, the parents will be called on the 1st postoperative day and training will be provided. On the postoperative 2nd, 3rd and 4th days, counseling will be provided. on the postoperative 4th day Parents will be asked to fill in the Beck Anxiety sScale and Health Care Satisfaction scale.
46053333|NCT05540392|Procedure|Acupuncture|10 treatments of acupuncture over the course of 10 weeks
45371409|NCT05387187|Drug|Pu Yang Wan Wu Tang plus Pentoxifylline|Pu Yang Wan Wu Tang 5g TID Pentoxifylline 100mg TID
45371410|NCT05387187|Drug|Pentoxifylline|Pentoxifylline 100mg TID
45371411|NCT05383872|Device|Focused Ultrasound (Exablate Model 4000)|BBB opening via Exablate Type 2 system with microbubble resonators and drawing blood before and after opening
45371412|NCT05382325|Biological|MK-1484|Subcutaneous (SC) injection
45371413|NCT05382325|Biological|Pembrolizumab|Intravenous (IV) infusion
45371414|NCT05378139|Device|Vital signs measurements with new app|Patients vital signs are monitored through an app for the nurses to use
45692554|NCT01795495|Drug|Remifentanil|
46053334|NCT05540392|Other|Waitlist Control|The waitlist control group will not receive any acupuncture treatments during the 14-week waiting period. Patients in waitlist control group will have the option to receive up to 10 acupuncture treatments after a 14-week waiting period.
46053335|NCT05535023|Drug|SAR444245|Given by vein (IV)
46053336|NCT05535023|Drug|Cemiplimab|Given by vein (IV)
45371418|NCT05365893|Combination Product|Paricalcitol, Hydroxychloroquine, Losartan|Paricalcitol 25 mcg IV administered M-W-F Hydroxychloroquine 600 mg PO BID Losartan 50 mg PO daily
45371419|NCT05365893|Other|Neoadjuvant therapy and surgery only (Control)|Control arm These patients will proceed to surgery at completion of neoadjuvant therapy.
45371420|NCT05364073|Drug|Furmonertinib|Furmonertinib tablet
45371421|NCT05364073|Drug|Furmonertinib|Furmonertinib tablet
45371422|NCT05364073|Drug|Furmonertinib|Furmonertinib tablet
45371423|NCT05364073|Drug|Furmonertinib|Furmonertinib tablet
45371424|NCT05364073|Drug|Furmonertinib|Furmonertinib tablet
45371425|NCT05362344|Procedure|Stool tests|Non-invasive, stool-based tests for colorectal cancer screening.
45692555|NCT04765527|Dietary Supplement|Turmeric Strength for Joint|Turmeric-based tablets
45692556|NCT04765527|Dietary Supplement|Placebo|Placebo tablets
45692557|NCT04570111|Other|MOD Diet|The macro-optimized diet alters the timing of macronutrient intake to provide fewer carbohydrates at breakfast, while maintaining recommended amounts of macronutrients delivered throughout the course of the day
45753533|NCT04193774|Drug|Oxybuprocaine Hydrochloride 0.4% Eye Drops|One drop of topical anesthesia in one eye
46053337|NCT05526144|Drug|Synthroid|Synthroid tablets 25 mcg. Subjects in the study group will receive Synthroid at a titrated dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for one year duration that will maintain TSH at normal level.
45371426|NCT05359679|Behavioral|Value Champion Training Program|Clinicians from primary care clinic sites randomized to the intervention arm of the study will complete a 6-month clinician value champion training program by participating in a series of 12 web-based training sessions. No intervention will be conducted at clinics in the control arm.
45371427|NCT05359679|Other|No Intervention|Usual clinical care - no value champion present at this clinical setting
46053338|NCT05526144|Drug|Placebo|Placebo tablets 25 mcg daily. Subjects in the placebo group will receive placebo tablets at a dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for a one year duration.
46053339|NCT05526066|Biological|ARCT-810|ARCT-810 is messenger RNA (mRNA) coding for Ornithine Transcarbamylase (OTC) formulated in a lipid nanoparticle (LNP) under development.
45371430|NCT05340855|Behavioral|Wiidookaage'win Facebook Group|A 30-day Facebook group prototype that is moderated by two women who will post various forms of media addressing opioid recovery, mindfulness, stress management, and resiliency.
45371431|NCT05337553|Drug|taldefgrobep alfa|DB Phase: 35 mg/50 mg weekly subcutaneous injection
45692558|NCT04570111|Other|Standard Care Diet|The standard care diet provides macronutrients within standard amounts (40% carbohydrate, 20% protein, 40% fat) at all meals and snacks per day.
45371432|NCT05337553|Drug|Placebo|DB Phase: matching placebo 35 mg/50 mg weekly subcutaneous injection
45490024|NCT05255016|Combination Product|PXL Platinum 330 system + Riboflavin 0.25% TE Solution|"Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition CXL + Riboflavin 0.25% TE solution.~After topical anesthesia, the surgeon or trained designee will apply topical riboflavin (1 drop every 2 min for 40 min with PESCHKE TE solution [0.25%], or longer as needed to assure adequate corneal penetration). At the end of this pre-treatment period, the eye will be examined at the slit lamp with the blue filter for the presence of riboflavin throughout the stroma. When sufficient corneal riboflavin penetration is confirmed, the eye will be aligned under the PXL Platinum 330 light. The correct aperture setting (3 to 12 mm) will be selected for the size of the eye and area needing to be treated (2 mm larger than the maximal ulcer diameter), and the eye will be irradiated at 18 mW/cm2, with pulsed mode (5 seconds on, 5 seconds off) for 10 min, during which time instillation of riboflavin will continue (1 drop every 2 min)."
45490025|NCT05255016|Other|Sham CXL + Artificial Tears|Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition, for subjects in the sham group, artificial tears (1 drop every 2 min for 40 min) will be administered. after instillation of artificial tears, the eye will be aligned under the PXL Platinum 330 light. The instrument will be kept off and the subject will be kept under the device for 10 min during which time instillation of artificial tears will be performed (1 drop every 2 min) to maintain corneal hydration. The operator will keep track of sham exposure time independently to confirm the actual duration.
45490026|NCT05610397|Device|STALIF®|STALIF® C, or M, Ti or FLX
45371433|NCT05337553|Drug|taldefgrobep alfa|Extension Phase: 35 mg/50 mg weekly subcutaneous injection
45371434|NCT05330455|Drug|GSK3965193|GSK3965193 will be administered
45371435|NCT05330455|Drug|Placebo to match GSK3965193|Placebo to match GSK3965193 will be administered
45371436|NCT05330455|Drug|Bepirovirsen|Bepirovirsen will be administered
45371437|NCT05326516|Drug|SNDX-5613|Participants will receive SNDX-5613 until meeting criteria for discontinuation.
45371438|NCT05326516|Drug|Chemotherapy Regimen 1|Participants will receive 2 treatment cycles of chemotherapy. During Cycle 1, participants will receive prednisone, vincristine, pegaspargase, and daunorubicin. During Cycle 2, participants will receive etoposide and cyclophosphamide.
45490027|NCT05598528|Other|Genomic profiles detection|The Paraffin-embedded tumor tissue at diagnosis is collected and assessed by Next- generation gene sequencing
45490028|NCT05598528|Other|circulating tumor DNA detection|The Plasma at diagnosis and at 1-month treatment are collected and assessed by Next-generation gene sequencing
45490029|NCT05598450|Device|rTMS and MEG for auditory hallucinations via single arm|a 4 weeks, weekly 230 minutes, 1Hz, 100%RMT-rTMS protocol
45490030|NCT03645395|Drug|MT-3724|Experimental treatment with MT-3724 in combination with LEN therapy.
45490031|NCT04074018|Other|Self-rehabilitation program|facial self-rehabilitation for a duration of 6 months
45490032|NCT04074018|Other|Conventional rehabilitation program|Conventional facial rehabilitation for a duration of 6 months
45490033|NCT03342469|Other|Artificial Food Coloring|225mg mixed powdered Artificial Food Coloring (AFC)
45753534|NCT04193774|Drug|artificial tears|One drop of artificial tears in the other eye
45753535|NCT03023540|Drug|PXT3003|Liquid oral solution, 5 mL (Dose 1 or Dose 2) bid OR 10 mL (Dose 1) bid
45371439|NCT05326516|Drug|Chemotherapy Regimen 2|Participants will receive 2 treatment cycles of chemotherapy. During Cycles 1 and 2, participants will receive fludarabine and cytarabine.
45371440|NCT05322096|Drug|RGH-706|"Capsules~Oral administration"
45371441|NCT05322096|Drug|Placebo|"Capsules~Oral administration"
45371442|NCT05317663|Behavioral|Test Health Warning Label (HWL)|Effect of Health Warning Label (HWL)
45371443|NCT05317663|Behavioral|Test without Health Warning Label (no-HWL)|Effect of no Health Warning Label (no-HWL)
45371444|NCT05317416|Drug|Elranatamab|BCMA-CD3 bispecific antibody
45490034|NCT03342469|Other|Placebo|Placebo chocolate cookies
45753536|NCT04197674|Other|Dialysis modality|This is a observational cohort study, and there is no intervention for all participants. Our aim is to evaluate dialysis modality (PD and HD) on patient survival
46053340|NCT05526066|Other|Placebo|Normal Saline
46053341|NCT05519579|Drug|Methotrexate|Methotrexate 12mg given intrathecally within 24 hours prior to blinatumomab administration
46053342|NCT05519579|Drug|Blinatumomab|Blinatumomab 28ug/day continuous infusion for 4 weeks
45371445|NCT05317416|Drug|Lenalidomide|Immunomodulatory drug
45371446|NCT05317416|Drug|Lenalidomide|Immunomodulatory drug
45371447|NCT05317416|Drug|Elranatamab|BCMA-CD3 bispecific antibody
45371448|NCT05312671|Drug|Atezolizumab|Atezolizumab 20 mL (1200 mg) on Day 1, once every 3 weeks for up to 20 cycles (each cycle = 21 days)
45371449|NCT05312671|Drug|Carboplatin|Carboplatin AUC 5 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).
45371450|NCT05312671|Drug|Cisplatin|Cisplatin 70 mg/m2 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).
45371451|NCT05312671|Drug|Etoposide|Etoposide 100 mg/m2 IV on Days 1 - 3 every cycle for the first 4 cycles (each cycle = 21 days)
45371452|NCT05312671|Procedure|Cystectomy|Cystectomy should be performed within 42 days after completion of last administered study therapy of induction phase (first 4 cycles of chemotherapy).
45371453|NCT05306496|Device|Pre-shaped 4DMESH®|The 4DMESH® mesh is semi-resorbable parietal reinforcement implant made of 25% Polypropylene (non-resorbable) and 75% Poly-L-Lactic Acid (resorbable). 4DMESH® meshes are designed for the repair and reinforcement of inguinal and femoral hernias. 4DMesh is a CE-marked, class III medical device manufactured by Cousin Biotech.
45371454|NCT05306288|Other|Blood Sample Collection|Subjects enrolled in DELFI-L201 will have blood specimens collected (~30 mL) at enrollment or up to 30 days from enrollment.
45753537|NCT00547729|Device|HeartPOD™ System|HeartPOD™ device with DynamicRx® automatically measures left heart pressures throughout the day.
45490035|NCT05598372|Behavioral|shotblocker|infant pain during vaccination and mother anxiety
45846703|NCT03139344|Other|High-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of high-frequency electrical stimulation.
45846704|NCT02960646|Drug|Cyclophosphamide|Given IV
45846705|NCT02960646|Biological|Filgrastim|Given SC
45371455|NCT05304208|Biological|Mesopher|autologous monocyte-derived DCs loaded with PheraLys (tumor cell lysate)
45371456|NCT05291351|Other|Crackers made with whole, coarse, or fine pea and/or wheat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
45371457|NCT05291351|Other|Crackers made with whole, coarse, or fine lentil and/or wheat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
45371458|NCT05291351|Other|Porridge made with oat flour or oats|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
45371459|NCT05291234|Drug|ABBV-916|Intravenous administration
45371460|NCT05291234|Drug|Placebo|Intravenous administration
45371461|NCT05291091|Drug|EDG-5506 Dose 1|EDG-5506 is administered orally once per day
45490036|NCT05598372|Behavioral|lullaby|infant pain during vaccination and mother anxiety
45490037|NCT05178888|Drug|MRTX849|KRAS G12C inhibitor
45846706|NCT02960646|Drug|Fludarabine Phosphate|Given IV
45846707|NCT02960646|Other|Laboratory Biomarker Analysis|Correlative studies
45846708|NCT02960646|Drug|Melphalan|Given IV
45846709|NCT02960646|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA depleted peripheral blood stem cell transplantation
45846710|NCT02960646|Biological|Rituximab|Given IV
45846711|NCT02960646|Drug|Tacrolimus|Given IV or PO
45490038|NCT05178888|Drug|Palbociclib|CDK 4 and 6 inhibitor
45371462|NCT05291091|Drug|EDG-5506 Dose 2|EDG-5506 is administered orally once per day
45371463|NCT05291091|Drug|EDG-5506 Dose 3|EDG-5506 is administered orally once per day
45371464|NCT05291091|Drug|EDG-5506 Dose 4|EDG-5506 is administered orally once per day
45371465|NCT05291091|Drug|EDG-5506 Dose 5|EDG-5506 is administered orally once per day
45371466|NCT05291091|Drug|Placebo|Placebo is administered orally once per day
45490039|NCT03581825|Device|senofilcon A Multifocal|JJVC Investigational Multifocal Contact Lens
45490040|NCT03581825|Device|senofilcon A Sphere|ACUVUE OASYS 2-WEEK with HYDRACLEAR PLUS
45692559|NCT04170907|Other|standardized vaping protocol|The following questionnaires will first be completed: Modified Minnesota Nicotine Withdrawal Scale, Tiffany Questionnaire on Smoking Urges-Brief total (global) craving score, Positive and Negative Affect Schedule. The assigned product will then be given to the participant, and one puff will be taken every 30 seconds (total of 10 puffs). Blood samples will be collected 15 minutes before vaping and 2, 5, 15, 30, 60, 120, and 180 minutes after the last puff. Heart rate and blood pressure will be measured 15 minutes before and 2, 10, 15, 30, 60, 120, and 180 minutes after the last puff. Post-use withdrawal, craving, reward, and satisfaction will be assessed 10 minutes and 1 and 3 hours after the last puff. Respiratory Symptoms will be assessed at baseline and 5 minutes after the last puff. Ten minutes post-use, the direct effects will also be assessed.
45371468|NCT05284435|Behavioral|Cognitive Behavioral Therapy-Email (iCBT-E)|"Participating families will receive an access to the website that contains treatment materials for both parent and child.~During each of the weekly emails, therapists will serve to provide encouragement and support as the parent works through the program independently."
45490041|NCT03581825|Device|etafilcon A Multifocal|1-Day Acuvue Moist Brand Multifocal Contact Lens
45490042|NCT03581825|Device|etafilcon A Sphere|1-Day Acuvue Moist Brand Contact Lens
45371469|NCT05284435|Behavioral|Cognitive Behavioral Therapy-Email and Videoconferencing (iCBT-EV)|"Participating families will receive an access to the website that contains treatment materials for both parent and child.~During each of the weekly emails and six videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently. Therapists will also assist the parent with any problem-solving as needed."
45490043|NCT03342001|Drug|Calcitonin|calcitonin nasal spray
45490044|NCT03730025|Other|Auscultation plus NeoTapAS|Pediatric resident responsible for HR assessment will estimate the HR by listening to the praecordium with a stethoscope. When using NeoTapAS, he/she will simultaneously tap the same pace on the screen of an iPad with the NeoTapAS app installed and will verbally communicate the HR displayed on the screen.
45490045|NCT03730025|Other|Auscultation without NeoTapAS|Auscultation without NeoTapAS
45490046|NCT03987282|Other|Enhanced usual care (EUC)|Provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).
45490047|NCT03987282|Behavioral|Peer-based counseling|Peer-based counseling intervention focused on behavioral skills and strategies that patients can learn and master to achieve uninterrupted, long-term ART treatment participation while continuing OUD recovery through MMT
45692560|NCT03156387|Procedure|Diode laser|2.8 W diode laser surgery were applied on high frenulum attachment and follow-up VAS scores were evaluated
45692561|NCT03156387|Procedure|Scalpel|Scalpel surgery were performed after local anesthetic administration and VAS scores were recorded.
45490048|NCT03985020|Other|Stevia Intervention|We will use commercially available stevia sweetened soft drink Zevia.
45490049|NCT03985020|Other|Water Intervention|Bottled Water
45490050|NCT03341923|Device|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily disposable wear
45490051|NCT03341923|Device|Etafilcon A multifocal contact lenses|Hydrogel multifocal contact lenses for daily disposable wear
45490052|NCT03579719|Drug|Balovaptan|"In Period 1, balovaptan was administered orally once daily (qd) on Days 1 to 10.~In Period 2, balovaptan was administered qd on Days 6 to 20."
45846712|NCT02960646|Radiation|Total-Body Irradiation|Undergo TBI
45846713|NCT02909556|Device|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement via transfemoral access
45371470|NCT05284227|Other|Electronic Clinical Decision Support Application|Preoperative anaesthesiological assessment and risk evaluation using a clinical decision support application, that calculates perioperative risks for the patient and informs the anaesthesiologist on indicated diagnostics and procedures according to clinical guidelines in real-time.
45371471|NCT05284227|Other|Standard procedures of the hospital and Sham Clinical Decision Support Application|Preoperative anaesthesiological assessment using standard procedures of the hospital. In addition a sham clinical decision support application will be used. Information on perioperative risks and indicated diagnostic procedures according to clinical guidelines is not given to the physician.
45371472|NCT05283720|Drug|Epcoritamab|Subcutaneous Injection (SC)
45371473|NCT05283720|Drug|Lenalidomide|Oral; Capsule
45371474|NCT05283720|Drug|Ibrutinib|Oral; Capsule
45371475|NCT05283720|Drug|Rituximab|Intravenous (IV); Injection
45371476|NCT05283720|Drug|Cyclophosphamide|IV; Injection
45371477|NCT05283720|Drug|Doxorubicin Hydrochloride [HCl]|IV; Injection
45371478|NCT05283720|Drug|Prednisone|Oral; Tablet
45371479|NCT05283720|Drug|Polatuzumab Vedotin|IV; Injection
45371480|NCT05283720|Drug|Venetoclax|Oral; Tablet
45371481|NCT05283720|Drug|CC-99282|Oral; Capsule
45371482|NCT05265845|Behavioral|Intervention|The intervention aims to support infant feeding decisions and teach responsive feeding strategies.
45371483|NCT05265845|Behavioral|Text4Baby|Free health and wellness text messages timed to due date through pregnancy and up until the baby's first birthday.
45490053|NCT03579719|Drug|Itraconazole|In Period 2, 200 mg itraconzole was administered bid for 4 days and qd on Days 5-20, approximately 12 hours apart. On Days 6-20, 200 mg itraconazole was administered qd.
45490054|NCT03631602|Drug|antifungal prophylaxis|posaconazole oral suspension vs itraconazole oral solution
45371484|NCT05264779|Other|Periviable GOALS DST|An iPad application that contains outcomes information, values clarification and embedded short documentary style videos. The tool was designed with low-literacy and low-numeracy populations in mind, and utilizes graphics and video content to enhance meaning-making of complex medical information and jargon. The GOALS DST refers patients back to their physicians to discuss specific treatment options, local outcomes, and management strategies available to them. The DST's content focuses largely on helping patients better understand the choice they have between comfort care and life-sustaining efforts in the context of periviable delivery.
45371485|NCT05262270|Drug|Extended-Release Naltrexone|XR-NTX (Extended-Release Naltrexone) doses of 380mg (Weeks 0, 3 and 6) via intramuscular (IM) injections in the gluteus.
45371486|NCT05262270|Drug|Extended Release Buprenorphine|Extended-Release buprenorphine (XR-BUP) two doses of 300mg XR-BUP (Weeks 0, 4) via subcutaneous injections in the abdomen. Option for 100mg at Weeks 3 and 6 (if needed to alleviate side effects).
45371487|NCT05262270|Drug|Placebo (PLB) Injectable|3 doses of intramuscular injections (Week 0, 3, 6)
45371488|NCT05262270|Drug|Placebo (PLB) Injectable|2 doses of subcutaneous injections (Week 0, 4)
45371489|NCT05259839|Drug|ABBV-383|Intravenous (IV) Infusion
45371490|NCT05259839|Drug|Dexamethasone|Oral; Tablet or IV Infusion
45371491|NCT05259839|Drug|Lenalidomide|Oral; Capsule
45490055|NCT03732989|Device|Interactive toy prototype|The interactive toy prototype takes the form of a hand-crafted plush toy, which was designed to support in-the-moment calming down strategies. The interaction relies on a number of sensors embedded in the 'creature' that register haptic interactions with the toy. In addition, a small vibration motor is used to indicate the creature's state by mimicking a frantic 'heartbeat'. If the creature is calming down in response to the child's touching of the sensors, the heartbeat slows down and eventually turns into happy purring (cf. paper linked below for more details about the design process).
45692562|NCT03586713|Diagnostic Test|light induced fluorescence camera|The light induced fluorescence intraoral camera works with a visible blue light frequency (wavelength 450 nm) for the illumination of the dental surface and produces an overlapping image of the green fluorescence image on the image of the white light. The green fluorescence image is considered an indicator of healthy dental tissues. The colour of the fluorescence signal is green when the dentin is healthy. The healthy enamel is blue due to the scattered green light of the dentin, despite the lack of a fluorescence signal. On the other hand, caries can be easily detected by dark red fluorescence.
45692563|NCT01794949|Device|Resolute Integrity stent|Drug eluting stents used to treat coronary artery blockages
45371492|NCT05259839|Drug|Pomalidomide|Oral; Capsule
45490056|NCT03732989|Device|Non-interactive toy prototype|This toy is the same as the interactive one, but with the interactivity features (haptic feedback) turned off so that it looks and feels like a regular, hand-crafted plush toy.
45490057|NCT03341533|Procedure|Ice packs plus usual post-op analgesia|A 9 inch by 12 inch zip lock bag filled with ice chips, placed inside a cotton pillow case, placed directly on the abdomen. Ice chips will be replaced as they thaw. Monitoring of surgical sites, skin integrity, and comfort with ice pack in place by nursing per current procedural guidelines.
45490058|NCT03341533|Other|Usual post-op analgesia|Standard post-operative analgesia orders will be followed.
45490059|NCT03732911|Behavioral|Intervention|Participants will receive the following intervention bundle (1) educational materials about child development and developmental monitoring checklists; (2) age and language appropriate picture books; and (3) two tailored text messages per week for a 6-month period.
45490060|NCT03631524|Device|Telerehabilitation|The treatment arm will be given up to 1 hour of physiotherapist-prescribed resistive training exercises administered via a telerehabilitation device per day in addition to standard therapy for a total of 10 sessions over a 2 week period.
45692564|NCT04414501|Behavioral|Separation Anxiety|Perioperative anxiety is a common, undesirable outcome in pediatric surgical patients and has been associated with adverse outcomes.
45692565|NCT03586557|Device|Corticosteroid & Plasma exchange|High-dose intravenous methylprednisolone 1000mg 3~5 days and subsequent taper, combined simultaneous plasma exchange 5 times in all
45692566|NCT03586557|Drug|Corticosteroid|High-dose intravenous methylprednisolone 1000mg 3~5 days and subsequent taper
45846714|NCT02894658|Device|LipiFlow system|LipiFlow System is an in-office FDA approved treatment that relieves meibomian gland obstruction through the use of heat and pulsatile pressure.
45371493|NCT05259839|Drug|Nirogacestat|Oral; Tablet
45371494|NCT05259839|Drug|Daratumumab|Subcutaneous Injection (SC)
45371495|NCT05257408|Drug|Nab-paclitaxel 80 mg/m^2|Nab-paclitaxel is administered as intravenous (IV) infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.
45371496|NCT05257408|Drug|Relacorilant 150 mg once daily (QD)|Relacorilant is administered as capsules for oral dosing.
45371497|NCT05257408|Drug|Nab-paclitaxel 100 mg/m^2|Nab-paclitaxel is administered as IV infusion on Day 1, 8, and 15 of each 28-day cycle.
45371498|NCT05254574|Device|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.
45371499|NCT05254574|Device|Placebo Sustained Acoustic Device with 0% Diclofenac Patch|Patients apply the placebo SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% Diclofenac patches.
45371500|NCT05254574|Drug|1% Diclofenac Topical Gel|Topical pain-relief gel
45371501|NCT05254340|Dietary Supplement|Inulin|Inulin ingestion is not being used to diagnose, treat, or prevent irritable bowel syndrome. Inulin is being used to study an individual's ability to ferment dietary fiber.
45371502|NCT05254327|Drug|BMX-001|Loading dose of 28 mg per subject, followed by maintenance doses of 14 mg per subject twice per week.
45490061|NCT03729791|Device|tDCS|Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head. It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way
45490062|NCT03708445|Diagnostic Test|Cytology staining|"Two staining will be performed in cytology specimens obtained from same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography~conventional cytology staining method~new cytology staining method using antibody of aminoacyl-tRNA synthetases"
45490063|NCT03898596|Diagnostic Test|ECG|An ECG collects superficial readings of heart activity
45490064|NCT02688088|Drug|Drug Cocktail|Administered orally
45490065|NCT02688088|Drug|Abemaciclib|Administered orally
46053343|NCT05517863|Device|laser therapy|"All patients received 2 sessions of laser therapy / week in two consecutive months of treatment aiming complete wound closure , patients received & infrared laser therapy plus traditional wound care:~(I) Use red & infrared laser therapy device with 4 different wavelengths in a synchronized mode:~980 nm for wound decontamination, improve circulation, lymphatic drainage~915 nm enhances O2 delivery~810 nm increases ATP production~650 nm accelerate surface healing, tissue regeneration plus traditional wound treatment mentioned before"
45371503|NCT05243875|Behavioral|Vaccine Concierge|The vaccine concierge intervention involves COVID-19 education, testing, and vaccination information in the context of living with an autoimmune disease. Participants assigned to the experimental group will also receive information on the availability of COVID-19 testing and vaccination, and if desired, study staff will arrange for testing/vaccination appointments or mailing of at-home testing kits, transportation to appointments (if requested), and follow-up of testing/vaccination status.
45371504|NCT05236764|Device|CliniMACS|Peripheral blood stem cells from closely matched unrelated donors will be processed using the CliniMACS device to remove TCRalpha/beta (alpha beta+) T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
46053344|NCT05515978|Drug|Metformin|In this study, patients on the Metformin arm will be started on 850 mg daily for 2 weeks, then escalated to a final dose of 850 mg twice daily, which is lower than the maximum recommended dose of 2550 mg total daily.
46053345|NCT05515978|Behavioral|Lifestyle Modification|"Patients randomized to this arm will receive standard lifestyle modification recommendations. This will include the general recommendation to increase exercise level mildly, after discussing with the medical provider. There is a potential low-level risk in increasing one's exercise levels.~Here are some examples of the educational material from the American Diabetes Association website, and topics will be rotated on quarterly basis:~Healthy eating: https://www.diabetes.org/nutrition/healthy-food-choices-made-easy Prediabetes: https://www.diabetes.org/diabetes-risk/prediabetes Fitness: https://www.diabetes.org/fitness/get-and-stay-fit Weight loss: https://www.diabetes.org/fitness/weight-loss"
46053346|NCT05513469|Drug|Lutathera|regulair PRRT of 4 cycles with 7.4GBq
45490066|NCT05598216|Diagnostic Test|no intervention, Serum LDL cholesterol calculation|The serum LDL cholesterol concentrations will be calculated using at least three different equations (Friedewald, Sampson, Martin-Hopkins)
45498145|NCT04109274|Behavioral|Exercise|Exercise component: Aerobic exercise, using recumbent bikes, delivered within the cancer institution. Participants will take part in up to 30-minutes of moderate intensity (50-70% HRmax or 4-6/10 on Rate of Perceived Exertion scale)6 exercise for eight sessions during chemotherapy. An exercise specialist with experience in cancer rehabilitation will supervise the exercise component.
46053347|NCT05510687|Device|Glasses to correct presbyopia|Participants will receive eyeglasses to correct presbyopia, as per the power determined in the eye examination.
46053348|NCT05501548|Drug|Olaparib|Olaparib 300mg by mouth twice daily
46053349|NCT05501548|Dietary Supplement|Vitamin C|Ascorbic acid 1g/kg administered intravenously twice weekly
45846715|NCT02894658|Procedure|Warm compresses|"Warm compresses will be applied to fellow eye and that eye will undergo daily treatment with eyelid scrubs using a warm wash cloth and no tears baby shampoo every morning and warm compresses on the eyelids for 5-10 minutes twice a day. Patients will be instructed on how to perform proper lid hygiene at the initial visit."
46053350|NCT05497973|Behavioral|E-health ecosystem of stepped psychosocial care|"Screening and monitoring: weekly administration of an emotional state thermometer. If the score is >5, participants are asked to complete the HADS. If HADS' score >10, step 2 is assigned. The same procedure is followed for steps 3 & 4. Participants remain in each step for 2 weeks, and all level changes are preceded by a videoconference with a health professional~Online psychoeducation campus: displays co-constructed videos and posts developed by health professionals and patients about LC diagnosis and treatment aspects.~Online support community: anonymous survivors with LC diagnoses are included. Professionals and patient mentors supervise and foster debate, peer support, and resolve health Q&As.~Weekly online group psychotherapy led by a clinical psychologist and composed of eight 90-minute sessions. Eligible users are placed on a waiting list, starting when 5-6 users are available."
45371508|NCT05234983|Behavioral|LifeFirst SWASTH brief advice intervention|This intervention will support tobacco cessation among patients of high-reach, low-resource community healthcare settings in Mumbai (TB clinics, dental practices, and NGO-run health centers). The intervention will also use technology to build the capacity of practitioners in these settings to use evidence-based practices in their work and allow them to network and exchange best practices with one another.
45371509|NCT05233436|Drug|PF-07265028|PF-07265028 will be administered orally
45371510|NCT05233436|Biological|Sasanlimab|Administered subcutaneously
45371511|NCT05225324|Drug|Equfina 50 mg|Equfina 50 mg tablets.
45371512|NCT05222750|Other|Pre-COVID-19|Pre-COVID-19
45371513|NCT05222750|Other|COVID-19|COVID-19
45371514|NCT05222750|Other|COVID-19 vaccination roll-out|COVID-19 vaccination roll-out
45371515|NCT05220098|Drug|TAK-280|Participants will receive TAK-280 as IV infusion.
45371516|NCT05219929|Drug|Tetracycline 500 Mg|500 mg three times daily
45371517|NCT05219929|Other|Placebo|Placebo for Tetracycline given same way as Tetracycline.
45498146|NCT04109274|Behavioral|Self-Management|Eight SM modules will be delivered to participants. They will be viewed on an iPad prior to or after the exercise component. The goal of these modules is to aid participants in developing physical activity goals and action plans to continue with between sessions, with an overarching goal of helping them reach exercise guidelines for cancer survivors and the Canadian Physical Activity Guidelines
45846716|NCT02758626|Drug|ataluren|Powder formulation
45846717|NCT02758626|Drug|Placebo|Powder formulation
45846718|NCT02587572|Biological|Peripheral Intravenous (IV) infusion of LMSCs|Peripheral Intravenous (IV) infusion of LMSCs
45846719|NCT02517684|Drug|Infliximab|
45846720|NCT02517684|Drug|Prednisolone|
45371518|NCT05210530|Combination Product|VCTX210A unit|CRISPR-Cas9 genetically modified PEC210A cells loaded into a delivery device
45846721|NCT02517684|Other|Exclusive enteral nutrition|
45371519|NCT05205382|Other|5% nicotine|Effects of e-cigarette pods (JUUL/NJOY/SREC) with 5% nicotine concentration nicotine concentration
45846722|NCT02517684|Drug|Azathioprine|
46053351|NCT05497973|Behavioral|Usual psychosocial care|Usual psychosocial care for cancer survivors at ICOHospitalet centre led by a clinical psychologist. Usual psychosocial care consists of 7 individual sessions of 45-60 minutes, with 2-3 weeks of space between sessions, based on Individual Meaning-Centered Psychotherapy (IMCP) for Patients With Advanced Cancer (Breitbart et al., 2012). Moreover, they will be offered the education materials from the 2nd step of the platform, as they are compiled on a website open to all patients and relatives.
46053352|NCT05494593|Drug|ELAPRASE|Participants will receive 0.5 milligram per kilogram (mg/kg) of body weight of ELAPRASE, intravenous, infusion for 104 weeks.
46053353|NCT05494593|Drug|Rituximab|Participants will receive 375 milligram per square meter per dose (mg/m^2/dose) of intravenous rituximab weekly for 4 weeks in 5-week cycle.
46053354|NCT05494593|Drug|Methotrexate|Participants will receive 0.4 mg/kg of methotrexate by mouth (PO) 3 times per week for 5 weeks in each cycle.
46053355|NCT05494593|Drug|Intravenous Immunoglobulin (IVIG)|Participants will receive 500 mg/kg of IVIG every 4 weeks in 5-week cycle.
46053356|NCT05492396|Device|Standard gluteus medius repair with Tapestry Biointegrative implant|Patients will undergo standard gluteus medius repair utilizing augmentation.
46053357|NCT05484349|Drug|Tizanidine Hydrochloride|Tizanidine Hydrochloride 1 mg Tid for 12 consecutive weeks and were followed up for 12 weeks
45846723|NCT02357784|Device|Neurometer|The purpose of Current Perception Threshold (CPT) testing is to help physicians better understand how Sacral Neuromodulation affects the nerves of patients with dual incontinence. CPT Testing involves the use of a portable battery-operated machine which will stimulate the subject's nerves via an electrical stimulation. Electrodes will be placed via a catheter in to the subject's urethra and rectum, and the electrical current will be increased gradually until the subject feels the onset of tingling, buzzing, or warmth at the site of the electrode. The electrical current will then gradually decrease until no sensation of stimulation is felt. The procedure will then be repeated where the subject will be asked to hold the test button to increase the stimulus intensity above their sensory threshold (above the point where they can feel it) until the device automatically shuts off.
45846724|NCT02022384|Other|Blood sample and life quality questionnaires|Blood will be drawn at distinct time points during and after radio(chemo)therapy
45371520|NCT05205382|Other|3% nicotine|Effects of e-cigarette pods (JUUL/NJOY) with 3% nicotine concentration
45371521|NCT05205382|Other|0% nicotine|Effects of e-cigarette pods (SREC) with 0% nicotine concentration
45846725|NCT01448616|Drug|TDF|Oral tenofovir will be administered as tablets. TDF (Viread®) tablets contain 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
45371522|NCT05203185|Other|Pulmonary Embolism Risk Kalculator (PERK)|Nudges are applications of behavioral science, defined as positive reinforcement and indirect suggestions that have a non-forced effect on decision making. Nudges will be to the PE CALC CDS tool to develop the new CDS tool, PERK.
45371523|NCT05202847|Procedure|pulsed radiofrequency ablation to modifined points group|Point 1 place 10mm higher than the boundary between Femur's medial epicondyle and shaft. The 2nd point is targeted 20mm above the patella. Point 3 is targeted 10mm above the femur lateral epicondyle and shaft boundary. At point 4, find the boundary position between the tibia epicondyle and the shaft in the AP view and move it superolateral by 10 mm to target the central part of the medial shaft of the tibia and perform the main touch. Point 5 targets the center of the fibular head.
45371524|NCT05202847|Procedure|pulsed radiofrequency ablation to conventional points group|Under AP view X-ray fluoroscopy, enter the cannula into the tunnel view until reaching the bone, reaching the border of the shaft and epicondyle, then stop the cannula tip at the anterior 2/3 junction in the lateral view. A total of three target points are the boundary position between the femur medial epicondyle and the shaft, the boundary position between the femur lateral epicondyle and the shaft, and the boundary position between the tibia meidal epiconcyle and the shaft. Subsequent procedure will be proceed same as Arm 1
45490067|NCT03641651|Other|Rehabilitation technology|"Series of tailored rehabilitative training with the use of new technology which provide feedback and allow for a targeted and intensive and dense training.~With supervision based on patients preconditions and therapy device (e.g. patient/ therapist ratio= 3/1).~A training series lasts four weeks and comprises 3-5 training-days per week. Maximum training break of 7 days.~Five sessions of training with duration of 45 min per session, and up to four hours each day are foreseen.~The training can take place in an outpatient or inpatient setting.~Training will be organized in individual one-to-one or group session"
45490068|NCT04728204|Behavioral|Depresijos terapija|Intervention is based on the principles of cognitive behavioral therapy and culturally adapted to elderly Lithuanian population. The main purpose of the intervention is to reduce the symptoms of depression and increase psychological well-being. Intervention contains psychoeducation, examples, exercises and consultation with a psychologist.
45490069|NCT03341299|Biological|LY900014|Administered SC
45490070|NCT03341299|Biological|Insulin Lispro|Administered SC
45490071|NCT05653960|Other|EMR or ESD|Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are two main endoscopic treatment options for colorectal neoplasms
45490072|NCT05666219|Drug|Aminophylline Injection|Injection Aminophylline IV 240 mg will be given over 10 minutes. After 1 hour, Aminophylline 240 mg second dose will be given over 10 minutes.
45490073|NCT02949271|Other|Programmed Intermittent Epidural Bolus|
46053358|NCT05484349|Drug|Tizanidine Hydrochloride|Tizanidine Hydrochloride 2 mg Tid for 12 consecutive weeks and were followed up for 12 weeks
46053359|NCT05484349|Drug|Tizanidine Hydrochloride Placebo|Tizanidine Hydrochloride Placebo Comparator 1 tablet Tid for 12 consecutive weeks and were followed up for 12 weeks
46053360|NCT05482906|Other|eGait|IMU sensor (as part of eGait device) worn at the hip during T25FW
45371525|NCT05198843|Drug|Dasatinib|Given PO
45371526|NCT05198843|Dietary Supplement|Icosapent Ethyl|Given PO
45490074|NCT02949271|Other|Continuous Epidural Infusion|
45490075|NCT02949271|Drug|Ropivacaine|
45490076|NCT02949271|Drug|Fentanyl|
45490077|NCT03732755|Device|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
46053361|NCT05474105|Dietary Supplement|Oral nutritional supplement|Daily drink 125 ml together with meal
46053362|NCT05471843|Drug|BGB-11417|Administered orally
45490078|NCT03706807|Other|Mindfulness-Based Intervention|This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol
45490079|NCT03706807|Other|Cognitive Stimulation|A basic computer workshop in order to develop the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks
45490080|NCT03640559|Drug|Seroguard|
45490081|NCT03640559|Drug|Placebos|
46053363|NCT05470244|Other|Routine Physical Therapy and Intra-venous analgesic regimen|ROM Exercises will be performed and analgesics including the NSAIDs and narcotics as per prescription of surgeon/physician will be given to all subjects
46053364|NCT05470244|Other|Transcutaneous Electrical Nerve Stimulation along with Routine Physical Therapy and Intra-venous analgesic regimen|High frequency stimulations via Transcutaneous Electrical Nerve Simulator will be applied. ROM Exercises will be performed and analgesics including the NSAIDs and narcotics as per prescription of surgeon/physician will be given to all subjects
45371529|NCT05160168|Drug|THE-630|Oral THE-630 administered once daily in a continuous regimen
45371530|NCT05153746|Device|3D colonoscopy|3D colonoscopy is a new device to enhance endoscopic imaging.
45371531|NCT05153148|Drug|NDI-034858|Randomized participants will receive NDI-034858 capsule orally
45371532|NCT05153148|Other|Placebo|Randomized participants will receive placebo orally
45371533|NCT05145413|Drug|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
45371534|NCT05145413|Drug|Placebo|Placebo Capsules
45371535|NCT05144516|Behavioral|Behavioral: COPE +|Six sixty minute sessions that teaches participants distress and communication coping skills.
45371536|NCT05143957|Drug|sapablursen|Sapablursen will be administered by SC injection.
45371537|NCT05139810|Drug|Donidalorsen|Donidalorsen will be administered by SC injection.
45490082|NCT03339583|Behavioral|Brief behavioral therapy|"program included a question-and-answer part; a didactic presentation of sleep regulation mechanisms; the review of causes of onset and chronification of illness; an examination of patient's sleep log; explanation of sleep restriction method and prescription of individual regimen of sleep; explanation of stimulus control method; sleep hygiene education; discussion of relaxation techniques. Participants were supplied with 32 minute audio recording Relaxation and refreshment session for insomnia created for this study by Dr. A.Tabidze with verbal relaxing instructions with quiet musical composition behind it. Participants were instructed to listen to this recording in headphones each day for 2-week BBT-I period after laying into bed and turning the light off."
45490083|NCT03339583|Drug|Zopiclone|zopiclone intake in a dose of 7,5 mg 30 minutes before bedtime for two weeks
45490084|NCT03639779|Drug|Sodium Thiosulfate|A volume of 0.1 ml/cm2 of STS will be injected into each lesion.
45490085|NCT03639779|Other|Saline Solution|A volume of 0.1 ml/cm2 of normal saline will be injected into the control lesion.
45490086|NCT05239195|Other|Video Laryngoscope|Laryngoscope with a camera and a video screen
45490087|NCT05239195|Other|Direct Laryngoscope|Laryngoscope without a camera or a video screen
45490088|NCT03575975|Device|Total Ankle Replacement Prosthesis|Comparison of functional range of motion in users of Stryker Scandinavian Total Ankle Replacement (STAR) prosthesis to users of INBONE 2 Total Ankle Replacement prosthesis and to matched controls with intact ankle joints.
45371538|NCT05139810|Drug|Placebo|Donidalorsen-matching placebo will be administered by SC injection.
45371539|NCT05139225|Drug|TTI-622|"(-2) 0.4 mg/kg (-1) 0.8 mg/kg~(1 ) 1.2 mg/kg (2) 2 mg/kg (3) 4 mg/kg (4) 8 mg/kg (5) 12 mg/kg~The appropriate dose of TTI-622 will be administered IV over 60 minutes, however, can be extended up to 4 hours to mitigate Infusion-related reactions."
45371540|NCT05139225|Drug|Daratumumab Hyaluronidase-fihj|Daratumumab hyaluronidase-fihj SC 1800 mg days 1, 8, 15, and 22.
45371541|NCT05132829|Drug|Azithromycin 1 gram IV|Perioperative addition of azithromycin at the time of physical exam indicated cerclage placement.
45371542|NCT05132829|Drug|Cefazolin and indomethacin|Perioperative standard of care with cefazolin and indomethacin
45371543|NCT05126355|Behavioral|On the Move group exercise|The OTM exercise program is a group-based program led by a certified OTM instructor. The frequency and duration of OTM is 50 minutes, twice weekly for 12 weeks for a total of 24 classes. The OTM exercise program is based on principles of motor learning that enhance smooth and automatic movement control. The program contains a warm-up (5 minutes), stepping patterns (15 minutes), walking patterns (15 minutes), strengthening exercises (10 minutes), and cool-down exercises (5 minutes). The warm-up and cool down contain gentle range of motion exercises and stretches for the lower extremities and trunk. Considered essential components, the stepping and walking patterns are progressively more difficult, goal-oriented patterns that promote the timing and coordination of stepping integrated with the phases of the gait cycle.
45490089|NCT05174923|Behavioral|Short Performance Physical Battery (SPPB Test)|The SPPB includes balance stands, a 4-meter walk and 5 timed chair stands.
45490090|NCT05174923|Behavioral|30 Second Chair Stand Test (30CST)|The 30CST measures the number of times a person can rise from a seated to standing position within 30 seconds.
45490091|NCT05174923|Behavioral|Hand grip dynamometry|Grip strength is used as a marker of overall muscle strength.
45490092|NCT03636893|Drug|FLOT Chemotherapy|5-FU+Leucovorin+Docetaxel+Oxaliplatin
45490093|NCT03636893|Drug|SOX Chemotherapy|Oxaliplatin+Tegafur gimeracil oteracil potassium capsule (TGO)
45490094|NCT05174689|Diagnostic Test|Exercise challenge in the cold chamber (ECC)|Exercise challenge (defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber. Gradient: 10%, temperature 2-4°C. After the exercise challenge controlling bodyplethysmography and spirometry after 5, 10, 15 and 30 minutes. A positive reaction is a decrease of ≥ 10% of FEV1 in comparison to the initial value.
45846726|NCT01448616|Drug|Placebo Vaginal Gel|"Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.~The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects - negative or positive - on study endpoints."
45371544|NCT05122689|Dietary Supplement|Nitrate|Dietary inorganic nitrate (0,12 mmol sodium-nitrate/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
45371545|NCT05122689|Dietary Supplement|Control|Dietary sodium-chloride (0,12 mmol sodium-chloride/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
45371546|NCT05117450|Device|Decrease per-dialytic heparin therapy|Decrease per-dialytic heparin therapy with the HYDROLINK membrane (dialyzer NV-21U, surface 2.1m², Toray industry, Tokyo, Japan) and with the HeprAN membrane (dialyzer Evodial 2.2, surface 2.15 m2, Hospal SAS, Meyzieu, France)
45753538|NCT03969680|Biological|Auotologous BMSCs plus autologous PRP|30 mL of bone marrow will be aspirated from the iliac crests of patients in case group. BMSCs will be isolated from bone marrow and cultured. Before injection, 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation. Cultured BMSCs will be collected and suspended by 3ml autologous PRP.
45753539|NCT03969680|Biological|Auotologous PRP|30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.
45753540|NCT04199312|Device|The ZELTIQ System|The MMS device will be used to perform the treatments.
45753541|NCT00518089|Drug|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
45371547|NCT05104450|Behavioral|lifestyle intervention|Intervention Arm: Usual Care plus a lifestyle behavior change intervention aimed at improving eating habits and increasing physical activity. The lifestyle behavior change intervention encourages participants to gradually achieve and maintain a 5-10% loss of baseline body weight and at least 150 minutes of moderate-intensity physical activity, such as brisk walking, each week. The lifestyle intervention program consists of watching one video, completing corresponding written self-guided learning materials, and tracking food intake and physical activity each week for the first 12 weeks, then working through 10 additional written handouts and continued food and activity tracking for the next nine months. Intervention participants will have access to a lifestyle coach as desired for the full 12-month intervention period.
45490095|NCT05174689|Diagnostic Test|mRNA profile|Blood taking with full blood exam and PAXgene tube for investigation oft the micro RNA profiles. The PAXgene Blood RNA kit insulates total RNA inclusive miRNA and small RNA which are centrifugated, pelletised, washed and incubated to detach proteins. For mapping the particular miRNA there will be generated libraries with specifical codes to match the analysis to the original probe. Next generation sequencing will be performed by MISeq REagent Kit v3 and the analysis oft the different expressions in the R Version 3.2.3. The divergent expressions will be refurbished by computer and databased.
45490096|NCT05174689|Diagnostic Test|standard diagnostic|bodyplethysmography, spirometry, exhaled NO, skin prick test, asthma control test (ACT)
45371548|NCT05102669|Other|analysis of immunological response|collection and analysis of SARS-CoV2 Spike specific blood cells
45371549|NCT05102669|Diagnostic Test|analysis of serum antibodies|analysis of anti-SARS-CoV2 Spike specific antibodies
45371550|NCT05099874|Device|EndeavorRx|EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.
45371551|NCT05097989|Drug|ALXN2050|Oral tablets
45371552|NCT05097989|Drug|Placebo|Oral tablets
45371553|NCT05094089|Device|Hernia repair with mesh|Hernia repair with GORE® SYNECOR Biomaterial; technical approach laparoscopic, robotic or open surgical / minimally invasive surgery
45371554|NCT05090566|Drug|Elranatamab + Nirogacestat|BCMA-CD3 bispecific antibody + gamma secretase inhibitor
45371555|NCT05090566|Drug|Elranatamab + lenalidomide + dexamethasone|BCMA-CD3 bispecific antibody + immunomodulatory
45371556|NCT05079919|Drug|Olezarsen|Olezarsen will be administered by SC injection.
45371557|NCT05079919|Drug|Placebo|Olezarsen-matching placebo will be administered by SC injection.
45371558|NCT05077735|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
45371559|NCT05077735|Other|Quality-of-Life Assessment|Ancillary studies
45490097|NCT03729635|Procedure|Pectoral-intercostal fascial plane block (PIFB)|Local anesthetic is infiltrated into the fascial plane between pectoralis major and the intercostal muscles lateral to the sternum to anesthetize the anterior cutaneous branches of the intercostal nerves.
45490098|NCT05682547|Drug|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
45490099|NCT05682547|Drug|0.1% hyaluronate|0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
45490100|NCT05581693|Drug|L04RD1|1 tablet of L04RD1
45490101|NCT05581693|Drug|L04TD2|1 tablet of L04TD2
45490102|NCT05581693|Drug|L04TD2|1 tablet of L04TD2
45846727|NCT01448616|Drug|Vaginal TFV Gel|Tenofovir 1% gel (w/w) is a gel formulation of tenofovir. Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.
46053365|NCT05458323|Device|Free near and Distance Vision glasses|Intervention Description: All participants randomised to the intervention group will be provided with free near and/or distance spectacles based on the results of refraction.
45371560|NCT05077735|Other|Questionnaire Administration|Ancillary studies
45371561|NCT05071300|Drug|Eplontersen|Eplontersen will be administered by SC injection.
45371562|NCT05063357|Drug|131I-Omburtamab|Omburtamab is a murine IgG1 monoclonal antibody, recognizing CD276 (also known as B7-H3).
45371563|NCT05063357|Device|Convention Enhanced Delivery|The planned intervention includes surgical placement of a small caliber cannula into the tumor located in the pons using standard stereotactic techniques followed by CED of 131Iomburtamb.
45371564|NCT05050448|Device|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.
45371565|NCT05050448|Drug|1% Diclofenac Topical Gel|Topical pain-relief gel
45371566|NCT05035212|Biological|RSVpreF|RSV vaccine (RSVpreF)
45371567|NCT05035212|Biological|Placebo|Placebo
46053366|NCT05455476|Behavioral|CBT for Loneliness|CBT delivered over the course of 8, ~45 minute sessions delivered via telehealth more centrally focused addressing factors contributing to loneliness and social isolation.
46053367|NCT05455476|Behavioral|CBT for Chronic Pain|CBT delivered over the course of 8, ~45 minute sessions delivered via telehealth broadly focused on increasing quality of life despite being in pain.
45371568|NCT05030935|Device|mHealth App|In short, mHA contains three main functions for the user: a) a reminder for switching the patient position, b) training for preventive care habits and c) the possibility for patient evaluation in order to determine the need for the use of support surfaces.
45371569|NCT05027971|Device|Flexiva Pulse High Power Single-Use Laser Fibers|Flexiva Pulse High Power Single-Use Laser Fibers are intended to be used as a device that transmits Ho:YAG laser energy from cleared laser consoles to urological anatomy.
45371570|NCT05016245|Combination Product|TheraSphere™ Yttrium-90 Glass Microspheres|"TheraSphere™ Yttrium-90 Glass Microspheres TheraSphere™ is steam sterilized and supplied in 6 standard dose sizes: 3 GBq, 5 GBq, 7 GBq, 10 GBq, 15 GBq, 20 GBq. Custom dose sizes are also available in 0.5 GBq increments between 3 and 20 GBq.~TheraSphereTM is supplied with the following accessories:~Administration Set Administration Accessory Kit"
45371571|NCT05016245|Procedure|conventional Transarterial Chemoembolization(cTACE)|conventional Transarterial Chemoembolization(cTACE) is comprised of an anti-neoplastic agent(s) (i.e. cisplatin), lipiodol and embolic agent(s). The choice of agent(s) to be used is per usual local site practice. Chemotherapy agents can be as a single agent or used in combination, as per local practice.
45371572|NCT05013385|Drug|Spesolimab|Spesolimab
45371573|NCT05013385|Drug|Placebo|Placebo
45371574|NCT05005650|Procedure|debulking surgery|debulking surgery as primary debulking surgery or interval debulking surgery
45371575|NCT04993742|Behavioral|MOMS Intervention|Behavioral: Mentors Offering Maternal Support (M-O-M-S) 10, 1 hour, structured classes meeting every-other-week in person beginning in the first trimester of pregnancy and unlimited access to mentor support.
45371576|NCT04982198|Procedure|ROSA assisted TKA|Robotic assisted total knee arthroplasty
45371577|NCT04956250|Other|Traffic Calming Curbs|Temporary curb extensions, placed at intersections.
45371578|NCT04956250|Other|In-Street Pedestrian Sign|Yield sign placed in middle of road at intersection.
45371579|NCT04949256|Drug|Pembrolizumab|400 mg once every 6-week-cycle, via IV infusion.
45371580|NCT04949256|Drug|Lenvatinib|8 mg QD (induction) or 20 mg QD (consolidation) via oral capsule.
45490103|NCT05581693|Drug|L04RD1|1 tablet of L04RD1
45371581|NCT04949256|Drug|Cisplatin|80 mg/m^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 75 mg/m^2 Q3W via infusion, as part of investigator's choice TP chemotherapy.
45371582|NCT04949256|Drug|5-FU|4000 mg/m^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m^2 Q2W via bolus IV infusion followed by 2400 mg/m^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.
45371583|NCT04949256|Drug|Oxaliplatin|85 mg/m^2 Q2W via IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.
45490104|NCT05568121|Drug|L04RD1|1 tablet of L04RD1
45490105|NCT05568121|Drug|L04TD1|1 tablet of L04TD1
45490106|NCT05568121|Drug|L04TD1|1 tablet of L04TD1
45490107|NCT05568121|Drug|L04RD1|1 tablet of L04RD1
45490108|NCT01353586|Device|nMARQ™ System|The nMARQ™ System is indicated for catheter-based electrophysiological mapping for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillatioon.
45490109|NCT03708289|Radiation|DXA scan|total and hip and spine dual energy x-ray absorptiometry
45846728|NCT01448616|Drug|Placebo Tablets|TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
45371584|NCT04949256|Drug|Leucovorin|400 mg/m^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
45371585|NCT04949256|Drug|Levoleucovorin|200 mg/m^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
45490110|NCT03708289|Other|Achilles bone US|
45490111|NCT03708289|Other|Medical body composition measurements|
45371586|NCT04949256|Drug|Paclitaxel|175 mg/m^2 Q3W via IV infusion, as part of investigator's choice TP chemotherapy.
45371587|NCT04946344|Behavioral|Diet & Exercise|Participants will attend exercise and diet classes.
45371588|NCT04946344|Behavioral|Attention Control|Participants will attend healthy living classes and receive phone calls/emails/texts.
45371589|NCT04943328|Device|Total Hip Arthroplasty|cemented hip arthroplasty
45371590|NCT04932109|Other|No intervention|No intervention in this group
45371591|NCT04931251|Behavioral|Financial Navigation|providing financial navigation for cancer patients in NC to identify available financial assistance resources to assist patients with the cost of cancer
45490112|NCT03708289|Other|Resting energy expenditure measurement|
45371594|NCT04922606|Diagnostic Test|US ot the GSV|Ultrasound of the Great Saphenous Vein
45371595|NCT04919226|Drug|177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT|Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-edotreotide with a defined number of cycles will be administered.
45371596|NCT04919226|Drug|CAPTEM (Capecitabine and Temozolomide)|Best standard of care treatment (investigator's choice [from the protocol comparator list]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
45371597|NCT04919226|Other|Amino-Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
45490113|NCT05173441|Biological|Human COVID-19 immunoglobulin (pH4) for intravenous injection|The initial infusion rate is 0.01 ~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute.
45490114|NCT05173441|Drug|Placebo|The initial infusion rate is 0.01 ~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute
45490115|NCT05682469|Behavioral|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~All participants will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
45371598|NCT04919226|Drug|Everolimus|Best standard of care treatment (investigator's choice [from the protocol comparator list]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
45490116|NCT05682469|Behavioral|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
45490117|NCT03706651|Device|Infants hospitalized in health facilities performing Tele-expertise|
45490118|NCT05682313|Diagnostic Test|Elastography arm|Renal ultrasound elastography to detect and classify the degree of fibrosis
45371599|NCT04919226|Drug|FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)|Best standard of care treatment (investigator's choice [from the protocol comparator list]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
45371600|NCT04916990|Behavioral|CARES Intervention|Nurse navigators and masters levels counselors will meet with participants up to 10 times each (10 navigation and 10 counseling) over a 6 month period. The number of sessions will be determined by the length of the patient's treatment. The timing of each session will be guided by a regular assessment to reduce the time from diagnosis to initiation of treatment and the time between subsequent treatments. Sessions will occur at key transition points during treatment to target the factors associated with treatment delays, reduced Quality of Care and poor Patient Reported Outcomes
45490119|NCT03708133|Drug|Nifurtimox (Lampit, BAYA2502)_Test|Orally intake of 1 *120mg new formulation tablet as test treatment
45490120|NCT03708133|Drug|Nifurtimox (Lampit, BAYA2502)_Reference|Orally intake of 1 *120mg current clinical formulation tablet as reference treatment
45753542|NCT00518089|Drug|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
45753543|NCT02985242|Drug|Empagliflozin|Empagliflozin film-coated tablet
45753544|NCT02985242|Drug|Glimepiride|Glimepiride tablet
45846729|NCT01320696|Biological|Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine|Two intramuscular vaccinations; 5 dose groups: 3.75 µg, 7.5 µg, 15 µg, 30 µg or 45 µg HA antigen (strain A/H9N2/chicken/Hong Kong/G9/97; non-adjuvanted formulation
45846730|NCT00853632|Device|CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES|Mitral valve replacement
45846731|NCT00074412|Drug|Nevirapine|10 mg/ml oral suspension taken once daily up to 6 months of age. Dosage will increase throughout study.
45846732|NCT00074412|Drug|Nevirapine placebo|Oral suspension taken once daily up to 6 months of age
45846733|NCT02618772|Drug|Midazolam|Intranasal administration of midazolam at dose of 0.4mg/kg (max 10 mg) one time 10 minutes prior to laceration repair
45846734|NCT02618772|Drug|Saline|Intranasal administration of saline at a dose of 0.08ml/kg (max 2ml) one time prior to laceration repair as a placebo
45371603|NCT04913701|Other|Observation group 1|Subjects will be followed with 3 swabs and serological test
45371604|NCT04905069|Device|SpaceOAR Vue System|"The SpaceOAR Vue System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the SpaceOAR Vue System to reduce the radiation dose delivered to the anterior rectum.~The SpaceOAR Vue System is composed of biodegradable material, maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time."
45371605|NCT04899388|Procedure|Pericapsular Nerve Block|regional anaesthia
45371606|NCT04899388|Procedure|Lumbar Erector Spinae Plane Block|regional anaesthia
45371607|NCT04899388|Drug|Fentanyl|intavenous
45371608|NCT04893018|Biological|Efineptakin alfa|Given IM
45490121|NCT05075161|Drug|Pirfenidone|From days 1-7: 801mg/day; from days 8-14:1602mg/day, from day 15 to ICU discharge 2403 mg/day. All drugs will be delivered by a nasogastric tube divided in 3 daily doses.
45490122|NCT05075161|Drug|Placebo|All drugs will be delivered by a nasogastric tube divided in 3 daily doses.
45490123|NCT05073055|Procedure|İnguinal Hernia Repair|After hemodynamic stability, the patient was placed in the lateral position and infiltration anesthesia with 2% lidocaine was applied. Following aseptic preparation of the skin and probe, a medium-frequency curvey USG transducer was first placed in the midline to visualize the transverse projection of the first lumbar (L1) vertebra, then moved 2.5 cm laterally in the parasagittal plane, after imaging the transverse process, in-plane spreading was injected. Hydrodissection was achieved on the TP of L1 by using a 5 cm, 21G peripheral nerve block needle just below the erector spina muscle with real-time imaging of the substance. Afterwards, a unilateral injection of 15 ml at T12 and L1 levels was applied to each segment with the needle directed at two different angles from the same insertion point.
45490124|NCT03706573|Drug|alpelisib|50 mg and 200 mg film coated tablets administered orally once daily. Starting dose is 350 mg daily. Starting dose as a combination agent with endocrine partner is 300mg daily.
45490125|NCT05141227|Procedure|Two-stage Open reduction and internal fixation ( ORIF) using plates & screws|Two stage ORIF using initially temporary spanning fixator then conversion to plates & screws
45490126|NCT05141227|Procedure|single-stage external fixation (EX.FIX.) with minimal internal fixation using cannulated screws if needed|Single stage Ex.Fix. Using illizarov & minimal fixation of the articular surface using cannulated screws through mini open approaches
45371612|NCT04887571|Other|No Intervention - Observational Registry|All consecutive adult patients in the Cape Metropole and the Garden Route Health District with an Acute coronary syndrome (STEMI, NSTEMI, Unstable Angina) will be recruited into the PERFUSION Registry.
45490127|NCT05518357|Biological|LILRB4 STAR-T|Subjects with relapsed/refractory acute myeloid leukemia will be enrolled in the study, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#1E7 cells/kg。
45846735|NCT02619396|Procedure|Combination 1 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|20 W RF power and target LSI = 4 on LA posterior wall
45846736|NCT02619396|Procedure|Combination 2 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|40 W RF power and target LSI = 4 on LA posterior wall
45846737|NCT02619396|Procedure|Combination 3 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|20 W RF power and target LSI = 5 on LA posterior wall
45846738|NCT02619396|Procedure|Combination 4 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|40 W RF power and target LSI = 5 on LA posterior wall
45371613|NCT04880785|Drug|Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]|change of current antiretroviral treatment to DTG 50 mg/3TC 300 mg QD
45371614|NCT04878601|Other|Home-Based ART|Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and ART initiation with a 30-day supply. Monthly home-based ART follow-up visits with male-specific messaging and 30-day supply distribution will take place for 3-months. At 4-months providers will provide assisted linkage to a nearby facility to join the facility-based ART program. Additional counseling will be provided.
45371615|NCT04878601|Other|Facility-Based ART|Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and assisted linkage to a nearby facility for facility-based ART initiation and continuation. Male clients will receive a 30-day supply each visit and return monthly.
45371616|NCT04876586|Procedure|Lumbar fusion|Transforaminal Lumbar Interbody Fusion of the SPECT/CT positive degenerative disc disease
45490128|NCT03706495|Behavioral|The Group I Postural Exercise|Spine anatomy and daily life activities will be informed about proper posture. Strengthening of postural muscles, stretching (Pectoral Region, M. Psoas Major) and breathing exercise will be performed under the supervision of a physiotherapist. The Group I will receive postural exercise for 60 min/day 2 times/week for 8 weeks.
45490129|NCT03706495|Behavioral|The Group II Three-dimensional Exercise Therapy Program|The Group II Schroth method corrects the kyphotic posture, with the help of proprioceptive and exteroceptive stimulation and mirror control in the sagittal plane, using specific corrective breathing patterns. The Schroth method three-dimensional exercise therapy program adapted for the specific posture will be exercised in four specific positions (sitting, supine, standing, prone) under the supervision of a physiotherapist. Exercise include, trunk elongation, symmetrical sagittal straightening, shoulder traction, corrective breathing and muscle activation by increasing tension (isometric tension). The Group II will receive Schroth's three-dimensional exercise therapy program for 60 min/day 2 times/week for 8 weeks.
45498147|NCT04109274|Behavioral|Booster Sessions|Four booster sessions will be provided to participants in this group. These will occur at 2, 4, 6, and 8 months post intervention completion. An assessor trained in behavioural counselling will provide booster sessions by phone and will discuss the individuals physical and emotional condition, current exercise level, accomplishment of previously set goals and action plans, and perceived barriers to participation in exercise. The assessor will use facilitation strategies to aid participants in devising strategies to overcome barriers and set realistic goals and action plans.
45846739|NCT02620878|Device|artificial pancreas|Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence.
45846740|NCT02620878|Other|sensor augmented pump|During this control period (comparator arm) the patients will use sensor augmented pump. This period will be compared to the same period of artificial pancreas
46053368|NCT05452551|Other|Myotonometric measurement|MyotonPRO is a non-invasive myotonometer used to evaluate the viscoelastic properties of soft tissues. Data collection will be carried out by three researchers experienced in the use of myotonometer. Before the evaluations, participant and repeated measurement information for both researchers will be recorded on the device. All assessments will be made bilaterally. The first researcher will perform two measurements 30 minutes apart from the measurement point standardized with MyotonPRO to evaluate the plantar mechanical properties. Then, the second researcher will take two measurements with MyotonPRO from the same point with 30 minutes intervals. One day later, the first researcher will measure again from the same reference point once.
46053369|NCT05449548|Drug|Lenalidomide 10 mg|All subjects will be treated with lenalidomide 10mg/day with a regular follow-up of 12 weeks, followed by a 4-week observation after cessation of lenalidomide.
45371617|NCT04874246|Drug|Vasopressin|During robot-assisted laparoscopic myomectomy, vasopressin diluted to different concentrations will be injected before uterine serosal incision.
46053370|NCT05443438|Behavioral|Modality - 3D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and generalization as 2D
46053371|NCT05443438|Behavioral|Modality - 2D-3D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 3D
45371620|NCT04865731|Drug|Dermaprazole|Patients will be managed with twice daily prophylactic use of the proposed intervention (Dermaprazole) topical cream for radiation dermatitis. The amount of cream will be 2cc per application and will be measured in pre-filled capped syringes for every application.
45371621|NCT04865731|Drug|Aquaphor|Patients will be managed with twice daily prophylactic use of Aquaphor. The amount of Aquaphor will be 2cc per application and will be measured in pre-filled capped syringes for every application.
45371622|NCT04853017|Drug|ELI-002 2P|Amph-CpG-7909 admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
45846741|NCT02621892|Drug|Tenapanor|
45846742|NCT02621892|Drug|Placebo|
45490130|NCT05095831|Diagnostic Test|Pancreas EUS shear wave|"EUS Shear wave elastography (SWE) is a form of ultrasound elastography used in transabdominal ultrasonography. It measures tissue elasticity by generating shear waves inside the organ using the acoustic radiation force impulse (ARFI). The ultrasound machine monitors shear wave propagation and measures the velocity. The shear wave velocity, displayed in kilopascals [kPa] or meters per second. Also, the dispersion slope or ultrasound shear wave dispersion (SWD) will be recorded. It is the measure of viscosity [(m/sec)/kHz] using SWE.~A first endoscopist will perform EUS over pancreas tissue. Without any elastography assessment (strain ratio/histogram) , the endoscopist will take ten shear wave measurements of pancreas tissue elasticity by generating shear waves inside the pancreas using the ARFI."
45498148|NCT02451111|Drug|Ibrutinib|Patients will be instructed by the Investigator to take the amount of 560 mg Ibrutinib/Placebo (4 x 140 mg capsules) orally once daily with a glass of water at approximately the same time every day.
45371625|NCT04847466|Drug|N-803|N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every 4 weeks (1 week after starting treatment with the PDL-1 CAR-NK cells).
45371626|NCT04847466|Drug|Pembrolizumab|Pembrolizumab 400 mg will be administered as a 30-minute IV infusion every 6 weeks. Pembrolizumab will be administered on the same day as the PD-L1 CAR-NK cells.
45371627|NCT04847466|Biological|PD-L1 t-haNK|PD-L1 CAR NK cells (2x109) will be administered by IV infusion over approximately 30 minutes every week. After the week 6 treatment, these cells will be given every 2 weeks.
46053372|NCT05443438|Behavioral|Modality - 2D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 2D
46053373|NCT05442606|Other|Ultrasound Therapy|Using an Enraf Nonius Sonoplus 490 from the Netherlands, the patients were asked to lie supine while the therapist stood at the level of the patient's head. The patients received pulsed (duty cycle 50%) US therapy with intensities of 1 and 0.5 W/cm2 for maxillary and frontal sinus, respectively, and a collimating beam frequency of 1MHz. To deliver US to the treatment area, a small probe US applicator (0.8 cm2) with an effective radiating area (ERA) of 0.6 cm2 and a beam non-uniformity ratio (BNR) of 6:1 was used. The skin around the cheeks was used for the maxillary sinus and the forehead for the frontal sinus. Between the applicator and the skin, ultrasound transmission gel was employed, and a full contact technique in slow circular motion was used for 5 minutes over the maxillary sinuses and 4 minutes over the frontal sinuses on each pair of sinuses
46053374|NCT05442606|Other|Manual Drainage Techniques|Manual Drainage Techniques for the frontal and maxillary sinuses
45846743|NCT02624700|Drug|Experimental Arm A: Pemetrexed|Treatment schedule is administered on day 1 of each 14-day cycle by Intravenous infusion over 10 minutes with a dose of 500 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
45490131|NCT05095831|Diagnostic Test|Pancreas EUS-elastography and EUS-guided biopsy|"Pancreas EUS-elastography measures the pancreatic tissue stiffness through strain ratio (SR) and strain histogram (SH).~A second endoscopist blind to pancreas tissue shear wave findings will perform EUS-elastography with corresponding SR and SH measurements. The SR/SH will be measured and documented. Finally, a pancreas tissue biopsy will be performed. The impossibility of biopsy is an exclusion criterion (except in control patients). Due to ethical purposes, a biopsy will not be performed on patients from the control group."
45490132|NCT03638869|Drug|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 25 mg, 50 or 75 mg REL-1017 for 10 days, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL.
45846744|NCT02624700|Drug|Experimental Arm A: Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 14-day cycle with a dose of 400 mg.
45846745|NCT02624700|Drug|Experimental Arm B: Pemetrexed|Treatment schedule is administered on day 1 of each 21-day cycle by Intravenous infusion over 10 minutes with a dose of 375 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
46053375|NCT05442606|Other|Self Sinus Massage Technique|Patients will also encouraged to self-massage their frontal and maxillary sinuses while resting supine
46053376|NCT05441618|Device|Lyoplant®|replacement and extension of connective tissue structures in neurosurgery
45490133|NCT03638869|Drug|Placebo|
45490134|NCT03708055|Behavioral|Exercise Intervention|Undergo weight bearing exercise program
45490135|NCT03091920|Drug|IW-1973|Oral Tablet
45490136|NCT03091920|Drug|Placebo|Oral Tablet
45490137|NCT03338569|Drug|Vitamin C|Continuous infusion of vitamin C
45490138|NCT03338569|Drug|Placebo|Placebo designed to mimic intervention
45490139|NCT03338023|Drug|LY2963016|Administered SC
45490140|NCT03338023|Drug|Lantus®|Administered SC
45846746|NCT02624700|Drug|Experimental Arm B: Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 21-day cycle with a dose of 200 mg.
45846747|NCT02625402|Behavioral|Brief interactive decision aid|The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
45846748|NCT02625402|Behavioral|Long video decision aid|Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
45846749|NCT02627118|Device|FRESENIUS 160NR|2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR DIALYZER
45846750|NCT02627118|Device|NIPRO ELISIO-15H|2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H DIALYZER
45846751|NCT02631954|Drug|Vorico Injection 200mg(Voriconazole)|Vorico Injection 200mg(Voriconazole) to administered intravenously once
45846752|NCT02631954|Drug|Vfend®(Voriconazole) IV 200mg|Vfend®(Voriconazole) IV 200mg to administered intravenously once
45846753|NCT02632812|Drug|Rebamipide effervescent granules|Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
45846754|NCT02632812|Drug|Placebo effervescent granules|Placebo effervescent granules (oral), twice daily for 7 days
45846755|NCT02632812|Drug|Naproxen tablet|Naproxen tablet 550mg (tablet), twice daily for 7 days
45846756|NCT02633358|Device|Therapeutic hypothermia group|Therapeutic hypothermia
45490141|NCT03338023|Drug|Insulin Lispro|Administered SC
45490142|NCT05053633|Procedure|Combined spinal epidural anesthesia|Apply combined spinal epidural anesthesia
45371635|NCT04813159|Device|Remote Ischaemic Conditioning (RIC)|The RIC protocol will comprise inflation of the automated RIC device to 20 mmHg above systolic blood pressure for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total. The RIC protocol will be repeated daily for the next 2 days.
45490143|NCT05094115|Behavioral|Psychological Flexibility Training (PFT)|"A 2-day workshop lasting approximately 8 hours per day. Day 1: an overview of the training and to describe the posture or stance that prepares one to respond to challenging situations in a psychologically flexible manner.~Day 2: identifies common coping strategies that typically fail or even backfire over the long term and to practice skills that promote psychological flexibility. Experiential exercises will be integrated throughout the training.~Following the PFT, 4 optional, monthly, one-hour booster sessions to supply refresher information.~An experiential exercise to highlight one or more process/concept that was introduced during the 2-day training.~Questions from the attendees about applying the concepts in their lives.~Comments and questions from the booster session facilitators to encourage application of the concepts."
45371636|NCT04813159|Device|Sham-control|The sham protocol will comprise low-pressure inflation to 20 mmHg for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total by a visually identical pneumatic cuff used in the active arm. The sham control protocol will be repeated daily for the next 2 days.
45371637|NCT04808869|Other|Exercise|Cycling 3 times a week for 15 minutes at 70 rpm using blood flow restriction cuffs at different occlusions.
46053377|NCT05440097|Other|QIP intervention|"The QIP includes pulmonologist-targeted guideline education and guideline implementation.~Guideline education includes the initial comprehensive training and reinforcement learning. The initial comprehensive education will be delivered at each participating hospital by a dedicated national asthma expert team, immediately after last patient enrolled at each site. The PI of respiratory departments from participating hospitals are responsible for arranging the delivery of hospital-level reinforcement learnings and ensuring the quality and success of hospital-level guideline implementation.~The pulmonologists' guideline adherence and performance at participating hospitals will be regularly assessed during the study period."
45371639|NCT04793958|Drug|MRTX849|28 Day Cycle
45371640|NCT04793958|Biological|Cetuximab|28 Day Cycle
45371641|NCT04793958|Drug|mFOLFOX6 Regimen|"Fluorouracil~Oxaliplatin~Folinic acid"
45371642|NCT04793958|Drug|FOLFIRI Regimen|"Fluorouracil~Irinotecan~Folinic acid"
45371643|NCT04782167|Behavioral|BRACE|"Balance training,Static balance:~Romberg with eye open & eye close [30 sec repeat 3 times]~Tandem standing with eye open then with eye close. Right foot front first, then left foot front [10 Sec repeat 3 times]~Single leg stance 5 repetition with sec.~Static/Dynamic/Anti-cipatory Postural Control:~Sit to stand: 5 repetition~Functional reach test: forward, sideways & cross reach, practice 1 min for each~TUG test: with distance of 10 feet & time 10 sec. practice 2 min Cognitive exercises~1) Count reverse from 50 Repeat with eyes open and close Reps of 30s for each 2) Push wall and reverse count from 20 3) Remember 5 words, Name 5 animals, Repeat 5 words"
45371644|NCT04782167|Behavioral|Propirioceptive training|1st Phase - Steady phase (1st set: Eyes Open, 2nd set: Eyes Close) Preserve standup position Equally heels up and down Preserve standup on one leg by turns
45371645|NCT04781088|Drug|Lenvatinib|Given PO
45371646|NCT04781088|Drug|Paclitaxel|Given IV
45371647|NCT04781088|Biological|Pembrolizumab|Given IV
45490144|NCT03337477|Drug|Placebo|Suspension administered orally for a treatment period of 24h. 2 sachets administered up to three times over 10h (at 0, 4 and 10h).
45490145|NCT03337477|Drug|Sodium Zirconium Cyclosilicate(ZS)|Suspension administered orally for a treatment period of 24h. Single dose contains 2 sachets of ZS 5g. 10g administered up to three times over 10h (at 0, 4 and 10h).
45490146|NCT03337477|Drug|Insulin|Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
45490147|NCT03337477|Drug|Glucose|Glucose 25g administered IV <15 minutes before the insulin.
45490148|NCT03337477|Drug|Insulin|Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
45490149|NCT03337477|Drug|Glucose|Glucose 25g administered IV <15 minutes before the insulin.
46053378|NCT05438264|Drug|Donepezil|acetylcholinesterase inhibitor
46053379|NCT05438264|Drug|Placebo|placebo
46053380|NCT05425797|Other|In-Person Prevention Practitioner Visit|BETTER Intervention visit with PP which will take place in-person at the PP's office.
46053381|NCT05425797|Other|Video-Call Prevention Practitioner Visit|BETTER Intervention visit with PP which will take place virtually via a secure video system.
45846757|NCT02634684|Drug|Dextroamphetamine|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
46053382|NCT05425797|Other|Phone Prevention Practitioner Visit|BETTER Intervention visit with PP which will take place via telephone.
46053383|NCT05424341|Other|Muscle Energy Technique|For Gastrocnemius muscle, subject will be in supine position keeping knee fully extended and therapist on affected side in walking position. The subject's ankle joint will be dorsiflexed until a resistance feel and will ask to hold this position and exert 20% of force towards plantar flexion for a period of 5 to 7 seconds. Resistance will be released and relaxation of 5 seconds will be given during which the ankle will was passively dorsiflexed to a new barrier. 5 repetitions will be given.
45371648|NCT04778046|Drug|Hyperpolarized 129Xe|Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),
45371649|NCT04777006|Behavioral|Problem Management Plus|"PM+ is a cognitive-behavioral intervention that trains recipients to improve their management of practical problems, and uses the term problem management rather than problem solving to emphasize that many problems encountered by individuals living in adverse circumstances may not be solvable. The plus in PM+ underscores additional evidence-based behavioral strategies incorporated into the model, including: stress management strategies, behavioral activation, and social support strengthening. In total, PM+ comprises five sessions held once per week for 1.5. to 2.5 hours per session. The model has shown success in reducing depression symptoms in low-resource settings such as Nepal and Pakistan.4"
45753545|NCT02985242|Drug|Empagliflozin placebo|Placebo tablet manufactured to mimic Empagliflozin 25 mg film-coated tablet
45753546|NCT02985242|Drug|Glimepiride placebo|Placebo tablet manufactured to mimic Glimepiride 2 mg tablet
45371650|NCT04777006|Drug|Antidepressant Therapy|"Fluoxetine, a serotonin selective reuptake inhibitor (SSRI), and amitriptyline, a tricyclic antidepressant (TCA), are part of Malawi's national formulary. Neno District supply chain is supported by PIH, which reduces stock-outs relative to those observed in other Malawian settings. Fluoxetine is typically the first drug of choice because it is safer and better tolerated.~Daily dose will commence at 20 mg of fluoxetine, or 25 mg of amitriptyline. At monthly follow-up visits, a dose increment or medication change may be considered based on measures of treatment response and side effects, using an Antidepressant Side Effect Checklist. This algorithm-based process will be repeated every other week until the patient is fully responding to treatment (PHQ-9 < 5) for a period of three months. Dose escalations of more than one increment and medication changes will be reviewed with the doctor-in-charge. If on ADT at end of study, it will be sustained as part of usual care."
45371651|NCT04776252|Drug|MK-8591A|FDC tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for 96 weeks
45371652|NCT04766086|Biological|Multivalent Group B streptococcus vaccine|Multivalent Group B streptococcus vaccine
45371653|NCT04766086|Biological|Tetanus, diphtheria, and acellular pertussis vaccine|Tetanus, diphtheria, and acellular pertussis vaccine
45371654|NCT04766086|Biological|Placebo|Saline control
45371655|NCT04753697|Drug|CC-93538|Subcutaneous
45371656|NCT04753697|Other|Placebo|Subcutaneous
45371657|NCT04751435|Other|Cognitive interview|Researchers will use formative methods to adapt our previously-developed mainstreaming pre-genetic test educational materials plus standard post-test clinical communication materials used by the MSK CGS for use with the diverse patients. Specifically, it will adapt these materials to be responsive to patients' linguistic and literacy needs, and sensitive to their cultural diversity.
45371658|NCT04743765|Other|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
45371660|NCT04733547|Procedure|Placement of a central venous catheter|The right internal jugular vein is located at the first rib level under ultrasound-guidance. Using an out-of-plane technique, a needle is introduced into the lumen of the vessel. The aspiration of blood into the syringe connected to the hub of the needle confirms the placement of the needle tip in the lumen. After the syringe is detached from the needle, a guidewire is advanced into the vessel lumen through the needle. A dilator is introduced over the guidewire and subsequently is removed. Then, a central venous catheter is introduced over the guidewire into the vessel lumen through the pathway expanded by the dilator. The catheter tip is placed in the superior vena cava by inserting the catheter as far as the distance between the edge of the right transverse process of the first thoracic vertebra and the carina, which is preoperatively measured on a posteroanterior chest radiograph.
45371661|NCT04733547|Device|Monitoring of central venous pressure|Following the placement of a central venous catheter, a fluid-filled system for monitoring central venous pressure is connected to the proximal lumen of the catheter. The reference transducer is placed at the level of 4/5 of the anteroposterior diameter of the thorax.
45692567|NCT05702775|Procedure|Endoscopic treatment group (EUS-GBD group|The placement of a endoscopic drain performed using a linear echoendoscope that allows the gallbladder to be punctured from the gastric antrum or the duodenal bulb to generate a cholecystogastrostomy or a cholecystoduodenostomy, respectively. Transmural gallbladder drainage will be performed by placing a metal apposition stent (LAMS) with the 15x15mm Hot AXIOS device (Boston Scientific) in the case of cholecystogastrostomy or 15x10 or 10x10mm in the case of cholecystoduodenostomy. Subsequently, the interior of the gallbladder will be irrigated with saline solution until the vesicular content comes out.
45371662|NCT04733547|Drug|Furosemide-induced hypovolemia before graft procurement|Patients fast from 10 pm the day before surgery. On the arrival at the operating room, an intravenous catheter for Plasmalyte infusion is placed into the right cephalic or basilic vein. The distal lumen of the central venous catheter is used for the infusion of 6% hydroxyethyl starch. Fluid requirements due to anesthesia, surgery, and no per os intake are not replaced by minimizing the administration of the fluids. Five minutes after the collection of the baseline data, 20 mg of furosemide is administered to promote diuresis for facilitating the venous outflow of the liver. An additional dose of furosemide 20 mg is given if the urine output is <1 ml/kg within 30 minutes after the first dose. Unless the second dose of furosemide produces >1 ml/kg of urine within 30 minutes, 40 mg of furosemide is administered. In the absence of effective diuresis (1 ml/kg within 30 minutes after each dose), the use of furosemide is abandoned and the patients are excluded from the study.
45371663|NCT04733547|Drug|Replacement of fluid loss after graft procurement|Immediately after the graft procurement, 500 ml of 6% hydroxyethyl starch are infused over 25 minutes. Afterward, Plasmalyte is infused at a rate of 10 ml/min until the end of surgery.
45371664|NCT04733547|Device|Monitoring of stroke volume variation|Following anesthesia induction, the right radial artery is catheterized. The catheter is connected to the EV1000 monitor (Edwards Lifesciences, Irvine, CA) through the FloTrac transducer (Edwards Lifesciences). The transducer is level with the one for central venous pressure monitoring. Using pulse contour analysis without external calibration, the stroke volume for each heartbeat is measured. At a 20-second interval, stroke volume variation is calculated as (maximum stroke volume - minimum stroke volume)/mean stroke volume.
45371665|NCT04717986|Drug|Dapagliflozin 10Mg Tab|patients who meet the inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 12 months
45371666|NCT04717986|Drug|Placebo|patients meeting the inclusion criteria will be randomized to receive a placebo solution every 24 hours for 12 months
46053384|NCT05424341|Other|Counterstrain Technique|Therapist places thumb on tender point at plantar fascia insertion while patient in supine position with ipsilateral knee flexed. Plantar flex the toes and ankle while monitoring sore site with thumb, curling around tender point until monitoring thumb feels symptomatic relief. Supination/pronation of foot will be added if necessary. The position of ease will be maintained for 90 secs until tissues beneath monitoring thumb softens. Tender spot is re-evaluated once the foot is returned to neutral without moving the thumb. It will be repeated 3 times for 30 secs resting interval in-between
46053385|NCT05421624|Device|Digital music therapeutic|The digital music therapeutic is comprised of foot sensors, a smart phone with pre-installed proprietary software application, and headphones. The device obtains real-time walking data through movement sensors that communicate wirelessly with the smartphone application software. Music cues are tailored to the person's walking pattern, and are transmitted wirelessly to the headphones. Music cues are time-shifted to the user's baseline cadence and adjusted in real-time based on the user's walking performance metrics.
45371669|NCT04708418|Procedure|Biopsy|Undergo biopsy
46053386|NCT05421624|Behavioral|Active-Control|The Active-Control intervention will implement a similarly structured community-based walking program as Amped-PD, with the only exception the digital music therapeutic.
46053387|NCT05418413|Device|CTB|conventional Twin-block (CTB) will be comprised of maxillary and mandibular removable appliances having the labial bows, adam's clasps, and with no incisal capping.
45371670|NCT04708418|Procedure|Biospecimen Collection|Undergo collection of blood samples
45371671|NCT04708418|Procedure|Computed Tomography|Undergo CT or PET/CT
45371672|NCT04708418|Biological|Pembrolizumab|Given IV
45371673|NCT04708418|Procedure|Positron Emission Tomography|Undergo PET/CT
45371674|NCT04708418|Procedure|Surgical Procedure|Undergo surgery
45371675|NCT04708418|Drug|VLP-encapsulated TLR9 Agonist CMP-001|Given SC or intratumorally
45371676|NCT04697368|Device|Exoskeleton-Assisted Upper Limb Rehabilitation|"The patients will be undergone 25+/-3 Armeo-P training sessions, each lasting 40 minutes (i.e. five times a week for five consecutive weeks). During the first session, the device should be adjusted to the patient's arm size and the angle of suspension. The working space and the exercises will be selected once the UL has been fitted with the system. The selection of personalized exercises will be based on the motor skills of each patient and the difficulty can be gradually increased during training. In particular, a course of exercises has been defined in which the difficulty (suspension rate; the level of assistance; the complexity of movement (1D, 2D, 3D)).~The physiotherapist will choose the modality based on the patient's motor skills (standardized personalized training)."
45498149|NCT02451111|Drug|Rituximab|Rituximab 375 mg/m2 has to be administered i.v. for the first four (4) infusions in all patients. After i.v. administration of Rituximab for the induction therapy, the administration mode can be changed to s.c. (1400 mg) in the maintenance phase dependent on the local standard of care.
45490150|NCT05682079|Other|TCMS, PEDİ, respiration, GMFCS,PBS,functional capacity|"The Trunk Control Measurement Scale evaluates the two main components of trunk control, static sitting balance and dynamic sitting balance. The scale includes a total of 15 items. The Pediatric Disability Assessment Inventory evaluates ADLs in individuals between the ages of 6 months and 7.5 years. It is a detailed clinical assessment scale that evaluates the functional skills and performance of individuals. Items in this section are scored as 0=cannot and 1=can. The Pediatric Berg Balance Scale is an adapted version of the Berg Balance test for adults, which consists of 14 questions. It is a scale that consists of 14 questions and evaluates balance functionally. For the 2-minute walking test; They were asked to walk at their own pace without running for 2 minutes on a quiet, concrete walkway 15 m long. It was repeated 2 times with a 10-minute rest between each trial. Respiratory muscle strength was measured using a portable, electronic mouth pressure measuring device."
45490151|NCT02687542|Drug|Placebo|Placebo
45490152|NCT02687542|Drug|PF-06649751 low dose (1 mg QD)|PF-06649751 low dose (1 mg QD)
45490153|NCT02687542|Drug|PF-06649751 middle dose 1 (3 mg QD)|PF-06649751 lower middle dose 1 (3 mg QD)
46053388|NCT05418413|Device|ETB|will be comprised of maxillary and mandibular removable 1.5-mm biocryl sheet will be adapted separately on maxillary and mandibular casts with help of vacuum machine, and Acrylic bite blocks with the inclined plane will be fabricated on biocryl sheets sim
45371677|NCT04697368|Other|Traditional Upper Limb Rehabilitation|The control group (CG), in addition to the conventional treatment based on the routine rehabilitation program, will follow 25+/-3 sessions of traditional upper limb rehabilitation (i.e. five times a week for five consecutive weeks). Each session will consist of passive, active-assisted, and active exercises addressed for shoulder, arm and hand motor rehabilitation.
45371678|NCT04689529|Diagnostic Test|Preoperative imaging study|MRI, Breast ultrasound sonography, mammography
45371679|NCT04687137|Drug|TAK-743 300 mg|TAK-743 300 mg, subcutaneous injection every 2 or 4 weeks
45371680|NCT04680910|Drug|Propofol|Targeted propofol infusion in TRD patients will induce sedation. Dosage of propofol is determined based upon EEG markers and treatment arm.
45490154|NCT02687542|Drug|PF-06649751 middle dose 2 (7 mg QD)|PF-06649751higher middle dose 2 (7 mg QD)
45490155|NCT02687542|Drug|PF-06649751 high dose (15 mg QD)|PF-06649751 high dose (15 mg QD)
45490156|NCT03707899|Drug|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
45371681|NCT04680910|Diagnostic Test|Electroencephalography (EEG)|EEG will be recorded during propofol infusion and during overnight sleep. Sleep EEG data will be acquired for a minimum of one night prior to the first sedation session, providing a baseline measure. Additional overnight sleep recordings will be performed on day of sedation and subsequent nights.
45371682|NCT04680910|Diagnostic Test|Slow-Wave Activity|Duration of slow waves during sedation will be evaluated using automated approaches. SWA during sedation will be calculated as the total power in the 0.5-4 Hz frequency band/total time in minutes. SWA during N2/N3 sleep will be calculated as the total power in the 0.5-4 Hz frequency band/total time in minutes in the N2 and N3 sleep stages. Delta sleep ratio will be computed from the SWA measured during the first and second N2/N3 cycles.
45371683|NCT04678102|Drug|PHI-101 administration|Escalated doses of PHI-101 will be administered to each cohort.
45371684|NCT04653246|Drug|Isatuximab|Via IV at predetermined dosage and predetermined days during each cycle
45371685|NCT04653246|Drug|Lenalidomide|Oral, predetermined dosage and predetermined days during each cycle
45371686|NCT04653246|Drug|Bortezomib Injection|SQ Oral, predetermined dosage and predetermined days during each cycle
45371687|NCT04653246|Drug|Dexamethasone|IV or Oral predetermined dosage and predetermined days during each cycle
45371688|NCT04648436|Other|Early neurosurgical hematoma evacuation|Early neurosurgical hematoma evacuation (preferably within 2 hours)
45371689|NCT04648436|Other|Conservative treatment (best medical management)|Conservative treatment (best medical management) on the ICU or ward
45371690|NCT04643106|Procedure|Hemostatic agent (EVICEL®) application during laparoscopic ovarian cystectomy|During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL®)
45371691|NCT04643106|Procedure|suturing with barbed sutures during laparoscopic ovarian cystectomy|During laparoscopic ovarian cystectomy, suturing of ovarian inner surface will be conducted to stop bleeding
45490157|NCT03707899|Drug|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
45498150|NCT03689010|Drug|Azelaic acid foam 15%|Azelaic acid foam 15%
45498151|NCT03689010|Drug|Finacea® (Azelaic acid Foam) 15%|Azelaic acid foam 15%
46053389|NCT05415813|Other|Ischemic Compression|It includes conventional Physical therapy, hot packs (75°C) for 20 minutes, and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold, and 10-second relaxation between two repetitions) as a baseline treatment. For the Ischemic compression, the patient will be in the supine position with the cervical spine in opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were kept in a lengthened position physiotherapist will apply gradually increasing pressure to the Trigger points until the subject perceived the first noticeable pain. At that moment, the pressure will be maintained until the discomfort and/or pain eased by around 50% as perceived by the patient, at which time the pressure will be increased until the discomfort appears again. This process will be maintained for 90 seconds.
45371692|NCT04636437|Drug|Doravirine 100 Mg|Participants will receive 100 mg tablet by mouth daily with or without food.
45371693|NCT04636437|Drug|Tenofovir alafenamide/emtricitabine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
45371694|NCT04636437|Drug|tenofovir alafenamide/lamivudine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
45371695|NCT04636437|Drug|Integrase strand transfer inhibitors|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
45371696|NCT04636437|Drug|tenofovir disproxil fumarate/emtricitabine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
45371697|NCT04636437|Drug|tenofovir disproxil fumarate/lamivudine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
45371698|NCT04624204|Biological|Pembrolizumab 200 mg|Pembrolizumab 200 mg Q3W
45371699|NCT04624204|Biological|Pembrolizumab 400 mg|Pembrolizumab 400 mg Q6W
45692568|NCT05702697|Device|focus extracorporeal shock wave therapy|F-EWST with 0.15 mJ/mm2 intensity and 6 Hz frequency for 3 weeks. The shocking head was placed at the muscle positions of the long head of the bicep femoris, semitendinosus, and semimembranosus for 1,000, 500, and 500 shocks, respectively, accounting for 2,000 shocks in total/ session/week.
45846758|NCT02634684|Drug|Placebo|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
45371700|NCT04624204|Drug|Pembrolizumab placebo (saline)|Pembrolizumab placebo (saline) Q3W
45371701|NCT04624204|Drug|Pembrolizumab placebo (saline)|Pembrolizumab placebo (saline) Q6W
45371702|NCT04624204|Drug|Olaparib 300 mg BID|Olaparib 300 mg twice daily (BID)
45371703|NCT04624204|Drug|Olaparib matching placebo|Olaparib matching placebo BID
45371704|NCT04624204|Drug|Etoposide 100 mg/m^2|Etoposide 100 mg/m^2 intravenous (IV) Q3W, Day 1-3
45371705|NCT04624204|Drug|Platinum, investigator's choice|Carboplatin titrated to an area under the plasma drug concentration time curve (AUC) of 5 mg/mL/min IV Q3W OR Cisplatin 75 mg/m^2 IV Q3W on Day 1 of each cycle
45371706|NCT04624204|Radiation|Standard Thoracic Radiotherapy|Standard Thoracic Radiotherapy
45371707|NCT04624204|Radiation|Prophylactic Cranial Irradiation (PCI)|PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
45371708|NCT04622774|Drug|IMGC936|Antibody Drug Conjugate
45371709|NCT04620811|Drug|lirentelimab|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8
45371710|NCT04619797|Drug|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
45371711|NCT04619797|Drug|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
45371712|NCT04619797|Drug|Pemetrexed|Pemetrexed 500 milligrams per square meter (mg/m^2), administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
45371713|NCT04619797|Drug|Carboplatin|Carboplatin at dose of area under the concentration-time curve (AUC) of 5, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.
45692569|NCT05702697|Behavioral|Home stretching program|The leaflet on hamstring stretching exercises (in a sitting posture)
45692570|NCT02947503|Drug|Metformin TEVA 850 mg|At inclusion, patients (N=500) will be randomized 1:1 to metformin vs usual care (850 mg tablets, 3 times daily or, if tolerance is suboptimal, a lower maximally tolerated dose, 1-2 times daily), on top of diet and lifestyle, with an insulin rescue in both arms if needed.
45371714|NCT04619797|Drug|Cisplatin|Cisplatin 75 mg/m^2, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.
45371715|NCT04619797|Drug|Tiragolumab Matching Placebo|Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
45371716|NCT04619797|Drug|Pembrolizumab|Pembrolizumab at a fixed dose of 200 mg, administered by IV infusion, Q3W, on Day 1 of each 21-day cycle.
45371717|NCT04618016|Device|UHMWPE with Vitamin E|e.motion Pro (PS and UC) with MXE gliding surface
45692571|NCT03586323|Drug|superior laryngeal nerve block with lidocaine|SLNB was performed with 4 ml of 1.5% lidocaine below the thyroid membrane
45692572|NCT03586245|Dietary Supplement|Ferric pyrophosphate|57 Iron isotopically labeled FePP powder.
45692573|NCT03586245|Dietary Supplement|Aspiron|58 Iron isotope intrinsically labeled Aspergillus oryzae.
45692574|NCT03586245|Dietary Supplement|Ferrous sulfate|57 Iron isotopically labeled FeSO4 powder.
45692575|NCT03890991|Behavioral|SCOPE-DM|The 12-week programme aims to support motivation and enable capability for managing diabetes. To this end, the sessions will integrate the knowledge and practical skills components offered in traditional diabetes education with psychological techniques and principles for behavioural change: problem solving, goal-setting and monitoring. The programme offers the potential for older people to learn about their condition and treatment in a psychologically-motivating and confidence-enhancing structure - as such the emphasis is on empowering individuals to make choices and lifestyle changes in line with treatment recommendations through the use of problem solving, goal setting and feedback, and not just on knowledge transfer which has not been shown to be successful in behavioural change. The content and delivery format will largely be informed by motivational interviewing
45371718|NCT04618016|Device|UHMWPE without Vitamin E|e.motion Pro (PS and UC) with β-PE and MXE gliding surface
45371719|NCT04615078|Device|ETAPES Program|"The Chronic Care Connect Pneumology is a remote medical monitoring solution, combining:~A technical solution for the transmission and analysis of ventilator data, leading to alerts generated by an algorithm ;~An organizational solution relying on a nurse call center."
45371720|NCT04614233|Dietary Supplement|RiduZone (90% OEA)|Participants will be randomly assigned to take 2 capsules of RiduZone (each capsule contains 90% OEA ) daily for 16 months
45371721|NCT04614233|Drug|Placebo|Participants will be randomly assigned to take 2 capsules of placebo daily for 16 months. Placebo capsules will consist of 180mg of hypromellose.
45371722|NCT04606914|Drug|mirvetuximab soravtansine (MIRV; IMGN853)|Mirvetuximab soravtansine (also known as IMGN853 and MIRV) is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 [FOLR1] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridin-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB) linker. FRα is a glycosyl-phosphatidylinositol (GPI)-linked protein, which shows limited normal tissue expression and high expression on the surface of solid tumors, particularly epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (referenced herein collectively as EOC), endometrial cancer, non-small cell lung cancer (NSCLC), and renal cell cancer.
45371723|NCT04600648|Diagnostic Test|Serum insulin level|Measure levels before and after weight loss related to bariatric surgery
45371724|NCT04600648|Diagnostic Test|Serum Leptin test|Measure levels before and after weight loss related to lifestyle change weight loss
45692576|NCT03890991|Behavioral|SCOPE-DM with 3 months' supply of glucometer|Participants in this arm will participate in the SCOPE-DM programme and use the glucometer for 3 months.
45846759|NCT02635542|Drug|Succinylcholine|Succinylcholine will be used to facilitate endotracheal intubation for general anesthesia in the operating room. No additional neuromuscular blockade will be provided during general anesthesia.
46053390|NCT05415813|Other|Ischemic compression with Muscle Energy Technique|The Participants will receive all the treatments given to the active comparator group and they will also receive the Muscle Energy Technique treatment in supine position and the practitioner will stabilize the shoulder of the affected side with one hand, while the ear/mastoid area of the affected side will be held by the opposite hand. The head and neck were then bent towards the contralateral side, flexed, and ipsilaterally rotated. The subjects will then shrug the stabilized shoulder towards the ear at a sub-maximal pain-free effort (20% of the available strength). The isometric contraction will be held for 7-10s. This position will be maintained for 30 seconds and repeated three to five times per treatment session. Treatment sessions will be given on alternate days.
45371725|NCT04600180|Procedure|sigmoidoscopies and and venous blood sampling|Sigmoidoscopies will be performed at baseline and during immunotherapy. During these procedures biopsies will be taken from the sigmoid and rectum. At the same timepoints, venous blood samples will be taken.
45692577|NCT03890991|Behavioral|SCOPE-DM with 6 months' supply of glucometer|Participants in this arm will participate the in SCOPE-DM programme and use the glucometer for 6 months.
45753547|NCT04197518|Diagnostic Test|neuro trax system and a neurology test.|"the neurology will check the patience before and after tonsillectomy or adenotonsillectomy usung the neurotrax system, these parameters will be measured in this system : Non verbal memory, Go no go test, stroop interference, Visual spatial processing, Staged information processing speed, catch game, problem solving."
46053391|NCT05409651|Behavioral|Time restricted eating|Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study.
45371726|NCT04586023|Drug|Fenebrutinib|Participants will receive fenebrutinib.
45371727|NCT04586023|Drug|Teriflunomide|Participants will receive teriflunomide.
45753548|NCT04197440|Drug|BAM8-22 2mg/ml|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
45371728|NCT04586023|Drug|Placebo|Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
46053392|NCT05396768|Other|Assessment using the ACTION-tool.|Participants will be assessed using the ACTION-tool while they are performing a CTI on a porcine rib model and Thiel embalmed human cadavers.
46053393|NCT05393440|Biological|BS-006|BS-006 is an engineered recombinant type II herpes simplex virus (HSV2) designed and produced by Wuhan Binhui Biopharmaceutical Co., Ltd. It was derived from HSV2 strain HG52. ICP34.5 and ICP47 genes were deleted to ensure abortive infection and immune destruction in normal cells. Bispecific T cell engager of anti-CD3 antibody and anti-PD-L1 antibody were constructed and inserted into HG52 strain genome.
45490158|NCT05054569|Behavioral|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
45490159|NCT05490511|Drug|Tacrolimus single dose|5 mg once
46053394|NCT05386875|Diagnostic Test|rK28|"rK28 RDT (Index): The Leishmania Ab Rapid Test is a rapid immunochromatographic test that uses the recombinant antigen rK28 to detect antibodies against Leishmania species in human serum, plasma, or whole blood samples intended for primary VL diagnosis. It is a Research Use Only product commercialized by CTK Biotech, Inc. (USA).~IT-Leish rK39 RDT: Rapid immunochromatographic test for detection of antibodies against Leishmania species in human serum, plasma, or whole blood samples of utility in the VL diagnosis algorithm. It is a CE marked product commercialized by Bio-Rad (France). This is currently the recommended RDT for VL diagnosis in Kenya.~Kalazar Detect rK39, RDT: Rapid immunochromatographic test for detection of antibodies against Leishmania species in human serum, plasma, or whole blood samples of utility in the VL diagnosis algorithm. It is a CE marked product commercialized by InBios (United States)."
45490160|NCT05490511|Drug|Epidiolex single dose|Epidiolex 5 mg/kg
46053395|NCT05385575|Drug|KN056 (0.1mg)|The participants will receive assigned single dose of KN056 on Day 1
45490161|NCT05490511|Drug|Epidiolex steady-state and tacrolimus single dose|Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period
45490162|NCT05721976|Behavioral|"With Love, Grandma (Con Cariño, Abuelita)"|"Cancer survivor-Daughter dyads will log in to a secured website to access intervention content over a period of 10-12 weeks. The intervention will be delivered primarily through smartphones and will include 8 modules with didactic content on healthy lifestyle behaviors for cancer prevention and control, family behavior change content for setting weekly goals and self-monitoring health behaviors, and family communication and positive parenting/grandparenting content, all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in weekly 15-30 minute sessions regarding the family's progress throughout the intervention period."
45490163|NCT03336619|Drug|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
45490164|NCT03336619|Drug|Placebo|Placebo administered orally twice daily for five days
45490165|NCT03114904|Other|Variation of Jasinski score between H0 (stop of sedatives) and H6|To compare the effectiveness of a withdrawal management protocol with the usual management in cerebral patients (Subarachnoid haemorrhage (HSA), stroke and head trauma (CT))
46053396|NCT05385575|Drug|KN056 (0.3mg)|The participants will receive assigned single dose of KN056 on Day 1
45371737|NCT04564885|Device|BAGUERA®C Cervical Disc Prosthesis|surgery
45371738|NCT04564885|Device|Mobi-C Cervical Disc|surgery
45371739|NCT04564157|Drug|Carboplatin|"Structure: The cis-diamino (cyclobutan-1, 1 dicarboxilate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center."
45371740|NCT04564157|Drug|Paclitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexa-hidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines on Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
45490166|NCT05598138|Biological|Biological Collection|A blood sample (10 ml) will be taken for each patient included in the study.
45371741|NCT04564157|Drug|Nivolumab|"Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains.~Route of administration: Intravenous infusion.~Product Description: Nivolumab (BMS-936558-01) Injection drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated in 10 mg/ml.~Storage Conditions: It must be stored at 2 to 8 degrees Cº and protected from light and freezing.~Guidelines: The administration of nivolumab infusion must be completed within 24 hours of preparation.The dose of Nivolumab for the adjuvant treatment is 360 mg administered as an intravenous infusion over 30 minutes every 3 weeks (+/-3 days) for 4 cycles.~For the maintenance adjuvant treatment the dose is nivolumab 480 mg Q4W (+/-3 days) over 30 minutes for 6 months (6 cycles).~Subjects should be carefully monitored during nivolumab administration to follow infusion reactions.~Doses of nivolumab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment."
45371742|NCT04555577|Drug|Peposertib|Given PO
45371743|NCT04555577|Radiation|Radiation Therapy|Undergo radiation therapy
45490167|NCT03706339|Other|normal saline arm group|110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the placental bed during Cesarean section
45490168|NCT03706339|Drug|intravenous tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed during cesarean section
45490169|NCT03706339|Drug|Topical tranexamic acid|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 120 ml normal saline applied on the pelvic bed during cesarean section plus110 ml normal saline IV just before skin incision
45490170|NCT03739476|Drug|Quetiapine 25 milligrams capsule|Compare the incidence of postoperative delirium.
45753549|NCT04197440|Drug|BAM8-22 1mg/ml|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
46053397|NCT05385575|Drug|KN056 (1.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
45371744|NCT04555577|Procedure|Resection|Undergo surgical resection
45371745|NCT04555577|Drug|Temozolomide|Given PO
45371746|NCT04545502|Device|Gelsoft Plus Vascular Graft|Gelatin coated, knitted vascular prosthesis implanted to act as a conduit for channeling blood during repair of damaged or diseased vessels.
45371747|NCT04545502|Device|Vascular Bypass Graft|Gelatin coated, knitted vascular prosthesis implanted to act as an extra-anatomical bypass for channeling blood during repair of damaged or diseased vessels.
45490171|NCT03739476|Drug|Placebo oral capsule|Compare the incidence of postoperative delirium.
45490172|NCT05000268|Other|Progressive Myofascial Relaxation Exercise|"Participants will be given telerehabilitation methods, progressive myofascial relaxation techniques and simple posture correction exercises every other day for 2 weeks. The exercises will be performed as follows:~First, focus on creating tension in the body by contracting all your body muscles and feeling the body tension by holding this tight position for 3-5 seconds. Then relax and relax and focus on feeling the relaxed position of the muscles for 10-15 seconds. Then, the same contraction and relaxation movements will be applied in the feet, legs, hips, waist, chest, shoulders, arms and face areas, respectively. They will be asked to do these exercises in the morning and evening while lying in bed."
45490173|NCT03639558|Drug|Haloperidol + Promethazine + Chlorpromazine|This is the usual treatment given by this hospital during an aggressive psychiatric episode.
45498152|NCT03689010|Drug|Vehicle of the test product|Vehicle of the test product
45753550|NCT04197440|Drug|BAM8-22 0.5 mg/ml|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
46053398|NCT05385575|Drug|KN056 (3.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
46053399|NCT05385575|Drug|KN056 (6.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
46053400|NCT05385575|Drug|KN056 (12.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
46053401|NCT05383144|Other|Complete Positioning scans|Entire treatment zone imaging at mi-treatment and at end of treatment
46053402|NCT05365035|Drug|Cladribine|Given by Vein (IV)
46053403|NCT05365035|Drug|Cytarabine|Given under the skin; subcutaneous injection (SQ)
46053404|NCT05365035|Drug|Venetoclax|Given by PO
46053405|NCT05365035|Drug|Azacitidine|Given by IV or subcutaneous injection (SQ)
46053406|NCT05361356|Radiation|Spectral CT scanning|Volunteer accept spectral CT scanning
46053407|NCT05359861|Drug|SRF388|SRF388 will be administered by intravenous injection (IV)
45371748|NCT04545502|Device|Cardiovascular Patch|Cardiovascular knitted polyester patches are frequently used to treat the carotid or femoral arteries to prevent stroke and repair damage to vessels.
45490174|NCT03639558|Drug|Haloperidol + Promethazine|This is the second most used psycho-pharmacological combination used in this hospital during an aggressive psychiatric episode.
45490175|NCT03506646|Dietary Supplement|Beetroot juice|Beetroot juice serves as a mode of dietary nitrate supplementation. This will be a double-blinded, randomized, cross-over design to examine the effects of beetroot juice on endothelial function, leg function, and thermoregulation.
46053408|NCT05359861|Drug|Atezolizumab|Azezolizumab will be administered by IV
45371749|NCT04545502|Device|Gelweave Vascular Graft|The Gelweave woven polyester vascular graft allows replacement of large sections of arteries and, following anastomosis to the native blood vessel, provides a stable conduit for blood flow.
45371750|NCT04545502|Device|Gelweave Valsalva Vascular Graft|This woven polyester graft is designed to match the aortic root anatomy and is implanted to repair or replace a portion of the aorta in case of an aneurysm, dissection or coarctation at the level of the thoracic aorta.
45371751|NCT04542161|Drug|NAC 900mg/day|self administer NAC 900mg/day caplets for a four week period
45371752|NCT04542161|Drug|NAC 3600mg/day|self administer NAC 3600mg/day caplets for a four week period
45371753|NCT04542161|Drug|NAC 0mg/day (Placebo)|self administer NAC 0mg/day (placebo) caplets for a four week period
45371754|NCT04536792|Drug|AG-946|AG-946, oral encapsulated coated-granules or tablets.
45490176|NCT01353508|Drug|LCZ696|200 mg and 400 mg tablets
45371755|NCT04536792|Drug|AG-946 Matched Placebo|AG-946 matched-placebo, oral encapsulated sugar spheres or tablets.
46053409|NCT05359861|Drug|Bevacizumab|Bevacizumab will be administered by IV
45490177|NCT01353508|Drug|Valsartan|160 mg tablets
45490178|NCT05470855|Biological|Live attenuated varicella vaccine|The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm.
45490179|NCT01568268|Drug|Palonosetron|palonosetron 0.075 mg intravenous injection over 10 seconds when nausea with NRS >= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
46053410|NCT05359861|Drug|Placebo|Placebo will be administered by IV
46053411|NCT05355857|Diagnostic Test|brain PET-MRI with 18F-FDG|Realisation of a brain PET-MRI with 18F-FDG in 39 healthy volunteers
46053412|NCT05353244|Device|PrTMS|Each participant will receive a personalized rTMS treatment based on their individual alpha frequency.
46053413|NCT05353244|Device|Sham|Using a sham coil that looks and sounds like an actual TMS coil, each participant will receive sham rTMS treatments.
46053414|NCT05350280|Device|electric current|Electric current will be applied in this group of patients using removable device.
46053415|NCT05350280|Device|Traditional treatment|No acceleration method will be performed in this group.
45490180|NCT01568268|Drug|placebo control group|placebo intravenous injection over 10 seconds when nausea with NRS >= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
45490181|NCT03636269|Drug|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg administered three times/week
45490182|NCT03636269|Drug|Placebo|IV placebo administered three times/week
45490183|NCT04978519|Procedure|Cryotherapy|Cryotherapy is administered by using perineal needles, placed under ultrasound guidance to freeze the target tissue.
46053416|NCT05350085|Drug|Remimazolam besylate|① initial dose: use a micro injection pump to pump remimazolam at the rate of 50mg/h, and observe for 4 ~ 8 minutes until Ramsay Sedation grade III，then start dental operation ; ② Maintenance dose: maintain the pump speed at 5 ~ 10mg/h，adjust the pump dose to maintain the patient at Ramsay Sedation grade III. ③ Additional dose: During the operation, if the patient has body movement reaction or cannot cooperate with the dentist, local anesthetics shall be given as remedy. ④ After the operation, stop the microinjection pump.
45490184|NCT05598060|Radiation|Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.|Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.
45490185|NCT03114982|Biological|NBP608|Preparation of the Oka/SK strain of live, attenuated varicella virus
45371758|NCT04530526|Procedure|Regenerative Peripheral Nerve Interface|The regenerative peripheral nerve interface (RPNI) has emerged as a novel strategy to treat neuromas in peripheral nerves. The RPNI consists of the residual peripheral nerve end implanted in a skeletal muscle graft, following surgical resection of the injured terminal nerve portion (neuroma). The free muscle graft is separated from its native nerve innervation, leaving open neuromuscular junctions for ingrowth and attachment of nerve fibers from the implanted nerve.
45371759|NCT04509791|Drug|Anti-Human Thymocyte Immunoglobulin, Rabbit|MELD - ATG : Minimum effective low dose ant-human thymocyte globulin (rabbit)
45490186|NCT03114982|Biological|Varivax|Preparation of the Oka/Merck strain of live, attenuated varicella virus
45490187|NCT04919707|Behavioral|Header Session|Participant fit with commercially available Storelli ExoShield Head Guard that has been fit with head impact sensors; participant completes a set of basic standing header tasks which mimic the types of purposeful heading anticipated to occur in actual play in soccer practice and games.
45371760|NCT04504812|Drug|Duloxetine|Duloxetine is a drug that is used to improve pain and function in people with knee osteoarthritis (KOA). Duloxetine is approved by the Food and Drug Administration (FDA) for the treatment of depression, anxiety disorder, fibromyalgia, and joint pain. It will be titrated up from 20 or 30mg according to a schedule provided by a study provider.
45371761|NCT04504812|Combination Product|Intra-Articular Injection|Intra-Articular Injection is an injection of 3-6 milliliter (mL) hyaluronic acid (HA) mixed with 1mL depo methylprednisolone (a steroid) and 2mL 0.5% bupivacaine (an anesthetic) into the knee.
45371762|NCT04504812|Procedure|Nerve Procedure with long acting blocks|People assigned to receive this will have 1mL of a long-acting local anesthetic (a.k.a. liposomal bupivacaine or EXPAREL) and steroid injected into the knee.
45371763|NCT04504812|Procedure|Nerve Procedure with nerve ablation|People assigned to receive this will have heat applied to destroy the nerve signaling pain in the knee. Steroid will be administered after the procedure to reduce the risk of neuritis.
45490188|NCT04919707|Procedure|MRI Session|Scanning will include high resolution T1w imaging for 3-dimensional structural analyses, DTI and resting-state MRI for assessment of structural and functional brain network connectivity, as well as susceptibility-weighted imaging and multicomponent relaxometry to assess for microhemorrhages and myelin damage.
46053417|NCT05350085|Drug|Midazolam|① initial dose: use a micro injection pump to pump remazolam at the rate of 30mg/h, and observe for 4 ~ 8 minutes until Ramsay Sedation grade III，then start dental operation; ② Maintenance dose: maintain the pump speed at 3 ~ 6mg/h，adjust the pump dose to maintain the patient at Ramsay Sedation grade III. ③ Additional dose: During the operation, if the patient has body movement reaction or cannot cooperate with the dentist, local anesthetics shall be given as remedy. ④ After the operation, stop the microinjection pump.
46053418|NCT05333471|Drug|OpenBiome FMT product FMP250|Participants who weigh >= 20 kg will be instilled with 230 mL of the OpenBiome lower GI FMT product via colonoscopy. Participants who weigh <20 kg will be instilled with 10 mL/kg. The product will be delivered in the cecum is possible. If a full colonoscopy is not possible, then the product may be delivered more distally in the colon.
46053419|NCT05322941|Drug|AEF0117|AEF0117 (1.0, 0.3, and 0.1 mg) capsules
46053420|NCT05322941|Drug|Placebo oral capsule|Corn oil capsule manufactured to mimic AEF0117 capsule
46053421|NCT05322629|Behavioral|PrEP adherence biofeedback|Services for women in the intervention arm includes bio-feedback adherence counseling based on urine lateral flow assays of tenofovir to measure adherence with rapid PrEP delivery .
45490189|NCT03166072|Other|Low-vision rehabilitation program|Low Vision Rehabilitation Program includes functional vision assessments (low-vision refraction), prescription of a variety of visual aids including microscopes, magnifiers, telescopes, absorptive filters and electronic spectacle eyewear, large print books, and automatic self-transcending meditation plus essential skills for daily living and mobility training offered by CNIB including demonstration of visual aids as well as training on proper use of visual aids.
45490190|NCT03166072|Other|No Intervention|Participants will continue to receive treatment as usual
45371764|NCT04504812|Behavioral|Pain Coping Skills Training|Participants will be provided with a written manual that includes login information for the pain coping skills training website. They will be expected to log into the system weekly, work through the modules, and participate in skills practice. This intervention will be conducted in combination with best practices and duloxetine.
45371765|NCT04504812|Other|Best Practices|Best Practice includes treatments that experts recommend for knee arthritis pain. Best Practice can include topical or oral pain relievers, a structured exercise program, and weight management if BMI is over 30. Other non-invasive treatments such as acupuncture and yoga are also included.
45371766|NCT04497584|Drug|Afatinib + Prednisone|Afatinib (40mg) will be taken by mouth daily starting on Cycle 1, Day -7. Prednisone (40mg) will be taken by mouth daily starting on Cycle 1, Day 1.
45371767|NCT04493853|Drug|Capivasertib|400 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
45371768|NCT04493853|Other|Placebo|matched to capivasertib appearance (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
45371769|NCT04493853|Drug|Abiraterone Acetate|Administered orally as tablets at a dosage of 1000 mg daily. Administered continuously until criteria for discontinuation are met.
45490191|NCT04911361|Drug|Dexamethasone|Patients will be randomized for either topical loteprednol suspension in both eyes (control group) or lower eyelid canaliculi DEXTENZA insertion (study group)
45371770|NCT04491942|Drug|Cisplatin|Given IV
45371771|NCT04491942|Drug|Elimusertib|Given PO
45371772|NCT04491942|Drug|Gemcitabine Hydrochloride|Given IV
45371773|NCT04484623|Drug|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.
45371774|NCT04484623|Drug|Pomalidomide|Immunomodulatory imide drug (IMiD) will be administered.
45371775|NCT04484623|Drug|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity will be administered.
46053422|NCT05322629|Behavioral|Standard of care counseling|Adherence counseling based on self report and following national guidelines
45371776|NCT04484623|Drug|Bortezomib|Proteasome Inhibitor will be administered.
46053423|NCT05320939|Drug|Mepolizumab 100 MG|30 subjects (≥ 300 eosinophils/ul) will receive mepolizumab 100 mg subcutaneously every 4 weeks for 5 complete doses.
45371778|NCT04474366|Drug|Ropivacaine 0.2% Injectable Solution|Ropivacaine 0.2% Injectable Solution injected as part of the Pectoralis Nerve Block
45490192|NCT03166150|Other|Multi-modal rehabilitation program|Patients will receive 12 weeks of exercises.
45371779|NCT04474366|Other|Saline (0.9%)|Saline injection as sham block in identical fashion as Pectoralis Nerve Block
45371780|NCT04469595|Drug|Iluvien 0.19 MG Drug Implant|0.19 mg Fluocinolone Acetonide Intravitreal Implant
45490193|NCT03166150|Other|Pelvic Floor Physical therapy|Pelvic Floor Physical therapy
45490194|NCT04906993|Drug|camrelizumab； famitinib malate|Camrelizumab intravenously ; Famitinib Orally
45490195|NCT04906993|Drug|platinum-based chemotherapy|Physician's choice chemotherapy
45490196|NCT03165760|Procedure|protective ventilation|the aim of the intervention is to ovoid Ventilator induced lung injury and inflammatory stress
46053424|NCT05313308|Drug|Midazolam|Midazolam oromucosal solution
46053425|NCT05309577|Behavioral|Behavioral Self-Monitoring + Motivational Interviewing|Participants randomized to the self-monitoring arm (n=10) will record the timing of sleep, social activities and exercise twice daily using a diary-like Qualtrics website, for 6 weeks. The steps of behavioral self-monitoring include: (1) selecting a goal, (2) paying attention to some aspect of behavior, and (3) recording some details of that behavior in a daily diary. Participants will also interact with a 'health coach' about their recorded behaviors weekly. This health coach will use motivational interviewing to enhance older adult caregivers' confidence and intrinsic motivation to engage in regular self-care.
45371781|NCT04469595|Drug|Aflibercept|2 mg/0.05 mL Aflibercept Anti-VEGF intravitreal injection
45498153|NCT03681288|Behavioral|Mindful Self-Compassion|Mindful Self-Compassion Intervention
45490197|NCT02685202|Device|Mandibular advancement splint|A mandibular advancement splint (MAS), functions by comfortably positioning the patient's mandibular in a forward position, clearing the obstructed airway during sleep.
45490198|NCT04475731|Drug|Ponatinib|"Ponatinib 45 mg/day x 4 weeks x 3 courses.~+/- chemotherapy:~vincristine or~L-VAMP (leucovorin, vincristine, aracytin, methotrexate, prednisone)"
45490199|NCT04479592|Other|Particle counter|Particle counter to measure the aerosol generated
45490200|NCT03087786|Drug|Nicotine Bitartrate Lozenge 4mg|Test Product
45490201|NCT03087786|Drug|Nicotine Polacrilex 4Mg Lozenge|Active Comparator
45490202|NCT03635957|Biological|Pegloticase|pegloticase administered intravenously (IV)
45490203|NCT03635957|Drug|Methotrexate (MTX)|oral MTX
45490204|NCT03635957|Drug|Standard Gout Flare Prophylaxis|It is required that before a subject begins the Pegloticase + IMM Period, he or she has been taking at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day) for ≥1 week before the first dose of pegloticase and continues flare prophylaxis per American College of Rheumatology guidelines [Khanna D et al.2012] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA < 6 mg/dL) for patients with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA < 5 mg/dL) for patients with one or more tophi detected on initial physical exam that have since resolved.
45498154|NCT05451771|Drug|Venetoclax Oral Tablet, 200 mg|200 mg oral tablet daily
45692578|NCT05702619|Drug|Optional non-IMP pimonidazole|patients will be asked to ingest an oral formulation of pimonidazole hydrochloride (HCl) (Oral HypoxyprobeTM-1). Pimonidazole HCl is a marker for hypoxia in tumour tissue when ingested as an encapsulated solid. Following oral administration, pimonidazole distributes throughout the body where it covalently binds to normal and tumour tissues that have regions of low oxygen concentrations (pO2 of ≤ 10 mmHg at 37oC). The tissue binding can be visualised by immunohistochemistry / light microscopy. The capsules are to be taken within 8-16 hours (optimal timepoint 12 hours) before the planned first biopsy within Arm 1 and before radical prostatectomy for patients in Arm 2. If the patient refuses the pimonidazole, forgets to take it, or if it is not available, the patient can still participate in the study and their samples will be stained for hypoxia post-biopsy.
45371782|NCT04428151|Drug|Lenvatinib|20 mg once daily, taken as oral capsules
45371783|NCT04428151|Biological|Pembrolizumab|200 mg 30-minute IV infusion on day 1 of each 21-day cycle
45371784|NCT04428151|Drug|Docetaxel|75 mg/m^2 administered as an IV infusion on day 1 of each 21-day cycle
45371785|NCT04428151|Drug|Capecitabine|1250 mg/m^2 twice daily on days 1-14 of each 21-day cycle, taken as oral tablets
45371786|NCT04428151|Drug|Paclitaxel|80 mg/m^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle
45371787|NCT04428151|Drug|Cetuximab|400 mg/m^2 loading dose, followed by 250 mg/m^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle
45371788|NCT04428151|Drug|Lenvatinib|24 mg once daily, taken as oral capsules
45490205|NCT03635957|Drug|Infusion Reaction (IR) Prophylaxis|For IR prophylaxis, fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) will be taken the day before each infusion; fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) and acetaminophen (1000 mg orally) will be taken the morning of each infusion; and methylprednisolone (125 mg IV) given over the infusion duration 10-30 minutes (recommended) or hydrocortisone (200 mg IV) will be administered immediately prior to each infusion.
45490206|NCT03635957|Dietary Supplement|Folic Acid|Subjects will also take folic acid 1 mg orally every day beginning at Week -4 (the start of MTX) and continuing until prior to the Week 52 Visit.
46053426|NCT05309577|Behavioral|Enhanced Usual Care|In the enhanced usual care group (n=10), participants will be provided with the same educational information as the caregiver intervention arm, but without the tailored advice, motivational health coaching, or digital feedback (e.g. Qualtrics website/daily diary; lifestyle log) that participants in the caregiver intervention arm will receive. Enhanced usual care participants will have the same assessment schedule as caregiver intervention participants. They will also receive weekly calls from a staff member.
46053427|NCT05289349|Drug|Propofol|Propofol (2 mg/kg) for induction of anesthesia , and ( 6 mg/kg/h) for maintenance of anesthesia
46053428|NCT05289349|Drug|Sevoflurane|Sevoflurane 1.0-1.5 minimum alveolar concentration (MAC)
46053429|NCT05278091|Other|None, pure observationnal study|None, pure observationnal study
45371795|NCT04399460|Other|Dairy-based commercially available food products|Full-fat milk (3.25% milk, 250 mL), assortment of yogurts, and cheeses
45371796|NCT04399460|Other|Restrictive Eating|Dietitian will assist with 500 kcal/day reduction through limiting of macronutrients 45-65% energy from carbohydrates 20-35% energy from fat 10-35% energy from protein
45490207|NCT05241067|Drug|Normal Saline|Placebo (Dose: equal volume saline) + Standard of care
45490208|NCT05241067|Drug|Centhaquine|Centhaquine (Dose: 0.01 mg/kg) + Standard of care
45490209|NCT03732599|Procedure|Standard Deep Anterior Keratoplasty (S-DALK)|Standard (with the use of a blade) deep anterior lamellar keratoplasty (DALK), which is a partial thickness corneal transplant, which has been shown to be a safe and effective procedure.
45371797|NCT04380636|Biological|Pembrolizumab|intravenous (IV) infusion
45371798|NCT04380636|Drug|Olaparib|oral tablets
45371799|NCT04380636|Drug|Placebo for olaparib|oral tablets
45371800|NCT04380636|Drug|Etoposide|IV infusion
45371801|NCT04380636|Drug|Carboplatin|IV infusion
45371802|NCT04380636|Drug|Cisplatin|IV infusion
45371803|NCT04380636|Drug|Paclitaxel|IV infusion
45371804|NCT04380636|Drug|Pemetrexed|IV infusion
45371805|NCT04380636|Radiation|Thoracic Radiotherapy|external beam radiation
45371806|NCT04380636|Drug|Durvalumab|IV infusion
45371807|NCT04374877|Drug|SRF388|SRF388 is a fully human IgG1 antibody against IL-27. Inhibition of IL-27 with SRF388 reduces STAT1 phosphorylation leading to increased pro-inflammatory (anti-tumor) cytokine secretion (e.g., IFN-g, TNF-a) and decreased expression of inhibitory immune checkpoint receptors (e.g., PD-L1, TIGIT, LAG3) on immune cells that may result in anticancer therapeutic activity.
45371808|NCT04374877|Drug|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
45371814|NCT04370496|Procedure|Minimally invasive surgery using endoscopic stapler|Radical hysterectomy by minimally invasive surgery (laparoscopic or robotic) will be done with the help of an endoscopic stapler in cutting and suturing the uterine cervix.
45490210|NCT03732599|Procedure|IE-DALK (femtosecond)|Femtosecond deep anterior lamellar keratoplasty (DALK). The femotosecond laser technology allows for the creation of precise and reproducible corneal incisions.
45371816|NCT04335721|Drug|Voxelotor|Voxelotor 1500mg once a day
45371817|NCT04333576|Drug|Elagolix|Tablet:Oral
45371818|NCT04333576|Drug|Placebo|Tablet:Oral
45371819|NCT04333576|Drug|Combined Oral Contraceptive|Tablet:Oral
45371820|NCT04331340|Other|Pharmacist review of LUTS|Pharmacist review and recommendations, including education, behaviour, lifestyle, or medications
45371821|NCT04331340|Other|Pharmacist Provision of healthy aging leaflets|Pharmacist will inquire about presence of LUTS and provide patient with healthy aging leaflets
45371822|NCT04325022|Device|Primary Total Hip Arthroplasty|Primary Total Hip Arthroplasty using the OR3O Dual Mobility System in combination with compatible components
45371823|NCT04325022|Device|Revision Total Hip Arthroplasty|Revision Total Hip Arthroplasty using the OR3O Dual Mobility System in combination with compatible components
45371826|NCT04314544|Drug|TILD|one 1 mL injection of study medication
45371827|NCT04314544|Drug|matching placebo injections|one 1 mL injection of placebo
45371828|NCT04310644|Other|No intervention planned, but all patients get our standart treatment|Patients are selected from clinical Routine and get our standart Treatment based on their disease
45371829|NCT04294810|Drug|Atezolizumab|Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
45371830|NCT04294810|Drug|Tiragolumab|Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
45371831|NCT04294810|Drug|Matching Placebo|Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
45371832|NCT04294407|Other|No intervention|no intervention in this study
45371834|NCT04266795|Drug|Pevonedistat|Pevonedistat IV infusion.
45371835|NCT04266795|Drug|Venetoclax|Venetoclax tablets.
45371836|NCT04266795|Drug|Azacitidine|Azacitidine IV or SC injection.
45371837|NCT04254796|Behavioral|Training for Awareness, Resilience, and Action (TARA)|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
45371838|NCT04250636|Drug|3BNC117-LS|Intravenous infusion of 3BNC117-LS at 30mg/kg
45371839|NCT04250636|Drug|10-1074-LS|Intravenous infusion of 10-1074-LS at 30mg/kg
45371842|NCT04233749|Drug|Tranexamic acid tablets|325mg of tranexamic acid twice daily for six months
45371843|NCT04233398|Device|Device: Echopulse (HIFU ablation)|High-intensity focused ultrasound (HIFU) is a non-invasive, non-invasive treatment method. The principle is to focus high-intensity ultrasound on the target area. Energy is absorbed by the target tissue and converted into thermal energy. The local temperature quickly reaches a maximum of 85 ° C. It induces coagulative necrosis of focus tissue cells, but does not damage the tissues surrounding the treatment targ
45371844|NCT04231851|Drug|Glasdegib|Given PO
45490211|NCT05597982|Other|Kidney Transplant Fast Track (KTFT)|Streamlined KT evaluation involving completion of most or all testing on the same day a patient arrives for their first pre-transplant clinic appointment. Or, a transplant clinic scheduler secures testing within a 4 week period.
45753551|NCT04197440|Drug|Placebo|20 µl of water will be applied to a previously determined area on the volar forearm followed by a prick through the drop
45371845|NCT04231851|Drug|CPX-351|Given IV
45371846|NCT04225897|Drug|RV521|RV521 is an RSV F protein inhibitor administered orally
45371847|NCT04225897|Drug|Placebo|vehicle administered orally
45371853|NCT04214067|Procedure|Biospecimen Collection|Undergo collection of blood
45371854|NCT04214067|Radiation|Brachytherapy|Undergo vaginal brachytherapy
45371855|NCT04214067|Procedure|Computed Tomography|Undergo CT
45371856|NCT04214067|Radiation|External Beam Radiation Therapy|Undergo EBRT
45371857|NCT04214067|Procedure|Magnetic Resonance Imaging|Undergo MRI
45371858|NCT04214067|Biological|Pembrolizumab|Given IV
45371859|NCT04214067|Other|Quality-of-Life Assessment|Ancillary studies
45371860|NCT04214067|Other|Questionnaire Administration|Ancillary studies
45371861|NCT04214067|Procedure|X-Ray Imaging|Undergo x-rays
45371862|NCT04201561|Drug|sodium selenite pentahydrate|High-dose inorganic selenium (2000 μg/40 ml) will be administered before chemotherapy in patients assigned to the experimental group.
45371863|NCT04201561|Drug|Normal saline|Normal saline (40 ml) will be administered before chemotherapy in patients assigned to the control group.
45371864|NCT04201561|Drug|Chemotherapy|Paclitaxel (175mg/m2), carboplatin (AUC 5.0 or 6.0) IV, and bevacizumab IV (15mg/kg) D1, every three weeks.
45371865|NCT04198012|Device|HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
45371866|NCT04190589|Device|Robot-assisted laparoscopic extended right colectomy|An extended right hemicolectomy with total mesocolic excision and meticulous central dissection as described by Hohenberger will be performed with the DaVinci Xi robot by one of two dedicated surgeons
45692579|NCT05702619|Diagnostic Test|CT-guided Bone Biopsy|A CT-guided biopsy of a bone metastasis that is deemed to be easy to biopsy and in an area without major risk for pathological fracture or bleeding will be taken during the biopsy visit. Patients will receive routine local anaesthetic of the region to be biopsied followed by thorough disinfection of the biopsy site with antiseptic wipes. Patients will be asked to fast on the day of the procedure and to have an intravenous cannula inserted to allow the use of medication causing minimal sedation (for example midazolam and/or fentanyl) during the procedure if required to alleviate discomfort or pain.
45692580|NCT05702619|Diagnostic Test|TRUS-guided Targeted Transperineal Prostate Biopsy|Transperineal Prostate Biopsy will be performed following standard clinical practice of local department. This will include pre-operative oral analgesia and prophylactic antibiotic treatment according to local hospital policy for transperineal prostate biopsies.
45371867|NCT04184609|Other|Control|In this condition, the participants will not receive any medications or drugs before exercise
45371868|NCT04184609|Drug|Albuterol|180 mcg of Albuterol will be administered before exercise
45692581|NCT05702619|Procedure|Radical Prostatectomy|Radical Prostatectomy will be performed according to standard of care robotic approach and as relayed to the patient by the attending urologic surgeon. The side effects of the surgery are the ones reported in the literature and the latest participant information leaflet provided prior patient consent (e.g. risk of erection disfunction, incontinence, etc.).
45692582|NCT05702619|Diagnostic Test|Whole-body MRI|Whole-body MR imaging (wbMRI) will be performed once, before or after the biopsy study visit, depending on available examination slots in the Department of Radiology. WbMRI images will allow comparison of the numbers of bone metastases detected by routine bone scan and wbMRI for sensitivity assessment of both techniques for oligometastatic disease.
45692583|NCT05702619|Diagnostic Test|Prostate MRI scans|Patients within Arm 2 will be offered the option to undergo additional MR imaging of the pelvis in addition to any standard of care imaging acquired. In patients who agree to undergo additional scans, MRI scans will be performed on 2 occasions prior to the radical prostatectomy. MRI scans will be acquired on either the MR sim diagnostic scanner, on the MR Linac scanner or on both.
45753552|NCT04197440|Drug|BAM8-22 with 1 SPT|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 1 prick through the drop
45753553|NCT04197440|Drug|BAM8-22 with 5 SPT|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 5 prick through the drop
46053430|NCT05276180|Other|Arm A) Multifactorial intervention strategy|"Implementation of the multifactorial intervention strategy will be supported by the following components:~1) An implementation team at each intervention unit consisting of 5-6 HCWs is responsible for informing and engaging all HCWs at the unit. For implementing the various components of the strategy. They will have the role of planning regular workplace meetings. 2) One or two internal facilitators will be the link between the external facilitator and the care unit. The internal facilitator will give support with material, information and will be able to ask questions of the external facilitator.~3) External facilitator will ensure that the implementation process works according to plan. The research team will present the results of SMET to the implementation team.~4) The research group will be project leaders and support the external facilitators. They will provide workshops and will also be responsible for data collection."
45753554|NCT04197440|Drug|BAM8-22 with 25 SPT|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 25 prick through the drop
45371873|NCT04180215|Drug|HB-201 intravenous administration.|Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).
45371874|NCT04180215|Drug|HB-202 intravenous administration alternating with HB-201 intravenous administration.|Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).
45371875|NCT04180215|Drug|HB-201 intravenous administration + standard of care regimen including pembrolizumab.|Dose Expansion
45371876|NCT04180215|Drug|HB-202 / HB-201 alternating intravenous administration + pembrolizumab.|Dose Expansion
45371877|NCT04180215|Drug|HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab.|Dose Expansion
45371878|NCT04180215|Drug|HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)|Dose escalation; 10 patients
45371879|NCT04162873|Drug|Celecoxib|Given PO or via feeding tube
45371880|NCT04162873|Other|Placebo|Given PO or via feeding tube
45371881|NCT04162873|Other|Quality-of-Life Assessment|Ancillary studies
45371882|NCT04162873|Other|Questionnaire Administration|Ancillary studies
45371883|NCT04157348|Biological|Benralizumab|30 mg/mL solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC)
45371884|NCT04157348|Biological|Mepolizumab|3x100 mg vials of powder for solution for injection reconstituted into 3 separate 1 mL syringes for administration on each dosing occasion. Injection volume per syringe is 1 mL. Mepolizumab active solution will be administered subcutaneously (SC)
45371885|NCT04157348|Biological|Placebo to Mepolizumab|Matching placebo: 0.9% sodium chloride, solutions for injection in 1mL syringes (3 syringes will be used on each dosing occasion). Injection volume per syringe is 1mL. Placebo to Mepolizumban will be administered subcutaneously (SC)
45371886|NCT04157348|Biological|Placebo to Benralizumab|Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC)
45371887|NCT04151602|Behavioral|Smoked illicit drug use|The exposure of interest is current smoked illicit drug use, particularly methamphetamine and/or methaqualones
45371892|NCT04100018|Biological|Nivolumab|Specified dose on specified days
45753555|NCT04197440|Drug|BAM8-22 with inactivate cowhage spicules|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
45371893|NCT04100018|Drug|Prednisone|Specified dose on specified days
45371894|NCT04100018|Drug|Docetaxel|Specified dose on specified days
45753556|NCT03023774|Drug|Neupogen|neupogen 30 IU once intrauterine at the time of ovum pickup
45753557|NCT04021160|Device|High frequency repetitive transcranial magnetic stimulation (rTMS)|10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.
45371895|NCT04100018|Other|Placebo|Specified dose on specified days
45371896|NCT04098770|Biological|Allogeneic Adoptive Immune Therapy|A dose (2-3 times) of AAIT was added on conventional treatment for advanced AIDS patients
45371897|NCT04097184|Device|Neurostimulation with non-implanted electrodes|Neurostimulation with non-implanted electrodes
45371898|NCT04081220|Drug|IMG-7289|Single starting dose with individualized dose titrations throughout
45371899|NCT04061421|Drug|ASTX727|Taken by mouth daily during days 1-5 of every 28-day cycle.
45371900|NCT04061421|Drug|Itacitinib|Taken by mouth daily during each 28-day cycle
45371901|NCT04047303|Drug|CC-90010|CC-90010
45371902|NCT04046900|Biological|Vaginal microbiome transplant|Vaginal fluid from healthy donors
45371903|NCT04046900|Drug|Oral Metronidazole|500mg oral metronidazole twice daily for 7 days
45371904|NCT04046900|Other|Sterile saline|700 uL of sterile saline placed in the vagina as a placebo intervention.
45371905|NCT03992404|Drug|NT 201|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
45371906|NCT03992404|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
45371907|NCT03989115|Drug|RMC-4630|RMC-4630 for oral administration
45371908|NCT03989115|Drug|Cobimetinib|Cobimetinib for oral administration
45846760|NCT02635542|Drug|Cisatracurium|Cisatracurium will be used to maintain neuromuscular blockade during general anesthesia.
45846761|NCT02636712|Device|ImageReady™ MR Conditional Pacing System|
45846762|NCT02637804|Device|stenfilcon A|contact lens
45846763|NCT02637804|Device|narafilcon A|contact lens
45846764|NCT02637804|Device|delefilcon A|contact lens
45846765|NCT02638974|Other|Medical Skin Camouflage|Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions
45846766|NCT02639286|Drug|ISIS 304801|300 mg of ISIS 304801 administered as SC
45846767|NCT02639286|Drug|Placebo|Placebo administered via SC
45846768|NCT02642952|Other|non-invasive methods|To measure central hemodynamics and arterial stiffness by non-invasive methods using SphygmocoR (Atcor Medical, Sydney, Australia) before and after the procedure.
45490212|NCT05597982|Other|Peer Navigation (PN)|Uses trained, previous KT recipients who meet weekly to monthly with patient participants to provide tailored information and assistance in completing the necessary steps to proceed to transplant.
45692584|NCT05702619|Other|Baseline bloods - for germline testing|"Arm 1 -~1-2 x 3.5mL blood samples collected into EDTA tubes for germ line DNA extraction and processing to PBMC for banking and future profiling of immune cell populations~1 x 10mL serum tubes for future, biobank related research projects, ie lipidomics, metabolics and microRNA analysis~ARM 2 -~A blood sample (maximum 20ml) will be taken for standard of care blood tests prior to prostatectomy including Full Blood Count, Renal Function and PSA. At the same time these standard of care bloods are taken, additional bloods - a maximum of 30ml - will be taken for research purposes as required for the following downstream analysis:~Germ line DNA extraction and optional processing to PBMC for banking and future profiling of immune cell populations~Biobank related research projects, ie lipidomics, metabolics and microRNA analysis"
45692585|NCT05702619|Other|Baseline bloods for CTCs and ct DNA taken at same time as baseline bloods in Arm 1|2 x 10mL Streck cell-free DNA blood collection tubes® for circulating tumour cell (CTC) collection and circulating tumour DNA (ctDNA) extraction.
45692586|NCT05702619|Other|Post-pimonidazole bloods for CTCs and ctDNA|ARM 1 - 2 x 10mL Streck cell-free DNA blood collection tubes® for circulating tumour cell (CTC) collection and circulating tumour DNA (ctDNA) extraction.
45371909|NCT03989115|Drug|Drug: Osimertinib|Osimertinib for oral administration
45371910|NCT03988608|Drug|Eltrombopag 25 mg|film-coated tablets containing 25 mg of eltrombopag free acid in each tablet
45371911|NCT03971071|Drug|Erenumab 70 mg|Erenumab once every 4 weeks. Subcutaneous injection.
45692587|NCT03586089|Drug|Phenobarbital Sodium|Single IV dose of phenobarbital (7.5 mg per kg of body weight prepared in 250 ml D5W)
45371912|NCT03971071|Drug|Erenumab 140mg|Erenumab once every 4 weeks. Subcutaneous injection.
45371913|NCT03971071|Drug|Placebo|Placebo once every 4 weeks. Subcutaneous injection.
45692588|NCT03586089|Drug|Inactive placebo|Single dose of inactive placebo prepared in 250 ml D5W).
45692589|NCT01770379|Biological|Secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)"
45371914|NCT03969901|Drug|IMI/REL|"Age-based dosing:~12 to <18 years, IMI 500 and REL 250 mg, IV infusion every 6 hours~2 to <12 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~3 months to <2 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~Birth to <3 month, IMI 15 and REL 7.5 mg/kg, IV infusion every 8 hours NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention."
45371915|NCT03969901|Drug|Active Control|"All active control medications will be chosen from a list of acceptable approved agents for each infection type (HABP or VABP, cIAI, and UTI) and will be given via IV infusion, per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.~NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention. All oral switch medications will be chosen from a list of acceptable approved agents."
46053431|NCT05276180|Other|Arm B) Single intervention strategy|No further interventions other than access to the Swedish guideline for patient handling and movement and the results from the SMET questionnaire will be presented to the manager. Arm B will be assigned an external facilitator who provides information, is present at the start-up meeting and will be the contact person during the study period. No further support will be given to the care units in arm B.
46053432|NCT05275127|Other|changes of gingival crevicular fluid miRNA|Evaluation of changes of gingival crevicular fluid miRNA after periodontal treatment
46053433|NCT05273359|Drug|Benralizumab|15 subjects (≥220 eosinophils/microliter) will receive benralizumab 100 mg subcutaneous injection every 4 weeks for 4 complete doses.
46053434|NCT05273359|Other|Benralizumab placebo|15 subjects (>220 eosinophils/microliter) will receive a matching benralizumab placebo subcutaneous injection every 4 weeks for 4 complete doses.
45371928|NCT03946748|Drug|REGN3918|Single intravenous (IV) dose, then a subcutaneous (SC) dose once weekly (QW).
45371929|NCT03941080|Diagnostic Test|fecal sample|patients will collect fecal samples at home prior to treatment and at 3 months after start of treatment at the time of response evaluation using a standard stool-collection-kit.
45692590|NCT01770379|Biological|Placebo|
45692591|NCT01986881|Drug|Ertugliflozin|Oral, once daily, for up to approximately 6 years
45692592|NCT01986881|Drug|Placebo|Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years
45753558|NCT04021160|Device|Sham stimulation|A sham coil will be used that is shielded so that it produces sounds and sensations similar to the active coil but does not produce therapeutic effects. 10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.
45753559|NCT03023618|Device|FloTrac|Stroke Volume has been maintained at 90% of the maximal Stroke Volume as in NICE protocol 2011
45753560|NCT04020614|Other|Survey|A survey with 13 questions will be applied to the patients
45692593|NCT01986881|Drug|Glycemic Rescue|Doses of background anti-hyperglycemic agents (AHA), medications will be required to be held constant in all participants enrolled for the initial 18 weeks of the trial with 2 exceptions: First, participant will be prescribed glycemic rescue therapy if they meet specific, progressively more stringent, glycemic thresholds based on repeated, confirmed fasting plasma glucose (FPG) measured at a central laboratory. Second, a participant experiencing clinically significant hypoglycemia according to the investigator at any time during the trial is permitted to have the dose of appropriate background AHA (e.g., insulin, sulfonylurea [SU], glinide) reduced or discontinued as per the judgment of the investigator or the treating physician. Choice and dosing of glycemic rescue will be at the discretion of the investigator or the treating physician consistent with standards of care for management of patients with Type 2 diabetes mellitus (T2DM) within the country of the investigational site.
45692594|NCT04592653|Biological|Nemvaleukin alfa|IV infusion over 30 minutes
45692595|NCT04592653|Biological|Pembrolizumab|IV infusion over 30 minutes
45692596|NCT03156075|Behavioral|Nutrition and exercise program|"Nutrition education will be about increasing the intake calcium and vitamin D rich foods and exposure to sun will provided for the intervention group.~Education of the patients about exercises that increases the strength of lower limb and hip muscles to increase the mobility of the patients earlier and decrease the mortality in turn."
45692597|NCT03585855|Other|MSC transplantation|MSC transplantation: patients with ABMR treated with MSC transplantation
45371930|NCT03941080|Behavioral|questionnaire|At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.
45371931|NCT03941080|Diagnostic Test|Blood sample|4 tubes of blood are collected prior to treatment and at 3 months after start of treatment at the time of response evaluation and sent to the UMCG for storage.
45371932|NCT03939897|Drug|Abemaciclib|Given PO
45371933|NCT03939897|Procedure|Biopsy|Undergo tissue biopsy
45371934|NCT03939897|Procedure|Biospecimen Collection|Undergo blood sample collection
45371935|NCT03939897|Drug|Copanlisib Hydrochloride|Given IV
45371936|NCT03939897|Procedure|Diagnostic Imaging|Undergo imaging
45371937|NCT03939897|Procedure|Echocardiography|Undergo ECHO
45371938|NCT03939897|Drug|Fulvestrant|Given IM
45371939|NCT03939897|Procedure|Multigated Acquisition Scan|Undergo MUGA
45692598|NCT03580395|Drug|Apatinib|500mg, day1-21,neoadjuvant therapy
45371940|NCT03937843|Drug|Carboplatin|Patients in cohort 1 will receive a 60-minute i.v. infusion of carboplatin AUC 7 at day 1 of treatment.
45371941|NCT03937843|Drug|Cisplatin|"Patients in cohort 2 will receive on day 1 to day 5:~a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
45490213|NCT05681767|Behavioral|Motivational multicomponent lifestyle intervention + Treatment as usual|"Study intervention and treatment as usual~The study intervention is a multicomponent lifestyle intervention that targets exercise, diet, and stress management, and is conducted by motivational interviewing. The study nurse provides the study intervention. The intervention is conducted by motivational interviewing and includes the key elements of lifestyle interventions identified as effective (assessment of behavior at the baseline, giving information and advising, individualized goal setting, setting an action plan, monitoring a behavioral change, and giving feedback).~The intervention consists of individual appointments (2 x 45-60 min) and a telephone session ( 2 x 15 min) for three months. The participants receive a short educational guide (A4) on the lifestyle behavior recommendations."
45490214|NCT05681767|Other|Treatment as usual|Treatment as usual
45490215|NCT01310309|Device|Coronary artery placement of a drug-eluting stent|Coronary artery placement of a drug-eluting stent (XIENCE V® EECSS)
45490216|NCT01353274|Drug|Micamlo|Telmisartan plus Amlodipine T40/A5
45490217|NCT05005507|Drug|JNJ-73763989|JNJ-73763989 will be administered subcutaneously once every 4 weeks.
45490218|NCT05005507|Drug|PegIFN-alpha-2a|PegIFN-alpha-2a will be administered subcutaneously once weekly.
45490219|NCT05005507|Drug|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally once daily.
45692599|NCT03580395|Drug|paclitaxel|paclitaxel 165mg/m2 day 1
45490220|NCT05005507|Drug|TAF|TAF film-coated tablet will be administered orally once daily.
45490221|NCT05005507|Drug|ETV|ETV film-coated tablet will be administered orally once daily.
45490222|NCT04739358|Drug|Tepotinib|Subjects will receive tepotinib daily in cycles of 21-day duration. Subjects in the Combination Therapy arm will continue to receive their last tolerable dose of tyrosine kinase inhibitor (TKI) together with tepotinib.
45692600|NCT03580395|Drug|cisplatin|cisplatin 40mg, day 1-3
45371942|NCT03937843|Drug|Etoposide|"Patients in cohort 2 will receive on day 1 to day 5:~a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
45371943|NCT03924661|Device|Aortic Valve Replacement|SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve as a replacement device for patients with a diseased, damaged, or malfunctioning aortic valve
45490223|NCT03729479|Behavioral|DASH diet|Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).
45490224|NCT03729479|Behavioral|Very low carbohydrate, ketogenic diet|Participants will be taught to follow a very low-carbohydrate diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).
45490225|NCT03729479|Behavioral|Extras|Participants will be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior.
45692601|NCT01770145|Drug|APOKYN|"Apokyn will be titrated to an optimum dose which reproduces 90% of the subjects' best on UPDRS score during the Initiation Period. During the APOKYN Treatment Period, subjects will inject the dose identified in the initiation period once daily at the time of their normal scheduled L-Dopa dose (L-Dopa will be delayed by 40 minutes)."
46053435|NCT05273359|Other|Comparison (control) group; no intervention|15 subjects (<150 eosinophils/microliter) will not receive any intervention.
46053436|NCT05272059|Drug|MHS552|MHS552 will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
46053437|NCT05272059|Drug|Placebo|Placebo will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
46053438|NCT05266144|Procedure|radiofrequency ablation|Bilateral pulmonary vein isolation, a kind of radiofrequency ablation, is performed in atrial fibrillation patients for atrial arrhythmia therapy.
46053439|NCT05264129|Drug|Atogepant|Oral Tablet
46053440|NCT05264129|Drug|Ubrogepant|Oral Tablet
46053441|NCT05259345|Procedure|Bilateral SE-TAP|A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given between the internal oblique and transversus abdominis muscles toward the lateral border of the semilunar along the costal margin.
46053442|NCT05259345|Procedure|Bilateral M-TAPA|A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given into the layer between the transverse abdominal muscle and the inferior plane of the costal cartilage at the midclavicular line, in the sagittal plane.
45371946|NCT03919071|Procedure|Biospecimen Collection|Undergo collection of blood
45692602|NCT01770145|Drug|L-dopa|Subjects on a stable L-Dopa regimen will be entered into the study. For the L-Dopa Baseline Period through the Initiation Period, subjects will continue their normal L-Dopa dosing regimen. During the APOKYN Treatment Period, subjects will replace their normally scheduled first morning L-Dopa dose with an APOKYN injection, and then administer their normal first morning L-Dopa dose 40 minutes later.
45490226|NCT05221255|Other|spinal magnetic stimulation|"Biofeedback pelvic floor muscle training sessions will be performed for both groups for a total of 12 sessions. Menstruating women will be temporarily withdrawn from BF sessions till end of the menses. The session will last for 30 minutes of transrectal pressure biofeedback relaxation technique. Auditory and visual feedback will be provided in addition to positive verbal reinforcement.~Sham SMS will be used in the Sham group using the placebo program in the magnetic stimulation machine.~Spinal magnetic stimulation using the Neuro-MS/D machine. It will be used in spinal magnetic stimulation group, circular coil will be used to stimulate S2,3 and 4 sacral roots. Intensities will be adjusted to 50-70 % of maximal output (2.2 Tesla), stimulation frequency will be fixed at 20 Hz, burst length = 5 seconds, inter-burst interval = 25 seconds."
45490227|NCT04893343|Other|Antibiotic treatment|Antibiotic treatment
46053443|NCT05259345|Procedure|Bilateral RSB|A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given between the rectus muscle and posterior rectus sheath bilaterally.
45490228|NCT04893343|Other|No antibiotic treatment|No antibiotic treatment
45490229|NCT04831021|Procedure|Dialysis without physical exercise|Hemodialysis control condition
45490230|NCT04831021|Procedure|Dialysis with pre-dialytic physical exercise|Patients will pedal for 30 minutes using a ergometer directly attached to the dialysis bed. The exercise will be performed 60 minutes before connection to hemodialysis.
45490231|NCT04831021|Procedure|Dialysis with per-dialytic physical exercise|Patients will pedal for 30 minutes using a ergometer directly attached to the dialysis bed. The exercise will start 30 minutes after the start of dialysis.
45490232|NCT02690194|Device|Placebo Group|The placebo group will wear headphones and listen to nature sounds.
45490233|NCT02690194|Device|Buddhify Therapy|The experimental group will complete a Buddhify relaxation therapy session, before their injection. This therapy consists of wearing headphones and listening to guided meditation instructions.
45490234|NCT05399641|Drug|Ibrexafungerp|Each day dosing will consist of two 150mg tablets taken BID.
45490235|NCT05593666|Drug|LXE408|Film-coated tablets
45371947|NCT03919071|Drug|Dabrafenib Mesylate|Given PO
45371948|NCT03919071|Procedure|Lumbar Puncture|Undergo lumbar puncture
45371949|NCT03919071|Procedure|Magnetic Resonance Imaging|Undergo MRI
45371950|NCT03919071|Radiation|Radiation Therapy|Undergo RT
45371951|NCT03919071|Drug|Trametinib Dimethyl Sulfoxide|Given PO
45490236|NCT05593666|Other|Placebo|Placebo film-coated tablets
45490237|NCT05593666|Drug|AmBisome®|Sterile lyophilised powder in a 15 mL sterile clear glass vial
45490238|NCT04986163|Device|Non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDSTORM monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is ANSPEC and the second monitor used is MEDSTORM.
45371955|NCT03913273|Procedure|AMI transtibial amputation|Two Agonist-antagonist myoneural interfaces (AMIs) were surgically constructed during a modified transtibial amputation procedure. Each AMI was made of natively innervated and vascularized muscle segments - an agonist and antagonist - that were surgically connected in series within the amputated residuum. Tarsal tunnels, including segments of each tunnel's native tendon component, were procured from the amputated joint. The tunnels were affixed to the residual limb tibia and the AMIs were constructed by coaptation of an agonist and an antagonist muscle to either end of the tendon passing through the tunnel. Consequently, the force produced by one muscle stretches its partner such that the AMI can communicate signals from the mechanoreceptors in both muscles to the central nervous system.
45490239|NCT04986163|Device|Non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is ANSPEC-PRO and the second monitor used is MEDASENSE.
45490240|NCT04986163|Device|Non-invasive analgesia monitoring with MEDSTORM monitor and MEDASENSE monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is MEDSTORM and the second monitor used is MEDASENSE.
45490241|NCT02684344|Drug|Tamsulosin|Tamsulosin may have prophylactic properties against post-operative urinary retention
45490242|NCT02684344|Other|Education|Education about signs and symptoms of urinary retention
45490243|NCT05199571|Biological|Ofatumumab|Solution for injection in an autoinjector (pre-filled pen) containing 20 mg ofatumumab
45490244|NCT05694832|Behavioral|Expressive Writing|Creative writing, discussion and social support, in a group setting via videoconference
45490245|NCT03974100|Biological|GP2411|60 mg /mL subcutaneous injection every 6 months
45371956|NCT03913273|Procedure|Standard transtibial amputation|A standard transtibial amputation was performed according to traditional techniques. No surgical construction of agonist-antagonist myoneural interfaces (AMIs) was performed.
45490246|NCT03974100|Biological|EU-Prolia (EU-authorized Prolia®)|60 mg /mL subcutaneous injection every 6 months
45490247|NCT02689804|Drug|LNG-EC|FDA-approved emergency contraceptive pill containing levonorgestrel 1.5mg
45490248|NCT02689804|Drug|UPA-EC|FDA-approved emergency contraceptive pill containing ulipristal acetate 30mg
45490249|NCT02946931|Drug|Prizbind®|Prizbind®
45490250|NCT04360369|Device|IOP with Goldmann Applanation Tonometer|Measurement of intraocular pressure (IOP) with Goldmann Applanation Tonometer. Measurement will be used to categorize each subject as having Low IOP (7 to 16 mmHg), Medium IOP (>16 to <23 mmHg), or High IOP (>23 mmHg).
45490251|NCT04360369|Device|IOP with comparator ORA G3 and ic100 tonometers|Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers.
45490252|NCT04360369|Device|IOP with Tono-Vera Tonometer|Measurement of IOP with Tono-Vera Tonometer
45490253|NCT04769323|Device|Virtual Reality|Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.
45371957|NCT03913117|Biological|pNGVL4aCRTE6E7L2|Naked pNGVL4aCRTE6E7L2 DNA plasmid
45371958|NCT03913117|Biological|TA-CIN|TA-CIN is a single fusion protein comprised of HPV16 L2, E7 and E6 proteins linked in tandem.
45371959|NCT03900000|Other|Physiotherapy|Ambulatory leg-muscle oriented physiotherapy (2 x 45 minutes per week for at least 8 weeks) at Aachen University Hospital. Daily protocol of leg muscle training, exercises, sufficient fluid intake of 2liter/day, pressure stockings.
45371960|NCT03899155|Drug|Nivolumab|Solution for IV Injection
45371961|NCT03896711|Behavioral|MEMORI Corps program|Activity-based companion care program. Delivered by trained senior volunteers, supported by a clinical team, over a 12-week intervention period (8 hours per week, 2 or 3 days per week) for each person with dementia/family caregiver dyad. Primary roles of the volunteers are to provide in-home supervision, peer-to-peer companionship, and a evidence-based individualized activity program that focuses on meaningful, engaging and enjoyable activities that match PWD abilities and interests.
45490254|NCT04769323|Other|Traditional home exercises|Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.
45490255|NCT03959202|Behavioral|ELDERFITNESS|In-person training with the exercise trainer ( 3 sessions for participants without cognitive impairments over 24 weeks & 4 sessions for older adults with mild cognitive impairment over 16 weeks). Self-monitoring level of physical activity (steps & minutes of moderate activity) using the smart watch. . The Google calendar and Fitbit apps will send messages and alerts to the subject's smart watch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer. Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans.Financial incentives: when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects.
45490256|NCT03959202|Other|Control|General Education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life Program book from the National Institute on Aging
45490257|NCT04752085|Diagnostic Test|Chitotriosidase activity|The chitotriosidase activity will be measured in all the subjects
45490258|NCT05597670|Other|traditional knee rehabilitation program|Patients in this group will receive a traditional therapeutic knee rehabilitation program in the form of mini-squatting exercise (up to 45 degree knee flexion measured by a universal goniometer) , strengthening of hip abductors and external rotators
45490259|NCT05597670|Other|proximal stabilization|the principles of proximal stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
45490260|NCT04353271|Drug|Hydroxychloroquine|Hydroxychloroquine 800 mg initial dose then 6-8 hours later HCQ 600 mg, then 200 mg three times per day for 4 days.
45490261|NCT04353271|Other|Placebo|Placebo take 4 tabs, then 6-8 hours later take 3 tabs, then take 1 tab three times per day for 4 days.
45490262|NCT03417882|Biological|GRN-1201 + Pembrolizumab|GRN-1201 will be administered in combination with Pembrolizumab
45490263|NCT01374568|Drug|sitagliptin|sitagliptin 100mg daily
45692603|NCT01770145|Drug|Trimethobenzamide|Following the L-Dopa Baseline Period, subjects will initiate trimethobenzamide treatment TID for a minimum of 3 days during a Anti-Emetic Pretreatment Period. Subjects will continue trimethobenzamide therapy TID through the duration of the APOKYN Initiation Period and APOKYN Treatment Period.
45371962|NCT03896711|Other|Augmented Waitlist Control|"Persons with dementia/caregivers will continue any services and supports being used, will receive a free copy of A Caregiver's Guide to Dementia: Using Activities and Other Strategies to Prevent, Reduce and Manage Behavioral Symptom103), written educational materials on management of CG stress/well-being, and bi-weekly check-in calls to answer any questions about the materials. Volunteers randomized to waitlist control will continue with usual activities (volunteer or other), and will receive additional written educational materials on cognitive health (NIA) and exercise and Physical Activity (Go4Life), referrals to the Baltimore City Commission on Aging and Retirement Education for volunteering opportunities, and bi-monthly check-in calls to answer questions and maintain engagement. Waitlist dyads will be followed at specified intervals by the research team and then offered an opportunity for participation in the intervention arm."
45490264|NCT01374568|Other|Placebo|1 pill daily
45490265|NCT03706183|Diagnostic Test|Ischemia-modified albumin|The biomarker was investigated in many studies and it was associated with the ischemia and tissue injury.
45490266|NCT03706183|Diagnostic Test|Hearing thresholds|The hearing levels will be determined for each group.
45490267|NCT02991456|Drug|Rolapitant|single 180 mg dose by mouth
45490268|NCT02991456|Drug|Ondansetron|8 mg by mouth daily
45490269|NCT05509036|Other|No interventions|No interventions
45490270|NCT03706105|Behavioral|Cardiac Rehabilitation|3 x week ~1 hour of exercise + education
45490271|NCT03114826|Genetic|To study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker|Study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker of the occurrence of renal cell carcinoma in renal transplant patients.
45490272|NCT01312441|Drug|Ergocalciferol|Ergocalciferol capsules 50,000 IU once weekly for 6 months
45490273|NCT01312441|Drug|Placebo|Placebo by mouth once weekly for 6 months
45490274|NCT02682784|Drug|Oxytocin|Nasal spray based on naturally occurring hormone, oxytocin.
45490275|NCT02682784|Drug|Placebo|
45490276|NCT03165604|Other|standard information|The participates will be given a standard information regarding the water drink before physical activity
45490277|NCT03165604|Other|positive information|"The participates will be given positive information (the drink will be presented as an energy drink) regarding the drink before physical activity"
46053444|NCT05248178|Behavioral|CO-OP Procedures|CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the Goal-Plan-Do-Check process.The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
45490278|NCT03164824|Other|questionnaire|"Cross-cultural adaptation stage:~The FRI was cross-culturally adapted to Thai (called the Thai FRI) and the pre-final version of the Thai FRI was administered to patients.~Psychometric properties testing stage:~The questionnaires were administered 3 times: the first visit, the second visit and at 2 weeks.~At the first visit: the patients with back pain completed the Thai FRI , Thai Roland-Morris Disability (Thai RM), Thai modified Oswestry Low Back Pain Disability (Thai modified ODQ), Thai multi-level Roland-Morris Disability (Thai multi-level RM). The patients with neck pain completed the Thai FRI and Thai Neck Disability Index.~At the second visit: all patients completed the Thai FRI and Global Perceived Effect Scale (GPES).~At 2 weeks: the patients completed the same questionnaires as the first visit. All patients and their treating physical therapists completed the GPES."
45490279|NCT03164902|Device|Digital Medicine|The subjects in the study will be monitored using the Proteus Discover offering. Subjects will use Proteus Discover plus a digital version of HCV therapy (IS co-encapsulated with fixed-dose velpatasvir and sofosbuvir; fixed-dose ledipasvir and sofosbuvir; or fixed-dose glecaprevir and pibrentasvir; or fixed-dose sofosbuvir, velpatasvir, and voxilaprevir). The subject's prescribed HCV medication will be co-encapsulated with the Proteus Ingestible Sensor pill by an appropriately licensed and qualified pharmacy as per a licensed health care provider's order (prescription).
46053445|NCT05248178|Device|tDCS|Each session will begin with 20 minutes of anodal tDCS applied to the ipsilesional dorsolateral prefrontal cortex (DLPFC) at 1.5 mA. The cathode will be placed over the contralesional supraorbital area. Direct current will be applied through two saline soaked sponges placed on the scalp. The tDCS device contains software for double-blinded delivery.
45371966|NCT03845985|Behavioral|Seeking Safety + Signs of Safety toolkit|"Seeking Safety is an existing, present-focused, first-stage manualized treatment for trauma and addiction. Session content engages clients in themes relevant to addiction and trauma, and to help them learn a specific skill to target symptoms of both AUD and PTSD (e.g., Coping with Triggers, Asking for Help).~Signs of Safety is a culturally and linguistically Deaf-accessible toolkit to be used alongside Seeking Safety. The toolkit includes a therapist guide and population-specific client materials (e.g., visual handouts; ASL teaching stories on digital video). It is designed for Deaf/signing clinicians, as well as non-signing clinicians working with ASL interpreters."
46053446|NCT05248178|Behavioral|Computer Cognitive Training Procedures|Individuals receiving computerized cognitive training will receive an equal dosage of 12, 45-minute sessions directly following the assigned tDCS condition. The online training software of BrainHQ will be used. BrainHQ is a well-recognized cognitive training program that targets the areas of attention, memory, processing speed, people skills, intelligence, and navigation. BrainHQ tracks progress and automatically grades difficulty as appropriate.
45490280|NCT03164746|Other|Dry sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in Dry damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
45490281|NCT03164746|Other|WET sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in wet damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
45371967|NCT03839823|Combination Product|Docetaxel / Capecitabine|"Docetaxel (IV Infusion) / Capecitabine (Tablets for oral use):~Docetaxel once, on day 1 of the 3-weeks cycle. Capecitabine twice daily, on Days 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Docetaxel (60 - 75 mg/m²)/capecitabine (1600 - 2500 mg/m²/day)"
45371968|NCT03839823|Combination Product|Capecitabine / Vinorelbine|"Capecitabine (Tablets for oral use) / Vinorelbine (Capsule for Oral use/IV infusion ).~Capecitabine twice daily on day 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Vinorelbine, once, on Day 1 and Day 8 in 3 weeks cycles.~Capecitabine (1600 - 2500 mg/m2/day)/vinorelbine (60 to 80 mg/m2/day [oral] or (25 to 30 mg/m2 [IV infusion]"
46053447|NCT05248178|Device|sham tDCS group|Sham tDCS will involve the same preparation as in tDCS, but the current will ramp up for only 30 seconds and then return to zero. This method allows for sensations on the scalp associated with tDCS without inducing any neural changes.
46053448|NCT05226455|Drug|venetoclax + azacitidine +/- donor lymphocyte infusion|Venetoclax will be given once daily orally on days 1 to 14 for all cycles. Venetoclax + azacitidine +/- donor lymphocyte infusion (12 cycles maximum)
46053449|NCT05225688|Behavioral|Bike exertion test|maximal exercise test
45490282|NCT05367895|Biological|COVID-19 Vaccine (Vero Cell), Inactivated|"Form: CoronaVac® is a milky-white suspension. Stratified precipitate may form that can be dispersed by shaking.~Presentation: Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen.~Administration and schedule: Two doses with an interval of 21 days should be administered for primary immunization. 0.5 mL per dose.~Route: IM in the deltoid region of the upper arm after shaking the vial well before use."
45490283|NCT03165448|Diagnostic Test|Pre-operative USOS scale testing|Patient has to self-report USOS questionnaire just before the procedure as main scale.
45490284|NCT03165448|Diagnostic Test|Pre-operative SDPQ, MDAS and VAS testing|Patient has to sel-report SDPQ, MDAS and VAS questions as control scales.
45490285|NCT03165448|Diagnostic Test|Post-operative doctor's reported USOS|Operating doctor has to fill the USOS doctor's part o questionnaire just after the procedure.
45490286|NCT03165448|Diagnostic Test|Re-testing 4-6 weeks later|All the participants has to refill USOS questionnaire 4-6 weeks later.
46053450|NCT05214170|Device|Electroanatomic mapping with the NeuTrace System|Patients with arrhythmias undergo electroanatomic mapping with the NeuTrace System.
45371969|NCT03839823|Combination Product|Paclitaxel / Gemcitabine|"Paclitaxel (IV Infusion) / Gemcitabine (IV Infusion):~Paclitaxel via 3-hour intravenous (IV) infusion on Day 1 in 3-weeks cycles, OR Paclitaxel via 1 hour intravenous (IV) infusion on Day 1 and day 8- in 3-weeks cycles.~Gemcitabine at via 30 minute IV infusion on Day 1 and Day 8 in 3 weeks cycles.~Paclitaxel (175 mg/m2) (on Day 1 in 3-weeks cycles)/ gemcitabine (1000 - 1250 mg/m2)~OR~Paclitaxel (80 - 90 mg/m2) (on Day 1 and Day 8 in 3-weeks cycles) / gemcitabine (800 - 1250 mg/m2)"
45371970|NCT03839823|Drug|Ribociclib|Dose: 600 mg (200 mg * 3) Days 1 to 21 of each 28 day cycle Tablets for oral use
45371971|NCT03839823|Drug|Letrozole OR Anastrozole|"Letrozole:~Dose: 2.5 mg All days of every cycle without interruption). Tablets for oral use~Anastrozole:~dose: 1 mg All days of every cycle without interruption. Tablets for oral use~The NSAI (letrozole or anastrozole) will be decided by the treating physician."
45371972|NCT03839823|Drug|Goserelin|"Dose: 3.6 mg Day 1 of each 28 day cycle (regardless of ribociclib treatment cycle) with an administration window of + 3 days.~Subcutaneous implant"
45490287|NCT05681533|Procedure|CT scan|coronary calcium score measurement by CT scan
45692604|NCT04405635|Other|No intervention or exposure|No intervention or exposure
46053451|NCT05210114|Device|Skin Hydration Sensor|The device is a skin hydration sensor. The sensor is placed on the skin at the inner arm. It is non-invasive and measures in seconds the percent water content of the dermis by quantifying its dielectric constant.
45371973|NCT03833167|Biological|Pembrolizumab 400 mg|Administered by IV infusion on Day 1 of each 42-day cycle
45371974|NCT03833167|Drug|Placebo|Administered by IV infusion on Day 1 of each 42-day cycle
45371975|NCT03822702|Other|Biofeedback Training|Biofeedback training targeted to goals that are relevant to the handwriting skills for children by using a force acquisitional pen.
45371976|NCT03822702|Other|Motor Training|Motor training targeted to goals that are relevant to the handwriting skills for children by using a personal designed motor training program.
45371977|NCT03811002|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
45371978|NCT03811002|Drug|Atezolizumab|Given IV
45490288|NCT05466994|Other|IPAD|Participant will play a game through (standard camera) participants will be able to the hospital room and decals as they appear in the real world
45490289|NCT05466994|Other|Augmented Reality|Participants will play a game through (devices camera and application) let us participants view the real world
45692605|NCT03888651|Other|Quality-of-Life Assessment|Complete quality of life assessment
45490290|NCT05354245|Dietary Supplement|Fibre supplement (potato-pectin)|Fibre supplement
45490291|NCT05354245|Dietary Supplement|Placebo|Maltodextrin
45692606|NCT03888651|Other|Questionnaire Administration|Complete questionnaire
45371979|NCT03811002|Procedure|Biospecimen Collection|Correlative studies
45371980|NCT03811002|Drug|Carboplatin|Given IV
45371981|NCT03811002|Drug|Cisplatin|Given IV
45490292|NCT05354245|Dietary Supplement|High-protein diet|High-protein diet
45490293|NCT05464888|Behavioral|+Short AAT|Interaction with therapy dog prior to dental exam, cleaning, and simulated radiographs.
45490294|NCT05464888|Behavioral|+Long AAT|Interaction with therapy dog throughout dental exam, cleaning, and simulated radiographs.
45371982|NCT03811002|Drug|Etoposide|Given IV
45371983|NCT03811002|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45371984|NCT03811002|Other|Quality-of-Life Assessment|Ancillary studies
45371985|NCT03811002|Other|Questionnaire Administration|Ancillary studies
45371986|NCT03805009|Device|Robot-Assisted Gait Training (RAGT)|The Robotic Group (RG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland).
45371987|NCT03803774|Drug|Birinapant|Given IV
45371988|NCT03803774|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRRT
45371989|NCT03800927|Device|Long duration ultrasound|Low-intensity long duration ultrasound treatment
45490295|NCT05464888|Behavioral|Active control; NO dog|Color dog picture for 3 minutes prior to dental exam, cleaning, and simulated radiographs.
45490296|NCT03165214|Device|coil|microcoils
45490297|NCT03165214|Device|hystoacryl glue|hystoacryl mixed with lipidol
45490298|NCT03705949|Drug|Sodium Hyaluronate 0.1% drops|Patients will be administered Drops of Sodium Hyaluronate 0.1% quid
45490299|NCT03705949|Drug|Sodium Hyaluronate 0.2% drops|Patients will be administered Drops of Sodium Hyaluronate 0.2% quid
45692607|NCT01609543|Drug|erlotinib [Tarceva]|150 mg orally daily, until disease progression, unacceptable toxicity or withdrawal due to any reason
45692608|NCT03585699|Diagnostic Test|Fluoroscopy Guided Spinal Biopsy|"Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under fluoroscopic guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis."
45371990|NCT03797898|Other|Parent Coach|The Parent Coach intervention uses a health educator who provides anticipatory guidance, psychosocial screening/ referral, and developmental/behavioral surveillance, screening, and guidance at each well-visit. The Parent Coach uses a parent-focused, pre-visit questionnaire to customize the visit to the parents' needs. Every well-visit includes a brief, problem-focused encounter with a clinician for a physical exam and any concerns that require a clinician's attention. Finally, an automated text message service provides for periodic, age-specific messages to reinforce key health messages from Parent Coach-led well-visits.
45490300|NCT04716127|Behavioral|Proximity-incentive strategy based on vaginal self-sampling for women 50 to 65 years who do not participate to cervical cancer screening|"Direct offer of a vaginal self-sampling kit with information to perform at home and send back to the laboratory for HR-HPV testing~The psychosocial determinants involved in decision-making process and compliance to cervical cancer screening will be collected from open questionnaires and by semi-directive phone interviews~Control ; Receive reminder to send the self-sample to the laboratory : After 3 and 6 months without return, women receive a remind letter to send the vaginal self-sample to the laboratory. We call return the receipt of the vaginal self-sample at the laboratory.~Control ; Receive reminder to perform cervical smear in case of positive HR-HPV test : In case of a positive HR-HPV test, women are asked to perform a control cervical smear. After 3, 6 months and 12 months without return, women and their health-care professional will receive a remind letter to perform a cervical smear for control. We call return the performance of a pap smear."
45490301|NCT03162484|Behavioral|Experimental group|The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.
45490302|NCT04693039|Drug|Phenlarmide|Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
45490303|NCT04693039|Drug|Placebo|Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
45490304|NCT03162562|Biological|Oregovomab|Monoclonal antibody against CA 125
45490305|NCT03162562|Drug|Poly ICLC|Immune adjuvant
45490306|NCT05131945|Other|Standard Suction Thoracentesis|a procedure that removes excess fluid from the space in between your lungs and chest wall
45490307|NCT05131945|Other|Gravity Thoracentesis|a procedure that removes excess fluid from the space in between your lungs and chest wall
45490308|NCT03162718|Behavioral|Exercise|single arm feasibility study of an unsupervised, pre-operative exercise prescription (uPEP) augmented by a wearable fitness device.
45692609|NCT03585699|Diagnostic Test|CT guided Spinal Biopsy|"Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under CT guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis."
45371998|NCT03787680|Drug|Olaparib|300 mg by mouth twice a day for days 1-28 of a 28-day cycle.
45490309|NCT03705871|Device|Differential Expansion|Twenty-four patients will be treated with a rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm in the anterior screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
45490310|NCT03705871|Device|Fan-Fype Expander|Twenty-four patients will be treated with a rapid maxillary expansion using the fan-type expander. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
45490311|NCT03164590|Drug|Ketamine|patients receive local anesthetic wound infiltration with 1 mg /kg ketamine
45490312|NCT03164590|Drug|dexmedetomidine|patients receive local anesthetic wound infiltration with 1µg/kg dexmedetomidine
45490313|NCT03164590|Drug|bupivacaine|patients receive local anesthetic wound infiltration with bupivacaine 0.5 % diluted in 20 ml saline
45490314|NCT05119075|Other|Dopaminergic OFF-drug state|Dopaminergic OFF-drug state: Overnight withdrawal of dopaminergic antiparkinsonian drugs during visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.
45371999|NCT03787680|Drug|AZD6738|160 mg by mouth daily for days 1-7 of a 28-day cycle.
45372000|NCT03772899|Drug|Fecal Microbial Transplantation|"All patients in this trial will receive FMT at least one week prior to treatment with approved immunotherapy (either pembrolizumab or nivolumab). Samples for FMT are sourced at and by the microbiology group under the supervision of Dr. Silverman at St Joseph's Hospital. Donor screening procedures are described in appendix 4. Transplant will be from one single donor for all participants unless Dr. Silverman's lab considers the need for more than one donor based on availability of donors. There will be no mixture of donor samples.~Donor samples are manufactured into capsules according to Kao et al, 2017."
45490315|NCT05119075|Other|Dopaminergic ON-drug state|Dopaminergic ON-drug state: Patient will be evaluated in his/her regular treatment in dopaminergic ON-drug state at visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.
45490316|NCT04440046|Other|Manual therapy thoracic spine|Manual therapy mobilization directed to the costovertebral joint.
45490317|NCT04440046|Other|Manual therapy glenohumeral joint|Manual therapy mobilization directed to the glenohumeral joint.
45490318|NCT04440046|Other|Sham thoracic manual therapy|Sham manual therapy directed to the costovertebral joint.
45490319|NCT04440046|Other|Sham glenohumeral manual therapy|Sham manual therapy directed to the glenohumeral joint.
46053452|NCT05193877|Procedure|autologous bone marrow aspirate concentrate by centrifugation|"50 cc bone marrow aspirates concentrate after centrifugation with final volume up to 7 cc.~Assess total nucleated count and viability. Bone marrow aspirate concentrate is chosen as a source of mesenchymal stem cells, because of safe and easy procedure.~Bone marrow aspiration is done under local or general anesthesia, depending on the individual case. Around 50 cc of bone marrow is aspirated from the posterior iliac crest after proper sterilization using bone marrow aspiration needle (size according to the patient) and collected in heparinized syringes. Mononuclear cells (MNCs) are obtained by centrifugation. The isolated MNCs are checked for viability manually and confirmed on automated cell count machine.~The separated MNCs is administered intra-articularly immediately after centrifugation."
45372001|NCT03743636|Drug|Nicotinamide riboside|Participants randomized to the NR + resveratrol arm or the NR + placebo arm of the study will receive 1,000 mg of NR daily for six months.
45372002|NCT03743636|Drug|Resveratrol|Participants randomized to the NR + resveratrol arm of the study will receive 125 mg of resveratrol daily for six months.
45372003|NCT03743636|Other|Placebo|Participants randomized to the NR + placebo arm of the study will receiving placebo pills that are identical in appearance to resveratrol. Participants randomized to the placebo + placebo arm of the study will receive pills that are identical in appearance to NR and resveratrol. Participants will receive placebo pills daily for six months.
45372004|NCT03736226|Device|SYNERGYTM Stent System|no intervention design in the study
46053453|NCT05192148|Other|Patients|On the day of inclusion, as part of the research, an additional blood sample will be taken (2 dry tubes of 7 ml each).
46053454|NCT05188612|Combination Product|Observational (registry)|Observational (Patient Registry)
45372007|NCT03726775|Drug|Durvalumab|Infusion of durvalumab during RT and after RT during 6 months
45490320|NCT04440046|Other|Therapeutic exercise|Therapeutic exercise program consisting on isometric exercise with progressive load.
45490321|NCT05309707|Device|Endovascular exclusion|Endovascular exclusion by branch stent graft systems (Nexus stent-graft system®, Relay Branch® or Zenith arch branch graft®), with proximal landing at zone 0.
45490322|NCT03162016|Procedure|transplants|Transplant of palatine tissue and transplant of connective tissue Mucoderm
45490323|NCT03387852|Drug|SAR440340|Pharmaceutical form: Solution for Injection, Route of administration: SC
45490324|NCT03387852|Drug|Dupilumab|Pharmaceutical form: Solution for Injection, Route of administration: SC
45490325|NCT03387852|Drug|Fluticasone or Fluticasone/salmeterol combination|Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled
45490326|NCT03387852|Drug|Placebo for SAR440340|Pharmaceutical form: Solution for Injection, Route of administration: SC
45490327|NCT03387852|Drug|Placebo for dupilumab|Pharmaceutical form: Solution for Injection, Route of administration: SC
45490328|NCT02679274|Drug|Placebo|Intermittent intramuscular injections of saline (males and females).
45490329|NCT02679274|Drug|Testosterone|Intermittent intramuscular injections of 100 mg Testosterone Enanthate (males) or 25 mg Testosterone Enanthate (females).
46053455|NCT05184634|Other|PHYSICAL ACTIVITY LEVELS|Determination of physical activity levels of MetS individuals
46053456|NCT05184634|Other|DEPRESSION LEVELS|To determine the depression levels of MetS individuals
46053457|NCT05184634|Other|FATİGUE SEVERİTY|To determine the severity of fatigue of MetS individuals
46053458|NCT05184634|Other|QUALITY OF LIFE|To determine the quality of life of MetS individuals
45372008|NCT03725345|Behavioral|MRI Scanner|Participants will enter the MRI scanner and complete a series of computer tasks that include noise blasts while undergoing brain scans that measure the structure and function of the brain
45372009|NCT03718039|Drug|HTX-011|HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.
45372010|NCT03718039|Device|Luer Lock applicator|Applicator for instillation.
45372011|NCT03718039|Device|Vial access device|Device for withdrawal of drug product.
45372012|NCT03718039|Drug|aprepitant|Aprepitant, three single doses of aprepitant will be administered orally.
45490330|NCT04674319|Behavioral|external cues and cogntive movement strategies|"external cueing are sensory stimuli such as auditory (e.g. rhythmic metronome beats) or or visual (e.g. spaced lines on the floor). Cognitive movement strategies refer to focusing attention on a specific parameter of gait (e.g. step length, arm swing).~In the study participants walk under four walking conditions:1)usuall (baseline) walking 2)walking while attending to external cues wich will be applied via metronome beats. The number of beats per minute is adjusted to each participant's steps number per minute. 3)walking with movement cognitive strategy: participants are requested to focus on their step length- and focus on increasing their step length while walking 4) Dual tasking-walking while performing a cognitive task.~During the four walking conditions Brain engegament will be measured, using the single-channel EEG system (Brain-MARC LTD) described in the follwing outcomes measures section."
45490331|NCT05162833|Device|TheraNova Neuromodulation Device|TENS device
45490332|NCT03705715|Drug|PET with radiotracer [11C]PBR-28 ( or [11C]ER176)|[11C]PBR-28 or [11C]ER176 will be injected into subjects' veins during PET scanning.
45490333|NCT03705715|Other|Affective challenge|Affective challenge is the induction of, for example, mood or affective pain.
45490334|NCT01312285|Device|Resonator device|low level magnetic fields
45490335|NCT05044897|Drug|SI-B001|administration weekly by intravenous infusion（QW）.
45490336|NCT04961437|Other|Diaphragmatic ultrasound and electrical impedance tomography|"A diaphragmatic ultrasound in a half sitting position. The diaphragmatic excursion and the thickening fraction of the right hemi-diaphragm will be measured.~- Acquisition of 10 minutes of regional pulmonary ventilation by electrical impedance tomography."
45490337|NCT05309473|Device|Philips SmartSleep Acoustic Stimulation Device|Prior to bedtime on the first two recovery nights, a Philips SmartSleep device will be applied to the head of each subject. Subjects will receive acoustic stimulation during the four hours of sleep.
45490338|NCT05309473|Device|Sham (no Acoustic Stimulation)|Prior to bedtime on the first two recovery nights, a Philips SmartSleep device will be applied to the head of each subject. Subjects will receive Sham (no acoustic stimulation) during the four hours of sleep.
45490339|NCT05309317|Other|Virtual Simulation Game for the Prevention of Catheter-Associated Urinary Tract Infections|"A training on Prevention of CAUTI will be held for the experimental and control groups. The experimental group will be able to play a seven-day virtual simulation game devised by the researcher to prevent CAUTI."
46053459|NCT05183763|Behavioral|STAR-MAP health coaching|Interactive health coaching delivered in 11 sessions over one year; focusing on using adaptive change tactics to improve medication-taking behavior
46053460|NCT05183763|Behavioral|Medication reminder tools|Medication-taking reminder app and pillbox
45490340|NCT05309317|Other|Ongoing education|"Only a course on Prevention of CAUTI will be given to the control group."
45490341|NCT05309239|Other|ROX index|observation of ROX index to evaluate the efficacy of non invasive ventilation
46053461|NCT05181995|Drug|NYX-783|NYX-783
46053462|NCT05181995|Drug|Placebo|Placebo for 50 mg NYX-783
46053463|NCT05175170|Behavioral|Decision-aid|The decision aid consists of domains related to human reproduction, fertility, and fertility preservation. The domains address priority learning objectives in each domain to increase knowledge on the impact of gender-affirming medical interventions on fertility and fertility preservation options.
46053464|NCT05173818|Drug|Hyperbaric oxygen at 1.5 ATA|Hyperbaric oxygen (HBO2) at 1.5 ATA (active) group (hyperbaric oxygen-chamber compressed to 1.5 atmosphere absolute and breathing >99.9% oxygen). Each participant should complete 40 sessions, one session per day, five per week over the course of 3 months.
46053465|NCT05173818|Drug|Sham treatment|"Sham treatment includes pressurizing the chamber to 1.2 ATA with air for 5 minutes with noise of circulating air, return the chamber to 1.0 ATA after 5-7 minutes and maintain it at that pressure for until the end of the treatment, with noise of circulating air. Internal control knobs will be concealed. Participants will be instructed to undergo intermittent ear clearing technique during the initial 5 minutes of descent"
45372015|NCT03688165|Device|Treadmill-based Robotic Gait Training|All the stroke survivors admitted to the participating centers and eligible for the study will follow a gait training protocol (treadmill-based or overground). The data will be registered at baseline (T0), end of treatment (T1) and at three months follow up (T2). All robotic systems used for the study (Lokomat Pro - Hocoma AG, Volketswil, Switzerland); G-EO System - Reha technologies, Italy) are treadmill-based and do not provide the over-ground gait training. They are characterized by the possibility of a programmable weight support, as well as speed and stride length. The data relating to the patients' training is always displayed and stored with a computerized control system.
45372016|NCT03681080|Procedure|leg crossing|As Counter maneuvre legs will be crossed and cognitive tests will be performed.
45372017|NCT03672292|Drug|SCY-078|Oral tablets of SCY-078
45372018|NCT03672292|Drug|Voriconazole|Voriconazole IV vials or oral tablets
46053466|NCT05171790|Drug|QL1706 injection|5 mg/kg, IV, Q3w
46053467|NCT05169905|Combination Product|RSV MAT vaccine|"Single dose of the RSV MAT vaccine reconstituted with NaCl solution was planned to be administered intramuscularly, in the non-dominant arm, at Day 1 or at Day 31, depending on the vaccination schedule.~RSV MAT vaccine was no longer administered to participants at Day 31. No vaccine was administered in the dTpa_RSV-P Group, since there were no participants assigned to it."
45372019|NCT03672292|Other|Oral Placebo Tablets|Oral Placebo Tablets matching SCY-078
45490342|NCT03620929|Drug|Estradiol Valerate|In all cases hormone therapy will be started from the day of operation, consisting of estradiol valerate at a dose of 4mg/d for 21 days, with the addition of dydrogesterone at a dose of 10 mg/d for the last 7 days of the estrogen therapy. After the withdrawal bleed, the hormone therapy will be repeated for another cycle. Second-look hysteroscopy will be carried out in the early proliferative phase, 4 weeks after the initial operation; a third-look hysteroscopy will be carried out 8 weeks after the initial operation. After assessment of the extent and severity of any reformed adhesion, hysteroscopic adhesiolysis will be carried out at the time of the second-look or third-look procedure, if adhesion had recurred.
45372020|NCT03653507|Drug|zolbetuximab|Zolbetuximab will be administered as a minimum 2-hour IV infusion.
45490343|NCT04537741|Procedure|Coronary CT angiography|all patients being included will undergo CCTA before invasive coronary angiography
45372021|NCT03653507|Drug|oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion.
45372022|NCT03653507|Drug|capecitabine|Capecitabine will be administered orally twice daily (bid).
45372023|NCT03653507|Drug|placebo|Placebo will be administered as a minimum 2-hour IV infusion.
45372024|NCT03651505|Other|No intervention|Access to any treatment is through authorized commercial use and not as a part of this DMP
45372025|NCT03635164|Drug|Durvalumab|Patients will receive one dose of neoadjuvant durvalumab 1500 mg approximately 3-6 weeks prior to standard of care surgery. It will be given concurrently with the first dose of radiation (RT). Patients will receive up to six doses of durvalumab and radiation post-operatively.
45490344|NCT04537741|Procedure|Invasive coronary angiography|all patients being included will undergo CCTA before invasive coronary angiography
45490345|NCT05177497|Drug|SHR-1701|SHR-1701 administered by iv
45692610|NCT03580239|Drug|Everolimus|Everolimus will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
45372026|NCT03635164|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The starting RT dose level will be given as 6 Gy for 2 fractions (12 Gy total) every other day over approximately one week to sites of gross disease only to minimize exposure to normal tissue. If toxicity develops and surgery is delayed by more than 8 weeks (qualifying as a DLT), the radiation dose will be dropped per protocol for the next set of patients. If this dose is tolerated, the dose will be increased to 6 Gy for 3 fractions (18 Gy total) for the next 3 patients.
45490346|NCT04470427|Biological|mRNA-1273|Sterile liquid for injection
45490347|NCT04470427|Biological|Placebo|0.9% sodium chloride (normal saline) injection
45490348|NCT04429243|Device|GORE® VIABAHN® Stent Graft|On Day 1, participants will receive the GORE® VIABAHN® Stent Graft.
45490349|NCT04969861|Drug|Bempegaldesleukin|Specified dose on specified days
45490350|NCT04969861|Drug|Pembrolizumab|Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.
45490351|NCT04967521|Drug|Abemaciclib|Abemaciclib will be administered 200mg orally twice a day. Each cycle is 28 days.
45490352|NCT04967521|Drug|Placebo|Placebo will be administered orally twice a day. Each cycle is 28 days.
45692611|NCT03580239|Drug|Placebo|Placebo will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
45372027|NCT03635164|Procedure|Standard of Care Therapy|Patients will proceed to surgical resection 3-6 weeks after radiation as recommended by the ENT surgeon.
45372028|NCT03626701|Device|RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device|Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings.
45372029|NCT03626701|Combination Product|Mepilex® Ag Wound Dressing|Application of Mepilex® Ag Wound Dressing
45372030|NCT03626701|Procedure|Conventional autografting (only when indicated)|When indicated, conventional autografting in accordance with Investigator's standard practice
45372031|NCT03602014|Drug|Northera|Study 1 is a dose optimization, open-label trial of Northera from a dose range of 200mg up to 800mg.
45372032|NCT03602014|Other|Placebo|Study 2 is blinded placebo controlled trial using the individualized optimal dose of droxidopa determined by study 1.
45372033|NCT03593070|Behavioral|Chronic Grief Management Intervention-Video|The CGMI-V participant manual will be provided to participants either mailed or emailed. We will mail hard copies of the manual to caregivers who prefer them over the e-format. The technology assistant will review with each participant the use of technology Cisco WebEx and iPads) via e-mailed step-by-step written instructions and over-the-phone conferencing. Group sessions will take place using WebEx (an internet platform providing video connection) and iPads, at mutually agreed-upon times and days of the week. All group sessions will be audio and video-recorded for fidelity purposes, with caregivers' approval documented in the informed consent. The interventionists will label each recorded meeting group identification number, session number, and date.
45372034|NCT03559868|Drug|Digoxin|Different doses of oral digoxin to test if digoxin has an effect on the immune response of peripheral blood levels (PBLs).
45372035|NCT03559868|Other|Placebo|Oral placebo
45372036|NCT03559192|Drug|JNJ-67953964|JNJ-67953964 10 mg will be administered as two 5-mg capsules orally once daily.
45372037|NCT03559192|Drug|Placebo|Matching placebo will be administered as 2 capsules orally once daily.
45372038|NCT03552718|Biological|YE-NEO-001|Personalized recombinant yeast-based vaccine engineered to express multiple neoantigen epitopes (neoepitopes) based on an individual subject's tumor molecular profile.
45372039|NCT03552471|Other|Laboratory Biomarker Analysis|Correlative studies
45372040|NCT03552471|Biological|Mirvetuximab Soravtansine|Given IV
45372041|NCT03552471|Other|Pharmacokinetic Study|Correlative studies
45372042|NCT03552471|Drug|Rucaparib Camsylate|Given PO
45372043|NCT03552276|Drug|SUNPG18_07 I|injection
45372044|NCT03552276|Drug|SUNPG18_07 II|injection
45372045|NCT03552276|Drug|SUNPG18_07 III|injection
45490353|NCT05308849|Other|Dosage of serum and peritoneal of the betalactam used for antibiotic treatment|"All patients will have antibiotherapy according to French recommendation.~Antibiotics recommended are:~cefotaxime 200mg/kg/d / OR amoxicillin/clavulanic acid 25 mg/kg x 3 /d OR piperacilline/tazobactam 100 mg/kg/d~Blood samples will be collected before surgery and after surgery (for all patients).~Peritoneal sample will be collected during surgery (for all patients). Additionnal optionnal blood sample could be collected on Day 5 after surgery. Additionnal optionnal peritoneal samples could be collected on Day 2 and Day 5.~Dosage of serum and peritoneal of the used betalactam will be performed by High Performance Liquid Chromatography Method"
45490354|NCT02678416|Drug|IV Acetaminophen (Treatment A)|Acetaminophen administered by intravenous (IV) infusion
45490355|NCT02678416|Drug|Oral Acetaminophen (Treatment B)|Acetaminophen administered by oral tablets
46053468|NCT05169905|Combination Product|dTpa vaccine|"Single dose of the dTpa vaccine was planned to be administered intramuscularly, in the non-dominant arm, at Day 1 or at Day 31, depending on the vaccination schedule.~Two formulations of dTpa vaccine are licensed in the US and outside of the US (ex-US), respectively. dTpa-US formulation was administered to participants in centers located in the US, while dTpa-ex-US formulation was planned to be administered to participants in centers ex-US. The dTpa-ex-US formulation was not applicable in this study anymore as no non-US sites were initiated before the decision to stop the study.~The participants in RSV_dTpa-P and RSV_dTpa-A study groups were provided with an option to decide to receive dTpa vaccination as part of standard of care/local recommendation on immunization.~No vaccine was administered in the dTpa_RSV-P Group, since there were no participants assigned to it."
45372046|NCT03542409|Other|MR Perfusion Scan|MR perfusion scan before and during surgery.
45372047|NCT03542409|Other|2HG Spectroscopy Scan|2HG spectroscopy scan before and during surgery.
45490356|NCT02678416|Drug|Placebo (Treatment C)|Placebo administered by IV infusion or oral tablets
45372048|NCT03542409|Other|Standard of Care Intraoperative MRI|The standard of care intraoperative MRI sequences used routinely will be sufficient for these 10 new samples.
45372049|NCT03538652|Behavioral|JITAI|Just-In-Time Adaptive Intervention delivered via smartphone app
45372050|NCT03538652|Other|Placebo|Placebo
45372051|NCT03533946|Drug|Rucaparib|Treatment with rucaparib will begin on Cycle 1 Day 1 and continue at 600 mg twice daily. Therapy continues until PSA progression or intolerable toxicities.
45372052|NCT03525951|Behavioral|Enhanced Milieu Teaching|The parent training will incorporate the EMT strategies of responsive interaction, matched turns, language modeling, and expansions. There will be three, hour-long parent training sessions following the teach-model-coach-review format (TMCR). The TMCR framework teaching component will involve 10 minutes of verbal and visual instruction on the language stimulation target of interest. The teaching component will be followed by 15 minutes of clinician modeling of the target strategies with the child while the parent watches. The parent will then have the opportunity to practice using the strategy during naturalistic interaction with their child. The clinician will provide individualized coaching on the use of the target strategy during this 20-minute, parent-child interaction. Finally, the clinician will review the target strategies and set goals.
45372053|NCT03525951|Other|no intervention comparison group|No intervention for observational (Study 1 and 2) and training (Study 2) data comparison.
45490357|NCT02678416|Other|Morphine (Treatment D)|Morphine administered by IV infusion
45490358|NCT03164668|Other|menthol flavored e-cigarette|menthol flavored e-cigarette
45490359|NCT03164668|Other|tobacco flavored e-cigarette|tobacco flavored e-cigarette
45490360|NCT03164512|Drug|Oral or vaporized cannabidiol|Acute drug exposure
45490361|NCT03164512|Drug|Placebo|Placebo capsule/vapor
45490362|NCT03164200|Other|High fat breakfast|High fat breakfast
45372054|NCT03523585|Drug|Trastuzumab deruxtecan|DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as intravenous (IV) dose
45372055|NCT03523585|Drug|Capecitabine|Investigator's choice Standard of Care when combined with trastuzumab or lapatinib
46053469|NCT05167955|Behavioral|Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy|An online mindfulness-based cognitive intervention is used as a proposed treatment intervention for erectile dysfunction among African- Caribbean men based in the United Kingdom.
45372056|NCT03523585|Drug|Lapatinib|Investigator's choice Standard of Care when combined with capecitabine
45372057|NCT03523585|Drug|Trastuzumab|Investigator's choice Standard of Care when combined with capecitabine
45372058|NCT03495986|Device|Functional Electrical Stimulation Leg Cycle Ergometry|Exercise training will consist of three to five, 40-67 minute sessions (200 minutes at target intensity) each week for a total of 16 weeks at 70% maximal heart rate; 10-minute warm-up and cool-down sessions will accompany each exercise session.
45372059|NCT03495986|Behavioral|Diet|An individualized, detailed dietary plan consistent with My Healthy Plate Dietary Guidelines of America will be followed under supervision of Registered Dietitian with weekly telemedicine conferences and monitored dietary intake via MyFitnessPal.
45372060|NCT03493581|Procedure|BIOPSY|re-biopsy (primitive tumor or metastasis) specifically for the study, at V2(6 weeks)
45372061|NCT03493581|Diagnostic Test|blood-sampled|"after 3 or 4 weeks (V1-1st assessment of PK/PD, after the 2d course),~after 6 weeks (V2),~after 8 or 9 weeks (V3-2nd assessment of PK/PD, after the last course),~- after 12 weeks of treatment (V4- samples for 3rd assessment of PK/PD and other analyses ).~after 18 weeks (V5- samples for 4th assessment of PK/PD and other analyses,),~after 24 weeks of treatment (V6-5th assessment of PK/PD and other analyses)."
45372062|NCT03493581|Other|feces samples|If they are amenable to collect feces samples at home, an auto collection kit will be supplied to them, before the first injection (Vs) and when they come for the 2nd course (i.e after 3 or 4 weeks post initiation) in order to self-collect feces within the week beforeV2 - 6 weeks post initiation).
45490363|NCT03164200|Other|Higher carbohydrate breakfast|Higher carbohydrate breakfast
45490364|NCT02680834|Device|Dual Action Pneumatic Compression Device|Dual action pneumatic compression device used to treat chronic VLUs.
45490365|NCT02680834|Device|Multi-Layer Bandaging|Multi-layer bandaging used to treated chronic VLUs
45490366|NCT03343704|Drug|Idarucizumab|Intravenous
46053470|NCT05163665|Procedure|Closure type|Patients will have their endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) as per standard-of-care. Afterwards, patient will receive one of two intervention options for the closure of the GI defect following polyp removal.
46053471|NCT05163223|Biological|AST-301(pNGVL3-hICD)|Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
46053472|NCT05163223|Drug|rhuGM-CSF|Q3W, 3 cycles, Plus a booster at 24weeks post the third vaccination, Intradermal injection
45372063|NCT03486873|Drug|Pembrolizumab|200 or 400 mg IV infusion
45372064|NCT03486873|Drug|Standard of Care (SOC)|IV infusion or oral tablets
45372065|NCT03485911|Drug|BCX7353 capsules|BCX7353 oral capsules administered once daily
45372066|NCT03485911|Drug|Placebo oral capsule|Matching oral capsules administered once daily
45692612|NCT03156153|Drug|Bumetanide|bumetanide tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
45692613|NCT03156153|Drug|Placebo|placebo tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
45490367|NCT03840642|Behavioral|Mirror Me|Mirror Me is a telehealth parent training intervention that teaches parents to promote their child's social imitation during play and daily routines. It uses content from Reciprocal Imitation Training (RIT), an evidence-based NDBI that teaches social imitation within affect-laden playful interactions. Mirror Me presents intervention content in four interactive modules. Program development was guided by the technology acceptance model, media richness theory, and principles of instructional design.
45490368|NCT03840642|Behavioral|Remote Coaching|Trained therapists will provide feedback to parents as they use the RIT techniques with their child at home. All sessions will follow a similar format including a discussion of accomplishments and challenges, parent practice with feedback, problem solving, and planning for the next week
46053473|NCT05163223|Drug|Placebo|Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
45372067|NCT03470025|Other|Psychological Intervention|"F-TPI group will be followed for a period of six months with a telephone-based and a face to face psychological intervention, performed by a clinical psychotherapist .~TPI group will be followed for a period of six months with a TPI characterized by 10 telephone clinical interviews, performed by a clinical psychotherapist.~CTRL group with COPD SoC without PI will follow the standard follow-up program for COPD patients after PR."
45372068|NCT03460977|Drug|PF-06821497|Oral continuous
45372069|NCT03454256|Device|Virtual Reality|Virtual Reality Rehabilitation System
45372070|NCT03446690|Drug|MI Varnish|MI Varnish with RECALDENT™ (CPP-ACP) enhances enamel acid resistance and boosts salivary fluoride levels. This product remains on the teeth longer than other fluoride varnishes and contains high levels of fluoride and calcium released in the oral cavity. The difference is in the RECALDENT™ (CPP-ACP), which makes MI Varnish a natural and unique choice for your patients. Casein phosphopeptides (CPP) naturally occurs in milk casein; Amorphous Calcium Phosphate (ACP), which is found in the RECALDENT™, is also the source of calcium and phosphate. In the oral cavity, CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. Calcium and phosphate ions are the building blocks for healthy teeth and MI Varnish delivers bioavailable calcium and phosphate ions into the saliva.
46053474|NCT05163223|Drug|Pembrolizumab|Q3W; IV infusion
45372071|NCT03446690|Other|Control group|Participants received routine treatment and oral hygiene regimes. No intervention for this group.
45372072|NCT03442465|Behavioral|Toronto Extremity Salvage Score|Participant-reported outcome score. For lower extremities, this is a 33 item questionnaire containing 32 5 point Likert scale items and 1 open ended response item. For upper extremities, this is a 31 item questionnaire containing 31 5 point Likert scale items and 1 open ended response item. Individual item responses range from 1-5 with higher values indicating a task is easier to complete. A total questionnaire score can also be calculated by taking the sum of the scores minus the number of total items answered, and dividing this by the maximum possible score based on the number of items answered. This results in a range from 0 -100% with higher values indicating greater ability to complete tasks 31. This scoring allows for the fact that some items may not be answered if they do not apply to an individual. It is anticipated that it will take 20 minutes to complete. Scores for the lower extremity and upper extremity may be combined, but we intend to treat them separately for analysis.
45372073|NCT03442465|Behavioral|Musculoskeletal Tumor Society Score|Clinician-reported global score. For lower extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, walking ability, gait, and necessary support. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. For upper extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, hand positioning, manual dexterity, and lifting ability. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. A total questionnaire score which is defined as the sum of the individual items divided by the maximum possible score (5 times the number of items) may also be computed. It is represented as a percentage from 0 - 100%.
45372074|NCT03442465|Behavioral|Timed Get Up and Go Test|Validated functional measurement, for lower extremities only. The patient is observed and timed while s/he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again. The test predicts the patient's ability to go outside alone safely and quantifies functional mobility. The test requires no special equipment and will take less than one minute to complete.
45490369|NCT02680756|Drug|Ferric Maltol|
45490370|NCT02680756|Drug|Ferric Carboxy Maltose|
45490371|NCT03631836|Drug|Monoclonal antibody|3 doses of Monoclonal antibody could be tested
45490372|NCT03631836|Drug|Bevacizumab|fixed dose of bevacizumab (10 mg/ kg every two weeks)
45490373|NCT03631836|Biological|Blood sample|Evaluate the biomarkers plasma levels during administration of drug
45490374|NCT03631836|Device|Dynamic Contrast Enhanced magnetic resonance imaging (DCE-MRI)|Assess antiangiogenic effects by DCE-MRI
46053475|NCT05163223|Drug|Capecitabine|On days 1-14 (Q3W), BID ; Oral administration,
46053476|NCT05156047|Drug|Pitolisant Oral Tablet|"Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant."
46053477|NCT05156047|Drug|Placebo oral tablet|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
46053478|NCT05146336|Device|CytoSorb|Sorbent hemoperfusion system
45372075|NCT03442465|Diagnostic Test|Orthogonal Radiographs|The distance of bone transport is measured, accounting for calibration of the radiographs. The presence of bone regenerate between the transported segment is determined by the presence of continuous calcified callus from the proximal segment to the distal segment. Each of the orthogonal radiographs is used to visualize two cortices: the AP radiographs visualizes the medial and lateral cortices and the lateral radiograph measures the anterior and posterior cortices. Each continuous calcified cortex is counted with a range from 0 to 4 cortices intact.
45372076|NCT03442465|Diagnostic Test|Weight Bearing for lower extremities only|As part of the current standard of care, patients are asked to stand on a scale with the affected lower extremity on the scale and the unaffected extremity on a block which is level with the scale. The patient is asked to place as much weight as possible on the affected extremity and this weight Is recorded. Each patient's total weight is then measured and the percent of weight bearing is calculated as the amount of weight bearing over the total body weight.
45372077|NCT03442465|Diagnostic Test|Range of Motion|As part of the current standard of care, the joints of the affected extremity are assessed for passive range of motion at each follow up visit by the clinician. If surgery is on the femur, the hip and knee joints are assessed for range of motion. Whereas for the tibia, the knee and ankle joints are assessed. These assessments would be measured using a goniometer placed alongside the extremity and recorded for each direction of movement. Hip range of motion includes flexion, extension, abduction, internal rotation and external rotation. Knee range of motion includes flexion and extension. Ankle range of motion includes dorsiflexion and plantarflexion.
45372078|NCT03442465|Diagnostic Test|Osteocalcin|This lab assesses bone metabolism and require 5 mL of blood
45372079|NCT03442465|Diagnostic Test|Amino terminal propepetide of type 1 collagen|This lab assesses bone metabolism and require 5 mL of blood
45490375|NCT03196310|Drug|Platelet Concentrate|Platelet Rich plasma
45490376|NCT03196310|Drug|Corticosteroid injection|Kenalog
45490377|NCT03196310|Other|Normal Saline|Control Group - Placebo
45372080|NCT03442465|Diagnostic Test|N-telopeptide of type 1 collagen|This lab assesses bone metabolism and require 5 mL of blood
45372081|NCT03436745|Drug|Zolpidem|In men with prostate cancer, males (pre-castration, n=8-10) will receive oral zolpidem in the form of a 5 mg tablet. Blood samples will be collected for pharmacokinetic analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose. This cohort of men will then undergo androgen deprivation therapy with standard doses of goserelin. When castrate testosterone levels reach <50 ng/dL (post-castration), they will receive another 5 mg single dose of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Normal healthy females (n=5-8) will receive treatment with a single dose of 5 mg tablet of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Blood samples will be collected for PK analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose.
45490378|NCT03162094|Drug|AVX012 Ophthalmic Solution Low dose|Ocular topical administration of AVX Ophthalmic Solution Low dose
45490379|NCT03162094|Drug|AVX012 Ophthalmic Solution High dose|Ocular topical administration of AVX Ophthalmic Solution High dose
45490380|NCT03162094|Drug|Placebo (vehicle)|Ocular topical administration of placebo (vehicle Ophthalmic Solution)
45692614|NCT04405089|Device|Device: Active Transcranial Direct Current Stimulation (tDCS) coupled with cognitive training|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the right prefrontal cortex for total of 26 minutes.
45490381|NCT03670862|Other|CT|Non-contrast computed tomography , computed tomography angiography, computed tomography perfusion imaging
45490382|NCT03674918|Diagnostic Test|24 h ambulatory blood pressure measurements|24 h ambulatory blood pressure measurements : an ambulatory 24 h blood pressure device that automatically measures blood pressure every 15 minutes is given to the patient for 24 h
45692615|NCT04405089|Device|Device: Sham Transcranial Direct Current Stimulation (tDCS) coupled with cognitive training|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning of session).
45692616|NCT03155919|Dietary Supplement|TAUchoc|The supplements were offered during eight weeks in capsules containing three grams of taurine powder and 400 ml of chocolate milk ready to drink.
45692617|NCT03155919|Dietary Supplement|PLAchoc|The supplements were offered during eight weeks in capsules containing three grams of placebo (starch powder) and 400 ml of chocolate milk ready to drink.
45692618|NCT03887715|Device|Vagus Nerve Stimulation (VNS)|VNS is an implantable device that delivers stimulation to the vagal nerve.
45692619|NCT02003183|Radiation|[F-18]FDDNP|Each participant was injected with [F-18]FDDNP, a radiolabeled molecular imaging probe, prior to receiving a PET scan.
45490383|NCT03086460|Drug|CHF 1531 pMDI|Dose Response: Test one of five different doses of CHF 1531
45490384|NCT03086460|Drug|Formoterol Inhalation Solution|Active Control
45490385|NCT03086460|Drug|Placebo pMDI|Matched Placebo
45692620|NCT03156231|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
45692621|NCT03156231|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
45692622|NCT03585387|Procedure|Navigation|Navigation of a balloon catheter using two navigation methods (1-Fluoroscopy only; 2- Fluoroscopy + CPS).
45692623|NCT05702151|Procedure|ESP Block|After induction of anesthesia in the operating room, the patient is positioned in lateral decubitus. Under strict aseptic conditions, and guided by ultrasound, an Erector Spinae Plane block is performed injecting ropivacaine 0.2% 20ml, and a catheter is placed. Ropivacaine 0.2% infusion at a 10ml/h rate is started during the surgery.
45692624|NCT05702151|Drug|Morphine injection|Intravenous morphine infusion 50mcg/kg/h with Patient Controlled Analgesia extra bolus on demand (1mg bolus with 20 minutes lockout time), and paracetamol 1g every 8 hours.
45490386|NCT05422066|Drug|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg on day 1,8,15 for 21 days cycles
45490387|NCT05422066|Drug|Rituximab|Induction Chemotherapy: 375mg/sqm, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
45490388|NCT05422066|Drug|Cyclophosphamide|Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
45372082|NCT03435250|Drug|AG-270|AG-270, orally, once or twice daily, on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
45372083|NCT03435250|Drug|AG-270|AG-270, orally, once or twice daily, for 1 week prior to the first dose of docetaxel. Thereafter, AG-270 continues to be given daily, on Days 1 through 21 of each 21-day cycle, until disease progression or unacceptable toxicity.
45372084|NCT03435250|Drug|AG-270|AG-270, orally, once or twice daily for 1 week prior to the first doses of nab-paclitaxel and gemcitabine. Thereafter, AG-270 continues to be given daily on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
45372085|NCT03435250|Drug|docetaxel|Docetaxel, IV, once during each 21-day cycle, until disease progression or unacceptable toxicity.
45490389|NCT05422066|Drug|Doxorubicin|Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
45490390|NCT05422066|Drug|Vincristine|Induction Chemotherapy: 1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
45490391|NCT05422066|Drug|Prednisone|Induction Chemotherapy: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
45490392|NCT02674490|Device|A-tDCS (1 mA)|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 45-minute treatment session.
45490393|NCT02674490|Behavioral|SALT|Computer-delivered naming treatment requires matching word (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red response button if the word does not match the picture.
45490394|NCT02674490|Device|Sham|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
46053479|NCT05142384|Behavioral|Mom-Net|"Mom-Net is a guided Internet intervention. Mom-Net is distinct from other CBT interventions for depression in addressing the link between maternal depression and parenting. Mom-Net's content includes core CBT skills taught in ways that are relevant to one's parenting interactions. Mothers will participate in Mom-Net with either high- or low-intensity coaching as determined by which version their HS was randomized to offer. Coaching is provided by HS staff.~In the high-intensity version, coaches provide support both for engaging with the intervention and for learning content. Coaching phone calls occur weekly (20-30 min call per session). In the low-intensity version, coaches provides supportive accountability for engaging with the intervention. Mothers participate in 4 (10-15) min calls occurring post-randomization, and 3- and 6-weeks later."
45490395|NCT03162250|Drug|DSTA4637S|DSTA4637S will be administered as an IV infusion at 3 dose levels.
45490396|NCT03162250|Drug|Placebo|Placebo matched to DSTA4637S IV infusion will be administered as specified.
45490397|NCT03162250|Drug|SOC|Anti-staphylococcal SOC antibiotics dosage and duration of therapy will be based on relevant health-authority approved indications and local and national treatment guidelines.
45490398|NCT03670706|Behavioral|Exercise|Package of care
45490399|NCT03670706|Other|analgesic optimisation|optimisation
45490400|NCT03114280|Drug|TPF2|Combination drugs : docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days
46053480|NCT05142384|Combination Product|Treatment as Usual/Waitlist|HS sites provide ongoing social and instrumental support to parents, including helping to connect families to needed services including community mental health providers. Additionally, research staff will provide lists of local mental health providers and information to support treatment seeking. Research staff will also provide National Crisis Lines for Mental Health Emergencies. Staff will inform participants to call research staff if they have trouble accessing services so that staff may provide additional help. Finally, staff will share a case note documenting referrals with the women's family service worker, so that worker may provide locally based assistance to the woman in accessing services. Subsequent to T2 assessment, participants in the TAU/Waitlist condition, will be offered the Mom-Net intervention variant (high- v low-intensity coaching) being provided by their respective HS agencies
46053481|NCT05138809|Behavioral|Exercise|Use online exercise platform
45372086|NCT03435250|Drug|nab-paclitaxel|Nab-paclitaxel, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
45372087|NCT03435250|Drug|gemcitabine|Gemcitabine, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
45372088|NCT03429413|Behavioral|Protect Me 4 Application + External Quality Improvement Support|Participants will be asked to interact with the Protect Me 4 application, using an iPad tablet. During the implementation period (months 4-6), intervention clinics will receive the Protect Me 4 app and External Quality Improvement Support (practice facilitation and external and internal provider peer opinion leaders and provider incentives). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates with the assistance of the practice facilitator. Providers at the intervention clinic will complete a pre-intervention survey to obtain background information (demographics, approximate HPV vaccination rates, comfort with the use of technology etc.)
45372089|NCT03429413|Behavioral|Protect Me 4 Application Alone|During the maintenance period (months 7-9), intervention clinics will receive Protect Me 4 without external support (practice facilitation and external provider peer opinion leaders). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates without the assistance of the practice facilitator. Providers at the intervention clinic will complete a post-intervention survey to gain provider feedback regarding the feasibility of Protect Me 4 and changes in perceptions regarding the use of technology.
45372090|NCT03422822|Drug|Abrocitinib 100 mg|In the initial treatment period, Abrocitinib 100 mg, administered as two tablets to be taken orally once daily.
45372091|NCT03422822|Drug|Abrocitinib 200 mg|In the initial treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
45372092|NCT03422822|Drug|Placebo|For subjects whose dose was changed from 100 mg Abrocitinib to placebo, one tablet will be administered to be taken orally once daily for the remainder of the study.
45372093|NCT03422822|Drug|Abrocitinib 100 mg|For subjects whose dose was changed from 200 mg Abrocitinib to 100 mg PF-04965842, one tablet will be administered to be taken orally once daily for the remainder of the study.
45372094|NCT03422822|Drug|Abrocitinib 100 mg|In the secondary treatment period, Abrocitinib 100 mg, administered as one tablet to be taken orally once daily.
45372095|NCT03422822|Drug|Abrocitinib 200 mg|In the secondary treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
45372096|NCT03421964|Behavioral|Resilience/Adjustment Counseling|The Resilience and Adjustment Intervention (RAI) consists of seven 60-minute sessions scheduled over seven weeks. Before the first session, participants will be mailed an empty loose-leaf binder to store and organize completed self-assessments, reading materials, and homework assignments from each session. They will be asked to review materials and complete worksheets between sessions. The RAI will be implemented by experienced, licensed therapists.
45372097|NCT03421964|Behavioral|Resilience/Adjustment Counseling with Booster Sessions|"The Resilience and Adjustment Intervention (RAI) consists of seven 60-minute sessions scheduled over seven weeks. Before the first session, participants will be mailed an empty loose-leaf binder to store and organize completed self-assessments, reading materials, and homework assignments from each session. They will be asked to review materials and complete worksheets between sessions.~For the RAI+ participants, three booster sessions will be implemented. The three weekly booster sessions will be scheduled to start three months following completion of Session 7 of the RAI. The program will be implemented by experienced, licensed therapists."
45372098|NCT03416153|Drug|Carboplatin|AUC=1 weekly during radiation therapy. Carboplatin will be given once a week in combination with paclitaxel (standard treatment), concurrent with radiation therapy. Given IV.
45490401|NCT03114280|Other|Radiotherapy with carboplatin|Radiotherapy (RT) combined with carboplatin
45692625|NCT01986647|Behavioral|On the Move exercise - exercise leader|exercise physiologists
45692626|NCT01986647|Behavioral|Standard program - exercise leader|This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by research staff who are PTs, PTAs, or exercise physiologists
45692627|NCT01986647|Behavioral|On the Move exercise - staff activity personnel|this is a group exercise program focusing on the timing and coordination of walking. The program is taught by a person from the facility that the research team trained.
46053482|NCT05134142|Other|Electronic Health Record Review|Undergo medical record review
46053483|NCT05134142|Other|Physical Performance Testing|Undergo physical performance testing
46053484|NCT05134142|Other|Quality-of-Life Assessment|Complete assessments
46053485|NCT05134142|Other|Questionnaire Administration|Complete questionnaire
45372099|NCT03416153|Radiation|Radiation Therapy|Patients will initially receive a single prescription of 70 Gy to PTV1 in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy). Dose will be reduced to 54Gy to high risk PTV and 43.2Gy to low risk PTV all in 27 fractions for patients who meet pPET-CT and iPET-CT parameters.
45372100|NCT03416153|Drug|Paclitaxel|30 mg/m2 weekly during radiation therapy. Paclitaxel will be given once a week in combination with carboplatin (standard treatment), concurrent with radiation therapy. Given IV.
45372101|NCT03410823|Behavioral|PUSH|Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
45372102|NCT03410823|Dietary Supplement|Protein|Participants will receive a whey-based protein supplement in the form of a powder containing 27.6g of protein. This dose induces maximum muscle protein synthesis post-exercise. Participants will mix the supplement in 8 oz of water (or other beverage) or soft food (e.g., yogurt, soup) and consume immediately following each exercise session with the study PT. On days when they do not have a physical therapy visit with the study PT, participants will be instructed to take the supplement at the meal time closest to the time of scheduled PT visits to maintain regular daily dosing schedule.
45490402|NCT03678818|Other|Medium Supplemented with Latrunculin A|A medium with in-house supplementation of Latrunculin A to decrease oocyte degeneration after ICSI and improve the survival rate
45490403|NCT03678740|Other|Odyssey 2 Survey|Odyssey2 will retain the strengths (simplicity, brevity, confidentiality, and data quality assurance measures) which made Odyssey1 successful. While Odyssey2 adds some refinements based on experience learned from Odyssey1, the basic questions are changed as little as possible to maximize comparability, and the additions are limited. Odyssey1 consisted of between 16 and 23 questions, depending on skip patterns, and took an estimated 15 minutes to complete. Odyssey2 consists of between 23 and 33 questions, depending on skip patterns and we estimate that it will take approximately 20 minutes to complete.
45490404|NCT03163654|Procedure|Surgery 1|Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Porcine-derived acellular dermal collagen matrix (PADM) was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
45490405|NCT03163654|Procedure|Surgery 2|Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Connective tissue graft was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
45692628|NCT01986647|Behavioral|Standard program - staff activity personnel|This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by a member of the facility that the research staff trained.
45692629|NCT03582657|Device|dental implant (KONTACT N)|Implant-supported prosthetic restoration
45692630|NCT03585309|Procedure|The impact of electrocoagulation on ovarian reserve after laparoscopic excision of ovarian cysts:|"Randomization Randomization will be conducted using computer generated table. Group A (48 CASES) without coagulation~Group A 6 89 92 35 1 15 21 16 60 49 53 91 34 5 94 64 88 58 7 33 8 75 29 56 10 23 37 19 32 71 55 84 36 77 50 2 46 70 82 9 51 54 72 18 25 31 14 63~Group B (48 CASES) with coagulation Group B 79 38 93 43 52 44 62 47 68 76 86 95 81 83 42 80 94 30 78 61 12 17 66 13 41 59 22 73 39 65 4 90 28 26 3 87 40 85 69 48 27 24 74 57 11 20 67 45~Allocation and concealment Nineteen six opaque envelopes will be numbered serially and in each envelope the corresponding letter which denotes the allocated group will be put according to randomization table then all envelopes will be closed and put in one box. When the first patient arrives the first envelope will be opened and the patient will be allocated according to the letter inside."
45692631|NCT03585231|Behavioral|Immediate access to novel messaging program intervention|The experimental arm includes an immediate intervention using a novel messaging program for smoking cessation.
45692632|NCT03585231|Behavioral|Immediate access to standard of care messaging program intervention|The immediate control intervention uses a standard of care messaging program for smoking cessation.
45692633|NCT03585231|Behavioral|Delayed access to novel novel messaging program intervention|The delayed control intervention uses the novel messaging program for smoking cessation.
45372103|NCT03410823|Dietary Supplement|Nutrition|Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at baseline to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of baseline testing Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level >3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level >3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
45372104|NCT03409718|Device|Biomet Comprehensive Shoulder System|Total shoulder system designed to provide intraoperative flexibility for surgeons with unmatched humeral stem options, and infinite humeral head offset possibilities while meeting the growing demand for ease of glenoid preparation through a streamlined, low-profile, cannulated instrument platform
45372105|NCT03407144|Biological|pembrolizumab|2 mg/kg intravenous (IV) up to a max of 200 mg (3 to 17 years of age) or 200 mg IV (18 to 25 years of age); cycle frequency Q3W
45372106|NCT03407144|Drug|doxorubicin|"25 mg/m^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~40 mg/m^2 IV on Days 1 and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~25 mg/m^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)"
45372107|NCT03407144|Drug|vinblastine|"6 mg/m^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~6 mg/m^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)"
45372108|NCT03407144|Drug|dacarbazine|"375 mg/m^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~375 mg/m^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)~250 mg/m^2 IV on Days 1 to 3 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
45372109|NCT03407144|Drug|cyclophosphamide|500 mg/m^2 IV on days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
45372110|NCT03407144|Drug|vincristine|"1.5 mg/m^2 IV with maximum single dose 2 mg on Days 1, 8, and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~1.5 mg/m^2 IV with maximum single dose 2 mg on Days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
45372111|NCT03407144|Drug|prednisone/prednisolone|"60 mg/m^2/day orally divided in 3 doses on Days 1 to 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~40 mg/m^2/day orally divided in 3 doses on Days 1 to 15 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
45372112|NCT03407144|Drug|bleomycin|10 units/m^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)
45498155|NCT05451771|Device|FISH assay|Cytogenetic analysis is intended for evaluation of relapsed/refractory AL amyloidosis using fluorescence in situ hybridization (FISH) using known translocation probes. Bone marrow aspirate (BMA) samples are collected in lavender top (Ethylenediaminetetraacetic acid (EDTA)) or green top (Sodium heparin) tubes. Specimen tubes shall be transported at room temperature to the laboratory on the same day of collection.
45692634|NCT02002091|Other|no specific treatment|lifestyle counseling, antihypertensive drugs, antidiabetic drugs (oral and / or insulin)treatment of comorbidity or complications of diabetes.
45692635|NCT02926521|Device|2-octyl cyanoacrylate|Addition of 2-octyl cyanoacrylate liquid adhesive to nerve catheter dressing
45498156|NCT05451771|Drug|Venetoclax Oral Tablet, 400 mg|400 mg oral tablet daily
45498157|NCT05451771|Drug|Dexamethasone Oral, 10 mg|10 mg oral tablet weekly
45692636|NCT02926521|Device|Gum Mastic|Addition of gum mastic liquid adhesive to nerve catheter dressing
45692637|NCT05701995|Drug|Deucravacitinib|Specified dose on specified days.
45692638|NCT05701995|Other|Placebo|Specified dose on specified days.
45692639|NCT03584997|Procedure|ABB And Autogenous Particulate|Mixing the autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
45692640|NCT03584997|Procedure|PRF, ABB & Autogenous Particulate|adding an injectable platelets rich fibrin to a Mixture of autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
46053486|NCT05130944|Behavioral|Entre Nosotras|"A series of five 2-hour group sessions that are administered weekly by two trained female peer facilitators, who are selected by HIAS outreach workers and/or community leaders. The content of the sessions is based on the principles of Psychological First Aid and the Participatory Action Cycle, which is intended to generate community-led problem solving around priority issues affecting their wellbeing.~Entre Nosotras is a community- and strengths-based intervention designed to mobilize social support, strengthen community connectedness, and stimulate collective action to promote the safety and wellbeing of women."
45372113|NCT03407144|Drug|etoposide|125 mg/m^2 IV on Days 1 to 5 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)
45498158|NCT05451771|Drug|Dexamethasone Oral, 20 mg|20 mg oral tablet weekly
45692641|NCT01985321|Drug|ethanol/glycolic acid solution|ethanol/glycolic acid solution
45692642|NCT01985321|Drug|Placebo/Ethanol|ethanol solution
45692643|NCT03584919|Drug|doxycycline|patients received oral doxycycline 100 milgrams bid for 15 days
45372114|NCT03407144|Radiation|Radiotherapy (RT)|RT administered daily, dose dependent on randomization group and disease response.
45372115|NCT03395717|Device|Exoskeleton-Assisted Gait Training|
45490406|NCT03678662|Other|Hypoalgesia expectation|"Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know about the effect of exercise on the experience of pressure pain is that after eg. cycling or walking, more pressure can be applied before the pressure starts to hurt and more pressure is required before you can't withstand anymore.~Whether this applies to a squat exercise, as the one you are about to perform, has not yet been investigated, but we expect that the same applies here, namely, that more pressure is required before you feel the pressure begins to hurt you and you will be able to endure a greater pressure.~Supported by visual information."
45490407|NCT03678662|Other|Hyperalgesia expectation|"Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know is that exercise can cause muscle pain, both during and after training. You may have experienced muscle soreness yourself in relation to training? We expect that the same will apply here. Namely, after performing this squat exercise, which will likely hurt your thigh muscles while doing it, you will experience that the pressure applied afterwards, with the two devices you have just become acquainted with, should be less before it starts to hurt and that you can endure less pressure.~Supported by visual information."
45490408|NCT03678662|Other|Neutral|"Soon you are going to do a training exercise in a squat position up against the wall for 3 min. Following the squat exercise, we will repeat the measurement of how you experience pressure pain with the 2 devices you have just become acquainted with. While doing the squat exercise you will be asked to indicate pain in the thigh muscles."
45490409|NCT03163810|Device|Erchonia Verju Laser|The Erchonia Verju Laser is applied 2 times a week to the front and back of the waist, hips and upper abdomen for 30 minutes each time over 8 to 12 weeks.
45490410|NCT03163810|Device|Erchonia EVRL Laser|The Erchonia EVRL Laser is applied under the right ribcage angled towards the liver for 10 minutes, one time per week over the same 8 to 12 weeks as the Verju Laser is administered.
45490411|NCT01312363|Drug|Rivastigmine patch|Rivastigmine patch (5-10cm2, daily, 24hr)
45490412|NCT03163888|Procedure|Navigation TKR|Traditional over Conventional TKR
45490413|NCT03674762|Device|Microgrooved dental implants|Dental Implant placement
45490414|NCT03678584|Other|Medium Supplemented with Chaetoglobosin A|A medium with in-house supplementation of Chaetoglobosin A to decrease oocyte degeneration after ICSI and improve the survival rate
45490415|NCT02600234|Device|Inter-Atrial Shunt Device|An implantable device placed in the interatrial septum
45490416|NCT02600234|Other|Intracardiac Echo|Patients randomized to the control arm will undergo intra cardiac echocardiography, with examination of the atrial septum and left atrial appendage.
45490417|NCT02677714|Radiation|99mTc-rhAnnexin V-128|Kit for the preparation of 99mTc-rhAnnexin V-128
45490418|NCT03670550|Device|Ossur Rebound ACL Brace|ACL-reconstruction patients will be issued an Ossur Rebound ACL Brace at the time of enrollment in the study, prior to surgery. They will use this brace throughout their rehab and physical therapy. The intervention (brace) will be applied only to the surgical limb.
46053487|NCT05130944|Behavioral|Doing What Matters in Times of Stress|The stress management components are derived from the World Health Organization Doing What Matters in Times of Stress illustrated guide for coping with adversity (World Health Organization, 2020). The illustrated guide and accompanying audio files are publicly available: https://www.who.int/publications/i/item/9789240003927. During five sessions, the intervention involves 15-20 minute exercises covering a range of stress management and coping skills.
46053488|NCT05126277|Drug|ianalumab s.c. q4w|ianalumab s.c. q4w in addition to SoC
46053489|NCT05126277|Drug|ianalumab s.c. q12w|ianalumab s.c. q12w in addition to SoC
46053490|NCT05126277|Drug|placebo s.c.|placebo s.c. q4w in addition to SoC
46053491|NCT05123963|Behavioral|High-intensity interval training|3 times per week high-intensity interval training (HIIT) on a cycle ergometer for 12 weeks.
45372116|NCT03395314|Drug|Ketamine|1 single dose of IV ketamine
46053492|NCT05119569|Drug|Fenebrutinib|Fenebrutinib will be administered orally.
45372117|NCT03395314|Drug|Midazolam|1 single dose of IV midazolam
45372118|NCT03386500|Drug|BMX-001|BMX-001 at escalating doses in combination with standard RT, 33 fractions to 59.4 Gy, plus Mitomycin at the standard dosing of 10 mg/m2 administered IV bolus at day 1 and day 29 as well as 5FU 1g/m2/d day 1-4 and 29-32.
45372119|NCT03372733|Drug|control olive oil (COO)|2 capsules, 2 times a day after meals in a total of 4 capsules a day
45372120|NCT03372733|Drug|palmitoleate-rich oil (PLO)|2 capsules, 2 times a day after meals in a total of 4 capsules a day
45692644|NCT03584919|Drug|Cefuroxime Axetil 500Mg Tab|patients received cefuroxime axetil 500 milgrams bid for 15 days
45372121|NCT03329092|Drug|ATM-AVI|"(Creatinine clearance > 50 mL/min) 6500 mg ATM/2167 mg (loading dose, extended loading dose and maintenance dose) by iv infusion on Day 1 followed by a total daily dose of 6000 mg ATM/2000 mg AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1417 mg AVI on Day 1 (loading dose, extended loading dose, maintenance dose) followed by total daily dose 3000 mg ATM/1000 mg AVI~(Creatinine clearance 16 - 30 mL/min) 2700 mg ATM/900 mg AVI on Day 1 (loading dose, extended loading dose maintenance dose), followed by total daily dose 2025 mg ATM/675 mg AVI"
45372122|NCT03329092|Drug|MTZ|For cIAI only; 500 mg/100 mL metronidazole iv infusion over 1hr q8h
45372123|NCT03329092|Drug|MER|"Where pathogen initially not suspected of being MER-resistant:~(Creatinine clearance > 50 mL/min) 1000 mg meropenem by 30 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 1000mg meropenem by 30 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 500 mg meropenem by 30 min iv infusion q12h~Where pathogen initially suspected of being MER-resistant (Creatinine clearance > 50 mL/min) 2000 mg meropenem by 180 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 2000 mg meropenem by 180 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 1000 mg meropenem by 180 min iv infusion q12h"
45372124|NCT03329092|Drug|COL|"Loading dose 9 million IU by 30 -60 min iv infusion (6 million IU where weight < 60 kg) followed by one of the following maintenance doses:~(Creatinine clearance > 50 mL/min) after a 12h interval, commence maintenance dosing 9 million IU daily in 2 or 3 divided doses by 30 -60 min iv infusions.~(Creatinine clearance 31 - 50 mL/min) After a 24 hr interval, commence maintenance dosing of 6 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 21 - 30 mL/min) After a 24 hr interval, commence maintenance dosing 5 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 16 - 20 mL/min) after a 24 hr interval, commence maintenance dosing 4 million IU daily in 2 divided doses by 30 -60 min iv infusion"
45372125|NCT03293680|Drug|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg, every 3 weeks
45372126|NCT03290261|Other|Hypnosis|3 hypnosis sessions performed at 4 - 6 weeks apart
45372127|NCT03245541|Drug|Durvalumab|Durvalumab will be given 750 mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q14 days beginning D1. Four doses of durvalumab will be administered on the Q14 day schedule. Subsequently Durvalumab will continue as maintenance 1500mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q28 days up to 1 year or until progression (11 doses), unacceptable toxicity or other reason. If a patient undergoes resection, they will resume durvalumab once appropriately healed from surgery (approximately 4-8 weeks) at discretion of treating medical oncologist.
45372128|NCT03245541|Radiation|Stereotactic Ablative Body Radiotherapy (SABR)|SABR delivered as 6.6 Gy/fraction x 5 fractions given within two weeks will be administered weekdays and will begin D8.
45490419|NCT03161678|Drug|Clopidogrel|Clopidogrel (75 mg/d for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
45490420|NCT03161678|Drug|Ticagrelor|Ticagrelor (90 mg twice daily for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
45490421|NCT03114670|Biological|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|a single dose of CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells will be infusion after preconditioning.
45490422|NCT05597280|Drug|BE-PEP Bedaquiline|bedaquiline
45490423|NCT05597280|Drug|SDR-PEP Rifampicin|SDR-PEP: rifampicin
45490424|NCT05597280|Drug|BE-PEP Rifampicin|BE-PEP rifampicin
45692645|NCT03584919|Other|control subjects|no intervention
45490425|NCT03670472|Other|smear of nasal fossae|1 smear of nasal fossae during a usual or scheduled visit
45490426|NCT02933736|Drug|Ribociclib|
45490427|NCT03674684|Other|hydroxyethyl starch|After induction to anaesthesia patients received either hydroxyethyl starch or gelatin or crystalloids
45692646|NCT03584841|Diagnostic Test|Iontophoresis sessions in forearm of subjects with pilocarpine|The test with two iontophoresis sessions is performed in a forearm of subjects. Pilocarpine is applied during the first iontophoresis session to evoke cholinergic-induced sweat secretion. Atropine, isoprenaline and aminophylline are applied during the second iontophoresis session, to block the cholinergic component and to evoke β-adrenergic-induced sweat secretion.
45692647|NCT02000921|Other|VLNC cigarettes|Modified risk tobacco product
45692648|NCT02000921|Other|Combusted Products|Options for combusted tobacco products include cigars, cigarillos, and little cigars, .
45372129|NCT03240900|Device|Electrical Stimulation|Electrical stimulation - a needle attached to an cathode polarity will be placed within the intercostal space near the 4th intercostal nerve. A second needle attached to the anode polarity will be inserted into the serratus anterior muscle. Both electrodes will then be attached to a Grass SD9 stimulator and the voltage and frequency of the stimulation will be titrated to the point where contraction of the intercostal muscles is palpable. It will be maintained at this level for one hour at which point the wires will be removed. This technique is part of the standard of care for peripheral nerve surgeries of the extremities and is proven to be safe in humans.
45372130|NCT03240900|Procedure|Placebo|This breast will receive no electrical stimulation; the mastectomy and reconstruction will proceed with no intervention.
45372131|NCT03239340|Drug|Osimertinib|Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR-tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer with a significant selectivity margin over wild type EGFR.
45490428|NCT05596656|Diagnostic Test|skin prick test|"Skin prick testing was performed to all diabetic child with history of allergy. The recommended method of prick testing includes the appropriate use of specific allergen extracts, positive and negative controls, interpretation of the tests after 15 - 20 minutes of application, with a positive result defined as a wheal ≥3 mm diameter more than negative control for detection of specific IgE to one or more of common aeroallergens.~The location of each allergen was marked with a pen on the volar aspect of forearm to properly identify test results, at least 2 cm from the wrist and the antecubital fossae. The distance between two skin prick tests should be appropriate to avoid false-positive reactions due to direct contamination of a nearby test. A drop of each test solution should be placed on the skin in identical order for each subject tested and immediately pricked with a single-head metal lancet."
45490429|NCT03678272|Procedure|HERNIOPLASTY WITH PANAVALE MESH|Polypropylene mesh fixed with 3 points. Preformed polypropylene mesh will be used by fixing it with one point to the pubis, another to the inguinal ligament and another to the joint tendon.
45692649|NCT02000921|Other|Non-combusted products|Options for non-combusted tobacco products include smokeless tobacco, novel snus products, e-cigarettes and medicinal nicotine.
45692650|NCT02000921|Other|CN cigarettes|Experimental cigarettes with conventional nicotine content.
45490430|NCT03678272|Procedure|HERNIOPLASTY WITH PARIETEX PROGRIP MESH|"Preformed polypropylene mesh will be used which presents a self adhesive system not based on glue, but on the arrangement of the fibers of the mesh as hooks, and to which we will give a single point to the pubis."
45490431|NCT03678272|Procedure|HERNIOPLASTY WITH ADHESIX MESH|It will use a self-adhesive mesh without giving points to fix this one, since it is a mesh that integrates the glue.
45490432|NCT03678272|Procedure|HERNIOPLASTY WITH TIMESH MESH|Titaniumized polypropylene mesh will be used without fixing points, since liquid cyanoacrylate (Ifabond) will be used to fix it.
45490433|NCT03632070|Behavioral|Data acquisition of functional abilities|MRI data, motor evoked potentials, and behavior data acquisition
45490434|NCT03674606|Drug|Low dose aspirin|One 75 mg aspirin dose taken daily
45490435|NCT03670394|Diagnostic Test|Capillary Refill|We are measuring capillary refill to assess it's correlation with dehydration in children
45692651|NCT03584685|Device|Mask|All participants will initially be treated without the mask. In the next appointment, half will be treated with the mask.
45692652|NCT03584685|Procedure|Routine wound treatment|All participants will initially be treated for their wounds without the mask. In the next appointment, half will again be treated for their wounds without the mask.
45692653|NCT03587337|Other|POEM|Pt. are going to submit a POEM procedure.
45490436|NCT02677324|Drug|ABT199|Oral BCL-2 antagonist
45692654|NCT03586947|Drug|Vitamin D3 400 UNT Oral Capsule|50,000 IU of vitamin D once a week for 8 weeks, 1500-2000 IU/day.
45692655|NCT04765215|Biological|CoronoVAC|SARS-CoV-2 IgM and IgG will be measured from blood samples between 3-6 weeks after the 2nd dose of vaccination
45692656|NCT03155763|Procedure|Intraoperative kidney allograft preimplantation biopsy; Intraoperative kidney allograft postreperfusion biopsy|
45692657|NCT03155529|Procedure|radical hysterectomy|A standard radical hysterectomy with lymphadenectomy was performed. Static and dynamic MRI were performed. A suggested urodynamic examination was done according to the ICS. A 3D reconstruction technique was used to construct the 3D model of the pelvis, pelvic floor muscle, pelvic organ such as bladder and urethral.
45692658|NCT04764981|Other|Essence oils|Consists in olfactory training using essence oils
45692659|NCT03584451|Behavioral|rehabilitation sport|rehabilitation Sport over 52 weeks after THA, start 6 weeks postoperatively
45692660|NCT03584529|Drug|Vitamin D 3|Non-Vitamin D3 Drops group Patients in this group would take nothing.
45692661|NCT00724984|Drug|PCI-24781|"Phase I Dose Escalation: Up to 5 cohorts will receive PCI-24781 orally at doses starting at 30mg/m2 two times a day approximately 4-6 hours apart (BID), up to 90mg/m2 administered 5 days/week during the first 21 days of each 28 day cycle until the maximum tolerated dose (MTD) is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle).~Phase II Efficacy Evaluation: All patients will receive PCI-24781 orally at the dosage and regimen determined in Phase I."
45372132|NCT03208374|Behavioral|Prior Exercise Behavior Questions - Harvard Health Professionals Exercise Questionnaire|Participants will be asked how often on average over the year prior to their most recent diagnosis they participated in walking or hiking; jogging; running; calisthenics, aerobics, rowing, Nordic track; bicycling; tennis, squash, racquetball; lap swimming; weightlifting; and other aerobic exercise (e.g. heavy outdoor work), as well as their usual walking pace and flights of stairs climbed daily over the past 12 months prior to diagnosis.
45372133|NCT03208374|Behavioral|Current Exercise Behavior Questions: International Physical Activity Questionnaire Short Form (IPAQ SF)|The purpose of this questionnaire is to provide common instruments that can be used to obtain internationally comparable data on exercise exposure in adults aged 15 to 80 years old.
45372134|NCT03205124|Procedure|Electrical Stimulation|"The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is given at a fixed continuous frequency of 20Hz. The stimulus intensity is the maximum tolerable limit. The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery."
45372135|NCT03205124|Procedure|Sham Stimulation|"The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is begun until the patient senses the stimulation, then the stimulation is discontinued.The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery."
45372136|NCT03187106|Drug|Cephalexin|Other name(s): Keflex (cephalexin) Cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
45372137|NCT03187106|Drug|Placebo|Placebo representing standard of care
45372138|NCT03187106|Drug|Metronidazole|Other name(s): Flagyl (metronidazole) Metronidazole at 500 mg per oral every 8 hours for a total of 6 doses
45372139|NCT03172975|Biological|Na-GST-1/Alhydrogel|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel
45372140|NCT03172975|Biological|Na-GST-1/Alhydrogel + CPG 10104|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with CPG 10104, a synthetic oligodeoxynucleotide
45372141|NCT03172975|Biological|Na-GST-1/Alhydrogel + GLA-AF|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)
45490437|NCT03670238|Device|Orogastric intubation|Patient was placed in Fowler position (45º) and intraoral infiltrative anesthesia was carried out with Lidocaine 2% (without vasoconstrictor) at gingival papilla in the vestibular-palatine direction. A polyurethane enteral tube (Medicone®, Cachoeirinha - Brazil) was inserted through the mouth and passed into de stomach, followed by fixation of the tube tip to a superior molar or premolar, in its palatine surface. For dental amarry it waas used a suture wire in stainless steel size 1.0
45372142|NCT03172975|Biological|Placebo|Physiological sterile saline solution
45490438|NCT03670238|Device|Nasogastric intubation|After nostril anesthesia with xylocaine gel, a polyurethane enteral tube was inserted through the nose and its tip was positioned in the gastric lumen, according to the nose-ear-xiphoid method. The tube was attached to the face using antiallergic adhesive tape.
45372143|NCT03172975|Drug|Albendazole|Treatment with 3 daily oral doses of 400 mg albendazole at end of study.
45372144|NCT03172975|Other|Necator americanus Larval Inoculum|50 infectious Necator americanus larvae applied via dermal application (challenge infection).
45372145|NCT03167203|Biological|Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells|Participants who have received sub-retinal transplant of hESC-RPE cells in an AIRM sponsored clinical trial
45372146|NCT03155022|Device|Remote ischemic conditioning and intracoronary ischemic conditioning|"RIC: Four cycles of [5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation] started as soon as possible prior to PCI reperfusion. At least one full cycle (inflation + deflation) has to be completed before PCI reperfusion.~ICIC: Four cycles of [1 min balloon inflation followed by 1 min balloon deflation] started as soon as possible after reopening of the culprit coronary artery (maximum within 3 minutes after reflow). The balloon will be placed carefully above the culprit lesion so as to minimize potential micro-embolization."
45490439|NCT03674450|Behavioral|Heart Rate Variability Biofeedback Training|The study will utilize the Physiolab GP8 heart rate variability and respiration system on a laptop computer used solely for the study with the proper security passwords to protect participant information. The equipment consists of two electrocardiogram sensors (one per wrist) attached by sports wrist bands, a respiration monitoring belt placed around the upper abdomen, two galvanic skin conductance sensors attached to the fingertips, and a thermistor sensor attached to one of the finger tips. Participants will perform a series of monitored breathing exercises.
45490440|NCT03114748|Other|EEG|
45490441|NCT03114748|Other|DBS switched OFF and ON|
46053493|NCT05119569|Drug|Placebo|Placebo will be administered orally.
46053494|NCT05101122|Drug|Dosing 1: Atomoxetine|Oral administration at bedtime
46053495|NCT05101122|Drug|AD313|Escalating dose of AD313; Oral administration at bedtime
46053496|NCT05092945|Other|Cold exposure|The liquid-conditioned tube suit will be perfused with 18°C water using a temperature- and flow-controlled circulation bath from time 0 to 180 min.
46053497|NCT05092945|Drug|Oral Nicotinic acid|A total of 500 mg of nicotinic acid will be given orally, at a rate of 2 doses of 150 mg and 2 doses of 100 mg: one dose of 150 mg at time 0 and 60 minutes, one dose of 100 mg at time 120 minutes and 180 minutes.
45372147|NCT03155022|Device|Patients with no remote ischemic conditioning and no intracoronary ischemic conditioning|Brachial cuff is positioned during 40 minutes but not inflated. No intracoronary balloon inflation.
45372148|NCT03114527|Drug|Ribociclib|Orally bioavailable, highly selective small molecule inhibitor of CDK4/6
45372149|NCT03114527|Drug|Everolimus|mTOR inhibitor
45372150|NCT03109288|Drug|Pioglitazone|15-45 mg po qd
45372151|NCT03109288|Drug|clemastine fumarate|8 mg/day (divided into 3 doses of 2, 2, and 4 mg)
45372152|NCT03109288|Drug|Dantrolene|Up to 200 mg/day (divided into 3 doses of 50mg, 50mg, and 100 mg)
45372153|NCT03109288|Drug|Pirfenidone|"Up to 801 mg po tid. Slow titration over weeks based on tolerability:~267mg po tid x >= 7d 534 mg po tid x >= 7d 801 mg po tid"
45372154|NCT03073785|Drug|Capecitabine|Given PO
45372155|NCT03073785|Drug|Fluorouracil|Given IV
45372156|NCT03073785|Other|Laboratory Biomarker Analysis|Correlative studies
45372157|NCT03073785|Other|Pharmacological Study|Correlative studies
45372158|NCT03073785|Radiation|Stereotactic Body Radiation Therapy|Undergo hypofractionated stereotactic radiotherapy
45490442|NCT02461784|Procedure|Semen & Data Collection|"If participants decide to participate in this research they will be asked to complete the informed consent process as well as asked a few questions such as age and race/ethnicity. If participants volunteered for this study because tehy have IBD, investigators will also collect some information from the participants medical record. Completing this portion of participation will take less than 1 hour.~Participants will then be scheduled to complete the semen collection at the UW Health Generations Fertility Clinic located at 2365 Deming Way in Middleton, WI. This collection visit will take less than 1 hour to complete. Once participants have finished the collection visit they will have completed their participation in this research project."
45490443|NCT03108846|Drug|Escitalopram|5-15 mg/day (target: 15mg/day if tolerated)
45490444|NCT03108846|Drug|Placebo|Masked placebo
45372159|NCT03073785|Drug|Zoledronic Acid|Given IV
45372160|NCT03065335|Drug|Ketamine|N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist
45372161|NCT03065335|Other|Placebo|Placebo comparator
45372162|NCT03065335|Device|Cobot TS MV robotic arm for TMS|TMS-Cobot TS MV [Axilum Robotics] robotic arm for spatial positioning and orientation of the TMS coil
45372163|NCT03065335|Device|NeurOptics PLRTM-30000 Pupillometer|The Neu-rOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.
45372164|NCT03037879|Other|SPT|Participants in the SPT group will receive 10 training sessions over 5 weeks.
45372165|NCT03037879|Other|SPT Control|Participants in the SPT control group will receive 10 computer-based control sessions over a five-week period during which they will engage in computer-based training. However, they will not be exposed to the training materials central to the SPT.
45372166|NCT03037879|Other|mSMT|Participants in the mSMT group will meet with the trainer twice per week for five weeks. Sessions last 45-60 minutes each and are spread over 5 weeks.
45372167|NCT03037879|Other|mSMT Control|Participants in the mSMT control group will meet with the therapist at the same frequency and for the same duration as those in the mSMT experimental group. However, subjects will not be exposed to the training materials central to the mSMT.
45372168|NCT03030417|Drug|LMP744|Indenoisoquinolines, such as LMP744, are potent inhibitors of the enzyme topoisomerase I (Top1). Top1 is necessary for transcription, replication, recombination, and the repair of double-strand DNA breaks. It relaxes the supercoiled DNA by introducing a single-strand break, generating a free strand that rotates around the Top1-bound DNA complex. In the absence of external triggers, Top1-DNA cleavage complexes are generally short lived. Top1 inhibitors are potent anticancer agents because they stabilize the formation of the Top1-DNA cleavage complex in tumor cells, which induces DNA damage, delays DNA repair, and results in cell cycle arrest and apoptosis. LMP744 exhibited antitumor activity with lower toxicity than other agents in preclinical studies. Treatment of patients with LMP744 is expected to reduce tumor burden at doses that are well-tolerated.
45372169|NCT03028103|Drug|Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2
45372170|NCT03028103|Drug|Fluconazole|200mg will be orally administered QD for 4 days in order to determine CYP3A4 inhibition when administered concomitantly with tazemetostat
45372171|NCT03028103|Drug|Omeprazole|Using omeprazole as a probe substrate, 20mg will be orally administered for a total of 5 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C19. Omeprazole is also being used to determine the effect of increased gastric pH on metabolism of tazemetostat.
45372172|NCT03028103|Drug|Repaglinide|Using repaglinide as a probe substrate, 25mg will be orally administered for a total of 2 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C8.
45372173|NCT03023163|Other|Longitudinal|Participants that completed the Impact of Age on Cardiovascular, Cerebrovascular, Cerebrovascular and Cognitive Health study, will be re-assessed again to compare longitudinal (3-5 years) change in blood pressure, cerebral blood flow, arterial stiffness and cognitive health.
45372174|NCT03020589|Drug|Tacrolimus|See description in arm/group sections
45490445|NCT03161782|Other|PNF stretching|For hold-relax stretching, each subject in PNF Stretching group will be comfortably positioned in a supine lying position, and patient will move the joint to the end of the passive or pain-free ROM. The therapist will ask for an isometric contraction of the restricting muscle or pattern (antagonists) with emphasis on rotation. The patients will be asked to perform submaximal isometric contractions of the target muscle for 10 seconds. After the contraction, the patients will be instructed to relax for 5 seconds. The joint will be repositioned actively to the new limit of range, and then therapist will passively control the new ROM. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
46053498|NCT05090774|Behavioral|Adapted Otago Exercise Program (OEP)|A modified version of the 8- week evidence-based Otago Exercise Program (OEP), adapted for integration into supervised exercise therapy (SET). The OEP exercises will include 12 static and dynamic standing balance movements (knee bends, backwards walking, walking and turning, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, heel-toe walking backwards, sit to stand, stair walking). The OEP also contains additional behavior change techniques embedded within the intervention protocol (i.e. feedback on behavior, self-monitoring of behavior, biofeedback).
46053499|NCT05087771|Drug|injectable naltrexone|360 mg dose to be given prior to hospital discharge
46053500|NCT05087771|Drug|oral naltrexone|50 mg tab dispense 30 day supply to be given at hospital discharge
45490446|NCT03161782|Other|Static Stretching|For static stretching, each subject in Static Stretching group will be comfortably positioned in a supine lying position, and the stretching of target muscle will be maintained for 20 seconds followed by 10 seconds of rest. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
45490447|NCT03161782|Other|Exercise|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extansion self-stretching exercises Elbow and wrist strengthening exercises Proprioception exercises for elbow. Grip strengthening exercises.
45490448|NCT03161782|Other|Cold Therapy|Cold therapy will be applied over the elbow for 15 minutes in the form of cold pack after stretching and exercise protocol.
45490449|NCT03670082|Drug|Lu AF35700|20 mg Lu AF35700 single oral dose
45490450|NCT03670082|Drug|Lu AF35700 iv|100 μg [14C]-Lu AF35700 (4.7 μCi/174 kBq) single intravenous micro-dose
46053501|NCT05087329|Behavioral|Virtual Mindfulness Meditation|Four week virtual mindfulness meditation course composed of four weekly group Zoom webinars during which participants will listen to a 15-20 minute pre-recorded meditation, facilitated by a study provider
46053502|NCT05084235|Drug|Empagliflozin 10 MG|Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days
46053503|NCT05084235|Drug|Placebo|Placebo matches the active drug in appearance, odor and labelling
45372175|NCT03010982|Drug|Tazemetostat and [14C] Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2.
45372176|NCT02964208|Device|AMPLATZER™ LAA Occluder|The AMPLATZER™ LAA Occluder is intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular Atrial Fibrillation (AF). It may be considered for use in patients who have a high risk of stroke and bleeding and are deemed by their physician to have an appropriate rationale to seek a non-pharmacologic alternative to long term anticoagulants.
45372177|NCT02933489|Diagnostic Test|Contrast-enhanced Magnetic Resonance Imaging|Undergo AB-MR
45372178|NCT02933489|Diagnostic Test|Digital Tomosynthesis Mammography|Undergo DBT
45372179|NCT02933489|Other|Quality-of-Life Assessment|Ancillary studies
45372180|NCT02933489|Other|Questionnaire Administration|Ancillary studies
46053504|NCT05082142|Drug|Tranexamic acid|Patients in the intervention arm will receive 1g of intraoperative IV TXA during the HoLEP procedure.
46053505|NCT05062252|Device|Mirror Medacta Shoulder System|Anatomic total shoulder arthroplasty system
46053506|NCT05062252|Device|Medacta Shoulder System|Anatomic total shoulder arthroplasty system - standard configuration
46053507|NCT05061017|Drug|Pixatimod|Pixatimod is an investigational drug that is being evaluated in studies involving melanoma, non-small cell lung cancer, and microsatellite stable colorectal cancer.
45372181|NCT02932475|Drug|Metformin|1000 mg twice a day
45372182|NCT02932475|Drug|Placebo|Delivered to match active drug
45372183|NCT02919917|Drug|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
45372184|NCT02919917|Drug|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
45372185|NCT02915198|Drug|Metformin XR|The study medication dose may be increased by a step-wise fashion up to a maximum of 4 tablets per day.
45372186|NCT02915198|Drug|Placebo|"For patients < 80 years of age at the time of a study visit, and with most recent eGFR 45 mL/min/1.73 m2, study medication dose may be increased in a stepwise fashion to a maximum of 4 tablets daily, corresponding to metformin XR 2000 mg or matching placebo.~For patients 80 years of age or with most recent 30 eGFR < 45 mL/min/1.73 m2, the maximum dose of study medication is 2 tablets daily, corresponding to metformin XR 1000 mg or matching placebo"
45490451|NCT02443220|Device|TEAS (transcutaneous electric acupoint stimulation)|"transcutaneous electric acupoint will commence at 30 min on Danzhong and Hegu before anesthesia in distal-proximal group"
45490452|NCT02443220|Device|TEAS|"transcutaneous electric acupoint will commence at 30 min on Danzhong and Juque before anesthesia in regional group"
45490453|NCT02443220|Device|TEAS|"The device will be connected to Danzhong and Hegu but no stimulation to the acupoints 30 min before anesthesia"
46053508|NCT05061017|Drug|Nivolumab|Nivolumab is approved by the FDA for the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of head/neck, urothelial carcinoma, MSI-H colorectal cancer, hepatocellular carcinoma, gastric carcinoma and gastroesophageal junction (GEJ) cancer
46053509|NCT05061017|Drug|Cyclophosphamide (low dose)|Cyclophosphamide is approved by the FDA for the treatment of acute lymphoblastic leukemia, acute monocytic leukemia, acute myeloid leukemia, breast cancer, chronic granulocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin lymphoma, multiple myeloma, mycosis fungoides, neuroblastoma, non-Hodgkin lymphoma, ovarian cancer, retinoblastoma. Low-dose (immunomodulatory) cyclophosphamide is being studied in combination with various types of immunotherapy including nivolumab and pembrolizumab
45372187|NCT02893553|Drug|Midodrine Hydrochloride|study 1 will be single blind. study 2 will be blinded randomized-control trial.
45372188|NCT02893553|Drug|Pyridostigmine Bromide|study 1 will be single blind. study 2 will be blinded randomized-control trial.
45372189|NCT02893553|Drug|Mirabegron|study 1 will be single blind. study 2 will be blinded randomized-control trial.
45372190|NCT02893553|Other|Placebo|placebo will only be used for study arm 2, the randomized blinded phase.
45372191|NCT02886936|Device|iFIT Transtibial Prosthesis|Transtibial amputee volunteers will be fit with the iFIT device and instructed on its use. Patient will wear the iFIT device for a two week time period according to a provided wear schedule. At the end of this time patient will rate it for comfort, stability and ease of use.
45372192|NCT02886936|Device|iFIT Transfemoral Prosthesis|Transfemoral amputee volunteers will be fit with the iFIT device and instructed on its use. Patient will wear the iFIT device for a two week time period according to a provided wear schedule. At the end of this time patient will rate it for comfort, stability and ease of use.
45490454|NCT03163966|Drug|CR6086|oral CR6086 capsules
45490455|NCT03163966|Drug|Methotrexate|oral Methotrexate tablets
46053510|NCT05054387|Drug|Agalsidase beta|Powder for concentration into a solution Intravenous (IV) infusion
45490456|NCT03163966|Drug|Placebo|oral CR6086 Placebo capsules
45490457|NCT03678116|Drug|Sugar Pill (placebo)|Taken orally in capsule form
45490458|NCT03678116|Dietary Supplement|Caffeine (plus Teacrine and Cayenne)|Taken orally in capsule form
45490459|NCT03678116|Dietary Supplement|Caffeine (plus Teacrine)|Taken orally in capsule form
45490460|NCT03163498|Other|No intervantion. It´s a Cross-Sectional Study|No intervential
45490461|NCT03768648|Other|Clinical assessment|EDSS (Kurtzke JF; 1983) and the modified MS functional composite (MSFC) score. MS history and MS treatment will be recorded
45490462|NCT03768648|Other|Ecological evaluation|Virtual reality task : Urban DailyCog© and Actual reality
45372193|NCT02861573|Biological|Pembrolizumab 200 mg|IV Q3W
45372194|NCT02861573|Drug|Olaparib 400 mg|Eight 50-mg capsules PO BID
45372195|NCT02861573|Drug|Docetaxel 75 mg/m^2|IV Q3W
45372196|NCT02861573|Drug|Prednisone 5 mg|One 5-mg tablet PO BID
45372197|NCT02861573|Drug|Enzalutamide 160 mg|Four 40-mg capsules, four 40-mg tablets, or two 80-mg tablets PO QD
45372198|NCT02861573|Other|Dexamethasone 8 mg|Premedication for Cohort B given PO at 12, 3, and 1 hours prior to docetaxel infusion Q3W
45372199|NCT02861573|Drug|Olaparib 300 mg|Two 150-mg tablets PO BID
45372200|NCT02861573|Drug|Abiraterone acetate 1000 mg|Two 500-mg or four 250-mg tablets PO QD
45372201|NCT02861573|Drug|Lenvatinib|20 mg PO QD
45372202|NCT02861573|Biological|Pembrolizumab/Vibostolimab coformulation|IV Q3W
45372203|NCT02861573|Drug|Carboplatin|IV Q3W
45372204|NCT02861573|Drug|Etoposide|IV on Days 1, 2 and 3 of each cycle
45372205|NCT02861573|Biological|Belzutifan 120mg|PO QD
45692662|NCT03583983|Behavioral|Personalized Health Recommendations|Includes 3-month gym membership, personalized exercise and meal plans, and genetic information related to health and wellness traits. The genetic information provided to study participants will consist of scores ranging from 0 to 100 based on the population percentile of the combined effects of many genetic variants, herein referred to as polygenic scores (PGS). PGS for approximately twenty traits related to health, fitness and nutrition will be provided to study participants. These traits are chosen for their relevance to healthy lifestyle habits (e.g. genetic predisposition to adiposity or muscle strength), entertainment value (e.g. preference for mornings) or both (e.g. bitterness taste perception, which while entertaining can also help guide vegetable choices).
45692663|NCT03583983|Behavioral|Generic Health Recommendations|Includes 3-month gym membership and generic recommendations (Canada Food Guide / Health Canada Physical Activity guidelines)
45692664|NCT05703165|Behavioral|animal-assisted intervention|horse-assisted intervention
45372206|NCT02858310|Biological|E7 TCR cells|T cells genetically engineered with a TCR targeting HPV-16 E7 (E7 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells
45372207|NCT02858310|Drug|Aldesleukin|Following cell infusion the patient receives high-dose bolus aldesleukin, which is dosed to individual patient tolerance. Aldesleukin improves the survival of E7 TCR cells after infusion.
45372208|NCT02858310|Drug|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
45372209|NCT02858310|Drug|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
45372210|NCT02851706|Other|No Treatment|Survey or Questionnaire Completion with or without Sample Submission
45372211|NCT02831049|Behavioral|Retrieval-extinction|Retrieval-extinction
45372212|NCT02831049|Behavioral|Extinction|extinction
45372213|NCT02831049|Behavioral|Retrieval|Retrieval
45372214|NCT02788227|Biological|rVSV-Zebov GP vaccine|primary vaccination for all participants, one-to-one randomization at Month 18 to receive booster vaccination or no booster.
45372215|NCT02756702|Device|All-Poly|Implantation of the VEGA PS using all-polyethylene tibia components
45692665|NCT05703165|Behavioral|watching the countryside|just watching the countryside
46053511|NCT05049694|Device|zirconia crowns|esthetic crowns for capping permanent molars with caries
46053512|NCT05049694|Device|stainless steel crowns|stainless steel crowns for capping permanent molars with caries
46053513|NCT05048901|Drug|Cabozantinib|Oral Cabozantinib 40-60 mg daily .every 4 weeks as a cycle
46053514|NCT05048901|Drug|Lanreotide|Lanreotide 120 mg deep SC on day 1 every 4 weeks.every 4 weeks as a cycle
46053515|NCT05042973|Drug|Empagliflozin 10 MG|Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days
46053516|NCT05042973|Drug|Placebo|Placebo matches the active drug in appearance, odor and labelling.
45372216|NCT02755272|Drug|Pembrolizumab|IV Infusion of 200 mg given on day one of each 21 day treatment cycle.
45372217|NCT02755272|Drug|Carboplatin|IV infusion of a calculated dose (AUC 2 mL/min) given on days one and eight of each 21 day treatment cycle.
45372218|NCT02755272|Drug|Gemcitabine|IV infusion of 800 mg/m^2 given on days one and eight of each 21 day treatment cycle.
45372219|NCT02734485|Device|active Deep TMS|"The Brainsway DTMS produces a time-varying magnetic field and, based on Faraday's Law, it can be assumed that a time-varying magnetic field generates an electrical current in a nearby conductive substance. The induced electric current in the cortex travels in an orthogonal path in the direction of the magnetic field with the maximum strength and current located beneath the coil in the helmet placed on the patient's head and transmits magnetic pulses to the patient's brain. The induced current is tangential to the scalp at the cortical surface, and decreases in magnitude with increasing depth.~Patients underwent 12 sessions, 3 times a week, of repetitive DTMS using the novel H2-coil (Brainsway LDT)."
45372220|NCT02734485|Device|sham Deep TMS|The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an INACTIVE DTMS coil.
46053517|NCT05038163|Other|Nutrition Facts|The nutritional information label for each beverage is enlarged.
45372222|NCT02629120|Drug|Alemtuzumab|Transplant Conditioning Drug: Monoclonal antibody that targets recipient and donor T-cells to prevent graft verses host disease. Not an IND. This is a well studied drug, and is not under an IND.
45372223|NCT02629120|Drug|Busulfan|Transplant Conditioning Drug: Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under an IND.
45372224|NCT02629120|Drug|Sirolimus|Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.
45490463|NCT03768648|Other|Neuropsychological evaluation|cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
45490464|NCT03768648|Other|Psychological evaluation|questionnaires for depression, anxiety and fatigue
45490465|NCT03768648|Device|MRI Evaluation|morphological MRI and resting state functional MRI (fMRI)
45490466|NCT03678038|Drug|Triamcinolone (Shincort) injection to rotator interval|via rotator interval.
45372225|NCT02629120|Drug|Cyclophosphamide|Post transplant cyclophosphamide given to prevent graft verses host disease. This is a well studied drug, and is not under an IND.
45372226|NCT02629120|Radiation|Total Body Irradiation|Transplant Conditioning Total Body Radiation (300cGy in 2 fractionated doses), given only to patient receiving matched unrelated donor cells, to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow.
45372227|NCT02629120|Biological|Peripheral blood stem cells|Donor Peripheral blood stem cells, either matched unrelated donor or matched related relative to replace the patient's immune cells with functional immune cells. The peripheral blood stem cells are not regulated by the FDA.
45490467|NCT03678038|Drug|Triamcinolone (Shincort) injection to posterior glenuhumeral recess|via posterior glenuhumeral recess
45372228|NCT02628067|Biological|pembrolizumab|intravenous infusion
45372229|NCT02628067|Biological|pembrolizumab|intravenous infusion
45372230|NCT02589522|Drug|Berzosertib|Given IV
45692666|NCT03589287|Biological|Chondrochymal®|Allogeneic Bone Marrow Derived Mesenchymal Stem Cells
45372231|NCT02589522|Other|Quality-of-Life Assessment|Ancillary studies
45372232|NCT02589522|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45372233|NCT02589522|Radiation|Whole-Brain Radiotherapy|Undergo whole-brain radiation therapy
45372234|NCT02579967|Drug|Immunosuppression Only Conditioning -Closed with amendment L|Pentostatin 4 mg/m2/day IV on days -9 and -5, cyclophosphamide 5 mg/kg orally daily on days -9 through -2 (Closed with amendment L)
45372235|NCT02579967|Drug|Reduced Intensity Conditioning|pentostatin 4 mg/m2/day IV on days -11 and -7, cyclophosphamide 3 mg/kg orally daily on days -11 through -4; busulfan IV, pharmokinetically dosed, on days -3 and -2.
45372236|NCT02579967|Drug|Myeloablative Conditioning-Closed with amendment L|Pentostatin 4 mg/m2/day IV on days -13 and -9, low-dose cyclophosphamide orally daily on days -13 through -6; busulfan IV, pharmokinetically dosed, on days -5, -4, -3, and -2. (Closed with amendment L)
45372237|NCT02579967|Drug|GVHD Prophylaxis|High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, sirolimus 6 mg on days +5 through +90, and mycophenolate mofetil (MMF) on days +5 through 0, +18, +25, or +35 depending on treatment arm and cohort.
45372238|NCT02579967|Procedure|Allo BMT|Allogeneic blood or marrow transplantation
45372239|NCT02542293|Biological|Durvalumab +Tremelimumab|
45372240|NCT02542293|Drug|Paclitaxel + carboplatin|Chemotherapy Agents
45490468|NCT03163420|Drug|Diclofenac potassium|Diclofenac potassium 50 mg granules for oral solution
45490469|NCT03163420|Other|Placebo|Fructose
45490470|NCT04744272|Device|myAsthma|myAsthma is an online digital self-management application to support asthma patients by offering education, inhaler technique, pulmonary rehabilitation, symptoms and medication usage tracking remotely.
46053518|NCT05038163|Other|Text Warning|The health risks of sugary beverages are communicated to subjects using words/text and simple images.
45372241|NCT02542293|Drug|Gemcitabine + cisplatin|Chemotherapy Agents
45490471|NCT03677960|Drug|Topical ABI-1968 cream|Multiple doses of Topical ABI-1968 Cream administered by the Investigator in the clinic up to Day 29
45490472|NCT04440436|Drug|IM19 CAR-T Cells|"IM19 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days"
46053519|NCT05038163|Other|Graphic Warning|The health risks of sugary beverages are communicated to subjects using a combination of words/text and graphic images/photographs.
46053520|NCT05034003|Device|Zirconia crown|Esthetic crowns for capping primary incisor with caries
45490473|NCT01568814|Drug|Low volume PEG|low volume polyethylene glycol 2 liter one time
45490474|NCT01568814|Drug|high volume PEG|high volume polyethylene glycol 4 lilter split-dosing 2L/2L two times
45498159|NCT05451771|Drug|Daratumumab Injection|Daratumumab will be administered at a dose of 16 mg/kg by IV infusion once weekly for weeks 1 to 8, every 2 weeks for weeks 9 to 24, and every 4 weeks thereafter for a maximum of 6 months of therapy. If subcutaneous formulation is available, participants can also receive subcutaneous daratumumab (1800 mg in 15 ml) in the same schedule.
46053521|NCT05034003|Device|composite strip crown|Esthetic resin restoration for primary incisor with caries
45372242|NCT02542293|Drug|Gemcitabine + carboplatin|Chemotherapy Agents
45372243|NCT02542293|Drug|Pemetrexed + cisplatin|Chemotherapy Agent
45372244|NCT02542293|Drug|Pemetrexed + carboplatin|Chemotherapy Agent
45372245|NCT02511028|Drug|Ferumoxytol|510mg (17mL) IV
45692667|NCT03113253|Drug|Tranexamic Acid|
45692668|NCT03113253|Drug|Placebo|0.9% sodium chloride to mimic tranexamic acid
46053522|NCT05030272|Device|"Quit on the Go App (formerly Learn to Quit  App)"|A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms.
45372246|NCT02507687|Drug|Bimatoprost SR|Up to two Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).
45372247|NCT02507687|Drug|Sham Bimatoprost SR|Up to two Sham Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).
46053523|NCT05030272|Behavioral|Brief advice|Brief Advice will consist of 20 minutes of guidance about the use of nicotine replacement therapy, and strategies to initiate and maintain a quit attempt.
45372248|NCT02507687|Procedure|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty administered on Day 1.
45372249|NCT02507687|Procedure|Sham Selective Laser Trabeculoplasty|Sham Selective Laser Trabeculoplasty administered on Day 1.
45372250|NCT02466971|Radiation|Brachytherapy|Undergo brachytherapy
45372251|NCT02466971|Drug|Cisplatin|Given IV
45498160|NCT05451771|Drug|Bendamustine|Bendamustine will be given at an initial dose of 100 mg/m^2 intravenously on days 1 and 2 in each 28-day cycle.
45498161|NCT05451771|Drug|Pomalidomide|Pomalidomide will be administered at an initial dose of 2 mg per days on days 1-21 every 28 days.
46053524|NCT05030272|Drug|Nicotine patch|All participants will receive an 8-week course of transdermal nicotine patches. The first 4 weeks of use will be 21mg/24 hours, followed by 2 weeks of 14mg/24 hours patches, and finally 2 weeks of 7mg/24 hours patches.
46053525|NCT05030272|Behavioral|Smartphone coaching|Participants randomized to the smartphone app intervention will receive 4 weeks of smartphone coaching given by research staff. The coaching is meant to be a time to address any issues that may rise with the participants' study smartphone or app.
45372252|NCT02466971|Radiation|External Beam Radiation Therapy|Undergo EBRT
45372253|NCT02466971|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45372254|NCT02466971|Other|Laboratory Biomarker Analysis|Correlative studies
45372255|NCT02466971|Radiation|Radiation Therapy|Undergo conventional RT
45372256|NCT02466971|Drug|Triapine|Given IV
45372257|NCT02453282|Biological|MEDI4736 (Durvalumab)|
45372258|NCT02453282|Biological|MEDI4736 (Durvalumab)+Tremelimumab|
46053526|NCT05030272|Drug|Nicotine gum|Each participant enrolled will be given NRT gum (5-10week course) to be taken orally as nicotine cravings arise. Depending on participants' nicotine dependence, they will receive either the 2mg or 4mg (if they smoke within the first 30 minutes of waking) gum pieces per package instructions. We will direct subjects to use them for the first weeks following their quit date, using no more than one every 1-2 hours.
45372259|NCT02453282|Drug|Paclitaxel + Carboplatin|Chemotherapy Agents
45372260|NCT02453282|Drug|Gemcitabine + Cisplatin|Chemotherapy Agents
45372261|NCT02453282|Drug|Gemcitabine + Carboplatin|Chemotherapy Agents
45372262|NCT02453282|Drug|Pemetrexed + Cisplatin|Chemotherapy Agents
45372263|NCT02453282|Drug|Pemetrexed + Carboplatin|Chemotherapy Agents
45372264|NCT02453282|Biological|Tremelimumab|
45372265|NCT02438306|Biological|Autologous cell therapy|Autologous cell therapy delivered into the heart muscle using the CardiAMP Cell Therapy System. The CardiAMP Cell Therapy System consists of the CardiAMP Cell Separator, a cardiac delivery catheter, and flexible tip guide catheter.
45372266|NCT02438306|Other|Sham|An introducer guidewire is placed into the heart and left ventriculography is performed just like it is in the Experimental Arm but no autologous cell therapy is delivered.
45372267|NCT02393859|Drug|Blinatumomab|15 μg/m^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
45372268|NCT02393859|Drug|Dexamethasone|10 mg/m^2/day intravenous (IV) on Days 1-6
45372269|NCT02393859|Drug|Vincrisitne|1.5 mg/m^2/day IV on Days 1 and 6
45372270|NCT02393859|Drug|Daunorubicin|30 mg/m^2 IV over 24 hours on Day 5
45372271|NCT02393859|Drug|Methotrexate|1 g/m^2 IV over 36 hours on Day 1
45372272|NCT02393859|Drug|Ifosfamide|800 mg/m^2 IV for 1 hour on Days 2-4
45372273|NCT02393859|Drug|PEG-asparaginase|1000 U/m^2 IV for 2 hours or intramuscularly (IM) on Day 6
45372274|NCT02393859|Drug|Erwinia-asparaginase|In case of allergic reaction to PEG-asparaginase, participants could change to erwinia-asparaginase, 20,000 units/m2 every 48 hours for a total of 6 doses
45372275|NCT02392442|Other|Saline|Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6 hours after 1800 of normal Saline installed in six 30 mL aliquots into the left (lingual) and right (middle lobe) lung segments (360 mL total).
45372276|NCT02392442|Biological|Endotoxin|Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6, 24, or 48 hours after endotoxin segmental lung challenge.
45372277|NCT02383407|Device|Medtronic Deep Brain Stimulation|
46053527|NCT05030272|Drug|Nicotine Lozenges|In cases where participants are unable to chew nicotine gum, lozenges will be sent as a replacement of Nicotine gum. Depending on participants' nicotine dependence, they will receive either the 2mg or 4mg (if they smoke within the first 30 minutes of waking) lozenge pieces per package instructions. We will direct subjects to use them for the first weeks following their quit date, using no more than one every 1-2 hours.
46053528|NCT05020496|Drug|Diphenylcyclopropenone (DPCP)|Drug will be applied topically on the skin. It will cause contact hypersensitivity in patients
46053529|NCT05017233|Device|Spectral CT|Using Spectral CT to scan Breast
46053530|NCT05013333|Device|AED 3 with Uni-padz|Use of AED 3 with Uni-padz by lay rescuer
46053531|NCT05002803|Other|Otago Exercise Program|A Home-based Exercise Program to improve strength and balance and prevent falls.
46053532|NCT04998149|Device|Peanut Ball positioning device|Peanut Ball manufactured by Clinton industries at graylinemedical.com https://www.graylinemedical.com/products/clinton-industries-peanut-ball-peanut-ball-40-cm-yellow-8540?_pos=3&_sid=d6e52e63c&_ss=r
46053533|NCT04984356|Biological|WU-CART-007|A single IV infusion of WU-CART-007 Cells on Day 1
45372285|NCT02321501|Drug|Ceritinib|Given PO
45372286|NCT02321501|Drug|Everolimus|Given PO
45372287|NCT02321501|Other|Laboratory Biomarker Analysis|Correlative studies
45372288|NCT02321501|Other|Pharmacological Study|Correlative studies
46053534|NCT04976257|Procedure|Angiogram|Undergo angiogram
46053535|NCT04976257|Procedure|Catheterization|Undergo prostatic arterial catheterization
45372289|NCT02242942|Drug|Chlorambucil|Chlorambucil 0.5 milligrams per kilogram (mg/kg) orally at Day 1 and Day 15 at of each 28 day cycle for 12 cycles.
45372290|NCT02242942|Drug|Venetoclax|Venetoclax, oral tablet: 20 mg daily during Cycle 1, Day 22-28; 50 mg daily during Cycle 2, Day 1-7; 100 mg daily during Cycle 2, Day 8-14; 200 mg daily during Cycle 2, Day 15-21; 400 mg daily during Cycle 2, Day 22-28 and on Day 1-28 for all subsequent cycles until the end of Cycle 12.
45372291|NCT02242942|Drug|Obinutuzumab|Obinutuzumab, IV infusion: 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6
45372292|NCT02237079|Drug|Bazedoxifene/Conjugated Estrogens (BZA/CE)|Daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg.
45372293|NCT02237079|Drug|Placebo Oral Tablet|Daily placebo tablet
45372294|NCT02233868|Other|connectivity|Magnetic resonance imaging (MRI) scans will be done to assess brain structure, functional reactivity and functional connectivity.
45372295|NCT02233868|Drug|neuroinflammation|The use of [11C]PBR28 will allow us to assess for the first time in vivo if there is neuroinflammation in the brain of alcoholics. It will also allow us to assess if it recovers with alcohol detoxification.
45372296|NCT02233868|Other|neurofunction|To assess regional brain glucose metabolism.
45372297|NCT02233829|Drug|Brain Dopamine Reactivity|IV methylphenidate, used under IND #124, 912 is injected into the subject s bloodstream to be used in conjunction with PET imaging to show displacement of [11C]raclopride.
45372298|NCT02233829|Radiation|Brain Dopamine Receptor|The radiotracer [11C] raclopride is used for imaging dopamine receptors and dopamine release.
46053536|NCT04976257|Drug|Gallium Ga-labeled PSMA-11|Given IV and IA
45692669|NCT03020277|Other|Ecological Momentary Assessment with Smartphone© Application|Filling of the application every 3 days for 6 months by subjects (parents of patients with ASD)
45498162|NCT05451771|Drug|Ixazomib|Ixazomib will be administered at an initial dose of 4 mg per days on days 1, 8, and 15 every 28 days.
45372299|NCT02211768|Procedure|MRI, FDG-PET/CT scans|Standard of care to be obtained as part of the study
45372300|NCT02211768|Drug|[18F]-FLT-PET/CT scans|FLT PET to be performed as a research imaging study as it is not considered standard imaging in NF1
46053537|NCT04976257|Procedure|Positron Emission Tomography|Undergo PET scan
46053538|NCT04975698|Biological|HST-NEETs|HST-NEETs are manufactured from an autologous peripheral blood collection and will be administered as a single intravenous (IV) infusion of 2x10^7/m^2 cells between 3 Days and 7 Days post-ASCT.
46053539|NCT04975698|Biological|Bone Marrow Transplant|Day 0 is the day of bone marrow transplantation.
46053540|NCT04969783|Other|Ventilated Cigarette Filter|Ventilated Cigarette Filter
46053541|NCT04969783|Other|Unventilated Cigarette Filter|Unventilated Cigarette Filter
45692670|NCT02800317|Procedure|RISAS|RISAS procedure contains Radioactive Iodine Seed localisation in the Axilla in axillary node positive breast cancer combined with a Sentinel node procedure.
46053542|NCT04968574|Drug|taladegib|hedgehog pathway inhibitor dosed once daily
46053543|NCT04968574|Drug|placebo|identical tablets to the experimental arm with no active ingredient
46053544|NCT04966637|Other|COPD cohort|as this a retrospective descriptive study no intervention will be administered to study participants
46053545|NCT04959448|Drug|DUPIXENT®|No investigational agents will be provided. All treatments will be prescribed at the discretion of the study physician and other healthcare providers.
46053546|NCT04955691|Other|low carbohydrate diet|Participants will engage in a diet that limits carbohydrate intake to 15% of total daily calories for 2 weeks.
46053547|NCT04955691|Other|standard carbohydrate diet|Participants will engage in a diet that recommends standard carbohydrate intake with respect to total daily calories for 2 weeks.
46053548|NCT04954365|Drug|Rescue Post-Operative Nausea and Vomiting (PONV) treatment according to the standard of care (SOC)|Rescue Post-Operative Nausea and Vomiting (PONV) treatment
46053549|NCT04954365|Drug|Amisulpride|Rescue Post-Operative Nausea and Vomiting (PONV) treatment with Amisulpride
46053550|NCT04952389|Device|Acupuncture Therapy|Consists of two treatments per week for five weeks
46053551|NCT04952389|Drug|Budesonide|Twice daily nasal rinses with steroid medication (budesonide)
46053552|NCT04952389|Other|Olfactory Training|involves smelling 4 different essential oils (e.g. rose, lemon, clove, and eucalyptus) twice a day for 20 seconds each (after the nasal rinse)
46053553|NCT04937647|Other|collection of endoscopic images and videos|collection of endoscopic images and videos
46053554|NCT04936009|Behavioral|Transcranial Magnetic Stimulation (TMS)|Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
45692671|NCT02753751|Other|AKI Alert|"Provider's will receive a pop-up alert in the electronic health record until AKI is documented in the problem list or AKI resolves."
45692672|NCT01836523|Drug|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
45490475|NCT03677882|Behavioral|Mind Body Bridging Group Session|Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in four, 90-minute Mind Body Bridging group sessions that will occur for four weeks in a row. Each group will involve up to 15 participants and will be led by a trained MBB facilitator. Participants will receive a workbook at the beginning of the training that contains an explanation of all the major concepts involved in Mind Body Bridging. The workbook has homework assignments to be completed daily between group sessions.
46053555|NCT04930965|Behavioral|Community health worker engagement|3-4 in-person or virtual engagements (individual or group sessions) over 1 month, each engagement lasting 30 minutes to 1 hour
46053556|NCT04923685|Other|Trier Social Stress Test|The TSST is a standardized test to induce acute psychological stress in humans. Participants will abstain from caffeine for 12 hours and nicotine for 2 hours prior to the test. An IV butterfly catheter will be placed in an arm vein and flushed with saline. Participants will rest for 15 minutes. A 10ml baseline blood sample will be drawn. They will perform the TSST task and then have 10ml of blood drawn at 0, 15, 30, 60, and 90 minutes post-TSST.
46053557|NCT04920617|Drug|DPX-Survivac|SC injection on D7 and D28, then every 8 weeks
45372317|NCT02162511|Device|CliniMACS CD34+ cell enrichment and T-cell depletion|
45372318|NCT02065869|Biological|BPX-501 T cells|1x10E6 cells/kg infused on Day 0
45372319|NCT02065869|Drug|Rimiducid|0.4mg/kg administered IV to treat GVHD
45372320|NCT02065375|Drug|Omaveloxolone Ophthalmic Suspension 1.0%|
45372321|NCT02065375|Drug|Omaveloxolone Opthalmic Suspension 0.5%|
45372322|NCT02065375|Drug|Placebo|
45490476|NCT05405686|Drug|Lutropin alfa|addition of recombinant luteinizing hormone
45490477|NCT05405686|Drug|Follitropin alfa|recombinant follicle stimulating hormone (FSH)
45490478|NCT05405686|Diagnostic Test|Endometrial biopsy|pipelle de cornier biopsy
46053558|NCT04920617|Drug|Pembrolizumab|IV infusion every 3 weeks
46053559|NCT04920617|Drug|CPA|50 mg twice daily, week on then week off
46053560|NCT04913766|Behavioral|Problem Management Plus|Five session psychological intervention focusing on problem management skills.
46053561|NCT04913766|Behavioral|Services as Usual|Mental health services provided by a mental health specialists according to their standard practices of care
45372323|NCT01992861|Procedure|Computed Tomography|Undergo FDG PET/CT
45372324|NCT01992861|Procedure|Diffusion Weighted Imaging|Undergo DW MRI
45372325|NCT01992861|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
45372326|NCT01992861|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
45372327|NCT01992861|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopy
45372328|NCT01992861|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
45372329|NCT01900132|Device|EIM testing|EIM device is placed on the muscle and a high frequency current is delivered to the skin.
45372330|NCT01900132|Device|Nerve &amp; muscle ultrasonography|Ultrasound waves to examine the muscles and nerves
45372331|NCT01900132|Device|Nerve conduction studies|Small metal disk electrodes attached to wires onto skin to measure how fast nerves conduct electrical impulses and the strength of the connection between nerves and muscles.
45372332|NCT01900132|Device|Electromyography (EMG)|Thin needle placed into muscles to record electrical activity-adults only
45372333|NCT01897610|Drug|Immuncell-LC|intravenous dripping of 200ml(10^9~2x10^10 lymphocytes/60kg adult) for 1 hour
45372334|NCT01895517|Other|LBC|Cervical cancer screening by using liquid based cytology as a standard screening modality
45372335|NCT01895517|Other|LBC plus HPV DNA testing|Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
45372336|NCT01842386|Drug|Rituximab|Subjects will receive intravenous (IV) infusions of rituximab 1 gram on days 1 and 15, and subsequently if indicated up to once a month for 5 months (+/-5 days for each visit) starting approximately on day 42. Subjects whose infections respond positively to the treatment but then relapse may be offered additional treatment.
45490479|NCT04711122|Drug|Third generation cephalosporin antibiotics|Assessment of antibiotic effect
45372337|NCT01799538|Drug|albuterol inhaler|2 puffs of Metered Dose inhaler for Bronchodilation
45372338|NCT01799538|Drug|albuterol nebulizer|Albuterol administered by nebulization will produce a greater increase in FEV1
45372339|NCT01799538|Procedure|PFT|Breathing Test
45372340|NCT01767675|Procedure|Secondary Cytoreductive Surgery|
45372341|NCT01767675|Drug|Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|
45372342|NCT01767675|Drug|platinum-based systemic chemotherapy postoperatively|5 cycles
45372343|NCT01767675|Drug|platinum-based systemic chemotherapy postoperatively|6 cycles
45372344|NCT01747213|Drug|BNC|
45372345|NCT01747213|Other|Placebo|Microcrystalline cellulose fiber
45372346|NCT01728363|Drug|Antibiotic|Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.
45372347|NCT01621581|Genetic|Convection enhanced delivery/AAV2-GDNF|Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) Administered via Bilateral Stereotactic Convection-Enhanced Delivery
45490480|NCT05272696|Drug|Nab-paclitaxel, cisplatin and Pembrolizumab combination|Pembrolizumab in combination with Nab-paclitaxel and cisplatin as induction therapy
45372348|NCT01581580|Procedure|Deep Brain Stimulation|standard of care DBS surgery for patients with Parkinson's Disease, dystonia, and essential tremor
45490481|NCT05272696|Procedure|surgery|Patients with PR but the maximum diameter of tumor > 3cm or SD or PD can receive surgery directly.
45490482|NCT05272696|Radiation|Adjuvant Chemoradiotherapy|After surgery, adjuvant Chemoradiotherapy or radiotherapy will be given for patients with high-risk factors.
45490483|NCT05272696|Drug|Radical concurrent chemoradiotherapy|Patients with PR and maximum tumor diameter ≤ 3cm or CR evaluated by MDT after 2 courses induction therapy can receive Radical concurrent chemoradiotherapy. Evaluation was performed 3 months after CRT. After MDT discussion, patients with high-risk factors need maintenance treatment.
45490484|NCT05563116|Diagnostic Test|Computed tomography coronary artery calcium (CAC) score (part of routine workup)|Agatston method quantified coronary calcification. A prospectively ECG-triggered, non-contrasted CAC score used a non-enhanced low radiation cardiac CT scan provided onsite at both centers. Quantification of CAC was performed using a SOMATOM Definition Edge or SOMATOM Force (Siemens Medical Solutions) with standard mediastinal parameters (width, 350 Hounsfield units; level, 50 Hounsfield units), and according to the current guidelines for CAC scoring of non-contrast non-cardiac chest CT scans.
45490485|NCT03520946|Drug|Ramucirumab|8 mg/kg iv over 60 min on d1+15, q4w
45490486|NCT03520946|Drug|TAS 102|35mg/m2 p.o. twice daily (BID) d1-5 and d8-12, q4w
45490487|NCT02863068|Drug|Topical Sodium Nitrite|"Subjects will have 0.1 cm of 2% sodium nitrite cream applied per 1 cm2 of the total ulcerated area. Areas will be rounded to the nearest 1 cm2. If a subject has more than one ulcer, all of them will be treated with either study cream in this intervention."
45490488|NCT02863068|Other|Placebo|Subjects will have Placebo applied to total ulcerated area. If a subject has more than one ulcer, all of them will be treated with placebo in this intervention.
45490489|NCT05254990|Drug|Reparixin|Reparixin 600 mg tablets, administered orally at the dose of 1200 mg TID (2 tablets TID) as add-on therapy to standard of care up to 21 days. IMP can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that reparixin is taken with food. However, if the patient is unable to eat, the study drug may still be administered without concomitant food ingestion.
45490490|NCT05254990|Other|Placebo|"Administered orally three times a day (TID) as add-on therapy to standard of care up to 21 days.~Placebo can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that placebo is taken with food. However, if the patient is unable to eat, the placebo may still be administered without concomitant food ingestion."
45490491|NCT03677726|Behavioral|Mindfulness Based Therapy for Insomnia|The mindfulness-based intervention consists of eight 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to people with sleep problems and insomnia. Participants will be provided handouts for the information covered during these talks and discussions.
45490492|NCT03677726|Other|Sleep Hygiene Education Exercise Program|The Sleep Hygiene Education and Exercise Program has known relationships with good sleep quality. It will comprise 8 weekly 2-hour sessions. Each session will introduce a concept related to sleep and sleep hygiene. The facilitator will provide the theory and rationale behind the concept, and encourage participants to share and discuss their experiences related to the concept. The session will end with the participants evaluating how to implement the specific concept in their daily lives, and its potential implications for their sleep. Participants will be provided with a manual that outlines the concept and how they intend to apply it to their daily lives.
45490493|NCT05547906|Drug|ASCA101|IV infusion Twice a Week, 8 times per each Cycle
45490494|NCT03709758|Drug|Venetoclax|Venetoclax blocks an important pathway that promotes cell survival in tumor cells that overexpress BCL-2, so venetoclax causes cells to die
45490495|NCT03709758|Drug|Daunorubicin|Chemotherapy is most effective at killing cells that are rapidly dividing.
46053562|NCT04906499|Behavioral|Physical Activity Promotion|"After enrolling, participants will be outfitted with a Fitbit Charge 2 activity monitor. The monitor will be worn during all waking hours, and compliance will be considered as a day with ≥ 1,000 steps. Participants will complete a 14-day run-in observation period while wearing the Fitbit but no PA promotion will occur. Individuals who are noncompliant during the run in period (<10 days with <1,000 steps) will be removed. Participants will receive a text message each morning with a personalized, daily step count goal and a link used to confirm receipt of the goal. The preceding 10 days of step data will be rank ordered and the 60th percentile step count will be set as the goal for the next day."
46053563|NCT04874233|Drug|HU6|HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
46053564|NCT04874233|Drug|Placebo|Non-active study drug N = 20
45490496|NCT03709758|Drug|Cytarabine|Chemotherapy is most effective at killing cells that are rapidly dividing.
45372349|NCT01572532|Other|Screening treatment and referral|"Women who are symptomatic at any study visit will be immediately referred to the sub-district hospital for full evaluation and treatment and will be visited on the following day to follow clinical status and ensure referral compliance. Referral will be reinforced by arranging transportation to the sub-district hospital and payment of hospital fees if the family is unable to afford out-of-pocket expenses. CHWs will conduct a home visit to women with positive test results within 24 hours of receiving the results to initiate treatment. All asymptomatic women will be treated for positive test results. For symptomatic women, the CHW will confirm the woman's clinical and treatment status, and provide treatment to those women who have not already received the appropriate treatment at the sub-district hospital for their infection.~Antibiotic Treatment Regimens AVF: Oral clindamycin 300 mg per oral (po) twice daily (bid) for 5 days.UTI: Macrobid/Nitrofurantoin 100 mg po bid x 7 days."
45372350|NCT01534598|Drug|FdCyd + THU|Intravenous FdCyd with THU has been evaluated in a Phase I clinical trial with some preliminary evidence of activity. This trial will investigate oral administration of the drugs, which was shown to be feasible in an expansion cohort of the previous trial.
45372351|NCT01439659|Behavioral|Nutritional Counseling|Initial interview and subsequent telephone contact once per week for two months, once every other week for the following two months, and once per month for the remaining two months.
45372352|NCT01439659|Dietary Supplement|Daily Supplements|Two capsules daily in the morning and two capsules daily in the evening of Juice Plus+ in addition to regular meal. Also a beverage, Juice Plus+ Complete (a powder mixture to be added to one cup of fluid) daily in the evening.
45372353|NCT01419561|Drug|Zidovudine|Zidovudine 600 mg will be administered orally 4 times a day or i.v. at 300 mg every 6 hours for 14 days for cycle 1 and for 7 days (up to additional 7 days if ongoing symptoms) for following cycles.
45372354|NCT01419561|Drug|Liposomal Doxorubicin|Liposomal doxorubicin (20 mg/m2) will be administered i.v. over 1 hour at day 1 of each cycle
45490497|NCT03674060|Drug|SYO-1644|"100mg: SYO-1644 tablet, PO, 1 100mg tablet~150mg: SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet~200mg: SYO-1644 tablet, PO, 2 100mg tablet"
45372355|NCT01419561|Drug|Valganiclovir|Valganciclovir (900mg) will be administered orally twice/day or Ganciclovir (5 mg/kg) will be administered i.v. over 1 hour for 14 days for cycle 1 and for 7 days (up to additional 7 days if ongoing symptoms) for following cycles.
45372356|NCT01419561|Drug|Rituximab|"Rituximab (375 mg/m2) will be admnistered i.v. at 50 mg/hr up to 100 mg/hr at day 1 of the first cycle and at 100mg/hr up to 400 mg~/hr at day 1 of following cycles."
45372357|NCT01419561|Other|Standard Therapies|Standard of Care drugs
45372358|NCT01362803|Drug|AZD6244|AZD6244 orally (at recommended Ph2 dose) every 12 hours on continuous daily schedule for cycles of 28 days until unacceptable toxicity, patient withdrawal or PD
46053565|NCT04861714|Device|Regeneten|Augmentation of standard subscapularis repair with regeneten patch
46053566|NCT04861714|Procedure|Standard repair|Standard subscapularis repair
46053567|NCT04860804|Drug|Aspirin and Ketamine|Drug: Proprietary oral formulation of 0.5mg/kg of ketamine + 324mg of aspirin
46053568|NCT04860804|Drug|Oral Ketamine|Proprietary oral formulation of 0.5mg/kg of ketamine
46053569|NCT04817345|Drug|Plerixafor|Subcutaneous
45372364|NCT01294332|Other|Aerobic Exercise Training|supervised exercise on the treadmill at target heart rate range for 12 weeks, 3 times a week for 30 minutes.
45372365|NCT01267448|Drug|Glipizide XL|The control group will receive Glipizide XL (10mg orally) for a total duration of 12 weeks.
45372366|NCT01267448|Drug|Saxagliptin + Metformin XR|The intervention group will receive Saxagliptin 5 mg daily for a total duration of 12 weeks.
45692673|NCT01836523|Drug|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
45372367|NCT01267448|Drug|Metformin XR|The intervention group will receive Metformin XR 1000 mg daily and will be automatically titrated weekly in 2 weeks to Metformin XR 2000 daily for a total duration of 12 weeks.
45490498|NCT03674060|Drug|Nexavar tab|Nexavar 200mg/tablet, PO, 1 tablet
45490499|NCT03163186|Procedure|Transarterial embolization|Transarterial hepatic embolization of liver cancer
46053570|NCT04812080|Device|EXPLORER PET/CT|FDG PET Scans on the total body EXPLORER PET/CT scanner
46053571|NCT04795427|Drug|asciminib|Asciminib comes in 20 mg and 40 mg tablets and is taken orally twice daily
46053572|NCT04795427|Other|best available treatment|Best available treatment will be based on investigator's choice identified prior to randomization. Dose and frequency will depend on label and institutional guidelines for various BAT
46053573|NCT04773834|Other|Digital diabetes prevention program (dDPP)|The digital diabetes prevention program is through the Noom app, and the three devices (Fitbit physical activity tracker, Fitbit weight scale, and self-check hemoglobin a1c kit). This is a one year diabetes prevention program where participants will be expected to participate in 5 to 7 interviews over a 18 month period.
45372368|NCT01265030|Drug|Sirolimus|"Loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligrams)~Starting 24 hours after the initial loading dose, patients will receive a dose of 4 milligrams/meter2 daily; Per Os (PO), by mouth days 2 through 28 (Max dose 4 milligram/day)"
45372369|NCT01174121|Biological|Young TIL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes (one to four days after the last dose of fludarabine).
45372370|NCT01174121|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses.)
45372371|NCT01174121|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X2 days over 1 hr.
45372372|NCT01174121|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
45490500|NCT02049632|Procedure|Omission of axillary clearance|
45490501|NCT03163576|Drug|Niacin|tablets
45490502|NCT03163576|Drug|Phosphate Binder|tablets
45498163|NCT05451771|Drug|Venetoclax MTD with Dexamethasone|Venetoclax MTD (200 mg or 400 mg) with Dexamethasone (10 mg or 20 mg) as determined by the phase I results
45692674|NCT01836523|Drug|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
46053574|NCT04773834|Other|Adapted dDPP-EHR tool|This is a product of Phase 1 and 2 of this study where participants will receive detailed text messaging regarding their engagement levels in Noom app.
46053575|NCT04764396|Combination Product|Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe)|The fine needle biopsy (FNB) needle will be flushed with 1 mL of heparin (100 USP/mL) and then flushed with air. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed with 1 mL of heparin (100 USP/mL) and flushed with air before next pass is made.
45372373|NCT01174121|Drug|Pembrolizumab (Keytruda)|Arm 3: Pembrolizumab 2mg/kg IV over approximately 30 minutes on Days -2, 21, 42, and 63 Arm 4: Pembrolizumab 2mg/kg IV over approximately 30 minutes (for patients who meet progressive disease per RECIST criteria and have resolved major toxicities after cell infusion or anytime during the post-treatment evaluation period; starting within 4 weeks of progression; may receive up to 8 doses every 3 weeks).
45372374|NCT01125228|Drug|Ziodovudine and Alpha Interferon|
45490503|NCT05250856|Drug|CNP-201|CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of ~5 μg of PPE per mg of PLGA.
45490504|NCT05250856|Drug|Placebo|Placebo, (0.9% Sodium Chloride for IV infusion)
45846769|NCT05588622|Behavioral|Meru Health Program|The Meru Health Program is a 12-week, evidence-based, smartphone-delivered, therapist-supported digital mental health intervention with as-needed psychiatrist oversight. Enrolled participants work through the program with a cohort of peers similarly affected by depression, with whom they can engage in confidential, anonymous, voluntary group chats overseen by a licensed clinical therapist. The MHP incorporates a continuous care model including daily interaction with a dedicated clinician, several evidence-based treatment components such as cognitive behavioral therapy (CBT), behavioral activation therapy, and mindfulness meditation (MM), as well as promising newer types of depression treatments such as HRVB, nutritional psychiatry, and sleep training. Practices are introduced to weekly topics via video lessons that are reinforced via CBT practices, meditations, and biofeedback sessions and therapist messaging.
45372375|NCT01019343|Procedure|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation involves the application of weak direct currents, delivered between two surface electrodes, placed over the scalp.
45372376|NCT01019343|Device|Eye-tracking Device|The purpose of this device is to assess eye movement. Participants may sit down in front of a computer screen or a real-world environment, stand on a treadmill, or lie down in an MRI scanner. Small infrared cameras attached to the cap or glasses will be positioned in front of their eyes. Eye tracking might be performed alone, or in conjunction with EEG, EMG, fMRI or treadmill. The eye- tracking device is FDA approved and commercially available.
45372377|NCT01019343|Device|Pulsed vibrator|This device would be used in experiments to see if gait can be improved and, if so, what parameters of stimulation are optimal.
45372378|NCT01019343|Other|Gait Trainer Treadmill (GTT)|The Gait Trainer is a specialized rehabilitation treadmill, which operates in both the forward and backwards mode allowing subjects to both train and undergo performance tasks in a relatively safe and expedient manner. The GTT is equipped with a mounted deck with built in sensors which monitors and records subjects gait speed, step length, right to left time distribution, and symmetry in real time in both forward and reverse modes.
45490505|NCT01971008|Device|Elastic abdominal binder|
45490506|NCT01971008|Device|Placebo binder|
45490507|NCT04691544|Biological|Fecal microbiota transplantation (FMT)|Delivered by enema
45490508|NCT04058912|Genetic|PTEN-AKT-FOXO3 Gene Expression|In the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.
45490509|NCT02781870|Procedure|LiquiBand Fix8 glue fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.
45490510|NCT02781870|Procedure|No-fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible without glue fixation.
45490511|NCT03673982|Behavioral|iCASK|Materials and support to aid transitions
45490512|NCT04759846|Drug|Encorafenib + Binimetinib|The doses administered to patients with normal hepatic function will be the same as the recommended commercialised doses
45846770|NCT05588544|Procedure|Er,Cr:YSGG laser|Use of laser at the degranulation step of the treatment
45846771|NCT05588076|Other|no intervention|no intervention
45490513|NCT04759846|Drug|Encorafenib + Binimetinib|A smaller dose than the dose approved for patients with normal hepatic function has been defined
45692675|NCT01836523|Drug|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
45372379|NCT01019343|Other|Standard psychiatric scales SCID-I, YBOCS and SCI-OBS-lifetime and cognitive scales MMSE and MOCA|Scales of motor function, cognitive function and psychiatric function are valuable supplements to clinical assessments of patients, giving quantitative information concerning these different aspects of brain function. Selected scales would be used only when potentially useful in a sub-study where such quantitative information would be correlated with a physiological or imaging result.
45372380|NCT01019343|Device|iMobility|This test uses the iMobility system. iMobility Device is a small device designed to measure movement through sensors (test monitors) worn by a patient via Velcro straps around an ankle or wrist or worn as a pendant around the neck to lie over the sternum. The device is a nonsignificant risk device.The iMobility Device has been used before, in the same format with a similar paradigm, in previous NIH studies.
45372381|NCT01019343|Device|QMAT|The purpose of this study is to assess the ability of the QMAT (quantitative motor assessment tool) to assess slowness of movement associated with Parkinson Disease. The QMAT device is FDA approved and has been used before, in the same format with a similar paradigm, in previous NIH studies.
45490514|NCT04759846|Drug|Encorafenib + Binimetinib|A smaller dose than the dose approved for patients with normal hepatic function has been defined
45498164|NCT02414139|Drug|INC280 (capmatinib)|
45498165|NCT03680976|Drug|CXA-10|Liquid-filled capsule containing 150 mg CXA-10 in super refined olive oil.
45498166|NCT03680976|Drug|Placebo|Liquid-filled capsule containing olive oil manufactured to mimic CXA-10 150 mg capsule
45846772|NCT05587842|Procedure|Early Weightbearing management post operation|Subjects will be instructed to be weightbearing, as tolerated, on their ankle starting at two weeks post operation.
45498167|NCT01383057|Procedure|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
45692676|NCT01836523|Drug|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
45692677|NCT01836523|Drug|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
45692678|NCT03020121|Procedure|Colposcopy/biopsy|Colposcopy/biopsy will be performed on all subjects
45692679|NCT01275196|Drug|Nilotinib|
45846773|NCT05587842|Procedure|Delayed Weightbearing management post operation (Traditional)|Subjects will be instructed to be non-weightbearing on their ankle until at least 6 weeks. After 6 weeks, the subject will be instructed to be weightbearing as tolerated.
45498168|NCT03684954|Other|Prf|Take 10 cc blood from patient and gain prf
45692680|NCT01275196|Drug|Imatinib|
45692681|NCT03584139|Device|IRIS HOOK|iris hook assisted maneuver in phacoemulsification
45692682|NCT03584139|Device|TRADITION|traditional phacoemulsification or phacoemulsification with 25-gauge vitreous irrigation
45846774|NCT05587218|Behavioral|Self-production|After participants learn L2 lexical items via hearing or observing them paired with L1 translations, they are prompted to produce them themselves
45372382|NCT01019343|Diagnostic Test|Treadmill Test|Subjects will be fitted in a weight support harness for safety. Sensors will be placed on the subject s shoes and harness. The sensors (VICON system) will be used to record their stride length, position and velocity as they walk on a treadmill. This system is a motion-tracking system that is designed to measure various aspects of a person s gait.
45372383|NCT01019343|Device|Arm Intellistretch Device|The purpose of the Arm Intellistretch device is to objectively quantify wrist tone. It is used for rehabilitation applications in hospitals and office settings. Currently, rigidity is evaluated clinically using a subjective scale, zero to four and is part of the UPDRS. The Arm Intellistretch device is manufactured by Rehabtek, Inc., is FDA approved, and has been determined to be a non-significant risk device by the CNS IRB.
45372384|NCT01019343|Procedure|Transcranial Sonography (TCS)|Transcranial sonography will be conducted by a physician in the Clinical Center using the Acuson Antares ultrasound machine. This techniques uses ultrasound signals to image the brain. It entails having the subject sit in a chair or lay in a bed while the sonographer places a lubricated 2-inch ultrasound probe over the skin of the temporal area just above the patient s ear. Ultrasound images are then recorded. The procedure is not invasive and will last about 45 minutes.
45692683|NCT03152643|Procedure|blastocyst-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single blastocyst-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
45692684|NCT03152643|Procedure|cleavage-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single cleavage-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
45692685|NCT03153579|Drug|LSD|"Lysergic Acid Diethylamide~200ug per os, single dose"
45498169|NCT03680898|Device|Rectal swab collection|Patient will provide a rectal swab by following hospital-provided instructions.
45692686|NCT03153579|Drug|Placebo|Capsules containing mannitol looking identical to LSD
45692687|NCT03583905|Drug|CKD-330|CKD-330 Tab.
45692688|NCT03583905|Drug|Placebo of CKD-330|Placebo of CKD-330 Tab.
45692689|NCT03583905|Drug|D086|D086 Tab.
45372385|NCT01019343|Other|Behavioral tasks|To assess the changes in cerebral physiology in the brain, subjects will be presented sensory stimuli (e.g., primary visual stimulation with flashing lights or checkerboard, auditory with tone or speech, or olfactory stimuli), or will be asked to perform non-exercise motor tasks (e.g., tapping of fingers, squeezing ball, moving joystick), to perform cognitive tasks such as a working memory task (e.g., n-back with or without catch rules, word finding), or to just rest or sleep.
45372386|NCT01019343|Procedure|TMS single/paired pulse|For MEP acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles (see sub-section EMG 7.1.3.1 for the details of the procedure).
45692690|NCT03583905|Drug|Placebo of D086|Placebo of D086 Tab.
45372387|NCT01019343|Procedure|MEG|MEG recordings will be performed together with experienced personnel in the NIMH MEG lab in the NMR center in Building 10. For these recording sessions, subjects will sit in a chair or lay down with a helmet placed over the head. The helmet used for MEG does not require the application of conductive gel. Scan times vary from 20 minutes to 2 hours.
45372388|NCT01019343|Procedure|EEG|EEGs will be recorded by, or together with, experienced personnel in the HMCS EEG lab in Building 10, or in the NMR center.
45372389|NCT01019343|Procedure|MRI techniques|MRI sub-studies will be conducted on 3.0 T or 7T units in the NMR Research Center. All volunteers will comply with the yearly requirement of a standard clinical diagnostic MRI scan of the head performed at 3.0T, to be submitted to the Diagnostic Radiology Department of the Clinical Center for interpretation. If the subject does not have a clinical scan performed within 12 month of the exam, a standard clinical MRI will be performed and reviewed before the research MR. The standard examination takes approximately 15 minutes to complete; after that, the research MR scans will be performed. Standard clinical MRI of the head will be repeated on an annual basis and read by the Diagnostic Radiology Department of the Clinical Center.
45372390|NCT01019343|Procedure|Peripheral Nerve Stimulation|Constant-current, 0.1 to 0.5 ms square-wave single pulses of electrical stimulation will be delivered through standard bar electrodes to nerves of the upper limb or of the lower limb. To study somatosensory evoked potentials, for example, the stimulus intensity will be set at just above the motor threshold for evoking a slight limb movement. Location of the electrical stimulation will depend on the specific objective of the sub-study. Peripheral nerve stimulation might be delivered during other types of experiments as well.
45692691|NCT03583905|Drug|D723|D723 Tab.
45692692|NCT03583905|Drug|Placebo of D723|Placebo of D723 Tab.
45692693|NCT01984697|Biological|V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)|V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
45692694|NCT03583827|Other|Virtual reality|Virtual reality is a simulation of the real world generated by computer software and experienced by users via a man-machine interface, providing them with intensive repetition of complex tasks, directed by visual and auditory stimuli, creating dynamic individual-task interaction, a motivating environment and immediate feedback on performance and results, stimulating motor skill learning and motor control of complex behaviors.
45692695|NCT03583827|Other|Conventional physical therapy|Exercises of stretching and strengthening of the upper and lower limbs, as well as coordination, gait and balance.
45692696|NCT03155607|Behavioral|Virtual Reality Distraction|Patient will utilize a virtual reality device during wound care.
45692697|NCT03583749|Drug|Subcutaneous (SC) route for antibiotic treatment|Patients receiving one of the three antibiotics by SC route without any randomization because the route will be chosen before inclusion by the physician in charge.
45692698|NCT03583749|Drug|Intravenous (IV) route for antibiotic treatment|Patients receiving one of the three antibiotics by IV route without any randomization because the route will be chosen before inclusion by the physician in charge.
45692699|NCT02000531|Drug|Erlotinib|150 mg oral dose of erlotinib given once daily
46053576|NCT04764396|Drug|Saline|FNB will be performed as current standard methods in the medical procedure unit without the use of heparin priming. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed saline and or air as per current standards of care.
46053577|NCT04763317|Genetic|Prostate cancer risk gene panel|A list of genes created by study experts, thought to increase the risk of prostate cancer from from review previous research, this list is regularly reviewed for accuracy
45490515|NCT01810718|Drug|nilotinib|Maximum tolerated dosage (MTD) will be defined in Phase I. First 3 patients (pts) will receive Nilotinib 200mg daily dose. If no dose limiting toxicities after at least 1month the next 3 pts will be treated with 300mg. If are>=2 dose limiting toxicities the Phase I will end and MTD will be defined as the next lower dosage. If they will observe 1dose limiting toxicities, they will treat other 3 pts (same dosage); if there isn't dose limiting toxicity, they will increase the dosage in the next cohort; but if they will observe another dose limiting toxicity (tot limiting toxicities 2/6 pts), the study will continue using the previous dose. MTD will be considered the maximum dosage used to treat 6 pts achieving at most 1 dose limiting toxicities, or the previous dosage if with this dosage they we will achieve 2 dose limiting toxicities. Doses will not be escalated beyond >600 or <200mg/die The MTD will be used for phase II
45490516|NCT01383798|Dietary Supplement|Placebo|100 mg lactose per day for 6 weeks
45490517|NCT01383798|Dietary Supplement|Ferrous sulfate|100 mg per day of ferrous sulfate for 6 weeks
45490518|NCT01644578|Procedure|Real-time imaging for MRI-guided procedures|Real-time imaging for improvement of workflow in MRI-guided procedures
45372391|NCT01019343|Procedure|EMG|EMG measures the electrical activity of muscles. For our research purposes, only surface EMG will be used to measure the effects of central and peripheral nervous system stimulation. For surface EMG, electrodes will be coated with a conductive gel and taped to the skin. For motor evoked potential (MEP) acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles.
45372392|NCT01019343|Procedure|Trancutaneous spinal direct current stimulation (tsDCS)|Direct current (DC) stimulation is a non invasive tool used to promote plasticity of the central nervous system. Recently, DC stimulation has been applied to the human spinal cord, and known as transcutaneous spinal direct current stimulation (tsDCS).
45490519|NCT01374178|Drug|LY2963016|Administered subcutaneously
45490520|NCT01374178|Drug|Lantus|Administered subcutaneously
45490521|NCT03673592|Diagnostic Test|PGT-A|PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
45490522|NCT03161314|Procedure|Conservative physical therapy treatment with strengthening exercise program, and Conservative physical therapy treatment with stretching exercise program|(Sub-project 3) conservative physical therapy treatment with self-strengthening and with self-stretching home based exercises
45490523|NCT03163108|Device|Closed-loop automatic oxygen control (CLAC) fast in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 30s).
45490524|NCT03163108|Device|Closed-loop automatic oxygen control (CLAC) slow in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 180s).
45490525|NCT03161392|Diagnostic Test|Follow-up|"Group No ductal lesion will be submitted to follow-up with periodic breast ultrasonography/mammography every 6 months for 2 years."
45490526|NCT03161392|Diagnostic Test|Ultrasound-guided percutaneous biopsy|"Group Ductal lesion will be submitted to ultrasound-guided percutaneous biopsy and the specimen will be histologically analysed."
45372393|NCT00977977|Drug|Rituximab Infusion|Drug Rituximab Infusion 2 infusions (each 1000 mg) separated by 2 weeks; repeated after 6 months
45372394|NCT00977977|Drug|Oral Cyclosporine|Daily therapy for 6 months (3-5 mg/kg), then tapered and discontinued
45372395|NCT00901511|Procedure|Baseline WLL|Scheduled bilateral WLL
45490527|NCT03161470|Other|Standard Repositioning|It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.
45490528|NCT03161470|Other|Mechanical Chair Repositioning|It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.
45490529|NCT03161470|Other|Sham Treatment|Participants will be placed into the mechanical chair and moved into various positions that do not treat BPPV.
45372396|NCT00901511|Drug|Sargramostim|Inhaled GM-CSF
45372397|NCT00901511|Procedure|Rescue WLL|Unscheduled bilateral WLL
45372398|NCT00862433|Drug|Alpha tocopherol|intravenous deuterated vitamin E at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.
45372399|NCT00862433|Other|Vitamin E|Deuterated vitamin E, oral and intravenous, at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.
45372400|NCT00862433|Other|Vitamin C|Oral vitamin C, one gram daily.
45372401|NCT00835133|Other|biologic sample preservation procedure|one blood sample
45372402|NCT00835133|Other|medical chart review|confirmation of cancer diagnosis
45372403|NCT00835133|Other|survey administration|at baseline enrollment and 12 months post-enrollment
45372404|NCT00830557|Other|medical chart review|baseline, 12 month and 36 months
45372405|NCT00830557|Other|survey administration|baseline, 6 month, 12 month
45372406|NCT00830557|Other|biospecimen collection|baseline
45372407|NCT00775476|Drug|N-acetylcysteine|Capsules of NAC, each containing 600 mg of NAC between dosages of 2.4 g to 4.8 g daily
45372408|NCT00775476|Drug|Placebo|placebo (sugar) twice daily, daily dosage will match that of NAC that was tolerated between daily dosages of 2.4 g and 4.8 g during the open-label titration phase.
45372409|NCT00702533|Device|Pentagastrin Injection BP|
45372410|NCT00702533|Drug|Pentagastrin|
45372411|NCT00669188|Other|Information absent|Information
45372412|NCT00669188|Other|Information|Information
45490530|NCT03161548|Drug|Induction chemotherapy|"All eligible subjects will receive ICT with DCU regimen every 21 days as follows:~Docetaxel 36 mg/m2 intravenous infusion over 1 hr, followed by Cisplatin 30 mg/m2 intravenous infusion over 1 hr, on day 1 and day 8, Oral tegafur/uracil 300 mg/m2/day plus leucovorin 90 mg/day on days 1 - 14"
45490531|NCT03161548|Procedure|Tongue conservation surgery|Surgical excision of residual oral tongue tumor will be performed in 3-4 weeks after the start of the last cycle of ICT. Neck dissection will also be done as indicated.
45490532|NCT03161548|Radiation|postoperative CCRT|"Post-op CCRT will be started 4-6 weeks after surgery, with regimen as follows:~Radiotherapy in 2 Gy once-daily fraction size, Monday to Friday, with dose up to 60 Gy (total of 30 fractions); Cisplatin 25 mg/m2 intravenously for 4 hours every week a cycle to total 6 cycles; Tegafur/uracil (UFUR) 200 mg po bid for whole course of radiotherapy"
45490533|NCT03025542|Drug|Bimekizumab|Based on their randomization subjects will receive a combination of several injections of Bimekizumab.
45490534|NCT03025542|Other|Placebo|Subjects will receive injections of Placebo.
45490535|NCT03114436|Other|Observational Data Collection|All aspects of deceased donor care in the ICU.
45372413|NCT00664456|Drug|Adjuvant therapy|AHT group receives 9 cycle of LHRH-A (goserelin acetate 3.6 mg/4 weeks or leuprorelin acetate 3.75 mg/4 weeks) after Iodine I-125 implantation (TPPB).
45372414|NCT00664456|Drug|Neoadjuvant therapy|3 cycle of LHRH-A (goserelin acetate 3.6mg/4 weeks or leuprorelin acetate 3.75mg/4 weeks).
45372415|NCT00664456|Radiation|Brachytherapy（iodine I 125）|Undergo Iodine I-125 transperineal prostatic brachytherapy (TPPB).
45372416|NCT00646022|Drug|[18F]-DOPA|
45372417|NCT00578721|Drug|Aspirin|325 mg taken daily with an arginine-restricted diet
45372418|NCT00534196|Radiation|Permanent iodine-125 (Brachytherapy)|Observational research was conducted by grouping Brachytherapy with/without PI (permanent iodine) seed implantation.
45372419|NCT00500500|Drug|EGb 761® (Tanakan®)|
45372420|NCT00469339|Behavioral|Family Health History|
45372421|NCT00353158|Drug|Doxycycline|100mg twice daily for 3 days. Two hours after the last dose of doxycycline is taken in the clinic, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
45372422|NCT00353158|Drug|Voriconazole|After taking voriconazole for (Bullet)7 days to achieve a steady state of voriconazole for subjects, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
45372423|NCT00202813|Device|Cook Spectrum Pediatric Central Venous Catheter Anti-microbial Impregnated Polyurethane and Arrow Pediatric Central Venous Catheter|
45372424|NCT00117143|Drug|Romiplostim|Administered subcutaneously on day 1 and on day 15 or 22 if the platelet count was ≤ 50 x 10⁹/L and not rising, peak platelet count was ≤ 450 x 10⁹/L and no serious adverse events related to treatment were observed.
45372425|NCT00109174|Device|3T and 7T device|3T and 7T device
45372426|NCT00098072|Procedure|Heart Catheterization|Heart Catheterization and collection of samples
45372427|NCT00025935|Drug|Lithium|
45372428|NCT00007150|Procedure|Phlebotomy|Therapeutic phlebotomy, the periodic, frequent removal of the iron contained in the hemoglobin of red blood cells.
45372429|NCT00004180|Drug|rosiglitazone maleate|
46053578|NCT04745169|Behavioral|8 week home-based exercise program|Participants will be asked to complete an 8-week home-based exercise program according to guidelines from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation. At study baseline, participants will receive exercise equipment and an individualized exercise prescription from an exercise physiologist followed by 8 weekly phone calls from an exercise physiologist. Participant safety will be monitored.
45372430|NCT00001711|Procedure|MRI|
45372431|NCT00001595|Procedure|MRI|
45372432|NCT00001595|Procedure|Tissue specimen collection|
45372433|NCT00001521|Drug|Fludrocortisone|Since hydrocortisone dosage will be reduced , some patients may develop symptoms or signs of adrenal insufficiency. Patients will continue to receive an optimal fludrocortisone dose
45372434|NCT00001521|Drug|Hydrocortisone|reduced hydrocortisone dose can normalize the growth and adult stature of children with congenital adrenal hyperplasia
45372435|NCT00001521|Drug|Letrozole|Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization.
45372436|NCT00001521|Drug|Flutamide|Non steroidal anti-androgen that prevents the action of androgens by blocking receptor sites in target tissue. It may also produce changes in testosterone and estradiol
45372437|NCT00001481|Drug|Estradiol|To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
45372438|NCT00001481|Other|Placebo|To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
45372439|NCT00001481|Drug|Progesterone|To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
46053579|NCT04742712|Device|CoronaCheck Device|All participants breath normally into the device for up to 6 minutes
46053580|NCT04732663|Other|No Intervention|Cross-sectional study, no intervention.
45372442|NCT00001247|Drug|Sirolimus|
45382240|NCT05186090|Behavioral|24-week resistance exercise program|This group will perform a 24-week resistance exercise program. Participants will engage in 180 minutes/week of resistance exercise (3 supervised sessions peer week, 60 min/session). The training will consist of a combination of upper and lower body exercises using elastic bands and participants' body weight as the primary resistance. Exercise load and intensity will be based on the number of repetitions (i.e.,10-12 repetitions), resistance of the elastic bands, in ascending order with seven intensities, and also on the exercises' difficulty (i.e., three levels). The prescribed targeted intensity will reach 70-80% of the participants' maximum rating perceived exertion (i.e., 7-8 RPE).The progression (horizontal) will be standardized according to the execution time and RPE, and individualized according to execution speed and band resistance. Heart rate will be monitored in all sessions. Further, intrinsic motivation before and after session and sleep quality will be registered.
45382241|NCT05181475|Drug|Sodium Oligomannate Capsules (GV-971)|Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
45382242|NCT05180669|Other|OARSCM Software Application|Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
45382243|NCT05180669|Other|MyMAT Software Application|Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.
46053581|NCT04731051|Drug|HCQ01|HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
46053582|NCT04731051|Drug|standard of care (SOC) for COVID-19|Standard of care (SOC) for COVID-19
46053583|NCT04706923|Drug|BCV|BCV 0.2 mg/kg BIW, 0.3 mg/kg, or 0.4 mg/kg dosed BIW or 0.4 mg/kg dosed QW via IV infusion for 2 hours
45382247|NCT05178862|Drug|SCY-078|Oral ibrexafungerp (SCY-078) as step-down therapy.
45382248|NCT05178862|Drug|Fluconazole|Oral fluconazole (SCY-078) as step-down therapy.
45382249|NCT05178862|Drug|Echinocandin|Intravenous echinocandin
45490536|NCT03673514|Procedure|Total hip arthroplasty|Two fellowship-trained surgeons in two separate hospitals performed all procedures. Both surgeons had previously performed over 100 cases with each approach, before initiating this study
45490537|NCT03161236|Other|home exercise program|Subjects in the exercise group will be instructed to follow the intervention protocol for eight weeks. The intervention consists of five exercises: standing on one foot, walking heel to toe, heel walking, side kicks, and wall squats. Each exercise will be repeated three times per week for eight weeks.
45490538|NCT03161236|Other|non exercise program|continue usual lifestyle
46053584|NCT04684589|Drug|Tadalafil 20 MG|Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
46053585|NCT04684589|Drug|Placebo|Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
45372443|NCT00988494|Drug|DE-105 ophthalmic solution|Topical ocular application
45372444|NCT00988494|Drug|DE-105 ophthalmic solution|Topical ocular application
45372445|NCT00988494|Drug|Placebo ophthalmic solution|Topical ocular application
45490539|NCT03673436|Procedure|Lumbar spinal fusion|The patient got a instrumented fusion of a maximum of 3 adjacent vertebrae
46053586|NCT04682509|Drug|Glecaprevir/pibrentasvir|Manufacturer is AbbVie, Inc., North Chicago, IL Mavyret® is commercially available and FDA approved for the treatment of HCV genotype 1, 2, 3, 4, 5, or 6 infection in patients without cirrhosis or with compensated cirrhosis and also for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor. An immediate release bilayer oral tablet containing a fixed-dose combination of 100 mg of glecaprevir and 40 mg of pibrentasvir. The daily dose of glecaprevir/pibrentasvir used will be the standard FDA approved dose: 3 tablets taken once daily (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg).
45372446|NCT05347290|Device|Rampart IC, M1128|Rampart IC, M1128 aims to address the challenge of radiation protection in the cardiac catheterization laboratory without the burden of wearing a heavy lead apron. Rampart M1128 is a compactly designed, portable, fully adjustable system that provides radiation protection for interventionalists and their technicians. It has independently adjustable flexible panels, allowing interventionalists multiple vascular access points, including right radial, bi-lateral femoral, and bi-lateral pedal. Participants in this arm will conduct catherization procedures using only the Rampart System, and radiation exposure will be measured using real-time dosimeters.
45372447|NCT05347290|Device|Lead Apron and Ancillary Shield|Participating providers in this arm will use conventional skirt and vest, thyroid collar, and 100% use of 2 types of ancillary shields. Most wrap-around skirts and vests were (0.25-0.5 mm) Pb. Thyroid shields were 0.5 mm Pb equivalent. Under the table lead x 2. Radiation exposure will be measured using real-time dosimeters.
45490540|NCT03114514|Biological|PRP|PRP will be injected subcutaneously around the eyes at three different time points with one-month interval
45372448|NCT05347290|Device|Rampart IC, M1128 and Lead Apron|Participating providers will use both the lead apron and the Rampart Shield. Radiation exposure will be measured using real-time dosimeters.
45372449|NCT00539994|Drug|retapamulin|200mg BID retapamulin 3 days
45372450|NCT00539994|Drug|Retapamulin|200mg BID retapamulin 5 days
45372451|NCT00539994|Drug|Placebo|200mg BID placebo 5 days
45372452|NCT04508790|Drug|Dexamethasone|Given PO
45372453|NCT04508790|Drug|Leflunomide|Given PO
45372454|NCT04508790|Drug|Pomalidomide|Given PO
45372455|NCT05711706|Other|Su Jok Application|Su Jok massage appplication
45490541|NCT03673358|Behavioral|Cognitive Behavioural Therapy|"Participants who are randomized to the CBT intervention will be encouraged to begin CBT immediately following randomization. The CBT intervention will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses to baseline questionnaires. All other aspects of post-operative care will be at the discretion of participant's surgeon.~Other Name: CBT"
45490542|NCT03114358|Other|Early Carbapenem de-escalation|The intervention group is de-escalation carbapenems early within 24 hours or no later than 72 hours of prescription by ID specialist (early de-escalation).
45490543|NCT03669692|Behavioral|Caloric Restriction|Subjects will be trained to perform intermittent caloric restriction, based on an early time restricted feeding, with a 16/8 hour fasting / feeding schedule, respectively.
45490544|NCT03669692|Behavioral|Control|Subjects will receive diet and lifestyle recommendations from the Spanish Association of Urology, for symptoms secondary to HBP, without restriction in the meal schedule.
45372456|NCT04004676|Behavioral|20 km time trial performance|20 km time trial cycling test will be conducted to measure the effect of different drinks on performance time
45372457|NCT04004676|Behavioral|Glycogen lowering exercise|Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
45372458|NCT05711550|Device|Real Neurofeedback|Real Neurofeedback with visual and acoustic feedback presentation based on the EEG-signal from the participant (Signals used described in corresponding study arm). The NFB-signals are obtained from the T4 and P4 positions according to the 10-20 EEG placement consensus. NFB is done using the software package Cygnet (BEE Medic GmbH Technologies, Kirchberg, Switzerland) and for all participants the same neurofeedback-animation is used. NFB training duration is approx. 30min
45490545|NCT03051464|Procedure|Complete responders and Non-complete responders|Patients that are complete responders will not have surgery. Patients that are non-complete responders will have surgery.
45372459|NCT05711550|Device|Sham Neurofeedback|The sham neurofeedback is performed in identical fashion using the same software, feedback, electrode placement, duration as in the real neurofeedback. Only difference is that a pre-recorded EEG-dataset will be used and the feedback signal is thus independent from the brain activity of the participant.
45372460|NCT04564560|Procedure|Endovascular aortic repair with Zenith Alpha Spiral-Z®|The Zenith Alpha Spiral-Z® stent graft may have an increased risk of thrombosis. The intervention in this study is to assess the extent and degree of thrombosis in patients treated with the Zenith Alpha Spiral-Z® during endovascular repair of aortic aneurysm
45372461|NCT04005222|Drug|SELENIUM|Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by selenium supplementation.
45490546|NCT03051464|Radiation|Chemoradiation + EBRT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5
45372462|NCT04005222|Drug|MELATONIN|Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by melatonin supplementation.
45490547|NCT03051464|Radiation|Chemoradiation + HDRBT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions
45490548|NCT05452902|Behavioral|EXCAP Exercise|12 weeks of at-home walking and resistance exercise.
45490549|NCT05452902|Behavioral|Nutrition Education|12 weeks of implementing eating tips and tracking food.
45490550|NCT03161002|Genetic|detection of genotype|detection of genotype by next generation sequencing
45490551|NCT03669848|Other|Pulse CO-oximetry|Measuring blood Carbon Monoxide levels with Pulse CO-oximetry (SpCO)
45372463|NCT05711472|Other|birth ball exercise|birth ball exercise used in childbirth
45490552|NCT02664870|Procedure|Arthroscopy|Arthroscopic Surgery on the hip, shoulder, or knee
45490553|NCT02664870|Procedure|Arthroplasty|Total hip, shoulder, or knee arthroplasty
45490554|NCT05746312|Behavioral|healing attempt|The intervention consists of pre-composed and pre-recorded guided meditations, songs, and poems that total 25 minutes in duration. The elements of the intervention were set to background music tracks that were informed by Black diasporic music traditions and anxiety reduction principles from the music therapy literature.
46053587|NCT04632654|Behavioral|A personalized Physical Activity intervention with fitness graded Motion Exergames (PAfitME)|A total of 7 weekly intervention sessions will occur in a period of 6 weeks. Week 0 is a setup session conducted at the participant's home, including equipment set up, safety instruction, personalized exergame prescription development, exergame physical activity practice, discussion of barriers and strategies, and Q&A session. Weeks 1 and 2 are coaching sessions delivered by the interventionist using the FaceTime application in iPad, including exergame minutes and prescription review, exergame physical activity practice, discussion of barriers and strategies, and Q&A session. Week 3 is a progress session conducted at the participant's home. The personalized exergame prescription will be adjusted. This session also will include exergame minutes review, exergame physical activity practice, discussion of barriers and strategies, and Q&A session. Weeks 4 and 5 are the same as weeks 1 and 2. Week 6 is the final session. Exergame platform will be picked up at the participant's home.
46053588|NCT04626141|Drug|Abaloparatide|Abaloparatide will be dispensed as a 30-day supply of disposable pen injections of the standard, FDA approved dosage (80 mcg abaloparatide).
46053589|NCT04626141|Drug|Placebo|Placebo will be dispensed as a 30-day supply of disposable pen injections.
45372464|NCT04441710|Other|Questionnaire|Participants will be invited to complete a detailed questionnaire to collect prospectively and retrospectively data around the CoViD19 serological screening.
45372465|NCT01563744|Procedure|EGD-assisted administration of colonoscopy prep|Interventional group receive the first 2 liters of prep solution during EGD through the scope channel if colonoscopy expected the following day.
45372466|NCT01563744|Procedure|Control Group received standard prep by oral administration|Control group receive standard oral colonoscopy prep.
45372467|NCT05298306|Drug|LAT8881|"In Part A, LAT8881 will be given as a single intravenous infusion at doses of 0.8, 1.2 and 1.8 mg/kg.~In Part B, a single intravenous infusion of LAT8881 will be given, the dose to be determined by the results in Part A"
45372468|NCT05298306|Drug|Placebo|Matching placebo'given as a single intravenous infusion at all dose levels
45372469|NCT05710536|Other|Formulation X|This formulation containing stem cell secretome, CTX peptides,lLiquorice root and Sophora Flavescens root extract
45490555|NCT03673280|Procedure|Quadratus Lumborum Block|Instead of using morphine in the classical spinal anaesthesia we will be performing in the experimental group the Quadratus Lumborum Block
45490556|NCT04612062|Drug|CEE321|CEE321 administered to all subjects
45498170|NCT03688932|Other|WBV + IMT|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.
45372470|NCT00098839|Drug|L-asparaginase|Given IM
45372471|NCT00098839|Drug|doxorubicin hydrochloride|Given IV
45490557|NCT03167788|Device|rejuvesol Solution|The rejuvenation process involves incubation of stored red cells with a rejuvenating solution, rejuvesol Red Blood Cell Processing Solution (rejuvesol® Solution), Citra labs, MA, a Zimmer Biomet Company, IN, USA) which restores red cell adenosine triphosphate (ATP), 2,3-DPG (diphosphoglycerate), oxygen transfer characteristics and rheology. Post rejuvenation red cells are washed to remove the rejuvesol Solution, and cells are re-suspended in additive solution for transfusion.
45490558|NCT03167788|Other|Standard Care|Allogeneic red cells, harvested in citrate-phosphate-dextrose (CPD), leucocyte depleted, saline-adenine-glucose-mannitol (SAGM) stored red cell units, issued by National Health Service Blood & Transplant (NHSBT) will be administered to cardiac surgery patients as per standard practice, and according to established unit protocols.
45692700|NCT02000531|Drug|Chemotherapy|Cisplatin (75 mg/m^2 intravenously [IV]) on Day 1 and gemcitabine (1250 mg/m^2 IV) on Days 1 and 8 of 3-week chemotherapy cycles until disease progression, unacceptable toxicity or up to 4 cycles (whichever comes first)
45692701|NCT05647161|Device|BAX602|Consists of the spray agent, spray set, and spraying device (regulator). Dissolves a polyethylene glycol (PEG) derivative with an N-hydroxysuccinimide group at the end (COH102) and a PEG derivative with a thiol group (COH206) as an anti-adhesion agent, which is sprayed on the surgical surface to reduce the degree, frequency, and extent of organ adhesions after surgery.
45372472|NCT00098839|Drug|therapeutic hydrocortisone|40 mg/m2/day PO divided BID or TID
45372473|NCT00098839|Drug|vincristine sulfate|Given IV
45372474|NCT00098839|Biological|epratuzumab|Given IV
45372475|NCT00098839|Drug|cytarabine|Given IT
45372476|NCT00098839|Drug|prednisone|Given orally
45692702|NCT05647161|Device|No Intervention|Control Group
45692703|NCT01609231|Drug|Dalotuzumab|Dalotuzumab will be administered intravenously after the completion of irinotecan infusion at a dose of 10 mg/kg once weekly.
45490559|NCT03673202|Diagnostic Test|Cx bladder Monitor test|Cxbladder Monitor is a non-invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma and also two clinical variables (whether the previous tumor was primary or recurrent and the time since the previous tumor was resected).
45490560|NCT01383642|Other|No intervention, observational study|
45490561|NCT03167944|Device|Low thermal electrosurgery system|PEAK Plasmablade
45490562|NCT03167944|Device|Conventional Electrocautery|Conventional Electrocautery
45490563|NCT03036254|Device|HBOT intervention|"HBOT is a treatment in which oxygen-enriched air (up to 100%) is administered to patients at a pressure.~HBOT intervention arm - 3 months of HBOT treatment, 9 months observation~all participants receive HBOT treatment for 3 months at year 2"
45490564|NCT03036254|Device|Sham intervention|"Sham was selected as the control condition rather than usual care to equate intervention groups with respect to other variables that could influence cognition and functional status, such as a new challenge (completing an activity program), peer socialization, and attention from staff."
45692704|NCT01609231|Drug|Irinotecan|Irinotecan 180 mg/m^2 will be administered intravenously once every two weeks either prior to dalotuzumab (Arm A) or after cetuximab (Arm B). Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
45372477|NCT00098839|Drug|pegaspargase|Given IM
45372478|NCT00098839|Drug|dexrazoxane hydrochloride|Given IV
45372479|NCT00098839|Drug|methotrexate|Given IT
45372480|NCT00098839|Drug|etoposide|Given IV
45372481|NCT00098839|Drug|cyclophosphamide|Given IV
45372482|NCT00098839|Drug|leucovorin calcium|Given IV
45372483|NCT00098839|Biological|filgrastim|Given SC
45372484|NCT05268744|Drug|Micronutrient|Subject will take micronutrient supplement daily for 8 weeks
45372485|NCT02531191|Drug|peficitinib|oral
45372486|NCT01087177|Other|Exposure to practice that has been trained in Pedialink CEASE|Child has had an appointment at a practice that was trained in Pedialink CEASE at the time of the interview.
45372487|NCT01081639|Drug|Follitropin alfa liquid formulation|Follitropin alfa (Gonal-f) liquid pen (300, 450 and 900 IU) was applied by subcutaneous (sc) administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
45372488|NCT01081639|Drug|Follitropin beta liquid formulation|Follitropin beta (Puregon) liquid cartridge (300 and 600 IU) used with the Pen was applied by sc administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
45372489|NCT01081717|Drug|systemic non-biological treatments|as prescribed
45372490|NCT01081717|Biological|anti-TNF biologics|as prescribed
45372491|NCT01081717|Biological|golimumab|as prescribed
45372492|NCT01081717|Biological|non-anti-TNF biologics|as prescribed
45372493|NCT01081717|Other|general population|non-treated cohort
45372494|NCT03963973|Drug|RDN-929 oral capsule|low, medium and high dose
45372495|NCT03963973|Drug|Placebo oral capsule|matching placebo dose
45372496|NCT01085305|Behavioral|Parent-Child Interaction Therapy|Parents will be trained in interaction with their children in ways which foster non-hostility and cooperation in their children. By means of an ear-plug they will receive instruction on how to play and set limits for their child from their therapist who watches the interaction through a one-way mirror. Treatment is given until the parent masters these skill, which commonly takes 15-20 session of 1 hour.
45372497|NCT01085305|Behavioral|TAU|Usual treatment for behavioral disorders
45372498|NCT01085383|Drug|Aripiprazole|Aripiprazole will be started at 5 mg daily and increased in a treat-to-target fashion by 5 mg steps until the primary outcome or the maximum tolerated or permitted dose of 30 mg is reached
45372499|NCT03811093|Device|Care as Usual Group|"Each participant randomly assigned to the Care As Usual Group will undergo nine therapy sessions over three weeks using a fully functioning invisa-RED Technology Elite device."
45692705|NCT01609231|Drug|Cetuximab|Cetuximab will be administered intravenously prior to irinotecan at an initial dose of 400 mg/m^2 followed by weekly infusions of 250 mg/m^2. Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
45372500|NCT03811093|Device|Sham Group|"Each participant randomly assigned to the Sham Group will undergo nine therapy sessions over three weeks using a non functioning invisa-RED Technology Elite device."
45372501|NCT01087255|Device|Electronic Pillbox Monitoring System|Daily exposure for six months
45692706|NCT03583593|Dietary Supplement|DIAMEL|Diamel is administered 6 capsules a day divided into three doses that are ingested before each meal.
46053590|NCT04609514|Device|Learn to Quit-HIV|A smartphone app developed by the research team designed for people with HIV that provides Acceptance and Commitment Therapy skills to address smoking cessation.
46053591|NCT04609514|Behavioral|QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines.
46053592|NCT04609514|Drug|Nicotine patch|All participants will receive an 8-week course of nicotine patches. They will start off with 4 weeks of 21mg/24 hours patches, then move to 2 weeks of 14mg/24 hours patches, and finally end with 2 weeks of 7mg/24 hours patches.
46053593|NCT04609514|Behavioral|Smartphone coaching|All participants will partake in over-the-phone smartphone coaching lead by the PI or a research assistant. This will be a time for participants to bring up any technical issues they are experiencing with the study smartphone or app.
46053594|NCT04607668|Drug|Trilaciclib|Trilaciclib or placebo
46053595|NCT04607668|Drug|Placebo|dextrose 5% in water or normal saline (sodium chloride solution 0.9%)
45372502|NCT01087411|Behavioral|Motivational Interviewing|The method motivational interviewing according to Miller and Rollnik is used as an behavioral intervention to support the child and family in their own behavioral change towards a more physically active life style.
45372503|NCT01087411|Behavioral|Physical activity|Group sessions with different kinds of physical activity is arranged for the participants in the intervention program.
46053596|NCT04606095|Diagnostic Test|EEG|EEG with QST (evoked Pain and Visual Stimulation Assessment)
45372504|NCT01087411|Dietary Supplement|Supplementation with fish liver oli capsules|This group will receive capsules containing omega-3 and omega-6 fatty acids and vitamine E. The dosage is six capsules daily containing omega-3 (558 mg of eico-pentaenoic-acid, EPA, and 174 mg of docosahexaenoic acid, DHA), omega-6 (60 mg of γ-linolenic acid, GLA) plus 9.6 mg vitamin E (in natural form, d-α-tocopherol), gelatin and glycerol. Participants will be instructed to eat three capsules each morning and evening.
45372505|NCT01087411|Dietary Supplement|Placebo oil capsules|This group will receive capsules containing rape seed oil. Participants will be instructed to lead their life in the same manner as before the intervention but eat three capsules each morning and evening.
45692707|NCT03583593|Dietary Supplement|Placebo|Placebo is administered 6 capsules a day divided into three doses that are ingested before each meal.
45692708|NCT03583515|Behavioral|Alcohol-Specific Personalized Normative Feedback|Participants will receive personalized normative feedback about drinking.
45490565|NCT03631212|Behavioral|Flexiquit|Digital avatar-led Acceptance and Commitment Therapy for smoking cessation
45490566|NCT03162874|Drug|Placebo oral capsule|BID
45372506|NCT00485589|Drug|Methotrexate|Oral repeating dose
45692709|NCT03583515|Behavioral|Social Media Personalized Normative Feedback|Participants will receive personalized normative feedback about social media use.
46053597|NCT04606095|Diagnostic Test|Neuroimaging EEG/fMRI|This will be done to monitor areas of the brain that are involved in thinking and processing pain. The scanner stimulates the brain to send out signals that will be recorded and analyzed. Additionally, during the MRI the participants brain's electrical activity with will be measured with an EEG machine for part of the MRI. About halfway through the scan, participants will have the EEG equipment removed and then will return to the fMRI scanner for a few additional scans.
45372507|NCT00485589|Drug|Ocrelizumab|Intravenous repeating dose
45372508|NCT00485589|Drug|Placebo|Intravenous repeating dose
45372509|NCT01014273|Procedure|Percutaneous Coronary Intervention|
45490567|NCT03162874|Drug|PXT002331 - dose 1|Oral
45372510|NCT01018797|Procedure|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Intrastromal corneal ring segments implantation was indicated because of the existence of reduced best spectacle-corrected visual acuity (BSCVA) or contact lens intolerance.
45372511|NCT01015599|Behavioral|HOP'N After-school Program|Daily 30 minutes of physical activity following CATCH guidelines, Daily healthful snack with fruit/vegetables, Weekly nutrition and physical activity education based on social cognitive theory.
45372512|NCT00490971|Drug|Olanzapine|Once daily in dose range of 5 to 20 mg/day for 15 weeks, then until recurrence
45372513|NCT00490971|Drug|Paliperidone ER|Once daily in dose range of 3 to 12 mg/day for 15 weeks, then until recurrence
45490568|NCT03162874|Drug|PXT002331 - dose 2|Oral
45490569|NCT03672968|Genetic|GS010|
45490570|NCT03672890|Other|Telestroke|Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST, inpatient telestroke rounding will be used to oversee the urgent diagnostic stroke evaluation, secondary stroke prevention, health screening & evaluation, and stroke education in patients admitted with stroke.
45490571|NCT05420220|Biological|KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)|5 mg/kg Q3W IV
45490572|NCT05420220|Combination Product|Axitinib|5mg bid po
45692710|NCT04438187|Other|antimicrobial initiation|antimicrobial initiation based on protocol assignment.
45846775|NCT05585658|Biological|Erythropoietin alpha|To analyze bio-similarity of GBPD002 with Eprex®, the Globe Biotech Ltd performed quite a few experiments to determine total analytical study of GBPD002. They performed peptide mapping to determine amino acid composition of GBPD002 and found similar result with erythropoietin alpha. The molecular weight was determined through SDS-PAGE analysis of GBPD002 and was compared with Eprex. The western blot analysis was performed to determine immune chemical characterization. Characterization of different isoforms was conducted through 2D gel electrophoresis.
46053598|NCT04606095|Device|HD-tDCS treatments|HD-tDCS treatments (5 active and 5 sham)
46053599|NCT04606095|Device|Sham HD-tDCS treatments|HD-tDCS treatments (5 active and 5 sham)
46053600|NCT04597086|Other|Best Practice|Receive standard of care
46053601|NCT04597086|Procedure|Bright White Light Therapy|Receive BWLT
46053602|NCT04597086|Other|Survey Administration|Ancillary studies
46053603|NCT04582617|Dietary Supplement|Cocoa Extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
45372514|NCT00490971|Drug|Placebo|Once daily until recurrence (only after initial 15 weeks on paliperidone ER)
45490573|NCT03022370|Behavioral|Stepping Stones and Creating Futures|"Stepping Stones consists of 10 sessions. It seeks to strengthen relationships and to transform views on gender and in the process impact on exposure to, or participation in, gender-based violence and HIV risk. These cover gender and peer influences our actions; sex and love; conception and contraception; STIs and HIV; safer sex and condoms; GBV; motivations for behaviour (including influences of alcohol and poverty); and communication skills.~Creating Futures is a facilitated group intervention of eleven sessions. It seeks to strengthen livelihoods. The key sessions include: setting medium term livelihood goals, the need for assets and coping with crises; social resources for livelihoods (trust and community participation); getting and keeping jobs; and savings and spending."
45692711|NCT03583125|Drug|EOC317|tablet(s) PO
45692712|NCT01793935|Drug|Sensoril®|Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera
45490574|NCT05383560|Biological|mRNA-1273.214 Vaccine|Omicron Variant-Matched Vaccine
45490575|NCT05383560|Biological|MRNA-1273 Vaccine|Moderna's commercial COVID-19 Vaccine
45490576|NCT05383560|Biological|Placebo|Normal Saline for injection
45490577|NCT03631758|Other|Evidence-based information|Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
45490578|NCT03631758|Behavioral|Patient Decision Aid|Patient Decision Aid for breast cancer screening decision
45490579|NCT03631758|Other|Sham information|Educational information not specific to mammography or cancer screening
45490580|NCT02642562|Drug|Ferric Derisomaltose|
45490581|NCT03623204|Other|Dyspnea evaluation|
45490582|NCT04601610|Drug|KN046 （PD-L1/CTLA4 BsAb）|KN046 5mg/kg Q3W
45490583|NCT04601610|Drug|Ningetinib Tosylate（multi-target TKI）|ningtinib QD, dose will be decided by investigator
45692713|NCT01793935|Drug|Placebo|Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.
45692714|NCT03292029|Diagnostic Test|T50 Calcification Inhibition Test (CIT)|Measurement of predialysis T50 CIT and fetuin-A values in serum of hemodialysis patients
45692715|NCT02092025|Drug|Azilsartan|Azilsartan tablets
45692716|NCT04405011|Drug|24-week Entecavir|Entecavir 0.5mg for 24 weeks will be delivered
45372515|NCT04286295|Drug|Cytisine|Cytisine is a plant-based smoking cessation medication. Cytisine acts by reducing the rewarding effect of nicotine and attenuating nicotine withdrawal symptoms. A recent review concluded that cytisine is the most promising future smoking cessation treatment. Cytisine is inexpensive to produce and is currently priced much lower than other cessation medications. It is well-tolerated by smokers and requires a shorter treatment period than conventional treatments. Because it is plant-based, cytisine may be attractive for smokers who prefer 'natural' medicines. Numerous placebo-controlled studies have demonstrated the safety and efficacy of cytisine. One high-quality pragmatic non-inferiority trial (n = 1310) found that cytisine was superior to nicotine replacement therapy (NRT) in improving self-reported continuous abstinence rates at 1 week, and 1, 2 and 6 months when both groups received minimal behavioural support.
45372516|NCT04286295|Drug|Nicoderm C-Q Transdermal Product|The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants will be instructed to apply a new patch each day. They will continue to wear patches for 25 days.
45372517|NCT04286295|Drug|Nicorette Lozenge Product|Participants in the NRT group will receive Nicorette Lozenges to use during their 25-day quit attempt. They will receive enough lozenges to last for the 25-day treatment period.
45490584|NCT02490306|Device|Strokefinder MD100 measurement|A microwave measurement will be performed with the patient lying in the hospital bed or another suitable surface. Follow-up microwave measurements will be performed after the acute phase.
45490585|NCT03668912|Behavioral|Guided participation discharge programme|A nurse-led GP discharge intervention (3 structured 30- to 60-minute GP sessions and 1 follow-up phone call)
45692717|NCT04405011|Drug|12-week Entecavir|Entecavir for 12 weeks will be delivered and serve as the active comparator arm
45846776|NCT05522634|Drug|TJAOA101|Once enrolled, participants will be administrated TJAOA101
45846777|NCT05510856|Other|Duloxetine|Duloxetine 30mg / day for 12 cycles (up to 6 months)
45846778|NCT05510856|Other|Gabapentin|Gabapentin 300 mg / day for 12 cycles (up to 6 months)
45846779|NCT05510856|Other|Lacosamide|Lacosamide 50 mg / day for 12 cycles (up to 6 months)
45490586|NCT01382004|Drug|Penicillin-G-benzathine|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
45490587|NCT01382004|Drug|Azithromycin|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
45490588|NCT03669224|Other|Nano Care Gold|Mixture of Gold and Silver nano particles suspended in 70 % Isopropyl alcohol. This group will be compared with no intervention group.
46053604|NCT04582617|Dietary Supplement|Cocoa Extract Placebo|Cocoa extract placebo
46053605|NCT04582617|Dietary Supplement|Multivitamin|Multivitamin
46053606|NCT04582617|Dietary Supplement|Multivitamin placebo|Multivitamin placebo
46053607|NCT04580121|Drug|RO7283420|RO7283420 will be administered to participants by intravenous (IV) infusion Q3W at a starting dose of 0.15mg. Starting dose levels (double step-up regimen, Q3W) for SC injections was the same as the highest dose levels that have been cleared in the IV double step-up cohorts at that timepoint. Each participant will receive up to 6, 9, and 18 cycles of treatment with RO7283420, when treated with Q3W, Q2W, or QW dosing regimens, respectively.
46053608|NCT04580121|Drug|RO7283420|RO7283420 at RP2D will be administered by IV infusion or SC injection as per dosing schedule determined in Part B.
45490589|NCT03669224|Other|No intervention|No intervention will be applied in this group. It will be the negative comparator. In this group only the standard of care will be applied, which means the steps will be cavity preparation followed by adhesive system then resin composite without any surface pre-treatment
46053609|NCT04580121|Drug|Tocilizumab|Tocilizumab will be administered as an IV infusion 8 mg/kg (for participants with a weight of 30 kg and above) and 12 mg/kg (for participants with a weight of less than 30 kg). Tocilizumab will be given as rescue medication.
46053610|NCT04580121|Drug|Dasatinib|Dasatinib 100 mg film-coated tablets will be administered daily until symptom resolution (up to 100 mg twice daily [BID] for a maximum 3 days); orally. Dasatinib will be given as rescue medication.
46053611|NCT04580121|Drug|Dexamethasone|20 mg IV of dexamethasone will be administered as pre-medication at least 60 minutes prior to the all RO7283420 infusions or injections during cycle 1.
45372518|NCT04284267|Device|Transcranial Magnetic Stimulation|TMS is a non-invasive tool for modulating patterns of brain activation and circuit connectivity. It uses electromagnetic pulses to induce electric currents over the cortex that serve to depolarize or hyperpolarize neurons, thereby changing patterns of synaptic activity. This study will use intermittent theta burst stimulation (iTBS), an efficient TMS protocol that uses high frequency (50Hz) triplets of TMS given every 200 milliseconds (i.e. at 5 Hz).
45372519|NCT00686075|Biological|MEDI-534, Cohort 1|Participants aged 6 to less than (<) 24 months will receive MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
46053612|NCT04580121|Drug|Paracetamol/acetaminophen|500 or 1000 mg of paracetamol/acetaminophen will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.
46053613|NCT04580121|Drug|Diphenhydramine|25 mg or 50 mg of diphenhydramine will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.
45372520|NCT00686075|Other|Placebo, Cohort 1|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
45372521|NCT00686075|Biological|MEDI-534, Cohort 2|Participants aged 6 to <24 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
45490590|NCT03669224|Other|Chlorhexidine|2 % chlorhexidine gluconate. This group will be compared with no intervention group.
45490591|NCT04584528|Other|Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP)|"The IPPs will be developed by the Sickle Cell Disease providers at each study site based on patients' outpatient chronic opioid use and analgesic agent normally required for treatment of VOE in the ED. The Sickle Cell Disease provider will review the IPP with the patient, then upload the IPP to the patient's EHR in a location that will be accessible by the patient and ED provider. Each participating site will train patients and Emergency Department (ED) providers on how to access the IPP in the Electronic Health Record. The following required elements will be included in the EHR-embedded IPP:~Genotype~Individual pain plan-preferred analgesic agent, route, dose and dosing interval, last update time~Name and contact information for the SCD provider~If the enrolled patient has a VOE visit at a nonparticipating ED, the patient will be able to access their IPP via the web or the patient portal app through their EHR. However, data will not be collected from these visits."
45490592|NCT03669458|Device|Below the Knee peripheral intervention|Treatment of infrapopliteal disease using SPUR/DCB, SPUR only and DCB alone
45490593|NCT01381848|Drug|Doripenem|Type=exact number, unit=mg/kg, number=5, form=solution for injection, route=intravenous use, once on Day 1 for patients <8 weeks CA.
45372522|NCT00686075|Other|Placebo, Cohort 2|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
45372523|NCT00686075|Biological|MEDI-534, Cohort 3|Participants aged 2 months will receive MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
45692718|NCT01769443|Drug|bortezomib|Bortezomib dosed at 1.3 mg/m^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
45692719|NCT01769443|Procedure|plasmapheresis|Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
45692720|NCT03154827|Drug|BL-8040|Subjects will receive once daily SC injections of 1.25 mg/kg of BL-8040 on the first 3 days of each cycle.
45692721|NCT03154827|Drug|Atezolizumab|Subjects will receive Atezolizumab 1200 mg by IV infusion on Day 2 of every cycle.
46053614|NCT04569461|Drug|pembrolizumab|200 mg of Pembrolizumab (KEYTRUDA) will be given by IV every 3 weeks for 5 cycles, a total of 15 weeks of treatment.
45372524|NCT00686075|Other|Placebo, Cohort 3|Participants aged 2 months will receive placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
46053615|NCT04569461|Radiation|Stereotactic body radiation therapy|SBRT will begin on week 7 of the study. The radiation will be given every other day in 5 fractions of 6 Gy for a total of 30 Gy of radiation exposure.
46053616|NCT04569461|Drug|Short-term androgen deprivation therapy|Short-term ADT will last for five months. It will consist of treatment with a 1 month dose beginning on Day 0 of the study. Then it will continue with either a single 4 month dose on week 5, or 4 additional 1 month doses, depending on patient and physician preference.
46053617|NCT04569461|Procedure|Radical Prostatectomy|Radical prostatectomy surgery will be performed between week 17 and week 20 of the study, as scheduling permits.
45372525|NCT00686075|Biological|MEDI-534, Cohort 4|Participants aged 2 months will receive MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
45372526|NCT00686075|Other|Placebo, Cohort 4|Participants aged 2 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
45372527|NCT00686075|Biological|MEDI-534, Cohort 5|Participants aged 2 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
45372528|NCT00686075|Other|Placebo, Cohort 5|Participants aged 2 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
45372529|NCT02562677|Device|Transcutaneous Trigeminal Nerve Stimulation|
45372530|NCT02563613|Behavioral|Physical Exercise (PE)|Core session: 2 hours, Booster session: 1 hour
45692722|NCT03159507|Dietary Supplement|MAG-EPA|Based on the result of the participant's Omega-3 index obtained from the blood sampling of visit 1, the daily dose of MAG-EPA will be adjusted to obtain an Omega-3 Index of 8.
46053618|NCT04527289|Drug|Amantadine (100mg) as add on therapy.|Amantadine (100mg) as add on therapy to the management regimen of traumatic brain injury - 100mg twice daily Oral or feeding tube
45372531|NCT02563613|Behavioral|Healthy Diet (HD)|Core session: 2 hours, Booster session: 1 hour
45372532|NCT02563613|Other|Wait-list Control (C)|The wait-list control group will receive the intervention at 3 months.
45372533|NCT00750347|Drug|Rimonabant and Paracetamol and placebo|evaluation of an possible inhibiting effect of rimonabant on the analgesic effect of paracetamol in healthy volunteers
45372534|NCT00750425|Drug|cediranib (RECENTIN TM, AZD2171)|20 mg cediranib once daily from Days 1 to 7; then 20 mg cediranib plus 400 mg ketoconazole from Days 8-10; then 20 mg cediranib once daily from Days 11-23. At Day 24 patients may dose escalate to 30 mg tablet once daily providing the treatment is well tolerated (this may be escalated up to 45 mg if the 30mg dose is tolerated for a minimum of 14 days)
45372535|NCT02563457|Other|periodontal manual treatment|periodontal manual treatment
45372536|NCT02563457|Other|no periodontal manual treatment|blood sampling
45490594|NCT01381848|Drug|Doripenem|Type=exact number, unit=mg/kg, number=8, form=solution for injection, route=intravenous use, once on Day 1 for patients >=8 weeks CA.
45490595|NCT03668834|Procedure|Dermabrasion with NCES|"The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~Dermabrasion will be done using Manekshaw's dermabrader until tiny pinpoint bleeding spots are seen and extended 5mm beyond margins to prevent halo phenomenon.~The denuded area will be washed with PBS and covered with a PBS moistened gauze piece.~With 18 G needle attached to tuberculine syringe, few small drops of non cultured epidermal cell suspension will be placed over the denuded surface and spread evenly.~Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
45372537|NCT00745589|Drug|sevelamer hydrochloride|First-line higher dose (that is, 800mg TDS and up to a maximum of 1200mg TDS) sevelamer hydrochloride will be compared against low dose second-line sevelamer hydrochloride (that is, fixed dose of 400mg TDS)
45372538|NCT00750503|Behavioral|Behavioural and Pharmacotherapy for tobacco cessation|Professional help in the form of health awareness sessions, focus group discussion, one to one counseling and pharmacotherapy was provided to the employees by a team of doctors and counselors from Tata Memorial Hospital. Self reporting of tobacco history was validated with Rapid Urine cotinine test. Naked eye examination of oral cavity of all employees for detection of oral pre-cancers and cancers was conducted. Nursing staff and Doctors attached to the industry and from the local referral hospital were invited to participate as trainees during the active intervention sessions for local manpower development.
45372539|NCT00750581|Drug|Indomethacin|Infants randomized to Escalating Dose group will receive indomethacin (0.2 mg/kg/dose) at 12 hr intervals for 2 doses, followed by indomethacin (0.3 mg/kg/dose) at 12 hr interval for 2 doses, then Indomethacin (0.4 mg/kg/dose) at 12 hr interval for 2 doses, increased to indomethacin (0.5 mg/kg/dose) at 12 hour interval for 2 doses and finally indomethacin 0.6 mg/kg/dose at 12 hourly interval for 2 doses.
45372540|NCT00685763|Radiation|Proton radiation and chemotherapy|"Proton radiation 59.4 CGE in 33 fx at 1.8 CGE per fx over 7 weeks .~Chemotherapy:~Capecitabine (Xeloda ®) 1,000 mg by mouth twice a day, 5 days/week (M-F) Consolidation Chemotherapy: Suggested Regimen - Gemcitabine total of 12 doses"
45372541|NCT00745667|Procedure|laparoscopic surgery|laparoscopic correction perforated peptic ulcer
45372542|NCT00745667|Procedure|Upper laparotomy|upper laparotomy for correction of perforated peptic ulcer
45692723|NCT01768117|Biological|rLP2086|0.5 ml intramuscular injection of 120 microgram bivalent rLP2085 administered at 0, 2 and 6 months
45372543|NCT00745745|Device|Device Implantation|ICD lead implantation
45692724|NCT03582969|Other|Fecal transplantation|Fecal transplantation administered orally via frozen capsules.
45692725|NCT03582969|Other|Placebo|Placebo capsules
45692726|NCT01767493|Drug|[18F]Florbetapir PET imaging|[18F]Florbetapir and PET imaging
45692727|NCT03159429|Behavioral|Standard rehabilitation|The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing usual procedures, which include: maintaining a diary, breathing coordination excercises, voluntary control of breathing rate, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
46053619|NCT04527289|Drug|Placebo|patients will be managed with placebo as add on to the standard regimen.
46053620|NCT04516746|Biological|AZD1222|AZD1222 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2-5 surface glycoprotein.
46053621|NCT04516746|Biological|Placebo|Commercially available 0.9% (n/V) saline for injection.
46053622|NCT04505735|Drug|11C-PiB|Pittsburgh Compound-B (11C-PiB) is a diagnostic imaging agent that binds to beta-amyloid plaques and allows them to be viewed using positron emission tomography (PET) imaging.
46053623|NCT04502524|Behavioral|Smoking Cessation Intervention (New website)|Complete the new website smoking cessation program
46053624|NCT04502524|Behavioral|Smoking Cessation Intervention (Standard of care website)|Complete the standard of care website smoking cessation intervention
45372544|NCT00750659|Drug|Nilotinib|Nilotinib 400 mg po/BID until transplant. Nilotinib 200-400 mg po/BID post transplant in escalated doses.
45372545|NCT02561663|Dietary Supplement|NWT-03, an egg-white protein hydrolysate|egg-white protein hydrolysate
45372546|NCT02561663|Other|Placebo|
45372547|NCT00098293|Drug|Maraviroc + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
45372548|NCT00098293|Drug|Efavirenz + Zidovudine/Lamivudine|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
45372549|NCT00098293|Drug|Maraviroc (UK-427,857) + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
45372550|NCT04056065|Drug|Normal Saline|In addition to standard of care normal saline to be used as vehicle in the phase-II study to assess efficacy of PMZ-2010 as a resuscitative agent for hypovolemic shock
45372551|NCT04056065|Drug|Centhaquine|In addition to standard of care PMZ-2010 to be used as an experimental drug in the phase-II study to assess its efficacy as a resuscitative agent for hypovolemic shock
45372552|NCT00923741|Drug|Talactoferrin|
45692728|NCT03159429|Behavioral|Nasal breathing rehabilitation|The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing the experimental procedures, which include: maintaining a diary, evaluating nasal breathing by the nostril-alternating technique according to Anuloma Viloma Pranayama Yoga, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
46053625|NCT04502524|Behavioral|Health Education|Receive information about the cost of smoking, benefits of quitting, ways to prepare for quitting, ways to handle triggers and withdrawal symptoms, and available medications to help with quitting. And will receive additional resources available at the VA handout via email at the end of the study.
45372553|NCT00923741|Procedure|Apheresis|
45372554|NCT04055285|Procedure|Sympathetic Renal Denervation|Catheter-based sympathetic renal denervation (RDN) using radiofrequency, ultrasound, or perivascular injection of neurotoxic agents such as alcohol has been introduced as a minimally invasive alternative treatment option for patients with resistant hypertension. RDN consists of endovascular catalysis of the kidney sympathetic nerves running in the wall of the renal arteries.
45372555|NCT04055285|Device|Implantable Loop Recorder|Implantable Loop Recorders (ILRs) are small, subcutaneously implanted devices that are able to detect and store atrial fibrillation episodes lasting longer than 2 minutes with high sensitivity (96.1-100%) and good specificity (67-85.4%) for a period of up to three years.
45372556|NCT00685685|Drug|Lovastatin 40 mg tablets|40 mg tablet administered after an overnight fast of at least 10 hours
45372557|NCT00685685|Drug|Lovastatin (Mevacor®) 40 mg Tablets|40 mg tablet administered after an overnight fast of at least 10 hours
45372558|NCT01087567|Drug|Intensive insulin|A weight-based basal bolus insulin regimen starting with 0.1 units/kg/day of Glargine and 4 units/meal of Glulisine.
45692729|NCT04569799|Drug|Lumason|2.4 mL per lesion
45692730|NCT03159819|Genetic|CAR-CLD18 T Cells|Dose escalation will be applied in this study.
46053626|NCT04502524|Other|Health Promotion and Education|Receive motivational and reminder text messages
45692731|NCT01274182|Biological|GP2013|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
45692732|NCT01274182|Biological|MabThera|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
46053627|NCT04502524|Other|Questionnaire Administration|Ancillary studies
46053628|NCT04492215|Behavioral|Interaction between patient and trained general practitioners in motivational interviewing|Impact of the medical interview on the patient
45692733|NCT01274182|Biological|Rituxan|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
46053629|NCT04487886|Drug|Duvelisib|Duvelisib will be taken orally at an initial dose of 25 milligrams (mg) twice per day for 14 days. The dose will be de-escalated to 15 mg, twice per day, under certain clinical circumstances.
46053630|NCT04487886|Drug|Placebo|A placebo to match duvelisib will be taken orally twice per day for 14 days.
45372559|NCT01087567|Drug|Routine Care|Treatment in routine care will be based upon the 2009 ADA treatment recommendations.
45372560|NCT00684671|Biological|Twinrix|Intramuscular injection, single dose in left deltoid.
45372561|NCT00684671|Biological|Engerix-B|Intramuscular injection, single dose in left deltoid.
45372562|NCT00684671|Biological|Havrix|Intramuscular injection, single dose in right deltoid.
45490596|NCT03668834|Procedure|Dermaroller with NCES|"The recipient site will be shaved, cleaned with betadine and surgical spirit.~Microneedling will be done with a device containing 540 microneedles in 8 rows, each 0.25 mm in length. Microneedling will be extended 5 mm beyond margins to prevent halo phenomenon.~The roller will be passed repeatedly over the skin in a star-shaped way for about 10 minutes~The noncultured epidermal cell suspension will be carefully transferred to a tuberculin syringe.~NCES will be applied to the skin surface with a tuberculin syringe with an 18G needle and spread evenly after dermarolling treatment.~Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
45498171|NCT03688932|Other|WBV + IMTsham|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.
45372563|NCT00684671|Biological|HBVAXPRO|Intramuscular injection, single dose in the left deltoid.
45372564|NCT00684671|Biological|Vaqta|Intramuscular injection, single dose in right deltoid.
45372565|NCT03859323|Drug|SHP681|Participants will receive SC injection of SHP681 in the abdomen.
45372566|NCT03859323|Other|Placebo|Participants will receive SC injection of placebo matched to SHP681 in the abdomen.
45372567|NCT00750971|Procedure|Immunoablation and Autologous Hematopoietic Stem Cell Transplantation|Transplantation of purified CD34+ autologous hematopoietic stem cells mobilized with cyclophosphamide (200mg/m2)and G-CSF (10µg/kg/d) after immunoablation with cyclophosphamide (200mg/kg)and rabbit-antithymocyteglobulin (90mg/kg)
45372568|NCT00751049|Drug|timolol|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
45372569|NCT00751049|Drug|PhXA41|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
45372570|NCT00751985|Other|Personalised normative feedback (PNF)|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The brief personalised normative feedback will comprise the result of the participant's amount of alcohol consumption, previously given in an online questionnaire.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. The feedback is also comparing their drinking, in graphical format, to the average drinking in the municipality concerned. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
45372571|NCT00751985|Other|Self-help material|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The intervention comprises of on-line self-help material informing about the participant's response from an online questionnaire shows that the participant's alcohol consumption exceeds the recommended limits.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
45372572|NCT00751985|Other|Control|The participant is being informed about their allocation to the control group.
45372573|NCT03857841|Biological|UNEX-42|UNEX-42 is a preparation of extracellular vesicles that are secreted from human bone marrow-derived mesenchymal stem cells suspended in phosphate-buffered saline.
45372574|NCT03857841|Biological|Phosphate-buffered saline|Phosphate-buffered saline
45372575|NCT01014429|Drug|NMS-1286937|Single Arm, dose escalation study. No. of cycles: until progression or unacceptable toxicity develops.
45372576|NCT00500331|Drug|GSK189075|Experimental Drug
45372577|NCT00500331|Drug|pioglitazone|Active Control
45372578|NCT00500331|Other|Placebo|Placebo Comparator
45372579|NCT01015755|Behavioral|combined therapy treatment|mouth care
45372580|NCT01019109|Device|Posterior Spinal Fusion Device: Titanium rod arm used titanium rods, and CoCr rod arm used Cobalt Chrome rods as a part of the construct.|PASS LP Implant System is designed to contribute to correction and surgical stabilization of the thoracic, lumbar and sacral spine only. These implants are designed to stabilize the spine during normal development of solid bony consolidation which takes about 18 months. The internal fixation devices are composed of screws, hooks,rods, plates, cross links, connection and locking devices. The range of different sizes and shapes of the implants allows the surgeon to adapt to the pathology and morphology of each of his patients.
45372581|NCT00499863|Drug|methylphenidate transdermal system|dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
45372582|NCT00499863|Drug|Placebo|Placebo patch
45372583|NCT04475835|Drug|Bivalirudin|Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 4 hours after PCI. A prolonged infusion of 0.2 mg/kg/h for ≤20h could be considered at the operator's discretion. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is <225 s (Hemotec method), intravenous injection of 0.30 mg/kg of bivalirudin should be administered.
45372584|NCT04475835|Drug|Heparin|Heparin is dosed at 100 U/kg. ACT is monitored 5 min after the first administration, and if the ACT <225 s (Hemotec method), an intravenous injection of heparin should be administered by need.
45372585|NCT01014507|Drug|8 cycles BEACOPPesc plus oral contraceptive|
45372586|NCT01014507|Drug|8 cycles BEACOPPesc plus Goserelin|
45490597|NCT03668834|Procedure|Liquid nitrogen induced blister with NCES|"The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~The site to be grafted is outlined with a surgical marking pen.~To induce blisters on the achromic areas, freezing with liquid nitrogen spray was performed during 10 to 20 seconds inside round circles previously drawn on the skin.~The patient is asked to visit 24 hours later.~The blister fluid is aspirated and NCES taken in tuberculin syringe with 18 G needle is injected into it such that the blister roof is preserved.~Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
45490598|NCT04546620|Drug|R-CHOP|Arm A patients will receive R-CHOP alone.
45372587|NCT00484185|Drug|BeneFIX (coagulation factor IX (recombinant))|BeneFIX will be administered according to physician's discretion.
45372588|NCT00097981|Drug|Thalidomide|Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.
45372589|NCT00097981|Drug|Dexamethasone|Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.
45372590|NCT00097981|Drug|DOXIL|DOXIL 40 mg/m2 will be administered iintravenously (into a vein) on Day 1.
45372591|NCT01015911|Drug|SGN-75|SGN-75 (IV) in 21- or 28-day cycles; dose range: 0.3-9 mg/kg
45372592|NCT03997149|Behavioral|Acute Laboratory Stressor|The TSST was 20 minutes long and consisted of a five-minute instructional period where participants listened to a pre-recorded tape; a five-minute speech preparation period; a five-minute challenging serial subtraction task; and a five-minute videotaped public speaking task in front of a panel of three evaluative, non-affirming judges dressed in white coats.
45692734|NCT04591093|Device|FineHearing Strategy with 10 more apical electrodes or with 10 more basal electrodes activated|Cochlear implant with FineHearing Strategy with 10 more apical electrodes activated or with 10 more basal electrodes activated
46053631|NCT04464603|Device|InterFACE (mHealth tool)|"Participants will be asked to perform consecutively two 20-min highly realistic, scripted CPR scenarios (first: PALS-based scenario, second: ATLS-based scenario) on a high-fidelity WiFi manikin.~Within each scenario, 3 separate freeze periods will occur at random points in time to assess the shared and complementary Situation Awareness of each team member individually regarding the CPR in progress at that exact moment in time. The scenarios will be standardized to strictly follow the 2018 AHA algorithms and the 2018 ATLS guidelines.~Both scenarios will be completed in the same order and the procedure will be standardized across all teams to follow the same chronological progression and range of difficulty in order to ensure that each participant is exposed to exactly the same case, with similar challenges in technical and non-technical skills.~Participants allocated to Arm A will not be allowed to use any other cognitive support."
45372593|NCT03997149|Behavioral|Low affect video|The 20-minute TSST was replaced with a 20-minute low-affect educational film screening.
45372594|NCT01016145|Drug|Antipsychotics|Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg
45490599|NCT04546620|Drug|R-CHOP + acalabrutinib|Arm B patients will receive R-CHOP in combination with acalabrutinib.
45490600|NCT04058210|Drug|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration.
45490601|NCT04058210|Drug|IVA|150-mg tablet for oral administration.
46053632|NCT04464603|Other|Conventional methods|"Participants will be asked to perform consecutively two 20-min scripted CPR scenarios (PALS and ATLS-based scenario) on a high-fidelity WiFi manikin.~Within each scenario, 3 separate freeze periods will occur at random points in time to assess the shared and complementary Situation Awareness of each team member individually regarding the CPR in progress at that exact moment in time. The scenarios will be standardized to strictly follow the 2018 AHA algorithms and 2018 ATLS guidelines.~Both scenarios will be completed in the same order and the procedure will be standardized across all teams to follow the same chronological progression and range of difficulty in order to ensure that each participant is exposed to exactly the same case, with similar challenges in technical and non-technical skills.~Participants allocated to group B will be allowed to use the PALS pocket reference cards and a conventional calculator, but not any other cognitive support or mHealth tool."
45372595|NCT01016145|Drug|Antipsychotics|Haloperidol 2,5-10 mg; chlorpromazine 25-600 mg.
45372596|NCT03741283|Other|Optimisation of nutrition and medication|"Inter-professional optimisation of medication prescribing:~Study participants in the intervention group receives optimisation of medication prescribing at admission day (baseline) regardless of nutritional state. The intervention is performed in cooperation between a clinical pharmacist and a medical physician.~Nutritional intervention:~If positive screening for malnutrition or risk of malnutrition a dietetic intervention is initiated and if positive screening below interventions are initiated:~Dysphagia: occupational therapy intervention.~Oral cavity problems: odontological intervention.~Depression: geriatric intervention.~Low ADL: occupational therapy intervention and if positive screening for poor muscle strength: physiotherapeutic intervention."
45372597|NCT01016223|Drug|Beclomethasone dipropionate|Beclomethasone dipropionate 80 mcg two puffs twice daily for 8 weeks
45372598|NCT01016223|Drug|placebo|Matched placebo swallowed two puffs twice daily
45372599|NCT01087645|Drug|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation
45372600|NCT01087645|Drug|NN9925 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit
45372601|NCT01087645|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels
45372602|NCT01087645|Drug|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations. The dose will be selected based on the results of part 1
45372603|NCT01087645|Drug|placebo|Subjects will be randomised to receive a single dose of placebo
45372604|NCT04151121|Behavioral|MBCT (Mindfulness Based Cognitive Therapy)|MBCT is recognized behavior therapy for patients with recurrent depression. The program will be adapted for patients with chest pain.
45372605|NCT04151017|Other|Autologous fibrin glue|Conjunctival graft fixation with autologous fibrin glue
45372606|NCT04151017|Other|Suture|Graft fixation using 10.0 mononylon
45372607|NCT01019265|Drug|Buprenorphine 5mg, 10mg, 20mg vs Tramadol 100mg|Comparing pain intensity between intervention drugs (Norspan® and Tridol®)
45372608|NCT01085617|Biological|palifermin|
45490602|NCT03021668|Device|Prevena Peel & Place Dressing|Prevena Peel & Place Dressing is a device that can be used for closure of the surgical site. It provides negative pressure to the surgical wound
45490603|NCT03021668|Other|Standard Closure of the Surgical Incision|This would involve standard closure of the incision site
45490604|NCT03668756|Procedure|Computer-Assisted Navigation TKA|TKAs were performed using the image-free CAS navigation system VectorVision
45490605|NCT03669380|Other||
45490606|NCT03669068|Procedure|Gastrointestinal endoscopy|"Two separated groups will be included in the registry:~Patients with oral anticoagulants-induced gastrointestinal bleeding unrelated to an endoscopic procedure.~Patients undergoing elective gastrointestinal endoscopy."
45692735|NCT01984229|Drug|Alectinib|Alectinib will be administered as a single oral dose on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants).
45692736|NCT01984229|Drug|Posaconazole|Posaconazole will be administered as a 400-mg BID oral dose after a high-fat meal on Days 8 to 14 (Period 2) and Days 15 to 18 or 21 (Period 3).
45372609|NCT01085617|Biological|rituximab|
45372610|NCT01085617|Drug|cyclophosphamide|
45372611|NCT01085617|Drug|cytarabine|
45372612|NCT01085617|Drug|daunorubicin hydrochloride|
45372613|NCT01085617|Drug|etoposide|
45372614|NCT01085617|Drug|fludarabine phosphate|
45372615|NCT01085617|Drug|imatinib mesylate|
45692737|NCT03582735|Other|Nerve gliding exercise|A 4-week home-based nerve-gliding exercise program (NGEP) including isolated and coupled upper limb and neck movements. A specific mobilization was elaborated for each week of the program allowing to gradually increase the range of movement and inter-articular coordination.
45846780|NCT05462028|Device|Vibration training|The vibration sessions were performed and supervised by a stroke care experienced registered nurses/researchers who had both nurse and physiotherapist license. The wearable leg vibration training with vibration frequency = 30 Hz, vibration amplitude = 1 mm in the WG was applied by the wearable leg vibration device (Myovolt, New Zealand) which fits comfortably around the knee and hamstring or calf and delivers focal vibration treatment. While the lower-extremity weight bearing vibration training with vibration frequency = 20 Hz, vibration amplitude = 3 mm in the LG was applied the Cozy Fit (HY-806, China) vibration device with vertical direction, which participants stand with both feet upright on the vibrator in a seated position.
45846781|NCT05462028|Behavioral|ergometer exercise|ergometer exercise training
45372616|NCT01085617|Drug|melphalan|
45372617|NCT01085617|Drug|mercaptopurine|
45372618|NCT01085617|Drug|methotrexate|
45692738|NCT03582501|Other|Lower body negative pressure|Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
45692739|NCT01835899|Drug|Placebo|Placebo to BI 1015550
45692740|NCT01835899|Drug|BI 1015550|medium dose 1 powder for oral solution
45692741|NCT01835899|Drug|BI 1015550|medium dose 2 powder for oral solution
45846782|NCT05393466|Drug|BPI-361175|BPI-361175 is an oral fourth-generation EGFR inhibitor. The activation of EGFR signaling pathways is associated with various biological events such as proliferation, migration, differentiation, and apoptosis.
46053633|NCT04464200|Drug|19(T2)28z1xx CAR T cells|2-7 days following the completion of the conditioning chemotherapy, patients will receive the CAR- T cells by IV infusion over 1-3 days depending on the dose level and formulation of the final CAR- T cells.
45372619|NCT01085617|Drug|nelarabine|
45372620|NCT01085617|Drug|pegaspargase|
45372621|NCT01085617|Drug|vincristine sulfate|
45372622|NCT01085617|Procedure|allogeneic hematopoietic stem cell transplantation|
45372623|NCT01085617|Radiation|total-body irradiation|
45372624|NCT00499083|Biological|therapeutic autologous dendritic cells|injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments. If, after a cycle(s) of chemotherapy, no tumor can be localized by ultrasound, the DCs will be injected where the tumor bed was localized by the clip or marker.
45372625|NCT00499083|Drug|aromatase inhibition therapy|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
45372626|NCT00499083|Drug|cyclophosphamide|600 mg/m2 IV day 1 every 2 weeks for 4 cycles
45372627|NCT00499083|Drug|doxorubicin hydrochloride|60 mg/m2 IV day 1 every 2 weeks for 4 cycles
45372628|NCT00499083|Drug|paclitaxel|175 mg/m2 intravenously (IV) over at least 3 hours day 1 every 2 weeks for 4 cycles.
45372629|NCT00499083|Drug|tamoxifen citrate|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
45372630|NCT00499083|Genetic|gene expression analysis|IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).
45692742|NCT01835899|Drug|BI1015550|low dose 2 powder for oral solution
45846783|NCT05281770|Drug|Erenumab|treatment with erenumab as chosen by treating physician
46053634|NCT04460872|Drug|Testosterone Enanthate|Subjects receive testosterone (100 mg/week) by intramuscular injection
46053635|NCT04460872|Behavioral|Locomotor Training|Subjects receive locomotor training (4 sessions/week for 2-3 months)
46053636|NCT04457401|Dietary Supplement|Probiotic|This probiotic is commercially available and contains Bifidobacterium (3 x 10^9 colony forming units/capsule) as the active ingredient and potato starch, magnesium stearate and ascorbic acid as excipients.
45490607|NCT03668678|Other|iGrow Readers Curriculum|As part of the iGrow Readers curriculum, the primary teacher first reads a book as a group with a specific health behavior theme. Then, children participate in nutrition and physical activities that relate and reinforce the lessons learned in the book. Informational newsletters highlighting healthy behaviors from the stories' themes are provided to parents. All implementation strategies are reinforced by research to promote positive choices in young children's health behaviors through the use of literature and language strategies and modeling of others in the children's microsystems.
45490608|NCT03668990|Other|IMUs (Xsens, MVN Studio)|It is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
45490609|NCT03668210|Procedure|Isokinetic evaluation|Isokinetics is used to measure the peak of strength of quadriceps and hamstrings, in concentric or eccentric, at slow and fast speed to determine a hamstring / quadriceps ratio to highlight a deficit or imbalance.
45490610|NCT03623126|Other|Questionnaire|A questionnaire to evaluate clinical improvement and quality of life after ESSURE removal will be completed by patients at least one month after the procedure.
45490611|NCT03020888|Device|Magseed and Sentimag|Magseed marker and Sentimag probe for lesion localization
45692743|NCT01835899|Drug|BI 1015550|low dose 1 powder for oral solution
45692744|NCT01274026|Drug|sapropterin dihydrochloride|"In 30 PKU patients found previously to exhibit no decrease in blood PHE levels behavioral and cognitive function, neurotransmitter levels, and gene expression of enzyme activity will be measured at baseline and after 4 weeks of Kuvan administration. Rating inventories of executive function performance and behavior will be administered to patients and parents.~Urine neurotransmitters, blood microarray expression, and plasma amino acids will be measured (plasma PHE and TYR levels will also be measured at weeks 1 and 2). Nutrient analysis of 3 day food diaries will be conducted."
45692745|NCT03582423|Other|electro-acupuncture|Eight acupoints are chosen: he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
46053637|NCT04457401|Dietary Supplement|Placebo|The placebo contains potato starch, magnesium stearate and ascorbic acid.
46053638|NCT04446351|Drug|GSK6097608|GSK6097608 will be administered as an IV infusion.
46053639|NCT04446351|Drug|Dostarlimab|Dostarlimab will be administered as an IV infusion.
46053640|NCT04446351|Drug|GSK4428859A (EOS884448)|GSK4428859A (EOS884448) will be administered as an IV infusion.
45372631|NCT00499083|Genetic|protein expression analysis|Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration.
45372632|NCT00499083|Genetic|reverse transcriptase-polymerase chain reaction|delta Ct (quantitative real time- reverse transcription-polymerase chain reaction (qRT-PCR)) of COX-2 and VEGF will be divided into the upper or lower median and Fisher Exact test used to assess the difference in response.
45490612|NCT03668522|Other|Genetic testing|To determine whether H3F3AK27M exist in spinal glioma
45490613|NCT03668132|Other|ischemic brain damage|Have or not have the ischemic brain damage and the location of the damage
45490614|NCT02250300|Drug|MLN9708 (2.3 mg)|2.3 mg
46053641|NCT04446351|Drug|Cobolimab|Cobolimab will be administered as an IV infusion.
46053642|NCT04437602|Diagnostic Test|Contrast Enhanced Mammography (CEM)|Additional CEM in preoperative staging
46053643|NCT04428905|Other|Quality-of-Life Assessment|Ancillary studies
46053644|NCT04428905|Other|Questionnaire Administration|Ancillary studies
46053645|NCT04428905|Other|Survivorship Care Plan|Receive personalized care plan/resource manual
46053646|NCT04428905|Other|Telemedicine|Participate in telehealth sessions
45372633|NCT00499083|Other|immunoenzyme technique|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
45372634|NCT00499083|Other|immunohistochemistry staining method|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
45372635|NCT00499083|Other|laboratory biomarker analysis|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
45372636|NCT00499083|Procedure|adjuvant therapy|Hormone manipulation Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
45490615|NCT02250300|Drug|MLN9708 (4.0 mg)|4.0 mg
45490616|NCT02250300|Drug|MLN9708 (3.0 mg)|3.0 mg
45490617|NCT04403490|Behavioral|HABIT-ILE|2 weeks HABIT-ILE
45490618|NCT04403490|Behavioral|Conventional intervention|2 weeks usual intervention (waitlist group)
45490619|NCT03020966|Drug|Acetaminophen|Oral acetaminophen, intravenous placebo
45692746|NCT01274104|Dietary Supplement|Vitamin D3|15,000 IU of Vitamin D3 every day for 14 days
45692747|NCT01274104|Other|Placebo|Placebo
45846784|NCT05281770|Drug|Fremanezumab|treatment with fremanezumab as chosen by treating physician
45490620|NCT03020966|Drug|Acetaminophen|Intravenous acetaminophen, oral placebo
45490621|NCT01381770|Biological|platelet-derived repairing factors|autologous platelet lysate injection within 24 hours from lesion
45846785|NCT05281770|Drug|Galcanezumab|treatment with galcanezumab as chosen by treating physician
45372637|NCT00499083|Procedure|biopsy|Two tumor biopsies will be performed. The first tumor biopsy will be performed before apheresis for diagnostic purposes, and again after completion of the first four chemotherapy treatments. Patients will undergo local anesthesia with lidocaine and 1% epinephrine followed by 1-2 core biopsies of the breast primary and/or palpable axillary node with a 14 gauge, 16 cm. Bard needle or other similar needle. The procedure may be done under ultrasound guidance. If a metal clip or marker has not been previously placed in the tumor, it will be placed before treatment.
45372638|NCT00499083|Procedure|conventional surgery|Definitive breast surgery Surgery will occur two to four weeks after the last course of chemotherapy. Modified radical mastectomy or lumpectomy and standard axillary dissection could be performed and the specific procedure will be decided by the patient and physician team. If a sentinel node dissection was done prior to chemotherapy and was negative, no further node dissection is necessary. A standard node dissection will be necessary if no node assessment was done prior to chemotherapy or if the pre- chemotherapy sentinel node was positive.
45372639|NCT00499083|Procedure|neoadjuvant therapy|Chemotherapy: Paclitaxel (T) 175 mg/m2 intravenously (IV) over at least 3 hours day 1. Repeat every 2 weeks for 4 cycles. IT DCs will be injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.
45372640|NCT00499083|Radiation|radiation therapy|Radiation therapy Radiation is started two to four weeks after surgery for all patients receiving lumpectomy and those patients after mastectomy that the physician feels chest wall radiation is warranted (example: T3 or T4 breast lesion, four or more axillary nodes etc.). The exact doses and methods of administration will be determined by the treating radiation therapist, but should be standard breast radiotherapy and not partial breast or investigational methods.
45372641|NCT03963661|Behavioral|c-SIGHT (computorized spatial innatention grasping home-based therapy)|C-SIGHT will be self-administered at people's homes. c-SIGHT is a computerized therapy administered via people's television. The therapy involves performing repeated rod lifts with the less impaired arm in response to auditory and visual instructions presented on the television screen connected to a laptop. A small motion-tracking camera monitors rod lifts during therapy sessions. People will be asked to self-administer c-SIGHT for 1 hour a day (30min after breakfast and 30min after lunch) for 7 consecutive days. The first day of therapy will be performed with a therapist there for training purposes.
45490622|NCT01383564|Procedure|CPAP group|Patients will be given a CPAP education program by our respiratory nurse supplemented by education brochure and a video. Attended overnight CPAP titration will be performed with the auto-titrating device. The CPAP level for each patient in the therapeutic CPAP arm is set at the minimum pressure needed to abolish snoring, obstructive respiratory events and airflow limitation for 95% of the night as determined by the overnight CPAP titration study. Patients in the CPAP therapy will be provided careful mask-fitting, chin strap to prevent mouth leak, regular review by our nurses, a basic CPAP device with intrinsic time clock to monitor CPAP usage and standard stroke rehabilitation programme. Patients on conservative treatment will only be offered standard treatment for asthma
45490623|NCT01383564|Procedure|non CPAP group|Patients who are randomised to non CPAP group will receive general health advice and no CPAP therapy will be arranged for them during the study period.
45692748|NCT03582345|Procedure|EEG/fMRI|"All the patients recruited will undergo to the following interventions:~1. Presurgical assesment protocol of the recruited patients (RU1 and RU2) that will includes: (a) detailed medical and epilepsy patients' history; (b) neurologic evaluation; (c) structural 3 Tesla MRI; (d) prolonged video-EEG monitoring including one-overnight EEG recording; (e) neuropsychological evaluation including quality of life evaluation. 2. EEG-fMRI coregistration: All subjects will undergo to a Video-EEG/fMRI study. This protocol will include a 32-channels EEG recorded simultaneously to fMRI data acquisition (3T scanner, Philips). This phase will be articulated in two steps: (i) acquisition of the EEG-fMRI data; (ii) fMRI data analysis (conventional and DCM analysis). RU1 will be charged for both steps. 3. Surgical resection of the epileptic foci and/or intracranial electrode recording (icEEG). The DRE patients in whom an intracranial recording will be considered unnecessary, will be operated at the RU2."
45692749|NCT01766401|Drug|Placebo|
45692750|NCT01766401|Drug|Vilazadone|Viibryd
45692751|NCT03159273|Dietary Supplement|Beetroot Juice Group|Beetroot juice drink- 7 daily doses (70 ml, containing 0.4-0.5 mg nitrate) taken over a week
45692752|NCT01279096|Drug|Clofarabine|escalating doses of clofarabine starting from 20 mg/m2/day to 40 mg/m2/day from day 1 to day 5 used in association with etoposide, asparaginase, mitoxantrone and dexamethasone
45846786|NCT05225610|Other|Valsalva Manoeuvre|Blowing into rubber tubing connected to a sphygmomanometer and raising the mercury column to 30 mmHg for at least 20 seconds
46053647|NCT04428866|Diagnostic Test|Continuous Glucose Monitoring|A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed during visit 1 in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.
46053648|NCT04428866|Diagnostic Test|activity monitor|The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days to assess activity, concurrent with CGM sensor wear.
46053649|NCT04428866|Diagnostic Test|Mixed meal tolerance test|After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.
45372642|NCT01087879|Drug|Desogestrel-Ethinyl Estradiol contraceptive pill|150 microg Desogestrel and 20 microg Ethinyl Estradiol combination. One pill once a day for 9 weeks, continual administration.
45372643|NCT01087879|Drug|Etonogestrel-Ethinyl Estradiol vaginal ring|Etonogestrel-Ethinyl Estradiol vaginal ring, which consists of 11,7 mg etonogestrel and 2,7 mg ethinyl estradiol. It delivers 0,120 mg etonogestrel and 0,015 mg ethinyl estradiol per day. Treatment continues continual for 9 weeks and the vaginal ring is changed every three weeks.
45372644|NCT01087879|Drug|Norelgestromin-Ethinyl Estradiol contraceptive patch|A combination transdermal contraceptive patch with 6 mg of norelgestromin and 600 microg of ethinyl estradiol. It delivers 203 microg of norelgestromin and 33,9 microg ethinyl estradiol per day. A continual use of patch for 9 weeks and the patch is changed every week.
45372645|NCT01019421|Drug|Lu AE58054|Add-on treatment to donepezil
45372646|NCT01019421|Drug|Placebo|Add-on treatment to donepezil
45490624|NCT03020576|Device|Amadeo Hand Robot Device|This is a robotic device designed to offer rehabilitation to remediate weakness and limitations of range of motion of the hand and fingers.
45490625|NCT03020576|Other|Conventional Therapy|This arm involves treatment using conventional methods designed to promote range of motion, strength, coordination and function at the level of the shoulder, elbow, wrist and hand.
45490626|NCT00892866|Other|Cytology Specimen Collection Procedure|Correlative studies
45490627|NCT00892866|Other|Laboratory Biomarker Analysis|Correlative studies
45490628|NCT03667976|Behavioral|SATHI|see above
45372647|NCT01085695|Drug|rabeprazole|10 mg normal tablet
45372648|NCT01085695|Drug|rabeprazole|Type 1 granule containing rabeprazole 10 mg
45372649|NCT01085695|Drug|rabeprazole|Type 2 granule containing rabeprazole 10 mg
45490629|NCT04051268|Biological|Vi-DT Typhoid Conjugate Vaccine|1 dose of Investigational Product
45490630|NCT04051268|Biological|PQed Typhoid Conjugate Vaccine|1 dose of Active Comparator
45490631|NCT04051268|Biological|Vi Polysaccharide Vaccine|1 dose of Active Comparator
45372650|NCT01085695|Drug|rabeprazole|Type 3 granule containing rabeprazole 10 mg
45372651|NCT00572195|Device|RNS® System|The previously implanted RNS® System is programmed to provide responsive stimulation. Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. Patients with epilepsy treated with responsive direct-brain stimulation with the RNS System typically receive less than 6 minutes of stimulation a day.
45372652|NCT01088035|Drug|Carboplatin|Patients will receive daily carboplatin as a radiation sensitizer prior to radiation each day.
45490632|NCT05420298|Other|cervical mobilization|All participants will receive only single session of cervical mobilization
45490633|NCT05420298|Other|cervical manipulation|All participants will receive only single session of cervical manipulation
45490634|NCT03017612|Device|Raindrop Near Vision Inlay|A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near and intermediate vision.
45490635|NCT03635099|Drug|Placebo (fasted)|Placebo matching BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
45846787|NCT05225610|Drug|Dexmedetomidine Injection [Precedex]|The study drugs will be kept at room temperature, preservative-free and will be prepared by an independent anaesthetist into 5 ml of total volume with the addition of 0.9 % normal saline. Tourniquet will be left inflated for 1 minute. Dexmedetomidine mixture and saline will be injected over 5 seconds. After the injection of the drugs, the tourniquet will be released
45372653|NCT03961477|Other|Interferential therapy|Exercise therapy
45372654|NCT01085851|Drug|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days
45372655|NCT01085851|Drug|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
45372656|NCT00751127|Drug|PhXA41|One drop in the affected eye once daily for six months.
45372657|NCT00751127|Drug|timolol|One drop in the affected eye twice daily for six months.
45692753|NCT03582267|Dietary Supplement|Docosahexaenoic Acid (DHA)|Daily administration of docosahexaenoic Acid (DHA). 2 grams of DHA liquid concentrate administered per day throughout trial period.
45846788|NCT05225610|Drug|normal Saline|5 ml saline will be administered.
45490636|NCT03635099|Drug|BI 25 mg (fasted)|25 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
45846789|NCT05209386|Behavioral|Dimension-Based Statistical Learning|"Each participant will complete self-paced blocks of stimuli that will first establish a baseline for neural activity and behavioral responses with clear speech, and will then record responses for experimentally manipulated blocks to introduce 1) speech-in-noise and 2) a Canonical-Reverse block to model an accent. Auditory stimuli will be adjusted to a comfortable level for each participant as determined by a calibration process completed by the participant. Each block involves listening to sound via earphones and making a categorical decision between initial consonants (/b/ or /p/) by tapping a button to indicate the word heard by the participant."
45490637|NCT03635099|Drug|BI 50 mg (fasted)|50 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
45692754|NCT01279174|Other|Conventional physiotherapy|Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
45692755|NCT03582111|Other|Study of medical records|Study of medical records
45372658|NCT00751205|Drug|Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. In addition, subjects will receive Acetyl-L-Carnitine (ALC) 1000 mg tid. Treatment with Sagopilone and ALC will be continued as long as there is benefit. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
45372659|NCT00751205|Drug|Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. Treatment will be continued as long as there is benefit. In addition, subjects will receive 21 weeks of placebo 1000 mg tid. After all patients have completed 6 cycles of treatment, an analysis will be performed to see whether ALC was better than placebo. If this is the case, patients still under placebo treatment will be offered to switch to ALC. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
45372660|NCT00572039|Behavioral|PST|PST will be delivered in subjects' homes over the course of 6 weeks.
45372661|NCT00572039|Behavioral|ST|ST will be delivered in subjects' homes over the course of 6 weeks.
45372662|NCT00751283|Device|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
45372663|NCT00752063|Drug|Sorafenib with Capecitabine and Oxaliplatin|Regimen 1: Oxaliplatin 85 mg/m2 (50 mg per vial) administered intravenously on day 1 of each cycle Regimen 2: Capecitabine 1700 mg/m2 p.o. (850 mg/m2 BD) day 1 to 7 Regimen 3: Sorafenib 400 mg (200 mg/tablet) orally BD day 1 to 14
45490638|NCT03635099|Drug|BI 100 mg (fasted)|100 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
45490639|NCT03635099|Drug|BI 200 mg (fasted)|200 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
45490640|NCT03635099|Drug|Placebo (fed)|4 film-coated tablets of matching Placebo were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
45692756|NCT01272934|Drug|Diclofenac Sodium|Topical gel 1%-4 times daily
45692757|NCT01272934|Other|Placebo|Topical gel-4 times daily
45846790|NCT05185830|Other|Interactive robots|Children will mobilize with the interactive robot when control group will mobilize with nurse.
45846791|NCT05150652|Drug|Anastrozole 1mg|Participants will take 1mg of anastrozole once daily, orally, for up to six cycles of 28 days.
45846792|NCT05150652|Drug|Letrozole 2.5mg|Participants will take 2.5mg of Letrozole once daily, orally, for up to six cycles of 28 days.
45372664|NCT00751361|Device|Rheopheresis / double filtration plasmapheresis|Rheopheresis is a specific method of therapeutic apheresis, using the methodology of double filtration plasmapheresis.
45846793|NCT05150652|Drug|Exemestane 25 mg|Participants will take 25mg of Exemestane once daily, orally, for up to six cycles of 28 days.
45372665|NCT00684593|Drug|Navarixin 10 mg|Navarixin capsules orally, once daily for 28 days.
45372666|NCT00684593|Other|Placebo|Matching placebo capsules to Navarixin orally, once daily for 28 days.
45372667|NCT00752141|Drug|oxybutynin chloride immediate-release|capsule containing oxybutynin chloride immediate-release 5 mg tablet administered three times daily, and placebo gel administered once daily
45372668|NCT00752141|Drug|oxybutynin chloride topical gel|oxybutynin chloride topical gel applied once daily, and capsule containing placebo tablet administered three times daily
45372669|NCT00752141|Other|placebo|capsule containing placebo tablet administered three times daily, and placebo gel administered once daily
45372670|NCT03879317|Device|Continuous NIRS monitoring|Septic shock patients who have continuous NIRS and blood pressure monitoring at same time will be included. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP.
45372671|NCT00752375|Drug|Trimethoprim Sulfamethoxazole|"Children >3months of age will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)per day for one year.~Children under 3 months of age will receive amoxicillin 10mg/kg once per day for one year.~Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day for one year."
45372672|NCT00752375|Drug|placebo|"Placebo matching Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)for children more than 3 months of age~Placebo matching amoxicillin 10mg/kg once per day for children under 3 months of age~Placebo matching nitrofurantoin (1mg/kg) once per day for children with a sulfa allergy."
45372673|NCT00751517|Drug|Methotrexate|
45372674|NCT00751517|Drug|Cyclophosphamide|
45372675|NCT00751595|Biological|Tat protein|Biologically active recombinant Tat protein
45372676|NCT00685373|Drug|Canakinumab (ACZ885)|6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with water for a subcutaneous injection every 8 weeks. Dosage based on body weight.
45372677|NCT02561117|Drug|Metronidazole|Administration once daily
45372678|NCT00684515|Drug|Vorapaxar 2.5 mg|Oral tablets; once daily for 60 days.
45372679|NCT00684515|Drug|Vorapaxar 1 mg|Oral tablets; once daily for 60 days
45372680|NCT00684515|Drug|Placebo|oral tablets; once daily for 60 days
45372681|NCT00684515|Drug|Aspirin 75-150 mg|oral tablets; once daily for 60 days
45372682|NCT00751751|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets taken once daily for 52 weeks + oral hydrochlorothiazide tablets, once daily, after 12 weeks if needed to control BP
45372683|NCT00751751|Drug|losartan + hydrochlorothiazide, if necessary|oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tablets, after 12 weeks, if needed to control BP.
45372684|NCT00490815|Drug|Fluocinolone Acetonide|0.5 mg fluocinolone acetonide intravitreal insert
45372685|NCT00490815|Drug|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
46053650|NCT04428866|Diagnostic Test|Glucagon Sensitivity Testing|After baseline blood sampling, glucagon will be administered by injection, and blood samples will be collected for analysis of glucose and hormone responses. This will allow us to assess whether sensitivity to glucagon is altered in PBH.
46053651|NCT04428866|Diagnostic Test|Hypoglycemic Hyperinsulinemic Clamp|This test will assess hormonal responses to hypoglycemia. Participants will arrive after an overnight fast. After baseline blood sampling, an infusion of insulin and glucose will be started, and infusions will be adjusted to allow glucose levels to drop very gradually. Blood samples will be collected for measurement of hormonal responses to lowering of glucose. This test will allow us to determine whether secretion of hormones which counteract hypoglycemia (counterregulatory hormones) is reduced in patients with PBH as compared with other groups.
46053652|NCT04428866|Diagnostic Test|analysis of fecal microbiome|Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.
46053653|NCT04428723|Other|Entry of demographic and medical history data into a deidentified database|Entry into repository for analysis.
45372686|NCT01016301|Other|Pharmacist service|Medication Review, medication report
45372687|NCT01014663|Behavioral|Traditional Therapeutic Exercise|The therapeutic exercise program will consist of warm-up and stretching, seated and standing range of motion activities, endurance and resistance training, balance training and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
45372688|NCT01014663|Behavioral|Non-Contact Boxing Training|Non-contact boxing training will consist of warm-up and stretching, non-contact boxing training (including punching a focus mitt, speed and heavy punching bags), endurance training activities, strength and resistance training, and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
45372689|NCT01019499|Other|berry products|"effects of berry consumption on cardiovascular indicators~two portions daily"
45372690|NCT01019499|Other|control products|two portions daily
45372691|NCT04453137|Biological|Adalimumab originator|Subcutaneous injection every other week
45372692|NCT04453137|Biological|Adalimumab biosimilar|Subcutaneous injection every other week
45372693|NCT03855189|Drug|Mometasone Furoate (MF)|Mometasone furoate nasal spray administered as 200 mcg total dose per day for 4 weeks.
45372694|NCT03855189|Drug|Beclomethasone Dipropionate (BDP)|Beclomethasone dipropionate nasal spray administered as 168 mcg twice daily (BID) [336 mcg total dose per day] for 4 weeks.
45372695|NCT03855189|Drug|Placebo|Placebo nasal spray administered for 4 weeks.
45372696|NCT03853551|Drug|Osimertinib|Osimertinib is an oral, potent, selective, irreversible inhibitor of both epidermal growth factor receptor - Tyrosine kinase inhibitors (EGFR-TKI) sensitizing and resistance mutations in nonsmall cell lung cancer (NSCLC) with a significant selectivity margin over wild-type EGFR.
45372697|NCT00423670|Drug|boceprevir (SCH 503034)|200 mg capsules taken as 800 mg orally three times daily (TID)
45490641|NCT03635099|Drug|BI 400 mg once daily (fed)|4 film-coated tablets of 100 milligram (mg) BI 730357 (400 mg in total) were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
45490642|NCT03635099|Drug|BI 200 mg twice daily, 400 mg total (fed)|2 film-coated tablets of 100 milligram (mg) BI 730357 were taken orally with a meal in the morning and evening (twice daily; total daily dosage: 400 mg) for 12 weeks.
45490643|NCT03667898|Procedure|Lumbar plexus block using NTT|An lumbar plexus block is performed using ultrasound guidance with needle tip tracking.
45490644|NCT03667898|Procedure|Lumbar plexus block without NTT|An lumbar plexus block is performed using ultrasound guidance without needle tip tracking.
45498172|NCT03688932|Other|WBVsham + IMTsham|Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
46053654|NCT04428723|Genetic|Blood sample for DNA analysis|Targeted resequencing of DNA to identify variants associated with hypoglycemia, comparing participants with hypoglycemia (both surgical and non-surgical) and healthy controls.
46053655|NCT04428723|Diagnostic Test|Stool sample for microbiome analysis|Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.
46053656|NCT04428723|Diagnostic Test|Mixed meal tolerance test|For a subset of participants: After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.
45372698|NCT00423670|Drug|peginterferon-alfa 2b (PegIntron)|1.5 μg/kg subcutaneously (SC) once weekly (QW)
45372699|NCT00423670|Drug|ribavirin|200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily
45372700|NCT00423670|Drug|ribavirin (low-dose)|200 mg capsules in doses of 400 to 1000 mg/day (based on weight) taken orally divided twice daily
45372701|NCT03996759|Diagnostic Test|Laboratory diagnostic medicine|Metabolomic profiling and laboratory diagnosis including blood routine examination, liver function, renal function, myocardial enzyme, coagulation, arterial blood gas analysis, C-reactive protein, procalcitonin, B-type natriuretic peptide, myoglobin, lipopolysaccharide, cytokines (TNF-α, IL-1β, IL-6, etc.), immune cell markers (CD3+, CD4+, CD8+, etc.), and stool routine as well as intestinal microecology analysis.
45372702|NCT01016379|Genetic|DNA analysis|
45846794|NCT05150652|Drug|Tamoxifen|Participants will take 20mg of Tamoxifen once daily, orally, for up to six cycles of 28 days.
45846795|NCT05133024|Dietary Supplement|concentrated beetroot juice|Nitrate supplementation; natural source of dietary nitrate
45372703|NCT01016379|Other|biologic sample preservation procedure|
45372704|NCT01016379|Other|laboratory biomarker analysis|
45372705|NCT01019577|Drug|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, Maximum 9 cycles
45372706|NCT05072535|Drug|HA121-28 tablet B|HA121-28 tablet B 200 mg
45372707|NCT05072535|Drug|HA121-28 tablet A|HA121-28 tablet A 200 mg
45372708|NCT03996837|Other|Intra uterine infusion of platelet rich plasma|Platelet Rich Plasma (PRP) is a blood product with a high platelet and a normal plasma fibrinogen level. Given the effective factors of RPR in repairing damaged tissues, its application in the field of regenerative medicine has widely been interested over the last three decades. According to the literature, PRP is an effective and safe treatment in the fields of orthopaedics, dermatology, ophthalmology, and repair of neurological, vascular, and connective tissue damage, but its application in the field of infertility is limited to a few pilot studies in which the effects of PRP on endometrium and recurrent implantation failure (RIF) were investigated.
45372709|NCT03996681|Drug|methylcantharidimide tablets|"Drug: methylcantharidimide tablets~Methylcantharidimide is a single molecule drug used for the treatment of primary liver cancer.~Procedure: TACE~Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor."
45372710|NCT01019655|Drug|Nadroparin calcium|nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
45372711|NCT01019733|Procedure|Intrathecal Autologous Stem Cells|Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 5 times, harvest bone marrow and infused 8 to 10 mL of stem cells (CD34+) by intrathecal via.
45372712|NCT00483717|Drug|Ketorolac tromethamine|31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)
45372713|NCT00483717|Drug|Placebo|Intranasal (IN) placebo
45372714|NCT00406354|Drug|Atomoxetine|Dosage form for the atomoxetine fast and slow titration arms consists of 2.5 mg, 10 mg, 20 mg, 25 mg, and 40 mg capsules. Double-blind treatment will consist of 3 capsules taken once per day for approximately 9 weeks.
45372715|NCT00406354|Drug|Placebo|Double-blind treatment will consist of 3 matching placebo capsules taken once per day by mouth for approximately 9 weeks.
45372716|NCT01037842|Drug|Mitiglinide|"mitiglinide 10 mg three times a day added to metformin 500 mg three times a day~for 16 weeks"
45692758|NCT03159117|Drug|PF-06688992|(PF-06688992) will be administered on Day 1 of each 21-day cycle per the Dose Preparation and Administration Instructions (DAI) located in the Investigational Product Manual (Appendix 4Appendix 3) as an IV infusion over approximately 60 minutes. A cycle is defined as the time from Day 1 dose to the next Day 1 dose. If there are no treatment delays, a cycle will be 21 days. Each patient may receive PF-06688992 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
45692759|NCT01279252|Drug|metronidazole, clarithromycin, ciprofloxacin and lansoprazole|
45692760|NCT03159351|Device|active rTMS treatment|active rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz, intensity=110% motor threshold(MT), times per train=200 seconds, trains=10, duration= 40 seconds, total times=20;localization of right DLPFC: frequency=1 Hz, intensity=100%MT, times per train=30 seconds, trains=10, duration= 10 seconds, total times=20.
45692761|NCT03159351|Device|sham rTMS treatment|sham rTMS treatment protocol parameters: sham rTMS treatment in the localization of left DLPFC and right DLPFC for 30 minutes,total times=20.
45692762|NCT01279330|Other|Co-signed Letter|Patients receive a personalized stimulus letter co-signed by their general practitioner and the medical coordinator of ADECA.
45692763|NCT01279330|Other|Control|No intervention (Patients receive by mail the materials needed for stool samples).
45692764|NCT05701293|Procedure|Endovascular implantation of Renzan Stent|Endovascular treatment of LEAD patients with Renzan Stent
45692765|NCT00739336|Behavioral|Diabetes Prevention and Control|The program will be delivered over 3 months in 12 one hour weekly mid-day sessions at the worksite. The curriculum has been adapted from the Diabetes Prevention Program, the National Diabetes Education Program and Conversation maps from Healthy Interactions Inc. Topics relate to healthy eating, physical activity, coping with disease and depression, and cardiovascular disease prevention. Additional topics may be included per feedback and need of the participants. After completion of the 3 month program, there will be monthly meetings.
46053657|NCT04428723|Diagnostic Test|Continuous glucose monitoring|A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.
45372717|NCT01037842|Drug|Placebo|placebo three times a day added to metformin 500 mg three times a day for 16 weeks
45372718|NCT01037920|Behavioral|Self-affirmation exercise|The intervention exercise asks subjects to reflect on a list of 11 personal values and to circle 2 or 3 items that are most important to them. Subjects are asked then to write a few sentences to describe why they are important.
46053658|NCT04428723|Diagnostic Test|activity monitor|The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days, to assess activity, concurrent with CGM sensor wear.
46053659|NCT04703920|Drug|Talazoparib|Talazoparib will be administered in increasing doses up to 1 mg orally once a day.
46053660|NCT04703920|Drug|Belinostat|Belinostat will be administered in increasing doses up to 1000 mg/m2 IV once daily on days 1-5 of a 21-day cycle.
45372719|NCT01037920|Behavioral|Control|The control exercise is the same as the intervention exercise except that subjects reflect and write about values important to someone else.
45490645|NCT03668444|Behavioral|TXS- Supportive Text Group|TXS participants will receive one treatment supportive text message each day for 30 days.These messages will address three domains 1) Recovery oriented messages, 2) Avoiding relapse and sanctions,and 3) Commitment to family, community and the Drug Treatment Court program. After receiving each text message, participants will receive a second message asking them to reply with a rating of how helpful the original message was. Ratings will use a 5-point Likert scale,ranging from 1-not at all helpful to 5-extremely helpful. Participants will also be asked to describe, via text message, what they liked or did not like about the original message, and suggest a better message for those they did not like.
45490646|NCT03668444|Behavioral|TAU- Treatment As Usual|Participants randomized to the TAU arm of the study will continue to participate in court-ordered treatments as usual with no additional intervention. Participants will receive one motivational text message for the 30-days.
45692766|NCT03158415|Behavioral|T1DToolkit.org mobile diabetes education|"Participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.~Six weeks after enrollment, participants will complete the Modified Diabetes Distress Scale: Parents of Young Adults."
45692767|NCT04385836|Drug|alpha one antitrypsin inhalation|- we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) as nebulizer every 12 hours for 5 days
45692768|NCT04385524|Biological|Adjuvanted Hepatitis B Vaccine|Adjuvanted Hepatitis B vaccine will be provided to healthcare workers previously vaccinated with the standard 3-dose series of Hepatitis B vaccine but who have failed to respond to two complete 3-dose series
45692769|NCT01274260|Drug|methylprednisolone|Subjects in this group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
45372720|NCT00483405|Biological|cetuximab|250 mg/m2, intravenously, once per week
45372721|NCT00483405|Drug|capecitabine|850 mg/m2, orally, twice daily (dose rounded to accommodate 150 mg and 500 mg tablet sizes. Capecitabine given on days 1-14 of 21 day cycle.
45372722|NCT00483405|Drug|oxaliplatin|130 mg/m2, intravenously on Day 1 of each 21 day cycle
45372723|NCT00483327|Drug|Megestrol Acetate|
45372724|NCT01019811|Procedure|The innervated sensory cross-finger flap|The innervated sensory cross-finger flap is a modified method for repair fingertip degloving injury
45490647|NCT03668366|Drug|S-1|The patients will receive IMRT combined with S-1 concurrent chemoradiotherapy. The specific treatment description is included in arm description.
45490648|NCT03668288|Other|Data record and questionnaires passation|Data record and questionnaires passation (SF36)
45490649|NCT04595786|Drug|Tranexamic acid|20mg/kg TXA was prepared in a 50ml syringe for intravenous pump
45490650|NCT04595786|Drug|0.9% saline|0.9% saline was prepared in a 50ml syringe for intravenous pump
45490651|NCT04584164|Device|sialendoscopy|The patients applying the hygiene rule and benifiting in addition a sialendoscopy treatment with a local injection of corticostéroïdes (at the end of the procedure) in the treatment for Xerostomia.
45490652|NCT02108652|Drug|Atezolizumab|Atezolizumab 1200 mg given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria/loss of clinical benefit or unmanageable toxicity.
45490653|NCT01383408|Other|exhalation analysis of breath sample|study participants exhale 5 times into a test tube; test tube is presented to sniffer dogs for analysis
45490654|NCT05419752|Drug|bioceramic sealer|bioceramic based obturating sealer
45490655|NCT05419752|Drug|MTA|MTA based obturating sealer
45490656|NCT05419752|Drug|resin sealer|resin based obturating sealer
45490657|NCT03634085|Drug|BDM-2 in Bottle (50 mg - 3600 mg); oral suspension|BDM-2 in bottle will be reconstituted with a 100 mL vehicle (0.2% Sodium Dodecyl Sulfate and water) to achieve a suspension for oral administration.
45692770|NCT01274260|Drug|Normal Saline (0.9%)|The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline.
45692771|NCT03154983|Drug|docetaxel|Diagnosed with metastatic gastric cancer patients (including the esophagogastric junction adenocarcinoma), DS(docetaxel and Tegafur)and Mesylate apatinib 6 cycles, the specific amount of usage: DS Docetaxel 75mg/m2 D1 IV.drop 1H（one hour）, Tegafur(BSA<1.25 40mg Po bid(twice a day), BSA >=1.25-<1.5 50mg Po bid, BSA >=1.5 60mg Po bid, Q21d(21 days a cycle)); Mesylate Apatinib 500mg Po QD（once a day)） continuous use, until disease deterioration.
46053661|NCT04422795|Device|External thermomechanical device delivering cold and vibration stimuli|the thermomechanical device will be placed on the digit 2 cm proximally to the injection site with the ice wings frozen and the vibration mechanism switched on, delivering vibration and cold stimuli to the area for 30 seconds before the intramatricial injection and until needle withdrawal
46053662|NCT04422795|Device|External thermomechanical device without delivering cold and vibration stimuli|the thermomechanical device will be placed on the digit 2 cm proximally to the injection site with the ice wings at unfrozen and the vibration mechanism switched off, for 30 seconds before the intramatricial injection and until needle withdrawal
45372725|NCT00684203|Drug|Vorapaxar|Oral tablets; single 20-mg or 40-mg loading dose on first day followed by daily 1-mg or 2.5-mg maintenance dose for 59 days
46053663|NCT04422795|Drug|Ethyl chloride skin refrigerant spray|Ethyl chloride skin refrigerant spray is applied to the area of injection for 3 seconds immediately before needle insertion
46053664|NCT04416126|Biological|ARCT-810|ARCT-810 is an investigational medicinal product comprising OTC mRNA formulated in a lipid nanoparticle (LNP) under development.
46053665|NCT04416126|Other|Placebo|The placebo for this study is 0.9% sterile saline.
46053666|NCT04413617|Drug|PF-06650833|400 mg
46053667|NCT04413617|Drug|PF-06651600|100 mg
45372726|NCT00684203|Drug|Placebo|Oral tablets; matching placebo for SCH 530348 loading and maintenance doses for 59 days
46053668|NCT04413617|Drug|Tofacitinib|11 mg
46053669|NCT04408625|Biological|PR006|Participants will receive a single dose of PR006, administered intra cisterna magna
45490658|NCT05419596|Procedure|Urologic Surgery|Patients undergoing major urologic surgery will be examined with blood samples that will be taken preoperatively and postoperatively. Accordingly several gene variants and proteins will be examined for patients with or without postoperative cognitive dysfunction. These proteins consist of APOE, phosphatidyl-inositol-binding clathrin assembly protein, CR1 - complement receptor 1 , ATP-binding cassette transporter, IL6, Triggering receptor expressed on myeloid cells2 (TREM2).
45372727|NCT00684203|Drug|Aspirin|Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.
45372728|NCT00684203|Drug|Clopidogrel|100 mg two or three times daily for 60 days.
45490659|NCT04373148|Other|There is no intervention|There is no intervention
45490660|NCT01381614|Drug|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
45692772|NCT01274416|Behavioral|Acceptance and Commitment Therapy|The stated goal of this intervention is to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in flexible action.
45692773|NCT01274416|Behavioral|Parent Skills Training|Skills Training for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
45692774|NCT03154593|Other|Stage 2 - Bariatric Surgery|This observational study follows patients after routine bariatric surgery.
45692775|NCT00252850|Genetic|CERE-120: AAV2-NTN|
45692776|NCT01983683|Drug|Cadazolid|Cadazolid 250 mg as oral suspension twice daily.
45846796|NCT05079906|Device|Fractional Flow Reserve (FFR)|Fractional Flow Reserve (FFR) for all enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
45846797|NCT05079906|Device|High Definition Intravascular Ultrasound (HD-IVUS)|High Definition Intravascular Ultrasound (HD-IVUS) in addition to FFR for last 50 enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
45846798|NCT05069142|Other|Rehabilitation|Pre- and post-operative exercise and education.
45846799|NCT05058300|Device|CT Thorax|CT Thorax (GE Revolution with chest pain algorithm)
46053670|NCT04408625|Drug|Methylprednisolone|1-2 IV pulses administered as concomitant medication
45372729|NCT00423592|Drug|ambrisentan|All eligible subjects received 2.5 mg ambrisentan once daily for a period of 4 weeks before increasing the dose to 5 mg once daily. After Week 24, investigators were allowed to adjust the dose of ambrisentan as clinically indicated (available doses were 2.5, 5, and 10 mg).
45372730|NCT00752531|Behavioral|Home Automated Telemanagement (HAT)|The HAT was designed as an Internet-based telemedicine system that (1) provides ongoing education to patients about their chronic disease, (2) helps patients follow their self-care plans, and (3) helps health care practitioners monitor their patients' self-management processes according to current clinical guidelines. During each telecommunication session, patients perform self-testing and receive structured disease-specific education, patient-tailored counseling, and advice on how to follow their individual self-care plans based on the current results of self-testing.
45372731|NCT04055987|Behavioral|Visual biofeedback, auditory feedback and models|The EPG software program allows the speech clinician to model and comment upon the visual patterns during tongue/palate contact and to replay the participant's production for additional correction or reinforcement productions. Auditory feedback will be used to facilitate participant's perception of differences in production.
45372732|NCT01037998|Drug|UFUR and Iressa|Iressa 250 mg daily plus UFUR 1# bid
45692777|NCT01983683|Drug|Vancomycin|Vancomycin 125 mg as oral capsules 4 times daily
45692778|NCT01983683|Drug|Cadazolid-matching placebo|Placebo matching cadazolid and administered orally twice daily
46053671|NCT04408625|Drug|Sirolimus|Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
45692779|NCT01983683|Drug|Vancomycin-matching placebo|Placebo capsules matching vancomycin and administered orally 4 times per day
46053672|NCT04408625|Drug|Prednisone|Administered orally as concomitant medication, followed by dose tapering.
46053673|NCT04408625|Drug|Rituximab|Single IV pulse administered as concomitant medication.
46053674|NCT04405115|Behavioral|Geriatric Assessment|Geriatric Assessment Visit
46053675|NCT04371666|Drug|Pamrevlumab|Pamrevlumab per dose and schedule specified in the arm description
46053676|NCT04371666|Drug|Placebo|Matching placebo per schedule specified in the arm description
45372733|NCT00752687|Drug|ABT-072|Capsule or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
45372734|NCT00752687|Drug|placebo|Capsule, or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
45372735|NCT02561429|Procedure|SPT|SPT of histamine concentration 1, 5 and 10 mg/ml
45372736|NCT02561507|Behavioral|Survey|
45692780|NCT05610111|Device|CLC + BAM|Closed Loop Control with the Behavioral Adaption Module for 4 weeks
45692781|NCT05610111|Device|CLC + ABC|Closed Loop Control with Adaptive Biobehavioral Control for 16 weeks
45692782|NCT04405713|Procedure|from the onset of symptoms within the first 3 days|ELC within 3 days of onset of ACC
45372737|NCT00751907|Drug|atorvastatin|40mg daily for 4 months
45372738|NCT00751907|Drug|Placebo|Matching placebo daily for 4 months
45372739|NCT00752843|Drug|mifepristone + fluvastatin|Subjects will receive a single oral dose of 40 mg PO of fluvastatin on three occasions: alone (Day 1), at the same time as a single dose of CORLUX 1200 mg (Day 8) and during concomitant administration of CORLUX 1200 mg/day (CORLUX on Days 8-14, fluvastatin on Day 14).
45372740|NCT00755729|Dietary Supplement|Preoperative Oral Carbohydrate|Patients in OCH group consumed 400 ml Nutricia preOp® (12.5% carbohydrates, 0.5 kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, The Netherlands) 3 hours prior to induction of anaesthesia and finished the ingestion within 1 hour
45372741|NCT00755729|Dietary Supplement|Preoperative Oral Carbohydrate|Patients in FSD group were fasted from midnight the night before surgery, and no preoperative oral carbohydrate loading
45372742|NCT00752921|Drug|etoricoxib|120 mg
45692783|NCT04405713|Procedure|: from the onset of symptoms within the 4-7 days|ELC 4-7days of onset of ACC
45692784|NCT04405713|Procedure|from the onset of symptoms beyond 7 days|ELC after 7days of onset of ACC
45372743|NCT00752921|Drug|placebo|placebo
45372744|NCT04051541|Other|Agitated saline push|Push of agitated saline to simulate adenosine used for supraventricular tachycardia
45372745|NCT00683657|Drug|Saxagliptin|Tablets, Oral, 5mg, once daily, 4 weeks
45372746|NCT00683657|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 4 weeks
45372747|NCT00755885|Drug|abiraterone acetate|
45372748|NCT00755885|Other|laboratory biomarker analysis|
45372749|NCT00755885|Other|pharmacogenomic studies|
45372750|NCT00755963|Drug|estradiol valerate|Progynova® 21; 2mg/d
45372751|NCT00755963|Drug|micronized progesterone|Utrogestan®; 200mg/d
45372752|NCT00755963|Drug|placebo|maltodextrin
45372753|NCT00752999|Drug|Fostamatinib Disodium (R935788)|150 mg tablet, oral, twice-a-day
45372754|NCT00752999|Drug|Placebo|Placebo tablet, oral, twice-a-day
45372755|NCT00756041|Drug|TAK-128|TAK-128 100 mg tablet, orally, once daily for up to 1 year.
45692785|NCT03154515|Drug|Ingavirin|
45692786|NCT03154515|Drug|Placebo|
45692787|NCT04417829|Device|Biological prosthesis in the aortic valve|Transcatheter aortic valve implantation of bioprosthesis in patients with severe symptomatic aortic stenosis (clinically indicated)
45692788|NCT03158103|Drug|MEK162|MEK162 at 30mg twice daily
45372756|NCT00753155|Behavioral|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day; psychosocial support
45372757|NCT00756197|Device|Cryo Spray Ablation Group 1|Cryo Spray Ablation
45372758|NCT00756197|Device|Cryo Spray Ablation Group 2|cryo spray ablation
45372759|NCT00753311|Drug|rizatriptan or placebo|Patient took 1 rizatriptan 10 mg wafer or placebo as soon as their migraine headache became of moderate or severe intensity.
45372760|NCT00756431|Device|Hip Fracture reduction Screw without HA Coating (Hiploc)|Hip Fracture reduction Screw without HA Coating (Hiploc)
45692789|NCT03158103|Drug|Pexidartinib|pexidartinib 600mg daily (400mg in the morning, 200mg at night) for 4 weeks (1 cycle)
45372761|NCT00756431|Device|Hip Fracture reduction Screw with HA Coating (Hiploc)|Hip Fracture reduction Screw with HA Coating (Hiploc)
45372762|NCT00756587|Device|Cup Feeding|using a cup feeding technique for feeding the preterm infants during NICU stay
45372763|NCT00756587|Device|Bottle Feeding|receiving all feeding by bottle
45372764|NCT00756743|Drug|PF-04802540|Multiple ascending doses for 10 days; planned doses include 5, 10 and 15 mg capsules q12 hours, doses may be adjusted based on accumulating data
45372765|NCT00756743|Drug|Placebo|Placebo capsules q12 hours for 10 days
45372766|NCT00753389|Other|None (anesthesia)|anesthesia
45372767|NCT00753467|Drug|IFN-γ 1b (Actimmune)|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose
45692790|NCT03581799|Other|Oral dispersible tablet|Administration of a 5 mm calcium carbonate based ODT placed in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
45372768|NCT00753467|Drug|Adefovir dipivoxil|Adefovir dipivoxil: 1 tablet of 10mg given orally QD
45372769|NCT00753467|Drug|IFN-γ 1b and Adefovir dipivoxil combination|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose Adefovir dipivoxil: 1 tablet of 10mg given orally QD
45372770|NCT00482703|Drug|Dasatinib|tablets, Oral, 100 mg, once daily
45372771|NCT00482703|Drug|dasatinib|tablets, Oral, 50 mg, twice daily
45372772|NCT00757055|Drug|Ivabradine|Ivabradine titrated to heart rate starting at 5 mg bd and increasing to maximum of 7.5 mg bd or reducing to 2.5 mg if heart rate < 60 bpm.
45372773|NCT00757055|Drug|Placebo|No active treatment given
45372774|NCT04052867|Drug|Lignocaine|Slow bolus of lignocaine is given over 15 min before the start of surgery, followed by infusion of lignocaine
45372775|NCT04052867|Drug|Normal saline|An equivalent volume of normal saline is given
45372776|NCT00757133|Procedure|Conventional laparotomy closure|Recommended technique: The laparotomy is closed with a slowly resorbable running suture (f.e. PDS) in a single layer. The length of the suture should approximately be four (4) times the length of the fascial incision. The skin is closed with the usual technique of the department
45692791|NCT03158025|Drug|Zolpidem tablets|Zolpidem 3 x 10 mg tablets will be administered orally.
45372777|NCT00757133|Procedure|Laparotomy closure with mesh augmentation|"Recommended technique: Mesh augmentation can be done in a retromuscular or a prefascial position. By consensus of the initial primary investigators a retromuscular (sublay) position of the mesh was chosen and as a mesh a light weight polypropylene mesh will be used. Retromuscular (sublay): (see reference no. 11: Rogers et al.) At the end of the vascular procedure the plane behind the rectus muscles (retromuscular-preperitoneal) is dissected as in a Stoppa repair for incisional hernias"
45372778|NCT00482391|Biological|trastuzumab|
45372779|NCT00482391|Drug|cyclophosphamide|
45372780|NCT00482391|Drug|doxorubicin hydrochloride|
45372781|NCT00482391|Drug|lapatinib ditosylate|
45372782|NCT00482391|Drug|paclitaxel|
45372783|NCT00482391|Other|laboratory biomarker analysis|
45372784|NCT00753779|Drug|colesevelam HCl tablets, and simvastatin tablets|colesevelam HCl tablets, 6/day simvastatin tablet, 1/day
45372785|NCT00753779|Drug|simvastatin tablets and colesevelam HCl placebo|simvastatin tablet, 1/day; Welchol placebo tablets, 6/day
45372786|NCT00757211|Genetic|polymorphism analysis|
45372787|NCT00757211|Other|laboratory biomarker analysis|
45372788|NCT00757211|Other|questionnaire administration|
45372789|NCT00757289|Biological|PRP Injection|PRP Injection
45372790|NCT00757289|Biological|Corticosteroid Injection|Corticosteroid Injection
45372791|NCT00757367|Drug|TI Inhalation Powder|1 60-U dose of TI Inhalation Powder before the bronchoscopy. Cohort 1 will undergo bronchoscopies at 30 minutes and again at 6 hours after the 60-U dose inhalation of TI Inhalation Powder. Cohort 2 bronchoscopies will occur at 4 hours and again at 8 hours after TI Inhalation Powder. The need to run and the timepoints for bronchoscopies for Cohort 3 will be determined based on the results from Cohort 1 and 2. All subjects will undergo 2 bronchoscopies at Visit 2.
45372792|NCT00757523|Drug|Epiduo Gel|Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
45372793|NCT00757523|Drug|Duac Gel|Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
45372794|NCT00753857|Other|Drug Facts Box|Educational intervention of 1 page summary of drug efficacy and side effects
45372795|NCT00753857|Other|Standard Brief Summary|Ads consisted of the standard second page called the brief summary
45372796|NCT00423046|Biological|GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)|Three doses administered intramuscularly at months 0, 1 and 6
45372797|NCT00423046|Biological|Gardasil ® (Merck & Co. Inc)|Three doses administered intramuscularly at months 0, 2 and 6
45372798|NCT00423046|Biological|Placebo|One dose administered intramuscularly at month 1 to maintain blinding
45372799|NCT00423046|Biological|Placebo|One dose administered intramuscularly at month 2 to maintain blinding
45372800|NCT00757679|Drug|Milnacipran|capsules
45372801|NCT00757679|Drug|Placebo|capsules
45372802|NCT02561351|Other|FeNO measurement|FeNO was performed repeatedly every 3 months in every cases. exacerbations were recorded each visit
45372803|NCT00754091|Device|Polymer based lubricating liquid|three sprays of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
45692792|NCT03158025|Drug|Suvorexant tablets, over-encapsulated|Suvorexant 2 x 20 mg tablets, over-encapsulated, will be administered orally.
45372804|NCT00496587|Drug|Capecitabine|800 mg/m^2 By Mouth Twice Daily On Days 1-21.
45372805|NCT00496587|Drug|Gemcitabine|900 mg/m^2 By Vein Over 30 Minutes on Days 1 and 15.
45372806|NCT00496587|Drug|Bevacizumab|10 mg/kg By Vein On Days 1 and 15.
45372807|NCT00757835|Drug|treatment with latanoprost/timolol fixed combination|dosing in the evening with the two fixed combinations
45372808|NCT00757835|Drug|latanoprost/timolol fixed combination drops|once in the evening
45372809|NCT04052633|Radiation|intraoperative cholangiography|success or failure of cholangiography
45372810|NCT01038076|Behavioral|MedCHEC Tablet Computer & Adherence Care|Patients answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates patient and provider reports. Patients may be referred to an Adherence Care Manager on the basis of the reports.
45372811|NCT00757913|Dietary Supplement|n-3 enriched nutrition|
45372812|NCT01038154|Drug|Pravastatin|Receive one tablet of 40 mg of pravastatin, orally every 24 hours (at breakfast) for 2 years.
45372813|NCT02560727|Device|transendoscopic enteral tubing|Investigators designed transendoscopic enteral tubing (TET).The enteral segment of the tube is fixed in the ileocecum with distal segment fixed buttocks. The tube was used for FMT and colonic local administration
45372814|NCT02560727|Device|colonoscope|FMT via colonoscope is the most common approach.
45372815|NCT00757991|Genetic|polymorphism analysis|
45372816|NCT00757991|Other|laboratory biomarker analysis|
45372817|NCT00757991|Other|questionnaire administration|
45372818|NCT00405652|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|experimental
45372819|NCT04052321|Other|3D optical surface scan|A 3D optical surface scan is acquired utilizing a handheld 3D scanner. Such a scanner is comparable to an ordinary photo camera, however, it also records depth.
45692793|NCT03158025|Drug|Lemborexant tablets|Lemborexant 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg tablets will be administered orally.
45490661|NCT03729323|Behavioral|Motivational interviewing|In Diabetes and hypertension, nursing consultations to support the care should be focused on their educational component the orientation of measures that prove to reduce blood pressure, improve the glycemic indices, the lipid profile and the Cardiovascular risk classification, among them: adherence to drug therapy, proper diet, body weight maintenance, stimulating active life and regular physical exercise, reducing alcoholic beverage consumption, reducing stress and abandoning Smoking. In this group, these care will be addressed based on the principles and techniques of the Motivational Interviewing.
45372820|NCT01324180|Drug|Metformin|Will be dosed orally BID as per dose level of subject as defined in dose escalation schema. Both liquid and tablet forms are allowed and can be chosen based on convenience. Metformin will be continued throughout the cycle until Day 28 or until the patient is removed from study (e.g. to pursue new lines of therapy such as transplant), whichever occurs sooner.
45692794|NCT03158025|Drug|Placebo lemborexant|Placebo 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg lemborexant tablets will be administered orally.
45692795|NCT03158025|Drug|Placebo zolpidem|Placebo 3 x 10 mg zolpidem tablets will be administered orally.
45372821|NCT01324180|Drug|Vincristine|1.5 mg/m^2/dose IV push (maximum single dose 2 mg) on days 2, 9, 16 and 23
45372822|NCT01324180|Drug|Dexamethasone|"10 mg/m^2/day divided BID~Take dexamethasone by mouth days 2-15"
45372823|NCT01324180|Drug|PEG-asparaginase|"2500 IU's/m^2/day~Intramuscular injection (IM) or intravenous infusion per institutional standard on days 3, 9, 16 and 23~If the patient develops an allergic reaction to PEG while being treated on this protocol, eliminate all future doses of PEG and substitute Erwinia if not intolerant of Erwinia and has no history of pancreatitis.~Patients will receive Erwinase® 25,000 IU/m^2 x 6 doses intramuscularly (IM) on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase on the original protocol."
45372824|NCT01324180|Drug|Doxorubicin|60 mg/m^2/day IV over 15 minutes on day 2
45372825|NCT01324180|Drug|Intrathecal chemotherapy|"IT cytarabine given intrathecally to all patients on day 1 of each cycle. Dose defined by age. May be given with staging lumbar puncture before enrollment, but must be within 72 hours of starting therapy. If not done at study entry or before, may be done on Day 2 prior to doxorubicin administration.~30 mg for patients age 1-1.99~50 mg for patients age 2-2.99~70 mg for patients greater than 3 years of age IT methotrexate given Intrathecally to all patients who are CNS negative at study entry on day 16 at the dose defined by age."
45692796|NCT03158025|Drug|Placebo suvorexant|Placebo 2 x 20 mg suvorexant tablets, over-encapsulated, will be administered orally.
45372826|NCT02560649|Drug|Peginterferon alfa-2a plus Entecavir|Peginterferon alfa-2a 180μg /wk plus Entecavir 0.5mg qd for 48 weeks(Arm A and B)
45372827|NCT02560649|Drug|Peginterferon alfa-2a plus Lamivudine|Peginterferon alfa-2a 180μg /wk plus Lamivudine 0.1g qd for 48 weeks(Arm A and B)
45372828|NCT02560649|Drug|Peginterferon alfa-2a plus Adefovir|Peginterferon alfa-2a 180μg /wk plus Adefovir 10mg qd for 48 weeks(Arm A and B)
45372829|NCT02560649|Drug|Peginterferon alfa-2a plus Tenofovir|Peginterferon alfa-2a 180μg /wk plus Tenofovir 300mg qd for 48 weeks(Arm A and B)
45692797|NCT01998893|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse
45846800|NCT04922190|Behavioral|Physical Activity Coaching|Participants will receive up to 5 coaching sessions by a physical or occupational therapist. The intervention will focus on facilitating physical activity engagement and development of specific and measurable goals. The recommended program will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. At the follow up sessions the therapist will review progress with the current exercise plan and progress and discuss barriers and facilitators for exercise engagement. Participants will have the option to use a Fitbit or other device to monitor their heart rate and physical activity during the course of the intervention period.
45372830|NCT02560649|Drug|Entecavir|Entecavir 0.5mg qd for 24 weeks(Arm C)
45372831|NCT02560649|Drug|Lamivudine|Lamivudine 0.1g qd for 24 weeks(Arm C)
45372832|NCT02560649|Drug|Adefovir|Adefovir 10mg qd for 24 weeks(ArmC)
45372833|NCT02560649|Drug|Tenofovir disoproxil|Tenofovir 300mg qd for 24 weeks(Arm C)
45372834|NCT00758147|Device|Exercise with force feedback joystick|System consists of a commercially available force feedback joystick, and specially written software. Patients will work with the system 5 times a week for 4 weeks, a half hour each time, 2 weeks with visual and haptic feedback and 2 weeks without the feedback.
45372835|NCT04052165|Procedure|Glaucoma Implant|
45372836|NCT04052009|Other|Conventional gait training|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
45372837|NCT04052009|Other|End-effector based gait training|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
45372838|NCT04052009|Other|combined training (conventional and end-effector-based)|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
45372839|NCT00754403|Drug|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
45490662|NCT03729323|Behavioral|Nursing Consultation|In Diabetes and hypertension, nursing consultations to support the care should be focused on their educational component the orientation of measures that prove to reduce blood pressure, improve the glycemic indices, the lipid profile and the Cardiovascular risk classification, among them: adherence to drug therapy, proper diet, body weight maintenance, stimulating active life and regular physical exercise, reducing alcoholic beverage consumption, reducing stress and abandoning Smoking. In this group, these care will be approached in a conventional manner, as routine of the services, based on the recommendations of the Primary Care Strategy Notebooks for the care of chronic conditions in DM2 and SAH and the SSC-GHC Institutional Protocol for SAH and DM2 Patient Care.
45372840|NCT00754403|Drug|Metformin|Pioglitazone placebo-matching tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
45372841|NCT00754481|Other|Normothermia|Patients randomized to the Normothermia arm (esophageal temp 36.5-37.5 ºC) were maintained at an esophageal temperature of 36.5-37.5ºC for 48 hours. Patients who were hypothermic (temperature < 35 ºC) when randomized to the normothermia group were rewarmed slowly using the servo-controlled mattress. Patients who were hyperthermic following randomization to the normothermia group were actively cooled to normothermia using the servo-controlled mattress. Neuromuscular blockers were administered as needed intravenously in both groups of patients to prevent shivering.
45490663|NCT01381536|Drug|GSK1550188 1mg/kg or 10mg/kg|IV one shot
45490664|NCT02676778|Drug|E7777|
45490665|NCT03160924|Other|Enhanced Recovery After Surgery (ERAS)|"same as above as described in the arms."
45490666|NCT01381458|Drug|FSC|fluticasone propionate / salmeterol xinofoate combination
45490667|NCT01381458|Drug|ACs|tiotropium alone, ipratropium alone, or in combination with albuterol
45490668|NCT05419440|Procedure|laparoscopic drainage of appendicular abscess|access to caecum and remove any adhesions with surrounding by sharp & blunt dissection , then access to appendicular abscess by sharp and blunt dissection after complete separation of the appendix from surrounding & complete drainage of pus & removal of all necrotic tissue , removal of the remnant appendix , in cases with healthy base of appendix ,we closed the stump with endo-loop , in case with unhealthy base , we closed the stump by suturing by ethibond 2/0 in two layers in case with little edema & inflammation of caecum ( sutures not cut through ) , in cases with marked edema and inflammation of caecum , we close the site of base by omental patch fixed by taking full thickness sutures in wall of caecum and pass through omental patch , we examine any leak by pressing on caecum and observe any fecal matter comes & air leak test , in all cases we put large drain at pelvis
45692798|NCT01791985|Drug|AZD4547 / anastrozole or letrozole|"Patients will continue or restart the NSAI which they have progressed* on: either anastrozole (1mg) or letrozole (2.5mg), orally, once daily but together with twice daily AZD4547 (80mg).~AZD4547 will be given on an intermittent schedule of one week on / one week off.~*Prior to study entry, patients must have taken anastrozole or letrozole at some stage in their treatment to date for breast cancer; and shown evidence of resistance to this therapy. The NSAI does not have to be the most recent line of treatment."
45692799|NCT03157869|Device|Transcranial Direct Current Stimulation|Anodic tDCS during 20 minutes ON, intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
45692800|NCT03157869|Other|Simulated|Simulated anodic tDCS (only 30 seconds ON), intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
45692801|NCT04664621|Diagnostic Test|HepQuant|Patients undergoing TIPS procedure will receive a HepQuant test prior to and then after TIPS.
45692802|NCT04176497|Drug|68Ga-HBED-CC-PSMA|Radioactive tracer used during imaging to help detect PSMA expressing tumor cells.
45372842|NCT00754481|Other|Hypothermia|Patients randomized to the Hypothermia arm (esophageal temp 33º to 34 °C) were cooled rapidly using the cooling protocol developed for the Hypothermia Paediatric Head Injury Trial. A temperature probe was placed in the esophagus and its position confirmed using a chest radiograph. Patients were placed on a servo-controlled cooling blanket and covered in crushed ice (in sealed plastic bags covered by pillow cases) and a second cooling blanket. Once the esophageal temperature reached 34.0ºC, the ice and second cooling blanket was removed and esophageal temperature was maintained at 33º to 34 °C for 48 hours using the servo-controlled cooling mattress. Patients treated with ECMO were cooled using the extracorporeal circuit cooling-device. Rewarming was done at a rate of 0.5 ºC every 2 hours until an esophageal temperature of 36.5 ºC was reached. Thereafter temperature was recorded but not controlled by surface cooling.
45372843|NCT02560571|Device|ultrasound|
45372844|NCT02560571|Other|blood test|
45372845|NCT00758225|Drug|Idebenone|Patients ≤ 45 kg: 450 mg/day (1 tablet 3 times a day) Patients > 45 kg: 900 mg/day (2 tablets 3 times a day)
45692803|NCT03157947|Behavioral|Decision Aid Tool|Subjects will be given an I-pad with the decision aid program on it. A member of the study team will enter some preliminary information, then the subject will be able to review the tool with his doctor.
45692804|NCT03157947|Behavioral|baseline survey|patients will be given baseline surveys to gather demographic information and readiness to make a decision regarding prostate cancer care
45692805|NCT03157947|Behavioral|follow-up surveys|at 3, 6, 9, and 12 months patients will be given follow-up surveys regarding prostate cancer care
45692806|NCT02665377|Drug|ANP|
45692807|NCT02665377|Drug|Placebo|
45692808|NCT03154437|Biological|Emicizumab|Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) per week subcutaneously (SC) for 4 weeks, followed by a maintenance dose of 1.5 mg/kg per week SC thereafter. Treatment with emicizumab will continue until unacceptable toxicity, withdrawal of consent, participant or physician decision to discontinue treatment, death, the participant is able to obtain commercial drug after emicizumab becomes commercially available, or the sponsor decides to discontinue emicizumab clinical development, whichever occurs first.
45692809|NCT05703087|Behavioral|Positive cueing in the information video before a primary TKA|Two weeks before the surgery, in the outpatient clinic (during their preoperative appointment), the pre-surgery information video was shown to the patients. Patients were randomly allocated to either the positive cueing group (intervention) or the standard care group (control) with Castor EDC (14) using a variable block randomization model. Patients did not know whether they watched the adapted video or the standard video.
45846801|NCT04872660|Drug|Gushen Antai Pill|The Gushen Antai Pill (GSATP, Z20030144) is composed of 10 herbs including radix-polygoni multiflori, radix rehmanniae praeparata, cistanche salsa, radix dipsaci, uncaria, semen cuscutae, rhizoma atractylodis macrocephalae, radix scutellariae, radix paeoniae lactiflorae. Its production follows GMP standards and takes the form of water honey pills, each bag of 6g.
45372846|NCT00754715|Drug|AZD2516|Solution administered once orally
45372847|NCT00754715|Drug|Placebo|Solution administered only once
45372848|NCT02561039|Drug|Ibandronate|Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.
45372849|NCT00422734|Drug|tadalafil|5 mg tadalafil tablet taken by mouth once a day for 12 weeks
45372850|NCT00422734|Drug|Placebo|placebo tablet taken by mouth once a day for 12 weeks
45372851|NCT02560415|Device|Experimental|Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
45372852|NCT02560415|Behavioral|Comparator|Treatment as usual
45490669|NCT05746156|Diagnostic Test|lymphatic mapping|"Peritumoral injection of [99mTc]Tc-nanocolloid in 6-8 evenly distributed depots on both sides of the tumor, during investigation under anaesthesia. Number of depots depending on the size and localisation of the tumor.~Planair and SPECT/CT imaging van de abdomen/pelvis 3h and 12-24h after injection at the department of radiology and nucleair medicine."
45490670|NCT05419284|Other|GAPP+Care|"standard physiotherapy 45 minutes per day, 5 day a week (GAPP)~+ 3 extra exercise sessions led by a caregiver (+Care)"
45490671|NCT05419284|Other|+Care|"3 extra exercise moments led by a caregiver: one physiotherapist-caregiver-patient exercise session: the physiotherapist will educate and train the caregiver on the exercises and hands-on skills.~Two caregiver-patient exercise sessions"
45490672|NCT05419284|Other|Observation of GAPP+Care|Healthcare workers in the geriatric rehabilitation ward will be interviewed on their opinions on GAPP+Care
45490673|NCT05179486|Procedure|Biospecimen Collection|Undergo collection of tissue, and blood
45692810|NCT01791517|Other|Solution 1 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to all four lens care solution in a random order
45692811|NCT01791517|Other|Solution 2 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
45692812|NCT01791517|Other|Solution 3 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
45372853|NCT03916198|Drug|Polydeoxyribonucleotides|Just after arthroscopic rotator cuff repair, 3cc polydeoxyribonucleotide will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
45372854|NCT03916198|Drug|Normal saline|Just after arthroscopic rotator cuff repair, 3cc normal saline will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
45372855|NCT00422422|Drug|Brivaracetam|"Oral solution~Evaluation period (3 weeks up-titration):~For subjects ≥8 years:~~0.4 mg/kg bid for Week 1~~0.8 mg/kg bid for Week 2~~1.6 mg/kg bid for Week 3~For subjects <8 years:~~0.5 mg/kg bid for Week 1~~1.0 mg/kg bid for Week 2~~2.0 mg/kg bid for Week 3~Down-titration period (up to 2 weeks):~For subjects ≥8 years:~~0.8 mg/kg bid for Week 4~~0.4 mg/kg bid for Week 5~For subjects <8 years:~~1.0 mg/kg bid for Week 4~~0.5 mg/kg bid for Week 5"
45372856|NCT00413374|Drug|Enoxaparin|Patient takes 1.5 mg per kilogram, once daily, subcutaneous injections until INR is therapeutic, then medication is stopped.
45490674|NCT05179486|Other|Questionnaire Administration|Complete questionnaire
45692813|NCT01791517|Other|Solution 4 (Control)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
45846802|NCT04872660|Drug|Placebo pill|The placebo pill is produced by Beijing boran Pharmaceutical Co., Ltd. It can simulate the appearance, color and smell of GSATP formula, but it has no clinical effect because it has no active ingredients.
45490675|NCT05419206|Diagnostic Test|CMV DNA analysis|CMV DNA quantitative viral load levels were studied
45372857|NCT00682643|Drug|fluticasone furoate nasal spray|fluticasone furoate nasal spray
45372858|NCT00682643|Drug|vehicle placebo nasal spray|placebo
45372859|NCT00758381|Drug|Sorafenib 400 mg po bid, continuously|"NEXAVAR*112CPR RIV 200MG~Titolare AIC:~BAYER SpA~Numero di AIC dell'IMP:~037154010"
45372860|NCT00758381|Drug|Gemcitabina, Cisplatino|Gemcitabina 1000 mg/mq, Cisplatino 25 mg/mq day 1 and 8 every 21 days
45372861|NCT05436119|Dietary Supplement|GrowBaby|Virtual group educational visits will cluster women in the same trimester of pregnancy teaching trimester-specific diet and lifestyle modification, further customized to the individual using limited micronutrient and gene variant analysis. Each woman will receive base multi-nutrient and probiotic supplementation with customization if identified needs cannot be met with diet and lifestyle modification alone.
45372862|NCT00754871|Drug|Dienogest (81150037)|daily oral intake of 0.5 mg dienogest over two cycles or a max. of 72 days
45692814|NCT01998581|Device|JUVEDERM VOLBELLA® XC|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL. Up to 6.0 mL allowed for repeat treatment.
45692815|NCT01998581|Device|Restylane-L®|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL.. Up to 6.0 mL allowed for repeat treatment.
45372863|NCT00754871|Drug|Dienogest (81150231)|daily oral intake of 1.0 mg dienogest over two cycles or a max. of 72 days
45372864|NCT00754871|Drug|Dienogest (SH T00660A)|daily oral intake of 2.0 mg dienogest over two cycles or a max. of 72 days
45372865|NCT00754871|Drug|Dienogest (81150746)|daily oral intake of 3.0 mg dienogest over two cycles or a max. of 72 days
45372866|NCT00755027|Drug|Rasagiline|rasagiline 1 mg daily, oral use, during 12 weeks
45372867|NCT05435807|Behavioral|Therapeutic Neuroscience Education|Therapeutic Neuroscience Education (TNE) is an intervention used by physiotherapists, which can be defined as a cognitive behavioral therapy method. By helping patients better understand the biological process that underlies their painful condition, it aims to achieve therapeutic effects such as reducing pain and the fear associated with musculoskeletal injuries and increasing movement and functionality.
45490676|NCT05746000|Behavioral|Intervention Group (IG)|Three individual diet counselling that includes sugar calculation (sugar exchange) (60 minutes per session) at baseline, week-4 and week-8.
45490677|NCT05746000|Behavioral|Control Group (CG)|Three individual diet counselling (60 minutes per session) at baseline, week-4 and week-8.
45692816|NCT03154203|Other|No intervention in this study|No intervention in this study
45692817|NCT03581565|Other|zinc polycarboxylate (with the requirements of ISO 9917)|intraoral cementation of single-tooth implant crowns with three different technique, intraoral removal of cement excess upon setting
45846803|NCT04835766|Diagnostic Test|Urodynamic study|Uroflowmetry, voiding cystometrogram, maximum flow rate (Qmax) and detrusor pressure at maximum flow (Pdet Qmax).
45846804|NCT04820790|Other|Mobile applications|Monitoring of patients with home oxygen through a mobile application
45846805|NCT04511052|Dietary Supplement|Probiotic|Daily intake of 10 x 10^9 CFU of a proprietary strain for a total duration of 10 weeks
45372868|NCT00421408|Dietary Supplement|Whey protein supplement|40-g whey protein supplement daily for 18 months
45372869|NCT00421408|Dietary Supplement|Placebo|Placebo supplement daily for 18 months
45372870|NCT02560337|Drug|Cabazitaxel|
45692818|NCT03154281|Drug|niraparib|Niraparib 100 mg will be administered orally once daily continuously. Niraparib will be administered as a flat-fixed dose (100mg, 200 mg, or 300 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.
45692819|NCT03154281|Drug|everolimus|Everolimus 5 mg tablets will be used. Everolimus will be self-administered orally on a daily basis and doses will either be 5 mg (1 tablet) thrice weekly or 5 mg daily depending on the cohort the patient is enrolled to. Each cycle will be 28 days; everolimus will be taken continuously with no rest between cycles.
45372871|NCT05435729|Drug|DSP-9632P 27.5 mg|Single dose of DSP-9632P 27.5 mg
45372872|NCT05435729|Drug|DSP-9632P 82.5 mg|Single dose of DSP-9632P 82.5 mg
45372873|NCT05435729|Drug|Placebo|Placebo for DSP-9632P
45692820|NCT03157791|Drug|Simethicone 180Mg Cap|Simethicone Group A will take a total of 360mg prior to colonoscopy of Simethicone 180Mg Cap.
45692821|NCT01983293|Device|QLV based implant strategy|
45372874|NCT05435729|Drug|DSP-9632P 55.0 mg|Multiple dose of DSP-9632P 55.0 mg
45372875|NCT05435729|Drug|Levodopa formulation|Single dose of Levodopa formulation
45372876|NCT01038388|Drug|Bortezomib|1.3mg/m² given IV or subcutaneously
45372877|NCT01038388|Drug|Lenalidomide|25 mg given PO
45692822|NCT01983293|Device|Standard of care implant strategy|
45846806|NCT04511052|Other|Placebo|1 capsule daily containing the same carrier material that is similar in size, shape and taste to the probiotic, for a duration of 10 weeks
45372878|NCT01038388|Drug|Dexamethasone|20 mg given PO
45372879|NCT01038388|Drug|Vorinostat|100, 200, or 300 mg given PO
45372880|NCT02560259|Other|Physiotherapy|Physiotherapy
45372881|NCT02560259|Other|Conservative treatment|Conservative treatment
45846807|NCT04511052|Dietary Supplement|Carotenoid supplement|1 capsule daily containing ~20 mg of total carotenoids for a total duration of 10 weeks
45846808|NCT04444050|Drug|BMS-986331|Specified dose on specified days
46053677|NCT04371666|Drug|Corticosteroids|Systemic deflazacort or equivalent potency of corticosteroids administered orally
46053678|NCT04343274|Drug|Tozuleristide|
45846809|NCT04444050|Other|Placebo, Matching BMS-986331|Specified dose on specified days
45846810|NCT04225416|Other|Questionnaire/Structured Interview|No intervention
45846811|NCT03693846|Drug|Nivolumab|IV infusion per institutional guidelines and the Package Insert
45846812|NCT03693846|Drug|Ipilimumab|IV infusion per institutional guidelines and the Package Insert
45846813|NCT03529890|Drug|Nivolumab|"Experimental intervention:~Immunotherapy with 4 cycles of Nivolumab: 240 mg intravenously every 2 weeks, starting one week before radiotherapy (week1, d1), last infusion on week 7, d1"
45846814|NCT03529890|Radiation|Radiation therapy of the pelvis|Neoadjuvant radiation therapy of pelvis with 45+5,4 Gy for 6 weeks: 28 x 1.8 Gy including a boost of bladder with 5.4 Gy, starting with week 2 (d1)
46053679|NCT04318327|Biological|PHE885|Infusion
46053680|NCT04248257|Behavioral|PeACE|3 session peer coaching intervention
45372885|NCT05435183|Device|Non-invasive high-frequency oscillatory ventilation|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
45372886|NCT05435183|Device|Noninvasive Bilevel Positive Pressure Ventilation|Noninvasive Bilevel Positive Pressure Ventilation
45372887|NCT04050059|Drug|EMLA cream|EMLA cream (5g tube Aspen pharma trading limited) will be applied topically in dose of 2.5 grams (half tube of cream) and area will be covered with tegaderm dressing. Application of EMLA will at least stay for 30 minutes before spinal needle insertion
46053681|NCT04248257|Behavioral|Community peer coaching|Peer coaching provided by community organizations that support the HBOC community
45372888|NCT04050059|Drug|2% lidocaine|In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited), skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60 mg) before spinal needle insertion
45372889|NCT05435105|Behavioral|Virtual reality|Distraction method
45372890|NCT05435105|Behavioral|Local cold-vibration|Distraction method
45372891|NCT00679913|Procedure|Standard pancreatoduodenectomy|Standard pancreatoduodenectomy
45372892|NCT00679913|Procedure|Extended pancreatoduodenectomy|Extended pancreatoduodenectomy
45372893|NCT05434949|Diagnostic Test|Blood test|"Three blood samples to be taken at 08.00, 10.00 and 12.00 on day 1 of the study.~The following day, after an overnight fast, a blood sample will be taken at 8.00, followed by a standardized breakfast provided by the study team at 8.30, and then two further blood samples at 10.00 and 12.00."
46053682|NCT04244123|Combination Product|integrated information and nurse led telephone clinic|combining web-based information from easypod connect with nurse led telephone clinic
46053683|NCT04242446|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
46053684|NCT04242446|Other|Placebo|Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
46053685|NCT04233086|Other|No intervention, observational only|No intervention, observational only
45692823|NCT05701059|Procedure|Cervical arthroplasty|A joint replacement procedure administered by inserting an artificial disc between the vertebrae to replace a natural spinal disc after it has been removed.
45372894|NCT05434949|Other|Analyses of samples|C4 will be measured in surplus serum from 30 adult lipid patients before starting on lipid-lowering therapy (either statin of PCSK9 therapy) and then again 3 months after starting on therapy. Blood samples will be collected as part of routine lipid management, no additional samples are required.
45692824|NCT05701059|Device|Semi-Constrained Nuvasive Simplify|This weight-bearing implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile zirconia toughened alumina (ZTA) ceramic core will be administered by cervical arthroplasty into the specified single-level cervical region.
45372895|NCT02150967|Drug|BGJ398 (infigratinib)|Capsule for oral use
45692825|NCT05701059|Device|Unconstrained Biomet Zimmer Mobi-C|This unconstrained, three-piece implant will be administered by cervical arthroplasty into the specified single-level cervical region.
45372896|NCT02560103|Other|Transmeridian travel across multiple time zones|
45372897|NCT00482001|Drug|donepezil|
45372898|NCT00482001|Drug|Placebo (cornstarch)|
45372899|NCT00490035|Other|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period
45372900|NCT00490035|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period
45692826|NCT04765293|Other|Physical Therapy|Physical Therapy Gravity strengthening exercises vs standard physical therapy
45692827|NCT03157479|Drug|Intravenous anesthetic|Anaesthesia induction will be obtained with i.v. 2-3 mg/kg propofol, 0,6-0,8 mcg/kg fentanyl, and 0.9-1,2 mg/kg rocuronium. Anaesthesia will be maintained with i.v. propofol continuous infusion, with a dose titrated to achieve a bi-spectral index value between 40 and 50
45692828|NCT03157479|Drug|Crystalloid Solutions|Balanced crystalloids will be administered to patients in both groups as a standard rate of 3-5 ml/kg/h. Treatment of eventual hemodynamic instability will be left to the attending physician
45846815|NCT03529890|Procedure|Radical cystectomy with standardized pelvic lymphadenectomy|Radical cystectomy with standardized bilateral pelvic lymphadenectomy: performed between week 11 - 15 (Aim: week 13)
46053686|NCT04231760|Drug|Inhaled Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
46053687|NCT04231760|Drug|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
45692829|NCT03157479|Diagnostic Test|Esophageal pressure measurement|A nasogastric polyfunctional tube (Nutrivent, Sidam, Italy) will be placed after anaesthesia induction in all enrolled patients to measure esophageal pressure, estimate pleural pressure and compute transpulmonary pressure
45692830|NCT03157479|Diagnostic Test|Lung volume measurement with the nitrogen washin-washout technique|Lung volume will be measured through nitrogen wash-in wash-out technique and low-flow Pressure-volume curve will be recorded to estimate differences in alveolar recruitment between the two study groups.
46053688|NCT04218565|Biological|Golimumab (GOL)|Patients with refractory BD associated uveitis will receive Golimumab therapy, the efficacy and corticosteroids-sparing effects will be evaluated.
46053689|NCT04193449|Diagnostic Test|colonoscopy|colonoscopy procedure
46053690|NCT04193293|Drug|Duvelisib|Phosphoinositide 3-kinase (PI3K) Inhibitor
46053691|NCT04193293|Biological|Pembrolizumab|Immunotherapy (programmed cell death protein 1 [PD-1] inhibitor)
45372901|NCT00490035|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.
45372902|NCT00490035|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.
45372903|NCT01014897|Device|tDCS|tDCS and sham will be applied in random order during standardized occupational therapy
45372904|NCT01016457|Device|Guardian RT|The sensor is inserted similarly to the insulin pump. It measures sub cutaneous glucose every 5 minutes. It alerts of high and low glucose levels, according to set limits.
45490678|NCT03162406|Dietary Supplement|Vitamin D3|Oral supplementation 25000 IU once per week for 6 months
45490679|NCT03162406|Dietary Supplement|Placebo|Oral supplementation once per week for 6 months
45372905|NCT00404248|Drug|terameprocol|terameprocol will be given IV 5 consecutive days every 28 days. Starting dose 750mg/day. Cohorts of 3pts. A Dose Limiting Toxicity (DLT) target rate of Less than or equal to 33%. Dose levels: 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, 9300 mg.
45372906|NCT00404248|Other|pharmacological study|All pts on both arms will have pks, blood collections. 5ml of blood will be drawn on Cycle 1 day 1, Cycle 1 Day 5, Cycle 2 day 1 and Cycle 2 day 5. A total of 10 samples will be drawn at each of these time points. 1hr pre-infusion, 15 min, 1hr, 1.15, 1.5, 2, 3,4,6 and 24hr post infusion.
45490680|NCT04719832|Biological|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.
45490681|NCT04719832|Drug|Placebo|Matching placebo will be administered as a normal saline using a pre-filled syringe.
45490682|NCT02946385|Biological|Meningococcal ABCWY Vaccine|Intramuscular injection of one booster dose at Day 1 to follow-on subjects in the ABCWY_ 0_2 Group, ABCWY_ 0_2_6 Group and ABCWY_ 0_6 Group, primed with 2 or 3 doses of the study vaccine and 2 doses at Days 1 and 61 to naïve subjects in the ABCWY naïve group.
45490683|NCT02946385|Biological|Meningococcal B Recombinant vaccine|Intramuscular injection of one booster dose of the rMenB+OMV vaccine to subjects in the B_0_2 group, primed with 2 doses of the vaccine and intramuscular injection of 2 doses at Days 1 and 61 in the deltoid area of the non-dominant arm to naïve subjects in the rMenB+OMV Naïve group.
45490684|NCT05177341|Other|Determining Preferred Walking Speed|In the beginning, sensors of the gait analysis system (RehaGait®), which can record the time-distance characteristics of consecutive multiple steps (step length, step width, double step length, and timing information, etc.) will be installed. The 7 sensors of this system are attached to the shoes of the individual, proximal to the ankle, distal thigh, and sacroiliac joint level (Aminian et al., 2014). Individuals will be required to wear casual athletic shoes and comfortable, non-knee-covering shorts. Next; Each individual will walk freely on the treadmill at their own pace. To find the preferred walking speed of the individual, Hinton et al. protocol will be used (Hinton et al., 2018). The speed of the treadmill will be increased or decreased in line with the direction of the participants. After being determined according to the protocol, the individual will practice walking at this speed for 4-5 minutes. The individual will rest as much as he or she wants.
45372907|NCT00421174|Drug|Etanercept|Etanercept will be given eight doses of study drug over a 4-week period. The initial dose of etanercept will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.
45490685|NCT05308771|Device|VPC syringe|Use of the visual pressure control syringe for epidural space detection
45490686|NCT05676190|Combination Product|CIK combined with chemotherapy group|Combination of chemotherapy and autologous cytokine induced killer cells
45490687|NCT05676190|Combination Product|CIK combined immunotherapy group|Combination of immunotherapy and autologous cytokine induced killer cells
45490688|NCT05676190|Combination Product|CIK combined targeted therapy group|Combination of targeted therapy and autologous cytokine induced killer cells
45490689|NCT05676190|Combination Product|CIK in combination with other therapies|CIK combined with any two or three of them (i.e. chemotherapy, immunotherapy and targeted therapy)
45490690|NCT04917211|Procedure|Virtual reality mask|"The virtual reality mask is a mask with a screen that is put on the patient's face in the theatre before the surgery. It offers 3D scenarios of about 20 to 40 minutes on five different themes (the Zen garden, the mountain, the forest, the beach, the scuba diving) with music. The video-headset, equipped with head movement sensors, allows the 3D vision of a natural virtual world and the audio-headset emits sounds adapted to the virtual world and music therapy. The RV mask, via multi-sensorial immersion, focuses on two therapeutic targets which are pain and anxiety. It is a non-drug approach cousin to hypnosis. Its therapeutic effects are based on a distractive effect: attentive capture, an emotional effect: playfulness and positive suggestion, and a behavioral effect: the patient participates and is an actor in his care.~"
46053692|NCT04181359|Drug|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
46053693|NCT04181359|Drug|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
46053694|NCT04178122|Genetic|Result disclosure|Disclosure of clinically confirmed, medically actionable genetic testing results and post-test genetic counseling session.
46053695|NCT04149457|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets visual processing speed, memory, attention and alertness.
46053696|NCT04149457|Other|Commercially available computerized training|Thirty minutes of training on computerized, casual video games.
46053697|NCT04145635|Device|Aortix System|Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) with worsening renal function.
46053698|NCT04129502|Drug|TAK-788|TAK-788 capsule
45372908|NCT00421174|Drug|Placebo plus corticosteroid|"Patients will receive a total of eight doses of placebo over a 4-week period. The initial dose of placebo will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. The placebo will be the inert diluent used for the etanercept formulation.~Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated."
45372909|NCT00496197|Drug|Eraxis (anidulafungin)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
45372910|NCT00496197|Drug|Diflucan (fluconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis.
45372911|NCT00496197|Drug|Vfend (voriconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
45372912|NCT03996993|Drug|Casodex, Axumin|Patients will receive hormone therapy if Axumin positive area appears.
45372913|NCT03996993|Radiation|Salvage Radiation, Axumin|Patients will receive salvage radiation therapy if Axumin positive area appears.
45372914|NCT01019889|Drug|SCRT|4 capsules,three times daily, for 7days or within symptom disappearance
45372915|NCT01019889|Drug|YPS|4 capsules, three times daily, for 7days or within symptom disappearance
45372916|NCT01019889|Drug|Placebo|4 capsules, three times daily, for 7days or within symptom disappearance
45372917|NCT01015053|Procedure|bilateral ultrasound-guided rectus sheath block|Ultrasound is used to guide the deposition of Ropivacaine 0.2% 1cc/kg in the posterior sheath of the rectus muscle containing the peripheral nerves that innervate the abdomen.
45372918|NCT01015053|Procedure|Wound infiltration|Ropivacaine 0.2% 1cc/kg is injected subcutaneously at the site of incision by the surgeon.
45846816|NCT03471624|Drug|Tenofovir Alafenamide|Tenofovir alafenamide (TAF) is a new formulation of tenofovir with higher intracellular active drug concentration allowing for dosing of only 25 mg once daily and thus can potentially lower the already low risk of renal toxicity and bone loss with tenofovir disoproxil fumarate (TDF).
45846817|NCT03441048|Biological|Lintuzumab-Ac-225 (Dose 1: 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab)|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
45846818|NCT03441048|Drug|Cladribine|Cladribine 5mg/m^2/day IV over two hours on days 2-6.
45372919|NCT00495495|Device|Ozone treatment|Ozone treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three, Six and Nine-Month visits.
45372920|NCT00495495|Device|Placebo treatment|Placebo treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three-, Six- and Nine-Month visits.
45372921|NCT00404092|Drug|caspofungin|i.v.
45372922|NCT00481767|Biological|Cervarix|The vaccine was administered according to a 0, 1, and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.
45846819|NCT03441048|Drug|Cytarabine|Cytarabine 2 gm/m^2/day IV over four hours on days 2-6.
45372923|NCT00481767|Drug|Placebo Al(OH)3|Placebo was administered according to a 0, 1 and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.
45372924|NCT04261491|Procedure|scaling and root planing|scaling and root planing
45372925|NCT00489489|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
45372926|NCT00489489|Drug|Placebo (for Teriflunomide)|"Film-coated tablet~Oral administration"
45372927|NCT00489489|Drug|Interferon-β|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
45372928|NCT00489411|Drug|duloxetine hydrochloride|Given orally
45372929|NCT00489411|Other|placebo|Given orally
45372930|NCT00420784|Drug|Telaprevir|tablet
45372931|NCT00420784|Drug|Ribavirin|tablet
45372932|NCT00420784|Drug|Pegylated Interferon Alfa 2a|Solution for injection
45372933|NCT00420784|Drug|Matching Placebo|Tablet
45372934|NCT00420628|Drug|loteprednol etabonate/tobramycin opthalmic suspension|Topical ophthalmic drug: 0.5% loteprednol etabonate with 0.3% tobramycin 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
45372935|NCT00420628|Drug|vehicle|topical ophthalmic vehicle was applied 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
45372936|NCT03993808|Behavioral|Revision of congregate meal menus and recipes to align with parameters of DASH eating plan|On a programmatic level, congregate meal menus and recipes have been adapted to align with DASH eating. The changes, which include the introduction of additional servings of fruits, vegetables, seeds, grains, replacement of simple or processed carbohydrates with healthier alternatives, introduction of more fish, reduction in added salt, and replacement of animal fats and butter with olive oil, will be phased-in in stages over 6 weeks, concurrent with the start up the study's educational programs addressing nutrition, BP, and medication adherence. The fully DASH-aligned menus will begin by week 7. The dietary intervention affects all seniors eating congregate meals at the center, not only those enrolled in this protocol to study the impact of DASH implementation.
45372937|NCT03993808|Behavioral|On-site blood pressure monitoring|At baseline (Month 0), and at Months 1, 3, and 6 after the full implementation of the DASH aligned congregate meals, participants will have blood pressure measured by professionals, on-site at the senior center, following established standard procedures. They will receive verbal and written information about their blood pressure results, and encouragement to share the results with their providers.
45372938|NCT03993808|Behavioral|Home self blood pressure monitoring|Provision of personal Omron 10 home blood pressure monitoring device, training in proper use, and schedule for home self monitoring of BP over the course of the study.
45372939|NCT03993808|Behavioral|Medical adherence education|One required educational session with the community pharmacist to learn about medication adherence strategies
45372940|NCT03993808|Behavioral|Nutrition Education|One required educational session to review the elements of the DASH eating plan, how to overcome barriers to healthy eating, recipes, cooking demonstrations and materials for household members.
45372941|NCT00489255|Drug|Tigan®|Oral capsule, 300mg three times daily
45372942|NCT00489255|Drug|Placebo|Oral capsule, three times daily
45372943|NCT00413218|Drug|Isavuconazole|Administered by intravenous infusion.
45692831|NCT03031587|Other|Additional MRI acquisition sequences|It deals with specific sequences of rapid imaging acquisition in gradient echo (4 to 5 slices/cardiac cycle) with synchronization on the surface ECG systematically included in a cardiac MRI examination, together with update of the slice position depending on the respiratory state (established technique of navigator echo). The acquisition is repeated over 300 cardiac cycles to monitor myocardial temperature changes
45692832|NCT03031587|Device|MRI|cardiac MRI
45372944|NCT00413218|Drug|Caspofungin|Administered by intravenous infusion.
45692833|NCT03023085|Drug|BLI4700|BLI4700 bowel preparation
45372945|NCT00413218|Drug|Voriconazole|Administered by intravenous infusion.
45372946|NCT02303392|Drug|Selinexor|Given PO
45372947|NCT02303392|Drug|Ibrutinib|Given PO
45372948|NCT02303392|Other|Pharmacological Study|Correlative studies
45372949|NCT02303392|Other|Laboratory Biomarker Analysis|Correlative studies
45372950|NCT03994042|Device|Mental imagery neurofeedback training|Mental Imagery (MI)-neurofeedback training, 2-3 hours, 3 times/week for 4 weeks.
45372951|NCT00420316|Biological|Rotarix (primary vaccination study)|GlaxoSmithKline Biologicals' oral live attenuated human rotavirus vaccine.
45372952|NCT00420316|Biological|Placebo (primary vaccination study)|Two liquid oral doses of placebo
45372953|NCT03993886|Device|CorBand|The CorBand device is a wrist-worn biosensor measuring heart rate, heart rate variability, respiration rate, skin temperature, bioimpedance, and activity.
45372954|NCT03993886|Other|Activity Monitor|commercially available accelerometer to be worn on wrist
45372955|NCT03993886|Other|Bioimpedance spectrometer|Commercially available bioimpedance monitor.
45372956|NCT03993886|Other|ECG|Commercially available electrocardiogram machine
45372957|NCT03993886|Other|respiratory rate sensor|Commercially available respiratory rate sensor.
45372958|NCT00494871|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Participants orally administered rivaroxaban 15 mg OD (CrCL [creatinine clearance] >= 50 mL/min) or 10 mg OD (CrCL 30-49 mL/min)
45372959|NCT00494871|Drug|Warfarin|Participants orally administered a warfarin potassium tablet (INR [international normalized ratio] target was 1.6-2.6 for patients >70 years and 2.0-3.0 for patients <70 years)
45372960|NCT00494871|Drug|Rivaroxaban placebo|Participants orally administered a rivaroxaban placebo tablet
45372961|NCT00494871|Drug|Warfarin placebo|Participants orally administered a warfarin placebo tablet (adjusted based upon sham INR values)
45372962|NCT00420238|Drug|Etanercept (Enbrel)|50 mg injection once weekly
45692834|NCT01670331|Behavioral|Psychological preparation|"Session 1: Help patients understand their relationship to food. Patients complete a 'food diary' as 'homework'. Give information about lifestyle changes after surgery. Presents the model of 'stress' and how it influences 'overeating', to develop a more balanced lifestyle and better QoL.~Session 2: 'Intervention' using Compassion Focussed Therapy model to understand relationship to food from their diary. Help develop a 'minimising overeating plan' (a 'relapse prevention' plan). Help learn to meet needs in other ways than food.~Session 3: Focus on physical body. Current body image, explore hopes and expectations for after surgery. Consider how to manage changes to social reactions and sexual relationships that may occur."
45372963|NCT00420238|Other|Placebo|placebo
45372964|NCT01016925|Procedure|tunnelized perineural catheter|the catheter will be tunneled 2-3 cm subcutaneously.
45372965|NCT04362657|Diagnostic Test|Computer Aided Diagnosis|Computer Aided diagnosis is an environment-enhancing technology developed to aid humans to improve their accuracy, speed and confidence by providing live feedback during the procedure, on request, or after the procedure has been completed.
45372966|NCT03994432|Behavioral|intervention group|"follow a mediterranean diet and practice a regular aerobic exercise according to the 7-minutes workout model."
45372967|NCT00420004|Drug|LY2216684|3-mg and 6-mg tablets
45692835|NCT03013491|Drug|CX-072|
45692836|NCT03013491|Drug|ipilimumab|
45846820|NCT03441048|Drug|Mitoxantrone|Mitoxantrone 10mg/m^2/day IV on days 2-4.
45846821|NCT03441048|Drug|G-CSF|G-CSF at a dose of 300 µg on days 1-6.
45846822|NCT03441048|Biological|Lintuzumab-Ac-225 (Dose 2: 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab)|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
45692837|NCT03013491|Drug|vemurafenib|
45692838|NCT01272232|Drug|liraglutide|Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
45692839|NCT01272232|Drug|liraglutide|Liraglutide 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
45372968|NCT00420004|Drug|Placebo|
45372969|NCT00420004|Drug|Escitalopram|10-mg capsules
45372970|NCT00494481|Drug|Vandetanib (ZD6474)|once daily oral dose
45372971|NCT00494481|Drug|Docetaxel|intravenous infusion
45372972|NCT01040494|Drug|Aliskiren|all eligible patients will be randomized to receive aliskiren 150 mg on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
45372973|NCT01040494|Drug|Placebo|all eligible patients will be randomized to receive placebo on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
45372974|NCT01017081|Other|Physiotherapy|Physiotherapy: three times per day, for 10 to 12 minutes, during hospital admission
45372975|NCT01017081|Other|Positioning and cough|Non-mandatory request to maintain lateral positioning to improve air exchange and cough
45372976|NCT01038544|Procedure|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
45372977|NCT01038544|Procedure|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
45372978|NCT00097591|Drug|Prasugrel|Administered orally
45372979|NCT00097591|Drug|Clopidogrel|Administered orally
45372980|NCT01082029|Drug|Lansoprazole|The dosage of Lansoprazole will be administered based on guidelines set out by the prescription drug information outlined in the official Lansoprazole package insert and will remain the same for each patient during the 3 month period and is as follows: a) 1 to 11 years of age, weight less then or equal to 30 kg, 15 mg orally once daily. b) 1 to 11 years of age, weight greater then 30 kg, 30 mg orally once daily. c) 12 years of age and older, 15 mg orally once daily. The doses of Lansoprazole will be prepared in liquid form by the Inpatient Pharmacy at Hamilton Health Sciences.
45372981|NCT01082029|Drug|Placebo|Lactose powder in 8.4% Sodium Bicarbonate (Liquid placebo)
45372982|NCT00419926|Drug|Enteric-coated mycophenolate sodium (Myfortic)|1440 mg/day for the standard dose. 2880 mg/day for the initial intensified dosage, reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
45692840|NCT01272232|Drug|placebo|Liraglutide placebo of either 3.0 mg or 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
45692841|NCT03157401|Drug|intravenous infusion group|In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
45372983|NCT00419926|Drug|Cyclosporine (Neoral)|cyclosporine microemulsion in galenic form capsules starting at twice a day for a dose of 8-10 mg/kg/day adjusted if necessary to achieve protocol specific target levels
46053699|NCT04129502|Drug|Pemetrexed|Pemetrexed IV infusion
45372984|NCT00419926|Drug|Prednisone|20 mg orally per day reduced according to center practice for a minimum dose of 5 mg/day.
45372985|NCT01038622|Drug|L-arginine|5-day L-arginine treatment
45372986|NCT01038622|Drug|placebo|5-day placebo treatment
45372987|NCT00419770|Drug|deferasirox|20 mg/kg enterally per day
45372988|NCT00419770|Drug|Placebo|
45372989|NCT00419770|Drug|Liposomal amphotericin B|
45372990|NCT00080119|Drug|Isoniazid (INH)|Antibiotic for the prevention and treatment of TB
45372991|NCT00080119|Drug|Trimethoprim/Sulfamethoxazole (TMP/SMX)|Antibiotic for the prevention and treatment of pneumocystis pneumonia (PCP)
45372992|NCT00080119|Drug|Isoniazid Placebo (PL)|Isoniazid placebo and TMP/SMX
45692842|NCT03157401|Drug|intra-articular injection group|In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
46053700|NCT04129502|Drug|Cisplatin|Cisplatin IV infusion
46053701|NCT04129502|Drug|Carboplatin|Carboplatin IV infusion
46053702|NCT04114136|Drug|Nivolumab or Pembrolizumab (dependent upon approved indication)|Anti-PD-1 mAb (monoclonal antibody)
46053703|NCT04114136|Drug|Metformin|Acts directly or indirectly on the liver to lower glucose production, and acts on the gut to increase glucose utilisation, increase GLP-1 and alter the microbiome.
45692843|NCT03157401|Drug|control group|In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
45372993|NCT00419380|Drug|dornase alfa (Pulmozyme®)|This study will compare two treatment arms. Patients will be randomized to either traditional treatment (Ofloxin)or to experimental treatment [dornase alfa (Pulmozyme®)]. Each arm will have subjects instilling 5 drops twice daily for 7 days to the affected ear.
45490691|NCT02694718|Drug|Capecitabine|Capecitabine is available as 50 mg and 500 mg tablets. It will be administered as a 1000mg/m^2 bid orally on Days 1-14, and at a dose of 825mg/m^2 bid on Days 22-35 and 43-56.
45692844|NCT03153735|Device|CMDHA0101|Maximum injection dose : 22 ml
45372994|NCT03961633|Behavioral|AWARE intervention|"will attend the AWARE group counseling sessions, which are 90 minutes, once a week, for 8 weeks. Each week's session is focused on a specific theme related to the cultural and gender-specific issues typical among young Asian American women. The sessions are led by staff therapists at either institution. For more info on each session's content, please see the Study Description - Detailed Description section.~Participants will fill out forms that detail their therapeutic goals (commitments) and any adverse emotional / behavioral events from the past week. Participants will also receive daily text messages that reinforce the group session themes."
45372995|NCT01082107|Other|Solar disinfection in transparent containers (plastic bottles)|Participants in the study drink solar disinfected (SODIS) water. Solar disinfected water is water (> 3 L) that has been placed in direct sunlight for 6 hours. Participants are expected to drink SODIS treated water for the duration of the study.
45372996|NCT01085929|Procedure|Incision and Drainage|Surgical incision of the skin surface followed by expression of purulence with or without debridement or manual exploration of abscess cavity.
45372997|NCT01085929|Procedure|Ultrasound Guided Aspiration|Ultrasound is used to identify the abscess cavity. An 18 gauge needle is introduced into the abscess cavity and manual aspiration of the abscess contents is attempted.
45372998|NCT03961399|Device|Abbott Medical® CRT device with SyncAVTM stimulation function|patients with Abbott Medical® CRT device will be randomized and SyncAVTM stimulation will be activated.
45372999|NCT03961399|Device|Abbott Medical® CRT device with biventricular stimulation (BiV)|patients with Abbott Medical® CRT device will be randomized and biventricular (BiV) stimulation will be activated.
45373000|NCT00413062|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
45373001|NCT00413062|Drug|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
45373002|NCT01082185|Device|Ovation Abdominal Stent Graft System|Endovascular implant of Abdominal Aortic Aneurysm Stent Graft
45373003|NCT01034878|Drug|Sunitinib|Sunitinib will be administered orally at a dose of 50 mg once daily, in six weeks cycles consisting of 4 weeks of treatment followed by 2 weeks without treatment.
45490692|NCT02694718|Drug|Oxaliplatin|Oxaliplatin is available in vials containing 50 mg or 100 mg. It will be administered as a oxaliplatin 130mg/m^2/d intravenously on Day 1 and 50mg/m^2/d on Days 22, 29, 43 and 50 prior to radiotherapy up to Week 9 followed by surgery period.
45490693|NCT05681299|Drug|growth hormone and lirglutide|GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects and liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
45692845|NCT03153735|Device|PowerFill®|Maximum injection dose : 22 ml
45692846|NCT03153891|Other|Natural Environment|the natural environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
45692847|NCT03153891|Other|Built Environment|the built environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
45692848|NCT01670643|Behavioral|Video camera magnifier|reading with video camera magnifier
45692849|NCT03153813|Drug|capsaicin 8% patches (Qutenza)|
45692850|NCT03153813|Other|Placebo patches|
45692851|NCT03157167|Drug|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
45373004|NCT01082263|Drug|Lurasidone HCl|Day1: 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day6: 120 mg lurasidone (three 40 mg tablets) + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day 7-12: 120 mg lurasidone (three 40 mg tablets) 120 mg lurasidone (three 40 mg tablets) on Day 13 + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup)
45373005|NCT02208544|Procedure|Diagnostic Thyroid Surgery|Diagnostic Thyroid Surgery
45692852|NCT03157245|Diagnostic Test|DOPPLER ULTRASOUND|MESURE OF THE PRESENCE OR NOT OF A CATHETER RELATED VEIN THROMBOSIS
45692853|NCT03156855|Drug|14-day sequential therapy|D1-D7: (esomeprazole 40mg qid + amoxicillin 500mg qid) for 7 days D8-D14: (esomeprazole 40mg qid + clarithromycin 500mg bid + metronidazole 500mg bid) for another 7 days
45373006|NCT02208544|Device|Ultrasound of the head and neck|Confirmatory Neck Ultrasonography in FDG-PET/CT negative patient in the experimental arm
45490694|NCT05681299|Drug|growth hormone|GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects.
45490695|NCT05681299|Drug|liraglutide|Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
45373007|NCT02208544|Radiation|FDG-PET/CT|Head and Neck FDG-PET/CT
45373008|NCT00494091|Drug|Temsirolimus (CCI-779)|20 mg/m2 IV TEMSR weekly (Japan, n=6)
45373009|NCT00494091|Drug|Temsirolimus (CCI-779)|25 mg IV TEMSR weekly (all other pts)
45373010|NCT01017159|Drug|Subcutaneous immunoglobulin|The subcutaneous immunoglobulin is infused in the subcutaneous tissue on the abdomen twice or thrice a week, with a maximal speed of 2 mL/h. Every time 20 mL is infused, the needle is removed to a new place.
45373011|NCT00494013|Drug|Insulin Lispro Protamine Suspension|Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
45490696|NCT05681299|Drug|Placebo|Placebo will be taken by nightly subcutaneous injection at 9-11 pm.
45692854|NCT03156855|Drug|Bismuth quadruple therapy|D1-D10: (esomeprazole 40mg bid + dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
45692855|NCT01791127|Device|market-released BIOTRONIK pacemaker system including one or two Siello S leads.|
45490697|NCT04378153|Other|Discontinuation of hypertonic saline (HS)|Discontinuation of current hypertonic saline (HS) therapy in Study A during 6-week study period.
45490698|NCT04378153|Other|Continuation of hypertonic saline (HS)|Continuation of current hypertonic saline (HS) therapy in Study A during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily). The concentration of HS is according to clinical prescription (e.g., 7% sodium chloride or 3.5% sodium chloride) and at least 3%.
45490699|NCT04378153|Other|Discontinuation of dornase alfa (dnase)|Discontinuation of current dornase alfa (dnase) therapy in Study B during 6-week study period.
45692856|NCT03157011|Other|Global symptom score (GSS) questionary|systematic research of digestive symptoms in patients with SGSp with Global symptom score (GSS) questionary, which allowed to grades severity of 10 digestive symptoms (absent, mild, moderate, or severe), asthenia and fever.
45692857|NCT01274650|Procedure|Indirect Calorimetry|Indirect Calorimetry
45692858|NCT03157323|Behavioral|Low Glycemic Index Diet|The nutritional intervention is theory-based and will provide nutritional education and counseling to children and their families. Nutritional counseling will be provided by the institutional designate and will focus on increasing patients' understanding of the benefits of a low GI diet, increase knowledge of low GI diet, overcoming barriers, and establishing expectations of the diet.
45692859|NCT00739960|Drug|Abatacept|10mg/kg IV (infusion directly into the vein of the arm) Day 1, week 2, week 4 and then every 4 week for 44 weeks.
45846823|NCT03441048|Biological|Lintuzumab-Ac-225 (Dose 3: 0.75 μCi/kg with 4.7μg/kg lintuzumab)|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
45373012|NCT00494013|Drug|Detemir|Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
45373013|NCT00079339|Radiation|radiation therapy|Undergo radiotherapy
45373014|NCT00079339|Drug|tipifarnib|Given orally
45373015|NCT00493779|Procedure|Blood Collection|4 weeks
45373016|NCT01088191|Biological|MSB-CAR001 Combined With Hyaluronan|"Knee Injection of Biological: MSB-CAR001 Combined With Hyaluronan~Single Injection Into the Knee Joint of Single Doses of MSB-CAR001 Combined With Hyaluronan"
45373017|NCT01088191|Drug|Hyaluronan|Hyaluronan alone
45490700|NCT04378153|Other|Continuation of dornase alfa (dnase)|Continuation of current dornase alfa (dnase) therapy in Study B during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily).
45490701|NCT03106090|Other|educational materials|The eSCP includes a treatment summary section, a section detailing follow-up and test recommendations, a section on anticipated and potential side effects, as well as additional information specific to their experience/concerns. They will receive a patient education notebook outlining symptoms and their management that is tailored to those that the subject may be likely to experience during their survivorship care trajectory.
45490702|NCT03105778|Diagnostic Test|standard blood draw as part of routine and fingerprick for capillary sample|All blood sample collection methods are standard routine procedures. These patients usually have an indwelling cannula from which blood samples are drawn. So no additional venipuncture is performed according to this study. The finger prick sample - taken only for study purposes - might be accompanied by small pain at the fingertip. But this pain is usually of short duration and tolerated very well. No unanticipated adverse events are expected to occur in this study.
45490703|NCT03161080|Device|Neovis Total Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), lipoic acid, hydroxypropyl methylcellulose
45373018|NCT01082341|Biological|Immunization with P. vivax irradiated sporozoites|"Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use.~14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials."
45373019|NCT01017315|Drug|Baby talcum|50 grams apply locally prior cast application
45373020|NCT00541866|Drug|Voreloxin injection and cytarabine|"Dose-escalation Phase~Schedule A: vosaroxin injection (dose-escalation from 10 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion of 400 mg/m2/day × 5 days)~Schedule B: vosaroxin injection (dose-escalation from 70 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (2-hour intravenous [IV] infusion of 1 g/m2/day × 5 days)~Expansion Phase The MTD determined in the dose-escalation phase was used in the expansion phase.~Schedule A: 80 mg/m2 vosaroxin on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion at 400 mg/m2/day × 5 days)~Schedule B: 90 mg/m2 vosaroxin (dose-escalation) on Days 1 and 4 in combination with cytarabine (2 hour IV infusion at 1 g/m2/day × 5 days)"
45490704|NCT03161080|Device|Vismed Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), potassium chloride, disodium phosphate
45490705|NCT03161080|Device|Hydrabak® Eye Drops|Eye Drops containing sodium chloride (0,9%), sodium dihydrogen phosphate dehydrate
45490706|NCT04908787|Drug|BD0801|Subjects receive BD0801 , intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
45490707|NCT04908787|Drug|Paclitaxel|Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, d22, q4w, Dosage form: injectable, Strength: 80 mg/m2
45490708|NCT04908787|Drug|Placebo|Subjects receive Placebo, intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
45490709|NCT04908787|Drug|Topotecan|Subjects receive Topotecan, intravenously, d1, d8, d15, q4w, Dosage form: injectable, Strength: 4mg/m2
45490710|NCT04908787|Drug|doxorubicin liposome|Subjects receive doxorubicin liposome, intravenously, d1, , q4w, Dosage form: injectable, Strength: 40mg/m2
45490711|NCT04923139|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Dosage at the discretion of the treating physician
45490712|NCT04891627|Diagnostic Test|Gingival crevicular fluid|GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.
45490713|NCT04365829|Device|"virtual reality headset Occulus GO"|"Use of a virtual reality headset for one week at a frequency of 3 days per week (D1, D3 and D5). During each session (1 hour), the subject will visualize a scene of natural virtual environment (a garden, animals in the wild, a grand Canyon) lasting 7 min using an virtual reality headset Occulus GO."
45490714|NCT04692688|Drug|APX3330|APX3330, a small-molecule oral tablet, is a Ref-1 inhibitor that can potentially reduce proinflammatory and hypoxic signaling that contributes to several eye diseases.
45490715|NCT04692688|Drug|Placebo|Placebo tablets are identical to APX3330 tablets except for the absence of the active pharmaceutical ingredient.
45490716|NCT05681221|Other|Nano silver particles and calcium hydroxide|Combination of two materials that can possibly eradicate the mixed odontogenic infection in the periapical area and dentinal tubules in necrotic primary second molars.
45846824|NCT03441048|Biological|Lintuzumab-Ac-225 (Dose 4: 1.00 μCi/kg with 6.4 μg/kg lintuzumab)|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
46053704|NCT04114136|Drug|Rosiglitazone|A member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity. Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).
46053705|NCT04112940|Other|Starch-based Thickened Liquids|Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
46053706|NCT04112940|Other|Xanthan-gum Thickened Liquids|Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
46053707|NCT04112576|Device|Wearable cardiac monitor|Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.
46053708|NCT04102020|Drug|Venetoclax|Tablet: Oral
46053709|NCT04102020|Drug|Azacitidine|Subcutaneous (SC) or intravenous (IV) injection
46053710|NCT04102020|Drug|Placebo for Venetoclax|Tablet; Oral
46053711|NCT04102020|Drug|CC-486|Tablet; Oral
45373021|NCT01082419|Device|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For group A the measurement is made by a second and a third investigator during the same examination."
45373022|NCT01082419|Device|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For all other groups (B, C, D, E) ARFI is measured only once."
45373023|NCT01082419|Device|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For groups F and G : ARFI is measured again after clinical healing."
45373024|NCT00493467|Drug|Ibritumomab Tiuxetan (Zevalin)|"111In Zevalin (5 mCi of ^111In, 1.6 mg of Ibritumomab Tiuxetan) Intravenously Over 10 minutes on Day 1.~90Y Zevalin 0.3 or 0.4 mCi/kg Intravenously Over 10 minutes on Day 8."
45490717|NCT05681221|Other|TAP|Triple antibiotic paste (TAP) is considered the gold standard in LSTR. It is a combination of ciprofloxacin, metronidazole and minocycline. Many anaerobic bacteria are resistant to ciprofloxacin. Hence, it is often used with metronidazole in treating mixed infections to compensate for its limited scope. Therefore, TAP can affect gram-negative, gram-positive, and anaerobic bacteria, and this combination can be effective against odontogenic microorganisms.
45490718|NCT04644952|Other|Electronic Health Record Review|Review of medical records
45490719|NCT04303507|Drug|Chloroquine or Hydroxychloroquine|A loading dose of 10 mg base/ kg followed by 155 mg daily (250mg chloroquine phosphate salt or 200mg of or hydroxychloroquine sulphate) will be taken for 3 months
45490720|NCT04303507|Drug|Placebo|Placebo
45373025|NCT00493467|Drug|Rituximab|250 mg/m^2 Intravenously Over 4-6 Hours On Days 1 and 8.
45373026|NCT00090493|Biological|MAGE-A3|vaccinations at 2- week intervals (days 22,36,50) with the MAGE-A3 or NY-ESO-1 peptide and GM-CSF adjuvant. The peptides will be given s.c. in a dose of 300μg; GM-CSF (250μg) will be administered to promote attraction, maturation and longevity of DCs. #2 will be thawed and re-infused after transplant on day 81 and any anti-myeloma T-cells in this leukapheresis product will be boosted immediately by re-vaccinating the patient 3 times at 14 day intervals (vaccination #4-6: days 82, 96, and 110). Vaccines #4-6 will be identical to vaccines 1-3. Thereafter, 6 monthly vaccines will be given to further boost the anti-MM-T-cells.
45373027|NCT00090493|Biological|MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY|Three injections with 300µg per injection (in 1.5mls) of peptide will be given subcutaneously together with the adjuvant GM-CSF at 500µg (same site in 0.5 mls) at two-week intervals
45373028|NCT04236336|Device|TSV dental implant|Qualified patient will be those patients who have been newly diagnosed with needing a dental implant (or more than one) in one or more edentulous areas in the maxilla and/or mandible.
45373029|NCT01088347|Drug|mapatumumab|Mapatumumab (10 or 30 mg/kg) intravenously on days 1, 22, and 45. In phase 2 the MTD established in phase 1 will be used.
45373030|NCT01088347|Drug|cisplatin|Cisplatin 40 mg/m2 intravenously on days 8, 15, 22, 29, 36, and 45
45490721|NCT04296643|Device|Medical Mask|Medical Mask (known also as Surgical Mask)
45490722|NCT04296643|Device|N95 respirator|N95 respirator
45490723|NCT05308693|Other|Education material - Patient Compatible Stoma Educational Material|It is an educational material made of rubber, similar to a stoma, that can be placed on the patient.
45490724|NCT03202537|Drug|dexlansoprazole|dexlansoprazole treatment for Gastroesophageal Reflux symptoms
45490725|NCT02944513|Device|Quell|
45490726|NCT03638557|Other|Nutritious Lunch|"The intervention package consists of the following;~Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.~Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein"
45373031|NCT01088347|Radiation|radiotherapy|Radiotherapy: a total dose of 45 Gy will be given in fractions of 1.8 Gy, five fractions per week (days 8-12, 15-19, 22-26, 29-33, and 36-40), by external beam irradiation by photon beam of at least 6 MV. After completing the five weeks of external beam irradiation, evaluation will take place to determine whether the boost can be given by brachytherapy. If brachytherapy is not feasible, the boost will be given by external beam irradiation to a total dose of 70.2 Gy in fractions of 1.8 Gy.
45490727|NCT05018299|Biological|FB704A placebo|lacebo
45490728|NCT05018299|Biological|FB704A|Anti-IL-6 antibody
45490729|NCT04289935|Procedure|Vacuum assisted biopsy (VAB)|The trial intervention consists of a diagnostic interventional procedure, US-guided or mammographically guided VAB post-NAC, prior to the standard breast surgery.
46053712|NCT04093362|Drug|TAS-120|TAS-120 is an oral FGFR inhibitor
46053713|NCT04093362|Drug|Cisplatin/Gemcitabine|Cisplatin/Gemcitabine is currently 1st line standard of care
45373032|NCT05257824|Drug|Aspirin 100mg|"short-term dual antiplatelet: dual antiplatelet agents for 6 months~long-term dual antiplatelet: dual antiplatelet agents for 12 months"
45373033|NCT05257824|Drug|Clopidogrel 75mg|"short-term dual antiplatelet: dual antiplatelet agents for 6 months~long-term dual antiplatelet: dual antiplatelet agents for 12 months"
45373034|NCT04329702|Behavioral|Coping skills training mobile app with call from CST therapist|The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. A therapist will call participant to introduce the intervention and perform a brief relaxation exercise.
45373035|NCT04329702|Behavioral|Coping skills training mobile app only|The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. App chat room access will be provided.
45373036|NCT05220930|Other|Foot bath for heel warming|In this study, in line with the literature, the attempt to apply heat with a foot bath will be carried out by immersing both legs of the newborn in a basin filled with 15-20 cm of water at 38-40C, 5 minutes before the heel blood collection, starting just below the knee level. The intervention will be applied while the newborn is held in an upright position on his mother's lap.
45373037|NCT05220930|Other|Ineffective heel warming with thermofor|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
45373038|NCT04302558|Behavioral|Exercise Blood Flow Restriction training|While exercising, an Inflatable cuff, similar to a blood pressure cuff, is applied to the proximal aspect of the femur of the affected lower extremity inflated to occlude blood flow
45490730|NCT04235413|Behavioral|Real-Time Incentives Group|The use of a novel computer program with a mobile phone interface to provide real-time financial incentives at the point of purchase for discounts on fruit and vegetables in low-income families. This intervention will be applied to subjects randomized to the intervention arm. They will receive 50% off eligible fruits and vegetable products at the point of purchase, up to $10 a week for 6 months. Maximum amount they can receive is $260 in discounts over the 6 month period.
45846825|NCT03441048|Biological|Lintuzumab-Ac-225 (Dose 5: 1.25 μCi/kg with 8.0 μg/kg lintuzumab)|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
45373039|NCT04302558|Behavioral|SHAM Exercise Blood Flow Restriction training|While exercising Inflatable cuff, similar to a blood pressure cuff, applied to the proximal aspect of the femur of the affected lower extremity with limited inflation pressure to not occlude blood flow
45373040|NCT04268004|Behavioral|FP Decision Tool and Discussion|The intervention will be administered by a trained interventionist. The interventionist will administer the digital FP Decision Tool to families in the intervention arm. The tool asks questions examining each AYA's thoughts or feelings regarding parenthood and fertility preservation. The parent version asks the same questions, plus additional questions asking the parent to rate their son's feelings on certain topics (i.e., whether their son wants to have a child, whether their son would be as happy with an adopted child versus a biological child). Items are coded based on the domains of the Health Belief Model (perceived benefits, perceived barriers, perceived threats, self-efficacy, and cues to action). Items are scored and the trained interventionist will facilitate a guided discussion based on the family's responses and discrepancies.
45373041|NCT05692440|Device|Intracept Procedure|Intraosseous radiofrequency ablation of the basivertebral nerve
45373042|NCT05692050|Drug|Epcoritamab|Subcutaneous Injection
45490731|NCT04762537|Other|Standard Induction Procedure (SP)|SP includes stabilization on buprenorphine (6-8 mg) on Day 1 followed by a taper over the subsequent 4 days. After the completion of buprenorphine taper, participants will enter a washout period of at least 8 days. On the last day of the washout period, participants will be evaluated for eligibility to receive XR-NTX injection. Once found eligible, an XR-NTX injection will be given.
45490732|NCT04762537|Other|Rapid Induction Procedure (RP)|RP includes 1 day of buprenorphine 6-8 mg, followed by a day of washout and 4 days of oral naltrexone titration. If the participant is able to tolerate the last dose of the naltrexone titration, an XR-NTX injection will be given
45490733|NCT04932265|Dietary Supplement|HRG80™ Red Ginseng|Capsules containing red ginseng preparation HRG80 capsules, 200 mg - reference product
45692860|NCT05537181|Device|BTL-899; HPM-6000UF Treatments|The two devices will be used separately in two different treatments. However one treatment visit can comprise both treatments. The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered. The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
45692861|NCT00751972|Device|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
45692862|NCT03153657|Drug|Piroxicam-Beta-Cyclodextrin|The patients will receive a single-dose of Piroxicam-Beta-Cyclodextrin (20 mg) thirty minutes before the bleaching procedure.
45373043|NCT04004832|Diagnostic Test|there is not any intervention procedure|there is not any intervention procedure
45490734|NCT04932265|Combination Product|HRG80™ Red Ginseng + gamma cyclodextrin|Chewable tablets containing red ginseng preparation HRG80 (100 mg) incorporated in gamma-cyclodextrin (GCD) - experimental modified product
45490735|NCT04779229|Behavioral|Parent Activation|Parent Activation (PA) is comprised of concrete social learning theory steps (i.e., direct instruction, modeling, practice opportunities, and reinforcement) that aim to enhance a parent's confidence, knowledge, and ability to manage his/her child's health. PA is applicable across a range of conditions, including behavioral and psychiatric problems, and it can be delivered by varied providers, including paraprofessionals.
46053714|NCT04089059|Device|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management and comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~Cordella Sensor~Cordella Delivery System~myCordella Patient Reader~Reader Dock~Cordella Calibration Equipment (CalEQ)~myCordella Hub~Cordella Data Analysis Platform (CDAP)"
46053715|NCT04088318|Drug|OQL011|OQL011 is an ointment containing active ingredient.
46053716|NCT04088318|Drug|Vehicle Ointment|Vehicle ointment is an ointment containing no active ingredient.
46053717|NCT04074135|Drug|68-Gallium DOTATATE|68-Gallium DOTATATE, to be used in yearly PET/CT research scans
45490736|NCT04779229|Behavioral|Usual Services|This intervention refers to the typical techniques that JPOs employ to monitor the juveniles on their caseloads (e.g., regular meetings with youth and parents to ensure the youth is following conditions of probation and issuing swift sanctions [community service; detention] if conditions are not being followed).
45373044|NCT04221828|Drug|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles. For clinical administration, the NanoPac powder in vial is suspended with Sterile Reconstitution Solution (1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP) and then further diluted with 0.9% Sodium Chloride for Injection, USP, to achieve the final clinical formulation.
45490737|NCT04755673|Other|Atrantil (Medical Food)|All participants will be given 28 days supply of Atrantil. The impact of the intervention will be measured by daily symptom surveys as well as a hydrogen methane breath test administered at the end of the 28 days of treatment to identify if methane levels have changed.
45692863|NCT03153657|Drug|Placebo|The patients will receive a single-dose of placebo with the same presentation of the experimental drug thirty minutes before the bleaching procedure.
45373045|NCT05138328|Device|Treatment of basal cell carcinoma with Nd:YAG laser under imaging guidance of optical coherence tomography (OCT)|This will use optical coherence tomography (OCT) to assess the margins of basal cell carcinoma. Treatment will be completed by Nd:YAG laser.
45373046|NCT04221750|Behavioral|Lifestyle therapy|Weight management program, in which participants are prescribed a balanced diet that provides and energy deficit of 500 to 750 kcal per day to induced ~10% weight loss plus Supervised combined aerobic and resistance exercise training three times weekly
45490738|NCT03620851|Other|effect of age|effect of age on the efficiency of enhanced recovery program
45490739|NCT04920643|Procedure|Ultrafiltration|Ultrafiltration is used during cardiac surgery with cardiopulmonary bypass to remove both fluid and small molecules such as inflammatory cytokines from the patient's circulation.
45490740|NCT03631134|Drug|SGLT2 inhibitor|Patients will be gave SGLT2 inhibitor 10mg per day
45490741|NCT05291143|Behavioral|Short videos on blood pressure monitoring|Short videos on blood pressure monitoring
45490742|NCT01381380|Procedure|Manual therapy|Manual therapy, once a week for 8 weeks
45692864|NCT01670955|Dietary Supplement|Jobelyn|Jobelyn is a sorghum bicolor extract marketed as dietary supplement
45692865|NCT01670955|Drug|Ferrous Sulphate + Folic Acid|Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
45692866|NCT01274806|Other|Physical Therapy|Core Stability Exercise, Endurance training, recovery massage
45692867|NCT01274884|Procedure|Tightrope fixation|Arthroscopic repair
45692868|NCT03156933|Other|Assessment of splicing variants|This is a biological study with primary samples without any intervention on patients.
45373047|NCT04221750|Drug|Metformin Hydrochloride|Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of metformin will be increased to 1000 mg (two tablets) daily. After another week, the dose of metformin will be increased to 1500 mg (three tablets) daily.
45373048|NCT04221750|Drug|Placebo|Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of placebo will be increased to 1000 mg (two tablets) daily. After another week, the dose of placebo will be increased to 1500 mg (three tablets) daily.
45373049|NCT04221750|Behavioral|Healthy Lifesylte|Group educational sessions that focus on healthy diet, exercise, and social support once a month
45373050|NCT04198428|Other|Opioid Wizard|The Opioid Wizard is an OUD clinical decision support tool for primary care providers to help assess, diagnose, and treat OUD in primary care (where appropriate).
45373051|NCT04182126|Other|Regular long-lasting insecticidal nets|Olyset nets: containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn
45373052|NCT04182126|Other|LLIN plus Piperonyl butoxide-treated LLIN|Olyset Plus: containing 2% permethrin and 1% PBO
45373053|NCT04182126|Other|Long-lasting microbial larvicide|Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet
45373054|NCT04182126|Other|Indoor residual spraying with micro-encapsulated pirimiphos-methyl|each dwelling's interior walls and ceilings will be sprayed with micro-encapsulated pirimiphos-methyl at the recommended dosage of 1g/m² and at the recommended frequency of once a year
45373055|NCT04145466|Behavioral|High-fat diet|"The high-fat diet will consist of ~40% energy from fat and ~45% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of ~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed"
45373056|NCT04145466|Behavioral|High-carbohydrate diet|"The high-carbohydrate diet will consist of ~20% of energy from fat and ~65% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of ~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed"
45373057|NCT04113018|Drug|Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab|Experimental
45490743|NCT04909645|Diagnostic Test|Clearsight (finger cuff)|Clearsight (Edwards Lifesciences, Irvine, CA), a noninvasive technique, uses a finger cuff to measure blood pressure, cardiac output (CO) and cardiac index. Systemic vascular resistance (SVR) is calculated by the following equation: SVR=(Mean arterial pressure-Central venous pressure)*80/CO.
45490744|NCT04011618|Drug|Ellagic Acid / Pomegranate Extract|Polyphenol, ellagitannin, it is found in a wide variety of fruits and nuts; in this particular case, pomegranate extract with 90% ellagic acid, 500 mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
45490745|NCT04011618|Drug|Placebo oral capsule|Calcined magnesia in 500mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
45490746|NCT04163809|Device|Virtual Reality with Oculus Go headset|The investigator will place the Oculus Go VR headset on the patient. VR will provide distracting, pleasant visual stimulus from the beginning of the procedure (while the patient is being cleaned and draped) and removed immediately after the regional anesthesia procedure is complete for roughly 10-20 minutes. All patients receiving VR will view the same scene.
45490747|NCT04153279|Biological|CMV-TCR-T cells|Patients with CMV emias or CMV disease will be enrolled, and donor derived CMV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).
45490748|NCT04725318|Other|One-lung ventilation|One-lung ventilation as part of routine clinical care for patients undergoing thoracic surgery under general anesthesia
45490749|NCT04138615|Drug|Morphine|Subjects will receive Morphine while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
45490750|NCT04138615|Other|Placebo|Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
45490751|NCT01383330|Drug|megace|800mg
45490752|NCT01383330|Drug|DW-ES(A)|625mg
45490753|NCT01383330|Drug|DW-ES(B)|625mg
45490754|NCT03018938|Drug|Insulin Analog Mid Mixture|Administered SC
45490755|NCT03018938|Drug|Basal Insulin Analog|Administered SC
45490756|NCT03631368|Drug|Botox|Intradermal injection with Botox 100U/mL will be performed using a 25g needle. Each subject will receive three treatments spaced 1 month apart.
45490757|NCT02943577|Drug|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
45373058|NCT00481065|Biological|MF59-eH5N1|
45373059|NCT00481065|Biological|eTIV_a|
45373060|NCT00481065|Biological|MF59-eH5N1 + eTIV_a|
45373061|NCT01017393|Drug|Ketamine|
45373062|NCT01017393|Drug|ketamine free|
45373063|NCT00493311|Drug|IV Placebo|IV Placebo
45373064|NCT00493311|Drug|IV Acetaminophen|Intravenous acetaminophen solution 1 g / 100 ml
46053718|NCT04072393|Procedure|Home-based cardiac rehabilitation|-Patients will be evaluated by the clinical team at The Heart Care Institute (HCI). They will receive a heart rate monitor, blood pressure monitor, and weight scale that they will take home with them. They will receive training on how to use the heart rate monitor and blood pressure monitor. They will receive training on how to record their exercises and weights in the teleHeart application by an exercise physiologist from HCI. Within 6 weeks of completion of standard of care radiation therapy or cytotoxic chemotherapy (whichever is last), they will be prescribed a course of home-based CR by a cardiologist at HCI and be instructed on the regimen by an exercise physiologist from HCI.
45373065|NCT00493311|Biological|Reference Standard Endotoxin (RSE)|Administration of Reference Standard Endotoxin (RSE) to induce fever. Applicable to both study arms: Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
45373066|NCT00571649|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days
45490758|NCT02943577|Drug|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
46053719|NCT04060849|Drug|Nozin|Given via nasal single-use popswabs or single-use cotton tipped applicators
45373067|NCT00571649|Drug|Enoxaparin|Subcutaneous enoxaparin 40 mg once daily (OD) administered for 10 +/- 4 days
45373068|NCT00571649|Drug|Rivaroxaban placebo|Oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days
45373069|NCT00571649|Drug|Enoxaparin placebo|Subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
45373070|NCT05434793|Device|RJ-LASER, LASERPEN®; Reimers & Janssen, Germany|The device was frequently used in laser acupuncture on the superficial skin of the acupuncture point Tsu San Li (St-36).
45373071|NCT05434715|Procedure|Thyroidectomy|removal of the thyroid gland
45373072|NCT05434403|Device|Vagus nerve stimulation|vagus nerve electrical stimulation through ear skin
46053720|NCT04060849|Other|Best Practice|Receive standard of care
46053721|NCT04055116|Drug|Buffered Lidocaine|Investigator will prepare 1:10 dilution of sodium bicarbonate to 2% lidocaine with 1:100,000 epinephrine on one occasion. 8.4% Sodium Bicarbonate will be used.
45373073|NCT05434403|Device|sham vagus nerve stimulation|sham vagus nerve electrical stimulation through ear skin
45490759|NCT05398380|Other|Liver transplantation|Liver transplantation
45373074|NCT00546572|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
45373075|NCT00546572|Biological|23vPS|0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1
45846826|NCT03441048|Biological|Lintuzumab-Ac-225 (Recommended Phase 2 Dose)|The maximum-tolerated dose for lintuzumab-Ac225 is defined as the highest level at which no more than one patient experiences a dose-limiting toxicity. The RP2D is defined as the dose level below the dose where two or more dose-limiting toxicities were observed. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
45373076|NCT03917472|Drug|Brolucizumab|Intravitreal injection
45373077|NCT03917472|Drug|Aflibercept|Intravitreal injection
45373078|NCT00681863|Drug|pramipexole 0.125 mg BID|titrated dose for those patients whose symptoms were not controlled on the 0.0625 mg BID dose
45373079|NCT00681863|Drug|pramipexole 0.0625 mg QD|dose down titrated for those patients unable to tolerate the 0.0625 mg BID dosing
45373080|NCT00681863|Drug|pramipexole 0.125 mg TID|titrated up for those patients whose symptoms were not adequately controlled on 0.125 mg BID dose
45373081|NCT00681863|Drug|pramipexole 0.25 mg BID|titrated for those patients whose symptoms were not adequately controlled on 0.125 mg TID dose
45373082|NCT00681863|Drug|pramipexole 0.0625 mg BID|0.0625 mg BID given for first 4 wks of treatment
45846827|NCT02828592|Drug|Fludarabine|30 mg/m2 IV QD x 5 days (Days -6 to -2)
45846828|NCT02828592|Drug|Cyclophosphamide|14.5 mg/kg/day IV x 2 doses (Days -6 & -5)
45846829|NCT02828592|Radiation|Total Body Irradiation|300 cGy x1 dose (Day -1)
45373083|NCT02559791|Biological|Reslizumab|Reslizumab 3ml/kg once monthly for 4 months
45373084|NCT02559791|Drug|Placebo|Matching placebo once monthly for 2 months
45373085|NCT05677620|Radiation|Pharyngeal Computed Tomography|To assess the presence of a possible level/level of collapse, a pharyngeal CT with cephalometry will be performed, and a standard classification system, VOTE, will be used. After obtaining said CT, the dentist will place the recording in MCP and perform a new CT scan of the pharynx with cephalometry and with the MCP recording set intraorally to assess whether this position reduces or eliminates the collapse from UA.
45846830|NCT02828592|Drug|Rabbit ATG|1.5 mg/kg/day x 3 days (Days -3 to -1)
45846831|NCT02828592|Drug|Cyclophosphamide|Post-transplant: 50 mg/kg IV QD (Day +3 to +4)
45846832|NCT02751060|Other|No intervention|
45846833|NCT02703480|Biological|d-PTFE|high-density polytetrafluoroethylene (d-PTFE) membrane
45846834|NCT02703480|Biological|Ti-mesh|Titanium mesh
45846835|NCT02369406|Drug|Nevirapine|
45846836|NCT02369406|Drug|Kaletra|
46053722|NCT04053335|Behavioral|Multicomponent Physician Performance Peer-Comparison Feedback Intervention|"The intervention will consist of 5 components delivered simultaneously~Clinical Leadership Team: Each site will develop a Clinical Leadership Team (CLT), typically consisting of quality officers, clinician champions, etc. to implement and monitor the intervention~Speaker Series: VCHI will offer the CLTs access to national experts via a CME-approved speaker series and office hours to support the intervention.~Education Materials: The CLTs will distribute clinician and consumer education throughout the health systems calling to avoid 9 low-value services.~Clinician Report Cards: VCHI will distribute quarterly customized clinician performance report cards to the CLTs teams using the Milliman Health Waste Calculator and Virginia APCD~Quality improvement training: The intervention will provide the CLTs with in-person quality improvement and clinician performance feedback training, using principles of self-determination theory, and will include monthly check-in calls"
46053723|NCT04045028|Drug|Tiragolumab|Administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle (Q3W)
46053724|NCT04045028|Drug|Daratumumab/rHuPH20|Administered by SC injection 1800 mg/30,000 U rHuPH20 weekly for a total of 6 doses, then every 3 weeks for a total of 16 doses (first dose given at Week 7), then every 4 weeks from Week 55 onward until disease progression
45490760|NCT05379738|Other|6 sessions of adapted physical activity after stem cell transplant|"physical assessement before and after stem cell transplant:~weight loss~brachial muscle circumference~grip strength evaluation~short physical battery test~psychometric assessment before and after stem cell transplant:~quality of life questionary~physical activities questionary"
45846837|NCT02369406|Drug|Lamivudine|
45846838|NCT02369406|Drug|Zidovudine|
45373086|NCT05677620|Drug|Drug-Induced Sleep Endoscopy (Propofol)|The DISE technique will be performed by an otorhinolaryngologist (ENT) with a nasopharyngoscope in a operating room. This technique is complemented with bite registration (MCP). Artificial sleep will be induced by intravenous administration of propofol through an infusion system controlled by an anesthesiologist (2.0-3.0 mcg/mL). The following variables will be continuously monitored: electrocardiography, oxygen saturation, and bispectral index (BIS). In this phase of the DISE, the upper airways will be evaluated during sleep with the MCP positioned intra-orally.
46053725|NCT04045028|Drug|Rituximab|Administered for a total of 8 doses. Rituximab will be administered by IV infusion for the first dose at a dose of 375 mg/m^2. After administration of at least one full infusion of IV rituximab, the SC formulation of rituximab (rituximab and rHuPH20) may be used for the remaining doses per institutional guidelines. SC rituximab will be administered at a dose of 1400 mg rituximab/23400 U rHuPH20 once weekly (QW).
45373087|NCT05677620|Device|Mandibular Advancement Device|A duo-block, titratable, and customized MAD (NOA®; Orthoapnea) will be fitted for each patient who starts treatment with MAD. The MAD consists of two CAD/CAM polyamide intraoral devices (one for the upper and one for the lower arch). The adaptation period takes place over one month. After this adaptation, patients will undergo a new PSG using MAD.
45373088|NCT00681629|Drug|Quetiapine XR|400-800 mg, oral, bid
45373089|NCT00681629|Other|Integrated Care Program (ICP)|Integrated care program (ICP), this is a legally based integrated care program covered by a contract according to §§ 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance.
45373090|NCT00969176|Drug|paracetamol|Intravenous paracetamol administration in neonates, loading dose 20 mg/kg, followed by a Gestational age-dependent maintenance dose of 10-20 mg/kg/24 h, divided in 4 doses (each 6h)
45373091|NCT05669586|Drug|Antitumor therapy guided by organoid drug sensitivity test|Antitumor therapy guided by organoid will be given to Multi-line Drug-resistant Non-small Cell Lung Cancer patients.
45373092|NCT00969254|Drug|Pílulas de Lussen|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.~* Drug A: Pílulas de Lussen®~** Drug B: placebo."
45373093|NCT00969254|Drug|Pyridium®|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.~* Drug A: Pyridium®~** Drug B: placebo."
46053726|NCT04045028|Drug|Atezolizumab|Administered by IV infusion at a fixed dose of 1200 mg Q3W
45490761|NCT03174535|Drug|Qilong capsules (QLC), produced by Jining Huaneng Pharmaceutical Factory Co., Ltd.|The recommended dosage of QLC was 0.4g each time, 3 times a day. The course of treatment was 12 weeks.
45490762|NCT04776499|Drug|Propylthiouracil, Riociguat, Perphenazine|"Administration of propylthiouracil, riociguat, and perphenazine in combination~Investigational medicinal product (IMP):~Propylthiouracil: 100 mg, Riociguat: 1 mg, Perphenazine: 16 mg"
46053727|NCT04039867|Drug|Oxaliplatin with Gemcitabine|Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.
46053728|NCT04010747|Behavioral|Motivational Interviewing for Loved Ones (MILO)|4 sessions of behavioral coaching in motivational interviewing communication techniques
46053729|NCT04010747|Behavioral|Mental Health Services Consultation and Waitlist|1 session of individualized consultation on relevant mental health services for the IP and participating PCSO and 6 weeks on a waitlist, followed by opportunity to participate in MILO sessions.
45373094|NCT00921791|Device|HBPM|Automatic oscillometric device for home blood pressure measurement and usual care.
45373095|NCT00921791|Device|HBPM and Pharmaceutical care|Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists
45373096|NCT00921791|Behavioral|Pharmaceutical care|consultations with the pharmacists
45373097|NCT00921791|Other|Usual care|Consultation with the physician.
45373098|NCT04503252|Other|Blood samples for the measurement of the concentration of cefazolin|Blood samples for the measurement of the concentration of cefazolin will be collected on the 1st (mid-dose and trough sample), 3rd (mid-dose and trough sample),7th and 14th day (for both only trough sample) of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (usually within 4 weeks after inclusion; only in patients on outpatient continuous parenteral antibiotic treatment).
45846839|NCT01690728|Behavioral|Physical Activity|The intervention program will continue for six month consisting of two weekly sessions of 40 min exercise supervised by physiotherapists. The supervised exercise program will take place at the training center Fitness.dk in Esbjerg and Kolding. It will be in cooperation with physiotherapists at the Therapy Department of Sydvestjysk Sygehus Esbjerg and the Therapy Department of Fredericia and Kolding Sygehus, Sygehus Lillebælt. The exercise program at the two centers will be equal. In addition the patients will be provided with free access to a fitness center. The patient will be encouraged to do at least 3.5 hours of moderate to vigorous physical activity per week.
45373099|NCT04503252|Other|S. aureus culture isolate|The S. aureus culture isolate will be subjected to exact cefazolin MIC determination and to measurement of the level of cefazolin tolerance.
45373100|NCT04503252|Other|structured telephone interview|Structured telephone interview for Patient follow- up after 30 days
45846840|NCT00938106|Radiation|optimised magnetic resonance image-guided intra-uterine brachytherapy|Brachytherapy treatment will be planned based on the MRI test and will be individualized for each study participant,based on participant's cancer and body inside.Brachytherapy will be as an inpatient over 2-3 days. All other care will follow standard procedures.
45373101|NCT04503252|Other|Sub-study quantitative measurement of Torque Teno virus|An additional EDTA sample will be drawn for quantitative polymerase chain reaction (PCR) of TTV DNA and analyses of cytokines and other parameters of the activation state of the immune system.
45373102|NCT04503252|Other|Sub-study investigating cefazolin concentrations in sweat|For each visit of included patients, a sweat sample will be collected via a CE certified Macroduct Sweat Collector. Eccrine sweat glands of the lower forearms are stimulated by pilocarpine (a parasympathomimetic) as well as a local current for 5min. Sweat is subsequently collected by capillary containers during 30min and transferred to small tubes on dry ice. Sweat sample analysis is conducted using mass spectrometry.
45373103|NCT00969410|Biological|AV-299|AV-299 will be given as an intravenous infusion in dose-escalating doses of 2, 10, and 20 mg/kg once every 2 weeks.
45373104|NCT00546260|Drug|placebo|administration of iv bolus prior to angiography
45373105|NCT00546260|Drug|PRT060128 Potassium|administration of iv bolus prior to angiography
46053730|NCT04007900|Behavioral|Positive Affect Treatment|PAT was designed as a 15-week intervention delivered in 3 modules. Module 1 (Pleasant Events Scheduling) uses behavioral activation methods to enhance positive experiencing before, during, and after rewarding events. Module 2 (Attending to the Positive) applies cognitive training techniques to promote shifting attention towards rewarding aspects of daily situations and to learn behavior mood associations. Module 3 (Cultivating the Positive) uses mindfulness approaches to foster reward experiencing. Treatment length has been expanded to 20 sessions to enhance the suitability of the intervention for AN and target the reward mechanisms that characterize AN. Additional adaptations include: 1) An emphasis on a mindful balance between reward and inhibition; 2) Additional module on shifting attention away from AN-specific rewards; 3) Addition of exercises to work towards long-term life goals and enhance healthy experiences; and 4) Further focus on navigating social rewards.
46053731|NCT04000256|Behavioral|Activity based rehabilitation|Activity based rehabilitation for the upper extremity involves various gross and fine movements, reach and object transportation, and object manipulation. The rehabilitation equipment used during training will include gaming and instrumented training equipment, conventional table-top tasks, and exercise aids.
45373106|NCT00969488|Other|High protein diet|"INTERVENTION is to stimulate the consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group.~The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats)."
45373107|NCT03485430|Behavioral|Tapering|Tapering with follow up by nurse at weekly basis in beginning of tapering. Tapering in an outpatient setting. Follow-up to doctor after four months.
45373108|NCT00679367|Drug|dexamethasone|40 mg once weekly
45373109|NCT00679367|Drug|lenalidomide|10 mg/day D1-21
45373110|NCT00679367|Drug|melphalan|5 mg/m2 D1-4
45373111|NCT00969566|Drug|sitagliptin, metformin|sitagliptin 100mg once daily and metformin 500mg twice daily, orally, for 24 weeks.
45373112|NCT05091918|Device|Motionsense Wearable|Remote patient monitoring
45373113|NCT00973544|Other|Cultures taken from the drain discharge|Cultures will be taken from drain's fluids discharge in Post Operative Day 4,8,10,12. When drain is removed cultures of the drain tip are taken. Clinical signs of surgical signs infections will be observed.
45373114|NCT00755495|Drug|Ramelteon and doxepin|Ramelteon 8 mg, tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
45373115|NCT00755495|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
45373116|NCT00755495|Drug|Doxepin|Ramelteon placebo-matching tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
45373117|NCT00755495|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
45373118|NCT00964184|Drug|Metformin|
45373119|NCT00964184|Behavioral|Lifestyle modification|
45373120|NCT04005300|Dietary Supplement|standard enteral nutrition|Enteral nutrition was treated within 48 hours after ICU and the calories were 500-750kcal/d
45373121|NCT04005300|Dietary Supplement|restricted enteral nutrition|Enteral nutrition was treated within 48 hours after ICU and the calories were 10-20kcal/kg/d for 3 days
45373122|NCT00969644|Drug|Somatropin|s.c injections once daily 10-30 mícrogram/kg/day
45373123|NCT00969644|Drug|Pegvisomant|s.c. injections once daily (10-15 mg/day)
45490763|NCT03668054|Drug|Bevacizumab (Lumiere®)|The first three doses of bevacizumab (Lumiere®) were administered via intravitreal injection on a monthly basis. A safety evaluation was conducted in the first month. Following the first three doses, continuation of the treatment (up to 6 doses) was decided according to response.
45490764|NCT04698187|Drug|CMP-001|Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
46053732|NCT03998527|Device|Transcutaneous Electrical Spinal Cord Stimulation (TcESCS)|TcESCS is a non-invasive DC battery powered device. Investigators and/or research team members will continually assess the appropriate stimulation parameters including configurations, current, voltage and frequency delivered by up to five active electrodes applied on skin of the back from cervical to lumbar levels. Stimulation parameters used during experimental assessments and interventions will be closely monitored by the research team. Every research participant will be slowly acclimated to stimulation. Blood pressure, heart rate, respiratory rate, and electromyography will be closely monitored while we are determining the correct stimulation parameters in the lab. During the stimulation training sessions, we will monitor blood pressure regularly throughout the session.
45373124|NCT05646420|Other|Blood sampling|A blood sample of 15 ml will be collected for each patient.
45373125|NCT00969800|Device|Cleverin Gel|Chlorine dioxide gas concentration at a range of 0.005 to 0.03 ppm.
45373126|NCT00969800|Device|Inactive Cleverin Gel|Seemingly same chlorine dioxide gas-generating device, but no gas is generated.
45490765|NCT04698187|Drug|Nivolumab|Nivolumab 360 mg IV is administered Q3W.
46053733|NCT03990623|Radiation|Computed Tomography Perfusion Imaging|Undergo perfusion CT
46053734|NCT03990623|Procedure|Liver Biopsy|Undergo liver biopsy
46053735|NCT03959904|Procedure|Small stitch|Wound closure will be using small stiches or larger spaced stitches
45373127|NCT05061888|Other|Smart Intervention for Food Waste Management and Replacing current diet with Fruits and Vegetables|Will receive a Smart Intervention on Food Waste Management and replacing less healthy foods with fruits and vegetables.
45373128|NCT05061888|Other|Smart Intervention for Stress Managment|Will receive a Smart Intervention on stress management practices and strategies.
45373129|NCT04008914|Other|retrospective observation|Retrospective review of study patients excluded from the CONNECT- HF trial who were discharged with a diagnosis of HFpEF between August 1, 2017 and March 1, 2018. Readmission rate at 30 and 90 days along with patient demographics and associated comorbidities were analyzed.
45373130|NCT04073394|Behavioral|Standard Lifestyle Intervention|Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the Mayo Clinic Diet program.
45373131|NCT04073394|Behavioral|Modified Lifestyle Intervention|Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the participants obesity phenotype.
45373132|NCT00964262|Drug|SR Exenatide (PT302)|0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg dosage(dose escalation), single subcutaneous injection
45490766|NCT03667742|Diagnostic Test|analysis of sweat and serum samples for protein markers|collection of blood and sweat samples (with Macroduct Sweat Collecting System) in patients with suspected tuberculosis or proven acute tuberculosis or pulmonary diseases (pneumonia, bronchitis, COPD) and analyzing serum and sweat for protein markers (Early Secretory Antigenic Target (ESAT-6) and Culture Filtrate Protein 10 (CFP-10) and C-reactive protein (CRP) and Amyloid A2 and complement component 1q (C1q)) by mass spectrometry and enzyme-linked immunosorbent assay (ELISA)
45846841|NCT00793806|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
46053736|NCT03959904|Other|Blood sample|A blood sample to look for biological markers of Hernia formation will be taken
46053737|NCT03959904|Other|Tissue Sample|A tissue sample will be taken to measure markers of wound healing.
45373133|NCT00964262|Drug|Placebo|Plcacebo of each doasage, single subcutanoeus injection
45373134|NCT00973778|Other|Preoperative Chemoradiotherapy|Patient will receive pre-operative radiotherapy with intensity modulated radiotherapy to primary and any grossly enlarged pelvic nodes 5Gy in 5 fractions over 5 days with concurrent capecitabine 1500mg p.o. bid for 1 week, then undergo surgery.
45373135|NCT05623410|Biological|ATGC-110|ATGC-110 is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.
45373136|NCT05623410|Biological|Xeomin®|Xeomin® is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.
45373137|NCT00964340|Drug|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.
45373138|NCT00964340|Drug|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of the SRT2104 powder into a size 00 opaque capsule, which is then stored in dosing bottles.
45373139|NCT04004598|Behavioral|golf training|12 weeks of training by Professional Golf Association professional
45373140|NCT00973934|Device|Magstim Theta|
45373141|NCT00973934|Device|Thymatron System IV|
45373142|NCT00970112|Procedure|Open Flap Debridement|Open flap debridement - access flap + scaling and root planning
45373143|NCT00964418|Drug|insulin degludec|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
45490767|NCT03623048|Other|chlorhexidine|antibacterial and anti-inflammatory mouthwash
45490768|NCT03623048|Other|saline|anti-inflammatory cleansing mouthwash
45490769|NCT03623048|Other|Propolis extract|antibacterial mouthwash
45490770|NCT03623048|Other|pomegranate extract|antibacterial mouthwash
45490771|NCT01312597|Other|Fruit juice beverage|500ml fruit juice beverage, single dose per visit
45490772|NCT03016598|Drug|Intranasal oxytocin|Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a oxytocin nasal spray 40 International Units (IU) to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
45490773|NCT03016598|Drug|Intranasal placebo|Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a placebo nasal spray 40IU to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
45490774|NCT04618315|Device|Hearing Aids|Receiver-in-the-ear hearing aids.
45846842|NCT00580944|Procedure|laser treatment of port wine stain birthmarks|Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
45846843|NCT00540540|Device|Diffuse Optical Spectroscopy|Breast properties scanning
46053738|NCT03959904|Other|Pain Score|A pain score will be recorded following the surgical procedure.
46053739|NCT03959904|Other|Quality of Life Score|A Quality of Life Score will be recorded at 1 month 6 months and 12 months post surgery
46053740|NCT03950973|Behavioral|CareAvenue|CareAvenue is an e-health tool providing information about diabetes management and low-cost resources. Participants in this group have access to CareAvenue and receive a weekly automated phone call and text messages related to CareAvenue and its resources as well as diabetes management.
45373144|NCT00964418|Drug|insulin glargine|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
45373145|NCT00974012|Drug|Divalproex Sodium|500 mg ER Tablet
45373146|NCT00974012|Drug|Depakote®|500 mg ER Tablet
45373147|NCT04009226|Other|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
45373148|NCT00964574|Drug|INSULIN GLULISINE (HMR1964)|"Pharmaceutical form:~APIDRA 100U/ml flacon for the titration period in the hospital APIDRA 100U/ml solution for injection in cartridge in OptiSet~Route of administration:~3-4 subcutaneous injections per day"
45373149|NCT00964574|Drug|INSULIN GLARGINE|"Pharmaceutical form:~LANTUS 100U/ml solution for injection in cartridge~Route of administration:~Once daily subcutaneous injection in the evening"
45373150|NCT04008680|Other|EQ-5D-5L survey internal consistency|To see how increasing the number of questionnaires affects the internal consistency of the EQ-5D-5L.
45373151|NCT00970346|Drug|OligoG CF-5/20|Inhaled OligoG CF-5/20 will be given to healthy volunteers with different concentrations to test tolerability of the drug
45373152|NCT03937778|Behavioral|Deep pressure block|Apply deep pressure block by using blood pressure cuff.
45373153|NCT03935126|Diagnostic Test|Diagnostics|Diagnostics
45692869|NCT01275040|Other|Mobile screening; Health Education|Active screening for diabetes complications - neuropathy screening, retinopathy screening, blood and urine tests. Health education for both patients and health workers on diabetes. Active collaboration between primary and tertiary care in the public health system.
45846844|NCT00540306|Device|Diffuse Optical Spectroscopy|Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
45846845|NCT02644278|Drug|VX-984 120 mg + PLD 40 mg/m^2|Participants received VX-984 orally 120 milligram (mg) orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 120 mg in combination with pegylated liposomal doxorubicin (PLD) 40 milligram per square meter (mg/m^2) administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m^2.
45373154|NCT00964652|Other|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):~treadmill training with additional body load (A1), control condition (conventional physical therapy) (B). and treadmill training with additional body load again (A2). Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
45373155|NCT00970580|Drug|BIIB022 With Paclitaxel and Carboplatin|Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin
45373156|NCT00974168|Radiation|Cumulative BED ≤ 100|Radiation
45373157|NCT00974168|Radiation|Cumulative BED ≤ 130 Gy2|Radiation
45846846|NCT02644278|Drug|VX-984 240 mg + PLD 40 mg/m^2|Participants received VX-984 orally 240 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 240 mg in combination with PLD 40 mg/m^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m^2.
45846847|NCT02644278|Drug|VX-984 480 mg + PLD 40 mg/m^2|Participants received VX-984 orally 480 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 480 mg in combination with PLD 40 mg/m^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m^2.
45846848|NCT02644278|Drug|VX-984 720 mg + PLD 40 mg/m^2|Participants received VX-984 orally 720 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 720 mg in combination with PLD 40 mg/m^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m^2.
45846849|NCT02645760|Other|Core stabilization exercise|7-weeks of core stabilization exercise
45846850|NCT02645760|Other|Conventional treatment|7-weeks of conventional treatment include therapeutic ultrasound and hot pack
46053741|NCT03950973|Behavioral|Guest Assistance Program|The Guest Assistance Program (GAP) is a resource, which provides assistance with medical and non-medical needs and resources to patients receiving medical care at University of Michigan health system. Participants in this group are provided with GAP information and receive text messages related to diabetes management.
46053742|NCT03929315|Behavioral|OLV technique on tracheo-bronchial model|Models will range in size from 6 yrs to 6 weeks.
46053743|NCT03929120|Biological|Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)|Subjects will be treated with regular standard of care plus 0.5-1 million MSC/Kg intravenously.
46053744|NCT03924102|Drug|Cardiac Perfusion and Metabolism with [11C] Acetate PET/CT|A rest and stress imaging study will be conducted on the PET/CT scanner with [11C] Acetate.
45373158|NCT04009304|Behavioral|OSNAP|Afterschool practice and policy change to support healthy eating and physical activity
45373159|NCT00974324|Drug|endostar and CHOP|"endostar, 7.5m g/m2, intravenous, Day 2-15, repeat every 3 weeks~CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone"
45692870|NCT01275040|Other|Health education|Health education given to both patients and healthcare workers. No mobile screening team will visit facilities and no interaction between primary and tertiary care will be evaluated.
45373160|NCT00545714|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
45373161|NCT00545714|Drug|Fludarabine|Fludarabine 25 mg/m^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
45373162|NCT00545714|Drug|Rituximab|Rituximab 375 mg/m^2 as IV infusion will be administered on Day 0 of Cycle 1; 500 mg/m^2 as IV infusion will be administered on Day 1 of Cycle 2-6; and 375 mg/m^2 as IV infusion every 2 months from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
45373163|NCT00970658|Drug|Salonsip plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
45373164|NCT00970658|Drug|Sabia plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
45373165|NCT00964730|Drug|Talampanel|titrated to 50mg three times a day over 9 days and a single dose administered on Day 10
45373166|NCT00964730|Drug|Moxifloxacin|Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10
45373167|NCT00964730|Drug|Placebo|administered three times a day over 9 days and a single dose administered on Day 10
45373168|NCT00974402|Behavioral|Cognitive Behavioral Therapy|The study investigators have developed a 4-session PTSD treatment plan including a behavioral health consultants (BHC) manual and a patient guide for use in primary care. Therapists will be psychologists who are functioning as behavioral health consultants (BHC) in an integrated primary care clinic. The study will adapt intervention methods for use in the time-constrained primary care environment from Cognitive Behavioral Therapy(ies) that have proven effective for PTSD in specialty mental health care settings. Study participants will receive four 30-minute treatment sessions over six weeks.
45373169|NCT00539838|Drug|Prednisone|Oral repeating dose
45490775|NCT03667664|Behavioral|Physical exercises et nutritional counseling in elderly people at risks of loss of autonomy|"Pre-program : eligibility criteria, nutritional status (MNA score, BMI, recent loss of weight), previous history, comorbidities, clinical examination, number of loss in the previous year, Rapid Assessment of Physical Activity score, activities of daily living and Instrumental activities of daily living, Medical Outcome Study Short Form 36 score, physical tests (Hand grip, Short Physical Performance Battery, Knee extension, Neurocom platform physical tests, Dual X-Ray Absorptiometry and Bio-impedance for Body Mass measurement, Muscular echography.~Implementation of a one year multimodal program based on physical exercises and nutrition counseling as a way of preventing dependence and loss of autonomy in elderly people."
45846851|NCT02648022|Behavioral|Brief mental health interventions and case management|The mental health practitioner (MHP) provided brief interventions and follow up sessions designed to reduce the risk factors that are barriers to successful antiviral treatment (substance use, depression, PTSD. Second, MHP provided ongoing case management services to these patients, with an emphasis on navigating the complex HCV care process, preparation for antiviral treatment, and managing the treatment process (adherence, side effects, etc). Third, the MHP also activated the patient and facilitate the medication management of depression and other psychiatric disorders when possible by collaborating with the prescribing HCV physicians.
45373170|NCT00539838|Drug|Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)|Oral repeating dose
45373171|NCT00539838|Drug|Methylprednisolone|Intravenous repeating dose
45373172|NCT00539838|Drug|Ocrelizumab|Intravenous repeating dose
45373173|NCT00539838|Drug|Placebo|Intravenous repeating dose
45846852|NCT02648178|Device|HALO|HALO manufactures e-cigarettes which will be distributed to patients. Two products, the G6 and tank model will be used.
46053745|NCT03918421|Other|Clinical examination and patients' questionnaires regarding activity and participation (preliminary Immunogloblin M (IgM)-Rasch-built overall Disability Scale (RODS), and finalized IgM-RODS)|Rasch-built overall Disability Scale (RODS) is a disease-specific, patient-based, linearly weighted scale that captures activity and social participation limitations to detect activity limitations in patients with Immunogloblin M (IgM) anti-myelin-associated-glycoprotein peripheral neuropathy. For this study, the preliminary RODS is a 146 item patient-reported outcome instrument that assesses activity and social participation limitation. Rasch Measurement Methods examine the extent observed data (patients' actual responses to scale items) accord with predictions of those responses from a mathematical model.
46053746|NCT03916328|Drug|B/F/TAF|A third of the women will be randomized to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy®).
46053747|NCT03916328|Drug|TDF/3TC/EFV or DTG or NVP|A third of the women will remain on Tenofovir Disoproxil Fumurate.(TDF) containing ART.
46053748|NCT03916328|Other|DMPA|Two thirds of the women will be on DMPA for contraception.
46053749|NCT03916146|Behavioral|Parent Training Intervention|Adapted version of the Family Check-Up/Everyday Parenting intervention
46053750|NCT03901638|Drug|Tllsh2910|Tllsh2910 80mg twice per day orally for 12 weeks
46053751|NCT03901638|Drug|Placebo|Placebo
45373174|NCT00970892|Drug|Warfarin dose titration|Dosage
45373175|NCT00964808|Drug|Buprenorphine|Start: Day 0 (T=0), 10 micrograms/t until the day of discharge from the Hospital. New plaster at T= 7 days.
45373176|NCT00964808|Drug|Oxycodone|Start: 10 hours (+/- 2 hours) after the operation. Dosage: 10 mg * 2 pr. day until time to discharge from the Hospital or latest at day 12.
45373177|NCT05011890|Device|Moovcare® use|Moovcare® performs symptom monitoring by automatically delivering ePRO surveys on common symptoms experienced by lung cancer patients. Results are stored in a secure web-based portal for provider review. Providers will manage ePRO responses through a combination of reports graphically displaying responses over time and e-mail alerts about concerning levels or combinations of symptoms.
45373178|NCT00970970|Other|89Zr bevacizumab PET scan|Patients will be injected intravenously with 37 MBq, protein dose 5 mg 89Zr-bevacizumab at day 0. PET scans will be done at day 4.
45373179|NCT03765450|Drug|Infliximab|Patients will receive infliximab at the discretion of their physician as part of standard of care.
45373180|NCT00974558|Device|handheld fan directed to cheeks|Handheld fan directed to cheeks for 5 minutes
45373181|NCT05258084|Behavioral|sexual minority awareness training|sexual minority awareness training is planned as 4 interviews (1 interview per week) for a total of 4 hours. Gender and sexuality-related terminologies and concepts will be discussed in the 1st meeting. Expression of sexual identity and gender transition processes will be examined in the 2nd meeting. In the 3rd meeting, the determining factors in the inadequate utilization of health services by LGBT individuals will be discussed. In the 4th meeting, what can be done to create a safe and health-friendly environment for LGBT individuals and healthcare professionals will be discussed.
45373182|NCT00974636|Dietary Supplement|Low Salt Diet|Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day
45373183|NCT00974636|Dietary Supplement|Usual Salt Diet|Usual salt intake (approximately >180-200 mmol/day in the average American diet).
45373184|NCT05257772|Device|AV Delay Optimised RV Pacing|AV Delay Optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems) and Echo to assess LVOT gradient change.
45373185|NCT04024020|Other|lumbar puncture|Subjects will have a lumbar puncture to collect cerebrospinal fluid collection
45373186|NCT00974714|Drug|L-arginine|Oral L-arginine 2 g twice a day for 14 weeks
45373187|NCT00974714|Other|placebo|oral placebo 2 g twice a day for 14 weeks
45373188|NCT00971126|Drug|sorafenib (Nexavar®), thalidomide (Thado®)|"Phase I Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and Escalation dose of Thalidomide at dose Level I: 50 mg/day (50mg, p.o., qd); Level II: 100 mg/day (50mg, p.o., bid); Level III: 150 mg/day (100mg/50mg, p.o., bid); Level IV: 200 mg/day (100mg, p.o., bid).~Phase II Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and MTD of Thalidomide at phase I study."
45373189|NCT04001946|Device|Button Huggie|low profile, external securement device for G-buttons
45373190|NCT00971360|Other|conversion disorder|Proinflammatory cytokine levels in conversion disorder
45373191|NCT00964964|Drug|insulin degludec|Insulin degludec injected s.c. (under the skin) three times weekly
45373192|NCT00964964|Drug|insulin degludec|Insulin degludec injected s.c. (under the skin) once daily for one week
45373193|NCT00964964|Drug|placebo|Placebo injected s.c. (under the skin) four times weekly
45373194|NCT04183998|Other|Trans-spinal Electrical Stimulation (tsES)|Stimulation will be achieved with two self-adhesive stimulation electrodes attached to the dorsal aspect of the neck overlying the cervical vertebrae and two self-adhesive rectangular return electrodes placed over the shoulders. Spinal motor evoked potentials (sMEP) induced by trans-spinal electrical stimulation (parameters, 1 Hz with a 0.1-1 ms pulse width and monophasic waveform) to determine recruitment profiles of proximal and distal motor pools with increasing stimulation intensity ranging from 10 to 200 milliampere. Stimulation parameters for the therapeutic stimulation will be ranged from 5-40 Hz and 20-100 milliampere.
45373195|NCT00965042|Drug|Ceftobiprole|ceftobiprole 500 mg by intravenous infusion every 8 hours for 7 days
45373196|NCT03676764|Drug|Azithromycin|biannual azithromycin in eligible communities to children 1 to 59 months old Targeted azithromycin to children aged 5 to 8 weeks old at the vaccine visit
45373197|NCT03676764|Drug|Placebos|biannual placebo in eligible communities to children 1 to 59 months old Targeted placebo to children aged 5 to 8 weeks old at the vaccine visit
45846853|NCT02648646|Other|Otago Exercise Programme and Walk with Ease|The Otago Exercise Programme is a falls prevention program that is successful at reducing falls in adults 65+ years of age. Briefly, this program includes flexibility, progressive lower extremity strengthening with ankle weights, and balance exercises. The investigators are replacing the Otago walking program with the evidence-based Arthritis Foundation's Walk With Ease program.
45373198|NCT00974792|Biological|pegfilgrastim|
45490776|NCT04052737|Drug|Normal Saline along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients. In this arm normal saline along with standard treatment will be given for active comparison.
46053752|NCT03896438|Device|Transcranial Direct Current Stimulation (tDCS)|Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
46053753|NCT03876769|Biological|CTL019|"Based on the subject's weight, one of two possible dose ranges will be prepared for the subject:~Subjects ≤ 50 kg: 0.2 to 5.0 x 10(6) CAR-positive viable T cells per kg body weight~OR~Subjects > 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells"
45373199|NCT00974792|Biological|rituximab|
45373200|NCT00974792|Drug|cyclophosphamide|
45373201|NCT00974792|Drug|cytarabine|
45373202|NCT00974792|Drug|doxorubicin hydrochloride|
45373203|NCT00974792|Drug|etoposide phosphate|
45373204|NCT00974792|Drug|ifosfamide|
45373205|NCT00974792|Drug|leucovorin calcium|
46053754|NCT03870217|Behavioral|Site selection|Turning off electrodes on the electrode array based on imaging and psychophysical measures
45373206|NCT00974792|Drug|methotrexate|
45373207|NCT00974792|Drug|vincristine sulfate|
45373208|NCT03659214|Behavioral|Questionnaires|Answering 4 questionnaires : anxiety, depression, quality of life and adherence
45490777|NCT04052737|Drug|PMZ-1620 (sovateltide) along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients.
45373209|NCT00971438|Procedure|Diagnostic imaging|Patients with a scoring suggesting an equivocal diagnosis of appendicitis are randomised to diagnostic imaging (CT or US) or repeat examination after inhospital observation
45373210|NCT03657888|Behavioral|Family Club Denmark (FCD)|Participation in Family Club Denmark
45846854|NCT02648880|Behavioral|Exercise program|"Individual exercise sessions in this program implement a whole body approach and consist of a 10-min cardiovascular warm-up and 50 minutes of cardiovascular endurance, resistance, and flexibility exercises. Target intensity of exercise will be based on the American College of Sports Medicine recommendations for cancer survivors. Prior to the start of exercise sessions, participants will be questioned on significant changes in symptoms or the presence of new symptoms (such as nausea or fever), which will used to modify the exercise session for that day to allow maximum symptom-limited participation."
45846855|NCT02648880|Other|Standard Care|The services that participants receive as standard care include their medical care, symptom control, social worker support, and nutrition. These services are provided by their oncology team.
45373211|NCT03657888|Other|Wait-list control|Participants on the waiting list
45373212|NCT00965120|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
45692871|NCT01275274|Drug|Retinoic acid|Patients will be started at half the recommended dose of retinoic acid for the treatment of acute promyelocytic leukemia (APL), i.e. 22.5mg/m2/day orally in two divided doses, to minimize the risk of adverse events. If there is no decrease in PR3/MPO gene expression to a fold change of < 2 by quantitative polymerase chain reaction(QT-PCR) technique for PR3 at the end of 4 weeks, the dose will be increased to 45 mg/m2/day in two divided doses for an additional 8 weeks. If the patient shows a decrease in PR3/MPO gene expression to < 2 at 4 weeks, the patient will remain on the same dose for the remainder of 12 weeks. All patients will be followed for a total of 12 months for safety evaluations and to assess changes in disease activity and the incidence of disease relapse.
45692872|NCT01275274|Drug|Standard of care|maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone. Dose, frequency and duration depend on disease activity (partial or complete remission).
45692873|NCT01671033|Behavioral|Biofeedback|Patients with panic disorder practice muscle relaxation with temperature biofeedback monitor, and send the temperature data to server via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
45373213|NCT00965120|Drug|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140).
45373214|NCT00965120|Drug|Placebo (saline)|Systemic infusion of placebo (saline).
45692874|NCT01671033|Behavioral|Muscle Relaxation|Patients with panic disorder practice muscle relaxation via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
45692875|NCT01997333|Drug|CDX-011|
45692876|NCT01997333|Drug|Capecitabine|
46053755|NCT03867500|Drug|Niacin|All participants will receive intravenous Niacin and each participant will serve as their own saline control on the second study
46053756|NCT03867500|Other|Saline|All participants will serve as their own controls with a saline infusion study day.
46053757|NCT03867136|Drug|PZA sensitivity guided ultra-short all Oral Regimen|Pyrazinamide 1500 mg daily; Levofloxacin ≤50kg 500 mg daily, >50kg 750mg daily; Linezolid: 600 mg daily; Cycloserine ≤50kg 500 mg daily, >50kg 750mg daily; Clofazimine 100 mg daily; All treatment is taken daily;
46053758|NCT03867136|Drug|Standardized Shorter Regimen|Pyrazinamide 1500 mg daily;Levofloxacin 400 mg daily,; Prothionamide ≤50kg 500 mg daily, >50kg 750mg daily; Ethambutol: ≤50kg 750 mg daily, >50kg 1000mg daily; Clofazimine: 100 mg daily; Amikacin 600mg daily; High-dose isoniazid 600mg daily. All treatment is taken daily.
46053759|NCT03867058|Behavioral|Electrode selection/electrode configuration|Electrodes will be chosen based on their spatial tuning curves. Focused stimulation will be applied to electrodes with good temporal processing acuity.
46053760|NCT03867032|Behavioral|Auditory training|Training with psychophysical tests (amplitude modulation detection on single electrodes) for improving speech recognition
46053761|NCT03866850|Behavioral|Phase duration|We will vary the phase duration in the stimulation, and examine detection threshold, spatial spread of neural excitation, and speech recognition as the outcomes.
46053762|NCT03862014|Device|SDF only|Molar with MIH will be treated with SDF
46053763|NCT03862014|Device|SDF+ARR|Molar with MIH will be treated with SDF+ARR
45373215|NCT00971516|Procedure|Implant placement|dental implant placement
45373216|NCT00971516|Procedure|Implants surgery|dental implant surgery
45373217|NCT00971594|Behavioral|Dietary counseling|1 hour sessions, once per week, with a registered dietitian on the American Heart Association Step I diet with caloric intake for each volunteer adjusted by the dietitian to elicit a WL of ~0.2-0.4 kg/wk
45846856|NCT02649192|Biological|Influenza virus vaccine|Children will have the first influenza virus vaccine dose (dose 1) administered on day 0 of the trial, and the second dose (dose 2) administered 28 days later.
45373218|NCT00971594|Behavioral|AEX|Moderate aerobic exercise (75-80% HRR for 45 min) at the Baltimore GRECC exercise facility using treadmills 3 times per week for 6 months.
45373219|NCT00971672|Other|Questionnaire filling and laboratory analysis|"A questionnaire that included demographic characteristics, nutrition and iron supplementation in the first year, growth status, and laboratory results will be filled for each patient.~The laboratory analysis will include complete blood count and serum ferritin analysis."
45373220|NCT00679289|Drug|HDI|20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression
45373221|NCT00679289|Drug|KW2871|5 mg/m^2 IV every 2 weeks until disease progression
45373222|NCT00679289|Drug|KW2871|10 mg/m^2 IV every 2 weeks until disease progression
45373223|NCT00679289|Drug|KW2871|20 mg/m^2 IV every 2 weeks until disease progression
45373224|NCT00679211|Drug|Trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
45373225|NCT00545948|Drug|Vinorelbine followed by Cisplatin|Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes on day 1 (every 21 days x 4 cycles).
45373226|NCT00545948|Drug|Pemetrexed followed by Cisplatin|Pemetrexed 500 mg/m2 IV infusion over approximately 10 minutes on day 1, followed by Cisplatin 75 mg/m2 IV over 60 min on day 1 (every 21 days x 4 cycles)
45373227|NCT00755573|Drug|Pregabalin|Pregabalin 300 mg - 600 mg BID
45373228|NCT00755573|Drug|placebo|Regime as described for pregabalin
45692877|NCT01271920|Drug|AUY922|
45692878|NCT01271920|Drug|Trastuzumab|
45373229|NCT00971906|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen & adjuvant,or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups
45373230|NCT00755651|Procedure|Endometrial biopsy|Endometrial biopsy taken on completion of office/outpatient diagnostic hysteroscopy
45373231|NCT00974948|Procedure|EUS-guided celiac plexus neurolysis|Injection of 20cc of absolute alcohol + 10c of 0.5% bupivicaine on either side of the celiac axis.
45373232|NCT02559869|Drug|[18F] GE-180|PET Tracer Ligand
45373233|NCT00975026|Procedure|Massages ± Stretches|Chair Massage
45373234|NCT00971984|Other|Medical records summary|Summary of Medical files and laboratory results.
45373235|NCT00975104|Drug|AMG 745 0.3 mg/kg|AMG 745 0.3 mg/kg IV QW
45373236|NCT00975104|Drug|AMG 745 1.0 mg/kg|AMG 745 1.0 mg/kg IV QW
45373237|NCT00975104|Drug|AMG 745 3.0 mg/kg|AMG 745 3.0 mg/kg IV QW
45373238|NCT00975104|Drug|Placebo|Placebo IV QW
45373239|NCT00679055|Drug|MK-0736|MK-0736; 7mg once daily, orally at approximately the same time each morning for 12 weeks.
45373240|NCT00679055|Drug|Comparator: placebo (unspecified)|Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks.
46053764|NCT03857048|Other|Weight Loss|12-wk weight loss intervention using a meal replacement strategy (Health & Nutrition Technology, Carmel, CA), with an 8-10% weight loss goal
46053765|NCT03857048|Other|Exercise training|16-wk supervised endurance exercise training program
45692879|NCT05479149|Other|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
45692880|NCT05479149|Other|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
45692881|NCT01275352|Drug|Eplerenone|Eplerenone 50 mg/day
45692882|NCT01275352|Drug|placebo|placebo
45846857|NCT02649192|Dietary Supplement|Vitamins A and D|The chewable gummy contains either Vitamin A (20,000 International Units) and Vitamin D3 (2,000 International Units), which should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
46053766|NCT03857048|Other|Overfeeding|3-day hypercaloric diet designed to overfeed by 40% above total daily energy requirements
45692883|NCT01279720|Biological|Intravenous infusion of transduced cells|Intravenous infusion of transduced cells
45692884|NCT01676259|Drug|siG12D-LODER|The implantation of siG12D-LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.
45692885|NCT01676259|Drug|Gemcitabine+nab-Paclitaxel|Gemcitabine+nab-Paclitaxel
46053767|NCT03840434|Diagnostic Test|MyotonPRO|Each patient will perform a stress test to trigger the painful. Measurements will be done by intramuscular punction as usually, and by non invasive tool : MyotonPRO
46053768|NCT03839446|Drug|mitoxantrone + etoposide + gemtuzumab ozogamicin|10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6.
46053769|NCT03838146|Behavioral|Types of Exercise|moderate intensity exercise
45373241|NCT04008290|Drug|0.6 mg Liraglutide|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 0.6 mg liraglutide. The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
45373242|NCT04008290|Drug|Placebo|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of placebo (0.9% saline solution). The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
45373243|NCT02559167|Drug|Cannabidiol|The investigators will carry out a double-blind, randomized, controlled trial comparing the effects of 92 days of 400 (only for the first 2 Days starting on the Day 2 of the study) or 800 mg CBD (subjects who report side effects with the 800mg dose will be administered the CBD 400 mg dose for the remainder of the trial) vs. placebo administration on cocaine craving and relapse in 110 cocaine-dependent subjects.
45373244|NCT00975182|Drug|GDC-0941|Oral repeating dose
45373245|NCT00975182|Drug|erlotinib HCl|Oral repeating dose
45373246|NCT05271071|Diagnostic Test|Ultrasound guided piriformis muscle and gluteus maximus muscle lidocaine injection|Ultrasound guided piriformis muscle (piriformis syndrome) and gluteus maximus muscle 5 ml %1 lidocaine injection
45373247|NCT00972062|Other|Bach's Rescue Remedy Cream|0.5 ml of cream applied to skin site reactions as needed
45373248|NCT00972062|Other|Placebo Cream|Placebo cream 0.5 ml two times a day as needed
45692886|NCT01676259|Drug|Folfirinox|Folfirinox or modified Folfirinox
45692887|NCT01270282|Drug|AM-101 0.81 mg/mL|
45373249|NCT05270291|Procedure|rectal swab|rectal swab
45373250|NCT00972140|Drug|Formoterol|Formoterol-HFA pMDI 12µg twice daily
45373251|NCT00972140|Drug|Formoterol|Formoterol-DPI 12 µg twice daily
45373252|NCT05261945|Other|Routine Physical Therapy|Routine Physical Therapy treatment with hot pack, TENS, and ultrasound helps in improving and relaxing the muscle spasm and soft tissue elasticity along pain reduction.
45373253|NCT05261945|Other|Manual Therapy And Routine Physical Therapy|Mulligan is consider one of the most effective technique of mobilization.it is also important treatment for neck pain so that many physiotherapist used mulligan by including several methods such as Natural Apophyseal Glides or Sustained Natural Apophyseal Glides.
45373254|NCT05261945|Other|Stretching Exercises And Routine Physical Therapy|Regular stretching helps increase your range of motion in the joints, improves blood circulation and posture and alleviates muscular tension throughout the body.
45373255|NCT00972218|Biological|Adalimumab|Adalimumab subcutaneous injections 40 mg dose every other week for 24 weeks
45373256|NCT05230901|Other|Standard of Care|Patients with CMR-derived ECV% levels ≥25.9% will be treated with standard of care according to current guidelines (Control group).
45373257|NCT05230901|Drug|Spironolactone 25mg|"Patients with CMR-derived ECV% levels ≥25.9% in Arm Spironolactone will receive spironolactone 25 mg/d in addition to standard of care medication ."
45373258|NCT05230901|Drug|Dihydralazine|"Patients with CMR-derived ECV% levels ≥25.9% in arm Spironolactone + Dihydralazine will receive spironolactone 25 mg/d + dihydralazine (2x12.5 mg/d p.o. in slow acethylators, and 2x25mg/d p.o. in fast acethylators, confirmed by genetic testing)"
45373259|NCT02559557|Other|Educational Intervention|Participate in focus groups
45373260|NCT02559557|Other|Educational Intervention|Undergo Spanish-adapted skills training and homework assignments
45692888|NCT01270282|Drug|Placebo|
45692889|NCT01671189|Other|SMS Reminder Software Tool|The 150 patients in the intervention arm of the study will receive SMS reminders regarding their upcoming appointments. Working in parallel with the SMMC electronic medical records system, the software tool will automate reminders that request text responses from patients to either confirm or request to reschedule their upcoming appointments. This bidirectional text messaging system would not interfere with the clinics' existing reminder protocol.
46053770|NCT03824496|Diagnostic Test|Cranial Accelerometry Measurement|Measuring the HeadPulse using cranial accelerometry
46053771|NCT03781986|Drug|APG-115|APG-115 at 150mg (or lower, if dose is reduced) is taken orally every other day through day 13 of each cycle. Cycle length 21 days.
45692890|NCT01273012|Drug|Probiotic - Infloran|Drug:Probiotic - Infloran (TM) 1 cap (1 billion CFU of L. acidophilus and 1 billion CFU of B. bifidum) PO bid or tid
45692891|NCT01676337|Other|Text message appointment reminder|Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
45692892|NCT04539483|Drug|HDIT101 (blinded therapy)|Patients will be treated with with topical HDIT101 (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
46053772|NCT03781986|Drug|Carboplatin|Carboplatin is given IV at AUC=4.5 on day 1 of each cycle. Cycle length 21 days.
46053773|NCT03743402|Behavioral|Pain self-management training|"This intervention will have 4 components:~telephone-delivered evidence-based pain self-management training,~web-based video of successfully tapered patients with motivational interviewing debriefing,~a voluntary, self-paced opioid taper~opioid and non-opioid prescribing guidance for the patient's primary care provider."
46053774|NCT03743402|Behavioral|video education, motivational interviewing|web-based video of successfully tapered patients with motivational interviewing debriefing
45373261|NCT02559557|Other|Quality-of-Life Assessment|Answer questionnaires
46053775|NCT03743402|Behavioral|voluntary self-paced opioid taper|Voluntary self-paced opioid taper where patient chooses whether, when and how much to taper opioids. Taper schedule and strategy will be proposed to patients, but they will negotiate details with their primary care provider.
45373262|NCT02559557|Other|Questionnaire Administration|Answer questionnaires
45373263|NCT00972296|Device|Carbon fiber ankle foot orthosis versus cast boot|Relief of ankle pain and normalizing of gait using either device.
45373264|NCT03908099|Behavioral|Fit-For-Fertility program|The Fit-for-Fertility Program aims at implementing progressive and sustainable lifestyle changes. Participants will attend individual sessions with a dietitian and a kinesiologist every 6 weeks for the first 6 months, then every 8 weeks for the 6 following months, and then every 12 weeks until end of the study. Follow-up by telephone/e-mail will be offered between in-person meetings. These professionals will be trained in motivational counselling skills. Participants will also benefit from weekly group sessions divided into 2 parts: 1) Workshops covering 8 different topics (45 minutes) addressing healthy lifestyle and 2) Supervised classes of physical activity where one of 8 different types of exercise (45 minutes) will be practiced. Women will be required to attend all 8 different sessions within the first 6 months. Pregnant women will be met to set new lifestyle objectives specific to pregnancy, including optimal gestational weight gain based on the Institute of Medicine guidelines.
45373265|NCT03908099|Other|Standard of care|The control intervention will consist of immediate initiation of usual fertility care, as recommended by each fertility specialist, for a maximum of 24 months. The experimental intervention will be the Fit-for-Fertility Program alone for the first 6 months, then in combination with usual fertility care for an additional 12 months and thereafter, usual fertility care can continue to be provided alone for a maximum follow-up of 24 months. The lifestyle program is provided for a maximum of 18 months if there is no pregnancy, or otherwise, up to the end of pregnancy or to a total study follow-up of 24 months (whichever comes first).
45373266|NCT03927950|Drug|escitalopram|escitalopram 10-20mg per day 12 weeks
45373267|NCT03927950|Drug|bupropion|bupropion 150-300mg per day 6 weeks
46053776|NCT03743402|Behavioral|prescribing guidance for primary care provider|Based upon review of medications and diagnoses in the electronic medical record, the principal investigator will offer guidance on opioid taper rate and strategy. He will also offer suggestions to adjust or initiate other psychotropic medications to treat pain or psychiatric comorbid illness that may be unmasked through opioid taper. All prescriptions will be written by the primary care provider.
46053777|NCT03743402|Other|usual care|Usual care will consist of any and all regular care that may be offered by primary care for chronic pain and related illnesses
45373268|NCT00678899|Device|Nucleus Hybrid L24|Implantation with Nucleus Hybrid L24 cochlear implant
45373269|NCT00965432|Drug|STX107|Single dose of an oral suspension
45373270|NCT03827993|Behavioral|dedicated sexual health clinic appointment|Intervention will consist of a dedicated sexual health clinic appointment with a physician provider focused on sexual health in this population. This provider will perform a focused history and physical, and will then determine need for appropriate treatment and management, which may consist of recommendations for medications, psychosocial counseling, physical therapy, and/or dilator use, but are not required.
45373271|NCT00972452|Behavioral|Exercise|short period of exercise training (5-10 days)
45373272|NCT00965510|Behavioral|care coordination|patients receive care coordination to improve their type II diabetes
45373273|NCT00972686|Drug|GSK2126458|GSK2126458 is an experimental treatment for patients with cancer.
45692893|NCT04539483|Drug|Placebo (blinded therapy)|Patients will be treated with with topical placebo (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
45692894|NCT04539483|Behavioral|Photo documentation of orolabial herpes lesions|Patients will be asked to document their orolabial lesions with photos by using their smart phone
45373274|NCT00921869|Drug|E7050|The starting dose of E7050 will be 50 mg given orally, twice-daily, in patients with advanced tumors that have progressed following effective therapy.
45373275|NCT00965588|Biological|UB 311|Single liquid dose by intramuscular route at weeks 0, 4, 12.
45373276|NCT04008992|Drug|BMS-986259|Single and Multiple ascending dose from Dose 1 to Dose 5
45373277|NCT04008992|Other|Placebo|Placebo matching BMS-986259
45692895|NCT04539483|Behavioral|Completion of questionnaires (patient-reported outcomes)|Patients will be asked to document their health status in questionnaires by using their smart phone
45692896|NCT04539483|Procedure|28-day swabbing of orolabial region|Patients will be asked to complete 3 episodes of 28-day swabbing of orolabial lesions
45692897|NCT04539483|Procedure|Blood drawings|Blood will be drawn for e.g. safety lab, HSV-analysis, pharmacokinetic etc.
45692898|NCT00746122|Procedure|Open repair|Standard treatment of emergency open surgery
45692899|NCT00746122|Procedure|EVAR|Emergency endovascular aneurysm repair
45373278|NCT04008992|Diagnostic Test|P-Aminohippurate|Diagnostic Agent
45373279|NCT04008992|Diagnostic Test|Iohexol|Diagnostic Agent
45490780|NCT03017846|Drug|Cantharidin|Application of topical cantharidin
45373280|NCT05248490|Other|pharmaceutical interview|Pharmaceutical interview with pharmacist: to be informed treatment taken and related SAE informations at the end of hospitalization
45373281|NCT00972842|Drug|Vorinostat, Lenalidomide|"Lenalidomide: Dose escalation 10 /15 /20 /25mg/d d1-21 q28d; for 6 treatment cycles~Vorinostat: 400 mg d1-21 q28d, for 6 treatment cycles"
45373282|NCT00972920|Procedure|Transversus abdominis plane (TAP) block|Application of local anaesthetic solution (LA) levo-bupivacaine (dose 1mg/kg for each side, concentration 2.5 mg/mL) between internal oblique abdominis muscle and transversus abdominis muscle on both sides.
45373283|NCT00975494|Drug|Sildenafil|
45373284|NCT00975494|Drug|Placebo|
45373285|NCT00975572|Biological|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
45373286|NCT00975572|Biological|Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 μg|440 participants (110 elders,110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
45373287|NCT00975572|Biological|Experimental: split-virion, adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
45373288|NCT00975572|Biological|Experimental: split-virion, adjuvanted H1N1 vaccine of 30 μg|330 participants (110 elders, 110 adults, and 110 adolescents) to receive split-virion, adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
45373289|NCT00975572|Biological|Experimental: split-virion, non-adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
45373290|NCT00975572|Biological|Placebo Comparator: Placebo control|110 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
45373291|NCT00678587|Drug|Eltrombopag|75 mg, once daily, oral
45490781|NCT04691869|Device|Achilles EXPII|Portable ultrasound machine that measures a patient's bone density at the calcaneus.
45490782|NCT04613791|Biological|Blood test|Collection of epidemio-clinical, biological, radiological and therapeutic patient data. Study samples collected from 154 patients to determine whether a particular immune profile could identify individuals prone to insulin resistance
46053778|NCT03736395|Behavioral|Idaho Rural Implementation Model|The Idaho Rural Implementation Model (I-RIM) includes several aspects to support implementation of schoolwide positive behavioral interventions and supports (SWPBIS). In the first year, schools will send a staff member to a coaching institute to build internal capacity. Schools will also receive technical assistance (on-site twice per year and virtual support as needed). Schools will also receive statewide professional learning opportunities, through one group meeting per year, and through access to an invitation-only professional learning community.
46053779|NCT03736395|Behavioral|Control|Schools in this condition will receive a four-day training session about SWPBIS.
46053780|NCT03735433|Drug|162mg aspirin dose|2 pills of 81mg aspirin
46053781|NCT03734861|Device|BreatheSmart System|"BreatheSmart System: a mobile application that tracks medication usage and sends real time reminders~HeroTracker sensor that counts dosage and monitors real-time medication adherence~CoheroConnect provider portal that allows the Investigator to monitor adherence"
46053782|NCT03734861|Other|Standard of Care|These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
45373292|NCT00678587|Drug|Placebo|placebo, once daily, oral
45373293|NCT00972998|Drug|Phenyephrine|Phenyephrine coated suppositories
45373294|NCT00965666|Drug|Etanercept|All qualified subjects receive 24 weekly subcutaneous injections of Etanercept.
45373295|NCT00965744|Device|Vessel sealing system LigaSure|Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
45373296|NCT00973076|Drug|AZD8055|Tablets, orally administered, twice daily
45373297|NCT02559479|Behavioral|Weight loss interventional study with a low-calorie 18%-protein diet|
45373298|NCT02559479|Behavioral|Weight loss interventional study with a low-calorie 35%-protein diet|
45373299|NCT00975728|Dietary Supplement|Alixir - Pomegranate, apple and Açai drink / Placebo|250 ml/day Alixir/Placebo for Group 2 for 8 weeks 500 ml/day Alixir/Placebo for Group 1 for 8 weeks
45490783|NCT03667118|Dietary Supplement|Food Supplement|A powder blend of 16 common allergenic proteins ([oat, milk, egg, sesame, wheat] [almond cashew, hazelnut, peanut, pecan, pistachios, soy, walnut] [cod, shrimp, salmon]) combined with 400 IU of Vitamin D3
45490784|NCT02857855|Procedure|80% fraction of inspired oxygen for 6 postoperative hours|80% fraction of inspired oxygen delivered for 6 postoperative hours, either by a nonrebreathing facemask with a reservoir or by a respirator
45490785|NCT02857855|Procedure|28% fraction of inspired oxygen for 6 postoperative hours|28% fraction of inspired oxygen delivered for 6 postoperative hours, either by a Venturi facemask or by a respirator
45490786|NCT03666728|Drug|SHR-1210|SHR-1210 was administered 200 mg iv every 3 weeks
45490787|NCT03666728|Drug|BP102|BP102 was administered 15 mg/kg iv every 3 weeks
45490788|NCT03666871|Biological|SB-728-T|Autologous CD4+ T cells with ex vivo modification of the CCR5 gene by zinc finger nucleases
45490789|NCT03666871|Biological|Expanded unmodified autologous CD4+ T cells|Autologous CD4+ T cells without ex vivo modification of the CCR5 gene by zinc finger nucleases
45373300|NCT04919057|Device|GelPOINT®|The patient is laid in the exaggerated lithotomy and 15 degree Trendelenburg position. An incision is made between both ischial tuberosities. Perineal dissection is performed till the apex of the prostate is seen. Subcutaneous tissue laying under the incision borders is dissected deeply over the superficial perineal fascia to place the GelPOINT®.Once the robotic system is docked, dissection of prostate is started.
45373301|NCT04049747|Procedure|Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]|Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]
45373302|NCT04049747|Procedure|Focal therapy|Focal therapy (high intensity focused ultrasound or cryotherapy)
45373303|NCT04049747|Procedure|Focal therapy after Finasteride 5Mg tablets for 12 weeks|finasteride 5mg tablets 12 weeks prior to focal therapy
45373304|NCT04049747|Procedure|Focal therapy after Bicalutamide 50Mg tablets for 12 weeks|Bicalutamide 50mg per day - 12 weeks prior to focal therapy
45373305|NCT00973154|Drug|Prednisone|50mg per day of prednisone orally for 7 days versus placebo
45373306|NCT00965822|Other|North American ginseng|3 day, once daily, dosing
45373307|NCT00965822|Other|Placebo|3 day, once daily dosing
45373308|NCT04822025|Biological|MVC-COV1901 (High-Dose)|Approximately 300 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
45373309|NCT04822025|Biological|MVC-COV1901(Mid-Dose)|Approximately 100 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
45490790|NCT03014180|Device|"In-Clinic LVAT"|Algorithm offers automatic threshold measurement of differents vectors of left ventricular stimulation.
45692900|NCT04538079|Device|Multimodal objective non-invasive Monitoring|Multimodal objective non-invasive monitoring including cerebral oxygenation (NIRS), pulse oximetry with Pulsatility Index (PI) and non-invasive Cardiac Output Monitoring will be recorded but not used for clinical decision making. 2 ECHOs will be performed (one within the first 24h, one in the 2nd 24 hours after birth)
45490791|NCT03638401|Procedure|This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.|This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.
45692901|NCT02662257|Drug|Sevoflurane|"Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
46053783|NCT03729401|Drug|Active Comparator: Dual Antiplatelet Therapy (DAPT) - Aspirin 81 mg + Ticagrelor 60mg twice daily|DAPT with aspirin and ticagrelor
46053784|NCT03729401|Drug|Ticagrelor Monotherapy: Ticagrelor 60 mg twice daily|Ticagrelor monotherapy
46053785|NCT03729401|Drug|Personalized Therapy Arm: Aspirin 81 mg or Ticagrelor 60mg twice daily or Clopidogrel 75 mg once daily|Personalized therapy based on risk score and genotyping
46053786|NCT03727438|Behavioral|Tele-Self CBTI|The tele-self intervention is comprised of two treatment components: 1) self-management via a workbook with weekly readings, and 2) weekly telephone-based nurse support over 6 weeks
46053787|NCT03727438|Other|Health Education Control|6 weekly phone calls from a study nurse on a range of health topics (non-sleep), similar call duration to intervention phone calls. At the end of the study, participants will be offered assistance through the Durham Behavioral Sleep Medicine clinic.
45373310|NCT00965900|Procedure|Endoscopic band ligation|"Perform EBL within 7 days after randomization~Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~Acid suppression using proton pump inhibitor until eradicated.~After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months)."
46053788|NCT03714334|Drug|DNX-2440 injection|DNX-2440 virus will be injected stereotactically
45373311|NCT00965900|Drug|Propranolol|"start with 20 mg of propranolol b.i.d~Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
45373312|NCT00965900|Procedure|EBL+Propranolol|"EBL~Perform EBL within 7 days after randomization~Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~Acid suppression using proton pump inhibitor until eradicated.~After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months).~Propranolol~start with 20 mg b.i.d~Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
45373313|NCT03486197|Other|Laboratory Biomarker Analysis|Correlative studies
45373314|NCT03486197|Biological|Pembrolizumab|Given IV
45373315|NCT03486197|Radiation|Radiation Therapy|Undergo neutron radiation therapy
45373316|NCT00973232|Drug|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fasting conditions
45373317|NCT00973232|Drug|DDS-06C (650 mg acetaminophen and 75 mg tramadol)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fed conditions
45373318|NCT00973232|Drug|Zaldiar®|Zaldiar® (325 mg acetaminophen and 37.5 mg tramadol HCl): two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
46053789|NCT03712527|Other|Injection of Platelet rich plasma|The blood of the PRP patients group will be centrifuged by the nurse using the dedicated device. A single centrifugation is required to separate the red and white blood platelets and plasma. This method of centrifugation is carried out using specific kits (Mini-GPS System III, Zimmer Biomet Company). The PRP is then collected by the nurse into a syringe that will be provided to the injector physician. Duration of preparation: 20 to 25 minutes. After a standardized sterile preparation, a local anaesthesia will be performed. Then, the injector will inject a volume of 2 mL of PRP into the median portion of the suspected disc under radiographic guidance.
45373319|NCT00973232|Drug|Ultracet®|Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
45373320|NCT00973232|Drug|Two tablets of DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl), multiple doses, under both fed and fasting conditions|Two tablets of DDS-06C, twice daily at 12-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
45373321|NCT00973232|Drug|Zaldiar®, multiple doses,(fed & fasting):|Two tablets of Zaldiar®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
45373322|NCT00973232|Drug|Ultracet®, multiple doses, (fed & fasting)|Two tablets of Ultracet®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
45373323|NCT03440099|Other|Resistance exercise training|16-week exercise training program, wherein one leg undergoes traditional low-velocity, high-load resistance training and the other leg undergoes high-velocity, low-load power training.
45373324|NCT04049435|Device|Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla|Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla
45373325|NCT00973310|Other|Radiation Therapy and EGFR-TKI target therapy|Patients with locally advanced NSCLC received oral erlotinib (150 mg, qd) for about 6-7 weeks during the course of radiation therapy (60-70Gy in a fraction dose of 2 Gy, 5 fractions per week)
45373326|NCT00973388|Drug|Telaprevir; Moxifloxacin; Placebo|
45373327|NCT04762823|Device|Cerebellar transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
45373328|NCT04762823|Device|Sham cerebellar transcranial direct current stimulation|Uses weak electrical current (4 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo effects or participant expectation bias.
45373329|NCT04728815|Behavioral|TAU - Phase 1|4-8 weeks of TAU treatment
45373330|NCT04728815|Behavioral|CAMS - Phase 1|4-8 weeks of CAMS treatment
45373331|NCT04728815|Behavioral|DBT - Phase 1 and 2|up to 16 weeks of DBT treatment
45373332|NCT04728815|Behavioral|CAMS - Phase 2|Up to 8 weeks of CAMS treatment
45373333|NCT04728815|Behavioral|DBT - Phase 2|Up to 8 weeks of DBT treatment
45373334|NCT00965978|Drug|ONO-5920 / YM529|oral
45373335|NCT00975962|Drug|Actilyse|Actilyse according to guidelines without pretreatment with remote persconditioning
45373336|NCT00975962|Procedure|Thrombolysis + remote perconditioning|The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC.
45373337|NCT00966056|Drug|Mitomycin C|Cotton wick soaked with 1mg/ml of mitomycin c placed for 2 minutes between the raw surfaces after synechiolysis with surgical blade no.15
45373338|NCT00966056|Device|Teflon nasal septal splint|Teflon internal nasal septal splint placed between the raw surfaces and secured at the anterior end of septum with catgut 3-0 sutures, following synechiolysis with surgical blade no.15. Splint removed at the end of one week
45373339|NCT00976040|Other|Early antiretroviral therapy|"The intervention is early initiation of antiretroviral therapy after diagnosis of Cryptococcal meningitis.~In the intervention/experimental arm, triple-drug highly active antiretroviral therapy regimens will be initiated within 7 days of diagnosis of Cryptococcal meningitis."
45373340|NCT04008212|Other|Fusion imaging|Fusion imaging during aortic endovascular procedures with a mobile C-arm through the use of the EndoNaut® angio-navigation station
45373341|NCT03523728|Drug|Venglustat|Pharmaceutical form: capsule; Route of administration: oral
45373342|NCT03523728|Drug|Placebo|Pharmaceutical form: capsule; Route of administration: oral
45373343|NCT00979706|Drug|HAART|"Patients assigned to this arm will receive Trizivir and kaletra. After the first 9 months of HAART, all patients will stop HAART until HIV viral load in plasma became detectable (>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months.~All patients will be followed-up during 1 year."
45373344|NCT00979706|Drug|HAART + Immunotherapy|"Patients assigned to this arm will receive Trizivir + Kaletra + cyclosporin A during the first two months. This group also will receive GM-CSF plus pegylated-interferon-alpha until HIV viral load in plasma became detectable (>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months. At this moment they will stop HAART.~All patients will be followed-up during 1 year."
45373345|NCT00979784|Behavioral|Better Weight|Standard cognitive behavioral treatment focused on dietary & exercise behavior
45373346|NCT00979784|Behavioral|Better Weight & Better Sleep|Standard CBT to support dietary and exercise change plus sleep hygiene and sleep focused CBT
45373347|NCT00979862|Drug|Cediranib Maleate|Given PO
45373348|NCT00979862|Drug|Cilengitide|Given IV
45373349|NCT00979862|Other|Laboratory Biomarker Analysis|Correlative studies
45373350|NCT00966134|Other|exposure to high altitude|
45373351|NCT00976118|Drug|masitinib (AB1010)|oral masitinib 3 or 6 mg/kg/day
45373352|NCT00976118|Drug|placebo|matching placebo to masitinib
45373353|NCT00966212|Behavioral|parent education|Especially for Daughters audio-cd parent education
46053790|NCT03712527|Other|Injection of NaCl|The placebo will be a single-dose of saline solution which corresponds to NaCl 0,9% ProAmp 10 ml (Laboratoire Aguettant). The vials will be kept at room temperature (≤ 25°C) within the local pharmacy of each centre. 2 mL of this solution will be intra-discal injected.
46053791|NCT03703765|Device|lower limb volume estimation|"The 3D scanner system is a three-dimensional measurement system.~It allows to evaluate the volume of the lower limbs in order to quantify the evolution of the edema of the lower limbs in the venous pathology in pre and post therapeutic technique.~It is a non-invasive, easily accepted, non-invasive, non-invasive technique that minimizes discomfort."
46053792|NCT03646487|Dietary Supplement|Probiotic LP299v 10x10 colony forming units in capsule form|Daily lactobacillus plantarum (LP299v) 10x10 colony forming units in capsule form
46053793|NCT03646487|Other|Placebo in capsule form|Daily placebo in capsule form
45692902|NCT02662257|Drug|Propofol|"Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
45692903|NCT03153267|Drug|Doxycycline 100 MG Oral Tablet bid, 7 days|Patients will receive doxycycline for 7 days.
45692904|NCT03153267|Drug|Doxycycline 100 MG Oral Tablet bid, 14 days|Patients will receive doxycycline for 14 days.
45373354|NCT00980252|Behavioral|Cognitive Behavioral Therapy|Brief intervention of Cognitive Behavioral Therapy sessions compared to Team Solutions
45373355|NCT00966290|Drug|Anticoagulant (warfarin, acenocoumarol, fluindione)|Anticoagulant clinic based shared-care group
45373356|NCT00966290|Drug|Anticoagulant (warfarin, acenocoumarol, fluindione)|Usual care group
45373357|NCT04004052|Other|Ultrasound guided injection|
45373358|NCT04004052|Other|Transcutaneous Electrical Nerve Stimulation (TENS)|
45373359|NCT04004052|Other|Sham Transcutaneous Electrical Nerve Stimulation (TENS)|
45373360|NCT00966368|Drug|insulin degludec|Single dose of NN1250, formulation 1, 0.4U/kg body weight injected subcutaneously (under the skin)
45373361|NCT00966368|Drug|insulin degludec|Single dose of NN1250, formulation 2, 0.4U/kg body weight injected subcutaneously (under the skin)
45373362|NCT00980408|Drug|Sugar pill|250 mg, one dose, 60 min prior
45373363|NCT00980408|Drug|Sugar pill|250 mg, one dose, 60 min prior
45373364|NCT00980408|Drug|Sugar pill|20 mg, one dose, 8 hours prior
45373365|NCT00980408|Drug|Sugar pill|20 mg, one dose, 8 hours prior
45373366|NCT00980408|Drug|Glutamic Acid|250 mg, one dose, 60 minutes prior
45692905|NCT03153267|Drug|Controls without a history of lyme disease.|No intervention.
46053794|NCT03634397|Behavioral|Less-Impaired Arm Training|Participants receive virtual reality and manipulation training in their less impaired arm.
45373367|NCT00980408|Drug|Glutamic Acid|250 mg, one dose, 60 minutes prior
45373368|NCT00980408|Drug|Memantine|20 mg, one dose, 8 hours prior
45490792|NCT04747873|Behavioral|e-CBT|The focus of the sessions is placed on the connection between thoughts, behaviours, emotions, physical reactions, and the environment. We work on evaluating negative beliefs and thought processes and their relationship with depression. Our goal is to adjust the negative thinking so that participants can think about and adapt to the things that are happening to them. This allows them to adjust the way they behave and think about their problems in a way that is not as negative and replaces those thoughts and behaviours with potentially more realistic and productive ones. Participants will be offered e-CBT program over 12 weeks with approximately 30 slides in each module. Participants will complete pre-designed modules and homework assignments while receiving personalized feedback and asynchronous interaction with a therapist through the platform.
45373369|NCT00980408|Drug|Memantine|20 mg, one dose, 8 hours prior
45373370|NCT01563822|Biological|Follicular fluid|The intervention is flushing the uterine cavity with 2 ml of clear follicular fluid surrounding mature oocytes after ovum pick-up through an IUI catheter
45490793|NCT04747873|Behavioral|Stepped Care|Stepped care procedure (see arm/group descriptions).
45373371|NCT04007822|Behavioral|Pain Navigator Tool|The Pain Navigator Tool (PNT) was developed recently with the aim to empower patients through helping them to discuss their main concerns about pain, and to help therapists to prioritise addressing these concerns (Blomkvist et al., 2018). The initial pilot study with this tool improved the content of the consultations and patient engagement, and led to better patient-therapist interaction in a small population of healthcare providers and patients (Blomkvist et al., 2018). As it endeavours to facilitate the implementation of self-management in patients with chronic pain, the PNT aligns with the Scottish Intercollegiate Guidelines Network (SIGN) guideline for chronic pain and the Scottish Government's strategic vision (Scottish Government, 2011; SIGN, 2013).
45490794|NCT03667040|Behavioral|JOOL app|Participants will use the JOOL app for 30 days
45490795|NCT03987217|Dietary Supplement|Creatine Monohydrate|Given orally
45490796|NCT03987217|Behavioral|Exercise Intervention|Complete POWER resistance training program
45490797|NCT03987217|Other|Questionnaire Administration|Ancillary studies
45490798|NCT03666650|Drug|Edoxaban 60 MG|Viscoelastic analysis and standard laboratory tests after edoxaban ingestion
45490799|NCT04679857|Other|TKA|Total Knee Arthroplasty
45490800|NCT03011840|Other|Information leaflet|Patient information leaflet with instructions to be carried out before procedure under general anesthesia
45692906|NCT03153501|Diagnostic Test|CT-guided Abrams needle biopsy, US-guided cutting needle, medical thoracoscopy|
46053795|NCT03634397|Behavioral|Contralesional Arm Comparison|Participants receive therapy in their paretic arm, based on the best-practices framework for arm recovery post stroke.
45373372|NCT03980340|Behavioral|Short Nap Intervention|Study participants may be asked to have a 1-2 hour nap in between the breath analysis tests.
45373373|NCT03980340|Behavioral|No Nap Intervention|Study participants may be asked to sit or lay down remaining awake for 1-2 hours in between breath analysis tests.
45490801|NCT03666572|Other|Bifidobacterium infantis|Bifidobacterium longum subsp. infantis (EVC001)
46053796|NCT03606421|Radiation|SRS and neurocognitive assessments|Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
45490802|NCT03666572|Other|Bifidobacterium infantis with prebiotic Lacto-N-neotetraose [LNnT]|Bifidobacterium infantis with prebiotic Lacto-N-neotetraose [LNnT]
45490803|NCT03666572|Other|Placebo (Lactose)|Placebo (Lactose)
45490804|NCT03667508|Procedure|Rapid Maxillary Expanding Device|The expansion screw will be turned two times in the first day, and then daily until the correction is achieved.
45490805|NCT03667508|Procedure|Slow Maxillary Expanding Device|The expansion screw will be activated every five days until correcting the crossbite.
45490806|NCT02942485|Drug|Metronidazole|P/r suppositories
45490807|NCT02942485|Drug|Tinidazole|P/o tablets
45490808|NCT03666494|Drug|Ketamine Hydrochloride|As part of anesthetic induction, the addition of ketamine hydrochloride 0.5mg/kg.
45490809|NCT03666494|Drug|Propofol|As part of the patient's anesthetic induction, they will receive propofol.
45490810|NCT03666494|Drug|Fentanyl|As part of the patient's anesthetic induction, they will receive fentanyl.
46053797|NCT03606421|Radiation|WBRT and neurocognitive assessments|Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
45692907|NCT01671579|Procedure|Bowel ultrasound|The ultrasound imaging will take place prior to the clinically ordered MRE exam. The subject will be asked to lie on the ultrasound table for approximately 60 minutes while a variety of ultrasound images are completed.
45846858|NCT02649192|Other|Placebo|The chewable gummy matched placebo will be formulated with gelatin base and tangerine oil and match the Vitamin A and D in shape, taste, texture, and appearance. Gummies should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
45373374|NCT04007978|Genetic|Third generation CAR-T cells|Patients receive CD22 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity.
45373375|NCT03970590|Behavioral|CTC Intervention|"An integrated peer narrative-based intervention (VIEW > SELECT > GET), beginning with VIEW In-person viewing of VA Stories narratives, followed by SELECT a favorite Veteran] Storyteller, and then GET favorite Storyteller narrative-aligned text messages over 6 months"
45373376|NCT03970590|Behavioral|Control|6-month HTN management assessment text messages without narrative component
45373377|NCT00980876|Drug|Cipro HC|Cipro HC (Ciprofloxacin HCl and Hydrocortisone)
45373378|NCT00980876|Drug|Ciprofloxacin HCl and Hydrocortisone|Ciprofloxacin Hydrochloride and Hydrocortisone
45490811|NCT03622970|Device|VGBT with Nintendo® Wii and LMC games|Nintendo Wii and LMC games will be used for upper limb rehabilitation in Cerebral Palsy. The games are tennis and boxing for Nintendo Wii, Leapball and CatchApet for LMC.
45373379|NCT04004130|Other|Ultrasound imaging|Ultrasound imaging of the lumbar spine/subarachnoidal space
45373380|NCT00981032|Behavioral|Pre-visit Summary|The intervention is a pre-visit summary given to the patient prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
45373381|NCT00981032|Behavioral|Clinical Decision Sharing Tool|This intervention includes a pre-visit summary and a clinical decision sharing tool. Patients will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
45490812|NCT03622970|Behavioral|NDT-based upper limb rehabilitation|NDT-based upper limb rehabilitation includes using real materials (clothes, spoons, pencils, buttons, rope, etc.) such as getting dressed and eating etc. Also, It will practised with the materials such as velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools.
45490813|NCT03666884|Drug|COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1|clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
45490814|NCT03666884|Biological|AS 50% eye drops 8*1|clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
45373382|NCT03914196|Diagnostic Test|Liver Stiffness Ultrasound|Research imaging will include liver assessments of stiffness (ultrasound shear wave elastography), tissue attenuation (if available), and blood flow (gray-scale and Doppler imaging).
45373383|NCT03902184|Biological|IPH4102|Patients will receive a flat dose of 750mg
45490815|NCT04057664|Behavioral|Learning of Coping Strategies|Group sessions with psychotherapy and physiotherapy
45490816|NCT02942407|Drug|apixaban|oral anticoagulant
45490817|NCT02942407|Drug|warfarin|oral anticoagulant
45373384|NCT00981110|Device|AQUAGEL Ag Hydrofiber Wound Dressing|Hydrofibre dressing containing ionic silver: medication performed as for frequency and duration according standard procedure
45373385|NCT00981110|Device|Mepore Self-adhesive absorbent dressing|Standard dressing: medication performed as for frequency and duration according standard procedure
45373386|NCT00981266|Device|Mentor Spectra/Becker 80 Breast Implant|The Mentor Smooth Spectra/Becker 80 Adjustable Breast Implant has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over a period of time via the fill tube by injecting saline through the injection dome. Once filled to the desired volume, the fill tube and injection dome are removed, and the prosthesis remains in position as a breast implant. Its purpose is to provide volume flexibility and projection adjustability.
45373387|NCT00976430|Procedure|Autologous Bone marrow derived stem cells transplant|Stem cells are derived from the bone marrow of the patient and processed at Reliance life sciences.The stem cells are the stereotactically implanted in the striatum.
45373388|NCT05279040|Drug|Trikafta|Elexacaftor/Tezacaftor/Ivacaftor combination therapy
45373389|NCT00976742|Behavioral|Endurance exercise training|
45373390|NCT03813654|Behavioral|8-h Afternoon-Evening Sleep|8 consecutive hours time in bed during the afternoon/evening.
45373391|NCT03813654|Behavioral|8-h Free Sleep|8 consecutive hours time in bed at any time.
45373392|NCT04931862|Drug|WVE-004|WVE-004 is a stereopure antisense oligonucleotide (ASO)
45373393|NCT04931862|Drug|Placebo|Artificial cerebrospinal fluid (aCSF)
45373394|NCT04328532|Device|MRI|MRI examination (45 min max) with potential oxygen delivery for 10 min
45490818|NCT03666806|Biological|Influenza vaccine|The randomized FLUVACS trial demonstrated the benefits of influenza vaccination in the prevention of cardiovascular death. In the VIPS study the risk for acute ischaemic stroke (AIS) in children increased by 6-fold compared to the baseline population. It was postulated that infections and in particular upper respiratory tract infections acts as a stroke trigger in a child who is otherwise predisposed to stroke and why it would occur at a particular point in that child's life. It should be noted that major infections such as meningitis have been causes of stroke while this study has shown that minir infections can also act as a trigger for stroke in adults
45490819|NCT03638089|Behavioral|Fall-recovery training|Participants practice recovering from simulated, treadmill-induced slips and trips.
45692908|NCT01671579|Procedure|magnetic resonance enterography (MRE)|The subject will have a small intravenous (IV) catheter placed in on of their arms before the MRE exam. Medications called Glucagon and MultiHance will be given thru the IV catheter during the imaging study. The glucagon will decrease the movement of the intestines, which helps provide better images of the bowel. MultiHance is a contrast that helps create clearer MRE images. In addition to the MultiHance, the subject will be given an oral contrast medication called VoLumen to drink approximately 45 minutes before the MRE imaging is started. These medications are used for all clinically necessary MRE studies performed in children and adults at the UMHS. The MRE will take approximately 50 to 60 minutes to complete.
45692909|NCT00746512|Drug|Prednisone 15 mg|Prednisone 15 mg tablets once daily for 15 days.
45692910|NCT00746512|Drug|Placebo Tablets|Prednisone placebo tablets once daily for 15 days.
45692911|NCT00746512|Drug|Prednisone 7.5 mg|Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days
45692912|NCT00746512|Drug|Placebo Over-Encapsulated Tablets|Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days
45373395|NCT00989898|Other|Automated closed-loop insulin delivery|Insulin infusion rates via the insulin pump will be dictated by a computer-based control algorithm according to the CGM glucose readings and automatically adjusted on the pump.
45373396|NCT05400954|Procedure|Breast reconstruction with silicone breast implant|(i) mastectomy followed by immediate implant-based reconstruction, (ii) mastectomy followed by implant-based reconstruction at a later stage and (iii) latissimus dorsi flap reconstruction with a silicone breast implant.
45373397|NCT05400954|Procedure|Breast conserving surgery/Mastectomy/Autologous reconstruction|(iv) simple mastectomy without reconstruction, (v) autologous reconstruction and (vi) breast conserving surgery,
45373398|NCT05400954|Procedure|Breast Augmentation|(vii) cosmetic augmentation with silicone breast implants
45373399|NCT00989976|Behavioral|normal sleep times|8.5 h bedtimes
45373400|NCT00989976|Behavioral|bedtime restriction|4.5 h restricted bedtimes
45373401|NCT00990054|Drug|Plerixafor|240 mcg/kg/dose and proceeding to escalating dose levels for determination of the single-dose maximum tolerated dose (MTD) provided that there are no unacceptable dose limiting toxicities
45373402|NCT00990132|Device|Home mechanical ventilation|Nocturnal non-invasive ventilation
45373403|NCT00990132|Device|Long term oxygen therapy|LTOT established as per national guidelines
45373404|NCT05361564|Drug|Brigatinib|After 7-day lead-in 90mg/day, brigatinib 180mg/day from 4 to 10weeks(optimal duration: 6 weeks)
45373405|NCT03388632|Drug|rhIL-15|IL-15 is a stimulatory cytokine that activates the immune system, inducing proliferation of T lymphocytes and NK cells. Administration of recombinant human IL-15 (rhIL-15) has been shown to result in a dramatic increase of circulating CD8+T cells and NK cells; these changes in immune cell populations suggest potential for anti-tumor activity.
45490820|NCT02921035|Drug|Rebif (Interferon beta-1a)|Rebif will be administered at a dose of 44 mcg, sc, tiw.
45490821|NCT03009344|Drug|Tazemetostat|Tazemetostat tablets.
45490822|NCT03322423|Device|Multifocal Contact Lens 1|Dailies Total 1 Multifocal Contact Lens
45692913|NCT05409027|Drug|SPI-62|SPI-62 is supplied as 1 mg tablets for oral dosing.
45692914|NCT05409027|Drug|Cortisone-d8|Cortisone-d8 is supplied as a 1 mcg/mL solution for infusion
45846859|NCT02650440|Procedure|Novel Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Novel (discrete) robot-assisted LT-BWST used progressive decrease in speed. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject.
45373406|NCT03388632|Drug|Ipilimumab|Ipilimumab is a fully human monoclonal antibody against CTLA-4, a receptor present on the surface of activated T cells that functions as an immune checkpoint. Immune checkpoints pathways typically act to downregulate T cell activity and are co-opted by tumors to allow the malignant cells to evade the immune response. Blocking the engagement of CTLA-4 with ipilimumab allows infiltrating T cells to mount an anti-tumor response. Ipilimumab is approved by the FDA for the treatment of certain patients with melanoma and has shown clinical activity in other tumor types as well.
45490823|NCT03322423|Device|Multifocal Contact Lens 2|Biotrue ONEday for Presbyopia Contact Lenses
45490824|NCT03322423|Device|Spherical Contact Lens 2|BioTrue ONEDay Spherical
45490825|NCT03007472|Device|CI532|Cochlear implant
45490826|NCT03007472|Device|Nucleus 7|Sound processor
45490827|NCT03321721|Procedure|Suture for wound repair|Repair of wound with suture
45490828|NCT03321721|Device|Suture for wound repair|Repair of wound with suture
45490829|NCT04621981|Drug|Sodium Bicarbonate Ringer's Solution|This group was treated with Sodium Bicarbonate Ringer's Solution.
45490830|NCT04621981|Drug|Normal Saline|This group was treated with normal saline.
45490831|NCT03015116|Other|Stretching|Daily foot and ankle stretching protocol
45490832|NCT03015116|Other|Cryotherapy|Daily cryotherapy in conjunction with stretching
45490833|NCT03015116|Device|Photobiomodulation Low Power|Photobiomodulation treatment with 10W power output
45490834|NCT03015116|Device|Photobiomodulation High Power|Photobiomodulation treatment with 25W power output
45490835|NCT03667430|Dietary Supplement|Porous silica|The particle is rod shaped and approximately 1-3 x 0.4-0.5 micrometers with pore sizes in the range of 70-130 Ångström or 7-13 nanometer.
45490836|NCT03667430|Dietary Supplement|Placebo (microcrystalline cellulose)|All participants starts with five days placebo run in period
45490837|NCT03006848|Drug|Avelumab|Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.
45373407|NCT03388632|Drug|Nivolumab|Nivolumab is a humanized monoclonal antibody against programmed death 1 (PD-1), a receptor present on the surface of activated T cells that functions as an immune checkpoint. One of the ligands for PD-1, PD-L1, is commonly expressed by tumor cells. Similar to inhibition of the CTLA-4 pathway by ipilimumab, blocking of PD-1/PD-L1 signaling by nivolumab allows infiltrating T cells to mount an an immune response against the tumor. Nivolumab is approved as a single agent for several cancer types, as well as for the treatment of advanced melanoma in combination with ipilimumab.
45490838|NCT03006848|Other|Questionnaires|To assess quality of life, patients will complete questionnaires at four time points.
45490839|NCT03667352|Procedure|Unilateral Scalp Block|Scalp block is provided by injecting local anaesthetic in the scalp at specific areas to block 6 nerves which are responsible for sensory innervation of the scalp - Supraorbital and supratrochlear nerves, Zygomaticotemporal nerve, Auriculotemporal nerve, Greater and lesser occipital nerves.
45490840|NCT03667352|Procedure|Transversus abdominis plane block|The transverse abdominis plane (TAP) block is a peripheral nerve block designed to anesthetize the nerves supplying the anterior abdominal wall (T6 to L1). It is usually accomplished by a single bolus injection into the transversus abdominis plane through the lumbar triangle of Petit and can be accomplished either by blind landmark based technique or alternatively under ultrasound guidance (as in this study).
45490841|NCT03667352|Drug|Intravenous Fentanyl|Fentanyl is a commonly used opioid drug administered for analgesia in the perioperative period. It may be used as either intermittent bolus administration or continuous infusion or a combination of the two. Usual infusion doses range from 1-2 microgram/kg/hr, which may be titrated based on intraoperative haemodynamics or postoperative patient reported pain scores.
45490842|NCT03666338|Other|Early, goal-directed mobilization|Early, goal directed mobilization using (1) the SOMS algorithm and (2) facilitator
45490843|NCT03665948|Other|Dietary Intervention - Ketogenic Diet (KD)|The experimental procedure for each randomly assigned participant included a 4-week of KD diet.
45490844|NCT03665948|Other|Dietary Intervention - Low-Glycemic Index Diet (CHO-LGI)|The experimental procedure for each randomly assigned participant included a 4-week of CHO-LGI diet.
45490845|NCT03667274|Procedure|cardiac valve surgery|cardiac double valve surgery (aortic and mitral valve)
45490846|NCT03665870|Behavioral|Hypoglycemia Education|Two in-person visits to the home of the participant and 4 phone calls will be conducted to provided education on prevention of hypoglycemia.
45490847|NCT03006458|Device|comfilcon A|toric contact lens
45490848|NCT03006458|Device|omafilcon B|toric contact lens
45490849|NCT04056104|Diagnostic Test|SpO2 and PIx Measurement|Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured
45490850|NCT03320941|Drug|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally daily.
45490851|NCT03320941|Drug|Placebo|Placebo will be supplied as tablets to be taken daily orally.
45490852|NCT03005288|Drug|BYM338 10 mg/kg|intravenous infusion every four weeks
45490853|NCT03005288|Other|Placebo|intravenous infusion every four weeks
45490854|NCT04055246|Dietary Supplement|Inulin|9 grams of food grade inulin added to custom made fiber bars.
45490855|NCT04055246|Dietary Supplement|Placebo (maltodextrin)|9 grams of food grade maltodextrin - replaces inulin in fiber bars.
45490856|NCT03665792|Device|nociception index qNOX|non-invasive, real time, monitoring for nociception stimulation
45490857|NCT03533816|Drug|EAGD T-cell infusion (Phase I)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
45490858|NCT03533816|Drug|EAGD T-cell infusion (Expansion)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
45490859|NCT03666260|Procedure|Quadratus Lumborum Block|Quadratus Lumborum Block with echography
45490860|NCT03666260|Procedure|femoral block|femoral block with echography
45490861|NCT03665714|Other|Impact Oral|Impact Oral belongs to Food for Special Medical Purpose (FSMP) according to China registration regulation, including Omega-3 fatty acids, Arginine and Nucleotides immunonutrition.
45490862|NCT03665714|Other|Enteral Nutrition Emulsion(TPF-T)|TPF-T
45490863|NCT03003494|Drug|Spiolto® Respimat®|observations taken in a period of approximately 6 weeks
45490864|NCT04730947|Drug|Dapagliflozin|10 mg orally once a day
45490865|NCT04730947|Drug|Placebo|Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient
45490866|NCT03559699|Drug|AG-348|"Part 1 (Dose Optimization Period): Participants began by receiving 5 mg orally, BID. Each participant's dose of AG-348 was sequentially increased to 20 mg BID followed by 50 mg BID depending on their response to AG-348 and their tolerance.~Part 2 (Fixed Dose Period): Optimized dose determined in Part 1."
45373408|NCT05399472|Diagnostic Test|Dorsiflexion lunge test|The dorsiflexion lunge test (DLT) will be used to measure ankle dorsiflexion. To perform this test, the participant stands in front of a wall holding the foot of their limb to be measured perpendicularly to it. The other foot is to be kept behind it. The participant is asked to perform a lunge (to dorsiflex the ankle and bring the knee into flexion) until the front knee touches the wall without the heel lifting off the ground. The participant steps away from the wall as much as possible as long as the knee keeps touching the wall. Measurement in centimeters is taken from the heel of the examined leg to the wall.
45490867|NCT03557281|Drug|GSK3036656|GSK3036656 will be available as an oral capsule with dosing strengths of 1 milligrams or 5 milligrams or 25 milligrams.
45490868|NCT03557281|Drug|RIFAFOUR e-275|RIFAFOUR will be available as an oral tablet with a standard dose of 150/75/400/275 milligrams of rifampicin, isoniazid, pyrazinamide and ethambutol per tablet respectively.
45490869|NCT03951103|Other|rFVIIIFc|Drug according to prescription
45373409|NCT05399472|Diagnostic Test|Jack Test|The Jack Test will be used to measure the first toe dorsiflexion under load. The examiner pulled the proximal phalanx of the hallux to dorsiflexion with his hand until the maximal amount of mobility was reached with the subject standing. The static arm of the goniometer was placed along the first metatarsal longitudinal axis while the free movable arm followed the proximal phalanx of the hallux axes.
45490870|NCT04324645|Other|Noona Software|Enrolled patients will be provided with login information for their Noona account. Patients will log in to the Noona symptom monitoring system using their own computer hardware. Any type of personal computer or compatible mobile device will be allowed (i.e. iPhone, Android phone). Patients will be able to access the Noona system from any internet access point and will be provided with the hospital/clinic public WiFi information.
45490871|NCT02449681|Drug|TH-4000 (Tarloxotinib)|
45753757|NCT04026152|Behavioral|Resistance training|Following randomization, all participants assigned to receive the resistance training intervention will receive a comprehensive exercise program. The exercise program participants will be using is similar to past research using resistance training programs with people with anxiety-related disorders and has been developed and reviewed by a team of certified personal trainers, including the primary investigator. All participants assigned receive this resistance training intervention will complete a total of six sessions with a personal trainer and six session independently over four weeks to allow for a gradual, rather than abrupt, transition to fully independently completed exercise by the 4th week. After this time participants will be encouraged to exercise independently.
46053798|NCT03582189|Other|MRI|Patients who consent to this study will have an abdominal MRI prior to or immediately after each fraction of radiation treatment in the case of those patients that are undergoing SBRT or those receiving palliative treatment. On patients receiving definitive chemoradiation, an abdominal MRI will be performed prior to or immediately after radiation treatment once per week during the any five weeks of treatment
46053799|NCT03562416|Drug|Nintedanib|Nintedanib (BIBF 1120, Ofev)
46053800|NCT03562416|Drug|Placebo Oral Tablet|Placebo
46053801|NCT03518736|Behavioral|Supporting Play Exploration and Developmental Intervention (SPEEDI)|Physical Therapy intervention
45373410|NCT05360004|Drug|Chinese herbal medicine|CHM is in the form of granules (9 g/sachet), which is comprised of 10 commonly used medicinal herbs: Codonopsis Radix, Astragali Radix, Lonicerae Japonicae Flos, Saposhnikovia Radix, Schizonepetae Herba, Mori Folium, Poria, Atractylodis Rhizoma, Atractylodis Macrocephala Rhizoma, Glycyrrhizae Radix et Rhizoma.
45373411|NCT05359926|Other|Experimental|Early urethral foley removal after the surgery
45373412|NCT05359926|Other|Active comparator|Delayed urethral foley removal after the surgery
45490872|NCT03085758|Biological|Adrecizumab|Single i.v. dose of 2 mg/kg (treatment arm A) or 4 mg/kg (treatment arm B)
45490873|NCT03085758|Biological|Placebo|Single i.v. dose of placebo (control group)
45490874|NCT02573233|Drug|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
45490875|NCT02573233|Drug|Dupilumab SAR231893/REGN668|Pharmaceutical form:solution Route of administration: subcutaneous
46053802|NCT03517293|Behavioral|Aerobic Exercise training|
45373413|NCT05361408|Drug|Zoledronic acid, once|Intravenous infusion of 5mg zoledronic acid, once
45490876|NCT02573233|Drug|fluticasone propionate and salmeterol|Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled
45490877|NCT02573233|Drug|budesonide and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
45490878|NCT02573233|Drug|mometasone furoate and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
45490879|NCT03867487|Drug|Empagliflozin 10 MG|Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)
45373414|NCT05361408|Drug|Zoledronic acid, twice|Intravenous infusion of 5mg zoledronic acid for 6month interval, twice
45373415|NCT05590806|Other|Direct composite build-ups|Direct composite build-ups application
45373416|NCT03227406|Behavioral|Sleep deprivation|Subjects are kept awake all night.
45490880|NCT03867487|Drug|Placebo Oral Tablet|Participants will take an identical appearing oral tablet with zero active ingredient.
45490881|NCT01381224|Other|Observation of biomechanical effects post injection|Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection
45373417|NCT03227406|Behavioral|Nap|Participants are given a 90-minute nap opportunity in the early afternoon.
45373418|NCT03069690|Behavioral|HABITpreg|"Treatment during pregnancy will consist of up to 10 in person sessions taking place at regularly scheduled obstetric appointments, at the investigator's research building, or a nearby location. Participants in the HABITpregnancy group will also receive texts and phone calls between sessions. HABIT will focus on weight, physical activity, eating and psychosocial issues. Women will receive consultation about nutritional balance, dietary guidelines for pregnant women and advice to maintain an optimal rate of weight gain according to prepregnancy BMI. Women will use self-monitoring forms to identify and modify cues for unhealthy behaviors. Beliefs about body weight and eating during pregnancy will be addressed and effects of physical activity on body weight, health, and mood will be included.~Due to COVID-19(coronavirus disease) restrictions and safety guidelines, HABIT pregnant treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020."
45373419|NCT03069690|Behavioral|HABITpost|"Treatment during the postpartum period (HABITpost) will consist of an intervention over the 24 weeks immediately following delivery. Treatment will include 12 biweekly sessions completed over the phone or in person. In person sessions will be done at the participant's home or another convenient location. Additionally, participants will receive calls and texts between sessions. Sessions will focus on weight, physical activity, eating and psychosocial issues.~Due to COVID-19 restrictions and safety guidelines, HABIT post treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020."
45373420|NCT00990366|Device|Cook´s biliary stent with an antireflux stent, normal biliary stent|arms are assigned randomly by closed envelope method
45692915|NCT01275742|Behavioral|Brief Cognitive Therapy Intervention|The intervention group will receive an individual, 30 minute, scripted cognitive therapy session. This intervention will be delivered by an Advanced Practice Registered Nurse or a trained research nurse. An iPad will guide the outline of the intervention. The nurse will discuss depression in heart disease and the connection between thoughts, emotions, and behaviors. The nurse will ask the patient to describe a recent stressful experience and discuss thoughts that the patient has been experiencing. Two techniques for challenging negative thinking will be introduced to the patient: thought stopping and affirmations. The nurse will ask the patient to practice these techniques at home. After the patient has practiced both techniques, the nurse will leave the patient with a booklet with the intervention. At 1-2 weeks, the nurse will administer a booster session over the phone. This session will last 10-15 minutes and will reinforce the techniques learned during the brief CT intervention.
45692916|NCT04385134|Other|No intervention|No intervention
45373421|NCT05590572|Drug|Sulfatinib|(1) Sulfatinib: 300 mg, oral once a day (QD), 21 days as a cycle
45692917|NCT03153423|Procedure|Strabismus surgery|Recession and resection of horizontal extra ocular muscles
45373422|NCT05590572|Drug|Etoposide|(1) Etoposide: 100 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle, a total of 5 cycles. The dose of etoposide can be reduced to 80 mg/m2/day and 60 mg/m2/day.;
45373423|NCT05590572|Drug|Isophosphamide|(1) Isophosphamide: 3000 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle for 5 cycles. The dose of ifosfamide can be reduced to 2400 mg/m2/day and 1800 mg/m2/day.
45373424|NCT05359614|Device|CoolSculpting Elite combined with CoolTone Treatments|Coolsculpting treatment combined with Cooltone treatments for the banana roll region of the buttocks.
45373425|NCT05359614|Device|CoolSculpting Elite|Coolsculpting treatment alone for the banana roll region of the buttocks
45490882|NCT04127539|Behavioral|Strong & Steady exercise program|The community-based group exercise program S&S, with strengthening and balance exercise as the main components. The participants will attend a once-weekly, one hour supervised session. The exercises that will be used can be found in the S&S handbook which includes different difficulty levels. All instructors are volunteers and have completed the S&S education. Each exercise session will consist of a warm-up (5-8 min.), endurance exercises (10-15 min.), strength exercises (15 min.), balance exercises (20 min.) and a cool down/stretching (5 min.). In addition to attending the group exercises, the participants will be taught and encouraged to do home exercises twice a week from hand out leaflets that can be found at www.sterkogstodig.no.
45490883|NCT01381146|Behavioral|Impact of Crime Modules|5 session/1 week modules of a restorative justice inspired victim impact group intervention
45490884|NCT01381146|Behavioral|TAU|have access to other jail programs and services
45373426|NCT03069378|Drug|Talimogene Laherparepvec (T-VEC)|Talimogene laherparepvec treatment will be given at Day 1 Week 1, and every 3 weeks thereafter .
45373427|NCT03069378|Drug|Pembrolizumab|Pembrolizumab will be given at Day 1 week 1 and every 3 weeks thereafter.
45373428|NCT03050502|Device|Chest tube drain|This group will have an intra-pleural catheter placed with the intent of draining all intra-pleural blood (HTX). The size and nature of the catheter, manner of placement, and timing of removal will be at the discretion of the attending clinician.
45373429|NCT03050502|Other|Expectant management|This group will not have an intra-pleural catheter placed on the basis of the HTX, but will undergo standard observation/conservative management by the trauma service. Intra-pleural catheters may be placed after enrollment at the attending clinician's discretion.
45373430|NCT05590416|Drug|Adalimumab|Adalimumab is administered subcutaneously at an initial loading dose of 80 mg, followed by a 40 mg dose every other week (q2w) starting from the second week. Therapy will be continued 6 months after the disappearance of active ocular inflammation. Then, injection will extend for 3 days until withdrawal after 40 days apart.
45692918|NCT00746668|Behavioral|Module 1: Visual Awareness and Eccentric Viewing|"In this module, awareness of the PRL location and eccentric viewing were trained. Exercises based on published sources were administered. One example of these exercises is the clock face display adapted from Holcomb and Goodrich and Maplesden.~This module also focused on awareness of the perceptual consequences of using a PRL. The purpose of these training exercises was to allow the subjects to appreciate perceptual alterations that occur when using a PRL and to practice making perceptual discriminations with the peripheral retina. Previously published work has demonstrated that perception in the peripheral retina can be affected by practice."
45373431|NCT00990444|Drug|Insulin in Dextran Matrix|Fixed dose capsule with 100 IU of insulin in dextran matrix. Investigational drug or placebo are administered in conjunction with food intake on a background of metformin.
45373432|NCT00990522|Procedure|debridement|There will be two (2) subject groups in the study. Subjects will be randomized into either the monthly debridement group or the weekly debridement group.
45490885|NCT01569048|Drug|Propofol and dexmedetomidine|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
45692919|NCT00746668|Behavioral|Module 2: Control of Reading Eye Movements|In this module, control of eye movements was trained. These exercises began with a series of saccade tasks to nonalphabetical stimuli and then progressed to single letter, letter pairs, and word stimuli. Subjects were instructed to make a saccade between the dots. The experimenter provided feedback concerning the appropriateness of the saccades, and the alternation rate of the dots was increased as performance improved.
45846860|NCT02650440|Procedure|Standard Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Standard (rhythmic) robot-assisted LT-BWST used progressively increased speed each week. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject
45846861|NCT02652390|Drug|Methylprednisolone 80 mg|2 mL methylprednisolone (40 mg/mL) + 1 mL lidocaine
45846862|NCT02652390|Drug|Methylprednisolone 40 mg|1 mL methylprednisolone (40 mg/mL) + 1 mL saline + 1 mL lidocaine
45846863|NCT02652390|Other|Saline|2 mL saline + 1 mL lidocaine
45846864|NCT02652780|Biological|GS010|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
45373433|NCT05590338|Drug|GSK1070806|Participants will receive GSK1070806
45373434|NCT05590338|Drug|Placebo|Participants will receive placebo
45373435|NCT00990600|Other|reduced number of pills|Switch to a fixed dose combination one pill/daily HAART
45373436|NCT02897076|Drug|betamethasone 24 mg|
45373437|NCT02897076|Drug|12mg betamethasone +placebo|
45373438|NCT02797548|Drug|Aspirin only|Aspirin only during surgery
45373439|NCT02797548|Drug|No antiplatelet therapy|No antiplatelet therapy will be during surgery
45490886|NCT01569048|Drug|propofol and remifentanil|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
45373440|NCT05590182|Device|Angiography|"Randomization either in the study arm (CO2) or in the control arm (iodine-CM) occurs right before angiography. Stenosis graduation and length are measured after diagnostic angiography and before intervention. The calculated values through the software-quantification-tool, including also a final sequence of the distal outflow with the same contrast media used during intervention, are be compared and statistically analyzed.~A pain protocol to the current pain-situation is led by the present medical-laboratory assistant after administration of CO2 and iodine-CM during intervention."
45490887|NCT03808987|Behavioral|Child-Parent Psychotherapy (CPP)|Child-Parent Psychotherapy (CPP) focuses on parent-infant relationships, increases efficacy for improved mother-child relationships, more sensitive parenting, healthier child development, and maltreatment prevention. A primary goal is to strengthen the parent-child relationship to improve family functioning and child security of attachment. Through respect, empathic concern, and positive regard, the therapeutic relationship provides mothers with corrective emotional experiences, through which they are able to differentiate current from past relationships, form positive internal representations of themselves and of themselves in relationship to others, particularly their children. Parents are encouraged to process their experiences of trauma and restore parental roles as protective shields, improve affective regulation capacities, enhance understanding of the meaning of behavior, acknowledge the impact of trauma, and support children in a more positive developmental trajectory.
45490888|NCT03808987|Behavioral|Community Health Worker (CHW) home visitation|Community Health Worker (CHW) home visitation includes assistance with concrete support needs, such as transportation to medical appointments, referrals for food, housing, and employment services, and attention to developmental needs of young children.
45373441|NCT00990678|Drug|Rocaltrol|tablet, Vitamin 1-OH-D3, total 1.25-2.5 mg daily
45373442|NCT00990678|Drug|Vitamin D|tablets, vitamin D3, 30 microgram daily
45373443|NCT00990678|Drug|Calcium|tablets, 400 mg calcium, 3 times daily
45490889|NCT03941574|Drug|HLX10|HLX10 developed by our company is sterile intravenous injection, with specification of 100 mg/10 mL/bottle. The main ingredient is 10.0 mg/mL of recombinant humanized anti-PD-1 monoclonal antibody. The excipients include 0.95 mg/mL citric acid (citric acid monohydrate), 4.56 mg/mL sodium citrate (sodium citrate dihydrate), 3.0 mg/mL sodium chloride, 30.0 mg/mL mannitol and 0.20 mg/mL polysorbate 80 (tween 80), with pH of 5.5.
45490890|NCT01384344|Other|observational|Observation during a physical exercise
45490891|NCT03935880|Device|Cartiva Implant|Cartiva hemiarthroplasty: The procedure starts with a small incision over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected, leaving approximately 2 mm of surrounding bone on the metatarsal head. A guide pin is placed within the metatarsal and a drill is then used to create a site for the implant. The implant is then placed using the implant introducer. The incision is then closed and a sterile dressing is placed.
45490892|NCT03935880|Procedure|Cheilectomy|Cheilectomy: A small incision is made over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected. The top of the metatarsal head is then cut with a sagittal saw. Additional bone spurs are resected. The incision is closed and a sterile dressing is placed.
45490893|NCT05304234|Diagnostic Test|Ultrasound or abbreviated MRI|Abdominal ultrasound or abbreviated MRI
46053803|NCT03512262|Drug|Abaloparatide|Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.
45490894|NCT04008420|Other|monitoring of the oxygen reserve index|The investigators will enroll adult patients who will undergo robotic esophagectomy under general anesthesia. The oxygen reserve index will be monitored continuously during anesthesia. The postoperative complications will be recorded after surgery.
45490895|NCT01380912|Drug|methylprednisoloneacetate|Either methylprednisoloneacetate 80 mg or saline solution will be injected first day after operation, when the drain is removed.
46053804|NCT03512262|Drug|Placebo|Abaloparatide-matched placebo.
46053805|NCT03503058|Biological|PfSPZ Vaccine|Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
45373444|NCT05265468|Other|Jones Group (Strain Counterstrain)|No pain positioning technique with diaphragmatic breathing
45373445|NCT05265468|Other|Lewit Group|Isometric muscular exercise acompained with stretching technique
45373446|NCT05265468|Other|Chaitow Group|Isometric muscular exercise acompained with stretching technique and diaphragmatic breathing
45373447|NCT05265468|Other|Placebo Group|No pain positioning of participants
45373448|NCT05359458|Behavioral|Emotional Freedom Liberation Technique|The investigators will apply Emotional Freedom Liberation Technique
45373449|NCT05590104|Procedure|Hysteroscopic CS scar defect repair|Dilatation of the cervix till 7 mm. Introduce the resctoscope through the cervix. The surgical correction of the isthmocele is done by resection of the inferior and superior edges or just the inferior edge of the defect with a resectoscopic loop, using pure cutting current, until reaching the muscular layer. Coagulation of fragile vessels at the base or even entire niche. At the end of procedure, flow and pressure of distending medium can be reduced to ensure adequate haemostasis.
45373450|NCT00990756|Drug|PF-03526299|dry powder for inhalation, 1.396 mg, BID for 14 days
45373451|NCT00990756|Drug|PF-03526299|dry powder for inhalation, 4 mg, BID for 14 days
45373452|NCT05589870|Other|Multi-drug analysis of polypharmacy treatment|Multi-drug analysis to assess and provide insights for lowering the risk of ADRs and increasing the benefit of polypharmacy treatment
45373453|NCT00538590|Device|Collagen Matrix in Glaucoma Filtering Surgery|Collagen Matrix implantation in Glaucoma Filtering Surgery
45490896|NCT03315793|Drug|Duloxetine Hydrochloride|Administered orally
45490897|NCT03315793|Drug|Placebo|Administered orally
45373454|NCT00538590|Drug|Mitomycin-C(MMC) and glaucoma filtering surgery|If mitomycin -C is applied, a single cellulose sponge soaked with Mitomycin-C(MMC) (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
45490898|NCT01569204|Drug|Etoposide|
45490899|NCT01569204|Drug|Cyclophosphamide|
45490900|NCT01569204|Drug|Doxorubicin|
45490901|NCT01569204|Drug|Prednisone|
45692920|NCT00746668|Behavioral|Module 3: Reading Practice with RSVP|In module 3, we wanted to assess only the higher-level effects of reading practice. Subjects practiced reading using stimuli that did not require reading eye movements. An example is short sentences that were presented one word at a time at a single location on a screen (Rapid Serial Visual Presentation [RSVP]). At the end of the sentence, subjects reported whether the sentence made sense or not. We also had our subjects practice reading scrolled text. Although, eye movements and saccades may spontaneously occur under the text presentation conditions of this module, they are not the efficient saccades necessary for reading.
45692921|NCT01275118|Device|Tecnis Multifocal IOL|Presbyopia correcting IOL
45692922|NCT01275118|Device|crystalens Accommodating IOL|Presbyopia correcting IOL
45373455|NCT00990834|Drug|simvastatin|simvastatin 80 mg PO daily for one to eight months.
45490902|NCT01569204|Drug|Procarbazine|
45692923|NCT01982435|Drug|Ranibizumab|Monthly injections of Intravitreal Ranibizumab 0.3 mg for 12 months in patients previously treated with Avastin for Diabetic Macular Edema.
45692924|NCT01982435|Drug|Ranibizumab|Three Monthly injections of Intravitreal Ranibizumab 0.3 mg in patients previously treated with Avastin for Diabetic Macular Edema. Then follow-up visits may be extended by 2 weeks for a total of 12 months.
45692925|NCT00747214|Drug|CRx-102|
45692926|NCT00747214|Drug|Placebo|
45692927|NCT00747214|Drug|DMARD Therapy|DMARD therapy can include methotrexate or other DMARD therapy
45490903|NCT01569204|Drug|Dexamethasone|
45490904|NCT01569204|Drug|Dacarbazine|
45490905|NCT01569204|Drug|Brentuximab Vedotin|
45692928|NCT01279798|Biological|Lucanix® (belagenpumatucel-L)|Subjects will receive up to 12 monthly (28-35 day interval) Lucanix injections at a dose of 2.5 × 10e7 cells per injection.
45692929|NCT04669691|Biological|H5N1 antigen combined with MF59 adjuvant|Eligible subjects will be stratified by age at the time of enrollment into one of 2 age cohorts and within each age cohort will be randomly assigned (equally) to 1 of 6 study vaccine groups. Subjects in each study vaccine group will be scheduled to receive 2 injections of aH5N1 vaccine 3 weeks apart
45373456|NCT05589636|Dietary Supplement|Bergamot Juice|Bergamot Juice (35% in water)
45373457|NCT00990990|Drug|PNU-100480|100 mg BID for 14 days
45373458|NCT00990990|Drug|Placebo|to match 100 mg BID for 14 days
45373459|NCT00990990|Drug|PNU-100480|300 mg BID for 14 days
45373460|NCT00990990|Drug|Placebo|to match 300 mg BID for 14 days
45373461|NCT00990990|Drug|PNU-100480|600 mg BID for 14 days
45490906|NCT02676466|Dietary Supplement|Omega-3 fish oil|The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by >40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.
45373462|NCT00990990|Drug|Placebo|to match 600 mg BID for 14 days
45490907|NCT02676466|Drug|Losartan|The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by >40% vs. baseline (average of screening visits 1 and 2), an increase to the dose of 100 mg/day.
45490908|NCT02676466|Other|Corn Oil (Fish oil Placebo)|The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil.
45373463|NCT00990990|Drug|PNU-100480|1200 mg QD for 14 days
45490909|NCT02676466|Other|Cellulose Based (Losartan Placebo)|The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules.
45490910|NCT03350269|Other|Information provision|Kidney transplant recipients are informed that their donors may be eligible for lost wage reimbursement
45490911|NCT03926520|Device|Electroconvulsive Therapy (ECT)|Stimulus method of delivery will be RUL electrode placement, and ultra-brief (UB) pulse width (0.25-0.37ms). At the first ECT session, seizure threshold (ST) will be determined by titration with the empirical dose titration method and subsequent treatments will be approximately 6 times the ST. Following other NIMH sponsored multicenter ECT studies (PRIDE, U01 MH055495), stimulus settings will be adjusted as needed during the ECT course based on seizure quality and treatment efficacy. Participants will be administered anesthesia.
45490912|NCT03926520|Other|Simulated Electroconvulsive Therapy (S-ECT)|The participant is brought to the ECT suite for the length a session would normally take (approximately 2 hours). While in the ECT suite, conducting gel will be placed on the scalp of the S-ECT subjects to parallel the ECT procedures in the ECT active group. An IV will be placed to provide PRN medication and fluids as needed. IV placement will also provide a method for study staff to assess physical interference and subject resistance to treatment. Participants will not be administered anesthesia.
45490913|NCT01383252|Procedure|Water infusion in lieu of air insufflation|Air pump is turned off, water is infused using a peristaltic pump to aid colonoscope insertion until the cecum is reached. Air pockets and dirty water are suctioned before clean water is infused (exchange) to facilitate scope insertion.
45490914|NCT01383252|Procedure|Air method|Conventional air method with minimal insufflation of air to aid scope insertion until the cecum is reached. Water in aliquots will be used for irrigation and cleansing.
45490915|NCT03314857|Device|SAPIEN XT THV with the NovaFlex+ delivery system|Edwards SAPIEN XT™ Transcatheter Heart Valve along with NovaFlex+ delivery system
45373464|NCT00990990|Drug|Placebo|to match 1200 mg QD for 14 days
45373465|NCT00990990|Drug|PNU-100480|600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
45373466|NCT00990990|Drug|Placebo|placebo to match 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
45373467|NCT00990990|Drug|PNU-100480|PNU-100480 dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
45373468|NCT00990990|Drug|Placebo|placebo to match dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
45373469|NCT00990990|Drug|Linezolid|300 mg QD for 4 days (open label)
45490916|NCT05094466|Behavioral|Behavioral Intervention|Receive peer support sessions
45490917|NCT05094466|Other|Counseling|Receive health coaching sessions
45490918|NCT05094466|Procedure|Discussion|Attend focus groups
45490919|NCT05094466|Other|Educational Intervention|Receive handbook
45490920|NCT05094466|Other|Informational Intervention|Receive navigation sessions
45490921|NCT05094466|Other|Interview|Participate in interview
45490922|NCT02353819|Radiation|Stereotactic Ablative Radiotherapy|SABR x5 fractions CBCT based image-guidance prior to each fraction: localize based on prostate/seeds positions SCORE system
45490923|NCT01380756|Drug|Arm 1- Dose Escalation|AMG 900 is a small molecule aurora kinase inhibitor. AMG 900 will be administered daily for 4 days every 2 weeks or daily 7 days every 2 weeks (ie.g., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
45490924|NCT01380756|Drug|Arm 2- Dose Expansion|AMG 900 is a small molecule aurora kinases inhibitor. The dose expansion phase would be conducted to gain further clinical experience with AMG 900 in AML at the optimal dose schedule.
45373470|NCT05361096|Other|Educational approach (Flipped learning)|"In the intervention group, the out-of-class stage started one week before the in-class stage of the relevant week. The researchers covered the topic of the week asynchronously in the virtual classroom in the learning management system. Students have been able to log into the system at anytime and anywhere and study the course video and other course materials repeatedly.~The in-class stage is the session in which the students in the intervention group come together with the researcher synchronously and conduct an online lesson. It was conducted one session per week for four weeks. The course was carried out synchronously on the Zoom platform during the in-class stage."
45373471|NCT05589558|Procedure|consequently performed 4 biopsy methods (TRUS-guided biopsy, cognitive, fusion and transperineal template mapping biopsy)|TRUS-guided biopsy - extensive number of biopsies taken transrectally involving peripheral and transitional zones (8-12 cores); cognitive biopsy - targeted biopsy with MRI information and TRUS guidance but without fusion technology (2-4 cores); fusion biopsy - targeted biopsy with MRI information using MRI/TRUS fusion technology (2-4 core); transperineal template mapping biopsy - systematic transperineal TRUS-guided biopsy with special template use to aid accurate placement of biopsy needles (more than 20 cores).
45373472|NCT05589480|Other|preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.|preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.
45373473|NCT05589402|Drug|Lidocaine Cream 5%|Ebanel 5% Lidocaine Topical Numbing Cream Maximum Strength 1.35 Oz, Numb520 Pain Relief Cream Anesthetic Cream Infused with Aloe Vera, Vitamin E, Lecithin, Allantoin, Secured with Child Resistant Cap
45373474|NCT05589402|Other|Rehabilitation Movement Training|reaching tasks, hand exercises (e.g., putty, grip exerciser, resistance bands, etc).
45373475|NCT04003662|Device|Vital Signs Measurement|Vital signs are measured twice with standard of care equipment while recording digital video data at the same time.
45692930|NCT03808012|Other|Braking performance in a brake simulator|Braking performance is tested in a real middle size car cabin to simulate ergonomic conditions of driving a car. This testing cabin has been equipped with customised equipment to allow measurement of reaction time, foot transfer time, brake response time and brake force.
45692931|NCT00753142|Drug|Intralipid 20%|Participants receive a 48-hour infusion with Intralipid at 40 milliliters per hour (mL/hr).
45373476|NCT00991146|Drug|canakinumab|canakinumab
45490925|NCT04439890|Drug|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
45490926|NCT04439890|Drug|Carboplatin injection|Carboplatin injection AUC 5mg/mL/min, intravenous drip, on Day 1 in 21-day cycle.
45490927|NCT04439890|Drug|Pemetrexed disodium f Injection|Pemetrexed disodium f Injection 500mg / m2, intravenous drip, on Day 1 in 21-day cycle.
45692932|NCT00753142|Drug|Glucose infusion|Participants receive a glucose infusion consisting of 10% dextrose infused intravenously at a rate of 200 mg/m^2/min for 20 hours.
45692933|NCT00762424|Drug|Flowmax|0.4 mg once a day until stone passage total = 9 tablets
45490928|NCT04439890|Drug|Placebo|Placebo
45490929|NCT03695497|Procedure|Direct anterior approach|total hip arthroplasty with DAA
45490930|NCT03695497|Procedure|Direct Lateral Approach|total hip arthroplasty with DLA
45490931|NCT03635892|Drug|cabozantinib|cabozantinib 40mg, self administered orally once daily on a continuous schedule (days 1-28) Patients will continue to take cabozantinib until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.
45692934|NCT00762424|Drug|placebo|cornstarch
45490932|NCT03635892|Drug|nivolumab|Patients will receive an intravenous infusion of nivolumab, per institutional standards, at 240 mg on Cycle 1, Day 1 and will return to the center approximately every two weeks (14 ± 3 days) for subsequent infusions until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.
45692935|NCT01620983|Behavioral|Pain Coping Skills Training|
45692936|NCT01620983|Behavioral|Arthritis Education|
45692937|NCT01620983|Other|Usual Care|
45373477|NCT05589324|Behavioral|3D-printed writing aids task|Briefly explain how to wear assistive devices, confirm that the case understands how to operate, and conduct a writing task test. Situation includes no wearable assistive device,three pen placement designs with different angles (5 degrees, 20 degrees, and 30 degrees). Record the writing speed, legibility, posture, and satisfaction of the assistive device after each writing task, etc.
45490933|NCT02324725|Drug|Naltrexone|Up to three monthly injections of 380 mg of naltrexone suspended in dissolvable polymer microspheres and administered intramuscularly
45373478|NCT00991224|Biological|WT-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
45373479|NCT00991224|Biological|α/6-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
45373480|NCT00991224|Other|STI or Drug Holiday|Subjects will stop taking antiviral medications for 16 weeks.
45373481|NCT00466947|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 4 doses
45490934|NCT03633695|Device|IC-8 IOL Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) implanted in the first eye for use over the lifetime of the patient. The IC-8 IOL implanted in the second eye for use over the lifetime of the patient.
45373482|NCT00466947|Biological|Havrix|Intramuscular injection, 2 doses in Synflorix group and 3 doses in Control group
45490935|NCT03633695|Device|Control Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) bilaterally implanted for lifetime use of the patient.
45373483|NCT00466947|Biological|Engerix-B|Intramuscular injection, 3 doses
45490936|NCT01380678|Drug|Intralesional injection of bevacizumab|single dose of 2 mg of bevacizumab intralesional injection on pterygium Combination of topical antazoline and tetrahydrozoline four times a day
45490937|NCT01380678|Drug|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
45490938|NCT02213809|Behavioral|Case method education in COPD|In case method a rich narrative describing of a real-life situation (teaching case) is presented, in which the learning group must make a decision or solve a problem. The teaching case provide information, but neither analysis nor conclusions. The analytical work of explaining the relationships among events in the case, identifying options, evaluating choices and predicting the effects of actions is the work done by students during the discussion.
45490939|NCT02213809|Behavioral|Traditional education in COPD|Traditional education in this study means that the teacher mainly speaks to the group. Although short cases may be used for illustration, the main focus is not that the group shall solve problems from a narrative case.
45490940|NCT03314233|Procedure|DING|"Immediately after birth, the infant will be placed on a Lifestart trolley with an intact umbilical cord, intubated, and ventilated with the Children's Hospital of Philadelphia (CHOP) gentle ventilation protocol."
45373484|NCT00466947|Biological|Infanrix hexa|Intramuscular injection,3 doses
45373485|NCT00466947|Biological|GSK Biologicals' DTPa-IPV/Hib vaccine|Intramuscular injection, 1 dose in Synflorix group and 4 doses in Control group
45373486|NCT00991380|Behavioral|HEALD|A six month, two phase pedometer-based walking program. For weeks one and two of phase I, participants will attend a group-based 60 minute education/supervised walking session. They will be asked to set a daily step goal and to attempt to achieve this on a daily basis over three months. Their steps will be recorded in a step log. For weeks one and two of phase II, participants will learn how to increase the speed of a portion of their daily steps and will learn the concept of low glycemic index and how to set dietary goals related to this concept. They will attend two sixty minute group-based education/supervised walking sessions.
45373487|NCT00991380|Behavioral|Usual Care|Control
45490942|NCT02675998|Drug|Tenapanor|
45490943|NCT02675998|Drug|Placebo|
45490944|NCT01384188|Drug|ONO-5334|150 mg for 5 days administered in the morning or in the evening
45490945|NCT01384188|Drug|ONO-5334|150 mg QD for one day. Administered either in the fasted state or after the standard meal or high fat meal.
45490946|NCT04588519|Device|Spark Biomedical Roo Transcutaneous Auricular Neurostimulation (tAN) System|Spark Roo tAN System programmed to a pulse width of 250ms; channel 1: 5 Hz, mean intensity 0.3±0.2 mA; channel 2: 100 Hz, mean intensity 0.6±0.2 mA.
45692938|NCT01279876|Drug|Melatonin|3mg oral, daily, one hour before sleep
45373488|NCT00537810|Drug|Sibutramine|15 mg daily
45373489|NCT00537810|Drug|Placebo|Daily
45373490|NCT00537810|Behavioral|Self-help CBT + Sibutramine|Cognitive behavioral treatment manual for binge eating Sibutramine 15 mg daily
45373491|NCT00537810|Behavioral|Self-help CBT + Placebo|Cognitive behavioral treatment manual for binge eating Placebo daily
45373492|NCT05589246|Device|regional analgesia with cryolesia|The regional analgesia (erector spine plane block) will be added to intraoperative cryolesia of intercostal nerves
45373493|NCT05589168|Behavioral|Triage nurse|Triage nurse joins 911 call
45373494|NCT05589168|Behavioral|No triage nurse|Triage nurse does not join 911 call (business as usual)
45373495|NCT01017471|Procedure|Limited incision using PSU retractor|carpal tunnel release using limited incision with PSU retractor will be done by orthopaedic hand surgeons
45373496|NCT01829568|Drug|Ibrutinib|Given PO
45373497|NCT01829568|Other|Laboratory Biomarker Analysis|Correlative studies
45373498|NCT01829568|Drug|Lenalidomide|Given PO
45373499|NCT01829568|Other|Pharmacological Study|Correlative studies
45373500|NCT01829568|Biological|Rituximab|Given IV
45373501|NCT05589012|Biological|Cell line and virus|C6/36 cells will be cultured in L15 culture medium (Leibovitz's L-15 medium), supplemented with 5% FBS (Fetal Bovine Serum) and 1% penicillin/streptomycin at 28°C in a humidified atmosphere containing 5% C02. ZIKV and TONV will be expanded and titrated using C6/36 cells. The viral stock will be aliquoted in 100 µL aliquots and stored at -80°C.
45373502|NCT05589012|Biological|Infection of human placental culture explants|"Placental tissues will be handled within one hour of delivery. The chorionic villi will be dissected into 5mm sections and the tissues washed abundantly, minimum 3 times with a standard culture medium (RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% L-Glutamine and 1% Penicillin/Streptomycin) to remove maternal blood, membranes and blood clots.~Collagen gel sponges will be placed in 6-well plate wells containing 3mL of culture medium (RPMI-1640 supplemented with 15% heat-inactivated fetal bovine serum (FCS), 1% Penicillin/streptomycin, 0 1% Gentamycin, 1% Amphotericin B, 1% L-Glutamine, 1% non-essential amino acid, 1% sodium pyruvate) per well. Chorionic villi will be dissected into 5mm sections and placed on top of collagen gel sponges at the interface between culture medium and air."
45692939|NCT01996709|Device|Hydrogen peroxide-based contact lens solution|
45692940|NCT01996709|Device|Habitual contact lens solution|Biguanide-preserved
45373503|NCT05589012|Biological|Determination of viral load in tissues by qRT-PCR|"The tissues will be lysed by mechanical disruption in a lysis buffer + 4%TCEP (Tris(2-carboxyethyl)phosphine hydrochloride) (Machery-Nagel ref: 740395.107) with the Precellys system. The lysed tissues will be diluted in 100 mg/mL of Macherey-Nagel lysis buffer, aliquoted and stored at -80°C until extraction. Total RNA will be extracted in duplicate using the Nucleospin 96 RNA Core kit (Macherey Nagel ref: 740466.4), following the supplier's instructions.~Standard samples, controls and ZIKV and TONV viral RNA will be extracted and tested in parallel under the same conditions. The extracted RNA will be subjected to reverse transcriptase, using the Superscript One-Step RT-qPCR kit (Invitrogen ref: 11732088) according to the manufacturer's recommendations, with a probe and primer specific for ZIKV and TONV."
45373504|NCT01355094|Device|KCI AbThera|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
45373505|NCT01355094|Device|"Stampede VAC"|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
45373506|NCT05588232|Procedure|scheduled outpatient interventions in interventional cardiology|coronary angiography, coronary angioplasty, peripheral angioplasty (carotid arteries or lower limbs)
45373507|NCT00991614|Device|EVOLUTION® Duodenal Stent|EVOLUTION® Duodenal Stent
45373508|NCT05358054|Other|Mobilization with movement lateral Glides and Conventional Physiotherapy|"(The Mobilization with movement technique is(lateral glide) applied to the patient by a physiotherapist to patients at supine level position.~First we identify pain free region each patients. The lateral humerus above the condyle of elbow joint are fixed by therapist. Then therapist ask to patients perform the active movement ten times. The same procedure repeats number of 3 sets, 10 number of repetition. The rest of interval fifteen to twenty seconds with in the sets Grip strength (pain Free Strength ) was evaluated in kilogram using a dynamometer. The measurements using dynamometer patients posture is erect sit position , the elbow at 90 degree flexion , shoulder would be abducted , rest of joint forearm and wrist in neutral during measurements.~conventional therapy list of conventional physiotherapy are therapeutic ultrasound , deep transverse friction massage and stretching"
45692941|NCT01996709|Device|Habitual contact lenses|Silicone hydrogel contact lenses with a biweekly or monthly replacement schedule
45692942|NCT00753220|Biological|VDC2008|"Intratumoral injection of VDC2008 post-cryotherapy.~Dosage will depend on cohort: 2.5 x 10^7, 7.5 x 10^7 or 1.0 x 10^8 cells"
45373509|NCT05358054|Other|Progressive Resistance Exercises and Conventional Physiotherapy|4 STEPS Progressive resistive EXERCISES have a 4 step to application Step 1 Clenching fist strongly, resisted wrist Flexion, Extension, wrist rotation with a stick) Step 2 The therapeutic band exercised performed at wrist Flexion(WF), Wrist Extension(WE), Wrist Ulnar Deviation(WED) , and Wrist Radial Deviation(WRD).Step 3 Patient asked to perform combined wrist rotatory movements using e.g. table top as a support. Step 4 Soft ball compressing exercises, Transferring buttons from cup into another, Twisting a towel into the roll, Hand Rotating both directions at table AND CONVENTIONAL PHYSIOTHERAPY and list of conventional physiotherapy are therapeutic ultrasound , deep transverse friction massage and stretching
45373510|NCT01287936|Biological|SB623|SB623, a modified stem-cell product
45373511|NCT05586984|Procedure|Laparoscopic uterine lateral suspension|Laparoscopic uterine lateral suspension done with four trocar sites. Fix a 1.5cm*32cm mesh to uterus at anterior lower segment and bilateral round ligaments by non-absorbable sutures (Surgilon 2-0, Ethicon, Norderstedt, Germany), and to lateral abdominal fascia by non-absorbable sutures (Prolene 1-0, Ethicon, Norderstedt, Germany). Reperitonization done to avoid mesh exposure in peritoneal cavity. Concomitant anterior and posterior colporrhaphy may be performed.
45373512|NCT05586984|Procedure|Transvaginal sacrospinous fixation|Transvaginal sacrospinous fixation done by hand suturing uterus to right sacrospinous ligament with non-absorbable suture (Prolene 1-0, Ethicon, Norderstedt, Germany). Concomitant anterior and posterior colporrhaphy may be performed.
45373513|NCT00848328|Biological|Rituximab|Injection for Intravenous Use, 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15.
45373514|NCT00848328|Drug|Lenalidomide|Supplied as 5mg capsules; Dosage: 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
45692943|NCT00753220|Drug|Cyclophosphamide|Cyclophosphamide i.v. given at day -3 (dose: 300mg/m2); Low-dose Cyclophosphamide pill given twice daily (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles [1 cycle = 4 weeks] starting Week 2 after cryoablation and going to Week 26)
45692944|NCT01279642|Device|ultrasound|Doppler vascular ultrasound guidance to PICC insertion in children -
45692945|NCT01279642|Other|traditional puncture|traditional approach of PICC insertion by visualization and inspection of insertion site
45373515|NCT00991692|Other|Therapy services (ACQUIREc Therapy)|Dosage levels that are associated with the efficacy of intensive therapeutic services provided by OT and PT professionals.
45692946|NCT00753298|Device|LoFric Primo (POBE) single-use urinary catheter|LoFric Primo (POBE) single-use urinary catheter
45373516|NCT05583786|Diagnostic Test|Tracing intracoronary electrocardiogram|icECG ST-segment shift remission time (τ-icECG) tracing during reactive-hyperemia, obtained immediately after a 1-minute upstream coronary artery balloon occlusion.
45373517|NCT00991770|Other|Massage Therapy|Two 20 minute chair massages: one before surgery and one after
45692947|NCT00753298|Device|LoFric Primo (PVC) single-use urinary catheter|LoFric Primo (PVC) single-use urinary catheter
45692948|NCT01996319|Drug|QVA149|QVA149 (110/50 µg) once a day via Breezhaler® device
45373518|NCT00991770|Other|Attention Control|Two 20 minute sessions where the Massage Therapist will talk to the patient about how they are feeling, listen, and provide empathetic support.
45373519|NCT04003428|Device|High Intensity Focused Ultrasound|HIFU shots will be performed on the placental tissue to produce necrotic lesions of approximately 30% of the total volume. A latency time of 2 minutes between each shot will be observed to avoid the accumulative heat effect, and to ensure optimal positioning of the treatment probe. The maximum duration of the operating time for HIFU shooting shall not exceed 60 minutes.
45373520|NCT00989352|Drug|Methotrexate|3g/m² i.v. max. 9 times
45373521|NCT00989352|Drug|Lomustine|110 mg/m² p.o., max. 3 times
45373522|NCT00989352|Drug|Procarbazine|60 mg/m² p.o. for 10 days, max. 3 times 100 mg p.o. for 5 days, max. 6 times
45373523|NCT00989352|Drug|Rituximab|375 mg/m² i.v., max. 10 times
45373524|NCT05566626|Device|Hyperspectral retinal image|Hyperspectral image of both eyes
45373525|NCT05566626|Drug|Mydriacyl Ophthalmic Product|Mydriatic drops before retinoscopy
45373526|NCT05549544|Device|Left bundle branch area pacing|Left bundle branch area pacing is a novel physiological pacing modality and is reported to be feasible and safe in patients with heart failure and left bundle branch block.
45373527|NCT05549544|Device|Biventricular pacing|Biventricular pacing is a widely-established modality to treat heart failure in patients with heart failure
45373528|NCT00989430|Behavioral|Prism Adaptation Treatment|Wearing prism goggles and performing visuomotor tasks during therapy sessions.
45373529|NCT00989508|Drug|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
45373530|NCT00989508|Drug|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
45373531|NCT05408442|Other|No intervention|No intervention
45373532|NCT05408364|Dietary Supplement|probiotic or natural yoghurt|Bifidobacterium animalis subsp. lactis DN-173010 containing probiotic yoghurt
45373533|NCT05408364|Procedure|SRP|Scalling and root planing
45373534|NCT05492448|Dietary Supplement|Placebo|Subjects take one pack containing maltodextrin twice daily after breakfast and dinner.
45373535|NCT05492448|Dietary Supplement|L. salivarius and L. reuteri|Subjects take one pack containing L. salivarius and L. reuteri twice daily after breakfast and dinner.
45692949|NCT01996319|Drug|Placebo|Placebo once a day via Breezhaler® device
45692950|NCT04276948|Dietary Supplement|NAD3|NAD3 is an over-the-counter dietary supplement available online to consumers.
45692951|NCT01279954|Drug|Abatacept|"Subjects will receive approximately 10 mg/kg rounded to the nearest 25 mg for the first 6 months of the trial. At 6 months subjects will then be randomized to receive either 5 mg/kg or 10 mg/kg.~Abatacept will be administered as a 30-minute intravenous infusion. Following the initial administration, abatacept will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for up to 2 years."
45692952|NCT01278862|Device|DVS veneer|CAD/CAM milled porcelain veneer for Lava crown
45692953|NCT01278862|Device|Conventional Veneer|CAD/CAM milled Lava crown with lab fabricated veneer
45373536|NCT05492448|Dietary Supplement|L. reuteri|Subjects take one pack containing L. reuteri twice daily after breakfast and dinner.
45373537|NCT05424978|Other|Standardized green channel treatment methods for stroke|The measures include six measures: timely triage by triage desk nurses; Rapid evaluation by emergency room physician; If stroke is suspected, the green channel for nosocomial stroke should be activated immediately. Stroke greenway doctors and stroke nurses accompanied patients to complete CT examination; Intravenous thrombolysis in emergency rooms or CT rooms; Suspected macrovascular disease, if the onset time is less than 6 hours, quickly go to the catheter room for intravascular treatment; If the onset time was more than 6 hours, multi-mode imaging was used to quickly evaluate the ischemic penumbra and vascular occlusion, and then the patients were sent to the catheter room for intravascular treatment as soon as possible.
45373538|NCT05408286|Behavioral|administration of questionnaires|administration of questionnaires
45373539|NCT05360394|Device|Paclitaxel Coated Balloon|CAS treated with PCB only
45373540|NCT05360394|Device|Paclitaxel Coated Balloon and Stent Graft|CAS treated with PCB first before deployment of stent graft
45373541|NCT00090259|Drug|Losartan 50 mg|50-mg losartan oral tablet
45373542|NCT00090259|Drug|Losartan 150 mg|100-mg losartan oral tablet + 50-mg losartan oral tablet
45692954|NCT03807388|Device|ReMindCare Intervention Group|Daily and weekly assessments of patient´s health status, and generation of alarms related to these answers. Moreover, patients can contact clinicians by an urgent consultation tab.
45692955|NCT03807388|Other|Treatment as Usual|Psychiatric usual treatment at First Episode of Psychosis Unit at Clinical Hospital of Valencia, Spain.
45692956|NCT00763048|Drug|Fluoride|Brush twice daily for 6 weeks
45692957|NCT00763048|Drug|Fluoride, triclosan|Brush twice daily
45373543|NCT01082497|Behavioral|Mindfulness training|A course in mindfulness based stress reduction with 8 weekly group meetings and home practice between the meetings. Each meetings last for 90 minutes. Participants get workbook and cds to support home practice.
45692958|NCT03807466|Behavioral|Dynamic/Interactive vs. Static/Paginated Report|Evaluate whether a stand-alone interactive audit-and-feedback report highlighting antibiotic prescribing can lead to greater reductions in antibiotic use, than a report embedded in a broader static feedback system
45490947|NCT05666063|Diagnostic Test|Ambulatory Urodynamic Study|Ambulatory urodynamic study is started after spontaneous diuresis of the patients. Ambulatory monitoring time is limited to each patient's own voiding cycle. The patient and a family member are instructed on the use of the event buttons on the patient module to flag incontinence, urgency, physical activity, and water drinking. With the use of catheters attached to microcomputers attached to their shoulders, patients are free to move around and engage in activities that may cause urinary incontinence. After voiding, the residual urine volume is first measured and then urethral and rectal catheters are placed. Monitoring is terminated when the patient feels that he cannot delay the urination sensation.Questionnaires that are routinely applied in our clinic will be applied in order to objectively evaluate the symptoms. Before urodynamics, urinary tract infection, whether symptomatic or not, must be routinely excluded with a complete urinalysis and urine culture.
45490948|NCT03693690|Procedure|Vaginal laser thermotherapy|Laser thermotherapy can increase the stiffness of vaginal wall. It has been reported that vaginal laser therapy can be used to treat stress urinary incontinence.
45373544|NCT03961711|Procedure|Telemedicine|Patients will undergo a Telemedicine encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
45373545|NCT03961711|Procedure|In-Person Clinic Visit|Patients will undergo an in-person clinic encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
45373546|NCT00079183|Drug|sirolimus|Given PO
45490949|NCT01380600|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dose Range: 1x10^6 pfu/kg, 1x10^7 pfu/kg, 3x10^7 pfu/kg Up to 4 intravenous infusions administered over 60 minutes every 2 weeks.
45490950|NCT03264118|Procedure|Scaling and root planing|Furcation treatment by scaling and root planing
45373547|NCT03961243|Biological|YUVA-GT-F901|Lentiviral factor IX gene modified autologous hematopoietic and mesenchymal stem cells
45373548|NCT01589341|Other|laboratory biomarker analysis|Correlative studies
45490951|NCT03264118|Drug|Toluidine Blue O|Antimicrobial photodynamic therapy with toluidine blue O (10mg/ml) and red laser.
45692959|NCT03807466|Behavioral|LTC Physicians Enrolled vs. Not Enrolled in Reports|Evaluate whether being provided an audit-and-feedback report (regardless of dynamic or static) can lead to greater reductions in antibiotic use, than those who do not receive either report
45373549|NCT01086085|Drug|Adefovir|Adefovir 10 mg po once daily for 36 weeks
45373550|NCT01086085|Drug|peginterferon alfa-2a [PEGASYS]|Early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
45373551|NCT01086085|Drug|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
45373552|NCT01086085|Drug|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 96 weeks
45373553|NCT01088425|Other|Observation|"Alberta infant motor scale~Griffiths test~Kauffmann ABC"
45373554|NCT01086163|Drug|Omacor, omega-3 fatty acids in CAD patients|Omacor 1g versus 2g daily versus placebo
45373555|NCT01589419|Drug|veliparib|see arm description
45490952|NCT03539406|Biological|UCB-NK cells|Intraperitoneal allogeneic UCB-NK cells infusion
45490953|NCT03539406|Drug|Chemotherapy|Cyclofosfamide/fludarabine treatment
45490954|NCT05675878|Behavioral|Dietary Intervention|This is a whole food, nutrient-dense diet that aims to remove exposure to specific food additives thought to have negative neurological effects, while also optimizing micronutrient intake.
45490955|NCT03064048|Dietary Supplement|Neo-ASA|Dietary supplement with nitric oxide in the form of a lozenge called Neo-ASA.
45490956|NCT03064048|Dietary Supplement|Placebo|Dietary supplement with no nitric oxide in the form of a lozenge to look and taste like the dietary supplement Neo-ASA
45490957|NCT05044312|Other|Sleeping Disturbances|most common complaints of patients after surgery and may affect the ability to carry out daily activities, quality of life, and post-surgery recovery.
45490958|NCT05231434|Other|water|hydration with mineral water in 10 equal portions, administered at regular intervals from the 15th minute of exercise until the end of the recovery period.
45490959|NCT05231434|Other|aerobic activity|aerobic activity
45490960|NCT03113812|Drug|ABvac40|
45373556|NCT01589419|Drug|capecitabine|see arm description
45373557|NCT01589419|Radiation|radiation|see arm description
45373558|NCT00676403|Drug|placebo|Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks
45373559|NCT00676403|Drug|Pregabalin|50 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
45373560|NCT00676403|Drug|Pregabalin|100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
45373561|NCT00676403|Drug|Pregabalin|150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
45373562|NCT00676403|Drug|Pregabalin|300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
45373563|NCT00676403|Drug|Pregabalin|450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
45490961|NCT03113812|Drug|Placebo|
45490962|NCT04605874|Other|Package Quantity (cigarillos)|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to one of two conditions, 2 cigarillos per pack versus 4 cigarillos per pack.
45490963|NCT02674204|Drug|Atorvastatin|Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.
45490964|NCT02674204|Drug|Placebo|A substance that has no therapeutic effect, and will be used as a control in testing the study agent.
45490965|NCT05675644|Drug|Drospirenone-only pill|Single dose based on adaptive dose-finding design
45490966|NCT03113890|Genetic|Phlebotomy - Folate|This will be a blood draw performed at Visit 1 for Folate (one 7mL tube)
45490967|NCT03113890|Genetic|Cheek Swab|Participants will undergo a cheek swab to then be analyzed using the Genecept Assay created by Genomind, Inc. This will occur once during Visit 1.
45490968|NCT03113890|Other|Self-report surveys|At visit 1 and at visit 3 and 4, participants will be asked to complete self report diagnostic surveys and surveys related to the objective aims of the study.
45490969|NCT05010772|Drug|Decitabine and Cedazuridine|Given PO
45490970|NCT05010772|Drug|Enasidenib|Given PO
45490971|NCT05010772|Drug|Gilteritinib|Given PO
45490972|NCT05010772|Drug|Ivosidenib|Given PO
45490973|NCT05010772|Drug|Venetoclax|Given PO
45490974|NCT02579044|Drug|Everolimus and lonafarnib|
45373569|NCT01086241|Procedure|2D Mammogram|Those patients randomized to the mammogram arm will receive a regular 2D mammogram. Compression lasts several seconds in order to obtain 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
45490975|NCT02464696|Drug|Methylprednisolone|IPS cohort only
45490976|NCT02464696|Procedure|Oxygen Therapy|Receive high flow oxygen therapy
45373570|NCT01086241|Procedure|Tomosynthesis|Those patients randomized to the tomosynthesis arm will receive a combination of 3D and 2D screening mammogram. The additional tomosynthesis data is obtained immediately after acquisition of the 2D study, with the patient and breast remaining in the same position and compression. Compression lasts about 7 seconds longer for each of the 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
45373571|NCT00078325|Drug|Armodafinil 250 mg/day|Armodafinil 250 mg once daily in the morning
45373572|NCT00078325|Drug|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
45490977|NCT02464696|Device|Positive Air Pressure Device|Undergo NIPPV
45373573|NCT00078325|Drug|Placebo|Matching placebo tablets once daily in the morning
45373574|NCT03963271|Diagnostic Test|ECG-Imaging|A body surface potential mapping and a cardiac + low dose CT-scan.
45490978|NCT03160690|Procedure|Non penetrating deep sclerectomy|Non penetrating deep sclerectomy for open angle glaucoma
45490979|NCT04503694|Drug|Nivolumab 10 MG/ML Intravenous Solution|"Nivolumab will be given at a dose of 240 mg during the pre-operative phase only as indicated below:~On day 1 and 15, during the Induction treatment~On day 29, 43 and 57, during the Consolidation treatment"
45490980|NCT04503694|Drug|Regorafenib 40 MG Oral Tablet|"Regorafenib will be administered orally once a day at a dose of 80 mg/day (2 tablets of 40 mg), during the pre-operative phase only as indicated below:~From day 1 to 14, during the Induction treatment~From day 29 to 49, during the Consolidation treatment"
45490981|NCT04503694|Radiation|Radiotherapy|All study subjects will receive 5 daily fractions of radiotherapy. Each fraction will consist of 5 Gy for a total dose of 25 Gy. Radiotherapy is to start on day 22 and to finish on day 26.
45490982|NCT04503694|Procedure|Surgery|Subject will undergo surgical resection of the primary tumour in the rectum between day 74 and 87. Surgery must be performed according to the principles of total mesorectal excision as described by Heald et al. The type of surgical approach (low anterior resection or abdominoperineal resection, etc.) will be left to the discretion of the treating surgeon.
45490983|NCT04503694|Procedure|Non-operative Management|"Subjects who achieve cCR after pre-operative treatment can, after discussion with the local investigator, decline surgery and opt for a non-operative management. cCR will need to be confirmed between day 67 and 74 by the following procedures per local practise:~Digital rectal examination~Rectal endoscopy~Rectal MRI Subjects who achieve near cCR at the first assessment time point after pre-operative treatment, can be re-assessed 6 to 8 weeks later with the same procedures. If cCR is diagnosed, they can opt for watch & wait, otherwise they would need to undergo surgical resection.~Subjects who opt for a non-operative management will be followed for tumour recurrence and survival for 5 years after end of treatment visit. Follow-up for these subjects will be more intensive than that for subjects undergoing surgery"
45490984|NCT04461106|Other|Social Marketing Campaign|aims to raise awareness about the benefits of eggs - 'why eggs': increasing the value of eggs from a consumer perspective and encourage consumption of eggs by children (<5yrs) and pregnant/lactating women
45373575|NCT03963193|Drug|Etoposide|Etoposide 100mg/m^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m^2 ivggt on days 1, 2, 3, repeated every 21 days.
45373576|NCT03963193|Drug|Irinotecan|Irinotecan 65 mg/m^2 ivggt on days 1, 8, Cisplatin 30 mg/m^2 ivggt on days 1, 8, repeated every 21 days.
45373577|NCT01088581|Drug|Adjuvant group|Adjuvant chemotherapy (5FU and cisplatin) after resection
45373578|NCT01082653|Biological|autologous bone marrow-derived stem cells|All patients will receive a unique one-time intrathecal infusion of the cell product suspended in infusion medium.
45373579|NCT03961867|Drug|Docetaxel|"S-1 (BSA <1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; >1.5m2,120 mg) divided into two doses /day after breakfast and dinner, 14 days / 3 weeks, totally 16 cycles.~Docetaxel 40mg/m2/3w from the second to the seventh cycles."
45373580|NCT03961867|Drug|Oxaliplatin|"S-1 (BSA <1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; >1.5m2,120 mg) divided into two doses /day after breakfast and dinner, 14 days / 3 weeks, totally 16 cycles.~Oxaliplatin 130mg/m2/3w from the first to the eight cycles."
45373581|NCT04626245|Behavioral|Mindfulness training|Phone-delivered brief mindfulness training based on principles of MBSR
45373582|NCT03962179|Device|VACStent|Evaluation of the suitability of the medical device for sealing leaks in the gastrointestinal tract
45373583|NCT00077857|Drug|capecitabine (Xeloda®)|825 mg/m^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.
45373584|NCT00077857|Drug|docetaxel (Taxotere®)|75 mg/m^2 intravenous on day 1 of each 3 week cycle
45373585|NCT01086397|Procedure|Urine sample collection|All subjects have non-invasive urine sample collection performed
45373586|NCT00545402|Drug|Mycophenolate mofetil, adjusted dose|3 g/d PO BID during meals from Day 0 to Day 4, followed by dose adjustment based on AUC using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12.
45373587|NCT00545402|Drug|Tacrolimus|Target trough level of 8-2 ng/mL from Day 0 to Month 1, adjusted to a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12
45373588|NCT00545402|Drug|Corticosteroids, IV|10-15 mg/kg IV pre-operation on Day 0
45373589|NCT00545402|Drug|Mycophenolate mofetil, Standard dose|2 g/d PO BID during meals from Day 0 to Month 12
45373590|NCT00545402|Drug|Corticosteroids, PO|20 mg/d QDS from Day 0 through Month 1; 15 mg/day, TID from the end of Month 1 through Month 2; 10 mg/d BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
45373591|NCT03963115|Drug|Epinephrine or normal saline|epinephreine or normal saline coated syringe before drawing allergen for injection.
45373592|NCT01583023|Drug|Bupropion|150mg daily for first week, 300mg daily thereafter for a total of 8 weeks
45373593|NCT01583023|Device|Active Repetitive Transcranial Magnetic Stimulation|Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 5-second trains with a 10-second inter-train interval, for 30 trains per session. This treatment will be provided for the first 4 weeks of the study.
45373594|NCT01583023|Other|Placebo|150mg daily first week, 300mg daily thereafter for a total of 8 weeks.
45373595|NCT01583023|Device|Sham repetitive transcranial magnetic stimulation|Sham rTMS will also begin their treatment 5 times a week for 4 weeks in junction with pharmacotherapy (Wellbutrin). Sham rTMS will be delivered at a frequency of 10 Hz and stimulation will be applied in 5-second trains with a 20-second inter-train interval, for 30 trains per session.
45373596|NCT00976976|Drug|docetaxel, capecitabine, cisplatin|Docetaxel 60 mg/m2 IV (day 1) every 21 days capecitabine 1,875 mg/m2/day PO, divided two (day 1-day14) every 21 days Cisplatin 60 mg/m2 IV (day 1) every 21 days
45373597|NCT00977054|Drug|DFPP + Peg-IFN + RBV|Double filtration plasmapheresis: day 1,2,4,8,9 from the onset of treatment (4 hours for each session) Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight < 75 kg, 1,000 mg/day; body weight loss >= 75 kg, 1,200 mg/day)
45373598|NCT00977054|Drug|Peg-IFN + RBV|Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight < 75 kg, 1,000 mg/day; body weight loss >= 75 kg, 1,200 mg/day)
45373599|NCT00966524|Procedure|Endotracheal intubation|Pregraduates medical students will be randomized to perform endotracheal intubation with video-guided feedback (experimental arm) or endotracheal intubation using direct visualization feedback (standard technique).
45373600|NCT00977132|Drug|Valproic aicd|"Treatment with VPA starts at day1, the dose ist slowly increase according to the following scheme~day morning dose midday dose evening dose contents of 1 tablet~1+2 0 0 1 500 mg~3+4 ½ 0 1 500 mg~5+6 1 0 1 500 mg~7+8 1 ½ 1 500 mg~9+10 1 1 1 500 mg~11+12 1 1 1 500 mg~In the morning of day 13 trough level of VPA will be checked. The target range will be 50-110 µg/l. The dose of VPA will be adjusted depending on the trough level. In the first eight weeks of therapy weekly controls of VPA levels are required. Thereafter, VPA levels will be checked every four weeks."
45373601|NCT00977132|Drug|Lenalidomide|"5 mg/day, continuous therapy~Dosing will be in the morning at approximately the same time each day. Capsules may be taken before or after a meal.~Only one cycle of study drug (28 days) will be supplied to the patient every four weeks"
45373602|NCT00977210|Drug|OXi4503|OXi4503 will be administered weekly for 3 weeks followed by a week with no treatment. The starting dose will be 0.06 mg/m2 given as an intravenous infusion over 10 minutes.
45373603|NCT00545792|Drug|Avastin|Avastin will be administered intravenously (vein) at 10mg/kg every two weeks starting day 1 for a total of 3 doses.
45373604|NCT00977288|Drug|anacetrapib|10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
45373605|NCT00977288|Drug|Comparator: atorvastatin|atorvastatin tablet, 10mg, once daily for 8 weeks
45373606|NCT00977288|Drug|Comparator: Placebo|Placebo tablet, once daily for 8 weeks
45373607|NCT00966602|Drug|VX-809|VX-809 capsule, once daily for 14 days
45373608|NCT00966602|Drug|VX-770|VX-770 tablet, once every 12 hours for 14 days
45373609|NCT00966602|Drug|VX-809 & VX-770|VX-809 capsule, once daily, and VX-770 tablets, once every 12 hours, for 14 days
45373610|NCT00966602|Drug|Placebo|Matching Placebo
45373611|NCT00977366|Other|Hydrochloric acid (0.15 molar)|Hydrochloric acid (0.15 molar) will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
45373612|NCT00977366|Other|Saline|Normal saline will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
45373613|NCT00966680|Other|Anesthesia|How long anesthesiologists take to administer general and spinal anesthesia.
45373614|NCT00977444|Drug|kondrium|intraarticular injections once month
45490985|NCT05676970|Behavioral|Telehealth: Wellness and Vaccination|Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. In addition, they will complete education and counseling on vaccination. All educations will be completed one-on-one as well as small group.
45490986|NCT05676970|Behavioral|TeleHealth: Wellness Only|Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. All educations will be completed one-on-one as well as small group.
45490987|NCT02941627|Device|Neuro Zti|Cochlear implant
45692960|NCT00160732|Drug|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression varies but may include prograf, celcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
45490988|NCT02941627|Device|Neuro One|Sound processor
45692961|NCT00160732|Procedure|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
45692962|NCT01278394|Drug|AN2690 Solution, 5.0%|Once daily application for 360 days
45692963|NCT01981187|Drug|LGX818|LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
45692964|NCT00240916|Biological|Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous)|
45692965|NCT00240916|Biological|MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)|
45692966|NCT01278160|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a dosage of 2/3 and 1/3 total daily dose before breakfast and before dinner, in combination with metformin.
45373615|NCT00977444|Drug|kondrium f|intraarticular injections once month
45373616|NCT00977444|Drug|methyl prednisolone (corticosteroid)|intraarticular injections once month
45373617|NCT04093934|Behavioral|Psychosocial stimulation|Children will receive fortnightly sessions of psychosocial stimulation and nutritional support for one year during the study period.
45373618|NCT00966758|Procedure|Computed Tomography|1 low dose CT scan is taken
45373619|NCT00966758|Procedure|Single Photon Emission Computed Tomography|1 SPECT scan is taken
45373620|NCT00977600|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as Buphenyl. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbutyric acid (PBA). PBA is converted to phenyl acetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (~17.4mL) delivers equivalent amount of PBA that 40 tablets of NaPBA do.
45373621|NCT00977600|Drug|Ammonul|
45373622|NCT00977600|Drug|Buphenyl|
45692967|NCT01278160|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a split dosage of 1/2 and 1/2 total daily dose before breakfast and before dinner, in combination with metformin.
45692968|NCT01278160|Drug|metformin|Tablets 500 mg administered orally with meals. Pre-trial dose and regimen unchanged
45692969|NCT01996241|Behavioral|Multi-level, structural and norms-based intervention|Receive multi-level, structural and norms-based intervention
45692970|NCT00248404|Drug|NB1011|
45692971|NCT02091869|Other|Paper Asthma Action Plan|Participants will utilize a paper based asthma action plan to record asthma symptoms and medication usage.
45373623|NCT00966836|Drug|Pre-emptive strategy with valganciclovir plus everolimus|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Everolimus plus cyclosporine and prednisone will be used for maintenance immunosuppression
45490989|NCT03525379|Drug|Resveratrol|"Subject participation will be approximately 10 weeks in duration. Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.~The schedule for the study is:~Week 0 Screening and randomization Weeks 1-2 Run-in; no treatment Weeks 3-10 Treatment Phase (resveratrol or placebo)"
45490990|NCT03525379|Drug|Placebo|Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.
45373624|NCT00966836|Drug|Prophylaxis with valganciclovir plus mycophenolate|Patients will receive 3 months of oral valganciclovir with mycophenolate and standard cyclosporine and prednisone for maintenance immunosuppression
45490991|NCT03476551|Drug|Hydrochlorothiazide|Patients are tested for their normal prescription hydrochlorothiazide medication
45373625|NCT00966836|Drug|Prophylaxis with valganciclovir plus everolimus|Patients will receive valganciclovir for 3 months after transplant. Everolimus plus reduced cyclosporine and prednisone will be used for maintenance immunosuppression
45373626|NCT00966836|Drug|Pre-emptive mycophenolate|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Mycophenolate plus standard cyclosporine and prednisone will be used for maintenance immunosuppression
45373627|NCT00967070|Drug|Nicotine Patch|25 mg nicotine patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
45373628|NCT00967070|Drug|Placebo Patch|Placebo patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
45490992|NCT04702789|Drug|Dorzolamide-timolol-brimonidine and latanoprost|Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
45490993|NCT04702789|Drug|Dorzolamide-timolol and latanoprost|Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
45373629|NCT00977678|Other|open access gastroscopy|access to gastroscopy without preceding appointment
45373630|NCT00977678|Other|Gastroscopy by appointment|Gastroscopy after preceding appointment in a conventional outpatient clinic
45373631|NCT00977756|Drug|Raltegravir (RAL)|400 mg twice daily (BID)
45373632|NCT00977756|Drug|Atazanavir (ATV)|300 mg daily
45373633|NCT00977756|Drug|Ritonavir (RTV)|100 mg daily, dosing by weight in Group I
45846865|NCT02652780|Device|Sham Intravitreal Injection|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
45373634|NCT00977756|Drug|Tenofovir (TDF)|300 mg daily
45373635|NCT00977756|Drug|Etravirine (ETV)|200 mg BID
45373636|NCT00977756|Drug|Darunavir (DRV)|Dosing by weight
45373637|NCT00977756|Drug|Maraviroc (MVC)|150 mg BID in groups J and K; 600 mg BID in group L
45373638|NCT00977756|Drug|Lopinavir/ritonavir (LPV/r)|Coformulation of 400 mg lopinavir and 100 mg ritonavir, taken twice daily
45373639|NCT00981344|Other|Wheeled Mobility in Everyday Life:Effects of Wheelchair Type on Mobility Performance of Elders in Public Environments|We are studying how wheeled mobility performance and the impact of device type on a group of community dwelling Veterans.
45373640|NCT04938206|Procedure|The Clinical Decision Rule|The Clinical Decision Rule will be applied to all patients included in the study at different times depending on the type of cancer: at H12-H24 of admission for patients with solid tumor; at H24-H48 for patients with hematological cancer. Patients classified as being at low risk of severe infection by the DRC were then randomized to a control group under standard management or to an experimental group with therapeutic relief. Treatment reduction for the experimental group was started immediately after randomization, in hospital. Discharge was proposed 24 hours later, with follow-up every two days, by telephone or in
45373641|NCT00981500|Procedure|gastric bypass|Roux-en-Y gastric bypass
45373642|NCT00981500|Procedure|gastric banding|laparoscopic adjustable gastric banding
45373643|NCT00981500|Procedure|sleeve gastrectomy|vertical sleeve gastrectomy
45373644|NCT00967148|Drug|Tinzaparin|The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
45373645|NCT00981734|Other|Hiking|Three times by a week, thirty minutes, controlling heart frequency between fifty five per cent and seventy five per cent.
45373646|NCT04007588|Drug|Nivolumab|Nivolumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
45373647|NCT04007588|Drug|BMS-986205|BMS-986205 is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. BMS-986205 work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
45373648|NCT04007588|Drug|Ipilimumab|Ipilimumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
45846866|NCT02653560|Drug|Potassium chloride powder|
45846867|NCT02653560|Drug|Potassium magnesium Citrate (KMgCit)|
45846868|NCT02653560|Drug|Potassium citrate powder|
45846869|NCT02653560|Drug|Placebo|
45373649|NCT00977912|Dietary Supplement|Probiotic supplementation|one capsule containing probiotics per day added to milk
45373650|NCT00977912|Dietary Supplement|Milk containing placebo|one capsule containing placebo per day added to milk
45373651|NCT00967304|Other|"Application of theMen continue and HER DOO2 rule"|"Consecutive patients will have theMen continue and HER DOO2 rule applied by the attending physician between 5 - 12 months after treatment for a first unprovoked objectively proven major VTE.~Men continue and HER DOO2 rule: all men continue oral anticoagulants and women with 2 or more of the following features after 5-7 months of OAT should continue oral anticoagulants:1) HER - any Hyperpigmentation, Edema and Redness of either lower extremity, 2) Vidas D-dimer ≥250ug/L, 3) Obesity - BMI ≥30 kg/m2 and 4) Older age - Age ≥65 years."
45373652|NCT00978146|Drug|Hydroxyurea|Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients will remain on hydroxyurea as long as there is a response or stability in tumor size and associated toxicities are manageable. Maximum treatment duration will be one year.
45846870|NCT02653872|Drug|AZD7986|Oral solution, single dose, dilution from concentrate
45846871|NCT02653872|Drug|Verapamil|Extended release tablet for oral use
45373653|NCT00981968|Drug|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single and multiple oral doses for 7 days
45373654|NCT00981968|Drug|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single oral dose
45373655|NCT00982046|Device|Opti-Free RepleniSH multi-purpose disinfecting solution|Contact lens solution CE-marked for intended use.
45373656|NCT00982046|Device|ReNu MultiPlus multi-purpose solution|Contact lens solution CE-marked for intended use.
45373657|NCT00982046|Device|Clear Care cleaning and disinfecting system|Contact lens care system CE-marked for intended use.
45490994|NCT03521934|Drug|Sotagliflozin|"Pharmaceutical form: tablet~Route of administration: oral"
45490995|NCT03521934|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
45490996|NCT03434353|Drug|Inarigivir Soproxil|Administered orally once daily one hour before or one hour after a meal
45846872|NCT02653872|Drug|Itraconazole|Oral solution
45373658|NCT00982046|Device|Senofilcon A contact lens (ACUVUE OASYS)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
45373659|NCT00982046|Device|Lotrafilcon B contact lens (AIR OPTIX AQUA)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
45373660|NCT00982046|Device|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
45373661|NCT00967382|Drug|dalteparin sodium|"Subject's randomize to treatment arm will receive dalteparin sodium 5,000 IU s.c. daily starting on randomization day until 20 weeks gestational age then;~dalteparin sodium 5,000 IU s.c. bid from 20 weeks to onset of labour or 37 weeks gestation (discontinued at the discretion of the investigator/obstetrician)~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
45373662|NCT00982124|Drug|Zoledronic Acid|Each patient is to receive an initial dose of zoledronic acid of 0.0125 mg per kg body weight, then subsequent doses of zoledronic acid at a dose of 0.025 mg per kg body weight once every 12 to 13 weeks for 104 weeks (total of 8 doses).
45373663|NCT04007354|Other|Ventilation method|Depending on the group assignment, mechanical ventilation or spontaneous breathing was performed.
45373664|NCT00982202|Drug|pioglitazone|15mg tablet daily, increase by one pill at one-week intervals based on reported tolerability; maintain best tolerated dose (1 to 3 tablets daily) for ~18months
45373665|NCT00982202|Drug|Placebo|1 to 3 tablets daily for ~18 months
45373666|NCT04893824|Device|Grappler® Interference Screw System|Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler® Interference Screw System
45373667|NCT00967460|Behavioral|Lifestyle intervention|Promoting unstructured spontaneous physical in childcare through an adaptation of the built environment and the provision of a supportive social environment
45373668|NCT00978224|Dietary Supplement|Viusid|3 Viusid bags (Orally administered) per day, for 60 weeks
45373669|NCT00978224|Dietary Supplement|Placebo|3 Placebo bags (Orally administered) per day, for 60 weeks.
45373670|NCT00967538|Drug|etanercept 50 mg|All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
45373671|NCT00978302|Drug|Avotermin|Intradermal injection, 50ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
45373672|NCT00978302|Drug|Avotermin|Intradermal injection, 100ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
45373673|NCT00978302|Drug|Avotermin|Intradermal injection, 500ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
45373674|NCT00978302|Drug|Avotermin|Intradermal injection, 1000ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
45373675|NCT00978302|Drug|Avotermin|Intradermal injection, 1μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
45373676|NCT00978302|Drug|Avotermin|Intradermal injection, 10μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
45373677|NCT00978302|Drug|Placebo (vehicle)|Intradermal injection at time of biopsy and again 24 h later
45373678|NCT00984776|Other|Contrast enhanced MRI with Gadofosveset|0.03 mmol/kg bodyweight of gadofosveset will only once be administered during MRI procedure via an intravenous catheter
45490997|NCT03434353|Drug|TAF|Administered orally once daily with food
45490998|NCT03374137|Biological|obinutuzumab|Obinutuzumab 1000 mg solution used for infusion according to routine clinical practice.
45490999|NCT03415776|Procedure|Hemodialysis|Renal replacement therapy
45491000|NCT02914184|Biological|HRV PCV-free liquid vaccine|Subjects will receive two doses of PCV-free HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
45373679|NCT00978536|Other|Cognitive impairment of multiple sclerosis|Patients will get a lumbar puncture in order to measure the biomarkers in the CSF, a neuropsychological exam, an evaluation of the hippocampal volume by MRI and a cerebral scintigraphy.
45373680|NCT00978614|Drug|Neramexane|"Dosage form:~25 mg immediate release [IR] tablets (=15.9 mg neramexane free base)~37.5 mg IR tablets (=23.9 mg neramexane free base)"
45373681|NCT00982358|Drug|Valsartan|
45491001|NCT02914184|Biological|Rotarix|Subjects will receive two doses of currently licensed lyophilised HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
45373682|NCT00982358|Other|Placebo|
45373683|NCT00982436|Drug|Docetaxel/cisplatin|Docetaxel 75 mg/m2 intravenous every 3 weeks for 3 cycles Cisplatin 75 mg/m2 intravenous every 3 weeks for 3 cycles
45373684|NCT00982436|Radiation|Radiotherapy|70 Gy in 35 fractions to gross tumor and lymph node metastases
45373685|NCT00982436|Drug|Carboplatin|Carboplatin AUC 1.5 intravenous weekly during radiotherapy
45373686|NCT00982748|Behavioral|Pranayama (Yoga Breathing) Techniques|1-hour long yoga breathing classes, taught once per week for 2-8 consecutive weeks. Dose (Number of classes) administered is dependent on randomization arm and individuals' chemotherapy cycle length.
45373687|NCT00982826|Drug|ABT-072|See Arms information for a detailed description.
45373688|NCT00982826|Drug|Placebo|See Arms information for a detailed description.
45373689|NCT00978692|Device|Toric Orthokeratology lenses|Children wearing toric orthokeratology at night for correcting astigmatism and myopia will be the study group
45373690|NCT00978692|Device|Single-vision spectacles|Children wearing single-vision spectacles in the daytime for correcting the refractive errors will serve as the control group
45373691|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 50mM (1.41mg/100μl) administered just prior to wounding and 200μl administered 24 h later
45373692|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered just prior to wounding and 200μl administered 24 h later
45491002|NCT01380522|Drug|Metronidazole|Capsules, single-dose, fed
45491003|NCT01380522|Drug|Flagyl|Capsules, single-dose, fed
45491004|NCT03611712|Drug|Astragalus Polysaccharides 500 mg|PG2 Lyo. Injection 500 mg will be given on 1 week before CCRT (Week 1, PG2 Lyo. Injection 500 mg, b.i.w), during CCRT (Week 2-6, PG2 Lyo. Injection 500 mg, t.i.w for 5 weeks), and after CCRT (Week 7-8, PG2 Lyo. Injection 500 mg, t.i.w for 2 weeks)
45491005|NCT03633227|Drug|Obeticholic Acid (OCA)|OCA will be administered per dose and schedule specified in the arm description.
45373693|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered just prior to wounding and 200μl administered 24 h later
45491006|NCT03633227|Drug|Placebo|OCA matching placebo will be administered per the schedule specified in the arm description.
45491007|NCT03383874|Combination Product|Probio-Tec BG-VCap-6.5|"The product under investigation is a probiotic containing two microorganisms (Lactobacillus rhamnosus, LGG® and Bifidobacterium animalis subsp. lactis, BB-12®, referred to as LGG® and BB-12®, respectively) and is offered commercially as Probio-Tec BG-VCap-6.5. This composition is formulated to contain a minimum of 1 billion (1.0 x 10^9) CFU (Colony Forming Units) per dose (capsule), including equal numbers of the two strains; i.e. 0.5 x 10^9 CFU of each of LGG® and BB-12® at the time of manufacture. The product will be administered orally."
45373694|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 300mM (8.46mg/100μl) administered just prior to wounding and 200μl administered 24 h later
45373695|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered just prior to wounding and 200μl administered 24 h later
45373696|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 600mM (16.93mg/100μl) administered just prior to wounding and 200μl administered 24 h later
45491008|NCT03383874|Other|Placebo|This placebo is made almost identically to the Probio-Tec but without active microorganisms.
45692972|NCT02091869|Device|Mobile Phone|Participant will be able to log peak flow data, medications, and symptoms in their mobile phones utilizing the mobile app.
45692973|NCT00748072|Drug|DDAVP|0.3 mcg/kg subcutaneous
45692974|NCT00748072|Drug|saline solution|saline solution 1 ml subcutaneous
45692975|NCT03806920|Dietary Supplement|Intervention A|
45692976|NCT03806920|Dietary Supplement|Intervention B|
45373697|NCT00984854|Drug|Placebo|Intradermal Placebo (0.9% phosphate buffered saline, pH 7.0), 100μl administered just prior to wounding and 200μl administered 24 later
45373698|NCT00978770|Drug|systemic chemotherapy|
45373699|NCT00978770|Procedure|diffusion-weighted magnetic resonance imaging|
45373700|NCT00978770|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
45373701|NCT00978770|Procedure|magnetic resonance spectroscopic imaging|
45373702|NCT00978770|Procedure|neoadjuvant therapy|
45373703|NCT00545168|Drug|Spinosad|10 minute topical application of product, followed by a complete rinse off.
45373704|NCT00545168|Drug|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen.
45373705|NCT00545168|Drug|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
45373706|NCT00982904|Drug|Fexinidazole/Placebo|
45373707|NCT04869020|Device|Otoband|Participants with vertigo will wear the Otoband set at their chosen power level when experiencing symptoms.
45373708|NCT04869020|Device|Sham A|Sham Device A is an OtoBand in which the transducer is modified so that the vibrations are not targeted at the vestibular system.
45491009|NCT03665324|Other|Evaluation of the relationship between atrial remodeling evaluated by ECG and ETT with the occurrence of supraventricular arrhythmias|"Subjects will be retrospectively retrieved from the Sport Medicine Service of Rennes University Hospital database.~Medical data will then be collected from the athletes' medical records. The ECG present in the medical file will be reinterpreted to obtain the resting heart rate, the amplitude of the P wave, the morphology of the P wave and the duration of the PR space.~The data from the stress test will be found from reports in the medical records: resting heart rate, maximum heart rate, sustained peak load, arrhythmia during the test.~ETTs will be retrieved from the local server. They will be reinterpreted to collect anatomical and functional cardiac data necessary for the study."
45491010|NCT03665246|Behavioral|Integrated Mothers and Babies Course|The Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) will be implemented along side normal C-PrES programming (key MNCHN behaviors). The iMBC curriculum is a prevention model based on cognitive behavioral therapy with the aim of supporting pregnant women and mothers with children under two years of age to become more resilient, decrease risk for future depression, and manage daily stressors effectively. In addition, the updated version of the iMBC is integrated with selected early childhood development (ECD) messages. The integration of these messages is intended to increase mothers' knowledge of the stressors associated with pregnancy and parenting young children and promote early stimulation behaviors and bonding to support child development.
45373709|NCT04869020|Device|Sham B|Sham Device B is an OtoBand that operates at power settings found to be nontherapeutic against vertigo associated with virtual reality.
45491011|NCT03297372|Device|IOL implantation|Implantation of monofocal IOL Micropure 1.2.3
45692977|NCT03806920|Dietary Supplement|Intervention C|
45692978|NCT03806920|Dietary Supplement|Intervention D|
45373710|NCT00984932|Drug|Rosuvastatin|40 mg of rosuvastatin daily
45373711|NCT00983138|Drug|recombinant asparaginase|10 000 Units/m² adjusted to age, 6 i.v. infusions (day 15, day 18, day 22, day 25, day 29, day 33) during the induction therapy
45692979|NCT04731701|Diagnostic Test|Hemophilia Joint Health Score (HJHS)|Joint examination with Hemophilia Joint Health Score (HJHS)
45373712|NCT00544544|Drug|Riluzole|50 mg twice daily for 2 weeks 50 mg in the morning and 100 mg in the evening for 1 week 100 mg twice daily for 3 weeks
45373713|NCT05015270|Diagnostic Test|Medications or percutaneous coronary intervention|In this study, we will for the first analyze the correlation of proteins concentration with coronary artery disease burden. Next, the prediction of proteins for one-year clinical events will be further analyzed
45692980|NCT00248794|Behavioral|Cognitive Rehabilitation Therapy (CRT) + Skill Training (SDG)|CRT is a one on one cognitive skills training and Skill training is a group intervention to develop concrete skills of daily living.
45692981|NCT00248794|Behavioral|Individual Computer Based Cognitive Rehabilitation (ICBCR) and Skills Training (SDG)|ICBCR is a computerized cognitive skills training program and Skill training is a group intervention to develop concrete skills of daily living.
45373714|NCT04810364|Radiation|Quantitative coronary angiography, intravascular imaging with percutaneous intervention|Coronaries will be shot with AXIOM Artis dFC (Siemens, Munich,Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (OCT, IVUS, VH-IVUS, NIRS) and/ or percutaneous intervention (with implantation of the medical device).
45373715|NCT00979160|Drug|Dasatinib|Starting dosage 20mg once daily, that can be escalated up to 100mg once daily. Patient will remain on treatment for 12 months.
45373716|NCT00979316|Drug|BMS-708163|Oral Solution, Oral, 800 mg, Once on Day 1, approximately 14 days
45373717|NCT00979316|Drug|BMS-708163|Oral Solution, Oral, 200 mg, Once on Day 1, approximately 14 days
45373718|NCT00979316|Drug|Placebo|Oral Solution, Oral, 0 mg, Once on Day 1, approximately 14 days
45373719|NCT00979316|Drug|Moxifloxacin|Tablets, Oral, 400 mg, Once on Day 1, approximately 14 days
45373720|NCT00983450|Other|watching a normal walking clip|the study group will gain an intervention consisting of 12 therapy sessions, administered for 12 consecutive days (apart of weekends). The intervention will include 6 minutes of watching a movie clip alternately showing a healthy man and a healthy woman at their sixties, walking while being filmed from various angles. Immediately after watching, the subject will perform 6 minutes of walking, under the experimenters supervision, but without his or hers intervention. Immediately following the walking, the whole procedure will be repeated (watching a clip and walking).
45373721|NCT00983450|Other|watching walk backward clip|The control group will undergo 12 treatments of the same nature, but will watch the movie clip shown backwards, so that the people filmed will seem to walk backwards (it was established that watching a reversed action does not activate the MNS system activated by a regular execution of the activity [Celnik et al., 2008]), followed by 6 minutes of walking under the experimenters supervision, then watching the movie again and walking again.
45491012|NCT05042232|Other|SARS-CoV-2 Positive|Participants who have tested positive for SARS-CoV-2, both with and without symptoms
45692982|NCT00248794|Behavioral|Skills Group (SDG)|Skill training is a group intervention to develop concrete skills of daily living. This is augmented with the opportunity to receive up to 5 hours of individual staff contact.
45491013|NCT05042232|Other|SARS-CoV-2 Negative|Participants who have tested negative for SARS-CoV-2
45491014|NCT02913326|Drug|Dabigatran etexilate|
45491015|NCT02913326|Drug|Warfarin|
45373722|NCT00983684|Device|Intrabeam|A dose of 20 Gy at the surface of the applicator or 6 Gy at 1cm (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 30 minutes, depending on the size of the applicator.
45373723|NCT00983684|Radiation|Post-operative radiotherapy|All patients randomised to receive conventional radiotherapy within this trial should be treated in accordance with a pre-specified policy. Dosage should only be applied to the breast; axillary, supra-clavicular and internal mammary nodes should not generally be irradiated by discrete fields.
45373724|NCT00983840|Other|Family Eats|8-session web-based program on healthy eating for African American families
45373725|NCT00983996|Drug|Alendronate Sodium Tablets, 10 mg|10 mg, single-dose fasting
45373726|NCT00983996|Drug|Fosamax Tablets, 10 mg|10 mg, single-dose fasting
45373727|NCT00984074|Procedure|blood-oxygen-level-dependent functional magnetic resonance imaging|
45373728|NCT00984074|Procedure|diffusion tensor imaging|
45491016|NCT03434028|Drug|Early Vasopressors|"Norepinephrine will be used as preferred vasopressor and titrated to achieve mean arterial pressure (MAP) between 65 mmHg and 75 mmHg. Rescue fluids may be administered as 500ml boluses if predefined rescue criteria are met."
45491017|NCT03434028|Drug|Early Fluids|"Additional 2 liter intravenous fluid infusion upon enrollment (may forego second liter if MAP/SBP and heart rate are normalized and clinical assessment if patient is fluid replete after the first liter). Administer 500ml fluid boluses for fluid triggers until 5 liters administered or development of clinical signs of acute volume overload develop. Rescue vasopressors may be administered after 5 liters of fluid, for development of acute volume overload, or if other predefined rescue criteria are met. Any type of isotonic crystalloid (normal saline, ringers lactate, balanced solution such as plasmalyte) is permitted."
45692983|NCT03806686|Biological|Placebo|Sterile normal saline
45692984|NCT03806686|Biological|ID93+GLA-SE|ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
45692985|NCT01995539|Behavioral|therapy regimen|Subjects will be recommend changes in therapy regimens.
45846873|NCT02653872|Drug|Diltiazem|Extended release capsule
45373729|NCT00984074|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
45373730|NCT00984074|Procedure|functional magnetic resonance imaging|
45373731|NCT00984074|Radiation|intensity-modulated radiation therapy|
45373732|NCT00984074|Radiation|radiation therapy treatment planning/simulation|
45373733|NCT00985244|Drug|Azithromycin|Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin during 1 year.
45373734|NCT00985244|Drug|Placebo|Persons in this group will receive 3 times a week placebo of azithromycin during 1 year.
45373735|NCT00979472|Drug|Solifenacin|oral
45373736|NCT04007120|Drug|RVT-1601|Inhaled RVT-1601 administered once daily over two days
45692986|NCT01835587|Drug|CC-486|Cohorts of 3 to 6 subjects will be treated at escalating or de-escalating sequential dose levels until a preliminary Maximum Tolerated Dose (MTD) is identified.
45373737|NCT00984152|Drug|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
45373738|NCT00984152|Drug|TDF/FTC + Efavirenz (Atripla) Once-Daily|TDF/FTC + Efavirenz (Atripla) Once-Daily
45373739|NCT00985322|Drug|ACE inhibitor Ramipril|The ACE inhibitor (Ramipril) will be started at 1.25 mg/day and will be up-titrated to 2.5 mg/day, to 5 mg/day, and then to 10 mg/day according to BP control and tolerability.
45373740|NCT00985322|Drug|non-RAS inhibitor antihypertensive therapy|Blood Pressure lowering regimen not including RAS inhibitors
45373741|NCT00984230|Other|BSF|feeding amount according to individual baby need
45373742|NCT00984230|Other|BSF + Lactoferrin + Probiotics|feeding amount according to individual baby need
45373743|NCT00984230|Other|BSF + Lactoferrin + Probiotics + OS|feeding amount according to individual baby need
45373744|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.02μg/100μl administered once before punch biopsy
45373745|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.1μg/100μl administered once before punch biopsy
45373746|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.2μg/100μl administered once before punch biopsy
45373747|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.4μg/100μl administered once before punch biopsy
45373748|NCT00984386|Drug|Placebo|Intradermal placebo, 100μl administered once before punch biopsy
45373749|NCT00984464|Biological|REOLYSIN|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1,2,3,4 and 5 of a 21-day cycle
45373750|NCT00984464|Drug|Carboplatin|6 AUC mg/ml min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
45373751|NCT00984464|Drug|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
45373752|NCT00988130|Other|laboratory biomarker analysis|
45373753|NCT00988130|Other|questionnaire administration|
45373754|NCT00988130|Procedure|assessment of therapy complications|
45373755|NCT00988130|Procedure|high-intensity focused ultrasound ablation|
45373756|NCT00988130|Procedure|quality-of-life assessment|
45373757|NCT00985478|Drug|SLV342|25 mg once daily - Maximal Tolerated Dose
45373758|NCT00985478|Drug|placebo|matching placebo
45491018|NCT01384110|Dietary Supplement|Reduction of glycemic index of ingested foods|Oral administration of the experimental lemon tea powder(56.1 g) and the placebo lemon tea powder (55.6 g) dissolved in water. Each participant will receive both treatment in a cross-over protocol design during 2 visits separated by a 2-weeks period. The day before both intervention, participants will consume a standardised meal for the supper.
45491019|NCT03666182|Other|No Intervention|No Intervention
45692987|NCT01736917|Drug|Fosaprepitant|Fosaprepitant 150mg IV D3 for acute prophylaxis Fosaprepitant 150mg IV on Day 5 for delayed prophylaxis
45373759|NCT00988286|Procedure|CEP, MEP, TMS|Patients and healthy volunteers will undergo cortical evoked potentials (CEP), motor evoked potentials (MEP) and transcranial evoked potentials (TMS).
45373760|NCT05593796|Behavioral|cognitive behavioral therapy|12 weekly, individual sessions of manual-guided CBT delivered by trained clinician .
45373761|NCT05593250|Drug|SHR-1905|subcutaneous
45373762|NCT05593250|Drug|placebo|subcutaneous ,placebo
45373763|NCT04454372|Other|demographic and clinical data obtained from hospital's electronic medical record.|This retrospective observational study. . Demographic and severity data will include age, sex, SAPS 3 and SOFA scores at admission, nutritional risk determined by NRS-2002 and commodities. Clinical and laboratory data on arrival at the ICU including PaO2 / FIO2, blood count and PCR D-dimer, ferritin, fibrinogen, DHL. Drug interventions including use of hydroxychloroquine, corticosteroids, heparin, tocilizumab. Characteristics of invasive and non-invasive respiratory support, use of prone position and ECMO and vasoactive drugs. The main complications, acute kidney injury requiring renal replacement therapy, secondary infectious complications will be documented as well as the outcomes.
45373764|NCT00985556|Drug|capecitabine|Given orally
45373765|NCT00985556|Drug|oxaliplatin|Given IV
45373766|NCT00985556|Drug|tegafur-gimeracil-oteracil potassium|Given orally
45373767|NCT04780490|Other|liberal fluid management|10 ml/ kg/ hr Ringer's lactate solution
45373768|NCT04780490|Other|restrictive fluid management|2 ml/ kg/ hr Ringer's lactate solution with 2 mcg / kg / hr norepinephrine infusion
45373769|NCT05542160|Dietary Supplement|Pumpkin seed extract (IRK-19)|Placebo: Dietary fiber powder, two capsules/day (600 mg/day), continued use for 3 months Treatment: Pumpkin seed extract powder, two capsules/day (600 mg/day), continued use for 3 months
45373770|NCT05537402|Drug|Atezolizumab and bevacizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle and Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle
45373771|NCT05537402|Radiation|transarterial chemoembolization (TACE) or transarterial radioembolization (TARE|TACE cycles occur every 8 weeks +/- 7 days OR TARE cycles occur every 12 weeks +/- 7 days
45491020|NCT01384032|Dietary Supplement|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
45491021|NCT01384032|Dietary Supplement|Hgih saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
45373772|NCT04445246|Drug|Inhaled ILOPROST|Inhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization.
45373773|NCT00541346|Drug|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
45373774|NCT00988520|Drug|Rocuronium bromide|Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation
45373775|NCT00988520|Drug|Rocuronium bromide|Intubation dose of 0.6 mg/kg injection
45373776|NCT00988520|Drug|Rocuronium bromide|Intubation dose of 0.9 mg/kg injection
45373777|NCT00988520|Drug|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
45373778|NCT00988520|Drug|Propofol|4010 mg/kg/hr intravenous maintenance anesthesia
45373779|NCT00985634|Device|LeGoo|LeGoo internal vessel occluder. Usage (dose) as required and determined by surgeon.
45373780|NCT00985634|Device|Control|Vessel loops
45373781|NCT00985868|Drug|multikinase inhibitor AT9283|
45373782|NCT00985868|Other|enzyme-linked immunosorbent assay|
45373783|NCT00985868|Other|immunohistochemistry staining method|
45373784|NCT00985868|Other|laboratory biomarker analysis|
45373785|NCT00985868|Other|pharmacological study|
45373786|NCT05498090|Drug|Fenofibrate 145 mg|Fenofibrate 145 mg PO daily for 4 weeks
45373787|NCT00077623|Drug|epoetin alfa or beta|iv 3 times weekly, as prescribed
45373788|NCT00077623|Drug|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 2 weeks
45373789|NCT00077623|Drug|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 4 weeks
45373790|NCT00541034|Biological|rituximab|
45373791|NCT00541034|Drug|cyclophosphamide|
45373792|NCT00541034|Drug|pentostatin|
45373793|NCT00986024|Behavioral|aerobic exercise|carried out 3 times per week for 12 weeks
45373794|NCT00986024|Behavioral|strength training|carried out 3 times per week for 12 weeks
45373796|NCT01090375|Other|Exercise|
45692988|NCT01736917|Drug|Dexamethasone|Dexamethasone 20mg PO daily on D1 and 2 for acute prophylaxis Dexamethasone 4mg PO BID on Days 6 through 8
45373797|NCT01090375|Other|Non Exercise|
45373798|NCT00540644|Drug|lenalidomide (Revlimid®)|25 mg p.o. daily on days 1-21 of each 28 day cycle
45373799|NCT00540644|Drug|Cyclophosphamide|50 mg p.o. BID daily on days 1-21 of each 28 day cycle
45373800|NCT00540644|Drug|Prednisone|50 mg p.o. Q.O.D.
45373801|NCT05470400|Biological|FP conjugate vaccine (25 mcg)|"FP8v1-rTTHC (FP conjugate vaccine) is an HIV-1 fusion peptide conjugated to recombinant tetanus toxoid heavy chain fragment C (rTTHC) via sulfo-SIAB chemical linker.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
45373802|NCT05470400|Biological|FP conjugate vaccine (200 mcg)|"FP8v1-rTTHC (FP conjugate vaccine) is an HIV-1 fusion peptide conjugated to recombinant tetanus toxoid heavy chain fragment C (rTTHC) via sulfo-SIAB chemical linker.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
45373803|NCT05470400|Biological|Trimer 6931 (100 mcg)|"HIV-1 Trimer 6931 (Trimer 6931) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from consensus clade C sequence (ConC).~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
45373804|NCT05470400|Biological|Trimer 6931 (200 mcg)|"HIV-1 Trimer 6931 (Trimer 6931) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from consensus clade C sequence (ConC).~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
45692989|NCT01736917|Drug|5HT3|Any 5HT3RA on D1-5; D1, 3 and 5 if palonosetron is used.
45373805|NCT05470400|Biological|Trimer 4571 (200 mcg)|"HIV-1 Trimer 4571 (Trimer 4571) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
45373806|NCT05470400|Biological|Trimer 4571 (100 mcg)|"HIV-1 Trimer 4571 (Trimer 4571) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
45373807|NCT05450900|Drug|Choriogonadotropin Alpha|drug, active
45373808|NCT05450900|Dietary Supplement|biotin|supplement, oral
45373809|NCT05450900|Other|Microcellulose filler|supplement, oral
45373810|NCT04004858|Radiation|External beam radiation therapy|Patient will receive 60Gy in 20 fractions as per standard practice
45373811|NCT00988754|Behavioral|School children and adolescents as health experts|Experimental group: Weekly health lesson for children; Monthly training for teacher; 2-3 trainings/year for the parents
45373812|NCT00988910|Drug|EE30-DRSP (Yasmin, BAY86-5131)|DRSP-containing combined oral contraceptives according to the normal routine praxis
45373813|NCT00988910|Drug|Other combined oral contraceptives|Other combined oral contraceptives according to the normal routine praxis
45373814|NCT04768244|Other|maternal SARS-CoV-2 infection|positive PCR in nasopharinx and/or presence of antibodies in serum
45373815|NCT00988988|Drug|AGEE cream|AGEE cream is a creatine ethyl ester based product (an amino acid) that can be purchased over-the-counter without a prescription and is not FDA controlled. It will be used immediately after injection and repeated as needed.
45373816|NCT00988988|Drug|1% Steroid Cream|comparing to AGEE cream or placebo. 1% steroid cream is available over the counter. To be used immediately after injection and as needed.
45373817|NCT00988988|Drug|topical placebo cream with no active ingredients|Cream to be applied immediately after injection and repeated as needed.
45373818|NCT00986336|Drug|topiramate|1-25 mg plus 1-100 mg tablet twice daily for 2 weeks (250 mg/day)
45373819|NCT00986336|Drug|topiramate|2-100 mg tablets twice daily for 2 weeks (400 mg/day)
45373820|NCT00986336|Drug|risperidone|Twice daily, individualized dosing to stabilization at 1-6 mg/day.
45373821|NCT00986336|Drug|topiramate|2-25 mg tablets twice daily for 2 weeks (100 mg/day)
45373822|NCT00989222|Procedure|closed reduction and external fixation|Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation
45373823|NCT00989222|Procedure|Internal fixation with a volar locked plate|Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
45373824|NCT00989300|Drug|Treatment A - rabeprazole|20 mg rabeprazole sodium once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
45373825|NCT00989300|Drug|Treatment B - omeprazole|20 mg omeprazole once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
45373826|NCT00989300|Other|Treatment C - placebo|placebo once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
45692990|NCT01277302|Drug|Ranibizumab|Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.
45491022|NCT01384032|Dietary Supplement|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
45846874|NCT02654652|Dietary Supplement|Symbiotic|Intervention will consist of the adminitration of symbiotic product twice a day during seven days after surgical treatment
45846875|NCT02654652|Dietary Supplement|Maltodextrin|Intervention will consist of the adminitration of placebo product twice a day during seven days after surgical treatment
45373827|NCT05378672|Drug|Dasiglucagon|Dasiglucagon, 0.6 mg/0.6 mL will be administered as an under the skin (subcutaneous, s.c.) injection by a prefilled syringe, into the abdominal region.
45373828|NCT04005014|Other|Myopia prediction algorithm|Candidate predictors included age at examination, SE, and annual progression rate. Using these predictors, the algorithm will be used to predict SE and whether patients will progress to high myopia in the subsequent 10 years.
45373829|NCT03437720|Drug|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
45491023|NCT03665558|Device|Temporary DDD pacing|Measurements will be performed in patients otherwise undergoing invasive catheterization procedure. Baseline ventricular and aortic hemodynamic parameters (continuous pressure recordings) will be recorded. Thereafter, DDD pacing with stepwise changing of the AV delay will be performed. During each pacing steps left ventricular and aortic pressures at different aortic levels will be continuously recorded. From these hemodynamic data, left ventricular and aortic dP/dt values will be calculated off line.
45373830|NCT03437720|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
45373831|NCT03393182|Procedure|TLDG arm|After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy(TLDG)
45596377|NCT03531931|Drug|Apatinib/Capecitatine|Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2), now being developed by Jiangsu Hengrui Medicine (China). Even at a low concentration apatinib can still perform magnificent VEGFR2 inhibitory activities, meanwhile at little higher concentration it can inhibit PDGFR and kinases as well, such as c-Kit and c-Src .The action sites of apatinib are the intracellular ATP binding site of the protein tyrosine receptor. Pharmacodynamical study shows that apatinib is able to inhibit the tyrosine kinase activity of VEGFR, block signal conduction after the combination of VEGF, finally contribute to stopping new blood vessel formation in tumor tissue.
45373832|NCT03393182|Procedure|LADG arm|After lymphadenectomy, gastrectomy and reconstruction procedure are performed extracorporeally through mini-laparotomy(LADG)
45373833|NCT04005950|Device|Scalpel Bougie technique|ScalpelCric Set
45373834|NCT04005950|Device|modified Scalpel Bougie technique|ScalpelCric Set plus speculum
45373835|NCT00986414|Drug|AFQ056|
45373836|NCT00986414|Drug|AFQ056|
45373837|NCT00986414|Drug|AFQ056|
45373838|NCT00986414|Drug|AFQ056|
45373839|NCT00986414|Drug|AFQ056|
45373840|NCT00986414|Drug|Placebo|
45373841|NCT05712668|Behavioral|Preoperative counseling|Providers will review the diagnosis, surgical planning, risks/benefits/alternatives to surgery, post-operative care, and long term scope of care.
45373842|NCT05712668|Behavioral|Asynchronous telemedicine|An asynchronous video will be delivered by Mytonomy. This platform allows investigators to track user analytics relating to the time, frequency, or duration watched by the user.
45373843|NCT01563614|Radiation|Brain radiotherapy (WBRT alone, SRT/SRS alone or WBRT plus SRT/SRS)|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
45373844|NCT01563614|Drug|Lomustine|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
45373845|NCT01563614|Drug|Liposomal cytarabine|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
45373846|NCT00543296|Drug|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
45373847|NCT00543140|Device|REALIZE™ Swedish Adjustable Gastric Band|Laparoscopic placement of the Swedish Adjustable Gastric Band
45373848|NCT05265026|Behavioral|High Intensity Interval Training|A training session consists of 38 minutes as follows: 4x4 minutes at > 85% of heart rate maximum (HRmax) alternated by 3x3 minutes active recovery at (50-70% of HRmax) and a 10-min-warm-up (60-70% of HRmax) and 3- minute cool-down at ~ warm up intensity. HRmax was determined during the VO2max test at baseline visit. Minutes spent in the different heart rate zones is monitored during the session (zone 1: 60-69%, zone 2: 70-74%, zone 3: 75-79%, zone 4: 80-84%, zone 5: >85% of HRmax).
45373849|NCT00543062|Drug|Inhaled placebo|Inhaled Staccato placebo (0 mg)
45373850|NCT00543062|Drug|Oral placebo|Oral placebo (identical to 400 mg moxifloxacin)
45373851|NCT00543062|Drug|Inhaled prochlorperazine 5 mg|Staccato prochlorperazine 5 mg, single dose
45373852|NCT00543062|Drug|Inhaled prochlorperazine 10 mg|Inhaled prochlorperazine 10 mg, single dose
45373853|NCT00543062|Drug|Oral moxifloxacin|Oral moxifloxacin 400 mg, si/ngle dose
45373854|NCT05235074|Biological|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
45373855|NCT03911960|Behavioral|Acceptance and Commitment Therapy|2 in person and 5 telephone sessions of acceptance and commitment therapy for tobacco cessation plus up to 8 weeks of nicotine patch
45373856|NCT03911960|Behavioral|Enhanced Usual Care|2 in person sessions of tobacco cessation counseling, up to 8 weeks of nicotine patch, referral to state quitline.
45373857|NCT05222594|Other|Behavioral tasks during intracranial monitoring|Participants will listen to sentences and stories while neural data are recorded through electrodes placed for clinical purposes.
45373858|NCT05221580|Drug|Ryzodeg®|Patients will be treated with commercially available Ryzodeg® in a prefilled device (FlexTouch®) or in a penfill according to the label and routine clinical practice at the discretion of the treating physician
45373859|NCT05712512|Behavioral|Neurodevelopmental assessment|individual behavioral and socio-communicative assessment from 6 to 36 months
45373860|NCT05712512|Other|Electrophysiological and eyetracking recordings|Investigation of neural and behavioral biomarkers of autism from 6 to 24 months
45373861|NCT04005092|Device|hCPAP versus HFNC|The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or HFNC.
45373862|NCT04004624|Device|Ablation|Cardiac Ablation
45373863|NCT03360578|Device|Garmin|A commercial grade health wearable
45373864|NCT04006574|Other|Exercises|Core stabilization
45373865|NCT05195606|Other|Auditory stimulus|Auditory stimulus will be applied to the patients in intervention group A. For the auditory stimulus, the sound recording of the relatives of the patients will be taken and the patients will be listened to with headphones.
45373866|NCT05195606|Other|Tactile stimulus|Tactile stimulus will be applied to the patients in the intervention group B. The tactile stimulus will be performed by the researcher with a foot massage to be applied to the patient.
45596378|NCT04474821|Other|Educational Intervention|Receive educational materials on HPV
45596379|NCT04474821|Other|Survey Administration|Ancillary studies
45373867|NCT05192720|Dietary Supplement|Andosan|See also detailed study design, Mushroom juice based on Agaricus Blazei and two other types of mushroom.
45373868|NCT05192720|Dietary Supplement|Placebo|drinking water with food colour
45373869|NCT04006184|Other|Chart review|Retrospective review of medical records at a single site with six physicians
45373870|NCT00986804|Drug|Decitabine|
45373871|NCT05712122|Procedure|stellate block|stellate blockade effect on Ventricular arrytmia
45373872|NCT00676091|Biological|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
45373873|NCT00676091|Biological|7-Valent Pneumococcal Conjugate Vaccine (7vPnc)|
45373874|NCT04599569|Device|indirect calorimetry|indirect calorimetry with and without renal replacement therapy
45373875|NCT02558933|Dietary Supplement|Epigallocatechin gallate|Pre and post study, non randomized, controlled and without placebo, to evaluate the efficacy of Epigallocatechin gallate (EGCG). It is a pilot study in a cohort of 40 FAS children, between 7 ans 14 years old. An oral dose of 9 mg/Kg/day will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment.
45373876|NCT02558855|Other|Thrust Joint Manipulation of the Lumbar Spine|
45373877|NCT02558855|Other|Non-thrust Joint Manipulation of the Lumbar Spine|
45373878|NCT00812201|Device|No intervention is used. Collection of signals only.|Device received per standard of care.
45373879|NCT00678041|Drug|Nitrofurantoin|nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
45373880|NCT00678041|Drug|Placebo|Placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
45373881|NCT04331561|Behavioral|sensory re-weighting|Participants will be supported in quiet standing by a safety harness and crisscrossing strap system. A cervical collar will be used to maintain consistent alignment between the head and trunk. A virtual reality headset is used to create a virtual environment in which visual stimuli will be presented. Three different body positions will be used during training: earth-vertical and clockwise and counterclockwise tilted 16º in the frontal plane. Sensory re-weighting will be driven by priming upregulation of somatosensory cues. In each training trial, participants must determine the direction of gravity and then indicate if the rod being displayed is aligned with gravity or if it needs to rotate clockwise or counterclockwise for that to be so. Participants will be instructed to pay attention to what they feel from their feet, legs, and gut during training and to use that pressure, stretch, movement, and muscle tension feedback to help them sense gravity.
45373882|NCT03903822|Drug|PF-06700841|PF-06700841 topical cream
45373883|NCT03903822|Drug|Vehicle (Placebo)|Vehicle topical cream
45373884|NCT00677807|Drug|Indacaterol|Indacaterol once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
45373885|NCT00677807|Drug|Placebo|Placebo once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
45373886|NCT03743142|Procedure|endovascular repair of the AAA|The Investigator will ensure that investigational devices are used only in subjects properly enrolled in the clinical study in accordance with the protocol. Subjects will undergo endovascular repair of their AAA. Procedural details may vary between sites, but will follow standard hospital protocol for EVAR and patient care management.
45373887|NCT04003350|Drug|Oxycodone|Patients are given, for up to 4 weeks, Oxycodone 5m PRN every four hours (up to 30 tablets)
45373888|NCT04003350|Drug|Tramadol|Patients are given, for up to 4 weeks, Tramadol 50mg PRN every 6 hours (up to 30 tablets)
45373889|NCT04003350|Drug|Tylenol|Tylenol 1000 mg: take as needed every 8 hours
45373890|NCT04003350|Drug|Meloxicam|Meloxicam 15 mg as need once per day
45373891|NCT04003350|Drug|Gabapentin|•Gabapentin 200 mg with morning and evening Tylenol dose
45373892|NCT04003350|Drug|Metaxalone|Metaxalone 800mg TID
45373893|NCT04003350|Drug|Esomeprazole 20mg|Esomeprazole 20mg daily
45373894|NCT00748007|Drug|Rivastigmine|Exelon (1.5mg/cap) 1.5 mg bid
45373895|NCT00748163|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
45373896|NCT00748163|Drug|sunitinib malate|
45373897|NCT00748319|Other|Detection of KIR receptor by RT PCR|Detection on biopsy cutaneous (3mm) and on blood sample of 30 ml
45692991|NCT04414579|Drug|Faster Insulin Aspart (Fiasp®)|Subjects will be randomized either to use Fiasp or conventional insulin aspart in CSII. CSII settings (basal, bolus, and correction factors) will be optimized using a meal challenge for a 2-week run in period followed by a 10-week period of CSII use with the assigned insulin. After a 12-week maintenance period, each group will cross over to the other insulin (conventional insulin aspart or Fiasp) by CSII for a second 2-week optimization period followed by a 10-week treatment period.
45373898|NCT00748397|Device|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
45373899|NCT00687401|Biological|Infliximab|Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6 (induction phase), and 14 (maintenance phase).
45373900|NCT00485693|Drug|Bupivacaine HCl|150 mg Bupivacaine HCl
45373901|NCT00485693|Drug|SKY0402|600 mg SKY0402 (study drug)
45373902|NCT00748475|Behavioral|Neurofeedback|
45373903|NCT00538902|Biological|Placebo|Placebo administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
45373904|NCT00538902|Biological|Adalimumab 80 mg|Adalimumab 80 mg administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
45373905|NCT00538902|Biological|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously every other week for 104 weeks
45373906|NCT00541970|Biological|Cervarix|Intramuscular injection, different dosing /schedule
45373907|NCT00541970|Drug|Placebo|Intramuscular injection, different dosing /schedule
45373908|NCT00687323|Drug|temozolomide|
45373909|NCT00989742|Drug|Doxycycline|50mg od
45373910|NCT00989742|Drug|Placebo|50mg od
45692992|NCT01980875|Drug|Idelalisib|150 mg tablet administered orally twice daily
45373911|NCT05408208|Drug|Intralesional Injection of Methotrexate|"One psoriatic lesion will treated with Intralesional injection of methotrexate (25mg /ml) at dosage of 0.1 ml /cm Another plaque will treated with intralesional ingection of distilled water as controlled plaque.~Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment ."
45373912|NCT05408208|Drug|Triamcinolone Acetonid|One lesion will treated with Intralesional injection of trimethinolone acetonide (10mg/ml) at dosage of 0.1 ml/ cm2 . another plaque will treated with Intralesional injection of distilled water as controed plaque Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment .
45373913|NCT02559245|Other|Descurainia Sophia|
45373914|NCT02559245|Other|Ficus carica|
45373915|NCT05358756|Drug|SACT-1|Single administartion of 150mg SACT-1
45373916|NCT05358756|Drug|EDURANT 25Mg Tablet|Single administartion of six EDURANT 25mg tablets (Total 150mg)
45373917|NCT00758615|Behavioral|Walking School Bus|Students are chaperoned to and from school by adults (study staff or parent volunteers) along set routes.
45373918|NCT00758693|Drug|Bendamustine|Bendamustine 100 mg/m2 intravenously on days 1 and 2 on a 28-day cycle for 6 cycles
45373919|NCT00758693|Drug|Rituximab|Rituximab 500 mg/m2 on a 28-day cycle for 6 cycles
45373920|NCT01564212|Other|standard airflow with forced air warming.|Subjects will lie on operating room bed with standard airflow and forced air warming.
45373921|NCT01564212|Other|laminar airflow with surgical drapes|
45373922|NCT01564212|Other|laminar airflow with forced air warming|Subjects will lie on operating room bed with laminar airflow and forced air warming.
45373923|NCT01564212|Other|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow on and surgical drapes surrounding bed.
45373924|NCT05092646|Biological|Axolotl Ambient|Axolotl Ambient is an allogeneic amniotic intra-articular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells.
45373925|NCT05092646|Drug|"Drug/Placebo: 0.9% Normal Saline"|"Drug/Placebo: 0.9% Normal Saline"
45373926|NCT05407896|Other|myKIDNEY decision aid|Patients and caregivers will be counselled using myKIDNEY decision aid which includes a video. Patients will be asked to complete a values clarification exercise (VCE). If a caregiver is recruited without their patient, he/she will be asked to complete the VCE on patient's behalf (i.e., surrogate). At the end of VCE, the participant will be given real-time feedback on which treatment might be the best fit for the patient. With the patient's consent, this information will be shared with the treating physician who can then make recommendations based on the patient's preferences.
45373927|NCT05078450|Behavioral|Mood Lifters|Participants will need to attend 12 hour long virtual weekly meetings on Zoom that focus on helpful mental health strategies and skills. Participants will be encourage to practice what they learn at home in order to improve their mood or mental wellness.
45373928|NCT00989820|Drug|hyperbaric oxygen|30 session inhalation of 100% oxygen in a pressure chamber under 2.4 ATA for 90 minutes a day before surgery and 10 session hyperbaric oxygen therapy (as mentioned before) after surgery
45596380|NCT02031263|Procedure|bronchial thermoplasty system|Check on the quality of life, emergency room uses, and sudden progress of the disease of the patients before and after the treatment by using bronchial thermoplasty system by using paired t test.
45692993|NCT01980875|Drug|Chlorambucil|2 mg tablets administered at a dose of 0.5 mg/kg orally every other week for a total of 12 doses
45692994|NCT01980875|Drug|Obinutuzumab|1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks
45373929|NCT00748631|Device|balloon kyphoplasty|A bilateral approach is chosen to insert working cannulas into the posterior part of the vertebral body through a posterior transpedicular approach.Once inserted, the balloons are inflated using visual, volume and pressure control to create a cavity.The balloons are then deflated and removed. The Bone Filler Device is then advanced through the working cannula towards the anterior part of the cavity and cement is slowly extruded by a stainless steel stylet, acting as a plunger. When the amount of cement from the first Bone Filler Device is delivered in the cavity, it is removed and another Bone Filler Device is advanced through the working cannula.
45373930|NCT04742114|Device|use the face mask with Expiratory Positive Airway Pressure(EPAP).|The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.
45373931|NCT04742114|Device|use the face mask without Expiratory Positive Airway Pressure(EPAP).|The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.
45373932|NCT00758849|Drug|Placebo|One placebo tablet administered tid for 12 days in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
45373933|NCT00758849|Drug|Fipamezole|One 30-mg tablet of Fipamezole tid from day 1 to 3; one 60-mg tablet of Fipamezole tid from Day 4 to 6; and one 90-mg tablet of Fipamezole tid from Day 7 to 12 in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
45373934|NCT05334186|Behavioral|Telehealth Reasoning Training|The current study is explores the feasibility and preliminary relative effectiveness of a telehealth-delivered inductive reasoning intervention. The results of the study can help to provide insight on whether a telehealth-adapted reasoning training shows promise with older adults and can also be used to power future clinical trial studies to more definitively evaluate the effectiveness of telehealth delivered training.
45373935|NCT05070884|Other|The development of new clinical AI solutions to predict treatment response to neoadjuvant chemotherapy (NAC) in breast cancer|Evaluate response to neoadjuvant treatment in advanced breast cancer
45373936|NCT05357820|Drug|AB-106, Itraconazole|single dose AB-106 at Day1, Itraconazole QD at Day14~Day28, single dose AB-106 at Day17
45373937|NCT05357820|Drug|AB-106, Rifampicin|single dose AB-106 at Day1, Itraconazole QD at Day14~Day32, single dose AB-106 at Day21
45373938|NCT00748787|Drug|Ispaghula husk|1 sachet of effervescent powder containing 5 gr of product (3.5 g of Ispaghula husk), b.i.d. during 16 weeks. Oral route.
45373939|NCT00748787|Drug|Placebo|1 sachet of effervescent powder b.i.d. during 16 weeks, oral route.
45373940|NCT05712044|Drug|Folic Acid 5 MG|Folic acid 5mg tablets will be administered orally every 8 hours then samples from buccal mucosa will be taken 15 days and 30 days after suplementation.
45373941|NCT05360316|Device|ESWT|extracorporeal shock wave therapy
45373942|NCT04059731|Dietary Supplement|Nutrition supplement|Administration twice a day of Survimed OPD or Impact/Atempero depending on arm assigned during 5 postoperative days
45373943|NCT05407740|Other|no intervention study|no intervention study
45373944|NCT00986960|Drug|repository corticotropin injection|IM ACTH: 80 units of Acthra gel I.M. once a day for 5 consecutive days at study time points 0, 3, 6, 9, and 12 months
45373945|NCT00986960|Drug|Saline|I.M. placebo - 1ml of saline I.M. once per day for 5 consecutive days at 0, 3, 6, 9, and 12 months.
45373946|NCT00758927|Drug|Omega-3 acid 4 grams per day|OMACOR 4 grams per day is administered simultaneously with exercise and diet therapy
45373947|NCT00758927|Drug|Placebo control|Placebo will be administered simultaneously with exercise and diet therapy in same intensity with the experimental arm
45373948|NCT05711966|Device|Ventilator for High-frequency Oscillatory Ventilation (HFOV)|This device will be used to perform an HFOV recruitment maneuver before surfactant administration
45373949|NCT05711966|Device|Less invasive surfactant administration (LISA)|SurfCath™ tracheal instillation catheter, or a 4- 6 F end-hole catheter, according to local protocols will be used for surfactant administration
45373950|NCT05407506|Diagnostic Test|THYROID AI|thyroid artificial intelligence diagnosis system and fine needle puncture in the diagnosis of benign and malignant thyroid nodules
45373951|NCT00759005|Drug|propranolol and cortisol|
45373952|NCT04360070|Drug|Ketamine Hydrochloride|Parenteral General Anesthetic
45373953|NCT00748943|Other|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®) contained 0.16% sodium chlorite (NaClO2)
45373954|NCT05407428|Other|NeuraLight software-based platform|NeuraLight is an investigational software-based platform that is used for assessment and evaluation of neurological conditions including ALS patients
45373955|NCT04354688|Device|T3 Certain Tapered Implant|Patients will be randomized to receive either the T3 Certain Tapered with DCD (Test) or the T3 Certain Tapered without DCD (control/active comparator). Both types of implants will be rehabilitated in the same manner (early loading)
45373956|NCT00749021|Drug|Ranibizumab|0.5 mg of intravitreal ranibizumab monthly for 12 months
45373957|NCT00749021|Drug|Ranibizumab|0.5 mg intravitreal injection of ranibizumab for 4 months followed by PRN dosing
45373958|NCT00749021|Drug|Ranibizumab|2.0mg of intravitreal ranibizumab monthly for 12 months
45373959|NCT00749021|Drug|Ranibizumab|2.0mg of intravitreal injection of Ranibizumab for 4 months followed by PRN dosing
45373960|NCT04733846|Other|data collection|Collection of clinical and paraclinical data during preoperative consultation Collection of clinical and paraclinical data during post-operative consultations Tele-consultation to determine if criteria for good healing / adherence, treatment tolerance / response to questions Remote follow-up 6 and 12 months after the trauma
45373961|NCT05407350|Diagnostic Test|Ultrasound, Colonoscopy, MRE|After the initiation of an established treatment of known efficacy for CD (biologic agents including infliximab, adalimumab, ustekinumab or vedolizumab either with or without corticosteroids), repeat IC and MRE will occur at Week 30 (± 6 weeks) (6-9 months); the IUS, IC, and MRE examinations will occur within a 4-week window and with no intervening change in medical therapy. All imaging data will be captured electronically (IUS and MRE with Digital Imaging and Communications in Medicine [DICOM] images, and IC with video recordings) for central, blinded reading. Two biopsies will be collected from each segment of the bowel (rectum, sigmoid, descending, transverse, ascending and terminal ileum) during IC, fixed in formalin collection containers, and shipped for histopathology processing and evaluation.
45373962|NCT04048889|Drug|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca
45373963|NCT04048889|Drug|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca.
45373964|NCT04048889|Drug|Ropivacaine 0.5% Injectable Solution|Popliteal plexus block with injection of 15 mls of Ropivacain 0.5% inside the distal end of the adductor canal close to the adductor hiatus, adjacent to the femoral artery, between the medial vastus muscle and the adductor Magnus muscle, done under general anesthesia.
45373965|NCT04005560|Other|no interventional study|no interventional study
45373966|NCT04901442|Device|Aetrex L700 Speed orthotic|An orthotic insole to be inserted into running shoes. Features Aetrex Arch Support to help biomechanically align the body & help prevent common foot pain such as Plantar Fasciitis, Arch Pain, and Metatarsalgia. Helps prevent injury, alleviate discomfort and helps reduce fatigue while running
45373967|NCT00987038|Drug|PF-04171327 25 mg|One 25 mg tablet administered once a day for 15 days
45373968|NCT00987038|Drug|Midazolam 2 mg|Midazolam oral syrup 2mg dose administered once on Day 1 and once on Day 15
45373969|NCT00761033|Behavioral|music|
45373970|NCT05711810|Drug|Nifedipine 30 MG|Due to initial availability of drugs and the intensities of the patient's symptoms, Nifedipine was used for initial intervention in preventing acute myocarditis from happening.
45373971|NCT05711810|Diagnostic Test|Kangzhu BPCB0A-3A|The diagnostic test has been used to confirm objective parameters to guide the intervention drug dosages and accessing the risks in sudden death and long term adverse effects.
45373972|NCT05711810|Behavioral|Low Mobility|The behavioral intervention aimed at reducing the risks of sudden and strong blood flows in the patient's system.
45373973|NCT05711810|Drug|Enalapril Maleate 10Mg Tab|The intervention aims to reduce the vein flows in Diastolic Blood Pressure, and the risks in blood clot formation and internal vein scratch bleeding.
45373974|NCT05711810|Drug|Lansoprazole 30Mg Ec Cap|The intervention aims to server the allergy-inducing proteins to induce renal hemodialysis.
45373975|NCT05711810|Drug|Metoprolol Succinate|Metoprolol Succinate is used to control the cardiac artery flow amounts and stabilize the patient's heart rate.
45373976|NCT05711810|Dietary Supplement|Coenzyme Q10|200 mg per day is used for supplement with the cardiac interventions.
45373977|NCT05711810|Dietary Supplement|d-alpha tocopherol acetate|The 268 mg twice per day dietary healthcare is the patient's usual daily use.
45373978|NCT05711810|Dietary Supplement|Omega-3|The 900 mg twice per day dietary healthcare is the patient's usual daily use.
45373979|NCT05711810|Drug|Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release|Duloxetine hydrochloride is used for the patient's neurodiverse conditions.
45373980|NCT05711810|Drug|Superoxide Dismutase|Superoxide Dismutase is used to substitute the missing of antiviral drugs.
45373981|NCT00759083|Drug|bivalirudin|Bivalirudin; 0.75mg/kg/h IV bolus followed immediately by 1.75 mg/kg/h infusion for the duration of the procedure
45596381|NCT03531775|Diagnostic Test|Upright MRI|Participants will be scanned using an upright MRI in sitting/standing position and supine position. They will also be scanned in supine position using a conventional MRI.
45596382|NCT04462419|Radiation|Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography|Undergo PET-MRI imaging
45596383|NCT04462419|Other|Fluciclovine F18|Given IV
45596384|NCT02197793|Behavioral|Community Mobilization Program|
45596385|NCT03534557|Diagnostic Test|FEV6 spirometry|During the same spirometry, to compare the relative value of FVC and FEV6
45596386|NCT03601455|Biological|Durvalumab|Given IV
45596387|NCT03601455|Radiation|External Beam Radiation Therapy|Undergo EBRT
45596388|NCT03601455|Biological|Tremelimumab|Given IV
45596389|NCT02195453|Drug|Yangzhengxiaoji Capsule|"Gemcitabine 1000mg/m² or Pemetrexed 500mg/m² IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection,21 days for a cycle.~Yangzhengxiaoji Capsule four granules t.i.d po."
45373982|NCT04864236|Device|Novel isolation device to contain aerosol|"The novel isolation device is called SLACC (Suction-assisted Local Aerosol Containment Chamber). SLACC has the ability to isolate the atmosphere around the patient's upper airway (nose, mouth, throat) via negative pressure in a manner analogous to isolation rooms used to house patients with communicable diseases spread by aerosol (e.g. tuberculosis).~The SLACC uses an external suction source to maintain a negative pressure micro-atmosphere around a patient's head (the source of infectious aerosols). The components of SLACC include a clear polymer frame, a flexible drape, and integrated sealed arm sleeves to protect the hands and forearms of the health care provider. The structure is flexible during use, transparent, can be rapidly assembled, and easily collapsible for removal and transport. Once deployed with the patient's head inside the chamber, the drape is secured across the open side of the chamber with adhesive and covers the patient's torso."
45373983|NCT00759239|Drug|Travoprost 0.004% / Timolol maleate 0.5%|Solution, morning dosing
45373984|NCT00759239|Drug|Travoprost 0.004% / Timolol maleate 0.5%|Solution, evening dosing
45373985|NCT00761111|Behavioral|Assessment of the Your Back Operation|to translate and assess an evidence based educational booklet on low back pain patients beliefs after lumbar discectomy
45373986|NCT03899064|Drug|Induction: Application of MC2-01 Cream, irradiation|Repeated applications of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
45373987|NCT03899064|Drug|Induction: Application of MC2-01 Cream, no irradiation|Repeated applications of MC2-01 Cream, CAL/BDP, 0.005%/0.064%, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
45373988|NCT03899064|Drug|Induction: Applications of MC2-01 vehicle, irradiation|Repeated applications of MC2-01 cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
45373989|NCT03899064|Drug|Induction: Applications of MC2-01 vehicle, no irradiation|Repeated applications of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
45373990|NCT03899064|Drug|Challenge: Application of MC2-01 Cream, irradiation|Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
45373991|NCT03899064|Drug|Challenge: Application of MC2-01 Cream, no irradiation|Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
45373992|NCT03899064|Drug|Challenge: Applications of MC2-01 vehicle, irradiation|Single application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
45373993|NCT03899064|Drug|Challenge: Applications of MC2-01 vehicle, no irradiation|Single application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
45373994|NCT03899064|Drug|Challenge: Control, irradiation|No application, but irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
45373995|NCT05305950|Other|Patient population|Questionnaire, standard of care
45373996|NCT03742908|Drug|Cefazolin/clindamycin|Local implant immersion and/or breast pocket irrigation
45373997|NCT05357274|Diagnostic Test|Diagnostic testing|Data will be uploaded to a server where algorithms will be deployed that incorporate features related to treatment use and variables of airflow will allocate the care pathway into one of the 4 pathways. Treatment will be directed by this using a validated automated decision support system
45373998|NCT05407116|Other|NCI PRO-CTCAE Questionnaire / EORTC QLQ-C30 Questionnaire|"PROs data will be collected prospectively via electronic questionnaires (PRO-CTCAE™), which is a patient-reported outcomes measurement system created to assess symptomatic toxicity in patients of cancer clinical research. PRO-CTCAE items evaluate frequency, severity, interference, amount, presence/absence symptoms. Each symptomatic adverse effect is measured by 1-3 features. GI items included nausea, vomiting, flatulence, bloating of the abdomen, constipation, diarrhea, abdominal pain, and loss of control of bowel movements. Urinary symptoms include the urge to urinate suddenly, frequency, urine colour change, loss of urine control (leakage).~Patients will also self-report health-related quality of life (QoL) in real-time, electronic PRO questionnaires (EORTC QLQ CX24, EN 24, C30) about QoL. Question 29 and 30 ask the patients to rate their overall health and QOL respectively during the past week on a scale between 1-7, where one is equivalent to very poor and seven is excellent."
45373999|NCT04003194|Other|Pinto Beans|The intervention was 1/2 cup of pinto beans each day.
45374000|NCT04003194|Other|Green Beans - control|The control was 1/2 cup of green beans each day.
45374001|NCT05406960|Dietary Supplement|Tea infusion|Herbal tea infusion will be administrated by the oral route before food
45374002|NCT05406882|Drug|Live Combined Bifidobacterium and Lactobacillus Tablets、Compound Glutamine Entersoluble capsules|Live Combined Bifidobacterium and Lactobacillus Tablets：probiotics. Compound Glutamine Entersoluble capsules：combined traditional Chinese medicine and glutamine
45596390|NCT02195453|Drug|Placebo Capsule|"Gemcitabine 1000mg/m² or Pemetrexed 500mg/m²IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection, 21 days for a cycle.~Placebo Capsule four granules t.i.d po."
45374003|NCT01564134|Biological|hepatitis B vaccine|hepatitis B vaccine with 5ug,10ug,20ug,60ug HBsAg
45374004|NCT05357196|Drug|PT-112|"Drug: PT-112, The MTD(Maximum Tolerated Dose ) and RP2D of PT-112 when used in combination with gemcitabine will be determined during dose escalation.~Drug: Gemcitabine, Gemcitabine will be administered at a fixed dose of 1000 mg."
45374005|NCT05232630|Drug|Fenfluramine|"Administration of fenfluramine. Fenfluramine treatment dose: Between 0.2 and 0.7 mg/kg/day if no concomitant Stiripentol (STP), maximum dose: 40 mg/day [or 0.5 mg/kg/day, maximum 30 mg/day, for subjects taking concomitant STP]. Dosing will be started with 0.1mg/day per one week, then 0.2mg/kg/day per one week, then as investigator clinical decision-making, up to 0.4, 0.6 or 0.7mg/kg/day, with a maximum of 0.2mg/kg/day escalation every week.~Visits: There will be four visits; (visit 1) screening; (visit 2) treatment initiation, +2 weeks; (visit 3, telematic) +8 weeks; (visit 4) +14 weeks."
45374006|NCT03902574|Drug|Brexpiprazole ODT 2mg with water|Brexpiprazole ODT 2mg is administered with water.
45374007|NCT03902574|Drug|Brexpiprazole ODT 2mg without water|Brexpiprazole ODT 2mg is administered without water.
45374008|NCT03902574|Drug|Brexpiprazole conventional tablet 2mg|Brexpiprazole conventional tablet 2mg is administered with water.
45374009|NCT04646850|Other|Color duplex ultrasound of the carotid arteries|Examinations carried out according to the American Society of Echocardiography guidelines 25 using a Vivid 7 US instrumentation with a linear M12L probe (14 MHZ; General Electric).
45374010|NCT04874454|Diagnostic Test|ultrasound|evaluate the vocal cord movement among the stroke patients
45374011|NCT01564290|Dietary Supplement|Probiotic yogurt|Lactobacilus Rhamnonsus 100000000 UFC per mL. Dosage 50 mL twice daily fo 5 days.
45374012|NCT01564290|Drug|Placebo probiotic|Lyophilized probiotic, containing 250 mg per sachet dosage to about 2 times a day for 5 days.
45374013|NCT04584294|Behavioral|MyPath Web-Based Informational and Decision Support Tool|"The MyPath Decision Support Tool includes the following sections and features:~Questions to capture reproductive goals and orientations towards a potential pregnancy~Education modules about the menstrual cycle, fertility, and prepregnancy health with the opportunity to flag topics that are relevant and of interest to the patient~A contraceptive decision module that provides education, elicits patient preferences about different aspects of contraception, and suggests methods most appropriate based on the patient's preferences~A feature for adding free-text questions that patients may have for their provider~An email with a summary page that the patient can bring to a visit to guide discussions with primary care providers about reproductive needs"
45374014|NCT05189262|Other|Blood and urine collection|No intervention - Biological specimen collection
45374015|NCT01004874|Drug|Bevacizumab|Bevacizumab (Avastin) at 10 mg/kg every other week during standard radiation therapy (XRT). Following XRT, bevacizumab will remain at 10 mg/kg every other week.
45374016|NCT01004874|Drug|Temozolomide|Daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation therapy (XRT). Following XRT, temozolomide will be dosed at 150 mg/m2 daily the first 5 days of each 28-day cycle.
45374017|NCT01004874|Radiation|Radiation Therapy (XRT)|Standard radiation therapy for approximately 6.5 weeks
45374018|NCT01004874|Drug|Topotecan|Following standard radiation therapy, patients will receive topotecan on days 2 through 6 of each 28-day cycle at a dose of 1.5 mg/m2 for patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs) and 2.0 mg/m2 for patients taking EIAEDs.
45491024|NCT01382862|Other|Stroke Emergency Mobile Unit (STEMO)|Patients treated in the STEMO may receive a CT-scan and point-of-care laboratory work up. This depends on the results of the neurological examination including assessment of medical history and the indication for scanning by the radiologist on call. In case of no contraindications patients with acute ischemic stroke will receive intravenous tissue Plasminogen Activator (0.9 mg/kg BW) according to the routine use of tissue Plasminogen Activator in Germany within 4.5 hours of symptom onset but with no formal upper age limit. (In other words, patients older than 80 years will not be excluded.) In case of increased INR and intracerebral hemorrhage patients will receive Prothrombin Complex Concentrate (PCC). All other indications will be treated according to national guidelines or as considered appropriate by the neurologist.
45374019|NCT05356026|Other|Online postpartum follow-up|The women in the experimental group were administered three follow-ups (education/consultancy) in line with the timing and content in the T.R. Ministry of Health Postpartum Care Management Guide (2014). The follow-ups were performed using the Zoom® program, which enabled video talk.
45374020|NCT04002804|Biological|Dendritic Cells Vaccine|"Right after the surgical resection of the recurrent tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Starting at week 3, immunotherapy will include 4 bi-weeekly vaccinations first (injections I, II, III, IV), two further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) two months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only.~Vaccine doses will be injected in the forearm of the patient."
45491025|NCT03630978|Procedure|Liver resection|Major or minor, open or laparoscopic liver resection
45596391|NCT03531697|Drug|Generic Loteprednol Etabonate|Drug
45596392|NCT03531697|Drug|Reference Listed Drug (RLD)|Drug
45374021|NCT05355948|Device|MEMO Patch PLUS for 1 day|Individuals randomized to one-day monitoring will wear MEMO Patch PLUS for 1 day. After that, confirm the monitoring result and carry out a fixed schedule.
45374022|NCT05355948|Device|MEMO Patch PLUS for More than 8-days|Individuals randomized to More than 8-days monitoring will wear MEMO Patch PLUS for 8 days ~ 14 days at their voluntarily. After that, confirm the monitoring result and carry out a fixed schedule.
45374023|NCT04302818|Behavioral|SKOLKONTAKT|N=21 participants are offered manualized and structured group training SKOLKONTAKT. The intervention includes 12 weeks, 3 sessions (50 minutes) per week.
45491026|NCT03665480|Drug|G-SCF|In G-CSF treatment group, all patients are treated with G-CSF at the dose of 5ug/kg pre day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28, respectively, with flow cytometry and quantity PCR if a fusion gene is available.
45374024|NCT04302818|Behavioral|Social activity group|N=21 participants. The active comparison group includes 12 weeks, 3 sessions (50 minutes) per week. Sessions will include socially oriented activities such as board games, sports or baking as well as a recommended, general agenda.
45374025|NCT00987116|Drug|Prednisone - Azathioprine|"Rapid strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for improvement or minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 0.75 mg/kg/day.~Classical strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 1.5 mg/kg/2days."
45374026|NCT04866680|Procedure|Personalized Circulating DNA follow-up|FFPE tissue sample will be collected before and after surgery blood samples will be collected before and after surgery and every 3 to 4 months
45374027|NCT05711732|Diagnostic Test|MyCare Oncology Busulfan Assay Kit|This is a sample collection study only. Patient treatment will not be determined by the outcome of the analytical test results.
45374028|NCT04853810|Other|CUTADIAB questionnaire|During a regular diabetes follow-up consultation, the patient is asked to complete the CUTADIAB questionnaire on a tablet, entirely dedicated to the study
45374029|NCT04006340|Combination Product|triple therapy|esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg twice a day for 10 days
45374030|NCT04006340|Combination Product|quadruple therapy|esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days
45374031|NCT04006340|Diagnostic Test|dual-priming oligonucleotide-based multiplex (DPO)-PCR test|Resistance of clarithromycin 23S rRNA point mutation
45374032|NCT04282304|Behavioral|Preoperative usual care|"Usual care during the preoperative preparation for bariatric surgery consists of:~Endocrinologist work-up and follow-up, with at least 2 consultations;~Dietary advice, provided during the endocrine consultation or dietician consultation~Psychological counselling with the patient's usual psychiatrist (at least 2 consultations~Physical activity and nutrition are encouraged, but entrusted to the patient's freedom of choice. Weight loss, or at least, weight stabilization, is recommended before the surgery, without initiating a specific behavioural procedure."
45491027|NCT03725891|Drug|Aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
45491028|NCT03725891|Drug|Aspirin 81 mg|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
45491029|NCT03725891|Drug|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
45374033|NCT04282304|Behavioral|Preoperative intensive behavioral lifestyle intervention|"The intensive behavioral lifestyle intervention program takes place over 4 weeks of 5 days. It includes:~Rehabilitation to physical exercise every morning~Therapeutic cooking sessions; during these sessions, the patients prepare the day's meals under the supervision of a nutritionist~Psychological counselling~One swimming session per week~One relaxation session~Regular physical activity (aerobics, work-up)~Individual entertainment with the physiotherapist physician and discussion groups~Weight, BMI and waist circumference control at the end of each week."
45692995|NCT01995461|Drug|bilateral transforaminal epidural steroid injections|BTESI with local anesthetic and steroid, and the use of x-ray contrast, under fluoroscopy guidance performed by the PI. 10mg of dexamethasone (1cc) mixed with 1cc of 2% preservative-free xylocaine (lidocaine) will be injected on each side of the stenotic segment under fluoroscopic guidance after confirming epidural x-ray contrast (1-2cc) spread right before the steroid mixed with local anesthetic injection. The injection may be repeated, but not before 2 weeks after the first injection.
45846876|NCT02654808|Device|AirSeal trocar|"The AirSeal® trocar is a valveless trocar that has been designed to replace the trap door and silicone valve of standard trocars with a curtain of forced CO2 gas. With the AirSeal® trocar, escaping gas is collected at the proximal end of the trocar, filtered, and redirected into the peritoneal cavity to maintain the pressure differential. The result is an invisible barrier that instantaneously responds to changes in intra-abdominal pressure, either by allowing more CO2 inflow with pressure drops or by serving as a pressure relief valve during pressure spikes."
45374034|NCT05711654|Behavioral|Health coaching|Coaching interview will be held with patients at regular intervals.
45374035|NCT04005326|Procedure|quadratus lumborum block; (Anterior QLB or QLB III)|The patient will be in the lateral position. A low frequency convex probe will be vertically attached above the iliac crest and a needle will be inserted in plane from the posterior edge of the convex probe through the quadratus lumborum in an anteromedial direction. The needle tip will be placed between the psoas major muscle and the quadratus lumborum muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected into the fascial plane incrementally, aspirating every 5 ml.
45374036|NCT04005326|Procedure|suprainguinal fascia iliaca block|In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest & iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
45374037|NCT04005326|Procedure|Subarachnoid block|"Patients will receive SAB using 25g spinal needle in the lateral position. Fifteen milligrams of hyperbaric bupivacaine will be administered at L3-L4 or at L4-L5 interspace in addition to 25 mcg fentanyl with rapid crystalloid co-load.~Spinal anesthesia will be considered successful when a bilateral block to T12, as assessed by loss of cold (cold ice) and pain (a 23-gauge needle) sensations, will be established 10 -minutes after the intrathecal injection. If spinal anesthesia failed, such patients will be administered general anesthesia and will be excluded from this study."
45374038|NCT04004702|Drug|Levetiracetam|Levetiracetam 500mg twice a day
45374039|NCT04767854|Behavioral|OA school|Patient education according to guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
45374040|NCT04767854|Other|Virtual Training mobile health application|Individually tailored home exercise programs delivered through a mobile health application
45374041|NCT04767854|Other|Usual care|Individually tailored exercise programs conducted in weekly supervised individual or group sessions
45374042|NCT00542828|Biological|Thymoglobulin®, Rabbit Anti-thymocyte Globulin (rATG)|All patients were to be treated with rATG 3.75 mg/kg/day administered by intravenous (IV) infusion over ≥6 hours for 5 consecutive days (cumulative dose: 18.75 mg/kg)
45374043|NCT04731974|Drug|Melatonin 3 MG|Participants in the melatonin group will be instructed to take 3-mg liquid melatonin pill 1 hour prior to their habitual fall asleep time daily for 30 days.
45374044|NCT04731974|Other|Placebo|Participants in the placebo group will be instructed to take liquid placebo pill 1 hour prior to their habitual fall asleep time daily for 30 days.
45491030|NCT01383876|Behavioral|Collar|Have a hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
45692996|NCT04731623|Drug|ION904|ION904 will be administered by SC injection.
45692997|NCT04731623|Drug|Placebo|Placebo (0.9% sterile saline) will be administered by SC injection.
45374045|NCT04533074|Biological|Single-visit regeneration protocol|In a single visit, access opening, minimal instrumentation and irrigation will be done. After irrigation and drying, the apical tissue will be irritated to evoke bleeding in the canal, using a precurved K-file 2mm past the apical foramen, with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. The bleeding will be stopped at a level that allows for 3-4 mm of restorative material. Three millimeters of Biodentine will then be placed directly over the blood clot of each tooth. A 3-4 mm layer of glass ionomer is flowed gently over the capping material. Each access cavity will be restored using composite resin.
45374046|NCT04533074|Biological|Multiple-visits regeneration protocol|In the first visit, access opening, minimal instrumentation and irrigation will be done. The root canal will be then dried and filled with calcium hydroxide paste. The tooth will be sealed with an intermediate restorative material (IRM), and the patient will be dismissed for 1-4weeks. In the second appointment, response to initial treatment will be assessed and the steps will be repeated if symptoms are persistent. If there are no symptoms, evoking bleeding to the level of the cemento-enamel junction will be done followed by Biodentine application over the blood clot with final glass ionomer and composite restorations.
45374047|NCT04722692|Diagnostic Test|Delayed SLND|"SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients have received SPIO in the breast at the first operation, prior to dissection and resection and the SLN has already been marked with SPIO. These SLNs are to be removed.~SLND is divided into the following steps:~Transcutaneous signal~Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~SLN identification in situ~SLN excision and signal ex vivo~Background axillary counts. For step d the radioactive counts are registered for each SLN that has been excised. When the procedure is completed successfully with SPIO, then background axillary isotope counts are registered and, if present, SLND continues as described above with the isotope as primary tracer."
45374048|NCT04722692|Diagnostic Test|Late SLND|"SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients will be injected with radioisotope in the operated breast before SLND according to standard of care. Any SLNs detected with this intervention are to be removed.~SLND is divided into the following steps:~Transcutaneous signal~Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~SLN identification in situ~SLN excision and signal ex vivo~Background axillary counts. For step d the magnetic counts are registered for each SLN that has been excised. When the procedure is completed successfully with the isotope, then background axillary iSPIO counts are registered and, if present, SLND continues as described above with the SPIO as primary tracer."
45374049|NCT05711420|Behavioral|Gamification method group|Gamification method group
45374050|NCT05711420|Behavioral|Flipped learning group|Flipped learning group
45374051|NCT05711342|Behavioral|Aggression|"The intervention consists of 10 lessons:~Motivation - where are you now?~Where do you want to go?~Circle of aggression.~Thoughts.~Emotions.~Bodily sensations.~Techniques for self-control.~Asking for help.~Assertiveness.~Relapse-prevention. Each lesson consists of multiple components, i.e. written text, assignments and videos with therapists and/or experts by experience. After each lesson, the therapist sends written feedback on the assignments to the patient. Because 'Aggression' is a blended intervention, each lesson is briefly discussed in an in-person treatment session. Generally, participants work on one lesson per week."
45374052|NCT05711342|Behavioral|Treatment as usual|In-person aggression treatment as usual (TAU), as delivered by the organization. This refers to any form of psychotherapy that is delivered by a licenced psychologist to a patient. The main focus of treatment as usual should lie on aggression regulation.
45374053|NCT05710796|Behavioral|Difference in gender, response to disease, diagnostic test values|Gender difference: Prevalence of disease in male vs female Response to disease: Which group is more prone to cardiac involvement Diagnostic tests: Diagnostic confirmation of disease
45491031|NCT01383876|Behavioral|No Collar|Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
45491032|NCT03751163|Drug|Tranexamic Acid Oral Product|Encapsulated tranexamic acid 250 mg
45491033|NCT03751163|Drug|Hydroquinone 4% Cream|Hydroquinone 4% Cream
45374054|NCT04266470|Device|Lara Scan|"Four (4) sensors will be placed prior to the injection of 18 F-fludeoxyglucose (18FDG) at the following sites: 7 cm above injection site; injection site; surface of palpable presumed malignant tissue; palpable carotid artery.~Standard doses of 18-FDG will be injected per Department of Radiology protocols~All injections will be evaluated to insure the total dose of 18-FDG has been injected. Injections resulting in moderate to severe extravasations, as interpreted by Lara software, will be segregated and evaluated on an individual basis.~The sensors will remain in place for 60 minutes during the 18-FDG uptake period with the patient in a reclined chair.~After the uptake time is complete, the sensors will be removed by the technologist and the participant will be released.~The study team will then upload the sensor data to a personal computer in the treatment planning room where it will be coded and processed as a Lara scan."
45374055|NCT04266470|Diagnostic Test|PET/CT Scan - Pre-treatment and Post-treatment|The PET/CT imaging will be conducted according to standard of care. The main alteration to process flow will be the addition of the Lucerno sensors just prior to the injection of the PET material.
46053806|NCT03503058|Biological|PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis|"Infectious, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Challenge) administered under CQ chemoprophylaxis~Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on PfSPZ-CVac Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of PfSPZ Challenge."
45374057|NCT00987350|Device|LectraJet|LectraJet is a new jet injector studied for the first time in humans. It is in the category known as disposable-syringe jet injectors that have the advantage of eliminating the risk of disease transmission between subjects. A new syringe and nozzle is used for each patient so that no splash back of blood can occur onto the jet apparatus itself.
45374058|NCT00987350|Device|TIV by jet injection|Administration of seasonal trivalent influenza vaccine (TIV) by jet injection
45374059|NCT00987350|Biological|Seasonal Trivalent Influenza Vaccine|Licensed trivalent influenza vaccine provided by either jet injection or traditional needle and syringe.
45491034|NCT03751163|Other|Sunscreen|Sunscreen SPF 30
45374060|NCT00987428|Procedure|ultrasonography with or not sphincterotomy|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
45374061|NCT00987428|Procedure|Usual procedure|The control group includes patients with predicted severe ABP undergoing conservative treatment or endoscopic sphincterotomy (without EUS) within 72 hours of the onset of symptoms in case of cholangitis or biliary obstruction.
45374062|NCT00987506|Device|XIENCE V®|Participants with placement of a XIENCE V® EESS
45491035|NCT03751163|Device|Placebo|Encapsulated placebo
45374063|NCT04567082|Diagnostic Test|Examination of saliva|Collection of saliva samples
45491036|NCT03393546|Behavioral|Auricular Point Acupressure|It includes 4 weekly auricular point acupressure treatments.
45491037|NCT01379430|Biological|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 1x10^10 vp intramuscularly, MVA ME-TRAP 2x10^8 pfu intramuscularly
45491038|NCT01379430|Biological|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 5x10^10 vp intramuscularly, MVA ME-TRAP 2x10^8 pfu intradermal
45491039|NCT01380444|Procedure|Gamma3 Intramedullary Nails (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
46053807|NCT03503058|Other|Normal Saline|0.9% Sodium chloride
46053808|NCT03503058|Drug|Chloroquine chemoprophylaxis alone|"Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on NS Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of NS."
45374064|NCT04518722|Radiation|CT Scan|Dual-energy mid-tibia CT, high-resolution single energy MDCT imaging of the distal tibia (ankle), and low radiation hip CT scans
45374065|NCT04518722|Radiation|DXA Scan|Basic DXA scans will be performed to measure areal BMD and body composition measures at the whole body, spine, and hip
45374066|NCT04518722|Other|Steroid Intake Questionnaire|Questionnaire designed to quantify lifetime oral glucocorticoid intake
45374067|NCT00987662|Drug|Irbesartan|Treatment with irbesartan 300mg for 4 weeks. IF ABP>135/85 mmHg add hydrochlorothiazide 12.5 mg.
45374068|NCT00987662|Drug|Amlodipine|Treatment with amlodipine 10 mg for 4 weeks. If ABP>135/85 mmHg add hydrochlorothiazide 12.5 mg
45374069|NCT00987740|Device|Hemolung Respiratory Assist System|Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive ventilation and then the Hemolung. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
45374070|NCT04430426|Other|Controlled Diet|Participants will consume a controlled low oxalate diet for five days.
45374071|NCT04430426|Other|Glycolate Administration|Participants will come to the UAB Clinical Research Unit (CRU) and be administered a glycolate load via intravenous (IV) catheter.
45374072|NCT00987818|Other|Procalcitonin measurement|Daily procalcitonin measurement. Antibiotic discontinuation policy dependent on procalcitonin value. In the control group standard duration of antibiotic therapy.
45374073|NCT05690126|Dietary Supplement|Saffron extract|Food supplements are taken during 6 weeks by healthy volunteers
45374074|NCT05690126|Dietary Supplement|Maltodextrin|Food supplements are taken during 6 weeks by healthy volunteers
45846877|NCT02654808|Device|Standard trocar|"A standard insufflation trocar delivers CO2 into the abdominal cavity to create workspace and uses either a trap door or silicone valve to prevent the egress of CO2 during laparoscopy in order to maintain intra-abdominal pressures. The standard trocars are not equipped to respond to changes in the intra-abdominal pressures in order to trigger an increase or decrease in the flow rate of CO2 gas."
45846878|NCT02655354|Behavioral|Motivational Interviewing|
45846879|NCT02655354|Behavioral|Cognitive Behavioral Therapy Elements|
45374075|NCT00987896|Device|Colonoscopy with Megachannel™ device loaded|Before colonoscopy, megachannel is loaded on the endoscope, during colonoscopy megachannel will be inserted into the patient via the endoscope placed in the colon
45846880|NCT02655354|Behavioral|Care Management|
45846881|NCT02655354|Drug|Fluoxetine|Anti-depressant
45846882|NCT02655354|Drug|Fluvoxamine|Anti-depressant
45374076|NCT00090103|Drug|dutasteride 0.5mg once daily for 4 years|combination or single agent
45846883|NCT02655354|Drug|Paroxetine|Anti-depressant
45846884|NCT02655354|Drug|Sertraline|Anti-depressant
45374077|NCT00090103|Drug|tamsulosin 0.4mg once daily for 4 years|combination agent or single agent
45374078|NCT01088659|Drug|peginterferon alfa-2a [Pegasys]|180mcg sc weekly, 96 weeks
45374079|NCT01088659|Drug|placebo|orally daily, 96 weeks
45374080|NCT01088659|Drug|tenofovir|245mg po daily, 96 weeks
45846885|NCT02655354|Drug|Citalopram|Anti-depressant
45846886|NCT02655354|Drug|Venlafaxine|Anti-depressant
45846887|NCT02655354|Drug|Duloxetine|Anti-depressant
45846888|NCT02655354|Drug|Mirtazapine|Anti-depressant
45846889|NCT02655354|Drug|Diphenhydramine|Sleep medication
45846890|NCT02655354|Drug|Trazodone|Sleep medication
45846891|NCT02655354|Drug|Prazosin|Sleep medication
46053809|NCT03499600|Behavioral|Clinical Assessment and CFI|CA and CFI families will participate in the Cultural Formulation Interview prior to their standard intake.
46053810|NCT03499600|Behavioral|Clinical Assessment|CA families will participate their standard intake procedures.
46053811|NCT03494153|Other|Non applicable - Non interventional study|Non interventional study
46053812|NCT03481777|Device|Remote Ischemic Conditioning|RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion.
46053813|NCT03481777|Device|Sham Remote Ischemic Conditioning|Sham Comparator (Sham-RIC)
46053814|NCT03475212|Biological|Virus Specific T-cell (VST) infusion|Patients will receive partially HLA-matched VSTs as a single infusion. Patients who have a partial response (>1 log decrease in viral load without clearance) or no response and do not have treatment-related dose-limiting toxicities are eligible to receive up to 3 additional doses from day 30 after the initial infusion and at 2 weekly intervals thereafter. The viral load of the virus (or viruses) that patients are initially treated for are monitored by viral PCR.
46053815|NCT03474965|Drug|Crizanlizumab|Crizanlizumab (SEG101) is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab.
45374081|NCT03962257|Other|EngagedMD online learning platform|The EngagedMD online learning platform is a compilation of learning modules and questions designed to give patients at-home access to visual and audio aids in infertility treatment. It also gives patients the ability to read and sign consents from home.
45374082|NCT00087607|Drug|Ribavirin|1000/1200mg/day po
45374083|NCT00087607|Drug|Peginterferon alfa-2b (PEG-Intron)|1.5 micrograms/kg sc weekly
45374084|NCT00087607|Drug|Ribavirin|1000/1200mg/day po
45374085|NCT00087607|Drug|Peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly
45374086|NCT01088737|Drug|Imiquimod|Imiquimod 5% cream is applied once daily. Each patient will begin with the application 3x/week. After two weeks of treatment the inflammation response to imiquimod will be assessed. If no or only minor inflammation is detectable in the treatment area, the dosing schedule will be increased to 5x/week. After four weeks of treatment the inflammation response will be assessed again. If still no or only minor inflammation is detectable, application will be extended to daily use.
45491040|NCT01380444|Procedure|Sliding Hip Screws|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
45491041|NCT03639545|Drug|Empagliflozin 25mg|The patients receive empagliflozin (25 mg daily) for 12 weeks.
45491042|NCT03639545|Drug|Metformin|The patients receive metformin (2000 mg daily) for 12 weeks.
45491043|NCT03639545|Drug|Empagliflozin/Metformin|The patients receive empagliflozin 25 mg daily and metformin 2000 mg daily or placebo for 12 weeks.
45491044|NCT03639545|Drug|Placebos|The patients receive for 12 weeks.
46053816|NCT03418129|Device|Mindfulness|Neuromodulatory intervention for pain management
45374087|NCT00069823|Drug|Esomeprazole|Proton pump inhibitor 40 mg orally twice daily
45374088|NCT00069823|Drug|Placebo proton pump inhibitor|Placebo proton pump inhibitor
45374089|NCT01088815|Drug|Gemcitabine, nab-Paclitaxel, GDC-0449|"One cycle of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 (28 days cycle) then~Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with oral GDC-0449 150 mg daily"
45374090|NCT03960307|Other|Microcirculation and Glycocalyx assessment|Non-invasive assessment of endothelial glycocalyx dimensions (PBR) and microcirculatory parameters (e.g. PPV, PVD, TVD, MFI)
45374091|NCT00086515|Drug|Sitagliptin (MK0431)|Sitagliptin 100 mg once daily, from Visit 4 through Final Visit, week 104
45374092|NCT00086515|Drug|Placebo/Glipizide 5 mg|Placebo (to match Sitagliptin 100 mg) from Visit 4 through Visit 8; Glipizide 5 mg from Visit 8, week 24 to Final Visit (Week 104)
45374093|NCT00086515|Drug|Metformin|Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)
45374094|NCT00086515|Drug|Pioglitazone|Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period [Phase A], from Visit 5 (Week 6) to Visit 8 (Week 24)
45491045|NCT03181386|Drug|Rivaroxaban|Rivaroxaban 15 or 20mg tablet by mouth, every 24 hours, continuous use.
45692998|NCT01980095|Drug|RHB-105|"The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~Rifabutin 150 mg~Amoxicillin 3000 mg~Omeprazole 120 mg~Subjects will take study drug every 8 hours with food for 14 consecutive days."
46053817|NCT03418129|Device|Neurofeedback|Neuromodulatory intervention for pain management
46053818|NCT03418129|Device|Relaxation|Neuromodulatory intervention for pain management
45374095|NCT01090609|Device|Stent implantation|Stent implantation
45374096|NCT00541658|Drug|risedronate|5 mg Immediate-release Risedronate Administered At Least 30 Minutes Before Breakfast Daily
45374097|NCT00541658|Drug|risedronate|35 mg Delayed-release Risedronate Administered Immediately Following Breakfast Weekly
45374098|NCT00541658|Drug|risedronate|35 mg Delayed-release Risedronate Administered At Least 30 Minutes Before Breakfast Weekly
45374099|NCT04384952|Other|Parent-administered reading therapy.|Parent-administered reading therapy program: 15min each day, 5 days a week during 6 weeks during the summer break. Repeted reading with feedback from the parent and time control.
45374100|NCT04384952|Other|Dyslexic's Holiday Workbook|Use of a special Dyslexic's holiday book, no parent-guided training.
45374101|NCT04378868|Drug|Antibiotics, cefuroxime and metronidazole|Patient receives antibiotics while waiting appendectomy
45491046|NCT03181386|Drug|Dabigatran and Apixaban|Dabigatrana 110 or 150 mg tablet and Apixaban 2,5 or 5mg tablet by mouth, every 12 hours, continuous use.
45491047|NCT03181386|Drug|Warfarin|The dosage of Warfarin is individualized for each patient, according to the patient's TP/INR value. The value of TP/INR should be in the therapeutic dosage of 2.0 to 3.0
45491048|NCT02912468|Drug|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
45491049|NCT02912468|Drug|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
45692999|NCT01980095|Drug|Placebo|Subjects will take 4 placebo capsules every 8 hours with food for 14 days.
45693000|NCT04667741|Other|Post-dialysis recovery group|Before the hemodialysis session, the patients were asked by the investigators how long it took them to recover from a dialysis session, taking the last treatment month into account.
45693001|NCT01980017|Behavioral|Ottawa Model for Smoking Cessation|
46053819|NCT03412396|Drug|Apalutamide|Given PO
46053820|NCT03412396|Other|Quality-of-Life Assessment|Ancillary studies
46053821|NCT03412396|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
46053822|NCT03396211|Drug|Apatinib|Apatinib tablets
46053823|NCT03396211|Drug|Nivolumab|Fixed dose of nivolumab given intravenously every 2 weeks
46053824|NCT03326167|Other|Myocardial Perfusion Imaging by Single Photon Emission Computed Tomography (MPI SPECT)|Evaluation of the improvement of the sensitivity, in tri-truncular patients, provided by the estimation of the coronal reserve by territory, during the realization of a myocardial perfusion tomoscintigraphy on CZT camera dedicated to cardiology (Discovery NM 530 ).
45491050|NCT02912468|Drug|Mometasone furoate 50 micrograms|"Pharmaceutical form: Suspension (Nasal spray)~Route of administration: Intranasal"
45693002|NCT04416347|Other|SARS-CoV2 Infection|Laboratory confirmed SARS-CoV2
45374102|NCT04378868|Drug|No antibiotics|No antibiotics are given while waiting surgery.
45846892|NCT02655510|Drug|F-652|Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg.
45374103|NCT04378868|Other|urgent schedule|Patients can wait up to 8 hours for surgery.
45693003|NCT04659707|Drug|Hyperpolarized Xe129|Subjects will inhale up to 4 doses of hyperpolarized Xenon gas in order to image pulmonary function.
45846893|NCT02656836|Other|Home tonometry, diagnostic study|Evaluating intraocular pressure
45846894|NCT02657538|Other|Non invasive caries treatment|If the active comparator does not detect cavitation, fluoride varnish is applied on the test surface.
45846895|NCT02657538|Other|Invasive caries treatment|If the active comparator does detect cavitation, a composite restauration is placed
45374104|NCT04378868|Other|less urgent schedule|Patients can wait up to 24 hours for surgery.
45596393|NCT02197871|Dietary Supplement|enteral nutrition emulsion|The patient should drink the oral nutritional supplements according to the estimated energy intake and make a record everyday.The patients will be followed up regularly.
45693004|NCT01978145|Drug|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device -or multi-dose dry powder inhalation device BID for each treatment periods
45374105|NCT04334174|Drug|Brentuximab Vedotin|Brentuximab Vedotin will be dosed at 1.8 milligram (mg) per (/) kilogram (Kg) of participants body weight will be infused intravenously every three weeks for up to ten infusions.
45374106|NCT04333706|Drug|Capecitabine|Capecitabine 1000 mg BID
45374107|NCT04333706|Combination Product|Sarilumab 150mg or 200 mg plus Capecitabine|Sarilumab 150mg or 200 mg plus Capecitabine 1000 mg BID
45374108|NCT04333706|Combination Product|Sarilumab 150mg plus Capecitabine|Dose escalation schedule of sarilumab. The starting dose for sarilumab is 150 mg SQ every 21 days, given 3 days prior to the first 4 of 8 cycles of capecitabine 1000 mg BID.
45374109|NCT00987974|Drug|rosuvastatin|rosuvastatin 20 mg/day for 3 days.
45693005|NCT01978145|Drug|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment periods
45374110|NCT00987974|Drug|atorvastatin 3 days|atorvastatin 80 mg/day for 3 days.
45374111|NCT00987974|Drug|placebo|placebo for 3 days.
45374112|NCT00987974|Drug|rosuvastatin 7 days|rosuvastatin 20 mg/day for 7 days
45374113|NCT00987974|Drug|atorvastatin 7 days|atorvastatin 80 mg/day for 7 days.
45374114|NCT00987974|Drug|placebo 7 days|placebo 7 days
45693006|NCT01967537|Drug|68Gallium DOTATATE|Fasting is not required prior to the imaging study. An IV line with a large bore (21 gauge or more) will be placed preferably in the antecubital vein, and, with the patient supine, around 5mCi of the 68Ga-DOTATATE will be administered intravenously, followed by incubation for approximately 60 minutes. Then the patient will be positioned in a PET/CT scanner and images from the upper thighs to the base of the skull will be obtained. In patients with tumor induced osteomalacia, images from the top of the head to the toes will be obtained.
45693007|NCT01967537|Procedure|Radio-guided surgery|Using 68Gallium DOTATATE
45374115|NCT04324580|Other|Splint|Participants will have their open reduction internal fixation of distal radius fractures treated with volar locked plating. for 2 weeks. Which will be replaced by a custom thermoplastic splint for 5 weeks.
45374116|NCT04324580|Behavioral|Formal Physical Therapy|Participants will also receive a prescription for formal physical therapy. Supervised physical therapy will be prescribed 1- 2 times per week for a total of 8 weeks along with a home exercise program. Active range of motion and strengthening exercises will be performed at home twice daily for 20 minutes for a total of 8 weeks.
45374117|NCT04324580|Behavioral|Self directed physical therapy|Participants will be given a pamphlet with detailed instructions and demonstrations in home exercises. Active range of motion and strengthening exercises will be performed twice daily for 20 minutes for a total of 8 weeks.
45374118|NCT04324580|Other|Soft dressing (No Splint)|Participants will have their open reduction internal fixation of distal radius fractures placed in a soft dressing which will be kept in place for 2 weeks.
45374119|NCT04229888|Device|LipiFlow|Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
45374120|NCT04229888|Device|Light Based (Sham) Treatment|A light based (sham) treatment will be used to compare effectiveness to the LipiFlow treatment.
45374121|NCT04004546|Behavioral|Health literacy-based intervention|Participants in the intervention group will receive a: i) 30-min video about medication adherence, ii) medication adherence booklet, and iii) 2-week telephone call by a nurse.
45374122|NCT04236284|Device|Home-based tDCS|tDCS is a non-invasive neuromodulation technique that has been used to improved cognitive functions. It will be administered with a constant current intensity of 2 mA57 for 20 min per session/ 10 sessions total daily for 2 weeks (Monday to Friday). The device is a Soterix 1x1 tDCS mini-CT Stimulator (Soterix Medical Inc., NY) with headgear and 5 _ 7 cm saline-soaked surface sponge electrodes.
45374123|NCT04236284|Behavioral|Prolonged Exposure Therapy|Prolonged Exposure Therapy is a treatment for PTSD that includes the following components: a) psycho-education about the common reactions to traumatic events and presentation of the treatment rationale (sessions 1 and 2), b) repeated in vivo exposure to traumatic stimuli (in vivo exercises are assigned as homework during sessions 3 through 11), c) repeated, prolonged, imaginal exposure to traumatic memories (imaginal exposure is implemented during sessions 3 through 11; patients listen to session audiotapes for homework between sessions), and d) relapse prevention strategies and further treatment planning (session 12).
45596394|NCT04424979|Device|High power prisms|High power prisms designed to shift images from blind areas into portions of the wearer's remaining, seeing, field of vision
45693008|NCT01967225|Drug|Tedizolid Phosphate (Sivextro, BAY1192631)|BAY1192631 solution or tablet 200 mg, once daily, Intravenous (IV) or By Mouth (PO) for 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
46053825|NCT03301896|Drug|LHC165|LHC165 intratumoral injection
46053826|NCT03301896|Biological|PDR001|PDR001 infusion
46053827|NCT03269084|Other|No intervention. DIPP is an observational study.|
46053828|NCT03268993|Dietary Supplement|Avmacol|Avmacol is a dietary supplement available over the counter
46053829|NCT03260322|Drug|ASP8374|intravenous
46053830|NCT03260322|Drug|Pembrolizumab|intravenous
46053831|NCT03257761|Biological|Durvalumab|Given IV
46053832|NCT03257761|Drug|Guadecitabine|Given SC
46053833|NCT03233256|Procedure|Feasibility of measuring 2H:1H and 18O:16O in saliva and breath.|The investigators propose to demonstrate the feasibility of measuring 2H:1H and 18O:16O in saliva and breath. The natural abundances of 2H:1H and 18O:16O of urine, saliva, and breath samples will be determined from samples obtained simultaneously from 50 relatively healthy human subjects. We will also measure 2H:1H and 18O:16O enrichments in urine, saliva, and breath of 10 relatively healthy human subjects obtained after consuming a standard DLW dose and compare the estimates of TDEE using these different matrices.
45374124|NCT04005248|Diagnostic Test|HCV IgG test|An HCV IgG test (performed on blood already collected for regular STI tests), combined with a questionnaire on sexual risk behavior. If client is HCV IgG positive, a HCV RNA test will be performed.
45374125|NCT03519074|Drug|TS-1 combined with cisplatin|Cisplatin 60mg/m2, day 1, every 21 days Oral TS-1 30mg/m2 bd, days 1-14, every 21 days (absolute dose of oral TS-1 will be 40-60mg bd days 1-14, every 21 days, depending on body surface area)
45374126|NCT03767582|Radiation|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy over 5 days) will be administered between 2 to 4 weeks after chemotherapy. (Prior to surgery)
45374127|NCT03767582|Drug|Nivolumab|Nivolumab (480 mg) will be administered IV over 30 minutes, on day 1 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery Nivolumab will be given on Day 1 of cycles 2-5. Cycles are 4 weeks long.
45693009|NCT01967225|Drug|Linezolid|Linezolid solution or tablet 600 mg, twice daily, every 12 ±3 hours, Intravenous (IV) or By mouth (PO) 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
45374128|NCT03767582|Drug|CCR2/CCR5 dual antagonist|CCR2/CCR5 dual antagonist (150 mg capsules) will be administered orally twice a day, on days 1-28 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery CCR2/CCR5 dual antagonist will be given daily on cycles 2-5. Cycles are 4 weeks long.
45374129|NCT03767582|Drug|GVAX|Vaccine (5x10^8 cells) will be administered on day 2 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery GVAX will be given on Day 2 of cycles 2-5. Cycles are 4 weeks long. Six intradermal injections every 4 weeks.
45374130|NCT02661542|Drug|FF-10502-01|
45374131|NCT05659316|Other|MRI imaging|Knee MRI imaging
45374132|NCT03907280|Drug|BI 1265162 (T1)|oral solution
45374133|NCT03907280|Drug|BI 1265162 (T2)|Solution for inhalation
45374134|NCT03907280|Drug|BI 1265162 (R)|concentrate for i.v. solution
45374135|NCT03907280|Drug|BI 1265162 (T3)|Solution for inhalation
45374136|NCT02609750|Other|Structured care & workplace intervention|In addition to structured care a workplace intervention named Convergence Dialogue Meetings (CDM) are carried out. CDM is a three step structured dialogue and meeting model supporting the patient, health care professionals and employer to summarize concrete suggestions to support sustainable work ability and a return to work if sick listed.
45596395|NCT05724979|Other|ZP-binding|The ZP is selective with regard to binding and can bind to normally functioning sperm, especially those with a normal acrosomal region
45596396|NCT02375763|Other|Software instruction|
45374137|NCT02609750|Other|Treatment as Usual|Patients will follow the primary health care's standard time schedule and procedures as of ordinary care and the rehabilitation guarantee. For each patient all treatment measures are recorded in a manual, regarding number of treatments, time used per treatment and type of treatment.
45374138|NCT04004468|Behavioral|Resistance Training|Standard barbell resistance training programs
45374139|NCT03730454|Device|Transanastomotic Tube (5FR)|5FR tube left in place for 5 days after completion of esophageal anastomosis.
45374140|NCT03730454|Other|No Transanastomotic Tube|No transanastomotic tube used during repair
45374141|NCT04120376|Behavioral|Contraception Counseling|Each participant will receive a 10 minute confidential contraception counseling session with an APP in the Emergency Department
45374142|NCT03644732|Procedure|SEEG Group|Visual and quantitative SEEG signal analysis. As available, collection of behavioral and neuropsychological postsurgical data
45374143|NCT04108130|Other|Preoperative Education|Brochure and video about relevance of postoperative pulmonary complications, postoperative mobilization and use of incentive spirometry.
45374144|NCT04108130|Procedure|Intraoperative PEEP (Positive End-Expiratory Pressure) Individualization|PEEP will be set by maximizing respiratory system compliance along a decremental PEEP titration following an incremental recruitment maneuver.
45374145|NCT04108130|Other|Individualization of Neuromuscular Blockade|Administration of neuromuscular blocking agents and their reversal will be done based on established protocol.
45374146|NCT04108130|Procedure|Postoperative Incentive Spirometry|Participants will be encouraged to adhere to incentive spirometry to be started 2 hours after surgery and maintained until participant freely ambulates. Supervision will be provided 3 times/day for continuous education and management of barriers to optimal performance.
45693010|NCT01967147|Drug|Propylene Glycol, 0.6% eye drops|Commercially available eye drops used during Treatment Phase
45374147|NCT04108130|Behavioral|Postoperative Ambulation|Participants will be encouraged to adhere to prescription of early ambulation.
45693011|NCT01967147|Drug|Preservative-free 0.9% Saline solution|Commercially available solution used as Run-in (1 drop in each eye 4 times a day for 15 days) and during Treatment Phase
45846896|NCT02657538|Device|Near-infrared light transillumination device (DIAGNOcam, KaVo, Biberach, Germany)|
45374148|NCT03905642|Drug|Arikayce™|Amikacin (aminoglycoside) in a liposomal formulation.
45374149|NCT04499300|Other|Data collection from medical files|Data collection from medical files
45374150|NCT03518294|Behavioral|Aerobic Exercise|Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
45693012|NCT01967069|Drug|DFD01 Spray|
45693013|NCT01967069|Drug|Vehicle Spray|
45693014|NCT01790503|Drug|PLX3397|
45846897|NCT02657538|Other|Visual examination and bitewing (BW) radiography|established diagnostic methods
45846898|NCT02657928|Other|Laboratory Biomarker Analysis|Correlative studies
45374151|NCT05613374|Device|The C-Mill virtual reality treadmill|The C-Mill treadmill is an innovative device used for the training of impaired gait and balance. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications.The instrument is supplied with a safety frame, body weight support, treadmill force plates, treadmill belt, adjustable handrails, cameras, user operating system, interactive visual screen and augmented reality projection.
45374152|NCT05613374|Other|Conventional Physical Therapy Program|"The Conventional Physical Therapy Program include the following:~Postural reactions exercises. (using balance board, balance beam, and manual balance perturbations)~Indoor open environment gait training exercises (over ground gait training exercises.). (using obstacles,cones , stepper, balance board , and uneven surfaces) (either between or outside the parallel bar)"
45374153|NCT03743012|Other|Integrated cardiac rehabilitation|Participants enrolled to the integrated cardiac rehabilitation arm will participate in individually tailored rehabilitation sessions that will involve aerobic activity focused on exertion at the participant's aerobic threshold (AT) over a duration of three months.
45374154|NCT03743012|Other|Usual Care|Participants randomized to the usual care arm will be instructed on the benefits of exercise and continue with usual care. Participant activity will be tracked monthly using pedometers for three months of follow up.
45374155|NCT04004156|Device|PerQdisc® Nucleus Replacement Device.|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
45693015|NCT01790503|Radiation|Radiation Therapy|
45374156|NCT04038476|Diagnostic Test|Standard monitoring + transcutaneous CO2 monitoring|The transcutaneous CO2 Monitoring measures the CO2 partial pressure of the skin and in condition of good circulation these values approximate the arterial/venous CO2 partial pressure. The sensor is placed on the forehead. The physician adapts the sedation Management according to the transcutaneous CO2 monitoring.
45374157|NCT04038476|Diagnostic Test|Standard monitoring|The transcutaneous CO2-sensor is also positioned on the patients' forehead, but the transcutaneous CO2-monitoring is not available for the physician to adapt the sedative management.
45374158|NCT03504020|Device|ECG Belt Research System|The ECG Belt Research System is used to identify the best vector and programming parameters.
45374159|NCT04126538|Drug|pirfenidone capsule|In the patient group, pirfenidone capsule was taken orally once for 400mg
45374160|NCT04126538|Drug|pirfenidone capsule|Healthy subjects took pirfenidone capsule 400mg once orally
45491051|NCT03725813|Other|Person-centred inpatient care|"The intervention comprises three sequential steps in the care process. The first two steps follow one after the other in conjunction with admission to the ward: 1) person-centred assessment, and 2) creation of a person-centred health plan. Persistent person-centred inpatient care, the third step, is practiced throughout the hospital stay, and is a component of the quality and patient safety program.~The model is systematically applied to all patients admitted to the unit. All staff are trained in PCC before implementation of the intervention."
45374161|NCT04004234|Drug|Manganese Chloride|Administered by inhalation at 0.2 or 0.4mg/kg/d once daily in a 3-week cycle
45491052|NCT04835298|Other|Dyspnea|questionnaires
45491053|NCT03639467|Drug|Anlotinib plus gemcitabine/cisplatin|"In the phase Ib portion, patients received dose escalation of anlotinb (from 8mg to 12mg orally once daily on days 1-14 of a 21-day) in combination with fixed dose of gemcitabine (1000mg/m2 intravenously on days 1 and 8) and cisplatin (80mg/m2 intravenously on day 1) every 3 weeks.~In the phase II portion, patients received anlotinb at recommended phase II dose determined in the phase Ib portion, in combination with fixed dose of gemcitabine and cisplatin every 3 weeks.~The combination of anlotinib plus gemcitabine / cisplatin was repeated every 3 weeks for up to six cycles. Patients with disease control (defined as a complete response, a partial response, or stable disease) continue to receive anlotinb until disease progression or unacceptable toxic effects, whichever occurred first."
45491054|NCT03729167|Procedure|Scaling and root planing|Non-surgical instrumentation will be performed with specific instruments prior to treatment planned extraction by another provider.
45491055|NCT01382706|Drug|docetaxel|Given IV
45491056|NCT01382706|Drug|lapatinib ditosylate|Given PO
45491057|NCT01382706|Other|immunohistochemistry staining method|Correlative studies
45491058|NCT01382706|Genetic|fluorescence in situ hybridization|Correlative studies
45491059|NCT01382706|Other|laboratory biomarker analysis|Correlative studies
45491060|NCT03725735|Behavioral|CBT for problem gambling with emotion regulation|CBT group treatment for problem gambling with emotion regulation focus, with 8 sessions.
45491061|NCT04752462|Behavioral|Telemedicine Intensive Motivational Enhancement|Participants will attend a telemedicine motivational enhancement visit to improve PAP adherence along with regular follow up for sleep apnea
45491062|NCT03665402|Drug|Isoniazid|One of the first line anti-tubercolosis drug
45491063|NCT03665090|Behavioral|Diabetic eye disease screening|Community-based, prospective cohort study from three consecutive years (2016 to 2018) to determine the prevalence and impact of diabetic eye disease, especially diabetic retinopathy (DR), in adults with diabetes living in Shanghai.
45374162|NCT04004234|Drug|nab-paclitaxel|Administered intravenously, 125mg/m2/d on day1 and day8 in a 3-week cycle
45374163|NCT04004234|Drug|Gemcitabine|Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
45374164|NCT04004234|Drug|anti-PD-1 antibody|Administered intravenously, 2-4mg/kg on day 3 in a 3-week cycle
45374165|NCT04095416|Device|ACE compression wrap|Bilateral lower extremity ACE compression wraps
45374166|NCT00990080|Biological|Pediacel® and Infanrix™-IPV/Hib|0.5 mL IM at 2,4 and 6 months of age
45374167|NCT00990158|Drug|Phytonadione (Vitamin K1)|A daily dose of 150 micrograms of vitamin K medication given orally for a total of 7 months
45491064|NCT01380288|Drug|rivastigmine patch|rivastigmine patch 5cm2 for 4 weeks and then augmented to 10cm2 for 20 weeks
45491065|NCT03665012|Other|Pediatric Development Clinic (PDC)|All children enrolled in PDC will be at screened for any medical condition they may have and be referred for treatment as required. Nutrition and development support are also provided to clinic enrollees, based on clinic protocols which include regular monitoring and intervention.
45491066|NCT03110484|Drug|Pemetrexed 500 MG|Pemetrexed 500 mg/m2
45491067|NCT03110484|Drug|Erlotinib|Erlotinib 100mg once daily
45491068|NCT03110328|Drug|MK3475|anti-PD1 immunotherapy
45693016|NCT01790503|Drug|Temozolomide|
45374168|NCT00990158|Drug|Placebo|A daily dose of matching placebo medication given orally for a total of 7 months
45374169|NCT02736344|Device|BioNIR Ridaforolimus Eluting Coronary Stent|
45374170|NCT02682992|Device|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
45374171|NCT05279066|Device|Biostrap Wristband|The Biostrap Wristband device is a non-invasive optical sensor that monitors changes in arterial pulse volume using Photoplethysmography (PPG). PPG is frequently used in wearable sensors to detect heart rate as well as other metrics such as heart rate variability (HRV) and respiratory rate. The raw biosignals recorded by the wristband device will be further processed to estimate the ejection fraction and cardiac output.
45374172|NCT01563770|Dietary Supplement|Salvia miltiorrhiza extract|3 capsules of 500 mg Salvia miltiorrhiza extract, twice daily for four consecutive weeks
45374173|NCT01563770|Dietary Supplement|Placebo|3 placebo capsules, twice daily for four consecutive weeks
45374174|NCT00412984|Drug|warfarin|Oral tablets, 2.0 mg, adjusted to an INR of 2.5 (range 2.0 to 3.0)
45491069|NCT04438499|Device|eSense 7fr Single Sensor Bladder Catheter|Urinary and abdominal catheters inserted in to the body to measure pressure for urodynamics.
45491070|NCT01562015|Drug|Ganetespib|Ganetespib 200 mg/m2 administered 1 time per week for the first three weeks of a four week treatment cycle (Days 1, 8, and 15 of the 28 Day treatment cycle).
45491071|NCT03751085|Device|AW frame|AW stereotactic frame for intracranial lesion biopsy
45491072|NCT03729089|Other|Modified Biophysical Profile scan|Modified biophysical profile scan to be done in third trimester for eligible pregnant mothers
45491073|NCT00002874|Drug|bicalutamide|One (150 mg) tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
45491074|NCT00002874|Radiation|radiation therapy|64.8 Gy in 36 fractions (1.8 Gy in 5 daily sessions per week) to the original prostate volume, the tumor resection bed, and the proximal membranous urethra.
45491075|NCT00002874|Drug|placebo|One tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
45491076|NCT03001076|Drug|Bempedoic acid|bempedoic acid 180 mg tablet
45491077|NCT03001076|Drug|Ezetimibe|ezetimibe 10 mg tablet
45491078|NCT03001076|Other|Placebo|matching placebo tablet
45374175|NCT00412984|Drug|apixaban|Oral tablets, 5.0 mg or 2.5 mg, twice daily
45374176|NCT03471182|Behavioral|Psychiatric and Cognitive Testing|Interviews, questionnaires, and computer testing.
45491079|NCT03555305|Drug|Insulin Glargine|Administered SC
45491080|NCT03555305|Drug|Lantus|Administered SC
45491081|NCT01310387|Behavioral|Active pain management|Active pain management will be provided by specialized pain nurse, such as telephone counseling for toxicity control and opioid dose modification.
45491082|NCT03725579|Drug|mepivicane hydrochloride|Pain will be assessed during access cavity preparation and instrumentation
45491083|NCT03725579|Drug|articane hydrochloride|Pain will be assessed during access cavity preparation and instrumentation
45374177|NCT03471182|Drug|Cocaine Self-adminstration|The intervention will include a training and safety session that consists of physician/nurse-administered cocaine followed by a self-regulated cocaine administration period under carefully controlled and closely monitored conditions.
45491084|NCT03728855|Behavioral|Self-administration of medication (SAM)|Patients use medication from their own stock, self-administered.
45491085|NCT03018834|Drug|ANAKINRA 100 mg/daily subcutaneously|ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
45491086|NCT03018834|Drug|Placebo|PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
45693017|NCT01790113|Device|Univers™|Control
45693018|NCT01790113|Device|Eclipse™ Total Shoulder Replacement|Investigational
45491087|NCT03553823|Procedure|Skin biopsies|At Baseline, two 6-mm punch biopsies were taken, one from the identified active plaque (TCS ≥ 6) and one from never-lesional skin. At the End-of-study Visit, one biopsy was taken from the same area of the active plaque sampled at Baseline.
45491088|NCT05422716|Device|Epidural implant stimulation device|Individuals randomized to the Baclofen pump device group will continue with their clinical surgical and maintenance plan while also participating in all of the outcomes (assessments). The epidural implant group will undergo the research protocol for epidural stimulator surgical implant followed by mapping studies to identify targeted stimulation configurations for spasticity.
46053834|NCT03229551|Drug|Xylitol|Topical 5% Xylitol (wt/vol) diluted in saline nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
45374178|NCT03471182|Radiation|Positron Emission Tomography|PET scans will be performed on a High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available. Antecubital venous catheters will be used for IV administration of the radiotracer and for venous blood sampling. A radial artery catheter may also be inserted by an experienced physician before the PET scan. At the beginning of each scan, the participants's head will be immobilized and a 6-minute transmission scan, using an orbiting 137Cs point-source, is obtained and used for attenuation correction. PET scans will be acquired using bolus or bolus plus constant infusion administration of [18F]FPEB.
45374179|NCT03471182|Other|Magnetic Resonance Imaging|Structural and functional MRI data will be acquired using a Siemens Trio TIM 3.0T system at the Yale Magnetic Resonance Research Center. High-resolution structural MRI data will be acquired to facilitate analysis of PET data and may be used in additional analysis of tissue volume and brain structure. Resting-state and task-based functional MRI data will be acquired using state-of-the-art multiband echo-planar imaging (EPI) gradient-echo sequences. Diffusion-weighted MRI data will also be acquired using multiband imaging sequences to investigate anatomical connectivity.
45491089|NCT03728777|Dietary Supplement|Resveratrol|Resveratrol supplementation 1000 mg /day or placebo
45491090|NCT05422404|Procedure|Anti-Reflux Mucosectomy|ARMS will be performed using gastroscope . The preparation and endoscopy procedure will be done as in regular practice with conscious sedation. The upper gastrointestinal tract will be evaluated in detail first. Then Endoscopic mucosal resection(EMR) will performed at E-C junction, gastric cardia side. About 50%-70% of the EGJ circumference will be resected to create artificial ulcer which will lead to mucosal contraction during the healing process.
45693019|NCT01789567|Device|Engager™ aortic valve|Implantation of the Medtronic Engager™ bioprosthesis via direct aortic approach
45846899|NCT02657928|Drug|Letrozole|Given PO
46053835|NCT03229551|Drug|Saline|Saline as a standard-of-care nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
46053836|NCT03218085|Drug|Tenofovir|Two cervical biopsies, blood plasma, PBMC, and two cervicovaginal swabs will be collected at a single study visit
46053837|NCT03218085|Drug|Emtricitabine|Two cervical biopsies, blood plasma, PBMC, and two cervicovaginal swabs will be collected at a single study visit
46053838|NCT03215849|Device|CRT-pacemaker device set to Routine Medical Therapy|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy
45846900|NCT02657928|Drug|Ribociclib|Given PO
45491091|NCT05422404|Procedure|Anti-reflux mucosal ablation|ARMA will be performed using gastroscope . The preparation and endoscopy procedure will be done as in regular practice with conscious sedation. Mucosal ablation will be performed in retroflex fashion following. Then APC with soft coagulation(effect 2, 40W) will be used to mark the area that not going to be ablated at gastric carida over the great curvature direction, about 1.5 scope width. Then submucosa injection with saline and indigo carmine dye will be performed using a 25 guage needle.
45491092|NCT03000686|Biological|GSK2586881|GSK2586881 will be a clear colorless liquid for IV infusion over 3- 5 mins and will be administered as unit dose 0.8 mg/kg.
45491093|NCT03000686|Other|Placebo|Normal saline (0.9%) will be administered as a single IV dose infusion over 3 to 5 min.
45491094|NCT02646228|Other|molecular profiling, patient derived cells|"molecular profiling,patient derived cells sample and experimental methods-Blood sample,tumor tissue or primary cultures of human effusions.~Malignant ascites, pleural effusions, or pericardial effusions will be collected from patients with metastatic cancer."
45374180|NCT00539864|Biological|FluBlok Influenza Vaccination|0.5mL dose for intramuscular injection
45374181|NCT00539864|Biological|TIV (Fluzone) Influenza Vaccination|0.5mL dose for intramuscular injection
45374182|NCT04003376|Device|fractional carbon dioxide laser alone|six sessions of fractional carbon dioxide laser will be done for alopecia areata lesions
46053839|NCT03215849|Device|CRT-pacemaker device set to Routine Medical Therapy + LVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + LVP
45374183|NCT04003376|Drug|Triamcinolone Acetonide 10mg/mL|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of triamcinolone acetonide
45374184|NCT04003376|Biological|platelet rich plasma|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of autologous platelet rich plasma
46053840|NCT03215849|Device|CRT-pacemaker device set to Routine Medical Therapy + BiVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + BiVP
45374185|NCT04003376|Drug|vitamin D solution|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of vitamin D solution
45491095|NCT04701138|Dietary Supplement|SPM Active|Each capsule contains 145 mg of SPMs (fractionated marine lipids standardized to 18-HEPE, 14-HDHA, and 17-HDHA). All subjects will take 4 capsules orally each day for a total daily dose of 580 mg.
45491096|NCT01382550|Drug|long-lasting OAT or 12-month OAT|"The antithrombotic treatment will be decided according to usual practice of enrolling Centers. The duration of the initial treatment with parenteral anticoagulation (Low Molecular Weight Heparin or Fondaparinux), the beginning of oral anticoagulation (OAT) with Vit K inhibitors and the International Normalized Ratio (PT-INR) target will be recorded.~According to Center indications the OAT duration (6 months, 12 months or long-lasting) will be recorded and population will be stratified accordingly. The length of therapy will be counted from the date when a stable PT-INR is achieved.~The occurrence of surgery, trauma, prolonged immobilization (>7 days), pregnancy (VTE risk periods) during the follow-up and the use of adequate anti-thrombotic prophylaxis will be recorded."
45491097|NCT05421936|Drug|Osimertinib|Treatment as the first EGFR-TKI
45846901|NCT02658240|Drug|Ropivacaine|Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
45846902|NCT02658240|Drug|Epinephrine|0.5 mg epinephrine
45846903|NCT02660112|Drug|(+)-Epicatechin|25mg (+)-Epicatechin capsules. Starting dose 75mg total daily dose (one 25mg cap taken three times per day). Dose escalation at 12 weeks for non-responders to 150mg total daily dose (two 25mg caps taken three times per day)
45846904|NCT02661126|Drug|MK-3682B|FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.
45846905|NCT02661828|Other|Two-Week Antidepressant Taper Regimen|Days 1-7: 50% of baseline antidepressant dose taken; Days 8-14: 25% of baseline antidepressant dose taken; Day 15: Stop antidepressant.
46053841|NCT03197077|Procedure|blood sampling|comparison between corifollitropin alfa and follitropin beta in IVM cycles
46053842|NCT03197077|Procedure|transvaginal ultrasound scanning|comparison between corifollitropin alfa and follitropin beta in IVM cycles
46053843|NCT03197077|Procedure|oocyte retrieval for IVM|comparison between corifollitropin alfa and follitropin beta in IVM cycles
45374186|NCT01563848|Procedure|Cryoballoon ablation|After double transseptal puncture, selective PV angiography was performed to identify the PV ostia in 2 projections (right anterior oblique 30º, left anterior oblique 40 º). Baseline potentials of all PVs were recorded with a Lasso catheter (Biosense Webster, Inc., Diamond Bar, California). To assess the exact position of the inflated balloon in relation to the left atrial (LA)-PV junction, contrast medium was injected from the distal lumen of the cryoballon catheter . CBA was performed for a target time of 300 seconds. The right phrenic nerve was constantly paced from the superior caval vein during freezing at the septal PVs. After each freeze, PV conduction was revaluated by the Lasso catheter.
45374187|NCT01563848|Procedure|Implantation of loop recorder|"The RevealXT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a toolthat allows each patient to store the ECG through the implanted device during symptoms: datawere collected in order to analyze heart rhythm during symptomatic events"
45374188|NCT01563848|Procedure|Radiofrequency ablation|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
45374189|NCT04086212|Drug|Icodextrin, xylitol and carnitine solution for peritoneal dialysis|Patients will receive a long dwell exchange for three days.
45374190|NCT04086212|Drug|EXTRANEAL 7.5G/100Ml Peritoneal Dialysis Solution|Patients will receive a long dwell exchange for three days.
45374191|NCT05404490|Drug|Bupivacain|20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
46053844|NCT03197077|Drug|Corifollitropin Alfa|Single injection of 100 micrograms of corifollitropin alfa
45374192|NCT05404490|Drug|Placebo|20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
45374193|NCT05359874|Drug|Bevacizumab-IRDye800CW|In order to be able to detect this marker in vivo, special multispectral fluorescence-reflecting cameras (MFRI) were developed, which can be used for the intraoperative display of the tumor and potentially affected lymph nodes and which are now to be evaluated together with the fluorescence marker.
45491098|NCT01380132|Procedure|Anal injection of Nasha Dx|Submucous injection of Nasha Dx 5-10 mm above dentate line
46053845|NCT03197077|Drug|Follitropin beta|Daily injection (three days) of follitropin beta
46053846|NCT03197077|Drug|oral contraceptive pill pretreatment (Marvelon)|Daily administration of the oral contraceptive pill (Marvelon) for 21 days. Administration of the combined oral contraceptive pill will start after a blood test that demonstrates basal E2 levels and a negative serum hCG level.
46053847|NCT03165487|Other|Breast tissue collection|During Breast Conservation Surgery, one sample will be collected before and after IORT.
46053848|NCT03165487|Other|Blood sample collection|Blood will be collected before and after IORT, and at the two week follow-up.
46053849|NCT03158922|Genetic|Genetic SNP profiling|Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.
45491099|NCT02493660|Device|InSpace sub-acromial tissue spacer system|Arthroscopic implantation of InSpace sub-acromial tissue spacer system
45491100|NCT02493660|Procedure|Partial repair of rotator cuff|Arthroscopic partial repair of rotator cuff
45491101|NCT01382472|Drug|Rosuvastatin|40 mg per operative in PPCI, the 40 daily during hospital stay
45491102|NCT01382472|Drug|Simvastatin|No statin acutely. Simvastatin 20 mg from day 2.
45491103|NCT05421468|Other|L-Thyroxine time B (5-15 minutes Before dawn)|Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.
45491104|NCT03552029|Drug|Quizartinib|20 or 30 mg tablets for oral administration
45491105|NCT03552029|Drug|Milademetan|5, 20, 80 or 200 mg capsules for oral administration
45846906|NCT02661828|Other|One-Week Antidepressant Taper Regimen|Days 1-3: 50% of baseline antidepressant dose taken; Days 4-7: 25% of baseline antidepressant dose taken; Day 8: Stop antidepressant.
45374194|NCT05359796|Biological|Chronic hyperglycemia|For each follow-up, the glycated albumin(GA) reflecting glycemic control of the past 2-3 weeks, the glycated hemoglobin(HbA1c) reflecting glycemic control of the past 2-3 months, and the advanced glycation end products(AGEs) will be measured.
45374195|NCT05359796|Biological|Residual islet function|For each follow-up, fasting and stimulated C-peptide levels will be measured.
45491106|NCT03552029|Drug|Milademetan|5, 20, 80 or 200 mg capsules for oral administration; 30, 45, 80, or 100 mg capsules may be utilized
45491107|NCT03725423|Drug|Apatinib|250mg, qd once a day, take it half an hour after meal (the time for taking the medicine should be the same as possible), and take it with warm water. 28 days is a drug delivery cycle.
45491108|NCT03521141|Drug|Nicotine patch|FDA-approved smoking cessation pharmacotherapy
45491109|NCT03521141|Drug|Varenicline|FDA-approved smoking cessation pharmacotherapy
45491110|NCT03521141|Genetic|Nicotine metabolism|Information on nicotine metabolism will be used to inform selection of medication.
45491111|NCT03521141|Genetic|Genetically-informed lung cancer risk score|This intervention uses information from a person's genes and smoking and family medical histories to estimate lung cancer risk compared to current smokers.
45491112|NCT03521141|Behavioral|"NCI Clearing the Air"|A booklet-led intervention designed by the NCI to support cessation at any stage of a quitter's journey, whether they are still thinking about quitting, have made the decision to quit, or have already taken steps to quit and just need help maintaining their new lifestyle.
45374196|NCT05359796|Genetic|Genetic variation|Genetic variations of interest will be detected with the blood sample collected at baseline.
45374197|NCT05359796|Dietary Supplement|Dietary constitutes|For each follow-up, the dietary constitutes for the past 3 days will be recorded.
45374198|NCT05359796|Genetic|Microbiome composition and function|For each follow-up, the fecal and oral samples will be collected for measurement.
45374199|NCT05359796|Biological|Metabolome composition|For each follow-up, the serum and urine samples will be collected for measurement.
45374200|NCT05359796|Biological|Composition of peripheral blood immune cells|For each follow-up, the peripheral blood mononuclear cells will be collected for measurement.
45374201|NCT05359718|Other|Questionnaire|Questionnaire
45374202|NCT00990392|Drug|Polysporin Triple Therapy ointment|Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
45374203|NCT00990392|Other|Petroleum Jelly|Petroleum jelly applied to the insertion point at the time of CVC placement and twice within the first week.
45374204|NCT05385536|Diagnostic Test|Guidance UTI Test|Guidance® UTI was designed at Pathnostics a CLIA certified/CAP-accredited lab for use clinically to detect bacterial DNA in the urine via M-PCR and to characterize genotypic/phenotypic antibiotic resistance. Microbes are reported semi-quantitatively as cells per milliliter. In addition to bacterial identification, an antimicrobial susceptibility profile is generated through a patented technique referred to as P-AST (pooled antibiotic susceptibility testing); a high-throughput, broth microdilution spectrophotometric assay applied to a panel of antibiotic agents' array on a microplate to determine the MIC of the polymicrobial culture, if more than organism is present. Guidance® UTI is approved by CLIA for use and therefore is not IUO or RUO. Both components of the Guidance® UTI are analytically validated.
45491113|NCT03728621|Behavioral|Normocaloric and balanced diet, physical activity|Promotion of normocaloric & balanced diet and physical activity
45491114|NCT03722147|Biological|AK105|AK105 200 mg intravenously (IV) every-2-weeks (Q2W)
45491115|NCT03722069|Other|Low sodium diet|Patients received low sodium diet (3g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
45491116|NCT03722069|Other|Normal sodium diet|Patients received normal sodium diet (7g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
45491117|NCT03725267|Drug|Melatonin Pill|Patients will receive 1 pill of melatonin each day during polymyxin B therapy for a maximum of 14 days.
45491118|NCT03725267|Drug|Placebo oral capsule|Patients will receive 1 pill of placebo each day during polymyxin B therapy for a maximum of 14 days.
45491119|NCT02997176|Drug|Talazoparib|Daily oral doses of talazoparib 0.5 mg
45491120|NCT03000452|Drug|DARATUMUMAB|DARATUMUMAB
45491121|NCT03000452|Drug|DURVALUMAB|DURVALUMAB
45491122|NCT03664856|Other|interview|The patient will be asked to answer the questions that the interviewer will ask him.
45491123|NCT03664388|Drug|Dual antiplatelet therapy with ticagrelor/prasuglre|Compare bleeding and ischemic events according to the type and duration of dual antiplatelet therapy
45491124|NCT03664310|Other|FSET Anxiety and Sleep Treatment|Computerized anxiety and insomnia intervention.
45374205|NCT05590988|Other|Tablet-based training|"Each task is performed for one minute, followed by a 2-minute break. After the task has been performed three times, there is a 5-minute break. The training block is then carried out twice more. This means that three blocks are carried out for each therapy unit."
45374206|NCT05590988|Other|ergotherapeutic training|A task is performed for one minute at a time, followed by a 2-minute break. Once three rounds have been completed, there is a 5-minute break. As in the intervention group, there are a total of three training blocks.
45374207|NCT05590910|Other|Music|Fifteen minutes of classical music will be played overhead in the classroom. The students will be instructed not to use other electronic devices such as ear buds or phones during this time.
45374208|NCT05590832|Behavioral|Activity of Whatsapp messages|Informative messages will be sent to the initiative group on Mondays, Wednesdays and Fridays for the first 10 weeks / three times a week (up to the 28th week), and reminder messages will be sent once a week on Wednesdays between the 29th-36th weeks.
45374209|NCT03367754|Other|Placebo|Placebo
45374210|NCT03367754|Drug|Pembrolizumab|Pembrolizumab, 200 mg, or placebo via intravenous (IV) infusion, single dose.
45374211|NCT03335072|Drug|Azithromycin|Mass Drug Administration
45374212|NCT01563926|Drug|somatropin|Dosed by individual needs as judged by the Investigator (trial physician). Injected subcutaneously (s.c./under the skin)
45374213|NCT05590520|Procedure|Botulinum injection|Botox injection to be injected in internal anal sphincter to see the curative response in comparison to gtn cream application
45374214|NCT05590520|Drug|GTN OINTMENT|0.2%GTN applied on anal canal.
45374215|NCT05590442|Other|Tests|Cognitive assessments and olfactory tests
45374216|NCT01034956|Device|hyaluronic acid or calcium hydroxylapatite filler|Intradermal and subdermal injection of facial soft tissue filler within the past 24 months; survey of patients to assess satisfaction and determine the presence of treatment related adverse events.
45374217|NCT01040884|Other|ActiSight Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera
45374218|NCT05590052|Device|Bipolar Electrosurgery|Achievement of hemostasis using bipolar electrosurgery
45374219|NCT05590052|Device|Thermocautery|achievement of hemostasis using thermocautery
45374220|NCT01580878|Drug|Butenafine Hydrochloride Cream, 1%|Butenafine Hydrochloride Cream, 1% applied twice daily for 7 consecutive days
45374221|NCT01580878|Drug|Lotrimin Ultra®|Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) applied twice daily for 7 consecutive days.
45374222|NCT01580878|Drug|Butenafine Vehicle|Butenafine Vehicle applied twice daily for 7 consecutive days.
45374223|NCT05589974|Drug|Verteporfin|Chronic CSC are receiving one treatment before the observation period.
45374224|NCT05589896|Drug|Busulfan|pre-transplant conditioning treatment
45374225|NCT05589896|Drug|Fludarabine|pre-transplant conditioning treatment
45374226|NCT05589896|Radiation|Total Body Irradiation|pre-transplant conditioning treatment
45374227|NCT05589896|Drug|Cyclophosphamide|pre-transplant conditioning treatment
45374228|NCT05589896|Drug|Mesna|given with Cyclophosphamide
45374229|NCT05589896|Procedure|Bone Marrow Transplant|Bone marrow transplant with Ossium HPC, product
45374230|NCT05589896|Drug|Cyclophosphamide|post-transplant treatment
45374231|NCT05589896|Drug|Tacrolimus|post-transplant treatment
45374232|NCT05589896|Drug|Mycophenolate Mofetil|post-transplant treatment
45374233|NCT05589896|Drug|Filgrastim|post-transplant treatment
45374234|NCT00673049|Drug|CP 751,871 (Figitumumab)|CP 751,871 (20 mg/kg) will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter.
45846907|NCT02662608|Drug|Brontictuzumab|1.5 mg/Kg intravenously every three weeks.
45374235|NCT00673049|Drug|Erlotinib|Erlotinib (one tablet of 150 mg/day PO).
45374236|NCT00673049|Drug|Erlotinib|Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food.
45846908|NCT02665260|Drug|Cantharidin|cantharidin 0.7% topical liquid
45374237|NCT04003844|Drug|Immunoglobulin G|single dose of IGIV 10% (2 g/kg) administered intravenously for at least 12 hours
45374238|NCT04003844|Drug|Acetylsalicylic acid|Coadministration
45374239|NCT05589584|Drug|N acetyl cysteine with weight reduction|high dose 2400mg/day
45374240|NCT05359484|Diagnostic Test|Uroflowmetry|according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post-void residual urine (PVR), and value of Qmax minus Qaverage (DeltaQ) were obtained.
45374241|NCT00412750|Drug|Telbivudine (LdT)|600 mg orally once daily for 104 weeks.
45374242|NCT00412750|Drug|peginterferon alpha-2a|180 μg subcutaneous injection once a week for 52 weeks.
45846909|NCT02665260|Drug|Placebo|Placebo topical liquid
45374243|NCT05361278|Other|Chlorhexidine solution|"Irrigate the root canal with 1 ml of 2% CHx solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~Irrigate the root canal with 3 ml of the solution after using the last file.~Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine solution.~Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~Follow-up of endodontic treatment procedures for the treated tooth."
45374244|NCT05361278|Other|Activated chlorhexidine solution|"Irrigate the root canal with 1 ml of 2% CHx solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle with activation using an ultrasonic irrigation head.~Irrigate the root canal with 3 ml of the solution after using the last file with activation using an ultrasonic irrigation head.~Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine solution.~Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~Follow-up of endodontic treatment procedures for the treated tooth."
45491125|NCT03664310|Other|Control|Physical health control
45491126|NCT04056416|Device|MedBIKE|A MedBIKE will be installed into a participants home and connected to clinicians via telehealth for monitoring during exercise sessions. Sessions will be based on standardized guidelines for aerobic exercise. Heart rate, ECG, oxygen saturation and rating of perceived exertion will be monitored throughout the session.
45846910|NCT02665260|Device|Gauze occlusion bandage|Gauze occlusion bandage with adhesive tape
45846911|NCT02665728|Drug|BLI400 Laxative|
45491127|NCT03663686|Drug|Litapiprant Tablet|Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells
45491128|NCT01373164|Drug|Galunisertib|Administered orally
45491129|NCT01373164|Drug|Gemcitabine|Administered intravenously
45491130|NCT01373164|Drug|Placebo|Administered orally
45846912|NCT02666352|Drug|Uprifosbuvir|A single dose of uprifosbuvir 450 mg (given as three 150-mg tablets) taken by mouth.
45491131|NCT04349332|Device|Helmet non-invasive ventilation (NIV)|After application of the helmet, arterial blood gas sampling will be utilized to follow gas-exchange; Noninvasive support will be reduced progressively in accordance to clinical improvement and will be discontinued if patient maintains respiratory rate <30breaths/min and PaO2 >75mm Hg with FiO2 0.5 without ventilatory support. If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay.
45491132|NCT02999984|Genetic|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)|autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
45846913|NCT02666352|Drug|Ruzasvir|A single dose of ruzasvir 60 mg (given as six 10-mg capsules) taken by mouth.
45846914|NCT02666508|Other|Plaque identifying toothpaste|Plaque identifying toothpaste with targetol
45846915|NCT02666508|Other|Non-plaque identifying toothpaste|Non-plaque identifying toothpaste without targetol
45374245|NCT05361278|Other|Chlorhexidine gel|"Irrigate the root canal with 1 ml of 2% CHx gel between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~Irrigate the root canal with 3 ml of the gel after using the last file.~Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine gel.~Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~Follow-up of endodontic treatment procedures for the treated tooth."
45374246|NCT05361278|Other|Activated chlorhexidine gel|"Irrigate the root canal with 1 ml of 2% CHx gel between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle with activation using an ultrasonic irrigation head.~Irrigate the root canal with 3 ml of the gel after using the last file with activation using an ultrasonic irrigation head.~Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine gel.~Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~Follow-up of endodontic treatment procedures for the treated tooth."
45374247|NCT05361278|Other|Sodium hypochlorite solution|"Irrigate the root canal with 1 ml of 5.25% sodium hypochlorite solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~Irrigate the root canal with 3 ml of the solution after using the last file.~Irrigating the canal with 3 ml of 5% sodium thiosulfate solution to remove residual of sodium hypochlorite.~Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~Follow-up of endodontic treatment procedures for the treated tooth."
45693020|NCT01765543|Drug|Rifampin|Rifampin at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 23 (Periods B and C).
45693021|NCT01765543|Drug|Vemurafenib|Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 mg as film-coated tablets orally on Day 1 (Period A) and on Day 17 (Period C).
45693022|NCT01765153|Behavioral|Endurance|Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training.
45693023|NCT01765153|Behavioral|Precision|Participants train daily to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto.
45693024|NCT00248170|Drug|Letrozole|2.5 mg tablets
45693025|NCT00248170|Drug|Anastrozole|1 mg tablets
45693026|NCT01764997|Drug|Sarilumab|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
45693027|NCT01764997|Drug|Etanercept|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
45693028|NCT01764997|Drug|Methotrexate|Dispensed according to local practice.
45374248|NCT00764855|Procedure|Automatic administration of propofol and opiates during routine clinical practice|"The clinical effect of administration of pharmaca can be measured in the changes of heartbeat, blood pressure, respiration and the changes of brain activity by registering EEG. These measurements are performed standard, to secure the safety of the patient.~The heartbeat and the EEG will be measured by non invasive adhesive electrodes on the skin of the patient.~The blood pressure will be measured by non invasive blood pressure cuff around the arm and the respiration parameters will be measured by non invasive spirometry, which are all standard available on a anesthesia device."
45491133|NCT02999984|Drug|busulfan|Busulfan is used for non-myeloablative conditioning
45491134|NCT02999984|Drug|PEG-ADA ERT|PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
45491135|NCT01965184|Behavioral|Cognitive-Behavioral Therapy for Anger and Aggression|
45693029|NCT01764997|Drug|Placebo (for sarilumab)|
45693030|NCT01764997|Drug|Placebo (for etanercept)|
45693031|NCT01764997|Drug|Adalimumab|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
45693032|NCT01276756|Drug|Pegylated interferon alfa-2a|Pegylated interferon 160ug once weekly 48 weeks
45693033|NCT01276756|Drug|Nitazoxanide|Nitazoxanide 500mg twice daily 4 weeks lead-in followed by triple therapy 48 weeks
45693034|NCT01276756|Drug|Ribavirin|Ribavirin (> 75kg:1200 mg, <75kg:1000mg daily)48 weeks
45693035|NCT00246376|Behavioral|Diet|ATP-III diet
45693036|NCT00246376|Behavioral|Exercise|Supervised exercise in study gym
45693037|NCT00246376|Drug|Niacin|Niaspan, titrated up to 2 grams per day
45374249|NCT02161900|Other|Yogic and routine exercises|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
45374250|NCT05589506|Device|Removable partial denture PEEK|A removable partial denture incorporating PEEK and acrylic resin in its composition used as definitive prosthesis to rehabilitate partial edentulism in the maxilla or mandible.
45374251|NCT00759317|Drug|venlafaxine (Effexor)|Matching capsules containing either venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule.
45374252|NCT00764933|Behavioral|Structured information|Participants will receive structured information about their ICU-stay and course of therapy and care. They get information about procedures, sensory impressions and coping strategies. The intervention will last about 10 to 15 minutes depending on the state of the participant.
45374253|NCT00764933|Other|Unspecific conversation|Participants will receive a short conversation with the study personnel. This conversation will last about 10 to 15 minutes. No specific informations will be given about procedures, sensory impressions or coping strategies. Control intervention is designed to control for personal attention and care.
45374254|NCT00076999|Drug|TPV oral solution|Tipranavir oral solution
45374255|NCT00076999|Drug|TPV oral solution|Tipranavir oral solution
45374256|NCT00076999|Drug|RTV oral solution|Ritonavir oral solution
45374257|NCT00076999|Drug|RTV oral solution|Ritonavir oral solution
45374258|NCT01041040|Drug|gemtuzumab|gemtuzumab ozogamicin (GO) during consolidation for patients with acute myeloid leukemia (AML)
45374259|NCT00765011|Drug|TPF, radiotherapy and cetuximab|3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
45374260|NCT00765011|Procedure|H&N surgery|Rescue surgery
45374261|NCT01035034|Procedure|Hybrid MIDCAB/PCI|"MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia. PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
45374262|NCT01035034|Procedure|PCI with DES|Polymer-based Sirolimus-Eluting Stents (SES)
45374263|NCT00765089|Procedure|Isolation of pulmonary veins with Bipolar radiofrequency ablation|
45374264|NCT00765167|Drug|Fluoride|Brush half mouth twice daily for four days
45374265|NCT00765167|Drug|Triclosan|Brush half mouth daily for four days
45374266|NCT00765167|Drug|Chlorhexidine gluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days
45374267|NCT00765167|Drug|Fluoride|Brush half mouth daily for four days
45693038|NCT00246376|Drug|Fenofibrate|Tricor, 120 mg per day
45374268|NCT00759551|Drug|Azilsartan|Azilsartan 2.5 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
45374269|NCT00759551|Drug|Azilsartan|Azilsartan 5.0 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
45374270|NCT00759551|Drug|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
45374271|NCT00759551|Drug|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
45374272|NCT00759551|Drug|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
45374273|NCT00759551|Drug|Placebo|Azilsartan placebo-matching tablets, orally, once daily and olmesartan placebo-matching capsules, orally, once daily for up to 8 weeks.
45374274|NCT00759551|Drug|Olmesartan|Azilsartan placebo-matching tablets, orally, once daily and olmesartan 20 mg, capsules, orally, once daily for up to 8 weeks.
45374275|NCT03905096|Drug|BI 425809|Film coated tablet
45693039|NCT00246376|Other|Placebos|Placebos for Niaspan and Tricor
45693040|NCT03806218|Device|Bipolar RFA|Bipolar RFA in which RF currents flow between two electrodes
45374276|NCT03905096|Drug|Donepezil|Film coated tablet
45693041|NCT03806218|Device|SM-RFA|Monopolar RFA using multiple electrodes with switching mode
45374277|NCT02557919|Other|Motivational Interviewing Training|1.5 day training on Motivational Interviewing (MI) techniques plus 2 booster sessions to address real experiences using MI with families.
45374278|NCT02557919|Other|Usual Best Practice|.5 day training on tobacco control and emerging products.
45374279|NCT00412360|Biological|Single Umbilical Cord Blood Unit Transplant|Unrelated donor, single umbilical cord blood unit; conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
45374280|NCT00412360|Biological|Double Umbilical Cord Blood Unit Transplant|Unrelated donor, double umbilical cord blood unit; Conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
45374281|NCT00412360|Radiation|Total Body Irradiation|The TBI will be delivered from either a linear accelerator or cobalt source at a dose rate of between 4 and 26 cGy/minute using energies of between 1 and 25 MV.
45374282|NCT00412360|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.
45374283|NCT00412360|Drug|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -10 through -8. Fludarabine will not be dose adjusted for body weight.
45374284|NCT00412360|Drug|Cyclosporine A|CSA will be administered beginning on Day -3 and doses will be adjusted to maintain a level of 200-400 ng/mL by TDX method (or 100-250 ng/mL by Tandem MS or equivalent level for other CSA testing methods). CSA can be administered per institutional practice.
45374285|NCT00412360|Drug|Mycophenolate Mofetil|MMF will be given at a dose of 1 gram IV q 8 hours if > 50 kg or 15 mg/kg IV q 8 hours if < 50 kg beginning the morning of Day -3.
45374286|NCT00761423|Biological|PRP Injection with eccentric exercises|PRP Injection with eccentric exercises
45374287|NCT00761423|Biological|Placebo Injection with eccentric exercises|Placebo Injection with eccentric exercises
45374288|NCT03957967|Other|video taken|Patients enrolled will be operated in our institution. Facial expression will be collected before and after surgery, and pain intensity will be collected at the same time. Facial expression will be analyzed using Facial Action Coding System (FACS) .This step will seek to confirm that the subset of Action Units (AUs) defined in previous studies is correlated with the presence and intensity of an acute pain or to identify a different original subset of facial AUs better correlated to pain intensity. . The developed algorithm (or model) here should be able to correlate facial AUs to pain intensity reported by the patients on the numerical rating scale. The developed model at this stage will be then validated on an additional sample of patients.
45374289|NCT00761501|Drug|PN400|Oral
45374290|NCT00761501|Drug|Naproxen (Proxen S)|Oral
45693042|NCT03806218|Device|Twin internally cooled-wet electrodes|Saline-enhanced twin internally cooled electrodes allow intratumoral injection of a saline solution during the application of the RF current that alters the tissue conductivity
45693043|NCT03806218|Device|Separable clustered electrodes|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
45374291|NCT00761501|Drug|Naproxen (Naprosyn E)|Oral
45374292|NCT01564160|Dietary Supplement|Fish Oil|Source of omega-3 fatty acids.
45374293|NCT01564160|Dietary Supplement|PCSO-524|Extract of Greenshell Mussel
45374294|NCT01088893|Drug|Everolimus|10mg/d) for three weeks 1 week after completion of neoadjvuant treatment and before surgery
45374295|NCT03026036|Radiation|PET Scan with Raclopride|A subsample (21 per group) will complete the PET imaging.
45374296|NCT00759629|Other|Interventional treatment group|Patients assigned to PCI will receive the loading dose of clopidogrel (300 mg), 500 mg aspirin plus a bolus of 70 U/kg heparin i.v. and be transferred immediately for interventional treatment. They will receive abciximab as a bolus of 0.25 mg/Kg of body weight followed by a continuous infusion of 0.125 µg/Kg/minute (up to a maximal dose of 10 µg/minute) for 12 hours. All patients will undergo coronary angiography and left ventriculography in the conventional way. During the procedure patients will receive the weight-adjusted heparin doses (70 U/ kg). Post-procedural antithrombotic therapy will consist of clopidogrel in a daily dose of 75 mg for at least 4 weeks (6 months recommended) and aspirin, 100 mg to 350 mg daily, indefinitely.
45491136|NCT01965184|Behavioral|Supportive Psychotherapy (SPT)|
45693044|NCT03806062|Drug|domperidone|10 mg domperidone 3 times a day after meals
45374297|NCT00759629|Other|Conservative treatment group|Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards. Per protocol, all patients in this arm will receive a loading dose of clopidogrel (300 mg) followed by 75 mg/day for at least 4 weeks (6 months recommended) after randomization and aspirin, indefinitely. Recommended additional regimen will include heparin, ß-blockers, ACE inhibitors and statins
45374298|NCT01088971|Dietary Supplement|Duolac7S|1 capsule two times everyday for 6 weeks
45374299|NCT01088971|Dietary Supplement|starch|1capsule two times everyday for 6 weeks
45374300|NCT00990860|Drug|doxorubicin|After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)
45374301|NCT00990860|Procedure|TACE (Transcatheter arterial chemoembolization)|TACE (Transcatheter arterial chemoembolization)
45374302|NCT02558543|Drug|Stromal Vascular fraction|
45374303|NCT02558543|Drug|Ringer lactate|
45374304|NCT01035190|Drug|Budesonide|Inhalation, 200 µg/puff
45374305|NCT01090687|Radiation|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
45374306|NCT01090687|Device|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
45374307|NCT02557841|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
45374308|NCT02557841|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
45693045|NCT03806062|Device|He-Ne laser (Bravo TrezaSerie) device|The laser scan beam was adjusted to the size of the treated breast for 10 minutes with wave length 632.8 nm and power output 25 mw after the end of treatment session
45374309|NCT02557841|Device|tDCS|Sham ctDCS (NeuroConn Plus, Germany) will be applied at the same parameter settings used on cathodal ctDCS however, current duration will be only 30 seconds. Moreover, device automatically turned off without volunteer's perception, but volunteers will be with electrodes montage for 20 minutes.
45374310|NCT00765479|Dietary Supplement|soy protein isolate|Given orally
45374311|NCT00765479|Other|placebo|Given orally
45374312|NCT01035268|Procedure|fatty tissue transfer|It will be proceeded to aspiration of the fat at the level of the natural steatomeries (hip, stomach), then in a transfer of the fat prepared in the breast by following the standardized protocol.
45374313|NCT00571103|Drug|acamprosate|Two 333mg tablets taken three times daily.
45374314|NCT03742934|Other|Short peptide|Short peptide formula during bowel preparation
45596397|NCT05161871|Device|Cathodal transcranial direct current stimulation|The cathodal transcranial direct current stimulation protocol will consist in five daily sessions, each lasting 20 min. The montage will provide a bilateral stimulation on occipital areas, with the reference anodal electrodes positioned on the M1 areas. The stimulation will be applied via 4 conductive-rubber square electrodes (5x5 cm) placed in sponges saturated with high conductivity gel and connected to a battery-operated stimulator system. Direct current with maximal intensity of 1.5 mA with be provided for 20 minutes.
45693046|NCT03806062|Device|faradic current|faradic stimulation (Body shaping System, model B-333, made in China) , at the following acupuncture points on both sides: Spleen 6 (Sanyinjiao), Liver 3 (Taichong) and Small Intestine 1 (Shaoze)
45374315|NCT03742934|Other|Liquid diet|Liquid diet during bowel preparation
45374316|NCT00084799|Biological|monoclonal antibody hu3S193|
45374317|NCT00991016|Drug|PF-04805712|ascending single and multiple doses starting at 30 mg
45374318|NCT03993652|Behavioral|Kids FIRST|family- and school-based intervention to reduce unhealthy screen-time and snacking
45374319|NCT02558777|Other|Multicomponent nurse-led intervention|"Participants in the intervention group received the first intervention in the first 24 hours from admission, and thereafter daily until hospital discharge. The intervention was carried out exclusively by the intervention nurses, and was composed of two main parts, being the first one a risk factor analysis, and the second one the intervention on the risk factors detected (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain). Furthermore, the intervention nurses identified the principal caregiver in the first 24 hours from admission, and provided an informative booklet about strategies and recommendations to prevent delirium incidence, including ambient strategies, orientation abilities, and identification of alert signs."
45374320|NCT01089049|Dietary Supplement|FemMED Breast Health Formula|Two capsules daily, with meals. FemMED Breast Health Formula containing lignans.
45374321|NCT01038934|Procedure|samples collected by buccal cytobrush|
45374322|NCT00765557|Drug|MiraLAX|Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
45374323|NCT00765557|Drug|Placebos|Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
45374324|NCT02828618|Procedure|PDS (Primary Debulkdung Surgery)|PDS with maximum effort to achieve the goal of complete gross resection
45374325|NCT02828618|Procedure|6 cycles of standard chemotherapy|6 cycles of standard chemotherapy after Primary Debuling Surgery
45374326|NCT02828618|Procedure|Timing of surgery after 3 cycles of standard NACT, IDS|Timing of surgery after 3 cycles of standard NACT
45374327|NCT02828618|Procedure|IDS|IDS with maximum effort to achieve the goal of complete gross resection after NACT
45374328|NCT02828618|Drug|3 cycles of standard chemotherapy|3 more cycles (for a total of 6) of standard chemotherapy after IDS
45374329|NCT01086553|Drug|budesonide|9mg budesonide OD
45374330|NCT01086553|Drug|budesonide|3mg budesonide TID
45374331|NCT01041352|Device|laryngeal mask|LMA Proseal
45374332|NCT01041352|Device|endotracheal tube|Unomedical endotracheal tube
45374333|NCT00765635|Drug|drops intilation (Taponoto ® )|four drops, unique doses
45374334|NCT00765635|Drug|drops intilation (Otocerum®)|four drops, unique doses
45374335|NCT00765635|Drug|drops intilation (Placebo)|Placebo
45693047|NCT04385914|Other|COVID positive via testing|Following pregnancy outcomes whether they are COVID positive or negative
45693048|NCT00754156|Device|ABRA Abdominal Closure System|ABRA Abdominal Closure System
45374336|NCT05585918|Behavioral|SEL + Equity|For the SEL + Equity (experimental) condition schools, activities include those in the SEL Only condition, as well as equity lessons designed by the project team, as well as training and individualized support for implementing classroom equity lessons, five 45-minute equity professional development sessions, and one-on-one coaching to support equitable practices and the implementation of the 6 classroom equity lessons.
45693049|NCT00754156|Device|V.A.C. Therapy|V.A.C. Therapy Alone
45693050|NCT00754156|Device|KCI ABThera|KCI ABThera
45693051|NCT03805984|Drug|INO-4500|INO-4500 will be administered ID on Day 0 and Week 4.
45693052|NCT03805984|Drug|Placebo|Placebo will be administered ID on Day 0 and Week 4.
45693053|NCT03805984|Device|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device will be administered following ID drug administration.
45693054|NCT03805906|Procedure|L5 Dorsal ramus block|Ultrasound-guided L5 dorsal ramus block
45374337|NCT05585918|Behavioral|SEL Only|For the SEL Only (active comparator) condition schools, activities involve school-wide technical assistance and implementation support for SEL curriculum implementation, as well as individualized technical assistance for the SEL curriculum. In the year following participation, SEL Only condition schools are offered access to and training and technical support for the classroom equity lessons.
45374338|NCT04049513|Biological|WZTL002-1 (1928T2z CAR-T cells)|WZTL-002 comprises autologous third-generation anti-CD19 chimeric antigen receptor T-cells (termed 1928T2z). The chimeric antigen receptor in WZTL-002 incorporates the FMC63 anti-CD19 soluble chain variable fragment extracellularly, and portions of both CD28 and the Toll/interleukin-1 receptor (TIR) domain of Toll Like Receptor 2 (TLR2) as intracellular co-stimulatory domains, alongside CD3ζ. WZTL-002 (autologous 1928T2z CAR T-cells) will be administered on D0 as a single IV infusion, following lymphodepleting chemotherapy.
45374339|NCT04049513|Drug|Cyclophosphamide and Fludarabine lymphodepleting chemotherapy|Cyclophosphamide 500 mg/m^2 IV on days -5 to -3, inclusive. Fludarabine 30 mg/m^2 IV on days -5 to -3, inclusive
45374340|NCT02810990|Drug|Bosutinib|"Bosutinib is given orally accordingly with this scheme:~A. 200 mg OD: starting dose (wash-in period) at week 1 and week 2 B. 300 mg OD: from week 3 to the end of week 16~At the end of week 12 evaluation of molecular response (BCR-ABL1 level by RT-Q-PCR).~Bosutinib dose is then managed as follows :~C1. if BCR-ABL1 ≤1% at week 12: 300 mg OD from week 17 to week 52 C2. if BCR-ABL1 > 1% at week 12: 400 mg OD from week 17 to week 52~All the responsive patients who are still on Bosutinib at the end of week 52, will continue Bosutinib at the same dose (300 mg OD or 400 mg OD) for the next two years ( if tolerated and in absence of safety concerns)."
45374341|NCT01041430|Other|day surgery group|inguinal hernia repair, discharge from the hospital on the day of surgery
45374342|NCT01041430|Other|inpatient group|inguinal hernia repair, patient admitted overnight to hospital
45374343|NCT00069277|Drug|E7389|
45374344|NCT00765713|Device|Nasal continuous positive airway pressure|Nocturnal
45374345|NCT01041508|Drug|Clofarabine|Clofarabine will be given as an intravenous infusion over 2 hours on days -6 though -2. The dose of Clofarabine will be assigned at study entry.
45374346|NCT01041508|Radiation|Total Body Irradiation|"Low dose (2 Gy) TBI will be administered from a linear accelerator at ≤ 20 cGy/min on day 0 according to institutional guidelines."
45374347|NCT01041508|Other|Stem Cell Infusion|Patients will be infused with 'unmanipulated' hematopoietic stem cells from a related or unrelated donor on day 0 of the treatment regimen according to institutional practice guidelines.
45374348|NCT01041508|Drug|Cyclosporins|"Cyclosporin (CSP) should be started on day -1 after completion of Clofarabine. CSP levels should be maintained between 300-400 ng/ml.~Age ≤ 6 years old: 6 mg/kg IV QD. in divided doses (e.g. 2 mg/kg q8hrs). Age > 6 years old: 3 mg/kg IV QD in divided doses (1.5mg/kg q12hrs)"
45374349|NCT01041508|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) will be at 15 mg/kg, based on adjusted body weight, every 8 hours (45 mg/kg/day; max.3g/day) PO, or IV if indicated, from the evening of day 0 (i.e. first dose 4-6 hours following stem cell infusion) to day +40 post-transplant.
45374350|NCT00765869|Other|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
45374351|NCT00765869|Other|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
45374352|NCT00765869|Other|Australian Government Bowel Cancer Screening booklet|A consumer booklet developed by the Australian Government for people taking part in the National Bowel Cancer Screening program
45374353|NCT00766025|Drug|Rosuvastatin Calcium|single oral dose on days 1, 4, 5, 6, 10-16, 17
45374354|NCT01039012|Other|Tai Chi|Participants randomized to the Tai Chi group select a Tai Chi school from a pre-screened list of community-based Tai Chi programs and enroll for 9 months. Participants are asked to attend classes twice a week for the first month and once a week for the remaining 8 months. They are also asked to practice at home, or attend more classes for 2-3 additional hours per week. While in the study they are also encouraged to follow the standard care as recommended by their physician.
45374355|NCT01039012|Other|Standard Care|Participant follow the standard care recommended by their physician.
45374356|NCT02789228|Biological|Tumor associated antigen lymphocytes (TAA-CTL)|"This protocol is designed as a phase I dose-escalation study. In each treatment group (A and B), patients will be enrolled to one of the following TAA-T dose levels:~Dose Level One: 1 x 107 cells/m2 Dose Level Two: 2 x 107 cells/m2 Dose Level Three: 4 x 107 cells/m2"
45374357|NCT04049357|Device|Camera Capsule Endoscopy/ PillCam|Camera Capsule Endoscopy in screening
45846916|NCT02669784|Drug|Low Dose Contrast (Omnipaque) 40mL|The patient will be administered a low dose, 40mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
45374358|NCT02732834|Behavioral|Questionnaire|patients will fill out a questionnaire about their perceived stigma, satisfaction with communication, and psychological distress.
45374359|NCT02732834|Behavioral|Patient Interview|Then they will participate in a brief in-person interview about their perceived stigma during the clinical consultation
45374360|NCT02732834|Behavioral|Audio recordings of clinical consultations|
45374361|NCT02732834|Behavioral|Questionnaire|Patients will fill out a questionnaire about their perceived stigma and satisfaction with their clinician's communication.
45374362|NCT02732834|Behavioral|2-hour empathic communication skills training|2-hour empathic communication skills training
45374363|NCT02732834|Behavioral|Standardized Patient Assessments|pre-training SPA, post-training SPA
45374364|NCT02732834|Behavioral|Training evaluation|Clinicians will complete an evaluation assessing the empathic communication training module.
45374365|NCT02732834|Behavioral|Patient recruitment|6 of the clinician's patients (3 pre-training, 3 post-training) will be recruited to complete brief surveys assessing clinician communication
45596398|NCT05161871|Device|Sham cathodal transcranial direct current stimulation|Sham stimulation will be performed by the same protocol as active stimulation; however, the device will be switched off 30 seconds after the beginning of stimulation. This way, the patient will experience the same sensations as with active stimulation without receiving actual stimulation.
45596399|NCT02375607|Device|Algometer|Algometer performed patients
45374366|NCT00766103|Other|mild hypo- and hyperventilation|induction of mild hypo- and hypercarbia
45374367|NCT05577572|Dietary Supplement|Probiotics packets|The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1~10 and Probiotics packets is taken from day 1~56.
45374368|NCT05577572|Dietary Supplement|Placebo packets|The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1~10 and Placebo packets is taken from day 1~56.
45374369|NCT00760097|Device|Transcranial direct stimulation|sessions of 20 minutes each
45374370|NCT00766181|Behavioral|Zingo TM (lidocaine hydrochloride monohydrate) powder intradermal injection system|0.5 mg lidocaine hydrochloride
45596400|NCT03529747|Other|Online self-help|As detailed in experimental arm description.
45596401|NCT02369133|Drug|paracetamol|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol, patients in group S (n = 30) received 100 ml iv %0.9 NaCl
45374371|NCT05358002|Procedure|Frontalis flap|Fashonizing a flap from frontalis muscle and connecting it to the tarsus of the upper eyelid
46053850|NCT03158922|Other|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.
46053851|NCT03158922|Procedure|Prostate biopsy|Prostate biopsy will be offered to men identified within the top 10% genetic risk score profile.
45374372|NCT04048577|Drug|Dosing Interruption of Natalizumab|Planned 12 week dosing interruption of natalizumab
45374373|NCT00991250|Biological|SentoClone®|SentoClone® are autologous tumour-reactive lymphocytes which are expanded and infused to the patient, where they have the opportunity to seek out and attack the primary tumour and metastases. The first step is to identify the tumour draining lymph node(s), which is done in parallel to surgical resection of the primary tumour or metastasis. The sentinel and/or metinel node(s), the initial meeting place between tumour antigen and the immune system, are further dissected and collected during the surgery. The lymphocytes are extracted from the collected lymph nodes and expanded in vitro, the lymphocytes are thereafter stimulated with tumour extract and returned to the patient intravenously as an autologous cell transfusion. The administered volume will be 100 ml for cell densities less than 3x106 cells/ml and 200 ml for cell densities of 3x106 cells/ml or more.
45596402|NCT02369133|Drug|Placebo|
46053852|NCT03153280|Drug|Lithium|Dose escalation of Lithium to determine the maximum tolerated dose (MTD)
46053853|NCT03153280|Drug|Oxaliplatin|Dose as used in standard of care - 130 mg/m2.
46053854|NCT03153280|Drug|Capecitabine|Dose as used in standard of care - 800 - 1000 mg/m2
46053855|NCT03136562|Diagnostic Test|Synacthen test|250 microg synacthen test performed fasting, in the morning. P-cortisol measured before and 30 minutes after Synacthen injection.
46053856|NCT03112369|Behavioral|Narrative Exposure Therapy (NET)|An international evidence-based program (EBP) for PTSD based on exposure therapy, an oral tradition of story-telling, and use of tactile medium of natural elements.
45374374|NCT00991250|Drug|Temodal® or Dacarbazine Medac®|"Dacarbazine (5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide) is a widely used systemic treatment against advanced malignant melanoma. Dacarbazine is a cytostatic agent, which inhibits tumour growth by interfering with DNA-synthesises. The DNA-synthesis is inhibited by alkylation of the DNA molecule; however, it is unclear whether dacarbazine has other cytostatic impacts on cell mechanisms. Dacarbazine is inactive until liver passage, the liver converts dacarbazine to its reactive metabolites MTIC and HMMTIC, which alkylate DNA. Dacarbazine is light sensitive and needs to be administered intravenously.~A newer analogue to dacarbazine, temozolomide (Temodal®), has been developed for oral administration. Temodal® is administered in capsules and is rapidly absorbed reaching peak concentrations after 20 minutes. Temodal® is converted to MTIC at physiological pH, the same reactive molecule as dacarbazine is metabolized to in the liver."
45374375|NCT00762047|Device|Durasphere FI|Durasphere Injection
45374376|NCT00762047|Device|Sham|Sham injection with anesthesia
45596403|NCT02195609|Dietary Supplement|Omega-3|600 mg oral twice a day
45596404|NCT02195609|Dietary Supplement|Soy Isoflavones|54.4 mg oral twice a day
45596405|NCT02377635|Dietary Supplement|Anhydrous selenite|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
46053857|NCT03112369|Behavioral|Motivational Interviewing w/Skills Training (MIST)|Motivational interviewing (MI) coupled with skills training is based on enhancing motivation to change and building skills to address substance use behaviors.
46053858|NCT03098836|Drug|ARN-509|240 mg orally daily
46053859|NCT03098836|Drug|Abiraterone Acetate|1000 mg orally daily
46053860|NCT03098836|Drug|Prednisone|5 mg orally twice daily (for total daily dose 10 mg)
45596406|NCT02377635|Dietary Supplement|Sodium chloride|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
46053861|NCT03096509|Other|MISSION ABC Integrated Care clinic|The Investigators have developed a model of care incorporating key innovations for patients with asthma, COPD and undifferentiated breathlessness. This service is being implemented within Wessex CCGs.
46053862|NCT03078855|Dietary Supplement|Vitamin D|vitamin D3 2,000 IU daily
46053863|NCT03078855|Biological|Rituximab|Administered weekly x 4
46053864|NCT03078855|Other|Placebo|methylcellulose
46053865|NCT03066349|Other|Questionnaires|FertiQoL and HADS (Hospital Anxiety and Depression Scale) questionnaires
45491137|NCT03664154|Behavioral|Stress and Feeding (SAFE)|"The Stress Management component of the intervention acknowledges the mind-body connection between stress and adverse outcomes and consists of four web-based modules based on Lazarus and Folkman's Transactional Model of Stress and Coping designed to improve health outcomes.~The Guided Feeding component of the intervention is based on the synactive theory of development. The synactive theory of development provides insight in to reading the physiological and behavioral cues of infants born preterm and involves weekly viewing of video clips of adaptive and maladaptive feeding behaviors of mothers and infants, practice opportunities, and follow-up phone calls."
45491138|NCT03664700|Device|LMA Protector|The LMA Protector will be inserted when a supraglottic device is needed
45491139|NCT03550313|Biological|Multivalent|Pneumococcal conjugate vaccine
45491140|NCT03550313|Biological|Prevnar 13|Pneumococcal conjugate vaccine
45491141|NCT03312907|Drug|Belimumab|Belimumab will be administered as SC injection once weekly via autoinjector in thigh or abdomen
45491142|NCT03312907|Drug|Rituximab|Rituximab will be administered as IV infusion of 1000mg at Week 4 and Week 6
45491143|NCT03312907|Drug|Rituximab-placebo|Saline will be administered as IV infusions at Week 4 and Week 6
45491144|NCT03312907|Drug|Standard therapy (Including Immunosuppressants)|Standard therapy will contain stable SLE medications including immunosuppressant to be administered from baseline through Week 104.
45491145|NCT03312907|Drug|Standard therapy (Excluding Immunosuppressants)|Standard therapy excluding Immunosuppressant will contain anti-malarials, NSAIDs, and/or corticosteroids with prednisone dose equivalent to <= 5 mg/day will administered through Week 104.
45491146|NCT03312907|Drug|Steroid Taper|Steroid taper will include prednisone doses equivalent to =< 5 mg/day in all Arms through Week 104.
45374377|NCT00418522|Drug|Insulin glargine|Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
45374378|NCT00418522|Drug|Inhaled Insulin (Exubera)|Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
45374379|NCT00991328|Procedure|SctO2 < 60 %.|The following intervention protocol will be applied when SctO2 level falls below 60 %. First, the patients head position will be checked for suitable position and the face will be observed for plethora. Then the efforts will be made to maintain PaCO2 between 40-50 mmHg and MAP of 60 - 80 mm Hg. Cardiac index will be maintained between 2.0 - 2.5 L/min/m2. The hematocrit should be more than 20 %. The red blood cells or hemoconcentration will be used for this purpose.
45374380|NCT00762125|Behavioral|CR+ST|Addresses maladaptive beliefs in general and includes education and training in the use of specific coping strategies
45374381|NCT00762125|Behavioral|ET|Addresses beliefs and emotional arousal during confrontations with feared element (exercising) through use of counter-conditioning and corrective feedback
45491147|NCT02999672|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered as Regimen A (2.4 mg/kg qw via IV infusion) or Regimen B (3.6 mg/kg q3w via IV infusion) until unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.
45491148|NCT03664076|Diagnostic Test|COMISS score|cow's milk protein symptoms score awareness tool to select cow's milk protein allergy in infants
45491149|NCT03664622|Drug|Ketamine|Ketamine group to whom intravenous ketamine was administered in a loading dose of 0.15 mg/kg over 5 min, 10 minutes pre incision, followed-by an infusion at 2 micg/kg/min until the end of surgery.
45491150|NCT03664622|Drug|Morphine|a loading dose of 0.1 mg/kg over 20 min intravenously, 10 minutes pre incision, then infused with morphine an infusion rate of 5 - 40 microgram/kg/hour till the end of surgery.
45491151|NCT05276869|Other|WeeFIM instrument|In a formative setting, the WeeFIM tool examines functional independence in kids aged 6 months to 7 years old. It can also be used with children over the age of 7 who show functional ability. The instrument may be controlled by observational data or a meeting, and it takes 15 to 20 minutes to create [10].
45491152|NCT01911676|Drug|PF-03463275|
45491153|NCT01911676|Drug|Placebo|
45596407|NCT03534479|Drug|Polyclonal IgG|Measurement of vascular reactivity before and after Infusion of plyclonal Immunoglobulins G in patients with Common variable immunodeficiency
45596408|NCT00162253|Drug|BMS 587101|
45846917|NCT02669784|Drug|Low Dose Contrast (Omnipaque) 50 mL|The patient will be administered a low dose, 50mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
45374382|NCT00762125|Behavioral|AC treatment|Provides support and controls for nonspecific factors associated with exposure to therapists and other FMS sufferers, but does not directly address either maladaptive beliefs or emotional arousal
45374383|NCT00762281|Device|MEL 80 Hyperopic LASIK Treatment|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
45374384|NCT02719106|Device|Ultimaster stent|
45374385|NCT00760175|Biological|Vaxigrip (Aventis-Pasteur Canada)|The intramuscular dose (0.5 mL contains 15 micrograms antigen from each strain and the intradermal doses (2 x 0.1 mL)contain 6 micrograms antigen from each strain.
45374386|NCT02703662|Device|Strattice biologic mesh|Patients randomized to this group will be inserted one or more Strattice biologic meshes during the abdominal wall reconstruction surgical procedure.
45374387|NCT02703662|Device|Permacol biologic mesh|Patients randomized to this group will be inserted one or more Permacol biologic meshes during the abdominal wall reconstruction surgical procedure.
45374388|NCT00762437|Device|Zeltiq Dermal Cooling Device|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
45374389|NCT02557763|Device|Oxford unicompartmental knee arthroplasty|The patients with medial osteoarthritis knee with patellofemoral arthritis were performed surgery and applied Oxford unicompartmental knee arthroplasty.
45374390|NCT05394818|Drug|SHR-A2009|The total dosage of SHR-A2009 was calculated according to the weight weighing results of the subjects before each administration, and was administered by intravenous drip.
45491154|NCT03663998|Biological|CN54ENV DNA|"CN54ENV DNA concentration 4 ± 0.7 mg/mL is formulated in 1 x PBS~All administrations of CN54ENV will be by in vivo electroporation using the Ichor Medical Systems TriGrid Delivery System for intramuscular (TDS-IM) or intradermal use (TDS-ID) and will be delivered into the upper thigh(s)."
45491155|NCT03663998|Biological|GENEVAX® IL-12 DNA|"GENEVAX® IL-12 DNA, concentration 2 mg/mL with a fill volume of 1.0 mL (1.0 ± 0.1mL), is formulated in 30 mM citrate buffer.~GENEVAX® IL-12 DNA is mixed with the CN54ENV DNA immediately prior to administration."
45491156|NCT01793233|Other|Laboratory Biomarker Analysis|Correlative studies
45491157|NCT01793233|Other|Questionnaire Administration|Ancillary studies
45491158|NCT03113734|Other|Construction and validation of a functional score|"All patients will be treated at the same way:~Completion of questionnaire by the physician with him. Once the consultation has been completed, the physician will issue prescriptions for the usual medical treatment, laximetry prescription (GNRB) to be performed when the knee is indolent and the prescription of the MRI to be performed .The physician will inform the patient that they should consult with the investigator's orthopedic surgeon once the results of GNRB and MRI are available.The study will end there for the patient. The surgeon will then follow his usual diagnostic procedure to decide on the future care of the patient."
45491159|NCT04051658|Device|Transcranial direct current stimulation|tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
45491160|NCT04316182|Drug|Cabozantinib|Cabozantinib 60 mg/day. Cabozantinib dose will be modified upon development of adverse events.
45491161|NCT04505540|Other|Bridge Clinic|Specialized addiction bridge clinic
45491162|NCT04505540|Other|Local Waivered Physician|Direct referral to local waivered physician
45596409|NCT02377557|Drug|Topical Steroids|
45596410|NCT02195765|Drug|enamel matrix derivative|Open flap debridement associated with enamel matrix derivative
45596411|NCT02195765|Procedure|Open flap debridement|Open flap debridement
45846918|NCT02671032|Device|Nucleus CI532 cochlear implant|
45374391|NCT00766337|Drug|Sirolimus in combination with ranibizumab|Combination therapy of 440 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
45374392|NCT00766337|Drug|Sirolimus in combination with ranibizumab|Combination therapy of 1320 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
45374393|NCT00766337|Drug|Placebo in combination with ranibizumab|Combination therapy of placebo injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
45374394|NCT02495090|Genetic|Exome sequencing|Plain DNA sequencing
45374395|NCT05381792|Diagnostic Test|Bacterial gene markers test|Bacterial gene markers test using qPCR
45374396|NCT01564004|Other|Clinical hypnosis or neuro-linguistic programming|20 minutes tape recording intervention
45374397|NCT00762593|Device|transvaginal placebo device|Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
45374398|NCT00762593|Device|transvaginal electrical stimulation device|Use of a transvaginal electrical stimulation home use programmable device used 30 minutes every day during 8 weeks
45374399|NCT00991562|Drug|IMGN901|dose escalation study. dosing on days 1, 8 and 15 every 28 days
45374400|NCT00762671|Drug|Ebselen|150 mg BID for 2 weeks
45596412|NCT02368977|Device|Third Eye Panoramic device|A Third Eye Panoramic device will be attached to the tip of the colonoscope and will provide two additional views from laterally-oriented video cameras during the colonoscopy procedure.
45491163|NCT04054778|Behavioral|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
45491164|NCT04054778|Behavioral|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
45374401|NCT00762671|Drug|Placebo|Placebo 1 po BID for 2 weeks
45374402|NCT05306483|Procedure|Ventricular septal defect closure surgery|Ventricular septal defect closure surgery
45491165|NCT05276713|Drug|Tucidinostat|Tucidinostat in combination with endocrine drugs
45491166|NCT05276635|Behavioral|The Sleep Hygiene Education (SHE)|Patients were randomized into two equal groups of 30 participants each. One group received a Sleep Hygiene Education (SHE) intervention
45491167|NCT05276635|Behavioral|Emotional Freedom Techniques (EFT)|30 participants had a form of Emotional Freedom Techniques (EFT) adapted for use with insomnia (EFT-I).
45491168|NCT04056182|Drug|Lofexidine 0.18 MG|Lofexidine prescribed as three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals for 2-10 days for the management of opioid withdrawal symptoms prior to receiving Vivitrol.
45491169|NCT03573323|Drug|Ixekizumab|Administered SC
45491170|NCT03573323|Drug|Guselkumab|Administered SC
45491171|NCT03573323|Drug|Placebo|Administered SC
46053866|NCT03055923|Device|The Inflammacheck Device|A new hand-held, Non-invasive breathing test, that only requires tidal breathing.
45491172|NCT01895842|Drug|Ruxolitinib|"Starting dose level for Part 1: 5 mg by mouth twice a day for a 28 day cycle.~Starting dose level for Part 2: Maximum tolerated dose from Part 1."
45491173|NCT04058054|Device|KeraStat® Cream|Administered 0.025 gm of KeraStat Cream per subject on day 1 of the study.
45491174|NCT04058054|Device|KeraStat Gel|Administered 0.025 gm of KeraStat Gel per subject on day 1 of the study.
45491175|NCT04058054|Device|Biafine|Administered 0.025 gm of Biafine per subject on day 1 of the study.
46053867|NCT03039309|Procedure|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection is an endoscopic resection technique that utilises an endoscopic knife to remove lesions within the gastrointestinal tract in an en bloc fashion.
45491176|NCT04058054|Drug|Histamine|Administered 1 drop of Histamine Dihydrocl (6 mg/mL) per subject on day 1 of the study.
45491177|NCT04058054|Drug|Saline (0.9% NaCl)|Administered 1 drop of saline per subject on day 1 of the study.
45491178|NCT03306043|Drug|Mepolizumab|Mepolizumab will be available as 100 mg vial for injection. Subjects will receive three 100 mg SC injections for every 4 Weeks for a total of 5 doses during 20 Week treatment period.
45491179|NCT01728220|Combination Product|Inhaled NO delivered via INOpulse DS-C Device|Subjects will be treated with nitric oxide by means of an INOpulse DS-C device using an INOpulse nasal cannula.
45846919|NCT02672514|Device|Minimally invasive extracorporeal circulation (MiECC)|Minimally invasive extracorporeal circulation (MiECC) is an extracorporeal circulation systems used for cardiopulmonary bypass.
46053868|NCT03007979|Drug|Palbociclib|Palbociclib at a dose of 125 mg should be taken by mouth with food on a 5 days on/2 days off schedule
46053869|NCT03007979|Drug|Letrozole|Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle, at a dose of 2.5 mg.
46053870|NCT03007979|Drug|Fulvestrant|Patients who are receiving fulvestrant will receive it at a dose of 500 mg as two 5 mL intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
45374403|NCT05306483|Procedure|Ventricular septal defect closure catheter|Catheter closure of VSD
45374404|NCT02558387|Drug|BIBF1120|Nintedanib will be given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
45491180|NCT01728220|Combination Product|Placebo delivered via INOpulse DS-C Device|Subjects will be treated with nitrogen gas by means of an INOpulse DS-C device using an INOpulse nasal cannula.
45491181|NCT04057430|Device|GumChucks|GumChucks® is an innovative flossing system resembling mini nunchucks. The two-handle design eliminates the need to wrap the floss around fingers, and a proper flossing technique is facilitated by the nature of its curved shaped.
45491182|NCT04057430|Device|String floss|Traditional string floss used in this study was Oral-B Glide® Pro-Health Original Floss
45491183|NCT04498286|Diagnostic Test|Testing of SARS-CoV-2 antibodies|Sars-CoV-2 RBD total antibody test developed by Sanquin
45491184|NCT01313533|Drug|Polyarginine|Vein soak treated with polyarginine
45491185|NCT01313533|Drug|Vein soak treated with Lactated Ringers Solution|Vein soak
46053871|NCT03007979|Procedure|Optional research biopsy|Patients may consent to paired tumor biopsies at baseline and time of progression.
45491186|NCT05676736|Other|No intervention|No intervention to be done for the group
45491187|NCT03663842|Other|Physical therapy treatment|All patients underwent the same techniques, and there was no modification of the intervention protocol during the study: (1) Myofascial release technique - piriformis muscle and biceps femoral muscle; (2) Hip joint mobilization; (3) Cross-fiber friction over the sacroiliac joints; (4) Neural mobilization to improve sciatic nerve excursion.
45491188|NCT03725189|Device|PPG during exercise|PPG use for pulse waveform evaluation of healthy exercise group
45491189|NCT04479904|Drug|Famitinib|po
45491190|NCT03725111|Device|venous compression|venous compression
45491191|NCT01069172|Device|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery to perform capsulotomy, lens segmentation, and lens softening, which are all part of cataract surgery when this femtosecond laser is used.
45491192|NCT01069172|Procedure|CCC Surgery|Subjects will receive the standard of care for CCC and U/S cataract surgery to facilitate removal of the crystalline lens. CCC is a procedure that is part of cataract surgery.
45491193|NCT04245280|Drug|Ropivacaine 0.5% Injectable Solution|ropivacaine 0.5% with epinephrine 2.5 mcg/ml
45491194|NCT04245280|Drug|Saline Solution|normal saline solution (NaCl 0.9%)
45491195|NCT03724955|Drug|Estradiol 2 mg|Participants in this arm will receive Estradiol 2 mg oral daily for 6 months
45491196|NCT03724955|Other|Placebo|The placebo group will receive placebo oral daily for 6 months
45491197|NCT04220008|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
45491198|NCT04220008|Drug|Busulfan|Given IV
45491199|NCT04220008|Drug|Clofarabine|Given IV
45491200|NCT04220008|Drug|Cyclophosphamide|Given IV
45491201|NCT04220008|Drug|Gemcitabine|Given IV
45491202|NCT04220008|Drug|Mycophenolate Mofetil|Given IV
45491203|NCT04220008|Biological|Rituximab|Given IV
45491204|NCT04220008|Drug|Tacrolimus|Given IV
45491205|NCT04220008|Drug|Vorinostat|Given PO
45491206|NCT03721991|Dietary Supplement|Gama amino butyric acid (GABA)|food supplement Gama amino butyric acid (GABA) as capsules
45491207|NCT03721991|Dietary Supplement|placebo|matching placebo
45491208|NCT02911688|Drug|gamma tocopherol|The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after γT dosing.
45491209|NCT02911688|Drug|Placebo|The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after placebo dosing.
45491210|NCT05580250|Drug|LY3526318|Administered orally.
45491211|NCT05580250|Drug|Placebo|Administered orally.
45491212|NCT05580250|Drug|Iohexol|Administered intravenously (IV).
46053872|NCT03007979|Drug|Goserelin|Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- and peri-menopausal women only.
46053873|NCT03007979|Procedure|Research blood draw|"-Blood will be drawn at the following time points for serum, plasma, cfDNA, and germline DNA (only at baseline):~Baseline~C1D15~C2D1~Every 2-3 months thereafter (to coincide with imaging studies)~Time of progression"
46053874|NCT03007979|Procedure|Circulating tumor cell blood draw|-Baseline, cycle 2 day 1, post 2 or 3 months of therapy (to coincide with first tumor imaging), and progression
46053875|NCT03007979|Procedure|Tumor biopsy (optional)|-Baseline and progression
45491213|NCT05580250|Drug|Simvastatin|Administered orally.
45491214|NCT05580250|Drug|Metformin|Administered orally.
45491215|NCT03663374|Drug|Odelepan|Tablets, 125 mg
45491216|NCT03663374|Drug|Placebo|Contains the same excipients as Odelepran but it does not contain the active agent. Placebo is identical to Odelepran in terms of drug form and external characteristics (colour, smell, etc). Doses and route of administration are identical to those for Odelepran.
45491217|NCT03431948|Drug|Nivolumab|Nivolumab 240 mg given by intravenous infusion every 2 weeks
45491218|NCT03431948|Drug|Cabiralizumab|Cabiralizumab 4 mg/kg given by intravenous infusion every 2 weeks
45491219|NCT03431948|Drug|Urelumab|Urelumab 8 mg given by intravenous infusion every 4 weeks
45491220|NCT03431948|Radiation|Stereotactic Body Radiation Therapy|Radiation to metastatic lesion(s) given at assigned dose levels based on lesion location and dose level being tested at time of enrollment. Doses range from 30 - 50 Gy.
45491221|NCT02670928|Behavioral|Lifestyle intervention|Patients of active group were assigned to receive activities of the program for life style changes. Patients in control group were managed in frames of routine clinical practice. No any investigational drug therapy was used.
45491222|NCT03662516|Drug|PF-04965842|Orally bioavailable small molecule that selectively inhibits JAK 1 by blocking the adenosine triphosphate (ATP) binding site.
45491223|NCT03662516|Drug|Ethinyl estradiol (EE) and levonorgestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
45491224|NCT04978168|Behavioral|Core Intervention|Staff are provided with a core set of implementation strategies to facilitate interorganizational linkages between probation agencies and local community treatment providers.
45491225|NCT04978168|Behavioral|Peer Support Specialists (PSS)|Participants randomized to PSS will meet with a PSS for 12 months. Contact scheduled is flexible and based on the participant's needs and wants, plus written guidance for PSS-participant interactions.
45491226|NCT04978168|Behavioral|Treatment as Usual (TAU)|Participants randomized to TAU will receive the services that will be offered at the time the Core Implementation intervention is completed.
45491227|NCT04057508|Other|Modulation of muscle sympathetic nerve activity|Assessment of muscle sympathetic nerve signal and exposition to external non invasive modulation.
45491228|NCT04887077|Device|Kiplin|"The Kiplin intervention will be composed of four components within a smartphone application: a) a gamification of Physical Activity through multiple games called animations, b) a remote adapted physical activity program with telecoaching sessions, c) an interface for exchange and conversation and, d) an activity monitoring tool."
45491229|NCT04887077|Behavioral|face-to-face|three-month program of face-to-face adapted physical activity, three sessions a week, for a total of 36 sessions.
45491230|NCT04144738|Diagnostic Test|mt-sDNA 2.0 screening test|Stool samples will be collected by the subject for the mt-sDNA screening test.
45491231|NCT04144738|Diagnostic Test|FIT test|Stool samples will be collected by the subject for the FIT test.
45491232|NCT04144738|Procedure|Colonoscopy|Subjects will undergo a screening colonoscopy.
45491233|NCT03663062|Diagnostic Test|Colonoscopy|All patients would undergo colonoscopy as part of standard care. Patients recruited for this study would have their past medical history, family history, medication history, as well as waist circumference, BMI and blood pressure recorded. All patients would also have blood tests (described earlier) and a subset will undergo Fibroscan.
45491234|NCT03728543|Drug|Sugammadex|"Introductory anesthesia: sevoflurane up to 8 rev /% + Air + O2 or propofol 1% 2 mg / kg intravenously.~Maintenance: sevoflurane up to 3 rev /% + Air + O2, introduction of rocuronium bromide in a dose of 0.4 mg / kg, intravenously, as a bolus injection.~At the end of anesthesia: sugammadex in a dose of 2 mg / kg, intravenously, as a bolus injection"
45491235|NCT03728465|Biological|Nivolumab|In the induction phase of this study nivolumab is administered as a IV infusion in combination with ipilimumab at a dose of 1 mg/kg for 4 cycles at three weeks interval and in a maintenance phase alone at a dose of 3 mg/kg every two weeks.
45491236|NCT03728465|Biological|Ipilimumab|In the induction phase of this study ipilimumab is administered as a IV infusion in combination with nivolumab at a dose of 3 mg/kg for 4 cycles at three weeks interval.
45491237|NCT03728387|Other|Clinical Pilates Exercise|All evaluations of the individuals included in the study will be done by the physiotherapist.. For the second evaluation the same individuals will be visited by the same physiotherapist at least 7 days after the first evaluation and only the FAB-T scale will be applied. 34 volunteer individuals who will be randomly choosen among 84 individuals will be given a 6-week exercise training program. According to this 6 week program, individuals will be admitted to the exercise training program for 45-60 minutes with a physiotherapist for 3 days in a week. The exercise program will consist of a warm-up, a strength training and a cool-down section. Various exercise methods (clinical pilates exercises) and tools will be utilized to improve balance and mobility. Third assessment of FAB-T will be applied only to individuals participating in the 6-week exercise training program.
45491238|NCT03662984|Drug|Ciprofibrate 100Mg Tablet|Ciprofibrate is a PPARα ligand and is considered to be a major regulator of the lipid metabolism. PPARα regulates the genes involved in mitochondrial function and fat metabolism and is therefore abundantly expressed in tissues that require high rates of FFA oxidation, like for instance in the heart and activation of PPARα in the heart may have beneficial effects on mitochondrial function and fat oxidative capacity.
45491239|NCT03662984|Drug|Placebo Oral Tablet|To compare ciprofibrate
45491240|NCT03724799|Device|Intravascular laser irradiation of blood for the patients with cerebral infarction|Intravenous low level therapy has been a variety of applications in many different areas of medicine with a growing interest. It possesses laser specific biomodulation, analgesic, spasmolytic and even sedative effects among many other.
45374405|NCT00766805|Drug|EVL + Propranolol + Isosorbide 5 mononitrate|Treatment was started with propranolol at a dose of 40 mg twice a day. The heart rate and blood pressure were checked after 12 to 24 hours. The dose of propranolol was increased at increments of 20 to 40 mg per day until the patient achieved a heart rate of 55 bpm, or a maximum dose of 320 mg/day was achieved.ISMN was added at a dose of 10 mg twice a day. The dose was escalated at increments of 10-20 mg/day till a maximum dose of 40 mg/day was reached.
45491241|NCT01592968|Other|Cognitive Assessment|Ancillary studies
45491242|NCT01592968|Other|Quality-of-Life Assessment|Ancillary studies
45491243|NCT01592968|Radiation|Stereotactic Radiosurgery|Undergo SRS
45753813|NCT04192058|Device|Active transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) it is a therapeutic method that modulates membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it. The position of the electrodes will be performed based on a 10-20 system according to the international EEG unit system, with the location of the electrodes at C3 and F3, respectively. The anode will be positioned over the left hemisphere at C3 while the cathode will be positioned over the contralateral hemisphere F3. During active stimulation a 2.0mA current released by a 35 cm2 electrode will be used for 20 min.
45374406|NCT00766805|Other|EVL alone|
45374407|NCT00766883|Behavioral|Problem Solving Education|
45374408|NCT00766961|Procedure|Trans-catheter arterial embolization|Trans-catheter arterial embolization
45374409|NCT00766961|Procedure|Surgery|Surgery
45374410|NCT00762749|Drug|diphenhydramine HCl|A single liquid dose of diphenhydramine HCl (12.5 mg /5 mL) followed by water, according to an age-weight dosing schedule
45491244|NCT01592968|Radiation|Whole-Brain Radiotherapy|Undergo WBRT
45491245|NCT03728231|Other|Complete blood count|taking blood sample from venous blood
45491246|NCT03724721|Procedure|vacuum bottle|using vacuum bottle plus catheter for drainage of pneumothorax
45491247|NCT03721835|Device|CONQUEST FN Femoral Neck Fracture System|Fracture fixation device consisting of a single plate and three screws
45491248|NCT03305809|Drug|LY3154207|Administered orally.
45693055|NCT03805828|Other|Educational program on parenting stress and coping mechanism|The educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism. The contents of the educational program deliver through the use of PowerPoint slides, Whiteboard and marker, practical exercise, video clips followed by group discussion and provision a hard copy booklet containing all items which were supposed to discuss. As well as each session will approximately be taken one hour. Each group will consist of 10 participants.
45693056|NCT00754468|Device|Cryo Spray Ablation|Cryo Spray Ablation 4 cycles x 10 seconds treatment
45374411|NCT00403546|Drug|Ziprasidone 80-160 mg/d|Participants will be instructed to take one study capsule of ziprasidone orally twice daily (80 mg/d). After the first week, the study drug will be increased to two capsules twice daily (160 mg/d).
45374412|NCT00403546|Drug|Placebo|Participants will be instructed to take one study capsule of matching placebo orally twice daily. After the first week, the matching placebo will be increased to two capsules twice daily.
45374413|NCT00403546|Drug|Ziprasidone 160 mg/d|Participants will be taking open-label ziprasidone 80 mg orally twice daily for a total dose of 160 mg/d from at least 3 weeks before randomization to end of study 8 weeks after randomization.
45374414|NCT00767117|Drug|Etravirine; Lopinavir; Ritonavir|
45374415|NCT02558621|Device|AQrate Robotic Assistance System|Robotic guidance during spinal fusion surgery
45374416|NCT00760565|Drug|RO4905417|3mg/kg iv every 28 days for 3 infusions
45491249|NCT03305809|Drug|Placebo|Administered orally.
45491250|NCT02994056|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
45491251|NCT02994056|Drug|RBV|Tablets administered orally at 600 mg, if well tolerated then up to a maximum total daily dose of 1000 to 1200 mg (based on weight) divided twice daily.
45491252|NCT01492036|Other|Blood Tests|If participant received retroviral gene therapy, blood test performed to check for a type of infection called the replication-competent retrovirus (RCR). Blood (up to 4 tablespoons each time) drawn every 3 months for first year after gene transfer therapy and once a year after that.
45491253|NCT01492036|Behavioral|Questionnaires|"Once a year during Years 1-5, questionnaire completions that asks about medical history (general health, the status of any medical conditions, and any illnesses or hospitalizations that may have occurred). It should take about 15-30 minutes to complete.~Once a year during Years 6-15, completion of mailed questionnaire. Participant will be asked about medical history (including if participant has had any children since the infusion) and whether there have been any changes in contact information. The questionnaires should take about 15-30 minutes each time."
45491254|NCT03728153|Drug|Fluoxetine 20 MG Oral Tablet|Once-daily dosing for 90 days
45491255|NCT04934488|Behavioral|Online Peer-Delivered 1-Day CBT-Based Workshop|It is a day-long intervention delivered in 4 modules. Each participant is given a professionally designed manual to facilitate learning. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays.
45491256|NCT04056806|Drug|Terlipressin 1Mg Powder for Conventional Release Solution for Injection Vial|efficacy comparison between 2 days and 5 days
45491257|NCT03724643|Other|Protocolized wean|Respiratory therapist determined extubation readiness based on: patent and protected airway; adequate secretion clearance; suction requirement ≤ every 2 hours; FiO2 < 50% and PEEP = 5; and hemodynamic stability without circulatory support. The SBT included CPAP = 5 mmHg at FiO2 ≤ 0.4. Patients were assessed after 3-minutes for appropriateness to continue (SaO2 ≥ 92%; no arrhythmia; RSBI < 105 breaths/min/L). Respiratory distress signs included RR > 30 breaths/min, SaO2< 90%, HR > 140 beats/min, or a sustained change in HR of >20%, systolic BP >200 mmHg or <80 mmHg, or agitation, anxiety, or diaphoresis without other cause. The SBT lasted 120 min in accordance with prior studies. Upon SBT completion, the RSBI was re-measured and an ABG was obtained.
45491258|NCT04056884|Behavioral|SIBS intervention|SIBS is a manual-based group intervention for siblings and parents of children with chronic illness
45491259|NCT04057118|Drug|SKI-O-703|Oral administration, twice per day
45491260|NCT04057118|Drug|Placebo|Oral administration, twice per day
45491261|NCT03548051|Procedure|Fecal Microbiota Transplantation (FMT)|100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema
45491262|NCT03548051|Drug|Saline|250 ml of saline delivered by retention enema
45491263|NCT03728075|Device|Neuromuscular electrical stimulation (NMES)|NMES was placed on the quadriceps muscle of both legs
45491264|NCT03305731|Behavioral|Activating Behavior for Lasting Engagement|Activating Behavior for Lasting Engagement (ABLE) is a behavioral intervention in which participants learn skills to schedule, self-monitor, and problem solve strategies to overcome barriers to engagement in meaningful daily life activities.
45693057|NCT00754468|Device|Cryo Spray Ablation|Cryo Spray Ablation 2 cycles x 20 seconds
45693058|NCT00754546|Drug|Arformoterol tartrate|15 mcg in two ml solution administered via nebulizer
45693059|NCT00754546|Drug|Placebo: Normal Saline|Normal saline was nebulized.
45693060|NCT00754546|Other|Treadmill Exercise|
45693061|NCT00754546|Other|Cycle Exercise|
45693062|NCT03806140|Behavioral|text messages|receive about one health-related text message a day for 16 weeks
45693063|NCT01764841|Drug|Ciprofloxacin DPI (BAYQ3939)|Participants received 32.5 mg ciprofloxacin hydrated (corresponding to 50 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
45693064|NCT01764841|Drug|Placebo|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
45693065|NCT03806842|Device|Easytech group|total shoulder replacement
45693066|NCT00245050|Dietary Supplement|pyridoxine hydrochloride|Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine twice 100 mg daily on days 1-28.
45374417|NCT00760565|Drug|RO4905417|20mg/kg iv every 28 days for 3 infusions
45693067|NCT00245050|Drug|Placebo|Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.
45374418|NCT00760565|Drug|RO4905417|7mg/kg iv every 28 days for 3 infusions
45374419|NCT00760565|Drug|placebo|3mg/kg iv every 28 days for 3 infusions
45374420|NCT00760565|Drug|placebo|7mg/kg iv every 28 days for 3 infusions
45693068|NCT00245050|Drug|doxorubicin HCL liposome|IV, 40mg/m2
45693069|NCT04345588|Drug|Dexamethasone injection|we use injection lignocaine 10 mL, injection bupivacaine 0.5% 20 mL, 5 mL normal saline (NS). In group , injection dexamethasone 0.05 mg/kg will be added to the solution along with IV NS 1cc while the other group will receive 0.05 mg/kg injection dexamethasone intravenously.
45693070|NCT00778648|Dietary Supplement|Juice Plus|"Juice Plus+® is a dietary supplement from concentrated fruits (apple, orange, pineapple,cranberry, cherry (acerola), papaya and peach) and vegetables (carrot, parsley, beet, broccoli, kale, cabbage, spinach, and tomato).~Subjects will take four capsules of Juice Plus+® daily."
45693071|NCT00778648|Dietary Supplement|Placebo|Four capsules of placebo daily.
45693072|NCT03806374|Drug|Ketamine|ketamine
45693073|NCT03806374|Drug|Propofol|propofol
45693074|NCT03806374|Drug|Fentanyl|fentanyl
45693075|NCT03806374|Drug|Cisatracurium|cisatracurium
45374421|NCT00760565|Drug|placebo|20mg/kg iv every 28 days for 3 infusions
45374422|NCT00403390|Drug|Brand Name Levothyroxine (Synthroid)|Randomized crossover study using 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott), then 8 weeks of the generic formulation of levothyroxine (manufactured by Sandoz). The dose of medication does not change throughout the duration of the study.
45374423|NCT00403390|Drug|Generic formulation of Levothyroxine|Randomized crossover study using 8 weeks of the generic formulation of levothyroxine (manufactured by Abbott, then 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott). The dose of medication does not change throughout the duration of the study.
45374424|NCT00767273|Procedure|PET Scan|
45374425|NCT00767273|Drug|FLT|
45374426|NCT00767273|Drug|FDG|
45374427|NCT00762905|Device|LiquiBand Laparoscopic|LiquiBand Laparoscopic™ is a sterile, liquid adhesive made up of a blend of n-butyl and 2-octyl cyanoacrylate intended for soft tissue approximation of skin wounds. It is packaged in a sterile, single-use, nylon applicator with internal glass ampoule containing 0.8g of adhesive and sealed in a PETG/Tyvek blister pack. LiquiBand Laparoscopic™ is intended to be applied topically to pre-apposed wound edges. The tissue adhesive sets rapidly (5 - 10 seconds) to hold the wound closed. Following wound closure the product is designed to apply a broad coverage of adhesive to act as a liquid dressing to protect the wound.
45693076|NCT03806374|Drug|Lidocaine|lidocaine
45491265|NCT03305575|Drug|Chloroprocaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
45491266|NCT03305575|Drug|Bupivacaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
45491267|NCT04916782|Other|Quality of life Questionnaire|Quality of life questionnaire
45491268|NCT00496522|Procedure|Proton Beam Therapy|A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
45491269|NCT02993822|Drug|Orvepitant Maleate|Tablet, once daily, oral
45491270|NCT02993822|Drug|Placebo|Tablet, once daily, oral
45491271|NCT04846972|Behavioral|FASTRACS intervention|"Intervention (4 steps) :~Penultimate to last chemotherapy : patient will receive tools of the intervention~1 month after the end of oncological treatment (OT): patient will attend a general medicine consultation with the GP RTW checklist~2 months after OT: patient will attend a pre RTW visit with the OP RTW checklist~5 months after the end of OT: if the patient has not returned to work 10 months after inclusion, they will have a visit with an OP-RTW to work coordinator~Self-questionnaires will evaluate quality of life (EORTC QLQC30, BR23, Euroqol (EQ-5D-5L)), anxiety and depression (HAD), employment status, self-efficacy to return to work (RTW-SE11), pre-RTW and RTW visit with the OP, social support, care consumption, physical activity (short IPAQ), perceived performance (WRF), work conditions. The implementation and use of the intervention tools will also be assessed: the patient guide, the employer guide, RTW checklists for the GP and the OP."
45491272|NCT02391844|Drug|Oxycodone|Oxycodone with Acetaminophen Extended Release
45491273|NCT05675332|Behavioral|Task-based behavioral intervention|Brief behavioral intervention is absent of stressors.
45491274|NCT05675332|Behavioral|Task-based behavioral intervention|Brief behavioral intervention involves interacting with common everyday types of stress.
45491275|NCT03663296|Other|Airway Ex App|30 minutes of self-directed learning and practice using the mobile application
45491276|NCT03285854|Diagnostic Test|Collection of blood, urine and stool samples|Collection of blood, urine and stool samples, diet diary and bone scans
45491277|NCT03663140|Diagnostic Test|gingival crevicular fluid (GCF) and peri-implant sulcular fluid(PISF) collection|GCF/PISF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva.
45491278|NCT02391922|Behavioral|First aid course|
45491279|NCT02391922|Behavioral|First aid instructions by mobile phone|
45491280|NCT04056728|Biological|Eupenta Inj.|fully liquid pentavalent vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [recombinant-deoxyribonucleic acid])-Haemophilus influenzae type b conjugate vaccine single dose 0.5 mL/vial The vaccine is given at 6, 10 and 14 weeks of age in infants.
45491281|NCT04800562|Drug|PCS499|PCS499 900mg twice a day with food
45491282|NCT04800562|Other|placebo|placebo comparator
45491283|NCT04056338|Other|No intervention|No intervention.
45693077|NCT00763360|Device|DisCoVisc®|Injection of DisCoVisc® Ophthalmic Viscosurgical Device (OVD) into the anterior chamber prior to and throughout the cataract surgery procedure
45374428|NCT00762905|Device|Dermabond|High viscosity DermaBond Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D & C Violet #2. It is provided in a single use applicator packaged in a blister pouch. The applicator is comprised of a crushable glass ampule contained within a plastic vial with attached applicator tip. As applied to skin, the liquid is syrup-like in viscosity and polymerizes within minutes.
45374429|NCT00762983|Drug|loratadine|"Claritin Tablet 10 mg, Claritin RediTabs 10 mg: For pediatric patients aged 7 years and older, 10 mg of loratadine is orally administered once daily after a meal in usual cases.~Claritin Dry Syrup 1%: For pediatric patients aged 3 to < 7 years, 5 mg loratadine (0.5 g dry syrup); and for pediatric patients aged 7 years and older, 10 mg of loratadine (1 g dry syrup) is dissolved immediately before use and orally administered once daily after a meal in usual cases.~The observation period will not be specified."
45374430|NCT00403234|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
45374431|NCT00403234|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
45374432|NCT00403234|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patches 10 mcg/h and 20 mcg/h (total of 30 mcg/h) applied for 7-day wear.
45374433|NCT00403234|Drug|Placebo BTDS|Placebo to match BTDS transdermal 10 and 20 patches applied for 7-day wear.
45374434|NCT00767429|Device|fall risk detector|fall risk detector: stumbles, specific fall related movements, falls
45374435|NCT00760721|Behavioral|Educational Small Group Session|1 hour small group health-related discussion
45374436|NCT04049201|Procedure|elective surgery|investigators will compare the effect of interactive tablet on preoperative anxiety in children to the effect ofMidazolam in elective surgery
45491284|NCT02391766|Behavioral|empowerment|"The groups of 10 participants meet once a week for eight weeks. last for four hours~topics on dementia and prevention of further cognitive decline, active lifestyle and emotional well-being, spousal relationship, future planning kinds of active learning used are working in pairs and brainstorming sessions."
45491285|NCT02391766|Behavioral|usual care|
45491286|NCT04056260|Procedure|ICG-NIR guided surgery|ICG 0.5mg/ml x 0.5ml x 4 sites injection through intra-operative endoscopy
45491287|NCT05675020|Behavioral|Zoom Intervention|"This educational program will be delivered via a 45-minute presentation via Zoom.~The educational presentation will be recorded and emailed to participants within 1 week of intervention to re-watch/review.~The educational program will promote a healthy lifestyle knowledge and behaviors through education evidenced by the CDC, WHO, and the American Academy of Pediatrics. Educational sessions will include the importance of healthy lifestyle modifications in the adolescent population with a mental health condition(s), lifestyle recommendations versus reality, nutrition, physical activity, screen time, and sleep recommendations and guidelines.~We will compare the effects of an educational program on healthy lifestyle knowledge and behaviors pre-and post-program (after one month) via a REDCap survey for the adolescent and their parent/legal guardian."
45491288|NCT05674864|Drug|Bifidobacterium Infants plus Enterococcus Feacium plus Lactobacillus Acidophilus|Bifidobacterium Infants, Enterococcus Feacium, and Lactobacillus Acidophilus combination will be given as one capsule three times daily for 14 days
45491289|NCT02391688|Drug|Caffeine, omeprazole, flurbiprofen, dextromethorphan, midazolam|
45491290|NCT02391688|Drug|Bupropion|
45491291|NCT02391688|Drug|Fexofenadine|
45491292|NCT05676502|Device|AIRVO 2|Patients with chronic obstructive pulmonary disease and chronic respiratory failure use Nasal High Flow therapy during daytime sessions of 1.5 h.
45491293|NCT04117360|Other|Orthognathic surgery and Orthodontics|This study is observational. All subjects identified to participate will be undergoing orthognathic jaw surgery and orthodontic treatment.
45374437|NCT04049201|Drug|Midazolam|Oral Midazolam
45374438|NCT04049201|Device|Interactive Tablet|interactive Tablet containing many cartoon's videos
45491294|NCT02391454|Device|RunKeeper App|Group B will use the RunKeeper app for 12 weeks to self-monitor PA. In the scope of this study, patients merely have to self-monitor PA (e.g. swimming, biking, hiking, running) by GPS or stopwatch function with RunKeeper. Furthermore, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is explained in the user's manual.
45491295|NCT02391454|Other|Usual care|
45491296|NCT01068860|Drug|Canakinumab 150 mg|Single subcutaneous injection of Canakinumab 150 mg.
45491297|NCT01068860|Drug|Placebo to Canakinumab|Single subcutaneous injection of Placebo to Canakinumab.
45491298|NCT03661736|Other|Food for Specific Medical Purpose|Infants aged 1 to 8 months with moderate-to-severe cow's milk allergy fed an amino acid-based formula with two added human milk oligosaccharides
45491299|NCT03662594|Other|ECMO|In this project, the investigators will apply a new technique of atomic layer deposition (ALD) to coat biocompatible and hemocompatible ZrO2/Al2O3 nanolaminate thin films on the inner surface of ECMO tubing to suppress the device-induced coagulopathy. ALD is a thin-film deposition technique for preparing high-quality oxides with atomic-layer accuracy. It offers many benefits including accurate thickness control. These characteristic clear accounts of the high-quality hemocompatible oxide thin films on the whole surface of complex 3-D structures, such as the inner surface The newly-prepared ECMO circuit will then undergo in vitro tests and animal study to carefully examine the safety and effectiveness of improvement of hemocompatibility.
45491300|NCT04056572|Drug|TQ-B3139|TQ-B3139 is competitive multi-target protein kinase inhibitor of Met/ALK/ROS.
45491301|NCT04056650|Drug|L-theanine|up to 250 mg
45491302|NCT04056650|Dietary Supplement|Caffeine supplement|50-400mg
45491303|NCT04056650|Device|N1 app|N1 App on mobile device
45491304|NCT03662438|Other|Home-based physiotherapy program|The home-based physiotherapy program will consist of a total of 2 home visits by a physiotherapist which will be scheduled at the start and midpoint of the 10-week program. The visit will include activity education, goal setting and establishment of a home exercise regimen in patient's own home and community environment). Participants will be contacted weekly via telephone to provide encouragement for patient on the program, enquire about compliance to the exercise program and safety (e.g. falls and healthcare utilisation).
45491305|NCT03662438|Device|Prescription of a Portable Oxygen Concentrator (POC) device|Participants will be prescribed a lightweight Portable Oxygen Concentrator (POC) device [Philips SimplyGo Mini] to be used during exercise and when going into the community setting. Familiarisation and training on the usage of the device will also be provided in conjunction with the home-based physiotherapy program.
45491306|NCT03661658|Procedure|Using short dental implant|Using short dental implant for patients with atrophic posterior mandible.
45753814|NCT04191902|Behavioral|orientation|patients will be oriented
45374439|NCT00767663|Drug|dipyridamole|dipyridamole slow release 200mg twice daily, minimal 3 days pretreatment
45374440|NCT00767663|Drug|placebo|placebo twice daily, minimal three days pretreatment
45374441|NCT00767741|Device|with heat and massage|For the with intervention group a treatment to the injection site is applied after each insulin bolus injection.
45374442|NCT00763295|Other|T-Spot.TB test|diagnostic test
45374443|NCT00402688|Drug|levofloxacin|750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
45374444|NCT00402688|Drug|levofloxacin|750mg tablet once daily for 3 weeks followed by 1 week of placebo.
45374445|NCT00402688|Drug|levofloxacin|500mg tablet once daily for 4 weeks.
45491307|NCT03661658|Procedure|Inferior alveolar nerve lateralization with simultaneous implant placement|Inferior alveolar nerve lateralization with simultaneous implant placement in atrophic posterior mandible.
45491308|NCT03661580|Behavioral|Behavioural Activation|The BA intervention will be the outpatient version of the Life Enhancement Treatment for Substance Use (LETS ACT; Daughters et al., 2008). This brief, manualised BA intervention has been specifically developed to meet the needs of patients with comorbid substance misuse and depression in drugs and alcohol treatment settings. LETS ACT targets the link between mood, substance use and behaviour, and focuses on identifying and increasing rewarding, substance-free activities that are based on the patient's own personal values.
45491309|NCT03661580|Behavioral|Treatment as Usual|The control intervention in this study is Treatment as Usual at the CDAT service. Treatment as Usual consists of planned key-working sessions every 2-4 weeks with an allocated caseworker plus monthly prescribing review appointments with a medical practitioner for patients who require drug treatment medication. Key-working sessions are primarily focused on addressing substance misuse issues using a range of intervention techniques such as motivational interviewing and brief solution-focused therapy.
45491310|NCT03661502|Device|VVV|ventilation mode with variable tidal volume is chosen. the average tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
45491311|NCT03661502|Device|PCV|ventilation mode with constant tidal volume is chosen. the tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
45491312|NCT02989610|Device|Omnidirectional stimulation|At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated at the best level for omnidirectional stimulation with the Infinity DBS lead.
45491313|NCT02989610|Device|Directional stimulation|At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated using directional contacts at the best segmented level of the Infinity DBS lead.
45491314|NCT01372774|Radiation|stereotactic radiosurgery|Undergo RT
45491315|NCT01372774|Radiation|whole-brain radiation therapy|Undergo radiotherapy (RT)
45491316|NCT04055402|Other|Ecological momentary assessments|The staff will help the participants in the EMA group to install and set up the EMA App. The briefing will also emphasise the role of EMA participants that they should perform their normal activities as usual instead of finding out the alcohol advertisements and PADC intentionally. Within 2 weeks after completing the baseline survey, participants in EMA group will complete 5 EMAs prompted regularly every day for 14 consecutive days. The participants will then be contacted for a follow-up survey 2 weeks after the completion of EMA.
45491317|NCT04055402|Other|Control|Completion of a baseline questionnaire and a 1-month follow-up survey.
45491318|NCT04055480|Device|Closed-loop using standard rapid-acting insulin|Closed-loop using standard rapid-acting insulin
45374446|NCT04049045|Drug|Empagliflozin 25 mg|Empagliflozin 25 mg film-coated tablets, for oral use administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
45374447|NCT04049045|Drug|Placebo|matching Placebo, film-coated tablets, for oral use, matching to investigational product Jardiance® administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
45491319|NCT04055480|Device|Closed-loop using faster insulin aspart|Closed-loop using faster insulin aspart
45491320|NCT03660800|Drug|CTAP101 Capsules|Calcifediol Extended-Release Capsules
45491321|NCT03158090|Procedure|Transnasal butterfly surgery|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient.
45491322|NCT03158090|Drug|sandostatin|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
45491323|NCT03158090|Radiation|radiotherapy|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
45693078|NCT00763360|Drug|Healon|Injection of Healon into the anterior chamber prior to and throughout the cataract surgery procedure
45693079|NCT00763360|Drug|Amvisc Plus|Injection of Amvisc Plus into the anterior chamber prior to and throughout the cataract surgery procedure
45693080|NCT00763750|Drug|PPX +TMZ+XRT|PPX 50 mg/m2/week x 6 weeks (Days #1, 8, 15, 22, 29, 36) XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide 75 mg/m2/day: Day #1 of XRT until completion (including weekends and holidays)
45693081|NCT03805516|Behavioral|SCOPP-CW|The proposed intervention integrates the Social Cognitive Theory, use of everyday technology (WeChat), and an adaptation of an evidence-based program that is tailored to the behavior patterns, preferences, and cultures of premenopausal Chinese American women. The intervention includes three components: (1) daily tracking of physical activities, (2) 12 weekly educational modules on healthy lifestyle, physical activity, and breast cancer prevention, and (3) 6 bi-weekly tailored messages to include tips for lifestyle modification, stress management, and healthy weight maintenance based on the user's personal characteristics and behavior patterns.
45846920|NCT02672514|Device|Conventional extracorporeal circulation (CECC)|Conventional extracorporeal circulation (CECC) is an extracorporeal circulation system used for cardiopulmonary bypass.
45374448|NCT00763373|Other|Implementation of antibiotic switch guidelines|Implementation of antibiotic switch guidelines
45374449|NCT00760799|Procedure|Discectomy with anular repair|Comparison of discectomy with and without repair to the anulus fibrosus of the intervertebral disc
45491324|NCT02670538|Drug|Cariprazine|Cariprazine capsule one per day orally.
45491325|NCT02670538|Drug|Placebo|Matching placebo capsule one per day orally.
45491326|NCT03131414|Other|Diet|Dietary intake
45491327|NCT03131414|Other|Gastrointestinal microbiome|Genomic sequencing of stool for gut bacteria
45491328|NCT03114592|Other|mHealth tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing the post-hospital discharge stories of two hypothetical AKI survivors. opics of emphasis included NSAID risk awareness and avoidance of volume depletion when ill (Sick Day Protocol)."
46053876|NCT02960893|Drug|Troriluzole|Randomization Phase: Neat (i.e., drug substance without excipients); loose filled capsule.
45491330|NCT03547583|Drug|Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets|Oral use. Vericiguat, which will be started at 2.5 mg at randomization and up-titrated to 5 mg at week 2, and to 10 mg at week 4, with sham titration or up-titration to 15 mg at week 6.
45491331|NCT03547583|Drug|Placebo|Placebo and sham up-titration at weeks 2, 4, and 6
45491332|NCT04040296|Other|Kidney Action Team Recommendations|Upon review of the patient's medical information, the Kidney Action Team will create personalized recommendations that will be delivered to the patient's primary care team via a specialized note in the electronic medical record system within 30 minutes of AKI development. The attending of record will be identified as a cosigner to ensure that a member of the care team is made aware of the note's presence.
45491333|NCT02391298|Behavioral|Mindfulness Meditation|
45491334|NCT02391532|Dietary Supplement|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 12 weeks
45491335|NCT02391532|Dietary Supplement|Placebo|Ingestion of placebo lozenge twice daily for 12 weeks
45374450|NCT01035580|Drug|Curcumin|Curcumin 500 mg capsules will be inserted intravaginally once daily for 14 days for a maximum daily dosage of 2000 mg
45374451|NCT01035580|Drug|curcumin|all patients received the drug
45374452|NCT03993730|Device|ICD|Insertion of ICD in patients with LVEF <45% and LGE on CMR.
45374453|NCT03993730|Device|ILR|Insertion of ILR in patients with LVEF <45% and LGE on CMR.
45491336|NCT03114202|Other|intensive nutritional counseling|Individualised nutrition intervention in the form of regular and intensive nutrition counselling by a dietitian, following a predetermined standard nutrition protocol, the Medical Nutrition Therapy (Cancer/Radiation Oncology) protocol of the American Dietetic Association (ADA) every week during radiotherapy. Individually tailored sample meal plans, recipe suggestions and hints to minimise the side effects of the tumour and therapy will be provided.
45693082|NCT03805516|Behavioral|Control|This is the comparative/control group for the intervention. The control group receives daily tracking of physical activity and 12 weekly non-tailored educational information on general health topics.
45846921|NCT02673138|Drug|canagliflozin|basal interruption with canagliflozin
45846922|NCT02673138|Other|basal interruption without canagliflozin|basal interruption
45846923|NCT02673372|Drug|Morphine|intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.
46053877|NCT02960893|Drug|Placebo|Drug: Placebo Randomization Phase: Matching placebo loose filled capsule.
45374454|NCT01041586|Device|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
45374455|NCT00671879|Drug|Carisoprodol SR 700 mg|700 mg twice daily tablet
45374456|NCT00671879|Drug|Carisoprodol SR 500 mg|carisoprodol SR 500 mg tablet
46053878|NCT02960893|Drug|Troriluzole|Extension phase: Neat capsule or formulated capsule (i.e., drug substance with excipients).
46053879|NCT02912572|Drug|Avelumab|Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Premedication Antihistamine and Paracetamol will be administered prior to treatment
45374457|NCT00671879|Drug|Placebo|placebo tablet
45374458|NCT00402298|Drug|3,4-methylenedioxymethemphetmaine (MDMA_|Participants will receive an initial dose of 125 mg MDMA orally followed 2.5 hours later by 62.5 mg MDMA orally during the course of a day-long therapy session.
46053880|NCT02912572|Drug|Talazoparib|Talazoparib will be taken one time per day by mouth Each Cycle lasts 28 days
46053881|NCT02912572|Drug|Axitinib|Axitinib will be taken twice per day by mouth Each Cycle lasts 28 days
45491337|NCT03114202|Other|Standard care|Nutritional counseling / education performed by hospital nurses and nutritional care performed by the hospital nutritionist.
45491338|NCT02391610|Other|No intervention|
45491339|NCT03727763|Drug|Vemurafenib|960mg po bid
45491340|NCT03727763|Drug|Cetuximab|500mg/m2 iv gtt (14 days per course)
45491341|NCT02391220|Other|LCA symbiotic fermented milk|LCA symbiotic fermented milk with the probiotic cultures Lactobacillus acidophilus La-5® and Bifidobacterium animalis ssp. lactis BB-12® and the Beneo dietary fibers.
46053882|NCT02910414|Drug|Dehydrated alcohol|Dehydrated Alcohol Injection, USP is used in the study.
46053883|NCT02910414|Device|Peregrine System Kit (Sham Procedure)|Pre-procedural diagnostic renal angiography only, performed for confirmation of anatomical eligibility prior to randomization
45491342|NCT02391220|Other|heat-treated fermented milk|heat-treated fermented milk without probiotic cultures and dietary fibres
45491343|NCT03724565|Procedure|Method of endoscopic procedure|Air quality according to the method of endoscopic procedure will be checked (for example, upper diagnostic endoscopy, colonoscopy, endoscopic submucosal dissection, endoscopic mucosal resection, etc)
45491344|NCT02670382|Dietary Supplement|EPA|10 week supplementation
45491345|NCT02670382|Dietary Supplement|DHA|10 week supplementation
45491346|NCT02670382|Dietary Supplement|sunflower oil|4-week lead-in
45491347|NCT01310621|Drug|Bovine surfactant|"Dose of diluted surfactant : 20ml/kg~Type :Bovine surfactant~Phospholipid concentration: 5 mg/ml~Number of lavages to be given: 2 (10ml/kg each)"
45491348|NCT02991482|Drug|Pembrolizumab|Pembrolizumab (MK-3475) is a potent and highly selective humanised monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumour regression and ultimately immune rejection.
45491349|NCT02991482|Drug|Gemcitabine|"Gemcitabine replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumour growth, as new nucleosides cannot be attached to the faulty nucleoside, resulting in apoptosis (cellular suicide)."
45491350|NCT02991482|Drug|Vinorelbine|Vinorelbine is a vinca alkaloid cytotoxic chemotherapy that is available in intravenous and oral preparations with EMA licenses in lung cancer and breast cancer. Vinorelbine blocks mitosis in phase G2-M, causing cell death in interphase or at the following mitosis.
45491351|NCT04743466|Other|Electronic Health Record Review|Biobank records are reviewed
45491352|NCT03660644|Behavioral|WhatsApp, Pedometer and Step Diary|"Participants will be provided with a daily step diary and added to a group chat on WhatsApp. The group chat will be populated by other members of pulmonary rehabilitation programme (cluster) and the WhatsApp group leader will encourage participants to keep active. Participants will be encouraged to record the number of steps walked in a paper diary at the end of each day (i.e. prior to bedtime). This diary will simply have three columns: day of the week; number of steps; comments (optional).~The intervention will last 52 weeks."
45491353|NCT02674750|Drug|CUDC-907|
45693083|NCT00756106|Drug|temozolomide|Temozolomide is administered according to standard of care practice guidelines. Dosing may be modified at the discretion of the treating investigator.
45693084|NCT00756106|Other|Imaging biomarker analysis|MRI
45693085|NCT00756106|Radiation|Photon Radiation Therapy|Radiation is administered to the tumor plus edema with a 1-2 centimeter margin for a total dose of 60 Gy in 30 fractions.
45693086|NCT00243412|Drug|folate|Minimum of 1 mg/day oral (or folinic acid 5 mg/week)
46053884|NCT02867813|Biological|Evolocumab|subjects will receive evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
46053885|NCT02845596|Drug|cyclosporine|cyclosporine
45374459|NCT00402298|Drug|3,4-methylenedioxymethamphetamine|Participants will receive an initial dose of 25 mg MDMA orally followed 2.5 hours alter by a supplemental dose of 12.5 mg MDMA orally during the course of each of two day-long therapy sessions.
45374460|NCT01039168|Behavioral|Workplace dialogue|
45374461|NCT01039168|Other|Care as usual|
45491354|NCT03998566|Device|TraceIT Tissue Spacer implantation|The TraceIT Tissue Spacer will be implanted between duodenum and pancreas using endoscopic procedure. After implantation patient will have radiotherapy treatment per standard of care.
45491355|NCT04740736|Procedure|Saline Infusion|Patient with hypovolemia on day 1 will be randomized to a saline or sham infusion prior to the Day 2 exercise test.
45491356|NCT02389192|Drug|ZMAPP|ZMappTM, a combination of three mouse/human chimeric monoclonal antibodies (mAbs; c4G6, c2G4, and c13C6-FR1) directed against Ebola virus glycoprotein epitopes
45491357|NCT05672758|Behavioral|Sprint training|One-year cycle including specific sprint-oriented athletic training
45491358|NCT05672758|Behavioral|Endurance training|One-year cycle including specific endurance-oriented athletic training
45491359|NCT05672758|Behavioral|Recreational Training|One year of nonspecific recreational training
45491360|NCT02391376|Other|moist heat pack; ;|Three sessions of 15 minutes of superficial heat through a moist heat pack-MHP applied on the lower back.
45491361|NCT02391376|Other|seed pack|Three sessions of 15 minutes of superficial heat through a seed pack-SP applied on the lower back.
45491362|NCT02391376|Other|gel pack|Three sessions of 15 minutes of superficial heat through a gel pack-GP applied on the lower back.
45491363|NCT02391142|Drug|Lidocaine|0.5% lidocaine 5ml epidural injection every 2 hours per day or 0.2% ropivacaine 5ml epidural injection every 4 hours per day, last for 4weeks
45693087|NCT00243412|Drug|methotrexate|15-25 mg/week oral or parenteral (10-14 mg/week if intolerant)
45693088|NCT00243412|Drug|methylprednisolone|100 mg intravenous (IV) prior to each rituximab infusion (For Arm B, for the Months 6 and 18 cycles, IV saline was administered prior to each placebo infusion)
45693089|NCT00243412|Drug|Placebo|To maintain the blind, patients in Arm B (Rituximab 1000 mg) received placebo infusions at Months 6 and 18.
45693090|NCT00243412|Drug|Rituximab|500 mg or 1000 mg IV*2.
46053886|NCT02845596|Procedure|Matched Unrelated Donor Hematopoietic Stem Cell Transplant|Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)
46053887|NCT02845596|Drug|horse anti-thymocyte globulin (ATG)|horse anti-thymocyte globulin (ATG)
46053888|NCT02845596|Drug|rabbit anti-thymocyte globulin (ATG)|rabbit anti-thymocyte globulin (ATG)
46053889|NCT02845596|Drug|methotrexate|methotrexate
46053890|NCT02845596|Drug|fludarabine|fludarabine
46053891|NCT02845596|Drug|cyclophosphamide|cyclophosphamide
45491364|NCT02388334|Other|to develop a standardized questionnaire|"to develop, from the caregivers' point of view, a standardized questionnaire evaluating 1) their quality of life (QOL) as related to the disease of the assisted and 2) their expectations concerning the global quality of professional management (care, coordination, information...).~The development of this standardized tool will also :~identify the specific support needs of the caregivers~study the links between the quality of care as perceived by the professionals, patients and caregivers~identify the characteristics of the caregivers (status) and patients (disease type, disease-modifying drug (DMD) initiation, disease duration) associated with questionnaire results."
45491365|NCT02391064|Behavioral|Cognitive evaluation|"Questionnaires for assessment of confounding factors~Cognitive evaluation~Walking tests and 9 Hole Peg Test"
45491366|NCT02391064|Behavioral|Expanded Disability Status Scale (EDSS) score|- EDSS score
45491367|NCT02390986|Drug|LON002|Extension study to provide continuing access to LON002 medication.
45491368|NCT02987972|Biological|V114 Lot 1|Lot 1: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
45491369|NCT02987972|Biological|V114 Lot 2|Lot 2: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
45491370|NCT02987972|Biological|Prevnar 13™|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
45491371|NCT03305419|Drug|GSK2982772 capsule|GSK2982772 will be available as size 00, white, opaque capsule containing white to almost white Solid (120 mg maximum fill per capsule). It will be administered orally with water to receive total dose of 120 mg, 240 mg or 360 mg per randomization.
45491372|NCT03305419|Drug|Placebo capsule|Placebo will be available as size 00, white, opaque capsule containing white to almost white Solid. It will be administered orally with water.
45491373|NCT04479202|Drug|Berberine|Patients in the intervention group received berberine daily, regardless of gastrointestinal symptoms.If the patient has a serious drug-related adverse event, the drug will be discontinued and the patient will be excluded from the study.
45491374|NCT04479202|Drug|Montmorrillonite|Patients in the control group were routinely not given special treatment.However, if the patient has diarrhea symptoms, montmorillonite powder should be given orally.
45491375|NCT02388256|Device|acupuncture|"Points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4) and Pericardium 6 (PC6) will be used. Electrical stimulation with alternating frequency of 2 to 100 Hz will be applied to the selected points (LI4 to LI11, ST36 to ST37, and bilateral SP6).~Rationale of acupuncture treatments will include both traditional theory of harmonizing gastrointestinal function and strengthening vital energy as well as modern experimental and clinical evidence of regulating gastrointestinal motility and other symptom managements. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience."
45491376|NCT02388256|Other|early recovery program after surgery|An enhanced recovery program after surgery that was designed and is currently implemented by surgeons, anesthetists, dietitians, and nurses will be provided. The program includes preoperative education, early water/food intake, early mobilization, early removal of Foley catheter and drains, structured nursing care, and nutritional support.
45491377|NCT02388100|Procedure|Capillary HbA1c collection|
45491378|NCT01372618|Drug|SOM 230 / Pasireotide|SOM230/Pasireotide is a multi-receptor targeted somatostatin analogue. In this trial, 600 mcg of SOM230/Pasireotide are taken twice daily subcutaneously.
45491379|NCT03304873|Drug|Retapamulin|Retapamulin is a topical antibiotic ointment. The ingredients include retapamulin and white petrolatum as the vehicle. The composition is 10mg retapamulin per 1g of ointment (1%).
45491380|NCT03304873|Drug|Placebo Ointment|The placebo that will be used is triple-purified pharmaceutical-grade petrolatum.
45491381|NCT02669758|Drug|ALKS 3831|Tablets were administered for daily dosing
45491382|NCT02987660|Procedure|Topography Guided LASIK|Corneal surgery for refractive error correction
45693091|NCT00765232|Drug|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
45693092|NCT00765232|Drug|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
45491383|NCT02987660|Procedure|Small Incision Lenticular Extraction|Refractive surgical procedure for the correction of myopia with or without astigmatism
45491384|NCT02987660|Device|WaveLight EX500 Excimer Laser System|As used for corneal stroma ablation (refractive error correction). The treatment is intended to last the subject's lifetime.
45693093|NCT03805282|Drug|Lidocaine|Continuous infusion, variable dose of lidocaine.
45693094|NCT03805750|Drug|CBD/THC|Oral formulation of combined Cannabidiol (CBD) and Tetrahydrocannabinol (THC).
45693095|NCT03805750|Drug|Placebo oral capsule|Matched Placebo
45693096|NCT04385446|Procedure|Amniotic membrane transplantation|Amniotic membrane transplantation was used as covering material during pterygium surgery.
45693097|NCT03804268|Other|Vehicle|Vehicle, one drop in each eye, once daily, for up to 30 days.
45693098|NCT03804268|Drug|Pilocarpine HCl Ophthalmic Solution|Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
45693099|NCT00765856|Drug|Oxymorphone ER|"Oxymorphone ER dosing adjustments made under the direction of the Investigator during the Titration Period.~Oxymorphone IR (Opana) IR 5mg tablet - used as rescue medications"
46053892|NCT02845596|Radiation|low-dose total body irradiation (TBI)|low-dose total body irradiation (TBI)
46053893|NCT02845596|Procedure|Immunosuppressive Therapy (IST)|Immunosuppressive Therapy (IST)
46053894|NCT02834884|Genetic|RP-1828 IMMUcan|WES, lcWGS and RNAseq, multiplex IF and IMC
46053895|NCT02834884|Genetic|RP-1759 AYA/TYA|WES, RNAseq and EPIC array
46053896|NCT02834884|Genetic|RP-1843 Arcagen|NGS panel
46053897|NCT02834884|Genetic|RP-1920 BioRadon|NGS panel
46053898|NCT02829606|Other|small scotoma using Head Mounted Display No re-mapping|re-mapping software turned off
45491385|NCT02987660|Device|VisuMax Surgical Laser|As used for lenticule creation/removal (refractive error correction). The treatment is intended to last the subject's lifetime.
45491386|NCT04528069|Device|ACRYSOF® IQ PanOptix® Toric Trifocal IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism. This device is approved in Australia.
45491387|NCT04528069|Procedure|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use
45491388|NCT03661268|Other|fluid chanllenge|A bag of 500ml of normal saline is infused within 15 minutes using a bag pressurized to 300 mmHg.
45491389|NCT03660566|Procedure|Test - Implant with L-PRF|The patient's blood will be collected and the tubes (4) will be inserted into a tabletop centrifuge (Kasvi). Using a 2500rpm for 12 minutes protocol, the leucocyte- and platelet-rich fibrin clot will be prepared using a kit consisting of a perforated metal box where the clots will be positioned and covered by a metal plaque. The pressure exerted on the clot will lead to the formation of L-PRF membranes, which will be used to cover the ridge after placement of the implant. Then, the flap will be sutured.
45491390|NCT03660566|Procedure|Control - Implant without L-PRF|Single implant installation surgery in maxillary esthetic area.
45491391|NCT04526509|Drug|GSK3901961|GSK3901961 as an IV infusion.
45491392|NCT04526509|Drug|GSK3845097|GSK3845097 as an IV infusion.
45491393|NCT04526509|Drug|GSK4427296|GSK4427296 as an IV infusion.
45491394|NCT04526509|Drug|Cyclophosphamide|Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
45491395|NCT04526509|Drug|Fludarabine|Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.
45491396|NCT03660410|Other|Anamnesis|A detailed anamnesis should be carried out in order to know the habits, the presence of systemic pathologies, the use of medication
45491397|NCT03660410|Other|Oral clinical examination|Clinical examination should be carried out evaluating the presence of caries, tooth loss, periodontal condition, occlusal factors
45491398|NCT03660332|Procedure|Infusion of a liquid meal intraduodenally|Infusion of IL-6/NaCL before a liquid meal intraduodenally
45491399|NCT03303469|Drug|FMISO|FMISO PET/CT imaging at baseline
45491400|NCT03303469|Drug|FMISO|FMISO PET/CT post TACE
45491401|NCT03303469|Drug|FMISO|FMISO PET/CT post SBRT
45491402|NCT02990000|Behavioral|Scientific Match|We have developed an innovative, personalized Match System based on provider track records determined with a multidimensional outcomes tool - the Treatment Outcome Package (TOP). Specifically, patients are assigned to therapists with previously established strengths (i.e., being historically effective) in treating their primary problems (e.g., depression, anxiety).
45491403|NCT04521127|Other|Kinesio Taping|Taping will be performed on sitting position with contralateral lateral flexion and flexion of the neck, using muscle technique with I strip and stretching the head at the maximum level in order to benefit from the muscle release effect. Kinesio tape was applied directly on muscle with 0% stretching.
45491404|NCT04521127|Other|Dry needling|The trigger point on the taut band will be held with the thumb and forefinger from below and above. In the needling technique, a 0.25 * 25-mm with nickel handle, disposable sterile steel acupuncture needle will be used. The needle tip will be inserted perpendicularly into the subcutaneous tissue and inserted into the muscle until the trigger point in the taut band was found. The same point will be pinned 8-10 times with fast needle movements inside and out. Then the needle tip will pulled back so that it did not come out of the skin, and the bottom, top and sides of the first entered point were also pinned. This procedure was applied to all trigger points in the trapeze muscle.
45491405|NCT03660254|Behavioral|tai chi|tai chi exercise intervention，two times a week and each time cost one hour
45491406|NCT03660176|Drug|butyrate enemas + routine management|10ml/kg volume of butyrate enemas in addition to the colonic irrigations
45491407|NCT03660176|Other|routine management|the colonic irrigations
45491408|NCT04056026|Biological|Fecal Microbiota Transplant|Fecal material from a healthy family donor will be transplanted into the patient via colonoscopy
45491409|NCT03661190|Other|Grammatical Reasoning|START measures the ability to determine the relationships among different shape combinations which are assigned to grammatical statements about them which can be either correct or incorrect. It is a measure of attention, working memory and executive control.
45491410|NCT03661190|Other|Card Pairs|A basic picture-matching task.
45491411|NCT03660020|Drug|Local anesthetic|ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy with local anaesthetics only
45491412|NCT03660020|Drug|Hyaluronidase|hyaluronidase will be added to ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy
45491413|NCT03659942|Other|CAST questionnaire|the CAST questionnaire will be used to answer the main objective of the study and to identify consumers with problematic cannabis use. This is a validated self-questionnaire in France (Legleye et al., 2011), specific to the adolescent population, which is interpreted according to the score obtained (Bastiani et al., 2013, Legleye et al. 2007, Legleye et al., 2011). It includes 6 items with answer modes coded from 0 to 4. The total score obtained by summing these 6 items can therefore vary from 0 to 24. We define users without risk for a score of less than 3, users with low risk for a score greater than or equal to 3 and less than 7, and finally those with a risk of problematic use for a score greater than or equal to 7
45491414|NCT03659864|Other|diesel exhaust particulate|aerosolised diesel exhaust particulate
45491415|NCT03659864|Other|carbon nanoparticles|aerosolised 'clean' carbon nanoparticles
45491416|NCT03659864|Other|small graphene oxide|aerosolised 'small' graphene oxide
45491417|NCT03659864|Other|ultrasmall graphene oxide|aerosolised 'ultrasmall' graphene oxide
45491418|NCT03659864|Other|filtered air|control: filtered air
46053899|NCT02829606|Other|Large scotoma using Head Mounted Display PLUS re-mapping|re-mapping software turned on
46053900|NCT02813083|Other|No intervention (observational)|No intervention (observational)
45491421|NCT04055714|Device|Balloon dilation of the Eustachian tubes|Use the Aera Balloon through the nose to dilate the Eustachian tubes
45491422|NCT03661034|Device|GammaSense Stimulation System (non-invasive, non-significant risk)|Non-invasive, non-significant risk audio-visual sensory stimulation device
45491423|NCT03659786|Other|CC-Test|Classification of the oocyte/embryo based on the expression pattern observed in the cumulus cells
45491424|NCT03659708|Procedure|Lyon-VTE score|follow-up at 3 months, 5 months, 7 months during pregnancy and 3 months and 12 months after delivery.
45491425|NCT03659708|Procedure|recommendations currently available|follow-up at 7 months during pregnancy and 3 months and 12 months after delivery.
45491426|NCT03659630|Behavioral|MyCompass|Self-help tools to change behaviours in various different domains including sleep deprivation, anxiety and depression.
45491427|NCT03659630|Behavioral|Comparison group|An email containing a brief text on general tips regarding mental health was sent out once a week.
45491428|NCT03659552|Device|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left jugular vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
45491429|NCT03659474|Other|compression|compression by Game Ready
45374462|NCT00770393|Procedure|induction chemotherapy|Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging. If a complete response (CR) or partial response (PR) of more than 80% is identified in the primary tumor, the patient was offered conventional radiotherapy as part of the protocol treatment. Radiotherapy was administered in 35 fractions of 2 Gy each over a 7 weeks period to the primary tumor (50 Gy) and the neck lymph nodes. The dose to the pathologically positive nodes was supplemented (20 Gy) at a total dose of 70 Gy. Doses and schedules of radiotherapy were identical in both treatment arms of the study.
45374463|NCT00770393|Procedure|Conventionnal chemotherapy|"Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.~- Surgery was recommended to all patients who had a response less than 80%, stable disease or progressive disease in the primary tumor. If surgery was not feasible, the treatment choice was left up to the investigator's discretion."
45491430|NCT03659474|Other|ice pack|cryotherapy for ice pack
45491431|NCT03659474|Other|immersion|immersion therapy
45491432|NCT03659396|Other|individualized Tai Chi|individualized Tai Chi training exercise
45491433|NCT03659396|Other|Entire Tai Chi|the classical Yang style Tai Chi program
45491434|NCT03659396|Other|home-based program|Home-based exercise
45491435|NCT03662048|Behavioral|Safe|Feedback, according to the 2016 national American Academy of Pediatrics (AAP) guidelines on Sudden Unexplained Infant Death (SUID) risk factors, will be generated by the study team and communicated with parents. Feedback will be given to parents in the intervention group at ages 1 and 2 months. The control group parents will only receive this feedback at age 2 months.
45491436|NCT04055870|Procedure|EUS-guided liver biopsy at MDMC|Endoscopic ultrasound (EUS) guided liver biopsy sampling is emerging as an alternative to the aforementioned approaches that offers several advantages, including decreased sampling variability and procedure-related complications.
45491437|NCT03660956|Behavioral|Exercise|Twelves-week exercise training sessions include a variety of strength, flexibility, and coordination exercises. Each exercise session lasts for one hour. Participants are expected to attend exercise session once a week and are encouraged to continue exercising at home.
45693100|NCT03805126|Behavioral|Medical Legal Partnership|With the medical legal partnership, lawyers are embedded in clinics, and lawyers consult with patients who are identified as having health-harming legal needs (HHLNs). This arm will also receive usual care, which includes consultation with a social worker and a community health worker.
46053901|NCT02775695|Drug|Doxycycline|Treatment with doxycycline hyclate will be administered as an oral agent on an outpatient basis. Patients will receive doxycycline 100 mg twice daily for a period of 8 weeks (56 days). Upon registration (baseline) and at the first, third, and fifth days of doxycycline therapy, patients will be seen to obtain trough serum concentrations for pharmacokinetic studies. Additional serum levels will be checked on days 8, 15, 22 and 29.
46053902|NCT02737787|Biological|WT1 Vaccine|
46053903|NCT02737787|Drug|Nivolumab|Nivolumab will be administered intravenously as a 30-minute infusion per institutional guidelines on weeks 0, 2, 4, 6, 8, 10 and 12.
46053904|NCT02737787|Biological|NY-ESO-1 Vaccine|Patients will be vaccinated with the NY-ESO-1 OLP4 vaccine. Patients will receive a 1.0 mL emulsion of NY-ESO-1 OLPs with Poly-ICLC and Montanide.
45374464|NCT03994276|Dietary Supplement|Chickpea powder|Chickpea powder is produce using novel production techniques to maintain chickpea cell structure. It will be incorporated into a drink (Dextrose control), or baked into bread rolls at 30% or 60% substitution of wheat flour(100% Wheat flour control).
45374465|NCT01036048|Device|drug eluting stent|pts with cabg disease treated with drug eluting stent
45374466|NCT01036048|Device|bare metal stent|pts with cabg disease treated with bare metal stent
45374467|NCT00767897|Drug|Human Papillomavirus Vaccine|The HPV vaccination will be administered by intramuscular injection in three separate 0.5mL doses. The recommended schedule is a 3-dose series with dose #2 and #3 administered 2 and 6 months after dose #1, respectively. The minimum interval between dose #1 and #2 of the vaccine is 4 weeks. The minimum recommended interval between dose #2 and #3 of the vaccine is 12 weeks.
45374468|NCT00767975|Drug|isoniazid , randomized, open label|isoniazid 300mg/tab 1 tab qd, 6 months (the other treatment arm is rifampin)
45374469|NCT00767975|Drug|rifampin, randomized, open label|rifampin 300mg/capsule 2 caps qd, 4 months (the other treatment arm is isoniazid)
45374470|NCT00768131|Drug|Cetuximab|Vial, Intravenous, 400 mg/m² week 1 then 250 mg/m², Weekly, Until PD/Toxicity/Pt-PI Decision
45374471|NCT00768131|Drug|Paclitaxel|Vial, Intravenous, 225 mg/m2, Every 3 weeks, 6 cycles maximum
45374472|NCT00768131|Drug|Carboplatin|Vial, Intravenous, AUC = 6.0, Every 3 weeks, 6 cycles maximum
45374473|NCT00401830|Drug|Lacosamide|Tablet 400mg daily (200mg twice daily) during 8-week maintenance phase following 4-week titration phase starting at 100mg/day and increasing to 400mg/day at weekly intervals of 100mg
45374474|NCT00401830|Other|Placebo|Matching placebo tablet administered twice daily
45374475|NCT05285033|Drug|Lurbinectedin|Patients who received at least one dose of treatment with lurbinectedin as part of the French Early Access Program (ATU program).
45374476|NCT00768209|Drug|Phentermine and Topiramate|Each subject will be dosed with a single oral dose of VI-0521 (PHEN/TPM 15/92 mg).
45374477|NCT02471144|Biological|Experimental : Secukinumab low dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 50 kg b) 150 mg if weighing 50 kg or more. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
45374478|NCT02471144|Biological|Experimental: Secukinumab high dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 25 kg b) 150 mg if weighing between 25 and less than 50 kg c) 300 mg if weighing more than 50 kg. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
45374479|NCT02471144|Biological|Placebo Comparator: Secukinumab Placebo|Placebo secukinumab (one or two subcutaneous injections per dose, depending on weight group) at Randomization and Weeks 1, 2, 3 4 and 8. At Week 12, subjects in the placebo group based on their PASI 75 response status at Week 12 will proceed as follows: • PASI 75 responders will discontinue study treatment at Week 12 and enter the treatment-free follow-up period • PASI 75 non-responders will receive high dose or low dose secukinumab, according to the pre-assignment at the Randomization visit. They will receive their treatment based on the weight category(<25 kg, 25- <50kg, ≥50 kg), on Weeks 12, 13, 14, 15, and then every four weeks starting at Week 16 until Week 48 during the maintenance period; thereafter at week 52 and every 4 weeks during the extension treatment period until Week 232.
45374480|NCT02471144|Biological|Active Comparator: Etanercept|Etanercept 0.8 mg/kg of subject weight and up to a maximum of 50 mg per dose. Subcutaneous etanercept 0.8 mg/kg (one or two injections per dose) once per week, for 51 weeks administered at home (self-injected or by caregiver) or at the study site. At Wk 52 subjects in the etanercept group will move into the treatment-free follow up period and terminate the study.
45374481|NCT02557685|Biological|Fecal Microbiota Transplantation|Fecal Microbiota Translantation involves administering fecal material from a healthy donor to a sick patient, with relapsing C-difficile infection, to restore missing components of normal intestinal flora. Subjects will receive Fecal Microbiota Translantation via sigmoidoscopy.
45374482|NCT00401752|Drug|Esomeprazole|
45374483|NCT00401752|Drug|Ranitidine|
45693101|NCT03805126|Behavioral|Usual Care|Usual care includes consultation with a social worker and a community health worker.
45491438|NCT03660956|Behavioral|Back counselling|Procedure of back counselling includes one session back counselling, lasting one hour. The topics of back counselling session are as follows: (1) Anatomy of lumbar; (2) Factors causing low back pain; (3) Problems of physical inactivity for the lumbar; (4) Risk of poor postures for developing persistent/chronic low back pain; (5) Maintaining right posture of the lumbar; (6) Avoiding harmful loading of the back during work and leisure time.
45693102|NCT00756496|Device|Mammography screening and diagnosis|Mammography screening and diagnosis
45374484|NCT04048967|Behavioral|Professional development|professional development of preschool staff
45374485|NCT00770471|Drug|temozolomide|
45374486|NCT00770471|Drug|veliparib|
45374487|NCT00770471|Genetic|DNA methylation analysis|
45374488|NCT00770471|Genetic|gene expression analysis|
45374489|NCT00770471|Genetic|mutation analysis|
45374490|NCT00770471|Genetic|proteomic profiling|
45374491|NCT00770471|Other|high performance liquid chromatography|
45374492|NCT00770471|Other|immunoenzyme technique|
45374493|NCT00770471|Other|laboratory biomarker analysis|
45374494|NCT00770471|Other|mass spectrometry|
45374495|NCT00770471|Other|pharmacogenomic studies|
45374496|NCT00770471|Other|pharmacological study|
45374497|NCT00770471|Procedure|adjuvant therapy|
45374498|NCT00770471|Radiation|radiation therapy|
45374499|NCT01039324|Other|Reports|Primary care event reports and patient letters
45374500|NCT01039324|Other|Reports and Notices|Primary care event reports, patient letters and care manager notices
45374501|NCT01039324|Other|Usual care|This is the study's control group
45374502|NCT00539240|Drug|Rabeprazole 20mg, placebo dinner and bedtime|Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime
45374503|NCT00539240|Drug|Rabeprazole 20 mg two times, Placebo at bedtime|Breakfast & Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime
45374504|NCT00539240|Drug|Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant|Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime
45374505|NCT00770627|Dietary Supplement|Omega 3 caps|Children between 6 and 8 years must take 2 caps/day Children between 9 and 11 years must take 3 caps/day Children between 12 and 15 years must take 4 caps /day
45374506|NCT00417976|Drug|Gemcitabine|1000 mg/m2 over 100 minutes every 2 weeks.
45374507|NCT00417976|Drug|Bevacizumab|10 mg/kg every 2 weeks.
45374508|NCT00417976|Drug|Infusional 5-Fluorouracil|2400 mg/m2 over 48 hours every 2 weeks.
45693103|NCT00780208|Drug|Daytrana (methylphenidate patch)|Subjects will be provided with a 7-day supply of medication at each study visit. The dose will be flexible and will be titrated based on effect and tolerability. Unless a subject is experiencing side effects, the dose will be increased if a 25% reduction in ADHD symptoms as determined by the WRAADDS is not obtained. A proposed dosing schedule is as follows: Week 1: 12.5 cm2, Week 2: 18.75 cm2, Week 3: 25 cm2, Week 4: 37.5 cm2. The dose may be decreased as needed for tolerability.
45374509|NCT00770705|Drug|Phenoxybenzamine|The drug will be administered in the operating room. After induction of anesthesia and the pIacement of appropriate cardiovascular monitoring lines, an initial loading dose of 0.25 mg/kg will be administered intravenously immediately prior to cardiopulmonary bypass.For up to 72 hours postoperatively, 0.25 mg/kg/day will be administered Based on published pharmacokinetic data these doses should block 90 -95% of alpha-peripheral receptors with a half life of 24 - 36 hours for regeneration.
45693104|NCT00243022|Drug|Boswellia serrata extract|given orally
45693105|NCT00243022|Dietary Supplement|cyanocobalamin|given orally
45693106|NCT03805360|Drug|Ropivacaine|Ropivacaine is a local anesthetic that is expected to provide numbness to the chest wall when injected into the erector spinae plane.
45374510|NCT00770705|Other|Standard surgical approach|Historical controls
45374511|NCT00991718|Drug|GDC-0449 oral capsules (non-labeled)|150 mg oral capsule
45374512|NCT00991718|Drug|GDC-0449 IV injection (labeled)|10 mcg (in 2 mL) IV dose of 14C-GDC-0449
45374513|NCT00991718|Drug|CDC-0449 oral suspension (labeled)|30-mL oral suspension containing 6.5 mcg 14CGDC-0449 and 150 mg GDC-0449
45374514|NCT01036282|Behavioral|Computerized Cognitive Skill Training|Behavioral: Cognitive Remediation 45 mins 2 times per week sessions of cognitive remediation (COGPACK) over twelve weeks.
45374515|NCT01036282|Behavioral|CRT and Social Cognition|Mind Reading, The Interactive Guide to Emotions for one 45 minute session per week for 12 weeks.
45374516|NCT04048733|Device|patchy-type wireless 12-lead ECG|Perform 12-lead ECG using patchy-type wireless 12-lead ECG. This device automatically record 12-lead ECG in every 15 minutes by its algorithm.
45374517|NCT01036360|Other|metabolic chamber|20 adolescent boys (10 obese and 10 leans) and 20 men (10 obese and 10 lean) will complete a sub-maximal test on a ergo cycle to draw their linear relationship between VO2 and Fc. Then they will enter a metabolic chamber three times, for 24 hours each
45374518|NCT00991796|Drug|CS-1008|CS-1008 powder for concentrate for solution for infusion. six cycles of combination therapy with 3 weeks equal to one cycle. 10 mg/kg
45374519|NCT00991796|Drug|Placebo|Placebo
45693107|NCT03805360|Drug|Normal Saline Flush, 0.9% Injectable Solution|Normal Saline Flush, 0.9% Injectable Solution is not expected to provide numbness to the chest wall when injected into the erector spinae plane.
45491439|NCT03659318|Procedure|Robotic-assisted TKA|Total knee arthroplasty is carried out with help of robotic surgery system, using a Robodoc system. CT-based preoperative planning using ORTHODOC (Integrated Surgical Technology Corp) performed in the first step before the day of surgery, and the robotic-assisted surgery using the ROBODOC surgical assistance in the second step. The bone markers are registered to the computer, and the computer arm does all the cutting and preparation of bones. This is in contrast to conventional jigs and cutting blocks. Actual implantation of the implants is done by a surgeon. A Duracon posterior cruciate-substituting total knee prosthesis (Stryker Orthopedics, Mahawh, NJ, USA) are used in all knees.
45491440|NCT03659318|Procedure|Conventional TKA|Total knee arthroplasty is carried out with classical, conventional, manual method. A surgeon measures the angle, length of the cuts with bone landmarks and specialized surgical instruments. After all the cuts actual implantation is done. A Duracon posterior cruciate-substituting total knee prosthesis (Stryker Orthopedics, Mahawh, NJ, USA) are used in all knees.
45491441|NCT03661892|Drug|Syndros|"As noted in arm description. For patients who have side effects secondary to Sydnros, the dose will be decreased as below:~Dose subject is taking Reduction recommendation 8.4mg BID Decreased to 8.4mg AM , 4.2mg PM (or it can be 4.2g in AM and 8.4mg in PM- depending on their side effect timing) 8.4mg AM, 4.2mg PM (or vice versa) 4.2mg BID 4.2mg BID 4.2mg once a day 4.2mg once a day Stop and take off study"
45491442|NCT03658850|Drug|Hydrochlorothiazide 50Mg|for the experimental group received a hydrochlorothiazide tablet on presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally on day 0 (D0) until day 3
45491443|NCT03658850|Drug|Placebos|for the placebo group will receive one tablet or equivalent volume of enteral solution of inert substance, identical to the hydrochlorothiazide presentations, every 12 hours until day 3
45491444|NCT03659162|Drug|Azole Antifungal|oral gel & injections
45491445|NCT03659084|Drug|EXJADE|The patient having given his consent, will begin the Exjade at 10 mg / kg per day if the ferritin level reached 1000 ng / ml at 6 months after allograft, for a minimum duration of three months and up to 6 months. The iron parameters will be evaluated at 3, 6, 9, 12, 18 and 24 months after the beginning of the exjade treatment. The evaluation of the disease will be carried out according to the practices of the center. It is recommended to have a washout period of one week between stopping the ciclosporin and the beginning of treatment by exjade.
45491446|NCT01068626|Drug|Rosuvastatin|10 mg once daily
45491447|NCT01068626|Drug|Placebo for rosuvastatin|once daily
45753815|NCT05622565|Diagnostic Test|Various modalities of ocular fundus imaging|Through various modalities of ocular fundus imaging, combining with clinical data and the experience of clinicians to diagnose different fundus diseases.
46053905|NCT02701712|Radiation|Magnetic resonance - guided radiation therapy (MRgRT)|Use of magnetic resonance (MR) visualization for interventional radiotherapy in cancer patients
45374520|NCT00991796|Drug|Paclitaxel|Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2
45374521|NCT00991796|Drug|Carboplatin|Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2
45374522|NCT00673673|Drug|FOLFOX|Oxaliplatin 85/mg/m2 IV infused over two hours followed by Leucovorin 400 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
45374523|NCT00673673|Drug|bevacizumab|bevacizumab will be used at a dose of 10 mg/kg administered every 2 weeks on day one of FOLFOX chemotherapy
45374524|NCT00770783|Device|Thymatron|Right unilateral placement, 3x seizure threshold, 3 times per week for 4 weeks
45491448|NCT03060668|Other|Peptamen intense|Study group will receive a nutritional formula containing 1.0 kcal/ml and 93 g/L of protein
45491449|NCT03060668|Other|Novasource senior|Control group will receive a nutritional formula containing 1.2 kcal/ml and 65 g/L of protein
45491450|NCT02921750|Device|Exufiber Gelling Fibre Dressing|Gelling fibre dressing
45491451|NCT02921750|Device|Aquacel Extra Hydrofiber® Dressing with Strengthening Fibre|Hydrofiber® Dressing with Strengthening Fibre
45491452|NCT03659006|Biological|Biological Collection|Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year
45491453|NCT03657836|Dietary Supplement|Sublimated mare milk supplement|The dietary supplement consisting of sublimated mare milk packed in single-dose sachet.
46053906|NCT02646839|Device|CliniMacs TCR alpha-beta-Biotin system|Graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells
46053907|NCT02611570|Other|LDCT|LDCT at enrollment, annually for two years and biennially for 6 years if no lung cancer is detected
46053908|NCT02543905|Procedure|Prostate MRI and Biopsy|All men will be offered a MRI and prostate biopsy and they can either opt to undergo these procedures at baseline irrespective of PSA level at baseline or they can undergo PSA-only screening until clinically indicated based on an age-defined PSA threshold, at which point, they will undergo prostate MRI and biopsy once their PSA reaches the threshold.
45374525|NCT00770783|Device|Tonica MagPro MST|100% power, vertex placement, 3 times per week for 4 weeks
45374526|NCT00763685|Drug|etoricoxib|etoricoxib 120 mg, paracetamol 1 g
45374527|NCT04048655|Drug|Neostigmine, Combinations|All patients have neostigmine induced recovery of neuromuscular block.
45374528|NCT04002986|Genetic|Genetic Testing|A blood draw or saliva kit will be provided to collect subject cells
45491454|NCT03657836|Drug|Standard antibiotic therapy|Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.
45491455|NCT03622502|Drug|Dexmedetomidine|Dexmedetomidine 0.5mcg/kg was infused over 10 min before end of the surgery
45491456|NCT03622502|Drug|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 2.0 ng/ml)
45491457|NCT03622502|Drug|Normal saline|Normal saline was infused over 10 min before end of the surgery
45374529|NCT02557997|Other|Blood tube bottom analyses|
45491458|NCT03658460|Other|DNA sequencing|Targeted next generation sequencing and gene expression analysis with focus on immuno-oncology signatures
45491459|NCT03658382|Other|Virtual Visit|Patients will receive the results of their genetic testing via a virtual visit.
45491460|NCT04401566|Other|Internal myofascial release|Internal myofascial trigger point release therapy consist of 30 minutes massage directly to the pelvic floor musculature by vaginally. Patients were instructed in internal myofascial relase techniques. Experienced pelvic health physiotherapist (A.B.) to use her fingers with a lubricated glove when the finger could easily reach internal trigger points and follows these steps: (a) finding internal and external trigger points associated with pelvic muscles, especially around sensitive areas of the vagina, anus, and/or pelvic floor; (b) releasing with the fingers the trigger point associated pelvic muscle tension by carefully pressing on the trigger point
45491461|NCT04401566|Other|External myofascial release|Eksternal myofascial trigger point release therapy consist 30 minutes massage to the abdominal wall, gluteal area and adductors and hamstring muscles. Pain in trigger points may exist at both locations of muscle insertion as well as in the belly and lower extremity of the muscle.
45491462|NCT04401566|Other|Control Group|The Control group will have a paper about exercises recommended in pelvic pain for 30 minutes. A physiotherapist will teach and show the exercises for pelvic pain. The home exercise for pelvic pain contains diaphragm breating, pelvic floor muscle stretching and releasing.
45491463|NCT04397354|Drug|Intracochlear Dexamethasone|intracochlear injection of dexamethasone with cochlear implantation
45491464|NCT04397354|Drug|Intratympanic Dexamethasone|intratympanic injection of dexamethasone with cochlear implantation
45491465|NCT04397354|Drug|No additional drugs(control Group)|Control group: No drugs will be injected middle ear with cochlear implantation
45491466|NCT02970344|Behavioral|Diabetes Coping Skills Training (DCST)|Diabetes Coping Skills Training (DCST) consist of twelve 50 minutes sessions delivered over 6 months using a faded contact model ( 6 weekly session, 3 biweekly sessions and 3 monthly sessions)
45491467|NCT03658226|Behavioral|Psychodynamic Interpersonal Therapy (PIT)|PIT is conversational model of psychotherapy; participants will receive 8 sessions of this therapy once weekly. The first session will be 2 hours and all remaining sessions will be 50 minutes.
45491468|NCT04387916|Drug|KC1036|Part 1: Dose-escalation phase , KC1036 10mg~80mg, consists of 5 Cohorts. Part 2: Dose-expansion phase, consists of 3~4 Cohorts based on part 1. Part 3:RP2D-extension phase, Recommended dose of KC1036 based on part 1and part 2.
45491469|NCT03657758|Drug|EPA and rosuvastatin|To take EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
45491470|NCT03657758|Drug|High dose rosuvastatin|To take high dose rosuvastatin (10mg/day) for ９ months.
45491471|NCT02920970|Device|narafilcon A|contact lens
45491472|NCT02920970|Device|stenfilcon A|contact lens
45491473|NCT03658148|Procedure|Cardiac Surgery with Cardiopulmonary Bypass|Cardiac Surgery with Cardiopulmonary Bypass
45491474|NCT01068158|Drug|0.5% Ivermectin Cream|Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.
45491475|NCT01068158|Drug|Placebo control|up to 4 ounces of topical vehicle control to head and scalp on day 1.
45491476|NCT03303079|Drug|TEV-48125|TEV-48125 will be subcutaneously administered once monthly for 3 months.
45374530|NCT05273918|Other|cognitivo-comportmental therapy|15 workshops once a week during 90 minutes
45491477|NCT03303079|Drug|TEV-48125 or placebo|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
45491478|NCT03303079|Drug|Placebo|Placebo will be subcutaneously administered once monthly for 3 months.
45491479|NCT01067846|Drug|Seromycin (D-cycloserine, DCS)|250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
45491480|NCT01067846|Drug|Placebo|Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
45491481|NCT01067846|Behavioral|Computerized Cognitive Behavioral Therapy|All participants received Computerized Cognitive Behavioral Therapy sessions 3 times per week for 4 weeks as a drug relapse intervention.
45491482|NCT03657680|Other|Evaluation|The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
45491483|NCT04505839|Drug|STP1002|Oral capsule, QD
45491484|NCT03658070|Drug|XY0206|Dosage form:Tablet;Single dose treatment:Take the drug once on day 1,each time 1 tablet. Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the criteria for stopping treatment or determine the duration and interval of treatment according to the accumulated condition after multiple dose.
45491485|NCT04745143|Drug|NMDAE|Use of an NMDA enhancer for the treatment of schizophrenia
45374531|NCT05273918|Other|body mediation|15 workshops once a week during 90 minutes
45374532|NCT00768677|Drug|topiramate|
45374533|NCT00770939|Device|Vivostat PRF|Ulcer will be treated week 1,2,3,4,5 and 6 with Vivostat PRF
45374534|NCT04003064|Diagnostic Test|Blood|3ml blood
45374535|NCT05257694|Procedure|Surgery|hepatectomy
45374536|NCT05257694|Procedure|Ablation (Microwave ablation or Radiofrequency ablation)|image-guided ablation
45374537|NCT02557451|Other|Surgery|
45374538|NCT02557451|Other|Intravitreal injections of gas|
45374539|NCT02557451|Procedure|injections of an antiangiogenic|
45374540|NCT05408936|Drug|SGLT2 inhibitor|Patients receive an SGLT2 inhibitor as part of theirn routine care.
45374541|NCT02558153|Device|DEB, drug eluting balloon|Percutaneous angioplasty performed with a DEB - drug eluting balloon
45491486|NCT04745143|Drug|Placebo Cap|Use of placebo as a comparator
45491487|NCT03657914|Procedure|Single-hole inflatable mediastinal mirror|The radical resection of single-hole inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma is new minimally invasive operation for esophageal carcinoma. All enrolled subjects will receive this operation for their ESCC.
45491488|NCT03657524|Other|echocardiography|Speckle tracking echocardiography
45491489|NCT03311659|Biological|Boostrix|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm in dTap group.
45491490|NCT03874234|Drug|GSK3186899|GSK3186899 will be available as white to slightly colored, spray dried powder in a bottle to be administered orally along with mixture of propylene glycol and water.
45491491|NCT03874234|Drug|Placebo|Placebo will be available as white to slightly colored, blend powder in a bottle to be administered orally along with mixture of propylene glycol and water.
45491492|NCT03657446|Drug|Clazosentan|Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h
45491493|NCT03657446|Drug|Placebo|Matching placebo infusion
45374542|NCT02558153|Device|standard PTA|Percutaneous angioplasty performed with a standard balloon
45374543|NCT01945814|Drug|CTL for CMV seropositive donors|CTL for CMV seropositive donors-Allogeneic Multivirus Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV seropositive donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
45491494|NCT03657446|Drug|Moxifloxacin|Film-coated tablet containing 400 mg moxifloxacin
45491495|NCT05276323|Drug|Medihoney Derma Cream|applied topically, twice a day, on all affected areas in the body for two weeks.
45491496|NCT05276323|Drug|Hydrocortisone 1% cream|applied topically, twice a day, on all affected areas in the body for two weeks.
45491497|NCT02727452|Other|Skin-to-skin contact|
45491498|NCT05276245|Behavioral|Structured Protocol of Nature Contact|This structured protocol was a 10-day nature-based program with high level of nature engagement and involvement of multiple sensory processes. The program was held in lunch breaks between 12:00 noon and 2:00 p.m. Each session consisted of 30 minutes in the Eco Garden of The Education University of Hong Kong. Activities of this program included walking, ecological photography, sketching butterflies, planting vegetables, drinking herbal tea, observing birds, and taking a nap in nature. Each activity corresponded to specific sensory pathways. For example, butterfly sketching is focused on the use of visual sense, whereas drinking herbal tea involved sense of taste, smell, and touch. Trainers with master's degrees in environmental education and rich experience in guiding ecological tours provided instructions and guidance to participants during the activities. Participants were also asked to pay attention to their surroundings and focus on their five senses during participation.
45491499|NCT05275777|Drug|ADG106|Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.
45491500|NCT05275777|Drug|Doxorubicin|Administered as an intravenous infusion.
45491501|NCT05275777|Drug|Cyclophosphamide|Administered as an intravenous infusion.
45491502|NCT05275777|Drug|Paclitaxel|Administered as an intravenous infusion.
45491503|NCT02985398|Biological|ALD403 (Eptinezumab)|
45491504|NCT03856060|Other|Questionnaire Administration|Complete questionnaires
45491505|NCT03856060|Other|Video|Watch videos of doctor and patient interaction in different settings
45753950|NCT00452387|Drug|Mitoxantrone|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Mitoxantrone 9mg/m2~Dose Level -1 Mitoxantrone 12mg/m2~Dose Level 1 Mitoxantrone 12mg/m2"
46053909|NCT02494570|Drug|nab-Sirolimus|Patients received nab-sirolimus at 100 mg/m2 on Days 1 and 8 of a 21-day cycle by intravenous infusion over 30 minutes.
46053910|NCT02437071|Drug|Pembrolizumab|Pembrolizumab will be administered as a 30 minute IV infusion (every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
46053911|NCT02437071|Radiation|Radiotherapy|
46053912|NCT02437071|Procedure|Radiofrequency ablation|
45491506|NCT05275621|Device|Virtual Reality|"A Virtual Reality game is provided through a headset. Subjects play in a virtual environment. Positioning of the headset occurs before starting the procedure and is maintained throughout the procedure. The headset used will be Oculus Rift 2 by Facebook Tech. ltd.. The software is designed specifically for the purpose by Softcare Studios. The game played is called Drums."
45491507|NCT05275621|Procedure|PICC positioning|A PICC is inserted under ultrasound guidance through a modified Seldinger technique in a deep vein of the upper arm. The skin is infiltrated with 0.5-1ml 2% lidocaine before dilation of the skin. Tip guidance and positioning is achieved through intracavitary ECG.
45491508|NCT04460144|Diagnostic Test|Mass spectrometry|Proteomic analysis
45491509|NCT03310723|Device|Face Mask preoxygenation|Standard face mask preoxygenation.
45491510|NCT03310723|Device|OptiFlow preoxygenation|Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
45491511|NCT02760290|Procedure|Extraperitoneal cesarean section|
45491512|NCT02760290|Procedure|Intraperitoneal cesarean section|
45491513|NCT05672212|Device|ANI (Analgesia/Nociception Index) monitoring|Intraoperative analgesia was provided by injection of sufentanil, which was performed according to ANI monitor.
45491514|NCT05672212|Device|standard monitoring|Intraoperative analgesia was provided by injection of sufentanil, which was performed according to the clinician's assessment.
45491515|NCT05672212|Drug|Sufentanil|Sufentanil
45491516|NCT05275309|Other|Exploration of optimal PEEP in supine and prone position|"General anesthesia is done in routine manner~A sensor for electrical impedance tomography (EIT) is applied around the patient's chest.~In supine position, lung recruitment maneuver is done, followed by decremental PEEP trial. Based on EIT parameter, optimal PEEP which induces minimal overdistension and collapse of lungs is determined.~One hour after prone position, optimal PEEP is determined again."
45491517|NCT02388022|Device|Degenerative Disc Disease|lumbar interbody with posterior screw and rod instrumentation
45491518|NCT02725892|Other|NIS observational stud|NIS observational study : Epidemiologic registry
45491519|NCT05275153|Other|Home based cognitive rehabilitation program|The home based cognitive rehabilitation program intervention was conducted for 30 minutes each time, 3 times a week for 8 weeks, a total of 24 times.
45491520|NCT02390674|Drug|Ciclosporin|Comparison between ciclosporin and placebo
45491521|NCT02390674|Drug|Saline|
45491522|NCT03657290|Drug|vadadustat|Vadadustat Tablets
45491523|NCT02390830|Other|Falls Prevention|
45491524|NCT02390830|Other|Reduction of limitations at body function and activity levels|
45491525|NCT03622346|Procedure|Semi-constrained total knee arthroplasty|Semi-constrained total knee arthroplasty
45374544|NCT01945814|Drug|CTL for CMV naïve donors|CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV naïve donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
45374545|NCT04048187|Device|Phone Application|Phone application is developed to adjust hearing aids. It incorporates functionalities like volume control and program change.
45374546|NCT05408858|Behavioral|LGBTQ-affirmative cognitive behavioral group therapy|10 sessions of supportive, LGBTQ-affirmative psychotherapy
45374547|NCT01041742|Procedure|fluid loading|fluid loading will be performed by using 6% hydroxyethyl starch solution , at 10 mL/kg.
45374548|NCT00763763|Drug|Imatinib mesylate|imatinib 600 mg/day for 2 years
45374549|NCT00763763|Drug|Interferon|45 micrograms per week during 2 years
45491526|NCT02613728|Behavioral|Accelerated Recovery Plan|
45491527|NCT02613728|Behavioral|Early Discharge|
45491528|NCT02613728|Other|Telemedicine|
45491529|NCT02613728|Behavioral|Standard Enhanced Care|
45491530|NCT02390596|Drug|Anakinra|The dose of Anakinra will be 2mg/kg (patients <10kg and/or <8 months: 4mg/kg). If the patient remains febrile (fever >38°C), he will receive a double dose of anakinra 4mg/kg (patients <10kg and/or <8 months: 6mg/kg) at day1 instead of 2mg/kg. If the patient does not respond to the 4mg/kg dose at visit 3; d1 within 24 hours, he will receive at visit 4; d2, 6mg/kg of anakinra (patients <10kg and/or <8 months: 8mg/kg). Treatment will be continued until they have achieved complete response as defined in the outcome measurement section, and during a maximum of 15 days.
45491531|NCT02663674|Drug|Fluconazole|Fluconazole is a synthetic triazole antifungal agent. It will be supplied as 200 mg over encapsulated tablets. Each gelatin capsule will contain two-100 mg fluconazole tablets and microcrystalline cellulose for overfill.
45491532|NCT02663674|Other|Placebo|Placebo will be supplied as matching gelatin capsules containing microcrystalline cellulose only. Capsules are the same size, weight, and color as capsules containing fluconazole tablets.
45491533|NCT02908880|Device|MANTA vascular closure device|The appropriate size of MANTA closure device will be selected and used for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.
46053913|NCT02396823|Behavioral|Respiratory Muscle Training|Standard threshold Positive Expiratory Pressure Device and threshold Inspiratory Muscle Trainer assembled together using a T-shaped connector with flanged mouthpiece will be used. The participants will be instructed to perform inspiratory and expiratory efforts against a resistive load. Training session lasts 45 minutes per day, 5 days per week, for 4 weeks.
45491534|NCT03657212|Drug|Zolpidem|The research involves oral administration of zolpidem (ZOL) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced.
45491535|NCT03310411|Drug|Lasmiditan|Administered orally
45491536|NCT03310411|Drug|Sumatriptan|Administered orally
45491537|NCT03310411|Drug|Placebo for Lasmiditan|Administered orally
45491538|NCT03310411|Drug|Placebo for Sumatriptan|Administered orally
45491539|NCT03301831|Behavioral|Resourcefulness Training|Cognitive-behavioral intervention that includes personal and social resourcefulness skills.
45491540|NCT02909504|Drug|Lithium|Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels > 0.6 mEq/L
45491541|NCT02505230|Behavioral|Eating|Participants will have 20 minutes to eat as much or as little of a meal (consisting of pasta alone or pasta with zucchini and squash presented in 3 different ways)
45491542|NCT02390440|Drug|EXPAREL|
45491543|NCT03739372|Other|Specialized tumor board recommendation|Based on the molecular profile, the specialized tumor board will determine an individualized treatment recommendation for each patient using up to four FDA approved drugs. In special circumstances, Investigational new drug (IND) study agents may be used.
45491544|NCT03677830|Drug|Acetaminophen|Scheduled intravenous acetaminophen for post-operative pain to minimize opiate exposure.
45491545|NCT03677830|Drug|Saline|Intravenous saline will be administered at appropriate volume and schedule for control group as a placebo.
45491546|NCT02387866|Drug|AG-221|
45491547|NCT02199691|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
45491548|NCT02199691|Biological|Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|0.5 mL, IM
45491549|NCT02199691|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
45491550|NCT02199691|Biological|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
45693108|NCT03805048|Procedure|Percutaneous coronary intervention|PCI of the bypass graft will be performed by current standards and at the discretion of the operator. Only commercially available second generation DES - XIENCE Sierra will be used. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using 4 complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation, retrograde dissection reentry. In case of PCI failure, a second attempt can be performed within 1 month. Patients will be hospitalized for a min. of 6-8 hours after PCI and receive DAPT prior to the procedure or triple therapy in case of indication for oral anticoagulation, their duration according to the current guidelines of the ESC for stable coronary disease or ACS.
45693109|NCT03804892|Diagnostic Test|Body Composition|Participants undergo a 5 minute body scan to determine their body composition.
45374550|NCT00763763|Drug|Vincristine|2 mg IV injection repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
45374551|NCT00763763|Drug|Dexamethasone|40 mg PO repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
45374552|NCT04003298|Device|Electric toothbrush|Electric toothbrush and power interdental device
45374553|NCT04003298|Device|Control|Oscillating-rotating
45374554|NCT01041820|Behavioral|Exercise|Children will be exposed to a 10-week exercise intervention
45374555|NCT00763841|Device|Transcranial magnetic stimulation|Stimulation will be given daily at a particular site for three days a week
45374556|NCT00763841|Device|Sham|
45374557|NCT01037140|Drug|Cholecalciferol|oral cholecalciferol tablets of 175 micrograms daily for 6 months
45491551|NCT02199691|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (IM)
45491552|NCT02199691|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
45491553|NCT02199691|Biological|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
45693110|NCT03804892|Diagnostic Test|Maximal aerobic fitness test|Participants will complete a walking fitness text until exhaustion to determine maximal aerobic capacity.
45693111|NCT03804892|Diagnostic Test|Oral glucose tolerance test|Participants will undergo an OGTT to determine insulin sensitivity.
46053914|NCT02389387|Other|Intensive Intervention|I.A multi-module, secure, web-enabled software application called Transplant Referral EXchange (T-REX):1) real-time communication between staff across healthcare settings, documenting the use of transplant education materials, 2) sending/receiving electronic referrals for transplant specific to a transplant center's requirements and 3) tracking patients' status in the transplant process (e.g., patient interest in transplant, referral for transplant, evaluation start/completion, waitlist status, and transplant) II. Educational webinars/seminars for staff, III. Facility-specific performance feedback reports, IV. Assistance with and review of center-specific action plans to increase transplant referral, V. Scheduled bi-annual phone calls with an SETC member to monitor progress, VI. Patient education on transplant via creation of an Education Station in facility lobby, VII. Development of a Peer Mentor program.
46053915|NCT02341274|Drug|Tacrolimus|Bioequivalence study
45374558|NCT01037140|Drug|placebo|oral placebo tablets similar to active comparator
45374559|NCT05357456|Behavioral|Cognitive function assessment; functional magnetic resonance imaging|cognitive function measurement
45374560|NCT05357456|Procedure|laparoscopic adrenal surgery|Only a subgroup of the autonomous cortisol secretion patients will have the laparoscopic adrenal surgery
45374561|NCT00069121|Drug|Capecitabine|1000 milligrams per square metre of body surface area (mg/m^2) orally twice daily on days 1-15 of each 3-week cycle.
45491554|NCT05671978|Procedure|back-up head elevated position|The patient was then placed in the back-up head elevated position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table
45491555|NCT05671978|Procedure|neutral position|The patient was then placed in the netural position
45491556|NCT05667454|Drug|Atropine Ophthalmic 0.05%|Atropine 0.05% sulphate ophthalmic solution
45491557|NCT05667454|Drug|Atropine Ophthalmic 0.5%|Atropine 0.5% sulphate ophthalmic solution
45491558|NCT02390128|Other|observational only|
45491559|NCT03113578|Device|DiLumen|The study device is placed over a compatible endoscope to facilitate endoscopic diagnosis and treatment of any large intestine pathology with the use of double balloons
45491560|NCT03105856|Biological|CERVARIX|- HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 month). This group will receive the HPV16/18 vaccine containing HPV16 and HPV18 L1 virus-like-particles (20 μg of each) adjuvanted with 50 μg 3-O-desacyl-4'-monophosphoryl lipid A and 0.5 mg aluminum hydroxide (GlaxoSmithKline Biologicals, Rixensart, Belgium). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
45374562|NCT00069121|Drug|Oxaliplatin|130 mg/m^2 intravenous (IV) infusion over two hours on Day 1 of each 3-week cycle.
45491561|NCT03105856|Biological|GARDASIL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) recombinant vaccine according to a two dose schedule (0-12 month). This group will receive amorphous aluminum hydroxyphosphate sulfate adjuvanted quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine (Merck Sharp & Dohme Corp. Whitehouse Station, NJ, USA). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
45491562|NCT03299881|Device|Transcutaneous Nerve Stimulator (TENS)|The Elira wearable patch system is a RF coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.
45491563|NCT03299881|Behavioral|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
45491564|NCT02389972|Drug|Dasatinib|
45491565|NCT03105934|Procedure|Patients with Pulmonary Arterial Hypertension|2 repeated measurement session to enable assessment of technical and medium-term reproducibility of IV-US and IV-OCT.
45374563|NCT00069121|Drug|Leucovorin (LV)|Administered by one of two regimens, as specified in the arm description.
45374564|NCT00069121|Drug|5-Fluorouracil (5-FU)|Administered by one of two regimens, as specified in the arm description.
45374565|NCT00768911|Drug|CT-322|"Intravenous solution, intravenous administration, starting dose level of 0.5 mg/kg/week~Dose levels: 0.5 mg/kg/week, 1.0 mg/kg/week, 2.0 mg/kg/week"
45374566|NCT00768911|Drug|Temozolomide|"75 mg/M2/day p.o. continuously 7 days per week during concurrent RT (max: 49 days)~150 mg/M2/day X 5 days; adjuvant cycle #1~200 mg/M2/day X 5 days; subsequent adjuvant cycles (# 2-12) if tolerability criteria met"
45374567|NCT00768911|Procedure|Radiation Therapy|RT will consist of fractionated focal irradiation administered using 2 Gy/fraction, QD x 5 days/week for 6 weeks, for a total dose of 60 Gy
45374568|NCT01860404|Drug|Branched Chain Amino Acids|The three BCAA's will be combined together and dissolved in a flavored solution.
45374569|NCT01860404|Drug|Placebo solution|The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.
45491566|NCT04703647|Other|Administration of questionnaires for prospective group|Questionnaires: administration at T0, T1,T2,T3 and T4 of Short Form Health Survey (SF-36),Brief Pain Inventory (BPI),Disabilities of the Arm, Shoulder and Hand (DASH) for upper limb,Foot and Ankle Ability Measure (FAAM) for lower limb,Hospital Anxiety And Depression Scale (HADS),Tampa Scale of Kinesiophobia (TSK),Pain Catastrophizing Scale (PCS),Pattern Of Activity Measure - Pain (POAM-P) .
45491567|NCT04703647|Other|Blood samples for prospective group|Blood samples at T0,T1,T2 and T3.
45491568|NCT04703647|Other|Blood samples for control group|Blood samples just one time
45491569|NCT03299101|Other|Prehabilitation|Prehabilitation will last 4 weeks and consist of a novel, home-based regimen of (a) aerobic conditioning; (b) strength and coordination training; (c) respiratory muscle training; and (d) nutritional coaching and supplementation.
45491570|NCT02663128|Drug|Lanabecestat|Administered orally
45491571|NCT03502330|Drug|APX005M|APX005M is a humanized Immunoglobulin G (IgG) 1 agonistic monoclonal antibody that binds cluster of differentiation (CD) 40. APX005M is administered by intravenous infusion.
45491572|NCT03502330|Drug|Cabiralizumab|Cabiralizumab is a humanized Immunoglobulin G (IgG) 4 monoclonal antibody directed against Colony stimulating factor 1 receptor (CSF1R). Cabiralizumab is administered by intravenous infusion.
45491573|NCT03502330|Drug|Nivolumab|Nivolumab is a humanized IgG4 monoclonal antibody directed against programmed cell death 1 (PD-1). Nivolumab is administered by intravenous infusion.
45374570|NCT00769145|Drug|Ranibizumab|0.5mg subconjunctival dose of ranibizumab 3 days prior to corneal transplantation and at the time of corneal transplantation (total 2 injections).
45374571|NCT00399802|Drug|ZA|Single ZA 4 mg IV infusion at the start of treatment
45374572|NCT00399802|Drug|Odanacatib|Once-daily odanacatib 5 mg tablet for 4 weeks
45374573|NCT00399802|Drug|Odanacatib matching placebo|Once-daily odanacatib matching placebo for 4 weeks
45374574|NCT00399802|Drug|ZA matching placebo|Single IV infusion of ZA matching placebo given at the start of treatment
45491574|NCT03495232|Device|Zimmer Biomet Persona total knee system|Product manufactured by Zimmer Biomet used to replace the knee joint.
45491575|NCT02389582|Drug|Dabigatran|Use for 5 days
45491576|NCT02389582|Drug|Enoxaparin|Use for 5 days
45491577|NCT03298867|Biological|Teprotumumab|Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses > 1800 mg).
45491578|NCT03298867|Other|Placebo|Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses > 1800 mg).
45491579|NCT02906930|Drug|semaglutide|Oral administration once daily.
45491580|NCT02906930|Drug|placebo|Oral administration once daily.
45491581|NCT05198596|Biological|MVC-COV1901|Approximately125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
45491582|NCT05198596|Biological|AZD1222|Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
45693112|NCT03804892|Other|Muscle biopsy|Participants will give a small muscle sample pre-, immediately post and 3 hours post- the exercise trial to be assessed for lipid metabolites.
45374575|NCT00763997|Drug|dipyrone|Dipyrone is given in the operation room with 2,5 g intravenously, followed by an oral regime of 4x1g on the ward
45374576|NCT00763997|Drug|Ibuprofen|Ibuprofen is given orally 600mg in the Post Anesthesia Care Unit, followed by an oral regime of 800mg twice a day
45374577|NCT00763997|Drug|Acetaminophen|Acetaminophen is given 1g intravenously in the Operation room, followed by an oral regime of 1g fourth a day
45374578|NCT00763997|Drug|Acetaminophen|Acetaminophen is given 1g intravenously in the operation room, followed by 1g orally fourth a day
45374579|NCT00763997|Drug|Parecoxib/Valdecoxib|40mg Parecoxib are given intravenously in the operation room, followed by 40mg of Valdecoxib orally twice a day
45374580|NCT00763997|Other|Blood samples|Blood samples for aggregometry are taken before induction of anesthesia, 1h after first drug intake, 4hs and 24hs after first intake
45374581|NCT00771095|Behavioral|podcasting|
45374582|NCT00771251|Drug|CNTO 148|50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 116.
45374583|NCT00771251|Drug|Placebo|Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks until week 12 and then CNTO148 50mg SC injections every 4 weeks from week 16 until week 116.
45374584|NCT01420250|Drug|Cabazitaxel|"Administered weekly on the same day of radiation according to the following infusion levels:~Level 1 (Initial): 4 mg/m2; Level -1: 2 mg/m2; Level 2: 6 mg/m2; Level 3: 8 mg/m2; Level 4: 10 mg/2;"
45491583|NCT02389426|Device|TCD baseline|"Measurement of cerebral circulation parameters with transcranial doppler baseline.~This examination will be performed in patients with multiple sclerosis and in healthy controls."
45491584|NCT02389426|Device|TCD after bosentan administration|"Measurement of cerebral circulation parameters with transcranial doppler after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.~This examination will only be performed in patients with multiple sclerosis."
45491585|NCT02389426|Device|NIRS baseline|"Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy baseline.~This examination will be performed in patients with multiple sclerosis and in healthy controls."
45491586|NCT02389426|Device|NIRS after bosentan administration|"Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.~This examination will only be performed in patients with multiple sclerosis."
45491587|NCT05274841|Other|Support of relatives|Screening of the support needs of relatives
45491588|NCT02389660|Behavioral|Blended Cognitive Behavioural Therapy (CBT)|
45491589|NCT02389660|Behavioral|Treatment as usual|
45491590|NCT04580407|Biological|TAK-672|B-Domain Deleted Recombinant Porcine Factor VIII
45374585|NCT01420250|Radiation|Intensity Modulated Radiation Therapy (IMRT)|Starts 8 weeks after initiation of androgen deprivation therapy, given daily at 1.8 Gy for a total of 75.6 Gy
45374586|NCT01420250|Drug|Anti-Androgen Therapy: Bicalutamide|"Taken once daily by mouth starting between 2 weeks and 1 day before the first administration of Luteinizing Hormone-Releasing Hormone (LHRH)~Will continue once daily until the final day of IMRT"
45491591|NCT02389504|Other|Dynamic Exertional Physical Therapy|By contrast, the dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
45491592|NCT02389504|Other|Standard Exertional Physical Therapy|Standard treadmill running, monitoring heart rate
45491593|NCT05256589|Diagnostic Test|Sona Saliva C-19 Rapid Self-test|Rapid Antigen diagnostic device performance comparative to RT-PCR
45491594|NCT02387320|Other|Self-Care Toolkit|The self-care toolkit was designed and created for individuals undergoing surgery and/or invasive medical procedures. It provides individuals with guided instruction to learn several evidence-informed mind-body skills (e.g., breathing, relaxation, meditation, guided imagery) and tools (e.g., acupressure wristbands, journal) in order to regulate their own physiologic and emotional reactions to stressful situations and to lessen symptoms associated with surgery (principally pain, anxiety, nausea, fatigue, sleep disturbance).
45491595|NCT05255497|Device|Biodex Balance Exercise System|Patients in the intervention group (n=14) performed exercises using the computerized BBS. The control group (n=13) was just informed about diabetes self-management.
45491596|NCT02389348|Drug|DSM265|Single oral doses of DSM265
45491597|NCT02389348|Drug|OZ439|Single oral doses of OZ439
45491598|NCT05255341|Procedure|roll pedicle connective tissue graft with bovine bone|rotated pedicle connective tissue graft together with bovine bone applied for socket preservation after tooth extraction
45491599|NCT03656978|Behavioral|dynamic|Use the according methods in dynamic arm descriptions.
45374587|NCT01420250|Genetic|Luteinizing Hormone-Releasing Hormone (LHRH) Agonist|"First administration will occur 1 day to 2 weeks after the start of Bicalutamide and 8 weeks prior to the start of IMRT (+/- 4 weeks)~Will continue for 24 months after IMRT~Total administered duration and agent used must be documented on the case report form"
45491600|NCT03656978|Behavioral|Regular-triangle|Use the according methods in regular-triangle arm descriptions.
45491601|NCT02383108|Drug|DTG +DRV/r|NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
45491602|NCT02383108|Drug|SOC|Standard of care (continuing triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI)
45491603|NCT02383186|Procedure|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
45491604|NCT02383186|Procedure|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
45491605|NCT03656822|Diagnostic Test|Routine CT|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions.
45491606|NCT03656822|Diagnostic Test|Routine imaging CT with a 3D printed model|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + 3D Printed Model
45491607|NCT03656822|Diagnostic Test|Routine imaging MRI with a 3D printed model|will measure post-operative lesion volume as visualized on the post-operative MRI + 3D Printed Model
45491608|NCT03656822|Diagnostic Test|Routine MRI|will measure post-operative lesion volume as visualized on the post-operative MRI
45491609|NCT03656822|Diagnostic Test|Routine imaging CT with a VR model|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + VR Model
45491610|NCT03656822|Diagnostic Test|Routine imaging MRI with a VR model|will measure post-operative lesion volume as visualized on the post-operative MRI + VR Model
45374588|NCT00399568|Drug|IV Acetaminophen|Intravenous acetaminophen 1 g/100 mL
45374589|NCT00399568|Drug|IV Placebo 100 mL solution|IV Placebo 100 mL solution dosed at same frequency as IV Acetaminophen every 6 hours (q6h)
45374590|NCT03960853|Procedure|pressure-controlled ventilation-volume guaranteed|patients will be allocated to pressure-controlled ventilation-volume guaranteed in operation
45374591|NCT03960853|Procedure|volume controlled ventilation|patients will be allocated to pressure-controlled ventilation volume guaranteed in operation
45374592|NCT05088356|Drug|Purified regulatory T-cells (Treg) plus CD34+ HSPC|"Purified regulatory T-cells (Treg) plus CD34+ hematopoietic progenitor cells (CD34+ HSPC), Manufactured at SCTT Laboratory, dose 1x10^6 cells/kg to 3x10^6 cells/kg"
45491611|NCT02387242|Drug|Rifampicin|Single oral dose of rifampicin
45491612|NCT03656588|Drug|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol
45491613|NCT03656588|Drug|Iodine scrub and ChloraPrep alone|Iodine scrub and ChloraPrep alone
45491614|NCT02387086|Drug|Thalidomide|
45491615|NCT02387086|Drug|placebo|
45491616|NCT02387086|Drug|Gefitinib|
45491617|NCT02387086|Drug|Aspirin|
45491618|NCT02383030|Drug|Fulvestrant|After randomization patients will receive (Arm A, experimental Arm) fulvestrant as the following schedule: 500 mg i.m. on Days 0, 14, 28 followed by fulvestrant 500 mg im given every 28 days until progression disease. Study will start after 42 days from the last cycle of chemotherapy
45491619|NCT02382952|Device|Differential Dissector|
45491620|NCT02382952|Other|Standard Dissection Method|
45491621|NCT02386930|Behavioral|Behvarioal lifestyle modification|A six months behavioral lifestyle program composed of 8 sessions; 4 individual consultations and 4 telephonic calls. The cognitive behavior theory (CBT) is the underpinning theory for the lifestyle intervention; hence CBT behavioral strategies like self monitoring and goal setting are used to improve compliance to healthy lifestyle practices
45491622|NCT02389114|Other|Soy Protein|Soy protein is commonly consumed in Asian diet.
45374593|NCT05088356|Drug|Fludarabine|Fludarabine (160 mg/m2)
45374594|NCT05088356|Drug|Melphalan|Melphalan (50 mg/m2) in Arm A; Melphalan (100 mg/m2) in Arm B
45491623|NCT02389114|Other|Polydextrose|Polydextrose is a randomly bonded polymer of glucose developed in the 1960s. It is widely recognized as a soluble fiber that is not digested in the upper gastrointestinal tract due to the complex structure and nature of the glycosidic bonds, but is partially fermented by the microbiota in large intestine generating short chain fatty acids.
45491624|NCT02386852|Drug|Placebo|Study subjects received, in a double blind fashion, placebo pills identical to the drug (drug 1-ginseng, group 1; drug 2-ginkgo biloba-group 2)
45491625|NCT02386852|Drug|Ginseng|The ginseng group received two capsules containing either 1000 mg or 500 mg of Panax Ginseng extract standardized to 3% of ginsenosides (GNC, USA) or similarly looking placebo capsules over a period of three days of testing.
45374595|NCT05088356|Device|CliniMACS CD34 Reagent System|The CliniMACS® CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations is manufactured by Miltenyi Biotec
45491626|NCT02386852|Drug|Ginkgo Biloba|The ginkgo group received two capsules containing either 240 mg or 120 mg of ginkgo biloba extract standardized to 24% ginkgo flavone glycosides and 6% terpene lactones (GBE24/6) or similarly looking placebo capsules over a period of three testing days.
45491627|NCT02388802|Procedure|Oocyte retrieval and freezing|10 Patients will undergo oocyte retrieval and freezing
45491628|NCT02388802|Procedure|Deceased Donor Allograft Excision|Appropriately matched uterine transplant allografts will be excised from deceased donors
45491629|NCT02388802|Procedure|Uterine Transplantation|Following egg freezing the patients will undergo uterine transplant from deceased donors
45491630|NCT02388802|Drug|Immunosuppressive Agents|Patients will be appropriately immunosuppressed, whilst being closely monitored clinically, radiologically and immunologically.
45491631|NCT02388802|Procedure|In-vitro fertilisation|12 months after successful transplantation,the patients will undergo IVF
45491632|NCT02388802|Procedure|Caesarean Section|Following successful conception and antenatal period, the babies will be born by Caesarean Section
45491633|NCT02386696|Other|Ultrasound|Lung ultrasound examination on healthy volunteers
45491634|NCT05358964|Behavioral|African American Family Health History Education Program|The AAFHHEP arm is an intervention to increase utilization of FHH and increase preventative screening. This tool will be culturally tailored by African Americans for African Americans.
45491635|NCT02382874|Biological|Intravenous injection|Intravenous injection of AD-MSC to the patients with FSGS
45491636|NCT02382718|Biological|FAST fish mCyp c 1|Subcutaneous immunotherapy
45491637|NCT02382718|Biological|Placebo|Subcutaneous immunotherapy
45374596|NCT05088356|Drug|Tacrolimus|4-6ng/mL
45374597|NCT05088356|Drug|Cyclophosphamide|40mg/kg
45491638|NCT02382484|Device|A dual chamber pacing system (BackBeat Medical)|For each patient, one pacing electrode was placed in the right atrium and the second electrode was placed in the right ventricle. With a dual chamber pacing system (BackBeat Medical) it was possible to pace the heart with a wide variety of pacing settings.
45374598|NCT05088356|Drug|Plerixafor|Dose 0.24 mg/kg, manufactured by Genzyme
45374599|NCT05088356|Drug|Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent|Single-use vials contain either 300 mcg or 480 mcg filgrastim at a fill volume of 1.0 mL or 1.6 mL
45374600|NCT01326949|Procedure|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. Postoperatively, intravenous heparin (8,000-12,000 u/d) for five days, warfarin for six months were given.
45374601|NCT01326949|Procedure|ET+NSBB|"ET-Esophageal varices was treated by endoscopic variceal ligation (EVL). EVL was repeated at intervals of 1-2 weeks until the varices were obliterated or reduced to grade-I size.~NSBB-Propranolol started at a dose of 20mg twice a day. The dose is adjusted to the maximal tolerated doses to heart rate (HR) of 55 bpm or to decrease the HR 25% from baseline.~AT-A continuously intravenous infusion of unfractionated heparin followed by oral warfarin is employed. Initially, heparin is administered intravenously for 5 days. Subsequently, oral warfarin is prescribed at the dosage of 2.5 mg/d for 6 months or until complete portal vein recanalization and adjusted to maintain the INR at a target of 2.5 (range 2.0-3.0)."
45374602|NCT00764075|Device|Beutel TM|application of BeutelTM
45374603|NCT00764075|Other|standard|standard procedure will be applied but no Beutel TM software
45374604|NCT00764075|Device|software Beutel TM|application of BeutelTM to patients data for determination of site of latest contraction
45374605|NCT01039558|Drug|ecabet sodium|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
45374606|NCT01039558|Drug|lansoprazole|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
45491639|NCT02382562|Behavioral|Brief Behavioral Activation Intervention|Clinical psychologists (investigators) will instruct the participant in ways to become more active in life, particularly with regards to activities that the participant finds pleasurable and meaningful. The intervention will take one hour to complete. Following the intervention, the participant will receive brief, weekly text or email reminders for the next 4 weeks (total of 4) to engage in pleasurable and meaningful activities during the week.
45491640|NCT02386306|Drug|GC021109|
45491641|NCT02386306|Other|Placebo|
45491642|NCT02382172|Behavioral|Social Cognition and Interaction Training for Autism (SCIT-A)|The group therapy program is aimed at improving social cognitions and skills of individuals who find social situations difficult, stressful and/or uncomfortable and with a desire to enhance skills required for social interactions.
45491643|NCT02382172|Other|Treatment as Usual (TAU)|Participants in the treatment as usual (TAU) group will continue to receive other interventions (e.g., individual therapy, job skills coaching) during the Social Skills Clinic. No participants in either group will participate in other group-based interventions concurrently with their participation in this study.
45491644|NCT02983604|Drug|GS-5829|Tablet(s) administered orally once daily
45491645|NCT02983604|Drug|Exemestane|25 mg tablet administered orally once daily (or in accordance with locally approved labeling)
45374607|NCT01039558|Drug|placebo|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
45374608|NCT03900728|Device|Auriculotherapy with needles|Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
45374609|NCT03900728|Device|Auriculotherapy with beads|A trained co-investigator will place the beads onto prespecified acupoints of the participant's ears. An adhesive disk will adhere the beads to the ears.
45374610|NCT03900728|Device|Placebo Adhesive disks|Single-use adhesive disks without needles or beads.
45374611|NCT04994912|Drug|EI-001|EI-001 IV infusion
45374612|NCT04994912|Other|Placebo|Placebo IV infusion
45491646|NCT02983604|Drug|Fulvestrant|"Administered every 28 days (± 3 days) intramuscularly in accordance with locally approved labeling~Participants initiating fulvestrant on Cycle 1 Day 1 and have not received any prior dose of fulvestrant will receive a single additional dose of fulvestrant on Cycle 1 Day 15."
45374613|NCT01324258|Drug|GSK1120212|Part1 and Part2
45374614|NCT01324258|Drug|Gemcitabine|Part2
45374615|NCT00769457|Device|Access Arm|Active OptiVol-System with CareAlert via CareLink
45374616|NCT05408546|Drug|TS23|Monoclonal antibody to a2-antiplasmin
45374617|NCT05408546|Drug|Placebo|Placebo
45374618|NCT01037296|Procedure|catheter ablation|ablation procedure performed with Hansen robotic navigation system
45374619|NCT01037296|Procedure|catheter ablation|Ablation will be performed as normal treatment
45374620|NCT05120999|Device|Train of four measurement|Use of either TetraGraph or TOFScan to measure the neuromuscular blockade
45374621|NCT01415882|Drug|Cyclophosphamide|Given PO
45374622|NCT01415882|Biological|Daratumumab|Given IV
45374623|NCT01415882|Drug|Dexamethasone|Given PO or IV
45374624|NCT01415882|Drug|Ixazomib Citrate|Given PO
45374625|NCT01415882|Other|Laboratory Biomarker Analysis|Correlative studies
45374626|NCT00068419|Drug|tamoxifen citrate|Given orally
45374627|NCT00068419|Drug|sulindac|Given orally
45374628|NCT00068419|Other|laboratory biomarker analysis|Correlative studies
45374629|NCT01039636|Drug|FBS0701|Oral FBS0701 for 7 days at one of the following doses: 3 mg/kg/day or 8 mg/kg/day or 16 mg/kg/day or 32 mg/kg/day or 40 mg/kg/day
45374630|NCT00769535|Genetic|Polymorphisms of HSP70 and TNF promoter|To assess the relationship between clinical relevance and polymorphisms of HSP70 and tumor necrosis factor-alpha with PCR_RFLP
45374631|NCT00769613|Biological|cytomegalovirus IE-1-specific cytotoxic T lymphocytes|
45374632|NCT00769613|Biological|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
45374633|NCT00769613|Biological|therapeutic allogeneic lymphocytes|
45374634|NCT00769613|Genetic|polymerase chain reaction|
45374635|NCT00769613|Other|flow cytometry|
45374636|NCT00769613|Other|immunological diagnostic method|
45693113|NCT03804892|Other|Blood samples|Participants will give 16 blood samples, to be assessed for fatty acids in the blood.
46053916|NCT02327481|Procedure|3D Laparoscopic Surgery|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, 3D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
45374637|NCT00769613|Other|laboratory biomarker analysis|
45374638|NCT01037374|Other|Preoperative assessment form|(based on the american society of anesthesiologists)components of the form include: neck measurements; neck mobility; mallampati; wilson's test; pre-existing conditions; and predictions of difficult mask ventilation, supraglottic airway, laryngoscopy, intubation, and surgical airway.
45374639|NCT00764153|Procedure|Bipolar hemiarthroplasty|Lateral approach. FWB.
45374640|NCT00764153|Procedure|Internal fixation|Fluoroscopic Control. Percutaneous. FWB. Two parallel screws (Olmed)
45753951|NCT00452387|Drug|Prednisone|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Prednisone 5mg bid~Dose Level -1 Prednisone 5mg bid~Dose Level 1 Prednisone 5mg bid"
46053917|NCT02327481|Procedure|2D Laparoscopic Surgery|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, 2D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
46053918|NCT02289209|Radiation|Reirradiation|Reirradiation 1.2 GY BID 5 days a week for 5 weeks.
46053919|NCT02289209|Drug|MK-3475|MK-3475 will be given at 200mg intravenous every 3 weeks starting day one of reirradiation and will be continued once every 3 weeks until 3 months post completion of reirradiation. Further continuation of MK-3475 will be determined by response evaluation at 3 months post completion of reirradiation
46053920|NCT02278055|Drug|Radium-223|
45374641|NCT01042054|Other|Standard optimised recovery protocol.|"Epidural analgesia for the first 48 hours postoperatively.~Sham wound catheter attached to anterior abdominal wall, for purposes of blinding.~Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~Optimised recovery protocol followed throughout."
45374642|NCT01042054|Other|Wound catheter plus patient-controlled analgesia.|"Continuous infusion of local anaesthetic administered via wound catheters for the first 48 hours postoperatively.~Additional patient-controlled intravenous opiate analgesia available to patient during this time period.~Sham epidural catheter applied to the patient's back for purposes of blinding.~Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~Optimised recovery protocol followed throughout."
45374643|NCT02557373|Dietary Supplement|Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation.
45374644|NCT02557373|Dietary Supplement|Rice Bran + Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation. Dietary rice bran consumed daily and amounts increase throughout the 3 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 3 g/day)
45374645|NCT00811148|Procedure|Tissue Bank|Collection of clinical data and tumor tissue.
45374646|NCT01757626|Biological|Hu3F8 With GM-CSF|Ph I: 1 cycle consists of treatment with hu3F8 for 3 days (day 1, 3 & 5). GM-CSF starts 5 days in advance of each hu3F8 cycle at 250 mcg/m^2/day (day -4 to day 0), & at 500 mcg/m^2/day x 5 days (day 1 to day 5). Hu3F8 cycles are 5 days. Ph II pts may receive treatment on a modified schedule of 3 doses of IV hu3F8 over a maximum of 10 days, as needed. With modified schedules of hu3F8, GM-CSF will be administered at 250 mcg/m2/day x5 days before the 1st dose of hu3F8, as with the standard schedule, but then GM-CSF at 500 mcg/m2/day will be administered on day of the 1st dose of hu3F8, on the day before and on the day of the 2nd dose of hu3F8, and on the day before and on the day of the 3rd dose of hu3F8. Cycles are repeated at 2-4 week intervals between 1st days of hu3F8, through 4 cycles. Pts who complete 4 cycles of treatment w/o complications or disease progression have the option of continuing treatment for up to 24 months from their 1st dose of hu3F8.
45491647|NCT02386618|Procedure|Standardized endoscopic treatment of local residual neoplasia|Endoscopic treatment will be performed according to the type of local residual neoplasia (LRN): A - endoscopically negative scar and neoplastic tissue found only in biopsy specimens - treatment by argon plasmacoagulation, B - endoscopically aparent LRN < 5 mm - forceps biopsy + argon plasmacoagulation, C - endoscopically evident LRN > 5 mm + lifting during submucosal injection - endoscopic mucosal resectio + argon plasmacoagulation, D - endoscopically evident LRN > 5 mm + non-lifting during submucosal injection - endoscopic submucosal disection (ESD) or surgical resection
45491648|NCT03656432|Drug|CPP-ACP paste|The complex CPP-ACP derived from a milk protein called casein. CPP-ACP represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
45491649|NCT02386462|Drug|Dexmedetomidine|The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg)
45491650|NCT02386462|Drug|Propofol|
45491651|NCT03656276|Behavioral|Tool to improve Participation In Clinical Trials (ToPIC)|The Tool to improve Participation In Clinical Trials (ToPIC) is a communication tool to facilitate clinical trial decision making conversations between oncologists and patients.
45374647|NCT01757626|Biological|Hu3F8 With GM-CSF|As determined by the phase I component of the study, the hu3F8 dosage in the phase II portion is 3 mg/kg/day. Patients who were treated in the phase I component are eligible for treatment in the phase II portion. Cycles are repeated approximately monthly through 5 cycles. Group 1 and Group 3 patients can continue to receive cycles every 1-2 months for up to 24 months from study enrollment or until they receive 5 cycles after a major response (CR or PR) is achieved, whichever comes first. If HAHA becomes (+), cycles are deferred until it becomes (-) again. Patients who develop HAHA which precludes timely treatments with hu3F8+GM-CSF are eligible to receive low-dose maintenance regimens such as irinotecan alone,61 temozolomide alone,62 irinotecan-temozolomide,63 or cyclophosphamide-topotecan.64 They can also receive anti-HAHA agents such as rituximab and cyclophosphamide. They resume treatment with hu3F8+ GM-CSF if HAHA becomes negative. Patients may receive local radiation therapy.
45491652|NCT02382328|Drug|alpha lipoic acid|comparison of 600mg/24h oral, alpha lipoid acid, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
45491653|NCT02382328|Drug|Placebo|Placebo oral pills, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
45374648|NCT00764231|Behavioral|Home-based exercise program|Subjects will be given a personalized 12-week exercise program consisting of cardiovascular, musculoskeletal and flexibility exercises by a certified exercise physiologist. They will receive fitness assessments at baseline, 6 weeks and 12 weeks.
45491654|NCT03656198|Biological|Rabivax-S|Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg).
45491655|NCT03656198|Drug|Sterile Water Injection|The vaccine diluent (sterile water for injection) is provided in a separate 1 mL ampoule.
45491656|NCT02382250|Behavioral|Survey|Survey will be given to all participants
45491657|NCT02388490|Drug|brentuximab vedotin|Brentuximab vedotin administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg q 3 weeks.
45491658|NCT02386540|Behavioral|Health Coaching|The Alameda County Health Coach program pairs patients with a language-concordant health coach for six months following an ED visit. Health coaches are young adults from the local community employed through Alameda County and trained for three months in topics such as self-management support and motivational interviewing. Health coaches work one-on-one with participants in order to develop an action plan in order to achieve patient-identified health goals. Communication between the health coach and participant includes text messages (weekly), phone calls (twice a month), face-to-face visits (at least once), and accompaniment to a primary care visit (at least once). Health coaches may also assist participants in accessing community resources as related to the individualized action plan.
46053921|NCT02256865|Drug|Ketoconazole|Ketoconazole is taken 4 times a day
45693114|NCT03801772|Device|Metronome|Pacing aquatic exercises to the beats per minute of a metronome. The metronome will be adjusted to each patient's pain free exertion level. Patients will start with 10-20 repetitions of the exercises depending on their physical ability. The repetitions will be progressed as the patient's strength and endurance improve and noted in the chart and the flow sheet. The metronome will be synchronized during their second aquatic therapy treatment. The beats per minute (BPM) will be increased on the metronome during the series of treatments until the patient can no longer maintain proper technique with the exercises. The exercises will continue at this BPM during future visits. The patient will be instructed to keep pace with the beat of the metronome for the duration of the exercise.
46053922|NCT02256865|Drug|Hydrocortisone|Hydrocortisone is taken 3 times a day
46053923|NCT02256865|Drug|Testosterone|Testosterone gel is applied once a day
46053924|NCT02256865|Drug|Placebo for ketoconazole|Placebo for ketoconazole
46053925|NCT02256865|Drug|Placebo for hydrocortisone|Placebo for hydrocortisone
46053926|NCT02256865|Drug|Placebo for testosterone|Placebo for testosterone
46053927|NCT02231879|Drug|Plerixafor|Twice daily low dose injection for 14 months.
46053928|NCT02231879|Drug|G-CSF|Twice daily low dose injection for 14 months.
46053929|NCT02118649|Behavioral|Game|
46053930|NCT02111018|Device|CytoSorb Device|
46053931|NCT02111018|Procedure|CVVH|
46053932|NCT02091518|Behavioral|MR Screening Questionnaire|All participants will complete the MR Screening Questionnaire before the MRI exam. During the MRI exam, all participants will be observed through the window from the operator console. Verbal communication will be kept with the participant throughout the exam via a speaker system.
45693115|NCT00756964|Drug|Rasburicase|Rasburicase (Dose: 7.5mg in 50ml of normal saline administered over 30 minutes) or identical placebo will be administered as an (dosage form)intravenous infusion preoperatively.
45693116|NCT00756964|Drug|Placebo|Placebo drug (color-coded to appear identical to study drug) administered as an (dosage form) intravenous infusion preoperatively.
45374649|NCT00764231|Behavioral|Wait list|Subjects will have a 12-week waiting period, during which time they will be asked not to change their exercise habits. These subjects will receive the same fitness assessments as the experimental group (baseline, 6 weeks, 12 weeks), but will not receive an exercise program during the wait-list period. Following the 12-week wait-list period, subjects will be given the same home-based exercise intervention as the experimental group.
45374650|NCT05408234|Other|Smart Foot Exercise|"The patient lies supine (supine) with the legs raised 450 while supported for 1-3 minutes until blanching occurs (the skin becomes pale).~The patient sits on the edge of the bed with the legs hanging down and then performs dorsiflexion, plantarflexion, inversion, and eversion for 3 minutes until the skin appears red.~The patient lies supine with the legs covered with a blanket for 3-5 minutes. This whole cycle is repeated 3-6 times per session, and each session is repeated 2-4 times a day.~Movement using newspaper media, namely by:~Place a sheet of newspaper on the floor, then shape the sheet into a ball with both feet.~The ball shape is then opened into a sheet as before with both feet. Tear the newspaper into two parts, and separate the two parts of the newspaper. Tear the first newspaper into small pieces with both feet. Remove the bunch of stubs and place them in a second, whole newspaper. Wrap everything into a ball shape with both feet. This step is enough to do once."
45374651|NCT01042132|Procedure|the effect of delayed intramedullary reaming|in one group intramedullary reaming and nailing is performed immediately, femoral fractures in the second group are external fixated and than secondary nailed.
45374652|NCT01042132|Procedure|the reaming of the femoral canal is performed with two different reaming devices|the reaming of the femoral canal is performed with two different reaming devices; a traditional reamer (TR)and the reamer-irrigator-aspirator (RIA)
45374653|NCT00068107|Drug|Replagal|enzyme replacement therapy
45374654|NCT04048811|Drug|HSK3486|The induction dose is 0.4mg/mg. The initial maintenance dose of the first 6 subjects is 1 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 6 subjects, so as to explore the optimal initial maintenance dose. The range of the initial maintenance dose is 1 (± 0.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 0.5 mg/kg/h, and the maximum should not be more than 1.5 mg/kg/h.
45374655|NCT04048811|Drug|Propofol|The induction dose is 2.0mg/mg. The initial maintenance dose of the first 2 subject is 5 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 2 subjects, so as to explore the optimal initial maintenance dose. The adjustment range of the initial maintenance dose is 5 (± 2.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 2.5 mg/kg/h, and the maximum should not be more than 7.5 mg/kg/h.
45374656|NCT04048811|Drug|Propofol HSK3486|The induction dose of Propofol is 2.0mg/mgThe initial maintenance dose of HSK3486 is fixed at 1 mg/kg/h, without adjustment.
45374657|NCT01564082|Device|ETT First (GlideScope)|Patients will have the endotracheal tube (ETT) introduced into the pharynx under direct vision prior to GlideScope insertion. The ETT will then be advanced under GlideScope guidance into the trachea.
45374658|NCT00764387|Drug|Gadovist® (Gadobutrol, BAY86-4875)|0,1 mmol/kg of body weight in the vein, single administration
45374659|NCT00764387|Drug|Dotarem|0,1 mmol/kg of body weight in the vein, single administration
45374660|NCT03957889|Other|Educational simulation|
45374661|NCT01086631|Drug|Rituximab|
45374662|NCT04909502|Drug|EHP-101 25 mg OD|25 mg OD during the first 28 Days of the trial
45374663|NCT04909502|Drug|EHP-101 25 mg BID|25 mg BID during the first 28 Days of the trial
45374664|NCT04909502|Drug|EHP-101 50 mg OD|After 28 Days of treatment with 25 mg OD, patients will escalate to 50 mg OD up to the end of the trial
45693117|NCT00780442|Drug|D-cycloserine|50 mg DCS
46053933|NCT02091518|Device|Magnetic Resonance Imaging Acquisition and Analysis|MRI Studies: The MRI scans will be performed on a 1.5T or 3T MRI scanner. Conventional MRI studies will be performed using the standard clinical sequences. The new research sequences will be performed.at any point during the clinical exam. Total imaging time for volunteers will be 30-45 minutes.
45374665|NCT04909502|Drug|EHP-101 50 mg BID|After 28 Days of treatment with 25 mg BID, patients will escalate to 50 mg BID up to the end of the trial
45374666|NCT00769769|Behavioral|Psychotherapy|Participants will receive 12 sessions of cognitive behavioral therapy delivered weekly over a period of 3 months.
45693118|NCT00780442|Drug|Placebo|Placebo
45693119|NCT00767338|Behavioral|Timed intercourse|Timed intercourse
45693120|NCT00767338|Procedure|Microsurgical varicocelectomy|Microsurgical varicocelectomy
45693121|NCT00767338|Procedure|Intrauterine insemination|Intrauterine insemination
46053934|NCT01968460|Drug|P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily
46053935|NCT01968460|Drug|Placebo|placebo
46053936|NCT01968460|Drug|P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
46053937|NCT01906853|Biological|BCG|
45491659|NCT02377414|Drug|Retosiban solution for Infusion|Retosiban will be supplied as clear, colorless IV solution for infusion in 5 mL vial with a unit dose strength of 15 milligrams per milliliter (mg/mL) (each 5 mL vial contains 75 mg retosiban), dosed at up to 300 mg over 48 h infusion
45491660|NCT02377414|Drug|Placebo|Placebo will be supplied as a clear, colorless IV solution for infusion with a unit dose strength of 0.9% sodium chloride (NaCl) normal saline
45491661|NCT02377336|Drug|GS-6615|GS-6615 tablets administered orally
45491662|NCT02377336|Drug|Placebo|Placebo to match GS-6615 tablets administered orally
45491663|NCT02381938|Behavioral|Healthy Lifestyles|6-month intervention to increase physical activity and improve other health related behaviors
45491664|NCT02381938|Other|Healthy Finances|6-month intervention to educate and improve financial health
45491665|NCT02662582|Drug|Reldesemtiv|Oral tablet
45491666|NCT02662582|Drug|Placebo|Oral tablet
45374667|NCT00769769|Behavioral|Psychotherapy|Participants will receive 12 sessions of telephone-based cognitive behavioral therapy delivered weekly over 3 months.
45374668|NCT00769847|Procedure|Endoscopic strip craniectomy|Surgery
45491667|NCT02382094|Drug|Bicalutamide|
45491668|NCT04439500|Behavioral|Real World Strategy Training|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
45491669|NCT04439500|Behavioral|Brain Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.
45491670|NCT02386150|Biological|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial
45374669|NCT00394654|Biological|MEDI-528 9 mg/kg|MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
45374670|NCT00394654|Other|Placebo|Placebo administered as a single intravenous infusion
45374671|NCT01086787|Other|Surgery|Patients undergoing surgery for either cardiac surgery or orthopedic surgery
45374672|NCT04048265|Device|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
45374673|NCT03900416|Behavioral|Mindfulness App|Mindfulness exercises will last 1-12 minutes. Each one asks participants to focus on something (e.g., breath, sounds, physical sensations) using guided instruction.
45374674|NCT02557607|Device|MRI|An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
45374675|NCT00769925|Behavioral|Cognitive Behavior Therapy-Primary Care|Children will receive cognitive behavioral therapy from a child anxiety specialist at their doctor's office (the primary care clinic). The children will learn skills to cope with fear and anxiety, and parents will learn how to support their children in using these new skills.
45491671|NCT02908100|Drug|GDC-0853|Participants received GDC-0853 at dosages of 150 or 200mg as per the dosing schedules described above.
45491672|NCT02908100|Drug|Placebo|Participants received matching placebo to GDC-0853 at dosages of 150 and 200mg as per the dosing schedules described above.
45491673|NCT02377180|Procedure|Intramuscular capsaicin injection|Intramuscular injection of capsaicin: 50 mcg/0.5 ml
45491674|NCT02377180|Procedure|Suprascapular nerve block|"Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus or trapezius muscle in randomized order, followed by suprascapular nerve block (ultrasound-guided) using Lidocaine 1%; nerve block is expected to be effective only in pain arising from the supraspinatus muscle. Trapezius pain serves as control condition.~Evaluates the diagnostic validity of suprascapular nerve block for muscle pain."
45491675|NCT02377180|Procedure|Local anesthetic infiltration|Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus muscle in two different sessions; suprascapular nerve block in one session and intramuscular local anesthetic infiltration in one session (in randomized order) using Lidocaine 1%; the aim is to investigate which procedure provides faster and more efficient pain relief. Compares effectivity of suprascapular nerve block vs. intramuscular local anesthetic infiltration.
45491676|NCT02377024|Dietary Supplement|TF 600mg|
45491677|NCT02377024|Dietary Supplement|TF 1200mg|
45491678|NCT02377024|Dietary Supplement|placebo|
45491679|NCT02377102|Procedure|Physical Therapy|12 weeks of supervised physical therapy.
45491680|NCT02386228|Genetic|collection of CSF and blood|collection of CSF and blood
45491681|NCT03656120|Drug|0.2mg group|Thienorphine hydrochloride dose was set as 0.2mg per day,last for 12 weeks.
45491682|NCT03656120|Drug|0.5mg group|Thienorphine hydrochloride dose was set as 0.2mg per day for the first week and increased to 0.5mg per day from the second week, last for 11 weeks.
45491683|NCT03656120|Drug|placebo control group|Participants only take placebos for 12 weeks during the research.
45491684|NCT04341298|Other|11-point pain scale|Subjects will be asked to rate their headache pain using an 11-point scale, i.e. on an integer scale from 0 to 10 inclusive, with 0 indicating no pain and 10 indicating the worst pain imaginable.
45491685|NCT04341298|Other|Headache diary|Subjects will be asked to record specific information for the first (and all subsequent) severe or very severe migraine headaches that they experience while enrolled in the study.
45491686|NCT04341298|Device|Avulux®|Avulux® device
45491687|NCT04341298|Device|Sham Avulux®|Sham Avulux®
45491688|NCT02166242|Drug|ethaselen|ethaselen is a specific thioredoxin reductase inhibitor, which has finished phase 1a study in China, phase 1 study of ethaselen showed that 600 mg ethaselen bid could be well tolerated
45491689|NCT03656042|Drug|Filgrastim (75mcg/0.3ml)|"Subjects who meet all eligible requirements for entry into the study will be randomized into one of the two treatment groups in 1:1 ratio as shown below:~10 microgram/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks; repeat dosing regimen every 12-weekly (12 weeks / cycle) for 2 cycles~Non-treatment"
45491690|NCT02381860|Other|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
45491691|NCT02381860|Dietary Supplement|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
45491692|NCT03655964|Drug|Olmesartan|At Day 4 of stroke onset, patients with clinic BP >160/100 mmHg will receive olmesartan 20 mg once daily until Day 7 of stroke onset
45491693|NCT03655964|Drug|Nebivolol|At Day 4 of stroke onset, patients with clinic BP >160/100 mmHg will receive nebivolol 5mg once daily until Day 7 of stroke onset
45491694|NCT03655964|Other|No antihypertensive treatment|Patients will be left without treatment
45374676|NCT00769925|Behavioral|Therapist-Assisted Bibliotherapy-Primary Care|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
45374677|NCT00770003|Drug|AZD8848|nasal spray solution; 30 or 60 µg administered intranasally once weekly for one month
45374678|NCT00770003|Drug|Placebo|nasal spray solution. Once weekly intranasal administrations for one month.
45374679|NCT00771329|Drug|BIIB023|Single IV doses of BIIB023 in dose-escalating cohorts
45491695|NCT02385994|Device|enLighten Laser|enLighten Laser treatment with dual-pulse width and dual-wavelength
45693122|NCT04384666|Drug|LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)|LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)
46053938|NCT01863056|Other|Sit-Stand Desk|Subjects were asked to participate in the study for a total period of three months. Based on randomization, either the first or third month involved the active intervention to use an adjustable sit-stand desk. The other two months required the subjects to follow their usual work routine without the adjustable sit-stand desk. The control period month involved all the same measurements as the active intervention month, whereas the washout period, which was the 2nd (middle) month, did not involve any measurement and there was no contact with the subjects during the washout month.
45374680|NCT00771329|Other|Placebo (sterile normal saline)|Single IV dose of Placebo
45374681|NCT04837820|Procedure|Acupuncture|Each participant will receive 10 treatments of acupuncture (real or sham) over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.
46053939|NCT01833806|Device|ExAblate MRgFUS|Focused Ultrasound Ablation
45374682|NCT04837820|Procedure|Sham Acupuncture|Each participant will receive 10 treatments of acupuncture (real or sham) over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.
45374683|NCT04837820|Other|Wait-List Control (WLC)|Patients in the WLC group will continue to receive their standard medical care as prescribed by their oncologists/primary care physicians.
45374684|NCT04837820|Other|Questionnaires|Will follow patients for 26 weeks from baseline and collect assessments at baseline and Weeks 4, 10, 14, and 26. Average time to complete the surveys is 30 minutes, which has been judged to be acceptable with minimal missing data.
45491696|NCT02381236|Drug|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle for up to 3 cycles
45491697|NCT02982590|Drug|Apixaban 5 MG Oral Tablet [ELIQUIS]|Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.
45491698|NCT02982590|Drug|Warfarin Sodium|as controlled arm since warfarin is the standard therapy for LV thrombus
45491699|NCT02381548|Drug|Adavosertib|Given PO
45491700|NCT02381548|Drug|Belinostat|Given IV
45491701|NCT02381548|Other|Laboratory Biomarker Analysis|Correlative studies
45491702|NCT02381548|Other|Pharmacological Study|Correlative studies
45693123|NCT04384666|Other|Neupro 4 mg / 24 Hr. Transdermal Patch|Neupro 4 mg /24 Hr. Transdermal Patch
45491703|NCT02103140|Behavioral|Facility-based Exercise|Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
45491704|NCT02103140|Behavioral|Home-based Exercise|Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
45491705|NCT02381314|Biological|enoblituzumab plus ipilimumab|enoblituzumab is administered by IV infusion once per week. Ipilimumab is administered by IV infusion every 3 weeks for up to 4 doses.
45491706|NCT02345408|Drug|CCX872-B|Tablets (oral administration)
45491707|NCT04282018|Drug|BGB-10188|Administered as specified in the treatment arm
45491708|NCT04282018|Drug|Zanubrutinib|Administered as specified in the treatment arm
45693124|NCT00767572|Drug|atorvastatin|Atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout period, then cross over groups to complete another 12 weeks. (Total study time is 28 weeks (12+4+12)
45693125|NCT00767572|Drug|Sugar pill|atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout, then cross over groups X 12 weeks. Total study time is 28weeks (12+4+12).
45374685|NCT00771485|Drug|FM-602|Study of Efficacy of Bowel Preparation Before Colonoscopy
45374686|NCT00771485|Drug|Marketed Bowel Cleanser|Marketed bowel cleanser
45374687|NCT04002752|Drug|JNJ-73763989|Participants will receive JNJ-73763989 as single subcutaneous injection.
45374688|NCT04002752|Drug|Placebo|Participants will receive placebo matching to JNJ-73763989 as single subcutaneous injection.
45374689|NCT00770159|Drug|odanacatib|Panel A: MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: MK0822 tablets 100 mg once weekly for 6 weeks.
45374690|NCT00770159|Drug|Comparator: placebo to MK0822|Panel A: placebo to MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: placebo to MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: placebo to MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: placebo to MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: placebo to MK0822 tablets 100 mg once weekly for 6 weeks.
45374691|NCT00399490|Drug|RN624 (PF-04383119)|50 mcg/kg
45374692|NCT00770237|Behavioral|Smoking Cues|In the smoking cue condition, a pack of the participants preferred brand of cigarettes, a lighter, and an ashtray will be under the tray cover. In the neutral cue condition, a pack of unsharpened pencils, a pencil sharpener, and a small notepad will be under the cover. When instructed, the participant will lift the cover on the tray. In the smoking cue condition, participants will take one cigarette out of the pack, light it without puffing, hold it for 1 minute, extinguish the cigarette, and replace the cover on the tray.
45374693|NCT00770237|Behavioral|Neutral Cues|In the neutral cue condition, participants will take one pencil out of the pack, sharpen it, hold it for 1 minute as if to write on the notepad, and then replace the cover. Participants will complete the VAS during cue exposure and the TCQ-SF, VAS, and mood form immediately and 15 minutes after cue presentation; physiological measures will be recorded continuously.
45374694|NCT02557529|Behavioral|Progressive Resistance Training|12 weeks supervised resistance training program. Details of the program: 12 weeks, 3 sessions per week, 7 exercises in training machines (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
45374695|NCT02557529|Behavioral|physical activity|Weekly diary of performed physical activity using the Physical Activity Score (PAS) during the 12-weeks intervention
45491709|NCT04282018|Drug|Tislelizumab|Administered as specified in the treatment arm
45491710|NCT03655808|Biological|Bronchial basal cells|Bronchial basal cells transplantation
45491711|NCT02386072|Drug|mirabegron|oral
45491712|NCT02386072|Drug|antimuscarinic medication|oral
45491713|NCT03655730|Other|weekly psychotherapeutic individual sessions|weekly psychotherapeutic individual sessions following the IPT method during one year
45491714|NCT03655730|Other|Usual care|the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
45693126|NCT00240370|Drug|Muraglitazar|
45693127|NCT03804736|Biological|FMT-c|Patients in the FMT-c receive FMT-c (15 capsules every 12 h for 2 days)
45491715|NCT03656900|Device|rTMS BA9/BA46|10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 9, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 46.
45491716|NCT03656900|Device|rTMS BA46/BA9|10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 46, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 9.
45491717|NCT03656900|Radiation|brain MRI|T1 weighted full-head high-resolution MRI with 1 mm seam cuts and sagittal orientation.
45491718|NCT03656900|Other|Medical evaluation|complete evaluation with 6 scales (HDRS, MADRS, Beck, CGI, COVI, UKU)
45491719|NCT03656900|Other|Psychological assessment|Subjective Life Profile Assessment (SLPA) and Helping Alliance Assessment
45491720|NCT03655496|Device|Home-based tool|The tool consists of a tablet computer and a Bluetooth connected weight scale. The patient is encouraged to use the tool daily. The weight is titrates the dose of diuretics and a short tip about how to improve living with heart failure, this is presented on the screen. Every five days the patient assess their self-perceived symptoms on the tablet computer. If the weight increases by 2kg or more in 3 days or less, the high dose is recommended for two days, after which the effect on the weight is assessed. If the weight increased was reverted, the dose is returned to normal and if it is still elevated, an alert on the table computer. If the self-assessed symptoms deteriorate, the same type of alert will appear on screen, urging the patient to contact the health care provider.
45491721|NCT05023486|Drug|NP-G2-044 Monotherapy|1600 mg QD and 2100 mg QD
45491722|NCT05023486|Drug|Anti-PD-1 Therapy|previously initiated per standard of care, at a dose and frequency in accordance with the package insert
45491723|NCT05023486|Drug|NP-G2-044 Combination therapy|1600 mg QD or 2100 mg QD
45491724|NCT04439422|Behavioral|Short ADHD Intervention|Short, intensive psychological intervention based on CBT and DBT practices
45491725|NCT04439422|Other|Self-help material with limited therapist support|Self-help material from an evidence-based treatment manual for adult ADHD with access to limited therapist support via Internet (control group)
45491726|NCT02381470|Drug|Faropenem|Faropenem 600mg
45491727|NCT02381470|Drug|Amoxicillin/clavulanic acid|Amoxicillin 500mg/ clavulanic acid 125mg
45491728|NCT02381470|Drug|Cefadroxil|Cefadroxil 1g
45491729|NCT02381470|Drug|Rifampicin|Rifampicin 10mg/kg
45491730|NCT02381158|Drug|Nebulized beclomethasone dipropionate|Nebulized beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg)
45491731|NCT04241536|Procedure|Blood draw and urine collection|Patients will collect blood and urine for metabolome analysis
45693128|NCT03804736|Biological|FMT-c Lactobacillus|Patients in the FMT-c Lactobacillus receive FMT-c Lactobacillus (15 capsules every 12 h for 2 days)
45693129|NCT04384588|Biological|Convalescent Plasma from COVID-19 donors|Patients that will participate in this clinical trial will be treated with Convalescent Plasma from COVID-19 donors regardless of the arm where they will be included
45693130|NCT00780676|Drug|Dasatinib|100 mg tablet by mouth daily
46053940|NCT01761929|Radiation|Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance|All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.
46053941|NCT01712490|Drug|brentuximab vedotin|Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle.
45374696|NCT02557529|Behavioral|Diet diary|Weekly diet diary during the 12-weeks intervention
45374697|NCT00764543|Device|24-hour ambulatory blood pressure monitor|Patients will go home with the 24-hour ambulatory blood pressure monitor to be returned at the clinic after 24 hours.
45374698|NCT00398866|Drug|Synvisc (Hylan G-F20; hyaluronan injection)|1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks
45374699|NCT00398866|Drug|Bupivicaine (local anesthesia injection)|1 ml of bupivicaine 0.5% injected once a week for 2 weeks
45491732|NCT02385682|Device|Percutaneous coronary intervention|Percutaneous coronary intervention
45491733|NCT02385682|Device|Percutaneous coronary intervention|Percutaneous coronary intervention
45491734|NCT02385838|Behavioral|5-CNL|The 5-CNL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
45491735|NCT02385838|Behavioral|MTL|The MTL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
45491736|NCT02385838|Behavioral|GDA|The GDA front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
45491737|NCT02385838|Behavioral|Tick|The Tick front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
45491738|NCT02381080|Drug|Ibrutinib|Ibrutinib capsule (at dose level of 140 or 420 or 560 mg) will be taken orally QD up to six, 28-days cycles.
45491739|NCT02381080|Drug|Erythromycin|Erythromycin 500 mg tablet will be taken orally TID (Part1 Cycle 1: on Days 5-10 and morning dose on Day 11; Part2 Cycle 1: on Days 5-17 and morning dose on Day 18).
45491740|NCT02381080|Drug|Voriconazole|Voriconazole 200 mg tablet will be taken orally BD (Part1 Cycle 1: on Days 19-25; Part2 Cycle 1: on Days 5-17).
45491741|NCT04724824|Device|Brain-Computer Interface|Passive hand movement will be provided to patients' paralyzed hand by means of a robotic hand orthosis that will be activated by the brain-computer interface based on hand movement intention.
45693131|NCT00780676|Drug|AZD6244|75 mg by mouth twice daily.
46053942|NCT01712490|Drug|doxorubicin|Doxorubicin: 25 mg/m^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
46053943|NCT01712490|Drug|bleomycin|Bleomycin: 10 units/m^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
46053944|NCT01712490|Drug|vinblastine|Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
46053945|NCT01712490|Drug|dacarbazine|Dacarbazine (DTIC): 375 mg/m^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
46053946|NCT01527747|Drug|Saxagliptin|5 mg daily
45491742|NCT04724824|Device|Sham Brain-Computer Interface|Passive hand movement will be provided to patients' paralyzed hand by means of a robotic hand orthosis which activation will be independent of the output of the brain-computer interface based on hand movement intention.
45491743|NCT02385760|Drug|CTX-4430|
45491744|NCT02385760|Drug|Placebo|
45491745|NCT04694248|Drug|Rivaroxaban|For anticoagulant, it is rivaroxaban 20mg once a day for 6 months.
45693132|NCT03800212|Drug|treatment for ampullary adenocarcinoma|all patients treated for ampullary adenocarcinoma (particularly survival without recurrence and prognostic indicators for excised tumours and the duration of disease control for tumours treated with palliative chemotherapy).
45693133|NCT03806998|Dietary Supplement|Ketoacids|Provision of 1 Tablet containing 630 mg of ketoacids every 5 kg of body weight during 16 weeks
45693134|NCT03806998|Dietary Supplement|Placebo|Provision of placebo capsules similar to active supplement
45693135|NCT03804502|Device|TearCare|The TearCare System warms the eyelids to melt the meibum by applying heat to the external surface of the eyelids for 15 minutes. Following completion of the thermal portion of the procedure, the clinician performs manual expression of each of the eyelids.
45374700|NCT00398866|Drug|Kenalog (triamcinolone; corticosteroid injection)|1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation
45374701|NCT00771563|Drug|cisplatin + docetaxel|docetaxel 75 mg/m2 d1 and cisplatin 75mg/m2 d1 (q 3wks for 4 cycles)
45491746|NCT04694248|Drug|Aspirin|For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
45491747|NCT04724980|Drug|PRGN-2012|"In the Phase I, 3+3 dose escalation clinical trial evaluating PRGN-2012 at two dose levels (1x10^11 and 5x10^11 particle units (PU)) administered as adjuvant therapy prior to standard-of-care debulking surgery.~In the Phase II segment, PRGN-2012 is evaluated at the RP2D."
45491748|NCT02376478|Drug|TNF-alpha inhibitors|therapy for at least 6 months
45491749|NCT02376478|Drug|Alternative/no medication|therapy for at least 6 months or no therapy
45491750|NCT02376478|Other|Alternative/no medication|phototherapy for at least 6 months
45491751|NCT02376478|Drug|Purine/folic acid analogues|therapy for at least 6 months
45491752|NCT02385448|Drug|Dienogest|The dienogest group will receive dienogest 2mg daily for 24 months postoperatively
45491753|NCT02385448|Drug|Microgynon|The combined oral contraceptive pills group will be given cyclical Microgynon for 24 months.
45491754|NCT02376634|Behavioral|Hypnosis|Patients will be taught self-hypnosis.
45491755|NCT02376400|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]) on Day 1, 29 or 57.
45491756|NCT02376400|Biological|Ad26.ZEBOV|One 0.5 mL IM injection of 5*10^10 viral particles (vp) on Day 1, 29 or 57.
45491757|NCT02376400|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
45491758|NCT03106012|Procedure|Hysteroscopy|rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30o panoramic optic which is 4mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
45491759|NCT03106012|Procedure|Laparoscopy|Veress needle was placed through the umbilicus and into the peritoneal cavity,After a pneumo-peritoneum has been achieved with a Veress needle, the primary trocar with sleeve (5mm in diameter) was placed at a similar angle in to the Veress needle
45491760|NCT02385370|Drug|MMC|using 0.02 MMC soaked sponged under the conjunctiva for 1 to 3 minutes
45491761|NCT02385370|Drug|MMC|0.1 cc of 0.01% MMC is injected into the tenon.
45491762|NCT02385058|Drug|Mebendazole|Mebendazole 600 milligram (mg) tablet orally once starting on Day 1 and 21.
45693136|NCT03804658|Device|Continue glucose monitor system|The cardiovascular risks and data from continue glucose monitor system
45693137|NCT00768118|Dietary Supplement|curcumin/green tea extract/Polygonum cuspidatum extract/soybean extract capsule|
45693138|NCT00768118|Genetic|electrophoretic mobility shift assay|
45374702|NCT00771563|Drug|cisplatin + docetaxel + enoxaparin|cisplatin 75 mg/m2 d1 and docetaxel 75 mg/m2 d1 (q 3 wks for 4 cycles) + daily enoxaparin 1mg/kg/d sc
46053947|NCT01439802|Device|Copper IUD placement at time Cesarean Delivery (Copper T 380A)|Placement of Paragard IUD at time of Cesarean Delivery
46053948|NCT01434316|Drug|Dinaciclib|Given IV
45382255|NCT05164406|Procedure|Blood salvage therapy|In the blood salvage group, blood is systematically given back when the minimal amount of blood loss required for reprocessing is met
45491763|NCT02385058|Drug|Quinfamide|Quinfamide 200 mg tablet orally once starting on Day 1 and 21.
45491764|NCT02385058|Drug|Placebo|Placebo tablet orally once starting on Day 21.
45693139|NCT00768118|Other|laboratory biomarker analysis|
45753952|NCT00452387|Drug|Sorafenib|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Sorafenib 400 mg QD~Dose Level -1 Sorafenib 400 mg QD~Dose Level 1 Sorafenib 400 mg bid"
45846924|NCT02673372|Drug|Ketamine|Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.
46053949|NCT01434316|Drug|Veliparib|Given PO
46053950|NCT00932581|Other|Bradykinesia UPDRS Motor Full Examination|The first group will receive the full motor examination section in its original order.
46053951|NCT00932581|Other|Bradykinesia subscale of UPDRS Motor Examination|The second group will receive the bradykinesia subscale first followed by the remainder of the motor examination section.
46053952|NCT00646230|Drug|fenretinide|
46053953|NCT00646230|Other|high performance liquid chromatography|
46053954|NCT00646230|Other|pharmacological study|
46053955|NCT00544414|Drug|cisplatin|
46053956|NCT00544414|Drug|docetaxel|
45374703|NCT04780802|Procedure|The balloon catheter is placed at the various arterial feeders of the tumor|use of a balloon catheter for providing balloon occlusion, in addition to the standard microcatheter for drug delivery, both catheters are to be placed in parallel through a single guide catheter. Only one arterial puncture wound is involved. The inflated balloon provides temporary occlusion of all arterial tumor feeders except for the one which is selectively catheterized with a microcatheter for delivery of the therapeutic agent. The therapeutic agent consists of Lipiodol mixed with a chemotherapeutic drug, it is delivered through the microcatheter under fluoroscopic control.
45491765|NCT02376088|Drug|Methimazole|All enrolled subjects with GD were treated with methimazole. The initial dose for the GA1 and GB1 sungroups were 30 mg/d (10 mg, tid), TH levels were tested every month, and the dose was titrated accordingly over a period of 2-3 months, the dose was then decreased to 15-20 mg/d and thyroid function was monitored periodically until it eventually reached the maintenance dose of 2.5 mg-5.0 mg/d. The dose and adjustment method for GA2 and GB2 were the same with GA1 and GB1, while the dose for GA3 and GB3 was gradually decreased to 2.5-5.0 mg/d. All subjects underwent a treatment course over a period of 6 months.
45374704|NCT00775073|Drug|Everolimus, Bevacizumab|Everolimus 5 mg tablet per day orally. Bevazicumab 5 mg per kg intravenous every 2 weeks.
45374705|NCT00398632|Drug|Duloxetine|dosage form: capsule. dosage: 60 mg. frequency: once daily, or twice daily if 120 mg/day is needed to control symptoms of major depression. duration: 12 weeks
45491766|NCT03310021|Biological|Andexanet alfa|fXa inhibitor antidote
45491767|NCT03310021|Drug|Apixaban|factor Xa inhibitor
45491768|NCT03310021|Drug|Rivaroxaban|factor Xa inhibitor
45491769|NCT03310021|Drug|Edoxaban|factor Xa inhibitor
45491770|NCT03310021|Drug|Placebo|Placebo
45491771|NCT04630717|Other|Medical hypnosis session|"the therapist will use a standard and identical protocol in all patients: the International characteristics of the hypnosis protocol are the following hypnotic induction through conversational hypnosis and interviewing about leisure activity.~A catalepsy of the hand or the finger will be done, also to stabilize hypnosis if it is accepted by the patient"
45491772|NCT04630717|Other|control groupe|the therapist will use usual voice,loud and strong voice,. clear, high position of the doctor, medical speech focused,no question about the patient's privacy will be made.
45491773|NCT03333109|Biological|Erenumab|70 mg/mL pre-filled syringe administered subcutaneously
45491774|NCT03333109|Other|Placebo|Matching placebo in pre-filled syringe administered subcutaneously
45491775|NCT02940223|Drug|Ethyl Icosapentate|Given by mouth 2 gm orally daily plus physical activity
45491776|NCT02940223|Behavioral|Exercise Intervention|Complete resistance exercises and undergo walking program
45491777|NCT02940223|Behavioral|Exercise Intervention|Meet with exercise specialist and complete stretching exercises
45846925|NCT02673918|Other|Home-based upper-body rehabilitation with online support|"Participants will be given written educational material, in which the physiotherapist marks the exercises specifically recommended for the individual patient. In addition, participants will get a personal password giving access to the BRECOR website for 12 weeks. The website contains professionally filmed videos of upper-body rehabilitation exercises (joint mobility and muscle strength) and instructions in scar tissue massage and manual lymph drainage. Furthermore, mindfulness sessions and additional information about prevention and early detection of late effects after breast cancer treatment are available on the website.~On average, participants will complete three rehabilitation exercises 5-7 times weekly with an anticipated duration of approximately 20 minutes."
45374706|NCT03993418|Dietary Supplement|stevia|This arm will be required to consume 5 stevia drops twice daily in habitual drinks
45491778|NCT02940223|Other|Laboratory Biomarker Analysis|Correlative studies
45491779|NCT02940223|Other|Placebo|Given PO
45491780|NCT02940223|Behavioral|Quality-of-Life Assessment|Ancillary studies
45491781|NCT02940223|Other|Questionnaire Administration|Ancillary studies
45491782|NCT01312831|Other|Vitamin B12 (cyanocobalamin)|
45491783|NCT01312987|Dietary Supplement|Lipid-based nutritional supplement|"After gradual introduction of the lipid-based nutritional supplement, daily dose per child is as follows:~3 teaspoons 3 x day for children younger than 12 months 4.5 teaspoons 3 x day for children older than 12 months"
45491784|NCT03296527|Drug|Follitropin alfa|GONAL-F dose was fixed for the first 5 stimulation days.
45491785|NCT03296527|Drug|Follitropin delta|REKOVELLE (FE 999049) was fixed throughout the stimulation period.
45491786|NCT04431193|Drug|Oxytocin|Oxytocin infused to maintain serum concentrations of 4, 16, 64, and 256 picogram/millilitre
45491787|NCT04430335|Behavioral|Telephone interview|Interested participants will complete a telephone interview to determine eligibility for the study. If found to be eligible for the study, participants will be registered and set up a time to speak with an assigned study coach.
45491788|NCT04430335|Behavioral|Cognitive Behavioral Therapy|Participants will speak with their assigned coach over the phone for 12 weeks to discuss the cognitive behavioral therapy (CBT) study workbook and provide feedback. CBT is a type of treatment that teaches people different ways to handle anxiety and/or depressive symptoms, such as by relaxing the body, changing thoughts, and solving problems. Participants will receive a workbook focused on teaching these strategies.
46053957|NCT00544414|Drug|fluorouracil|
46053958|NCT00544414|Drug|gemcitabine hydrochloride|
46053959|NCT00544414|Drug|leucovorin calcium|
46053960|NCT00544414|Genetic|gene expression analysis|
46053961|NCT00544414|Genetic|protein expression analysis|
46053962|NCT00544414|Other|laboratory biomarker analysis|
46053963|NCT00544414|Procedure|adjuvant therapy|
46053964|NCT00544414|Procedure|biopsy|
46053965|NCT00544414|Procedure|conventional surgery|
46053966|NCT00544414|Procedure|neoadjuvant therapy|
46053967|NCT00544414|Procedure|quality-of-life assessment|
45491789|NCT03295201|Other|Active cycle of breathing techniques (ACBT)|ACBT involves three phases (Breathing control, chest expansion exercise, and huff coughing). These phases will apply with a sequence to remove secretion. ACBT will apply 1 per a week for 6 weeks.
45491790|NCT03295201|Other|Postural Exercise|Postural exercise program will include thoracic vertebra mobilization, pectoral stretching, scapula and thoracic extensors strengthening and core stability exercises. Postural exercise program will apply 1 per a week for 6 weeks.
45491791|NCT03293485|Drug|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, 30-minute IV infusion once every 6 hours
45491792|NCT03309943|Drug|Propranolol|Participants will take one dose of Propranolol (40mg IR) on two separate occasions.
45491793|NCT03309943|Drug|Placebo|Participants will take one dose of Placebo on two separate occasions.
45491794|NCT01313065|Drug|VX15/2503|Dose escalation will begin at low doses and will gradually increase in each future cohort. The current trial design provides for 7 study cohorts with a 20 mg/kg expansion phase.
45491795|NCT01732627|Biological|Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
45491796|NCT01732627|Biological|Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined|0.5 mL, Subcutaneous (SC)
45491797|NCT03307837|Drug|CA-008|Local administration during surgery
45374707|NCT04048031|Dietary Supplement|Nutrafol Supplement Capsules|NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested. The Nutafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
45491798|NCT03307837|Drug|Placebo|Local administration during surgery
45491799|NCT05065255|Device|SpeediCath® catheters|Patients using SC catheters will be followed up in order to understand the major criteria in the choice of the catheter by the patients.
45491800|NCT04296799|Drug|SMP-100|SAD/MAD
45491801|NCT04296799|Drug|Placebo|Placebo
45491802|NCT03637933|Procedure|endoscopic tattooing|The tattoo has to be placed 1 or 2 cm distal to the lesion and tattooing has to be performed in at least 2 of the 4 quadrants of the bowel. A 0.5-1 mL saline bleb has to be raised submucosally and then a similar quantity of India Ink or Sterile Carbon Particle Suspension has to be injectiected into that bleb.
45491803|NCT03331315|Drug|Celecoxib|
45374708|NCT04048031|Other|Placebo Capsules|The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial amount of food.
45491804|NCT03331315|Drug|Ketorolac|
45491805|NCT03329989|Biological|Collagenase Clostridium Histolyticum|During 3 treatment visits 12 injections will be given per treatment area
45491806|NCT03287869|Drug|Brexpiprazole|Brexpiprazole tablets
45491807|NCT02661490|Biological|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide, without MPL for IM injection
45491808|NCT02661490|Drug|0.9% sodium chloride (saline)|norovirus bivalent placebo-matching vaccine
45491809|NCT02661490|Biological|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with MPL and aluminum hydroxide for IM injection
45491810|NCT03287791|Drug|Generic Azelaic Acid Foam|Topical foam, generic formulation of the brand product.
45491811|NCT03287791|Drug|Finacea® (Azelaic Acid) Foam|Topical foam, brand product.
45491812|NCT03287791|Drug|Vehicle Foam|Topical foam, placebo. Has no active ingredient.
45491813|NCT03287791|Other|Cleanser|A mild cleanser provided to participants, so they can wash their face prior to applying the study drug.
45491814|NCT03287791|Other|Sunscreen|Sunscreen provided to participants, so they can apply it to their face when outdoors.
45491815|NCT03287791|Other|Towel|A soft towel provided to participants, so they can pat their face dry after washing and prior to applying the study drug.
45491816|NCT03287791|Other|Moisturizing Lotion|Moisturizing lotion provided to participants, so they can apply it to their face, as needed.
46053968|NCT00544414|Radiation|radiation therapy|
45491817|NCT02381002|Other|Weight reduction program|Overweight and obese children (6-12 years old) from patient group accepting enrollment were assigned to weight reduction program for 6 months with monthly follow up. The program comprise: 1) Diet regimen: Healthy balanced diet was prescribed. The amount of calories was determined according to 24-hour recall then 250-500 calories were subtracted from total intake which decrease weight by 0.25-0.5 kg/week. 2) Exercise:were instructed to practice walking for at least 30 minutes 3-4 times per week.
46053969|NCT00261456|Behavioral|PSA test|Patients tested for their level of Prostate Specific Antigen.
46053970|NCT00261456|Procedure|Prostate Biopsy|A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.
46053971|NCT00816556|Drug|Estriol|Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for 2 weeks and then twice weekly for 10 weeks.
46053972|NCT00816556|Drug|Estradiol valerate|Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
45374709|NCT04734548|Drug|ApTOLL|ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatory response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.
45491818|NCT03287635|Drug|Corticotropin 80Unit/Ml Repository Injection|H.P. Acthar Gel (repository corticotropin injection) is an adrenocorticotropic hormone (ACTH) analogue used for: Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus.
45491819|NCT02380924|Drug|DSP loaded RBC using EryDex System|Intravenous infusion of 10 mg DSP encapsulated in autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
45491820|NCT02380924|Drug|Sham treated RBC using the EryDex System|Intravenous infusion of sham treated autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
45491821|NCT04051918|Behavioral|Piano Training|Cognitive training via music learning
45491822|NCT03694405|Biological|MenACWY-CRM|Booster vaccination with MenACWY-CRM
45491823|NCT03694405|Biological|MenACWY-DT|Booster vaccination with MenACWY-DT
45491824|NCT03694405|Biological|MenACWY-TT|Booster vaccination with MenACWY-TT
45491825|NCT03287089|Drug|Nitrofurantoin 100 MG|Patients will receive nitrofurantoin 100mg twice daily by mouth for 5 days
45491826|NCT03287089|Drug|Placebo Oral Tablet|Matching placebo
45491827|NCT02380768|Device|Ambu AuraGain (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
45374710|NCT04734548|Other|Placebo|White freeze-dried powder which is indistinguishable to ApTOLL for taste, color, texture and size.
45374711|NCT01589146|Drug|Heparin, Low-Molecular-Weight|4 weeks heparin prophylaxis
45374712|NCT00775151|Drug|amlodipine 10 mg tablet|
45374713|NCT04694300|Drug|Naproxen|"440 mg by mouth immediately after completion of implant surgery followed by 220 mg 12 hours later.~Then 220 mg every 8 hours for the next two days."
45374714|NCT04694300|Drug|Acetaminophen|1000 mg by mouth immediately after the completion of implant surgery followed by 1000 mg every 6 hours for 3 days after surgery with a maximum daily dose of 3000 mg.
45374715|NCT04694300|Drug|Tramadol|50 mg by mouth every 6 hours as needed for pain
45374716|NCT03554902|Procedure|Endoscopic gastric tubulization|Endoscopic gastric tubulization is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA).
45374717|NCT02556983|Radiation|CT|Contrast-enhanced CT images of the abdomen and pelvis will be obtained during the portal venous phase using a 256-channel CT system (Philips Healthcare, Cleveland, OH). The target median dose-length product (DLP) is 130 mGy·cm, which corresponded to an effective dose of 2 mSv with a conversion factor of 0.015 mSv·mGy-1·cm-1. The radiation output was automatically adjusted according to the individual patient's body size.
45382256|NCT05162846|Other|Publicly available genetic testing resources|Participants may view the publicly available Michigan Department of Health and Human Services (MDHHS) website as they wish.
45491828|NCT02380768|Device|LMA Supreme (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
45491829|NCT02384980|Device|FES (Gait MyoElectric Stimulator)|Functional Electrical Stimulation (FES) will be tested in a group of peripheral arterial disease patients using the Gait MyoElectric Stimulator. The FES device will be applied to the calf and shin muscles on both of the patients legs.
45491830|NCT02385136|Drug|Temozolomide|
45491831|NCT02380534|Procedure|H.E.L.P. apheresis|High cardiovascular risk patients will undergo H.E.L.P. apheresis procedure every 3 weeks for 1 year.
45491832|NCT02375932|Behavioral|Pre-Visit Tool|Patients receive a secure electronic message from their primary providers asking them to prepare for their visit by reviewing important areas of care and identifying their top priorities for discussion at a scheduled visit
45491833|NCT02375932|Behavioral|Usual Care Control|Patients continue to receive usual care from their primary care provider
45491834|NCT03113188|Drug|CBP501|CBP501, CDDP plus Nivolumab
45491835|NCT02376322|Radiation|Radiotherapy|Hypofractionated radiotherapy regimen, 16 Gy in 2 fractions in complicated bone metastases in patients with poor performance status
45491836|NCT04927780|Drug|Leucovorin Calcium|IV
45491837|NCT04927780|Drug|Fluorouracil|IV
45491838|NCT04927780|Drug|Irinotecan Hydrochloride|IV
45491839|NCT04927780|Drug|Oxaliplatin|IV
45491840|NCT04927780|Procedure|Resection|Open or minimally-invasive pancreatectomy.
45491841|NCT02375776|Other|"CORA- Device:smartphones"|Participants will download and use Multi - modal mobile smartphone application (CORA -Device:smarthpones) designed for renal cell and prostate cancer patients taking anti-cancer medications
45491842|NCT02376244|Other|High intensity interval training (HIIT)|Standard care cardiac rehabilitation classes, delivered at a higher exercise intensity
45491843|NCT02376244|Other|Standard care|Standard care cardiac rehabilitation according to current guidelines
45491844|NCT03286543|Device|SPRINT Beta System|"The SPRINT Beta System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT Beta System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Beta Stimulator)."
45491845|NCT02380846|Other|White rice|Control - white rice
45848010|NCT05304000|Behavioral|Cyclic Sighing Breathing|Participants are informed they should sit down in a chair or, if they prefer, to lie down, and to set a timer for 5 minutes. Then they are told to inhale slowly, and that once their lungs are expanded, to inhale again once more to maximally fill their lungs -- even if the second inhale was shorter in duration and smaller in volume than the first, and then to slowly and fully exhale all their breath. They are told to repeat this pattern of breathing for 5 minutes. They are also informed that ideally, both inhales would be performed via their nose and the exhale would be performed via their mouth, but that if they preferred, they are welcome to do the breathing entirely through their nose. They are also informed that it is normal for the second inhale to be briefer than the first.
45374718|NCT04002596|Device|ExAblate Neuro Thalamotomy Treatment|Non-invasive Focused Ultrasound Ablation of Thalamus Vim nucleus using ExAblate MRgFUS system for treatment Tremor Dominant Parkinson Disease
45374719|NCT00764621|Procedure|Primovist MRI|Contrast-enhanced MRI with an i.v. application of Primovist in the approved dosage
45374720|NCT00764621|Procedure|Extracellular contrast media (ECCM) MRI|Contrast-enhanced MRI with an i.v. application of an approved extracellular contrast medium in the approved dosage
45374721|NCT00764621|Procedure|Contrast-enhanced CT|Contrast-enhanced 3 phase multidetector CT with an i.v. application of an approved iodinated contrast medium in the approved dosage
45374722|NCT01043770|Behavioral|Group lifestyle education|Structured group education programme based on lifestyle changes (dietary and increased physical activity)
46053973|NCT00816556|Drug|Vanicream Lite|Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
46053974|NCT04100473|Drug|Inhaled Human Insulin|Dance 501 administered using the Dance 501 Inhaler
46053975|NCT04100473|Drug|Insulin Lispro (Humalog U-100)|Lispro
46053976|NCT02797197|Procedure|handgrip strength test|
46053977|NCT02797197|Drug|chemotherapy|
45374723|NCT04642820|Drug|Methamphetamine|Participants will be given 20 mg of Methamphetamine.
45374724|NCT04642820|Drug|placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
45374725|NCT00771641|Procedure|conventional surgery|
45374726|NCT00771641|Radiation|low-LET cobalt-60 gamma ray therapy|
45374727|NCT00771641|Radiation|low-LET electron therapy|
45374728|NCT00771641|Radiation|low-LET photon therapy|
45374729|NCT00771641|Radiation|radiation therapy|
45374730|NCT05408078|Device|SLEEPexpert|"SLEEPexpert 1.0 is the first version of an online Program to treat Insomnia. The internet-based self-help platform used for the implementation of CBT-I in this study has been developed by the University of Bern (Prof. Dr. Thomas Berger), has been used successfully in previous trials and has received a CE mark in 2018.~The device is intended for patients with mental disorders and insomnia who are treated for mental disorders in a hospital or an outpatient unit. No specific training is needed to operate the application.~There is no available clinical research data to date on exactly this product. However, the therapeutic content that is used in this study is based on Cognitive Behavioral Therapy for insomnia (CBT-I). This intervention has been found to be highly effective and without lasting adverse effects in many studies and is recommended for the treatment of insomnia in current clinical guidelines."
45374731|NCT05408078|Other|TAU plus sleep monitoring|Treatment aus Usual and a Sleep Monitoring App will be used. This is already described in the Arm Section
45374732|NCT05408000|Drug|ketofol vs propofol|Patients planned for electroconvulsive therapy meeting the inclusion criteria and not having exclusion criteria will be randomized into two groups. Group K will receive titrated dose of Ketofol and Group P will receive titrated dose of Propofol for induction of anaesthesia
45491846|NCT02380846|Other|Rice with chicken breast|Treatment 1 - steamed white rice with steamed chicken breast
45491847|NCT02380846|Other|Rice with fish|Treatment 2 - steamed white rice with steamed fish
45491848|NCT02380846|Other|Rice with egg white|Treatment 3 - steamed white rice with egg white
45491849|NCT02380846|Other|Rice with beancurd|Treatment 4 - steamed white rice with steamed beancurd
45491850|NCT02380222|Other|Interview|Single interview lasting approximately one hour
45491851|NCT03306433|Device|UDMA-K18 smooth surface sealant|The K18 as part of the UDMA polymer network (UDMA-K18) is hypothesized to prevent microbial attachment to the surface.
45491852|NCT02380144|Other|Fresh orange fruit and pasteurized fruit juice|
45491853|NCT02384902|Other|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
45491854|NCT02384902|Other|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
45491855|NCT02384902|Other|conventional diet|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
45491856|NCT02940691|Drug|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) once daily for 12 weeks.
45491857|NCT02379910|Drug|AM1030-CREAM or placebo|
45491858|NCT04949269|Drug|Deucravacitinib|Specified dose on specified days
45374733|NCT00771719|Drug|Ceftobiprole|Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days
45374734|NCT05407922|Procedure|Laparoscopy vs Non-laparoscopy approach|Pregnant women who will undergo a laparoscopic or open surgical exploration of the abdomen
45374735|NCT00771797|Dietary Supplement|high dose flavanoids|flavanoid rich cocoa 2 times daily over 60 days
45374736|NCT00771797|Dietary Supplement|low dose flavanoids|treatment with flavanoid-low cocoa two times daily over 60 days
45491859|NCT04949269|Drug|Famotidine|Specified dose on specified days
45491860|NCT02380066|Drug|Anyu Peibo|Placebo
45491861|NCT04938271|Device|HEAL-122 microcurrent electroceutical with e-textile sports knee sleeve|Using a bluetooth connected iPhone, subject activates the HEAL-122 electroceutical device that is docked onto an e-textile sports knee sleeve worn on the osteoarthritic knee
45491862|NCT02379754|Drug|Gentamicins|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
45491863|NCT04914793|Device|Antimicrobial prescribing guideline mobile phone application (MicroGuide)|This session is given to all hospital doctors in all study hospitals at the start of the intervention period of each paired hospital. All participating hospitals will join AMS knowledge survey three times during the study period (1st time= at the start of the project, 2nd time= before entering to the intervention period and 3rd time= at the end of the project).
45491864|NCT02375620|Biological|PEG-somatropin|
45491865|NCT04911673|Behavioral|music|Participants listened a song with headphones that lasts 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation).
45491866|NCT04911673|Dietary Supplement|Chocolate group|Participants ate 40 mg of dark chocolate with 60% cocoa per a day for four days (three days before menstruation and the first day of menstruation) that was given by researchers to them.
45491867|NCT02384824|Procedure|Primary Percutaneous Intervention|angiography, manual aspiration thrombectomy and antiplatelet therapy
45491868|NCT01313377|Drug|gemcitabine hydrochloride|
45491869|NCT01313377|Drug|oxaliplatin|
45491870|NCT01313377|Other|clinical observation|
45491871|NCT01313377|Procedure|adjuvant therapy|
45491872|NCT01313377|Procedure|quality-of-life assessment|
45491873|NCT02384746|Drug|Fulvestrant|500 mg intramuscular every 28 days
45491874|NCT02384746|Drug|MLN9708|Subjects will be treated in 3 dose cohorts of MLN9708, at 2.3, 3, and 4 mg orally on days 1, 4, 8, and 11 every 21 days.
45374737|NCT00673361|Drug|Concurrent decrescendo biochemotherapy regimen|"Temozolomide: 200mg/m^2, daily, PO, days 1-4~Vinblastine: 1.5mg/m^2, daily, IV, days 1-4~Cisplatin: 20mg/m^2, daily IV, days 1-4~IL (interleukin)-2: - 18 milli-International unit (MIU)/m^2, IVCI (intravenous continual infusion), day 1~9 MIU/m^2, IVCI, day 2~4.5 MIU/m^2, IVCI, days 3 & 4~Interferon (IFN) alpha: 5 MIU/m^2, daily, SC (subcutaneously), days 1-5~5-day inpatient regimen, to be repeated every 21 days"
45374738|NCT00673361|Drug|Low-dose Temozolomide plus Sorafenib|Temozolomide: 75mg/m^2, PO, QD (quaque die), 6 weeks on/2 weeks off Sorafenib: 400mg, PO, BID, 8 weeks
45374739|NCT00393718|Drug|liraglutide|0.9 mg/day. Injected s.c. (under the skin) once daily.
45491875|NCT02375464|Drug|Gallium-68 DOTATOC|Imaging with Gallium-68 DOTATOC
45491876|NCT02375386|Procedure|Spinal manipulation|Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
45491877|NCT02375386|Procedure|Therapeutic touch|"Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of hands-on contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment."
45491878|NCT02375386|Procedure|fMRI|Both groups will receive an fMRI.
45491879|NCT02375386|Behavioral|Pain Sensitivity Testing|Both groups will receive an Pain Sensitivity Testing
45491880|NCT02375386|Other|Questionnaires|Both groups will receive Questionnaires
45491881|NCT02375386|Behavioral|Physical Impairment|Both groups will receive testing on physical impairment.
45491882|NCT03113344|Drug|cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs|According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
45491883|NCT03112954|Drug|Buccal-relaxant formula|Following physical examinations, 60 patients were randomly allocated to 2 groups of 30 patients each, who had been diagnosed with sleep bruxism. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group F, the group of patients who received the floral remedy.
45491884|NCT03112954|Drug|Placebo|30 patients diagnosed with sleep bruxism received a small amber glass bottle containing the saline solution and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group P, the group of patients who received the placebo.
45491885|NCT03113266|Biological|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
45491886|NCT02375230|Procedure|Control group|Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise.
45491887|NCT02375230|Procedure|MR SOPA|"Health care provider randomized to the MR SOPA group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. The alternative airway practice will be performed on an intubation mannequin in the DR also placed on the DR resuscitation unit. Each participant will receive five minutes of training at the start of each shift."
45491888|NCT02384590|Behavioral|Computerized cognitive behavioral therapy|"The Beating the Blues computerized cognitive behavioral therapy (CCBT) program is eight 50-minute online sessions that teach the participant how to better manage stress using cognitive behavioral therapy techniques. Cognitive behavioral therapy involves helping people change their thoughts and behaviors so they can limit the negative impact stress will have on their mood and pain experience."
45491889|NCT02384278|Behavioral|Internet-based CBT for alcohol problems|A 12-week internet-based program based on cognitive behavior treatment (CBT) and relapse prevention
45491890|NCT02379598|Dietary Supplement|Aminoacid based formula|Formula based on aminoacid
45491891|NCT02379598|Dietary Supplement|Hydrolyzed whey formula|Formula based on hydrolyzed whey protein
45491892|NCT02379676|Drug|Ticagrelor|Ticagrelor 90mg twice daily for 30 days
46053978|NCT04235127|Other|sociodemographic variables, somatic conditions, mental disorders, treatment and drug use|"sociodemographic variables~history of self-injurious behaviours; all types of somatic conditions; neurodevelopmental, mental, behavioural, personality and substance use disorders; all types of medical procedures performed; and number and type of healthcare contacts.~prescriptions for psychopharmacological products~the Suicidal Scale of the Mini-International Neuropsychiatric Interview, the type and lethality of the attempt that warranted evaluation, presence and type of mental disorder, hopelessness, impulsivity, aggressiveness, altered state of conscience, use or dependence of alcohol, use or dependence of illicit drugs, serious somatic disease (including chronic diseases, chronic pain, and disabilities), living status, presence of family or social support, social problems, stressful life events, access to lethal means, and family history of suicide"
45374740|NCT00393718|Drug|glibenclamide|1.25-2.5 mg tablet. Given orally once or twice daily.
45374741|NCT00393718|Drug|placebo|liraglutide placebo. Injected s.c. (under the skin) once daily.
45374742|NCT00393718|Drug|placebo|glibenclamide placebo. Given orally once or twice daily.
45374743|NCT00669071|Drug|Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%|Applied once daily at bedtime on one side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
45374744|NCT00669071|Drug|Cetaphil® Moisturizing Cream as Inactive Control|Applied once daily at bedtime on the opposite side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
45374745|NCT00398320|Drug|Capecitabine|850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle
45374746|NCT00398320|Drug|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 21 day cycle
45374747|NCT00398320|Drug|Bevacizumab|7.5mg/kg Intravenous on day 1 of a 21 day cycle
45374748|NCT00670007|Biological|Alpha1- proteinase inhibitor [human]|Lyophilized preparation of 60 mg/kg body weight intravenously once per week
45374749|NCT00775307|Drug|PAZOPANIB|400 mg/day (24 weeks)
45374750|NCT00775307|Drug|Placebo|Placebo 400 mg/day (24 weeks)
45491893|NCT02379676|Drug|Clopidogrel|Clopidogrel 75mg once daily for 30 days
45374751|NCT05407298|Other|Non applicable|Non Applicable
45374752|NCT00775385|Drug|Standard Chemotherapy|Pemetrexed Cisplatin Schedule : CDDP 75 mg/m² D1, pemetrexed 500 mg/m² D1 D1=D21, 4 cycles
45374753|NCT00775385|Drug|Customized Treatment|"Mutated EGFR : Erlotinib 150mg/day (1 year)~Wild-type EGFR or undetermined depends on ERCC1 status :~ERCC1 high : no treatment~ERCC1 low or undetermined : Pemetrexed Cisplatin, 4 cycles (63 days)"
45491894|NCT02379364|Device|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
45491895|NCT02379130|Behavioral|Family Nurture Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period the child will sit on the mother's lap. The pair will be asked to talk and play with each other as they customarily do. If the child becomes restless the mother will be coached by the nurture specialist to further engage the child with soothing and calming; the mother will be helped to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact. The mother will also be helped to verbally express her feelings toward her child and to tolerate her child's full range of feeling.
46053979|NCT02796807|Drug|68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT|
46053980|NCT02796729|Procedure|Magnetic resonance imaging|MRI offers excellent images of the brain and is an important tool for diagnosing metastatic brain tumors. MRI scans are often used to plan treatments such as surgery and radiotherapy. When imaging participants with metastatic brain tumors, a contrast agent is often injected intravenously to highlight the relatively small tumours in the MRI. The standard metal-based MRI contrast agent is Health Canada approved and contains a material called gadolinium. MRI studies that use gadolinium-based contrast agents are called gadolinium enhanced MRI.
45374754|NCT05407220|Drug|HCP1904-1|take it once per period
45374755|NCT05407220|Drug|HCP1904-3|take it once per period
45374756|NCT04003688|Drug|Magnesium sulfate through real weight group|Magnesium sulfate dose 40 mg/kg of actual patient's weight
45374757|NCT04003688|Drug|Placebo group|Saline solution (instead of magnesium sulfate, as in the other groups)
45374758|NCT04003688|Drug|Magnesium sulfate through ideal corrected weight group|Magnesium sulfate dose 40 mg/kg of ideal corrected patient's weight
45374759|NCT00775541|Dietary Supplement|Vitamin C|One IV infusion of 2 gm vitamin C
45374760|NCT05406986|Other|care bundle application|The patients in the experimental group will be given care according to the current care bundle for 14 days
45374761|NCT00764777|Device|iliac stenting|Absolute Pro (Abbott Vascular) or Omnilink Elite (Abbott Vascular) stents
45374762|NCT00779129|Drug|Pegylated Lyposomal Doxorubicin|Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
45374763|NCT00779129|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
45374764|NCT00779207|Behavioral|weight loss and exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
45374765|NCT00779207|Behavioral|weight loss|10 percent weight loss through diet and behavioral modification
45374766|NCT00779363|Device|rechargeable TANTALUS II|Subjects will undergo an approximately two week baseline screening process. Eligible subjects will undergo device implantation. This will be followed by therapy initiation approximately one week after implantation. The device will then be activated to automatically deliver gastric contractility modulating (GCM) for 12 weeks of therapy. Stimulation will continue in for a safety monitoring period of 18 months following the therapy period.
45374767|NCT00535496|Drug|sugammadex|Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary. Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.
45374768|NCT00772187|Drug|morphine|Single dose: 0.1-0.5 mg
45374769|NCT00772187|Drug|intrathecal analgesia (morphine)|0.1-0.5 mg of morphine
45374770|NCT00772187|Drug|general anesthesia (fentanyl)|general anesthesia alone
45374771|NCT00772265|Biological|Wosulin N|Total Dose per subject will be 0.4IU/Kg given Subcutaneously.
45374772|NCT00772265|Biological|Novolin N|Total dose per subject will be 0.4 IU/Kg given Subcutaneously.
45374773|NCT04002128|Other|Tracheal aspirates and nasal smears were taken in all the patients. Laparotomies were performed in all patients.|Nitrous oxyde and sevoflurane anesthesia may alter mucus transport in the early postoperative period. In colonized patients it may result in more respiratory complications.
46053981|NCT02796729|Drug|Gadovist (Gadobutrol)|Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).
46053982|NCT02796729|Drug|50% dextrose solution|50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for intravenous injection.
46053983|NCT00760747|Drug|Atomoxetine|1.2 mg/kg/day up to 1.8 mg/kg/day, orally (PO)
45374774|NCT00779441|Drug|Zolpidem 10mg tablets|
45374775|NCT00989378|Behavioral|baseline study|normal bedtimes
45374776|NCT02556437|Drug|HyQvia|Human immunoglobulin 10% with recombinant hyaluronidase for subcutaneous injection
45374777|NCT02556437|Drug|Subcuvia|Human immunoglobulin 16% for subcutaneous injection
45374778|NCT04946006|Drug|Oxytocin|Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
45374779|NCT00779597|Behavioral|SCION (Self care improvement through oncology nursing)-PAIN program|The intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve self care regarding pain management beginning with admission followed by booster session every third day and one follow up telephone counseling within 3 to 4 days after discharge from hospital.
46053984|NCT02802579|Radiation|standard protocol|tube voltage: 120 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
46053985|NCT02802579|Radiation|enhanced protocol|tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
46053986|NCT02802579|Radiation|enhanced obesity protocol|tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 180° (with two detectors in a 90° angle)
45374780|NCT00775619|Drug|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol 12.5 mg tablets fed conditions
45491896|NCT02379130|Behavioral|Play and Nutrition Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period, the child and mother will play nutrition-focused games using the Healthy Habits for Life program designed by Michelle Obama.
45491897|NCT02379286|Other|Investigation|Investigation of relationships between French teenagers' attitudes and beliefs towards alcohol and tobacco products and the degree to which they watch and relate to television series and music videos
46053987|NCT02794467|Drug|Epelsiban|Epelsiban will be supplied as modified capsule shaped, white coated, oral tablet with a unit dose strength of 25 or 150 mg; to be taken with food or immediately after a meal, without chewing
45374781|NCT00775697|Drug|Montelukast|the arm will be treated with Montelukast 4 mg die for 4 weeks
45374782|NCT00775697|Drug|Montelukast|montelukast 4 mg day for 4 weeks
45374783|NCT05357066|Drug|Nitrous oxide gas for inhalation|Administration of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
45491898|NCT04715230|Biological|IXT-m200|IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.
45491899|NCT04715230|Drug|Lorazepam|Lorazepam is a benzodiazepine that is safe and commonly used to treat agitation and dysphoria in the emergency setting.
45491900|NCT04715230|Drug|Haloperidol|Haloperidol is commonly used to treat agitation due to psychosis.
45491901|NCT04439812|Other|Observation|The primary aim of this study was to evaluate the influence of positive margins on the tumour's recurrence and OS after gastrectomy for GC. The secondary outcome was to analyse the possible confounding factors that could affect the recurrence and OS after gastrectomy.
45491902|NCT04655326|Biological|Flore|personalized blend of GRAS approved probiotic strains, prebiotics, and botanicals
45491903|NCT02375308|Behavioral|HDT|20 sessions, individual psychotherapy
45491904|NCT02375308|Behavioral|ACDT|20 sessions, individual psychotherapy
45491905|NCT02375074|Behavioral|Supported Employment|Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
45491906|NCT02375074|Behavioral|Traditional Vocational Rehabilitation|Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment
45491907|NCT02375152|Procedure|Anterior Capsulotomy|
46053988|NCT02794467|Drug|Placebo|A matching placebo will be supplied as modified capsule shaped, white coated, oral tablet; to be taken with food or immediately after a meal, without chewing.
45491908|NCT03113032|Other|P-SEC Pre-Surgical Care|The P-SEC protocol is designed to deliver a focal mode of exercise-conditioning for motor performance to the knee extensor musculature. The latter requires a brief, machine-based gravity-resisted joint' movements (<2 seconds). An exercise session (6-minutes, approximately) will require a patient to undertake 4 sets of movement, with sets separated by 60-seconds recovery (delivering a total of 36 exercises across 3 interspersed days).
45491909|NCT03113032|Other|Normal pre-surgical care|Routine pre-surgical care
45491910|NCT03105544|Other|simulation-based training|As described under group descriptions
45374784|NCT05357066|Drug|Placebo|Administration of the placebo (oxygen-air mixture [FiO2 ≈0.3]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
45491911|NCT03105622|Behavioral|TV and music|Watching TV or listening to music while running on a treadmill
45846926|NCT02677428|Behavioral|Remotely-Delivered Benefits Counseling|Veterans will complete three intervention modules online. For the first module, Veterans will be instructed on how to use the website and its purpose; will be asked about their perception of the relationship between disability benefits and work. An explanation of relationship between disability benefits and work will be provided. For the second module, Veterans' feelings and attitudes towards employment will be solicited. Motivational Interviewing exercises will be implemented; barriers to work including the disabling condition and consideration of treatment for disabling conditions will be reviewed. An action plan will be developed. For the third module, inquiries will be made regarding the Veteran's reaction to the service-connection decision; information will be provided on how to appeal the decision. Veterans will be asked to reconsider work and financial goals in light of service-connection award. Their action plan will be reviewed. Follow-up resources will be provided.
45846927|NCT02677428|Behavioral|Control|The control condition will involve referrals to VA websites and represents enhanced treatment-as-usual. A Veteran who completes a Compensation examination ordinarily has no further treatment or referral as part of the Compensation examination. The information about benefits-related websites controls for having information available about benefits and receiving encouragement to pursue that information. The control condition involves being urged to explore links to three VA websites with Compensation & Pension-related information: (a) the VBA website with links about VA disability compensation, (b) the VBA site with fact sheets about the different types of benefits available to Veterans, and (c) the VBA websites for the local C&P office where issues pertaining to an individual Veteran's specific application are addressed.
45491912|NCT02378974|Biological|Cordstem-ST|
45491913|NCT02378974|Biological|Placebo|
45374785|NCT02556905|Drug|REVLIMID®|The recommended starting dose of REVLIMID® is 25mg/day with water orally administered as a single 25mg capsule on Days 1-21 of repeated 28-day cycles. Dose can be adjusted upon the clinical laboratory result.
45374786|NCT02556905|Drug|Dexamethasone|The recommended dose of dexamethasone is 40mg/day on Days 1-4, 9-12, and 17-20 of each 28-day cycle for the 4 cycle of therapy and then 40mg/day orally on Days 1-4 every 28 days.
45374787|NCT00772421|Device|There was no intervention.|There was no intervention. This study was designed as an in-clinic testing protocol to identify recruitment rhythms.
45374788|NCT00539006|Drug|FPNS|fluticasone propionate nasal spray
45374789|NCT00539006|Drug|FFNS|fluticasone furoate nasal spray
45374790|NCT00539006|Drug|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
45374791|NCT00539006|Drug|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
45374792|NCT00776087|Device|Home Monitoring provided by Biotronik ICD and CRT-D devices|Remote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety
45374793|NCT00776087|Device|No Home Monitoring|Home Monitoring option is switched off (in the same kind of devices as used in the other study arm).
45374794|NCT00776165|Biological|Recombinant Human GCSF (Shantha Biotechnics Limited)|Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
45374795|NCT00776165|Biological|Neupogen|Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
45491914|NCT02378896|Behavioral|Personalized Computer Program|Training with a personalized computerized inhibitory training program
45491915|NCT02378896|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
45491916|NCT02378818|Behavioral|Force task, preference task, discount task, learning task.|Force task, preference task, discount task, learning task.
45374796|NCT00989456|Behavioral|Self management education programme|"The structured patient educational self - management programme consists of 6 weekly sessions à 2 hours. The educational programme will take place prior to one of the two weekly training sessions.~After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care. During the last month of the intervention year educational self - management will be offered twice and focus on themes that the participants wish to refresh."
45374797|NCT00989456|Behavioral|exercise only|6 week waiting list, followed by two weekly training sessions. After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care.
45374798|NCT04521374|Behavioral|Preload meals that are solid or texture modified and are fortified with protein or not fortified with protein|Immediately after consuming the preload meal, volunteers will use a 100mm visual analogue scale (VAS) to rate their liking towards the meal, their hunger, fullness, desire to eat and prospective food intake. Subsequently, they will record these every 30 minutes until they consume their ad-libitum dinner
45374799|NCT04047329|Other|general anesthesia or neuraxial anesthesia|
45374800|NCT00779753|Dietary Supplement|Amino Acid Solution with different amount of Lysine|The infants will be placed on a standard Primene solution for the first 24 hours of the study to obtain baseline values. During the second 24 hours they will receive an amino acid solution that has a different amount of lysine currently found in Primene, all lipid, CHO, minerals, vitamins and trace elements will remain unchanged. The Parenteral lysine will be studied at the following intake levels: 100, 110, 120, 130, 135, 140, 145, 150 , 155, 165, 170, 180, 200, 230, 245, 260mg/kg/d. The minimum energy intake will be 85-90 kcal/kg/day.
45374801|NCT00537056|Procedure|FDG PET CT|nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body
45491917|NCT02374684|Drug|Methosulide|"Tolerability Study:~Period I:Single oral administration,dose-escalation of Methosulide(six dose groups:25mg-250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg ,group 2:depending on the adverse drug reaction,150mg/250mg)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Methosulide(three dose groups:50mg,100mg,200mg/250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg~,group 2:depending on the adverse drug reaction,150mg/250mg)~Food Effect on the Pharmacokinetics:~single dose(100mg),two status(Feeding and fasting), washout period(7 days)"
45374802|NCT00537056|Procedure|DCE MRI|DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg).
45491918|NCT02374684|Drug|Placebo|Placebo to match with experimental groups
45491919|NCT02374528|Procedure|Negative pressure wound therapy|Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.
45491920|NCT02374528|Procedure|standard pressure bolster dressing|This method is traditional used in skin grafting wound.
45491921|NCT02378740|Drug|Saline|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
45846928|NCT02677740|Device|Inhibitory rTMS (1 Hz)|Participants receive rTMS at a rate of 1 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% resting motor threshold (RMT) for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the inhibitory rTMS intervention.
45374803|NCT00537056|Drug|F-18 Fluoro-deoxi-glucose|15 mCi iv
45374804|NCT00537056|Drug|Gadolinium-DTPA|0.1 mmol/kg iv
45374805|NCT00537056|Drug|Sunitinib|50 mg/day po
45846929|NCT02677740|Device|Excitatory rTMS (5 Hz)|Participants receive rTMS at a rate of 5 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% RMT for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the excitatory rTMS intervention.
45374806|NCT00779831|Drug|120 mg Pseudoephedrine hydrochloride extended release tablets|
45374807|NCT04494698|Device|Duotherm VibraCool Back Device|Active New multimodal pain device
45374808|NCT04494698|Device|TENS 8-channel unit|LG Smart TENS unit
45374809|NCT00776321|Drug|Eprotirome|
45374810|NCT00776321|Drug|Placebo|
45374811|NCT00535262|Drug|EmSam|Selegiline Transdermal System (STS); monoamine oxidase inhibitor patch
45374812|NCT00776399|Device|Lung radiofrequency ablation|A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
45374813|NCT00989534|Behavioral|Fixed restricted bedtimes|Sleep restricted to 5 hours per night for 8 nights
45374814|NCT00989534|Behavioral|Sleep restriction with circadian misalignment|Sleep restricted to 5 h per day for 8 days, alternating night sleep and day sleep
45374815|NCT00772499|Drug|olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
45374816|NCT00772499|Drug|atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
45374817|NCT00989690|Drug|docetaxel|
45374818|NCT00989690|Drug|erlotinib hydrochloride|
45491922|NCT02378740|Drug|Ketamine|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
45846930|NCT02678442|Device|Fine Needle Biopsy (FNB)|The Shark Core FNB is an FDA approved device for sampling of submucosal lesions, mediastinal masses, lymph nodes and intraperitoneal masses. FNB will be performed by 22 gauge for pancreas head and by 19 gauge for all the other sites.
45374819|NCT00989690|Drug|pemetrexed disodium|
45374820|NCT00989690|Genetic|fluorescence in situ hybridization|
45374821|NCT00989690|Genetic|mutation analysis|
45374822|NCT00989690|Genetic|proteomic profiling|
45374823|NCT00989690|Other|immunohistochemistry staining method|
45491923|NCT02383732|Behavioral|Universal Safety Measures Module (All participants)|During the first session, the therapist conducts a home safety evaluation. During the second visit the therapist provides the caregiver with an individualized Elopement Prevention & Safety Plan (EPSP) based upon the results of the evaluation. The remainder of the session is spent helping caregivers make plans to implement the EPSP to reduce the risk of elopement or lessen the risk of harm to the child if they do successfully elope.
45374824|NCT00989690|Other|laboratory biomarker analysis|
45374825|NCT00989690|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
45374826|NCT00989690|Procedure|breath test|
45374827|NCT00779987|Drug|Autologous serum - Systane|20% autologous serum solution used four times a day for two weeks. Then 0.9% sodium chloride four times a day for one week. Finally, Systane (r) four times a day for two weeks.
45374828|NCT00779987|Drug|Systane - Autologous serum|Systane (r) four times a day for two weeks. Then 0.9% sodium chloride used four times a day for one weeks. Finally, 20% autologous serum solution four times a day for two week.
45374829|NCT04819022|Device|Acute and post-acute|These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
45491924|NCT02383732|Behavioral|Proximity Training Module (Bolting Prevention Participants)|During the first session a functional behavioral assessment (FBA) of bolting is conducted to identify the motivator(s) that evoke bolting. Caregivers identify a setting that is most problematic because it contains the item/activity that most frequently serves as a motivator for elopement. In the next session, caregivers are taught to identify effective alternative reinforcers. In subsequent sessions, antecedent and consequence based strategies are employed to reduce motivation for elopement and reinforce remaining within the designated proximity of a caregiver for increasing durations.
46053989|NCT02796417|Behavioral|REHACOP|REHACOP group consists of 90-minute-long sessions 3 days per week. Specifically, REHACOP group remediation consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas
45374830|NCT04819022|Device|Chronic|These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
45374831|NCT04819022|Device|Post-surgical|These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
45374832|NCT03875027|Procedure|proximal femur replacement|patient with proximal femur fracture or those in whom previous surgery on hip is failed and treated with replacement of proximal femur implant
45846931|NCT02678442|Device|Fine Needle Aspiration (FNA)|Fine needle aspiration is a type of biopsy procedure. In fine needle aspiration, a thin needle is inserted into an area of abnormal-appearing tissue or body fluid, and histological material is obtained. FNA will be performed with a standard 25g needle in the usual fashion using back and forth passes for 30 seconds.
46053990|NCT02796417|Behavioral|Occupational activities|Occupational group activities conducted included drawing, gardening, reading the daily news and constructing using different materials (such as paper or wood).
46053991|NCT05432271|Behavioral|Exposure to calorie information|Calories for all beverages and foods
45374833|NCT00074581|Drug|Atazanavir|300 mg taken orally once daily
45374834|NCT00074581|Drug|Didanosine|400 mg taken orally once daily
46053992|NCT05432271|Behavioral|Exposure to healthy labels only|Green labels only for beverages and foods scored as healthy
46053993|NCT05432271|Behavioral|Exposure to healthiness information|All beverages and foods labeled as either healthy (green), moderately healthy (yellow), or less healthy (red)
46053994|NCT05432271|Behavioral|Exposure to physical activity equivalents|All beverages and foods labeled with physical activity required to burn their calories
45846932|NCT02679690|Behavioral|Standard Dietary Sodium Education|Standard dietary education for sodium restricted diets for patients with heart failure.
45491925|NCT02383732|Behavioral|Check-In Training Module (Wandering Prevention Participants)|This module employs behavioral strategies to teach a child to check in with a caregiver at frequent fixed intervals during periods of low supervision. Delivering potent reinforcement for checking in counteracts any motivation to wander. Furthermore, if the child does wander caregivers become aware of it immediately because they failed to check in. During the first session caregivers are taught to identify effective reinforcers. A vibrating alarm that can be carried in a participating child's pocket serves as a prompt to seek out a caregiver and check-in. Participants receive access to a previously identified and individualized reinforcer for checking-in with the caregiver.
45491926|NCT01411267|Drug|AC220|Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
45374835|NCT00074581|Drug|Efavirenz|600 mg taken orally once daily
45374836|NCT00074581|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily
45374837|NCT00074581|Drug|Lamivudine|300 mg taken orally once daily
45374838|NCT00074581|Drug|Lopinavir/Ritonavir|200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily
45374839|NCT00074581|Drug|Nevirapine|200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily
45374840|NCT00074581|Drug|Stavudine|Dosage depends on weight
45374841|NCT00074581|Drug|Tenofovir disoproxil fumarate|300 mg taken orally once daily
45374842|NCT00074581|Drug|Zidovudine/Lamivudine|150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily
45491927|NCT01411267|Drug|Cytarabine|"All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~20 mg for patients age <1 yr~30 mg for patients age 1-1.99 years of age~50 mg for patients age 2-2.99 years of age~70 mg for patients >3 years of age"
45374843|NCT00776477|Drug|clopidogrel and aspirin|clopidogrel 75mg daily and aspirin 100mg daily
45374844|NCT00776477|Drug|aspirin|aspirin 100mg daily
45374845|NCT04692116|Device|ExAblate treatment|Subthalamotomy using the ExAblate
45374846|NCT00772655|Drug|90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab|A single course of 90Y-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111In-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 [if platelets are below 150000/µl only 11 MBq/kg are administered).
45374847|NCT00772655|Drug|Rituximab|Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
45374848|NCT04299542|Procedure|Percutaneous lung biopsy using conventional MDCT|Conventional CT biopsy will be performed using a 64 slice CT scanner. A preliminary plain CT is acquired covering the entire target lesion with a skin marker, and the interventional radiologist would decide on the skin puncture site and the needle pathway. A post-procedural CT scan will be made to detect pneumothorax or pulmonary haemorrhage. All images will be archived in the picture achieving and communication system (PACS).
45374849|NCT04299542|Procedure|Percutaneous lung biopsy CBCT|CBCT guided biopsy will be performed in the angiography suite. A preliminary CBCT (DynaCT) is acquired covering the entire target lesion is first performed. Image data will be displayed and processed using Syngo iGuide system. A potential needle trajectory will be drawn from skin to lesion. Integration of the cross-sectional images and real time fluoroscopy will result in three system positions: one bull's eye view and two progression views. During fluoroscopy, the planned needle trajectory and target will be overlaid on the real time fluoroscopy image. After the needle reaches the target, another CBCT will be performed to confirm needle position. Biopsy using coaxial system and post-procedural CT scans will be performed in similar fashion as the conventional CT group.
45374850|NCT04272086|Drug|Bupivacaine|0.25%
45374851|NCT04272086|Drug|Bupivacaine liposome|10mL
45374852|NCT04272086|Drug|normal saline|10ml
45374853|NCT01086865|Drug|Apetiviton BC|"Administer the recommended dosage preferably one hour before the main meal:~Children (2 to 6 years): 2.5 mL 3 x daily. Adults (18 to 50 years): 5 mL 3 x daily. Elderly (60 to 80 years): 5 ml 3 x daily."
45382257|NCT05162846|Behavioral|Virtual genetics navigator|A mobile-optimized website/online genetic tool developed by investigators from the University of Michigan's Center for Health Communications Research (CHCR).
45382258|NCT05162846|Behavioral|Motivational interviewing (MI)|At least 2 phone calls delivered by trained genetic health coaches using motivational interviewing and providing genetic testing information.
45846933|NCT02679690|Behavioral|Color-Coded Cue Cards|The use of a color-coded cue card to designate ranges of acceptable sodium content of food for comparison to labels while grocery shopping.
45846934|NCT02680158|Device|Oculeve Intranasal|Oculeve device, intranasal (test) application for approximately 3 minutes.
45846935|NCT02680158|Device|Sham|Sham device (control), intranasal application for approximately 3 minutes.
45491928|NCT01411267|Drug|Etoposide|150 mg/m2/day IV on days 1 through 5.
45491929|NCT01411267|Drug|Methotrexate|"IT methotrexate given intrathecally to patients with ALL on day 0 of course 1 and 2. Dose defined by age~6 mg for patients age < 1yr~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age"
45693140|NCT04278586|Behavioral|Live-Online M-ROCC|"LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50-60 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder.~MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 16 weeks with 60 minutes/wk.~MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for graduates of LDM for 50-60 mins/wk.~After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness."
45846936|NCT02680158|Device|Oculeve Extranasal|Oculeve device, extranasal (control) application for approximately 3 minutes.
45491930|NCT02378584|Other|embryo transfer|healthy blastocyst transfer in natural and hormonal cycle
45491931|NCT03113110|Drug|Empagliflozin 10 mg|PTDM patients on previous antidiabetic treatment (<40 IU insulin (in some cases plus oral antidiabetics)) receive Empagliflozin, ideally as monotherapy
45491932|NCT02378428|Drug|MIBG|
45491933|NCT02661880|Behavioral|preferred music|listening to preferred music choices
45491934|NCT03306277|Biological|Onasemnogene Abeparvovec-xioi|Non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
45491935|NCT04805788|Radiation|Proton Stereotactic Body Radiation Therapy|Undergo SBPT
45491936|NCT04805788|Other|Quality-of-Life Assessment|Ancillary studies
45491937|NCT02383888|Drug|BI 425809|
45491938|NCT02383888|Drug|BI 425809|
45491939|NCT02383888|Drug|Placebo|
45491940|NCT02383888|Drug|BI 425809|
45491941|NCT04664569|Other|observational study|observational study
45491942|NCT02378194|Drug|Placebo|24 weeks, once daily oral administration
45491943|NCT02378194|Drug|HD-003 (800mg/day)|24 weeks, once daily oral administration
45491944|NCT02378194|Drug|HD-003 (1600mg/day)|24 weeks, once daily oral administration
45374854|NCT01090843|Procedure|Video capsule endoscopy (VCE)|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
45491945|NCT00579709|Biological|Thymus Tissue for Transplantation|"3 Thymoglobulin doses given prior to thymus tx. Atypical subjects given Cyclosporine (Csa) pre-tx. Desired Csa concentration 180-300ng/ml. If post-tx T cell count remained <4000/cumm Csa weaned over 8 weeks. If T cell >4,000/cumm, Csa held at 180-300ng/ml.~Thymus tissue, donor, & mother of donor were screened for transplant safety. In operating room, thymic slices were transplanted into quadriceps muscle in 1 or both legs.~Subjects had routine blood research immune evaluations. 2-3 months post-tx, open biopsy of allograft. Immune blood studies continued on surviving subjects until January 2010. Biological Mother: Mother provided blood sample used for DNA extraction, to identify/look for maternal T cell presence in recipient pre-tx, and/or for immune testing post-tx."
45491946|NCT02374294|Device|Epiflo|"EPIFLO: Small, silent disposable, battery-operated oxygen concentrator capable of delivering 98% to 100% oxygen (balance moisture) for seven days at a rate of ~3.0 ml/hour; and 60 long sterile cannula (tube) that conveys the oxygen concentrator to the area beneath the bandage overlying the wound."
45491947|NCT02374216|Procedure|Insertion of dental implants|Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 to August 31st 2017
45491948|NCT02383498|Other|GI-6301 Placebo|GI-6301 Placebo will consist of USP-grade or equivalent 0.9% Sodium Chloride for Injection. Doses of GI-6301 placebo will be drawn into labeled syringes by an independent, unblinded pharmacist or designee.
45491949|NCT02383498|Biological|GI-6301 Vaccine (Yeast- Brachyury)|GI-6301 Vaccine is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
45491950|NCT02383498|Radiation|Radiotherapy|Standard of care
45491951|NCT02383498|Device|wGT3X-BT Actigraph|wGT3X-BT is small, non-invasive, portable watch accelerometer worn on the subject's wrist for Cycle 1 through Cycle 9
45491952|NCT02378350|Device|Hemodialysis treatment (no specific device is defined)|
45491953|NCT02378350|Drug|Peritoneal Dialysis treatment (no specific drug is defined)|
45491954|NCT02383654|Procedure|Autologous Adipose-Tissue Derived Stem Cells|"Intravenous and Intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells~Patient will receive brain implantation of approximately 100 -400million Autologous Adipose-Tissue Derived Stem Cells.~Patient will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice , before brain implantation, and will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice, after brain implantation ."
45491955|NCT02378116|Procedure|Surgical closure of the left atrial appendage|When patients are randomized to surgical closure, the surgeon is informed to close the left appendage. Closure is documented by a member of the research group at the site.
45491956|NCT02377960|Behavioral|IMB model-based initiation of antihypertensive medication|1.An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time
45491957|NCT02377960|Behavioral|Tailored SMS-text message support|2.Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication. After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments.
45491958|NCT02377960|Behavioral|Usual care|Usual care
45693141|NCT04278586|Behavioral|Live-Online Control|A time- and attention-matched live online control group. The manualized control intervention developed for the basic group-based opioid treatment group in primary care uses 16 core modules and 8 elective modules that are common to eclectic approach in treatment as usual addiction recovery groups (including engagement and group development activities with a mix of basic CBT skills, twelve-step facilitation, community reinforcement, and motivational interviewing). As an active group control, this method will help to isolate mindfulness as the putative mechanism of action by controlling for the therapeutic aspects of group without any reference to mindfulness.
45374855|NCT01090843|Device|MiroCam|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
45382259|NCT05159362|Other|Software Application|Access is granted to participants for 4 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
45382260|NCT05158517|Drug|Subcutaneous vedolizumab|Patients will be switched from IV vedolizumab into subcutaneous vedolizumab
45374856|NCT01090843|Device|Enteropro EndoCapsule|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
45374857|NCT00780299|Device|hemodialysis with high permeability (HDHP)|HDHP (hemodialysis with high permeability) is a specific plasma epuration of inflammatory mediators
45374858|NCT00780299|Procedure|CVVH|hemofiltration intermittent dialysis
45374859|NCT03895034|Device|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Eligible eyes will receive Light adjustable lens with Light delivery Device treatments
45374860|NCT03960931|Other|Aquatic rehabilitation|Rehabilitation sessions using hydrophysiotherapy will occur in a pool of Grand Nancy Thermal, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.
45374861|NCT03960931|Other|Land based physical activities|Rehabilitation sessions on treadmill will occur at Physical Medicine and Rehabilitation Regional Institute (IRR), on the University Hospital's site, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking, where intensity of effort can be modulated by speed and inclination of treadmill. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.
45491959|NCT02377804|Other|Dry needling|Patients will receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pect
45491960|NCT02377804|Other|Physical Therapy|Patients will receive 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity
45491961|NCT02377804|Device|stainless steel needles (0.3mm x 50mm)|
45491962|NCT02373748|Device|BioGaming YuGo System|Subjects will perform a customized training program predefined in the BioGaming YuGo system.
45491963|NCT02373904|Device|Photodynamic Bone Stabilization System|Treatment of impending and actual pathological fractures of the humerus
45491964|NCT02372032|Procedure|percutaneous lumbar discectomy|process percutaneous lumbar discectomy
45693142|NCT04275076|Procedure|Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia|comparison between 2 energy sources of enucleation in management of benign prostatic hyperplasia, holmium laser versus bipolar energy source in trans-urethral enucleation of the prostate
45693143|NCT03803332|Behavioral|Exposure Therapy|Psychotherapy including imaginal and in vivo exposure for PTSD.
45693144|NCT03803332|Behavioral|Interpersonal Psychotherapy|Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning.
45374862|NCT03960931|Other|Conventional rehabilitation|Conventional rehabilitation sessions will occur in private practices in which patients receive their habitual care (same physiotherapist). This care will be guided by prescription delivered by the neurologist. This prescription suggests to work on active and passive upper and lower limb stretching, on hip and shoulder dissociation, and balance control management on unstable ground.
45374863|NCT00776633|Drug|aspirin|6 weeks triple therapy with aspirin, clopidogrel and oral anticoagulation
45374864|NCT00776633|Drug|clopidogrel|6 months triple therapy with aspirin, clopidogrel and oral anticoagulation
45374865|NCT00776633|Drug|oral anticoagulation|
45374866|NCT01093963|Drug|Lisdexamfetamine|oral; 20-70mg/day
45374867|NCT01093963|Drug|Placebo|oral; 20-70mg/day
45374868|NCT03956563|Device|Youlaser MT Group 2|"Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications.~Each patient in the control arm will receive 3 simulated laser treatments every 30 days.~A placebo consists in a sham device laser that simulates the acoustic signal even if it does not deliver any laser radiation to the subject."
45491965|NCT02372032|Procedure|ozone therapy|percutaneous intradiscal ozone injection
45491966|NCT03130959|Biological|Nivolumab|Specified dose on specified days
45491967|NCT03130959|Biological|Ipilimumab|Specified dose on specified days
45374869|NCT03956563|Device|Youlaser MT Group 1|"Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications.~Each patient in the active arm will receive 3 laser treatments with the laser: one treatment administration every 30 days."
45374870|NCT00776711|Drug|Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005|
45374871|NCT00776711|Drug|VRC-AViDNA036-00-VP|
45374872|NCT00336128|Behavioral|attitude change|TigerKids: setting based prevention program to reduce obesity risk factors in children
45374873|NCT00336128|Behavioral|adiposity prevention program|The behavioral intervention aimed at modifying physical activity and food and drink choices at the kindergarten setting
45374874|NCT03956485|Other|Type of center|Tertiary versus non-tertiary
45382261|NCT05152459|Drug|Tazemetostat|Given PO
45382262|NCT05152459|Biological|Ublituximab|Given IV
45491968|NCT02377726|Behavioral|Alkoholhjälpen counselor support|Users will have access to counselor support through secure comments at the end of every module they complete in the self help program.
45491969|NCT02377726|Behavioral|eChange Alkoholhjälpen|An internet based intervention program (iCBT) consisting of 5 modules. Fully automated self-help
45491970|NCT02377726|Behavioral|Alkoholhjälpen|A swedish, open access website that includes information on alcohol, on how to find treatment and an internet discussion forum
45491971|NCT02371954|Behavioral|Happy Older Latinos are Active|Health promotion intervention desgined to prevent anxiety and depression in at risk older Hispanics
45491972|NCT02371954|Other|Fotonovela|Comic book style informational booklet designed for people with low literacy to educate them on mental illness.
45491973|NCT04525222|Other|Health Promotion and Education|Receive motivational messages and smoking cessation information via text messages
45846937|NCT02681172|Drug|Neuraceq (florbetaben 18F)|Florbetaben 18F is given as an i.v. injection followed by a flush of sodium chloride solution to ensure full delivery of the dose.
46053995|NCT05432271|Behavioral|"Exposure to high in nutrient warning labels"|Warning labels only for beverages and foods that exceed the thresholds for sugar, sodium, saturated fat, or calorie content
46053996|NCT02796495|Device|Operation of hand prosthesis with direct nerve stimulation|"Four TIME-4H electrodes will be implanted in the median and ulnar nerves of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the two sensorized hand prosthesis. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prosthetic hand movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention."
46053997|NCT00760669|Drug|Infliximab; observational study|This is an observational study. Participants with RA, AS and PA receiving induction intravenous infusions (a fluid or a medicine delivered into a vein by way of a needle) of infliximab will be observed. Participants with RA will receive infliximab 3 milligram per kilogram (mg/kg) as an intravenous infusion over a 2-hour period followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks (maintenance) thereafter up to 30 weeks. Participants with AS and PA will receive 5 mg/kg infliximab as an intravenous infusion over 2-hour period followed by additional doses at 2 and 6 weeks up to 24-30 weeks and 30 weeks, respectively.
46053998|NCT00760669|Drug|Methotrexate; observational study|Participants with RA will receive methotrexate based on physician's clinical judgement.
46053999|NCT02802267|Drug|Inecalcitol|vitamin D receptor agonist
46054000|NCT02802267|Drug|Placebo Oral Tablet|placebo
46054001|NCT02794623|Device|Tinnitus masking|Tinnitus masking via CI system
45491974|NCT04525222|Behavioral|Smoking Cessation Intervention (Actify app)|Use Actify app
45491975|NCT04525222|Behavioral|Smoking Cessation Intervention (Current Standard Care app)|Use (USCPG) Current Standard Care app
46054002|NCT04235049|Drug|Glecaprevir/pibrentasvir|Treatment for HCV Infection
45374875|NCT03743090|Diagnostic Test|Polysomnography.|A polysomnography will be performed for all of the patients the day before surgery (value of reference), and on the second postoperative day (in order to examine the influence of ECC on the development of OSA).
45374876|NCT00772811|Drug|Flu-Mel|"Fludarabine and Melphalan will be infused intravenously over 30 minutes in D5W 100 mL.~Melphalan will be administered following the completion of Fludarabine infusion at day -2."
45374877|NCT04256018|Drug|Mogamulizumab|Administered 1 mg/kg as an intravenous infusion over at least 60 minutes on Days 1, 8, 15, and 22 of the first 28 day cycle and on Days 1 and 15 of each subsequent cycle.
45374878|NCT04256018|Radiation|LD TSEBT|Patients will receive total skin dose of 12 Gy fractionated at 4 to 6 Gy per week, for 2-3 weeks
45374879|NCT03961087|Drug|Coenzyme Q10|Coenzyme Q10 will be given twice
45374880|NCT03961087|Drug|MECLOFENOXATE|MECLOFENOXATE will be given as 500 mg once daily.
45374881|NCT03960775|Drug|dexmedetomidine|Dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum.
45491976|NCT04525222|Other|Survey Administration|Ancillary studies
45491977|NCT02373670|Behavioral|Promotion of positive deviance behaviors|Using locally derived positive deviance findings to inform a behavioral intervention
45491978|NCT02373670|Behavioral|Promotion of healthy behaviors|Using standardized healthy behavior education (EatPlayGrow curriculum from NHLBI)
45491979|NCT01367769|Other|No intervention|There will be no intervention in this study.
45491980|NCT02373592|Behavioral|SMS and voice messaging|"This group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages have been developed and validated their delivery through both, SMS and voice messaging.~During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.~Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care)."
45374882|NCT03960775|Drug|saline|Saline infusion during same time period.
45374883|NCT00536978|Drug|ARA-C|100 mg/m^2 IV Daily Over 1 Hour for 4 Days
45374884|NCT00536978|Drug|BCNU|300 mg/m^2 IV Over 1 Hour for 1 Day
45374885|NCT00536978|Drug|Campath-1H|15 mg IV Daily Over 30 Minutes for 3 Days
45491981|NCT02373592|Device|Thermometry|Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet. (See Detailed description)
45491982|NCT01370031|Drug|Clenil® Modulite® via AeroChamber Plus™|Clenil® Modulite® 250 µg via AeroChamber Plus™ spacer during 14 days
45374886|NCT00536978|Drug|Cyclophosphamide|1000 mg/m^2 IV Daily Over 1 Hour for 3 Days
45374887|NCT00536978|Drug|Etoposide|100 mg/m^2 IV Daily Over 3 Hours for 4 Days
45374888|NCT00536978|Drug|Fludarabine|30 mg/m^2 IV Daily Over 1 Hour for 3 Days
45374889|NCT00536978|Drug|Melphalan|100 mg/m^2 IV Over 30 Minutes for 1 Day.
45374890|NCT00536978|Drug|Rituximab|375 mg/m^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m^2 IV Over 5-7 Hours Weekly for 3 Weeks.
45374891|NCT00536978|Other|Allogeneic Stem Cell Transplantation|Stem Cell Infusion on Day 0.
45374892|NCT00536978|Radiation|Total body radiation (TBI)|TBI on Day 5 following chemotherapy, before stem cell infusion.
45491983|NCT01370031|Drug|Clenil® Modulite® via Volumatic™ spacer|Clenil® Modulite® 250 µg via Volumatic™ spacer during 14 days
45491984|NCT01370031|Drug|Clenil® Modulite® via AeroChamber Plus™ plus charcoal block|Clenil® Modulite® via AeroChamber Plus™ spacer during 14 days (plus charcoal block at Day 14)
45491985|NCT01370031|Drug|Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block|Clenil® Modulite® administered via Volumatic™ spacer during 14 days (plus charcoal block at day 14)
45491986|NCT02373514|Drug|Paracetamol|1 gr paracetamol in 100 ml saline with rapid infusion
45491987|NCT02373514|Drug|Dexketoprofen|50 mg dexketoprofen in 100 ml saline with rapid infusion
45491988|NCT01364493|Drug|Trastuzumab+Capecitabine+Oxaliplatin|"Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.~Capecitabine 2000mg/m2d, d1-14; q3w, Trastuzumab and capecitabine are to be continued until disease progression or intolerable toxicity.~Oxaliplatin 130mg/m2 d1; q3w, 6 cycles"
45491989|NCT02371798|Drug|Gadopentetate dimeglumine|IV administration of 0.2 mmol/kg of Gd-DTPA
45374893|NCT00536978|Drug|Methotrexate|5 mg/m2 IV on Days +1, +3, and +6.
45491990|NCT02373358|Behavioral|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety & boundaries, strength & power, assertiveness, intuition, trust, & community) using mindfulness, breath work, and physical yoga poses.
45374894|NCT00536978|Drug|Tacrolimus|0.03 mg/kg/day IV starting on Day -2, to be given through day 60, tapered by 20% every week, then discontinue by day 90.
45491991|NCT01367925|Device|Stryker Triathlon® CS Tibial Insert|
45491992|NCT01367925|Device|Stryker Triathlon® PS Tibial Insert|
45491993|NCT01370187|Drug|Montelukast|Montelukast 4mg daily for 2 months
45491994|NCT04483960|Drug|Nafamostat Mesilate|Nafamostat continuous IV infusion for 7 days or until day of hospital discharge at a dose of 0.2mg/kg/hour. No adjustment in dose is needed for renal impairment, including for renal dialysis. The daily dose of nafamostat should be administered in 500 mL (rate of infusion 20.8 mL/hour) of normal saline. Normal saline is recommended (due to the tendency for patients with COVID-19 towards hyponatraemia) but not mandated, and 5% dextrose would be acceptable if felt clinically appropriate.
45491995|NCT04483960|Drug|Enoxaparin|"Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Enoxaparin will be 1mg/kg q12h or 1.5mg/kg q24h."
45491996|NCT04483960|Drug|Dalteparin|"Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Dalteparin will be 100IU/kg q12h or 200IU/kg q24h."
45491997|NCT04483960|Drug|Tinzaparin|"Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Tinzaparin will be 175IU/kg q24h (not available within Australia)."
45491998|NCT04483960|Biological|Hyperimmune globulin|2 doses of 30mL (3x10mL vials) of COVID-19 Hyper-Immunoglobulin (Human) given over 2 days within 48 hours of randomisation. Three vials will have approximately 10500 AU of neutralising antibodies, equivalent to approximately 200mL of convalescent plasma
45491999|NCT01370343|Drug|PF-04991532 alone|a single dose of 150 mg PF-04991532, fasted
45492000|NCT01370343|Drug|PF-04991532 + cyclosporine|a single dose of 150 mg PF-04991532 + a single dose of 600 mg cyclosporine, fasted
45492001|NCT01368003|Drug|STA9090|200 mg/m^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
45492002|NCT01368003|Drug|STA9090 with Dutasteride|Dutasteride 3.5 mg orally per day STA9090 200 mg/m^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
45846938|NCT02681172|Procedure|PET|A brain PET scan is usually taken 90 minutes after the i.v. injection of florbetaben 18F.
45374895|NCT00536978|Procedure|Adback NK or T Cell|Adback natural killer (NK) cells or T cells after transplantation to enhance full engraftment of donor cells. Cell adback after transplantation applies only if there is no active GVHD, and no previous episode of grade II-IV GVHD.
45374896|NCT05356832|Diagnostic Test|Pelvic Floor Health Knowledge Quiz|It is a questionnaire to measure the knowledge level of the participants about pelvic floor health.
45374897|NCT03809611|Drug|UNR844-Cl|1.5% Ophthalmic solution for topical ocular administration
45374898|NCT03809611|Drug|Placebo|placebo
45846939|NCT02682030|Device|High Frequency Chest Compression Device (HFCC)|A vest designed to help clear the airway of mucus and other secretions through mechanical knocking of the chest area.
45846940|NCT02682030|Device|Cough Assist|A device that aids patients to clear mucus and secretions that they would otherwise be unable to clear with coughing.
45846941|NCT02682420|Device|everlinQ endoAVF System|
45846942|NCT02682498|Drug|(Bupivacaine Liposome Injectable Suspension)|Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-lipsomal bupivacaine will be administered at the end of the surgery.
45374899|NCT05360342|Drug|Vitamin K supplement|Single dose of vitamin K supplement
45374900|NCT00989846|Other|biomarker|measuring serum-biomarkers
45374901|NCT05356754|Device|The Vital Labs Digital Blood Pressure Monitor|The Vital Labs Digital Blood Pressure monitor is a software-as-a-medical device (SaMD) that is capable of determining blood pressure, after calibration, using waveform changes observed in photoplethysmogram signals.
45374902|NCT03807739|Drug|GDC-0134 F09 Formulation|Participants will receive a single oral dose of GDC-0134 reference capsule F09.
45374903|NCT03807739|Drug|GDC-0134 F15 Formulation|Participants will receive a single oral dose of GDC-0134 prototype capsule F15.
45374904|NCT03807739|Drug|GDC-0134 F16 Formulation|Participants will receive a single oral dose of GDC-0134 prototype capsule F16.
45374905|NCT05290220|Drug|HLX07|1500 mg
45374906|NCT05290220|Drug|HLX10|300 mg
45374907|NCT05290220|Drug|HLX04|15mg/kg
45374908|NCT05290220|Drug|lenvatinib|12 mg (BW≥60 kg) or 8 mg (BW <60 kg)
45374909|NCT01583257|Behavioral|Workout based on active video gaming|A personalized workout regimen will be provided using the Microsoft Kinect Active Gaming Console with EA Sports Active 2 program
45492003|NCT01364571|Biological|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
45492004|NCT01364571|Procedure|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
45492005|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
45492006|NCT01364571|Biological|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
45492007|NCT01364571|Procedure|Blood sample|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
45492008|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
45492009|NCT01364571|Biological|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
45492010|NCT01364571|Procedure|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
45492011|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
46054003|NCT02802189|Other|Exercise programme|"Endurance and Resistant training exercise program (Duration: 45 minutes)~Muscle retraining of longus colli and endurance training of the deep cervical flexors.~Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM).~Active ROM exercises for the neck muscles~Upper limbs exercises with resistant bands~Stretching exercises for the neck and upper limbs muscles"
45374910|NCT03956329|Other|Standardised Digital Intervention|Video intervention designed to induce an increase in positive mood in older adults. Includes comedy clips, uplifting music and positive imagery. Intervention approximately 15-20 minutes in length. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
45382263|NCT05152459|Drug|Umbralisib|Given PO
45374911|NCT03956329|Other|Individualised Digital Intervention|Similar to the standardised digital intervention, however, participants will be able to individualise the intervention by choosing video clips from a limited menu of choices. Intervention approximately 15-20 minutes in length. The 4 categories include stand-up comedy (Michael McIntyre, Tim Vine and Victoria Wood), sit-com (Fawlty Towers, Only Fools and Horses and Two Ronnies), music (Elvis Presley, Last Night at the Proms, Roy Orbison) and variety (Britain's Got Talent, Strictly Come Dancing, Terry Wogan). Participants are able to select 3 of the videos, which are roughly 5 minutes in length, to reach a total of 15-20 minutes of content.
45492012|NCT01364571|Biological|Placebo|Subjects receive one intramuscular injection (0.5 mL) of commercially available normal saline.
45374912|NCT01583413|Procedure|Daily SAT & SBT|Nurse and/or respiratory therapist led daily awakenings from sedation (spontaneous awakening trial, or SAT) and daily performance of a spontaneous breathing trial (SBT) among mechanically ventilated, critically ill patients in participating ICUs.
45374913|NCT00536744|Device|acoustical pulse energy (extracorporeal shockwave)|Acoustical pulse energy (extracorporeal shockwave) + Standard of care wound dressing.
45374914|NCT00536744|Other|Sham|Non-energized (inactive - Sham) application + standard of care
45374915|NCT01094041|Other|Gluten free diet|A 4-week gluten free diet provided
45374916|NCT01094041|Other|Gluten rich diet|A 4-week gluten rich diet is provided
45492013|NCT01364571|Procedure|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
45492014|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
45492015|NCT04469296|Dietary Supplement|iso-caloric ketogenic diet|Each patient will be offered a daily diet plan that includes the different groups of low glycemic index foods to bring to each meal and snack, with the notion of quantity. Carbohydrate-free foods can be consumed ad libitum. Dietary advice will be given to increase the consumption of lipid foods (vegetable oils, butter, cheeses, fatty fish, etc.) so that 65% of the total energy intake is provided by lipids. In addition, a list of unauthorized sugars and sweeteners substitutes will be proposed as well as a low glycemic index food composition table centered on carbohydrates for better control of food choice
45846943|NCT02682498|Drug|Standard Preparation|A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
45374917|NCT04076072|Device|Utravit High-Speed 10000 cpm Beveled Probe|This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
45374918|NCT04076072|Device|standard vitrector probe- Alcon (non-beveled) Ultravit 7500 cpm|This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
45374919|NCT04026230|Drug|Atorvastatin 80mg|Capsules including 80 mg of atorvastatin
45374920|NCT04026230|Drug|Placebo oral capsule|Similar capsules as in the atorvastatin arm, but without the active ingredient
45374921|NCT03884504|Device|Ventricular Assist Device System|Ventricular Assist Device System
45374922|NCT00536510|Drug|laropiprant/niacin (MK0524A)|"Treatment Period 1: one 20mg/1g tablet laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization"
45374923|NCT00536510|Drug|Comparator: placebo|"Treatment Period 1: one 20mg/1g tablet placebo to laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets of placebo to laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization."
45492016|NCT04469296|Dietary Supplement|protein restricted diet|A diet reducing by 20% the amount of protein compared to the usual intake of the patient will be proposed. This new ration will be carried out by calculating the proportion of total energy intake provided by the amount of protein reduced by 20% compared to the usual intake, and by modifying lipid and carbohydrate intakes to obtain an isocaloric ration.
45846944|NCT02684136|Drug|suvorexant|suvorexant 20 mg taken before sleep
45846945|NCT02684136|Drug|placebo|placebo taken before sleep
45374924|NCT04526600|Other|Fidget ball|Access to a prototype 'smart' fidget ball with pressure sensors embedded, that produces touch traces and transmits real time data
45374925|NCT04496258|Behavioral|Positive Emotion Induction|Participants are expected to have a positive emotional response to the more positive beach scene.
45374926|NCT04496258|Behavioral|Neutral Emotion Induction|Participants are expected to have a neutral emotional response to the neutral office scene.
45374927|NCT04424264|Drug|Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid|TDF/FTC/EFV 300/200/600 mg once daily plus RIF/INH 600*/300 mg daily from screening until enrolment (days -15 to 0)
45374928|NCT04424264|Drug|Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid|TAF 25 mg + 3TC 300 mg + EFV 600 mg once daily plus RIF/INH 600/*300 mg daily (days 1 to ≤ 56)
45374929|NCT04424264|Drug|Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz|TDF/FTC/EFV 300/200/600 mg once daily. RIF/INH 600mg <70kg, 750mg >70kg
45492017|NCT02371720|Behavioral|Mobile DOT|Daily reminders via text or email to send a video of themselves taking their Hydroxyurea, positive feedback, and be encouraged to contact the research coordinator with any questions, concerns, etc.
45492018|NCT04223583|Drug|Anlotinib Hydrochloride|The standard first-line chemotherapy regimen (adriamycin + ifosfamide) failed
45492019|NCT04222257|Drug|Antibiotics|Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
45846946|NCT02687412|Procedure|pre-operative assessment, counseling and education|pre-operative assessment, counseling and FT management education
45846947|NCT02687412|Procedure|Preoperative nutritional drink up to 4 h prior to surgery|Preoperative nutritional drink up to 4 h prior to surgery mechanical bowl preparation should not be used
45846948|NCT02687412|Procedure|bowel preparation|patients are not received mechanical bowel preparation, only oral intestinal cleaner 12 h pre-operation can be accepted, but no need of liquid stool
45374930|NCT03790670|Drug|sargramostim|Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
45374931|NCT05355662|Other|Age|The study was retrospective and did not involve the application of interventions.
45374932|NCT00398086|Drug|Gemcitabine|Administered by intravenous infusion over 30 minutes.
45374933|NCT00398086|Drug|Albumin-bound paclitaxel|Administered by intravenous infusion over 30 minutes.
45374934|NCT05280860|Procedure|ultrasound-guided bilateral rectus sheath block|Bilateral RSB was guided by ultrasound before surgery after the completion of general anesthesia, First, the probe is placed transversely and perpendicular to reveal the anterior, hypoechoic, and posterior rectus sheath of the hyperechoic rectus abdominis. Moving the probe outward to reveal the sound images of the lateral margin of the rectus abdominis, external oblique, internal oblique, and transverse abdominis muscles. After the scanning, the needle was inserted from any segment of the probe under the guidance of real-time ultrasound; the tip reached between the rectus abdominis muscle and the posterior sheath of the rectus abdominis muscle. After no blood was extracted, 1 ~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct, If the needle tip was correctly positioned, 0.5 % ropivacaine 10 mL of local anesthetic was injected on each side. The same anesthesiologist was performed bilateral RSB under ultrasound guidance.
45374935|NCT04364360|Dietary Supplement|Sulforaphane extract|2x BroccoMax® capsules day, giving a total daily dose of 30 mg of Sulforaphane Glucosinolate Per day
45374936|NCT04361942|Biological|Mesenchymal Stromal Cells|Intravenous injection of 1 million MSV cells/Kg diluted in 100 ml saline
45374937|NCT04361942|Other|Placebo|Intravenous injection of 100 ml saline containing no cells
45374938|NCT04286516|Device|Transcranial Magnetic Stimulation|Paired pulse transcranial magnetic stimulation
45492020|NCT04222257|Drug|Antibiotics|Patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
45492021|NCT02373436|Other|Constraint Induced Therapy|"They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.~The training will consist of 30 minutes for the transfer package, interview by items of MAL, and 2 hours and 30 minutes with four tasks of Shaping, and Task Practice.~The Transfer Package consists of a compromise agreement, held at the end of the first day of practice, in which the individual undertakes to complete:~The Shaping is a training method that makes it difficult gradually according to the motor capacity of each individual. It will be taken care of including tasks using all joints (shoulder, elbow, wrist and fingers), giving priority to the individual in need.~The individual will be instructed not to remove the trunk of the chair, and each task is repeated 10 times in no more than 45s.~The Task Practice promotes increased motor function during functional activities. For all individuals will be held the same function: meal."
46054004|NCT02802189|Other|Integrated Neuromuscular Inhibition Technique application.|"Integrated Neuromuscular Inhibition Technique application.~(Duration: 15min)~The protocol was applied to the following muscles:~Upper border of the trapezius muscle~sternocleidomastoid~levator scapulae muscle~splenius capitis muscle~Integrated Neuromuscular Inhibition Technique includes the combination of the following technique:~Ischemic compression~Muscle energy technique~Strain-counterstrain technique"
46054005|NCT02796339|Dietary Supplement|Mastiha|
46054006|NCT02796339|Dietary Supplement|Placebo|
46054007|NCT02796183|Drug|Subconjunctival bevacizumab (Altuzan)|Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.
46054008|NCT02796105|Drug|Progevera|
46054009|NCT02796105|Drug|Orgalutran|
45374939|NCT00536198|Drug|Sertraline|50 mg of sertraline will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
45374940|NCT00536198|Drug|Placebo|50 mg of placebo will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg.
45374941|NCT00393484|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily (0-96 weeks) and (96-240 weeks)
45374942|NCT00393484|Drug|Lamivudine Placebo|Capsules, Oral, 0 mg, once daily (0-96 weeks)
45374943|NCT00393484|Drug|Lamivudine|"Capsules, Oral, 100 mg, once daily (0-96 weeks)~Tablets, Oral, 100 mg, once daily (96-240 weeks)"
45374944|NCT00393484|Drug|Entecavir Placebo|Tablets, Oral, 0 mg, once daily (0-96 weeks)
45374945|NCT00667823|Drug|Macitentan|Tablet, oral administration, 10 mg dose once daily
45374946|NCT00397930|Procedure|Standard Care Control Condition|Cancer survivors assigned to this condition continued with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS program gratis after completing all study requirements.
45374947|NCT00397930|Procedure|Yoga Intervention (YOCAS)|The Yoga for Cancer Survivors (YOCAS) intervention uses two forms of yoga: Gentle Hatha yoga and Restorative yoga. The YOCAS sessions are standardized, and each session includes physical alignment postures, breathing and mindfulness exercises. The intervention is delivered in an instructor taught, group format, twice a week for 75 minutes each time over 4 weeks for a total of eight sessions of yoga. All sessions were taught in community-based sites (eg. yoga studios, community centers, community oncology practices) with an average group size of 12 (range, 10-15) in the late afternoon or evening after 4pm.
45374948|NCT03649178|Other|salt|Participants will randomly eat a high salt diet for 8 weeks and a low salt diet for 8 weeks
45374949|NCT05356676|Other|Isometrics|"Isometric neck extension -individuals will be taught to place their dominant hand posterior to their head at occiput. Then, they will be told to firmly push the head backwards against that hand, and hold for five seconds and repeat 5 times. • Participants will be asked to place the right hand flat on the same side of the head. Next.~they will be instructed to firmly push the head against right hand and hold for 5 seconds and repeat five times. Same exercise will be repeated with the left hand against the left side of the head as well.~• Participants will be taught to place their right hand on their right cheek. Then, they will be told to rum the face against the right hand and wait for 5 seconds and repeat five times. Same exercise was repeated with the left hand on the left cheek as well."
45492022|NCT02373436|Other|Control|This group has no intervention. They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
45492023|NCT03634761|Behavioral|Competency based model|Qualified Learning course and workshop to preschool staff combined with monthly on-site coaching at preschool sites to improve overall intervention setting quality and use of evidence bases practices, provided by external expert from habilitation center.
45846949|NCT02687412|Procedure|preoperative treatment with carbohydrates|preoperative treatment with carbohydrates (patients without diabetes).
45492024|NCT03634761|Behavioral|Comprehensive program|Comprehensive program of EIBI for Children with ASD supervised by external expert from habilitation center (treatment as usual)
46054010|NCT02794701|Other|People with silicosis|
45374950|NCT05356676|Other|Combination Therapy|"In supine position, the patient will be instructed to take a deep breath in order to relax the body whilst holding his/her shoulders and neck in a comfortable posture.~the patient will bend his/her knees and place their feet flat on the floor, and will hold the posture without any other neck movement. Then the patient will be asked to raise their dominant arm to 90° shoulder flexion along with full elbow extension and scapular protraction.~This posture will be held for 10 seconds before returning to the prior position with 3 laps, 10 repetitions with a one-minute break between.~in quadruped position, the patient will lift up their arms alternatively with shoulder abduction and 120 ° flexion. This posture will be held for 10 seconds before returning to the starting position for three laps, 10 repetitions with a 30-second break in between. Participants will be instructed to perform these for 3 times a week for 4 weeks."
45374951|NCT00397540|Procedure|PEIT|Percutaneous Ethanol Injection Therapy
45374952|NCT00397540|Procedure|RFTA|Radiofrequency Thermal Ablation
45374953|NCT03993496|Diagnostic Test|Abdominal Aortic Aneurysm Sac Pulsatility|"Measurements of aortic wall pulsatility will be performed using trans-abdominal ultrasound through the non-sterile field of the upper abdomen, while the surgeons operate through the groins. The pulsatilty of the aneurysm will then be measured using transverse views in 'M-Mode' of the ultrasound, and measures the aneurysm wall displacement during a cardiac cycle; the minimum diameter (diastole) and maximum diameter (systole) will be measured. These measurements will occur during surgery:~Prior to EVAR deployment~After EVAR deployment, but before balloon affixation to the aortic wall~After EVAR deployment and after affixation"
45374954|NCT00536120|Biological|BG00002 (natalizumab)|
45374955|NCT00536120|Biological|keyhole limpet hemocyanin (KLH)|KLH 1 mg administered subcutaneously (SC) in accordance with the Immucothel investigator's brochure.
45374956|NCT00536120|Biological|tetanus diphtheria toxoid vaccine (Td)|Td administered in accordance with the manufacturer's prescribing information.
45374957|NCT00057811|Drug|doxorubicin hydrochloride|Given IV, IT, or orally
45374958|NCT00057811|Drug|cyclophosphamide|Given IV
45492025|NCT02371564|Device|High flow humidified oxygen|
45492026|NCT02371564|Device|Standard flow humidified oxygen|
45492027|NCT04981275|Other|No intervention study|This observational study will only collect data, not provide any intervention to participants.
45374959|NCT00057811|Drug|methotrexate|Given IV or IT
45374960|NCT00057811|Drug|rasburicase|Given IV
45374961|NCT00057811|Drug|leucovorin calcium|Given IV or orally
45492028|NCT02371486|Procedure|hysteroscopic repair of cesarean section defect|Operative hysteroscopy for the repair of cesarean section defect is performed under general anesthesia. the cervix is dilated and the cesarean section defect opened. polypoid tissue is ablated
45492029|NCT02371486|Procedure|Diagnostic Hysteroscopy|Betthochi's method for diagnostic hysteroscopy: No anesthesia will be used. vaginoscopy will be performed, followed by diagnostic hysteroscopy. saline will be used as a distension media. 4.2 mm Storz hysteroscope will be used.
45846950|NCT02687412|Procedure|fast solid|fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia;
46054011|NCT02794545|Procedure|cART course|The investigators would start regular cART course immediately for early infection patients to achieve functional cure.
46054012|NCT02795949|Drug|Antipseudomonal beta-lactam antibiotic|Pharmaceutical form: solution for infusion
46054013|NCT02795949|Drug|De-escalation(short-spectrum antibiotic)|Pharmaceutical form: solution for infusion
46054014|NCT00769483|Drug|MK-0646|Starting Dose Level: 5 mg/kg given intravenously over 60 minutes Days 1, 8, 15, 22 of 28 Day Cycle.
46054015|NCT00769483|Drug|Gemcitabine|1000 mg/m^2 given intravenously over 1-1/2 hours Days 1, 8, and 15 of each 28 Day Cycle.
46054016|NCT00769483|Drug|Erlotinib|100 mg by mouth daily.
46054017|NCT02794389|Drug|N-acetyl cysteine|
45374962|NCT00057811|Drug|prednisone|Given IV or orally
45374963|NCT00057811|Drug|methylprednisolone|Given IV or orally
45374964|NCT00057811|Biological|filgrastim|Given subcutaneously
45374965|NCT00057811|Biological|rituximab|Given IV
45374966|NCT00057811|Drug|cytarabine|Given IT
45374967|NCT00057811|Drug|etoposide|Given IV
45374968|NCT00057811|Drug|vincristine sulfate|Given IV
45374969|NCT00057811|Drug|hydrocortisone sodium succinate|Given IT
45846951|NCT02687412|Procedure|avoiding hypothermia|avoiding hypothermia, keeping the intra-operative lowtemperature at 36 ±0.5 degree centigrade; antiemetics at end of anaesthesia.
45374970|NCT00057811|Other|laboratory biomarker analysis|Correlative studies
45374971|NCT03502148|Drug|PRV111 (Cisplatin Transmucosal System)|Each treatment visit will include one application of a permeation enhancer and then 2, 3 or 5 PRV111 (Cisplatin Transmucosal System) applications depending on the Stage subject is enrolled in.
45374972|NCT03957811|Other|Whole body Vibration exercise|Intervention will consist of sessions of exercise on a whole body vibration platform, three times a week for 12 weeks.
45374973|NCT03247634|Behavioral|Getting Ahead in a Just-Gettin'-By World|The Getting Ahead program is a unique welldeveloped program that allows carefully guided introspection toward the crafting of tailored solutions aimed at addressing complex social determinants of health among individuals living in vulnerable populations where the achievement of health equity often seems unattainable. The important lens of health equity is a key component of this proposal and is consistent with the American Cancer Society overarching emphasis on reduction of health disparities and achievement of health equity.
45374974|NCT01090999|Other|long-term maintenance respiratory rehabilitation program|To determine whether a long-term maintenance program after respiratory rehabilitation (group active comparator), in contrast to the usual minimal maintenance therapy (group no intervention), improves the cost-effectiveness through: a.- maintaining long term effects in terms of effort capacity, HRQL, and reduced exacerbations b.- reducing the total cost of care to patients, largely through reduction of exacerbations.
45374975|NCT02530801|Drug|Bevacizumab|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
45846952|NCT02687412|Procedure|Postoperative glycaemic control|Postoperative glycaemic control;
45846953|NCT02687412|Procedure|postoperative nausea and vomiting (PONV) control;|
45374976|NCT02530801|Drug|5 fluorouracil|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
45374977|NCT01091077|Dietary Supplement|Naringenin|1 gram of naringenin mixed with 16 grams of hydroxypropyl-β-cyclodextrin in 250 mL of water
45374978|NCT01094275|Drug|Clopidogrel 75mg, Omeprazole 20mg|Clopidogrel and or Omeprazole as applicable
45846954|NCT02687412|Procedure|early postoperative diet|early postoperative diet(3-6 h after surgery, patients resumed a liquid diet, 12 h after surgery patients began to take solid diet).
45374979|NCT05355506|Device|Application|Knowledge & record
45492030|NCT02371486|Procedure|Ultrasound Scan|"Scanning the uterus with the ultrasound probe . Transvaginal ultrasound usually produces better and clearer images of the female pelvic organs, because the ultrasound probe lies closer to these structures.~The transvaginal ultrasound probe is thin, about 2cm diameter. The probe is covered with a disposable protective sheath. A small amount of ultrasound gel is placed on the end of this probe. The probe is then gently inserted a short distance into the vagina."
45846955|NCT02687412|Procedure|pre-operative fasting at least 8h|
45846956|NCT02687412|Procedure|bowel preparation for traditional surgery|Oral bowel preparations or mechanical bowl until liquid stool
45846957|NCT02687412|Procedure|began to take solid diet after anal exhaust|6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust
45846958|NCT02693262|Device|CLS Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
46054018|NCT02794389|Drug|Placebo|
46054019|NCT02601703|Drug|Tacrolimus Ointment 0.1%|apply thin layer of ointment to affected area
46054020|NCT02601703|Drug|Protopic® ointment, 0.1%|apply thin layer of ointment to affected area
46054021|NCT02601703|Drug|Placebo of Tacrolimus Ointment|apply thin layer of ointment to affected area
46054022|NCT02790489|Dietary Supplement|Valedia|
45374980|NCT01094353|Procedure|Mini-sling|The minisling is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
45374981|NCT01094353|Procedure|Transobturator|Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
45374982|NCT05263310|Behavioral|Prepare for Your Diabetes Care|Educational video and Action Plan handout
45374983|NCT05263310|Behavioral|Usual Care|Control arm patients will continue with usual care
45374984|NCT01089205|Drug|Metformin|
45374985|NCT02866682|Drug|Prograf|Brand Drug for the duration of the study.
45492031|NCT02371486|Procedure|IVF Cycle|Controlled ovarian hyperstimulation, followed by Human chorionic Gonadotropin ( hCG) administration, Ovum Pickup and Embryo transfer
45374986|NCT02866682|Drug|Tacrolimus|Generic
45374987|NCT02822924|Procedure|Prostate artery embolization (PAE)|Right femoral arterial puncture is performed under local anesthesia. The blood supply to the prostate is mapped by angiography of the iliac vessels and the prostate arteries. Microcatheters are used for super-selective catheterization of the right and left inferior vesicle arteries. Embolization is performed with a microcatheter to deliver microspheres of 300 micron diameter. The microsphere mixture is slowly injected under fluoroscopic guidance. The endpoint of embolization is flow stasis in the prostatic vessels with prostatic gland opacification, without reflux of the mixture to undesired arteries.
45374988|NCT01089439|Drug|Nitric oxide by inhalation INOMAX|"Nitric oxide by inhalation INOMAX 800 ppm~40 ppm during 24 hours then 20 ppm during 24 hours then 10 ppm during 24 hours"
45374989|NCT01089439|Drug|Placebo|placebo
45374990|NCT02774642|Behavioral|CBTI-PE|Integrates CBT-I and PE with the goal of enhancing both insomnia and PTSD outcomes. Integrated treatment will be delivered in 14 90-minute weekly sessions. CBTI-PE starts with VA rollout CBT-I for the first 3 weeks with a focus on the effects of PTSD on insomnia. PE protocol (psychoeducation) begins on week 4 of treatment and both treatments overlap till week 6 when CBT-I ends and the active treatment of PE begins (i.e., imaginal and in-vivo exposures). However, CBT-I sleep diary review and sleep time adjustment will continue till the end of treatment to increase adherence
45492032|NCT03933904|Drug|Sirolimus|Sirolimus (also known as rapamycin) inhibits the mTOR protein kinase and is approved by the USA FDA for the prevention of allograft rejection in renal transplant patients ≥ 13 years of age and for the treatment of lymphangioleiomyomatosis.
45492033|NCT04961697|Behavioral|Hospital diaries|Diaries will be used by family members, PICU staff or even the patient himself. They will take daily notes expressing feelings and thoughts and describing events that might help chronologically to better understand the course of disease and PICU stay. Photographs and other important PICU memories may also be used in the diary.
45492034|NCT02377648|Device|Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)|Placement of bioresorbable vascular scaffold in presence of at least one critical angiographic de novo lesion (DS ≥70%) or a non-critical angiographic de novo lesion (50% ≤ DS <70%) associated with concomitant signs or symptoms of myocardial ischemia.
45846959|NCT02693262|Device|Accelerometer Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
45492035|NCT01368159|Device|Compression Stockings|"The trial objectives are to compare efficacy relative to pain, along the route of the vein following echoguided endovenous injection of sclerotherapeutic foam into the Great Saphenous vein, of class III microfibre compression (centred at 25 mm Hg) versus class I (10-15 mm Hg) versus class III cotton compression (20 to 36 mm Hg) over 21 days. The main contrast will be the comparison between the first two groups mentioned. All other contrasts will be secondary. The Class I compression versus The two class III compressions contrast will also be studied."
45492036|NCT02371408|Drug|ravidasvir hydrochloride|200 mg
45492037|NCT02371408|Drug|sofosbuvir|400 mg
45374991|NCT02774642|Behavioral|Hygiene-PE|The investigators have included a non-active sleep control arm (3 Sessions)to allow for the dose response of 14 90 minute sessions. The non-active sleep control condition used in this study is a manualized protocol developed to exclude the active components of standard CBT-I treatment. Hygiene includes presentation of sleep hygiene education and reviewing daily stressors that may impact sleep before starting PE on week 4.
45374992|NCT00992030|Drug|Rituximab|I.V. infusion weekly x 6 weeks at a dose of 375 mg/m2
45374993|NCT00992030|Radiation|Involved field irradiation|Radiation therapy, limited to initially involved nodal sites, will start within four weeks from the last cycle of ABVD chemotherapy and after complete restaging with TAC total-body and PET total-body. The planned total dose is 30,6 Gy.
45374994|NCT00992342|Drug|PF-03893787|oral solution, 5 mg, QD for 14 days
45492038|NCT02371408|Drug|ribavirin|1000 mg - 1200 mg per day, weight-based dosing
45492039|NCT01364805|Drug|Intravenous Vitamin C|The first 5 study visits will all take place in the General Clinical Research Center (GCRC). During these visits you will receive IV doses of Vitamin C. The dose of Vitamin C will be started at 25 grams and may be increased up to 125 grams over a two week period. There may be changes in the amount of Vitamin C that you receive based on your blood test levels. The study staff will go over this in more detail with you. The amount of fluid you receive depends on the dose and can be from 2 1/3 cups to 5 cups.
45374995|NCT00992342|Drug|PF-03893787|oral solution, 15 mg, QD for 14 days
45374996|NCT00992342|Drug|PF-03893787|oral solution, 50 mg, QD for 14 days
45374997|NCT01976390|Drug|Everolimus|0.75mg twice a day, Orally, starting on day of transplant
45374998|NCT01976390|Drug|Sirolimus|5mg, Orally, starting on day of transplant; decreasing to 3mg
45374999|NCT00570713|Drug|MORAb-009|Monoclonal antibody administered once weekly by intravenous injection.
45375000|NCT00570713|Drug|Placebo|As per package insert.
45375001|NCT00570713|Drug|Gemcitabine|Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
45375002|NCT04002440|Combination Product|AMIA with SHARESOURCE Connectivity Platform|The investigators will conduct a randomized, cross-over study in peritoneal dialysis patients in which patients are randomized to either Home Choice Pro (which remains the most widely used Baxter cycler) versus treatment with the Baxter AMIA automated peritoneal dialysis system with SHARESOURCE connectivity.
45375003|NCT04002440|Device|HomeChoice PRO|Usual care
45375004|NCT05294939|Dietary Supplement|Ketone monoester|Consumption of 800mg/kg body weight of ketone monoester, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, every hour they should consume 90g of carbohydrates.
45375005|NCT05294939|Dietary Supplement|Control product consumption|Consumption of placebo product (carbohydrates) masked with citric, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, 90g of carbohydrates should be consumed every hour.
45375006|NCT00773045|Other|A Pain training program and pain measurement|Comparing patients treated with and without analgesia and sedation protocol
45375007|NCT00556946|Drug|Combined Photodynamic & Pulsed Dye Laser Treatment|Treatment of Port Wine Stains using Combined Photodynamic and Pulsed Dye Laser
45375008|NCT00776867|Drug|perifosine|Open label, phase I study of oral perifosine in recurrent/progressive pediatric solid tumors. This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level. All patients will receive perifosine at a loading dose on the first day, followed by a maintenance dose to start on day two until progression each patient will be assigned to a dosing group based on one's body surface area (BSA).
45375009|NCT05267132|Behavioral|Other-Focused Acts of Kindness Intervention with Reflection|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine. Participants will then reflect on their kind acts after each week.
45375010|NCT05267132|Behavioral|Other-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.
45375011|NCT05267132|Behavioral|Daily Reports|Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
45375012|NCT02556515|Procedure|Interpositional arthroplasty (Burton-Pellegrini procedure)|Burton-Pellegrini procedure
45375013|NCT02556515|Procedure|Total joint replacement|Total joint replacement
45492040|NCT01364805|Drug|Gemcitabine|Participants receive dexamethasone 10 mg as pretreatment antiemetic; may be given ondansetron, granisetron, or dolasetron, per oncologist. Gemcitibane 1,000mg/m2 IV over 30 minutes Q 21 days. Cycle of treatment: infusions once weekly for 2 consecutive weeks followed by 1 week of rest to continue treatment schedule until they experience disease progression or unacceptable toxicity. CR, PR or SD: treatment will be continued for at least 6 cycles. Discontinuation of therapy may be considered if agreed upon by the participant and oncologist. Dose Modifications: If the patient experiences more than one toxicity, each requiring a dose reduction, follow the guidelines that give the largest dose reduction for the drug. Subsequent doses can be adjusted to as low as 500 mg/m2 for gemcitabine.
45693145|NCT04273438|Device|Visual field testing using Oculus Rift and Humphrey Visual Field Perimeter|Glaucoma patients at Queen's University, Belfast, will be invited to undergo both Visual field testing using the Oculus Rift and the gold-standard Humphrey 24-2 (Carl Zeiss Meditec, Dublin, CA) at two visits, and evaluating consistency for detecting visual field impairments.
45693146|NCT04273438|Device|Visual Field Testing using HUmphrey 24-3 Perimeter|Glaucoma patients at Queen's University, Belfast, will be invited to undergo both Visual field testing using the Oculus Rift and the gold-standard Humphrey 24-2 (Carl Zeiss Meditec, Dublin, CA) at two visits, and evaluating consistency for detecting visual field impairments.
45375014|NCT02556515|Device|Elektra prosthesis|Elektra prosthesis
45375015|NCT05356286|Device|epidural electrical stimulation|Electrical spinal cord stimulation will be used to modulate respiratory function during general anesthesia.
45375016|NCT00780377|Drug|Bradykinin|Bradykinin 0, 0.2, 0.6, 2.0 ug/min intracoronary, for 5 minutes at each dose.
45375017|NCT05219942|Drug|Glargine|regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous Glargine insulin (made by Sanofi®) within the first 2 hours of ICU admission. The dose of insulin glargine will be adjusted according to the calculated (eGFR > 90 dose = 0.27 IU/kg/day, eGFR 60-89 dose = 0.25 IU/kg/day, eGFR <60 dose = 0.19 IU/kg/day.
45375018|NCT05219942|Other|normal saline|regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous saline instead of insulin glargine will be given in the control group.
45375019|NCT04002206|Other|Muscle Energy Technique|In experimental group, post-isometric relaxation technique has given to the athletes. The position of athlete was prone and the involved group of muscle was quadriceps. Firstly end range of the quadriceps muscle group assess and guide the athlete to put 20% of their maximum voluntary contraction and physiotherapist resist the athlete and isometric contraction of quadriceps remain for 6-10 seconds
45375020|NCT04002206|Other|Static Stretch|Control group has treated with static stretching after the pre-assessment that includes three repetitions with duration of fifteen seconds with twenty second rest intervals on lower extremities
45375021|NCT04002284|Drug|Anlotinib Hydrochloride|Anlotinib 12mg p.o. d1-14, 21days/cycle
45375022|NCT00669617|Drug|Indacaterol|Indacaterol 150 and 300 μg, delivered via single-dose dry-powder inhaler (SDDPI)
45375023|NCT00669617|Drug|Salmeterol/fluticasone (50/500 μg)|Salmeterol/fluticasone 50/500 μg fixed-dose combination delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
45375024|NCT00669617|Drug|Salbutamol (200 µg)|Salbutamol 200 μg delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
45375025|NCT00669617|Drug|Placebo to Indacaterol|Placebo to indacaterol delivered via SDDPI
45492041|NCT04399018|Other|Diagnostic Test: Flow cytometry analysis of neutrophil myeloperoxidase expression|"Flow cytometry analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be performed within 24 h of MDS diagnostic evaluation and blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed within 24 h maximum of collection.~Blood sample will be stained according to the manufacturers' recommendations with a lyophilized cocktail (LyotubeTM ready-to-use, BD Bioscience).~At least 10,000 neutrophils will be acquired on a 3-laser, 8-color BD FACSCanto-II TM flow cytometer (BD Biosciences, San José, CA).~Each marker will be expressed as median, geometric and arithmetic mean, regular and robust coefficient of variation."
45492042|NCT01370889|Drug|resveratrol|Given PO
45375026|NCT00669617|Drug|Placebo to Salmeterol/fluticasone|Placebo to salmeterol/fluticasone delivered via MDDPI
45375027|NCT00669617|Drug|Placebo to salbutamol|Placebo to salbutamol delivered via MDDPI
45375028|NCT05355428|Other|Nasogastric tube|Aspirate gastric content and check gastric content PH
45375029|NCT04000724|Behavioral|Text Messaging (Text+Step)|Participants receive three culturally competent, theory-based pre-written messages per day sent on a predetermined schedule. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.
45375030|NCT04000724|Behavioral|WebApp (App+Step)|Participants receive access to a culturally competent password-protected web-based application with transgender-specific resources, support, and health information. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.
45375031|NCT04000724|Behavioral|Information/No Step|Participants in the Information/No Step intervention will receive access to a static website with information about trans health, HIV/STI information and local resources tailored for transgender persons.
45375032|NCT03979352|Drug|empagliflozin|Treatment with empagliflozin 25mg orally once a day
45375033|NCT03979352|Device|artificial pancreas|Insulin delivery via a closed loop single-hormone artificial pancreas system.
45375034|NCT00780767|Device|ANGIOJET RHEOLYTIC THROMBECTOMY|The Angiojet catheter is a double lumen catheter percutaneously introduced via the common femoral vein into the main pulmonary trunk or the affected pulmonary artery respectively. One lumen serves to deliver high pressure saline jets into the thrombus and the other effluent lumen serves for clot removal utilizing a localized pressure region (Venturi effect) that attracts the thrombus for fragmentation into small particles. The fragmented debris are then pushed out through the evacuation line as a result of the retrograde high pressure saline jets, finally transporting them into a collection bag.
45375035|NCT00773201|Drug|Sotalol 80 mg|healthy subjects will receive an unique dose of Sotalol and will have an effort test on ergonomic bicycle, an auditive stimulation and a taking of DNA
45492043|NCT01370889|Other|laboratory biomarker analysis|Correlative studies
45492044|NCT01364883|Biological|Vaccination Schedule One|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
45492045|NCT01364883|Biological|Vaccination Schedule Two|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
45375036|NCT05355194|Other|Kinesiotape|"Patients will be instructed to inhale while taping the application. The tape will be applied in a vertical direction from just below the navel to the pubic region, another tape will be applied over the initial tape in the horizontal direction with minimal stretch. Another tape will be applied over the lumbosacral region making a V shape. The arms of V shall lie over the lumbar region while the base shall rest over the caudal region. Taping will be maintained for at least 48 hours.~The interventions shall be applied for two consecutive menstrual cycles."
45375037|NCT05355194|Other|Pelvic Tilts|Patients will be asked to lie in a supine position with legs bent and toes facing forward. Afterward, they will be instructed to pull their belly inwards while pushing pelvis towards the ceiling and keep hip muscles tightened. This position will be maintained for 5 seconds with 3 sets of 20 repetitions. Pelvic tilts must be performed throughout the menstrual cycle.
45375038|NCT03905174|Device|custom made device|surgical intervention to place custom made orthopaedic device
45375039|NCT05064527|Device|wearable biosensor|The E4 wristband will be worn by all groups for the duration of the study. It measures blood volume pulse, electrodermal activity, skin temperature, and movement. Patients will be asked to press the event tagging button when they feel stressed by OCD. Control will be asked to press the button when they feel anxious. Parents will be asked to press the button with they notice their child feels stressed by OCD or anxious.
45375040|NCT05064527|Behavioral|Treatment as usual (TAU)|Patients will receive treatment as usual at the child and adolescent mental health center. TAU can range from waitlist to one session of psychoeducation to group or individual psychotherapy to medication.
45375041|NCT05064527|Behavioral|Exposure and response prevention (ERP)|One ERP session will be offered in Week 0 and Week 8.
45375042|NCT05063045|Behavioral|smart-cloth assisted home nursing care|Older persons with dementia or hip fracture were asked to wear a smart vest, which contained a coin-size monitor in a hidden inner pocket. Sensors were installed in bedrooms and living areas to receive signals from the smart clothing. The home care nurses then gave feedback from the sensor signals to family caregivers.
45375043|NCT05355038|Behavioral|lifestyle modification (dietary modification)|low glycemic index diet the researcher gave detail information about (importance of LGI diet, component of food, number of meals and snake, example of food taken in breakfast, lunch, dinner and snake in between, food allowed and not allowed). After that, the researcher required from the woman to make an example of food for one day according to her income level, if correction of the content of food needed, the researcher will explain this point again.
45492046|NCT01364883|Biological|Vaccination Schedule Three|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
45492047|NCT01364883|Biological|Vaccination Schedule Four|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
45492048|NCT01364883|Biological|Vaccination Schedule Five|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
45375044|NCT05355038|Behavioral|lifestyle modification (physical activity)|health teaching about choose between two types of exercise to be selected according to the ability of GDM women to perform : brisk walking or seated arm exercise or selected both. Brisk walking should be performed for at least half an hour three time /week, while, seated arm exercise done three time after each meal for10 minute in each time. The researcher given a detail information about both types and its importance in decreasing blood glucose level, also how to perform and what should be done in case of appearance of fatigue manifestation during exercise, and the women have choice for perform both or selected one to perform according to your health condition.
45375045|NCT05355038|Behavioral|lifestyle modification( self glucose monitoring)|self-glucose monitoring the researcher explain the important of monitoring blood glucose level and instruct the women about how to perform self- glucose measuring, recording way of the result in schedule and to bring this result in the next antenatal visit. The women who have digital blood glucose monitoring instructed to measure it at least 5 time/day. while, the women who didn't have digital blood glucose monitoring measure went to nearest pharmacy to measure blood glucose at least one time per day especially when the woman felt the signs and symptoms of hypo or hyperglycemia and recorded the result in paper or sent the result in whatsapp for the researcher if you have whatsapp application. In addition to give the woman instruction about sings symptoms of hypoglycemia and hyperglycemia and the proper ways for management
45375046|NCT00777413|Drug|Minocycline 100mg Tablets|
45375047|NCT05199974|Procedure|Midline abdominal closure|Abdominal Closure in Emergency Midline Laparotomy
45375048|NCT05189912|Device|Specimen retrieving bag|Specimen retrieving bag was used to retrieve resected polyps.
45375049|NCT05189912|Behavioral|Sucking polyps to the instrument channel port|Remove the colonoscope suction valve and connect a polyp trap to suction onto the instrument channel port.
45375050|NCT02556827|Other|Obtaining a blood sample|Total oxidant capacity (TOC), total antioxidant capacity (TAC), oxidative stress index (OSI), paraoxonase-1 (PON-1), aryl esterase (ARES), myeloperoxidase (MPO), tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-9 (MMP-9) levels in venous blood were measured.
45375051|NCT02556827|Device|Reflectance confocal microscopy|1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM.
45375052|NCT02556827|Device|Sebumeter|Sebum rate at forehead and right cheek were evaluated with sebumeter
45375053|NCT02556827|Device|Video dermoscopy|Dermoscopic photoaging scale were assessed by using video dermoscopy.
45375054|NCT05162690|Drug|Dapagliflozin 10 milligram|10mg per day of Dapagliflozin will be given to the patients
45375055|NCT05162690|Other|Placebo|Metformin DPP4 inhibitors
45375056|NCT00773435|Biological|Echinacea purpurea 100 mg/ml in liquid formulation|10 ml BID for 10 consecutive days at the start of 3 consecutive 30 day periods
45375057|NCT00773435|Other|placebo|10 ml PO BID for 10 consecutive days at the beginning of 3 consecutive 30 day periods
45375058|NCT00992576|Drug|Active Hydromorphone PR + Active Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
45375059|NCT00992576|Drug|Active Hydromorphone PR + Placebo Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
45375060|NCT00777569|Drug|Nicotine free cigarettes|Quest Step 2 contains 0.05 mg nicotine
45375061|NCT00777569|Drug|Extra-low nicotine cigarettes|Quest 2 cigarettes contains 0.3 mg nicotine
45375062|NCT00777569|Drug|Nicotine Lozenge|4 mg nicotine lozenge
45375063|NCT00777647|Other|Sugar-sweetened soft drink|One litre a day for six months.
45375064|NCT00777647|Other|Aspartame-sweetened soft drink|One litre a day for six months.
45375065|NCT00777647|Other|Semi-skimmed milk|One litre a day for six months
45375066|NCT00777647|Other|Water|One litre a day for six months.
45375067|NCT00777725|Device|FibroScan|Liver scan, similar to an ultrasound.
45375068|NCT02556749|Dietary Supplement|Cranberry Juice Beverage|16 ounces of 54% cranberry juice cocktail
45375069|NCT02556749|Dietary Supplement|Placebo Beverage|Color, calorie, and taste matched beverage without cranberry bioactives
45375070|NCT02556593|Radiation|IMRT|Daily IMRT at 45 Gy in 15 fractions to brain metastases
45375071|NCT02556593|Radiation|WBRT|3DCRT at 30 Gy in 10 fractions to whole brain
45375072|NCT02556593|Drug|erlotinib|erlotinib 150mg daily
45375073|NCT00535730|Biological|Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™|0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period
45375074|NCT00535730|Biological|Comparator: placebo (concomitant-vaccine matched)|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL Placebo injection over 4 week vaccination period.
45492049|NCT01364883|Biological|Vaccination Schedule Six|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
46054023|NCT04098913|Behavioral|Reduced screen-based media use|Participants must remove all recreational screen-based media use beyond 3 hours/week. This includes all recreational screen-based media use inside and outside the household. As a tool to comply with the intervention the families will hand-over all portable screen-based media devices. In return, each participant who own a smartphone will receive a regular cell-phone which can only make phone calls and send text messages. For a maximum of ½ an hour a day, adult participants may use screen-based media for necessary contact/errands. If one of the adult participants can not hand over their smartphones due to daily use for work purposes we will install an app tracking screen use on these devices.
46054024|NCT04234191|Drug|Buprenorphine/naloxone|Buprenorphine/naloxone is an opioid agonist treatment for opioid use disorder. It is administered via sublingual tablet form.
45492050|NCT01364883|Biological|Vaccination Schedule Seven|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
46054025|NCT04234191|Drug|Hydromorphone|Hydromorphone is an opioid used for managing pain, craving, and withdrawal. It is administered orally via tablet or liquid form; or administered intravenously, subcutaneously, or intramuscularly via liquid form.
46054026|NCT02790567|Other|HEP score|"The HEP score is a clinicobiological score evaluating the probability of the HIT diagnosis.~The HEP score is based on the blood platelet count, the timing of the platelet decrease, the existence of clinical manifestations of HIT (thrombosis, haemorrhage, skin necrosis) and the existence of an other cause of thrombocytopenia."
45375075|NCT00535730|Biological|Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL injection over 4 week vaccination period.
45375076|NCT00780923|Device|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
45375077|NCT02556125|Device|Diaphragm pacing|Intramuscular diaphragm implantation is achieved by a laparoscopic approach whereby phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller.
45375078|NCT05354960|Other|Questionnaire validation|Validation and cultural adaption of the German version of the LIMB-Q
45375079|NCT00781001|Drug|Cannabis|400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit
45375080|NCT00992654|Drug|Open Label Treatment Access: Maraviroc|Oral dosing twice daily. The dose will depend on the optimized background therapy.
45375081|NCT02556047|Device|Star Intradermal Safety Device|Star Intradermal Safety Device 1.2mm needle length, Star Intradermal Safety Device 1.5mm needle length, Mantoux technique by N&S
45375082|NCT05252234|Other|Observation of hemodynamic status and post operative pain|No intervention
45375083|NCT00773591|Drug|NT 201, a Botulinum neurotoxin type A, free of complexing proteins|"NT 201: Solution for injection, one dose of 5 U will be administered. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.~Placebo: Solution for injection, Dose n.a.; identical injected volume as active study medication. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge."
45375084|NCT00992810|Procedure|Lateral-to-Medial Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a lateral-to-medial direction.
45492051|NCT02373046|Drug|LX4211|Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9
45375085|NCT00992810|Procedure|Media-to-Lateral Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a medial-to-lateral direction.
45375086|NCT00995306|Drug|Civamide (Zucapsaicin)|"Civamide Cream 0.075%, TID for 12 weeks~Civamide Cream 0.01%, TID for 12 weeks"
45375087|NCT05354570|Radiation|Intensity-Modulated Pleural Radiation Therapy (IMPRINT)|Radiation therapy will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions, including an optional dose-painting SIB to gross residual disease up to 60 Gy while respecting normal tissue constraints.
45375088|NCT05352074|Procedure|subtotal colectomy with cecal-rectal anastomosis|The intervention involves, after a complete mobilization of the colon, a resection 2-3 cm distal to the ileocecal junction and at the upper part of the rectal ampulla; the cecum is then lowered into the pelvis, without any rotation, and an antiperistaltic cecorectal anastomosis is performed between the cecal fundus (after appendectomy) and the rectum, after introduction of a stapler through the cecal resection line. In the laparoscopic approach we use 5 trocars (trocar 1 periumbilical, trocars 2-3-4-5 drawing a 15-cm side square around trocar 1), using a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The cecal-rectal anastomosis is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
45375089|NCT05352074|Procedure|total colectomy with ileorectal anastomosis|After a complete mobilization of the colon, a resection 2-3 cm proximal to the ileocecal junction is conducted. Use a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The ileorectal anastomosis (end to end) is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
45375090|NCT00992888|Device|Prometheus Liver Dialysis system (Fresenius Medical Care)|6 hour dialysis for 3 consecutive days
45375091|NCT05351372|Radiation|Ultra-low dose protocol|
45375092|NCT05351372|Radiation|Standard dose protocol|
45375093|NCT00666965|Drug|SPM 962|transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks
45375094|NCT05350358|Device|LeMaitre Cardial Dialine II|Surgical treatment for the replacement or bypass with LeMaitre Cardial Dialine II
45375095|NCT00781157|Drug|Phenylephrine bolus|"The initial dose of phenylephrine will be 100 mcg, a dose within the clinical range currently in use at our center. The subsequent dose is based upon the response of the preceding subject in the usual up-and-down method (UDM), which is outlined in the data analysis section of the protocol. The dosing changes will be in increments of 20 micrograms. A successful response to this dose will be entered into a spreadsheet, designed by our statistician, which will determine the subsequent dose based upon the UDM. If a failure is observed in the previous subject, the dose is stepped up in the next subject. If a success is observed the next subject is randomized with probability of 0.10 to the next lower dose and with probability 0.90 to the same dose."
45375096|NCT00995462|Behavioral|Lifestyle intervention seminars|The first sessions emphasize acquisition of new knowledge during interactive group seminars designed to maximize attendant's participation by adapting wellknown quiz-show or parlour games to deliver key concepts. A number of sessions are aimed at increasing self-efficacy through problem-solving, time-management strategies, individual self monitoring and goal-setting.During the second year, the intervention focuses on maintenance of healthy behaviour with empowerment of the participants using problem-solving, goal-setting, planning, and self-monitoring skills.
45375097|NCT00777959|Drug|ridaforolimus (MK8669)|Three 10 mg tablets administered daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
45375098|NCT00777959|Drug|Comparator: Placebo|Three tablets of matching placebo to ridaforolimus administered daily for 5 consecutive days each week followed by 2 days without matching placebo and on 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
46054027|NCT02790567|Other|4Ts score|The 4Ts score is a clinicobiological score evaluating the probability of the HIT diagnosis. The 4Ts score is based on the change in blood platelet count during heparin therapy, the timing of platelet decrease, the existence of a thrombosis, and the existence of an other cause of thrombocytopenia.
45492052|NCT02373046|Drug|LX4211|Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9
45693147|NCT03809572|Behavioral|Mindfulness Based Cognitive Therapy|See Arm description
46054028|NCT02790567|Other|ID-PaGIA test|The ID-PaGIA test is a particle gel immunoassay that detects immunoglobulins (Ig) G, A and M specific to the heparin/PF4 complexes.
46054029|NCT02790567|Other|HIT-Ab(PF4-H) test|The HIT-Ab(PF4-H) test consist in the incubation of plasma samples with latex beads coated PF4/polyvinylsulfate complexes. After binding of the plasma antibodies a monoclonal antibody recognizing PF4/heparin complexes is added. In the presence of human anti-PF4/heparin antibodies, binding of the monoclonal antibody and subsequent agglutination of latex beads is inhibited. Inhibition of agglutination is quantified and reported in arbitrary units (U/ml). A value equal or higher than 1.0 u/ml may indicate the presence of HIT antibodies.
45492053|NCT01368237|Radiation|Computed tomography scan|Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and imaging of myocardial perfusion, function and viability.
46054030|NCT04233957|Dietary Supplement|High Sodium|10 days of 3900 mg of sodium/day in excess of normal dietary intake delivered via enteric capsules filled with table salt.
45375099|NCT00777959|Drug|open-label ridaforolimus (MK8669)|Single dose of three 10 mg tablets ridaforolimus on Day 1, and 50 mg bicalutamide once daily starting on Day 2. On Day 8, patients will begin taking three 10 mg tablets of ridaforolimus daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide once daily for 7 days each week. Treatment will continue until disease progression.
45375100|NCT00995540|Drug|INGAP Peptide|100 mg INGAP Peptide tid subcutaneous injection for 12 weeks
45375101|NCT00995540|Drug|INGAP Peptide|200 mg INGAP Peptide tid subcutaneous injection for 12 weeks
45375102|NCT00995540|Drug|Placebo|Placebo tid subcutaneous injection for 12 weeks
45375103|NCT00778037|Drug|Cyclobenzaprine hydrochloride 10 mg tablet|
45375104|NCT05187650|Device|Ekso (EksoNR, Ekso Bionics)|The EksoNR is a powered exoskeleton designed to be used in a rehabilitation setting. The device meets the provision of the Council Directive 93/42/EEC concerning medical devices and is used for gait training in neurorehabilitation.
45375105|NCT05187650|Device|FES (RehaMove2, Hasomed)|RehaMove 2 sends electrical impulses via electrodes to nerves to evoke muscle contraction. The device meets the provision of the Council Directive 93/42/EEC concerning medical devices.
45375106|NCT00778115|Drug|Loperamide HCl 2 mg and simethicone 125 mg tablets|
45375107|NCT05186948|Device|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
46054031|NCT04233957|Other|Placebo|10 days of enteric capsules filled with dextrose.
45375108|NCT02557217|Drug|NP202|Active
45375109|NCT02557217|Other|Placebo|Placebo
45375110|NCT03474224|Device|Ev1000 Clinical Platform from Edwards Lifesciences|The EV1000 Hemodynamic monitoring platform will be used to guide fluid administration following a volume-based parameter such the stroke volume.
46054032|NCT02801799|Drug|Varying infusion rates of Ropivacaine 0.2%|"Participants will receive one nerve catheter adjacent to the common peroneal nerve (trial day 1) and adjacent to the sciatic nerve (trial day 2). Each catheter will be randomly allocated to one of five infusion groups. All peroneal nerve catheters will receive the same volume of ropivacaine 0.2%. All the sciatic nerve catheters will receive the same volume of ropivacaine 0.2%.~The only inter-group variable will be the infusion rate. The fixed volume of ropivacaine will be determined in a separate study ('The Volume Study'), which is also part of the project: 'A novel technique for reliable, precise and safe postoperative management'.~The largest volumes tested in The Volume Study are 30 mL for the sciatic nerve and 20 mL for the common peroneal nerve. Therefore the highest volume for the two intervention days cannot exceed 30 mL (150 mg of ropivacaine).~We will ensure constant infusion rate and precise delivery of LA by using an electronic infusion pump and a nerve catheter."
46054033|NCT02690103|Drug|pegylated IFN|Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months.
45375111|NCT00993122|Drug|ribavirin pre-treatment|patients receive ribavirin (10,4 mg/kg/day) and pegylated interferon alfa-2b (1,5 mcg/kg/week).Pre-treatment arm will receive a 8-week monotherapy treatment with only ribavirin (same dosage) and the controlled arm will receive 48 week of standard combined therapy (ribavirin plus pegylated interferon)
45375112|NCT00778193|Drug|Naproxen|1 tablet 500mg BID for 8 days
45375113|NCT00778193|Drug|Aspirin|1 tablet 81mg QD for 8 days
45375114|NCT00778193|Drug|Celecoxib|1 capsule 200mg QD for 8 days
45375115|NCT00778193|Drug|Clopidogrel|Day 0: 4 tablets QD for 1 day; Days 1-7: 1 tablet QD for 7 days
45492054|NCT04382404|Drug|Sofosbuvir-Velpatasvir Drug Combination|One pill once a day for 12 weeks
45492055|NCT01368315|Drug|CT327 application|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
45375116|NCT00778193|Drug|Placebo|1 capsule BID for 8 days
45375119|NCT00778271|Drug|Gabapentin 400mg capsules|
45375120|NCT00778349|Drug|Metformin solution 100 mg/mL|
45375121|NCT00995618|Drug|Tranilast|Tranilast tablets, 300 mg, QD
45375122|NCT00995618|Drug|Febuxostat|Febuxostat Tablets, 40 mg, QD
45375123|NCT00995618|Drug|Combination - Tranilast and Febuxostat|Tranilast, 300 mg QD; Febuxostat, 40 mg QD
45693148|NCT04274218|Other|Perturbation|Participants from both cohorts will experience a simulated trip while walking on the treadmill. The trip is induced through a rapid acceleration and deceleration of the treadmill belt speed.
45846960|NCT02694198|Other|fetal fibronectin measurement|All patients will be put in the dorsal lithotomy position.Using a proper light source and sterile gloves, a sterile speculum free of lubricants will be placed into the vagina before vaginal examination by senior resident and the special Dacron swab from the FFN kit will be used to collect a sample of secretions from the posterior fornix. The sample should be obtained prior to collection of any vaginal wet preparations, before any cervical manipulation or cervical cultures, and if enough amount of fluid (about 2 ml) is not found, vagina will be washed with 2 ml of normal saline.The swab will be placed in sterile plastic containers which will be stored until assayed quantitatively with an Enzyme-Linked Immuno Sorbant Assay.
45846961|NCT02695290|Drug|Afatinib|
45846962|NCT02695446|Drug|Minocycline|Oral extended release minocycline
45846963|NCT02696070|Device|Provant Therapy System|
45375124|NCT00778427|Drug|metformin hydrochloride 1000 mg tablets|
45375125|NCT00773981|Procedure|Transrectal vacuum assisted drainage|Treatment with vacuum drainage (VD) is a new method primarily developed for wound therapy. The principle of the method is application of negative pressure on the wound surface with the help of a sponge that is connected to a pump. Sponge dressings should be changed 3 times pr week as long as vacuum therapy is used. If there has been no development of granulation tissue or no shrinking of the cavity in 3 weeks Vacuum therapy can be stopped. Maximum vacuum therapy is 8 weeks.
45846964|NCT02697240|Drug|Intravenous citrulline|Intravenous citrulline at a bolus dose of 20 mg/kg over 5 minutes and then continuous at a rate of 7 mg/kg/hour for the next 23 hours for the first 7 participants, and depending on safety and pharmacokinetic profile, increase or decrease the continuous rate to 9 or 5 mg/kg/hour for the next 7 participants.
45846965|NCT02698566|Drug|Ranibizumab|Patients will receive single ITV injection of ranibizumab 0.5 mg delivered via PFS on Day 1.
45846966|NCT02698800|Device|Blue blocking (BB) lenses|Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime.
45375126|NCT03889886|Drug|SDP-4 Ophthalmic Solution (0.1%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
45693149|NCT05744284|Device|electrocautery|advantages reported in this study in terms of wound infections, healing time, postoperative pain and cosmetic results in association with economic gain for saving in the purchase of scalpels, represent a formidable motivation for the surgeons to abandon the scalpel in favors of diathermy
45693150|NCT05744206|Other|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
45846967|NCT02698800|Device|Clear lenses|Participants will wear clear lenses each night for 1 week for 2 hours preceding bedtime.
45846968|NCT02701062|Device|AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems|
45846969|NCT02701062|Drug|Anticoagulation Therapy|Anticoagulation Therapy- Standard of Care at the discretion of the Investigator.
45846970|NCT02704104|Device|AC5 Topical Hemostatic Device|Randomized application of the hemostatic agent AC5 to one of two freshly excised lesions in each patient
45846971|NCT02705352|Drug|5-Fluorouracil|Treatment medication
45375127|NCT03889886|Drug|SDP-4 Ophthalmic Solution (1.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
45375128|NCT03889886|Drug|SDP-4 Ophthalmic Solution (3.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
45375129|NCT03889886|Drug|Vehicle|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
45375130|NCT00774059|Device|Breast lift system|During a breast operation for ptosis a device is brought into the breast and attached to the ribs, to provide lifting of the breast
45375131|NCT03888482|Device|Verofilcon A contact lenses|Investigational daily disposable soft contact lenses
45375132|NCT03888482|Device|Somofilcon A contact lenses|Commercially available daily disposable soft contact lenses
45375133|NCT00995696|Behavioral|PhaST IVR Calls|Participants in this condition receive 7 computer automated IVR calls.
45375134|NCT00993278|Dietary Supplement|Low-Carbohydrate (Modified Atkins) Diet|Low-Carbohydrate (Modified Atkins) Diet
45375135|NCT00993278|Dietary Supplement|Low-Fat (Heart Healthy) Diet|Low-Fat (Heart Healthy) Diet
45375136|NCT00667355|Biological|adalimumab|40 mg or 80 mg every other week, subcutaneous
45375137|NCT00778505|Drug|Propofol|closed-loop administration using bispectral index as the controller
45375138|NCT00778505|Drug|remifentanil|closed-loop administration using bispectral index as the controller
45492056|NCT01368315|Drug|Placebo|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
45375139|NCT00778505|Drug|Propofol|manual administration according bispectral index values
45375140|NCT00778505|Drug|Remifentanil|manual administration according bispectral index values
45492057|NCT01368315|Drug|Active comparator|Topical administration of an active comparator administered twice daily for ten days to one out of four test fields marked on the patient's back.
45492058|NCT01368315|Drug|No intervention|No intervention to one out of four test fields marked on the patient's back.
45492059|NCT02371096|Drug|MabThera (rituximab)|
45492060|NCT02371096|Drug|RGB-03|
45492061|NCT04420455|Drug|Enoximone|Patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval.
45375141|NCT00532844|Drug|Sapropterin Dihydrochloride|Sapropterin Dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
45375142|NCT00532844|Drug|Sapropterin Dihydrochloride and Vitamin C|Sapropterin Dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
45375143|NCT00778583|Drug|Nitrofurantoin 100 mg capsules|
45375144|NCT00778661|Drug|amoxicillin 400mg + clovalunic acid 57.5mg tablets|
45492062|NCT04381936|Drug|Lopinavir-Ritonavir|Lopinavir 400mg-Ritonavir 100mg by mouth (or nasogastric tube) every 12 hours for 10 days.
45492063|NCT04381936|Drug|Corticosteroid|Corticosteroid in the form of dexamethasone administered as an oral (liquid or tablets) or intravenous preparation 6 mg once daily for 10 days. In pregnancy or breastfeeding women, prednisolone 40 mg administered by mouth (or intravenous hydrocortisone 80 mg twice daily) should be used instead of dexamethasone. Corticosteroid (in children ≤44 weeks gestational age, or >44 weeks gestational age with PIMS-TS only) in the form of Hydrocortisone or Methylprednisolone sodium succinate (see Protocol for timing and dosage)
45492064|NCT04381936|Drug|Hydroxychloroquine|Hydroxychloroquine by mouth for a total of 10 days (see Protocol for timing and dosage).
45492065|NCT04381936|Drug|Azithromycin|Azithromycin 500mg by mouth (or nasogastric tube) or intravenously once daily for 10 days.
45492066|NCT04381936|Biological|Convalescent plasma|Single unit of ABO compatible convalescent plasma (275mls +/- 75 mls) intravenous per day on study days 1 (as soon as possible after randomisation) and 2 (with a minimum of 12 hour interval between 1st and 2nd units).
45492067|NCT04381936|Drug|Tocilizumab|Tocilizumab by intravenous infusion with the dose determined by body weight (see Protocol for dosage)
45492068|NCT04381936|Biological|Immunoglobulin|Intravenous immunoglobulin (IVIg) for children >44 weeks gestational age and <18 years with PIMS-TS only (see Protocol for dosage)
45492069|NCT04381936|Drug|Synthetic neutralising antibodies|For participants ≥12 years only with COVID-19 pneumonia: A single dose of REGN10933 + REGN10987 8 g (4 g of each monoclonal antibody) in 250ml 0.9% saline infused intravenously over 60 minutes +/- 15 minutes as soon as possible after randomisation
45492070|NCT04381936|Drug|Aspirin|150 mg by mouth (or nasogastric tube) or per rectum once daily until discharge, for adults ≥18 years old.
45693151|NCT04345432|Drug|Gabapentin|"Gradually increasing doses of medication from 100 mg on day 1 to 300 mg twice a day on day 6. On day 7, the patient received a 300-mg dose from the day 7 envelope, about two hours after a light breakfast and 1 hour before data collection. The relatively low dose and gradual titration were selected to enhance compliance and reduce adverse effects, based on a rectal mechanosensitivity study."
45375145|NCT00993356|Drug|Preoperative lanreotide treatment|Patients received lanreotide for 16 weeks before the surgical resection [starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH > 5 mU/L on GH day curve (GHDC)] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
45375146|NCT00993356|Procedure|Transsphenoidal surgery|
45375147|NCT00781547|Drug|recombinant human growth hormone|The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
45375148|NCT00995852|Device|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
45375149|NCT00995852|Device|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
45375150|NCT00774293|Drug|placebo|5 placebo granules for Arnica 5 CH and 5 placebo granules for Bryonia 5 CH
45375151|NCT00774293|Drug|Arnica and Bryonia|Arnica 5CH granules, 5 per day plus Bryonia 5CH Granules, 5 per day for 5 days
45375152|NCT04000958|Drug|PIRF measured by InCheck DIAL|Peak inspiratory flow rates(PIFR) will be measured using the InCheck DIAL(Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical). The InCheck DIAL is accurate to +/- 10% or 10 L/min, whichever is greater, and can measure flows in the range of 15 to 120 L/min. Dry powder inhaler(DPI) is to be prescribed if PIFRr is over 60L/min, otherwise pressure metered dose inhaler(pMDI) with spacer is given. All the patients will be given inhaled corticosteroid（ICS）/long-acting β agonist（LABA）. For symptomatic patients, long-acting anticholinergic agents(LAMA) will also be used.
45492071|NCT04381936|Drug|Colchicine|1 mg after randomisation followed by 500mcg 12 hours later and then 500 mcg twice daily by mouth or nasogastric tube for 10 days in total, for men ≥18 years old and women ≥55 years old only
46054034|NCT02690103|Dietary Supplement|Biobran|Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose. Biobran was kindly provided by Daiwa Pharmaceuticals Co. Ltd., Tokyo, Japan.
45492072|NCT04381936|Drug|Baricitinib|UK [age ≥2 years with COVID pneumonia] and India [age ≥18 years with COVID-19 pneumonia]: 4 mg once daily by mouth or nasogastric tube for 10 days in total.
45693152|NCT03803410|Procedure|blood test, noninvasive test for liver fibrosis|blood test of HCV serology and virology.noninvasive test including M2BPGi and fibroscan for liver fibrosis
45693153|NCT05744128|Biological|Zirconium 89Zr crefmirlimab berdoxam|Zirconium-89 labelled minibody for whole body PET imaging to visualize CD8+ cell distribution.
45693154|NCT05744050|Behavioral|Low energy density lunch|Particpants will be provided with a lunch low in energy density (~1.1kcal/g)
46054035|NCT02690103|Drug|Ribavirin|Ribavirin is prescribed according to patients body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).
46054036|NCT00760513|Drug|OMACOR|4 grammes daily, oral capsule
46054037|NCT00760513|Drug|Placebo oral capsule|4 grammes daily, oral capsule (olive oil)
46054038|NCT02794311|Other|Alcoolpredict|psychological (personality), neuropsychological (executive functions, memory), genetic (snp polymorphisms) and neuro-anatomical (fMRI)
46054039|NCT02689947|Device|Restylane Silk|
46054040|NCT04100239|Behavioral|Mindfulness-based stress reduction (MBSR)|MBSR is designed to complement any existing medical treatments, and focuses on the development of mindfulness meditation practice to alleviate psychological distress. MBCL is designed as a follow-up intervention to MBSR and aims to help individuals to turn towards suffering and developing a kind attitude to the self.
45375153|NCT04000958|Drug|Regular treament|The choice of inhalers depends on physician's evaluation. The medication is the same as experimental group.
45375154|NCT00778739|Drug|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
45375155|NCT00781625|Dietary Supplement|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
45375156|NCT00781625|Dietary Supplement|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
45375157|NCT00781625|Dietary Supplement|Placebo Y cap G-3|Size 3, white/white capsule, each contaiing180 mg placebo blended powder. Daily oral and vaginal intake for a total duration of 6 months
45693155|NCT05744050|Behavioral|Medium energy density lunch|Participants will be provided with a lunch medium in energy density(~1.7kcal/g)
46054041|NCT02794233|Other|Impedance measurements|Refer to study description
46054042|NCT04098289|Procedure|Hysteroscopic septum resection|Hysteroscopic septum resection, using a 26 French continuous-flow resectoscope with monopolar energy and electrolyte-free distension medium.
46054043|NCT04098289|Procedure|In vitro fertilization|Fertilization of oocytes with the spermatozoa of the partner, after induction of ovulation and capacitation of the sperm, using fertilization in vitro and embryo transfer (FIVET) or intracytoplasmic sperm injection (ICSI).
45375158|NCT03190460|Other|Cognitive Training|Web-based cognitive training intervention targeting specific cognitive tasks. Subjects complete 3 training sessions per week with at least 24 hours in between sessions.
45375159|NCT03190460|Other|Technology-based Education|Subjects complete 16 web-based educational modules on healthy aging content. Following each module, subjects complete a learning reflection.
45375160|NCT00774371|Behavioral|Cognitive behavioral therapy CBT) for weight loss|The intervention program emphasizes regular physical activity, healthy eating, and psychological components within the structure of CBT for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity and strength training. A deficit of 500-1000 kcal/day is the recommended level of dietary modification to promote weight loss and maintenance. Group sessions are held weekly for 4 months, every other week for two months, and monthly sessions through 18 months. Data are collected at baseline, 6 months, and 18 months. Wait-list group subjects will receive general contact without specific reference to weight management topics through a 24-month period of data collection and will then be provided intervention materials in a seminar format.
45693156|NCT05744050|Behavioral|High energy density lunch|Participants will be provided with a lunch high in energy density (~3kcal/g)
45693157|NCT03804190|Other|questionaire|dutch musculoskeletal questionaire
45375161|NCT00993434|Behavioral|Booklet on nutrition and physical activity.|Parents will be asked to read the booklet and complete a pre- and post-questionnaire.
45375162|NCT00993434|Behavioral|Safety Booklet|Parents will be asked to read a safety booklet and complete a pre- and post-questionnaire.
45693158|NCT00757666|Device|Rate adaptive pacemaker|Accelerometer sensor
46054044|NCT02790333|Procedure|traditional reloads|Blue cartridge with3.0mm height staple was used for pancreatic stump
46054045|NCT02790333|Procedure|Tri-Staple reloads|Purple cartridge with2.0-2.5-3.0mm varied-height staples was used for pancreatic stump
46054046|NCT04096105|Drug|CC-93538|a single dose CC-93538 SC
46054047|NCT02790099|Drug|Bupivacaine|Surgical rectus sheath block will be performed by injection of 40ml bupivacaine (2.5mg/ml) before closure of rectus sheath during the operation.
45375163|NCT00781703|Other|DIAMOND depression care model|Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the PHQ9, treatment adjustment as indicated, psychiatric consultation, relapse prevention.
45375164|NCT02557061|Procedure|Colorectal surgery (resection)|Colorectal surgery (resection) is done for patient with colorectal cancer
45492073|NCT04381936|Drug|Anakinra|For children ≥1 <18 years old only: subcutaneously or intravenously once daily for 7 days or discharge (if sooner). NB Anakinra will be excluded from the randomisation of children <10 kg in weight.
45492074|NCT04381936|Drug|Dimethyl fumarate|Early phase assessment. UK adults ≥18 years old only (excluding those on ECMO). 120 mg every 12 hours for 4 doses followed by 240 mg every 12 hours by mouth for 8 days (10 days in total).
45492075|NCT04381936|Drug|High Dose Corticosteroid|Adults ≥18 years old with hypoxia only. Dexamethasone 20 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days follow by dexamethasone 10 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days.
45846972|NCT02705352|Other|Normal saline|Placebo
45375165|NCT02557061|Biological|Blood sampling|Pre-operative blood sampling is done for patient with colorectal cancer
45375166|NCT00781781|Drug|Alemtuzumab|High risk: Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive) Low risk: Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive).
45375167|NCT00666263|Biological|Immune Globulin Intravenous (human), 10%|Dose: Previous dose with 3, 4, or 6 cycles depending on previous schedule (patient specific)
45375168|NCT00666263|Biological|0.25% human albumin solution (Placebo)|Cross-over Period 1 (Randomized) / Cross-over Period 2 (opposite of the treatment received in Cross-over Period 1); Dose: Same volume/frequency as Stabilization Phase 1
45375169|NCT00667277|Drug|bevacizumab (Avastin)|15 mg/kg of bevacizumab by IV infusion once every 3 weeks (1 cycle) for 12 weeks (4 cycles)
45375170|NCT00774527|Drug|Cyclophosphamide-fludarabine-anti thymocyte globulin|"Cyclophosphamide 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 5 consecutive days (days -6 to -2).~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2."
45375171|NCT00778973|Drug|sertraline 100 mg tablets|
45375172|NCT00774605|Drug|Varenicline free base solution|A single application of a 4.8 mg varenicline solution will be applied to the upper back over a 24 hour period
45375173|NCT00774605|Drug|Varenicline free base patch|A single application of a nominal 1.2 mg dose of a varenicline transdermal delivery system (5 cm2 patch, 4.8 mg drug payload) will be applied to the upper back over a 24 hour period
45375174|NCT00779051|Drug|Zolpidem 10mg tablets|
45375175|NCT00774683|Drug|Raltegravir (Isentress®)|400 mg p.o. BID x 7 days
45492076|NCT04381936|Drug|Empagliflozin|Adults ≥18 years old only. 10 mg once daily by mouth for 28 days (or until discharge, if earlier).
45492077|NCT04381936|Drug|Sotrovimab|UK Adults ≥18 years old. 1000 mg in 100 mL 0.9% sodium chloride or 5% dextrose by intravenous infusion over 1 hour as soon as possible after randomisation.
45492078|NCT04381936|Drug|Molnupiravir|Patients ≥18 years old. 800 mg twice daily for 5 days by mouth.
45492079|NCT04381936|Drug|Paxlovid|UK patients ≥18 years old. 300/100 mg twice daily for 5 days by mouth.
45492080|NCT01368393|Procedure|Electroacupuncture|Patients randomized to the experimental group will receive electroacupuncture at acupoints relevant to the treatment of abdominal pain and anxiety, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), and Neiguan (pericardium meridian PC-6). Electric stimulation will be employed to the needles
45492081|NCT01368393|Procedure|Sham acupuncture|"Sterile blunt-tip needles will be placed (without skin penetration) 15 mm away from the acupoints. Pseudostimulation will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current."
45492082|NCT02372968|Other|Full body composition and of plasma and urine metabolites|"Full body composition in lean, fat and bone mass will be assessed from DXA scans.~Plasma and urine metabolites will be measured using metabolomics"
45846973|NCT02707146|Behavioral|Visit Planner|The Visit Planner is an application hosted on an iPad that guides the patient in preparing for the primary care visit
45846974|NCT02707146|Other|Attention Control Pamphlet|Patients in the attention control arm will receive an approved educational handout on health lifestyle
45846975|NCT02707146|Device|iPad|
45375176|NCT02556281|Biological|Blood sampling|Blood sampling is done for patient with colorectal cancer
45375177|NCT00782015|Dietary Supplement|Almonds|3 oz. of almonds per day, supplied as 1 oz. snack packs to be consumed for 6 weeks.
45375178|NCT00782015|Dietary Supplement|Placebo Comparator:|NCEP Step 2 diet
45492083|NCT03124407|Drug|Capsaicin Topical Solution|Over-the-counter Tentative Final Monograph compliant product with 0.25% capsaicin
45492084|NCT03124407|Other|Drug product vehicle|This is the vehicle for the active treatment drug product, but without capsaicin
45375179|NCT00774839|Behavioral|Patient Interview|The patient will participate in a semistructured interview conducted by a trained staff member and designed to last approximately 45 minutes. All interviews will take place at least 4 months into or up to 7 months after the end of the treatment, if possible and will be scheduled to occur at the time of the chemotherapy infusion, or at another time at the care facility when it is convenient for the patient. If the patient is not scheduled or chooses not to be at the care facility within a time frame that fits the study parameters, the patient may opt to be interviewed at another location, including the patient's home.
45693159|NCT00757666|Device|Rate adaptive pacemaker|Minute ventilation sensor
45693160|NCT03803956|Device|Active PBMT|The PBMT will be performed using the dose of 10J per diode, previously determined by a previous study and power output of 100 mW per diode, also previously determined. PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 850 J of energy. The active PBMT will be performed before a progressive running test.
45693161|NCT03803956|Device|Placebo PBMT|The placebo PBMT will per performed using the dose of 0 J per diode. Placebo PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 0 J of energy. To ensure blinding, the device emitted the same sound regardless of the programmed mode (active or placebo PBMT). The placebo PBMT will be performed before a progressive running test.
45693162|NCT01736683|Drug|Sotatercept|Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.
45693163|NCT05743972|Diagnostic Test|Contrast-enhanced ultrasound-guided core biopsy|Core biopsy was used to collect samples for pancreatic diseases under contrast-enhanced ultrasound-guided.
45693164|NCT05743972|Diagnostic Test|Conventional ultrasound-guided core biopsy|Core biopsy was used to collect samples for pancreatic diseases under conventional ultrasound-guided.
45375180|NCT00782093|Drug|volociximab|volociximab intravitreal injection
45375181|NCT00784433|Dietary Supplement|alcohol|150 cc
45375182|NCT00774917|Device|Numen|Numen Co-Cr coronary stent implant
45375183|NCT00784511|Dietary Supplement|cholecalciferol|4000 IU/d
45492085|NCT02371018|Dietary Supplement|Nepro|Patients will be asked to consume a single 8 oz can of Nepro
45492086|NCT01370967|Other|Study formula feeding|Infants who are exclusively fed the new study formula at time of enrollment
45375184|NCT00784511|Other|microcrystalline cellulose|1/d
45375185|NCT00784589|Drug|General Corticotherapy|for patients with severe pemphigus : general corticotherapy Arm : 1.5mg/kg/d for 1 month, then 1.25mg/kg/d for 1 month, then 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 3 months, then 0.3 mg/kg/d for 3 months, then 0.2 mg/kg/d for 4 months, then 0.1 mg/kg/d for 4 months, for patients with moderated pemphigus : general corticotherapy Arm : 1mg/kg/d for 1 month, then 0.75mg/kg/d for 1 month, then 0.5mg/kg/d for 2 months, then 0.3 mg/kg/d for 2 months, then 0.2 mg/kg/d for 3 months, then 0.1 mg/kg/d for 3 months,
45375186|NCT00784589|Drug|Rituximab|for patients with severe pemphigus : rituximab Arm : 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 1 month, then 0.3 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month, then 0.1 mg/kg/d for 1 month for patients with moderated pemphigus : rituximab Arm : 0.5mg/kg/d for 1 month, then 0.30 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month,
45492087|NCT01370967|Other|Human milk feeding|Infants who are exclusively fed human milk at time of enrollment
45492088|NCT01370967|Other|Mixed feeding|Infants who are exclusively fed human milk and the new study formula at time of enrollment
45492089|NCT02370940|Other|High phytate intake|
45492090|NCT02370940|Other|Low phytate intake|
45846976|NCT02707770|Other|Pulmonary Rehabilitation|
45492091|NCT01368471|Device|MGuard|MGuard™ stent comprises a balloon-expandable, thin-strut stainless steel (316L) bare metal stent platform (strut width 100 µm) with mesh sleeve fibers of polyethyleneterephtalate (fiber width of 20 µm) attached to its outer surface. These fibers act like a net (aperture size 150 x 180 µm) preventing distal embolization of the plaque debris/thrombus placed between the vessel wall and the stent.
45375187|NCT00789893|Device|Vaginal Dilator|Participants will be instructed to use the dilators 3 times per week, regardless of frequency of sexual intercourse. At 5 time points, data will be collected to determine vaginal dilator size, grade vaginal stenosis & assess vaginal symptoms. 1)Baseline: patient self-assessment following consultation up until the end of the first week of radiation 2)Post-radiation: patient self-assessment one month ± 2 weeks follow-up from last day of radiation 3)Post-radiation: 3 month ± 4 weeks follow-up from initiation of dilator use 4)Post-radiation: 6 month ± 4 weeks follow-up from initiation of dilator use 5)Post-radiation: 12 months ± 4 weeks follow-up from initiation of dilator use. At the 1st & 2nd time points, the nurse will telephone the patient to retrieve her responses. The 1st phone call will occur between the time following consultation up until the end of the first week of radiation, & the 2nd will be one month ± 2 weeks from last day of radiation.
45492092|NCT01368471|Device|Control BMS or DES|Control BMS or DES
45492093|NCT02365246|Device|immunoadsorptions with an IgE-specific adsorption column|immunoadsorptions
45492094|NCT01364961|Dietary Supplement|Resveratrol capsules|2 x 75 mg resveratrol each day, for 4 weeks
45492095|NCT02370862|Drug|Neostigmine and Glycopyrrolate|
45492096|NCT01371045|Other|Oral Glucose Tolerance Test (OGTT)|An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
45492097|NCT02365324|Behavioral|Peer-Education Family Fitness Program (PE-FFP)|The proposed integrated project will be implemented by peers and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns [i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010] and SCT variables.
45492098|NCT02365324|Behavioral|Family Fitness Program (FFP)|The proposed integrated project will be implemented by adults and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns [i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010] and SCT variables.
45492099|NCT03620578|Drug|DA-EPOCH-R followed by Nivolumab|5 induction cycles of DA-EPOCH-R protocol, for patient with Deauville imaging response criteria proven complete metabolic response followed with one year Nivolumab consolidation therapy
45492100|NCT04945083|Other|Experimental Nutritional Pudding|High Calorie, High Protein pudding
45492101|NCT02370628|Procedure|Percutaneous vertebroplasty|"The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae, and has been used for treatment of patients with osteoporosis who have severe or prolonged pain following vertebral compression fracture, as well as those with painful, aggressive hemangiomas and osteolytic neoplasms.~In our trial, vertebroplasty shall be performed in two steps:~Step 1: facet block~Step 2: cement infusion~Therefore, patients in both arms will undergo Step 1 since our control intervention serves as a routine first part of our active intervention."
45492102|NCT02370628|Procedure|Facet block|"A long-acting local anesthetic agent and corticosteroids are injected in the spinal articular facets at the affected level.~All patients will undergo facet block since it serves as a routine first part to percutaneous vertebroplasty."
45492103|NCT02929407|Drug|FE 204205|"In Part 1 of the trial, each subject will receive increasing IV doses of FE 204205, given once daily as 2 hour infusion, on three consecutive days.~In Part 2 of the trial, each subject will receive a 2 hour IV infusion of the maximum tolerated dose of FE 204205 as defined in Part 1 of the trial."
45492104|NCT02929407|Drug|Placebo|In Part 2 of the trial, each subject will receive a 2 hour IV infusion of placebo.
45492105|NCT02373280|Drug|10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole)|In this group, patients will receive the 10 day sequential regimen for eradication of H. pylori. 10 day sequential regimen is like follows; Esomeprazole 40 mg bid 10 days (D1-D10)+amoxicillin 1 g bid 5 days (D1-D5)+clarithromycin 500 mg bid 5 days (D6-D10)+metronidazole 500 mg tid 5 days (D6-D10).
45693165|NCT00757822|Drug|Dronabinol|Dronabinol (5mg) will be administered orally (p.o.) 20-60 min pre-operatively.
45693166|NCT00757822|Drug|Ondansetron|Ondansetron (4mg) will be administered intravenously (iv) intraoperatively in those patients not receiving Dronabinol.
45693167|NCT04561765|Device|iCanCope|The iCanCope mobile and web-based self-management program has been empirically evaluated for multiple painful diseases
45846977|NCT02708238|Dietary Supplement|Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)|
45846978|NCT02708238|Dietary Supplement|Lactobacillus reuteri DSM 17938 (108 CFU)|
45492106|NCT02373280|Drug|7 day tailored PPI triple therapy (clarithromycin-containing triple therapy)|the participants received PPI based triple therapy[Esomeprazole 40 mg bid 7 days (D1-D7)+amoxicillin 1000mg bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)]
45375188|NCT05022641|Device|PTeye|The surgeon will first take 5 baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent) using the disposable sterile fiber probe that is connected to the PTeye console (see Figure 1), as per device functionality requirements.
45375189|NCT00784667|Drug|Cetuximab|400mg/m2 intravenously week 1, then 250 mg/m2 weekly intravenously
45375190|NCT00784667|Drug|Erlotinib|100mg orally daily continuously
45375191|NCT00784745|Drug|Dexamethasone|2mg morning and night for 5 days.
45375192|NCT00534638|Biological|Cervarix|Intramuscular injection, 3 doses
45375193|NCT00534638|Biological|Engerix-B|Intramuscular injection, 3 doses
45375194|NCT00996008|Drug|placebo|0.5 g (w/w) placebo cream applied to each target lesion twice daily
45375195|NCT00996008|Drug|CT 327|0.5 g CT 327 cream will be applied to 2 target lesions twice daily 0.5 g placebo cream will be applied to remaining 2 target lesions twice daily
45375196|NCT00993512|Drug|Amphinex (TPCS2a)|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
45375197|NCT00993512|Drug|Bleomycin|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
45375198|NCT00993512|Other|Illumination with CeramOptec laser|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
45375199|NCT00996086|Device|CRT device implant|CRT device-recipients
45375200|NCT00993590|Behavioral|M CHESS|Smartphone with access to MCHESS, an asthma control system that provides easy-to-access, just-in-time information and support.
45375201|NCT00662129|Biological|bevacizumab|
45375202|NCT00662129|Drug|gemcitabine hydrochloride|
45846979|NCT02708238|Drug|Simethicone|
45375203|NCT00662129|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
45375204|NCT00996242|Drug|L-lysine|6 g/day for four weeks
45375205|NCT00996320|Other|Reduced work hour schedule|Interns on the intervention schedule work an average of 60 hours per week over 4 weeks, with maximum shift length 16 hours.
45375206|NCT05346224|Drug|HLX11|Neoadjuvant(q3w/cycle，total 4cycle): HLX11(loading dose of 840 mg IV , followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophosphamide( 600 mg/m2 IV q3w),total 4 cycle; trastuzumab(loading dose of 8mg/m2 IV , followed by 6 mg/m2 IV q3w)+HLX11(loading dose of 840 mg IV , followed by 420 mg IV q3w), 13cycle
46054048|NCT02790099|Drug|Morphine|0.1mg preservative free morphine will be injected intrathecally by anaesthesiologist at the time of spinal anaesthesia.
46054049|NCT04100005|Other|No intervention|There is no intervention for this study.
45375207|NCT05346224|Drug|EU-Perjeta®|Neoadjuvant(q3w/cycle，total 4cycle): Perjeta (loading dose of 840 mg IV , followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophosphamide( 600 mg/m2 IV q3w),total 4 cycle; trastuzumab(loading dose of 8mg/m2 IV , followed by 6 mg/m2 IV q3w)+HLX11 or Perjeta (loading dose of 840 mg IV , followed by 420 mg IV q3w), 13cycle
45375208|NCT00993746|Drug|Bupivacaine plus lidocaine|Bupivacaine 20 ml plus lidocaine 10 ml
45375209|NCT00993746|Drug|Bupivacaine 30 ml|Bupivacaine 30 ml for ultrasound guided infraclavicular brachial plexus block
45375210|NCT00789971|Drug|triamcinolone acetonide|40 mg of triamcinolone acetonide given inferotemporally perioperatively during phacoemulsification
45375211|NCT00789971|Drug|Maxitriol|one month of topical G. Dexamethasone 0.1% with Neomycin sulphate 3500IU/g
45375212|NCT05345522|Biological|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
45375213|NCT05345522|Biological|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
45492107|NCT02373280|Drug|7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]|moxifloxacin triple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+Moxifloxacin, 400 mg qd 7 days (D1-D7)+Amoxicillin 1 g bid 7 days (D1-D7)].
46054050|NCT02790177|Drug|Hyaluronic Acid|
46054051|NCT02790177|Drug|NORMAL SALINE|
45492108|NCT02373280|Drug|7 or 14 days tailored EBMT therapy group (bismuth quadruple therapy)|bismuth quadruple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+amoxicillin 1 g bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)], bismuth quadruple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, 300 mg qid 7 days (D1-D7)+Metronidazole, 500 mg tid 7 days (D1-D7)+Tetracycline 500 mg qid 7 days (D1-D7)] If there was no metronidazole resistance, the treatment was 7 days in duration. If metronidazole resistance was evident, treatment duration was 14 days.
45492109|NCT01368549|Other|Metanx® (a medical food)|Metanx® is an orally-administered medical food, and each tablet contains 3mg of L-methylfolate, 35mg of Pyridoxal-5'-phosphate, and 2 mg of Methylcobalamin- which are the biologically active and immediately bioavailable forms of folate, vitamin B6, and vitamin B12, respectively. Dosage will be 1 tablet BID.
45492110|NCT02370550|Drug|Cyclosporin A|CsA 2-3 mg/kg/d, BID PO
45492111|NCT02370550|Drug|Prednisone|Prednisone 0.5mg/kg/d QD PO starting at Week 0. After 2-4 weeks, the initial dose is gradually tapered by 2.5 mg each week until a maintenance dosage of 5-7.5 mg/d through week 52 (visit 6). The initial and maintenance doses are determined by the investigators of each center depending on the patients.
45375214|NCT05345522|Biological|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
45492112|NCT02370550|Drug|Placebo|Placebo tablet 2-3 mg/kg/d, BID PO
45492113|NCT02370550|Drug|Calcium carbonate D|Calcium carbonate D 600 mg, QD PO
45375215|NCT00996398|Other|Tepid water immersion|28°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
45375216|NCT00782405|Drug|quetiapine|XR, 150-300mg
45375217|NCT00782405|Drug|mirtazapine|30-45 mg
45375218|NCT04000646|Other|standard care|standard care non-pharmacologic interventions during anesthesia induction
45375219|NCT04000646|Other|breath-controlled app|breath-controlled app and custom-designed tablet (equipped with a breathing sensor)
45375220|NCT05250362|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|"MYELOABLATIVE CONDITIONING REGIMEN: Patients with myeloid malignancies receive busulfan on days -7 to -4, fludarabine IV over 1 hour on days -7 to -3, cytarabine IV over 4 hours on days -7 to -3. Patients with lymphoproliferative disorders receive busulfan on day -7 to -4, cladribine IV over 1 hour on days -7 to -3, gemcitabine IV over 4 hours on days -7 and -3.~TRANSPLANT: Patients undergo PBSC transplant on day 0.~POST-TRANSPLANT CYCLOPHOSPHAMIDE AND GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, cyclosporin IV beginning on day 5 for 2 weeks and then PO for approximately 4 months, and mycophenolate mofetil PO BID beginning on day 5 for 30 days.~NK CELLS: Patients receive NK cells IV over 30 minutes on days 7 and 28."
45375221|NCT00790283|Device|PTCA with stent implantation|"Eligible patients will be randomly assigned to the implantation of one (or more) Numen or Vision/Mini Vision stent.~Each patient will undergo a 1-month follow-up and a clinical visit at 6 months from the procedure."
45492114|NCT02365168|Other|Cod_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with cod in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
45492115|NCT02365168|Other|Salmon_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with salmon in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
45375222|NCT00996554|Procedure|double layer-suture|Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
45375223|NCT00996554|Procedure|Single-layer suture|Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread)
45375224|NCT00782561|Drug|FG-3019|FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks
45375225|NCT02996396|Device|Nellix Endovascular Aneurysm Sealing System (Nellix®-System)|The Nellix system is comprised of two independent flow channels, one to each iliac artery. Each flow channel consists of a balloon-expanded ePTFE covered stent surrounded by a Polymer-filled EndoBag which fills the blood lumen within the aorta, and seals the aneurysm from side-branch flow.
45492116|NCT02365168|Other|Mackerel_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with mackerel in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
45492117|NCT02365168|Other|Placebo_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with placebo covered in chocholate dessert over one day
45492118|NCT02365402|Drug|Entecavir|After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow-up after treatment.
45492119|NCT02370472|Other|tool developed using cameras and a computer|cameras allowing subject to be able to visualize hand and needle movements as well s the position of the transducers along with the image from the ultrasound on a computer screen
45492120|NCT02364934|Drug|Propofol|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.
45846980|NCT02708862|Device|Preoxygenation|After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed below, the exhaled oxygen content will be measured. All participants were enrolled in a single arm in which they underwent 4 interventions in series: 1) Simple mask at 60 L/min for 3 minutes 2) Non-rebreather at 60 L/min for 3 min 3) Non-rebreather at 15 L/min for 3 minutes 4) Bag valve mask at 15 L/min for 3 minutes
45375226|NCT00785135|Device|Lenses containing prismatic correction|The patient will receive lenses containing prismatic correction for heterophoria, as well as correction for hyperopia, myopia and astigmatism as indicated during initial examination.
45375227|NCT00785135|Device|Lenses not containing prismatic correction|The patient will receive lenses containing correction for hyperopia, myopia and astigmatism as indicated during initial examination. The patient will not receive prismatic correction in these lenses.
45375228|NCT00993902|Procedure|Intrauterine insemination (single)|Single IUI after 36-38 hours of HCG
45375229|NCT00993902|Procedure|Double intrauterine insemination|Double insemination after 18 and 40 hours of HCG administration.
45375230|NCT02555735|Drug|Standard of Care Chemotherapy|Physician's Choice Chemotherapy Treatment (non-guided)
45375231|NCT05343260|Drug|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.
45375232|NCT05343260|Drug|Propofol|Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
45375233|NCT05014295|Other|Accessing personal medical records online via online portals|The participants will receive details on accessing personal medical records online via online portals, for each of the major hospital systems
45492121|NCT02364934|Drug|Sevoflurane|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
45693168|NCT04561765|Device|iCanCope+Contingency Management|In addition to the iCanCope-NF activities outlined above, individuals will be rewarded with incentives (contingency management) such as points that are redeemable for prize-based gift card vouchers. Points will be accrued through access to new sections, daily check-ins, and engagement of the mobile application. Based on research, the total amount of money that can be earned by the patient over the course of the two months is 50 dollars USD.
45375234|NCT05340686|Behavioral|Aerobic Physical Exercise|Moderate to vigorous physical exercise 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 12 weeks
45693169|NCT01788163|Genetic|EGFR mutation test|EGFR mutation being tested in tissue and blood
45693170|NCT00758758|Device|Anterior Cervical Discectomy and Fusion|Implantation of Hedrocel
45693171|NCT00758758|Device|Anterior Cervical Discectomy and Fusion|Implantation of Allograft
45693172|NCT00758758|Device|Anterior Cervical Discectomy and Fusion|Implantation of Autograft
45846981|NCT02709018|Drug|losartan|Angiotensin receptor blocker (ARB)
45846982|NCT02709018|Drug|Placebo|Placebo
45492122|NCT02364856|Device|Analgesia Nociception Index|"The Analgesia Nociception Index (ANI, MDoloris Medical Systems, Lille, France), based on Heart Rate Variability analysis, measures continuously and non-invasively the influence of Respiratory Sinus Arrhythmia on the heart rate. This 0-100 index indicates the proportion of paraS over sympathetic activity. In adults during surgery under general anesthesia, ANI decreases after painful stimulation and has been related to the balance between analgesia and nociception.~ANI is calculated from heart rate recording."
45492123|NCT02372656|Drug|Placebo gel|Placebo gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
45492124|NCT02372656|Drug|1% Metformin|1% Metformin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
45492125|NCT02372656|Drug|1.2% Simvastatin|1.2% Simvastatin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
45492126|NCT03123939|Biological|CTL019|CTL019 transduced T cells were given as a single dose of 0.2 to 5.0 × 10^6 autologous CTL019 transduced viable T cells per kg body weight (for patients ≤ 50 kg) and 0.1 to 2.5 × 10^8 CTL019 transduced viable T cells (for patients > 50 kg)
45492127|NCT01368627|Device|Supralimus® Sirolimus-Eluting Coronary Stent|Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
45492128|NCT02358681|Drug|Ketorolac, intranasal|Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route.
45492129|NCT02358681|Drug|Ketorolac, intravenous|Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route.
45492130|NCT02358681|Drug|Placebo, intravenous|Placebo of equal volume to IV ketorolac, to be administered by intravenous route.
45492131|NCT02358681|Drug|Placebo, intranasal|Placebo of equal volume to IN ketorolac, to be administered by intranasal route.
45492132|NCT03123861|Drug|Gabapentin|Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.
45375235|NCT05340686|Behavioral|Relaxing Physical Exercise|Relaxing exercises (stretching, light yoga) 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 12 weeks
45375236|NCT05340686|Behavioral|Information about physical exercise|Written and oral information about physical exercise recommendations, on one occasion, by researcher
45375237|NCT01564472|Other|PSG Scoring|No participants will be enrolled and no interventions, besides PSG scoring will be utilized.
45492133|NCT03123861|Drug|Placebo oral capsule|Patients randomized to this arm will receive 2 weeks of placebo post-operatively..
45492134|NCT01368705|Dietary Supplement|Standard protein delivery|Protein delivery of 1.5 g/kg/day.
45492135|NCT01368705|Dietary Supplement|Intervention 1 (2.2g/kg/day)|protein delivery of 2.2g/kg/day
45492136|NCT01368705|Dietary Supplement|Intervention 2 (3.0 g/kg/day)|protein delivery of 3.0 g/kg/day
45492137|NCT04116645|Other|genital and rectal swab|6. Swabs for GBS culture should be obtained, ideally before digital examination or use of lubricants, from both the lower vagina (vaginal introitus) and rectum (insert swab through the anal sphincter) to achieve maximum sensitivity. Either two swabs (one for each site) or a single swab can be used; one swab is more cost saving. The swabs will be obtained by the patient herself after appropriate instruction or by the provider healthcare, as studies have shown equivalent sensitivity between the healthcare provider and the patient herself.
45492138|NCT01368783|Drug|atazanavir|400 mg/day for 2 days
45492139|NCT01368783|Drug|Atazanavir(ATZ) and Tenofovir(TDF)|ATZ 400 mg with TDF/day for 2 days
45492140|NCT01368783|Drug|Atazanavir(ATZ) + Ritonavir|ATZ 300 mg + Ritonavir 100 mg/day for 2 days
45492141|NCT01368783|Drug|atazanavir(ATZ) + tenofovir(TDF) + ritonavir|ATZ 300 mg + Ritonavir 100 mg with TDF/day for 2 days
45492142|NCT01509339|Drug|Vancomycin|250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
45492143|NCT01371279|Device|Intra-Cardiac Echocardiography guided atrial fibrillation ablation|8-F or 10-F phase array ICE-probe
45492144|NCT03123471|Drug|Apremilast|Apremilast 30 mg tablets BID from weeks 0 to 32.
45492145|NCT03123471|Other|Placebo|Placebo tablets twice daily (BID) for 16 weeks; placebo participants were switched to apremilast 30 mg at week 16.
45492146|NCT02661178|Drug|emodepside (BAY 44-4400)|
45492147|NCT02661178|Drug|placebo|
45492148|NCT01365117|Drug|Technosphere® Insulin Inhalation Powder|15 subjects in a three-way crossover (three different doses of TI Inhalation Powder [one 20 U, two 20 U and one 40 U cartridges)
45492149|NCT01365117|Drug|Technosphere® Insulin Inhalation Powder|16 subjects in a four-way crossover (four different doses of TI Inhalation Powder [one 20 U, one 20 U plus one 10U, one 30 U (3 U per mg), one 30 U (4 U per mg cartridges)])
45492150|NCT02370316|Behavioral|Metacognitive Interpersonal Therapy (MIT-SA)|MIT-SA consists of weekly individual therapy (1 year) and weekly group sessions (six months)
45492151|NCT02370316|Behavioral|Clinical Structured Treatment|structured case management and symptom-targeted medication
45492152|NCT02372500|Dietary Supplement|Chewing gum|Sugar free chewing gum
45846983|NCT02713230|Drug|bupivacaine liposome injectable suspension|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline
45375238|NCT04001660|Procedure|Subbrow Blepharoplasty Combined with Double Eyelid Surgery|An upper incision is made along the inferior margin of the eyebrow. A lower incision is determined according to necessary amount of skin excision. Then the skin and subcutaneous tissue were excised. The orbicularis oculi muscle (OOM) was separated and an OOM flap dissection was extended to the width of 15mm. A dissected OOM flap was lifted up and three transverse 3-0 nylon sutures were placed to fix it to the periosteum and then covered by the upper myocutaneous flap of the supraorbital rim. Through eyelid-crease approach the supratarsal upper eyelid skin and orbital fat was excised, adjusted and reshaped double-fold eyelids at the same time.
45375239|NCT04001816|Other|Orthodontic Brackets|Self ligating and Conventional brackets
45375240|NCT00664859|Drug|LCP-AtorFen|All subjects will be assigned to receive open-label LCP-AtorFen combination therapy for 52 weeks. Subjects will take a single oral dose of study drug in the evening without regard to meals.
45375241|NCT00996788|Drug|Rebamipide|Rebamipide 100 mg tid for 28 days
45375242|NCT00785369|Device|Reflectance confocal microscopy|Reflectance confocal microscopy (VivaScope 1500)
45492153|NCT03840447|Behavioral|Chronic Disease Self-Management programme|"The primary aim of the intervention is to achieve greater self-management of the chronic condition by changing the role of the passive citizen to empowerment in self-confidence and self-reliance. The intervention consists of a series of 6 workshops (with 7 to 8 activities), 2.5 hours each, which are held once a week for 6 weeks. One professional and one peer will volunteer together to lead a series of workshops. To this end, professionals and peers will be recruited and trained in the CDSMP principles.~Over 6 workshops, citizens set realistic health goals, learn to self-manage pain and discomfort, to self-manage their diet, self-manage physical activity, mood and the way the disease influences their personal relationships. The intervention is designed to actively involve citizens."
45492154|NCT02372812|Drug|dexamethasone|12 mg of dexamethasone
45492155|NCT02372812|Drug|Placebo|
45375243|NCT01564550|Drug|Insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
45375244|NCT01564550|Drug|insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
45375245|NCT01564550|Other|diet|The subjects ingest a three day isocaloric diet (55 % carbohydrate,30% fat, 15 % protein)prior to the study day.
45492156|NCT02365012|Drug|Midodrine|Crossover intervention comparing midodrine to placebo for subjects with orthostatic intolerance
45492157|NCT01369017|Drug|Anakinra|Active treatment will consist of 2 doses of 1 mg/kg up to 100 mg of anakinra SQ injection.
45492158|NCT01369017|Drug|Placebo|Injection of NS
45492159|NCT01371357|Drug|TEST 1|2.4 g/day of guanidinoacetic acid
45693173|NCT00783952|Device|Cerebral/Somatic Tissue Oximeter device|"Measurement of tissue oxygen saturation and simultaneous sampling for blood gas analysis.~Four sensors of the 'Cerebral/Somatic Tissue Oximeter' device will be placed on subject's both sides of the forehead, palm and calf area. Simultaneously, blood samples will be drawn from the pulmonary artery catheter and arterial line for blood gas analyses. The values obtained from the device measurements will be used in a new equation to calculate the mixed venous oxygen saturation. The calculated value will be compared to the real value from the blood gas analysis for accuracy."
45375246|NCT01564550|Other|no diet|The subjects will ingest a non-restricted diet prior to the study day.
45375247|NCT00996866|Drug|Vitamin D3|Vitamin D supplementation will follow an algorithm for initial vitamin D dosing and for dose changes. Subjects will receive 100 ug/day of vitamin D3 if their 25(OH)D level is less than 50nmol/L and 50 ug/day if their 25(OH)D level is between 50 and 80 ug/day.
45375248|NCT00996866|Drug|placebo|The placebo group will receive sugar pills appearing similar to the vitamin D capsules.
45375249|NCT00785447|Other|Mouth-to-mouth or mouth-to-nose breathing|Patients undergoing elective surgery under general anesthesia will be given mouth-to-mouth and mouth-to-nose breaths. The respiration process will be measured and recorded by the help of elastic bands put around the chest and abdomen. The efficiency of the breathing methods will be evaluated.
45375250|NCT00790439|Drug|Low Molecular Weight Sulfated Dextran|Inhibitor of instant blood-mediated inflammatory reaction
45375251|NCT00790439|Drug|Heparin|Anticoagulant
45375252|NCT00790439|Drug|Mycophenolate Mofetil|Cell proliferation inhibitor, Transplantation (immunosuppressive)
45492160|NCT01371357|Drug|TEST 2|2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogencitrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
45693174|NCT00783952|Device|Pulmonary artery catheter|Blood will be drawn form the pulmonary artery catheter for measurement of mixed venous oxygen saturation.
45846984|NCT02713230|Drug|bupivacaine liposome injectable suspension|20 mL EXPAREL (bupivacaine liposome injectable suspension)
45846985|NCT02713230|Drug|Placebo|20 mL normal saline as single-injection
45492161|NCT01371357|Drug|TEST 3|2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
45375253|NCT00790439|Drug|Sirolimus|Cell proliferation inhibitor, immunologic (immunosuppressive)
45492162|NCT01371357|Drug|TEST 4|2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
45492163|NCT01369173|Other|Mexican or American foods|Participants will be randomized to an isocaloric Indigenous Mexican or a Western diet for 24 days. All foods and beverages will be prepared by the Human Nutrition Laboratory at the Fred Hutchinson Cancer Research Center. After a 4-week wash-out period, participants will cross over to the other arm and be given the alternate diet for 24 days. Blood and urine specimens will be collected before and after each feeding period to test baseline and post-intervention metabolic response as defined by various inflammatory and cancer susceptibility biomarkers including insulin-like growth factor 1 (IGF1), insulin-like growth factor binding protein 3 (IGFBP3), leptin, adiponectin, interleukin-6 (IL-6), C-reactive protein (CRP) and SAA (serum amyloid-A). DNA extracted from whole blood will be used to test whether a panel of 128 Ancestry Informative Markers (AIMs) is associated with metabolic response to the diets and other phenotypic traits of obesity, which relate to breast cancer risk.
45492164|NCT01369251|Behavioral|Hygiene|
45375254|NCT00790439|Drug|Tacrolimus|Calcineurin inhibitor
45375255|NCT00790439|Drug|Cyclosporine|Calcineurin inhibitor, immunosuppressant
45375256|NCT00790439|Drug|Daclizumab|Monoclonal IL-2 receptor blocker
45375257|NCT00790439|Drug|Basiliximab|Monoclonal IL-2 receptor blocker
45375258|NCT00790439|Biological|Allogeneic Pancreatic Islet Cells|
45492165|NCT01369251|Procedure|Usual alcohol care|
45492166|NCT02660944|Drug|RSLV-132|RNase-Fc fusion protein
45492167|NCT02660944|Drug|Placebo|Saline placebo
45492168|NCT01365351|Other|Growth hormone|Drug given by prescription
45375259|NCT00785603|Drug|Paroxetine|tablets of 20 mg paroxetine
45492169|NCT02370082|Device|Localization of breast lesion|localization of breast lesion for removal
45492170|NCT03625245|Other|Control Yogurt|125 g/day
45492171|NCT03625245|Other|Yogurt Variety 1|125 g/day
45375260|NCT00785603|Drug|Paroxetin placebo|capsules with lactulose to hide, whether the volunteer are receiving 0, 10, 20, 30 or 50 mg paroxetine
45375261|NCT00785603|Drug|Tramadol|Capsules of 50 mg tramadol
45375262|NCT00570401|Drug|dasatinib|
45375263|NCT00785681|Drug|Dermacyd PH_DETINBACK (Lactic Acid)|
45375264|NCT00785759|Drug|AH110690 (18F) Injection|All subjects will receive an I.V. dose of [18F]AH110690 (less than 10 mg of total AH110690). The target activity of a single administration of [18F]AH110690 will be 185 MBq (equivalent to a dose of approximately 6 mSv).
45375265|NCT00785837|Other|Aquatic Physical Therapy|The Physiotherapy was performed with gentle movements in eight shape, from left to right, in addition to movements of unbundling girdle, light and slow the trunk and extremities posture and body by flexing the organization Wrapping the body.
45375266|NCT00785915|Drug|AZD6765|single administration and once daily for 5 days
45375267|NCT00785915|Drug|Placebo|single administration and once daily for 5 days
45492172|NCT03625245|Other|Yogurt Variety 2|125 g/day
45492173|NCT04562896|Device|Custom Carbon Fiber Dynamic Orthosis (CDO)|The custom carbon fiber dynamic orthoses will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
45492174|NCT04894071|Drug|QA102|"Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of QA102 capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration."
45492175|NCT04894071|Drug|Placebo|"Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of Placebo capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration."
45375268|NCT00785993|Other|Vitrification of oocytes for IVF treatment|
45375269|NCT00785993|Other|Protocolary IVF treatment with fresh donor oocytes|
45375270|NCT00532298|Biological|GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
45375271|NCT00532298|Biological|GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
45375272|NCT00532298|Biological|Fluarix [NH 2006/07 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
45375273|NCT00532298|Biological|Fluarix [NH 2007/08 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
45375274|NCT02555579|Behavioral|Dietary Protein Counting and Free Fruits and Vegetables|Subjects will be educated on new simplified diet approach and phenylalanine levels will be monitored for 1 year, and will be compared to 12 months prior to study enrollment
45375275|NCT04047017|Drug|Apatinib|250mg, po, qd
45375276|NCT04047017|Drug|Camrelizumab|200mg, q2w
45375277|NCT00997022|Drug|Sorafenib|"Dose escalation:~Dose level 1: 200mg of sorafenib daily~Dose level 2: 200mg of sorafenib BID (twice daily)~Dose level 3: 200mg QAM (taken every morning) and 400mg QPM (taken every evening)~Dose level 4: 400mg BID (twice daily)"
45375278|NCT00786149|Other|Varenicline plus Motivational Interviewing counseling|Motivational Interviewing; 8 weeks of counseling
45375279|NCT00786149|Other|Varenicline without counseling|Brief advice, one time during initial session
45375280|NCT00997100|Drug|paquinimod (ABR-215757)|The initial daily dose of ABR-215757 is changed to 1.5 mg/day. There will be an option to increase the dose to 3.0 mg/day following 28 days of treatment
45375281|NCT02555501|Other|PDT + Low level laser|"Two days before the laser treatment, the side of the oral cavity chosen for the experimental treatment was pigmented with aqueous solution of 0.005% methylene blue. A ball of sterile cotton was soaked in the dye solution and placed in the center of the lesion. Photosensitizer remained in the place for 5 minutes (pre-irradiation period). Then, to activate the dye, the lesion was irradiated with red light (InGaAlP / phosphide and Indium, Gallium and potassium).~From the 3rd to the 10th day was carried out only laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium)."
45375282|NCT02555501|Radiation|Low level laser|Two days before the laser treatment, the lesion of the side of the oral cavity chosen for the control treatment was treated with ball of sterile cotton soaked in distilled water and the laser unit placed on the lesion without activation of the light. From the 3rd to the 10th day was carried out laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium).
45375283|NCT04001738|Other|Direct Transfer to Angio Suite|Patient will be direct transferred to angiography suite where EVT team will be waiting for it.
45492176|NCT02372422|Other|Transvaginal ultrasound determination of cervical length|Transvaginal ultrasound was used to measure the length of the cervix from the internal to external os relying on a standard approach and clinicians caring for the patients were made aware of the results.
45492177|NCT02372422|Other|Routine care|Routine prenatal care of twins. Digital exams were permitted, but transvaginal ultrasound assessment of cervical length was not.
45492178|NCT03550287|Dietary Supplement|Experimental product|10 g/day
45375284|NCT00993980|Procedure|qigong|one therapy session once a week during three months, that is 12 therapy sessions altogether
45492179|NCT03550287|Dietary Supplement|Placebo product|10 g/day
45492180|NCT02372266|Other|Early Maternal-Newborn Infant Discharge|Discharge from the hospital between 12-24 hours of life
45375285|NCT00993980|Procedure|exercise therapy|one therapy session once a week during three months, that is 12 therapy sessions altogether
45492181|NCT02372266|Other|Routine discharge|Discharge of the mother and newborn 2 to 3 days after delivery
45492182|NCT03293667|Other|Exploratory synovial fluid analysis|An additional blood sample (3 10 ml tubes) and an additional specific analysis to characterize subpopulations of regulating T lymphocytes infiltrating the synovium of RA patients and comparing them with those of peripheral blood.
45375286|NCT02725814|Other|24% Sucrose Solution|Two minutes prior to the start of a painful procedure neonates will receive 0.12ml of 24% sucrose solution, over a period of no more than 1 minute. A pacifier will be offered immediately following sucrose administration for non-nutritive sucking if the infant is able to hold the pacifier securely. The sucrose study dose is to be repeated as needed based on pain response and procedure duration.
45492183|NCT01372449|Drug|Memantine|Memantine will be initiated at 3 mg. The dose will be increased every week by 3 mg for a maximum of 12mg for subjects weighing ≥ 60kg, 9mg for subjects weighing ≥ 40 kg but <60 kg, and 6 mg for subjects weighing ≥ 20 kg but < 40kg.
45492184|NCT01372449|Drug|Placebo|
45492185|NCT02369926|Procedure|Multiple Sclerosis Functional Composite|The MSFC is a diagnostic test that measures multiple sclerosis symptoms. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. The MSFC is administered in-person at the study site.
45492186|NCT02369926|Procedure|Mobile Multiple Sclerosis Functional Composite|The mMSFC is a diagnostic test that measures multiple sclerosis symptoms from. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. All aspects of this exam are completed from a participant's home using remote sensing technology and video conferencing.
45492187|NCT04688541|Device|Optitip Catheter (LinC Medical)|The Optitip catheter, unlike the Foley catheter design which has a protruding tip, the Optitip has a blunt open end (eyelet) that protrudes slightly beyond a single fluid-filled 10ml balloon. It has an additional drainage eyelet underneath the balloon.
45375287|NCT00410410|Drug|abatacept (ABA)|"Dextrose 5% in water, IV. Placebo on days IP-1, IP-15,IP-29, IP-57; 3 mg/kg on days IP-1, IP-15,IP-29, IP-57; 10 mg/kg on days IP-1, IP-15,IP-29, IP-57; or 30 mg/kg on days IP-1,IP-15 and ~10 mg/kg on days IP-29, IP-57 (ABA 30/~10 mg/kg Group).~Induction Period 3 months~Maintenance Period 12 months"
45492188|NCT04688541|Device|Foley catheter|Foley catheter
45492189|NCT02364622|Device|Tranditional fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by tranditional fiberoptic bronchoscopy.
45492190|NCT02364622|Device|Modified fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by modified fiberoptic bronchoscopy
45492191|NCT02364622|Device|Flexible Trachway intubating stylet|The accurate placement of left-sided DLT into the left main bronchus was faciliated by using flexible Trachway intubating stylet.
45492192|NCT04666389|Drug|Atorvastatin|To compare the preventive role of low- and high-dose statin regimens in the prevention on contrast-induced acute kidney injury in statin-naive patients with cardiovascular diseases undergoing computer tomography with intravenous contrast media administration
45492193|NCT02364544|Behavioral|Relapse Prevention Plan|brief, in-person, relapse prevention counseling with supplemental web-based learning modules,
45375288|NCT00410410|Drug|placebo|"Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months"
45492194|NCT02364544|Behavioral|Daily Support Website|web-based program for patients and families that provides psychoeducation about schizophrenia and its treatments to improve knowledge, increase problem-solving skills and offer social support through the use of web-based therapist facilitated sessions
45846986|NCT02713698|Drug|Propofol|"The whole anaesthetic procedure is standard except for additional body composition assessment with Body Composition Monitor - BCM (Fresenius Medical Care, Germany) and arterial blood samples collection.~In all included patients, propofol will be started at 2000mg/h until LOC, defined by loss of eye-lash reflex and loss of response to name calling. During surgery propofol infusion will be guided by targeted BIS values between 40 and 60.~Arterial blood samples will be obtained immediately after LOC and after every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples will be acquired every 10 minutes until recovery of consciousness. The maximum blood sample per patient will be 20 mL."
45846987|NCT02714400|Drug|Venlafaxine|Venlafaxine 50mg before sleep
45846988|NCT02714400|Drug|Placebo|One piece of placebo before sleep
45375289|NCT00410410|Drug|abatacept|"~10 mg/kg, once monthly~Open- Label Extension Period until the drug is marketed for UC or the UC development program for abatacept is discontinued"
45375290|NCT00997178|Procedure|Non-surgical periodontal therapy|Non-surgical periodontal therapy (scaling and root planing)and supportive periodontal therapy with chlorhexidine rinse
45375291|NCT00997178|Other|Delayed non-surgical periodontal therapy|Delayed non-surgical periodontal therapy (scaling and root planing) after the 6 month visit
45375292|NCT00782951|Drug|Org 28611|single IV dose of Org 28611 3 mcg/kg after dental impaction surgery
45375293|NCT00782951|Drug|morphine sulfate|single IV dose of morphine sulfate 0.12 mg/kg after dental impaction surgery
45375294|NCT00782951|Drug|Placebo|single IV dose of placebo after dental impaction surgery
45375295|NCT00997256|Drug|Neurapas® balance (Herbal product (Hypericum, Passionflower, Valerian))|3 x 2 tablets / day over 3 days
45375296|NCT00997256|Drug|film-coated sugar-pill|3 x 2 tablets / day over 3 days
45846989|NCT02716506|Procedure|POP surgery|Any surgical procedure that is done to treat the symptomatic POP
45846990|NCT02716818|Drug|Chronocort®|Chronocort® is a patented oral modified release formulation of hydrocortisone which is intended to mimic, or closely match, the serum levels of endogenous cortisol.
45492195|NCT02364544|Behavioral|Computer CBT for voices and paranoia|A ten-session CBT programs, one to address voices and the other for paranoia. The web-based programs incorporate the essential elements of CBT for psychosis such as normalizing behavior and offering behavioral coping strategies
45492196|NCT02364544|Behavioral|FOCUS|an interactive smart phone text-messaging application to support medication adherence, facilitate coping with symptoms and improve daily functioning in individuals with schizophrenia
45492197|NCT02364544|Other|Prescriber Decision Assistant|is a web-based prescriber decision support system that includes a brief patient-completed assessment describing symptoms and adverse events which prompts the prescriber to conduct a detailed clinical assessment. Embedded in the program are decision supports for medication choices based on best evidence-based practices regarding symptoms, side effects, information from laboratory tests and history of prior treatment response
45492198|NCT01369407|Other|No Intervention|Not an interventional study
45492199|NCT02372110|Drug|HPA, ANS stimulation|Oral administration of Hydrocortisone will increase HPA axis activity. Oral administration of Caffeine will boost ANS activity
45846991|NCT02716818|Drug|standard glucocorticoid therapy|Subjects in this arm will continue on their standard hydrocortisone therapy
45375297|NCT02555813|Drug|Abraxane|Abraxane By IV infusion on Days 1, 8, 15 and 28 until progression or toxicity
45375298|NCT02555813|Drug|Gemcitabine|Gemcitabine 1000mg IV infusion on Days 1, 8, 15 and 28 until disease progression or toxicity
45375299|NCT00994058|Device|Electrical Inhibition (EI) Uterine Pacemaker|"An external powered pulse generator, pacemaker for external stimulation of the uterine muscle through the vaginal canal for the therapeutic use of preventing preterm birth.~Patients with preterm contractions (< 37 weeks gestation) will be monitored for contraction frequency for 20 minutes before, 20 minutes during use of EI and 20 minutes after EI/uterine inhibitor/pacemaker. Device generates a weak electrical current (0-10mA, 0-50 Hz, 0-50mS)."
45375300|NCT00997412|Drug|Mycophenolic acid|180 mg/tablet, 4 tablets twice daily
45375301|NCT00997412|Drug|AZA|1 tablet AZA (50 mg/tab) and 4 tablets MA placebo twice daily
45375302|NCT04047407|Device|Suprathreshold pain stimulation|"Suprathreshold pain stimulation will be applied in the infraspinatus muscle (point equidistant between the midpoint of the spine of the scapula, the inferior angle of the scapula and the midpoint of the medial border of the scapula) with a pressure algometer (Force Ten ™, Wagner Instruments, USA). Four suprathreshold pressure stimulations (pressure pain threshold + 20%, +30%, +40% and +50%) will be made for 60 seconds, with a minimum rest of 5 minutes between each stimulation.~The sequence of stimulation (ascending or descending) will be randomized."
45375303|NCT00997490|Drug|Neurapas® balance (Herbal combination out of hypericum, valerian, passionflower)|3 x 2 tablets/day over 6 weeks
45375304|NCT00997490|Drug|film-coated sugar-pill|3 x 2 tablets / day over 6 weeks
45492200|NCT02372110|Drug|Placebo|Two cellulose placebo capsules filled with acidophilus powder will be administered to subjects who are randomly assigned to the placebo condition
45492201|NCT02372188|Other|water|Control
45492202|NCT02372188|Dietary Supplement|caffeine|
45492203|NCT02372188|Dietary Supplement|caffein + homoeriodictyol sodium salt|
45492204|NCT02372188|Dietary Supplement|homoeriodictyol sodium salt|
45492205|NCT02369692|Device|Magellan Robotic 6 Fr Catheter|The Hansen Medical Magellan™ Robotic Catheter 6 Fr (Magellan™)
45492206|NCT04652505|Other|Questionnaire Administration|Complete questionnaires
45492207|NCT01371435|Drug|Paroxetine|
45846992|NCT02719158|Drug|6 mg ciprofloxacin|Single administration of OTO-201
45846993|NCT02719158|Drug|12 mg ciprofloxacin|Single administration of OTO-201
45375305|NCT00783107|Drug|Cyclosporine|Cyclosporine Inhalation Solution, Once Daily
45375306|NCT00783107|Drug|Placebo|
45375307|NCT00997568|Device|PET-511BTM|Transesophageal Transducer
45375308|NCT00783185|Behavioral|Cannabis-Consumption-Reduction-Training|8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse
45492208|NCT03634449|Device|i-gel|i-gel is a supraglottic airway devices with a gastric suction channel.
45492209|NCT03634449|Device|endotracheal tube|Endotracheal intubation is a traditional use for protect airway during the laparoscopic surgery.
45492210|NCT01319643|Drug|Oxygen|The lowest inspiratory fraction of oxygen between 21 and 100% in as a short time as possible to maintain SpO2 between 94 and 98% or PaO2 between 70 and 100 mmHg.
45492211|NCT02975336|Drug|Placebo|Participants received placebo matched to M2951 orally for 52 weeks.
45846994|NCT02719158|Other|Sham|
45846995|NCT02719938|Behavioral|Specialty Palliative Care|Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
45846996|NCT02723916|Behavioral|ezParent Program|Tablet-based behavioral parent training program.
45492212|NCT02975336|Drug|M2951|Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 52 weeks.
45492213|NCT02975336|Drug|M2951|Participants received 75 mg of M2951 orally QD for 52 weeks.
45492214|NCT02975336|Drug|M2951|Participants received 50 mg of M2951 orally twice daily (BID) for 52 weeks.
45492215|NCT02975336|Drug|M2951|Participants who had received Placebo or M2951 (25 mg QD, 75 mg QD or 50 mg BID) during DBPC period were switched to receive 50 mg M2951 orally BID in LTE period for 104 weeks.
45492216|NCT01371513|Other|continuous screening|practice patterns for screening prostate cancer
45492217|NCT02364154|Other|Control group-Blood sampling|Determine the metabolic phenotype of blood plasma by NMR spectroscopy
45492218|NCT02364154|Other|Blood sampling|determine amount and type of free circulating miRNA in blood plasma
45492219|NCT02369614|Other|Active Comparator: 1 Hz rTMS|1 Hz rTMS
45492220|NCT02369614|Other|Active Comparator: 10 Hz rTMS|10 Hz rTMS
45492221|NCT02369614|Other|Sham Comparator:|Sham rTMS
45492222|NCT03124563|Behavioral|Control Group|Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants in this condition will begin receiving daily emails asking them to report their step count in a questionnaire. Participants in the control group will be matched with the intervention group for how much contact they have with the researcher.
45375309|NCT00783185|Behavioral|Social competence Training|8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences
45375310|NCT00783341|Drug|GAP-134|
46054052|NCT04100083|Drug|Spironolactone 50 MG|"Study visit timeline: initial visit [consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
45492223|NCT03124563|Behavioral|Implementation Intention Condition|Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants will be asked to increase their steps incrementally by 2,000 steps each week for the subsequent four weeks. To help achieve their step goals, they will receive maps of different routes near their home and/or work of varying distances and step counts. They will be asked to review their schedule for the next day and identify times when they could add steps into their schedules, and to record their daily step data in the daily questionnaire.
45492224|NCT02364232|Behavioral|bilateral training with and without mirror feedback|
45492225|NCT02359396|Drug|MZRW|MZRWs is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo). All MZRW granules will be prepared by PuraPharm International (H.K.) Limited. The entire manufacturing process, from authenticating the raw materials to the final products, is in strict compliance with the standards of Good Manufactory Practice (GMP) and Chinese Pharmacopoeia.
45492226|NCT01369719|Drug|osveral|receive 20 mg/kg daily orally
45492227|NCT01369719|Drug|Desferal|40-50mg/Kg for 6 nights in each week subcutaneously
45492228|NCT04479046|Other|PMMA crowns|New type of pediatric crowns
45492229|NCT01369797|Other|specific intervention|"Patients included in the specific intervention group will benefit from a personalized action plan presented in a multidisciplinary staff that will be established according to the detected frailties. In follow up visits, a new evaluation will be done and the action plan reviewed."
45492230|NCT02369380|Device|Hyaluronic acid|Injections of Hyaluronic acid under the metatarsal heads
45492231|NCT02038816|Drug|Deferasirox + Azacitidine|"Deferasirox:~20 mg/kg/d for < 14ml/kg/mo pRBCs (~ <4U/mo), 30mg/kg/d for ≥14ml/kg/mo pRBCs(≥4U/mo), 10mg/kg/d for transfusion-independent patients"
45846997|NCT02723916|Behavioral|Health-e Kids Control App|Tablet based health promotion information App
45846998|NCT02726178|Drug|Advil® Pediatric drops for infants|Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
45375311|NCT00783341|Drug|placebo|
45846999|NCT02726178|Drug|Placebo|Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
45847000|NCT02727816|Device|filcon IV I (BC 8.6)|control lens
45847001|NCT02727816|Device|filcon IV I (BC 8.7)|control lens
45847002|NCT02727816|Device|ocufilcon D|test lens
45847003|NCT02727816|Device|methafilcon A (BC 8.6)|control lens
45375312|NCT00534404|Drug|Nicotine patches|Participants will wear nicotine patches.
45375313|NCT00534404|Behavioral|Telephone counseling|Participants receiving telephone counseling will receive five phone calls over a 2-month period to discuss their personal smoking cessation plan.
45375314|NCT00534404|Behavioral|iQuit Smoking website|Participants will access the Project Quit (iQuit Smoking) website.
45375315|NCT00393094|Biological|Bevacizumab|10 mg/kg intravenous injection
45375316|NCT00393094|Drug|Irinotecan hydrochloride|125 mg/m^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
45492232|NCT02038816|Drug|Azacitidine|Azacitidine 75mg/m2 sc daily X 7 days (5-2-2 schedule permitted) on a 28 day cycle for 6 cycles
45375317|NCT04047485|Diagnostic Test|Visual Acuity|During T0, T2 and T3, every subject has been evaluated with a Snellen Chart, to measure visual acuity in number of letters (BVCA)
45375318|NCT04047485|Diagnostic Test|CAM (Confusion Assesment Method)|"During the first 48 hours of post-op follow-up, any episode of post-operative Delirium is checked and evaluated."
45492233|NCT04809831|Other|Domiciliary oral care with Biorepair Peribioma Toothpaste + Mousse|Patients will use Biorepair Peribioma Toothpaste and Mousse for domiciliary oral hygiene twice a day until T2 session.
45375319|NCT04047485|Diagnostic Test|CATQUEST 9-SF|The questionnaire contains questions evaluating the benefits of cataract surgery. The questionnaire has been used during T0, T2 and T3
45375320|NCT04047485|Diagnostic Test|OCT|Using the RNFL and the Macular Topography protocol, the macula and optical nerve are measured during the T2 phase of each patient the risk of Irvine Gas's syndrome or any other retinal complication.
45375321|NCT04047485|Diagnostic Test|6CIT|This Cognitive Impairment test doesn't require Visual function to be executed. Cognitive function is evaluated at T0, T1 and the post-operative trend at T2 and T3.
45375322|NCT04047485|Diagnostic Test|Barthel Index|To evaluate the everyday independence of the subject and it's trend durin the follow-up
45375323|NCT04047485|Diagnostic Test|Endothelial Microscopy - Cornea|Endothelial cell density is evaluated before surgery (T0) and during the follow-up (T2 and T3). The reason of the choice of this test is to evaluate the trend of these instrumental parameters in the elderly population.
45492234|NCT04809831|Other|Domiciliary oral care with Curasept Toothpaste (chlorhexidine 0,2%)|Patients will use Curasept Toothpaste (chlorhexidine 0,2%) for domiciliary oral hygiene twice a day until T2 session.
45492235|NCT02358850|Drug|Norco (Hydrocodone and Acetaminophen)|Norco (Hydrocodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN (as needed) pain following Tonsillectomy for 14 days
46054053|NCT04100083|Drug|Spironolactone 100mg|"Study visit timeline: initial visit [consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
45375324|NCT01043848|Procedure|external electric pudendal nerve stimulation|"intervention timing: twice daily for 20 minutes during 3 consecutive months.~intervention procedure: electrodes will be placed around the penile shaft (in males) or clips will be directly placed on the clitoris (in females).~intervention device: contic+~stimulation parameters: 10 Hz, 200μs pulse width, 10mA (or less, if too uncomfortable)."
45375325|NCT00783653|Drug|Sunitinib|25 mg or 37,5 mg daily dose until DLT
45375326|NCT00409786|Behavioral|Virtual Lifestyle Management (VLM)|16 weekly lessons followed by monthly maintenance lessons
45375327|NCT00786305|Drug|ceftazidime and amikacin|Nebulized ceftazidime 15 mg/kg/3h during 8 days and nebulized amikacin 25 mg/kg/day during 3 days
45847004|NCT02727816|Device|methafilcon A (BC 8.7)|control lens
45847005|NCT02727816|Device|somofilcon A|test lens
45492236|NCT02358850|Drug|Percocet (Oxycodone and Acetaminophen)|Percocet (Oxycodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
45492237|NCT02358850|Drug|Dilaudid (hydromorphone)|Dilaudid (hydromorphone) 2 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
45847006|NCT02730234|Device|JetStream XC with balloon angioplasty|JetStream XC to treat femoropopliteal in-stent restenosis followed by adjunctive balloon angioplasty (same arm). The control arm in this study is historic.
45492238|NCT02358850|Drug|Tylenol (Acetaminophen)|Tylenol (Acetaminophen) 325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
45492239|NCT02359162|Drug|Gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
45492240|NCT02359162|Drug|Oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
45492241|NCT02359162|Drug|Pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
45847007|NCT02733588|Drug|G-Pump™ (glucagon infusion)|0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
45847008|NCT02734056|Other|Music|Listening to music that the patient likes
45375328|NCT00786305|Drug|ceftazidime and amikacin|Intravenous infusion of ceftazidime 30 mg/kg over 30 min followed by continuous infusion 90 mg/kg/day during 8 days and intravenous infusion of amikacin 15 mg/kg/day over 30 min during 3 days
45375329|NCT00790517|Behavioral|Premier Lifestyle Intervention with DASH Diet|Comprehensive group lifestyle intervention focused on caloric restriction and increased moderate exercise using the DASH Diet. 6 months intensive intervention (weekly, group meetings) followed by 6 months of a less-intensive maintenance intervention (monthly group meetings with monthly telephone/e-mail consult)
45375330|NCT01044004|Drug|Armodafinil|Armodafinil 150 mg/day for 13 weeks
45375331|NCT01044004|Drug|placebo|Placebo 150mg/day for 13 weeks
45375332|NCT01044004|Drug|Armodafinil|Armodafinil 150 mg/day for 13 weeks
45492242|NCT02359162|Drug|Etoposide|50 mg/m 2 /day 24 h continuous infusion on days 1-4
45492243|NCT02359162|Drug|Vincristine|0.4 mg/m 2 /day 24 h continuous infusion on days 1-4
45847009|NCT02734056|Other|Control|Control
45847010|NCT02735382|Behavioral|Tobacco quitline EHR referral|Using an EHR-based referral to the tobacco quitline from primary care outpatient clinics.
45375333|NCT01044004|Drug|placebo|Placebo 150mg/day for 13 weeks
45847011|NCT02735382|Behavioral|Tobacco quitline Fax referral|Using an Fax--based referral to the tobacco quitline from primary care outpatient clinics.
45847012|NCT02737332|Drug|Zytiga® (Abiraterone Acetate)|Zytiga® 1,000 mg (4 x 250 mg qd) tablets plus one 5 mg prednisone tablet to be taken bid, spaced approximately 12 hours apart
45847013|NCT02737332|Drug|SoluMatrix™ (Abiraterone Acetate)|SoluMatrix™ 500 mg (4 x 125 mg qd) tablets plus one 4 mg methylprednisolone tablet bid, spaced approximately 12 hours apart
46054054|NCT04100083|Drug|Spironolactone 200 mg|"Study visit timeline: initial visit [consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
45492244|NCT02359162|Drug|Doxorubicin|10 mg/m 2 /day 24 h continuous infusion on days 1-4
45492245|NCT02359162|Drug|Cyclophosphamide|cyclophosphamide 750 mg/m2 /day over 15 min intravenously on day 5
45492246|NCT02359162|Drug|Prednisone|60 mg/m 2 /day 60 mg/m 2 /day on days 1-5
45492247|NCT02359162|Radiation|IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions.
45492248|NCT03634605|Procedure|Chemical pleurodesis|
45492249|NCT03634605|Drug|Tetracycline Topical Ointment|
45492250|NCT03634605|Drug|Normal saline|
45375334|NCT00786383|Biological|IMC-1121B|"Cohort 1~6 mg/kg I.V., once every other week for 4 weeks"
45375335|NCT00786383|Biological|1121B|"Cohort 2~8mg/kg I.V., once every other week for 4 weeks"
45375336|NCT00786383|Biological|1121B|"Cohort 3~10 mg/kg I.V., once every other week for 4 weeks"
45375337|NCT00786383|Biological|1121B|"Cohort 4~15 mg/kg I.V., once every 3 weeks for 6 weeks"
45492251|NCT03634605|Drug|Lidocaine 2% Injectable Solution|
45492252|NCT05653804|Procedure|tele-visit|The remote visit content for CPAP follow up is based on home visit framework and carried out from a secure platform for sharing health data.
45492253|NCT02363764|Procedure|Nasal swab|"Will be obtained by the physiotherapist in:~Expectorating CF patients~Non-expectorating CF patients~Bronchoscopy CF patients"
45492254|NCT02363764|Procedure|Cough swab|"Will be obtained by the physiotherapist in:~Expectorating CF patients~Non-expectorating CF patients~Bronchoscopy CF patients"
45492255|NCT02363764|Procedure|Spontaneous expectorated sputum|"Will be obtained by the physiotherapist in:~- Expectorating CF patients"
45492256|NCT02363764|Procedure|Induced sputum|"Will be obtained by the physiotherapist in:~Non-expectorating CF patients~Bronchoscopy CF patients"
45492257|NCT02363764|Procedure|Bronchoalveolar lavage|"Will be obtained by the pulmonologist in:~- Bronchoscopy CF patients"
45492258|NCT02363764|Other|Questionnaire|Completing questionnaire on acceptability of different sampling methods by patients >6 years of age
45847014|NCT05446428|Other|study of IFNGS expression biomarkers|Blood tests for serum biomarkers, autoantibodies, cytokine profile etc.
45847015|NCT05446116|Procedure|partial splenic artery embolization|embolization of the splenic artery for the treatment of hypersplenism
45847016|NCT05446038|Behavioral|Multi-Family Guided Self-Help FBT|Previous research has shown that Family-Based Treatment (FBT) is an effective treatment for Anorexia. We hope to learn whether an adaptation of Family-Based Treatment (FBT), called online Multi-Family Guided Self-Help FBT, is feasible and acceptable for families of young people with Anorexia. The 'Self-Help' aspect of the treatment consists of a series of educational videos for parents about how to help their child with Anorexia, which parents watch on an online platform. The 'Multifamily' and 'Guided' aspects of the treatment consists of weekly meetings by Zoom for a group of parents of young people with Anorexia, with a facilitator present to guide a group discussion around whether parents feel they understood the content of the videos and whether the content is helpful.
45847017|NCT05445960|Procedure|Tourniquet|This arm will have a tourniquet placed about the thigh and inflated to 250mmHg for the duration of ankle fracture surgery or 2 hours, whichever is shorter.
45847018|NCT05445180|Behavioral|Contingency management|Contingency management will be used to encourage abstinence
45492259|NCT03655418|Other|Resilience Curriculum (RESCUR)|"The method of the present project, developed by experts in Europe, concerns giving children their own self-empowerment, strengthening protective factors, and, in the long run, their resilience. In Sweden, the material has been named Jag vill, jag kan, jag törs!.~The methodology that will be further developed and evaluated in this project is called RESCUR (the resilience curriculum) aimed at increasing children's resilience, i.e., children's ability to cope with crises, changes and stressors without falling apart. The method is rooted in research on human resilience."
45492260|NCT02363842|Device|Skin IQ™ MCM Coverlet|Test article is the Skin IQ™ MCM, a Class II 510k exempt product. It is an overlay coverlet indicated to be used in conjunction with a pressure redistribution surface in order to aid in the prevention and treatment of skin breakdown and pressure ulcers for patients who require microclimate management of the skin.
45492261|NCT02363842|Other|Pressure redistribution surface|Standard of Care (SOC): pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
45492262|NCT02369302|Drug|DWC20141|Tablet
45492263|NCT02369302|Drug|DWC20142|Tablet
45492264|NCT02369302|Drug|DWC20141, DWC20142|Tablet
45492265|NCT03079869|Drug|Ferric Citrate|One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.
45492266|NCT03653936|Device|HITT device|Rebion has developed a noninvasive, handheld device that uses retinal polarization scanning (RPS) to rapidly assess eye fixation and retinal integrity in adults and children. RPS can automatically detect the fixation of the human eye with proprietary technology that uses a scanned annulus of polarized laser light to create a signature that confirms central fixation within seconds. RPS requires no calibration or imaging, and eye movement recordings are not required. The HITT device is a repurposed Pediatric Vision Scanner (PVS), Rebion's first commercial product which has passed all applicable safety and performance standards.
45492267|NCT02363920|Device|HOF|the addition of high oxygen flow to patients breathing spontaneously
45492268|NCT02363920|Device|noninvasive mechanical ventilation (NIV)|the addition of a ventilatory support delivered with a oro-nasal interface
45492269|NCT03654794|Biological|Cell pharmacokinetics of tacrolimus|"Three levels of tacrolimus will be tested. Each aliquot will be supplemented with an amount of tacrolimus to achieve one of these three levels of concentration.~At 0, 5, 15, 30, 60, 120, 240mn, the samples will be separated into 2 aliquots : one dedicated to the determination of tacrolimus in mononuclear cells, the other dedicated to the determination of calcineurin activity. in mononuclear cells."
45492270|NCT03654170|Drug|BI 425809 mixed with [C-14] BI425809|Oral Solution
45492271|NCT03000153|Other|Completing the Goals Form|The Goals Form is a personalised outcome measure where clients enter their goals in collaboration with their assessor. Goals are then rated at the start of every session and open the therapeutic dialogue.
45492272|NCT02369146|Drug|UB-421|The UB-421 (dB4C7 mAb) will be supplied at a concentration of 10 mg/mL (100 mg in 10 mL vial). Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly (Cohort 1, 8 weeks) or 25 mg/kg bi-weekly (Cohort 2, 16 weeks).
46054055|NCT02790021|Procedure|Lymphaticovenous anastomosis (LVA)|LVA is a minimally invasive procedure that can be performed under local anesthesia. Indocyanine green (ICG) lymphography is used to visualize the (obstructed) lymphatic vessels. When using the images as a guide, the lymphatic pathways and the sites for incisions for lymphaticovenous anastomoses are marked with a pen. The patient's limb is then prepared for surgery. Under a surgical microscope the lymphatic vessels are identified and viable lymphatic vessels are anastomosed to similarly sized adjacent recipient venules in the subdermal plane.
46054056|NCT02794155|Drug|HDV Insulin Lispro|HDV Insulin Lispro: ~1% of the Insulin Lispro is bound to HDV (Hepatocyte Directed Vesicle)
45492273|NCT02363452|Drug|Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir|Oral Solution (syrup) or Tablets
45492274|NCT02939313|Device|medial prefrontal cortex|a form of theta burst stimulation that noninvasively induces a depression in brain reactivity
45492275|NCT02939313|Device|dorsolateral prefrontal cortex|a form of transcranial magnetic stimulation that noninvasively induces an increase in brain reactivity
45492276|NCT02939313|Device|sham|sham stimulation
45492277|NCT02363608|Other|standard post surgery care|
45492278|NCT02363608|Behavioral|Caring Canine program|The therapy dogs who visit at MSKCC. A visit by a therapy dog typically lasts about 10-15 minutes with the patient interacting with the therapy dog while the dog is supervised by the handler.
46054057|NCT02794155|Drug|Insulin LISPRO|Insulin Lispro: no bound insulin
45375338|NCT00786383|Biological|1121B|"Cohort 5~20 mg/kg I.V., once every 3 weeks for 6 weeks"
45847019|NCT05445102|Procedure|autogenous demineralized dentin graft as bone substitute in treatment of intrabony defect|after extraction of tooth it will be grinded using hand bone mill and demineralized and placed in intrabony defect
45375339|NCT01042444|Device|GARDEX™|"GARDEX is an embolic protection system to contain and remove embolic material (thrombus/debris) during cardiovascular interventions.~The diameter of the vessel at the site of filter basket placement should be between 3.5 mm to 6.0 mm. The GARDEX Embolic Protection System may be used with commercially available 0.014 guide wires."
45375340|NCT00790595|Drug|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
45847020|NCT05444790|Diagnostic Test|Rapid Diagnostic Test|The performance of two index tests and two comparator tests will be compared to reference tests and gold standard microscopy.
45847021|NCT05444088|Drug|Adebrelimab|intravenous infusion
45847022|NCT05444088|Drug|Bevacizumab|intravenous infusion
46054058|NCT03798015|Other|mitral valve surgery|assessment of ischemic or hemorrhagic stroke subsequent to mitral valve surgery
46054059|NCT02790255|Other|Cold air|
46054060|NCT02790255|Other|Cold water|
45375341|NCT00790595|Drug|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
45375342|NCT00790595|Drug|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
45375343|NCT00790595|Drug|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
45375344|NCT00790595|Drug|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
45375345|NCT00783731|Drug|Low dose midazolam|
45375346|NCT00409708|Drug|Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy|
45375347|NCT00409708|Behavioral|Behavior Therapy|
45375348|NCT00790985|Dietary Supplement|flavocoxid|medical food
45847023|NCT05444088|Drug|SHR-8068|intravenous infusion
45847024|NCT05443932|Drug|Dapagliflozin|10mg Dapagliflozin daily for 8 weeks
45847025|NCT05443932|Drug|Hydrochlorothiazide|50mg Hydrochlorothiazide daily for 8 weeks
45847026|NCT05443854|Drug|Aminoglycosides intervention|"Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines [3, 28, 50].~Systematic aminoglycoside therapy using Amikacin at a dose of 25 to 30 mg/Kg per dose, at a rate of a maximum of 1 infusion per day will be delivered.~Recommended duration will be of three days or until microbiological documentation."
46054061|NCT04234581|Dietary Supplement|Lysulin|Participants will be randomly allocated for 3 months to LysulinTM (1,110 mg TID, i.e. 3.3 g/day) or matching placebo.
46054062|NCT02801955|Procedure|gastrectomy|radical total/subtotal gastrectomy with D2 lymph node dissection
45375349|NCT00790985|Drug|Naproxen|antiinflammatory drug
45375350|NCT01044082|Procedure|controlled cord traction|In the intervention group, controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs
45492279|NCT02363608|Behavioral|baseline and post assessment|The baseline and post assessment will include the Professional Quality of Life Scale (ProQOL R-IV) (Stamm, 1997-2005) and qualitative questions.
45693175|NCT00784030|Other|Water|Participants will be first asked to drink 6 8-oz glasses of water over 2.5 hours on the first day, and then about 12 8-oz glasses of water over the course of the day for one week.
45693176|NCT03803644|Drug|CC-92480|Part 1 dose escalation
45693177|NCT03803644|Drug|CC-92480|CC-92480
45375351|NCT01044082|Procedure|Clinical signs of placental separation|Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
45492280|NCT03634137|Drug|Afamelanotide Group 1|One 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
45693178|NCT01787461|Dietary Supplement|Imedeen|Two tablets per day for 6 months
45693179|NCT01787461|Dietary Supplement|Placebo|Two tablets per day for 6 months
45693180|NCT03803488|Device|DropSafe safety pen needle|
45492281|NCT03634137|Drug|Afamelanotide Group 2|One 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.
45492282|NCT02358772|Other|thrombolysis in a pre-hospital setting (STEMO concept)|
45693181|NCT03803722|Device|Eyestil Protection® unidose|to demonstrate the non-inferiority of Eyestil Protection® in terms of performance and safety, when compared to Vismed® in treatment of dry eye disease.
45375352|NCT01324336|Drug|6-Mercaptopurine|75 mg/m2/dose/day
45375353|NCT00783887|Other|Blood sample|Blood sample of 5 ml
45375354|NCT01039870|Procedure|paravertebral block|postoperative pain is controlled with local analgesics delivered via PVB
45693182|NCT00758836|Drug|placebo|
45693183|NCT00758836|Drug|ibuprofen|
45693184|NCT00758836|Drug|acetominophen|
45693185|NCT00758836|Drug|telcagepant|
45693186|NCT03809806|Procedure|4-arm polypropylene mesh surgery|Pelvic reconstructive procedures were performed with the use of 4-arm mesh:upper arms through- anterior part of obturator foramens, lower arms-ischiorectal fossas and sacrospinal ligaments.
45693187|NCT03809806|Diagnostic Test|The Female Sexual Function Index (FSFI) questionnaire|patients fulfilled questionnaire before and 1 year after procedure
45693188|NCT03809806|Diagnostic Test|King Health Questionnaire (KHQ)|patients fulfilled questionnaire before and 1 year after procedure
45693189|NCT03809806|Diagnostic Test|Pelvic Organ Prolapse Quantification (POPQ) staging|Pelvic Organ Prolapse staging before and 1 year after the procedure
45693190|NCT03809806|Diagnostic Test|Postoperative questionnaire|Postoperative questionnaire assessing quality of life fulfilled by patients 1 year after procedure
45693191|NCT03809806|Diagnostic Test|The Short Form Health Survey (SF 36) questionnaire|patients fulfilled questionnaire before and 1 year after procedure
45693192|NCT03803800|Other|Classic, progressive endurance training|Moderate intensity endurance training will be performed following a sequence of 5 training sessions every 2 weeks throughout the 12-week intervention. Sessions will include 60min of cycling on a stationary bicycle. Exercise intensity will match 60-80% of the maximal heart rate (HRmax)
45375355|NCT01039870|Procedure|thoracic epidural analgesia|postoperative pain is controlled with local analgesics and fentanyl delivered via thoracic epidural catheter
45847027|NCT05443854|Behavioral|Lack of protective isolation intervention|"Protective isolation will be avoided until ICU discharge is deemed possible. Specific measures regarding nutrition (including avoidance of food consider at risk of fungal contamination) and water protection will be maintained.~Extended universal hygiene measures will be maintained and use of mask will be advocated during viral epidemic periods.~A high degree of compliance as regard to antifungal prophylaxis guidelines and local standard hygiene procedures will be advocated"
45375356|NCT00784121|Drug|Lactic Acid|Lactic Acid (Dermacyd Breeze)
45375357|NCT04047173|Radiation|stereotactic body radiotherapy (SBRT)|Radiotherapy dose is 33-54 Gy, irradiated in 3 times, every other day, completed within 1 week.
45375358|NCT04047173|Procedure|Radiofrequency ablation (RFA)|RFA with a safe margin, RFA again if residual,no more than 2 times.
45375359|NCT01324492|Drug|RAD001|
45375360|NCT01042834|Other|Air pollution study on healthy volunteers.|"The subjects are examined three times:~First the volunteers get used to equipments.~Second and third the volunteers sleep in a pollution or purified air."
45375361|NCT01039948|Biological|AV-299 + gefitinib|AV-299 is a humanized anti-HGF IgG1 monoclonal antibody directed against free HGF, ligand for c-Met tyrosine kinase receptor.
45375362|NCT01039948|Drug|Gefitinib|Gefitinib is a small molecule (drug) which selectively inhibits epidermal growth factor receptor's (EGFR) tyrosine kinase domain.
45375363|NCT00391846|Drug|Captopril|
45375364|NCT00391846|Drug|Enalapril|
45375365|NCT00391846|Drug|Lisinopril|
45375366|NCT00391846|Drug|Ramipril|
45693193|NCT03803800|Other|Periodized exercise training|Throughout the 12-week periodized intervention, subjects will perform four recurrent 3-week cycles of moderate endurance training (week 1,three sessions, 60min/session, 60-80% HRmax), high intensity interval training (week 2, three sessions, 10min/session, 3x20sec supramaximal sprint interspersed with recovery intervals of 2min), and recovery weeks (week 3, one high intense interval session as described above)
45847028|NCT05443854|Other|No systematic aminoglycosides intervention - standard arm|"Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines [3, 28, 50].~No systematic aminoglycoside therapy will be provided except in presence of predefined specific organ infection (such intra-vascular infection such endocarditis for example) or drug-resistant infection requiring aminoglycosides."
45375367|NCT00391846|Drug|Trandolapril|
45375368|NCT00391846|Drug|Bisoprolol|
45375369|NCT00391846|Drug|Carvedilol|
45375370|NCT00391846|Drug|Metoprolol succinate|
45492283|NCT02358694|Dietary Supplement|Serum-Derived Bovine Immunoglobulin|Patients who weigh less than 40 Kg will receive Serum Derived Bovine Immunoglobulin -5 g daily (2.5 g PO BID) and patients who weigh 40 Kg or more will receive Serum Derived Bovine Immunoglobulin- 10 g daily (5 g PO BID)
45492284|NCT02358694|Other|Placebo|"Matching placebo packets will be supplied and will appear identical to SBI with respect to volume, appearance and taste.~Patients who weigh less than 40 Kg will take one-half packet BID (2.5 g BID) Patients who weigh 40 Kg or more will take one packet BID (5 g PO BID)."
45693194|NCT03803800|Dietary Supplement|beta-alanine|Some subjects will receive the ergogenic supplement beta-alanine.
45693195|NCT04384432|Other|Routine Physical Therapy with Thoracic mobility exercise|Combınatıon of routıne Routine Physical Therapy with Thoracic mobility exercise
45693196|NCT04384432|Other|Routıne Physıcal therapy|Exercise for Chronic Neck Pain
45693197|NCT01786993|Device|MultiPoint Pacing|Subjects are programmed to MPP between 3 and 9 months. MPP programming is stipulated by the Echocardiographic measurements (e.g. EA VTI) during an acute hemodynamic assessment at the 3-month visit in the MPP IDE study.
45693198|NCT01786993|Device|Traditional Biventricular Pacing|Subjects are programmed to Quadripolar BiV pacing between 3 and 9 months using any of the 10 vectors available.
45375371|NCT00391846|Drug|Candesartan|
45375372|NCT00391846|Drug|Valsartan|
45375373|NCT00391846|Drug|Eplerenone|
45375374|NCT00391846|Drug|Spironolactone|
45375375|NCT00391846|Drug|Diuretics|
45375376|NCT00391846|Drug|HF treatment according to Swedish guidelines|
45375377|NCT00391846|Procedure|Blood samples|
45375378|NCT00391846|Procedure|The Kansas City Cardiomyopathy Questionnaire (KCCQ)|
45375379|NCT00448630|Other|No intervention|Non-interventional study
45375380|NCT01042990|Other|Adaptive Physical Activity|Structured gait, balance, and progressive walking program performed in a group gym setting 3x/week for 6 months
45375381|NCT00534248|Biological|Zoster Vaccine, Live (Zostavax™)|A single dose 0.65 ml Zostavax™ (Live, attenuated Zoster Vaccine) was administered by subcutaneous injection on Day 1.
45375382|NCT00534248|Biological|Comparator: Placebo|A single dose of 0.65 ml Placebo (A vaccine stabilizer of Zostavax™ with no live virus) was administered by subcutaneous injection on Day 1.
46054063|NCT02801955|Procedure|sampling of peritoneal washing aspirate|After thoroughly examination of the peritoneal cavity revealing the absence of peritoneal dissemination, the peritoneal cavity was washed with 200 ml of saline, and at least one third was aspirated from several regions of the peritoneal cavity, including near the primary tumor, the left and right subphrenic areas and the pouch of Douglas with suction tubes to a clean bottle and designated as the peritoneal sample for determination of peritoneal levels of CEA and CA 19-9.
45492285|NCT04473807|Drug|Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients with Atrial Fibrillation|The hypothesis to be tested is that the intravenous loading regimen followed by oral sotalol administration 4 hours after the conclusion of the IV infusion (every 12 hours thereafter) will result in sotalol peak concentrations at the end of IV loading dose (IV to oral loading) which are comparable to the steady state and maximum QTc seen on Day 3 after the last in-hospital oral dose.
45492286|NCT02323659|Drug|Methotrexate|Methotrexate 20mg per dose, administered orally, once every week
45375383|NCT00994136|Drug|normal saline|Ten milliliters of normal saline will be injected at the end of the intravenous therapy. Injection is performed with the start/stop method and with the positive pressure technique (clamping the catheter while injecting the last milliliters of normal saline)
45375384|NCT00997724|Procedure|a-VATS|In brief, general anesthesia with selective lung ventilation was performed with the use of a double-lumen endotracheal tube. When postoperative mechanical ventilation was necessary, a standard endotracheal tube was substituted for the double-lumen tube. Patients were placed in the lateral decubitus position. Two thoracoports were placed in the sixth or seventh intercostal space (ICS) on the anterior axillary line and in the seventh or eighth ICS on the posterior axillary line; an anterolateral minithoracotomy (7 cm) was made in the fourth ICS for an upper lobectomy or in the fifth ICS for a middle or lower lobectomy.
45375385|NCT00997802|Device|CT colonography and optical colonoscopy|All patients will undergo CT colonography and optical colonoscopy.
45375386|NCT00391768|Drug|oseltamivir (Tamiflu®)|Oseltamivir is supplied as a white powder blend for constitution to a suspension. It is supplied in 100 ml amber glass bottles with 30 grams of powder for oral suspension, a plastic adapter, a plastic oral dispenser and a plastic measuring cup. Initially subjects in Cohort I received oseltamivir 30 mg orally twice daily for 5 days. The DSMB recommended on 05-Aug-2009 that weight based dosing of oseltamivir for subjects subsequently enrolled in Cohort I. Based on pharmacokinetic data available as of that date, the initial weight-based dose to be evaluated for Cohort I is 3.5 mg/kg twice a day. Cohort II and Cohort III will receive oseltamivir at 3.0 mg/kg/dose orally twice daily for 5 days. Cohorts IV and V will receive 3.0 mg/kg/dose orally twice daily for 5 days, this dose may be adjusted.
45375387|NCT00391222|Drug|Olanzapine|Intramuscular injections of placebo every 2 weeks and oral olanzapine 10 mg daily
45375388|NCT00391222|Drug|Placebo|Intramuscular injections of placebo every 2 weeks and oral placebo daily
45375389|NCT00391222|Drug|Risperidone Long Acting Injectable (LAI)|Intramuscular injections of risperidone LAI (25, 37.5, or 50 mg) every 2 weeks and oral placebo daily
45375390|NCT01043068|Drug|Cancer pain management|Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
45375391|NCT00409006|Drug|Pemetrexed|500 milligrams per meter squared (mg/m2), administered by intravenous (IV) infusion every 21 days for 4 cycles (1-4) or 500 mg/m2, IV, every 21 days until disease progression or unacceptable toxicity.
45375392|NCT00409006|Drug|Cisplatin|75 mg/m2, IV, every 21 days for 4 cycles (1-4) or 75 mg/m2, IV, every 21 days for 4 cycles with optional continuation for 2 additional cycles until disease progression or unacceptable toxicity
45375393|NCT00409006|Drug|Gefitinib|250 mg, administered orally once daily beginning at Cycle 5 until disease progression or unacceptable toxicity
45375394|NCT00534092|Device|X STOP® Interspinous Process Decompression System|The X STOP is a titanium implant that fits between the spinous processes of the lumbar spine. It is made from Ti-6AI-4V Eli titanium alloy (ISO 5832/3) and consists of two components: a spacer assembly and a wing assembly.
45375395|NCT00997880|Drug|Rosuvastatin calcium 40mg|Rosuvastatin calcium 40mg
45375396|NCT00997880|Drug|Rosuvastatin calcium10mg|Rosuvastatin 10mg
45375397|NCT00408928|Drug|Bortezomib|Bortezomib at 1.3 mg/m2/dose given twice weekly for two weeks followed by a 10-day rest period. If patients have a complete response, they will receive additional cycles of bortezomib.
45375398|NCT00997958|Drug|Mycophenolate mofetil|"Dose escalation increasing successively from 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 5.0 grams p.o. bid.~Each patient will be treated for eight weeks (56 days)."
45492287|NCT02323659|Drug|Interferon Alfa-2b|Interferon Alfa-2b 3 million international units (MIU), administered 3 times per week
45492288|NCT01372527|Other|TopCare: Use of provider knowledge vs. automated system|We will be evaluating the system in practices where providers are involved in determining to contact a patient, including the most appropriate outreach method, compared with practices where the system is fully automated without provider input.
45492289|NCT02358460|Device|Ventilation delivered by SLE5000 ventilator|"In pressure-limited ventilation arm, ventilator settings as required to maintain appropriate oxygenation and carbon-dioxide elimination.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits."
45693199|NCT00769600|Drug|Itraconazole|Itraconazole 200 mg once daily
45693200|NCT00769600|Drug|Pemetrexed|Pemetrexed every 21 days.
46054064|NCT02793843|Drug|Ondansetron (Zofran)|Intravenous administration of 4 mg ondansetron 15 minutes before spinal anesthesia
46054065|NCT02793843|Drug|Dexamethasone (Decadron)|Intravenous administration of 8 mg dexamethasone 15 minutes before spinal anesthesia
45375399|NCT00998036|Drug|Temsirolimus|"Temsirolimus will be administered intravenously weekly on days one and eight of a three week cycle. Temsirolimus will not be given on week three (usually dosed weekly) for increased tolerability given its possible plasma accumulation during week three. Temsirolimus will be given second over a 30 minute infusion during posthydration.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Temsirolimus 15mg~Dose Level 2: Temsirolimus 15mg~Dose Level 3: Temsirolimus 25mg"
45375400|NCT00998036|Drug|Cisplatin|Cisplatin at 30mg/m2 will be administered intravenously weekly on days one and eight of a three week cycle. Cisplatin will be given first over a 30 minute infusion with prehydration.
45375401|NCT00998036|Drug|Erlotinib|"Erlotinib will be taken by mouth daily starting at 100mg. On days of cisplatin and temsirolimus infusions, erlotinib should be taken at least two hours after the beginning of the temsirolimus infusion.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Erlotinib 100mg~Dose Level 2: Erlotinib 150mg~Dose Level 3: Erlotinib 150mg"
45492290|NCT04422249|Procedure|laparoscopic middle hepatic vein guidance anatomic hemihepatectomy|95 patients with primary HCC were divided into the middle hepatic vein guidance group(n=45) and the traditional group(n=45) according to the odd and even Numbers, and sealed into envelopes.Outcomes were monitored and evaluated during the 3-year follow-up period
45492291|NCT02368834|Behavioral|psychoeducation|The intervention included a presentation by a psychiatrist, with parent manual provided, and then two group sessions at the 2nd and 4th weeks to address further concerns of the parents
45492292|NCT03634059|Drug|Apatinib|apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po
45492293|NCT02358382|Drug|pH Stat|pH stat blood gas management - increased carbon dioxide content of administered gas mixture.
45492294|NCT03633981|Other|clinical examinations|"Collection of data from the following tests at H0 (as soon as the ECLS is put in place), H12 (within 12 hours following stabilisation of the dynamic state), H24 and every day until complete neurological recovery:~right and left pupillometry (3 times)~BIS values~right and left NIRS values~right and left transcranial Doppler~neurological clinical examination"
45375402|NCT05309876|Behavioral|Lifestyle tool|Regular use of the digital Lifestyle tool
45375403|NCT05254808|Drug|Fosfomycin|Fosfomycin is a phosphoenolpyruvate (PEP) analogue that is produced by Streptomyces spp. It has a bactericidal action, primarily by inhibiting bacterial cell wall (peptidoglycan) synthesis. In the Netherlands, Fosfomycin is orally available as fosfomycin-trometamol (Monuril). Fosfomycin-trometamol is identical to fosfomycin-tromethamine. Fosfomycin-trometamol is a phosphoric acid derivative of fosfomycin, available in a single dose sachet containing white granules. One sachet contains 5.63 g of fosfomycin-trometamol, corresponding with 3000mg fosfomycin.
45492295|NCT03633981|Other|neurological assessment when a neurological event occurs|"next neurological event:~seizures~pupillary asymmetry~myoclonias~brain stem reflex abnormalities~osteotendinous reflex abnormalities"
45492296|NCT03633981|Other|mortality assessment|to 28 days
45492297|NCT02358304|Drug|nasal spray calcitonin|recurrence rate of aggressive CGCG will be recorded after the use of nasal spray calcitonin
45492298|NCT02358304|Drug|Placebo|
45492299|NCT02363218|Radiation|CyberKnife|Patients will undergo a CT scan with and without contrast and MRI scan for radiation treatment planning and target delineation.SBRT will be delivered on the CyberKnife with Synchrony Respiratory Tracking capabilities. The tumor will be tracked with 3 implanted fiducial seeds for targeting. Treatment will be delivered in 3 fractions within a 7 day window at the discretion of the investigator.
45492300|NCT01319955|Biological|Trivalent inactivated influenza vaccine|Two doses of 0.25 ml vaccine delivered IM at least 4 weeks apart.
45492301|NCT02363530|Device|Hydroxypropyl ethylcellulose (HPMC) 2% gel|We use the hydroxypropyl ethylcellulose (HPMC) 2% gel instead of the traditional balanced salt solution during the cataract surgery.
45492302|NCT02363530|Device|BSS|Balanced Salt Solution including normal saline and glucose
45492303|NCT01316523|Drug|Rituximab|Rituximab 375 mg/m2/wk x 4 weeks, to begin Day 15 of cycle 1. After 4 cycles of therapy if patient does not respond to treatment, the patient will receive a second course of Rituximab.
45492304|NCT01316523|Drug|Lenalidomide|Lenalidomide will be taken at 20 mg daily, days 1-21 of a 28 day cycle, to be continued until the disease progresses, there are too many side effects, or after twelve cycles if the patient responds to treatment.
45492305|NCT02363140|Other|Will undergo a single MRI assessment with intravenous dye|
45492306|NCT02363140|Other|pre and post surgery MRI scan|
45492307|NCT02362906|Drug|Xiyanping injection|ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection
45492308|NCT02362906|Drug|wind-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
45375404|NCT05254808|Drug|Nitrofurantoin|Nitrofurantoin belongs to the group of nitrofuranes. Both nitrofurantoin and its metabolites have antibacterial activity, which is enhanced under acidic conditions. Nitrofurantoin is reduced to (active) metabolites by bacterial enzymes. These metabolites inhibit bacterial enzymes that are essential for energy metabolism and inhibit bacterial protein synthesis by binding to ribosomes. Active therapeutic concentrations are only reached in urine and not in other tissues. Several manufacturers produce generic nitrofurantoin in the solid oral form. Three different formulations exist: a macrocrystalized form, nitrofurantoin monohydrate (microcrystals) and a mixture of macrocrystals (75%) and monohydrate 25%) contained in a delayed-release gel matrix (Furabid®) In this trail only Furabid® will be used. Macrocrystals are slower dissolved and absorbed in comparison to the monohydrate.
45375405|NCT02275286|Drug|Trabectedin|"Escalating or deescalating dose of 1.3 or 1.5mg/m2, i.v 24h, once every 3 weeks.~Cohort A: unlimited cycles. Cohort B: 3 cycles. Cohort C: 3 cycles. Cohort D: cycles of trabectedin will be provided and patients will subsequently be evaluated for surgery."
46054066|NCT02793843|Other|Spinal anesthesia|Intrathecal anesthesia by 10 mg hyperbaric marcain, 5 mcg sufentanyl and 150 mcg morphine using 27 G spinal needle (27 G Quincke needle)
45492309|NCT02362906|Drug|phlegm-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
45375406|NCT02275286|Radiation|Radiotherapy|3D conformal radiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT) providing: Cohort A: 30Gy in 10 fractions (3Gy/fraction). Cohort B: 45Gy in 25 fractions (1.8Gy/fraction). Cohort C: 45Gy in 25 fractions (1.8Gy/fraction). Cohort D: 45Gy in 25 fractions (1.8Gy/fraction).
45492310|NCT02362906|Drug|Fu-xiong San|external application; 8-10 cm wide, 0.3-0.5 cm thick;10 mins for patient aged 1 to 3-year old; 15 mins for those aged 3 to 5-year old; once daily
45492311|NCT02362906|Drug|second generation cephalosporin|
45693201|NCT05743894|Device|Symplicity Spyral RENAL DENERVATION (RDN) SYSTEMTM Livewire™ Reflexion™ Catheter|Renal sympathetic denervation (RDN) was considered an effective alternative for patients whose blood pressure (BP) is not optimally controlled. The RDN works mainly by selectively ablating the sympathetic fibres around the renal arteries and damping the sympathetic overdrive. Blood pressure response by renal nerve stimulation (RNS) during the RDN procedure using the previous generation of the Symplicity Flex catheter have been reported to be potential parameter to assess the intra-procedure efficacy and predict the BP response 6 months after RDN
45492312|NCT02362906|Drug|Erythromycin|ivd. 30 mg/(kg•d), plus 5% Glucose Injection, 80 to 500 ml, ivd. Once a day injection
45492313|NCT02362906|Drug|Azithromycin|ivd. 10 mg/(kg•d), plus 5% Glucose Injection, 100 to 500 ml, ivd. Once a day injection
45492314|NCT02368912|Drug|ASP1707 single dose of dose levels 1 -7|Oral, dose escalation
45492315|NCT02368912|Drug|Placebo single dose of dose levels 1-7|Oral, dose escalation, healthy young male
45492316|NCT02368912|Drug|ASP1707 single dose fasted|Oral, healthy young male
45492317|NCT02368912|Drug|ASP1707 single dose fed|Oral, healthy young male
45492318|NCT02368912|Drug|ASP1707 multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
45492319|NCT02368912|Drug|Placebo multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
45693202|NCT03809650|Drug|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
45693203|NCT01966445|Biological|GSK2849330|Solution containing 100 mg/millilter (mL) GSK2849330 for intravenous infusion
45492320|NCT02368912|Drug|ASP1707 multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
45492321|NCT02368912|Drug|Placebo multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
46054067|NCT02793687|Drug|MEXIDOL® (ethylmethylhydroxypyridine succinate)|
46054068|NCT02793687|Other|Placebo|
46054069|NCT02801487|Radiation|Carbon ion radiotherapy (CIRT)|Five dose levels (52.5GyE, 55GyE, 57.5GyE, 60GyE, 62.5GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 62.5 GyE are safely delivered, the recommended dose (or 62.5 GyE) will be the prescribed dose in the Phase II part of the study. Ninety-five percent (95%) of the isodose line should cover the GTV+3~5mm.
46054070|NCT02801487|Drug|Cisplatin|Cisplatin (40mg/m^2) monotherapy will be given weekly along with radiotherapy.
45492322|NCT02368912|Drug|ASP1707 parallel multiple dose of dose levels 1-3|Oral, multiple dose, healthy pre-menopausal female
45375407|NCT04000412|Device|CardioZ multifrequency impedance recording system|Patients will be submitted to mapping of both voltage and tissue impedance. The accuracy of the two maps identifying the extent and transmurality of the infarction will be assesssed by gadolinium imaging.
45492323|NCT02368912|Drug|Placebo parallel multiple dose|Oral, dose escalation, healthy pre-menopausal female
45375408|NCT00998114|Behavioral|Exercise|Aerobic exercise for 30-45 minutes five times a week for six months
45375409|NCT00998192|Biological|REOLYSIN|3x10E10 TCID50 1 hour intravenous infusion, administered on Days 1,2,3,4,and 5 of a 21-day cycle
45375410|NCT00998192|Drug|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
45375411|NCT00998192|Drug|Carboplatin|6 AUC mg/mL min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
45375412|NCT00998270|Procedure|Autologous bone marrow transplantation|"Autologous transplantation:~Endoxan (for mobilization) Dose: 2.5 g/m2 IV Time: -11 Duration: 1 day~G-CSF (Neupogen) Dose: 0.5 micg/kg subcutaneous Time: -6 to -3 Duration: 4 days~Melphalan Dose: 100 mg/m2 IV Time: -2 and -1 Duration: 2 days"
45375413|NCT00998270|Procedure|Allogeneic bone marrow transplantation|"Allogeneic~Melphalan Dose: 70 mg/m2 IV Time: Duration: 2 days~Fludarabine Dose: 30 mg/m2 IV Time: Duration: 5 days"
45492324|NCT03160144|Procedure|open lung approach|
45492325|NCT04059796|Device|Omega Gemini III Rev 2 Device|Eyes randomized to receive the Gemini III Rev 2 device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction
45492326|NCT04059796|Device|Control Eye|Control eyes will receive an approved monofocal or toric IOL post cataract extraction
45492327|NCT02362984|Drug|Placebo|Placebo of DLBS1033 will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
45693204|NCT03809494|Device|HemaTrate™ Blood Filtration system|Anticoagulated whole blood is loaded into the filtration system. During gravity filtration, the majority of platelets, plasma, and red blood cells pass through the filter into a filtrate bag. The TNCs are captured in the filter material and recovered via a back-flush with 0.9 % saline into a syringe.
45492328|NCT02362984|Drug|DLBS1033|DLBS1033 enteric-coated tablets will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
45492329|NCT02362750|Other|Organizational Interview|Survivorship program leaders will participate in a phone-based organizational interview regarding the organization of the clinical survivorship care program.
45492330|NCT02362750|Other|Organizational Survey|Survivorship program leaders will participate in a brief web-based organizational survey regarding the organization of the clinical survivorship care program.
45492331|NCT02362750|Other|Survivor Survey (1): Pre-Visit Baseline|Survivors will participate in a baseline survey regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
45492332|NCT02362750|Other|Survivor Survey (2): Post-Visit|Survivors will participate in a survey within one week after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
45375414|NCT00998348|Behavioral|Parenting Program|The parenting program is an 8-month intervention for parents with preschool-age children designed to teach strategies and skills that help parents better manage their day to day stresses of parenting while also promoting healthy lifestyle behaviors. Topics will include stress management, child management, family routines, emotion regulation, and coparenting. In later sessions parents will be encouraged to draw on these general parenting skills to promote healthier nutrition and physical practices at home. The intervention will be delivered through in-person group sessions (n=12) and tailored one-on-one telephone calls (n=11). A complementary child program will be delivered to children while parents are attending the group sessions.
45375415|NCT03742856|Combination Product|A multi-omics analysis|A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics.
45693205|NCT03809494|Other|Saline|Normal (0.9%) saline
45375416|NCT00994526|Other|Ham|Ham : 180 g per day during 4 days
45375417|NCT00994526|Other|Ham + calcium|Ham : 160g/d during 4 days calcium : 1000mg/d during 4 days
45375418|NCT00994526|Other|Ham + vitamin E|Ham : 160g/d during 4 days Vitamin E : 80 mg/d during 4 days
45375419|NCT00998504|Dietary Supplement|resVida|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
45375420|NCT00998504|Dietary Supplement|placebo|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
45375421|NCT00788684|Drug|rituximab|IV infusion once weekly for four doses
45375422|NCT00788684|Drug|ABT-263|ABT-263: oral solution or tablets, once daily dosing until disease progression
45375423|NCT00454220|Other|Placebo|33 patients to placebo + 131-I arm
45375424|NCT00454220|Drug|MRrhTSH|33 patients to 0.01 mg MRrhTSH + 131-I arm
45375425|NCT00454220|Drug|MRrhTSH|33 patients to 0.03 mg MRrhTSH + 131-I arm
45375426|NCT05219552|Behavioral|personalized lactation support|Our intervention design aims to address food insecurity and mental health by providing an unconditional cash transfer and lactation support across the perinatal period, when women are out of the workforce caring for their infant child. The study will include pregnant women living with HIV in Kisumu Kenya. The lactation support component will focus on milk insufficiency primarily as that has been a main concern of women we've worked with in this population, in addition to general breastfeeding support which will all be delivered in one-on-one sessions with a professional lactation consultant. The cash transfer will be delivered to women from their third trimester to 6 months postpartum. The amount of the cash transfer is based on preliminary data and consultation with key stakeholders to determine a reasonable and sufficient amount to basic living expenses during this period.
45375427|NCT00998972|Drug|N-acetylcysteine|600 mg intravenous before and 2 hours after cerebral arteriography
45375428|NCT00390910|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
45375429|NCT00390910|Biological|Infanrix hexa|Intramuscular injection, 3 doses
45375430|NCT00998816|Drug|Pregabalin|pregabalin capsules (150mg,oral) will be administered 1 hour before lateral thoracotomy, 12 hours after the thoracotomy and then 12 h BID for 10 additional days.
45375431|NCT05219084|Drug|hip denervation|Lidocaine 2% 2ml was injected into each genicular nerve
45375432|NCT05219084|Drug|intra-articular hydration|10 ml; of normal; saline were injected inside the hip joint
45375433|NCT05219084|Drug|Combined group|hip denervation and intra-articular hydration were conducted together
45375434|NCT05219084|Drug|Control group|Normal; saline was injected subcutaneously
45375435|NCT05133908|Behavioral|Sleep Hygiene and Self-Monitoring Control|An app with self-monitoring function and videos and written materials about sleep hygiene will be provided.
45375436|NCT05133908|Behavioral|dCBTi-ADHD|The dCBTi adopts a multi-module approach, consisting of 7 weekly modules including psychoeducation on sleep and ADHD, insomnia, organization strategies and distractibility reduction skills, sleep hygiene, sleep restriction and prescription, circadian-related activity scheduling, stimulus control, relaxation and worry time, cognitive restructuring, and relapse prevention. In each module, participants will watch short videos to learn strategies to improve their sleep. A virtual coach is also included in the app functionality. It will be in the form of a text-based forced-choice conversation bot. It will initiate conversations with the users to check their understanding of treatment materials and guide them to come up with specific action plans to implement the treatment strategies.
45382264|NCT05151887|Other|Muscle protein synthesis|The meals contain a total of 0.45 g protein/kg body mass (36 g protein for an 80 kg person). To account for differences in body mass, the investigators will scale the meal content to ensure 0.45 g/kg body mass for different body mass ranges (i.e., 65-75 kg, 75-85 kg, etc.). As such, carbohydrate, fat, and total energy content of the meals will also be scaled to body mass. The test meals are composed out of regular whole food items which will be purchased from local shops. The muscle protein synthetic response following meal ingestion will be assessed by the use of stable isotope tracer methodology
45492333|NCT02362750|Other|Survivor Survey (3): 3 Month Post-Visit|Survivors will participate in a survey three months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
45375437|NCT00999050|Procedure|Gastric bypass for diabetic patients <35 BMI|The operation is performed under general anesthesia. It is done laparoscopically, meaning that several small openings are made in the abdomen for insertion of long, thin surgical instruments, one with an attached camera. The operation is video monitored. The top of the stomach is divided across, leaving a small pouch for food. The rest of the stomach remains but can receive no food. The gut is divided just past the stomach, and it is attached to the small stomach pouch so that food can get back into the bowel. A second connection is made so that the bile and digestive juices pass into the bowel with the food.
45375438|NCT00533702|Biological|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
45375439|NCT00533702|Drug|Dacarbazine|1000 milligrams/square meter (mg/m2) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
45375440|NCT00408694|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
45375441|NCT00408694|Biological|Bevacizumab|Given IV
45375442|NCT00408694|Drug|Cisplatin|Given IV
45375443|NCT00408694|Drug|Fluorouracil|Given IV
45375444|NCT00408694|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
45375445|NCT05239754|Other|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula and at least 2 hours of career readiness workshops over the course of 9 weeks. Participants also receive ongoing job readiness support and post-employment support.
45375446|NCT03993340|Device|Rescue stenting|The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, modern endovascular thrombectomy using a stent retriever, contact aspiration thrombectomy, or both are allowed. The number of thrombectomy attempts is at the operator's discretion. After failure of standard thrombectomy procedure, rescue stenting with Solitaire will be done. Additional balloon angioplasty, glycoprotein IIb/IIIa inhibitor (GPI), or thrombolytic infusions are optional and at the operator's discretion. After successful recanalization with rescue stenting, intravenous maintenance of GPI at least for a 12 hours and then changed to oral antiplatelet are recommended.
45375447|NCT00999128|Drug|GDC-0941|Oral repeating dose
45375448|NCT00999128|Drug|rabeprazole|Oral repeating dose
45375449|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
45375450|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
45375451|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
45375452|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
45375453|NCT00999284|Drug|ZK200775|Intravenous infusion of 0.3 mg/kg/h of ZK200775 over a period of 4 hours.
45375454|NCT00999284|Drug|ZK200775|Intravenous infusion of 0.75 mg/kg/h of ZK200775 over a period of 4 hours.
45375455|NCT00999284|Drug|Sodium Chloride|Intravenous infusion of sodium chloride over a period of 4 hours.
45375456|NCT01043224|Drug|Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle|Once daily application
45375457|NCT01044238|Drug|methylphenidate|18mg/day in week 1; 36mg/day in week 2; 54mg/day in week 3 - participants randomized to either active medication (methylphenidate) or placebo matched to active drug
45375458|NCT01044238|Drug|Methylphenidate|18mg/day for week 1; 36mg/day for week 2; 54mg/day for remainder of study - participants randomized to either active medication (methylphenidate) or placebo
45492334|NCT02362750|Other|Survivor Survey (4): 6 Month Post-Visit|Survivors will participate in a survey six months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
45492335|NCT02362750|Other|Clinician Survey|Survivorship program clinicians will complete a survey for each survivor who enrolls in the study indicating services provided through the survivorship visit.
45375459|NCT01043380|Drug|Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]|Zetia 10 mg/dl + Lipitor. The dosage of Lipitor will be titrated up to a maximum of 20 mg/day with a treatment goal of lowering LDL-C below 70 mg/dl.
45375460|NCT01043380|Drug|Lipitor (Atorvastatin) monotherapy|The dosage will be titrated up to a maximum of 20 mg/day, which is the highest approved regimen by the Ministry of Health, Labor and Welfare of Japan, with a treatment goal of lowering LDL-C below 70 mg/dl.
45375461|NCT01044316|Biological|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines - a monovalent glycoprotein-conjugated (diptheria toxin - CRM197) vaccine and a tetanus toxoid-conjugated vaccine.
45375462|NCT01044394|Drug|polyethylene glycol (PEG-ELS) and bisacodyl tablets|2 liters of PEG-ELS and 10mg of bisacodyl tablets once the morning of the colonoscopy
45375463|NCT01040104|Other|Skin sample|Taken from regularly discarded tissue during routine operation
45375464|NCT01040104|Other|Skin biopsy|Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
45375465|NCT01040104|Other|Skin biopsy|Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
45375466|NCT01040104|Other|Blood taking|Blood taking on day 0
45375467|NCT01040104|Other|Blood taking|Blood taking on day 90
45375468|NCT01043458|Drug|ABT-126|ABT-126 Low Dose & ABT-126 High Dose
45375469|NCT01043458|Drug|Placebo for ABT-126|Matching Placebo for Arms 1 & 2
45375470|NCT00396136|Device|Corox OTW Steroid Left Ventricular Lead|This is a registry: no study required interventions necessary.
45375471|NCT00530894|Device|Edwards SAPIEN Transcatheter Heart Valve|
45375472|NCT00530894|Device|Surgical Valve Replacement|
45375473|NCT00530894|Other|medical management and/or balloon aortic valvuloplasty|
45492336|NCT02368678|Procedure|Scaling and Root Planning (SRP)|"Scaling and Root Planing (n=15): quadrant-wise scaling and root planing performed within four weekly session (30 min. per quadrant).~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants."
45492337|NCT02368678|Procedure|Full Mouth Scaling (FMS)|"Full Mouth Scaling (n=15): scaling and root planning was performed in a single stage (within 24 hours); two sessions (60 min. per session) in two consecutive days.~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants."
45492338|NCT04497220|Behavioral|Negative Connotation Langauge|"The study intervention consists of two separate scripts read to the patient by the anesthesiologist performing their labor epidural. The control script includes language containing the wording Poke and a burn said prior to numbing medication for the epidural procedure. There will be no difference in the epidural placement, medications, or the rest of the script."
45492339|NCT04497220|Behavioral|Positive Connotation Language|"The study intervention consists of two separate scripts read to the patient by the anesthesiologist performing their labor epidural. The experimental script includes language containing the wording this is numbing medication, which will make the rest of the procedure go easier said prior to numbing medication for the epidural procedure. There will be no difference in the epidural placement, medications, or the rest of the script."
45492340|NCT04469530|Drug|Sirolimus|Sirolimus is given at a dose of 2 mg/m2 once daily. The amber oral dose syringe should be used to withdraw the prescribed amount of sirolimus oral solution from the bottle. The solution can be drunk or administered at once to assure delivery of all of the medication. It is safe for administration through a nasogastric or G-tube. For tablets, the tablet should not be crushed, split, or otherwise altered. As with the liquid dosing form, the tablets should be given within two hours each day and should be at consistent intervals with regard to meals.
45492341|NCT04469530|Drug|Cyclophosphamide|"A synthetic antineoplastic drug chemically related to the nitrogen mustards. The drug is administered orally daily, in the formulation appropriate for age.~The solution should be diluted in 20-30 ml of appropriate liquid before administration through nasogastric (NG) tube or gastrostomy (G) tube, with adequate flushing after administration to prevent obstruction of the feeding tube."
45492342|NCT04469530|Drug|Etoposide|A semisynthetic derivative of podophyllotoxin which functions as mitotic inhibitor but does not interfere with microtubular assembly. The drug is administered orally daily, in the formulation appropriate for age.
45492343|NCT04469530|Drug|Celecoxib|The drug is administered orally daily, in the formulation appropriate for age.The solution is safe for administration through a nasogastric or G-tube.
45492344|NCT02358226|Behavioral|Soccer League (SL)|Participants will be invited to attend soccer practice in the late afternoons, roughly 2-3 times per week. Competitive games will be held on Saturdays so that friends and family may attend. Using a mobile phone application, coaches will regularly record information on participants' arrival and departure times, sportsmanship, volunteering in the community, the results of saliva tests for drugs and alcohol. The SL intervention arm will last for one year.
45492345|NCT02358226|Behavioral|Soccer League/Vocational Training (SL-V)|In addition to the SL intervention, participants will gain access to vocational training. The Vocational Training will take place through the Silulo or Zenzele programs based in Khayelitsha for a period of 6 months. These programs offer practical and market-related training in computer skills, woodwork, or welding. The SL-V intervention arm will last for one year; with six months dedicated to soccer and six months dedicated to vocational training.
45492346|NCT02368600|Behavioral|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
45375474|NCT00300898|Procedure|Nucleoplasty|
45375475|NCT00300898|Procedure|Percutaneous decompression|
45375476|NCT00300898|Procedure|Intervertebral electrothermal disc decompression (IDET)|
45375477|NCT00300898|Behavioral|Conservative treatment|
45375478|NCT03474094|Combination Product|Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery|"W1,W2, W3, W4 & W5: RADIOTHERAPY. A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.~W6 and W9: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval~W11: SURGERY. Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent"
45375479|NCT03474094|Combination Product|2 cycles of atezolizumab followed by surgery then post-operative radiotherapy|"W1 and W4: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval~W6: SURGERY Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent~W7, W8, W9, W10 & W11: RADIOTHERAPY A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized."
45375480|NCT03474094|Combination Product|Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.|"W1,W2, W3, W4 & W5: RADIOTHERAPY A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.~W6: SURGERY Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent~W11 and W14: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval"
45375481|NCT01004120|Dietary Supplement|Bimuno|5.5g daily intake
45375482|NCT01004120|Dietary Supplement|Maltodextrin|5.5g daily intake
45375483|NCT01043536|Radiation|radiotherapy|patients will receive from 6 to 7 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
45492347|NCT03085914|Drug|Epacadostat|Epacadostat oral twice-daily continuous daily dosing at the protocol-defined dose.
45375484|NCT01043536|Drug|temozolomide|patient will receive whatever the level 7 days a week, temozolomide at the dose of 75mg/m2 during radiotherapy period. They will then follow one month after the end the radiochemotherapy an adjuvant treatment corresponding to a 5 days treatments of temozolomide at the dose of 200mg/m2 every 28 days.
45492348|NCT03085914|Drug|Pembrolizumab|Pembrolizumab
45492349|NCT03085914|Drug|Oxaliplatin|Oxaliplatin
45492350|NCT03085914|Drug|Leucovorin|Leucovorin
45492351|NCT03085914|Drug|5-Fluorouracil|5-Fluorouracil
45492352|NCT03085914|Drug|Gemcitabine|Gemcitabine
45492353|NCT03085914|Drug|nab-Paclitaxel|nab-Paclitaxel
45492354|NCT03085914|Drug|Carboplatin|Carboplatin
45492355|NCT03085914|Drug|Paclitaxel|Paclitaxel
45847029|NCT05443854|Other|Protective isolation intervention - standard arm|"Protective isolation will be provided systematically as currently practiced in participating centers. Modality will be in line with recent SRLF guidelines, we will recommend for the patients to receive an isolation the maximal available isolation with the aim to provide:~High-efficiency air filtration [filtration of 99.7% of particles greater than or equal to 0.3 µm; International Organization for Standardization (ISO) class 5 or better]~Geographical isolation in an individual room~Technical isolation, including a face mask and a cap. This approach of isolation will however be pragmatic on the basis of the best available level of isolation in line with recommendation, while not delaying ICU admission and patients' care"
45492356|NCT03085914|Drug|Pemetrexed|Pemetrexed
45492357|NCT03085914|Drug|Cyclophosphamide|Cyclophosphamide
45492358|NCT03085914|Drug|Carboplatin|Carboplatin
45492359|NCT03085914|Drug|Cisplatin|Cisplatin
45492360|NCT03085914|Drug|5-Fluorouracil|5-FU
45492361|NCT03085914|Drug|Investigator's choice of platinum agent|Investigator's choice of platinum agent: carboplatin or cisplatin
45492362|NCT02357680|Other|Diary|"The intervention is a notebook in which the relative will be asked to keep a diary of the time when the patient is critically ill in the ICU. At least two photos of the patient will be added to the diary upon full consent from the patient.~The diary contains a written description on how to use the diary during and after the patients stay in the ICU."
45492363|NCT01736956|Procedure|Fetal Aortic Valvuloplasty|Fetuses in the intervention group will undergo in utero balloon aortic valvuloplasty via a transuterine, perventricular approach. Fetuses in the control group will have no invasive intervention while in utero.
45375485|NCT01004198|Drug|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
45375486|NCT01004198|Drug|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
45375487|NCT01004198|Drug|Ringers Lactate solution|Ringers Lactate solution for Injection
45375488|NCT01004276|Other|New, improved smoking cessation management module|The intervention that will be tested is an improved smoking cessation management module in an existing chronic disease management system, P-PROMPT CDMS. This module includes the following components: a) the Patient Care Status and Update Form, b) the smoking registry and c) patient prompts.
45492364|NCT01081288|Other|Invitation for breast screening|Invitation for breast screening to women in different age groups
45492365|NCT02467608|Drug|Isoniazid with HUEXC030 and RZE|Subjects will receive oral study drug daily in accordance with the following regimen, that is, INH, RMP, PZA, and EMB for the first 2 months followed by INH, RMP and EMB (if medically indicated) daily for 4 additional months
45375489|NCT03742778|Behavioral|Incentivizing reflection|Participants receive bonus incentives for reflecting on their workouts
45492366|NCT02467608|Drug|HRZE|the same as experimental group,without the excipient of HUEXC030 only
45492367|NCT02368288|Drug|entecavir|in this group, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 week.
45492368|NCT01380054|Behavioral|Evaluation of quality of life|-Psychological interviews-Questionaires : HAD, STAI, CHIP, MHLC, WCC, SSQ scales-Quality of life : SF-36
45492369|NCT01063114|Radiation|proton beam radiation|Given once a day, 5 days a week (Monday-Friday)
45492370|NCT02450136|Drug|pazopanib|
45375490|NCT03742778|Behavioral|Incentivizing exercise|Participants receive bonus incentives for exercising
45492371|NCT02357524|Drug|Oritavancin|
45492372|NCT05421312|Drug|sampling blood|During the reimplantation, 3 serum samples will be taken at different timepoint during the procedure.
45492373|NCT05421312|Drug|Sampling synovial fluid|During the reimplantation 1 synovial fluid sample will be taken prior to incision.
45492374|NCT05421312|Drug|Sampling bone tissue|During the reimplantation 2 cortical bone samples will be taken at different timepoints during the procedure.
45492375|NCT02368054|Drug|Bupivacaine|Infiltration anesthesia
46054071|NCT04234503|Behavioral|Ethics Quarter|"In the intervention, nurse managers have two educational packages per week, one taking 15 minutes (one quarter).The structure of the whole intervention is made according to the dimensions of ethical activity profile of nurse managers (Laukkanen et al. a2016; Laukkanen et al b2016) consisting of managers:~Developing of own ethics knowledge,~Influencing ethical issues,~Conducting/implementing ethics research,~Identifying and~Solving ethical problems.~Intervention includes also orientation and summary, in total 12 educational packages.~After every dimension, NMs have to make self-reflection and development plans, in total five times. This provides them the opportunity to link their everyday experience with ethical theory."
46054072|NCT02801565|Drug|Conventional controlled ovarian stimulation proctol|Conventional controlled ovarian stimulation proctol without rhGH.
45375491|NCT01004588|Dietary Supplement|Protein drink|total of 15 g protein/d in a protein drink consumed every morning after breakfast during 24 weeks
45375492|NCT01004588|Dietary Supplement|placebo drink|subjects consume a placebo drink every morning after breakfast over a period of 24 weeks.
45375493|NCT00056407|Drug|Dutasteride|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily dosing of 0.5mg of dutasteride orally for up to 4 years.
45375494|NCT00056407|Drug|Placebo|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily orally for up to 4 years.
45375495|NCT00388726|Drug|E7389|1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.
45375496|NCT00388726|Drug|Physician's Choice|Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
45492376|NCT02368054|Drug|Adrenaline|Infiltration anesthesia
45492377|NCT01569282|Procedure|Hepaticojejunostomy and gastroenterostomy|Standard surgical techniques
45492378|NCT01569282|Procedure|Stent strategy|Biliary and/or enteral stents on demand
45847030|NCT05443776|Other|Biomaterial implantation|Implant a approved biomaterial by European Regulatory Agencies
46054073|NCT02793765|Drug|Docetaxel|
46054074|NCT02793765|Biological|Sipuleucel-T|
45492379|NCT02357602|Drug|GS-7340|Medication is supplied in 10 or 25mg tablets, so subjects will receive either 1/2 or one tablet in a single dose.
45492380|NCT01379196|Drug|Azithromycin|Tab. Azithromycin 500 mg PO three times weekly for 3 months
45492381|NCT03112720|Device|Epidural Blood Patch|A device: 17 gauge Tuohy needle will be placed to the epidural space using the loss of resistance technique. Once positioned a sterile stylet will be replaced within the needle to maintain the sterility of the epidural space. A tourniquet may be used to identify a peripheral venous site, which will be sterilely prepped with betadine x3 and then chloraprep. Venipuncture will be performed with a device: 20gauge or larger needle. 20mL of blood will be aspirated in a sterile system into an appropriately sized syringe. After sterile transfer, this autologous blood will be slowly injected into the epidural space.
45847031|NCT05443308|Diagnostic Test|Cerebral [15O]H2O PET before and after diamox infusion|Cerebral [15O]H2O PET before and after diamox infusion
45492382|NCT03112720|Drug|Sphenopalatine Ganglion Block|The drug: 5% lidocaine ointment, a local anesthetic, will be applied to the end of a device: long channeled cotton tipped applicator inserted into both nares and placed over the mucosa in the area of posterior aspect of the middle ethmoid, toward the presumed anatomic location of the sphenopalatine ganglion, evidenced by a slight resistance at the appropriate depth. 5mL of drug: 1% lidocaine solution will then be injected into the hollow shaft of the device: applicator and allowed to topically anesthetize the ganglion by gravity flow for 30 minutes.
45375497|NCT01043614|Behavioral|PEER group intervention|An exercise and nutrition intervention that is based on self-efficacy principles and delivered primarily by peer educators to reduce the risk for obesity in female college freshman over one academic year
45375498|NCT01043692|Other|Acupuncture|Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
45492383|NCT01382316|Behavioral|Making Alcoholics Anonymous Easier (MAAEZ)|6-week, 90-minute, manualized, 12-step facilitation intervention consisting of 6 weekly session. First session is introduction. Four following core sessions attended in any order: sponsorship, principles not personalities, spirituality, living Sober. Last session, return to intro session as graduate.
45492384|NCT01382316|Behavioral|Usual care|Group format, six weekly education sessions about alcohol and drugs
45492385|NCT01382238|Drug|Dolutegravir 50 mg tablet|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
45492386|NCT01382238|Drug|Dolutegravir 50 mg oral granules|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
45492387|NCT03112564|Other|Avoidance of rocuronium/cisatracurium|Anesthesia induction was performed at tidal volume, avoiding the use of analgesics and/or muscle relaxants with FGF of 6 L/min. Induction time was shortened as the FGF was increased. Once 5% sevoflurane end-tidal volume was reached, ventilation with facial mask was maintained for three more minutes. The time lapsed until the loss of blink reflex was achieved and orotracheal tube (OTT) was placed, difficulties in OTT placement, sevoflurane end-tidal volume after OTT placement, complications related to OTT insertion (movement, coughing, rigidity, apnea), mean arterial pressure (MAP) variations were measured. No muscle relaxants were given during surgery.
45492388|NCT03112564|Drug|Sevoflurane 8% + Intravenous fentanyl|Sevoflurane 8% + Intravenous fentanyl was the regimen used for induction and maintenance of anesthesia
45492389|NCT01379976|Drug|Acetylcarnitine|"ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal."
45492390|NCT01379976|Drug|Placebo|"ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal."
45492391|NCT01379898|Drug|Phenoxybenzamine|Starting dosage of phenoxybenzamine in hypertensive subjects:20 mg q.d. (=10 mg b.i.d.) and in normotensive subjects 10 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 140 mg q.d. (=70 mg b.i.d.)
45492392|NCT01379898|Drug|Doxazosin|Starting dosage of doxazosine in hypertensive subjects:8 mg q.d. (=4 mg b.i.d.)and in normotensive subjects starting dose 4 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 48 mg q.d. .(=24 mg b.i.d.)
45492393|NCT02368366|Behavioral|Therapist Guided Face to Face Family Problem Solving|Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.
45753953|NCT03931616|Procedure|STEMO|STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure management (choice of drug at discretion of treating physician), use of telemedicine for image transfer as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
45375499|NCT03957655|Biological|SHED group|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 4 times at week 0,4,8,12
45375500|NCT01091233|Procedure|paracentesis|as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
45375501|NCT02530723|Other|power training|Resistance training machines with CAM devices will be used for training.
45375502|NCT00387790|Drug|motexafin gadolinium|Given IV
45375503|NCT00387790|Radiation|3-dimensional conformal radiation therapy|Undergo focal cranial radiotherapy
45375504|NCT00073021|Drug|Asacol 800 mg (mesalamine)|tablets, 4.8 g/day for 6 weeks, 2 - 800 mg Asacol tablets and 2 placebo tablets 3 times daily
45375505|NCT00073021|Drug|Asacol 400 mg (mesalamine)|tablets, 2.4 g/day for 6 weeks, 2 - 400 mg Asacol tablets and 2 placebo tablets 3 times daily
45375506|NCT01091311|Device|Blephasteam|Eye lid warming goggles
45375507|NCT00407758|Drug|enzastaurin hydrochloride|
45375508|NCT01583725|Procedure|Liquid meal responses|Subject ingests a meal-replacement shake and gut peptide levels are measured before and after intake.
45375509|NCT01583725|Behavioral|fMRI responses to food-cues|Subjects undergo a 40 min fMRI neuroimaging session while receiving auditory and visual food cues.
45375510|NCT01094509|Behavioral|Tai Chi|Tai Chi classes and exercises
45375511|NCT01094509|Behavioral|Guided autobiography|Autobiographical writing in class and at home
45375512|NCT01094509|Behavioral|Qigong|Qigong classes and exercises (exploratory)
45375513|NCT01094509|Behavioral|Successful aging|Seminar series on the theme of successful aging
45375514|NCT01094509|Behavioral|Combination|Combination of Tai Chi exercises and autobiographical writing
45375515|NCT01094509|Behavioral|Comparison|No assigned behavioral activity (exploratory)
45375516|NCT01094587|Procedure|Gastroschisis closure with suture|
45492394|NCT02368366|Behavioral|Therapist Guided Online Family Problem Solving|Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
46054075|NCT02793609|Other|Intervention is to let patient to go home.|Intervention is to let patient to go home.
46054076|NCT02793609|Other|Intervention is to observe women in the ward.|Intervention is to observe women in the ward.
46054077|NCT02793531|Other|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
46054078|NCT02793453|Other|periodontal smears|
46054079|NCT02793219|Biological|Sipuleucel-T|
45375517|NCT01094587|Procedure|Gastroschisis closure without suture|
45375518|NCT01584115|Biological|NY-ESO-1 combined with MPLA|Each patient will receive six doses of the formulation, administered intra-muscular, with an interval of 4 weeks between doses, and the first immunization performed 6 weeks after the completion of standard treatment. NY-ESO-1 (250 mcg) amd MPLA (100 mcg).
45375519|NCT01584115|Biological|NY-ESO-1 combined with MPLA vaccine|Immunization os cancer patients with NY-ESO-1 combined with MPLA vaccine
45375520|NCT01089673|Other|data collection|retrospective data collection
45375521|NCT00531752|Drug|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 0.5 mg QD for Days 1-7, then 1.0 mg QD Days 8-14, then 2.0 mg QD Days 15-21
45375522|NCT00531752|Drug|Placebo capsules|Dosage Form: matching placebo capsules Dosage: Subjects will take two placebo capsules each morning throughout the 3 week double-blind treatment placebo treatment period.
45375523|NCT00531752|Drug|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 1 mg (2 x 0.5 mg capsules) of PF-03654746 given daily for three weeks
45375524|NCT00395746|Drug|sulfonylurea|SU agent
45375525|NCT00395746|Drug|liraglutide|Liraglutide 0.6 mg/day or placebo. Injected s.c. (under the skin) once daily.
45375526|NCT00395746|Drug|liraglutide|Liraglutide 0.9 mg/day or placebo. Injected s.c. (under the skin) once daily.
45375527|NCT00994838|Other|reduced calorie diet|10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
45375528|NCT00055471|Drug|ZD4054 10 mg|1 x 10 mg oral tablets once daily
45375529|NCT00055471|Drug|ZD4054 15 mg|1 x 10 mg + 2 x 2.5 mg oral tablets once daily
45375530|NCT00055471|Drug|ZD4054 22.5 mg|2 x 10 mg + 2 x 2.5 mg oral tablets once daily
45375531|NCT01004900|Procedure|Selective Laser Trabeculoplasty|This is a laser procedure used to treat glaucoma by reducing the pressure in the eye. SLT works by using laser light to stimulate the body's own healing response to lower your eye pressure. Using a special wavelength and energy, the laser affects only pigmented (melanin containing) cells of your eye. SLT improves the flow of fluid in the eye, which in turn lowers your eye pressure.
45375532|NCT01004900|Drug|Travoprost/ Timolol/ Azopt/ Brimonidine|Travoprost (Topical eye drops) administered once daily before sleep
45375533|NCT01583491|Procedure|autologous platlet rich fibrin|one dose immediate after surgery
45375534|NCT01583491|Procedure|one side in control group|control group insert any things after surgery
45753954|NCT03931616|Procedure|Regular care|A regular ambulance, the comparator, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
45753955|NCT03945656|Drug|insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin 287 OW for 6 weeks
45753956|NCT03945656|Drug|Insulin glargine|Participants will receive daily s.c. injections of insulin glargine U100 for 12 days
45753957|NCT02761837|Behavioral|IVR call/text|For patients under filling their inhaled corticosteroid or overusing B-agonist, the patient is contacted via IVR call or text
45753958|NCT02761837|Behavioral|Email|Patients under filling their inhaled corticosteroid or overusing B-agonist, the the patient is contacted via email
45753959|NCT00452543|Drug|acamprosate|Acamprosate 333mg, 2 capsules by mouth (i.e., PO), three times per day (i.e., TID), for 12 weeks.
46054080|NCT02793219|Drug|Docetaxel|
45492395|NCT02368366|Behavioral|Self-Guided Online Family Problem Solving|Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
45492396|NCT02367898|Other|Lumosity Cognitive Training|adaptive online cognitive training
45847032|NCT05443230|Diagnostic Test|gait speed; ct scan; grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
45375535|NCT04001348|Device|Acti-Lance Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
45375536|NCT04001348|Device|Acti-Lance Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
45382265|NCT05151315|Device|Total Knee Arthroplasty with Evolution® NitrX™ Knee System|Patients will receive cemented Evolution knee system with NitrX coating for their total knee arthroplasty.
45492397|NCT02367898|Other|Crossword Puzzles|timed online crossword puzzles
45492398|NCT04479280|Device|Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA|studying coagulation disorders in COVID19 critically ill patients
45492399|NCT03160222|Other|Body Composition Measurements|Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
45492400|NCT03160066|Dietary Supplement|Lactobacillus Rhamnosus (JB-1)|Lactobacillus Rhamnosus (JB-1) capsule
45492401|NCT03160066|Dietary Supplement|Placebo|Placebo
45492402|NCT02367742|Behavioral|Endurance Activity (EA)|Subjects have followed a program of endurance activity consisting in a 30 minute walk, 5 times/week. Exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.
45753960|NCT00452543|Drug|escitalopram|Escitalopram is given for 12 weeks. Dosing is flexible, starting at 10mg PO once per day (i.e., QD) with the possibility of increasing to 30mg PO QD.
45753961|NCT00452543|Behavioral|Medical management|Based on the COMBINE study. 1 hour of medical management / behavioral intervention at every study visit (7 times over 12 weeks).
45753962|NCT00452543|Drug|Placebo|Placebo, 2 capsules PO TID, for 12 weeks
45753963|NCT04146818|Behavioral|Adapted Tango Dancing|Treatment will include sessions of Adapted Tango (90 min per week for a total of 6 months) together with sessions of comprehensive cognitive intervention (90 min per week for a total of 6 months) consisting in music therapy, engagement in social activities, cognitive training and psycho-education.
45492403|NCT02367742|Behavioral|EA + Resistance Training (RT)|"Subjects have followed a program combining endurance activity (EA) and resistance training (RT) consisting in a 60 minute work session, 3 times/week consisting in:~Walk (30 minutes): exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.~Musculation (30 minutes): training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutei and legs). Exercise intensity started from the 65% of the maximum rated load and raised up to the 75%."
45492404|NCT04334356|Behavioral|Mobile Web App|App for preventing development of posttraumatic stress based on cognitive behavioral techniques.
45492405|NCT04326010|Device|Surgery|THA surgery
45492406|NCT02362516|Drug|BI 425809|
45492407|NCT02367664|Biological|0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
45492408|NCT02367664|Biological|0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 28 days interval, a booster dose 12 months after the first dose
45492409|NCT02367664|Biological|0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell)|inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell) produced by Beijing Tiantan Biological Products Co., Ltd. /0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
45492410|NCT05421000|Procedure|WALANT|Wide awake local anesthesia without tourniquet for distal radius fracture surgery
45492411|NCT05421000|Procedure|Locoregional anesthesia and tourniquet|Locoregional anesthesia and tourniquet for distal radius fracture surgery
45492412|NCT04275934|Behavioral|Health Management; Blood Pressure|Pharmacists will work with the patient/study subject, referred to as the participant hereafter, and the participant's other health care providers to manage their blood pressure, making recommendations for medication and lifestyle adjustments as needed.
45492413|NCT05419362|Drug|GEN-001|The capsules taken by mouth once a daily. Each capsule will contain ≥ 3x10^11 colony-forming units (CFU)
45492414|NCT05419362|Drug|Avelumab|800 mg given by intravenous (IV) infusion once every 2 weeks
45492415|NCT02367274|Device|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
45492416|NCT01379820|Device|OROTRACHEAL cpap WITH COMPENSATION BAG ( GREGORY CPAP)|USE OF OROTRACHEAL CPAP FOR RESPIRATORY DISTRESS SYNDROME IN NEWBORNS .
45492417|NCT02357212|Procedure|coronary angiography|invasive procedure performed to determine coronary anatomy
46054081|NCT02801721|Other|psycho social stimulation|The psychosocial intervention lasted for 9 months and included play demonstrations at home by a play leader (PL) who was trained to visit homes and teach the mothers about child development and care practices. They also showed the mothers how to play with children using toys in a way to promote good child development. In the original study all anemic children in early childhood received 30 mg ferrous sulphate daily based on recommendations from both the WHO (2003) and IOM reports (2001) for 6 months.
45492418|NCT02357212|Procedure|adenosine stress test|non-invasive procedure to determine area of cardiac ischemia
45492419|NCT01382160|Biological|adalimumab|40 mg every two weeks, by subcutaneous way
45492420|NCT00735748|Drug|Tramadol per os (Tradonal Odis® orodispersible tablets)|Administration of 1 unit dose of 50 mg tramadol perorally given in 3 unit dosages
45492421|NCT00735748|Drug|Tramadol IV (Tradonal® IV)|Administration of tramadol IV given in 3 unit dosage of 35 mg
45492422|NCT03630900|Other|Sequential O2 Culture|We investigate the effect of sequential O2 levels on human embryo culture after Intracytoplasmic sperm injection (ICSI)
45492423|NCT02367196|Drug|CC-90002|
45492424|NCT02367196|Drug|Rituximab|
45492425|NCT05418504|Drug|Dental anesthesia|Dental anesthesia, used to do any dental procedure
45492426|NCT02362126|Device|Endoscopic full thickness resection (EFTR)|Patients undergo EFTR using the FTRD
45492427|NCT05406414|Behavioral|Transdiagnostic sleep and circadian treatment|"The intervention group receives sleep treatment consisting of 6 sessions of 60 minutes each over 6 weeks. The sessions are delivered individually and have the following content:~Assessment and introduction to the sleep diary~Review of sleep diary - agreements on behavior changes and goals.~Information on normal sleep, sleep problems and circadian rhythm~Cognitive techniques~Introduction to relaxation training~Follow-up on goals and plan for prevention relapse of sleep problems"
45492428|NCT05406414|Behavioral|Active waitlist control group|The control group receives sleep hygiene education consisting of a single session in which 10 points of sleep advice are presented. They receive a booklet on how to promote good sleep practice and must work on their own for the next 6 weeks to implement this while waiting for the intervention.
45492429|NCT01377792|Drug|Hypertonic saline|comparison of different dosages of drug
46054082|NCT02801409|Drug|General anesthesia alone|General anesthesia is performed during surgery; patient-controlled intravenous analgesia is provided after surgery.
46054083|NCT02801409|Drug|Combined epidural-general anesthesia|Combined epidural-general anesthesia is performed during surgery; patient-controlled epidural analgesia is provided after surgery.
45492434|NCT02356978|Device|Arm1 homemade phototherapy treatment|"session of 10 or 12 hours phototherapy treatment using the homemade device during the first night and then the DRAP device during the next nights."
45492435|NCT02356978|Device|DRAP|
45375537|NCT04001348|Device|Acti-Lance Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
45375538|NCT04001348|Device|Medlance Plus Super Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
45375539|NCT04001348|Device|Medlance Plus Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
45375540|NCT04001348|Device|Medlance Plus Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
45375541|NCT04001348|Device|Medlance Plus Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
45375542|NCT04001348|Device|Medlance Plus Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
45375543|NCT04001348|Device|Prolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
45375544|NCT04001348|Device|Prolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
45375545|NCT04001348|Device|Prolance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
45375546|NCT04001348|Device|Prolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
45382266|NCT05151315|Device|Total Knee Arthroplasty with Evolution Knee System|Patients will receive cemented Evolution knee system without NitrX coating for their total knee arthroplasty.
45382267|NCT05143372|Device|Vibrolung|Vibroacoustic respiratory therapy
45492436|NCT03408886|Drug|Vancomycin|Oral vancomycin is administered to reduce pathogenic bacteria.
45492437|NCT03408886|Drug|MoviPrep|MoviPrep is given at the end of vancomycin therapy to remove the vancomycin and remaining bacteria prior to administering Full-Spectrum Microbiota
45492438|NCT03408886|Biological|Full Spectrum Microbiota|Gut bacteria from healthy human donors are administered orally in a pill form
45492439|NCT02357056|Other|Wet Lab|ITA dissection and Annuloplasty Sutures in porcine model.
45492440|NCT02357056|Other|Dry Lab|Camera and clutching, peg transferring, intracorporeal knot tying
45492441|NCT02357056|Other|Virtual Reality|daVinci Surgical Skills simulation
45753964|NCT04146818|Behavioral|Control|Sessions of psycho-education and advice on healthy life-style (once per month for a total of 6 months)
45753965|NCT04148690|Other|Group antenatal care (GANC)|Group antenatal care (GANC) is a service delivery model where women with pregnancies of similar gestational age are brought together for antenatal care (ANC), incorporating information sharing and peer support.
45375547|NCT04001348|Device|Prolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
45375548|NCT04001348|Device|Prolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
45375549|NCT04001348|Device|MediSafe Solo 29 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
45375550|NCT04001348|Device|MediSafe Solo 23 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
45375551|NCT03956251|Procedure|Combined Mineralized/Demineralized Putty Allograft|At time of extraction, 15 test patients will receive ridge preservation using Combined Mineralized/Demineralized Putty Allograft
45375552|NCT03956251|Procedure|Demineralized Putty Allograft|At time of extraction, 15 control patients will receive ridge preservation using Demineralized Putty Allograft
45375553|NCT00395512|Drug|Alogliptin|Alogliptin tablets.
45375554|NCT00395512|Drug|Pioglitazone|Pioglitazone tablets.
45375555|NCT00395512|Drug|Placebo|Matching placebo tablets.
45375556|NCT03956017|Drug|Ubiquinone|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
45847033|NCT05443152|Behavioral|Fetal movement and position tracking training|In the first stage, pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
45375557|NCT03956017|Drug|Placebo|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
45375558|NCT00994916|Drug|3,4 diaminopyridine|3,4 diaminopyridine up to 80 mg daily in divided doses
45375559|NCT01005212|Drug|Definity|An intravenous line will be placed and 1.3 mL of the ultrasound contrast agent DEFINITY® will be added to 50 mL sterile saline. Flow will be initiated at 4.0 mL/minute and adjusted for optimal imaging. A maximum of 1.3 mL or one vial of ultrasound contrast will be used per patient per session according to the manufacturer's guidelines.
45492442|NCT02367508|Behavioral|MODEL Care|The Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) intervention is two-pronged and mutually interactive with: (1) a patient and family caregiver group, and (2) an oncology provider group. Patients and family caregivers meet as a group for 6 weekly sessions of 2 hours each, for a total of 12 hours of class time. Oncology providers will have 5 class sessions for a total of 16 hours of class time. One class is held conjointly with patients, family caregivers, and providers to practice newly-learned skills. The course curriculum is generally based on mindfulness practices, group discussion, and didactic teaching with an emphasis on embodying interpersonal mindfulness in dialogue in daily life.
45492443|NCT02356822|Other|Patient registry|Oncology data registry
45375560|NCT00999440|Drug|Methadone|ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done. Patients who start with any opiate and then switch to methadone, move to methadone follow up
45375561|NCT05192954|Device|LigaSureTM vessel sealing device|Device will be used to clamp, cauterize, seal, and transect tissue during vaginal hysterectomy.
45375562|NCT00054691|Drug|Iressa|250 mg by mouth daily
45375563|NCT02530879|Drug|Omeprazole, Lansoprazole, Esomeprazole, Rantidine|1.Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 2.Lansoprazole-Dose range 15mg per day- 30mg twice a day 3.Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 4.Rantidine-Dose range: 150 mg twice a day or 300 mg
45375564|NCT02530879|Behavioral|Voice therapy|Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.
45375565|NCT02530879|Other|Combination of anti-reflux medication and voice therapy|Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
45375566|NCT03957421|Other|aquatic exercise, land based exercise|general warm up and cool down. general exercises and treadmill training at self-selected intensity.
45375567|NCT03957499|Drug|Bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml of normal saline (total volume 30 ml).(
45375568|NCT03957499|Drug|Dexamethasone/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed with 28 ml bupivacaine 0.25% + 2 ml dexamethasone (8mg) (total volume 30 ml)d using
45492444|NCT02362204|Behavioral|therapeutic education and psychological support|Intervention consists of alternate face-to-face consultations (anticipated duration: 60-90 minutes) and telephone consultations (anticipated duration: 15-30 minutes). All interventions will include: i) a focused assessment of physical and psychological symptoms, ii) information about lung cancer (disease) and its treatment, iii) a review of disease-related and treatment-related side effects and strategies to manage these symptoms, and iv) printed listing and review of available support resources.
45492445|NCT03078582|Drug|Zilucoplan (RA101495)|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
45375569|NCT03957499|Drug|Magnesium Sulfate/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml magnesium sulphate (200mg) (total volume 30 ml).
45375570|NCT00387712|Other|Velocity based treadmill training|6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill speed is gradually progressed to meet the training heart rate goals for moderate aerobic exercise, when hemiparetic gait velocity can no longer be progressed, incline is added to achieve heart rate training goals. Progression is also based on participant's tolerance, abilities and safety.
45375571|NCT00387712|Other|Duration based treadmill training|6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill duration is gradually progressed to meet the endurance goals for low aerobic intensity exercise, gait velocity and incline do not progress. Progression is based on participant's tolerance, abilities and safety.
45492446|NCT02361892|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle for two courses of 3 months each
45492447|NCT04013334|Drug|MTG201|MTG201, 3 x 10E12 vp delivered by intratumoral injection on days 1, 8, 22 and 50
45492448|NCT04013334|Drug|Nivolumab Injection [Opdivo]|Nivolumab 480 mg by IV infusion every 4 weeks
45492449|NCT03285412|Drug|Ribociclib|Ribociclib is a drug designed to block certain proteins called cyclin-dependent protein kinases 4 and 6 (CDK4/6). These proteins are needed for cells to divide and may also control the ability of certain cancers to grow.
45375572|NCT01091389|Procedure|Totally Thoracoscopic PV isolation|Surgery is performed through three ports bilaterally in the intercostal spaces. PVI is performed with a bipolar radiofrequency clamp and confirmed with a custom made multi-electrode probe with closely spaced (1mm) electrode terminals. Additional left atrial ablation lines are created and conduction block is verified in patients with persistent and permanent AF.
45375573|NCT01040338|Drug|Nicotine|Participants shall receive an intravenous injection of nicotine during their practice session and one of their PET scans (double-blind). The dose of IV nicotine will be 1mg/70kg and the maximum dose that shall be injected is 1.2mg.
45375574|NCT01089829|Other|Foot examination|"Non-invasive neurological sensory testing~Non-invasive doppler assessment of peripheral arterial system"
45375575|NCT00066703|Drug|exemestane|
45375576|NCT00066703|Drug|tamoxifen|
45375577|NCT00066703|Drug|triptorelin|
45375578|NCT01091545|Radiation|DBT and FFDM|Women in the study will once undergo both standard FFDM screening (2-views) and DBT (1 view, MLO). This will result in a doubled radiation dose compared to only 2-view FFDM, which is the standard procedure for women in the screening program.
45492450|NCT03285412|Other|Endocrine therapy|Hormone therapy
45492451|NCT03077724|Drug|Fish oil|Fish oil supplementation
45492452|NCT03077724|Drug|Placebos|Olive Oil capsules
45492453|NCT02361814|Procedure|The use of amnionic membrane allograft|After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
45492454|NCT01379742|Device|RapidStrand seeds for use with 18g needle|Rapidstrand seeds are standard size and are used with 20 g needles
45492455|NCT01379742|Device|ThinStrand|ThinStrand seeds are smaller in diameter and used with 20g needles
45492456|NCT02361658|Other|Ultrasonographic of the optic nerve sheath diameter|On both eyes of all subjects in supine position by two investigators.
45492457|NCT02361658|Other|RespirAct™|Carbon dioxide Manipulation by RespirAct™ sequential gas delivery breathing circuit at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia).
45693206|NCT04384042|Other|Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances|This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.
45693207|NCT03809260|Drug|Metformin (part 1)|1~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch), 16d~19d: Metformin 1000 mg bid (Except for 500 mg after 16d lunch).
45492458|NCT02361658|Other|Neck collar|Internal jugular compression using a Neck collar will be applied at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia) and ONSD measurements will be done before and after the collar.
45492459|NCT02356744|Other|Ultrasound|Ultrasound assessment of fetal growth, anomalies , liqour and placenta
45693208|NCT03809260|Drug|Vancomycin|11d: Vancomycin 250 mg bid, 12~17d: Vancomycin 500 mg bid
45693209|NCT03809260|Drug|Metformin (part 2)|1~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch)
45492460|NCT02356510|Procedure|Primary PCI|
45492461|NCT02366884|Drug|Anti-Bacterial Agents|Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine
45693210|NCT01763905|Biological|Evolocumab|Subcutaneous injection
45693211|NCT01763905|Drug|Placebo to Evolocumab|Subcutaneous injection
45693212|NCT01763905|Drug|Ezetimibe|Tablet for oral administration
45693213|NCT01763905|Drug|Placebo to Ezetimibe|Tablet for oral administration
45693214|NCT05743504|Drug|Tiragolumab|Neoadjuvant Tiragolumab, Atezolizumab, Paclitaxel, Cisplatin and Radiotherapy Followed by Surgery
45693215|NCT02091167|Device|transcranial Direct Current Stimulation|Direct currents are transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current is delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode is placed over F3 according to the 10-20 international system while the anode is placed over the contralateral F4 region. The currents flows continuously for 20 minutes with an intensity of 2 milliamperes.
45492462|NCT02366884|Drug|Anti-Fungal Agents|Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole
45847034|NCT05442996|Drug|HLX35|The dose of HLX35 is set at 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. It is administered intravenously every 2 weeks on day 1 of each cycle.
45847035|NCT05442996|Drug|HLX10|The dose of HLX10 is fixed at 200 mg. It is administered intravenously once every 2 weeks on day 1 of each cycle.
45847036|NCT05441046|Drug|Genakumab|genakumab plus tislelizumab 200 mg
45847037|NCT05440188|Diagnostic Test|Breath Detect Platform|Use of the Breath Detect platform for respiratory health monitoring.
45375579|NCT03955939|Drug|LY3295668 Erbumine|Administered orally.
45375580|NCT03955939|Drug|Endocrine therapy|Administered according to label instructions.
45375581|NCT03955939|Drug|Midazolam|Administered orally.
45375582|NCT01094665|Procedure|MRI Targeted Focal Laser Thermal Therapy|A 980nm wavelength diode laser will be fired for up to 30 minutes. Temperature probes will be inserted to ensure that the local temperature does not exceed 55 degrees Celsius for more than 5 minutes.
45375583|NCT01091623|Other|training|
45375584|NCT01091623|Other|training|
45375585|NCT01091623|Other|training|
45375586|NCT01094821|Drug|ATI-7505|3 mg three times daily for 9 days
45375587|NCT01094821|Drug|Placebo|Placebo capsule three times daily for 9 days
45375588|NCT01094821|Drug|ATI-7505|10 mg ATI-7505 three times daily for 9 days
45375589|NCT01094821|Drug|ATI-7505|20 mg ATI-7505 three times daily for 9 days
45492463|NCT02366884|Drug|Anti-Protozoal Agents|Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole
45492464|NCT02356276|Procedure|D2 lymphadenectomy|
45492465|NCT02356276|Procedure|Hyperthermic Intraperitoneal Chemotherapy|The first HIPEC is conducted within 48 h after surgery: Normal saline 3000 -4000ml, Paclitaxel 75mg/m^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m^2, 43°C, 60min.
45375590|NCT00072475|Drug|vatalanib|Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or > tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)
45375591|NCT02530645|Behavioral|OnTrack|
45375592|NCT02530645|Behavioral|Treatment as Usual|
45847038|NCT05439564|Drug|Dexmedetomidine|Group morphine-Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine plus 5 mcg of dexmedetomidine.
45375593|NCT02530645|Behavioral|Brief Motivational Interviewing|
45375594|NCT01094899|Radiation|Radiography|Radiography, microscanner, osteodensitometry
45375595|NCT01094899|Other|Urine and Blood sampling|mainly dosage of bones metabolism
45375596|NCT01094899|Other|Echography|body bones echography
45847039|NCT05439564|Drug|Morphine|Group morphine (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine.
45375597|NCT01091701|Biological|Ex vivo cultured adult allogenic MSCs|Single IV dose of allogenic MSCs
45375598|NCT01091701|Other|Plasmalyte-A|Single IV dose of Plasmalyte-A
45375599|NCT03960229|Other|MicroFluidic Sperm Sorting Chips|sperm selection of IVF treatment
45375600|NCT03960229|Other|Gradient-Density Centrifugation|sperm selection of IVF treatment
45375601|NCT01091857|Behavioral|STRIDE|
45375602|NCT00066469|Biological|rituximab|Cycles 1 and 2 only: Given IV Incremental: First dosage: < 21 years of age: 0.5mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 50 mg/hr for the 1st hour. Subsequent dosages: < 21 years of age: 1.0mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 100 mg/hr for the 1st hour. Days 1, 8 and 15.
45375603|NCT00066469|Drug|cyclophosphamide|Given IV over 30-60 minutes Dose 600 mg/m2 in 50-250 mL of normal saline (NS) or Dextrose-Water 5%(D5W) (at a maximum concentration of 20 mg/ml) over 30-60 minutes on day 1 of each cycle
45375604|NCT00066469|Drug|methylprednisolone|Methylprednisolone 0.8 mg/kg IV over 12 hours on days 1,2,3,4 and 5 of each cycle.
45375605|NCT00066469|Drug|prednisone|Dosage 1 mg/kg orally every 12 hours on days 1,2,3,4 and 5 of each cycle. Oral prednisone may be rounded up to the nearest 2.5 mg as necessary for tablet size
45375606|NCT01094977|Drug|Tranexamic Acid|10 mg/kg bolus with a 5 mg/kg/h infusion
45375607|NCT01094977|Drug|Tranexamic Acid|100 mg/kg bolus with a 10 mg/kg/h infusion
45847040|NCT05439564|Drug|Dexmedetomidine|Group Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 5 mcg of dexmedetomidine.
45847041|NCT05412264|Behavioral|Website intervention|12 week motivational emails, recording pedometer steps and waist circumference
46054084|NCT00907296|Biological|Romosozumab|Administered by subcutaneous injection
45375608|NCT01094977|Drug|Saline Placebo|
45375609|NCT01095055|Biological|AdCh63 AMA1|Group 1A - single dose of AdCH63 AMA1 5x10^9 vp intramuscularly Group 2A - single dose of AdCH63 AMA1 5x10^10 vp intramuscularly
46054085|NCT00907296|Drug|Placebo|Administered by subcutaneous injection
45375610|NCT01095055|Biological|AdCh63 AMa1 and MVA AMA1|Group 1B - single dose of AdCH63 AMA1 5x10^9 vp intramuscularly and single dose of MVA AMA1 5x10^8 pfu 8 weeks later intramuscularly Group 2B - single dose of AdCH63 AMA1 5x10^10 vp intramuscularly and single dose of MVA AMA1 5x10^8 pfu 8 weeks later intramuscularly
45375611|NCT01095133|Drug|Amiloride|dosage form: intraesophageal amiloride infusion dosage: liquid 1 mM amiloride concentration duration: 5 minute infusion given once frequency: 1 time
45375612|NCT01095133|Drug|Placebo|dosage form: intraesophageal saline infusion dosage: normal Saline (0.91% w/v of NaCl) duration: 5 minutes given once frequency: 1 time
45375613|NCT01092013|Behavioral|Training on laparoscopic simulator in skills lab|Laparoscopic camera training in a skills lab following training protocol for a total of 6 hours during 3 weeks.
45375614|NCT01092013|Behavioral|Training at actual laparoscopic surgery|Assisting at 6 laparoscopic surgeries navigating the camera during 3 weeks
45375615|NCT01092013|Behavioral|Technical instruction|Technical instruction on proper handling of an angled laparoscope before randomization for 1 hour
45375616|NCT00387088|Device|Respimat|
45375617|NCT00387088|Drug|Tiotropium|
45382268|NCT05142618|Other|Supervised Physical Therapy|The twice-per-week 8-week course of supervised physical therapy begins 2 weeks after surgery. It targets abdominal core function through progressive muscle retraining and strengthening, and patient-specific posture and body mechanics education.
45693216|NCT03803254|Procedure|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
45693217|NCT03803254|Drug|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
45693218|NCT03803254|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
45693219|NCT03803254|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
45693220|NCT02091089|Device|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of wrinkles
46054086|NCT03787251|Drug|Apatinib|It is recommended that the initial dose of apatinib is 500mg po qd. Adjust the dose to 750mg po qd or maintain the original dose according to the patient's medication response for about 2 weeks. If there is grade III or above, or grade II and above non-hematologic toxicity, allow the dose to be lowered 2 times.
46054087|NCT03787251|Drug|The chemotherapeutic drug chosen by the investigator.|"The choice of chemotherapy regimen is based on the medication habits of the drug delivery doctor and the specific circumstances of the patient.~In addition, the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient death. If grade 3 and above or non-hematologic toxicity of grade II and above adverse event appeared, allowing the dose to be lowered twice."
45492466|NCT02356276|Drug|Systemic chemotherapy (XELOX or SOX regimens)|"XELOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~SOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40 mg/m^2 bid, po, day 1-14 (S-1: BSA <1.25m^2, 40mg bid, 1.25m^2≤ BSA ≤1.5m^2, 50mg bid, BSA>1.5m^2, 60 mg bid) bid, d1-14, po, every 3 weeks for a total of 6-8 cycles."
46054088|NCT02789865|Drug|Ertapenem, Levofloxacin and Metronidazole|The patients will be treated with intravenous broad-spectrum antibiotics (Ertapenem 1g/d) for 3 days and oral antibiotics (Levofloxacin 500mg once daily and Metronidazole 500mg 3 times per day) for 7 days. If patients in the antibiotic group deteriorate during the hospital stay (suspicious perforation or any symptoms of peritonitis) patients will be operated.
45375619|NCT01095211|Drug|B-vitamin complex|5 mg Folic acid, plus 1 mg cyanocobalamin and 40 mg vitamin B6) oral/ day. The placebo capsule contained 400 mg of mannitol: aerosil (99.5: 0.5). In addition, 1 mg/s.c cyanocobalamin daily
45375620|NCT01089985|Drug|Autologous serum eyedrops|3 times a day for the duration of the study
45375621|NCT00053365|Drug|irofulven|Given IV
45375622|NCT00387010|Drug|Fentanyl Buccal Tablets|"Fentanyl buccal tablets (FBT) placed in the buccal cavity above a rear molar until disintegrated, approximately 14-25 minutes.~Dose titration: Participants self-administered FBT, starting at 100, 200 or 400 mcg (depending on analgesic used pre-study) and titrated to 600 and 800 mcg as needed. For each breakthrough pain (BTP) episode, participants took a dose, and did not take further study drug if adequate pain relief was achieved. If pain was not controlled within 30 minutes, the same dose level was repeated. If pain relief was inadequate 30 minutes after the second dose, usual rescue medication was taken for that BTP episode. Doses were adjusted until pain relief was adequate and side effects were tolerated.~Open-label: Once the successful dose of FBT was identified (100, 200, 400, 600, or 800 mcg), participants were dispensed a 4-week supply at the successful dose. Participants were not to use FBT for more than 6 BTP episodes or take more than 8 FBT daily."
45375623|NCT01092091|Biological|Pegylated Recombinant Human Arginase I|Weekly dose of PEG-BCT-100 for at least 8 weeks (or until disease progression) at 1600U/kg
45375624|NCT01092169|Other|No intervention|
45492467|NCT02361502|Drug|mirabegron|
45492468|NCT02361502|Drug|placebo|
45492469|NCT02356354|Procedure|Skin biopsy|2 biopsies are done on the same patient : 20 cutaneous biopsies from post-burn scar and from healthy skin
45492470|NCT02366962|Biological|ASP7374|subcutaneous
45492471|NCT02356120|Other|Echocardiogram|Tricuspid annular plane systolic excursion will by measured by emergency physician performed echocardiogram
46054089|NCT02789865|Procedure|Endoscopic retrograde appendicitis therapy (ERAT)|The procedures of ERAT will be performed as below：1.Cannulation of the appendiceal lumen. 2.Endoscopic retrograde appendicography (ERA). 3.Irrigation and appendicolith removal. 4.Stenting for drainage.
46054090|NCT02789865|Procedure|Appendectomy|The patients will receive laparoscopic appendectomy according to standard routines.
45375625|NCT03960385|Biological|CYD-TDV|Dengue vaccine
45375626|NCT00386776|Other|Computer-based medical history|The intervention is a computer-based medical interview, which contains 232 primary questions that are asked of all respondents, and over 6000 frames (questions, explanations, suggestions, recommendations, and words of encouragement) that are available for presentation as determined by the patient's responses and the branching logic of the program.
45492472|NCT02367118|Drug|Prednisone|
45492473|NCT02367118|Drug|Placebo|
45492474|NCT02361268|Behavioral|Intradialysis-yoga|The experimental intervention in this study is intra-dialysis yoga. The intra-dialysis yoga protocol consists of yoga instruction and practice being offered three times a week for 12 weeks. Subjects will have the opportunity to participate in 15 to 60 minutes of yoga during dialysis.
45492475|NCT02361268|Behavioral|Educational program|The educational intervention in this study consists of 12 modules of an educational course, Kidney School, developed and maintained by the Medical Education Institute, Inc. Kidney School is a comprehensive, free, educational curriculum for people with kid
45492476|NCT02355808|Behavioral|Tailored Leaflet|
45492477|NCT02355808|Behavioral|GP visit|
45492478|NCT02355730|Procedure|Venepuncture|Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy.
45492479|NCT00979212|Drug|panitumumab|Induction: 2.5 mg/kg, IV, days 1, 8, 15, 22, 29, 36 of radiation therapy before administration of chemotherapy and radiation therapy.
45492480|NCT00979212|Drug|carboplatin|Induction: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, AUC=6, IV, days 1 and 22.
45492481|NCT00979212|Drug|paclitaxel|Induction: 50 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, 200 mg/m2, IV, days 1 and 22.
45492482|NCT00979212|Procedure|surgery|A lobectomy or pneumonectomy performed 4-6 weeks after completion of induction chemoradiation
46054091|NCT02789943|Procedure|Cardiac Bypass Surgery|elective cardiac bypass surgery during which a sample of right atrial appendage and/ or aortic button can be removed
45375627|NCT01092247|Other|Nutritional support with Standard diet|Nutritional support with Standard diet
45693221|NCT03803176|Procedure|Open Flap Debridement|Full thickness flaps are elevated to fully expose the periodontaldefects. Defects are then fully debrided and the roots are carefully planned. Flaps are repositioned and sutured to obtain primary closure of the interdental space. This will be done for chronic periodontitis patients
45375628|NCT01092247|Other|Nutritional intervention with the Ketogenic diet|Nutritional intervention with ketogenic diet. The Diet plan will be based on each patient individually according to his nutritional needs. Age, weight, activity levels, culture and food preferences are taken in consideration
45375629|NCT00065065|Drug|Rosiglitazone|4mg orally twice daily for 12 weeks
45375630|NCT00065065|Drug|Placebo|pill that looks identical to rosiglitazone
45375631|NCT00386308|Drug|Tranexamic acid tablets|3900 mg/Day
45375632|NCT00386308|Drug|Placebo tablets|
45492483|NCT02356042|Other|Geriatric inclusive art (GIA) activity|The frequency of GIA sessions in this study was from 1 to 2 per month. The time of a session was around 1 hour 30 minutes. Participants of intervention group benefited GIA activity during a 6-month follow-up period.
45492484|NCT02355964|Behavioral|Exercise|Aerobe exercise 3 times a week in 8 weeks
45492485|NCT02355964|Behavioral|Diet|Diet (a diet with an overall high protein content and a low glycemic index) in 8 weeks
45492486|NCT02355652|Device|Surgical total knee replacement using cemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using cemented femoral and tibial prosthetic components.
45693222|NCT04730999|Drug|Etoposide|Induction phase: 100 mg/sqm on days 1-3, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
45693223|NCT04730999|Drug|Carboplatin|Induction phase: AUC 5 on day 1 for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
45375633|NCT00064987|Procedure|Testicular biopsy|Outpatient surgical procedure.
45375634|NCT00064987|Drug|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
45375635|NCT00064987|Drug|follicle stimulating hormone (FSH)|75 IU subcutaneous injection daily for four months.
45375636|NCT00374452|Other|ATHENA-CDS-HTN plus Guideline Link|ATHENA display provides guideline-based recommendations to clinicians at the time of patient care.
45375637|NCT00374452|Other|Guideline Link Only|Primary care providers were sent, once, a link (URL) to the VA/DoD and JNC7 hypertension guidelines.
45375638|NCT00064753|Drug|High Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 50 mg Folic acid: 5.0 mg Vitamin B12: 1.0 mg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
45492487|NCT02355652|Device|Surgical total knee replacement using uncemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using uncemented femoral and tibial prosthetic components.
45753966|NCT04148690|Other|Standard antenatal care|Routine antenatal care as recommended by th Ministry of Health of Tanzania
45375639|NCT00064753|Device|Low Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 1.4 mg Folic acid: 0.0 mg Vitamin B12: 2.0 mcg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
46054092|NCT02793297|Other|refined wheat crisp bread|Refined wheat crisp bread (52 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
45375640|NCT00374140|Drug|RAD001 (everolimus)|10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities
45375641|NCT00665561|Drug|Maraviroc along with an optimized background antiretroviral drug regimen|Maraviroc prescribed per approved local label.
45375642|NCT00665561|Drug|Optimized background antiretroviral drug regimen without maraviroc|Optimized background antiretroviral therapy prescribed per approved local label and treatment guidelines.
45375643|NCT04064086|Other|Comprehensive Pre-ESRD Patient Education (CPE)|Structured education session/s
45375644|NCT04064086|Other|Provision of the freely available resources for Kidney Disease Education|freely available resources
45375645|NCT03955705|Drug|Nefopam 20 mg/ml|Nefopam is a benzoxazocine derivative which is non-opioid and non NSAIDs. The previous studies showed that nefopam can inhibit reuptake of serotonin, norepinephrine and dopamine.
45693224|NCT04730999|Drug|Bevacizumab|"Induction phase: 7.5 mg/kg on day 1, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration.~Maintenance phase: 7.5 mg/kg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal."
45375646|NCT03955705|Drug|Normal saline|0.9% Sodium chloride (normal saline or NSS)
45375647|NCT03154138|Device|The prismatic adaptation (PA)|Prismatic adaptation (PA) is based on the wearing of a pair of glasses producing a visual field deviation of 10° to rightward. While wearing theses glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements with a shift toward the right side (initial errors consecutive to the prism deviation). Taking into account theses errors, the patient then compensates the optical deviation. After removing the prismatic glasses, the asked pointing movement to the targets is once again shifted but to the left side this time (after-effects attesting the prismatic adaptation)
45382269|NCT05142618|Other|Post-operative Precautions|This intervention includes standard of care post-operative instructions typically given to patients undergoing ventral hernia repair across the world. These include limiting strenuous physical activity and a lifting restriction of no more than 10 pounds for 6 weeks. Binder use is also encouraged for 4-6 weeks after the operation.
45382270|NCT05139914|Drug|Dapagliflozin|10 mg/day (in capsule form) of dapagliflozin for 6 weeks
45382271|NCT05139914|Other|Placebo|Placebo capsule for 6 weeks
45693225|NCT04730999|Drug|Atezolizumab|"Induction phase: flat dosing of 1200 mg on day 1, for a maximum of 6 cycles ( each one of 21 days duration). Intravenous administration.~Maintenance phase: flat dosing of 1200 mg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal, loss of clinical benefit."
45693226|NCT00759772|Drug|Placebo|sc daily for 6 months
45693227|NCT00759772|Drug|Teriparatide|20 mcg sc daily for 6 months
46054093|NCT02793297|Other|sourdough fermented rye crisp bread|Sourdough fermented rye crisp bread (59.4 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
46054094|NCT02793297|Other|unfermented rye crisp bread|Unfermented rye crisp bread (59.8 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
46054095|NCT02793141|Other|No intervention|No intervention will be administered
45492488|NCT03630744|Other|Fluid therapy|"Analyze the type of fluid administered:~crystalloids:~Saline serum 0.9% ....... ml~Ringer Lactate ........ ml~Isofundin ® ........ ml~Plasmalyte® ... ... ml~Glucose Serum 5% ....... ml~Glucose serum 10% ........ ml~Glucosaline serum ........ ml~colloids:~Hydroxyethyl starch 130 / 0.4 ... ... ml~Hydroxyethyl alimdon 130 / 0.42 ... .... ml~Gelatins ... ....... ml~Albumin 5% .......... ml~Albumin 20% .......... ml.~Analyze the total amount of crystalloids and liquid colloids administered in 24 hours in milliliters.~Analyze the form of administration:~Standard~Standard with dosimeters~on pump"
45492489|NCT03160534|Other|preoperative exercise|Each intervention session contains a stretching part and aerobic training
45492490|NCT01379586|Drug|ONO-4053|Part A: ONO-4053 doses proposed are 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg as a single dose administered by mouth once daily
45375648|NCT03154138|Device|The sham prismatic adaptation (S-PA)|"The sham prismatic adaptation (S-PA) is based on the wearing of a pair of glasses producing no visual field deviation. Theses sham glasses is identical with theses used in PA group without the optical deviation. The conditions are similar with theses in the PA group.~The procedure with the sham glasses are similar with these one used in the PA group: While wearing the sham glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The support with targets are the same as these one used in the PA group. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements without shift. No compensation of movement is observed. After removing the prismatic glasses, the asked pointing movement to the targets is not shifted (No after-effects observed)"
45375649|NCT01090219|Procedure|two different meshes in the repair of inguinal hernias|A Lichtenstein tension-free hernia repair was accomplished by emplacing Heavy-weight versus low-weight polypropylene meshes for repair of incisional hernia, marked next to the lips with six titanium clips (LT200)
45375650|NCT01090297|Device|S8 Spirit 2|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
45375651|NCT01090297|Device|Somnosmart 2|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
45375652|NCT01090297|Device|Remstar Auto|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
45382272|NCT05138835|Drug|Botox Cosmetic|"BOTOX® Cosmetic is approved and commercially available for use in Canada.~BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe frown lines between the eyebrows, crow's feet lines, and forehead lines in adults."
45382273|NCT05132231|Biological|Brodalumab|Brodalumab
45847042|NCT05394870|Other|manual lymphatic drainage (massage)|Patients will begin treatment with manual lymphatic drainage in the affected extremity. In this context, while the patients are in the supine hook position, lymph drainage will be applied first to the neck and then to the abdomen. After the stimulation of the central lymph nodes, the lymph circulation will be increased by stimulating the axillary lymph nodes of the relevant region. First, the proximal part will be drained and it will be advanced towards the distal. Drainage will be repeated depending on the edema at the distal forearm-wrist level.
45382274|NCT05132231|Biological|Matched cohort|Matched cohort
45492491|NCT01379586|Drug|Placebo|Placebo to match ONO-4053 tablets dosed in a similar manner to ONO-4053
45492492|NCT02038738|Drug|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.|
45492493|NCT02361424|Drug|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
45492494|NCT02361424|Drug|placebo|
45492495|NCT05347368|Other|Control group (conventional therapy)|Physical therapy will be performed using physical agent modality that include hot pack (15 min), and therapeutic exercises (5 repetition per set, 2 sets each session) therapeutic exercises include spinal extension exercise, prone hip extension exercise, posterior pelvic tilt, cat-camel exercise
45492496|NCT05347368|Other|Primal Reflex release Technique|The SI/Lumbar release Iliopsoas release Piriformis release Hamstring release Gastrocnemius release
45492497|NCT02366416|Behavioral|Exercise training|Physical activity
45693228|NCT01763203|Behavioral|Care Management+Community Health Worker|Over a period of a year subjects randomized into the Intervention arm of the study will receive support from a Care Manager. Subjects will also participate in educational group sessions on chronic disease self-management and have home visits by a Community Health Worker who will use mobile health technology.
45847043|NCT05394870|Other|Splint treatment|The splint routinely given to patients diagnosed with mild to moderate carpal tunnel syndrome will be given to both groups in these patients
45375653|NCT03955549|Behavioral|Insight Enhancement Program (IEP)|"IEP is comprised of 8 sessions, administered twice weekly, across a one month period. The session duration is 60-90 minutes. IEP will be administered in a group format with 8-12 patients in each group.~During sessions, different topics representing 8 different stages of illness are discussed according to a chronological schedule. These stages are presented on an Illness March Graph (IMG) and include: Stage I: Personality formation, Stage II: Pre onset confusion, Stage III: Prodroma, Stage IV: The illness, Stage V: Resistance, Stage VI: Remission, Stage VII: Maintenance, Stage VIII: Relapse. Patients actively participate through the exchange of their own experiences and interpretations, which are then reinterpreted by the therapist and by the patients themselves."
45375654|NCT03955549|Behavioral|Metacognitive Training for Psychosis (MCT)|The training consists of eight modules that are administered within the framework of a group intervention program that involves eight 1-hour group sessions with 4 to 10 patients in each group. MCT is manualized and currently available in thirty languages and can been downloaded via the following web address: http://www.uke.de/mct. Among the problematic thinking styles recognized as potential contributors to the development of delusions are attributional distortions (module 1), a jumping to conclusions bias (module 2 and 7), a bias against disconfirmatory evidence (module 3), deficits in theory of mind (module 4 and 6), over-confidence in memory errors (module 5) and depressive cognitive patterns (module 8).
45492498|NCT01377558|Other|Aerobic endurance training intervention|"The aerobic endurance training group will use cardiovascular training devices~week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT two times per week~week 5-13: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT two times per week~week 14-26: 15 minutes warm up (group) 45 minutes intervention at 95-110% vAT two times per week"
45375655|NCT03955549|Drug|Treatment As Usual (TAU)|"Treatment As Usual (TAU) consists of psychiatric management by a clinical team including at least one psychiatrist and one psychologist. Treatment involves antipsychotic medication, regular office-based contacts with the clinical team for treatment monitoring, recreational group activities, and unstructured psycho-educational groups. Participants in the interventional groups also will receive TAU.~Medications: In order to standardize treatment, Risperidone (Risperdal ) will be used as the antipsychotic medication in all three groups with a dose up to 6-8 milligrams according to clinical severity. The same dose will be used for 1 month prior to starting interventions). In case of occurrence of mild extrapyramidal symptoms associated with high doses of risperidone, an anticholinergic drug (Benztropine) might be used."
45375656|NCT00786461|Procedure|silver nitrate application to the Bartholin´s cyst|5 mm in diameter and 5 mm in length crystalloid silver nitrate stick is inserted into the cyst or abscess cavity.
45375657|NCT00786461|Procedure|silver nitrat stick|The silver nitrate treatment is performed under local anaesthesia on an outpatient basis. A simple vertical incision 1 cm in length is made in the vaginal mucosa and the underlying cyst or abscess wall. A crystalloid silver nitrate stick of 5 mm in diameter and 5 mm in length is inserted into the cyst or abscess cavity.
45375658|NCT00786695|Drug|esomeprazole|esomeprazole (40 mg o d) for 14 days
45375659|NCT00786695|Drug|Placebo|Identical looking Placebo, same regimen, for 14 days
45375660|NCT00786851|Drug|Lenalidomide and Dexametasone|Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
45375661|NCT00786929|Procedure|Catheter drainage|
45375662|NCT00786929|Drug|Conservative treatment|
45375663|NCT00663923|Procedure|photorefractive keratectomy (PRK)|comparison of PRK by cross-cylinder approach in one eye and conventional (single) method in the other eye for laser correction of astigmatism
45375664|NCT00787007|Drug|S-equol|capsule, oral, single dose
45847044|NCT05350332|Device|Negative Pressure Ventilator|The negative pressure ventilator is an off-the-shelf FDA-approved device designed to treat respiratory patients with hypoventilation syndromes. This ventilator places the torso within a fixed container that is connected to a vacuum source, which inflates the lungs by pulling a negative pressure around the chest and abdomen. After the clinically routine DISE, a negative pressure ventilator will be placed on the participant's chest to increase lung volumes and the DISE evaluation will be repeated to observe changes.
46054096|NCT02591706|Device|MIS Implants|The implantation procedure will be carried out according to a standard surgical protocol, and according the manufacture protocol. Patient will be randomly assigned to one of the two groups after flap opening. The implant stability will be measured using the wench key and recorded in N/cm. The implants will be covered with healing abutments for trans-gingival healing for a period of 4 months. The area will be sutured with thin nylon sutures for a primary passive fit closure. Immediately after the surgery the patient will perform a CBCT of the treated area with a cotton roll on the buccal side in order to be able to evaluate the buccal soft tissue thickness.
46054097|NCT02793063|Other|Web-based Survey|This study will occur online. Participants will be asked to complete multiple surveys one time. Participants may receive study reminder emails to complete surveys. Participants will be able to complete the surveys all at once or in multiple sessions. Participants will have approximately 3 months to complete the surveys after consenting.
46054098|NCT00816400|Drug|MEDI-575|MEDI-575 as an IV infusion
45375665|NCT00787007|Drug|Placebo|capsule, oral, single dose
45375666|NCT00787163|Procedure|amnioinfusion|serial amnioinfusions aimed at restoring amniotic fluid volume
45375667|NCT00791063|Other|18F ML-10|Patients will undergo 2-3 brain PET/CT sessions; A pre-treatment session and 1-2 sessions post WBRT treatment. Each PET/CT session will be done following intravenous administration of 18F-ML-10, to assess tracer uptake by the tumor.
45375668|NCT00784355|Procedure|Laparoscopic cholecystectomy|Surgery
45375669|NCT00795119|Device|Near Infrared Spectroscopy (NIRS)|NIRS of the head is undertaken at the time of CT or MRI examination
45375670|NCT00787397|Behavioral|Cognitive Behavioral Therapy-Sleep|Cognitive Behavioral Therapy: 6 sessions of CBT
45375671|NCT00791141|Drug|Cetuximab|Loading dose prior to chemoradiotherapy 400 mg/m², followed by every week infusion of 250 mg/m² during chemoradiotherapy. After chemoradiotherapy every 2 week infusions of 500 mg/m² over 6 months.
45375672|NCT04046783|Device|patch|an overnight application of a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks.
45375673|NCT04046393|Device|"Taiwan Scientific noninvasive blood pressure meter TS-0411"|measure autonomic nerve
45375674|NCT04046393|Device|Meridian Energy Analysis Device(MEAD)|measure meridian energy
45375675|NCT04046393|Procedure|bacteria culture|use culture swab to culture nasal discharge
45375676|NCT04046393|Procedure|nasopharyngoscopic examination|use nasopharyngoscopy to determine the modified Lund-Kennedy endoscopic scoring system
45375677|NCT04046393|Combination Product|TCM nasal irrigation|Chinese herbal medicine (licorice) extract solution with buffered salt packet and water in rinse bottle
45375678|NCT00386152|Drug|epoetin alfa|80,000 Units and 120,000 Units of epoetin alfa (PROCRIT) injected subcutaneously once every 3 weeks for up to 13 weeks
45375679|NCT00386152|Drug|darbepoetin alfa|500 mcg of darbepoetin alfa (ARANESP) injected subcutaneously the skin once every 3 weeks for up to 13 weeks
45375680|NCT00787475|Other|Community Health worker|Community Health workers with at least 4 home visits, 8 phone calls, and 10 group visits.
45375681|NCT00787553|Drug|cefazolin|2.0 g, IV, 2 hours before surgery
45375682|NCT00787553|Drug|tinidazole|2.0 g orally, 12 hours before surgery
45375683|NCT00787553|Drug|cefazolin plus tinidazole|cefazolin, 2.0 g IV 2 hours before surgery plus tinidazole 2.0 g orally 12 hours before surgery
45375684|NCT00795353|Drug|Amevive exposure|Commercial alefacept prescribed by Physician
45375685|NCT00791297|Drug|CDB-2914|Contraceptive Vaginal Rings delivering a daily dose of 1500 or 2500 μg of CDB-2914
45375686|NCT00385918|Device|Lokomat Training|The Lokomat is a robotically assisted partial weight suspension treadmill training device that has the potential to restore leg function in persons with incomplete leg paralysis.
45375687|NCT00385918|Other|Home stretching then Lokomat training|Patients will be instructed by a physical therapist on how to perform a home stretching protocol 3 times per week for 3 months. The stretching will be monitored via telephone by the study coordinator. This will be an active control arm. After 3 months the patients will be crossed over to Lokomat training for an additional 3 months. This training will be the same as given to the individuals originally randomized to the Lokomat treatment intervention.
45375688|NCT02554409|Biological|Quadrivalent Intradermal Influenza Vaccine (QIV)|No Intervention as part of this protocol
45375689|NCT00791375|Behavioral|Physical activity intervention|Comparison of providing access to a targeted physical activity web-site v. providing information on cancer-related websites
45375690|NCT00385840|Biological|Influenza Vaccine GSK1247446A|Single dose, intramuscular injection
45375691|NCT00385840|Biological|FluarixTM|Single dose, intramuscular injection
45375692|NCT01045876|Drug|Dexamethasone|One dose of 8 mg of Dexamethasone intravenously at induction of anesthesia
45375693|NCT01045876|Other|Placebo|2 ml of 0.9% Saline Solution administered intravenously at induction of anesthesia
45375694|NCT01044550|Procedure|Laparoscopy|Treatment group will undergo a laparoscopy, with repair of the diaphragm if injury found
45375695|NCT01044550|Other|Clinical follow up|Control group will undergo no treatment except suturing of wounds and drainage of the hemo-pneumothorax, if present. Then clinical follow up.
45375696|NCT00385762|Drug|paroxetine|paroxetine 10-40mg daily x 5 weeks
45375697|NCT00385684|Drug|hydrocodone/APAP w placebo PRN|Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid three times daily (TID). With liquid placebo available PRN.
45375698|NCT00385684|Drug|hydrocodone/APAP|Participants judged as responders during Phase A continue the same dose of study medication (hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID). Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
45375699|NCT00385684|Drug|placebo with hydrocodone/APAP PRN|Liquid placebo PRN. Also available PRN is Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid.
45492499|NCT01377558|Other|Strength endurance training intervention|"The strength endurance training intervention group will perform eight exercises on weight machines (Milon circuit training- 60 seconds activity, 30 seconds break)~week 1-4: 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) two times per week~week 5-13: 15 minutes warm up (group) 2 sessions resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 3 sessions resistance training intensity 5 (Buskies) two times per week"
45375700|NCT01044628|Device|Concentrator|Patients allocated to the study group will receive oxygen overnight from an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, AirSep Corporation, Buffalo, NY, USA), to allow the oxygen saturation to be >90%
45693229|NCT01763203|Behavioral|Usual Care|Subjects randomized into the Usual Care arm will receive educational materials about stroke distributed to the Intervention patients and will receive their post-stroke care as usual.
45375701|NCT01044628|Device|Sham concentrator|Patients allocated to the control group will receive ambient air delivered overnight through an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, Airsep Corporation, Buffalo, NY, USA) rendered ineffective by bypassing the sieve beds. The ineffective concentrators will have the same external appearance as the effective ones, allowing the trial to be double-blinded. We have requested approval by Health Canada in order to proceed with the modifications on the oxygen concentrators. Written permission is pending.
45375702|NCT00661661|Drug|CP-690,550|5 mg BID up to 10 mg BID until launch
45375703|NCT00791453|Behavioral|Education|Patients will receive literacy appropriate health information.
45375704|NCT00038467|Drug|Tamoxifen|Tamoxifen 20 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
45375705|NCT00038467|Drug|Exemestane|Exemestane 25 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
45693230|NCT00771238|Device|P500 Mattress|Study mattress
45693231|NCT03809416|Device|Lasers|Fractional carbon dioxide laser will be applied only over spots of deep post-acne scars, while Erbium: Glass will be applied all over face except to the two predetermined spots, i.e. control and another spot where NSS will be injected.
45847045|NCT05350332|Device|Pulmonary Function Testing (PFT)|PFT is a routine standardized clinical test to evaluate lung function. PFT is an outpatient procedure that consist of two parts: spirometry and body plethysmography. In spirometry, participants are asked to breathe through a mouthpiece that measures airflow and volume. Several breathing maneuvers are used to determine normal and maximal volume of inspiration/expiration. Body plethysmography is performed to calculate residual lung volumes. Participants are placed in an enclosed chamber where they are asked again to breathe through a mouthpiece. Changes in pressure in the sealed chamber during breathing can be used to calculate the volume of air that remains in the lung after expiration. The combination of values measured on spirometry and body plethysmography allow for calculation of residual lung volumes including the functional residual capacity and expiratory reserve volume.
45375706|NCT01095367|Procedure|Seprafilm™|"Seprafilm™ Adhesion Barrier is an approved temporary, bioresorbable adhesion barrier to reduce the incidence, extent, and severity of adhesions in patients undergoing abdominal or pelvic laparotomy.~Seprafilm sheets are size 5 x 6 individually-wrapped, sterile membranes. Three or more Seprafilm™ sheets will be placed in the randomized cohort."
45375707|NCT00051025|Drug|ONTAK|
45375708|NCT01095445|Drug|Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)|Dosage Form: Pegetron - powder for solution; Rebetol - capsules Strength: Pegetron Redipen - 120 mcg per pen; Rebetol - 200 mg Route of Administration: Pegetron - subcutaneous; Rebetol - oral
45375709|NCT00660179|Drug|macitentan (ACT-064992)|Tablet, 3 mg dosage, once daily
45375710|NCT00660179|Drug|macitentan (ACT-064992)|Tablet, 10 mg dosage, once daily
45375711|NCT00660179|Drug|placebo|Matching placebo, once daily
45375712|NCT00050167|Drug|Paclitaxel|80 mg/m^2 by vein (IV) Weekly Over 1 Hour x 12 Weeks
45375713|NCT00050167|Drug|Docetaxel|75 mg/m^2 by vein (IV) Over 1 Hour Once Every 3 Weeks
45375714|NCT00050167|Drug|Capecitabine|1500 mg/m^2 by mouth Twice Daily x 2 Weeks
45375715|NCT01095523|Procedure|Laparotomy+ HIPEC +/- CRS|
45375716|NCT01092325|Drug|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020
45375717|NCT01092325|Drug|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020 at dosages higher than in Cohort 1
45375718|NCT01092325|Drug|Placebo for CXL-1020 Cohort 1|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
45375719|NCT01092325|Drug|Placebo for CXL-1020 Cohort 2|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
45375720|NCT01092325|Drug|CXL-1020 Dose for Echo Cohort A|A 4 hour fixed dose of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
45375721|NCT01092325|Drug|CXL-1020 Doses for Echo Cohort B|A 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect followed by another higher 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
45375722|NCT03957265|Procedure|Tapered abutment connection|Rehabilitation of completely edentulous patients with overdentures prostheses.
45375723|NCT01096927|Drug|Amoxicillin and Clavulanic Acid|7 days antibiotic therapy with Amoxicillin and Clavulanic Acid, 1 gr 3 times daily PO
45492500|NCT01377558|Other|Combined aerobic endurance and strength endurance training|"week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT once per week and 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) once per week~week 5-13: 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) once a week and 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 2 sessions resistance training intensity 5 (Buskies) once a week"
45492501|NCT05331612|Behavioral|Blended intervention condition|Participants receive the online protocol treatment and face-to-face sessions during 13 weeks.
45492502|NCT02361190|Drug|Testosterone|Administration of 1ml aqueous nasal spray containing 7mg testosterone propionate
45693232|NCT03809416|Other|Platelets Rich Plasma|Platelet Rich Plasma (PRP) will be prepared from autologous blood collection in a syringe prefilled with anticoagulant solution followed by centrifugation then adding calcium gluconate 10% for induction of platelet activation. Activated PRP will be injected for all carbon dioxide laser spots in each patient immediately after each laser session except for two predetermined spots, i.e. control and sham comparator, which will be injected by normal saline solution (NSS).
45693233|NCT03809416|Combination Product|Lasers plus Normal Saline Solution|Normal Saline Solution will be injected only in one spot after combined lasers resufacing to act as sham comparator compared to the other spot of Lasers plus PRP injection
45375724|NCT01092403|Drug|ASM-024|ASM-024 50 mg of ASM-024 or 200 mg once daily by inhalation
45375725|NCT01092403|Drug|Placebo|Placebo once daily by inhalation
45375726|NCT00660023|Drug|Methoxy polyethylene glycol-epoetin beta|Participants will receive intravenous CERA/Mircera every month, with starting dose based on previous ESA therapy. Treatment will continue for 52 weeks.
45492503|NCT02361190|Drug|Placebo|Administration of 1ml aqueous saline spray
45492504|NCT02361112|Drug|pyrotinib combined with capecitabine|
45492505|NCT03080454|Device|sham Doublestim|PathMaker MyoRegulator device
45492506|NCT03080454|Device|anodal Doublestim|PathMaker MyoRegulator device
45693234|NCT03802942|Dietary Supplement|Glucerna|1 bottle in the morning with breakfast and 1 bottle in the evening with dinner
45693235|NCT03803098|Device|reference measure|measure of a physiological parameter performed with the gold standard medical device
45693236|NCT03803098|Device|alternative measure|measure of a physiological parameter performed with the connected device under evaluation
45492507|NCT05327712|Behavioral|Control group|No outreach during the intervention period beyond an initial eligibility notice.
45492508|NCT05327712|Behavioral|Email only|Email reminders in addition to an initial eligibility notice.
45492509|NCT05327712|Behavioral|Phone only|Phone call offering enrollment assistance in addition to an initial eligibility notice.
45492510|NCT05327712|Behavioral|Phone and email|Phone call and email reminders in addition to an initial eligibility notice.
45693237|NCT01763047|Device|etafilcon A|To be worn in a daily wear modality for a minimum of 6 hours per day.
45693238|NCT01763047|Device|lotrafilcon B|Lenses will be worn in a reuseable modality; cleaned and disinfected each night.
45375727|NCT03953521|Device|intermittent Theta burst stimulation|Stimulation of the left dorsolateral prefrontal Cortex with a specific repetitive transcranial magnetic Stimulation protocol (intermittent Theta burst Stimulation) according to Blumberger et al., 2018, Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692.
45375728|NCT00787709|Behavioral|Pathways|3-year, 30 lesson, School-based universal health promotion curriculum with parent component.
45375729|NCT02554955|Drug|Daclizumab|Participants will receive IV daclizumab (2 mg/kg within 6 hours after transplantation and 1 mg/kg every 2 weeks) for a total of five doses.
45375730|NCT02554955|Drug|Mycophenolate mofetil|Participants will receive mycophenolate mofetil orally (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg BID within first week and 1 g/day BID from second week onwards) for 6 months.
45375731|NCT02554955|Drug|Silrolimus|Participants will receive sirolimus orally (3 mg/day) for 6 months.
45375732|NCT00062647|Drug|Telavancin|Telavancin 10mg/kg/day IV every 24 hrs for up to 14 days
45375733|NCT00062647|Drug|Vancomycin, nafcillin, oxacillin, or cloxacillin|Vancomycin 1 Gram every 12 hr IV (intravenously) OR nafcillin, oxacillin, or cloxacillin 2 Grams every 6 hr IV (intravenously) for up to 14 days.
45375734|NCT00570323|Drug|Arimidex|Aromatase inhibitors
45375735|NCT00570323|Drug|Faslodex|Hormone Receptor
45375736|NCT00791531|Drug|Methotrexate|Oral methotrexate 5mg once daily for 5 consecutive days
45375737|NCT00788099|Drug|Plitidepsin and Sorafenib|Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).
45375738|NCT00788099|Drug|Gemcitabine and Plitidepsin|Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).
45375739|NCT00795587|Drug|variation of mannitol dose|in case of intracranial hypertension up to 20 mmHg lasting more than 10 minutes and without nociceptive stimulation or systemic instability: injection of either 0.4 g/ kg or 0.8 g/ kg of mannitol 20% (randomized) on 20 minutes, with monitoring of neurologic, systemic and biologic datas during 120 minutes
45375740|NCT00788177|Drug|Pegaptanib (Macugen®)|Pegaptanib administered to the subretinal space (first dose) and to the vitreous cavity (following doses)
45693239|NCT04384120|Device|Blood Flow Restriction Therapy|Blood flow restriction cuffs which are FDA approved will be provided to patients randomized into the BFR group. Patients will be provided video instruction and training on how to conduct the traditional therapy exercises with the use of BFR.
45693240|NCT04384120|Procedure|Traditional Therapy|Patients will be provided video instruction and training on how to conduct the traditional therapy exercises.
45375741|NCT00661505|Drug|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms iv every 4 weeks (starting dose)
45375742|NCT04047095|Dietary Supplement|Immunonutrients + normal daily meal|"Glutamine Plus by Fresenius Kabi (one sachet composition: glutamine 10 g, carbohydrate 10 g, β-carotene 1.7 mg, vitamin E 83 mg, vitamin C 250 mg, zinc 3.4 mg, selenium 50 μg, and fibre 1.2 g)."
45375743|NCT04047095|Dietary Supplement|Normal daily meal|Normal daily meal (75-80 g protein)
45375744|NCT00788333|Drug|BMS-754807|Tablets, Oral, Dose escalation to MTD, then MTD to response/EOT, once daily, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
45375745|NCT00788333|Drug|trastuzumab (Herceptin®)|IV solution, IV, 4mg/kg Day 1 loading dose, 2mg/kg once weekly, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
45492511|NCT02943304|Other|Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV|
45693241|NCT04569097|Other|standard of care lingual strengthening|standard or care lingual strengthening approaches with outcome measured with novel pressure metrics
45693242|NCT05743348|Behavioral|Telepsychotherapy|Remotely delivered psychotherapy sessions
45693243|NCT03809338|Diagnostic Test|amh test|Antral follicle count with ultrasound on the 3rd day of menstruation
45693244|NCT01977677|Radiation|radiation therapy|Undergo radiation therapy
45693245|NCT01977677|Drug|temozolomide|Given PO
45693246|NCT01977677|Drug|plerixafor|Given IV
45693247|NCT01977677|Other|laboratory biomarker analysis|Correlative studies
45693248|NCT01977677|Other|pharmacological study|Correlative studies
45375746|NCT00922103|Procedure|Ileal Neo Rectal Anastomosis|Comparison of the Ileal Neo Rectal Anastomosis to the Ileal Pouch Anal Anastomosis in patients treated for medical refractory Ulcerative Colitis
45375747|NCT00922103|Procedure|Ileal Pouch Anal Anastomosis|Comparison of the Ileal Pouch Anal Anastomosis to the Ileal Neo Rectal Anastomosis in patients treated for medical refractory Ulcerative Colitis
45375748|NCT00795899|Drug|Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab|"Cycles 1-4 Epirubicin: 90 mg/m2, i.v. day 1 Cyclophosphamide: 600 mg/m2, i.v. day 1 Every 22d~Cycles 5-8 Paclitaxel: 175 mg/m2, i.v., 3h-infusion day 1 Trastuzumab: 8 mg/kg i.v. at day 0 of the 5th cycle and thereafter each 6 mg/kg i.v. day 1 in the cycles 6-8 Every 22d"
45375749|NCT00795977|Biological|dendritic cells, OK-432|Single Group Assignment
45375750|NCT00796055|Drug|MEDI-547|Administered at a dose and schedule as determined by the subject's enrollment cohort as a 60 minute IV infusion as part of a 21-day treatment cycle.
45375751|NCT00796133|Drug|NES/E2 gel|Lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P<10nmol/L) in 90-95% of the cycles. The high dose will deliver 4.5mg of NES; the medium dose will deliver 3mg of NES, and a low dose of 1.5mg of NES. Based on a 10% absorption rate, 450 µg/d, 300 µg/d and 150 µg/d will be absorbed respectively. The doses of Estradiol will also be tailored to the 3 formulations.
45375752|NCT00796211|Drug|CRx-197|CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
45375753|NCT00796211|Drug|CRx-197|CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
45693249|NCT01762345|Device|pessary (disposable intra-vaginal device)|pessary device(disposable intra-vaginal device)manufactured by Procter & Gamble
45693250|NCT04384744|Drug|growth hormone|growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.
45693251|NCT03803020|Other|fractional flow reserve and SPECT detection|fractional flow reserve and SPECT detection
45693252|NCT01761565|Drug|Single dose of SUF NT 15 mcg|
45693253|NCT01761565|Drug|40 consecutive doses of SUF NT 15 mcg taken every 20 minutes|
45693254|NCT04385056|Biological|MSCTC-0010|MSCTC-0010 is a suspension product for infusion. The active ingredient is the umbilical cord-derived allogeneic mesenchymal stem cells (US-MSCs).
45693255|NCT04576741|Behavioral|bMBI standard practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using standard practices for Mindfulness-Based Cognitive Therapy (30-minutes/day).
45753967|NCT05621785|Device|Lung Ultrasonografi|All babies under 32 weeks of gestation will be included in the study. All data of postnatal corticosteroid users will be recorded using lung USG
45375754|NCT00796211|Drug|Nortriptyline|0.1% nortriptyline HCl topical cream
45375755|NCT00796211|Drug|Calcipotriol|0.005% calcipotriol topical cream
45375756|NCT00796211|Other|Placebo|Vehicle of CRx-197 topical cream (placebo)
45375757|NCT00792233|Other|Withdrawal of anti-TNF therapy|Anti-TNF therapy will be discontinued at the third visit in children who demonstrate persistent inactive disease for at least 6 months.
45375758|NCT00788567|Drug|mycophenolate mofetil|1
45375759|NCT00792311|Procedure|Tsui test|The stimulator is set at frequency of 1Hz with 200ms pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
45375760|NCT00788645|Behavioral|COPD self care advice|Information leaflets on COPD and thermometers to monitor the ambient temperature in the bedroom and living room
45375761|NCT00788645|Behavioral|Poor weather forecast warning|Interactive automated telephone service to contact patients prior to anticipated periods of poor weather
45375762|NCT00792389|Other|Warm humidified C02|Insufflation of warmed humidified gas during laparoscopic cholecystectomy
45375763|NCT00792389|Other|Cool dry C02|Insufflation of cool dry gas during laparoscopic cholecystectomy
45375764|NCT00788723|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) using paired-pulse technique at different interstimulus intervals (ISIs) allows the study of the excitatory and inhibitory system of human motor cortex non-invasively. Motor evoked potentials (MEP) will be recorded, and stored on a VikingSelect (Viasys Healthcare, USA). Two magnetic stimulators (Magstim 200, The Magstim Company Ltd, U.K.) connected through a Bistim and a Magstim figure-of-eight coil will be used for TMS.
45375765|NCT00788801|Drug|ABT-614|Baseline PET scan with radiotracer only, PET scan with radiotracer and ABT-614 Low Dose or ABT-614 High Dose
45375766|NCT00662909|Drug|Mirabegron|Oral
45375767|NCT00662909|Drug|Placebo|Oral
45375768|NCT00050011|Drug|Zoledronic Acid|Participants received Zoledronate 4 mg IV 15-minute infusion every 6 months.
45375769|NCT00050011|Drug|Letrozole|Participants received Letrozole 2.5 mg daily.
45375770|NCT00661427|Biological|cetuximab|Cetuximab 500 mg/m^2 IV over 2 hours every other week
45375771|NCT00661427|Biological|cetuximab|Cetuximab 750 mg/m^2 IV over 3 hours every other week
45375772|NCT00049543|Drug|gefitinib|Given PO
45375773|NCT00049543|Other|placebo|Given PO
45375774|NCT00049543|Other|laboratory biomarker analysis|Correlative studies
45375775|NCT03955393|Other|18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS|18F-FAZA is a highly selective PET radiotracer of hypoxia, which has been recently developed and tested in several studies (10-14). 18F-FAZA has been demonstrated to be a marker of hypoxia and pathological metabolic patterns which are common to all renal cancers.
45375776|NCT00048997|Radiation|Radiation therapy|PCI is given to the whole brain in a dose of 2 Gy per fraction, 5 days per week, for 3 weeks for a total dose of 30 Gy.
45375777|NCT00048997|Other|Observation|
45375778|NCT01092481|Drug|oxaliplatin|to confirm that first 3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX treatment is not inferior to 6 months of oxaliplatin in modified FOLFOX-6 or CAPOX treatment in terms of disease free survival in patients with stage II/III colon cancer.
45375779|NCT01097083|Drug|Coriolus Versicolor|
45375780|NCT01097161|Behavioral|speech therapy with the assistance of an acoustical analysis program|Two weekly speech sessions realized on individual basis for three months period
45375781|NCT01097239|Device|Sonablate 500 (High Intensity Focused Ultrasound (HIFU))|High Intensity Focused Ultrasound (HIFU) Delivered by the Sonablate 500 Transrectal Device
45375782|NCT03955315|Biological|IDCT|Discogenic Cells + Sodium Hyaluronate Vehicle
45375783|NCT03955315|Procedure|Sham|Needle puncture under the muscular layer in front of the intervertebral disc
45375784|NCT00035815|Drug|Insulin like growth factor, type 1|0.05 mg per kg body weight given subcutaneously twice daily
45375785|NCT00035815|Drug|Placebo|The placebo represented the inert suspension vehicle for the IGF-1. It was given as equal volume as the active drug based upon body weight, subcutaneously twice daily.
45375786|NCT00662831|Drug|Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.
45375787|NCT00662831|Drug|Placebo for Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.
45375788|NCT00788879|Behavioral|TSSC|The intervention community is exposed to the media messages of the TSSC campaign. Residents of this community also receive the lay health worker visits as well as benefit from the positive built environment changes.
45382277|NCT05130853|Behavioral|Social Skills and Neurocognitive Individualized Training (SoCIAL)|"SoCIAL is composed of two modules:~Social Cognition Training The Emotions recognition training will train the subject's ability in discriminating between different emotional states through photos and videos. The Theory of Mind (ToM) training will help subjects discriminate between emotional expressions in social contexts and understand other people's mental state with videos that display actors expressing several emotional states. More details in Palumbo et al., 2017.~Narrative Enhancement Training The narrative enhancement training consists in story-telling exercises focused on improving the subject's capacity to comprehend his/her emotional experience."
45753968|NCT03658694|Procedure|Conventional rTMS - study 1|Patients will be undergoing to 10Hz transcranial magnetic stimulation session
45753969|NCT03658694|Procedure|Sham rTMS - study 1|Patients will be undergoing to sham transcranial magnetic stimulation session
45492512|NCT02360956|Drug|Olmesartan medoxomil tablets|Dosage must be individualized. The usual recommended starting dose of Benicar is 20mg once daily when used as monotherapy in patients who are not volume-contracted.For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.
45492513|NCT02360956|Drug|Antihypertensive medication (per doctor suggestion)|Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except ACE inhibitors or ARBs.The drug dose must be individualed.Dosage must be individualized.The patients should take the antihypertensive drugs according to doctors'suggestion.
45375789|NCT00788879|Behavioral|TSSC Randomized Behavioral Intervention for weight loss|"We will enroll up to 200 weight-loss challenge participants to receive text messages on personal mobile phones throughout the challenge. Consent and enrollment in the trial will take place at registration for the weight-loss community challenge in the language of their choice. Recruited participants will be randomly assigned to a group after consenting to the study and the timing and content of text messages will vary according to group assignment (Groups A - D).~Group A will receive weekly reminders for upcoming weigh-in events. Group B will receive the same weekly reminders but will also receive one-way messages every two weeks providing the participant motivational messages/topics and weight loss health tips. Group C will receive the same text messages as Group B but will also receive weekly prompts to self-monitor weight status. Group D will receive the same text messages as Group C plus daily prompts that will act as a guide for the participant to monitor behavior changes."
45375790|NCT00796601|Drug|Esreboxetine|Film coated tablets (2, 6, 8, 10 mg esreboxetine), once daily for 6 months
45375791|NCT00796601|Drug|Placebo|Film coated tablets (0 mg esreboxetine), once daily for 6 months
45375792|NCT00796679|Drug|paricalcitol|oral paricalcitol capsule 1 microgram once daily if iPTH <500pg/mL or 2 microgram once daily if iPTH >=500pg/mL. Thereafter, dose titration in 1 microgram decrement will be done based on safety reasons (that is, for low PTH or high calcium and phosphorus level). The duration of treatment will be for 1 year.
45375793|NCT02554643|Other|Diet|Nutrition intervention, once a week during 12 weeks
45375794|NCT02554643|Other|Soccer|Nutrition intervention, once a week during 12 weeks + Soccer training, 3 x week, during 12 weeks
45375795|NCT02554643|Other|Running|Nutrition intervention, once a week during 12 weeks + Running training, 3 x week, during 12 weeks
45375796|NCT02555423|Drug|Local anaesthetic - chirocaine|
45375797|NCT00792779|Drug|Propofol|Patients in the Propofol Group (PG) will be induced with target-controlled infusion (TCI) of propofol (Diprifusor, AstraZeneca) and remifentanil (Asena PK, Cardinal Health) at the target dose of 6.0 µg.ml-1 and 8.0 ηg.ml-1, respectively. The patients in the Sevoflurane Group (SG) will be induced with remifentanil TCI at target dose of 8.0 ηg.ml-1 and etomidate 0.5 mg.kg-1 in bolus.
45492514|NCT05461716|Device|periodic use of Continuous Glucose Monitoring (CGM)|Identification of hypoglycaemia events, based on use of Continuous Glucose Monitoring (CGM) for at least 14days, in subgroups of T2DM patients with high risk of hypoglycaemia
45847046|NCT05340270|Drug|PD-1 inhibitor+GP|PD-1 inhibitor (200-240mg), gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
45375798|NCT00662363|Drug|Lubiprostone|24 µg po BID given with meals for 6 days
45375799|NCT00662363|Drug|Senna|2 tabs daily for 6 days
45375800|NCT02555033|Other|Resistance training|traditional resistance training
45375801|NCT02555033|Other|Instability resistance training|training under unstable conditions
45375802|NCT00796835|Drug|ER OROS Paliperidone|
45375803|NCT04887155|Behavioral|Cognitive behavioral therapy (CBT)|Group-based transdiagnostic cognitive-behavioral treatment
45375804|NCT00792857|Drug|CTAP201 Injection|Comparison of different dose strengths of CTAP201 after single dose.
45375805|NCT00792857|Drug|Doxercalciferol|Comparison of different dose strengths of doxercalciferol after single dose.
45375806|NCT00796913|Other|Stop medication|Stop medication Stop medication + se supplement
45375807|NCT02554175|Drug|Propofol|Propofol was administered to achieve target propofol Ce
45492515|NCT02367976|Drug|rhprouk|rh-prouk will be administrated within 60 minutes after the patients eligibility confirmed
45492516|NCT05461638|Procedure|Mechanical Alignment and Unrestricted Kinematic Alignment using Medacta GMK Sphere with MyKnee Custom guides|MA places the implant in an average position for all patients based on pre-determined definition of acceptable knee alignment and has become the most common surgical approach for TKA and Unrestricted KA places the implant in a custom position for each patient, completely matching individual anatomy and restoring natural alignment to that of the prearthritic knee.
45753970|NCT03658694|Procedure|Conventional rTMS - study 2|Patients will be undergoing to 10Hz transcranial magnetic stimulation session
45753971|NCT03658694|Procedure|Patterned rTMS - stage 2|Patients will be undergoing to theta-burst transcranial magnetic stimulation session
45753972|NCT04990375|Device|tDCS|5 sessions of 20-minute tDCS at 2 mA over the dorsolateral prefrontal cortex (35cm² sponge)
45375808|NCT00789269|Drug|rhubarb|14 days of rhubarb
45375809|NCT00789269|Drug|placebo|14 days of placebo
45382278|NCT05130853|Other|Treatmment-as-usual|Subjects that will be randomized in this group will receive their treatment as usual for the whole length of the study. TAU includes all the psychiatric therapies (pharmacological, psychological, occupational etc) that subjects may have begun before study's enrollment.
45375810|NCT00793013|Device|Volume-Cycled Assist-Control (AC) mode|"Patients ventilated with volume-cycled assist-control mode with PEEP and goal FIO2 < 40%~Rate of mandatory time-cycled, pressure controlled breaths,initially at 12 per breaths/min~Initial tidal volume set at 8mL/kg using predicted body weight (PBW) with a goal of 6mL/kg & setting positive end-expiratory pressure (PEEP) based on level of initial FiO2~Inspiratory to Expiratory ratio set at 1:1 to 1:3~If frequency of triggered breaths increased greater than 10 per min sedation will be increased. If needed,rate of mandatory breaths increased~Mgmt of PEEP will be conducted as per the ARDSnet Protocol~Oxygenation goal PaO2: PaO2-55-80 mm Hg O2 Sat: 88-95%~Tidal volume and respiratory rate adjusted to the desired pH and plateau pressures per ARDSnet protocol"
45375811|NCT00793013|Device|Airway Pressure Release Ventilation (APRV) mode|"Ventilation uses Drager Model X1~Spontaneous breathing allowed throughout ventilatory cycle at 2 airway pressure levels~Time periods for the high & low pressure levels can be set independently~Duration of the lower pressure level will be adjusted to allow expiratory flow to decay to 75% of total volume~Duration of higher pressure levels will be adjusted to produce 12 pressure shifts per min~Spontaneous frequency will be targeted for 6 to 18 breaths/per min~If spontaneous breathing is achieved,level of sedation will be decreased~If spontaneous respirations are >20 breaths/min, sedation will be increased~If spontaneous breathing frequency increased greater than 20/per min, sedation was increased and if needed the mechanical frequency increased"
45492517|NCT05461638|Procedure|Mechanical Alignment and Restricted Kinematic Alignment using Medacta GMK Sphere with custom cutting guides|MA places the implant in an average position for all patients based on pre-determined definition of acceptable knee alignment and has become the most common surgical approach for TKA and Restricted KA places the implant in a custom position for each patient, closely matching with anatomy and natural alignment of the individual's knee.
45492518|NCT02360800|Procedure|Spray Fibrin Sealant|Baxter Tisseel (Fibrin Sealant) is sprayed in the mediastinum at the end of the operation afetr routine chest hemostasis protocol has been completed, right before closing the chest.
45693256|NCT04576741|Behavioral|bMBI shorter more frequent practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using shorter, more frequent practice than standard Mindfulness-Based Cognitive Therapy (2x15-minutes/day).
45693257|NCT01619579|Device|AVACEN Thermal Exchange System|Non-invasive device forms vacuum around subject's hand, enabling efficient core body temperature adjustment using heating element inside device.
45693258|NCT03830476|Behavioral|Acceptance- and Commitment therapy group for parents to children with disabilities|ACT groups adjusted for parents to children with (any kind of) disabilities.
45693259|NCT03830476|Behavioral|Treatment as usual.|Treatment as usual within outpatient disability services.
46054099|NCT02792985|Behavioral|Multisensory stimulation protocol|"Participation in occupation-based multisensory stimulation (e.g. personal care with aromatic soaps, varying water temperatures and textured sponges, drink preparation of different flavoured beverages) with a variety of different sensory stimuli (e.g. strong smells, different shapes and weights). The participant will receive two individual 30-minute therapy sessions with an Occupational Therapist.~An enriched environment will be set up in the participant´s bedroom. It will include items that provide a range of meaningful sensory stimuli (e.g. familiar personal objects, projection of photos and known places, familiar music). The participant is encouraged to follow a timetable including regular rest breaks through out the day in their room."
46054100|NCT02792985|Behavioral|Control protocol|"Retraining of basic activities of daily living or participation in table top tasks and games in an individual 30 minute session or a one hour small group session with an Occupational Therapist.~Minimal changes are made to the participant´s room (e.g. orientation board, photos of family and friends)."
46054101|NCT05758402|Diagnostic Test|Routine practice groups|Routine practice groups
46054102|NCT05758402|Diagnostic Test|EARP group|EARP group
46054103|NCT02789631|Other|assessment|
45375812|NCT00789425|Dietary Supplement|Standardized Extract of Olive Polyphenols|"Dietary supplement containing 250 mg of a standardized extract of olive polyphenols per day in 1 capsule.~A supplement with 1000 mg calcium per day will be supplied together with the active treatment."
45375813|NCT00789425|Dietary Supplement|Placebo|Placebo (starch). A supplement with 1000 mg calcium per day will be supplied together with the active treatment.
45375814|NCT00793091|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 120 days
45375815|NCT00793091|Drug|Placebo|4 drops applied daily for 120 days
45375816|NCT00789503|Dietary Supplement|Bread fortified with vitamin D3 and calcium|Bread fortified with vitamin D3 (5000 IU per bun) and calcium
45375817|NCT00789659|Other|Negative pressure dressing|A completely occlusive dressing that is attached to a device that allows a constant negative pressure of 125 mmHg to be generated.
45375818|NCT00797069|Other|standard nutritional product (medical food)|once during crossover
45375819|NCT00797069|Other|nutritional product for diabetes (medical food)|once during crossover
45375820|NCT00797069|Other|diabetes specific experimental nutritional product (medical food)|once during crossover
45375821|NCT00793247|Drug|PRU-PLA-PRU-PLA|
45375822|NCT00793247|Drug|PLA-PRU-PLA-PRU|
45375823|NCT00793247|Drug|PLA-PRU-PRU-PLA|
45375824|NCT00793247|Drug|PRU-PLA-PLA-PRU|
45375825|NCT00797303|Drug|Bevacizumab|subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months
45375826|NCT00800579|Drug|GS-9411|Inhaled GS-9411 dissolved in sterile saline
45375827|NCT00800579|Drug|Placebo|Inhaled volume-matched placebo in sterile saline
45375828|NCT00661271|Behavioral|Mindfulness-based stress reduction (MBSR)|8 weekly sessions with instruction designed to enhance mindfulness--mindful meditation, mindful yoga, and discussion of mindfulness practice, with one retreat session.
45375829|NCT00661271|Behavioral|Healthy topics|8 week health education program with one retreat session
45375830|NCT00800657|Procedure|Pacing and Stem Cells Implantations.|Implantation of Cardiac Ressyncrhonization combined with the implantation of Stem Cells Hematopoietics.
45375831|NCT00800657|Procedure|Pacing and Stem Cells Implantation|Pacing and Stem Cells Implantation.
45693260|NCT01736215|Drug|Erythropoietin: Observational study|This is an observational study. Participants receiving erythropoietin (dosage and regimen will comply with Thai Food and Drug Administration approval package insert) will be observed.
45693261|NCT04384900|Procedure|Prone position ventilation|Patients are placed in a prone position using specialized equipment.
46054104|NCT02789709|Procedure|Surgery|Segmental resection for colon cancer and anterior resection in patients with rectal cancer
46054105|NCT02789787|Procedure|Maxillary Protraction|"Maxillary protraction is an alternative non-surgical approach to correct the Cl III malocclusion. At ages 11- 14, the maxillary sutures have not fused and can be mobilized by alternating weekly expansion and constriction with a rapid palatal expander (RPE), thereby allowing the maxilla to be protracted in order to correct the underbite. This treatment is offered to the patients, age 11-14, who have the Cl III malocclusion with or without cleft lip and palate."
45375832|NCT00922181|Device|Microwave ablation|Liver tumors are destructed/ablated using single-probe microwave energy device
45375833|NCT00922181|Device|Radiofrequency ablation|Liver tumors are destructed/ablated using radiofrequency energy device
45375834|NCT00661193|Drug|carboplatin|given IV
45375835|NCT00661193|Drug|erlotinib hydrochloride|given orally
45375836|NCT00661193|Drug|paclitaxel|given IV
45375837|NCT04046315|Diagnostic Test|CMR|GLS measurement with CMR
45375838|NCT00797537|Procedure|Echography|Echography
45375839|NCT00800813|Behavioral|Penile Exam, Peyronie's Plaque and Erectile function assessment|"At the baseline visit, the patient's co-morbidities, height, weight with calculation of body mass index will be documented.~After surgery, the patient will be instructed to keep a diary to record erectile function including how often they use a PDE-5 inhibitor or injection therapy and each time they get an erection and the level of rigidity. The diary is required to document PDE-5 inhibitor and injection therapy use and response in each sexual encounter, unlike the IIEF questionnaire, which addresses erectile function over a 4-week period. Accurate documentation is essential for erectile function assessment, as patient choice of erectile function medication may differ in each sexual encounter, and accordingly, the achieved rigidity level."
45375840|NCT00793481|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy non-invasively measure changes in the microvasculature
45375841|NCT00800969|Procedure|FDG-PET-CT|Radiologic standard procedure
45375842|NCT00801047|Drug|Bupivacaine epidural|Bupivacaine 0.1%, fentanyl 1 mic/kg
45375843|NCT00801047|Drug|Remifentanil|40-50 mic per 1-2 min via PCA
45375844|NCT00801125|Drug|natalizumab|
45375845|NCT00801203|Drug|IRCT|Up to two administrations of the IRCT during a single cough testing session
45693262|NCT03808714|Behavioral|TOUCHDOWN|We expect the intervention to consist of 3 to 4 group sessions and at least one individual session plus pharmacological consultation(s) via Skype, but this will be determined during pretesting. CHWs will have IPads with cellular connectivity and will be present when the pharmacological approach is discussed with the participant so that they can reinforce the message with the participant and be the liaisons between the participant and physician.
45693263|NCT03808714|Behavioral|Control Group|Alabama Quitline
45693264|NCT05743114|Device|Elemind Neuromodulation (ENMod)|The ENMod is a headband that measures electroencephalogram (EEG) activity, computes the phase of neural oscillations in real-time, and delivers auditory pulses intended to interact with ongoing neural oscillations.
45492519|NCT02360800|Procedure|Traditional Hemostasis and chest Closure Routine|Routine chest hemostasis and closure protocol (gauzes and inspection till satisfactory according to the surgeon)
45492520|NCT02360878|Device|EndoBarrier Gastrointestinal Liner|Implantation with the EndoBarrier
45492521|NCT03501966|Drug|Acetazolamide|Medical therapy including diet
45492522|NCT03501966|Procedure|Optic Nerve Sheath Fenestration|Medical therapy including diet + optic nerve sheath fenestration
45847047|NCT05340270|Drug|GP|Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
45847048|NCT05336760|Diagnostic Test|Iowa Oral Performance Instrument (IOPI)|IOPI measures the peak pressure of the tongue strength and endurance using a disposable bulb placed on a hard palate behind the front teeth or at the base of the tongue. The participants will be asked to press the bulb with their tongue with maximum pressure, three times. To measure the endurance, the participants will be asked to hold the pressure for as long as they can.
45375846|NCT00801281|Drug|Rituximab|Rituximab 375 mg/m2 i.v. d. 1 q. 21 d.
46054106|NCT02789787|Procedure|Orthognathic Surgery|The orthognathic surgery is the current standard of care for treating the Cl III malocclusion after pubertal growth. This treatment is offered to the patients, after pubertal growth, who have the Cl III malocclusion with or without cleft lip and palate.
45375847|NCT00801281|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 i.v. d. 1 q. 21 d.
45375848|NCT00801281|Drug|Doxorubicin|Doxorubicin 50 mg/m2 i.v. d. 1 q. 21 d.
45375849|NCT00801281|Drug|Vincristine|Vincristine 1.4 mg/m2 (max. 2 mg) i.v. d. 1 q. 21 d.
45375850|NCT00801281|Drug|Prednisone 1|Prednisone 100 mg p.o. d. 1-5 q. 21 d.
45375851|NCT00801281|Drug|Prednisone 2|Prednisone 40 mg/m2 p.o. d. 1-5 q. 21 d.
45492523|NCT03501966|Procedure|Ventriculoperitoneal CSF Shunting|Medical therapy including diet + ventriculoperitoneal CSF Shunting
46054107|NCT03935607|Diagnostic Test|Transvaginal sonography|Transvaginal sonography for the evaluation of an amniotic fluid pocket preceding the fetal presenting part.
45492524|NCT02361034|Drug|GRC 27864|
46054108|NCT02792751|Device|Bispectral Index Monitorisation (BIS)|Standard monitoring was performed with electrocardiography, pulse oximetry and non invasive blood pressure. Additionally, Bispectral index (Aspect Medical Systems, Natica, MA) electrodes were connected to Group B patients
46054109|NCT02792751|Other|Ramsey Sedation Scale|Propofol administration was done to keep the Ramsey Sedation scale of 3 or 4
46054110|NCT02690025|Drug|ZP1848|
45492525|NCT02361034|Drug|Placebo|
45492526|NCT02355184|Drug|PRO 140 350mg weekly SQ injection.|CCR5 Antagonist
45492527|NCT05326854|Other|supportive care|After Medical Termination Navigation Assisted Care Program admission to the service will be held in the form of three interviews in the clinic before and after termination. The planned training will be given in three sessions and a different training module will be applied in each meeting. After the patient is discharged, three sessions will be held remotely via telephone.
45492528|NCT02355262|Other|Informational Intervention|Receive CATCH-UP intervention
45492529|NCT02355496|Other|Displaying medicare fee data|Using the computerized order entry system to make medicare fee data for a randomly selected inpatient laboratory tests transparent to providers at the time of order entry.
45492530|NCT03477630|Biological|Platelet Rich Plasma|intra-articular infiltration of 8 ml of autologous PRP every 15 days.
45492531|NCT03477630|Drug|Hyaluronic Acid|intra-articular infiltration of a single dose of HA
45492532|NCT01379040|Other|Cystic Fibrosis patients|
45492533|NCT02981342|Drug|Abemaciclib|Administered orally
45375852|NCT00801359|Procedure|Phacoemulsification|
45375853|NCT00801359|Drug|BSSPlus solution|
45375854|NCT00801359|Drug|Lactated Ringer's solution|
45375855|NCT00801437|Drug|Xalacom|Xalacom 1 drop into the affected eye daily
45492534|NCT02981342|Drug|LY3023414|Administered orally
45492535|NCT02981342|Drug|Gemcitabine|Administered IV
45492536|NCT02981342|Drug|Capecitabine|Administered orally
45492537|NCT02794246|Biological|CART-19 cells|
45492538|NCT02355106|Device|PolarStart System|Atrial flutter Ablation
45847049|NCT05336760|Diagnostic Test|Mann Assessment of Swallowing Ability (MASA)|MASA is a standard clinical swallowing assessment protocol including general patient examination, on-the-outside visible signs of oral preparatory and transportation phase and pharyngeal phase of swallowing function.
45375856|NCT00801515|Drug|Maraviroc|150 mg twice per day
45375857|NCT00797615|Behavioral|Active intervention|12-week family-based weight gain intervention program focused on dietary intake and physical activity for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
45375858|NCT00797615|Behavioral|Alternative Intervention|12-week alternative intervention addressing self-esteem, for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
45375859|NCT00797693|Drug|Misoprostol ( Cytotec) 200 microgram a tablet|In this study, two arms we put under study ... and to find how far a single drug, Misoprostol, is effective to have changes on the cervix.
45375860|NCT00797771|Device|"Adi Insulin pump"|insulin delivery will be defined by the physician
45375861|NCT00797849|Device|Farabloc Limb Cover|Wear prosthetics, sock or glove laminated with Farabloc
45375862|NCT00797849|Device|Sham Limb Cover|Wear prosthetics, sock or glove laminated with sham material
45375863|NCT00793559|Drug|terlipressin|1 mg of terlipressin one time only
45375864|NCT00793559|Drug|terlipressin|1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
45375865|NCT00797927|Drug|quetiapine|quetiapine (with equivalent dose to original antipsychotic agent) would replace the original antipsychotic agent for 28 days
45375866|NCT00797927|Other|no intervention|keep the original conventional antipsychotic agent for 28 days
45375867|NCT00798005|Drug|XRP0038 (NV1FGF)|
45375868|NCT00801593|Procedure|Steroid injection into the TMJs.|In case of otherwise noncontrollable TMJ involvement steroids are injected into arthritic TMJs under MRI guidance.
45375869|NCT02554097|Procedure|endoscopic sphincterotomy|Sphincterotomy (EST) is performed to remove the common bile duct stone.
45693265|NCT01786603|Drug|Rasagiline|Rasagiline 2mg once a day for 12 months.
45375870|NCT02554097|Procedure|laparoscopic common bile duct exploration|Transductal exploration was carried out to remove the common bile duct stone. Primary closure or a T tube drainage was performed according to the results of transductal surgery.
45375871|NCT02554097|Procedure|laparoscopic transcystic common bile duct exploration|A wide local dissection of Calot's triangle is performed and a 2.8mm, 3-mm or 5-mm flexible choledochoscope according to the diameter of the cystic duct is inserted through the cystic duct into the common bile duct. After the common bile duct stone is removed, the cystic duct was ligated with Hem-o-lok.
45375872|NCT02554097|Procedure|laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed to remove the gallbladder.
45375873|NCT00793715|Procedure|Decompressive laparotomy with temporary abdominal closure|Surgical intervention including midline incision with temporary abdominal closure and several planed staged relaparotomies
45375874|NCT00793715|Procedure|Percutaneous puncture with placement of abdominal catheter|Installation of abdominal catheter percutaneously via abdominal centesis 2cm bellow the umbilicus
45375875|NCT00801671|Procedure|cPAP|After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)
45375876|NCT04045925|Other|Taïso|Taiso is a physical preparation practice of which the French Judo Federation is a state delegate. It is practiced in most French dojos. During each course, Taiso's practice works the fundamental motor skills (coordination, static and dynamic balance, locomotion and grip), muscle strengthening, target work by simulated attacks-defenses exercises without blows or projections, relaxation and the specific work of knowledge to fall and rise with graduation and progressivity in the intensity and complexity of the exercises as and when practiced.
45375877|NCT00801749|Behavioral|sleep|
45375878|NCT02553785|Device|Revivent TC|
45375879|NCT00798083|Drug|topical amitriptyline 2%, ketamine 1%, and lidocaine 5% in pluronic lecitine organogel(AKL in PLO gel)|Subjects will be taught to apply topical 2%amitriptyline, 1% ketamine and 5% lidocaine(AKL) in PLO gel to the sites of maximum neuropathic pain three times per day for up to 2 weeks after completion of radiotherapy.
45375880|NCT00794027|Behavioral|Yoga Classes|8 weeks of yoga training that occurs 2 times per week. The patients will also perform yoga breathing at home 3 times per week.
45375881|NCT00794027|Behavioral|Yoga classes|Heart failure patients will undergo 8 weeks of yoga training 2 times per week and perform yoga breathing at home 3 times per week
45375882|NCT00798239|Device|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micorgrams/cc BVF
45375883|NCT00798239|Other|Iliac crest autograft|autograft
45492539|NCT02360722|Other|Oral Nutritional Supplement|Will receive ONS twice a day for 6 months and two nutritional education at baseline and 3 months after intervention
45693266|NCT01786603|Drug|Placebo|Placebo (looks like study drug but has no active ingredients) once a day for 12 months.
45375884|NCT00798239|Device|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|750 micrograms/cc BVF
45375885|NCT00798395|Drug|Org 50081|1.5 mg on day 1-7
45492540|NCT02360722|Other|Nutritional Education|Two nutritional education courses at baseline and 3 months after intervention
45492541|NCT02639026|Radiation|Radiotherapy|two schedules of radiotherapy (8 Gy x 3 fractions and 17 Gy x 1 fraction)
45492542|NCT02639026|Drug|MEDI4736|20 mg/kg MEDI4736 every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses
45847050|NCT05336760|Diagnostic Test|Fiberoptic Endoscopic Evaluation of Swallowing|The subjects will ingest up to 10 boluses ranging in thickness and volume (from thin to extremely-thick and a cookie).
46054111|NCT02792907|Device|Compressive stocking|"After hindfoot and middlefoot surgery the patients from the Intervention Group will be treated with compressive stockings the removal of the suture. That means from the end of week 2 until the end of week 6 after surgery.~Additionally the patients wearing behaviour is monitored by a electronic sensor, which is implanted in the patient´s stocking."
45375886|NCT00798395|Drug|Org 50081|4.5 mg on Day 1-7
45375887|NCT00798395|Drug|Placebo|Once daily on Day 1-7
45375888|NCT00798395|Drug|zopiclone|Single dose of 7.5 mg
45375889|NCT00801905|Drug|Nepafenac|Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
45375890|NCT00801905|Other|Lubricant|Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
45375891|NCT00658541|Drug|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
45375892|NCT00658541|Drug|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
45375893|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|2.5mg po daily
45375894|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|100mg po monthly on a single day
45375895|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|100mg po monthly over 2 consecutive days
45375896|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|150mg po monthly
45375897|NCT00048061|Dietary Supplement|Calcium|500 mg/day
45375898|NCT00048061|Dietary Supplement|Vitamin D|400 IU/day
45375899|NCT00802061|Behavioral|Sleeping position in glaucoma patient|
45375900|NCT00802139|Drug|venoferrum(iron sucrose)|administer once weekly calculated quantity of Venoferrum® ampoules according to body weight and Hb level.
45375901|NCT00802139|Drug|Bolgre (Iron acetyl-transferase)|Twice daily administration with Bolgre® soln (one pouch per dosing which is equivalent to 40mg of iron) for 5 weeks
45375902|NCT00802217|Drug|Civamide|5 mg liquid filled softgel capsules
45375903|NCT00802217|Drug|Civamide|5 mg x 2 liquid softgel capsules
45375904|NCT04808141|Device|Digital program|Patients in the digital intervention group will benefit from an 8-week program composed of therapeutic exercise, education and cognitive behavioural therapy (CBT) program provided by SWORD Health. These patients will be referred to SWORD Health by the investigator who identified the candidate. SWORD Health will then assign a physical therapist to each patient. The physical therapist will contact the patient for onboarding and will manage the case.
45375905|NCT04808141|Other|Conventional PT|Patients in this group will benefit from a 8-week program consisting of two 30 min face-to-face PT sessions per week in an outpatient clinic setting, for a total of 16 sessions. The program will follow the protocol outlined in Annex 3, which can however be adapted by the physical therapist to the specific needs of the participant. Participants in this group will be considered as dropouts if they: a) choose to abandon the study; b) miss four consecutive scheduled PT sessions.
45375906|NCT03955159|Dietary Supplement|Probiotic supplementation|The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.
45375907|NCT00802295|Drug|Gonadotrophins|Administration of standard ovarian stimulation protocol
46054112|NCT02792673|Other|embryos will be transferred using a medium of 0.5 mg/mL of Hyaluronan-enriched medium (EmbryoGlue®, Vitrolife, Sweden)|
45375908|NCT00802295|Drug|Low dosis Gonadotrophin|
46054113|NCT02792673|Other|embryos will be transferred using a medium of 30% Protein-supplemented Culture Medium (Global total®, Life Global group, Canada)|
46054114|NCT02792673|Other|a novel technique in which embryos will be transferred using a medium of autologous Follicular Fluid|
46054115|NCT02792673|Device|Labotect embryo transfer catheter|
46054116|NCT02792595|Other|Negative Control|Untreated area
46054117|NCT02792595|Other|Positive Control|High SPF Standard P3/SPF 15
46054118|NCT02792595|Other|Test Product A|Yosemite Falls (Forte Day SPF upgrade) Variant A
46054119|NCT02792595|Other|Test Product B|Yosemite Falls (Forte Day SPF upgrade) Variant B
46054120|NCT02792595|Other|Test Product C|Yosemite Falls (Forte Day SPF upgrade) Variant C
46054121|NCT02792595|Other|Test Product D|Yosemite Falls (Forte Day SPF upgrade) Variant D
46054122|NCT02792595|Other|Test Product E|Yosemite Falls (Forte Day SPF upgrade) Variant E
45375909|NCT03954925|Procedure|Anatomic anterior cruciate ligament with short hamstring graft technique|ACL and short hamstring graft
45847051|NCT05336760|Diagnostic Test|Respiratory function measurements|Respiratory function measurements will include forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP), all expressed in percentage of predicted values. Conventional methods of testing will be applied.
45492543|NCT02639026|Drug|Tremelimumab|1 mg/kg every 4 weeks for 4 doses
45492544|NCT02360644|Dietary Supplement|Cholecalciferol|Vitamin D deficient patients, in both Arms, will be administered Cholecalciferol 5,000 IU daily.
45492545|NCT02354716|Device|EndoFLIP|The Endolumenal Functional Lumenal Imaging Probe Imaging System is a technology developed to measure the dimensions & function of a variety of hollow organs throughout the body. Since receiving FDA clearance for sale in the United States EndoFLIP has been used in a variety of clinical applications. We intend to investigate the potential clinical applications of EndoFLIP in the upper GI tract in patients with esophageal stenoses who require endoscopic therapy for benign esophageal strictures. The use of EndoFLIP to characterize a stricture pre- & post- dilation may offer insight in to the clinical and endoscopic predictors of successful stricture dilation, & what characteristics determine & predict refractory & recurrent strictures.
45492546|NCT02366026|Biological|IR103|REMUNE HIV/AIDS Vaccine with two adjuvants IFA + Amplivax
45492547|NCT02354794|Dietary Supplement|One form of arginine|3 capsules containing 0.5g of one form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 month
45492548|NCT02354794|Dietary Supplement|placebo|3 capsules containing 0.5g cellulose (non active product) 3 times daily (4.5g per day) for 1 month
45492549|NCT03159910|Behavioral|Shoulder-Café|Education and individual counselling, clinical examination, supervised shoulder exercise. Some participants can be offered a workplace visit.
45693267|NCT00786916|Drug|normal saline|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive saline placebo IV (Group A) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
46054123|NCT02792595|Other|Test Product F|Yosemite Falls (Forte Day SPF upgrade) Variant F
45375910|NCT03954925|Procedure|Anatomic anterior cruciate ligament with a standard hamstring graft technique|ACL with standard hamstring graft
45693268|NCT00786916|Drug|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.25 mg/kg IV (Group B) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
45847052|NCT05313594|Diagnostic Test|Mixed meal challenge test|Mixed meal consumption followed by postprandial blood sampling
45375911|NCT00802373|Drug|Solifenacin succinate|oral
45375912|NCT00802373|Drug|Tolterodine|Oral
45375913|NCT01092715|Procedure|Spinal mobilization|Non thrust mobilization to the cervical spine
45375914|NCT01092715|Procedure|Massage|Sedative massage to cervical paraspinal muscles
45375915|NCT01092715|Procedure|Neck exercises|Range of motion exercises to include foraminal opening
45375916|NCT03957109|Procedure|general anesthesia|
45375917|NCT03952975|Other|Vaginal bleeding|Vaginal bleeding was classified into four categories according to the timing. Intraoperative bleeding (defined as bleeding that occur during the LEEP procedure), early postoperative bleeding (defined as bleeding that occur between end of the LEEP procedure and home discard), late postoperative bleeding (defined as bleeding that occur within two weeks after the home discard, and required hemostatic interventions such as electrocauterization, gauze packing, or cervical suturing, excluding menstrual bleeding), and persistent postoperative bleeding (defined as vaginal bleeding that occurs more than 2 weeks after the procedure with or without required hemostatic interventions, excluding menstrual bleeding).
45375918|NCT00802451|Drug|Mesalamine|
45375919|NCT03956953|Drug|BMS-986165|Dose 1 or Dose 2 on Day 1, and from Days 5-19'
45375920|NCT03956953|Other|Placebo|Placebo matching Dose 1 or Dose 2 on Day 1, and from Days 5-19
45375921|NCT00798473|Drug|zoledronic acid|Zoledronic acid 0.066 mg/kg (maximum 4 mg) given as a single intravenous infusion over ten minutes
45375922|NCT00798473|Other|IV saline infusion|
45375923|NCT01583881|Procedure|renal denervation|Renal denervation
45375924|NCT00798551|Behavioral|Risk counseling|cardiovascular risk counseling regarding elevated blood pressure
45375925|NCT03955003|Behavioral|Group Drumming|Cancer patients will be led by a Board Certified Music Therapist to participate in group drumming for one hour per week, for six weeks.
45375926|NCT03955003|Other|Attention Control|This is intended to control for time, place, and group affect.
45375927|NCT03955237|Procedure|Drug: dextrose containing infusion|Drug: infusing dextrose containing or non glucose fluid according to blood glucose level
45847053|NCT05313594|Diagnostic Test|MRI|MRI imaging
45847054|NCT05313594|Diagnostic Test|DEXA|DEXA scan
45847055|NCT05313594|Device|Freestyle Libre|Continuous blood glucose measurement
45847056|NCT05313594|Device|ActivPAL3|Continuous physical activity measurement
45847057|NCT05289414|Device|Radiofrequency|patients with diagnosis of cervicogenic headache will be subjected to radiofrequency treatment
45492550|NCT03159910|Behavioral|Shoulder-Guidance|Home-based shoulder exercise and written counselling.
45492551|NCT03159442|Drug|AZD8871|Powder for inhalation administered via single dose DPI 300 and 600 µg/inhalation.
45492552|NCT03159442|Drug|Placebo|Powder for inhalation administered via single dose DPI
45492553|NCT02360332|Behavioral|Project SEARCH plus ASD Supports|Project SEARCH program (Rutkowski, Daston, Kuiken, and Riehle, 2006) is a work based learning model for high school transition that was developed at Cincinnati Children's Hospital Medical Center. The model provides complete immersion in the workplace. Students spend their entire school day at the workplace for a full school year. Consistent with principles of work based learning, Project SEARCH facilitates the development of a broad range of high-quality jobs within the employer organization and provides over 700 of supervised work experience. The model also relies on the intensive application of supported employments strategies (task analysis and customization, systematic instruction, ongoing support, etc.) to allow the participation of individuals with extensive support needs.
45492554|NCT03160300|Device|Music with Binaural Beats|Relaxing music with embedded binaural beats at a frequency of 5 Hz
45492555|NCT03160300|Device|Music|Relaxing music without a binaural beat component
45492556|NCT02360566|Behavioral|Participatory Video Intervention for Early Psychosis|The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
45492557|NCT03428100|Drug|Baricitinib|Administered orally.
45492558|NCT03428100|Drug|Placebo|Administered orally.
45492559|NCT03428100|Drug|Topical corticosteroid|Administered as standard-of-care.
45847058|NCT05289414|Procedure|Greater occipital nerve block|patients with diagnosis of cervicogenic headache will be subjected to Greater occipital nerve block
45847059|NCT05269368|Procedure|Wicking|Absorbable or non-absorbable wicking
45847060|NCT05269368|Procedure|No wicking|No wicking after surgery
45847061|NCT05266404|Drug|Dapagliflozin/sitagliptin FDC|Subjects will receive single dose of Dapagliflozin/sitagliptin FDC orally.
45847062|NCT05266404|Drug|Sitagliptin|Subjects will receive 100 mg single dose of Sitagliptin orally.
45847063|NCT05266404|Drug|Dapagliflozin|Subjects will receive 10 mg single dose of Dapagliflozin orally.
45847064|NCT05212584|Biological|CD7CAR T cells|CD7 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
45847065|NCT05206188|Behavioral|Mastering the World of Work (MWW)|Mastering the World of Work (MWW) is a 29-session individual intervention comprised of 7 modules each covered in 4 sessions, and a wrap-up session. Participants in the randomized clinical trial will be offered to meet on a weekly basis with the MWW clinician assigned to work with them.
45847066|NCT05184738|Other|Experimental Treatment, Oligomeric nutritional formula|Intervention group will receive a oligomeric nutritional formula (Bi1 peptidic Adventia Pharma, Spain).
45847067|NCT05184738|Other|Control Treatment|Standard nutritional formula (isocaloric and isoprotein compared to the experimental treatment).
45847068|NCT05175924|Other|Nanpharmacological method|Virtual Reality
46054124|NCT02792595|Other|Test Product G|Yosemite Falls (Forte Day SPF upgrade) Variant G
46054125|NCT02792595|Other|Test Product H|Yosemite Falls (Forte Day SPF upgrade) Variant H
46054126|NCT00906204|Biological|Single-dose rabbit Anti-thymocyte Globulin induction|6 mg of rATG administered in a single dose on the day of kidney transplantation
46054127|NCT00906204|Biological|Divided-dose rabbit Anti-thymocyte Globulin induction|6 mg/kg total rabbit Anti-thymocyte Globulin dose administered as 1.5 mg/kg doses on 4 sequential days, beginning on the day of kidney transplantation.
46054128|NCT02792361|Procedure|Standard Suction Drain|The intervention of the experimental group will be a standard suction drain placed at the surgical site following a Pterional Craniotomy.
45847069|NCT05150418|Drug|Oxygen gas|Oxygen 15 l/min
45847070|NCT05150418|Drug|Air|Room air 15 l/min
45847071|NCT05146206|Other|Observational|In this observational study, participants initated on RYALTRIS/DYMISTA nasal spray will complete a cross-sectional online survey that includes a Best-Worst Scaling task to capture their satisfaction and importance of various treatment attributes.
45847072|NCT05127564|Drug|Diroximel fumarate|Administered as specified in the treatment arm
45847073|NCT05122494|Drug|Hemay022+AI|hemay022：orally once daily，A 21-day cycle
45847074|NCT05122494|Drug|Lapatinib+Capecitabine|Take the pills according to the instructions
45492560|NCT02365948|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol~Pharmaceutical Form: Prefilled syringes~Concentration: 200 mg/mL~Route of Administration: Subcutaneous injection"
45847075|NCT05107518|Behavioral|Children Participation Assessment Scale|Evaluation is carried out to examine the validity and reliability of the Turkish version of the Children Participation Assessment Scale. While examining the validity of the scale in children, it was planned to use the Child Health Questionnaire scale, which had previously been shown to be reliable and valid in healthy children with different disability levels.
45375928|NCT04045769|Drug|Saroglitazar magnesium 4mg|1 tablet of 4 mg Saroglitazar magnesium; 4 tablets of placebo to be administered orally
45375929|NCT04045769|Drug|Placebos|5 tablets of placebo to be administered orally
45375930|NCT04045769|Drug|Moxifloxacin 400mg|1 tablet of 400 mg Moxifloxacin to be administered orally
45375931|NCT04045769|Drug|Saroglitazar magnesium 20 mg|5 tablets of 4 mg Saroglitazar magnesium to be administered orally
45375932|NCT01095601|Drug|Avanafil|"Treatment A: 2x100 mg Formulation II avanafil tablet, fasted~Treatment B: 2x100 mg Formulation II avanafil tablet, fed~Treatment C: 2x100 mg Formulation I avanafil tablet, fasted~Treatment D: 1x50 mg Formulation II avanafil tablet, fasted"
45375933|NCT03953365|Procedure|Prophylactic Mesh|Prophylactic Mesh after closure of the abdominal wall after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
45375934|NCT00798629|Biological|Autologous dendritic cell-adenovirus CCL21 vaccine|Intradermal injections of adenovirus-CCL-21 transduced class I peptide-pulsed DC
45375935|NCT01097317|Drug|carboplatin|
45375936|NCT01097317|Drug|vinorelbine tartrate|
45492561|NCT02365948|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Prefilled syringes~Concentration: 0.9 % Saline~Route of Administration: Subcutaneous injection"
45847076|NCT05097924|Other|NAN Supreme HypoAllergenic Starter Infant Formula in ready-to-feed format|Post-market observational study with formula feeding administered via standard of care
45847077|NCT05063604|Drug|Citalopram|20 mg tablet one or twice daily for 12 weeks
45847078|NCT05063604|Behavioral|Psychotherapy|One session weekly for 12 weeks
45847079|NCT05051514|Diagnostic Test|Evaluation|To examine the differences in postural stability, anxiety/depression, and quality of life of the patients according to the severity of Obstructive Sleep Apnea Syndrome.
45847080|NCT04978428|Drug|Cannabidiol|Epidiolex oral solution (2.5 mg/kg and 5 mg/kg)
45847081|NCT04960332|Device|Prevena|RCT (no blinding) where the patients will be randomized to wound closure with staples and either Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System) for 7 days or a conventional wound dressing.
46054129|NCT00638001|Device|custom-molded insoles and custom-molded shoes|"custom-made insoles in PELITE foam (hypoallergenic prosthesis grade foam) or leather top cover cork insoles for patients suffering of mild to moderate ankle arthropathy~custom-molded shoes in leather for patients suffering of end-stage ankle arthropathy"
46054130|NCT03554148|Other|No intervention|This is purely an observational study. Groups SSI/No SSI are defined by the occurence of a surgical site infection.
45375937|NCT01097317|Other|neuromuscular electrical stimulation|
45375938|NCT01097317|Other|physiologic testing|
45847082|NCT04956120|Device|Citrate Dialysate|Dialysate is generated during dialysate from two concentrates (acid concentrate and bicarbonate concentrate) mixed with treated water. When used, citrate is provided in the acid concentrate. The acid concentrate with citrate is approved for this use by the FDA and will be used according to standard procedures without altered dialysis machine settings.
45847083|NCT04956120|Device|Standard Dialysate|Dialysate is generated during dialysate from two concentrates (acid concentrate and bicarbonate concentrate) mixed with treated water. The acid concentrate without citrate is approved for this use by the FDA and will be used according to standard procedures without altered dialysis machine settings.
45847084|NCT04940364|Drug|Pozelimab|Administered intravenous (IV) or subcutaneous (SC) per protocol
45375939|NCT01097317|Procedure|fatigue assessment and management|
45375940|NCT01097317|Procedure|quality-of-life assessment|
45375941|NCT04046705|Procedure|Allogeneic matched related haematopoietic stem cell transplantation|Allogeneic matched related haematopoietic stem cell transplantation after a reduced intensity conditioning regimen
45375942|NCT04046705|Other|Standard arm|In the standard arm, patients who will not be transplanted, will receive the best standard care according to their situation and their previous treatment: initiation of hydroxyurea, continuation or optimization of the dose of hydroxyurea, initiation or continuation of transfusion program, initiation of a new drug proved to improve SCD and having authorization to use in France
45375943|NCT01097473|Procedure|Exercise training|Exercise training in outpatient sport groups once weekly with a duration of 60 min each
45375944|NCT00802763|Device|NORMA-SENSE|Should be used by the clinician. the test usage will take up to 6 hours. The result reading will take few second.
45375945|NCT01095679|Drug|Baclofen|Breaking tablets of 10 mg of baclofen. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
45492562|NCT02360410|Behavioral|Check Yourself App with Feedback|
45492563|NCT02360176|Procedure|Sleeve gastrectomy single port|Bariatric surgery: one incision of 2.5 to 3 cm
45492564|NCT02360176|Procedure|Sleeve gastrectomy multi trocar|Bariatric surgery: 4 to 7 incisions of 1 to 2 cm
45375946|NCT01095679|Drug|Placebo|Breaking tablets of 10 mg of placebo. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
45375947|NCT00794183|Device|CRT device settings|Comparision of A-V delay settings
45492565|NCT02354950|Drug|GSK1265744 30mg|GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.
45492566|NCT02980874|Drug|suprachoroidal CLS-TA|suprachoroidal injection of CLS-TA
45492567|NCT02980874|Drug|suprachoroidal sham|suprachoroidal sham procedure
45693269|NCT00786916|Drug|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.5 mg/kg IV (Group C) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
45492568|NCT02980874|Drug|IVT aflibercept|2 mg intravitreal injection of aflibercept
45492569|NCT02365792|Procedure|Clinical Decision Support Tool for Prehospital Care|"A clinical decision support system (CDSS) is a health information technology system that is designed to assist physicians and other health professionals with clinical decision-making tasks. A working definition of the Centre for Health Evidence: Clinical Decision Support systems link health observations with health knowledge to influence health choices by clinicians for improved health care."
45492570|NCT02354872|Drug|Nicotine Mini-Lozenge|If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges. Mini-Lozenges will be given at the initial visit and over the course of the whole study. Participants will be instructed to use 9 pieces daily for the 12 months.
45492571|NCT02354872|Behavioral|Behavioral Reduction Counseling|We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions. Sessions are front-loaded to enhance acquisition of new behaviors. BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time. BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control. The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals. The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
45693270|NCT03802708|Diagnostic Test|Metabolomic analysis urine sample|a urine sample will be anlayzed for metabolic pathways involving Nitric Oxide Nitric Oxide level will be measured at the exhaled air sample
45693271|NCT04414267|Biological|BCG vaccine|Patients susceptible to SARS-CoV-2 infection will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine
45693272|NCT04414267|Biological|Placebo|Patients susceptible to SARS-CoV-2 infection will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
45693273|NCT01619423|Drug|PledOx (2 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
45375948|NCT01092793|Dietary Supplement|Krill|
45375949|NCT01092793|Dietary Supplement|Fish oil|
45375950|NCT00794261|Drug|Injection of Pegfilgrastim|Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
45375951|NCT00794261|Drug|Injection of Filgrastim|Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN > 0.5 G/L)
45375952|NCT03953287|Drug|Paracetamol|A randomized, cross over design
45375953|NCT02554565|Procedure|Tumor biopsy|Tumor biopsy before treatment
45375954|NCT02554565|Procedure|Blood sampling|Blood sample before, during and after treatment
45375955|NCT01092949|Device|MRI|MRI, 45 minutes
45492572|NCT02354872|Behavioral|5Rs Motivation Counseling|"The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period. Participants in the on condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation. The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis. The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions."
45492573|NCT02354872|Behavioral|Behavioral Activation Counseling|The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions. This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction. Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking. The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
45492574|NCT02354872|Other|No Treatment|No Treatment
45492575|NCT02354638|Behavioral|Tobacco users|Various tobacco cessation interventions in the form of one to one counseling, focus group discussions, role plays, games etc. will be used in the tobacco users.
45492576|NCT02354638|Drug|Pharmacotherapy|"Pharmacotherapy will also be prescribed as per the need assessment consisting of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings.Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks"
45693274|NCT01619423|Drug|PledOx (5 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
45693275|NCT01619423|Drug|PledOx (10 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
45693276|NCT01619423|Drug|Placebo (0,9% NaCl)|Placebo (0,9% NaCl) is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
45693277|NCT03802552|Drug|Cefadroxil|oral one-time dose of cefadroxil
45693278|NCT03802552|Drug|Cephalexin|oral one-time dose of cephalexin
45693279|NCT01735279|Drug|Omega 3|Each fish oil capsule contained 210.99 mg of EPA and 129.84 mg of DHA.
45847085|NCT04940364|Drug|Cemdisiran|Administered SC per protocol
45375956|NCT00803075|Device|Endovascular Repair of Abdominal Aortic Aneurysms Using TALENT AAA Stent Graft System|
45375957|NCT03952819|Diagnostic Test|serum sclerostin|blood samples obtained
45375958|NCT00803153|Procedure|Panretinal Photocoagulation [Pattern Scan Laser (PASCAL) system]|
45375959|NCT02530333|Other|Neuromuscular Prevention Program|Participants in the intervention group will complete at 6 week ACL injury prevention program previously described in the literature as being effective at reducing ACL injury risk. The prevention program lasts 20-25 minutes in duration and will take place as a warm-up prior to any practice. The frequency will depend solely on the number of practices each team holds throughout the given 6-week time period.
45375960|NCT01097551|Drug|Trinitrin|Trinitrin: 2 sublingual pulverisations of 0.3 mg/dose
45375961|NCT01097551|Drug|Neosynephrine 10% collyrium|Neosynephrine 10% collyrium: 2 drops
45375962|NCT01097551|Drug|Iontophoresis with acetylcholine delivery|Iontophoresis with acetylcholine delivery
45375963|NCT01097551|Device|Dynamic Vessel Analyzer|Dynamic Vessel Analyzer
45375964|NCT00803309|Drug|pegylated interferon alpha-2b|1.5 µg/kg once weekly, syringe, 24 weeks
45375965|NCT00803309|Drug|Ribavirin|800-1400 mg per os, daily, tablets, 24 weeks
45492577|NCT02354404|Biological|cAd3-EBOZ|cAd3 vaccine vector expressing Ebola glycoprotein from the Zaire strain in single dose vials at 1x10(11) PU/mL.
45492578|NCT02354404|Biological|cAd3-EBO|1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each [2x10(11) PU/mL total].
45492579|NCT02354404|Biological|MVA-EbolaZ|MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
45375966|NCT00803309|Drug|pegylated Interferon alpha-2b|1.5 µg/kg once weekly, syringe, 12 weeks
45375967|NCT00803309|Drug|Ribavirin|800-1400 mg per os, daily, tablets, 12 weeks
45492580|NCT01066052|Drug|r-hGH|Subcutaneous administration.
45492581|NCT02360254|Drug|Insulin degludec|Once daily injection of insulin degludec
45375968|NCT03953209|Drug|Spironolactone 50Mg Tablet|Oral administration of one spironolactone 50 mg tablet once daily for 12 weeks
45492582|NCT02360020|Device|XLimus|Techniques attempted for facilitating stent delivery in such a complex lesions are: maximize guide catheter support, optimize predilatation of the stenosis, use of a stiffer guidewire. Specific tricks include: a) buddy-wire; anchoring balloon; GuideLiner catheter. In case of severe calcification, rotational atherectomy was electively performed with the Rotablator® system (Boston Scientific Corporation, Natick, MA, U.S.A.). Following stent implantation, postdilatation is performed in all instances with a non-compliant balloon
45375969|NCT03953209|Drug|Spironolactone 100Mg Tablet|Oral administration of one spironolactone 100 mg tablet once daily for 12 weeks
45375970|NCT03953209|Drug|Spironolactone 200Mg|Oral administration of two spironolactone 100 mg tablets once daily for 12 weeks
45375971|NCT01583959|Drug|Folic Acid|Folic acid tablets 5 mg
45375972|NCT01583959|Drug|Placebo|Matched placebo to folic acid 5 mg tables, to be given for 4 days a week
45375973|NCT00803387|Drug|Travaprost without BAC (Travatan Z)|A double blind comparison was used to assess whether Xalatan or TrvatanZ affects the tear breakup times, corneal staining, and baseline tear secretion tests in patients that are already taking latanoprost regularly with complaints of dryness and irritation. Patients included in the study will be given two bottles, one labeled for their right eye and the other for their left eye. Each pair of bottles will be identical in appearance and randomized with either latanoprost or travoprost and each pair will be assigned a number to aid in future analysis of the final results. One Drop from both bottles will be dispensed in the respective eye once a day.
45375974|NCT03952897|Other|balneotherapy|10 days of balneotherapy with immersion techniques using Fitero spa water.
45375975|NCT02553551|Drug|Vitamin C|"During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.~After discharge, no additional vitamin C pill was given."
45375976|NCT02553551|Drug|Placebo|"During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given."
45375977|NCT00803465|Drug|Fluticasone Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of two days
45375978|NCT00803465|Drug|Fluticasone Propionate 0.05% Cream-Test product|Small amount applied and evaluated over the course of two days
45492583|NCT03121014|Drug|Fludarabine|40 mg/m^2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2
45492584|NCT03121014|Drug|Busulfan|targeting a 4800μM/min/ day from day -5 through day -2
45492585|NCT03121014|Drug|ATG|0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1
45492586|NCT03121014|Radiation|Total Marrow Irradiation|dose of 3Gy on days -3, -2 and -1
45492587|NCT03121014|Procedure|Stem Cell Product Infusion|Day 0 according to BMT unit policy
45492588|NCT03121014|Drug|Tacrolimus|The starting dose is at 0.03 mg/kg/day IV continuous infusion over 24 hr from 4 PM on day -2. Dose will be adjusted to target trough levels of 5-15 ng/mL. More information is available in the protocol document.
45492589|NCT03121014|Drug|Methotrexate|5mg/m^2 on Day 1, 5 mg/m^2 on Days 3, 6 and 11
45492590|NCT03112642|Procedure|Local anesthetic block [0.35% marcaine]|In the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block [0.35% marcaine] will be administered.
45693280|NCT01735279|Drug|Placebo|mineral oil + food dye #2 (simulating the colour of essential fatty acids); 1000 mg of mineral oil per capsule
45693281|NCT03802786|Drug|Imeglimin|Single administration dose of imeglimin
45375979|NCT00803621|Other|Toxoplasma PCR assay|Toxoplasma PCR assay
45375980|NCT01095913|Drug|Indocyanine green (ICG)|Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
45375981|NCT00803699|Dietary Supplement|placebo|daily placebo capsules for 12 months
45492591|NCT03112642|Device|Braun DIG-R-C Stimuplex Blockade Monitor System|The blockade system will be initially set at 1 milliamp. As the proximity of the tip of the needle to the components of the brachial plexus becomes evident by ultrasound approximation and the stimulation pattern of the hand and wrist, the output of the system will be reduced to .3-.5 milliamps. With use of the Braun DIG-R-C Stimuplex Blockade Monitor System.
45375982|NCT00803699|Dietary Supplement|selenium as L-selenomethionine|daily capsules of 50, 100, or 200 micrograms of L-selenomethionine for 12 months
45375983|NCT03952741|Behavioral|Physical Therapy|
45375984|NCT00798785|Drug|ATG-MMF-TAC|"ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant subcutaneous (total n=5) at the time of the first clinical implant in the liver."
45375985|NCT00798785|Drug|ATG-Rituximab-MMF-TAC|"ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Rituximab: the day before transplantation, day 5; 12 and 19 after implantation. Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver."
45375986|NCT00798785|Drug|ATG-basilixumab-MMF-TAC|"First transplantation:~ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Second transplantation:~Basilixumab:~the day before the second transplantation followed by 4days after transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver."
45492592|NCT01377324|Other|Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol|A FES-PET/(CT) will be performed thrice during protocol execution. Patients will be injected with ~200MBq 18F-FES
45492593|NCT01569516|Drug|Octohydroaminoacridine Succinate Tablets|1mg, tid
45492594|NCT01569516|Drug|Octohydroaminoacridine Succinate Tablets|1st-2nd week, 1mg, tid 3rd -16th week, 2mg, tid
45492595|NCT01569516|Drug|Octohydroaminoacridine succinate Tablets|1st-2nd week, 1mg, tid, 3rd -4th week, 2mg, tid, 5th-16th week, 4mg, tid
45492596|NCT01569516|Drug|Placebo|0mg, tid
45492597|NCT02359942|Drug|Citric acid|Giving the citric acid (4g) solving in 200 ml of water before UBT
45492598|NCT02359708|Procedure|Surgical hand disinfection.|Bacterial recolonization
45492599|NCT05461248|Procedure|stoma drainage reinfusion|1 month after radical rectal surgery, the stoma drainage fluid was reinfused once a week for 2 months. For each reinfusion, eat liquid food the day before, collect 400-600mL of stoma discharge on the same day (if the stoma fluid is too small, it can be mixed with warm water), and use an enema bag to reinfuse from the patient's anus. Generally, the flow rate is controlled at about 100mL/min.
45492600|NCT05461248|Procedure|Standard of Care - No Return of Stoma Drain|No Return of Stoma Drain
45492601|NCT02359630|Device|EasyTube|Insertion for ventilation
45492602|NCT02359630|Device|Endotracheal tube|Insertion for ventilation
45693282|NCT04663061|Behavioral|Medical weight loss|Participants will be prescribed intensive medical weight loss with the goal of achieving 15% weight loss from initial weight
45693283|NCT04663061|Behavioral|Diabetes education|Participants will receive standard of care diabetes education
45693284|NCT04663061|Behavioral|Continuous glucose monitoring|Participants will use CGM devices to track blood glucose levels in near real time
45693285|NCT03808792|Diagnostic Test|Ultrasound, CT and WB-DWI/MRI|Preoperative assessment with Ultrasound, CT and WB-DWI/MRI
45693286|NCT01759381|Device|Negative pressure wound therapy (NPWT)|
45693287|NCT03802318|Drug|Rabeprazole|Rabeprazole daily four time (Bid) or daily four times (Qid) Amoxicillin used daily two times (1000 mg bid) or daily four times (500 mg qid) apply in the first line or the second line H pylori eradication therapy
45847086|NCT04870944|Drug|FACT Complex-targeting Curaxin CBL0137|Given IV
45375987|NCT00798785|Procedure|omentum|"Two clinical implants: first in omentum followed by a clinical implant in the liver:~In a group of 10 patients, a clinical implant in the omentum will be implanted. If random C-peptide levels >= 0.5 ng/ml are measured at 2 months post-transplantation, a second omental implant will be done. If no clinical relevant beta cell graft function is measured, two intraportal implants will be given as a compassionate use procedure. An interim analysis after 5 patients has to shown clinical relevant function at month 2 in 3 out of 5 patients before the subsequent 5 patients can be transplanted in the omentum."
45375988|NCT01095991|Drug|AZD1656|Oral tablet bd,
45375989|NCT01095991|Drug|Sitagliptin|Oral tablet od
45375990|NCT00798863|Procedure|video assisted submandibular sialadenectomy|Step 1: A 15 to 20 mm skin incision is performed. The anterior part of the gland is then dissected off the mylohyoid muscle. The superficial part of the gland is dissected free. Now, the free superficial part of the gland is resected .Step 2: The scope is inserted into the wound to view the deeper part of the gland. The latter is dissected and removed after identifying the tendon of the digastric muscle, the hypoglossal nerve, the lingual nerve and the submandibular duct. The lingual nerve is released from its attachment to the gland. The submandibular duct is ligated using 3/0 vicryl. The deep part of the gland is extracted through the wound. Hemostasis is secured.
45375991|NCT00798941|Behavioral|mouth care|mouth spray, mouth swab, moisturizer
45375992|NCT00798941|Behavioral|pain intervention|music and massage
45693288|NCT04662671|Device|RD-X19|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens.
45375993|NCT00803855|Drug|AZD1446|oral, single dose
45375994|NCT00794807|Drug|Alefacept|Alefacept=LFA-3/IgG1 fusion protein, once weekly, 15mg i.m.
45375995|NCT00794885|Drug|Enalapril/folic acid|Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
45375996|NCT00794885|Drug|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
45375997|NCT00803933|Drug|DB289|Pafuramidine maleate (DB289), 100 mg BID orally
45375998|NCT00803933|Drug|Pentamidine|Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
45375999|NCT02553707|Drug|Ibandronate|Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
45376000|NCT00804011|Other|ATC|Automatic tube compensation
45376001|NCT00804011|Other|PSV|Pressure support ventilation
45376002|NCT00799175|Drug|ropivacaine, ketorolac and epinephrine|In Group A, 400 mg ropivicaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue. After 21 postoperative hours in Group A, 200 mg ropivicaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
45376003|NCT00799175|Drug|saline|In Group P (placebo) no injections were given intraoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
45376004|NCT00799331|Drug|AZD5985|Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits.
45376005|NCT00799331|Drug|placebo|Oral suspension.
45376006|NCT00804089|Procedure|Traditional needle acupuncture|Traditional needle acupuncture using traditional meridian acupoints and Ashi (tender) points
45492603|NCT02354560|Drug|Erythromycin|Oral Treatment with Erythromycin 250-500mg, twice daily, for 16 weeks.Exact dose is subjected to body weight and will be determined by the study's pediatrician.
45492604|NCT01378884|Drug|Domperidone|Patient to receive treatment with Domperidone
45693289|NCT01758523|Drug|Dutasteride|
45693290|NCT01758523|Drug|sugar pill|
45693291|NCT00773422|Drug|naltrexone|25 mg/day, with 1-week lead-in medication period. The starting dose is 0 mg/day for days 1-3, followed by 12.5mg/day for day 4, followed by 25mg/day for days 5-7, plus during the laboratory session (day 8).
45693292|NCT00773422|Drug|varenicline|2mg/day, with 1-week lead-in medication period. The starting dose is 0.5mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5, followed by 1.0 mg twice daily for days 6-7, plus during the laboratory session (day 8).
45376007|NCT00804089|Procedure|Myofascial trigger point dry needling|Superficial dry needling of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
45376008|NCT00804089|Procedure|Myofascial trigger point acupressure|Blunt needle acupressure of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
45376009|NCT00656513|Drug|Pilocarpine|5mg by mouth 3 times a day for 12 weeks
45376010|NCT00656513|Procedure|ALTENS|Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) twice weekly for 12 weeks via a Codetron unit
45693293|NCT00773422|Drug|placebo|placebo
45693294|NCT00786994|Drug|Oleogel-S10 100 mg/g|topical use once or twice daily
45693295|NCT00786994|Drug|Placebo (petroleum jelly)|topical use once or twice daily
45376011|NCT04017221|Drug|Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Current exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) alone or in combination with other antidiabetic drugs, excluding DPP-4 inhibitors and insulin.
45492605|NCT05457504|Behavioral|Remote blood pressure monitoring|Participants assigned to this arm will participate in the experimental intervention
45492606|NCT05457504|Behavioral|Usual Care|Participants assigned to this arm will participate in a placebo intervention
45376012|NCT04017221|Drug|Dipeptidyl peptidase-4 (DPP-4) inhibitors|Current exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with other antidiabetic drugs, excluding SGLT2 inhibitors and insulin.
45376013|NCT04017221|Drug|Other treatment combinations|Current exposure to other treatment combinations will be defined as a prescription of other antidiabetic drugs (metformin, sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, alpha-glucosidase inhibitors, meglitinides, insulin, or combinations of these drugs), current use of insulin (alone or combination with other antidiabetic drugs), and non-current use of antidiabetic drugs.
45376014|NCT00804245|Procedure|needle biopsy|Biopsy of positive findings found on CT scan
45376015|NCT00804245|Drug|PET-CT scans supplemented with 11C-Choline tracer|Use of 11C-Choline tracer to enhance diagnostic utility of 11C-Choline tracer
45376016|NCT00805883|Procedure|Focal Phothtermal Ablation|Under general anasthesia and in Lithotomy position 2-4 14 Fr laser fibers will be placed into the prostate using 3D US guidance.
45492607|NCT02354326|Radiation|virtual non-calcium dual-energy computed tomography|Undergo VNC DECT
45492608|NCT02354326|Radiation|computed tomography|Undergo CT without VNC
45492609|NCT02039050|Drug|Tiotropium|
45492610|NCT02039050|Drug|Aclidinium|
45492611|NCT05764200|Dietary Supplement|Two day supplementation of a complex fiber mixture|Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
45492612|NCT05764200|Dietary Supplement|Placebo supplementation|Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
45492613|NCT02354248|Procedure|Triple stimulation technique|Evoked motor potentials obtained by magnetic transcranial stimulation are usually used, in standard practice, to evaluate the corticospinal tract. This procedure combines two techniques: the magnetic stimulation and the electroneuromyography. It is based on the double collision principle between the descending central stimulation (magnetic) and the ascending peripheric stimulation, hereby suppressing the issue of desynchronisation of evoked motor potentials. The Triple stimulation technique allows a better quantification of the proportion of motor units activated by the transcranial stimulation.
45376017|NCT00804323|Procedure|Patter Scan Laser System (OptiMedica, Santa Clara, CA, USA)|Pattern Scan Laser trabeculoplasty
45376018|NCT04045847|Biological|CD147-CART|Three doses of CD147-CART cells were injection to intracavity by Ommaya Reservoir.
45376019|NCT00804401|Drug|Naproxen Tablets, 500 mg|
45376020|NCT00804479|Other|No intervention.|
45376021|NCT00655889|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of biopsy from palate~Papillary priming procedure~Seven injection treatments to target sites~Performance of study assessments (investigator and subject)"
45376022|NCT00806039|Other|Early Renal Involvement|Renal Consultation
45492614|NCT05383482|Drug|Afuresertib|Afuresertib 125 mg PO on days 1-5, 8-12, 15-19 or Afuresertib 125 mg QD
45492615|NCT05383482|Drug|Nab paclitaxel|Nab-paclitaxel 80 mg/M2 IV D1,8, Q3W or 100 mg/M2 IV D1,8, Q3W
45376023|NCT00804791|Other|Systane Ultra Lubricant Eye Drops|artificial tears solution for lubricating the cornea
45492616|NCT05383482|Drug|Docetaxel|Docetaxel 50 mg/M2 IV D1 Q3W or Docetaxel 60 mg/M2 IV D1 Q3W
45847087|NCT04848558|Drug|Nipocalimab|Participants will receive IV infusion or SC injection of nipocalimab.
45847088|NCT04848558|Other|Placebo|Participants will receive IV infusion or SC injection of placebo.
45376024|NCT00804791|Other|Unisol 4 Saline Solution|saline solution for irrigating the cornea
45376025|NCT02553239|Device|CoolLoop®|Cryoablation of Atrial Fibrillation Using the CoolLoop Cryoablation System
45376026|NCT00806117|Radiation|Radiotherapy (RT)|"External irradiation 50Gy/5 weeks~Lateral: 2 cm lateral to the bony margin of the pelvis~Superior: Between L5 and S1~Inferior: 2 cm below the obturator foramen Intracavitary boost 30-35Gy/4 weeks(positive vaginal margins only)"
45376027|NCT00806117|Other|Concurrent chemoirradiation (CCRT)|Cisplatin 40mg/m2 every week during external irradiation
45376028|NCT00806117|Other|Sequence chemotherapy and radiotherapy (SCRT)|Paclitaxel 135~175mg/m2 over 3 hours Cisplatin 60~75mg/m2
45376029|NCT00804869|Device|PalmScan A2000 ultrasonography system (Micro Medical Devices, Calabasas, CA)|PalmScan biometric measurements
45376030|NCT00804869|Device|Standard A-mode ultrasound (Eye Cubed™, Ellex, Adelaide, Australia).|A-mode biometric measurements group
45376031|NCT02553083|Drug|Nexium 40 mg|Nexium 40 mg twice daily for 14 days
45492617|NCT05383482|Drug|Sintilimab|Sintilimab 200 mg Q3W
45492618|NCT02354170|Drug|Mifepristone|
45492619|NCT02354170|Drug|Placebo|
45492620|NCT05348382|Procedure|Intradermal acupuncture|In addition to basis standard pharmacological treatments, intradermal needles will be inserted in each selected acupoint and retained in place for 48 hours. Points around the herpes zoster sites (about 1 cm peripherally) are selected for intradermal acupuncture (IDA) encircled needling. Meanwhile, intradermal acupuncture is also performed in Ashi acupoints in the distribution area of herpes zoster. The operator will tear off the adhesive tape of intradermal needles and stick them on the selected acupoints, and then apply pressure on intradermal needles over the selected acupoints perpendicularly according to the patient's tolerance. In addition, patients will be instructed to press the intradermal needles 4 times per 24 hours throughout the needle retention period, with the aim to increase stimulation for treatment enhancement, each time lasting around 30 seconds.
45492621|NCT05348382|Procedure|Sham intradermal acupuncture|In addition to basis standard pharmacological treatments, sham intradermal acupuncture will be implemented in the same acupoints as the intradermal acupuncture group using pseudo-intradermal needling. Additionally, participants in the sham intradermal acupuncture group will be treated in another room to avoid direct communications with subjects in the IDA group.
45847089|NCT04844736|Procedure|CT Simulation|"Patient will undergo routine CT simulation to initiate radiation treatment planning process. For the purposes of this study, the day of CT simulation mapping scan will be counted as day 0. After the patient completes the CT simulation scan, the CT images and plan/structure files will be sent to the treatment planning system. The treating physician will contour the gross tumor volume (GTV) including the involved primary lung tumor and/or the involved lymph nodes."
45492622|NCT03112876|Other|Skin Surface Lipid Collection and Skin Barrier Function|All five groups will undergo the same study intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
45693296|NCT01757821|Device|real 6-Hz primed low-frequency rTMS|10 minutes of 6-Hz stimulation (real priming) followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
45693297|NCT01757821|Device|Sham 6-Hz Primed low-frequency rTMS|10 minutes of sham priming stimulation followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
45847090|NCT04814706|Dietary Supplement|Carbohydrate drinking|Administration of carbohydrate fluid
45376032|NCT02553083|Drug|amoxicillin 1.5 gr|amoxicillin 1.5 gr twice daily for 14 days
45376033|NCT02553083|Drug|doxycycline 200 mg|doxycycline 200 mg twice daily for 14 days
45376034|NCT02553083|Drug|Nexium 20 mg|Nexium 20 mg twice a day for 10 days
45376035|NCT02553083|Drug|clarythromicin 500 mg|clarythromicin 500 mg twice a day for 10 days
45693298|NCT01757821|Device|real 1-Hz rTMS only|20 minutes of low-frequency rTMS delivered to the nonstroke primary motor region
45376036|NCT02553083|Drug|amoxicillin 1gr|amoxicillin 1gr twice a day for 10 days
45376037|NCT00804947|Drug|Intravenous busulfan and melphalan|BU is administered intravenously at a dose of 3.2 mg/kg over three hours once a day on days -5 to -3 (total dose 9.6 mg/kg), followed by MEL at a dose of 140 mg/m2 on day -2. After one day of rest, progenitor cells are infused on day 0.
45376038|NCT02553005|Procedure|Acupuncture|
45376039|NCT00806273|Device|Vista Ultrasonic Bleach Bypass System|The ultrasonic needle will be activated by depressing the foot pedal which will begin the debridement process. Irrigants will be delivered constantly at the recommended rate via the syringe pump and the needle tip will be moved up and down with a 2mm amplitude for the entire 1 minute activation cycle, which will deliver a total of 3ml of irrigant. The ultrasonic unit will be turned off and the needle will be withdrawn from the canal.
45376040|NCT00806273|Device|Needle Irrigation|irrigation with 3ml 6% NaOCl is performed moving the needle from just short of binding to 2mm coronal in constant motion for 60 seconds and left untouched in a full canal for 60 seconds.
45376041|NCT00805103|Radiation|Hypofractionated stereotactic radiotherapy|Patients will be initially administered 8 Gy RT (level). The dose at each level will be increase by 2 Gy up to level 4. If ≥ 2 of the patients in a dose cohort encounter a DLT, then that dose level will be declared the maximum administered dose. An additional 3 patients will then be entered at the previous dose level and provided no more than one patient experiences a DLT, that level will be declared the maximum tolerated dose (MTD). Up to 6 more patients can be treated at the given dose level while awaiting the results of 6 months of follow-up.
45693299|NCT00774202|Drug|Rituxan, Cyclophosphamide, Vincristine, Prednisone|'Rituximab, Cyclophosphamide, Vincristine, Prednisone interventions are as follows: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses. However, the schedule of the infusions will be different than the usual one: Rather than administrating the 4 doses once weekly, the first infusion will be given 5 days (± 3 days) prior to the first infusions of C and V and oral P, and the following 3 rituximab infusions will be given on the same day as the 3 cycles of C, V, and P.
45376042|NCT00655733|Drug|HMPL-004|HMPL-004 1200 mg/d
45376043|NCT00655733|Drug|Placebo|Placebo 1200 mg/d
45376044|NCT00806429|Procedure|transvaginal appendectomy|patient undergoes transvaginal appendectomy
45376045|NCT00657371|Device|Third Eye Retroscope Auxiliary Imaging System|A thin, flexible probe that is inserted in a standard colonoscope in order to display very detailed images of the colon tissue.
45376046|NCT00805259|Behavioral|Financial incentives|Financial incentives based on use of software designed to promote cognitive function
45693300|NCT00774202|Drug|Higher Dose of Rituximab|rituximab 750mg/m2 (twice the standard dose of 375mg/m2) will be given weekly for 4 weeks. Premedication and infusion rate escalation will be exactly the same as for standard dose rituximab. The additional dose will thus run at 400ml/hr.
45693301|NCT01735201|Drug|AGN-199201 Dose A|AGN-199201 Dose A applied once or twice daily to the face for 28 days.
45693302|NCT01735201|Drug|AGN-199201 Dose B|AGN-199201 Dose B applied once or twice daily to the face for 28 days.
45693303|NCT01735201|Drug|AGN-199201 Dose C|AGN-199201 Dose C applied once or twice daily to the face for 28 days.
45376047|NCT00806507|Procedure|Echocardiograms|Additional views performed in 5-10 minutes of regularly scheduled echocardiograms.
45376048|NCT00806507|Procedure|Blood Test|Measuring of hormones and metabolic proteins (such as sugars and acids).
45376049|NCT04017065|Device|DePuy Synthes MAXFRAMETM system|Patients treated with the MAXFRAMETM system will be followed up from before the surgery until the removal of the device. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
45376050|NCT00805337|Device|Intrabuccally-administered amplitude-modulated RFEM|Generation of amplitude-modulated electromagnetic fields: the device consists of a battery-driven radiofrequency (RF) electromagnetic field generator connected to a 1.5 meter long 50 Ohm coaxial cable, to the other end of which a spoon-shaped mouthpiece made of steel is connected with the inner conductor. The RF source of the device corresponds to a high-level amplitude-modulated class C amplifier operating at 27.12 MHz. The modulation frequency can be varied between 0.01 Hz and 150 kHz with a modulation depth of 85 ± 5%. The RF output is adjusted to 100 mW into a 50 Ohm load using a sinusoidal modulated test signal, which results in an emitting power identical to that of the device used in the treatment of insomnia (Pasche et al 1996, 19:327-336).
45847091|NCT04804488|Procedure|nasal polyp surgery|A retrospective study for patients with recurrent nasal polypi operated at Otorhinolaryngology Department, Sohag University Hospital will be carried out.
45376051|NCT00806663|Drug|sunitinib added to FOLFIRI|sunitinib 37 mg once daily (4 weeks on/2 weeks off)
45376052|NCT00805415|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 2 and 3 mg
45376053|NCT00805415|Drug|EV/DNG (SH T00658L)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 3 and 4 mg
45376054|NCT02553863|Procedure|Acupuncture|Acupuncture for 30min [twice weekly for 8 weeks]
45376055|NCT02553863|Procedure|Standard care|Standard care
45376056|NCT00799565|Genetic|catch of blood|"4 tubes of blood are taken on subjects. Samples are sent in Pr Jeunemaître to extract DNA and stock it.~This DNA bank aims to search for susceptibility genes in MVP using a genome wide analysis and comparing results obtained in 1000 patients with MVP and 1000 non-MVP subjects"
45376057|NCT00806741|Drug|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
45376058|NCT00806741|Drug|Phenylephrine|1μg/kg/min, infusion period 20 minutes
45376059|NCT00806741|Drug|Physiological saline solution (as placebo)|infusion period 20 minutes
45376060|NCT00806741|Device|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
45376061|NCT00806741|Device|Goldmann applanation tonometer|intraocular pressure measurements
45376062|NCT00806741|Other|squatting|Subjects will perform squatting for 6 minutes while blood flow is measured
45376063|NCT00806897|Drug|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
45492623|NCT03077646|Behavioral|Be SMART|An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART
45693304|NCT01735201|Drug|AGN-199201 Vehicle|AGN-199201 Vehicle applied once or twice daily to the face for 28 days.
45376064|NCT00805649|Procedure|Low fluorescence Photodynamic therapy|42 J/cm2 for 72 sec
45376065|NCT00805649|Procedure|core pars plana vitrectomy|24 hours after photodynamic therapy, 1.5 mL core pars plana vitrectomy
45376066|NCT00805649|Drug|dexamethasone|intravitreal injection of 0.8 mg dexamethasone
45376067|NCT00805649|Drug|bevacizumab|intravitreal injection of 1.25 mg bevacizumab
45376068|NCT00805649|Procedure|core pars plana vitrectomy|0.4 mL core pars plana vitrectomy
45376069|NCT00805649|Drug|triamcincolone|intravitreal injection of 8 mg triamcincolone
45376070|NCT00799799|Biological|NK cells|NK cells infusion after immunosuppressive chemotherapy
45376071|NCT00806975|Device|KwikPen® and FlexPen®|The treatment is changed to twice a day injection of the same unit of Novo Rapid 30 Mix injection FlexPen® or Humalog Mix 25 injection KwikPen®for 3 months, after which the final assessment is made.
45376072|NCT00809315|Other|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
45376073|NCT00809315|Behavioral|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
45693305|NCT05742880|Other|Wearing a mask|6 Minute walking test while wearing a Mask
45693306|NCT03808324|Diagnostic Test|Diagnostic investigations|Participants will undergo tests and diagnostics investigations to identify signs of chronic rejection after heart transplantation.
45693307|NCT01734811|Biological|Biological vaccine|daily spray (2 puff of 100 µL) for six months
45693308|NCT03802006|Diagnostic Test|Ultrasound assessment of gastric content|Ultrasound assessment of gastric body is performed
45693309|NCT03808168|Drug|Nivolumab|Protocol dose: 3mg/kg mg as a 30-minute IV infusion on Day 1 (Arm I) or Days 1, 15, 29 (Arm II).
45693310|NCT03802162|Drug|CKD-355A (D797/Memantine HCl 20mg)|once a day
45492624|NCT03077646|Behavioral|Control: TSE|"A video called Kids and Smoke Don't Mix and handouts on tobacco smoke exposure (TSE) developed by the New York state quit-line."
45492625|NCT03077646|Behavioral|Be SMART + MD review|"An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART.~After being presented to parents/guardians via video and handouts, this information will be reviewed in person with a Physician."
45376074|NCT03870971|Other|blood glucose measurement|After the patient has performed the manual reading, the investigator or staff member will obtain another capillary blood sample and a reference reading by means of the YSI 2300 Stat plus analyzer will be performed and recorded. If patients need more than one attempt to get a successful blood glucose reading, the number of attempts will be documented. A questionnaire needs to filled by the participant
45492626|NCT02359240|Procedure|therapy according to SSC guidelines and muscle biopsy|Septic patients will be treated according to the international guidelines for management of severe sepsis and septic shock 2012. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
45492627|NCT02359240|Procedure|standard surgery for femoral fracture and muscle biopsy|Patients with femoral fracture will under standard surgery for fracture fixation. Percutaneous needle muscle biopsies will be performed. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
45492628|NCT02352610|Procedure|LRTI|
45492629|NCT02352610|Device|Biotenodesis Screw|
45693311|NCT03802162|Drug|CKD-355B (D797/Memantine HCl 20mg)|once a day
45693312|NCT03802162|Drug|D797|once a day
45693313|NCT03802162|Drug|D324 (Memantine HCl 10mg)|twice a day
45847092|NCT04780464|Drug|Doxorubicin|60 to 75 mg/m² intravenous, every 3 weeks for max 6 cycles until PD
45376075|NCT00807053|Drug|Ciclesonide HFA|75 mcg Ciclesonide HFA versus Placebo
45376076|NCT00807053|Drug|Ciclesonide HFA|150 mcg Ciclesonide HFA versus Placebo
45693314|NCT01757275|Drug|Esomeprazole Na|Given as 80mg bolus infusion during 30 min and then 8mg/h constant infusion during 71.5 hous
45693315|NCT01757275|Drug|Cimetidine|Given as 200mg bolus infusion during 30 min and then 60mg/h constant infusion during 71.5 hours
45693316|NCT01757275|Drug|Esomeprazole Mg|40 mg tablet once daily for 27 days
45376077|NCT00807053|Drug|Ciclesonide HFA|300 mcg Ciclesonide HFA versus Placebo
45376078|NCT00807053|Drug|Placebo|Placebo
45376079|NCT00809393|Drug|tranexamic acid|10 mg/kg
45376080|NCT00809393|Drug|tranexamic acid|30 mg/kg
45376081|NCT00799955|Procedure|Placebo block|100 micrograms of spinal morphine
45376082|NCT00799955|Procedure|Ultrasound-guided TAP block|1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected into the transversus abdominis plane, on each side
45376083|NCT00807131|Behavioral|Patient follow-up|Dader method, which was developed to provide pharmaceutical care, which consists of seven steps covering the evaluation of services, benefits of interventions, and identification of unexpected occurrences. Its objectives are to improve the patient quality of life.
45376084|NCT00807131|Behavioral|Counseling|The pharmacist proceeds the counseling when the patient comes to the pharmacy to take their medicines.
45376085|NCT00807131|Behavioral|Drug dispensing|The pharmacist gives the drugs to the patient with the minimum of information necessary to guarantee a safe and effective drug intake.
45376086|NCT00807131|Behavioral|pharmacy usual care|The patient receives no information about their medicines in the pharmacy, unless he asks for it.
45847093|NCT04780464|Drug|Doxorubicin|12 mg/m2 intravenous weekly for a maximum of 450 mg/m2 until PD
45492630|NCT02927964|Drug|Ibrutinib|Given PO
45376087|NCT00658775|Drug|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
45376088|NCT00658775|Drug|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
45376089|NCT00807287|Procedure|Jejunal tube placement using the unguided frictional method|The self-advancing nasal jejunal feeding tube has small alternating cilia-like plastic flaps to help to advance it into the small bowel via peristalsis. The tube is placed in the stomach (50-60 cm mark). Then the tube is left in place for 1 hour to allow the patient's peristalsis to advance the tube by catching its small plastic tabs. Thereafter, the tube is manually advanced 10 cm every hour until the 100 cm mark of length is reached. To improve peristalsis, 10mg metoclopramide i.v. and 200mg erythromycin i.v. 15 minutes before the procedure are administered.
45376090|NCT00807287|Procedure|Jejunal tube placement using the endoscopic method|Jejunal feeding tubes are placed using endoscopy
45376091|NCT00800033|Behavioral|Aerobic exercise training|Walking, jogging, rowing, cycling to be done 5 times per week for 45 minutes per session (3 supervised sessions, 2 sessions at home) for 5 months
45376092|NCT00800033|Dietary Supplement|pulse based diet|Two pulse-based meals per day (lentils, beans, chickpeas, or peas) for 2 months, followed by 1-month washout and then a normal diet for 2 months (order of diets is randomized)
45376093|NCT00800111|Procedure|endothelial keratoplasty|Endothelial keratoplasty is surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea).
45376094|NCT00488631|Biological|Placebo|Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
45376095|NCT00488631|Biological|Golimumab 50 mg|Participants receive golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
45492631|NCT02927964|Radiation|Radiation Therapy|Undergo radiation therapy
45492632|NCT02927964|Drug|TLR9 Agonist SD-101|Given IT
45492633|NCT03147586|Drug|Bio-tech and omega-3 plus|immune nutrition : Bio-tech ( multivitamins and essential amino acids), and omega-3 plus (omega-3 fatty acids)
45492634|NCT03147586|Drug|placebo|placebo
45492635|NCT01377246|Drug|Octreotide-LAR|40 mg every 28 days (in two intragluteal 20 mg injections) for three years
45376096|NCT00488631|Biological|Golimumab 100 mg|Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
45376097|NCT00488631|Biological|Golimumab 200 mg|Participants receiving golimumab 100 mg initially who on loss of clinical response receive golimumab 200 mg administered every 4 weeks through Week 52.
45376098|NCT00809549|Drug|Filgrastim|10 ug/kg sc once daily x 4 days. Repeated once, 6 weeks later.
45376099|NCT00809627|Drug|Caffeine|Caffeine 500 mg IV
45376100|NCT00809627|Drug|saline|Normal saline
45492636|NCT01377246|Other|Saline solution.|At the same volume of study drug every 28 days (in two intragluteal injections) for three years.
45847094|NCT04780464|Drug|Cyclophosphamide Oral Product|100 mg BD on day 1 to day 7 of each 14 day cycle until PD
45492637|NCT02353936|Drug|BIBW2992|"International Nonproprietary Name (INN): BIBW 2992 Pharmacological dosage form: Film-coated tablet Supplier: Boehringer Ingelheim Pharma GmbH & Co. KG Unit content: 40 mg, 30 mg, 20 mg film-coated tablet (BIBW 2992 content in film-coated tablet is related with equivalent free base BIBW 2992.) Daily dose: 40 mg Dosing period: To be successively administered once daily until a disease will develop, an unacceptable adverse event will occur, or another reason requiring discontinuation of the study will occur; For administration, study treatment consists of periods(each 4 weeks(28 days)).~Route of administration: Orally (Take by swallowing) Dosage: Once daily"
45492638|NCT02353858|Other|Deep regional hyperthermia|Deep regional hyperthermia of the pelvis, Total time 90 min, Target temperature 41-42°C.
45492639|NCT02353858|Radiation|Radiotherapy|Radiotherapy of the primary tumor and pelvis, 5 x 1,8 Gy per week, total Dose: 50,4 Gy.
45376101|NCT00809705|Drug|Placebo|sc once weekly for 12 weeks
45376102|NCT00809705|Drug|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20mg sc once weekly for 8 weeks
45376103|NCT00809705|Drug|taspoglutide|10mg sc once weekly for 12 weeks
45492640|NCT02353858|Drug|Chemotherapy (5-Fluorouracil)|5-Fluorouracil, continuous venous infusion week 1 and 5. 1000 mg per square meter of body-surface area per day.
45492641|NCT02578758|Behavioral|Transdiagnostic internet-based protocol|Transdiagnostic internet-based protocol is an Internet-based Protocol for ED, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in 12 modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
45492642|NCT02578758|Behavioral|Transdiagnostic internet-based protocol + positive affect component|Transdiagnostic internet-based protocol + positive affect component is an Internet-based protocol for ED. This protocol contains several transdiagnostic components (present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention) and a specific positive affect regulation component. These components are organized in 16 treatment modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; Learning to move on; Learning to enjoy; Learning to live; Living and learning; and Relapse Prevention.
45492643|NCT02578758|Other|Waiting List Control Group|Participants in a 18-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the wating list period.
45376104|NCT00655499|Drug|Panitumumab|6 mg/kg
45492644|NCT02353702|Procedure|Sniff test|Evaluation of diaphragmatic function by sniff test after continuous parietal infusion of ropivacaine or placebo
45376105|NCT00655499|Drug|Irinotecan hydrochloride|180 mg/kg
45376106|NCT00655499|Genetic|Chromogenic in situ hybridization|
45376107|NCT00655499|Genetic|Fluorescence in situ hybridization|
45376108|NCT00655499|Genetic|Gene expression analysis|
45847095|NCT04780464|Drug|Prednisolone|10-20 mg on day 1 to day 7 of each 14 day cycle until PD
45376109|NCT00655499|Other|Laboratory biomarker analysis|
45376110|NCT00809861|Procedure|volar locking plating|open reduction and internal fixation
45376111|NCT00809861|Procedure|external immobilisation|closed reduction and external fixation
45376112|NCT00800189|Radiation|Anterior electronic portal images (EPI)|EPI's are taken for the first three consecutive days of treatment to detect set-up errors.
45376113|NCT00654875|Drug|Aliskiren|Aliskiren supplied in 150 mg and 300 mg tablets.
45376114|NCT00654875|Drug|Placebo to Aliskiren|Placebo to Aliskiren matching 150 and 300 mg tablets
45376115|NCT00800267|Drug|latanoprost 0.005%|placebo in the morning and latanoprost .005% in the evening
45376116|NCT00800267|Drug|fixed combination latanoprost-timolol|one drop in the morning and placebo in the evening
45376117|NCT00800267|Drug|timolol 0.5%|one drop in the morning and evening
45376118|NCT00809939|Drug|17 alfa hydroxyprogesterone caproate|weekly injection of 250 mg until 34 weeks gestation
45376119|NCT00809939|Drug|natural progesterone|previous preterm delivery, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
45376120|NCT00809939|Drug|17 alfa hydroxyprogesterone caproate|weekly injection, 250 mg until 34 weeks gestation
45376121|NCT00809939|Drug|vaginal progesterone|daily vaginal progesterone 200 mg until 34 weeks gestation.
45376122|NCT00807443|Drug|Raltegravir|Raltegravir (INN), 400 mg tablets, developed and supplied by Merck Sharp & Dohme. A dose of 400 mg will be administered every 12 hours
45492645|NCT02353702|Drug|Infusion of Ropivacaine during 48 hours|"20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml) during 48 hours of Ropivacaine.~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour, during 48 hours of NaCl 0.9 %."
45492646|NCT02353702|Device|Continuous parietal infusion with parietal catheter|Continuous parietal infiltration of Ropivacaine or placebo
45492647|NCT02353702|Drug|Infusion of placebo during 48 hours|
45492648|NCT02353702|Drug|NaCl|
45492649|NCT02532660|Drug|Escitalopram 10mg|Escitalopram 10mg (1 pill once a day)
45492650|NCT02532660|Drug|LABCAT TCJUSS|LABCAT TCJUSS 1000mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night)
45492651|NCT02532660|Drug|LABCAT TCJUSS Placebo|LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
45492652|NCT02532660|Drug|Escitalopram Placebo|Escitalopram Placebo (1 pill once a day)
45492653|NCT02353546|Behavioral|CALM|
45492654|NCT01377168|Drug|oral naltrexone|
45492655|NCT01377168|Drug|Placebo pill|
45492656|NCT02892149|Drug|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
45492657|NCT02892149|Drug|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
45492658|NCT02353624|Behavioral|Cycling|Cycling distance of 2880 km in 14 days
45376123|NCT00807521|Drug|Dexamethasone|Single high dose bolus of dexamethasone before surgery
45492659|NCT02352532|Other|Dry Needling|"The dry-needling treatment will consist of inserting a sterile needle into needling the prone participant's lumbar multifidus and paraspinal muscles, 1-2 times each, in regions of local tenderness to palpation and/or regions with palpable trigger points. All needling treatment will be performed with FDA approved (FDA regulation # 880.5580) disposable 0.30 x 50-60 mm stainless steel Seirin J-type needles (Seirin, Japan). Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique."
45492660|NCT02352532|Other|Sham Needling|The sham dry-needling procedure will mimic the dry needling procedures by placing a sharp object in a needling guide tube against the skin (see figure). The sharp object will be rocked and twisted to simulate treatment, but will not pierce the skin. We have used this sham dry-needling technique in a previous study performed at AMEDDC&S and have found it to be indistinguishable from real dry needling by the great majority of participants.
45492661|NCT02348476|Other|No Intervention|No study drug is administered in this study.
45492662|NCT05046912|Behavioral|Yoga|8 weeks of online weekly yoga or chair yoga class
45492663|NCT05046912|Behavioral|Mindfulness|8 weeks of online weekly mindfulness class
45492664|NCT02348398|Drug|Pazopanib|600 mg by mouth daily in a 28 day cycle.
45492665|NCT02348398|Drug|Topotecan|0.25 mg by mouth daily for 21 days of a 28 day cycle.
45492666|NCT02348398|Behavioral|Phone Call|During follow up if disease gets worse, participant called by study staff every 3 months. Each call should last about 5 minutes.
45492667|NCT02352688|Procedure|Enhanced Colorectal Geriatric Care|
45492668|NCT03147352|Device|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy with 100 % oxygen at 1.8 ATA for 2 hours.
45492669|NCT02352454|Device|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
45376124|NCT00807521|Drug|Placebo|Placebo for dexamethasone
45376125|NCT00810173|Behavioral|phone call support|The intervention group received a phone call support for 6 weeks to incentive to increase the number of steps/day.
45376126|NCT00922259|Biological|Influenza A H7N7 vaccine|Participants will be administered two doses of the candidate vaccine at a dosage of approximately 10^7.5 50% tissue culture infectious dose (TCID50), in the form of nasal spray. The doses will be administered 28-62 days apart.
45376127|NCT00800423|Drug|Brimonidine Tartrate 0.2%|"Brimonidine Tartrate 0.2% drops~1 drop twice a day for 1 month in the operated eye"
45376128|NCT00800423|Drug|Timolol maleate 0.5%|"timolol maleate 0.5% drops~1 drop twice a day for 1 month in the operated eye"
45376129|NCT00800501|Drug|sNN0029|Continuous ICV infusion at one of three dose levels
45376130|NCT00800501|Drug|Placebo|Continuous ICV infusion
45376131|NCT00807677|Drug|TAK-901|TAK-901 will be administered via IV infusion over a 3-hour period on Days 1,4,8,11,15,18,22, and 25 of each 28-day cycle.
45492670|NCT01378806|Behavioral|Nutrition and exercise education and coping skills training|A 12-week intensive intervention on nutrition and exercise education and coping skills (Phase I), 9 months of continued monthly contact (Phase II), and then 6 months on their own.
45492671|NCT03147274|Behavioral|Intervention|Patients randomized to the intervention group will attend 3 SMART T1D group curriculum sessions over the study period, in addition to usual diabetes clinic care. Each interactive group session will last 2 hours and will be facilitated by a diabetes nurse educator.
45492672|NCT05278338|Drug|JMT103|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
45492673|NCT05278338|Drug|Denosumab|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
45492674|NCT05278338|Drug|Placebo|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
45492675|NCT03721757|Biological|Nivolumab, Surgery, Radiotherapy|A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to radiotherapy commencing. Six further doses of nivolumab will be received post radiotherapy
45492676|NCT03721757|Biological|Nivolumab, Surgery, Chemoradiotherapy|A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to Chemoradiotherapy (cisplatin) commencing. Six further doses of nivolumab will be received post radiotherapy
45376132|NCT00651755|Drug|Aprepitant|125 mg By Mouth (PO) On Day 1, followed by 80 mg PO Daily On Days 2-3.
45492677|NCT02352376|Other|Conventional ventilator|A ventilator designed for invasive ventilation was used has mode non-invasive ventilation with leakage compensation (50% of the predetermined tidal volume).
45492678|NCT02352376|Other|Specific ventilator|A ventilator was used designed for non-invasive ventilation has an algorithm that calculates the loss of pressure and automatically compensates for leak
45492679|NCT05232942|Other|Headache calendar completion|The patient will complete an in-paper or electronic calendar, depicting the presence/absence of headache, the median intensity and the need of acute medication.
45492680|NCT03727607|Drug|Desflurane|Desflurane vs TIVA, bariatric surgery. Postoperative nausea and pain
45492681|NCT05157516|Procedure|erector spinea block|the patients will receive a single injection erector spinea block after induction of general anesthesia
45492682|NCT05157516|Procedure|Caudal epidural block|the patients will receive caudal epidural block after induction of general anesthesia
45376133|NCT00651755|Drug|Cyclophosphamide|750 mg/m^2 By Vein On Day 1
45492683|NCT02348242|Device|Aqueous Gel|1 drop of Dexpanthenol® 0.2% aqueous gel in the eye every 6 hours
45492684|NCT02348242|Device|Eyelid Occlusion Dressing|Eyelid occlusion using pro-ophta® eyelid occlusion dressing, dressing to be verified every 6 hours and replaced daily
45492685|NCT02348242|Device|Artificial Tears|1 drop of Phylarm® artificial tears in the eye every 6 hours
45492686|NCT05665049|Behavioral|Social Transfer|Social transfers are defined as a cash or in-kind transfer. Using results from a qualitative study, we identified the following culturally grounded social transfer options that is responsive to the identified needs of new mothers. Based on the monthly Lao PDR minimum wage and an estimated 15 full working days needed to exclusively breastfeed over a 6-month period, a social transfer of approximately $75 would fairly subsidize women's breastfeeding efforts. Therefore all social transfer options equate to approximately 75 USD. The options include: diapers, child developmental toys, cash, or a combination of these.
45376134|NCT00651755|Drug|Doxorubicin|25 mg/m^2 By Vein Over 48 Hours On Days 1-2
45376135|NCT00651755|Drug|Vincristine|2 mg By Vein On Day 1
45376136|NCT00651755|Drug|Prednisone|100 mg PO for 5 Days
45376137|NCT00651755|Drug|Rituximab|375 mg/m^2 By Vein On Day 1.
45376138|NCT00651755|Drug|Ondansetron|8 mg daily for 2 days
45376139|NCT02552381|Other|Fibrin Structure|Modifications of Fibrin Structure in patients who have developed VTE in comparison with patients without VTE.
45376140|NCT02552771|Procedure|Mitral repair with leaflet preservation|Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
45376141|NCT02552771|Procedure|Mitral repair with leaflet resection|Removing one or both of the mitral leaflets that flop or bulge back.
45693317|NCT00787852|Drug|Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47|"Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib & Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43~Dasatinib is to be taken 1x daily~50 mg daily 100 mg daily~70 mg daily 100 mg daily~100 mg daily 100 mg daily~Maintenance x 2 years*"
45693318|NCT00787852|Drug|Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38|"Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib & Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36~Dasatinib is to be taken 1x daily~50 mg daily 100 mg daily~70 mg daily 100 mg daily~100 mg daily 100 mg daily Maintenance x 2 years*"
45376142|NCT00810251|Device|MatrixRIB (FDA Approval # K081623)|MatrixRIB implants are comprised of anatomic rib plates and intramedullary rib splints for internal surgical stabilization of rib fractures.
45693319|NCT01757197|Drug|Toclizumab|8 mg/kg IV, once every 1-2 weeks. The maximum dose per infusion should not exceed 800 mg.
45693320|NCT00788008|Drug|inhalation anesthesia with isoflurane vs. TIVA with propofol|variable depending upon patient
45376143|NCT00807755|Drug|Carboplatin|Intravenous (IV) on Day 1 of each 21-day cycle, as per dose escalation schedule (dose levels 1 and 2: dose levels 3 and 4). Number of cycles: 6 maximum.
45376144|NCT00807755|Drug|Etoposide|80mg/m2, Intravenous on Days 1, 2, 3 of a 21-day cycle (all dose levels). Number of cycles: 6 maximum.
45376145|NCT00807755|Drug|RAD001|Orally on Days 1-21 of a 21-day cycle, as per dose escalation schedule (dose level 1: 2.5 mg, dose level 2: 5 mg, dose level 3: 5.0 mg, and dose level 4: 10.0 mg). Number of cycles: unlimited (drug taken from Day 1 until progression of disease or unacceptable toxicity).
45376146|NCT00813527|Drug|Lapaquistat acetate and fenofibrate|Lapaquistat acetate 100 mg, tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
45376147|NCT00813527|Drug|Fenofibrate|Lapaquistat acetate placebo-matching tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
45376148|NCT00654641|Procedure|Negative pressure wound closure|Applying negative pressure to primary wound closure
45376149|NCT00654641|Procedure|Standard wound closure|Standard wound closure
45376150|NCT00810485|Drug|ADX10059|oral administration
45376151|NCT00810485|Drug|ADX10059|oral administration
45693321|NCT00760006|Drug|Unasyn|Subjects will receive the antibiotic or the saline placebo 30 minutes prior to the initial incision in their palatoplasty procedure. The FDA approved antibiotic used for this study is Unasyn. Unasyn is a first-line measure, used by ENT surgeons at Children's Hospital of Pittsburgh for antibiotic treatment of virtually all ear, nose and throat infections. The use of Unasyn for this study is off-label as with the majority of antibiotics used with children. Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm
45693322|NCT00760006|Other|saline solution|Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm.
45693323|NCT01784965|Drug|liraglutide|Dosing begins at 0.6 mg subcutaneous injection and increases each week, to 1.2 mg and maximum dose of 1.8 mg.
45376152|NCT00810485|Drug|ADX10059|oral administration
45376153|NCT00810485|Drug|ADX10059 Matching Placebo|oral administration
45376154|NCT00810563|Drug|Saline solution (laparoscopic tubal ligation)|5ml of saline solution in each portal of the trocar (2 portals)
45376155|NCT00810563|Drug|Bupivacaine|5ml of bupivacaine 0.5% in each trocar portal
45376156|NCT00807911|Drug|Adjuvant FL|5-Fluorouracil 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles
45376157|NCT00807911|Drug|Adjuvant FOLFOX|oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-Fluorouracil bolus 400 mg/m2 on D1, 5-Fluorouracil continuous infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles
45376158|NCT00808145|Drug|Gemcitabine / Cisplatin / Sorafenib|All patients will receive gemcitabine 1000mg/m2 cisplatin 30mg/m2 sorafenib 400mg orally twice daily
45376159|NCT00922337|Device|MGuard Coronary Stent system|MGuard Coronary Stent system implanted within a PCI
45376160|NCT02552459|Drug|Sufentanil|sufentanil 150μg， intravenous administration during post-operative 72 hours.
45376161|NCT02552459|Drug|dexmedetomidine 1|dexmedetomidine 0.05μg/kg/h, Continuous intravenous injection for 72 hours after operation
45376162|NCT02552459|Drug|dexmedetomidine 2|dexmedetomidine 0.1μg/kg/h, Continuous intravenous injection for 72 hours after operation
45376163|NCT02552459|Drug|dexmedetomidine 3|dexmedetomidine 0.15μg/kg/h, Continuous intravenous injection for 72 hours after operation recorded in the following 72h.
45376164|NCT00810953|Drug|Pentamidine|two dose of 6 mg/kg with or without standard chemotherapy.
45376165|NCT00811031|Drug|Taxotere|75 mg/m^2 Day 1 of every 21-day cycle by vein for 4 cycles prior to surgery.
45376166|NCT00811031|Drug|Prednisone|5 mg twice a day by mouth.
45376167|NCT03870659|Radiation|Breast MRI|Magnetic resonance imaging to the breast
45693324|NCT01784965|Drug|Placebo|Double blinded will receive study pen with same dosing instructions starting at 0.6 mg, and each week increase to 1.2 mg and finally 1.8 mg at week three.
45693325|NCT05742724|Drug|Tetrahydrocannabinol-Cannabidiol Combination|Oral THC 0.1mg/kg and CBD 2.5mg/kg
45376168|NCT02552537|Drug|Omeprazole|patients with walnut allergy will be exposed during 5 days before food challenge with Omeprazole
45376169|NCT02552537|Drug|Placebo|patients with walnut allergy will be exposed during 5 days before food challenge with Placebo
45492687|NCT04187092|Other|KneeBright Group|"The KneeBRIGHT group will use KneeBright device which consists of an EMG biofeedback interface software that guides users through exercise routines. The wireless EMG sensors includes two small electrodes that will be made to stick to the quadriceps muscles both sides. KneeBRIGHT software features a virtual world wherein patients complete challenges controlling the in-game avatar with the EMG units during exercises specific to knee osteoarthritis rehabilitation.~The KneeBRIGHT software will incorporates a variety of exercises for strengthening the quadriceps and will employ algorithms based on the Daily Adjustable Progressive Resistance Exercise (DAPRE) technique, in which the quantity of repetitions performed in these sets is then used to determine the appropriate increase (or possibly decrease) in target resistance for the next sets/sessions."
45492688|NCT04187092|Other|Standard Rehabilitation group|Participants in this group will undergo standard clinic based knee rehabilitation. Both groups will perform exact same exercises, however, no KneeBRIGHT device will be used in this group.
45492689|NCT05100966|Other|FitJoints Multi-modal Intervention|"Exercise: The study physiotherapist will prescribe an exercise program tailored to the participant's individual ability and preference with functional movements to mimic activities of daily living.~Nutritional consultation and protein supplement: The site research assistant will coach participants to improve their nutrition, determine their daily protein target, and provide educational tools on how to achieve their target. Protein supplements will be provided to participants.~Vitamin D: Participants will be provided with vitamin D3 (1000 IU) tablets to reduce the risk of falls and to preserve muscle strength and functional ability. They will be instructed to take one tablet daily for the duration of the intervention period.~Medication optimization: The study pharmacist will conduct a medication review and provide, if required, recommendations for medication optimization."
45492690|NCT05084976|Behavioral|COVID 19 vaccine counseling|After surveys are completed, pulmonary provider (nurse practitioner or physician) will provide counseling via phone or in person about the COVID 19 vaccine. Safety, efficacy and side effects will be reviewed.
45492691|NCT03157804|Procedure|IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)|
45376170|NCT00811109|Device|Standard Hemodialysis|Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity performed with Fresenius 4008S monitor (Fresenius Medical Care, France)
45376171|NCT00811109|Device|with Blood Volume Management (BVM®) only|Hemodialysis using Blood Volume on-line monitoring only. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® device (for blood volume monitor; Fresenius Medical Care, France)
45376172|NCT00811109|Device|with Blood Volume (BVM®) and Temperature (BTM®) on-line monitoring|Hemodialysis using Blood volume and Blood temperature on-line monitoring. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® and BTM® devices (for blood volume monitor and blood temperature management, respectively; Fresenius Medical Care, France)
45492692|NCT03157804|Biological|Genetically Engineered Hematopoietic Stem/Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
45492693|NCT03157804|Other|Laboratory Biomarker Analysis|Correlative studies
45492694|NCT03157804|Biological|Filgrastim|Given subcutaneously (SC)
45492695|NCT03157804|Drug|Plerixafor|Given SC
45693326|NCT01784419|Drug|ivacaftor|Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
45693327|NCT01784419|Drug|Placebo|Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
45376173|NCT00811265|Device|ExAblate MRgFUS for prostate cancer|Simulated use of ExAblate MRgFUS system
45376174|NCT00808223|Biological|alefacept|IM injection
45376175|NCT00811343|Biological|QFTB-G and T-SPOT.TB tests|QFTB-G and T-SPOT.TB test before TST
45376176|NCT04045535|Other|Physical Activity Program|Usual Care and a nurse-led physical activity program once a week for 8 weeks. Each session last for 60 minutes, 15 for warming-up and 45 for different exercises.
45492696|NCT03157804|Procedure|Bone Marrow Aspiration|
45492697|NCT02352142|Other|Full Term EEG|Full-term infants assigned to this arm of the study will receive one sleep EEG (one hour in duration). These EEGs will be used as healthy control comparisons to those of premature infants at 40 weeks.
45376177|NCT04045535|Other|Usual care|Usual clinical care based on current clinical practice guidelines.
45376178|NCT00811421|Drug|Sulphadoxine-pyrimethamine|SP oral administration (500mg sulphadoxine and 25mg pyrimethamine) as IPTp at the 1st and 2nd Antenatal Clinic visit
45376179|NCT00811421|Drug|Mefloquine (full dose)|MQ oral administration (15 mg/Kg) on 1 day at the 1st and 2nd Antenatal Clinic visit as IPTp
45376180|NCT00811421|Drug|Mefloquine (split dose)|MQ oral administration (15 mg/kg) split dose over 2 days at the 1st and 2nd ANC visit as IPTp
45376181|NCT00811421|Drug|placebo|MQ-placebo oral administration at the 1st, 2nd and 3rd Antenatal Clinic visit as IPTp
45376182|NCT00811421|Drug|mefloquine|MQ oral administration (15 mg/Kg) at the 1st and 2nd Antenatal Clinic visit as IPTp
45492698|NCT02352142|Behavioral|Facilitated Infant Care|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
45492699|NCT02896127|Drug|Secukinumab|"Induction: 4x 150 mg Secukinumab s.c. weekly~Maintenance: 150 mg Secukinumab s.c. monthly~All Subjects received blinded treatment weekly starting at baseline, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4 until Week 16. At Week 16, Group 1 patients continued using secukinumab 150 mg and Group 2 patients started receiving secukinumab 150 mg dosing every four weeks. Treatment was provided open-label from Week 16 onward, as all patients took 150 mg s.c. every 4 weeks; however, subjects, investigators, and site staff remained blinded to initial randomized group assignment."
45492700|NCT02896127|Drug|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
45492701|NCT02351986|Procedure|physical therapy|A 20 minutes ice pack cryotherapy applied for 4 consecutive days
45492702|NCT02351986|Other|ice pack|
45376183|NCT00808301|Other|Gluten-free products|Gluten-free bakery products containing oatmeal.
45376184|NCT00808379|Drug|Chemoradiation|Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles.
45376185|NCT00808379|Radiation|Additional Radiation boost to the primary tumor volume|15-20Gy
45376186|NCT00569777|Device|K-Lens (generic name not established) and Ketotifen|combination drug-device product: contact lens (device) and anti-allergy drug
45376187|NCT00569777|Device|Placebo Lens|contact lens without drug
45376188|NCT00808535|Procedure|Cardiac Perfusion MRI w Vasomotor Stress|All participants will undergo Cardiac Perfusion MRI with Vasomotor Stress. Vasomotor Stress will include both Cold Pressor Test and Adenosine Stress Test.
45376189|NCT00811811|Behavioral|Behavioral neurocardiac training|6 training sessions scheduled over 8 weeks
45492703|NCT03153592|Procedure|Transpulmonary pressure driven ventilation strategy|Patients will receive volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, an inspiratory transpulmonary pressure less than 20 cmH2O, and an expiratory transpulmonary pressure (PLexp) equal or greater than 0. At PLexp increasing from 0 up to 10 cmH2O, inspired fraction of oxygen would also be increased from 40% to 100%. Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and to ensure a physiological pH. Whenever the clinician will deem it appropriate, an alveolar recruitment maneuver as previously described
45376190|NCT00811811|Behavioral|Autogenic relaxation training|6 training sessions scheduled over 8 weeks
45376191|NCT00569231|Drug|Candida Antigen|Intralesional injection of 0.3ml candida antigen into largest wart at baseline visit and then every 3 weeks +/- 3 days for a maximum of 10 treatments.
45693328|NCT03801850|Device|3D surface scan|measurement of inter fractional deformations by surface scanning
45376192|NCT00654095|Drug|Ezetimibe|Ezetimibe 10 mg once daily
45693329|NCT03808246|Other|using the demo version of a self-injector pen|Participants, whatever the arm they are included in, will have to use the demo version of the auto-injector pen during a simulation of an anaphylactic shock.
45376193|NCT00654095|Drug|atorvastatin|atorvastatin 20 mg once daily
45376194|NCT04016831|Behavioral|Mapping Enhanced Counseling (MEC)|a motivational enhancement clinical intervention derived from cognitive-behavioral models that addresses problem recognition, treatment motivation, thoughtful and objective decision making, and therapeutic engagement
45693330|NCT01784029|Drug|Vitamin D3|Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.
45693331|NCT00789256|Drug|Melphalan|Melphalan: 2mg orally, once daily
45376195|NCT04016831|Other|Mapping Approaches to Prepare for Implementation Transfer (MAP-IT)|an implementation intervention to explore and address agency preparation needs in order to promote implementation success
45693332|NCT00789256|Drug|Bortezomib|Bortezomib: 1.0mg/M2 IV on days 1, 4, 8, 11
45693333|NCT00789256|Drug|Melphalan and bortezomib|
45693334|NCT01733329|Drug|Misoprostol|At cord clamping 2 tablets (400 mcg) were placed in the patient´s buccal space by anesthesiologist.
45376196|NCT00808691|Other|Critical care|Standard care for each group of patients
45376197|NCT00811967|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at a dose of 1.5 ug/kg QW SC for up to 48 weeks
45376198|NCT00811967|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered at a dose of 600, 800, or 1000 mg/day, orally, for up to 48 weeks.
45376199|NCT02552615|Other|body awareness therapy|
45376200|NCT02552615|Other|core stabilization exercises|
45376201|NCT02552615|Other|traditional exercises|
45376202|NCT00812045|Drug|AZD1236|Oral tablet, 75 mg twice daily during 4 weeks
45376203|NCT00812045|Drug|Placebo|
45376204|NCT04046159|Drug|Low-dose tamoxifen|Low-dose tamoxifen is not inferior than radiotherapy in decreasing ipsilateral breast tumor recurrence and side effect
45376205|NCT04046159|Radiation|Whole breast radiotherapy|Ipsilateral breast tumor recurrence and side effect
45376206|NCT00650585|Behavioral|Project ALERT|Project ALERT (Adolescent Learning Experiences in Resistance Training) is a drug prevention curriculum designed for middle-school students (11 to 14 years old). The 11 lessons in the first year and 3 booster lessons in the second year focus on alcohol, tobacco, marijuana, and inhalants - the substances that adolescents are most likely to use. Project ALERT uses participatory activities and videos to help motivate youth to avoid drug use, to teach youth skills and strategies to resist peer pressures to use drugs, and to establish social norms against drug-use. More information about Project ALERT may be found at http://www.projectalert.best.org/.
45376207|NCT02552069|Device|Tritanium® cup|
45376208|NCT00653939|Drug|Fosbretabulin|Arm 2 only: Fosbretabulin (60 mg/m2) on Days 7,14 and 21 for 6 cycles.
45376209|NCT00653939|Drug|Carboplatin|Chemotherapy: Carboplatin (AUC 6) on Day 1 of each 21 day cycle for 6 cycles.
45693335|NCT01733329|Drug|Folic Acid|At cord clamping 2 tablets (10 mg) were placed in the patient´s buccal space by anesthesiologist.
45376210|NCT00653939|Drug|Paclitaxel|Chemotherapy: Paclitaxel (20 mg/m2) on Day 1 of each 21-day cycle for 6 cycles.
45376211|NCT00653939|Drug|Bevacizumab|Bevacizumab (15 mg/kg) on Day 1 of each 21-day cycle for 6 cycles.
45376212|NCT00812123|Drug|Sirolimus|Loading dose 30 mg for three days, trough level of 10-20 ng/ml month 1-3, 8-15 ng/ml month 4 - 6
45376213|NCT00812123|Drug|Cyclosporine A|Loading dose of 300 mg for three days, trough levels 250-300 ng/ml months 1-3, 150-250 ng/ml months 4 to 6
45376214|NCT00812123|Drug|Prednisone|0.5 mg/kg, tapering every two weeks until 0.1 mg/kg
45376215|NCT00812123|Drug|Mycophenolate mofetil|2 x 1000mg, through level above 2ug/ml
45376216|NCT00812123|Procedure|Protocol biopsies|protocol kidney biopsies at month one and three
45376217|NCT00808925|Other|exposure to heat|Dressed in shorts and tennis shoes the subjects will be exposed to exercise-heat stress for 12 consecutive days (excluding Saturday). Daily exposure will last 120 min, under the controlled environmental conditions of 40oC and 40% relative humidity. The exercise will consist of walking on a treadmill at a pace of 5km/h and 2% incline.
45693336|NCT05742646|Behavioral|MATADORS|Youth will have access to the MATADORS app to include basic information and expanded educational features. They will be asked to log into the app daily for one month and they will be asked to report within the app how they are feeling each day and their medications taken.
45376218|NCT00809081|Procedure|Enteral Feeding and Total Parental Support|"Enteral Feeding : 20ml/hr on POD1~Velocity is progressively increased by 20ml/d until full nutritional goal (25Kcal/Kg)"
45376219|NCT00646451|Drug|pregabalin (Lyrica)|75 mg bid to 300 mg bid based on per subject tolerability
45492704|NCT03153592|Procedure|Conventional ventilation strategy|13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure <28 cmH2O Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and in any case to ensure a physiological pH. In addition, whenever the clinician will deem it appropriate, an alveolar recruitment maneuver will be performed as previously described
45492705|NCT03724097|Other|RNA sequencing|Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
45492706|NCT03724097|Other|Transcriptome analysis|Analysis of RNA-seq data using the Oncobox algorithm.
45693337|NCT05742646|Behavioral|MATADORS Control|Youth will have access to the MATADORS app basic information. They will be asked to log into the app daily for one month and they will be asked to report within the app their medications taken.
45492707|NCT03724097|Drug|target drug with the score above 0,1|target drug with the score above 0,1
45847096|NCT04780464|Drug|Prednisone|10-20 mg on day 1 to day 7 of each 14 day cycle until PD for those Countries where Prednisolone in tablets is not available
45847097|NCT04660422|Other|VitalTalk communication skills training|Clinicians will receive VitalTalk intensive communication skills training via highly structured Zoom conference. They will learn skills relevant to discussions about ACP and COVID-19 including delivering serious news, eliciting goals of care, and managing difficult conversations via telehealth platforms.
45376220|NCT00646451|Drug|placebo|up to 4 capsules bid as tolerated
45376221|NCT02552849|Other|No intervention|
45376222|NCT02552927|Device|Chest shield with aluminum foil (CALF)|
45376223|NCT02552927|Device|SHIELD|
45492708|NCT03724097|Drug|target drug with the score equal or below 0,1|target drug with the score equal or below 0,1
45492709|NCT03724097|Drug|non-target drug|non-target drug
45492710|NCT03724097|Drug|palliative care|palliative care
45693338|NCT01783483|Device|SternaLock Blue closure system|SternaLock Blue closure system is a primary closure system plate-based
45693339|NCT01783483|Device|Suture Wire|Closure system wire-based used to approximate the two halfs of the sternum following a median sternotomy.
45376224|NCT00813683|Other|Acupuncture stimulation|"Acupuncture by stimulation of 67 Bladder point"
45376225|NCT00813683|Other|Acupuncture stimulation|"Acupuncture stimulation of 45 Stomach point (sham)"
45376226|NCT00809237|Drug|Gefitinib, Hydroxychloroquine|Gefitinib 250 mg om Hydroxychloroquine at maximally tolerated dose
45376227|NCT00813839|Other|daily weaning trails|daily SmartCare vs SBT until extubation criteria met
45376228|NCT02552693|Other|Enhanced training, supervision and support|"The intervention includes the following activities:~Conduct of pre-intervention facility audits; Cross-verification of appointment diaries with facility attendance records; Development and implementation of job aids and tools; Provides supplemental training and technical support to focal facility point (FFP) and other staff, and community health workers (CHWs); Improves coordination, supervision and reporting systems at the health facilities."
45376229|NCT02551913|Behavioral|Control|the adolescents will not receive any specific intervention
45376230|NCT02551913|Behavioral|Intervention|A theory based sleep hygiene intervention based on the theory planned behavior will be conduced on the adolescent
45376231|NCT00817505|Drug|AZD1656|Single dose oral tablet
45376232|NCT00817505|Drug|AZD1656|Single dose oral suspension
45376233|NCT00817583|Drug|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
45376234|NCT00817583|Radiation|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|
45376235|NCT02551679|Biological|ACP-01|Injection into lower extremity
45376236|NCT02551679|Biological|Placebo|Injection into lower extremity
45693340|NCT02145676|Biological|onabotulinumtoxinA|OnabotulinumtoxinA injected into predefined muscles of the study limb on Day 1.
45693341|NCT02145676|Drug|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
45693342|NCT05742568|Drug|Esomeprazole|High-dose dual therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablet TID plus amoxicillin 500 mg 2 capsules TID
45693343|NCT05742568|Drug|Amoxicillin|High-dose dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 20mg 2 tablet TID
45492711|NCT03157414|Drug|Empagliflozin|Empagliflozin tablets enclosed with red capsules (Capsugel AAEL) by Kragerø Tablettproduksjon AS for blinding purpose
45376237|NCT00817661|Dietary Supplement|Vitamin A|10000 IU Vitamin A or placebo per week
45376238|NCT00817661|Dietary Supplement|Placebo|10000 IU Vitamin A or placebo per week
45376239|NCT00642707|Drug|PRO 140 (humanized monoclonal antibody to CCR5)|
45492712|NCT03157414|Other|Placebo|Placebo tablets made by Kragerø Tablettproduksjon AS and enclosed with red capsules (Capsugel AAEL) for blinding purpose
45492713|NCT03157024|Device|Ring Sham (RS)|
45492714|NCT03157024|Device|Real Needle (RN)|
45492715|NCT03157024|Device|Kim Sham (KS)|
45492716|NCT03546647|Device|Dailies Aqua Comfort Plus Toric|Daily disposable soft toric contact lens
45492717|NCT03546647|Device|Dailies Aqua Comfort Plus Sphere|Daily disposable soft spherical contact lens
45492718|NCT03156478|Behavioral|Digital lifestyle intervention group|Intervention with digital application for lifestyle changes
45492719|NCT03156478|Behavioral|Combined digital and face-to-face lifestyle intervention group|Intervention with digital application and group meetings for lifestyle changes
45693344|NCT05742568|Drug|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
45693345|NCT05742568|Drug|Esomeprazole|BBismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
45492720|NCT03727529|Other|Treadmill + VR|Patients will walk on the tredmill with the virtual reality headset. Patients will walk in a straight line in a coherent, immersive and simple virtual environment. Before the first session, a 15-minute session will focus on patient familiarization with iVR
45693346|NCT05742568|Drug|Amoxicillin|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
45693347|NCT05742568|Drug|Clarithromycin|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
45693348|NCT01607593|Drug|sertraline (Zoloft)|Dosage form: Tablet, Dosage: over 25 mg/day, duration: Not defined
45693349|NCT00789724|Drug|Anakinra|100 mg daily subcutaneous injection for 14 days
45693350|NCT00789724|Drug|Placebo|0.67 ml of NaCl 0.9% subcutaneously daily for 14 days
45693351|NCT01755637|Drug|Albendazole|Albendazole tablets 400 mg
45376240|NCT00642707|Drug|Placebo Comparator|
45376241|NCT02551523|Drug|Dolutegravir|92 patients will be simplified to once daily dolutegravir monotherapy
45376242|NCT02551523|Drug|Standard of care combinational antiretroviral therapy|
45376243|NCT00814151|Other|MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)|"In vitro diagnostic: The MicroPhage Intervention was to perform the MicroPhage diagnostic test to detect S. aureus in the blood culture sample and determine MSSA or MRSA status at 4 and 5 hours of test incubation. The Intervention results were not made available to the patient or their physician."
45376244|NCT00817739|Drug|Leuprorelin|Leuprorelin injection
45376245|NCT00817739|Drug|Flutamide|Flutamide tablets
45376246|NCT00817895|Drug|sustained released 5-FU and sustained released cisplatin|600mg sustained released 5-FU and 60mg sustained released cisplatin will be implanted into liver incisal margin after tumor is resected.
45376247|NCT00817895|Drug|sustained released 5-FU|600mg sustained released 5-FU will be implanted into liver incisal margin after tumor is resected.
45492721|NCT03727529|Other|Treadmill|Patients will walk on the treadmill without iVR. Patients will also receive a short familiarization to the treadmill before strating the experimentation.
45492722|NCT01310543|Behavioral|Teens and Toddlers|The T&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
45492723|NCT02348164|Other|Pink grapefruit first followed by tangerines two weeks later|A 504 gram serving of pink grapefruit was fed as a single meal followed by 234 grams tangerines two weeks later
45492724|NCT02348164|Other|Tangerines first followed by pink grapefruit two weeks later|A 234 gram serving of tangerines was fed as a single meal followed by 504 grams pink grapefruit two weeks later
45376248|NCT00817895|Procedure|TACE|All patients will accept TACE one month after tumor was resected.
45376249|NCT00814229|Biological|H9N2 whole virus vaccine, IM, 1.5microg|influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection
45492725|NCT02347930|Other|kidney ultrasound|kidney ultrasound
45492726|NCT03147196|Drug|Bicalutamide|Given PO
45492727|NCT03147196|Other|Laboratory Biomarker Analysis|Correlative studies
45492728|NCT03147196|Other|Questionnaire Administration|Ancillary studies
45492729|NCT03147196|Drug|Raloxifene Hydrochloride|Given PO
45693352|NCT03801538|Drug|Peginterferon Alfa|Peginterferon Alfa-2A 180 micrograms/week or Peginterferon Alfa-2B 180 micrograms/week, for at most 96 weeks.
45693353|NCT03801538|Drug|Nucleoside Analog (Substance)|Patients do not need to change their NAs treatment.
45376250|NCT00814229|Biological|H9N2 whole virus vaccine, IM, 5microg|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection
45376251|NCT00814229|Biological|H9N2 whole virus vaccine vaccine, IM, 15microg|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection
45492730|NCT03153436|Biological|Myoinositol|
45492731|NCT03077412|Drug|Filgotinib|Tablet(s) administered orally once daily
45492732|NCT03077412|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
45492733|NCT03544229|Drug|TAK-906 Maleate|TAK-906 maleate capsules.
45492734|NCT03544229|Drug|Placebo|TAK-906 maleate placebo-matching capsules.
45492735|NCT03147118|Diagnostic Test|Arthrogram|Contrast dye will be included in the standard injection of lidocaine and corticosteroid. After injection, the participant will have 2 radiograph views of the thumb.
45492736|NCT02353312|Drug|Kuvan|Kuvan® (sapropterin dihydrochloride) will be initiated at 10mg/kg/day with meals for one week. After telephone contact on day 7, assuming no adverse effects are noted, the patient will be instructed to increase their daily dose to 20mg/kg/day with meals for the remainder of the 3 months.
45492737|NCT02351908|Drug|Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat)|
45492738|NCT02351908|Drug|Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet|
45492739|NCT02351908|Drug|Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)|
45492740|NCT01371240|Drug|Secretin Synthetic Human (RG1068)|A maximum dose of 100 consumer unit (CU) of RG1068, synthetic human secretin (Repligen Corporation) or one CU per kg body wt for patients that weight less than 100 kg will be injected (0.2µg of RG1068 are equal to 1CU) (RepliGen Co., Waltham, MA, USA). This dose will be given as an intravenous bolus at 3 minutes before injecting the contrast.
45492741|NCT02353390|Other|Oral Water Hydration|Subjects in the hydration group will be allowed up to 15 minutes to drink up to 500 milliliters (mL) of water prior to the vaccines. Subjects will be encouraged to drink the entire 500 mL; however, they are free to drink as much as they want and can finish before the end of the 15-minute period. Subjects will be instructed not to share the water and to not otherwise empty the bottle. As with the control group, subjects will be instructed not to eat or drink anything else for the duration of the study, unless clinically indicated (e.g., as part of management of presyncope or syncope).
45492742|NCT02352064|Procedure|PET (18-FDG)|Every patient will have a PET
45693354|NCT03801226|Drug|Two-hour dwell with 10% dextrose in sterile water|Patients will be randomized to undergo a two-hour dwell with 10% dextrose in sterile water at their first or second study visit and will receive the alternate intervention at the other study visit.
45693355|NCT03801226|Drug|Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose|Patients will be randomized to undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first or second study visit and will receive the alternate intervention at the other study visit.
45693356|NCT04567693|Other|Early spaced-out appointments|Newly-diagnosed PLWH currently attend health centers monthly for ART pick-up and quarterly for clinical visits. In the intervention arms, participants will attend health centers quarterly for ART pick-up and semi-annually for clinical visits.
45693357|NCT02145754|Other|MKP media|one half of skin specimen was put in MKP media
45693358|NCT02145754|Other|BSK-H media|one half of skin specimen was put in BSK-H media
45376252|NCT00814229|Biological|H9N2 whole virus vaccine, IM, 45microg|influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection
45376253|NCT00814229|Biological|H9N2 whole virus vaccine, alum, IM, 1.5microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection
45376254|NCT00814229|Biological|H9N2 whole virus, alum, IM, 5microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection
45492743|NCT03078816|Device|Activa PC Primary Cell Neurostimulator - (Model 37601)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
45492744|NCT03078816|Device|Activa RC Rechargeable Neurostimulator - (Model 37612)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
45492745|NCT03078816|Device|Activa SC Single Cell Neurostimulator (Models 37602/37603)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
45492746|NCT03078816|Device|DBS Lead - (Model 3387|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
45376255|NCT00814229|Biological|H9N2 vaccine, whole virus, alum, IM, 15 microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection
45376256|NCT00814229|Biological|H9N2 vaccine, whole virus, alum, IM, 45microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection
45376257|NCT00814229|Biological|H9N2 virosome vaccine, IM, 1.5microg|influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection
45492747|NCT03078816|Device|DBS Extension - (Models 37085/6)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
45492748|NCT03078816|Device|Patient Programmer - (Model 37642)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
45693359|NCT03837808|Drug|Nimotuzumab|nimotuzumab 200mg/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
45376258|NCT00814229|Biological|H9N2 virosomal vaccine, IM, 5microg|influenza H9N2 vaccine virosome containing 5microg haemagglutinin by intramuscular injection
45376259|NCT00814229|Biological|H9N2 virosomal vaccine, IM, 15microg|influenza H9N2 vaccine virosome containing 15microg haemagglutinin by intramuscular injection
45376260|NCT00814229|Biological|H9N2 virosomal vaccine, IM, 45microg|influenza H9N2 vaccine virosome containing 45microg haemagglutinin by intramuscular injection
45376261|NCT00814229|Biological|H9N2 whole virus vaccine, ID, 5microg|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection
45376262|NCT00814229|Biological|H9N2 whole virus vaccine, ID, 15microg|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection
45376263|NCT00568685|Drug|Atomoxetine Hydrochloride|Patients receive 0.2 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
45376264|NCT00568685|Drug|Atomoxetine hydrochloride|Patients receive 0.5 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
45693360|NCT03837808|Drug|Cisplatin|cisplatin 40mg/m2/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
45693361|NCT05741398|Device|VR system by Demaod|non-invasive light pulse generated by a non-contacting device for the treatment of the symptoms of dry eyes and MDG
45693362|NCT05739838|Device|Biolase ;Low Level Laser|Low Level laser ,940 nm
45492749|NCT03078816|Device|Test Stimulator - (Model 3625)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
45376265|NCT00568685|Drug|Atomoxetine hydrochloride|"Patients initially receive atomoxetine 0.5 mg/kg/day administered orally in two divided doses for approximately 7 days. Patients will then receive atomoxetine 0.8 mg/kg/day administered orally in two divided doses for approximately 7 days.~Patients will receive atomoxetine 1.2 mg/kg/day administered orally in two divided doses for the remainder of the study, lasting approximately 28 days"
45376266|NCT00814385|Biological|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
45376267|NCT00814385|Biological|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
45376268|NCT00814385|Biological|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
45376269|NCT00814385|Biological|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
45376270|NCT00814385|Biological|Aflunov (Double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
45376271|NCT00814385|Biological|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
45376272|NCT00814385|Biological|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
45376273|NCT00814385|Biological|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
45376274|NCT00814385|Biological|Aflunov (No prime, single boost)|No Priming then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
45376275|NCT04044911|Behavioral|Task model (CogWatch)|
45376276|NCT04045379|Procedure|LASER|Use of the SmartXide Touch V²LR, Co2 Laser System to perform ambulatory intravaginal and vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
45693363|NCT03801070|Procedure|endoscopic drainage of walled off pancreatic necrosis|transmural drainage and mechanical debridement of solid debris (necrosectomy)
45376277|NCT04045379|Procedure|Microablative Radiofrequency|Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured.
45492750|NCT03078816|Device|N'Vision Clinician Programmer - (Model 8840)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
45492751|NCT03078816|Device|N'Vision Software Application Card - (Model 8870)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
45492752|NCT02039128|Dietary Supplement|Krill oil or Fish oil|
45492753|NCT02039128|Dietary Supplement|Placebo|
45492754|NCT03723941|Drug|Cisplatin plus Etoposide|"Etoposide 100 mg/m2 will be administered IV on days 1, 2, 3 diluted in 500 mL of isotonic NaCl or 5% dextrose.~Cisplatin, 80 mg/m2 will be administered IV on day 1, diluted in 500 mL of isotonic NaCl."
45492755|NCT03723941|Other|Observation or Mitotane|Observation or mitotane alone according to the investigator's preference
45693364|NCT03800914|Other|High intensity interval training|36 minutes of interval exercise on cycle ergometer alternating every 30 seconds between 100% peak work rate achieved on cardiopulmonary exercise test and unloaded cycling
45693365|NCT03800914|Other|Traditional pulmonary rehabilitation|30 minutes of continuous exercise on cycle ergometer at 60% peak work rate achieved on cardiopulmonary exercise test.
45693366|NCT05596708|Drug|Telitacicept|Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for 104 weeks.
45376278|NCT04045379|Drug|Estriol|The patient will perform self application of this vaginal estriol daily for 2 weeks and after that the applications will occur twice a week.
45376279|NCT04045457|Procedure|dry needling|insertion of needle into active myofascial trigger point
45376280|NCT02551601|Other|measure subfoveal choroidal thickness|measure subfoveal choroidal thickness using optical coherence tomography
45376281|NCT00061945|Drug|allopurinol|Given PO
45376282|NCT00061945|Drug|cyclophosphamide|Given IV
45376283|NCT00061945|Drug|daunorubicin hydrochloride|Given IV
45376284|NCT00061945|Drug|vincristine sulfate|Given IV
45376285|NCT00061945|Drug|dexamethasone|Given PO and as eye drops
45376286|NCT00061945|Drug|asparaginase|Given SC
45376287|NCT00061945|Biological|filgrastim|Given SC
45376288|NCT00061945|Drug|imatinib mesylate|Given PO
45376289|NCT00061945|Drug|methotrexate|Given IT, IV, and PO
45376290|NCT00061945|Drug|cytarabine|Given IV
45693367|NCT01732549|Drug|Tasquinimod|A patient's dose will escalate from one level to the next, once tolerability of the current dose is established. If tolerability issues arise at 0.5 or 1 mg/day, patients will have their dose reduced to 0.25 or 0.5 mg/day, respectively.
45376291|NCT00061945|Drug|trimethoprim-sulfamethoxazole|Given PO
45376292|NCT00061945|Drug|mercaptopurine|Given PO
45492756|NCT03153046|Dietary Supplement|prebiotics|Bimuno (BGOS): The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; <01g Fat; <0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless. Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.
45376293|NCT00061945|Drug|leucovorin calcium|Given IV and PO
45376294|NCT00061945|Biological|alemtuzumab|Given SC
45376295|NCT00061945|Drug|acyclovir|Given PO
45376296|NCT00061945|Other|laboratory biomarker analysis|Correlative studies
45376297|NCT00061945|Other|pharmacological study|Correlative studies
45376298|NCT00817973|Dietary Supplement|Casein|
45376299|NCT00817973|Dietary Supplement|Whey|
45376300|NCT00817973|Dietary Supplement|Cod|
45376301|NCT00817973|Dietary Supplement|Gluten|
45376302|NCT00818051|Radiation|intensity-modulated radiation therapy|Given as 48, 53, or 56 Gy
45376303|NCT01097941|Biological|Live Attenuated H1N1 Influenza Vaccine|0.2 ml dose of live monovalent vaccine delivered through nasal spray, 2 doses given 28 days apart
45376304|NCT01097941|Biological|Influenza A (H1N1) 2009 Monovalent Vaccine|0.5 ml IM, 2 doses given 28 days apart
45376305|NCT01097941|Biological|Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live|0.5 ml IM given X1 with 0.1 ml intranasally given 28 days later
45376306|NCT00642473|Drug|Erlotinib|Participants will receive erlotinib 150 milligrams (mg) orally daily for 4 weeks.
45693368|NCT01732549|Drug|Placebo|Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food
45376307|NCT00642473|Drug|Metronidazole Actavis|Metronidazole actavis 1% topical cream will be applied on the face and chest twice daily for 4 weeks.
45376308|NCT00642473|Other|Non-active Moisturizing Cream|Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
45376309|NCT00818129|Drug|AZD7295|ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution
45376310|NCT00818129|Drug|Placebo|multiple ascending dose (tbd based on single dose results), oral solution
45376311|NCT00645671|Drug|0.5% Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
45376312|NCT00645671|Drug|Vehicle of Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
45376313|NCT00366340|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
45376314|NCT00366340|Biological|7-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
45693369|NCT04383964|Device|Distraction Osteogenesis for Reconstruction of Ramus-Condyle|transport distraction osteogenesis in restoring the deficient condyle/ramus unit of patients with TMJ ankylosis to correct the resultant deformity either unilaterally or bilaterally.
45693370|NCT05593978|Behavioral|Culinary Medicine|The CM-group will receive weekly cooking demonstrations and education videos via electronic links for 16 weeks, and three nutrition education based on the content of the Nutrition Care Manual from the Academy of Nutrition and Dietetics to show age-appropriate recipes with correct preparation methods and different cooking methods for lean ground red meat to increase protein consumption.
45693371|NCT05593978|Behavioral|Control|The CN-group will receive weekly recipes via electronic links without the culinary medicine intervention.
45693372|NCT02148874|Biological|influenza virus vaccination|comparison of immune responses to the flu vaccine in obese and non-obese populations
45376315|NCT03992326|Other|TIL|Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
45376316|NCT03992326|Drug|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
45376317|NCT03992326|Drug|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
45376318|NCT03992326|Drug|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
45376319|NCT03992326|Other|Radiotherapy|Low-dose irradiation (1Gy) will be administered using tomotherapy to up to 20 measurable tumor lesions once before TIL infusion.
45376320|NCT01049386|Other|No intervention|In obese and lean subjects the intestinal absorption will be examined under normal conditions with sugar drink, and when disturbed by a high-fat breakfast.
45376321|NCT01049386|Procedure|Sugar absorption test|On one of the test days the subjects will consume a high-fat breakfast.
45376322|NCT01045954|Drug|Lispro Insulin and glargine insulin|Continuous glucose sensor will be inserted. Subject will be on an isocaloric diet and CGM downloaded daily. Insulin basal and bolus will be adjusted based upon treatment goals until goals reached
45376323|NCT01046032|Drug|Metformin|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
45376324|NCT01046032|Drug|Placebo|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
45693373|NCT01755091|Drug|Dronabinol|
45693374|NCT01755091|Drug|Placebo (for Dronabinol)|
45376325|NCT01046188|Other|Knowledge Questionnaire|Administered before and after teaching intervention
45376326|NCT01046188|Other|Perceived Stress Scale|Administered before and after teaching intervention
45376327|NCT01046188|Other|Satisfaction questionnaire|Administered after the intervention and at study completion
45376328|NCT01046188|Other|Web-based IVF teaching|Web-based IVF teaching
45376329|NCT01046188|Other|Didactic lecture|Didactic lecture
45376330|NCT00061633|Drug|Telavancin|Telavancin 7.5 mg/kg/day IV (intravenously) for up to 14 days
45376331|NCT00061633|Drug|Vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
45376332|NCT00645593|Drug|Gemcitabine,|Gemcitabine will be administered intravenously at a dose of 1000 mg/m2 on Days 1, 8 and 15 of cycle. One treatment cycle is 28 days.
45693375|NCT00789802|Drug|transdermal estradiol|transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.
45376333|NCT00645593|Drug|Cisplatin|Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle.
45376334|NCT00645593|Drug|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 mg/m2 on Days 1 and 15 of each cycle. One treatment cycle is 28 days.
45376335|NCT01093261|Drug|Placebo|"Placebo:~continuous intra venous infusion of placebo n°1 for 10 days. enteral administration of placebo n°2 for 10 days."
45376336|NCT01093261|Drug|Hydrocortisone Fludrocortisone|HYDROCORTISONE: 200 mg.day-1 for 7 days, 100 mg.day-1 on day 8 and 9, 50 mg on day-10 (continuous intravenous infusion) FLUDROCORTISONE: 50 microg.day-1 for 10 days (per os)
45376337|NCT02550977|Drug|Gestodene/EE Patch (BAY86-5016)|7 day patch containing 0.55 mg ethinyl estradiol and 2.1 gestodene in a 21 day regimen.
45376338|NCT03832738|Drug|JTE-451 Tablets|Active drug tablets containing JTE-451
45376339|NCT03832738|Drug|Placebo Tablets|Placebo tablets matching in appearance to the active drug tablets
45376340|NCT01045018|Drug|Placebo|placebo 400 mg
45693376|NCT00789802|Drug|naproxen|naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks
45693377|NCT00789802|Drug|oral placebo|oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks
45376341|NCT01045018|Drug|Mesalamine|
45492757|NCT03153046|Dietary Supplement|Maltodextrin|Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria. The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink. This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention.
45693378|NCT04567225|Drug|Early Glargine|A dose of insulin glargine, 0.4 unit/kg, will be given within 4 hours from initiating the IV Insulin Infusion
45693379|NCT04567225|Drug|Late Glargine|A historical retrospective control group for the adult patients admitted to the same ICU with a diagnosis of DKA and received insulin glargine after anion gap closure.
45693380|NCT04567225|Other|IV insulin infusion|Continuous weight based IV insulin infusion as per Cleveland Clinic DKA Protocol
45376342|NCT01045018|Drug|Mesalamine|
45376343|NCT00267904|Other|Coffee|Caffeinated coffee and decaffeinated coffee ingestion
45376344|NCT00267904|Other|Banana|Banana ingestion
45376345|NCT00267904|Other|Olives|Olives ingestion
45376346|NCT00267904|Other|Temp. manip.|Manipulate temperature at skin of the back
45376347|NCT01049464|Drug|Placebo|5%D/W 20 ml intravenous in 10 min then 5%D/W 100 ml intravenous in 6 hours.
45376348|NCT01049464|Drug|Magnesium sulphate|Magnesium sulphate 2g diluted with 5%D/W into 20 ml solution, intravenous infusion in 10 min then Magnesium sulphate 6g diluted with 5%D/W into 100 ml solution, intravenous infusion in 6 hours.
45376349|NCT01046266|Drug|RO5083945|700mg iv weekly
45376350|NCT01046266|Drug|cetuximab|400mg/m2 iv 1st dose, 250mg/m2 iv subsequent weekly doses
45376351|NCT00046891|Drug|Ginkgo Biloba|Patients will take 120 mg per day (60 mg BID)
45693381|NCT04567225|Other|IV fluid and electrolytes replacement|The IV fluid and electrolytes replacement will be left to the treating physician's discretion. IV fluid to contain dextrose to keep Target Blood Glucose 150 - 200 mg/dl during the DKA management and 140 - 180 mg/dl after DKA resolution.
45693382|NCT04384510|Procedure|Planned Cesarean hysterectomy|This procedure refers to planned delivery of the fetus through Cesarean incision, leaving the placenta in situ and proceeding with hysterectomy
45376352|NCT00046891|Other|Placebo|Patients will take 1 tablet BID
45693383|NCT04384510|Procedure|Conservative management|This term describes a single or combined intervention of uterine artery ligation, internal iliac artery ligation, prophylactic balloon placement in the aorta or internal iliac artery, uterine artery embolization, compression sutures, or excision and reconstruction of uterine wall
45693384|NCT01754467|Behavioral|NEAT!|Participants will wear the accelerometer and use the NEAT! application during waking hours for 1 month. The NEAT! app will prompt participants to stand up when they have been sitting for a prolonged period.
45376353|NCT01045330|Behavioral|a modified NTU-HELP|The intervention consists of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
45376354|NCT00365794|Drug|Topical testosterone gel 10 g/day|Testosterone gel therapy for 20 weeks
45382279|NCT05128474|Other|Neuromuscular Control-Based Exercise Training Group|Exercises for the neuromuscular control of the shoulder will be progressed by starting with the body weight, and in the following phases, a program that progresses to exercises that will improve the dynamic stabilization, coordination and proprioception of the shoulder will be applied to train the sensorimotor system. The exercise program will be performed twice a week for 8 weeks (16 sessions).
45693385|NCT01753999|Device|Standard CPAP|Use of the REMstar Auto A-Flex in standard CPAP therapy mode
45376355|NCT03954457|Behavioral|A-CWS|The A-CWS intervention is a 15-session culturally-grounded, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills for coping with stress. The intervention structure allows implementation within traditional school and other community settings. The A-CWS uses standard cognitive-behavioral strategies (e.g., relaxation training, cognitive restructuring) to help African American youth identify and cope with individual and contextual stressors, using culturally consistent coping strategies. The intervention emphasizes the identification and management of stressors associated with suicide risk (e.g., racism-related stress, community violence exposure) and the unique experiences of low-resourced, urban African American adolescents (e.g., community violence exposure). The structured, manualized A-CWS curriculum is designed to be sustainable and user-friendly, to ensure that the A-CWS is delivered effectively and with a high degree of fidelity.
45376356|NCT03954457|Behavioral|Standard Care Control|The standard care control condition consisted of standard case management services delivered by the SBHC. Participants randomly assigned to the standard care control condition were referred to the SBHC social worker for case management. Standard care ranged from brief intervention by the SBHC social worker, to more intensive intervention by the SBHC social worker, to outside referral to local community service providers. SBHC social workers determined type and duration of services based on individual participant needs.
45376357|NCT00383500|Device|Flexitouch|A standard of care intermittent pneumatic compression device (aka, lymphedema pump)
45492758|NCT03155698|Combination Product|microneedling and Platelet rich plasma|"Patient's skin is first cleaned with ethyl alcohol. Topical anaesthetic cream is then applied to skin for 30 min. Once anaesthesias is fully developed, Dermapen will be applied on the lesional skin in four direction, vertical, horizontal and the two diagonal until pin point bleeding occur which will be gently massaged.~After ten minutes the prepared platelet rich plasma will be applied topically and after about 2 minutes. Occlusive dressing will be done and kept for 1 day then the patient will use topical antibiotic. The procedure will be repeated every 15 days."
45492759|NCT03155698|Radiation|NB-UVB phototherapy|All patients will receive NB-UVB twice weekly for maximum 6 months, starting with a dose of 0.21 J/cm² independent of skin type and increased by 20% every session until we reach the minimal erythema dose
45492760|NCT03723863|Behavioral|Occupational Therapy|Receive in-person occupational therapist-led work consultation
45492761|NCT03155308|Device|Pentax chromoendoscopy (i-scan and Optical Enhancement)|All lesions will be evaluated using the 3 i-scan modes and the 2 OE modes without magnification. The lesion size data, location and macroscopic shape of the lesions based on the Paris classification will be recorded. Finally all lesions will be classified in real-time into 3 types based on NICE classification (NICE 1, hyperplastic polyps; NICE 2, adenoma and superficial submucosal carcinoma; NICE 3, SM-d invasive carcinoma). A level of confidence (high or low) will be assign in each stage. Polyp's images will be photographically and videotape recorded. All polyps will be resected or biopsied for histopathological examination used as the criterion standard for the analysis.
45492762|NCT03721679|Biological|Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months|Same as above
45492763|NCT04674228|Other|Electronic Health Record Review|Review of medical records
45492764|NCT03639948|Drug|Carboplatin|Intravenous solution
45492765|NCT03639948|Drug|Docetaxel|Intravenous solution
45492766|NCT03639948|Drug|Pembrolizumab|Intravenous solution
45492767|NCT03639948|Drug|Pegfilgrastim|Injectable product
45492768|NCT03146728|Other|exercise|energy expenditure will be measured for each of the participants during different conditions, rest, during exercise with the arm crank height high or low. Energy expenditure will also be measured during exercise using different modes (arm ergometer, wheelchair and arm-bike). Results will be compared between rest and exercise and between individuals with SCI and able-bodied.
45693386|NCT01753999|Device|CPAP - Flex|Use of Philips Respironics REMstar Auto A-Flex in C-Flex mode
45693387|NCT02149342|Drug|Hexylaminolaevulinate cream|0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)
45693388|NCT02149342|Drug|Methylaminolaevulinate cream|MAL 16% is used as photosensitizer for daylight-PDT
45693389|NCT03800446|Diagnostic Test|Point of care ferritin test|Point of care test that uses capillary blood sample from finger to determine ferritin level
45693390|NCT03800368|Other|Exercise|Indoor cycling exercise intervention
45492769|NCT02347852|Drug|Regorafenib (Stivarga, BAY73-4506)|Stivarga is available as tablets (40 mg). It is taken in four-week treatment cycles at a recommended starting dose of 160 mg once every day for three weeks, followed by a week off.
45492770|NCT03968406|Other|Quality-of-Life Assessment|Ancillary studies
45492771|NCT03968406|Radiation|Radiation Therapy|Undergo radiation therapy
45376358|NCT00383500|Device|Class 1 compression garment|Manual lymphatic drainage therapy to provide lymphatic massage, using a Class 1 compression garment supporting the arm during heavy exercise or where the risk of trauma maybe increased (ie, flight, elevation, etc).
45492772|NCT03968406|Drug|Talazoparib|Given PO
45492773|NCT02347696|Behavioral|Control|Subjects will follow a diet based on INRAN guidelines without doing any physical activity.
45492774|NCT02347696|Behavioral|LGIMD|Subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) without doing any physical activity.
45492775|NCT02347696|Behavioral|Endurance Activity (EA)|"Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity:~weeks 1-4: 14.2 kcal*kg-1*week-1;~weeks 5-8: 18.9 kcal*kg-1*week-1;~weeks 9-12: 23.6 kcal*kg-1*week-1."
45492776|NCT02347696|Behavioral|EA+Resistance Training (RT)|"Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity (for Endurance activity):~weeks 1-4: 14.2 kcal*kg-1*week-1;~weeks 5-8: 18.9 kcal*kg-1*week-1;~weeks 9-12: 23.6 kcal*kg-1*week-1.~Resistance activity:~Muscolation: Training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutes and legs);~Progression: increase of 1-2.5 kg*week-1~Training of all muscle groups in the same session"
45492777|NCT02347696|Behavioral|LGIMD+EA|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of endurance activity.
45492778|NCT02347696|Behavioral|LGIMD+EA/RT|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of both endurance activity and resistance training.
45492779|NCT04879914|Dietary Supplement|Butyrate|3 cps/die 300 mg/cps
45492780|NCT04879914|Dietary Supplement|Placebo|3 cps/die 300 mg/cps
45847098|NCT04660422|Other|ACP Decisions Video Program|All clinicians will also be trained remotely on the ACP Decisions Video Program using the ACP app. Training will instruct clinicians on how to: 1. Introduce the COVID-19 videos to patients and caregivers; 2. Select the appropriate video(s) from the entire suite according to patients' needs; and, 3. Prescribe videos for patients and caregivers using the electronic platform. The suite of ACP videos is designed to address common ACP decisions confronting patients at risk or with COVID-19 and the caregivers.
45847099|NCT04660422|Other|Intervention training:|Training will instruct the clinicians on how to: i. more effectively communicate with patients regarding COVID- 19, ii. have ACP conversations with patients, iii. introduce the videos to patients and families, iv. use the videos as an adjunct to ACP counseling by clinicians, v. select the appropriate video(s) from the entire suite as according to patients' needs, and, vi. use the app or electronic platform for prescribing videos to be seen at home (telehealth visits), or to be viewed in clinic with an iPad.
45376359|NCT03954301|Diagnostic Test|Anthropometric measures|Q, valgity angle, subtalar joint, medial longitudinal arch and hallux valgus angles were measured with a goniometer. The height from the ground of the navicula was calculated by caliper, using the Navicular drop test. Metatarsal width was also calculated with this device. Medial longitudinal arch angle, metatarsal width and nacivular drop tests were performed under weight-bearing and non-weight-bearing conditions.
45492781|NCT03155074|Behavioral|High-intensity training|The exercise program will include a cardiovascular warm-up, high intensity interval training and progressive resistance training (PRT). The intervention will focus on high-intensity training, mainly by uphill walking on a treadmill at 80-95 % of the maximal heart rate and PRT in three series at 6-12 RM by leg press, chest press, back extension, seat row, and front raises. During the first four weeks, the patients will be introduced to the program while focusing on safety, techniques and familiarization. The endurance intensity and strength load will then continuously increase based on the patients' improvement, tolerance of dyspnea, and feelings of well-being or fatigue on each exercise day.
45492782|NCT02353234|Other|Bread|In each arm subjects consume bread
45492783|NCT01569360|Device|Corset|the patients are assigned the use of a custome made corset during daytime
45693391|NCT03800368|Other|Non-exercise|Psycho-education
45693392|NCT01783015|Drug|Etanercept|Etanercept 50 mg once-weekly
45376360|NCT01098019|Drug|Xeomin|Patients will receive Xeomin only at Day 0.
45376361|NCT01098019|Drug|Placebo / Xeomin|Patients will receive 0.9% mL NaCl alone at Day 0. After unblinding (at week 12) patients who were randomized to placebo will receive Xeomin.
45376362|NCT03956641|Other|Adaptated Physical Activity|Evaluation of the physical condition and the quality of life during the course of treatment (after 8 weeks of treatment) and at the end of the treatment's line (except for breast cancer patients)
45376363|NCT00365716|Biological|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20|20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
45693393|NCT01783015|Drug|Etanercept|Etanercept 50 mg once-weekly
45376364|NCT00365716|Biological|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
45492784|NCT03510455|Drug|BGJ398|BGJ398, a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor will be orally administered over six 4-week cycles (4 weeks on drug continuously). After the initial dose, escalation/de- escalation of BGJ398 will be based on FGF- 23 blood levels and adjusted according to protocol procedures. The six cycles of BGJ398 will be followed by 3 months off the drug and an optional extension phase.
45492785|NCT02353156|Other|Electronic bidet|electronic bidet after hemorrhoidectomy for relieving pain and inducing wound healing
45492786|NCT02353156|Other|Sitz bath|sitz bath after hemorrhoidectomy for relieving pain and inducing wound healing
45492787|NCT03630432|Behavioral|Pulmonary rehabilitation|"The pulmonary rehabilitation course will be provided on a rolling basis and for each individual will be of 8 weeks duration including once weekly, 1.5 hour hospital sessions and encouragement to perform twice weekly home exercise sessions. Hospital sessions will include 1 hour of supervised exercise and 30 minutes education.~Exercise Component: This will include a combination of aerobic, resistance and flexibility training.~Educational Component will cover many topics including what is asthma, treatments and inhaler technique, self-management, importance of exercise and health promotion.~On completion of the formal pulmonary rehabilitation course, participants will be encouraged to continue regular exercise sessions by accessing community based Vitality Classes."
45376365|NCT00365716|Biological|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
45376366|NCT00365716|Biological|Placebo (mcg) (Aluminum Adjuvant)225|placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
45376367|NCT00365716|Biological|Placebo (mcg) (Aluminum Adjuvant) 450|placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
45376368|NCT01049542|Drug|Astressin 2B|After an initial saline washout, increasing doses of Astressin 2B (at 0.032, 0.32, 3.2, 32, 320 and 3200 pmol/min) will be infused, for 10 minutes at each dose,intra arterially using forearm venous occlusion plethysmography. Forearm blood flow will be measured with each incremental dose of Astressin 2B.
45693394|NCT01783015|Drug|Placebo|Etanercept placebo once-weekly
45693395|NCT01783015|Drug|Placebo|Etanercept placebo once-weekly
45693396|NCT05567770|Drug|Actinium-J591|Cohort 1 with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
45693397|NCT05567770|Radiation|Stereotactic Body Radiation Therapy|Cohort 1 patients with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
45382280|NCT05128474|Other|Conventional Exercise Training Group|In this group, which will mainly benefit from conventional open kinetic chain strength exercises, a strengthening exercise program will be applied by advancing from body weight to elastic bands and weights. The exercise program will be performed twice a week for 8 weeks (16 sessions).
45492788|NCT03630432|Other|Usual Care|Usual Care
45382281|NCT05127252|Diagnostic Test|Vaginal and rectal microbiome and metabolome|Vaginal- and rectal sampling as a self-kit will be taken by the pat when ceasing the contraception at the midwife clinic when confirmed a clinical pregnancy and if a miscarriage occurs. If a miscarriage occurs additionally to the self-kit an endometrial biopsy will be taken.
45492789|NCT02353000|Radiation|Stereotactic Radiosurgery|Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases
45492790|NCT02353000|Radiation|Whole Brain Radiotherapy|Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases
45492791|NCT02351596|Other|Physiotherapy Core Stability Group Programme|"The aim of the intervention is to teach the participants active alignment and core stability, in order to influence their balance strategies. The exercises carried out will teach participants how and when to activate deep core stabilizing muscles. These exercises will be taught in a child-friendly way using imagery appropriate for the age of the participants. They will carry out activities like wall squats, 4-point kneeling, Transverses abdominis activation and gym ball sitting.~Participants will also be supplied with a Home Exercise Programme (HEP) sheet with explanations for exercises that they will be asked to carry out on their 'off' days over the 4 week period. They will be asked to keep a record of their compliance with this."
45492792|NCT02351596|Other|Control Group|The control group will partake in their usual physiotherapy care during the 4 week control period. They will not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration and frequency of this intervention is recorded
45492793|NCT03630510|Other|Ventilator hyperinflation|The ventilator hyperinflation maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
45492794|NCT03509675|Drug|Ibuprofen suspension 5mg/100ml|Non-Steroidal Anti-inflammatory Topical Rinse will be used for Symptomatic OLP patients.
45492795|NCT03509675|Drug|Placebos|Placebo
45492796|NCT01376934|Procedure|procedure hysteroscopy|office hysteroscopy with gas or saline solution
45492797|NCT02351752|Drug|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate: 0.1 Tid(eGFR 30-59);0.2 Bid (eGFR>60)
45492798|NCT04852224|Drug|Androgen deprivation therapy|Prostate cancer survivors in the ADT+ group will have been prescribed androgen deprivation therapy for a period of 6-months or more by their treating oncologist prior to consent for this study.
45492799|NCT02353078|Drug|Sucralfate|Sucralfate slurry 1 gram four times daily for four weeks
45492800|NCT02353078|Procedure|Intraluminal Impedance|During the initial endoscopy, esophageal mucosal impedance will also be measured. This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
45693398|NCT05567770|Drug|Androgen Deprivation Therapy|Cohort 2 patient with Polymetastatic disease will receive Actinium-J591 and Androgen Deprivation therapy (ADT)
45693399|NCT01782859|Drug|Prednisone|
45492801|NCT02353078|Device|Intraluminal Impedance|The mucosal impedance probe is a 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
45376369|NCT01049620|Drug|RAD001, Capecitabine, Oxaliplatin|"Dose level -1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 5mg po qd D1-21~Dose level 1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 2 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3A : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 3B : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 4 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 5 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21"
45376370|NCT00059839|Drug|doxorubicin hydrochloride|Given IV
45492802|NCT03509207|Drug|Vorinostat Oral Capsule|Vorinostat, 400 mg orally once daily for the first 14 days of a 21 day cycle Treatment will be continued for 4 cycles. Patients with a response or stable disease after 4 cycles will be continued on vorinostat therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity or patients' withdrawal of the consent. At the maximum, a total of 12 cycles will be administered over a period of 9 months.
45376371|NCT00059839|Drug|mercaptopurine|Given by mouth
45376372|NCT00059839|Drug|methotrexate|Given IV and intrathecally
45376373|NCT00059839|Drug|prednisone|Given by mouth
45376374|NCT00059839|Drug|vinblastine sulfate|Given IV
45492803|NCT04808778|Drug|Hydroxyurea therapy per standard care|Moderate-dose of 20mg/kg/day
45492804|NCT03727295|Drug|Idebenone/placebo|The two control group will be given Idebenone in two different doses，and the placebo group will be given placebo
45492805|NCT03145792|Behavioral|Seeking Safety|Seeking Safety (SS) is a present-focused, evidence-based cognitive-behavioral therapy for trauma and/or addiction. It offers safe coping skills and education relevant to both problem areas.
45492806|NCT03145792|Behavioral|CBT for Pathological Gambling|Cognitive Behavior Therapy for Pathological Gambling (CBT-PG) is an evidence-based therapy for gambling problems. It focuses on cognitive correction, problem solving, social skills and relapse prevention.
45492807|NCT03727217|Diagnostic Test|Pre and postoperative ultrasound|An ultrasound is performed in preoperative and in postoperative
45492808|NCT04438798|Other|F Group|In Group F, pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring.
45492809|NCT04438798|Other|H Group|In Group H, high-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds.
45492810|NCT01378650|Drug|Cilostazol|Administration of Cilostazol 100mg twice a day for 4 weeks
45492811|NCT01378650|Drug|Placebo|placebo one tablet matching for cilostazol twice a day for 4 weeks.
45693400|NCT01782859|Drug|Hydrocortisone|
46054131|NCT02792127|Behavioral|Online Program for Social Anxiety|This program will be completed from participants' homes using their own computers. This online format is based on a Cognitive Behaviour Therapy framework (CBT) and involves seven modules that ask participants to engage in a variety of thinking exercises and activities.
45376375|NCT00059839|Drug|vincristine sulfate|Given IV
45376376|NCT00059215|Drug|Prasugrel (CS-747)|Administered orally
45376377|NCT00059215|Drug|Clopidogrel|Administered orally
45376378|NCT01096147|Device|Spinal cord stimulation with eight polar electrode|In SCS a lead is positioned in the epidural space on the dorsal aspect of the spinal cord as to produce electrically induced paraesthesia in the painful area.
45376379|NCT00058825|Biological|Campath 1H|Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
45376380|NCT00058825|Drug|Fludarabine|Day -5 to Day -2: Fludarabine 30 mg/m2.
46054132|NCT03124212|Other|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
46054133|NCT02794077|Drug|Cyclophosphamide|Patient receive oral cyclophosphamide 50 to 150mg daily continuously in the absence of disease progressive or unacceptable toxicity.
46054134|NCT02792283|Biological|whole blood collection|
45492812|NCT03721601|Device|Heart rate monitor chest strap|Simultaneously with 5min Holter recording, 5min recording of chest strap ECG.
45376381|NCT00058825|Procedure|Stem Cell Transplant|Day 0: Donor stem cells infused.
45376382|NCT00058825|Radiation|Total Body Irradiation (TBI)|Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
45376383|NCT00058825|Drug|FK506 (Tacrolimus) or Cyclosporine|Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.
45492813|NCT03721601|Device|Wrist band photoplethysmography|Simultaneously with 5min Holter recording, 5min recording wrist band photoplethysmography.
45492814|NCT02351830|Other|Birch Pollen|Participants will be exposed to birch pollen to activate their allergy symptoms therefore validating the unit.
45492815|NCT02351830|Procedure|Nasal Brushing|To assess allergic biomarkers participants will provide a nasal sample which will be collected using a cytobrush. This procedure will be performed twice; once at screening and once following pollen exposure in the EEU.
45376384|NCT00364858|Drug|Cerezyme|Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).
45376385|NCT01098409|Drug|sodium nitrite|0.2mcg/kg/min or 1mcg/kg/min intravenous for 30minutes at 1ml/min
45376386|NCT01098409|Drug|0.9% sodium chloride|intravenous 0.9% sodium chloride over 30minutes at 1ml/min
45376387|NCT03956719|Drug|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells is extracted from human abdominal fat, which is crushed, filtered and immediately returned to the articular cavity through a specific device.
45376388|NCT03956719|Procedure|abdominal liposuction|50 ml abdominal fat was extracted by abdominal liposuction to prepare autologous adipose-derived mesenchymal stem cells
45376389|NCT02535208|Other|Restrictive transfusions based on SCOR assessment|RBC transfusions will be given to subjects either when participants' Hgb levels fall below defined values based on respiratory status or, despite not having reached their Hgb trigger threshold, if they manifest symptoms judged by the clinical care team to be consistent with anemia (i.e. apnea, bradycardia, or desaturation episodes) and subsequently have a NIRS evaluation that demonstrates an SCOR < 0.73.
45492816|NCT04530162|Procedure|Ultrasound guided nerve block|nerve block using bupivacaine and dexamethasone.
45492817|NCT03721523|Diagnostic Test|3 Dimensional tomographic Ultrasound|3-D tUS at five timepoints following acute ipsilateral stroke or Transient Ischaemic attack (TIA) to document carotid plaque volume and presence or absence of adverse plaque features.
45492818|NCT03721523|Diagnostic Test|Platelet Aggregometry|Blood test to test for platelet resistance to aspirin or clopidogrel and to measure effect of acute inflammatory response post event.
45847100|NCT04660422|Other|Medical Record Review|13,000 (total) patients aged 65 or older for our primary (completed advance care plans) outcome. ACP can include designating a health care proxy, discussion of advance directives, goals-of-care discussions, CPR discussions, palliative care discussions and referrals, as well as hospice. Each of these ACP outcomes will also be compared in secondary analyses using NLP. These data will be obtained from the EHR. All patient participants will only be included for medical record review.
45492819|NCT04478422|Other|Muscle strengthening with vascular occlusion|The muscle strengthening group with partial vascular occlusion will perform the strengthening exercises: single leg squat on 25 ° inclined plane, eccentric + isometric + concentric quadriceps exercise and deep squat. The equipment for vascular occlusion will be positioned over the proximal portion of the lower limb to be treated, just below the gluteal fold and inguinal ligament (Tennent et al. 2017). The pressure must be maintained during all series of exercises (approximately 5 minutes) (Bryk et al. 2016; Ferraz et al. 2018; Giles et al. 2017). If necessary, the pressure can be adjusted at intervals and after the end of the exercise, an interval of 5 minutes is suggested for blood reperfusion.
45847101|NCT04636710|Procedure|Lymphoscintigraphy|An imaging procedure using an injected radioactive substance or dye to identify lymph drainage A doctor reviews the images to identify the sentinel lymph nodes based on where the dye goes to first.
45492820|NCT04478422|Other|Conventional muscle strengthening|The conventional muscle strengthening group perform the same exercises as the intervention group: One-legged squat on a 25 ° inclined plane, eccentric + isometric + concentric quadriceps exercise and deep squat, however, without restriction on blood flow.
45376390|NCT02535208|Other|Liberal transfusions|In the liberal group, RBC transfusions will be given to participants when their Hgb level falls below defined values that are based on respiratory support status, as is standard practice.
45376391|NCT01093495|Device|CPAP|CPAP
45376392|NCT01093495|Device|Nasal Cannula|Nasal Cannula
45492821|NCT04796922|Drug|parsaclisib|parsaclisib will be administered once daily at 20 mg for 8 weeks followed by 2.5 mg once daily.
45492822|NCT04796922|Drug|rituximab|rituximab will be administered intravenously on select days as per protocol.
45492823|NCT04796922|Drug|obinutuzumab|obinutuzumab will be administered intravenously on select days as per protocol.
45492824|NCT03721445|Device|continuous positive airway pressure|Could the changes of HRV between PSG night and CPAP titration night predict the CPAP adherence?
45847102|NCT04601922|Other|Semi-structured interview|The interview will have the audio recorded, and will explore the ideas of each participant around long term cardiovascular care pathways
45492825|NCT04305678|Drug|Mepolizumab|Mepolizumab (Nucala) 400 mg SC every 4 weeks x 24 weeks
45376393|NCT02535052|Biological|Seasonal influenza and pneumococcal polysaccharide vaccines|Vaccination
45376394|NCT03741205|Device|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
45376395|NCT02534974|Device|NOSTEN|
45492826|NCT03723785|Drug|Insulin icodec|Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1
45376396|NCT03953989|Drug|Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die|Patients enrolled in the study, at the end of the titration phase will be treated with ranolazine 750 mg or 500 mg, 1 oral tablet twice a day for 4 months on top of standard of care treatment
45376397|NCT01096225|Biological|split-virion, H1N1 vaccine of 15 μg|split-virion inactivated S-OIV vaccine of 15 μg on day 0 and 21.
45376398|NCT01049698|Behavioral|Resistance Training|3 d/wk resistance training
45376399|NCT01049698|Behavioral|Resistance Training + Diet|3 d/w resistance training plus 600 kcal/d deficit
45376400|NCT02535130|Device|Positive expiratory pressure|
45376401|NCT02535130|Drug|amikacine nebulization|
45376402|NCT03803059|Device|SkinPen Precision|Surgical instrument motors and accessories/attachments/Hydrogel
45376403|NCT01046500|Dietary Supplement|myo-inositol|2 grams twice a day
45376404|NCT01046500|Drug|Metformin|pill, 250 mg, twice a day
45376405|NCT01046578|Drug|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 12 mm in diameter
45376406|NCT01046578|Drug|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 18 mm in diameter
45376407|NCT01046578|Drug|Letrozole|20 mg, one tablet a day for one day, starting 24-48 hours after ovulation of the dominant follicle is observed
45376408|NCT01046578|Drug|Letrozole|2.5 mg, one tablet a day for five days, starting 24-48 hours after ovulation of the dominant follicle is observed
45376409|NCT01046578|Drug|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
45376410|NCT01046578|Drug|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
45376411|NCT01098565|Device|Study device HFR0001|Study device will be tested for up to 2 hours prior to chronic device implant.
45376412|NCT03956875|Other|yoga|yoga is a mind-body practice that guides the body through a series of poses and breathing exercises
45376413|NCT01098643|Other|computer-assisted intervention|
45376414|NCT01098643|Other|medical chart review|
45376415|NCT01098643|Other|questionnaire administration|
45376416|NCT01098643|Other|survey administration|
45376417|NCT01096381|Other|laboratory biomarker analysis|Blood collection
45376418|NCT01096381|Other|questionnaire administration|Survey regarding baseline health and activity level.
45376419|NCT00372424|Drug|Herceptin|Trastuzumab will be administered intravenously on Day 1 before docetaxel - loading dose of 4 mg/kg over 90-minute on Day 1 followed by weekly maintenance doses of 2 mg/kg on Days 1, 8, 15 given as 30-minute infusions if the initial loading dose was well tolerated. Loading dose of 8 mg/kg over 90-minute on Day 1 followed by 3-weekly maintenance doses of 6 mg/kg given as 90-minute infusions. The administration of 6 mg/kg will be repeated on Day 1 every 3 weeks.
45492827|NCT05255614|Device|Virtual reality Simulator|LapSim is a device designed by Surgical Science Device & software at Swedan
45693401|NCT01782859|Drug|Placebo (for Prednisone)|
45693402|NCT05723536|Procedure|Partial Left Atrial Isolation|Partial electrical isolation of the left atrium endo-epicardially (pulmonary veins, posterior wall and left atrial appendage) and left atrial appendage isolation using Atriclip (Atricure, Mason OH, USA) in a single procedure in patients with persistent atrial fibrillation.
45376420|NCT00372424|Drug|Sunitinib|SU011248 will be administered at 37.5 mg once daily for 2 weeks every 3 weeks (Schedule 2/1) starting from Day 2, when in combination with docetaxel. SU011248 will be administered at the starting dose of 37.5 mg daily in a continuous regimen when docetaxel is discontinued.
45376421|NCT00372424|Drug|Taxotere|The starting dose of docetaxel will be 75 mg/m2 every 3 weeks, administered on Day 1 of each cycle as a 1-hour IV infusion.
45376422|NCT01098721|Drug|WBI-1001|Comparison of two doses (0% and 1.0%) of the the WBI-1001 cream applied topically, twice daily for 12 weeks.
45376423|NCT03952507|Drug|JNJ-64417184 600 (Oral Tablet Formulation)|Participants will receive 600 mg of JNJ-64417184 as oral tablet.
45376424|NCT03952507|Drug|JNJ-64417184 (Oral Suspension Formulation)|Participants will also receive JNJ-64417184 600 mg as oral suspension.
45376425|NCT02872792|Device|Early mobilisation with cyclo ergometer|Early mobilisation with cyclo ergometer is done daily during hospitalization for sepsis in an Intensive Care Unit
45376426|NCT02872792|Other|Standard physiotherapy|Standard physiotherapy included passive and active manual mobilization, sitting on bed, sitting in chair, walking
45376427|NCT02530411|Drug|Fulvestrant|The pharmacology and mode of action studies established that fulvestrant is the first agent in a new class of anti-estrogens that down-regulate the estrogen receptor (ER), and can therefore be described as an ER down-regulator.
45376428|NCT02530411|Drug|Vandetanib|Vandetanib is a potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR; also known as kinase insert domain containing receptor)-2, an endothelial cell receptor for vascular endothelial growth factor (VEGF), and also possesses activity against epidermal growth factor receptor (EGFR) and Rearranged during Transfection (RET) tyrosine kinases.
45376429|NCT00372190|Device|Tensionfree vaginal mesh kit (Prolift)|Insertion of a tension free vaginal mesh using a Prolift mesh kit
45376430|NCT00372190|Procedure|classic vaginal prolapse surgery (fascia plication)|classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse
45376431|NCT01096459|Procedure|Nerve Rerouting|All subjects will receive the unilateral nerve rerouting procedure.
45376432|NCT01093729|Drug|HM11260C|HM11260C 0.5mcg/kg or Placebo
45376433|NCT01093729|Drug|HM11260C|HM11260C 2mcg/kg or Placebo
45376434|NCT01093729|Drug|HM11260C|HM11260C 4mcg/kg or Placebo
45376435|NCT01093729|Drug|HM11260C|HM11260C 8mcg/kg or Placebo
45376436|NCT01093729|Drug|HM11260C|HM11260C 14mcg/kg or Placebo
45693403|NCT05723536|Procedure|Catheter Ablation|Catheter Ablation of Atrial Fibrillation
45376437|NCT03992794|Diagnostic Test|Measurement of MR-proADM|It is an observational study. The only intervention was the measure of MR-proADM, but no clinical decision was made based on its value, since the physician attending the patient did´n know the value of MR-proADM
45376438|NCT01327027|Drug|Vasopressin, Arginine, ADH|Vasopressin will be dissolved in sterile saline and intranasally delivered in one of 2 doses to each subject (20IU, 40IU)
45492828|NCT05255614|Device|Pelvic trainer:|Video-box trainers include a box with a lid and holes cut on the lid for the trocar's insertion. A laparoscope inside the box is connected with a digital camera and provides video output to a monitor on which the trainees are watching their own movements, while performing the teaching task. Laparoscopic instruments, such as laparoscopic graspers and laparoscopic scissors are inserted through the trocars into the box, where the tasks are taught
45376439|NCT01327027|Drug|Placebo; Sterile Saline|Sterile saline will be delivered intranasally on a second test day, in counterbalanced order with vasopressin administration.
45376440|NCT01046656|Dietary Supplement|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for the entire duration of hospital stay
45376441|NCT01093807|Drug|Placebo|once daily for 10 weeks
46054135|NCT02791971|Behavioral|SpeakOut|"SpeakOut aims to increase social communication about IUDs and implants between adolescent IUD and implant users and their peers. SpeakOut has four components:~Coaching session. Research staff will deliver a script to encourage recipients to share information about their contraceptive method with peers.~Printed materials for recipients to keep and/or share with friends.~Websites with information and resources. Staff will refer recipients to a website, either SpeakOutIUD.org or SpeakOutImplant.org, which contain information about their method.~Text messages with information about recipients' method and about how to share their experience. Recipients will be given the opportunity to sign up for text messages that will be sent for 8 weeks following receipt of SpeakOut in clinic."
45376442|NCT01093807|Drug|Lercanidipine|10 mg once daily for 10 weeks
45376443|NCT01093807|Drug|Lercanidipine|20 mg once daily for 10 weeks
45492829|NCT05255458|Biological|AK102|Administered AK102 by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
45492830|NCT05255458|Drug|Placebo|Administered placebo by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
45376444|NCT01093807|Drug|Enalapril|10 mg once daily for 10 weeks
45376445|NCT01093807|Drug|Enalapril|20 mg once daily for 10 weeks
45376446|NCT01093807|Drug|Lercanidipine + Enalapril|10/10 mg once daily for 10 weeks
45376447|NCT01093807|Drug|Lercanidipine + Enalapril|10/20 mg once daily for 10 weeks
45376448|NCT01093807|Drug|Lercanidipine + Enalapril|20/10 mg once daily for 10 weeks
45376449|NCT01093807|Drug|Lercanidipine + Enalapril|20/20 mg once daily for 10 weeks
45376450|NCT01046812|Drug|Caphosol|Caphosol 2-4 times daily oral rinse for two weeks duration minimum up to one month.
45376451|NCT01046890|Drug|Echinacea|darunavir/ritonavir 600/100 mg + root of Echinacea purpurea 500 mg every 6 hours
45376452|NCT01096615|Dietary Supplement|Placebo|"Description:~- capsule size 3~Composition of the product:~45 mg of microcristalline cellulose,~132 mg of maltodextrin,~3 mg of magnesium stearate.~Composition of the capsule:~46 mg of hypromellose,~1 mg of titanium dioxide.~Packaging:~Products are packaged in aluminium tubes of 30 capsules.~Storage:~The product should be stored in a fridge. Direction for use: subject should consume 1 capsule daily together with a meal, with a glass of water.~The study products will be consumed daily for 7 weeks."
45376453|NCT01096615|Dietary Supplement|Lactobacillus paracasei LP-33|"Description:~minimum 2.0x109 CFU of Lactobacillus paracasei LP-33~capsule size 3 1 capsule daily together with a meal, with a glass of water."
45376454|NCT01046968|Dietary Supplement|Lepticore|300 mg twice daily
45376455|NCT01047046|Other|Retrospective chart review|"This study is a retrospective chart review including all patients who received surgical placement of a SNM device with Dr. Noblett from 2001 to the present.~The following data will be collected from patient charts: age at time of surgery, gravidity/parity, body mass index, pre-existing medical conditions/surgical history, current medications, menopausal status, form and severity of OAB symptoms, other previously or currently used interventions, method of SNM device placement, observed motor/sensory response, percent improvement of symptoms, follow-up OAB symptoms, frequency of InterStim settings adjustments, adverse events, significant changes in health, and incidence/reason for drop out."
45376456|NCT01098877|Drug|PF-04634817 Placebo|Oral solution, placebo, single dose
45376457|NCT01098877|Drug|PF-04634817|Oral solution, 1mg, single dose
45376458|NCT01098877|Drug|PF-04634817|Oral solution, 3mg, single dose
45492831|NCT04441320|Device|Coated metal ureteral stent(CMUS)|Coated metal ureteral stent aims to treat the patients with refractory ureteral stricture, such as radiation induced ureteral stricture. In this study, CMUS is indwelled to observe the efficacy and safety in the treatment of radiation induced ureteral stricture compared with Double-J stent.
45492832|NCT04441320|Device|Double-J stent(DJS)|Double-J stent is commonly used for treatment of kinds of ureteral stricture. In this study, DJS is indwelled as a controlled group.
45376459|NCT01098877|Drug|PF-04634817|Oral solution, 10mg, single dose
45376460|NCT01098877|Drug|PF-04634817|Oral solution, 30mg, single dose
45492833|NCT04478656|Biological|BBV121|BBV121 or Placebo are administered intramuscularly in deltoid region on Day 0 and 28
45492834|NCT03149926|Other|Stimuli presentation|Different stimuli associated with self-injury are presented. Participants have to rate the emotional effect elected by the stimuli.
45376461|NCT01098877|Drug|PF-04634817|Oral solution, 100mg, single dose
45376462|NCT01098877|Drug|PF-04634817|Oral solution, 300mg, single dose
45376463|NCT01098877|Drug|PF-04634817|Oral solution, 600mg, single dose
45376464|NCT01098877|Drug|PF-04634817|Oral solution, 900mg, single dose
45492835|NCT03543137|Drug|Nicotine Prototype Mini lozenge|A single dose of a prototype nicotine 4mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
45492836|NCT03543137|Drug|Nicorette Mini Lozenge|A single dose of a 4 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
45376465|NCT01098877|Drug|PF-04634817|Oral solution, up to 900mg, single dose after food
45376466|NCT01098877|Drug|PF-04634817 Placebo|Oral solution, placebo, single dose after food
45376467|NCT00044083|Other|Placebo|Placebo: One capsule 3 times a day from Day 1 to Day 7
45376468|NCT00044083|Drug|Tolcapone|Tolcapone: One capsule 3 times a day from Day 1 to Day 7
45376469|NCT00058123|Drug|poly ICLC|
45376470|NCT00022633|Drug|gemcitabine hydrochloride|
45492837|NCT04478188|Other|Measuring Pressure Volume Loop Pre and Post Device Placement|To measure simultaneous pressure and volume of the heart (pressure volumes loops) before and after ventricular assist device placement for cardiogenic shock (a severe form of heart failure) and before and after device removal.
45492838|NCT03146650|Biological|Ipilimumab|Given IV
45376471|NCT00022633|Drug|paclitaxel|
45376472|NCT00021541|Drug|tipifarnib|Given orally, 200 mg/m^2/dose BSA every 12 hours by mouth (po) daily x 21 days, Course is every 28 days
45376473|NCT00021541|Other|placebo|Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.
45376474|NCT01100827|Other|EGFR mutation status in patients|
45376475|NCT00021229|Drug|imatinib mesylate|"Phase 1 Stratum I: Starting dose level of 350 mg/m2/day every 28 days X 13 courses (dose escalation)~Phase I Stratum IIA: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~Phase I Stratum IIB: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~Phase II: Phase I Stratum I determined dose (Maximum tolerated dose) every 28 days X 13 courses."
45492839|NCT03146650|Other|Laboratory Biomarker Analysis|Correlative studies
45492840|NCT03146650|Biological|Nivolumab|Given IV
45492841|NCT03723629|Other|No intercention|No intercention
45376476|NCT00021229|Radiation|local irradiation therapy|"Phase I Stratum I: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib.~Phase II: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib."
45376477|NCT00372112|Drug|GW642444|GW642444H
45376478|NCT00372112|Other|Placebo|Placebo administered twice daily
45376479|NCT02746588|Other|Office hysteroscopy|Diagnostic hysteroscopy with biopsy
45492842|NCT02347462|Device|Bilevel Positive Airway Pressure (BiPAP) (Trilogy BiPAP, Philips Respironics)|Children in the intervention group will receive BiPAP (Trilogy, Philips Respironics; spontaneous trigger mode) via a nasal or full face mask. End expiratory positive airway pressure (EPAP) will be set at 5cm H20. Inspiratory positive airway pressure (IPAP) will be titrated to achieve a tidal volume of 6 - 9 ml/kg. These settings will remain unchanged throughout the study period.
45492843|NCT02347462|Other|Standard care|Standard care according to the hospital severe asthma protocol
45376480|NCT02731144|Other|Peptamen intense|
45376481|NCT02731144|Other|Novasource senior|
45376482|NCT02688790|Drug|Dalbavancin|
45376483|NCT01047124|Other|Specialist Mood Disorders Team|The specialist mood disorders team will include a psychiatrist and health professionals providing cognitive behaviour therapy. Together the team will assess participants and then provide a co-ordinated and supervised combination of pharmacological and psychological treatment according to guidelines developed by NICE and the British Association of Psychopharmacology. Each participant will receive a treatment plan that is tailored to his/her specific needs.
45376484|NCT00488475|Drug|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
45492844|NCT02895347|Behavioral|Surgical Simulation Practice Modules|The surgical simulation practice modules simulate surgical settings for suturing.
45376485|NCT01020279|Drug|Celecoxib, Ketoprofen|"Ketoprofen in Transfersome® gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d.~Celecoxib, 200 mg, one capsule b.i.d."
45492845|NCT05763966|Other|No intervention|Observational study where participants are followed over time
45376486|NCT01020279|Drug|Ketoprofen|Placebo gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d. Oral placebo, one capsule b.i.d
45376487|NCT01621659|Behavioral|Multidisciplinary team intervention|Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
45376488|NCT01020357|Drug|Caffeine citrate injection|"Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy."
45492846|NCT02347306|Other|Telephone interview|
45376489|NCT01020357|Drug|placebo|normal saline
45376490|NCT01017627|Other|Early anemia diagnosis and treatment|Patients returning to the unit are immediately assessed and treated for anemia
45376491|NCT01017627|Other|No change from normal routine|Normal unit policy for labs and anemia treatment
45376492|NCT00042991|Drug|gefitinib|Given orally
45492847|NCT02343484|Drug|Gelified ethanol combined to pulsed radiofrequency|Gelified ethanol (Discogel) is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain. The intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.
45492848|NCT02343484|Drug|Gelified ethanol|Gelified ethanol is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally.
45492849|NCT03630276|Diagnostic Test|Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP|Lab
45492850|NCT03539549|Drug|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.
45492851|NCT04173000|Other|Mehealth for ADHD software with medication continuity tools|Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommends tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
45376493|NCT00042991|Radiation|radiation therapy|Undergo standard brain irradiation
45492852|NCT04173000|Other|Mehealth for ADHD software without medication continuity tools|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
45376494|NCT00042991|Other|pharmacological study|Correlative studies
45492853|NCT04478032|Device|deep transcranial magnetic stimulation with H7 coil|low frequency(1Hz) deep transcranial magnetic stimulation on ACC .Duration:20 days.
45492854|NCT04158024|Other|Erector Spinae Plane Block|The ESPB is a fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
45376495|NCT00042991|Other|laboratory biomarker analysis|Correlative studies
45376496|NCT01022385|Dietary Supplement|24-hour low-residual diet|
45376497|NCT01017783|Behavioral|Dietary substitution A|Substitution of calorie-dense item with lower calorie choice A
45376498|NCT01017783|Behavioral|Dietary Substitution B|Substitution of calorie-dense item with lower calorie option B
45376499|NCT01017783|Behavioral|Healthy Choices|Multiple healthy choices presented with self-selection of choices used
45376500|NCT00466167|Drug|Pramipexol Extended Release|
45376501|NCT00466167|Drug|Pramipexol Immediate Release|
45376502|NCT00466167|Drug|Placebo|
45376503|NCT01017939|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg tablets administered orally once daily beginning on Cycle 1 Day 1 up to the time of disease progression
45376504|NCT01017939|Drug|Prednisone|Prednisone 5mg tablets administered orally twice daily beginning on Cycle 1 Day 1 up to the time of disease progression
45376505|NCT01017939|Drug|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide 30 mg capsules administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
45376506|NCT01017939|Drug|Theophylline|Theophylline 100 mg tablets administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
45376507|NCT00480441|Drug|Dronabinol|10mg capsules taken 4 times daily for 2 weeks and then tapered over 1 week
45376508|NCT00480441|Behavioral|BRENDA therapy|weekly therapy sessions for 6 weeks
45376509|NCT00480441|Drug|Placebo|4 capsules daily for 2 weeks followed by a 1 week taper
45376510|NCT01022463|Drug|Ivabradine|Ivabradine 5 mg BId for 4 weeks
45376511|NCT01022463|Drug|Atenolol|50 mg od for 4 weeks
45376512|NCT00488319|Drug|Paliperidone ER|1.5 to 12 mg tablet once daily for 6 months
45376513|NCT01018017|Drug|Placebo|For placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
45492855|NCT02039206|Device|Deep TMS|1Hz Stimulation
45492856|NCT03506477|Drug|Enstilar® foam|for 4 weeks
45376514|NCT01018017|Drug|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg SRT2104.
45376515|NCT01018251|Other|3'-deoxy-3'-[18F]fluorothymidine|Given IV
45376516|NCT01018251|Procedure|Positron Emission Tomography/computed tomography|
45376517|NCT01018251|Radiation|FLT-PET/CT|
45376518|NCT01018329|Procedure|Magnetic Resonance Imaging|
45376519|NCT01018329|Procedure|Diffusion Tensor Imaging|
45376520|NCT01018329|Procedure|Magnetic Resonance Spectroscopic Imaging|
45376521|NCT01018329|Procedure|Dynamic Contract-Enhanced magnetic resonance imaging|
45376522|NCT01018329|Procedure|Diffusion-weighted magnetic resonance imaging|
45492857|NCT03506477|Drug|Vehicle foam|for 4 weeks
45492858|NCT03630042|Drug|Pembrolizumab|200 mg IV dose given on day 1 of a three week cycle
45492859|NCT03630042|Drug|Rituximab|375 mg/m2 IV dose given up to 8 times in the trial
45492860|NCT03149692|Other|Penile allograft transplantation|Proof of concept of surgical procedure
45376523|NCT00463047|Drug|Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone|Patients will be randomly assigned in a 1:1 ratio either to titrate immediate-release oxycodone first and to titrate FBT second, or to titrate FBT first and immediate-release oxycodone second, followed by 2 double-blind crossover treatment periods (in randomized order). For the double-blind treatment period of the study involving FBT administration, a patient is randomly assigned to receive FBT at the 200, 400, 600, or 800 mcg strength found to be successful during open-label titration. For the double-blind treatment period of the study to which a patient is randomly assigned to receive immediate-release oxycodone, the patient will receive immediate-release oxycodone at the strength (15, 30, 45, or 60 mg) found to be successful during open-label titration.
45492861|NCT02351206|Radiation|x-ray, MRI|
45492862|NCT03629964|Device|Wiersma Head Stabilizer|Experimental device attached to treatment table.
45492863|NCT03629964|Device|AlignRT system|The AlignRT system (an FDA approved medical device that automatically turns off the radiation beam if the head moves beyond a set distance) will be used to track real-time motions of the head. This system is used with radiation therapy as standard of care.
45492864|NCT03726983|Other|Experimental group|Pregnant women who agree to take part will be assigned to a group: experimental group and control group. The experimental group will received health management support and counseling that were conducted by the researchers through the e-health management platform.
45492865|NCT02343328|Biological|Fecal Microbiota Transplant|
46054136|NCT02791971|Behavioral|Alcohol Control Intervention|The active comparator intervention is an alcohol assessment and education intervention using an SBIRT (Screening, Brief Intervention, and Referral to Treatment) framework. SBIRT is an evidence-based practice model aimed at preventing problematic use and identifying potential abuse and dependency issues. Research staff will ask two screening questions developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the American Academy of Pediatrics to screen for adolescents potentially at risk. Using a script based on tenets of motivational interviewing to assess alcohol related consequences, the research staff will guide teens in identifying personally relevant motivators for healthier behaviors, assess readiness to change, and offer educational materials and referrals.
46054137|NCT02551068|Other|60% Oxygen|While participants are exercising, they will be inhaling 60% oxygen through a mask
45492866|NCT02343328|Biological|Placebo|
45492867|NCT04428606|Dietary Supplement|Metabolic Rheostat|Metabolic Rheostat™ Ingredients: Ginseng extract, Ginseng root extract, berberine chloride, Livaux (gold kiwi powder), MegaSporeBiotic, and MenaquinGold (vitamin K2-7) powder
45492868|NCT04428606|Dietary Supplement|Butyrate Ultra|An anerobic probiotic supplement that contains butyrate-producing Butyricicoccus pullicaecorum 25-3T, vitamin K2, and fenugreek to maintain healthy glucose balance.
45492869|NCT04428606|Dietary Supplement|Placebo|Placebo
45492870|NCT02343016|Device|Near-InfraRed Spectroscopy (NIRS)|NIRS is a non invasive monitoring system that enables assessment of tissue oxygenation through a quantitative estimation of haemoglobin oxygen-saturation within tissues.
46054138|NCT02551068|Other|Standard of Care|While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.
46054139|NCT02791737|Behavioral|Exercise Intervention|Complete individualized exercise program
46054140|NCT02791737|Other|Laboratory Biomarker Analysis|Correlative studies
46054141|NCT02791737|Procedure|Physical Therapy|Complete individualized exercise program
46054142|NCT02791737|Other|Quality-of-Life Assessment|Ancillary studies
46054143|NCT02791737|Other|Questionnaire Administration|Ancillary studies
45492871|NCT02343094|Drug|PBA 7,5g/d|Treatment for 14 days with PBA
45492872|NCT02343094|Drug|PBA 15g/d|Treatment for 14 days with PBA
45376524|NCT00487695|Device|confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy is done by performing standard endoscopy, then using a microscope on the tip of the endoscope to obtain microscopic images of the mucosa. This is done by gently placing the tip of the endoscope on the lining of the esophagus.
45376525|NCT00487695|Device|standard endoscopy (EGD)|Standard upper endoscopy (EGD) is performed using a regular upper endoscope, which is used to look at the lining of the esophagus.
45492873|NCT03073980|Drug|IV Acetaminophen|IV Acetaminophen for pain control during procedure
45492874|NCT03073980|Drug|PO Acetaminophen|PO Acetaminophen for pain control during procedure
45492875|NCT03073980|Other|Placebo IV Acetaminophen|Placebo IV Acetaminophen
45492876|NCT03073980|Other|Placebo PO Acetaminophen|Placebo PO Acetaminophen
45376526|NCT00487539|Biological|Placebo|Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
45376527|NCT00487539|Biological|Golimumab 100 mg|Golimumab 100 mg subcutaneous injection administered at Week 0 for Golimumab 100 mg -> 50 mg arm group and at Week 2 for Golimumab 200 mg -> 100 mg arm group.
45492877|NCT02347384|Device|Delta PLUS Femoral Head + SL-TWIN Stem|Subject will undergo total hip arthroplasty with Delta PLUS Femoral Head & SL-TWIN Stem
45492878|NCT02347384|Device|BIOLOX forte ball head + SL-PLUS Stem|Subject will undergo total hip arthroplasty with BIOLOX forte ball head & SL-PLUS Stem
45492879|NCT03146416|Drug|Evinacumab|SC or IV administration of Evinacumab
45492880|NCT03146416|Drug|Placebo|Matching placebo
45492881|NCT04117932|Drug|Ustekinumab|Ustekinumab (90 mg subcutaneously at weeks 0, 4, 16), in association with topical superpotent corticosteroid (10-30 g per day during the first 4 weeks, then every other day during 4 weeks).
45693404|NCT05562778|Other|Chatbot|A chatbot is a software program designed to simulate human conversation, typically via text. Chatbots utilize natural language processing to gather patient data, anticipate questions, and predict responses. In this study, the Chatbot will simulate a text-like conversation with patients via a smartphone and use this platform to deal with the time-consuming nature of family history collection. The chatbots can then triage the collected family history against medical guidelines to determine which patients warrant genetic testing. For those patients meeting criteria for genetic testing, the chatbot can offer pre-test education and assist physicians with ordering genetic testing for interested patients meeting high-risk criteria.
45693405|NCT05718622|Device|real EECP|Real EECP treatment is delivered 45min per day for 14 sessions continuously. The treatment pressure sets at 150 millimeters of mercury.
45693406|NCT05718622|Device|sham EECP|Sham EECP treatment is delivered 45min per day for 14 sessions continuously. The treatment pressure sets at 75 millimeters of mercury.
45693407|NCT01782313|Drug|tivozanib|Given PO
45847103|NCT04495608|Drug|Fluconazole|"Fluconazole 50 mg/capsule or placebo, per os during 18 weeks :~From W0 to W2 : 1 caps/ day~From W2 to W4 : 1 or 2 caps/day~From W4 to W6 : 1, 2 or 3 caps/day~From W6 to W18 : 1, 2, 3 or 4 caps/day~The number of capsules to take will be determined by 24-hours calciuria results performed every 2 weeks during the titration period (W2, W4 and W6).~During the titration period, if 24-hours calciuria is > 0.1 mmol/kg/day, fluconazole dose will be increased every 2 weeks to 50 mg per intake, with a maximum dose of 200 mg/day. If 24-hour calciuria is ≤ 0.1mmol/kg/day, fluconazole dose will remain stable.~After W6 and until the end of the study, the treatment dose will remain stable (stable period)."
45376528|NCT00487539|Biological|Golimumab 200 mg|Golimumab 200 mg subcutaneous injection administered at Week 0 for Golimumab 200 mg -> 100 mg arm group and at Week 2 for Golimumab 400 mg -> 200 mg arm group.
45376529|NCT00487539|Biological|Golimumab 400 mg|Golimumab 400 mg subcutaneous injection administered at Week 0 for Golimumab 400 mg -> 200 mg arm group.
45492882|NCT03146572|Behavioral|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room
45693408|NCT01782313|Other|laboratory biomarker analysis|Correlative studies
46054144|NCT02535936|Procedure|3Tesla MRI with DTI-MRI and rsfcMRI under general anesthesia|2 post-operative MRI's at 2 months and 12 months
46054145|NCT02788539|Behavioral|Our Whole Lives Website|OWL is a nine-session, web accessible, self-paced curriculum that has interactive components of self-monitoring and social support (online community).
46054146|NCT05332470|Drug|Lamivudine and Dotiravir Sodium Tablets|3TC (300 mg p.o. q 24 h) plus DTG (50 mg p.o. q 24 h)
46054147|NCT02789319|Device|Blood Glucose Meter Systems|
46054148|NCT04222374|Procedure|Intervention in the UroCCR sites|"Blood sampling of a 5ml tube per patient. (for eligible patients recruited in the study, after signing the consent)~DNA extraction:~For the patients of Bordeaux University Hospital, 2 aliquots will be constituted:~1 aliquot for Expanded GWAS, containing at least 2 μg of DNA,~1 aliquot for the UroCCR biobank.~For patients from other UroCCR centers, only 1 aliquot will be constituted:~1 aliquot for Expanded GWAS, containing at least 2 μg of DNA.~Transmission of the extracted DNA samples to the Biological Resource Center (CRB) of Bordeaux."
45376530|NCT00487539|Biological|Golimumab 50 mg|Golimumab 50 mg subcutaneous injection administered at Week 2 for Golimumab 100 mg -> 50 mg arm group.
45382282|NCT05121545|Radiation|Pro-GRID|Study participants will receive a single treatment of Pro-GRID therapy. After which, the participants would be able to resume standard therapy (after one week) and receive additional radiotherapy one month after Pro-GRID therapy, if recommended. Participants will be in the study for one year. Follow-up appointments will be scheduled at 1, 3, 6 and 12 months posttreatment, and may include a history and physical exam, labs and/or a CT scan and toxicity assessments.
45376531|NCT01018407|Behavioral|Discrete Trial Training|"UCLA model, developed by Lovaas and colleagues (Smith, Groen & Wynn, 2000). Two 30-minute sessions daily (5 hours/week) of 1:1 intervention focusing on imitation, match-to-sample, receptive and expressive language. Using operant conditioning, the therapist works individually with a child in a distraction-free setting and administers approximately 10 trials in a sitting, with breaks between sittings.~During months 5 and 6, we will provide parents with training in an apprenticeship format one day per week for an hour per day. The clinician will demonstrate a DTT instructional program, then the parent will take a turn implementing it. The clinician and parent will give each other feedback on their implementation of the program."
45376532|NCT01018407|Behavioral|Interpersonal Developmental Approach|"Focus on teaching joint attention and symbolic play developmentally via floor play milieu teaching approach. Principles applied include following the child's lead and interest in activities, talking about what the child is doing, repeating back what the child says, expanding on what child says, giving corrective feedback, sitting close to the child and making eye-contact, and making environmental adjustments to engage the child (Kasari et al., 2006).~Parents will be incorporated into the treatment to encourage joint engagement with their child and to focus specifically on joint attention and play skills in their interactions. Each home session will last one hour (once a week) during month 5 and 6 and will involve therapist modeling, and coaching of parent in child-directed activities."
45492883|NCT03146572|Other|Handout|Handout providing written descriptions of strategies to encourage positive parenting behaviors
45492884|NCT03149458|Other|dance|dance program
45492885|NCT03149458|Other|control|upper limb rehabilitation
45492886|NCT03930186|Drug|Apremilast|Tablets for oral administration
45492887|NCT03930186|Drug|Topical Therapy|Participants continued to use their existing topical treatment for psoriasis for the first 16 weeks. After 16 weeks, participants could decrease the use of topical therapy at their discretion under the direction of their physician.
45376533|NCT00486837|Drug|Alpha1-Proteinase Inhibitor (Human)|25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.
45376534|NCT04199247|Behavioral|Sub symptom aerobic exercise|Participants will meet with a member of the research team to undergo a bike-based exercise test at the initial test. Heart rate will be obtained at the completion of the test, and intervention participants will be asked to complete exercise at 80% of that level, 5x/week for 20-30 minutes/session over the next two months.
45376535|NCT00486759|Drug|Bevacizumab|Bevacizumab was administered at a dose of 15 mg/kg IV on Day 1 of each 21-day cycle for 8 cycles or at a dose 10 mg/kg IV on Day 1 of each 14-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
45376536|NCT00486759|Drug|Rituximab|Rituximab was administered at a dose of 375 mg/m^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
45382283|NCT05114421|Drug|Lenvatinib|Given PO
45492888|NCT02351362|Behavioral|Incentive Group|A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
45492889|NCT02351440|Drug|duloxetine|patients will be randomized to receive either duloxetine or placebo
45492890|NCT02351440|Drug|placebo|placebo
45492891|NCT03504917|Drug|Balovaptan|Participants will receive 10 mg of oral administration balovaptan once a day (QD).
45492892|NCT03504917|Drug|Placebo|Participants will receive matching placebo.
45492893|NCT02343172|Drug|HDM201|
45492894|NCT02343172|Drug|LEE011|
45492895|NCT03899688|Procedure|Maxillary sinus augmentation|Surgical technique for increasing the vertical bone height of the posterior maxilla an antrostomy of about 5 mm in height and 10 mm long will be prepared using a diamond insert mounted on a sonic-air surgical instrument. The Schneiderian membrane will be elevated and clinical measurements will be performed using an UNC 15 probe. The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites.
45492896|NCT02351128|Drug|Lanreotide|
45492897|NCT01378182|Genetic|allogeneic mesenchymal stem cell transplantation|1.000.000(one million) cells/kg, IV (1/2 of dose in the Peripheral vein and 1/2 of dose into the right hepatic artery)
45492898|NCT02343250|Drug|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
45492899|NCT02343250|Drug|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
45492900|NCT02343250|Drug|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
45492901|NCT02343250|Drug|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
45693409|NCT04575259|Drug|ANAVEX2-73|Oral capsules
45693410|NCT04574947|Drug|Intravenous lidocaine|Lidocaine IV 1.5 mg / kg BMI will be administered during induction into anaesthesia followed by infusion at a dose of 1.5 mg / kg / h until the end of the surgery.
45376537|NCT00486759|Drug|CHOP|Cyclophosphamide was administered at a dose of 750 mg/m^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
45376538|NCT00486759|Drug|Placebo|Placebo to bevacizumab was administered on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
45376539|NCT00486603|Drug|hydroxychloroquine|see arm description, the first 10 week cycle is call initiation cycle, Post the 10 week cycle of just HCQ, 4 week cycles are called Maintenance Cycles
45376540|NCT00486603|Drug|temozolomide|TMZ daily 75mg/m2 for 6wks with RT+HCQ (TMZ is given only during Initiation cycle)
45492902|NCT03781440|Procedure|Bilateral ESP catheter with lidocaine|All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
45376541|NCT00486603|Other|pharmacological study|Seven samples in total will be collected baseline, initiation cycle -week3-4, week9-10, Maintenance Cycle 1 Week 4 (C1W4), Cycle2 Week4, Cycle3 Week4, Cycle6 Week4
45376542|NCT00486603|Radiation|Radiation|Radiation during the first six weeks of treatment Monday-Friday
45492903|NCT03781440|Procedure|Bilateral ESP catheter with saline|All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
45376543|NCT00486291|Drug|VI-0521|phentermine 15mg/topiramate 100mg
45376544|NCT00486291|Drug|Placebo|matched placebo
45492904|NCT02342938|Procedure|MEG or fMRI And INtracranial EEG|
45492905|NCT02342938|Procedure|fMRI|
45492906|NCT01569672|Behavioral|Patient Navigator matched with subject|Subject is matched with a patient navigator. The patient navigator calls the patient. The amount of time between the abnormal test and treatment will be measured.
45492907|NCT01569672|Behavioral|Subjects are mailed informational/educational materials|Subjects will be mailed informational/educational materials. The amount of time between the abnormal test and treatment will be measured.
45492908|NCT02342860|Other|WASH in Schools (WinS) programme|"The intervention group will receive the UNICEF/DFAT-supported WinS programme, which consists of the following intervention package:~Hardware: water supply system, handwashing station for group handwashing, and gender-segregated toilets with one facility accessible to students with physical disabilities;~Software: operations and maintenance (O&M) training for teachers, hygiene training, and basic hygiene package."
46054149|NCT04222374|Procedure|Intervention in the CRB of Bordeaux University Hospital|"Temporary storage of DNA samples for Expanded GWAS before shipping to the NCI. Storage of samples for the DNA biobank.~Overall packing of GWAS samples for shipment to the NCI.~Shipping to the NCI: Constitutive DNA samples must be sent to the NCI by May 1, 2020 for inclusion in the Expanded GWAS study."
46054150|NCT04222374|Procedure|Intervention at the Methodology and Data Management Centre of Bordeaux University Hospital|Transfer of the data associated with the samples to the NCI.
46054151|NCT04222374|Procedure|Subsequent intervention at the NCI (for information)|"Samples will be genotyped at the NCI Cancer Genomics Research Lab using the Illumina Global Screening Network.~GWAS combined meta-analysis, based, among others, on the results from the UroCCR samples."
46054152|NCT02791815|Drug|Midazolam|Single oral dose of 7.5 mg midazolam (tablet)
45376545|NCT04194723|Procedure|Antireflux Mucosectomy|ARMS aimed at resection of mucosa at gastric cardia to induce fibrosis and tighten the gastroesophageal junction and reduce acid reflux
45376546|NCT00474045|Drug|insulin detemir|Treat-to-target, dose titration, s.c. (under the skin) injection
45376547|NCT00474045|Drug|NPH insulin|Treat-to-target, dose titration, s.c. (under the skin) injection
45376548|NCT00474045|Drug|insulin aspart|Treat-to-target, dose titration, s.c. (under the skin) injection
45376549|NCT01020825|Drug|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million.
45376550|NCT01020825|Drug|Fibrin glue|After curettage, the fistulous tract was sealed with fibrin glue.
45492909|NCT03146260|Procedure|Conventional TESE|usual procedure for sperm extraction
45492910|NCT03146260|Procedure|Microdissection TESE|Procedure of extraction is performed under the operating microscope
45492911|NCT03536663|Device|Optiflux and Dialyzer with Endexo|Hemodialysis (HD) on Optiflux dialyzer from Visit 1 to 12 and followed by HD on the dialyzer with Endexo at visit 13 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention will be 17 weeks.
45492912|NCT03770052|Drug|duvie|take the intervention drug once daily according to the randomized groups
45492913|NCT02351050|Device|Sonolysis|continual transcranial Doppler monitoring of middle cerebral artery
45492914|NCT02351050|Other|Sham procedure|sham transcranial Doppler monitoring of middle cerebral artery
45492915|NCT02350894|Behavioral|Graded and behavevial theraphy|Graded and behavevial theraphy
45492916|NCT03565211|Drug|Progesterone vaginal ring|A flexible, non-degradable PVR containing progesterone in micronized formulation and dispersed evenly throughout the ring.
45492917|NCT02346994|Dietary Supplement|Melt Test Blend 3.2|Participant will be given a standard breakfast (containing 20 g of fat from test blend 3.2) to consume over a 10-min period. Test blend 3.2 will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
45693411|NCT04574947|Drug|Intravenous placebo|During induction and maintenance of anaesthesia, 0.9% sodium chloride solution will be injected intravenously at a rate equivalent to lidocaine solution.
45847104|NCT04495608|Drug|Placebo|Placebo (1, 2, 3 or 4 pills to take daily during 18 weeks), same appearance to experimental drug
45492918|NCT02346994|Dietary Supplement|Corn Oil|Participant will be given a standard breakfast (containing 20 g of fat from corn oil) to consume over a 10-min period. Corn oil will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
45693412|NCT04574947|Procedure|Intra-cuff lidocaine|The lidocaine solution will be applied to the intubation tube and the cuff will be filled with an alkalinised lidocaine solution.
45693413|NCT04574947|Procedure|Intra-cuff placebo|The intubation tube will be lubricated 0.9% sodium chloride, the tube cuff will be filled with 0.9% sodium chloride solution.
45376551|NCT01020825|Drug|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million in combination with fibrin glue.
45693414|NCT00790192|Drug|Lurasidone|Lurasidone 80 mg tablets
45693415|NCT00790192|Drug|Lurasidone|Lurasidone 4 40 mg tablets
45693416|NCT00790192|Drug|Quetiapine XR|Quetiapine XR 600mg
45693417|NCT00790192|Drug|Placebo|Matching Placebo to Lurasidone or Quetiapine
46054153|NCT02791815|Drug|Selexipag|Oral administration of selexipag (200 µg film-coated tablet) for 12 consecutive days (with a titration scheme from 400 to 1600 μg b.i.d. )
46054154|NCT02389374|Drug|chloroquine|standard dose
45376552|NCT01018485|Drug|Botulinum Toxin Type A|Intramuscular injection in affected limb up to 100 Units. Two doses (one placebo, one active) 3 months apart.
45693418|NCT01781611|Drug|extended release dipyridamole 200mg/aspirin 25mg|one tablet twice daily for 24 weeks
45693419|NCT01781611|Drug|81mg aspirin|half a tablet twice daily for 24 weeks
45693420|NCT00777634|Other|No intervention.|There is no intervention used in this study. Cohort members are interviewed and blood pressure, weight, and laboratory specimens are obtained.
46054155|NCT02389374|Drug|Artemether-lumefantrine combination|standard dose
46054156|NCT02389374|Drug|Primaquine|single dose
46054157|NCT02389374|Drug|Primaquine|14 days
45376553|NCT00462501|Biological|bevacizumab|
45376554|NCT00462501|Drug|fluorouracil|
45376555|NCT00462501|Drug|leucovorin calcium|
45376556|NCT00462501|Drug|oxaliplatin|
45376557|NCT00462501|Procedure|conventional surgery|
45376558|NCT00462501|Radiation|radiation therapy|
45382284|NCT05114421|Biological|Pembrolizumab|Given IV
45693421|NCT01781299|Device|AlloDerm RTU|
46054158|NCT02789475|Drug|Amlodipine|Amlodipine administration
46054159|NCT02789475|Drug|Rosuvastatin|Rosuvastatin administration
45492919|NCT03740100|Drug|Bimiralisib|Bimiralisib capsules
45693422|NCT01781299|Device|SurgiMend PRS|
45376559|NCT03996603|Drug|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 8 weeks
45376560|NCT01018641|Biological|SA3Ag vaccine|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive 0.5 mL IM of the same dose level he/she received in stage 1."
45693423|NCT03802084|Drug|vactosertib/imatinib combination|"Phase 1 : Imatinib 400mg QD P q28days Vactosertib 1 cohort 200mg bid (D1-5, 8-12, 15-19, 22-26)~1 cohort 100mg bid Phase 2 : Imatinib 400mg QD PO q28days. Vactosertib RP2D, bid (D1-5, 8-12, 15-19, 22-26)"
45376561|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
45376562|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
46054160|NCT05379777|Drug|Remimazolam|Remimazolam The starting dose of remimazolam is 1 mg/kg/hr. If sedation does not proceed successfully, increase the infusion rate by 0.2 mg/kg/hr in the next patient. (However, if the infusion rate is less than 0.6mg/kg/hr, the dose is increased by 0.1mg/kg/hr.) If sedation has progressed successfully until the end of surgery, the next patient will use the same dose with a probability of 0.89 or 0.11 It is reduced by 0.2 mg/kg/hr with a probability of (However, if the infusion rate is 0.6mg/kg/hr or less, reduce it by 0.1mg/kg/hr.)
45376563|NCT01018641|Biological|SA3Ag followed by Placebo|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive one injection of 0.5 mL IM of the placebo."
45376564|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
45376565|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
45376566|NCT01018641|Biological|Placebo|In both stage 1 and stage 2, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl for a total of 2 injections throughout the study.
45376567|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
45376568|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
45376569|NCT01018641|Biological|SA3Ag with no booster in stage 2|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive no vaccine."
45376570|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
45376571|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
45376572|NCT01018641|Procedure|Placebo with no booster in stage 2|"In stage 1, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl.~In stage 2 the subject will receive no vaccine."
45376573|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
46054161|NCT03649347|Behavioral|Augmented reality exposure therapy|Exposure therapy via utilization of augmented reality. Virtual objects will be placed on the patient's real environment for exposure therapy.
46054162|NCT02791347|Other|Nutrition Intervention|
46054163|NCT04202484|Drug|Toripalimab combined with oxaliplatin and Tegafur,Gimeracil and Oteracil Porassium Capsules|Toripalimab: 240mg IV Q3W;Tegafur,Gimeracil and Oteracil Porassium Capsules: 40mg/m2 Bid PO×14d Q3W;Oxaliplatin: 130mg/m2 IV Q3W
45376574|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
45376575|NCT01018719|Device|MDCT, ECG, Echocardiography|Multi-detector computed tomography to evaluate coronary artery patency; ECG and Echocardiography - to evaluate cardiac function.
46054164|NCT02791425|Device|Brain Computer Interface (BCI) device|A BCI system to facilitate communication in intubated patients. Patients use the device in the ICU for communication for 2 hours a day for 3 consecutive days.
46054165|NCT02791425|Other|Communication picture board|The patient then uses a communication picture board for 2 hours a day for 3 consecutive days on the same days that the BCI device is used for comparison.
45376576|NCT00383188|Drug|placebo|Capsule, once daily (QD) for 12 weeks
45492920|NCT02346760|Drug|UB-621|100 mg/ml, subcutaneous injection
45492921|NCT03736512|Device|GreenLight XPS™ 532 nm Laser System with MoXy™ laser fiber|observational registry
45492922|NCT02342626|Behavioral|Dashboard|With the health care provider, subjects will use the decision dashboard to augment the discussion of treatment options.
45492923|NCT03723395|Drug|tucatinib|300mg dose, orally administered
45492924|NCT03723395|Drug|itraconazole|200mg dose
45376577|NCT00383188|Drug|PH-797804|Capsule, 0.5 mg of PH-797804, once daily (QD) for 12 weeks
45376578|NCT00383188|Drug|PH-797804|Capsule, 3 mg of PH-797804, once daily (QD) for 12 weeks
45376579|NCT00383188|Drug|PH-797804|Capsule, 6 mg of PH-797804, once daily (QD) for 12 weeks
45376580|NCT00383188|Drug|PH-797804|Capsule, 10 mg of PH-797804, once daily (QD) for 12 weeks
45376581|NCT01021059|Biological|rh IL-15|rh IL-15 daily for 12 days of 42 days cycle. Additional cycles may be given if patient is responding to therapy.
45376582|NCT00462345|Drug|rituximab|1000 mg i.v. on Days 1 and 15
45376583|NCT00462345|Drug|Methotrexate|10 to 25 mg/week p.o. or parenteral from Day 1 through Week 24
45376584|NCT00462345|Drug|Corticosteroid or NSAID|≤10 mg/day prednisone p.o., or equivalent corticosteroid, or NSAIDs p.o. from Day 1 through Week 24
45376585|NCT00462345|Dietary Supplement|Folate|≥5 mg/week, once daily or b.i.d. from Day 1 through Week 24
45376586|NCT01025115|Dietary Supplement|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
45376587|NCT01025115|Dietary Supplement|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
45376588|NCT01022541|Drug|Capecitabine|"Capecitabine 1700mg/m2/day in two divided doses to be administered orally for 14 days followed by 7 days rest. For 4 courses initially.~(For patients aged 75+ 1300mg/m2/day in two divided doses or 650mg/m2 twice daily)~Courses as per detailed description above."
45376589|NCT01022541|Drug|Oxaliplatin|"Oxaliplatin 130mg/m2 diluted in 5% dextrose will be given as an i.v. infusion over 2 hours. This will be administered on day 1 after bevacizumab. For 4 courses.~(Patients aged 75+ should receive oxaliplatin at a reduced dose i.e. 100mg/m2)~Courses as per detailed description above."
45376590|NCT01022541|Drug|Bevacizumab|"Bevacizumab at a dose of 7.5 mg/kg, diluted in normal saline, will be administered as an iv infusion over 30 to 90 minutes before the administration of oxaliplatin on day 1 of every cycle.~The first infusion should be administered over 90 minutes. If well tolerated, the second infusion can be administered over 60 minutes. Provided that this is tolerated subsequent infusions can be administered over 30 minutes. If a patient experiences an infusion related adverse event with the 60 minute infusion, all subsequent infusions will be administered over 90 minutes. If a patient experiences an infusion related reaction with the 30 minute infusion, all subsequent infusions will be administered over 60 minutes~Courses as per detailed description above."
45492925|NCT03723395|Drug|rifampin|600mg dose
45847105|NCT04376658|Other|COVID-19 Severity|Disease severity characterized by the highest six-level ordinal scale during the hospital stay, which consists of the following categories: a score of 1 indicated not hospitalized; 2, hospitalized and not receiving supplemental oxygen; 3, hospitalized and receiving supplemental oxygen; 4, hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or noninvasive ventilation; 5, hospitalized and receiving mechanical ventilation; and 6, death
45847106|NCT04368702|Radiation|Viewray MRIdian® Linac|MR-image guided radiation will be administered per disease site standards.
45376591|NCT01022541|Procedure|Liver metastasectomy|Patients with liver metastases which have become resectable and in whom surgery is still deemed appropriate should proceed to surgery after a 6 week interval from the last administration of capecitabine chemotherapy (at least 8 weeks from last administration of bevacizumab).
45376592|NCT01045408|Dietary Supplement|Berry extract|Berry extract for weeks
45376593|NCT01047202|Biological|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
45382285|NCT05112497|Other|No intervention procedure|No intervention procedure
45492926|NCT03723395|Drug|gemfibrozil|600mg tablets
45492927|NCT03723395|Drug|repaglinide|1mg dose
45492928|NCT03723395|Drug|tolbutamide|500mg dose
45492929|NCT03723395|Drug|midazolam|2mg dose
45492930|NCT03723395|Drug|digoxin|0.5 mg dose
46054166|NCT04225650|Other|Pulmonology consultation|In case of functional respiratory signs, a consultation with a pulmonologist will be booked. At the end of this consultation, if the doctor deems it necessary, other investigations will be proposed and/or regular follow-up will be organised.
46054167|NCT02380404|Procedure|Implants-supported locators placement|Antibiotics will be prescribed 1 day before surgery and continued for 5 days. Three calibrated surgeons will place 4 NN or RN Roxolid tissue level implants. Two implants have to be placed in the ANT region (lateral or canine) and 2 implants in the POST region (as distal as possible). Angulated implant and placement of implant in the tuberosity region can be considered.
46054168|NCT05375565|Other|weight bearing exercises|"Standing knee raise 10 rep x 2sets~Standing knee bend 10 rep x 2sets~Standing hip extension 10 rep x 2sets~Shallow squats 5 rep x 2 sets After 4 week gradually restricting the use of assistive device when patient become able to walk and stand for 10 mins then add stair climbing and descending with a step height not higher than 7 inch.~The session will be around 45 to 60 minutes on each patient with 2 sessions per week on alternate days to observe the long term effects."
46054169|NCT05375565|Other|non weight bearing exercises|"Seated knee flexion 10 rep x 2sets~Seated knee extension 10 rep x2sets~Use of stationary bicycle 10 mins~Side lying leg lift 10 rep x2sets~Straight leg raise 10 rep x 2sets The session will be around 45 to 60 minutes on each patient with 2 sessions per week on alternate days to observe the long term effects."
46054170|NCT03068910|Drug|Micronized progesterone|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
45492931|NCT01377948|Behavioral|ACT with RAGE-Control|This is an open trial of ACT with RAGE-Control which is a behavioral intervention. The therapy involves five psychotherapy sessions taking place over five consecutive days.
45492932|NCT02350738|Other|Period I MCET (8 wks)|MCET_Mock group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk) Mock_MCET group: mock-therapy (3 sessions/wk)
45492933|NCT02350738|Other|Washout (4 wks)|4 weeks wash-out period in both arms and cross-over
46054171|NCT03068910|Drug|Spironolactone|Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
46054172|NCT03068910|Drug|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
45376594|NCT01047202|Biological|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
45376595|NCT01047202|Biological|Seasonal trivalent vaccine|Trivalent Inactivated Influenza Vaccine (ANFLU), 7.5 micrograms of each strain per dose per 0.25 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
45376596|NCT01047280|Dietary Supplement|Clarinol G-80 ® treatment|dietary supplement of 3.5g/day 50-50 mixture of t10, c12 and c9, t11 CLA. In addition, the amount of mixed natural tocopherols is 5mg/g (0.05%).
45376597|NCT01047280|Dietary Supplement|Safflower oil|3.5 g/d of safflower oil
45376598|NCT01047280|Dietary Supplement|G-c9, t11|3.5 g/day of c9, t11 CLA
46054173|NCT02791113|Other|Fractional Flow Reserve (FFR) Measurement|FFR is defined as the distal pressure to coronary lesion divided by the proximal coronary pressure. FFR is measured through a standard diagnostic catheter during coronary angiogram. FFR is used to guide whether to perform angioplasty or stenting or not in patients with coronary stenosis.
46054174|NCT02790957|Drug|Plerixafor|Single injection of 0.24 mg/kg Plerixafor
46054175|NCT02790957|Drug|Placebo|Single injection of an equal volume of NaCl solution
46054176|NCT00905424|Drug|Antidepressant + SPD489 (lisdexamfetamine dimesylate)|Escitalopram oxalate (antidepressant) 20 mg/day oral + 20, 30, or 50 mg SPD489 oral once daily for 6 weeks
46054177|NCT00905424|Drug|Antidepressant + placebo|Escitalopram oxalate (antidepressant) 20 mg/day oral + placebo oral once daily for 6 weeks
46054178|NCT04234269|Other|Assessment|Evaluation forms will be applied to the patients who meet the inclusion criteria by face to face interview method.The sociodemographic information of the patients and the time taken to answer the questions in the questionnaires will vary according to each patient, but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1 week intervals.
45376599|NCT02672956|Procedure|Ten mm trocar|
45376600|NCT01047514|Behavioral|Chronic Disease Self-Management Online Workshop|6 week, online, small group self-management workshop
45376601|NCT01047592|Drug|sarcosine|sarcosine, 2 g/d , oral, for 12 weeks
45376602|NCT01047592|Drug|sarcosine+ BE|sarcosine(2 g/d) + BE (1 g/d ), oral, for 12 weeks
46054179|NCT02791035|Drug|Oral administration of Ipragliflozin|
46054180|NCT03753243|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
46054181|NCT03753243|Drug|Enzalutamide|Patients will receive daily oral doses of study drug (enzalutamide 160 mg/day), which will be administered as four capsules/day to be taken at or near the same time each day.
46054182|NCT02788617|Device|Diafert|The Diafert output, the G-CSF concentration in FF, will be recorded but will not be used in patient management.
46054183|NCT02339532|Drug|FEC100|"3 cycles of FEC 100 administered IV q3w~5-Fluorouracil (5-FU) 500 mg/m²~Epirubicin 100 mg/m²~Cyclophosphamide 500 mg/m²"
46054184|NCT02339532|Drug|Docetaxel|TOP2A amplified : DOCETAXEL 75 mg/m² IV escalating at 100 mg/m² IV as tolerated q3w TOP2A not amplified : DOCETAXEL 75 mg/m² IV
45376603|NCT01047592|Drug|placebo|placebo,oral, for 12 weeks
45376604|NCT01049854|Drug|Full Intensity with TBI|Patients will start their pre-conditioning regimen on Day -8. Fractionated TBI will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5, -4, Cyclophosphamide on Days -3, -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
45492934|NCT02350738|Other|Period II MCET (8 wks)|MCET_Mock group: mock therapy (MCET) (3 sessions/wk) Mock_MCET group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk)
45492935|NCT04459728|Behavioral|Wellness Element 1: Exercise|Daily wellness element focusing on Exercise; adherence documented online daily
45492936|NCT04459728|Behavioral|Wellness Element 2: Mindfulness|Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
45492937|NCT04459728|Behavioral|Wellness Element 3 - Sleep Hygiene|Daily wellness element focusing on sleep hygiene; adherence documented online daily
45492938|NCT04459728|Behavioral|Wellness Element 4 - Social Connectedness|Daily wellness element focusing on social connectedness; adherence documented online daily
46054185|NCT02339532|Drug|Trastuzumab|Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.
45376605|NCT01049854|Drug|Full Intensity|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with stem cell infusion on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
45376606|NCT01049854|Drug|Reduced Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -9. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
45376607|NCT01049854|Drug|Reduced Intensity (Fanconi)|Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and antithymocyte globulin (horse) on Days -5, -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
45376608|NCT01045486|Drug|ATP mixed probiotics|- Patients in Group A will receive ATP mixed probiotics for 6 weeks. And after 4 weeks wash-out period, they will receive placebo for 6 weeks
45376609|NCT01045486|Drug|Placebo|- Patients in Group B will receive placebo for 6 weeks. And after 4 weeks wash-out period, they will receive ATP mixed probiotics for 6 weeks
45693424|NCT01732471|Drug|Kuvan®|Kuvan® (sapropterin dihydrochloride) will be administered orally at a dose of 20 milligram per kilogram per day (mg/kg/day) once daily for 8 days. If there is 30 percent (%) decrease in blood phenylalanine levels from baseline at the end of Day 8, then treatment will be continued at the same dose for further 6 weeks.
46054186|NCT02339532|Drug|Pertuzumab|Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.
45492939|NCT04459728|Behavioral|Wellness Element 5 - Nutrition|Daily wellness element focusing on nutrition; adherence documented online daily
45693425|NCT00790270|Drug|Cyclobenzaprine|5 mg orally every 8 hours as needed
45693426|NCT00790270|Drug|Ibuprofen|Ibuprofen 400 mg every 8 hours as needed
45693427|NCT00790270|Drug|Ibuprofen plus Cyclobenzaprine|Ibuprofen 400 mg plus cyclobenzaprine 5 mg every 8 hours as needed
45693428|NCT01780987|Drug|Apixaban|10 mg BID for 7 days followed by 5 mg BID for 23 weeks (total 24 weeks)
46054187|NCT02339532|Drug|Carboplatin|CARBOPLATIN AUC 6 IV q3w
46054188|NCT02790879|Other|Transition pediatric - adult|
46054189|NCT02790801|Other|observation|observation
46054190|NCT02790645|Other|Group 2a. Telemedicine program|CSII (Accu-Chek Spirit®) and medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
46054191|NCT02790645|Other|Group 1a. Control|Treatment with CSII (Accu-Chek Spirit®) and follow-face doctor visits (conventional treatment -SMC-) (6 months).
46054192|NCT02790645|Other|Group 1b.Telemedicine program|After a washout period of 3 months and the crossing, Group 1 begins with medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
46054193|NCT02790645|Other|Group 2b. Control|After a washout period of 3 months and the crossing, Group 2 begins with face doctor visits (conventional treatment -SMC-) (6 months) .
46054194|NCT00632580|Drug|intraarticular injection with ropivacaine|
45376610|NCT01045564|Biological|GSK influenza virus H5N1 vaccine 1557484A|Three doses of GSK 1557484A administered intramuscularly (IM), the first and third in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm
45376611|NCT00453999|Drug|Peramivir 200 mg|Peramivir (200 mg in 100 mL of solution) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 mL) treatment
45376612|NCT00453999|Drug|Peramivir 400 mg|Peramivir (400 mg in 100 mL of solution ) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 ml)
45376613|NCT00453999|Drug|Oseltamivir|Placebo peramivir infusion (over 15 minutes) and a 75-mg dose of oseltamivir suspension (6.25 mL)
45376614|NCT00453921|Drug|Methylphenidate|Dosage dependent on weight
45376615|NCT00453921|Behavioral|Memory and Attention Training|Weekly Memory and Attention Training with at home practice.
45376616|NCT00453921|Other|Placebo as both treatments|Placebo capsules and Placebo Memory and Attention Training
45492940|NCT04459728|Behavioral|Wellness Element 6 - Wellness Exercises|Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
45693429|NCT01780987|Drug|Unfractionated Heparin (UFH)|Dosing adjustment based on APTT = 1.5-2.5 times the control value, and until INR ≥ 1.5 for 5 days or more
45693430|NCT01780987|Drug|Warfarin|Dosing for 24 weeks to target INR range between 1.5-2.5
45693431|NCT00790738|Drug|Liothyronine (T3)|liothyronine (T3) up to 50 micrograms a day
45693432|NCT00790738|Drug|placebo|placebo
45693433|NCT03800290|Drug|Clenbuterol Hydrochloride|Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 14 days with a wash-out period of 4 weeks.
45376617|NCT03995745|Behavioral|Medication adherence and financial incentives|Provision of wireless devices and financial incentives to motivate medication adherence among HIV-positive adults who have not reached viral suppression.
45376618|NCT00382720|Drug|Docetaxel + Oxaliplatin|"Dose level 1 (non-optimal dose):~Docetaxel 75 mg/m² as an 1-hour intravenous (IV) infusion on day 1 followed by Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1~Dose level 2 (optimal dose):~Docetaxel 75 mg/m² as an 1-hour IV infusion on day 1 followed by Oxaliplatin 130 mg/m² as a two to six-hour IV infusion on day 1"
45492941|NCT04459728|Behavioral|Wellness Element 7 - Motivational Messages|Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
45492942|NCT02350972|Biological|Autologous cytokines|Sterile autologous cytokines were injected weekly into multiple metastatic nodules while other nodules in the patient were never injected and were monitored for the development of dense lymphocytic infiltrates as evidence of an induced immune response.
45492943|NCT02342470|Drug|Placebo|Drug : Placebo
45376619|NCT00382720|Drug|Docetaxel + Oxaliplatin + 5-FU|"Dose level 1 (non-optimal dose):~Docetaxel 40 mg/m² as a 1-hour intravenous (IV) infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m2 as a 46-hour continuous infusion day 1.~Dose level 2 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour IV infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m² as a 46-hour continuous infusion day 1."
45492944|NCT02342470|Drug|PMK-S005 1|Drug : PMK-S005 1 (50mg)
45376620|NCT00382720|Drug|Docetaxel + Oxaliplatin + Capecitabine|"Dose level 1 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour intravenous (IV) infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m2 two times a day continuously.~Dose level 2 (non-optimal dose):~Docetaxel 65 mg/m² as a 1-hour IV infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m² two times a day continuously."
45492945|NCT02342470|Drug|PMK-S005 2|Drug : PMK-S005 2 (100mg)
45376621|NCT01025349|Drug|Bevacizumab, docetaxel, cisplatin|"Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.~docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.~cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks."
45376622|NCT02473276|Drug|Morphine|preservative free morphine given either via an epidural or intrathecal catheter
45376623|NCT02473276|Drug|Sterile normal saline|sterile normal saline, given either via an epidural or intrathecal catheter
45376624|NCT01022697|Other|Glucose drink|200 mL each 3 hours up to 8 cm of dilatation
45492946|NCT02342470|Drug|PMK-S005 3|Drug : PMK-S005 3 (150mg)
45492947|NCT04436952|Device|H7 coil|The H7 coil arm will receive a medial prefrontal cortex (mPFC) DTMS 5 days a week for 8 consecutive weeks = 40 Sessions 20 Hz at 100% MT, 2 s on 20 s off intertrain interval, 50 trains, 2000 stimuli per session.
45492948|NCT04436952|Device|Cool D-B80|The Cool D-B80 arm will receive dorsomedial prefrontal cortex (DMPFC) rTMS 5 days a week for 8 consecutive weeks = 40 sessions 10 Hz at 120% MT, 5 s on 10 s off intertrain interval, 60 trains, First 3000 pulses to the left DMPFC then 3000 pulses to the right DMPFC. TMS will be done at active state by provocation
45492949|NCT04436952|Behavioral|Exposure Response Prevention (ERP)|The ERP will be conducted for 2 hours on week 1 and week 8 and for 1 hour on Weeks 2 to 7 for a total of 10 hours
45492950|NCT03531905|Drug|Bempedoic acid + Ezetimibe FDC Oral Tablet|Experimental therapy of bempedoic acid 180 mg + ezetimibe 10 mg FDC tablet
45492951|NCT03531905|Drug|Ezetimibe 10 mg Oral Tablet|Ezetimibe 10 mg tablet, overencapsulated for blinding purposes
45492952|NCT03531905|Drug|Placebo Oral Tablet|Placebo tablet, matched for the FDC product for blinding purposes
45492953|NCT03531905|Drug|Placebo oral capsule|Placebo over-encapsulated for blinding purposes
45492954|NCT02350426|Other|Gadobutrol|Gadobutrol is a solution for intravenous (IV) injection in prefilled syringe/cartridge with a unit dose strength of 1.0 millimole (mmol)/mL solution, and will be administered at up to 0.1mmol/kg.
45492955|NCT02350426|Other|18F-FDG|18F-FDG is a solution for IV injection in multidose vial, maximum 10 mL with unit dose strength of 160 megabecquerel (MBq) at maximum.
45492956|NCT02350426|Other|18F-GE-180|18F-GE-180 solution for IV injection in 10mL glass vial. Patients will receive a maximum activity of 195 MBq in a maximum volume of 10 mL (bolus) of 18F-GE-180, containing not more than 2 microgram (mcg)/mL 18F-GE-180 (20 mcg for a 10 mL dose).
45492957|NCT02346682|Drug|venlafaxine|Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks. Patients were prescribed a combination of venlafaxine and Benzodiazepines for sleep disturbance.
45492958|NCT04385706|Behavioral|Applied Coaching Model|The Applied Coaching Model incorporates key learning opportunities and coaching strategies with evidence-based practices, approaches and theories and will serve as a tool for all healthcare providers wanting to implement coaching techniques within their practice.
45693434|NCT03800290|Drug|Placebos|Daily ingestion of placebo capsules for a total period of 14 days with a wash-out period of 4 weeks.
45376625|NCT01021371|Behavioral|Two step intervention including patient interview followed by an extended information routine to the patients' GP about the patients' rehabilitation needs|The intervention consists of an extended information routine from hospital to GP based on individual interviews with the patients in the intervention group and a specific encouragement of the patients' GP to play a proactive role in the patients' rehabilitation course. The individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus. The control group is assigned to usual procedures.
45376626|NCT01022775|Procedure|Dynamic humeral centering|Dynamic humeral centering performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
45376627|NCT01022775|Procedure|Nonspecific mobilisation|Nonspecific mobilisation performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
45492959|NCT04300296|Drug|Cutaneous lichen planus secukinumab 300 mg Q4W|All cutaneous lichen planus patients assigned to active secukinumab will receive 2x 1ml PFS at randomization, Week 1, Week 2, Week 3, Week 4, Week 8 and Week 12. At Week 16, they will stay on the weekly placebo dosis and monthly secukinumab until Week 32.
45492960|NCT04300296|Drug|Cutaneous lichen planus placebo|All cutaneous LP patients assigned to placebo will receive 2x 1ml placebo PFS at randomization , Week 1, Week 2, Week 3, Week 4, Week 8 and Week 12. At Week 16, they will be switched to secukinumab (if no spontanoues remision) for weekly dosis until Week 20, then bi-weekly injection of secukinumab until Week 30
45376628|NCT00453063|Drug|mometasone furoate|50 mcg/spray, two sprays in each nostril once daily (ie, 200 mcg QD) in the morning
45376629|NCT00453063|Drug|Placebo|Two sprays in each nostril once daily in the morning
45376630|NCT00371566|Drug|Lapatinib oral tablets|
45492961|NCT04300296|Drug|Mucosal lichen planus placebo|All mucosal lichen planus patients assigned to placebo will receive 2x 1ml placebo PFS at randomization , Week 1, Week 2, Week 3, Week 4, Week 8 and Week 12. At Week 16, they will be switched to secukinumab (if no spontaneous remission) for weekly dosis until Week 20, then bi-weekly injection of secukinumab until Week 30
45492962|NCT04300296|Drug|Lichen planopilaris placebo|All lichen planopilaris patients assigned to placebo will receive 2x 1ml placebo PFS at randomization , Week 1, Week 2, Week 3, Week 4, Week 8 and Week 12. At Week 16, they will be switched to secukinumab (if no spontanoues remision) for weekly dosis until week 20, then bi-weekly injection of secukinumab until Week 30
46054195|NCT00632580|Drug|extraarticular injection with ropivacaine|
45376631|NCT00371566|Drug|Placebo|
45376632|NCT00382408|Biological|DR-5001|All randomized subjects received a single tablet of both Type-4 and Type-7 ADV vaccines on Day 0. Both vaccine tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
45376633|NCT00382408|Other|Placebo|All randomized subjects received a single tablet each of the placebos matching Type-4 and Type-7 ADV vaccines on Day 0. Both placebo tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
45376634|NCT00371254|Drug|Dasatinib|Tablets, Oral, 100 mg, twice daily as long as the patient benefits (avg <6 months)
45376635|NCT00371254|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily as long as the patient benefits (avg <6 months)
45376636|NCT00452673|Drug|Dasatinib|Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression
45376637|NCT00452673|Drug|Capecitabine|Tablets, Oral, 660 - 1250 mg/m^2 twice a day (BID). Treatment may continue until disease progression.
45492963|NCT04300296|Drug|Mucosal lichen planus secukinumab 300 mg Q4W|All mucosal lichen planus patients assigned to active secukinumab will receive 2x 1ml PFS at randomization , Week 1, Week 2, Week 3, Week 4, Week 8 and Week 12. At week 16, they will stay on the weekly placebo dosis and monthly secukinumab until Week 30.
45492964|NCT04300296|Drug|Lichen planopilaris secukinumab 300 mg Q4W|All lichen planopilaris LP patients assigned to active secukinumab will receive 2x 1ml PFS at randomization , Week 1, Week 2, Week 3, Week 4, Week 8 and Week 12. At Week 16, they will stay on the weekly placebo dosis and monthly secukinumab until Week 30.
45492965|NCT05764590|Drug|AP-306|A blood phosphorus lowering drug with a novel mechanism
45492966|NCT05764590|Drug|Sevelamer Carbonate|A phosphate binder
46054196|NCT02787993|Behavioral|Cognitive Behavioral Mult-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via Cognitive Behavioral Multi-Symptom Management(CBT). Four sessions will be conducted each session is approximately one hour.
46054197|NCT02789397|Drug|Rituximab (RTX) and Azathioprine (AZA)|Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12 for the active comparator arm Rituximab (RTX) and Azathioprine (AZA).
46054198|NCT02789397|Drug|Placebos|IV placebo will be administered on the same schedule as Rituximab and oral placebo will be administered by mouth daily for 18 months.
46054199|NCT03485274|Drug|Vortioxetine|oral medication taken once daily
45376638|NCT00461253|Device|Levonorgestrel-releasing IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
45376639|NCT00461253|Device|Copper IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
45376640|NCT00469833|Drug|insulin glargine|Diabetic subjects will be treated with insulin glargine once daily for 2 months. Subjects will monitor their blood glucose and have their insulin dose adjusted in steps of 4-6 units to achieve a goal of less than or equal to 120 mg/dl for fasting blood glucose.
45376641|NCT00382174|Drug|Placebo|Topical administration of 0.00% thymosin beta 4 qd up to 84 days
45376642|NCT00382174|Drug|Thymosin Beta 4|Topical Administration of 0.01, 0.02, and 0.1% thymosin beta 4 gel qd for up to 84 days
45376643|NCT00641537|Drug|Cladribine|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
45376644|NCT00641537|Drug|Placebo|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
45492967|NCT04141774|Device|Functional Electric Stimulation (FES)|FES uses low energy electrical pulses to artificially generate body movements in individuals with muscle paralysis. FES can be used to generate muscle contraction in otherwise paralyzed limbs to restore function.
45492968|NCT04141774|Behavioral|Behavioral Assessments|These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.
45492969|NCT04141774|Other|Magnetic Resonance Imaging|A functional magnetic resonance image will be collected.
46054200|NCT03485274|Other|Treatment as Usual|Any pharmacological or non-pharmacotherapy modalities other than use of vortioxetine
46054201|NCT03286725|Behavioral|Physical Education (PE) Programme|"A programme of activities for PE lessons has been developed by Oxford Brookes University (in collaboration with Oxfordshire Sport and Physical Activity) to try to optimise the benefit of PE for brain function. Staff from Oxford Brookes University will train PE teachers to deliver this programme.~The Intervention involves roughly 20 minutes of prescribed activities per week, to be delivered within school PE lessons."
46054202|NCT05301972|Drug|BET Inhibitor|Bromodomain and Extra-Terminal Inhibitor
45376645|NCT00641537|Drug|Cladribine|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
45382286|NCT05101707|Device|transcutaneous auricular vagus nerve stimulation|Applying a pulsed microcurrent to the auricular branch of the vagus nerve, timed with motor activity of the weaker arm/hand
45492970|NCT04141774|Other|EEG|EEG electrodes will be attached to the subject's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
45492971|NCT03131934|Biological|Autologous EBV-CTL transduced with vector SFG-CNA12|Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12 conferring resistance to tacrolimus
45492972|NCT03131934|Biological|Autologous EBV-CTL transduced with control vector SFG-CNA8|Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8
45492973|NCT03131934|Procedure|Leucapheresis|Patients will undergo an unstimulated leucapheresis to isolate the required immune cells to produce the EBV-CTLs
45492974|NCT03531827|Drug|enzalutamide|enzalutamide is an androgen receptor (AR) antagonist that is standard care therapy for metastatic prostate cancer
45492975|NCT03531827|Drug|CRLX101|CRLX101 is a nanoparticle-drug conjugate (NDC) comprised of a linear cyclodextrin-polyethylene glycol-base polymer conjugated to multiple 2 (S)-camptothecin (CPT) molecules (Poly-CD-PEG-Camptothecin)
45693435|NCT00777790|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
45693436|NCT00777790|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
45693437|NCT00777790|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
46054203|NCT02789163|Device|Ultrasound|breast ultrasound; hand held and automated volume breast scanner
45376646|NCT00641537|Drug|Cladribine|Participants who received placebo in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
46054204|NCT05134428|Device|ADAM System|The ADAM System consists of an injectable hydrogel and delivery apparatus that is intended to provide long-lasting, non-permanent vasal occlusion for men, resulting in azoospermia. ADAM is designed to be inserted into the vasa deferentia through a minimally invasive procedure, similar to the no-scalpel vasectomy.
45376647|NCT00641537|Drug|Placebo|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
45376648|NCT01025583|Dietary Supplement|hypotonic oral rehydration solution|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
45376649|NCT01025583|Dietary Supplement|Hypotonic oral rehydration solution with Zn and prebiotics|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
45376650|NCT03840135|Drug|Polyoxidonium 6 mg/ml|"Nasal and sublingual spray Polyoxidonium 6 mg/ml will be administered at a dose of 0,15 mg/kg daily for 7 days:~in children aged from 1 to 2 years - 1 spray sublingually 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 spray intranasally (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 spray intranasally (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 spray intranasally (in each nasal passage) 2 times a day (every 12 hours)."
45376651|NCT03840135|Other|Placebo|"Placebo nasal and sublingual spray will be administered for 7 days:~in children aged from 1 to 2 years - 1 spray sublingually 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 spray intranasally (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 spray intranasally (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 spray intranasally (in each nasal passage) 2 times a day (every 12 hours)."
45376652|NCT00814541|Drug|Bortezomib|
45376653|NCT00814541|Drug|Doxorubicin|
45376654|NCT00814541|Drug|Dexamethasone|
45376655|NCT01021527|Other|Comparator: Treatment A|No Treatment
45376656|NCT01021527|Drug|Comparator: Treatment B|single dose administration of exenatide 5ug by subcutaneous injection
45693438|NCT05535478|Behavioral|STRIDE|a. Targeted providers for STRIDE program: i. Clinical staff at the LTCF who participate in deprescribing at the facilities (physicians (MDs), physician's assistants (PAs), nurse practitioners (NPs), clinical pharmacists): clinical staff members caring for LTCF residents with ADRD and diabetes at 6 LTCFs in the Ohio and Michigan areas will be invited via email from the LTCF leadership to participate in the STRIDE education program. The STRIDE program consist of practical algorithms and educational material, which they are free to view at any time, and participation in 2 webinars and monthly telementoring calls
46054205|NCT02789241|Biological|Endotoxin|Reference Endotoxin is a purified LPS prepared from Escherichia coli O:113 (US Standard Reference Endotoxin); Clinical Center Reference Endotoxin (CCRE) Lot #94332B1 manufactured and vialed under GMP guidelines by List Biological Labs, Inc., 540 Division St., Campbell, CA 95008, for the Pharmacy Development Service, Clinical Center, National Institutes of Health, Bethesda, MD, USA. The material has been approved by the FDA (Food and Drug Administration) for 'Investigational Use Only'. This specific Lot from List Biological Labs specified for use in this study contains 1 mcg/vial.
45376657|NCT01021527|Drug|Comparator: Treatment C|single dose administration of exenatide 10ug by subcutaneous injection
45376658|NCT01021527|Procedure|Comparator: graded glucose infusion|A stepwise graded infusion of glucose (20% dextrose [D20]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.
45376659|NCT00814619|Biological|panitumumab|Given IV
45376660|NCT00814619|Drug|capecitabine|Given orally
45693439|NCT00808834|Device|Lotrafilcon A contact lens|Investigational, silicone hydrogel, spherical, soft contact lens
45693440|NCT00808834|Device|Senofilcon A contact lens|Commercially marketed, silicone hydrogel, spherical, soft contact lens
46054206|NCT02789241|Other|Placebo|Normal saline will be administered as the control to evaluate the effects on the biomarkers over time and to compare the responses following LPS to those following the control injection of normal saline.
45376661|NCT00814619|Procedure|therapeutic conventional surgery|Patients undergo surgical resection
45376662|NCT00814619|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
45376663|NCT01023009|Procedure|vitrectomy|
45382287|NCT05101707|Other|Constraint induced movement therapy|Applying a custom-made splint constraint to the stronger hand/arm to encourage use of the weaker hand/arm in intensive therapy sessions
45382288|NCT05100056|Other|No Intervention|This is a non-interventional study.
45382289|NCT05099107|Drug|Salbutamol (as Salbutamol Sulfate) 2 Mg Oral Tablet|taken 3 times daily for 6 months
45382290|NCT05099107|Drug|Salbutamol Only Product in Oral Dose Form|taken 3 times daily for 6 months
45693441|NCT00809146|Drug|Intramuscular route of active treatment|IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.
45492976|NCT05764512|Other|Endorphin massage|"With the anterior surface of the fingertips of the hand, a V will be drawn slowly, starting from the sacral region and towards the ribs. The same process will be continued from the sacral region until the 7th cervical vertebra.~From the 7th cervical vertebra, the front surface of the fingertips will be descended first to the shoulders and then to the dorsal region of the upper and forearms in turn.~Starting from the dorsal region of the forearm, the first stage of the massage will end by descending to the upper arm, shoulders, 7th cervical vertebra, spine and sacral region with the back of the thumbs. These massage steps will be repeated until 20 minutes are completed.~Endorphin massage will be applied every 2 hours."
45492977|NCT04105816|Device|892.1550 Ultrasonic pulsed doppler imaging system|Use of the ultrasound to measure quadriceps volume
45376664|NCT01025661|Other|Chiropractic care|Clinical examinations and treatments were performed at the outpatient clinic. The patients were assessed and treated by research assistants and the clinical care was supervised by state registered chiropractors. The choice of therapy and modality was pragmatic and based on the analysis of different functions such as mobility, tenderness, muscle tension and tone, and each patient's relative symptoms. Chiropractic care included high-velocity and low-amplitude techniques, soft-tissue or myofascial techniques, and arthrokinematic stabilizing exercises or a combination of these. Patients were treated in 1-2 sessions per week during the trial.
45376665|NCT01025739|Device|EsophyX™ system with SerosaFuse fasteners|The EsophyX™ system with SerosaFuse fasteners (EndoGastric Solutions, Redmond, WA, USA) was designed to reconstruct the gastroesophageal junction through anterior partial fundoplication with tailored delivery of multiple fasteners during a single-device insertion.
45376666|NCT00641147|Drug|Curcumin|Given PO
45376667|NCT00641147|Other|Laboratory Biomarker Analysis|Correlative studies
45376668|NCT00641147|Other|Placebo|Given PO
45376669|NCT00460239|Drug|Buprenorphine|Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.
45376670|NCT00460239|Drug|Morphine|Intramuscular; up to 1-2 times per week; doses (15, 30 mg) double blind
45376671|NCT00460239|Drug|Placebo|Intramuscular; double blind; once per week
45382291|NCT05093634|Drug|Setmelanotide|Subcutaneous Injection
45382292|NCT05093634|Drug|Placebo|Subcutaneous Injection
45492978|NCT04105816|Diagnostic Test|Thigh circumference measurement|Tape measure used to measure thigh circumference of all participating patients in the study at the same visit in which they receive ultrasound measurements of thigh muscles.
45492979|NCT02346448|Procedure|endoscopic sphincterotomy|sphincterotomy during ERCP
45492980|NCT02346448|Procedure|balloon dilatation for 3 minutes|balloon dilatation during ERCP using 10mm balloon
45492981|NCT02346448|Procedure|balloon dilatation for 6 minutes|balloon dilatation during ERCP using 10mm balloon
45492982|NCT03057678|Other|Testing of Pre-Positioning Frame|Placement of bone screws, CT scanning, Surgical planning, Robot motion planning
45693442|NCT00809146|Drug|Intravenous route of active treatment|IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.
45693443|NCT00791908|Procedure|Electrodessication|Treatment applied to a third of the torso at each study visit.
45693444|NCT00791908|Procedure|Pulsed dye laser (PDL)|Laser treatment applied to a third of the torso at each study visit.
45492983|NCT01377870|Biological|intravenous injection of mesenchymal stem cells|15 patients with relapsing remitting multiple sclerosis underwent intravenous injection of mesenchymal stem cell
45492984|NCT01377870|Biological|injection of cell free media|Patients who are in control group underwent media injection but after 6 months they will be transplanted by stem cell.
45693445|NCT00791908|Procedure|potassium titanyl phosphate (KTP)|Laser treatment applied to a third of the torso at each study visit.
45492985|NCT03146026|Behavioral|Combined Exercise Training|The CET program was performed for 60 minutes with 5 minutes of warm-up and cool-down per day, 3 times a week for 12 weeks. Combined exercise consisted of 20 minutes of various resistant band exercises (Upper body: seated rows, biceps curl, shoulder flexion, elbow flexion, chest press; Lower body: hip flexion, hip extension, calf raise, leg press, squat) and 30 minutes of treadmill walking. The warm-up and cool down consisted of static stretching. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4, and to 60-70% HRR in weeks 9-12. Each training session was fully supervised by the researchers. Every subject wore a heart rate monitor during the whole training session so as to maintain the correct training intensity.
45492986|NCT02342392|Drug|ranibizumab|Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.
45492987|NCT04075656|Behavioral|Standard of Care|Participants will be provided a folder of educational material on NS, including general information on symptoms, treatments, and possible complications; healthy diet for children taking corticosteroids; and low sodium diet. Site research staff will demonstrate how to check urine for protein with test strips, and educate patients on the definitions of disease relapse and remission. Urine test strips and urine protein logs will be provided to ensure that each participant can check their urine daily for protein. Participants will be instructed to check their urine daily for protein and call their provider within 1 business day for relapses and remissions.
45492988|NCT04075656|Behavioral|UrApp|Caregivers/parents will download UrApp at the baseline visit. UrApp contains instructional videos to guide users. The telephone number of the patient's provider will be entered into UrApp and participants will be able to call their providers directly through UrApp. The email address of the Emory study staff will also be entered. UrApp will automatically e-mail test results to the research staff when elected by the users. Participants will be asked by study staff, and reminded by the app, to call their providers and send urine testing results to the study staff whenever there is a relapse or remission. When the study staff receives alerts of a relapse/remission via UrApp, the information will be communicated to the treating physician within 1 business day.
45492989|NCT02342236|Device|cemented or cementless type of hip prothesis|
46054207|NCT02306382|Procedure|Perianal abscess drainage|The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
46054208|NCT02306382|Device|3D ultrasonography|The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
46054209|NCT04233411|Other|Mycoprotein ingestion|
45382294|NCT05091645|Other|GFI|Two trained raters who will be blinded and will have no access to each other's evaluation, will administer the GFI questionnaire within 24 hours of patients' hospital admission.
46054210|NCT00816166|Device|Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel)|Implantation of one or more balloon-expandable Pharos Vitesse stents to treat neurovascular ischemic lesions + Medical therapy [Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)]
46054211|NCT00816166|Drug|Aspirin and Clopidogrel (Medical therapy)|Medical therapy alone [Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)]
45492992|NCT02342158|Procedure|biopsy or surgical sampling|
45492993|NCT02342158|Other|blood sampling|
45492994|NCT02342080|Other|Training sessions|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period.
45492995|NCT02342080|Device|Lokomat system (Hocoma AG Switzerland)|For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
45492996|NCT05764434|Diagnostic Test|Magnetic Resonance Imaging|Magnetic Resonance Imaging of the spinal cord using radially acquired Averaged Magnetization Inversion Recovery Acquisitions (rAMIRA)
45492997|NCT05462964|Behavioral|Pacifiers Group (İntervention Group 1)|Camera recording was started 2 minutes before OGT placement and only a pacifier was given to the newborn. After the pacifier in the OGT intervention group was placed in the mouth of the given baby in the form of leaking from the mouth, it was inserted by advancing the baby's swallowing reflex from the esophagus to the stomach. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the recording was stopped.
45492998|NCT05462964|Behavioral|Pacifier group sweetened with 25% dextrose (İntervention Group 2)|Camera recording was started 2 minutes before OGT insertion and the newborn was given a pacifier sweetened with 25% dextrose. After the dextrose-sweetened pacifier in the OGT intervention group was placed in the mouth of the baby in the form of a leak from the mouth, it was inserted by advancing the baby's esophagus and then to the stomach with the swallowing reflex of the baby. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the registration was stopped.
45492999|NCT02342002|Drug|Mifepristone|Mifepristone for treatment of missed abortion
45693446|NCT05709184|Combination Product|Lyophilized fecal microbiome transfer|Five days of vancomycin followed by five days of lyophilized fecal microbiome transfer, administered in a loading dose of 15 capsules, and a daily maintenance dose of 10 capsules.
45493000|NCT02342002|Drug|Misoprostol|Misoprostol for treatment of missed abortion
45693447|NCT05709184|Drug|Vancomycin|Ten days of oral vancomycin 125 mg four times daily
45693448|NCT00794170|Behavioral|Telephone and Print based intervention|Thiss intervention consisted of tailored phone calls and follow-up mailings.
45693449|NCT03831334|Drug|oral minoxidil|Participants will be provided with minoxidil (2.5 mg tablets) for 90 days (45 tablets + 5 extra in case of splitting difficulty) of treatment drug in dispensing containers and instructed to take half a pill (1.25mg), once a day.
45693450|NCT03831100|Behavioral|BRIGHT|The BRIGHT intervention consists of 5 weekly, 60-minute, tablet-based, one-one telehealth sessions with a licensed therapist. BRIGHT Therapist: A licensed clinical psychologist with extensive experience managing pyscho-oncologic concerns in patients with HNC will deliver BRIGHT.
45493001|NCT04478110|Behavioral|interactive group education, navigation services and engagement of health care providers for referrals, and linkage to care.|The interactive group education was aimed to increase participant overall understanding of CRC, screening methods, and utilization of available resources such as home test kit and navigation services, with the ultimate goal of increasing screening rates. Clinical partners provided clinical support and ensured successful screening assessment and follow-ups by offering more flexible hours of clinic operation with bilingual medical staff on site. Patient navigation assistance was also offered based on participants' needs. The range of assistance included scheduling appointments with clinical partners for sigmoidoscopy/colonoscopy for screening and diagnosis after a FIT positive result, assisting paper.
45493002|NCT04478110|Behavioral|Education Session on General Health|Participants in the control group received a group education session in a similar format with that of the intervention group delivered by trained Korean community health educators. Different from the intervention group, the education focused on general health education and primary prevention issues, including routine health examinations and screening for various diseases such as cancer. Korean version of work and communication with a physician, and arranging transportation. standard printed materials and guidelines related to the education contents were also provided, including CRC screening guidelines.
45493003|NCT02341768|Device|ICD|ICD single, dual or triple chamber, upgrade, replacement or primo implant
45493004|NCT02341846|Other|Qualitative interviews|
45493005|NCT05230966|Device|Remote Ischemic Conditioning (RIC)|RIC is a non-invasive method that achieves a state of intermittent hypoxia, and is performed by inflating the cuff of the pressure gauge on the left upper arm to 200 mmHg in 4 episodes of five-minute ischemia and reperfusion alternately for 45 minutes.
45493006|NCT02350582|Device|Telerehabilitation eCUIDATE system|Resistence and endurance exercise adapted to individual requeriment during chemotherapy
45493007|NCT02350504|Behavioral|Full interactive instruction|This is a prospective randomized controlled trial in which the level of the child's exposure to instruction is controlled according to the group he is attributed to. The children are divided randomly, each Sunday (the day there is an available anesthesia staff) we change the extent of the instruction. In the intervention group, we use Full interactive instruction- which include an instructional booklet, a movie and a simulator's practice.
45493008|NCT03149536|Diagnostic Test|Pharmacogenetic test|To develop a pharmacogenetic prediction test
45493009|NCT02341690|Other|Interval walking training|"Interval Walking Training with the InterWalk Application An Interval-walking bout will consist of repeated cycles of 3 minutes of fast and 3 minutes of slow walking at 70% and 40% of the smart-phone assessed peak VO2-rate, respectively.~IWT is conducted for at least 60 minutes per day, three days per week. Compliance is monitored continuously using the on-board accelerometer logger"
45493010|NCT02341690|Other|control|Standard care at the promotion centre in the municipality
45493011|NCT03657264|Drug|P03277 0.1 mmol/kg|Single intravenous bolus injection at 2 mL/sec
45493012|NCT03657264|Drug|Moxifloxacin 400mg|One tablet per os
45493013|NCT03657264|Drug|NaCl 0.9%|Single intravenous bolus injection at 2 mL/sec
45493014|NCT03657264|Drug|P03277 0.3 mmol/kg|Single intravenous bolus injection at 2 mL/sec
46054212|NCT02788851|Drug|Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine|Medication is titrated over a 4-week period with stepwise increments each week. Participants and their significant others will complete ADHD symptom scales at baseline and before each medication visit. Participants also complete a side effects scale at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participant will remain on this dose for the remainder of the study. Additionally, once the optimal dose is reached participants will attend 8 weekly educational sessions about ADHD in adulthood.
45493015|NCT02345824|Drug|Ribociclib|CDK4/6 INHIBITOR
46054213|NCT02788851|Behavioral|Aerobic Exercise|Participants will attend a structured aerobic exercise class twice a week for 8 weeks. Each class will last 60 minutes.
46054214|NCT03479580|Other|Patients with a cardiomyopathy|Prognostic value of coronary artery disease and microvascular disease in the different types of cardiomyopathies.
45376672|NCT01021605|Device|Hemolung Respiratory Assist System|Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive or invasive ventilation and then the Hemolung RAS. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
45376673|NCT00640835|Drug|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by sublingual route
45376674|NCT00640835|Drug|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by buccal route
45376675|NCT03839355|Drug|Apixaban|Dosage either 5mg or 2.5mg for 2 years
45376676|NCT03839355|Drug|Warfarin|Dosage assessed by your treating physician for 2 years
45376677|NCT00382018|Drug|chemotherapy|No administration details available
45493016|NCT02345902|Drug|Haloperidol|haloperidol 1.25 mg P.O q.d
45493017|NCT02345902|Other|Placebo|placebo 1.25 mg P.O q.d
45493018|NCT02345902|Other|non-pharmacologic measures|A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)
45493019|NCT05462808|Drug|High viscosity glass ionomer cement|High viscosity glass ionomer cement
45493020|NCT05462808|Device|Stainless steel crown|Stainless steel crown
45493021|NCT03149614|Other|Spine Mobilizations|Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000
45493022|NCT03149614|Other|Vertebral Resonant Oscillation|"The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens ; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992."
45493023|NCT05763654|Device|Linovera emulsion|Apply Linovera emulsion in clinical routine
45493024|NCT02350270|Other|gait and cognitive testing|
45493025|NCT04477954|Combination Product|Hyperbaric Oxygen|Hyperbaric oxygen therapy (HBOT): inhalation of pressurized oxygen through a hyperbaric chamber (Revitalair430)
45376678|NCT00640601|Drug|Quetiapine Fumarate Extended- Release|Open-label seroquel XR tablets: On Day 1 Patients received 300 mg, on Day 2 600 mg, on Day 3 600-800 mg and between Day 4-168 400-800 mg Seroquel XR, according to clinical judgement of investigator. Dose changes were in 200 mg fixed doses. Investigational product (IP) was supplied in open label wallet blister cards and subjects were instructed to take the IP once daily in the evening.
45376679|NCT03838731|Drug|REGN1908-1909|Single subcutaneous (SC) dose of REGN1908 and REGN1909
45376680|NCT03838731|Drug|Placebo|Single subcutaneous (SC) dose of matching placebo
45376681|NCT02551133|Drug|dexamethasone|1 hour before surgery
45376682|NCT00814853|Device|NAVA (Extubation readiness testing failures)|Patients who fail the ERT will be place in the mode of ventilation NAVA.
45376683|NCT00818285|Device|CDS for psychotropic drug management|Computerized decision support (CDS) for patients with available supplies of psychotropic medications. The decision support will consist of a screen displaying to the physician the patient's current risk of falling as well as what their risk could be lowered to with modifications to medications.
45376684|NCT00452439|Drug|Actonel (Risedronate)|35 mg (pill) by mouth weekly
45376685|NCT00452439|Dietary Supplement|Calcium|500 mg by mouth twice a day for a total of 24 months.
45493026|NCT03601806|Other|Laboratory Biomarker Analysis|Correlative studies
45493027|NCT03601806|Drug|Pomalidomide|Given PO
45493028|NCT02345980|Drug|Sildenafil|
45493029|NCT02345980|Drug|Placebo|
46054215|NCT05758324|Dietary Supplement|Nutri PNEA|4 sequences of 10 tablets (one intake)
46054216|NCT05758324|Dietary Supplement|Placebo|4 sequences of 10 tablets (one intake)
45376686|NCT00452439|Dietary Supplement|Vitamin D|400 IU by mouth twice a day for a total of 24 months.
45376687|NCT02550899|Procedure|Transanal submucosal injection group 1|Transanal submucosal injection using an anoscope using four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
45376688|NCT02550899|Procedure|Transanal submucosal injection group 2|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
45376689|NCT02550899|Procedure|Transanal submucosal injection group 3|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
45376690|NCT00814931|Drug|CXB722|900 mg CXB722 oral liquid suspension twice a day for 8 days
45376691|NCT00814931|Drug|Placebo|matching oral liquid suspension placebo twice a day for 8 days
45376692|NCT01023087|Drug|Polymyxin E (Colistin)|Antibiotic medication; dosage to be decided according to infectious disease consultant recommendation.
45376693|NCT01023087|Drug|Non-nephrotoxic antibiotics|To be decided by the infectious disease consultant
45376694|NCT00815009|Behavioral|Mod Fat/Low Processed Carb Diet and Moderate Exercise|Follow a moderate fat with low processed carbohydrate diet with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
45376695|NCT00815009|Behavioral|Low Fat Diet and Moderate Exercise|Follow a low fat diet along with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
46054217|NCT02787915|Biological|DC1-CTL|Autologous cytotoxic of T lymphocytes (CTL) were induced by type-1 polarized dendritic cells (DC1) loaded with MAGE-3/MAGE-4/survivin/ her2 /COX-2 CTL epitope peptides .
46054218|NCT04200027|Procedure|total mesorectal excision|Total Mesorectal Excision Total Mesorectal Excision is currently the standard technique for surgical treatment of RC. It was first described in 1982 by Bill Heald, and relies on the excision of the whole mesorectum within an intact mesorectal fascia, with the contained lymphatic system along with the tumour bearing bowel segment Total mesorectal excision
46054219|NCT05326594|Procedure|Mckenzie Extension Protocol|Mckenzie Extension Exercise Protocol will be performed by participants in prone position
45376696|NCT00815009|Behavioral|Moderate Exercise Only|No special dietary meal plan. Moderate exercise in the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
45376697|NCT00381940|Drug|ifosfamide|Given IV
45376698|NCT00381940|Drug|bortezomib|Given IV
45376699|NCT00381940|Drug|vinorelbine tartrate|Given IV
45376700|NCT00381940|Biological|filgrastim|Given IV or SC
45376701|NCT00818597|Device|EISS|Two six hour-treatments with the EISS-Immune-cell bioreactor device within 72 hours post inclusion.
45376702|NCT00818675|Drug|Lead-In Ridaforolimus|Four 10mg tablets of ridaforolimus once daily for five consecutive days each week followed by 2 days days of treatment holiday, during the 8 week lead in treatment period.
45376703|NCT00818675|Drug|Comparator: Blinded Ridaforolimus|Four tablets of blinded ridaforolimus administered daily for 5 consecutive days each week followed by 2 days days of treatment holiday
45493030|NCT02346058|Drug|Esarin Gel|
45493031|NCT03895320|Behavioral|Sexual Health Risk Assessment|The self-assessment ('Sexual Health Risk Assessment'), will pertain to sexual and reproductive health. The self-assessment, will include a valid clinical prediction tool, established to predict STI positivity.
45493032|NCT03895320|Behavioral|Sexual Health Score|The results of the 'Sexual Health Risk Assessment' will produce a score ('Sexual Health Score'). The 'Sexual Health Score' will be presented as a number (0/10) and will be organized by category: Low, Medium or High Risk.
45493033|NCT03895320|Behavioral|Sexual Health Messaging|After the score ('Sexual Health Score') the participant will receive personalized messaging ('Sexual Health Messaging') that relates to their score and risk level (i.e. Low, Medium or High). Short messages that indicate key steps the person can take to lower their risk for STIs will be displayed on the screen that correspond to their 'Sexual Health Score.'
45493034|NCT03895320|Behavioral|Water SSB Quiz|The self-assessment ('Water SSB Quiz') will pertain to consumption of water, soda and sugar sweetened beverages. There will not be a comparable clinical prediction tool in the control self-assessment ('Water SSB Quiz).
45493035|NCT03895320|Behavioral|Water SSB Score|The results of the 'Water SSB Quiz' will produce a score ('Water SSB Score'). The 'Water SSB Score' will be presented as a number (0/10).
45493036|NCT03895320|Behavioral|Water SSB Messaging|After the score ('Water SSB Score') the participant will receive personalized messaging ('Water SSB Messaging') that relates to their score. Short messages that indicate key steps the person can take to meet the recommended daily intake for water and sugar sweetened beverages will be displayed on the screen that correspond to their 'Water SSB Score.'
45493037|NCT03895320|Behavioral|STI Screening|All participants regardless of group, will be offered a STI screening kit immediately after receipt of their respective program (intervention or control). Participants will have the option of completing the kit at the first study visit, taking it with them after the first study visit is over, or receiving it later from one of our staff either at our local project office or the kit can be dropped off at a location the participant chooses. Completed kits can be returned to our office or picked up by a study staff. (NOTE: while the STI screening kit will be available to all participants should they request it at subsequent study visits, e.g. the 3- and 6-month follow-ups, the STI screening kit will only be explicitly offered by the study team at the first study visit immediately after participants complete their respective quiz).
45376704|NCT00818675|Drug|Comparator: Blinded Placebo|Four tablets of blinded placebo (to match ridaforolimus) administered daily for 5 consecutive days each week followed by 2 days of treatment holiday
45376705|NCT00364156|Drug|Standard Patch Treatment|8-weeks of nicotine patch + 16-weeks of placebo
45493038|NCT02345746|Drug|Oxaliplatin|infusion over 12 hours via HAI
45376706|NCT00364156|Drug|24-weeks of nicotine patch|24-weeks of 21mg nicotine patch
45376707|NCT00818831|Drug|QBI-139|QBI-139 is being administered once a week over a two hour infusion in escalating doses.
45493039|NCT02345746|Drug|Folinic Acid|as a 2-hour infusion via HAI on day 2
45493040|NCT02345746|Drug|5-Fluorouracil|Following Folinic Acid as a continuous infusion over 48 hours on days 2, 3
45493041|NCT03629808|Procedure|4-6cm from starting point of gastrectomy to pylorus|The starting point of gastrectomy of the distance from the pylorus is 4-6cm during operative.
45493042|NCT03629808|Procedure|2-4cm from starting point of gastrectomy to pylorus|The starting point of gastrectomy of the distance from the pylorus is 2-4cm during operative.
45493043|NCT02341612|Other|single exposure at 5°C in CWI|The subjects of this group performed cold water immersion immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
45493044|NCT02341612|Other|single exposure at 15°C in CWI|The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
45493045|NCT02341612|Other|multiple exposures at 10°C in CWI|The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
45493046|NCT02341612|Other|whole body cryotherapy (WBC)|The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
45493047|NCT02341612|Other|passive recovery|The control group was exposed to treatment after the EIMD protocol.
45493048|NCT02341378|Biological|TissueGene-C(Low dose)|TissueGene-C at 6.0x10^6 cells
45493049|NCT02341378|Biological|TissueGene-C(High dose)|TissueGene-C at 1.8x10^7 cells
45493050|NCT03794778|Drug|pegylated liposomal doxorubicin|PLD 30 mg/m2, i.v.,d1; once every 21days
45493051|NCT03794778|Drug|paclitaxel|paclitaxel 175 mg/m2, i.v.,d1; once every 21days
45376708|NCT00452361|Drug|Sirolimus+MMF or MPS or AZA+Steroid|Corticosteroids will be administered according to local practice, within a daily maintenance dosage range of 2.5 to15 mg for prednisone or prednisolone (2 to 12 mg/day for methylprednisolone) or the alternate day equivalent.
45376709|NCT00452361|Drug|Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid|"The maintenance dose of:~MMF will not exceed 1500 mg/day or PMS will not exceed 1080 mg/day~AZA will not exceed 75 mg/day~Thereafter, at the discretion of the investigator, MMF/MPS or AZA may be:~continued for the entire 104-week period of randomized therapy~subsequently discontinued~restarted after discontinuation"
45376710|NCT03334318|Other|Mean blood glucose|Mean of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
45376711|NCT03334318|Other|Blood glucose CV|Coefficient of variation of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
45376712|NCT03334318|Other|% time 70-180 mg/dL|Percent of time with blood glucose in the 70-180 mg/dL range as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
45376713|NCT03334318|Other|% time below 54 mg/dL|Percent of time with blood glucose below 54 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
45493052|NCT03794778|Drug|Carboplatin|carboplatin AUC 5, i.v.,d1; once every 21days,
45493053|NCT03530345|Drug|Neridronic acid 100 mg|100 mg neridronic acid supplied in glass vials in 8 mL of excipients.
45493054|NCT03530345|Drug|Placebo|Glass vials with matching placebo.
45493055|NCT02350114|Procedure|6 Minute Walk Test|Evaluation of walking distance on standardized 6 minute walk test
45376714|NCT03334318|Other|% time above 180 mg/dL|Percent of time with blood glucose above 180 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
45493056|NCT03790332|Drug|Ibrutinib|Ibrutinib capsule, tablet, or suspension administered orally once daily
46054220|NCT05326594|Procedure|Lumbar SNAGs|Lumbar SNAGs will be performed in lumbar flexion and extension in standing Position
45493057|NCT02350192|Behavioral|e-health educational intervention (eHEI)|The e-HEI link (e-health link http://ehealth.nur.cuhk.edu.hk) provides the content of culture-specific cognitive knowledge related to CVD and measures to modify risk factors. The member area and interactive platform of the e-HEI website allows the self-monitoring of individual health and exercise records. Members can view and retrieve their own exercise records daily, and health measures trend regularly.
45376715|NCT03334318|Other|% time above 250 mg/dL|Percent of time with blood glucose above 250 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
45376716|NCT03334318|Other|MAGE (Mean amplitude of glucose excursions)|Mean amplitude of glucose excursions as measured by continuous glucose monitoring as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
45493058|NCT02341300|Device|Cast Iron Pot|Cast iron pot
45493059|NCT02341300|Device|Alumnium Pot|Aluminum Skillet
45493060|NCT05462496|Procedure|Biopsy|Pre-treatment tumor biopsy
45493061|NCT05462496|Drug|FOLFIRINOX|"Patients will receive FOLFIRINOX chemotherapy every 2 weeks for 5 cycles. One cycle of mFOLFIRINOX = 14 days.~Cycles of mFOLFIRINOX are delivered as follows*:~Oxaliplatin: 85 mg/m2 IV over 2 hours on Day 1, followed by,~Irinotecan: 150 mg/m2 IV over 90 minutes on Day 1, followed by,~Leucovorin**: 400 mg/m2 IV over 2 hours on Day 1, followed by,~5FU: 2400 mg/m2 IV over 46-48 hours on Days 1-3"
45493062|NCT05462496|Drug|Ciprofloxacin|Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer ciprofloxacin 500mg PO BID on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
45493063|NCT05462496|Drug|Metronidazole|Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer metronidazole 500mg PO every 8 hours on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
45493064|NCT05462496|Drug|Pembrolizumab|Pembrolizumab will be initiated 7 days post initiation of antibiotics. Subjects will receive a flat dose of pembrolizumab 200mg IV over 30 minutes.
45493065|NCT05462496|Procedure|Surgical Resection|Following completion of 21 days of antibiotics, participant will undergo repeat imaging studies. If there is no progressive disease which renders participant surgically unresectable (based on NCCN guidelines 2.2021), subject will undergo definitive surgical resection.
45493066|NCT02341222|Device|BP self-standing felt device|BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.
46054221|NCT05326594|Device|Inferential therapy|4 pole inferential therapy in combination with superficial heating for 20 minutes
45376717|NCT03334318|Other|LBGI (Low Blood Glucose Index)|Low blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
45376718|NCT03334318|Other|HBGI (High Blood Glucose Index)|High blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
46054222|NCT05326594|Procedure|Heat Therapy|superficial heating for 20 minutes
46054223|NCT02786823|Dietary Supplement|Folic acid|tab. Folic acid 5 mg
46054224|NCT02786823|Dietary Supplement|Vitamin B12|tab. Vitamin B12 500 mcg
46054225|NCT02786823|Drug|Oral hypoglycemic agents [Metformin +/- Sulfonylurea]|"Patients receiving either of the following oral hypoglycemic agents~Sulfonylurea~Metformin~Metformin plus Sulfonylurea"
45493067|NCT02341222|Device|PR Parietene mesh device|Fifteen rats (hereafter defined as BPR16-BPR30 B-group control subjects) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
45493068|NCT03723317|Procedure|Liver transplantation|First deceased-donor liver transplantation
45493069|NCT05462418|Procedure|electrosurgery|incisions completed using use the unipolar diathermy from Whiteline till we reach the parietal peritoneum (cutting the Whiteline then coagulation till reaching the peritoneum). The used diathermy frequency was 50-70 MHz.
45493070|NCT05462418|Procedure|scalpel|patients had their incisions completed using the surgical scalpel till we reach the parietal peritoneum.
45493071|NCT03721211|Drug|[11C]Martinostat|a type of dye used for radiographic imaging of the HDAC protein
45376719|NCT03334318|Drug|Allopurinol|Oral allopurinol tablets administered in the PERL Clinical Trial
45376720|NCT03334318|Drug|Placebo|Oral placebo tablets administered in the PERL Clinical Trial
45693451|NCT03831100|Behavioral|Active Control|AC consists of 5 weekly sessions of videos about HNC survivorship that are delivered using a telemedicine platform. Each AC session (Table 5) is a compilation of shorter videos featuring HNC survivors, caregivers, and oncologists discussing non-body image aspects of HNC survivorship.
45847107|NCT04352010|Behavioral|Res-Up!|Res-Up! is an internet-based intervention focusing on patients' strengths and positive experiences that have effects on distress, protective factors and quality of life. The intervention is based on the Personal Model of Resilience (PMR; Padesky and Mooney, 2012), which is a positive intervention that utilizes patients' strengths to overcome problems.The PMR activates resilient emotions, thoughts, metaphors, images and behaviors in four steps during five sessions about the aquisition of resilient strategies and their use in daily life. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Positive Therapy etc.) are integrated in the program. Participants should work through one module per week. The intervention is conducted as I-CBT via the platform Minddistrict.Res-Up! is administered as a standalone or an add-on treatment to psychotherapy.
46054226|NCT05332314|Drug|NSAIDs|The patients will be given NSAIDs with a reduced dose of the standard opioids treatment.
46054227|NCT03283449|Drug|18F-AV-1451|
46054228|NCT03283449|Device|PET|PET scanner for brain imaging
45376721|NCT00640289|Drug|Fibrogammin P|Prophylaxis treatment
46054229|NCT00815308|Drug|cetuximab (Erbitux)|Cetuximab,injection,loading dose400 mg/m^2,(Day1 in Week1) followed by 250 mg/m^2(Day1, every week for Weeks 2-8)
46054230|NCT00815308|Drug|Paclitaxel|Paclitaxel,injection,loading dose 45 mg/m^2,(Day1 in every week for Weeks 2-8)
45376722|NCT03877809|Drug|Sirolimus 0.5 mg|Daily administration of 1 or more tablets
45376723|NCT00818909|Other|Systane|Systane prescription
45376724|NCT01049932|Drug|TMC278LA|TMC278LA 600mg injected intramuscularly (i/m)
45376725|NCT00818987|Other|Open reduction internal fixation; reduction and immobilization|
45376726|NCT01047670|Drug|Hydrocortisone|Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
45376727|NCT00819065|Drug|Botulinum toxin type A from laboratory Lanzhou|Patients will receive botulinum toxin type A from laboratory Lanzhou either at time of allocation (arm BTA Lanzhou/Allergan) or three months later (arm BTA Allergan/Lanzhou), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of TBA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
45493072|NCT03721211|Device|MR-PET scanner|PET, or positron emission tomography, is a type of imaging test that uses a tracer, or dye, to make detailed pictures showing the activities of the cells that make up tissues and organs
45693452|NCT04843774|Drug|SARS-COV-2 mRNA Vaccine|Pfizer-BioNTech and Moderna messenger RNA (mRNA)-platform vaccines developed against SARS-CoV-2 virus will be given as standard of care (SOC)
45693453|NCT04818268|Behavioral|Adaptation|Sensorimotor adaptation in speech
45693454|NCT04818268|Other|cTBS|continuous theta-burst stimulation
45693455|NCT04383652|Other|Biological sample and clinical data collection|Plasma and serum will be collected at day 0, day 7, day 14, 1 month and 4 months post diagnosis. Clinical data related to COVID-19 diagnosis, symptoms, and outcomes will be collected.
46054231|NCT00815308|Drug|Cisplatin|Cisplatin,injection,loading dose 20 mg/m^2,(Day1 in every week for Weeks 2-8)
46054232|NCT00815308|Radiation|Radiation|Radiation, External beam therapy, total 59.4 Gy , 33 fractions, 1.8 Gy per fraction.(Day 1-Day 5 in every week 2-week 8).
45376728|NCT00819065|Drug|Botulinum toxin type A from laboratory Allergan|Patients will receive botulinum toxin type A from laboratory Allergan either at time of allocation (arm BTA Allergan / Lanzhou) or three months later (arm BTA Lanzhou /Allergan), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of BTA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
45376729|NCT01047748|Drug|intra-fetal digoxin injection|Single transabdominal injection of digoxin 1 mg into the fetus
45376730|NCT01047748|Drug|intra-amniotic digoxin injection|Single transabdominal injection of digoxin 1 mg into the amniotic fluid
45493073|NCT03426072|Other|modified IHI breakthrough series|"There are five main elements to the intervention:~Establishment of the team and set up~Establishing baseline performance and knowledge~Ongoing developmental support~Learning sessions (3)~Action periods (3)~The actual facilitative actions (e.g., coaching, guiding, mentoring, supporting) occur in combination with limited teaching, largely during telephone conferences but also in any visit, which may occur up to quarterly.~5. The concluding session is an opportunity for networking, sharing successes and making plans for the continuation of project work following the end of formal support"
45376731|NCT01047826|Procedure|Minimally Invasive Plate Osteosynthesis|Fractures well be treated with locked plates using M.I.P.O. Technique
45376732|NCT01047826|Procedure|intramedullary tibial Nailing|Fractures well be fixed using intramedullary nails
45376733|NCT00568451|Drug|carboplatin|AUC=2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
45376734|NCT00568451|Drug|paclitaxel|100mg/m^2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
45376735|NCT00568451|Drug|temozolomide|150mg/m^2 at cycle 1, 200mg/m^2 at cycle 2 and beyond, orally on days 1-5. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal. One treatment cycle=four weeks
45376736|NCT00459537|Drug|terbinafine hydrogen chloride|10 % terbinafine hydrogen chloride (HCL)
45376737|NCT00459537|Drug|amorolfine nail lacquer|5 % amorolfine nail lacquer
45376738|NCT00819299|Device|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
45493074|NCT02341066|Device|Endothelial Dysfunction evaluation by EndoPAT|Endothelial dysfunction will be measured assessing reactive hyperemia of digital arteries by using Endo-PAT2000 (Itamar, Israel).
45493075|NCT03726827|Other|Fibroscan screening|A single Fibroscan screening for fat content and liver stiffness
45493076|NCT05764356|Genetic|Detection of genotype and RNA profile in platelet and white blood cell|Detection of genotype by next generation sequencing Detection of RNA profile in platelet and white blood cell by RNA sequencing
45493077|NCT05764356|Other|Indicators test related to coagulation function|Indicators test including prothrombin time (PT), activated partial thrombin time (APTT), thrombin time (TT), diluted TT (dTT), snake vein enzyme coagulation time (ECT), anti-XA or IIa activity, etc.
45493078|NCT05764356|Other|Indicators test related to platelet function|Indicators test related to platelet function. Platelet reactivity was measured by VASP. Platelet aggregation rate was measured by turbidimetric method. Platelet and fibrinolytic function were measured by thrombologram, etc.
45693456|NCT04795336|Drug|Melatonin 5 mg|Melatonin is a widely sold synthetic molecule in various forms including tablets, gummies and liquid. In the present study, the tablet version of the medication will be used at a dose of 5mg
46054233|NCT05261958|Other|SAQ training|interventions listed above were applied on the players which will improve running mechanics and impove speed power and agility in football players
46054234|NCT03251313|Combination Product|JS001 120mg+GP|In this arm, JS001 120mg will be given at d1; Gem 1000mg/m2 d2,9; DDP(cisplatin) 75mg/m2 d2
45376739|NCT03850509|Drug|OPS-2071|OPS-2071 300 mg, tablets, orally, BID.
45693457|NCT04795336|Other|Placebo|The placebo ingredients are Microcrystalline Cellulose, Silica, Gelatin, Titanium Dioxide, Red #3, and Blue #1.
45693458|NCT00809848|Drug|AGN-210669 ophthalmic solution, 0.075%|AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
46054235|NCT03251313|Combination Product|JS001 240mg+GP|In this arm, JS001 240mg will be given at d1; Gem 1000mg/m2 d2,9; DDP 75mg/m2 d2
46054236|NCT03251313|Combination Product|JS001 480mg+GP|In this arm, JS001 480mg will be given at d1; Gem 1000mg/m2 d2,9; DDP 75mg/m2 d2
45376740|NCT03850509|Drug|Placebo|OPS-2071-matched placebo, tablets, orally, BID.
45376741|NCT00635999|Behavioral|Applied relaxation and self-control desensitization|Applied relaxation and self-control desensitization sessions will teach participants relaxation techniques and the use of imagery for coping with anxiety. Treatment will include 14 weekly sessions.
46054237|NCT03251313|Combination Product|GP followed by JS001|In this arm,Patients receive 6 cycles of GP without JS001 and then receive JS001 maintenance therapy for up to approximately 2 years. JS001 will be given at RP2D.
46054238|NCT01039376|Biological|Ofatumumab|Ofatumumab for maintenance therapy as IV infusions every 8 weeks . The first dose was 300 mg followed 1 week later by 1000 mg and 1000 mg every 8 weeks thereafter for up to 2 years.
46054239|NCT01039376|Other|Observation|Observation/Safety Evaluation
46054240|NCT04729686|Other|Pericapsular Nerve Block|Per Standard Institutional Practice
46054241|NCT04729686|Other|Fascia Iliaca Nerve Block|Per Standard Institutional Practice
45493079|NCT02345668|Behavioral|Emotion Regulation Protocol|Emotion Regulation Protocol is an Internet-based Self-administered Protocol for emotional disorders, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in twelve modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
45376742|NCT00635999|Other|Cognitive therapy (CT)|CT sessions will teach participants to identify ways in which they perceive themselves and the world and how to modify these thoughts to reduce anxiety. CT will include 14 weekly sessions.
45493080|NCT02345668|Drug|Treatment as Usual (Pharmacological Treatment)|The Pharmacological Treatment provided by a psychiatrist in the mental health unit.
45493081|NCT02345668|Behavioral|Treatment as Usual (Psychological Treatment)|The Psychological Treatment provided by a clinical psychologist in the mental health unit.
45493082|NCT03500159|Drug|AQX-1125 200 mg|Synthetic SHIP1 activator
45493083|NCT03500159|Drug|Placebo|Appearance and weight matched tablets without the active product ingredient
45493084|NCT02345278|Drug|SUBLIVAC FIX Mite mixture|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
45493085|NCT02345278|Other|Placebo|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
45493086|NCT03785340|Drug|Brimonidine Tartrate|Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks.
45493087|NCT03785340|Drug|Placebos|Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks.
45493088|NCT02345590|Drug|Eplerenone|25mg of eplerenone
45493089|NCT03499067|Device|Test lens|Contact lens
45493090|NCT03499067|Device|Control lens|Contact lens
45493091|NCT02345200|Procedure|bioelectrical impedance analysis|electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
45493092|NCT02345200|Procedure|blood draw|blood samples are taken at 8 am in order to pay attention to the circadian rhythmicity to get a detailed hormonal status
45493093|NCT05462184|Behavioral|Cognitive-Behavioral Therapy (CBT)|
45493094|NCT05462184|Behavioral|Acceptance and Commitment Therapy (ACT)|
45847108|NCT04352010|Behavioral|REMOTION|REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as a standalone or an add-on treatment to psychotherapy.
45847109|NCT04352010|Other|Wait-Control Group|In the waiting control group participants will answer questionnaires and they will gain access to either REMOTION or Res-Up! after twelve weeks.
45847110|NCT04280952|Device|CONVIVO|tumor tissue with the CONVIVO system
45847111|NCT04238754|Drug|Epidiolex 100 mg/mL Oral Solution|8 mL of Epidiolex (800 mg of cannabidiol) + 16 mL of inactive cherry syrup delivered every 12 hours for 48 hours total (4 doses)
45376743|NCT00635999|Behavioral|Cognitive-Behavioral Therapy|Includes all of the techniques in the other 2 interventions.
45376744|NCT03866421|Diagnostic Test|MR spectroscopy of the liver|Magnetic resonance spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD
45376745|NCT03866421|Diagnostic Test|Fibroscan of the liver|Transient Elastography for Measurement of liver fibrosis.
45376746|NCT03866421|Device|Continuous glucose monitoring (CGM) for four days.|CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.
45376747|NCT03866421|Diagnostic Test|Oral glucose tolerance test (OGTT)|OGTT with incretin hormones. Measured for three hours.
45493095|NCT03146182|Behavioral|CRP-algorithm|a strategy based on CRP guided antibiotic stewardship
45493096|NCT03146182|Behavioral|PCT-algorithm|a strategy based on PCT guided antibiotic stewardship
45493097|NCT03723083|Drug|CC-2001|CC-2001 will be administered orally
45493098|NCT03774810|Drug|Zolpidem tartrate|Zolpidem Tartrate, 5mg for men older than 60 and women of all ages. 10 mg for men younger than 60.
45493099|NCT03348540|Behavioral|Attention Control Training|Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).
45493100|NCT03348540|Behavioral|Comparison Task|Neutral- neutral stimuli prior to response task
45376748|NCT03866421|Diagnostic Test|Intra venous glucose infusion (IIGI)|This test is combined with the OGTT to compare responses of parenteral vs enteral stimulation. The test is followed by a bolus of 5 g of L-arginin.
45376749|NCT03866421|Radiation|Dual Energy X-ray Absorptiometry (DEXA) scan|DEXA-scan of the body composition.
45376750|NCT03866421|Biological|Blood samples|Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.
45376751|NCT03866421|Other|Clinical and demographic data|Measurements of blood pressure, pulse, height, weight.
45376752|NCT00819377|Drug|Milrinone|inhaled milrinone 5 mg (as for the injectable solution)
45376753|NCT00819377|Drug|Normal saline|5 ml normal saline by inhalation over 15 min
45376754|NCT01023165|Procedure|Humulin, Humalog, Novolog|Supervising Physician reviews patient activation after intravenous bolus insulin treatment each week and adjusts the amounts of insulin and carbohydrates to be given in the next treatment session based on patient treatment outcomes.
45376755|NCT01025895|Procedure|acl reconstruction - double bundle technique|
45493101|NCT03562481|Drug|1% Buffered Lidocaine 1:100,000 Epinephrine|A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.
45493102|NCT03562481|Drug|2% Unbuffered Lidocaine 1:100,000 Epinephrine|A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.
45493103|NCT02349880|Behavioral|shared decision making training|
45376756|NCT01025895|Procedure|acle reconstruction - single bundle technique|
45376757|NCT01023243|Other|Brochure: Care of the Feet for Those at Risk|Patient education materials and key messages for care of the feet for those patients at risk
45376758|NCT01023243|Other|Quality Survey: foot exam, tobacco and aspirin use|NCQA Patient Survey
45376759|NCT01023321|Drug|GLPG0555|single ascending doses, oral solution
45376760|NCT01023321|Drug|placebo|single dose, oral solution
45376761|NCT01023321|Drug|GLPG0555|multiple dose, oral solution, 7 or 14 days
45376762|NCT01023321|Drug|placebo|multiple dose, oral solution, 7 or 14 days
45376763|NCT03762915|Drug|minocycline HCl microspheres|Minocycline HCl microspheres, 1 mg are approved by the Food and Drug Administration (FDA) as an adjunct to SRP procedures for reduction of pocket depth in patients with adult periodontitis.
45376764|NCT00469209|Drug|Trisenox (Arsenic Trioxide)|0.25 mg/kg by vein over 2 hours, once a day for 7 days (Days -9 to -3).
45376765|NCT00469209|Drug|Velcade (Bortezomib)|"Arm 1 (Level 1):~1.0 mg/m^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).~Arm 2 (Level 2):~1.5 mg/m^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute)."
45376766|NCT00469209|Drug|Melphalan|100 mg/m2 by vein days -4,-3, over 30 minutes
45493104|NCT04029298|Behavioral|Lifestyle Interventions|Educational based intervention to enhance lifestyle modifications such as diet, exercise, patient activation, and medication adherence
45493105|NCT03760224|Other|WhatsApp group|WhatsApp group will allow real-time group discussion for 8 weeks
45493106|NCT03760224|Other|SMS group|SMS group for 8 weeks
45693459|NCT00809848|Drug|AGN-210669 ophthalmic solution, 0.05%|AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
45376767|NCT00469209|Drug|Vitamin C (Ascorbic Acid)|1000 mg once a day through the vein for 7 days.
45376768|NCT01322919|Procedure|Supracor|"All patients will undergo LASIK treatment on their non-dominant eye with a new laser software algorithm designed to treat both the distance and near vision components.~The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. This part of the treatment does not show any difference to a regular LASIK treatment for ametropic cases.~In addition to the treatment for the distance vision a central ablation component will be added to address the near vision."
45376769|NCT00635219|Drug|Placebo|capsules; daily; orally
45376770|NCT00635219|Drug|Vortioxetine (Lu AA21004)|2.5 mg/day; encapsulated tablets; orally
45376771|NCT00635219|Drug|Vortioxetine (Lu AA21004)|5 mg/day; encapsulated tablets; orally
45376772|NCT00635219|Drug|Vortioxetine (Lu AA21004)|10 mg/day; encapsulated tablets; orally
45376773|NCT00635219|Drug|Duloxetine|60 mg/day; encapsulated capsules; orally
45376774|NCT03987477|Behavioral|Interpretation bias modification program|Brief online program aimed at the modification of negative interpretation biases.
45376775|NCT03987477|Behavioral|Waiting list|Waiting list procedure for the control group.
45493107|NCT03726593|Drug|Artesunate and Pyronaridine|Standard weight based dosing
45493108|NCT03726593|Drug|Atovaquone Proguanil and Artesunate Pyronaridine|Both drugs (AP) and (ASPY) are administered once a day, on days 0, 1, and 2.
45493109|NCT03726593|Drug|Atovaquone Proguanil and Artesunate Mefloquine|Sequential treatment with ASMQ (on days 0, 1, and 2) followed by the treatment with AP for 3 more days (total 6 days treatment)
45493110|NCT04007224|Drug|Intranasal oxytocin|daily administration of oxytocin, 10 UI intrnasal, 5 UI bid, and if needed curcumin orally 250 mg bid, and/or lecithin 500 mg bid, and/or pironoquinolinquinone, 20 mg qd
45847112|NCT04238754|Other|Cherry Syrup Oral Solution|20 mL of inactive cherry syrup delivered every 12 hours for 48 hours total (4 doses)
45847113|NCT04185792|Diagnostic Test|NBSS, Qualiveen and SF-Qualiveen|NBSS, Qualiveen and SF-Qualiveen are self-reported questionnaires.
45376776|NCT00363766|Drug|LY573636-sodium|A loading dose to target 420 micrograms/milliliter (µg/mL) maximum concentration (Cmax) or 380 µg/mL Cmax followed by a lower chronic dose to maintain Cmax within these target ranges, intravenous, every 21 days until disease progression.
45376777|NCT00468819|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|In an open-label design, all patients will receive a total dose of 0.1 mmol/kg BW Gadovist 1.01 Days Injection
45376778|NCT01026129|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0,25 mcg/kg given once before emergence of general anesthesia.
45376779|NCT01026129|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
45376780|NCT01026129|Drug|lidocaine|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
45376781|NCT01026207|Device|Polysomnography|Sleep study polysomnography compared with portable monitoring
45376782|NCT01026285|Drug|Risperidone Long-Acting injectable or oral antipsychotics|According to label
45376783|NCT01026363|Drug|Ergocalciferol|Ergocalciferol 50,000 IU capsule, one dose every other day x 5 doses
45493111|NCT04007224|Biological|Autologous umbilical cord blood|patients aged between 3 and 7 years will receive one-time intravenously the processed umbilical cord blood collected at the respective child's birth
45493112|NCT05664893|Drug|Ribociclib Oral Tablet|"600mg per day during registration phase (3 cycles); de-escalation phase (600 to 200mg per day associated to radiotherapy) during 3 other cycles; maintenance phase until 24 months of treatment in total (600mg per day).~All over th etimme, hormonotherapy is received in concomitance"
45493113|NCT03971266|Device|Activity Monitor|Wear a Fitbit
45493114|NCT03971266|Other|Media Intervention|Complete smartphone based PRO diary
45376784|NCT01026363|Drug|Calcitriol|0.25 mcg tablet once daily for 14 days
45376785|NCT01026441|Device|Vela100 (Aesthetic)|6 treatments once a week
45493115|NCT03145948|Drug|ABBV-553|It is administered orally.
45493116|NCT03145948|Drug|Placebo|It is administered orally.
45847114|NCT04076202|Device|Cementless Vanguard DD RP|Patients treated with the Cementless Vanguard DD RP knee implant
45376786|NCT01322997|Device|Myomo e100 Robot and repetitive task specific training|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include about 1/2 an hour of use of a robot that targets arm function and assists with the movement of the affected arm, and about 1/2 an hour of repetitive task specific training (TRP) using the affected arm.
45493117|NCT03197064|Drug|Fosaprepitant 150 mg|Antiemetic used to prevent nausea and vomiting after general anesthesia.
45493118|NCT02345044|Drug|CS-3150|
45493119|NCT02345044|Drug|placebo|
45493120|NCT02345044|Drug|eplerenone|
45847115|NCT04017468|Drug|Vancomycin|Patients randomized into the treatment arm will receive 1-2 g of vancomycin powder (Vancocin® i.v.) which will be administered above the closed muscle fascia (suprafascially) before closing the subcutaneous tissue and skin. The dose of the drug will depend on the length of the skin incision: 1 g for incisions ≤ 20 cm, 2 g for incisions ≥ 20 cm.
45847116|NCT03947814|Drug|Pimodivir|Participants will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
45493121|NCT03529409|Behavioral|Project Khanya|This treatment involves integrating a behavioral intervention for substance use with a behavioral intervention for adherence.
45493122|NCT02345122|Behavioral|Intervention: Mental Health Technician|In addition to structured assessments at baseline, four, eight and twelve months (the results will be shared with their Primary Care Provider), subjects will receive psychoeducation regarding their depression, anxiety, and alcohol use disorder or at-risk drinking; symptom monitoring; and medication adherence support. Their Primary Care Provider will also be provided evidence-based recommendations regarding their treatment.
45493123|NCT02345122|Other|Enhanced Usual Care|Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve months. The results will be shared with their Primary Care Provider.
45376787|NCT01322997|Behavioral|Repetitive task specific training (RTP) targeting the affected arm|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include consist of repetitive task specific training (RTP) using the affected arm, in which patients use the arm to relearn valued movements using their arms.
45693460|NCT00809848|Drug|AGN-210669 ophthalmic solution, 0.025%|AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
45693461|NCT00809848|Drug|bimatoprost ophthalmic solution 0.03%|Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
46054242|NCT04200183|Behavioral|iACTwithPain (ACT+compassion)|This intervention will deliver a eHealth ACT and compassion-based therapy (iACTwithPain) designed for chronic pain
46054243|NCT04200183|Behavioral|ACT-only intervention|This intervention will deliver the iACTwithPain intervention but without the delivery of explicit compassion.
46054244|NCT02610712|Drug|Ketamine|
46054245|NCT02789085|Device|ULF TENS stimulation|
46054246|NCT00705952|Other|Lifestyle intervention|Diet, exercise and behavioural change intervention.
46054247|NCT00905034|Drug|Methotrexate|200 mg/m^2 by vein on days 1 and 15.
45376788|NCT01322997|Device|Myomo e100 neurorobotic brace|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. Subjects will use a robot that targets arm function and assists with the movement of the affected arm.
45376789|NCT01023399|Drug|Artesunate + Amodiaquine|Artesunate + Amodiaquine fixed dose combination
45376790|NCT01026519|Drug|REGN88|Single dose of REGN88 and 43 day follow up.
45376791|NCT01026519|Other|Placebo|Placebo to match REGN88 administration
45376792|NCT00451191|Drug|botulinum toxin type A (BoNT/A)|100 unit and 300 unit dosages: Dilute each 100 U vial with 1.3 ml of normal saline. Each reconstituted vial is then drawn up into a single syringe with a total of 4 ml = 300 U. The instrument used to inject the botulinum toxin is an ultrasound device with a transrectal ultrasound probe specially designed for prostate biopsies which has a special canal to introduce and direct a needle in to the selected prostatic area.
45376793|NCT00451035|Drug|LBH589|
45376794|NCT00468585|Drug|Capecitabine|
45376795|NCT00468585|Drug|Bevacizumab|
45376796|NCT01021839|Procedure|Grafts placement|Graft placement (upper or lower extremity); surgical or radiographic revision as needed.
45376797|NCT01026597|Drug|REGN727|5 IV cohorts (dose 1, 2, 3, 4, and 5)
45376798|NCT01026597|Drug|Placebo|5 IV cohorts (dose 1, 2, 3, 4, and 5)
45376799|NCT00450801|Drug|Rituximab|Rituximab 375 mg/m2 IV, Days 1 of all cycles
45376800|NCT00450801|Drug|Cyclophosphamide|Cyclophosphamide 800 mg/m2 IV, Day 1, Cyclophosphamide 200 mg/m2 IV Days 2 - 5, Cycles 1 and 3. Cyclophosphamide will be given in 100 cc NS IV over 30 minutes.
45376801|NCT00450801|Drug|Cytarabine|Cytarabine 2 grams/m2 IV every 12 hours x 4 doses, Days 1 and 2, Cycles 2 and 4.
45376802|NCT00450801|Drug|Doxorubicin|Doxorubicin 45 mg/m2 IV bolus, Day 1, Cycles 1 and 3
45376803|NCT00450801|Drug|Etoposide|Etoposide 60 mg/m2 IV daily x 5 days, Cycles 2 and 4
45376804|NCT00450801|Drug|Ifosfamide|Ifosfamide 1.5 grams/m2 IV once a day (QD) x 5 days, Cycles 2 and 4
45376805|NCT00450801|Drug|Leucovorin|Leucovorin 180 mg/m2 IV beginning 36 hours after start of methotrexate infusion and then 12 mg/m2 IV every 6 hours until methotrexate level is below 0.01 nM. Day 10, Cycles 1 and 3.
45376806|NCT00450801|Drug|Methotrexate|Methotrexate 1,200 mg/m2 in 250 cc 5 percent dextrose in water (D5W) IV over 1 hour followed by Methotrexate 5,520 mg/m2 in 1,000 cc D5W by continuous infusion over 23 hours (240 mg/m2 every hour for 23 hours). Day 10, Cycles 1 and 3.
45376807|NCT00450801|Drug|Thalidomide|Maintenance therapy.
45493124|NCT02350036|Other|ultrasound monitoring|Uterine artery Doppler assessment
45493125|NCT03722771|Behavioral|Inhalation|lavender oil inhalation in a separate room for 3 minutes prior to surgery
45493126|NCT03722771|Other|Anxiety Questionnaires 1|Modified Dental Anxiety Scale was used to describe the level of the dental anxiety.
45493127|NCT03722771|Other|Anxiety Questionnaires 2|State-Trait Anxiety Inventory-State Scale was used to distinguish the true anxiety level of the patients from the anxiety level for a particular situation.
45493128|NCT03722771|Diagnostic Test|Vital Signs 1|Changes in vital signs 1 - blood pressure - before, during and after the procedure were noted.
45493129|NCT03722771|Diagnostic Test|Vital Signs 2|Changes in vital signs 2 - respiratory rate - before, during and after the procedure were noted.
46054248|NCT00905034|Drug|Vincristine|1.4 mg/m^2 by vein (maximum dose 2 mg) on days 1, 8 and 15.
46054249|NCT00905034|Drug|PEG-l-asparaginase|2500 International units/m^2 by vein on days 2 and 16
46054250|NCT00905034|Drug|Dexamethasone|40 mg by vein or by mouth daily days 1-4 and 15-18.
45376808|NCT00450801|Drug|Vincristine|Vincristine 1.5 mg/m2 IVP (maximum of 2 mg), Day 1 and 8 , Cycles 1 and 3.
45376809|NCT00450801|Drug|Mesna|Mesna 360 mg/m2 IV every 3 hours x 5 days, Cycles 2 and 4
45376810|NCT00450801|Drug|Filgrastim (G-CSF)|G-CSF 480 mcg subcutaneous (SQ) starting Day 13 (Cycles 1 and 3), Day 7 (Cycles 2 and 4)
45376811|NCT00450801|Drug|Granisetron|Granisetron 1 mg IV on Day 1, Cycle 1 and 3
45376812|NCT00450801|Drug|Decadron|Decadron 10 mg IV on Day 1, Cycles 1 and 3
45376813|NCT01023555|Other|1cc of blood in a single aerobic culture bottle|The efficacy of using 1cc of blood in a single aerobic bottle for cultures in neonatal bacteremia will will be compared with the traditional 0.5cc of blood in 2 Bottles
45376814|NCT01023633|Drug|Oxaliplatin, LV, 5-FU|"Arm B(Intervention arm) will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles.~FOLFOX4 regimen:~OXA 85mg/m2 , 2 hour infusion, d1 , Leucovorin 200 mg/m2 plus 5-FU 400mg IV bolus, then continuous 22 hour 600 mg/m2 infusion on day 1 and 2 Q2W"
45376815|NCT01026675|Procedure|50 g oral glucose challenge test - 75 g oral glucose tolerance test|50 g oral glucose challenge test at 6-13 weeks of gestation and 75 g oral glucose tolerance test at 24-28 weeks of gestation.
45376816|NCT00458211|Drug|ziprasidone|Ziprasidone by mouth 40mg twice a day (bid) for one day, then 80mg bid; may be increased to 120mg bid after three weeks
45376817|NCT00450723|Drug|Isosulfan blue|Administered pre-surgery; injection of 2 cc of Isosulfan Blue in four equal aliquots of 0.5 cc as routinely done for the axillary sentinel node procedure.
45376818|NCT00450723|Procedure|Axillary Lymph Node Dissection|Axillary Lymph Node Dissection
45376819|NCT00450723|Procedure|Surgery|The surgery will be performed under general anesthesia with a single lumen endo-tracheal tube. The patient will be laid in a semi decubitus position on the opposite side with the ipsilateral arm bent over the head and attached to an arm rest.
45376820|NCT00450723|Procedure|Sentinel Lymph Node Biopsy|Sentinel Lymph Node Biopsy
45376821|NCT00450723|Procedure|Thoracoscopic Surgery|Performed only if internal mammary sentinel node cannot be retrieved via same incision of lumpectomy/mastectomy.
46054251|NCT00905034|Drug|Rituximab|Rituximab 375 mg/m^2 by vein on days 1 and 15 (first 4 cycles) for patients CD20 positive or positive by immunostain.
46054252|NCT03195777|Device|PET/CT|PET/CT imaging will be performed (with fluorodeoxyglucose, [FDG] as a tracer). Thereafter, subjects will be monitored for development of PTS. We will then assess the ability of PET/CT top predict the subsequent development of PTS.
46054253|NCT02611804|Drug|Diclofenac sodium|
46054254|NCT02611804|Drug|Diclofenac sodium|
46054255|NCT02611804|Drug|Placebo|
45376822|NCT00450723|Radiation|Technetium Tc 99m Sulfur Colloid|Two to three hours prior to surgery, a peritumoral injection of filtered Technetium Sulfur Colloid will be performed in four 0.25 mci/2cc aliquots
45376823|NCT01026753|Behavioral|Refrigerator Magnet|The refrigerator magnet contains a telephone number for a Provincial Health Contact Centre and a URL for a colorectal cancer Website that patients can access to learn more about colorectal cancer, screening and the fecal occult blood test. Patients can also have their questions answered.
45493130|NCT03722771|Diagnostic Test|Vital Signs 3|Changes in vital signs 3 - heart rate - before, during and after the procedure were noted.
45376824|NCT00467961|Combination Product|Miltenyi system|Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach.
45493131|NCT03722771|Diagnostic Test|Vital Signs 4|Changes in vital signs 4 - saturation - before, during and after the procedure were noted.
45376825|NCT03996213|Other|head down position|Head-down position will be achieved by 30 degrees tilting of the whole operating table 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
45493132|NCT02349802|Drug|Auto-injector with exenatide suspension|A flexible study design to accommodate multiple cohorts.
45376826|NCT03996213|Other|leg elevation position|Leg elevation position will be achieved by raising the patient legs for 30 cm using two standard pillows positioned under the heels 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
45376827|NCT04889157|Drug|PF-06882961|Participants will be administered active doses, taking 3 tablets twice daily (BID) for 8 weeks except Day 1 (QD)
45376828|NCT04889157|Drug|Placebo|3 matching placebo tablets taken twice daily (BID) except Day 1 (QD)
45376829|NCT00457821|Drug|Ivacaftor 25 mg/75 mg|25 mg or 75 mg q12h for a total of 28 days (Part 1)
45376830|NCT00457821|Drug|Ivacaftor 75 mg/150 mg|75 mg or 150 mg q12h for a total of 28 days (Part 1)
45376831|NCT00457821|Drug|Ivacaftor 150 mg or 250 mg|150 mg or 250 mg of ivacaftor q12h for 28 days (Part 2)
45376832|NCT00457821|Drug|Placebo|Given q12h for 28 days each in Part 1 and Part 2 of the study
45493133|NCT02349802|Drug|Syringe with exenatide suspension|A flexible study design to accommodate multiple cohorts.
45376833|NCT00633893|Drug|Apixaban|Tablets, Oral, twice daily, 12 months
45376834|NCT00633893|Drug|Placebo|Tablets, Oral, twice daily, 12 months
45493134|NCT03145714|Drug|Maintainance of anesthesia with Intravenous Propofol infusion|The dosage of Intravenous Propofol will be titrated to maintain BIS Values between 40 -60.
45376835|NCT02550587|Behavioral|satisfaction|anesthesia satisfaction rates
45376836|NCT02550665|Drug|donepezil|using different titration method for the first 4 weeks, and after the 4 weeks, 23mg/day orally
45493135|NCT03145714|Drug|Maintainance of anesthesia with Intravenous Dexmedetomidine|The dosage of Intravenous Dexmedetomidine will be titrated to maintain BIS Values between 40 -60.
45376837|NCT00819455|Behavioral|Experimental|Active Life style modification-motivation by I.T technology
45376838|NCT00819455|Behavioral|Control arm (usual care/standard care arm)|Life style modification only once
45376839|NCT00819533|Device|sensor (ActiSight™ Needle Guidance System)|Patients will have their lung sample obtained under CT and ActiSight needle guidance system
45376840|NCT00819611|Behavioral|Cogmed Working memory training|15 minutes of working memory training, 5 days a week for a period of 5 weeks
45376841|NCT00819611|Behavioral|Control version of Cogmed working memory training|15 minutes of 'sham' working memory training, 5 days a week for a period of 5 weeks
45376842|NCT04044677|Device|tDSC-active|10 sessions of active Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of sham Transcranial Direct Current Stimulation
45376843|NCT04044677|Device|tDCS-sham|10 sessions of sham Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of active Transcranial Direct Current Stimulation
45376844|NCT00819845|Drug|carvedilol|carvedilol vs ramipril
45493136|NCT03498287|Device|Study Device|Real study device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks).
45493137|NCT03498287|Device|Sham Device|Sham device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks). *Note: participants in the sham group are given the real study device at the end of the Post-Treatment/Follow-up Phase.
45493138|NCT02349724|Biological|Anti-CEA-CAR T|T cells modified with CEA targeted chimeric antigen receptor.
45493139|NCT02939820|Drug|patisiran (ALN-TTR02)|patisiran (ALN-TTR02) administered by intravenous (IV) infusion
45493140|NCT03721055|Radiation|18F-(2S,4R)4-fluoroglutamine|Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
45493141|NCT05254522|Other|not aplicable since it is a Registry|not aplicable since it is a registry
45493142|NCT05763420|Device|AH Plus Bioceramic Sealer|A bioactive, calcium silicate-based sealer will be used in combination with the core root canal filling material (gutta-percha). It's premixed and is dispensed in the root canal via a fine disposable syringe.
46054256|NCT04233333|Device|method of fixation of the orogastric tube|Methods of fixation of the orogastric tube will be randomized
46054257|NCT02157636|Drug|CPI-0610|
46054258|NCT00706108|Behavioral|Observational study|Observational (descriptive) study of technical and non-technical performance
46054259|NCT00706186|Drug|Sodium Oxybate|The patient will maintain a dosage of 4.5 g/day for a duration of 7 days leading to Treatment Visit 1. After successful assessment at Treatment Visit 1, the dosage will be increased to 6 g/day for the duration of the trial. At Treatment Visit 2 (day 21), the dosage will be increased to a dosage of 9 g/day, if tolerated by the patient.
45376845|NCT00819845|Drug|ramipril|carvedilol vs ramipril
45493143|NCT05763420|Device|AH Plus Sealer (resin-based)|A resin-based sealer will be used in combination with the core root canal material (gutta-percha). It consists of two pastes that are mixed together in equal amounts prior to application.
45493144|NCT02349958|Device|HIPEC: MMC 30mg @ T0, 10mg @ T45min|MMC 30mg @ T0, 10mg @ T45min for Appendix, Psuedomyxoma, colorectal, small bowel
45493145|NCT02349958|Device|HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0|Gastric and Pancreato-biliary HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min
45847117|NCT03797586|Other|Electroacupuncture group|Bilateral Tianshu (ST25), Fujie (SP14), Shangjuxu (ST37) will be used in the EA group. With the local skin of the patients was routinely sterilized in a prone position in relaxation, acupuncturists will insert needles into the acupuncture points. For ST25 and SP14, 0.30×50mm or 0.30×75mm needles will be vertically inserted to the muscle layer of the abdominal wall, where participants will feel sharp pain and acupuncturists will feel resistance from the needle tip. For ST37, 0.30×40 mm needles will be vertically inserted approximately 15 mm deep, followed by three-time manipulation of even lifting and twisting method to elicit the sensation of deqi. Then paired alligator clips of the EA apparatus will be attached to the needle holders of the bilateral ST25, SP14, and ST37. EA stimulation will be retained for 30 minutes with a continuous wave of 10 Hz and current intensity of 0.5 to 4 mA.
45493146|NCT02349958|Device|HIPEC: CDDP 75 mg/m2 @T0|Ovarian/peritoneal/fallopian tube, Uterine CDDP 75 mg/m2 @T0
45493147|NCT02349958|Device|HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0|CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0 Mesothelioma and Sarcoma
45493148|NCT04894266|Drug|Apabetalone|Apabetalone 100mg BID
45493149|NCT04894266|Other|Standard of care|Standard of Care
45493150|NCT04872426|Other|Exercise, insulin infusion|Acute one-legged exercise, Insulin infusion 3 hours after one-legged exercise
45493151|NCT02039284|Device|SES|SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted three times per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove for 20-30 minutes and arm with wrap for 20-30 minutes. The pulse width was set to 300 us for all stimulation levels. The frequency was set to 40-50 Hz.
45493152|NCT02039284|Device|VCT|The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.
45493153|NCT02039284|Device|VRCIT|VRCIT group received the VRCIT training in addition to traditional rehabilitation, conducted three times per week, for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training.
45376846|NCT00819923|Device|Percutaneous coronary intervention|Intra-coronary stenting
45493154|NCT02039284|Device|traditional rehabilitation program|The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
45376847|NCT00819923|Device|Percutaneous coronary intervention|Intra-coronary stenting
45376848|NCT00820001|Behavioral|Booster Treatment|Based on this collective evidence, booster treatment was designed to address three general goals: a) clarify key child and parent/family problems and family preferences regarding target problems, b) directly target and resolve these existing problems using the eight domains contained in the existing treatment protocol administered in the initial outcome study, and c) provide the family with clinical recommendations and information to promote the maintenance of skill developments in targeted domains or adaptive routines designed to prevent any further deterioration in clinical functioning. Thus, the clinician may provide a review of prior content or administer new material specifically for older adolescents, as needed, and will attempt to apply these skills to specific problematic situations identified by the family.
45376849|NCT00820001|Behavioral|No-Booster|All cases randomized to this condition will simply participate in all of the proposed routine assessments and will receive assessment feedback. Specifically, these families will be provided with a brief summary of the significant clinical findings obtained in their 36-month follow-up assessment (assessment feedback). Such an assessment was provided to clinicians in the original study in order to highlight specific areas in need of clinical attention based on a review of the normative data and clinical cutoffs available for each instrument. Selected information will be conveyed by phone to the participating parent/guardian in a straightforward manner followed by a discussion of some clinical recommendations designed to address these clinical problems. In addition, the parent/guardian will be provided with a listing of professionals who provide services appropriate for this age group and for children with similar problems.
45376850|NCT00820001|Other|No intervention|No intervention was administered with this arm. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
45847118|NCT03797586|Other|Sham electroacupuncture group|Bilateral sham ST25, SP14, and ST37 will be used in the SA group. After sterilizing the skin, 0.30×40mm needles will be straightly inserted at the sham points about 2-3mm until they can be fixed on the skin when attached by the alligator clips. No manipulation will be used, and no deqi sensation are elicited for all sham points. The bilateral sham ST25, SP14, and ST37 points will be attached by the same EA apparatus with a continuous wave of 10 Hz and current intensity of 0.1 to 0.2 mA for 30 minutes with only the initial 30 seconds on.
45376851|NCT00820001|Other|Treatment As Usual|All cases assigned to this arm simply participated in all of the proposed routine assessments.
45376852|NCT00457743|Drug|Sunitinib malate (SU011248)|SU011248
45847119|NCT03770130|Drug|Dexmedetomidine|Dexmedetomidine, a selective α2-adrenoceptor agonist which is widely used as an adjuvant to general anaesthesia
45847120|NCT03770130|Drug|Saline|Saline, a kind of crystalloid widely used in clinical treatment
46054260|NCT04232865|Device|Biop System|"Stage 1 - Training:~Up to 320 women in whom a complete procedure with the Biop System will be performed. Biopsies will be taken solely based on colposcopy examination. Enrolled participants will include at least 80 participants Histopathology identified with a high-grade lesion and at least 80 participants Histopathology identified as normal or with a low-grade lesion.~Stage 2 - Validation:~Up to 330 HIV negative women in whom a complete procedure with the Biop System will be performed.~Validation stage will also include up to 165 HIV positive participants. All participants will be enrolled in up to 3 sites in South Africa."
46054261|NCT02611492|Drug|Nilotinib|400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase
46054262|NCT02611492|Drug|Methotrexate|1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase
46054263|NCT02611492|Drug|Aracytine (Ara C)|Age<45 years: 3 mg/m2/12h D2, D3 cycles 2 and 4 Age>=45 years: 1.5 mg/m2/12h D2, D3 cycles 2 and 4
45376853|NCT00820079|Drug|ADX10059|oral administration
45847121|NCT03759834|Device|Cochlear promontory stimulation|Promontory stimulation is an established otologic procedure that was initially developed as a diagnostic tool to assess patient candidacy for cochlear implantation. Promontory stimulation is most commonly performed in the outpatient setting on an awake patient by placing a single insulated probe through a topically anesthetized tympanic membrane and applying monopolar current for several seconds to minutes. The initial session of promontory stimulation will define optimal stimulation parameters (i.e., location, current level, pulse-width, phase polarity), where maximal tinnitus suppression occurs with minimal or no auditory percept. Additional stimulation testing visits will confirm these findings.
45376854|NCT00820079|Drug|ADX10059 Matching Placebo|oral administration
45847122|NCT03758664|Drug|ICP-192|"Drug: ICP-192 Dose levels will be escalated following accelerated titration and modified 3+3 dose escalation scheme,"
45847123|NCT03694626|Device|Pupillography|A hand-held pupillometer/electroretinogram device (RETeval, LKC) will be held in front of the subject's eye, but will not touch the eye. The device will provide a brief, a series of brief light stimuli and then record the pupil response and the elicited electrical response from the retina from a surface skin patch (electrode) placed below each eye, from the light as a measure of whether the inherent sensitivity of the eye in the retina is normal. The investigators will repeat this in the left eye. The visible light stimulus is safe and is given at an intensity experienced in normal daily light exposures. The test takes about 2 minutes per eye.
45493155|NCT04806594|Device|Papix acne scar|PapiX acne scar, class IIa medical device, gel for acne scar. to be applied 2 times per day during the 8 weeks of study duration
45493156|NCT02344888|Drug|Clomiphene citrate and Prednisolone|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of the cycle) and prednisolone (5 mg/day for 10 consecutive days from day 2 of the cycle)
46054264|NCT02611492|Drug|Granulocyte Colony-Stimulating Factor (G-CSF)|5µg/kg/d (SC) D6 until neutrophils > 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4
45493157|NCT02344888|Drug|Clomiphene citrate and folic acid|Women will receive clomiphene citrate alone (150 mg/day for 5 consecutive days from day 2 of the cycle) and folic acid (0.5 mg/day for 10 consecutive days from day 2 of the cycle)
45493158|NCT02921022|Drug|Gemcitabine|
45493159|NCT02921022|Drug|Nab-paclitaxel|
45493160|NCT02921022|Drug|PEGPH20|
45693462|NCT00809848|Drug|AGN-210669 vehicle ophthalmic solution|AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
45753973|NCT04023032|Behavioral|multicomponent cognitive intervention|"The intervention takes place in groups of 6-10 participants and is leaded by one occupational therapist. It includes 16 sessions, 90 minutes each.~The first part of each session starts with a 15-minute review of previous homework or relaxation. The second part, which lasts 35 minutes, involves structured training with activity-sheets, board games, role-playing and computerized games. The third part, which lasts 30 minutes, is the lifestyle interventions. The instructor explains the generalization of the previous activities toward daily life, and introduces healthy lifestyles. Through group discussions, the therapist guides participants to develop solutions and strategies for their memory or cognition-related problems and application to daily life. The last 10 minutes are used to suggest homework."
46054265|NCT02611492|Drug|Depomedrol|40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1
46054266|NCT02611492|Drug|Dexamethasone|40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3
46054267|NCT02611492|Drug|Vincristine|2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3
46054268|NCT02611492|Drug|Imatinib|300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years
45376855|NCT00820157|Procedure|Cytoreductive Surgery|Cytoreductive Surgery followed by TACE for MNHCC
45376856|NCT00820157|Procedure|TACE|TACE alone or TACE followed by downstage resection for MNHCC
45376857|NCT00820313|Behavioral|Dr. Dean Ornish Program for Reversing Heart Disease|"Exercise: At least 3 hours of aerobic exercise per week, 30 minutes per session. Additionally, patients are asked to perform a minimum of 2 strength training sessions per week.~Stress Management: Integrates stretching, relaxation, breathing techniques, meditation and guided imagery. Patients are asked to practice these techniques at least 1 hour per day.~Diet: Approximately 10% daily calories from fat, 15% protein and 75% complex carbohydrates (low-fat, whole foods, primarily plant-based).~Group Support: Weekly group support sessions provide social support to help patients adhere to and sustain the lifestyle-change program."
45376858|NCT04044599|Drug|Gynoflor|VAGİNAL GYNOFLOR
45376859|NCT01023867|Drug|donepezil|from 5mg to 10mg, once a day, 12 months
45376860|NCT00820391|Behavioral|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
45376861|NCT00820391|Behavioral|Meditation-Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
45376862|NCT03696303|Other|Urinary antigen detection assay|Screening for Ag level in S. pneumoniae urinary antigen detection assay.
45493161|NCT02349334|Device|Percutaneous Tibial Nerve Stimulation|
45493162|NCT03497429|Drug|Niraparib|Niraparib capsule
46054269|NCT02611492|Drug|6 Mercaptopurine (6MP)|60 mg/m2 per os, D1 to D14, interphase
45847124|NCT03694626|Device|Ocular Coherence Tomography (OCT)|The thickness of the optic nerve and macula will also be measured inside of the eye using a special camera that forms an image of the layers of the retina without pupil dilation. The imaging is harmless and measures the structural health of the optic nerve and retinal layers. This test takes 5-10 minutes per eye.
45376863|NCT00820469|Drug|Rituximab 375|rituximab 375 mg/m2 IV weekly, during 4 weeks
45376864|NCT00820469|Drug|rituximab 1000|rituximab 1000 mg IV, two infusions on day 1 and day 15
45376865|NCT00450411|Radiation|125-Iodine|Brachytherapy to the prostate via 125-iodine (I-125) seeds with a planned dose of 140 Gy
45376866|NCT00450411|Radiation|103-palladium|Brachytherapy to the prostate via 103-palladium (Pd-103) seeds with a planned dose of 120 Gy
45376867|NCT00815243|Procedure|Telemedicine consultation|Standard synchronous or asynchronous telemedicine consultations according recommendations and best practice models of ISfTeH
45376868|NCT00815243|Procedure|Treatment plan|Treatment plan include diagnostic tests (physical examination, laboratory tests, xray, CT, MRI), medications and surgical treatment (debridements, osteosynthesis, arthroplasty, ORIF etc)
45753974|NCT04961359|Biological|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
45753975|NCT04961359|Biological|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.
45376869|NCT02551289|Other|Gluten free diet|Patients will follow a gluten free diet
45376870|NCT00815321|Biological|Autologous CIK cell infusion|4 CIK cells will be infused into patients at regular 3-weekly intervals for 4 infusions. The target cell dose per infusion is 1x10e10 CD3 cells. For patients with uncontrolled accelerated or blastic transformation undergoing chemotherapy, this will be given at the nadir of lymphopenia following chemotherapy. For other patients this will be given without interruption of the ongoing treatment with Imatinib or other kinase inhibitor.
45847125|NCT03694626|Device|Wrist-watch sensor device|A wrist-watch sensor device (E4, Empatica) will be place on each wrist to measure skin conductance, heart rate, skin temperature and arm movement during testing. These wrist-watch devices are being used to monitor changes in sympathetic nerve activity to light intensity, (the sympathetic nerves supply the blood vessels to the skin and heart).
45376871|NCT00815399|Drug|Pioglitazone|15-45 mg/die
45376872|NCT00815399|Drug|Metformin|500-2000 mg/die
45376873|NCT00644969|Drug|placebo|Randomization 2:1 treatment to placebo
45376874|NCT00644969|Drug|varenicline (CP-526,555)|One week of titration up to 1mg bid and 11 weeks of dosing at 1mg bid
45376875|NCT00815477|Behavioral|Web-based lifestyle counseling messages|10 email messages based on readiness-to-change over a 4 month period
45376876|NCT00815477|Behavioral|Generic Information|Waitlist control plus educational material on lifestyle behavior and hyptertension
45376877|NCT02551445|Behavioral|Gradual exposure to food stimuli|Patients with anorexia nervosa will be encouraged to confront their fears and avoidance in relation to food and will be gradually exposed to different food items during the sessions.
45376878|NCT00815555|Other|There is no intervention - this is an observational study|
45493163|NCT02762604|Behavioral|Imagined Gait Intervention|Phone-based imagined gait intervention: participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
45493164|NCT02762604|Behavioral|Visual Imagery Intervention|Phone-based visual imagery intervention: participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
45376879|NCT00815789|Behavioral|Tailored cardiovascular risk management (Nurse-administered )|A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
45376880|NCT04016909|Procedure|aerobic exercise plus calorie restriction|both a 6-month aerobic exercise program (moderate intensity) and caloric restriction (12.5% energy deficit)
45376881|NCT00812279|Other|Distillation based smoking article (SMAR cigarette)|Subjects randomised to the SMAR arm will be trained by the site staff on the usage of SMAR and the corresponding lighter prior to smoking the first SMAR. Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times but have to request each SMAR from the site staff when they wish to smoke.
45376882|NCT00812279|Other|conventional cigarette|Subjects randomised to the CC arm will continue to smoke their preferred CC brand during the exposure period. Subjects will be allowed to smoke without any limit on consumption during the designated smoking times but will have to request each CC from the site staff when they wish to smoke.
45376883|NCT00812279|Other|smoking cessation|Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
45376884|NCT04046081|Drug|Dichloroacetate|6.25 mg/kg BD for 6 weeks increasing to 12.5 mg/kg BD for 6 weeks
45376885|NCT00812435|Drug|eptifibitide|Patients will be randomized to eptifibatide or no eptifibatide. If randomized to eptifibatide: 180 mcg/kg Bolus; 2 mcg/kg/min infusion immediately prior to primary PCI or at the time of PCI and for 18 - 24 hours following the PCI Second 180 mcg/kg Bolus 10 min after the first
45376886|NCT00812513|Drug|R-Pdf/Gbb 0.01% gel|rhPDGF 0.01% gel is applied to the wound, then covered with dressing once daily for 3 months
45376887|NCT00812591|Procedure|OGTT and CLAMP|"Oral Glucose Tolerance Test (OGTT):~Oral glucose tolerance test combined with subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.~Hyperinsulinemic euglycemic clamp (CLAMP):~Hyperinsulinemic euglycemic clamp with simultaneous subcutaneous insulin delivery and glucose sampling using microdialysis and microperfusion probe."
45376888|NCT00812747|Other|observation|
45376889|NCT00820547|Biological|bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 8 cycles During adjuvant phase:15 mg/kg, d1 q3w, 10 cycles
45493165|NCT03146104|Drug|Propofol|Intraoperative anesthesia will be maintained using propofol 100-150 mcg/kg/min, oxygen and air and FiO2 of 40% in propofol group (GROUP P)
46054270|NCT00706576|Drug|Infusion of opioid growth factor|Volunteers will be treated with an intravenous infusion of opioid growth factor(OGF) starting at 100 µg/kg with a 50 µg/kg dose escalation with each succeeding group. The investigational drug, OGF, will be diluted in sterile saline to its appropriate concentration based upon the body weight of the volunteer and administered in a volume of 60 ml over 45 minutes (rate of 2 ml/min)
45376890|NCT00820547|Drug|cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
45493166|NCT03146104|Drug|Isoflurane|in(GROUP I) maintenance will be done with 1 MAC of isoflurane, oxygen and air and FiO2 of 40%.
45493167|NCT04752150|Other|Analgesia management; group ESPB and RIB|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
45376891|NCT00820547|Drug|docetaxel|Neoadjuvant: 100 mg/m2 q3w, 4 cycles
45376892|NCT00820547|Drug|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
45493168|NCT05254444|Behavioral|Social marketing|Multi-tiered nutrition social marketing intervention focused on sustainable fish nutrition, dietary diversity and food safety.
45493169|NCT05254444|Behavioral|social marketing + gear modification|Multi-tiered nutrition social marketing intervention plus fishing gear modification (basket trap) and training.
45493170|NCT04682340|Diagnostic Test|Serum BPA|Serum BPA levels will be compared between women with autoimmune thyroid disease and normal women.
45493171|NCT05254366|Drug|Remimazolam Tosilate for Injection|Remimazolam Tosilate for Injection
45493172|NCT05254132|Procedure|Liquid biopsy|Participants in the aRECIST group will undergo a blood draw for liquid biopsy analysis at baseline and follow up visits
46054271|NCT02788071|Dietary Supplement|FMT capsules|25 capsules per day for 12 days
46054272|NCT02788071|Dietary Supplement|FMT placebo|25 capsules per day for 12 days
46054273|NCT00828568|Drug|Imiquimod 5% manufactured by Taro|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
46054274|NCT00828568|Drug|Aldara - Imiquimod 5%|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
46054275|NCT00828568|Drug|Imiquimod Vehicle manufactured by Taro|Treatment applied as a thin layer to target area once daily, 2 days each week, for 16 weeks
45376893|NCT00820547|Drug|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
45376894|NCT00815867|Drug|epoetin beta (NeoRecormon ®)|"comparison of administration of high dosage of epoetin vs no administration of epoetin~30000 UI: 4 injections"
45376895|NCT00820625|Procedure|pulmonary vein isolation|common pulmonary vein isolation procedure
45376896|NCT00820625|Procedure|pulmonary vein isolation with additional ablation of fragmented potentials|common pulmonary vein isolation with additional but also common ablation of fragmented potentials
45376897|NCT02550509|Device|ultrasound echogenicity|ultrasound echogenicity to patient with stroke
45376898|NCT02550509|Device|elastography|elastography to patient with stoke
45376899|NCT00815945|Drug|PegLiposomal Doxorubicin|PegLiposomal Doxorubicin, intravenous, 40mg/m², every 28 days for up to 6 months
45376900|NCT00815945|Drug|Carboplatin|Carboplatin, intravenous, AUC 6, every 28 days for up to 6 months
45376901|NCT00820703|Drug|Nexagon®|
45376902|NCT00820703|Drug|Nexagon® vehicle|
45493173|NCT05254054|Other|whole body vibration|The whole body vibration is used when vibrations (mechanical oscillations) of a certain frequency are transferred to the human body. Humans are exposed to vibration through a contact surface that is in a mechanical vibrating state. It has been considered as an alternative and safe method for neuromuscular training and may be incorporated into current neuromuscular rehabilitation programs so as to enhance muscle recovery
45493174|NCT05254054|Other|Conventional exercise training|A set of conventional exercises designed for ACL rehabilitation
45493175|NCT03497039|Drug|Diclofenac Diethylamine (DDEA) gel|Diclofenac Diethylamine (DDEA) gel consists of 2.32% DDEA. DDEA gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of study treatment will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery.If surgery is delayed by up to 7 days dosing with DDEA gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
45493176|NCT03497039|Other|Placebo gel|Placebo gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of placebo gel will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery. If surgery is delayed by up to 7 days dosing with placebo gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
45376903|NCT00820781|Procedure|Portacaval shunt|Subject taken to the operating room and undergoes portacaval shunt surgery
45376904|NCT00820781|Procedure|Sclerotherapy|Subject taken to Endoscopy Suite and undergoes endoscopic sclerotherapy
45376905|NCT00644423|Drug|Omega-3 Fatty Acid|One capsule three times per day x 1 day (325mg EPA/225mg docosahexaenoic acid (DHA) tid) Two capsules three times per day x 1 day (650mg EPA/450mg DHA tid) Three capsules three times per day thereafter (975mg EPA/675mg DHA tid)
45376906|NCT00644423|Drug|Placebo|Matching Placebo
45493177|NCT02340910|Procedure|Short Duration|During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 6 minutes of WBV at a frequency of 50 Hz.
45376907|NCT00820859|Behavioral|TREA (Treatment Routes for Exploring Agitation)|Individualized non-pharmacological treatment plan for agitation
45376908|NCT00820859|Behavioral|Placebo Control Group|A presentation on the treatment of behavior problems in dementia given to the staff caregivers of the comparison group
45376909|NCT04644497|Procedure|ACL-reconstruction|Surgery technique in skeletally immature patients
45376910|NCT00812825|Drug|PF-04171327|PF-0417327 will be provided as an oral solution administered at doses of 1, 3, 10 and 30 mg. If an additional cohort is required, the dose selected will not exceed 100 mg. Solution will be administered once daily for 14 days.
45376911|NCT00812825|Drug|Prednisolone|Oral doses of prednisolone (5, 10, and 20 mg) will be administered to the first three cohorts. The fourth cohort will receive between 1 and 20 mg to be determined after the third cohort completes dosing. If an additional cohort is required, the dose selected will not exceed 40 mg. Prednisolone tablets will be administered once daily for 14 days
45376912|NCT00812825|Drug|Placebo|Tablets similar in appearance to prednisolone will be administered once daily for 14 days.
45376913|NCT00812825|Drug|Placebo Solution|Placebo solution will be administered to those volunteers who are randomized to the placebo or prednisolone arms. This will be administered orally each day for 14 days.
45376914|NCT00812825|Drug|PF-04171327 Tablet|A single 10 mg dose of PF-04171327 tablet formulation will be administered orally to volunteers in Part 2 of this study.
45376915|NCT00820937|Procedure|Single photon emission computed tomography and Magnetic Resonance Imaging|
45376916|NCT00628355|Drug|lidocaine|Women randomized for this treatment was submitted to 2mL of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point. Patients received lidocaine injections once a week for 4 weeks
45376917|NCT00628355|Procedure|Ischemic compression|Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation(TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
45376918|NCT00627497|Procedure|Single-Level Posterior Decompression|The single level posterior decompression is a posterior surgical procedure.
45376919|NCT00627497|Device|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach.
45376920|NCT00627497|Device|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach
45376921|NCT00627497|Device|Fusion|Posterolateral Interbody Fusion
45376922|NCT00648167|Drug|ferric citrate|ferric citrate will be provided as a 375mg capsule. Dosing and frequency are dependent on patient's serum phosphorus levels. Dosing will occur over the 28-day study.
45376923|NCT00812903|Behavioral|Exercise|Training exercises chosen with background in knowledge of intelligent training
45376924|NCT03691623|Drug|EDP-938 Dose 1|Oral suspension for 5 days
45376925|NCT03691623|Drug|EDP-938 Dose 2|Oral suspension for 5 days
45376926|NCT03691623|Drug|Placebo|Oral suspension for 5 days
45376927|NCT03691623|Drug|EDP-938 Dose 3|Oral suspension for 5 days
45376928|NCT03691623|Drug|EDP-938 Dose 4|Oral suspension for 5 days
45376929|NCT03691623|Drug|Placebo|Oral suspension for 5 days
45376930|NCT00647699|Drug|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
45376931|NCT00647699|Device|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
45376932|NCT00813059|Drug|Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)|Pars plana intra-vitreal injection of bevacizumab (1.25 mg/0.05 ml)
45376933|NCT01323075|Procedure|Truncal block|Patients will have a truncal block during hand or wrist surgery.
45376934|NCT00467649|Drug|pramlintide acetate (Symlin)|subcutaneous injection (60 mcg or 120 mcg), immediately prior to major meals
45376935|NCT00467649|Drug|rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])|subcutaneous injection, dosing based on titration guidelines
45376936|NCT00467649|Drug|basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])|subcutaneous injection, dosing based on titration guidelines
45376937|NCT01023945|Drug|ASP1941|oral
45376938|NCT01023945|Drug|Placebo|oral
45376939|NCT00450333|Drug|Dynepo (Epoetin delta)|subcutaneous, BIW for 24 weeks
45376940|NCT00450333|Drug|Dynepo|subcutaneous, QW for 24 weeks
45376941|NCT00450333|Drug|Dynepo|subcutaneous, QW for 24 weeks
45493178|NCT02340910|Procedure|Long Duration|"During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 12 minutes of WBV at a frequency of 50 Hz.~Interventions will occur for a total of 20 sessions over 4 consecutive weeks ."
45376942|NCT00450333|Drug|Dynepo|subcutaneous, Q2W for 24 weeks
45376943|NCT00643565|Drug|Standard chemotherapy|As prescribed
45376944|NCT00643565|Drug|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of 9 x 3-week cycles, followed by 5 mg/kg iv on days 1 and 15 of each 4-week cycle
45376945|NCT00643487|Procedure|observation of the behavior of the infrapatellar plica|Local anesthesia using bupivicaine will be initiated. The IPP, if present will be injected with contrast material. In order to minimize discomfort, lidocaine 1%, in as small a volume as possible, will be injected into the fat pad under direct vision to avoid any intra-articular damage from the #25 needle. Radiographic visualization will be verified and the knee taken through a full range of passive and active exercises. Active quadriceps contraction in the subject will be performed at 0, 15, 30 60 and 90 degrees of flexion. In so far as is technically possible, the behavior of the IPP will be videotaped and recorded on lateral fluoroscopy.
45376946|NCT00816179|Procedure|Transgastric diagnostic endoscopic peritoneoscopy|Endoscopic abdominal exploration utilizing an endoscopically created gastrotomy.
45376947|NCT02551211|Procedure|blood drawn|blood drawn
45493179|NCT04871087|Device|Green Light|"The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10lux)narrow band (20nm) green light (peak wavelength 520nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k). However, we believe that light likely also has benefits for sleep. To better understand its effects,we are planning to conduct the proposed study. In that context, the Allay Lamp would be considered an investigational medical device because it has not been cleared or approved by FDA for the intended purpose of treating sleep. No FDA submission should be necessary for this study using 21 C.F.R. 812.3, because the Allay Lamp is a non-significant risk (NSR) device:~It is not an implant It is not intended for use in supporting or sustaining human life The Allay Lamp provides a very low risk light-based therapy. The light provides no more risk than any other table lamp available on the market today."
45493180|NCT02349490|Device|Seraseal / Fastact Hemostatic agent (combined activated factors IIa, VIIa, IXa, Xa )|Following endoscopic confirmation of a bleeding, 2,5-5ml of liquid Seraseal / Fastact, is topically applied to the bleeding site via catheter
45376948|NCT02551211|Procedure|surgical resection of cancer|
45376949|NCT00450255|Biological|ziv-aflibercept|Given IV
45376950|NCT00450255|Other|pharmacological study|Correlative studies
45376951|NCT00816335|Procedure|PET/CT scan|For all patients undergoing a preoperative PET/CT scan on the day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained on a Siemens Biograph 16 PET/CT scanner (Siemens, Knoxville, TN).
45376952|NCT00816335|Drug|18F-FDG Injection|Patients undergoing a preoperative PET/CT scan the day of surgery, are required to have fasted for at least 4 hours prior to the anticipated preoperative PET/CT scan. Patients participating in this pilot study (whether they have had their preoperative PET/CT scan prior to the day of surgery or whether they are having their preoperative PET/CT scan on the day of surgery) will receive a preoperative IV injection into a peripheral vein of 15 mCi of 18FFDG at time interval of approximately 60 to 180 minutes prior to anticipated time of surgery.
45376953|NCT00816335|Procedure|Preoperative 18F-FDG PET/CT Scan|Patients undergoing preoperative PET/CT scan day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained. PET imaging will immediately be preceded by noncontrast transmission CT (for attenuation correction and anatomic correlation purposes) and will be obtained from the base of the skull to the mid thighs. Bed positions will be scanned for 3 minutes each, moving the patient through the scanner in a craniocaudal direction. Once the preoperative PET/CT scan is acquired, images will be reviewed by the nuclear medicine physician and the surgeon.
45376954|NCT00816335|Drug|18F-FDG for patients with Bladder Cancer|Elimination of 18F-FDG by the urinary system and accumulation in the bladder impacts the differentiation between residual 18F-FDG in the bladder and activity in tumor and adjacent lymph nodes. For patients with bladder cancer, the urinary catheter routinely placed in the operating room will be inserted in the Ambulatory Surgery Unit (ASU) by the urologist on-service or the urology research nurse. A 3-way Foley catheter will be placed for continuous bladder irrigation with Normal Saline (0.9%) initiated in ASU and will continue for the duration of the imaging procedure at a standard rate of 10cc/minute. The urology research nurse will transport the patient to and from the PET/CT area and monitor the continuous bladder irrigation during the imaging session.
45376955|NCT00816335|Procedure|Surgical Procedure|Previously determined operative procedure based on type of solid malignancy. Factors include extent and location of disease, physiologic status of patient intraoperatively, any technical considerations influenced by anatomic constraints, and a risk: benefit analysis of proposed procedure. The decision to proceed with resection on these factors, and will constantly re-evaluate during resection to ensure patient well-being, both short and long term, is foremost consideration. Evaluation of extent of disease during surgical exploration will include inspection and palpation of entire area being evaluated. Tissue that is highly suspicious for involvement with metastatic disease that alters the surgical decision making plan of resection will be biopsied or resected for histologic confirmation if feasible and safe. If patient is found to have resectable disease, deemed safe patient, surgeon will continue and proceed with definitive surgical resection with assistance of handheld gamma probe.
45376956|NCT00816335|Procedure|Specimen PET/CT Scan|Resected surgical specimen will be placed on top of paraffin block. Digital photos of the specimen will be obtained for visual correlation of specimen placement on paraffin block. Two bed position 10 minute specimen PET/CT scan will be performed on surgical specimen. If remnant tissue is available, a second image maybe acquired via MRI. Images will be processed and reviewed for quality and presence or absence of hypermetabolic foci and correlated with anatomical information provided by CT and MRI imaging that were originally noted in the preoperative clinical PET/CT scan. During the time when the excised surgical specimens are transported to radiology for specimen PET/CT scanning, additional evaluation of these ex-vivo specimens with other tumor detection devices may be undertaken. Specimen will then be transported back to the operating room in order to be sent to and processed by surgical pathology for standard pathologic evaluation.
46054276|NCT01038752|Drug|Suramin Drug:Docetaxel Drug: Carboplatin|Suramin dosage will be determined by nomogram and administered over 30 minutes. Suramin is followed by docetaxel (56 mg/m2, administered over 1 hour), followed by carboplatin (dosage calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
45376957|NCT00816413|Drug|cyclosporine|2 mg/kg IV over 2 hours every 12 hours starting at 0700 on days -1, 0, and +1 (total of six doses).
45376958|NCT00816413|Drug|mycophenolate mofetil|15 mg/kg orally twice a day starting day 0 until day +27 then stopped without tapering in the absence of aGVHD then tapered over two months in the absence of aGVHD. Doses will be rounded to the nearest 250 mg.
45376959|NCT00816413|Drug|pentostatin|4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0).
46054277|NCT01038752|Drug|Placebo Drug: Docetaxel Drug: Carboplatin|Placebo (100 ml of 0.9% sodium chloride or 5% dextrose in water) will be administered over 30 minutes, followed by docetaxel (75 mg/m2, administered over 1 hour), followed by carboplatin (dose calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
46054278|NCT04233021|Drug|Osimertinib|Osimertinib 80 mg/d
45376960|NCT00816413|Genetic|cytogenetic analysis|At days +28 and +70 post-transplant, patients' blood will be evaluated for CD3 and overall WBC chimerism.
46054279|NCT00627380|Behavioral|Yoga lifestyle intervention|Sixteen weeks of 2-3 yoga sessions per week, 1.5 hrs per session administered by a certified yoga instructor. Sessions include breathing exercises and yoga postures/positions.
46054280|NCT00627380|Other|Standard of care|Participants are observed/followed for 16 weeks during which lifestyle and medication changes are discouraged, unless medically necessary.
46054281|NCT00903630|Drug|Lenalidomide|administered by mouth at the assigned dose daily for each 28 day cycle
45376961|NCT00816413|Genetic|fluorescence in situ hybridization|Mixed chimerism is defined as the detection of 95% or less donor T cells (CD3+), expressed as a proportion of the total T cell and WBC population as measured by DNA.
45376962|NCT00816413|Genetic|protein analysis|Blood samples will be at baseline(day -11 or before) , days -8 and -1, prior to transplant on day 0, then weekly (days +7, +14, +21 and +28) post-transplant through day +28. Five ml's of blood will be drawn at each collection through a central line using heparinized vaccutainers. Samples will be spun down at 1200 g and plasma aspirated and stored in -80 oC until analyzed for the ELISA Assays being done for research purposes in this protocol.
45376963|NCT00816413|Other|flow cytometry|Peripheral blood Peripheral blood flow cytometry for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
45376964|NCT00816413|Other|immunoenzyme technique|Peripheral blood for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
45376965|NCT00816413|Other|laboratory biomarker analysis|Donor mononuclear cells from the stem cell product (SCP) obtained with apheresis will be analyzed for surface markers, including CD3, CD4, CD8, CD19, CD14, CD56, TCR+CD8+ cells, Th/c1 and Th/c2, Fas and FasL, and DCs, as well as for apoptosis
45376966|NCT00816413|Other|reduced-intensity transplant conditioning procedure|"Allopurinol 300 mg orally once daily x 10 days, to begin one day prior to treatment with Pentostatin (day -11 to day -2) .~Pentostatin 4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0) .~Pre and Post Pentostatin Hydration: 1000ml Normal Saline IV over 2 hours pre each dose of Pentostatin and 1000ml Normal Saline IV over 4 hours post each dose of Pentostatin on days -10, -9, -8.~Pre Pentostatin Recommended Antiemetics: Ondansetron 32 mg IV over 30 minutes to be given 30 min. before each dose of Pentostatin on days -10, -9, -8. Alternative ondansetron equivalent or other ancillary antiemetics may be used at the discretion of the treating physician.~Pred Forte Eye Drops: two drops in each eye every 4 hours while awake x 7 days after starting Pentostatin (day -10 to day -4)."
45376967|NCT00816413|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Each patient will receive up to four IV infusions administered over 30 minutes of donor T cells at increasing cell doses given at intervals.
45376968|NCT00816413|Procedure|peripheral blood stem cell transplantation (PBSC)|PBSC are infused intravenously either by infusion or IV push on day 0 through a secure intravenous access (i.e. the double-lumen central catheter place pre transplant) according to institutional guidelines.
45376969|NCT00816413|Radiation|total-body irradiation|2.0 GY will be administered on day -1. Total-body irradiation (TBI) will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. It is anticipated that TBI will be given on day -1; however, the timing of TBI administration may be altered by factors beyond the control of the Principal Investigator because of the delivery of unrelated donor stem cells.
45376970|NCT00450177|Drug|Ferrous Sulfate|Iron group
45376971|NCT00450177|Drug|Placebo Oral Tablet|Placebo group
45376972|NCT00816569|Device|Orthokeratology contact lenses|Wearing Orthokeratology lens in one eye of a keratoconus patient
45376973|NCT00813137|Drug|Folfox4 plus recombinant human endostatin (Endostar)|Endostar 15mg iv drip D1~7, D15~21, Oxaliplatin 85mg/m2 iv drip D1,15, CF 200mg/m2 iv drip D1,2,15,16, 5-Fu 400mg/m2 iv D1,2,15,16, 5-Fu 600mg/m2 civ D1,2,15,16
45376974|NCT00813215|Dietary Supplement|Meal challenge|Meal challenge with a test meal rich on saturated fat.
45376975|NCT00813215|Dietary Supplement|Meal challenge|Meal challenge with a test meal rich on monounsaturated fat
45376976|NCT01024023|Device|EWA|Suitable participants randomised to the treatment arm to receive early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
45376977|NCT00816647|Procedure|Patellofemoral stabilizing surgery|Comparison of surgical techniques
45376978|NCT01024179|Device|Polymer-based sirolimus-eluting stent (Partner stent )|Partner stent (polymer-based sirolimus-eluting stent) implanted in culprit coronary artery
45376979|NCT00821483|Drug|Frovatriptan|2.5mg, qd
45376980|NCT01021995|Drug|echinacea|drops, 0.9 ml, tid for 4 months
45376981|NCT01021995|Drug|placebo|drops, 0.9 ml tid for 4 months
45376982|NCT02551367|Drug|Letrozole|2.5 mg will taken from day 2 to day 6 of the cycle , for 3 consecutive cycles
45376983|NCT02551367|Drug|Clomiphene citrate|50 mg twice daily orally from day 2 to day 6 , for 3 consecutive cycles
45376984|NCT02551367|Drug|hcg hormone|10.000 iu im injection when follicle diameter reach 18 mm by transvaginal ultrasound
45376985|NCT00813371|Device|Airway Pressure Release Ventilation|Airway Pressure Release Ventilation (APRV) also known as Bi-Vent or Bi-Level ventilation is a time-cycled, pressure-limited mode of ventilation that allows spontaneous respiration throughout the ventilator cycle.
45376986|NCT00813371|Device|ARDSnet protocol|ARDSnet protocol
45376987|NCT03848949|Device|Evenup|Orthotic which increases effective leg length.
45376988|NCT00821561|Drug|Nexagon®|
45376989|NCT00821561|Drug|Nexagon® vehicle|
45376990|NCT00821639|Behavioral|Counseling, educational pamphlet and a sticker|Infants exposed to secondhand smoke will be recruited and randomized based on parents to receive or not receive counseling, an educational pamphlet and a sticker on SHS.
45376991|NCT00813449|Drug|dacarbazine plus Endostar (Experimental group)|dacarbazine plus Endostar
45376992|NCT00813449|Drug|dacarbazine plus placebo (control group)|dacarbazine plus placebo
45376993|NCT00816725|Behavioral|Mothers and babies Internet course and PPD informational brochure|An eight-lesson, self-help, Web-based program for the prevention of postpartum depression based on cognitive behavioral therapy, social-learning, and attachment theory. The PPD informational brochure is a four-page pamphlet that contains information about postpartum depression.
45376994|NCT00821717|Drug|Ferinject ® (Ferric carboxymaltose)|"Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase)."
45376995|NCT00821717|Drug|Normal saline (0.9%)|During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
45376996|NCT00822029|Drug|FOSAMAX|patient receiving one tablet (oral use) 70 mg Fosamax by week
45376997|NCT00822029|Other|PLACEBO|patient receiving one tablet (oral use) placebo by week
45493181|NCT03720899|Drug|NicoBloc|For Session 1, participants will use one drop of NicoBloc (which will block 33% of tar and nicotine) on their conventional cigarette and then will smoke this cigarette in session. Following smoking, they will discuss the effects of the NicoBloc on their withdrawal, cravings, and overall enjoyment of their cigarette. To bolster their in vivo NicoBloc experience, participants will be provided with NicoBloc to use between sessions to acclimate to the NicoBloc and to make practice quit attempts (PQAs). Sessions 2 and 3 are similar to Session 1 except they will use more NicoBloc product during the session and will be instructed to use the product between sessions.
45493182|NCT03720899|Drug|Nicotine Lozenge|Participants who receive nicotine lozenge (mini lozenge) will be given either a 2 or 4 mg lozenge to use in session, depending on how soon they smoke after waking. If a participant smokes within 30 minutes of waking, they start with the 4 mg lozenge; more than 30 minutes, they start with the 2 mg lozenge. They will be given lozenges between sessions to make PQAs.
45493183|NCT02340988|Drug|Single-Dose IV Oritavancin Diphosphate and Warfarin|Oritavancin will be administered as a single IV infusion simultaneously with Warfarin. The infusion will last approximately 3 hours.
45493184|NCT02340988|Drug|Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose|Oritavancin will be administered as a single IV infusion and 24 hours post dose subjects will receive 25mg of Warfarin. The infusion will last approximately 3 hours.
45493185|NCT02340754|Behavioral|Mindfulness-based Stress Reduction|
45493186|NCT02340754|Behavioral|MS Education Control|
45493187|NCT03145870|Other|Echoing of the lower limbs and measuring the systolic pressure index|Echoing of the lower limbs and measuring the systolic pressure index
45493188|NCT03145636|Device|vBloc Maestro Rechargeable System|Intra-abdominal vagal blocking neuromodulation device for the treatment of obesity
46054282|NCT00903630|Drug|liposomal doxorubicin|administered at a fixed dose of 40 mg/m^2 intravenously (IV) on day 1 of each 28 day cycle
45376998|NCT00816803|Procedure|Autologous bone marrow transplant|
45376999|NCT00816803|Procedure|Physical therapy|
45377000|NCT00467259|Drug|Testosterone Transdermal System|Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
45377001|NCT00467259|Drug|Placebo patch|placebo patch, changed twice a week for 52 weeks
45377002|NCT00816881|Device|flutter mucus clearance device|five minutes every session, four sessions per day
45377003|NCT01022151|Drug|Placebo [group P]|receive intravenous injection of 0.2 mL/kg of saline 0.9%L [group P]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
45493189|NCT03145636|Other|vBloc Achieve Weight Management Program|Remotely accessible web-based program to add additional support to subjects with vBloc therapy
45493190|NCT03145636|Other|Control Weight Management (CWM) program|In person visits with Registered Dietician, or trained staff who will counsel subjects on energy balance, dietary intake, physical activity and eating behavior modification.
45493191|NCT05663567|Behavioral|solution oriented approach|Implementing a solution-focused approach to support breastfeeding
46054283|NCT05507008|Dietary Supplement|Kenetik Ketone Drink|BHB supplementation
45377004|NCT01022151|Drug|0.2 mL/kg of aminophylline 10 mg/mL [group A2]|receive intravenous injection of 0.2 mL/kg of aminophylline 10 mg/mL [group A2]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
46054284|NCT04302584|Drug|norepinephrine / Vasopressin|• The drug infusion was prepared as 100 IU of AVP (Pressyn; Ferring Inc., Toronto, Ontario, Canada) in 250 ml D5W, infused at the rate of 4.5 ml/h for 0.03 IU/min and 15 mg of Norepinephrine (Arterenol; Sanofi-Aventis, Frankfurt, Germany) in 250 ml D5W infused at the rate of 10 ml/h for 10 mcg/min using infusion pump.
45377005|NCT01022151|Drug|0.2 mL/kg of aminophylline 15 mg/mL [group A3]|receive intravenous injection of 0.2 mL/kg of aminophylline 15 mg/mL [group A3]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
45377006|NCT01022151|Drug|0.2 mL/kg of aminophylline 20 mg/mL [group A4]|receive intravenous injection of 0.2 mL/kg of aminophylline 20 mg/mL [group A4]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
45377007|NCT01022151|Drug|0.2 mL/kg of aminophylline 25 mg/mL [group A5]|receive intravenous injection of 0.2 mL/kg of aminophylline 25 mg/mL [group A5]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
45377008|NCT01022151|Drug|Doxapram 1 mg/kg [group D]|receive intravenous injection of 0.2 mL/kg of doxapram 5 mg/mL [group D]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
45377009|NCT01022229|Dietary Supplement|Compound Natural Health Product|"15-35 mg zinc citrate~150-350 mg magnesium lactate~30-70 mg pyridoxine hydrochloride~150-350 mg calcium ascorbate~Doses are weight based. Chewable tablets are taken 2 times/day with food for the duration of the study"
45693463|NCT03839836|Other|Backpack child's body weight|Children are asked to walk naturally, facing forward, with their hands out of pockets; wearing light, comfortable clothes, with the BP placed correctly. As the children start walking, the researchers select the foot of the first step inside the bars, in the Optogait software. After being instructed to 'walk slowly at a comfortable speed', the children walk from a point two metres in front of the bar and stop at a point two metres behind the last bar, to minimize effects of acceleration and deceleration . A three-minute interval occurs between individual assessments to transmit the data, as well as to prepare for the next assessment. Only steps in the sensor areas are included in the analysis. Recording six to eight strides is reported as sufficient to obtain representative data for unimpaired adults. Subsequently, five experimental conditions are measured: without BP, BP loads of 5%, 10%, 15%, and 20% of body weight. The order of these loaded conditions are random.
45377010|NCT01022229|Dietary Supplement|Placebo|Placebo
45377011|NCT01027455|Device|Fisher and Paykel Insuflow (MR 860) Surgical Humidification Device|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
45377012|NCT01027455|Procedure|Laparoscopic Appendicectomy|Dry and Cold carbon dioxide gas insufflation
45847126|NCT03694626|Device|Videography|"The subject will sit comfortably in front of miniature combination infrared/visible light video cameras and infrared diode light source located within 1 meter to provide video recording of the face during testing with light and during darkness, described next.~After the 10 minutes of dark-adapting, the subject will put his/her chin on a chin rest in front of the video cameras and a light emitting diode (LED) array give diffuse red, blue, and white stimuli over a range of intensities. None of the stimuli are as bright as a flash from a camera and are in the range of intensities normally experienced during daily activities.~At the end of the test the investigators will add filters over the glasses: orange (blue-blocking) filters and neutral density filters. Subjects will grade independently, both the brightness and discomfort they feel from each light stimulus intensity."
45693464|NCT04382716|Other|No intervention|No intervention; observation only
46054285|NCT04233255|Device|Neuromuscular Ultrasound (US)|"Quantitative ultrasound measurements will be performed to studied muscles according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.The study will be performed using My lab 7 ultrasound system (Esaote company, Italy) that is equipped by 7-19 MHz linear array transducer and color and power Doppler.~Technique: evaluation of studied muscles for echo intensity (ECHO), quantitative assessments of echointensity, muscle perfusion, transverse and longitudinal sections of the muscle and its thickness at rest and during maximal voluntary contractions (MVC), overlying subcutaneous fat, cross-sectional area (CSA), and angled fibers of pennate muscles."
46054286|NCT04233255|Device|Electrophysiological studies|"Includes: Motor and sensory nerve conduction study, F-wave and H-reflex study to assess the proximal roots, Electromyography (EMG) of the studied muscles.~using machine: recordings will be performed with a Nihon Kohden equipment (model 7102) with the following parameters: sweep time 8 ms/D, sensitivity 0.5 mV/D, low frequency filter 2 Hz, high frequency filter 10 kHz, stimulation duration 0.1 ms and stimulation frequency 1 Hz."
46054287|NCT04233255|Diagnostic Test|Seum CPK, CK-MM levels, Lactate dehydrogenase and alanine aminotransferase.|measured in U/L using ELISA.
45377013|NCT01027455|Procedure|Laparoscopic Appendicectomy|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
45377014|NCT01566045|Procedure|Core Needle TRUS Needle biopsy (Transrectal ultrasound)|Standard of care 12-core TRUS sextant needle biopsy of the medial and lateral margins of the right and left apex, mid-gland and base of the prostate
45377015|NCT01566045|Procedure|Core Needle MRI/US image fusion guided needle biopsy|Directed prostate needle biopsies at MR-image identified targets in addition to the standard ultrasound 12-14 core biopsies
45377016|NCT01566123|Radiation|Neoadjuvant intensity-modulated radiation therapy (IMRT)|neoadjuvant intensity-modulated radiation therapy, single dose 2.0-2.4 Gy, total dose 50-56 Gy
45693465|NCT01730053|Drug|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
45693466|NCT01730053|Drug|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
45693467|NCT01730053|Drug|Ezetimibe|Ezetimibe over-encapsulated tablets orally.
45693468|NCT01730053|Drug|Placebo|Placebo for alirocumab and ezetimibe.
45377017|NCT01566123|Radiation|intraoperative radiation therapy (IORT)|during surgery, 10-12 Gy (90% isodose) to the tumor bed or residual disease
45377018|NCT00449865|Drug|creatine|"Creatine, a widely used dietary supplement is thought to improve exercise performance. In animal models and human studies, creatine has been shown to be well tolerated and may have some ability to protect brain cells.~The study is comparing creatine 5 grams twice daily with placebo."
45377019|NCT00449865|Other|placebo|an inactive substance
45377020|NCT00449787|Drug|Sumatriptan 100 mg|Sumatriptan 100mg tablet
45377021|NCT00449787|Drug|Naproxen|Naproxen 500mg tablet
45377022|NCT01566201|Drug|anakinra|Inhibition of Interleukin-1 activity by anakinra (Kineret®) 100mg od, sc injection
45377023|NCT01566201|Drug|placebo|water for injection
45377024|NCT01566279|Drug|Everolimus|All patients will receive everolimus 10mg q.d.
45377025|NCT00449163|Biological|Bevacizumab|
45377026|NCT00449163|Drug|Floxuridine|
45377027|NCT00449163|Drug|Irinotecan|
45377028|NCT00449163|Drug|Leucovorin|
45693469|NCT00794560|Behavioral|patient education|"Possible, individualized interventions:~Improvement of patient's knowledge about medication, therapy and drug application by providing detailed written information material~Providing a complete equipment package for self-injection (disinfection patches, patches, plasters, waste disposal box for used syringes)~Patient training: oral instructions for self-injection (and application, if required), exercising the injection technique on a phantom~First self-injection under control of a specially trained pharmacist"
45693470|NCT01752985|Drug|BMS-813160|
45693471|NCT01752985|Drug|Placebo matching with BMS-813160|
45693472|NCT01751113|Drug|fluticasone propionate/salmeterol|250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)
46054288|NCT00706732|Biological|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks via the IM route
45377029|NCT01026987|Drug|G-CSF|Unrelated donors will receive only G-CSF (10 ug/Kg S/C qDay x5-6 days) prior to pheresis (collection of the stem cells). Unrelated donors will only be followed per NMDP guidelines.
45377030|NCT01026987|Drug|AMD3100|
45377031|NCT01026987|Procedure|Leukapheresis|
45377032|NCT01026987|Procedure|Stem Cell Infusion|
45377033|NCT00448539|Drug|Rufinamide|Dose will be maintained within the range of 2400 to 4800 mg/day (i.e., 1200 to 2400 mg twice daily).
45377034|NCT01024257|Radiation|beta-irradiation|
45377035|NCT01024257|Procedure|conjunctival autograft|
45377036|NCT00457665|Drug|Nelfinavir|
45377037|NCT00457665|Drug|Efavirenz|
45377038|NCT00447603|Drug|hydrochlorothiazide (+) losartan potassium|losartan/hydrochlorothiazide 12.5mg tablet po qd; for a 4 week study period.
46054289|NCT00706732|Biological|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks given via the SC route
46054290|NCT00706732|Biological|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the IM route
46054291|NCT00706732|Biological|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the SC route
46054292|NCT02875106|Device|12-point-ECG|routine recording will be 300 seconds
45377039|NCT00447603|Drug|losartan potassium|Losartan 50mg titrating up to Losartan 100mg tablet po qd; for a 4 week study period
45377040|NCT00447603|Drug|Placebo for Losartan|
45377041|NCT00447603|Drug|Placebo for Losartan/HCTZ|losartan/hydrochlorothiazide 12.5mg Pbo tablet po qd; for a 4 week study period.
45377042|NCT00447057|Drug|Pemetrexed|500 mg/m² intravenous (iv) over 10 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity
45377043|NCT00447057|Drug|Erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
45377044|NCT00447057|Drug|Pemetrexed|500 mg/m² iv over 10 minutes on the first day of each 21-day cycle until PD or unacceptable toxicity
45377045|NCT00447057|Drug|Erlotinib|150 mg given po, QD, starting on the first day of the first cycle
45377046|NCT01027533|Other|Implantation of a multifocal Intraocular lens|Bilateral implantation of a multifocal IOl
45377047|NCT01027611|Drug|proparacaine HCL 0.5%|
45377048|NCT01027611|Drug|proparacaine HCL 0.5% + 4% lidocaine solution|
45377049|NCT01027611|Drug|3.5% viscous lidocaine gel|
45377050|NCT01024413|Drug|erlotinib|study arm.erlotinib 150 mg oral till disease progression
45377051|NCT01024413|Drug|gefitinib|study arm.gefitinib 250 mg oral till disease progression
45377052|NCT03577587|Dietary Supplement|Silitidil for 21 days|daily ingestion of herbal galactagogue Silitidil over time period of 3 weeks
45377053|NCT03577587|Dietary Supplement|Placebo for 21 days|daily ingestion of Placebo preparation over time period of 3 weeks
45377054|NCT00446511|Drug|Valsartan|Valsartan (80, 160, and 320 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
45377055|NCT00446511|Drug|Enalapril|Enalapril (10, 20, and 40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
46054293|NCT02875106|Device|Polar V800|routine recording will be 300 seconds
46054294|NCT02875106|Device|360° eMotion FAROS SET + Belt|routine recording will be 300 seconds
46054295|NCT02875106|Device|Adidas Micoach smart run|routine recording will be 300 seconds
46054296|NCT02875106|Device|TomTom Runner Cardio HRM|routine recording will be 300 seconds
46054297|NCT00703144|Drug|piperacillin/tazobactam|piperacillin 4 g and tazobactam 500 mg during 30 min IV infusion every 8h during 2 consecutive days
46054298|NCT00703144|Procedure|Pharmacokinetic|
45377056|NCT00446511|Drug|placebo matched to enalapril|Placebo matched to enalapril. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
45693473|NCT01751113|Drug|tiotropium bromide|18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
45693474|NCT01751113|Drug|fluticasone propionate/salmeterol plus tiotropium bromide|250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
45693475|NCT00795340|Drug|carboplatin|Given IV
45693476|NCT00795340|Drug|cediranib maleate|Given orally
46054299|NCT02788929|Device|Fitbit Charge HR|Patients randomized to the FitBit group will receive Fitbit Charge HR, a simple, user-friendly, wrist-worn, commercially available device which provides feedback on exercise goal adherence, in combination with the Fitbit mobile platform application.
45377057|NCT00446511|Drug|placebo matched to valsartan|placebo matched to valsartan. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
45693477|NCT00795340|Drug|paclitaxel|Given IV
46054300|NCT01037114|Procedure|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
45377058|NCT01024491|Drug|paroxetine|daily dose of paroxetine 15mg for 12 weeks
45377059|NCT01024491|Drug|paroxetine|active daily treatment with paroxetine 20 mg
45693478|NCT00795340|Other|placebo|Given orally
45693479|NCT04761406|Dietary Supplement|Phaeosol group|"In a double blind, randomized manner, 40 pre-menopausal females will ingest one of the following for 12 weeks:~Treatment 1 -Placebo (218 mg/d of 100% sunflower Oil) Treatment 2 - PhaeoSOL (218 mg/d)~Supplements will be prepared in softgel capsules for double blind administration by the sponsor."
46054301|NCT01037114|Biological|Engerix-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B.
45377060|NCT01024491|Drug|placebo|active daily treatment with placebo
45377061|NCT00446199|Drug|0.5mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
45377062|NCT00446199|Drug|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
45693480|NCT04761406|Dietary Supplement|Placebo group|"In a double blind, randomized manner, 40 pre-menopausal females will ingest one of the following for 12 weeks:~Treatment 1 -Placebo (218 mg/d of 100% sunflower Oil) Treatment 2 - PhaeoSOL (218 mg/d)~Supplements will be prepared in softgel capsules for double blind administration by the sponsor."
45693481|NCT04753294|Device|Avance Solo NPWT System|Wound treatment with Avance Solo NPWT System for up to 28 days.
46054302|NCT01037114|Biological|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies.
46054303|NCT02979366|Drug|S64315 once a week|S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours once every week (21- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
45493192|NCT03145480|Drug|Obinutuzumab|100 mg on day 1 and 900 mg on day 2 Cycle 1, 1000 mg on day 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6
45493193|NCT03145480|Drug|Ibrutinib|560mg po daily
45377063|NCT00446199|Drug|Estradiol (E2 0.3mg)|One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).
45377064|NCT00446199|Drug|Placebo|Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
45847127|NCT03694626|Device|Electrophysiology|Next, electrodes will be placed above, below and to the side of the test eye to record the electromyogram (EMG) for measuring eyelid opening and blink rate.
45377065|NCT01027689|Drug|alprazolam commercial immediate release oral tablet|1 mg tablet, single dose
45377066|NCT01027689|Drug|alprazolam test sublingual tablet|1 mg tablet, single dose
45377067|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 200 mg every 2 weeks
45377068|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
45377069|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 400 mg every 4 weeks
45847128|NCT03670914|Diagnostic Test|WatchPAT 200|The WatchPAT200 device has been approved by the Food and Drug Administration (FDA) for testing sleep related disorders in patients ages 17 and older. They are widely used with thousands of studies performed in the United States to validate the devices accuracy and efficacy. It is also routinely used in many other countries. The devices are not currently being used for patients who are currently taking narcotic medications at Kaiser Permanente. Therefore, we are asking patients to simultaneously wear this device during an in-lab study, so we can test how effective and accurate the WatchPAT 200 is in diagnosing sleep breathing disorders in patients on narcotic medications.
45377070|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
45377071|NCT01027767|Device|Molecular Breast Imaging|Molecular Breast Imaging
45377072|NCT01027923|Drug|Plerixafor|
45377073|NCT01027923|Drug|Mitoxantrone|
45377074|NCT01027923|Drug|Etoposide|
45493194|NCT03145480|Other|CHOP|cyclophosphamide, doxorubicin, vincristine, and prednisone
45493195|NCT03726515|Biological|CART-EGFRvIII T cells|autologous T cells that have been engineered to express an extracellular Humanized single chain antibody (scFv) with specificity for EGFRvIII linked to an intracellular signaling molecule comprised of a tandem signaling domain of the 4-1BB and TCRζ signaling modules.
45493196|NCT03726515|Biological|Pembrolizumab|humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
45493197|NCT02349568|Procedure|High risk group|Patients with high risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. All patients even if negative EUS examination of CBD stone were underwent ERCP in the same session. The ERCPs were performed in standard manner. All patients were contacted by phone on day 1, 3 and 30 after the procedure.
45493198|NCT02349568|Procedure|Intermediate risk group|Patients with intermediate risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. ERCPs were done at the discretion of the attending physicians. The ERCPs were performed in standard manner. The patients without ERCP done were contacted at 3 months interval to assess symptoms and LFT for 12 months.
45493199|NCT05665283|Drug|Ensartinib Hydrochloride|oral ALK inhibitor
45493200|NCT03071094|Biological|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 10^9 pfu at day 1 and weeks 2 and 4
45493201|NCT03071094|Drug|Nivolumab|Nivolumab will be administered intravenously every 2 weeks (from week 2)
45493202|NCT02340364|Behavioral|Education + Patient Navigation|208 patients randomized to self-care Education+ Patient Navigation-delivered self-care plan.
45377075|NCT01027923|Drug|Cytarabine|
45377076|NCT01565733|Drug|biphasic insulin aspart 30|Biphasic insulin aspart 30 prescribed solely on the basis of clinical judgement. Initial dose, frequency of injections and further dosage amendments at the discretion of the treating physician.
45377077|NCT01565811|Procedure|perihepatic lymphadenectomy|Hepatic pedicle lymph node dissection according to the protocol of the prospective multicentric study.Namely the six main groups of lymph nodes removed (HA,hepatic artery; CA, celiac axis; BD, common bile duct).
45377078|NCT01027065|Drug|CYT107+GenHevac+entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107 and vaccine) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
45377079|NCT01027065|Drug|CYT107+ entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
45377080|NCT00456495|Drug|ranibizumab|Subconjunctival injection of drug every 2 to 4 weeks
45847129|NCT03642834|Drug|ICP-105|25mg, 100mg capsule
45377081|NCT01027143|Dietary Supplement|omega-3 polyunsaturated fatty acids|ProEPA Xtra 1000mg softgels: 3 softgels twice daily
45377082|NCT01027143|Drug|Omega-3 Fatty Acid|Soybean oil: 3(age 12-25) matched softgel caps twice daily
45377083|NCT00445341|Drug|Flavopiridol|Flavopiridol 30 mg/m^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
45377084|NCT03846453|Biological|HL036 Ophthalmic Solution|HL036 Ophthalmic Solution
45377085|NCT03846453|Biological|Placebo|Placebo vehicle solution
45377086|NCT00444951|Biological|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
45493203|NCT02340364|Behavioral|Self-care Education|208 patients randomized to self-care education alone.
45693482|NCT04753294|Device|Avance Solo Adapt NPWT System|Wound treatment with Avance Solo Adapt NPWT System for up to 28 days.
45693483|NCT01750879|Drug|Peanut Flour|Peanut Flour
45693484|NCT01750879|Drug|Oat Flour|Oat Flour
45693485|NCT01719380|Drug|LGX818|
45693486|NCT01719380|Drug|Cetuximab|
45693487|NCT01719380|Drug|BYL719|
45377087|NCT00444951|Biological|Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine|0.5 mL, Subcutaneous
45377088|NCT00444951|Biological|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
45377089|NCT00444795|Drug|Sunitinib malate|Sunitinib : dosing not pre-determined
45377090|NCT00444795|Drug|Sunitinib malate|Sunitinib : dosing not pre-determined
45377091|NCT00444795|Drug|sunitinib malate|Sunitinib : dosing not pre-determined
45377092|NCT03846219|Drug|IMU-838 (30 mg/day)|"Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 15 mg tablet IMU-838 daily) and then start taking the full assigned dose from Day 7 onwards (two 15 mg tablets IMU-838 once daily).~Optional extended treatment period (optional): Participants who were re-randomized to a 30 mg/day dose will take the full assigned dose which consists of two 15 mg tablets IMU-838 once daily."
45377093|NCT03846219|Drug|IMU-838 (45 mg/day)|"Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 22.5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 22.5 mg tablets once daily).~Optional extended treatment period (optional): Participants who were re-randomized to a 45 mg/day dose will take the full assigned dose of two 22.5 mg tablets IMU-838 once daily."
45693488|NCT00792142|Drug|bortezomib|Given IV
45693489|NCT00792142|Drug|dexamethasone|Given orally
45693490|NCT00792142|Drug|melphalan|Given IV
45693491|NCT00792142|Drug|thalidomide|Given orally
45693492|NCT00792142|Genetic|cytogenetic analysis|Performed on baseline and post transplant bone marrow specimens
45693493|NCT00792142|Genetic|fluorescence in situ hybridization|Performed on baseline and post transplant bone marrow specimens
45693494|NCT00792142|Other|laboratory biomarker analysis|Baseline, post transplant and prior to start of bortezomib, every 3 months post transplant for the first year, after 6 cycles of bortezomib, every year after transplant for 2-4 years.
45693495|NCT00792142|Other|questionnaire administration|Completed at baseline (within 6 weeks prior to enrollment) and at 2 months post transplant and once a month after that for the first year. For the second year the questionnaire will be completed every 3 months as long as on thalidomide for the duration of the study.
45693496|NCT00792142|Procedure|autologous hematopoietic stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
46054304|NCT02979366|Drug|S64315 twice a week|S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours twice every week (28- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
45493204|NCT05761392|Other|Precise management|The daily pain state assessments contain three components, the visual analogue scale (VAS) based on pain intensity, time-intensity curve throughout the day, and pain locations. The VAS scores from the first seven post-operative days will be collected as the baseline data. The interventional threshold will be determined by adding 30 mm (if the scale length were 100 mm) to the baseline mean. If participants score above the threshold three times in a row, a warning will be sent to their physicians. A remote meeting will be scheduled and stimulation settings will be adjusted accordingly.
45493205|NCT04478968|Other|presence of AVF|Functioning AVF may have cardiotoxic potential
45493206|NCT02525406|Other|All surgeries performed from Jan 01, 2010 to Aug 31, 2020|
45493207|NCT04595292|Other|older adults, assessment|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
45493208|NCT03145402|Biological|Intracoronary injection of stem cell|Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed in patients with Heart failure via conventional percutaneous intracoronary intervention techniques.
46054305|NCT03114033|Other|Targeted therapeutic mild hypercapnia|Patients allocated to the TTMH protocol will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of -4). Arterial blood gases and end- tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 50-55 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change >5 mmHg
45377094|NCT03846219|Drug|Placebo|"Main treatment period (Cohort 1 and Cohort 2): All patients will receive 1 tablet per day during the first 7 days of the main treatment period and then start taking 2 tablets once daily from Day 7 onwards.~Optional extended treatment period: Placebo not applicable as participants were re-randomized to a 30 mg/day dose or a 45 mg/day dose."
45377095|NCT03846219|Drug|IMU-838 (10 mg/day)|"Main treatment period for Cohort 2: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 5 mg tablets once daily).~Optional extended treatment period (not applicable to Cohort 2): IMU-838 10 mg/day not applicable."
45377096|NCT00455325|Drug|Placebo Comparator: First Intervention (3 weeks)|once daily placebo tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
45377097|NCT00455325|Drug|Active Comparator: Second Intervention (3 weeks)|Once daily 80mg chloroquine or placebo tablet 3 Weeks followed by euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
45377098|NCT00455325|Drug|Active Comparator: Third Intervention (3 weeks)|Once daily 80mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
45377099|NCT00455325|Drug|Active Comparator: Fourth Intervention (3 weeks)|Once daily 250mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
45377100|NCT01028079|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Aspirin 1000 mg (solid dose caplet) to be given three times daily as for 2 consecutive days (48 hours), followed by Aspirin 1000 mg (solid dose caplet) to be taken as per need, but not more than three times daily for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 3000 mg Aspirin.
45377101|NCT01028079|Drug|Ibuprofen|Ibuprofen 400 mg caplet to be given three times a day as for 2 consecutive days (48 hours), followed by ibuprofen 400 mg caplet to be given as per need, but not more than three times a day for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 1200 mg ibuprofen.
45377102|NCT01028079|Drug|Placebo|Placebo (two placebos: Placebo Aspirin and Placebo Ibuprofen) to be given three times a day for a maximum of 5 consecutive days in the same regimen as for Experimental Drug and Active Comparator.
45377103|NCT01028157|Behavioral|STARS: Sistas Talking About Real Solutions|The intervention consisted of 2, 4-hour workshops. The first workshop focused on enhancing ethnic/gender pride, self-esteem, realizing values/setting goals, healthy/unhealthy relationships, partner violence, HIV/STD knowledge, heightening awareness of HIV susceptibility, safer-sex options/skills. The second workshop covered realistic choices in sexual decision making, consistent/proper condom use, setting limits/boundaries, communication styles, and condom skills negotiation. Participants received 3-hour booster sessions at 6- and 9-months to reinforce materials from the initial intervention. Bi-monthly phone calls and quarterly mailings were used to reinforce workshop material and facilitate retention.
45493209|NCT03145402|Biological|Placebo|Injection of Placebo in patients with Heart failure via coronary arteries
45693497|NCT00792142|Procedure|peripheral blood stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
46054306|NCT03114033|Other|Targeted normocapnia (Standard care)|Patients allocated to the standard care (TN) protocol will be managed according to current practice and in accordance with ILCOR guidelines which recommend maintaining normocapnia in these patients. They will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of - 4). Arterial blood gases and end-tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 35-45 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change >5 mmHg.
46054307|NCT02850198|Device|scalp electroacupuncture|
46054308|NCT02850198|Device|sham scalp electroacupuncture|
46054309|NCT00840970|Device|non-coated Intranasal Splint|placement of non-coated intranasal splint following FESS
46054310|NCT00840970|Device|Sinexus Intranasal Splint|placement of Sinexus Intranasal Splint placed following FESS
46054311|NCT04232475|Other|1 minute of stair climbing and descending|1 minute of stair climbing and descending
45377104|NCT01028157|Behavioral|General Health & Nutrition|Participants in this condition received a 2 hour group session which consisted of general health information and women's health brochures facilitated by a trained health educator. The control group received bi-monthly phone calls and quarterly mailings for retention purposes only, with no intervention material provided.
45377105|NCT01024725|Other|Follow-up|Nasopharyngeal/oropharyngeal and blood samples, interviews, questionnaires, register data
45377106|NCT01323231|Behavioral|XY-Zone|"The XY-Zone works to empower students to decrease risk factors and increase protective factors through three linear treatment steps. The first step is driven by guiding principles known as the five R's: respect, responsibility, relationship, role modeling, and reaching out. Through these principles, the participant explores healthy psychosocial behaviors and thoughts in a structured 10 session group setting. The leadership step builds upon the guiding principles and employs activities exploring true leadership through 10 sessions. During the leadership step, participants organize and carry out a service learning projects in their community. The third and final step is ambassador. Those in the ambassador step become a mentor to those in step one and are expected to explore the principles of leadership and the five R's, and determine their personal relevance to their lives as young men (Allen, 2009, p. i)."
45377107|NCT01024803|Device|"Device name: Retina Implant model Alpha. Surgical implantation of medical device into eye"|"Surgical implantation of medical device named Retina Implant into eye to restore vision partially.~Randomized intra-individual implant activation in patient under test conditions such as: FrACT, BaLM, BaGA, maze, ADL."
46054312|NCT04232475|Other|3 minute of stair climbing and descending|3 minute of stair climbing and descending
45377108|NCT00443781|Procedure|functional anesthetic discography|Functional Anesthetic Discography (F.A.D.) involves the placement and anchoring of a small catheter into a disc. After placement, functional testing is performed, in which the subject elicits his/her back pain via functional maneuvers or postures. Local anaesthetic is then delivered into the target disc through the catheter and the effect on functional back pain is noted.
45377109|NCT00443781|Procedure|provocative discography|"Provocative discography (PD) has been used as a preoperative diagnostic tool for patients with back pain attributed to degenerative disc disease considering lumbar disc surgery. During PD, a clinically suspected disc is accessed with a needle and injected under pressure with radiopaque contrast dye. The subject rates his/her experience of pain for intensity and whether the pain is exactly the same as (concordant) or different from (not concordant or discordant) typical back pain."
45377110|NCT01024881|Procedure|neutral shoulder position|neutral shoulder position during infraclavicular subclavian catheterization
45377111|NCT01024881|Procedure|lowered shoulder position|lowered shoulder position during infraclavicular subclavian catheterization
45377112|NCT00443703|Drug|MK0518 (raltegravir)|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
45377113|NCT00443703|Drug|Comparator: KALETRA™ (lopinavir (+) ritonavir )|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment.
45377114|NCT00443703|Drug|Comparator: placebo|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
45377115|NCT00443703|Drug|Comparator: placebo|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment.
45377116|NCT00381706|Biological|cetuximab|given IV
45377117|NCT00381706|Drug|ECF|epirubicin and 5-fluorouracil given IV
45377118|NCT00381706|Drug|IC|cisplatin and irinotecan given IV
45377119|NCT00381706|Drug|FOLFOX|oxaliplatin , leucovorin and 5-fluorouracil IV
45377120|NCT01045642|Drug|Omeprazole|Omeprazole Magnesium DR Capsules 20 mg
45377121|NCT00535236|Biological|V212|0.65 ml V212 in 4 dose regimen. Treatment period of 125 days
45377122|NCT00535236|Biological|Placebo|0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days
45377123|NCT05357430|Drug|Remimazolam|0.3μg/kg of remifentanil was injected slowly in advance, then different doses of Remimazolam was injected to two groups of D1 and D2, according to up-and-down method.
46054313|NCT04232475|Other|10 minute of stair climbing and descending|10 minute of stair climbing and descending
46054314|NCT02961348|Other|Early start of NOAC|Initiation of NOAC up until day 4 after acute ischemic stroke in patients with atrial fibrillation
46054315|NCT02961348|Other|Late start of NOAC|Initiation of NOAC between day 5 and day 10 after acute ischemic stroke in patients with atrial fibrillation
46054316|NCT01054820|Drug|FLECTORÂ® Patch (diclofenac epolamine topical patch) 1.3%|One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.
45847130|NCT03586284|Drug|Valganciclovir Hydrochloride|21 to 28 days of oral valganciclovir treatment
45847131|NCT03586284|Drug|Ganciclovir Sodium|21 to 28 days of topical ganciclovir solution treatment
45847132|NCT03586284|Drug|Placebo Oral Tablet|21 to 28 days of placebo pill treatment
45847133|NCT03586284|Drug|Topical placebo|21 to 28 days of topical placebo treatment
45847134|NCT03567642|Drug|Osimertinib|Osimertinib 80mg daily
45847135|NCT03567642|Drug|Platinum|Cisplatin 60mg/m2 or Cisplatin 45mg/m2 Carboplatin AUC 5 or Carboplatin AUC 4
45847136|NCT03567642|Drug|Etoposide|Etoposide 100mg/m2 or Etoposide 80mg/m2
45847137|NCT03449784|Other|Detection of patients with dyslipidemia|Detection of patients with dyslipidemia
46054317|NCT03105843|Drug|Methacholine (MCh) Challenge Testing|Visit 1: Informed consent, Baseline screening and pulmonary function tests and Low-dose methacholine challenge testing using partial and full flow-volume loops.
46054318|NCT03105843|Diagnostic Test|Eucapneic Voluntary Hyperventilation (EVH) and Hypertonic Saline (HS) Challenge Tests|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
45377124|NCT05357430|Drug|Remimazolam|0.3μg/kg of remifentanil was injected slowly in advance, then the calculated dose from groups of D1 and D2 of remimazolam was injected to group R.
45377125|NCT05357430|Drug|Propofol|0.3μg/kg of remifentanil was injected slowly in advance, then 1.5-2mg/kg of Propofol was injected to group C
45377126|NCT00370552|Drug|Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg|Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
45377127|NCT00370552|Drug|Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg|Ixabepilone, 40 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity (After Cycle 4, dose reduction to 32 mg/m^2 was to be implemented for all subsequent cycles.) Bevacizumab, 15 mg/kg, administered as IV infusion every 3 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
45377128|NCT00370552|Drug|Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg|Paclitaxel, 90 mg/m^2, given as a 1-hour IV infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab infused over 90 minutes for the first dose, and if well tolerated, over 60 minutes for the second dose. If still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
45377129|NCT00537030|Drug|Asparaginase|Given IM
45377130|NCT00537030|Other|Laboratory Biomarker Analysis|Correlative studies
45377131|NCT00537030|Other|Pharmacological Study|Correlative studies
45377132|NCT01047904|Device|Acclarent Iontophoresis System|Administration of local anesthesia using the Acclarent Iontophoresis System
45377133|NCT05357352|Other|NAFLD/NASH|the characteristics of patients with advanced fibrosis in a community-based referral center.
46054319|NCT02062164|Procedure|bariatric surgery|The intervention takes place in the clinical care setting. The decision for surgery is made by a multidisciplinary team, according to the international guidelines and the recommendations of the German working group on obesity (AGA, www.a.g.a.de). The choice of procedure is made on an individual basis taking into consideration patient inherent factors as well as the recommendations of the operating center. Operations are conducted at certified bariatric centers according to the policies of the German working group on bariatric surgery (CAADIP), and in the context of a structured preparation and follow-up program. The program is offered by a multidisciplinary team (pediatrician, endocrinologist, surgeon, dietician, psychologist/psychiatrist, social worker) and comprises preparation for and education about the surgery and expected lifestyle changes, as well as a structured, multidisciplinary follow-up plan. Subjects sign a contract agreeing to adhere to the recommended follow-up schedule.
45377134|NCT00381238|Drug|rosiglitazone|Extended Release Tablets
45377135|NCT05044026|Other|Jakavi|Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
45377136|NCT04639596|Behavioral|Mindfulness-based Therapeutic Sailing (MBTS) versus a standard recreation therapy activity, bowling, (SRT).|This study will be a prospective randomized controlled trial (RCT) of Mindfulness-based Therapeutic Sailing (MBTS) versus a standard recreation therapy activity (bowling) among Veterans with psychiatric and/or substance use disorders.
45493210|NCT04438876|Other|Functional Power Training|The exercise intervention encompassed high-velocity movement, balance, and mobility exercises with the use of body weight and resistance bands as resistance. Participants were instructed to move rapidly during the concentric phase and slowly during the eccentric phase when performing the dynamic exercises.
45493211|NCT04438876|Other|Usual care|Participants either continued the usual exercise program provided by their respective community senior activity centers or their personal exercise routine.
45493212|NCT04477798|Diagnostic Test|PCT-DIA/MS|PCT-DIA/MS will be validated to classify FNA biopsy specimens
45377137|NCT04446468|Behavioral|PEACE|The intervention consists of three synergistic components that work to support the patient after inpatient psychiatric discharge: 1) Brief educational component, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study psychologist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed; and 3) Mobile app, which aims to improve the patient's social connectedness and provide additional educational materials on suicide.
45377138|NCT04446468|Other|Standard Psychiatric Hospital Discharge Care|Current VA standard discharge care includes five core elements. First, patients and their outpatient providers are required to be involved in discharge planning. Second, patients should be offered evidence-based treatments to address their mental health symptoms. Third, the inpatient team should work with the patient to complete a safety plan prior to discharge. Fourth, the inpatient team should arrange two follow-up care visits within 30 days of discharge. Fifth, the inpatient team in conjunction with the SPC assess whether patients are appropriate to be placed on the High Risk for Suicide List. Patients who are placed on the High Risk for Suicide List receive enhanced oversight as outlined in VA policy.
45377139|NCT04400994|Drug|Rituximab|"Rituximab would be given intravenously.~IV Rituximab is prediluted at a dose of 500mg in 500ml of 0.9% normal saline (i.e. 1:1 dilution, 1 mg/ml)~Initial infusion rate starts at a rate of 50mg/hr (50ml/hr)~If no hypersensitivity/anaphylaxis reaction occurs, increase infusion rate in 50mg/hr (50 ml/hr) increments every 30 minutes~Maximum infusion rate is 400 mg/hr (400 ml/hr)~Subsequent infusion: start at rate of 100mg/hr (100 ml/hr), increase 100mg/hr (100 ml/hr) increments every 30 minutes~Monitor temperature, BP HR, respiratory rate and SpO2 every 30 minutes"
45377140|NCT04400994|Other|IVIg|"IVIg would be given in combination with Rituximab intravenously. Infusion plan of IVIg:~0 min: 50ml/hour 15 min: 75ml/hour 30 min: 100ml/hour 45 min: 125ml/hour 60 min: 150ml/hour 75 min & beyond: 180ml/hour"
45377141|NCT05355714|Device|Sofwave|High-Frequency Non-Focused Ultrasound Device
45377142|NCT05355714|Device|Ultherapy|Microfocused Ultrasound with Visualization
45377143|NCT05260476|Other|Reablement|The service provider customizes a training plan and formulates training goals based on the patient's level of disability, family environment, and the needs of the patient and the caregiver.
45377144|NCT04928820|Procedure|Computed Tomography|Undergo PET/CT
45377145|NCT04928820|Other|Gallium Ga 68 Gozetotide|Given IV
45377146|NCT04928820|Procedure|Positron Emission Tomography|Undergo PET/CT
45377147|NCT03896022|Device|Acupressure with Beads|Single-use gold-plated 1.2mm beads/balls attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
45377148|NCT03896022|Device|Acupuncture with Needles|Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
45377149|NCT03896022|Device|Placebo Adhesive Disks|Single-use adhesive disks without needles or beads.
45377150|NCT04430946|Diagnostic Test|Standardized test meal|A test meal of ~700 kcal consisting of protein and fat will be consumed within 10 minutes
45377151|NCT03831880|Drug|Genotropin|Genotropin (dose [mg] at time of enrollment) given subcutaneously once daily
45493213|NCT03148990|Biological|Measles and Rubella vaccine|Administration of the experimental vaccine (MR).
45493214|NCT03148990|Biological|Measles, Mumps and Rubella vaccine|Administration of the comparator vaccine (MMR).
45493215|NCT02340598|Other|cold vest|The lowering of body temperature increases basal metabolic rate
45493216|NCT03559517|Biological|Ontamalimab|Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.
45493217|NCT03559517|Other|Placebo|Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
46054320|NCT02062164|Other|conservative care|Subjects will be seen by a trained study physician every 6 months. Stuctured health assessments will be conducted, and individual treatment recommendations will be made based on the patients motivation and ability(e.g. inpatient obesity rehab, exercise, dietary or behavioral intervention etc.)
45493218|NCT02340442|Other|Obstetrical care parameters|
46054321|NCT05343819|Drug|AON-D21|AON-D21 is a PEGylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
46054322|NCT05343819|Drug|Placebo|Isotonic glucose solution identical in appearance to AON-D21.
45377152|NCT03831880|Drug|somatrogon|0.66 mg/kg/week given subcutaneously once weekly
45377153|NCT00924456|Behavioral|Transcendental Meditation program|a natural effortless mental technique
45377154|NCT04429152|Drug|Doravirine/Lamivudine/Tenofovir|DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination
45377155|NCT04257552|Behavioral|Healthy Beyond Pregnancy|Web-based application grounded in tenants of behavioral economics.
45377156|NCT04257552|Behavioral|Pre-Scheduled Postpartum Visit|Participants will have their postpartum visit scheduled while they are still in the hospital after delivery.
45377157|NCT04257552|Other|Attention Control|Participants will receive texts related to infant care to mirror the attention participants receive in the Healthy Beyond Pregnancy intervention.
45377158|NCT04001400|Drug|Rabeprazole 20mg bid|Rabeprazole 20mg tablet b.i.d.
45377159|NCT04001400|Drug|Rabeprazole 20mg qd|Rabeprazole 20mg tablet q.d.
45377160|NCT04219566|Device|VeNS|Non-invasive electrical vestibular nerve stimulation
45493219|NCT02340442|Other|DVA measurements|
45493220|NCT02340442|Other|Fundus photographs|
45493221|NCT04477642|Drug|Abatacept|10mg/kg intravenously administered on Day 1
46054323|NCT00840658|Behavioral|Interactive injection and sexual risk intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of both, a) unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared; and b) unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
45377161|NCT04219566|Device|Placebo device|Sham non-invasive electrical vestibular nerve stimulation
45377162|NCT00380692|Drug|Atomoxetine|
45377163|NCT00380692|Drug|Placebo|
45377164|NCT04384770|Radiation|CT-guided Stereotactic Body Radiation Therapy|Undergo CT-guided SBRT
45377165|NCT04384770|Radiation|MRI-guided Stereotactic Body Radiation Therapy|Undergo MRI-guided SBRT
45493222|NCT03149146|Other|Clinical Decision Making (CDM) Workshop|Participants will be provided the Clinical Decision Making workbook which will be used as a guideline to practice decision making. A workshop was chosen rather than other methods of presenting the guideline so that participants could receive feedback and guidance from the instructors and from the other participants. Active learning educational environment will be encouraged and the workshop require group and individual participation and also assist the participants in reflection on their decisions.
45493223|NCT03149146|Other|Clinical Decision Making (CDM) Workbook|Participants are encouraged to read and do exercises which was written in the workbook for a week and they also are asked to recall their recent patient case or use their patient as the example case and answer the questions from the Clinical Decision Making workbook.
45493224|NCT02344732|Drug|Dexamethasone 0.1%, Neomycin Sulfate and Polymyxin B Sulfate topical eye drops four times daily|
45493225|NCT02344732|Drug|Homatropine 2% eye drops thrice daily|
45377166|NCT04384770|Other|Questionnaire Administration|Ancillary studies
45377167|NCT05355636|Behavioral|Fertility Management Counseling|counseling
45377168|NCT04285866|Drug|Durvalumab|Durvalumab after chemoradiotherapy
45377169|NCT01047982|Dietary Supplement|myo-inositol|myo-inositol 2 grams plus folic acid 400 mcg twice a day
45377170|NCT01047982|Other|folic acid 400 mcg|2 pills a day
45377171|NCT05355558|Diagnostic Test|[18F]FLT-PET/MRI body scan|"[18F]FLT-PET/MRI body scan will be done at~Visit 2 (Baseline-Pre-Treatment FLT-PET/MRI) which will occur between 1 to 28 days prior to initiation of radiotherapy.~Visit 3 (During Treatment FLT-PET/MRI) which will occur between week 4 to week 5 of External Beam Radiotherapy (before brachytherapy).~At these visits:~Obtain vital signs and weight in kg before FLT administration.~Record the dose of FLT received and injected. (**specify dose: 1mCi per 10kg. Maximum injected dose: < 10mCi per patient.)~Place one (1) IV catheters into the participant's arm vein to inject the bolus of FLT.~Perform a saline flush following the FLT injection.~Body PET/MRI will be performed after FLT injection.~Time of injection of FLT and time of scan will need to be recorded."
45377172|NCT00536874|Drug|gemcitabine hydrochloride|1,000 mg/m2 IV over 100 minutes on day 1 every 14 days for 4 cycles
45493226|NCT02344732|Drug|Oxygen gas|
45493227|NCT03720743|Other|Biodanza|Intervention group received a total of 10 sessions, once a week, over the course of two months. Each session lasted 60 minutes. All sessions began with a 10-minute warm-up period combining music and low-intensity movements as a welcome round, followed individual exercises, in pairs and/or groups, which included dance combined with exercises based on the five lines of Biodanza (vitality, sexuality, creativity, affectivity and transcendence). Finally, a celebration and farewell round of 10 minutes was held. At the end of each session, the participants were asked to share their experiences with the rest of the group.
45493228|NCT02344654|Drug|Indocyanine green|
45493229|NCT02344654|Device|Near-infrared illumination|To see the fluorescence from indocyanine green
45493230|NCT02344654|Drug|Urografin|
45493231|NCT02344654|Radiation|X-ray|
45493232|NCT03720665|Combination Product|Caffeine_TMS|Caffeine group: participants will receive a caffeine tablet and all electrical stimulations in a random order [transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)] Placebo tablet: participants will receive a placebo tablet and all electrical stimulations in a random order [transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)]
45377173|NCT00536874|Drug|oxaliplatin|80 mg/m2 IV over 2 hours on day 1 every 14 days for 4 cycles.
45377174|NCT00536874|Genetic|protein expression analysis|
45377175|NCT00536874|Genetic|proteomic profiling|
46054324|NCT00840658|Behavioral|Interactive Sexual Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
45377176|NCT00536874|Other|diagnostic laboratory biomarker analysis|
45377177|NCT00536874|Procedure|adjuvant therapy|
45377178|NCT00536874|Procedure|neoadjuvant therapy|
45377179|NCT00536874|Procedure|therapeutic conventional surgery|
45377180|NCT04275102|Other|SPARK|Prompt to complete symptom screening three times weekly via SPARK with corresponding feedback sent to healthcare providers with each completed assessment.
45377181|NCT00991848|Drug|Lidocaine|received 240 mg lidocaine diluted in 125 mL 0.9% saline.
45377182|NCT05281068|Drug|Iguratimod|Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
45377183|NCT05281068|Drug|Danazol|Oral danazol (200 mg twice daily) for 12 weeks.
45493233|NCT05253742|Other|No intervention - the investigators are evaluating a new image acquisition method on an MRI scanner|The investigators will evaluate the performance of a modified MRI acquisition method against an existing method in fetal imaging in volunteers
45493234|NCT05253664|Behavioral|Woman-Centered Care Group|Each woman in the experimental group was given woman-centered care as from 2 hours postpartum and this process continued until 24 hours postpartum. Physiological parameters (systolic-diastolic blood pressure, pulse, body temperature) of women assigned either to the experimental group or the control group were measured at 2 hrs postpartum. The State, Trait Anxiety, and Postpartum Comfort Scales were pretested. A dynamic interaction was ensured between the researcher and the women in the experimental group who received woman-centered care. In the processes of determining and meeting the care needs of women in the early postpartum period, both the women and the researcher took equal responsibilities and the common goal of achieving safe results was shared. Clinical guidelines were used while providing woman-centered care.
45493235|NCT03722537|Procedure|Osteochondral Allograft|The arthritic bone that the thumb rests on (the trapezium) is removed and replaced with femoral trochlear osteochondral allograft that is designed to be similar in morphology to the human trapezium articular surface.
46054325|NCT00840658|Behavioral|Interactive Injection Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared.
45377184|NCT00380068|Drug|Ambrisentan|Oral tablets taken once daily.
45377185|NCT04088370|Other|Blood Draw|Blood Draw Only
45377186|NCT00991926|Drug|Orlistat|orlistat (Xenical, Roche, UK)120 mg tid
45377187|NCT00991926|Other|normo-caloric diet|Food intake and dietary history were assessed by a skilled dietitian who used a computer-assisted interview (Winfood 1.5, Medimatica srl, Martinsicuro, Italy)
45377188|NCT04004364|Other|Coordinated Specialty Care (CSC)|CSC is an integrated and team-based treatment model for first episode psychosis elements include psychotherapy, supported employment and education, family education and support, and pharmacotherapy.
45377189|NCT01048060|Procedure|Bone marrow specimen banking|
45377190|NCT04230954|Drug|Cabozantinib 40 MG oral once a day|Cabozantinib 40 mg oral once a day
45377191|NCT04230954|Drug|Pembrolizumab 200 mg IV every 3 weeks|Pembrolizumab 200 mg IV every 3 weeks
45377192|NCT05265702|Device|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 12 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
45377193|NCT04127838|Behavioral|Low Vision Occupational Therapy|Occupational therapy may include methods to effectively modify environments (such as addition of task lighting), training in the use of assistive technology (such as voice activated devices), teaching new skills (such as sensory substitution) and prevention of accidents and injury (such as home safety modifications).
45377194|NCT04081974|Other|Distal leg perfusion|On arrival in the operating room, oximeter pads of a NIRO-200NX (NIRO,Hamamatsu® , Japan) NIRS monitor will be placed on the muscles of the calf bilaterally. Lower extremity NIRS is an added monitoring tool as it is currently not being used in our institutional clinical management. Neither anesthetic nor surgical plans will be altered by the study and are left to the discretion of the attending consultant. Also, perfusion goals may not be altered to the results of the leg NIRS. Therefore, the NIRS display will be covered in the operating room throughout the surgery.
45377195|NCT03981432|Behavioral|REST-Fixed|condition without exercise / rest condition. The participants will be asked to remain quiet and at rest during the morning and will receive a fixed meal at lunch. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
45377196|NCT03981432|Behavioral|REST-AdLib|condition without exercise / rest condition. The participants will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
45377197|NCT03981432|Behavioral|EX-AdLib|condition with an acute exercise set 30 minutes before the lunch meal that will be served ad libitum This will be a 30-minute exercise set at 65% of their capacities (cycling), 30 minutes before lunch.
45377198|NCT00536484|Drug|Fesoterodine|4mg tablets once daily for 2 weeks, then either 4mg or 8mg tablets once daily for 10 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
45377199|NCT00536484|Drug|Placebo|Matched placebo tablets once daily for 12 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
45377200|NCT00370396|Biological|Synflorix|1 dose injected IM in the right thigh or deltoid.
45377201|NCT00370396|Biological|Prevenar|1 dose injected IM in the right thigh or deltoid.
45377202|NCT00370396|Biological|Infanrix hexa|1 dose injected IM in the right thigh or deltoid.
45377203|NCT00992004|Dietary Supplement|Arantal® (highly bioavailable turmeric extract)|4 capsules a day, before breakfast
45377204|NCT03862716|Drug|IDegLira|Dose is titrated to achieve fasting normoglycemia
45377205|NCT03862716|Drug|insulin degludec|In those who need additional insulin or who cannot tolerate IDegLira, insulin degludec will be used. Dose is titrated to achieve fasting normoglycemia.
45377206|NCT03862716|Drug|Metformin|Dose is titrated to 2000 mg per day or maximal tolerated dose
45377207|NCT03862716|Behavioral|Lifestyle Therapy|Lifestyle intervention includes individualized dietary and exercise advice targeting at least 5% weight loss with frequent visits and coaching for goal reinforcement, behavior modification and problem-solving
45493236|NCT03722537|Procedure|Ligament Reconstruction Tendon Interposition|During the LRTI, the arthritic bone that the thumb rests on (the trapezium) is removed. A small cut is made in the forearm to release a tendon, which is moved to the base of the thumb to fill in the area from which the trapezium bone was removed. A small suture anchor is then placed into a thumb bone which holds everything together.
45377208|NCT00992082|Drug|ropivacaine, ketorolac and epinephrine|Spinal injection: bupivacaine 17.5 mg (3,5 mL) + 0.25 mL 0.9% saline. Local Infiltration Analgesia: 400 mg ropivacaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation. On the first and on the second postoperative morning, 200 mg ropivacaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
45377209|NCT00992082|Drug|morphine|Spinal injection: bupivacaine 17.5 mg (3.5 mL) + 0.1 mg (0.25 mL) morphine. No intraarticular injections are given.
45377210|NCT00455013|Drug|Thymoglobulin|Induction therapy, IV infusion, All subjects will receive thymoglobulin 1.5-mg/kg i.v. infusion on Days 1 (day of transplant), 2, 3, and 4 (up to a maximum total dose of 6 mg/kg) i.v. infusion over at least 4 hours
45847138|NCT03447834|Other|Selective intracoronary hypothermia + PPCI|Selective intracoronary hypothermia is a new technique, recently tested for safety and feasibility in the SINTAMI trial. The procedure starts by advancing a guidewire beyond the occlusion in the culprit artery, followed by an OTWB that is inflated at the location of the occlusion, at a low pressure (4 atm), to prevent reperfusion. After that, a pressure/temperature wire will be advanced along the inflated OTWB and is placed in the distal coronary artery. Then the guidewire is removed and the lumen is used for infusion of saline. During the 'occlusion phase', saline at room temperature is infused for 10 minutes with distal coronary temperature 6-8°C below body temperature. After that, the balloon of the OTWB is deflated. Simultaneously, infusion is started with saline of 4°C, the so called 'reperfusion phase'. This is continued for 10 more minutes. After that, the OTWB can be retracted and the procedure can continue not different from routine PPCI.
45377211|NCT00455013|Drug|Belatacept|Belatacept arms will receive i.v. belatacept (10 mg/kg) on Days 1 and 5, and then every other week through Month 3 (Weeks 2, 4, 6, 8, 10, and 12), and then every 4 weeks through Month 6 (Weeks 16, 20, and 24). After 6 months, subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial
45847139|NCT03447834|Other|Standard PPCI|PPCI per routine
45847140|NCT03190668|Drug|Bolus dose of Cefazolin|Mode of Cefazolin administration will be a intermittent bolus
45847141|NCT03190668|Drug|Continuous Cefazolin drip|Mode of Cefazolin administration will be a continuous drip
45847142|NCT03190668|Device|Paraspinal muscle microdialysis catheters|Two dialysis probes will be inserted into a paraspinal muscle
45847143|NCT03190668|Device|Subcutaneous microdialysis catheters|Two dialysis probes will be inserted into a paraspinal subcutaneous region
46054326|NCT00840658|Behavioral|Lecture-format presentation|60 minute lecture-format presentation on safer sex and safer injection based on CDC guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). There are no theory-driven active skill building elements oriented towards safer sex or safer injection.
45377212|NCT00455013|Drug|Sirolimus|Sirolimus will be initiated at 5 mg/day on Day 1 (day of transplant) and continued through Day 2. The dosing will be adjusted subsequently to keep pre-dose (C0) levels at 7 - 12 ng/mL for the first 6 months, followed by 5 - 10 ng/mL thereafter
45493237|NCT04029844|Device|Colibri TAVI System|Implantation of Colibri heart valve
45493238|NCT03726281|Drug|Nivolumab|Nivolumab 240 mg, IV
45493239|NCT05664815|Biological|Human Amniotic Membrane|"After conventional/standard treatment, hAM will be applied in a single layer against the bone defect with, if possible, a burial of a few millimeters under the mucous edges.~With the idea of apprehending a possible dose effect, the hAM will be adapted to the size of the bone/mucous defect, mesenchymal side against the bone.~For closure after hAM grafting : 2 options are possible:~Edge-to-edge closure if sufficient mucosal laxity, Edge rapprochement by cross points. If necessary: possible incision of the periosteum to give laxity to the mucosa."
46054327|NCT02874248|Drug|15 mg E4/3 mg DRSP|a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days
46054328|NCT02874248|Drug|30 mg E4/6 mg DRSP|a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days
46054329|NCT02874248|Drug|60 mg E4/12 mg DRSP|a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days
46054330|NCT02874248|Drug|Visually matching placebo|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
46054331|NCT02874248|Drug|75 mg E4/15 mg DRSP|a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
46054332|NCT02787603|Other|Interruption of antibiotic treatment due to PCT measurement|In group A at day 5, if the patient shows no clinical signs of infection and PCT levels < 0,25ng/mL OR PCT > 0,25 ng/mL AND 80% reduction in comparison with day 0 PCT levels, antibiotic will be interrupted. If there is a constant level or decrease less than 80% when compared day 0 or 5, there is no change in antibiotic treatment.
46054333|NCT02004834|Drug|levobupivacaine|Comparing: 0,5% levobupivacaine with 2% lidocaine
45377213|NCT00455013|Drug|Tacrolimus|The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally up to and including week 52. Post week 52 subjects assigned to the tacrolimus arm will receive tacrolimus orally in accordance with local practice and the package insert until completion of the trial
45377214|NCT00455013|Drug|Mycophenolate Mofetil (MMF)|Administered orally in a capsule or solution formulation in 2 divided doses on a consistent schedule in relation to time of day and meals. The dose should be 1 g bid; however 1.5 g bid may be administered at the investigator's discretion until completion of the trial
45377215|NCT00363298|Drug|dextro-amphetamine|dextro-amphetamine dosage form: 15 mg capsules, in Bottles A and B. Dosage: One capsule from Bottle A and one capsule from bottle B each morning. Frequency: once daily. Duration: 5 weeks.
45693498|NCT00792610|Biological|hepatitis B vaccine|Recombinant HBsAg, 20mcg/ml/vial (GSK) one vial IM at Day 0, Month 1, month 6 during follow-up, respectively.
45377216|NCT00363298|Drug|Sham Comparison|caffeine dosage form: capsules identical to those in dextro-amphetamine arm, but containing 200 mg caffeine in Bottle A and 100 mg caffeine in Bottle B. Frequency: once daily. Duration: 5 weeks
45377217|NCT05261412|Other|Standard Consent|Participants in the control arm will undergo Standard Consent which will consist of paper PIL provided by EIDO healthcare followed by a verbal discussion (standardized by following a checklist of topics to discuss) with the responsible consultant surgeon and signing of the consent form. The time taken to read the PIL (self-recorded by the patient) will be recorded. The time spent with the responsible surgeon will also be recorded, as will the number of questions asked by the participant.
45693499|NCT00792688|Drug|GLYC-101 Gel (0.1%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
45693500|NCT00792688|Drug|GLYC-101 Gel (1.0%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
45693501|NCT00792688|Drug|GLYC-101 Placebo|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
45693502|NCT05640778|Drug|Dalpiciclib combined with aromatase inhibitors|Dalpiciclib combined with letrozole or anastrozole
45693503|NCT05640778|Drug|anthracycline-cyclophosphamide followed by taxane|4 cycles of anthracycline-cyclophosphamide (EC) followed by 4 cycles of taxane
45693504|NCT01743560|Drug|RAD001|All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
46054334|NCT02788305|Drug|Misoprostol|Misoprostol 25 micrograms every 6 hours will be given to obese and non obese groups
46054335|NCT01036724|Device|Cardiac Mapping|Generating a cardiac map using the study device (CARTO 3) compared to the control device (NAVX[TM]) and measuring the amount of radiation exposure duration for each.
46054336|NCT05758012|Drug|oxytocin|Participants will be randomized to receive Oxytocin after delivery of the baby's head and shoulders
46054337|NCT05758012|Drug|Carbetocin|Participants will be randomized to receive Cabetocin after delivery of the baby's head and shoulders
45377218|NCT05261412|Other|Digital health education tool (dHET)|Participants randomized to the intervention dHET will receive the dHET followed by a verbal discussion (as above) and signing of the consent form. The dHET will be delivered on a tablet computer and facilitated by a research assistant who will ensure all technological issues are overcome but will not engage with the participant with regard facilitating better understanding of the content. The digital offering will be interactive; participants will be able to traverse through each section at their own pace with the ability to re-visit sections. It also contains a two-minute narrated animation of the procedure, which can played, rewinded or fast forward. The time spent reading each section of the dHET and time spent watching the animation will be recorded. The time spent with the responsible surgeon will also be recorded, as will the number of questions asked by the participant.
45493240|NCT05664815|Other|Conventional/Standard treatment|"Surgical procedure: Endo-oral approach:~Trimming of the mucous edges if they are necrotic or inflamed (granulation tissue)~For the bone: either simple sequestrectomy (the mobile sequestered bone is grabbed using forceps); either reaming until bleeding is obtained; either resection with the rongeur; either monobloc resection of the entire necrotic fragment with a saw or with a piezzotome (ultrasound); or a combination of different techniques. Rq: the resection of the necrotic bone (according to the practices of the center) will operate until the appearance of an apparently healthy bone (bone bleeding, clean appearance of the bone site)~Closure of the mucosa with possible incision of the periosteum to provide laxity: Suture points by points separated in one plane with non-absorbable braided thread of the 3.0 silk thread type and round needle."
45498173|NCT05084313|Other|Manual Therapy|This group of patients will receive manual therapy techniques to harmonize vegetative nervous system. PPG and GSR will be recorded during the intervention. The techniques consist of CV-4 technique, suboccipital decompression, lumbo-sacral decompression, release of the transverse diaphragms, frontal lift technique, parietal lift technique, temporal techniques, temporo-mandibular joint myofascial release, deep cervical fasciae technique as described in Upledger's protocol. In addition to the protocol; rib raising technique, larynx and sternocleidomastoid muscle fascial release and occipito-mastoid suture release will be applied. All intervention is planned to take approximately 20 minutes. The group will include forty healthy individuals.
45693505|NCT01743560|Drug|Exemestane|All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were to be treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
45693506|NCT00796744|Drug|NorLeu3-A(1-7) in a gel formulation|Gel will be applied to the wound once daily for four weeks (treatment period). Gel will have either no active ingredient (placebo), 0.03% or 0.01% active ingredient.
45377219|NCT05254548|Drug|ACT-539313|100 mg ACT-539313 (hard capsules) will be administered twice per day in period 2 (morning and evening of Day 8), period 3 (morning and evening of Day 9 to 14) and period 4 (morning and evening of Day 15).
45693507|NCT01743092|Behavioral|Webinar|Some clients will receive a webinar as part of their treatment.
46054338|NCT05013528|Other|Bal-A-Vis-X training|"Bal-A-Vis-X training Performed thrice a week for 10 minutes after baseline assessment Standard Physical therapy treatment along with following exercises.~ball Rectangle~ball rectangle and 2 ball drop/pass/catch two-foot jumping forward, tandem walking on ground and tandem walking on the balance beam. ."
45377220|NCT05254548|Drug|Flurbiprofen|One daily dose of flurbiprofen 50 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
45377221|NCT05254548|Drug|Omeprazole|A single dose of omeprazole 20 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
45377222|NCT05254548|Drug|Midazolam|A single dose of midazolam 2 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
45693508|NCT01743092|Behavioral|Tutuorial workbook|A work book about their addiciton
46054339|NCT05013528|Other|Aerobic Training Group|"Aerobic training group performed exercises thrice a week for 10 minutes after baseline assessment.~Standard Physical therapy treatment along with aerobic training as Running is performed"
46054340|NCT02786667|Drug|Rotigotine|6 months treatment with Rotigotine up to 8 mg per day with a titration period for one month
46054341|NCT02786667|Drug|Placebo|6 months treatment with Placebo up to 8 mg per day with a titration period for one month
46054342|NCT00913276|Drug|Propofol|
46054343|NCT00913276|Drug|Sevoflurane|
46054344|NCT04302116|Drug|Combination therapy with vigabatrin and prednisolone|High dose prednisolone (40 - 60 mg/day) for 1 month combined with vigabatrin treatment (50-150 mg/kg/day) twice daily for 4 months
45377223|NCT00363142|Drug|Half-boosted Fosamprenavir|Once daily, reduced dose ritonavir-boosted fosamprenavir
45377224|NCT00363142|Drug|Full Boosted Fosamprenavir|Full ritonavir-boosted fosamprenavir
45377225|NCT05246982|Drug|HLX07+HLX10+oxaliplatin+capecitabine|HLX07 1500mg+HLX10 300mg+oxaliplatin 130mg/m2+capecitabine 1000mg/m2 q3w
45377226|NCT05246982|Drug|HLX07|HLX07 1500mg q3w
46054345|NCT04302116|Drug|Vigabatrin Tablets|Vigabatrin (50-150 mg/kg/day) twice daily for 4 months
45377227|NCT01027221|Radiation|neoadjuvant photon radiation|single fraction, four dimensions (4D) planned, image guided, Radiation at a dose of 0,5 Gy in Intensity modulated radiotherapy (IMRT)-technique 2 days before resection
45377228|NCT01027221|Radiation|neoadjuvant photon radiation|single fraction, 4D-planned, image guided, 2 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
45377229|NCT01027221|Radiation|neoadjuvant photon radiation|single fraction, 4D-planned, image guided, 5 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
45377230|NCT04002492|Behavioral|Bodyweight training|Video guided and physical therapist guided bodyweight training sessions will be performed twice a week for 6 (to 8) weeks. These sessions include the following five workouts at 3 sets of 10 repetitions: step ups, calf raises, wall push ups, chair squats, and chair dips.
45377231|NCT00454857|Other|Retrospective Chart Review|Retrospective chart review for up to 36 months of enrollment date.
45377232|NCT00454857|Other|Patient-reported Outcome Questionnaires|Quality of lige questionnaires as well as treatment satisfaction questionnaires are required monthly. Includes QOL, ITP-PAQ (immune thrombocytopenic purpura - patient assessment questionnaire), EQ-5D, and TSQM (Treatment Satisfaction Questionnaire for Medication).
45377233|NCT00454857|Other|Physician Survey|Physician characteristics to be collected include demographics, years of practice, medical specialty or primary treating physician, and the referral process.
45377234|NCT05243004|Other|Phone Nurse consultation|"A phone call will be made by the nurse 72 hours before the surgery. During this phone call, the nurse :~underlines the preoperative preparation instructions (skin preparation, fasting period, specific medical instructions given by the anesthesiologist, administrative instructions)~ensures that the reason for hospitalization is understood~answers the patient's questions."
45377235|NCT02534818|Drug|lower fluorescein sodium dosage 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on gastric intestinal metapalsia
45377236|NCT02534818|Drug|conventional fluorescein sodium dosage 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on gastric intestinal metapalsia
45377237|NCT04002024|Other|Moisturizer with active ingredients|Moisturizer with active ingredients: 1 fingertip unit to cover one side of the face twice a day
45377238|NCT04002024|Other|Placebo|Placebo: 1 fingertip unit to cover one side of the face twice a day
45377239|NCT01027299|Device|Biventricular pacing|Optimised temporary biventricular pacing.
45377240|NCT05355324|Other|no intervention|no intervention
45377241|NCT01028313|Drug|LBH589|20 mg PO three times weekly
45377242|NCT01028313|Drug|Methylprednisolone|1 mg/kg/day PO continuously
45377243|NCT04001712|Drug|Caffeine Citrate|caffeine citrate is given early to preterm neonates in need of respiratory support
45377244|NCT03794193|Procedure|Radical resection of colon cancer|The patients with colon cancer will receive radical surgery. Adjuvant chemotherapy will be given according to the results of postoperative histological results.
45377245|NCT05355246|Other|assisted sit-up exercises|Group A patients will be instructed to perform assisted sit-up exercises by lying on their back and lifting their torso. They will use their body weight to strengthen and tone the core stabilizing abdominal muscles. This exercise will perform a minimum of five and maximum of 10 repetitions, two times a day and two days a week. Isometrics, back stretching, and strengthening exercises will be given as a common intervention for both groups before starting treatment session.
46054346|NCT02786511|Drug|Safety and efficacy assessments|Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term implications of autologous transplant
45377246|NCT05355246|Other|swiss ball pikes exercises|Group B patients will be instructed to perform swiss ball pikes by getting into the pushup position, the rest of the tops of their feet on a swiss ball. Each patient should keep her legs as straight as possible, bend her hips and try to pull her feet towards their chest so that the ball rolls forward. Hold at the top for three to four seconds, then slowly roll back to the starting position. This exercise will perform a minimum of one or two and a maximum of 10 repetitions, two times a day and two days a week. Both exercises will be performed for 12 weeks in both groups. Isometrics, back stretching, and strengthening exercises will be given as a common intervention for both groups before starting the treatment session.
45377247|NCT01028469|Device|Artelon MTP Spacer|Metatarsophalangeal hemi-implant
45377248|NCT01027377|Drug|rFVIIIFc|Single dose
45377249|NCT01027377|Drug|rFVIIIFc|Single dose
45377250|NCT00992160|Drug|GW597599|GW597599 15mg tablet
45377251|NCT00992160|Drug|Placebo|Placebo to match GW597599 15mg tablet
45377252|NCT00379912|Drug|Azacitidine|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
45493241|NCT03148834|Procedure|Controlled Reperfusion|"Patients will be treated in the occluded coronary with a solution of venous blood and Dextran, prior to the Stenting procedure.~Controlled Reperfusion PCI consists of crossing the culprit lesion with guidewire and then advancing a balloon (over the wire) to the distal segment of the culprit vessel. Proximal to the main distal branch, inflate the balloon to low atmospheres, remove the guide wire and inject the solution through the light of the balloon. Then reposition the guidewire, perform angioplasty as usual on the lesion. If there is a large residual thrombus load and at the operator's discretion, change the balloon by a manual thromboaspiration catheter and use it.~Then perform stenting of the lesion. The solution will be given with a 1 cc syringe as a slow bolus, controlling symptoms and ST segment response.~The compounds in solution are venous blood drawn from the patient after administration of heparin and mixed with dextran in a 3/1 ratio."
45493242|NCT03720587|Other|Semi-structured interviews|Semi-struuctured telephone interviews
45493243|NCT03148912|Diagnostic Test|Diagnostic algorithm|The treating physician will complete an enrollment assessment including the 4T score pretest probability assessment14. All patients will have laboratory testing for HIT anti-PF4 as well as SRA testing. Results of the anti-PF4 assay (OD value) will be available to the treating physician who will be instructed to follow the study diagnostic algorithm
45693509|NCT00797212|Device|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with blood taken from the palm and forearm. These blood glucose AST results are compared with results obtained by healthcare professionals (HCPs) from subject fingersticks.
46054347|NCT05756998|Device|Copper T380 IUD ( Paragard 380 A ,CooperSurgical, Inc. © 2022) (classic technique)|During CS , placement of CuT380 IUD at the top of the uterine fundus with ring forceps or manually; before closing the uterine incision, the strings were placed in the lower uterine segment. If the cervix was closed, dilatation from above with ring forceps or manually. Strings passed through the cervix with ring forceps, then checking that IUD remains at the fundus of the uterus prior to closing the uterine incision. The surgeon took a good care not to include IUD strings within the sutures. Six weeks postpartum; Patients will be questioned for any symptoms of complications or side effects. Pelvic examination (per speculum) and transvaginal ultrasound will be performed. Patient satisfaction will be assessed: pain using (VAS score), missed threads.
45693510|NCT00792922|Drug|Azithromycin|Comparison of community coverage rate
45693511|NCT00792922|Drug|Azithromycin|Comparison of coverage levels at baseline treatment followed by annual treatment if prevalence of trachoma is >5%. In Niger, there will be a comparison of coverage levels in everyone versus in children ages twelve and under who are treated every 6-months.
45693512|NCT01780831|Drug|Raltegravir|RAL was given as oral granules for suspension.
45377253|NCT00379912|Drug|Erythropoietin|Erythropoietin 60,000IU subcutaneous injection weekly while on protocol therapy
45377254|NCT00379912|Drug|Azacitidine (Monotherapy)|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
45377255|NCT05239650|Drug|HLX07|1000mg
45377256|NCT05239650|Drug|HLX10|200mg
45377257|NCT05239650|Drug|mFOLFOX6|OXA：85 mg/m2;LV:400 mg/m2；5-FU：400 mg/m2
45377258|NCT00992238|Drug|Flavoxate Hydrochloride Tablets, 100mg|
45377259|NCT00992238|Drug|Urispas® Tablets, 100mg|
45377260|NCT00379834|Drug|Cosopt|Cosopt twice daily in both eyes
45377261|NCT04001322|Other|Community engagement|The government will conduct a cascade of sensitization meetings with traditional leaders at all levels to promote newborn line listing (birth registration), reconciliation of child's vaccination status and defaulter tracking (home-based follow up of children who have missed their vaccination doses) by health providers and community leaders
45377262|NCT04001322|Other|IRISS advert for opt-in|A module to advertise and demonstrate how individuals can opt-in to IRISS to receive the messages will be included in the community engagement sensitization meetings.
45377263|NCT04001322|Other|One-time SMS broadcast on immunization|General broadcast of SMS messages on the importance of immunization to all active mobile phone subscribers in the intervention LGAs
45377264|NCT04001322|Other|Scheduled weekly SMS reminder of health facility RI schedule to community leaders|"Traditional and religious leaders who have a phone or access to a phone and have been registered on IRISS will receive SMS messages on the immunization session schedule of the health facilities in their communities, so they can disseminated the information through their town announcers to inform parents and caregivers. For example, Ribah clinic is holding a vaccination session tomorrow from 8am to 2pm. Please take your child there to vaccinate them and encourage your neighbors to vaccinate their children."
45377265|NCT04001322|Other|Scheduled bi weekly RI messages to community leaders|"Traditional and religious leaders who own or have access to a phone and have been registered on IRISS will receive SMS messages on immunization, to share same with community members. The message categories are: 1) Educational messages that provide facts and increase knowledge, e.g. Have you heard of Penta vaccine? It protects against 5 diseases: they are diphtheria, whooping cough, tetanus, HiB and Hepatitis B. 2) Informative messages that dispel myths about immunization, e.g. Getting more than one vaccine at the same time does not harm a child. It is very important to completely receive all vaccine doses for full protection. 3) Normative messages to promote positive norms, e.g. Our religious leaders have immunized their children, what are we waiting for? 4) Motivational messages to inspire action, e.g. Each visit to the health center for vaccination will reap many health benefits. Say YES to good health, be on time and complete your child's vaccination."
45377266|NCT04001322|Other|Responsive individualized child vaccination schedule reminder to caregivers who opt-in|"Parents and caregivers who voluntarily registered their child's information into IRISS will receive a reminder, a day before, about their child's due vaccines and the schedule of vaccination sessions in the health facilities within their locality (wards), e.g. Greetings! Amina is due for Penta 1 tomorrow, kindly visit Ribah clinic. They vaccinate on Mondays and Thursdays."
45377267|NCT04001322|Other|Responsive one-time SMS message on hand washing to those that erroneously register on IRISS|"If individuals from control LGAs encounter IRISS adverts inadvertently and erroneously register into IRISS expecting a message, to avoid a loss in trust if no message is sent, they will receive a one-time general message about the importance of hand-washing, e.g. Wash your hand with soap and water every time you finish from to the toilet, to maintain clean hands and avoid germs that make you sick."
45493244|NCT03726203|Device|laparoscopic gynecologic surgery with the MiniLap System.|Subjects participating in the study will undergo laparoscopic gynecologic surgery as planned in the routine care, but using the MiniLap System instead of the conventional single-use trocars used usually.
45493245|NCT03726203|Device|laparoscopic gynecologic surgery with the conventional single-use trocars.|Subjects participating in the study will undergo laparoscopic gynecologic surgery as planned in the routine care using the conventional single-use trocars used usually.
45493246|NCT05233306|Device|MRI scanner (7 Tesla)|MRI and MRS examination at 7 Tesla; protocol duration of approx. 75 min
45493247|NCT03720353|Drug|SAS2094AH and SAS2094BH|SAS2094AH and SAS2094BH for 7 days, preceded by SAS2094AL and SAS2094BH for 3 days.
45493248|NCT03720353|Drug|SAS2094AL and SAS2094BL|SAS2094AL and SAS2094BL for 10 days
45693513|NCT05449132|Drug|RTX-GRT7039|RTX-GRT7039 intra-articular injection.
46054348|NCT05756998|Device|Copper T380 IUD ( Paragard 380 A ,CooperSurgical, Inc. © 2022) ( New technique)|During CS, the plunger will be removed, the introducer remains in place and the arms of the IUD were released to be in a transverse position. The introducer will be inserted in the cervical canal through the uterine incision, threads might be shortened if needed or if couldn't be advanced into the cervical canal, The introducer containing the IUD will be then pushed upwards , towards the uterine fundus.The IUD will be placed at the uterine fundus and the IUD will be stabilized at its fundal position by grasping the fundus between the thumb anteriorly and the other fingers posteriorly. The uterine incision was closed while the introducer is in situ , then the introducer will be removed vaginally at the end of CS. Six weeks postpartum; Patients will be followed as in the classic technique group.
45693514|NCT05449132|Drug|Placebo|Placebo matching RTX-GRT7039 intra-articular injection.
45693515|NCT04383730|Drug|Intravenous sedation|Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
46054349|NCT05756998|Procedure|cesarian section|Under general or spinal anathesia , the abdomen is opened in layers , the bladder is dissected downwards . The uterus is incised at its lower segment & the fetus is extracted , followed by the placenta & membranes . The CU T 380 IUD is inserted either by the classic technique or the standard technique . The uterus is closed in 2 layers by continous non - locked sutures .Proper hemostasis & closure of the abdomen in layers .
45493249|NCT03720353|Drug|Placebo|Placebo for 10 days. Capsules will mimic active treatments.
45377268|NCT00992316|Drug|PF-04531083|solution. doses to be selected based upon safety/tolerability/PK at preceeding dose
45377269|NCT00379210|Behavioral|Mindfulness Meditation Training (MMT)|8-week training course in mindfulness meditation
45377270|NCT00379210|Behavioral|Nutrition Education course|8-week course in nutrition
45377271|NCT02292706|Drug|Sofosbuvir|Exposure of interest for participants who received a sofosbuvir-based regimen in a previous Gilead study for chronic hepatitis C virus infection.
45377272|NCT00992472|Drug|Prochlorperazine suppositories, 25mg|
45377273|NCT00992472|Drug|Compazine® suppositories, 25mg|
45377274|NCT03453840|Drug|Artemether-lumefantrine|Children will receive the dispersible formulation of AL which contains 20 mg artemether, 120 mg of lumefantrine (Coartem® Dispersible). Weight-based dosing will be as below: <15kg, 1tablet; 15-25kg, 2 tablets; 25-35kg, 3 tablets; >=35kg, 4 tablets.
45377275|NCT05356650|Other|Mulligan Mobilization|The patient will be in a prone position. With one hand, the physiotherapist will fix the sacrum and place the fingers of her other hand under the anterior superior iliac spine. The therapist then pull the ilium on the sacrum and will instruct the patient to do press-ups. Treatment will be given with frequency of 3 sets with 10 repetitions on sacroiliac joint 3 times a week for 6 weeks
45493250|NCT02344264|Drug|Ropivacaine|"Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml."
45493251|NCT02344264|Drug|Saline|"Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml."
45493252|NCT03148678|Behavioral|Mindfulness|Subjects are provided with smartphone-based mindfulness intervention.
45493253|NCT03148678|Other|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of their own brain activity.
45493254|NCT03148678|Other|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
45493255|NCT03148678|Behavioral|Mind Wandering|Subjects are provided with smartphone-based mind wandering intervention.
45493256|NCT03112252|Other|no specifications. Depending on the patients|patients with allergic rhinitis
45493257|NCT02344030|Device|channeled blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
45377276|NCT05356650|Other|PNF|"PNF stretching will be performed using contract-relax techniques of agonists in supine, prone and side-lying. Contract-relax will be applied with a 6-second contraction with 80% force of the maximal isometric contraction on the muscles (iliopsoas, hamstrings and gluteal muscles) and will be followed by a 15-second passive static stretching in the opposite direction of that muscles. Three sets of stretching of each muscle will be performed for each position with the frequency of 3 times a week for 6 weeks.~Patient will be in supine, prone, side lying. Both groups will receive a baseline treatment (Moist Heat Pack for 10 minutes and 10 minutes of Ultrasound (0.75 MHz, continuous wave)"
45377277|NCT03439254|Drug|Obeticholic acid (10 mg)|Tablets administered orally once daily.
45377278|NCT03439254|Drug|Obeticholic acid (10 mg to 25 mg)|Tablets administered orally once daily.
45493258|NCT02344030|Device|standard blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
45493259|NCT03145246|Procedure|regeneration treated teeth loss|number of regeneration treated teeth loss
45493260|NCT03145246|Procedure|regenerated treated teeth with clinical attachment loss|regenerated treated teeth with clinical attachment loss ≥ 2 mm
45493261|NCT02343874|Other|No intervention|No intervention will be done. The exposure of interest in this study is alcohol consumption in patients attended in primary health.
45377279|NCT03439254|Drug|Placebo|Tablets administered orally once daily.
45493262|NCT02340208|Drug|L-DOS47|A treatment cycle will be 21 days with patients receiving L-DOS47 on cycle Days 1 and 8.
45493263|NCT02340052|Drug|Pain treatment|Registration af actual analgesic treatment and outcomes
45493264|NCT02340130|Biological|DP/MG/14-1|The administration regimen will consist of a rush build-up régimen and a follow up period
45493265|NCT02340130|Biological|DP/MG/14-2|The administration regimen will consist of a rush build-up régimen and a follow up period
45493266|NCT03112330|Device|Plasma rich platelet injection|Plasma rich platelet injection with 26-gauge needle and 2cc syringe on inferior turbinate mucosa
45493267|NCT03112330|Device|Saline nasal spray|two puffs of isotonic saline nasal spray twice daily
45377280|NCT00378898|Device|BRAVO capsule|
45493268|NCT03112486|Procedure|blood draw|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72, 96, 120, 144 (10 draws total). Each draw would be approximately 20 mL of blood (but no less than 10 mL).
45493269|NCT02339662|Drug|Gabapentin|muscles pain treatment
45493270|NCT02339662|Drug|Amitriptyline|muscles pain treatment
45693516|NCT04383730|Drug|Inhaled sedation|Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
45377281|NCT00378898|Procedure|Fluoroscopy|"one time xray to determine evacuation of bravo"
45377282|NCT00378898|Other|sham BRAVO capsule placement|
45377283|NCT02276950|Procedure|Coronary artery bypass surgery|Primary isolated coronary artery bypass surgery with or without use of cardio-pulmonary bypass
45377284|NCT02276950|Procedure|Heart valve surgery|Heart valve surgery, aortic valve replacement or other heart valve procedures
45377285|NCT01045720|Drug|Suo Quan Wan, Wu Lin San|Suo Quan Wan Wu Lin San Placebo 2/daily
45377286|NCT01045720|Drug|Placebo|Placebo (starch)
45377287|NCT00992550|Drug|Cigarette|
45377288|NCT00992550|Drug|Hookah|
45377289|NCT05354700|Drug|HLX07|HLX07 is a recombinant humanized anti-EGFR monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
45377290|NCT05354700|Drug|HLX10|HLX10 is a recombinant humanized anti-PD-1 monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
45377291|NCT05354700|Drug|carboplatin and etoposide|chemotherapeutics
45377292|NCT03339258|Drug|Doxazosin Mesylate, Extended Release|Doxazosin is FDA-approved for the treatment of hypertension and urinary outflow problems associated with benign prostatic hyperplasia. The immediate-release formulation is approved for use from 1mg up to 16mg. Based on drug company information and Micromedex, the SFVA pharmacy on-line reference resource for drug information, the only contraindication to use of doxazosin is hypersensitivity to doxazosin, its contents, or other quinazolines (e.g. prazosin, terazosin).
45377293|NCT03339258|Drug|Placebo|Placebo, or inactive pill.
45377294|NCT04002570|Other|blood samples collection|blood samples collection are performed at 4 different timepoints: preop, pre rt, week 6 rt, week 12-14 (fu) for GROUP I and GROUP II; blood samples collection are performed at 3 different timepoints: pre rt, week 6 rt, week 12-14 (fu) for GROUP I bis; blood samples collection are performed just once for control GROUP.
45493271|NCT02343796|Other|Fibreglass reinforced composite restoration-everStick|For those subjects with space availability on interocclusal distance, composite resin restorations with fibreglass reinforcement will be applied without any tooth preparation by using adhesive techniques.
45377295|NCT00992628|Device|Macintosh (direct vision) laryngoscope|Macintosh (direct vision) laryngoscope
45377296|NCT00992628|Device|GlideScope videolaryngoscope (indirect vision)|GlideScope videolaryngoscope (indirect vision)
46054350|NCT04202562|Procedure|Ab interno trabeculectomy|Ab interno trabeculectomy performed after pupil contraction and 90 degrees ablation of the nasal trabecular meshwork
45493272|NCT02343796|Device|everStick|GC, Belgium
45493273|NCT02343718|Drug|Vinblastine|
45377297|NCT00378508|Drug|mAb hOKT3gamma1(Ala-Ala), Teplizumab|This is a randomized, two-arm, double blind placebo controlled phase II trial in which 60 participants with recent-onset T1DM are randomized at a 1:1 ratio to receive Teplizumab or placebo over a 14 day treatment period. The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2.
45377298|NCT00378508|Drug|Placebo Arm|
46054351|NCT04202562|Procedure|Cataract|Cataract surgery with minimal clear cornea incision and phacoemulsification
46054352|NCT04302194|Dietary Supplement|phenylalanine restricted diet|Infants with hyperphenylalaninemia on special formula and diet
45377299|NCT03212976|Procedure|Phase contrast magnetic resonance imaging|Phase-contrast magnetic resonance imaging will be done to assess intracranial pressure
45377300|NCT00992706|Drug|antiperspirant cream F511|Placebo and verum cream once daily, in the morning, during the first week of the first PLD treatment only, then once daily, three times per week (in the morning). Tube R for right hand and foot, tube L for left hand and foot.
45377301|NCT00992706|Drug|pegylated liposomal doxorubicin hydrochloride|According to local practice. 1, 2 and 4 week schedules with at least 10mg/m2 per week are allowed.
45493274|NCT02343718|Drug|Temsirolimus|
45377302|NCT02534740|Drug|tafamidis|relative bioavailability
45377303|NCT02534740|Drug|tafamidis|fasted
45377304|NCT02534740|Drug|tafamidis|fed
45377305|NCT03112200|Procedure|Subchondroplasty with Arthroscopy|The Subchondroplasty® (SCP®) Procedure targets and fills bone defects with AccuFill® Bone Substitute Material utilizing an arthroscopic / percutaneous approach. Using intraoperative fluoroscopy, the bone defect is localized relative to MRI findings The appropriate AccuPort® Delivery Cannula is drilled to the bone defect. AccuFill® Bone Substitute Material is then injected into the subchondral bone defect. The calcium phosphate (CaP) fills the edematous void and hardens within the Bone Marrow Lesion. The CaP is resorbed over time and replaced with new bone during the healing process.
45377306|NCT03112200|Procedure|Arthroscopy Alone|An endoscopic examination, therapy and surgery of the knee joint.
45377307|NCT01580956|Other|VARIABLE-PSV ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
45493275|NCT02343562|Dietary Supplement|Probiotics|Probiotics in the form of sachet will be given twice daily for a period of at least 6 months during the trial period.
45493276|NCT02343562|Dietary Supplement|Placebo|Multivitamin off-the-counter.
45377308|NCT01580956|Other|STANDARD-PSV ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
45377309|NCT03025308|Drug|Filgotinib|Tablet(s) administered orally once daily
45377310|NCT03025308|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
45377311|NCT00454779|Drug|Cisplatin|chemotherapy arm
45377312|NCT00454779|Drug|Panitumumab|experimental arm
45377313|NCT00454779|Drug|Docetaxel|chemotherapy arm
45377314|NCT00454779|Drug|Cisplatin|experimental arm
45377315|NCT00454779|Drug|Docetaxel|experimental arm
45377316|NCT00992862|Drug|Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.|
45493277|NCT03148522|Drug|Escitalopram|receive escitalopram
45377317|NCT00992862|Drug|Univasc® 15mg Tablets|
45377318|NCT00992940|Procedure|Patient-Controlled Sedation/Analgesia|Patient controls delivery of sedation and analgesia requirements.
45377319|NCT00992940|Procedure|Anesthetist-Controlled Sedation/Analgesia|All sedation and analgesia requirements are determined and delivered by the attending anesthetist.
45377320|NCT05350254|Other|Chiropractic maintenance care|Manual Therapy, individual exercises and lifestyle advice
45493278|NCT03148522|Drug|Duloxetine|receive duloxetine
45493279|NCT03148522|Drug|Mirtazapine|receive mirtazapine
45493280|NCT02339896|Biological|rabies vaccine|rabies vaccine 0.1 ml intradermal two site for 4 times
45493281|NCT03148444|Drug|cefalexin 500 mg qid or roxithromycin 150 mg bid|antibiotics treatment for five days following implantation of cardiac device
45493282|NCT03148132|Drug|Bevacizumab Injection|0.5mg/0.02 mL
45493283|NCT03148132|Drug|Ranibizumab Ophthalmic|0.25mg/0.025 mL
45493284|NCT02339350|Drug|high dose methotrexate|HD-MTX IV 5,000 mg/m2 I.V. over 4hr on day 0, 14, 28, 42 of SER interim maintenance schedule
45493285|NCT02339350|Drug|Intrathecal triple chemotherapy|Intrathecal triple chemotherapy for SEG group instead of radiotherapy
46054353|NCT05756920|Drug|ABL301|single dose, IV infusion
46054354|NCT05756920|Drug|Placebo|single dose, IV infusion
46054355|NCT04219176|Diagnostic Test|Spectral optical coherence tomography|Swept-source optical coherence tomography (SS-OCT) is the latest milestone in retinal and choroidal imaging. Because its wavelength of 1050 nm, which is superior to the 840 nm of spectral domain optical coherence tomography (SD-OCT), it is able to overcome ocular opacities such as cataracts and vitritis, wich allows retinal and choroidal visualization of eyes whose fundus is not clearly visible. Consequently , SS-OCT allows visualization of the retinal and choroidal vascular networks, even in eyes with medium opacity
46054356|NCT04198077|Drug|Oxygen|Administered via invasive or non-invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1.0
46054357|NCT04301960|Other|Single task training|The single task group includes balance gaining and cognitive training. The single task group will have 30-40 minutes of single-task training for 3 sessions per week for 8 weeks.
46054358|NCT04301960|Other|Dual task training|The dual-task group includes CSRT Mat training. The dual-task group will have CSRT Mat training for 30-40 minutes of dual-task training for 3 sessions per week for 8 weeks.
46054359|NCT02890212|Dietary Supplement|selenium supplementation|administration of selenium pills (400 micrograms) for randomized subjects
46054360|NCT02890212|Dietary Supplement|placebo|administration of placebo pills for randomized subjects
45377321|NCT05350254|Other|Standard chiropractic care|Standard care based on clinician's judgement
45377322|NCT02416206|Drug|BeEAM|BeEAM
45377323|NCT05350176|Dietary Supplement|Probiotic|Probiotic capsules will be composed of 10 billion CFU of Lactobacillus plantarum.
45493286|NCT05166304|Drug|Rebamipide|patients will receive the standard therapy plus 100 mg Rebamipide three times daily
45493287|NCT05166304|Drug|Placebo|patients will receive the standard therapy (methotrexate) plus placebo tablets
45377324|NCT05350176|Dietary Supplement|Placebo|Capsules containing dextrose (1 capsule per day)
45493288|NCT02339428|Drug|diclophenac sodium|Patients will be given 100mg p.o. diclophenac sodium tablets
45377325|NCT00993096|Drug|insulin degludec/insulin aspart|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
45377326|NCT00993096|Drug|insulin degludec/insulin aspart|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
45377327|NCT00993096|Drug|insulin degludec/insulin aspart|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
45377328|NCT00993096|Drug|biphasic insulin aspart 30|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
45493289|NCT02339428|Drug|Placebo|Inactive pill manufactured to mimic diclofenac tablet
45493290|NCT02337322|Drug|Dolutegravir|
45493291|NCT02337322|Drug|Darunavir/r|
45493292|NCT02337166|Device|a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate|0.2ml of a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate MW 1.3 x 106
46054361|NCT03756051|Other|Prospective Longitudinal Data|We will prospectively follow the cohort using electronic medical record to document the hepatocellular carcinoma screening process and characterize physical and financial harms related to positive or indeterminate screening results and burden of inappropriate screening. Patients are anticipated to undergo hepatocellular carcinoma screening every 6-12 months, so each patient will have ~4-8 screening encounters over the study duration. We will use manual chart review to determine intent of ultrasound exams (screening vs. diagnostic) and test results. Receipt of follow-up tests after positive or indeterminate screening results will be identified through electronic medical record extraction using Current Procedural Terminology (CPT) codes for CT, MRI, and biopsy.
46054362|NCT03756051|Other|Surveys and Semi-structured Interviews|"We will use surveys and semi-structured interviews to characterize psychological harms after positive or indeterminate screening tests. Patient surveys will include patient-reported scales to measure psychosocial factors at three times points: baseline, 1 month after screening result, and 4 months after screening result. Semi-structured interviews will be conducted via telephone to explore patient attitudes toward risk perception, test follow-up, competing demands, and downstream harms, particularly financial issues (e.g., out-of-pocket costs, access to insurance, and juggling hepatocellular carcinoma screening process completion with competing demands-work and family)."
46054363|NCT02850432|Procedure|Invasive treatment|Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol
45377329|NCT00993096|Drug|biphasic insulin aspart 30|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
46054364|NCT02850432|Other|Conservative treatment|rehabilitation with medical therapy
46054365|NCT05387577|Drug|Estradiol Tablets|Oral estradiol will be taken sublingually, 1 mg BID for 8 weeks
46054366|NCT05387577|Drug|Transdermal patch|Estradiol patch therapy for 8 weeks
45377330|NCT00993096|Drug|biphasic insulin aspart 30|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
45377331|NCT00439569|Drug|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD
45377332|NCT00443079|Drug|IdB 1016 (Siliphos)|1 pill 3 times daily x 6 weeks
45377333|NCT00443079|Drug|Matched placebo|1 pill 3 times daily x 6 weeks
45377334|NCT01033929|Biological|rdESAT-6 + rCFP-10 (C-Tb)|rdESAT-6 + rCFP-10 (C-Tb) skin test +/- phenol administered intradermally by the mantoux injection technique. Each patient receives the unpreserved version in one arm and the preserved version in the other arm in double blind manner.
45377335|NCT02188836|Device|Electromagnetic stimulation|Electromagnetic stimulation with a new device produced by the investigators for this study.
45377336|NCT02188836|Device|Sham stimulation|This is a device that look exactly the same to the electrostimulation device, but that does not generate the electromagnetic field. It is a placebo device.
45493293|NCT02337166|Procedure|Periodontal flap surgery|
45493294|NCT03148288|Dietary Supplement|Vitamin D|VItamin D
45493295|NCT03148288|Dietary Supplement|placebo|placebo
46054367|NCT05387577|Drug|Estradiol Tablets|Oral estradiol 1 mg BID for 8 weeks
45377337|NCT00993174|Procedure|Topical strabismus surgery|Surgery is carried out after instilling drops for anesthesia and administering lidocaine gel during the procedure
45377338|NCT00993174|Procedure|Sub-Tenon's strabismus surgery|Surgery is carried out after sub-Tenon's injection of xylocaine
45493296|NCT02339272|Other|non interventional|
45493297|NCT02348944|Other|serum and urine sample|Serum and urine samples will be collected at baseline, weeks2, 16, 52 and 68 to assess intra-individual biological variability of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 / FIB3-1 and FIB3-2.
45493298|NCT02039362|Drug|Tenofovir DF|Tenofovir DF will be started at week 28 of pregnancy and stopped or not, according to the physician's decision, at week 12 after birth
45493299|NCT04948138|Dietary Supplement|Glutamine oral supplementation|Oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations).
45493300|NCT02348866|Other|method of laundering and donning scrubs|
45493301|NCT04895956|Procedure|Intra-sheath injection|Ultrasound guided corticosteroid injection composed of 1ml of 1% lidocaine and 1ml (20mg) of dexamethasone. Injection will be administered directly into the abductor pollicis longus/ extensor pollicis brevis sheath.
45493302|NCT04895956|Procedure|Extra-sheath injection|Ultrasound guided corticosteroid injection composed of 1ml of 1% lidocaine and 1ml (20mg) of dexamethasone. Injection will be administered surrounding the abductor pollicis longus/ extensor pollicis brevis sheath.
45693517|NCT04572139|Diagnostic Test|Pituitary stimulation test|Pituitary stimulation with 0.1 mg LHRH, 0.2 mg TRH and 0.25 mg ACTH
45377339|NCT02088372|Device|Vanguard with E1 PS Bearing|Evaluate Clinical Performance of Vanguard Knee with E1 Bearing in Korean Patient Population
45377340|NCT05348616|Other|epidemiology|To review of medical records to describe diagnosis and severity of the disease.
45377341|NCT05348616|Other|epidemiology|To compare pre- and per-Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
45377342|NCT00993252|Procedure|CT Scan|CT scan
45377343|NCT03190278|Biological|UCART123v1.2|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor
45377344|NCT02553915|Other|Placebo|Soybean oil placebo
45377345|NCT02553915|Drug|EPA 1 g/day|Omega-3 fatty acid extracted from fish oil, 1 g/day
45377346|NCT02553915|Drug|EPA 2 g/day|Omega-3 fatty acid extracted from fish oil, 2 g/day
45377347|NCT02553915|Drug|EPA 4 g/day|Omega-3 fatty acid extracted from fish oil, 4 g/day
45377348|NCT04001868|Procedure|Suboccipital inhibition|With the patient in the supine position and the therapist sitting at the head of the bed with the elbows resting on its surface. The therapist palpates the cervical spinous processes and slides the fingers upwards until contacting the posterior projection of the posterior arch of the atlas. Then, flexing the metacarpophalangeal at 90 degrees slowly raises the skull. The therapist's hands should remain together and the base of the skull should rest on his palms pressing with the index, middle and ring fingers of each hand in a sustained manner, but without causing pain. This pressure must be maintained during 4 minutes.
46054368|NCT02850354|Other|anti-g maneuvers|investigate the effects of anti-g maneuvers on cardiovascular and respiratory tolerance to the push-pull-effect.
45377349|NCT04001868|Procedure|Placebo technique|A superficial contact in the same area as the intervention, to rule out the exteroceptive effect associated with the therapist's contact.
45377350|NCT01034007|Combination Product|Tissue Engineered Vascular Grafts|Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance angiography (MRA)
45377351|NCT00993408|Device|ACT-293987 (NS-304)|
45377352|NCT01031199|Drug|F-18 FEDAA1106 (BAY85-8101)|MS/CIS patients: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer < 5 µg, PET
45377353|NCT01031199|Drug|F-18 FEDAA1106 (BAY85-8101)|Healthy controls: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer < 5 µg, PET
45377354|NCT03994107|Drug|Pegylated Liposomal Doxorubicin|"First phase PLD: 30mg/m2；35mg/m2；40mg/m2；IV, d1, q21d×6.~Second phase~PLD：MTD. IV, d1, q21d×6."
46054369|NCT02787759|Other|Hands-Free Walking|Walking on a treadmill at 60-80% maximum heart rate without holding onto anything
45377355|NCT03994107|Drug|Albumin-bound paclitaxel|220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.
45377356|NCT03994107|Drug|Trastuzumab|8mg/kg IV for the first infusion. Subsequent infusions 6mg/kg. d1, q21d×6.
45377357|NCT03119766|Drug|Kolofort|Oral administration
45377358|NCT03119766|Drug|Placebo|Oral administration
45693518|NCT04571749|Behavioral|Customized handoff|A customized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
46054370|NCT02787759|Other|Challenge Based plus Hands-Free'|Walking on a treadmill at 60-80% maximum heart rate without holding onto anything under 9 different challenging conditions
46054371|NCT03044613|Drug|Nivolumab|240mg or 1 mg/kg administered IV
45377359|NCT03474393|Other|systematic intensive therapy|intensive telephone och internet Contact with diabetes nurse for coaching and guidance over 4 months and 4 Control visits
45377360|NCT03469713|Drug|Nivolumab|"Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab)."
45377361|NCT00993486|Biological|Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)|Single intravenous infusion
45377362|NCT05346042|Other|duration infectiousness|is the probability and the duration of being infectious in hospitalized COVID-19 patients, consequently influencing the decision on cessation of isolation
45377363|NCT00427635|Drug|Esomeprazole|
45377364|NCT00993642|Drug|Panobinostat (LBH589)|Patients will be given five 30mg doses of HDAC inhibitor (LBH) over a period of two weeks. A dose will be taken on Days 1,3,5,8 and 10. Patients will have a diagnostic tumor biopsy prior to drug administration and a diagnostic biopsy within 48 hours (2 days) of the last dose.
45377365|NCT01564446|Other|Participants will receive a internet based secure message confirming adherence to post-discharge medication regimen|Participants will receive a internet based secure message via My HealtheVet (MHV), The VA's online medical record and secure messaging portal. The message will specify post-discharge prescribed medications and inquire about adherence to these medications.
45377366|NCT01028547|Drug|dexamethasone|single Bolus dose of dexamethasone 8mg
45377367|NCT01028547|Other|normal saline|2 ml 0.9% saline
45377368|NCT04001790|Behavioral|Project Search plus ASD Supports|Nine month job training program embedded on Fort Eustis military base.
45377369|NCT01031355|Drug|Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)|Oral, single dose, 3 mg EV + 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
45377370|NCT01031355|Drug|Estradiol Valerate (EV) (BAY86-4980)|Oral, single dose, 3 mg EV, washout phase between treatments: at least 7 days
45377371|NCT01031355|Drug|Levomefolate Calcium (BAY86-7660)|Oral, single dose, 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
46054372|NCT03044613|Drug|Relatlimab|80mg administered IV
46054373|NCT03044613|Drug|Carboplatin|standard care dose
46054374|NCT03044613|Drug|Paclitaxel|standard care dose
46054375|NCT03044613|Radiation|Radiation|standard care dose
45377372|NCT00993720|Drug|Liraglutide|after optimal treatment on insulin alone 10 patients with type 1 diabetes are treated for four weeks with Liraglutide : in the first week at 0.6 mg sc and after one week optitration to the recommended 1.2 mg sc pr day.
45377373|NCT00993720|Drug|Liraglutide|after optimal treatment with insulin alone, 10 type 1 diabetic patients are treated with Liraglutide at a dose of 0.6 mg sc. After one week the dose is optitreted to the recommended 1.2 mg sc pr. day.
45377374|NCT00993720|Other|continuous insulin therapy|after optimal treatment with insulin, patients continue on insulin for four weeks
45377375|NCT03006666|Behavioral|CHW Training|"CHWs will be trained in DM concepts, motivational interviewing, brief action planning, and stages of behavior change. CHWs will participate in a 105- hour core competency training. CHWs will conduct mock telephone counseling calls with trained standardized patients to enhance skills, gain feedback and develop confidence in these techniques.~In addition to these training experiences, CHWs will have letter templates, motivational interviewing scripts, and protocols available for patient outreach to standardize and guide patient outreach .~The completion of the CHW training will be followed by a final examination of knowledge and evaluation of trial encounters with mock participants (consisting of research staff and advisory board members).~Individuals who do not pass will receive intensive remediation and be required to repeat the examination.~Community Health Worker Coaching Intervention."
45377376|NCT03006666|Behavioral|Data Only|The teams randomly allocated will not have access to Community Health Workers.
45377377|NCT00427011|Drug|E2007|E2007 2mg tablets. Dose (2mg, 4mg, 6mg or 8mg), is taken orally at nighttime.
45377378|NCT05269992|Other|Real food products|As per arm/group descriptions.
45377379|NCT03891264|Drug|Cannabidiol|Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution. The recommended starting dosage is 2.5mg/kg taken twice daily (5mg/kg/day). After one week, the dosage will be increased to a maintenance dosage of 10 mg/kg twice daily (20 mg/kg/day). At the end of the first week, the patient will increase the dose to 10 mg/kg twice daily for the following week.
45493303|NCT04895956|Device|Ultrasound|To ensure accuracy of fluid deposition into the tendon sheath in the intra-sheath injection arm and outside of the tendon sheath in the extra-sheath injection arm, all injections will be performed under ultrasound guidance. The ultrasound machine used will be a portable ultrasound machine located at the UC Davis orthopaedic clinic in Sacramento
45377380|NCT00439179|Drug|cohort 1|Weekly gem + GW572016, 1000mg/day (combination)
45377381|NCT00439179|Drug|cohort 2|Weekly gem + GW572016, 1500 mg/day (combination)
45377382|NCT00439179|Drug|cohort 3|GEMOX + GW572016 1000 mg/day (combination)
45377383|NCT00439179|Drug|cohort 4|GEMOX + GW572016 1500 mg/day (combination)
45493304|NCT02339194|Procedure|Denture fabrication technique|"Both arm groups are composed by patients present severely resorbed mandibular alveolar bones who will receive complete dentures fabricated by means of a simpler techinique previously proved to be effective. Although for the traditional protocol group a second more complex impression step will be performed in order to evaluate if the simpler approach for this anatomical condition could be safely applied."
45493305|NCT02339116|Drug|fluoruracil|
46054376|NCT01052714|Behavioral|Lifestyle Balance|Patients assigned to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient - Be given a 7% weight loss goal - Be assisted in obtaining a 500 calorie reduction per day -Exercise for at least 30 min/day, at least 5 days a week - Maintain weekly food and exercise diaries -Be quizzed on their knowledge of healthy eating habits and nutrition
45377384|NCT03452007|Device|Epidural Stimulation|Spinal cord epidural stimulation will be administered through a multi-electrode array implanted in the epidural space over the dorsum of the spinal cord. An implanted package containing stimulating circuits, rechargeable battery, and wireless communication activates the electrodes (16 platinum electrodes arranged in three columns of [5-6-5]). The pattern of electrically active electrodes, as well as electrode voltage, stimulating frequency, and stimulating pulse width will be varied to facilitate effects toward bladder function.
45377385|NCT01034241|Dietary Supplement|Control|Diet consists of 15 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
45377386|NCT01034241|Dietary Supplement|High dairy protein|Diet consists of 25 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
45377387|NCT01034241|Dietary Supplement|vegetable protein|Diet consists of 15 En% vegetable protein and low GI, 55 En% carbohydrates and 30 En% fat
45377388|NCT01034241|Dietary Supplement|High GI|Diet consists of 15 En% dairy protein and high GI, 55 En% carbohydrates and 30 En% fat
45377389|NCT01031511|Behavioral|Cognitive Behavioural Therapy|16 weekly sessions of 1.5 hrs in small groups of 3-4 children conducted by 2 therapists
45377390|NCT01031511|Other|Social Recreational|16 weekly sessions of 1.5 hrs in small groups of 3-4 children, conducted by 2 therapists
45377391|NCT00438399|Drug|C. propionate - Corticosteroid 1|Twice daily application
45377392|NCT00438399|Drug|C. propionate- Corticosteroid 2|Twice daily application
45377393|NCT00438399|Drug|C. propionate -Corticosteroid 3|Twice daily application
45377394|NCT00438399|Drug|Corticosteroid 1- C. propionate|Twice daily application
45493306|NCT02339116|Drug|Oxaliplatin|
45493307|NCT02339116|Drug|Irinotecan|
45493308|NCT02339116|Drug|Bevacizumab|
45493309|NCT02349100|Device|Nellix Endoprosthesis|Implantation of Nellix
45493310|NCT02348710|Behavioral|Exercise OE workbook|The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many and diverse positive outcomes breast cancer survivors may experience. Participants will then be asked to focus on the three OEs they would most like to experience. Each section of the OE guide contains activities to target specific OE dimensions. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes
45493311|NCT02348710|Behavioral|Diet workbook|The workbook will contain the same activities as the intervention workbook but be focused on diet instead of exercise.
45493312|NCT03964402|Drug|intervention treatment|intervention treatment (any)
45493313|NCT02338804|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
45493314|NCT02338804|Other|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
46054377|NCT02834364|Drug|Encorafenib|450 mg p.o. once daily. One cycle is defined as 28 days
45377395|NCT00438399|Drug|Corticosteroid 2 - C. propionate|Twice daily application
45493315|NCT02338726|Other|Gynecological examination|Comparison of questionnaires and gynecological examination
45493316|NCT04824274|Drug|fentanyl|Fentanyl 10 mcg will be injected intrathecally during spinal anesthesia.
45493317|NCT04824274|Drug|morphine|Morphine 75 mcg will be injected intrathecally during spinal anesthesia.
45377396|NCT00438399|Drug|Corticosteroid 3 - C. propionate|Twice daily application
45377397|NCT00426231|Behavioral|Navigation by a health worker|Help provided by health worker to navigate medication access programs
45377398|NCT00426231|Behavioral|Information control|Information about medication access programs provided to the participant and their healthcare provider
45377399|NCT03386409|Behavioral|Free safe firearm storage device distribution|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a free device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
45377400|NCT03386409|Behavioral|Low cost safe firearm storage device|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a low cost ($5) device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
45377401|NCT00425607|Drug|Lonafarnib|Lonafarnib will be taken orally, twice per day, by all patients enrolled on this study. The drug is supplied to patients in capsule form, and for patients who are unable to swallow pills, the drug may be dissolved into solution. Every patient will start lonafarnib therapy at a dose of 115mg/kg. The study allows for patients to receive a dose escalation (up to 150mg/kg) if the drug is being well-tolerated. Every patient enrolled on this study will undergo two years of lonafarnib therapy.
45377402|NCT00437073|Drug|capecitabine|capecitabine 2000mg/m2/day orally, Days 1-14, every 21 days
45493318|NCT04824274|Procedure|Transversus abdominis plane block|Ultrasound-guided bilateral transversus abdominis plane block will be done. 0.375% ropivacaine 15 ml per side will be injected.
45493319|NCT04824274|Procedure|Sham block|Ultrasound-guided bilateral transversus abdominis plane sham block will be done. Normal saline 15 ml per side will be injected.
46054378|NCT02834364|Drug|Binimetinib|45 mg p.o. twice daily. One cycle is defined as 28 days
45377403|NCT00437073|Drug|topotecan|topotecan intravenous (IV, in the vien) 3.2mg/m2 Days 1, 8 and 15; every 28 days
45377404|NCT00437073|Drug|lapatinib|lapatinib administered 1250mg once daily orally
45493320|NCT03112018|Behavioral|data strengthening|Data strengthening: initial training, monthly data collection and feedback on data quality, access to dashboards, periodic Data Quality Assessments
45493321|NCT03112018|Behavioral|modified Safe childbirth checklist - control|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, limited feedback and mentoring on its use
45493322|NCT03112018|Behavioral|modified Safe childbirth checklist - enhanced|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, ongoing intensive feedback and mentoring on its use
45493323|NCT03112018|Behavioral|PRONTO training|Health provider training (PRONTO): initial 2-days modular training followed by a 6-week mentoring sessions (Kenya) or periodic modular refreshers and supplemental mentoring (Uganda), each over a 9-12 month period
46054379|NCT02786433|Other|conventional physiotherapy|
46054380|NCT02786433|Other|Virtual Reality with X- Box Kinect®|
46054381|NCT03021135|Procedure|Conventional Endoscopic Mucosal Resection|Conventional Endoscopic Mucosal Resection
46054382|NCT03021135|Procedure|Underwater Endoscopic Mucosal Resection|Underwater Endoscopic Mucosal Resection
46054383|NCT03573609|Device|Supranav|Continuous supraglottic suction device for patients with orotraqueal intubation an mechanical ventilation
45377405|NCT00425373|Drug|Valsartan + amlodipine 40/2.5 mg|Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
45377406|NCT00425373|Drug|Valsartan + amlodipine 40/5 mg|Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
45377407|NCT00425373|Drug|Valsartan + amlodipine 80/2.5 mg|Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
46054384|NCT04702620|Device|Ventica® device from Revenio|Measurement of expiratory flow variability for the detection of bronchospasm in infants
46054385|NCT05385393|Procedure|Arthroscopic posterior capsulotomy of the knee|"The arthroscopic posterior capsulotomy of the knee is performed according to the predefined surgical technique, which was described in detail in the following publication:~Malinowski K, Góralczyk A, Hermanowicz K, LaPrade RF, Więcek R, Domżalski ME. Arthroscopic Complete Posterior Capsulotomy for Knee Flexion Contracture. Arthrosc Tech. 2018 Oct 15;7(11):e1135-e1139. doi: 10.1016/j.eats.2018.07.008. PMID: 30533360; PMCID: PMC6262078."
46054386|NCT02850120|Procedure|Tension-free vaginal tape (TVT)|Surgical insertion of Tension-free vaginal tape (TVT) polypropylene mesh in the treatment of stress urinary incontinence.
45377408|NCT00425373|Drug|Valsartan + amlodipine 80/5 mg|Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
45377409|NCT00425373|Drug|Valsartan 40 mg|Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
45377410|NCT00425373|Drug|Valsartan 80 mg|Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
45377411|NCT00425373|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
45493324|NCT03112018|Behavioral|QI cycles|Quality Improvement Cycles (QI): facility teams performing PDSA cycles with mentoring support and twice annual Learning Collaborative sessions, plus opportunities to apply for small amounts of funds to support change efforts
45493325|NCT03112096|Drug|[18F]THK-5351|Imaging for evaluating the biodistribution, pharmacokinetics and safety of abnormal tau protein in the brain
45693519|NCT04382170|Drug|Dexmedetomidine sublingual film|Dexmedetomidine sublingual film for the management of agitation in hospitalized patients with delirium.
45693520|NCT01778023|Drug|somatropin|A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.
45377412|NCT00425373|Drug|Amlodipine 5 mg|Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
45377413|NCT00425373|Drug|Placebo|4 tablet and 2 capsule placebos taken once daily
45377414|NCT03742479|Device|Restylane® Silk|Injectable Hyaluronic Acid (HA)
45377415|NCT01031589|Drug|TMC278 (Rilpivirine) LA; Placebo|
45693521|NCT04933006|Diagnostic Test|Pulsevelocity|arterial stiffness evaluation with pulsewave velocity
46054387|NCT02850120|Procedure|Trans-obturator tape (TOT)|Surgical insertion of Trans-obturator tape (TOT) polypropylene mesh in the treatment of stress urinary incontinence.
46054388|NCT02850120|Procedure|Suprapubic sling (SS)|Surgical insertion of Suprapubic sling (SS) polypropylene mesh in the treatment of stress urinary incontinence.
46054389|NCT05383677|Drug|Anifrolumab|Anifrolumab 300 mg will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
46054390|NCT05383677|Drug|Placebo|Placebo will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
46054391|NCT02850042|Behavioral|Occupation-based practice (OBP)|
46054392|NCT02850042|Behavioral|Modified-constraint induced therapy (m-CIT)|
46054393|NCT03742635|Other|General Movements Assessment|Prechtl's Assessment of General Movements (GMA) is a tool used in early infancy to identify infants at high risk of cerebral palsy and neurodevelopmental impairment. General movements are complex motor patterns that involve the entire body, moving fluidly in different directions through the arms, legs, and trunk with variable speed, amplitude, force and intensity. During fetal development, spontaneously generated motor patterns, including general movements, can already be observed. The GMA is a functional assessment of the maturing nervous system that takes advantage of the fact that typically developing infants will have a progression in their general movements. This pattern is characterized by a writhing pattern in the early weeks post-term, followed by the emergence of fidgety movements at 3-5 months of age.
46054394|NCT02785575|Other|HeProCalc algorithm|Heparin and protamine dosage calculated by the algorithm HeProCalc
46054395|NCT05058144|Dietary Supplement|Drinkable solution|the volunteer will consume the volume 300 ml of water with
45377416|NCT03894540|Drug|IPN60090|Oral capsules given daily
45377417|NCT03894540|Drug|pembrolizumab|An intravenous solution in single-use vial to be diluted for infusion.
45377418|NCT03894540|Drug|paclitaxel|An intravenous solution in single-use vial to be diluted for infusion.
45377419|NCT03894540|Drug|IPN60090 single administration|Oral capsules given once
45377420|NCT00993876|Drug|citalopram|20 to 30 mg per day for 4 weeks
45377421|NCT00993876|Drug|reboxetine|4 to 8 mg per day for 4 weeks
45377422|NCT00993876|Behavioral|interpersonal psychotherapy|
45493326|NCT03111862|Diagnostic Test|NSTEMI Rule-Out according to hs-TnT|Rule-Out according to the rapid rule-out protocol of the current ESC Guidelines
45493327|NCT02509494|Biological|Ad26.ZEBOV|Ebola Zaire vaccine, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles.
45493328|NCT02509494|Biological|MVA-BN-Filo|MVA-BN-Filo- is a non-replicating vaccine, 0.5 mL IM injection of 1*10^8 Infectious Unit (Inf. U.).
45493329|NCT02509494|Biological|MenACWY|MenACWY is a WHO-prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.
45493330|NCT02509494|Biological|Placebo|0.9% saline for injection.
45693522|NCT01753297|Drug|Triptorelin 11.25 mg|Triptorelin, one injection every 3 months. A total of 3 injections (at baseline, 3 and 6 months)
45693523|NCT04382794|Drug|Retrospective case-control analysis|Evaluation of clinical, laboratory and instrumental parameters of diabetic patients during hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study
45377423|NCT05356260|Device|URincontrol4men|The intervention is built as an app
45377424|NCT05356260|Other|Care as usual|CAU will be that typically provided by GPs. Also patients will be informed about a page on thuisarts.nl regarding male LUTS. The pragmatic trial design means that care can vary depending on the preferences of patients and GPs in this group.
45377425|NCT04002336|Behavioral|Traditional Voice therapy|Traditional method of voice therapy
45377426|NCT04002336|Behavioral|Voice Therapy App|Smartphone app, which allows participants to record home practice sessions in real time and upload sessions to the app server for the clinician to access and track.
45693524|NCT04929496|Procedure|post-PCI FFR|final invasive physiology measurements after successful stent implantation, followed by functional optimization if physiology indexes remain positive.
45693525|NCT04920370|Drug|ALXN1720 SC|ALXN1720 will be administered via SC route.
46054396|NCT04232709|Other|Shared electronic patient record|MedChart allows access to a shared electronic patient record that contains selected information related to a patient's cancer treatment. If a patient contacts the after-hours telemedicine service, the oncology nurse will have access to this shared record
45377427|NCT05175612|Device|Lung auscultation with LungPass device (electronic auscultation)|Lung auscultation with electronic stethoscope
45493331|NCT02348554|Behavioral|Controlled conditions|The 13 volunteers in controlled conditions performed each of the nine activities several times according to the activity scenario: sitting, slow, normal and brisk walking, climbing and descending stairs (eight floors), standing, slow running and taking public transportation (tramway). The duration of each activity varied from 2 to 20 minutes.
45493332|NCT02348554|Behavioral|Free-living conditions|The spontaneous activities of 30 volunteers were recorded in the free-living conditions for a full day selected either during the week or the weekend.
45493333|NCT02348788|Drug|Artemether-lumefantrine + Primaquine|
45493334|NCT02348788|Drug|Chloroquine + Primaquine|
45493335|NCT03147976|Drug|AMG 337|6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4- yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2- methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
45493336|NCT05763108|Diagnostic Test|genetic test|COL1A1 or COL5A1 genetic test
46054397|NCT04232241|Drug|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation
46054398|NCT01372254|Behavioral|Standard Treatment|Participants will receive a standard smoking cessation treatment in individual format. Treatment will be delivered in five, 90-minute individual sessions, and with two booster sessions assessed scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
46054399|NCT01372254|Behavioral|BAD-AS|The Behavioral Activation for Drug Abusing Smokers (BA-DAS) treatment protocol will incorporate elements of the ST along with behavioral activation strategies, modified for smoking. Treatment will consist of five, 90-minute individual sessions, and with two booster sessions scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
46054400|NCT01372254|Drug|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level. Participants in both intervention arms will receive transdermal nicotine patch.
45493337|NCT05763108|Other|Beighton joint laxity test|Based on Beighton scale.
45377428|NCT05129358|Device|Dehydration|"The subject performs physical exercise (on an ergometer bicycle) at 80% of maximum heart rate for 60 minutes.~The subject is kept at this dehydrated state for an additional 60 minutes."
45377429|NCT05129358|Drug|Dehydration|The subject is given 20ug Furosemide, followed by up to two times 10ug after every 10 minutes until subject diuresis is above 1,5% of body weight. (Maximum total dose of Furosemide is 40ug). The subject is kept at this stage for an additional 60 minutes.
45377430|NCT05129358|Dietary Supplement|Rehydration|The subject is rehydrated through the use of 1.5 liters Resorb Sport (Nestle HealthScience). The intake must be made during 20 minutes. The subject is monitored for the following 60 minutes.
45377431|NCT05332626|Dietary Supplement|Probiotic group|The probiotic gorup is focused on the treatment of postmenopause osteoporosis women with a capsule cointained 1x10^9 CFU of Lactobacillus acidophilus UALa-01™/day (30 people)
45377432|NCT05332626|Dietary Supplement|Placebo group|The group is assigned on the treatment of postmenopause osteoporosis women without probiotic intervention (30 people)
45493338|NCT04811482|Behavioral|TCIT-CALM (Teacher-Child Interaction Training-CALM)|This intervention is designed to treat early childhood anxiety. It is an adaptation of parent-child interaction therapy (PCIT), in which teachers rather than parents are targeted as the therapeutic agent of change. The intervention follows the procedures of the CALM protocol, in which caregivers are taught play therapy skills to support and address anxious behaviors and avoidance.
45693526|NCT04920370|Drug|ALXN1720 IV|ALXN1720 will be administered via IV route.
45693527|NCT04920370|Drug|rHuPH20|rHuPH20 will be administered via SC route.
45693528|NCT04920370|Drug|Placebo SC|Placebo will be administered via SC route.
45693529|NCT04920370|Drug|Placebo IV|Placebo will be administered via IV route.
45693530|NCT01777321|Biological|Herpes zoster vaccine GSK1437173A|HZ/su vaccine administered either into the subcutaneous tissue of the upper arm (deltoid region) of the non-dominant arm or intramuscularly in the deltoid region of non-dominant arm on a 0,2-month schedule.
45693531|NCT04718350|Drug|levosimendan at a dose of 6 mcg/kg|levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
45693532|NCT04718350|Drug|milrinone at a dose of 50 mcg/kg|milrinone will be administered via inhalation at a dose of 50 mcg/kg after anesthesia induction
45693533|NCT01729819|Drug|Tolterodine tartrate extended release capsules|
45693534|NCT01729819|Drug|Desmopressin orally disintegrating tablets|
45693535|NCT01729819|Drug|Placebo orally disintegrating tablets|
46054401|NCT02785653|Drug|Sevoflurane|Patients were ventilated with 2 % inspired concentration of sevoflurane in a fresh gas flow of 5 litres containing 66.6% nitrous oxide and 33.3% percent of oxygen
45693536|NCT01776541|Biological|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
45377433|NCT05236296|Behavioral|EASE-CG|EASE-CG is an adapted brief psychotherapeutic intervention with relational support and trauma-based cognitive behavioral therapy (CBT) components.
45377434|NCT04001478|Diagnostic Test|Breath test|Patients will provide a breath test prior to gastroscopy or resection of Barrett's HGD lesion or oesophageal cancer.
45377435|NCT05088018|Other|Cannabigerol|Cannabigerol is a non-psychoactive cannabinoid obtained from the cannabis plant.
45377436|NCT05088018|Other|Placebo|A placebo form of the same swallowable tablet with no cannabigerol
45377437|NCT00535626|Device|Trident® Tritanium™ Acetabular Shell|Trident® Tritanium™ Acetabular Shell
45693537|NCT05434156|Drug|ELE-101|ELE-101 solution for intravenous infusion
45693538|NCT05434156|Drug|ELE-101 Placebo|ELE-101 placebo matching solution for intravenous infusion
45377438|NCT00994032|Procedure|percutaneous injection of cement into the vertebral body|percutaneous injection of cement into the vertebral body
45377439|NCT00994032|Other|Medical treatment|standard antalgic medical treatment
45377440|NCT05252286|Other|video watching|"Watching video In this group, when the patient conducts their rehabilitation exercise, the therapist would record the poor physical movement pattern from his/her performance by using the mobile phone or tablet. The patients will be provided with watching video exercise, containing 3-5 items of their poor physical performance, selected by the therapist as a feedback to let the patient practice when they return their bedside ward after their rehabilitation time. The content of video-watching exercise program will be changed or modified once weekly as the patient improve the physical movement performance."
45377441|NCT05252286|Other|paper group|In the paper sheet group, the therapist will give three to five poor movement patterns, selected from the patient conducting their rehabilitation program, to practice when returning bedside ward.
45377442|NCT05252286|Other|oral education group|the patient only receives the oral exercise education about how to improve their physical performance during their hospital stay.
45377443|NCT05315544|Device|CSI pVAD system|The CSI percutaneous ventricular assist device (pVAD) is being investigated as a temporary left ventricular system intended to support and/or provide hemodynamic stability during high-risk percutaneous coronary interventions.
45377444|NCT00994188|Procedure|Restored Kidney Transplant Between Family Members|Tumor part of the kidney or ureter and ureteral stricture is surgically removed or repaired and the kidney is restored and transplanted to a family member recipient
45377445|NCT00995280|Device|single lumen needle oocyte retrieval|single lumen needle use during oocyte retrieval
45377446|NCT00995280|Device|double lumen needle oocyte retrieval|double lumen needle with 1 time follicle flushing with at least 2 ml during oocyte retrieval
45377447|NCT05224518|Behavioral|elastic band training|elastic band training include stretching exercises
45377448|NCT00994266|Dietary Supplement|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
45493339|NCT04435158|Drug|SHR-1222|Pharmaceutical form: water injection Route of administration: subcutaneous injection
45493340|NCT04435158|Drug|Placebo|Pharmaceutical form: water injection Route of administration: subcutaneous injection
45693539|NCT00811564|Drug|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day
45693540|NCT00811564|Drug|latanoprost 0.005%|1 drop of study medication taken once daily
45693541|NCT00811798|Biological|Cervarix|Subjects will receive three doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
45693542|NCT04520776|Device|BAGUERA®C Cervical Disc Prosthesis|surgery
45377449|NCT00994266|Dietary Supplement|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
45377450|NCT05302674|Other|Hot Dry|98°F (36.7°C) and 20% relative humidity environment
45377451|NCT01646814|Drug|PL2200|PL2200, containing 325 mg aspirin active ingredient
45377452|NCT01646814|Drug|Aspirin tablets|325 mg aspirin tablets (USP)
45377453|NCT00994344|Drug|Darunavir/ritonavir|Darunavir/ritonavir 800/100 mg once daily
45377454|NCT00994344|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 400/100 mg twice daily
45377455|NCT00994500|Drug|vorinostat|Given orally
45493341|NCT02337010|Device|CeVOX|Central venous saturation was continuously monitored by using a CeVOX monitor (Pulsion Medical Systems, Munich, Germany). The CeVOX probe (PV2022-37; Pulsion Medical Systems, Munich, Germany) was inserted into the internal jugular central venous catheter as described in the user's manual.
45377456|NCT00994500|Drug|bortezomib|Given IV
45377457|NCT00994500|Other|pharmacological study|Correlative studies
45493342|NCT02337010|Device|CVP|Central venous pressure was continuously monitored by using a central venous catheter. The probe was inserted into the internal jugular central vein as described in the user's manual.
45493343|NCT02337010|Drug|Fluid bolus|If hypovolaemia was suspected fluid bolus was given in the form of 250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.
45493344|NCT02337010|Drug|Vasopressor|If hypotension was present it was treated with vasopressor as 10 mcg bolus or continuous infusion of norepinephrine (Arterenol® Sanofi, Germany).
45493345|NCT02338570|Drug|Everolimus|Patients will start study treatment on day 1 and will be treated with daily doses of everolimus (10 mg daily tablets).
46054402|NCT02785653|Drug|Rocuronium|rocuronium 0.6mg per kg body weight was given intravenously after induction of anaesthesia
46054403|NCT01052480|Biological|Anti-Influenza Immune Plasma|2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
46054404|NCT01052480|Drug|Standard Care|All subjects will receive an anti-influenza antiviral (e.g., oseltamivir or zanamivir), but may include treatment with licensed antivirals in patient populations or at doses not covered in the package insert, or with medications available under a EUA. Standard care may also include antibiotics and other medications.
45377458|NCT00994500|Other|laboratory biomarker analysis|Correlative studies
45377459|NCT01416636|Drug|Treprostinil sodium|
45377460|NCT00995358|Biological|peptide|Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
45377461|NCT00994578|Behavioral|CHESS|Patients randomized to the CHESS intervention will be trained to access the website. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support
45377462|NCT00994578|Behavioral|COPE|Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each of two oncologists visits over a maximum of a 9 month period, and access to the patient's audio-recorded conversations for review.
45377463|NCT00994578|Behavioral|CHESS/COPE|Participants in the CHESS/COPE arm will be given access to the University of Wisconsin CHESS modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired and receive technical support. COPE arm will receive training and access to the COPE patient intervention an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to two oncologists visits over a maximum period of 9 months, and access to the patient's audio-recorded conversations for review.
45493346|NCT02348320|Biological|Personalized polyepitope DNA vaccine|
45693543|NCT04520776|Device|Mobi-C® Cervical Disc|surgery
46054405|NCT02758860|Procedure|Colonoscopy|Patients will be submitted to diagnostic colonoscopy
46054406|NCT02787447|Drug|TKI|Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
46054407|NCT02787447|Radiation|Thoracic Hypofractionated Radiotherapy|40-45 Gy/5-15f
46054408|NCT02787447|Drug|Thymosin Alpha 1|Initiating thymosin alpha 1 therapy(1.6mg, qd, d1-d14;1.6mg, biw, d15-d90) at the second week of radiotherapy.
46054409|NCT00904722|Drug|CT-011|Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days).
45377464|NCT00995592|Behavioral|Philani nutrition intervention program (mentor mothers)|Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
45377465|NCT00994656|Device|Masimo multi-wavelength pulse co-oximeter|Subjects will have a finger probe that will measure the pleth variability index. They will also have an arterial line (as standard of care) from which arterial pulse tracings will be obtained.
45377466|NCT00999180|Procedure|Botulinum toxin type A and kinesiotherapy|Stroke, Botulinum Toxin
45377467|NCT00999180|Procedure|Saline and Kinesiotherapy|Saline and Kinesiotherapy
45377468|NCT03889704|Device|Omnistim® FX²|The Omnistim® FX² is a neuromuscular stimulation device that provides patterned electrical neuromuscular stimulation (PENS) via cutaneous electrodes placed over relevant musculature. The device mimics physiologic patterns of neuron firing.
45377469|NCT05280132|Procedure|Personalized antibiotic treatment|Personalized antibiotic treatment based on mPCR results, PCT (values and kinetics) and appearance of sputum.
45377470|NCT05280132|Other|Usual antibiotic treatment|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
45377471|NCT00999258|Drug|sirolimus|"The subjects assigned to the sirolimus conversion group will be initiated on sirolimus 5mg po daily at which time their tacrolimus dose will be decreased by 50%. Sirolimus levels will be checked within a week and adjusted in a linear fashion to achieve a trough goal of 12-15ng/ml in subjects within 1 year post-transplant, and 8-12 ng/ml in subjects more than 1 year post-transplant. Tacrolimus will be continued in these subjects until sirolimus target trough levels are achieved. Thereafter, tacrolimus will be discontinued indefinitely.~The subjects assigned to the tacrolimus maintenance group (control group) represent our present standard of care."
45377472|NCT05210712|Device|RS001.2 Respiree Cardio-Respiratory Monitor|The RS001.2 Respiree Cardio-Respiratory Monitor is intended as a noninvasive multiparameter monitor on the adult population
45377473|NCT00994734|Drug|Mifepristone|home administration of mifepristone
45377474|NCT00999336|Drug|Betrixaban|80 mg betrixaban qd for 8 days
45493347|NCT02337088|Procedure|Delayed cord clamping at 30 seconds|For subjects enrolled in the 30 second arm, the umbilical cord will be clamped at exactly 30 seconds after delivery
46054410|NCT00904722|Drug|Rituximab|Administered intravenously at the standard dose of 375 mg/m^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).
45377475|NCT00995826|Drug|CS-8958|Inhaled CS-8958
45377476|NCT00995826|Other|Placebo|Inhaled placebo
46054411|NCT02909361|Drug|Fulvestrant|500 mg on days 0, 14, and 28, and every 28 days thereafter
45377477|NCT00994812|Drug|metformin|The obese women will be randomized either to metformin (2g/day) or to placebo, and the non-obese either to metformin (1.5g/day) or to placebo. All subjects will be evaluated 1 to 7 days after spontaneous menstruation (oligomenorrheic patients), or at any other convenient time (amenorrheic subjects). After the treatment of 3 months with metformin/placebo alone, another appropriate infertility treatment will be combined with metformin/placebo (clomiphene, ovulation induction, insemination or in vitro fertilization) if no pregnancy has occurred. This treatment will be continued another 6 months' period. If pregnancy occurs, subjects will be re-examined at 7-8 weeks of gestation.
45377478|NCT00994968|Drug|cyclophosphamide|
45377479|NCT00994968|Drug|docetaxel|
45377480|NCT00994968|Drug|doxorubicin hydrochloride|
45377481|NCT00994968|Drug|tegafur-gimeracil-oteracil potassium|
45377482|NCT00994968|Procedure|neoadjuvant therapy|
45377483|NCT00994968|Procedure|therapeutic conventional surgery|
45377484|NCT03887442|Drug|Paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, every week.
45493348|NCT02337088|Procedure|Delayed cord clamping at 60 seconds|For subjects enrolled in the 60 second arm, the umbilical cord will be clamped at exactly 60 seconds after delivery
45493349|NCT05114902|Diagnostic Test|Nasopharyngeal swab|A sample obtained from the nasopharynx for detection of live pneumococci and pneumococcal respiratory carriage
46054412|NCT02873858|Other|smell and taste tests|
46054413|NCT05354349|Drug|PRA023 IV Low Dose|Drug
46054414|NCT05354349|Drug|PRA023 SC|Drug
46054415|NCT05354349|Drug|Placebo IV|Placebo
46054416|NCT05354349|Drug|Placebo SC|Placebo
46054417|NCT05354349|Drug|PRA023 IV High Dose|Drug
45377485|NCT03887442|Drug|Cetuximab + Paclitaxel|Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.
45377486|NCT00995982|Biological|VRC-FLUDNA056-00VP|
45377487|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort -1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~In this cohort, Hydralazine is administered at 10 mg/day."
45377488|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 0|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 25 mg/day in this cohort."
45377489|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 50 mg/day in this cohort."
45377490|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 2|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 100 mg/day in this cohort as 25 mg four times per day."
46054418|NCT02787525|Other|Questionnaire|"A clinical sweep follow up will be performed in all patients of both groups and results will be analyzed. It will be in form of a standardized questionnaire and if necessary telephone interviews asking about thrombo-embolic events, stroke, death, any bleeding but also on their current medication, comorbidities (i.e. arterial hypertension, diabetes mellitus, renal impairment and liver disease), any hospitalizations and their quality of life. For all events, the source documents will be gathered from general physicians, cardiologists, hospitals or registry offices.~The questionnaire will be sent by mail to the patients. If information is missing or unclear, patients and if necessary their treating physician will be contacted by phone."
46054419|NCT04301024|Other|assessing the nitrous oxide misuse|assessing the nitrous oxide misuse among teenagers consulting in an addioctology center dedicated to young drug users in montpellier
45377491|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 3|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 200 mg/day in this cohort as 50 mg four times per day."
46054420|NCT02849886|Drug|T lymphocytes iCASP9 ΔCD19|Intravenous injection of the T lymphocytes armed with the iCASP9 suicide gene
45493350|NCT02338414|Drug|Romiplostim|Subcutaneous Romiplostim (weekly injection) -> if titrated with maintaining PLT count between 50-200 x 10^9/L -> Subcutaneous Romiplostim (biweekly injection)
46054421|NCT02849886|Drug|Dimerizer drug AP1903|"AP1903 drug will be administrated at a dose of 0.4 mg/kg by intravenous route in the two following cases:~Acute Grade ≥II or symptomatic Grade I GvHD justifying systemic immunosuppression therapy;~Grade ≥3 toxicity attributable to GMC."
45493351|NCT02336776|Other|Functional electrical stimulation|"Functional electrical stimulation will be applied through self adhesive electrodes on the quadriceps muscle of both thighs, and these will be positioned at 60° of flexion and contained by a band for that exercise happen isometric form.~Parameter settings in the electrical stimulator are as follows: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20 s time off, intensity according to the patient's tolerance but enough to cause visible muscle contraction. The total time of each session starts at twenty minutes and is increased every week a total thirty-four minutes at the end of the eighth week. Intervention will be held three times a week for eight weeks and during hemodialysis session."
45493352|NCT02336854|Drug|Tacrobell tab. 2mg|
45493353|NCT02336854|Drug|Prograf cap. 2mg|
46054422|NCT02785497|Other|Control group|will be turn on the equipment, positioning the patient but no put intensity
46054423|NCT02785497|Other|Treatment group|This group will receive electrostimulation
46054424|NCT01340430|Drug|Trastuzumab|neoadjuvant FEC (fluorouracil, epirubicin, cyclophosphamide) followed by weekly paclitaxel and concomitant trastuzumab
46054425|NCT01029782|Drug|IV cefazolin plus oral probenecid and placebo cephalexin|Intravenous cefazolin 2 g IV plus probenecid 1 g daily plus cephalexin placebo orally four times daily.
45377492|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 4|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 300 mg/day in this cohort as 75 mg four times per day."
45377493|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 5|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 400 mg/day in this cohort as 100 mg four times per day."
46054426|NCT01029782|Drug|Oral cephalexin and saline IV plus probenecid placebo|Cephalexin 500 mg orally four times daily plus saline IV and oral probenecid placebo daily
45377494|NCT00999414|Drug|Carfilzomib|"Carfilzomib (20mg/m2) IV push to be given at maximum rate of 10ml/minute on Days 1 and Day 2 of Cycle 1 only.~Carfilzomib (27mg/m2) IV bolus to be given at maximum rate of 10ml/minute on Day 8, 9, 15, and 16 of Cycle 1, then through Cycle 2 and beyond if initial dosing with 20mg/m2 tolerated.~For patients who tolerated 27mg/m2 through cycle 2 Days 1 and 2, Carfilzomib dose may be escalated to 36mg/m2 on days 8, 9, 15 and 16 of cycle 2. If tolerated, subsequent cycles will utilize 36mg/m2."
45493354|NCT02338024|Behavioral|Modified Antiretroviral Treatment Access Study intervention|
45693544|NCT01742078|Drug|LY2541546 - IV|Administered IV
45693545|NCT01742078|Drug|LY2541546 - SC|Administered SC
45693546|NCT01742078|Drug|Placebo|Administered IV or SC
45693547|NCT01741688|Biological|Tocilizumab|Tocilizumab was administered according to the local label.
45693548|NCT01709084|Drug|Rilpivirine|Type=exact number, unit=mg, number=25, form=tablet, route=oral. Rilpivirine will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
45377495|NCT00999492|Device|Tecnis® Multifocal (TMF)|Aspheric, diffractive multifocal intraocular lenses
45377496|NCT00996138|Biological|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
45377497|NCT00995046|Drug|FVIII|6 months of prophylaxis treatment administered 3 or 4 times weekly according to patient's initial regimen, (standardized Malmö protocol 25 - 40 IU/kg/infusion). Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.
45377498|NCT00995046|Drug|FVIII|"1 month period where thrombin generating capacity will be evaluated, followed by 6 months of individually tailored prophylaxis regimen according to TGT results. Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done."
45377499|NCT00995124|Drug|NeutraLice Lotion|Head lice topical application to be applied once for 10 minutes.
45377500|NCT00995124|Drug|NeutraLice Advance Solution|head lice application to be applied once for 10 minutes
45377501|NCT00995124|Drug|Moov Head Lice Solution|Single application for head lice with 10 min application time.
45377502|NCT04001010|Drug|PPP011|1 capsule inhaled 3 times a day with a vaporizer device
45377503|NCT04001010|Drug|Placebo|1 capsule inhaled 3 times a day with a vaporizer device
45377504|NCT00999570|Other|Specialty training for knee surgeons|
45493355|NCT02338180|Other|proximal preventive sealants|On sound mesial surfaces of first permanent molars adjacent to a caries active lesion of second primary molar, after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
45377505|NCT04000542|Other|Pharmacist Intervention|The pharmacist will record a 30 second rhythm strip from patients using the KardiaMobile device and calculate the QTc interval using the Bazett calculation formula. The pharmacist will discuss the result with the patient and if necessary, will contact the prescriber to effect a medication change. If the QTc interval is greater than the 99th percentile, (470 ms for males, 480 ms for females) the pharmacist must contact the prescriber. The pharmacist will record any prescription changes which resulted from the intervention and the prescriber response. The pharmacist will email the rhythm strip (with study participation number) to a secure email at the Northeast Iowa Family Practice Center (NEIFPC). Rhythm strips will be archived for future potential research evaluation in a secure, electronic file.
45493356|NCT02338180|Other|proximal therapeutic sealant|On mesial surfaces of first permanent molars with caries active lesion adjacent to a caries active lesion of second primary molar , after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
45377506|NCT00999648|Other|Myofascial trigger point pressure release (deactivation)|The deactivation of MTP will be performed always by the same physiotherapist researcher using the same technique. Afterwards, a myofascial maneuver is performed in each treated muscle. All patients of the experimental group will be advised to perform complimentary procedures at home during the 10-week period treatment in order to maintain the status of the muscle up to the next session and to avoid losing the obtained result:(1) Stretching of the treated muscles, once a day for 25 seconds each, (2)Superficial heat in each treated muscle, once a day for 20 minutes, (3) Watch the correct postures during daily activities and sleeping.
45377507|NCT00999648|Other|Placebo myofascial trigger point pressure release|The physiotherapist researcher will press in an adjacent nontender muscle fibers of the same muscle that have MTP about 3cm to the right or to the left of each diagnosed MTP, using just a slight pressure on it, not enough for deactivation.
45377508|NCT04000698|Drug|Preparative regimen|"Preparative chemotherapy before allogeneic HSCT~Fludarabin~Cytarabine~Venetoclax~Daratumomab~Vecanoid Condition~treosulfan~fludarabine~thiophosphomide~Venetoclax~Plerixafor GVHD prophylaxis~abatacept~tocilizumab~rituximab~HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes"
45377509|NCT00996294|Procedure|biliopancreatic diversion, gastric bypass|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
45377510|NCT05272956|Procedure|enteral feeding with pushed syringe by the parents|enteral feeding pushed by parents with a syringe
45377511|NCT01004016|Drug|KPS-0373|
45377512|NCT01004016|Drug|Placebo|
45377513|NCT05181696|Diagnostic Test|Chest X-ray|Retrospective analysis of chest x-rays of patients with COVID-19
45493357|NCT02039440|Other|Blood draw|One-time blood draw
45377514|NCT04000932|Drug|Local platelet rich plasma (PRP) injection-T-Lab PRP kit|Platelet rich plasma (PRP) will be obtained by centrifugation of autologous anticoagulated whole blood. 1 ml PRP extract will be injected into the carpel tunnel (of the side with a diagnosis of carpel tunnel syndrome) via the distal wrist line using 23 gauge needle.
45493358|NCT02332330|Device|VEST|
45493359|NCT02338102|Other|Saline mixture|premeasured salt packets mixed with distilled water
46054427|NCT04232319|Behavioral|Sleep Hygiene Training|"The intervention will last approximately 45 minutes, and will be provided once/week for 3 weeks. The intervention is delivered live using web-cameras (e.g., Microsoft Zoom).~Registered and licensed occupational therapists will deliver the intervention. Each week, the interventionist will guide the participant through a workbook to provide knowledge regarding sleep hygiene strategies and examples on how to apply these strategies to improve sleep quality."
45493360|NCT02332174|Drug|rufinamide|comparison of different doses, sex and medication conditions
46054428|NCT01146990|Drug|ASQ-3, Bayley III, Neurologic exam|Developmental Scales of infant development - Children born to mothers who participated in the 17P-ES-003 study will be enrolled in this study and evaluated using the ASQ-3. Those meeting protocol criteria based on ASQ-3, will be evaluated using the Bayley III and have a neurologic examination.
45493361|NCT02338258|Device|Anti-rotational plate|
45493362|NCT02338258|Device|Exchanged Intramedullary nailing|
45493363|NCT02332252|Device|Scalpel|Skin incision performed with a scalpel during cesarean section.
45493364|NCT02332252|Device|Electrocautery|Skin incision performed with an electrocautery during cesarean section.
45493365|NCT02332252|Procedure|Skin incision|
45493366|NCT03493451|Drug|Tislelizumab|Administered intravenously
45493367|NCT02332096|Device|Home Sleep Testing Device|Patients will undergo obstructive sleep apnea screening with a FDA approved home sleep testing device.
45493368|NCT03726125|Drug|LY3374849 - SC|Administered SC
45493369|NCT03726125|Drug|Insulin Degludec - SC|Administered SC
45493370|NCT03726125|Drug|LY3374849 - IV|Administered IV
45493371|NCT03726125|Drug|Insulin Degludec - IV|Administered IV
46054429|NCT04232007|Device|closed-loop system for vasopressor administration|closed-loop system for vasopressor administration
46054430|NCT02785419|Behavioral|Arm Training with Action Selection|Treatment occurs in 1.5 hour sessions, 5 times a week for 3 weeks. In each treatment session, you will practice functional tasks with your weaker arm and hand. Additionally, you will be given cues on a computer screen that dictate your movement response (action selection). Practice will be scaled to match your current level of function and progressed over time as able.
46054431|NCT04583748|Behavioral|Sahaj Samadhi Meditation|Sahaj Samadhi Meditation (SSM) is a form of automatic self-transcending meditation that involves relaxed attention to a precise sound (mantra), to allow stress reduction and deep relaxation. This technique is easy to learn and offers the support of a group and facilitator.
46054432|NCT04583748|Behavioral|Health Enhancement Program|The Health Enhancement Program (HEP) is a standardized program used to teach participants about health promotion, including the benefits of a lifestyle of healthy diet, music, recreation, and exercise. In HEP, participants get the support of a group and facilitator, and talk through and try to implement positive health-enhancing life changes.
45493372|NCT02337868|Biological|HydroVax-001|HydroVax-001 West Nile Virus inactivated vaccine, alum-adsorbed given at doses of 1 mcg (low dose) and 4 mcg (high dose) IM on days 1 and 29
45493373|NCT02337868|Other|Placebo|0.9% Sodium Chloride Injection diluent will be given IM on days 1 and 29
45493374|NCT02336620|Drug|Ringer acetate|Ringer acetate 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
45493375|NCT02336620|Drug|Normal saline|NSS 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
45493376|NCT03725969|Dietary Supplement|Camel milk|Camel Milk administered 10 minutes before a mixed meal of carbohydrate and protein; 2-week washout between interventions
45493377|NCT03725969|Dietary Supplement|Cow milk|Cow milk administered 10 minutes before a mixed meal of carbohydrate and protein;2-week washout between interventions
45493378|NCT02336308|Drug|Ketamine|
45493379|NCT02336308|Drug|Placebo, Normal Saline|
45493380|NCT02332018|Radiation|Biplanar x-ray images|biplanar x-ray images with microdose and low-dose protocol
45493381|NCT02336386|Drug|CDD|Chemotherapy
45847144|NCT03064074|Drug|Fresolimumab|The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.
45493382|NCT02336386|Drug|CDD Plus Bortezomib|Chemotherapy plus Proteasome Inhibitors
45493383|NCT02337712|Radiation|q.d. RT|65 Gy in 26 fractions
45493384|NCT02337712|Radiation|b.i.d.RT|45 Gy in 30 fractions
45493385|NCT02337712|Drug|etoposide and cisplatin|etoposide and cisplatin concurrent with radiotherapy
45377515|NCT04000932|Drug|Local steroid injection-Diprospan ®, Schering Plough|The local steroid injection ((1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be performed once into the carpal tunnel.1 ml Diprospan ®, Schering Plough extract will be injected by using 23 gauge needle from the distal wrist line through the carpal tunnel only once.
45377516|NCT01004094|Behavioral|simple goal setting|This group will set goals only
45493386|NCT03093844|Device|Miltenyi CliniMACS® CD34 Reagent System|Miltenyi CliniMACS® CD34 Reagent System will be used to prepare CD34+ enriched/T-cell depleted cells from haploidentical mobilized peripheral blood.
45847145|NCT03043716|Other|PAP therapy with telemonitoring|Patients will receive a prescription for PAP therapy in the course of their clinical Routine pathway and afterwards be asked to enrol in the registry. The will be asked if they are willing to use telemonitoring technology.
45377517|NCT01004094|Behavioral|goal setting plus action intentions|This group will set goals and form action intentions (plans)
45377518|NCT01004094|Behavioral|goal setting plus coping intentions|This group will set goals and form coping intentions (plans)
45377519|NCT01004094|Behavioral|goal setting plus action intentions plus coping intentions|This group will set goals and form action intentions and coping intentions
45377520|NCT00999882|Drug|AZD8055|Dose escalation phase: Tablet taken orally, a single dose of AZD8055 on Day 1, followed by twice daily continuous dosing from Day 3 onwards, till discontinuation or withdrawal.Expansion phase: twice daily continuous dosing from Day 1 onwards till discontinuation or withdrawal.
45493387|NCT02337556|Other|Peptamen Bariatric|Commercially available enteral diet
45493388|NCT02337556|Other|Replete|Commercially available enteral diet
45493389|NCT04564534|Other|MoCA cognitive assessment|cognitive assessment using the validated MoCA test administered via an application on an iPad
45493390|NCT04490902|Procedure|Limbal transplantation combined with central penetrating keratoplasty|Limbal transplantation combined with central penetrating keratoplasty with single donor cornea
45493391|NCT04490902|Procedure|Limbal transplantation combined with central penetrating keratoplasty|Limbal transplantation combined with central penetrating keratoplasty with mixed component cornea
45493392|NCT02337400|Behavioral|"Cognitive behavioral smoking reduction program Smoke_less"|Duration: 5 weeks, 4 sessions over 2,5 hours and 2 phone calls
45493393|NCT02337400|Behavioral|15 minute counseling interview|
45493394|NCT02899858|Other|Movement Assessment|Documentation of ASIA A (T2-8) status at Belmont Gait Lab
45493395|NCT02899858|Other|MRI Scan|Total MRI of spine to evaluate condition of spinal cord
45493396|NCT02899858|Procedure|IntraSpinal Micro-Stimulation|IntraSpinal Micro-Stimulation will be performed using a maximum of 16 electrodes inserted along each side of spinal cord that correlate with movements created across all 3 joints (hips, knees, and ankles)
45493397|NCT02899858|Other|Follow up clinical exam|All subjects will be expected to return for a follow-up visit with Drs. Konrad at 1, 3 and 6 month follow up visits.
45493398|NCT02899858|Other|Post Op MRI Scan|An MRI will be obtained at 3 months following the procedure to document the impact of the mapping procedure on spinal cord anatomy.
45847146|NCT03012282|Diagnostic Test|Computed Tomography Perfusion Imaging|Undergo CT perfusion sequence
45493399|NCT02899858|Other|Follow up gait assessment|Follow-up assessment with the Belmont Gait Lab will be performed at the 6 month follow up visit
45493400|NCT03492281|Drug|vibegron|single daily oral dose of vibegron 75 mg for 12 weeks
45493401|NCT03492281|Drug|Vibegron placebo|placebo to match vibegron (experimental drug)
45493402|NCT03492281|Drug|Tolterodine Tartrate ER|single daily oral dose of tolterodine tartrate ER 4 mg for 12 weeks
45493403|NCT03492281|Drug|Tolterodine placebo|placebo to match tolterodine (active comparator)
45847147|NCT02945436|Behavioral|Substance Use Brief Intervention|SUBI is a counseling intervention based on Motivational Interviewing techniques that focuses on the substance use and sexual health risks of participants.
45847148|NCT02945436|Behavioral|Standard of Care (SOC)|Standard of care is Counseling Testing and Referral (CTR). CTR is a standardized service in which counselors provide HIV testing, risk-related counseling and appropriate referrals (medical, social, prevention, and partner services) to clients.
45847149|NCT02445456|Drug|Sienna+ injection|Endoscopic injection of magnetic tracer
45493404|NCT02331784|Behavioral|Computerized Plasticity-based Software|Participants will be asked to use their assigned training program for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
45377521|NCT00996528|Behavioral|Philani Intervention Program|Offered to pregnant women / mothers through mentor mothers, i.e. mothers in community who are selected because they are doing well. They are trained to conduct home visits, 2 times a months through pregnancy. After childbirth, visits are spaced depending on the perceived need. If the baby is thriving and mother is coping well with health risks, mentor mother will visit once a month.
45377522|NCT05170230|Drug|Terlipressin|intracapsular injection of Terlipressin versus Carbetocin for decreasing blood loss in women undergoing laparoscopic myomectomy
45377523|NCT00999960|Procedure|Laparoscopic Radical Prostatectomy (without a simulator)|without simulator
45377524|NCT00999960|Procedure|Laparoscopic Radical Prostatectomy (with a simulator)|Learning with a simulator
45377525|NCT01004328|Other|Intervention 1: Electronic medical record (EMR)-based transitional care intervention|Electronic delivery of enhanced discharge information to the ambulatory physician with plans for follow-up appointment, notice of any new medications, and recommendations for laboratory monitoring
45493405|NCT02331784|Behavioral|Commercially available Video Game|Participants will be asked to use their assigned video games for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
45493406|NCT02327494|Drug|neuromuscular blockade|to determine the influence on oxygantion saturation parameters of the administration of neuromuscular blockade drug, rocuronio, to provide intense neuromuscular blockade during laparoscopic colorectal surgery
45493407|NCT02336152|Device|Anaesthesia, Teles Pro, Body suit|
45377526|NCT01000038|Other|Wii-Fit intervention|Half hour daily, 5 days a week for 8 weeks
45377527|NCT01000038|Other|Walking|Half hour daily, five days a week for 8 weeks
45493408|NCT02331862|Drug|Methylprednisolone|Add methylprednisolone in addition to the experience antibiotics in children with urinary tract infection to see if the frequency of the renal scar formation could be decreased
45493409|NCT02327182|Drug|MT-4666|
45493410|NCT03784846|Behavioral|Mindfulness-Based Resilience Training|MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, CBT, and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
45493411|NCT03784846|Behavioral|Stress Management Education|SME was designed as an active control condition for other Mindfulness-Based Intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
45847150|NCT02445456|Other|MRI scan|MRI scan of pelvis to detect spread of magnetic tracer
45847151|NCT02445456|Procedure|Surgery to excise rectal cancer|Surgery as scheduled according to size and stage of rectal cancer. This will be either radical surgery or transanal endoscopic microsurgery (TEM)
45847152|NCT02445456|Device|Sentimag probe|Probe to detect the previously injected magnetic tracer (Sienna+)
45847153|NCT02316132|Drug|Stress|Corticotropin-Releasing Hormone
45847154|NCT02316132|Drug|Control|Saline 0.9%
45847155|NCT01871766|Drug|Vincristine|"Dosage and route of administration:~< 1 year of age=0.025 mg/kg intravenously (IV)~> 1 year and < 3 years= 0.05 mg/kg IV~≥ 3 years=1.5 mg/m^2 IV. Maximum dose 2 mg in all participants."
45377528|NCT01000116|Procedure|Fibrin glue|Tissucol 2 ml
45377529|NCT01000116|Procedure|Tacks|Protacks
45377530|NCT00996684|Drug|Microplasmin|Microplasmin, 1.875 mg, will be given by intravitreal injection,on Day 0.
45377531|NCT00996684|Drug|Placebo control|The placebo control will be the microplasmin vehicle without the microplasmin.
45377532|NCT00996762|Drug|lapatinib|1250 mg or 1500 mg lapatinib commercial tablet
45377533|NCT05162196|Radiation|SBRT|24Gy/3F
45377534|NCT05162196|Drug|Toripalimab|Toripalimab 240mg, ivgtt, d1, q3w.
45377535|NCT05162196|Drug|Niraparib|200mg qd
45377536|NCT04000464|Behavioral|CLIPP|Diabetes Prevention program and Comprehensive Lifestyle Improvement Program consisting of low calorie diet, physical activity, sleep optimization and stress management
45377537|NCT01000194|Dietary Supplement|High fat meal|A high fat milkshake containing 55g of fat
45377538|NCT01004484|Other|A probiotic yogurt with inulin|A 4 oz. cup with a probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10^7 cfu/g; 5x10^9 cfu/serving) and Inulin (3gr/serving), once daily.
45377539|NCT01004484|Other|Acidified dairy snack|A 4 oz. cup of acidified dairy snack, once daily.
45493412|NCT02327026|Procedure|bag-valve-mask ventilation|Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative.
45493413|NCT02327026|Procedure|tracheal intubation|Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management
45493414|NCT03720275|Genetic|Systematic screening of TTR mutations|The diagnosis of TTR-FAP requires genetic analysis using direct sequencing of TTR gene.The diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
45847156|NCT01871766|Drug|Dactinomycin|"Dosage and route of administration:~< 1 year=0.025 mg/kg IV push~≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes."
45377540|NCT01004562|Other|informational intervention|
45377541|NCT00997074|Drug|ibuprofen|The most common side effect observed during medical abortion using mifepristone together with misoprostol is abdominal pain. The use of ibuprofen was not shown to interfere with the action of misoprostol to induce uterine contractions and pregnancy expulsion.
45377542|NCT01004796|Genetic|cytogenetic analysis|
45493415|NCT02327104|Behavioral|Mindfulness Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems, and to prevent relapses.
45493416|NCT02327104|Other|Brazilian Ministry of Health Protocol|The control group will receive maintenance sessions based on the Ministry of Health protocol after the four sessions of cognitive-behavioral approach.
45493417|NCT03070782|Drug|ISIS 681257|ISIS 681257 solution for SC injection.
45493418|NCT03070782|Drug|Placebo|Sterile normal saline (0.9% NaCl)
45493419|NCT02335840|Other|CAF-1|In this intervention the volunteers ingested one dose of caffeinated coffee containing 144 mg of caffeine
45493420|NCT02335840|Other|CAF-2|In this intervention the volunteers ingested two doses of caffeinated coffee containing 288 mg of caffeine
45493421|NCT02335840|Other|CAF-3|In this intervention the volunteers ingested three doses of caffeinated coffee containing 432mg of caffeine
45377543|NCT01004796|Genetic|microarray analysis|
45377544|NCT01004796|Genetic|mutation analysis|
45377545|NCT01004796|Other|immunohistochemistry staining method|
45377546|NCT01004796|Other|immunologic technique|
45377547|NCT01004796|Other|mass spectrometry|
45493422|NCT02335840|Other|DESC|In this intervention the volunteers ingested one dose of decaffeinated coffee containing 108 mg of caffeine
45493423|NCT03756688|Device|RestoreX PTT - 6 months|Penile traction therapy in straight position for all 6 months.
45493424|NCT03756688|Device|RestoreX PTT - 3 months|Penile traction therapy in straight position for first phase (3 months)
45493425|NCT03525119|Biological|TDV|TDV SC injection
45493426|NCT03525119|Biological|HAV Vaccine|HAV Vaccine IM injection.
45493427|NCT03525119|Biological|TDV Placebo|Placebo-matching (normal saline (0.9% NaCl) SC injection.
45493428|NCT03525119|Biological|HAV Vaccine Placebo|Placebo-matching (normal saline (0.9% NaCl) IM injection.
45493429|NCT04423614|Other|Inspiratory Muscle Training|Inspiratory muscle training exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
45493430|NCT04423614|Other|Relaxation Breathing|Relaxation breathing exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
45493431|NCT05230654|Drug|Fosaprepitant|Fosaprepitant: 4 mg/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S<0.6m2, 2 mg/dose, q12h IV/PO; S>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.
45493432|NCT05230654|Drug|Placebo(normal saline)|Placebo(normal saline): 4 ml/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S<0.6m2, 2 mg/dose, q12h IV/PO; S>0.6m2, 4 mg/dose, q12h , IV/PO.
45493433|NCT05761314|Diagnostic Test|Molecular characterization of solid tumor in RASopathies|NGS analysis on tumor sample
45493434|NCT02039518|Drug|gemcitabine|gemcitabine 1000mg/m2，d1，d8，Q3W
45493435|NCT02039518|Other|observation group|observation group
45493436|NCT02228304|Drug|NT-503-3 ECT implantation|NT-503-3 ECT implantation is a biological sustained drug delivery device that could provide continuous delivery of an anti-VEGF therapy
45377548|NCT00997308|Drug|AZD1446|Solution, oral, for 4 weeks
45377549|NCT00997308|Drug|Placebo|
45377550|NCT01000584|Biological|Arepanrix, Vaxigrip 2009/2010|Group A: Single dose of Arepanrix and single dose of Vaxigrip 2009/2010 given concurrently
45377551|NCT01000584|Biological|Arepanrix, Vaxigrip 2009/2010|Group B: Single dose of Vaxigrip 2009/2010 given 3 weeks after single dose of Arepanrix
45377552|NCT01000740|Genetic|EGFR Mutation Test|Explore the EGFR mutation status from both tumour tissue sample and the free DNA in the peripheral blood using appropriate method(s) which may include ARMS assay, ME-PCR coupled sequencing and regular sequencing.
45377553|NCT01000740|Genetic|Ki-67 protein expression|Ki-67 protein expression in tissue will be analysed by IHC method.
45377554|NCT05249712|Drug|Darolutamide 300 mg|600 mg (300 mg × 2 tablets) twice daily with meals, equivalent to a total daily dose of 1200 mg.
45493437|NCT02228304|Drug|Eylea® injected intravitreally administered every 8 weeks|The first part, stage 1, Phase I is open label with the experimental treatment arm only. Eylea® injected intravitreally is only used as a comparator in the stage 2, Phase II, portion of the study.
45493438|NCT03722381|Drug|Amlodipine Besylate|Pharmacokinetics
45493439|NCT04352608|Biological|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.
45377555|NCT05249712|Other|Androgen deprivation therapy|The ADT regimen used by each patient will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescribing information.
45377556|NCT01005030|Other|Blood draw|Blood draw, two tubes, used for isolation of cell-free blood plasma
45377557|NCT01000896|Drug|AZD0530|film coated tablet, PO, daily
45377558|NCT01000896|Drug|Carboplatin|intravenous, 3 weeks
45847157|NCT01871766|Drug|Cyclophosphamide|"Dosage and route of administration:~During VAC chemotherapy:~< 3 years of age = 40 mg/kg IV~≥ 3 years of age = 1200 mg/m^2 IV, with MESNA.~During maintenance for intermediate-risk participants:~oral cyclophosphamide 50 mg/m^2/dose/day (liquid or tablet)"
45377559|NCT01000896|Drug|paclitaxel|intravenous, 3 weeks
45377560|NCT00425061|Biological|IMA-638|SC Injection, 12 weeks
45377561|NCT00425061|Biological|IMA-638|SC Injection, 12 weeks
45493440|NCT04352608|Biological|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.
45693549|NCT01709084|Drug|Efavirenz|Type=exact number, unit=mg, number=600, form=tablet, route=oral. Efavirenz will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
45847158|NCT01871766|Procedure|Surgical Resection|Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.
45493441|NCT04352608|Biological|Two doses of placebo at the emergency vaccination schedule|Two doses of placebo at the schedule of day 0,14 and one dose of booster immunization with placebo 6 months after the schedule of day 0,14 in phaseⅡ.
45847159|NCT01871766|Procedure|Radiation|Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.
45847160|NCT01871766|Drug|Bevacizumab|Dosage and route of administration: 15 mg/kg/dose/day IV.
45847161|NCT01871766|Drug|Sorafenib|Dosage and route of administration: 90 mg/m^2/dose twice daily.
45847162|NCT01871766|Drug|Myeloid Growth Factor|"If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice.~High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used."
45847163|NCT01871766|Procedure|Lymph Node Sampling|"Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in at risk patients."
45847164|NCT01871766|Drug|Irinotecan|Dosage and Route Administration: During interval compressed therapy - irinotecan 50mg/m^2 IV (maximum dose 100 mg/day) daily x 5.
45377562|NCT00425061|Other|placebo|placebo
45377563|NCT04000308|Drug|Quadratus Lumborum Block type 2|The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).
45847165|NCT01871766|Drug|Ifosfamide|Dosage and Route of Administration: During interval compressed therapy - Age > 1 year: 1800 mg/m^2/day IV x 5 Age <1 year: treat with 50% doses calculated on a m^2 basis.
45377564|NCT04000308|Drug|Wound Infiltration|Participants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
45377565|NCT01005186|Behavioral|Eating habits, diet and exercise|Programme of change to eating habits, diet and exercise
45377566|NCT00997542|Drug|Allopurinol|
45377567|NCT00997542|Drug|Placebo|
45377568|NCT01001130|Drug|fluticasone furoate group|patients who are administered fluticasone furoate at least once
45493442|NCT04352608|Biological|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ.
45693550|NCT01709084|Drug|Tenofovir disoproxil fumarate|Type=exact number, unit=mg, number=300, form=tablet, route=oral. Tenofovir disoproxil fumarate will be administered in a fixed dose combination along with rilpivirine and emtricitabine in Group 1, and along with efavirenz and emtricitabine in Group 2.
45493443|NCT04352608|Biological|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ
45847166|NCT01871766|Drug|Etoposide|"Dosage and Route of Administration:~Age >1 year 100 mg/m^2/day IV x 5 Age < 1 year treat with 50% doses calculated on a m^2 basis"
45377569|NCT01005264|Device|non-removable fiberglass|Two types of fiberglass bandages (Softcast3M®, 3M Health Care, St. Paul, MN (USA)) were used for construction of the pressure-relief apparatus
45377570|NCT01005264|Device|Stabil-D®|Stabil-D Stabil-D® is composed of a specifically designed rigid, boat shaped, and rocker sole
45847167|NCT01871766|Drug|Etoposide Phosphate|Dosage and Route of Administration: Used in substitution for etoposide in participants who experience allergic reaction. It will be administered 100 mg/m^2/day IV.
45377571|NCT00424827|Drug|Gemcitabine/Fluorouracil with External Beam Radiation|This protocol will assess the antitumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (400mg/m2 loading dose followed by 250 mg/m2 weekly) when given with continuous infusion 5-FU (200 mg/m2/day/M-F) and daily concurrent external beam radiation therapy (50.4 Gy) in patients with non-metastatic, locally advanced pancreatic carcinoma.
46054433|NCT02785341|Other|questionnaires every 6 weeks (T0, T1, T2, T3 and T4)|Questionnaire MFI 20 Questionnaire life satisfaction Scale of measurement of the positive and negative affects Questionnaire QLQ-C30 (EORTC) Questionnaire on the personal goals
45377572|NCT01001286|Behavioral|Questscope Non-Formal Education|"Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators)."
45377573|NCT01028625|Behavioral|Cognitive Behavior Therapy|CBT utilizes a variety of strategies and techniques to modify cognitions and behaviors that contribute to depression such as behavioral activation; identifying and challenging distressing thoughts, beliefs, and attitudes; and systematic problem-solving. In this trial, CBT will be integrated with an intervention aimed at improving heart failure self-care, and with attention to primary caregiver stress. The CBT sessions will usually last about 50 minutes and will be scheduled weekly for up to 6 months, with additional maintenance contacts after that. The frequency of sessions will be tapered prior to 6 months if the participant meets the study criteria for depression remission and has acquired relapse-prevention skills.
45377574|NCT01028625|Other|Heart Failure Self-care Education|Participants in both arms will receive heart failure educational material from the Heart Failure Society of America. In addition, a RN will review educational material with participants during baseline visit and with 3 weekly follow up phone calls.
45377575|NCT01001364|Drug|Formoterol/Budesonide|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
46054434|NCT02785341|Other|6-minute walk test) every 6 weeks (T0, T1, T2, T3 and T4)|
46054435|NCT02785341|Other|leptin level with a blood test every 12 weeks (T0, T2 and T4)|blood sample
46054436|NCT02901717|Drug|Mino-Lok|Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter.
46054437|NCT02901717|Drug|Antibiotic lock|Standard of Care antibiotics appropriate for the infecting organism with an antibiotic lock solution using the same standard of care antibiotic delivered systemically. The antibiotic lock arm may include subjects with S. aureus, including methicillin-resistant S. aureus, vancomycin intermediate S. aureus, or vancomycin-resistant S. aureus; vancomycin resistant enterococci; Candida, Pseudomonas; other Gram negative organisms; or other organisms deemed to be of high virulence per the Investigator. The standard of care antibiotic will be determined by the investigator at the start of treatment.
46054438|NCT02849730|Device|Fentanyl/ropivacaine based Epi-PCA|Fentanyl and ropivacaine was diluted and administered to the patients according to the clinician's determination. The clinician decided dose, infusion rate, bolus dose, lockout time and total amount of drug mixed in the Epi-PCA.
46054439|NCT02786043|Drug|Propionyl-L-Carnitine Hydrochloride|1g twice a day on first 4 days and 1g/ day on day 5 during Phase III
46054440|NCT03530163|Device|Respiratory Muscle Training|Subjects will breathe through a custom isocapnic Respiratory Muscle Training method developed in-house. The initial breathing frequency will be 30 breaths per minute. Subsequent sessions will begin with 20 minutes of breathing at the highest rate attained on the previous training day. During the last 10 minutes of each session, breathing rate will increase by 1-2 breaths/min.
45377576|NCT01001364|Drug|Foraseq|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
45377577|NCT03994185|Device|Placement of WRAPSODY stent graft|Placement of WRAPSODY stent graft into the iliac arteries and/or aortic bifurcation.
45377578|NCT01031667|Drug|Cilostazol, Probucol / placebo of probucol|An investigator-initiated, placebo-controlled, randomized, multi-center study. Enrolled patients will be randomized after PCI either to the combination therapy group or to the control group. In the combination therapy group, cilostazol 200 mg and probucol 500 mg will be administered daily, whereas the control group will receive cilostazol 200 mg daily only.
45377579|NCT03885726|Device|Precision Flow Plus|High velocity nasal insufflation
45493444|NCT04352608|Biological|Two doses of placebo at the routine vaccination schedule|Two doses of placebo at the schedule of day 0,28 and one dose of booster immunization with placebo 6 months after the schedule of day 0,28 in phaseⅡ.
45493445|NCT04352608|Biological|Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,42
45377580|NCT03885726|Device|Treatment as Usual|Conventional therapy per institution
45377581|NCT03995277|Dietary Supplement|Biotin|Daily intake of 10 mg or 50 µg per day
45377582|NCT01034319|Behavioral|Diabetes Genetic Counseling|Subjects will be genotyped based on a 37-allele aggregate score and counseled regarding the implications of the results prior to enrollment in a 12-week diabetes prevention program
45377583|NCT01034319|Behavioral|No genetic counseling|These subjects will not be genotyped or counseled prior to enrollment in a 12-week diabetes prevention program
45377584|NCT00997776|Other|progressive resistance exercise|lower extremity strengthening: 3 sets of 8 repetitions at the 8 repetition maximum (8RM)for the hip and knee extensors, hip abductors, plantarflexors twice weekly for 10 weeks.
45377585|NCT00997776|Other|TENS|Transcutaneous electrical nerve stimulation (TENS) to elicit sensory information (comfortable tingling) for 7 minutes to bilateral muscle groups including the gluteal muscles, quadriceps, and gastroc-soleus muscles. TENS administered twice weekly for 10 weeks.
45377586|NCT01034475|Drug|CPI-613|"This is a Phase I open label trial using a 2-stage dose-escalation scheme (single-patient & traditional stages):~Single-Patient Dose-Escalation Stage: In the single-patient stage, a single patient will be accrued per dose level. The starting dose will be 420 mg/m². Dose level will be escalated (by doubling the previous dose) if there is no toxicity or if the toxicity is grade 1 or less. If toxicity is >Grade 1, the traditional dose-escalation stage will be triggered.~Traditional Dose-Escalation: All dose escalations conducted in this Traditional Dose-Escalation stage will be escalated according to the modified Fibonacci Dose-Escalation scheme."
45377587|NCT00997854|Other|Length of time for feed administration|Group 1 will consist of babies fed by bolus method, administered over no more than 30 minutes. Group 2 will be fed by slow infusion by pump over 2 hours.
45377588|NCT04000386|Other|zinc oxide nanoparticles coated socks|zinc oxide nanoparticles coated socks were given to subjects for 2 weeks
45377589|NCT04000386|Other|placebo socks|placebo socks were given to subjects for 2 weeks
45377590|NCT00998088|Other|erythropoietin and cell saver|weekly 40.000 IU s.c. for 4 weeks pre-operatively; use of cell saver includes intra- and post-operative drainage and reinfusion
45377591|NCT00998088|Drug|erythropoietin|weekly 40.000 IU s.c. for 4 weeks pre-operatively
45377592|NCT00998088|Device|OrthoPAT|for intra- and post-operative re-infusion of autologous wound blood
45377593|NCT00998088|Device|Post-operative drain device|For post-operative re-infusion of unwashed wound blood
45377594|NCT00998088|Other|Erythropoietin and OrthoPAT|weekly 40.000 IU s.c. for 4 weeks pre-operatively
45377595|NCT00998088|Other|Erythropoietin and drain device|weekly 40.000 IE s.c.for 4 weeks pre-operatively; drain use in post-operative period
45377596|NCT00998088|Device|OrthoPAT|For intra- and post-operative reinfusion of autologous blood
45493446|NCT04352608|Biological|Three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14,42
45377597|NCT03994341|Diagnostic Test|A FLIR Thermovision a320M thermal IR camera|"Clothing removed if necessary~ECG leads, temperature probes, or transcutaneous monitors will be relocated for abdominal imaging.~Axillary temperature prior to starting the thermographic imaging.~Baby's mattress slid out of the isolette and warming bed will be turned off for no more than 60 seconds. This step is necessary since infrared radiation does not pass through the Plexiglas walls of an isolette and the infant's skin surface needs to cool off slightly.~After surface cooling, thermal imaging will be recorded for ~60 sec to allow for the infrared radiation naturally emitted by the subject's body to be recorded by the infrared camera. The timestamp corresponding to the removal of the heat source will be noted, to indicate the start of the cooling of the abdomen.~After ~60 seconds of image recording, the recording will stop, the mattress pushed back into isolette.~Axillary temperature to ensure temperature stability, any clothes will be put back on."
45377598|NCT00377962|Drug|Everolimus|0.75-1.5 mg twice daily. At the week 1 visit and thereafter, the dose was adjusted to target blood concentration in the range 3-8 ng/mL.
45377599|NCT00377962|Drug|Mycophenolic acid (MPA)/azathioprine (AZA)|In the standard CNI arm, all immunosuppressants including (MPA) and azathioprine (AZA) continued unchanged as per local practice.
45377600|NCT00377962|Drug|Calcineurin inhibitors (CNI)|Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.
45377601|NCT00377962|Drug|Steroids|Steroid treatment was according to local practice. If steroids were given, the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration, unless a medical condition dictated a change.
45377602|NCT00424749|Drug|Rituximab|Patients received 4 weekly doses of rituximab 375 mg/m^2.
45377603|NCT00424749|Drug|Prednisone|Prednisone 1 mg/kg/day (not to exceed 80 mg/day) for 4 weeks followed by a taper to 0 mg by 6 months
45493447|NCT04352608|Biological|Three doses of placebo at the emergency vaccination schedule|Three doses of placebo at the schedule of day 0,14,42
45493448|NCT04352608|Biological|Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,56
45493449|NCT04352608|Biological|Three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28,56
45493450|NCT04352608|Biological|Three doses of placebo at the routine vaccination schedule|Three doses of placebo at the schedule of day 0,28,56
45377604|NCT01031745|Behavioral|Contingency|Participants are provided a non-monetary incentive for achieving particular tasks between study visits. Tasks include initiation of HAART, timely refill of medications from the government ART centers, suppression of HIV RNA
45377605|NCT01031745|Other|Prize bowl drawings|"Control participants receive counseling and referral, but no incentives for engagement in HIV care. At study visits they are eligible to receive bonuses through prizebowl drawings to offset the inability to earn incentives."
45377606|NCT01048216|Radiation|radiation therapy|CT based 3D treatment shall be used for all patients. There will be 10 equal fractions delivered over 2 weeks. The prescribed dose and fraction will be individualised according to effective liver volume treated
46054441|NCT03530163|Device|Sham Breathing Training|Each subject in the sham group will be prompted to hold his breath for 10 seconds every 30 seconds (two times each minute) while breathing on a circuit visibly identical to that used in Respiratory Muscle Training. The subject will breathe ambient air normally after each breath hold. Each sham session will last 30 minutes total.
46054442|NCT02847546|Device|True™ Flow Valvuloplasty Perfusion Catheter|Balloon Aortic Valvuloplasty as preparation step in implantation of a Tanscatheter Aortic Valve Implantation (TAVI).
45377607|NCT01048294|Device|Original Energy Light,|9000 lux, 30 minutes in the morning
45377608|NCT01048294|Device|Original Energy Light prototype|9000 lux 20 minutes in the morning
45377609|NCT01048294|Device|Original Energy Light prototype|9000 lux 30 minutes in the morning
45377610|NCT03246022|Other|continuous positive airway pressure|Continuous positive airway pressure (CPAP) prevents the airway collapse, avoids the occurrence of intermittent hypoxemia and arousal, is the preferred treatment for OSAS and has been widely used in clinical. The investigator would compare the effect of CPAP treatment on awake and sleep BP level at the first night and 2 weeks therapy among three groups. Moreover, whether or not the sympathetic-parasympathetic nerve balance and the renin-angiotensin-aldosterone system are different in three groups would also be evaluated.
45377611|NCT00424593|Drug|Duloxetine|30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
45377612|NCT00424593|Drug|Placebo|every day (QD), by mouth (PO), 13 weeks
45377613|NCT01031823|Behavioral|Multi-Media Social Skills Training Program|All individuals will participate in a twelve week social skills training program designed to enhance the social skills of adolescents with Asperger's Disorder or high-functioning autism. The intervention is comprised of both group therapy and peer generalization.
45377614|NCT00369382|Drug|cyclosporine or tacrolimus|Cyclosporine and tacrolimus are provided by the sites and dosed to achieve a target trough level determined by the investigator; therefore, form, dosage, and frequency are site and patient specific. Duration should be 52 weeks on-therapy.
45377615|NCT00369382|Drug|sirolimus|Oral (1 and 2 mg) tablets, dosing should be once daily to achieve a target trough level of 7- 15 ng/mL. Duration should be 52 weeks on-therapy.
45377616|NCT01324648|Behavioral|Telephone-supported self-help and GP treatment as usual|"Participants' use of the BB self-help materials will be supported by three to five telephone coaching sessions that occur approximately every 2-3 weeks. Total contact time will be approximately 2 hours (2 hour total contact time will be considered brief in our study). Participants will also continue to receive whatever current treatment their general practitioner is providing."
45493451|NCT03722303|Other|Fat Injection|Used by plastic surgeons, lipografting injects autologous fat to correct contour deformities. Plastic surgeons have witnessed the regenerative properties of fat transfer, and these clinical manifestations have fostered numerous studies defining fat as a rich source of pluripotent stem cells with the potential for reducing scar formation, bringing neo-angiogenesis, and providing a barrier against scar adhesions. This study applies the regenerative properties of autologous fat transfer to treat mild to moderate carpal tunnel syndrome in comparison to the current standard of care, corticosteroid treatment. Ideally, fat transfer would prevent scar formation and aid in nerve excursion along the canal, while the neoangiogenic and regenerative growth factors stimulate nerve regeneration.
45493452|NCT03722303|Drug|Steroid Injection|Standard of care non-operative treatment for the treatment of Carpal Tunnel Syndrome
45493453|NCT05203146|Device|PIMPmyHospital (mHealth tool)|Each participant will first be asked to retrieve a factious patient's laboratory results on the app when randomly made available, and then reach a colleague (role played by a study investigator) when asked to do so by a text message on the app.
45377617|NCT01324648|Behavioral|Unsupported self-help and GP treatment as usual|This treatment was chosen as a control for the telephone coaching component of the BB program. Participants will be sent a package containing the BB self-help materials and along with instructions on how to utilize these materials. Participants will use the materials on their own and at their own pace. Participants will also continue to receive whatever current treatment their general practitioner is providing.
45377618|NCT01324648|Other|General practitioner treatment as usual|This group will receive treatment as usual - whereby the clinic staff will inform the participant's GP of their PHQ-9 score. They will also be informed that their GP will be contacted that they are taking part in the research and that their GP will continue to support them with their depression as usual.
45377619|NCT00424515|Drug|Imatinib|Imatinib was given at a dose of 400 mg orally daily (4 100mg pills). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Dosage may have been increased to twice daily if disease worsened and patient was in otherwise good clinical condition.
45377620|NCT01581112|Biological|Microbial transplant|Every subjects has 2 armpits and 2 feet. One armpit/foot is treated, the other is not treated.
45377621|NCT05131204|Drug|Cemdisiran|Administered per protocol
45377622|NCT05131204|Drug|Eculizumab|Administered per protocol
45377623|NCT05131204|Drug|Pozelimab|Administered per protocol
45377624|NCT05131204|Drug|Ravulizumab|Administered per protocol
45377625|NCT04619745|Other|Individualized Home and Play-Based Physical Activity Plans|Play-based, parent led interventions optimized to support age appropriate physical activity, and motor skills among young children with congenital heart defects.
45377626|NCT03994263|Device|ITind device implant|device implanted for 5-7 days
45493454|NCT05203146|Other|Conventional method|Each participant will first be asked to retrieve a factious patient's laboratory results from the emergency department's computerized patient data system when randomly made available, and then contact a colleague (role played by a study investigator) when asked to do so (request made by a second study investigator).
45377627|NCT00377260|Drug|amoxicillin-clavulanate|Augmentin ES-600™: Amoxicillin-clavulanate potassium (600/42.9 mg per 5 mL), administered at a dose of 90/6.4 mg/kg/day in 2 divided doses for 10 days with strawberry cream flavor.
45377628|NCT00377260|Drug|Placebo|Same base formulation of the licensed product Augmentin ES-600™, with the same strawberry cream flavor.
45377629|NCT00441441|Drug|fluticasone propionate|fluticasone propionate 100mcg HFA
45377630|NCT00441441|Drug|fluticasone propionate/salmeterol|fluticasone propionate/salmeterol 100/50mcg HFA
45377631|NCT05127148|Other|Evaluation of survival and toxicities in AYA Ph-negative ALL patients treating in first line depending on risk category.|Evaluation of survival (event free survival and overall survival) and toxicities in AYA Ph-negative ALL patients treating in first line with argentinian pediatric-like protocol depending on risk category.
45377632|NCT00436917|Drug|zoledronic acid|zoledronic acid
45377633|NCT00436917|Procedure|Letrozole as adjuvant therapy|standard care
45493455|NCT02326792|Other|Exercise|The groups will perform the trunk extensor exercise on a roman chair by 2 x week, for a total of 10 weeks of training (20 sessions). The load will be progressive and tested to each 14 days with regard to the number of repetition reached by the participant. The exercise is safe and will be supervised by a health sport professional.
45377634|NCT00436605|Drug|dasatinib|
45377635|NCT01034787|Drug|CP-675,206|Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of ever 90 cycle for up to 4 cycles or until progression or intolerance of toxicity. Tumor assessments will be done ever 3 months. Additional scans will be done if clinically indicated.
45377636|NCT01323543|Device|Elaspine™|Implantation of device
45493456|NCT05203068|Diagnostic Test|Recombinant tuberculosis allergen (RTA)|Single intradermal inpplication of 0.2 µg/0.1 mL RTA (CFP10-ESAT6) in the middle of the forearm
45377637|NCT01028781|Drug|Thalidomide|Pill form, 50mgs with increasing dosage up to a maximum of 250 mg qd based on pain reports, taken once daily for 14-16 weeks with one 6 month follow-up appointment.
45377638|NCT01031901|Drug|Skincerity|Study subjects will apply a study product containing polyvinylidene fluoride coating alone to either facial angiofibromas or cutaneous neurofibromas
45377639|NCT01031901|Drug|Skincerity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
45377640|NCT01031901|Drug|Skinercity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
45377641|NCT00368992|Biological|cetuximab|Given IV
45377642|NCT00368992|Drug|paclitaxel|Given IV
45377643|NCT00368992|Biological|bevacizumab|Given IV
45377644|NCT00376246|Drug|Ezetimibe|
45377645|NCT00368836|Device|BreathScreen PE|One minute of breath collection by tidal breathing into the BreathScreen PE and blood draw for D-dimer level
45377646|NCT03992716|Drug|SmofKabiven® extra Nitrogen|SmofKabiven® extra Nitrogen (Fresenius Kabi) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
45377647|NCT03992716|Drug|Olimel N9E|Olimel N9E (Baxter) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
45377648|NCT01050010|Other|MRI|dedicated extremity MRI
45377649|NCT01050088|Dietary Supplement|sucrose solution|5cc 5% sucrose solution P/O
45377650|NCT01050088|Dietary Supplement|Saline|5cc saline p/o
45377651|NCT00376168|Drug|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks for 9 months
45493457|NCT02336542|Biological|5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
45377652|NCT00376168|Drug|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every 2 weeks for 9 months
45493458|NCT02336542|Biological|5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
45377653|NCT00375934|Drug|diclofenac potassium (XP21L)|25 mg capsule, every 6 hours
45493459|NCT02336542|Biological|10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
45377654|NCT00375934|Drug|Placebo|Oral placebo capsule, every 6 hours
45377655|NCT01052584|Drug|Chloroquine- P. vivax|Total of 25mg base per kg over 3 days (10 mg base/kg on Days 1 and 2, and 5 mg base/kg on Day 3)
45493460|NCT02336542|Biological|10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
45493461|NCT03558503|Drug|UGN-102|"UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL)."
45493462|NCT04351984|Device|MitraClip|Transcatheter Mitral Valvuloplasty with MitraClip
45377656|NCT01052584|Drug|Artemether-Lumefantrine: P. vivax|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
45693551|NCT01709084|Drug|Emtricitabine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. Emtricitabine will be administered in a fixed dose combination along with rilpivirine and tenofovir disoproxil fumarate in Group 1, and along with efavirenz and tenofovir disoproxil fumarate in Group 2.
45693552|NCT01776307|Drug|BBI608|BBI608 is administered at 500 mg po bid continuously.
45693553|NCT01776307|Drug|Panitumumab|Panitumumab will be administered IV on day 8 and 22 of each 28 day cycle at 6 mg/kg over 60 minutes.
45693554|NCT01776307|Drug|Capecitabine|Capecitabine will be administered orally at 1000 mg/m2 bid daily on days 8-21 every three weeks.
45847168|NCT01871766|Drug|Doxorubicin|"Dosage and route of Administration:~Age ≥1 year, 37.5 mg/m^2 IV over 1 hour x 2 days Age <1 year, 18.75 mg/m^2 (i.e., a 50% dose reduction) IV over 1 hour x 2 days."
46054443|NCT02785965|Device|electroacupuncture|Disposable, single-use, sterilized stainless-steel needles (Yunlong, Beijing, China; length 40/100 mm, diameter 0.30 mm) are inserted into waist, bilaterally. All of the six points are located in the Dai Meridian route corresponding to the ovaries. Four needles, 0.25mm in diameter and 25mm in length, are also placed in distal acupuncture points which are located in the feet and lower arms to enhance local points' effects. Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into GB26(Daimai) with a depth of 25-65mm by an angle of 15°, following the path of Dai Meridian (towards medial and downside). The other needles are inserted vertically into the acupoints with a depth of 10-30mm, depending on the thickness of muscles. Electro-acupuncture is applied to both sides of GB26 and ST25(Tianshu): cathode is connected to GB26; anode to ST25. Needles are stimulated electrically with low frequency (2 Hz) for 20 min.
46054444|NCT02785965|Behavioral|lifestyle modification|The diet restricts patients to 1400 calories a day for 12 weeks.The exercise included 12 weeks of aerobic exercise in moderate level (60 to 70% of maximum heart rate), for 3 sessions a week, each session for 60 min. The exercises included: Warning up: 10 min, main phase (aerobic exercise): 40 min and cooling down: 10 min. Polar Pulse measuring device from China was used to control the intensity of the exercises.
46054445|NCT04682028|Other|professional care|The trained nurses provide professional care for the patients.
46054446|NCT04682028|Other|coventional care|nurses provide coventional care for the patients.
46054447|NCT04232397|Drug|Anlotinib|anlotinib 8mg qd po
45377657|NCT01052584|Drug|Artemether-lumefantrine: P. falciparum|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
45377658|NCT01050166|Other|Transplantation of labeled islets|
45377659|NCT01050244|Dietary Supplement|Whole soybean soymilk powder|
45377660|NCT01050244|Dietary Supplement|Whole milk powder|
45493463|NCT05761236|Other|Exercise|Sessions are consisted of scoliosis-specific pilates-based exercises.The exercises were kept constant in total content, but the bilateral or unilateral application directions, the number of repetitions for the right and left sides, and the extremities used were modified for each patient according to the localization of the major curve and the type of the curve. The taught postural corrections were requested to be maintained during all exercises. Exercises for flexibility were performed asymmetrically or symmetrically according to the chosen exercise, extremities were chosen according to the curve type, with 5 repetitions and 30 seconds for each repetition. Exercises aimed at strengthening were performed for a total of 12 repetitions, during a 5-second contraction, by arranging the number of repetitions for the right and left in line with the target muscles, again considering the curve type, and the patients were asked to rest between the exercises.
45493464|NCT02331706|Drug|Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily|
45493465|NCT04400838|Biological|ChAdOx1 nCoV-19 (Abs 260)|A single dose of 5x10^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260
45493466|NCT04400838|Biological|MenACWY vaccine|Standard single dose of MenACWY vaccine
45377661|NCT02534506|Drug|Urelumab|
45377662|NCT02534506|Drug|Nivolumab|
45377663|NCT01050322|Drug|Lapatinib Vinorelbine|The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
45377664|NCT01050322|Drug|Lapatinib Capecitabine|The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
45377665|NCT01050322|Drug|Gemcitabine Lapatinib|The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
45377666|NCT01048450|Radiation|Joint Resection- Keller Procedure|These subjects had received a surgical intervention of removing the proximal portion of the proximal phalanx of the hallux
45377667|NCT01048450|Procedure|Joint Fusion|Those who had a surgical intervention of fusion of the 1st metatarsal phalangeal joint.
45377668|NCT01048450|Procedure|Hemi-metallic Joint Implant|Those who had a surgical procedure of a hemi-metallic joint implant
45377669|NCT01048528|Behavioral|Cognitive Behavioral Stress Management (CBSM)|The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Relaxation techniques include progressive muscle relaxation, guided imagery, autogenics, meditation, and deep breathing. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
45377670|NCT03990844|Dietary Supplement|Okra seed|Noodle enriched with 10% and 20% Okra seed flour.
45493467|NCT04400838|Biological|ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost|A single dose of 5x10^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260 and 2.2x10^10vp ChAdOx1 nCoV-19 boost measured by qPCR 4-6 weeks later
45377671|NCT02534662|Device|ENDOMINA|Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
45493468|NCT04400838|Biological|Two dose MenACWY vaccine|Two standard doses of MenACWY vaccine 4-6 weeks apart
45493469|NCT04400838|Biological|ChAdOx1 nCoV-19 (qPCR)|A single dose of 5x10^10vp of ChAdOx1 nCoV-19 measured by qPCR
45493470|NCT04400838|Biological|ChAdOx1 nCoV-19 0.5mL prime plus boost|Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10^10 vp Abs 260)
45493471|NCT04400838|Biological|Two dose MenACWY vaccine min. 4 weeks apart|Two standard doses of MenACWY vaccine minimum 4 weeks apart
45493472|NCT04400838|Biological|Two dose ChAdOx1 nCoV-19/Covishield 0.5mL|Two dose ChAdOx1 nCoV-19 0.5mL (Covishield 0.9 x 10^11 vp/mL), 4-6 weeks apart
45847169|NCT01871766|Drug|Dexrazoxane|"Dosage and Route of Administration: Dexrazoxane dose should be 10x that of doxorubicin.~Age ≥1 year, 375 mg/m^2 IV over 15-30 minutes Age <1 year, 187l.5 mg/m^2 (i.e., a 50% dose reduction) IV over 15-30 minutes."
45377672|NCT00642941|Drug|RG1507|Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.
45377673|NCT00531960|Drug|Erlotinib|150 mg, PO, daily
45377674|NCT00531960|Drug|Bevacizumab|15 mg/kg, IV, Day 1 of Cycles 1 through 7
45377675|NCT00531960|Drug|Standard platinum-based chemotherapy|At the discretion of the investigator
45377676|NCT01001676|Device|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty with the use of Conventional balloon
45493473|NCT04400838|Biological|Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL|Two dose ChAdOx1 nCoV-19 (Covishield 0.9 x 10^11 vp/mL), 0.25mL prime and 0.5mL boost 4-6 weeks apart
45493474|NCT02326870|Device|AutoLap|
45493475|NCT03489863|Drug|Prasugrel|Maintenance dose will be maintained for 10±3 days.
45377677|NCT01001676|Device|Paclitaxel Eluting Balloon Angioplasty|Angioplasty with the use of paclitaxel eluting balloon
45493476|NCT03489863|Drug|Ticagrelor|Maintenance dose will be maintained for 10±3 days.
45377678|NCT00816959|Drug|R-mabHDI and ABVD|"The subjects will receive R-mabHDI intravenously, separately for about 7 hours on days 1,8,15 and 22 (once a week) of every cycle. Each cycle is 4 weeks. R-mabHDI will be given for 2 cycles.~Also the subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles."
45693555|NCT01776307|Drug|Cetuximab|Cetuximab will be administered IV on day 5 at 400 mg/m2 intravenous infusion over 120 minutes as the initial dose, then weekly at 250mg/m2 over 60-minutes at subsequent cycles.
45693556|NCT01729039|Behavioral|standard balance rehabilitation|All subjects perform balance and gait exercises in addition to eye exercises and receive a written home exercise program (HEP) of balance and gait exercises to improve postural stability and mobility with progressively challenging tasks. Balance exercises include maintaining stability with vision and somatosensory cues altered, dynamic weight shifts and performing ankle, hip and step strategies. Gait activities include negotiating uneven terrains and obstacles, gait with head turns, varied speed, and unpredictable starts and stops. Walking for endurance is included in the HEP. Each participant receives a customized balance and gait HEP based on identified impairments and is progressed according to ability and level of assistance at home.
45377679|NCT00816959|Drug|ABVD|The subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles.
46054448|NCT02847468|Other|FDG Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FDG) before treatment with Sorafenib is started and 1 month after treatment started.
46054449|NCT02847468|Other|FCH Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FCH) before treatment with Sorafenib is started and 1 month after treatment started.
46054450|NCT02785887|Other|Geriatrician review|In addition to routine oncological care, patients will be reviewed by a geriatrician and may receive intervention if CGA deficits are found
46054451|NCT02849340|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
46054452|NCT02849340|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
45377680|NCT01001754|Drug|PEG-rIL-29|Weekly SC injections in combination with ribavirin for up to 48 weeks
45377681|NCT01001754|Drug|Peginterferon alfa-2a|Weekly SC injections in combination with ribavirin for up to 48 weeks
45377682|NCT01001754|Drug|Ribavirin|Daily oral administration (400-600 mg BID)
45377683|NCT00825851|Drug|Transdermal nicotine patch|15mg/16h + 10mg/16h to be used 24h
45377684|NCT00825851|Drug|Placebo patch|
45377685|NCT00825851|Behavioral|Smoking cessation|
45377686|NCT00825851|Behavioral|Continuous smoking|subjects smoke 20 cigarettes per day
45377687|NCT00361504|Drug|Oxycodone CR|Oxycodone CR 10 mg oral tablet BID administered for first 3 days, 20 mg oral tablet BID administered for next 4 days, 20 to 50 mg oral tablet BID administered for the next 51 weeks.
45493477|NCT03144934|Drug|GX-I7|Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
45493478|NCT03144934|Drug|Placebo|This is the placebo of GX-I7 described above.
45498174|NCT05084313|Other|Deep-slow breathing|Patients in this group will do slow paced breathing to increase heart rate variability as it can be partially modulated by respiratory effects. The patients will be able to cease the session in case of feeling uncomfortable. The main purpose will be that the individuals should breathe six breaths per minute to increase respiratory sinus arrhythmia which is also reflected at PPG waveforms and in reduction in GSR. The group will include forty healthy individuals.
45377688|NCT00361504|Drug|Tapentadol (CG5503) ER|Tapentadol (CG5503) ER 50 mg oral tablet BID administered for first 3 days, 100 mg oral tablet BID administered for next 4 days, 100 to 250 mg oral tablet BID administered for the next 51 weeks.
45498175|NCT05084313|Other|Control|Control group patients will be attached to the sensors, and they will rest in a quiet and controlled indoor environment without any intervention. The aim of including this group is to to understand whether the parasympathetic effects expected in the manual therapy group were due to the intervention. The group will include forty healthy individuals.
45847170|NCT01871766|Drug|^1^1C-methionine|Participants receive ^1^1C-methionine to relate the distribution, intensity and change in ^1^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.
45847171|NCT01770756|Behavioral|Self-Care Training|
46054453|NCT02785731|Procedure|Pelvic imaging|Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
46054454|NCT02785731|Procedure|Blood draw|Within 60 days prior to, or on the day of the pelvic mass surgery, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
45377689|NCT04446611|Diagnostic Test|First antenatal care + test-of-cure|Single point-in-time molecular point-of-care diagnostic screening and treatment for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis at first antenatal care visit and infection-specific test-of-cure 3 weeks post-treatment. Women with a positive test-of-cure will be re-treated. As CT/NG is a combined Xpert test, women who present with an incident infection (newly diagnosed infection) will be treated and managed accordingly.
46054455|NCT02785731|Procedure|laparotomy or laparoscopy|A laparotomy or laparoscopic procedure will be performed by a qualified individual for excision of the pelvic mass. Representative tissue samples will be taken from the excised pelvic mass and evaluated in pathology departments within each institution according to institutional guidelines. Results from the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
46054456|NCT03936192|Drug|glucosamine sulphate 1500mg and meloxicam 15mg|glucosamine sulphate 1500mg plus meloxicam 15mg, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.
46054457|NCT03936192|Drug|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®)
46054458|NCT03936192|Drug|Placebos|Placebo administered once daily for 12 weeks.
45498176|NCT03688854|Dietary Supplement|SCFA mixture|Intracolonic administration
45498177|NCT01382979|Behavioral|AlcoholEdu for College|Online course for college freshmen.
45498178|NCT05042193|Other|SARS-CoV-2|Observational
45847172|NCT01276002|Procedure|pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting.
46054459|NCT00930228|Drug|Flutamide|Flutamide, 250 mg capsule for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
46054460|NCT00930228|Drug|Placebo|Placebo, for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
45377690|NCT04446611|Diagnostic Test|First antenatal care + week 30-34 gestation (no test-of-cure)|Repeated molecular point-of-care diagnostic screening and treatment for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis at first antenatal care visit and at week 30-34 gestation. No test-of-cure will be conducted for women with positive test results; however, additional treatment will be provided to women with persistent/recurrent vaginal discharge.
45377691|NCT00826085|Drug|ThermoDox in combination with Microwave Hyperthermia (heat)|"ThermoDox is a 30 minute intravenous infusion followed by hyperthermia within 60 minutes of infusion completion.~Hyperthermia is a therapy used to heat tumors for 60 minutes. Using heat energy, the tumor is heated to a certain temperature. The heat can damage cancer cells at levels that are usually safe for normal cells and can be used to attack cancer in four major ways: 1) heat damages or weakens the cells of the tumor; 2) heat increase blood flow through the weakened tumor; 3) increased blood flow raises oxygen levels in tumors; and 4) when the body senses fever it can stimulate the nature immune system.~All patients will receive up to six ThermoDox/hyperthermia treatments at 21-day intervals."
45377692|NCT01002144|Other|blood sampling|
45377693|NCT00361270|Behavioral|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
45377694|NCT00361270|Behavioral|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
45377695|NCT00361270|Behavioral|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
45377696|NCT00361270|Behavioral|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
45377697|NCT00361270|Behavioral|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
45377698|NCT00361270|Behavioral|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
45498179|NCT05031429|Other|Time Limited Eating|Includes an 8-hour feed/16-hour fast for 7 days per week, with consumption of all of calories in the afternoon/evening. Can consume non-caloric beverages (water, tea, coffee) during the fasting period. No caloric restriction will be used.
46054461|NCT05043870|Drug|Infliximab and immunosuppressives|the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks, the immunomodulatory agent was azathioprine 1-2mg/kg per day or methotrexate 10-25 mg/m2 week
46054462|NCT05043870|Drug|Infliximab|the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks
45377699|NCT00361270|Behavioral|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
45377700|NCT00361270|Behavioral|BIO|8 weekly 1-hour sessions of EMG Biofeedback without hypnotic suggestion
45377701|NCT00826163|Drug|Budesonide|Inhaled budesonide 400 mcg twice a day for 2 weeks
46054463|NCT02845635|Other|Personal history of multiple sclerosis|Participants will be stratified into one of four cohorts based on their experience (or lack of experience) with the three major forms of multiple sclerosis.
45498180|NCT03688776|Other|1805AA|A moist snuff product
45498181|NCT03688776|Other|1805AB|A moist snuff product
45498182|NCT03684798|Other|MCII|In this study, the research staff will work through the MCII approach with the participant as an interactive, face-to-face training. The desired future consists of imaging an abstinent life and comparing it with personally relevant obstacles. Afterwards, the most relevant obstacle will be chosen and an if-then-plan will be formed, that refers to this obstacle.
46054464|NCT02847390|Other|Education intervention|The investigators will develop and deliver a diabetes physician and nursing inpatient diabetes superuser educational curriculum focused on delivering safe, evidence-based diabetes care in the hospital setting. The physician educational curriculum will consist of 10 case-based modules taught to internal medicine residents at two academic hospitals and taught to hospitalists at two academic hospitals and one community hospital. The nursing educational curriculum will consistent of 12 case-based modules taught to unit-based nurses at two academic hospitals and one community hospital. These educational interventions will be delivered over a 6-month time frame from August 2016-April 2017.
45377702|NCT00998166|Drug|Pemetrexed, Cisplatin, Bevacizumab|"Pre-hydration for 1-1/2 hours at 250 ml/hour~Pemetrexed 500 mg/m2 IV over 10 minutes~Return to hydration for 30 minutes at 250 ml/hour~Cisplatin 75mg/m2 IV over 60-120 minutes~Bevacizumab 15mg/kg IV over 90 minutes"
45493479|NCT05763030|Behavioral|Adapted Sleep Well, Bee Well|The SWBW is a 3-week multilevel behavioral sleep intervention that targets organizational (daycare worker-parent), interpersonal (parent-child, daycare worker-child), and individual (child) levels. It provides parent education supporting parent-child interaction at bedtime, helps to adopt a bedtime routine and early bedtime (Table 4). At the beginning of the 3-week intervention period, the parent and teacher co-develop tailored sleep health goals towards meeting the Bedtime, Environment, and Duration (BED) recommendations139-141 for the child. Parents receive an inexpensive bedtime kit, a storybook, and an informational brochure. The parent and child select four activities from the kit to perform at bedtime every night. The brochure has a section for the parents to write sleep goals. During the intervention, daycare teachers provide daily feedback support to parents at pick-up or drop-off. The program has a manualized structured curriculum suitable for use by paraprofessionals.
45493480|NCT05665205|Other|Aerobic plus strength group|A 8 week program of aerobic exercise plus strength exercise of upper and lower limbs in the hospital with a supervised trained physiotherapist
45377703|NCT03990922|Procedure|Continuous Paravertebral block with ropivacaine|Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
45377704|NCT03990922|Procedure|"Continuous Paravertebral block with saline"|Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
45493481|NCT05665205|Other|Aerobic group|This group has a 8 weeks program of only aerobic exercise in the hospital with a supervised trained physiotherapist.
45493482|NCT04344444|Drug|Hydroxychloroquine|tablets provided as described in Arm B
45493483|NCT04344444|Drug|Azithromycin|tablets provided as described in Arm C
45377705|NCT03990922|Drug|Patient-controlled analgesia with morphine|Morphine given as intravenous patient-controlled analgesia bolus: 2mg, lock time: 5min, 1h limitation: 8mg
46054465|NCT02787135|Behavioral|emotion-oriented Cognitive Behavior Therapy|Emotion-oriented Cognitive Behavior Therapy with a focus on delusions: Aim of the intervention is to change factors that are involved in the formation and maintenance of delusions: emotional stability and regulation of negative emotions, sleep quality and self-esteem.
45377706|NCT01005342|Other|Oat bran|82 g oat bran was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12.6 g total fiber).
45377707|NCT01005342|Other|Spray-dried oat drink|62 g spray-dried oat drink was added to 250 ml blackcurrant beverage with pulp to give 2.7 g soluble fiber (3.3 g total fiber).
45493484|NCT03489551|Drug|Haldol|
45493485|NCT03144544|Procedure|Pediatric surgical procedures|Eligible surgical procedures were identified using Canadian Classification of Health Interventions (CCI) therapeutic intervention codes.
45493486|NCT05762952|Drug|Dapagliflozin 10mg Tab|Once daily oral dapagliflozin 10mg
45493487|NCT05762952|Drug|Placebo|Placebo capsules formulated by pharmacy to be indistinguishable from active drug
45493488|NCT03722225|Other|Carbohydrate loading and high intermittent carbohydrate intake during physical exercise|The intervention consisted of carbohydrate loading prior to and intermittent high carbohydrate intake during PE and a proactive use of Real-Time Continuous Glucose Monitoring (rtCGM) to achieve and maintain glucose control
45493489|NCT05202834|Device|UltraClear|Evaluation of the UltraClear Laser Workstation for Skin Treatment - Histology Study of Laser Ablation on human skin
45493490|NCT02331550|Procedure|Ablative treatment|Use of an ablative treatment (cryotherapy) for the management of Low-Grade Squamous Intraepithelial Lesions of the cervix.
45493491|NCT02331550|Procedure|Expectant management|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions were managed with observation and evaluation at 6 and 12 months after diagnosis.
46054466|NCT01029704|Drug|EGT0001442|"Segment 1 is a single center, open labeled, ascending dose study in diabetic subjects who will receive 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days.~Segment 2 is a multi-center, double-blind, placebo-controlled parallel group study. Diabetic subjects will be randomly assigned to receive oral EGT0001442 at 5, 10, 20, or 50 mg/day for 28 days."
45377708|NCT01005342|Other|Rye bran|31 g rye bran was added to 250 ml blackcurrant beverage with pulp to give 1.7 g soluble fiber (12 g total fiber).
45493492|NCT02335684|Other|CF-LVAD pump speed baseline.|Submaximal exercise test with baseline pump speed.
45493493|NCT02335684|Other|CF-LVAD pump speed increased.|Submaximal exercise test with increased pump speed (+800RPM).
45493494|NCT05198388|Diagnostic Test|βeta endorphins, interleukin 6 and interleukin 38|"- Collection of peripheral blood samples in gel tube.~- Creparation of samples in centrifuge to obtain serum.~- Measurement of interleukin 6 and interleukin 38 and βeta endorphins using ELISA method."
45493495|NCT03557801|Behavioral|Mammography with Community Health Worker (individual)|Immediately following consent and completion of the baseline assessment, alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
46054467|NCT01029704|Drug|Placebo capsules to match EGT0001442|"Segment 1: Not applicable.~Segment 2: Diabetic subjects will be randomly assigned to receive oral placebo once daily for 28 days."
46054468|NCT02786979|Drug|Beraprost|Oral
46054469|NCT02786979|Drug|Aspirin|Oral
45377709|NCT01005342|Other|Sugar beet fiber|19 g sugar beet fiber was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12 g total fiber).
45377710|NCT01005342|Other|Mixture of fiber|38 g spray-dried oat drink, 30 g rye bran and 6 g sugar beet fiber were added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (18 g total fiber).
45377711|NCT01005342|Other|Control|No fiber was added to control meal (250 g black-currant beverage)
45377712|NCT00822263|Drug|N-acetyl-cysteine (NAC)|Anti-oxidant in a pill format
45377713|NCT00822263|Drug|Placebo|Control for study
45493496|NCT03557801|Behavioral|Mammography with Community Health Worker (group)|Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
45377714|NCT03992170|Drug|Daratumumab|Daratumumab is a human monoclonal antibody (mAb) IgG1 that binds to the highly expressed CD38 protein on the surface of multiple myeloma cells and, at various levels, also in other types of cells and tissues. The CD38 protein has multiple functions, such as receptor-mediated adhesion, signal transduction activity and enzymatic activity.
45377715|NCT04044755|Other|Myopia prediction algorithm|Candidate predictors mainly includes age at examination, SER, and annual progression rate. Using these predictors, the algorithm will be used to predict SER at 3 years.
45377716|NCT05154474|Other|Standard|Standard follow-up with clinical exams, functionnal test at baseline, Ct scan MNA, IPAQ, SARC-F and SarQOL questionnaires
45377717|NCT00817037|Drug|Sitaxsentan|Sitaxsentan 100mg once daily oral dosing for 6 weeks
45377718|NCT00817037|Drug|Nifedipine|Nifedipine 30mg once daily oral dosing for 6 weeks
45377719|NCT00817037|Drug|Placebo tablet|Placebo tablet once daily oral dosing for 6 weeks
45377720|NCT00998244|Other|Diet - very low carb or low fat|Diet comparison in Gastroesophageal Reflux Disease
45377721|NCT00817115|Device|Region-of-Interest Imaging (X-ray Fovea Imaging)|Use of an experimental fluoroscopy system fitted with a region-of-interest attenuator (fovea) to evaluate or treat lesions during cardiac interventional procedures.
45377722|NCT00998322|Biological|REOLYSIN|1E10 TCID50, 1-hour intravenous infusion on Days 1 and 2 and then Days 8 and 9 of a 21-day cycle.
45377723|NCT00998322|Drug|Gemcitabine|800 mg/m2 30-min infusion on Days 1 and 8 of a 21-day cycle.
45377724|NCT04044833|Behavioral|Health life style behaviour ,|Training: applying Personal Information Form, HLBS-II, and MSQ to the intervention and control groups determined randomly and distributing the Student Follow-up Schedules; c) Providing trainings to the intervention group; d) Monitoring the weights, BMIs, and menstrual symptoms of intervention and control groups; and e) After the Training: Applying HLBS-II and MSQ scales to intervention and control groups, collecting the follow-up schedules, and providing training to the control group and all other students. Trainings: First stage: 120 minutes basic training per week for four weeks (40 minutes on diet, 40 minutes on physical activity, and 40 minutes on menstrual symptoms)
45377725|NCT00367744|Drug|Rosiglitazone|Rosiglitazone 4mg BID
45377726|NCT00367744|Drug|Placebo|Placebo for rosiglitazone
45377727|NCT01002222|Drug|MCS-2|15 or 30 mg/day of MCS-2 soft-gel capsules Qd for 24 weeks, depending on which dose level is selected after the phase 2b part of the protocol MCS-2-US-a.
45493497|NCT03557801|Other|Standard of Care Mammography|Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard protocol.
45493498|NCT05762874|Drug|Ruxolitinib|JAK inhibitor
45493499|NCT04210180|Drug|Varenicline|0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7; then 1 mg twice daily for the remaining 11 weeks.
45847173|NCT05452824|Other|Tai Chi Prehabilitation|The intervention arm will be oriented to a WaQi (youthful vitality) program 8 weeks prior to their scheduled surgery date. The WaQi program uses a Tai Chi curriculum previously successfully implemented in older adults, and at the Memorial Sloan Kettering Cancer Center (MSKCC). It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting or standing. Intervention participants will also receive printed materials from Prostate Cancer Canada about prostate cancer management. These materials include information about how to cope with prostate cancer including pelvic floor exercise, physical activity, healthy eating, and mental wellbeing.
45847174|NCT05452824|Other|Usual care|Control arm participants will receive printed materials identical to intervention arm participants with general information on a healthy lifestyle. The control arm will receive an 8-week online Tai Chi teaching module subscription at the end of the study.
45377728|NCT04018625|Behavioral|SMART Mom|SMART Pregnancy is an 8-session online stress management program offered in a group format. SMART Pregnancy is an adaptation of the Stress Management and Resiliency Training Program (Park et al., 2012).
45377729|NCT04018625|Behavioral|Mama Support|Participants will be enrolled in an 8-week time and attention matched, process-based support group.
45493500|NCT04210180|Other|e-cigarette|Each G6 prefilled cartomizer contains a 50/50 blend nicotine salt with 35mg nicotine strength.
45493501|NCT03523871|Drug|Mavyret|Patients will be on 8 weeks of Mavyret
45493502|NCT04031820|Procedure|Unipolar cup|Cemented unipolar acetabulum cup for primary THA
45493503|NCT04031820|Procedure|Dual mobility cup|Cemented dual mobility acetabulum cup for primary THA
45493504|NCT04017390|Drug|Theraworx Foam|Apply Theraworx Foam alone
45377730|NCT01002300|Drug|intranasal oxytocin|Participants will receive 24 IU of oxytocin or placebo (Salinex saline nasal spray) intranasally 30 minutes prior to completing the experimental tasks. Two weeks later participants will return for a second visit and receive the alternate drug (either intranasal oxytocin or Salinex) prior to completing the experimental tasks.
45377731|NCT01005498|Dietary Supplement|Low carbohydrate - high fat diet|The diet has an energy content of 1600 kcal or 1800, with 50% from fat, 20% from carbohydrates and 30% from proteins.
45377732|NCT01005498|Dietary Supplement|High carbohydrate - low fat diet|The diet has an energy content of 1600 or 1800 kcal, with 30% from fat, 55-60% from carbohydrates and 10-15% from proteins.
45377733|NCT00822341|Drug|TG-0054|0.10, 0.14, 0.28, 0.56, 1.12, 2.24, 3.14, and 4.40 mg/kg of TG-0054/placebo via 15 min IV infusion
45493505|NCT04017390|Drug|Placebo Foam|Apply placebo foam alone
45493506|NCT04017390|Other|Theraworx Foam and night splint|Apply Theraworx Foam and night time splint
45493507|NCT04017390|Other|Placebo Foam and night time splint|Apply placebo foam and night time splint
45377734|NCT01002378|Drug|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a high fat breakfast
45493508|NCT03523715|Dietary Supplement|Prunes|12 oz of prunes daily
45493509|NCT03523715|Drug|Docusate Sodium|Oral docusate sodium twice daily
45493510|NCT03980730|Drug|Azeliragon|Azeliragon 5 mg capsule administered orally, once daily
45493511|NCT03980730|Drug|Placebo|Matching placebo capsule administered orally, once daily
45493512|NCT03523091|Drug|OnabotulinumtoxinA 100Unit Injection|Initial treatment with the option of repeat injections every 3 months
45493513|NCT02512510|Drug|TD-4208|
45493514|NCT02512510|Drug|Placebo|
45493515|NCT00753090|Device|Vanguard™ Deep Dish Rotating Platform Knee|Vanguard™ Deep Dish Rotating Platform Knee
45493516|NCT00753090|Device|Vanguard™ Cruciate Retaining Knee|Vanguard™ Cruciate Retaining Knee
45493517|NCT03438383|Device|Bi-PAP|The Bi-PAP system combines inspiratory support-IPAP (inspiratory positive airway pressure) with expiratory support-EPAP (expiratory positive airway pressure) and has been used, with good results, in a number of different clinical conditions such as COPD, respiratory failure due to neuromuscular disease, cardiogenic pulmonary edema and immediately post-operatively with pro-phylactic purpose.
45493518|NCT03438383|Device|Sham Bi-PAP|"Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of the conventional Bi-PAP system. By doing so, the applied pressure by sham Bi-PAP was constant and equal to 2 cm H2O."
45493519|NCT04477408|Other|plantar sensory exercise group|"plantar sensitive exercises~Plantar sensitive exercises:~30 minutes / 3 days per week / 8 weeks Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min)"
45493520|NCT05762016|Procedure|Bedside Mini-Incision and Self-Express (MISE)|To perform bedside mini incision and encourage patients to self express the pus following the intervention
45493521|NCT03105310|Drug|Pegylated interferon alfa|Pegylated interferon alfa
45493522|NCT03105310|Drug|Ezetimibe|Ezetimibe
45377735|NCT01002378|Drug|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a low fat breakfast
45493523|NCT05179434|Procedure|Retrograde renal graft reperfusion|Retrograde venous reperfusion of the renal graft during the kidney transplant procedure with consequent arterial reperfusion
45377736|NCT01002378|Drug|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered following an overnight fast
45377737|NCT00822419|Drug|lidocaine|lidocaine cream 5%
45377738|NCT00822419|Drug|ketamine|ketamine 5%
45377739|NCT00822419|Drug|non-drug cream|will be put on the skin
45377740|NCT01050400|Genetic|Cytochrome P450 2D6 (CYP2D6) genetic screening.|Genetic screening for cytochrome P450 2D6 (CYP2D6) polymorphism will be conducted on genetic information obtained from non-invasive salivary samples.
45493524|NCT05179434|Procedure|Conventional antegrade renal graft reperfusion (without retrograde reperfusion)|Conventional arterial antegrade renal graft reperfusion during the kidney transplant procedure
45377741|NCT01006044|Biological|autologous dendritic cells|Patients will receive standard first-line therapy (surgery before radio-chemotherapy) along with the experimental treatment. The experimental treatment consists in subcutaneous vaccination with a suspension of autologous dendritic cells (cells from the same patient) produced by cell culture from monocytes from the same patient extracted by leukapheresis and pulsed with a lysate of the patient´s tumoral tissue. The first four vaccines will be administered on a monthly basis, concomitantly with the standard chemo and radiotherapy treatments, the next four vaccines, every other month and the four last vaccinations every three months.The results obtained will be compared with those of an historical control study, where patients received a standard treatment without the experimental vaccine.
45377742|NCT00817193|Behavioral|Physical Activity|Physical Activity program
45377743|NCT00817193|Behavioral|Wellness|Wellness program
45377744|NCT02534428|Other|wool clothing|superfine merino wool ensembles for baby wear
45377745|NCT01002534|Drug|Vardenafil|Nasal instillation of Vardenafil
45377746|NCT01002534|Drug|Placebo|Nasal instillation of placebo matching in appearance with the Vardenafil instillation
45377747|NCT00817271|Drug|AZD1656|Dose titration of oral suspension during 2 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose for another 6 days. On day 5 and 8 the dose will be given as a single dose
45377748|NCT00817271|Drug|Glucagon|1 mg injected 3 hr post AZD1656 morning dose on day 5 alt. day 8
45377749|NCT01052896|Drug|Gabapentin|300mg po TID
45377750|NCT01052896|Drug|Placebo|Look-alike of gabapentin 300mg given po tid
45377751|NCT00822497|Behavioral|Music-Based Imagery (MBI)|MBI is form of music-assisted relaxation with imagery. This protocol is used at the patients' bedside before and after the debridement process.
45377752|NCT00822497|Behavioral|Music Alternate Engagement (MAE)|MAE consisted of a menu of music therapy interventions aimed at engaging the patients in music and diverting them away from the debridement process.
45377753|NCT01002690|Drug|Etoricoxib|90 mg/day orally for 10-13 days
45377754|NCT01048684|Drug|Mannitol|Variation of mannitol dose
45377755|NCT01048684|Drug|Mannitol|Variation of mannitol dose
45377756|NCT01002768|Drug|insulin degludec|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
45377757|NCT01002768|Drug|insulin glargine|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
45377758|NCT01048762|Other|physical exercise and dyspnoea counseling|Exercise training in group, 1 hour once a week for 10 weeks, based om aerobic exercises 60-80% of VO2 max (Borg 11-12), resistance training and dyspnea counseling. Participants are urge to exercise training for at least twice a week.
45377759|NCT01048762|Other|home training|one instruction in home based exercise training
45377760|NCT01002846|Procedure|acupuncture|acupuncture group : subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth sham acupuncture group : subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
45377761|NCT00826397|Procedure|Acupuncture|Each acupuncture session will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
45377762|NCT00826397|Procedure|Sham Acupuncture|The sham acupuncture session will consist of superficial needling at nonspecific body points, administered twice weekly for six weeks, and will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
45377763|NCT00998478|Other|Activity Knowledge Circuits|The activity knowledge circuits were implemented, where in addition to regular physical education (PE) activity was increased by two hours a week over an 18-week period. Participants briskly walked 3200 m twice weekly during curriculum lessons (60 min). Short tasks, in line with current curriculum, were provided by subject teachers for participants to complete at stations set every 400 or 800 m. Crucially participants continued to follow national curriculum whilst exercising. Tasks designed by teachers lasted no longer than 60 seconds at each station. With the exception of PE, each curriculum subject delivered a total of four intervention lessons. Circuits were performed outdoors on school premises, with an indoor course of equal distance used during adverse weather conditions.
45377764|NCT01050478|Drug|Paliperidone ER|paliperidone ER at 2 dosage levels (6 and 9 mg/day)
45377765|NCT01050478|Drug|Benzodiazepine|Participants may receive the benzodiazepine lorazepam [0-7.5 milligram (mg) per day] as needed for sedation or rescue medication at the investigator's discretion.
45377766|NCT00822575|Device|ZapperClick|The ZapperClick is a therapeutic device that employs the piezo-electricity principle to soothe itching and ease the swelling from mosquito and horsefly bites as well as jellyfish and nettle stings. It accomplishes this by discharging 13KV at 0.7mA for 10 microseconds over the area of the bite or sting each time it is activated.
45377767|NCT00826475|Behavioral|Mindfulness Based Stress Reduction MBSR|Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
45377768|NCT00826475|Behavioral|Psychoeducation|Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
46054470|NCT02689869|Drug|Ibrutinib|Ibrutinib (PCI-32765; JNJ-54179060) is a first-in-class, potent, orally-administered covalently-binding small molecule inhibitor of Bruton's tyrosine kinase currently being co-developed by Janssen Research & Development, LLC and Pharmacyclics, Inc for the treatment of B-cell malignancies.
45847175|NCT05452746|Device|Acupuncture|"Unilateral and bilateral acupuncture points:~Du 20 and GV 29,39 MS1, MS2, MS3 and MS4,40~Location of points:~Number of needles: 9~Depth of insertion:~MS1, MS2, MS3: insert the needle obliquely in the frontal direction for 1 cm Du 20: insert the needle obliquely in the frontal direction for 0.5 cm GV 29: insert the needle obliquely and downward for 0.5 cm Needles retained for 20 min Needle type: Han Yi 0.25x25 mm Treatment regimen: once per day for 2 weeks"
46054471|NCT02689869|Drug|GA 101|Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
45377769|NCT00998556|Drug|Bromocriptine|Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks. The study medication is taken on top of standard therapy for heart failure.
45377770|NCT01052974|Drug|ropivacaine|"A widespread collectively practice for the analgesia in prehospital or preoperative period is the single injection of local anesthetic with the technique of the femoral or iliofascial block.~Intervention: Analgesic treatment using a femoral perineural catheter (inserted from the hospital admission) with continuous infusion of ropivacaïne controlled by placebo."
45377771|NCT00817427|Other|Controls Short sleep|Healthy control subject's bedtime will be decreased by 2 hours/night with acoustic sleep disruption
45377772|NCT00817427|Other|CKD- sleep extension|Sleep will be increased by 2 hours each night for 3 nights
45377773|NCT00998634|Drug|LITHIUM CARBONATE|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
45377774|NCT04044989|Device|Laser|Diode laser device was used for photobiomodulation
45377775|NCT04044989|Device|light-emitting diode (LED)|LED device was used for photobiomodulation
45377776|NCT04044989|Device|Placebo|Diode laser device was used for placebo effect
45377777|NCT01003002|Drug|Levodopa (delivered intravenously)|One mg/kg/hr of Levodopa will be given intravenously during inpatient testing days from 0900 to 1100.
45377778|NCT01008774|Device|Paxman Cooling Machine|Scalp cooling procedures
45377779|NCT01008774|Device|Cold Caps|Scalp cooling procedures
45847176|NCT05452746|Other|Treatment as usual|Inpatient psychiatric care for depression
45847177|NCT05452434|Drug|mirabegron|mirabegron 50mg QD for 12 weeks.
46054472|NCT02847312|Other|High avenanthramide, phenolic acid|High avenanthramide and high phenolic acid, matched with energy and insoluable fibre.
46054473|NCT02847312|Other|Low avenanthramide, medium phenolic acid|Low avenanthramide and moderate phenolic acid, matched with energy and insoluable fibre.
46054474|NCT02847312|Other|Control|Control are matched with energy and insoluable fibre.
46054475|NCT02785809|Other|Pausing oral contraceptive|
46054476|NCT02847156|Other|Physical assessment|1 year follow-up in CF infants with clinical, microbiological and therapeutic assessments
46054477|NCT04405830|Procedure|Renal replacement therapy|Renal replacement therapy (RRT) refers to modalities of treatment that are used to replace the waste filtering functions of a normal kidney.
46054478|NCT05321745|Other|Standardized FMT|Fecal microbiota transplantation of fresh bacteria from healthy donor to the whole colon
45493525|NCT02326714|Other|Auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
45493526|NCT02326714|Other|Placebo auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
45493527|NCT05761158|Other|questionnaire|patients are asked to complete a questionnaire
45377780|NCT01008930|Procedure|HR PEM Scan|PEMFlex Solo II, a high-resolution camera for PET scan imaging, on an area of body that has, or is suspected to have cancer following routine, standard, positron emission tomography/computed tomography (PET/CT) scan
45377781|NCT01003158|Drug|AZD8931|Tablet Oral bid
45493528|NCT03144466|Combination Product|Pembrolizumab|antiPD1 monoclonal antibody
45493529|NCT03144310|Other|lung ultrasound|lung ultrasound and blood gas
45847178|NCT05452200|Behavioral|Solicitation for lung cancer screening|3 levels of solicitation will be cumulated. First : a Simple collective solicitation of all staff via internal media 4 months later : Personalized indirect solicitation of at-risk groups with information posted in identified areas 4 months later : Personalized direct solicitation of at-risk groups
45377782|NCT01003158|Drug|Paclitaxel|IV once weekly for 3 weeks followed by a week off
45377783|NCT01003236|Drug|placebo|140 mg placebo tablets, 3 times per day for 3 months
45493530|NCT00497952|Biological|hematopoetic stem cell infusion|Enriched hematopoietic stem cell infusion
45493531|NCT05173350|Other|RETAIN KY|The experimental group receives a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Services offered by the project include individualized intensive vocational services from RETAIN RTW Coordinators, with an emphasis on assistive technology, universal design, and peer support. The project provides training on SAW/RTW best practices and RETAIN, as well as financial incentives to health care professionals. The treatment group is eligible to receive the full set of RETAIN intervention activities.
45377784|NCT01003236|Drug|Milk Thistle extract|1 tablet equal to 140mg silymarin administered 3 times a day for 3 months
45377785|NCT03883386|Drug|Loratadine|10 mg in a capsule
45493532|NCT05173350|Other|Active Comparator|Those in the active comparator arm continue to receive medical services. A RTW coordinator creates a RTW plan with the enrollee and refers them to existing resources. The RTW coordinator works with enrollees for 2.5 hours total.
45493533|NCT03105466|Procedure|Deep anterior lamellar keratoplasty|Deep anterior lamellar keratoplasty using acellular porcine cornea; 0.05%Tacrolimus eye drops, four times a day for at least one year; 0.3% Tobradex eyedrops, four times-one times a day for one year.
45493534|NCT03105466|Device|Acellular Porcine Cornea|
45493535|NCT03105466|Drug|Tacrolimus eye drops|
45493536|NCT03105466|Drug|Tobradex eyedrops|
45493537|NCT02335528|Behavioral|SimCoach|
45493538|NCT03478787|Drug|risankizumab|Subcutaneous (SC) injection
45493539|NCT03478787|Drug|secukinumab|Subcutaneous (SC) injection
45493540|NCT03105154|Other|Prevena Dressing|Prevena dressing is applied on one groin
45693557|NCT01729039|Behavioral|gaze stability|Vestibular adaptation and substitution exercises will be performed by the experimental group (GS). Adaptation exercises involve head movement while maintaining focus on a target, which may be stationary or moving. Typical progression of adaptation exercises involve increased velocity of head movement, movement of both target and head, target placed in a distracting visual pattern and maintenance of a challenging posture. During active eye-head exercise, a large eye movement to a target is made prior to the head moving to face the target, potentially facilitating use of preprogrammed eye movements.
45377786|NCT03883386|Drug|Placebo|Administered via capsule
45377787|NCT00530946|Drug|Amlodipine 2.5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
45377788|NCT00530946|Drug|Amlodipine 2.5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
45377789|NCT00530946|Drug|Amlodipine 5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
45377790|NCT00530946|Drug|Amlodipine 5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
45377791|NCT00424047|Drug|CC-5013 plus dexamethasone|25 mg daily for 21 days every 28 days.
45693558|NCT01729039|Behavioral|Control|The placebo exercises will consist of saccadic eye movements while the head is stationary and will be performed by the control group. These eye movements will be performed against a plain background in order to eliminate retinal slip and, therefore, eliminate the error signal for vestibular adaptation.
45377792|NCT00424047|Drug|Dexamethasone plus Placebo|Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
45377793|NCT00530790|Drug|ropinirole controlled release (CR)-RLS|White film-coated round-shaped tablet
45493541|NCT03105154|Other|Conventional Dressing|Conventional dressing is applied on the contralateral groin
45493542|NCT03105076|Other|Decision aids|Shared decision making with decision aids
45493543|NCT02331628|Device|ESWT - Extracorporeal Shockwave Therapy|"Patients will receive:~Four applications of EWST to be delivered to the affected hip and /or knee over a period of eight weeks : starting week 8\52 from baseline until and including week 14\52, one dose every two weeks ± 3 days), administered by the principal investigator.~Dosage will be calculated for each participant, by the manufacturer, according to the size of NHO as recorded on X-ray.~The energy flux density (EFD) will be 'high level'~All participants will be supplied with headphones to reduce the noise level emitted by the machine."
45377794|NCT02869971|Device|Embosphere® (Prostatic Arteries Embolization)|Prostatic Arteries Embolization with 300-500 µm trisacryl microspheres
45377795|NCT02869971|Drug|Drug therapy|Combodart (dutasteride 0.5 mg/tamsulosin 0.4 mg)
45377796|NCT01032057|Drug|capecitabine|
45377797|NCT01032057|Drug|gemcitabine hydrochloride|
45493544|NCT02887482|Biological|GLS-5700|GLS 5700 at 2 mg DNA/dose
45493545|NCT02887482|Biological|Placebo|
45377798|NCT01032057|Procedure|quality-of-life assessment|
45377799|NCT01032057|Radiation|3-dimensional conformal radiation therapy|
45377800|NCT01003314|Biological|AdCh63-MSP1 (lower dose) vaccine and MVA-MSP1 vaccine|Group 1A: single dose of AdCh63-MSP1 vaccine 5 x 10^9 vp administered IM. Group 1B: single dose of AdCh63-MSP1 vaccine 5 x 10^9 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10^8 vp administered IM 8 weeks later
45377801|NCT01003314|Biological|AdCh63-MSP1 vaccine (higher dose) and MVA-MSP1 vaccine followed by challenge|Group 2A: single dose of AdCh63-MSP1 vaccine 5 x 10^10 vp administered IM. Group 2B: single dose of AdCh63-MSP1 vaccine 5 x 10^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10^8 vp administered IM 8 weeks later. Group 2C: single dose of AdCh63-MSP1 vaccine 5 x 10^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10^8 vp administered IM 8 weeks later and subsequent sporozoite malaria challenge 12-28 days post second vaccination
45693559|NCT01775995|Behavioral|Meditation-CBT Intervention + Usual Care|"The intervention combines meditation and standard-of-care CBT strategies for chronic low back pain. It consists of eight weekly 2-hour group sessions guided by trained instructors. In addition to session attendance, experimental participants are asked to practice meditation at home at least 6 days/week, 30 minutes/day during the 26-week study.~Control participants will be offered the intervention after completing the study.~All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
45693560|NCT01775995|Other|Usual Care Alone|All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.
45693561|NCT01741532|Drug|Deferiprone oral solution|Deferiprone 80 mg/mL oral solution will be administered twice daily (b.i.d.) for 18 months. An initial dose of 5 mg/kg b.i.d. will be administered for 6 weeks. The dose will then be escalated to 10 mg/kg b.i.d. and finally to 15 mg/kg b.i.d.
45693562|NCT01741532|Drug|Placebo|A deferiprone matching placebo oral solution will be given twice daily for 18 months.
45693563|NCT01719224|Procedure|elevated body position|45 degrees elevated upper body position
45693564|NCT01719224|Procedure|supine body position|non-elevated upper body position
45377802|NCT00530088|Drug|porfimer sodium|IV
45377803|NCT00530088|Drug|Photdynamic Therapy (PDT)|
45693565|NCT01717976|Behavioral|DISPO ED|primary care based nurse telephone support
45377804|NCT01009008|Device|Patient Activated Controlled Expansion Device|Patient activated controlled expansion for post-mastectomy breast reconstruction
45377805|NCT01006434|Other|Recording of body weight estimations, approximations and tPA dose|Body weight estimation, patients are weighed, actual tPA dose is recorded
45498183|NCT03684798|Other|Treatment as usual|The patients in the control group will receive a 2 x 2 contingency table about the disadvantages and advantages of being abstinent and of drinking. In addition, abstinence intentions of patients in the control group will also be supported and risk situations and relapse events since the last trainings will be reappraised, but without the use of MCII.
45693566|NCT01740440|Device|BMR Face|BMR Face used in accordance with manufacturer IFU
45693567|NCT01740128|Device|Robotic body weight supported treadmill training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
45693568|NCT01740128|Other|Harness-supported multimodal balance training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
45493546|NCT03488927|Behavioral|Supporting Survivors and Self: An Intervention for Social Supports of Survivors of Partner Abuse and Sexual Aggression (SSS)|The SSS intervention consists of a two-hour session followed by a 90-minute booster session a month following the initial program session. The SSS intervention is delivered in groups of approximately 20 students facilitated by peer educators. The SSS intervention provides participants with specific information on the reasons why positive social reactions are important and negative social reactions can be harmful, examples of what to say and what not to say (including ways to promote healthy coping and discourage unhealthy coping, e.g., drinking to cope), opportunities for roleplay, and an emphasis on the importance of self-care and ways in which self-care can be balanced with the needs of IPV and SA victims.
45377806|NCT01003470|Other|acupuncture|Xing Nao Kai Qiao Acupuncture
45377807|NCT01003470|Behavioral|rehabilitation|Kinesitherapy
45377808|NCT01003470|Other|acupuncture and rehabilitation|Xing Nao Kai Qiao Acupuncture plus Kinesitherapy
45493547|NCT02335372|Procedure|Wide-Field White Light Imaging|Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes during cervical colposcopy.
45493548|NCT02335372|Drug|Acetic Acid|3-6% acetic acid applied to cervix after wide-field while light imaging during colposcopy.
45693569|NCT01976741|Drug|Rogaratinib (BAY1163877) oral solution|Participants received Rogaratinib oral solution as a single dose on Cycle 1 Day 1 (C1D1) and twice daily (BID) from Cycle 1 Day 3 (C1D3) onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
45693570|NCT01976741|Drug|Rogaratinib (BAY1163877) oral tablet|Participants received Rogaratinib oral tablet as a single dose on C1D1 and BID from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
45693571|NCT01976741|Drug|Rogaratinib (BAY1163877) 800 mg BID|Participants received Rogaratinib 800 mg oral tablet as a single dose on C1D1 and BID (in total 1600 mg) from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
45377809|NCT01003548|Device|SMART dynamic system of embryo culture|Embryos will be cultured in a dynamic system of microfluidics.
45377810|NCT01003548|Device|Static culture|Embryos cultured in 40 microliters microdrops of G-IVF plus series V
45493549|NCT02335372|Drug|Proflavine Solution|Topical application of 0.01% proflavine solution applied for 1 minute to cervix after sites for biopsy have been identified during colposcopy.
45493550|NCT02335372|Procedure|Wide-Field Fluorescence Imaging|Wide-field imaging in fluorescence mode performed during cervical colposcopy after topical proflavine solution applied.
45693572|NCT01727713|Drug|Aripiprazole|Open Label: Once-Daily formulation of aripiprazole flex dose regimine
45693573|NCT04658927|Drug|Dexamethasone, 0.4mg|iLUX + dextenza
45377811|NCT01006668|Drug|Administration of sevoflurane|Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
45377812|NCT01006668|Drug|Administration of propofol|Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary.
45377813|NCT01003626|Procedure|Tumor Interstitial Fluid Pressure (IFP) assessments|The tip of a needle will be inserted in a skin lesion (similar to a biopsy needle) for up to 3 tumors. The needle is connected to a machine that reads the pressure inside the tumor. The whole process, including cleaning and numbing the lesion, will take about 3-4 minutes.
45377814|NCT01003626|Device|Transducer-catheter SPC-320 + Amplifier|Transducer-tipped catheter Mikro-Tip SPC-320 and transducer Millar with Power Lab used to assess the interstitial fluid pressure in a malignant melanona nodule
45377815|NCT01003704|Procedure|Lower extremity amputation|
45493551|NCT01569750|Drug|Part 1, Cohort 1|Type=exact number, unit=mg, number=280, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
45693574|NCT04658927|Drug|Prednisone acetate|Prednisolone acetate 1% and iLux
45693575|NCT04658927|Other|Control|iLUX alone.
45693576|NCT01965431|Drug|BI 207127|Medium dose oral administration
45693577|NCT01965431|Drug|BI 207127 placebo|
45493552|NCT01569750|Drug|Part 1, Cohort 2|Type=exact number, unit=mg, number=420, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
45493553|NCT01569750|Drug|Part 1, Cohort 3|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
45377816|NCT04000230|Behavioral|TCIT|"TCIT consists of the following:~CDI Teach Session: Teachers will participate in two training workshops in Child-Directed Interaction (CDI) skills. Specifically, teachers will learn to use positive attention skills and active ignoring.~CDI Coaching: Teachers will receive 90 minutes of CDI coaching in the classroom once or twice weekly for 6 total coaching sessions over a period of 4-6 weeks. The coach will observe the class and coach the teacher live using a microphone and bug-in-the-ear device.~TDI Teach Session: Teachers will complete two training workshops in Teacher Directed Interaction (TDI) skills, which focus on increasing compliance and reducing disruptive behavior. Teachers will learn to present developmentally appropriate, direct, and clear instructions and consistent positive and negative consequences.~TDI Coaching: Teachers will receive six 90-minute TDI coaching sessions once or twice weekly for 4-6 weeks."
45377817|NCT04000230|Behavioral|Booster|Teachers in the Intervention group will receive additional booster sessions during the second half of the school year. Booster sessions consist of coaching teachers in CDI and TDI skills. Teachers receive 4-8 booster sessions.
45377818|NCT05734326|Device|Ultrasound elastography|ultrasound elastography (USE) is emerging as a promising additional tool to discern malignant thyroid nodules, allowing increased diagnostic accuracy, Due to its ability to assess stiffness as an indicator of malignancy, USE has recently become an additional tool for thyroid nodule differentiation, in combination with conventional US and FNA [18].
45377819|NCT00360568|Drug|Levodopa-carbidopa intestinal gel|Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
45377820|NCT00360568|Device|CADD-Legacy® 1400 ambulatory infusion pump|
45377821|NCT00360568|Device|PEG tube|percutaneous endoscopic gastrostomy tube
45377822|NCT00360568|Device|J-tube|jejunal tube
45377823|NCT00436215|Drug|Bevacizumab|bevacizumab 5 mg/kg intravenous (IV) every two weeks
45377824|NCT00436215|Drug|BAY 43-9006|BAY 43-9006 200 mg po (by mouth) twice daily 5 out of 7 days each week (Mon-Fri)
45377825|NCT03742674|Other|Follow up|No intervention
45377826|NCT01006746|Other|Remote monitoring by Home Monitoring system|Standard of care completed with remote monitoring for ICD patients follow-up
45377827|NCT01028859|Drug|CKD-516 inj|5.0 mg/2ml; 1.0, 2.0, 3.3, 5, 7, 9 ~ mg/m2; Day 1, Day 8 every 3 weeks
45377828|NCT05734248|Procedure|Facial filler injection|Hyaluronic acid will be injected on the cheek, based on the aesthetic evaluation of the face.
45377829|NCT05602974|Radiation|stereotactic body radiation therapy|adjuvant stereotactic body radiation therapy
45377830|NCT05602974|Other|regular follow-up|regular follow-up
45377831|NCT00441363|Drug|Bromocriptine Mesylate|0.8 mg tablet
45377832|NCT05139186|Device|Artificial Intelligence|Artificial intelligence
45377833|NCT03992248|Behavioral|Time restricted feeding|Eating within a time frame of 10hrs during the day. Outside of this time frame, participants need to refrain from food and energy containing drinks.
45377834|NCT03992248|Behavioral|Control|Eating for at least 14hrs per day.
45377835|NCT05734170|Dietary Supplement|Chia Seeds and instant oatmeal breakfast|The final group was to consume one packet of instant oatmeal with two tablespoons of chia seeds mixed in with oatmeal for breakfast for 30 days.
45493554|NCT01569750|Drug|Part 2, Cohort 1|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma.
45693578|NCT01965431|Drug|Faldaprevir placebo|
45377836|NCT05734170|Dietary Supplement|Cheerio Breakfast|Patients were instructed to consume one serving of Cheerios according to package instructions each morning for 30 days.
45377837|NCT05734170|Dietary Supplement|Instant Oatmeal breakfast|The second group was assigned to consume one packet of instant oatmeal for 30 days.
45377838|NCT01006824|Other|Capsule endoscopy|Capsule endoscopy
45693579|NCT01965431|Drug|Faldaprevir|Medium dose oral administration
45377839|NCT01006824|Other|Dedicated small bowel contrast radiography|Dedicated small bowel contrast radiography
45493555|NCT01569750|Drug|Part 2, Cohort 2|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed with B-cell non-Hodgkin lymphoma.
45493556|NCT02335138|Behavioral|Couples HIV Testing and Counseling (CHTC, CVCT)|Male couples randomized to the experimental group (Couples HIV Testing and Counseling, CHTC/CVCT) will receive HIV counseling and testing as a couple via an online, HIPPA-compliant videoconferencing service. The dyad-centered session will last less than one hour and focus on couples agreement, prevention strategies, and/or linkage to HIV care, depending on each couple's test results. Participants will complete follow-up surveys at 3 and 6 months post-testing.
45847179|NCT05452200|Other|added exams to the usual lung cancer screening|"spirometry examination~Questionnaires~Blood samples and breath samples to find biomarkers"
45847180|NCT05451576|Dietary Supplement|Zelnite®|2pc intravenous Zelnite® will be given for 7 weeks (5 days/week).
45377840|NCT05734092|Device|Traditional orthodontic treatment|As for patients in the control group, the strength of the nickel-titanium coil will be adjusted every 4 weeks to the required strength of 40 g on each end until reaching normal coverage.
45377841|NCT05734092|Device|Low-Level Laser|"The laser will be applied to the root of each of the upper incisors in 8 points (4 points from the labial and 4 points from the palatine), and the head of the device will be placed from the labial side of the root in the center of each of the apical and middle thirds and the mesial and distal of the cervical third in contact with Oral mucosa perpendicular to the root axis, with the application of the laser beam for (16) seconds at one point, and the laser will be re-applied in the same way from the palatal side of the root. So that it was the total application time is (128) seconds for one tooth.~The laser will be applied on the day the upper incisor intrusion started (T1), then on days (3, 7, and 14) of the first month, and starting from the second month, the laser will be applied every (15) day, in addition to adjusting the force gauge every 4 weeks until the end of intrusion stage (T2) and reaching normal coverage."
45377842|NCT04000074|Behavioral|Telephonic Services|Provides linkage services to local programs that address the social determinants of health remotely via phone, email and/or fax
45377843|NCT04000074|Behavioral|In-Person Services|Provides linkage services to local programs that address the social determinants of health directly to the client during face-to-face visits as well as remotely via phone, email, etc.
45493557|NCT02335138|Behavioral|at-home test kit|Male couples in the control group will receive test kits, but will not receive any testing intervention. Once individual results are reported,participants will be contacted via phone by study staff with options for referrals to services for the reactive partner(s). Participants will complete follow-up surveys at 3 and 6 months post-testing.
45493558|NCT02326558|Procedure|laparoscopic microwave ablation-assisted enucleation|
45493559|NCT02326558|Procedure|conventional laparoscopic partial nephrectomy|
45493560|NCT03488225|Drug|Cyclophosphamide|Given IV
45493561|NCT03488225|Drug|Cytarabine|Given IT or IV
45493562|NCT03488225|Drug|Dexamethasone|Given IV or PO
45493563|NCT03488225|Drug|Doxorubicin Hydrochloride|Given IV
45493564|NCT03488225|Biological|Inotuzumab Ozogamicin|Given IV
45493565|NCT03488225|Other|Laboratory Biomarker Analysis|Correlative studies
45847181|NCT05451576|Dietary Supplement|Placebo|Placebo will be given for 7 weeks (5 days/week).
45847182|NCT05451342|Diagnostic Test|Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling|Blood samples and BALD samples will be collected for further integrated transcriptomics, metabolomics, lipidomics analysis, and exosome extraction.
45847183|NCT05450874|Procedure|hepatectomy|
46054479|NCT00221988|Drug|Levetiracetam (Keppra)|
46054480|NCT04200105|Device|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 22G EBUS needle
46054481|NCT04200105|Device|Acquire TBNB|Mediastinal and hilar lymph node sampling using the Acquire TBNB needle
46054482|NCT04231071|Device|Onlay Mesh group|Primary suture repair with a small only mesh on the closed defect
46054483|NCT02849262|Drug|Omiganan (CLS001) topical gel|
46054484|NCT02849262|Drug|Vehicle topical gel|
46054485|NCT02341911|Drug|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
46054486|NCT02341911|Drug|Gemcitabine,carboplatin|Gemcitabine 1000 mg/m2, IV drip 30 minutes, D1, D8 Carboplatin AUC 2, IV drip 120 minutes, D1
45493566|NCT03488225|Drug|Leucovorin Calcium|Given IV
45493567|NCT03488225|Drug|Mercaptopurine|Given PO
45493568|NCT03488225|Drug|Methotrexate|Given IT, IV or PO
45493569|NCT03488225|Biological|Ofatumumab|Given IV
45493570|NCT03488225|Drug|Prednisone|Given PO
45377844|NCT00530712|Device|PROTÉGÉ® EverFlex™ Self-Expanding Stent System|Implantation of a single study device in the native superficial femoral artery or superficial femoral artery and proximal popliteal artery.
45493571|NCT03488225|Biological|Rituximab|Given IV
45493572|NCT03488225|Drug|Vincristine Sulfate|Given IV
45493573|NCT02331316|Other|Daily extra water intake|"Intervention-A: Timing of assigned daily extra water intake specified~Intervention-B: Daily extra water assigned at any time during 24 hour period"
45493574|NCT02331004|Other|Intervention for fine motor skills|Implementation of an well known activity to improve the function of upper extremities
45847184|NCT05450328|Drug|Combined Epoprostenol Sodium & Milrinone|"One syringe containing 4mg of milrinone (1mg/mL, 4mL) and one syringe containing 60 mcg of epoprostenol (15 mcg/mL, 4mL).~The drugs will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions."
45377845|NCT05733936|Other|rehabilitation protocol|rehabilitation protocols after ACLR have been described, aiming to improve muscle strength and knee stability through muscle strengthening exercises in addition to exercises to improve joint proprioception
45377846|NCT05733858|Device|tRNS|For tRNS, the electrical current is delivered alternatively (an alternating current). The stimulation intensity will be set as 1.5 to 2 mA (based on the tolerance of participants). The stimulation frequency will be random frequencies ranging from 101 and 640 Hz.The stimulation period of tRNS and tDCS will be 20 minutes.
45493575|NCT02331004|Other|Support to activities of daily living|Participants are supported and orientated when they are performing some activity of daily living scheduled by the institution
45493576|NCT02326480|Other|Identification of genetic causes of obesity|A blood test will be performed to the child and his/her parents with the aim of identifying genetic causes of obesity. Different analysis will be as follows: caryotypes, Raindance, whole exome, in order to find potential mutations or new genes associated to this condition
45493577|NCT02326636|Biological|Fecal Microbial Transplantation|Participants with refractory Clostridium difficile infection will be given healthy donor stool administered by colonoscopy or enema.
45493578|NCT02331160|Behavioral|Rebozo|Shaking of the maternal pelvis by the midwife to increase the spontaneous cephalic version rate in breech presentation.
45493579|NCT02334904|Drug|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study)
45377847|NCT05733858|Device|tDCS|For tDCS, the electrical current is delivered in a continuous and consistent manner (direct current). The stimulation intensity will be the same as that of tRNS (1.5 to 2 mA based on the tolerance of participants), which is safe for stroke patients.The stimulation period of tRNS and tDCS will be 20 minutes.
45493580|NCT02334904|Drug|Risperidone|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
45493581|NCT02331238|Behavioral|"Coaching Boys into Men program"|"Coaching Boys into Men program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth."
45493582|NCT03717077|Procedure|learned resourcefulness intervention|The LR program includes: 1) Solving problem strategy, 2) Organizing daily actions, 3) Using self-regulation, 4) Reframing positive situations, 5) Changing negative self-thinking, 6) Exploring new thinking and skills. It is conducted one time per week.
45493583|NCT02326090|Drug|cis-UCA ophthalmic solution 1.0%|
45493584|NCT02326090|Drug|cis-UCA ophthalmic solution 2.5%|
45493585|NCT02326090|Drug|Placebo ophthalmic solution|
45493586|NCT01311011|Procedure|SCT|SCT
45493587|NCT02326246|Other|multi-parametic MRI|
45493588|NCT03437447|Drug|Cisticid|Participants received single oral dose of 1200 mg (two 600 mg tablets) Cisticid (Test) on Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2) or Day 15 (Treatment Period 3).
45493589|NCT03437447|Drug|Biltricide|Participants received 600 mg of Biltricide (Reference) tablet at a dose of 1200 mg on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
45493590|NCT02459080|Drug|TD-4208|
45493591|NCT02459080|Drug|Placebo|
45498184|NCT05407857|Behavioral|multi-modal non-pharmacological intervention|multi-modal non-pharmacological intervention including the management with nutrition, exercise and cognitive programs
45377848|NCT05733858|Device|sham stimulation|For the sham stimulation condition, the electrode placement will be the same as the other real eletrical stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds to provide sensory feeling without actually stimulating the brain.
45377849|NCT05733858|Behavioral|digital MT|For the digital MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand while looking at the real-time image on the computer screen. The activities practiced during digital MT will include intransitive movements (e.g., flexion and extension of the wrist) and transitive movements (e.g., picking up a pen). The amount of time exposed to intransitive and transitive movements will be balanced for each participant. The participants will practice 30 intransitive and 30 transitive tasks over the 20 training sessions, and the actual movements will be selected based on each individual's ability and his/her needs.
45377850|NCT00626795|Drug|TD1414 2% cream|BID 7 days
45377851|NCT00626795|Drug|TD1414 2% cream|TID 7 days
45377852|NCT00626795|Drug|Bactroban® (mupirocin) 2% cream|BID 7 days
45377853|NCT01007214|Procedure|Prostatectomy|Elective prostatectomy
45377854|NCT00826553|Drug|Dexmedetomidine|Standard of care sedative. Dosage, frequency, and duration will be determined by the managing clinical team.
45377855|NCT00826553|Drug|GABA agonist|Patients sedated with GABA agonists (e.g. propofol, benzodiazepines) during mechanical ventilation will be enrolled. Patients randomized to the GABA agonist arm will continue the sedative that is active at enrollment. The specific drug as well as dosage, frequency, and duration will be determined and titrated by the managing clinical team.
45377856|NCT00626639|Drug|Placebo|Administered by intravenous (IV) bolus injection
45377857|NCT00626639|Drug|palifermin|Administered by intravenous (IV) bolus injection
45377858|NCT00626639|Radiation|Radiotherapy|Once daily irradiation of 20 centigray (cGy)/day x 33 fractions for a total target dose of 6600 cGy (conventional radiation therapy using standard fractionation [one fraction per day])
45377859|NCT00626639|Drug|Cisplatin|100 mg/m^2 intravenously (IV) on days 1, 22 and 43.
45377860|NCT00626561|Drug|Bevacizumab|10 mg/kg IV twice weekly on days 1 and 15.
45377861|NCT00626561|Drug|Paclitaxel|60 mg/m^2 IV weekly on days 1, 8, 15, and 22.
45377862|NCT00822653|Device|Calf Muscle Pump Stimulation|Stimulation of the postural reflex arc to activate the soleus muscle during dialysis
45377863|NCT00822731|Drug|Chemotherapy with or without radiotherapy|Treatment regimen will be determined by the sub-type of lymphoma
45377864|NCT03859661|Dietary Supplement|Fitabisc|Fitabisc is a chocolate cookie with vanilla cream filling which contains the most important antioxidants Vitamin C, Vitamin E, and the mineral Selenium. Fitabisc is not commercially available and for the purposes of this study it will be manufactured by Calerrific Ltd, which already produces a biscuit called CalBisc 100 as a simple calorie and nutritional supplement. Production takes place in a BRC Global Standard Grade A certified bakery operated by Farringford Foods in Portadown, Northern Ireland.
45377865|NCT00826631|Procedure|Fast food arm|Doubling of regular caloric intake based on fast food, no exercise allowed
45377866|NCT03880266|Drug|Glycopyrronium cloth, 2.4%|Pre-saturated 100% polypropylene, nonwoven, fabric cloth with glycopyrronium
45377867|NCT03880266|Drug|Vehicle|Pre-saturated 100% polypropylene, nonwoven, fabric cloth
45377868|NCT00423891|Drug|Entecavir|Tablets / Oral Solution, Oral, Naïve: 0.015 mg/kg up to 0.5 mg; Experienced: 0.030 mg/kg up to 1 mg, once daily, 48 - 120 weeks depending on response
45377869|NCT00830609|Drug|Peginterferon alfa 2 A|Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 800 mg/day po (Control Group) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epoetin β (450 IU/kg/week) SC over 4 weeks (Arm B1) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epo beta 450 UI over four weeks (Arm B1) If RNA-HCV positive at week 4, Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day plus Epo beta 450 UI to keep Hb>12 g/dL if required over 20 additional weeks (Arm B2)
45377870|NCT00830609|Drug|Peginterferon alfa 2 A, ribavirin + Epo Beta|Ribavirin 1,600 mg/day plus peginterferon alfa 2A 180 mcg/week plus Epo beta 450 IU/Kg/day to maintain Hb>12g/dl over 4 or 24 weeks
45377871|NCT00830609|Drug|ribavirin|RBV 1600 mg/day 24 weeks
45377872|NCT00830609|Drug|ribavirin|ribavirin 800 mg/day for 24 weeks
45377873|NCT00830609|Drug|Peginterferon alfa 2|Peginterferon alfa 2 a 180 mcg/week for 4 weeks and then peginterferon alfa 2A for 20 weeks
45377874|NCT00830609|Drug|ribavirin|RBV 1600 mg/day 4 weeks and then ribavirin 800 mg/day 20 weeks
45498185|NCT03688698|Radiation|PET/MRI|PET/MRI scans
45377875|NCT00822809|Drug|Catumaxomab|"Catumaxomab will be infused 4 times within 11 days as follows:~10 µg on day 0, 20 µg on day 3, 50 µg on day 7, 150 µg on day 10"
45377876|NCT00822809|Drug|Prednisolone|25 mg premedication
45377877|NCT00830687|Device|TARGON FN|The Targon FN implant consists of a small side plate with six locking screw ports
45377878|NCT01007370|Procedure|Tracheal intubation|Tracheal intubation through a supraglottic airway device(LMA-Fastrach).
45377879|NCT01007370|Procedure|Tracheal intubation|Tracheal intubation through a supraglottic airway device(I-gel).
45377880|NCT00822887|Drug|Vandetanib|Dose level 1:100 mg qd Dose level 2:200 mg qd Dose level 3:300 mg qd
45377881|NCT00822887|Radiation|Fractionated Stereotactic Radiotherapy|All patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
45377882|NCT02549651|Drug|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion
45377883|NCT02549651|Drug|tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion
45377884|NCT02549651|Drug|AZD9150|AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion
45377885|NCT03999762|Device|sample prep|Effectiveness of a sample preparation protocol
45377886|NCT03999372|Biological|Hyaluronan binding system|Hyaluronan binding system for sperm selection for ICSI procedures (PICSI)
45377887|NCT03999372|Other|ICSI|Normal ICSI procedure
45377888|NCT00826709|Device|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC).
45377889|NCT00822965|Other|Questionnaires|3 sets of questionnaires at the beginning of the study, at 2-months and at 4-months.
45377890|NCT00822965|Other|Phone Interviews|2 follow-up phone interviews.
45377891|NCT00822965|Behavioral|Educational Packet|Video or DVD of device information, updates, recalls, on-line resources and benefits of routine follow-up for device(s).
45377892|NCT05733468|Drug|Theracal LC|After hemorrhage control , 1-1.5mm of TheraCal LC will be placed on the radicular pulp stumps followed by light curing, followed by the placement of IRM and composite restorative material after 2 weeks
45377893|NCT05733468|Drug|MTA|After hemorrhage control , a small ball like consistency of 2-3mm of MTA will be placed on the radicular pulp stumps, followed by the placement of IRM and composite restorative material after 2 weeks
45377894|NCT00830843|Drug|Propofol|Propofol(3-4 mg/kg/ora)administrated for 2 hours.
45693580|NCT01965431|Drug|Moxifloxacin (Avalox®)|
45377895|NCT00830843|Drug|Isoflurane|Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
45377896|NCT00826787|Drug|Levetiracetam|750 mg tablet
45493592|NCT03720041|Drug|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm|"In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol. All participants will be given the following starting doses:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally~Lenalidomide: 25mg/day on days 1-21, taken orally~Dexamethasone: 40mg on days 1, 8, 15 and 22 for participants aged ≤75 years, or 20mg on days 1, 8, 15 and 22 for participants aged > 75 years; taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
45493593|NCT03720041|Drug|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm|"In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail. The starting doses for each frailty category are described below:~Fit category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 25mg on days 1-21, taken orally Dexamethasone: 40mg on days 1, 8, 15 and 22, taken orally~Unfit category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 15mg on days 1-21, taken orally Dexamethasone: 20mg on days 1, 8, 15 and 22, taken orally~Frail category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 10mg on days 1-21, taken orally Dexamethasone: 10mg on days 1, 8, 15 and 22, taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
45493594|NCT03720041|Drug|R2: Lenalidomide plus placebo maintenance|"Participants randomised to receive lenalidomide plus placebo maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg*/day on days 1-21, taken orally Placebo: 4mg*/day on days 1, 8 and 15~* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
45377897|NCT00823121|Procedure|freezing embryos by vitrification|vitrification by Cryotop method
45493595|NCT03720041|Drug|R2: Lenalidomide + ixazomib maintenance|"Participants randomised to receive lenalidomide plus ixazomib maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg*/day on days 1-21, taken orally Ixazomib: 4mg*/day on days 1, 8 and 15~* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
45493596|NCT02326168|Drug|Bacillus Calmette-Guerin (BCG)|Intravesical instillation for non-muscle invasive bladder cancer
45377898|NCT00823121|Procedure|fresh embryo transfers|fresh embryo transfers
45377899|NCT00823121|Drug|buserelin|Daily administration of 500 µg subcutaneous buserelin from day 21 of menstrual cycle; reduce to 250 µg daily when ovarian suppression is confirmed.
45377900|NCT00823121|Drug|recombinant FSH|gonadotropin stimulation with rFSH 150 IU/day from day 2 of menstrual cycle
45377901|NCT00823121|Drug|human chorionic gonadotropin (pregnyl)|hCG 10,000 IU is administered when at least 2 follicles reach a mean diameter of 18 mm.
45377902|NCT00423813|Drug|placebo|Oral Solution
45377903|NCT00423813|Drug|Xyrem®|two doses
45377904|NCT01007604|Device|Peristaltic pulse PCD|Daily use for two hours
45377905|NCT01007604|Other|Exercise and lifestyle counseling|Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
45377906|NCT03687372|Drug|A-101|hydrogen peroxide topical solution 45%
45377907|NCT03687372|Other|vehicle|vehicle as a topical solution
45377908|NCT00626405|Biological|bevacizumab|Given IV over 30-90 minutes
45377909|NCT00626405|Drug|carboplatin|Given IV over 30 minutes
45377910|NCT00626405|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV over 30 minutes
45377911|NCT00626405|Drug|temozolomide|Oral temozolomide on days 1-5
45493597|NCT02334826|Procedure|PCI -BVS|All patients in the PCI arm will be treated with bioresorbable scaffolds (Absorb). Lesions in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate) will be treated after confirmation of functional significance with iFR/FFR.
45493598|NCT02334826|Procedure|CABG|In the CABG arm the surgery will be carried out according to the routine practice, with the intention of complete revascularization and frequent use of arterial grafts.
45493599|NCT03487445|Drug|Selatogrel 8 mg|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water and further diluted with 1 mL sodium chloride (NaCl) 0.9%.
45847185|NCT05450328|Drug|Normal saline|"The control group will receive two syringes of 4mL of Normal Saline, before CPB start.~The placebo will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions."
45493600|NCT03487445|Drug|Selatogrel 16 mg|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
45493601|NCT02109172|Drug|TD-4208|
45493602|NCT02109172|Drug|Placebo|
45493603|NCT02326012|Behavioral|Emotion Regulation Individual Therapy for Adolescents|
45493604|NCT02334592|Radiation|Sunbed tanning|Invention groups undergo a 12-week tanning protocol that follows Health Canada's RED Act
45493605|NCT05076916|Behavioral|The effectiveness of the web-based education programme among cancer patients|The web-based education program was introduced to the patients with cancer in the intervention group during face-to-face interviews. They were asked to examine the program for at least two hours a week for three months. During the follow-up period, the patients in the intervention group were called twice a week and reminded to use the education program. The researchers get in contact with the patients online via the website. The patients contact the research team by calling or writing messages via the website 24/7. An e-mail account was created by the research team using the email system of the university, and it was shared with the patients. The clinical researchers of the team answered the patients' questions via this e-mail account.
45493606|NCT02331082|Other|Structured Quality Improvement|For structured quality improvement, trained healthcare providers (primarily doctors from referral hospital) will serve as mentors to mid-level providers. The mentors will facilitate on-site trainings of primary care with mid-level providers at the district hospital. Mentors will also travel monthly to the healthcare facilities themselves to provide training both in the direct context of clinical care and to provide feedback based upon surveillance and monitoring data. The focus will be on the techniques from the Institute for Healthcare Improvement's Model for Improvement, including Plan-Do-Study-Act cycles, run charts, and root cause analyses. Finally, they will work with the clinical healthcare staff to identify resource needs from the local government for maintenance, water, electricity, and supplies. These resource needs will be addressed through an integrated supply chain management system across the tiers of the healthcare system.
45847186|NCT05450172|Other|QoR-15 questionnaire|The QoR-15 is a 15-item questionnaire on postoperative quality of recovery. The DN4 is a 10-item questionnaire on neuropathic pain. Both questionnaires will be given to the patients preoperatively, on postoperative days 2 and 3, and 1, 3 and 6 months after surgery.
45847187|NCT05449938|Procedure|Scaling and root planing|Scaling and root planing involves removal of plaque and calculus on tooth surface.
45847188|NCT03018912|Other|Sleep VS|"During check in patients are instructed to complete the Sleep VS survey packet only. The Sleep VS survey packet will take approximately 4 minutes to complete. The packet includes the subjective Sleep VS and additional sleep questionnaires, such as ESS, FOSQ-10, ISI, and sleep-wake pattern questions.~The subjective Sleep VS is composed of the following 2 questions:~How many days a week are you satisfied with your sleep?~How many days a week is sleepiness a problem?"
45847189|NCT05449860|Procedure|Radiofrequency ablation using combined bipolar and monopolar energy deliver with Twin Cooled-Wet electrodes|Radiofrequency ablation will be performed by using twin cooled-wet electrodes. Two electrodes will be places on the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF, bipolar mode and switching monopolar mode) will be applied to two electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C. The RF energy will be delivered by using the 200 watts single generator.
45377912|NCT05454306|Device|Anser Clavicle Pin|The Anser Clavicle Pin is an intramedullary device that has been studied in 20 patients in an EU-based prospective case series.28 A 100% union rate was found. The Constant-Murley score at 1-year was 96.7 (SD 5). The Disabilities of Arm, Shoulder and Hand score was 5.1 (SD 10). There were no infections, neuropathy of the supraclavicular nerve or hardware irritation requiring removal of hardware. Three device-related complications (15%) occurred including plastic deformation, protrusion and hardware failure. VAS satisfaction was 8.9 (SD 1) at the 1-year follow up.
45377913|NCT05733234|Device|Laser ,Fotona, Light Walker AT, Ljubljana, Slovenia|Laser is used adjunctively in the surgical treatment of peri-implantitis for decontamination of the implant surface
45377914|NCT05733234|Drug|Mechanical Treatment|Dental instrument is used in combination with Chlorhexidine to decontaminate the implant surface
45377915|NCT00826865|Drug|Levetiracetam|750 mg tablet
45377916|NCT01007682|Other|Show distressing movie and tell half of the two study groups to suppress memories of the movie|A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
45493607|NCT02331082|Other|Chronic Care Model|Senior physicians trained in mentorship of non-physician mid-level providers will provide decision support for mid-level providers in the current district healthcare system with specific protocols for target conditions. We will add the following elements: focus on mid-level, non-physician providers as the primary clinicians within the intervention; intensive Community Health Worker (CHW) outreach for detection, screening, follow-up of patients, and encouragement of patient self-care and behavior change; and focused effort on the seamless care coordination of patients across the tiers of the system. Through trainings of CHWs, much of patient self-management comes in the form of home visits that reinforce clinic and hospital counseling, including risk management and prevention. CHWs will be trained in the counseling of each target condition, with counseling largely occurring in the patients' homes, where much of the challenges of chronic disease management and behavior change lie.
45498186|NCT05387343|Diagnostic Test|Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity Test|Boosters will be given after month 3 after transplant, and the 2nd booster will be given 3 months after the first.
45377917|NCT00830921|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method for altering brain activity in vivo.
45847190|NCT05449782|Dietary Supplement|Cocoa flavanol|Commercially available Cocoa Via Brand capsules containing 1350 mg cocoa flavanols (6 capsules)
45377918|NCT00358150|Drug|Eliglustat tartrate|Eliglustat (Genz-112638) capsule as single 50 mg dose on Day 1 then eliglustat 50 mg twice daily (BID) from Day 2 to Day 19, then either eliglustat 50 mg BID (if Genz-99067[active moiety of eliglustat in plasma] trough plasma concentration was greater than or equal to [>=]5 nanogram per milliliter [ng/mL] on Day 10) or eliglustat 100 mg BID(if Genz-99067 trough plasma concentration was less than [<] 5 ng/mL), from day 20 to Year 4. After primary completion date (Week 52) participants underwent treatment interruption period of approximately 2 weeks before continuing same treatment through study completion (Year 9). Participant receiving 100 mg BID could be considered for further dose increase to 150 mg BID at Week 24 if they met certain criteria (for example, had been on treatment for at least 24 months, had not reached therapeutic goals established for participants receiving Cerezyme, and if all other causes for lack of treatment effect had been evaluated and ruled out).
45377919|NCT00830999|Behavioral|Positive energy balance|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands.
45377920|NCT00830999|Behavioral|Energy balance with exercise|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands but will perform 2 hours of exercise that will be sufficient to burn off the excess calories consumed resulting in subjects being in net energy balance.
45493608|NCT02331082|Device|Integrated Electronic Medical Record|Clinical information systems. We are developing a system for tracking patients that integrates across each of the tiers using an electronic medical record. This is a key technology in supporting each of the above delivery system design elements.
45493609|NCT02331082|Device|Solar-powered electrical supply|As a component of our comprehensive healthcare systems strengthening intervention, we are installing solar panels at community-level clinics to ensure continuous electrical supply for medical devices and technology.
45493610|NCT02331082|Behavioral|Performance-based financing|As part of our healthcare systems strengthening intervention, we have established a performance-based financing agreement with the Government of Nepal that conditionally funds healthcare delivery based on population-level health outcomes and quality healthcare service delivery. In this arrangement, the Government serves as a regulator of healthcare delivery rather than a primary provider of healthcare services.
45377921|NCT00830999|Behavioral|Negative energy balance|Subjects will consume over a 24 h period only 66% of the calories required to meet their energy demands such that they will be in a net negative calorie balance in this trial.
45377922|NCT00830999|Behavioral|Negative energy balance with exercise|Subjects will consume over a 24 hour period the same amount of calories as ingested in the isocaloric trial but will also perform 2 hours of exercise that will be sufficient to burn off a third of the calories they consumed during this day resulting in subjects being in net negative energy balance in this trial
45377923|NCT00830999|Behavioral|Energy balance|Subjects will consume over a 24 hour period a sufficient amount of calories to meet their energy needs.
45493611|NCT02331082|Other|Existing healthcare system|This is the current rural, district-level public sector healthcare infrastructure of rural Nepal that is not strengthened during the study.
45847191|NCT05449782|Other|Placebo|Capsules identical to ccocoa flavanol capsules filled with calorically matched brown sugar (6 capsules)
45377924|NCT00831077|Drug|ORM-14540|i.v.
45377925|NCT00831077|Drug|ORM-12741|i.v.
45377926|NCT01007760|Other|Respirable suspended particles (RSP) PM 2.5 dose of second-hand smoke|acute one time exposure
45377927|NCT00823355|Drug|forodesine hydrochloride|Cohort 1: 100mg / body (1 x 100mg tablet once daily)
45377928|NCT00823355|Drug|forodesine hydrochloride|Cohort 2: 200mg / body (2 x 100mg tablets once daily)
45377929|NCT00823355|Drug|forodesine hydrochloride|Cohort 3: 300mg / body (3 x 100mg tablets once daily)
45377930|NCT00823355|Drug|forodesine hydrochloride|Cohort 4: 400mg / body (4 x 100mg tablets once daily)
45377931|NCT03999450|Behavioral|brief motivational intervention (BMI)|The intervention typically takes 45 minutes to administer and is designed to enhance motivation to change and includes the following components: establishing rapport, asking permission to discuss substance use and providing feedback regarding the substance use assessment, exploring personal consequences of drug use, eliciting the gap between real and desired quality of life, and discussing readiness to change. The therapist then negotiates a written action plan, during which the subject is supported with empathy and verbal reinforcement.
45377932|NCT03999450|Behavioral|cognitive behavioral therapy|This evidence-based, online, Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT) program covers six lessons: 1) changing patterns of use, 2) coping with craving, 3) refusing drugs, 4) problem-solving skills, 5) changing drug-related thoughts, and 6) improving decision-making. The program is designed to be user-friendly and includes videotaped instructions and examples, interactive assessments, and practice exercises.
45493612|NCT03144154|Behavioral|Self-hypnosis + Self-care|Our groupal intervention is divided into 8 weekly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, self-respect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
45847192|NCT05449704|Drug|DA-5218|single dose administration (DA-5218 one tablet once a day)
45377933|NCT05435586|Other|Web Based Breastfeeding Education and Counseling with Digital Game Support|The educational content prepared by the researcher on the web page will be integrated into the game program designed with the gamification technique. In this designed program, users will be notified at appropriate times to enter the system and play games from the link sent via e-mail. After the users have finished the game, they will fill the scale in the relevant week and will only be able to exit the system in that way.
45498187|NCT04220775|Drug|Bintrafusp Alfa|Given IV
45498188|NCT04220775|Other|Quality-of-Life Assessment|Ancillary studies
45498189|NCT04220775|Other|Questionnaire Administration|Ancillary studies
45498190|NCT04220775|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45847193|NCT05449704|Drug|DA-5218-R1 + DA-5218-R2 + DA-5218-R3|single dose administration (DA-5218-R1 one tablet once a day + DA-5218-R2 one tablet once a day + DA-5218-R3 one tablet once a day)
45847194|NCT05449158|Procedure|left atrial pressure regulation|For patients after atrioventricular node ablation combined with left atrial appendage closure, the regulation of left atrial pressure can be controlled by adjusting the frequency of pacemaker.
45693581|NCT01976663|Device|JUVEDERM VOLIFT® XC|Up to 4 mLs JUVEDERM VOLIFT® XC injected intradermally in one NLF (total; including initial and touch-up treatments) and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. For asymmetric correction, only the more severe NLF is eligible for asymmetric correction.
45693582|NCT01976663|Device|Control|Up to 4 mLs Control injected intradermally in opposite NLF (total; including initial and touch-up treatments). Up to 4 mLs JUVEDERM VOLIFT XC is allowed for asymmetry correction and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. Only the more severe NLF is eligible for asymmetric correction.
45693583|NCT01775137|Drug|TBM100|Tobramycin inhalation powder (TIP) 112mg/b.i.d
45693584|NCT01976507|Drug|dabigatran etexilate mesylate|Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
45377934|NCT01049074|Other|Acupuncture Treatment|Acupuncture is a technique of inserting and manipulating fine needles into specific points on the body to relieve pain or for therapeutic purposes.
45693585|NCT04661579|Biological|RTS,S/AS01E|Vaccine
45377935|NCT01049074|Other|Sham acupuncture|Sham acupuncture is inserting needles superficially, without manipulating, into specific points on the body.
45377936|NCT05427630|Drug|THC ~2.5%|Cannabis flower containing THC ~2.5%
45377937|NCT05427630|Drug|THC ~5%|Cannabis flower containing THC ~5%
45377938|NCT05427630|Drug|THC ~10%|Cannabis flower containing THC ~5%
45377939|NCT05427630|Drug|Sham Cannabis|Cannabis flower from which the THC and CBD have been extracted
45377940|NCT01050556|Other|Placebo|daily, 24 weeks
45377941|NCT01050556|Dietary Supplement|folic acid|400 ug/d for 12 or 24 weeks
45493613|NCT02334670|Drug|Fluconazole|HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.
45493614|NCT02330848|Dietary Supplement|Walnut Ad libitum diet|Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum
45493615|NCT02330848|Dietary Supplement|Walnut Calorie controlled|The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan for 6 months.
45847195|NCT05449080|Diagnostic Test|Karyotype|Patients were subjected to karyotype to determine their genotype
45847196|NCT05448924|Diagnostic Test|Hormone panel tests|Patient was subjected to a battery of hormone tests, including FSH, LH, estrogen, progesterone and growth hormone
45847197|NCT05448846|Procedure|Enhanced Recovery After Surgery|ERAS protocol includes preoperative counselling, optimization of nutrition, standardized analgesic and anesthetic regimens and early mobilization.
45377942|NCT01050556|Dietary Supplement|folic acid|800 µg/d for 12 or 24 weeks
45377943|NCT01050556|Dietary Supplement|creatine|3 mg/d for 12 weeks
45377944|NCT01050556|Dietary Supplement|creatine + folic acid|3 mg creatine/d + 400 µg folic acid/d for 12 weeks
45377945|NCT05890027|Drug|Phenylephrine Ophthalmic|One drop of Phenylephrine 2.5% ophthalmic solution to be administered to the eye with ptosis to evaluate for surgical repair.
45377946|NCT05890027|Other|Eyelid Tape|Participants will have the affected eye with ptosis manually lifted using tape.
45377947|NCT05890014|Dietary Supplement|Flavonoid-rich diet|Inclusion of foods rich in flavonoids.
45377948|NCT05890001|Drug|BLI5100|Patients will take BLI5100 once daily, orally, for up to 29 weeks.
45377949|NCT05889975|Device|interdental brush|cleaning the inter dental areas after manual tooth brush twice daily by the patient for 30 days
45377950|NCT05889975|Device|single tufted brush|cleaning the inter dental areas after manual tooth brush twice daily by the patient for 30 days
45377951|NCT05889975|Device|water irrigator|using water irrigator after manual tooth brushing twice daily with 300ml distal water placed in its container. The patients instructed to use the entire 300ml during each irrigation for 30 days
45377952|NCT05889962|Procedure|Pudendal nerve block|Patients who are randomized in the pudendal block group will receive bilateral pudendal nerve block with ropivacaine.
45377953|NCT05889962|Procedure|Placebo block|Patients who are randomized in the placebo group will receive bilateral pudendal block with normal saline.
45377954|NCT05889923|Device|With EDU|using the EDU to perform the procedure
45498191|NCT02925312|Other|Diabetes Pathway|Medication algorithm, survival skills education, enhanced patient-provider communication facilitated by near, real-time blood glucose monitoring
45693586|NCT04661579|Biological|Abhayrab rabies vaccine|Vaccine
45693587|NCT01964963|Drug|Alogliptin|Alogliptin tablets
45693588|NCT04175639|Behavioral|Mobile Health Pain Coping Skills Training (mPCST)|Participating in Mobile Health Pain Coping Skills Training will involve four 50-minute individual intervention sessions conducted over the course of 8 weeks with tele-video-conferencing at patient's community-based clinic. The therapist delivering the intervention will be at Duke University Medical Center, and patients will be at their community clinic.
45377955|NCT05889910|Procedure|Health education workshop|"The intervention will consist of 5 initial sessions, plus a reinforcement session at 6 months. The sessions will last 2 hours and will preferably be distributed one day a week.~The objective of the intervention is to reduce the fear of falling and falls in people over 65 years of age who live in the community. To this end, nursing interventions will be included to improve the knowledge, skills and attitudes of the participants regarding the improvement of their functional capacity, the prevention of falls and their preventive measures, as well as the improvement in the management of anxiety and coping with the fear of falling and falls.~The activities carried out during the intervention have been extracted from standardized nursing interventions through the Nursing Interventions Classification (NIC).~The following interventions and activities will be addressed: 1665, 5612, 6490, 6486, 4700, 5820 and 5230."
45493616|NCT02334202|Behavioral|Interpersonal Psychotherapy-Weight Gain|Participants will have 1 individual pre-group session when each participant meets with the group leaders so that they can learn about each girl's significant relationships, set goals for the program, and so each girl can learn about group participation and format. Participants then will begin IPT-WG which is designed to decrease excessive weight gain among adolescents ages 12-17 years who are at risk for adult obesity. The IPT-WG program has been adapted to be appropriate for military dependents. The IPT-WG group meets for 12 consecutive, weekly group meetings and involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. At the 6th week of the group, the group leaders meet with each participant to review their progress and goals.
45493617|NCT02334202|Other|Health Education|"The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each with a 90 minute session). Girls will come in for a 1.5-hour group meeting once a week for 12 weeks (12 times total). Before beginning the group, girls will meet with group leaders to review each adolescent's family health history. The curriculum includes focus on various health topics, including avoiding alcohol, drug and tobacco use, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence."
45377956|NCT05889884|Device|Extended maxillary fixed retainer|Bonding extended maxillary fixed retainer from right first maxillary premolar to left maxillary first premolar for 6 months then assessment of relapse using 3D superimposition , little index , lateral cephalometric assessment along with PDL assessment with quality of life ,function and speech assessment
45377957|NCT05889871|Drug|Standard endocrine therapy plus Apatinib|Standard endocrine therapy plus Apatinib
45377958|NCT05889845|Drug|Candin, Intradermal Solution|Injection at the base of the selected wart
45377959|NCT05889845|Drug|Placebo|Injection at the base of the selected wart
45493618|NCT02334280|Behavioral|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
45493619|NCT02974868|Drug|PF-06651600|200 mg QD during induction and 50 mg QD during Maintenance
45493620|NCT02974868|Drug|PF-06700841|60 mg QD during induction and 30 mg QD during maintenance
45493621|NCT02974868|Drug|Placebo|Placebo
45493622|NCT03144076|Other|RSBY Health Insurance|RSBY is a national inpatient public insurance plan in India, made available through this study to participants in Groups A, B, and C.
45493623|NCT02330770|Drug|GnRHa and HCG|Final oocyte maturation will be triggered by dual administration of 0.2 mg of GnRHa preparation (Triptorelin) SC and 1500 IU of HCG preparation IM
45493624|NCT02330770|Drug|GnRHa then HCG (single low-dose)|Final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC then a single IM bolus of 1500 IU HCG will be administered 35-37 hours after GnRHa trigger (1 hour after oocyte retrieval)
45493625|NCT02330770|Drug|GnRHa then HCG (multiple low-doses)|Final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC then 3 IM boluses of 500 IU HCG will be administered day 1, day 4 and day 7 after oocyte retrieval
45493626|NCT05076526|Biological|Hyaluronic acid (Synolis VA)|"Synolis VA harbours the following characteristics:~NaHA (Sodium hyaluronate): 20mg/mL, biofermantative and pharmaceutical grade origin.~Sorbitol: 40mg/mL~Molecular weight of 2MDa, sterilized in moist heat"
45493627|NCT05076526|Biological|Cellular Matrix platelet-rich-plasma with hyaluronic acid (CM PRP-HA)|"The CM-PRP-HA tube is under vacuum containing the following:~2mL of hyaluronic acid gel in phosphate buffer (Sodium chloride, Dipotassium hydrogenphosphate, Potassium dihydrogenphosphate, Potassium chloride and water for injection). Not crosslinked Hyaluronic Acid (40mg per tube) is obtained from fermentation~3g of inert cell-selector gel~0.6mL of anticoagulant (sodium citrate 4%)"
45493628|NCT03111784|Other|Fish consumption and lipid profiles|
46054487|NCT00152334|Drug|Botox|All patients meeting the inclusion criteria will undergo manipulation and casting until hindfoot stall is encountered. Hindfoot stall is defined as forefoot abduction to 60 degrees but persistence of hindfoot equinus. At hindfoot stall, subjects received Botox injections at 10 IU/kg into the gastrosoleus muscle complex. Following injections, subjects were recasted.
46054488|NCT02849028|Behavioral|sleep disorder|The study is to investigate whether exist the relationship between sleep disorder and circadian rhythm of patients with TBI or not.
45847198|NCT05448846|Behavioral|Home-based multicomponent exercise program (EXE)|"Home-based multicomponent exercise program:~A) Strength and balance (20 to 40 minutes, 2 days/week):~Chair sit to stand exercise | 1 to 3 sets completing repetitions until rating 5 to 8 in the Rated of Perceived Exertion, 0-10 scale (RPE).~Seated curl to press exercise | 1 to 3 sets completing repetitions until rating 5 to 8 RPE.~Monopodal balance | 1 to 3 sets with progressive time targets up to 60-second for each leg.~B) Gait (at least 30 minutes at an intensity that allows for comfortable conversation, 2 days/week on separate days from strength and balance exercise)~C) Inspiratory Muscle Training: 30 inspirations at 40% of maximal inspiratory pressure through a Power Breathe device, 2 times per day)"
45377960|NCT05889832|Diagnostic Test|measurement of physiological parameters wih Shen.AI Vitals software on various camera-equipped devices (smartphones, tablets, laptops)|"Resting heart rate (HR), heart rate variability (HRV) and breathing rate (BR) will be measured (estimated) with the use of remote photoplethysmography (1-minute face video analysis with Shen.AI Vitals software).~Reference measurements will be taken simultaneously (chest ECG for the calculation of HR and HRV; impedance pneumography for BR)."
45377961|NCT05889806|Other|Observational Study Only. NO Intervention.|Observational Study Only. NO Intervention.
45377962|NCT05889767|Other|Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)|"All participants will complete two exercise sessions:~VO2 max test on a cycle ergometer~Moderate exercise session (45 minutes at 65% measured VO2 max)"
45377963|NCT05889728|Drug|[68Ga]GA-NeoB|Is a positron emission tomography (PET) imaging agent, intended as a selection tool for [177Lu]Lu-NeoB treatment in patients with tumors overexpressing gastrin releasing peptide receptor (GRPR).
45377964|NCT05889715|Other|Green Wellness Program: Plants-2-Plate|A 6-month, intensive interprofessional program focused on a WFPB predominant eating pattern
45377965|NCT05889702|Behavioral|KATR Linkage Strategy|"The Kentucky ATR (KATR) strategy is a 25-county program that links county residents at or below the 200% national poverty level who have an illicit SUD and are in treatment or early recovery to evidence-based RSSs such as recovery housing, and to other RSSs.~The KATR linkage approach uses vouchers as a linkage strategy for individuals in SUD treatment who have no other funding options to acquire critical RSSs. As such, KATR's linkage through vouchers is a last resort approach for linking to RSSs."
45377966|NCT05889689|Behavioral|Relationship Smarts Plus & Mind Matters|18.5 hours long intervention that combines the Relationship Smarts Plus teen pregnancy prevention curriculum with lessons from the Mind Matters trauma-coping skills curriculum
45377967|NCT05889689|Behavioral|Relationship Smarts Plus alone|14-hour-long curriculum that addresses pregnancy prevention within the context of teaching relationship skills for young teens.
45693589|NCT04807907|Behavioral|Infant Directed Speech (IDS) Video + IDS Wall Calendar|"IDS Video: The IDS video was developed by the research team. It is a simple animation with a voiceover describing the value of IDS and encouraging the viewer to speak to her babies and to tell family members to do so as well. The video has been translated into Dagbani and English (viewers select the language). They may choose to watch it twice.~Breastfeeding women are told by the surveyor following the video, For instance, you could talk to your baby in full sentences when your baby is breastfeeding.~Wall Calendar: The calendar contains images from the video of parents practicing IDS, and key facts about IDS in bullet points. The 12-month calendar contains an empty star next to each week that the respondent can fill in if they perform IDS at least once a day in that week. The calendar also provides a link to a Facebook page where the respondents can re-watch the video or show it to others (https://www.facebook.com/ghanababytalk/videos)."
45377968|NCT05889689|Behavioral|Preparing Adolescents for Young Adulthood (PAYA).|A financial literacy curriculum
45493629|NCT02330614|Other|Bleaching by peroxide carbamide 10%|bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications
45493630|NCT02330614|Other|Nothing - control group|Only NEO-FFI test , data used as control
45493631|NCT02330692|Other|No intervention|
45493632|NCT03653858|Device|Vercise GEVIA deep brain stimulation (DBS) system|DBS to the superolateral branch of the Medial Forebrain Bundle (slMFB)
45493633|NCT05076136|Other|Regional treatment|In reginal treatment patients were given physiotherapy exercises and manual therapies on hip joint as well as on surrounding areas of hip joint such as lumber area and sacroiliac joint.
45847199|NCT05447988|Device|Breast Tissue Expander|tissue expander based breast reconstruction
45377969|NCT05889676|Diagnostic Test|VEMP by bone conduction|New bone conducted VEMP elicited by transducer B250
45377970|NCT05889624|Behavioral|CBT|"During an 8-week active treatment, participants will receive 6 telehealth CBT sessions, followed by a maintenance phase (16 weeks) when participants will receive 3 booster CBT sessions. The sessions will be conducted by teletherapists from the Clinical Coordinating Center at Cincinnati Children's using a standardized treatment manual. A parent/legal guardian will be included in 2 sessions teaching ways to be active coaches, encouraging use of effective coping skills and refraining from reinforcement of maladaptive coping. Each session will be about 45 minutes."
45493634|NCT05076136|Other|Standard physiotherapy treatment|In this treatment patients were given just hip joint mobilizations and quadriceps and hamstrings stretching.
45493635|NCT03654482|Device|SuperSeton|The SuperSeton will be placed at the outpatient clinic in patients that already have a seton in situ. This seton will then be exchanged by the SuperSeton. In case patients do not have a seton in situ, the SuperSeton can be placed at the operating theatre in day care setting instead of a regular seton.
45493636|NCT02330536|Device|Insufflation of carbon dioxide (CO2)|After patients were positioned, CO2 was insufflated into right pleural cavity at eight or twenty L/min. during video-assisted thoracoscopic surgery, thoracic pressure, hemodynamic and respiratory parameters were recorded.
45377971|NCT05889624|Drug|Amitriptyline|During an 8-week active treatment, participants will begin taking a daily pill (amitriptyline) prescribed and managed clinically by the site headache provider. Amitriptyline will be taken once a day before bedtime. The weight based dosage will gradually be increased based on tolerability and a standardized titration protocol during the 8 week active treatment. The participant will remain on a maximum tolerated dose for the final 16 weeks (maintenance).
45493637|NCT03653780|Device|Ekso GT|Walking in the Ekso GT with maximum bilateral assistance for 20 minutes
45493638|NCT05076058|Dietary Supplement|Tablet of silybum marianum, Pueraria lobate and salvia miltiorrhiza|"Brand names: BY-HEALTH；~Main contents (per 100g): silibinin 2g, salvianolic acid B 0.72g，Puerarin 0.68g"
45377972|NCT05889598|Other|Ballistic Resistance Lower Body Strength Training|The exercise programme involves two supervised sessions per week at University. Each session will involve 30-40 minutes of exercise, comprising warm-up , two main exercises: a hack squat and calf raise using a hack squat machine, and core exercises. After a warm-up period involving 5 minutes cycling and one set of 5 conventional repetitions at 40%1RM, the ballistic training group will complete eccentric phase hack squat exercise in approximately 3 seconds and the concentric phase as fast as possible with throwing type contractions. If participants can, participants will be allowed to take off in the concentric phase. To maintain high velocity in this group, lower loads will be used compared to the conventional group. The load will be decided according to regular maximal muscular strength test (1RM) to use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.
45493639|NCT05076058|Other|Placebo tablet|"Brand names: BY-HEALTH；~Main contents : starch"
45493640|NCT03143998|Drug|MK-5172A|A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
45693590|NCT04739657|Device|Insight Lifetech IVUS System|The Insight Lifetech IVUS System is intended for examination of coronary intravascular pathology only, including TrueVision IVUS diagnostic catheter and VivoHeart IVUS diagnostic device. IVUS imaging is used in patients who will undergo percutaneous coronary intervention.
45693591|NCT04739657|Device|Boston Scientific IVUS System|The Boston Scientific IVUS System is intended for the examination of coronary intravascular pathology only, including Opticross IVUS diagnostic catheter and iLAB IVUS diagnostic device. IVUS imaging is used in patients who will undergo percutaneous coronary intervention.
45693592|NCT01964105|Device|3D Imaging|
45693593|NCT01974323|Drug|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
45693594|NCT01974323|Drug|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
45693595|NCT01963403|Drug|EE 30mcg/LNG 150mcg|1 pill per day; daily during study participation (up to 84 days)
45693596|NCT01963403|Drug|Placebo|1 pill per day; daily during study participation (up to 84 days)
45493641|NCT05075902|Behavioral|Aerobic training|The program consists of aerobic exercise performed three times a week on non-consecutive days for 12 weeks at an intensity of 65% to 75% of the reserve heart rate. During the first 4 weeks of training, the exercise duration was 40 minutes (5' warm up + 30 minutes in the intensity zone + 5' cool down). From the fifth week onwards, there was only an increase in volume to 50 minutes in duration (5'warm-up + 40 minutes in the intensity zone + 5'warm-up). The aerobic fitness assessment was performed on a maximal effort ergospirometric treadmill under the supervision of a qualified physician, using the Bruce protocol (adapted) to assess cardiopulmonary capacity (to assess possible cardiovascular capacity that prevents the proposed training) and for individualized training prescription.
45377973|NCT05889598|Other|Conventional Resistance Lower Body Strength Training|The exercise programme involves two supervised sessions per week at Loughborough University. Each session will involve 30-40 minutes of exercise, comprising warm-up , two main exercises: a hack squat and calf raise using a hack squat machine, and core exercises. After a warm-up period involving 5 minutes cycling and one set of 5 conventional repetitions at 40% of 1RM, the conventional training group will complete eccentric and concentric phases of hack squatting exercises for approximately 3 seconds each, with appropriate breathing techniques. The load will be decided according to regular maximal muscular strength test (1RM) to use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.
45493642|NCT05075668|Device|CPAP face mask|Two types of CPAP therapy for OSA support are compared; CPAP face mask vs HFNC at different flow rates
45493643|NCT05075668|Device|High flow nasal cannula (HFNC)|Two types of CPAP therapy for OSA support are compared; CPAP face mask vs HFNC at different flow rates
45493644|NCT02334046|Drug|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in elderly patients (65-80 years) .
45493645|NCT02334046|Drug|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in adult patients (20-60 years) .
45493646|NCT02334046|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane with 1.5-2.0 vol% in air/50%oxygen mixture, and sevoflurane was adjusted to about 1.0 vol% 10 min before end of surgery.
45493647|NCT03486899|Drug|BMS-986036|Specified dose on specified days.
45493648|NCT03486899|Other|Placebo|Specified dose on specified days.
45493649|NCT02918552|Drug|sodium nitrite|Subjects to receive active study drug three times daily during treatment period and then post treatment testing period.
45493650|NCT02918552|Drug|Control|Subjects randomized to placebo to receive three times daily during treatment period and then post treatment testing period.
45493651|NCT02330458|Procedure|Small bowel ultrasound|Small Bowel Ultrasound will be performed by a single radiologist using an Acuson S2000 machine with 6 MHz convex and 9 MHz linear array transducers (Siemens, Germany). Participants will be asked to not eat for at least 8 hours prior to the ultrasound, and to drink 500ml of a fluid of their choice just prior to the SBUS, for bowel distension and better visualization. Bowel wall thickness (BWT), the length of any segment of thickened bowel wall >3mm, hyperemia using doppler, and the presence of free fluid, stricture, intestinal dilation, or enlarged lymph nodes will be documented
45493652|NCT05068882|Dietary Supplement|Immunonutrition|Oral immunonutrition containing arginine, omega-PUFAs and antioxidants
45493653|NCT05068882|Dietary Supplement|High-protein nutrition|Oral nutrition with high-protein content
45493654|NCT05068882|Dietary Supplement|Standard nutrition|Oral nutrition with standard ingredients
45493655|NCT02330380|Drug|Methotrexate|"Subjects will receive Methotrexate as detailed in the Group description."
45493656|NCT02330380|Drug|Ustekinumab|"Subjects will receive Ustekinumab as detailed in the Group description."
45493657|NCT02330380|Drug|Etanercept|"Subjects will receive Etanercept as detailed in the Group description."
45493658|NCT02330380|Drug|Adalimumab|"Subjects will receive Adalimumab as detailed in the Group description."
45493659|NCT02330380|Drug|Acitretin|"Subjects will receive Acitretin as detailed in the Group description."
45493660|NCT02330380|Other|UVB Excimer Laser|"Subjects will receive UVB Excimer Laser therapy as detailed in the Group description."
45493661|NCT02330380|Other|Narrowband UVB|"Subjects will receive Narrowband UVB as detailed in the Group description."
45493662|NCT04278404|Drug|The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:|The prescribing of drugs to children is not part of this protocol. Participants will receive DOIs as prescribed by their treating provider.
45493663|NCT02038348|Device|PET with 18F-FDOPA|
45493664|NCT03719963|Device|Cochlear implant|Cochlear implant for hearing process by surgical intervention
45493665|NCT02333812|Other|Stroboscopic nasopharyngeal laryngoscopy|
45493666|NCT02333812|Other|Stroboscopic nasopharyngeal laryngoscopy|
45493667|NCT02333812|Other|Stroboscopic nasopharyngeal laryngoscopy|
45493668|NCT02333890|Drug|Chloroquine|chloroquine 500 mg daily as an oral capsule during the wait time to surgery.
45377974|NCT05889559|Device|Tissue Ultrafiltration Catheters|patients randomized to the experimental arm will have three TUF catheters placed in the anterior muscle compartment of the injured limb. The TUF catheters will be connected to a closed suction drain and will remove interstitial fluid from the muscle.
46054489|NCT04200261|Drug|Banapenem|2000 mg group is performed firstly. After completion of observation and confirming that the drug can be safely tolerated, study on 3000 mg group is then performed
45377976|NCT05889494|Other|Autologous Whole Blood Management|Intraoperative high volume autologous whole blood withdrawal with re-transfusion following weaning from CPB.
45377977|NCT05889494|Other|Standard Care involving allogenic and/or derivative transfusion.|Therapeutic treatment of CPB-induced coagulopathy using donated allogenic blood products including plasma, platelets, and cryoprecipitate and/or derivative administration using prothrombin complex and fibrinogen concentrates.
45377978|NCT05889468|Drug|Aspirin 81Mg Ec Tab|Participant may be provided with a 6-week supply of 81 mg of aspirin prior to discharge from the delivery admission.
45493669|NCT02333890|Drug|Placebo|
45377979|NCT05889468|Drug|Placebo|Participant may be provided with a 6-week supply of placebo to discharge from the delivery admission.
45377980|NCT05889455|Drug|Sildenafil|Oral administration of 100mg
45693597|NCT04416503|Other|Foot reflexology|Foot reflexology was performed for 12 week in the study group,whereas the control group continued their routine treatment and follow-up.
45493670|NCT03143686|Device|ACURATE TA™ Transapical Aortic Bioprosthesis|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
45493671|NCT03485495|Drug|Divaza|Oral administration.
45377981|NCT05889455|Other|Placebo|Placebo
45377982|NCT05889442|Drug|Levcromakalim|Continuous intravenous infusion of 20 mL levcromakalim (0.05 mg/min (50 μg/ mL) over 20 minutes
45377983|NCT05889442|Other|Placebo|Continuous intravenous infusion of 20 mL isotonic saline over 20 minutes
45493672|NCT03485495|Drug|Placebo|Oral administration.
45493673|NCT03652532|Behavioral|Alternate Day Fasting|"During the 8-week intervention, participants consumed 25% of their daily recommended energy intake (approximately 500 kcal) on each fast day (24 h), and consumed food ad libitum on each feed day (24 h). The fast day and feed day were repeated every other day, and the fast day occurred 3 days per week."
45493674|NCT03652532|Behavioral|Exercise|During the 8-week intervention, participants visited the research center gym at least three times per week and received exercise logs. Each exercise session began with 5 minutes of warm-up and ended with 5 minutes of cool-down. Resistance training was performed using weight training machines, barbells, and dumbbells for 40 minutes. Aerobic exercise was performed on motorized treadmills for 20 minutes.
45493675|NCT02330302|Drug|Ropivacaine|Ultrasound-guided femoral nerve block with Ropivacaine 0.5% 30mls
45693598|NCT01973387|Drug|Rituximab|Up to 6 cycles (total of 8 doses administered by intravenous infusion): 375 mg/m2 on Day 1 of Cycle 1, 500 mg/m2 on Day 15 of Cycle 1 (Weeks 1-4); 500 mg/m2 on Day 1 and Day 15 of Cycle 2 (Weeks 5-8); and 500 mg/m2 on Day 1 of Cycles 3-6 (Weeks 9-24).
45693599|NCT01973387|Drug|Ibrutinib|420 mg capsules administered by mouth daily until disease progression or unacceptable toxicity, whichever occurs first.
45693600|NCT04657445|Diagnostic Test|visual analogue scale|A visual analog scale (VAS) is a measurement device used to quantify a subjective experience.
45693601|NCT01973231|Drug|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial metformin (equal to or above 1000 mg/day and up to 3000 mg/day).
45493676|NCT02330302|Drug|Ropivacaine|Ultrasound-guided suprainguinal approach to fascia iliaca block with Ropivacaine 0.5% 30mls
45493677|NCT03653702|Drug|Lumason|Lumason will be used as the contrast agent. Standard Lumason dose will be used: 0.03mL/kg up to a maximum dose of 2.4 milliliter (mL) per injection
46054490|NCT04200261|Drug|sodium chloride|sodium chloride
46054491|NCT02847000|Drug|Tetrahydrouridine|"Starting dose is by weight:~THU is supplied as 250 mg/capsule Weight 40-60kg = 2 capsules of Tetrahydrouridine. Weight 61-80kg = 3 capsules of THU. Weight 81-100kg or higher = 4 capsules of THU.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
45493678|NCT02330224|Other|Hypertension Management Intervention|"The multifaceted intervention consists of three main components:~Structured treatment algorithm with fixed dose antihypertensives for high cardiovascular disease risk patients~Motivational conversation by nurses and nurse practitioners for high risk patients at baseline~Telephone based follow-up for all patients by nurses"
45493679|NCT03653624|Other|No intervention|No intervention is involved int his study. Fully anonymised blood pressure data will be collected from the vital signs monitors in the operating room.
45493680|NCT03719807|Other|Rehabilitation protocol|A physiotherapy rehabilitation protocol - comprising of pragmatic exercises.
45493681|NCT03719807|Other|Usual Care|No routine outpatient physiotherapy. Normal inpatient physiotherapy to match intervention group.
45493682|NCT03143530|Procedure|Pectoralis block|Pectoralis block involving injection near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior muscles (pecs II).
45493683|NCT03143530|Drug|Normal saline injection|Pectoralis block involving injection of normal saline 30ml near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
45493684|NCT03143530|Drug|Ropivacaine Injection|Pectoralis block involving injection of ropivacaine injection 30ml of 0,25% (75 mg) near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
45493685|NCT01065818|Drug|Fluoro-L-Thymidine|4D-PET/CT imaging with an injection of Fluoro-L-Thymidine at pre-Neoadjuvant Therapy and post-3 weeks Neoadjuvant Therapy prior to surgery.
45493686|NCT02333968|Behavioral|Self-management support|The 12-week intervention consists of an iPad application for patients that is connected to a web application for nurses. Every morning and evening patients register pain and related symptoms by use of a pain diary. Patients are also requested to register medication intake. Graphical feedback is provided based on registered pain scores and medication intakes. Patients receive education on causes and treatment of pain, symptoms that require action, and methods to better control pain. Patients communicate with nurses via text message functionality within the application. Specialized nurses remotely monitor and analyze the patients' situation once every workday. Nurses have the opportunity to collaborate with the treating physician, pain specialist or multidisciplinary team.
45493687|NCT03483623|Other|NATO WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
45493688|NCT03483623|Other|NATO FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
45693602|NCT01973231|Drug|lixisenatide|Starting dose of 10 microg to be administered s.c. once daily, within the hour prior to the first meal of the day or the evening meal in addition to subject's stable pre-trial metformin (equal to or above 1000mg/day and up to 3000mg/day). Dose escalation to 20 microg s.c. once daily from day 15 after randomization.
45693603|NCT01961687|Device|Resorbable Mesh|Phasix Mesh
45693604|NCT04656275|Drug|BI 1323495|BI 1323495
45693605|NCT04656275|Drug|Placebo|Placebo
45847200|NCT05447832|Device|Lung function monitoring equipment at home - 2 weeks|The parent/carer setup the lung function monitoring equipment (Ventica®), and placed the WheezeScan® device on the child's chest at home before the child goes to sleep. This is performed once daily for 2 weeks.
45377984|NCT05889429|Diagnostic Test|MRI scans|The MRI protocol will include standard anatomical, functional, and diffusion imaging, and spectroscopy sequences.
45377985|NCT05889429|Behavioral|clinical assessments|Several clinical assessments will be performed to evaluate the recovery of motor functions. Initially and for screening, the cognitive ability will be assessed using the Montreal Cognitive Assessment (MoCA), and visuospatial neglect will be assessed using the Star Cancellation Test (SCT). eligible participants that meet all inclusion criteria will undergo a series of clinical function tests during each test session (t1-t4) to assess clinical outcomes.
45493689|NCT03483623|Other|RAVEN WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
45493690|NCT03483623|Other|RAVEN FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
45377986|NCT05889416|Other|Audit and feedback through a quality registry|Centres answer CR process and structure variables through the SWEDEHEART registry every six months for three years. Feedback will be accessible online and through annual reports, enabling comparisons with own prior and other centres´ results.
45493691|NCT02329990|Dietary Supplement|phosphorus|phosphorus supplement
45493692|NCT03653468|Behavioral|Concurrent training (CT)|The core part of each session included resistance training (RT) followed by aerobic training exercises (for 50 and 30 minutes, respectively) and was preceded and followed by a 5-minute warm-up and cool-down with callisthenic movements.
45493693|NCT03143608|Device|Esophyx|Laparoscopic hiatal hernia repair followed immediately by transoral incisionless fundoplication under general anesthesia using the Esophyx device
45493694|NCT03652844|Procedure|AAM|Subcutaneous injection procedure
45493695|NCT03697408|Drug|Itacitinib|A JAK 1 selective small molecule inhibitor
45493696|NCT03697408|Drug|Everolimus|A mammalian target of rapamycin (mTOR) inhibitor
45493697|NCT03653312|Device|NMES|Neuromuscular electrical stimulation of the paretic lower limb during exercise
45493698|NCT03143764|Behavioral|Commuting with electrically assisted bicycles|25 participants were provided with electrically assisted bicycles fitted with GPS bike computers to record usage
45493699|NCT03622034|Other|posterior condylar offset measurement|the tangent to the medial tibial plateau is considered to be the proximal reference line. This is the line connecting the highest anterior and posterior points of the medial plateau. The second reference is the axis of the tibia, defined as a line through the middle of the shaft at 10 and 20 cm. The angle between these two lines is the tibial slope
45493700|NCT02333734|Other|Physical training|Performed supervised high intensity interval training 3 times a week over 8 weeks on a bicycle ergometer (with watt meter). During the training period, the trainee individually established program, each time with 10 × 60 sec. workout (interspersed with 60 sec. break) corresponding to a force which during the test cycle induces ~ 90% of the maximum heart rate. The time spent per session is expected to last ~ 25 minutes.
45493701|NCT02318277|Drug|MEDI4736|MEDI4736 administered intravenously (IV) every two weeks (q2w)
45493702|NCT02318277|Drug|INCB024360|INCB024360: Oral daily dosing
45377987|NCT05889416|Other|Implementation support|On-site support to implement guidelines on secondary prevention applying practice facilitation - a multifaceted approach carried out by CR experts who enable personnel at intervention centres to address and overcome challenges in implementing guidelines.
45493703|NCT03653234|Device|TV-based Assistive Integrated Service|"TV-AssistDem is an interactive platform which has been adapted specifically for people with MCI and mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal caregivers. The device consists of an Android software and hardware TV (a Digital TV STB with Android technology).~The core services of the platform are: 1) Calendar and reminders, 2) Health tracking and data transmission and 3) Videoconference; service-oriented applications are: 4) Cognitive stimulation (Stimulus© software); 5) Reminiscences; and 6) Patient and caregiver advice."
45847201|NCT05447832|Device|Lung function monitoring equipment at home - 4 months|The parent/carer setup the lung function monitoring equipment (Ventica®), and placed the WheezeScan® device on the child's chest at home before the child goes to sleep. This is performed once weekly for 4 months.
45493704|NCT02333656|Other|New OA model|"The general practitioners and the physiotherapists will attend an inter-active workshop and deliver osteoarthritis care in line with international recommendations for osteoarthritis treatment. The general practitioner will refer eligible patients to treatment by physiotherapists at Healthy Living Center or by physiotherapists in private practice. This treatment will include a standardized patient education program followed by structured exercise program with individual adjustments. The general practitioner will schedule a follow-up after the 12-week treatment and will receive a treatment report from the physiotherapist."
45377988|NCT05889390|Device|Oncotherm EHY-2030|Oncotherm EHY-2030 is a non-invasive electromagnetic devices with known anti-tumoral effects. It operates in a precision capacitive coupled impedance matched way, working on a radiofrequency of 13.56 MHz. mEHT exploits various biophysical differences of cancer cells. For example, energy absorption on the membrane rafts is different than those of healthy host cells, and damage-associated molecular patterns (DAMPS) will also occur leading to programmed or immunogenic tumor cell death. mEHT can enhance DNA fragmentation of tumor cells, increase the fraction of cells with low mitochondrial membrane potential, increase the concentration of intracellular Ca2+, increase the Fas, c-Jun N-terminal kinases and MAPK/ERK signaling pathways, increase the expression of pro-apoptotic Bcl-2 family proteins and can up-regulate the expression of genes associated with the molecular function of cell death (EGR1, JUN, and CDKN1A) and silencing others associated with cytoprotective functions.
45377989|NCT05889390|Drug|Paclitaxel|weekly paclitaxel for 12 weeks
45493705|NCT03143452|Drug|lidocaine gel|2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification
45377990|NCT05889390|Drug|Carboplatin|added to weekly paclitaxel if patient has triple-negative breast cancer
45377991|NCT05889390|Drug|Cyclophosphamide/Doxorubicin|according to the AC protocol
45377992|NCT05889390|Procedure|Breast cancer removal surgery|Either breast-conserving surgery or total mastectomy after the neoadjuvant chemotherapy with or without mEHT (if feasible)
45493706|NCT03143452|Drug|tetracaine eye drop|0.5% tetracaine eye drop was given 5 minutes before phacoemulsification
45493707|NCT03693742|Diagnostic Test|18F-DCFPyL PET/CT scan|"Participants will have their weight recorded and baseline vital signs (blood pressure, heart rate, and oxygen saturation level) measured prior to the tomato juice ingestion, immediately prior to 18F-DCFPyL injection and 5 to 15 minutes after injection.~The participant will receive a bolus intravenous dose of 18F-DCFPyL.~After 60 min, the vital signs will be recorded and again two hours after 18F-DCFPyL. Immediately before scanning, the participants will be taken to a designated washroom and asked to void.~The PET/CT image acquisition time will be approximately 30 minutes."
45493708|NCT03693742|Other|Placebo drink|Participants will consume 300mL of tomato juice 30 minutes prior to 18F-DCFPyL injection.
45377993|NCT05889377|Procedure|Socket preservation|Socket preservation will be done after tooth extraction. For each group we will use a bone substitute.
45493709|NCT03693742|Other|MSG drink|Participants will consume 300mL of tomato juice with MSG 30 minutes prior to 18F-DCFPyL injection.
45493710|NCT01063868|Drug|Tapentadol extended release (ER)|100, 150, 200, 250 mg twice daily for 52 weeks
45493711|NCT01063868|Drug|Oxycodone controlled release (CR)|20, 30, 40, 50 mg twice daily for 52 weeks
45493712|NCT04054934|Behavioral|Reversed Circadian Rhythm|Revered day/ night sleep cycle
45493713|NCT04054934|Behavioral|Normal Circadian Rhythm|Normal day/ night sleep cycle
45377994|NCT05889364|Diagnostic Test|"AI-based x-ray analysis and triage (normal/tuberculosis suspected)"|All included x-rays will be analysed by the AI-based system. Then results will be compared with opinions of 2 experienced radiologists (they make peer-review of all included images independently of each other).
45493714|NCT02333266|Other|Candidemia|
45493715|NCT02692443|Device|Magnetic Resonance Imaging|Brain MRI without Contrast
45493716|NCT02692443|Behavioral|Neurodevelopmental Testing|Validated battery of neurodevelopmental and psychological tests.
45693606|NCT04174391|Behavioral|Mediterranean diet supplemented with extra-virgin olive oil|Dietary advice on how to follow a Mediterranean diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. A total of 0.5l/week of EVOO for free will be received by participants of this group. In addition, advice on physical activity will be provided.
45493717|NCT02974088|Device|Neem-based lotion plus louse comb|Neem-based conditioning lotion was applied to washed and towel dried hair followed by systematic combing using a head louse detection and removal comb
45493718|NCT02974088|Device|Neem-based lotion plus grooming comb|Neem-based conditioning lotion was applied to washed and towel dried hair followed by combing through using a regular grooming comb
45493719|NCT02329912|Device|SmartPill|Application of the SmartPill at the end of surgery
45493720|NCT01372683|Other|Dietary Intervention|Comparison of oat based breakfast cereals
45493721|NCT02333500|Other|olfactory workshop|olfactory workshop
45493722|NCT02333500|Other|other workshop|other workshop: discussion group, dance and body Expression
45493723|NCT02333500|Other|No intervention|control group
45493724|NCT05193435|Other|Pelvic floor exercises|Pelvic floor exercises for types I and II muscle fibers will be performed
45493725|NCT05193435|Other|Stabilization exercises|Lumbar spinal stabilization exercises will be performed
45377995|NCT05889351|Drug|Vehicle gel, 4 + 4 applications or 4 + 2 applications|Control arm/placebo
45377996|NCT05889351|Drug|LTX-109 3% gel, 4 + 4 applications|Cohort 1 active treatment
45493726|NCT05060536|Procedure|Removal of infrapatellar fat pad|"There is no agreed protocol for retaining or excising the infrapatellar fat pad with many surgeons routinely completely removing the fat pad to improve view of the proximal tibia while others opt to retain or minimally excise the tissue.~We are aware of no risks involved in performing this procedure and current practice of many orthopaedic surgeons is either to routinely remove or routinely retain the infrapatellar fat pad when performing total knee arthroplasty.~The potential benefits are that we will understand better whether removing or retaining this tissue does have a role in influencing outcomes after total knee replacement surgery. The results will be disseminated to the wider orthopaedic community to inform practice with the aim or improving outcomes from total knee arthroplasty."
45493727|NCT05060536|Procedure|No removal of infrapatellar fat pad|Retaining the infrapatellar fat pad during total knee replacement- no surgical removal.
45493728|NCT04210869|Dietary Supplement|Mixed Nuts|Study volunteers will receive daily 60 g of mixed nuts (15 g walnut, 15 g cashew, 15 g hazelnut, 15 g pistachio) for 16 weeks.
45493729|NCT04993924|Drug|Cetrorelix Acetate, Ganerelix Acetate|3-6 days of 0.25 mg starting on day 2-3 of the menstrual cycle
45493730|NCT02546895|Other|chart review|"The patient charts will be reviewed to determine pretreatment characteristics, treatment-related adverse events, time to progression and overall survival.~Behavioral: Questionnaires Completion of 3 questionnaires 1 week before treatment(radiotherapy or chemotherapy) begins or been hospitalized for surgery the same day, 1 week after the end of treatment(expected average of 8 weeks), and again 3 months after treatment. It may take about 30 minutes to complete the questionnaires each time."
45493731|NCT02330068|Drug|citalopram|Cases
45493732|NCT04904458|Other|"Experimental group (enfacement illusion)"|Virtual reality enfacement illusion exposure
45493733|NCT04904458|Other|Control Group (Pleasant virtual environment exposure)|Pleasant virtual environment exposure
45493734|NCT05193357|Device|home-based intermittent pneumatic compression (IPC) device|During the intervention, two programmed modes were used. The first mode, which mimics the MLD massage technique, begins with the inflation of the proximal chamber. After reaching the target pressure, the next chamber consecutively inflates while the initially inflated proximal chamber deflates. The inflation time of each chamber is 3 seconds with holding time of 1 second. The deflation and resting time of each chamber is 7 seconds (pressure setting: 40-60 mmHg). After 30 minutes of the first mode, the second mode, which is the conventional mode of sequential inflation from distal to proximal chambers while sustaining the pressure of the previously inflated chambers, was applied for 30 minutes (pressure setting: 80-100 mmHg, inflation time of each chamber: 6 seconds, holding time: 1 second, deflation time of each chamber: 7 seconds). Participants were instructed to use the IPC device with that 1-hour cycle twice a day for four weeks.
45493735|NCT02494869|Behavioral|Nonlinear Aerobic Training|
45493736|NCT02494869|Other|Height, Weight, BMI measure|
45493737|NCT02494869|Other|Blood draw|
45493738|NCT02494869|Other|Cardiopulmonary exercise test|
45693607|NCT04174391|Behavioral|Low-fat diet|Dietary advice on how to follow a low-fat diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. Allotments of commercial foods - equivalent to the extra-virgin olive oil allotment - will be received by participants of this group for free. In addition, advice on physical activity will be provided.
45847202|NCT05447832|Diagnostic Test|Inflammation and remodelling from clinical indicted bronchoscopy|For patients who are undergoing clinically indicated bronchoscopy, consent will be obtained to use any surplus clinical samples for this study. The samples to be collected are broncho-alveolar lavage and endobronchial biopsies. Both of these are taken from the airways during clinical bronchoscopy.
45377997|NCT05889351|Drug|LTX-109 3% gel, 4 + 2 applications|Cohort 2 active treatment
45377998|NCT05889338|Drug|adalimumab and methotrexate|Adult patients (> 18 years) with severe psoriasis who will start treatment with either adalimumab or methotrexate
45693608|NCT02151994|Drug|BIA 5-1058|oral administration
45693609|NCT02151994|Drug|Placebo|oral administration
45693610|NCT04640974|Device|Cingal|CINGAL® is a chemically cross-linked sodium hyaluronate combined with Triamcinolone Hexacetonide supplied as a 4-mL unit dose in a 5-mL glass syringe.
45377999|NCT05889325|Procedure|DEB-TACE plus HAIC|the patients received HepaSphere DEB-TACE plus HAIC
45378000|NCT05889312|Diagnostic Test|18F-FSPG PET/CT in NSCLC|Stage 3 NSCLC with radical curative intent at baseline (pre-treatment) and at 4-8 weeks into treatment.
45378001|NCT05889312|Diagnostic Test|18F-FSPG PET/CT in HNSCC|Stage 3 and 4 HNSCC with radical curative intent at baseline and at 2-4 weeks into treatment.
45378002|NCT05889299|Drug|OMS906 study drug|OMS906 study drug dose repeat-dose 5mg/kg SC administration at 4-week intervals
45493739|NCT03810196|Device|CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback|Peripheral stem cell (PSC) product will be processed using the CliniMACS device for TCRαβ and T cell depletion. Approximately 10% of the PSCs will undergo CD45RA depletion and cryopreservation. Patients will receive CD45RA depleted infusion after the TCRab PSCT.
45493740|NCT02385045|Device|i-scan|i-scan function is located on the head of the Pentax endoscopes
45493741|NCT02385045|Device|narrow band imaging|narrow band imaging function is located on the head of Olympus endoscopes
45493742|NCT02330146|Drug|RCT-01|
45493743|NCT02330146|Drug|Placebo|
45493744|NCT02329444|Procedure|Remote ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 200mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
45493745|NCT02329444|Procedure|Sham ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 50mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
45493746|NCT01990521|Procedure|MS3TMRI / TRUS Guided Biopsy|Patients would undergo MS3TMRI and then have a transrectal ultrasound (TRUS) biopsy performed within one month after the MRI. The initial cores would be obtained using TRUS without MRI information (TRUSBx). During the same biopsy session, the MS3TMRI information would be given to the physician performing the biopsy and additional cores specifically targeted to suspicious areas would be performed (MS3TMRI-TRUSBx).
45378003|NCT05889286|Drug|[F-18]MHF|Following intravenous injection of 10 ± 2 mCi (370 ± 74 MBq) [F-18]MHF as a bolus, dynamic PET imaging of the lower limbs will be acquired for approximately 90 minutes. The acquired images will be processed. The uptake pattern of [F-18]MHF around infected orthopedic knee implant will be determined and compared with its uptake pattern around non-infected knee implants.
45493747|NCT01990521|Device|MS3TMRI / TRUS Guided Biopsy|"Multispectral 3T MRI (MS3TMRI) is a device that uses a 3T MRI system without an endorectal receiver coil and with a surface phased array coil. 3T MRI in addition to established computer aided diagnosis (CAD) has been used to perform guided biopsies in an active surveillance population and demonstrated a positive predictive value and negative predictive value of 83% and 81%.~A recently completed a study looking at repeat prostate biopsies in men followed on an active surveillance population at Sunnybrook has shown that the PPV of MS3TMRI guided biopsy to be 85%, while the negative predictive value was 100% (Haider, Vesprini and Milot, unpublished)."
45493748|NCT02333344|Drug|Zoledronic acid 5mg|two-year Zoledronic acid 5mg infusion treatment
45493749|NCT01312857|Drug|panitumumab|"All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization to panitumumab 6 mg/kg day 15 and 29 Each cycle repeats every 36 days for a total of 6 cycles"
45493750|NCT01312857|Drug|Randomization to No Panitumumab|"All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization (to no panitumumab) Each cycle repeats every 36 days for a total of 6 cycles"
45493751|NCT02974010|Drug|NRX-101 Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
45493752|NCT02974010|Drug|Lurasidone Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
45493753|NCT02974010|Drug|Ketamine Intravenous Infusion|Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
45493754|NCT02974010|Drug|Saline Solution Intravenous Infusion|Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
45493755|NCT05193201|Drug|recombinant human thrombopoietin injection|recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days
45493756|NCT02030938|Device|SERI® Surgical Scaffold|Standard revision augmentation (with or without implant exchange) with the adjunctive use of SERI® Surgical Scaffold placed intra- or extra-capsularly.
45493757|NCT03122535|Device|FS-LASIK 70 degree side-cut angle|FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
45493758|NCT03122535|Device|FS-LASIK 110 degree side-cut angle|FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
45493759|NCT04835818|Diagnostic Test|Provide the panel report to the primary care physician|Point-of-care Multiplex PCR Respiratory Panel (BIOFIRE FilmArray) and Pneumonia Panel results (BIOFIRE FilmArray)
45847203|NCT05447754|Other|Combined RAGT and TBT|Combined RAGT and TBT: Participants will be treated with Lokomat for 40 minutes, twice a week for 5 weeks, and RAGT with a body weight support system and combined TBT for 40 minutes each session 3 times a week. During RAGT, 30-40% of each participant's body weight will be taken with the body weight support system. In patients without drop foot and knee instability in the sessions after the first session, the body weight will be reduced by 10% and progression will be achieved. The speed of the treadmill will be adjusted between 1.2-2.6 km/h and the maximum speed tolerated by the patient will be reached during the sessions. TBT exercises 3 times a week for 40 minutes (weight transfer to the paretic leg during sitting and standing, weight transfer during sitting and standing with or without an assistive device) will be personalized according to the patient. Progression of exercises will be provided by adding upper extremity and trunk activities in addition to exercises.
45847204|NCT05447754|Other|balance exercises|TBT
45847205|NCT05447364|Drug|Pregabalin 75mg|1 tab of Pregabalin Brillior 75 mg and 1 tab of Placebo
45378004|NCT05733156|Radiation|SBRT + LDRT|Stereotactic body radiotherapy (SBRT) and low-dose radiotherapy (LDRT) are administered concurrently. SBRT is administered three times, at intervals of 1-2 days, and patients are treated with LDRT along with SBRT. LDRT is planned to irradiate EQD2 6 Gy considering the scattered dose caused by SBRT.
45493760|NCT01061606|Drug|temsirolimus|Given IV
45493761|NCT02329678|Procedure|Peripical surgery|Thirty patients meeting inclusion criteria were selected and allocated randomly into two groups: collagen membrane group and control group. Clinical and radiographic measurements were recorded during follow up at regular intervals of 0, 3, 6, 9, and 12 months after surgery. The criteria for success included the absence of clinical signs and symptoms, and complete or incomplete radiographic healing.
45493762|NCT04118361|Diagnostic Test|HINTS Test|"The HINTS test is a clinical test composed of 3 oculomotor examinations:~Search for high-frequency vestibulo-ocular reflex during a passive head impulse test~Highlighting of spontaneous nystagmus: it must be sought without, then with Frenzel glasses because they allow to temporarily interrupt the ocular fixation.~Vertical divergence~This test is performed at the patient's bedside in about 3 minutes. Presence of at least one of the three items of central locator value is sufficient to diagnose a central cause of VAS, including normal early brain imaging."
45493763|NCT04118361|Diagnostic Test|STANDING Algorithm|The STANDING algorithm consists of clinical elements that can be evaluated in about 10 minutes at the patient's bedside: two oculomotor examinations (Head Impulse Test and detection of a nystagmus), detection of ataxia and the practice of release maneuvers.
45493764|NCT02333578|Procedure|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
45493765|NCT01872975|Radiation|regional nodal XRT|
45493766|NCT01872975|Radiation|chestwall XRT|
45493767|NCT01872975|Radiation|WBI|
45378005|NCT05889247|Other|Circulating tumor DNA treatment monitoring|A comparison of treatment monitoring by circulating tumor DNA and CT scans (standard) in patients with newly diagnosed advanced Non-Small Cell Lung Cancer (NSCLC)
45493768|NCT02329522|Device|Ultrasonic Cardiac Output Monitor|"An Ultrasonic Cardiac Output Monitor (USCOM; USCOM Pty Ltd, NSW, Australia) is a non-invasive Doppler ultrasonography. It is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD).~USCOM scans will be performed on patients to measure direct and derived haemodynamic variables, which will be performed in the supine position wherever possible. A transducer will be placed on the chest in either the suprasternal position to measure trans-aortic blood flow, or the left parasternal position to measure transpulmonary blood flow."
45493769|NCT02329522|Device|Spirometry|Spirometry assesses lung function through measuring the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Patients are regarded as COPD if their Forced expiratory volume in 1 second (FEV1) to Forced vital capacity (FVC) ratio are smaller than 70%. Patients were required to perform three blowing manoeuvres, and post-bronchodilator test results were obtained within 20 minutes to 4 hours after inhaling 400 mg of salbultamol.
45493770|NCT02333422|Other|NIRS Neurofeedback|The sensor will be placed on 4 specific regions defined by the International 10/20 System for Electrode Placement. F7, Fp1, Fp2 and F8. Each region will be initially trained for 4 minutes, with the eyes open, gradually increasing training time throughout the sessions to a maximum of 10 minutes. Training will amount to 24 sessions, occurring 2 times per week over a period of 3 moths. The procedure will be interrupted at any time, should the subject demonstrate the desire to stop.
45493771|NCT04729192|Other|ObsQoR-10T Questionnaire|The ObsQoR-10T questionnaire consists of 10 items assessing physical comfort and pain, physical independence, and emotional status. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
45493772|NCT04696822|Drug|Epinephrine Nasal Product, 1.6 mg|Single dose Nasal powder spray without allergen challenge
45493773|NCT04696822|Drug|Epinephrine nasal product, 1.6 mg + allergen|Single dose Nasal powder spray with allergen challenge
45493774|NCT04696822|Drug|Epinephrine Injection 0.3 mg|Intramuscular injection
45493775|NCT04696822|Drug|Epinephrine Nasal Product, 3.2 mg|Twice dose Nasal powder spray without allergen challenge
45493776|NCT04696822|Drug|Epinephrine Nasal Product, 3.2 mg + allergen|Twice dose Nasal powder spray with allergen challenge
45493777|NCT01542580|Device|Vanguard SSK 360 with PS Bearing|non-constrained tibial bearing
45493778|NCT01542580|Device|Vanguard SSK 360 with PSC bearing|constrained tibial bearing
45493779|NCT01542580|Device|Vanguard DA 360|Dual-articulation device, only cleared in EU
45493780|NCT01542580|Device|Vanguard 360 TiNbN Femur with PS bearing|non-constrained tibial bearing, titanium niobium nitride coated Vanguard 360 femur
45493781|NCT01542580|Device|Vanguard 360 TiNbN Femur with PSC bearing|constrained tibial bearing, titanium niobium nitride coated Vanguard 360 femur
45493782|NCT02329756|Drug|Tranexamic Acid (TXA)|1g Tranexamic Acid (TXA) will be given at the time of delivery. If in 30 minutes, heavy bleeding continues, a 2nd dose will be administered.
45493783|NCT02329756|Drug|Sodium Chloride 0.9%|"Dose 1: 1 gram - to be administered by intravenous injection at an approximate rate of 1 mL/minute to all randomized women approximately 10 minutes prior to induction of anesthesia~Dose 2: 1 gram - If 30 minutes after beginning the cesarean section there is significant bleeding as defined by the need for the transfusion of 4 or more units of blood products, or if there is a rebleed within the 24 hours after the first dose, a second dose may be given. To be administered by intravenous injection at an approximate rate of 1 mL/minute.~The trial treatment injections should not be mixed with blood for transfusion, or infusion solutions containing penicillin or mannitol."
45493784|NCT04567342|Other|1 automated message|Parents of eligible patients will receive 1 HIPAA compliant automated call or text reminder (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.
45493785|NCT04567342|Other|2 automated messages|Parents of eligible patients will receive 2 HIPAA compliant automated call or text reminders (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.
45493786|NCT04567342|Other|No personal contact attempt|No personal contact attempts will be made.
45378006|NCT05889234|Device|Modified Electroconvulsive Therapy|MECT is performed using the Thymatron System IV (Somatics LLC, LakeBluff, IL, USA) electroconvulsive therapy (ECT) machine. Prior to ECT, all patients undergo laboratory tests such as routine blood, liver, kidney and thyroid function and an ECG and remain fasted for 12 hours. Initial treatment power is considered by age: percentage of power = age x 0.7. Stimulation power is adjusted according to seizure duration. If the seizure duration is less than 25 seconds, the energy is increased by 5% in the subsequent treatments. Anaesthesia and muscle relaxation were administered with propofol (1.5-2 mg/kg) and succinylcholine (0.5-1 mg/kg), respectively, and subjects were awakened after ECT treatment and adverse effects, such as subjective memory impairment, headache or nausea/vomiting, were recorded. Frequency of ECT treatment: 3-4 times per week for a total of 6-8 sessions
45493787|NCT04567342|Other|1 personal contact attempt|Parents of eligible patients will receive a text from a medical assistant informing them that their child is due for a check up. This will be followed by personal call from the medical assistant to assist the parent with scheduling an appointment.
45493788|NCT03985072|Drug|Andes-1537 for Injection|Andes-1537 administered subcutaneously five days per week.
45493789|NCT02329288|Drug|Triamcinolone Acetonide|
45493790|NCT02329288|Drug|placebo|
45493791|NCT05366907|Other|No intervention is done|It is a descriptive cross-sectional study so no groups like case/controls are present. All the cases are included in the study.
45493792|NCT01861353|Other|Cranberry-lingonberry juice|
45493793|NCT01861353|Other|Placebo juice|Juice iwth similar sugar concentration as cranberry-lingonberry juice but without berry extracts
45493794|NCT02329054|Drug|Favipiravir|"Group A1: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group A2: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group C: daily dosages will be adapted to their body weight."
45493795|NCT03122457|Drug|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination|At Day 15, patients will be re-assessed and dispensed the investigational product and instructed on its daily use. Patients will continue to return every 14 days to have their skin assessed until their final visit on day 99, one week after their 3rd menses on treatment (4th menses on study).
45493796|NCT02328976|Other|functional Magnetic Resonance Imaging (fMRI)|both chronic and episodic patients with migraine have a specific functional Magnetic Resonance Imaging (fMRI)
45493797|NCT02333032|Other|Inclined treadmill training|
45493798|NCT04407988|Drug|Pyrotinib Maleate plus Letrozole|pyrotinib(400 mg once daily) + Letrozole (2.5 mg once daily)
45493799|NCT05192967|Behavioral|Pandemic preparedness via video|A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a video demonstration.
45493800|NCT05192967|Behavioral|Pandemic preparedness via classical method|A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a classical method.
45493801|NCT02329132|Drug|Ranibizumab|Each eye will be treated with three initial monthly injections of intravitreal ranibizumab 0.5 mg (Lucentis), followed by retreatment as needed, guided by monthly clinical examinations including biomicroscopy, VA measurement, and optical coherence tomography (OCT) examination.
45493802|NCT03634371|Drug|Drug Levothyroxine 150 mcg|Administration of a 600 mcg levothyroxine dose
45493803|NCT03634371|Drug|Drug Eutirox 150 mcg|Administration of a 600 mcg levothyroxine dose
45693611|NCT00812110|Drug|Influenzae vaccine|0.5 mL Deltoid Intramuscular Injection X 1
45847206|NCT05447364|Drug|Pregabalin 150mg|2 tabs of Pregabalin Brillior 75 mg
45493804|NCT04342078|Dietary Supplement|Vitamin D|To investigate the effect of one year vitamin D supplementation in preterm born adults (4000 IU = 100 micrograms a day if serum concentration is < 30 nmol/l, 2000 IU = 50 micrograms a day if 30-50 nmol/l and 1000 IU = 25 micrograms a day if > 50-80 nmol/l, and no additional supplement if > 80 nmol/l) on health outcomes (bones, teeth, muscles, heart, lungs) . The target level of vitamin D concentration by every 4 months interval is 80 - 120 nmol/l .(Preterm Adult group)
45493805|NCT05192811|Dietary Supplement|Lactobacillus paracasei K56|probiotic K56 capsule, 1capsule/day (10^9cfu) ,for 60days
45493806|NCT05192811|Dietary Supplement|placebo|placebo capsule(maltodextrin) , 1capsule/day ,for 60days
45693612|NCT05356468|Other|Structured pain neuroscience education|"Structured pain neuroscience~Neurophysiology of pain~The PNE occurred with the use of pictures, examples, metaphors and drawings as needed~Metaphor Alarm system: Your nerves working like an alarm system to protect you.~BOOKLET Consist of education about pain neurophysiology.(31)~Steps of booklet :~Extract content~English to Urdu translation~Content Validity~Expert Panel review by Physiotherapists~Content validity Analysis review(Focus Group)~Pilot study 4 to 5 patients~Content improved (PNE) and Finalized~After Analysis RCT"
45847207|NCT05447052|Device|Bio-MIMICS 3D Stent|Bio-MIMICS Stent implantation
45693613|NCT05356468|Other|Conventional Treatment|"ELECTROTHERAPY MODALTIES-15 min~IFC (interferential current)IFC will be administered using following parameters: 80-150 watts, 4000 Hz, sweep on, 16.0-17.0 CV(26)~Hot pack(27)~Therapeutic exercises~Strengthening (Back extensors, quadriceps, hamstring and VMO, gluteus maximums, gluteus medius, transverse abdominis.~Stretching hamstring and, calf stretching. Soft tissue mobilization(5) McKenzie based exercises(28) BALANCE EXERCISES~Single Leg Stance (static balance) Patient is instructed to stand on one leg,close his/her eyes and maintain this position as long as they could.~Tandem gait (dynamic balance) patient is instructed to walk a total of 5 laps on a 2-meter-long line with the heel of the front foot touching the fingertip of the back foot.(29)~POSTURAL TRAINING~good posture when sitting standing and while driving~Avoid weight lifting~Avoid too much bed rest~Sit in firm places. (30)"
45693614|NCT04382950|Combination Product|Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid|In this study, the experimental group will receive 0.4 mg/kg rbACE2 IV plus Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
45378007|NCT05889234|Drug|Conventional pharmacotherapy|Conventional pharmacotherapy: SSRIs including fluoxetine, paroxetine, sertraline, cetinopram, fluvoxamine, vortioxetine, escitalopram; SNRIs including venlafaxine, duloxetine; NaSSA including mirtazapine; other antidepressants including trazodone, bupropion, agomelatine; potentiators including aripiprazole, olanzapine, quetiapine, risperidone.
45378008|NCT05889221|Other|Drug and medical device|Isatuximab will be administered in the hospital by an healthcare professional in the periumbilical region at a single site, using an investigational device injector; injection site will be rotated from one administration to the other.
45847208|NCT05447052|Device|Innova Stent|Innova Stent implantation
45378009|NCT05889208|Device|Prophylactic pacemaker implantation|Pacemaker implantation prior the TAVI-procedure
45378010|NCT05889195|Diagnostic Test|Cxbladder urine test|Cxbladder tests uses mRNA and DNA biomarkers in the urine to direct the management of UC from diagnosis to surveillance for disease recurrence.
45847209|NCT05446974|Other|Nursing Competency Enhancement Training Program in PTSD Intervention|This program was for nurses who work at the Mental Health Welfare Center and consisted of a workbook, self-learning online education, and workshop. It included a spoken audio track that was accompanied by visual prompts to provide knowledge on traumatic stress and introduce trauma recovery methods. Its online format made it convenient and widely accessible, and allowed for a low-intensity, cost-effective educational program. The program focused on providing self-learning guidelines for nurses to develop their capacity for PTSD intervention.
45378013|NCT05889169|Other|Neurorehabilitation|Four to eight weeks motor rehabilitation (500 minutes per week across 6 day per week)
45378014|NCT05889156|Drug|NST-1024|400 mg BID
45493807|NCT03143296|Other|Simulated reverberant environment|Reverberant environments simulate real-life situations mimicking a living room, classroom and auditorium. Each simulation lasts up to 2 hours.
45493808|NCT02332954|Drug|vortioxetine|The starting and recommended dose of vortioxetine is 10 mg once daily; film-coated 10 mg tablets for oral use once daily for 52 weeks.Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.
45493809|NCT01372059|Other|RGRM|RGRM is multi-sensory method. The group including 6-8 participants is headed by a certified therapist of the method using a unique note system. The Note system is the combined body of body symbols in red and blue, with the audio codes and movements and be assembled in countless combinations to stimulate different parts of the brain. The movements are exercised by the hands tapping on the knees and feet stamping on the floor without the need for tools other than the body. The RGRM is developed to stimulate mobility, reading and speech, rhythm-esteem, body image, balance, memory, coordination, motor skills, concentration, perseverance and social skills. The group will have two sessions per week during 12 weeks.
45493810|NCT01372059|Other|Therapeutic riding|The horses walk provides sensory input through movement, which is variable, rhythmic, and repetitive. The many textures, sounds, sights, movement experiences of working around a horse provide an enriched sensory environment. The participants gain from the physical benefits of being on a moving horse and are socially and emotionally stimulated by interacting with a horse and the rest of the group. The intervention is headed by educated therapists (occupational therapist and physical therapist), in conjunction with experienced horse handler and specially trained therapy horses. The treatment is held in group format (4-6 participants) twice per week in 12 weeks which runs in sessions where two participants ride at the same time.
45493811|NCT01372059|Other|Receives no intervention|Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
45493812|NCT00230607|Drug|agalsidase beta|Pharmaceutical form: powder for reconstitution Route of administration: intravenous
45493813|NCT02328664|Procedure|Flexible sigmoidoscopy or colonoscopy|Depending on the localization of the scar of the malignant polyp, either a flexible sigmoidoscopy or colonoscopy will be done to take biopsies from the polypectomy scar.
45493814|NCT02332642|Other|Immuno-monitoring|
45493815|NCT03111160|Procedure|SMILE procedure using lower energy (100, 105, and 110 nJ)|Based on the review of literature, we regarded SMILE using energy levels of 115 nJ or higher as 'conventional' energy-SMILE (C-SMILE). Since 500kHz VisuMax femtosecond laser used in this study had a threshold photodisruption energy level of 100 nJ, lowest energy level of L-SMILE was set at 100 nJ. Because the spot distance must be changed by approximately 1 μm when laser energy changed by 50 nJ, we could set the maximum laser energy to 150 (100 + 50) nJ as highest one of C-SMILE while keeping the spot distance constant. Finally, we established two groups divided by different laser energies: L-SMILE group using lower energy levels of 100, 105, and 110 nJ, and C-SMILE group using 'conventional', not higher, energy levels of 115 to 150 nJ.
45378015|NCT05889156|Other|Placebo|matched placebo to active arm
45378016|NCT05889143|Drug|Ezetimibe/Rosuvastatin|Patient treated with Crezet Tablet
45378017|NCT05889130|Other|Resistant Exercise|"The exercises were planned to be performed in 3 sets, 10 repetitions in each set, with 3 minutes rest between sets. Before starting the main exercises, it was planned to do 1 set of the same exercises without weight as a warm-up and cool-down exercise.~Exercises were planned as lower extremity hip abduction, adduction, flexion and extension, straight leg raise, terminal knee extension, ankle flexion and bridge exercises. During the exercises, it was planned to be combined with breathing, paying attention to respiratory control."
45378018|NCT05889117|Device|Intermittent theta-burst treatment (iTBS) using MagPro Transcranial Magnetic Stimulator (manufacturer: Magventure)|3-10 minute sessions of brain stimulation applied to the left dorsolateral prefrontal cortex, up to 10 sessions a day, 30 sessions in total, planned within 2 weeks.
45378019|NCT05889104|Other|Randomization Program|The subjects in the Control Group will undergo twelve weeks of low impact Aerobics Training along with a health awareness program
45378020|NCT05889104|Other|Progressive Loading Protocol (PLP):|he subjects in the Progressive Loading Group will undergo 4-7 days of moderate to high impact loading activities per week.
45378021|NCT05889091|Other|HRQOL instruments|These instruments include Face Q for Appearance, Eating & drinking, Swallowing, and Saliva (patient-reported); the Neck Dissection Impairment Index (patient-reported); the Long-term ENT-Subjective/Objective/Management/Analysis (LENT-SOMA) for skin-subcutaneous tissue, muscle-soft tissue, mucosa - oral and pharyngeal, salivary gland, and mandible (patient- and clinician-reported); modified barium swallow study (8-point penetration aspiration scale).
45378022|NCT05889091|Other|LENT SOMA instrument|LENT SOMA instrument will also be provided to summarize objective quality-of-life-related measures recorded at 12 months postoperatively, including interincisor distance (mm); neck range of motion measured in degrees of flexion, extension, lateral flexion, and rotation to both sides; and shoulder range of motion, measured in degrees of abduction.
45378023|NCT05889078|Behavioral|A 4-week walking intervention|Participants will walk along a predetermined route 3 times per week for a period of 4 weeks, answering a pre- and post-intervention questionnaire as well as weekly questionnaires measuring their affect and other variables related to wellbeing. Participants will be randomly assigned to one of two conditions (nature vs urban setting), determining whether the predetermined route they will walk is in a nature or urban setting.
45378024|NCT05889065|Procedure|Conventional Physical Therapy|"group A will receive conventional physical therapy including~10~ultrasound(1.5w/cm2~,3 MHz continuous type, duration 10 minutes),hot packs (on affected region of shoulder for 10 minutes),shoulder ROM, stretching exercises, and joint mobilization five times per week for two weeks with 40 minutes duration of each session. Maitland mobilization will be given in supine position.~· After giving glenohumeral joint distraction, caudal, dorsal, and ventral glides will be given at a rate of 2-3 oscillation/second for 1 to 2 minutes to patients. Grade I or II rhythmic oscillations will be applied in free range."
45378025|NCT05889065|Procedure|PNF techniques|In this group 20 repetitions of diagonal scapular pattern (anterior elevation and posterior depression, posterior elevation and anterior depression) with 20 seconds rest period will be given to subjects. PNF techniques of rhythmic initiation and repeated contractions will be used in all patterns, applied for 40 minutes.
45378026|NCT05889052|Drug|Sulfadoxine pyrimethamine|Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
45378027|NCT05889039|Device|BEMER|Bio-Electro-Magnetic Energy Regulation (BEMER) is an emerging therapeutic modality that deploys a biorhythmically defined stimulus through a pulsed electromagnetic field and has been shown to reduce musculoskeletal pain.
45378028|NCT05889039|Procedure|OMT|Osteopathic manipulative therapy (OMT) is a form of manual therapy utilized by osteopathic physicians and some allopathic physicians to treat a broad variety of musculoskeletal ailments, including neck pain.
45493816|NCT03111160|Procedure|SMILE procedure using conventional energy (115 to 150 nJ)|The SMILE procedures were conducted in the Eyereum Eye Clinic (Seoul, South Korea). The target postoperative refraction was emmetropia. The surgery, using standardized techniques, was performed by an experienced surgeon (D.S.Y.K.) using the VisuMax system. The surgical parameters used during SMILE were as follows: repetition rate of 500 kHz, pulse energy 100 to 150 nJ (100, 105, and 110 nJ, L-SMILE; 115 to 150 nJ, C-SMILE), spot distance 4.5 μm (regardless of FSL energy), cap thickness 120 μm, and side-cut width 2 mm in the 12-o'clock position with an angle of 90°. After the anterior (upper) and posterior (lower) delineated plane of the intrastromal lenticule were well defined, the anterior and posterior interface were dissected with a micro-spatula with a blunt circular tip and extracted with micro-forceps. The integrity of the lenticule was also checked subsequently.
45493817|NCT03953859|Genetic|double strand break|an induction of a double strand break will be made in the embryos generated for this research and the repair mechanism observed
45493818|NCT05365191|Procedure|Near infrared fluorescence navigated sentinel lymph node mapping|Participants undergo sentinel lymph node biopsy for breast cancer, and use blue dye/Tc99m radioisotope as primary tracer. Indocyanine green near infrared fluorescence as secondary tracer for mapping.
45378029|NCT05889039|Procedure|Sham OMT + Sham BEMER|Participants in the CONTROL group received light touch and BEMER sham treatments. Researchers placed their hands lightly on the subject's cervical paraspinal muscles in the supine position and on the upper thoracic paraspinal muscles in the prone position for approximately 5 minutes. This was done to mimic myofascial release techniques; however, no pressure or action was done. In addition, the subject's laid supine on the BEMER mat (as they would do during a BEMER session), but the device was not activated.
45378030|NCT05889026|Device|Extracorporeal shock wave therapy|Stimulation was given to the brachial muscle, 1000 times, 4Hz, and energy flux density was 0.030mJ/mm2.
45378031|NCT05889026|Procedure|Botulinum toxin treatment|The toxin dose was established for each patient: it ranged between 80 unit and 300 unit.
45493819|NCT02328820|Other|Percutaneous coronary intervention (PCI)|For lesions with both FFR<=0.8 and CFR<2.0
45493820|NCT02328820|Other|Optimal medical therapy (OMT)|For lesions with FFR>0.8 or CFR>=2.0 or both
45493821|NCT01372761|Drug|ZGN-433|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
45493822|NCT01372761|Drug|Normal Saline|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
45493823|NCT03866512|Behavioral|Forearm immobilization|Two days of forearm immobilization
45493824|NCT03634527|Behavioral|Auricular Point Acupressure|Light touch using vaccaria seeds on specific points of the ear
45493825|NCT03634527|Behavioral|Control Auricular Point Acupressure-|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
45493826|NCT03778606|Dietary Supplement|Potato starch|Potato starch will be given twice a day for up to 14 days, discharge, or death, whichever occurs first.
45847210|NCT05446896|Device|AR guidance with Hololens 2|The AR instructions were developed as a step-by-step guide with the same text and images as in the printed manual, utilizing the dynamic 365 Guide (Software, Microsoft Corporation, Redmond, WA, USA). The AR instructions were delivered using the Microsoft HoloLens 2.
45847211|NCT05446818|Dietary Supplement|Cocoa flavanol (CF)|2 times per day 750 mg cocoa flavanols (each delivered in 6 CocoaVia capsules)
45378032|NCT05889013|Device|Nasal Nitric Oxide testing|Collection of already performed clinical data and nNO testing
45378033|NCT05889000|Other|questionnaire responses|questionnaire responses - Pelvic Varicose Veins Questionnaire (PVVQ) and Pelvic Venous Clinical Severity Score (PVCSS)
45378034|NCT05888974|Diagnostic Test|Cardiac ultrasonography|During the inclusion visit, the patient will receive 3 cardiac ultrasonography. The first one will be performed at the time of the initiation of the 500mL vascular filling (T0), without delaying and the second one after the end of the filling (Tfin). These first two ultrasound are part of standard practice. A third will be performed 20 minutes after the end of the vascular filling (Tfin+20).
45378035|NCT05888922|Drug|Minoxidil Tablets|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
45378036|NCT05888922|Drug|Minoxidil Topical|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
45378037|NCT05888922|Drug|Placebo oral tablet|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
45378038|NCT05888922|Drug|Vehicle solution|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
45378039|NCT05888857|Drug|MEDI5752|A treatment cycle consists of 3 weeks. MEDI5752 will be administered by intravenous infusion at a fixed dose on Day 1 of each cycle
45493827|NCT03873675|Diagnostic Test|parathyroid hormone|10-20ml blood samples taken from the arterial catheter every 12 hours to obtain parathyroid hormone serum concentration. 6-8 samples per patient
45493828|NCT03111706|Procedure|Cesarean section|During Cesarean delivery the lower uterine segment (LUS) was defined as the part of the uterus below the uterovesical peritoneal reflection. After opening the visceral peritoneum and performing the bladder dissection, the LUS was assessed for integrity of the CS scar by the operating surgeon to avoid bias by the sonographic findings. Scar dehiscence was defined as the presence of either transparent LUS with visible contents, presence of well-circumscribed scar defect or presence of frank uterine rupture.
45493829|NCT03863769|Other|Lumbar Spinal Stenosis|Posture and Performance testing: ABC-6 Scale, low back pain NRS, buttock or leg pain NRS, five times sit-to-stand, timed up-and-go, PGIC, eyes open force plate assessment (30 seconds), and eyes closed force plate assessment (30 seconds).
45493830|NCT03111472|Other|Self-management guide for people with Parkinson's who fall and their informal caregivers|The self-management guide will be developed utilising information from people with Parkinson's, informal caregivers of people with Parkinson's, healthcare professionals and a systematic review of self-management interventions for people with Parkinson's who fall.
45493831|NCT02328898|Device|Cre8 Stent|Comparison of the Resolute Integrity stent with the Cre8 stent.
45493832|NCT02328898|Device|Resolute Integrity stent|
45493833|NCT02332408|Radiation|Cybernetic microradiosurgery|Cybernetic microradiosurgery (6MV) using tracking to TD 25Gy given in five fraction (5Gy p fr) two or three days a week, during 2 weeks
45493834|NCT02332408|Radiation|Conventional radiotherapy|Conventionally fractionated linac based external beam radiation therapy - EBRT, (conformal or dynamic) to the TD of 36 Gy, in 2.0 Gy per fraction 5 days a week over the period of 3.5 weeks)
45493835|NCT03775785|Dietary Supplement|Tailored enteral nutrition|"The mean of three measurements per batch (3 x 2-3ml) will be used to calculate the required amount of extra fat, protein, and carbohydrate for the following 3 days of fortification using a predefined Excel spread sheet (Microsoft Inc, Redmond, Washington).~The intervention will consist of adding fat, protein, and/or carbohydrate to achieve target levels of macronutrients.~The defined macronutrient concentration in breast milk is 4.4 g/100 mL of fat, 3 g/100 mL of protein, and 8.8 g/ 100 mL of carbohydrate to meet the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) guidelines (6.6 g/kg/d of fat, 4.5 g/kg/d of protein, and 13.2 g/kg/d of carbohydrate) assuming an intake of 150 mL/kg/d."
45847212|NCT05446818|Other|Placebo (P)|2 times per day 0 mg cocoa flavanols calorically matched control (delivered in 6 identical capsules)
45847213|NCT05444322|Drug|RD14-01 cell infusion|Autologous CAR T cells
45493836|NCT05174715|Other|BIA|nutritional status was evaluated using BIA
45493837|NCT02328742|Biological|Hysteroscopy + endometrial biopsy|"The day of the first diagnostic hysteroscopy an endometrial biopsy is performed (biopsy A1). These biopsies will be used for the evaluation of TGFbeta, Activin A and inhibin.~This intervention is required for the observational needs of this study."
45493838|NCT02328742|Other|Telephone call|"Patients will be contacted via telephone 6 months after first hysteroscopy.~This intervention is required for the observational needs of this study."
45493839|NCT02328742|Biological|Resection + endometrial biopsy|"If patients are found to have synechia or another intracavitary pathology, resection is scheduled 1-2 months later. A second endometrial biopsy is performed at this time.~This intervention is required for the observational needs of this study."
45493840|NCT02328742|Biological|Follow-up hysteroscopy + endometrial biopsy|"For patients having had resection, a follow-up hysteroscopy is performed 1 to 3 months later. An endometrial biopsy will be performed at this time.~This intervention is required for the observational needs of this study."
45378040|NCT05888844|Drug|INCB099280|Administered as specified in the treatment arm description.
45847214|NCT05439018|Other|Integrated Neuromuscular inhibition|Integrated Neuromuscular Inhibition in addition to traditional treatment will be received three times a week for eight weeks. Integrated Neuromuscular Inhibition will be contain three combined manual treatment ( ischemic compression , strain counter strain , Muscle energy technique ) traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
45378041|NCT05888818|Other|Cold application|A cold application (with a cold gel pack) will be applied to the upper part of the neck for 5 minutes.
45378042|NCT05888779|Other|Beverage One (Milk)|Participant will consume beverage one (milk) and complete novel cognitive assessment questionnaire on paper.
45847215|NCT05439018|Other|traditional treatment|traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
45847216|NCT05435664|Behavioral|Progressive relaxation exercise|It consists of sessions involving deep breathing and stretching and relaxing the body.
45847217|NCT05430750|Drug|Nitrous oxide|In conventional nitrous oxide carrier group 2% Sevoflurane in O2-N2O (60 % FiO2) @3L/min will be delivered to achieve MAC 0.5.
45378043|NCT05888779|Other|Beverage Two (Juice)|Participant will consume beverage two (fruit drink) and complete novel cognitive assessment questionnaire on paper.
45378044|NCT05888766|Drug|Rimegepant 75 milligrams|At the screening visit patients with episodic migraine, which will be prescribed Rimegepant 75 mg as abortive treatment, will be asked to participate in the study.
45378045|NCT05888740|Device|VibratoSleeve Therapeutic Ultrasound Device|The VibratoSleeve is compromised of a 16-transducer array that is mounted within a wrap that conforms to the posterior calf
45493841|NCT05296239|Other|SimpleC Wellness Platform with Social Robot Interaction|"Once respondents enroll, they will receive the SimpleC Wellness Platform, including introduction training on the SAR system. During the study period, participants and others will receive instructions for the SAR system and use it as part of scheduled interactions, which includes interactions as part of the general schedule. In the third week, the social robot will be installed, and staff trained in group sessions as available. Participants may use the full SAR system as they are willing.~Interactions specific to the virtual and physical robot include notifications to join activities as per community schedule as well as trivia."
45493842|NCT05256459|Other|Long term follow-up|No extra intervention.
45493843|NCT02328586|Other|Group Acupuncture|
45493844|NCT03604107|Genetic|Preimplantation Genetic Testing-Aneuploidy|trophectoderm biopsy samples will be analyzed for karyotype after clinical outcome is determined
45847218|NCT05430750|Drug|Nitrous oxide|In streamed-in nitrous oxide carrier group 2% Sevoflurane in O2 -Air (60 % FiO2) will be delivered @3.0L/min to achieve a MAC of 0.5. Then, the FGF will be decreased to 1.0 L (low flow) and N2O will be 'streamed-in' @ 40 %.
45847219|NCT05430750|Drug|Sevoflurane|Ventilation will be initiated with 2% sevoflurane in all the groups
45847220|NCT05418036|Drug|Sotalol Oral Tablet|Dose of sotalol is prescribed by the attending physician. Accepted for this protocol when the dose is no greater than 160 mg/day
45847221|NCT05392920|Other|assessment study|there is no intervention in this study
45847222|NCT05378178|Drug|HS-10381|Each subject will receive a single dose(C0) of HS-10381 and then repeat doses(C1, C2…) for 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
45378046|NCT05888727|Behavioral|"Seated Physical activity INtervention for persons with MS, SPIN program- Intervention Condition"|"The proposed exercise training program is based on Social Cognitive Theory (SCT) for promoting aerobic and strength training in wheelchair users with MS. The 16-week program includes one-on-one video chats with a behavioral coach and various tracks for progressive increases in both strength and aerobic training. The proposed strength training includes 15 exercises with step-by-step instructions using resistance bands and/or wrist weights that were adapted for seated body-position that can be executed in a wheelchair. The proposed aerobic training is arm cycle ergometry; this is a low-cost and modifiable option that fits the needs of both power and manual wheelchair users. Other proposed equipment includes a comprehensive Training Manual, fitness tracker for use during exercise training sessions, and Rate of Perceived Exertion (RPE) scale for guiding individualized exercise intensity. The research team created 12 Newsletters that align with 12 proposed coaching calls."
45378047|NCT05888727|Behavioral|Wellness for MS (WellMS)- Control Condition|The attention/contact wellness control condition will mirror the exercise training intervention condition, but focuses on implementing health behaviors other than physical activity (e.g., diet and emotional wellbeing). This program is an adapted version of the WellMS program from Prof. Motl's Phase III clinical trial (NCT03490240). The program is based on SCT principles of behavior change and integrates wellness resources from the National MS Society (NMSS). The research team has created 12 Newsletters that will be delivered on the same chat schedule as the exercise training intervention. All coaching chats and newsletters will occur with the same frequency as in the exercise training intervention condition. Participants will be provided with a participant manual, logbook, and calendar. Participants will work with their behavioral coach on goal setting specific to wellness behaviors.
45378048|NCT05888714|Device|Experimental FES cycling|Using the experimental, new FES cycling device, provide neuromuscular electrical stimulation of the gluteal, quadriceps and hamstring muscles at sufficient intensity to cause muscle contraction and push the cycle ergometer pedals for 30 minutes, for 16 treatment sessions (twice a week, for 8 weeks), in addition to conventional physical therapy for muscle strengthening.
45378049|NCT05888714|Device|Comparator FES cycling|Using the comparator, marketed FES cycling device, provide neuromuscular electrical stimulation of the gluteal, quadriceps and hamstring muscles at sufficient intensity to cause muscle contraction and push the cycle ergometer pedals for 30 minutes, for 16 treatment sessions (twice a week, for 8 weeks), in addition to conventional physical therapy for muscle strengthening.
45493845|NCT02332486|Drug|Qingxuan Decoction|In Qingxuan Decoction, there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China.
45493846|NCT05173857|Device|Advance PTX|PTA in Dysfunctional Haemodialysis Access
45493847|NCT05173857|Device|Advance LP (Low Profile)|Plain Old Balloon Angioplasty (POBA)
45493848|NCT05173857|Drug|Paclitaxel (PTX)|Paclitaxel (PTX)
45378050|NCT05888714|Other|Conventional physical therapy|Conventional physical therapy for muscle strengthening, for 16 treatment sessions (twice a week, for 8 weeks).
45378051|NCT05888675|Drug|Weifuchun|The treatment group#Weifuchun group#was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and Ticeo monotherapy regimen.
45493849|NCT03111238|Drug|REX-001|REX-001 is administered through an intra-arterial catheter.
45493850|NCT03111238|Drug|Placebo|Placebo is administered through an intra-arterial catheter.
45493851|NCT01372137|Drug|NOX-H94|Dosage form: NOX-H94 25 mg (oligonucleotide basis) Solution for Injection Strength: 14.6 mg NOX-H94 / mL Dose: 0.3 - 4.8 mg/kg single dose Route: IV infusion over 15 minutes / SC administration
45493852|NCT01372137|Other|Glucose 5%|Placebo
45493853|NCT03620097|Dietary Supplement|EuPoly-3 DHA Infant|Children will be selected in the first 18 months of the study, and patients with ASD will be included in the trial consecutively, and will be divided into two parallel groups according to the randomization generated by the SIGESMU® computer program with random assignment 1: 1: 30 subjects will receive 800mg of DHA per day and another 30 children, a placebo with similar lipid characteristics except that it will not have DHA content, and for a period of 6 months, double blind. After 6 months, a clinical evaluation and the same baseline analytical study will be carried out again.
45493854|NCT03620097|Other|Placebo|Children will be selected in the first 18 months of the study, and patients with ASD will be included in the trial consecutively, and will be divided into two parallel groups according to the randomization generated by the SIGESMU® computer program with random assignment 1: 1: 30 subjects will receive 800mg of DHA per day and another 30 children, a placebo with similar lipid characteristics except that it will not have DHA content, and for a period of 6 months, double blind. After 6 months, a clinical evaluation and the same baseline analytical study will be carried out again.
45493855|NCT05078086|Other|No intervention|No intervention
45493856|NCT05133297|Drug|TLL-018|Oral tablets administered at dose1 BID daily for 24 weeks.
45493857|NCT05133297|Drug|TLL-018|Oral tablets administered at dose2 BID daily for 24 weeks.
45493858|NCT05133297|Drug|TLL-018|Oral tablets administered at dose3 BID daily for 24 weeks.
45493859|NCT05133297|Drug|Tofacitinib|Oral tablets administered at 5 mg BID daily for 24 weeks.
45493860|NCT05078008|Procedure|Physiotherapy modalities|parafango in the lumbar region 20min/day; High frequency Transcutaneous Electrical Nerve Stimulation (TENS), 100 Hz, 0,04-0,2mseg, 20 min/day; lumbar flexibility self-exercise plan
45493861|NCT05078008|Procedure|Balneotherapy modalities|Immersion in a thermal pool with 15 minutes of automatic hydromassage and 15 minutes of spine flexibility exercises; thermal steam treatment to spinal column; hydromassage bath with Vichy thermal water
45378052|NCT05888662|Procedure|Endo-epicardial ablation|Endo-epicardial ablation of ventricular tachycardia
45378053|NCT05888662|Procedure|endocardial ablation only|endocardial-only catheter ablation of ventricular tachycardia
45493862|NCT03417999|Drug|Dexmedetomidine|Dose-escalation of atomized intranasal dexmedetomidine
45493863|NCT02328430|Device|Kinnect 3 camera|comparison of Kinnect 3 measures of chest wall movement during standard spirometry
45493864|NCT03142516|Drug|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
45493865|NCT03142516|Drug|Irinotecan|Irinotecan 150 mg/m2 will be administered as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle
45493866|NCT03142516|Drug|Folinic acid|Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
45493867|NCT03142516|Drug|5-FU|5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
45493868|NCT03482453|Drug|TAK-788|TAK-788 capsules.
45493869|NCT03482453|Drug|Placebo|TAK-788 placebo-matching capsules.
45493870|NCT03482453|Drug|TAK-788|TAK-788 DiC.
45493871|NCT05077930|Biological|Convalescent plasma|The intervention group will receive 200 or 400 mL of high-titer COVID-19 convalescent plasma, ABO compatible with the patient, within 24 hours of randomization.
45493872|NCT05077930|Drug|Standard of care|The active comparator group will receive oxygen supplementation, corticoids, antiretrovirals, and/or monoclonal antibodies according to the institutional protocol.
45847223|NCT05337618|Diagnostic Test|Full-band Electrocorticography|Diagnosis of spreading depolarizations in continuous electrocorticography
45847224|NCT05337618|Combination Product|Treatment Algorithm|Protocol for escalation and de-escalation of physiologic-targeted and pharmacologic therapies to treat and prevent spreading depolarizations
45847225|NCT05316714|Procedure|Nanofat grafing|NANOFAT REGENERATIVE SURGICAL GRAFTING IN PRNILE ALBUGIANEA OF PATIENTS AFFECTED BY PEYRONIES' DISEASE
45378054|NCT05888649|Behavioral|Community Clusters|Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.
45378055|NCT05888636|Other|ChIP-seq, NGS, ATAC-seq|Bone narrow sampling
45378056|NCT05888623|Device|Computer Assisted Detection|Computer-aided polyp detection system that utilizes artificial intelligence (AI) during colonoscopy
45378057|NCT05888610|Behavioral|Digital Outpost|A mobile application that allows caregivers of patients diagnosed with Alzheimer's Disease and Related Dementias to report patient symptom remotely to their clinical team.
45493873|NCT05077696|Other|Drawing a tube of blood (serum)|dosage of neurofilaments and comparison with a final diagnosis one year after sampling.
45493874|NCT05077618|Other|sampling of dental plaque and blood sample during the treatment|sampling of dental plaque and blood sample analysed on day 1
45493875|NCT03480425|Diagnostic Test|Measuring extubation force|Intubation of the esophagus of anesthetized participants who are having planned endotracheal intubate for surgery; inflation of the cuff; attachment of a force transducer to the tube connector; and gently tugging the tube out of the mouth. Then intubating the esophagus and repeating the tugging procedure. Meanwhile, the force of resistance to tugging is measured with a force transducer.
45493876|NCT05387512|Drug|Camrelizumab|Patients with EGFR-mutation-negative and ALK-negative advanced non-squamous non-small cell lung cancer were treated with first-line chemotherapy in combination with camrelizumab.
45493877|NCT03719729|Drug|Rifaximin|Administer daily rifaximin to modify intestinal microbiome to alter the course of the disease.
45378058|NCT05888597|Drug|L-menthol|(Sigma-Aldrich, St. Louis, US)
45378059|NCT05888597|Other|Placebo|Strawberry scent (Sigma-Aldrich, St. Louis, US)
45493878|NCT05077462|Drug|C52R1M Tab. and C52R2 Tab.|Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
45493879|NCT05077462|Drug|AJU-C52H|Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 160/5/25 mg FDC tablet
45493880|NCT03719651|Behavioral|LOCI|LOCI includes training of leaders in general leadership, implementation leadership, and implementation climate.
45847226|NCT05274048|Drug|Neratinib Pill|Patients will be enrolled in cohorts of 3 at each dose level of Neratinib (120 mg, 160 mg, 200 mg) daily (days 1 through 21)
45378060|NCT05888584|Other|Research readiness tool|Online/paper based tool for use by nurses to aid discussions with lung cancer patients about clinical trials opportunities.
45378061|NCT05888558|Device|Body fluid diagnosis|miRNAs derived from exosomes in the serum
45378062|NCT05888519|Other|FID123300 ocular lubricant|Investigational ocular lubricant
45378063|NCT05888519|Other|FID123301 ocular lubricant|Investigational ocular lubricant
45378064|NCT05888519|Other|FID122505 ocular lubricant|Comparator ocular lubricant
45378065|NCT05888506|Dietary Supplement|Ketone Ester|Participants will consume the ketone ester beverage produced by KetoneAid prior to bedtime. Participants will consume 60 mL (30 grams ketones) of the ketone beverage.
45378066|NCT05888506|Dietary Supplement|Placebo|Participants will consume the placebo supplement prior to bedtime. The placebo supplement will be a ketone ester-free, taste and viscosity-matched, beverage produced by KetoneAid.
45378067|NCT05888493|Biological|Tisagenlecleucel|Tisagenlecleucel is a solution for infusion of 0.6 to 6 x 10^8 CAR-positive viable T-cells taken intravenously (i.v.).
45378068|NCT05888493|Drug|Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.|Lenalidomide 20 mg daily on days 1-21 for up to 12 cycles Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 2-5
45493881|NCT03719651|Behavioral|EMDR|EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
45493882|NCT03719651|Behavioral|CT-PTSD|CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
45378069|NCT05888493|Drug|Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles|Rituximab 375 mg/m2 i.v. on day 1 Cyclophosphamide 750 mg/m2 i.v. day 1 Doxorubicin 50 mg/m2 i.v. day 1 Vincristine 1.4 mg/2 (capped at 2 mg) i.v. day 1 Prednisone or prednisolone 40 mg/m2 PO days 1-5
45493883|NCT03719651|Behavioral|TF-CBT|TF-CBT (Trauma-Focused Cognitive-Behavioral Treatment) treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
45493884|NCT02328508|Device|Hyperbaric oxygen therapy|HBOT was carried out in a hyperbaric chamber for 120-min per session, five days a week for four consecutive weeks (20 treatment sessions).
45493885|NCT03714113|Diagnostic Test|Anti-HLA donor-specific antibodies monitoring|Monitoring anti-HLA donor-specific antibodies in the patients serum at the time of kidney transplantation and 3, 12 and 24 months after the procedure. Blood samples from patients will be collected.
45493886|NCT03111004|Other|New Care|All settings that are in any way relevant to the provision of health and social care are integrated, including: out-of-hospital (community) services as well as hospitals, GPs' offices, community nurses, and any type of care practitioners, users' homes and volunteer service providers' offices
45493887|NCT03472547|Drug|diacerein 1% ointment|All subjects were exposed to diacerein 1% ointment, vehicle ointment, and 0.9% saline (negative control) at 3 randomly assigned, adjacent skin sites on the infrascapular area of the back 3 times weekly for 3 weeks (9 applications) during the Induction Phase, and one time during the Challenge Phase (10 times in total).
45493888|NCT00799396|Drug|Clopidogrel|300 mg on first day, then 75 mg per day for the next 6 days
45493889|NCT00799396|Drug|Aspirin|Single dose of 324 mg on the last day of clopidogrel treatment
45493890|NCT05077306|Other|music therapy group|individual bedside single session of receptive music therapy (RMT) by a certified Music therapist- GIM fellow in presence. STAI Y-1 was administered 5 min. before session (STAI Y-1 PRE) and 15 min. after session (STAI Y-1 POST) in paper form. HR and O2Sat were recorded from the bedside monitor 3 times: start session (T0), 10 min. (T1), end session (T2).Participants i were asked to fill in an optional open-ended question concerning their experience with music therapy.
45493891|NCT02624128|Drug|Valproic Acid|Treatment will be administered orally starting at day -14, with 500 mg slow releasing tablet at evening. Thereafter, the dose will be increased also using 300 mg tablets until reaching 1500 mg on day -1. The titration strategy is to reach a target VPA serum level of 50-100 μg/ml.
45493892|NCT02624128|Drug|Cisplatin|administered intravenously at dose of 75 mg/m2 given every three weeks for 6 cycles
45378070|NCT05888493|Drug|Lymphodepleting chemotherapy|"Fludarabine (25 mg/m^2 intravenously [i.v.] daily for 3 doses) OR Cyclophosphamide (250 mg/m^2 i.v. daily for 3 doses starting with the first dose of fludarabine).~OR Bendamustine 90 mg/m^2 i.v. daily for 2 days (If there was previous grade IV hemorrhagic cystitis with cyclophosphamide, or the participant demonstrated resistance to a previous cyclophosphamide-containing regimen)"
45378071|NCT05888493|Other|Corticosteroids and/or Radiation (Bridging therapy)|Corticosteroids and/or Radiation
45378072|NCT05888480|Other|The end-of-life communication skills training|Training methods include lectures, video demonstrations, and simulation in small groups (4-5 trainees per group with multidisciplinary roles). Written and audiovisual learning materials will be offered. Each session will be 150 minutes, including lectures and video demonstration (90 min/session) and simulation and feedback (60 min/session). One session will be conducted in two weeks. Totally there will be four sessions completed in 8 weeks.
45378073|NCT05888480|Other|Routine training activity|Routine training activities arranged by relevant departments in hospitals
45378074|NCT05888467|Other|supervised infrared exercise group|Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. During the exercise session, the participant is assigned to an individual 'sport cabin' in which they are standardly exposed to infrared light.
45378075|NCT05888467|Other|supervised non-infrared exercise group|Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. Participants assigned to the supervised non-infrared exercise group will exercise in the sport-cabin with the infrared light turned off.
45378076|NCT05888467|Other|Control group|Participants of the control group are advised to perform moderate intensity aerobic exercise at least 3 days per week for an average of 30-50 minutes per session and a total duration of 12 weeks.
45493893|NCT02624128|Drug|Cetuximab|administered intravenously at induction dose of 400 mg/m2 followed by maintenance doses of 250 mg/m2 given weekly
45493894|NCT03143062|Diagnostic Test|NEWS|NEWS
45493895|NCT03469349|Drug|Actovegin|Actovegin intravenous infusion and tablets.
45493896|NCT03469349|Drug|Placebo|Actovegin placebo-matching intravenous infusion and tablets.
45493897|NCT03639233|Behavioral|YESS!|Web based self-management education
45493898|NCT03467945|Drug|Metformin/Gliclazide Fixed Combination|Participants received single oral dose of Metformin and Gliclazide fixed combination tablet in treatment period 1, 2, 3 or 4.
45493899|NCT03467945|Drug|Metformin|Participants received single oral dose of Metformin tablet in treatment period 1, 2, 3 or 4.
45378077|NCT05888454|Other|Integrative Group Program|The integrative group program consists of 6 in-person sessions directed by a health coach and occurring every other week, and 6 asynchronous educative sessions during a period of 12 weeks.
45493900|NCT03467945|Drug|Gliclazide|Participants received single oral dose of Gliclazide tablet in treatment period 1, 2, 3 or 4.
45493901|NCT03719261|Drug|chitosan nanoparticles|Chitosan is a bioactive polymer obtained from deacetylation of chitin and is used in biomedical application due to its antimicrobial properties and biocompatibility and ability to resist aging for longer periods provide antibacterial effect in root canal disinfection.10ml of cs-np will be used during instrumentation in intervention group
45493902|NCT03719261|Drug|Sodium Hypochlorite|Sodium hypochlorite (NaOCL) is the most recommended irrigant due to its broad antibacterial effect, necrotic tissues and dentin collagen dissolving capability and inactivation of endotoxins.10ml of 2.5%NaOCL will be used during instrumentation in control group
46054492|NCT02847000|Drug|Decitabine|"Starting dose is by weight:~DEC is supplied as 5 mg/capsule. Weight 40-60kg = 2 capsules of Decitabine. DEC capsules are ingested ~60 minutes after THU capsules. Weight 61-80kg = 3 capsules of DEC. DEC capsules are ingested ~60 minutes after THU capsules. Weight 81-100kg or higher = 4 capsules of DEC. DEC capsules are ingested ~60 minutes after THU capsules.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
45378078|NCT05888454|Other|Conventional treatment for T2DM|Conventional medical treatment for T2DM
45378079|NCT05888441|Other|Obstacle characteristics|"In the walking trials, when an obstacle is present, the obstacle height and obstacle contrast level will be varied across the trial repetitions.~Each participant will be exposed to obstacles of two heights: the first will be 1 centimeter in height, and the second will be approximately 20% of the subject's leg length (ranging in physical height between 16 - 22 centimeters to cover a range of leg lengths in the population).~Obstacles (of both heights) will also be painted such that their measured luminance (or contrast) level against the floor luminance is varied. High contrast obstacles will have approximately 90% Michelson contrast and low contrast obstacles will have approximately 6% Michelson contrast."
45493903|NCT00069238|Biological|Alemtuzumab (Campath)|Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles.
45493904|NCT00069238|Drug|EPOCH|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) + Alemtuzumab (Campath) every 3 weeks for up to 6 cycles.
45493905|NCT03435497|Behavioral|Game Changers|Game Changers is an intervention that aims to empower and mobilize PLHA to be agents for HIV prevention and behavioral change in their social networks.
45493906|NCT03143140|Other|PAFA|percutaneous ablation of tumor feeding artery
45493907|NCT03143140|Other|tumor ablation|ablation of tumor area directly
45493908|NCT03639155|Drug|vadadustat reference tablets|oral tablet
45493909|NCT03639155|Drug|vadadustat test tablets|oral tablet
45493910|NCT03145324|Other|Collection of vaccine histories|
45493911|NCT02328274|Procedure|A Modified Technique for Laparoscopic Subtotal Hysterectomy|incorporation of two methods of vessels ligation and laparoscopic in situ morcellation
46054493|NCT02784327|Drug|PRF110|
45847227|NCT05274048|Drug|Fam-Trastuzumab Deruxtecan-Nxki (TDxD)|standard dosing of TDxD (5.4mg/m2) on day 1of a 21 day treatment cycle
45847228|NCT05273658|Drug|Cannabis|Participants will smoke a cannabis cigarette ad libitum as per their usual routine
45378080|NCT05888428|Device|MyoTrain|MyoTrain is a virtual prosthesis control training system. From a hardware perspective it consists of an Apple iPad tablet computer and an eight-channel EMG armband, based on the Element electrode platform, which interfaces with the tablet via Bluetooth™. From a software perspective, MyoTrain was developed in the cross-platform Unity 4.0 game development environment.
45378081|NCT05888428|Behavioral|Motor Imagery|Motor imagery describes the process by which a prosthesis user mentally simulates the execution of a desired limb movement and activates the musculature of the residual limb that would generate the desired movement.
45378082|NCT05888402|Drug|Toripalimab|Toripalimab 240mg every 3 weeks with a total of 2 cycles as induction immunotherapy; Toripalimab 240mg every 3 weeks with maximum 1 years as consolidation immunotherapy after concurrent chemoradiotherapy.
45378083|NCT05888402|Radiation|Radical thoracic radiotherapy|60 Gy/2 Gy/6 week
45378084|NCT05888376|Device|Vascular access catheter to support dialysis or CRRT|A specialised vascular access catheter to support bi-directional blood flow at high rates to allow extracorporeal removal of toxins by dialysis or CRRT
45378085|NCT05888363|Other|No Intervention|Difference in outcomes in patients with rectal foreign bodies removed in the emergency department or in the operating room.
45378086|NCT05888350|Drug|Beclometasone Dipropionate and Formoterol Inhalation Aerosol|Inhaled Foster (Beclometasone Dipropionate and Formoterol Inhalation Aerosol) , 1puff, BID, 4weeks
45378087|NCT05888350|Drug|Placebo|Inhaled Placebo, 1puff, BID, 4weeks
46054494|NCT03362541|Behavioral|MS INFoRm|MS INFoRm incorporates principles of self-management and adult learning theory. The contents address the sources of fatigue, ways of monitoring fatigue, and strategies to reduce fatigue.
46054495|NCT03362541|Behavioral|Usual Care Control Group|The usual care webpage will contain content from widely available resources about MS fatigue.
46054496|NCT02849106|Procedure|biopsy to obtain a chemogram|All patients enrolled will have biopsies (on primary tumor or on a metastasis) before treatment in order to obtain a chemogram by ex vivo 3D culture cells
45378091|NCT05888298|Procedure|Greater occipital nerve radiofrequency|Greater nerve block and radiofrequency will be performed at the C2 vertebra level or occipital protuberance
45378092|NCT05888285|Procedure|Erector spina plane block|The transverse processes of the thoracic vertebrae are treated with ultrasound-guided drug injection
45378093|NCT05888285|Procedure|Erector spina bale block and pulsed radiofrequency|The transverse processes of the thoracic vertebrae are treated with ultrasound-guided drug injection and pulsed radiofrequency treatment
45378094|NCT05888272|Behavioral|Stress managment|The Doing What Matters in Times of Stress self-help manual materials and lay helper scripts utilized in the study are rooted in the principles of Acceptance and Commitment Therapy (ACT). They are designed to improve psychological flexibility which refers to an individual's ability to adapt to changing situations, reallocate mental resources, shift perspectives, and balance competing priorities. The ACT approach teaches individuals how to manage challenging thoughts and emotions through mindfulness techniques, while also guiding them to live in alignment with their personal values.
45378095|NCT05888259|Other|foot insole|The foot insole is 5 mm thick under the flat part of the forefoot and the modification is done by changing the position of the metatarsal bar. This was another 5 mm above the flat part of the foot insole. The proximal/distal position of the metatarsal rod and the cavity distal to the rod (large cavity) were defined using the plantar pressure distribution. The position and shape of the distal end of the metatarsal bar were defined by a line in the area where the plantar pressure was 75% of the maximum plantar pressure The void measured 3 mm in depth.
45493912|NCT05080348|Procedure|Ropivacaine iPACK Injection|Injection of 20mL of 0.25% Ropivacaine with 1:400,000 Epinephrine between in the Interspace between the Popliteal Artery and the Capsule of the Knee (iPACK) using ultrasound guidance at the level of the femoral condyles
45493913|NCT05080348|Procedure|Normal Saline iPACK Injection|Injection of 20mL of 0.9% Normal Saline between in the Interspace between the Popliteal Artery and the Capsule of the Knee (iPACK) using ultrasound guidance at the level of the femoral condyles
45493914|NCT02328196|Behavioral|The Danish McGill Ingestive Skills Assessment (MISA-DK)|The MISA measures the performance of dysphagic patients during the patient's usual mealtime routine.
45493915|NCT03073200|Drug|Ixekizumab|Administered SC
45493916|NCT03073200|Drug|Placebo|Administered SC
45493917|NCT03073200|Drug|Etanercept|Administered SC
45493918|NCT03142126|Device|Early ambulation with Angioseal closure device|To reaffirm safety and efficacy of using Angioseal for early ambulation by patients after femoral artery arteriotomy
45847229|NCT05273658|Drug|Alcohol|Participants will ingest alcohol to achieve the target breath alcohol level
45847230|NCT05249322|Other|Follow-up alternating between face-to-face consultation and teleconsultation every three months.|"The intervention will be an alternate follow-up every three months with:~A tele-consult: with paramedical consult (with assistance for home-spirometry) and medical consult for about 1h30 in total, make with a HCL platform for telemedicine.~An usual in-hospital consult of about 1h30 with paramedical and medical consult."
46054497|NCT04231149|Device|Test product 2|Test catheter 2
46054498|NCT04231149|Device|Test product 3|Test catheter 3
46054499|NCT04231149|Device|Comparator|SpeediCath Flex
46054500|NCT04202250|Procedure|CEMP (closed-ended multiport catheter) group|After sterile preparation and large inguinal crease draping, with the US probe in a sterile sleeve or cover , we will proceed to hydrolocalization with 5-10 mL 5% dextrose in order to open the space between the femoral nerve and the superior part of the ilio-psoas muscle. The Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the closed-tip multiport catheter will be then inserted under control and its position assessed between the femoral nerve and the superior aspect of the ilio-psoas muscle. Some aliquots of 5% dextrose will inject to confirm correct dispersal of the solution along the femoral nerve. The catheter will be tunnelled subcutaneously.A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
45493919|NCT05080114|Procedure|Modified Bakay technique (MT)|The conventional standard technique for laparoscopic hysterectomy was followed until the colpotomy. The remaining steps were as follows: A 0-Monocryl™ violet (poliglecaprone-25) or a 0-PDS-II (polydioxanone) suture with a 36-mm needle (Ethicon Inc., NJ, USA) was placed first on the right USL, proximal to the ischial spine and 1-3 cm away from its uterine insertion, then helically proceeded by 1 to 3 bite(s) (depending on the length of the ligament) for suspension/plication. The suture continued circumferentially in counter clockwise direction on the line between the cervicovaginal junction and the bladder in a full-thickness purse string fashion, at least 1 cm away to the bladder. This suture symmetrically ended in the left USL, with forming nearly an Ohm sign (Ω). Colpotomy was performed circumferentially using laparoscopic cold scissors and/or knife, maintaining a safe distance from the suture line. Following removal of the uterus, both ends of the prior suture line were knotted.
45493920|NCT05080114|Procedure|Standard technique (ST)|"The conventional standard total laparoscopic hysterectomy technique was used in this control group.~All operations were performed under general anaesthesia with nasogastric intubation and a bladder catheter in place. Cefazolin 2 g was administered to all patients for prophylaxis 30 min prior to surgery. Operations were performed with a 10-mm laparoscope (Karl Storz, Germany) through the trocar placed usually in the umbilicus. Two lateral 5-mm trocars and one midline 10-mm trocar were used. The placement of trocars varied according to the uterine size. Haemostasis was usually performed using bipolar forceps (Karl Storz Robi, Germany), whereas dissection was performed using the LigaSure™ (Covidien, Medtronic, USA). Maryland jaw laparoscopic sealer/divider, bipolar forceps and scissors. Colpotomy was performed with electrocautery devices and sutured intracorporeally."
45378096|NCT05888246|Diagnostic Test|Magnetocardiogram|Magnetocardiogram consists of acquisition and control system (including software) and detection part. Acquisition and control system mainly includes: cabinet, display, host, sensor. The detection part mainly includes: inspection bed, array sensor support frame, magnetic shielding equipment.
45378097|NCT05888220|Other|warm salt water bath|Warm water and warm salt water bath were applied to the hands and feet of the patients. It is a non-pharmacological intervention
45847231|NCT05234346|Drug|150 mg 5-ALAPhosphate + SFC|2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.
46054501|NCT04202250|Procedure|OESP (open-ended single port catheter) group|After sterile preparation and large inguinal crease draping, with the US probe in a sterile sleeve or cover , we will proceed to hydrolocalization with 5-10 mL 5% dextrose in order to open the space between the femoral nerve and the superior part of the ilio-psoas muscle. The Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the open-ended catheter will be then inserted under control and its position assessed between the femoral nerve and the superior aspect of the ilio-psoas muscle. Some aliquots of 5% dextrose will inject to confirm correct dispersal of the solution along the femoral nerve. The catheter will be tunnelled subcutaneously. A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
46054502|NCT02784249|Procedure|Goniotomy|Procedure: Goniotomy and trabecular excision with a novel ophthalmic knife in combination with planned cataract extraction via Phaco and PCIOL implant.
45378100|NCT05888194|Device|Mucogyne® gel|In Mucogyne group, each eligible patient will receive a box of Mucogyne® gel. The patient will apply Mucogyne® gel, 48-hours after delivery, everyday, twice a day, massaging it into the intimate area, for a 10-day period.
45493921|NCT05079958|Behavioral|cognitive-behavioral education|four-week cognitive-behavioral education course
45493922|NCT05079958|Behavioral|12-week brisk walking|12-week brisk walking
45493923|NCT02328352|Procedure|BP selfstanding felt|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.
45493924|NCT02328352|Procedure|PP mesh|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PR (polypropylene) prosthesis was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia
45493925|NCT02328352|Procedure|BP intraperitoneal mesh|Laparotomy on the linea alba carried out deeply for entering into the abdominal cavity, a 2x2cm2 BP sample implantation with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut
45847232|NCT05234346|Other|Placebo|No Description for the intervention
46054503|NCT02784249|Device|Trabecular Micro-Bypass Stent|Procedure: Trabecular Micro-Bypass stent implantation in combination with planned cataract extraction via Phaco and PCIOL implant.
46054504|NCT02784249|Procedure|Cataract Extraction|Cataract extraction via Phaco and PCIOL implant.
46054505|NCT04908462|Drug|AL01211 or Placebo (Part A)|Five dose groups with doses ranging from 2mg to 60 mg
45378101|NCT05888181|Other|Mobile app-based self-management intervention|"The self-management program, accessible via a smartphone app, comprises several components. First, the app contains an RA-specific educational program presented as videos in 16 weekly modules. Second, the app provides patients with tailored lifestyle advice, both as part of the educational program and in the form of personalized messages from a certified health coach. Third, the study app includes remote monitoring features underpinned by goal-setting principles. For instance, participants can use the app to log daily steps and physical activity, as well as their diet, sleep, and mental health. Personal goals, as well as physical challenges and meditation or mindfulness exercises, can be set up within the app to encourage behavioral change.~Finally, patient-reported disease burden can be monitored within the study app via the RAID instrument. Based on random allocation to one of both intervention groups, the RAID will be prompted either weekly (group A) or monthly (group B)."
45493926|NCT02328352|Procedure|control group|observational intervention in 5 rabbits with the same body weight and the same age will be observed and will be feeded in the same way of the BP device intraperitoneal implanted group
46054506|NCT04908462|Drug|AL01211 or Placebo (Part B)|Five dose groups with doses ranging from 2-60 mg daily. Each separate dose given for 14 days
45493927|NCT02030860|Drug|Paricalcitol|Dose: 25 micrograms Route: IV Frequency (within a 28 day cycle):Three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days) (for subjects randomized to receive paricalcitol), then three times weekly for 3 cycles post-operatively (for all subjects).
45493928|NCT02030860|Drug|Abraxane|Dose: 125mg/m2 Route: IV infusion over 30 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
45493929|NCT02030860|Drug|Gemcitabine|Dose: 1000mg/m2 Route: IV infusion over 30-100 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
45493930|NCT03290781|Drug|Ontamalimab|Participants will receive 1 milliliter (mL) of ontamalimab sterile aqueous buffered solution at an appropriate oncentration to provide an intended dose of drug (25 or 75 mg).
45493931|NCT03290781|Other|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
45493932|NCT01569984|Radiation|Stereotactic body radiotherapy|Avastin 7.5 mg/kg IV x 2 doses 14 days apart
45493933|NCT02328118|Drug|Ranibizumab|A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
45493934|NCT02328118|Drug|Triamcinolone Acetonide|A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetone group will receive Triamcinolone Acetone 4mg/0.1 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
45493935|NCT03466073|Drug|Recombinant Human Plasma Gelsolin|Recombinant human plasma gelsolin lyophilized for reconstitution, reconstituted in sterile water
45493936|NCT03466073|Other|Normal Saline Placebo|Normal saline in volume equivalent to drug
45493937|NCT02602314|Drug|Imatinib|
45493938|NCT02602314|Drug|Nilotinib|
45493939|NCT03412019|Other|Music|Selections of Mozart piano sonatas
45493940|NCT05079880|Drug|300 mg of caffeine citrate infusion|At the end of the surgery, the study drug was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period
45493941|NCT05079880|Drug|Placebo|At the end of the surgery, the placebo was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period
45493942|NCT05021146|Other|usual care and topical essential copaiba oil|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).
45493943|NCT05021146|Other|usual care and placebo treatment|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).
46054507|NCT04218006|Genetic|Mutation Analysis|Specific members of nuclear and extended family relatives will be contacted to propose genetic counseling. Approvals for genetic testing will be asked and necessary information forms will be provided. A total of 5 ml of blood will be collected from each patient for DNA analysis. Blood samples will be analyzed at the Damagen Genetic Diagnosis Center (Ankara), after which no samples will be stored and all samples will be destroyed.
45493944|NCT05021146|Other|usual care|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay.
45493945|NCT03714035|Other|no intervention|no intervention
45493946|NCT05018338|Device|Brain shift monitoring|For use to monitor brain shift during craniotomy
45493947|NCT03716765|Dietary Supplement|locally injected vitamin D|locally injected vitamin d as non surgical method for periodontal regeneration of vertical bony defects
46054508|NCT02850510|Behavioral|Brief Incredible Years parent training|The IY parent training programme (3-8 years) developed by Webster-Stratton at the Parenting Clinic, University of Washington, is a manualised and video-based training programme for parents of young children with conduct problems (Webster-Stratton and Reid, 2003a). Parents assigned to the short IY Basic (S-IY) condition were divided into groups of 10-12 parents. The S-IY was led by two experienced group leaders and parents met weekly for two-hour sessions at a public health care center in the community. The group leaders led discussions regarding central aspects of parenting on the basis of the video vignettes, role play and homework.
46054509|NCT02845050|Drug|Vinflunine|"One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy"
45493948|NCT03716687|Device|Prophylactic negative pressure wound dressing after laparotomy|Five days of -90 Hgmm continuous negative pressure wound dressing left on primary closed laparotomy wound.
45493949|NCT03687060|Behavioral|Knowledge assessment|Investigators will conduct semi-structured interviews with medical directors, clinical leadership and all participating physicians to gain insight on knowledge about and barriers to prescribing statins for people living with HIV. People living with HIV will participate in focus groups.
45493950|NCT03687060|Behavioral|Education Intervention|"Education intervention will be adapted from the the findings of these interviews and focus groups.~Clinics will be randomized to receive the education intervention and feedback implementation strategies at different times.~Medical directors and providers will receive a brief educational intervention about cardiovascular disease risk in people living with HIV. Providers will additionally receive a web-based survey before and after the education intervention.~Patients will receive pamphlets tailored to the effects of cardiovascular disease treatment for people living with HIV."
45493951|NCT03687060|Behavioral|Provider Feedback|Six months after the education intervention, providers will receive monthly emails with feedback regarding their rates of prescribing statins, with language targeted at increasing motivation to prescribe by leveraging social norms and self-image.
45493952|NCT05017324|Device|WGS DST strategy|WGS DST strategy for diagnosing the TB drug resistance profile and an algorithm-determined individualised RR-TB treatment recommendation
45493953|NCT01311323|Procedure|PCI|Percutaneous Coronary Intervention with contemporary drug eluting stent, fractional flow reserve or iFR measurement and optimisation with intravascular imaging
45493954|NCT01311323|Procedure|CABG|Coronary Artery Bypass Graft
45493955|NCT05079646|Other|class 1 and class 2 cavity preparation and restored with contemporary materials|class 1 and class 2 cavities prepared in extracted teeth after endodontic procedure and then these cavities were filled with new contemporary core buildup materials.
45493956|NCT03070002|Biological|Denosumab|Given SC
45493957|NCT03070002|Other|Laboratory Biomarker Analysis|Correlative studies
45493958|NCT02327728|Procedure|Botulinum toxin A injection (5 sites: 12.5U)|
45493959|NCT02327728|Procedure|Botulinum toxin A injection (4 sites: 10U)|
45493960|NCT02327728|Drug|Botulinum toxin A 12.5U|
45493961|NCT02327728|Drug|Botulinum toxin A 10U|
45493962|NCT03142672|Procedure|pulpotomy|vital endodontic procedure
45493963|NCT03142672|Procedure|tooth filling|tooth filling
45493964|NCT02918318|Drug|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
45493965|NCT02918318|Drug|Intranasal esketamine (28 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
45493966|NCT02918318|Drug|Intranasal esketamine (56 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
45493967|NCT02918318|Drug|Intranasal esketamine (84 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
45378102|NCT05888168|Procedure|CABG|All participants in the study will undergo the standard procedure of CABG. Continuous electrocardiogram monitoring and electrocardiography were used to identify the cardiac rhythm.
45378103|NCT05888142|Behavioral|in clinic pain VR reduction exercises|"During the first two weeks of treatment, participants will use commercially available VR during in clinic VR physical therapy exercises, to help reduce their pain and improve functionality."
45378104|NCT05888142|Behavioral|In clinic VRpain reduction exercises + VR homeworks|"During the first two weeks of treatment, participants will use commercially available VR during in clinic physical therapy exercises, and during homeworks to help reduce their pain and improve functionality."
45493968|NCT03713957|Drug|GRF6021|GRF6021 for IV infusion
45493969|NCT03713957|Other|Placebo|Placebo for IV infusion
45493970|NCT01374321|Drug|TRO40303|6 mg/kg, peripheral IV, single dose just before balloon inflation, slow bolus (35ml/min)
45493971|NCT01374321|Drug|Placebo|single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV)
45493972|NCT04960150|Device|Press tack needle|"Press tack needle acupuncture using Seirin Pyonex sized 0.20x1.2mm"
45493973|NCT04960150|Device|Plesterin|Plesterin
45493974|NCT02327806|Device|pulsed electromagnetic field therapy|
45493975|NCT04926454|Drug|Dexmedetomidine|"Patients will be monitored using standard monitoring (heart rate, non-invasive blood pressure, ECG and pulse oximetery) After the child is adequately anesthetized, intra-venous access with appropriate size cannula will be obtained Appropriate size LMA (2 and 2.5) will be inserted and patients will be allowed to breathe spontaneously.~patients will receive 0.25% Bupivacaine (0.3ml/Kg) with 1 μg/kg dexmedetomidine After general anaesthesia"
45493976|NCT03196167|Drug|Sugammadex|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
45493977|NCT03196167|Other|Placebo|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
45493978|NCT03652376|Drug|Benralizumab|Treatment with Benralizumab 30 mg s.c. every 4 weeks (three times)
45378105|NCT05888129|Procedure|surgery after neoadjuvant chemotherapy|surgery after neoadjuvant chemotherapy
45493979|NCT04875988|Procedure|Butterfly iQ+ Ultrasound|ultrasound will be used in the intervention group for IV access
45493980|NCT04875988|Procedure|Traditional|ultrasound will not be used in the traditional IV placement group
45493981|NCT03411863|Device|CES at rest|"CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits."
45493982|NCT03411863|Device|CES plus active hand or wrist movements|"CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
45493983|NCT04262726|Behavioral|REMOTION|REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and monitoring/modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as an add-on to treatment as usual (TAU), which is psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
45493984|NCT04262726|Behavioral|TAU|Treatment as usual (TAU) refers to psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern. Psychotherapy at the outpatient clinic is based on Psychological Therapy (Grawe, 1998) principles, which are largely rooted in academic psychology and which mainly draw on interventions from Cognitive Behavior Therapy. Individual case conceptualization are key in Psychological Therapy, along with general therapeutic factors and a focus on the therapeutic relationship.
45378106|NCT05888103|Drug|Inclisiran|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran*) in 1.5 mL
45378107|NCT05888103|Drug|Matching Placebo for Inclisiran|Matching s.c. placebo in 1.5 mL
45493985|NCT05200143|Drug|Ipilimumab|Ipilimumab is a fully human IgG1 kappa monoclonal antibody that binds the co-inhibitory receptor CTLA-4. Antibody binding prevents interaction with the CTLA-4 ligands CD80 and CD86. Blockade of CTLA-4 results in increased T cell activation and proliferation. Ipilimumab was the first immune checkpoint inhibitor to receive FDA approval as a cancer therapy. Treatment of patients with advanced metastatic melanoma with ipilimumab monotherapy resulted in improved overall survival. Subsequent clinical trials with ipilimumab alone and in combination with anti-PD-1 antibodies have demonstrated impressive clinical activity in patients with melanoma, renal cell carcinoma, non-small cell lung cancer and other cancers. Side effects of ipilimumab result from autoimmune attack on healthy tissues. Side effects may include dermatitis, colitis, hepatitis, hypophysitis, pneumonitis, endocrinopathies, nephritis, arthritis, neuropathies and others.
45693615|NCT04382560|Other|Deep Breathing training|The intervention will comprise a psychoeducational part on the theorethical background underlying this technique and a pratical session in which partecipant will be instructed to inhale air with his/her nose and exhale with his/her mouth for a period of 3 seconds of inhalation and 7 seconds of exhalation (i.e., 6 cycles of breaths per minute;). During the session, the participant will be encouraged to put one hand over his/her chest and the other over the abdomen in order to see the difference between normal breathing and deep breathing. To help the subjects in the training, an online pacer will give the rhythm of respiration and will be used as visual feedback.
46054510|NCT02845050|Drug|Cisplatin|"One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy"
46054511|NCT02845050|Procedure|Radical cystectomy|max. 4 weeks after 4 cycles of neo-adjuvant treatment radical cystectomy will be performed
46054512|NCT02690922|Drug|Dasatinib|100mg (d1-d84)
46054513|NCT02690922|Drug|prednisone|60mg/m2 d1-24
46054514|NCT02690922|Drug|dexamethasone|10mg/d 3-7days
46054515|NCT02690922|Drug|methotrexate|3g/m2 1day
46054516|NCT04636944|Other|web-based COMPASS intervention|COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). COMPASS is tailored to gain an understanding of the difficulties that LTC patients experience and provide information and tools on how to manage these. This qualitative study will explore participants' perspectives on using COMPASS for managing depression and anxiety in heart failure.
45378108|NCT05888090|Other|Positioning (Prone, right lateral and semi-raised supine position)|One of the developmental care practices applied to preterm newborns is positioning. It is one of the important nursing interventions for nurses to position newborns in the most appropriate position according to their condition (Sajadi et al., 2019). There are studies expressing that positioning affects gastric residual volume and feeding tolerance in preterm newborns. However, the results differ from one study to another (Yayan et al., 2018). No study has been found to evaluate the effects of body position on abdominal oxygenation in preterm neonates.
45378109|NCT05888077|Other|ESWL_LL|Extracorporeal shock wave lithotripsy using latest lithotripter and laser lithotripsy for difficult Bile duct stones
45493986|NCT05200143|Drug|Nivolumab|Nivolumab is a fully human IgG4 kappa monoclonal antibody that binds the co-inhibitory receptor PD-1. Nivolumab binding to PD-1 blocks interaction with the PD-1 ligands PD-L1 and PD-L2. PD-1 blockade can lead to reinvigoration of exhausted T cells and prevent T cell exhaustion of newly activated T cells. Nivolumab has been shown to have excellent clinical efficacy in treating a wide range of cancers as monotherapy and in combination with ipilimumab.
45378110|NCT05888064|Diagnostic Test|diffusion MRI sequences|Diffusion MRI sequences will be optimized to derive more accurate estimates of microstructure and microvasculature of tumour and healthy organs: multiple b-values will be acquired and advanced diffusivity models considered. MRI sequences to derive tumour hypoxia (i.e. indicative of radioresistance) will be also considered along with MR spectroscopy to evaluate tumour microenvironment.
45378111|NCT05888038|Device|virtual reality|virtual reality
45378112|NCT05888025|Behavioral|Telephone-Delivered Mindfulness-based Cognitive Therapy (MBCT-T)|MBCT-T will be delivered in groups of four to eight subjects by telephone using a conference line with NYULH WebEx. Participants will receive a workbook containing session content and home practice logs and audio guides for home practice. Subjects will complete individual orientation sessions with the MBCT-T facilitator prior to start of the group sessions. The four subsequent weekly group sessions are approximately 90 minutes long. Participants will be encouraged to practice daily meditation in between group sessions for 20-30 minutes, six days per week
45378113|NCT05888012|Device|basket catheter|Stone extraction is completed with either a basket or balloon catheter at the time of ERCP. The basket catheter is made of nickel-titanium wires which can be manipulated to trap and withdraw stones.
45378114|NCT05888012|Device|balloon catheter|Stone extraction is completed with either a basket or balloon catheter at the time of ERCP. The balloon catheter is made of latex, which is inflated after passing the stone, thus pushing the stone outwards.
45378115|NCT05887999|Drug|LY3532226|Administered subcutaneously (SC).
45753976|NCT04022642|Other|High-Intensity Interval Training|"The program will be applied in the first 10-15 minutes of each PE class, twice a week, including a brief warm-up, ranged from 14 to 20 intervals, adopting a 2:1 work to rest ratio (ie, 30-s work, followed by 30-s rest)~A cut-point of >=90% of maximal heart rate was used as our criterion for satisfactory compliance to high-intensity exercise~In order to estimate effort, fatigue and training load, a subjective effort scale will be used throughout each session. The heart rate will be monitored throughout the session in real time through Bluetooth technology.~Actigraph accelerometers (wGT3X-BT), randomly distributed by the students in each session, will be used to characterize the intensity of the sessions."
45378116|NCT05887999|Drug|Placebo|Administered SC.
45378117|NCT05887986|Other|hand-held fan airflow stimulation|"Outcome dyspnea measures:~After the fan training application given to the hand-held fan airflow stimulation group by the researchers, the hand fan application will be made for 5 days. On the baseline, day 3, and day 5 of the study, the dyspnea level will be evaluated.~Outcome comfort measures:~After the fan training application given to the hand-held fan airflow stimulation group by the researchers, the hand fan application will be made for 5 days. On the baseline, day 3, and day 5 of the study, the comfort level of the patients will be evaluated."
45378118|NCT05887973|Behavioral|The T.R.I.G.G.E.R Project|"The T.R.I.G.G.E.R Project includes the following core components to address root causes of gun violence:~Summer Employment~Social and Emotional Learning~Future Orientation~Adult and Peer Support~Critical Consciousness~Civic Efficacy and Engagement"
45378119|NCT05887960|Other|CBC and flow cytometry test for monocyte|all groups assigned Cbc with leukocyte differential and flow cytometry for monocyte population
45378120|NCT05887947|Other|Electronic Cigarette Nicotine Concentration Order 1.8% 5% 1.8%|"At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
45493987|NCT05200143|Drug|Cabozantinib|Cabozantinib is a potent small molecule inhibitor of multiple receptor tyrosine kinases. Cabozantinib inhibits VEGFR2, MER, KIT, and MET at single digit nanomolar IC50 concentrations. Other kinases including ROS1, RET, FLT3, RON, AXL, and TIE2 are also inhibited with nanomolar concentrations of cabozantinib. Cabozantinib has been shown to have clinical activity in a variety of solid tumors and has been approved by the FDA for treatment of medullary thyroid cancer, renal cell carcinoma and hepatocellular carcinoma.
45493988|NCT03719027|Diagnostic Test|Study population|Dyspnea assessment (NYHA functional class) EKG Echocardiography
45493989|NCT04256876|Device|TTNS|See section 'arms' Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
45493990|NCT04256876|Device|TTNS Sham|See section 'arms'
46054517|NCT03890718|Procedure|Photorefractive keratectomy in mile keratoconus|Topo-guided photorefractive keratectomy will be performed using an excimer laser (Allegretto Wave Topolyzer, Alcon, Inc.) with a 6 mm optical area and a transition area of 2 mm in all eyes. At that point, the partial topography-guided photorefractive keratectomy laser treatment will be finished. The arrangement will be to treat 70% of the cylindrical and spherical part to not surpass 50μm of stromal expulsion. The estimation of 50μm as the most extreme removal depth recommended by Kanellopoulos in Athens protocol will be chosen
46054518|NCT00840034|Drug|LY2216684|Starting dose is 6 milligrams (mg), then titrate up to 9 mg, 12 mg, or 18 mg (3 tablets) administered orally (PO), once daily (QD) for up to 10 weeks followed by a 2 week taper.
46054519|NCT00840034|Drug|Placebo|3 tablets PO QD for up to 12 weeks
46054520|NCT02848950|Drug|Metformin|Supplementation of the study group with Metformin till the day of pregnancy confirmation
46054521|NCT00813904|Biological|rThrombin, 1000 IU/mL|At least 1 application of reconstituted rThrombin, 1000 IU/mL, applied topically directly to the bleeding site, per product labeling.
45378121|NCT05887947|Other|Electronic Cigarette Nicotine Concentration Order 1.8% 5% 5%|"At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
45378122|NCT05887947|Other|Electronic Cigarette Nicotine Concentration Order 5% 1.8% 1.8%|"At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
45378123|NCT05887947|Other|Electronic Cigarette Nicotine Concentration Order 5% 1.8% 5%|"At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
45378124|NCT05887934|Device|X-Ray Fluorescence Analyzer|The XRF analyzer (the ThermoFisher Niton XL3t GOLDD+) is a portable x-ray fluorescent analyzer specifically configured to measure low levels of metals, lead in particular, in bone. The device is designed to rapidly assess cumulative lead exposure, not to support or sustain human life.
45378125|NCT05887921|Procedure|Inguinal Lymphadenectomy|arm A: open lymphadenectomy performed by a surgical team with extensive experience in traditional surgery arm B: laparoscopic lymphadenectomy performed by a surgical team with extensive experience in minimally invasive surgery
45378126|NCT05887908|Drug|co-administration of cefepime and nacubactam|2 g cefepime and 1 g nacubactam
45378127|NCT05887908|Drug|co-administration of aztreonam and nacubactam|2 g aztreonama and 1 g nacubactam
45378128|NCT05887908|Drug|imipenem/cilastatin|1 g imipenem/1 g cilastatin
45378129|NCT05887895|Drug|INS062 injection、INS068 injection、HR20014 injection|"INS062 injection：A single dose of 0.4 DU/kg is administered to healthy subjects.~INS068 injection：A single dose of 0.4 U/kg is administered to healthy subjects.~HR20014 injection：A single dose of 0.4 U/kg is administered to healthy subjects."
45378130|NCT05887882|Biological|Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells|The TGFβi NK cell product will be manufactured in the Cell Therapy Laboratory at Nationwide Children's Hospital and given via infusion.
45378131|NCT05887882|Procedure|Implantation|Undergo placement of Ommaya reservoir
45378132|NCT05887869|Behavioral|Telehealth solution|Telehealth solution offered for nutrition education and breastfeeding support.
45378133|NCT05887778|Drug|Sodium Chloride 0.9% Inj|administration of 5ml 0,9% sodium chloride - 30 minutes before the supraclavicular brachial plexus block
45378134|NCT05887778|Drug|0,1mg/kg Dexamethasone|administration of 0,1mg/kg Dexamethasone - 30 minutes before the supraclavicular brachial plexus block
45378135|NCT05887778|Drug|0,2mg/kg Dexamethasone|administration of 0,2mg/kg Dexamethasone - 30 minutes before the supraclavicular brachial plexus block
45378136|NCT05887765|Drug|Sodium Chloride 0.9% Inj|administration of 5ml 0,9% sodium chloride - 30 minutes before the popliteal nerve block
45378137|NCT05887765|Drug|0,1mg/kg Dexamethasone|administration of 0,1mg/kg Dexamethasone - 30 minutes before the popliteal nerve block
46054522|NCT04202406|Drug|Acetaminophen and codeine and caffeine|The patient will receive pretreatment oral single dose of Combination of 1000mg acetaminophen- 16mg codeine- 60mg caffeine 1 hour before treatment.
46054523|NCT04202406|Drug|Acetaminophen|The patient will receive pretreatment oral single dose of 1000mg acetaminophen alone 1 hour before treatment.
46054524|NCT04202406|Drug|Placebo|The patient will receive placebo (starch) 1hour before treatment.
46054525|NCT02846766|Drug|Lenvatinib|Lenvatinib is administered orally at a starting dose of 24 mg per day. Lenvatinib is administered in cycles of 28 days.
46054526|NCT00839956|Drug|Bortezomib|Given IV
46054527|NCT00839956|Drug|Vorinostat|Given PO
46054528|NCT04905732|Device|NHFOV|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NHFOV
46054529|NCT04905732|Device|NCPAP|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NCPAP
46054530|NCT04545528|Behavioral|Dietary recommendations|The test group will be seen by a nutritionist and will receive specific dietary recommendations according to their specific comorbidities and drugs
45493991|NCT04808284|Device|Transcranial direct-current stimulation|A single tDCS session will be delivered to the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be used, with one electrode (anode) placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region, according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
45493992|NCT04808284|Device|Transcranial direct-current stimulation|A single tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed over F3 (anode) and F4 (cathode), according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
45493993|NCT04808284|Device|Sham Transcranial direct-current stimulation|A single Sham-tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) or over the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). A pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed according to the International 10-20 EEG system. For SMA , one electrode (anode) will be placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region. For DLPFC, electrodes will be placed over F3 (anode) and F4 (cathode). Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 seconds current intensity will be ramp down for 15 seconds.
45378138|NCT05887765|Drug|0,2mg/kg Dexamethasone|administration of 0,2mg/kg Dexamethasone - 30 minutes before the popliteal nerve block
45493994|NCT05197803|Device|Hearing aid model|Amplification
45493995|NCT04054700|Device|distal upper rehabilitation robot|Intervention with distal upper rehabilitation robot
45493996|NCT04054700|Device|proximal upper rehabilitation robot|Intervention with proximal upper rehabilitation robot
45493997|NCT05387044|Radiation|SBRT|Patients with oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors will be treated with SBRT for all progressing lesions.
45493998|NCT03142828|Drug|Chlorhexidine|Healing abutment with Clorhexidine
45493999|NCT03142828|Other|Placebo|Healing abutment without any antiseptic
45494000|NCT01372839|Drug|Atorvastatin|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
45494001|NCT01372839|Drug|Statin|Usual care, but statin dose should not be higher than that described in exclusion criteria
45494002|NCT01065350|Drug|Propofol|As part of the induction, subjects will be given 2 milligrams per kilogram of body weight (mg/kg) of propofol. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL. The clinician and observer will be blinded to the medication and doses being administered during induction given that both syringes, syringes in the propofol and ketofol groups, will look identical (will both appear to be propofol only). The propofol group will also be given an additional 10 mL syringe of propofol due to any patient responding to stimulus after induction. The 10 mL syringe represents 1 mg/kg of propofol. If patient receives both the 20 and 10ml syringe, he or she will receive a total of 3mg/kg of propofol.
45494003|NCT01065350|Drug|Ketamine|As part of the induction, patients will be given 20ml syringe of ketofol which is weight based such that ketamine will represent 0.75mg/kg of the dose and propofol, 1.5mg/kg. The clinician and observer will be blinded to the medication and doses being administered during induction given that both 20ml syringes (propofol group and ketofol group) will look identical (will both appear to be propofol only). Additional 10ml syringe will be given due to any patient responding to stimulus after induction. The 10ml syringe will represent 0.25mg/kg of ketamine and 0.5mg/kg of propofol. If the patient receives both the 20 and 10ml rescue syringe, he or she will receive a total of 1mg/kg of ketamine and 2mg/kg of propofol.
45494004|NCT03434249|Dietary Supplement|Bifidobacterium, BB-12® (Bifidolactis Infant)|
45378139|NCT05887726|Drug|Zanubrutinib|Zanubrutinib 160mg bid p.o d0-d20(21-day cycles)
45494005|NCT03434249|Dietary Supplement|Bifidolactis Infant Placebo|
46054531|NCT02844738|Biological|[StroMed + platelet rich plasma (PRP)]|Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit and Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated as direct injections to the joint with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product. Day 0 [StroMed + platelet rich plasma (PRP)], Days 7 and 14 [PRP]
46054532|NCT02844426|Drug|bifid triple viable capsule and pectin|
46054533|NCT02844426|Drug|maltodextrin|
46054534|NCT04886388|Device|BT-001|BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.
46054535|NCT04886388|Other|Physician-guided Standard of Care for type 2 diabetes|Current ADA Standard of Care Guidelines for type 2 diabetes
46054536|NCT00839800|Drug|Symbicort Turbuhaler|160/4.5 µg
46054537|NCT00839800|Drug|Terbutaline Turbuhaler|0.4 mg
46054538|NCT00867321|Biological|bevacizumab|Given IV
45378140|NCT05887726|Drug|Rituximab|Rituximab 375 mg/m2 i.v d0(21-day cycles)
45378141|NCT05887726|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 i.v d1(21-day cycles)
45378142|NCT05887726|Drug|Epirubicin|Epirubicin 75 mg/m2 i.v d1 or liposome adriamycin 35mg/m2 i.v d1(21-day cycles)
45378143|NCT05887726|Drug|Vincristine|Vincristine 1.4 mg/m2 i.v d1 (2 mg max) (21-day cycles)
45378144|NCT05887726|Drug|Prednisone|Prednisone 100 mg p.o d1-d5 (21-day cycles)
45378145|NCT05887713|Device|Experimental: Alpha-Stim 100|Subjects in CES intervention group will run CES at home daily for 6 weeks. Study staff will call weekly to ensure adherence to CES treatment, gather CES usage data for the week and to answer any questions.
45378146|NCT05887713|Device|Sham Comparator|Subjects in CES sham group will run sham CES at home daily for 6 weeks. Study staff will call weekly to ensure adherence to sham CES treatment, gather sham CES usage data for the week and to answer any questions.
45494006|NCT03142906|Diagnostic Test|Scan|The preoperative point of care ultrasound includes a protocolized focused cardiac ultrasound, lung and pleural ultrasound and a gastric volume and content ultrasound assessment, all of which will be performed as an adjunct to the anesthesiologist's assessment. The result of this ultrasound examination will be disclosed to the anesthesiologist and patient care teams. Repeat ultrasounds may be done as the patient's clinical condition changes, or as requested by the anesthesiologist or patient care team.
45494007|NCT03033693|Other|Bispectral index will be targeted at 50|The depth of general anesthesia will be monitored by bispectral index (BIS) at 50.
45494008|NCT03033693|Other|Bispectral index will be targeted at 35|The depth of general anesthesia will be monitored by bispectral index (BIS) at 35.
45494009|NCT05079490|Behavioral|motor intervention|gross motor skill intervention combined with fitness training
45494010|NCT02914977|Drug|Daunorubicin|"Agent: Daunorubicin~Dose: 6.75 mg/m2/day~Route: IV~Schedule: Days 1-5~Duration: One cycle"
45494011|NCT03718715|Drug|Metformin|Receiving Metformin is no study intervention. The investigators have no influence on the Metformin treatment. All participants receive Metformin provided by the health care system. The individual case determine dose and frequency of the treatment as part of the usual therapy guidelines.
45378147|NCT05887700|Device|CeraFlex™ Atrial Septal Defect (ASD) Closure System|The CeraFlex™ ASD Occluder have two types of occluders, CeraFlex™ ASD Occluder and CeraFlex™ Multi-fenestrated (Cribriform) ASD Occluder. The CeraFlex™ ASD Occluder is percutaneous, transcatheter closure devices for the non-surgical closure of atrial septal defects.
45378148|NCT05887674|Behavioral|Diet intervention|Low inflammatory-index diet
45378149|NCT05887674|Behavioral|Exercise|Guided muscle strength training and stretching exercises
45378150|NCT05887674|Behavioral|Cognitive training|Cognitive training will be implemented in person
45378151|NCT05887661|Procedure|hypovolemic phlebotomy|hypovolemic phlebotomy was performed after induction of anesthesia and before the star of parenchymal division, with a goal-directed low central venous pressure drop to 5mmHg.
45494012|NCT05079100|Other|postpartum contraception method counselling|It will be face-to-face counseling with females about the use of postpartum contraception methods within 6 weeks postpartum.
46054539|NCT00867321|Drug|sorafenib tosylate|Given orally
46054540|NCT00753415|Biological|V935|A 0.5 mL vaccine administered IM every 2 weeks as either a LD (1 x 10^9 vector genomes/mL) or a HD (1 x 10^11 vector genomes/mL).
45494013|NCT05053347|Dietary Supplement|Flaxseed oil capsule|The participants were asked to take flaxseed oil capsule 5d/day(ALA 2.5g/d). The intervention period is about 6 months separated by a one-month washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
45494014|NCT05053347|Dietary Supplement|Corn oil capsule|The participants were asked to take corn oil capsule 5d/day. The intervention period is about 6 months separated by a one-month washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
45494015|NCT05079022|Drug|Furmonertinib|Furmonertinib at 80mg dose will be administered orally once daily.
46054541|NCT00753415|Biological|V934-EP|A 0.5 mL vaccine administered by EP as either a LD (0.5 mg plasmid/mL) or a HD (5.0 mg plasmid/mL).
46054542|NCT00913666|Drug|Interferon beta-1a (Avonex)|30 mcg by intramuscular injection once a week
46054543|NCT05194137|Other|a proprioception protocol associated with vaginal palpation and feedback|A total of 13 previously established examples of voice commands can be used by the physiotherapists to help women understand how to perform a PFM contraction.
45378152|NCT05887648|Behavioral|SinDance|"One face-to-face briefing session (20 min) will be offered to participants in the SinDance group as part of promoting physical activity and safe exercise for older adults.~Participants will be asked to engage in SinDance 3 times a week for 6 weeks. Each session will last for about 30-40 mins, including 5 mins warm up exercise before the game and 5 mins cool down exercise afterwards.~All the game play sessions will be conducted in LB centres. Each participant will play the game individually.~To play the game, participants will dance to the dance moves shown on the screen (on the external monitor or the projected screen) and as they get each move right, they will be awarded points. The more accurate their moves are, the more points they get in the game.~During the gameplay, the participants will be instructed to stop and rest if they are tired. A RN/RA will be on site to observe the safety of exergaming and to help resolve technical issues as they arise."
45494016|NCT05078788|Procedure|Laser uretherotomy|Holmium YAG Laser with pulse energy from 1-2 Joule, frequency from 10-15 Hertz and total power from 3.0 to 30.0 Watt were set up, respectively, based on the extent of the lesions. Scar tissue was incised at the position of 12-o'clock under the guidance of guidewire or ureteric catheter till fresh mucosa appeared.
45494017|NCT05078788|Procedure|Laser uretherotomy with triamcinolone|After laser urethrotomy, 80 mg of triamcinolone (diluted with normal saline to 10 ml) will be injected by using an injection needle (5 F size and 23 G needle size) at 10 sites, 1 ml each, along the site of urethrotomy and circumferentially.
45494018|NCT02032654|Drug|Flucloxacillin|
45378153|NCT05887635|Device|RF Vapor Ablation|RF Vapor ablation of the duodenum
45494019|NCT02032654|Drug|Placebo (for flucloxacillin)|Sugar capsule manufactured to mimic flucloxacillin 500mg capsules
45494020|NCT04750486|Device|Sequential compression devices|Two lower limb intermittent compression devices to be placed on the mid-calf of each leg.
45378154|NCT05887622|Dietary Supplement|Potassium chloride supplement|Subjects will receive 64 mmol of KCl on the high potassium/high sodium condition.
45378155|NCT05887622|Dietary Supplement|Placebo|Subjects will receive a placebo capsule on the moderate potassium/low sodium diet and the moderate potassium/high sodium diet
45847233|NCT05194410|Behavioral|First 3 months of virtual, team-based exercise|Participants will be randomized onto mixed teams of medical students, residents, fellows, and attendings and registered for the virtual, team-based exercise intervention on FitRankings.com. All exercise (including walking, biking, lifting, yoga, and 40+ exercises) will be tracked via user's smartwatches (ie Apple, Garmin), smartphone fitness apps (ie MapMyRun), or manual upload, converted into Metabolic Equivalent of a Task (MET) minutes, and displayed on online leaderboards. Group activities will be encouraged by awarding raffle tickets for prizes to those who submit pictures with their teammates.
45494021|NCT04737694|Dietary Supplement|Ketone ester|Oral ketone ester + glucose supplement
45378156|NCT05887609|Drug|Mirvetuximab Soravtansine|is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 [FOLR1] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridine-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB).
45378157|NCT05887609|Drug|Olaparib|Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair.
45378158|NCT05887050|Dietary Supplement|Active|Blend of chromium, amla fruit extract, and citrus bioflavonoids
45494022|NCT04737694|Dietary Supplement|Glucose|Glucose supplement
45494023|NCT04734886|Dietary Supplement|L. reuteri DSM 17938 + vitamin D|1 * 10^8 CFU of L. reuteri DSM 17938 + 10 ug vitamin D3, two capsules per day for 6 months
45494024|NCT04734886|Dietary Supplement|Placebo + vitamin D|Placebo tablet + 10 ug vitamin D3, Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
45378159|NCT05887050|Dietary Supplement|Placebo|Maltodextrin tablet
45378160|NCT05886985|Drug|MatriPlax|MatriPlax contains pcMSCs (placenta choriodecidual membrane-derived mesenchymal stem cells) and will be given intravenously on Day 1 and Day 4
45378161|NCT05886712|Other|Naloxone|Naloxone
45378162|NCT05886712|Other|Usual intervention|usual administered drug for overdose
45494025|NCT03142282|Drug|maintenance chemotherapy|National Comprehensive Cancer Network (NCCN) or European Society for Medical Oncology (ESMO) suggested maintenance chemotherapy regimens: xeloda, bevacizumab
45494026|NCT03142282|Radiation|Consolidative Radiotherapy|Stereotacticbodyradiationtherapy (SBRT) or intensity modulated radiation therapy (IMRT) for metastatic sites (less than 5)
45494027|NCT03114969|Device|Relvar ELLIPTA|ELLIPTA inhaler containing Relvar will be used by subjects as their maintenance treatment to control COPD.
45494028|NCT03114969|Device|Symbicort TURBUHALER|TURBUHALER inhaler containing Symbicort will be used by subjects as their maintenance treatment to control COPD.
45494029|NCT03114969|Device|Seretide DISKUS|DISKUS inhaler containing Seretide will be used by subjects as their maintenance treatment to control COPD.
45494030|NCT03114969|Device|Spiriva HANDIHALER|HANDIHALER inhaler containing Spiriva will be used by subjects as their maintenance treatment to control COPD.
45494031|NCT03114969|Device|BREEZHALER|BREEZHALER inhaler containing either Seebri or Ultibro will be used by subjects as their maintenance treatment to control COPD.
45494032|NCT03114969|Device|Incruse ELLIPTA|ELLIPTA inhaler containing Incruse will be used by subjects as their maintenance treatment to control COPD.
45847234|NCT05194410|Behavioral|Second 3 months of virtual, team-based exercise|Same as above
45378163|NCT05886283|Procedure|phacoemulsification|"we started with a clear corneal incision of 2.2 mm at 9 o'clock and a port incision of 1 at 2 o'clock. Continuous Circular Capsulorhexis of 6 mm was performed under the same ophthalmic viscosurgical device. A hydro dissection was performed, then followed by phacoemulsification.~the Nucleus has been treated using 2 different techniques After bimanual infusion/aspiration cortex removal and Visco expansion of the capsular bag, a hydrophobic single-piece: AcrySof acrylic IOL was implanted."
45378164|NCT05886283|Procedure|utrasound phacoemulsification|US group:The nucleus was held with the phaco tip at a high vacuum. The phaco choppe was drawn towards the phaco tip to cleave it by a manual separation between the two instruments. The fragments were then aspirated with phaco power. The standard parameters used during phacoemulsification were a vacuum level of 500 mmHg, pressurized irrigation of 90 mmHg, and 40% of phaco power
45378165|NCT05886283|Procedure|nanolaser phacoemulsification|Laser group: The nucleus was fragmented using the shockwaves emanating from the phaco tip and then aspirated. The phaco chopper was used to accelerate the mechanical fragmentation of the nucleus and minimize the dissipated energy.
45378166|NCT05885789|Procedure|Intubation in Bed-Up-Head-Elevated (BUHE) position|Comparing laryngoscopic view in paediatric patients during sniffing position and BUHE position
45378167|NCT05885581|Other|Arm A Grow Well|"the preliminary efficacy of the adapted intervention on mothers' and caregivers' infant feeding knowledge, use of recommended feeding practices, and infant anthropometric measurement outcomes.~the feasibility of implementing the intervention and its acceptability among mothers and caregivers.~the feasibility of collecting infant anthropometric data."
45378168|NCT05885581|Other|Arm B Healthy Steps|Group B: Healthy Steps and will receive the Healthy Steps curriculum or treatment as usual as this is the curriculum commonly shared during well baby visits (n= 15 mother-infant-caregiver triad).
45378169|NCT05885464|Biological|BEAM-201|A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens
45378170|NCT05884515|Diagnostic Test|SARS CoV-2 antigen tests|The intervention is to compare antigen tests
45378171|NCT05883774|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is applied using a transcranial magnetic stimulator with a figure-of-8 coil once per day for 10 consecutive days. rTMS is delivered to the right dorsolateral prefrontal cortex (DLPFC) at a frequency of 1 Hz for 20 minutes (1200 total pulses).
45494033|NCT03114969|Device|Anoro ELLIPTA|ELLIPTA inhaler containing Anoro will be used by subjects as their maintenance treatment to control COPD.
45494034|NCT05078710|Drug|Telitacicept|160mg once a week for 24 weeks
45494035|NCT05078632|Other|Montreal-Toulouse Test adapted in eye tracking|participant pass an eye tracking test to evaluate comprehension
45753977|NCT05621707|Drug|chemotherapy combined with PD-1 inhibitors|Induction chemotherapy combined with PD-1 inhibitors followed with standard concurrent chemoradiotherapy
45378172|NCT05883774|Device|Sham Repetitive Transcranial Magnetic Stimulation|Sham-rTMS is performed in the same way as the treatment group except that the coil is rotated 90° away from the scalp.
45378173|NCT05883072|Behavioral|Exploring AI-Chatbot|All participants will be provided access to AI-Chatbot and will be asked to enquire their daily life problems related to diabetes. They will also be asked to review the replies of the Chatbot after their interaction.
45378174|NCT05883007|Radiation|Accelerator-based BNCT with borofalan(10B)|Patients will be treated with BNCT regulated as 12, 15, or 18 Gy-Eq of the mucosal maximum dose.
45378175|NCT05882617|Other|implants supported overdentures|implant supported and retained with different number of implants retained by ball attachments
45378176|NCT05882253|Other|Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI)|An advanced imaging software that supports improved prostate cancer detection and diagnosis
45753978|NCT04022720|Procedure|Platelet Rich Fibrin Application|Platelet Rich Fibrin application at first post-op visit.
45753979|NCT04906057|Behavioral|Forced Aerobic Exercise (FE)|High-rate aerobic exercise on a semi-recumbent custom-designed stationary cycle ergometer
45753980|NCT04906057|Behavioral|Voluntary Aerobic Exercise (VE)|Voluntary-rate aerobic exercise on a semi-recumbent stationary cycle ergometer
45753981|NCT03832088|Diagnostic Test|Berg Balance Scale|Berg Balance Scale performed for balance disorder
45378177|NCT05882188|Procedure|Oil-based contrast|oil-based contrast fluid, Lipiodol Ultra Fluid. Lipiodol is a solution of iodinated ethyl esters of fatty acids of poppyseed oil. Equivalent to 480 mg iodine per ml. The maximum dosage is 15ml. Lipiodol is produced by Guerbet, France. Lipiodol is FDA approved and registered as contrast agent for HSG.
45494036|NCT05078398|Behavioral|POINT Protocol|Patients will receive counseling on risks and benefits of opioids for pain control, asked to choose whether they need opioid prescription when ready for discharge.
45494037|NCT05078398|Behavioral|Usual care|Will prescribe standardized amount of opioid for postoperative pain without patient input
45494038|NCT03144778|Biological|Durvalumab|Given IV
45494039|NCT03144778|Biological|Tremelimumab|Given IV
45494040|NCT02046096|Device|Günther Tulip® Vena Cava Filter|Temporary or permanent filter placement for the prevention of pulmonary embolism
45494041|NCT02046096|Device|Cook Celect® Vena Cava Filters|Temporary or permanent filter placement for the prevention of pulmonary embolism
45494042|NCT03142360|Drug|Beraprost sodium (Berasil)|Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
45494043|NCT05124678|Drug|Isoniazid Tablets|High dose of isoniazid
45494044|NCT04668820|Diagnostic Test|video Pediatric Gait, Arms, Legs and Spine (V-pGALS)|The Video-pGALS includes maneuvers from pediatric regional examination of the musculoskeletal system (pREMS) and derived from the pediatric gait arms legs spine examination assessment which is a validated simple basic musculoskeletal (MSK) examination for children. V-pGALS offers a structured approach to a cursory overview MSK exam with a focus on range of movement and symmetry. Utilizing the parent or caregiver to feel the joint in question for obvious warmth/ swelling or to palpate for point of maximal tenderness can add important information.
45494045|NCT03463577|Other|Safety assessment following routine immunization with Boostrix|Subject-level data was collected for pregnant women and their infants through the Electronic Health Records.
45494046|NCT04667884|Dietary Supplement|Prebiotics or Probiotics|All the supplements were provided in solid drinks，and required to drink with plain water 35-40℃, and lifestyle intervention was provided to all the groups by reading materials.
45494047|NCT05761002|Biological|the Quadrivalent Vaccine (Gardasil)|• Intralesional injection of the quadrivalent HPV vaccine (Gardasil) at a dose of 0.5ml, into the largest wart at 4-week intervals until complete clearance is achieved or for a maximum of three sessions.
45494048|NCT03424824|Drug|BP1.3656 low dose|Tablet, once daily oral administration at the low dose
45494049|NCT03424824|Drug|BP1.3656 intermediate dose|Tablet, once daily oral administration at the intermediate dose
45494050|NCT03424824|Drug|Placebo|Tablet, once daily oral administration
45378178|NCT05882188|Procedure|ExEm Foam|ExEm Foam which is created by mixing 5ml ExEm-gel and 5ml of purified water. ExEm-gel contains hydroxyethylcellulose and glycerol. The ExEm Foam is distributed by IQ Medical Ventures, the Netherlands. ExEm Foam is FDA approved, CE marked and registered as contrast agent for HyFoSy.
45378179|NCT05882149|Dietary Supplement|Single strain probiotic|"Sugar-free chewing gum with single strain probiotic and zinc.~The dosage will be 2 chewing a day, served at the same time and chewed for 6 minutes outside meals (for example 2h after breakfast or lunch)."
45494051|NCT03424824|Drug|BP1.3656 high dose|Tablet, once daily oral administration at the high dose
45494052|NCT04661956|Procedure|Transbronchial cryobiopsy/Transbronchial lung biopsy (forcep)|Transbronchial lung biopsy by cryoprobe or by forcep
45494053|NCT05060172|Device|Bloomlife MFM-Pro|"Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate, maternal heart rate, and uterine activity during antepartum (non-stress) testing on pregnant women with a singleton pregnancy.~The system acquires biopotential signals from abdominal surface electrodes and measures the fetal electrocardiography, maternal electrocardiography, electrohysterography, as well as accelerometer data."
45494054|NCT04983927|Device|cASPECTS|Clinical decision support system for scoring ASPECTS score
45494055|NCT01477008|Device|BiPhasic Cartilage Repair Implant|1 or 2 BiCRI devices, depending on lesion size
45494056|NCT01477008|Procedure|Marrow Stimulation|Microfracture or Subchondral Drilling
45494057|NCT01374399|Behavioral|exercise and relaxation|resistance and endurance exercise, 3-5 times per week
45494058|NCT04598386|Other|PR Lotion - AMP Human Performance|Sodium Bicarbonate Topical Solution. For use of the PR Lotion solution, consumers are instructed to apply the lotion to areas of the body that have been identified as most likely to use during their activity (i.e. calves and thighs for runners, shoulders and forearms for swimmers, etc.). Moreover, the product can be applied up to 2 hours prior to beginning a workout or event with one use supporting a 4-6 hour workout. AMP Human has also verified the safety of their product as being well tolerated in consumers >2 years of age unless there is a known allergy to an ingredient on the label. Moreover, to the company's knowledge no side effects have been reported per the SAFETY Section at https://amphuman.com/pages/faq.
45494059|NCT04598386|Other|Placebo Lotion|Placebo Topical Solution. Lotion will be created by the AMP Human Performance company and will include all ingredients similar to the PR Lotion product except for the exclusion of sodium bicarbonate.
45494060|NCT05056350|Other|Questionnaires|Quality of life questionnaires, work perception questionnaires, psychological distress questionnaire
45494061|NCT05056350|Other|back to work coaching|Back-to-work support program including an individual interview to identify patient needs and expectations, 7 coaching workshops (every 3 weeks +/- 15 days) and a final individual assessment post workshops
45753982|NCT03832088|Diagnostic Test|Timed Up and Go Test|Timed Up and Go Test for walking speed
45378180|NCT05882149|Dietary Supplement|Placebo|"Sugar-free chewing gum.~The dosage will be 2 chewing a day, served at the same time and chewed for 6 minutes outside meals (for example 2h after breakfast or lunch)."
45378181|NCT05881382|Drug|Dutogliptin + Filgrastim|dutogliptin twice daily subcutaneously for 14 days and filgrastim daily subcutaneously for 5 days.
45378182|NCT05881382|Drug|Placebo|Placebo dutogliptin twice daily subcutaneously for 14 days and placebo filgrastim daily subcutaneously for 5 days.
45494062|NCT02861820|Device|MRI: Brain Imaging Data Collection|This study has no intervention, it is observational. The investigator will collect brain imaging data and behavioral assessments.
45494063|NCT05761860|Drug|OxyCODONE 5 mg Oral Tablet|Oxycodone 5mg oral administration
45494064|NCT05761860|Drug|OxyCODONE 2.5 mg Oral Tablet|Oxycodone 2.5mg oral administration
45494065|NCT05761860|Other|Placebo oxyCODONE Oral Tablet|Oxycodone 0mg (placebo) oral administration
45494066|NCT05761860|Drug|Oxytocin Nasal Spray (48 IU)|Intranasal oxytocin administration (48 IU)
45378183|NCT05881291|Drug|ciprofol|"induction of anesthesia：group ciprofol received an IV injection of ciprofol at a dose of 0.2-0.4 mg/kg, and administration time of 30 s.When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia: group ciprofol received an IV infusion of ciprofol 0.8-2.4 mg·kg-1·h-1."
45378184|NCT05881291|Drug|propofol|"induction of anesthesia：group propofol received an IV injection of propofol at a dose of 1.0-2.0 mg/kg, and administration time of 30 s. When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia:group propofol received an IV infusion of propofol 4-6 mg·kg-1·h-1."
45494067|NCT05761860|Other|Placebo Oxytocin Nasal Spray|Intranasal oxytocin placebo administration
45494068|NCT03122145|Drug|Capsaicin|Participants will inspire deeply through the nebulizer coupled to the facemask and pneumotachograph. Each test inhalation will be separated by an interval of 2 minutes. This experimental trial consists of six (instead of 8) test solutions: 0, 25, 50, 100, 200 and 500 μM capsaicin in 80% physiological saline, 20% ethanol. Participants will inhale single vital capacity breaths of capsaicin solution via an air-powered dosimeter (KoKoDigidoser; Pulmonary Data Services Instrumentation Inc; Louisville, CO). The reflex cough test ends when the participant coughs at least 2 times in response to one inhalation dose, or receives a dose of the highest concentration (500 μM).
45494069|NCT03122145|Device|Videofluoroscopic swallow study|The swallowing systems core laboratory is fully equipped to perform videofluoroscopy with a c-arm (OEC 9900) that is dedicated solely to research purposes. Videofluoroscopy recordings will be kept to a minimum and turned on only during completion of a specific testing task. Video recording and images captured during the videofluoroscopy will be synced and saved for data analysis. Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic of the base of tongue, oropharynx, and hyolarynx complex during swallowing) to be analyzed cannot be visualized with any other technique. All swallowing tasks will be completed using barium in order to visualize the bolus during movement of various swallowing muscles and structures.
45494070|NCT05081830|Behavioral|Transdiagnostic online intervention|Based on the theoretical proposal of Barlow et al. (2011) a treatment applicable to all anxiety and mood disorders (unipolar depression) will be implemented. The unified protocol incorporates proven emotion-focused psychological techniques (Ellard et al., 2010). The main components are: (1) motivation for change, understanding emotions, and recognition and observation of emotional response; (2) learn to observe experiences, evaluate and reevaluate thoughts; (3) what is emotional avoidance, emotion and behavior, and awareness and tolerance of physical sensations; (4) emotional exposure to physical sensations and situations and achievements, maintenance and prevention of relapses.
45494071|NCT05081830|Behavioral|TCC online intervention|This program incorporates psychological techniques under the cognitive-behavioral model that have demonstrated their effectiveness in online mode (De la Rosa, 2019; Flores et al., 2014). The main components are: (1) psychoeducation, (2) cognitive restructuring, (3) identification and expression of emotions, (4) assertiveness training and (5) problem solving, and (6) relapse prevention. The order of application of each technique is established by the advisor derived from the formulation of treatment of each case to solve the problems raised, under supervision.
45494072|NCT05081674|Drug|Alectinib|600mg 1OD
45378185|NCT05879393|Dietary Supplement|OMNi-BiOTiC® Active|Multistrain probiotic
45494073|NCT05081674|Drug|Pembrolizumab|200mg every 21 days
45494074|NCT05081674|Drug|Nivolumab|6mg/kg every 4 weeks
45494075|NCT05081674|Drug|Erlotinib|150mg
45494076|NCT05150535|Radiation|Hypofractionation Radiotherapy.|Patients will receive 40 Gy in 15 fractions to the entire breast and or chest wall over the course of 3 weeks.
45494077|NCT05150535|Radiation|Ultra-hypofractionation radiotherapy|Patients will receive 26 Gy in 5 fractions to the entire breast and or chest wall over the course of one week.
45494078|NCT05037942|Other|Blood flow restriction at 40% limb occlusion pressure|A 13-cm-wide pneumatic cuff will be applied to the most proximal portion of the chosen thigh (as determined by randomisation), immediately distal to the inguinal fold, prior to a bout of lower-body resistance exercise. The cuff will be inflated to 40% of limb occlusion pressure pressure and will remain inflated throughout the exercise (total occlusion time: ~5 mins).
45378186|NCT05879393|Other|Placebo|rice starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate
45378187|NCT05879094|Other|Morton extension|A Morton extension with a height of 5 mm was insert from the proximal area of the first metatarsal head to the base of the proximal phalanx of the Hallux of the subjects' bare feet using a paper bandage. The material, shape, size, and thickness of the Morton Extension were the same.
45753983|NCT03832088|Diagnostic Test|Jamar hand dynamometer|Jamar hand dynamometer for grip strength which correlates with muscle strength of patient
45753984|NCT03832088|Diagnostic Test|Calf circumference|Calf circumference for muscle mass evaluation. Calf circumference is an anthropometric measurement which correlates with muscle mass.
45378188|NCT05876078|Device|Doraya catheter|Temporary deployment of the Doraya catheter in ADHF patients
45378189|NCT05875415|Other|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle in flatfoot
45494079|NCT05037942|Other|Blood flow restriction at 80% limb occlusion pressure|A 13-cm-wide pneumatic cuff will be applied to the most proximal portion of the chosen thigh (as determined by randomisation), immediately distal to the inguinal fold, prior to a bout of lower-body resistance exercise. The cuff will be inflated to 80% of limb occlusion pressure pressure and will remain inflated throughout the exercise (total occlusion time: ~5 mins).
45494080|NCT03140800|Device|intrauterine device|a method of contraception inserted in the uterus
45494081|NCT02327650|Procedure|The examinations for bones in joints of OA and RA patients|
45494082|NCT05003076|Drug|Methamphetamine|Participants will be given 20 mg of Methamphetamine.
45494083|NCT05003076|Drug|Placebo|Participants will be given a placebo capsule that will only contain lactose.
45494084|NCT03144856|Drug|Apatinib|Apatinib 500mg, po, qd, every 4 weeks.
45494085|NCT05002374|Other|Vestibular rehabilitation with optokinetic stimulation|Vestibular rehabilitation incorporated with optokinetic stimulation in virtual reality environment for five consecutive days
45494086|NCT05002374|Other|Vestibular rehabilitation|Customized vestibular rehabilitation for five consecutive days
45494087|NCT05081050|Other|Only Follow-up|No intervention is planned.
45494088|NCT04986930|Radiation|SBRT+mFOLFIRINOX|Stereotactic body radiotherapy: 3500 cGy (5 fractions) mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
45494089|NCT04986930|Drug|mFOLFIRINOX|mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
45378190|NCT05875415|Other|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle in flatfoot
45494090|NCT05080894|Device|Virtual reality|Embodiment of a healthy virtual body in virtual reality and action observation/motor imagery of the subject's virtual body performing high-level lower limb exercises.
45494091|NCT05762640|Drug|Ruxolitinib|"Form: tablets, 50 mg/m2/day in two administrations. Maximum dose is 100 mg/day. Administration in association with Methylprednisolone IV (or Prednisolone PO) starting at 2 mg/kg/day in two administrations.~Duration of treatment: until D-1 of conditioning for allogeneic HSCT OR 9weeks for patients who are not eligible for HSCT."
45494092|NCT03141970|Drug|Prednisolone|Prednisolone for 12 weeks as follows 30 mg/m2 on alternate days for 4 weeks 20 mg/m2 on alternate days for 4 weeks 10 mg/m2 on alternate days for 4 weeks
45494093|NCT04949022|Device|Medronic 780G insulin pump|Commercial hybrid closed loop system Medronic 780G
45494094|NCT05762562|Other|Telerehabilitation with open source platforms|"Telerehabilitation with opensource platforms. Patients enrolled were dived into three groups based on their score in SPPB. Each group corresponded to a Program (Pr): • Pr. A is for patients with capable motor skills, Pr. B is for patients with reduced motor skills, • Pr. C is for patients who didn't show having sufficient motor skills to support a TR program. Patients who were included in TrP.A and TrP.B underwent a TR program using OS platforms for 8 consecutive weeks. A specific exercise program for the parkinsonian patients was structured in relation to the individual residual motor skills based on the FITT - frequency/intensity/type/time - protocol.~Twice a week, the activity was performed with the support of a physiotherapist through OS TR platform.~Subjects included in TmP.C participated in an 8-weeks program. A video-call was scheduled once a week to monitor the patient's clinical condition without any exercise program."
45498192|NCT04108299|Behavioral|Wait-list control group|For patient participants, they will continue to receive the standard of usual care for their T2D at the CBWCHC during the course of our study. For family/friend participants, they will continue to receive their routine care with their own doctors during the study. At the end of the study, the wait-list control group (both patient and family/friend participants) will be provided the opportunity to receive the counseling videos delivered to them via SMS links.
45378191|NCT05875116|Behavioral|Virtual reality|The activities will be carried out with the Virtual Reality team, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, on similar equipment and with the same or similar software, at least 1 hour a day, at least 3 days a week.
45494095|NCT04457752|Biological|Dual Layer Amniotic Membrane (DLAM). Artacent®|"Artacent® is a double layer of dehydrated amniotic membrane. The amnion is harvested from human placenta obtained during planned Caesarean sections. Tides Medical uses a proprietary process to clean and decellularize the amniotic membrane. The amnion is then folded into a bi-layer with the stromal sides facing outward. The dual layer is dried and cut into various sizes. In the final step the DLAM is terminally sterilized.~Atracent®, like all other placental-derived products, is FDA cleared for homologous use through the 361 pathway. It is indicated for non-healing ulcers applied to a debrided, clean and uninfected ulcers."
45494096|NCT02327338|Device|thermacare heat wraps|off the shelf thermacare continuous heat wraps made by thermacare to produce low level heat on the neck
45378192|NCT05875116|Behavioral|Modified constraint-induced movement therapy|"Physical and occupational therapy activities will be carried out with the paretic upper limb, while the patient has the healthy upper limb attached to the chest, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, 1 hour a day, at least 3 days a week. In addition, the participant will perform activities of daily living with the free paretic arm and the fixed healthy arm, for 5 hours a day."
45378193|NCT05875116|Behavioral|Usual Physical and Occupational Therapy|The physical and occupational therapy activities that are usually practiced in the Medical Unit will be carried out for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, for 1 hour a day, at least 3 days a week.
45378194|NCT05874414|Drug|GNS561 + Trametinib|GNS561: 50mg, 100mg, 150mg, 200mg and trametinib: 1mg, 1.5mg and 2mg
45494097|NCT02327338|Drug|Ibuprofen|1200 mg ibuprofen administered 400mg at 4 hour intervals
45494098|NCT05080816|Dietary Supplement|Parenteral nutrition (PN)|Overnight infusion of parenteral nutrition. Supplied as all-in-one-bag format. Infusion rate of 0.2 g N/kg/day.
45494099|NCT05080816|Dietary Supplement|Enteral nutrition|Oral nutrition drink. 2 * 200 ml on the night before operation. 1* 200 ml on the morning of operation day.
45494100|NCT05080816|Other|Control|Overnight infusion of crystalloid fluid (Ringer acetate) infused at the same rate (ml/kg) as intervention PN
45494101|NCT02327416|Drug|Y peginterferon alfa-2b|In arm 2 and 3, Y peginterferon alfa-2b is used for 96 weeks
45494102|NCT02327416|Drug|Granulocyte-macrophage colony stimulating factor|In arm 3, Granulocyte-macrophage colony stimulating factor is used for 48 weeks intermittently
45494103|NCT02327416|Drug|Entecavir and or adefovir dipivoxil|In arm 1, Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir and or adefovir dipivoxil are used for 48 weeks.
45378195|NCT05874297|Other|Best Practice|Receive standard of care
45378196|NCT05874297|Behavioral|Internet-Based Intervention|Access to enhanced Cook for your life website
45378197|NCT05874297|Other|Questionnaire Administration|Ancillary studies
45494104|NCT05080582|Behavioral|Mother-Scented Simulated Hand|Preterm neonates wrapped with a warm Mother-Scented Simulated Hand during the invasive procedures
45494105|NCT05080582|Behavioral|NICU Standard Care|Neonates were placed in a side-lying position, while their extremities were flexed close to the body and wrapped with rolled sheets or towels to simulate the intrauterine posture.
45753985|NCT04765904|Procedure|SDF|1)Dry with cotton to affected tooth surfaces 2) Apply the SDF material 3)Dry with a gentle flow of compressed air for at least one minute. and Remove excess SDF with gauze
45753986|NCT04765904|Procedure|Hall technique|Orthodontic separator being stretched between two pieces of floss, then placed between the contact points of primary molars (for five days.) 2)The correct size of crown will not impinge on the teeth on either side, and a slight 'spring back' will be felt when the PMC is gently pushed up
45378198|NCT05873179|Other|role-playing for learning the clinical interview|role-playing for learning the clinical interview
45494106|NCT05230576|Diagnostic Test|Deep learning training cohort|train the deep learning model
45494107|NCT05230576|Diagnostic Test|Deep learning validation cohort|evaluate the model
45378199|NCT05868265|Drug|Enfortumab Vedotin|All patients will receive enfortumab vedotin at 1.25 mg/kg on days 1 and 8 of 21 days cycle, for a total of three cycles.
45378200|NCT05868265|Procedure|Radical surgery|Radical surgery, such as radical nephroureterectomy, nephrectomy or ureterectomy is to take place within 60 days from the last dose of treatment end of cycle 3 (i.e., cycle 3 day 22).
45378201|NCT05866601|Other|Role-playing for learning the clinical interview|"Thirty-one first-year physiotherapy students will carry out the role-playing methodology to learn how to take a clinical history in physiotherapy.~Before and after the realization, they will be measured by means of a validated questionnaire in Spanish, the language in which they study, the variable of empathy and anxiety."
45494108|NCT05077072|Other|Best Practice|Receive SOC
45494109|NCT05077072|Other|Counseling|Participate in CHAT counseling intervention
45494110|NCT05077072|Procedure|Electroencephalography|Undergo EEG
45494111|NCT05077072|Behavioral|Neurofeedback|Undergo NFB intervention
45494112|NCT05077072|Other|Questionnaire Administration|Ancillary studies
45494113|NCT03114657|Drug|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
45378202|NCT05866419|Device|ThecaFlex DRx System|The ThecaFlex DRx™ System consists of an implantable intrathecal catheter, and an implantable subcutaneous port, designed specifically to meet the implantation, Cerebrospinal Fluid (CSF) aspiration, and intrathecal delivery and dosing needs of patients (aged ≥ 3 years) requiring repeated/on-going intermittent chronic bolus intrathecal treatment for life threatening, debilitating Central Nervous System (CNS) disorders who are precluded from Lumbar Puncture (LP) due to complex spine conditions, or who are resistant to LP for therapy administration or CSF aspiration.
45494114|NCT03114657|Drug|Placebo|Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
45494115|NCT05071456|Other|Collects of skin's hydration|Collects of skin's hydration will be made by using patch using electrochemistry.
45494116|NCT02926950|Drug|Sotagliflozin (SAR439954)|Pharmaceutical form: tablet. Route of administration: oral.
45494117|NCT02926950|Drug|Placebo|Pharmaceutical form: tablet. Route of administration: oral.
45494118|NCT02926950|Drug|Metformin|Pharmaceutical form: tablet. Route of administration: oral.
45494119|NCT03410693|Drug|Rogaratinib (BAY1163877)|Rogaratinib administered as oral (p.o.) tablets twice daily (b.i.d.) continuously
45494120|NCT03410693|Drug|Chemotherapy|Chemotherapy as taxane (docetaxel or paclitaxel) or vinflunine administered through intravenous (i.v.) infusion every 3 weeks (on day 1 of a 21-day cycle) The choice of the chemotherapy is at the discretion of the investigator, taking into consideration the status of the authorization or treatment guidelines in the given country.
45494121|NCT02039752|Other|Treatment|
45494122|NCT05203198|Behavioral|Competent Adulthood Transition with Cognitive-Behavioral, Humanistic and Interpersonal Training|Self-directed, technology-based, depression prevention program for adolescents and parents.
45494123|NCT01064414|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
45494124|NCT01064414|Drug|Placebo|One matching placebo capsule orally once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
45494125|NCT04255810|Procedure|Surgical collection of biospecimens|Systemic blood and implant capsule tissue will be collected from two cohorts with breast implants, systemic blood only will be collected from Mastopexy cohort
45494126|NCT04254172|Device|Activity Monitor|Wrist and ankle sensors to be worn continuously for 2-week intervals.
45494127|NCT01859130|Device|Zimmer Persona Total Knee System|
45494128|NCT04944849|Diagnostic Test|Reaction Time Tests|While doing our research, the reaction time test in the Human Benchmark application, where the reaction time to many different stimuli on the computer can be evaluated, the Aim Trainer test and the auditory reaction time tests at https://playback.fm/audio-reaction-time will be applied.
45753987|NCT00565045|Device|Neuromuscular electrical stimulator|"Intervention Characteristics Common to Both Groups~• 6-week intervention~Home exercise, daily~Exercise (at home) 2 sessions/day~A session consists of 3 (for CCFES) or 4 (for cNMES) 15-min sets separated by 5 min rest~A set entails hand opening, closing, and relaxing in response or synchrony to light and sound cues and according to group-specific instructions~Lab therapy, 2x/week~Two 1.5-hr sessions/week, working on functional hand tasks and tracking task (if possible)."
45494129|NCT03433703|Drug|Lenvatinib|"Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles.~Body weight (BW) ≥60 kilograms (kg) - Lenvatinib 12 mg (taken as three 4-mg capsules); BW <60 kg - Lenvatinib 8 mg (taken as two 4-mg capsules)"
45378203|NCT05860231|Device|Foley catheter|"Silicone Foley catheters are transurethral balloon catheters used for the treatment of bladder emptying disorders, as well as for drainage of urine from the urinary tract, continuous fluid irrigation, and/or medication administration. Its use is suitable for a prolonged period of no more than 29 days and is used in Urology, Internal Medicine, Surgery, Obstetrics and Gynaecology Services.~For this study, conventional Foley-type catheters whose use is approved in Spain for routine use will be used. Silicone Foley catheters, usually available in 2- and 3-way, are made of silicone and consist of a body, drainage funnel, inflation funnel, irrigation funnel (if present, only on 3-way catheters) and balloon valve. The product is sterile and single use."
45494130|NCT03652766|Behavioral|Daily Weight Tracking|Daily weight tracking + weekly email or text message feedback
45494131|NCT05202600|Procedure|Appendectomy|Surgical removal of the vermiform appendix.
45378204|NCT05860231|Device|T-Control catheter|The T-control® catheter is a flexible, sterile silicone tube with an inflatable balloon at the distal tip, a polytetrafluroethylene membrane integrated into its body, and a sliding fluid control valve. The valve, built into the catheter, provides additional functions to the catheter, such as turning urine flow on and off after insertion (functions currently provided by accessories such as caps or valves) and controlling urination during the insertion process (function that is not provided by any other device). In this way, accidental loss of urine can be avoided from the first moment of use until its withdrawal. Additionally, it has a safety cap that reduces the possibility of accidental movements of the valve before use or during transport and fixing. The design has been developed in such a way that, once inserted, it facilitates autonomous use even for the elderly or patients with limited manual dexterity. The device is sterile and single use, like any conventional Foley catheter.
45378205|NCT05858463|Other|Modality of exercise training|muscle adaptations following intermittent high intensity interval exercise training and continuous low intensity exercise training
45378206|NCT05857345|Other|Collection of breastmilk|Collection of breastmilk and other information about the participant
45494132|NCT04904601|Dietary Supplement|Kale supplement|Kale (blanched freeze-dried Kale) group1
45494133|NCT04904601|Dietary Supplement|Peas supplement|placebo (Blanched Freeze-dried Peas) group2
45378207|NCT05855863|Drug|Ginkgo Ketone Ester Tablets|Ginkgo Ketone Ester Tablets (Styron), taken orally, 3 times a day, 0.25g each time, continuously administered for 6 months
45378208|NCT05855863|Drug|Placebo|placebo，taken orally, 3 times a day, 0.25g each time, continuously administered for 6 months
45494134|NCT03653078|Device|Three dimensional printed digital guide|A CAD/CAM printed plate with a channel for mini-screw insertion
45494135|NCT03713723|Device|NICaS bioimpedance system|NICaS is a bioimpedance system focusing on noninvasive assessment and monitoring of cardiovascular, respiratory, and fluid parameters.Cardiovascular monitoring will be carried out using non-invasive NICAS cardiac impedance cardiography by the use of two electrodes stickers which are pasted on the wrists for 6 minutes
45494136|NCT05202444|Procedure|Osteotomy using piezoelectrical device|"osteotomy were utilized using piezoelectric from device (Woodpeker) with its internal irrigation system. We used US2 tip using the maximum bone cutting program and maximum irrigation program for lateral maxillary wall osteotomy and USIR tip for the posterior maxillary wall osteotomy.~The pterygoid osteotome was placed between the tuberosity and pterygoid plates while the hamulus is palpated palatally with the index finger to guide the osteotome direction preventing palatal perforation.With the pterygoid osteotome still in position, we used a thin osteotome to complete the osteotomy of the posterior wall of the maxilla."
45494137|NCT01374633|Drug|1: Sevoflurane|"Mean sevoflurane infusion rate will be around 6 ml/h or 72 ml for 12 hours. Maximal infusion rate will be around 12 ml/h, or 144 ml for 12 hours. Packaging: bottle containing 250 ml of liquid sevoflurane for evaporation. Administration mode: anaesthetic conserving device for volatile anaesthetics."
45494138|NCT03652922|Drug|Reactivation Mismatch|"Ninety minutes prior to each of six weekly traumatic memory reactivation sessions, the subject will be given 0.67 mg/kg of short-acting propranolol (or placebo), rounded up to the nearest 10 mg (minimum 40 mg) and 1 mg/kg of oral long-acting propranolol or placebo (minimum 60 mg). rounded so as to achieve a dose of 60, 80, 120, or 160 mg. The subject will then read a narrative of their personal traumatic event aloud. During each weekly reading, a simple, different mismatch condition will be created by having the subject do such things as whisper the narrative, skip over every word that contains the letter e, pronounce the narrative in a different accent, or alter the tense and/or person of the narrative."
45494139|NCT03713567|Behavioral|Experimentally induced plaque|Experimentally induced plaque by suspension of oral hygiene only in the tested areas (tooth / implant), protected by a personalized stent made of plastic, according to the experimental gingivitis and mucositis model of 21 days of duration
45494140|NCT01178814|Drug|Revlimid (Lenalidomide)|The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.
45494141|NCT04053920|Behavioral|Low Load Resistance exercise|leg extension, leg press, leg curl and calf press
45494142|NCT04053920|Behavioral|High Load Resistance exercise|leg extension, leg press, leg curl and calf press
45494143|NCT03713489|Procedure|platelet|Participants in platelet transfusion group will receive one unit of apheresis platelets transfusion 3 times for the first week after enrollment, then 2 times a week in the following three weeks.
45494144|NCT04053686|Behavioral|Breaks|3-min breaks every half hour at work
45494145|NCT05202288|Biological|Ervebo|Administration of r-VSV-ZEBOV vaccine
45378209|NCT05855447|Other|NIRS device usage during 6MWT|It will be performed by placing a traffic cone as the sign of the turning point in a straight 30 meter long corridor, after patients have rested for a sufficient time (> 30 minutes) by sitting in a chair. Participants will be asked to walk as fast as possible but without running along the corridor within 6 minutes. Before and after the test, the patient's fatigue and dyspnea conditions will be questioned using the Modified Borg Scale and blood pressure using a digital sphygmomanometer, and saturation and pulse measurement will be evaluated using finger pulse oximetry before, during and after the test. During the 6-minute walk test, the muscle oxygenation of the patients and the amount of muscle oxygen will be measured using Moxy (Fortiori Design LLC, Minnesota, USA) brand NIRS technology. During the walking test, the change in intramuscular oxygenation will be monitored and recorded with the company's software program.
45494146|NCT05202288|Drug|Inmazeb|Administration of Inmazeb
45494147|NCT03652298|Other|Memory structuring intervention + Vagal breathing|"The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).~In the MSI part, the patient will talk, and the therapist will note the different event parts and their real timing. Each time the patient says a feeling or sensation, the therapist will ask to verbally elaborate and provide the cause of these feelings and sensations. Then, the therapist will retell the story in a chronological manner, with verbal titles and causes for feelings and sensations. Finally, the patient will be asked to retell the story in this structured manner, after being explained how to do so.~vagal breathing (i.e., deep, paced breathing) is a way to increase HRV, and thus parasympathetic activation"
45847235|NCT05130294|Dietary Supplement|CARDIO®|"CARDIO® is manufactured according to Good Manufacturing Practices for food facilities complying with the Hazard Analysis and Critical Control Points (HACCP) principles.~The product is intended for use in manufacturing of human food products and human consumption, including food supplements, and have been Generally Recognized as Safe (self-affirmed GRAS). The fresh unrefined salmon oil is produced by Hofseth Biocare ASA"
45847236|NCT05130294|Dietary Supplement|Placebo|MCT oil
45378210|NCT05855447|Other|Peripheral Muscle Strength Measurement|The muscle strength of shoulder flexors, abductors, elbow flexors, hip flexors, abductors, and knee extensors will be evaluated using a Lafayette® 01165 model electronic hand dynamometer. The force measurement will be repeated 3 times and it will be requested to maintain muscle strength against the dynamometer for at least 5 seconds in each trial. The best value out of 3 test results will be recorded
45378211|NCT05855447|Other|Pulmonary Function Test|Pulmonary Function Test (PFT) with desktop type spirometry for FVC (Forced Vital Capacity), Forced expiratory flow rate (FEV1), FEV1/FVC.
45378212|NCT05854472|Other|smartphone based application use|A smartphone application content will be developed to facilitate the use of immunosuppressive drugs by individuals with liver transplantation and to provide guidance to patients. The effect of smartphone application usage on immunosuppressive drug compliance, anxiety and quality of life in liver transplant patients will be evaluated.
45494148|NCT03652298|Other|support and attention (usual care)|support and attention (usual care)
45494149|NCT03463031|Drug|GSP 301 NS|1 spray in each nostril twice daily for 14 days
45494150|NCT03463031|Drug|GSP 301 Placebo NS|1 spray in each nostril twice daily for 14 days
45494151|NCT04054388|Behavioral|LINE re-education|
45494152|NCT05202132|Diagnostic Test|Questionnaire|A 3 item validated questionnaire assessing masticatory function
45494153|NCT05202132|Diagnostic Test|Chewing gum test|The test is based on the ability of a subject of mixing a two colour chewing gum with 20 masticatory cycles. Mixing of the two colour chewing gum will be assessed as variance of hue in a scanned image of the flattened chewing gum. The method has been validated in independent studies.
45494154|NCT03652688|Behavioral|Three 0's|A group approach to reducing unwanted outcomes was implemented prior to entering the nightclub. The focus was on peer-to-peer intervention.
45494155|NCT03652688|Behavioral|Fire Safety|Groups were asked to read information about fire safety prior to entering the club and to answer some questions about fire safety
45494156|NCT05762484|Procedure|Nd:YAG laser hair removal|Using the Nd:YAG laser (cynergy), hair of the axillae will be removed.
45494157|NCT05762484|Drug|Clindamycin 1 % Topical Lotion|Clindamycin 1% lotion if needed
45494158|NCT03462641|Drug|Flumazenil|1mg in 10cc normal saline
45378213|NCT05851677|Drug|Disitamab vedotin|recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks
45494159|NCT03462641|Drug|Placebo|10 cc normal saline
45494160|NCT04150796|Procedure|Ventral Hernia Repair|Participants will undergo robotic ventral hernia repair according to the assigned treatment arm.
45494161|NCT05206968|Radiation|pelvic radiograph|Patients with hip involvement underwent a pelvic radiograph
45378214|NCT05849753|Device|Advanced artificial pancreas closed-loop technology|Study is an observational capture of data in patients that qualify, before and after the use of any FDA-approved closed-loop system of Subject's/Family's choosing that uses a CGM that does not require fingerprick calibrations. Devices prescribed available through their insurance (including Medicaid).
45378215|NCT05848817|Device|Contoura LASIK|Subjects receiving Phorcides Planned Contoura LASIK
45378216|NCT05846230|Drug|BI 1291583|Tablet
45494162|NCT04858074|Drug|Hypoestoxide|Its active pharmaceutical ingredient (API) is Hypoestoxide, discovered in 1983, which was recently shown to be active against alpha synuclein and was very effective in modifying disease progression in a transgenic mouse model of PD
45494163|NCT04856202|Behavioral|Advance Care Planning interview|The facilitator will clarify the patients' preferences, asking specific questions regarding personal goals, including religious and cultural beliefs. The facilitator will discuss life supporting treatments that might be applicable to the patient and encourage the patient to weigh up personal benefits and burdens. Treatments may include: invasive therapy (such as chemotherapy or dialysis), hospitalization, resuscitation, ventilation, artificial nutrition or hydration and administration of antibiotics. The patient will also be encouraged to identify specific situations that are likely to improve or diminish his or her quality of life. The facilitator will assist the patient in documenting their wishes, including the assignment of a health care proxy.
45494164|NCT02974634|Other|Ostomy self management training|Ostomy Self management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
45494165|NCT04814316|Diagnostic Test|Blood and urine specimens|Blood and urine samples will be taken at baseline and at the end of the second month. For this purpose, 5 ml of blood samples will be taken to plain blood tubes for evaluation of calcium, magnesium, alkaline phosphatase, parathormone, 25-OH vitamin D and osteocalcin quantities. And 3 ml of urine for calcium, creatinine, deoxypyridinoline, C-terminal telopeptides type-1 collagen and N- terminal telopeptides type-1 collagen.
45494166|NCT04113122|Diagnostic Test|Skin biopsy|A 4 mm skin biopsy will be performed at the upper leg of the patient. Before the skin biopsy local anesthesia is applied subcutaneously. In these skin biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels in the skin biopsies.
45378217|NCT05846230|Drug|Placebo matching BI 1291583|Tablet
45494167|NCT04113122|Diagnostic Test|Subcutaneous fat biopsy|"An abdominal subcutaneous fat biopsy will be performed 7-10 cm on the right side of the umbilicus. Before the fat biopsy local anesthesia is applied subcutaneously. An amount of 30 mg fat tissue will be collected using needle aspiration.~In these fat biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels (ICP-MS), adipocytokines (leptin, adiponectin, interleukin-6, PAI-1, TNF-α), p53 activation indirectly by measuring p21 or mdm2 expression using immunohistochemistry, microRNA regulation of insulin signaling in adipose tissue: miR-103, miR-107, miR-29."
45494168|NCT05201352|Drug|trifluridine/tipiracil + XB2001|trifluridine/tipiracil every 28 days + XB2001 1000mg intravenous infusion every 2 weeks
45378218|NCT05845931|Dietary Supplement|Berberine|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 11 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine concentrations. (Women will undergo the Intervention twice, once in the 1st half and once in the 2nd half of their menstrual cycle.) In addition urine will be collected over the time of 0-10 h after berberine intake and body composition will be measured by bioelectrical impedance analysis (BIA).
45494169|NCT05201352|Drug|trifluridine/tipiracil + placebo|trifluridine/tipiracil every 28 days + Placebo intravenous infusion every 2 weeks
45693616|NCT04382560|Other|Compassion focused intervention|"The short compassion focused intervention will begin with a short psychoeducation on the evolved nature and difficulties of the human mind, such as tendencies for negativity bias, negative rumination, and self-criticism. Participants will then be offered insights into how humans can work with their 'tricky brains' using body-based and psychological-based practices aimed at increasing a grounding and soothing compassionate attitude towards ourselves and others. In particular, participants will be instructed to pratice a mindfulness technique designed to help them to become more aware of their present moment-to-moment and more compassionate towards their own emotions. They will then be guided to create an image conveying warmth and compassion to them. Lastly, participants will be guided to bring the image to mind and then write write a brief self-compassionate letter to themselves from that point of view."
45378219|NCT05843708|Drug|Vorasidenib 40 mg Oral Tablet|"Single oral dose of 1×40 mg vorasidenib tablet administered :~under fasted conditions (all subjects will fast overnight for at least 10 hours prior to dosing and for at least 4 hours after dosing.~or following a low fat meal (approximatively 400 to 500 calories) (Substudy A)"
45378220|NCT05843708|Drug|Ciprofloxacin 500 mg Oral Tablet|Twice daily (morning and evening) oral doses of ciprofloxacin 1×500 mg tablet on Days 1 through 14 (Substudy B)
45378221|NCT05843708|Drug|Vorasidenib 10 mg Oral Tablet|Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1 (Substudy B)
45378222|NCT05841563|Drug|PM54|"PM54 powder for concentrate for solution for infusion (3 mg/vial) is a sterile, preservative-free, lyophilized white to yellowish cake in a single-dose vial for reconstitution prior to intravenous infusion. Each vial contains 3 mg PM54.~Route of administration: Intravenous infusion"
45378223|NCT05841030|Other|No Intervention|There is no interventional treatment administered to the participants as a part of this study.
45494170|NCT04804332|Procedure|Operative hysteroscopy|Operative hysteroscopy is performed without or under local, regional or general anesthesia according to the local protocol preferably within 2 to 3 weeks after randomization. In case of highly vascularized RPOC, a repeat sonogram is performed 2 to 4 weeks after randomization to check for persistence of vascularity and to optimize operative timing. Operative hysteroscopy is then performed within 2 to 3 weeks after the repeat sonogram. Removal of the RPOC is performed by an experienced gynecologist using hysteroscopic morcellation (TruClearTM Hysteroscopic Tissue Removal System (Medtronic, Minneapolis, MN, USA)) and according to the local protocol.
45378224|NCT05840991|Device|elastic bandage|3M™ Coban™ elastic bandage
45378225|NCT05840991|Device|compression stocking|Class 2 compression full-length stocking (23-32mm Hg)
45378226|NCT05840224|Biological|GS-4528|Administered intravenously
45494171|NCT04804332|Other|Expectant management|No treatment will be offered. Patients will be given telephone numbers to contact a doctor. In case of severe complaints, defined as heavy uterine bleeding and/or severe abdominal pain, not responding to conservative treatment, an emergency curettage or operative hysteroscopy may be performed.
45494172|NCT04788576|Diagnostic Test|Invasive physiologic evaluation (fractional flow reserve, coronary flow reserve, index of microcirculatory resistance)|In case of heart failure with preserved ejection fraction confirmed by HFA-PEFF scoring system without functionally significant coronary artery disease, coronary angiography with invasive physiologic evaluation including fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance will be performed to evaluate the distribution and clinical implication of coronary microvascular dysfunction.
45494173|NCT04737876|Biological|BX002-A|bacteriophage cocktail
45494174|NCT04737876|Other|Placebo|Placebo
45378227|NCT05840224|Drug|Zimberelimab|Administered intravenously.
45494175|NCT04128956|Drug|Aspirin 100mg|Aspirin® cardio (CH) or Aspirin® protect (DE, AT) Film coated tablets Acetylsalicylic acid 100 mg Once daily oral intake for 6 months
45494176|NCT05206578|Drug|AGT2, AGZ|Tablet, q.d.
45494177|NCT05206578|Drug|AGT2|Tablet, q.d.
45494178|NCT05206578|Drug|AGT4, AGZ|Tablet, q.d.
45494179|NCT05206578|Drug|AGT4|Tablet, q.d.
45494180|NCT03651908|Procedure|Conventional Flap Surgery|"After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back.~After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back."
45847237|NCT05028426|Procedure|Enhanced recovery program|Enhanced recovery programs are a multimodal approach to optimize patients' physiological and psychological states in the preoperative, intraoperative and postoperative care domains.
45378228|NCT05839431|Behavioral|Virtual Reality for Youth Phobias|The intervention will consist of up to 10, 50-minute-long weekly in-person individual sessions of virtual reality-assisted exposure therapy. This intervention also includes psychoeducation about anxiety/phobias and their maintenance, youth strategies for tolerating distress, and parent strategies for reducing accommodation of anxiety.
45378229|NCT05839145|Other|Strength force measurment|The grip and pinch strength of the patient will be evaluate using dedicated devices (MyoGrip and MyoPinch)
45847238|NCT05023278|Drug|Venlafaxine 37.5 MG|venlafaxine 37.5mg daily for 7 consecutive days.
45378230|NCT05839145|Other|Time tests|Lower and upper limb capacities of the patients will be measured during timed tests
45378231|NCT05839145|Other|Motor scales|Patient's motor functional abilities will be evaluated using specific motor scales (MFM32, RULM)
45378232|NCT05839145|Other|Questionnaires|Patients and caregivers quality of life will be measured with different questionnaires (SMA-FRS, QOL-gNMD, SMAIS, PREM)
45378233|NCT05839145|Device|Accelerometry|Patients physical activity will be measured at home using accelerometer sensors
45378234|NCT05839145|Other|MNR|Sub-group of patients will perform an NMR imaging to evaluate the intramuscular fatty infiltration in thighs and muscle volume in thighs
45494181|NCT05206032|Other|Raman spectroscopy|Blood (serum or plasma) will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
45494182|NCT05201274|Behavioral|Baduanjin sequential therapy|"A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003."
45494183|NCT05201274|Behavioral|Aerobic exercise|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located at home or cardiac rehabilitation centre lasting 3 months. The program is consistent with the current recommended guidelines of moderate-intensity exercises for MI.
45847239|NCT05023278|Drug|Placebo|placebo filled pill daily for 7 consecutive days.
45847240|NCT05021172|Other|Best Practice|Receive usual care
45378235|NCT05839145|Other|Bio-impedance analysis|The patients' muscular and fatty volume will be evaluated using BIA technic (compared to MNR)
45378236|NCT05837910|Dietary Supplement|Calm Active Study Product 1.1 Usage|Participants will use their Radicle Calm Active Study Product 1.1 as directed for a period of 6 weeks.
45378237|NCT05837910|Dietary Supplement|Calm Active Study Product 1.2 Usage|Participants will use their Radicle Calm Active Study Product 1.2 as directed for a period of 6 weeks.
45494184|NCT03629496|Other|Arts-based intervention|6x1 hourly facilitated art sessions during haemodialysis. Participants will be provided with an option of visual art or creative writing, the artistic materials used will include graphite pencils, colouring pencils, water colour paints and graphic pens. Participants will be provided with their own art supplies for infection control purposes. During each session participants will be allowed to self-select a subject matter or be provided with binary prompts to facilitate decision making. Participants will also have an option of displaying completed work in the reception area of the unit during their haemodialysis sessions.
45378238|NCT05837910|Dietary Supplement|Calm Active Study Product 1.3 Usage|Participants will use their Radicle Calm Active Study Product 1.3 as directed for a period of 6 weeks.
45378239|NCT05837910|Dietary Supplement|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
45378240|NCT05837910|Dietary Supplement|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
45378241|NCT05837910|Dietary Supplement|Calm Active Study Product 2.1 Usage|Participants will use their Radicle Calm Active Study Product 2.1 as directed for a period of 6 weeks.
45378242|NCT05836844|Device|The Anchorsure System®|Sacrospinous ligament fixation performed with the Anchorsure Device
45378243|NCT05836584|Biological|Atezolizumab|Given IV
45494185|NCT05762406|Device|Respiratory protective mask|"Subjects will perform a cardiopulmonary exercise test (CPET) and a series of standardized daily activities while wearing a protective mask.~During the exercises, oxygen consumption, ventilation and other cardiorespiratory parameters will be assessed using a portable device (K5, Cosmed)"
45494186|NCT05761704|Drug|Dual antiplatelet|Aspirin 100 mg + clopidogrel 75 mg for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
45378244|NCT05836584|Procedure|Biospecimen Collection|Undergo collection of blood samples
45378245|NCT05836584|Drug|Capecitabine|Given PO
45378246|NCT05836584|Procedure|Computed Tomography|Undergo CT or PET/CT
45378247|NCT05836584|Drug|Docetaxel|Given IV
45378248|NCT05836584|Procedure|Echocardiography|Undergo ECHO
45378249|NCT05836584|Drug|Fluorouracil|Given IV
45378250|NCT05836584|Drug|Leucovorin Calcium|Given IV
45494187|NCT05761704|Drug|Novel oral anticoagulant|Conventional dose NOAC for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
45494188|NCT05205798|Behavioral|Food consumption using plates with a diameter of 23 cm.|In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 23 cm.
45494189|NCT05205798|Behavioral|Washout period|No interventional food consumption for 1 week
45847241|NCT05021172|Other|Informational Intervention|Receive Passport to Health booklet
45378251|NCT05836584|Procedure|Lymphadenectomy|Undergo lymphadenectomy
45378252|NCT05836584|Procedure|Magnetic Resonance Imaging|Undergo MRI
45378253|NCT05836584|Drug|Oxaliplatin|Given IV
45847242|NCT05021172|Other|Questionnaire Administration|Complete ePrognosis
45847243|NCT05021172|Other|Survey Administration|Ancillary studies
46054544|NCT05194137|Other|a proprioception protocol associated with biofeedback|The software has five different interfaces for visualize PFM contraction: sign itself and signal transformed into the movement of a balloon; an airplane; a fairy; or a bird. Positive reinforcements will be verbalized after each PFM contraction using one of 4 previously established examples of voice commands.
46054545|NCT05756764|Drug|Liraglutide or Semaglutide|Medication for reducing obesity
46054546|NCT05756764|Drug|Phentermine-Topiramate combination|Medication for reducing obesity
45378254|NCT05836584|Procedure|Positron Emission Tomography|Undergo PET/CT
45378255|NCT05836584|Procedure|Surgical Procedure|Undergo surgery
45378256|NCT05836142|Procedure|progressive pressure release|Bilateral progressive pressure release in latent trigger points of the Flexor digitorum Brevis Muscle
45378257|NCT05835843|Other|In-Person and Remote Disease Assessment|Disease severity will be assessed during the in-person visit and standardized digital photographs of different body regions and/or the full body will be collected for remote evaluations by external dermatologists.
45378258|NCT05833035|Drug|BI 1291583 mixed with [C-14] BI 1291583|BI 1291583 mixed with [C-14] BI 1291583
45378259|NCT05829694|Other|Parental Status|The aim of the study is to assess the impact parenthood has on health outcomes.
45378260|NCT05820139|Procedure|Control Group|Patients will be randomized to a 200mL (control group)
45378261|NCT05820139|Procedure|Test Group|Patients will be randomized to a cut-off of 150mL (test group)
45378264|NCT05816759|Drug|CKD-383|QD, PO
45378265|NCT05816759|Drug|CKD-501, D744, D150|QD, PO
45378266|NCT05814822|Behavioral|Cognitive Behavioral Therapy for insomnia (CBTi-CB-TM)|Participants randomized to CBTi-CB-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn cognitive and behavioral strategies for insomnia.
45378267|NCT05814822|Behavioral|Sleep Hygiene Education (SHE-TM)|Participants randomized to SHE-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn sleep hygiene and educational strategies for insomnia.
45378268|NCT05810038|Drug|Rimegepant|Rimegepant
45378269|NCT05810038|Drug|Placebo|matching placebo
45378270|NCT05805826|Biological|C. difficile vaccine (previously studied formulation)|Toxoid based Clostridioides difficile vaccine (previously studied formulation) given as an intramuscular injection
45378271|NCT05805826|Biological|C. difficile vaccine formulation 1|C. difficile vaccine formulation 1 given as an intramuscular injection
45378272|NCT05805826|Biological|C. difficile vaccine formulation 2|C. difficile vaccine formulation 2 given as an intramuscular injection
45378273|NCT05805826|Biological|C. difficile vaccine formulation 3|C. difficile vaccine formulation 3 given as an intramuscular injection
45378274|NCT05805826|Other|Saline Placebo|0.9% sodium chloride solution given as an intramuscular injection
45378275|NCT05802693|Drug|Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection|Infusion of Epidermal Growth Factor Receptor Variant III Chimeric antigen receptor T(EGFRvIII CAR-T) with Omaya capsule
45378276|NCT05802004|Device|Acoustic Stimulation (STIM)|During the in-lab overnight, the Dreem 2 Headband will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power). Tones are phase-locked to the up-phase of the delta wave. Tone delivery is paused when an arousal is detected.
45378277|NCT05802004|Device|No Acoustic Stimulation (SHAM)|During the in-lab overnight, the participant will wear the Dreem 2 Headband, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
45378278|NCT05802004|Device|Daily acoustic stimulation (STIM2)|During the ~2 weeks at home, the Dreem 2 Headband will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power). Tones are phase-locked to the up-phase of the delta wave. Tone delivery is paused when an arousal is detected.
45378279|NCT05802004|Device|No daily acoustic stimulation (SHAM2)|During the ~2 weeks at home, the participant will wear the Dreem 2 Headband, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
45378280|NCT05798520|Drug|BIIB091|Administered as specified in the treatment arm.
45378281|NCT05798520|Drug|DRF|Administered as specified in the treatment arm.
45378282|NCT05798520|Drug|Placebo|Administered as specified in the treatment arm.
45378283|NCT05798104|Behavioral|Collaborative nurse-pharmacist counseling|At the interventional appointment, study participants will first complete a modified Okere-Reiner pre-survey assessing patient perceptions of confidence and knowledge in their biologic therapy. Subsequently, a pharmacist will perform a refresher medication counseling, detailing indication, dosing, storage, and side effects. Upon completion of this counseling, an infusion nurse will then provide education demonstrating proper self-administration to the patient. The patient will then self-administer the medication with coaching and direct observation from the nurse. Afterwards, the patient will complete the Okere-Reiner post-survey to determine the effectiveness of the counseling session at improving perceived confidence and knowledge. Patients will complete both the pre-and post-surveys with direct entry to REDCap on an institution iPad during the study intervention visit.
45378284|NCT05796388|Device|Virtual Reality|Both groups will receive standard of care linaclotide 290 mcg.
45378285|NCT05796297|Device|Transcutaneous Capnography|Transcutaneous Capnography will be realized at patient home to monitoring nocturnal concentration of carbon dioxide during nocturnal sleeping ventilation
45378286|NCT05794906|Drug|Darolutamide (BAY1841788, Nubeqa)|Coated tablet, 300 mg / tablet, oral.
45378287|NCT05794906|Other|Placebo matching darolutamide|Coated tablet, oral
45378288|NCT05794906|Other|ADT|Luteinizing hormone-releasing hormone [LHRH] agonist/antagonists
45494190|NCT05205798|Behavioral|Food consumption using plates with a diameter of 31 cm.|In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 31 cm.
45378289|NCT05790590|Diagnostic Test|Double low dose CT|Simultaneous reduction of both radiation dose and contrast media dose
45378290|NCT05790590|Diagnostic Test|Standard dose CT|CT with standard radiation dose and contrast media dose
45378291|NCT05789329|Behavioral|Trauma Informed Guilt Reduction Therapy|behavioral intervention aimed to reduce trauma-related guilt and shame
45378292|NCT05789329|Behavioral|Cognitive Processing Therapy|behavioral intervention aimed at reducing PTSD symptoms
45378293|NCT05785832|Device|t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM|The t:slim X2 insulin pump with Control-IQ technology 1.5 is derived from the commercially available t:slim X2 with Control-IQ, with additional features. It will be used with the Dexcom G6 CGM.
45494191|NCT01060670|Device|Integra® Dermal Regeneration Template|Application of Integra® Dermal Regeneration Template in diabetic foot ulcer
45494192|NCT01060670|Other|Conventional Wound Therapy|Conventional Wound Therapy
45494193|NCT05205642|Device|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise testing (CPET) using a Quark CPET metabolic cart (Rome, Italy) according to American Thoracic Society (ATS) guidelines. A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute) adapted to the patient's functional capacities according to the examiner's free judgment, up to exhaustion.
45494194|NCT05205642|Device|Peripheral Arterial Tonography (PAT) using the EndoPAT™ device|A volume sensor measuring reactive hyperemia is placed on the second fingertip of both hands. First the device evaluates the baseline volume of the pulse. Then, we will apply pressure that is 50 mmHg higher than the baseline systolic pressure of the examinee on the evaluated hand for five minutes, using a sphygmomanometer cuff. After the pressure is released on the evaluated hand, the new pulse volume is tested. To neutralize the effects of the autonomous systemic response, the program divides the difference of the pulse volume in the examined hand by the difference in the untested hand and we get the Reactive Hyperemic Index (RHI) which represents the endothelial function in the tested hand. During the examination, the calculated arterial tonometry graph is generated, and out of it the RHI will be automatically calculated, using the EndoPAT2000™ program.
45494195|NCT05205642|Diagnostic Test|Endothelin|For Endothelin levels we will use the Endothelin ELISA kit from R&D company, and for measurement 1 cc of serum will be needed.
45494196|NCT03652142|Other|Biomarker Research|The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks. Patient samples will be collected with appropriate written informed consent and analyzed.
45494197|NCT03652142|Drug|Nivolumab|The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks.
45494198|NCT04656678|Device|Cryo-ablation Using DynaCAD / UroNAV preplanning / guidance|Focal ultrasound guided cryoablation using uroNav system Version 4.0 and Dyna CAD software version 5.0.
45494199|NCT01176578|Other|Aerobic Exercise Training|6 months of aerobic exercise training, 3 days per week
45494200|NCT05762328|Behavioral|Reminders to the assistant clinicians of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment community-acquired pneumonia|Automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability
45693617|NCT04580680|Device|Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)|At each participating center, EBP treatments with commercial membranes will be delivered in accordance with local practice and local levels of expertise. Enrolled patients will not receive additional treatments other than those routinely administered in ICUs. Nonetheless, all parameters settings for EBP treatments will be recorded in the web-based registry and analyzed a posteriori to reveal potential correlations with patient outcomes.
45693618|NCT01961609|Biological|Secukinumab (AIN457)|Secukinumab was supplied in 150mg pre-filled syringes.
45378294|NCT05785832|Device|Standard Therapy plus continuous glucose monitoring (CGM)|Standard therapy is continuation of pre-study basal-bolus insulin delivery method, plus use of Dexcom G6 CGM.
45378295|NCT05785611|Drug|Filgotinib|Tablets administered orally once daily
45378296|NCT05785611|Drug|Placebo|Tablets administered orally once daily
45378297|NCT05783843|Behavioral|Pictorial Warnings|Participants will be shown 6 waterpipe tobacco packages with 6 different pictorial warnings about the health harms of waterpipe smoking. The order of the 6 packages within this trial arm will be randomized. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study and designed the warnings for this arm.
45378298|NCT05783843|Behavioral|Text Warnings|Participants will be shown 6 waterpipe tobacco packages with 6 different text-only warnings about the health harms of waterpipe smoking. The order of the 6 packages within this trial arm will be randomized. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study and designed the warnings for this arm.
45494201|NCT02971670|Biological|rTSST-1 Variant Candidate Vaccine|Immunization either according to their former allocated dose (group 4: 3 µg of candidate vaccine or placebo, group 5: 10 µg of candidate vaccine or placebo, group 6: 30 µg of candidate vaccine or placebo) or 3 µg of candidate vaccine or placebo (groups 1 - 3) from Phase I.
45494202|NCT04629378|Drug|Meropenem Injection|Meropenem IV 6 grams
45494203|NCT04629378|Drug|Amoxicillin Clavulanate|Amx/CA oral 1000/62.5mg 2 tablets
45494204|NCT04629378|Drug|Pyrazinamide|Pyrazinamide 20-30mg/kg
45494205|NCT04629378|Drug|Bedaquiline|Bedaquiline 400mg
45494206|NCT04629378|Drug|Rifafour|Rifafour (HRZE) Standard dose
45494207|NCT04615806|Drug|Indocyanine green solution|ICG solution was endoscopically injected into the esophageal submucosa at the four quadrants around the tumor.
45494208|NCT03651674|Device|ECT treatment|Patients had bilateral temporal modified ECT four times a week for 3 consecutive weeks
45494209|NCT03651674|Drug|Drug treatment|Patients only have antipsychotic drugs
45494210|NCT04594980|Procedure|lumbar fusion|Transforaminal Lumbar Interbody Fusion will be performed using minimally invasive approach or traditional open technique.
45494211|NCT01061840|Biological|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
45494212|NCT01061840|Biological|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
45494213|NCT01061840|Biological|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
45378299|NCT05783843|Behavioral|No Warnings (Control)|Participants will be shown a single package without a warning. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study.
45494214|NCT01569906|Radiation|Narrowband Ultraviolet B phototherapy|Twice weekly exposures for a total of 24 exposures using a standard phototherapy protocol.
45494215|NCT03651440|Other|PNF|PNF
45494216|NCT03651440|Other|lumbar stabilization training|lumbar stabilization training
45494217|NCT03651440|Other|Physical Therapy|Physical Therapy
45378300|NCT05779020|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|Quadrivalent Influenza Vaccine (split virion, inactivated) from Instituto Butantan (dose 0.25ml and 0.50ml)
45378301|NCT05779020|Biological|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage/dose 0.50ml
45378302|NCT05779020|Biological|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage/dose 0.25ml
45494218|NCT03651440|Other|Control|Control group
45494219|NCT05200728|Drug|SIM1910-09|"Part A-single ascending doses， SIM1910-09 will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, SIM1910-09 will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion, which will be tested sequentially from low dose to high dose."
45494220|NCT05200728|Drug|Placebo|"Part A-single ascending doses， placebo will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, placebo will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion, which will be tested sequentially from low dose to high dose."
45494221|NCT05762250|Other|Auricular Acupuncture|Within the NADA protocol, 5 defined points on the patient's ears are treated according to a standardized concept (shen men, kidney, lung, liver, vegetative I).
45494222|NCT02971202|Drug|Hyperinsulinemic, euglycemic clamp|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts."
45494223|NCT02971202|Drug|20% dextrose|A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study.
45494224|NCT05761548|Diagnostic Test|ultrafast ultrasound power Doppler imaging|ultrafast ultrasound power Doppler imaging for neonatal brain microvessels
45494225|NCT00702494|Biological|TB-403|Multiple IV
46054547|NCT02782611|Behavioral|ENHANCE: Enduring Happiness and Continued Self-Enhancement|ENHANCE is a skill-based intervention to teach people a wide variety of strategies that have been shown to boost happiness. Each session of ENHANCE follows a similar format targeted to address three central goals. First, in each session, participants will complete an active learning module designed to educate participants about one of the ten overarching topics featured in this program (e.g., goals, close relationships). Next, participants will engage in activities that put these principles into practice. Finally, this program is designed to encourage a skill-building mindset by helping participants develop habits to integrate these principles into maintained activity in their daily lives moving forward.
45494226|NCT02926638|Drug|Erlotinib Hydrochloride|Given PO
45494227|NCT02926638|Other|Laboratory Biomarker Analysis|Correlative studies
45378305|NCT05777356|Diagnostic Test|Urine collection and assessment of dietary intake by food frequency questionaire|urinary iodine, creatinine and methylmalonic acid, iodine and vitamin B12 dietary intake from foods and supplements
45494228|NCT02926638|Biological|Rilotumumab|Given IV
45494229|NCT00641420|Procedure|Fractionated Laser Resurfacing|
45494230|NCT03651596|Behavioral|mHealth Messaging Intervention Group|The newly developed intervention messages will be sent to individuals assigned to the intervention group during the study.
45494231|NCT03651596|Behavioral|Standard mHealth Messaging Group|Standard mHealth messages will be sent to individuals assigned to the active control group during the study.
45494232|NCT03650582|Drug|Glucagon|Intranasal glucagon
45494233|NCT03650582|Drug|Placebo|Intranasal placebo
45494234|NCT02903030|Drug|Maltose (placebo)|Maltose with a trace amount of silicon dioxide
45494235|NCT02903030|Drug|Visbiome Extra Strength|It is a mix of 8 strains of beneficial bacteria that should improve gut flora, improving GI function and hopefully anxiety
45378306|NCT05776602|Diagnostic Test|Fast MRI (Neuromix)|Diagnostic performance, correlation, agreement
46054548|NCT00754741|Behavioral|Adherence information|Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system.
45378309|NCT05775718|Drug|Zoster Vaccine Recombinant|Injection
45378310|NCT05774899|Drug|CB-103|First-in-class pan-NOTCH inhibitor, capsule taken orally.
45378311|NCT05774899|Drug|Venetoclax|BCL-2 inhibitor, tablet taken orally.
45378312|NCT05774899|Drug|Lenvatinib|Per standard care, capsule taken orally.
45378313|NCT05768607|Procedure|Quality of Life QUESTIONNAIRE (SF36)|Units of a scale of the patients will be compared pre and postoperatively by using SF36
45378314|NCT05768607|Procedure|INCONTINENCE IMPACT QUESTIONNAIRE (IIQ-7)|Units of a scale of the patients will be compared pre and postoperatively by using IIQ-7
45378315|NCT05768607|Procedure|UROGENITAL DISTRESS INVENTORY (UDI - 6)|Units of a scale of the patients will be compared pre and postoperatively by using UDI - 6
45378316|NCT05768477|Other|Consultation|Consultation with the pain specialist, which might entail prescription of medication of vitamins.
45378317|NCT05768477|Procedure|Interventions|Facet injections, nerve denervations, infiltrations, Qutenza, Spinal Cord Stimulation, Transcutaneous Electrical Nerve Stimulation
45378318|NCT05768477|Drug|Baxter therapy|Ketamine or Linisol baxter therapy
45494236|NCT03650504|Procedure|Above Artery Catheter Placement|Nerve catheter placed between superficial femoral artery and sartorial muscle
45494237|NCT03650504|Procedure|Between Artery and Vein Placement|Nerve catheter placed between superficial femoral artery and femoral vein
45494238|NCT03650426|Procedure|Total knee with onlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded on the patellar bone.The patellar implant is placed on top of a flat tibial osteotomy or cut-surfaced bone
45494239|NCT03650426|Procedure|Total knee with inlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded in the patellar bone.The patellar implant is surrounded by a rim of cortical bone and supported by hardened, sclerotic bone
45494240|NCT02969408|Drug|Albuterol Sulfate|Albuterol sulfate will be administered as per the dose and schedule specified in the arm.
45494241|NCT03462563|Device|INTERCEED™|when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo). In subjects assigned to the treatment arm, the INTERCEED™ must be applied beneath the target incision site (the midline incision mainly for the removal specimen)
45494242|NCT03462563|Device|Placebo|During the Phase 1 operation, when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo).
45494243|NCT03716453|Procedure|Standard protocol|Give narcotic according to vital signs
45494244|NCT03716453|Procedure|ANI protocol|"ANI score 50-70 indicates optimal narcotic effect. ANI score > 70 indicated overdosage of narcotic and narcotic should be withheld.~ANI score < 50 indicates inadequate narcotic and narcotic should be given."
45494245|NCT05180214|Drug|Bupivacain|analgesic
45494246|NCT05180214|Drug|Ketorolac|analgesia
45494247|NCT01060124|Drug|Fentanyl D-trans|Fentanyl D-trans will be applied as transdermal patch releasing drug at the rate of 12.5 microgram per hour (mcg/hr) for 3 days with a dose ranging from 12 mcg/hr to 50 mcg/hr.
45378319|NCT05768477|Behavioral|Interdisciplinary therapy|Interdisciplinary therapy provided by the physiotherapist, psychologist and occupational therapist.
45378320|NCT05766748|Drug|Azeliragon|Azeliragon is an orally administered inhibitor of Receptor for Advanced Glycation Endproducts (RAGE) which is formulated as a 5mg hard gelatin capsule.
45378321|NCT05759949|Drug|RLY-5836|RLY-5836 is a mutant-selective, oral PI3Kα inhibitor.
45378322|NCT05759949|Drug|Fulvestrant|Fulvestrant (500 mg) is administered IM into the buttocks (gluteal area) slowly (1 to 2 minutes per injection) as 2×5 mL injections, 1 in each buttock, on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of each subsequent cycle.
45378323|NCT05759949|Drug|Palbociclib|Palbociclib 125 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
45378324|NCT05759949|Drug|Ribociclib|Ribociclib 600 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
45378325|NCT05759949|Drug|Abemaciclib|Abemaciclib 150 mg BID will be taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles.
45494248|NCT03461003|Other|NICHE method|Based on underlying comorbidities at enrollment, patients will be assigned to either an unrestricted protocol (amlodipine versus lisinopril) or a restricted protocol (losartan versus lisinopril). Two drugs are tested in randomized order. Failure to achieve BP control at maximum doses of the first two drugs will result in augmentation with a diuretic (hydrochlorothiazide). BP control is assessed with 24 hour ambulatory monitoring at the end of each 2 week treatment period. Side effect tolerability is assessed with a questionnaire.
45494249|NCT03461003|Other|Usual care|Physician preference will dictate choice and adjustment of antihypertensive medication, BP measurement modality, interval between visits, and assessment of side effects.
45494250|NCT03461003|Drug|Amlodipine|Calcium-channel blocker; antihypertensive
45494251|NCT03461003|Drug|Lisinopril|Angiotensin-converting-enzyme (ACE) inhibitor; antihypertensive
45494252|NCT03461003|Drug|Hydrochlorothiazide|Thiazide diuretic; antihypertensive
45494253|NCT03461003|Drug|Losartan|Angiotensin II receptor blocker (ARB); antihypertensive
45494254|NCT05177172|Other|High beta glucans|higher dose betaglucans
45494255|NCT05177172|Other|Low beta glucans|lower dose beta glucans
45494256|NCT05177172|Other|Low beta glucans + low polar lipids|low dose betaglucans in a combination with low dose of polar lipids
45494257|NCT05177172|Other|Polar lipids|low dose polar lipids
45494258|NCT05177172|Other|Control|No beta glucans or polar lipids
45494259|NCT03650348|Drug|PRS-343 in Combination with Atezolizumab|HER2/4-1BB Bispecific
45494260|NCT05761470|Drug|Camrelizumab|"Camrelizumab at a fixed dose of 200mg via IV infusion on Days 1 each 21-day cycle.~Fluzoparibat at a fixed dose of 100mg BID, each 21-day cycle. Nab-paclitaxel at a fixed dose of 260 milligrams via intravenous (IV) infusion on Days 1 each 21-day cycle."
45378326|NCT05754918|Device|TnoFs then TFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting without fine structure coding then with fine structure coding
45378327|NCT05754918|Device|TFS then TnoFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting with fine structure coding then without fine structure coding
45378328|NCT05754073|Drug|1. Intranasal oxytocin spray|30 IU, twice daily for 12 months in the experimental arm in double-blinded phase
45378329|NCT05754073|Drug|2. Intranasal placebo spray|30 IU, twice daily for 12 months in the placebo comparator arm in double-blinded phase
45378330|NCT05754073|Drug|3. Intranasal Oxytocin spray|30 IU, twice daily for 6 months in both experimental and placebo comparator arm in open-label phase
45378331|NCT05751226|Drug|BI 1820237|BI 1820237
45378332|NCT05751226|Drug|semaglutide|semaglutide
45378333|NCT05751226|Drug|Placebo|Placebo
45378334|NCT05751226|Drug|BI 456906|BI 456906
45378335|NCT05750160|Other|music therapy|Music therapy that have been made by Music Therapist after Focus Group discussion, given three times a week for 4 weeks
45494261|NCT05761470|Drug|Fluzoparib|Fluzoparib
45494262|NCT05761470|Drug|Nab-paclitaxel|Nab-paclitaxel
45494263|NCT01372293|Drug|oral contraceptive pill|ethinyl oestradiol 20ug plus gestodene 75ug during 6 cycles
45494264|NCT05205096|Biological|Recombinant novel coronavirus vaccine (CHO cells)|At 3-9 months after the immunization with 2 doses of inactivated vaccine (CoronaVac), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
45494265|NCT05759598|Other|Rehabilitation protocol + guided spontaneous breathing exercises|Standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises
45494266|NCT05759598|Other|Rehabilitation protocol + specific respiratory muscle training program|Standard integrated metabolic rehabilitation protocol + specific respiratory muscle training program according to the protocol recently proposed by Spengler et al. (Wuthrich et al., 2015; Schaer et al., 2018), adapted according to the baseline characteristics of the respiratory function of the subjects
45494267|NCT02904902|Drug|adalimumab|Subcutaneous Injection
45494268|NCT03650270|Drug|Phenobarbital|Three repeated doses of pareneteral phenobarbital was compared to a single parenteral infusion of phenytoin followed by an infusion of parenteral midazolam
45494269|NCT03621722|Other|Elequil Aromatabs|There will be a variety of different Aromatabs such as orange/peppermint or lavender
45494270|NCT04425720|Device|LifeSignals Biosensor 1AX*|Shared-clinical decisions will be made based on the monitored data and patient diary. Two devices will be used to monitor data, LifeSignals Biosensor 1AX* and a pulse oximeter.
45494271|NCT04425720|Other|Standard of Care|This group will be treated based on standard of care at our institution.
45494272|NCT05285228|Behavioral|effect of choice on cooperation (pseudoalternative)|For the test group, before the standard check-up starts, the participant is given the choice of selecting the taste of the fluoride varnish (Profluorid VOCO, Germany) from a range of about five flavors (Melon, Caramel, Cherry, Bubble gum, Mint), which will be applied at the end of the visit. Post-placement instructions provided by the manufacturer will be given to the caregiver and the child and questionnaires will be handed out.
45494273|NCT05285228|Behavioral|given fluoride varnish (control)|For the control group the participant is provided with a given taste of the fluoride varnish (Profluorid VOCO, Germany) from a range of about five flavors (Melon, Caramel, Cherry, Bubble gum, Mint) according to the randomization list.
45494274|NCT03649568|Other|Pork|1 oz lean pork
45494275|NCT03649568|Other|Egg|1 large whole egg
45494276|NCT03649568|Other|Black beans|0.5 cups cooked black beans
45494277|NCT03649568|Other|Almonds|1 oz almonds
45494278|NCT03629574|Procedure|Ventilation during cardiopulmonary bypass|Mechanical ventilation during cardiopulmonary bypass
45494279|NCT04075526|Drug|Povidone iodine|To create the dilute solution, a staff member will draw up 17.5 mL of 10% povidone iodine with a syringe and mix it with 500 mL of normal saline, resulting in a dilution of 0.35% povidone iodine solution for use before wound closure.
45494280|NCT04075526|Drug|Vancomycin powder|2 grams of vancomycin powder will be applied to the wound and will be distributed so that approximately 1 gram is administered deep to the fascia and 1 gram superficial to the fascia
45494281|NCT04075526|Other|Conventional|No additional steps in management are required for the control arm of the study besides lavage with 1 L of isotonic sodium chloride solution without antibiotics. No vancomycin powder or dilute povidone iodine lavage would be utilized in this cohort
45494282|NCT05204628|Drug|XZP-3621|XZP-3621 tablets will be administered orally at a dose of 500 mg QD until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
45494283|NCT05204628|Drug|Crizotinib|Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
45494284|NCT05078190|Other|Social Determinants of Health|The study will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.
45494285|NCT05285072|Radiation|PET-CT scan|PET-CT scan using 68Ga-DFO
45494286|NCT03459443|Drug|Danicopan|Danicopan was to be administered as an oral tablet.
45494287|NCT05204394|Drug|VM-1500A-LAI|Injectable nanoformulation of depulfavirine (parent drug of elsulfavirine)
45494288|NCT05204394|Other|Standard of Care|Any oral 1st line approved HIV treatment regimen
45847244|NCT04964466|Biological|Amount of PDGF-BB in PRF preparation vs. GEM21|The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
45494289|NCT03650972|Other|Samarin|Arm: Active Comparator: B, Bicarbonate group When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
45494290|NCT05065398|Drug|HLX208|450mg bid, take orally
45494291|NCT02904512|Device|Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose|Testing Blood Glucose levels with Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose
45494292|NCT02904512|Other|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
45494293|NCT05065008|Other|Cranberry juice|The responders and non-responders will drink 20-30 oz of (590-885 mL) 27% cranberry juice daily for 3 weeks.
45494294|NCT05065008|Other|Apple juice|The participants will drink apple juice with matching sugar content and calories for 3 weeks
45494295|NCT03713333|Diagnostic Test|Digital Health Device Diagnostics|"Technology-enabled visitations with digital health will include the following devices used at the time of a patient-physician encounter. These findings will be available to the treating physician at the time the visitation and to be used for clinical decisions.~Handheld imaging - focused echocardiographic examination (Butterfly IQ)~Smartphone iECG for cardiac rhythm assessments (Alivecor)~Blood Pressure (CloudDX)~Oxygen Saturation (CloudDX)~Weight (CloudDX)~Point-of-Care Genetic Testing (Phosphorous)"
45494296|NCT05031624|Drug|CDX-0159|Single subcutaneous dose of one of four dosages of CDX-0159
45494297|NCT05031624|Drug|Normal saline|Single subcutaneous dose of normal saline
46054549|NCT00754741|Behavioral|Adherence information plus motivational interviewing|Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system. Moreover, patients randomized to this arm will be recruited into a clinic run by pharmacists and nurses with delegated prescription power. The clinic personnel will use motivational interviewing techniques with patients to improve adherence to medications and/or to intensify medical treatment if adherence is optimal.
46054550|NCT05190471|Drug|BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide|Dose escalation of BP1002 monotherapy
46054551|NCT05190471|Drug|Decitabine (in combination with BP1002)|Dose expansion of BP1002 in combination with decitabine
45494298|NCT03650738|Drug|Apatinib|Neoadjuvant program: apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.
46054552|NCT05342649|Procedure|P-CTG|soft tissue closure of extraction sockets was done by pediculated connective tissue grafts (P-CTG)
45494299|NCT04053530|Other|restorative materials|glass ionomer and bulk fill flowable composite
45494300|NCT02904200|Device|Silicon adhesive dressing|Sterile soft silicon adhesive dressing
45494301|NCT02904200|Device|Acrylic adhesive dressing|Sterile acrylic adhesive dressing
45494302|NCT03432533|Drug|romosozumab HCP administration with PFS|210 mg romosozumab SC QM by HCP administration with 2 PFS
45494303|NCT03432533|Device|romosozumab self-administration with AI/Pen|210 mg romosozumab SC QM by self-administration with 2 AI/Pens
46054553|NCT05342649|Procedure|CTG|soft tissue closure of extraction sockets was done by connective tissue grafts (CTG)
45494304|NCT03621800|Other|Menthol popsicle|The menthol popsicle composed of 0.05% menthol, 0.05% saccharin, 20ml ultrafiltered water and 2% cereal alcohol. The menthol popsicle was supported by a stick, allowing patients to taste more comfortably, with autonomy and safety
45494305|NCT05285462|Behavioral|VR Pain Education|pain education delivered via VR headset, up to 12 sessions
45494306|NCT05285462|Behavioral|Usual Care Physical Therapy|Normal course of PT without influence by study team on frequency or duration
45494307|NCT03649334|Drug|ketamine-ketorolac|The patient will receive ketamine 0.5mg.kg-1 + ketorolac 1mk.kg-1 in 2 ml syringe intramuscularly.
45494308|NCT03649334|Drug|fentanyl- ketorolac|The patient will receive fentanyl 1.5ug.kg-1 + ketorolac 1 mg.kg-1 in 2ml syringe intramuscularly
45378338|NCT05748834|Drug|Tucatinib|Participants will receive tucatinib 300mg by mouth twice daily continuously (days 1-28) of each 28 day cycle.
45378339|NCT05748834|Drug|Doxil|Participants will receive Doxil 40mg/m2 intravenously on day 1 of each 28 day cycle (with a maximum cumulative dose of 550mg/m2).
45378340|NCT05743946|Drug|Trikafta|Participants will be given elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (two pills once daily in the morning) and ivacaftor 150 mg (once daily in the evening), as the FDA-registered agent, Trikafta. Dose and schedule will be identical to what has already been FDA-approved for effective treatment of cystic fibrosis.
45494309|NCT05648279|Other|Personalized hemodynamic management|Personalized hemodynamic management: Intraoperative cardiac index will be maintained at least at the preoperative baseline cardiac index. Preoperative baseline cardiac index will be determined one day before surgery with the patient being awake and resting in the supine position using the Starling Fluid Management System (Baxter, Deerfield, IL, USA). We will define the individual preoperative baseline cardiac index as the average value over a 5 min period at rest (minimum cardiac index threshold: 2.2 L min-1 m-2). Intraoperative cardiac index will be measured using the Baxter Starling Fluid Management System.
45494310|NCT02901548|Drug|Durvalumab|Durvalumab will be given every 4 weeks at 1500 mg/kg IV for total of 12 months/13 doses.
45693619|NCT04468672|Behavioral|Portion size|The amount of food served (g) at the first two meals of each day. These amounts will vary across 4 weeks.
45693620|NCT04387162|Behavioral|Prism Adaptation Treatment|Spatial retraining treatment
45693621|NCT04267198|Behavioral|Intention Treatment for Anomia|Word retrieval treatment for aphasia that engages right hemisphere intention mechanisms using a left-hand circular gesture.
45494311|NCT02901548|Procedure|Cystoscopy with Biopsy|Cystoscopy with biopsy and transurethral resection of the bladder tumor (TURBT) (if indicated) will be performed at baseline, month 3, 6, 9, 12, 18, and 24. The month 6 and 24 cystoscopy will be done in the operating room with mapping biopsy. Rest of the cystoscopic exam with biopsy will be performed in the out-patient office setting and if clinically indicated will be repeated in the operating room. Participants will be off study if any of the biopsies document muscle invasive (T2 or above) urothelial carcinoma. Participants will also be off study if their month 6, 9, 12, 18 biopsies show persistent (month 6) or recurrent CIS or invasive (T1 or above) urothelial carcinoma. Otherwise, participants will remain on study until after the month 24 mapping biopsy.
45494312|NCT03649256|Diagnostic Test|Thickness of lower uterine segment scar|Ultrasound measurement of thickness of the uterine scar at 3 and 6 months
45494313|NCT04053374|Other|Blood sampling|Blood sampling +/- CSF sampling
45494314|NCT03650660|Other|Trans-thoracic ultrasound|Trans-thoracic ultrasound performed by an expert and a non-expert
45494315|NCT02903966|Drug|GSK2982772|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
45378341|NCT05742789|Drug|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor
45378342|NCT05742789|Drug|Isoflurane|В качестве анестетика использовали изофлуран - 1,1-1,2 MAC.
45378343|NCT05742789|Drug|Sevoflurane|в качестве анестетика использовали севофлуран в дозе - 1,7-1,9 ПДК.
45494316|NCT02903966|Drug|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
45494317|NCT03457727|Drug|Danirixin|Danirixin is being developed as a potential anti-inflammatory agent for the treatment of chronic obstructive pulmonary disorder (COPD) and other inflammatory diseases and influenza. Danirixin reference (600 mg) or test formulation (475 or 600 mg or 600 mg with 5 percent HPMC) immediate release tablets will be administered by oral route in a cross-over manner.
45378344|NCT05741385|Drug|Caffeine|Caffeine
45693622|NCT00800254|Device|Neuromuscular Electrical Stimulation (NMES)|NMES 20 minutes twice a day for 6 weeks plus standard physical therapy
45693623|NCT00800254|Other|Standard Rehabilitation Protocol|Standard physical therapy for 8 weeks after surgery
45378345|NCT05741385|Drug|Warfarin sodium|Warfarin sodium
45378346|NCT05741385|Drug|Omeprazole|Omeprazole
45378347|NCT05741385|Drug|Metoprolol|Metoprolol
45378348|NCT05741385|Drug|Midazolam|Midazolam
45378349|NCT05741372|Drug|Rosuvastatin|Rosuvastatin
45378350|NCT05741372|Drug|Digoxin|Digoxin
45494318|NCT03457727|Drug|Omeprazole|Omeprazole is used as an antacid. OMP 40 mg delayed-release capsule will be administered by oral route to randomized subjects.
45494319|NCT03647618|Other|Ultrasound|Ultrasound-guided regional anaesthesia
45378351|NCT05741372|Drug|Metformin hydrochlorid|Metformin hydrochloride
45494320|NCT05285384|Biological|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 μg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm
45693624|NCT03753646|Other|Lactating allowance and psycho social stimulation|Mothers will receive lactating allowance and psycho social stimulation
45693625|NCT04383418|Drug|dexmedetomidine nasal spray|dexmedetomidine nasal spray
45693626|NCT04383418|Drug|dexmedetomidine hydrochloride nasal spray blank preparation|dexmedetomidine hydrochloride nasal spray blank preparation
45693627|NCT03414112|Biological|Intranasal oxytocin|oxytocin is a peptide hormone that influences social affiliation
45693628|NCT02152540|Device|rTMS|Repetitive Transcranial Magnetic Stimulation
45693629|NCT02152540|Device|Sham rTMS|Placebo Device that simulates active rTMS treatment
45693630|NCT04383184|Procedure|tracheoplasty|tracheoplasty and only left pulmonary artery transplantation
45693631|NCT05287204|Diagnostic Test|Musculoskeletal ultrasound|Ultrasound of rectus femoris to determine cross-sectional area, muscle thickness, echo intensity.
45378352|NCT05741372|Drug|Furosemide|Furosemide
45378353|NCT05732454|Drug|etrasimod|PART 1 Double Blind one 2 mg tablet once daily for up to 16 weeks PART 1 Open Label Extension one 2 mg tablet once daily for an additional 52 weeks PART 2 Open Label one 2 mg tablet once daily for up 52 weeks
45378354|NCT05732454|Drug|Placebo|PART 1 DOUBLE BLIND Placebo - one table daily for up to 16 weeks
45378355|NCT05731895|Drug|BI 425809 (iclepertin)|BI 425809 (iclepertin)
45378356|NCT05729607|Procedure|Vertical soft tissue augmentation|Vertical soft tissue augmentation with autogenous connective tissue graft (CTG)
45378357|NCT05729607|Procedure|Vertical soft tissue augmentation|Vertical soft tissue augmentation with acellular dermal matrix (ADM) and enamel matrix derivative (EMD)
45378358|NCT05728502|Drug|Vericiguat (Verquvo, BAY1021189)|Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
45378359|NCT05728502|Drug|Standard of Care (SoC)|Dosage at the discretion of the treating physician.
45378360|NCT05726305|Procedure|Live donor uterus transplantation|Transplantation of uterus from a living donor.
45494321|NCT03431441|Device|JJVC Marketed Contact Lens|Female subjects that are habitual contact lens wearers between the ages of 18 to 39 will be dispensed 1 treatment of the JJVC Marketed Contact Lens during the 2-visit study.
45494322|NCT03648554|Drug|dulaglutide (TRULICITY®) 1.5 mg|dulaglutide (TRULICITY®) 1.5 mg subcutaneous administration, one weekly injection over 52 weeks of treatment
45494323|NCT03648554|Other|reinforced dietary monitoring|moderate caloric restriction individually adjusted according to the ideal weight and activity level, encouraging regular physical activity (about 30 minutes per day or 150-200 min per week)
45494324|NCT03457103|Device|Capnometry-Assisted Training for COPD to Slow the Breath (CATCH)|Tailored intervention emphasizing slow, quiet, regular nasal breathing pattern.
45494325|NCT03457103|Device|Pulmonary Rehabilitation (PR)|Patients in both treatment groups will participate in a 10 week (16-20 sessions) comprehensive PR program. The control group will receive the 10-Week PR program with traditional breathing training sessions (without biofeedback). The program comprises 2 or 3 exercise training sessions per week by physical therapists (each 1 hour duration).
45494326|NCT03648398|Other|EDUMICILOR|Patients will participate in the online therapeutic education program for about 6 months
45494327|NCT03648320|Other|Peanut oral immunotherapy|Daily doses of peanut flour (with 2-weekly incremental interval)
45494328|NCT05284994|Drug|TQ-B3525 Tablets, Osimertinib Mesylate Tablets|TQ-B3525 is a novel α/δ dual inhibitor PI3K kinase inhibitor. Osimertinib mesylate is a third-generation epidermal growth factor receptor inhibitor.
45494329|NCT03649100|Procedure|Implant placement|Conventional implant placement. Implant site development was prepared according to the manufacturer's instruction by the investigator, before knowing the randomized implant (NH or SA).
45494330|NCT03649022|Device|Catheter ablation|Ventricular Tachycardia ablation, that will be performed per clinical practice, by using EnSite Precision mapping system with the Flexability catheter (St.Jude, now Abbott)
45494331|NCT04053296|Other|Observational study|We follow up the results of patients.
45494332|NCT03648944|Other|Accelerated Rehabillitation|
45494333|NCT03648944|Other|Non-Accelerated Rehabillitation|
45378361|NCT05726305|Procedure|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor.
45378362|NCT05723822|Device|Walkasins|"Walkasins is a non-invasive, wearable, lower limb sensory prosthesis, prescribed by a healthcare professional for long-term daily use as a prosthesis. It directly replaces the part of the function of the sensory end organs that persons with peripheral neuropathy have lost, the sensation in the soles of their feet. The system is comprised of two primary operating components:~A Receptor Sole, properly placed in the shoe, detects and transmits plantar pressure information normally performed by the mechanoreceptors and distal axons in the soles of the feet.~A Haptic Module, worn around the lower leg, generates directional specific mechanical tactile stimuli that produce action potentials that signal relevant balance information to the nervous system."
45494334|NCT03455543|Device|Active Provant Therapy System|Treatment with active Provant Therapy System
45494335|NCT03455543|Device|Inactive (sham) Provant Therapy System|Treatment with inactive Provant Therapy System
45494336|NCT03648242|Behavioral|Interruptive Clinical Decision Support|"An interruptive, soft-stop alert will pop up when a pediatric primary care provider open a child's electronic health record (i.e., a new window in the forefront of the screen interrupting workflow and requiring the clinician to take an action) alerting them that the child meets criteria for obesity based on their age/sex-specific BMI percentile. The pop-up alert includes:~One-click addition of elevated BMI to problem list~Reminder to utilize Suggested PowerPlan~One-click access to a patient handout on evidence-based behavior change goals (screen time, sugary drinks, physical activity, sleep) and link to additional handouts and resources~Tables displaying trends in growth measures, blood pressure and relevant laboratory tests~Links to existing, evidence-based childhood obesity screening and management guidelines"
45494337|NCT03068754|Drug|Acthar|Repository corticotropin for subcutaneous injection
45494338|NCT03068754|Drug|Placebo|Matching placebo for subcutaneous injection
45494339|NCT02965820|Device|Opti-Free® PureMoist® contact lens solution|
45494340|NCT02965820|Device|Habitual Multi-Purpose Contact Lens Solution|
45494341|NCT02965820|Device|Habitual Contact Lenses|Subject's habitual contact lens brand worn in a daily wear modality for 30 days.
45494342|NCT03713099|Device|Microwave ablation|Microwave ablations will be performed under general anesthesia via a transbronchial approach by an interventional pulmonologist or thoracic surgeon. Prior to the ablation, the treating physician will perform an endobronchial ultrasound (EBUS) to confirm disease staging.
45494343|NCT03716375|Drug|Intrapleural Medications|urokinase
45494344|NCT04021472|Behavioral|Text message|Two months of daily text messages to support meeting a health goal
45693632|NCT05287204|Diagnostic Test|Assessments of muscle strength and physical function|A battery of tests of physical function and muscle strength (see outcomes section for details).
45693633|NCT05287204|Diagnostic Test|Metabolomics|Using metabolomic analysis, concentrations of amino acids and other important analytes will be measured in patient plasma and CRRT effluent
45494345|NCT05203848|Procedure|Community Dance Intervention|The main dance instructor for the CDP is Yarra Ileto, who is the Artistic Director for NUS Dance Synergy. Yarra was trained at LASALLE College of the Arts, graduating with a First Class BA (Hons) Dance in 2008. Also, she has experience with crafting and conducting Community Dance Programs (CDP) for Seniors. Yarra will be developing the dance lesson plan and also training selected students from NUS Dance Synergy to guide the seniors during the dance sessions. Older adults will learn and practice the basic steps together for the first few weeks. Then, the student dance instructors will start teaching the dance formation. During each session, participants will need to warm up first to prevent injuries before practicing dance steps. Small group practicing is reserved for older adults to interact with each other. All the participants will do relaxation exercises before ending the session to cool down their bodies and release muscle tensions.
45494346|NCT05203848|Other|Control group|Control group
45494347|NCT03648164|Other|CHAT-CS Survey|Students will complete a computer-based survey
45494348|NCT03430895|Drug|durvalumab and tremelimumab|Patients will receive durvalumab 1500 mg and tremelimumab 75 mg IV Q4W for up to 4 doses/cycles, then durvalumab 1500 mg Q4W starting 4 weeks after the last combination treatment for up to 9 doses.
45378363|NCT05721846|Drug|Nivolumab|3 mg/kg (up to 240 mg maximum) as i.v. infusion on day 1 (± 3 days) of each 14-day treatment cycle
45378364|NCT05721846|Drug|Ipilimumab|1 mg/kg as i.v. infusion on day 1 cycle 1 and subsequently every 6 weeks (± 3 days)
45494349|NCT03648086|Other|intestinal microbiota transplantation|Participants in Exprerimental group take 6 times IMT with 2-week intervals
45494350|NCT04334304|Procedure|Total Knee Prosthesis - type Bicruciate retaining|A total knee arthroplasty will be performed with a bicruciate retaining implant (Journey II, XR). The control group will consist out of patients receiving a posterior stabilized implant (Journey II, BCS).
45494351|NCT04334304|Procedure|Robot-assisted Total Knee Arthroplasty|A total knee arthroplasty will be performed with robot-assistance (NAVIO).
45494352|NCT04334304|Procedure|Total Knee Prosthesis - type Posterior Stabilized|A total knee arthroplasty will be performed with a bicruciate retaining implant (Journey II, XR). The control group will consist out of patients receiving a posterior stabilized implant (Journey II, BCS).
45494353|NCT03712709|Diagnostic Test|Truenat MTB|The Truenat MTB (including both MTB and MTB Plus) and the MTB-RIF Dx reflex assays (Molbio Diagnostics; Bangalore, India) utilize chip-based real-time micro-PCR for detection of tuberculosis (TB) and rifampicin (RIF) resistance from DNA extracted (on a separate device) from sputum samples. The Truenat MTB assay targets a single copy gene while the MTB Plus assay combines detection of a single copy and multi-copy gene.
45494354|NCT04312386|Other|OPTIMAT|Baseline menue, not optimized
45494355|NCT03718481|Other|ARCP Process|One Annual Review of Competence Progression (ARCP) cycle. In the U.K., doctors, across all specialities, undergo an Annual Review of Competence Progression (ARCP) to evaluate performance during each training year and determine progression to the next year of training. Similar processes exist in the Republic of Ireland. The process and requirements for ARCP in the UK are specified in the Gold Guide, the Reference Guide for Postgraduate Specialty Training [1]. It defines ARCP as a formal process that uses evidence collected by trainees to review and record performance, demonstrate competencies achieved and inform decisions regarding progression in training
45494356|NCT05745480|Other|Opioid Misuse Screening with an Addiction Consult Service|Opioid Misuse Screening with an addiction consult service for brief intervention/motivational interviewing (MI), medication assisted treatment (MAT), or referral to substance use treatment as an outpatient.
45494357|NCT03452189|Drug|Vancomycin|Oral vancomycin 250mg capsules
45494358|NCT03452189|Other|Placebo|"Placebo Pills distributed by Research Pharmacy labeled placebo."
45494359|NCT04306380|Other|no intervention, database study|data collection from EMR for database
45378365|NCT05721846|Radiation|SBRT|SBRT: 15 Gy x 1 on a single site of disease on day 1 cycle 1
45378366|NCT05721846|Biological|TGFβ-B-15 peptide|Vaccine (500 μl aqueous solution of 200 μg TGFβ-B-15 peptide mixed to an emulsion with 500μl Montanide ISA-51) as s.c. injection on day 1 of the first 6 cycles and subsequently every 4 weeks (± 3 days)
45378367|NCT05721573|Drug|ABC008|Given by subcutaneous injection
45378368|NCT05718648|Drug|BI 1015550|BI 1015550
45378369|NCT05715489|Procedure|Comparison of pre and postoperative POP-Q values of the patients|Pectopexy Without Using Mesh will be applied to the patients and POP-Q values will be compared pre and postoperatively
45378370|NCT05715489|Procedure|Comparison of pre and postoperative PISQ-12 scores of the patients|Pectopexy Without Using Mesh will be applied to the patients and PISQ-12 scores will be compared pre and postoperatively
45494360|NCT03451721|Device|ImageReady™ MR Conditional Defibrillation System|Subject will receive an ICD or CRT-D pulse generator in the left or right pectoral region ICD
45378372|NCT05708612|Procedure|Medical Device (SimplyFI)|Implantation a non-active medical device (SimplyFI) for the treatment of chronic fecal incontinence.
45378373|NCT05705401|Radiation|Standard of Care Adjuvant Breast Radiation|adjuvant breast radiotherapy per the current standard of care
45494361|NCT00603954|Drug|Conditioning regimen: TBI + Fludarabine|2 Gy TBI, Fludarabine 90 mg/m²
45378374|NCT05705401|Drug|Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation|participants are randomized to continue their standard of care systemic HER2-targeted therapy without adjuvant breast radiotherapy
45378375|NCT05704712|Behavioral|Monetary Incentives|Monetary incentives, provided in the form of pre-loaded Visa debit cards are provided to encourage exercise.
45378376|NCT05704049|Drug|Isatuximab|Pharmaceutical form: Solution for Subcutaneous administration; Route of administration: Subcutaneous
45494362|NCT00603954|Drug|Conditioning regimen:TLI (8 Gy) + ATG|TLI 8 Gy + ATG (Thymoglobulin) 7.5 mg/kg
45494363|NCT03712631|Procedure|tunneling technique bone augmentation|horizontal ridge augmentation using mixture of xenograft,autogenous bone
45378377|NCT05704049|Drug|Carfilzomib|Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
45378378|NCT05704049|Drug|Dexamethasone|Pharmaceutical form: Tablet; Route of administration: Oral
45378379|NCT05704049|Drug|Dexamethasone IV|Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
45378380|NCT05696782|Drug|Durvalumab|Participants will receive Durvalumab 1500 mg intravenously every two weeks for 60 minutes. Each treatment is called a cycle and lasts for four weeks (or 28 days).
45378381|NCT05696782|Other|the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30)|Participants will be asked to answer all 30 items on the EORTC Core Quality of Life questionnaire (EORTC QLQ-C30). This patient-reported outcome measure is designed to measure cancer patients' physical, psychological and social functions. The measure can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is approximately 11 minutes (
45378382|NCT05696782|Diagnostic Test|COPD Assessment Test (CAT)|Participants will be asked to answer all items on the COPD assessment test (8 items) and the patient-reported outcome measures designed to measure respiratory function. The measures can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is less than 5 minutes.
45494364|NCT03712553|Behavioral|Opt-Out|Opt-In messaging prompts participants to contact their primary care provider to receive Hepatitis C screening whereas Opt-Out messaging includes a signed laboratory order for Hepatitis C screening.
45494365|NCT03712553|Behavioral|Letter|Participants receive messaging prompting them to contact their primary care provider to receive Hepatitis C screening, either as a letter or an electronic message on the MyPennMedicine patient portal.
45494366|NCT03712553|Behavioral|Behavioral Economic Messaging|Participants receive standard messaging about HCV and ways to get screened and messaging that incorporates behavioral economic principles such as norms, reciprocity, anticipated regret, and pre-commitment to get screening.
45494367|NCT03712553|Behavioral|Usual Care Messaging|Participants receive standard messaging about HCV and ways to get screening.
45494368|NCT04285242|Other|Observational assessments|Clinical assessments
45494369|NCT04271748|Other|Time Restricted Feeding|The counseling on the regimen will involve instructing the subjects on study compliance and fasting times. Subjects will be instructed to choose an eight-hour eating window (e.g., 11:00am - 7:00pm) during which the patient will be able to eat his/her normal diet. During the 16-hour fasting window (e.g., 7:00pm - 11:00am), the participant will be able to drink regular water and black coffee.
45378383|NCT05696782|Diagnostic Test|Modified Medical Research Council (mMRC) dyspnea scale|Participants will be asked to answer the modified medical research council dyspnea scale (1 item), and the patient-reported outcome measures designed to measure respiratory function. The measures can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is less than 5 minutes.
45494370|NCT03427619|Drug|OK432|OK432 will be injected at dosage of 0.01 to 0.05 mg/mL 6-12 weeks apart up to 4 injections total.
45494371|NCT03407729|Other|Magnetic Resonance Imaging|MRI uses a strong magnetic field and radio waves to create detailed images of the brain while the person's head is positioned inside a round tunnel.
45494372|NCT03407729|Other|Cognitive Performance Testing|For the Grooved Pegboard task: After the MRI scan, children will be timed as they place pegs into holes with randomly positioned slots.
45494373|NCT03712475|Drug|Pregabalin|pharmacokinetic study under fasting conditions
45494374|NCT02435433|Drug|Ramucirumab|Administered IV
45494375|NCT02435433|Drug|Placebo|Administered IV
45494376|NCT01372371|Biological|Vancomycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) + 500 mg of vancomycin instilled on surgical site before closure
45494377|NCT01372371|Biological|Vancomycin and Gentamycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) and 500 mg of vancomycin powder on surgical site before closure with gentamycin bone cement for joint replacement cases.
45494378|NCT01372371|Biological|Cefuroxime|1 pre-operative dose of Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg)
45494379|NCT05167383|Device|VRH (Virtual Reality Hypnosis)|Hypnosis is delivered as a standardized therapeutic intervention through virtual reality, using a digital sedation software (AQUA ®, Onfomfort SA).
45494380|NCT05167383|Behavioral|Standard care|The standard treatment (ST) for labor pain as used in our hospital contains massage, aquatherapy and postural exercises. This is always available for any woman in labor.
45494381|NCT01374711|Drug|GM-CSF|GM-CSF (4microgram/kg/day subcutaneously) on days 2, 4 and 6.
45378384|NCT05696613|Drug|SNP-ACTH (1-39) Gel|Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
45378385|NCT05696613|Drug|Rituximab|Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
45378386|NCT05688696|Drug|Orelabrutinib (Low Dose)|Subjects will be administered with lower dose of Orelabrutinib orally once daily in combination with SOC therapy
45378387|NCT05688696|Drug|Orelabrutinib (High Dose)|Subjects will be administered with higher dose of Orelabrutinib orally once daily in combination with SOC therapy
45378388|NCT05688696|Drug|Orelabrutinib Placebo|Subjects will be administered with Orelabrutinib Placebo orally once daily in combination with SOC therapy
45378389|NCT05688254|Behavioral|FOREST-A|The internet-based psychosocial intervention will be delivered. The intervention comprises six modules: introduction, relaxation, psychological detachment, mastery, control, and summary, within psychoeducation and exercises in each module. The interactions with psychologists will be on demand. The whole intervention duration will be 4 weeks.
45378390|NCT05677880|Other|Study Procedures|"Participants will experience~Neurocognitive Tests and Self-Report Measures~Clinical Interviews~Neurological Exam~MRI screening at baseline, 18 months, 36 months~Fasted Blood draw"
45494382|NCT01374711|Drug|IFN-Y|IFN-Y (100 microgram/day, subcutaneously) on days 2, 4 and 6.
45494383|NCT01374711|Other|E.coli endotoxin|2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously
45494384|NCT05167071|Drug|HBM4003|Subjects will be treated with HBM4003 on Day 1 during each 21-day cycle.
45494385|NCT05167071|Drug|Toripalimab|Subjects will be treated with Toripalimab on Day 1 during each 21-day cycle.
45494386|NCT03120351|Drug|Lidoderm 5 % Topical Patch|Patients will receive Lidoderm topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off
45494387|NCT03120351|Drug|Placebo patch|2) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off
45494388|NCT05165355|Drug|Furmonertinib|Furmonertinib (80 mg orally, once daily) for 3 years.
45693634|NCT03839134|Device|DentalVibe® Comfort Injection System|Soft tissue vibration for 10 seconds using DentalVibe®. The device induces approximately 16 soft tissue vibrations of per second. The device will be in touch of oral mucosa (at the site of injection) before and during the local anesthesia injection.
45693635|NCT03839134|Drug|Lidocaine Epinephrine|Dental local anesthesia injection of 1.8 mL Lidocaine (2%) with Epinephrine (1:80000 w/v).
45378391|NCT05677139|Other|None (Observational Study)|Not applicable since it's an observational study.
46054554|NCT05308095|Other|Controlled hypoglycaemic state while driving|Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Initially, a euglycaemic state (5.0 - 8.0 mmol/L) is established and blood glucose is then declined to hypoglycaemia (3.0 - 3.5 mmol/L) by administering insulin. Thereafter, blood glucose is raised again to euglycaemia (5.0 - 8.0mmol/L). During the procedure, driving data is recorded. Additionally, eye movement, head pose, facial expression, heart rate, skin conductance, and CGM values are recorded throughout the glycemic trajectory. Participants are blinded to the blood glucose values during the procedure.
46054555|NCT02601391|Behavioral|Adapting STEPPS within forensic inpatient services.|This study will focus upon delivering the STEPPs-HI group within Forensic Healthcare Inpatient Services.
45494389|NCT01374789|Drug|GemCis + Panitumumab|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3 Panitumumab 9 mg/kg/body weight, i.v., day 1,q3
45494390|NCT01374789|Drug|GemCis|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3
45494391|NCT05164809|Device|Application of novel electrodes|Application of novel electrodes since 2017 for the dissection of extremity tumors in tumororthopedics
45494392|NCT05101083|Device|New Receiver-in-Canal Device|Successor of previous device generation
45494393|NCT05101083|Device|Legacy Receiver-in-Canal Device|Receiver-in-canal device available on the market
45494394|NCT02354703|Drug|Ondansetron|Ondansetron (0.33 mg) bid+ BBCET counseling
45494395|NCT02354703|Drug|Placebo|Placebo + BBCET counseling
45494396|NCT00740181|Drug|chemotherapy|
45494397|NCT00384111|Drug|Zevalin Therapeutic Regimen|Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
45494398|NCT00384111|Drug|R-CVP|Standard R-CVP
45494399|NCT05008887|Drug|Methotrexate|Fractional CO2 laser-assisted cutaneous delivery of methotrexate solution in stable, non-segmental vitiligo
45494400|NCT05008887|Drug|5-fluorouracil|Fractional CO2 laser-assisted cutaneous delivery of 5-fluorouracil solution in stable, non-segmental vitiligo
45494401|NCT05008887|Device|Fractional CO2 laser|Fractional CO2 laser-assisted cutaneous delivery of methotrexate and 5-fluorouracil solution in stable, non-segmental vitiligo
45494402|NCT01376115|Drug|Nelarabine|
45494403|NCT01376193|Drug|Naratriptan|Collection of safety data
45494404|NCT01373073|Other|Experimental human milk fortifier|Human milk fortifier to be added to human milk feedings
45378393|NCT05672576|Drug|Cenerimod|Cenerimod will be supplied as film-coated tablets at the dose of 4 mg.
45378394|NCT05672576|Drug|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
45378395|NCT05671237|Other|bilateral infraorbital+infratrochlear block|we will perform bilateral infraorbital+infratrochlear nerve block
45494405|NCT01373073|Other|Control human milk fortifier|Control human milk fortifier to be added to human milk
45494406|NCT04944771|Drug|Capivasertib|Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.
45494407|NCT04944771|Drug|Rabeprazole|Participants will receive twice daily oral doses of rabeprazole for 3 days (Days -3 to -1) and a single dose on the morning of Day 1 for Treatment C.
45494408|NCT01374945|Device|Clearpath Lower GI|Clearpath device for cleaning of colon by irrigation and evacuation
45494409|NCT05197413|Dietary Supplement|Arrae bloat supplement|The supplement contains organic dandelion root extract, organic lemon balm herb top extract, organic peppermint leaf extract, organic bromelain, organic slippery elm inner bark extract. The capsule itself is made of cellulose, which is not a main active ingredient.
45494410|NCT01375023|Radiation|Radiotherapy|daily radiation therapy for 10 days, total dose of 80 cGY
45494411|NCT01375023|Biological|Anti-Thymocyte Globulin|1.5 mg/kg/day, IV from day -11 through day -7 before transplantation
45494412|NCT05197101|Procedure|balloon catheter combined with oxytocin induction|Balloon catheter for 12 hours and oxytocin for up to 3days.If failed , they will be treated ceacrean.
45494413|NCT05039775|Device|EROS device|Eros is a small, hand-held device fitted with a removable, replaceable small plastic cup used as a natural way to initiate female sexual response. It was originally cleared by the FDA in April 2000 for the treatment of Female Sexual Arousal Disorder (FSAD), which includes problems with sexual arousal and orgasm.
45494414|NCT05039775|Behavioral|Psychosexual support|Strategies are suggested to improve the couple's emotional connection and communication, when couples are being consulted, they are encouraged to focus on the strengths as well as weaknesses in their relationship. Homework assignments are given for the couple to practice skills, such as turning the idea of sexual obligation into pleasure, learning to focus on sensations rather than anxieties and communicating openly with their partner.
45494415|NCT05197023|Drug|SHR-1819 injection or placebo|Drug: SHR-1819 injection or placebo Low-dose group, once per week Drug: SHR-1819 injection or placebo High-dose group, once per week
45494416|NCT03633669|Diagnostic Test|Fecal calprotectin|Testing every 3 months
45494417|NCT03633669|Other|Routine care|As per treating gastroenterologist
45494418|NCT01375101|Drug|placebo|The patient is directed to use placebo capsule two times a day, ,until the one mouth
45494419|NCT01375101|Drug|Quercetin|The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth
45378396|NCT05669833|Drug|Guselkumab|Guselkumab (GUS) subcutaneous injection
45378397|NCT05669833|Drug|Golimumab|Golimumab (GOL) subcutaneous injection
45378398|NCT05669833|Drug|Placebo|Guselkumab (GUS) matching placebo subcutaneous injection
45494420|NCT05196711|Drug|MAX-40070|"In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 6 subjects randomly assigned to MAX-40070.~During the MAD phase, the treatment will be administered once a day for 14 consecutive days."
45494421|NCT05196711|Drug|Placebo|"In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 2 subjects randomly assigned to placebo~In the MAD phase, the treatment will be administered once a day for 14 consecutive days. Each cohort will consist of 10 subjects, with 2 subjects randomly assigned to placebo"
45494422|NCT04878003|Drug|KRT-232|KRT-232, administration by mouth
45494423|NCT04878003|Drug|TL-895|TL-895, administration by mouth
45494424|NCT04865289|Drug|Lenvatinib|Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
45494425|NCT04865289|Biological|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
45494426|NCT04865289|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 IV infusion given on Day 1 of each cycle.
45378399|NCT05664113|Drug|Fecal microbiota transplant (FMT)|FMT Lower Delivery Microbiota Preparation, Dose: 250 mL of Microbiota Preparation Material and Route of administration: colonoscopy FMT Upper Delivery Microbiota Preparation, Dose: 60 mL of Microbiota Preparation Material and Route of administration: Naso-enteral tube
45494427|NCT04865289|Drug|Carboplatin|Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
45494428|NCT03633591|Drug|Tolcapone|Multiple doses of tolcapone tablets in the fasted state
45494429|NCT03633591|Drug|Tolcapone Modified Release Prototype|A single dose of tolcapone modified release prototype in the fasted state
45494430|NCT03633591|Drug|Tolcapone Divided Dose|Tolcapone (suspension) in equal divided doses in the fasted state
45494431|NCT03633591|Drug|Tolcapone Modified Release Prototype|A single dose of tolcapone modified release prototype (optionally two doses or fed state of prior MR prototype)
45494432|NCT01376271|Drug|Paroxetine|
45378400|NCT05657808|Dietary Supplement|Rest Study Active Product 1.1 Usage|Participants will use Radicle Rest Active Product 1.1 as directed for a period of 6 weeks.
45494433|NCT05196555|Procedure|Repair of cleft palate with intravelar veloplasty (IVVP)|A triangular flap is designed comprising new epithelial tissue which will be turned over to help close the nasal mucosa. Using a single hook, the oral mucosa and gland layer is separated from the muscle layer. Dissection of the greater palatine nerve-vessel bundle. The anterior palatal flap is raised by a curved elevator. The closure of the nasal mucosa and muscle is completed. Dissection of Velo Palatine Levator begins from the posterior rim of muscle and 5 mm from the midline.
45494434|NCT04885881|Procedure|Ozone therapy|Patients in the ozone therapy group will be treated with ozone (O2-O3) in a volume of 5 ml and a dose of 10 µg / ml for three consecutive weeks in a weekly session to the most painful trigger point.
45494435|NCT04885881|Procedure|Lidocaine injection group|Patients in the lidocaine injection group will be applied to the most painful trigger point in a volume of 2 ml of 1% lidocaine for three consecutive weeks, once a week.
45494436|NCT01375179|Drug|KRP203|
45494437|NCT01375179|Drug|Placebo matching KRP203|
45378401|NCT05657808|Dietary Supplement|Rest Study Active Product 1.2 Usage|Participants will use Radicle Rest Active Product 1.2 as directed for a period of 6 weeks.
45378402|NCT05657808|Dietary Supplement|Rest Study Active Product 2.1 Usage|Participants will use Radicle Rest Active Product 2.1 as directed for a period of 6 weeks.
45378403|NCT05657808|Dietary Supplement|Rest Study Active Product 2.2 Usage|Participants will use Radicle Rest Active Product 2.2 as directed for a period of 6 weeks.
45378404|NCT05657808|Dietary Supplement|Placebo Control Form 1|Participants will use Placebo Control Form 1 as directed for a period of 6 weeks.
46054556|NCT02538861|Diagnostic Test|SPECT Imaging Test at Baptist hospital|Single Photon Emission Tomography (SPECT) testing at Baptist Hospital.
45378405|NCT05657808|Dietary Supplement|Placebo Control Form 2|Participants will use Placebo Control Form 2 as directed for a period of 6 weeks.
45378406|NCT05657808|Dietary Supplement|Placebo Control Form 3|Participants will use Placebo Control Form 3 as directed for a period of 6 weeks.
45494438|NCT05196321|Other|sessions with ENF (Electro Neuro Feedback).|The study evaluates patients with clinical evidence of post-surgical hematoma / seroma after hip replacement surgery. These patients will undergo ultrasound evaluation in the 4th (+/- 2) day post surgery, in which triaxial parameters of the hematoma will be measured. This evaluation will then be repeated after 5 treatment sessions with ENF (Electro Neuro Feedback).
45494439|NCT01373307|Behavioral|LHA-delivered energy balance classes/activities|4-6 sessions delivered by local LHA to age-appropriate groups (i.e., children/adolescents and adults), based on We Can! And Media Smart Youth curricula.
46054557|NCT02538861|Diagnostic Test|CT Angiography and CT myocardial perfusion at West Kendall Baptist Hospital|The combined approach of CT Angiography and CT myocardial perfusion with new Revolution CT scanner
46054558|NCT02538861|Diagnostic Test|SPECT Imaging Test at West Kendall Baptist Hospital|Single Photon Emission Tomography (SPECT) testing at West Kendall Baptist hospital.
46054559|NCT02601157|Drug|3-months DAPT|Contrast to the conventional 1-year DAPT, patients in this group will be followed with 3-months DAPT schedule after the stenting
46054560|NCT02601157|Drug|1-year DAPT|Patients in this group will be followed with the conventional 1-year DAPT schedule after the stenting
46054561|NCT02785107|Behavioral|M-PAC Group|Participants attended a workshop, completed a worksheet and received a booster phone call follow-up at week four.
45494440|NCT04820205|Drug|Intranasal dexmedetomidine and ketamine|Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
45494441|NCT04820205|Drug|Oral chloral hydrate|Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
45378407|NCT05657808|Dietary Supplement|Rest Study Active Product 3.1 Usage|Participants will use Radicle Rest Active Product 3.1 as directed for a period of 6 weeks.
45378408|NCT05648500|Drug|Cenerimod|Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.
45494442|NCT01375257|Drug|Oral treatment with antibiotics for endocarditis|
46054562|NCT02784873|Other|High intensity interval training|High intensity interval training within a standard cardiac rehabilitation programme
45378409|NCT05648500|Drug|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
46054563|NCT04230993|Other|Sea water solution|Administration of different sea water solution is performed and the rating of cold symptoms according to the Jackson scale, the fluidity of mucus and the ease of blowing will be evaluated.
46054564|NCT04230915|Other|Intraoperative nerve monitoring|This group will determine as those who were administered 0.3 mg/kg rocuronium,
45378413|NCT05645523|Drug|Indocyanine Green|Given in to the vein (IV)
45378414|NCT05645146|Behavioral|Smoking Cessation treatment delivered by Tobacco Free Florida Quitline|Phone counseling with the state tobacco quitline
45378415|NCT05645146|Drug|Nicotine patch|Participants will be provided with a 12 week supply of nicotine patches
45378416|NCT05645146|Drug|Nicotine Lozenge|Participants will be provided with a 12 week supply of nicotine lozenges
45378417|NCT05645146|Behavioral|Motivation and Problem Solving (MAPS) intervention|MAPS is a phone counseling approach to facilitating smoking cessation among cervical cancer survivors, which uses a combined motivational interviewing and social cognitive theory based approach to smoking cessation. Participants will receive 6 MAPS based counseling calls over 12 months, along with personally-tailored SMS-delivered text based messages delivered to the participants phone over 2 years.
45378418|NCT05643950|Device|Foley catheter|"Silicone Foley catheters are transurethral balloon catheters used for the treatment of bladder emptying disorders, as well as for drainage of urine from the urinary tract, continuous fluid irrigation, and/or medication administration. Its use is suitable for a prolonged period of no more than 29 days and is used in Urology, Internal Medicine, Surgery, Obstetrics and Gynaecology Services.~For this study, conventional Foley-type catheters whose use is approved in Spain for routine use will be used. Silicone Foley catheters, usually available in 2- and 3-way, are made of silicone and consist of a body, drainage funnel, inflation funnel, irrigation funnel (if present, only on 3-way catheters) and balloon valve. The product is sterile and single use."
45494443|NCT01375257|Drug|Guideline treatment with parenteral antibiotics|
45494444|NCT01375335|Drug|Dobutamine|90 minutes of infusion 5 ug/kg/minute followed by isotonic saline for the same duration. The sequence of the above is randomized
45494445|NCT05195307|Other|Music Group|Pregnant women included in the practice group were given 20 minutes of music every day for ten days. Anxiety and stress levels of pregnant women were measured before and after the intervention.
45494446|NCT05194527|Other|Biomarker validation and VOC profile identification|Validation of a panel of plasma markers for the early diagnosis of acute intestinal ischemia with a panel consists of I-FABP, VIL-1, and SM22. Identification of an acute intestinal ischemia specific VOCs profile and evaluate exhaled breath analysis as a diagnostic tool for intestinal ischemia.
45494447|NCT01375413|Behavioral|physical therapy|Physical therapy consisting of gait training 3 times a week for 6 weeks
45494448|NCT01373463|Drug|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
45494449|NCT01373463|Drug|Carboplatin|Carboplatin by vein Every 21 days for 3 cycles
45494450|NCT01373463|Radiation|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
45494451|NCT01373463|Drug|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
45494452|NCT01373463|Drug|Cisplatin|Cisplatin by vein every 21 days for 3 cycles
45494453|NCT01373463|Radiation|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
45494454|NCT01373463|Procedure|Lobectomy|Surgery
45494455|NCT01373463|Procedure|Lobectomy|Surgery to remove a portion of the lung where the tumor is located.
45494456|NCT04597827|Other|Metacognition tests|Test on episodic or semantic memory
45494457|NCT04573647|Drug|Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]|Research subjects will use oxervate in affected eye following approved treatment regimen and have their eye measured with optical coherence tomography and a Cochet-Bonnet esthesiometer at various time points before, during and after treatment.
45494458|NCT05194371|Radiation|definitive radiotherapy or definitive chemoradiotherapy|A total dose of radiation therapy should be more than 50Gy
45494459|NCT05194215|Device|Ada WRA|The Ada WRA is a study-only device based on the Ada mobile app. The patient will use this device to answer questions regarding their symptoms but will not be given any feedback by the app.
45494460|NCT03113409|Drug|Buprenorphine|Buprenorphine will be administered daily
46054565|NCT00752791|Drug|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous injection, once every 4 weeks for up to 25 weeks. Initial dose based on patient's previous total weekly Epoetin dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
45378419|NCT05643950|Device|T-Control catheter|The T-control® catheter is a flexible, sterile silicone tube with an inflatable balloon at the distal tip, a polytetrafluroethylene membrane integrated into its body, and a sliding fluid control valve. The valve, built into the catheter, provides additional functions to the catheter, such as turning urine flow on and off after insertion (functions currently provided by accessories such as caps or valves) and controlling urination during the insertion process (function that is not provided by any other device). In this way, accidental loss of urine can be avoided from the first moment of use until its withdrawal. Additionally, it has a safety cap that reduces the possibility of accidental movements of the valve before use or during transport and fixing. The design has been developed in such a way that, once inserted, it facilitates autonomous use even for the elderly or patients with limited manual dexterity. The device is sterile and single use, like any conventional Foley catheter.
45378420|NCT05636111|Drug|Paclitaxel|Given by (IV) vein
45378421|NCT05636111|Drug|Bevacizumab|Given by (IV) vein
45378422|NCT05636111|Drug|Lurbinectedin|Given by (IV) vein
46054566|NCT04230603|Procedure|Hyperspectral imaging|Photos were taken with the hyperspectral camera of the human tissue
46054567|NCT04230603|Diagnostic Test|Lactate acid measurement|At the marked regions of the specimen, a lactate acid measurement was performed.
46054568|NCT04230603|Diagnostic Test|pathological examination|At the marked regions of the specimen, the pathological examination was performed.
45378426|NCT05631574|Drug|BMF-219|BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
45378427|NCT05631236|Device|Bright Light Therapy (AYO Glasses)|Bright light glasses that emit a more intense therapeutic blue light.
45378428|NCT05631236|Device|Bright Light Therapy (AYO Glasses)|Bright light glasses that emit a non-therapeutic blue light.
45494461|NCT03113409|Drug|Naltrexone|On study day 2, participants will receive increasing doses of oral naltrexone prior to administration of XR-NTX
45494462|NCT03113409|Drug|Vivitrol|Participants will receive one 380 i.m. injection on Study day 5 or 10, and another injection 4 weeks later.
45494463|NCT05193747|Other|Anesthesia depth monitoring|BIS monitor will be placed on the forehead according to the manufacturer recommendation and the anaesthesia team will be blinded to BIS monitor during the whole case. The initial BIS tracing will be recorded starting the surgery initiation (defined as the depth of anesthesia by the anaesthesiologist to initiate surgical intervention) and ending with end of surgical intervention.
45494464|NCT05193513|Device|hybrid expanders|tow maxillary hybrid expanders supported anteriorly with tow miniscrews
45494465|NCT03634293|Drug|Alirocumab Injectable Product|Alirocumab is an human monoclonal antibodies directed against Proprotein convertase subtilisin/kexin type 9 (PCSK9). It is administered once every two weeks subcutaneously.
45494466|NCT03634293|Drug|Saline Solution|The placebo will be 2 ml' of 0.9% saline injected subcutaneously.
45494467|NCT01373541|Other|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
45494468|NCT01373541|Other|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
45494469|NCT03633747|Drug|Propranolol Hydrochloride|Oral propranolol hydrochloride tablets are administration for 6 months at dose of 1.5 mg/kg or the maximum dose tolerable.
45494470|NCT01376739|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients who will need to undergo contrast enhanced MR angiography with Magnevist (a dosage of more than 0.2 mg/kg)
45494471|NCT05190783|Drug|Formocresol|mixture of formalin, cresol and glycerine used for fixation of pulp tissues
46054569|NCT05261529|Dietary Supplement|Extra Virgin Olive Oil (EVOO)|Daily intake of 40ml EVOO added to the normal intake of EVOO of the participants.
45494472|NCT05190783|Drug|MTA|material used for pulp regeneration, direct and indirect pulp capping
45494473|NCT05190783|Drug|TheraCal|light cured resin modified calcium silicate filled liner designed for use in direct and indirect pulp capping
45378429|NCT05625815|Device|Prototypes (816-v1 001) to (816-v1 050)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
45378430|NCT05625815|Device|Prototype (816-v1 051) to (816-v1 100)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
45378431|NCT05625815|Device|Prototypes (816-v1 101) to (816-v1 150)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
45378432|NCT05625815|Device|Prototypes (816-v1 151) to (816-v1 200)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
45378433|NCT05625204|Behavioral|Center based attention control|Center based attention control
45494474|NCT05190783|Procedure|pulpotomy|removal of the carious tooth structure and unroofing of the pulp chamber with a round carbide bur with high speed and water spray. The coronal pulp tissue will be then removed using a #4 carbide bur with slow speed and sharp spoon excavator.
45494475|NCT05190783|Procedure|partial pulpotomy|complete removal of caries till exposure occurs. The exposed surface of the pulp will be gently removed using a sterile round diamond bur and a high-speed, water-cooled handpiece with light hand pressure. The removal of the pulp did not exceed approximately two mm.
45494476|NCT01375647|Biological|IPV|Administered per protocol
45494477|NCT01375647|Biological|Rotarix|Administered per protocol
45494478|NCT01373619|Drug|Ivabradine|ivabradine titrated to 7.5 mg BID
45494479|NCT05177835|Drug|ABX464|All subjects will receive ABX464 given at 25 mg QD.
45693636|NCT03180580|Behavioral|HEAL guideline and healthy tiffin box intervention|"Healthy Eating and Active Living (HEAL) guideline and healthy tiffin box intervention is a combination of intervention to promote healthy eating behavior and improve physical activity level of school going children. The guideline was developed to deliver healthy lifestyle message encouraging healthy dietary habit and physical activity pattern in order to control childhood overweight and obesity. Investigators was designed a Healthy Tiffin Box for children that contained five different compartments of various sizes for stuffing with five different food types in order to ensure healthy balanced diet including low carbohydrate, moderate protein, low fat and high vitamin. We also provided with a recommended physical activity list for children."
45494480|NCT01376817|Drug|Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
45494481|NCT01376817|Drug|Fat emulsion with MCT and LCT|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
45494482|NCT01375803|Dietary Supplement|Novel dietary fiber|oral consumption in beverage
45494483|NCT01375803|Dietary Supplement|Novel dietary fiber|Oral consumption in beverage
45494484|NCT01375803|Other|Placebo|Oral consumption in beverage
45494485|NCT04812171|Procedure|non-surgical endodontic treatment|standard non-surgical endodontic treatment performed by endodontic specialist
45378434|NCT05625204|Behavioral|Center based HIIT|Center based HIIT
45378435|NCT05625204|Behavioral|Home based HIIT|Home based HIIT
45378436|NCT05624723|Drug|INCB054707|INCB054707 75 mg will be administered orally
45494486|NCT04745637|Drug|Ruxolitinib|provide access to ruxolitinib, for Patients with Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-Essential Thrombocythemia Myelofibrosis (PET-MF)
45378437|NCT05624281|Drug|nintedanib|nintedanib, for patients with fibrosing interstitial lung disease (ILD); in this EAP limited to children and adolescents
45378439|NCT05620719|Behavioral|Cognitive Behavioral Therapy for Posttraumatic Headache|CBT for Posttraumatic Headaches consists of 8 sessions of cognitive behavioral therapy that focus on (1) discussions and exercises that increase awareness of what may be related to headaches, (2) relaxation techniques to manage physiological stress, and (3) problem-solving techniques to manage common stressors. Sessions are delivered weekly and can last between 45 to 75 minutes based on clinical content and patient response to the material.
45378440|NCT05620719|Other|Treatment as Usual|Participants will continue to engage in medical care as usual for 8 weeks.
45378441|NCT05620719|Other|Telemedicine-based Cognitive Behavioral Therapy (TCBT)|Participants assigned to TCBT will receive 8 sessions of cognitive behavioral therapy using telemedicine rather than face-to face office visits.
45378442|NCT05618353|Drug|Colchicine|0.6 mg tablets
45378443|NCT05618353|Drug|Placebo|Matching placebo
45378444|NCT05613725|Other|Blood sample collection|Blood sample collection
45378445|NCT05610072|Drug|n-acetylcysteine|Subjects will be randomized to receive 2.4 oral n-acetylcysteine daily.
45378446|NCT05610072|Drug|Hydromorphone|Subjects will receive up to 90 mg oral hydromorphone daily.
45378447|NCT05610072|Drug|Placebo n-acetylcystine|Subjects will be randomized to receive placebo n-acetylcysteine daily.
45693637|NCT03906526|Drug|VTX-2337|Motolimod
45494487|NCT01373697|Drug|Ibuprofen|Apply the gel at the site of pain or injury, massaging gently to promote penetration of 8 in 8 hours for 5 days. Leave the gel on the premises at least 4 hours before removal
45494488|NCT01373697|Drug|Profenid|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
45693638|NCT03906526|Drug|Nivolumab|IV Nivolumab
45693639|NCT03088930|Drug|Crizotinib|Crizotinib is an oral receptor tyrosine kinase inhibitor of ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and ROS1 (c-ros). Crizotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of crizotinib is 250mg orally. Participants on this trial will receive this dose, unless dose modification is necessary.
45693640|NCT03035188|Drug|Vismodegib|1 capsule (150 mg vismodegib) taken once daily for a maximum of 12 weeks.
45693641|NCT05265754|Behavioral|sujok therapy|sujok therapy
45693642|NCT05250778|Behavioral|Nudge|Room intervention
45693643|NCT02923882|Other|'$100Kitchen and improved cookstove'|
45378448|NCT05610072|Drug|Placebo hydromorphone|Prior to some experimental sessions, subjects will receive placebo hydromorphone
45378449|NCT05609552|Combination Product|18F-Pretomanid PET/CT|A bolus of less than or equal to 10 mCi (370 MBq) of 18F-pretomanid will be injected into the intravenous line by slow IV push. Immediately after administration of 18F-pretomanid, dynamic PET acquisition will take place.
45378450|NCT05609435|Other|REASSURE|REASSURE is comprised of three components that are intended to be integrated into survivorship care at each follow-up visit: 1) An online patient-reported outcome (PRO) assessment to comprehensively evaluate survivors' symptoms and concerns; 2) A tailored follow-up recommendation based on pre-established thresholds for reported symptoms and concerns. Survivors who report symptoms or concerns have a follow-up visit to discuss findings whereas survivors without symptoms or concerns will avoid a follow-up visit; and 3) Online survivorship messaging sent after the visit, which includes reassurance about the low recurrence risk, an overview of what to expect from follow-up, and steps survivors can take to reduce cancer risk.
45378451|NCT05608343|Drug|Difamilast|Off-white ointment containing active ingredient, petrolatum and other ingredients
45378452|NCT05608343|Drug|Placebo|Matching Difamilast (Study drug) ointment without active ingradient
45378453|NCT05605340|Behavioral|Meal Delivery|10 healthy, home-delivered meals per week + brief weekly remote behavioral support
45378454|NCT05602766|Drug|NGENLA (Somatrogon)|Dosage, Frequency: Refer to the latest package insert.
45378455|NCT05602727|Drug|MK-1942|MK-1942 oral capsule
45378456|NCT05602727|Drug|Placebo|Placebo oral capsule
45378457|NCT05597085|Drug|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin is an Antibody drug conjugate directed against CD 22 positive B Cell ALL
45494489|NCT01375881|Drug|darunavir/ritonavir plus background regimen|darunavir/ritonavir, oral use, in naive and experienced patients at approved dosages
45494490|NCT03427073|Drug|ALM201|Drug: ALM201 administered subcutaneously
45494491|NCT05760885|Behavioral|Balance training with sensory augmentation|Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, sensory augmentation will be delivered with an intensity controlled in real-time by their center of pressure motion. The difficulty of the balance training task will progressively increase over successive training sessions.
45693644|NCT02152696|Drug|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
45494492|NCT05760885|Behavioral|Balance training|Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, no sensory stimulation will be delivered. The difficulty of the balance training task will progressively increase over successive training sessions.
45494493|NCT03716219|Other|Exercise Training|Physical activity in children and adults with asthma.
45494494|NCT04690023|Procedure|Pericapsular nerves group (PENG) block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided PENG block with injection 20 ml of ropivacaine 0,75%, between the anterior hip articular capsule, the ilii-psoas muscle, the ileo-pubic eminence and the antero-inferior iliac spine.
45494495|NCT04690023|Procedure|Supra-inguinal fascia-iliaca compartment block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided supra-inguinal fascia iliaca compartment block with injection over de inguinal ligament of 40 ml of ropivacaine 0,375%, between de ilio-psoas muscle and internal oblique muscle.
45494496|NCT04690023|Drug|Ropivacaine 0,75% in PENG block|20 ml injection of ropivacaine 0,75%
45693645|NCT02152696|Procedure|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
45378458|NCT05595642|Drug|Astegolimab|Participants will receive SC astegolimab Q2W or Q4W
45693646|NCT02152696|Other|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring
45378459|NCT05595642|Drug|Placebo|Participants will receive SC placebo Q2W
45378460|NCT05589935|Dietary Supplement|Relief Study Product Usage|Participants instructed to use study product daily as directed for a period of 4 weeks
45494497|NCT04690023|Drug|Ropivacaine 0,375% in SFICB block|40 ml injection of ropivacaine 0,375%
45494498|NCT03066804|Drug|sacubitril/valsartan|Sacubitril/valsartan is available as 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg, respectively in tablet form to be taken orally
45494499|NCT03066804|Drug|Enalapril|Enalapril is available as 2.5 mg, 5 mg, and 10 mg tablet form to be taken orally
45693647|NCT02153476|Drug|2.0mg of ALG-1001|
45378461|NCT05587712|Drug|Sotatercept|SC injection every 3 weeks (Q3W) of 0.3 mg/kg. Dosage may be adjusted based on protocol-specific guidelines.
45378462|NCT05583526|Drug|Ritlecitinib|50 mg capsule
45378463|NCT05583526|Drug|Placebo|Matching capsule
45378464|NCT05581004|Drug|RO7502175|RO7502175 will be administered as per the schedules specified in the respective arms.
45378465|NCT05581004|Drug|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
45378466|NCT05577702|Drug|Tislelizumab|Administered as an intravenous infusion
45378467|NCT05577702|Drug|Ociperlimab|Administered as an intravenous infusion
45378468|NCT05577702|Drug|LBL-007|Administered as an intravenous infusion
45378469|NCT05577481|Combination Product|sham iTBS combined with antidepressants|Two sessions of sham prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.
45378470|NCT05577481|Combination Product|iTBS combined with antidepressants|Two sessions of prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.
45494500|NCT03066804|Drug|Valsartan|Valsartan is available as 40 mg, 80 mg, 160 mg tablet form to be taken orally
45494501|NCT03066804|Drug|Placebo to match sacubitril/valsartan|Placebo to match LCZ696 50 mg, 100 mg, 200 mg tablet form to be taken orally
45494502|NCT03066804|Drug|Placebo to match enalapril|Placebo to match enalapril 2.5 mg, 5 mg, 10 mg tablet form to be taken orally
45494503|NCT03066804|Drug|Placebo to match valsartan|Placebo to match valsartan 40 mg, 80 mg, 160 mg tablet form to be taken orally
45494504|NCT03633357|Drug|JNJ-18038683|"JNJ-18038683 has been developed by Janssen Pharmaceuticals (Johnson and Johnson), and is a relatively selective high affinity functional 5-HT7 receptor antagonist.~Participants will take two 10-mg tablets daily, for seven days."
45494505|NCT03633357|Drug|Placebo|Participants will take two placebo tablets daily, for seven days.
45494506|NCT02954237|Device|AMPLATZER™ Cardiac Plug|The AMPLATZER™ Cardiac Plug is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage. The device is constructed from a nitinol mesh and consists of a lobe and a disc connected by a central waist. The device is designed to facilitate occlusion. The lobe has stabilizing wires to improve device placement and retention. The device has threaded screw attachments at each end for connection to the delivery and loading cables. The device has radiopaque markers at each end and at the stabilizing wires. Device Sizes: 16, 18, 20, 22, 24, 26, 28, and 30 mm (lobe diameter) Delivery System: AMPLATZER TorqVue® 45º x 45º (sheath sizes 9, 10, or 13 Fr)
45494507|NCT03629262|Drug|Dexmedetomidine|Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and sufentanil (1.25 ug/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
45494508|NCT03629262|Drug|Placebo|Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of placebo and sufentanil (1.25 ug/m), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
45494509|NCT04224090|Diagnostic Test|Echocardiographic assessment of coronary arteries origin and proximal course|Echocardiographic assessment of CAA utilizing 4 specific echocardiographic acoustic windows: parasternal short-axis (PSAX), parasternal long-axis (PLAX), apical 4/5-chambers views.
45378471|NCT05574634|Behavioral|Tablet based adaptive multimodal attention practice program|An adaptive at-home tablet-based program that includes variants of the Flanker Task, the Stroop Task, and a Visual Tracking Task. Each session of practice will include up to ten minutes with each of these task types, and the tasks will increase in difficulty in a way that further taxes attention (such as through more distractors or more incongruent trials) as participant performance improves.
45378472|NCT05574634|Behavioral|Tablet based adaptive criterion task practice program|An adaptive, at-home tablet-based variant of the criterion task, that is, the selective attention/distraction task used during the scanning portion of the human participant portions of the study, that takes up to 25 minutes to complete each session.
45494510|NCT05208372|Diagnostic Test|CTC test|Circulating tumor cells test of ascites and blood for patients with gastric cancer.
45494511|NCT05208372|Diagnostic Test|ctDNA test|Circulating tumor DNA test of ascites and blood for patients with gastric cancer.
45693648|NCT02153476|Drug|Balanced Salt Solution|
45693649|NCT05206942|Diagnostic Test|Doppler ultrasound|Power doppler measurements will be made using a portable Siemens S2000 ultrasound scanner
45693650|NCT05206942|Diagnostic Test|Long Ensemble Angular-coherence Doppler [LEAD] ultrasound|Long Ensemble Angular-coherence Doppler measurements will be made using a Verasonics Vantage 256 scanner with a C5-2v
45693651|NCT05206942|Diagnostic Test|Contrast-enhanced ultrasound (CEUS)|Contrast-enhanced ultrasound measurements will be made using Lumason IV contrast injection followed by an injection of normal saline
45693652|NCT03839290|Procedure|Early neonatal cheiloplasty|
45693653|NCT03836482|Device|Selective Cytopheretic Device|Treatment will be delivered for 6 hours a day for up to 6 consecutive days.
45693654|NCT03834922|Other|Prospective data collection|No intervention. It's a prospective data collection.
45693655|NCT03839992|Diagnostic Test|spirometry|measure spirometry and lung CT
45378473|NCT05572944|Other|to develop a risk model and assess the lung cancer risk|"Participants will receive the following things in sequence~Non-smoker lung cancer prediction model among Taiwanese population by questionnaire~Check autoantibodies against p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2 in the blood of recruited patients and detect 133 SNPs and 11 mitochondrial mutations which are highly correlated with never-smoking lung cancer in our preliminary data~In high risk group,arrange chest CT and detection, classification, prediction of lung cancer risk in CT using deep learning and radiomics~Optimization and validation of lung cancer risk and probability prediction model: prospective multicenter clinical study"
45378474|NCT05572021|Device|Propspective VHR with Fortiva|Ventral hernia repair using Fortiva biologic mesh
45378475|NCT05572021|Device|RetroSpective VHR with Strattice|Retrospective cohort of ventral hernia repair patients using Strattice mesh
45378476|NCT05557695|Drug|Acalabrutinib|Acalabrutinib
45378477|NCT05557474|Other|Early-stage lung cancer prognostic kit -- ELISA|blood sample with ELISA
45494512|NCT05208294|Drug|Sulpiride 400 MG|The substituted benzamide sulpiride is a selective D2-receptor antagonist that is generally well tolerated and has a low affinity to histaminergic, cholinergic, serotonergic, adrenergic, or GABA receptors. Sulpiride is slowly absorbed from the gastrointestinal tract and peak serum levels occur at 3 hours . In low doses (50-200 mg), sulpiride presumably blocks presynaptic autoreceptors, thereby elevating DA levels and reducing depressive symptoms, whereas higher doses lead to a predominant blockade of postsynaptic receptors. The dose in the present study (400 mg) is sufficient for behaviorally relevant modulations of dopaminergic processing with minimal risk of side effects. Note that participants in the sulpiride group actually receive a dose that is presumably too high to produce antidepressant effects.
45494513|NCT05208294|Drug|Placebo|Participants receive an inactive placebo capsule.
45494514|NCT05208294|Behavioral|High expectation manipulation|Participants will be told by the study clinicians that an antidepressive sulpiride capsule is administrated.
45494515|NCT05208294|Behavioral|Low expectation manipulation|Participants will be told by the study clinicians that an inactive placebo capsule is administrated.
45494516|NCT05213988|Dietary Supplement|Intermittent Fasting|Intermittent fasting meal pattern
45494517|NCT05213988|Drug|Fibrates|Bezafibrate 400 mg/day
45378478|NCT05557474|Other|Early-stage lung cancer prognostic kit -- IHC|surgical tumor part with IHC
45494518|NCT05213988|Dietary Supplement|Low-Carbohydrate/High-Protein diet|Low-calorie, low-carbohydrate, high-protein diet
45494519|NCT05207904|Drug|Tislelizumab, paclitaxel, Carboplatin|Tislelizumab, 200mg administered intravenously (IV) on Day 1 of each 21-day cycle paclitaxel 175 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6cycle Carboplatin AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6 cycle
45847245|NCT04964466|Biological|Amount of PDGF-BB available in PRF + bone substitutes vs. rhPDGF-BB+ bone substitutes following preparation|Growth factor release assessments will be made to determine the PDGF-BB present in the six prepared samples of the following: 1) PRF + mineralized freeze-dried corticocancellous allograft, 2) PRF + xenograft, and 3) PRF + B-TCP. Assessments will also be made for one sample of each of the following: 1) rhPDGF-BB + freeze-dried bone allograft, 2) rhPDGF-BB + xenograft, and 3) rhPDGF-BB+ B-TCP preparation. This assessment will be made at 60 minutes following the incorporation of the bone graft materials. During this time period, the samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At 60 minutes after preparation, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
45494520|NCT05207826|Diagnostic Test|Cystometrogram|Serial cystometrogram every 3 days for acute traumatic spinal cord injured patients
45494521|NCT04150692|Biological|Dara-SC|-Subcutaneous daratumumab and hyaluronidase-fihj
45494522|NCT04150692|Procedure|Blood for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
45494523|NCT04150692|Procedure|Bone marrow for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
45378479|NCT05552339|Drug|Finerenone (Kerendia, BAY94-8862)|Following the physicians' decision.
45378480|NCT05552339|Drug|Type 2 DM drugs|Following the physicians' decision
45378481|NCT05551364|Device|ATLAS 2030 exoskeleton|"Individualized Rehabilitation Treatment with the ATLAS 2030 Exoskeleton consists of the following phases:~Telephone contact phase (1 session)~Inclusion Phase (1 session)~Signing of informed consent (1 session)~Initial Evaluation Phase (1 session)~Treatment Phase (1st part) (7 sessions)~Monthly Evaluation Phase (1 session)~Treatment Phase (2nd part) (7 sessions)~Monthly Evaluation Phase (1 session)~Treatment Phase (3rd part) (7 sessions)~Final Evaluation Phase and results (2 sessions)"
45378482|NCT05546476|Drug|ponsegromab|Double-Blind ponsegromab Treatment followed by Open Label ponsegromab Treatment
45378483|NCT05546476|Drug|Placebo for ponsegromab|Double-Blind placebo Treatment followed by Open Label ponsegromab Treatment
45378484|NCT05544981|Dietary Supplement|Beetroot Juice|70 ml of beetroot juice containing ~5 mmol of inorganic nitrate
45378485|NCT05544981|Dietary Supplement|Beetroot Juice|70 ml of beetroot juice which is nitrate-depleted
45494524|NCT05715450|Procedure|Falciformopexy for Treatment Perforated Peptic Ulcer|use the falciform ligament on perforated peptic ulcer
45494525|NCT05213754|Procedure|Endovascular Treatment|Re-open the occluded cerebral artery using endovascular treatment
45494526|NCT05207514|Drug|Nanoxel M|75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
45494527|NCT05207514|Drug|Taxotere|75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
45494528|NCT05207514|Drug|Doxorubicin|60 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with cyclophosphamide
45494529|NCT05207514|Drug|Cyclophosphamide|600 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with doxorubicin.
45378486|NCT05538208|Drug|Mycophenolate Mofetil|MMF dosed 600mg/m2 body surface area per dose about every 12 hours
45378487|NCT05538208|Drug|Mycophenolate Mofetil|MMF dosed twice daily to achieve an area under the concentration-time curve (AUC 0-12h) of MPA >=60-70 mg*h/L
45378488|NCT05516069|Other|Our Healthbox (smart vending machine or interactive dispensing system)|Our Healthboxes or interactive dispensing systems (IDS) will be placed in various locations across Canada and will house HIV self-test kits (provided by REACH), harm reduction supplies (provided by the provincial governments / local community based organizations; e.g. sterile drug use kits for safer injection, naloxone kits, syringes), other community determined needs (including but not limited to hats, mittens and/or socks, rapid Covid-19 antigen kits, KN95 masks). Individuals will be able to access the HIV self-test kits and harm reduction and other materials directly from the machine. Our Healthbox will also provide health information, and a support services directory for people to find the health care they need - in their community.
45378489|NCT05514496|Drug|NX-019|NX-019 will be administered orally.
45378490|NCT05502328|Dietary Supplement|Energy Study Product Usage|Participants will use their Radicle Energy study product as directed for a period of 4 weeks.
45378491|NCT05499585|Other|Whole Dairy|2 1/2 servings of whole dairy per day
45378492|NCT05495334|Procedure|Treatment for Knee OA|Pain management treatment for knee OA.
45378493|NCT05490381|Other|Iodixanol|Given via injection
45378494|NCT05490381|Procedure|Angiogram|Undergo diagnostic cerebral angiogram
45378495|NCT05490381|Procedure|Arterial Embolization|Undergo tumor vessel embolization
45378496|NCT05490381|Drug|Polyvinyl Alcohol|Given via catheter
45378497|NCT05490381|Drug|Ethiodized Oil|Given via catheter
45494532|NCT04250337|Biological|Lebrikizumab|Subcutaneous injection
45494533|NCT04250337|Other|Placebo|Subcutaneous injection
45494534|NCT04250337|Other|Topical Corticosteroid|Topical Corticosteroid
45494535|NCT05207436|Drug|Oxytocin nasal spray|Veteran participants will self-administer 40 IU of intranasal oxytocin 30 minutes before the start of each B-CBCT session.
45494536|NCT05207436|Behavioral|Brief Cognitive-Behavioral Conjoint Therapy|Eight sessions of standardized B-CBCT, a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning.
45494537|NCT04011540|Behavioral|Digital data|Receiving digital data prior to a scheduled mental health session
45378498|NCT05490381|Procedure|Computed Tomography|Undergo head and neck CT scans
45378499|NCT05490381|Other|Chart Abstraction|Ancillary studies
45378500|NCT05486572|Other|Abbreviated Magnetic Resonance Imaging with serum AFP|Abdominal aMRI+ serum AFP every 6 months from the time of recruitment until the end of year 8
45378501|NCT05486572|Other|Abdominal Ultrasound Screening with serum AFP|abdominal ultrasound (US)+serum alpha fetoprotein (AFP) every 6 months from the time of recruitment until the end of year 8
45378502|NCT05486507|Dietary Supplement|Montmorency tart cherry|US grown Montmorency tart cherry 60ml per day for 6 weeks.
45494538|NCT04687059|Biological|PQ Grass|Suspension for injection
45494539|NCT04687059|Drug|Placebo Option 1|Suspension for injection
45494540|NCT04687059|Drug|Placebo Option 2|Solution for injection
45378503|NCT05486507|Dietary Supplement|Placebo|Taste matched placebo.
45378504|NCT05484622|Drug|Vorasidenib|Administered orally as tablets.
45378505|NCT05484622|Drug|Pembrolizumab|Administered as IV infusion.
45378506|NCT05480306|Drug|DKN-01|30 minute IV infusion (400mg) every two weeks with an additional loading dose in the first cycle of treatment
45378507|NCT05480306|Drug|FOLFIRI|90-min IV infusion of irinotecan, leucovorin, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks
45494541|NCT04682145|Drug|Turoctocog alfa pegol|Patients will be treated with commercially available turoctocog alfa pegol according to routine clinical practice at the discretion of the treating physician. A decision to initiate treatment with commercially available turoctocog alfa pegol has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in the registry in scope.
45494542|NCT05760729|Diagnostic Test|Cognitive testing|Cognitive tests will be carried: MOCA, trail making test, digit symbol substitution, forward and backward digit testing.
45494543|NCT01373775|Other|Patient charts reviewing|Reviewing chart and identifying risk factors
45378508|NCT05480306|Drug|Bevacizumab|90-min IV infusion (5mg)
45494544|NCT03118947|Drug|Pimavanserin|Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
45494545|NCT03998319|Drug|Tenecteplase (1/3 systemic weight based dose)|50mg reconstituted to 20mL for intracoronary infusion at 1/3 weight based dose.
45378509|NCT05480306|Drug|FOLFOX|2 hour IV infusion of oxaliplatin, folinic acid, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks
45378510|NCT05468515|Diagnostic Test|pulse oxygen saturation|preductal oxygen saturation
45378511|NCT05465135|Drug|Dihydroartemisinin|Dihydroartemisinin 40mg three times a day for 12 consecutive weeks.
45494546|NCT03998319|Other|Sterile water for injection (WFI)|Placebo comparative arm.
45494547|NCT03998319|Drug|Tenecteplase (1/6 systemic weight based dose)|50mg reconstituted to 20mL for intracoronary infusion at 1/6 weight based dose.
45494548|NCT03983733|Other|Dietary Intervention|To carry out an interventional dietary study using standardised meals to predict an individual's metabolic response to certain foods, using their gut microbiome, metabolic profile, and other measurable characteristics such as weight, sleep and exercise.
45693656|NCT05172232|Diagnostic Test|Dermalyzer|To evaluate the diagnostic accuracy of the Dermalyzer device to detect melanoma among cutaneos skin lesions by dermoscopy.
45378512|NCT05464342|Behavioral|Evening LGI Carbohydrate Consumption Group|Participants will receive in the evening food with low glycemic index
45378513|NCT05464342|Behavioral|Evening HGI Carbohydrate Consumption|Participants will receive in the evening food with high glycemic index
45378514|NCT05464342|Behavioral|Evening NO-CHO Carbohydrate Consumption|Participants will receive in the evening a meal with no carbohydrates at all.
45378515|NCT05464186|Behavioral|Whole milk|Weekly home delivery of whole milk, daily text messages, monthly virtual visits
45378516|NCT05464186|Behavioral|Nonfat milk|Weekly home delivery of nonfat milk, daily text messages, monthly virtual visits
45378517|NCT05461157|Device|Preoperative silicone ointment|The silicone ointment in this study is the Biodermis Scar Aid Silicone Stick, an FDA-approved silicone ointment that is available for purchase over the counter.
45378518|NCT05461157|Other|Preoperative placebo ointment|The placebo ointment in this study is a generic, non-flavored lip balm that is identical in packaging and texture to the Biodermis Scar Aid Silicone Stick used in the treatment arm.
45494549|NCT05759793|Drug|CAR-T (CAR-GPRC5D)|CAR-GPRC5D is an individualized, gene-modified autologous T cell immunotherapy product targeting GPRC5D that identifies and eliminates malignant and normal cells expressing GPRC5D. CAR specifically recognizes GPRC5D with a hypoimmunogenic human single-chain variable fragment (ScFv) that promotes car-T activation, proliferation and cytokine secretion. The persistence of CAR-T is enhanced by 4-1BB costimulation signal.
45494550|NCT03953079|Drug|Drug: GB-102|Intravitreal injection of GB-102
45494551|NCT03953079|Drug|Aflibercept|Intravitreal injection of aflibercept (2 mg dose)
45494552|NCT04572399|Device|UV Light Treatment|UV light therapy administered while patient is mechanically ventilated
45494553|NCT03885999|Device|Fecobionics|Fecobionics is a new device for studying defecation
45494554|NCT03879525|Other|EMR-based-interventional method|Questionnaire delivery method. Participants will complete standard care anxiety and depression screening and quality of life assessment directly into the patient entered section of the EMR, administered on arrival in the clinic.
45494555|NCT03879525|Other|Telephone-based-standard method|Questionnaires delivered via phone. Participants will complete standard care anxiety and depression screening and quality of life assessment via phone. Standard delivery method.
45494556|NCT03108027|Drug|Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)|Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
45378519|NCT05458011|Drug|Fremanezumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
45378520|NCT05458011|Drug|Placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
45494557|NCT03108027|Drug|Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)|QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
45494558|NCT03108027|Drug|Treatment C: Placebo (morning dose) and placebo (evening dose)|Placebo (morning dose) and placebo (evening dose)
45494559|NCT05760651|Other|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
45494560|NCT03812601|Procedure|Simultaneous bi-atrial electroanatomic mapping and ablation|Simultaneous bi-atrial electroanatomic mapping during atrial fibrillation and during pacing from 3 different vectors at varying cycle lengths followed by pulmonary vein isolation and AcQMap guided ablation of non-pulmonary vein mechanisms.
45494561|NCT03794427|Other|unilateral lumbosacral nerve block|Patients will receive unilateral lumbosacral nerve block (sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5). The sciatic nerve will be injected by 20 ml of the anesthetic mixture whereas levels L3-L4 and L4-L5 will be injected by a total of 20 ml of the anesthetic mixture without exceeding the maximum injected volume of 1 ml/kg.
45494562|NCT03794427|Other|Spinal anesthesia|Patients will receive spinal anesthesia (3 ml of 0.5% bupivacaine)
45494563|NCT03794427|Other|Placebo at the spinal anesthesia level|Patients will receive 1 ml normal saline at the spinal anesthesia level (L3-L4 or L4-L5).
45494564|NCT03794427|Other|Placebo at lumbosacral level|Patients will receive normal saline at the sciatic, L3-L4 and L4-L5 levels
45494565|NCT03606291|Radiation|isotoxic hypofractionation|the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible
45494566|NCT05759481|Drug|Propofol|Propofol is administered starting at surgery induction and ending at skin closure
45494567|NCT05759481|Other|Placebo|Placebo is administered starting at surgery induction and ending at skin closure
45494568|NCT03427827|Drug|Camrelizumab|Camrelizumab is an antibody targeting PD-1 developed by Jiangsu Hengrui Medicine, China.
45378522|NCT05442814|Procedure|Posterior suprascapular block|Diaphragmatic thickness fraction will be evaluated in the participant underwent suprascapular block performed by posterior approach
45378523|NCT05442814|Procedure|Anterior suprascapular block|Diaphragmatic thickness fraction will be evaluated in the participant underwent suprascapular block performed by anterior approach
45378524|NCT05441306|Device|Personal Health Library (PerHL) + MyChart|Participants randomized to the PerHL arm will have access to PerHL + the standard of care patient portal (Epic®MyChart).
45378525|NCT05441306|Device|Epic®MyChart|Participants randomized to the control arm will receive the standard of care patient portal (Epic®MyChart).
45378526|NCT05438927|Behavioral|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
45494569|NCT03633513|Diagnostic Test|LBT-3627|Immunomodulatory agent
45378527|NCT05438927|Behavioral|Nutrition Counseling|Participants will receive individually tailored, biweekly nutrition counseling from a dietician via telehealth
45693657|NCT02009176|Procedure|Laparoscopic Anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group A is Laparoscopic Anatomical Hepatectomy: Anatomy the corresponding liver segment pedicle and hepatectomy along the Glisson fiber sheath
45693658|NCT02009176|Procedure|Laparoscopic Aon-anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group B is Laparoscopic Aon-anatomical Hepatectomy:1 to 2 cm along the edge of the tumor complete hepatectomy
45494570|NCT03633513|Diagnostic Test|Immunological profiling|Comprehensive profiling of inflammatory and anti-inflammatory markers (incl. cellular, molecular) including cellular functional assays
45494571|NCT03410901|Biological|Anti-OX40 Antibody BMS 986178|Given IV, intratumoral
45494572|NCT03410901|Other|Laboratory Biomarker Analysis|Correlative studies
45494573|NCT03410901|Radiation|Radiation Therapy|Undergo radiation therapy
45494574|NCT03410901|Drug|TLR9 Agonist SD-101|Given intratumorally
45494575|NCT01373853|Procedure|Lens Fragmentation by means of a femtosecondlaser|In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery.
45494576|NCT01373853|Procedure|Manual Phacoemulsification|Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
45494577|NCT03357939|Drug|HLX03|A single dose of 40 mg HLX03 in 0.8 mL in subcutaneous injection.
45494578|NCT03357939|Drug|adalimumab|A single dose of 40 mg Humira in 0.8 mL in a pre-filled syringe
45494579|NCT05759403|Diagnostic Test|Cortical excitability using transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive neurophysiological technique for assessing human motor cortical function. With TMS, the underlying motor cortex is stimulated by an electric current induced by a transient magnetic field, generated in response to the passage of a large current through the stimulating coil located on the patient's scalp.
45494580|NCT03713073|Device|Allogenic amnion chorion membrane|Allogenic amnion chorion membrane (ACM) is a minimally manipulated allograft amnion chorion tissue for use as a wound covering in dental surgery.
45494581|NCT03713073|Device|Collagen dressing|Collagen dressing is used to cover wounds in dental surgery.
45494582|NCT05760495|Other|blood sampling|Blood sampling for evaluation of oxidative stress markers
45494583|NCT03633435|Procedure|assisted home hemodialysis patients|Arteriovenous fistula cannulation at the patient's home provided by a trained private nurse at each dialysis session with the rope-ladder technique, and connection to the Nxstage System One
45494584|NCT03107715|Behavioral|Breastfeeding Champion|iPad-based behavioral intervention facilitated by researcher
45378528|NCT05438927|Behavioral|Fact G Survey|Participants will take a survey at baseline and weeks 4,8,12 & 16. The questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
45378529|NCT05438927|Behavioral|General Anxiety Disorder (GAD)-7|Participants will take a survey at baseline and weeks 4,8,12 & 16. The questionnaire measures participants anxiety with a scale of 0=not at all, 3=Nearly everyday.
45378530|NCT05438927|Behavioral|Patient Health Questionnaire (PHQ)-9|Participants will take a survey at baseline and weeks 4,8,12 & 16. The questionnaire measures participants depression with a scale of 0=not at all, 3=Nearly everyday.
45378531|NCT05432284|Drug|Placebo|Placebo (ambient air)
45494585|NCT03107715|Behavioral|Positive Messaging|iPad based behavioral intervention facilitated by researcher
45494586|NCT03567057|Drug|ADS-5102, 274 mg|Oral capsules
45494587|NCT03508557|Behavioral|Advance care planning tools|Structured conversations between patients/substitute decision-maker and clinician based on education about advance care planning using locally relevant booklet/website, values clarification tool for patient engagement, clinician use of the Serious Illness Conversation Guide
45494588|NCT03316833|Device|Resolute Onyx|Percutaneous coronary revascularization of patients with unprotected left main coronary artery disease up to intermediate anatomical complexity (defined by a SYNTAX score <33), must be performed with the exclusive use of drug-eluting stents of the Resolute Onyx TM family
45494589|NCT03196245|Other|There is no intervention.|There is no intervention. This is a purely observational study. We enrolled pregnant women as they received a vaccine as part of their regular medical care; we did not administer the vaccine. We also enrolled pregnant women acutely infected with influenza.
45494590|NCT05760417|Other|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
45378532|NCT05432284|Drug|THC|Pure THC vapor
45494591|NCT04388787|Device|Stochastic resonance (SR) wraps|SR wraps will be applied to the one or both wrists depending on whether the impairment is unilateral or bilateral. Two additional actuators will be secured around the shoulder. The threshold for detection of SR will be determined by the examiner prior to initiating the test condition. The intensity of the stimulation is adjustable with a scroll bar on the app and ranges from a 0 - 100. The examiner will gradually increase the stimulus intensity until the participant reports being able to feel it. This will set the participant's detection threshold.
45494592|NCT03477357|Device|Geratherm non Contact thermometer|Temperature taken from subject using non-contact device as per manufacturers instructions
45378533|NCT05432284|Drug|Beta-Myrcene|Pure beta-myrcene vapor
45378534|NCT05427708|Behavioral|Interoceptive Exposure|See: Arm/group descriptions
45378535|NCT05427708|Device|Capnometry-Guided Respiratory Intervention|See: Arm/group descriptions
45378536|NCT05427708|Behavioral|Psycho-Education|See: Arm/group descriptions
45494593|NCT03057600|Drug|Paclitaxel|standard weekly paclitaxel in 28-day cycles
45378537|NCT05425732|Biological|V116|0.5 mL injection solution in prefilled syringe containing 4 μg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B) given by intramuscular (IM) injection.
45494594|NCT03057600|Drug|CB-839|CB-839 administered as oral tablets twice daily (BID)
45378538|NCT05425732|Biological|PCV20|0.5 mL injection suspension in prefilled syringe containing 2.2 μg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F) and 4.4 μg of PnPs antigen 6B.
45378539|NCT05424276|Drug|IkT-148009|Oral administration gelatin capsule
45494595|NCT04382937|Drug|P1101 + Ribavirin|P1101 400 µg SC Q2W + Ribavirin 800-1400 mg PO daily
45378540|NCT05424276|Drug|Placebo|Oral administration gelatin capsule
45378541|NCT05408260|Procedure|Ultrasonography|Undergo HHUS
45378542|NCT05408260|Procedure|Automated Breast Ultrasound|Undergo ABUS
45378543|NCT05398120|Behavioral|Skills Group|Adolescents and young adults with a CHR syndrome ages 13-18 will complete feasibility and outcome measures while participating in a weekly skills group for 6 months.
45494596|NCT04382937|Drug|PEG-Intron + Ribavirin|PEG-Intron 1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily
45494597|NCT04355169|Drug|Naldemedine|Oral tablet
45494598|NCT04355169|Drug|Placebo|Oral tablet
45494599|NCT05206890|Drug|fluzoparib monotherapy or combination therapy|patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy
45494600|NCT05212974|Other|Questionnaires|The questionnaires include demographic data and vaccine hesitancy questions in a total of 35 items.
45494601|NCT03371823|Other|Normotensive|FMD is a measure of endothelial function by assessing the degree to which vessel dilates in response to increased flow. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection in all women. Laser Doppler flowmetry is used in combination with cutaneous microdialysis as a minimally invasive technique to examine mechanisms of vascular function. ET-B and ET-A receptor antagonists will be perfused via intradermal microdialysis fibers while measuring cutaneous blood flow. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will also be assessed. Immunohistochemistry will be performed on skin punch biopsy samples to assess for protein expression of ET-A and ET-B receptors.
45494602|NCT03371823|Drug|Hypertensives|ANG II increases the synthesis of ET-1 and alters ET-A/B receptor expression, thus affecting ET-1 bioavailability. Losartan is an ANG II receptor antagonist which attenuates ET-1 production. Losartan 50 mg daily is administered for 14 days to hypertensive women. FMD is used to measure endothelial function. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection. Laser Doppler flowmetry with cutaneous microdialysis is used to examine vascular function when ET-A and ET-B receptor antagonists is perfused via intradermal microdialysis fibers. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will be assessed. Skin punch biopsy samples will be used to assess for protein expression of ET-A and ET-B receptors.
45494603|NCT03879642|Behavioral|REDCHiP|10 week video-based telemedicine intervention to reduce hypoglycemia fear
45378544|NCT05391061|Drug|Abrocitinib|Tablets
45378545|NCT05389514|Drug|Cyclophosphamide|Patients will receive a single dose of cyclophosphamide 60 mg/kg IV in 250 ml D5W over 2 hours on Day -3.
45378546|NCT05389514|Drug|Gemcitabine|Patients will receive a single dose of gemcitabine 600 mg/mg2 IVPB over 30 minutes on Day -2.
45378547|NCT05389514|Drug|Pembrolizumab|Patients will receive the anti-PD-1 immune checkpoint inhibitor pembrolizumab 200 mg IV over 30 minutes on Day -1 and will be dosed every 3 weeks.
45378548|NCT05389514|Biological|Cell Infusion|"Patient's T cells will be administered at a dose of between 1 x 10^9 to 5.0 x 10^10 TCR-transduced lymphocytes, which is a dose of genetically modified T cells that can be safely administered and is capable of mediating tumor regression in some patients with metastatic cancers.~The cells are to be infused intravenously over approximately 30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping."
45378549|NCT05384223|Behavioral|RRFT (Risk Reduction through Family Therapy)|RRFT is an adaptation and integration of existing empirically-supported interventions with similar theoretical rationales targeting similar populations, particularly Multisystemic Therapy principles (MST)for adolescent SUP and Trauma Focused-Cognitive Behavioral Therapy (TF-CBT) components for PTSD in youth. RRFT consists of seven primary components: Psychoeducation and Engagement, Coping, Family Communication, Substance Use, PTSD, Healthy Dating and Sexual Decision-Making, and Revictimization Risk Reduction.
45378550|NCT05384223|Behavioral|ENCOMPASS (Integrated Treatment for Adolescents and Young Adults)|Encompass is currently a research to practice treatment for adolescents with co-occurring substance use disorders and mental health problems and is used as the standard treatment in the target study settings.
45494604|NCT05760339|Behavioral|Time-restricted feeding|Subjects in the will be instructed to follow a TRF regimen consisting of a daily 8h ad libitum eating period and 16h water fasting period during the last 2 weeks before surgery. Participants will be encouraged to begin their eating period at 08:00h and end it at 16:00h, since the metabolic benefits of TRF appear to be considerably more pronounced when the eating period starts early in the day.
45494605|NCT05760339|Dietary Supplement|Carbohydrate loading|Subjects will continue their usual diet and will receive two quantities of a clear beverage containing 12.5 g/100 mL maltodextrin (50 kCal/100 mL, pH 5.0); 800 mL at 22.00h on the evening before surgery and 400 mL two hours before anaesthesia induction.
45494606|NCT05212896|Drug|BC006|BC006 monoclonal antibody injection
45494607|NCT05759247|Device|BORA Band (wristband)|Wristband collecting patient vital signs and activity
45494608|NCT03310905|Procedure|Abdominal Wall Transplant with another solid organ transplant|Transplant of abdominal wall in combination with another solid organ transplant.
45494609|NCT03310905|Procedure|Abdominal Wall Transplant alone|Abdominal Wall Transplant alone
45494610|NCT03619980|Other|No intervention|Retrospective study to evaluate time to event and healthcare resource utilisation of prostate cancer patients throughout the different disease stages, until progression or death.
45494611|NCT03125967|Other|Philips GoLite Blu HF3429/60|Exposure to daily morning colored light in the 440-485 nm wavelength range
45494612|NCT03125967|Other|Philips LivingColor Aura 70998/60/48|Exposure to daily morning colored light in the 625-740 nm wavelength range
45494613|NCT04308603|Diagnostic Test|NON-IMMUNE HYDROPS FETALIS diagnosis|Amniotic liquid of each selected patients will be tested by both technic to describe and detect etiological information. Each patient will be tested using the current procedure with a defined panel of genes as well as with the NGS procedure. The results of both procedures will be compared.
45494614|NCT05212506|Biological|vaccinated and unvaccinated|the vaccinated :Male patients who received more than 2 injections of the covid-19 vaccine;the unvaccinated :Male patients who did not receive the covid-19 vaccine
45494615|NCT03012789|Procedure|Surgery|Surgical excision
45494616|NCT02966301|Drug|Arsenic Trioxide Injectable Solution|"Each patient will receive eleven perfusions of arsenic trioxide (0,15 mg/kg/Day - IV administration) over a 4 weeks period (one cycle).~Patients in partial response after the 1st cycle of ATO will be eligible to receive a second cycle of ATO as consolidation therapy. A delay of 8 weeks (from the first infusion of ATO) will be observed between the two cycles of ATO therapy.~The study duration will be 2 years (12 months recruitment + 12 months follow-up)."
45494617|NCT03262623|Other|Radial nerve block|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed. At this point 3-5 ml of the anesthetic mixture is injected. Each 10 ml of the anesthetic mixture contained: 3ml lidocaine 2%, 3ml lidocaine 2% with epinephrine, 1:2000,000, 3ml bupivicaine 0.5% and 1ml clonidine 150 µg/ml.
45494618|NCT03262623|Other|Placebo|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed containing normal saline
45494619|NCT05759169|Other|Foot Bath Tub|A foot bath is generally a form of rest and care where feet are put in water. Feet are body areas where fatigue is most felt as organs that carry the body's total weight. This study uses a specially designed foot bath bath bath bath to give the patients in the experimental group foot bath. The cuvette has four-stage water heating (35-45°C). It has a magnetic field and operates at 390 Watts. It has a splash guard. The sole features non-slip rubber feet. It has a heat shield feature because it has a double wall construction for heat isolation.
45494620|NCT03107091|Drug|Terlipressin acetate continuous infusion|Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days
45693659|NCT01905436|Drug|Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration|Annual or semiannual Albendazole plus Ivermectin, administered by the Liberian Ministry of Health.
45693660|NCT00802204|Radiation|PET scan|"Both lean and obese undergo a PET scan of the brain using the radioligand,fallypride [18F] at baseline. Obese subjects who complete caloric restriction will have repeat scan after diet.~Completed at baseline and post-VLCD"
45693661|NCT00802204|Procedure|Oral glucose tolerance test|Subjects will be required to drink a glucose solution; blood samples will be taken over a 5-hour time period Completed at baseline by both lean and obese and in obese post-VLCD
45693662|NCT00802204|Procedure|MRI|An MRI of the brain and abdomen will be performed prior to PET scan One time at baseline in both lean and obese
45693663|NCT00802204|Behavioral|Psychological scales to assess attitudes and behaviors related to eating and quality of life|A series of short psychological scales will be administered during the study. Completed at baseline
45378551|NCT05379270|Other|Diet soda|Participants will be asked to drink 24 ounces of a commercially-available diet beverage sweetened with sucralose and acesulfame-potassium.
45378552|NCT05375474|Drug|Oral anticoagulation therapy|Vitamin-K antagonists (warfarin)
45378553|NCT05375474|Drug|Single antiplatelet therapy|Aspirin
45378554|NCT05371613|Drug|DNL310|Intravenous repeating dose
45378555|NCT05371613|Drug|Idursulfase|Intravenous repeating dose
45693664|NCT00802204|Other|Caloric Restriction|Obese participants only complete a short-term (~10days) very low calorie diet
45494621|NCT03849768|Drug|HS-10296|Drug: HS-10296 110 mg/55 mg + placebo The initial dose of HS-10296 110 mg once daily can be reduced to 55 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
45494622|NCT03849768|Drug|Gefitinib|Drug: Gefitinib 250 mg + placebo The initial dose of Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
45494623|NCT05759091|Behavioral|cognitive defusion techniques|"Defusing from your delusions helps to lessen their negative impact on your behaviour. So defusion is a vital step towards being able to act flexibly, in accordance with core values, instead of being dictated to by inflexible rules, reasons, judgments etc. There are numerous exercises in ACT Companion with a focus on identifying unhelpful thoughts which would benefit from defusion, or building defusion skills, most of which are found in the open up section of the app. Some of these are reading and writing exercises, and some are guided meditation audio recordings.~ACT Companion defusion exercises~Letting go~Not good enough~Thought defusion~Observing your thoughts~Labelling thoughts and feelings~I am having the thought that.....~milk.milk.milk exercise~silly voice exercise, passenger on the bus, tug of war with a monster"
45494624|NCT05760261|Drug|Midazolam|Midazolam will be administered.
45494625|NCT05760261|Drug|GSK3882347|GSK3882347 will be administered.
45494626|NCT03189693|Other|PVB|nerve stimulator-guided PVB will be performed at two levels
45494627|NCT03189693|Other|Placebo|nerve stimulator-guided PVB containing placebo will be performed at two levels
45494628|NCT03189693|Other|GA|All patients will receive general anesthesia.
45494629|NCT03189693|Other|Anesthetic injections|4 mL of the local anesthetic mixture is injected at each injection site. Each 20 mL of the local anaesthetic mixture contains: 8mL lidocaine 2%, 8 mL lidocaine 2% with epinephrine 5µg/mL and 4 mL bupivacaine 0.5%.
45494630|NCT03065400|Drug|Pembrolizumab|200 mg of Pembolizumab administered via intravenous infusion over 30 mins given every 3 weeks
45494631|NCT05200065|Procedure|Thulium laser enucleation of the prostate|Using the thulium laser to achieve complete endoscopic enucleation of the prostate.
45494632|NCT05200065|Procedure|Bipolar enucleation of the prostate|Using the bipolar plasma energy to achieve complete endoscopic enucleation of the prostate.
46054570|NCT05261529|Behavioral|Physical Exercise Program|Besides the EVOO supplementation in the same conditions as the 'Intervention 1 Group', participants will add the follow-up of a Multimodal Physical Exercise (MFE) program during the remaining 12 weeks of intervention, 3 days per week, online and face-to-face group sessions on non-consecutive days. Continuous and intervalic cardiovascular exercise at moderate-intense intensity, controlled by the HR in reserve, with a duration of 15-45 minutes, also including sympathetic modulation exercises (stretching, breathing and meditation) and methods to promote recovery, with a duration of 10-30 minutes.
45494633|NCT03629106|Behavioral|Weekly Behavioral Coaching Session|The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.
45494634|NCT05734989|Diagnostic Test|BP|Blood pressure measurements and HbA1c tests will be conducted to identify participants with or at risk for high blood pressure and/or Type 2 Diabetes. Those identified will be referred to PCP for follow up/treatment.
45494635|NCT05734989|Diagnostic Test|HbA1c|HbA1c will screen to identify patients with Type 2 diabetes
45494636|NCT05734989|Behavioral|PCP Guidelines for Screening and Monitoring Hispanic/Latinx patients for CKD|Guidelines will be developed and provided to PCPs to use with their Hispanic/Latinx patients with or at risk for CKD.
45494637|NCT05212350|Procedure|Total pancreatectomy|Patients randomized to receive total pancreatectomy at the time of transection of the pancreas will undergo completion total pancreatectomy according to each Institution's operative standards.
45494638|NCT05212350|Procedure|Pancreatic anastomosis|Patients randomized to receive pancreatic anastomosis at the time of transection of the pancreas will undergo pancreatico-jejunosomy or pancreatico-gastrostomy according to each Institution's operative standards.
45494639|NCT04165863|Procedure|total knee replacement surgery|total knee replacement surgery
46054571|NCT05259501|Other|RMIST|"RMIST will involve:~A study automated visual recognition web-based platform accessible on the participant's smartphone web browser.~A supply of methadone in single use bottles and previously described packaging to be kept securely at the methadone clinic/lab setting."
46054572|NCT02782299|Other|Decision Aid|Decision aid which is still under revision will include unbiased information to assist is clarifying values and informing patients with distal radius fractures.
46054573|NCT02784093|Drug|Gastrograﬁn|
46054574|NCT02784093|Procedure|enemas|
46054575|NCT04229589|Other|Clinic follow-up|Patients are regularly evaluated to asses the occurrence of syncopal relapses
45494640|NCT05199675|Behavioral|Digital Peer Support Training Program|The digital peer support training program will consist of bite size modules on the four active ingredients of youth mental well-being, which will be delivered through training workshops, simulation activities, and homework assignments. The training will be conducted over 8 sessions, each lasting for 45-60 minutes following the typical duration of a school lesson on Character and Citizenship Education. The training workshops will be conducted as part of the school's Character and Citizenship Education lessons. The proficiency of participants in applying these digital support skills will be evaluated through simulation and homework activities, in which they apply the four active ingredients in their responses to mock letters that are adapted from actual cases of peer emotional disclosure. At the end of the training, adolescents are expected to apply the four active ingredients to the homework assignments on peers' emotional experiences.
45494641|NCT03724110|Other|Telestroke|Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST-TIA, inpatient telestroke rounding will be used to oversee the urgent diagnostic TIA evaluation, secondary stroke prevention, and stroke education in patients admitted with TIA.
45494642|NCT05109156|Other|This is an observational study|This is an observational study
45494643|NCT05059314|Other|Brisk walking (moderate physical activity)|"Warm up and cool down~Brisk walk (30 mintues each session per week 5 days)~Week 1 to 6"
45494644|NCT05734716|Drug|Erythropoietin|use of erythropoietin to stimulate red blood cell development prior to ascent to altitude
45494645|NCT05734716|Drug|Iron sucrose (Venofer)|use of iron sucrose to stimulate red blood cell development prior to ascent to altitude
45378556|NCT05362955|Drug|Intravaginal 5-Fluorouracil (5-FU)|Participants will self-administer 2 g of 5% 5-FU intravaginally using an applicator, one night per week (every other week), on weeks 1, 3, 5, 7, 9, 11, 13, 15, for a total of 8 applications.
45378557|NCT05362149|Drug|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
45494646|NCT05734716|Drug|Sterile Sodium Chloride|sham treatment with sterile saline
45494647|NCT05044884|Other|Otago Exercise training|"Warm-up exercises. Chair March, Arm swings ( 30 second), Head movement, neck movement, back extension, trunk movement, ankle movement (repeat 5 times).~Back of thigh stretch, calf stretch, (hold for 8 seconds).~Strengthening exercises Front knee strengthening, back knee strengthening, side hip strengthening (2 or more sets of 10 reps) Calf raises, toe raises (repeat this exercises 10 to 20 times)~Balance improvement exercises Knee bends, heel-toe standing, heel toes walking, one leg stand ( start with 5 sec move up to 10 sec) Side walk, heel walking, sit to stand, backwards walking, heel toes walking backwards, walking and turning around, stair walking (10 steps).~Cool-down session Back of thigh stretch, calf stretches ( 10 to 20 sec hold, 1 to 3 reps)~Pulmonary rehabilitation program~Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~Stretch exercise for major respiratory muscles."
45494648|NCT05044884|Other|Circuit training|"Functional strength exercises Heel raise, toe raise, walking on toes, step ups in all directions ( forward, backward and sideways) (2 sets and 8 reps)~Stance exercises Tandem, narrow, one leg stance, and stand on uneven surfaces with open eyes (each exercise 30 seconds) Tandem, narrow, one leg stance, and stand on uneven surfaces with eyes closed (each exercise 15seconds).~Transition exercises Sit to stand from chair with arms (10 reps) and then without arms support (5 reps).~Sit on floor and stand up with assistance and then without assistance.~Gait training Walking tandem, sideway and backward with arm support. Walking tandem, sideway and backward without arm support Walking tandem, sideway and backward over obstacles~Pulmonary rehabilitation program~Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~Stretch exercise for major respiratory muscles"
45494649|NCT05211258|Device|a novel portable upper gastrointestinal endoscopy system|Patients arrived at the hospital in the morning after an overnight fast (>6 hours). The patients took oral dyclonine glue 15 mins before their examination. The doctors prepared the portable endoscopy system so that it was in working status and the disposable sheathed system was placed on the endoscope optical probe.
45494650|NCT05733390|Drug|JZP541|Oral suspension
45494651|NCT05733390|Other|Placebo|Oral suspension
45494652|NCT05733000|Procedure|Biospecimen Collection|Undergo blood sample collection
45494653|NCT05733000|Procedure|Computed Tomography|Undergo CT
45494654|NCT05733000|Drug|Devimistat|Receive IV
45494655|NCT05733000|Drug|Fluorouracil|Receive IV
45494656|NCT05733000|Drug|Gemcitabine Hydrochloride|Receive IV
45494657|NCT05733000|Drug|Hydroxychloroquine|Receive PO
45494658|NCT05733000|Procedure|Magnetic Resonance Imaging|Undergo MRI
46054576|NCT02163681|Drug|Hyperpolarized Helium-3 MRI of the chest|hyperpolarized helium-3 is an inhaled gaseous contrast agent for MRI and permits the acquisition of high quality imagined of lung ventilation.
46054577|NCT05342571|Other|Behavioral, Psychological or Informational Intervention|Participate in ABC session
46054578|NCT05342571|Procedure|Biospecimen Collection|Undergo blood sample collection
46054579|NCT05342571|Other|Electronic Health Record Review|Medical records reviewed
46054580|NCT05342571|Other|Informational Intervention|Receive patient guidebook
46054581|NCT05342571|Other|Survey Administration|Complete surveys
46054582|NCT02784717|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
45378558|NCT05362149|Drug|Enzalutamide|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
45378559|NCT05362149|Drug|Apalutamide|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
45378560|NCT05353166|Drug|REGN5381|Single dose administered via IV infusion
45378561|NCT05353166|Drug|Placebo|Single dose administered via IV infusion
45494659|NCT05210946|Drug|Pemigatinib|"Advanced non-small cell lung cancer patients with known FGFR 1-3 alterations (including but not limited to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening. The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/~1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0."
45494660|NCT05210868|Drug|CM355|"Dose Escalation Phase CM355 will be taken by patients and will be treated follow the 3+3 dose escalation scheme~Expansion Phase CM355 will be taken by patients and will assess the efficacy of CM355 in patients with specific histopathological Non-Hodgkin's Lymphoma, and the safety of drug"
45494661|NCT04879368|Drug|Regorafenib|Oral multi-targeted tyrosine kinase inhibitor (TKI) which targets angiogenic (VEGF, TIE-2), stromal (PDGF-β), and oncogenic (RAF, RET and KIT) receptor tyrosine kinases
46054583|NCT00902304|Drug|Valsartan and hydrochlorothiazide (HCTZ) - monotherapy|Monotherapy arm - if monotherapy valsartan 320mg per day orally was not sufficient, then could add HCTZ up to 25 mg per day orally
46054584|NCT00902304|Drug|Valsartan and amlodipine|From valsartan 80mg/amlodipine 5mg per day to valsartan 160mg/amlodipine 10mg per day orally
45494662|NCT04879368|Biological|Nivolumab|human IgG4 monoclonal antibody inhibitor of PD-1
46054585|NCT00902304|Drug|Usual care|As directed by investigator
45378566|NCT05341882|Behavioral|Mindfulness|Participants took part in a live, facilitated Zoom-delivered training that involved learning mindfulness and education about moral injury. The participants were interviewed regarding the program.
45378567|NCT05341882|Behavioral|Educational Support|As an active control condition, the investigators developed an education support (ES) group, which ran concurrently to the mindfulness intervention group. Within the military community, peer support and psychoeducation are considered critical components of alleviation of suffering from traumatic exposure.
45378568|NCT05336786|Drug|Perflutren Lipid Microspheres|Given IV
45378569|NCT05336786|Procedure|Ultrasound|Undergo ultrasound
45494663|NCT04879368|Drug|Docetaxel|"Docetaxel is taxane-derivative chemotherapy drug, used in the treatment of early, locally advanced and metastatic breast cancer. It is an anti-microtubule agent. Other uses are in the treatment of non-small cell lung cancer, advanced stomach cancer, head and neck cancers, soft tissue sarcoma, ovarian cancer, metastatic prostate cancer, etc.~microtubules, and simultaneously promotes assembly and inhibits disassembly of them"
45693665|NCT01853020|Drug|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low Dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
45693666|NCT01853020|Drug|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes.
45693667|NCT01256086|Drug|Formatris 24µg|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
45693668|NCT01256086|Drug|Formatris 12µg|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
45693669|NCT01256086|Drug|Foradil P 24µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
45378570|NCT05328167|Drug|Perflutren Protein-Type A Microspheres|Given IV
45378571|NCT05328167|Procedure|Contrast-Enhanced Ultrasound|Undergo CEUS
45378572|NCT05327790|Drug|Lyophilized fecal microbiota (LFMT)|vedolizumab or ustekinumab + FMT vs placebo
45378573|NCT05327790|Other|Placebo|Placebo
45378574|NCT05327777|Drug|Oxycodone|Investigators provided set opioid prescriptions for 10 pills each patient.
45378575|NCT05327777|Behavioral|Zero Opioid Protocol|Investigators provided no opioid prescriptions at discharge and instead provided information on non-narcotic pain control.
45378576|NCT05326074|Other|Animal assisted therapy cohort|A therapy dog will be present in the room during the routine outpatient psychiatric visit.
45378577|NCT05324943|Genetic|FLT201|FLT201 is a replication-incompetent single-stranded (ss) recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
46054586|NCT00902304|Drug|Valsartan|Valsartan 160mg per day to 320mg per day orally
46054587|NCT00902304|Drug|Valsartan and hydrochlorothiazide (HCTZ) - combination arm|Combination arm - from valsartan 80mg/hydrochlorothiazide 12.5mg per day to valsartan 160mg/hydrochlorothiazide 25mg per day orally
46054588|NCT02784795|Drug|LY3039478|Administered orally
46054589|NCT02784795|Drug|Taladegib|Administered orally
46054590|NCT02784795|Drug|Abemaciclib|Administered orally
46054591|NCT02784795|Drug|Cisplatin|Administered IV
46054592|NCT02784795|Drug|Gemcitabine|Administered IV
46054593|NCT02784795|Drug|Carboplatin|Administered IV
46054594|NCT02784795|Drug|LY3023414|Administered orally
45378578|NCT05316688|Procedure|Near Infrared Imaging|Undergo NIR imaging
45378579|NCT05316688|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45494664|NCT04879368|Drug|Paclitaxel|Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. Unlike other tubulin-targeting drugs, such as colchicine, that inhibit microtubule assembly, paclitaxel stabilizes the microtubule polymer and protects it from disassembly. Chromosomes are thus unable to achieve a metaphase spindle configuration. This blocks the progression of mitosis and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G0-phase of the cell cycle without cell division
45494665|NCT04879368|Drug|Irinotecan|Camptothecin, one of the four major structural classifications of plant-derived anti-cancerous compounds, is a cytotoxic alkaloid which consists of a pentacyclic ring structure containing a pyrrole (3, 4 β) quinoline moiety, an S-configured lactone form, and a carboxylate form. Irinotecan is activated by hydrolysis to SN-38, an inhibitor of topoisomerase I. This is then inactivated by glucuronidation by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). The inhibition of topoisomerase I by the active metabolite SN-38 eventually leads to inhibition of both DNA replication and transcription.
45494666|NCT04879368|Drug|Trifluridine/Tipracil|The drug consists of the cytotoxin trifluridine and the thymidine phosphorylase inhibitor (TPI) tipiracil. Trifluridine is incorporated into DNA during DNA synthesis and inhibits tumor cell growth. Trifluridine (TFT) is incorporated into DNA by phosphorylation by thymidylate kinase (TK) to TF-TMP; TF-TMP then covalently binds to tyrosine 146 of the active site of thymidylate synthase (TS) inhibiting the enzyme's activity. TS is vital to the synthesis of DNA because it is an enzyme involved in the synthesis of the deoxynucleotide, thymidine triphosphate (dTTP). Inhibition of TS depletes the cell of dTTP and causes accumulation of deoxyuridine monophosphate (dUMP), which increases the likelihood that uracil gets misincorporated into the DNA.
45378580|NCT05316688|Drug|Tozuleristide|Given IV
45494667|NCT03417180|Drug|Remifentanil|a rate of infusion of reminfentanil will be increased by 50% every 5 minutes, until SPI value decreases back to baseline level
45494668|NCT03417180|Device|surgical pleth index|every time SPI value increases by 15 a rate of infusion of reminfentanil will be increased by 50% every 5 minutes
45494669|NCT03085095|Drug|Relugolix|Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1
45494670|NCT03085095|Drug|Leuprolide Acetate|Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan, Taiwan, and China), every 3 months by subcutaneous injection
45378581|NCT05309187|Biological|IO-202|IO-202 given as monotherapy
45378582|NCT05309187|Biological|IO-202 + pembrolizumab combination therapy|IO-202 and fixed dose pembrolizumab combination therapy
45494671|NCT05758935|Other|Rule-based chatbot intervention with therapist-guidance|The intervention is a mobile application designed as a rule-based chatbot. The chatbot will present psychoeducational text, videos and ask questions based on cognitive behavioral techniques. The adolescents will receive weekly therapist support within the mobile application, in addition to weekly contact by phone. The intervention has a duration of six weeks, with a total of six modules.
45494672|NCT04097301|Drug|MLM-CAR44.1 T-cells at day 0 Single intravenous infusion|Lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3.
45494673|NCT02891811|Drug|Carfilzomib|Induction treatment: Cycle 1 day 1+2: 20 mg/m2; days 8,9, 15 and 16: 27 mg/m2; Cycle 2: 27 mg/m2 on days 1,2,8,9,15 and 16; Cycle 3-9: 56 mg/m2 on days 1, 8 and 15; IV duration: 30-60 minutes; Maintenance treatment with carfilzomib (last tolerated dose on day 1 and 15 (± 7 days) of each cycle)
45494674|NCT02891811|Drug|Thalidomide|100mg orally on days 1-28 in patients <75 years of age at Cycle 1; 50mg p.o. on days 1-28 in patients ≥ 75 years of age at Cycle 1
45494675|NCT02891811|Drug|Lenalidomide|25mg p.o. on days 1-21 of each cycle
45494676|NCT02891811|Drug|Dexamethasone|40mg p.o. on days 1, 8, 15,22 (± 1 day ) in patients <75 years of age at Cycle 1; 20mg p.o. on days 1, 8, 15, 22 (± 1 day) in patients ≥ 75 years of age at Cycle 1, given 4 hours-30 min prior to carfilzomib
45378583|NCT05309187|Biological|RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types|Expansion cohorts of the RP2D of IO-202 and fixed dose pembrolizumab combination therapy in multiple tumor types.
45378584|NCT05304546|Drug|Pembrolizumab|Solution for IV
45378585|NCT05304546|Drug|Encorafenib|Oral QD
45378586|NCT05304546|Drug|Binimetinib|Oral BID
45378587|NCT05302167|Behavioral|Molehill Mountain app|"The Molehill Mountain app (currently Version 2) was developed jointly by King's College London (Lead: Prof Emily Simonoff; Advisors: Dr Ann Ozsivadjian and Dr Rachel Kent) and UK autism charity Autistica (Product Owner: Andy Clarke; Product Designer: Joanna Alpe) for use by autistic people aged ≥12-years (https://www.autistica.org.uk/molehill-mountain).~The app was designed based on a self-guided paper-and-pencil CBT toolkit adapted for autism by Professor Emily Simonoff. Since the first version of Molehill Mountain (a two-week long programme) was launched in 2016, and based on surveys of autistic people and five rounds of prototype testing, the Molehill Mountain V2 app was relaunched in April 2021 as a three-month long app-based programme with enhanced interactive features. This 3-month V2 Molehill Mountain app, with enhanced interactive features supporting short daily logins, that will be implemented in the current study."
45494677|NCT05199363|Other|Information leaflet|"Before examination study participant will obtain an information leaflet which includes descriptive and illustrative sections Information for young patients and their caregivers. What is Magnetic Resonance Imaging and what is the examination like?"
45378588|NCT05302167|Device|Molehill Mountain app|As above.
45378589|NCT05295290|Diagnostic Test|Cardiac Imaging|ECG, echocardiogram, ambulatory monitor, exercise stress test
45378590|NCT05292534|Device|hearing aid amplification|Hearing aid will be fit to prescribed participant hearing loss.
45378591|NCT05292534|Device|hearing aid amplification with an added sound|Hearing aid will be fit to prescribed participant hearing loss and an added sound will be activated.
45494678|NCT05199363|Other|Educational movie|"Before examination study participant will be shown educational video with an radiology technologist and actors who role play the examination What is MRI and what is the examination like?"
45494679|NCT05199363|Other|Demonstration|"Before examination study participant will take a part in scenario-based demonstration with the use of props such as the scanner model and a multimedia presentation Scenario for a demonstration before a Magnetic Resonance examination for young patients and their caregivers"
45494680|NCT05760105|Other|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
45494681|NCT05199129|Drug|HCP1904-3|Take once daily for 8 weeks orally
45494682|NCT05199129|Drug|RLD2001-1|Take once daily for 8 weeks orally
45494683|NCT02811783|Drug|Naloxone Hydrochloride Lotion, 0.5%|Topical TID for 2 weeks
45494684|NCT02811783|Drug|Placebo Lotion|Topical TID for 2 weeks
45494685|NCT03632811|Other|A structured interview with every patient|The comprehension test will be done through structured interviews in which the principal investigator will ask if the patient has had difficulty understanding the recommendations and questions, will check the interpretation of all items and the understanding of each word by the patient. In case of problems, the investigator will propose and / or test translation alternatives, or will ask the patient to propose alternatives.
45494686|NCT02746029|Other|Clinical examination|
45494687|NCT02649855|Biological|PROSTVAC-V|It is a recombinant vaccinia virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules (B7.1, ICAM-1, and LFA-3). It will be given subcutaneously, 2x10(8) infectious units.
45494688|NCT02649855|Biological|PROSTVAC-F|It is a recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules (B7.1, ICAM-1, and LFA-3). It will be given subcutaneously, 1x10(9) infectious units.
45378592|NCT05291689|Drug|MORF-057|MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
45378593|NCT05269134|Drug|Bacteriophage|Phage Therapy
45378594|NCT05269134|Drug|Placebo|Placebo
45378595|NCT05267340|Behavioral|TARA|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
45378596|NCT05267340|Behavioral|Psycho-Education|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA) without the mindfulness meditation components
45378597|NCT05265351|Diagnostic Test|Transdiaphragmatic pressure measurement|Ultrafast ultrasound imaging of the diaphragm during artificially evoked responses
45378598|NCT05265351|Diagnostic Test|EMG|Surface electromyography of the diaphragm for phrenic nerve conduction study
45378599|NCT05263999|Biological|Itolizumab|Itolizumab [Bmab600]
45378600|NCT05263999|Drug|EQ001 Placebo|EQ001 Placebo
45378601|NCT05263544|Other|measuring uterocervical angle and uterine dimensions|in both groups with and without displaced IUD, uterus size, uterine width, cervical canal length, endometrial canal length, endometrial canal width, and the angle at the intersection of the imaginary lines corresponding to the middle of the endometrium and cervical canal, which can be detected by transvaginal ultrasound will be measured
45378602|NCT05263076|Other|Uterine Transplant|Transplant of a uterus from a live or deceased donor.
45378603|NCT05261490|Drug|maplirpacept (PF-07901801)|PF-07901801 Escalation (3-dose-level 12, 24, and 48 mg/kg), in combination with Pegylated Liposomal Doxorubicin (40mg/m2) will be administered by intravenous infusion.
45494689|NCT02649855|Drug|Docetaxel|It is commercially available. It will be administered at 75 mg/m(2) intravenously.
45693670|NCT01256086|Drug|Foradil P 12µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
45693671|NCT01149850|Biological|bevacizumab|Given IV
45693672|NCT01149850|Drug|temozolomide|Given orally
45693673|NCT01149850|Other|laboratory biomarker analysis|Correlative studies
45494690|NCT05198973|Behavioral|Bumblebee Breath|"Bumblebee Breath starts by finding a relaxed, supported posture, either laying supine or in seated and then bringing the minds attention to the space between the eyebrows (or third eye in yoga terms). With the eyes close the thumbs are placed over the tragus of the ears, the first finger gently rests on eye lids, middle finger touches the sides of the nose and then the index and pinkie rest just above and below the closed lips. Next, a sound is created by inhaling deeply through the nose and exhaling with a low-pitched humming sound. The result sounds very much like a bee buzzing to the person performing the breath and a sensation of vibration is experienced inside the head and over the face.~this will applied half an hour daily for ( 1 month)"
45494691|NCT05720715|Drug|cyclosporine A 0.05% eye drops|"Patients diagnosed with herpetic stromal keratitis are randomly divided into 2 groups; Group A: receive cyclosporine eye drops together with prednisolone eye drops.~Group B: receive topical prednisolone with placebo eye drops (tear replacement).~The 2 groups receive systemic acyclovir therapeutic dose 400 mg five times daily, which then tapered to twice daily prophylactic dose after one month of treatment. Follow up for patients is scheduled as a weekly visit for a duration of 2 months."
45494692|NCT05410353|Behavioral|Active Intervention Group|"The 3 major intervention components are diet, physical activity, and the behavioral modification curriculum. Scheduled interactions are educational podcasts (a series of audiovisual, digital media files) paired with a follow-up phone counseling session with a trained behavioral interventionist. A patient portal message will be sent to participants when a new podcast is posted. Interactive sessions will be weekly (weeks 1-16), biweekly (weeks 17-24), and monthly (weeks 25-52). The goal for weight loss is ≥ 7% of initial weight over the course of 12 months. Participants will restrict caloric intake with the goal of 1,200-1,500 kcal/day for those weighing < 114 kg and 1,500-1,800 kcal/day for those weighing ≥ 114 kg. The physical activity goal will be for participants to gradually increase to 175-200 minutes of moderate-intensity activity per week by the 24th week. Participants will also be asked to self-monitor their dietary intake and physical activity using the Lose It! app."
45494693|NCT05410353|Behavioral|Comparison Group|All participants in the Comparison Group will receive a mandatory 13 contacts per year including 3 informational sessions on nutrition, physical activity and social support and 10 contacts via patient portal or email regarding intervention topics. The Look AHEAD Comparison Group was designed to be realistic, achievable, and an acceptable intervention that encouraged optimal study retention.
45693674|NCT01149850|Other|immunohistochemistry staining method|Correlative studies
45693675|NCT01149850|Genetic|microarray analysis|Correlative studies
45693676|NCT01149850|Genetic|DNA methylation analysis|Correlative studies
45693677|NCT01774981|Drug|Placebo|Administered IV
45693678|NCT01774981|Drug|LY3016859|Administered IV
45378604|NCT05261490|Drug|Pegylated Liposomal Doxorubicin (PLD)|RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in combination with pegylated liposomal doxorubicin 40mg/m2
45378605|NCT05253807|Drug|Pemigatinib|13.5 mg tablet
45378606|NCT05243602|Drug|Switch to B/F/TAF|This is a combined pill containing 50mg of bictegravir, 200mg of emtricitabine and 25mg of tenofovir alafenamide
45378607|NCT05243602|Drug|Continue current regimen|Participants will continue taking the same ARV regimen they were on before enrollment with no change in drug or dosage for the duration of the trial
45378608|NCT05236010|Device|rTMS|Transcranial magnetic stimulation is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. During an rTMS session, an electromagnetic coil is placed against the scalp near the forehead. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain being targeted.
45378609|NCT05236010|Device|HD-tDCS|Transcranial direct current stimulation (tDCS), is a non-invasive, painless brain stimulation treatment that uses direct electrical currents to stimulate specific parts of the brain. A constant, low intensity current is passed through two electrodes placed over the head which modulates neuronal activity.
45378610|NCT05236010|Other|Attention Process Training|Attention Process Training (APT) is a multi-session exercise designed to help improve the ability to focus on relevant material while ignoring irrelevant distractions. Further, it helps improve the speed of processing information.
45378611|NCT05234099|Diagnostic Test|18F-FDG Positron emission tomography - MRI|All the examinations will be performed in the supine position on the same integrated 3T PET-MRI scanner
45378612|NCT05234099|Diagnostic Test|Multiparametric ultrasound imaging|Acquisitions of respiratory muscles (diaphragm, intercostal muscles) will be performed using two 6 MHz central frequency linear transducer (SL 10-2) driven by two identical ultrafast ultrasound devices.
45378613|NCT05234099|Diagnostic Test|Surface electromyography|sEMG recordings will be performed in the left side on the sternocleidomastoid muscle, the intercostal parasternal muscle, and the external oblique muscle using pairs of 20-mm-diameter silver chloride surface electrodes.
45378614|NCT05234099|Diagnostic Test|Transdiaphragmatic preasure measurmement|Esophageal and gastric pressures will be measured using 8-cm balloon-catheters.
45378615|NCT05234099|Diagnostic Test|Magnetic stimulation of the phrenic nerves|In order to quantify the contractile fatigue in diaphragm induced by the ventilatory task (described below), we will use bilateral anterior magnetic stimulation of the phrenic nerves using two Magstim 200 stimulator.
45378616|NCT05234099|Diagnostic Test|Ventilation against inspiratory loading|A POWERbreathe KH2 device (POWERbreathe International Ltd) will be connected on the inspiratory side of the two-way valve. Level of inspiratory loading will be randomized in order to produce different amounts of muscle work in each subject.
45378617|NCT05230537|Drug|Iptacopan (LNP023)|oral capsules
45378618|NCT05230537|Drug|Placebo|oral capsules
45494694|NCT05198661|Biological|Collection of biological sample with sera, CSF, buffy coat, PBMC, plasma.|"Blood is collected only one time by blood sample to obtain serum, buffy coat, plasma and PBMC.~2 *4ml of blood on dry tube 2 *4ml of blood on EDTA tube If possibility of delivery in 48 hours at the Centre of Biological Resources, 7*4ml of blood on heparin tube If cerebrospinal fluid has been drawn for diagnosis, remaining sample available will be stored in the collection"
45494695|NCT02364843|Dietary Supplement|Amino Acid: Threonine|Each of the 18 infants will have a different intake of dietary amino acid threonine for a 24 period and by cross-over regression analysis a break-point or requirement will be established
45494696|NCT02310867|Drug|Belatacept|This study will also test a new immunosuppressant drug called Nulojix® (belatacept) to see if it is able to prevent rejection in a hand transplant. Nulojix® (belatacept) is approved by the FDA for use in kidney transplants; however, it is investigational in this study.
45494697|NCT02310867|Procedure|Hand transplant|The purpose of this study is to see if a surgical procedure for transplantation of a hand from a deceased donor can help subjects perform daily living activities better than they are currently able to do.
45494698|NCT05406453|Other|Whole Genome Sequencing testing|Whole Genome Sequencing testing, community-based contact tracing
45494699|NCT03633123|Drug|D_PLEX|D_PLEX is reconstituted into paste and administered in a single application following closure of the fascia, on the fascia suture line, and on the soft tissues of the abdominal wall along the whole length of the surgical wound (including muscle, fat and dermis).
45494700|NCT03633123|Other|Standard of Care (SoC)|"Prophylactic, pre-operation: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.~Post-operation: this is each participating center standard practice for this type of procedure"
45494701|NCT05758857|Behavioral|Experimental: Guidelines-based physical activity|Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.
46054595|NCT04230837|Device|Inmediate abutment height|The placement of the implant was done following the manufacturing protocol and using a surgical guide according to the radiological guide previously used. At this time, the Permanent® abutment of 1 or 3 mm was chosen randomly and was placed at 35 Ncm.
45494702|NCT05758857|Behavioral|Experimental: Guidelines-based healthy eating|One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide.
45494703|NCT05758857|Behavioral|Stretching exercise|Twice weekly virtual instructor-led whole-body stretching class.
45494704|NCT02276547|Device|Mitral valve replacement|Transcatheter mitral valve replacement
45494705|NCT05296083|Dietary Supplement|G3P-01|G3P-01 is a food-grade pectic product derived from squash.
45494706|NCT01917903|Behavioral|Gait-cognitive training|Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.
45494707|NCT01917903|Behavioral|Identification of at risk variables|Participants will complete walking under three conditions: walking alone for six minutes; standing from a chair, walking 3 meters, turning, and returning to a seated position (TUG); and standing from a chair, walking 3 meters turning and returning to a seated postion while subtracting numbers (TUG Cognitive). Spatiotemporal measures of gait will be collected.
45494708|NCT05757219|Drug|Itacitinib|Participants start itacitinib 200 mg PO once daily within 1-4 days after apheresis while awaiting CAR-T-cell manufacturing, which is expected to take approximately from week -4 until day -7. Patients will remain on itacitinib 200 mg PO once daily from initiation until 30 days post-CAR-T-cell therapy (Day 30) including throughout lymphodepleting chemotherapy period (Days -5, -4, -3) and axi-cel infusion (Day 0) for a total of approximately 58 doses.
45494709|NCT05757219|Biological|Chimeric antigen receptor (CAR) T-cell therapy|Yescarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
45494710|NCT02966834|Drug|Placebo|GSK2330672 matching placebo will be supplied as white film-coated tablets.
45494711|NCT02966834|Drug|GSK2330672|GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.
46054596|NCT05282277|Drug|Transdermal Estradiol|Participants will be randomized to receive transdermal estradiol (100μg/day) patch for 3 weeks.
45378621|NCT05202301|Drug|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
45378622|NCT05202301|Drug|Enzalutamide|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
45378623|NCT05202301|Drug|Apalutamide|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
45378624|NCT05199233|Device|Muse S™ Headband system|Clinical grade, headband style, wireless EEG (electroencephalogram is a test used to evaluate the electrical activity in the brain) system and designed to interact with a mobile device (smartphone or tablet).
45378625|NCT05198245|Drug|Rimegepant|Rimegepant 75mg
45693679|NCT01972841|Drug|Solifenacin succinate|Oral tablet
45693680|NCT01972841|Drug|Mirabegron|Oral tablet
45693681|NCT01972841|Drug|Placebo to match solifenacin succinate|Oral tablet
45693682|NCT01972841|Drug|Placebo to match mirabegron|Oral tablet
45693683|NCT01774903|Drug|TTS-fentanyl|TTS-fentanyl patches releasing drug at the rate of 12.5 microgram (µg) per hour for 3 days. The patches will be replaced every 3 days until 30 days.
45693684|NCT01774591|Drug|Azilsartan medoximil|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
45693685|NCT01774591|Drug|Placebo|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
45378626|NCT05198245|Drug|Various|Various
45378627|NCT05198245|Other|No intervention|No intervention
45378628|NCT05192863|Other|No Intervention|This is a non-interventional study.
45378629|NCT05188521|Drug|Baricitinib (LY3009104) 2 mg|2 mg orally administered once daily for 16 weeks
45378630|NCT05188521|Drug|Baricitinib (LY3009104) 4 mg|4 mg orally administered once daily for 16 weeks
45378631|NCT05187624|Drug|RO7428731|Participants will receive RO7428731 as described.
46054597|NCT05282277|Drug|Micronized Progesterone|Participants will receive an additional week of micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
45498193|NCT04108299|Behavioral|SMS intervention|2-3 SMS-based diabetes videos will be sent to patients each week for 12 weeks (each video within 10 minutes in duration) to both patients and their family members. Patients and their family members will receive the same intervention videos, including basic information about T2D, importance of diabetes self-management at home, behavioral techniques, and family-oriented sessions. BrainShark will be used to determine whether participants view these,videos. For participants who miss 3 consecutive videos, the study team will follow-up with a phone call to identify barriers to watching the video and remind them to review the video.
46054598|NCT05282277|Drug|Matching Placebo Patch|Participants will be randomized to receive a transdermal estradiol-matching placebo patch for 3 weeks
45378634|NCT05180773|Drug|Bromocriptine|Bromocriptine 2.5 mg one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects not on anticoagulation at the time of entry will also receive rivaroxaban 10 mg tablets once daily for 8 weeks while on bromocriptine.
45378635|NCT05180773|Drug|Placebo|Placebo one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects who are not on anticoagulation will not receive rivaroxaban but will receive a second placebo once daily for 8 weeks while on study drug.
45378636|NCT05180773|Drug|Guideline Directed Medical Therapy for Heart Failure (GDMT)|GDMT will potentially include angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor antagonists (ARB), angiotensin receptor blocker-neprilysin inhibitors (ARNI), beta adrenergic receptor antagonists (beta blockers) , Mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i),
45498194|NCT01382823|Procedure|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
45378637|NCT05180773|Drug|Rivaroxaban|Subjects not on anticoagulation clinically who are randomized to bromocriptine will receive rivaroxaban 10 mg tablets once tablet by mouth daily for 8 weeks while on bromocriptine.
45378638|NCT05180773|Drug|Second Placebo|Subjects not on anticoagulation clinically who are randomized to placebo (rather than bromocriptine) will receive a second placebo one tablet by mouth daily for 8 weeks.
46054599|NCT05282277|Drug|Raclopride C11|All Participants will receive two PET-MR scans using [11C]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.
46054600|NCT00759109|Biological|Peginterferon alfa-2b|Peginterferon alfa-2b, 50 μg, weekly, SC, for a period of 3 years.
46054601|NCT00759109|Other|Observation (no treatment)|No treatment was given to participants enrolled in the control arm (Arm B).
46054602|NCT04214340|Other|evaluation of practices|Study of the management and follow-up of patients presenting with appendicitis in France.
46054603|NCT03982927|Other|Laparoscopic skills workshop|One day laparoscopic skills workshop was offered to the surgical residents
46054604|NCT02848794|Drug|Apatinib and Irinotecan|Patients were administered at apatinib (850mg po qd) and irinotecan(125mg/m2 d1,8) intravenously every three weeks for up to 6 cycles.Maintenance apatinib (500mg po qd) was administered until disease progression or unacceptable toxicity.
45378639|NCT05179577|Drug|Arbaclofen|Arbaclofen Extended Release Tablets
46054605|NCT04096027|Drug|Cabergoline Pill|0.5 mg cabergoline pill taken orally
46054606|NCT04836312|Behavioral|Soft Commitment Device|Patients randomized to the commitment device arm will be asked to visit the Way to Health platform. There, they will identify a support person, a family or friend who they speak to frequently and who is invested in their health. They will then complete a series of questions intended to create implementation intentions. Specifically, they will pick a time for their fast to begin each 24-hour period and a time for their fast to end. They will also develop strategies to deal with hunger arising during a fast period. After this process, they will sign a contract pledging to adhere to the 16:8 time-restricted feeding dietary pattern, and acknowledging that their support person will receive a copy of the contract and weekly updates about their adherence to the regimen.
45378640|NCT05179577|Drug|Placebo|Placebo tablets
45378641|NCT05176444|Behavioral|Music therapy|Individual music therapy sessions across 12-weeks with people with cognitive impairment/dementia. Music therapy training for care home staff at four time points across 12-weeks.
45378642|NCT05165095|Device|Pacemaker implantation|De novo implantation, device upgrade to dual chamber or device replacement
45378643|NCT05164133|Drug|Tocilizumab|Participants will receive intravenous (IV) tocilizumab
45378644|NCT05161780|Drug|Lactated Ringer's Irrigation|Lactated Ringers at 40C will be used for the entirety of the surgery including the approach and exposure of the tumor as well as tumor resection, After surgery, two blinded skull base surgeon reviewers will rate the clarity of the endoscopic field of view at the recorded intervals. The surgical field will be graded using a widely accepted numeric integer (Boezaart) scale.
45378645|NCT05161780|Drug|Normal Saline|Normal Saline at 40C will be used for the entirety of the surgery including the approach and exposure of the tumor as well as tumor resection, After surgery, two blinded skull base surgeon reviewers will rate the clarity of the endoscopic field of view at the recorded intervals. The surgical field will be graded using a widely accepted numeric integer (Boezaart) scale.
45494712|NCT05755815|Procedure|retrolaminar block|A high-frequency 12 MHz linear ultrasound probe will be used, patients will receive bilateral ultrasound-guided retrolaminar plane block with 20 mL of bupivacaine 0.25%. Their spines will be palpated from the vertebra prominens caudally to T7 and point will be marked to identify the spinous processes, which will be confirmed by ultrasound through counting from T12 with the characteristic last rib attached to its transverse process upward to the T7 lamina. The linear high frequency transducer (6-13 MHz) will be placed in the parasagittal plane one cm lateral to the midline. The needle will be inserted in the in-plane view of the ultrasound probe and will be advanced from downward to upward to target the T7 posterior lamina surface at an angle of 90˚ to the skin until the needle tip will be contacted the posterior surface of targeted lamina . After negative aspiration, 20 mL of bupivacaine 0.25% will be injected. The procedure was repeated following the same steps on the other side.
45494713|NCT05755815|Procedure|Peritoneal block|before giving an incision for the ports, 20 ml of 0.25% bupivacaine will be infiltrated subcutaneously over the port sites (6 ml will be infiltrated around each midline port site and 4 ml will be infiltrated around at the lateral port sites) and at the end of surgery and before the removal of trocars, 20 ml of 0.25% bupivacaine diluted in normal saline will be instilled by the surgeon intraperitoneally at gallbladder bed and under domes of both diaphragms under direct vision with a separate catheter passed through one of the trocars.. The pressure of the gas insufflation was kept within 10-12 mm Hg in all patients. At the end of surgery, CO2 was evacuated, and intraperitoneal anesthetic solution was left in situ.
45494714|NCT03106077|Biological|Mirvetuximab Soravtansine|Given IV
45494715|NCT05198271|Other|Management of risk factors|"For all patients:~Online dietician consultation (45 min 1st consultation with set objectives then 15-20 min for the following ones) then proposal of varied weekly menus, adapted to different cultural and social contexts by email and reassessment at M3 and M6~Clinical and radiographic periodontological evaluation at M0 and M6 by a specialist with dental hygiene advice with delivery of equipment and scaling~Initial teleconsultation with motivational interview by sports doctor / APA (30 min) with evaluation of initial physical activity, search for contraindications and development of a personalized program with aerobic and resistance training. Provision of filmed sessions and digital exercise materials for regular practice at home and self-assessment using data from the accelerometer with automatic online report.~Motivational supports on the MyGoodLife / MyGoodCare platform (weight, food questionnaire, pedometer, tobacco consumption)"
45494716|NCT05198271|Behavioral|Smoking cessation|"- For active smoking patients:~Tobacco consultations: S0, S4 and S8 then according to the opinion of the tobacco specialist~Nicotine substitutes +/- varenicline according to tobacco consumption~Online notebook to record tobacco consumption and triggers"
45378646|NCT05161689|Behavioral|HUG-M+|A multicomponent, multi-level, community mobilization, combination intervention (HUG-M+) to address the entire HIV Continuum of Prevention and Care.
45378647|NCT05161533|Drug|Carboplatin|Given IV
45378648|NCT05161533|Drug|Cisplatin|Given IV
45378649|NCT05161533|Biological|Durvalumab|Given IV
45378650|NCT05161533|Drug|Etoposide|Given IV
45378651|NCT05161533|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
45378652|NCT05161533|Other|Quality-of-Life Assessment|Ancillary studies
45378653|NCT05161533|Other|Questionnaire Administration|Ancillary studies
45378654|NCT05160922|Drug|crizotinib|crizotinib oral treatment
45378655|NCT05159713|Behavioral|dCBI|"The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation."
45494717|NCT05198271|Behavioral|weightloss|-For overweight or obese patients: Online dietician consultation every 15 days for 3 months, the consultation based on the online filling of food questionnaires and the weight curve
45494718|NCT05198271|Other|periodontal disease treatment|- For patients with periodontal disease: treatment of periodontal disease (planing, cast splint, tooth avulsion, etc.) between M0 and M3, dental panoramic M0 at inclusion and M6
45494719|NCT05198271|Behavioral|increased physical activity|- For patients with low physical activity: Follow-up by level gp session: 45 '/ week for 3 months
45494720|NCT05198271|Behavioral|Decreased anxiety|"- For anxious patients:~Teleconsultation with a psychiatrist specializing in stress management, global assessment, identification of the factors involved and training in the use of cardiac coherence~Delivery of connected equipment for the practice of cardiac coherence"
45494721|NCT04052984|Procedure|Delayed umbilical clamping and immediate skin-to-skin contact after birth by caesarean section|Mother: Placement of the insulating surgical arch was on the skin, between the abdomen and the thorax, electrocautery plate on the back, the gown superimposed, non-invasive blood pressure monitoring in legs and ear oximetry. The newborn was placed immediately on the mother's chest, passing it under the insulating arch and removing the mother's gown. Non-invasive monitoring was initiated with preductal pulse oximetry. The obstetrician cut the umbilical cord by not feeling the beats of the cord, or until 5 minutes. The newborn was reanimated without separating the baby from his mother. The temperature was taken with an infrared thermometer. Pulse oximetry was recorded. The newborn was colocated to the mother's breast as soon as possible, even if the mother was still in surgery. The mother's transfer to her room was with her baby skin to skin. The support staff was instructed not to separate the newborn until breast feeding occur for the first time or the mother required it.
45494722|NCT03648866|Other|interview|"Initial interview and potential follow-up interviews and focus group with Florida Hospital employees.~Interview participants in compassion rounds"
45494723|NCT03648788|Other|NA (Observation study)|NA (Observation study)
45494724|NCT03647540|Procedure|fluorescent laparoscopic radical gastrectomy|The gastrectomy for group F would be underwent by the fluorescence laparoscopy. All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
45494725|NCT03647540|Procedure|traditional laparoscopic radical gastrectomy|The gastrectomy for group L would be underwent by the laparoscopy.All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
45494726|NCT04009382|Other|Baduanjin Exercise|Subjects will participate in Baduanjin, a simple mind-body exercise, for 24 weeks.
45494727|NCT04009382|Other|Cognitive Fitness Program|Subjects will complete paper puzzles (Sudoku, crosswords, etc.) for 24 weeks.
45494728|NCT03648008|Drug|Hydromorphone|0.002 mg*kg-1 bolus with 0.002 mg*kg-1 background infusion for group BH 0.002 mg*kg-1 bolus without background infusion for group NBH Drug is administered through PCIA pump.
45494729|NCT03648008|Drug|Morphine|0.015 mg*kg-1 bolus without background infusion for group M Drug is administered through PCIA pump.
45494730|NCT03647930|Device|Microporous Polysaccharide Hemospheres (MPH)|Microporous Polysaccharide Hemospheres (MPH)
45494731|NCT03105297|Device|Prototype nasal dilator strip|External Prototype Nasal Dilator strip. GSK prototype nasal dilator AB 2R11. All the participants used nasal dilator strip throughout the active phase of the study (Day 1 to Day 28). Followed by that all the participants used the nasal strip on Day 29 or 30 in Nasal resistance phase of the study as per their randomization sequence.
45494732|NCT03105297|Other|No strip|
45378656|NCT05159713|Behavioral|Treatment as Usual|Participants who are randomly assigned to the Treatment as Usual (TAU) group will receive standard care, which will consist of a tiered stepped care model of behavioral therapy offered by the embedded behavioral therapist at each practice as part of routine care, with the provision of augmentation of therapy (or addition of an antidepressant) at the discretion of the clinical team. Psychotropic medications at baseline and previous behavioral treatment will be recorded at baseline. Number of therapy sessions, delivery modality (face to face versus telemedicine), and addition of antidepressant or other psychotropic medication or dose change will be monitored and recorded over the study period.
45378657|NCT05154760|Other|Pelvic floor muscle training, diaphragmatic breathing exercise, core exercises|An exercise program consisting of pelvic floor muscle training, diaphragmatic breathing exercise and core exercises will be applied to the patients.
45494733|NCT03647384|Drug|Gulingji capsules|Patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
45378658|NCT05135091|Biological|NRTX-1001|Biological: NRTX-1001 is an experimental neural cell therapy product candidate derived from an allogeneic human embryonic stem cell line. The stem cells were converted into inhibitory nerve cells that produce GABA.
45693686|NCT01708915|Drug|nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
45378659|NCT05135091|Procedure|Sham Comparator|Sham Comparator.
45378660|NCT05113927|Device|Selene|SELENE imaging of all margins, with record of each margin assessment and an opportunity to excise tissue from the lumpectomy cavity post-imaging. The new margin will be imaged with SELENE and the surgeon will record the assessment and may take additional tissue (up to a maximum of six total shaves, including up to two shaves in each orientation) or record why no further tissue may be taken.
45378661|NCT05105087|Drug|Perflubutane Microbubble|Given subdermally
45378662|NCT05105087|Procedure|Contrast-Enhanced Ultrasound|Undergo ultrasound
45494734|NCT03647384|Drug|Ginko Biloba Extract tablet|Patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
45494735|NCT05284916|Behavioral|liver diseases admissions|The different patterns of liver disease related admissions after the era of DAAS
45494736|NCT05702541|Device|Lehfilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses
45494737|NCT05702541|Device|Lotrafilcon B multifocal contact lenses|Silicone hydrogel multifocal contact lenses
45378663|NCT05103618|Drug|[F-18] Fluorodopa Positron Emission Tomography|Subjects will receive FDOPA imaging at baseline and 2-3 months after practicing the OM Meditation for evaluation of the dopamine function, [F-18] Fluorodopa (FDOPA), dose (5-10 mCi, ± 20%) will be injected intravenously into an antecubital vein. In accordance with the standard imaging protocol for FDOPA; subjects will be pre-medicated with 200 mg of carbidopa orally approximately one hour prior to injection.
45378664|NCT05103618|Behavioral|OM Meditation|Couple pairs will engage in OM Meditation together approximately 3-4 times a week approximately 2-3 months.
45494738|NCT05702541|Device|Hydrogen peroxide-based cleaning and disinfection system|Commercially available cleaning and disinfection system for silicone hydrogel contact lenses
45494739|NCT05198037|Device|Bihemispheric tDCS|The anode and cathode are placed over the ipsilesional and contralesional primary motor cortex (C3 or C4 based on 10-20 system), respectively. The size of the electrode is 5x5 cm.
45494740|NCT05253495|Drug|DOC Group B|Cyclophosphamide 300 mg x1; dexamethasone x 7; vincristine x1
45494741|NCT05253495|Drug|Pv-COMRAD 1 and 2 Group B|polatuzumab vedotin x1; dexamethasone x 5; vincristine x1, cyclophosphamide x 3; doxorubicin x1; methotrexate x; rituximab 2x; ITT x1
45494742|NCT05253495|Drug|Pv-R-CYM 1 and 2 Group B|polatuzumab vedotin x 1; methotrexate x 1; rituximab x 1; cytarabine x 5;
45494743|NCT05253495|Drug|DOC Group C|cyclophosphamide x 1, dexamethasone x 5; vincristine x1; IT triples x 3
45378665|NCT05097898|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion (including the EVEREST, Ambrosy and ASCEND score) will be performed during day hospitalization or consultation
45378666|NCT05097898|Procedure|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardiac, vena cava, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional/Cardiac echo is optional for patients included in consultation
45378667|NCT05097898|Procedure|Blood and urine sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation/ Urine analysis is optional for patients included in consultation
45494744|NCT05253495|Drug|MAD CPR 1 and 2|methotrexate x 1; dexamethasone x 5; polatuzumab Vedotin x 1, cyclophosphamide x 3; doxorubicin x 1; rituximab x2; IT triples x 2 in induction 1, IT triples x 2 in induction 2
45494745|NCT05253495|Drug|Pv-R CYVE 1 and 2|Polatuzumab Vedotin x 1; Rituximab x 1; Cytarabine x 5; Etoposide x4;
45494746|NCT05253495|Drug|Pv-R CYVE-MTX 1 and 2|Polatuzumab Vedotin x 1; Rituximab x 1; Cytarabine x 5; Etoposide x4; high dose cytarabine x4; high dose methotrexate x 1 (only consolidation 1); IT triples x 2 (only 1 in consolidation 2)
45494747|NCT05253495|Drug|MAD CP|dexamethasone x1; polatuzumab vedotin x 1; cyclophosphamide x 2; doxorubicin x 1; high dose methotrexate x 1; IT triples x 1
45494748|NCT05253495|Drug|Pv-Cytarabine/etoposide|polatuzumab vedotin x 1; cytarabine x 5; etoposide x 3;
45494749|NCT05253495|Drug|AD CP|polatuzumab vedotin x 1; cyclophosphamide x2; doxorubicin x 2;
45494750|NCT05253495|Drug|Bv-AVD-R 1 and 2: COHORT IIa|brentuximab vedotin x 2; doxorubicin x 2; vinblastine x 2; dacarbazine 2x; rituximab x 2
45494751|NCT05253495|Drug|Bv-NVD-R, Cycle 1-2|brentuximab vedotin x 2; nivolumab x 2; vinblastine x2; dacarbazine x 2; rituximab x 2;
45494752|NCT05253495|Drug|Bv-NVD-R, Cycle 1-4 SER|brentuximab vedotin x 2; nivolumab x 2; vinblastine x 2; rituximab x 2;
45494753|NCT05253495|Drug|Bv-AVD-R|Brentuximab vedotin x2; doxorubicin x2; vinblastine x 2; dacarbazine x 2; rituximab x2;
45494754|NCT05253495|Drug|Bv-NVD-R, Cycle 1-4 RER|brentuximab vedotin x 2; nivolumab x 2; vinblastine x 2; dacarbazine x 2; rituximab x 2;
45494755|NCT05253495|Drug|Bv-NAVD-R, Cycle 1-2|brentuximab vedotin x 2; nivolumab x 2; doxorubicin x 2; vinblastine x 2; dacarbazine x 2; rituximab x 2;
45494756|NCT05253495|Radiation|Involved Site Radiation Therapy|21 Gy in 14 fractions of 1.50 Gy per day. The treatment will be given 5 days per week. All fields shall be treated once each day. The total elapsed treatment time will be 2.8 weeks (14 sessions) for each field.
45498195|NCT01980381|Other|Tree Theme Method ® (TTM)|The TTM method is based on creative activities and occupational life story telling, implies that the paints trees representing different life periods, looking back and forward, as well as the present.
45498196|NCT01381965|Procedure|Vitreous surgery for macular hole|Vitreous surgery for macular hole
45378668|NCT05097898|Other|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24
45378669|NCT05097898|Behavioral|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
45498197|NCT01381887|Drug|Placebo|Treatment A: Form=capsule, route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
45693687|NCT01708915|Drug|placebo matching nonivamide + nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
45494757|NCT05225025|Behavioral|ROSE|"The ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns) program is an evidence-based intervention that has been proven to reduce cases of post-partum depression among low-income and racially and ethnically diverse women.~ROSE is administered to pregnant women in small group settings, typically in the same location that prenatal care is being provided (in this study, a hospital setting). It is divided into four 90-minute group sessions and teaches interpersonal psychotherapy-based skills that mitigate identified risk factors for PPD such as social support, stress management skills and communication.~ROSE curriculum will be implemented using groups in a continuous cycle, with patients entering into the intervention curriculum at the time of their enrollment and continuing through until all 4 total sessions have been accomplished."
45494758|NCT05225025|Other|Standard of Care|Usual hospital care with no behavioral intervention
45494759|NCT05054751|Drug|GB491+ Fulvestrant|"GB491: The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side."
45494760|NCT05054751|Drug|Placebo+Fulvestrant|"Placebo: The dose of Placebo is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side."
45494761|NCT04791735|Procedure|Laparoscopy|"Installations of the patient: the position of the patient will depend on both extent of resection and location of the lesion.~Absence of laparotomy with the exception of the extraction of the resected specimen and absence of costal retractors.~Use of laparoscopic specific devices:~Use of multiple (3-7) ports depending on the operator's preference and technical difficulty (mainly 5-6 ports for major liver resection).~Use of a laparoscopic camera system with 0° or 30°~Use of a dedicated laparoscopic ultrasound probe.~Use of specific laparoscopic devices for coagulation, parenchymal transection and sealing.~Placement of the resected specimen in a plastic bag and extraction without fragmentation, depending on the surgeon's preferenceand the diameter of the resected specimen"
45494762|NCT04791735|Procedure|Laparotomy|"Installation of the patient: patients will be placed in supine position, the surgeon operating on the right side of the patient and the assistant standing on the left side.~Incision: the type of incision will depend on both the nature of the resection and the operator's preference. Various incisions such as bi subcostal incision, J-shaped incision, right subcostal incision and midline incision can be used.~Use of open surgical instruments and devices for coagulation and parenchymal transection. These may include the crush-clamp technique or ultrasonic dissection for parenchymal transection, bipolar coagulation, clips, sutures or open vascular stapler for hemostasis and biliostasis.~Methylene blue injection through the cystic drain to rule out biliary leakage will be performed depending on the surgeon's preference."
45494763|NCT00604617|Procedure|Interferon-Gamma Release Assay|IGRAs
45494764|NCT00604617|Drug|RT-23|TST - tuberculin skin test
45494765|NCT05573295|Other|Diagnostic Test: Willems method|Willems method measures the developmental stages of the seven left permanent mandibular teeth and is frequently used for dental age estimation. The score of each stage is allocated, and the sum of the scores provides an evaluation of the subject's dental maturity.
45494766|NCT05573295|Other|Diagnostic Test: Cameriere method|Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
45494767|NCT05573295|Other|Diagnostic Test: London Atlas method|The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
45494768|NCT05007249|Procedure|Use of the Chalaxie pedagogical evaluation tool|Use of the Chalaxie pedagogical evaluation tool during two visits
45494769|NCT03426995|Drug|Placebo|Placebo will be administered as a matching oral solution or matching capsule to study drug GSK3358699, during Part A and C once daily
45494770|NCT03426995|Drug|GSK3358699|GSK3358699, will be administered from 1 mg to 45 mg as an oral solution (1 to 10 mg) or as a capsule (3 to 45 mg), in Part A, B and Part C once daily.
45494771|NCT03426995|Biological|GM-CSF|The GM-CSF will be administered as an intravenous infusion to subjects as 60 microgram per meter^2 in Part A (Day 1) and Part C (Day 14).This will be administered for 2 hours approximately, no later than 24 hours post -dose of the GSK3358699 or placebo in Part C
45494772|NCT03426995|Biological|LPS|LPS will be administered as an intravenous injection to subjects not exceeding 0.75 nanogram per kilogram in Part A (Day 1) and Part C (Day 14). This will be administered no later than 24 hours post -dose of the GSK3358699 or placebo in Part C.
45494773|NCT03426995|Other|Cantharidin|This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.
45494774|NCT05200533|Other|Task-sharing and shifting model between family physicians and physiotherapists|Medical consultations for acute low back pain patients are shifted from family physicians to physiotherapists.
45494775|NCT05200533|Other|Usual care|Medical consultations for acute low back pain patients are performed by family physicians
45494776|NCT05560815|Procedure|Any surgical procedure|Might differ for substudies.
45494777|NCT05200299|Drug|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150-165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400-2800mg/m2 as a 46-48 hour continuous infusion on day 1)
45494778|NCT05200299|Drug|mFOLFOX6 OR CapeOx|"mFOLFOX6(oxaliplatin 85 mg/m2, folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-48 hour continuous infusion on day 1)~CapeOx(Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)"
45494779|NCT05547867|Procedure|Radial head prosthesis|Radial head arthroplasty in comminuted radial head fractures.
45494780|NCT03940989|Other|HABIT-ILE|Goal-directed, task-specific training for both the upper (UE) and lower extremity (LE) and postural control.
45494781|NCT04867499|Other|No intervention|Descriptive study. No intervention.
45494782|NCT03875781|Drug|Chemotherapy|"Arm A : Experimental~Intervention Type : Drug~Intervention Name : Modified FOLFIRINOX (experimental arm)~Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively."
45494783|NCT03875781|Drug|Radiochemotherapy|"Arm B: Active comparator~Intervention Name : modified FOLFIRINOX followed by preoperative standardized radiochemotherapy (control arm)~Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively.followed by preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 25 fractions in pelvic volume and 50 Gy in 25 fractions to the tumor."
45494784|NCT03424265|Dietary Supplement|EAA mixture|Dietary supplement intervention for 12-weeks
45494785|NCT03424265|Dietary Supplement|Placebo (whey protein)|Dietary supplement intervention for 12-weeks
45494786|NCT05181423|Other|Biomarkers|Different serum and radiological biomarkers neonates undergoing abdominal surgery.
45494787|NCT04934319|Behavioral|Balance and Proprioceptive Training|"Step-by-step training (5 levels)~30 minute per training~3 times per week~Four weeks"
45494788|NCT03322566|Drug|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
45494789|NCT03322566|Drug|Epacadostat|Epacadostat administered orally twice daily.
45494790|NCT03322566|Drug|Platinum-based chemotherapy|Investigator selected one of the following regimens: pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin, depending on histology.
45494791|NCT03322566|Drug|Placebo|Matching placebo administered orally twice daily.
45494792|NCT03822975|Drug|Bivalirudin|Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is <225 s (Hemotec method), intravenous injection of 0.35 mg/kg of bivalirudin should be administered, and the ACT re-checked to ensure it is >225 seconds.
45494793|NCT03822975|Drug|unfractionated Heparin|Heparin 70 U/kg is started before coronary angiography. ACT is monitored 5 min after the first administration, and if the ACT <225 s (Hemotec method), an intravenous injection of 1000 U of heparin is administered, and the ACT re-checked to ensure it is >225 seconds.
45494794|NCT05543733|Behavioral|Home exercise program|Participants will complete a 6-month prescription telemedicine-based structured home exercise program. Baseline information will be used to develop a personalized home exercise program. This program will involve downloading the MyDataHelps application on a mobile device to securely collect wearable device information like step counts, activity minutes, and heart rate. Additionally, participants will have multiple virtual visits as well as the 2 in-person visits.
45494795|NCT05732532|Drug|Bupivacaine|2 mL of bupivacaine 0.5% (5 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
45494796|NCT05732532|Drug|Lidocaine|0.5 mL of lidocaine 1% (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
45494797|NCT05732532|Drug|Dexamethasone|0.5 mL of dexamethasone (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
45693688|NCT01708915|Drug|nonivamide + nicoboxil (Finalgon)|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
45693689|NCT01708915|Drug|nonivamide|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
45693690|NCT01708291|Behavioral|Mindfulness based stress reduction|an 8 week group intervention to teach mindfulness skills
45693691|NCT01708291|Behavioral|only pre and post evaluation measures|
45693692|NCT01708057|Drug|AZD8683|AZD8683 administered via inhalation
45378670|NCT05096130|Behavioral|Lifestyle Medicine Strategies|"LM addresses health risk factors in primary, secondary, and tertiary prevention of developing disease rather than limiting resources and medical expenditures on acute care and reacting to illness, injury, and disease.~The intervention will target the four pillars of the LM approach including physical activity, diet, stress, and sleep. Certified in LM strategies professionals will consult participants from the LM group in a biweekly base in order to improve their lifestyle habits."
45378671|NCT05094037|Device|Removable cam walker boot|Standard of care device given to diabetic foot ulcer patients.
45378672|NCT05094037|Other|Counseling|Additional education, counseling and encouragement of use of the orthosis beyond the current standard of care.
45378673|NCT05093933|Drug|Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
45693693|NCT01708057|Drug|Placebo|Placebo administered via inhalation
45378674|NCT05093933|Drug|Placebo|0 mg matching placebo for 2.5 mg, 5 mg, and 10 mg of vericiguat
45378675|NCT05092360|Biological|Nemvaleukin and Pembrolizumab Combination|Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes and Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes
45378676|NCT05092360|Biological|Pembrolizumab|Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes
45378677|NCT05092360|Biological|Nemvaleukin|Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes
45378678|NCT05092360|Drug|Pegylated Liposomal Doxorubicin (PLD)|40 mg/m2; Day 1 of 28-day cycles; IV infusion; 1 mg/min (Cycle 1); 60 min infusion (Cycles 2+)
45378679|NCT05092360|Drug|Paclitaxel|80 mg/m2; Days 1, 8, 15, and 22 of 28-day cycles; IV infusion over 60 min
45378680|NCT05092360|Drug|Topotecan|4 mg/m2; Days 1, 8, and 15 of 28-day cycles; or 1.25 mg/m2, Days 1 through 5 of 21-day cycles; IV infusion over 30 min
45378681|NCT05092360|Drug|Gemcitabine|1,000 mg/m2; Days 1 and 8 of 21-day cycles; IV infusion over 30 min
45378682|NCT05091593|Behavioral|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional.
45378683|NCT05091593|Behavioral|Enhanced Usual Care|Usual care from health providers
45494798|NCT05732532|Drug|Normal saline|0.5 mL of normal saline 0.9% injected at the origin of each bilateral greater and lesser occipital nerves
45693694|NCT01708057|Drug|Tiotropium|Tiotropium administered via inhalation
45693695|NCT01972529|Drug|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
46054607|NCT04095481|Device|Obalon Navigation/Touch System|The NTS Compatible Obalon Balloon System does NOT require the use of radiographic verification prior to the inflation of the intragastric balloon
46054608|NCT02846454|Other|inulin|Investigate the satiating effects of consuming 4g/d inulin in 2 daily doses of 2g
46054609|NCT02846454|Other|arabinoxylan|Investigate the satiating effects of consuming 4g/d arabinoxylan in 2 daily doses of 2g
45693696|NCT01972529|Drug|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
45693697|NCT01972529|Drug|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
45693698|NCT01972529|Drug|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
46054610|NCT04216134|Drug|Gallium Ga 68-labeled PSMA-11|Given IV
45378684|NCT05089162|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion (including the EVEREST, ASCEND and Ambrosy scores) will be performed during day hospitalization or consultation
45378685|NCT05089162|Procedure|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds are optional
45378686|NCT05089162|Procedure|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
45378687|NCT05089162|Other|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after day hospitalization or consultation
45378688|NCT05089162|Behavioral|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
45378689|NCT05089149|Procedure|Clinical examination centered on congestion|Clinical examination (including the EVEREST, ASCEND and Ambrosy scores) centered on congestion will be performed during day hospitalization or consultation
45378690|NCT05089149|Procedure|Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional
45378691|NCT05089149|Procedure|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
45494799|NCT05732532|Procedure|Greater/lesser occipital nerve blocks|Subjects will receive a total of 12 mL injectate divided equally between the 4 injection sites of the bilateral greater and lesser occipital nerves using the landmark-based technique.
45494800|NCT05178225|Dietary Supplement|ubiquinol (reduced coenzyme Q10)|supplementation with ubiquinol (reduced coenzyme Q10), in a daily dose of 2x100 mg. one morning after breakfast, and second dose after dinner.
45494801|NCT05178225|Other|mountain spa rehabilitation|special spa rehabilitation in the mountain High Tatras; Functional capacity of the lungs (6MWT) at before and after 16-18 days of rehabilitation, Borg scale for dyspnea and oxygen saturation SpO2 (%) were monitored.
46054611|NCT04216134|Procedure|Positron Emission Tomography|Undergo 68GA-PSMA-11 PET
45494802|NCT05178225|Diagnostic Test|2x14 ml of peripheral blood collected in a tube with anticoagulant|2x14 ml of peripheral blood collected in a tube with anticoagulant
45494803|NCT05210244|Dietary Supplement|Beetroot Juice (BJ) acute supplementation|One serving of 70 mL of BJ (6.4 mmol of NO3) 3h before initiating the testing session
45494804|NCT05210244|Dietary Supplement|Placebo Juice (PLA) acute supplementation|One serving of 70 mL of juice (0.005 mmol of NO3) 3h before initiating the testing session
45494805|NCT02969018|Drug|PF-06700841|
45494806|NCT02969018|Other|Placebo|
45494807|NCT04624620|Behavioral|Teaching Kitchen Collaborative Curriculum|This is a referral-based teaching kitchen intervention that synergistically provides basic cooking skills, an evidence-based nutrition curriculum, mindfulness skills, activity tracking, and support for behavior change to augment weight management and lifestyle change in the primary care setting.
45494808|NCT03255096|Drug|RO6870810|RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles.
45494809|NCT03255096|Drug|Venetoclax|Venetoclax tablets orally at dose of 400 mg once daily (QD) continuously for 21 days.
45378692|NCT05089149|Other|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after visit (during day hospitalization or consultation)
45494810|NCT03255096|Drug|Rituximab|Rituximab intravenously (IV) at dose of 375 mg/m^2 weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter.
45494811|NCT01319721|Procedure|MMC|Intraoperative 0.2mg/ml mitomycin C (0.02%) for 3 minutes will be applied topically after extensive excision of recurrent pterygium.
45494812|NCT01319721|Procedure|LCAG|Limbal conjunctival autograft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
45494813|NCT01319721|Procedure|AMG|Amniotic membrane graft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
45494814|NCT05284682|Diagnostic Test|Right hearted catheterization|Right hearted catheterization and collection of blood sampels in the coronary sinus, arterial blood and central venous blood for analysis of energy substrate metabolites.
45494815|NCT05210010|Device|CA-4F|"The study intervention is the CA-4F algorithm developed by Ensho Health.~The algorithm is a process for converting input parameters to a CA-4F Risk Score intended to facilitate clinical prioritization of patients suitable for follow-up investigation for ATTR-CM.~The algorithm is applied using the CA-4F Likelihood Estimator which encodes it in software and records its outputs. The CA-4F Likelihood Estimator is controlled through a graphical user interface called the CA-4F Controller.~The CA-4F Likelihood Estimator and its Controller are Class I medical devices in Canada registered under the Medical Device Establishment License of Ensho Health (license 16208)."
45494816|NCT03792867|Drug|Doxorubicin|Immediately after resection, 15mg/m2 doxorubicin will be administered by peritoneal perfusion for 60 minutes and then drained.
45494817|NCT03015324|Drug|Hydroxychloroquine|Hydroxychloroquine
46054612|NCT00916825|Behavioral|"rehabilitation programme getting better together"|Mothers and their children (age 0-16) take part in a 3-week, family-oriented oncological rehabilitation programme which consists of medical, psychological and psychooncological treatments for mothers and children.
46054613|NCT00638079|Drug|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered with a high fat meal
46054614|NCT00638079|Drug|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered following an overnight fast
46054615|NCT00759031|Drug|Sodium Monofluorophosphate|Brush teeth and evaluate plaque score after one use of the study toothpaste
45378693|NCT05089149|Behavioral|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
45378694|NCT05088395|Other|Blood sample|Depending on the clinical context studied and the biomarkers studied and/or sought, the timing of blood samples will vary between cohorts. There may be up to 4 samples taken per patient for up to 24 months.
45378695|NCT05088395|Other|Biopsy|If a specific tumor sample is required, it will be collected only once during the study
45494818|NCT03650673|Diagnostic Test|Identification of subgroups of patients with early AD with risk of progression|Clinical examination with questionnaires, Biological collection, Imaging (radiography, densitometry, ultrasound, and MRI)
45494819|NCT05754450|Drug|AVTX-803|L-fucose crystalline powder
45494820|NCT05338749|Behavioral|Cognitive Training|Gamified cognitive training intervention to improve mental speed and attention.
45494821|NCT04605744|Behavioral|Smoking cessation counseling|"Patients will be given a briefing on the benefits of smoking cessation in the peri-procedural period around their interventional pain procedure. They will also be provided an informational sheet from the American Society of Anesthesiologists promoting cessation. The sheet will contain the 1-800-QUITNOW national hotline phone number.~Additional an enrollment folder will provided that contains referral information to Cooper's Tobacco Cessation program. This service, free of charge to Cooper Health patients consists of 5 tobacco cessation counselors who use personalized cessation plans, individual and group counseling cessations, Chantix, and education to promote smoking cessation."
45494822|NCT05174871|Behavioral|Lifestyle intervention|Lifestyle intervention (usual treatment for patients with obesity). The behavioral intervention will last for 2 months.
45494823|NCT05174871|Behavioral|TRF intervention|Food intake restricted to 8 hours per day during the window between 10h and 22h. Time restricted feeding will take place 6 days per week, with the seventh day unrestricted. The intervention will last for 2 months.
45494824|NCT05193474|Behavioral|integrated palliative care|shared decision making with patient, and timely integrated palliative care according to patient's preference
45494825|NCT04793841|Other|self-sampling kits for STI testing in laboratory|participants in both groups will receive self-sampling kits and deliver the collected samples to laboratory for testing
45494826|NCT02985138|Procedure|TLIF and unilateral pedicle screw fixation|TLIF combined with posterior unilateral pedicle screw fixation
45494827|NCT02985138|Procedure|TLIF and bilateral pedicle screw fixation|TLIF combined with posterior bilateral pedicle screw fixation
45494828|NCT02985138|Device|Pedicle screw and cage|Pedicle screw and cage
45494829|NCT05139849|Drug|Vasopressin; Methylprednisolone; Hydrocortisone|"Vasopressin, the vasoconstrictive hypophysal hormone, alone has not shown increased survival when compared to adrenaline. However, animal data have shown increased diastolic pressure, cerebral perfusion pressure and cerebral oxygenation in cardiac arrest treatment with vasopressin, and have when compared to adrenaline been associated with better cerebral blood flow.~Corticosteroids are currently used in septic shock treatment as a means to reduce time to shock reversal and thereby potentially improving mortality. Steroids have therefore also been suggested for cardiac arrest treatment. The potential role in resuscitation includes the catecholaminerg potentiation, vasoconstriction and protection from reperfusion injury."
45494830|NCT05139849|Drug|Sodium chloride|Sodium chloride 9 mg/ml
45494831|NCT02932176|Device|Non-invasive vascular testing|Results of clinically indicated non-invasive vascular testing will be used to develop a machine learning algorithm
45494832|NCT02932176|Device|machine-learning algorithm|
45494833|NCT02905032|Behavioral|Decision Aid|Observation of clinical encounter using the electronic decision aid to facilitate treatment option conversation between clinician and patient.
45494834|NCT05504187|Drug|KP104|KP104 will be administered.
45494835|NCT05191368|Other|No intervention|No intervention
45494836|NCT02799186|Procedure|blood sample for genetic analysis|
45494837|NCT02767518|Behavioral|Prehabilitation|Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
45494838|NCT03351075|Other|Standard physical therapy program|"Mobilisations, stretching, scar tissue treatment and exercises~Start immediately after surgery, sessions are individual and take 30 minutes~Intensive phase (4 months): 1-2x/week~Maintenance phase (8 months, 3 sessions): 6, 8 and 12 months post-surgery"
45494839|NCT03351075|Other|Modern educational program|"This modern neuroscience educational approach is suited to explain more complex issues associated with pain such as the involvement of peripheral and central mechanisms, neuroplasticity and pain behaviour.~Sessions are individual and take 30 minutes, in addition to the standard physical therapy sessions~3 sessions during week 1-2, 3 booster sessions at 6, 8 and 12 months post-surgery"
45494840|NCT03351075|Other|Traditional biomedical educational program|"Traditional educational interventions are applied according to the biomedical model. This means that the patient's pain experience is explained from a tissue (injured versus healthy tissue) and biomechanics perspective~Sessions are individual and take 30 minutes, in addition to the standard physical therapy sessions~3 sessions during week 1-2, 3 booster sessions at 6, 8 and 12 months post-surgery"
45494841|NCT05312229|Behavioral|Critical Time Intervention|An evidence-based, structured, and time-limited case management practice
45494842|NCT05312229|Other|External Facilitation|Site-specific support to help sites develop tailored plans to implement CTI.
45494843|NCT05312229|Other|Replicating Effective Programs|A stakeholder-informed training and technical assistance implementation strategy
45494844|NCT03315741|Drug|Pirfenidone 267 MG [Esbriet]|Tolerability of drug
45494845|NCT05307393|Behavioral|Positioning|Upon admission to labor and delivery, following an initial ultrasound to confirm fetal OP position, women in this study will be randomly assigned to one of three groups; one control (Group A), and two experimental (Groups B and C) groups. Those assigned to Group A will be allowed to remain in any position they chose during their labor and delivery course. Group B will be placed in a dorsal recumbent, modified sims position on the side of fetal movement. Group C, will be placed in the same position but opposite that of which fetal kicks are felt.
45494846|NCT03632967|Device|Tricinch Coil System Implantation|Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve.
45693699|NCT01747915|Drug|Pregabalin Dose Level 1|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 300 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum dose of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
46054616|NCT00759031|Drug|Triclosan/Fluoride/Copolymer|Brush teeth and evaluate plaque score after one use of the study toothpaste
46054617|NCT02844504|Behavioral|Low Intensity Exercise Training 1|Subjects will perform handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
46054618|NCT02844504|Behavioral|Low Intensity Exercise Training 2|Subjects will perform a different handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
45494847|NCT05077449|Drug|XZP-3287+Fulvestrant|XZP-3287 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
45494848|NCT05077449|Drug|Placebo + Fulvestrant|Placebo 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
45494849|NCT03632733|Drug|Tetracycline|Tetracycline cream
45494850|NCT03632733|Drug|Clotrimazole|Clotrimazole cream
45494851|NCT03632733|Drug|Tetracycline and Clotrimazole|Combination cream
45494852|NCT03632733|Other|Placebo|Placebo cream without active drug ingredients
45494853|NCT05074485|Drug|anakinra|intravenous injection of 100 milligrams anakinra
45494854|NCT05074485|Drug|Placebo|intravenous injection of 1 milliliter normal saline
45494855|NCT05074485|Other|Nociceptive pain challenge|The experimental, standardized, nociceptive pain challenge will induce a moderate level of sustained pain. The pain challenge involves a masseteric injection in the left or right jaw muscle of normal saline (0.15 ml bolus of 0.9% normal saline) over a 15 second period followed by continuous infusion via a closed loop infusion system for 20 minutes.
45494856|NCT05305287|Drug|Pioglitazone|An insulin sensitizer and anti-diabetic agent. Participants will be started on 15 mg/day, increased to 30 mg/day at week 2 and then to 45 mg/day at week 4.
45494857|NCT05305287|Other|Placebo|Placebo for pioglitazone
45494858|NCT03259425|Drug|Nivolumab|Nivolumab at a dose of 240 mg given as an IV infusion starting on day 0. It will be given every 14 days for a total of 7 infusions; Then participant will undergo surgery. Nivolumab will then be administered at a flat dose of 480 mg IV every 28 days for up to one year.
45494859|NCT03259425|Drug|HF10|1 x 107th TCID50/mL, intratumoral injection to a single or multiple eligible tumors for a total of 5 mL; on days 0, 7, 14, 21, 28, 42, 56, 70, 84 for a total of 9 injections. All eligible tumors except one will be treated with HF10 up to the maximum volume allowed. The untreated tumor will be used as an untreated control lesion.
45494860|NCT03259269|Other|This is a non-intervention observational study|No applicable intervention; this is a secondary data analysis observational study.
45494861|NCT04923555|Behavioral|Vegetable proteins (VP) rich in leucine, cystein, arginine|33 volunteers will consume 400 ml of yogurt with vegetable proteins (VP) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of vegetable proteins.
45494862|NCT04923555|Behavioral|Animal proteins (AP)|33 volunteers will consume 400 ml of yogurt with animal proteins (AP) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of animal proteins.
46054619|NCT04197219|Drug|Pembrolizumab|200 mg IV day 1 of each cycle every 21 days
45494863|NCT04923555|Behavioral|No protein (T)|33 volunteers will consume 400 ml of yogurt without any protein (T) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of animal proteins.
45494864|NCT03101241|Drug|CX-8998|T-type calcium channel blocker
45494865|NCT03101241|Drug|Placebo|Placebo comparator
45494866|NCT03061188|Other|Laboratory Biomarker Analysis|Correlative studies
45494867|NCT03061188|Biological|Nivolumab|Given IV
45494868|NCT03061188|Other|Pharmacological Study|Correlative studies
45494869|NCT03061188|Drug|Veliparib|Given PO
45494870|NCT03449147|Drug|Placebo|Placebo tablet administered orally BID
46054620|NCT04197219|Drug|Axitinib|5 mg PO BID continuously
45494871|NCT03449147|Drug|Gefapixant 15 mg BID|Gefapixant 15 mg tablet administered orally BID
45494872|NCT03449147|Drug|Gefapixant 45 mg BID|Gefapixant 45 mg tablet administered orally BID
45494873|NCT04309266|Device|Amadeo by Tyromotion|Distal upper extremity/hand robot for robot-assisted therapy
45494874|NCT04309266|Behavioral|Active Learning Protocol for Stroke|Metacognitive approach involving active problem solving for using the affected upper extremity in motoric activities. Also includes a home program.
45378696|NCT05073081|Other|Prehab for LSS|The 8-week prehabilitation program will be delivered online by physiotherapists, chiropractors, and kinesiologists through synchronous and asynchronous exercise sessions, along with online educational sessions.
45494875|NCT03628638|Other|Blood Sample Collection|Subjects participating in the study will have blood sample collected at enrollment. . For any subjects scheduled for a 12 month follow-up, additional blood samples will be collected at 12 months from enrollment.
45494876|NCT04031040|Device|Genio(TM) system therapy|Hypoglossal nerve stimulation system
45494877|NCT05588453|Biological|Natural Killer Cell Therapy|Given UD TGFbi NK cell IV
45494878|NCT05588453|Drug|Temozolomide|Given PO
45494879|NCT01311401|Other|NONE intervention|NONE intervention
45494880|NCT03716141|Other|Autologous Platelets Rich Plasma Treatment|For PRP preparation 10 mL of the patient blood was collected. The blood was centrifuged at 2000 rpm for 5 min to obtain plasma. Then, this plasma was centrifuged at 3000 rpm for another 5 min to collect platelets. Platelets were diluted in 5 mL plasma to form PRP.
45494881|NCT03716141|Other|Conventional Saline dressing|saline dressing of diabetic wounds will be done
46054621|NCT04093687|Other|Endoscopist's training|"The training session will be divided into two parts: theoretical and practical. Trainees will be blinded to the criterion of being chosen due to their performance status.~During the first, theoretical part, the body of research on the phenomenon of colonoscopy pain will be presented. Aspects on how to deliver a painless colonoscopy (patient characteristics, insertion technique, endoscope characteristics, non-technical skills, additional manoeuvres) will be discussed. This part will be based on the findings from Phase I.~The second, practical part of the training, will consist of a one-day session of 7 colonoscopies. Participants will be matched with each other. Each participant, will perform one colonoscopy with an oversight of a matched partner, then in turn oversee the colonoscopy of another participant. The rest of the participants will observe a live transmission of each colonoscopy in a separate room, with a commentary from study coordinator."
46054622|NCT04834908|Biological|Equine COVID-19 Antiserum|Equine COVID-19 antiserum is a polyclonal antibody and it contains Equine COVID-19 immune globulin G.
45494882|NCT02366520|Device|handheld mirror|The child may see the dental treatments that are conducted in his or her mouth by a handheld mirror.
45494883|NCT05186454|Drug|Morphine Sulfate|analgesia
45494884|NCT05186454|Drug|Bupivacaine|Analgesia
45494885|NCT05186454|Drug|dexamethasone, morphine, midazolam|1 ml containing 2 mg dexamethasone, 50 µg morphine, and 500 µg midazolam
45494886|NCT05177640|Drug|99mTc-Duramycin|This is a single dose study of 99mTc-duramycin in healthy volunteers who will undergo serial SPECT scanning
46054623|NCT04834908|Drug|Standard of care|Standard of care for COVID 19 infection based on the current guidelines and institutional practice will be provided
45378697|NCT05073081|Other|Usual Care|Participants in the control group will receive usual care as per surgeons' current practice.
45494887|NCT02113878|Drug|BKM120|BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
45378698|NCT05067842|Diagnostic Test|Circulating tumor DNA(ctDNA) level measurement|The ctDNA level will be measured using the Signatera platform developed by Natera, Inc. Signatera is a patient-specific, tumor informed custom-built ctDNA monitoring assay.
45378699|NCT05061966|Behavioral|immi|The intervention has four main content areas: 1) gender identity (the gender guide), 2) sexual orientation (the queerness guide), 3)stress and coping (the stress guide), and 4) internalized stigma (the internalized stigma guide).
45378700|NCT05061966|Behavioral|Control|The control will have access to resources on the website, but will not receive any engagement reminders, matching the conditions present in real world contexts in which web-based resource lists are available.
45378701|NCT05050136|Drug|Volixibat|Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.
45494888|NCT02113878|Drug|Cisplatin|Cisplatin is a chemotherapy drug
45494889|NCT02113878|Radiation|Intensity-modulated radiotherapy (IMRT)|IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
45494890|NCT05162898|Drug|toripalimab|240mg,ivgtt, every three weeks as a cycle, the first day of each cycle.
45494891|NCT05162898|Drug|Lenvatinib|12mg (weight ≥60kg) or 8mg (weight <60kg) orally, once a day
45494892|NCT05162898|Device|Radiofrequency ablation|ultrasound-guided percutaneous radiofrequency ablation of recurrent hepatocellular carcinoma
45494893|NCT02076906|Device|Magnetic Resonance High Intensity Focused Ultrasound|MR-High intensity focused ultrasound (HIFU) is an ultrasound based technology which allows for non-invasive thermal ablation of tumors under the guidance of MR thermography.
45494894|NCT03628872|Procedure|Scaling and root planing|"A non-surgical procedure that treats periodontal disease, sometimes called a deep cleaning, is considered the gold standard (standard of care) of treatment for patients with chronic periodontitis."
45498198|NCT01381887|Drug|Canagliflozin 300mg/Placebo|"Treatment B: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule, route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
45494895|NCT03628872|Device|Er:YAG Laser|This laser is intended to be used for dental surgery. The Er:YAG Laser emits an infrared beam which is readily absorbed by water contained by both hard and soft tissues of the human body. As a result, energy of the laser beam instantly vaporizes the water molecules in soft and hard tissues of the tooth and surrounding tissues causing the tissues to crumble away or resection of the soft tissues of gingival.
45494896|NCT03628872|Device|Hand instruments|11/12 and 13/14 gracey, 4R/4L curette and sickle - standard of care choices for performing scaling and root planing.
45494897|NCT05113290|Drug|Recombinant Human Adenovirus Type 5 injection|Intratumoral injection of lesions with dose of 3 vials (1.5 × 10^12 vp) if the sum of the maximum lesion diameters was > 10 cm, 2 vials (1.0 × 10^12 vp) if the sum of the maximum lesion diameters was ≤ 10 cm. The cycle is 21 days up to 2-5 cycles.
45494898|NCT05113290|Drug|Sorafenib|Sorafenib will be administered as the original dose before enrollment, or be adjusted by the doctor according to the tolerance.
45494899|NCT03628794|Device|D-SCAN|"Subjects will receive a digital patient navigator service in the form of a mobile application (app), which has been designed at Duke, with feedback from Duke Cancer Institute (DCI) patients, caregivers and clinicians. Its purpose is to facilitate awareness of available Cancer Patient Support Program (CPSP) services at Duke, and to also help patients recognize their unmet symptom management needs. Subjects receiving the D-SCAN mobile app will also complete a survey every week within the app. The first 15 patients and 5 caregivers randomized into the intervention arm (those receiving the app) will also be asked to participate in a qualitative interview assessment at week 12, +/- 3 weeks"
45494900|NCT03477162|Drug|Metformin|Metformin will be given to patients prior to surgery.
45494901|NCT03461952|Drug|Nivolumab|240mg
45494902|NCT03461952|Drug|Ipilimumab|1mg/kg
45494903|NCT03423173|Biological|TAK-003|TDV subcutaneous injection
45494904|NCT03423173|Biological|Placebo|TDV Placebo-matching normal saline (0.9% NaCl) subcutaneous injection
45494905|NCT03348228|Dietary Supplement|Hydroxycitrate (HCA)|Hydroxycitrate supplements are available over the counter and are primarily promoted as a weight loss supplement. Each subject will be given 42 capsules of Swanson super citrimax (hydroxycitrate) Details of the product are provided above. The subjects will be asked to take the capsules over a seven period (6 capsules per day).
45494906|NCT05101824|Radiation|SABR|Two fractionation regimes are available (37.5 Gy in 3 fractions and 30.0 Gy in 3 fractions)
45494907|NCT05062746|Other|Matrix-Rhythm Therapy|One session Matrix-Rhythm Therapy will be applied to affected body parts.
45494908|NCT05062746|Other|Conventional physiotherapy and rehabilitation|Hemiparetics wil receive one session conventional physiotherapy and rehabilitation.
45494909|NCT03192540|Other|Exercise|Participants will undergo an exercise protocol once a week, for eight weeks. Exercise will be continuous for one hour.
45494910|NCT03619824|Drug|Sintilimab|Sintilimab 200mg ivdrip, every 3 weeks for 6 cycles
45494911|NCT03619824|Drug|Gemcitabine|Gemcitabine 1g/m2, d1 & 8 of every cycle, every 3 weeks for 3 cycles before radiation.
45494912|NCT03619824|Drug|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
45494913|NCT03619824|Radiation|intensity-modulated radiotherapy|Definitive IMRT of 66-70Gy will be given in six to seven weeks.
45378702|NCT05050136|Drug|Placebo|Capsules matched to study drug without the active pharmaceutical ingredient
45378703|NCT05046613|Other|Rimegepant|75mg
45378704|NCT05046613|Other|Not taking Rimegepant|No rimegepant
45378705|NCT05042362|Drug|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
45378706|NCT05042362|Drug|Placebo|Matching placebo orally once daily
45378707|NCT05037734|Device|Persona Partial Knee System|Unicompartmental Knee Replacement
45378708|NCT05030428|Drug|Inclisiran sodium 300 mg|Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit
45378709|NCT05030428|Drug|Placebo|Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit
45494914|NCT01759836|Drug|Atorvastatin 20mg|Atorvastatin 20mg daily for 1 year
45494915|NCT03447821|Drug|400 mg Rifamycin SV dosage|
45494916|NCT03447821|Drug|800 mg Rifamycin SV dosage|
45494917|NCT03447821|Drug|1200 mg Rifamycin SV dosage|
45494918|NCT03079284|Other|Holding during cooling|An initial set of vital sings will be recorded before the infant is removed from the isolette. The mother will sit in a reclining chair next to the isolette and place a thermal barrier over her chest and abdomen. The infant will be transferred to the mother by placing the hands under the cooling blanket so as to move the infant and cooling blanket together as one unit. The mother will be allowed to hold for thirty minutes provided that the infant's temperature does not increase by greater than one degree centigrade and the oxygen saturation does not drop below 90%. After thirty minutes, the infant will be returned to the isolette.
45494919|NCT05630339|Dietary Supplement|Magnesium chloride|Each 650 mg capsule contains 340 mg of magnesium chloride, which must be ingested twice a day with aliments.
45494920|NCT05630339|Dietary Supplement|Vitamin D|Each tablet contains 4000 IU of vitamin D, and must be ingested a pill per night.
45494921|NCT05630339|Dietary Supplement|Inert placebo|Instead of dietary supplements, sodium bicarbonate as inert placebo will be administered twice a day in 650 mg capsules.
45498199|NCT01381887|Drug|Canagliflozin 300mg/Canagliflozin 150mg|"Treatment D: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
45498200|NCT01381887|Drug|Canagliflozin 300mg|Treatment C: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
45693700|NCT01747915|Drug|Pregabalin Dose Level 2|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 600 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
45494922|NCT04968366|Biological|Autologous dendritic cells pulsed with multiple neoantigen peptides.|Each dosage of Dendritic Cells (DC) vaccine contains 2-10 million DC cells, loaded with 5-20 tumor neoantigen peptides. DC vaccine will be administered (i.d) around lymph nodes of the groin and Axillary at 2nd, 3rd, 4th, 7th and 11th week after the completion of concurrent Temozolomide chemoradiation. After 5 injections, the investigator will review subject's tolerance and compliance; and, decide whether to administer more DC vaccines up to 8 injections. For certain patients with good tolerance and clinical response of the DC vaccine, peripheral blood is extracted after completion of Temozolomide adjuvant chemotherapy to assess the patient's immune response. According to the result, investigators will decide whether to perform 1-2 more treatment cycles (5-8 injections/cycle) to strengthen the effectiveness
45494923|NCT04968366|Drug|Temozolomide adjuvant chemotherapy|Temozolomide is administered as the standard-of-care adjuvant chemotherapy, in combination with the DC vaccines to treat the enrolled patients.
45494924|NCT03447353|Drug|Xanax 1Mg Tablet|Single dose on two of four visits, one in conjunction with 1 tab of 10mg/325mg Norco
45494925|NCT03447353|Drug|Norco 10Mg-325Mg Tablet|Single dose on two of the four study visits, one in conjunction with 1mg alprazolam
45494926|NCT03447353|Drug|Placebo Oral Tablet|Single dose on two of the four study visits, double dose on one of the four study visits
45494927|NCT03055884|Device|tDCS|active tDCS versus sham tDCS
45494928|NCT03055884|Behavioral|Verbal paired-associate learning task|with or without repeated retrieval practice
45494929|NCT03718169|Behavioral|questionnaires|Female smokers will be asked to complete a structured questionnaire at smoking hotspots. In addition, the smokers will respond to the same questionnaire at 6 months via telephone. The structured questionnaire will collect information related to their demographic characteristics and quitting behaviors, i.e. self-reported abstinence, smoking reduction and quit attempts.
45494930|NCT03446885|Drug|Lisdexamfetamine Dimesylate 40 MG|Lisdexamfetamine Dimesylate 40 MG administered orally
45494931|NCT03446885|Drug|Placebo|Placebo capsule administered orally
45494932|NCT03712319|Behavioral|REM Volver a casa|The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. REM is an application available for Android and iOs. It proposes a guided training through 8 stages. They contain video recordings with explanations about the fundamentals of mindfulness, audio recordings that guide practices of mindfulness, as well as suggestions to bring it into everyday life. They can be used whenever it suits the user. The app counts the progress of each participant, as well as the mood changes according to a distress scale before and after performing a formal practice. The app has been designed following the international recommendations for the development of apps (MARS guide).
45494933|NCT03712319|Behavioral|Mindfulness-Based Stress Reduction program|The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. MBSR is a program developed at the University of Massachusetts Medical Center in the 1970s by Professor Jon Kabat-Zinn. MBSR uses a combination of mindfulness meditation, body awareness, and yoga to help people become more mindful. In recent years, meditation has been the subject of clinical research, that suggests it may have beneficial effects, including stress reduction, relaxation, and improvements to quality of life. While MBSR has its roots in spiritual teachings, the program itself is secular. The session is delivered to a small group of people by a certified instructor during two and a half hours, every week.
45494934|NCT00710970|Drug|Tamoxifen|Tamoxifen is administered at 20 mg/day as a single daily oral dose. Tamoxifen is continued until progressive disease or intolerable grade 3 or 4 side effects occur due to tamoxifen.
45693701|NCT01747915|Drug|Placebo|Placebo, either liquid or capsule, dosed twice daily beginning at Randomization to End of Study/Early Termination.
45693702|NCT03189004|Behavioral|Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh|"Identification and registration of pregnant women and services for them~Birth notification~Childhood vaccination services under EPI~Newly married couple identification~e-Referral.~e-monitoring"
45693703|NCT01961297|Drug|Sodium oxybate|Sodium oxybate
46054624|NCT02512497|Drug|Romidepsin|"Part 1: Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the maximal tolerated dose.~Romidepsin Maintenance Therapy - Part 2: Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle."
45378710|NCT05027815|Biological|Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells|cryopreserved cellular therapy product in cryostor CS5, for IV infusion
45378711|NCT05019430|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and zolmitriptan.
45378712|NCT05019430|Drug|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined.
45378713|NCT05019430|Drug|Zolmitriptan|The pharmacodynamic effects of zolmitriptan maintenance will be determined.
45378714|NCT05011058|Drug|Nanatinostat in combination with valganciclovir|"Drug: Nanatinostat, 20 mg orally once daily, 4 days per week in 28 day cycles~Other name: VRx-3996~Drug: Valganciclovir, 900 mg orally once daily in 28 day cycles"
45378715|NCT05003856|Other|Quality-of-Life Assessment|Ancillary studies
45378716|NCT05003856|Procedure|Radiofrequency Ablation|Undergo RFA
45378717|NCT04982653|Other|Quality-of-Life Assessment|Ancillary studies
45494935|NCT03716063|Drug|Jianpi Huatan dispensing granule|once a day in the morning and evening, every month for a course of treatment, a total of three courses
45494936|NCT04957524|Device|iStim TENS unit and Transvaginal Probe|"iStim TENS unit and Transvaginal Probe are both commercially available products. TENS units work by delivering small electrical impulses through electrodes either attached to the skin or through a transvaginal probe.~iStim transvaginal probe will be inserted vaginally to provide transvaginal electrical stimulation."
45494937|NCT03718013|Device|accelerated deep TMS|subjects treated with deep TMS twice a day (6-8 hours between two applications), during 2 weeks
45494938|NCT03718013|Device|standard deep TMS|standard deep TMS treatment: once a day, during 4 weeks
45494939|NCT02868528|Genetic|chromosome screening with NGS technology|
45378718|NCT04982653|Procedure|Surgical Procedure|Undergo hepatectomy using small bites fascial method for abdominal wall closure
45494940|NCT05567159|Drug|Donanemab|Administered IV.
45494941|NCT04945746|Procedure|AF ablation|"AF ablation using the Volta Medical VX1 CE marked software and a new criteria to establish a priority of the dispersed zones according to the stability of the core algorithm's response (thanks to the new software module under study named stability)."
45378719|NCT04982653|Procedure|Surgical Procedure|Undergo hepatectomy using conventional fascial method for abdominal wall closure
45378720|NCT04978493|Drug|BI 706321|BI 706321
45378721|NCT04978493|Drug|ustekinumab|ustekinumab
45378722|NCT04978493|Drug|Placebo|Placebo
45494942|NCT05209542|Procedure|Hysterosalpingo-Foam Ultrasonography|"Initial 3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging~Power Doppler is very helpful to confirm the direction of the flow as well as the acceleration during injection"
45494943|NCT05209542|Procedure|Laparoscopy|• Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia
45494944|NCT03421379|Drug|Glucagon Nasal Powder|Administered intranasally
45494945|NCT03421379|Drug|Glucagon Hydrochloride Solution|Administered IM
45494946|NCT03712241|Drug|K-285|Topical
45494947|NCT03712241|Drug|Indomethacin|Capsule
45494948|NCT01311479|Procedure|Osteopathic Manipulation Therapy|"Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction.~Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment."
45494949|NCT05208996|Drug|siCoV/KK46|"The modified phase I 3 + 1+1 study design was used in dose escalation from low dose to high dose to determine the maximum daily dose. Sequential assignment of Patient cohorts to one of three dose levels of inhaled siCoV/KK46: 3.7 mg, 11.1 mg, 22.2 mg."
45494950|NCT02739750|Other|No intervention|There is no intervention for this study. It is a MRS.
45494951|NCT02675946|Drug|CGX1321|
45494952|NCT02675946|Drug|Pembrolizumab|
45494953|NCT02675946|Drug|encorafenib|
45494954|NCT02675946|Drug|cetuximab|
45494955|NCT02900378|Drug|LCZ696 (Sacubitril/Valsartan)|LCZ696 (sacubitril/valsartan) was available in 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
45494956|NCT02900378|Drug|Placebo of LCZ696 (Sacubitril/Valsartan)|Placebo of LCZ696 (sacubitril/valsartan) was available to match 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
45494957|NCT02900378|Drug|Enalapril|Enalapril was available in 2.5 mg, 5 mg and 10 mg film-coated tablets
45494958|NCT02900378|Drug|Placebo of Enalapril|Placebo of Enalapril was available to match 2.5 mg, 5 mg and 10 mg film-coated tablets
46054625|NCT02512497|Drug|Busulfan|Part 1: First 2 doses of Busulfan of 80 mg/m2 administered on day -13 and -12. Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic (PK) studies. An additional standard of care (SOC) option is now added for those with an HCT-CI >4 or deemed unfit by the investigator to receive full dose (AUC 5000 umol-min) Time-Sequential (TS) Busulfan. SOC busulfan is administered per OSU SCT SOP with a targeted AUC of 4000 umol-min/day for a total exposure of 16,000 umol-min +/- 12% u-Mol-min based upon PK studies. Busulfan 'test-dose' PK studies will be performed prior to administration of full dose of busulfan per SOC. Romidepsin and fludarabine will be administered in an identical fashion using the SOC busulfan as with the TS busulfan. TS busulfan method of busulfan administration will be the preferred method of conditioning therapy for patients enrolled.
46054626|NCT02512497|Drug|Fludarabine|Part 1: Fludarabine 40 mg/m2 by vein on Days -6 to -3.
45494959|NCT03058692|Biological|Influenza Multimeric-001 Vaccine|The M-001 vaccine consists of 3 repetitions of 9 conserved linear epitopes that are prepared as a single recombinant protein. The M-001 vaccine is expected to protect against existing as well as future seasonal and pandemic virus strains.
45494960|NCT03058692|Other|Placebo|Placebo is saline injection
45494961|NCT03058692|Biological|Quadrivalent Recombinant Seasonal Influenza Vaccine|Quadrivalent Inactivated Influenza Vaccine (IIV4) for intramuscular injection is indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.
45494962|NCT03647228|Drug|IONIS-ENaCRx|Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
45494963|NCT03647228|Drug|Placebo|Placebo comparator calculated volume to match active comparator inhaled or nebulized.
45494964|NCT04052594|Drug|LY3475766 - IV|Administered IV
45494965|NCT04052594|Drug|LY3475766 - SC|Administered SC
46054627|NCT02512497|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
45494966|NCT04052594|Drug|Placebo - IV|Administered IV
45494967|NCT04052594|Drug|Placebo - SC|Administered SC
45494968|NCT04816812|Behavioral|Exercise intervention|A 12-week aerobic exercise program tailored to the individual patients by physiotherapists using the principles of Frequency, Intensity, Time, and, Type (FITT) aiming to increase or maintain the physical activity level to a weekly moderate activity level. This includes two supervised exercise sessions of 60 minutes per week, combined with one weekly home training session. The type of exercise is planned by a physiotherapist to fit each patient during sessions. We monitor the intervention by training diaries including frequency, intensity, time, and type of exercise (FITT) and the verbal BORG 15-point scale and heart rate monitors. We will also monitor the overall seven days' physical activity level by accelerometry using the AX3 device from the company Axivity at weeks 0 and 12.
45494969|NCT04816812|Behavioral|Lifestyle - online lesson intervention|The investigators offer one online lesson of 15-25 minutes on lifestyle guidance including general advice on healthy living.
45494970|NCT03621566|Other|No intervention|Routine care (registry)
45494971|NCT04795362|Biological|blood sample|"5 tubes of 1 milliliters (ml) will be sampled on a catheter placed as part of the usual practice every hour for 4 hours (at Time 0, at Time 1 hour, at time 2hours, at Time 3 hours, at time 4 hours) as soon as DCI is suspected.~In the event of a mechanical angioplasty decision, the samples will be continued (Time 0, Time 2 hours, Time 4 hours, Time 6hours, Time 12 hours, Time 24 hours, so 6 samples of 1 ml)."
45494972|NCT04052750|Behavioral|SMS follow-up|In addition to conventional treatment, the experimental group received SMS reminding every day until the end of the treatment.
46054628|NCT02512497|Drug|Thymoglobulin|Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
46054629|NCT00916669|Drug|Etoposide|Etoposide given as an infusion on day 1, day 2 and day 3 of a three-week cycle for a total of 6 cycles
46054630|NCT00916669|Drug|Cisplatin|Given as an infusion on day 1 of a three-week cycle for a total of 6 cycles
46054631|NCT00916669|Drug|enoxaparin sodium|Given as a subcutaneous injection in the abdomen daily during chemotherapy treatment and then continuing daily for 1 year. Dose will vary.
46054632|NCT02689557|Other|plethysmography|Validate the measurement made by electroactive polymer sensors (plethysmography) during walking tests in venous insufficient subjects and healthy subjects by comparing the measurement made by the reference technique by mercury gauge.
45378730|NCT04957758|Drug|OC-01 (varenicline) nasal spray 1.2 mg/ml|OC-01
45494973|NCT04379154|Device|Volatile Organic Compounds analysis|Volatile Organic Compounds analysis in exhaled air by electronic noses
46054633|NCT02844348|Other|Hypnosis session|
45378731|NCT04957758|Drug|Placebo (vehicle) nasal spray|Placebo (vehicle)
45494974|NCT04052438|Diagnostic Test|HLA-C and KIR determination for patients, couples, oocyte or semen donors, abortive tissue and newborn.|
45494975|NCT03647150|Drug|amoxicillin|At enrollment the child will receive a 1 week course of amoxicillin
45494976|NCT03647150|Dietary Supplement|Ready-to-use therapeutic food (RUTF)|1 sachet RUTF per day (508 calories) till child MUAC is greater than 12.4 cm or 12 weeks have elapsed
46054634|NCT04093453|Other|Placebo (Sodium Chloride)|Participant receive Placebo (Sodium Chloride)
46054635|NCT04093453|Other|Exercise|1 hour exercise
46054636|NCT04093453|Dietary Supplement|Sodium Propionate|Participant receive Sodium Propionate
46054637|NCT02784015|Drug|Cisplatin|
46054638|NCT02784015|Drug|Etoposide|
46054639|NCT02784015|Drug|Doxorubicin|
46054640|NCT02784015|Drug|Cyclophosphamide|
46054641|NCT02784015|Drug|Ifosfamide|
46054642|NCT02784015|Drug|Carboplatin|
46054643|NCT02784015|Radiation|Radiotherapy|
46054644|NCT02784015|Drug|Thiotepa|
46054645|NCT02784015|Drug|Melphalan|
45378732|NCT04951154|Other|Bronchoscopic Biopsy|Bronchoscopic biopsies will be used to evaluate biomarkers of tumor biology and immunology.
45494977|NCT03647150|Behavioral|Mother Care group|Nutrition education via mother care groups lead by a respected elder in the local community
45494978|NCT04373226|Behavioral|Magnitude comparison tasks and neuropsychological testing|neuropsychological testing (ZAREKI-R) and magnitude comparison tasks with stimuli of different types (visual, visuo-spatial)
45494979|NCT04708158|Biological|Novaferon|a novel recombinant antiviral protein drug
45494980|NCT04708158|Biological|Placebo|Saline
45494981|NCT02964338|Drug|Fremanezumab|Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
45494982|NCT02964338|Drug|Placebo|Placebo matching to fremanezumab will be administered as per the schedule specified in the respective arms.
45494983|NCT03056352|Drug|Metoclopramide|Intravenous medication drip
45494984|NCT03056352|Drug|Diphenhydramine|Intravenous medication drip
45494985|NCT04360980|Drug|Colchicine Tablets|1.5 mg loading then 0.5 mg BID P.O
45378733|NCT04951154|Other|Blood Sample|Blood samples will be obtained to measure circulating biomarkers.
45378734|NCT04947176|Dietary Supplement|Supplement|200mg C15:0 once daily
45494986|NCT03645278|Drug|SHR0532|Ascending dose oral adminstration
45494987|NCT03645278|Drug|Placebo|Ascending dose oral administration
45494988|NCT03647072|Drug|CHOP|CHOP only
45494989|NCT03647072|Drug|CHOP Plus Lanzoprazole|CHOP plus Lanzoprazole 60 mg
45494990|NCT03647072|Drug|CHOP Plus Famotidine|CHOP Plus Famotidine 40 mg
45494991|NCT05284136|Dietary Supplement|Crohn's disease exclusion diet (CDED)|16-week course of CDED+Partial Enteral Nutrition. During the first 6 weeks (phase 1 of CDED), patients will be prescribed the CDED and oral Modulen 1 liter (1000kcal) daily. Between week 6 and 16 (phase 2 of CDED), patients will be prescribed CDED and oral Modulen (500 mL).
45494992|NCT05284136|Drug|Oral prednisolone|oral prednisolone at an initial dose of 40 to 60 mg/day (or 1 mg/kg for those patients who weigh less than 40 kg), with a fixed, tapering regimen such that patients should be off steroids by the last day of week 12. Increases in steroid dose during tapering of corticosteroids is allowed but if the patient receives steroids (other than hydrocortisone for adrenal insufficiency) after week 12, he/she is in failure.
45847246|NCT04964466|Biological|Release kinetics of PDGF-BB in PRF + bone substitutes vs. rhPDGF-BB + bone substitutes|The release kinetics of PDGF-BB will be assessed for six preparations of each of following: 1) PRF+ mineralized freeze-dried corticocancellous allograft, 2) PRF + bone xenograft, and 3) PRF + B-TCP. The release kinetics of PDGF-BB will also be assessed for one preparations of each of following: 1) rhPDGF-BB + mineralized freeze-dried corticocancellous allograft, 2) rhPDGF-BB + bone xenograft, 3) rhPDGF-BB + TCP. The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
46054646|NCT02601235|Drug|Naridrin|Naridrin® : 2 drops in each nostril once daily as prescription
45378735|NCT04947176|Other|Placebo|Matching placebo once daily
45378736|NCT04945460|Drug|Sotatercept 0.3 mg/kg|Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
46054647|NCT02601235|Drug|Afrin|2 pumps in each nostril every 12 hours.
45378737|NCT04945460|Drug|Placebo|Administered by subcutaneous injection
45378738|NCT04945460|Drug|Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg|Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
45378739|NCT04942379|Other|Asthma Link|Providers enroll patients in school nurse supervised daily controller asthma medication delivery
45378740|NCT04942379|Other|Enhanced Usual Care|Providers counsel patients on behavioral strategies to improve medication adherence. Patients also receive an asthma workbook outlining behavioral strategies for asthma medication adherence.
45494993|NCT03646916|Drug|Dexamethasone|Gluco-corticosteroid
45494994|NCT03646916|Other|No dexamethasone|Nothing
45494995|NCT03446573|Drug|DTG + 3TC|DTG+3TC is supplied as white, oval, film-coated, fixed dose combination tablet. The tablets will be available in packed high density polyethylene (HDPE) bottles with induction seals and child-resistant closures.
45494996|NCT03446573|Drug|TAF based regimen (TBR)|Participants will continue to receive their TBR.
45494997|NCT04305756|Drug|Enoxaparin|Low molecular weight heparin
45378741|NCT04940000|Other|Patient managed at the IUCT-O and by a private speech therapist (near the patient's home).|"Each patient included will have a video-assisted remote speech therapy consultation with a private speech therapist (near the patient's home) and the expert speech therapist of IUCT-O center.~At the end of this video consultation, the patient and the private speech therapist will be asked to complete a satisfaction questionnaire."
45494998|NCT02898662|Drug|AZD1419|Inhaled AZD1419 administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
45494999|NCT02898662|Drug|Placebo|Inhaled Placebo administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is Placebo 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
46054648|NCT02783937|Biological|Filgrastim|"Each case will have two intervention phases done blindly at random with a wash-out period of 6 months:~Phase A:~Filgrastim vial (30 million IU/ml) SC injection twice daily for five consecutive days.~Phase B:~Injection of saline SC injection twice daily for five consecutive days."
46054649|NCT02783937|Drug|Saline|Injection of saline SC injection twice daily for five consecutive days
46054650|NCT00758485|Drug|Sugammadex|At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of 4.0 mg.kg-1 sugammadex (volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
45847247|NCT04964466|Biological|Release kinetics of PDGF-BB in rhPDGF-BB + PRF + bone substitutes|The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
45378742|NCT04934722|Biological|Pembrolizumab|Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.
45378743|NCT04934722|Drug|Enzalutamide|Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.
45847248|NCT04962048|Device|pulse-synchronized negative pressure (PSNP) device|The machine consists of four components: an electrocardiograph (ECG), a vacuum pump, a software computing the timing of suction and drainage, and an individual suction cap for each patient. One leg will be treated with the PSNP-device. The treatment course with PSNP will be applied twice a day (with 4h +/- 2h in between) for two consecutive days.
45495000|NCT04437810|Biological|Albumin|- Patients in the Albumin Arm will receive Human Albumin 20% 1.5g/kg body weight (Maximum 100g) within 6 hours from the time of diagnosis over a period of 12 hours, followed by 1g/kg bodyweight (Maximum 100g) over a period of 12 hours after 48 hours of diagnosis.(D3)
45495001|NCT04437810|Other|Standard Medical Treatment|standard medical therapy
45495002|NCT04368156|Device|gammaCore® (Vagus nerve stimulation)|Vagus nerve stimulation using the gammacore neurostimulation device
45495003|NCT05283980|Drug|0.25% Bupivacaine|The intervention group/ bupivacaine group will receive up to 25 ml of 0.25% bupivacaine hydrochloride for the Pecs block in comparison to the control group that would receive 0.9% normal saline
45495004|NCT04354272|Other|Questionnaire|Questionnaire for the satisfaction of patients consulting the odontological emergencies of the GHPS during COVID 19.
45847249|NCT04962048|Other|Control - no intervention|The other leg serves as non-treated control
45378744|NCT04934722|Procedure|Androgen Deprivation Therapy (ADT)|Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
45847250|NCT04949568|Behavioral|Diabetes Self-Management Behaviors|The intervention is to be delivered by a diabetes educator.
45847251|NCT04944810|Procedure|Magnetic Gastric Bypass|Perform a gastric bypass with the magnetic grasper to do the liver retraction, upper retraction of the stomach, upper retraction of the jejuno-jejunal anastomosis, upper retraction of the mesocolon to close petersen defect or the jejuno-jejunal anastomosis to close the intermesenteric defect also to do the retraction of the omega limb and perform the section of the limb and finish the gastric bypass
45378745|NCT04934722|Other|Placebo|Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.
45378746|NCT04924660|Drug|TXA127|TXA127 0.5 mg/kg/day infused 3 hours daily for 5 days or until hospital discharge whichever comes first.
45495005|NCT03645980|Drug|DKN-01 300 mg|DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
45495006|NCT03645980|Drug|DKN-01 600 mg|DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
45378747|NCT04924660|Drug|TRV027|TRV027 12mg/h as a continuous 24-hour infusion, infused for 5 days or until hospital discharge whichever comes first.
45495007|NCT03645980|Drug|Sorafenib|For combination with DKN-01, sorafenib will be administrated according to standard clinical practice. Part A: After 8 weeks monotherapy with DKN-01, the study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. Part B:After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
45847252|NCT04944810|Procedure|Magnetic Sleeve Gastrectomy|Perform a sleeve gastrectomy with the magnetic grasper performing the liver retraction and the upper retraction of the stomach
45378748|NCT04924660|Drug|Placebo|"NaCl 0.9% infused to match the duration of the agent (3 hours for TXA127 and continuous 24-hour infusion for TRV027, over 30 minutes for APN01.~Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses."
45378749|NCT04924660|Drug|Fostamatinib|Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
45378750|NCT04920383|Drug|ALPN-202|Various doses
45378751|NCT04920383|Drug|Pembrolizumab|Varies
45495008|NCT04315038|Procedure|spinal anesthesia|Plan to enroll 200 health volunteers and 40 neurodegenerative diseases patients with received spinal anesthesia. Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
45495009|NCT03645200|Drug|Fluzoparib combined with Apatinib|"Fluzoparib :~40mg.bid, morning and evening each time, interval of 12 hours or so, the first oral administration 72 hours later~Apatinib :~250mg or 500mg take one day, 72 hours later, the continuous drug delivery phase (B-C1D1) was entered into the Fluzoparib, that is, the Fluzoparib capsule with 40mg.bid, every morning and evening, each time, interval of 12 hours, the Apatinib tablets daily with the Fluzoparib capsule with the same service, fixed doses of 250mg or 500mg, daily. Continuous drug delivery for 28 days for one cycle"
45495010|NCT03645902|Diagnostic Test|Magnetic resonance imaging|
45495011|NCT04844567|Device|COVVR_Synch|"Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR_Synch provided synchronous feedback: participants receive real-time feedback of their respiration."
45495012|NCT04844567|Device|COVVR_Asynch|"Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR_Asynch provided asynchronous feedback: participants receive asynchronous, frequency modulated feedback of their respiration."
45495013|NCT03055338|Drug|MK-8189|Oral CR tablets (4 mg) administered QD at the following dose strengths: 4 mg (1 tablet); 8 mg (2 tablets); 12 mg (3 tablets)
45495014|NCT03055338|Drug|Risperidone|Oral capsules (2 mg) administered QD at the following dose strengths: 2 mg (1 capsule); 4 mg (2 capsules); 6 mg (3 capsules)
45495015|NCT03055338|Drug|Placebo matching MK-8189|Oral placebo tablet(s) matching the MK-8189 tablet, administered QD.
45495016|NCT03055338|Drug|Placebo matching risperidone|Oral placebo capsule(s) matching the risperidone capsule, administered QD.
45495017|NCT03913130|Drug|QR-110|First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
45495018|NCT03645746|Drug|REGN5069|REGN5069 will be administered by IV infusion or SC injection
45495019|NCT03645746|Drug|Placebo|Placebo-matching REGN5069
45495020|NCT03715907|Behavioral|Financial Incentives|Incentives for gap closure.
45495021|NCT03715907|Behavioral|Information|Information on care gap and closure process.
45495022|NCT03628482|Procedure|CRF|For continuous radiofrequency ablation the electrode tip temperature was raised to 80°C during 90 s.
45495023|NCT03628482|Procedure|PRF|The procedure for PRF is almost identical to that applied for CRF, except that the current is typically carried out in 20 ms pulses every 0.5 s at a temperature that does not exceed 42 °C during 360 s.
45495024|NCT03645668|Drug|Meropenem Injection|Different administration types between two groups
45378752|NCT04920045|Other|Red blood cell transfusion|All RBC transfusions will be administered in 1 unit increments to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, in the case of life-threatening bleeding clinicians will be able to transfuse patients without first checking a patient's Hb concentration. Once randomized, patients will be man-aged according to protocol until hospital discharge independent of transfer to another service and/or specialized hospital ward.
45495025|NCT05628779|Device|TriClip TTVr system (Abbott Vascular)|Edge-to-edge leaflet approximation for the tricuspid valve
45495026|NCT05628779|Device|PASCAL TTVr system (Edwards Lifesciences)|Edge-to-edge leaflet approximation for the tricuspid valve
45495027|NCT05284526|Other|electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements|electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements
45495028|NCT04186494|Drug|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|GLP-1 analogue treatment in combination with advice on diet and physical exercise
45495029|NCT04186494|Device|Continuous positive airway pressure treatment|Gold standard treatment for obstructive sleep apnea
45495030|NCT04186494|Combination Product|Liraglutide and CPAP|Combination of both treatments
45495031|NCT03712163|Drug|Norketotifen Oral Capsule (Cohort 1)|Single dose Norketotifen
45495032|NCT03712163|Drug|Norketotifen Oral Capsule (Cohort 2)|Single dose Norketotifen
45495033|NCT03712163|Drug|Norketotifen Oral Capsule (Cohort 3)|Single dose Norketotifen
45495034|NCT03712163|Drug|Norketotifen Oral Capsule (Multiple Dose Cohort)|Multiple dose Norketotifen
45495035|NCT03712163|Drug|Placebo Oral Capsule|Placebo
45495036|NCT04052360|Drug|Cenerimod|A single oral dose of 4 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
45495037|NCT04052360|Drug|Matching Placebo|A single oral dose of matching placebo will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
45495038|NCT05693142|Genetic|RGX-202|RGX-202 is a recombinant AAV8 containing a transgene encoding a novel microdystrophin
45378753|NCT04919967|Behavioral|Virtual implementation protocol|Participants assigned to the virtual implementation protocol plus e-learning/toolkit group will take the e-learning course and also receive additional assistance through Virtual Implementation support. The Virtual Implementation strategy will be provided through virtual assistance, training, and toolkits to help obstetric practices integrate perinatal mental health and obstetric care and is delivered over 2-3 months and includes two 1-hour virtual implementation e-meetings. Implementation will occur within the practice where a champion is identified who establishes a quality improvement team to implement the practice's change plan to achieve their goals of addressing perinatal mental health conditions.
45378754|NCT04919967|Behavioral|e-learning toolkit|A toolkit given to obstetric care providers to enhance knowledge about and screening for perinatal mood and anxiety disorders. Participants assigned to the e-learning/toolkit alone group will take an e-learning course.This four-part online learning course aims to help obstetric care practitioners address perinatal mental health conditions such as depression, anxiety, PTSD and bipolar disorder.
45378755|NCT04907201|Procedure|Cryoneurotomy|Cryoneurotomy or application of a low temperature probe with guidance of ultrasound which is offered to the patients with lower limbs refractory spasticity as a part of their medical cares.
45378756|NCT04899934|Behavioral|mobile and technology assisted aftercare|The mobile and technology assisted aftercare consists of mobile mental health professionals who travel to participants to provide mental health services including counseling, navigation of community referrals, motivational interviewing, solution focused therapy, psycho-education, and social support. Participants randomized to this condition will also receive 24/7 access to evidence-based behavioral health mobile applications that are recommended based on the participant's diagnostic status, learning style, and goals. Frequency of app use is up to the participant's discretion. However, during weekly aftercare sessions, the CSS may assist the participant with creation of an app use schedule that is realistic for the participant's needs and treatment goals.
45378757|NCT04899934|Other|Treatment as usual|Treatment as usual services include a personalized discharge plan, a follow up appointment within a month of discharge for evaluation and connection to other agency services if applicable. Some of these services may include outpatient counseling for behavioral and emotional problems, psychiatric services, group therapy, case management, rehabilitation services, homeless recovery services, employment services, medication-assisted treatment, group-based team building activities, primary care clinic, and forensic services. Individuals may also receive ancillary referrals for applicable healthcare services, access to residential and outpatient substance abuse treatment services, and access to a tablet.
45378758|NCT04899349|Drug|Alpelisib|Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 8 in a 28 days cycle.
45378759|NCT04899349|Drug|Fulvestrant|Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 after randomization and then at Day 1 of each subsequent cycle during the randomized treatment phase.
45378760|NCT04899349|Drug|Metformin XR|Metformin XR (tablets) administered at a starting dose of 500mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 500 mg once a day to 2000 mg once a day.
45378761|NCT04899349|Drug|Dapagliflozin + metformin XR|Dapagliflozin + metformin XR administered as a single tablet combination at a starting dose of 5 mg dapagliflozin + 500 mg metformin XR orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg dapagliflozin + 500 mg metformin XR orally once daily to 10 mg dapagliflozin + 2000 mg metformin XR once daily
45378762|NCT04899349|Drug|Dapagliflozin|Dapagliflozin (tablet) at a starting dose of 5mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg to 10 mg once daily
45378763|NCT04897841|Drug|Liposomal bupivacaine|20 mL prior to closing fascia, the active drug (bupivacaine) is encapsulated in a liposomal platform and released slowly over the course of days with an approximate 72 hour duration.
45378764|NCT04897841|Drug|Bupivacaine Hydrochloride|30 mL bupivacaine hydrochloride 0.25 percent, local post-surgical anesthetic
45378765|NCT04897841|Other|saline|post-surgical saline
45378766|NCT04868110|Behavioral|High fiber diet|A registered dietitian will delivered the lessons on consuming a high fiber diet to small groups to increased engage and material retention. These lessons will last 18 weeks.
45378767|NCT04854967|Other|Rescind home oxygen order|A note will be entered in the medical record describing the participants randomization into the intervention group. The note will be signed by study staff and will accompany the discontinuation of the patient's home oxygen by a study clinician.
45378768|NCT04854967|Behavioral|Provider Education|A note will be entered in the medical record informing the patient's individual medical providers (i.e. primary care provider, pulmonologist) of their randomization into the intervention group. The note will include the evidence-base for oxygen use among patients with COPD.
45378769|NCT04854967|Behavioral|Patient Education|"The patient will receive a patient education page about discontinuation of home oxygen after recovery from a hospitalization that was developed by Consumer Reports in conjunction with the Choosing Wisely Campaign."
45495039|NCT01311167|Drug|Dexamethasone|Daily administration of 2 mg of dexamethasone for 4 days
45495040|NCT01311167|Drug|Placebo|Daily administration of 2 mg of placebo for 4 days
45495041|NCT05691192|Behavioral|Cognitive Leisure Activities|Participants in the active phase of the study will be asked to increase engagement in certain cognitive leisure activities. The activities are chosen on the basis of previous research and measures of cognitive reserve-building activities.
45495042|NCT03628326|Other|Pulmonary arterial tree|The investigators performed 3D reconstruction of the pulmonary arterial tree on the CT angiography data set acquired during preoperative work-up.
45495043|NCT03419741|Device|Transcranial Magnetic Stimulation Clinical Research System|Transcranial Magnetic Stimulation Clinical Research System is a US FDA approved treatment system for depression. The treatment research system includes motor threshold TMS coil, active TMS coil and sham TMS coil.
45495044|NCT04233840|Drug|P1101 (Ropeginterferon alfa-2b)|solution for injection in prefilled syringe, 500 µg/ mL , 450μg /time, subcutaneous injection every 2 weeks
45495045|NCT04233840|Drug|Nivolumab|"Phase I study will use 0.3, 0.75, 1.5, 3mg/kg, Q2W for 3 doses after 6 doses of P1101.~Phase II study : Group I will use 3mg/kg, Q2W for 3 doses; Group III will use the dosage that determine from Phase I study 3 doses after 6 doses of P1101"
45378770|NCT04854967|Behavioral|Teach-to-goal inhaler training|Teach-to-goal (TTG) inhaler training is a patient-centered education strategy that has been shown to decrease inhaler misuse and decrease acute care utilization. The training is tailored to the patient and meets guideline recommendations for assessment and instruction of inhaler technique. The rounds of assessment and demonstration can be completed until acceptable skill level is attained and tailored to the specific medication prescribed.
45495046|NCT03787758|Drug|SAGE-718|SAGE-718
45378771|NCT04854967|Behavioral|Pursed lip breathing|Pursed lip-breathing will be taught to the participants randomized to the intervention arm. This simple technique relieves breathlessness and has been shown to improve functional capacity in patients with COPD. Participants will be given an instructional handout to refer to after the visit.
45378772|NCT04850599|Drug|Carfilzomib|Given IV
45495047|NCT02896400|Behavioral|Brief Negotiated Interview (BNI)|Brief motivational interview on smoking behavior
45378773|NCT04850599|Biological|Isatuximab|Given IV
45378774|NCT04850599|Drug|Pomalidomide|Given PO
45378775|NCT04848636|Diagnostic Test|Cardiac Sodium and Proton MRI|Sodium-23 MRI of the Heart Proton MRI of the Heart
45378776|NCT04848506|Drug|CK-3773274 (5 - 20 mg)|CK-3773274 tablets administered orally
45495048|NCT02896400|Drug|Nicotine replacement therapy (NRT)|6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
45693704|NCT04656041|Drug|FOLFOX/ nal-IRI|"A cycle will be two weeks (14 days) long, with FOLFOX/ nal-IRI administered on days 1-3.~The order of FOLFOX/ nal-IRI administration is as follows:~1) Liposomal Irinotecan free base via IV, predetermined dosage per protocol~2) Oxaliplatin via IV, predetermined dosage per protocol~3) Leucovorin via IV, predetermined dosage per protocol~4) 5-Fluorouracil via IV, predetermined dosage per protocol"
45378777|NCT04844580|Drug|Inhaled Aviptadil|Aviptadil is the synthetic analogue of the Vasoactive Intestinal Peptide (VIP), a biologically active 28 amino acid natural peptide that is endogenously synthesized in humans. It is one of the signaling molecules of the neuroendocrine immune network and has vasodilator, anti-proliferative, anti-inflammatory and immunomodulatory properties.
45378778|NCT04844580|Drug|Placebo|Aviptadil Placebo will be used for this arm.
45495049|NCT02896400|Other|CT Smokers Quitline (QL)|Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling.
45495050|NCT02896400|Other|SmokefreeText (Text)|Enrollment in a version of NCI's SmokefreeTxt, tailored for the study.
45495051|NCT03405935|Drug|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food.
45495052|NCT03644888|Other|Cycle ergometer training|Already in arm/group descriptions
45495053|NCT03644888|Other|Airway clearance program|Already in arm/group descriptions
45495054|NCT03644888|Device|Vibration therapy|Already in arm/group descriptions
45495055|NCT03644888|Device|Sham vibration therapy|Already in arm/group descriptions
45495056|NCT03055260|Device|Blood flow restriction cuff|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
46054651|NCT00758485|Drug|0.9% sodium chloride (NaCl)|At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of placebo (0.9% NaCl, volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
46054652|NCT02782455|Drug|Flavonoids|Daflon is administered
46054653|NCT02782455|Drug|CDobi|Calcium dobesylate is administered
45495057|NCT03055260|Device|Blood Flow restriction Cuff-Placebo|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
45495058|NCT03404843|Drug|Fasudil Hydrochloride|10 mg/mL vial of fasudil hydrochloride. 6 mL (60 mg) of fasudil hydrochloride are added to a 100 mL saline bag for delivery to subjects.
45693705|NCT04656041|Drug|Paclitaxel|Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
46054654|NCT02846220|Behavioral|Overcoming Immunity to Change health coaching|
46054655|NCT02783781|Procedure|Cardiac surgery (extracorporeal circulation; beating heart)|"Patient's usual care as part of cardiac surgery, analysis of biological data collected at the time of arrival of the patient in the operating room.~Blood sample collection Urine sample collection"
45378779|NCT04827134|Drug|TRIUMEQ|TRIUMEQ will be available as fixed dose combination (FDC) dispersible tablets to be administered orally as a dispersion.
45378780|NCT04827134|Drug|DOVATO|DOVATO will be available as FDC dispersible tablets to be administered orally as a dispersion.
45495059|NCT03404843|Other|Saline|100 mL saline bag.
45495060|NCT05283902|Biological|ChAdOx1 nCoV-19 or Comirnaty or Janssen COVID-19 Vaccine|In a Technical Note, the State of Espírito Santo decided to recommend the application of the fourth dose with vaccines using messenger RNA (mRNA) technology or viral vector vaccine, for all people aged 60 years or older, with an interval of 90 days from of the third dose, considering that, while there is no availability of vaccines adapted to the new variants, boosters with available vaccines are still the most appropriate ways to prevent hospitalization and deaths.
45495061|NCT05284448|Drug|pentoxifylline (Trental SR®)|400 mg three times daily
45495062|NCT03627936|Drug|Lorcaserin manufactured at Zofingen|Lorcaserin XR tablets manufactured at Zofingen.
45495063|NCT03627936|Drug|Lorcaserin manufactured at Kawashima|Lorcaserin XR tablets manufactured at Kawashima.
45495064|NCT03717779|Diagnostic Test|lung ultrasound|we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis
45495065|NCT03646682|Procedure|vitrectomy with membrane peeling|during vitrectomy with membrane peeling a prob of the vitreous body and the excised epiretinal membrane will be harvested for gas-chromatography/mass spectrometry
45495066|NCT03032250|Other|Communication Intervention|Attend interventionist sessions
45495067|NCT03032250|Other|Watch video|Watch video on a DVD
45495068|NCT03032250|Other|Module completion of the Prepare to Care kit|Complete modules of the Prepare to Care kit
45693706|NCT04656041|Drug|Carboplatin|Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
45693707|NCT04656041|Radiation|Proton Radiation Therapy|Chemoradiation with proton or photon radiation therapy concurrent with weekly Paclitaxel and Carboplatin for 5 weeks
45378781|NCT04826276|Other|smoking abstinence|participants will be asked to not smoke for at least 12 hours
45495069|NCT03032250|Other|Quality-of-Life Assessment|Ancillary studies
45495070|NCT03032250|Other|Survey Administration|Ancillary studies
45495071|NCT03032250|Other|Salivary cortisol collection|Obtained at three times a day (at awakening, 30 minutes post awakening and bedtime) for two consecutive days for eligible caregivers in both groups. Samples collected by placing a cotton ball under the tongue for approximately 1-2 minutes which is subsequently stored in a plastic tube and refrigerated.
45495072|NCT03645512|Behavioral|Corporate Athlete Resilience (CAR) Training Program|A 1-day training program developed by the J&J Human Performance Institute (HPI), which uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.
45495073|NCT03444155|Dietary Supplement|Natural Panmol-B-Complex|Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) - Synthetic Vitamin B-Complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
45495074|NCT03444155|Dietary Supplement|Synthetic Vitamin B-Complex|Synthetic Vitamin B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85µg) - Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
45495075|NCT03644810|Diagnostic Test|PPT measurement|The sensitivity to pressure which is gradually increased is assessed. The procedure is performed at the back and the lower leg
45495076|NCT03644810|Diagnostic Test|Pain catastrophizing scale|A validated questionnaire that measures three domains of pain-related catastrophizing thoughts: helplessness, rumination and excessive magnification
45495077|NCT03644810|Procedure|Cold Pressor Test|The participant submerges one hand into a tank of cold (5 deg C), circulating water. The procedure is commonly know to decrease the sensitivity to pressure (PPT procedure) so that a difference appears in pain sensitivity when comparing PPT values before and after the procedure
45495078|NCT03017898|Procedure|Laser Coagulation|Laser coagulation of anal fistula
45495079|NCT03715673|Diagnostic Test|von willebrand antigen and activity|Measuring von Willebrand antigen and activity (VWF: RCo and VWF: CB)
45693708|NCT01960907|Device|CHROMED monitoring system|Optimization of patient's treatment according to the data collected by the home monitoring devices
45693709|NCT01747837|Device|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
45693710|NCT01971203|Drug|seroquel xr|Quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day
45693711|NCT01971203|Behavioral|CBT|16 weeks of treatment
45847253|NCT04944810|Procedure|Revisional Bariatric Surgery|Perform liver retraction and also steps of the surgery like upper retraction of the stomach, upper retraction of the jejuno-jejunal anastomosis, upper retraction of the mesocolon to close petersen defect or the jejuno-jejunal anastomosis to close the intermesenteric defect also to do the retraction of the omega limb, upper retraction of the stomach
45847254|NCT04944810|Procedure|Nissen/Sleeve Gastrectomy with Magnetic Assistance|Perform a nissen-sleeve gastrectomy with the magnetic grasper performing the liver retraction and the upper retraction of the stomach, retraction of the stomach to close the hiatal defect and perform a nissen funduplication before do the sleeve gastrectomy
45378782|NCT04826276|Other|smoking satiety|participants will be asked to smoke as usual
45495080|NCT02962128|Dietary Supplement|High Linoleic Acid (LA) Diet|Volunteers will be randomly assigned to consumption of a high [10% energy] LA-containing diet for 12 weeks.
45693712|NCT04174703|Other|Self-compassionate letter-writing intervention|Participants in this condition will be asked to engage in an online self-compassionate letter-writing task once per day (10-20 minutes each) for 2 weeks.
45693713|NCT04654325|Diagnostic Test|conjunctival swab|Patients will have conjunctival swab for SARS-CV-2 genome detection
46054656|NCT05342493|Drug|Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution|The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks.
45378785|NCT04818593|Device|ZyMot Multi Sperm Separation Device (850 ul)|850 uL of untreated semen will be directly deposited into the inlet port of the ZyMotTM Multi device, followed by placement of 750 uL culture medium in the outlet port and throughout the upper collection chamber. The device will then be incubated in a humidified 37C CO2 incubator for 30 minutes. During incubation, the healthiest and most motile sperm will swim through the microporous filter and into the upper collection chamber, where they will be recovered via the outlet port. 500 uL of the sperm sample will be removed and placed in a separate tube for analysis and insemination.
45495081|NCT02962128|Dietary Supplement|Low Linoleic Acid (LA) Diet|Volunteers will be randomly assigned to consumption of a low [2.5% energy] LA-containing diet for 12 weeks.
45495082|NCT02898116|Drug|Ensartinib|Ensartinib was administered orally once daily at a dose of 200 mg during the Run-in Period. During combination therapy, the ensartinib starting dose was to be 200 mg. Based on observed toxicity at the starting dose level, the ensartinib dose may have been escalated to the recommended single-agent dose (225 mg) or de-escalated to the minimum effective dose (150 mg).
45495083|NCT02898116|Drug|Durvalumab|During combination therapy, durvalumab was to be administered as an IV infusion over 60 (± 5) minutes every 4 weeks at a dose of 1500 mg.
45495084|NCT03717701|Drug|metformin|Patients will take metformin single dose of 1000 mg orally once a day
45495085|NCT03717701|Drug|esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day
45495086|NCT03717701|Drug|Placebo|Patients will take inert tablets similar in appearance, color, and consistency
45495087|NCT04114110|Other|RTLS data|data extraction from RTLS
45495088|NCT03931902|Device|intubation with Endotracheal tube|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with endotracheal tube (ETT).
45495089|NCT03931902|Device|intubation with laryngeal mask airway|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with laryngeal mask airway (LMA).
45495090|NCT03712085|Other|Abdominal acupuncture|Abdominal acupuncture treatment method: 1.Acupoints selection :Zhongwan,Xiawan,Shangqu,Qihai,Guanyuan,Huaroumen,Upper rheumatic and Upper rheumatic external points etc.(Acupoints selection referred to Abdominal Acupuncture Therapy written by Bo Zhiyun ,the founder of Abdominal Acupuncture. 2.Treatment Duration: 30 minutes a session, once a day, 5 times a week for 3 weeks.
45495091|NCT03712085|Other|Sham abdominal acupuncture|Sham abdominal acupuncture Abdominal acupuncture treatment method: 1.Acupoints selection and treatment duration are the same as abdominal acupuncture. 3.Method：Using the sham abdominal acupuncture needles were produced by DONGBANG AcuPrime Acupuncture Instrument Co., Ltd. ( U.K.)The tip of the needle was exposed to 1mm of the cannula. The acupoint skin of patients was touched gently by the tip, and the tip of needle was lifted and removed from acupoint skin after 30s. Rest for 30 seconds ,then repeated 6 times, a total time of stimulation is 6min.
45495092|NCT03628170|Other|platelet rich fibrin|platelet rich fibrin will be prepared from patient's venous blood and inserted in the centrifuge at 2000 r.p.m. for 12 minutes Then, the Platelet rich fibrin plug will be placed in the socket after extraction for socket preservation covered by platelet rich fibrin membrane.
45495093|NCT03628170|Other|Free gingival graft|Free gingival graft will be taken from the palate to cover the socket after extraction of the tooth for socket preservation.
45495094|NCT03658304|Drug|Mitomycin c|All participants will receive a single 40 mg dose of mitomycin C intraoperatively during their scheduled nephroureterectomy. This single dose will be given through a catheter in the subject's bladder.
45495095|NCT03422159|Drug|Ascorbic Acid|Ascorbic Acid 1.5g IV piggyback every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
45495096|NCT03422159|Drug|Thiamine|Thiamine 200mg IV piggyback every 12 hours for 4 days (or discharge from ICU if prior to 4 days).
45495097|NCT03422159|Drug|Hydrocortisone|Hydrocortisone 50mg IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
45495098|NCT03422159|Drug|Sodium Chloride 0.9%|"Placebo Ascorbic Acid 100mL IV piggyback every 6 hours, Placebo Thiamine 50mL IV piggyback every 12 hours, and Placebo Hydrocortisone IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days)."
45495099|NCT04538040|Drug|Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch|Safety and efficacy of switching from rilpivirine/emtricitabine/tenofovir alafenamide in combination with dolutegravir, to bictegravir/emtricitabine/tenofovir alafenamide in combination with doravirine in male, 45+ year old subjects. The study will also include secondary outcomes of quality of life (QOL) and weight changes.
45693714|NCT01605877|Device|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
45693715|NCT01970501|Drug|bucindolol hydrochloride|
45693716|NCT01970501|Drug|metoprolol succinate|
45693717|NCT01970501|Other|Placebo oral capsule|
46054657|NCT03505554|Drug|Lorlatinib|100 mg QD
46054658|NCT04810416|Other|Texting- 10 minutes|Participants will practice texting for 10 minutes using smart phone.
46054659|NCT04810416|Other|Writing- 10 minutes|Participants will practice writing on notebook for 10 minutes.
46054660|NCT04810416|Other|Texting- 15 minutes|Participants will practice texting for 15 minutes using smart phone.
46054661|NCT04810416|Other|Writing- 15 minutes|Participants will practice writing on notebook for 15 minutes.
46054662|NCT05342415|Other|Internally Focused Exercise|While performing the exercises participants will be instructed to focus on the muscle itself.
45495100|NCT04033692|Device|JuggerKnot Mini Soft Anchor|Patient who have been implanted with one or more JuggerKnot Mini Soft Anchor(s) who have undergone repair, repositioning or reattachment of soft tissues, ligament and tendons to the mandible is require for surgical stabilization of the TMJ articular disc.
45495101|NCT03950024|Diagnostic Test|functional brain MRI|The functional brain MRI realized will be a examination with a resting sequence and a sequence during a movement imagination task. (knee bent)
45495102|NCT03964506|Drug|Hyperbaric oxygen|Reduced intensity conditioning Fludarabine and Melphalan with Hyperbaric Oxygen and Allogeneic Hematopoietic Stem Cell Transplant
45495103|NCT03403751|Drug|Reltecimod 0.5 mg/kg|Single IV infusion of 0.5 mg/kg Reltecimod (at a concentration of 1 mg/mL) over approximately 10 minutes
45495104|NCT03403751|Drug|Placebo|Single IV infusion of 0.5 mL/kg of 0.9% saline (volume equivalent to Reltecimod dosing schema) over approximately 10 minutes
45495105|NCT02297412|Drug|Minocycline Hydrochloride|Given PO
45495106|NCT02297412|Other|Placebo|Given PO
45495107|NCT02297412|Other|Quality-of-Life Assessment|Ancillary studies
45495108|NCT02297412|Other|Questionnaire Administration|Ancillary studies
45495109|NCT03644576|Drug|ozanimod|ozanimod
45495110|NCT03644576|Drug|Pseudoephedrine|Pseudoephedrine
45495111|NCT03644576|Drug|ozanimod placebo|ozanimod placebo
45495112|NCT04812821|Other|questionnaire|questionnaire post delivery
45693718|NCT01969799|Drug|Amikacin fosfomycin inhalation solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System
45378786|NCT04818593|Other|Density Gradient Centrifugation|Density gradient centrifugation will be performed using a one-layer preparation of 90% Isolate in 15 mL conical tubes. Semen will be layered over 1 mL of gradient and then centrifuged for 15 min at 300xg. The supernatant will be removed and discarded. The sperm pellet will be washed by mixing with Multipurpose Handling Medium Complete and centrifuging the sample for 5 min at 400xg. After the wash, the supernatant is removed and discarded and the pellet is re-suspended in culture medium, assessed for sperm parameters, and held at room temperature until insemination.
45378787|NCT04817670|Drug|VIT-2763 120 mg|"Participants receive 2 capsules of VIT-2763 30 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
45693719|NCT01969799|Drug|Aerosolized placebo|Placebo twice daily for 10 days to be administered by aerosol the eFlow Inline System
45495113|NCT03418727|Drug|Brimonidine|Two products delivered in sequence twice daily.
45693720|NCT01969721|Drug|fluticasone propionate|low dose
45693721|NCT01969721|Drug|salmeterol|
46054663|NCT05342415|Other|Externally Focused Exercise|While performing the exercises participants will be instructed to focus on the external target (towel, target line, etc.)
46054664|NCT02846142|Drug|PTI-428|
45378788|NCT04817670|Drug|VIT-2763 360 mg|"Participants receive 2 capsules of VIT-2763 60 mg in the morning, in the afternoon and in the evening for 8 weeks.~Capsules are to be taken orally."
45495114|NCT03418727|Drug|Brimonidine Mono Therapy|Brimonidine given twice daily along with placebo drops
45495115|NCT03418727|Drug|sodium carboxymethylcellulose|Placebo given twice daily.
45495116|NCT03418727|Drug|Corticosteroid Eye Drop|Eye drop to be administered after Brimonidine in treatment arm 1
45495117|NCT01180374|Drug|Cannabidiol|Active Cannabidiol 5mg.
45495118|NCT01180374|Drug|Delta-9-THC|"Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or joint."
45495119|NCT01180374|Drug|Placebo|Placebo (about a quarter spoon of alcohol with no CBD).
45495120|NCT01180374|Drug|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
45495121|NCT03418571|Biological|ALX-0171 1.5 mg/kg|ALX-0171 1.5 mg/kg was administered via a single inhalation once daily for 3 consecutive days.
45495122|NCT03418571|Other|Placebo|Placebo was administered via a single inhalation once daily for 3 consecutive days.
45693722|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
45693723|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
45693724|NCT01969721|Drug|tiotropium|tiotropium high dose
45495123|NCT03887520|Diagnostic Test|Blood draw for Lp(a)|Collect sample for Lipoprotein(a) testing
45495124|NCT03715595|Other|SSDM group|The patients can perform self-evaluation, including DAS28, morning stiffness duration (MSD) and HAQ, and input medical records (including medication and laboratory test results) every month.
45495125|NCT05545943|Other|2-days of zero calorie restriction and whole-body cold-water immersion|The 2-days (48 hours) of zero-calorie restricted diet (with water provided ad libitum) with two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min.
45495126|NCT05545943|Other|6-days of calorie restriction|The 6-days (144 hours) of prescribed zero-calorie prescribed diet with water provided ad libitum.
45693725|NCT01969721|Drug|olodaterol|
45693726|NCT01969721|Drug|olodaterol|
45693727|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
46054665|NCT02846142|Other|Placebo|
46054666|NCT02846142|Drug|ethinyl estradiol and levonorgestrel|
46054667|NCT02783703|Dietary Supplement|Medium chain triglycerides (MCT)|Subjects will consume 30 grams per 2000 kilocalories daily of medium chain triglyceride oil by mouth
46054668|NCT05243160|Other|medication review|The intervention consist of a medication review by a clinical pharmacologist.
45495127|NCT05545943|Other|2-days of zero calorie restriction without whole-body cold-water immersion|2 days (48 hours) of prescribed zero-calorie diet with water provided ad libitum .
45495128|NCT05545943|Other|2-days of usual diet with whole-body cold-water immersion|Two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min. During intervention, participants were instructed to maintain their previous eating habits.
45495129|NCT03717545|Other|second allogeneic stem cell transplantation|"Change another donor~conditioning regimen: FLU/CY/anti-CD25 moAb"
45495130|NCT03715517|Procedure|Continuous thoracic epidural analgesia|"Needle/catheter: 17 Ga. × 80 mm Tuohy epidural needle (Perican®, B. Braun Medical Inc., Bethlehem, PA, USA); Arrow FlexTip Plus® 19 Ga. epidural catheter (Arrow International Inc., Reading, PA, USA)~Level of insertion and patient positioning: T6-T8, upright sitting position for insertion of needle and catheter (to 5 cm beyond loss-of-resistance point) and for injection of test dose (3 mL 2% lidocaine with epinephrine 1:200,000); supine for injection of bolus dose~Confirmation of correct placement: Loss of resistance to air or saline; negative aspiration of the epidural catheter; negative test dose; and ease of injection of an initial bolus dose"
45495131|NCT03715517|Procedure|Spinal anesthesia with intrathecal morphine|"Needle/catheter: 25 Ga. × 90 mm high-flow Whitacre spinal needle (Becton-Dickinson, Franklin Lakes, NJ, USA)~Level of insertion and patient positioning: L2-L3, lateral decubitus position during injection; immediately post-injection, patient is placed supine in <5% degree of Trendelenburg~Confirmation of correct placement: Aspiration of cerebrospinal fluid"
45495132|NCT03715517|Drug|Bupivacaine 0.75% in Dextrose Inj 8.25%|0.25 mg⋅kg-¹ hyperbaric bupivacaine 0.75%
45495133|NCT03715517|Drug|Morphine|3 mcg⋅kg-¹ intrathecal morphine (preservative-free)
45495134|NCT03715517|Drug|Bupivacaine 0.25% Preservative-Free Injectable Solution|0.25 mg⋅kg-¹ bupivacaine 0.25%
45495135|NCT03715517|Drug|Bupicavaine 0.125% epidural solution|Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
45495136|NCT03715517|Drug|Hydromorphone 10 mcg/mL epidural solution|Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
45495137|NCT03402893|Drug|ONEXTON Topical Gel|Onexton gel applied once daily to face
45495138|NCT03715361|Diagnostic Test|SL-ECG|additional SL-ECG measurement
45495139|NCT03717467|Drug|isotonic saline|100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
45495140|NCT03717467|Drug|Magnesium Sulfate|40 mg/kg of magnesium sulfate in 100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
45495141|NCT03717389|Other|presence of soft tissue calcification in head and neck|soft tissue calcifications of the head and neck region in the Egyptian population
45378789|NCT04817670|Drug|VIT-2763 240 mg|"Participants receive 2 capsules of VIT-2763 60 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
45495142|NCT04464954|Device|Auricular semi-permanent (ASP gold) needles|ASP semi-permanent Battlefield Acupuncture needles are semi-permanent needles that will remain in subject ears for 2-8 days and will be allowed to fall out on their own
45378790|NCT04817670|Drug|Placebo BID|"Participants receive 2 capsules of placebo in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
45378791|NCT04817670|Drug|Placebo TID|"Participants receive 2 capsules of Placebo in the morning, in the afternoon and in the evening, for 8 weeks.~Capsules are to be taken orally."
45495143|NCT04464954|Device|Intradermal (long) needles using J-type No. 2 (.18)x 15mm|Intradermal (long) needles will remain in subject ears for 15-30 minutes and will be removed by a member of the study staff.
45495144|NCT04464954|Device|Pyonex needles (Seirin Yellow 0.2 x 0.6mm)|Pyonex needles will remain in subject ears for 2-21 days and allowed to fall out on their own.
45495145|NCT03628248|Procedure|embolization of the inferior mesenteric artery|proximal occlusion of the inferior mesenteric artery, before its divisional branches, by coils or plug 3-4 weeks prior to surgery.
45495146|NCT03628248|Procedure|Inferior mesenteric artery ligation|Endovascular ligation of Inferior mesenteric artery
45495147|NCT03442985|Drug|Palovarotene 2.5 mg|Subjects received a weight-adjusted dose equivalent of 2.5 mg palovarotene, once daily, for up to 24 months.
45495148|NCT03442985|Drug|Palovarotene 5.0 mg|Subjects received a weight-adjusted dose equivalent of 5.0 mg palovarotene, once daily, for up to 24 months.
45378792|NCT04811079|Other|419 nm Spectacle Filter|TEST
45378793|NCT04811079|Other|437 nm Spectacle Filter|TEST
45378794|NCT04811079|Other|456 nm Spectacle Filter|TEST
45378795|NCT04811079|Other|476 nm Spectacle Filter|TEST
45495149|NCT03442985|Other|Placebo|Subjects received placebo, once daily, for up to 24 months.
45693728|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
45693729|NCT01969721|Drug|tiotropium|tiotropium low dose
45378796|NCT04811079|Other|373 nm Spectacle Filter|CONTROL
45378797|NCT04804943|Device|NOA-001|NOA-001 will be replaced regularly (at 22 to 24 hours after the initiation of procedure), and will be continuously performed until 168 hours from the enrollment.
45693730|NCT01969721|Drug|fluticasone propionate|low dose
45693731|NCT01969721|Drug|salmeterol|
45693732|NCT01969565|Drug|Carfilzomib|
45378798|NCT04793516|Other|VR Therapy Game|Participants will complete 15 sessions of VR-based therapy modules developed for use in helping people with spatial neglect. These 15 sessions will be completed over 4-5 weeks.
45378799|NCT04792073|Drug|Avelumab|Avelumab 800 mg given intravenously over 60 minutes every 2 weeks (+/- 3 days)
45378800|NCT04792073|Radiation|Comprehensive Ablative Radiation Therapy|Comprehensive ablative radiation therapy 24 Gy in 3 fractions every 2-3 days
45495150|NCT05522075|Behavioral|Exercise Training|Subjects will be asked to perform exercise training (high-intensity interval training) under supervision, 3 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
45495151|NCT05522075|Behavioral|Alcohol Abstinence Intervention|Subjects will be asked to abstain from alcohol for 8 weeks. Education materials and bi-weekly consultations will be provided.
45495152|NCT03715283|Other|Home Ankle Strengthing Program|Patients in this arm will be given a USB or DVD video with description of ankle dorsi- and plantar- flexion resistance band exercise. They will also be given an outlined plan for there exercises, progression and an exercise diary. In general patients will start with a low resistance and low reps, over the 4 weeks they will increase the repetitions at the same resistance band. After the 4 weeks they will have the option to escalate the band resistance or continue at the same resistance and repetitions until comfortable progressing. The same 4 week progression will be used for each resistance band over the 12 weeks.
45495153|NCT03715283|Other|Standard of Care|Patients in this arm will be directed to continue there standard care program. They will be asked to refrain from resistance exercise for 12 weeks.
45495154|NCT01311635|Drug|AZD1981, current small-particle tablet|3x100 mg per oral, single dose in fasted state
45495155|NCT01311635|Drug|AZD1981, new small-particle tablet|3x100 mg per oral, single dose
45495156|NCT01311635|Drug|AZD1981, new large-particle table|3x100 mg per oral, single dose in fasted state
45495157|NCT01318122|Drug|Alogliptin and pioglitazone|Alogliptin 12.5 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.
45495158|NCT01318122|Drug|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.
45495159|NCT02954159|Drug|Tacrolimus|Oral tacrolimus tablet starting at 0.05mg/kg twice daily, with dose adjustments aiming for serum trough levels of 10-15 ng/ml during the first 2 weeks, and 5-10ng/ml subsequently.
45495160|NCT02954159|Drug|Vedolizumab|Intravenous Vedolizumab 300 mg at week 0, 2 and 6 followed by the same dose every 8 weeks. This drug will be given as per standard of care.
45495161|NCT02954159|Other|Placebo|Patients will be randomized 1:1 in Treatment arm (receive Tacrolimus) and Placebo Arm.
45495162|NCT01311245|Behavioral|Stage-tailored intervention|Based on the Trans-Theoretical Model of intentional behavior change (TTM). According to their stage of change, participants received two computer generated feedback letters on their risky drinking, stage of change, processes of change, self-efficacy, and decisional balance. The first letter included normative feedback (interpersonal comparison with other individuals in the same stage), and was sent out by mail after baseline. The second letter included normative and ipsative feedback (intrapersonal comparisons: baseline vs. 3 months later), and was sent out by mail three months later.
45495163|NCT01311245|Behavioral|Non-stage-tailored Intervention|Based on the Theory of Planned Behavior (TPB). Participants received two computer generated feedback letters on their risky drinking, beliefs (behavioral, normative, control), attitude, subjective norm, perceived behavioral control, intention, and they were asked to fill in a where-when-how to change plan. The first letter included normative feedback (interpersonal comparison with other women/ men), and was sent out by mail after baseline. The second letter included normative and ipsative feedback, and was sent out by mail three months later.
45378801|NCT04785820|Drug|Lomvastomig|2100 milligrams (mg) administered by intravenous (IV) infusion once every 2 weeks on Day 1 of each 14-day cycle.
45378802|NCT04785820|Drug|Tobemstomig|2100 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
45378803|NCT04785820|Drug|Nivolumab|240 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
45495164|NCT03737136|Drug|Bortezomib|one cycle of bortezomib (each cycle: 1.3mg/m2 intravenously on days 1, 4, 8, and 11)
45495165|NCT03442829|Behavioral|Sweet food consumption|Sweet food consumption at breakfast
45495166|NCT03442829|Behavioral|Non-sweet food consumption|Non-sweet food consumption at breakfast
45495167|NCT03675282|Drug|(11C)PE2I|Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits
45495168|NCT03675282|Drug|Ioflupane|Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits
45495169|NCT05218512|Other|WB-EMS|"The group has been submitted to 2 experimental conditions:~At rest with superimposed WB-EMS.~During uphill walking exercise with superimposed WB-EMS."
45495170|NCT03442595|Other|Intensive diabetes education and medication management|Patients receive intensive knowledge based diabetes education and algorithm driven medication management over a period of 12 weeks.
45495171|NCT03717311|Other|Nutritional Intervention|The intervention will be done on 1 day, time during which, each subject will stay at the CRNH. A breakfast containing the fibers will be given to them, then during 24h a following will be done to get fecal, urinary, plasmatic and expiratory samples. Standardized lunch, dinner and collation will be served during the day.
45495172|NCT03763422|Drug|Temozolomide|Oral Administration of Temozolomide
45495173|NCT03763422|Radiation|Radiotherapy|50.4 Gy in 28 fractions over 6 weeks
45495174|NCT03763422|Procedure|Surgery|Surgery
45495175|NCT05658029|Drug|ARINA-1|Fixed-dose solution of ascorbic acid and reduced glutathione nebulized twice daily for 4 weeks (28 days)
45495176|NCT05520281|Behavioral|Short-term psychodynamic psychotherapy for patients with serious physical illness (ORPHYS)|A short-term psychodynamic therapy that focuses on the special inner and outer situation of patients with a serious physical illness, especially with regard to the importance of relationships in a limited lifetime.
45495177|NCT03715049|Procedure|Fraxel Laser Treatment|The device to be used in this study is a FDA approved device [510(k) approval] used for aesthetic dermatological procedures. The Fraxel Repair laser system utilizes a sealed off, all metal carbon dioxide gas tube that is radio frequency (RF) excited and air cooled, emitting light at a wavelength of 10.6 μm with programmable pulse duration and frequency. The Fraxel Repair laser has a continuous motion (rolling) optical tracking system. The Fraxel system consists of a treatment component and an internal control component. The treatment component consists of the laser delivery handpiece. A computer with a touch screen keyboard to enter subjects' information also provides controls for the fractionated delivery of the 10.6 μm beam.
45495178|NCT03667716|Drug|COM701|COM701 monotherapy.
45495179|NCT03667716|Drug|COM701 with Opdivo (Nivolumab).|COM701 in combination with Opdivo (Nivolumab).
45495180|NCT03714971|Behavioral|WhatsApp embedded in smoking cessation service|The routine service delivery was ongoing as the intervention was conducted. In addition to the routine procedures in service delivery described above, WhatsApp messages were sent according to the plan.
45495181|NCT03712007|Device|MAMP therapy with MARPE expander|Twenty patients will be submitted to MAMP therapy with MARPE expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The maxillary and mandibular miniscrews will be placed in the same section. After a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks to the mandibular mini-implants.
45495182|NCT03712007|Device|MAMP therapy with Hyrax expander|Fifteen patients will be submitted to MAMP therapy with Hyrax expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The mandibular miniscrews will be placed and after a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks and the mandibular mini-implants.
45495183|NCT05218122|Other|cross-sectional study without intervention|cross-sectional study without intervention
45495184|NCT03740334|Drug|Ribociclib|Ribociclib, blocks a specific type of protein called a cyclin-dependent kinases (CDK)
45495185|NCT03740334|Drug|Dexamethasone|Corticosteroids are commonly used to treat ALL.
45495186|NCT03740334|Drug|Everolimus|Everolimus is an inhibitor of mTOR. mTOR inhibition blocks the translation of genes that regulate cancer cell proliferation
45693733|NCT01969565|Drug|Dexamethasone|
45378804|NCT04765059|Drug|Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin|Randomized patients will receive oral dose of osimertinib with intravenous (IV) pemetrexed plus either IV cisplatin or IV carboplatin
45378805|NCT04765059|Drug|Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin|Randomized patients will receive oral dose of placebo matching osimertinib with IV pemetrexed plus either IV cisplatin or IV carboplatin
45847255|NCT04944810|Procedure|Mangetic General Surgery|Use the magnetic grasper to do the gallbladder retraction in cholecystectomies and upper retraction of the stomach to close the defect on hiatal hernia cases.
45378806|NCT04757155|Behavioral|Internet Adaptation of Managing Cancer and Living Meaningfully (iCALM)|A online psychotherapy designed for patients with advanced and metastatic cancer.
45378807|NCT04752215|Drug|BI 765049|BI 765049
45378808|NCT04752215|Drug|ezabenlimab|ezabenlimab
45378809|NCT04742101|Drug|S65487 and azacitidine|Treatment cycle of combination of S65487 and azacitidine during 4 weeks preceded by ramp-up doses. Two administration schedules are set up. S65487 will be administered via intravenous (IV) infusion. Azacitidine will be administered via either subcutaneous (SC) or Intravenous (IV) infusion according to local practices.
45378810|NCT04736953|Drug|Sirolimus|Sirolimus
45378811|NCT04736953|Other|Placebo|Placebo
45378812|NCT04732221|Drug|MK-5475|MK-5475 (soluble guanylate cyclase stimulator) 380 µg, 100 µg or 32 µg administered as dry powder inhalation
45495187|NCT03695406|Behavioral|Mind-Body Program for Fear of Recurrence|An adapted protocol of the Relaxation Response Resiliency Program, a manualized, group-based, multimodal mind body program. Protocol adaptation includes refinement of content and study procedures to target fear of cancer recurrence (FCR) among adult cancer survivors.
45495188|NCT05217966|Radiation|Radiation: Single Pre-Operative Radiation Therapy|Ablative preoperative partial breast radiation therapy
45495189|NCT03633786|Procedure|standard laparoscopic surgery|removal of endometriotic lesions with laparoscopic instruments (KARL STORZ Gesellschaft mit beschränkter Haftung & Co., Tuttlingen, Germany) using 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm
45495190|NCT03633786|Procedure|robot-assisted surgery|"removal of endometriotic lesions with da Vinci Xi robotic system (Intuitive Surgical Inc., Sunnyvale, CA, USA), using 5 transperitoneal abdominal accesses and trocars from 8 and 12 mm.~The robotic mechanical arms are associated with the 8 mm abdominal trocars to allow intervention by the first operator, with the aid of a surgical console."
45495191|NCT03633786|Diagnostic Test|assessment of sexual function|assessment of sexual function using a validate questionnaire (Female Sexual Function Index (FSFI)), before and 3 months after surgery
46054669|NCT05243277|Other|Oculomotor tests|"There will be four visits. Each visit is associated with a different exposure in terms of level of oculomotor conflict.~At each visit, several oculomotor tests will be performed, followed by a comfort questionnaire. The oculomotor tests are subjective tests during which the participant will be asked to fix his/her eyes on one or more targets that can move in space and to indicate the way he/she perceives this/these target(s). Depending on the test, lenses may be inserted between the participant and the target to modify his/her perception.~The comfort questionnaire consists to rate on a scale of 1 (not at all) to 5 (very much) the presence of visual symptoms, such as burning, watering or dryness.~The participant will then have to perform four different perceptual tasks. His/her level of accommodation (i.e. focus) will be monitored throughout the tasks.~Each exposure is followed again by eye tests and a comfort questionnaire."
45378813|NCT04732221|Drug|Placebo to MK-5475|Placebo administered as dry powder inhalation
45378814|NCT04731610|Other|Radiotherapy|postoperative radiotherapy after complete resection of thymoma
45378815|NCT04731610|Other|Surveillance after resection|Surveillance after tumour resection
45378816|NCT04725617|Drug|Varenicline|Standard smoking cessation treatment.
45378817|NCT04725617|Behavioral|Smoking Cessation Counseling|Standard smoking cessation treatment
45378818|NCT04725617|Behavioral|Health Approach 1 to Reduce Smoking|Behavioral health intervention option 1
45378819|NCT04725617|Other|Health Approach 2 to Reduce Smoking|Behavioral health intervention option 2
45378820|NCT04707911|Behavioral|Social Media Intervention|Social media based intervention using Instagram with up to 3 posts per day for 30 days
45378821|NCT04707391|Combination Product|MenABCWY vaccine|2 doses of MenABCWY vaccine administered intramuscularly on Day 1 and Day 181 to participants in ABCWY group.
45378822|NCT04707391|Combination Product|Placebo|1 dose of placebo administered intramuscularly on Day 211 to participants in ABCWY group
45378823|NCT04707391|Biological|MenACWY vaccine|1 dose of MenACWY vaccine administered intramuscularly on Day 1 to participants in ACWY group
45378824|NCT04707391|Combination Product|MenB vaccine|2 doses of MenB vaccine administered intramuscularly on Day 181 and Day 211 to participants in ACWY group. MenB vaccine is a non-investigational medical product (NIMP) in this study and is administered only in compliance with standard of care.
45378825|NCT04703166|Device|Samsung Galaxy Watch Active2|The Samsung wearable device will collect data; photoplethysmography (PPG) waveforms, heart rate, heart rate variability, step counts, oxygen saturation levels, sleep pattern and quality.
45378826|NCT04703075|Drug|Rifapentine 600 mg and INH 300 mg|Participants will receive Rifapentine 600 mg and INH 300 mg
45378827|NCT04703075|Drug|Rifapentine 900 mg and INH 900 mg|Participants will receive Rifapentine 900 mg and INH 900mg
45495192|NCT03633786|Diagnostic Test|assessment of bowel symptoms|assessment of bowel symptoms using a validated questionnaire (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS)), before and 3 months after surgery
45378828|NCT04702737|Drug|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
45378829|NCT04691986|Dietary Supplement|Nicotinamide Riboside|Nicotinamide Riboside is a form of vitamin B3 and is naturally occurring in humans.
45378830|NCT04691986|Other|Placebo|Placebo pills contain micro cellulose powder.
45378831|NCT04685421|Drug|Bupivacaine liposome|Liposomal Bupivacaine PKs collections up to 96 hours on children from 2 to 17 years in pediatric cardiac surgeries.
45378832|NCT04683042|Device|Transcutaneous Electrical Nerve Stimulation (TENS) with PT|Use of TENS units along with routine PT therapy
45378833|NCT04683042|Other|PT only|Routine PT therapy only
45378834|NCT04682158|Drug|Carboplatin|Given IV
45378835|NCT04682158|Radiation|3 Dimensional Conformal Radiation Therapy|Undergo 3D CRT
45378836|NCT04682158|Drug|Propranolol|Subject will be treated with 30 mg po BID Propranolol for up to 6 weeks
45378837|NCT04682158|Radiation|Intensity Modulated Radiation Therapy|Undergo IMRT
45378838|NCT04682158|Drug|Paclitaxel|Given IV
45378839|NCT04681248|Drug|DKN-01|Administered by IV infusion
45378840|NCT04680975|Drug|Belumosudil|10 participants with dcSSc received belumosudil 200 mg PO BID for 52 weeks
45495193|NCT03633786|Diagnostic Test|assessment of urinary symptoms|assessment of urinary symptoms using a validated questionnaire (Bristol Female Lower Urinary Tract Symptoms (BFLUTS)), before and 3 months after surgery
45495194|NCT03421392|Other|non interventional study|non interventional study
45495195|NCT05217732|Drug|ZX-7101A|tablet
45495196|NCT05217732|Drug|Placebo|Tablet
45495197|NCT05217576|Device|NBM-200|Finger Prick and Venipuncture
45378841|NCT04680455|Other|Online home-based strength training|Body weight exercises (i.e., squats, tricep dips, lunges, and push-ups) delivered online through Teams
45378842|NCT04673786|Biological|CT-P43|45mg or 90mg dose subcutaneous administration
45378843|NCT04673786|Biological|Stelara|45mg or 90mg dose subcutaneous administration
45378844|NCT04672798|Behavioral|BRITEPath|BRITEPath will guide co-located mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.
45495198|NCT03440411|Drug|Pomalidomide|4 mg/daily as oral administration (PO) on days 1-21.
45495199|NCT03440411|Drug|Cyclophosphamide|50 mg every other day as oral administration (PO) on days 1-28
45495200|NCT03440411|Drug|Dexamethasone|40 mg as oral administration (PO) on days 1, 8, 15, 22.
45378845|NCT04672798|Behavioral|Treatment As Usual (TAU)|Participants in this group will receive usual care from their mental health care provider.
45495201|NCT03714893|Device|Sensor wrist watch|Participants will wear a sensor wrist watch which will collect data
45693734|NCT04173923|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
45378846|NCT04670783|Procedure|Surgery|Orthopedic surgery (i.e. tenotomy, tendon transfer) or percutaneous neuroablative procedures (i.e. cryoneurotomy) which will be done for upper limb refractory spasticity after being triaged by DNB.
45378847|NCT04669028|Drug|NE3107|NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Alzheimer's disease.
45378848|NCT04669028|Drug|Placebo|capsules that do not contain NE3107
45378849|NCT04666792|Drug|PrEP|A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
45495202|NCT03717233|Device|Exoskeleton|Ankle-foot exoskeleton - device to help reduce load on the bottom of the front of the foot
46054670|NCT02848482|Device|Photodynamic therapy|Photodynamic therapy (HELBO Photodynaimc Systems GmbH, Wels, Austria)
46054671|NCT02848482|Procedure|Mechanical debridement|Plastic scalers (Have implantrecallset, Kerr, Italy) will be used to curette the contaminated sites.
46054672|NCT02848482|Drug|Irrigation|0.2% chlorhexidine digluconate solution (Bioworld, Madision, US) will be irrigated at contaminated sites for 1 minute.
46054673|NCT02782533|Device|Deep Brain Stimulation V3|
46054674|NCT00757783|Drug|ritonavir|100 mg capsule or tablet once daily for 48 weeks
45495203|NCT03714737|Biological|experimental vaccine|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)
46054675|NCT00757783|Drug|ritonavir|100 mg capsule or tablet once daily for 48 weeks
46054676|NCT00757783|Drug|darunavir|800 mg tablet once daily for 48 weeks
45495204|NCT03714737|Biological|Positive control vaccine 1|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(WALVAX Biological Co., LTD)
45495205|NCT03714737|Biological|Positive control vaccine 2|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(Royal (Wuxi) Biological Co., LTD)
45495206|NCT03438539|Behavioral|Normative Feedback|Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
45495207|NCT03438539|Behavioral|Inhibitory Control Training|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control.
45495208|NCT03438539|Behavioral|Working Memory Training|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task.
45495209|NCT05657639|Drug|CAV Regimen|Cladribine 5 mg/m2/day , cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.
45495210|NCT05657639|Drug|MEC Regimen|Mitoxantrone 8mg/m2 d1-5, etoposide 100mg/m2 d1-5, cytarabine 1g/m2 d1-5
45495211|NCT05656625|Other|descriptive|The block performed (distal peripheral nerve block and/or brachial nerve block) and the volume applied, block performance time, first analgesia times, surgery times, surgery types, discharge times, presence of additional complaints will be recorded. The data obtained by grouping the patients according to the type of anesthesia applied (brachial plexus block and distal nerve blocks) will be subjected to statistical analysis.
45378850|NCT04647929|Device|Santen PRESERFLO MicroShunt|the PRESERFLO MicroShunt will be implanted to increase aqueous humor outflow
45378851|NCT04647929|Procedure|Trabeculectomy|a fornix-based trabeculectomy with a 3x4mm flap will be performed to increase aqueous humor outflow
45495212|NCT03400787|Device|Latera Implant|Treatment with implant
45378852|NCT04624243|Drug|MK-8189|MK-8189 administered QD at a dose of 8 mg, 16 mg, or 24 mg via oral tablet.
45378853|NCT04624243|Drug|Risperidone|Risperidone administered QD at a dose of 6 mg via oral capsule.
45378854|NCT04624243|Drug|Placebo to MK-8189|MK-8189-matching placebo administered QD via oral tablet.
45378855|NCT04624243|Drug|Placebo to risperidone|Risperidone-matching placebo administered QD via oral capsule.
45495213|NCT03400787|Device|Sham Procedure|Sham procedure where the Latera delivery device is inserted but no implant delivered.
45495214|NCT03639077|Device|Allograft bone alone|The subject will receive an allograft as graft material of choice for sinus augmentation
45495215|NCT03639077|Device|Allograft and xenograft mixture|The subjects will receive a mixture of allograft and anorganic bovine bone xenograft as graft material of choice for sinus augmentation
45495216|NCT03417245|Drug|fitusiran|by SC injection
45495217|NCT03417245|Drug|factor concentrates|by intravenous (IV) injection
46054677|NCT00757783|Drug|emtricitabine [FTC]/tenofovir [TDF]|200/300 mg tablet once daily for 48 weeks
45495218|NCT03711851|Behavioral|Self-help Acceptance and commitment therapy (Web-based)|9 week program with minimal contact with therapist (predominantly self-help)
45495219|NCT03711851|Behavioral|Self-help Acceptance and commitment therapy (bibliotherapy)|9 week program with contact with therapist (predominantly self-help)
45847256|NCT04928508|Drug|SHetA2|"SHetA2 orally in the form of 50 mg capsules. Four dose levels will be evaluated:~5.4mg/kg 7.0mg/kg 9.0mg/kg 12mg/kg"
46054678|NCT00757783|Drug|emtricitabine [FTC]/tenofovir [TDF]|200/300 mg once daily for 48 weeks
46054679|NCT00757783|Drug|atazanavir|300 mg capsule once daily for 48 weeks
46054680|NCT01770249|Procedure|Per-oral Endoscopic Esophagomyotomy (POEM)|The surgeon is cutting only through the innermost layers of muscles in the esophagus down to the stomach, leaving the outer layer intact.
46054681|NCT05242926|Drug|ModraDoc006/r|One time bi-daily dosing (30/20 mg) of ModraDoc006 in combination with ritonavir 100 mg tablets
45378856|NCT04623775|Biological|Nivolumab|Specified dose on specified days
45378857|NCT04623775|Biological|Relatlimab|Specified dose on specified days
45378858|NCT04623775|Drug|Carboplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
45378859|NCT04623775|Drug|Cisplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
45378860|NCT04623775|Drug|Paclitaxel|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
45378861|NCT04623775|Drug|Nab-Paclitaxel|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
46054682|NCT02782221|Drug|Growth Hormone|Subjects are receiving one injection of growth hormone (Genotropin) 0,5 mg
46054683|NCT02782221|Drug|Pegisomant|One the placebo day the subjects are receiving injection with pegvisomant (Somavert 30 mg) to block the action of endogenous growth hormone
45378862|NCT04623775|Drug|Pemetrexed|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
45495220|NCT03711851|Other|Self-help Education pamphlets on pain (active control group)|9 week program with contact with therapist (predominantly self-help)
45495221|NCT03389555|Drug|vitamin C, vitamin B1, hydrocortisone|Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9% NACL(normal saline) and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.
45495222|NCT03389555|Drug|Normal saline|Normal saline (0.9% NaCl solution) volume to match all components
45495223|NCT03714581|Device|Microablative Fractional CO2 Laser Therapy|5 laser therapies intravaginally administered will be applied at monthly intervals.
45495224|NCT03711461|Device|endotracheal tube (double lumen)|patients routinely use double lumen endotracheal intubation while they have received thoracoscopy
45495225|NCT03711461|Device|nonintubated|patients receiving nonintubated anesthetic plan while they have received thoracoscopy
45495226|NCT03395639|Drug|Edoxaban|Edoxaban 15 mg or 30 mg tablets for participants 12 to <18 years of age, or 60 mg edoxaban suspension (dosed as mg/kg) for participants under 12 years of age (and optionally, 12 or older), for oral administration
45495227|NCT03395639|Drug|Standard of Care (SOC)|Standard of care could include low molecular weight heparin (LMWH) and/or VKA according to the clinical site's SOC treatment regimen
45495228|NCT03353922|Drug|Cyclobenzaprine 10 Mg Oral Tablet|cyclobenzaprine 10 mg tablets
45495229|NCT03353922|Drug|Placebo Oral Tablet|sugar pill
45495230|NCT05677932|Device|Bright light therapy|Exposure to bright light therapy for 30mins a day for two weeks
45495231|NCT05677932|Device|Dim red light therapy|Exposure to 50lux dim red light therapy for 30mins a day for two weeks
45495232|NCT03395405|Drug|Nitazoxanide|One 500 mg tablet twice daily with food for 56 consecutive doses
45495233|NCT03395405|Other|Placebo|One tablet twice daily with food for 56 consecutive doses
45495234|NCT05492825|Other|Yoga|Each yoga class will follow a standardized structure, allowing participants to easily re-join if they miss classes. Yoga classes will be adapted to the abilities and limitations of each study participant, for example, using a chair for sitting exercises rather than the floor and to assist with balance. Postures (asanas) will target back pain and include mindfulness, relaxation, and breathing practices integral to hatha yoga, with focus on breath-based movement throughout. Each group will have 1-2 yoga instructors and no more than 5 participants per yoga instructor (up to 10 participants/group).
45495235|NCT05492825|Other|Physical Therapy|The assessment at the second screening visit by the Physical Medicine & Rehabilitation physician/Physical Therapy staff will be available to physical therapists in the Electronic Health Record and will guide the type of exercises, to focus on stabilization (strengthening core trunk muscles) and flexion or extension exercises. Sessions are divided into 30 minutes of working directly with a physical therapist and 30 minutes of supervised aerobic exercise (on treadmill or recumbent bike). Participants will receive a guidebook for guiding and recording home practice, based on Saper's guidebook and modified based on feedback from experts and stakeholders for clarity and cultural appropriateness.
46054684|NCT02781987|Other|chronic pancreatitis|patients with chronic pancreatitis
46054685|NCT02846064|Procedure|Autograft of cryopreserved ovarian tissue|Orthotopic transplantation
46054686|NCT04231617|Drug|glibenclamide|Oral administration of glibenclamide or placebo. To investigate the role of CGRP on cranial arteries in healthy volunteers after glibenclamide/placebo administration .
45378863|NCT04611399|Behavioral|VR for psychoeducation and relaxation|"Use of specifically developed VR contents to deliver psychoeducational content on stress and anxiety (i.e., MIND-VR) and to train on relaxation techniques (i.e., The Secret Garden)."
46054687|NCT04231617|Drug|CGRP infusion|CGRP infusion
46054688|NCT04231617|Drug|Placebo|placebo
45378864|NCT04611399|Other|Control (CR)|The CR Group will undergo pre- and post-protocol tests without undergoing any treatment.
45378865|NCT04607837|Drug|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
45378866|NCT04607837|Drug|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
45378867|NCT04606446|Drug|PF-07248144|KAT6 Inhibitor
45378868|NCT04606446|Drug|Fulvestrant|Endocrine Therapy
45378869|NCT04606446|Drug|Letrozole|Endocrine Therapy
45378870|NCT04606446|Drug|Palbociclib|CDK4/6 Inhibitor
45378871|NCT04606446|Drug|PF-07220060|CDK4 inhibitor
45378872|NCT04605978|Drug|S95011 concentrate for solution for infusion|IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.
45378873|NCT04605978|Drug|Placebo concentrate for solution for infusion|IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.
45378874|NCT04602533|Drug|Durvalumab|Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherapy) Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities.
46054689|NCT04810104|Drug|AZD0328|Active study drug
46054690|NCT04810104|Drug|Placebo|Non-active study drug
46054691|NCT00757705|Drug|Paliperidone ER|Participants will receive paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day orally once daily for 24 weeks as per Investigator's discretion based on the individual participant's clinical response to and tolerability of the study drug.
46054692|NCT02845908|Drug|POF|Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
45847257|NCT04914702|Device|Everion®|The Everion® is an on-skin wearable devices measuring vital signs. It will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
45847258|NCT04914702|Device|CORE®|The CORE® is an on-skin wearable devices measuring vital signs. It will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
45495236|NCT05492825|Other|Treatment As Usual|Participants in the Treatment As Usual group will receive routine clinical care. This includes: 1) pain assessment using a 10-point scale, at OTP admission and annual physical exams. This is documented on a templated form in the OTP electronic health record, as well as whether pain is acute vs chronic pain, and a treatment plan (e.g., on-site care, outside primary care clinician, pain management referral). 2) clinical treatment of pain by participants' on-site or outside clinicians. Those patients who receive on-site medical care have the opportunity to address nonpharmacological and pharmacological treatment with onsite physicians and physician assistants, and to receive referral to specialty care including physical therapy and orthopedics at multiple Montefiore locations throughout the Bronx.
45847259|NCT04881708|Device|Remote Monitoring|Subjects assigned to the Remote Care group will receive education from a clinical nurse from Mayo Clinic's Department of Connected Care on use of the equipment as part of Remote Monitoring. The equipment will be shipped along with instructions and Welcome Letter describing the Mayo Clinic Remote Patient Monitoring program. The Remote Patient Monitoring kit includes a digital tablet, a blood pressure cuff, a thermometer, a pulse oximeter, and a weight scale. Subjects will be contacted by phone at the end of the study to be instructed how to return the kit by mail.
45847260|NCT04810806|Procedure|Immediate coronary angiography within 2 hours after randomization|After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Immediate CAG group will receive CAG within 2 hours after randomization. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
45378875|NCT04602533|Drug|standard of care|"Radiochemotherapy: Cisplatin (75 mg/m² (BSA) D1#) or alternatively Carboplatin (AUC 5 D1) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles and concomitant Radiotherapy (60±6 Gy, 1.8-2 Gy/d or 45±1.5 Gy (1.5 Gy per fraction twice daily, with 4 hours or more between fractions) with start at latest at beginning of cycle 3, ideally during cycle 1) followed by prophylactic cranial irradiation (PCI, if clinically indicated and according to local standard at any time after completion of radio-chemotherapy))~A simultaneous administration of platinum-based chemotherapy (preferred Cisplatin) and radiotherapy for at least 2 cycles should be performed."
45378876|NCT04597671|Drug|Durvalumab|Durvalumab is used as standard of care
45378877|NCT04597671|Radiation|low-dose PCI|PCI will be given concurrently with durvalumab. PCI will be given to a dose of 15 Gy in 10 fractions
45847261|NCT04810806|Procedure|Delayed coronary angiography after stabilization of heart failure|After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Delayed CAG group will receive CAG after stabilization of ADHF; improvement of symptoms and signs of heart failure. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
45847262|NCT04744428|Behavioral|Autism Parent Navigators|The Autism Parent Navigator program consists of six sessions delivered to parents in the home, supporting adjustment to ASD, accessing services, and coparenting support.
45847263|NCT04744428|Behavioral|Peer mentoring|Six in-home or telephone sessions, depending on family uptake, providing non-manualized general support as usual from parent peer mentors regarding adjustment to ASD.
45847264|NCT04727424|Drug|Fluvoxamine Maleate 100 MG [Luvox]|One tablet every 12 hours since randomization through day 09.
45847265|NCT04727424|Drug|Budesonide Powder|"One Fluvoxamine tablet every 12 hours since randomization through day 09. PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 09."
46054693|NCT02845908|Drug|FOLFOX|Oxaliplatin plus Leucovorin plus 5-FU
46054694|NCT02845908|Drug|FOLFOX plus PAC(ip)|FOLFOX plus intraperitoneally PAC
46054695|NCT04197531|Other|Irrigation Method|Irrigation Method
45495237|NCT03711383|Dietary Supplement|Inulin and Resistant Starch|12g per inulin in combination 7.5 g resistant starch per day the day before the CID Resistant starch 7.5 g
45495238|NCT03711383|Dietary Supplement|Inulin|12g per inulin in combination with maltodextrin per day the day before the CID
45378878|NCT04589624|Drug|Hyperpolarized Carbon C 13 Pyruvate|Given IV
45378879|NCT04589624|Procedure|Magnetic Resonance Imaging|Undergo MRI
45378880|NCT04589624|Procedure|Magnetic Resonance Imaging|Undergo hpMRI
45378881|NCT04584320|Other|Stool sample|Stools samples taken daily to test for present of Clostridium butyricum and Clostridium neonatale
45378882|NCT04583969|Biological|Lenzilumab|Lenzilumab is a first-in-class recombinant monoclonal antibody targeting soluble human GM-CSF, with potential immunomodulating activity, high binding affinity in the pM range, and 94% specificity to the human germline, which reduces immunogenicity.
45495239|NCT03711383|Dietary Supplement|Placebo|isocaloric maltodextrin before test day
45378883|NCT04583969|Other|Placebo|Placebo for lenzilumab is commercially sourced 0.9% sodium chloride.
45378884|NCT04583969|Drug|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
45378885|NCT04576065|Other|WFIT|access to nurse practitioner for telehealth visits and activity monitor for 6 months after hospital discharge
45378886|NCT04575857|Drug|Atorvastatin|Participants in the intervention arm will receive a pill packet with atorvastatin (40mg) x 18 months.
45495240|NCT03387683|Drug|dapagliflozin|dapagliflozin 10mg
45495241|NCT03387683|Drug|placebo|placebo to match dapagliflozin
45495242|NCT03714347|Device|cerebral oxygen monitoring|probes will be placed on eyebrows on forehead
46054696|NCT05242614|Behavioral|The Hybrid Mindfulness-based Dementia caregiving program (MBDCP)|The hybrid MBDCP includes 6 weekly 90-minute group-based sessions delivered through a face-to-face (1st, 2nd, and 6th sessions) and online approach (3rd, 4th, and 5th sessions). The online session is designed for self-directed learning. The MBDCP includes different mindfulness practices (e.g., mindful eating, body scanning, and mindful walking), psychoeducation on caregiving, and group sharing, aimed at helping caregivers to develop mindfulness skills through the formal and informal practice of mindfulness, and to integrate these skills into their everyday life. The duration of each session is 90 minutes. Th MBDCP will be delivered by a qualified mindfulness therapist. In the MBDCP's online sessions, the caregivers will watch a teaching video (e.g., a video demonstrating mindfulness practices) through a website.
45378887|NCT04575857|Drug|Placebo|Participants in the control arm will receive a pill packet with placebo x 18 months.
45378888|NCT04569708|Other|Auditory stimulation|Quiet auditory stimulation timed with sleep physiology
45378889|NCT04561115|Biological|Gamunex-C|Intravenous infusion.
45378890|NCT04561115|Biological|IVIG-PEG|Intravenous infusion.
45378891|NCT04549779|Procedure|Low volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 5 ml levobupivacaine 0.25%
45378892|NCT04549779|Procedure|Intermediate volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 10 ml levobupivacaine 0.25%
45378893|NCT04549779|Procedure|High volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 15 ml levobupivacaine 0.25%
45378894|NCT04546425|Biological|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
45378895|NCT04546425|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
45378897|NCT04520711|Biological|TCR-transduced T cells|TSA-reactive TCR-engineered T cells
45378898|NCT04520711|Drug|CDX-1140|Recombinant fully human IgG2κ monoclonal antibody
45378899|NCT04520711|Drug|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody
45378902|NCT04509245|Behavioral|Low-calorie diet supported by an app-guided digital education program, nutritional coaching calls via phone|During the 12-week intervention participants were asked to adhere to a real food-based low-calorie diet supported by an app-guided digital education program as well as a low-calorie recipe book and received weekly coaching calls by nutritionists
45378903|NCT04502706|Drug|GS-0189|GS-0189 will be administered intravenously.
45378904|NCT04502706|Drug|Rituximab|Rituximab will be administered intravenously.
45378905|NCT04499690|Behavioral|Managing Cancer and Living Meaningfully|A brief, individual, manualized psychosocial intervention for patients with advanced and metastatic cancer
45495243|NCT03714347|Device|routine monitoring|We will use routine monitoring intervention such as hate rate, arterial pressure, BIS. cerebral oxygen monitoring will not be applied to this group
45495244|NCT05467553|Drug|Ursodeoxycholic acid|Ursodeoxycholic Acid 15 mg/kg PO QD for 60 weeks
45495245|NCT05467553|Drug|Ropeginterferon alfa-2b|P1101 450 µg SC Q2W add-on at treatment week 12 for 48 weeks
45495246|NCT05467553|Drug|Tenofovir Alafenamide|TAF 25 mg PO QD for 60 weeks
45495247|NCT03387059|Device|Forielle|Participants randomized to receive Forielle endometrial washing (an intrauterine solution) following oocyte retrieval on Study Day 0 (Randomisation).
45495248|NCT02942004|Drug|Placebo|Intravenous infusion of matching placebo for either SAGE-547 60 μg/kg/h or 90 μg/kg/h.
45495249|NCT02942004|Drug|SAGE-547 60 μg/kg/h|Intravenous infusion of SAGE-547.
45495250|NCT02942004|Drug|SAGE-547 90 μg/kg/h|Intravenous infusion of SAGE-547.
45495251|NCT03394391|Behavioral|Daily ART-adherence SMS reminder|Interactive and tailored SMS reminders that are acceptable to the participants to remind them to take their medications and to make clinic attendance.
45495252|NCT03394391|Behavioral|Standard Adherence Counselling/Patient experience group chat|"All the participants will receive the standard adherence counselling by trained counsellors at each visit.~All participants will also be enlisted in a group chat on social media where they will discuss their experiences with the quality of HIV services rendered at their respective clinics. A specialist who will have very minimal involvement will give weekly feedback and counsel on how best to resolve prominent challenges."
45495253|NCT03711695|Device|iBeat wristwatch device|The participant will be asked to wear one iBeat wristwatch device on each arm during the planned procedure.
45495254|NCT01311791|Device|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
45495255|NCT01311791|Drug|Standard medical therapy|as defined per protocol
45495256|NCT03714269|Other|measurement evaluated with an isokinetic dynamometer|measurement of the maximum dorsiflexion angle in degrees evaluated on an isokinetic dynamometer
45495257|NCT03714269|Other|measurement evaluated with an 2D ultrasound|"simultaneous recording of force torque, joint angle and myotendinous junction displacement in 2D ultrasound during 5 passive mobilization cycles of ankle flexion-extension at very low speed~recording of static images in 2D ultrasound representing the proximal insertion of the gastrocnemius muscle in the internal condyle of the femur, the myotendinous junction."
45495258|NCT03714269|Other|assessment of the level of discomfort|visual analogue scale (0 = no discomfort and 10 = maximal discomfort)
45378906|NCT04486833|Biological|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental non-viral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
45378907|NCT04486833|Drug|osimertinib|Osimertinib is a 3rd generation EGFR tyrosine kinase inhibitor (TKI) oral tablet administered daily, as indicated for treatment of patients with metastatic NSCLC whose tumors have EGFR genetic deletions or mutations.
45495259|NCT01311869|Dietary Supplement|EGCG ( Green Tea extract)|A randomized double-blind placebo-controlled clinical trial will be conducted with 80 women of reproductive age,the 80 women will be allocated into two groups, 40 each. Each group will be given one of two interventions: The first is 2 capsules of (EGCG which is green tea extract, taken orally with food on daily basis for 6 months, each capsule contain 326.25 mg decaffeinated EGCG,The second group will receive matched (color, taste and texture) placebo for a period of 6 months.
45378908|NCT04486833|Drug|Platinum-Based Chemotherapy|Cisplatin and carboplatin are intravenously administered platinum agents that are combined with other cytotoxic chemotherapy agents such as pemetrexed.
45378909|NCT04468776|Drug|Zolpidem|Zolpidem, as prescribed by physician
45378910|NCT04468776|Behavioral|Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)|6-week internet CBT-I multi-component intervention (SHUTi) including sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention
45378911|NCT04468776|Drug|Trazodone|Trazodone, as prescribed by physician
45495260|NCT01311869|Dietary Supplement|Brown rice pills|40 subjects will receive 800 mg EGCG orally daily for 6 months, the other 40 subject will receive brown rice pills for the same duration.
45495261|NCT03386435|Procedure|remote ischemic preconditioning|Remote ischemic preconditioning was performed following anesthesia induction in donors. The protocol involves 3 cycles of 5-minute inflation of a blood pressure cuff to 200 mm Hg to one upper arm, followed by 5-minute reperfusion with the cuff deflated
46054697|NCT05242614|Behavioral|Psychoeducation educational program|This program serves as a control for the social effects of the MBDCP. The brief education program consists of 6 weekly 90-minutes group sessions in which the sessions (1st, 2nd, and 6th) and (3rd 4th 5th) will be delivered through the face-to-face and online approach respectively, with the similar group size of the MBDCP. The education contents include caregiving skills, education on mood, and group sharing. The program will be led by a nurse.
46054698|NCT02784483|Drug|Atezolizumab (1200mg via IV infusion)|Patients will get atezolizumab every 21 days for up to 1 year
45378912|NCT04468321|Device|Apple Watch|Participants will be assigned to the Apple Watch arm to assess the impact of individual use of the Apple Watch on patient-reported and clinical utilization outcomes using Hugo.
45378913|NCT04468321|Device|Withings Move|Participants will be assigned to the Withings Move arm to assess the impact of individual use of the Withings Move on patient-reported and clinical utilization outcomes using Hugo.
45378914|NCT04461639|Drug|Damoctocog alfa pegol (Jivi, BAY94-9027)|Different prophylaxis regimens with damoctocog alfa pegol following approved local labels or any other regimen prescribed by the physician as part of normal clinical practice
45378915|NCT04456673|Drug|Dupilumab SAR231893|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
45495262|NCT03714191|Other|Patient Outcomes|The intervention includes different versions of the BPA design and message.
45495263|NCT03714191|Other|Billing documentation|The intervention includes different versions of the BPA design and message.
45378916|NCT04456673|Drug|Inhaled Corticosteroid|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
45378917|NCT04456673|Drug|Inhaled Long-Acting Beta Agonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
45378918|NCT04456673|Drug|Inhaled Long-Acting Muscarinic Antagonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
45495264|NCT03714191|Other|Regulatory|The intervention includes different versions of the BPA design and message.
45378919|NCT04456673|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
45495265|NCT02912208|Drug|Eltrombopag/Revolade|Eltrombopag 50 mg once daily has been selected as the starting dose for this study. Thereafter, dependent on platelet response the dose of study medication can be increased by 50 mg every 2 weeks, up to a maximum dose of 300 mg once daily (150 mg in subjects of East Asian ethnicity).
45495266|NCT02912208|Other|Placebo|The administration is the same of eltrombopag
45495267|NCT02793258|Device|transcranial direct current stimulation|"Subjects will receive 10 30-minutes sessions of two milliamps transcranial direct current stimulation , twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
45378920|NCT04424914|Diagnostic Test|Scintigraphy|scintigraphy
45495268|NCT02726880|Behavioral|Behavioral therapy|6-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors.
45495269|NCT02726880|Behavioral|Referral for care|Referral for mental health issues and family support services
45495270|NCT03275389|Biological|D-SUIV cH8/1N1+AS03|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 03 (AS03) was administered intramuscularly (IM) in the deltoid region of non-dominant arm.
45378921|NCT04416269|Drug|Oral Anti-diabetes Drugs alone|OADs will be continued at same outpatient dosage unless contraindicated. Participants will be switched to the preferred drug within the category of medication they take at home. Dose adjustment for OADs will be based on clinical/laboratory status. The OAD will be held if the participant is placed on strict nil per os (NPO) and is unable to take oral medications after enrollment.
45378922|NCT04416269|Drug|Basal bolus insulin|Basal insulin with glargine or detemir will be used as per the hospital formulary.
45378923|NCT04416269|Drug|Supplemental insulin|Supplemental (correction) lispro or aspart insulin following the supplemental/sliding scale standard of care protocol for BG >140 mg/dl.
45378924|NCT04416269|Device|Continuous glucose monitoring (CGM)|"A subset of participants (50 per study arm) will be randomized to take part in an optional study where a CGM device will be placed for the duration of the study. CGM reports will be reviewed at the end of the study to assess parameters of glycemic control and hypoglycemia, and not used for insulin dose adjustment.~The Dexcom CGM is a small sensor that inserts just under the skin to continuously monitor glucose levels. Results are transmitted to the wearer's smartphone every five minutes."
45378925|NCT04400292|Other|Injection of indocyanine green (ICG)dye|Patients will receive a perilesional injection of indocyanine green (ICG) before the laparoscopic phase of the esophagectomy.
45378926|NCT04400292|Device|Near-Infrared Image-Guided|Real-time near-infrared (NIR) fluorescence imaging will be performed by use of the Novadaq PINPOINT minimally invasive system with a laparoscopic camera.
45378927|NCT04400292|Procedure|Sentinel Lymph Node (SLN) mapping|Any identified SLNs will be dissected during the standard completion lymphadenectomy and esophagectomy.
45378928|NCT04398017|Procedure|Transesophageal echography|Ultrasound examination of the heart using a soft tube. The extremity is inserted through the mouth and positioned in the esophagus behind the heart.
45378929|NCT04394351|Drug|Dupilumab|Single-use, prefilled syringe
45378930|NCT04394351|Drug|Matching Placebo|Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance
45693735|NCT04173923|Procedure|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
45693736|NCT04173923|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
45378931|NCT04377555|Drug|Ocrelizumab|Ocrelizumab will be administered intravenously (IV) at a dose of 600 mg every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent dose, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
45378932|NCT04374461|Drug|N-acetylcysteine|Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician. Treatment interruptions for up to 48 hours are permissible if there is a clinical indication to hold the study drug. Patients can restart drug if they have been off drug for less than 48 hours. Patients are also eligible to restart N-acetylcysteine treatment on the same treatment arm without reconsent if they are within the 30 day followup period after their prior course of treatment on this protocol.
45378933|NCT04374461|Other|Peripheral Blood|A total of 16mL of research whole blood will be collected in CPT tubes at baseline, Cycle 2 Day 1 (or as close as feasible, when still coordinating sample collection across patients in a critical-care unit), and at end of study.
45495271|NCT03275389|Biological|D-SUIV cH5/1N1+AS03|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
45495272|NCT03275389|Biological|D-SUIV cH11/1N1+AS03|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
45495273|NCT03275389|Biological|D-SUIV cH8/1N1+AS01|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
45495274|NCT03275389|Biological|D-SUIV cH5/1N1+AS01|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
45495275|NCT03275389|Biological|D-SUIV cH11/1N1+AS01|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
45693737|NCT04173923|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
46054699|NCT05242536|Other|Nurse- led program|A nurse coordinated multidisciplinary program aiming to improve psychosocial problems has been developed and will be applied to the patients in the experimental group. This nurse-led program will start at discharge and continue for three months.
46054700|NCT02784561|Drug|Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd)|busulfan (3.2 mg/kg/day intravenously [i.v.], days -10 to -8)
46054701|NCT02784561|Drug|Cytarabine(Actavis Italy S.p.A)|cytarabine (1.6 g/m2/day, days -7 to -3)
46054702|NCT02784561|Drug|Fludarabine (Bayer)|fludarabine (30 mg/m2, day -7 to -3),
46054703|NCT02784561|Drug|granulocyte colony-stimulating factor (KirinKunpeng)|granulocyte colony-stimulating factor (5 ug/kg, day -8 to granulocyte recovery)
46054704|NCT02784561|Drug|rabbit ATG（Sanofi/Genzyme）|ATG; thymoglobuline, rabbit;2.5 mg/kg/day, days -5 to -2
45378934|NCT04367506|Behavioral|BecomeAnEX|This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
45378935|NCT04367506|Behavioral|Usual Care|Usual care represents what hospitalized psychiatric patients normally receive in terms of smoking cessation: brief individual counseling, NRT during the hospital stay and a prescription for NRT at discharge (consistent with standard hospital procedures), and referral to the MD quitline.
45378936|NCT04366258|Device|Transcranial Photobiomodulator|Delivers laser-generated Near-Infrared Radiation (NIR) to forehead at 3 doses of irradiance - High (770 mW/cm2), Middle (300 mW/cm2), and Low (50 mW/cm2).
45378937|NCT04366258|Device|Sham|Transcranial Photobiomodulator delivers sham irradiance dose of 0 mW/cm2.
45378938|NCT04365374|Device|Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)|GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile
45378939|NCT04365374|Radiation|Stereotactic Radiation Therapy|External Beam Radiation Therapy
45378940|NCT04363801|Drug|DKN-01 300mg|Administered by IV infusion
45378941|NCT04363801|Drug|DKN-01 600mg|Administered by IV infusion
45378942|NCT04363801|Drug|DKN-01 400mg|Administered by IV infusion
45495276|NCT03275389|Biological|D-SUIV cH8/1N1|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
45495277|NCT03275389|Biological|D-SUIV cH5/1N1|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
46054705|NCT00757627|Drug|etoricoxib|etoricoxib 60 mg QD for 4 weeks.
46054706|NCT02848248|Drug|SGN-CD123A|Intravenous infusion in 3-week cycles
46054707|NCT02600455|Drug|Orencia|
46054708|NCT02599987|Device|POWERbreathe® Classic Light|Inspiratory Muscle Training
46054709|NCT05342181|Other|Static exercises|"Participants will be treated with static core muscle exercises that are traditional group of exercises :~supine bridge~plank~oblique crunch~side lying with Abduction~This program includes static exercises performed thrice a week for 4 weeks.This exercise comprises 5 minutes warm up and slight stretching.Rest time of 2-3 minutes with proper stretching in between sets of activity. Subjects will be requested to undertake cool down exercises, which include aerobic workouts followed by stretching exercises, at the end of each day's exercise programme. Before beginning the next session's training, the subjects will be asked if they had any discomfort."
45495278|NCT03275389|Biological|D-SUIV cH11/1N1|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
45495279|NCT03275389|Biological|Placebo|1 dose of Phosphate Buffered Saline (PBS) was administered IM in the deltoid region of non-dominant arm.
45495280|NCT03275389|Biological|Fluarix Quadrivalent|1 Primary dose and 1 Booster dose was administered IM in the deltoid region of non-dominant arm.
45495281|NCT03414983|Biological|Nivolumab|Specified dose on specified days
45495282|NCT03414983|Drug|Oxaliplatin|Specified dose on specified days
45495283|NCT03414983|Drug|Leucovorin|Specified dose on specified days
45495284|NCT03414983|Drug|Fluorouracil|Specified dose on specified days
45378943|NCT04363801|Drug|Tislelizumab 200mg|Administered by IV infusion
45495285|NCT03414983|Drug|Bevacizumab|Specified dose on specified days
45495286|NCT03414359|Drug|2% Lidocaine|2% Lidocaine using a combined spinal-epidural (CSE)
45495287|NCT03414359|Drug|3% Chloroprocaine|3% Chloroprocaine using a combined spinal-epidural (CSE)
45495288|NCT03285295|Device|Alinity s HBsAg and Alinity s HBsAg Confirmatory Assay|For all donor specimens with investigational Alinity s HBsAg and Alinity s HBsAg Confirmatory results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
45495289|NCT03285295|Device|Alinity s HTLV I/II Assay|For all donor specimens with investigational Alinity s HTLV I/II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
45495290|NCT03285295|Device|Alinity s Anti-HCV Assay|For all donor specimens with investigational Alinity s Anti-HCV results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
46054710|NCT05342181|Other|Dynamic exercises|"Participants will be treated with dynamic core muscle exercises that were swiss ball exercises~bridging~straight leg raise in prone lying~straight leg raise with hand raise in prone lying~pelvic tilts~This program includes static exercises performed thrice a week for 4 weeks.This exercise comprises 5 minutes warm up and slight stretching.Rest time of 2-3 minutes with proper stretching in between sets of activity. Subjects will be requested to undertake cool down exercises, which include aerobic workouts followed by stretching exercises, at the end of each day's exercise programme. Before beginning the next session's training, the subjects will be asked if they had any discomfort."
45378944|NCT04363801|Drug|Tislelizumab 400mg|Administered by IV infusion
45495291|NCT03285295|Device|Alinity s HIV Ag/Ab Combo Assay|For all donor specimens with investigational Alinity s HIV Ag/Ab Combo results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
45495292|NCT03285295|Device|Alinity s Anti-HBc Assay|For all donor specimens with investigational Alinity s Anti-HBc results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
45495293|NCT03285295|Device|Alinity s Chagas Assay|For all donor specimens with investigational Alinity s Chagas results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
45495294|NCT02583048|Drug|Bedaquiline|Four 100 mg tablets (400 mg) orally once a day for 2 weeks, followed by two 100 mg tablets (200 mg) orally three times a week for 22 weeks.
46054711|NCT01023308|Drug|Panobinostat|Panobinostat was administered 3x week ( 2 weeks on 1 week off)
45378945|NCT04363801|Drug|Oxaliplatin|Administered by IV infusion
45378946|NCT04363801|Drug|Capecitabine 1000mg/ m2 BID|Administered orally
45378947|NCT04363801|Drug|Leucovorin Calcium|Administered by IV infusion
45378948|NCT04363801|Drug|Fluorouracil|Administered by IV infusion
45378949|NCT04349059|Other|Animal based diet|Food will be provided by Montefiore-Einstein Food Services
45378950|NCT04349059|Other|Plant based diet|Food will be provided by Montefiore-Einstein Food Services
45495295|NCT02583048|Drug|Delamanid|Two 50 mg tablets (100 mg) orally with food twice a day for 24 weeks.
45495296|NCT02583048|Drug|Dolutegravir|For HIV-positive participants only: one 50 mg tablet orally once daily, to be used in combination with two NRTIs until study completion. (NRTIs were not provided by the study.)
45495297|NCT02583048|Drug|Multidrug Background Treatment (MBT) for TB|A standardized MBT regimen for MDR- or RR-TB except in cases where a participant had known resistance to one of the components of local standard treatment. MBT was provided by the local program.
45495298|NCT02939599|Drug|QCC374|0.015mg and 0.06mg
45495299|NCT05217186|Diagnostic Test|Measurements|All infants wirth high risk of cp will be assessed by neuroimaging and Hammersmith Neonatal Neurological Examination (HNNE) at term age, Prechtl's General movements (GMs) assessments form birth up to 3-5 months, and will be assesed by Hammersmith Infant Neurological Examination (HINE) at 2,3,6,9 and 12th months, also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) at the 3rd, 6th, and 12th months.
45495300|NCT05198622|Procedure|Intercostobrachial Nerve Preserving Axillary Lymph Node Dissection|"A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be completely preserved during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery."
45495301|NCT05198622|Procedure|Intercostobrachial Nerve Sacrificing Axillary Lymph Node Dissection|"A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be sacrificed during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery."
45495302|NCT04661137|Drug|Selinexor 60 MG|Selinexor 60 mg PO on days 1, 8 and 15
45495303|NCT04661137|Drug|Selinexor 80 MG|Selinexor 80 mg PO on days 1, 8 and 15
45495304|NCT04661137|Drug|Selinexor 100 MG|Selinexor 100 mg PO on days 1, 8, 15 and 22
45495305|NCT04661137|Drug|Carfilzomib|56 mg/m2 IV on days 1, 8 and 15
45378951|NCT04344860|Drug|Recombinant Von Willebrand factor|Recombinant Von Willebrand factor(Vonvendi) is an intravenous therapy that replaces missing VWF to restore hemostasis and reduce bleeding with surgery or delivery.
45495306|NCT04661137|Drug|Pomalidomide|4 mg PO daily for 21 days
45378952|NCT04344860|Drug|Tranexamic Acid Injection [Cyklokapron]|Tranexamic acid (Cyclokapron) is an intravenous anti-fibrinolytic therapy that prevents clot breakdown and reduces bleeding with surgery or delivery.
45378953|NCT04343443|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
45378954|NCT04343443|Procedure|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
45378955|NCT04343443|Procedure|Biological: Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed before discharge from hospital
45378956|NCT04343443|Procedure|Telephone interview|Telephone interview will be performed at 3, 12 months and 24 months after discharge from hospital
45693738|NCT04173923|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
45693739|NCT04173923|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
45378957|NCT04343443|Behavioral|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
45693740|NCT04173923|Procedure|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
45693741|NCT01968707|Drug|ChloraPrep Hi-Lite Orange|Apply topically.
45693742|NCT01968707|Drug|Normal saline|Apply topically.
45693743|NCT01968707|Drug|3M CHG/IPA Prep Tint 10.5-mL|Apply topically.
45693744|NCT01968707|Drug|3M CHG/IPA Prep Tint 26-mL|Apply topically
46054712|NCT01023308|Drug|Bortezomib|Bortezomib was administered 2 x week ( 2weeks on 1 week off)
46054713|NCT01023308|Drug|Dexamethasone|Dexamethasone was adminstered on day of Bortezomib and the day after Bortezomib administration
46054714|NCT01023308|Drug|Placebo|Placebo was administered 3x week ( 2 weeks on 1 week off)
45495307|NCT04661137|Drug|Daratumumab|16 mg/kg IV days 1, 8, 15 and 22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on
45495308|NCT04661137|Drug|Dexamethasone|20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22
45495309|NCT05186766|Device|Video-Assisted Operating Room Introduce Program|Video demonstration about operation room
45495310|NCT05160714|Radiation|Real-time ADC-guided response adaptive Boost in HNC|"40 Gy in 20 fractions over 5 weeks (Monday to Thursday) to the adjuvant neck, simultaneous integrated boost with 56 Gy in 20 fractions in 5 weeks to the low-risk macroscopic tumor.~Once weekly Dose-escalated SBRT adaptive boost to an ADC-based high risk subvolume with graduated dose levels of 5x5 Gy, 5x5.5 Gy, 5x6 Gy, 5x6.5 Gy"
45495311|NCT02816658|Other|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
45495312|NCT02816658|Other|Robotic Inguinal Hernia Repair|Robotic Inguinal Hernia Repair
45495313|NCT05142774|Drug|Tapinarof cream, 1%|Tapinarof cream, 1%, applied daily
45495314|NCT03274687|Radiation|Hypofractionated radiation therapy|66.6 Gy in 37 daily fractions of 1.8 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
45495315|NCT03274687|Radiation|Conventional radiation therapy|62.5 Gy in 25 daily fractions of 2.5 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
45693745|NCT04650191|Other|Identification of genetic variants|DNA will be extracted from whole blood from study subjects
45378958|NCT04343430|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
45378959|NCT04343430|Procedure|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
45378960|NCT04343430|Procedure|Biological: Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed before discharge from hospital
45378961|NCT04343430|Procedure|Telephone interview|Telephone interview will be performed at 3, 12 months and 24 months after discharge from Hospital
45378962|NCT04343430|Behavioral|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
45378963|NCT04333420|Drug|IFX-1 + BSC|Phase II study part: IFX-1 + BSC
45378964|NCT04333420|Drug|BSC|Phase II study part: BSC
45378965|NCT04333420|Drug|IFX-1 + SOC|Phase III study part: IFX-1 + SOC
45495316|NCT03274687|Drug|Optional androgen deprivation therapy|Any luteinizing hormone-releasing hormone (LHRH) agonist/antagonist with or without an oral antiandrogen can be used up to a six-month administration dose, starting 7-9 weeks before radiation therapy and may begin as early as 42 days prior to or any time after screening. An oral antiandrogen alone is not allowed.
45495317|NCT03909750|Procedure|Lipoaspiration|Close syringe microcannula harvesting subdermal fat and perivascular stem/stromal cells
45495318|NCT03909750|Procedure|AD-cSVF|Isolation of AD-cSVF
45495319|NCT03909750|Procedure|Normal Saline IV|Normal Saline IV containing AD-cSVF
45495320|NCT04651218|Behavioral|exericse|participants perform aerobic exercise until they expend 500 kcal
45495321|NCT01997502|Device|Pulse CO-Oximetry Technology|"In addition to the standard pulse oximeter used for clinical care, up to six SpHb finger sensors will be applied to the patient. Additional sensors may also be applied to the forehead, neck, chest and ears.~Masimo FDA cleared pulse CO-Oximeter devices: Radical-7, Rad-87, Rad-57, Pronto, Pronto-7, for the noninvasive measurement of SpO2, PR, PI, PVI, SpCO, SpMet, and SpHb, total hemoglobin and respiratory rate.~No treatment decisions will be made based on the new technology and no extra medical procedures are required for the study."
45693746|NCT01959581|Device|Movement Enhancing Device|Naturalistic play activities using the hands while wearing the movement enhancing device.
45378966|NCT04333420|Drug|Placebo + SOC|Phase III study part: Placebo + SOC
45693747|NCT01746901|Drug|Placebo|Placebo solution + Placebo ALO-02 (intact)
45693748|NCT01746901|Drug|intact ALO-02 60 mg/7.2 mg|Placebo solution + ALO-02 60 mg/7.2 mg (intact)
45693749|NCT01746901|Drug|crushed ALO-02 60 mg/7.2 mg|crushed ALO-02 60 mg/7.2 mg in solution + placebo ALO-02 (intact)
45693750|NCT01746901|Drug|crushed oxycodone IR 60 mg|crushed oxycodone immediate-release (IR) 60 mg in solution + placebo ALO-02 (intact)
45495322|NCT01997502|Other|Blood draw|4mL arterial blood samples (up to 1 per hour), outside standard of care, are drawn throughout the surgical procedure and sent to UCDMC lab/Masimo lab for analysis.
45495323|NCT05114382|Procedure|EP Procedure|Intracardiac signals will be passively recorded using CathVision Cube® System in parallel with the commercial (CE marked) EP recording system during a scheduled electrophysiology procedure
45495324|NCT02542956|Drug|Exparel|receive Exparel by injection
45495325|NCT02542956|Drug|Marcaine|receive Marcaine in a pain pump
45495326|NCT02542956|Drug|Marcaine|receive Marcaine by injection
45495327|NCT03274453|Drug|Ketamine|0.12 mg/kg/hr of ketamine post surgery
45693751|NCT01746901|Drug|crushed ALO-02 40 mg/4.8 mg|crushed ALO-02 40 mg/4.8 mg in solution + placebo ALO-02 (intact)
45495328|NCT03274453|Drug|Saline|Saline will be administered at the same rate as the ketamine infusion.
45495329|NCT02313870|Drug|clobetasol propionate + Methotrexate|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, associated with methotrexate (MTX) received either orally or subcutaneously at a dose of 12.5 mg / week in patients weighing less than 60 kg and with creatinine clearance greater than 50 ml / min (planned dose reduction to 10 mg / week in patients less than 60 kg or with a creatinine clearance less than 50 ml / min) for four weeks followed by oral or subcutaneous methotrexate alone at the same dose during following 8 months
45495330|NCT02313870|Drug|clobetasol propionate alone|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, up to 14 days after control of the disease followed by 1 application every 2 days at the same dose for 4 weeks then an application twice a week for 4 weeks then once application a week until the end of the 9th month of treatment
45378967|NCT04332692|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
45378968|NCT04332692|Procedure|Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
45378969|NCT04332692|Procedure|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed before discharge from hospital
45378970|NCT04332692|Procedure|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after discharge from hospital
45495331|NCT02847949|Biological|IGN002|IGN002 is a monoclonal antibody fusion protein
45495332|NCT01942122|Drug|DLBS1442 100|Study treatment will be DLBS1442 capsules at a dose of 3x100 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
45495333|NCT01942122|Drug|Mefenamic acid|Control will be mefenamic acid 500 mg tablets, administered 3 times daily for 5 days during the menstrual period, i.e. day 1st to day 5th of the menstrual period. The drug will be given within the 8 weeks of study period (2 menstrual cycles).
45495334|NCT01942122|Drug|DLBS1442 200|Study treatment will be DLBS1442 capsules at a dose of 3x200 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
45495335|NCT04327999|Drug|Artificial Tears|Self-Administered - utilizing eye drop preservative free vials
45495336|NCT04297345|Device|Hemodialysis|"Blood enters the extracorporeal circuit from the arterial line of the femoral catheter. For this the investigators use a pump integrated in the monitor, equipped with control systems, exerting a negative pressure.~Subsequently, it enters the dialyzer through the internal part of the capillaries (porous), producing a passive exchange of inflammatory and oxidative substances (such as cytokines) with the dialysis fluid, which also circulates through the dialyzer, but through the external part of the capillaries. Blood is returned to the patient, through the venous line of the catheter, with a lower concentration of cytokines after passing through the dialyzer.~This circuit is repeated continuously during the 3 hours of the procedure to ensure maximum clearance of glutamate and interleukins, among other substances."
45378971|NCT04332692|Behavioral|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
45378972|NCT04317534|Drug|Pembrolizumab|Pembrolizumab 400mg IV
45378973|NCT04316546|Drug|MK-7075 (miransertib)|MK-7075 (miransertib) is a small molecule developed by ArQule Inc., a wholly owned subsidiary of Merck &amp; Co., that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a Phase 2 trial investigating the efficacy of miransertib as a treatment for adult and pediatric patients with Proteus syndrome.
45378974|NCT04304482|Drug|ANAVEX2-73 oral liquid|Liquid oral solution
45378975|NCT04304482|Drug|Placebo oral liquid|Liquid oral solution
45495337|NCT01816932|Procedure|Home Visit|The intervention is the location of the insertion visit.
45495338|NCT01816932|Procedure|Office visit|
45693752|NCT01746901|Drug|crushed oxycodone IR 40 mg|crushed oxycodone immediate-release (IR) 40 mg in solution + placebo ALO-02 (intact)
45693753|NCT01968551|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
45693754|NCT01968551|Drug|DRV|800 mg tablet administered orally once daily
45693755|NCT01968551|Drug|Baseline DRV- containing ARV regimen|Participants will take their baseline DRV- containing ARV regimen as prescribed.
45693756|NCT01707992|Drug|Laquinimod|Laquinimod will be administered as per the dose and schedule specified in the respective arms.
45495339|NCT01783704|Dietary Supplement|Nutrition|Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at time of randomization to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of randomization. Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level >3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level >3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
45495340|NCT01783704|Behavioral|PUSH|Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
45495341|NCT01783704|Behavioral|PULSE|During the AROM exercises, participants work to increase flexibility and range of motion. Exercises include the neck, shoulders, arms, trunk, hips, knees and ankles. During all AROM exercises, the participant focuses on deep breathing techniques. The second part of the session uses transcutaneous electrical nerve stimulation (TENS) on lower extremity muscle groups to decrease pain, thereby allowing greater ease of mobility. TENS uses low-level electrical current to stimulate superficial cutaneous nerve fibers through the skin. Flexible carbonized, disposable electrodes coated with a self-adhesive conductive polymer will be applied to the skin bilaterally near the motor points on muscle bellies (the gluteal complex, the quadriceps, and the gastrocnemius) for 7 minutes per muscle group.
45847266|NCT04727424|Drug|Placebo (mild disease)|"Placebo SC normal saline syringe (single day schedule):~Matching syringes containing 0,5 ml normal saline administered by SC route after randomization Day 0 (single dose SC).~OR~Placebo oral tablets (10-day schedule):~Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule) PLUS~Placebo Inhalation Therapy:~One dosing (inhalation) right after randomization (Day 0) followed by one dose BID for the following 09 days~OR~Paracetamol (07-day schedule - active comparator):~Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule)~OR~Placebo oral tablets (10-day schedule for patients with SPO2 < 94%):~One tablet after randomization (Day 0) followed by 01 tablet BID for the following 09 days (total of 10 days schedule)"
45847267|NCT04727424|Drug|Peginterferon Lambda-1a|One syringe of 180 mcg of Peginterferon Lambda SC right after randomization Day 0 (single dose SC administration).
45847268|NCT04727424|Drug|Fluoxetine 20 MG|"Two Fluoxetine tablets every day starting just after randomization through day 07.~PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 07."
45378976|NCT04282915|Other|Reducing Stigma among Healthcare Providers (RESHAPE)|Mental health service users are trained using Photo Voice to develop recovery story testimonials. They then participate in primary care providers mental health Gap Action Programme training. In addition, aspirational figures are trained to provider testimonials and conduct myth-busting.
45378977|NCT04282915|Other|mental health Gap Action Programme|The mental health Gap Action Programme is a training program for primary care providers in mental health services. The curriculum has been developed by the World Health Organization and was adapted in Nepal and certified by the Ministry of Health.
45378978|NCT04268485|Diagnostic Test|Serum KL-6 level|Serum blood biomarker which has been shown to be of interest in idiopathic pulmonary fibrosis
45378979|NCT04263766|Other|Transcranial magnetic stimulation|TMS will be delivered to different brain areas in order to establish their contribution to visual metacognition.
45378980|NCT04247165|Drug|Gemcitabine|800 mg/m2 Day 1, 8, 15: Q4W IV Infusion
45378981|NCT04247165|Drug|Nab-paclitaxel|100 mg/m2 Day 1, 8, 15: Q4W IV Infusion
45378982|NCT04247165|Drug|Nivolumab|3 mg/kg Day 1, Q4W IV Infusion
45378983|NCT04247165|Drug|Ipilimumab|1 mg/kg Day 1 Cycle 1 IV Infusion
45378984|NCT04247165|Radiation|SBRT|"Patients will be planned and treated with SBRT on a MRidian MR guided Linac.~Prescription dose shall be according to the following specifications:~Prescription dose shall be according to the following specifications:~A total dose of 24 Gy in 3 fractions (3 fractions/week) are prescribed as the mean dose to the PTV.~Pauses are accepted but the treatment should be delivered within 10 calendar days.~PTV should be covered by 95% isodose (PTV D99% >95%)."
45378985|NCT04245865|Drug|Fluorouracil|2800 mg/m2 iv
45378986|NCT04245865|Drug|Calcium folinate|400 mg/m2 iv
45495342|NCT03273907|Device|CyPass Micro-Stent implanted with CyPass 241-S applier|CyPass System (Model 241-S) consists of the CyPass Micro-Stent contained in a loading device (loader) and the CyPass applier.The CyPass Micro-Stent is an implantable medical device intended for long term use.
45495343|NCT03273907|Procedure|Cataract surgery|Cataract surgery, followed by implantation of the CyPass Micro-Stent in one eye (the study eye) at the surgery visit
45693757|NCT01707992|Drug|Placebo|Placebo matching to laquinimod will be administered as per the schedule specified in the respective arms.
45693758|NCT01946165|Drug|Abiraterone Acetate|1,000 mg by mouth daily for each 28 day cycle.
45693759|NCT01946165|Drug|Prednisone|5 mg by mouth once daily for each 28 day cycle.
45378987|NCT04245865|Drug|Oxaliplatin|85 mg/m2 iv
45378988|NCT04245865|Drug|Bevacizumab|5 mg/kg OR 7.5 mg/kg iv
45693760|NCT01946165|Drug|Enzalutamide|160 mg by mouth daily for each 28 day cycle.
45378989|NCT04245865|Drug|Capecitabine|2000 mg/m2 orally daily for two weeks
45378990|NCT04245865|Dietary Supplement|Tocotrienol|300 mg orally x 3 daily
46054715|NCT04230525|Diagnostic Test|non invasive whole body bioimpedence system|Noninvasive hemodynamic changes will be observed by using whole-body impedance method urgent or elective cesarian section patients under general anesthesia. The whole-body bioimpedance method will be used to monitör the hemodynamic changes non invasively. This method can evaluate such as cardiac output, cardiac index, stroke volüme, stroke index, stroke volüme variations, cardiac reserve, etc. Parameters with a completely noninvasive method by using only electrots. The device consists of a laptop, a software which calculates cardiac parameters and two electrodes. The measurement is done by the following process: one of these electrodes, which looks like ECG electrodes, is stuck to the wrist and the other one to the opposite ankle or each one to two wrists.
46054716|NCT02784639|Other|Plasma Analysis of circulating cell free DNA|
46054717|NCT02784639|Other|Tumor tissue analysis of circulating cell free DNA|
45378991|NCT04245865|Other|Placebo|Placebo orally x 3 daily
45378992|NCT04239157|Biological|Canakinumab|Given SC
45378993|NCT04234867|Drug|Dapagliflozin|once daily for 5 days
45378994|NCT04234867|Drug|Placebo oral tablet|once daily for 5 days
45378995|NCT04234867|Other|Stress|single dose after last administration of experimental drug
45378996|NCT04234867|Other|Placebo Stress|single dose after last administration of experimental drug
45495344|NCT05035368|Drug|Ladarixin|Ladarixin will be administered orally at the dose of 400 mg twice a day at about 12-hour interval (morning and evening).
45495345|NCT05035368|Other|Placebo|Placebo is administered with the same schedule of Ladarixin.
45495346|NCT03627780|Diagnostic Test|DNA extraction|DNA will be extracted from white cells
45495347|NCT04246021|Drug|Ferric carboxymaltose (FCM)|intravenous iron formulation
45495348|NCT03627702|Radiation|Irradiated VIP (Visible Incoherent Polarized)|20 irradiations were performed twice a day. The exposure time was 10 minutes. Exposure was made at a distance of 10 cm.
45495349|NCT02236806|Drug|Bisoprolol|5 mg daily
45495350|NCT02236806|Drug|Ramipril|5 mg daily
45693761|NCT01946165|Drug|LHRHa|Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
45693762|NCT04649411|Drug|ferric citrate|oral tablets
45693763|NCT04649411|Drug|standard of care|administered per the approved label and at the Investigator's discretion
46054718|NCT02783391|Device|ECoG and intracortical electrodes|
46054719|NCT02781909|Drug|Ibuprofen|Non-Steroid Anti-Inflammatory drug to be administered as adjunctive therapy
45378997|NCT04234048|Drug|Fenretinide|"Accelerated Phase 1a 100% Dose escalation in 8 single-patient cohorts~Standard Phase 1a 40% Dose escalation in 3-patient cohorts X 3 cohorts~Phase 1b Dosed at MTD in 20 patients as disease-specific expanded cohort"
45378998|NCT04222569|Procedure|T-piece|Spontaneous breath trial with a T-piece
45378999|NCT04222569|Procedure|PSV 7 and PEEP 0|Spontaneous breath trial with a pressure support ventilation of 7 cmH2O and no positive end expiratory pressure
45379000|NCT04222569|Procedure|PSV 0 and PEEP 0|Spontaneous breath trial without pressure support ventilation and positive end expiratory pressure, with a patient intubated and connected to the ventilator
45379001|NCT04219280|Drug|Quillivant XR|Long-lasting liquid solution of Quillivant XR.
45379002|NCT04219280|Drug|Placebo|Liquid solution to mimic the color and taste of Quillivant XR.
45379003|NCT04192981|Drug|GDC-0084|GDC-0084 in 3 + 3 dose-escalation in 3 cohorts: 45, 60, 75 mg daily
45495351|NCT02236806|Drug|Placebo|1 capsule daily
45495352|NCT01578954|Drug|Lenalidomide|"Reinduction/Consolidation - dose escalation of lenalidomide: Level 1 - 25mg, Level 2 - 35mg, Level 3 - 50mg, PO, QD, 28 days.~Maintenance Lenalidomide - 10mg, PO, QD, continuous dosing, 12 months"
45693764|NCT01707667|Drug|prucalopride|One 2 mg tablet orally administered on Day 1
45693765|NCT01707667|Drug|PEG 3350|13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water. Administered twice orally on Day 1(once in the morning and once prior to lunch).
45693766|NCT01959503|Device|Progel Vascular Sealant|
45693767|NCT01959503|Device|Gelfoam Plus|
45495353|NCT00659646|Drug|gentamicin-collagen sponge and levofloxacin|Topical Gentamicin Collagen Sponge: 10 × 10 cm in size And 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours.
45495354|NCT00659646|Drug|Levofloxacin only|levofloxacin, 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours
45379004|NCT04192981|Radiation|whole brain radiation therapy radiation|30Gy in 10 fractions
45379005|NCT04191096|Biological|Pembrolizumab|Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.
45379006|NCT04191096|Drug|Enzalutamide|Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.
45495355|NCT02236572|Drug|Everolimus|"Aromatase inhibitor plus everolimus by mouth daily for 26 weeks. All patients will begin treatment on Cycle 1 Day 1 with both the standard dose of one of the following 3 aromatase inhibitors ( physician's choice) plus everolimus 10 mg by mouth daily:~Anastrozole 1 mg~Letrozole 2.5 mg~Exemestane 25 mg"
45495356|NCT03054870|Drug|Xe-133|Xe-133 ventilation scintigraphy
45693768|NCT01605799|Behavioral|IOK Killing Treatment|The IOK Killing Treatment is based on Cognitive Behavioral Therapy theory and principals and target maladaptive cognitions related to killing in war.
45693769|NCT01605799|Behavioral|Wait list control group|Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
45693770|NCT01706575|Drug|Pegylated Interferon (Peginterferon) Alfa-2a|Peginterferon alfa-2a 180 mcg, subcutaneously (SC) once weekly for 48 weeks.
45379007|NCT04191096|Procedure|Androgen Deprivation Therapy (ADT)|Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
45379008|NCT04191096|Other|Placebo|Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.
45379009|NCT04186637|Drug|ALPN-202|Multiple dose levels and dose regimens of ALPN-202 will be administered
45379010|NCT04177693|Dietary Supplement|Epigallocatechin gallate (EGCG)|800 mg (4 capsules) of EGCG (green tea extract), taken orally on a daily basis for up to 2 months
45379011|NCT04177693|Drug|Clomiphene Citrate|100 mg for 5 days
45379012|NCT04177693|Drug|Letrozole|5 mg for 5 days
45495357|NCT03054870|Drug|Technegas|Technegas ventilation scintigraphy
45379013|NCT04173273|Drug|Etrasimod|Dose A taken by mouth, once daily.
45379014|NCT04173273|Drug|Etrasimod|Dose B taken by mouth, once daily.
45379015|NCT04173273|Drug|Placebo|Etrasimod matching placebo tablet taken by mouth, once daily.
45379016|NCT04169009|Biological|Zostavax|Intradermal injection of Zostavax
45495358|NCT03414047|Drug|Prexasertib|Administered IV
45495359|NCT03711227|Diagnostic Test|Procalcitonin lab test|A procalcitonin order bundle will be created for admitted patients with pneumonia. This prepopulated bundle includes an initial and 24 hour procalcitonin level.
45495360|NCT03709901|Other|Active Allograft|Injection of viable allograft into the nucleus pulposus of the degenerated disc
45495361|NCT03709901|Other|Placebo|Injection of sterile normal saline (0.9% sodium chloride) into the nucleus pulposus of the degenerated disc
45693771|NCT01706575|Drug|Nucleos(t)ide Analogues (NA)|Nucleos(t)ide analogues includes adefovir, entecavir, lamivudine or tenofovir.
45693772|NCT01959425|Other|Off OAT Group (Test)|Discontinuation of OAT Therapy
45693773|NCT01959425|Other|On OAT Group (Control)|Continuation of OAT Therapy
45693774|NCT01725529|Drug|TMC435|TMC435 100 mg or 150 mg capsules taken orally (by mouth) with food once-daily for 12 weeks (Week 12).
45495362|NCT05448677|Drug|Ezurpimtrostat|Patients in the experimental arm will be instructed to take their assigned oral dose every day.
45379017|NCT04169009|Biological|Shingrix|Given to subjects in Arm 4 who've never had a herpes zoster vaccine
45379018|NCT04146064|Other|Breathprint analysis and patient-reported outcomes|"Breathprint analysis: Patients will be providing breathprint samples into the eNose device at baseline and every 12 weeks thereafter as long as on immunotherapy treatment.~Questionnaires will be completed at the same timepoints."
45495363|NCT05448677|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
45495364|NCT05448677|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
45495365|NCT04858932|Device|Continuous Glucose Monitor|a handheld reader and a wearable sensor placed on the back of the arm used to obtain glucose measurements
45379019|NCT04129229|Device|LinguaFlex Tongue Retractor (LTR)|The LinguaFlex Tongue Retractor (LTR) is a small, flexible, implanted tongue retaining device that lessens the backward movement of the tongue during sleep. The LTR's flexible shaft and a nubbed tether passes through the center of the tongue beneath the tongue blade (frenulum area) and connects to a disc (head) that rests on the external surface of the tongue base mucosa. Underneath the tongue, on the external surface of the frenulum, a small anchor secures the shaft that can be adjusted to tension the LTR to maximize therapeutic effect and maintain comfort.
45379020|NCT04118387|Drug|Acetazolamide + supplemental oxygen + PAP therapy|Every participant will undergo measurement of the apneic threshold. The apneic threshold (AT) can be determined by inducing central apnea using non-invasive ventilation (NIV) or eliminating central apnea using supplemental CO2. The requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative. The central apnea index and the apneic threshold will be measured while participants receiving medication or oxygen (or both). In addition, participants will get PAP therapy during all the conditions.
45379021|NCT04118387|Drug|Zolpidem + PAP therapy|The central apnea index and the apneic threshold will be compared under two conditions: zolpidem or placebo. In addition, participants will get PAP therapy during both the conditions.
45495366|NCT04858932|Device|Wrist Actigraphy Device|a watch like wearable sensor
45495367|NCT04858932|Device|Food Weight Scale|a scale to measure food weight
45495368|NCT04858932|Device|Smart Body Weight Scale|a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends
45495369|NCT05216718|Procedure|Mini-flap|Mini-flap BABA robotic-thyroidectomy creates flaps up to the cricoid cartilage
45495370|NCT05216718|Procedure|Conventional flap|Conventional flap BABA robotic-thyroidectomy creates flaps up to the thyroid cartilage
45495371|NCT03351335|Device|Microfocused ultrasound with visualization|All subjects will receive an Ultherapy® treatment at dual depth using the 4-4.5mm and 7-3.0mm transducers. Treatments will be provided to the lower face, submental (under the chin) and neck area.
45495372|NCT05216640|Device|High Flow Oxygen Therapy|• The patient will be allocated into 2 groups, patients who will require ventilatory support via HFNC and those who will require HVNI
45495373|NCT03711149|Other|Activity monitor feedback loop|The intervention arm will test if the feedback system (i.e., activity monitor, real-time feedback, and art tours) increases daily step count, decreases length of stay, and improves patient and provider communication, patient awareness of step count goals, and patient confidence in accomplishment of daily goals.
45495374|NCT00472680|Behavioral|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
45495375|NCT00472680|Behavioral|Caloric restriction; normal protein|Weight loss with normal level of protein (18%) intake
45693775|NCT01725529|Drug|Peginterferon-alpha (PegIFNα-2a)|PegIFNα-2a (180 micrograms [μg] once weekly) administered as weekly subcutaneous (s.c.) (under the skin) injections of 0.5 mL for 24 or 48 weeks.
45847269|NCT04698876|Procedure|Self-tonometry by means of ICareHOME|Outpatient measurement of intraocular pressure at home
45379022|NCT04118387|Drug|Buspirone + PAP therapy|The central apnea index and the apneic threshold will be compared under two conditions: buspirone or placebo. In addition, participants will get PAP therapy during both the conditions.
45495376|NCT00472680|Behavioral|Nutrition Education|Participants will have the opportunity to speak with the dietitian about their diet by phone, or on-site twice per month
45495377|NCT05670912|Drug|Wei Li Bai capsules|The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
45495378|NCT05670912|Drug|Placebo Comparator of Wei Li Bai capsules|The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
45495379|NCT03619746|Behavioral|POCUS Educational Intervention|Midway through the study, all Pediatric Emergency Attendings and Fellows at Jacobi Medical Center will receive an educational session that describes how to properly perform a soft tissue examination using point-of-care ultrasound to differentiate between cellulitis and local allergic reaction.
45495380|NCT05216406|Dietary Supplement|5-HTP|CLEANMOOD is an organic 5-Hydroxytryptophan (5-HTP) ingredient.
45495381|NCT05216406|Other|Placebo|Maltodextrin capsule
45495382|NCT04811898|Biological|LNA-i-miR-221|LNA-i-miR-221, IV daily infusion on days 1-4 followed by 24 days washout (1 cycle lasting 28 days)
45495383|NCT05223270|Other|wound dressing under the NIMV mask|wound dressing under the NIMV mask
45693776|NCT01725529|Drug|Ribavirin (RBV)|Ribavirin 1000 or 1200 mg/day (taken as 100 mg or 200 mg tablets) depending on body weight (If body weight is < 75 kg the total daily dose of RBV will be 1000 mg, administered as 400 mg intake with food in the morning and 600 mg intake with food in the evening. If body weight is > or = 75 kg the total daily dose will be 1200 mg, administered as 2 x 600 mg per intake with food, morning and evening) for 24 or 48 weeks.
45693777|NCT01725529|Drug|Placebo|Matching placebo capsules taken orally with food once-daily for 48 weeks.
45693778|NCT01605097|Radiation|HDR interstitial brachytherapy|2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy
46054720|NCT02781909|Drug|Standard of Care TB treatment|Standard of Care (SoC) TB Treatment will be optimized and drugs selected according to the National and WHO Guidelines, sensitivity profile and as per routine.
46054721|NCT02781831|Procedure|Standard rehab|Standard hospital based rehabilitation for patients with stroke
46054722|NCT02781831|Device|Robot-assisted gait rehabilitation|An extra 30 minutes of robot-assisted gait rehabilitation after receiving standard hospital based rehabilitation for patients with stroke
46054723|NCT04302038|Dietary Supplement|Protein|Additional daily protein provided by potato protein.
46054724|NCT04302038|Dietary Supplement|Placebo control|No additional dietary protein (outside of 0.8 g/kg/day as provided by diet)
46054725|NCT02783313|Device|Pathogen reduced plasma-stored platelet concentrates|Platelet concentrates treated with the Mirasol PRT system (pathogen reduction technology) and stored in plasma.
45495384|NCT05669898|Behavioral|Pain scores (numerical rating scale at rest and motion): will be assessed with numerical rating scale at both rest and motion on both knees.|Pain scores will be assessed with numerical rating scale at both rest and motion on both knees.
45693779|NCT01605019|Device|CoSeal|3 - 8mls of Coseal
46054726|NCT02783313|Other|Plasma-stored platelet concentrates|Platelet concentrates stored in plasma
46054727|NCT04229823|Diagnostic Test|Video-oculography|Eye movement parameters will be measured in all of the subjects using video-oculography device (EyeSeeCam, InterAcoustics). Measurement sessions consist of the study subject wearing a goggle attached to a camera that detects the pupil and eye position and velocity. Evaluation start with vestibulo-ocular reflex testing, with video head impulse test. Afterwards, saccades, smooth pursuit and fixation are evaluated.
46054728|NCT04229823|Diagnostic Test|Clinical Scales|All subjects are examined by an investigator in order to score clinical scales for ataxia, including Scale for the Assessment and Rating of Ataxia (SARA), International Co-operative Rating Scale (ICARS), Neurological Examination Scale for SCA (NESSCA), Inventory of Non-ataxia Symptoms (INAS), SCA Functional Index (SCAFI) and Composite Cerebellar Functional Severity Score (CCFS).
45379023|NCT04118179|Other|Blood sample collection|A blood sample (1 tube) will be collected for the analysis of the CR signature.
45379024|NCT04112199|Drug|BIV201 continuous infusion|BIV201 continuous infusion with terlipressin for a total of two 28 day cycles. Initiate treatment at 3 mg per 24 hour period and titrate stepwise up to a maximum of 8 mg per 24 hour period based on tolerability and response.
45379025|NCT04105335|Drug|MTL-CEBPA|Intravenous administration
45379026|NCT04105335|Drug|Pembrolizumab|Intravenous administration
45379027|NCT04101331|Drug|AFM13|weekly intravenous infusions of 200mg
45379028|NCT04097379|Drug|LRX712|LRX712 intra-articular injections
45379029|NCT04097379|Drug|Placebo|Placebo intra-articular injections
45693780|NCT01605019|Device|BioGlue® Surgical Adhesive|Total amount applied - 8 mls
45693781|NCT04413721|Procedure|RBC transfustion|When the hemoglobin concentration fell below 7.0 g per deciliter, RBC were given to maintain the hemoglobin concentrations in the range of 7.0 to 10.0g /dL
45693782|NCT04413565|Procedure|Simultaneous bilateral total knee arthroplasty|Two surgeon bilateral TKA group
46054729|NCT04229823|Diagnostic Test|Genotyping|Individuals at 50% risk (offspring of subjects with molecular diagnosis of SCA3/MJD) will be genotyped in a double-blind manner so that they can be divided into pre-ataxic carriers and related controls (non carriers)
46054730|NCT02783079|Behavioral|CBT|
46054731|NCT02783079|Behavioral|MBSR|
46054732|NCT04229511|Diagnostic Test|Detection of CRKp colonization|Detection of CRKp colonization will be performed in all participants by sceening with rectal swab
46054733|NCT03411915|Biological|XmAb18087|monoclonal bispecific antibody
46054734|NCT01521039|Procedure|Blood samples|2-3 tablespoons of blood weekly for the first 100 days (about 14 weeks) following allogeneic transplant. In addition a blood sample will be obtained before starting the chemotherapy or radiation regimen for the transplant, in the day of the transplant and if your doctor suspects that you have acute graft-versus-host disease.
45693783|NCT04413565|Procedure|Sequenced bilateral TKA|Single surgeon bilateral TKA group
45379030|NCT04087538|Diagnostic Test|Troponin T and I|Does the use of troponin T or I increase the number of patients referred to coronary angiography
45495385|NCT05669898|Other|Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale|For the functional assessment both before and after TKA surgery.
45495386|NCT05669898|Behavioral|Rehabilitation physiotherapy|Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of both knees.
45495387|NCT05223114|Other|Not applicable (N/A)|Not applicable to this study
45495388|NCT05222958|Device|Gestob App|Gestop App is a mobile app that aims to help pregnant women quit smoking through gamification. It also allows you to obtain information about tobacco and pregnancy.
45495389|NCT04641156|Other|Exercise Therapy program added to laser therapy|a supervised physical therapy exercise program for the neck muscles in the form of manual mobilizations for sternocleidomastoid muscle and upper fibers of trapezius in addition to myofascial trigger point release
45495390|NCT04618614|Device|HD-tDCS 1 mA to S1|Anodal high definition transcranial direct current stimulation of the right primary somatosensory cortex with an intensity of 1 mA
45495391|NCT04618614|Device|HD-tDCS 1 mA to M1|Anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1 mA
45693784|NCT04551391|Other|Blood and urine sampling|Retinal OCT is a novel, non-invasive method for cross-sectionally imaging the eye's retina and choroid
45693785|NCT01744483|Device|PVC ETT|Placement of a PVC-cuffed ETT in the setting of emergent intubation.
45693786|NCT01744483|Device|PUC ETT|Placement of a PUC-cuffed ETT in the setting of emergent intubation.
46054735|NCT01022996|Drug|Everolimus (RAD001)|Everolimus (RAD001) 10 mg (two 5mg tablets) given orally once daily and packed in blisters.
46054736|NCT02781597|Drug|Tranexamic Acid|Patients will receive Inj Tranexamic acid, in IV in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h in 500ml normal saline
46054737|NCT02781597|Drug|Placebo|Patients will receive 0.9% normal saline
45379031|NCT04082884|Behavioral|Very Low Carbohydrate Diet|A very low carbohydrate diet (VLCD), is defined as limiting carbohydrate intake to 11% of total daily caloric intake.
45379032|NCT04072952|Drug|ARV-471|Parts A and B: ARV-471 administered QD or BID for 28 day cycles.
45379033|NCT04072952|Drug|ARV-471 in combination with palbociclib (IBRANCE®)|Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days
45379034|NCT04071470|Behavioral|Storytelling|Couples in the storytelling intervention will receive 3 storytelling sessions- the couple can include any family or friends who they feel could support them during their treatment. Stories will include stories of couples who are supportive, those who experience difficulties, and families who do/do not support their use of PrEP
45495392|NCT04618614|Device|Sham control|Sham stimulation of the right primary somatosensory cortex
45495393|NCT05222646|Drug|Metoclopramide|Will receive single dose of 10mg of Metoclopramide intramuscularly
45495394|NCT05222568|Behavioral|Lateral positioning|After the DLT intubation, the patient is placed in lateral decubitus position
45495395|NCT05222568|Device|Cuff pressure measurement|The pressure of the bronchial cuff should be measured with cuff-manometer in supine position, and then measurement should be repeated after lateral positioning
45693787|NCT01744483|Device|PUC-CASS ETT|Placement of a PUC-cuffed in the setting of emergent intubation, followed by continuous aspiration of subglottic secretions for the duration of mechanical ventilation.
45693788|NCT01744093|Drug|Doxycycline|100 mg twice daily (BID orally) x 24 weeks
45693789|NCT01744093|Drug|Placebo (sugar pill)|100 mg twice daily (BID orally) x 24 weeks
45379035|NCT04071470|Drug|PrEP|Patients at risk of HIV acquisition will be provided PrEP medications and counseling in ANC
45379036|NCT04069026|Drug|BAY2416964|Oral application of study drug daily in a predefined dose escalation scheme.
45379037|NCT04069026|Drug|BAY2416964|Oral application of study drug daily at the dose defined in the dose escalation scheme to determine the recommended phase 2 dose (RP2D).
45379038|NCT04068194|Drug|Avelumab|Given IV
45379039|NCT04068194|Procedure|Biopsy|Undergo biopsy of tumor
45379040|NCT04068194|Procedure|Biospecimen Collection|Correlative studies
45693790|NCT04565041|Behavioral|Social Support|Presence of an image of a social support figure (provided by participant) during a fear extinction procedure
45693791|NCT01725451|Drug|Testosterone|Administered topically to axillae
45693792|NCT01725451|Other|Deodorant Spray|Administered topically to axillae
45693793|NCT01725451|Other|Deodorant and Antiperspirant Combination Spray|Administered topically to axillae
45693794|NCT01725451|Other|Deodorant and Antiperspirant Combination Stick|Administered topically to axillae
45693795|NCT04558567|Drug|Vogelxo|50mg (1 tube, 5g gel) to 100mg (2 tubes, 10g gel)
45693796|NCT01707290|Drug|Ivacaftor|150 mg tablet, oral use, every 12 hours (q12h)
45693797|NCT04166552|Drug|Patients will be randomized to receive EHP-101 or Placebo|EHP-101 or placebo will be taken once a day
46054738|NCT02783235|Other|cervical cancer screening|for 50 ANMs/ASHAs/PHWs/ in conducting cervical cancer related health education , screening for cervical cancers using VIA, collection of PAP smears and HPV samples.
46054739|NCT00757237|Drug|Aztreonam for Inhalation Solution (AZLI)|Aztreonam for inhalation solution (75 mg) was administered 3 times a day (TID) for 28 days for each treatment cycle via the PARI eFlow electronic nebulizer.
46054740|NCT00757237|Drug|Tobramycin Inhalation Solution (TIS)|Tobramycin inhalation solution (300 mg) was administered 2 times a day (BID) for 28 days for each treatment cycle via the PARI LC Plus nebulizer with compressor or via another nebulizer compatible with country-specified labeling.
45379041|NCT04068194|Procedure|Computed Tomography|Undergo CT scan
45379042|NCT04068194|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
45379043|NCT04068194|Drug|Peposertib|Given PO
45495396|NCT04506684|Device|Investigational RAMware downloaded onto Reveal LINQ device|The study is utilizing an investigational RAMware, either LINQ HF or ALLEVIATE-HF, that will be downloaded onto the subject's market-released Medtronic Reveal LINQ ICM. The investigational RAMware enables the hardware to record and store additional sensor data from which a respiratory rate will be derived.
45693798|NCT04166552|Drug|Patients will be randomized to receive EHP-101 or Placebo|EHP-101 or placebo will be taken twice a day
45693799|NCT01717040|Drug|Pioglitazone|Pioglitazone will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
46054741|NCT01029392|Drug|Vitamin D|2000iu once a day
46054742|NCT02781753|Biological|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C. at Day0
45379044|NCT04040049|Genetic|FLT190|Gene Therapy product.
45379045|NCT04038359|Drug|Duvelisib|PI3K Inhibitor
45379046|NCT04032418|Biological|Pembrolizumab|Given IV
45379047|NCT04029480|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg, oral, 1 tablet QD
45379048|NCT04029480|Drug|Ertugliflozin 15 mg|Ertugliflozin 15 mg, oral, 1 tablet QD
45379049|NCT04029480|Drug|Placebo to ertugliflozin 15 mg|Placebo to ertugliflozin 15 mg, oral, 1 tablet QD
45379050|NCT04029480|Drug|Placebo to ertugliflozin 5 mg|Placebo to ertugliflozin 5 mg, oral, 1 tablet QD
45379051|NCT04029480|Biological|Insulin|The initiation and titration of insulin will be at the discretion of the investigator, based on local/regional/country guidelines.
45495397|NCT05222490|Device|Thermal Camera images acquisition - FeetSee|Thermal images will be collected according to the instructions for use of the Feetsee device.
46054743|NCT02781753|Biological|Peginterferon 180 μg single dose S.C.|Pegasys 180 mcg S.C. single dose on Day 0
46054744|NCT00903006|Drug|Fulvestrant|Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.
45847270|NCT04698876|Procedure|Intraocular measurement by means of rebound tonometry or Goldmann applanation tonometry|Stationary measurement of intraocular pressure in a clinic
46054745|NCT00903006|Drug|MK-0646|Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle.
45379052|NCT04029480|Drug|Metformin|Participants will receive stable dose of background metformin.
45379053|NCT04026412|Biological|nivolumab|Specified dose on specified days
45379054|NCT04026412|Biological|ipilimumab|Specified dose on specified days
45379055|NCT04026412|Biological|durvalumab|Specified dose on specified days
45379056|NCT04021784|Device|SDS|The patient is implanted with SDS.
45379057|NCT04021784|Device|NEMOST|The patient is implanted with NEMOST.
45495398|NCT05222490|Device|Thermal Camera images acquisition - Reference|After 15 minutes of resting, thermal images from the reference device will be collected according to their manufacturer
45495399|NCT05222412|Drug|Iptacopan|Patients receive Iptacopan
45495400|NCT05222334|Procedure|Intrafascial interscalene brachial plexus block|"After sterilization of skin with povidone-iodine (betadine) and skin infiltration with 1-3ml lidocaine 1%, interscalene brachial plexus block will be performed using an ultrasound machine (Phillips Cx-50,Amsterdam, Netherlands) with a linear probe (L12-3 MHz) will be used in both groups. The US transducer will be placed under aseptic fashion on the lateral side of the neck at the cricoid cartilage level to view three hypoechoic structures, that represent the roots of the brachial plexus.~The two outermost nerve roots (C5 and C6) between the anterior and the middle scalene muscles will be identified and the local anesthetic (10 ml 0.5% bupivacaine) is then injected, so that spread will be seen immediately between the C5 and the C6 nerve roots."
45693800|NCT01717040|Drug|Placebo|Placebo will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
46054746|NCT00903006|Drug|Dasatinib|Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.
45379058|NCT04006522|Drug|89Zr-DFO-Atezolizumab|89Zr-DFO-Atezolizumab infusion
45379059|NCT04006522|Procedure|Positron Emission Tomography/Computed Tomography|PET/CT scan 7 days (± 1 day) after infusion of 89Zr-DFO-Atezolizumab.
45379060|NCT03996018|Other|T-cell lymphocyte responses|T-cell lymphocyte responses to human immunodeficiency virus (HIV) with and without concomitant herpesvirus infections (specifically, the persistence of HIV-specific human CD8 T-cells in the context of antiretroviral therapy (ART).
45693801|NCT04552262|Drug|BAY2327949|Single dose of 90 mg BAY2327949
45379061|NCT03971734|Drug|Regadenoson 0.05mg|Regadensoson 0.05mg administered prior to MRI
45379062|NCT03971734|Drug|Regadensoson 0.1mg|Regadensoson 0.1mg administered prior to MRI
45379063|NCT03971734|Drug|Regadensoson 0.2mg|Regadensoson 0.2mg administered prior to MRI
45379064|NCT03971734|Drug|Regadensoson 0.4mg|Regadensoson 0.4mg administered prior to MRI
45847271|NCT04698876|Procedure|Blood pressure|Blood pressure measurement for 24 h
45847272|NCT04688034|Drug|OP-724|Twice a week for 4 hours continuous intravenous administration of OP-724.
45847273|NCT04596384|Other|Best Practice|Participate in a surgeon-only perioperative care program
45847274|NCT04596384|Procedure|Functional Assessment|Complete a functional assessment
45847275|NCT04596384|Other|Medical Device Usage and Evaluation|Wear an actigraph
45847276|NCT04596384|Procedure|Nutritional Assessment|Complete a nutritional assessment
46054747|NCT02873312|Device|StimRouter|"The StimRouter System is a neuromodulation system consisting of the following components and accessories:~An implantable multi-electrode lead with integrated receiver in loader and surgical tools for implantation of the implantable lead.~An external programming system with a clinician programmer, a clinician programmer cradle and charger, an external pulse transmitter tester and accessories.~A patient-operated system with an external pulse transmitter (StimRouter EPT), a disposable StimRouter Electrode, an external patient programmer and charger, and accessories."
45379065|NCT03971734|Drug|Regadensoson 0.7mg|Regadensoson 0.7mg administered prior to MRI
45379066|NCT03971734|Drug|Regadensoson 1.0mg|Regadensoson 1.0mg administered prior to MRI
45379067|NCT03971734|Drug|Regadensoson 1.4mg|Regadensoson 1.4mg administered prior to MRI
45379068|NCT03965494|Drug|BGB 324 (before surgery)|Given by mouth either BEFORE therapeutic conventional surgery
45379069|NCT03965494|Drug|BGB 324 (after surgery)|Given by mouth either AFTER therapeutic conventional surgery
45495401|NCT05222334|Procedure|Extrafascial interscalene brachial plexus block group|Final needle tip position will be 4 mm lateral to the brachial plexus sheath, at a level equidistant between C5 and C6 roots. The distance of 4 mm is chosen according to the calculated success rate over 90% reported. the local anesthetic (10 ml 0.5% bupivacaine) is then injected
45495402|NCT05222334|Drug|Bupivacaine|bupivacaine
45495403|NCT04465266|Drug|Tolperisone|tablets
45379070|NCT03964727|Drug|Sacituzumab Govitecan-hziy|Administered intravenously
45495404|NCT04434300|Drug|Daptomycin|Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.
45693802|NCT04552262|Drug|Placebo|Single dose of placebo to BAY 2327949
45379071|NCT03961061|Behavioral|Brenner mFIT (standard care)|Families attend an orientation, in which they are then scheduled for an initial introductory 2-hour intake group session and cooking class; these occur within 2-4 weeks of the orientation. Monthly 1-hour long visits with the dietitian, counselor, and PA specialist are held for 6 months, in which the child and caregiver see the pediatrician. During the 6 months of treatment, they attend 4 group classes, choosing from topics such as meal planning, PA, and parenting. Specialized visits with the PA specialist or dietician are scheduled as pertinent issues arise. Motivational interviewing, modified by Brenner FIT for use with families, is the key to treatment; family counselors are trained in cognitive behavioral therapy, parenting support/mindfulness, and employ these approaches to assist families in developing healthy habits.
45379072|NCT03961061|Behavioral|Brenner mFIT (standard care plus mobile health components)|"Brenner mFIT includes all components of the standard Brenner FIT program in addition to six mobile health components.~The six mHealth components that will be used in addition to standard Brenner Families in Training program include-~a mobile-enabled website,~diet and physical activity tracking apps and physical activity tracker~tailored self-monitoring feedback~caregiver podcasts~animated videos for adolescent patients~social support via social media."
45379073|NCT03950635|Dietary Supplement|Dietary Intervention|Consume whole-foods, fiber-rich diet
45379074|NCT03950635|Dietary Supplement|Dietary Intervention|Consume high fat, low carbohydrate (ketogenic) diet
45693803|NCT00803062|Biological|Bevacizumab|Given IV
45693804|NCT00803062|Drug|Cisplatin|Given IV
45379075|NCT03950635|Other|Questionnaire Administration|Ancillary studies
45379076|NCT03950232|Drug|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to approximately 8 years or until marketing authorization is obtained in the participant's country, whichever comes first
45693805|NCT00803062|Other|Laboratory Biomarker Analysis|Correlative studies
45495405|NCT04434300|Drug|Daptomycin|Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.
45495406|NCT05214690|Drug|DW1809-T2|pelubiprofen 25mg
45495407|NCT05214690|Drug|DW1809-1|pelubiprofen 30mg (PELUBI tab.)
45495408|NCT03055806|Drug|IX-01 400 mg|IX-01 400 mg caplet
45495409|NCT03055806|Drug|Placebo|Placebo caplet(s)
45495410|NCT03055806|Drug|IX-01 800 mg|IX-01 800 mg (Two 400 mg caplets)
45495411|NCT03055806|Drug|IX-01 1200 mg|IX-01 1200 mg (Three 400 mg caplets)
45693806|NCT00803062|Drug|Paclitaxel|Given IV
45495412|NCT05222100|Diagnostic Test|Mammography screening|Breast screening mammograms use X-rays to look for cancers that are too small to see or feel.
45495413|NCT05194644|Other|Routine physical therapy+ Sensorimotor stimulation|Gustatory, Tactile, Olfactory, Visual and Auditory Stimulation will be applied in sensory stimulation and in motor stimulation strengthening, Proprioceptive neuromuscular facilitation techniques, Balance exercises will be performed
45495414|NCT05194644|Other|Routine physical therapy|Active and passive Range of motion exercise of upper and lower limb, Transfer from bed to chair, Sit to stand practice
45693807|NCT00803062|Other|Quality-of-Life Assessment|Ancillary studies
45693808|NCT00803062|Other|Questionnaire Administration|Ancillary studies
45693809|NCT00803062|Drug|Topotecan Hydrochloride|Given IV
45693810|NCT01743469|Drug|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
45693811|NCT01743469|Drug|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
45693812|NCT01743469|Drug|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
45847277|NCT04596384|Other|Quality-of-Life Assessment|Ancillary studies
45379077|NCT03948971|Procedure|Venogram|The 5 French (5F) diagnostic catheter will be navigated into the inferior then superior vena cava and then into the internal jugular bulb on the dominant venous side (as determined from the arteriographic images). Next, a 0.027 inch microcatheter will be navigated using fluoroscopic guidance into the superior sagittal sinus and a venogram will then performed by injecting a small dose of contrast. Next, the venous sinus pressure waveforms will be recorded as the catheter is withdrawn into the jugular bulb and then in the superior vena cava to obtain a central venous pressure. Once completed, the catheters will be removed and the sheaths will be removed. Manual pressure will be held at the venous access site for a few minutes. The arterial sheath will be closed based upon standard arteriogram protocol.
45379078|NCT03948776|Diagnostic Test|BodyMetrix body composition ultrasound|Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. These will be compared to the reference technique of whole-body DXA imaging.
45379079|NCT03948776|Diagnostic Test|BodyMetrix body composition ultrasound only|Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. For inpatients currently admitted to the hospital, whole-body DXA imaging cannot be performed, as so the only assessment of body composition will be with the ultrasound.
45379080|NCT03938792|Drug|PF-06741086|300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
45495415|NCT04397796|Biological|BM-Allo.MSC|BM-Allo.MSC for Infusion, is manufactured from normal donor derived bone marrow product and are phenotypically CD73+, CD90+, CD105+, and negative for CD14-, CD34-, CD45-, HLA-DR-.
45495416|NCT04397796|Biological|Placebo|plasmalyte and human albumin
45495417|NCT04315896|Drug|Hydroxychloroquine|hydroxychloroquine 400mg day for 10 days
45495418|NCT04315896|Drug|Placebo oral tablet|Placebo oral tablet
45495419|NCT04311216|Other|3D movement analysis with surface electromyography|Single measurement session of 3D movement analysis with surface electromyography for upper limb movements
45495420|NCT03628092|Device|CO2 Fractional Ablative Laser|Vaginal / vulval laser treatment
45495421|NCT03628092|Device|Placebo|Sham Device
46054748|NCT02781675|Other|Dietary Intervention|3 wk dietary intervention with prescribed menus and ~50% foods provided.
46054749|NCT04229121|Other|nonintervention|nonintervention
46054750|NCT05242224|Other|Evolutionary Nutrition Package|The evolutionary nutrition package includes two key components: 1) one full meal per day from the evolutionary nutrition (EN) plate; 2) targeted messaging for high quality nutrition and removal of ultra-processed foods from the diet. The EN plate includes five food groups identified from the literature on evolutionary diets: animal source foods (ASF); berries and other fruits; tubers; vegetables, herbs and spices; and nuts and other legumes.
46054751|NCT04229277|Diagnostic Test|optical coherence tomography|comparison of four imaging technologies in skin tumour diagnosis
45693813|NCT01743469|Drug|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
46054752|NCT05242068|Device|Veinlite|Use of vein imaging device for visualization of veins during peripheral IV placement
46054753|NCT05242068|Other|Standard care|Patients received standard intravenous catheterization.
45495422|NCT03628014|Other|Inpatient-care program|"Patients enrolled in the Hospital Elder Life Program can receive four types of personalized volunteer-led interventions based on the needs identified by the care team. These interventions include:~Daily orientation and visiting program~Basic active movements~Meal assistance~Recreational activities"
45693814|NCT01743001|Drug|Macitentan 10 mg|Macitentan 10 mg oral tablet once daily
45693815|NCT01743001|Drug|Placebo|Macitentan-matching placebo oral tablet once daily
46054754|NCT04097899|Other|implementation of antimicrobial stewardship comprehensive care bundle program on ventilator associated pneumonia patients|"Construction of a comprehensive care bundle educational program. This program consisted of many elements: Antimicrobial stewardship programs, VAP bundles and infection control policy implementation and the investigators studied the impact of this program on:~Antibiotics cost.~Appropriates of antibiotic use (initiation, duration & time of discontinuation).~Rate of resistance~Clinical outcome, infection rate &length of stay."
45379081|NCT03922048|Drug|HTX-011|Single-dose instillation of approximately 0.17 mL/kg (total dose does not exceed 10.5 mL) of HTX-011.
45379082|NCT03922048|Drug|Bupivacaine HCl|Bupivacaine HCl 0.25% (without epinephrine) (total dose not to exceed 75 mg).
45379083|NCT03922048|Drug|HTX-011|Dose to be determined from Cohort 1.
45379084|NCT03922048|Drug|HTX-011|Dose to be determined from Cohorts 1 and 2.
45379085|NCT03922048|Drug|HTX-011|Dose to be determined from Cohort 1 Part A.
45379086|NCT03922048|Device|Luer Lock Applicator|Applicator for instillation.
45379087|NCT03918447|Drug|Bardoxolone methyl oral capsule|Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
45379088|NCT03918447|Drug|Placebo oral capsule|Capsule containing an inert placebo
46054755|NCT04201938|Combination Product|Symbiter-Omega|Symbiter-Omega contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera.
46054756|NCT04201938|Dietary Supplement|Placebo|Placebo
46054757|NCT02599831|Device|Electrical pudendal nerve stimulation|Four sacrococcygeal points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the root of the penis (perineum) or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the root of the penis (perineum). After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
46054758|NCT02599831|Device|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
45379089|NCT03914742|Drug|PARP Inhibitor BGB-290|Given PO
45379090|NCT03914742|Drug|Temozolomide|Given PO
45379091|NCT03914742|Procedure|Therapeutic Conventional Surgery|resection surgery
45379092|NCT03914508|Behavioral|Memory + Behavioral Weight Loss|BWL and memory enhancement (M+BWL) will be integrated to capitalize on the strengths of both treatments. All participants will be taught general behavioral weight loss skills including to decrease caloric intake and increase physical activity, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss. The proposed M+BWL program provides memory interventions based on the literature, including eating attentively, memory of previous meal, memory skills for planning, effects of diet on memory and the relationship between memory and satiety. The M+BWL program will also utilize experiential learning during the group program such as practicing memory enhanced skills during eating.
45379093|NCT03909178|Procedure|Hip Arthroscopy Surgery with Acetabular Labral Repair (SPT group)|Patients randomized to the SPT group provided consent for arthroscopic acetabular labral repair with femoroacetabular osteoplasty. As previously described in various technique publications from our group, the senior surgeon's (S.D.M.) hip arthroscopy technique includes intra-articular fluid distension for initial portal placement, puncture capsulotomy, autograft capsular augmentation if insufficient or degenerative labral tissue is encountered, intermittent traction, sparing use of electrocautery, and preservation of the chrondrolabral junction. All SPT patients underwent a standardized postoperative physical therapy protocol developed jointly by the senior author (a sports medicine fellowship-trained orthopaedic surgeon) and the physical therapists. Patients were kept weightbearing as tolerated on crutches for 6 weeks to maintain a level pelvis without lurching when walking and were instructed to avoid impact loading exercises for 6 months.
45498201|NCT03680664|Device|Active tDCS|Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied. The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation. Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband. The direct current will be of 2 mA (current density = 0.57 A/m2) for 30 min per day.
45847278|NCT04596384|Other|Questionnaire Administration|Ancillary studies
45847279|NCT04596384|Other|TapCloud|Use TapCloud app
45847280|NCT04569942|Drug|Vasopressor|Cease IV fluid resuscitation. If persisting hypotension and/or hypoperfusion commence a vasopressor infusion (e.g. noradrenaline) and titrate according to local practice to achieve target MAP. The target MAP will be determined by the treating clinician. Reassess at least hourly for up to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Boluses of 250ml of IV fluids are permitted if deemed indicated by the treating clinician.
45379094|NCT03909178|Procedure|Physical Therapy Focused on the Hip and Hemi-pelvis (PT group)|PTA patients were assigned a standardized, 24-week course of supervised, core-based PT. This course was designed in concert with physical therapists within our institution to help address symptoms of labral tear in patients older than 40 who had mild to moderate OA. Weeks 1 and 2 focused on normalizing gait, and weeks 3 through 24 focused on optimizing range of motion (ROM) while slowly integrating strength training. Unlike the prerandomization PT protocol, the PTA protocol was predominantly physical therapist-supervised (at least 1 in-person visit per week).
45379095|NCT03907475|Drug|Capecitabine|Given PO
45379096|NCT03907475|Drug|Carboplatin|Given IV
45379097|NCT03907475|Biological|Durvalumab|Given IV
45495423|NCT05221788|Procedure|Goal-directed hemodynamic therapy|Compounded sodium lactate 3 ml/kg/h was given intravenously as a basal rehydration volume before induction, and 200 ml of electrolyte solution was given after induction. If SV increased >10%, 200 ml of electrolyte solution was continued until SV increased <10%. After fluid shock, if SV increases <10% but mean arterial pressure (MAP) <65 mmHg and/or cardiac index (CI) <2.5l/min/m2 give low-dose norepinephrine continuous pumping and/or dobutamine continuous pumping. If hypotension was accompanied by hypovolemia (defined as urine output <0.5 ml /kg/h and/or heart rate more than 20% above baseline), plasma was administered until urine output and/or HR returned to normal. Fluid responsiveness and hemodynamic variables were reassessed at least every 15 minutes, and more frequently in cases of hemodynamic instability.
46054759|NCT02599831|Device|Transanal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
45379098|NCT03907475|Drug|Gemcitabine Hydrochloride|Given IV
45379099|NCT03907475|Drug|Nab-paclitaxel|Given IV
45379100|NCT03907475|Drug|Paclitaxel|Given IV
45495424|NCT05178654|Drug|[14C]PF-07321332|Single oral dose of 300 mg [14C]PF-07321332 containing approximately 100 µCi [14C]PF-07321332 coadministered with 100 mg ritonavir.
45495425|NCT04108962|Drug|Fasenra, 30 Mg/mL Subcutaneous Solution|Anti-IL5 receptor alpha monoclonal antibody
46054760|NCT05132361|Device|SELUTION SLR™ 018 DEB|a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
46054761|NCT05132361|Device|Plain (Uncoated) Balloon Angioplasty (PTA)|a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
46054762|NCT02845986|Procedure|Laparoscopic Spleen-Preserving No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Laparoscopic spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma.
46054763|NCT02845986|Drug|oxaliplatin|oxaliplatin or platinum-based chemotherapy is used when the patients undergo adjuvant chemotherapy after the surgery.
45379101|NCT03907475|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
45379102|NCT03891667|Drug|Disulfiram|Patients will receive disulfiram for 4 weeks followed by placebo for 4 weeks or disulfiram for 8 weeks.
45495426|NCT04031118|Device|Apioc Contact Lens|Measurement of corneal oxygen uptake with contact lens wear.
45495427|NCT04015362|Procedure|Sub-threshold intermittent pulsed magnetic stimulation|Application of sub-threshold intermittent pulsed magnetic stimulation to spinal cord
45379103|NCT03885622|Device|ANTHEM™ CR Total Knee System|The ANTHEM CR Total Knee System is a CE marked device. It is a cruciate retaining (CR) total knee system. It is intended to be used in patients for primary total knee replacement surgery where the posterior cruciate ligament and collateral ligaments remain intact. It is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties.
45379104|NCT03871855|Drug|SHR-1702|Administered IV
45379105|NCT03871855|Drug|Camrelizumab|Administered IV
45379106|NCT03866174|Drug|Psilocybin|The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.
45379107|NCT03866174|Drug|Niacin|The active placebo is encapsulated using a HPMC capsule and contains 100 mg of pharmaceutical grade niacin.
45495428|NCT04015362|Procedure|Sham|Application of sham magnetic stimulation to spinal cord
45495429|NCT05221710|Behavioral|electroacupuncture|"The acupuncture treatment will be performed by the technique of lifting, thrusting, twirling and rotating the needle until the patient is being De-qi (getting a numbness or other acupuncture feeling).The needle will be kept in place for approximately 30 minutes. The point of acupuncture is determined by a traditional Chinese medicine doctor.~Neuromuscular Electrical Stimulation(NMES) group received consecutive daily sessions of electrical stimulation at specific points.~On the basis of the above acupuncture treatment,two points that do not cross the joint will be chosen for electrical stimulation in electroacupuncture group."
45693816|NCT00362284|Behavioral|NYUCI-AC|Approximately six individual and family consultation sessions (2 individual, 3 family, 1 individual) within the first 4 months with adult child caregivers and/or their family members; support group participation (recommended at least once a month) after the completion of the individual and family consultation sessions for the duration of the project (up to 3 years after the intake interview); ad hoc consultation (ongoing in-person, telephone, or email support on an as-needed basis) for the duration of the project (up to 3 years after the intake interview); New York University Caregiver Intervention
45693817|NCT03839368|Procedure|fixation of angle fracture|open reduction and internal fixation of angle fracture
45693818|NCT00821626|Device|BD Directigen EZ Flu A+B|Naso-pharyngeal swab and rapid flu test
45693819|NCT00821626|Other|Control|No rapid flu test
46054764|NCT02598739|Other|Resistance exercise|"Underwent resistance exercise twice a week, for twelve weeks. The IG patients performed resistance exercises for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises were 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteo: standing hips extension."
46054765|NCT02598739|Other|Waiting list for the exercises|
46054766|NCT05340933|Other|Voice registration|Voice registration
46054767|NCT04095325|Device|Ultrasound guided erector spinae block|Group 2 (n: 50): those who underwent ESP block after propofol atropine induction and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
45379108|NCT03866174|Other|Set and Setting (SaS) Protocol|The SaS Protocol prescribes 6-8 hours of preparatory meetings with two facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two facilitators, and 4 hours of post-dose integration sessions with facilitators. During the dosing session participants are encouraged to wear eyeshades and listen to a curated playlist on headphones.
45379109|NCT03864926|Drug|Envarsus XR|"Envarsus XR is FDA approved for the prophylaxis of organ rejection in kidney transplant recipients converted from tacrolimus immediate-release formulations, in combination with other immunosuppressants. Envarsus XR, is designed to deliver tacrolimus more smoothly over the whole day.~Envarsus XR, a calcineurin-inhibitor immunosuppressant, is available for oral administration as extended-release tablets containing the equivalent of 0.75 mg, 1 mg, or 4 mg of anhydrous tacrolimus USP. Inactive ingredients include hypromellose USP, lactose monohydrate NF, polyethylene glycol NF, poloxamer NF, magnesium stearate NF, tartaric acid NF, butylated hydroxytoluene NF, and dimethicone NF. Tacrolimus is the active ingredient in ENVARSUS XR."
45495430|NCT04002102|Other|OLP treatment|Receive two open-label placebo pills twice a day after randomization. Will receive for 21 days and then stop. It will include educational materials and positive expectancy.
45495431|NCT04002102|Other|Usual care|Remain in standard care after randomization and educational materials.
45495432|NCT04002102|Other|Expectancy Group|Educational materials and positive expectancy orientation via Zoom or telephone
45498202|NCT03680664|Other|sham tDCS|The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation.
45693820|NCT04557787|Device|SpeediCath® Standard female|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard female.
45693821|NCT04557787|Device|New intermittent Variant 1 catheter for females|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 catheter.
45495433|NCT05657106|Behavioral|Harm reduction kiosk|The intervention involves enhancing an existing staffed harm reduction program (syringe service program) located in a local health department with a Kentucky Outreach Service Kiosk (KyOSK).
45495434|NCT04989582|Other|The trauma recovery nursing intervention program|The trauma recovery nursing intervention program was for adults who had experienced trauma and consisted of eight sessions, each lasting 30 min. It included a spoken audio track that was accompanied by visual prompts to provide knowledge on traumatic stress and introduce trauma recovery methods. Its online format made it convenient and widely accessible, and allowed for a low-intensity, cost-effective educational program. The program focused on providing self-help guidelines for clients to develop their mental and physical well-being.
45693822|NCT04557787|Device|New intermittent Variant 2 catheter for females|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 catheter.
45693823|NCT01704079|Drug|CTAP101 30 μg capsules|CTAP101 30 μg capsule taken daily at bedtime
46054768|NCT00839332|Drug|LY2603618|
46054769|NCT00839332|Drug|Gemcitabine|
46054770|NCT04180917|Other|Survey|survey
46054771|NCT03325452|Biological|venous lactate|value of venous lactate
46054772|NCT05341947|Biological|Activated T cells|Activated T cells (ATC) administered intravenously at one timepoint
45379110|NCT03864926|Drug|Tacrolimus|Tacrolimus (generic; immediate release) is FDA approved for the prophylaxis of organ rejection in heart, kidney and liver transplant recipients.
45379111|NCT03859869|Drug|Pancrelipase|Pancrelipase is administered orally as capsules with a meal or snack
45693824|NCT01704079|Other|Sugar pill to CTAP101 30 μg capsules|Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
45753988|NCT04022798|Other|Exercise, manual therapy|"Participants were randomly assigned into treatment (n=15) or control group (n=15). Participants in each group received 12 treatment sessions of 45 minutes each, 2 days a week for 6 consecutive weeks.~For each group, a menu of a lumbar stabilization program was designed. This program included 8 levels of exercise ( single leg knee to chest stretch, double leg knee to chest, supine piriformis stretch, supine hamstring stretch, lower trunk rotation stretch, lumbar rotation stretch, pelvic tilt, pelivic tilt with alternative legs). Exercises were tailored for each individual ability and, if possible, progressed at each session which would last approximately 30 minutes. Each single exercise was repeated many times based on the patient's clinical condition. All sessions were provided by physiotherapists."
45753989|NCT04022330|Other|Blood sampling|The blood sampling will be done just before surgery
46054773|NCT04095169|Diagnostic Test|Complement C3d test (blood sample)|Evaluation of C3d levels in EDTA samples from participants
46054774|NCT04230057|Dietary Supplement|Antitumor B|Single dose 2400 mg
46054775|NCT03265314|Behavioral|LeadHer|The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
45379112|NCT03859869|Drug|Placebo|Placebo is administered orally as capsules with a meal or snack
45379113|NCT03851380|Behavioral|Psychological / Functional Assessment|Psychological and functional assessment battery to characterize participants.
45379114|NCT03851380|Other|Structural and Functional MRI|Structural and functional magnetic resonance imaging session.
45379115|NCT03851380|Device|Transcranial Magnetic Brain Stimulation and MR Image Guidance|MRI guided transcranial magnetic stimulation and measurement of targeting accuracy.
45379116|NCT03851380|Device|Transcranial Electrical Stimulation (tES)|Home-based Transcranial Direct Current Stimulation
45379117|NCT03831932|Procedure|Biospecimen Collection|Undergo blood sample collection
45379118|NCT03831932|Procedure|Computed Tomography|Undergo CT scan
45379119|NCT03831932|Procedure|Magnetic Resonance Elastography|Undergo MRI
45379120|NCT03831932|Drug|Osimertinib|Given PO
45379121|NCT03831932|Procedure|Positron Emission Tomography|Undergo PET scan
45379122|NCT03831932|Drug|Telaglenastat Hydrochloride|Given PO
45379123|NCT03831932|Procedure|X-Ray Imaging|Undergo x-ray imaging
45495435|NCT04928040|Diagnostic Test|Measurement of optic nerve sheath diameter|The fluid challenge effects of optic nerve sheath diameter
45379124|NCT03828331|Other|Prosthetic/Bicycle Configuration|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects ride using an initial bike fit and three taller pylon lengths (PL) for the affected leg (AL) in increments of 6.8 mm using a pedal attachment position (PAP) beneath the prosthetic forefoot. Then, using the optimal (most efficient) PL, the investigators will measure the biomechanics and metabolic rates while subjects ride using three shorter crank arm lengths (CALs) for the AL in decrements of 6.8 mm using a PAP beneath the prosthetic forefoot. On Day 2, the investigators will repeat the protocol of Day 1, but have riders use a PAP beneath the pylon for their AL.
45495436|NCT04916730|Behavioral|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician but will not be required to adopt a 10-hr eating window.
45379125|NCT03822910|Diagnostic Test|Pattern Separation Paradigm|Will be used to investigate dentate gyrus (DG) and hippocampal CA3 subfield as reflected by the difference in brain activation in response to same as previously seen (OLD) vs similar to previously seen (SIM) objects in first episode (FEP) subjects before and after treatment.
45379126|NCT03822910|Diagnostic Test|Sequential Associative Mismatch Paradigm|used to reflect activation of CA1 in response to mismatching information compared to memory of the stimulus in FEP subjects before and after antipsychotic treatment and in matched Healthy Control (HC).
45379127|NCT03822910|Diagnostic Test|Encoding Plasticity Paradigm|Used to evaluate plasticity of hippocampal Intrinsic Functional Connectivity (IFC) in response to memory consolidation in FEP subjects before and after antipsychotic treatment and in matched HC.
45495437|NCT04916730|Behavioral|Time Restricted Eating|Participants in this arm will adhere to a daily, consistent self-selected 10-hr eating window for the course of the study intervention period as well as receive nutritional counseling from the study dietitian.
45495438|NCT04907292|Other|Obstetric Quality of Recovery-10 (ObsQoR-10©) Scoring Tool|The ObsQoR-10 tool aims to quantitatively measure functional recovery at 24 hours postpartum. It includes 10 questions on a 0 to 10 scale, aimed at pain management, the adverse effects of narcotics and the perception of recovery by the patient.
45495439|NCT05221476|Other|retrospective|The investigators retrospectively analyzed the short- and long-term outcome in polytraumatized patients and the possible influence of RDW values on admission as well as preexisting comorbidities on these outcomes.
45495440|NCT04865796|Other|Lactoferrin products|Patiens will use a toothpaste and 2 tablets per day (between foods) for home oral care.
46054776|NCT03265314|Behavioral|Sassy Science|The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
46054777|NCT00917215|Device|Disposable stainless steel acupuncture (0.2mmx4mm)|"For active acupuncture group, needles were inserted into nine acupoints (CV22 and bilateral LU5, ST40, BL13, EXB1)with De-qi three times a week for 4 weeks.~For sham acupuncture group, Nine non-acupoints corresponded with each active acupoint were treated with minimal penetration into skin three times a week for 4 weeks."
45379128|NCT03806803|Biological|Lyophilized fecal microbiota transplant|15 capsules
45379129|NCT03806803|Biological|Lyophilized sterile fecal filtrate|15 capsules
45495441|NCT04865796|Other|Probiotics products|Patiens will use a toothpaste and a chewing-gum (for 10 minutes a day) for home oral care.
45495442|NCT04865796|Other|Standard home oral care|Patiens will use a normal toothpaste for home oral care.
45495443|NCT04811118|Drug|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) by intravenous infusion
45495444|NCT04811118|Drug|Taxotere|Taxotere
45495445|NCT04795674|Behavioral|EWM Training|Training tasks will target Executive Working Memory areas of the brain. Task difficulty will be adaptively increased across the 5 weeks of training based on session-to-session performance.
45379130|NCT03799458|Device|Active High-definition transcranial direct current stimulation (HD-tDCS)|Active HD-tDCS delivers active current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates.
45379131|NCT03799458|Device|Sham High-definition transcranial direct current stimulation (HD-tDCS)|Sham HD-tDCS delivers sham current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates
45379132|NCT03764098|Drug|Guanfacine ER|Guanfacine Extended Release (6mg/day ER)
45379133|NCT03764098|Other|Placebo|Placebo
45495446|NCT04795674|Behavioral|Placebo Training|Computerized tasks with comparable engagement that do not tap executive working memory processes
45495447|NCT04979988|Drug|Lortlatinib|as provided in real world practice
45495448|NCT05221164|Drug|Aspirin 162 mg|Daily aspirin 162 mg during pregnancy to prevent preeclampsia
45495449|NCT04647084|Drug|Lidocaine 2% Injectable Solution|An elastic band will be placed around the subject's arm, and the elastic band will be removed once the IV is inserted. After the elastic band is placed on the subject's arm, the arm will be cleaned, and then a small skin wheel will be created with the lidocaine that will be injected very close to where the IV will be placed. The IV will be placed within about a minute from the time when the lidocaine was injected.
45495450|NCT04647084|Device|Buzzy|The Buzzy vibrating ice pack will be placed on the subject's arm with an elastic band around it, and it will remain there as the arm is cleaned and prepped and the IV inserted. The Buzzy device will be removed once the IV is inserted.
45495451|NCT05221008|Drug|SHR6508；Placebo|Group A:SHR6508 low dose
45495452|NCT05221008|Drug|SHR6508；Placebo|Group B:SHR6508 medium dose
45495453|NCT05221008|Drug|SHR6508；Placebo|Group C:SHR6508 high dose
45495454|NCT05221008|Drug|SHR6508；Placebo|Group D:SHR6508 high dose(single dose)
45495455|NCT03627546|Drug|Sofosbuvir and Velpatasvir|Sofosbuvir/velpatasvir (Epclusa) is an FDA-approved treatment for HCV. It is provided in the intervention arm as part of a rapid treatment strategy,
45379134|NCT03763565|Biological|Bivalent or Quadrivalent HPV vaccines|Vaccination with at least one dose of Bivalent or Quadrivalent HPV vaccines at least 5 years ago at the ages of 20-45 years
45379135|NCT03763565|Other|Control group|Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time
45379136|NCT03749447|Drug|Bardoxolone methyl|Bardoxolone methyl capsules
45379137|NCT03745924|Drug|Nonacog beta pegol|Participants are treated with commercially available nonacog beta pegol (N9-GP) according to local clinical practice at the discretion of the treating physician
45379138|NCT03740204|Drug|17-β estradiol transdermal patches with cyclic progesterone|17-β estradiol transdermal patches (100 mcg 17-β estradiol/day) with cyclic progesterone (200 mg micronized progesterone daily for 12 days every month)
45379139|NCT03740204|Drug|Placebo patch and pill|Placebo patch and pill
45379140|NCT03735563|Drug|Ketamine|Individuals will receive randomly either ketamine or fentanyl as a premedication
45379141|NCT03735563|Drug|Fentanyl|Individuals will receive randomly either ketamine or fentanyl as a premedication
45495456|NCT04620798|Behavioral|Immediate vs. delayed provision of antibody test results|The primary experiment will be assessing whether provision of the antibody test results leads to behavior change with respect to personal protective behaviors. To that end, we will randomize all participants to a trial arm that immediately receive results (within 24 hours) or a trial arm with a delayed provision of results (after 4 weeks).
45495457|NCT04940208|Other|Pain and neuropsychological questionnaires|Patient-reported outcomes, listed in the Secondary Outcome Measure Section
45495458|NCT04940208|Diagnostic Test|Quantitative Sensory testing|Summation pain threshold test and Heat pain threshold skin test
45495459|NCT05685966|Other|no intervention|no intervention
46054778|NCT05340777|Device|Training Obstetric staff on Ellavi UBT|The study team will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers, clinical officers) involved in PPH management at the participating healthcare facilities on use of the Ellavi UBT. This will be done to ensure staff are trained on the newly registered and provided medical device. We will gather feedback on how to improve the training curriculum from participants. We will also gather information from the healthcare workers immediately post-use of an Ellavi UBT device following their management of a refractory PPH case. These surveys will help us to understand the barriers to and facilitators of use in order to evaluate acceptability and feasibility among facilities providing different levels of PPH care.
46054779|NCT05756686|Behavioral|Breathing Group 1|The 8-week breathwork intervention incorporates a set of breathing practices under the guidance of a certified yoga teacher.
46054780|NCT05756686|Behavioral|Breathing Group 2|The 8-week breathwork intervention incorporates a set of slow breathing practices under the guidance of a certified yoga teacher.
45495460|NCT05220618|Behavioral|Autobiographical Memory Specificity Training PESCAR|An autobiographical memory specificity training has been developed by authors, based on previous training within the frame of Cognitive Bias Modification Interventions (CBM-I; Barry et al., 2019; Hitchcock et al., 2017). The training group will receive a self-guided intervention, which consists of an initial session (lasting 30 minutes approximately) and two-week training, conducted online. Participants will be provided with an online platform for following the intervention in a self-guided modality. The first session aims to give information about autobiographical memory functioning, to train in specificity recall through concrete processing steps and to explain the functioning of the self-guided modality. Then, during the next two weeks, participants will use the online platform once a day for practising the recall of autobiographical memories during 15-20 min approximately.
45379142|NCT03735095|Drug|Porfimer Sodium|Given IV
45379143|NCT03735095|Procedure|Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy|Undergo EBUS-TBN guided I-PDT
45495461|NCT05684328|Procedure|WLI Then NBI Withdrawal|Patients in WLI then NBI withdrawal group will first be carefully inspected by white light imaging(WLI), each polyp found should be removed by cold snare. Then change to narrow band imaging(NBI) for the second withdraw to detect the lesions which found in second time but not the first.
45379144|NCT03731585|Behavioral|Behavioral Intervention|Participate in psychological sessions
45379145|NCT03731585|Other|Educational Intervention|Participate in educational sessions
45379146|NCT03731585|Other|Questionnaire Administration|Ancillary studies
45379147|NCT03731585|Procedure|Support Group Therapy|Participate in group sessions
45379148|NCT03717402|Behavioral|Intervention Participants|Patients with advances cancer using opioids for chronic pain will be enrolled and asked to use the STAMP cancer pain management app for 4 weeks.
45379149|NCT03715153|Drug|BUMETANIDE (S95008) for week 0 - 26|Oral solution dosed at 0.5 mg/mL Taken twice daily.
45379150|NCT03715153|Drug|PLACEBO for week 0 - 26|Oral solution Taken twice daily.
45379151|NCT03715153|Drug|Open-Label BUMETANIDE (S95008) for weeks 26 - 52|Oral solution dosed at 0.5 mg/mL Taken twice daily.
45379152|NCT03685773|Drug|Diazoxide|"MRI studies: Non-diabetic and T2D participants will receive diazoxide (up to 7 mg/kg) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive diazoxide (up to 7 mg/kg) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the pancreatic clamp study."
45379153|NCT03685773|Drug|Placebo (for diazoxide)|"MRI studies: Non-diabetic and T2D participants will receive placebo (for diazoxide) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive a taste-matched placebo (for diazoxide) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive a taste-matched placebo (for diazoxide) the next morning and undergo the pancreatic clamp study."
45379154|NCT03685773|Drug|Nicotinic acid|Type 2 diabetic participants in this arm will receive a nicotinic acid infusion to lower free fatty acid levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the MRI or pancreatic clamp study.
45379155|NCT03683277|Drug|Ixazomib/Pomalidomide/Dexamethasone|"Treatment with association of Ixazomib, Pomalidomide and Dexamethasone (IPD)~Induction phase : 21-days cycles - maximum of 17 cycles Ixazomib (tablets) 3 mg D1, D4, D8 and D11 Pomalidomide (tablets) 4mg D1 to D14 Dexamethasone (tablets) 40 mg/d D1, D8 and D15 if patient aged <75 years Dexamethasone (tablets) 20 mg/d D1, D8 and D15 if patient aged ≥ 75 years~Treatment with association of Ixazomib and Pomalidomide (IP) Maintenance phase : 28-days cycles until disease progression Ixazomib (tablets) 4mg D1, D8 and D15 Pomalidomide (tablets) 4mg D1 to D21"
45379156|NCT03665207|Drug|Insulin|When blood glucose exceeds the preset target, insulin will be administered through continuous intravenous infusion. Insulin will be titrated according to frequent measurement of blood glucose and with use of the LOGIC-insulin algorithm in the experimental group. The intervention will be stopped upon ICU discharge, or until the patient is able to resume oral feeding, or until the patient no longer has a central venous catheter, whatever comes first.
45379157|NCT03660722|Other|blood and urinary samples|blood samples, rectal and urethral swabs , urine samples at inclusion, after 4 weeks then 12 weeks
45379158|NCT03660683|Drug|Dapagliflozin 10mg|Dapagliflozin 10mg PO QD
45379159|NCT03660683|Drug|Saxagliptin 5mg|Saxagliptin 5 mg PO QD
45379160|NCT03660683|Drug|Placebo Oral Tablet|Matching Placebo Tablets
45495462|NCT05684328|Procedure|NBI Then WLI Withdrawal|Patients in NBI then WLI withdrawal group will first be carefully inspected by narrow band imaging(NBI), each polyp found should be removed by cold snare. Then change to white light imaging(WLI) for the second withdraw to detect the lesions which found in second time but not the first.
45495463|NCT04900506|Procedure|Posterior SPAIRE approach, anterior approach|Based on power calculation a sub-group analysis of 50 patients will be examined with DXA, all patients for biochemical and clinical muscle damage (CK, CRP, TUG-test, Trendelenburg, strenght test)
45495464|NCT05220228|Drug|Prucalopride|1mg prucalopride x 2d, 2mg prucalopride x 5-8d
45495465|NCT05220228|Drug|Placebo|Lactose / sucrose placebo
45495466|NCT05635734|Drug|Azeliragon 5 mg|"Azeliragon 5 mg once a day (loading initial dose for 6 days of 10 mg daily). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
45495467|NCT05635734|Drug|Azeliragon 10 mg|"Azeliragon 10 mg once a day (loading initial dose for 6 days of 15 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
45495468|NCT05635734|Drug|Azeliragon 20 mg|"Azeliragon 20 mg once a day (loading initial dose for 6 days of 30 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
45495469|NCT05220150|Device|FFC-MRI scan|Undergo one FFC-MRI scan.
45495470|NCT05220072|Drug|Carbon-14 BIA 28-6156|Carbon-14 BIA 28-6156 60 mg, containing NMT 3.7 MBq Carbon-14
45495471|NCT05672862|Device|Percutaneous coronary intervention|PCI was performed using drug-eluting stents
45495472|NCT05219682|Other|electroencephalographic measurement|recording brain activity in mirror therapy, haptic and tactile stimulation and in mirror therapy using virtual reality
45753990|NCT05621551|Drug|Dapagliflozin|The patients is required to receive dapagliflozin(10mg, q.d.) at least for 3 days until 24 hours before the surgery. Then dapagliflozin will be discontinued and recovered as soon as the patient is able to take oral diet postoperatively. Dapagliflozin wil be ceased five days after surgery.
46054781|NCT04494594|Behavioral|Drinks:Ration app|Drinks:Ration (www.drinksration.app; formerly called InDEx) app has been developed following the Medical Research Council Complex Intervention Guidelines and using co-design methodology by the King's Centre for Military Health Research (at King's College London) and the University of Liverpool, supported by experts in smartphone app development, epidemiology, addiction psychiatry, and military mental health. The app is designed to support veterans drinking at a hazardous or harmful level by providing detailed advice and support over a minimum of 28-day period. The app is theoretically underpinned to enhance participants motivation and self-efficacy in modifying their alcohol consumption by means of Behaviour Change Theory in the content displayed, and the messaging sent to participants.
45379161|NCT03653637|Behavioral|Project Life Force|A novel, 10-session group intervention to enhance currently mandated VA suicide safety planning by involving Veterans who are at high-risk for suicidal. The PLF intervention augments the SSP in a group treatment with skills training, and psychoeducation, to maximize use and effectiveness of the plan. Overall, PLF aims to enhance suicide coping skills, safety planning and connection to others. The primary purpose is to enhance the safety plan with skills training in emotion regulation, building of support and distress tolerance, and enable even acutely-suicidal Veterans to be able to implement the steps of the safety plan.
45495473|NCT03822780|Drug|Hydroxychloroquin|Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg*d to 10mg/kg*d, p.o., bid ; the maximum daily dose is 400mg.
45495474|NCT05219526|Diagnostic Test|blood glucose measurement: BGM|measurement of blood glucose concentration using different BGM
45379162|NCT03653637|Behavioral|Treatment as Usual|The comparison condition will be an assessment-only treatment-as-usual (TAU). Participants in the TAU condition will receive safety planning and specified clinical support, as mandated by their high-risk status.
46054782|NCT02780973|Other|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
46054783|NCT03203460|Behavioral|High-intensity aerobic interval training (HIIT)|A 12-week, supervised, HIIT aerobic exercise program consisting of alternating vigorous- and low-intensity intervals
45495475|NCT05219526|Diagnostic Test|blood glucose measurement: reference method|measurement of blood glucose concentration using reference Method
46054784|NCT00922948|Procedure|Cryoablation|Cryoneedles and one temperature probe are inserted under endoscopic and sonographic guidance.
46054785|NCT00922948|Procedure|Radiofrequency ablation|Thermal injury is the predominant mechanism of action of RFA. A high-frequency alternating current emitted from the exposed noninsulated portion of the electrode generates frictional heat, agitating ions in the tissue surrounding the tip of the needle.
45495476|NCT04765644|Drug|Celecoxib|Two 200 mg capsules per day (400 mg/day) for 7 days
45495477|NCT04765644|Other|Placebo|2 capsules/day for 7 days
45495478|NCT04765644|Other|L-arginine + placebo|L-arginine = Five capsules of 2 mg per day (10 mg/day) for 7 days Placebo = 2 capsules/day for 7 days
45495479|NCT04765644|Other|L-arginine + celecoxib|L-arginine = Five capsules of 2 mg per day (10 mg/day) Celecoxib = Two 200 mg capsules per day (400 mg/day) for 7 days
45495480|NCT05216874|Device|Oclusal Splint|"Cl III Laterognati volunteer group using occlusal stabilization splint before orthognathic surgery~-Splint will be used for at least two months"
45495481|NCT04720872|Other|Manual therapy and vestibular rehabilitation treatment|The experimental group received manual therapy and vestibular rehabilitation treatment.
45495482|NCT05649774|Procedure|Therapy|Only Myofascial Release will be provided
45495483|NCT05649774|Procedure|Taping technique|Only Kinesiotaping will be provided
45495484|NCT05649774|Procedure|Therapy with taping|Myofascial release will be provided followed by Kinesiotaping
45495485|NCT05649774|Procedure|SHAM|Placebo Treatment will be given
45495486|NCT05214846|Behavioral|Education and counseling|After obtaining informed consent, the data collection form, Hospital Anxiety Depression Scale (HADS) was applied to both groups by face to face interview. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher.The experimental group was given a telephone number where they could receive consultancy services for 12 hours a day. Pre-test was applied. One day later, the pregnant woman was called and encouraged to call for all her questions, and she was informed that she would be returned when she called.
45495487|NCT03052764|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injection into the bladder.
45495488|NCT03052764|Drug|Placebo (saline)|Placebo (saline) injection into the bladder.
45495489|NCT05638698|Biological|TG01 Vaccine|used to assess molecular disease control rate when combined with other interventional methods.
45495490|NCT05638698|Drug|QS-21|used to assess molecular disease control rate when combined with other interventional methods.
45379169|NCT03569293|Drug|Placebo for Upadacitinib|Tablets taken orally once a day
45379170|NCT03569293|Drug|Upadacitinib|Tablets taken orally once a day
45379171|NCT03566511|Drug|Diazoxide|Healthy and T2D participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) between baseline MRI scan and second MRI scan.
45379172|NCT03566511|Drug|Placebo|Healthy and T2D participants will receive placebo between baseline MRI scan and second MRI scan.
45379173|NCT03535129|Behavioral|Real time fMRI neurofeedback|During fMRI study, display feedback of brain activity to practice and reinforce control of alcohol craving.
45379174|NCT03525262|Radiation|30Gy (Gray) planning target volume (PTV)|PTV1_30Gy represents a 3mm expansion on the prostate (and proximal seminal vesicle per physician discretion), excluding the neurovascular structures on the side to be spared (left or right). PTV1 will receive 6 Gy per fraction for 5 fractions (30 Gy).
45379175|NCT03507686|Drug|BIIB111|Administered as specified in the treatment arm.
45379176|NCT03494179|Drug|ICP-022|The drug product is a white, round, uncoated tablet.
46054786|NCT03167892|Device|Oral screen|Oral screen training three times per day with an effective training time of 1.5 minutes, for 3 mo
46054787|NCT02845284|Behavioral|enhanced group support|Routine Care plus enhanced group support, and peer education beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
46054788|NCT02845284|Behavioral|enhanced individual support|Routine Care plus individual peer education and support beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
45379179|NCT03472404|Procedure|Internal Brace augmented ankle Ligament reconstruction|internal brace augmented ankle ligament reconstruction and an accelerated revalidation protocol.
45379180|NCT03472404|Procedure|Brostrom-Gould ankle Ligament reconstruction|Brostrom-Gould and standard revalidation including 6 weeks immobilisation.
45379181|NCT03464136|Biological|Placebo for Ustekinumab|Participants will receive placebo as SC injection to blind adalimumab.
45379182|NCT03464136|Biological|Placebo for Adalimumab|Participants will receive placebo as IV infusion to blind ustekinumab.
45495491|NCT05638698|Drug|Balstilimab|used to assess molecular disease control rate when combined with other interventional methods.
45379183|NCT03464136|Biological|Ustekinumab (6 mg/kg)|Participants will receive ustekinumab 6 mg/kg (weight based dosing) as IV infusion.
45379184|NCT03464136|Biological|Ustekinumab (90 mg)|Participants will self-administer SC injection of ustekinumab 90 mg.
45379185|NCT03464136|Biological|Adalimumab (40 mg)|Participants will self-administer multiple SC injections of adalimumab (each 40 mg) and will receive total dose of 160 mg at Week 0, 80 mg at Week 2, and 40 mg q2w from Week 4 to 56.
45379186|NCT03427450|Diagnostic Test|Blood draw|Blood collected will be processed on Parsortix PC1 system for capture and harvest of circulating tumor cells to be used in subsequent evaluations.
45379187|NCT03397706|Drug|VRx-3996|Taken orally once or twice daily
45693825|NCT04550143|Other|Diaphragm ultrasound (DUS)|"DUS assessments of diaphragmatic thickness (TDI), thickness fraction (TFDI) and shear modulus (SMDI), this last measured by shear-wave elastography (SWE), will be performed for both right and left hemi-diaphragms.~A landmark between the 8th and 10th intercostal space in the mid-axillary or antero-axillary line, 0.5-2 cm below the costophrenic sinus, will be used. Here, the diaphragm can be seen as the less echogenic structure between two echogenic lines; TDI (cm) will be the calculated as the distance between the two lines at the end of expiration and TFDI as the rate of change between end-expiration and end-inspiration thicknesses (TFDI = thickness at end inspiration - thickness at end-expiration / thickness at end-expiration, %).~SMDI will assess muscle's stiffness. For each image, a region of interest covering the widest possible surface of diaphragm and allowing an acquisition frequency of 2Hz will be set; results will be retrieved in kilopascals (kPa)."
46054789|NCT04229433|Drug|SHR2285 tablet|Pharmaceutical form: SHR2285 tablet Route of administration: single dose and multiple doses.
45379188|NCT03397706|Drug|Valganciclovir|Taken orally once or twice daily
45379189|NCT03382587|Drug|Aflibercept (Eylea, BAY86-5321)|"Intravitreal aflibercept injections used in a routine treat and extend regimen, under which the intervals between the injections are extended if disease stability is maintained and no signs of worsening disease are observed on the injection day"
45693826|NCT04550143|Other|Peripheral Muscle Ultrasound (PMUS)|"PMUS assessments of quadriceps rectus femoris (RF) muscle cross-sectional area (CSARF), echogenicity (ECHORF) and shear modulus (SMRF), this last measured by shear-wave elastography (SWE), will be performed.~Probe will be placed perpendicularly to the anterior plane of the thigh, in 2 anatomical points, as follows:~(i) in the midpoint between the anterior superior iliac spine and the upper pole of the patella and (ii) the border of the lower 1/3 and upper 2/3 between the anterior superior iliac spine and the upper pole of the patella.~CSARF (cm2) will be calculated by outlining the area under the muscle hyperechoic line (aponeurosis). For ECHORF (differences in grey-scale images), the analysis of a region of interest (ROI) of 2cm x 2cm will be performed.~For SMRF (kPa), a ROI covering the widest possible area of the RF and allowing an acquisition frequency of 2Hz will be set for analysis.~All assessments will be performed with minimal compression and a copious amount of water-gel."
46054790|NCT04229433|Drug|Placebo|Pharmaceutical form: Placebo tablet Route of administration: single dose and multiple doses.
46054791|NCT02845206|Procedure|Patient specific cutting blocks|'MyKnee' Instrumentation
46054792|NCT02845206|Procedure|Conventional cutting blocks|Standard Instrumentation
46054793|NCT02783157|Device|Transcutaneous Low-Level Vagal Nerve Stimulation (LLVNS)|Low-level vagal nerve stimulation will be delivered via a clip applied to the ear throughout the surgical procedure. The voltage used will be individualized to each patient, based upon the voltage necessary to slow the sinus rate during testing.
46054794|NCT02783157|Device|Sham LLVNS|A clip will be applied to the ear, but no stimulation will be delivered throughout the procedure.
46054795|NCT02845362|Other|Sydney Swallow Questionnaire|The Sydney Swallow Questionnaire (SSQ) is a validated self-report symptom questionnaire, it contains 17 items recorded as visual analogue scales and is a tool specifically designed for evaluation of swallowing difficulties.
46054796|NCT02782689|Device|Kit Biflex|Two-layer reusable compression system
46054797|NCT02782689|Device|Profore|Four-layer compression system
45379190|NCT03367546|Procedure|Blood and Marrow Transplant|Reduced intensity conditioning (RIC) with rabbit ATG, fludarabine, cyclophosphamide, thiotepa and low dose (2 Gy) total body irradiation followed by T-cell replete, unmanipulated, haploidentical related donor stem cell transplant (HaploHCT) and post-transplant cyclophosphamide (PTCy)
45379191|NCT04118803|Device|ICD replacement or upgrade|Currently, it is common for patients to survive beyond their initial prophylactic ICD generator. It is unclear whether further benefit related to inappropriate shocks or ATP is derived from long-term device therapy, particularly if there has been a change in the patient's cardiovascular condition.
45379192|NCT03361306|Drug|Elotuzumab|Experimental
45379193|NCT03325972|Drug|Dexmedetomidine|The drug will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
45379194|NCT03325972|Other|Placebo Saline|Placebo will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
45379195|NCT03320304|Device|Vagal Nerve Simulation (VNS) Therapy|A VNS Therapy System used for vagus nerve stimulation and consisting of an implantable VNS Therapy generator, lead, and external programming system.
45379196|NCT03274492|Drug|Polatuzumab Vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
45379197|NCT03274492|Drug|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
45379198|NCT03274492|Drug|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
45379199|NCT03274492|Drug|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
45379200|NCT03274492|Drug|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
45379201|NCT03274492|Drug|Vincristine Placebo|Placebo matching to vincristine will be administered as per the schedule specified in the respective arm.
45495492|NCT05637138|Device|tcpCO2 measure|Measurement of tcpCO2 by medical grade sensor: non-thermostatted, at 35°C, 38°C, 41°C and 44°C
45495493|NCT05637138|Device|tcpO2 measure|Measurement of tcpO2 by medical grade sensor: non-thermostatted, at 35°C, 38°C, 41°C and 44°C
45753991|NCT04022486|Other|Incidence, management and risk factors of seizure|Incidence of seizure, management (treatment, paraclinical examinations) and risk factors of seizure in children admitted for severe bronchiolitis
46054798|NCT05341713|Biological|inactive SARS-Cov-2 vaccine|We included epilepsy patients who were vaccinated with inactive SARS-CoV-2 vaccines
46054799|NCT05241912|Drug|Dobutamine|administration of dobutamine 0.01 - 0.04 U/min after induction of anesthesia to maintain oxygen delivery
45379202|NCT03274492|Drug|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
45379203|NCT03274492|Drug|Polatuzumab vedotin Placebo|Placebo matching to polatuzumab vedotin will be administered as per the schedule specified in the respective arm.
45379204|NCT03269422|Radiation|MR-based image-guided, intensity-modulated radiotherapy|Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm as determined on pre-treatment diagnostic T2 MRI imaging.
45495494|NCT05637138|Device|measurement of tissue conductivity to CO2: KS|measurement of tissue conductivity to CO2: KS by CAPNOS sensor : non-thermostatted, at 35°C, 38°C, 41°C and 44°C
45495495|NCT05637138|Device|measurement of microcirculation|measurement of microcirculation by CAPNOS sensor : non-thermostatted, at 35°C, 38°C, 41°C and 44°C
46054800|NCT03247023|Device|Implantation of Integra Cadence Total Ankle Sysyem|Primary Ankle Arthroplasty
45379205|NCT03261362|Dietary Supplement|Branched-chain amino acids reduced intake|
45379206|NCT03247712|Drug|Nivolumab|Nivolumab 240mg IV q2wks or 480mg IV q4wks
45379207|NCT03247712|Procedure|Surgical Resection|Surgical Resection of Tumor
45379208|NCT03247712|Radiation|Radiation (5 days)|8Gy x 5 (Mon-Fri) GTV+3mm
45379209|NCT03247712|Radiation|Radiation (3 days)|8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm
45379210|NCT03237689|Drug|Hydrocortisone|Low dose hydrocortisone (10mg)
45379211|NCT03237689|Drug|Placebo Oral Tablet|capsules of starch 1500 powder
45379212|NCT03235076|Drug|BAY1101042|Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)
45379213|NCT03226106|Behavioral|Physical Activity Behavior Intervention|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and researcher. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
45379214|NCT03226106|Other|Attention Control|Conventional rehabilitation with supplemental 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.
45379215|NCT03224546|Behavioral|Contingency Management|Subjects will receive payments for providing cocaine negative urine samples.
45379216|NCT03213704|Procedure|Biospecimen Collection|Undergo blood sample collection
45379217|NCT03213704|Procedure|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
45379218|NCT03213704|Procedure|Bone Scan|Undergo a bone scan
45379219|NCT03213704|Procedure|Computed Tomography|Undergo a CT scan
45379220|NCT03213704|Drug|Larotrectinib Sulfate|Given PO or via nasogastric- or gastric-tube
46054801|NCT05212545|Dietary Supplement|Placebo|maltodextrin taken daily for 4 weeks with water
46054802|NCT05212545|Dietary Supplement|Prebiotic supplement|Prebiotic supplement taken daily for 4 weeks with water
46054803|NCT05212545|Dietary Supplement|Prebiotic combination|prebiotic oligosaccharides mixture taken daily for 4 weeks with water
46054804|NCT05212545|Dietary Supplement|Prebiotic oligosaccharides|Prebiotic oligosaccharides taken daily for 4 weeks with water
45379221|NCT03213704|Procedure|Magnetic Resonance Imaging|Undergo MRI
45379222|NCT03213704|Procedure|Radionuclide Imaging|Undergo a MIBG scintigraphy
45379223|NCT03213704|Procedure|X-Ray Imaging|Undergo an x-ray
45379224|NCT03213652|Procedure|Biospecimen Collection|Undergo blood sample collection
45379225|NCT03213652|Procedure|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
45379226|NCT03213652|Procedure|Bone Scan|Undergo a bone scan
45379227|NCT03213652|Procedure|Computed Tomography|Undergo a CT scan
45379228|NCT03213652|Drug|Ensartinib|Given PO
45379229|NCT03213652|Other|Laboratory Biomarker Analysis|Correlative studies
45379230|NCT03213652|Procedure|Magnetic Resonance Imaging|Undergo MRI
45495496|NCT05707338|Procedure|Gastrectomy with lymph node dissection|"prospective randomized comparative clinical trial study analyzing outcomes of gastrectomy for early gastric cancer using laporoscopy versus open approach. This will be a prospective comparative study at Sohag University Hospital, Egypt and National Cancer Institute(NCI), Cairo university ,Egypt.~Patients were divided randomizly into two groups; the first group included patients who will have laparoscopic gastrectomy (Lap group), and the second group included patients will receive open gastrectomy (Open group)."
45495497|NCT05707260|Behavioral|CKD SMS|The intervention begins with a face-to-face or digitally assisted session, entry into improving the knowledge and self-management of CKD through, using the four sources of manipulation of self-efficacy (achievement of performance, indirect experience, verbal persuasion, and self-evaluation). In this session, participants will be asked to identify their problems related to CKD and establish, based on these two goals, that they are real and achievable according to their priorities. These goals will be recorded in the monitoring format and will be monitored in the telephone or WhatsApp follow-ups. This using the performance achievement manipulation source, said session lasts 60 minutes, as does the final session at week 16.
46054805|NCT04210830|Diagnostic Test|Quantra-Device|Point of Care Coagulation Monitoring System
46054806|NCT05241756|Device|FLACS using FEMTO LDV-Z8|Performance of femtosecond laser-assisted capsulotomy in the anterior capsule.
45379231|NCT03213652|Other|Pharmacological Study|Correlative studies
45379232|NCT03213652|Procedure|Positron Emission Tomography|Undergo a PET scan
45379233|NCT03213652|Procedure|Radionuclide Imaging|Undergo radionuclide imaging
46054807|NCT05121129|Device|iTBS|25 active iTBS sessions (5 sessions of 9.5 minutes/day, 1,800 pulses per session, 90% of resting motor threshold, placed over the left DLPFC)
46054808|NCT05340543|Procedure|Confocal optical coherence tomography - OCTAVE|"An ex vivo examination of cutaneous resection with the OCTAV® prototype integrating the dermoscope function"
45379234|NCT03213652|Procedure|X-Ray Imaging|Undergo an x-ray
45379235|NCT03208049|Behavioral|Sleep Restriction Therapy|Sleep Restriction Therapy will regulate time spent in bed based on information collected from sleep diaries during evaluation and treatment. Sleep Restriction therapy is designed to improve sleep quality by matching opportunity for sleep to the amount of average total sleep calculated from sleep diaries. Once the quality of sleep has improved, sleep quantity is gradually increased by slowly increasing sleep opportunity. Stimulus control will strengthen the bed/sleep association by eliminating non-sleep activities from the bedroom.
45379236|NCT03208049|Behavioral|Cognitive Therapy|Cognitive Therapy is designed to identify maladaptive beliefs about sleep, challenge their validity, and replace them with more adaptive thinking patterns. This therapy aims to reduce sleep-related worry, anxiety, and fear. The treatment phase of the study lasts six weeks. During treatment, you will meet with a study therapist for a total of six sessions: once per week for six consecutive weeks. Each session lasts approximately 60 minutes.
45379237|NCT03198026|Drug|Ibrutinib|Given PO
45379238|NCT03198026|Drug|Obinutuzumab|Given IV
45379239|NCT03196518|Procedure|PET Imaging|PET/CT study immediately after injection
45379240|NCT03196518|Other|18F-tetrafluoroborate (18F-TFB)|administration of a single dose of approximately 5-10 mCi 18F-TFB (mass <= 50 μg) for imaging purposes
45379241|NCT03165734|Drug|Pacritinib|Oral administration. Supplied in capsules containing 100 mg (as the free base) in red cap/gray body size 0 opaque hard gelatin capsules. The inactive ingredients are microcrystalline cellulose, magnesium stearate, and polyethylene glycol 8000. Each capsule contains 146 mg of pacritinib citrate, which is equivalent to 100 mg pacritinib free base
46054809|NCT05341635|Diagnostic Test|Swab sampling|Collection of three nose-pharyngeal and oral swabs
46054810|NCT05234034|Other|online survey|participantion consists of filling in an online survey that will take approximately 53 minutes. An adapted battery of questionnaires is provided for each subgroup.
46054811|NCT02781441|Behavioral|Question prompt list (QPL)|
45379242|NCT03165734|Drug|Physician's Choice medications|Physician's Choice medications will be selected and administered according to the investigator's judgement. Investigators can select individual P/C agents but cannot combine agents or give them sequentially.
45379243|NCT03127722|Procedure|Blood draw|Decision for either treatment will be based upon clinical practice and physician/patient counseling. In addition of routine care practice, blood draws will be performed at baseline, 12 months and 60 months on subjects undergoing either an ESSURE procedure or a laparoscopic tubal sterilization.
46054812|NCT02781441|Behavioral|Education brochure of Groupe Français des Myélodysplasies|
46054813|NCT05227014|Procedure|Colorectal resection|All patients undergoing elective colorectal surgery with anastomosis will be included in a prospective database after written informed consent.
45379244|NCT03127722|Device|ESSURE (BAY1454032)|Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
45379245|NCT03127722|Procedure|Laparoscopic tubal sterilization|Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
45379246|NCT03125642|Drug|Etoposide|"BEAM: 100 mg/m^2 IV over 2 hours BID on Days -5, -4, -3, -2 | CBV: 150 mg/m^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4"
45379247|NCT03125642|Drug|BCNU|BEAM & CBV: 300 mg/m^2 IV over over 2 hours on Day -6
46054814|NCT04229043|Dietary Supplement|Sports drink|Drink that will be ingested
46054815|NCT04229043|Dietary Supplement|Water|Drink that will be ingested
45495498|NCT05197374|Drug|Estradiol Valerate 4mg|Estradiol valerate 2 mg (two tablet once daily) started 5 days before expected menses (or 7 days after ovulation of previous cycle). After start of menses, estradiol pretreatment was stopped and controlled ovarian stimulation started.
46054816|NCT04230291|Behavioral|Verbal consultation|Verbal consultation only without written information before receiving written action plan
45379248|NCT03125642|Drug|AraC|BEAM: 100 mg/m^2 IV over 1 hour BID on Days -5, -4, -3, -2
45495499|NCT05707104|Other|Pilates Exercises|"NO. Exercises Targeted muscles Repetitions~Pelvic curl Abdominals, Hamstrings & Quadriceps Femoris, Gluteus Maximums. 05~Chest lift Rectus Abdominus, Internal & External Oblique Muscles 10~Leg lift supine Quadriceps Femoris, Internal & External Oblique Muscles 10~Leg lift side Quadriceps Femoris, Posterior Spinal Group, Internal & External Oblique Muscle 10~Leg full side Adductor Longus Brevis, Magnus , gracilis, Pectineus, muscles 10~Spine twist supine Abdominals,Quadriceps & Hamstring group of Muscles 10~Chest lift with rotation Internal & External Oblique, Rectus & Transverses Abdominus Muscles 5 on each side~Back extension BACK EXTENSION Abdominal group, Gluteus Maximus & Hamstrings Muscle 5 each side Rest between exercises 20 seconds Rest between set of exercises 45 to 60 seconds"
45379249|NCT03125642|Drug|Melphalan|BEAM: 140 mg/m^2 IV over 20 minutes on Day -1
45379250|NCT03125642|Procedure|Peripheral blood stem cell transplantation|All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.
45379251|NCT03125642|Biological|G-CSF|All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is >2500 x 10^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm^3
45379252|NCT03125642|Drug|Cyclophosphamide|"CBV: 1.5 gm/M^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 | CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6"
45379253|NCT03125642|Radiation|Total Body Irradiation|CY/TBI: 165 cGy bid on Day -4, -3, -2, -1
46054817|NCT04230291|Behavioral|Written Action Plan|Written handout of treatment plan and disease management strategies
45379254|NCT03104699|Drug|AGEN2034|Anti-PD-1 Monoclonal Antibody
45379255|NCT03082612|Behavioral|Overcoming Psychological Distress through Hymns Intervention|The intervention will consist of participants viewing a selection of video recorded vignettes during 3 weekly sessions. There will be 5 vignettes included in each session with each vignette edited to a real time of 3-4 minutes (each session is 30 minutes). Since the intervention is designed to be self-administered, there will be a video recorded introduction and instructions for use narrated by the PI. The vignettes are of actual African American cancer survivors narrating stories of ways in which hymns can be used to overcome their anxieties and depressed moods through the use of a hymn. The hymns included represent exemplars from the 5 themes prevalent in the PI's previous research
45379256|NCT03082612|Behavioral|Usual care|Usual care includes education to increase cancer knowledge, treatment coaches, and psychological services.
45379257|NCT03060057|Device|U2 Knee™ System|The United U2 Knee™ System consists of several components and for this clinical evaluation it includes the (1) Femoral Component, (2) Tibial Insert, 3) Tibial Baseplate, and the 4) Patella.
45379258|NCT03048825|Drug|Colchicine|Colchicine 0.5 mg once daily
45379259|NCT03048825|Drug|Spironolactone|Spironolactone 25 mg once daily
45379260|NCT03048825|Device|SYNERGY Bioabsorbable Polymer Drug-Eluting Stent|Trial participants who receive a SYNERGY™ Bioabsorbable Polymer Drug-Eluting (everolimus) Stent during their index PCI for STEMI will be included in the SYNERGY Stent Registry.
45379261|NCT03048825|Drug|Colchicine-Placebo|Matching Colchicine-placebo once daily
45379262|NCT03048825|Drug|Spironolactone-Placebo|Matching Spironolactone-Placebo once daily
45379263|NCT03039413|Drug|Copper Cu 64 TP3805|Given IV
45379264|NCT03039413|Procedure|Positron Emission Tomography|Undergo Cu-64-TP3805 Positron Emission Tomography scan
45379265|NCT03039413|Procedure|Computed Tomography|Undergo Cu-64-TP3805 Computed Tomography scan
45379266|NCT03026790|Other|Medication management|Individualized management of medications for pain
45379267|NCT03026790|Other|Non-pharmacological pain management|Individualized management of non-medication pain treatment approaches
45498203|NCT03680664|Behavioral|MBSR|After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice.
46054818|NCT05217654|Drug|Dapagliflozin 10mg|Daily orally administration of 10mg dapagliflozin
46054819|NCT05217654|Drug|Placebo|Daily orally administration of 10mg dapagliflozin-placebo
46054820|NCT05340231|Drug|TACE protocol|"Transarterial infusion chemotherapy: Oxaliplatin(85mg/m^2)+Raltitrexed(3mg) Chemoembolization: Lipiodol emulsion (lipiodol 10ml+ Oxaliplatin 85mg +Lidocaine 1ml)，The endpoint for embolization was defined as stagnation of blood flow of the posterior mesenteric artery.~Intervention cycle：4W; Treatment times: 2. followed by mFOLFOX6"
46054821|NCT05340231|Drug|Neoadjuvant Chemotherapy|mFOLFOX6, Q2W
46054822|NCT04202016|Procedure|Piezocision Surgery|After a surgical cut using #15 surgical blade 2-3 mm distal to the canine a pizocision using piezo-surgery device is made.
46054823|NCT04229355|Drug|DEB-TACE plus Sorafenib|Drug-eluting bead transarterial chemoembolization plus sorafenib (400 mg/d, po, bid)
46054824|NCT04229355|Drug|DEB-TACE plus Lenvatinib|Drug-eluting bead transarterial chemoembolization plus lenvatinib (8 mg/d, po, qd)
46054825|NCT04229355|Drug|DEB-TACE plus PD-1 inhibitor|Drug-eluting bead transarterial chemoembolization plus PD-1 inhibitor
46054826|NCT02848170|Drug|CS-3150|CS-3150 2.5mg, oral
45379268|NCT03026790|Drug|Buprenorphine-Naloxone|Option of using buprenorphine-naloxone to assist with opioid dose reduction or discontinuation
45379269|NCT03020823|Drug|SCB01A|intra-subject dose escalation, 12, 18, 24 mg/m2, 24h-IV infusion (in the vein) on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
45379270|NCT02998528|Biological|Nivolumab|Specified dose on specified days
45495500|NCT05707104|Other|plyometrics exercises|"SIDE TO SIDE ANKLE HOPS STANDING JUMP AND REACH FRONT CONE HOPS 2×15 2×15 5×6~SIDE TO SIDE ANKLE HOPS STANDING JUMP LATERAL JUMP BARRIER 2×15 5×6 2×15~DOUBLE LEG HOPS LATERAL CONE HOPS 5×8 2×12~DIAGONAL CONE HOPS LATERAL SPRINT 4×8 4×8~LATERAL CONE HOPS SINGLE LEG BOUNDING LATERAL JUMP SINGLE LEG 4×12 4×7 4×7~DIAGONAL CONE HOPS HEXAGONAL DRILL CONE HOPS WITH CHANGE OF DIRECTION SPRINT DOUBLE LEG HOPS LATERAL JUMP SINGLE LEG 2×12 2×12 4×6 3×8 4×6"
45379271|NCT02998528|Drug|Cisplatin|Specified dose on specified days
45379272|NCT02998528|Drug|Vinorelbine|Specified dose on specified days
45379273|NCT02998528|Drug|Gemcitabine|Specified dose on specified days
45379274|NCT02998528|Drug|Docetaxel|Specified dose on specified days
45495501|NCT02951819|Drug|Daratumumab|"For induction therapy cycle 1 day 1 and day 2 doses of daratumumab will be 8 milligram/kilogram (mg/kg). Starting cycle 1 week 2 until the completion of week 8 of daratumumab patients will receive 16 mg/kg Intravenously (IV) weekly.~Starting week 9 until the completion of week 24 therapy daratumumab will be administered every other week at 16 mg/kg IV.~Starting week 25 and beyond for induction therapy daratumumab will be given once every 4 weeks."
45495502|NCT02951819|Drug|Cyclophosphamide|Subjects will receive 4 to 8 cycles of oral cyclophosphamide 300 milligram per meter square (mg/m^2 ) on Days 1, 8, 15, and 22 for every 28 days.
45495503|NCT02951819|Drug|Bortezomib|Subjects will receive 4 to 8 cycles of Bortezomib 1.5 mg/m2 subcutaneous (SC) on Days 1, 8, and 15 for every 28 days.
45495504|NCT02951819|Drug|Dexamethasone|Subjects will be given corticosteroids (Dexamethasone) as pre-infusion therapy prior to daratumumab and for the first 8 cycles will also receive post-infusion corticosteroids (Dexamethasone).
45379275|NCT02998528|Drug|Pemetrexed|Specified dose on specified days
45379276|NCT02998528|Drug|Carboplatin|Specified dose on specified days
45379277|NCT02998528|Drug|Paclitaxel|Specified dose on specified days
45379278|NCT02998528|Biological|Ipilimumab|This arm is closed and no longer enrolling patients.
45379279|NCT02974725|Drug|LXH254|LXH254 will be supplied as tablet for oral use.
45379280|NCT02974725|Drug|LTT462|LTT462 will be supplied as hard gelatin capsule for oral use.
45495505|NCT05481827|Genetic|GT005|GT005 is a gene therapy for GA and is a recombinant adeno-associated viral serotype 2 (AAV2) vector encoding for human complement factor I.
45379281|NCT02974725|Drug|Trametinib|Trametinib will be supplied as film-coated tablet for oral use
45379282|NCT02974725|Drug|LXH254|Trametinib will be supplied as film-coated tablet for oral use
45379283|NCT02974725|Drug|Ribociclib|Ribociclib will be supplied in tablets and hard gelatin capsules.
45379284|NCT02969369|Drug|SEP-363856|SEP-363856 (25, 50, or 75mg/day)
45379285|NCT02969369|Drug|Placebo capsule|Placebo once daily
45379286|NCT02955290|Other|Laboratory Biomarker Analysis|Correlative studies
45379287|NCT02955290|Biological|Nivolumab|Given IV
45498204|NCT04878471|Drug|Pudexacianinium chloride|Intravenous
45379288|NCT02955290|Biological|Pembrolizumab|Given IV
45379289|NCT02955290|Biological|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given CIMAvax IM
45379290|NCT02948036|Other|Mobile-device, plasticity-based adaptive cognitive treatment|This study employs a mobile-device delivered treatment program. Participants will be asked to use the assigned treatment program for approximately 30 minutes per session, up to seven sessions per week, over 6 weeks (42 total sessions).
45379291|NCT02926911|Other|Surgery|Surgery +/- radiation choice for endocrine therapy
45379292|NCT02926911|Other|Active Monitoring|Choice for endocrine therapy
45379293|NCT02848001|Drug|CC-90009|CC-90009
45847281|NCT04569942|Other|Fluids|An fluid bolus of up to 1000ml will be administered over a maximum of 1 hour, if required, for persisting hypotension and/or hypoperfusion. Reassess at least hourly to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Further IV fluid boluses of 500ml are recommended as clinically indicated to achieve the target MAP. The target MAP will be determined by the treating clinician. Haemodynamic resuscitation will be guided by usual clinical assessment including vital signs, mentation, perfusion, and urine output until the treating clinician determines fluid resuscitation is no longer clinically required. A minimum of 2-3 L (30 ml/kg), including pre-randomisation fluids, is recommended within 3 hours of ED arrival consistent with the SSC guidelines, unless clinically contraindicated. Vasopressors may be commenced if blood pressure remains below target despite optimal fluid resuscitation as determined by the treating clinician.
45495506|NCT03707717|Drug|Bimekizumab|Subjects will receive a pre-specified sequence of bimekzumab in the Treatment Period.
45847282|NCT04532658|Behavioral|Coaching program|"Charting system for outcomes feedback~Profiling of individual surgeon~Modules of improvement"
45495507|NCT05191290|Drug|unfractionated heparin|standard heparin at 2500 IU i.v. bolus and then 2000 IU/h continuously i.v. for anticoagulation during plasmapheresis
45495508|NCT05191290|Drug|Sodium Citrate|8% sodium citrate at approx. 27 mmol/h i.v. for anticoagulation during plasmapheresis
45847283|NCT04522206|Drug|Pre-op Multimodal analgesia (MMA) regimen + standard post-op oxycodone|"The study subjects will be assigned to the defined pre-op MMA regimen with standard postop oxycodone based pain control regimen given on an as needed basis. The treatment group outcomes will be compared to patients outside of the study including a historical control group (receiving only post-op pain regimen) prior to the implementation of the new regimen. The studied treatment group will receive within 3 hours before surgery an oral MMA regimen consisting of:~Acetaminophen 975 mg Celecoxib 200 mg Gabapentin 300 mg Oxycodone 10 mg Extended Release"
45847284|NCT04519944|Drug|Edoxaban|This is an observational, prospective study; no treatment will be administered.
45495509|NCT05627544|Procedure|Anesthesia management/Hip replacement surgery|The effect of anesthesia management on blood transfusion practices in hip replacement surgeries
45495510|NCT05627544|Procedure|Demographic data|The effect of demographic data on blood transfusion practices in hip replacement surgeries
45495511|NCT05627544|Procedure|Chronic diseases|The effect of chronic diseases on blood transfusion practices in hip replacement surgeries
45495512|NCT05627544|Procedure|Postoperative complication|The effect of blood transfusion applications on postoperative complications in hip replacement surgeries
45495513|NCT05707026|Other|cross fiber fascial manipulation|The group A received three sessions of fascial manipulation in two weeks. FM applied for 5 to 8 minutes at each point.
45495514|NCT05707026|Other|stretching techniques(sleeper stretch and cross body adduction stretch)|Group B received three sessions of sleeper and cross body adduction stretches. Group B received three sessions of sleeper stretch in a side lying position in 90o abduction, elbow at 90o flexion and then performing shoulder IR and cross-body adduction stretch was done in sitting position. Three sets of the each stretch position were held for 30 seconds with a 1 minute break between sets.
45495515|NCT05189028|Drug|gemcitabine and cisplatin|Neoadjuvant chemotherapy:gemcitabine and cisplatin
45847285|NCT04510116|Behavioral|Adults in the Making program|The AIM prevention program, modeled after an existing family-based skills-training intervention in a group format for rural African American preadolescents, consists of six consecutive weekly group meetings held at community facilities, with separate parent and youth skill-building curricula and a family curriculum. Each of the six meetings includes separate, concurrent training sessions for parents and youth, followed by a joint parent-youth session during which the families practice the skills they learned in their separate sessions. Concurrent and family sessions each last 1 hour. Thus, both parents and youth receive 12 hours of prevention training.
46054827|NCT02848170|Drug|olmesartan medoxomil|olmesartan medoxomil 10 mg, oral
45379294|NCT02777879|Procedure|Bronchoscopy|Flexible bronchoscopy with bronchoalveolar lavage (BAL) and bronchial brushings will be done in a standardized manner. The bronchoscope tip is sequentially wedged in sub-segments where BAL will be performed on a total of two segments of the lung (120 ml in each segment for a total of 360 ml). Two brushes will be done under direct visualization in both segments. Selection of segments to sample will be based on where abnormalities are in imaging.
45379295|NCT02770326|Biological|Fecal Microbiota Transplantation (FMT)|
45379296|NCT02764801|Drug|Ultrasound contrast agent (Contrast-enhanced ultrasound)|Intravenous injection of ultrasound contrast agent followed by saline flush though an angiocatheter in the arm or hand.
45379297|NCT02764801|Device|Logiq E9 Scanner (Contrast-enhanced ultrasound)|Ultrasound scanning using a commercial scanner with a C1-5-D broad-spectrum convex transducer followed by a RAB2-5-D broad-spectrum real-time 4D transducer.
45379298|NCT02761499|Device|U-Motion II+ Acetabular System|U-Motion II+ Acetabular System (1) U-Motion II+ acetabular cup, (2) U-Motion II+ acetabular liner, (3) Cobalt-Chrome or BIOLOX delta ceramic femoral heads, and the 4) UTF Reduced Stem
45379299|NCT02735707|Drug|Ceftriaxone|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
45847286|NCT04505592|Drug|Tenecteplase|First 20 patients randomized to treatment arm will receive 0.25 mg/kg of tenecteplase. Next 20 patients randomized to treatment arm will receive 0.50 mg/kg of tenecteplase. Both will receive concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
46054828|NCT05341479|Procedure|Surgery for early-stage OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Early-stage OPC patients (T1-2,N0) enrolled in this group will be treated with surgical resection. The surgical techniques of the primary tumor include transoral robotic surgery, conventional transoral surgery, transoral laser microsurgery (e.g., CO2 laser resection), and open surgery. Ipsilateral neck dissection should be performed for patients enrolled in this group. For patients with OPC at or approaching the midline, bilateral neck dissection should be strongly considered.~Postoperative radiotherapy (RT) or system therapy/RT should be considered for patients with adverse features (e.g., extranodal extension, perineural invasion or vascular invasion)."
46054829|NCT05341479|Radiation|RT for early-stage OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Early-stage OPC patients (T1-2,N0) enrolled in this group will be treated with RT."
45495516|NCT05609058|Device|dedicated treatment board with no degree|the patients were placed in the prone position on a dedicated treatment board with no degree incline using an arm support (with both arms above the head). Te board contained an open aperture on one side to allow for the ipsilateral breast to hang freely away from the chest wall
46054830|NCT05341479|Radiation|CRT for advanced OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with CRT."
45379300|NCT02735707|Drug|Moxifloxacin or Levofloxacin|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
45379301|NCT02735707|Drug|Piperacillin-tazobactam|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
45379302|NCT02735707|Drug|Ceftaroline|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
45379303|NCT02735707|Drug|Amoxicillin-clavulanate|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
45379304|NCT02735707|Drug|Standard course macrolide|"Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5.~The dosing of and route of administration is not protocolised, the following guidance is provided:~Initial IV administration of a macrolide is strongly preferred~The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.~The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted."
45498205|NCT04878471|Drug|Placebo|Intravenous
45753992|NCT00565669|Drug|Cyclosporin A Restasis®|
45753993|NCT00565669|Drug|Blink tears|blink tears to be used twice a day
45753994|NCT00565669|Drug|Systane|systane to be used twice a day
45753995|NCT00453479|Drug|GSK233705B|
45847287|NCT04505592|Drug|Placebo|Patients will receive placebo with concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
45847288|NCT04460508|Drug|Pegylated rhG-CSF|Pegylated rhG-CSF:6mg
45847289|NCT04460508|Drug|rhG-CSF|rhG-CSF:5ug/kg/d
45379305|NCT02735707|Drug|Extended course macrolide|"Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first).~The dosing of and route of administration is not protocolised, the following guidance is provided:~Initial IV administration of a macrolide is strongly preferred~The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.~The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted."
45379306|NCT02735707|Other|No systemic corticosteroid|Patients are not to receive any systemic corticosteroids, including hydrocortisone, to study day 28 or hospital discharge (whichever occurs first).
45693827|NCT04550143|Other|Airway occlusion pressure (P0.1)|"P0.1 is the pressure developed in the occluded airway 100 milliseconds after the onset of inspiration. Its use doesn't require any additional equipment since it can be easy measured by using patient's ventilator.~For the measurement itself, patients will be in semi-recumbent position (head elevation between 30° and 45°) with knee extended in neutral position and will be asked to stay as relaxed as possible. After 5 minutes breathing without any interruption or disturbance, 4 measurements will be observed and recorded as displayed on the ventilator screen."
45693828|NCT04550143|Other|Medical Research Council (MRC) sum score|"This is a manual muscle strength testing tool, used very often in the ICU setting. It's based on the assessment of the following muscle groups: shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, and dorsiflexion of the ankle, all scored bilaterally. Muscle strength is graded as follows: 0, no visible/palpable contraction; 1, visible/palpable contraction without movement of the limb; 2, movement of the limb, but not against gravity; 3, movement against gravity; 4, movement against gravity and some resistance; 5, normal.~The sum score ranges between 0 and 60 (between 0 and 5, in 12 muscle groups), with a score <48 indicating the presence of weakness."
45379307|NCT02735707|Drug|Fixed-duration Hydrocortisone|50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.
45379308|NCT02735707|Drug|Shock-dependent hydrocortisone|50mg IV hydrocortisone every 6 hours while the patient is in septic shock
45379309|NCT02735707|Drug|Fixed-duration higher dose Hydrocortisone|"100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.~Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed."
45379310|NCT02735707|Other|No antiviral agent for influenza|No antiviral agent intended to be active against influenza infection is to be administered
45379311|NCT02735707|Drug|Five-days oseltamivir|Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)
45379312|NCT02735707|Drug|Ten-days oseltamivir|Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)
45379313|NCT02735707|Other|No antiviral agent for COVID-19|No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
46054831|NCT05341479|Other|Surgery for advanced OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with surgical resection. The surgical techniques of the primary tumor include transoral robotic surgery, conventional transoral surgery, transoral laser microsurgery, and open surgery. Ipsilateral neck dissection should be performed for patients enrolled in this group. For patients with OPC at or approaching the midline, bilateral neck dissection should be strongly considered.~Postoperative radiotherapy (RT) or system therapy/RT should be considered for patients with adverse features (e.g., pT3 or pT4 primary, pN2 or pN3 nodal disease, extranodal extension, or vascular invasion)."
46054832|NCT05341479|Procedure|Neoadjuvant treatment for advanced OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with neoadjuvant treatment. The subsequent treatments include RT, system therapy/RT, and surgical resection with or without postoperative adjuvant therapy."
45379314|NCT02735707|Drug|Lopinavir / Ritonavir|"Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.~Note: this intervention is now closed."
45379315|NCT02735707|Drug|Hydroxychloroquine|"Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).~Note: this intervention is now closed."
45693829|NCT04556695|Other|Questionnaire survey|Online questionnaire, based on the International Sedentary Assessment Tool (ISAT)
45693830|NCT04556695|Device|Accelerometer study|Consenting participants will be asked to wear an accelerometer on the lateral aspect of the middle of the right thigh (over the midpoint of the iliotibial band), continuously over a seven-day period.
45753996|NCT04148378|Other|No intervention|There is no intervention for this study.
45847290|NCT04415892|Other|Cinnamaldehyde and capsaicin|Topical application of cinnamaldehyde and capsaicin on the fingers
46054833|NCT04202172|Procedure|Stent implantation in the infart-related artery in patients with ST elevation myocardial infarction|"The 6-month scheduled coronary angiography will perform 3 interventions:~Endothelial function assessment with intracoronary acetyl-choline infusion.~Microcirculatory function assessment with a pressure wire during endovenous adenosine infusion.~Stent healing assessment using optical coherence tomography"
45379316|NCT02735707|Drug|Hydroxychloroquine + lopinavir/ritonavir|"Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.~Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).~Note: this intervention is now closed."
45379317|NCT02735707|Drug|Ivermectin|Ivermectin administered enterally at a dose of 0.2 mg/kg once daily with a maximum daily dose of 24mg/day.
45379318|NCT02735707|Other|No immune modulation for COVID-19|"No immune modulating agent intended to be active against COVID-19 is to be administered.~Note: this intervention is now closed."
45379319|NCT02735707|Drug|Interferon beta-1a|"IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first.~Note: this intervention is now closed."
45379320|NCT02735707|Drug|Anakinra|"A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered every 6 hours.~In patients with renal impairment, anakinra will be administered on alternate days.~Note: this intervention is now closed."
45379321|NCT02735707|Drug|Tocilizumab|"Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg.~Note: this intervention is now closed.~Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period."
45379322|NCT02735707|Drug|Sarilumab|"Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period.~Note: this intervention is now closed."
45379323|NCT02735707|Drug|Local standard venous thromboprophylaxis|"Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
45379324|NCT02735707|Drug|Therapeutic dose anticoagulation|"Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician.~Note: this intervention is now closed."
45379325|NCT02735707|Drug|Conventional low dose thromboprophylaxis|Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
45379326|NCT02735707|Drug|Intermediate dose thromboprophylaxis|Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
45379327|NCT02735707|Drug|Continuation of therapeutic dose anticoagulation|Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first.
45379328|NCT02735707|Other|No immunoglobulin|"No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered.~Note: this intervention is now closed."
45379329|NCT02735707|Biological|Convalescent plasma|"Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation.~Note: this intervention is now closed."
45379330|NCT02735707|Biological|Delayed administration of convalescent plasma|Note: this intervention is now closed.
45379331|NCT02735707|Other|No vitamin C|No high dose intravenous vitamin C is to be administered
45379332|NCT02735707|Drug|Vitamin C|Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses
45379333|NCT02735707|Other|No antiplatelet|"No antiplatelet agent or NSAID to be administered.~Note: this intervention is now closed."
45847291|NCT04299048|Drug|PF-06946860|subcutaneous injection
46054834|NCT02848404|Device|Categorical Language Fluency Smartphone Application|4 weeks' training
45847292|NCT04272060|Diagnostic Test|CT angiography|Diagnostic CT angiography
46054835|NCT02782767|Other|Wound catheter infusion|Wound catheter has multiple holes spread around 360 degrees throughout its active length. It is placed in the musculofascial plane during closure of the wound. Local anaesthetic infusion will be delivered through the catheter.
46054836|NCT02782767|Other|Epidural infusion|Epidural catheter will be placed in the level T7-T9 , and local anaesthetic infusion will be given
46054837|NCT02782845|Drug|Chemotherapy|The choice of CT will be as per standard of care and protocol does not specify any particular CT drug.
45379334|NCT02735707|Drug|Aspirin|"Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
45379335|NCT02735707|Drug|P2Y12 inhibitor|"Site-selected P2Y12 inhibitor:~Clopidogrel: administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first.~Prasugrel: If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day.~Ticagrelor: administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
45379336|NCT02735707|Other|No simvastatin|No simvastatin intended to be active against COVID-19 is to be administered
45379337|NCT02735707|Drug|Simvastatin|Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation
45379338|NCT02735707|Other|Placebo|
45379339|NCT02735707|Drug|Eritoran|Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital
45379340|NCT02735707|Drug|Apremilast|"Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
45379341|NCT02735707|Procedure|Clinician-preferred mechanical ventilation strategy|Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters
45379342|NCT02735707|Procedure|Protocolised mechanical ventilation strategy|Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain.
45379343|NCT02735707|Other|No renin-angiotensin system inhibitor|No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10.
45379344|NCT02735707|Drug|Angiotensin converting enzyme inhibitor|Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.
45498206|NCT03684720|Other|Discover followed by direct instruction [DD]|The intervention group will be taught suturing using the principles of guided-discovery-learning. In its simplest form, this means allowing the participants to practice placing a simple interrupted suture using the materials needed, as well as a picture of a finished suture. They must then draw from their own learning experiences, as well as discover for themselves how to do it. After a discovery period, an instructor will then teach them, how to place a simple interrupted suture, and will them guide them, as they begin to practice again.
45693831|NCT04556695|Other|Semi-structured interview study|Semi-structured interviews will take place via telephone or webcam. Participants will be given feedback regarding their accelerometer data relating to their levels of physical activity and sedentary behaviour. Questions will examine participants' thoughts and opinions regarding sedentary behaviour and physical activity in the General Practice setting. Further questions will explore participants' experiences of wearing accelerometers, their knowledge of and attitudes towards physical activity and sedentary behaviour and their thoughts or suggestions on interventions to reduce sedentary behaviour among GPs and GPSTs.
45693832|NCT01703845|Drug|Tiotropium (high dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
45693833|NCT01703845|Drug|Tiotropium (low dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
45693834|NCT04556383|Drug|GB004|GB004, a small molecule hypoxia inducible factor 1 alpha (HIF-1α) stabilizer
45693835|NCT04556383|Drug|Placebo|Placebo
45693836|NCT01724359|Drug|Paliperidone ER|The recommended Paliperidone extended-release (ER) dose will be 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily. Adjustment of the dosage will be done at the investigator's discretion.
46054838|NCT02782845|Drug|Immunochemotherapy|The choice of ICT will be as per standard of care and protocol does not specify any particular ICT drug.
46054839|NCT02782845|Drug|Pegfilgrastim|Pegfilgrastim will be administered at a fixed dose of 6 mg subcutaneously 24 hours after the last dose of CT or ICT is received for 6 cycles.
46054840|NCT04420884|Drug|TAK-676|TAK-676 intravenous Infusion.
46054841|NCT04420884|Drug|Pembrolizumab|Pembrolizumab intravenous Infusion.
46054842|NCT04420884|Drug|Platinum|Carboplatin or Cisplatin intravenous infusion
46054843|NCT04420884|Drug|5-fluorouracil|5-fluorouracil intravenous infusion
46054844|NCT05341401|Drug|Budesonide MMX|Budesonide MMX is a second generator corticosteroid with prolonged colonic release used for management of ulcerative colitis
45379345|NCT02735707|Drug|Angiotensin Receptor Blockers|Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.
45379346|NCT02735707|Drug|ARB + DMX-200|"Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first.~ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily."
45379347|NCT02735707|Other|No cysteamine|No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first.
45379348|NCT02735707|Drug|Cysteamine|Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first.
45379349|NCT02735707|Drug|Fixed-duration dexamethasone|6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital.
45379350|NCT02735707|Drug|Baloxavir Marboxil|Baloxavir marboxil administered on days 1 and 4 post-randomisation.
45379351|NCT02735707|Drug|Five-days oseltamivir + baloxavir marboxil|Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
45379352|NCT02735707|Drug|Ten-days oseltamivir + baloxavir marboxil|Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
45379353|NCT02735707|Other|No endothelial modulator|No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered.
45379354|NCT02735707|Drug|Imatinib|Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge.
45379355|NCT02703246|Procedure|abdominal morcellation|patients will be randomized to receive abdominal morcellation
45379356|NCT02703246|Procedure|vaginal morcellation|patients will be randomized to receive vaginal morcellation
45379357|NCT02697448|Drug|propofol|Participant receives propofol as anesthetic for cardiac ablation.
45379358|NCT02697448|Drug|sevoflurane|Participant receives sevoflurane as anesthetic for cardiac ablations.
45379359|NCT02670837|Device|Cellutome Epidermal Harvesting System|
45379360|NCT02664610|Behavioral|Text Messaging|hypertensive participants will be randomized to receive tailored, motivational text messages
45379361|NCT02647203|Drug|Self-administered fluoridated dentifrices|Elderly participants will be instructed to self administer toothpastes, twice per day. Toothpastes will be provided.
45379362|NCT02637973|Drug|Empagliflozin|25 mg once daily
45498207|NCT04877379|Drug|VNRX-7145|β-lactamase inhibitor
45693837|NCT01703221|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
45693838|NCT01703221|Drug|Sitagliptin|Sitagliptin 50 mg tablet administered orally once daily
45379363|NCT02637973|Drug|Placebo|once daily
45379364|NCT02583269|Diagnostic Test|Laboratory Biomarker Analysis|Correlative studies
45379365|NCT02583269|Drug|Muscadine Grape Skin Extract|Given PO
45379366|NCT02583269|Procedure|Quality-of-Life Assessment|Ancillary studies
45379367|NCT02575794|Drug|Terameprocol|Given PO
45379368|NCT02575794|Other|Pharmacological Study|Correlative studies
45379369|NCT02546921|Drug|MOv18 IgE|The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.
45379370|NCT02546921|Drug|MOv18 IgE|The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
45379371|NCT02546921|Drug|MOv18 IgE|The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
45379372|NCT02546921|Drug|MOv18 IgE|The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
45498208|NCT04877379|Drug|VNRX-5024 (ceftibuten)|β-lactam antibiotic
45498209|NCT04877379|Drug|Placebo|Placebo
45498210|NCT03684486|Behavioral|rehabilitation by effort|
45498211|NCT01382745|Drug|Nimotuzumab|200mg Nimotuzumab once a week for 12 weeks
45693839|NCT01703221|Drug|Placebo to omarigliptin|Placebo to omarigliptin 25 mg capsule administered orally once weekly
45693840|NCT01703221|Drug|Placebo to sitagliptin|Placebo to sitagliptin 50 mg tablet administered orally once daily
45847293|NCT04272060|Diagnostic Test|Invasive coronary angiography|Diagnostic invasive coronary angiography
46054845|NCT05341401|Drug|Prednisolone|It is a corticosteroid used as a standard therapy for management of ulcerative colitis
46054846|NCT05337072|Diagnostic Test|Microbiome study|Investigation of the vaginal and endometrial microbiome
45379373|NCT02546921|Drug|MOv18 IgE|The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
45379374|NCT02546921|Drug|MOv18 IgE|The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
45379375|NCT02546921|Drug|MOv18 IgE|"Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks.~Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE.~Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment."
45379376|NCT02527681|Drug|Ceftobiprole medocaril|Ceftobiprole medocaril was administered as a single intravenous infusion, with a bodyweight-adjusted volume, at a constant rate over 4 hours. The ceftobiprole dose was 7.5 mg/kg, which corresponds to 10.0 mg ceftobiprole medocaril.
45379377|NCT02516696|Drug|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle.
45379378|NCT02516696|Drug|Lenalidomide|25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle
45379379|NCT02516696|Drug|Dexamethasone|20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.
45379380|NCT02513329|Drug|Bupivicaine|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive bupivacaine. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.10 mL .5% bupivicaine will be administered.
45379381|NCT02513329|Drug|Saline|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card. 5 mL sterile normal saline will be administered.
45379382|NCT02425826|Drug|Apremilast|Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
45379383|NCT02425826|Drug|Placebo|Participants randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally BID for from weeks 0-16.
45379384|NCT02425826|Drug|Placebo-Apremilast|At Week 16, those randomized to placebo were switched to apremilast 30mg BID for an additional 36 weeks (52 weeks total)
45495517|NCT05169606|Other|Tissue Flossing|Tissue flossing is a technique that requires wrapping of a thick rubber band around a joint or muscle concomitantly performing ROM tasks for 1-3 minutes. The results include increase in range of motion and a decrease in pain of the effected muscles. The phenomenon behind getting results through this technique is hypothesized to be blood reperfusion to an occluded area via tissue flossing augments exercise performance mechanisms such as growth hormone, catecholamine responses, muscle force contractility and the efficiency of excitation-contraction coupling in the muscles. In addition, tissue flossing may influence fascia tightness via the fascial mechanoreceptors, therefore reducing muscle activity, resulting in a greater ROM. Nevertheless, the underlying mechanism for tissue flossing, these mechanisms remain speculative.
45693841|NCT01722877|Device|JetStream Navitus|Study to use Jetstream device for use of in-stent restenosis in femoral popliteal artery.
45693842|NCT00822094|Drug|CPX-351|
45693843|NCT00822094|Drug|Intensive Salvage Therapy|
46054847|NCT05340153|Drug|Artemether-Lumefantrine Drug Combination|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains 1 blister of 12 tablets. It will be administered each day as two, four, six or eight tablets depending on the weight of the child.
46054848|NCT05340153|Drug|Dihydroartemisinin-Piperaquine drug combination|Dihydroartemisinin-piperaquine is a formulated as tablets and will be provided in blister packs. Each tablet contains 40 mg dihydroartemisinin and 320 mg piperaquine. Every pack has a picture showing how the drug should be given and contains 1 blister of 6 tablets. It will be given each day as a half, one, two or three tablets depending on the weight of the child.
46054849|NCT00902850|Device|SofLens Daily Disposable|Lenses to be worn for 8-16 hours
45379385|NCT02406027|Drug|JNJ-54861911, 10 mg|Participants will self-administer JNJ-54861911 tablet, 10 mg (2*5 mg), orally, once daily.
45379386|NCT02406027|Drug|JNJ-54861911, 25 mg|Participants will self-administer 1 tablet of JNJ-54861911, containing 25 mg orally, once daily.
45379387|NCT02406027|Drug|Placebo|Participants will self administer placebo matching to JNJ-54861911 orally once daily.
45498212|NCT01382745|Radiation|Intensity Modulated Radiation Therapy (IMRT)|IMRT radiation therapy with doses varying from 45Gy-54Gy in 25-30 fractions
45693844|NCT00822328|Dietary Supplement|Yakult®300|"Yakult®300 was given 100 ml once per day for four weeks.~Fermented or unfermented milk per 100 ml bottle per day for four week."
45693845|NCT00822328|Dietary Supplement|Lactobacillus casei strain Shirota|Lactobacillus casei strain Shirota
45847294|NCT04256070|Behavioral|education and tele-consultation|education and tele-consultation based on Watson's Human Care Theory
46054850|NCT00902850|Device|Marketed 1 Day Contact Lens|Lenses to be worn for 8-16 hours
46054851|NCT05078502|Dietary Supplement|Vitamin D3|One capsule of vitamin D3(40000IU) weekly for 8 weeks
45379388|NCT02406027|Drug|JNJ-54861911, 5 mg|Participants will self-administer JNJ-54861911 tablet, 5 mg, orally, once daily.
45379389|NCT02386774|Device|Handheld IVCM Vivascope 3000 (Caliber/Mavig) anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml|used anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml
45379390|NCT02386774|Device|Multifluorescence IVCM vivascope 1500 ML (Caliber/Mavig)|"used for Multifluorescence IVCM~anesthesic eyedrop : oxybuprocaïne (1,6 mg/0,4 ml)~Fluorescein 0,5%, Rose Bengal , Infracyanine"
45379391|NCT02386774|Procedure|microangiography|realization of the microangiography with intravenous injection of fluoresceine and indocyanine green.
45379392|NCT02384434|Device|THOR Laser System for Low Level Laser Therapy (LLLT)|Non-invasive, a cold laser output treatment.
45379393|NCT02380092|Device|LEGION™ Primary TKS with VERILAST™ Bearing Surface|All study subjects will be treated with LEGION™ Primary TKS with VERILAST™ Bearing Surface as per standard clinical practice.
45379394|NCT02354651|Other|Diaphragm conditioning via phrenic nerve stimulation|Diaphragm pacing will be prescribed by the patient's clinical team.
45379395|NCT02315612|Biological|CD22-CAR|CD22-CAR cells will be infused on Day 0 after induction chemotherapy regimen.
45379396|NCT02278120|Drug|LEE011|LEE011 600 mg daily oral
45379397|NCT02278120|Drug|Tamoxifen|tamoxifen 20 mg daily oral
45379398|NCT02278120|Drug|Letrozole|letrozole 2.5 mg daily oral
45379399|NCT02278120|Drug|Anastrozole|anastrozole 1 mg daily oral
45379400|NCT02278120|Drug|Goserelin|Goserelin 3.6 mg subcutaneous injection
45379401|NCT02278120|Drug|LEE011 Placebo|LEE011 placebo 600 mg daily oral
45379402|NCT02274155|Drug|Anti-OX40 antibody administration|Anti-OX40 antibody administration at 0.4 mg/kg IV x 3 doses given on Days 1, 3 or 4, and 5 or 6 of study
45379403|NCT02274155|Procedure|Surgical Resection|Surgical Resection of Tumor
45379404|NCT02255357|Drug|Placebo|Solution containing only the excipients of the original solution without Oxytocin.
45379405|NCT02255357|Drug|Intranasal Oxytocin|solution containing Oxytocin 6 IU/0.1cc or per puff is used in this arm
45379406|NCT02217943|Procedure|Roux-en-Y gastric bypass|
45379407|NCT02217943|Procedure|Sleeve gastrectomy|
45379408|NCT02211131|Drug|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection into the injectable cutaneous, subcutaneous, and nodal tumors initially at a dose of 10^6 plaque forming units (PFU)/mL at day 1 of week 1 followed by a dose of 10^8 PFU/mL at day 1 (±3 days) of week 4, 6, 8, 10 and 12 or until all injectable tumors have disappeared, or intolerance of study treatment or in the opinion of the investigator, immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first.
45379409|NCT02211131|Procedure|Immediate surgical resection of melanoma lesion(s)|Surgical resection of melanoma tumor lesion(s) will be performed after randomization any time during weeks 1 to 6.
45379410|NCT02155647|Drug|Avelumab|Avelumab was administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
45379411|NCT02153619|Behavioral|Meaning-Centered Grief Therapy (MCGT)|MCGT is a manualized, one-on-one intervention that uses psychoeducation, experiential exercises, and homework focusing on themes related to meaning, identity, purpose, and legacy. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention (see Appendix I). Participants randomized to MCGT will provide their feedback about MCGT and the measures (n = 33).
45379412|NCT02153619|Behavioral|Supportive Psychotherapy (SP)|"SP is the comparison condition in this study and is a standardized, manualized intervention developed by the MSK Psychiatry Service and utilized in our completed and ongoing RCTs of Meaning-Centered Psychotherapy."
45379413|NCT02153619|Behavioral|questionnaires assessments|
46054852|NCT02780739|Behavioral|Cognitive Training - 48 sessions|Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
46054853|NCT02780739|Behavioral|Fitness|Based on high intensity cardiovascular resistance training (HICRT), this intervention includes a combination of aerobic and strength training. Sessions are conducted in a group of ≤20 participants per class, with ≤5 participants per trainer. This intervention includes 28 70-min sessions (32.67 hrs) completed over 16 weeks: 3/wk weeks 1-4, 2/wk weeks 5-8, 1/wk weeks 9-16. At the first and last session, participants complete the Army Physical Readiness Test. All other sessions consist of: Warm-up; Walk/Run; 2 HICRT circuits with 3 sets of 3-4 exercises; 1-2 min jump rope and 4-min power series between HICRT segments; Drills & Skills; and Cool-down/stretch.
45379414|NCT02134587|Other|Multifaceted educational intervention|"Application of questionnaire of knowledge, attitudes and skills in pharmacovigilance.~Lecture regarding the theoretical framework and importance of pharmacovigilance, and distribution of educational material~Distribution of educational material~Practical class to explain the correct fill of adverse drug events form~Reapplication of questionnaire of knowledge, attitudes and skills in pharmacovigilance."
45379415|NCT02125786|Radiation|Irradiation|Radiation therapy on this protocol will be based on extent of disease, extent of resection and location. The allowed treatment modalities include conformal or intensity-modulated radiation therapy using photons or proton therapy using double-scattering or spot-scanning methods. The general goal is to initiate radiation therapy within 12 weeks of last surgery performed at the time of recurrence.
45379416|NCT02125786|Procedure|Surgery|When applicable, surgery will be used to remove metastases. The goal of surgery is to achieve gross total resection of all imaging visible residual tumor.
45379417|NCT02125786|Drug|^1^8F-Fluorodeoxyglucose|This is a contrast media that will be given intravenously to aid in tumor visualization.
45693846|NCT05098600|Other|Exposure of interest|Common autoimmune and atopic conditions consist of atopic dermatitis, allergic rhinitis, asthma, Crohn's disease, ulcerative colitis, Celiac disease, Pernicious anaemia, Type 1 diabetes, Autoimmune thyroiditis (Hashimoto's thyroiditis, Grave's disease, atrophic, unspecified), rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polymyalgia rheumatica, Systemic lupus erythematosus, Sjogren syndrome, psoriasis, vitiligo, Multiple sclerosis
46054854|NCT02780739|Behavioral|Active Control|The active control condition consists of 2 tasks (change detection and visual search) with 3 variants each. This intervention includes 48 70-min sessions (56 hrs) completed over 16 weeks: 3/wk. The 6 tasks are played in random order for 10 min each session.
46054855|NCT02780739|Device|active tDCS|Active HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants receive 2.0 mA current for 30 min, split over the 2 anodal electrodes, each drawing ≤1.0 mA. Stimulation is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period.
45379418|NCT02125786|Drug|^1^1C-methionine|This is a contrast media that will be given intravenously to aid in tumor visualization.
45847295|NCT04226118|Device|Vein Illumintion System device|Spotting veins of a patient by use of a Vein Illumintion System device
45379419|NCT02125786|Device|Photon therapy|Participants will receive one or both: Photon or proton therapy.
45379420|NCT02125786|Device|Proton therapy|Participants will receive one or both: Photon or proton therapy.
46054856|NCT02780739|Device|sham tDCS|Sham HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants do not receive sustained stimulation; it is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period to elicit the sensation of simulation and make the sham condition more convincing.
45379421|NCT02072772|Behavioral|Positively Smoke Free group treatment|See Arm Description
45379422|NCT02072772|Behavioral|Standard Care|See Arm Description
45379423|NCT02057107|Radiation|SBRT|8.8-10 Gy per fraction (total: 44-50 Gy)
45379424|NCT02057107|Drug|Cetuximab|"Day -7 (One week prior to commencement of stereotactic radiosurgery):~Cetuximab, 400 mg/m2~Days 0 and 8 (The 1st and 2nd week of radiosurgery):~Cetuximab, 250 mg/m2 Cetuximab, 250 mg/m2 will be given weekly ( following radiosurgery)"
45379425|NCT02057107|Drug|Docetaxel|Days 0 and 8 (The 1st and 2nd week of radiosurgery) Docetaxel, 25 mg/m2 Docetaxel, 25 mg/m2 will be given weekly (following radiosurgery)
45379426|NCT01953263|Other|Autologous Muscle Fiber Fragments|Autologous muscle fiber fragments administered via a single direct injection into the bladder neck sphincter region
45379427|NCT01948882|Device|ESS505 (BAY1454033)|
45379428|NCT01861106|Procedure|Allogeneic HSCT|Stem cell transplant
45379429|NCT01861106|Drug|Busulfan Test dose|0.8 mg/kg IV infusion over 3 hours one time dose administered 5 to 14 days prior to start of preparative regimen (Days -11 to -20)
45693847|NCT00803686|Drug|Oral rsCT tablet|On Study Day 1, subjects will be given their assigned treatment, based on one of two randomly ordered treatment sequences, at 10 PM (22:00). On Visit 3, subjects will return for administration of the second treatment with a minimum of 7 days washout interval between study drug administrations. On Visit 4, subjects will return for administration of third treatment of rsCT, either oral rsCT tablets or Fortical (rsCT) nasal spray. Interventions are described in Intervention Name, Other Names and in Intervention Description.
45379430|NCT01861106|Drug|Fludarabine (Fludara, Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
45379431|NCT01861106|Drug|Busulfan (Busulfex)|3.2 mg/kg IV (in the vein) over 3 hours once daily on Days -6, -5, -4 and -3 (weight based dosing). If in Arm B and if poor or very poor risk clonal chromosomal abnormalities, busulfan will also be given on day -2.
45379432|NCT01861106|Drug|Cyclophosphamide (CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing). For post-transplant, 50/kg IV once daily x2 doses on days +3 and +4
45379433|NCT01861106|Procedure|Total Body Irradiation (TBI)|200 cGy on Day -1
45693848|NCT00803686|Drug|Oral Placebo Tablet|Part 1, Double blind oral placebo tablet given once 4 hours after evening meal.
45379434|NCT01861106|Drug|Mycophenolate mofetil (MMF)|15mg/kg IV over 2 hours BID starting on day +5 will continue until day +35 (+/- 2 days)
45379435|NCT01861106|Drug|Tacrolimus|0.02mg/kg IV continuous infusion over 24 hours starting on day +5 until day +180
45693849|NCT00803686|Drug|Oral rsCT tablet|Part 2, Open-label, oral rsCT tablet given once 2 hours after the evening meal.
45379436|NCT01861106|Biological|Equine Anti-Thymocyte Globulin|(Deleted this intervention per amendment I): 30mg/kg IV (in the vein)once daily x 3 days on Days -6, -5, -4 (3 doses total)
45379437|NCT01753765|Device|Device: Cryo-Touch III Study treatment at Day 0.|Device: Cryo-Touch III Study treatment at Day 0.
45379438|NCT01752920|Drug|Derazantinib low dose range|Derazantinib was administered orally at dose levels from 25 mg QOD - 200 mg QD on a 28-day schedule.
45379439|NCT01752920|Drug|Derazantinib middle dose range|Derazantinib was administered orally at dose levels from 250 mg QD - 325 mg QD on a 28-day schedule.
45379440|NCT01752920|Drug|Derazantinib high dose range|Derazantinib was administered orally at dose levels from 400 mg QD - 425 mg QD on a 28-day schedule.
45379441|NCT01752920|Drug|Derazantinib at recommended phase 2 dose (RP2D)|Derazantinib was administered orally at the recommended phase 2 dose of 300 mg QD on a 28-day schedule.
45379442|NCT01728402|Procedure|blood draw, bone marrow procedure, or tissue biopsy|
45379443|NCT01479075|Drug|intransal insulin|4x 40mU intranasal insulin
45379444|NCT01479075|Drug|Placebo|
45379445|NCT01479075|Device|taVNS|
45379446|NCT01479075|Device|sham stimulation|
45379447|NCT01409330|Dietary Supplement|diet intervention|8-week diet lacking red meat, but containing increased fibers and coffee (verum) versus standard recommendation (control) eating red meat.
45379448|NCT01397279|Biological|intravenous glucose tolerance test|Administration of a 30% weight-adapted glucose bolus intravenously.
45379449|NCT01397279|Biological|hyperinsulinemic euglycemic clamp|Intravenous administration of 20% glucose and insulin over 3 hours
45379450|NCT01327105|Device|TVU|Use of transvaginal ultrasound to determine location of micro-insert
45379451|NCT01134172|Behavioral|survey web-based or telephone interview|Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. The patient will be contacted one and two years after the completion of their follow up questionnaire for a brief one-question survey regarding current employment status. A member of the study team will call a subset of patients who have completed both baseline and follow-up surveys to clarify responses to previous questions. Patients will be considered lost to follow- up if surveys A or C have not been completed two years from the participant's consent date (participants who enroll but do not complete survey A are not prompted for survey C). Deviations will not be filed until the end of the study, as there are opportunities over the course of study follow- up to collect previously missing information.
45379452|NCT01134172|Behavioral|survey web-based or telephone interview|Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. All three follow-up contact methods (email, postcard, call) contain the same question regarding current employment status with minor modifications in formatting. However, the employment question asked in all three follow-up contact methods is shown in the Postcard_Template document. Due to the recent COVID-19 pandemic study staff will be working from home. Therefore, calls will be made via MSK-approved platforms (e.g. Jabber, etc.). Participants who express concerns or request assistance related to COVID-19 will be referred to publicly available resources as needed (e.g., call 311 for access to health care or food panties, etc.) and will be noted in internal tracking logs. The data collected for these internal tracking logs will be managed through a REDCap database.
45379453|NCT01082679|Drug|Methadone|daily for 12 months
45379454|NCT01082679|Drug|buprenorphine (Suboxone)|daily for 12 months
45693850|NCT00803686|Drug|Fortical (rsCT) nasal spray|Intervention: Open label, Fortical nasal spray given once 2 hours after the evening meal.
45693851|NCT01703065|Drug|Cabozantinib|Given orally once a day
46054857|NCT02780739|Behavioral|Cognitive Training - 20 sessions|Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
46054858|NCT05026164|Dietary Supplement|CHI-202|Blend of cannabinoids & other ingredients
46054859|NCT05026164|Dietary Supplement|CHI-101|Placebo
45379455|NCT01008787|Behavioral|Training|In-person 8-hour group physical activity training session (either over 1 or 2 days) and receive workbook and pedometer.
45379456|NCT01008787|Behavioral|Questionnaire|Weekly during Weeks 2-7, complete question form given at training course about conversations with study partner, 5 minutes to complete.
45379457|NCT01008787|Behavioral|Interview|Weeks 4 and 8, 30 minute phone interview about mood and physical activity.
45379458|NCT01008787|Behavioral|PA Newsletter|At Weeks 5 and 9, receive a physical activity (PA) newsletter.
45379459|NCT00976963|Drug|TMP/SMX|Take one twice daily for 3 days for urinary tract infection
45379460|NCT00976963|Drug|Fosfomycin|Mix sachet with 1/2 glass cold water and stir. Drink immediately
45495518|NCT05169606|Other|Active Isolated Stretch|"AIS is a specific stretching program developed by Aaron Mattes. This technique is based on these four basic principles:~Isolate the muscle to be stretched. Repeat the stretch eight to 10 times. Hold each stretch for no more than two seconds. Exhale on the stretch; inhale on the release."
45847296|NCT04176354|Drug|Palbociclib + an aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
45379461|NCT00958633|Drug|Escitalopram|"Escitalopram will be prescribed in the dose range 10-30 mg daily.~In patients randomized to the 8-week group, escitalopram will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit.~The dose of escitalopram (or matching placebo) may be decreased in 10 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 10-30 mg daily at all time points."
45379462|NCT00958633|Drug|Wellbutrin XL|"Bupropion XL will be prescribed in the dosage range 150-450 mg daily.~In patients randomized to the 8-week group, bupropion XL will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit.~The dose of bupropion XL (or matching placebo) may be decreased in 150 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 150-450 mg daily at all time points."
45379463|NCT00911560|Biological|adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH|Pts receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8, 20, 32, & 52. Minor schedule adjustments are permitted, as needed. Vaccines must occur a minimum of 6 days apart. Induction of antibody response against the target antigens will be assessed. A fixed dose of oral β-glucan (40 mg/kg/day) is started at week 6 or 7(to allow time for generation of antibodies), & continued as approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination. Neutrophils will be tested for glucan effects on cytotoxicity. Antineuroblastoma activity will be monitored using standard radiographic & bone marrow studies, as well as RT-PCR for measurement of minimal residual disease in blood & bone marrow. Phase II treatment schema for patients in 1st CR/VGPR or >2nd CR/VGPR will be the same for the vaccine as in phase I except OPT-821 will be given at a fixed dose of 150 mcg/m2.
45379464|NCT00911560|Biological|oral β-glucan|Phase II Patients will be randomized to starting oral β-glucan (40 mg/kg/day) in week 1 or in week 6.
45379465|NCT00902590|Other|saliva sample and questionaire|"Urothelial Cancer Registry- Patients will complete a family history and urothelial cancer risk questionnaire, and will provide a buccal sample for germline DNA. If the cases have undergone germline sequencing as part of Protocol 12-245, they will not need to provide a buccal sample. If the cases have previously completed athe the Urothelial Baseline Questionnaire, in an MSKCC urology clinic they will not need to complete the urothelial cancer risk questionnaire."
45379466|NCT00902590|Other|saliva sample, questionaire|Urothelial Cancer Registry- These participants will be requested to complete the risk factor questionnaire and to provide a saliva sample for DNA extraction.
45379467|NCT00748254|Procedure|Laser Based Photoacoustic Tomography, MRI, Ultrasound|Healthy subjects will have scans on finger joints with any of the scanning methods described above.
45379468|NCT00748254|Procedure|laser based photoacoustic tomography, MRI, ultrasound|Subjects with arthritis will have scans on finger joints with any of the scanning methods described above.
45379469|NCT00591981|Behavioral|TOGA Tools|ADL's, Zubrod, IADL's, BFI, MMS, MNS, GDS
45379470|NCT00393783|Biological|MAB HER 2 (HERCEPTIN)|Rat HER2 DNA will be delivered intramuscularly at four different dose levels (0.5mg, 1mg, 3mg, or 6mg) during weeks 1, 4, 7, 10 and 13 for five injections.
45379471|NCT00271180|Device|Device|
45379472|NCT00167219|Biological|Stem Cell Transplant|Transplantation on Day 0.
45379473|NCT00167219|Drug|Preparative Regimen|"Busulfan~Cyclophosphamide~Mesna~Melphalan~Anti-thymocyte Globulin (ATG)"
45495519|NCT05169606|Other|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) technique has already been found to have beneficial effects in improving hamstring flexibility and reducing pain in the knee joint of knee OA patients
45495520|NCT05139264|Other|Observational|Observation of diet, physical activity, sleep and interstitial glucose
45847297|NCT04176354|Drug|Palbociclib + Letrozole|Palbociclib + Letrozole therapy
45379474|NCT00074269|Biological|anti-thymocyte globulin|
45379475|NCT00074269|Biological|filgrastim|
45379476|NCT00074269|Biological|graft-versus-tumor induction therapy|
45379477|NCT00074269|Biological|therapeutic allogeneic lymphocytes|
45379478|NCT00074269|Drug|cyclosporine|
45379479|NCT00074269|Drug|fludarabine phosphate|
45379480|NCT00074269|Drug|melphalan|
45379481|NCT00074269|Drug|methotrexate|
45379482|NCT00074269|Procedure|peripheral blood stem cell transplantation|
45379483|NCT00423735|Drug|Dasatinib|Given PO
45379484|NCT00423735|Other|Pharmacological Study|Correlative studies
45379485|NCT00626327|Biological|MenACWY-CRM + MMRV|One injection of MenACWY-CRM vaccine at 7-9 months of age; the second injection of MenACWY-CRM vaccine concomitantly administered with MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age.
45379486|NCT00626327|Biological|MMRV|one injection of MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age
45495521|NCT05599620|Behavioral|AWARE|AWARE addresses alcohol use, sexual distress, and sexual assault risk among college women with a history of sexual victimization.
45495522|NCT05599620|Behavioral|General Health Promotion|General Health Promotion is an attention and dose matched intervention with no overlapping components with AWARE.
45495523|NCT05706870|Drug|GN037|GN037
45495524|NCT05706870|Drug|Clobetasol 17-Propionate Cream|Clobetasol 17-Propionate
45495525|NCT05706870|Drug|Placebo|Placebo
45498213|NCT03684330|Dietary Supplement|Vitamin D|a dose once a week
45379487|NCT00626327|Biological|MenACWY-CRM|Two injections of MenACWY-CRM at 7-9 months and 12 months of age; one injection of MMRV (Measles, Mumps, Rubella and Varicella) at 13.5 months of age
45379488|NCT01032213|Drug|Magnesium Sulfate|Group M received 50 mg/kg of magnesium sulphate on 100 ml of isotonic saline over 10 minutes during the anesthesia induction, followed by the 15 mg/kg/h by continuous infusion during the operation
45379489|NCT01032213|Drug|normal saline|Group S received the same volume of isotonic saline as same method.
45379490|NCT00357994|Drug|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa per/hour)
45379491|NCT00357994|Drug|Placebo gel|
45379492|NCT00357994|Drug|Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets|
45379493|NCT00357994|Drug|Placebo (PBO) oral capsules|
45379494|NCT00357994|Device|CADD-Legacy® 1400 ambulatory infusion pump|
45379495|NCT00357994|Device|PEG tube|percutaneous endoscopic gastrostomy tube
45379496|NCT00357994|Device|J-tube|jejunal tube
45379497|NCT00823433|Drug|oral penicillin V|2 grams of oral penicillin V given within 4 hours of delivery.
45379498|NCT00423657|Drug|ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
45379499|NCT00423657|Drug|vancomycin plus aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
45379500|NCT00423657|Drug|Placebo|Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
45379501|NCT00831155|Drug|Nicotine Patches, Denicotinized Cigarettes|Both groups will receive standard Nicotine Replacement Therapy after the quit date. The Extinction Based group will receive Nicotine patches and denicotinized cigarettes before their quit date
45379502|NCT00827021|Drug|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|4000 IU/week I.V. Until the end of the trial
45379503|NCT00827021|Drug|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|18000 IU/week I.V. Until the end of the trial
45379504|NCT02533414|Device|RIRS with UAS|Ureteral access sheath (UAS) will be used during RIRS.
45379505|NCT02533414|Device|RIRS without UAS|Ureteral access sheath will not be used during RIRS.
45379506|NCT01029015|Procedure|cystometry|recording device measuring pressures though catheters placed in bladder and rectum
45379507|NCT01029015|Procedure|polysomnography|recording device measuring sleep activity through electrodes attached to the subject
45847298|NCT04176354|Drug|Letrozole|Letrozole monotherapy
45379510|NCT01050712|Drug|Inhaled Carbon Monoxide|Concentration of Carbon Monoxide to be inhaled by patients will be determined in a safety trial performed in healthy volunteers prior to the commencement of this trial. Patients randomized to received inhaled carbon monoxide will receive this concentration by cushioned face mask for one hour prior to colon resection and for one hour after colon resection
45379511|NCT01050712|Drug|Synthetic Air|Patients randomized to this intervention will receive this gas via cushioned face mask for one hour prior to colon resection and for one hour after colon resection
45379512|NCT02407509|Drug|VS-6766|
45379513|NCT02407509|Drug|Everolimus|
45379514|NCT02550119|Drug|Aprepitant|Given PO
45379515|NCT02550119|Drug|Dexamethasone|Given PO or IV
45379516|NCT02550119|Drug|Dolasetron Mesylate|Given PO or IV
45379517|NCT02550119|Drug|Placebo|Given PO
45379518|NCT02548403|Drug|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
45379519|NCT02548403|Drug|PEG-Asc with simethicone|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure. Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
45379520|NCT00823589|Other|Blood test and clinical test|Blood test and clinical test
45379521|NCT00367432|Drug|Levetiracetam|Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
45379522|NCT01086670|Other|Physical Exercise|Children will be assigned either an elliptical machine or cycle to take home. Each exercise will be performed for 20 minutes per day, 5 days per week for a period of 12 consecutive weeks, or 60 sessions in all. To avoid excessive fatigue or over-training effects, children are asked to adhere to this exact schedule and not to exercise more than this. Children are asked to complete as many of the sessions as they can. To allow for sick days or vacation during the program, the duration of the training can be extended up to 2 more weeks if needed to try to complete all 60 sessions. Compliance (percent sessions completed) will be correlated with outcomes in the statistical analyses.
45379523|NCT01053052|Device|Sonography with FemVue, and HSG|Sono HSG for FDA 510(k) cleared indication for use
45379524|NCT01050868|Device|Accu-Chek Combo Kit mg DE/de|
45379525|NCT00623363|Drug|piclozotan|piclozotan, intravenous (IV) infusion
45847299|NCT04173780|Drug|Atropine 0.01%|1 drop per day in both eyes for 1 year
45847300|NCT04173780|Drug|Placebo|1 drop per day in both eyes for 1 year
45847301|NCT04129554|Drug|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously once every 4 weeks up to 48 weeks.
45847302|NCT04129554|Drug|JNJ-56136379|JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
45495526|NCT05706792|Device|Nordic Sensi Chair|The Nordic Sensi Chair is an electrically operated rocking chair with built-in MusiCure music composed by Niels Eje. It is equipped with an integrated audio system with music recording based on more than 15 years of research on the calming and mentally stimulating effect of sound. The Nordic Sensi Chair has three different programs: Relax for deep relaxation, Refresh for recovery and Comfort for gentle relaxation. A 5 kg fiber blanket increases the feeling of security and relaxation, while helping users to perceive their own body. In addition to musical programming, the Nordic Sensi Chair provides predefined tactile stimulation and rocking motion, for a relaxing multi-sensory experience. All settings can be easily customized at the touch of a button. For the purposes of this study, the NSC deep relaxation program (Relax Program) was used.
45498214|NCT03684330|Other|whole body vibration (WBV)|03 months of WBV training three times per week
46054860|NCT02811744|Drug|11C-acetate|Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
45379526|NCT00623363|Drug|0.9% sodium chloride (normal saline)|0.9% sodium chloride (normal saline) intravenous (IV) infusion
45379527|NCT00827177|Drug|Treatment with ARQ 197 in combination with sorafenib|"Patients will be treated with ARQ 197 and sorafenib at Dose Level 1 (ARQ 197 360 mg twice daily (bid) and sorafenib 200 mg bid). Patients with HCC will start treatment with ARQ 197 at 240 mg bid and sorafenib 200 mg bid. Enrollment of subsequent patient cohort will depend on the safety and tolerability of the combination treatment in the initial cohort.~If < 33% patients treated at Dose Level 1 experience dose-limiting toxicity(ies) (DLT) by the end of first treatment cycle (4 weeks), then next cohort of 6 patients will be enrolled and treated at Dose Level 2 (ARQ 197 360 mg bid and sorafenib 400 mg bid). If ≥ 33% patients treated at Dose Level 1 experience DLT(s) by the end of first treatment cycle, the next cohort of 6 patients will be enrolled and treated at Dose Level 0 (ARQ 197 240 mg bid and sorafenib 200 mg bid)."
45379528|NCT00823667|Other|educational intervention|Palliative care intervention at weeks 3,4,5 and 6 post study enrollment
45379529|NCT00823667|Other|medical chart review|Occurs at 1 year post study enrollment
45379530|NCT00823667|Other|questionnaire administration|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
45379531|NCT00823667|Procedure|end-of-life treatment/management|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
45379532|NCT00823667|Procedure|psychosocial assessment and care|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
45379533|NCT00823667|Procedure|quality-of-life assessment|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
45379534|NCT00423267|Drug|Posaconazole|Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months
45693852|NCT00823966|Drug|Rescriptor|"RESCRIPTOR® TABLETS 200mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dose is 400mg of Delavirdine Mesilate administered orally 3 times daily.This drug must always be administered in combination with other anti-HIV drugs."
46054861|NCT05340075|Procedure|Patients who underwent percutaneous nephrolithotomy|Patients who underwent percutaneous nephrolithotomy to the contralateral kidney 2-4 weeks and 4-6 weeks after the percutaneous nephrolithotomy operation
46054862|NCT02844894|Drug|Dexmedetomidine|
46054863|NCT02844894|Drug|Esmolol|
45379535|NCT00423267|Drug|Fluconazole|Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months
45379536|NCT02549261|Drug|nimotuzumab|the nimotuzumab treatment: 200mg/w weekly, for 16 weeks. A treatment:nimotuzumab for 3 levels (100mg/w, 200mg/w, 400mg/w, weekly, for 16 weeks).
45379537|NCT02549261|Drug|Cisplatin|Concurrent Chemotherapy,50mg/m2 (d1,d8),4 weeks/cycle, for 2 cycles. the consolidation chemotherapy: Cisplatin: 50mg/m2 (d1,d8)4 weeks/cycle, for 2 cycles.
45379538|NCT02549261|Drug|Etoposide|"Concurrent Chemotherapy, Cisplatin: Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.~the consolidation chemotherapy:Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles."
45379539|NCT02549261|Radiation|radiotherapy|the tolerance trial of treatment A and B of treatment;95％PTV,60-66Gy/30-33/fraction,6-7weeks.
45379540|NCT01029093|Other|no intervention, MRI and motor skill test|Two MR Investigations at two different times
45498215|NCT03680430|Radiation|Adaptive radiation therapy|Patients will be treated by preoperative or definitive radiotherapy for a limb STS, using an intensity-modulated conformal irradiation (with a static or dynamic technic), over 5 to 7 consecutive weeks. The total dose delivered will be of 50 Gray (preoperative RadioTherapy), or 60 to 70 Gray (exclusive RadioTherapy).
45693853|NCT01702987|Dietary Supplement|ubiquinol|ubiquinol supplementation was given for 1 month to 12 patients
46054864|NCT02844894|Drug|Placebo|normal saline
46054865|NCT04196439|Procedure|continuous epidural analgesia|injection of local anaesthetic into epidural space
46054866|NCT04196439|Procedure|supra-inguinal fascia iliaca compartment block|ultrasound guided injection of local anaesthetic into fascia iliaca compartment
46054867|NCT02847780|Device|Active Comparator :C-Mac Videolaryngoscope|Real time assessment of Glottic aperture at the time of extubation by videolaryngoscope
45379541|NCT01032369|Other|Nutritional intervention and physical activity|"Nutritional intervention:~Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.~Physical activity:~All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking)."
45379542|NCT01032369|Other|Nutritional intervention, physical activity and behavioral treatment|"Nutritional intervention:~Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.~Physical activity:~All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking).~Behavioral treatment:~This group will undergo behavioral treatment focusing on self control techniques using the CBT technique (cognitive behavioral therapy) which will be conducted by a clinical psychologist from ONIM in weekly group sessions."
45379543|NCT02548325|Other|Not apply|None. Just registration epidemiology dates
45379544|NCT00823745|Drug|[14C]-PF-00868554|solution, single dose
45379545|NCT00626093|Device|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)|"Patients in the study who receive Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for Cardiac Resynchronization Therapy (CRT).~Patient undergoes Defibrillation threshold (DFT) testing at implant and at 6 months. Defibrillation threshold (DFT) testing will include 3 ventricular fibrillation (VF) inductions."
45379546|NCT00357760|Biological|VEGF Trap|Given IV
45379547|NCT04396535|Drug|Bintrafusp Alfa|Given IV
45379548|NCT04396535|Drug|Docetaxel|Given IV
45379549|NCT04018391|Behavioral|Stepped care for nonadherence and depression|"Problem Solving for Depression and Adherence: A 6-session adherence and depression intervention based on a culturally adapted LifeSteps and Problem Solving Therapy for Depression.~Stepped Care Assessment for Antidepressant Treatment: If a participant's depression score remains above threshold in Session 6, the study interventionist will refer the participant to a Research Mental Health Nurse for a psychopharmacological assessment to prescribe an antidepressant to augment Problem Solving for Depression and Adherence."
45379550|NCT04018391|Other|Enhanced Usual Care|Enhanced Usual Care: A combination of 1) clinic-provided adherence counseling, 2) access to providers trained in the World Health Organization Mental Health Gap Intervention Guide (mhGAP), 3) a letter to the participant's medical provider detailing the depression diagnosis, 4) access to the treatment components of the TENDAI intervention at no cost, after the participant has completed their 12-month follow-up assessment.
45379551|NCT02548013|Other|outpatient management|patients if stable will be discharged to continue treatment at home
46054868|NCT02847780|Device|Experimental: Airway ultrasound,|Airway ultrasound using portable ultrasound machine to assess vocal cords movement.
45379552|NCT02548013|Other|Inpatient management|patients will continue there treatment in hospital till delivery
45379553|NCT01049230|Radiation|Proton Beam radiation|Once a day, 5 days a week (Monday-Friday), for 4-8 weeks
45379554|NCT00622739|Drug|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20 mg to a maximum of 160 mg. Arm 1 will have the dose of Ziprasidone titrated at a rate of 20 mg every 2 days, reaching the maximum dose in 14 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
45379555|NCT00622739|Drug|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20mg to a maximum of 160mg. Arm 2 will have the dose of Ziprasidone titrated at a rate of 20mg every 3-4 days, reaching the maximum dose in 25 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
45379556|NCT03742336|Drug|PF-04965842|Single oral 200 mg dose of PF-04965842
45379557|NCT03742336|Drug|Dabigatran|Single 75 mg dose of dabigatran
46054869|NCT02780193|Drug|Omegaven|Therapy with Omegaven® will be initiated and maintained at 1 g/kg/day. It will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. If additional non-protein calories are needed, they will be provided as carbohydrates. No other parenteral form of fat emulsion will be used during Omegaven® therapy.The Omegaven® dose may be discontinued if the subject is receiving adequate enteral nutrition to meet metabolic and growth needs.
46054870|NCT05025540|Diagnostic Test|ultrasonic imaging|Two-dimensional ultrasound images of the patient's kidneys were obtained by ultrasound imaging.
45379558|NCT00435825|Drug|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms subcutaneous weekly for 24 weeks or 48 weeks.
45379559|NCT00824057|Drug|AZD6280|oral
45379560|NCT00824057|Drug|Midazolam|oral
45495527|NCT05061186|Other|Resistive Expiratory muscle Training Group|"Mild Resistive Expiratory Technique [Expiratory Muscle Strength Training (EMST150)- six-week training protocol approximately 20 min per day] The EMST requires the participant to forcibly blow into the device for 5 seconds with sufficient pressure to open the one-way valve. Each blow is one repetition. The device will be set at a resistance of 30 cmH2O. Participants will be instructed to complete five sets of five repetitions (total of 25 times and approximately 20 minutes per day), any five days per week, for six weeks. Whole exercise will be done in sitting position. Rest between repetitions will be given according to comfort level of patient."
45498216|NCT03688464|Drug|Melatonin|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
45379561|NCT00824057|Drug|Caffeine|oral
45379562|NCT01053130|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy plus dietary and physical activity support
45379563|NCT01053130|Behavioral|weight management program|1200-1500 kcal renal diet, increased physical activity, with optional orlistat therapy at 120 mg tds for 12 months
45379564|NCT02534272|Other|Stool sampling and sequencing of gut microbiota.|
45379565|NCT00574145|Procedure|Bio-field energy therapy|Practitioner's hands to influence the human energy field surrounding the patient's body.
45379566|NCT00574145|Procedure|fatigue assessment and management|duration
45379567|NCT00574145|Procedure|psychosocial assessment and care|duration
45379568|NCT00574145|Procedure|quality-of-life assessment|duration
45693854|NCT01702987|Dietary Supplement|placebo|placebo (identical in appearance to ubiquinol) was given for 1 month to 9 patients
45693855|NCT01702987|Drug|statin|statin was given for 1 month to 21 patients
45693856|NCT00824044|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT group will receive weekly 50-minute individual sessions over the course of 12 weeks conducted by experienced therapists who are trained in manual based CBT.
46054871|NCT05338203|Other|tandem breastfeedıng|mother mılk wıll collected from mothers and they wıll be analyzed in laboratuar.
46054872|NCT05341245|Procedure|Graphene oxide and open flap debridement|Using Graphene oxide with open flap debridement in management of periodontal intrabony defects in dogs
46054873|NCT05341245|Procedure|Open flap debridement|Using Open flap debridement in management of periodontal intrabony defects in dogs
45379569|NCT00574145|Procedure|therapeutic touch|Practitioner's hands to influence the human energy field surrounding the patient's body
45379570|NCT01053208|Drug|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
45379571|NCT00831467|Biological|CV9103|Over a period of 23 weeks 5 vaccinations with CV9103 will be administered.
45379572|NCT00423189|Drug|Ranibizumab (Lucentis)|as needed, one intravitreal injection of 0.50mg ranibizumab
45379573|NCT00423189|Drug|0.5mg ranibizumab|as needed, one intravitreal injection of 0.50mg ranibizumab
45379574|NCT03991858|Other|Phone call follow-up|A physical therapist made a phone call to the patient one month after his/her initial evaluation at the external rehabilitation clinic
45379575|NCT03991858|Other|Telerehabilitation follow-up|A physical therapist made a direct follow-up through telerehabilitation to the patient one month after his/her initial evaluation at the external rehabilitation clinic
45379576|NCT00831545|Drug|Temozolomide|150 mg/m2 given once a day for 7 consecutive days (Days 1 through 7) repeated every other week until disease progression or toxicity or for a maximum of one year. After amendment, schedule was modified: a second rest week was added after the second wash-out week (Days 1 through 7, 15 through 21 every 35).
45379577|NCT01051024|Dietary Supplement|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
45379578|NCT01051024|Dietary Supplement|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
45498217|NCT03688464|Drug|Diphenhydramine|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
45693857|NCT00824044|Drug|Escitalopram|The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.
45693858|NCT01702519|Drug|nicotine|nicotine transdermal patch
46054874|NCT04778904|Biological|ChAdOx1-HBV|Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus vaccine
45379579|NCT02549417|Drug|KHK7580|Oral administration
45379580|NCT00824135|Drug|Clofarabine|"One dose intravenously every 24 hrs for five days total.~Dose level 1 Clofarabine 40 mg/m2/day intravenous Dose level 2 Clofarabine 45 mg/m2/day intravenous Dose Level 3 Clofarabine 50 mg/m2/day intravenous"
45379581|NCT00824135|Procedure|Stem Cell Transplantation, Hematopoietic|Haploidentical Hematopoietic Stem Cell Transplantation (two infusions, one on day 0 and the other on day +1)
45379582|NCT00824135|Other|OKT3|"Start at 0.0125 mg/kg intravenous once a day, taper dose down incrementally and discontinue after 17 days total~Muromonab-CD3"
46054875|NCT04778904|Biological|MVA-HBV|Modified Vaccinia Ankara-vectored Hepatitis B virus vaccine
45379583|NCT00824135|Drug|Thiotepa|5 mg/kg/day intravenous every 12 hours (2 doses total)
45379584|NCT00824135|Drug|Melphalan|60mg/m2 intravenous every 12 hours for 2 doses total.
45495528|NCT05061186|Other|Conventional Breathing Exercise Group|"Breathing Exercises: (approximately 20 minutes per day)~● Pursed lip breathing: (Sit with your back straight. Inhale through your nose for two seconds. Purse your lips like you're blowing on hot food and then breathe out slowly, taking twice as long to exhale as you took to breathe in. 4-5 times a day)~● Diaphragmatic breathing: (Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs. Breathe in slowly through your nose Tighten your stomach muscles, letting them fall inward as you exhale through pursed lips. Practice this exercise 5-10 minutes about 3-4 times per day).~● Incentive spirometer: (Hold in an upright position. Breathe in slowly and as deeply as possible. Hold your breath as long as possible (at least for 5 seconds). Then exhale slowly Rest for a few seconds and at least 10 times every hour)"
45495529|NCT05706480|Diagnostic Test|colored periodontal probes (CPP)|The CPP will be placed with a force of approximately 0.2 N into the sulcus at the mid buccal surface of the tooth and the color that will be apparent from the tissue will be recorded
45495530|NCT05706480|Diagnostic Test|standard periodontal probes (SPP)|The SPP (William's graduated probe) will be placed with a force of approximately 0.2 N into the sulcus at the mid buccal surface of the tooth and the color that will be apparent from the tissue will be recorded
45379585|NCT00824135|Drug|Mycophenolate mofetil|"Mycophenolate mofetil 600 mg/m2 intravenous two times a day~(continue for approximately 2 months or as clinically indicated)"
45495531|NCT05706480|Diagnostic Test|transgingival sounding with an endodontic file|the gingival thickness using the transgingival sounding. After application of local anesthesia gel an endodontic file (ISO 20) with a rubber stopper will be inserted perpendicularly into the buccal aspect of the gingiva (1 mm below the gingival margin) until it touches the tooth surface. The insertion depth will be ensured through placing the rubber stopper in contact with the gingiva and fixing its position and the distance between the tip and the rubber stopper will be calibrated using a manual calibration device (endodontic ruler).
45379586|NCT00824135|Drug|Rituximab|375 mg/m2 intravenous for 1 dose total
45495532|NCT03383783|Drug|0 ppm F (placebo, negative control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
45495533|NCT03383783|Drug|250 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
45495534|NCT03383783|Drug|500 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
45495535|NCT03383783|Drug|1100 ppm F as NaF (positive control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
45495536|NCT03627390|Drug|BP-C1|BP-C1, 0.05% solution for injections; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
46054876|NCT04778904|Biological|Nivolumab|Human immunoglobulin G4 monoclonal antibody
45495537|NCT03627390|Drug|BP-C2|BP-C2, 0.15% solution for oral use; 15 ml orally once daily for 32 consecutive days
45693859|NCT04549129|Behavioral|Breastfeeding education video|"An introductory video (15 minutes) gives an overview of these ABCs (video titled Term baby which are further taught through brief text summaries (150-200 words) and short instructional videos (2-6 minutes)."
45693860|NCT04549129|Behavioral|Breastfeeding website|"The website firstdroplets.com is designed for prenatal education, focusing on the ABCs of breastfeeding that come before D (delivery) - attachment (latch), breastmilk production, and calories (transfer of milk to baby)."
45693861|NCT04549129|Behavioral|Usual breastfeed education|The usual breastfeed education includes brief counseling by study staff and provision of handouts on latch/positioning and common first week breastfeeding advice
46054877|NCT04228887|Diagnostic Test|Respiratory Muscle Strength|Respiratory muscle strengths will evalueted with inspiratory and expiratory mouth pressure devices.
46054878|NCT04228887|Device|Balance Training|Balance training will provide with Biodex® Balance Training System
46054879|NCT04228887|Device|Inspiratory Muscle Training|15 minutes twice a day, 5 times a week for 8 week with Threshold IMT device
46054880|NCT03986502|Other|Media Intervention|Watch web-based financial literacy video
46054881|NCT03986502|Other|Informational Intervention|Receive information on financial counseling and medical cost assistance
46054882|NCT03986502|Other|Best Practice|Utilize usual clinic procedures and clinic or community-based financial resources
46054883|NCT03986502|Other|Questionnaire Administration|Ancillary studies
46054884|NCT03986502|Other|Quality-of-Life Assessment|Ancillary studies
45379587|NCT00824135|Other|G-CSF|G-CSF 5 mcg/kg/day subcutaneous or intravenous until ANC greater than 2.000/mm3 for 2 consecutive days and then as clinically indicated.
45379588|NCT00422799|Drug|Bortezomib|Once weekly for 3 weeks
45379589|NCT00422799|Drug|Rituximab|Intravenously once a week for the first and fourth weeks of a cycle
45379590|NCT00827333|Other|educational intervention|Family Caregiver Palliative Care Intervention at weeks 7, 8, 10, and 12 post study enrollment
45379591|NCT00827333|Other|questionnaire administration|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
45495538|NCT05576376|Procedure|calcaneal osteotomy for intractable plantar fasciitis|plantar displacement calcaneal osteotomy
45495539|NCT05576376|Procedure|plantar fascia open release|open partial release with or without baxter's nerve decompression
45495540|NCT05576376|Procedure|plantar fascia endoscopic release|endoscopic partial plantar fascia release
45495541|NCT03709745|Drug|Aflibercept Injection [Eylea]|Intravitreal injection is given as described in the arm description
45495542|NCT03709745|Drug|Ranibizumab Injection [Lucentis]|Intravitreal injection is given as described in the arm description
45495543|NCT05570526|Dietary Supplement|Melatonin|Puritan's Pride ® Melatonin 5mg tablets orally once daily.
45495544|NCT05570526|Other|Placebo|Placebo tablet once daily.
45379592|NCT00827333|Procedure|end-of-life treatment/management|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
45379593|NCT00827333|Procedure|psychosocial assessment and care|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
45495545|NCT03707639|Drug|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
45379594|NCT00827333|Procedure|quality-of-life assessment|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
45495546|NCT03707639|Drug|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
45379595|NCT00827411|Drug|Aspirin and clopidogrel / Prasugrel|modification of aspirin and clopidogrel/Prasugrel maintenance doses based on a biological assay
45379596|NCT00827411|Device|VerifyNow|point of care assay VerifyNow (ACCUMETRICS San Diego USA)
45379597|NCT00827411|Drug|Aspirin and clopidogrel / Prasugrel|aspirin and clopidogrel/ Prasugrel maintenance doses (according to international guidelines)
45495547|NCT05343689|Procedure|Pneumatic compression|Pneumatic compression with preset pressure and cyclic manner is applied from immediately after anesthesia induction to 20 minutes after anesthesia induction in the both legs.
45495548|NCT05563974|Other|Family led postnatal care|"Family-led Postnatal Care-FPNC A midwife involves families and uses a visual checklist to assess and counsel. The midwife then gives families the checklist and guides them how to retrieve a home care kit that has a blood pressure machine, infrared thermometer, and health education booklet.~At home, families assess the health of postnatal mothers and newborns for 6 days, and then return the completed checklist and home care kit to the community location."
45495549|NCT05542914|Behavioral|electronic screening and brief intervention.|e-SBIs is an evidence based approach to engage non-treatment-seeking individuals who use substances to reduce use or enter treatment. It consists of completing screening instruments related to substance use and sexual risk behavior and receiving a tablet-based, Motivational Interviewing intervention to help individuals build motivation to reduce their use and plans to achieve their substance use and HIV risk reduction goals.
45753997|NCT04165135|Drug|Standard of Care for Haemophilia A|There is no pre-determined studied medicinal product. Any treatment (including treatments started during the observational period) will be administered according to standard clinical practice, independently of participation in the current study, according to clinician's independent therapeutic decision.
46054885|NCT02780895|Drug|Human Stem Cells|"MRI-guided stereotactic intraputaminal cell implantation into PD patients was performed.~For target locations, measurements were made using CT-scan images fused with previous MR images. Bilateral parasagittal incisions and corresponding 14 mm burr holes were made in preparation for cell suspension injections.~To ensure complete cell suspension delivery, injections were carried out slowly for 2 min with reciprocal withdrawal of the delivery needle to avoid both damage to stem cells and brain tissue, as well as to avert reflux or bubble formation.~After surgery, patients were kept in a conventional post-operative care unit for 1 h. The day following surgery, MR images were obtained to confirm correct placement of cell suspensions. All patients were discharged 24 h after surgery."
46054886|NCT02780817|Other|Error enhancement|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device, followed by one game with null force field, followed by 5 games as the main intervention with error enhancement force field, and another last game with null force field.
46054887|NCT02780817|Other|Control group|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device and another 7 games with null force field.
45379598|NCT00827411|Drug|Aspirin and clopidogrel / Prasugrel|maintenance dose of clopidogrel / Prasugrel and aspirin
45379599|NCT00827411|Drug|Aspirin|Interruption of clopidogrel / Prasugrel after one year of follow-up
45379600|NCT00435045|Drug|Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin|Lovaza + atorvastatin
45379601|NCT00435045|Drug|atorvastatin|atorvastatin + placebo
45379602|NCT01029171|Behavioral|Home-based balance and strength retraining exercise program.|A 12-month home-based balance and strength restraining program delivered by a physical therapist
45379603|NCT01029171|Behavioral|control; usual care|Usual care as prescribed by geriatrician.
45379604|NCT00441129|Device|Minimed paradigm Real Time Sytem|Minimed paradigm Real Time Sytem
45379605|NCT00441129|Device|Minimed Paradigm 512/712 Insulin pump|Minimed Paradigm 512/712 Insulin pump
45379606|NCT00622505|Drug|zoledronic acid|Zoledronic acid concentrate (4 mg/5 milliliters [ml]) was diluted in 100 mL sterile 0.9% calcium-free sodium chloride or 5% dextrose injection, administered IV, either 4 or 12 weeks for 96 weeks.
45379607|NCT02550275|Behavioral|neuropsychological test|
45379608|NCT02550275|Radiation|MRI|
45379609|NCT02549183|Device|Boston Scientific PRECISION Spinal Cord Stimulator System|Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.
45379610|NCT02550353|Procedure|lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully.
45379611|NCT02550353|Procedure|femtosecond laser-assisted laser in situ keratomileusis|track distance and spot distance were 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter was 8.0 mm, and flap thickness was set to 105 μm. Side-cut angle and hinge angle were 90°and 50° respectively. The flaps were created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system was used in the subsequent ablation of the stromal bed with a 6.0 mm optical zone. Once the excimer ablation was completed, the flap was repositioned in a similar fashion as in routine LASIK.
45379612|NCT00827489|Drug|HTC-867|
45753998|NCT03927638|Behavioral|sit/stand|Subjects will be asked to both sit and stand during a single trial.
45753999|NCT02132533|Drug|Nifedipine|Nifedipine 20 mg orally, then nifedipine 20 mg orally after 90 minutes if still contracting. Continue nifedipine 20 mg orally every 4 hours after the first dose for 48 hours.
46054888|NCT04229199|Behavioral|simulation|Dyads allocated to the IG were taken into a tour to a simulation operating room accompanied by an expert anesthesia technologist two weeks before the day of surgery. This simulation operating theater is a real operating room equipped with a surgical trolley, sealing surgical lights, anesthesia machine, vital signs monitor, stethoscope, surgical trays, surgical sink, and gas supply pendent. It was prepared with popular cartoon characters, child manikin, and face masks connected to the anesthesia circuit and re-breathing bag. After being assessed by anesthesia clinic doctors, children and their parents in the IG were given a chance to visit the simulation operating room, to receive orientation, education, and demonstration orientation about what they are going to experience in the operating room. Children were encouraged to apply vital signs monitoring, and to simulate providing mask anesthesia induction to a child manikin.
45379613|NCT00827489|Other|Placebo|
45379614|NCT00831857|Other|89Zr-Bevacizumab PET-scan|At baseline, after two weeks of treatment and after 6 weeks of treatment.
45379615|NCT04467515|Drug|CAM-H2|All patients will receive at least 1 cycle of CAM-H2. Patients with CB may receive 4 cycles of CAM-H2, each cycle given as 2 IV administrations, 4 weeks apart.
45379616|NCT00824447|Drug|Oralgen|allergen solution sublingually
45379617|NCT00824447|Other|placebo|placebo control
45379618|NCT02548169|Biological|DC Vaccine + Standard of Care Chemotherapy|"4 doses of DC vaccine at 2 weeks interval, combined with either:~Standard of care neoadjuvant folinic acid, oxaliplatin, irinotecan and 5- Fluorouracil (5FU) (FOLFIRINOX) regimen alone (6 cycles)~FOLRIRINOX regimen followed by 5-FU chemoradiation or Gemcitabine Chemoradiation~Gemcitabine + nab-paclitaxel~The first vaccination will include one intradermal injection of 100 μL at 15 x106 cells/mL in the upper thigh and one subcutaneous injection of 1 mL (15 x 106 cells/mL) .~The participants will receive 3 additional subcutaneous vaccinations, each injection of 1 mL at 15 x 106 cells/mL, at 2 weeks interval, on Day 2 of study weeks 3, 5 and 7.~Participants will receive 2 booster DC vaccinations subcutaneously of 1 mL at 15x106 cells/mL."
45379619|NCT04043429|Behavioral|Vision Restoration Training (VRT)|
45379620|NCT04043429|Behavioral|Vision Exploration Training (VET)|
45754000|NCT02132533|Drug|Placebo|Placebo orally, then placebo orally after 90 minutes if still contracting. Continue placebo orally every 4 hours after the first dose for 48 hours.
45754001|NCT02132533|Other|Usual care|Usual evaluation, monitoring and care for women with preterm labor.
45379621|NCT04043819|Drug|PSC-01|PSC-01 is a form of autologous cellular therapy resulting from the enzymatic processing of lipoaspirate to yield adipose-derived stromal vascular fraction cells.
45379622|NCT04016987|Behavioral|Automated structured education intervention based on an app and artificial intelligence|In the 24-week intervention period, the experimental group receives automated push notifications supported by artificial intelligent algorithm.
45495550|NCT05542914|Behavioral|Men's Health Project (MHP)|This intervention will be offered to participants with moderate or greater severity substance use. This is a 4-session Motivational interviewing based intervention that has shown efficacy in prior studies. We are providing this as a possible referral program for study participants (either arm) who are interested in receiving substance abuse intervention.
45693862|NCT01739803|Behavioral|Behavioral Contract|Intervention activities were performed by a study clinical pharmacist. Behavioral contract goal was achieving and maintaining IST adherence. Other components of the contract addressed: (a) motivation(s) or positive reinforcement for achieving IST adherence; (b) problems or barriers that may interfere with achieving IST adherence and possible solutions to overcome problems/barriers; (c) social support available to the RTR such as a significant other who may assist the RTR in following the IST dosing schedule; (d) tools/strategies the RTR may use to remind himself/herself to follow the IST dosing schedule; and (e) possible consequences of IST nonadherence (e.g., graft loss).
45379623|NCT00824681|Behavioral|Sound Of Family Together (S.O.F.T.) Music Program|Audio compact disk containing songs, music, special messages, poems from children of adults with major burns
45379624|NCT00824681|Other|Non-Therapy Related Activities (NTRA)|NTRA includes non-directed activities e.g. reading books/magazines, watching TV/movie in family lounge off the BICU, playing with toys, listening to music CDs/radio.
45379625|NCT00832013|Drug|Propofol|See detailed description
45379626|NCT00832013|Drug|Propofol|See detailed description
45379627|NCT00824759|Other|pure oxygen breathing versus air|one group will breath pure oxygen; the other will breath air
45379628|NCT00832169|Drug|AZD1386|1 dose of oral solution
45379629|NCT00824837|Other|Larger pore haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
45379630|NCT00824837|Other|Standard haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
45379631|NCT00832247|Genetic|Autologous bone marrow mononuclear cells infusion|At least 100.000.000 autologous BMMC will be infused in a peripheral vein once suspended in albumine during 10 minutes
45379632|NCT00832403|Other|implants of polytetrafluoroethylene in tha nasal fossa|surgical implants of polytetrafluoroethylene in the nasal fossa
45379633|NCT02550041|Other|T specific response for diagnostic of aspergillus bronchitis|
45379634|NCT00832481|Drug|Repaglinide|Repaglinide (NovoNorm®): 0.5 mg/tablet, 1.0 mg/tablet
45379635|NCT00832481|Drug|Metformin|2 mg/tablet Metformin (Glucophage®): 0.5 g/tablet
45379636|NCT00350272|Drug|elvucitabine|elvucitabine 10 mg orally daily
45693863|NCT00824434|Device|PROMUS Element™|Drug eluting coronary stent system
45693864|NCT01739335|Drug|Mifepristone Oral Tablet [Korlym]|2 Mifepristone 300 MG Oral Tablets once daily (600mg total) for 7 days
45693865|NCT01739335|Drug|Placebo Oral Tablet|2 Placebo Oral Tablets once daily for 7 days
46054889|NCT05098197|Biological|Tumor Infiltrating Lymphocyte|Adoptive transfer of 1x10^9-5x10^10 autologous TILs to patients i.v. in 30-120 minutes.
46054890|NCT02847936|Procedure|vicryl plus suture|episiotomy with triclosan-coated sutures
46054891|NCT02847936|Procedure|vicryl suture|episiotomy with non antibacterial coated suture
45379637|NCT00350272|Drug|Lamivudine|lamivudine 300 mg orally daily
45379638|NCT00350272|Drug|Tenofovir|tenofovir open-label 300 mg orally daily
45379639|NCT00350272|Drug|Efavirenz|efavirenze open-label 600 mg orally daily
45379640|NCT04044287|Drug|200 micrograms of misoprostol|200 micrograms of powdered misoprostol applied sublingually together with standard parenteral oxytocic therapy
45379641|NCT04044287|Drug|Placebo Oral Tablet|200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy
45379642|NCT00827801|Behavioral|MDASI-HF Questionnaire|M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) questionnaire rating symptoms given in clinic Day 1, Weeks 4 & 8.
45495551|NCT03334721|Drug|Gabapentin|5 day trial of gabapentin with titration to 1,200mg
45495552|NCT03334721|Drug|Placebo Oral Capsule|5 day trial of matched placebo
45693866|NCT00824512|Drug|EGb 761 120 mg|EGb 761® 120 mg bid, orally for 12 to 14 weeks
46054892|NCT05329233|Device|Masimo Radical-7 Pulse CO-Oximeter|The Masimo Radical-7 Pulse CO-Oximeter is a device for the measurement of pulse oximetry, oxygen reserve index (ORi), perfusion index (PI), and pleth variability index (PVI). The device is the product of a company called Masimo Inc, Irvine, CA, USA
46054893|NCT00634725|Drug|capecitabine|
46054894|NCT00634725|Drug|erlotinib hydrochloride|
46054895|NCT00634725|Drug|gemcitabine hydrochloride|
46054896|NCT00634725|Other|laboratory biomarker analysis|
45379643|NCT02549729|Behavioral|pelvic floor muscle training|Women will be instructed to perform pelvic floor muscle training daily at home 4 sets of 10 maximum perceived voluntary contraction of the pelvic floor muscle sustained for 6 seconds followed by 5 flick voluntary contraction of the pelvic floor muscle. The 4 sets will be performed in 4 different positions (supine, all four, sit and standing). Twice a week they will receive a supervised session using the same protocol described above.
45379644|NCT00827879|Behavioral|Strength at Home Couples Group|A multiple site randomized trial will compare 10 sessions of PF-RET to 10 sessions of a supportive group therapy. PF-RET focuses on 1) deployment stress and traumatic experiences impacting intimate relationships; 2) communication between intimate partners; 3) conflict and anger management; and 4) closeness and intimacy.
45379645|NCT00827879|Behavioral|Supportive Group Therapy|A general support group designed to enhance support for healthy relationship building.
45379646|NCT00832559|Biological|CVA21|1, 3 or 6 doses of CAVATAK (10^9 TCID50) at 48 hour intervals.
45379647|NCT02549807|Device|Muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured.
45495553|NCT05144880|Other|electroacupuncture|A total of 12 treatment sessions will be administered to each participant. The acupoints of needles inserted for each participant in each session are DU20, EX-HN1, DU29, HT17, PC6, RN6, RN4, LR3 and SP6. The needles will be manually stimulated by rotating, thrusting, stirring, etc. to produce ''De Qi'' sensation. Then we will use electroacupuncture for acupoint stimulation lasting 30min. The frequency will be set as 2Hz for the electroacupuncture with 2Hz group and the frequency will be set as 100Hz for the electroacupuncture with 100Hz group.
46054897|NCT00634725|Radiation|radiation therapy|
45495554|NCT03709589|Other|Modified Early Warning Score|Modified Early Warning Score
45379648|NCT03856307|Diagnostic Test|point of care ultrasound|to evaluate the reliability of simple pre-specified ultrasound findings acquired at the bedside with a hand-held apparatus with regards to five clinical scenarios most commonly encountered in the hospital, i.e. vaginal bleeding in early pregnancy, pre-eclampsia, prolonged/obstructed labor, antepartum hemorrhage (APH) and high risk pregnancies encountered in ANC.
45379649|NCT00357370|Drug|Dapagliflozin|Tablets, Oral, once daily, up to 12 weeks
45379650|NCT00357370|Drug|Placebo|Tablets, Oral, 0 mg, once daily, up to 12 weeks
45379651|NCT00832715|Procedure|EBUS-TBNA|Tissue sample collected bronchoscope using needle aspirate of lung lymph gland, procedure takes 1 hour.
45379652|NCT00825071|Drug|Dexamethasone|8 mg, Intravenous
45379653|NCT00825071|Drug|Ondansetron|4 mg, intravenously
45495555|NCT05531214|Behavioral|Multidisciplinary Care Coordination Team|The intervention group will be patients whose primary care clinicians will be receiving guidance and recommendations from the multidisciplinary team consisting of cardiologists, nephrologists, and specialty pharmacists.
45495556|NCT03707561|Diagnostic Test|Right Heart Catheterization (RHC)|RHC at the enrollment and every 12 months
45495557|NCT05706402|Drug|N-acetylcysteine|Patients will be randomized to receive oral N-acetylcysteine at 600 mg twice daily for 1 week. The randomization will be done via computer software with half of the patients randomized to receive NAC. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.
45693867|NCT00824512|Drug|Placebo|Placebo 1 tablet BID, orally for 12 to 14 weeks
45847303|NCT04129554|Drug|Placebo for JNJ-73763989|Matching placebo for JNJ-73763989 will be administered as subcutaneous injection up to 48 weeks.
46054898|NCT04228809|Device|tDCS|transcranial direct current stimulation
45379654|NCT00825071|Drug|normal saline|2 ml, intravenously
45379655|NCT00827957|Device|Internal Cooling|The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.
46054899|NCT05327673|Other|questionnaire|"quality of life score: FACT-BMT~decisional conflict scale~Discreet Choice Experiment questionnaire"
45379656|NCT00827957|Device|External Cooling|The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
45379657|NCT03987724|Other|Positron emission tomography (PET) imaging at rest and during supine bicycle exercise|Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
45379658|NCT00574847|Drug|Escitalopram|Dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
45379659|NCT00574847|Drug|Placebo|Placebo dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
45379660|NCT00348790|Drug|vatalanib|
46054900|NCT03639051|Device|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD) Therapy is a bronchoscopically guided, minimally invasive procedure using the Nuvaira™ Lung Denervation System.
46054901|NCT03639051|Other|Optimal Medical Care|Taking regular maintenance medication that minimally includes a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA).
46054902|NCT05325489|Drug|Nebulized Budesonide|use 0.5mg/2ml Pulmicort Respules BIS QD and oral montelukast sodium chewable tablets 4mg QD
46054903|NCT05325489|Drug|Intranasal Budesonide Spray|nasal spray 100μg QD and oral montelukast sodium chewable tablets 4mg QD
46054904|NCT00902538|Drug|Olmesartan medoxomil 40 mg - Amlodipine 10 mg|Oral tablets containing Olmesartan medoxomil-Amlodipine 40-10 mg, given once daily
45495558|NCT05706402|Drug|Placebo|Patients will be randomized to receive placebo for 1 week. The randomization will be done via computer software with half receive placebo. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.
45495559|NCT05706246|Diagnostic Test|diagnostics|Serum tryptase levels were evaluated in all suspected children with perioperative hypersensitivity
45495560|NCT05114538|Behavioral|Reciprocal Imitation Training|RIT is a relatively straightforward, brief NDBI. It employs four simple strategies to target motor imitation and IJA during play: (1) contingent imitation of the child's verbal and nonverbal behavior, (2) linguistic mapping, (3) direct elicitation of object and gesture imitation following the child's interest, and (4) contingent reinforcement. It has been used at low intensities (e.g., 1-3 hours per week) over short periods of time (e.g., 10-12 weeks) to produce robust changes in pivotal skills. It is easy to learn and can be implemented with fidelity by undergraduate-level therapists with limited backgrounds in ASD, as well as by parents and siblings.
45847304|NCT04129554|Drug|Placebo for JNJ-56136379|Matching placebo for JNJ-56136379 tablets will be administered orally up to 48 weeks.
45495561|NCT03627312|Combination Product|Omega-3|1g of omega-3 supplement to be taken per day for a duration of 3 months in the form of a fruit juice drink
45495562|NCT03627312|Combination Product|Placebo|Fruit juice drink only
45495563|NCT03627312|Other|Treatment as Usual|Young Offenders Intervention Programme
45495564|NCT03627000|Other|failure after reimplantation|description of cinical and microbiological failure
45495565|NCT03515551|Drug|IMCnyeso|Weekly IV infusions of IMCnyeso
45495566|NCT05558592|Dietary Supplement|Dietary supplementation with fresh oranges|"the subjects enrolled in this group, will have to consume 400gr of oranges Navelina net of waste / day / per person for a month. The oranges will be provided, to each participant, by the IRCCS Saverio de Bellis."
45495567|NCT05558592|Dietary Supplement|Balanced Diet without oranges|the subjects enrolled in this group, will have to consume 400 gr of fruit (with the exception of citrus fruits) net of waste / day / per person for a month.
45847305|NCT04129554|Drug|Entecavir (ETV) monohydrate|ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
45847306|NCT04129554|Drug|Tenofovir disoproxil fumarate (TDF)|TDF will be administered orally once daily up to 48 weeks as NA treatment.
45379661|NCT00828035|Procedure|laparoscopic surgery|comparison of two different laparoscopic surgeries : robot versus human
45379662|NCT00825149|Drug|Bendamustine|Bendamustine will be administered as per schedule specified in the respective arm.
45495568|NCT05706168|Device|treadmill exercise|Treadmill exercise is a form of aerobic exercise training that involves the use of a treadmill machine in a structured exercise programs.
45379663|NCT00825149|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per schedule specified in the respective arm.
45495569|NCT05706168|Device|Cycle ergometer exercise|Cycle ergometer exercise is a form of aerobic exercise training that involves the use of a stationery recumbent bike in a structured exercise programs.
45495570|NCT03626844|Procedure|Manual Lysis of Placenta after 15 minutes (Intervention)|Manual Lysis of Placenta after 15 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
45495571|NCT03626844|Procedure|Manual Lysis of Placenta after 30 minutes (Control)|Manual Lysis of Placenta after 30 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
45495572|NCT04694443|Procedure|Multidisciplinary tele-health intervention (physical therapy, neurologist, nurse, psychologist)|Non-pharmacological and pharmacological treatment provided by telemedicine plus in-office visits
45693868|NCT00824746|Drug|Gefitinib retreatment|phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous EGFR-TKI failure.
45693869|NCT01702363|Drug|GSK573719|GSK573719 inhalation powder inhaled orally once daily for 52 weeks.
45754002|NCT03927482|Behavioral|CARES mobile smart phone app|The CARES smart phone mobile app contains a number of features to support safety while drinking and reduced alcohol consumption plus regular test messages for personal support
45847307|NCT04129554|Drug|Tenofovir alafenamide (TAF)|TAF will be administered orally once daily up to 48 weeks as NA treatment.
45847308|NCT04128540|Drug|Fentanyl|fentanyl infusion at a dose of (1 μg/kg/hour) after induction of anesthesia and to be continued all through the whole operation.rescue analgesia by a bolus of (Fentanyl 1mcg/kg) will be given to the patients in either group, if either systolic blood pressure or heart rate increased more than 20% of the baseline readings.
46054905|NCT00902538|Drug|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
46054906|NCT00902538|Drug|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablets. All tablets are given once a day.
45379664|NCT00825149|Drug|Doxorubicin|Doxorubicin will be administered as per schedule specified in the respective arm.
45379665|NCT00825149|Drug|Fludarabine|Fludarabine will be administered as per schedule specified in the respective arm.
45379666|NCT00825149|Drug|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
45495573|NCT04694443|Other|Standard in-office medical care|Non-pharmacological and pharmacological treatment provided in-office visits
45495574|NCT05706090|Drug|fentanyl will be added|If adequate anagesia is not provided with the block, 1 microgram/kg of fentanyl will be added
45495575|NCT05706090|Procedure|general anesthesia|If adequate anagesia is not provided with the block, general anesthesia will be administered.
45379667|NCT00825149|Drug|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
45379668|NCT00825149|Drug|Vincristine|Vincristine will be administered as per schedule specified in the respective arm.
45379669|NCT00825383|Other|High Fiber and Moderate Fiber Diets|Dietary
45379670|NCT00360490|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
45379671|NCT00360490|Drug|Medroxyprogesterone acetate|Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
45379672|NCT02549105|Drug|EMLA CREAM 5 mg|EMLA CREAM APPLICATION FOR WOUND AFTER CS
45379673|NCT02549105|Drug|LIDOCAINE 1 %|LIDOCAINE 1 % INFILTERATION FOR WOUND AND ASSESSMENT OF PAIN IN FIRST 6 HOURS
45495576|NCT04418791|Behavioral|Modified Intermittent Fasting followed by Regular Diet|Modified intermittent fasting (MIF) means fasting for 2 non-consecutive days/week. Fasting is defined as consuming less than 500 kcalories in 1 day (in the course of max. 6 hours). After 12 weeks of fasting, a period of 12 weeks with a regular diet follows.
45495577|NCT04418791|Behavioral|Regular Diet followed by Modified Intermittent Fasting|Regular diet means subject can eat as usual for 12 weeks. Next, a period of 12 weeks fasting follows: modified intermittent fasting (MIF) means fasting for 2 non-consecutive days/week. Fasting is defined as consuming less than 500 kcalories in 1 day (in the course of max. 6 hours).
45379674|NCT00828269|Procedure|Comparator: Fine needle aspiration biopsy|"Visit 1: Screening Visit 2 (7-14 days from screening): Core needle biopsy and fine needle aspiration biopsy - liver.~Visit 3:(7 days from visit 2): Fine needle aspiration biopsy - liver. Visit 4: (14 days from Visit 3): follow-up visit"
45495578|NCT05513274|Behavioral|Pain Psychology Neuroscience + Written Emotional Disclosure|A 15 to 20-minute exercise which they examine variables in themselves that suggest that their pain is driven by central nervous system processes. Participants will then write for 20 minutes about their very deepest thoughts and feelings about the most traumatic experience of their lives. A 10-minute break followed by writing again for 20 minutes about how they have come to understand what happened and how they have changed because of the event.
45495579|NCT05513274|Behavioral|Pain Psychology Neuroscience + Healthy Habits Disclosure|This condition is a 15 to 20-minute exercise that patients complete in which they examine variables in themselves that suggest that their pain is driven by central nervous system processes in their brains. Followed by writing for 20 minutes a letter to a person of their choosing describing healthy behaviors, a 10 minute break and then a second 20 minute writing task describing a time when they performed a healthy behavior.
45498218|NCT03688464|Drug|Placebos|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
46054907|NCT00902538|Drug|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
46054908|NCT00902538|Drug|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
45379675|NCT00833183|Drug|MAL|80 mg/g cream one administration with incubation for 90 minutes
45379676|NCT00624377|Drug|Tiotropium|Tiotropium 18 mcg HandiHaler once daily
45379677|NCT02549963|Device|WATCHMAN Left Atrial Appendage Occlusion Device|
45379678|NCT02549963|Drug|Rivaroxaban|
46054909|NCT00902538|Drug|OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablet. All tablets are given once a day.
45379679|NCT00624065|Drug|carvedilol controlled release/lisinopril|carvedilol CR + lisinopril given as separate pills
45379680|NCT00624065|Drug|lisinopril + placebo|lisinopril plus placebo to match carvedilol CR
45379681|NCT00360412|Drug|E2007|
45379682|NCT00623831|Biological|Mixed bacterial vaccine|MBV was administered twice weekly by subcutaneous injection in Cohort 1 and by intralesional (preferred) or subcutaneous (if intralesional not possible) injection in Cohort 2. In Cohort 1, the MBV starting dose was 250 EU (dose level 1) with possible intrasubject escalations up to 547,000 EU (dose level 8). In Cohort 2, all subjects received MBV at a fixed dose of 60,800 EU (dose level 6).
45379683|NCT00833339|Drug|mifepristone|600 mg/day x 1 week
45379684|NCT00833339|Drug|placebo|placebo
45379685|NCT02549885|Other|PNF contract-relax|Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
45379686|NCT02549885|Other|Static stretching|Static stretching of neck muscles.
45379687|NCT00825617|Drug|Hormone replacement therapy|Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
45379688|NCT00825695|Dietary Supplement|cocoa|two servings of cocoa daily for one month
45379689|NCT00360334|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
45379690|NCT00360334|Drug|insulin glargine|subcutaneous injection, titrated to target blood glucose level, once a day
46054910|NCT02779335|Other|Enteral Formula|pediatric subjects will be fed a standard pediatric enteral formula tube feeding
45379691|NCT00422097|Drug|Ixabepilone, 5 mg/d|Ixabepilone, 5 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
45379692|NCT00422097|Drug|Ixabepilone, 10 mg/d|Ixabepilone, 10 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
45495580|NCT05513274|Behavioral|Health Behavior Control + Written Emotional Disclosure|This 15 to 20-minute exercise that relates to healthy behaviors. Participants are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections). Participants will then write for 20 minutes about their very deepest thoughts and feelings about the most traumatic experience of their lives. A 10-minute break followed by writing again for 20 minutes about how they have come to understand what happened and how they have changed because of the event.
45495581|NCT05513274|Behavioral|Health Behavior Control + Healthy Habits Disclosure|This 15 to 20-minute exercise that relates to healthy behaviors. Participants are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections). Followed by writing for 20 minutes a letter to a person of their choosing describing healthy behaviors, a 10 minute break and then a second 20 minute writing task describing a time when they performed a healthy behavior.
45495582|NCT03380429|Drug|RELVAR/BREO|RELVAR/BREO will be available at doses of 100/25 micrograms (µg) and 200/25 µg to be administered via ELLIPTA DPI. Subjects will be administered one inhalation of RELVAR/BREO once daily.
45693870|NCT05049928|Other|Telerehabilitation solution (m-Rehab)|"The telerehabilitation program consists of the following elements:~Mobile applications and website usable on smartphone and tablet for the patient.~Teleconsultation solution for the patient and the doctors.~Video conferencing solution for professionals involved in patient follow-up: educators in adapted physical activity, physiotherapists, psychologists, dieticians, etc.~Web interface for health professionals allowing the collection and monitoring of various parameters in physical activity and nutrition as well as progress in therapeutic education activities.~Withings® connected objects"
45379693|NCT00422097|Drug|Ixabepilone, 15 mg/d|Ixabepilone, 15 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
45693871|NCT01722097|Drug|Rocuronium|
45693872|NCT01722097|Drug|placebo|
45379694|NCT00422097|Drug|Ixabepilone, 20 mg/d|Ixabepilone, 20 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
45693873|NCT04383106|Other|no intervention|no intervention
45693874|NCT00824824|Drug|Dorzolamide 2%-timolol 0.5%|BID OU for 6 weeks
45693875|NCT00824824|Drug|Brimonidine 0.2%-0.5% timolol 0.5|BID OU for 6 weeks
46054911|NCT04228185|Procedure|sleeve gastrectomy|Comparison of banded and not-banded sleeve gastrectomy
46054912|NCT05339763|Radiation|chemoradiotherapy|exposure of patients with rectal cancer to radiotherapy and assessment of their bowel function after surgery
46054913|NCT05092035|Diagnostic Test|single high-fidelity expiratory CO2 analysis|in addition to regular pulmonary function testing a real-time high-fidelity assessment of expiratory CO2 will be performed
46054914|NCT04228653|Device|Renishaw Drug Delivery System|Device that allows pharmaceuticals to be delivered into the brain is to be assessed over a period of time to inform of the long term safety of the implanted device.
45495583|NCT03380429|Drug|Salbutamol|Salbutamol will be available at a dose of 100 µg to be administered via MDI. Subjects will be administered salbutamol as and when required.
45379695|NCT00422097|Drug|Ixabepilone, 25 mg/d|Ixabepilone, 25 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
45495584|NCT03380429|Device|Smart phone app|Subjects will be required to download an app associated with sensor on their smartphone. The sensors attached to the inhalers will be connected to the smartphone via Bluetooth.
45495585|NCT03380429|Device|HCP Dashboard|The information from sensors will be reviewed by the HCP via an online dashboard.
45495586|NCT03380429|Device|Sensors|Clip-on sensors will be fitted to electronically record the actuation data.
45495587|NCT05096442|Device|GENOSS® DCB|Drug Coated Balloon
45495588|NCT05096442|Device|SeQuent® Please NEO|Drug Coated Balloon
45495589|NCT01313143|Drug|AOP200704|Comparison of AOP200704 with Esmolol
45495590|NCT01313143|Drug|Esmolol hydrochloride, infusion|Comparison of AOP200704 with Esmolol
45495591|NCT05499780|Device|Sentinox|The treatment will be administered in a dose of 0.5 ml into each nostril (5 sprays) per 3 times/day (8 am, 2 pm and 8 pm), for 21 days from Visit 1.
45495592|NCT03280615|Dietary Supplement|Omega 3 fatty acids|Omega 3 fatty acids will be provided in a dose of 3.7 g/day, that should be enough to rise red blood cell levels of eicosapentanoic and docosahexanoic acids
45495593|NCT03280615|Dietary Supplement|Corn oil|Corn oil will be the placebo comparator for omega 3 fatty acids supplement
45495594|NCT05705934|Other|Exercise|Each session of the exercise program will last 50 minutes and will consist of 4 stages. At these stages, it is aimed to work the social, physical, spiritual and mental parameters of the holistic approach.
45495595|NCT05071794|Drug|Propofol|Antiemetic effect of propofol
45495596|NCT05071794|Drug|saline 0.9%|Placebo
45495597|NCT03711071|Other|"Workshop ICE training"|The workshop includes training in communication skills in relation to evidence based medicine.
45495598|NCT03710993|Device|oximeter|Participants breathe a controlled gas mixture to induce several reduced oxygen states while oximeter measurements are taken for comparison to corresponding transfer standard and reference devices to assess oximeter calibration and accuracy.
45495599|NCT03709433|Behavioral|ACT groups and mobile app|See arm description.
45495600|NCT05705778|Procedure|standard amblyopia treatment|amblyopia treatment following international guidelines and genetic tests.
45495601|NCT03280537|Drug|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.
45693876|NCT01701973|Drug|Sitagliptin|During Aim 1, given on one of two study days (other study day subjects receive placebo.) During Aim 2, given during both of two study days.
45379696|NCT00422097|Drug|Ixabepilone, 30 mg/d|Ixabepilone, 30 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
45379697|NCT00422097|Drug|Ixabepilone, 25 mg, with famotidine|Participants crossed over from Cycle 1 to receive famotidine, 40 mg, in an oral dose given 2 hours before ixabepilone, 25 mg, on Day 1 of Cycle 2 only.
45379698|NCT00422097|Drug|Ixabepilone, 25 mg, with food|Participants consume a low-fat meal starting 30 minutes before dose administration on Day 1 of Cycle 2. Food consumed within 30 minutes. Administration of the total oral dose should not exceed more than 10 minutes from start to finish.
45495602|NCT03280537|Drug|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
45495603|NCT04799327|Drug|SHR20004|SHR20004：low dose
45495604|NCT04799327|Drug|SHR20004|SHR20004: medium dose
45495605|NCT04799327|Drug|SHR20004|SHR20004: high dose
45495606|NCT04799327|Drug|placebo|Placebo
45495607|NCT03842826|Diagnostic Test|Palpation, resistance and stretch tests|Palpation, resistance and stretch tests performed by 2 blinded examiners.
45495608|NCT05705622|Other|Oral mukositis nurse's education for patients|Education given to patients by nurses on the prevention, treatment and care of oral mucositis
45495609|NCT05555550|Drug|18F-Fluciclovine|18F-Fluciclovine will be injected via IV prior to PET-MRI imaging
45495610|NCT05618730|Device|punctum plug insertion|"EXP-TC delivers the anti-inflammatory drug tacrolimus that acts as inhibitor of T lymphocytes and may therefore lead to the inhibition of release of inflammatory cytokines.~EXP-TC has a Pangolin design and has 3 different designs: big, medium and small with drug content ranging from 194 to 348 µg.~After plug insertion preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) is taken 4 times daily."
45495611|NCT05618730|Drug|Eye Drops, Lubricant|Preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) 4 times daily.
45495612|NCT05029050|Drug|Dexmedetomidine|Continous intravenous infusion
45495613|NCT05029050|Drug|Clonidine|Continous intravenous infusion
45495614|NCT05029050|Drug|Natriumchlorid|Continous intravenous infusion NaCl
45495615|NCT04690231|Drug|Apatinib Mesylate|apatinib orally daily and ifosfamide 1.8mg/m2/d d1-3, etoposide 100mg/m2/d d1-3
45495616|NCT04690231|Drug|ifosfamide and etoposide|ifosfamide and etoposide
45379699|NCT02534194|Other|Image acquisition|Images of baby's face (including ear) and feet
45495617|NCT03280381|Other|Nifty feeding cup|The 40 mL Nifty Feeding Cup features an extended reservoir off the lip of the cup that holds a small bolus of milk, ensuring efficient delivery of milk, is made of a durable, soft, silicone material that protects the infant's mouth from injury, has embossed measurements help with tracking volume and intake of milk, is ergonomically designed for frequent use and to enhance finger and wrist control of milk flow and is made from a quick-drying, ultraviolet radiation-resistant, durable, affordable silicone that can be boiled for sterilization. Mothers can directly express into the cup, reducing possible cross-contamination from other containers.
45379700|NCT01051102|Drug|insulin degludec/insulin aspart|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
45379701|NCT01051102|Drug|biphasic insulin aspart 30|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
45379702|NCT01053364|Device|NL-Prow interspinous spacer implant|Interspinous spacer implant
45379703|NCT00348556|Drug|Nesiritide|Nesiritide 0.005 ug/kg/min IV for 6 hours, then to 0.01 ug/kg/min for 6 hours then to 0.02ug/kg/min for 6 hours then to 0.03 ug/kg/min for the last 6 hours.
45379704|NCT00434967|Drug|Candesartan cilexetil|32 mg oral tablet
45379705|NCT00434967|Drug|Hydrochlorothiazide|25 mg oral tablet
45379706|NCT00434967|Drug|Candesartan/HCT 32/25 mg|
45379707|NCT00825773|Device|Percutaneous Transluminal Coronary Angioplasty|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
45495618|NCT03280381|Other|Generic medicine cup|The generic cup that will be used in this study is a small medicine cup 30 ml in size.Small medicine cups are manufactured by a variety of manufacturers and are commonly used in health facilities to feed breastmilk to infants who are having breastfeeding difficulties. The cups are generally translucent, calibrated with a variety of measurements including 2.5-30 mL.
45495619|NCT03343483|Behavioral|Volunteering|"Volunteers provide non-medical caregiving for frail seniors-care receivers-to help them maintain their independence and improve their well-being. Friendly visiting is the primary service provided. Structured, intensive training is provided prior to placement. The target expectation is of interactions in person and/or by telephone for at least 16 hours per month. On-going training (booster sessions) as well as volunteer support groups, and educational activities are provided. Participants not interested in serving as peer companions are allowed other volunteer options as long as the activities are deemed 'social' by the volunteer coordinator and are options routinely provided as part of the AmeriCorps Senior RSVP Program. COVID update: due to physical distancing requirements, volunteer placements have transitioned to remote friendly calling/letter writing or activities that can be conducted with physical distancing, such as delivery for Meals on Wheels."
45693877|NCT01701973|Drug|Pegvisomant|During Aim 2, given 72 hours prior to one of two study days (Group B subjects only)
45693878|NCT01701973|Drug|Placebo|During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)
45379708|NCT00833729|Drug|etanercept|50 mg twice weekly (BIW) for 12 wks followed by a dose reduction to 50mg once weekly (OW) for an additional 12 weeks.
45379709|NCT00837239|Drug|Gemcitabine|1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle).
45379710|NCT00837239|Drug|HuaChanSu|20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
45693879|NCT01701973|Drug|L-NMMA|During Aim 2, given during one of two study days (Group A subjects only)
45693880|NCT01701973|Drug|Exendin 9-39|During Aim 2, given during one of two study days (Group C subjects only)
45379711|NCT00837239|Drug|Placebo|500 ml saline only administered as a 2 hour infusion by central line.
45379712|NCT00833807|Drug|Nab-Paclitaxel (Abraxane)|"Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days."
45379713|NCT00833885|Device|Masks|Wearing of surgical masks
45379714|NCT00833885|Device|Masks & hand hygiene|Wearing of surgical masks and intensified hand washing
45495620|NCT03343483|Behavioral|Life Review|Subjects will complete a self-guided life review exercise over 12 months. Subjects will complete one section of the life review (with the self-help book) each month and send 'assignments' once per month to an email 'counselor' who will respond with supportive comments within three days.
45379715|NCT00833885|Other|Control|General information about virus transmission in households and basic means to prevent it
46054915|NCT05323539|Other|Evaluating Thyroid Volumes by ultrasonography|The inclusion criteria are ; having a prediagnosis of surgically planned endometrioma and to undergo gynecological surgery for a reason other than endometriosis (control group). Among the patients with pre-diagnosis of endometriosis, who applied to our clinic during the study period and accepted to participate in the study, thyroid volumes will be measured by ultrasonography during the preoperative hospitalization. The pathological diagnosis of the patients will be confirmed and patients with different results will be excluded from the study (such as malignancy, endometriosis prediagnosis but different pathology detected etc.) In the same period, gynecological surgery was planned for another reason and patients without endometriosis will form the control group.
45379716|NCT00833963|Drug|Trastuzumab|Participants will receive trastuzumab as determined by their treating physicians' standards of care.
45379717|NCT00833963|Drug|Pertuzumab|Participants will receive pertuzumab as determined by their treating physicians' standards of care.
45379718|NCT00833963|Drug|Ado-Trastuzumab Emtansine|Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.
45495621|NCT03270085|Drug|Colesevelam|Colesevelam (Welchol) is approved by the Food and Drug Administration (FDA) for the treatment of high blood cholesterol levels and to treat type 2 diabetes however, Colesevelam is not approved for the use proposed in this study and is considered investigational.
45495622|NCT03270085|Other|Placebo|A placebo looks exactly like the study drug, but it contains no active ingredient. This is used to learn if the effects seen in research participants are truly from the study drug.
45495623|NCT05615454|Device|bio-electromagnetic energy regulation therapy (BEMER) machine model type: B.BOX CLASSIC, model NO: 420100, 12-15 Volt, (BEMER Int.AG, Liechtenstein product).|The experimental group (receive the BEMER therapy) for five sessions/week for three weeks. Plus, pelvic floor exercise.
45495624|NCT05615454|Device|placebo BEMER|Comparison group (receive placebo BEMER therapy) for five sessions/week for three weeks. Plus, pelvic floor exercise.
45379719|NCT00837317|Dietary Supplement|Olive Oil, SF, SF+DMP, SF+phenols|All the volunteer subjects will be administered four breakfast meals that have been prepared with four different types of oil, each of which will have been subjected to a standardised frying. The meals will be administered according to a cross-randomized Latin squares design
45379720|NCT04043897|Drug|Rifaximin 550mg|Rifaximin 550mg
45693881|NCT00825370|Drug|Hydromorphone|1 mg IV hydromorphone followed by an optional 1mg IV hydromorphone 15 minutes later
46054916|NCT02780037|Behavioral|Regulatory frame: prevention|Exercise program presented as preventing deterioration.
45379721|NCT00356590|Biological|Etanercept|Etanercept (TNFR:Fc) will be administered 50 mg per week as two 25 mg subcutaneous injections at separate sites, given either on the same day or 3 or 4 days apart.
45693882|NCT00825370|Drug|IV opioid|Any IV opioid in the dose chosen by the treating physician. May include hydromorphone as well.
46054917|NCT02780037|Behavioral|Regulatory frame: promotion|Exercise program presented as promoting improvement.
46054918|NCT02780037|Behavioral|Regulatory frame: not implied|Exercise program presented without implied consequences.
46054919|NCT01628406|Procedure|Treatment at the neurosurgery departement|Treatment at the neurosurgery departement
45379722|NCT04043663|Device|Virtual Reality glasses|Children are encouraged to watch the virtual reality program at least 24 hours before surgery.
45379723|NCT04043663|Procedure|standard perioperative care without virtual reality program|standard perioperative care without virtual reality program
45379724|NCT00837551|Drug|WBI-1001|Doses of 0,0.5% and 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with one week follow-up.
45379725|NCT00834353|Drug|ATT|
45495625|NCT05703204|Drug|QLF32101|The dose is given weekly and observed for 28 days(DLT observation period).Single agent treatment.
45495626|NCT03267511|Drug|5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
45495627|NCT03267511|Drug|5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
45693883|NCT01721317|Drug|Ezogabine/Retigabine IR|Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.
45693884|NCT01721317|Drug|Placebo|Matching placebo will be available
45693885|NCT05038852|Device|smartphone applications|app is designed to help you learn relaxation skills.
46054920|NCT02019849|Device|Plasmafit® Total Hip Arthroplasty|
46054921|NCT02780505|Drug|vitamin c|"In the current prospective, double-blind, and randomized trial, 66 patients with peritoneal dialysis were enrolled, and 43 patients were detected with serum vitamin C level below 4 μg/ml to determine the effect of vit C on anemia in patients on CAPD.~The measured clinical parameters including plasma vitamin C level, hemoglobin (Hb), Ferritin, total iron-binding capacity (TIBC), serum Fe, C-reactive protein (CRP), and transferrin saturation. Consumption of vitamin supplements such as vitamin C (or any other form of it) either oral or parenteral were discontinued three weeks before collecting the samples."
45495628|NCT03267511|Drug|5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
45495629|NCT03267511|Drug|5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
45379726|NCT03987334|Other|Virtual Reality Treatment|Experimental Group (VRT) subjects will undergo Virtual Reality Motor Control exercises based on augmented feedback of their performance.
45379727|NCT03987334|Other|Control Group|Control Group (CT) subjects will undergo the same treatment of VRT subjects in terms of intensity, time and type, but with the VR turned off.
45495630|NCT05003544|Procedure|Group A|PENG BLOCK
45495631|NCT05003544|Procedure|Group B|Intra-articular
45495632|NCT05003544|Procedure|Group C|Quadratus lumborum block
45495633|NCT04998006|Drug|Alcohol and Cannabis vs. Alcohol only|Self-directed (ad-libitum) cannabis and alcohol vs. self-direct (ad-libitum) alcohol
45495634|NCT04234945|Drug|Doxycycline Capsule|Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding.
45495635|NCT04234945|Drug|Multivitamins W/Iron Tab|Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding
45495636|NCT03627156|Behavioral|guided counseling|Community-based guided counseling using Health Belief Model and Theory of Planned Behavior is the intervention package for this study.
45379728|NCT02548871|Behavioral|Teen Outreach Program|TOP® is a positive youth development and service learning program for youth ages 12 to 17, and its Changing Scenes curriculum is separated into age appropriate levels. The program uses an approach that involves a caring adult, positive self-efficacy, future planning and goal setting and life management skills to to reduce risky sexual behavior and improve school outcomes. TOP® is designed to be delivered in weekly sessions over 9 months and includes community service learning.
45495637|NCT04972578|Device|Suture Button vs Screw Fixation|Syndesmotic fixation utilizing suture button fixation versus Screw Fixation (placing one or two screws across the syndesmosis)
45495638|NCT03802110|Device|commercially released subcutaneous implantable cardioverter defibrillator (S-ICD) and the Investigational S-ICD Adapter.|The S-ICD System is a Subcutaneous (under the skin) Implantable Cardioverter Defibrillator for people who are at risk of Sudden Cardiac Arrest. A new electrode configuration will be tested for Defibrillation testing ( DFT). The unit of measure will be in Joules. VF will be induced and the device will deliver a shock at a certain defined energy level as described in the protocol
46054922|NCT02780505|Drug|placebo|"Active (ascorbic acid 250 mg) and placebo (same weight of starch) tablets were similar in shape and size for both study and control groups. Intravenous intervention was not advantageous for hemodialysis subjects and it was impossible for PD patients, therefore, oral administration was used. All follow-up records were stored.~The erythropoietin (EPO) injections was prescribed for each patient in weekly dose, started one month before collecting blood samples for vitamin C measurement."
46054923|NCT02690844|Drug|Clonazepam mixed with Mucolox®|1mg clonazepam in 5mL Mucolox® will be used TID. Mixture will be swished around mouth for 3 minutes then spat out.
45495639|NCT03316807|Biological|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
45495640|NCT03316807|Biological|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
45495641|NCT04948710|Diagnostic Test|Sonography|Sonographic Venous Doppler Imaging
46054924|NCT02690844|Drug|Mucolox® alone|5mL Mucolox® TID. Mixture swished around mouth for 3 minutes then spat out.
45495642|NCT04931550|Device|Pacemaker implantation|Different pacing sites will be chosen according to the patients condition.
45495643|NCT03379259|Drug|BGB-A333|Anti-PD-L1 antibody
45495644|NCT03379259|Drug|BGB-A317|Anti-PD-1 antibodies
45495645|NCT05586048|Drug|Yiqi Fumai Lyophilized Injection(YQFM)|No intervention was involved, but patients will be divided into exposed or non-exposed groups based on whether they received YQFM
45693886|NCT05038852|Device|smartphone applications|app is designed to help you increase your positive feelings, behaviors, and thoughts.
46054925|NCT02690844|Drug|Clonazepam|1mg Clonazepam tablet will be used TID. Tablet dissolved in mouth, swished around and then expectorated.
46054926|NCT04201860|Diagnostic Test|Arterial blood gas analyses and haemostasis measures|Under aseptic conditions, a puncture of radial artery was performed: three mL of the arterial blood sample were used for the haemostasis measure, while one mL was tested for the blood gases analysis.
45379729|NCT03987256|Other|Initial rehabilitation protocol|During 12 weeks, under kinesitherapist guidance, patients will perform daily eccentric stretching and strengthening of the ECRB and periscapular musculature, manual therapies, and kinesiotaping. They will also use orthotics after 6 weeks if kinesiotaping is not effective. At weeks 1-5, patients will undergo weekly ultrasound-guided focused shockwave therapy under the following protocol: 0,15- 0,30mJ/mm2 (the highest energy flux the patient can well tolerate), 1500 shocks at 5Hz at the origin of common extensor or flexor tendon.
45495646|NCT05405556|Diagnostic Test|eGFR reporting|"To test the proportion of patients successfully completing the protocol according to different eGFR reporting strategies, randomization in a 1:1 fashion at the patient level (n=50) will occur as follows:~only study-related eGFR values >25% below baseline will be reported to patients and providers~all study-related eGFR will be provided to patients and providers"
45379730|NCT03987256|Procedure|Needling with PRP|"In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with PRP.~Details of PRP preparation (ACP Arthrex): 15 ml of blood, no activators or anticoagulants, poor in white blood cells (the last mm of buffy coat above the red blood cells pellet is not collected).~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure."
46054927|NCT05075889|Drug|Indocyanine Green|Enrolled subjects will receive Indocyanine Green administered the day prior to surgery during their standard-of-care preoperative appointment
46054928|NCT02848014|Behavioral|Writing task|
45379731|NCT03987256|Procedure|Needling with saline solution|"In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with saline solution.~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure."
45379732|NCT00828503|Drug|Certican (everolimus) + valganciclovir|"Oral MED 1: Certican® initial dose: 1,5-3 mg day target trough level: 3-8 ng/mL (first levels will be performed after 3 days and then adjusted until - according to the judgement of the clinical investigator - a stable degree of immunosuppression is reached; thereafter Certican® trough levels will be performed at the scheduled appointments)~MED 2: Valganciclovir (or ganciclovir) will be administered in addition to Certican (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)"
45379733|NCT00828503|Drug|Valganciclovir|Valganciclovir (or ganciclovir) will be administered alone (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)
45495647|NCT04924998|Drug|current treatment of AL-CM|current treatment of AL-CM
45495648|NCT03328897|Drug|Omalizumab|injection of 150mg or 300 mg
45495649|NCT03328897|Drug|Placebo|Injection of placebo
45495650|NCT04918758|Device|Purastat Arm|"Generic name of device and principal intended use(s):~Still PuraStat from a CE mark perspective. PuraStat is an aqueous self-assembling peptide solution of 2.5% concentration RADA16~Indication for use:~PuraStat is indicated for haemostasis in the following situations encountered during surgery, when haemostasis by ligation or standard means is insufficient or impractical:~Bleeding from small blood vessels and oozing from capillaries of the parenchyma of solid organs. Oozing from vascular anastomoses~Bleeding from small blood vessels and oozing from capillaries of the GI tract following surgical procedures~Reduction of delayed bleeding following gastrointestinal endoscopic submucosal dissection (ESD) procedures in the colon."
45495651|NCT04918758|Drug|Standard Care Arm|Sucralfate enemas 2g twice daily for 8 weeks, this is standard care in patients with haemorrhagic radiation proctopathy in the short term
45495652|NCT03266107|Device|Intracept|Radiofrequency ablation of the basivertebral nerve using the Intracept System
45495653|NCT03378635|Drug|Dasiglucagon|Glucagon analog
45495654|NCT03378635|Drug|GlucaGen|Native glucagon
45847309|NCT04128540|Procedure|Erector spinae plane block|"ultrasound guided erector spinae plane block by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%). This will be performed at the same side of the planned thoracotomy under strict aseptic precautions.A high frequency 12 MHz linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process.~Three muscles; trapezius, rhomboids major, and erector spinae will be identified superior to the hyperechoic transverse process.~Using in-plane approach a 25 G needle will be inserted in caudal-cephalic direction, until the tip is deep to erector spinae muscle.~Correct needle tip location will be confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process.."
45847310|NCT04109976|Drug|Bimekizumab|Study participants will receive bimekizumab at pre-specified time points.
46054929|NCT04972929|Other|Spinal Manipulation|Diversified (i.e. crossed bilateral hypothenar contact) chiropractic technique will be administered at levels of identified spinal joint restriction/dysfunction (derived from thoracic spine x-rays, static and motion palpation, and confirmed or provoked localized tenderness in paraspinal soft tissues).
45495655|NCT03378635|Drug|Placebo|Placebo for dasiglucagon
45495656|NCT03326869|Device|Raindrop Near Vision Inlay|The Raindrop Near Vision Inlay was approved by the US FDA in June of 2016 for the improvement of near vision in presbyopic emmetropes. Raindrop is a clear device made of a hydrogel material and resembles a microscopic contact lens; it is the first implantable device that changes the shape of the cornea to correct the refractive errors that cause near vision problems.
45495657|NCT05692284|Other|routine care group|Firstly, informed consent was obtained from the patients in the control group, a pre-test was applied with the existing data collection methods, and routine nursing care continued. At the end of the 6-week follow-up period, the data collection process was ended with the post-test application.
45495658|NCT05692284|Other|Care in accordance with Orem's theory group|Firstly, informed consent was obtained from the Intervention group, for which the pre-test was applied, and then care was given during their stay in the hospital in accordance with Orem's theory. This care was performed when the patient came to each chemotherapy cycle. After discharge, patient follow-up and care continued with the mobile application designed with Orem's theory, which will ensure the continuity of this care given in the clinic. At the end of the 6-week follow-up period, the data collection process was ended with the post-test application.
45495659|NCT03710837|Other|Pain neuroscience education|Two different lectures covering essential clinical skills but one designed to explore the hypothesis
45495660|NCT03710837|Other|Red flag education|Two different lectures covering essential clinical skills but one designed to explore the hypothesis
45495661|NCT01182727|Drug|salsalate|Salsalate will be administered in 500 mg tablets. Salsalate will be administered in two divided doses of 2 grams in the morning and 2 grams in the evening. Salsalate will be administered for a total of 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until tolerated or a minimum dose of 2 grams per day is achieved.
45495662|NCT00624715|Drug|THC|"High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking a full joint~Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint~Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking 1/10 of a joint"
45495663|NCT00624715|Drug|Placebo|Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
45495664|NCT04279158|Behavioral|"experience 1 The negative priming task"|The targets are presented to the subject on a computer screen. The subject must make an eye or hand movement toward the target and ignore the distracters.
45495665|NCT04279158|Behavioral|"experience 2 Stop signal task"|The targets are presented to the subject on a computer screen. The subject must make an eye movement towards this target. Sometimes a stop signal will appear and the subject will have to avoid to look at the target
45495666|NCT04279158|Behavioral|"experience 3 Anti-saccades"|The targets are presented to the subject on a computer screen. The subject must make an eye movement toward this target. Sometimes an instruction will ask the subject to look at the opposite of the target
45495667|NCT03334409|Drug|Ascorbic Acid|Given IV
45495668|NCT03334409|Drug|Pazopanib Hydrochloride|Given PO
45495669|NCT04821726|Device|Drug eluting balloon (Vmoky)|Use Vmoky Drug Eluting Balloon to treat patients with symptomatic intracranial atherosclerosis stenosis
45847311|NCT05448612|Other|Active Release Technique and muscle energy technique|74 participants divided into two groups and 37 in each group.
46054930|NCT04972929|Other|Sham Spinal Manipulation|Sham-SM will be delivered by setting the expansion control knob on an Activator II (Activator Methods®, Phoenix AZ) device to the zero position (off; no thrust) and placed onto the dorsal thumb surface of the clinician (no actual instrument contact with study participant). At a setting of zero, no excursion of the Activator II stylus occurs, despite the device delivering an audible clicking sound, with no biomechanical force being imparted to the participant.
46054931|NCT02847702|Drug|VM902A 200-mg Capsules|Taken orally with food twice daily
46054932|NCT02847702|Drug|VM902A 400-mg Capsules|Taken orally with food twice daily
45495670|NCT04810260|Behavioral|Use mobile health app (WellXcel) to increase knowledge|Download the app (WellXcel) to the mobile device
45495671|NCT02891915|Drug|Amoxicillin|Amoxicillin is an aminopenicillin antibiotic
45495672|NCT02891915|Drug|Amoxicillin-clavulanate|A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.
45495673|NCT02891915|Drug|Cefdinir|Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.
45495674|NCT02891915|Other|Placebo|Placebo
45495675|NCT04741542|Drug|SP-420|This study aims to establish the safety of SP-420 administered orally three times per week (TIW).
45847312|NCT04104438|Drug|Basiliximab 20 MG|Basiliximab induction followed by tacrolimus, corticosteroids and mycophenolic acid with a switch to everolimus by post operative day 30
45847313|NCT04085796|Other|ICCI|Intentional Compassionate Communication Intervention
45495676|NCT04096092|Other|No intervention|No intervention
45847314|NCT04007640|Radiation|MRI with additional sequences|MRI with 15 min additional sequences to validate and assess pancreatic MRI sequences
45847315|NCT04007640|Radiation|MRI|MRI with 15 min additional sequences to validate and assess pancreatic MRI sequences
45847316|NCT04007640|Procedure|Left pancreatectomy or pancreaticoduodenectomy|Histological analysis :
45495677|NCT02891681|Device|Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound|
45495678|NCT05284032|Drug|isatuximab 10 mg/kg|Given by intravenous infusion
45495679|NCT03707483|Combination Product|combination of vitamin C and platelet rich fibrin|combination of vitamin C and platelet rich fibrin
45495680|NCT03626766|Behavioral|Photo in Verification Alert|Patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
45495681|NCT03626766|Behavioral|Photo in Banner|Patient photograph will be displayed in the banner at the top of the screen in the electronic health record.
45847317|NCT04007640|Radiation|MRI with additional sequences|MRI with 15 min additional sequences to assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients
45379734|NCT03990220|Dietary Supplement|Lactobacillus rhamnosus yoba 2012|"Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug."
45379735|NCT03990376|Other|Radioisotope I-131-labeled albumin|1 mL of radioisotope I-131-labeled albumin x 2
45847318|NCT03879018|Behavioral|Reach training with visual feedback|Reach training will be accomplished using an Oculus Rift and Touch 3D headset. Active markers will be placed on the shoulder, elbow, wrist, and finger in order to capture limb movement in real time. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed.Targets will be presented in a pseudorandom order and participants will reach a total of 400 times
45847319|NCT03762954|Other|Neurocognitive function assessment|Neurocognitive function will be assessed via a phone battery derived from standard cognitive tests proven feasible and valid to assess memory, attention, reasoning, and executive functioning. Functional status will also be assessed via phone. The duration of time required for the patient to complete telephone interview for neurocognitive and functional assessment will be approximately 45 minutes per time point.
46054933|NCT02847702|Drug|Naproxen 500-mg Capsules|Taken orally with food twice daily
46054934|NCT02847702|Drug|Placebo|Capsules to match VM902A and/or naproxen taken orally with food twice daily
45847320|NCT03752970|Drug|Spesolimab|Solution for infusion
46054935|NCT05236881|Device|ANíMATE mobile application|mHealth tool ANíMATE (Adherence, Nutrition, PhysIcal Activity, Motivation, medicAtion, Technology and Empowerment) allows the recording of data related to diet and exercise and feedback on behavior through an intelligent data analysis system.
46054936|NCT03904290|Other|PFO Closure|Subject will undergo percutaneous closure of PFO/ASD utilizing FDA-approved PFO/ASD closure device(s).
46054937|NCT02779413|Drug|insulin degludec|Patients will be treated with commercially available Tresiba® FlexTouch® according to routine clinical practice at the discretion of the treating physician.
45379736|NCT00834509|Device|CPAP|Use CPAP for 4-6 weeks as clinically prescribed.
45379737|NCT01051180|Procedure|HALO|Ligation of haemorrhoidal arteries
45379738|NCT04322825|Device|TENS incorporated into the Mollii suit|trans cutaneous electric stimulation,
45495682|NCT03626766|Behavioral|Photo in Banner and Verification Alert|Patient photograph will be displayed in the banner at the top of the screen in the electronic health record AND patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
45495683|NCT05683145|Behavioral|Computerized Cognitive Behavioral Therapy for Insomnia|This is a computerized version of cognitive behavioral therapy for insomnia that is augmented by support from a licensed mental health professional. The intervention consists of 6 modules designed to provide education regarding sleep and insomnia, establish behavioral modifications to reduce insomnia symptoms, and monitor progress. Participants will be able to complete these intervention at their own pace, which will take between 6-9 weeks.
45495684|NCT04671342|Device|DreamKit|The DreamKit device is a single-use device intended to aid the diagnosis of sleep-disordered breathing.
45495685|NCT04764929|Device|Helmet CPAP|Vyatil nonpowered oxygen tent system
45495686|NCT03627078|Other|motor interference therapy|
45495687|NCT03627078|Other|Relaxation exercises|In a top-down sequence, beginning with the upper body and proceeding to the lower parts. patients contract and relax a specific muscle group following the instructions given by the audio track. We use a shorter version that excludes the legs because of the time.
45379739|NCT03990142|Diagnostic Test|Cutaneous conductance to chlorine by SUDOSCAN|"The additional examination, related to this research protocol, corresponds to a record of cutaneous conductance with chlorine. This recording of 2 min 30 is done thanks to SUDOSCAN® within 30 minutes before the dialysis session (before the connection to the dialysis machine) and within 30 minutes after the end of the dialysis with a measurement of the tension blood pressure and heart rate immediately before SUDOSCAN®."
45495688|NCT05560854|Behavioral|Internet delivered prolonged exposure|Internet delivered prolonged exposure for ten weeks with therapist support.
45495689|NCT05232708|Drug|Semaglutide B, 1.34 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
45495690|NCT05232708|Drug|Semaglutide D, 1.0 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
45495691|NCT05232708|Drug|Semaglutide D, 1.0 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
45495692|NCT05232708|Drug|Semaglutide B, 1.34 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
45495693|NCT05230368|Drug|Decitabine cycle 1|Decitabine administration (5mg/m²) at days 1, 2, 3
45495694|NCT05230368|Drug|Romidepsin cycle 1|Romidepsin administration (5mg/m²) at days 4, 11, 18
45495695|NCT05230368|Drug|Decitabine cycle 2|Decitabine administration (5mg/m²) at days 35, 36, 37
45495696|NCT05230368|Drug|Romidepsin cycle 2|Romidepsin administration (5mg/m²) at days 38, 45, 52
45495697|NCT05230368|Drug|Decitabine cycle 3|Decitabine administration (5mg/m²) at days 70, 71, 72
45495698|NCT05230368|Drug|Romidepsin cycle 3|Romidepsin administration (5mg/m²) at days 73, 80, 87
46054938|NCT04887402|Drug|Clomiphene Citrate|"All patients will be treated with CC starting with 50 mg/day on the day 2 of their cycle for 5 days, a transvaginal ultrasound will be done 1 week after the last pill, if all follicles are below 10 mm the dose will subsequently be increased to 100mg/day for 5 days then 150mg/day for 5 days if a transvaginal is done a week from the last pill and showed no response (all follicles being below 10 mm ).Maximum cc dose will be 150 mg (ASRM, 2013). Medroxyprogesterone (10 mg/d Provera for 10 days)will be given to induce withdrawal bleeding to start these steps again in a new cycle. These steps will be repeated for 3cycles before declaring the patient CC resistant.~o Response: Response to CC will be assessed by ovulation. TVS will be done by the same observer using a Samsung ultrasound machine, HS40.~A scan will be done 1 week after the last pill of each dose. No response: if all follicles are below 10 mm (ASRM, 2013), follicles >10mm, follow up till ovulation"
46054939|NCT05336916|Behavioral|Buddy|Mindfulness-based Cognitive Behavioural Therapy
45379740|NCT00834665|Biological|hTERT vaccine, GM-CSF, PCV, T cell infusion|hTERT vaccine (multi-peptide vaccine), Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
45379741|NCT00834665|Biological|GM-CSF, PCV, T cell infusion|Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
45379742|NCT01051258|Device|AeriSeal System|AeriSeal System for Lung Volume Reduction
45379743|NCT00837707|Drug|aripiprazole|Flexible dose: 5-30 mg/day
45495699|NCT05230368|Drug|Decitabine cycle 4|Decitabine administration (5mg/m²) at days 105, 106, 107
45495700|NCT05230368|Drug|Romidepsin cycle 4|Romidepsin administration (5mg/m²) at days 108, 115, 122
45495701|NCT03046446|Drug|FX006 32 mg|Single intra-articular injection
45495702|NCT03051217|Other|Placebo|"Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 0.9 % saline~Route of Administration: Subcutaneous use Q2W"
45495703|NCT03051217|Drug|Certolizumab Pegol|"Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 200 mg/mL~Route of Administration: Subcutaneous use"
45495704|NCT05114785|Diagnostic Test|Multi Parametric Cardiac Magnetic Resonance|Research based Cardiac MRI evaluation to determine cardiovascular haemodynamics
45847321|NCT03752970|Drug|Placebo|Solution for infusion
45847322|NCT03703206|Drug|ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK)|nerve block for posterior knee pain after a TKA.
45847323|NCT03689244|Drug|Selexipag|oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 to 8 tablets at each administration
45847324|NCT03689244|Drug|Placebo|Oral tablets without active compound
45379744|NCT02548247|Dietary Supplement|Orafti® Inulin|Dietary fiber
45379745|NCT02548247|Dietary Supplement|Placebo|Maltodextrin
45379746|NCT01055938|Drug|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
45495705|NCT05080621|Drug|Ripretinib|50 mg tablets
45495706|NCT05080621|Drug|binimetinib|15 mg tablets
45495707|NCT05035303|Procedure|Nor-Epinephrine injection versus saline during PCNL|The PCNL tract is infiltrated by Nor-Epinephrine or Normal Saline before its dilatation.
45495708|NCT03637621|Other|ORIF|open reduction internal fixation of the distal humerus
45495709|NCT04179097|Diagnostic Test|Finger photoplethysmography|Bilateral finger photoplethysmogray, bilateral brachial artery Doppler, Aorta artery Doppler
45495710|NCT03046056|Drug|Filgotinib|Tablet(s) administered orally once daily
45495711|NCT03046056|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
45495712|NCT02849587|Drug|Cannabis|Participants will smoke a cannabis cigarette ad libitum as per their usual routine
45379747|NCT00837785|Drug|BG00012|240 mg (two 120 mg capsules) orally three times a day
45495713|NCT04647786|Device|Prototype medical device (SEA CtV)|A prototype device that delivers a controlled flow of gas to the upper airways via the subglottic suction port of an established tracheostomy tube. Gas flow may be timed, warmed and/or humidified.
45495714|NCT03347279|Biological|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
45495715|NCT03347279|Other|Placebo|Placebo subcutaneous injection
45495716|NCT04627428|Biological|RPESC-RPE-4W|RPESC-RPE-4W
45495717|NCT04250545|Drug|Sapanisertib|Given PO
45495718|NCT04250545|Drug|Telaglenastat Hydrochloride|Given PO
45495719|NCT04615104|Procedure|Operative|surgical treatment
45495720|NCT04615104|Procedure|Nonoperative|nonsurgical treatment
45379748|NCT00837785|Drug|BG00012|240 mg (two 120 mg capsules) orally twice a day
45379749|NCT00356278|Drug|D-Cycloserine|D-Cycloserine doses will be 50 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
45495721|NCT03998683|Drug|Guselkumab 100 mg|Guselkumab 100 mg will be administered as SC injection.
45495722|NCT03998683|Drug|Placebo|Placebo will be administered as SC injection.
45379750|NCT00356278|Drug|Alprazolam|Alprazolam doses will be 0.25 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
45379751|NCT00356278|Behavioral|Virtual Reality Exposure Therapy|VRE includes viewing scenes of virtual Iraq via a head mounted display. Other stimuli presented include sounds, smells and vibration. Each session will be 60 minutes with approximately 30 to 45 minutes of that wearing head mounted display.
45379752|NCT00356278|Drug|Placebo|Placebo will be administered in the same manner as the active drugs.
45495723|NCT03637465|Behavioral|Hydrate Philly|"Hydrate Philly is a multi-component intervention that includes water safety testing, provision of 1-2 hydration stations per recreation center, distribution of reusable water bottles for youth, a campaign to promote the acceptability of tap water, and the reduction of access to competing unhealthy beverages through vending machine standards and discouraging black bags (characteristic small, black, plastic bags provided to customers with their corner store purchases, typically including a sugar sweetened beverage and/or unhealthy snack foods)."
45379753|NCT00837863|Drug|Somatropin|ALTU-238 0.3 mg/kg daily
45379754|NCT00837863|Drug|Somatropin|ALTU-238 0.6 mg/kg daily
45495724|NCT03262441|Drug|Mycophenolate Mofetil 500Mg Tab|500 mg once daily for one week. If tolerating the drug, then initiate twice daily for 22 months
46054940|NCT04793568|Drug|Recombinant Interferon gamma 1b (IMUKIN®)|100 µg/0,5ml subcutaneous injections from day 1 to day 9 (5 injections, i.e. 1 injection of 100 µg every 48h)
46054941|NCT04793568|Drug|Recombinant Interferon gamma 1b placebo|5 subcutaneous injections from day 1 to day 9 (i.e. 1 injection of 0,5ml every 48h).
46054942|NCT01979211|Drug|Cetuximab|400 mg/m2 IV over 120 minutes week 1; 250 mg/m2 IV over 60 minutes weekly weeks 2-7
46054943|NCT01979211|Radiation|Radiation Therapy|Radiation Therapy 60-66 Gy in 2 Gy fractions starting week 2 of Cetuximab
46054944|NCT05339217|Drug|Telitacicept|160mg Telitacicept was subcutaneously injected to patients with systemic lupus erythematosus at the outer side of upper arm every week for 24 weeks.
45379755|NCT00837863|Drug|Somatropin|ALTU-238 0.9 mg/kg daily
45379756|NCT00837863|Drug|Somatropin|Nutropin AQ 0.043 mg/kg daily
45379757|NCT00834821|Behavioral|Parent Focused Training (PFT)|PFT will involve parenting skills training supplemented with a phone session between a therapist and teacher to cover ADHD, inattentive type. This intervention will include ten 90-minute parent group training sessions and up to five individual sessions with the study therapist.
45495725|NCT05201664|Procedure|Surgical Extrusion|Relocation of the remaining tooth structure to a more coronal position within the same original socket.
45495726|NCT04580394|Drug|AD109|Oral administration before bed
45495727|NCT04580394|Drug|Atomoxetine|Oral administration before bed
45495728|NCT04580394|Drug|R-oxybutynin|Oral administration before bed
45495729|NCT04580394|Drug|Placebo|Oral administration before bed
46054945|NCT05339217|Drug|Interleukin-2|Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
45495730|NCT04580394|Diagnostic Test|Digit System Substitution Test|a neuropsychological test sensitive to brain damage, dementia, age and depression where numbers are assigned symbols. Under each digit the subject should write down the corresponding symbol as fast as possible. The number of correct symbols within the allowed time is measured.
45495731|NCT03749148|Drug|Dupilumab|anti-IL4-Receptor alpha
45495732|NCT03749148|Drug|Placebo|Placebo
45495733|NCT03713580|Drug|Venetoclax|"Adding Venetoclax, a BCL-2 inhibitor, to standard high dose therapy prior to autologous stem cell transplant (ASCT).~Venetoclax is a novel, orally bioavailable, small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor."
45495734|NCT02781727|Drug|Once weekly subcutaneous injection of TransCon hGH|Once weekly subcutaneous injection
45379758|NCT00834821|Behavioral|Child Life and Attention Skills (CLAS) Program|CLAS will involve parenting skills training adapted for ADHD, inattentive type; child life skills training; and teacher consultation. This intervention will include ten 90-minute parent group training sessions; ten 90-minute child group training sessions; up to five individual family sessions with the study therapist; and up to six 30-minute sessions with the teacher, parent, and therapist.
45379759|NCT03991780|Drug|Fostamatinib|All patients will be given treatment with Fostamatinib. The initial treatment dose will be 100mg of Fostamatinib twice daily for 8 weeks. If after 8 weeks the participant has not experienced any side effects and are tolerant of this dose, then the dose will increase to 150mg twice daily. This dose will continue for the duration of the study.
45495735|NCT02781727|Drug|Once daily subcutaneous injection of Genotropin|Once daily subcutaneous injection
45495736|NCT03626610|Behavioral|Exercise prehabilitation during chemotherapy before surgery|Monitored exercise training in patients with a new diagnosis of oesophageal adenocarcinoma
45495737|NCT03707327|Other|Game Ready|the participants remained for 20 minutes with intermittent compression therapy + cryotherapy
45495738|NCT03707327|Other|Ice pack|the participants remained for 20 minutes with cryotherapy with ice pack
45379760|NCT02547389|Behavioral|Community support group|
45495739|NCT01343082|Drug|DE-111 ophthalmic solution|
45495740|NCT03374189|Device|EZ close|EZ close used.
45495741|NCT03374189|Device|Carter Thomason|Carter Thomason used.
45495742|NCT04385173|Drug|B7-H3 CAR-T|The B7-H3 CAR-T will be administrated via intratumoral or Intracerebroventricular injection through an Ommaya catheter in between Temozolomide cycles. Temozolomide will be stopped during the infusion of B7-H3 CAR-T
45495743|NCT04385173|Drug|Temozolomide|Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.
45495744|NCT03709199|Diagnostic Test|Ventilation Inhomogeneity|Ventilation inhomogeneity will be measured using the Lung Clearance Index (LCI), derived from multiple breath Nitrogen washout during tidal breathing, measured by a mouthpiece or mask covering nose and mouth.
45495745|NCT03709199|Diagnostic Test|Diaphragm Ultrasound|Diaphragm thickness and contractile activity measured during tidal breathing.
45495746|NCT03709199|Diagnostic Test|Respiratory Inductance Plethysmography|Measure of thoraco-abdominal asynchrony during tidal breathing
46054946|NCT04793490|Procedure|Sphenopalatine ganglion block|Patients will receive the SPGB via the transnasal approache by a cotton tipped applicator soaked in lignocaine 2% with 4 mg dexamethasone
46054947|NCT04793490|Drug|paracetamol|patients will receive paracetamol 1 g thrice daily intravenously
46054948|NCT00779532|Drug|Moxifloxacin|Capsules containing 400 mg moxifloxacin, on Day 14 only
46054949|NCT00779532|Drug|NOMAC-E2 (Org 10486-0 + Org 2317)|Tablets containing 2.5 mg NOMAC and 1.5 mg E2, once daily dosing, orally taken. Daily dose either NOMAC-E2 2.5/1.5 mg or 12.5/7.5 mg.
45379761|NCT02547389|Other|Printed material Supported|
45379762|NCT01051336|Device|TARIS Placebo|
45379763|NCT01051336|Procedure|Sham Procedure|
45379764|NCT00837941|Drug|Comparator: A: Pregabalin|1 Pregabalin 300 mg capsule
45495747|NCT03709199|Diagnostic Test|Spirometry|Measurement of Forced Expiratory Volume (FEV1), Forced Vital Capacity and other lung volumes using standard pulmonary function techniques
45495748|NCT03709199|Diagnostic Test|Functional Residual Capacity|Measurement using body box plethysmography of functional residual capacity and other lung volumes using standard pulmonary function techniques
45495749|NCT03709199|Diagnostic Test|MIP/MEP|Measurement of maximal inspiratory and expiratory pressures during airway occlusion
45495750|NCT03709199|Diagnostic Test|6 minute walk test|Measurement of cardio-respiratory function and capabilities during treadmill walking for 6 minutes.
45495751|NCT03709199|Diagnostic Test|Neurocognitive Testing|Detailed in person neuro-cognitive testing using standardized inventories using either the Battelle Developmental Inventory, second edition (Battelle-2) (age birth to 5 years 11 months) and the Wechsler Intelligence Scale for Children, fifth edition (WISC-5, for age 6 years to 19 years).
45495752|NCT03709199|Diagnostic Test|Emotional Health Assessment|In person and written assessments of children and parents using the Behavioral Assessment System for Children, third edition (BASC-3) for children ≥ 2 years and the UCLA PTSD Reaction Index (UCLA RI) for children ≥ 8 years.
45495753|NCT03709199|Diagnostic Test|Health Related Quality of Life|Standardized instruments to assess (in person, over the phone, or via mail) health related quality of life in children. Parent and child questionnaires.
45495754|NCT03709199|Diagnostic Test|Functional Status|Survey of overall functional status, administrated by asking a series of questions to patient and families.
45379765|NCT00837941|Drug|Comparator: B: Duloxetine|1 Duloxetine hydrochloride 60 mg capsule
45379766|NCT00837941|Drug|Comparator: C: Diphenhydramine hydrochloride|1 Diphenhydramine hydrochloride 25mg capsule
45379767|NCT01053442|Dietary Supplement|Porridge fortified with either NaFeEDTA|265g maize porridge is fortified with 2.5 mg iron as NaFeEDTA.
46054950|NCT00779532|Drug|Moxifloxacin placebo|Moxifloxacin-placebo capsule taken orally, Day -1 and Day 14 only
46054951|NCT00779532|Drug|NOMAC-E2 placebo|Tablets containing NOMAC-E2 placebo, once daily dosing, orally taken.
45379768|NCT01053442|Dietary Supplement|FeSO4|Maize porridge is fortified with 2.5 mg iron as ferrous sulphate and 45 mg ascorbic acid.
45379769|NCT00828659|Drug|Placebo|
45379770|NCT00828659|Drug|Active Comparator #1|
45379771|NCT00828659|Drug|Active Comparator #2|
45379772|NCT00828659|Drug|Active Comparator #3|
46054952|NCT01036022|Drug|GSK1399686|Each dose level of GSK1399686 will be subsequently tested in a cohort of approximately 20 patients, who will be randomized in a 3:1:1 ratio to receive GSK1399686 (once daily over 4 weeks, followed by 2 weeks dosing with placebo), placebo, or ASACOL (t.i.d. for 6 weeks), respectively.
45379773|NCT00828659|Drug|Lorcaserin Dose #1|
45379774|NCT00828659|Drug|Lorcaserin Dose #2|
45379775|NCT00828659|Drug|Lorcaserin Dose #3|
45379776|NCT00356200|Drug|Fluphenazine Decanoate|"Fluphenazine decanoate marketed by APP Pharmaceuticals (25 mg/mL, 5 mL vial) was used in this study. This was an ascending dose study with the first cohort of 5 subjects dosed at 10 µg/mL, followed by 5 subject dosed in the second cohort at 100 µg/mL. Note: APP Pharmaceuticals is the name of the pharmaceutical company; APP is not an acronym."
45379777|NCT00356200|Drug|Placebo|The sterile placebo (sesame oil with 1.2% (w/v) benzyl alcohol) was prepared at the University of Iowa, Division of Pharmaceutical Services, a FDA registered pharmaceutical manufacturing facility.
45379778|NCT04044053|Drug|PF-06865571 400 mg Immediate Release (IR) in Fed State|400 mg IR dose in fed state
45379779|NCT04044053|Drug|PF-06865571 50 mg Modified Release (MR) in Fed State|50 mg MR in fed state
46054953|NCT05055297|Device|SELUTION SLR™ DEB 014|a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
46054954|NCT05055297|Device|Plain (Uncoated) Balloon Angioplasty (PTA)|a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
45379780|NCT04044053|Drug|PF-06865571 400 mg MR in Fed State|400 mg MR in fed state
45379781|NCT04044053|Drug|PF-06865571 400 mg MR in Fasted State|400 mg MR in fasted state
45379782|NCT00835289|Dietary Supplement|n-3 polyunsaturated fatty acids|Omax3[TM] (Cenestra Health [TM]) is a 1 g softgel capsule containing 94.5% omega-3 fatty acids. Each serving size is a 1 gram capsule, which contains 690 mg of eicosapentanoic acid (EPA) and 182 mg of docosahexanoic acid (DHA). Inactive ingredients include: Vitamin E/Tocopherol 2294 ppm (in a carrier of partially hydrogenated vegetable oils including soybean oil), gelatin, glycerol, and purified water (components of the capsule shell). The study participants will be randomized to 3 softgel capsules a day for 6 months.
45379783|NCT00835289|Other|Placebo|3 capsules of matching corn oil placebo
45379784|NCT00838019|Procedure|Intrabone administration of umbilical cord blood|Single administration
45379785|NCT02548091|Other|Blood samples for assays of plasma inflammatory markers (cytokines InterLeukin-6, InterLeukin-8, InterLeukin-10)|"The same amount of blood sample is collected from both arms of study at the same time of the procedure.~In each patient, in the per procedure period, a total of 50 milliliters of blood sample is drawn from the pulmonary circulation downstream and upstream of obstructive lesion, the trunk of pulmonary artery, the superior vena cava and the femoral arterial line prior to angioplasty and at the end of procedure; in the post interventional care unit 10 milliliters of blood sample will be draw daily from the superior vena cava catheter line and femoral arterial line."
45379786|NCT02548091|Procedure|Non invasive ventilation|
45379787|NCT02548091|Procedure|monitoring system Pulse-Induced Contour Cardiac Output (Picco)|
45379788|NCT02548091|Procedure|Computed tomography (CT)|
45379789|NCT00828737|Drug|Gadobutrol (Gadovist, BAY86-4875)|Gadovist in approved indications at approved dosages
45379790|NCT00356122|Drug|Docetaxel|70 mg/m^2 administered intravenously (IV) on Day 1 for Cycles 1-6 (the treatment cycle is 3 weeks)
45495755|NCT03709199|Diagnostic Test|Respiratory Status Questionnaire|Survey of respiratory health, administrated by asking a series of questions to patient and families.
45379791|NCT00356122|Drug|Oxaliplatin|100 mg/m^2 administered IV on Day 1 for Cycles 1-6
45495756|NCT03261037|Other|Spirometry|Daily spirometry will be conducted by the participant at home using the study kit provided. Spirometry assessments (FVC) will be conducted at approximately the same time each day with the participant in a seated position. Additionally, site spirometry will also be performed during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
45495757|NCT03261037|Other|Accelerometry|Daily physical functional capacity assessments (e.g., steps per day, calorie expenditure) will be measured on an ongoing basis using the accelerometry device provided.
45379792|NCT00356122|Drug|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and every 3 weeks during maintenance therapy for a total treatment of one year, until disease progression or death due to any cause, whichever occurs first.
45495758|NCT03261037|Other|6MWT|The 6MWT will be performed only at sites where a formalized process is available and the test can be performed under safe conditions, during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
45495759|NCT03710759|Other|Assistive autogenic Drainage|Assistive autogenic Drainage : All the 3 components of Autogenic drainage was given passively to the patients. By placing the hands on the child's chest, the therapist manually increases the expiratory flow to achieve the different lung volume breathing.
45379793|NCT01056094|Drug|Lutein|Dietary Supplement: 20mg,10mg, 0mg Lutein; daily supplementation 12 week
45379794|NCT00838175|Procedure|suture mediated closure|Suture mediated closure of femoral venous access
45495760|NCT03650322|Behavioral|Yoga|12 weeks, total of 150 minutes of exercise per week.
45379795|NCT03989908|Other|Microfludic noodle|In this intervention arm, subjects will be served with noodles made using microfludic technology.
45379796|NCT03989908|Other|Control noodle|In this intervention arm, subjects will be served with normal noodle.
45495761|NCT03650322|Behavioral|Stretching and Toning|12 weeks, total of 150 minutes of exercise per week.
45495762|NCT03650322|Behavioral|Aerobic Walking|12 weeks, total of 150 minutes of exercise per week.
45495763|NCT03372551|Device|somofilcon A 1 day test lens|Contact lens
45495764|NCT03372551|Device|somofilcon A 1 day control lens|Contact lens
45495765|NCT03707249|Drug|Ferric Carboxymaltose Injectable Product|iv iron infusion: 15 mg / kg up to a maximum 1g dose of Ferinject diluted in normal saline (0.9%) up to a total volume of 250 ml
45495766|NCT03707249|Drug|Normal Saline 0.9% Infusion Solution Bag|250 ml of normal (0.9%) saline given by intravenous infusion over 20 minutes. This constitutes the control for the iron infusion.
45495767|NCT03326323|Procedure|Acute Normovolemic Hemodilution|Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.
45495768|NCT05682911|Drug|Zingiber officinale L. tablets|Zingiber officinale L. tablets 500mg twice daily
45495769|NCT05682911|Drug|Simvastatin 20mg|Simvastatin 20mg once a day for 2 months
45379797|NCT00828815|Drug|TMC125|
45495770|NCT05480592|Drug|HS-10380|Administered orally as a tablet
45495771|NCT05480592|Drug|Placebo|Administered orally as a tablet
45495772|NCT04990531|Diagnostic Test|Low-field magnetic resonance imaging|Imaging of lung parenchyma and function by LF-MRI
45495773|NCT04990531|Diagnostic Test|Blood sample|Blood sample for diagnostic testing
45495774|NCT05479890|Other|ClientBot|ClientBot is an AI-based simulated client that supports skills improvement for providers learning and using Motivational Interviewing
45495775|NCT05467332|Device|HIGH FLOW NASAL OXYGEN|"BEFORE EXTUBATION, AN AIRWAY EXCHANGE CATHETER (AEC) WILL BE PUT INTO THE PATIENTS' TRACHEA AND IT WILL REMAIN IN SITE AFTER EXTUBATION. THROUGH AN AEC CONNECTED TO A PRESSURE MONITOR, IT WILL BE RECORDED TRACHEAL PRESSURE DURING SPONTANEOUSLY BREATHING PATIENT AT DIFFERENT FLOW RATES OF HFNC THAT WILL BE APPLIED JUST AFTER EXTUBATION.~MEANWHILE, VITAL PARAMETERS RECORDED WITH A MULTIPARAMETRIC MONITOR WILL BE RECORDED.~FINALLY, MONITORING OF ELECTRICAL ACTIVITY OF DIAPHRAGM WILL BE RECORDED THROUGH A DEDICATED NASOGASTRIC TUBE TO EVALUATE IT AT DIFFERENT FLOW RATES."
45379798|NCT01053520|Drug|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation A Period 2: Single (oral) dose of 25 mg of Formulation B1 Period 3: Single (oral) dose of 25 mg of Formulation B2
45379799|NCT01053520|Drug|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B1 Period 2: Single (oral) dose of 25 mg of Formulation B2 Period 3: Single (oral) dose of 25 mg of Formulation A
45379800|NCT01053520|Drug|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B2 Period 2: Single (oral) dose of 25 mg of Formulation A Period 3: Single (oral) dose of 25 mg of Formulation B1
45379801|NCT00838253|Drug|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
45379802|NCT00838253|Drug|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
45379803|NCT00838253|Drug|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
45379804|NCT00838253|Drug|Placebo|Placebo continuous i.v. infusion for 24 hours
45379805|NCT00347932|Drug|ISV-403|Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.
45379806|NCT00347932|Drug|Vehicle|Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.
45379807|NCT03990688|Drug|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
45379808|NCT03990688|Drug|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
45379809|NCT00828893|Device|navigation station|navigation station for gestures (carried out under CT) guidance
45379810|NCT02548793|Other|Education: CPR Training via Mobile App|Using a mobile app to train users on chest-compression only CPR. Subjects will be encouraged to share the app with family and friends.
45379811|NCT02548793|Other|Education: CPR Training using the CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
45379812|NCT02547701|Drug|P-3058|
45379813|NCT00828971|Drug|Avelox (Moxifloxacin, BAY12-8039)|Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days.
45379814|NCT00828971|Drug|Amoxicilline/clavulanic|IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days
45379815|NCT02547467|Other|epidemiologic study|There is no intervention as it is a pure observational study for epidemiologic survey.
45379816|NCT02548637|Procedure|Acupuncture Therapy|The standard textbook of Chinese Acupuncture and Moxibustion is the source for the name and location of the points for this study. A total of 38 points will be used, divided between two acupuncture sessions: 20 points or 37 locations in the supine position; 18 points or 36 locations in the prone position. Other than points governing vessel (GV) 20, conception vessel (CV) 6, CV 10, all points will be performed bilaterally.
45379817|NCT00835835|Other|Body-weight supported treadmill training +/- Lokomat assistance|walking
45379818|NCT00835835|Other|Usual Care - no active intervention|No treatment used for comparison
45379819|NCT00528996|Drug|BEA 2180 BR|Solution
45379820|NCT00528996|Drug|Tiotropium Bromide|Solution
45379821|NCT00528996|Drug|Placebo|Solution
45379822|NCT00838487|Other|condroflex and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
45379823|NCT00838487|Other|sugar pill and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
45379824|NCT00359788|Drug|tiotropium|
45379825|NCT00359788|Drug|Combivent (Ipratropium/Albuterol)|
45379826|NCT00838721|Other|laser trabeculoplasty|Deliver laser energy to the trabecular meshwork using the Pascal Laser System
45379827|NCT00838877|Drug|radioligand [18F]AZD4694|single dose of iv. admin. 1-2 times per subject
45379828|NCT00838877|Drug|radioligand [11C]AZD2184|single dose of iv admin. 1 time per subject
45379829|NCT00836147|Drug|Avotermin (Juvista)|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
45379830|NCT00836147|Drug|Placebo|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
45379831|NCT04365569|Behavioral|Nutrition and physical activity counseling program|"6-month interventional, counseling program based on nutrition and physical activity consisting of:~1. Nutritional counseling by a Registered Dietitian (RD) 2) Implementation of an adequate physical activity program"
45379832|NCT05416476|Drug|Anisodine Hydrobromide|Anisodine Hydrobromide 1 mg oral tablet, twice times a day
45379833|NCT05416476|Drug|Anisodine Hydrobromide placebo|Anisodine Hydrobromide Placebo 1 mg oral tablet, twice times a day
45379834|NCT05732922|Device|A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants to use during their telemedicine consultations with health care providers.|A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants in the intervention arm to use during their telemedicine consultations with health care providers.
45379835|NCT03878160|Other|Individual Interview|Individual Interviews will focus on exploring (a) changes after ACS, such as psychosocial changes and health behavior changes; (b) specific preferences for the MBCT intervention; and (c) potential barriers and facilitators of group videoconferencing and (d) blood spot data collection. Individual interviews will use a semi-structured interview guide. Individual interviews will be conducted until thematic saturation is reached. Individual interviews will be audio-recorded for transcription and data analysis.
45379836|NCT02534116|Procedure|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
45379837|NCT02534116|Procedure|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
45379838|NCT03987490|Behavioral|Text Message|Vaccine reminder notification sent via text
45379839|NCT03987490|Behavioral|PostCard|Vaccine reminder notification sent via standard mail
45379840|NCT03987490|Behavioral|Standard of Care|No additional information given to parents
45379841|NCT03987490|Behavioral|Motivational Interview|Phone-based semi-guided discussion with parents who had not yet agreed to vaccination after reminders sent
45379842|NCT00623597|Drug|ritonavir|2.5-3.0mg/kg po bid (starting dose) for 48 weeks
45379843|NCT00623597|Drug|saquinavir [Invirase]|50mg/kg po bid (starting dose) for 48 weeks
45379844|NCT05732844|Device|Intervention group with Enna pelvic ball|"The home guideline for placement of the vaginal spheres will be as described in next:~st-2nd week 15 minutes, 1 time a day nd-4th week 30 minutes, 1 time a day 4th-8th week 1 hour, 1 time a day 8th-12th week 2 hours, 1 time a day 12th-16th week 3 hours, 1 time a day"
45495776|NCT04680390|Behavioral|Standard of care engagement practices|The control arm will be standard-of-care, which is as-needed case management for justice-involved women. The goals of case management services are to reduce recidivism, mitigate behavioral challenges, strengthen public safety, and build self-sufficiency skills. Case managers refer clients to appropriate services in the community (e.g., housing, food).
45379845|NCT05732844|Other|Control group|According to the PERFECT score, a daily home guideline for the performance of PFMT will be requested three times a day, two types of exercises (endurance and strength), and eight repetitions of each.
45498219|NCT03688386|Behavioral|Reading intervention|Written packet with 3 lessons. The first lesson includes how to begin to read and talk to their baby. The second lesson includes reading or talking about the day using parentese talk. The third lesson includes continuing to engage with the baby through interactive reading.
45379846|NCT01053676|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule|BAY77-1931 Granule TID for 4 days
45379847|NCT01053676|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet|BAY77-1931 Chewable tablet TID for 4 days
45495777|NCT04680390|Behavioral|Peer Navigators Addressing INtersectional Stigma to Improve HIV Prevention Among Criminal-Justice Involved Women|kINSHIP is a peer-led navigator intervention to address intersectional stigma and improve PrEP treatment initiation and engagement for justice-involved women. The key components of the kINSHIP intervention are to: 1) increase social support; 2) increase self-efficacy in accessing PrEP services; 3) enhance access to healthcare services; 4) improve adaptive coping skills to manage experiences of intersectional stigma.
45379848|NCT05732766|Biological|Hillchol vaccine|Hillchol® (BBV131) (The whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
45495778|NCT04663620|Behavioral|Saving Babies Lives Programme|Comprehensive neonatal healthcare package
45495779|NCT04663620|Behavioral|No Saving Babies Lives Programme|No comprehensive neonatal healthcare package
45495780|NCT04625088|Other|Standardized liquid test meal|During this study visit, a standardized liquid test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 4 hours after test meal.
45495781|NCT04625088|Drug|Atropine + Standardized liquid test meal|During this study visit, 1.0 mg atropine will be administered I.V and then a standardized liquid test meal will be administered. Blood samples will be collected at baseline, following atropine administration, and then every 30 minutes for 4 hours after test meal.
45495782|NCT03568422|Drug|CFI-402257|Orally taken on intermittent schedule (days 1, 2, 8, 9, 15 & 16
45495783|NCT03568422|Drug|Paclitaxel|80 mg/m2 IV days 1, 8 & 15 every 28 days
45379849|NCT01056172|Drug|Peginterferon alfa-2a and Ribavirin|"PegIFN alfa-2a (PEgasys) 180 ug/week~Weight-based ribavirin (<65kg: 800mg/day, 65-85kg: 1000mg/day, >85kg: 1200mg/day)~Treatment duration: 16 weeks"
45495784|NCT03535350|Drug|Ibrutinib|"Dose response of Ibrutinib. Level 1 starting dose is 420mg daily. Level 2 starting dose is 560mg daily. Level -1 starting dose is 280mg daily.~November 2020:~420 mg of ibrutinib plus temozolomide and radiation was found to be safe - up to 36 participants can betreated at the expansion cohort in both arm 1 and arm 2."
45495785|NCT03535350|Radiation|Radiation|2Gy x 30minutes for 6 weeks.
45495786|NCT03535350|Drug|Temozolomide (TMZ)|Cycle 1 150mg/m2 and cycle 2-6 will be up to 200mg/m2.
45495787|NCT03484494|Device|Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an application of a series of electromagnetic pulses to the brain through a small cylinder that the subject places the top of their head inside.
45379850|NCT01056172|Drug|Peginterferon alfa-2a and Ribavirin|"PegIFN alfa-2a (PEgasys) 180 ug/week~Weight-based ribavirin (<65kg: 800mg/day, 65-85kg: 1000mg/day, >85kg: 1200mg/day)~Treatment duration: 24 weeks"
45379851|NCT05732688|Diagnostic Test|Image-based ex-vivo drug screening platform (pharmacoscopy)|"Leukemic cells from a patient at relapse can be screened for sensitivity to single compounds. A drug score is calculated for each compound (defined as 1 - (% target cells in drug treated conditions / % target cells under control condition)). If a drug kills all target cells specifically, the best possible score is 1. If the drug is killing all non-target cells, the score goes to negative infinite. If a drug kills both target and non-target cell populations equally, or does nothing, the score is 0."
45379852|NCT00838955|Drug|Temsirolimus|Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
45495788|NCT03937141|Drug|ADU-S100|intratumoral
45495789|NCT02547493|Biological|pneumococcal polysaccharide vaccine|Vaccination with PPSV on first day. NB : PPSV vaccine Pneumo23 has been replaced in September 2017 by the equivalent vaccine Pneumovax because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company.
45495790|NCT02547493|Biological|pneumococcal conjugate vaccine|Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.
45379853|NCT00347776|Drug|azithromycin|oral antibiotic
45379854|NCT00347776|Drug|topical tetracycline|
45379855|NCT00839033|Device|mechanical insufflation - exsufflation|Patients will receive MI-E treatment with the following settings: insufflation pressure of at least +30 cm H2O and an exsufflation pressure ≥ -30 cm H2O. There will be at least 6 hyperinflation/exsufflation sequences per session of chest physiotherapy. There will be at least two daily sessions done routinely by the respiratory therapist at 8 hour intervals.
45495791|NCT02547493|Drug|Abatacept|Abatacept started on frst day
45495792|NCT03259789|Drug|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
45495793|NCT03259789|Drug|Bexagliflozin tablets, placebo|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
45495794|NCT03259789|Drug|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
45495795|NCT03259555|Drug|Brexpiprazole|Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.
45495796|NCT03259555|Drug|Placebo|Administered orally daily for 3 weeks.
46054955|NCT04172766|Behavioral|Advanced|"Advanced group users will receive prompts when an acutely high headphone audio level exposure (LEQ equivalent to >97 dBA for >30 minutes) occurs. Those in the WatchOS arm will be prompted when their weekly environmental sound level (7-day LEQ equivalent to >80 dBA for >40 hrs) is high. Either prompt will occur via notification, and will request that the participant review exposure data in the Research app and answer questions related to their exposure. The survey will ask for confirmation that they reviewed the exposure data and perceive it as accuracy, whether or not they used any hearing protection (e.g., ear plugs worn at a rock concert), and any intended listening behavior change resulting from their data review. To minimize notification burden for participants, exposure notification events will occur no more than twice per month. At this same frequency, they will be asked to take an abbreviated audiogram to test for temporary threshold shifts in their hearing level."
46054956|NCT04227795|Device|Artificial intelligence-Assisted real time colonoscopy|The colonoscopy was performed under artificial intelligence assistance
45379856|NCT00839033|Device|Standard respiratory physiotherapy|Traditional chest physiotherapy without mechanical insufflation-exsufflation
45495797|NCT03702751|Procedure|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
45495798|NCT03702751|Procedure|Continuous subcuticular skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
45495799|NCT03259087|Drug|MK-3866|Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.
45495800|NCT03257995|Drug|Indacaterol maleate|150 μg via Concept1 device
45495801|NCT03257995|Drug|Indacaterol acetate|150 μg via Concept1 device
45495802|NCT03257995|Drug|Placebo|Capsule containing no active ingredients delivered via Concept1 device
45495803|NCT03049488|Biological|VRC-RSVRGP084-00-VP|VRC-RSVRGP084-00-VP is an investigational respiratory syncytial virus (RSV) vaccine.
45495804|NCT03049488|Other|Aluminum Hydroxide Suspension|Aluminum Hydroxide Suspension, alum, is an adjuvant.
45495805|NCT04484922|Drug|Dexmedetomidine|continuous infusion of dexmedetomidine during the surgery
45495806|NCT04484922|Drug|Normal saline|continuous infusion of normal saline during the surgery
46054957|NCT05321901|Other|Biopsychosocial Exercise Therapy approach (BETY)|The BETY intervention is grouped under 4 headings: Patient education on chronic pain, functional body stabilization exercises (mind-body information management), dance therapy-authentic movement (emotion-state information management), and sexual information management.
45495807|NCT04481958|Behavioral|I-PROTECT|The I-PROTECT model is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes exercises based on physical and psychological principles of effective injury prevention training, specifically tailored for youth handball players, and support for developing a continuous implementation strategy. The intervention is delivered through a mobile application (the I-PROTECT GO), including modules tailored for coaches, players, club administrators, and caregivers, respectively. Coaches are introduced to the intervention in a workshop, and they will conduct the exercises with their teams during handball practice. Due to pandemic restrictions, the mobile application could not be finalized, and only the module for coaches was available.
46054958|NCT05321901|Other|Control group|The control group participants were those who did not want to receive exercise treatment with telerehabilitation and took their routine medications during the 8 weeks period.
45379857|NCT04961814|Diagnostic Test|gastric ultrasound|preoperative gastric ultrasound will be done for all patients to estimate gastric volume by measuring the antral cross sectional area and also, know the type of gastric content
45379858|NCT00829127|Drug|AZD8075|single dose, oral suspension, on Day 1. Repeated dosing will commence on Day 3 once daily for 14 days. The planned starting dose will be 35 mg with up to 2 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits or the exposure obtained so far in the SAD study.
45379859|NCT00829127|Drug|Placebo|Oral suspension
45379860|NCT04452136|Drug|68GA PSMA-HBED-CC|Given IV
45379861|NCT00829205|Biological|filgrastim|
45379862|NCT00829205|Biological|rituximab|
45379863|NCT00829205|Dietary Supplement|Se-methyl-seleno-L-cysteine|
46054959|NCT04156230|Drug|[18F]GP1 positron emission tomography/computed tomography|A radioactive dose of 250 MBq of the study drug with a total quantity of ≤ 10 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 120 ± 15 min after the administration of [18F]GP1.
46054960|NCT02779023|Behavioral|Cognitive-Behavior Therapy for Insomnia (CBT-I)|
46054961|NCT05319093|Drug|Ozanimod|Three-months, longitudinal observational period
45495808|NCT04446390|Other|Himalaya complete care toothpaste|Herbal toothpaste as a part of a caries preventive regimen
45495809|NCT04446390|Other|colgate cavity protection|fluoride toothpaste as a part of a caries preventive regimen
45495810|NCT03257137|Other|Diet Quality|Diets matched for calorie intake and macronutrient distribution but differing by overall diet quality will be provided in a random order, cross-over design study.
45495811|NCT02338921|Drug|Sitagliptin|"100mg qd per oral during 24months~compared with other treatment groups"
45495812|NCT02338921|Drug|Dapagliflozin|"10mg qd per oral during 24months~compared with other treatment groups"
45495813|NCT02338921|Drug|Lobeglitazone|"0.5mg qd per oral during 24months~compared with other treatment groups"
45379864|NCT00829205|Drug|carboplatin|
45379865|NCT00829205|Drug|etoposide|
45379866|NCT00829205|Drug|ifosfamide|
45379867|NCT00829205|Other|laboratory biomarker analysis|
45379868|NCT00829205|Other|pharmacological study|
45495814|NCT02338921|Drug|Glimepirde|
45379869|NCT04948476|Other|Standardized Dialysis and Structured Discontinuation (S2D2)|"Prescription to minimize dialysis-induced ischemia~Cool dialysate (35.0◦C)~Dialysate sodium of 145mmol/L~Dialysate calcium of 1.5mmol/L~Maximum ultrafiltration rate of 10mL/kg/hour (if no weight, maximum is 500mL/hour)~Note: If dialysis machines cannot get to the specified values, values closest to these are acceptable.~Structured dialysis discontinuation (all criteria met)~Most recent pre-dialysis potassium <6mmo/L and bicarbonate >12mmol/L~Most recent urine volume ≥1L/day OR last ultrafiltration on dialysis <1L/session~If available, timed urine collection with result for mean creatinine and/or urea clearance >12mL/min"
45495815|NCT02338921|Drug|Metformin|
45495816|NCT01313845|Drug|amantadine sulfate|infusion of amantadine sulfate 100mg/500ml/bottle over 3 hours twice a day
46054962|NCT03817086|Behavioral|Hand coordination and mental practice|"20 chronic (>1year) moderate to severe TBI patients, with upper extremity movement deficits, will be randomly and equally assigned to two groups.~In the experimental group, participants undergo 5 weeks (3 hrs/week) of physical practice training combined with mental practice (MP group)."
46054963|NCT03817086|Behavioral|Hand coordination and action observation|In the control group 2, participants undergo 5 weeks (3 hrs/week) of physical training (PP group).
46054964|NCT04693182|Other|Shift schedule without quick returns|The intervention entails implementing a shift schedule which abolishes or substantially reduces the number of quick returns (less than 11 hours of rest between two shifts) for a six-month intervention period.
45379870|NCT04948476|Other|Usual Care|Dialysis prescription ordered by their clinical team. Decisions on dialysis discontinuation will be left to individual clinicians and will not be guided by a standard protocol.
45379871|NCT02533882|Behavioral|Movement to Music|
46054965|NCT00752557|Drug|rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)|Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 1.0 mg/mL.
46054966|NCT00752557|Drug|rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)|Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 2.0 mg/mL.
45379872|NCT02533882|Behavioral|Adapted Yoga|
46054967|NCT00752557|Drug|bisphosphonates, calcium, and vitamin D|Oral bisphosphonate therapy
45379873|NCT00836225|Drug|ISIS 388626|"4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline"
45379874|NCT01053754|Biological|"long synacthen stimulation test"|IM injection of 1 mg of delate synacthen which can be realized in ambulatory conditions
46054968|NCT04228029|Device|Carboxytherapy|Carbon dioxide (CO2) gas in injection form
46054969|NCT04228029|Drug|Intralesional Steroid Injection|triamcinolone acetonide 8 mg/mL
46054970|NCT04683978|Other|Position|Neck extension
46054971|NCT04943913|Biological|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10^9-5x10^10 autologous TILs to patients i.v. in 30-120 minutes.
46054972|NCT04570176|Procedure|adrenalectomy for adrenal adenoma|adrenalectomy， cystectomy and nephrectomy
46054973|NCT00751218|Drug|desloratadine|desloratadine, 5mg oral tablets, once daily for 28 days
46054974|NCT00751218|Drug|placebo|placebo, once daily for 28 days
46054975|NCT00751218|Drug|cetirizine|cetirizine, 10 mg capsules once daily for 28 days
46054976|NCT05318079|Behavioral|Virtual Reality Gaming|Peer-to-peer gaming.
46054977|NCT02600533|Procedure|Video viewing group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
46054978|NCT02779569|Drug|decitabine|
45495817|NCT01313845|Drug|0.9% sodium chloride|infusion of normal saline 500ml/bottle over 3 hours twice a day
45495818|NCT04400058|Biological|Octagam 10%|Octagam 10%, 2 g/kg divided by 4 days (0.5 g/kg/day), administered by intravenous infusion over approximately 2 hours per day over 4 consecutive days
45495819|NCT04400058|Other|Placebo|Placebo
45495820|NCT04782661|Drug|JNJ-70075200|JNJ-70075200 solution or solid formulations will be administered orally.
45495821|NCT04782661|Drug|Placebo|Placebo solution will be administered orally.
45495822|NCT04745845|Procedure|Noradrenalin|Norepinephrine challenge (concentration 'A' ) in fluid responsive position
45495823|NCT04745845|Procedure|Noradrenalin|Norepinephrine challenge (concentration 'A') in non-fluid responsive position
45495824|NCT04745845|Procedure|Noradrenalin|Norepinephrine challenge (concentration 'B') in fluid responsive position
45495825|NCT04745845|Procedure|Noradrenalin|Norepinephrine challenge (concentration 'B') in non-fluid responsive position
45495826|NCT04492098|Diagnostic Test|MAIT cells|1- Decidual tissues will be washed in phosphate buffer saline (PBS), and then preserved in Rosewell Park Memorial Institute (RPMI) 1640 medium supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin and 5% fetal bovine serum (GIBCO BRL, Thermo Fisher Scientific, USA) until transfer to the laboratory. At the flow cytometry laboratory, the tissue samples will be minced finely and enzymatically digested by adding 3 ml collagenase enzyme type Ia and 2 ml PBS for 40 minutes at 37°C in shaking water path at 100 r.p.m. Cell suspensions obtained will be filtered, then the pellet after centrifugation will be treated with red blood cells lysing solution and washed with PBS.
45379875|NCT04944888|Drug|Eliglustat|Eliglustat, 84mg daily or 84mg twice daily; Enrolled patients will be assigned to Arm A and Arm B, respectively.
45379876|NCT04944888|Drug|Immune checkpoint inhibitor|immune checkpoint inhibitor (physician decided).
45495827|NCT04683991|Procedure|Subepithelial connective tissue graft|A de-epithelialized connective tissue graft is harvested from the homolateral palate and transplanted around the implant.
45379877|NCT03987178|Behavioral|Dunk|"If randomized to Dunk, the subject is asked to submerge his or her head in the hot tub at least up to brow level."
45495828|NCT05532150|Procedure|Arthroscopic Bankart repair|Participants in this group will undergo minimally invasive surgery to repair their shoulder with a technique called a Bankart repair.
45495829|NCT05532150|Procedure|Physical therapy|Participants in this group will follow a specific physical therapy rehabilitation protocol
45495830|NCT04173247|Device|KeraStat Cream|KeraStat Cream is a non-sterile, non-implantable, emollient-based wound dressing intended to act as a protective covering in the management of a variety of skin conditions.
45495831|NCT04173247|Other|Routine Skin Care - Commercially Available Agents|Commercially available skin moisturizers from an approved list that do not interfere with radiation.
45495832|NCT04361838|Behavioral|prayer|receive prayers daily while in ICU
45495833|NCT03242863|Other|Food proportionality|Proportions of high and low energy dense foods manipulated
45495834|NCT03044106|Device|CLRT|CLRT is a novel method of laser stimulation on specific cranial reflex points that modulate muscle tone.
45495835|NCT05571397|Device|Dexcom G6|Continuous Glucose Monitor
45379878|NCT03987178|Other|Exposure to Hot Tub|Subjects will be asked to sit in a hot tub for 15 minutes (with an individual timer).
45495836|NCT03196986|Drug|mil60|15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then maintains at 7.5mg/kg
45495837|NCT03196986|Drug|Bevacizumab|15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then switched to mil60 at 7.5mg/kg
45495838|NCT04542031|Other|Questionnaire|Questionnaire to be completed at 6 and 12 months
45495839|NCT04051632|Device|Medtronic 670G insulin pump|"percent of patients who continue to use Medtronic 670G over time~impact of 670G on glycemic control: hemoglobin A1c, time in range"
45495840|NCT04531969|Other|Spa therapy and conventional physical therapy|"HP application +deep heater application + TENS. HP application: A hotpack wrapped in a towel for 20 minutes will be placed on the knee and surrounding soft tissues.~Deep heater application: The application will be performed with a therapeutic ultrasound device at a dose of 1.5watt / cm2 for each string for 6 minutes.~TENS application:TENS device with two electrodes surrounding tendon will be performed for 30 minutes at low-frequency current application.~Spa therapy: A conventional water bath water at 38 ° C will be applied in the pool for 20 minutes a day."
45495841|NCT03170856|Other|Sub-maximal exercise|Subjects will participate in aerobic exercise 5 days a week. This includes walking, biking, jogging and running. While participating in these activities, they will be wearing their Polar Wrist Unit and Heart Rate Monitor to help subjects track their exercise intensity. They will exercise for 20 minutes 5times a week at 60% of their maximum heart rate or 80% of their symptom limited heart rate.
45495842|NCT04423237|Drug|Deferasirox|DEFERASIROX administered as per clinical practice and according to technical note
45495843|NCT03139968|Device|(sham) radiation absorbing drape (RADPAD®)|
45495844|NCT04377919|Dietary Supplement|Cranberry|The patients will receive 2 capsules per day containing 500mg of cranberry extract for 8 weeks
45495845|NCT04377919|Dietary Supplement|Placebo|The patients will receive 2 capsules per day containing 500mg of maize starch for 8 weeks
45495846|NCT04408092|Drug|Granulocyte Macrophage Colony Stimulation Factor|Recombinant Granulocyte Macrophage Colony Stimulation Factor (rGM-CSF) is a hematopoietic growth factor which supports survival, clonal expansion, and differentiation of hematopoietic progenitor cells. rGM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways. rGM-CSF stimulates the production of monocytes, granulocytes, erythrocytes, and sometimes, megakaryocytes in the bone marrow. It also induces mature macrophages to increase phagocytosis, superoxide generation, Antibody Dependent Cell-mediated Cytotoxicity (ADCC), tumoricidal killing and cytokine production (IL-1 and tumor necrosis factor). GM-CSF was used in the first successful phase III trial of immunotherapy in the pediatric COG protocol, ANBL0931, a national study in high risk neuroblastoma.
45379879|NCT00839111|Drug|sorafenib|Sorafenib 400mg twice daily from d3 to d14,d17-28
45379880|NCT00839111|Drug|FOLFIRI|Irinotecan 180 mg/m2,CF 400mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
45379881|NCT01053832|Device|VpS algorithm in EVIA and ENTOVIS pacemakers|For one group of patients, the VpS algorithm will be activated and for the other group, the VpS algorithm will be deactivated until the cross-over, where these conditions will be switched.
45379882|NCT00836303|Behavioral|Colorecatal Cancer Screening Activation|Research assistants showed intervention patients a colorectal cancer educational video in Spanish on a portable personal digital video display device while the patients were waiting for their visit. The 11-minute video was developed by the National Alliance for Hispanic Health and was accompanied by a brochure with key information from the video {http://www.hispanichealth.org/publication/}. Intervention patients were also given a one-page reminder to hand to their physicians notifying them 1) of their patients' eligibility for colorectal cancer screening, and 2) of their patients' receipt of CRC educational material.
45495847|NCT02903940|Device|CRT+NAVH|Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
45495848|NCT03043560|Drug|Ezogabine|daily for 5 weeks
45495849|NCT03043560|Drug|Placebos|placebo pill daily for 5 weeks
45495850|NCT04051554|Other|Neuromuscular and Proprioceptive Training|Myklebust's training program (floor exercises, mat exercises, and wobble board exercises for 5 weeks)
45495851|NCT04051554|Other|Conventional Training|Running, Sprinting, Agility training and Dynamic stretching for five weeks
45495852|NCT04051476|Other|3-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g ginger flour (3 g per l), followed by a ten-minute post-intervention rest period.
45495853|NCT04051476|Other|6-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g ginger flour (6 g per l), followed by a ten-minute post-intervention rest period.
45495854|NCT04051476|Other|12-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g ginger flour (12 g per l), followed by a ten-minute post-intervention rest period.
45693887|NCT01701193|Drug|L-Alanyl/L-Glutamine|Sterile solution of L-Alanyl-L-Glutamine, 400mg/mL in water for injection. It is dosed at 1g/kg of body weight and is instilled into the peritoneum at the time of surgery. The active ingredient, glutamine, is a conditionally essential amino acid component of nutritional supplements.
45379883|NCT01008228|Procedure|exsufflation|exsufflation will be performed with a specific thoracentesis system after introducing the device into chest pneumothorax, aspiration will be performed during 30 minutes
46054979|NCT04095013|Drug|Bupivacaine, fentanyl|Group A: hyperbaric Bupivacaine 10mg with fentanyl 10micrograms,
45693888|NCT01701193|Drug|Physiologic saline|Placebo
46054980|NCT04095013|Drug|Bupivacaine, dexmedetomidine|Group B: hyperbaric Bupivacaine 10 mg with dexmedetomidine5 micrograms
46054981|NCT05336526|Device|ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants|Bilateral brest augmentation in primary intention
46054982|NCT02600299|Behavioral|Psychoeducation group|On the basis of previous studies that evaluated PEG interventions for women with breast cancer, a structured program based on the Cognitive Behavioral Therapy (CBT) principles was developed. Patients in the PEG group will be involved in three sessions of psychoeducation. The PEG program is designed to cover the various aspects outlined by the IOM on quality cancer survivorship.
45495855|NCT04051476|Other|Warm water footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
45495856|NCT02145403|Drug|Carfilzomib|"Carfilzomib will be administered starting at dose level 1 (20 mg/m2 IV) on day +1, +2, +6 and +7.~Dose escalation will be performed on the day +6 and day +7 doses only in each dose level. Day +1 and day+2 doses will be fixed at 20 mg/m2 IV in all dose levels."
45495857|NCT02145403|Drug|Tacrolimus|Tacrolimus will be administered at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.
45495858|NCT03255733|Device|Intense Therapeutic Ultrasound Treatment|
45495859|NCT03255655|Device|Intense Therapeutic Ultrasound Treatment - ITU|
45495860|NCT02899988|Drug|Mirikizumab|Administered SC
45495861|NCT02899988|Drug|Placebo|Administered SC
45498220|NCT03688386|Behavioral|Infant bonding|Written packet with 3 lessons. The first lesson includes skin-to-skin and learning about their baby. The second lesson includes learning readiness cues and participation in feeding times. The third lesson includes developing routines and playing games.
45693889|NCT00826150|Biological|BC-819|"Cohort #1: 60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #2: 120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #3: 240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course."
45693890|NCT05035654|Drug|LYR-220 Design 1|LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1
45693891|NCT05035654|Drug|LYR-220 Design 2|LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
45693892|NCT05035654|Drug|Bilateral sham procedure control|Bilateral sham procedure control
45693893|NCT05024968|Drug|Sintilimab|Given by IV
45693894|NCT04382092|Diagnostic Test|FilmArray Pneumonia|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
46054983|NCT02600299|Behavioral|Usual Care|Usual Care
45379884|NCT01008228|Procedure|thoracic tube drainage|thoracic tube drainage will be performed with a tube Ch 16 or ch 20
45379885|NCT00836381|Drug|Tolterodine extended-release (ER) 4mg|Tolterodine extended-release (ER) 4mg once daily for 12 weeks
45495862|NCT02939131|Behavioral|Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm|Behavioral therapy based on a manualized approach developed specifically for youth living with both HIV and depression, using problem-solving, motivational interviewing and cognitive-behavioral strategies to decrease adherence obstacles and increase wellness. The medication management algorithm includes guidance for clinicians on strategies and tactics to treat depression in this population, including factors to consider when deciding on treatments (i.e., drug-drug interactions, side effects).
45379886|NCT00836381|Drug|Placebo|Identical Placebo once daily
45379887|NCT02533336|Drug|abamectin and fenpyroximate|
45379888|NCT00836459|Behavioral|Mini Booster|Two telephone-based physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
45495863|NCT02939131|Behavioral|Enhanced Standard of Care|Ongoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training on current principles for use of medication and psychotherapy in the treatment of depression.
45495864|NCT04052282|Device|Mobile Health App|There is no intervention
45495865|NCT03646526|Drug|Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）|Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）is a generic product manufactured by Hunan Dongting Pharmaceutical Co., Ltd.
45495866|NCT03646526|Drug|Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）|Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）is a generic product manufactured by Sandoz Inc;
45495867|NCT03643718|Procedure|Emergency General Surgery|Emergency General Surgery and Trauma operative/non operative management
45495868|NCT03646370|Drug|Tenofovir Alafenamide|Patients with HIV infection who are virally suppressed receiving a tenofovir disoproxil fumarate-based antiretroviral therapy regimen that switched to tenofovir alafenamide without switching any other components of their treatment regimen.
45495869|NCT04322448|Device|Mechanomyography (MMG)|MMG, as described in the cohort descriptions, to be used during surgery to see if they are predictive of patient outcomes.
45495870|NCT03644498|Other|Non-Interventional|Non-Interventional
45495871|NCT03643640|Behavioral|Optimune|Optimune is a web-based psychological intervention developed for women with breast cancer.
45495872|NCT03643640|Other|Care-As-Usual|Participants are free to continue to engage with any treatment they require (i.e., CAU).
45495873|NCT04166994|Behavioral|Exercise and diet|IMPACT Intervention
45379889|NCT00836459|Behavioral|Full Booster|Two face-to-face physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
45379890|NCT03991390|Other|Visual Feedback and Core Stability exercises protocol|"This arm consists of 5 sessions per week, 60 minutes each. One session consists of 30 minutes of conventional physiotherapy and 30 minutes of Core Stability exercises and laser visual feedback exercises, on alternate days.~All sessions will be performed by the same physiotherapist."
45379891|NCT03991390|Other|Control stroke|"This arm consists of 5 sessions per week, 60 minutes each comprising usual physiotherapy treatment.~All sessions will be performed by the same physiotherapist."
45495874|NCT04166994|Other|No Intervention: Usual Care|No exercise or diet specialization.
45495875|NCT03644420|Diagnostic Test|Clinical evaluation|Functional scores for the pathological joint will be determined
45495876|NCT03644420|Diagnostic Test|Radiology|
45495877|NCT03644420|Diagnostic Test|Dynamic contrast-enhanced magnetic resonance imaging|Patients will be examined using a 3T MR scanner (MR 750W, General Electrics, Milwaukee, WI) with a dedicated knee coil. Subchondral bone marrow vascularization in medial and lateral femorotibial compartments will be assessed with DCE-MRI and lesions will be graded on MR images.
45495878|NCT03644420|Diagnostic Test|Evaluation of histological status|Upper tibial resection pieces will be collected and the vascularization will be determined according to the OARSI score
45495879|NCT03646292|Drug|Pioglitazone|The investigators will compare the degree of liver fat between Pioglitazone monotherapy, Empagliflozin monotherapy, Combination of pioglitazone and empagliflozin following randomization.
45495880|NCT03646292|Drug|Empagliflozin|The investigators will compare the degree of liver fat between Pioglitazone monotherapy, Empagliflozin monotherapy, Combination of pioglitazone and empagliflozin following randomization.
45495881|NCT03646292|Drug|Combination of pioglitazone and empagliflozin|The investigators will compare the degree of liver fat between Pioglitazone monotherapy, Empagliflozin monotherapy, Combination of pioglitazone and empagliflozin following randomization.
45495882|NCT03345407|Drug|Placebo ELLIPTA|Placebo will be administered via oral inhalation route once daily in the morning.
45495883|NCT03345407|Drug|Nemiralisib ELLIPTA 50 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 50 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
45495884|NCT03345407|Drug|Nemiralisib ELLIPTA 100 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 100 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
45495885|NCT03345407|Drug|Nemiralisib ELLIPTA 250 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 250 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
45495886|NCT03345407|Drug|Nemiralisib ELLIPTA 500 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 500 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
46054984|NCT04107246|Device|use of the KaliJAR box|"KaliJAR® : validated device for single-dose eye drops collection. the patient will be asked to discard each single dose of eye drops in the KaliJAR box. The patient returns with the KaliJAR box at each consultation as part of normal practice. The KaliJAR box will be emptied at each consultation by the doctor and then returned to the patient.~No further examination or visit."
45495887|NCT03345407|Drug|Nemiralisib ELLIPTA 750 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 750 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
45495888|NCT03345407|Drug|Albuterol (Salbutamol) MDI or nebules|Albuterol (Salbutamol) MDI or nebules will be provided to all subjects as a rescue medication.
45495889|NCT03345407|Drug|Standard of care therapy|SoC therapy for the index exacerbation is defined as treatment with oral/systemic corticosteroid (prednisone 40 mg/day or equivalent) for 5 days and antibiotic for 7 days. Subjects will receive SoC as prescribed by the Investigator or medically qualified designee. The dose and/or duration of prednisone and/or the antibiotic can be modified according to the Investigator's/medically qualified designee's judgment or according to local country/institution practice.
45495890|NCT03621332|Other|Questionnaire|Online/paper questionnaires
45495891|NCT02537418|Drug|durvalumab|
45495892|NCT02537418|Drug|tremelimumab|
45495893|NCT01264549|Device|Procalcitonin assay - B.R.A.H.M.S PCT ultrasensitive Kryptor|The physician will be given access to a PCT value for Day 1 - 7. Depending on the PCT concentrations, the protocol recommends or discourages from the use of antibiotics
45495894|NCT05692752|Other|No intervention|Expression of miR-133a &208b at 4, 8, 12, 24 and 48 hours from the first appearance of myocardial infarction (MI) symptoms
45495895|NCT03626298|Drug|Adapalene|third-generation topical retinoid primarily used in the treatment of mild-moderate acne. It is effective against acne conditions where comedones are predominant.
45379892|NCT05367960|Drug|Zatolmilast/ BPN14770|25mg zatolmilast/BPN14770
45379893|NCT00829361|Other|Telemedicine|Two way site independent audio/video telemedicine system with DICOM.
45495896|NCT03626298|Drug|Nicotinamide, ABA and Zinc PCA|combination of three non-antibiotic active ingredients of nicotinamide, anti-bacterial adhesive agent (ABA) and zinc, or abbreviated as ANAZ to be well-tolerated by patients with acne vulgaris
45495897|NCT03626298|Drug|Placebos|Placebo cream. to resemble an active medication or therapy so that it functions as a control; this is to prevent the recipient(s) and/or others from knowing (with their consent) whether a treatment is active or inactive, as expectations about efficacy can influence results.
45495898|NCT03255187|Dietary Supplement|Fish oil supplementation|Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in fish oil group are assigned to receive 2.5 g/day in divided doses. Each capsule contains 60% n-3 PUFA [24% docosahexanoic acid (C22:6 n-3 DHA) and 36% eicosapentaenoic acid (C20:5 n-3 EPA)].
45495899|NCT03255187|Dietary Supplement|Sunflower seed oil supplementation|Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in sunflower seed oil group receive 2.5 g/day in divided doses, and the capsules are identical as the fish oil capsules.
46054985|NCT05316441|Behavioral|psychoeducation|Positive Psychotherapy is a recently emerged therapy method that works on talents. In the study, success skill development psychoeducation based on positive psychotherapy will be applied.
46054986|NCT02779881|Dietary Supplement|Extensively hydrolyzed casein formula plus LGG|
46054987|NCT00651378|Drug|Rosuvastatin|oral tablets: rosuvastatin 10 mg once daily for 6 weeks (switch from previous run-in with atorvastatin 10 mg daily)
46054988|NCT00651378|Drug|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg plus atorvastatin 10 mg once daily for 6 weeks (add ezetimibe to previous run-in with atorvastatin 10 mg daily)
46054989|NCT00651378|Drug|Double Atorvastatin|oral tablets: atorvastatin 20 mg once daily for 6 weeks (double dose from previous run-in with atorvastatin 10 mg daily)
46054990|NCT00747643|Drug|varenicline|Participants in this group received varenicline according to the schedule in the Arm Description.
45379894|NCT03829228|Dietary Supplement|Proglucamune|Following screening and enrollment, participants were treated with 2 tablets of Proglucamune per day for a total duration of 8 weeks. Each Proglucamune tablet contained ~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
45379895|NCT00839189|Biological|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 10,000 EU CCRE
45379896|NCT01053910|Drug|Ramipril|tablet of Ramipril once daily
45379897|NCT00829517|Other|computer-assisted provision of hormonal contraception|a computer program available at a kiosk will offer women information about and a prescription for hormonal contraception that they can ask their clinician to sign.
45379898|NCT00829517|Other|STI module|computer module available at a kiosk that will encourage women to be screened for chlamydia
45495900|NCT03646136|Procedure|Retained fluid|Retained fluid
45495901|NCT03646136|Procedure|Emptied fluid|Emptied fluid
45498221|NCT03688386|Behavioral|LENA recording|The LENA device provide 16 hours of language recordings placed inside an infant vest. The recordings are uploaded to a computer which analyzes total adult word counts, infant vocalizations, conversational turns, background noise, and silence.
45693895|NCT00827944|Device|Parietex Progrip|"Surgical technique:~Self-gripping lightweight Polyester and Polylactic acid meshes providing a sutureless fixation."
46054991|NCT00747643|Drug|placebo|Participants in this group received a placebo and did not receive any active medication according to the schedule in the Arm Description.
46054992|NCT02780271|Behavioral|In-person education|Four in-person hands-on nutrition and physical activity education classes and cooking sessions.
46054993|NCT02780271|Behavioral|E-communication|11 months of motivational text messages, emailed newsletters, and access to a website.
45379899|NCT03987412|Behavioral|Lifestyle intervention with APP|The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together. Then the lifestyle intervention will be launched by an APP that installed in participants' private mobile phones, including nutrition, exercise and phycological support. Nutrition guidance is conducted according to the Chinese Dietary Guide, Chinese and international guidelines of gestation diabetes management. Exercise support is given based on the Guidelines for National Fitness of China, Chinese and international guidelines of gestation diabetes. Phycological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP, and based on the data investigators will individualize the suggestions.
46054994|NCT02780271|Behavioral|Control|Written guidelines on diet and physical activity for breast cancer survivors, a pedometer to encourage physical activity, and a brief verbal overview of diet and physical activity guidelines for cancer survivors.
46054995|NCT05336292|Behavioral|Meaningful life-focused intervention|The intervention works different skills to increase the meaningful life in the general population and specifically in the army.
45379900|NCT00829595|Biological|23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)|0.5mL intramuscular, one time
45379901|NCT01054066|Behavioral|Chronic Kidney Disease Education|Instituting teaching programs to manage hypertension, diabetes, anemia, proteinuria and cardiovascular disease in patients.
45379902|NCT01008384|Dietary Supplement|Vitamin D3|50,000 units taken orally once a week for 8 weeks
45379903|NCT00836771|Dietary Supplement|Infant Formula|
45379904|NCT01008540|Biological|depistage|Virus isolation from urine, blood, or any suitable sample in case of CMV disease Resistance phenotype to antivirals UL97 and UL54 genes sequencing from blood, urines or any suitable samples for resistance mutations detection and polymorphism study
45498222|NCT03688386|Behavioral|LENA linguistic feedback|LENA recordings of adult word counts, infant vocalizations, and conversational turns will be provided in printed form after each recording with review of each recording and progress over time.
45498223|NCT03688386|Behavioral|LENA summary|All 3 LENA recording summaries of adult word counts, infant vocalizations, and conversational turns will be summarized in printed form and provided to mother at discharge.
45498224|NCT04058028|Drug|Rozibafusp Alfa|Rozibafusp Alfa will be presented in 5 mL glass vial
45693896|NCT00827944|Device|Low weight polypropylene mesh|"Surgical technique:~Lichtenstein repair with lightweight polypropylene mesh (inferior to 70gr/m2) secured to the posterior inguinal wall with sutures"
45693897|NCT05014438|Drug|BMS-986166|Specified dose on specified days
45693898|NCT05014438|Drug|Branebrutinib|Specified dose on specified days
46054996|NCT05336292|Behavioral|Meaningful life and emotional regulation-focused intervention|The intervention works different skills to increase the meaningful life and emotional regulation in the general population and specifically in the army.
46054997|NCT05336292|Behavioral|Control Group|This group does not do any intervention
46054998|NCT00627692|Drug|Prucalopride|0.5 mg o.d.
46054999|NCT00627692|Other|Placebo|o.d.
46055000|NCT00627692|Drug|Prucalopride|1 mg o.d.
46055001|NCT00627692|Drug|Prucalopride|2 mg o.d.
45693899|NCT05014438|Other|Placebo|Specified dose on specified days
45693900|NCT02153710|Behavioral|Semantic Feature Analysis therapy|Control therapy; current standard of care therapy
46055002|NCT00627692|Drug|Prucalopride|4 mg o.d.
46055003|NCT05436301|Other|Pain Catastrophizing Scale|"Personal and disease-related inquiries of the participants will be recorded in the demographic registration form. To assess the validity of the Pain Catastrophizing Scale-Child (PCS-C) scale, the Pediatric Quality of Life Questionnaire (PEDSQL) 3.0 Arthritis Module, Childhood Health Assessment Questionnaire (CHAQ), and Juvenile Idiopathic Arthritis Disease Activity Score (JADAS) will be administered to the participants. In this way, the consistency of the developed scale with similar questionnaires that were previously reported to be valid will be examined. In order to determine the reliability of the Pain Catastrophizing Scale-Child (PCS-C) scale, test-retest will be performed at one week intervals for the participants whose treatment has not undergone any change. The consistency of the scale will be determined by the data of the participants who have the first and second scale scores. Interviews will be conducted by face-to-face method."
45379905|NCT02547155|Procedure|Spinal anesthesia|8-12.5 mg of bupivacaine will be administered for spinal anesthesia
45379906|NCT02547155|Procedure|General anesthesia|propofol induction, in combination with a muscle relaxant and inhalational gas
45693901|NCT02153710|Behavioral|Phonomotor Therapy|Experimental therapy.
45693902|NCT04989556|Other|Interview|Participate in interview
45693903|NCT04989556|Other|Palliative Therapy|Receive standard symptom management by palliative care team
45495902|NCT05508672|Other|Community-Centered eHealth Smoking Cessation Intervention (CCeSCI)|We will equip CCeSCI with both core eHealth features and provider-side intervention. Patients assigned to the intervention group will receive a series of online interactive and personalization technologies, including an algorithm-based video curriculum with auto-texting, backstage monitoring system etc. Besides, the patients will also have the face-to-face meetings with community health workers. Provider-side intervention includes training for community workers, WeChat group discussion, and performance-based incentives. The training aims to provide essential skills for community workers so that they can provide face-to-face meetings with smokers during the first 3 months of quitting to prevent or revert relapse in a timely and proactive manner.
45495903|NCT05508672|Other|"Traditional smoking is harmful education"|"In the control group, the participants will receive traditional smoking is harmful education video, which is recorded by the clinical physicians."
45379907|NCT00836849|Drug|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
45379908|NCT00836849|Drug|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
45495904|NCT03643406|Other|Mental Fatigue|modified stroop task
45495905|NCT03643406|Other|Control|documentary
45495906|NCT03643328|Biological|blood samples|Blood samples will be collected at inclusion, at 6 months and 12 months for hematological and immunological analyses.
45495907|NCT03643328|Biological|nasal swabs|Two nasal swabs will be collected at inclusion, at 6 months and 12 months for virology analyses.
45495908|NCT04097262|Other|Own-Price Elasticity|The price of fruit will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
45495909|NCT04097262|Other|Cross-Price Elasticity|The price of fruit will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
45495910|NCT03644264|Drug|PA21|sucroferric oxyhydroxide is a mixture of polynuclear iron(III)-oxyhydroxide (about 33% m/m), sucrose (about 30% m/m), and starches (about 28% m/m) and contains ≤10% m/m water.
45495911|NCT03644264|Drug|sevelamer carbonate|sevelamer carbonate tablets containing 800 mg of sevelamer carbonate.
46055004|NCT00634881|Biological|Alemtuzumab i.v.|"Alemtuzumab will be administered once per week as a 2 h infusion~Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
45693904|NCT04989556|Other|Palliative Therapy|Receive provider initiated remote contact
45693905|NCT04989556|Other|Quality-of-Life Assessment|Ancillary studies
46055005|NCT00634881|Biological|Alemtuzumab s.c.|"Alemtuzumab will be administered once per week subcutaneously~Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
46055006|NCT04301882|Drug|interferon combined with ribavirin (PR) antiviral therapy|Patients with chronic hepatitis C treated with interferon combined with ribavirin (PR) antiviral therapy (PR therapy greater than or equal to 6 months)
46055007|NCT04301882|Drug|direct antiviral drugs (DAAs)|Patients with chronic hepatitis C treated with direct antiviral drugs (DAAs)
45379909|NCT03999294|Other|BMGIM Music Therapy Method|The BMGIM method is today one of the models recognized by the international music therapy community, deserving this distinction those approaches that develop a solid theoretical and practical body, with specific training programs as training for new therapists, and that also promote the scientific research as a way to develop the method and Music Therapy.
45495912|NCT04051788|Other|Step Aerobics|Alternating step knee-lift sequences; alternating leg up, up, down, down patterns; and step kicks, 120 to 126 foot strikes per minute, 20 to 30 minutes per session s, 3 sessions per week up to 6 weeks,The target intensity for all sessions will set at 50-70% heart rate (HR) reserve.
45495913|NCT04051788|Other|Aerobic exercise (Lower limb Cycling)|Lower Limb Aerobic cycling, 20 to 30 minutes per session, 3 sessions per week up to 6 weeks, The target intensity for all sessions will set at 50-70% heart rate (HR) reserve
45693906|NCT04989556|Other|Questionnaire Administration|Complete questionnaire
45693907|NCT01959347|Procedure|Miduretheral Sling|MUS can include the TVT™ (mechanical cut mesh only, Gynecare, ETHICON Women's Health & Urology, Somerville, NJ), TVT-O™ (mechanical cut mesh only, Gynecare), or Monarc™ (American Medical Systems, Minnetonka, MN).
46055008|NCT04300322|Device|Cervical pessary|Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
45379910|NCT00839345|Drug|clopidogrel|The intervention will involve the change of dosage or change of drug. The traditional maintenance dose of clopidogrel is 75 mg per day. We will test in non-responders to this classical dose higher doses up to 225mg per day. In patients,who will not respond to this 3times higher dose,clopidogrel will be replaced by ticlopidine.
45379911|NCT00829751|Device|PureVision lenses soaked in ReNu Multiplus|Purevision silicone hydrogel lenses
45379912|NCT00829751|Device|PureVision lenses soaked in OptiFree RePlenish|Purevision silicone hydrogel lenses soaked in OptiFree RePlenish
45379913|NCT00839501|Dietary Supplement|Potassium|40 mEq twice daily in pill form during the first 3-day inpatient visit, followed by 40 mEq twice daily in liquid form during the first 18-week treatment period, as is randomly scheduled, and continued during the second 18-week treatment period as long as there are no limiting side effects
45495914|NCT03641534|Procedure|Lung Ultrasound examination|Use of lung ultrasound to detect pulmonary complications
45495915|NCT03641534|Procedure|Compression ultrasonography (CUS)|CUS is a highly sensitive and specific modality used to recognize lower extremity deep venous thrombosis (DVT)
45495916|NCT03641534|Procedure|Echocardiography|Echocardiogram can be (i) identify imminent life-threatening causes of hemodynamic failure, (ii) recognize coexisting diagnoses that complicate management, (iii) follow the evolution of the disease process, and (iv) monitor response to treatment
45495917|NCT03641534|Procedure|Inferior Vena Cava ultrasound|Measurement of the inferior vena cava diameter
46055009|NCT04300322|Drug|Vaginal Progesterone|Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
45379914|NCT00839501|Drug|Acetazolamide|250 mg twice daily, orally, during the second 3-day inpatient visit and during the second 18-week treatment period, as is randomly scheduled
45379915|NCT05704062|Procedure|Diffusion Weighted Imaging|Undergo DW-MRI
46055010|NCT05457673|Device|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
46055011|NCT04517136|Behavioral|Assessment of work-related stress|Assessment of burnout, mindfulness, interoceptive awareness, anxiety, post-traumatic stress disorder, coping flexibility and sleep through questionnaires.
45379916|NCT05704062|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
45379917|NCT00839579|Other|1x4 min interval|Aerobic interval training
45379918|NCT00829907|Drug|ORM-12741|Single dose as a capsule, oral administration
45379919|NCT00529542|Drug|Lipitor|40mg caplets per day for six weeks
45495918|NCT03641534|Procedure|Passive leg raising test (PLR)|Baseline assessment (including pulse rate, systolic and diastolic blood pressure, velocity time integral (VTI) and stroke volume (SV) echocardiographic measurements) will be performed in the resting semi-recumbent position, defined as a position with the trunk elevated 30° to 45° relative to the lower limbs.
46055012|NCT04517136|Biological|Saliva sample collection|Saliva sample is collected before and after emotional stimulation in order to measure resting-state allostatic load biomarkers: Dehydroepiandrosterone (DHEA), cortisol and chromogranin A levels
45495919|NCT03641534|Procedure|Orthogonal polarization spectral imaging (OPS)|Measurement of capillary flow in the rectal microcirculation
45495920|NCT03641534|Procedure|Urine collection (Foley catheter)|For urinalysis, biochemistry, urine microscopy, pH, and culture.
45495921|NCT03641534|Procedure|Venous blood samplings|for: parasitological and microbiological diagnostics, complete blood count, biochemistry, red cell deformability analyzed by laser assisted rotational cell analyser (LORCA), markers of oxidative stress (peripheral intravenous catheter)
45495922|NCT03641534|Procedure|Electrocardiogram|all patients will have an ECG performed on enrolment as a non-invasive investigation
46055013|NCT04517136|Device|Cardiac and electrodermal recordings|Electrocardiogram and electrodermal activity (tonic and phasic) is collected at rest and after emotional stimulation.
46055014|NCT04517136|Behavioral|Assessment of behavioral response to emotional stimulation|"Emotional stimulation involves asking the participants to remember a recent event related to the COVID-19 crisis that has been emotionally difficult for them.~Perceived stress, situational awareness and emotions is assessed after emotional stimulation through questionnaires."
46055015|NCT04228341|Other|Glucose Reference 1|50 g of glucose dissolved in 250 ml of water (First glucose control visit)
46055016|NCT04228341|Other|Glucose Reference 2|50 g of glucose dissolved in 250 ml of water (Second glucose control visit)
45693908|NCT01959347|Other|Miduretheral Sling with behavioral/pelvic floor therapy|MUS is combined with components of behavioral therapy (designed to change behaviors to encourage continence), and pelvic floor muscle therapy (designed to strengthen the pelvic floor muscles, enhance the physiological closure of the bladder neck, and improve coordination). This is done prior to MUS (1 visit) and after MUS for 5 visits at 2, 4, 6, 8 weeks and 6 months.
45379920|NCT00529542|Drug|Placebo|1 placebo caplet per day for six weeks.
45379921|NCT04043741|Other|Dry Needling|stretching exercises :single knee to chest (15 reps x 3 sets) double knee to chest(15 reps x 3 sets) strengthening exercises: extension exercises (15 reps x 3 sets)
45379922|NCT04043741|Other|Sustain Pressure|"Sustain Pressure (Number of repetition and hold according to trigger point chronic level)~+ Hot pack 10 to 15 minutes + Active muscle stretching exercise (10 repetition twice daily)"
45379923|NCT00621959|Drug|levocetirizine dihydrochloride|5mg daily (oral tablet) for 14 days
45379924|NCT00621959|Drug|placebo|0mg (matching oral tablet)for 14 days
45498225|NCT04058028|Drug|Placebo for Rozibafusp Alfa|Placebo for Rozibafusp Alfa will be presented in 5 mL glass vial
46055017|NCT04228341|Other|Glucose Reference 3|50 g of glucose dissolved in 250 ml of water (Third glucose control visit)
46055018|NCT04228341|Other|Brown Rice|Unpolished brown rice containing 50 g of available carbohydrate was cooked using a rice cooker (Toyomi) at a ratio of rice to water of 1: 2
46055019|NCT04228341|Other|3 % polished rice|3% polished rice, containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2
45379925|NCT05702736|Behavioral|logotherapy-based intervention|Logotherapy-based intervention was administered to the individuals in the intervention group as a total of eight sessions, once a week.
45379926|NCT00839657|Behavioral|Genotype-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical and genetic information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical and genetic information.
45379927|NCT00839657|Behavioral|Clinical-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical information.
45379928|NCT05261568|Behavioral|PROGRESSIVE RELAXATION EXERCISE|Progressive relaxation exercise will be done for 6 weeks by watching the animation video in the mobile application program.
45379929|NCT02547857|Other|Pelvic US|To be eligible for inclusion, a woman will have pelvic US completed as part of her ED stay. This is a non-interventional study.
45379930|NCT03999528|Diagnostic Test|14-3-3η Protein assay|blood sampling for assessment of serum 14-3-3η Protein
45379931|NCT00839813|Behavioral|Yoga|10 weeks of a trauma-sensitive yoga class
45379932|NCT05259696|Biological|E-602|Subjects will receive E-602 (administered weekly, via IV infusion).
45379933|NCT05259696|Biological|Cemiplimab|Subjects will receive cemiplimab (administered once every 3 weeks, via IV infusion).
45379934|NCT00839891|Drug|VI-0521|PHEN/TPM 7.5/46 mg (a potential therapeutic dose) PHEN/TPM 22.5/138 mg (a supra-therapeutic dose)
45379935|NCT00839969|Procedure|Cystoscopy|Saline cystoscopy under general anaesthesia
45379936|NCT00839969|Procedure|Cystoscopy and urethral dilatation|Saline cystoscopy and urethral dilatation (using Hegar dilators) under general anaesthesia
45379937|NCT00830297|Drug|Insulatard (long-acting insulin)|In group No.1 (study arm 1 (=A)), patients will be treated with long-acting insulin (Insulatard) as soon as the glucose-level before supper surpasses 140 mg/dl. The normoglycemic goal in this group will be from 110 to 120 mg/dl.
45379938|NCT00830297|Drug|Conventional|In group No.2 (study arm 2 (=B)), patients will be treated conventionally according to the decisions taken by the physicians on the ward. The following suggestions will be brought to the attention of the ward in order to standardize the treatment of the patients in study arm B: 1. Treatment in this group should be initiated if the fasting glucose level surpasses the renal glucose threshold, i.e. 180 mg/dl. 2. As the proposed life-style modifications for the treatment of NODAT1 are not feasible during this very early post-transplant phase, the basis of the conventional therapy will be proposed to be sulfonyl urea drugs (i.e. Gliclazide - Diamicron®, 30 mg, not more than twice daily). 3. Short-acting insulin will be strongly recommended to be used for corrections of capillary blood glucose levels above 250 mg/dl.
45495923|NCT03641534|Procedure|GlycoCheck|GlycoCheck is a clinical sublingual handheld, bedside microscope that detects erythrocytes within the small sublingual blood vessels measuring 5 to 25 micrometers in diameter. The sublingual vasculature is a validated site for measuring thickness of the endothelial glycocalyx.
45495924|NCT03643250|Other|Smaller Portion Size and Standard Appeal (non-divided plate)|Food with Smaller Portion Size and Standard Appeal on a non-divided plate
45693909|NCT00828178|Drug|Omega-3|Omega-3-acid ethyl esters (Lovaza) 3 gram once a day for 12 weeks
45379939|NCT03877224|Drug|Dapagliflozin|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
45379940|NCT03877224|Other|Placebo|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
45379941|NCT00840125|Drug|erlotinib|150mg tablet daily
45379942|NCT00840125|Drug|docetaxel|30 mg/m2 days 1,8 of 22 days cycles, up to 6 cycles
45379943|NCT02548481|Other|BESTA scale|BESTA scale is administrated at T0, T1 and T2.
45693910|NCT00828178|Device|flow-mediated dilation of the brachial artery|flow-mediated dilation of the brachial artery measurement at baseline and after 12 weeks
45693911|NCT00828178|Other|corn starch|3 capsules qd for 12weeks
45693912|NCT00828412|Device|EpiCeram Skin Barrier Emulsion|topical cream, twice daily, 6 weeks
46055020|NCT04228341|Other|6 % polished rice|6% polished rice, containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2
46055021|NCT04228341|Other|9 % polished rice|9 % polished rice, containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2
46055022|NCT04228341|Other|20 % Polished rice|White rice (20% polished rice), containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2.
46055023|NCT02600377|Other|Vegetarian diet|Diets that omit all animal products (vegan diet) or all animal products with the exception of eggs and/or dairy products (vegetarian)
46055024|NCT04496310|Procedure|Telemedicine|Telemedicine versus usual care (face to face visit)
46055025|NCT05310435|Device|Single volume measurement with ESD|Single volume measurement with Edema Stocking device
46055026|NCT05310435|Device|Single volume measurement with WDV|Single volume measurement with water displacement volumetry method
45495925|NCT03643250|Other|Smaller Portion Size and Enhanced Appeal (divided plate)|Food with Smaller Portion Size and Enhanced Appeal on a divided plate
45495926|NCT03643250|Other|Larger Portion Size and Standard Appeal (non-divided plate)|Food with Larger Portion Size and Standard Appeal on a non-divided plate
45379944|NCT00840359|Procedure|Photodynamic therapy|Application of Metvix 16% cream followed by exposure to daylight for 2.5 hours
45495927|NCT03643250|Other|Larger Portion Size and Enhanced Appeal (divided plate)|Food with Larger Portion Size and Enhanced Appeal on a divided plate
45495928|NCT03643250|Other|Smaller Portion Size and Standard Appeal (divided plate)|Food with Smaller Portion Size and Standard Appeal on a divided plate
45379945|NCT00840359|Procedure|Cryotherapy|Cryotherapy for 2 times 20 sec
45379946|NCT00830453|Procedure|Hyperbaric oxygen therapy (HBO2)|60 daily hyperbaric oxygen sessions 1.5 atmospheres absolute, 100% oxygen 60 minutes per session, from door closing to door opening
45379947|NCT04016597|Device|Jaeger Masterscreen TM|Single-breath nitric oxide lung diffusing capacity
45379948|NCT04016597|Device|HypAir Medisoft|Single-breath nitric oxide lung diffusing capacity
45379949|NCT00528606|Biological|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500 into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
45495929|NCT05692674|Radiation|adjuvant hypofractionated intensity-modulated proton radiotherapy|CTV1: chest wall ± regional lymph drainage area, 40.05Gy (RBE) in 15 fractions with proton radiotherapy;
45495930|NCT02298348|Drug|Sorafenib|Sorafenib -100-200mg/m2/dose (dose escalation), Orally BID continuously Days 1 thru 28 Cyclophosphamide - 250 mg/m2/day IV x 5 days - day 1 thru day 5 Topotecan - 0.75 mg/m2/day IV x 5 days - day 1 thru day 5
45495931|NCT02298348|Drug|Cyclophosphamide|250mg/m2/day IV x5 days (Day 1 through Day 5 of each course)
45379950|NCT00528606|Biological|Placebo|Subjects could have received up to three injections of placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
45495932|NCT02298348|Drug|Topotecan|0.75mg/m2.day IV x5 days (Day 1 through Day 5 of each course)
45495933|NCT03643094|Dietary Supplement|Golden Black Seed|1 capsule per day for 8 weeks.
45495934|NCT02929329|Drug|Omecamtiv Mecarbil|Omecamtiv mecarbil tablets for oral administration
45495935|NCT02929329|Drug|Placebo|Matching placebo tablets
45693913|NCT00828412|Drug|Desonide Cream 0.05%|topical cream, twice daily, 6 weeks
45693914|NCT04638335|Biological|Blood test|blood test for Anti-HAV antibodies
45693915|NCT01959035|Drug|Aripiprazole once-monthly|400 or 300 mg/month; 6 intramuscular (IM) injections starting at baseline
46055027|NCT05310435|Device|Single circumference measurement with tape measure|Single circumference measurement with tape measure
46055028|NCT05310435|Device|Continuous volume measurement with ESD|Continuous volume measurement with Edema Stocking device
45379951|NCT00830531|Drug|Bumetanide|Bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
46055029|NCT02842788|Procedure|Prone positioning|Turning the patient face down for several consecutive hours
46055030|NCT01022762|Drug|repaglinide|Individually adjusted dose for 16 weeks
46055031|NCT01022762|Drug|gliclazide|Individually adjusted dose for 16 weeks
46055032|NCT04093141|Procedure|IRE|in situ irreversible electroporation
45379952|NCT00830531|Drug|Normal Saline as Placebo|Normal Saline as placebo for bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
45379953|NCT05014542|Procedure|Acupuncture|Acupuncture treatment includes pricking the skin with acupuncture needles 0.3 x 40 millimetres in size, in the places of prescribed acupuncture points. Placed needles should be manipulated three times, every ten minutes, three times in total. The complete time of treatment is 30 minutes. All treatments will be equal.
45379954|NCT05014542|Drug|Conventional Medical Treatment|Participants could take their standard conventional medical treatment or analgesics. Analgesics therapy is prescribed by their general practitioner. The dose of analgesics could be modified according to participants' symptoms intensity.
45495936|NCT02929329|Drug|Standard of Care|Participants were required to be optimally managed with standard of care therapies for chronic HF (eg, beta blockers, renin angiotensin aldosterone system inhibitors), consistent with regional clinical practice guidelines, unless contraindicated.
45495937|NCT03642938|Behavioral|Walking Exercise|Exercise groups will perform moderate intensity treadmill walking at a speed of 3.5 mph at a 0% incline for 30 minutes.
45495938|NCT03642938|Behavioral|Control|The Control group will perform 30 minutes of quiet rest.
45495939|NCT03240133|Drug|BCX7353|oral liquid formulation
45495940|NCT03240133|Drug|Placebo|oral liquid formulation to match BCX7353
45495941|NCT03814356|Drug|Methylphenidate|IV MPH
45495942|NCT03642860|Drug|Triheptanoin|Daily treatment with Triheptanoin oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
45495943|NCT03642860|Drug|Placebo Oil|Daily treatment with Safflower oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
45498226|NCT03684252|Behavioral|CBT-based intervention|Cognitive Behavioral Therapy (CBT) that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies.
45693916|NCT01700959|Drug|melatonin|Melatonin 3mg time release will be given. Participants will be instructed to take one 3mg time released tablet by mouth approximately 1-2 hours before initiating sleep onset, preferably at the same time each night.
45495944|NCT03707171|Drug|Liraglutide|Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. It has been proved that Liraglutide can improve insulin resistance and cognitive function in AD animals. Therefore, it is speculated that Liraglutide may interfere with the occurrence and development of cognitive dysfunction in patients with T2DM. In order to confirm the effects, the investigators conduct an open, prospective, positive controlled study in patients with T2DM.
45379955|NCT00840593|Procedure|Non-surgical group|The non-surgical treatment consisted of immobilisation of the injured AC-joint in a Kenny-Howard-type splint for four weeks. The patient was encouraged in mobilisation of the elbow several times per day and the mobilisation of the shoulder with pendulum type movements were initiated four weeks after the injury. Active mobilisation of the shoulder was allowed six weeks after the injury.
45379956|NCT00840593|Procedure|Surgical group|The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
45379957|NCT00843947|Procedure|Reduced Intensity Stem Cell Transplantation|Reduced Intensity Stem Cell Transplantation
45379958|NCT04925622|Diagnostic Test|Complex eye movement exam|"Subjects will undergo a complex eye exam which will capture fixation, optokinetic nystagmus, guided saccades, microsaccades, smooth pursuit, and pupillometry.~Eye tracking equipment will be set and calibrated to the participant who will then perform the full 10 minute testing protocol with instructions from the investigator. After this, they will take a five minute break. The oculomotor testing protocol will be repeated twice."
45379959|NCT04926324|Drug|Niraparib|Niraparib is a drug FDA-approved for use in maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
45379960|NCT04926324|Drug|Dostarlimab|Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody medication used for the treatment of endometrial cancer.
45379961|NCT04926324|Radiation|Short course radiation|Participants will be treated with intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) to minimize mean dose to femoral, pelvic, and lumbar bone marrow. The entire mesorectum will be treated to a total dose of 25 Gy.
45379962|NCT05219994|Other|Hyperoxia Exposure|2 hours of hyperoxia exposure during OGTT
45379963|NCT05219994|Other|Normoxia Exposure|2 hours of normoxia exposure during OGTT
45379964|NCT00621257|Dietary Supplement|ergocalciferol|8000 units/ml
45379965|NCT00621257|Dietary Supplement|Cholecalciferol|400 units per drop
45495945|NCT03707171|Drug|placebo|Any hypoglycemic drugs except glucagon-like peptide type 1 (GLP-1) analogue.
45495946|NCT03795246|Procedure|Consultation|Consultation in oncology: collection of oncological data and ongoing cancer treatments, clinical exam Consultation in gynecology: collection of gynecological data, contraception and reproductive medicine
45495947|NCT03795246|Biological|Biological Test|"Blood test:~FSH, LH, E2 and AMH~4 tubes of 7 mL"
46055033|NCT05338671|Drug|Local anesthetic|Patients will receive inferior alveolar nerve block injection following endodontic treatment.
46055034|NCT00311844|Drug|desloratadine|
45379966|NCT00528840|Biological|collagenase clostridium histolyticum|Up to five injections of AA4500 into cord(s) of the affected hand(s). Each injection was separated by at least 30 days.
45379967|NCT02547077|Procedure|Wound Closure with 2-octylcyanoacrylate|
45379968|NCT02547077|Procedure|Wound Closure with 5-0 Fast Absorbing Gut Sutures|
45379969|NCT00840671|Drug|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
45495948|NCT03795246|Procedure|Pelvic Ultrasound|Antral Follicles Count
45498227|NCT03684252|Other|Treatment as Usual|Participants' will receive treatment as usual.
46055035|NCT02116140|Other|[C11]Acetate and HED PET|
46055036|NCT05338515|Drug|Selpercatinib|Administered orally.
46055037|NCT01028378|Device|T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser|
46055038|NCT00747565|Device|Tecnis ZM900 Multifocal Intraocular Lens|Investigational intraocular lens
46055039|NCT00747565|Device|CeeOn 911A monofocal IOL|Monofocal Control IOL
45495949|NCT03642704|Drug|Reinforced preventive ARV therapy|"If the mother is HIV-1 or HIV 1/2 infected:~zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks.~nevirapine: 15mg/OD if weight ≥ 2500g / 10mg/OD if weight = 2000-2499g / 2mg/kg/OD if weight < 2000g for 12 weeks in case of HIV-1 infection. After 6 weeks, nevirapine will increase at 20mg/OD~If the mother is HIV-2 infected:~- zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks."
45379970|NCT00840671|Drug|0.9% Saline Solution|0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
45379971|NCT00851123|Behavioral|Modified Constraint-Induced Movement therapy|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing the affected arm. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own. A restraining mitt has to be worn 5 hours a day.
45379972|NCT00851123|Behavioral|Task-specific bimanual training|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing bimanual tasks. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own.
46055040|NCT04227561|Procedure|Pudendal nerve block|"Pudendal nerve block will be performed under general anesthesia and guided by neurostimulation.~The local anesthetic solution (chirocaine 2.5mg/ml) will be injected in the ischiorectal fossa with a needle (a BBraun Stimuplex Ultra 360 22G 50mm needle) connected to a neurostimulator (Stimuplex HNS 12 neurostimulator). The neurostimulator will be used to determine the localization of pudendal nerve and to identify the precise site of injection. The contraction of the anal sphincter or bulbocavernosus muscle occurs when the pudendal nerve is reached.~These procedure will be performed bilaterally."
46055041|NCT04227561|Procedure|Penile nerve block|"The local anesthetic solution (chirocaine 2.5mg/ml) will be injected under the fascia of Scarpa with a real-time ultrasound guidance.~These procedure will be performed bilaterally."
46055042|NCT02599675|Dietary Supplement|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
45379973|NCT05691114|Biological|hAESCs|human Amniotic Epithelial Stem Cells
45379974|NCT05686590|Behavioral|Augmented Reality Headset|The simulation scenario will be a pediatric hypoglycemia-induced seizure case, which will be done through an AR simulation. AR (Augmented Reality) headset, which is a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario.
45379975|NCT02545985|Device|Prolim stent deployment|Prolim stent was implanted in patients who signed the informed consent and met the exclusion and inclusion criteria.
45495950|NCT03706937|Other|Semi directive interview|Semi directive interview will be performed to try to define the management of addictions in the oncology care course. Thus, an approach in terms of social representations among paramedical professional actors involved in the care of patients treated for cancer and with an unresolved addictive disorder sounds the best way for this research.
45495951|NCT05682833|Procedure|Non surgical periodontal therapy|Subgingival ultrasonic debridement + manual root planning
46055043|NCT02599675|Dietary Supplement|Placebo|Olive oil, encapsuled
46055044|NCT01028300|Device|ProDisc™-L Total Disc Replacement (TDR)|The design is based on a ball and socket articulation, one surface being metal and the other an ultra-high molecular weight polyethylene (UHMWPE). Three components comprise this modular prosthesis.
45379976|NCT00851201|Behavioral|Intensive lifestyle|"The intensive lifestyle intervention will include the standard intervention plus 1)12 core group modules for parents (to address roles and skills) and for children (to enhance motivation and skills and to provide physical activity), 3) Tailored support using a toolbox approach from community health workers as extensions of the Family Weight Management professional education staff, and 4) monthly after-core follow-up groups."
45379977|NCT00851201|Behavioral|Standard intervention|The Standard Intervention will receive: 1) an initial consult, which includes an overview of lifestyle goals, 2) quarterly follow-up, 3) and a monthly newsletter.
45379978|NCT00844025|Behavioral|Pharmacist intervention|Medication review, medication reconciliation, and pharmacotherapy recommendation.
45379979|NCT05219760|Device|LIVIA|"The study aim to compare the efficacy of an IBI targeting complicated grief symptoms (LIVIA 2.0) compared to an already investigated IBI (LIVIA 1) using a guidance on demand design in a randomised controlled trial.~Both programs are composed of 10 weekly sessions proposing educational material, questionnaires and exercises. They are based on current scientific theories of grief but present their content differently. Compared to LIVIA 1, LIVIA 2.0 is less based on academic readings and participants can choose more freely which topics and exercises they want to do. LIVIA 2.0 also offers a system of reminder messages to maximize adherence as well as more elaborate automated guidance."
45379980|NCT02546531|Biological|Defactinib|
45495952|NCT02030964|Drug|DFMO|
46055045|NCT03741972|Drug|iSGTL2|Treatment with empaglifozine 10 mg/day (may be also dapaglifozine 10mg/day depending on clinical trial results)
46055046|NCT02778789|Drug|Tocilizumab|Patients will be treated with either i.v. Tocilizumab every 4 weeks or s.c. Tocilizumab weekly according to the label
45495953|NCT02030964|Drug|Celecoxib|
45495954|NCT02030964|Drug|Cyclophosphamide|
45495955|NCT02030964|Drug|Topotecan|
45495956|NCT03372083|Drug|Deferasirox|Deferosirox was provided in tablet forms of 90, 180 and 360mg. Tablets were crushed in the home environment and administered by sprinkling the full dose on to soft food to be consumed immediately.
45495957|NCT03044886|Dietary Supplement|vitamin D|Subjects took vitamin D or placebo
45495958|NCT02961764|Drug|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
45495959|NCT02961764|Drug|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
45495960|NCT03371459|Drug|AS MDI|AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
45495961|NCT03371459|Drug|Proventil|Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation
46055047|NCT02778789|Drug|TNF-alpha Inhibitor|Patients will be treated with TNF-Inhibitors either i.v. or s.c. according to the label
46055048|NCT04228497|Device|gastric ultrasound|Children in both groups will be scanned in two positions: supine position and right lateral position (RLP) one and two hours following the clear fluid intake and before admission to the operation room in groups 1 and 2 respectively. Gastric antrum will be located in the sagittal plane with simultaneous identification of left lobe of the liver and the descending abdominal aorta or inferior vena cava.
46055049|NCT04228497|Other|the clear fluid intake|the clear fluid intake
46055050|NCT00212784|Drug|asenapine|Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
46055051|NCT00212784|Drug|olanzapine|Oral capsules (5 mg or placebo); 1 to 2 tablets twice daily
46055052|NCT00752089|Drug|NaF/ KNO3/isopentane Dentifrice|Experimental toothpaste
46055053|NCT00752089|Drug|NaF/KNO3 Dentifrice|Experimental toothpaste
46055054|NCT00752089|Drug|NaF Dentifrice|Active comparator
45379981|NCT02546531|Biological|Pembrolizumab|
45379982|NCT02546531|Drug|Gemcitabine|
45495962|NCT03642548|Drug|bifico|Patients in BIFICO group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Bifico.
45495963|NCT03642548|Drug|placebo|Patients in control group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Placebo.
45495964|NCT02961920|Device|IE ratio 1:1|Set an I:E ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.
45495965|NCT02961920|Device|IE ratio 1:2|Set an I:E ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
45693917|NCT01700959|Drug|placebo|Placebo tablets to match the melatonin will be comprised of inert substances.
45379983|NCT00840983|Procedure|delayed cord clamping|cord clamping was delayed for 30 to 45 seconds and infant was held lower than the level of the placenta
45379984|NCT05205720|Procedure|Celiac plexus block|The surgeon is instructed to perform a single celiac plexus block under direct vision. 10ml 0.5% ropivacaine is injected into the nerve in both sides.
45379985|NCT05205720|Drug|Ropivacaine|Mixed solution for nerve block, made of 0.75% ropivacaine (Naropin, Astrazeneca AB) diluted in different proportions.
45379986|NCT04043195|Drug|Nivolumab|240 mg every 2 weeks. Nivolumab will continue for up to 2 years.
45379987|NCT04043195|Drug|Oxaliplatin|65 mg/m2 every 2 weeks. Oxaliplatin will continue for up to 12 cycles.
45379988|NCT04043195|Drug|Ipilimumab|1 mg/kg every 6 weeks. Ipilimumab will continue for up to 4 cycles
45495966|NCT05283668|Biological|i-PRF|"Local anesthesia was achieved using field block technique.~A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~Laser irradiation parameters were adjusted as follows: Wavelength [940 ± 10 nm], irradiation mode [contact continuous wave], Power [2 W] and 300 μm fiber tip diameter (Jokar et al., 2019).~The treatment was depigmentation by laser thin injection by I-PRF Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization."
45498228|NCT03503370|Drug|Chlorhexidine|Participants randomized to the intervention will wash their feet using 2% CHLORHEXIDINE GLUCONATE CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
45379989|NCT00844103|Drug|AZD8566|10ml oral solution administered once a day over 10 days. Specific dose will be selected by the safety review committee
45379990|NCT00844103|Drug|Placebo|10ml oral solution administered once a day over 10 days.
45379991|NCT04907526|Biological|Autologous mononuclear cells|Autologous mononuclear cells delivered into right ventricle at time of Stage III Fontan surgery.
45379992|NCT00841061|Dietary Supplement|electrolytic iron|1/4 a cup of cereal fortified with electrolytic iron per day between the ages of 112 days and 280 days of age
45379993|NCT00841061|Dietary Supplement|ferrous fumarate|1/4 cup of cereal fortified with ferrous fumarate to be fed per day between ages of 112 days and 280 days of age
45498229|NCT03684174|Device|Intraocular pressure measurement|Pressure tip or air puff is applied on eye
46055055|NCT00752089|Other|Placebo Dentifrice|Placebo comparator
46055056|NCT02779179|Procedure|Periodontal treatment|"Mechanical debridement (scaling, root planning, subgingival curettage)~Antimicrobial therapy (systematically administered: amoxicillin or clindamycin).~Antiseptic mouthrinses, gel or dentifrice~Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)"
45379994|NCT03999060|Device|Electric Current Stimulation|Electric stimulation with a Digitimer DS7AH HV Current Stimulator delivered with 4 shielded electrodes mounted on the participants head
45379995|NCT04042805|Biological|Sintilimab|200mg intravenously every 3 weeks
45379996|NCT04042805|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
45379997|NCT05643846|Procedure|QLB procedure after cesarean section|Bupivacaine local anesthetic drug used for QLB procedure after Cesarean section. Intervention of two different concentration of Bupivacaine, 0.125% or 0.25%, at a dose of 0.2 ml/kg.
45379998|NCT00841139|Drug|Perhexiline|100mg o bd
45379999|NCT00841139|Drug|Placebo|1 tablet bd
45380000|NCT00841217|Drug|GW501516|2.5mg/day
45380001|NCT00841217|Drug|placebo pill|
45380002|NCT00841295|Drug|Parenteral L-carnitine supplementation|Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
45380003|NCT00841295|Drug|Parenteral supplementation with sterile water|Parenteral supplementation with an equivalent volume of sterile water
45380004|NCT00851435|Biological|KBPA-101|1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
45380005|NCT00844337|Drug|Gentamicin & Amoxicillin x 7days|"Injectable gentamicin once daily and oral amoxicillin twice daily for seven days.~The dose for gentamicin is 4 - 5 mg/kg/24 hours. The dose for amoxicillin is 90-115 mg/kg/day."
45380006|NCT00844337|Drug|Penicillin & gentamicin x 2 d + Amoxicillin X 5 d|Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days. The dose for penicillin is 40,000 - 50,000 U/kg/24 hours, the dose for gentamicin is 4 - 5 mg/kg/24 hours, and the dose for amoxicillin is 90-115 mg/kg/day.
45380007|NCT00844337|Drug|Standard reference therapy|Injectable procaine-benzyl penicillin and gentamicin once daily each for seven days. The penicillin dose is 40,000 - 50,000 U/kg/24 hours, and the gentamicin dose is 4 - 5 mg/kg/24 hours.
45380008|NCT00841373|Procedure|Panretinal Photocoagulation|Panretinal Photocoagulation treatment
45380009|NCT00841373|Procedure|Panretinal Photocoagulation and intravitreal injection of ranibizumab|Panretinal photocoagulation and ranibizumab
45380010|NCT00841451|Drug|Lovaza (Fish Oils)|Double blinded placebo controlled
46055057|NCT02842554|Other|EPT|
46055058|NCT02842554|Drug|Drug Placebo Administration|
46055059|NCT02842554|Other|C|No Intervention
46055060|NCT05295147|Other|Palmar Grasp Reflex Stimulation|The palmar grasp reflex is an involuntary flexion-adduction movement involving the hands and fingers.
45380011|NCT00844493|Biological|E coli strain H10407 and buffer|7 or 8 logs of the bacteria with bicarbonate buffer
45495967|NCT05283668|Procedure|Diode Laser|"Local anesthesia was achieved using field block technique.~A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~Laser irradiation parameters were adjusted as follows: Wavelength [940 ± 10 nm], irradiation mode [contact continuous wave], Power [2 W] and 300 μm fiber tip diameter (Jokar et al., 2019).~Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization."
45380012|NCT00844493|Biological|E coli strain H10407 and buffer|Bacteria in a dose of 8 logs with CeraVacx buffer
45380013|NCT00844493|Biological|E coli strain H10407 and buffer|Bacteria in a dose of 7 logs and CeraVacx buffer
45380014|NCT00844493|Biological|E coli H10407 and buffer|Bacteria in a dose of 8 logs with bicarbonate buffer
45380015|NCT00851513|Drug|Lidocaine|local anesthetics
45380016|NCT00851513|Drug|Depmedrol|local steroids
45380017|NCT00851513|Other|physiological serum|important volumes of physiological serum
45380018|NCT00841607|Procedure|pancreaticojejunostomy vs pancreaticogastrostomy|
45380019|NCT00844571|Other|E-learning program|Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
45380020|NCT00841841|Drug|dipyrone and acetaminophen|The patients were randomly assigned to 2 groups of 15 patients, according to the drug prescribed as postoperative medication: Group I: dipyrone 500 mg every 6 hours (4 males, 11 females, mean age = 25.2 years) and Group II: paracetamol 750 mg every 6 hours (3 males, 12 females, mean age = 26.8 years)
45693918|NCT04637087|Other|Atrial fibrillation risk electronic health record alert|Electronic health record best practice alert which displays patient's 5-year risk of developing atrial fibrillation
45693919|NCT00829036|Device|Wayfinding Prototype|A Wayfinding Prototype is used by subjects to determine any advantages over current standard of rehabilitation.
45380021|NCT02545751|Radiation|Stereotactic Body Radiation Therapy|SBRT is given during combined therapy to one of the metastatic lesions, 25Gy in 5 fractions (5Gy per fraction) over one week, conformally to maximally spare normal tissue or organ.
45380022|NCT02545751|Drug|Thymalfasin|Thymalfasin treatment is given twice a week with an interval of 3-4 days until progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
45495968|NCT03371381|Biological|JNJ-64041757|Participants will receive intravenous (IV) infusions of JNJ-64041757 over approximately 60 minutes during each treatment cycle.
46055061|NCT03307356|Other|Uterine Transplant|Transplant of a uterus from a donor, deceased or living
46055062|NCT04227405|Behavioral|Connection to community services through case management|Case managers met with couple and conduct a needs assessment for the couple and their family. Then they developed an Individual and Couple Development Plan to take care of those needs, usually by accessing community services. Case managers met every 5 weeks with the couple to check on progress toward meeting the goals of the plan and assess for the present of any new needs.
45380023|NCT00841919|Drug|Glargine insulin|"The study group will receive Insulin Glargine as basal insulin. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
46055063|NCT04227405|Behavioral|TOGETHER Workshop|Couples were required to participate in a 20 hour workshop (8 sessions of 2 1/2 hours each)in groups of 3 to 8 couples. These groups were facilitated by a financial expert and a couples' expert. The workshop is interdisciplinary and psycho-educational. Couples learn about skills to improve their communication about stress and money problems, conflict resolution, individual and couple stress management in general and about money stress in particular, and financial management
46055064|NCT04227405|Behavioral|Employment Support Services|Only for those participants that were in need of employment support services. If the needs assessment conducted by the case manager indicated an employment or career need. After completion of the TOGETHER workshop, an employment case manager met with the participant, conducted an employment needs assessment and connected the participant with a workforce agency or one-stop employment centers. After doing so, the employment case manager followed through the various steps that the participant had to complete as part of the employment services for a period of 6 months
46055065|NCT00751933|Biological|Vaccine Vivotif + Vaccine Dukoral + oats|"Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.~One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months."
46055066|NCT00751933|Biological|Vaccine Vivotif + Vaccine Dukoral|Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.
46055067|NCT00751933|Dietary Supplement|Oats|One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months.
46055068|NCT00751933|Other|Placebo|Placebo capsules instead of Vivotif capsules Placebo mixture instead of liquid Dukoral vaccine
45495969|NCT03371381|Drug|Nivolumab|Participants will receive IV infusions of nivolumab over approximately 60 minutes during each treatment cycle.
45693920|NCT01738477|Biological|Boostrix|Single dose intramuscular administration.
45380024|NCT00841919|Drug|NPH insulin and regular insulin|"The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
45380025|NCT00841919|Drug|lispro insulin|"Bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
45380026|NCT00851669|Behavioral|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD)|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
45380027|NCT00851669|Behavioral|Treatment as Usual|Individual psychotherapy following usual care practice in a chemical dependency treatment program.
45380028|NCT04214327|Behavioral|Strengthening Families Program Online eLearning Game|Families (parent/caregiver and children) are to play-test a highly interactive online gamified version of the Strengthening Families Program called SFP Online, with 10 lessons that utilize three 10-minute mini-sessions and games that teach parents evidence-based parenting and family relationship skills and teach youth social, life, and alcohol and drug refusal skills. Skills are reinforced through gaming. Game points are achieved by right answers to self-correcting mini-quizzes for low-stakes failure and through actual reported home practice of the skills. The SFP parenting skills have been shown to reduce risk factors and increase protective factors that prevent youth substance abuse.
45380029|NCT04214327|Behavioral|SFP Home-use DVD|Family views an 11-session SFP video series online or at home using a DVD that contains the same program and lesson content as the online condition; however, the lesson material is more static without the interaction required in the gamified version of SFP Online.
45380030|NCT04214327|Behavioral|Wait-Listed Control|Families receive no active intervention for 22 weeks; however, during this wait time, participants receive weekly email reminders that contain riddles and puzzles for youth and parents receive nutritional information and food preparation recipes. Following conclusion of the initial trial the wait-listed control sites are then administered the 10-session SFP Online intervention
45380031|NCT03849911|Diagnostic Test|Neurophysiological Prognosis|SEP and EEG evaluation for Neurological Prognosis of Cardiac Arrest
45380032|NCT03849911|Diagnostic Test|Multimodal Prognosis for poor early neurological outcome|Brain CT, SEP and EEG evaluation
45380033|NCT00851981|Other|Placebo|TID
45495970|NCT03710681|Biological|SHR-1314|Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
45495971|NCT03044730|Drug|Capecitabine|Given PO
45380034|NCT00851981|Dietary Supplement|SAMe|300 mg TID
45380035|NCT00852059|Drug|Immediate release methylphenidate (Medikinet®)|Treatment: methylphenidate in the morning and 3-4 h later (twice daily), immediate release
45693921|NCT00829738|Drug|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs (20 or 40 mg pantoprazole).
45380036|NCT00852059|Drug|Extended release methylphenidate (Medikinet retard®)|Treatment: methylphenidate applied with breakfast(once daily), extended release
45380037|NCT00844727|Drug|Rofecoxib|
45380038|NCT00844727|Drug|placebo|placebo pills
45495972|NCT03044730|Other|Laboratory Biomarker Analysis|Correlative studies
45495973|NCT03044730|Biological|Pembrolizumab|Given IV
45495974|NCT03738852|Device|Continuous Glucose Monitor (CGM)|Continuous Glucose Monitor (CGM)
45495975|NCT03738852|Drug|Insulin|standard insulin regimen
45380039|NCT00844961|Behavioral|Internet delivered cognitive behavior therapy|10 weeks of internet delivered cognitive behavior therapy targeted at reducing experience of IBS symptoms and improving quality of life. Patients are offered guidance via email by a therapist.
45380040|NCT00845117|Procedure|Cultivated limbal stem cell graft transplantation|A limbal biopsy taken from the contralateral good eye in cases of unilateral disease or from a living related or cadaveric donor in cases of bilateral disease. The limbal stem cells from the biopsy are cultivated until a sheet of cells measuring approximately 12mm in diameter is obtained. This is then ready for transplantation onto the diseased eye.
45495976|NCT03737058|Behavioral|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
45495977|NCT05476887|Drug|KP104|KP104 intravenously (IV loading + subcutaneous [SC] maintenance every week [QW] or every 2 weeks [Q2W]) will be administered.
45495978|NCT02961374|Drug|Erlotinib|Given PO
45495979|NCT02961374|Drug|Erlotinib Hydrochloride|Given PO
45693922|NCT01737931|Drug|Topical steroid (Dexamethasone)|for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for steroid: twice daily administration of Dexamethasone (1 mg/g cream) to the application sites after the patch removal
45380041|NCT00528528|Drug|Telaprevir|Oval tablets containing 375 mg of telaprevir for oral administration.
45380042|NCT00528528|Drug|Peg-IFN-alfa-2a|Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.
45380043|NCT00528528|Drug|Peg-IFN-alfa-2b|Powder containing Peg-IFN-alfa-2b and solvent for solution for subcutaneous injection in a pre-filled pen.
45693923|NCT01737931|Drug|Topical antihistamine (Diphenhydramine)|for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for antihistamine: twice daily administration of Diphenhydramine (10 mg/g cream) to the application sites after the patch removal
45380044|NCT00528528|Drug|Ribavirin (RBV) tablet|Tablets containing 200 mg RBV for oral administration.
45380045|NCT00528528|Drug|Ribavirin (RBV) capsule|Capsules containing 200 mg RBV for oral administration.
45380046|NCT00620555|Drug|gabapentin|Orally administered gabapentin
45380047|NCT02546453|Biological|Tumoral specific genetic alterations|A buccal swab and a blood sample will be used at the diagnostic to identify the specific genetic alterations of tumoral cells.
45380048|NCT02546453|Biological|Tumoral specific genetic alterations|Collection of blood (maximum 9 samples of 3 to 5 ml), bone marrow (maximum 3 samples of 3 to 5 ml) and cerebral spinal fluid (maximum 3 samples 500µl to 1ml).
45380049|NCT00845273|Drug|Pegaptanib sodium|"Macugen Intravitreous Injection Kit 0.3mg depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows. Pegaptanib sodium is administered intravitreously once every 6 weeks at a dose level of 0.3 mg (on an oligonucleotide of pegaptanib basis )."
45380050|NCT00845351|Drug|Bexarotene|bexarotene at 300 mg/m2/day
45380051|NCT00529386|Drug|Botox|300 units
45380052|NCT02546141|Other|skimmed milk (UHT)|
45380053|NCT02546141|Other|skimmed milk (pasteurized)|
45495980|NCT05263245|Other|Light breakfast|Light breakfast, standardized by 7 menu options for patients. All breakfast options contain the same amount of fat (9-10 g). Example of a menu: 150 ml full-fat yoghurt, 40 gram muesli with sugar, 1 glass of tea.
45693924|NCT04564261|Behavioral|Personalized Healthy Relationship and Safety Planning Tool|"The app delivers evidence-based information and resources in three sections:~My Relationship: contains a series of activities (e.g., quizzes) to raise awareness of common myths about unhealthy relationships, determine characteristics of healthy relationships, examine the red flags in an unhealthy relationship, and assess risk factors for more severe abuse. Participants are provided with personalized messages about their relationship health and safety based on the answers they endorse.~My Strategies: personalized strategies to increase participants' safety and well-being based on responses in the previous section.~My Resources: direct links to the National Dating Abuse hotline, textline, and chatline, as well as personalized health and safety resources."
45693925|NCT04564261|Behavioral|Usual Care Teen Relationship and Health Website|The control group website will provide participants with tools to learn about health topics including examining healthy relationships. The resources will be targeted to adolescents. The control group website is not personalized to the participant or their relationship.
45693926|NCT01958489|Drug|Evacetrapib|Administered orally
46055069|NCT01701570|Behavioral|Placebo Attention Control|The placebo attention control group will receive weekly phone calls to monitor their blood glucose levels.
45380054|NCT02546141|Other|skimmed yoghurt|
45380055|NCT02546141|Other|full-fat milk (UHT)|
45495981|NCT05468853|Device|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting medial prefrontal cortex
45693927|NCT01958489|Drug|Pravastatin|Administered orally
45693928|NCT01721161|Biological|BIIB033 (anti-LINGO-1 mAb)|100 mg/kg via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
46055070|NCT01701570|Other|Supervised Exercise Training|The 20-week aerobic exercise training intervention provides supervised exercise training sessions 3 times weekly following the HERITAGE study training model that was feasible in prior studies with older, sedentary overweight adults (55%maximal oxygen uptake (VO2max) for 30 minutes per session at study entry with progressive titration to 70-80% VO2max for 50 minutes).
46055071|NCT04195269|Drug|Test Article|10 mg CBD, 10 mg of THC, and a proprietary blend of terpenes.
46055072|NCT04093063|Other|Micro-stellated Icosahedron|A portable, inexpensive microsurgery training model that requires the following materials for completion. a stereoscopic dissecting microscope, two jeweler style forceps, a pair of curved-tip micro scissors , 1 meter of monofilament nylon thread, 0.5 meter of polyimide microtubule material , one 15 cm metal ruler, a scalpel blade (#15), and double-sided tape. For a microsurgically-naive subject, a total of 20 hours are required to complete this model.
46055073|NCT03258138|Behavioral|Health and wellness learning sessions|The health and wellness learning sessions provide a platform for concepts from a variety of health behaviour theories and CBT to be combined with evidence- and practice-based recommendations for healthy lifestyles. They provide the basis for participants' development of an individualized action plan. The sessions will last one hour and participants will receive them in a group setting, 18 times throughout the duration of the program. Specifically, the sessions will be delivered during weeks: 1-8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48.
45380056|NCT02546141|Other|non-homogenized full-fat milk (pasteurized)|
45380057|NCT02546141|Other|full-fat cheese (semi-matured)|
45380058|NCT02546141|Other|whey protein|
45380059|NCT02546141|Other|micellar casein|
45380060|NCT05213286|Diagnostic Test|Application of ZAQ and RAADS-R-DK|Test of the questionnaires in each of the three groups.
45380061|NCT00845585|Device|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
45380062|NCT00845585|Device|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
45495982|NCT05468853|Device|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the inion
45495983|NCT05465655|Other|ECG monitoring for Conduction Disturbances|Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
45380063|NCT03875118|Behavioral|The mouth-opening training with follow-up telephone calls program|Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks. Subjects in the intervention group received additional 6 follow-up phone calls (at 1, 2, 3, 4, 8 and 12-week after discharge) from the interventionist to enhance mouth-opening exercise adherence.
45847325|NCT03679962|Behavioral|Triple Chronotherapy|"Day 0: One night of total sleep deprivation. The first 24 hours are spent with 1:1 nursing care for provision of comfort measures to stimulate wakefulness and to encourage completion of the intervention.~Day 1-4: Sleep phase advancement Day 1: Sleep from 6 PM to 1 AM Day 2: Sleep from 8 PM to 3 AM Day 3: Sleep from 10 PM and 5 AM Day 4: Awaken at 5 AM; discharge following light therapy~On days 1-4 patients will receive bright light therapy at 7am to 7:30am using a 10,000 Verilux light box. At discharge patients will be given a light box, strongly advised to continue the maintenance sleep schedule and bright light therapy at 7am daily for 30 minutes. Patients will be scheduled for follow-up appointments at 1-week, 1-month and 2-month following discharge."
45380064|NCT03875118|Behavioral|The mouth-opening training without follow-up telephone calls program|Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks.
45495984|NCT04700787|Drug|Sulopenem|sulopenem intravenous 1000 mg on Day 1 and then sulopenem etzadroxil/probenecid oral 500 mg/500 mg on Day 2
45495985|NCT04783233|Biological|Chitosan succinamide|Chitogel will be tested for suitability as a packing material in tympanoplasty surgery.
45847326|NCT03679962|Behavioral|Treatment as Usual|Normal inpatient care, including pharmacotherapy, psychotherapy, milieu therapy and social work interventions
45847327|NCT03604302|Device|fMRI Paradigms|T2*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR=2500ms, TE=30ms, FA=80°, slice thickness=4 mm, FOV= 240mm2, matrix=64×64) covering the whole brain.
46055074|NCT03258138|Behavioral|Brainstorming group sessions|The brainstorming group sessions allow for facilitated discussions where individuals explore barriers and facilitators to achieving their goals and provide an interpersonal component to the program through the building of social interactions. Participants will also receive help in finding community programs to support healthy lifestyles. These sessions will last one hour and participants will receive them in a group setting, 30 times throughout the duration of the program. Specifically, these sessions will be delivered during weeks: 9-11, 13-15, 17-19, 21-23, 25-27, 29-31, 33-35, 37-39, 41-43, 45-47.
45847328|NCT03494166|Behavioral|Telephone Interpersonal Counseling (TIP-C)|See arm/group descriptions
45495986|NCT04783233|Biological|Gelfoam|Gelfoam is the current packing material for tympanoplasty surgery.
45847329|NCT03476928|Drug|Vilaprisan (BAY1002670)|2mg, once daily, oral
45847330|NCT03443856|Drug|Nivolumab and Ipilimumab|Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year
45380065|NCT00845819|Drug|rhEGF + povidone iodine, chlorhexidine, & nystatin|"Topical application of 50 µg/mL rhEGF solution twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%) & nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of rhEGF, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
45495987|NCT05248035|Other|Adult patient hospitalized in ICU|acquisition of dynamic parameters in addition to pupillary diameter, such as . pupillary diameter, variation of the pupillary diameter, pupillary constriction speed, pupillary dilatation speed, photomotor reflex latency, NPi and symmetry of pupillary responses after a standardized light stimulus
45495988|NCT02714049|Behavioral|sex therapy|60 minutes each time, in person or on the telephone
45495989|NCT02714049|Drug|flibanserin|FDA approved medication for treatment of hypoactive sexual desire disorder in premenopausal women
45495990|NCT04777539|Other|At-home natalizumab treated MS patient|"MS patient who are treated with natalizumab in at-home hospitalization (HAD) setting / according at-home hospitalization program"
45495991|NCT04664829|Drug|Bexarotene|Administered orally once a day. Starting dosage: 200mg/m^2
45495992|NCT04664829|Drug|Capecitabine|Administered orally twice a day. Dosage: 1000mg/m^2
45495993|NCT02951429|Drug|Pirfenidone|Pirfenidone will be given in the range of 1602 to 2403 milligram per day (mg/day), as 3 divided doses.
45495994|NCT02951429|Drug|Placebo|Placebo matched with sildenafil.
45380066|NCT00845819|Drug|Placebo + povidone iodine, chlorhexidine, & nystatin|"Topical application of placebo drug twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%), and nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of placebo drug, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
45380067|NCT02546843|Drug|Rocuronium|rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)
45380068|NCT02546843|Drug|Cisatracurium|cisatracurium 0.15mg/kg intravenously
45495995|NCT02951429|Drug|Sildenafil|Sildenafil will be given as 20 mg, TID.
45495996|NCT04622709|Drug|Furosemide (loop diuretic) Tablets|Open label dose escalation study of furosemide in people receiving maintenance hemodialysis. Participants will take furosemide oral tablets twice daily for 18 weeks. Doses will be titrated every 2 weeks for 6 weeks if safe, effective, tolerated, and accepted by the participant. First 2 weeks of the study: participants not taking oral furosemide at enrollment will take 80mg furosemide twice daily, those taking oral furosemide at enrollment will stay on their prescribed dose, and those taking another loop diuretic at enrollment will discontinue their prescription and take an equivalent oral furosemide dose. At week 4: dose escalation if tolerated (from 80mg to 120mg twice daily for the 1st group, and a 50% increased dose not >320mg/day for the 2nd & 3rd groups). At week 6: dose escalation if tolerated (from 120mg to 160mg twice daily for the 1st group, and a 50% increased dose not >320mg/day for the 2nd & 3rd groups). Final 12 weeks: all participants will take the maximum tolerated dose.
45495997|NCT03706859|Procedure|Pneumatic tourniquet inflation pressure|Pneumatic tourniquet inflation pressure estimation using two different mathematical equations
45495998|NCT05682755|Drug|Chidamide|initial time：platelet count ≥50×10^9/L after allo-HSCT initial dose: 5 mg oral twice weekly initial adjustment: according to the platelet count tested weekly platelet count ≥50×10^9/L-increased by 5 mg 20×10^9/L≤ platelet count <50×10^9/L-remains unchanged platelet count <50×10^9/L- reduced by 5 mg maximum dose: 20 mg oral twice weekly terminal time: 180 days after allo-HSCT
45847331|NCT03443856|Other|chemotherapy|Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
46055075|NCT03258138|Behavioral|Individual sessions with a multidisciplinary health team|Monthly individual sessions with a family physician trained in medical CBT, a dietician and a physical therapist help individuals tailor their action plans and recommendations to their particular circumstances and provide supports based on their needs. The initial session will last 3 hours and occur at baseline. The follow-up sessions will last 1 hour.
45380069|NCT02546843|Drug|Nonspecific Neuromuscular Blockade reversal|neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously
45380070|NCT02546843|Drug|Specific Neuromuscular Blockade reversal|Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered
45380071|NCT02546843|Drug|maintaining the depth of neuromuscular blockade - rocuronium|repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1
45380072|NCT02546843|Drug|maintaining the depth of neuromuscular blockade - cisatracurium|repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1
45380073|NCT05136144|Drug|SM-020|Topical Akt Inhibitor SM-020 Gel
45380074|NCT00529308|Device|Transcranial Magnetic Stimulation (active)|Magstim Rapid2 stimulator with Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
45380075|NCT00529308|Device|Transcranial Magnetic Stimulation (sham)|Magstim Rapid2 stimulator with Sham Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
45380076|NCT03999840|Drug|cemdisiran|Cemdisiran has been designed to reduce the level of C5 mRNA in the liver, thereby reducing levels of circulating C5 protein, inhibiting terminal complement pathway activity, and preventing formation and deposition of the MAC (C5-b9) on endothelial cells in the kidney.
45380077|NCT03999840|Drug|Placebos|The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC administration). Placebo will be prepared and labelled identically to cemdisiran.
45380078|NCT04791540|Diagnostic Test|handgrip strenght|Muscle strenght measured with a handheld dynamometer, at admission (T0) and at decannulation time (T1)
45380079|NCT04791540|Diagnostic Test|Bioelectrical Impedance Analysis (BIA)|Muscle mass evaluated by Bioelectrical Impedance Analysis (BIA), at admission (T0) and at decannulation time (T1)
45380080|NCT04791540|Diagnostic Test|MUST|Malnutrition risk assessed by Malnutrition Universal Screening Tool (MUST), at admission (T0) and at decannulation time (T1)
45380081|NCT04791540|Diagnostic Test|GLIM|Malnutrition diagnosis performed by Global Leadership Initiative on Malnutrition (GLIM) criteria, at admission (T0) and at decannulation time (T1)
45380082|NCT04791540|Biological|Gut microbiota|A fecal sample obtained at admission (T0) and at decannulation time (T1)
45380083|NCT04791540|Biological|Blood Sample|A Blood sample obtained at admission (T0) and at decannulation time (T1)
45380084|NCT04791540|Other|Anthropometric measures|Measurement of weight and height (assessed only at admission) to calculate the Body Mass Index (BMI), at admission (T0) and at decannulation time (T1)
45380085|NCT05000424|Other|Clary Sage Massage Oil|This massage oil contains clary sage oil. Five drops will be used daily.
45693929|NCT01721161|Drug|Placebo|via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses)
45693930|NCT04564183|Other|Sample collection|Blood, Urine, Nail, Hair, Saliva, optional Stool
45693931|NCT04564183|Other|Questionnaires|SF-36, Food Frequency, Pulmonary Fibrosis Study questionnaire, COVID questionnaire
46055076|NCT03258138|Behavioral|Health goal development|Participants in both arms will develop health goals. Several components of these goals will be measured throughout the study, including the stage of change, self-efficacy and actual goal achievement. In the more intensive program arm, participants will develop health goals and learn about how to meet those goals through the group and individual sessions. In the less intensive program arm, participants will receive support in developing health goals from a research assistant trained in theories of health behaviour and in goal setting at baseline, 3 months, 6 months, 9 months and 12 months. The initial goal setting session will be provided within a time period of 2 hours, and the follow-up sessions will be provided within one hour time periods.
45495999|NCT01312103|Behavioral|Internet-based safety decision aid|"Participants will log into the the intervention website at baseline, 3 months, 6 months, and 12 months post baseline and receive:~Setting of priorities for safety; a sliding bar allows participants to establish priorities by making pairwise comparisons of importance between factors.~Danger Assessment; asks women to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger.~Personalized action plan. Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented to her. The participant is given the option to print her results and the personalized plan."
45380086|NCT05000424|Other|Inert Massage Oil|This massage oil consists entirely of plant based oils. Five drops will be used daily.
45496000|NCT01312103|Behavioral|Usual Care Safety Plan|"Participants will log into a control website at baseline, 3 months, 6 months and 12 months post baseline. Website will include the usual services provided to IPV survivors looking for safety planning resources on the internet. Participants will receive:~Danger Assessment, will see risk factors associated with lethal violence, but will not receive a score or feedback.~A brief emergency safety plan with links to national and state domestic violence resources as well as a suicide resource."
45496001|NCT05682677|Device|iTBS|iTBS over the left dorsolateral prefrontal cortex
46055077|NCT03258138|Behavioral|Physical activity and nutrition journals|Participants in both arm will be asked to maintain a physical activity journal and a nutrition journal for a week each every three months. These journals help participants reflect on current behaviours and areas for change.
46055078|NCT05338437|Device|Neuromuscular electrical stimulation|Bilateral quadriceps muscle stimulation
46055079|NCT04093375|Procedure|Radical Prostatectomy|Radical prostatectomy with or without androgen deprivation therapy
46055080|NCT04093375|Other|Radical Radiotherapy|Radical Radiotherapy with adjuvant androgen deprivation therapy
45380087|NCT03875508|Drug|Risankizumab|Risankizumab to be injected subcutaneously (SC)
45380088|NCT03875508|Device|Autoinjector|Single dose pre-filled autoinjector containing risankizumab for SC injection
45380089|NCT03998982|Drug|Glycyrrhetinic Acid|Compound glycyrrhizin tablets 75 mg three times per day, 1 month
45380090|NCT03998982|Drug|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d)
45380091|NCT04991766|Drug|[¹⁴C]-LY3484356|Administered orally.
45380092|NCT04991766|Drug|LY3484356|Administered orally.
45380093|NCT04991766|Drug|[¹⁴C]-LY3484356 (IV)|Administered IV.
45380094|NCT00620321|Drug|LY2181308 sodium|750 milligrams (mg) is administered as a 3-hour intravenous infusion on Days 1, 2, 3, 8, 15, 22 of Cycle 1 (28 days) and Days 1, 8, 15, 22 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
45496002|NCT05682677|Device|sham iTBS|sham iTBS over the left dorsolateral prefrontal cortex
45496003|NCT05682677|Behavioral|Personalized, Augmented Cognitive Training (PACT)|6 sessions of PACT
45496004|NCT03708887|Drug|Low dose omega-3 fatty acid supplementation|Omega-3 fatty acids capsules, 1 g/d by mouth for 1 year
45496005|NCT03708887|Drug|High dose omega-3 fatty acid supplementation|Omega-3 fatty acids capsules, 3 g/d by mouth for 1 year
45496006|NCT03708887|Drug|Control drug|Matching placebo capsules,1 g/d by mouth for 1 year
45496007|NCT05321537|Other|Therapeutic exercises|A somatosensory training and an endurance-strength training protocol
45496008|NCT05241015|Other|Control Group|Treatment protocol; It will be applied to improve posture, strengthen muscles, eliminate shortness, increase flexibility, balance/coordination, sit up/stand up and in-bed mobilization, and improve gait. Before taking the treatment, a general evaluation will be made and as a result of this evaluation, muscle shortness, loss of strength, postural disorders and the activities and positions they have the most difficulty in daily life will be determined. Treatment programs will be shaped according to the problems determined in line with the evaluations made.
45693932|NCT04564183|Radiation|High resolution CT scan of the chest|Upon enrollment, all participants will undergo single prone volumetric thoracic chest CT scan. This will be performed at full inspiration using a 64-slice CT scanner.
46055081|NCT05338359|Biological|Blood sample|Blood sample of 34 mL
46055082|NCT05338359|Other|Phone-call|Phone-call to the participant 15 days after recruitment to fix the final diagnosis
46055083|NCT04090255|Procedure|Renal puncture|The use of a needle for entering pelvicalyceal system of the kidney and put a guide wire for further pcn
46055084|NCT04094857|Drug|HBN-1|Intravenous infusion
46055085|NCT02842398|Behavioral|Balance Master|
46055086|NCT02842398|Behavioral|Customary Care|
46055087|NCT04988997|Drug|Vurolenatide 50mg/PBO|Vurolenatide - 50 mg biweekly SC administration, PBO alternate weeks
46055088|NCT04988997|Drug|Vurolenatide 100mg/PBO|Vurolenatide - 100 mg biweekly SC administration, PBO alternate weeks
46055089|NCT04988997|Drug|Vurolenatide 50/50 mg|Vurolenatide - 50 mg weekly SC administration
46055090|NCT04988997|Drug|Placebo|PBO - weekly SC administration
46055091|NCT04092751|Drug|PRA|Single oral 20-mg dose of PRA on Day 1 AM
46055092|NCT04092751|Drug|SCY-078 plus PRA|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later
46055093|NCT05334810|Drug|DP303c|DP303c injection, 3.0 mg/kg, every 3 weeks.
45380095|NCT00620321|Drug|cytarabine|1.5 grams per square meter (g/m²) will be administered as a 4-hour intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
45496009|NCT05241015|Other|Exercises Group|In addition to the standard physiotherapy program, sensorimotor training including the cervical region will be given to the this group. Deep cervical flexor and extensor muscles, which provide stability in the cervical region, will be trained. A Pressure Biofeedback Device will be used to train the deep cervical flexors. Both positional and kinesthetic sensory training will be provided by maintaining the stability of the cervical region by means of the laser kit that provides visual feedback.
45496010|NCT04595019|Radiation|SBRT|Stereotactic Body Radiotherapy. Ultrahypofractionated radiotherapy.
45380096|NCT00620321|Drug|idarubicin|12 milligrams per square meter (mg/m²) will be administered as a 30-minute intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and on Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
45380097|NCT00848315|Behavioral|Cognitive Behavioral Intervention|The intervention emphasizes patients' ethnic preferences and traditions (e.g., adapting ethnic recipes to meet dietary goals) and the use of available community resources (e.g., available areas for exercise), and is delivered utilizing strategies and materials appropriate for low-literate/illiterate patients.
45380098|NCT00848471|Device|Quark RMR|Quark RMR calorimeter (Cosmed)
45380099|NCT00848471|Device|Deltatrac II|Deltatrac II (GE health Care Clinical Systems)
45380100|NCT00852215|Device|Taxus stent|Stenting with Paclitaxel-eluting coronary stent system for coronary lesions with > 50% diameter stenosis with ischemic symptoms or positive functional study, or > 70% diameter stenosis without ischemic symptoms or positive functional study
45380101|NCT00852215|Device|Vision stent|Stenting with VISION coronary stent system for coronary lesions with > 50% diameter stenosis with ischemic symptoms or positive functional study, or > 70% diameter stenosis without ischemic symptoms or positive functional study
45380102|NCT00852293|Other|A blood test|A blood test of about 5ml of blood will be taken to determine Chitinase 3 like-1 protein levels.
45496011|NCT02670291|Device|MagPro Cool-B65A/P, Magventure|combined active and sham coil
45496012|NCT02670291|Device|MagPro Cool-B65A/P, Magventure|combined active and sham coil
45496013|NCT05423379|Device|XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS)|XIENCE Skypoint Large Vessel EECSS is composed of a L-605 CoCr stent and coated with poly (n-butyl methacrylate) (PBMA) primer and a drug coating formulation of polymer of vinylidene fluoride and hexafluoropropylene (PVDF-HFP)/everolimus pre-mounted on a balloon catheter delivery system.
45496014|NCT05228145|Genetic|NGN-101|Participants with confirmed mutations in the CLN5 gene who meet all the inclusion and none of the exclusion criteria will be treated with a single intracerebroventricular (ICV) dose and a single intravitreal (IVT) dose of the study treatment.
45380103|NCT00621023|Drug|Decitabine, Arsenic Trioxide and Ascorbic Acid|Subjects receive decitabine 20 mg/m2 IV over one hour for days1-5 of each cycle, and arsenic trioxide 0.25 mg/kg IV for days 1-5 of cycle 1 followed by 0.25 mg/kg twice weekly (Mon-Thursday or Tues-Fri) for all remaining cycles. Patients will have transfusion and supportive care therapy administered per the treating physician's discretion. Patients with a response after 4 cycles of therapy may choose to continue on two more cycles of decitabine with arsenic and ascorbic acid given only during the first week of those two additional cycles.
45380104|NCT02546687|Other|Venous blood sampling|"The investigators will take 1-2 cc of venous blood from proximal part of stomach before gastric tube creation and in the same time the investigators will take same amount of venous blood from peripheral vein. This blood will be analyzed in the ABL800 FLEX blood gas analyzer as a routine blood analyses that making by anesthesiologist during the operation. This blood sampling the investigators will make again after 15-30 minutes from the same area in proximal stomach (after creation of gastric tube) and peripheral vein just before anastomosis creation. The investigators will measure components of venous blood gases (O2, pH, CO2, lactate) from the area of future anastomosis before construction of gastric tube and just before creation of anastomosis ( after 15-30 minutes), compare the results of this analysis with systemic venous blood."
45496015|NCT05214807|Device|KiOmedine® CM-Chitosan|KiOmedine® CM-Chitosan is a fluid implant intended for synovial fluid supplementation for the symptomatic treatment of osteoarthritis (OA). This Investigational Medical Device (IMD) is administered via intra-articular injection and is classified as a Class III Device under Council Directive 93/42/EEC (Annex IX, rule 8). A key component of the IMD is a soluble derivative of highly purified chitosan of non-animal origin, an exclusive natural linear glucosamine polysaccharide extracted from the edible white mushroom, Agaricus bisporus. KiOmedine® CM-Chitosan is sterile, non-pyrogenic, resorbable and composed of 2% (w:w) carboxymethyl chitosan (CM-chitosan).
45380105|NCT00842465|Biological|blood collection for hormonal status analysis|for hormonal status analysis
45380106|NCT00842465|Procedure|breast Biopsy or surgery|breast Biopsy or surgery
45380107|NCT00842465|Genetic|blood collection|blood collection for prlR gene sequencing
45496016|NCT05214807|Device|Synvisc-One®|Synvisc-One (Hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing Hylan A and Hylan B polymers produced from chicken combs. Hylans are derivatives of hyaluronan (sodium salt of hyaluronic acid) and consist of repeating disaccharide units of N-acetylglucosamine and sodium glucuronate. Hylan A has an average molecular weight of approximately 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains Hylan A and Hylan B (8.0 mg ± 2.0 mg per ml) in buffered physiological sodium chloride solution (pH 7.2 ± 0.3) and is unique in that the hyaluronan is chemically crosslinked.
45496017|NCT02454855|Drug|melatonin|"Oral supplementation with melatonin (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line of anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).~Melatonin supplementation is achieved by the administration of (Circadin) at a dose of 2 mg / day according to its MA form of prolonged-release tablet of 2 mg."
45847332|NCT03427320|Drug|[131]I-IAZA|Injection of a single dose of 185MBq ( range 150-220MBq) of [131]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
46055094|NCT02842008|Behavioral|Exercise group|This group will receive a home exercise program of shoulder based on mobility, strength and strengthening exercises, lasting 10 weeks, 3 times per weeks. The target dose use for mobility consisted in 8 repetitions for each 4 movements, for strengthening using resistive bands, 3 sets (including 5 exercises) of 10 repetitions with a 45 second rest between sets and 5 repetitions for each 5 strength with a 30 second rest and general protocol of postural hygiene. The instructional of the program is 30 minutes each day during the time of the study (10 weeks) with a screening about the exercise program and the daily activities performed every 4 weeks. Physiotherapist provided support to subjects through email along 10 weeks.
45847333|NCT03260712|Drug|Pembrolizumab|The dose of pembrolizumab in this trial is 200 mg Q3W.
45847334|NCT03260712|Drug|Cisplatin|25mg/m2 cisplatin on days 1 and 8 of a 21 day cycle
46055095|NCT02598505|Drug|Indacaterol|
46055096|NCT02598505|Drug|Placebo|
46055097|NCT02778945|Drug|Rocuronium 0.9 mg/kg|Neuromuscular block with Rocuronium 0.9 mg/kg for anesthetic induction Infusion of Rocuronium 0.3mg/kg/hr titrated to maintain a post-tetanic count (PTC)0-2 during the operation.
46055098|NCT02778945|Drug|Rocuronium 0.6 mg/kg|Neuromuscular block with Rocuronium 0.6 mg/kg for anesthetic induction Intermittent bolus i.v injection of Rocuronium 0.15mg/kg for train-of-four (TOF) 1-2 during the operation
46055099|NCT02721342|Drug|Ramipril, Irbesartan and Atorvastin|
46055100|NCT02779101|Drug|pembrolizumab|Pembrolizumab 200 mg every 3 weeks
46055101|NCT05336058|Other|No intervention|In this non-intervention study, 10ml of whole blood of enrolled subjects was collected for multi-target PCR detection of cfDNA methylation.
46055102|NCT02779959|Drug|Prochlorperazine|
46055103|NCT05335278|Drug|Nintedanib 150 milligrams [Ofev]|All patients will be given nintedanib 150 milligrams orally twice daily
45380108|NCT00842465|Other|ultrasonography (pelvis and breast), bone mineral density|ultrasonography (pelvis and breast), bone mineral density
45380109|NCT00848627|Other|Specimen and questionnaires only|Specimen and questionnaires only
45496018|NCT02454855|Drug|placebo|Oral supplementation with placebo (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).
46055104|NCT05173233|Device|Transcatheter Annuloplasty|Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.
46055105|NCT00751621|Biological|IgPro20|
45496019|NCT03343067|Drug|elagolix|Tablets
45496020|NCT03343067|Drug|estradiol/norethindrone acetate (E2/NETA)|Capsules
46055106|NCT02778477|Drug|PF-06423264|Multiple ascending dose of PF-06423264
46055107|NCT02778477|Other|Placebo|Multiple dose of placebo
46055108|NCT00092898|Drug|MK0653, ezetimibe|
45380110|NCT00842621|Procedure|Clinical Evaluations|All clinical evaluations should be performed greater than 30 days from illness or hospitalization. Participants will have weight, height, body mass index (BMI), heart rate, respiratory rate, blood pressure (systolic and diastolic) and pulse oximetry recorded while at rest on room air by clinical staff. Cardiac examination will be performed by echocardiogram.
45380111|NCT00842621|Other|Laboratory Studies|"Blood for:~Complete Blood Count with Differential, Reticulocyte Count, Micronuclei enumeration, α-globin genotype, G6PD activity, genotype, SNP array,~Serum for:~Soluble VCAM-1, ICAM-1, Soluble CD40L, Arginase, Endothelin-1, Prothrombin Fragment 1+2, IL-6, -8, -10, Soluble E-selectin, NOx, Haptoglobin, Tumor necrosis factor alpha~Plasma for:~Chemistry 18, Cystatin-C, Ferritin, Lactate Dehydrogenase, C-reactive protein, Erythropoietin, NT-proBNP, Haptoglobin, Von Willibrand Factor Antigen, D-dimer, Factor VIII Assay, Quantitative amino acids, Free hemoglobin, Tumor necrosis factor- α, Thrombin-Antithrombin complex, endothelin-1~Urine for:~Urinalysis, Urine spot protein, creatinine, Microalbumin, Urine hemosiderin, Urine hepcidin"
45847335|NCT03260712|Drug|Gemcitabine|1000mg/m2 gemcitabine on days 1 and 8 of a 21 day cycle
46055109|NCT00092898|Drug|Comparator: placebo|
46055110|NCT04094467|Drug|Cetrorelix|0.25 mg subcutaneous injection daily for 6 days
46055111|NCT04094467|Drug|Leuprolide Acetate|0.1 mg subcutaneous injection daily for 12 days
46055112|NCT02842476|Device|Disposable Sensor|Two adhesive based Pulse Oximeter Probes, S0136J-L were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.
45380112|NCT04042883|Procedure|Acute normovolemic hemodilution|500 ml of blood will be taken from the patient with simultaneous replacement with hydroxyethyl starch (HES 130/0.4) in another IV line
45496021|NCT05205525|Other|Restrictive antibiotic strategy|Implementation of a restrictive (delayed) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
45380113|NCT00848705|Behavioral|YourWay Internet Intervention|The intervention is an 11 week program that teaches problem solving of barriers to self-management.
45847336|NCT03086616|Drug|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)|Nal-IRI will be given directly into the tumor using CED.
45847337|NCT03026712|Device|Real dual tDCS + Robotic Arm Therapy|"Dual tDCS (anodic on injured hemisphere, cathodic on healthy hemisphere). Motor cortex will be simultaneously stimulated at an intensity equal to 1-2 mA and for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
45847338|NCT03026712|Device|SHAM tDCS + Robotic Arm Therapy|"SHAM bilateral tDCS for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
45847339|NCT02952924|Drug|Midazolam|Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO7049389 or matching placebo
45847340|NCT02952924|Other|Placebo|Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
45847341|NCT02952924|Drug|RO7049389|RO7049389 will be administered as per schedule described in individual arm.
45847342|NCT02905578|Drug|Gemcitabine|"Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after nab-paclitaxel and before ascorbate~given for 3 weeks out of the 4 week cycle~standard dose reductions are used~up to 2 cycles are administered before standard of care CT scan~decision to continue therapy is based disease response to therapy as measured from the CT scan~treatment continues until disease progression is identified"
45847343|NCT02905578|Drug|nab-paclitaxel|"Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after before gemcitabine and ascorbate~given for 3 weeks out of the 4 week cycle~standard dose reductions are used~up to 2 cycles are administered before standard of care CT scan~decision to continue therapy is based disease response to therapy as measured from the CT scan~treatment continues until disease progression is identified"
45380114|NCT00848861|Drug|propofol (sedation for outpatient colonoscopy)|
45380115|NCT00848861|Drug|midazolam plus meperidine (sedation for outpatient colonoscopy)|
45380116|NCT00852371|Drug|sulfadoxine-pyrimethamine|25 mg/kg po once on day 0
45380117|NCT00852371|Drug|amodiaquine + sulfadoxine-pyrimethamine|Amodiaquine: 10 mg/kg po daily for 3 days (on days 0, 1, 2) SP: 25 mg/kg po once on day 0
45496022|NCT05205525|Other|Aggressive antibiotic strategy|Implementation of an aggressive (immediate) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
45496023|NCT05196165|Other|No Intervention|No investigational product (IP) will be administered in this study
45496024|NCT04707183|Drug|Lidocaine IV Infusion|Lidocaine will infused through erector spinae plane block catheter in patients with traumatic rib fracture.
45380118|NCT00852371|Drug|dihydroartemisinin-piperaquine|2.1/17.1 mg/kg daily for three days (on days 0, 1, 2)
45380119|NCT00852371|Other|Placebo|dosed as for amodiaquine (10mg/kg po daily on days 1, 2)
45496025|NCT04707183|Drug|2% Lidocaine via ESPB|10 ml of 2% lidocaine will be infused through ESPB in treatment group
46055113|NCT02842476|Device|Reusable Sensor|Two soft reusable Pulse Oximeter Probes, Model S0080D-S were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.
46055114|NCT02842476|Device|Control Pulse Oximetry|A Clinimark Control Pulse Oximetry system was also placed on the subject to evaluate the stability of the draws.
46055115|NCT04227249|Procedure|no lymph node dissection|do not undergo lymph node dissection
45496026|NCT04703205|Drug|Ivermectin 3 MG|Ivermectin approximately 200 μg/kg administered as a single oral dose on Day 1 (fasting state)
45496027|NCT04703205|Drug|Placebo|Placebo group: Placebo without ivermectin as an ingredient, single oral administration on Day 1 (fasting state)
45496028|NCT03706781|Drug|Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15% + mucus adhesive polymer|Test product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
45496029|NCT03706781|Drug|Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15%|Reference Product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
45496030|NCT04681365|Other|Staff will wear and evaluate Bubble-PAPR (non-CE marked PAPR)|Staff will wear and evaluate the Bubble PAPR instead of usual PPE consisting of FFP3/N95 facemasks. This novel, non-CE marked prototype PPE is a Powered air Purifying Respirator and is used 'in house' (not approved for use outside of the Sponsor organisation)
46055116|NCT02599597|Behavioral|Therapist-assisted iCBT|13 week long individualized prevention program containing, physical activation, sleep management, tailored cognitive behavioral therapy for individual problems.
45847344|NCT02905578|Drug|Pharmacological ascorbate|"Administered intravenously the same day as nab-paclitaxel and gemcitabine Administered after nab-paclitaxel and gemcitabine~given 3 times weekly~given for 4 weeks out of the 4 week cycle~no dose reductions are used~up to 2 cycles are administered before standard of care CT scan~decision to continue therapy is based disease response to therapy as measured from the CT scan~treatment continues until disease progression is identified"
45847345|NCT02823834|Device|PROFEMUR® Gladiator Plasma Femoral Stems|THA using PROFEMUR® Gladiator Plasma stems and PROCOTYL® L Beaded Acetabular Components
45847346|NCT02770638|Device|Scoop Stretcher|Participants recruited by community advertisement. Participant will complete forty five minutes on scoop stretcher first, followed by forty five minute washout period, finished with forty five minutes on the long back spinal board. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
45847347|NCT02770638|Device|Long Back Spinal board|Participants recruited by community advertisement. Participant will complete forty five minutes on the long back spinal board first, followed by forty five minute washout period, finished with forty five minutes on the scoop stretcher. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
46055117|NCT02599597|Behavioral|Monthly screening with feedback|Participants are screened with a depression inventory each month and receives feedback from a therapist on the results
46055118|NCT02842164|Other|Tension group|
45380120|NCT00842777|Behavioral|Parent manualized group treatment|"Parent manualized group treatment in childhood obesity; 10 manualized group treatment over a 6 months period.~Ten sessions will be conducted with the following content: 1) Expectancies and goal setting,; 2) Taking to the child about overweight; 3) Daily physical activity; 4) Everyday meals and nutrition; 5) Mastery and motivation; 6) Guidance and limit setting; 7) Who should join the team? The role of siblings and the social network; 8) Parents' history of eating and physical activity; 9) Self-concept and body image; and 10) Vacations and parties.~Thereafter booster-meetings every third month over 1,5 years, in all 2 years treatment"
45380121|NCT00842777|Behavioral|Parent self-help groups|Professionals initiate and organize the self-help groups initially and attend the two first meetings. Their role will be to organize group and facilitate group rules governing group behaviors to be formed. The sharing of experiences, feelings, and thoughts concerning being a parent to an overweight child is encouraged, in addition to sharing tips and advices concerning managing their child's behavior. The groups will not receive any teaching or counseling concerning eating and physical activity.
45380122|NCT00528372|Drug|Dapagliflozin|Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks
45380123|NCT00528372|Drug|Dapagliflozin placebo|Tablets, oral, 0 mg, once daily in the morning or evening for up to 102 weeks
45496031|NCT03706703|Drug|Endostar|continuous intravenous infusion Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
45496032|NCT03706703|Drug|Docetaxel|docetaxel is 75 mg/m2 intravenously over 1 hour on Day 1 of each 21-day cycle
45496033|NCT03706703|Drug|Carboplatin|carboplatin is administered on Day 1 of each 21-day，followed by docetaxol or pemetrexed
45496034|NCT03706703|Drug|Pemetrexed|pemetrexed is 500 mg/m2 intravenously on Days 1 of each 21-day cycle
45496035|NCT05279573|Dietary Supplement|Omega-3 and/or botanical ingredient|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
45847348|NCT02748408|Device|SMS femoral stem|
46055119|NCT02842164|Other|No tension group|
46055120|NCT02842164|Other|Foley catheter Balloon|
46055121|NCT05167461|Other|Collection of imaging by ultrasonography|The investigators will collect burn image data to be processed through the software combined with the deep machine learning to find automated diagnostic burn assessment with accuracy of >95% compared to human assessment
45380124|NCT00528372|Drug|Metformin|
45380125|NCT01564680|Other|placebo|normal saline
46055122|NCT02778711|Drug|secukinumab|anti-IL-17
46055123|NCT04209582|Device|measurement of TcPO2 with skin electrode|measurement of TcPO2 with skin electrode
46055124|NCT02599753|Drug|18-FDTBZ|"During this study, participants will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on the investigators' phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010)."
46055125|NCT04987281|Procedure|Computed Tomography|Undergo CT
45380126|NCT01564680|Drug|Paracetamol|IV paracetamol infusion
45380127|NCT01564680|Drug|Lornoxicam|16 mg at skin closure and 8 mg 12 hours postoperative
45693933|NCT04564183|Diagnostic Test|Pulmonary Function Test|All recruited participants will undergo a pre-bronchodilator spirometry test and a lung diffusion capacity test, both in accordance with ATS guidelines. Exercise capacity (maximum physical exertion) will be assessed by performing a 6-minute walk test, also according to ATS guidelines.
45693934|NCT01700179|Drug|ACH-0143102|
45693935|NCT01700179|Drug|Ribavirin|
45693936|NCT01699867|Device|Optical coherence tomography|Optical coherence tomography was used to image ex vivo breast tissue specimens.
45847349|NCT02632656|Other|Monitoring on heart failure therapy|This is a prospective observational study where participants will have serial blood collection on medical therapy for heart failure.
45847350|NCT02509962|Dietary Supplement|Slow sodium tablets|6 g sodium chloride per day over 14 days
46055126|NCT04987281|Drug|Indocyanine Green Solution|Given via injection
46055127|NCT04987281|Device|Therapeutic Bronchoscopy|Undergo bronchoscopy using Ion robotic bronchoscope
46055128|NCT00092820|Drug|MK0653, ezetimibe|
46055129|NCT00092820|Drug|Comparator: placebo|
46055130|NCT04094623|Other|Dialectical behavior therapy|15 patients in a group are treated by 2 psychotherapist by DBT including mindfulness skills, distress tolerance skills, emotional regulation skills and interpersonal effectiveness skills.
45380128|NCT01564836|Behavioral|Imatinib treatment discontinuing|Ph+ CP CML patients who were treated with IM for more than 3 years in sustained MR4.5 or undetectable transcript for at least 2 years are enrolled
45380129|NCT00527982|Drug|Celecoxib|600 mg by mouth daily for a total of 12 months.
45380130|NCT04121286|Drug|JAB-3312|JAB-3312 will be supplied as 0.25 mg, 1.0 mg and 4.0 mg capsules.
45380131|NCT00527904|Drug|PN400 (VIMOVO)|Subjects are instructed to take 2 tablets a day, one in the morning and one in the afternoon/evening. The morning tablet should be taken with water, on an empty stomach 30 to 60 minutes before breakfast, or the first meal. The afternoon/evening tablet should be taken with water, on an empty stomach 30 to 60 minutes before dinner. Tablets should be swallowed whole and not broken, crushed or chewed.
45380132|NCT00527904|Drug|PN 400 (VIMOVO)|500 mg delayed-release naproxen/20 mg immediate release esomperazole dosed twice daily for 12 months
45380133|NCT00619619|Drug|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|DVS SR Tablets of 10mg, 25mg, 50mg, and 100mg. Assigned DVS SR daily doses of 10mg, 25mg, 50mg, 100mg, or 200mg for up to 8 weeks.
45380134|NCT00852449|Other|restrictive and liberal fluid therapy|In both group, when hypovolemia is suspected (peak aortic velocity variation > 13%): fluid bolus (hydroxyethyl starch 130/0.4/6%) according to a predefined algorithm designed to maintain peak aortic velocity < 13% and no further increases in SV
45380135|NCT00848939|Drug|treprostinil diethanolamine|Cohort 1: Single 1 mg treprostinil diethanolamine sustained release tablet dose
45380136|NCT00848939|Drug|treprostinil diethanolamine|Cohort 2: treprostinil diethanolamine sustained release doses will be escalated up to a target dose of 4 mg BID
45380137|NCT00842933|Drug|Corticosteroid|Cessation of corticosteroids 24 hours after cessation of vasopressors
45380138|NCT00842933|Drug|Corticosteroid|Administer daily for 7 days after diagnosis of acute adrenal insufficiency during septic shock
45380139|NCT00849095|Drug|budesonide/formoterol combination (PRN)|budesonide/formoterol combination 160/4.5 mcg 1 inhalation used as needed for a period of 52 weeks
45380140|NCT00849095|Drug|budesonide/formoterol combination|budesonide/formoterol 160/4.5 mcg 1 inhalation bid
45380141|NCT00849095|Drug|placebo|bid inhaled placebo
45380142|NCT00849095|Drug|terbutaline|as needed terbutaline 500 mcg for a period of 52 weeks
45847351|NCT02476500|Procedure|LLETZ on a training model|LLETZ is performed on a sausage-based training model using all surgical devices used in the original procedure
46055131|NCT04094623|Other|Social support group therapy|15 patients in a group are treated by 2 psychotherapist by SSGT.(Giving support to each other.)
45380143|NCT00527826|Drug|Salmeterol / Fluticasone (50/500 µg) BID fixed combination|comparator
45380144|NCT00527826|Drug|Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers|comparator
45380145|NCT00843011|Drug|Orvepitant|Orvepitant 60 mg, single dose. 2 different formulation. Formulation 2 is administered with and without food.
45380146|NCT00849329|Drug|lapatinib|1250mg lapatinib
45380147|NCT00849329|Drug|lapatinib plus esomeprazole|1250mg lapatinib plus esomeprazole 40mg
45380148|NCT02545829|Drug|HIP1302|Tenofovir 292mg
45380149|NCT02545829|Drug|HGP1406|Tenofovir 300mg
46055132|NCT04228263|Drug|Hydroxychloroquine|400mg
46055133|NCT04228263|Drug|Folic Acid|5 mg
46055134|NCT04228263|Drug|Low-dose aspirin|75 mg
46055135|NCT04228263|Drug|Placebo|oral tablet
45380150|NCT02545595|Drug|Sugammadex 1 mg/kg|
46055136|NCT00092742|Drug|MK0663, etoricoxib|
45380151|NCT02545595|Drug|Sugammadex 2 mg/kg|
45380152|NCT02545595|Drug|Sugammadex 4 mg/kg|
45380153|NCT00843089|Other|Education|Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
45380154|NCT00923819|Procedure|Laparoscopic gastric bypass|Patients are referred to Morbid Obesity Center from Vestfold Hospital Trust and other hospitals in Norway. The procedure will take place at Morbid Obesity Center, Vestfold Hospital Trust.
45380155|NCT00923819|Behavioral|Standard conservative treatment|Participants from Child Obesity Registry who undergoes conservative treatment at Morbid Obesity Center, Vestfold Hospital Trust.
45380156|NCT03998670|Device|Prism Glasses|Spectacles with refractive correction and base-in relieving prism (40% of the greater of the exodeviation by PACT at distance or near) equally divided between the 2 lenses
45380157|NCT03998670|Device|Non-Prism Glasses|Spectacles with refractive correction (or plano spectacles if no significant refractive error) and no prism
45380158|NCT00843245|Other|No intervention|No intervention
45380159|NCT00849563|Other|Standardized Risk Assessment|patients interested in genetic testing will be randomly assigned to either get testing for type 2 diabetes or not. All arms with receive standardized risk asessements. This study is evaluating behavior after receipt of genetic risk information and different types of counseling.
46055137|NCT00092742|Drug|Comparator: Diclofenac sodium|
45847352|NCT02199366|Procedure|Cardiac magnetic resonance (cardiac MRI)|Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
46055138|NCT04094389|Other|Orthotic continuous wear group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~Participants in the continuous wear group will be instructed to wear their orthotic continuously around the clock as tolerated with removal for hygiene and home exercise program (HEP) performance. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated."
45380160|NCT05027178|Other|Chiropractic Care|Chiropractic care on stroke participants
45380161|NCT04840212|Other|Lavender-Sandalwood scented aromatherapy sticker|The Lavender-Sandalwood scented aromatherapy sticker will be placed on the patient gown.
45380162|NCT01564992|Other|Identification of genes|Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.
45380163|NCT00855491|Procedure|Phaco|AcrySof Single-Piece IOL
45380164|NCT00849719|Drug|a combination of PCA MO and continuous infusion of MO|Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
45380165|NCT00849719|Drug|PCA MO only|When visual analog scale [VAS] exeeds 5/10, and after the PACU drug-blinded attending physician had established that the patient is coherent and cooperative, a PCA system will be connected to the patient's IV line. The physician will start device, and deliver the first bolus. The subsequent drug boluses will be self-administered by the patient. Group 2 will be administered with only boluses of 1.5 mg/bolus of MO, by request. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
45380166|NCT04832256|Device|Radical-7 Pulse CO-Oximeter|COHb measurement monitoring from finger pulp with a non-invasive measurement device called Masimo Radical-7 Pulse co-oximeter (Masimo Corporation, Irvine, USA)
45380167|NCT02546219|Other|Eosinophil isolation and characterization.|Peripheral blood and esophageal biopsies will be obtained from study subjects for further analysis of eosinophils integrin profiles.
45380168|NCT01565070|Drug|Biofreeze|Use of Biofreeze ointment
45380169|NCT01565070|Other|Placebo|Use of placebo ointment
45380170|NCT00527748|Device|Non-Measuring Ankle Exerciser|Stretching exercise performed 10 times per day, for six (6) weeks.
45380171|NCT00852605|Other|Intermittent Non-Invasive Ventilation|
45380172|NCT03998280|Device|Assessment|Neck proprioception and postural stability
45380173|NCT00619385|Drug|Proellex|Proellex 25 mg capsules 100 mg, 150 mg or 200mg daily for 7 days
45380174|NCT00855569|Device|Stasilon|Stasilon and gauze will be applied to donor site. Dressings will be collected and evaluated for amount of shed blood.
45380175|NCT00852683|Drug|Pregabalin|75 mg twice a day
45380176|NCT00852683|Drug|Placebo|75 mg twice a day
45380177|NCT00855647|Procedure|Hypo-fractionated Radiotherapy|
45496036|NCT05279573|Other|Control product consumption|Product with identical characteristics to the experimental product. Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
45496037|NCT05182905|Drug|AZD1390|"Phase 0: AZD1390 administered orally daily for 3 days prior to resection~Phase 1b: AZD1390 administered daily for 5 days concurrently with standard of care radiation therapy"
45693937|NCT00830284|Procedure|Recruitment maneuver|"Three types of maneuvers will be performed.~6cc/kg tidal volumes at an appropiate rate on current prescribed PEEP level.~6cc/Kg tidal volumes at an appropiate rate following a 40 cmH2O for 40 seconds maneuver returning to a pflex plus 2 cmH2O PEEP level.~PEEP titration starting a 15 cmH2O and increasing in 5 cmH2O increases until the PaO2+PaCO2 is 400 or higher."
45693938|NCT00830362|Drug|Propranolol|40 mg administered once
45693939|NCT00830362|Drug|Placebo|administered once
45496038|NCT05682365|Behavioral|prevANS intervention|prevANS intervention will be self-guided and can be implemented from the prevANS web or from the participants' Smartphone (through an APP). The prevANS intervention will have different intensities depending on the risk level of the population, evaluated from the already validated risk algorithm for anxiety: predictA. Participants will be classified as moderate-high or low risk of anxiety. Both groups of risk will receive information on their level and profile (risk factors) of anxiety and psychoeducational information periodically; also, they will work towards manage stressors and enhance protective factors. However, participants with moderate-high risk of anxiety will also receive a cognitive-behavioral training (problem solving, decision-making, handling thoughts / concerns and emotions and communicational skills).
45380178|NCT04116671|Device|Neuromechanical Gait Assist|A hybrid powered knee orthosis combined with surface muscle stimulation to assist walking.
46055139|NCT04094389|Other|Orthotic wear during waking hours only group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~Participants in the waking hours only group will be instructed to wear their orthotic during all waking hours as tolerated, with removal for hygiene, HEP performance, but not at night while sleeping. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated."
45380180|NCT04103255|Other|High frequency and intensive prevention program|This study is a 4 week non-randomized controlled trial (RCT)
46055140|NCT04094389|Other|Orthotic wear only while sleeping group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~In the night-wear group, participants will be told to wear their orthosis only at night. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated"
46055141|NCT04587648|Other|NA, observational study|NA, observational study
45380181|NCT00619307|Drug|Rebif New Formulation + prophylactic Ibuprofen|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, receives systematically 400 mg ibuprofen as prophylactic treatment against flu-like symptoms on days when Rebif New Formulation 44 mcg three times a week is injected
45380182|NCT00619307|Drug|Rebif New Formulation + ibuprofen PRN|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, should not administer Ibuprofen before the first Rebif New Formulation injection. If flu-like symptoms occur after the 44 mcg Rebif New Formulation injection then the subject can administer 400 mg ibuprofen. This should only be administered after the Rebif New Formulation injection and not before the Rebif New Formulation injection.
45380183|NCT00850187|Biological|Bone marrow derived mesenchymal stem cells|Bone Marrow Aspiration A total volume of 300 ml bone marrow will be aspirated from the iliac crest and are cultured for mesenchymal stem cells
45380184|NCT00923897|Radiation|Palliative RT|Prior to receiving radiation treatment, it is recommended that you take medications to reduce the chance of nausea related to therapy. The treatment will take approximately 30 minutes.
45380185|NCT00855725|Other|fMRI|Subjects will undergo MRI scanning to gather data about cognetive functions.
45380186|NCT00855725|Other|Hamilton Depression Rating Scale|Investigator will evalute the subject during a one on one interview for depression using the Hamilton Depression Rating Scale.
45380187|NCT00855725|Other|Beck's Depressive Inventory|Subjects will complete self assessment to evaluate their level of depression.
45380188|NCT00855725|Other|Interictal Dysphoric Disorder Inventory (IDDI)|Subject will complete self assessment to determine if there have been any changes in mood, emotions and or feelings from time to time.
45380189|NCT00855881|Drug|tegafur-uracil|tegafur-uracil 1 cap, bid for 1 year
46055142|NCT04092985|Device|iECG recording|iECG tracings will be recorded simultaneously, starting and ending at the same time as the standard 12-lead ECG, using the built-in sensors of a smart watch (Apple Watch Series 4) with the ECG application
46055143|NCT04195035|Device|Air-Q intubating laryngeal airway|Air-Q intubating laryngeal airway will be used for ventilation & intubation through fiberoptic bronchoscope.
46055144|NCT04195035|Device|Ambu-Aura intubating laryngeal mask|Ambu-Aura intubating laryngeal mask will be used for ventilation & intubation through fiberoptic bronchscope.
45380190|NCT00850265|Device|Volumatic spacer|A spacer is a plastic device to inhaler medication
45380191|NCT00619229|Drug|Alprostadil (prostaglandin E1)|Alprostadil 20 µg ampoules; 60 µg alprostadil/d i.v. for 15 days.
45380192|NCT00619229|Other|Placebo|Placebo/d i.v. for 15 days
45380193|NCT02544971|Behavioral|Neurofeedback|Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop.
45380194|NCT02544971|Other|Control|Treatment as usual
45380195|NCT02545439|Drug|ALKS 5461|Sublingual tablet given alone and in conjunction with Rifampin
45380196|NCT00619151|Device|Top Hat|Implant of CarboMedics Top Hat mechanical valve.
45496039|NCT05270213|Drug|RBS2418|RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). RBS2418 as monotherapy potentially can have an activating effect on the anti-tumor innate immune response and lead to anti-tumor responses in adult subjects with advanced or metastatic tumors.
45496040|NCT04283175|Other|Posturological examination on KPlates and AMTI platforms|By an unique evaluator
45380197|NCT00619151|Device|Regent|Implant of the St. Jude Medical Regent mechanical valve
45380198|NCT02546297|Drug|Symbicort|drug are used for 12 months
45380199|NCT02546297|Drug|Spiriva|drug are used for 12 months
45380200|NCT00618995|Drug|Comparator: ER niacin (+) laropiprant|ER niacin 2 g/ laropiprant 40 mg daily for 7 days.
45380201|NCT00618995|Drug|Comparator: ER niacin|ER niacin 2 g daily for 7 days.
45496041|NCT04283175|Other|Berg Balance Scale (BBS)|Falls and fera of falling, motor and sensory impairments
45496042|NCT05682287|Device|448kHz capacitive resistive monopolar radiofrequency|Capacitive resistive monopolar radiofrequency (CRM) treatment is a type of medical procedure that uses radiofrequency energy to heat the targeted tissue.
45693940|NCT01699789|Other|Quality Improvement Program|The quality improvement program is an evidence-based toolkit from prior studies (see Names above) that supported team leadership, case and care management, medication management, and Cognitive Behavioral Therapy for Depression. The Case management manual supported depression screening and monitoring/tracking of outcomes; patient education and activation, care coordination, and behavioral activation and problem solving. The toolkit includes education on depression and a community health worker manual.
46055145|NCT02844270|Device|Rapamycin Drug-Eluting Bioresorbable Coronary Stent System|Implantation of the Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
46055146|NCT05261763|Other|Dry Needling|abc
45380202|NCT00618995|Drug|Comparator: laropiprant|laropiprant 40 mg daily for 7 days.
46055147|NCT05261763|Other|Sham Dry Needing|xyz
46055148|NCT02843958|Device|HEMOPTIC|
46055149|NCT02779647|Behavioral|The intervention consisted of physical activity based on play|The intervention consisted of physical activity based on play, with four 90-minute sessions per week for nine months (the school year). The total of sessions was 144, the minimum number of sessions to consider valid that a child has completed the intervention was 115 (80%) in order to perform the minimum level of physical activity recommended for their ages. In parallel, twice-monthly theoretical and practical sessions of nutritional advice were given to the children and their families. The study group performed the physical activity and received the nutritional advice, while the control group received only the theoretical and practical sessions on nutrition.
46055150|NCT04931823|Drug|CPO-100|Docetaxel albumin-bound
46055151|NCT04092517|Other|Control Corn Soya Diet|Ingredients (% by weight): Maize (78.30); Whole soya beans (20.00); Vitamin/Mineral FBF-V-13 (0.20); Dicalcium Phosphate anhydrous (1.23); Potassium chloride (0.27)
46055152|NCT04092517|Other|Test Corn Moringa Diet|Ingredients (% by weight): Maize (78.30); Moringa (20.0)
46055153|NCT04094233|Dietary Supplement|Beetroot extract|Ingestion of 600mg beetroot extract two hours before strength exercise (75% 1RM).
46055154|NCT04094233|Other|Placebo|Ingestion of 600mg starch two hours before strength exercise (75% 1RM).
46055155|NCT05453071|Other|Cognitive Exercise Therapy Approach (BETY)|BETY, based on function-oriented core stabilization exercises, will be applied in patients with systemic sclerosis. This exercise model includes pain management strategies, dance therapy-authentic movement. Function-oriented core stabilization exercises have the feature of being made difficult against gravity according to the person's ability to do. Initial exercises start from the stage where the distal segment of the extremity is on the ground, called closed-kinetic. This level, which is quite easy, becomes more difficult following the success of the individual. It can be started from the mat level and progressed by modifying it with theraband and exercise ball. It is used at the beginning and end of dance therapy and authentic movement sessions. In the session, cognitive restructuring technique is used to break the vicious cycle of pain-emotional-spasm during exercise. This exercise model is the main rehabilitation approach of the Rheumatological Rehabilitation Unit.
46055156|NCT00634959|Drug|Maraviroc (UK-427,857)|150 mg oral tablet twice daily while fasted on Days 1-9 and on Day 10 (morning dose only)
45380203|NCT00618995|Drug|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
45380204|NCT03685344|Drug|Loncastuximab Tesirine and Durvalumab|intravenous infusion
45380205|NCT00856037|Drug|Doxorubicin Hydrochloride|Given IV
45380206|NCT00856037|Other|Laboratory Biomarker Analysis|Correlative studies
45380207|NCT00856037|Other|Quality-of-Life Assessment|Ancillary studies
45380208|NCT00856037|Drug|Topotecan Hydrochloride|Given PO
45380209|NCT00850811|Drug|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
45380210|NCT00856115|Other|medical chart review|Patient charts are reviewed to obtain medical data.
45496043|NCT05682287|Other|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) is a type of physical therapy that uses techniques such as stretching and strengthening exercises to improve muscle function and movement patterns.
45496044|NCT05642403|Drug|XW001|Inhaled XW001
45496045|NCT05642403|Drug|Placebo|Matched inhaled placebo
45496046|NCT03706547|Biological|anti-CD19/BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
45496047|NCT03706547|Drug|Fludarabine|30mg/m2/d
45496048|NCT03706547|Drug|Cyclophosphamide|300mg/m2/d
45496049|NCT04640727|Procedure|open reduction|A sterile tourniquet is applied and an oblique posterolateral skin incision is made. Superficial dissection is carried out in the plane of the fracture hematoma until the distal lateral corner of the proximal fragment is identified. Once the metaphyseal side of the fracture has been identified, the dissection is carried across the joint to expose the medial articular surface. After exposure of the proximal fragment, the orientation of the distal fragment is defined and the soft tissues are sharply released off the anterior aspect of the distal fragment, with extension carried distally to the radial head. After irrigation and débridement of the fracture hematoma, the distal fragment is reduced with a towel clip. It is important to judge the reduction at the level of the articular surface rather than the metaphysis because plastic deformation or comminution of the metaphyseal fragment may be present. Pins (usually 0.062 inch) are placed percutaneously to secure the fracture.
45496050|NCT04640727|Procedure|closed reduction|we applied a gentle varus force to the elbow while the patient was under general anesthesia, and we attempted to reposition the rotated fragment by directly pushing or by using Kirschner wires as joysticks . After repositioning, we applied gradual direct compression to the distal fracture fragment anteromedially.We then applied slight valgus force to the elbow with the forearm supinated and the elbow fully extended to maintain the reduction. After the fracture reduction was confifirmed to be within 2 mm, especially as seen on the anteroposterior, lateral radiographs,and internal obliquewe used smooth Kirschner wires to perform percutaneous pinning
45496051|NCT05682209|Drug|Octreotide Injection|100µg of octreotide intravenously 8-hourly for 5 days from the first post-operative day
46055157|NCT00634959|Drug|Maraviroc (UK-427,857)|100 mg oral tablet once daily while fasted on Days 1-10
45380211|NCT00856115|Other|questionnaire administration|Patients undergo a 45-60 minute interview to obtain information on variations in symptom perception, assessment, and patient-physician communication process. Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity), information of close confidants (i.e., relationship, family history of cancer, and caregiver/decision-making status), and physician characteristics. Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
45380212|NCT00856115|Other|study of socioeconomic and demographic variables|Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity).
46055158|NCT00634959|Drug|Maraviroc (UK-427,857)|300 mg oral tablet once daily while fasted on Days 1-10
45380213|NCT00856115|Other|survey administration|Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
46055159|NCT00634959|Drug|Maraviroc (UK-427,857)|150 mg oral tablet twice daily with food on Days 1-9 and on Day 10 (morning dose only)
45380214|NCT00856271|Drug|olmesartan medoxomil|oral tablets, once daily for 8 weeks
46055160|NCT00634959|Other|Placebo|Matching placebo oral tablet on Days 1-10 (fed and fasted)
46055161|NCT02598427|Drug|Pertuzumab|Pertuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
46055162|NCT02598427|Drug|Trastuzumab|Trastuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
46055163|NCT02776215|Drug|tasimelteon|Melatonin receptor agonist
45380215|NCT00856271|Drug|losartan potassium|capsules, once daily for 8 weeks
45380216|NCT00856427|Radiation|radiation therapy treatment planning/simulation|Undergo implantation of radio-opaque markers
45380217|NCT00856427|Procedure|implanted fiducial-based imaging|Undergo implantation of radio-opaque markers
45380218|NCT00856505|Drug|Everolimus and mycophenolate sodium|Everolimus tablets, 1.5mg/day bid, dosage adjusted to plasma levels Mycophenolate sodium, 720mg/day bid Duration: Mycophenolate tapering starts at day 56 after stem cell transplantation Everolimus tapering starts at day 100 after stem cell transplantation if no GvHD evident
45380219|NCT02544893|Drug|bupivacaine|21 ml 0.5 %bupivacaine is applied paravertebral space
46055164|NCT04226001|Other|Quality of life questionnaire|Quality of life questionnaire
46055165|NCT04092439|Dietary Supplement|Watermelon Juice|100% Watermelon Juice
46055166|NCT04906707|Device|EaseVRx|EaseVRx is a commercially available pain management program. It is a multi-modal, skills-based, 8-week, VR, mind-body approach to daily management of chronic pain that is designed for home use to be worn over the eyes. The program contains five types of modules that are as follows: Interoception, Education, 360-degree relaxation videos, Games, and Dynamic breathing. All program content is mapped to a therapeutically designed curriculum with weekly themes. The following core themes are infused into the curriculum: Acceptance, Attention shifting, Awareness, Rehabilitation, Self-compassion, Healthy Movement, Deep relaxation, Visualization, Knowledge of pain, Distraction, and Immersive enjoyment.
45496052|NCT05682209|Other|Sterile water|1ml of sterile water intravenously 8-hourly for 5 days from the first post-operative day
45496053|NCT05258513|Dietary Supplement|Placebo Supplementation|8 weeks of placebo supplementation
45496054|NCT05258513|Dietary Supplement|GG sourced from Annatto|8-weeks of Geranylgeraniol supplementation
45496055|NCT04637841|Other|Kinesiology Taping Appliying|"Kinesiology tape will be applied to left foot plantar fascia of the participants in diabetes mellitus and control group.~During taping, participants will lie in the prone position while the knee joint will be kept 90 degrees of flexion and the ankle joint in a neutral position. A Palm Shape taping procedure will be applied to the plantar fascia."
45496056|NCT04637841|Other|Myofascial Release Technique Appliying|"Myofascial release technique will be applied (during 5 minutes) to right foot plantar fascia of the participants in diabetes mellitus and control group~During appliying technique, participants will lie in the prone position while the knee joint will be kept 90 degrees of flexion and the ankle joint in a neutral position."
45496057|NCT05682131|Drug|Realgar Indigo naturalis formula|Realgar Indigo naturalis formula was used in the induction, consolidation and intensive treatment of patients in intermediate or high risk
45496058|NCT05682131|Combination Product|Conventional chemotherapy|conventional chemotherapy
45496059|NCT03632577|Device|High Flow Oxygen (HFO)|HFO is a mix tap of air and oxygen. It permits to control FiO2 and generated controlled high flow air until 60/min. Air and oxygen are mixed, warmed, humidified and issued to patient by a warming monopod inspiratory circuit to nasal cannulas of a large diameter. Expiration is free.
45496060|NCT03632577|Device|Non Invasive Ventilation (NIV)|NIV was already evaluated in post-extubation. This technic is now used in daily consolidation processing after extubation because it provides a ventilator help with two levels of pressure helping in respiratory work. Adding Automated Flow Oxygen Titration could optimized patient's oxygenation and reduce workload of caregivers.
46055167|NCT04906707|Behavioral|Audio-only version of EaseVRx|Participants in the control group will be asked to use the audio-only version of EaseVRx, which excludes references to visual content, to complete 7 sessions weekly. They will receive an electronic link to the recordings on SoundCloud (a music streaming platform) where they can choose to stream or download the audio recordings on their smartphone, laptop, or desktop computer.
46055168|NCT04094077|Drug|AGuIX|2 IV injections (100 mg/Kg/injection) at day 4 and day 8 + Strereotactic Radiation from day 8 to day 15 as per standard practice.
46055169|NCT04092595|Drug|PF-06651600|PF-06651600: 200 mg dose provided as four 50 mg oral tablets
46055170|NCT04092595|Drug|Rosuvastatin|10 mg oral tablet
46055171|NCT04092205|Drug|Emeramide|Lipophilic, membrane passing Metal chelator and anti oxidant
45496061|NCT04620993|Other|Evaluation of biomechanics and viscoelastic properties of plantar fascia|"The biomechanical and viscoelastic properties of the plantar fascia will be measured in the side lying position.~Measurements will be made with the ankle in neutral position and maximum dorsi flexion position."
45496062|NCT04620993|Other|Evaluation of navıcular drop|The amount of navicular drop of both feet will be measured
45496063|NCT04620993|Other|Evaluation of plantar pressure distrubution|The distribution of foot plantar pressure and the amount of change in the center of gravity will be measured in the free standing position.
45496064|NCT03708497|Drug|carbetocin|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
45496065|NCT03708497|Drug|Tranexamic acid plus misoprostol|1000mg oral TA at the end of the first stage of labor plus 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
45496066|NCT03708497|Drug|misoprostol|600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
45380220|NCT02544893|Drug|dexmedetomidin|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied paravertebral space
45380221|NCT02544893|Drug|serum physiologic|21 ml serum physiologic is applied paravertebral space
45380222|NCT02546063|Other|Smartphone App|The GoCARB system is a smartphone application designed to support type 1 diabetic patients with carbohydrate counting by providing automatic, accurate and near real-time CHO estimation for non-packed foods.
45380223|NCT00520572|Drug|AZD9056|
45380224|NCT00520572|Drug|Etanercept|
45380225|NCT00520572|Drug|Placebo|
45380226|NCT00573833|Other|questionnaire administration|
45380227|NCT00573833|Procedure|quality-of-life assessment|
45380228|NCT00573833|Radiation|brachytherapy|
45380229|NCT00853463|Behavioral|Alert|The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
45380230|NCT00853619|Other|Service based decision support intervention|Delivering CDS via services
45380231|NCT00853697|Other|testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride|"Patients will be treated with dutasteride 3.5 mg once daily (oral administration). To avoid rapid conversion of testosterone to DHT in case 5α-reductase is not adequately inhibited during the first few days of concurrent treatment with dutasteride and testosterone, daily dutasteride treatment will be initiated 7 days prior to testosterone initiation.~Patients will receive AndroGel® at the dose of 15 g (3 times the standard replacement dose for hypogonadism) once daily (topical administration), starting on Day 8 and continuing for 12 weeks (or until disease progression or withdrawal from the study)."
45380232|NCT00856817|Drug|L-arginine + heme arginate|L-arginine first, heme arginate second three day treatment
45380233|NCT00856817|Drug|Heme arginate + L-arginine|Heme arginate first, L-arginine second three day treatment
45380234|NCT00520494|Drug|Vivaglobin|Human normal immunoglobulin G (IgG) for subcutaneous (SC) use.
45380235|NCT04041635|Procedure|Stimuli reduction|Phototherapy goggles and earmuffs will be placed 3 minutes before the venipuncture (leaving the patient in resting state after the manipulation) and will be maintained during the procedure. Monitor alarms and devices will be silenced and will remain silenced and noise in the unit will be minimized during the procedure.
45380236|NCT04041635|Procedure|Usual care|Babies in the control group will receive physical contention with administration of sucrose two minutes before carrying out the venipuncture procedure (usual care). Venipuncture will be performed with 22G extraction needles, or peripheric venous catheter. During the puncture the eyes will not be covered, and monitor alarms and devices be not be silenced.
45380237|NCT00853775|Other|No intervention, observational study|
45380238|NCT00861419|Drug|Sorafenib|Sorafenib 400 mg PO (BID)
45380239|NCT00861419|Drug|AMG 706|AMG 706 125 mg PO (QD)
46055172|NCT04226157|Device|Home Blood Pressure Monitoring Device (Qardio Arm)|The Home Blood Pressure Device with telemonitoring capability will allow the participants and physician to monitor blood pressure over time and titrate blood pressure medications as needed for persistently elevated blood pressure.
46055173|NCT04226157|Other|Primary Care Provider Blood Pressure Management|Participant will follow up as would normally do with primary care provider for blood pressure management.
45380240|NCT00861419|Drug|AMG 706|AMG 706 75 mg PO (QD)
45380241|NCT00861419|Drug|AMG 386|AMG 386 10 mg/kg IV (QW)
45496067|NCT04608903|Dietary Supplement|L-sulforaphane 1%|Administration of 4g L-Sulforaphane per day, for 2 months
46055174|NCT05117853|Drug|Autofluorescent detection + Injection of indocyanine green|"All four parathyroid glands will be actively sought for in every case selected for the use of AF/ICG, with AF verification of parathyroid tissue.~The timepoints of AF will be:~1 = after lateral dissection side 1 (side 1)~2= after lateral dissection side 2 (side 2)~The timepoints of ICG injection will be:~1 = after the first thyroid lobectomy (side 1)~2 = after the second thyroid lobectomy (side 2)~Scoring of the viability of parathyroid glands (adapted from Vidal Fortuny et al., 2016):~1 = black = not viable/vascularized~2 = grey = moderately viably/ moderately vascularized~3 = white = viable/well-vascularized"
45380242|NCT00861419|Drug|Sunitinib|Sunitinib 50 mg PO (QD)
45380243|NCT00861419|Drug|Bevacizumab|Bevacizumab 15mg/kg IV Q3W
45380244|NCT00861419|Drug|AMG 386|AMG 386 3 mg/kg IV (QW)
45380245|NCT00527514|Drug|Amlodipine|Tablets
45380246|NCT00527514|Drug|Olmesartan medoxomil plus amlodipine|Tablets
45380247|NCT00861497|Drug|Bifeprunox|Flexible dosage: 20, 30, or 40 mg/day
45380248|NCT00857051|Other|Hotline Service|A 24 hour hotline to answer questions about baby care or mother self-care. Hotline will be answered by a midwife and answers will be based on algorithms.
45380249|NCT00857051|Other|Film|A DVD addressing common stressors in the early postpartum.
45380250|NCT03998826|Drug|Piroxicam|20mg piroxicam
45380251|NCT03998826|Drug|Placebo|placebo
45380252|NCT00857129|Procedure|Normal Unit|low-risk patients randomised to Normal Unit
45380253|NCT00857129|Procedure|Special birth unit|Low-risk women are randomised to the Special birth unit. Organised to take care of women with extended need for surveillance before, under and after birth.
45380254|NCT04041401|Other|PICU storybook|Narrative and developmentally appropriate intervention
45496068|NCT04608903|Dietary Supplement|Placebo Group|Administration of 4g corn starch colored with chlorophyll, per day, for 2 months
45496069|NCT02961218|Drug|ACZ885|Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects
45496070|NCT02961218|Drug|Placebo|Monthly doses of placebo to match the administered dose of canakinumab s.c.
45380255|NCT00853853|Device|EnSeal Device|Hemorrhoidectomy using the EnSeal Device, which is an instrument cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding.
45380256|NCT00853853|Procedure|Ferguson Hemorrhoidectomy technique|The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve (such as 3.0 vicryl) are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced. This can be done from 1-3 hemorrhoidal groups at a single time.
45380257|NCT04607538|Other|No intervention is made|No intervention is made. This i an observational study.
45380258|NCT00853931|Drug|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 [i.e. Cycles 1, 2, 3, etc.]) until disease progression or intolerance panitumumab as determined by the investigator.
45380259|NCT00854009|Drug|BLI-489|
45380260|NCT00854009|Drug|Placebo|
45380261|NCT03998592|Biological|Streptococcus pyogenes vaccine (50 µg)|Vaccine containing 50 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
45380262|NCT03998592|Biological|Streptococcus pyogenes vaccine (100 µg)|Vaccine containing 100 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
45380263|NCT03998592|Biological|Streptococcus pyogenes vaccine (200 µg)|Vaccine containing 200 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
45380264|NCT03998592|Other|Placebo|Placebo without active component
45380265|NCT00861731|Drug|simvastatin|simvasatin therapy alone at the dose of 40 mg/day
45380266|NCT00861731|Drug|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/20 mg/day
45380267|NCT00861731|Drug|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/40 mg/day
45380268|NCT02544659|Drug|pamidronate disodium|the patients will be administered pamidronate disodium 1 mg/kg, IV, QD, for 3 days, and every 3 month (up to month 6)
45380269|NCT00861887|Drug|Standard Vancomycin|Vancomycin treatment 125 mg po every 6 hours x 2 weeks
45380270|NCT00861887|Drug|Extended Vancomycin|Vancomycin 125 mg every 6 hours x 2 weeks
45380271|NCT00857441|Device|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
45380272|NCT00857441|Device|Liberté|Bare metal stent
45380273|NCT00857441|Device|PTCA balloon catheter|Percutaneous transluminal coronary angioplasty catheter
46055175|NCT05117853|Procedure|Gold standard of visual identification and evaluation of viability of the parathyroid glands.|Gold standard of visual identification and evaluation of viability of the parathyroid glands.
45380274|NCT00857441|Device|Taxus|Paclitaxel eluting stent
45380275|NCT00857519|Drug|Melphalan, Carboplatin|Intra-arterial chemotherapy.
45380276|NCT00618449|Drug|Azithromcyin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given 30 days apart; at Day 0 & Day 30 for a total of 2 doses.
45380277|NCT00618449|Drug|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given at Day 30 for a total of 1 dose.
45380278|NCT00857597|Procedure|Transoral Incisionless Fundoplication|The TIF procedure using the EsophyX system with SerosaFuse fasteners was designed to create full-thickness serosa-to-serosa plications and construct valves of 3-5 cm in length and 200-300° in circumference.
45380279|NCT00857597|Drug|Proton Pump Inhibitors; active control|Proton Pump Inhibitors; active control
45380280|NCT00857675|Drug|AAAA|Adefovir Dipivoxil (12 weeks) + open lable Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260weeks)
45380281|NCT00857675|Drug|AAPA|Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + placebo (12 weeks) + open label-Adefovir Dipivoxil (52-260 weeks)
45380282|NCT00857675|Drug|PAAA|Placebo (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260 weeks)
45380283|NCT00861965|Biological|AlloStim-8|intravenous infusion of mis-matched AlloStim-8
45380284|NCT00861965|Biological|AlloStim-8|intravenous infusion of AlloStim-8 on day 7
45380285|NCT00861965|Biological|AlloStim-8|intravenous infusion of AlloStim-8 on day 14
45380286|NCT00861965|Biological|AlloStim-8|intravenous infusion of AlloStim-8 on day 21
46055176|NCT02776371|Drug|Modified non-clarithromycin triple therapy|H. pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.
46055177|NCT02776371|Drug|Sequential therapy|H. pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.
46055178|NCT01028222|Drug|Nilotinib|Nilotinib was provided as 200 mg hard gelatin capsules for oral use.
46055179|NCT01028222|Drug|DTIC|DTIC was supplied locally as sterile powder for i.v. infusion.
45380287|NCT00857753|Drug|Fentanyl patch 25 ug/nr Sandoz|
45380288|NCT00857753|Drug|Duragesic|
45380289|NCT03846401|Device|fiberoptic bronchoscopy|"Will be performed according to British Thoracic Society guidelines 2013.~-Microbiological methods The specimen (tracheal aspirate & BAL) will be collected under aseptic conditions in a sterile container and immediately sent to the laboratory for microbiological analyses.~Samples will be apply for:~Direct smear by Gram stain and ZeihlNelseen stain~Samples culturedinBact/alert bottle(BioMérieux, France).~Isolation of causative organism from positive cases by:~Subculture on MacConkey , blood , chocolate agar , Sabouroud's agar and Lowenstien Jensen media.~Identification of isolated organism and drug sensitivity test by Automated Vitek2 Compact(BioMérieux, France).~Multiplex PCR for detection of Respiratory viruses in lower respiratory tract"
45380290|NCT00854321|Drug|rituximab|rituximab two 1000 mg intravenous infusions separated by two weeks
45380291|NCT00854321|Drug|rituximab, observational study amon patients with active RA|two 1000 mg intravenous infusions separated by 2 weeks
45380292|NCT03684642|Drug|Efpeglenatide|Pharmaceutical form: solution for injection; Route of administration: SC
45380293|NCT03684642|Drug|Dulaglutide|Pharmaceutical form: solution for injection; Route of administration: SC
45380294|NCT03684642|Drug|Background therapy Metformin|Pharmaceutical form: tablet; Route of administration: oral; Dose to be kept stable throughout the study.
45380295|NCT04018547|Device|Patient wears a wrist sensor oximeter device for one to two nights.|Patients will be asked to complete a study questionnaires of STOPBANG, SCI-8 (Sleep Condition Indicator-8 questionnaire for insomnia), Epworth questionnaires and medical history. The clinician will record blood pressure, pulse rate and regularity, body mass index and neck circumference. Subjects will be required to wear the wrist sensor pulse oximeter for 1-2 nights. The Oxitone 1000M device measures pulse rate, blood oxygen saturation and movement. The oxygen desaturation events from the wrist sensor device will be statistically compared with the diagnosis assessed using the conventional PPG oximetry, Peripheral Arterial Tonometry and clinical assessment. (clinicians will be masked when analysing the data from the wrist sensor pulse device).
45380296|NCT00857831|Dietary Supplement|Vitamin D and Calcium|2000 IU/day Vitamin D3 (cholecalciferol) and 1.3 g/day calcium carbonate will be taken for 15-20 weeks.
45380297|NCT00854399|Procedure|Staging surgery or debulking surgery|Staging surgery or debulking surgery
45380298|NCT00862043|Drug|Sildenafil Citrate|40 mg t.i.d.
45380299|NCT00862043|Drug|Placebo|Placebo t.i.d.
45380300|NCT00519636|Drug|FPNS|fluticasone propionate nasal spray
45693941|NCT01699789|Behavioral|Resources for Services Expert Team|The expert team consisted for RS consisted of 3 psychiatrists, a psychologist expert in Cognitive Behavioral Therapy, a nurse care manager, a community engagement specialist, a quality improvement expert, and staff support. They team offered 12 web-based seminars to each community on components of collaborative care as well as site visits to primary care clinics on clinical assessment and medication management.
45380301|NCT00519636|Drug|FFNS|fluticasone furoate nasal spray
45380302|NCT00519636|Drug|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
45693942|NCT01699789|Behavioral|Community Engagement and Planning Council|The CEP Council was supported by a workbook developed by the overall CPIC Council that provided principles, approach, agendas, and resources for the multi-sector planning meetings. The CEP Councils met twice a month for 4-6 months to develop their plan and met monthly during implementation of trainings. The study Council supported CEP meetings. Community leaders co-led trainings with study experts to help assure sustainability. Each CEP council had $15K to defray costs of venues, materials, and consultations, while the study provided that for RS.
45693943|NCT00830596|Other|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
46055180|NCT00586495|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 200 mg tablets (400 mg [2 x 200 mg tablets] twice daily [bid] or 400 mg once daily [od] or 400 mg every other day [qod]) administered orally
46055181|NCT04226079|Diagnostic Test|Collection of exhaled breath|Collection of exhaled breath will be analyzed for specific volatile organic compounds which show different distribution between groups
46055182|NCT04225143|Procedure|urostim bilateral|Treatment by bilateral neurostimulation of the tibial nerve
45693944|NCT00830596|Other|LVVA-SM|Low velocity, variable amplitude lumbo-pelvic manipulation
45380303|NCT00519636|Drug|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
45380304|NCT00857909|Drug|Amiloride|1 tablet twice a day
45380305|NCT00857909|Drug|Spironolactone|1 tablet twice a day
45380306|NCT00857909|Drug|Placebo|Placebo
45380307|NCT00857909|Drug|Placebo and spironolactone|5mg twice daily
45380308|NCT00857909|Drug|Spironolactone|25mg twice daily
45380309|NCT00857987|Drug|EMS Expectorant|Guaifenesin - 100mg, Etafedrine hydrochloride 20mg, Succinate doxilamine 6mg.
46055183|NCT04225143|Procedure|urostim unilateral|Treatment by unilateral neurostimulation of the tibial nerve
46055184|NCT02776137|Drug|Docetaxel|Docetaxel: 20mg/m2/w for 6 weeks
46055185|NCT02776137|Radiation|Intensity-modulated radiotherapy|a total dose of 60Gy in 30 fractions over 6 weeks
45380310|NCT00857987|Other|Placebo|Vehicle
45380311|NCT03998514|Drug|CB4211 Dose 1|Administered by subcutaneous injection
45380312|NCT03998514|Drug|CB4211 Dose 2|Administered by subcutaneous injection
45380313|NCT03998514|Drug|CB4211 Dose 3|Administered by subcutaneous injection
45380314|NCT03998514|Drug|CB4211 Dose 4|Administered by subcutaneous injection
45380315|NCT03998514|Drug|CB4211 Dose 5|Administered by subcutaneous injection
45380316|NCT03998514|Drug|CB4211 Dose 6|Administered by subcutaneous injection
45380317|NCT03998514|Drug|CB4211 Dose TBD|Administered by subcutaneous injection
45380318|NCT03998514|Drug|Placebo|Administered by subcutaneous injection
45496071|NCT05682053|Diagnostic Test|Multiparametic MRI|patients will have a Multiparametric MRI
45380319|NCT00858065|Behavioral|Strengthening Families Program (SFP)|Prevention program with 7 weekly group sessions for parent and child.
45380320|NCT00858065|Behavioral|Family Matters|Prevention program with 4 booklets for families to do at home with their child.
45380321|NCT00854477|Drug|capecitabine|film-coated tablet 1250 mg/m2 twice daily for 14 days every 3 weeks. Number of cycles: 8 cycles unless there is evidence of disease progression, or unacceptable toxicity
45496072|NCT02949947|Drug|Ferric Carboxymaltose|15 mg/kg by vein (up to 750 mg) over 15 min infusion. Dose repeated 1 week later.
45380322|NCT00854555|Other|Locomotor training with robot|60 days locomotor training during 6 months period in out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
45496073|NCT02949947|Dietary Supplement|Iron Supplements|Participants take iron supplements by mouth every day for up to 3 months.
45496074|NCT02949947|Behavioral|Questionnaire|Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24.
45496075|NCT03642392|Other|Identification and treatment of early tendinopathy|Participants receive initial guidance about load reduction when tendinopathy
45496076|NCT05681975|Diagnostic Test|Food-specific Immunoglobulin G4 and/or Immunoglobulin E antibody reactions|Immunoassay kits (NutriSMART® and Fastcheckpoc20® In-Vitro Diagnostic kits, DST GmbH, Schwerin, Germany) are performed in a population with suspicion of having a food allergy or a food intolerance with related symptoms.
45380323|NCT00854555|Other|Locomotor training with manual assistance|60 days training during 6 months period on in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
45380324|NCT00854633|Drug|Talactoferrin|Enteral, 150 mg/kg twice per day
45380325|NCT00854633|Drug|Placebo|Oral, twice per day
45380326|NCT00618371|Drug|Raltegravir (MK-0518)|Antiretroviral drug intensification with Raltegravir (MK0518) 400mg orally every 12 hours for 28 days in addition to the prescribed antiretroviral therapy
45380327|NCT00858299|Drug|valsartan|160 mg oral once in a day for initial 8 weeks and 320 mg, oral, once in a day for subsequent 16 weeks
45380328|NCT00526890|Dietary Supplement|selenomethionine|Oral Twice daily
45380329|NCT00526890|Drug|carboplatin|Weekly IV
45380330|NCT00526890|Drug|paclitaxel|Weekly IV
45496077|NCT03642314|Diagnostic Test|HIV self test kit|HIVST receptor will be invited to priority access to PrEP sites
45496078|NCT03341507|Device|classical laryngoscopy|the laryngoscopy with the McIntosh laryngoscope performed prior the use of rigid tube and the Cormack-Lehane glottis visualisation noted.
45496079|NCT03341507|Device|rigid tube for laryngoscopy|the view of glottis achieved with the rigid tub for laryngoscopy and tracheal intubation with an elastic gum bougie performed
45496080|NCT05216744|Drug|Ceftriaxone 1000mg + doxycycline 100 mg|Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
45496081|NCT05216744|Drug|Cefixime 800mg + doxycycline 100 mg|Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
45380331|NCT00526890|Other|laboratory biomarker analysis|Correlative Study
45380332|NCT00526890|Radiation|radiation therapy|Undergoing radiation Therapy
45380333|NCT04041167|Drug|alpha lipoic acid|alpha lipoic acid treatment
45380334|NCT04041167|Drug|Saline|No alpha lipoic acid treatment
45380335|NCT03998124|Behavioral|Peer facilitator training|Peer facilitation of a project-based activity without staff present
45380336|NCT03998124|Other|Usual care|Staff-led social activity
45380337|NCT00858377|Drug|Arm 1- Dose Escalation|AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
45380338|NCT00858377|Drug|Arm 1- Dose Expansion|AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
45496082|NCT05681897|Procedure|Platelet-Rich Plasma Injections (PRP) on the Scalp|each subject will be treated with 3x PRP injections on the scalp with 2 weeks interval in addition to daily minoxidil administration.
45496083|NCT03641222|Device|Acupuncture|Traditional Chinese Medicine (TCM) Acupuncture
45380339|NCT03864900|Behavioral|The medication adherence intervention|The health belief model based medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
46055186|NCT04093999|Procedure|Sensory nerve coaptation|A recipient sensory nerve branch of the 11th-12th intercostal nerve was reattached to a donor nerve in the chest area. The anterior cutaneous branch of the second or third intercostal nerve was used as the donor nerve. Direct, end-to-end nerve coaptation was performed.
46055187|NCT01027754|Drug|Varenicline|Days 1-3: 0.5 mg once a day Days 4-7: 0.5 mg twice a day Days 8-84: 1 mg twice a day
46055188|NCT01027754|Drug|Placebo|Days 1-3: 1 pill daily Days 4-7: 2 pills daily Days 8-84: 2 pills daily
45496087|NCT01345058|Drug|lacosamide|"Lacosamide maximum of 200 mg/day, to be titrated as follows:~Week 1: 50 mg twice a day~Beginning Week 2: 100 mg twice a day."
45496088|NCT01345058|Drug|levetiracetam|Low dose ≤1500 mg/day, High dose >1500 mg/day
45496089|NCT05393739|Device|Theta burst transcranial magnetic stimulation (TBS) procedure|The procedure includes determining the specific occipital point at which place the stimulation coil; this corresponds to the area where magnetic stimulation is most capable of inducing phosphenes or transient visual phenomena. The phosphenes are directly induced by stimulation of the visual cortex and their presence indicates that the magnetic stimulation is in the correct location. The subjects would wear a personalized swimming cap with the determined area for stimulation marked on it. The major differences between iTBS and cTBS are the frequency and interval of stimulus.
45496090|NCT03642236|Drug|Ibrutinib|Ibrutinib 420mg day -3 to d14 combining with chemotherapy with/without sorafenib based on whether the patients are naive to sorafenib before relapse.
45496091|NCT02262117|Other|standard care|No specific medical care
45496092|NCT02262117|Drug|specific treatment|Regarding the immune endometrial profiling, medical care (personalization of treatment) should follow a step by step decision tree.
45496093|NCT03642158|Device|repetitive Transcranial Magnetic Stimulation|repetitive Transcranial Magnetic Stimulation (rTMS) utilizes a magnetic coil of wire to non-invasively and painlessly activate small sections of the brain through the skull.
45496094|NCT05389215|Drug|DWN12088|DWN12088 Xmg Tablet (BID)
45693945|NCT00830596|Other|Sham Intervention|2 weeks of light effleurage and a sham mechanically-assisted chiropractic treatment followed by 4 weeks active care with full spine spinal manipulation
45380340|NCT00854711|Procedure|inhaled nitric oxide|80 PPM
45380341|NCT00858455|Drug|GSK1349572 and MaaloxAdvanced Maximum Strength|A single dose of GSK1349572 co-administered with a single dose of 20 mL of Maalox Advanced Maximum Strength
45380342|NCT00858455|Drug|GSK1349572 and Maalox Advanced Maximum Strength|A single dose of GSK1349572 administered 2 hours prior to administration of a single dose of 20 mL of Maalox Advanced Maximum Strength
45380343|NCT00858455|Drug|GSK1349572 and One A Day|A single dose of GSK1349572 50 mg co-administered with a single dose of a One A Day Maximum multivitamin
45693946|NCT01944839|Drug|E10030|
45380344|NCT00858455|Drug|GSK1349572|A single dose of GSK1349572
45380345|NCT00862355|Drug|SPARC147609|IV infusion
45380346|NCT00862355|Drug|Reference147609|IV infusion
45496095|NCT05389215|Drug|Placebo|Placebo 0mg Tablet (BID)
45496096|NCT01345292|Device|Mouthwash|Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
45693947|NCT01944839|Drug|ranibizumab|
45693948|NCT01944839|Drug|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
45693949|NCT00805870|Drug|Lovaza (omega-3-acid ethyl esters)|Lovaza, 3 grams per day for 65 days
45693950|NCT00805870|Drug|Wheat Germ Oil|Wheat germ oil, 3 grams/day for 65 days
46055189|NCT02773017|Drug|Dexmedetomidine A|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
46055190|NCT02773017|Drug|Dexmedetomidine B|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
46055191|NCT02773017|Drug|Dexmedetomidine C|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
46055192|NCT02776293|Behavioral|Relaxation|
46055193|NCT02776293|Behavioral|Music|
46055194|NCT04301648|Other|STAR Nurse|"This intervention will consist in that the nurse who is in the hemodynamic nurse's office will do the STAR Nurse's tasks and competences.~Although the intervention will be detailed through phase 1 (integrative review) and 2 (Delphy methodology).~It is expected that the main STAR nurse's competencies and tasks in the nurse's office will be:~To guarantee a comprehensive evaluation and appropriate triage to candidates for an interventional procedure of structural heart disease, coordinating the request for complementary tests and previous visits.~Make education to the patient and family.~Make communication bridge with cardiologists.~Establish specific patient-centered care processes.~Promote continuity of care after discharge, follow up after discharge, and reevaluate quality of life and fragility."
46055195|NCT04301648|Other|Common Practice|Common practice will consist in that the nurse who is in the hemodynamic nurse's office will do her usual task that is exclusively health education.
45496097|NCT01345292|Drug|Potassium nitrate toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
45496098|NCT01345292|Drug|Sodium fluoride toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
45693951|NCT01944059|Drug|Theramine (medical food/old drug)|Theramine® is a prescription medical food that is composed of variety of amino acids and/or their precursors.
45847353|NCT02021448|Other|Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS)|Polygraphy/Polysomnography,Blood sampling, EKG,Lung function testing,Arterial blood gases,Thoracic radiography,Six-minute walk test,Respiratory questionnaires
45847354|NCT01450020|Other|educational intervention|Receive ACS material
45847355|NCT01450020|Other|questionnaire administration|Ancillary studies
45496099|NCT03340961|Drug|DFD-29 Extended Release Capsules (40 mg)|Oral Treatment
45496100|NCT03340961|Drug|DFD-29 Extended Release Capsules (20 mg)|Oral Treatment
45496101|NCT03340961|Drug|Oraycea® (doxycycline) Capsules|Oral Treatment
45496102|NCT03340961|Drug|Placebo Capsules|Oral Treatment
45693952|NCT01944059|Other|Placebo (l-alanine)|Theramine like placebo comparator
45693953|NCT04646057|Device|DuraSorb®|Monofilament Surgical Mesh
45380347|NCT02544737|Drug|Apatinib|Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
45693954|NCT01720225|Drug|Decitabine|20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
45693955|NCT01720225|Drug|Azacitidine|75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
45693956|NCT01943591|Device|Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils|Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.
45847356|NCT01450020|Other|counseling intervention|Undergo PN session
45847357|NCT01450020|Other|survey administration|Ancillary studies
45847358|NCT01450020|Procedure|quality-of-life assessment|Ancillary studies
45847359|NCT01368666|Device|Perceval S Valve Prosthesis|Replacement of diseased or malfunctioning native aortic valve with the Perceval S valve prosthesis
45847360|NCT00860730|Device|Aortic valve replacement with Perceval aortic heart valve|Replacement of diseased or malfunctioning native aortic valve via traditional surgery (open chest) with the Perceval S prosthesis
45847361|NCT00677586|Procedure|simultaneous resection of liver metastasis and the rectal primary tumor|simultaneous resection of liver metastasis and the rectal primary tumor
45380348|NCT00858533|Behavioral|Health at Work workplace health advice and support|The intervention group will receive additional support from a H@W Workplace Health Advisor who will deliver an intervention aimed at sickness absence prevention or sustained return to work, depending on individual circumstances. The intervention will be standardized as far as possible to show types of activity undertaken with participants, their GP, line managers, human resources departments and trade union representatives.
45496103|NCT04077879|Drug|ASP1617|Oral
45496104|NCT04077879|Drug|Placebo|Oral
45496105|NCT03340025|Device|PICO Single Use Negative Pressure Wound Therapy System|Class II negative pressure wound therapy powered suction pump
45496106|NCT03340025|Device|xeroform gauze|traditional surgical dressing of xeroform gauze and padding
45496107|NCT05283434|Drug|Arnica|Patients will be assigned to the placebo (e.g., unmedicated sugar pill) or experimental group (e.g., Arnica 1M pellets) via a randomization chart from that only the research pharmacist will have access to. Subjects assigned to the experimental group will take the recommended doses of Arnica 1M coated sugar pellets (i.e., 2 pills to be taken every 4 waking hours over a 24 hours period), and will track their pain scores, swelling measurements, sleep rate, ibuprofen doses, adverse reactions, further ED visits, and the number of days/activities the patient has missed for 3 days following their enrollment in the study.
45496108|NCT05283434|Drug|Placebo|Sugar pill placebo
45496109|NCT03708341|Drug|Melatonin 5 mg|Systematic daily administration of melatonin 5 mg during patient's ICU stay
45496110|NCT03708341|Drug|Placebo Oral Tablet|Systematic daily administration of placebo during patient's ICU stay
45496111|NCT03643874|Drug|Halix albuterol 90 mcg|albuterol unit dose disposable DPI delivers 90 mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 720 mcg
45693957|NCT01699087|Procedure|Photorefractive keratectomy (PRK)|In this corneal surgical procedure, the outer corneal epithelial layer will be removed, after which the corneal stroma will be reshaped by excimer laser ablation to reduce or eliminate refractive errors.
45693958|NCT01699087|Device|ALLEGRETTO WAVE EYE-Q excimer laser system|The ALLEGRETTO WAVE EYE-Q excimer laser system is used for corneal stroma reshaping during PRK surgery
45693959|NCT01943435|Drug|NSAIDs; adjunctive analgesics; adjunctive anti-depressants|Physician will administer these medications based upon the individual needs of each patient.
45693960|NCT01943435|Procedure|Lumbar epidural injection|The attending physician may refer subjects for epidural injections at a pain clinic that is affiliated with the University of Pittsburgh Medical Center. All epidural injections will be provided by licensed physicians who are board certified in physical medicine and rehabilitation or anesthesiology.
45847362|NCT00677586|Procedure|staged resection of liver metastasis and the rectal primary tumor|Patients received resection of the rectal tumor. 1 months later received resection of liver metastasis
45847363|NCT05454930|Other|Filtered Air|The vehicle is fitted with a (High-Efficiency Particulate Absorbing, HEPA) filter device incorporating a charcoal filter, as well as an augmented cabin filter
45693961|NCT01943435|Other|Joint Mobilizations (spine, sacroiliac, hip)|These joint mobilizations will be applied manually to the lumbar facet joints, sacroiliac joints, and/or hip joints by licensed physical therapists and chiropractors.
45693962|NCT01943435|Other|Individualized exercises: clinical setting|The treating physical therapist or chiropractor will work with each subject to develop a set of individualized exercises in the clinic setting. The goal is to have the subjects continue these exercises at home.
45380349|NCT00526656|Drug|sunitinib malate|50mg PO daily 4 weeks on -2 weeks off
45496112|NCT03643874|Drug|albuterol HFA MDI 90 mcg|albuterol HFA MDI delivers 90 mcg of albuterol with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 1440 mcg
45496113|NCT03641144|Device|Navigation laser|Navigation laser device is a scanning slit-based instrument.before treatment the surgeon plan laser spots on the screen based on image(infrared, colour, fluorescein angiography)and then apply automated patterns and single spots as appropriate.the device will automatically carry out the plan.
45693963|NCT01943435|Other|Group Exercise: community setting|The group exercise will take place at community centers that provide exercise classes for older adult. The exercises are taught by certified fitness instructors in a group setting at these community centers.
45693964|NCT04644809|Drug|LY3561774|Administered SC.
45693965|NCT04644809|Drug|Placebo|Administered SC.
45693966|NCT00805948|Device|Talent Thoracic Stent Graft System|endovascular repair of descending thoracic aortic aneurysms using the Talent Thoracic Stent Graft System.
45693967|NCT01942733|Drug|Brexpiprazole|2-3 mg/day, once daily, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgment.
45380350|NCT04042649|Behavioral|environmental intervention|provide environmental intervention (help sleep cycle, provide comfortable environment)
45496114|NCT03641144|Device|Traditional laser|Traditional laser is a slitlamp based instrument.Surgeon operate traditional laer device while watching Participant's image(infrared, colour, fluorescein angiography) and then manually aim at and trigger laser.
45496115|NCT03642002|Other|Toning|"Music therapist will begin gentle breathing and toning on a descending Ah vowel to stimulate vibration in the chest and increase awareness of the breath. The patient will be encouraged to join the music therapist as is comfortable"
45693968|NCT00807586|Drug|Solumedrol|100mg, given once within 2 hours of the end of the ablation procedure
45693969|NCT00807586|Drug|Placebo|Normal saline (1.6 cc)
45693970|NCT01957865|Device|Fixed SMS, real-time monitoring|SMS reminders will be sent daily for one month, then weekly for two months, then as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
45693971|NCT01957865|Device|Triggered SMS, real-time monitoring|SMS reminders will be sent as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
46055196|NCT04833309|Procedure|pharmacopuncture therapy|The procedure will be implemented to participants twice a week for total 5 weeks. The specific prescription including type and dosage will be determined according to the physician's choice, and information will be recorded in the case report form retrospectively.
46055197|NCT04833309|Procedure|physical therapy|The procedure will be implemented to participants twice a week for total 5 weeks. The specific prescription including type and body part will be determined according to the physician's choice, and information will be recorded in the case report form retrospectively.
46055198|NCT02872766|Device|CXL Myopia|Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to UVA light with the KXL II system according to the programmed treatment pattern.
46055199|NCT02772861|Dietary Supplement|Amino Acid Supplement - One dose|20gr
46055200|NCT02772861|Dietary Supplement|3-Methylhistidine|120mgr
45693972|NCT01957787|Device|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
46055201|NCT01034540|Drug|POM3|4 g/day
46055202|NCT01034540|Drug|Placebo|matching placebo capsule, 4 g/day
46055203|NCT02775981|Drug|RX0041-002|
46055204|NCT02776059|Drug|Standard of care + pegfiltrastim|prednisolone or pentoxifyline orally for 28 days + pegfilgrastim (Neulasta®) 6 mg in 0.6 mL SQ
46055205|NCT02776059|Drug|Standard of care|Oral prednisolone or pentoxifyline for 28 days only
46055206|NCT02772627|Drug|Nebicapone|Nebicapone 100 mg tablets; oral route.
45380351|NCT00858611|Drug|VRC-FLUDNA047-00-VP|
45380352|NCT00858611|Drug|Flulaval (Registered) Seasonal Influenza Vaccine|
45380353|NCT00854789|Biological|E75 + GM-CSF vaccine|The 1 ml by volume vaccine is administered intradermally in 0.5 ml inoculums at two different sites within 5 cm of each other on an extremity. Vaccinations will be given according to the schedule the patient has been assigned and will be administered in the same lymph node draining area (same arm or thigh). In addition, an optional booster inoculation as requested by previously vaccinated patients will be offered every 6 months for the duration of the protocol. The dose will be determined by the PI based on the patient's response to the initial vaccination series.
45380354|NCT00858767|Dietary Supplement|menaquinone-7 from casein capsules|90 µg menaquinone-7 daily during 8 weeks
46055207|NCT02772627|Drug|Placebo|Placebo tablets; oral route.
46055208|NCT00774930|Drug|Lanreotide|deep s.c. injection, 120 mg, every 4 weeks (±3 days).
45380355|NCT00858767|Dietary Supplement|menaquinone-7 from arabic gum capsules|90 µg menaquinone-7 daily during 8 weeks
45380356|NCT00858767|Dietary Supplement|menaquinone-7 from linseed oil capsules|90 µg menaquinone-7 daily during 8 weeks
45380357|NCT00617903|Drug|Azelaic acid|15% foam to be applied topically twice daily
45380358|NCT00617903|Drug|Vehicle foam|Active-ingredient-free vehicle to be applied topically twice daily
45380359|NCT00526110|Drug|5-Fluorouracil|2.2 Gm/m^2 IV over 48 hours on Day 1.
45380360|NCT00526110|Drug|Docetaxel|20 mg/m^2 IV over 60 minutes
45380361|NCT00526110|Drug|Oxaliplatin|85 mg/m^2 IV over 120 minutes on Day 1.
45380362|NCT02544581|Other|Soberlink combined with aftercare services|Soberlink Alcohol Breath Analyzer System combined with aftercare services
45380363|NCT00858923|Device|Energex HemoModulator|To use ultraviolet light to reduce HIV virus in the patient's blood
45496116|NCT03642002|Other|Ocean drum & SOK melody|Music therapist will introduce ocean drum to mimic breathing sounds and will hum the melody of Song of Kin to begin entrainment process. Patient will be invited to join the music therapist in humming as is comfortable
45380364|NCT04565730|Other|Grup I= General anesthesia group|"Preoperative and postoperative evaluation Pre-operative data will be collected 1 to 2 hrs before operation. Preoperative anxiety level will be assessed by the Hospital Anxiety and Depression Scale (HADS) and Amsterdam Preoperative Anxiety and Information Scale.~Patients will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) on the morning of discharge, 1 months and 3 months days after delivery. An online survey will be conducted post-Cesarean delivery to investigate the primary outcome of PND using EPDS, and those will not complete the online survey received phone calls to conduct the follow-up surveys."
45380365|NCT04565730|Other|Grup II= Spinal anesthesia group|"Preoperative and postoperative evaluation Pre-operative data will be collected 1 to 2 hrs before operation. Preoperative anxiety level will be assessed by the Hospital Anxiety and Depression Scale (HADS) and Amsterdam Preoperative Anxiety and Information Scale.~Patients will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) on the morning of discharge, 1 months and 3 months days after delivery. An online survey will be conducted post-Cesarean delivery to investigate the primary outcome of PND using EPDS, and those will not complete the online survey received phone calls to conduct the follow-up surveys."
46055209|NCT00774930|Drug|Placebo|deep s.c. injection of placebo (0.9% saline solution) every 4 weeks (±3 days) for 16 weeks, then deep s.c. injection of lanreotide 120 mg, every 4 weeks (±3 days).
45380366|NCT00859001|Drug|FM+R|Fludarabine-Mitoxantrone-Rituximab
45380367|NCT00859001|Drug|Zevalin (Ibritumomab Tiuxetan)|
45380368|NCT00862511|Device|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
45380369|NCT00862511|Device|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
45496117|NCT03642002|Other|SOK|Music therapist will introduce sung lyric content of Song of Kin accompanied on guitar. Patient will be invited to sing with music therapist as is comfortable.
45496118|NCT03642002|Behavioral|Process|Music therapist will process patient experience and provide psycho-education on strategies for using music to promote comfort and enhance breath.
45693973|NCT01698775|Drug|Omarigliptin|Participants with moderate renal insufficiency will receive one omarigliptin 25 mg capsule orally once a week; participants with severe renal insufficiency or end stage renal disease will receive one omarigliptin 12.5 mg capsule orally once a week
46055210|NCT02775825|Other|survey|
46055211|NCT02772471|Device|HS-1000|
46055212|NCT04201626|Procedure|Adapted ERAS|"Each woman in the intervention group will attend a preoperative counseling session with nurse and doctors. In addition to the standard preoperative counseling, explaining the purpose, process, and the importance of ERAS protocol compliance will be added to the session. Preoperative nutrition and laboratory assessment will be done according to adapted ERAS protocol on that same visit.~During admission, the intervention group participants are provided with care according to adapted ERAS protocol including no bowel preparation, no extended fasting before surgery, balanced intravenous crystalloid, thromboprophylaxis, multimodal pain control reducing opioid usage, multimodal anti-emetics medications, stepping diet up to regular diet within 24 hours, chewing gum for post-operative ileus prevention, early removal of Foley's catheter, and promote early ambulation using care checklist plan."
46055213|NCT02775747|Biological|platelet rich plasma gel|Platelet rich plasma is prepared from fresh whole blood which is collected from a peripheral vein stored in acid citrare dextrose solution A (ACD-A)anticoagulant and processed to increase platelets by separating various components of blood
46055214|NCT02775747|Biological|saline|64 controlled women with recurrent cesarean section and fullfit to all inclusion and exclusion craiteria will reseve saline injection at time of wound closure
45380370|NCT00854867|Drug|Whole Brain Radio Therapy (WBRT) with sequential Depocyte|
45380371|NCT00854867|Drug|Whole brain radiotherapy (WBRT) with concomitant Depocyte|
45693974|NCT01698775|Drug|Placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
45380372|NCT00859079|Drug|GLP-1|Patients received GLP-1 intravenously at a dose of 1.2 pmol/kg/min for at maximum 8 hours.
45380373|NCT00859079|Drug|Human regular insulin intravenously|Human regular insulin intravenously according to the Munich-registry.
45496119|NCT03642002|Other|Holding Harmonic Container|"Music therapist will provide a holding harmonic container of IM7 - IVM7 and will improvise a repeating melody on ah based on the ambient sounds in the patient's immediate environment"
45380374|NCT02544425|Drug|Etoposide|Subjects will receive Etoposide 100 mg/m2 + 5% dextrose in water 500 mL intravenous over 90 mins D1-3 of VIDL chemotherapy. After that, Etoposide will be administered 375mg/m2 D1-2 with G-colony stimulating factor (10 ug/kg) injection in step of Peripheral Blood Stem Cell Collection. Also It will be administered 400mg/m2 on conditioning regimen.
45380375|NCT02544425|Drug|Ifosfamide|It will be administered1.2g/m2 + 5% dextrose in water 100 mL intravenous over 1 hr D1-3
45380376|NCT02544425|Drug|Dexamethasone|It will be administered 40mg/day PO or IV D1-3
45380377|NCT02544425|Drug|L-asparaginase|It will be administered 4000 IU/m2 intramuscular D8, 10, 12, 14, 16, 18, 20
45380378|NCT02544425|Drug|Busulfan|"Conditioning regimen for autologous stem cell transplantation:~Busulfan 3.2 mg/kg D -8, -7, -6"
45496120|NCT03339713|Biological|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1*10^11 vp.
45496121|NCT03339713|Biological|Fluarix|Fluarix will be administered as intramuscular injection.
45496122|NCT03339713|Biological|Placebo|Placebo will be administered as intramuscular injection of sterile 0.9 percent (%) saline for injection.
45380379|NCT02544425|Drug|Melphalan|"Conditioning regimen for autologous stem cell transplantation:~Melphalan 70 mg/m2 D -3, -2"
45380380|NCT03889548|Other|Mental Imagery|Immediately after determination of the resting motor threshold and pre-test measurements, the TMS administrator will leave the room so as to be blinded to the treatment condition of the participant. At this time the participant will be given instructions regarding the mental imagery protocol from a separate investigator who will not be blinded to the condition. During the mental imagery protocol, participants will be instructed to close their eyes and imagine they are maximally contracting the muscles in their forearm and imagine that they are making their wrist flex and that they are pushing maximally against a hand grip in their hand. This will be a kinesthetic imagery task, in which they are urging their muscles to contract maximally.
45380381|NCT00862589|Other|GLP-1 infusion|physiological effect of GLP-1
45380382|NCT04130633|Drug|Placebo|Placebo vapor (distilled water)
45380383|NCT04130633|Drug|THC|Pure THC vapor
45380384|NCT04130633|Drug|Alpha-Pinene|Pure alpha-pinene vapor
45496123|NCT03641066|Device|Ankle Brace|Each participant will complete the 1 minute walking and 2 minute running under 5 conditions [1] un-braced, [2] Active Ankle 329 Ankle Sleeve, [3] AS1Pro (a lace-up brace), [4] Eclipse 1 (single-upright brace), and [5] Eclipse 2 (double upright brace)
45496124|NCT03641768|Device|MRI|You will be asked to undergo a scan of your brain called an MRI. The MRI scan can measure the functioning of your brain.
45496125|NCT03641768|Device|PET|You will be asked to undergo a scan of brain called a positron emission tomography (PET) scan. The PET scan is a test that uses radioactive glucose (sugar) and a computer to create images of how your brain is functioning. Abnormal cells in the body use glucose at a different rate than normal cells and this allows the scanner to create a detailed picture of how your body is working.
45380385|NCT00859157|Procedure|therapeutic conventional surgery|Patients undergo tumescent or standard mastectomy
45380386|NCT00512148|Device|Autologous neobladder construct|augmentation cystoplasty with autologous neo-bladder construct
45380387|NCT00859235|Drug|Chlorhexidine gluconate 0.2%|Mouth wash prior to procedure
45380388|NCT00859235|Other|Plain water|Mouth wash prior to procedure
45380389|NCT04523688|Biological|Autologous Dendritic Cells (DC) vaccine|10×10exp6 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)
45380390|NCT04523688|Drug|Temozolomide|Adjuvant temozolomide assumed orally from day 1 to 5 (start on week 5). Dosage: 150mg/m2/day for the first cycle and 200 mg/m2/day for subsequent cycles (q28).
45380391|NCT00862667|Drug|Treatment A|PF-00241939 300ug using Inhaler A
45380392|NCT00862667|Drug|Treatment B|PF-00241939 300ug using Inhaler B
45380393|NCT00862667|Drug|Treatment C|PF-00241939 300ug using Inhaler C
45380394|NCT02544347|Other|gingival crevicular fluid|gingival crevicular fluid was collected
45380395|NCT02544347|Other|non-surgical periodontal treatment|scaling and root planing were performed
45380396|NCT04041713|Drug|Rett-T|antioxidant cocktail
45380397|NCT04041713|Other|Placebo|Placebo
45380398|NCT00859625|Procedure|nurse observation during colonoscope withdrawal|nurse observation during colonoscope withdrawal
45380399|NCT00511836|Drug|VIVITROL 380 mg|Administered via intramuscular (IM) injection once during the double-blind phase and for 2 additional injections, 4 weeks apart, during the optional open-label extension.
45380400|NCT00511836|Drug|Placebo|Placebo matching VIVITROL 380 mg was administered by IM injection once during the double-blind phase, only.
45380401|NCT04041245|Device|Near infrared spectroscopy|"Near infrared spectroscopy will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~Experimental device: a four-channel INVOS 5100C Oximeter (Somanetics Corp., Troy, USA)~Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination.~They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. After ripping the transparent adhesive tape on the probe, the probes will be left at 4 measuring sites. Regional oxygen saturation (rSO2) will be recorded for 5 minutes.~Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
45380402|NCT00859703|Drug|Risedronate|35mg oral risedronate once per week for 24 months
45380403|NCT00859703|Drug|Placebo|Placebo 35 mg once a week for 24 months
45380404|NCT03998436|Drug|Esmolol Hydrochloride|Galnobax-14% gel application along with Standard of Care
45380405|NCT03998436|Other|Only Standard of Care|Only Standard of Care treatment
45380406|NCT03998436|Other|Vehicle Gel|Vehicle gel application along with Standard of Care
45380407|NCT00855101|Drug|voriconazole|6 mg/kg IV q12h on Day 1, and 4 mg/kg IV q12h on Days 2-7, then switch to 200 mg oral tablet q12h on Days 8-14.
45847364|NCT05454774|Genetic|Single dose intravenous injection of BBM 002|Single dose intravenous infusion of BBM 002, an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII (hFVIII) transgene in liver. The dose of BBM 002 will be 1×10^13 vg/ kg
45380408|NCT00573755|Drug|anastrozole|given orally
45380409|NCT00573755|Drug|exemestane|given orally
45380410|NCT00573755|Drug|letrozole|given orally
45380411|NCT00573755|Drug|sorafenib tosylate|given orally
45380412|NCT00573755|Other|placebo|given orally
45380413|NCT02545361|Drug|KAHR-102|"KAHR-102 is a dual signaling protein (DSP).KAHR-102 will be administrated subcutaneously. In Stage 1A, 3 KAHR-102 SC injections will continue to be given every 14 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~In Stage 1B and Stage 2, subjects will be administered 3 KAHR-102 SC injections given every 7 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~Planned doses for stage 1:~Cohort A: 2µg/kg Cohort B: 4 µg/kg Cohort C: 8 µg/kg Cohort D: 12 µg/kg Each cohort will only begin its first administration of KAHR-102 SC injection when the cohort preceding it will not meet criteria for a DLT (at least 7 days)."
45380414|NCT02544191|Drug|GnRHa/ hCG/ hMG|GnRHa was injected subcutaneously at a dose of 3.6mg every 28 days for 5 months. After 2 months from the first GnRHa injection, all subjects were treated with hCG at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG at a dose of 150 IU every 3 days for 2 months.
45380415|NCT00859859|Device|Vagus Nerve Stimulation|"Vagus nerve stimulation for 5 minutes with an oscillatory device (Brookstone) used in previous experimental animal studies for stimulating the vagus nerve on the neck by carotid massage. The oscillatory part of this pen-like device is approximately 0,5 cm2.~Basic lab tests (metabolic panel and CBC with differential) and monocyte cytokine synthesis and other inflammatory markers will be analyzed."
45380416|NCT00524316|Drug|doxorubicin hydrochloride|Transarterial chemoembolization
45496126|NCT03641768|Device|18F-Florbetapir|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
45693975|NCT01698775|Drug|Glipizide|Phase A: Participants may receive open-label glipizide as rescue therapy up to Week 24 of the study. Phase B: Participants who received placebo to omarigliptin during Phase A and are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study Week 1 through Week 24) will receive glipizide capsule(s) 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
45693976|NCT01698775|Drug|Placebo to glipizide|Matching placebo to glipizide daily
45693977|NCT01698775|Biological|Insulin|Participants on insulin therapy at screening will continue insulin therapy during the study. Insulin glargine therapy may be administered as rescue therapy as determined by the investigator.
45847365|NCT05454540|Device|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|"daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.~Other Name: RTMS"
45380417|NCT00524316|Drug|sunitinib malate|Given Orally
45380418|NCT00524316|Other|laboratory biomarker analysis|Correlative Study
45380419|NCT00524316|Procedure|hepatic artery embolization|Surgical procedure
45847366|NCT05454384|Other|Medical Record Examination|The patients' demographic features, related management and treatment process, the responses given to the consultations by OMFS clinic, the physicians' recommendations, the patient management, and the treatments applied by dentistry clinics were classified and recorded for statistical analyses.
46055215|NCT05335200|Diagnostic Test|(S)-[18F]FBFP PET/CT|Patients will be intravenously injected with 185-370MBq (S)-[18F]FBFP and undergo serial whole-body PET/CT scans at multiple time points (5min, 15min, 30min, 45min, 1h, 2h, 4h). Safety assessment and tolerability of the study will be conducted.
46055216|NCT02841774|Drug|Pravastatin|40mg daily (Weeks 2 - 14)
46055217|NCT02841774|Drug|Rosuvastatin|20mg daily (Weeks 2 - 14); at Week 6, if AST, AST, and CK <+1.5 x ULN, and LDL-c is >60 and decreased by less than 25% compared with week 2, then dose will be increased to rosuvastatin 40mg daily
46055218|NCT02772315|Other|omics|diagnostic procedures applying omics results
46055219|NCT02841384|Other|taping patellar McConnell|Taping patellar McConnell: Lateralization correction of the patella with self-adhesive rigid bandage Johnson® positioned lateral border of the patella to the medial condyle of the femur, allowing the lifting of the medial border of the patella and stretching of the knee lateral structures.
46055220|NCT02841384|Other|Placebo taping|Placebo taping through vertical application of patellar rigid taping, with the knee in flexion without medialization of the patella.
45380420|NCT00524316|Procedure|quality-of-life assessment|Correlative Study
45380421|NCT00860093|Other|placebo|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
45693978|NCT01941095|Drug|Azathioprine|Participants may receive azathioprine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
45693979|NCT01941095|Drug|Chloroquine|Participants may receive chloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
45380422|NCT00860093|Drug|MPC-5971|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
45380423|NCT00862901|Device|CLIPT patch|A Diomed laser will deliver 630nm (red spectrum) light through a Fiber optic Patch. The Fiber Optic Patch will be compatible with the laser, delivering light to a designated region on the patient's skin. Patients will receive a single intravenous injection of Photofrin (0.8mg/kg body weight) 36 - 48 hours prior to the CLIPT procedure. PDT will be delivered over 24 hours for the dose of each arm. Patients will be enrolled in sequential cohorts of six, at increasing laser intensity until the maximum tolerated dose is reached.
45380424|NCT00855257|Drug|Acid Nicotinique|
45380425|NCT00855257|Drug|Placebo|
45380426|NCT03861936|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A;BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1.
45380427|NCT03861936|Drug|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles on Day 1.
45380428|NCT02544269|Procedure|Ropivacaine|Lumbosacral plexus blockade with ropivacaine.
45380429|NCT02544269|Procedure|Bupivacaine|Regional anesthesia with bupivacaine titrated to the lowest effective dose
45380430|NCT04046471|Dietary Supplement|enhanced Stop Light Diet|Stop light diet enhanced with portion-controlled meals
45380431|NCT04046471|Behavioral|Group Remote|Participants will receive remotely delivered weight loss in a group setting.
45380432|NCT04046471|Behavioral|Individual In-Person|Participants will receive a weight loss intervention during individual, at-home visits.
45380433|NCT00434577|Biological|Herpes Zoster vaccine GSK1437173A Low Dose|Single or two-dose intramuscular injection.
45380434|NCT00434577|Biological|Herpes Zoster vaccine GSK1437173A Medium Dose|Single or two-dose intramuscular injection.
45380435|NCT00434577|Biological|Herpes Zoster vaccine GSK1437173A High Dose|Single or two-dose intramuscular injection.
45380436|NCT00434577|Biological|Herpes Zoster vaccine GSK1437173A Modified|Single or two-dose intramuscular injection.
46055221|NCT02772237|Biological|Riboflavin|Riboflavin 400mg daily
46055222|NCT02772237|Biological|Placebo|
46055223|NCT02841306|Drug|Ursodeoxycholic Acid|
46055224|NCT04225689|Other|CD-TREAT diet|Dietary intervention
46055225|NCT01027364|Drug|Factor IX (rFIXFc)|
46055226|NCT01027364|Drug|rFIX|
45380437|NCT00434577|Biological|Placebo|Single intramuscular injection
45380438|NCT04042181|Dietary Supplement|Placebo|standard food grade excipients
45380439|NCT04042181|Dietary Supplement|Bifidobacterium longum|Target dose of 1x10^10 CFU/day, plus standard food grade excipients
45380440|NCT00865085|Drug|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
45380441|NCT00865085|Drug|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fasting conditions
45380442|NCT00860483|Other|observational|PET Scan
45693980|NCT01941095|Drug|Hydroxychloroquine|Participants may receive hydroxychloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
45847367|NCT05454150|Device|balloon-expandable valve|Sapien 3/Ultra, Edwards Lifesciences©
45847368|NCT05454150|Device|self-expanding valve|Evolut R/Pro, Medtronic©
46055227|NCT01316250|Drug|Nilotinib|Nilotinib 300 mg orally twice per day for 12 months followed by imatinib mesylate at a dose of 400 mg orally daily
45380443|NCT00434421|Drug|Glycerinated German cockroach allergenic extract|Initially each subject underwent a 1-day, 8-dose escalation (e.g., one dose of placebo, 0.14 milliliters [mL], followed by 7 escalating doses of Glycerinated German Cockroach Allergenic Extract until the Maximum Study Dose [0.42 mL, 1:10 wt/vol] or Maximum Tolerated Dose was achieved). This maximum dose became the daily dose - maintenance dose- of Glycerinated German Cockroach Allergenic Extract for the following 14 days.The maintenance dose of 0.42 mL was calculated to contain 3685 bioequivalent allergy units (BAU), with approximately 4.2 mg of German cockroach allergen Bla g 2 and 50 mg of Bla g 1 per dose. Route of administration: sublingual-oral route.
45380444|NCT00434421|Drug|Placebo|Placebo was administered only as the first dose (e.g., representing no Glycerinated German Cockroach bioequivalent allergy units) during the initial 1-day, 8-dose escalation, otherwise referred to as the Preliminary Dosing Visit. Refer to the Glycerinated German cockroach allergenic extract treatment for more details. Route of administration: sublingual-oral route.
45380445|NCT00421707|Drug|GW876008|
45496127|NCT03641768|Device|Radioligand 18F-AV-1451|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
45380446|NCT00421707|Other|Placebo|
45380447|NCT00796068|Drug|Cyclosporine|Given IV or PO
45380448|NCT00796068|Drug|Fludarabine Phosphate|Given IV
45380449|NCT00796068|Other|Laboratory Biomarker Analysis|Correlative studies
45380450|NCT00796068|Drug|Mycophenolate Mofetil|Given IV
45496128|NCT03254485|Drug|IW-1973|Oral Tablet
45380451|NCT00796068|Radiation|Total-Body Irradiation|TBI administered day -1: 200 cGy (or escalated to 300 cGy, 400 cGy, or 450 cGy per protocol statistical section)
45496129|NCT03254485|Drug|Placebo Oral Tablet|Oral Tablet
46055228|NCT02771925|Drug|Gabapentin 2g/day divided in two doses for 24 weeks|"Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2000mg/day divided in two doses for 24 weeks.~All patients will receive standard of care treatment."
45380452|NCT00796068|Drug|Treosulfan|Given IV
45496130|NCT03621176|Other|Home-based exercise|A booklet with detailed information will be provided, and the exercises will be previously reviewed with every patient by the researcher. Participants will be encouraged to perform at least 3 sessions per week and monitor their heart rate. They will be instructed that the exercises should be perceived as 'somewhat hard' from a rate of perceived exertion. Adaptations to increase the intensity of the exercises will be provided so that participants can progress in exercise intensity
45496131|NCT01841736|Other|Laboratory Biomarker Analysis|Correlative studies
45380453|NCT00796068|Procedure|Umbilical Cord Blood Transplantation|Undergo single or double unit UCBT
45380454|NCT01032447|Behavioral|Navigator Support|Standard of Care
45380455|NCT01029483|Other|Low carbohydrate diet|Ad libitum low carbohydrate diet (<28g carbohydrate/day). Participants provided with research diet at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the food desired.
45496132|NCT01841736|Drug|Pazopanib Hydrochloride|Given PO
46055229|NCT02771925|Drug|Placebo 2g/day divided in two doses for 24 weeks|Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2000mg/day divided in two doses for 24 weeks. All patients will receive standard of care treatment. Concurrent with study medication, study clinicians will provide participants with 20 minutes of weekly manual-guided counseling designed to increase motivation, abstinence, and medication compliance.
45380456|NCT01029483|Other|High-carbohydrate ad libitum intervention|Participants provided with a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the foods provided as desired
45380457|NCT01029483|Other|High carbohydrate diet-energy matched intervention|Participants provided a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at ~70% of estimated energy needs to maintain weight. Participants required to eat all food provided and nothing else.
45380458|NCT03798288|Behavioral|selfBACK|Participants will use the selfBACK system and app in addition to receiving usual care
45380459|NCT03798288|Other|Usual care|Participants will receive usual care
45380460|NCT00518622|Drug|Comparator: MK7009|Depending on group assignment, patients will receive once daily (q.d.) dosing for 8 days or twice daily (b.i.d.) dosing for 7 days plus one additional dose on Day 8.
45380461|NCT00518622|Drug|Comparator: Placebo|MK7009 Placebo
45380462|NCT04732182|Device|BrightGo cognitive training|Training on the BrightGo experimental device in the home
45496133|NCT01841736|Other|Placebo Administration|Given PO
45496134|NCT01841736|Other|Quality-of-Life Assessment|Ancillary studies
45496135|NCT03641612|Other|one shape|canal fluid sample before and after root canal instrumentation
45496136|NCT03641612|Other|protaper next|canal fluid sample before and after root canal instrumentation
45496137|NCT00769327|Drug|imatinib mesylate|
45496138|NCT00769327|Drug|nilotinib|
45693981|NCT01941095|Drug|Leflunomide|Participants may receive leflunomide as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
45380463|NCT04732182|Drug|Standard of Care medication for early Alzheimer's Disease|Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease
45380464|NCT03783078|Drug|Pembrolizumab (MK-3475)|200 mg (adult participants) or 2 mg/kg (up to 200 mg; pediatric participants) on Day 1 of each 3-week cycle (Q3W) IV up to 35 administrations (approximately 2 years).
45380465|NCT04456842|Other|Patient Registry Data|To set data on demographic characteristics,documenting antithrombotic therapy, describe the INR control level of VKA users, discontinuation rates and clinical outcomes, such as stroke, hemorrhage and death.
45380466|NCT01009398|Other|Fluoroscopic examination|Localisation of the paravertebral catheter tip and documentation of the spread of contrast dye injected through the catheters by fluoroscopic examination
45380467|NCT01009476|Drug|Galantamine|Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of galantamine (8 mg,16 mg, 24 mg retard capsule) was to be in accordance with the recommendations given in the summary of product characteristics.
45380468|NCT01009476|Drug|Nootropics (ginkgo biloba, nicergoline, piracetam, or others)|Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of nootropics was to be in accordance with the recommendations given in the relevant summary of product characteristics.
45496139|NCT00769327|Genetic|cytogenetic analysis|
45496140|NCT00769327|Genetic|fluorescence in situ hybridization|
45496141|NCT00769327|Genetic|microarray analysis|
45496142|NCT00769327|Genetic|mutation analysis|
45847369|NCT05453838|Dietary Supplement|oral intake of one serving of the original and new product|1) Intervention type: Dietary Supplement Intervention name: (visits 1, 3 and 5) Reference product Intervention description: Glucose solution 2) Intervention type: Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: : One serving new product 3) Intervention type: : Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: One serving original product
45380469|NCT00517296|Procedure|EUA with seton placement if necessary|Patients randomized to the combination therapy group, the surgeon will have access to EUS findings.
45380470|NCT00517296|Drug|adalimumab|Patients began therapy with adalimumab using clinic standards for dosing.
45380471|NCT00517296|Procedure|EUS|Patients in combination therapy group had an EUS done every 12 weeks to help guide therapy.
45380472|NCT00516906|Drug|Chlorhexidine gluconate|2% Chlorhexidine Transparent Dressing applied as needed up to 7 days of wear
45380473|NCT00516906|Drug|Transparent Adhesive Dressing|Standard of Care Non-antimicrobial Transparent Adhesive Dressing applied as needed for up to 7 days of wear
45380474|NCT01565304|Behavioral|POWER Through Choices|10-session group-based sexual education curriculum
45380475|NCT00523848|Drug|bortezomib|IV
45380476|NCT00523848|Drug|pegylated liposomal doxorubicin hydrochloride|IV
45380477|NCT00523848|Drug|thalidomide|Oral
45496143|NCT00769327|Genetic|polymerase chain reaction|
45496144|NCT00769327|Genetic|polymorphism analysis|
45496145|NCT00769327|Other|laboratory biomarker analysis|
45693982|NCT01941095|Drug|Methotrexate|Participants may receive methotrexate as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
45380478|NCT04711200|Drug|Adipose derived stromal cells intravenously injected|2×10^6/kg of Adipose derived stromal cells A single injection at D0 (performed maximum three days post-admission).
45380479|NCT04414722|Drug|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
45380480|NCT04414722|Biological|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt
45380481|NCT04414722|Other|Control Yogurt|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
45496146|NCT01068704|Drug|BMS-690514|Tablets, Oral, 200 mg, once daily, ~ 12 months depending on response
45847370|NCT05453682|Radiation|hypo-IMRT|Twenty fractionation within 4 weeks are performed using hypofractionated intensity-modulated radiation therapy. As for the radiation dose, 2.8-3.2 Gy at a time, total dose 56-64 Gy, to the high-risk target volume, and 2-2.2 Gy at a time, and 40-44 Gy, respectively, to the low-risk target volume.
45380482|NCT00617669|Drug|Docetaxel|intravenous infusion given every three weeks
45380483|NCT00617669|Drug|ZD4054|10 mg oral once daily dose
45380484|NCT00617669|Drug|Placebo|placebo oral tablet once daily
45380485|NCT00863135|Device|CPAP|continuous positive airways pressure
45380486|NCT00863135|Device|Control|Patients are 3 months without any change in their treatment, and are in the waiting list to come into the CPAP procedure after that time
45380487|NCT04018157|Drug|"Ketamine and dexmedetomidine and propofol and 0.9%saline"|patients will receive single intravenous bolus of combination from ketamine 0.5mg/kg and dexmedetomidine 1ug/kg in one syringe diluted in 10 ml 0.9% saline.
45380488|NCT03682848|Drug|DTG + 3TC FDC|DTG + 3TC FDC will be available as 50/300 milligrams tablet to be given orally once daily.
45380489|NCT00865241|Drug|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
45380490|NCT00865241|Drug|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
45380491|NCT00863213|Procedure|Atrial fibrillation ablation|"Atrial fibrillation ablation with radiofrequency, guided by 3D navigation map. Either 4mm or cooled tip-catheters will be used.~It will include, at least, pulmonary veins isolation; all other radiofrequency lines, including roof and mitral isthmus line, and complex fractioned electrograms ablation will be performed according to each Hospital protocol. Radiofrequency lines block will be tested."
45380492|NCT00863213|Drug|Antiarrhythmic drug|Usual drug therapy for atrial fibrillation. In patients with structural heart disease, amiodarone is recommended, while flecainide plus diltiazem or beta-blockers are encouraged in patients without structural heart diseases.
45496147|NCT01068704|Drug|Lapatinib|Tablets, Oral, 1500 mg, once daily, ~ 12 months depending on response
45496148|NCT01068704|Drug|Letrozole|Tablets, Oral, 2.5 mg, once daily, ~ 12 months depending on response
45380493|NCT00860639|Drug|gemtuzumab ozogamycin|gemtuzumab ozogamycin = 6mg/m² during the induction course (Day 4) gemtuzumab ozogamycin = 6mg/m² during the first intensive consolidation course (Day 4)
45496149|NCT05179759|Behavioral|Tealeaf|Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
45847371|NCT05453604|Device|Colli-Pee UAS devices|Colli-Pee UAS device variants will be evaluated during this study
45847372|NCT05453448|Drug|tenofovir alafenamide|Antiviral therapy
45847373|NCT05453448|Drug|Entecavir|entecavir
45380494|NCT00860717|Procedure|Routine treatment|Subjects from the Control Group received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
45380495|NCT00860717|Radiation|Low level laser therapy (LLLT)|"The LLLT equipment was an indium-gallium-aluminnium-phosphide (InGaAlP) semiconductor laser with a maximum output power of 40 mW, continuous radiation emission of visible red light with 660 nm wavelength (+/- 10 nm) and a spot area of 0.04 cm². The energy density used was 4 J per point in the wound edges and 2 J/cm² in the wound bed with a power density of 1 W/cm2.~Wound beds were irradiated using a scanning technique with no direct contact."
45496150|NCT05179759|Behavioral|Enhanced Usual Care|Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment
45496151|NCT05179681|Other|Nasal High -Flow Oxygen Therapy|patients receiving transnasal humidified rapid-insufflation ventilatory exchange
45496152|NCT03339401|Other|Standard of Care|Local institutional standard of care (SoC) (i.e., investigator-assigned therapy) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
45496153|NCT03339401|Drug|Brincidofovir|Brincidofovir (BCV) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
45496154|NCT05179525|Drug|Risperidone ISM® 100 mg|100 mg of risperidone ISM® administered every 4 weeks
45496155|NCT05179525|Drug|Risperdal 4mg Tablet|4 mg oral risperidone once daily for 7 days
45496156|NCT05179291|Other|Buzzy Group|The Buzzy device was placed 5-10 cm above the injection area and making sure that it was in contact with the skin. The ice pack was kept in the deep freezer and placed into the device before the application. Buzzy was introduced to the children pre-procedure. Cold application and vibration were started pre-procedure and maintained until the procedure was completed. Following the Buzzy application, the device was wiped with 70% alcohol and used for other children. The Buzzy devices were kept in the deep freeze and refrozen. The same person conducted the pain reduction methods during phlebotomy.
45693983|NCT01941095|Drug|Sulfasalazine|Participants may receive sulfasalazine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
45693984|NCT01941095|Drug|Tocilizumab|Participants will receive tocilizumab at a fixed dose of 162 mg SC QW either as monotherapy or in combination with non-biologic DMARDs.
45693985|NCT00831766|Drug|Idarubicin|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
45693986|NCT00831766|Drug|Cytarabine|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
45693987|NCT00831766|Drug|Lenalidomide (Revlimid®)|Lenalidomide as outlined in Phase I and Phase II Treatment Arms.
45693988|NCT01957709|Other|Laboratory Biomarker Analysis|Correlative studies
45693989|NCT01957709|Biological|Recombinant Interferon Gamma|Given subcutaneously weekly for four weeks prior to surgery.
45693990|NCT00832390|Drug|sitagliptin phosphate|Patients will receive sitagliptin with metformin for 24 weeks, given as oral tablets
45693991|NCT01957553|Device|Coloplast test product|Coloplast test product is a newly developed 2-piece ostomy appliance
46055230|NCT03205956|Drug|Levodopa|"At least 1 hour after 200mg carbidopa p.o., each subject will receive an intravenous solution of levodopa in saline at a rate based on age and body mass according to the final dose described in Black et al 2003.The total dose for a 70-year-old, 70kg subject will be approximately 65mg.~Subjects with untreated PD will then take 6 ± 1 weeks of clinically dosed oral carbidopa-levodopa tablets for clinical purposes and then repeat the carbidopa plus intravenous levodopa dose as above."
46055231|NCT02840994|Biological|CV301|
46055232|NCT02840994|Biological|Pembrolizumab|
46055233|NCT02840994|Biological|Nivolumab|
46055234|NCT02775591|Drug|DA-9701|DA-9701 30mg Tablet
46055235|NCT02775591|Drug|DA-9701 placebo|Placebo pill manufactured to mask DA-9701 30mg Tablet
46055236|NCT02771847|Behavioral|survey|anonym survey is given to people
46055237|NCT02844036|Procedure|Percutaneous angioplasty|
46055238|NCT02844036|Procedure|Balloon angioplasty|
46055239|NCT02844036|Procedure|Right heart catheterization|
46055240|NCT02844036|Procedure|Echocardiography|
46055241|NCT02844036|Other|A six-minute walking test|
46055242|NCT02844036|Procedure|Functional respiratory investigations|
46055243|NCT02844036|Procedure|Pulmonary tomography or pulmonary angiography|
46055244|NCT02844036|Other|Biological parameters|
46055245|NCT02771457|Drug|Infliximab at weeks 0,2, and 6|
45496157|NCT05179291|Other|Virtual Realitiy-VR Group|VR glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses 2-3 minutes before starting the application and it continued until the end of the phlebotomy procedure (three minutes on average). 3D video suggestions (Space Experience, Blue Whale 360 VR Experience) were offered to the children before the phlebotomy procedure and they were asked to choose one of them.
45380496|NCT03660540|Dietary Supplement|Juven|Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations.
45380497|NCT00863291|Drug|buprenorphine|buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
45380498|NCT00863291|Drug|placebo|Placebo in a manner similar to the active comparator
45496158|NCT04160455|Biological|expression of a panel|Quantify, by droplet digital PCR, the expression of a panel of 7 genes (+ GALIG) involved in autophagy2 on sub-populations (CD4+ and CD8+ lymphocytes and monocytes) after their sorting using magnetic bead cell then RNA extraction Evaluate, on a functional test (as previously described1), whether the observed expression dysregulation is associated with a deregulation of the autophagic function, whether constitutive or induced.
45496159|NCT05692206|Other|evaluation|Surveys will be administered to the participants. Participants will be given a stroop TBAG test.
45496160|NCT03370289|Biological|BLB-750 Vaccine (Qinghai RG strain)|BLB-750 Injection
45496161|NCT01344824|Biological|bevacizumab|15 mg/kg once per 21 day cycle (up to 4 cycles).
45496162|NCT01344824|Drug|carboplatin|Area Under the Curve (AUC)=6, once every 21 day cycle (up to 4 cycles)
45496163|NCT01344824|Drug|erlotinib hydrochloride|150mg, daily for 21 day cycle (up to 4 cycles)
45496164|NCT01344824|Drug|pemetrexed disodium|500 mg/m2 on day 1 of a 21 day cycle (up to 4 cycles)
45496165|NCT04320511|Device|CT-V|CT-V is an image processing-based modality that recovers changes in local tissue volumes, induced by respiratory motion, from an inspiration-expiration CT (IE-CT) scan or a standard non-contrast 4D CT scan
45496166|NCT04292197|Drug|18-MC Compound|18-MC
45496167|NCT01311947|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a at 180 ug weekly for 24 weeks
45496168|NCT05137496|Drug|Ruxolitinib|0.3mg/kg/d, iv.gtt, for at least 2 weeks
45496169|NCT05137496|Drug|methylprednisolone|2mg/kg, d1-d5, gradually reduced, for at least 2 weeks
45496170|NCT03708185|Dietary Supplement|Beta-alanine|N/A: see arm description
45496171|NCT03708185|Dietary Supplement|Placebo|N/A: see arm description
45496172|NCT03640676|Device|FlowOx|FlowOx is a CE marked device developed to increase blood flow to the lower extremities. A pressure chamber is sealed around the leg below the knee and is connected to a control unit which induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure.
45847374|NCT05453214|Drug|Fludrocortisone Acetate 0.1 MG|Fludrocortisone acetate 0.1 mg tablet / 12 hours; dose to be titrated according to response.
46055246|NCT02771457|Drug|Infliximab at weeks 0,4, and 8|
46055247|NCT02771457|Drug|Infliximab at weeks 0 and 8|For physicians who do not feel comfortable enrolling patients in a randomized trial of infliximab re-induction they will have the option of enrolling their patients in an arm that resumes maintenance therapy only instead at 0 and 8 weeks.
46055248|NCT01027286|Device|Vitagel|Vitagel applied just prior to closure during primary total knee arthroplasty
46055249|NCT02771769|Other|blood draw|Participants will have a venous blood draw of ~20mLs before prostate biopsy. The biopsy will then be performed and histologically graded for any malignancy present. This grade will be statistically analyzed with respect to the Copy Number Instability (CNI) determined from the results of the molecular examination of the cell-free DNA in the blood.
46055250|NCT02843802|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
46055251|NCT02843802|Biological|NK Immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
46055252|NCT02771379|Drug|Idebenone|Raxone 900mg/day as per Raxone SmPC and medical judgement of treating physician.
46055253|NCT00627770|Device|bioimpedance spectroscopy ImpediMed SFB7 Brisbane Australia|edema evaluation using bioimpedance
46055254|NCT01026870|Drug|SCH 32088 mometasone furoate (MF) metered-dose inhaler|2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
46055255|NCT01026870|Drug|Placebo metered-dose inhaler BID|2 inhalations from a placebo metered-dose inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
46055256|NCT02771535|Behavioral|D-MCT|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
45496173|NCT03640598|Procedure|Ilioinguinal/iliohypogastric nerve blocks|The patient will receive ultrasound-guided Ilioinguinal/iliohypogastric nerve blocks with0.5 ml/kg 0.125 mg/kg bupivacaine + fentanyl 2ug/ml injectate
45380499|NCT04689282|Biological|Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs).|Intranasal delivery of M2-BFs is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
45380500|NCT00860873|Dietary Supplement|EMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
45380501|NCT00860873|Dietary Supplement|EMS Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
45496174|NCT03640598|Procedure|Erector spinae nerve block|The patient will receive ultrasound-guided erector spinae nerve block 0.5 ml/kg 0.125 bupivacaine + fentanyl 2ug/ml injectate.
45496175|NCT03339245|Other|Fructose Solution (75 Grams)|Fructose given in divided doses at breakfast and dinner.
45380502|NCT00860873|Dietary Supplement|Zodiac: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (Oral powder)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
45380503|NCT00860873|Dietary Supplement|Zodiac Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
45380504|NCT03648450|Other|Propeller EMD|Propeller electronic monitoring device is a sensor that fits on top of inhalers and uses Bluetooth connection to cell phones to remind patients to take their medication.
45380505|NCT00865319|Radiation|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG to be injected
45496176|NCT03339245|Other|Glucose Solution (75 grams)|Glucose given in divided doses at breakfast and dinner.
45380506|NCT00865319|Radiation|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20mCi)
45496177|NCT03044574|Device|SCD|Intermittent pneumatic compression (IPC) with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.
45496178|NCT03044574|Device|GCS|Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge
45847375|NCT05452980|Procedure|reestablishment of the acute angle of His|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
45496179|NCT03044574|Drug|LMWH|LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.
45496180|NCT02959892|Drug|Amphetamine|Amphetamine tablets.
45496181|NCT02959892|Drug|TAK -041|TAK-041 oral suspension.
45496182|NCT02959892|Drug|[11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)|[11C]PHNO injection.
45498230|NCT03623802|Other|Local Movement Therapy|Loads and intensity of exercises will be increased according to participants' abilities. Modifications of exercises are made through different body positions or increasing the load. When a participant will be able to perform a certain number of repetitions and sets of a required exercise, without any compensatory movements, he/she can proceed to the next level of exercise. Breaks between exercises and sets are the same as in the integral movement therapy protocol. Protocol consists of four basic exercises, which are progressed through sessions: (I) Abdomen curl. (II) Trunk extension on roman chair. (III) Hip bridge. (IV) Side plank.
45847376|NCT05452980|Procedure|sleeve gastrectomy|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
46055257|NCT02771535|Behavioral|Health Training|Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks
46055258|NCT04631406|Biological|Neural Stem Cells|NR1 is a human embryonic stem cell (hESC) derived product for the treatment of chronic ischemic subcortical stroke
46055259|NCT02771691|Other|Mentalization-Based Group Therapy for Adolescents|
46055260|NCT02696811|Dietary Supplement|White carrots|White carrots contain compounds called polyacetylenes, including falcarinol, falcarindiol and falcarindiol-3-acetate.
46055261|NCT02696811|Dietary Supplement|Oat biscuits|The 3 oat biscuits contain the same amount of fibre and sugar as the white carrot but without the polyacetylenes.
46055262|NCT02841228|Radiation|IMRT + SIB + Chemotherapy|For all patients, the dose to the PTV will be kept constant at 60 Gy in 30 fractions at 2.0 Gy per fraction , SIBV will be kept constant at 72 Gy in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks. All patients will receive standard concurrent chemotherapy.
45380507|NCT03639714|Biological|GRT-C901|a patient-specific neoantigen cancer vaccine prime
45380508|NCT03639714|Biological|GRT-R902|a patient-specific neoantigen cancer vaccine boost
45380509|NCT03639714|Biological|nivolumab|anti-PD-1 monoclonal antibody
45380510|NCT03639714|Biological|ipilimumab|anti-CTLA-4 monoclonal antibody
45380511|NCT00861029|Drug|Pazopanib|Subjects treated with pazopanib
45380512|NCT00861029|Other|Placebo for pazopanib|Control for comparison with pazopanib
45380513|NCT00861029|Drug|Moxifloxacin|Comparator for pazopanib
45380514|NCT00861029|Other|Placebo for moxifloxacin|Placebo for moxifloxacin
45380515|NCT00865397|Drug|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
45380516|NCT00861107|Biological|AlloStim-7|intradermal injection once a week for 3 weeks
45380517|NCT00861107|Procedure|percutaneous tumor cryoablation|ablation of a tumor by percutaneous cryoablation under CT guidance
45380518|NCT00861107|Biological|AlloStim-7|intratumoral injection into cryoablated tumor lesion 1 hour after ablation
46055263|NCT02844114|Drug|Ganoderma lucidum spore|G 300mg, 5 tablets by mouth
46055264|NCT02844114|Drug|Placebo|Sugar pill manufactured to mimic tramadol 1500mg tablet
46055265|NCT02844114|Drug|Chemotherapy|iv.30 minutes
46055266|NCT04810143|Device|Mitra Microsampler|an FDA Class I medical device for direct specimen collection of blood or other biological fluids
45380519|NCT00861107|Biological|AlloStim8 or AlloStim-9|intravenous infusion of AlloStim one week following ablation procedure. First cohort to receive 10^8 cell dose and if no toxicity dose escalates to 10^9 cell dose.
45380520|NCT00510510|Drug|NVA237 100 µg|Dry powder inhalation once a day for up to 28 days
45380521|NCT00510510|Drug|Placebo|Placebo to NVA237 dry powder inhalation once a day for up to 28 days
45380522|NCT00510510|Drug|NVA237 200 µg|Dry powder inhalation once a day for up to 28 days
45380523|NCT00863525|Drug|odanacatib|A single oral dose of 100 mg odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
45380524|NCT00863525|Drug|Comparator: Placebo|A single oral dose of Placebo to odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
45380525|NCT05226377|Diagnostic Test|Atherogenic Index of Plasma|- The atherogenic index of plasma (AIP) is defined as the base 10 logarithms of the ratio of plasma triglyceride (TG) to high-density lipoprotein cholesterol (HDL-c) (17). AIP was employed as a predictor of cardiac risk (CR) with values of -0.3 to 0.1 are associated with low, values of 0.1-0.24 are associated with the medium, and values above 0.24 with high CR
45380526|NCT01009632|Behavioral|Resonant voice|4-hr of resonant voice exercise
45380527|NCT01009632|Behavioral|Voice rest|4-hr of complete refrain from any voice use
45380528|NCT01009632|Behavioral|Spontaneous speech|
45380529|NCT00863603|Other|oxygen|5 Liter/minute by nasal cannula for 6 wks
45380530|NCT00865475|Drug|AZT+3TC+ABV (Trizivir)|Patients on treatment with TZV and viral suppression will be randomized to keep on TZV vs switching to LPV/r monotherapy
45380531|NCT00865475|Drug|Switching to LPV/r monotherapy (Kaletra)|Patients on AZT+3TC+ABV with viral suppression will be randomized to keep on vs switching to LPV/r
45380532|NCT04685694|Drug|Misoprostol|sl 800 mcg misoprostol
45380533|NCT00870311|Drug|Lithium Carbonate|300mg PO, three times daily with dose titrated to obtain a therapeutic plasma level of 0.8 to 1.2meq/L) over the first week of treatment. Total duration is a minimum of 3 weeks. Medication is dispensed in the form of blinded research capsules.
45380534|NCT01564602|Device|comparison multiple channel port laparoscopic surgery|to compare 2-channel single port and multiple channel port laparoscopic surgery
45380535|NCT00865553|Behavioral|computer-assisted smoking cessation intervention|
45380536|NCT00865553|Other|cancer prevention|
45380537|NCT00865553|Other|educational intervention|
45693992|NCT01957553|Device|SenSura|SenSura is the commercial available CE-marked SenSura Click 2-piece ostomy appliance from Coloplast A/S
45693993|NCT04644029|Drug|Islatravir|Oral 60 mg tablet administered once monthly during Part 1.
45380538|NCT00865553|Other|survey administration|
45380539|NCT03560388|Other|Acupuncture and touch/relaxation|Pre-operative integrative care (touch-relaxation) that follows with intra-operative acupuncture
45380540|NCT00865631|Drug|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
45380541|NCT00865631|Drug|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
45380542|NCT00865631|Drug|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
45380543|NCT00863759|Procedure|implantation of intraocular lens (IOL)|"implantation of intraocular lens during cataract surgery.~Arm 1: implantation of aspheric IOL Akreos AO in right eye and an spheric IOL Akreos Fit in left eye.~Arm 2: implantation of aspheric IOL Akreos AO in left eye and an spheric IOL Akreos Fit in right eye."
45380544|NCT00863837|Drug|terlipressin (vasoconstrictor)|Ligation plus terlipressin 1mg q6h
45380545|NCT00863837|Drug|pantoloc (proton pump inhibitor)|Pantoloc infusion (1 vial q.d.); Using pantoloc to reduce rebleed after EVL
45380546|NCT01009866|Biological|MR1-1|Based on preclinical toxicity studies, the starting total drug dose will be 0.5μg (500ng) which represents 1/20th of the MTD in rats. The infusion flow rate will be fixed at 0.5 mL/h from each of two catheters. A total of 96 mLs of drug solution will be delivered over 96 hours. MR1-1KDEL dose escalation will be accomplished by increasing drug concentration allowing flow rate and infusion volume to remain unchanged. Drug dose will be doubled in successive cohorts so long as DLTs are not observed as follows: 25 ng/mL (2.4 μg)(starting dose); 50ng/mL (4.8μg); 100 ng/mL (9.6μg); 200ng/mL (19.2μg); 400 ng/mL (38.4μg); 800 ng/mL (76.8μg); and 1600 ng/mL (153.6μg).
45380547|NCT00863915|Drug|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products sprinkled on one tablespoonful of applesauce
45693994|NCT04644029|Drug|Placebo to FTC/TDF|0 mg tablet administered once daily during Part 1.
45693995|NCT04644029|Drug|FTC/TDF|Each tablet contains 200 mg emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg tenofovir disoproxil fumarate or 201.22 mg tenofovir disproxil phosphate), administered orally once daily in Parts 1, 2, and 3.
45693996|NCT04644029|Drug|Placebo to ISL|0 mg tablet administered orally once monthly in Part 1.
45693997|NCT00807664|Device|Biatain Ag|Biatain Ag non adhesive ( ColoplastA/S), a polyurethane permeable backing film with an added silver complex, size 15X15. The product is CE marked
45693998|NCT00807664|Device|Biatain|A standard polyurethane foam dressing Biatain non adhesive permeable backing film, size15X15 cm. the product is CE marked
45693999|NCT04636619|Procedure|Colonic polypectomy|Cold snare resection of colorectal polyps
45694000|NCT04636619|Behavioral|Online training course|Polypectomy technique online course
45694001|NCT00843622|Drug|Low-nitrosamine smokefree tobacco product for oral use|Smokeless tobacco in paper sachets containing 1.0 or 0.5 g of the product. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke >15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
45380548|NCT00863915|Drug|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products sprinkled on one tablespoonful of applesauce
45496183|NCT05425277|Behavioral|Reciprocal Intervention Teaching (RIT)|RIT is a relatively straightforward, brief NDBI. It employs four simple strategies to target motor imitation and initiating joint attention during play: (1) contingent imitation of the child's verbal and nonverbal behavior, (2) linguistic mapping, (3) direct elicitation of object and gesture imitation following the child's interest, and (4) contingent reinforcement. It has been used at low intensities (e.g., 1-3 hours per week) over short periods of time (e.g., 10-12 weeks) to produce robust changes in pivotal social-communicative skills. RIT is easy to learn and can be implemented with fidelity by undergraduate-level therapists with limited backgrounds in ASD, as well as by caregivers and siblings.
45496184|NCT05425277|Behavioral|Daily Routines|The Routines webinar was adapted from a web-based tutorial developed by PI Stone and colleagues (Ibanez et al., 2018). The webinar covers topics such as why everyday routines are important, especially for children with ASD, specific steps for increasing children's participation in routines, and how to use strategies such as visual supports to clarify expectations, and provides numerous video examples of caregivers using different strategies. Providers are also given access to a video library of caregivers using the Daily Routines strategies with their children, as well as a workbook to use with families during treatment.
45380549|NCT01009944|Drug|Lisinopril, Atenolol|once a day for 14 weeks
45380550|NCT01010022|Drug|6% hydroxyethyl starch 130/0.4|Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
45380551|NCT01010022|Drug|6% hydroxyethyl starch 70/0.5 (Salinhes®)|Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
45380552|NCT04672746|Behavioral|Brief MI interaction via instant communication|Telephone peer counselling+referral to treatment if required+The interaction communication using brief motivational interviewing via the chatting function of instant messaging apps (e.g., WhatsApp, WeChat). The intervention will last for 6 month with a frequency of at least twice a week.
45694002|NCT00843622|Other|Non-tobacco, non-nicotine placebo product|Placebo product in paper sachets containing 1.0 or 0.5 g. Product made of cocoa bean fibers and oat fibers. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke >15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
45380553|NCT04672746|Behavioral|General health information|"Telephone peer counselling+referral to treatment if required+general health information via SMS, such as do physical exercise for at least 30 min per week will keep you healthy for 6 month with a frequency of least twice a week."
45380554|NCT00864071|Drug|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
45380555|NCT00864071|Drug|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under fasting conditions
45380556|NCT00870701|Radiation|Radiotherapy|50 grays in 25 fractions of 2 Gys or 50.4 grays in 28 fractions of 1.8 grays
45694003|NCT01957475|Device|Coloplast Test product Y|Coloplast Test product Y is a newly developed 2-piece convex ostomy appliance
45694004|NCT01957475|Device|Coloplast Test product Z|Coloplast Test product Z is a newly developed 2-piece convex ostomy appliance
45694005|NCT01940939|Device|Repetitive Transcranial Magnetic Stimulation|The MagPro X100 is connected to a Magnetic Coil which transfers the magnetic stimulation to the tissue. The original coils MC-B65 can be used with the MagPro X100.
45694006|NCT01957397|Device|Coloplast Test 1|Coloplast Test 1 is a newly developed 2-piece convex ostomy appliance
45694007|NCT01957397|Device|Coloplast Test 2|Coloplast Test 2 is a newly developed 2-piece convex ostomy appliance
45694008|NCT01957397|Device|Coloplast Test 3|Coloplast Test 3 is a newly developed 2-piece convex ostomy appliance
45694009|NCT01940705|Other|Hearing-Aid Informational Guide|Printed take-home guide on hearing aids
46055267|NCT05334498|Other|Motor dual-task gait training|Patients were instructed to walk either on treadmill or on the land. During walk; patients were instructed to perform five tasks. The patients performed tossing and catching the ball, rehanging loops on hoops, buttoning and unbuttoning the shirts, holding the cup in water without the spilling and receiving with returning the water. Each activity were performed for three minute and 15 minutes were provided for performing all the tasks
46055268|NCT05334498|Other|Cognitive dual-task gait training|Patients were instructed to walk either on treadmill or on the land. During walk; patients were instructed to perform five tasks. The patients performed sharp coloring, subtraction, counting, verbal analogical reasoning and backward spelling. Each activity were performed for three minute and 15 minutes were provided for performing all the tasks
46055269|NCT02775357|Behavioral|Measurement and communication of HIV risk|Measurement and communication of HIV risk in the context of HIV testing and counseling to inform HIV risk reduction counseling
46055270|NCT02775357|Behavioral|Standard HIV testing and counseling|Participants received HIV testing and counseling following standard Ministry of Health guidelines
45380557|NCT00870701|Other|absence of radiotherapy|absence of radiotherapy
45380558|NCT04264026|Drug|3,4-methylenedioxymethamphetamine|Bottles are labeled with a unique container number, protocol number, IMP name, lot number, sponsor name and a statement that the IMP is restricted to clinical trial use only.
45380559|NCT00864149|Drug|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
45380560|NCT00864149|Drug|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fed conditions
45380561|NCT01010100|Drug|Acarbose (Glucobay, BAYG5421)|50 mg TID
45380562|NCT01010100|Drug|Placebo|50 mg TID
45380563|NCT00870779|Drug|5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
45694010|NCT01940705|Other|Hearing-Aid DVD|Take-home DVD about hearing aids
45380564|NCT04201470|Other|Blood withdrawal|Measurement of serum neurofilaments light chain and GFAP
45380565|NCT04201470|Other|MRI|Cervical and cerebral MRI without contrast injection
45380566|NCT04201470|Other|Neurologic / neuropsychologic tests - Patients|EDSS (Expanded Disability Status Scale), NHPT (Nine Hole Peg Test), T25FW (Timed 25-Foot Walk Test), 6MWT (Six-Minute Walk Test), CSCT (Computerized version of the Symbol Digit Modalities Test)
45380567|NCT04201470|Other|Neurologic / neuropsychologic tests - Controls|NHPT, T25FW, CSCT
45380568|NCT01010178|Drug|Macrolid, Theophylline, Inhaler Corticosteroids|we have no permission to include them in detail because of privacy policy of mentioned journal for publication
45380569|NCT04196634|Other|Risk assessment|People on sick leave due to musculoskeletal conditions will be screened for potential risk factors for prolonged sickness absence. No intervention will be given.
45380570|NCT03998904|Procedure|Muscle preservation|Muscle preservation during graft preparation of hamstring graft
45380571|NCT03998904|Procedure|No muscle preservation|No muscle preservation during graft preparation of hamstring graft
45694011|NCT01940705|Behavioral|Teach-back Technique|Counseling/Educational session using the teach-back technique to review information about their hearing aids
45694012|NCT01940705|Other|Standard of Care|standard of care hearing-aid orientation as provided by clinical audiologist
46055271|NCT05335980|Device|Nu-V3|The Nu-V3 device provides a continuous flow of intermittent, low frequency electrical pulses to the ear's specific cranial nerve endings. This treatment is delivered 24 hours a day for the first 12 weeks, then is delivered two weeks on, one week off for the following 12 weeks.
45380572|NCT01010334|Other|standard of care|All patients failing to enroll in a specific therapeutic research protocol using FDA approved drugs or CTMS accepted therapies will be screened for this study. Patients will be randomized (Patient own choice) to either standard of care described in the NCCN guidelines and published as peer-reviewed phase II or III studies which show an efficacy, OR to one of the arms of the protocol they failed to enroll in, as determined by the treating physician.
45380573|NCT04643418|Drug|MPB-1734|Administered once daily in a 21-day cycle
45694013|NCT00834106|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine injection at Day 1, Month 2, and Month 6.
45694014|NCT00834106|Biological|Comparator: placebo (unspecified)|Aluminum-containing Vaccine placebo injection at Day 1, Month 2, and Month 6.
45694015|NCT01957163|Drug|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
45694016|NCT01957163|Drug|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
45694017|NCT01957163|Drug|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
45694018|NCT01957163|Drug|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
45694019|NCT00844090|Drug|methylphenidate or placebo|treat apathy to improve diabetes self care behaviors thereby improving glycemic control
45694020|NCT00844714|Drug|Rituxan|1000mg rituxan by intravenous infusion will be given on day 1 and day 15 of the study
46055272|NCT05335902|Diagnostic Test|ultrasound measurement of the optic nerve sheath diameter|ultrasound measurement of the optic nerve sheath diameter
46055273|NCT05335902|Diagnostic Test|MoCA test|MoCA test is a short bedside test for measuring cognitive disfunction
46055274|NCT02696733|Device|Ultrasound|Ultrasound-guided obturator nerve localization
46055275|NCT02696733|Drug|lidocaine 2%|local anesthetic used to block the obturator nerve
46055276|NCT02696733|Drug|0.9% Natrium Chloratum with a 2nd generation cephalosporin|
46055277|NCT02771613|Other|Multi professional in situ simulation|After the analysis of adverse effects in Morbidity Mortality reviews, we will create scenarios adapted to these events. Education of the randomized department's arm's staff will be performed by multi professional in situ simulation with these scenarios
46055278|NCT02771613|Other|Large diffusion of information|After the analysis of adverse effects in Morbidity Mortality reviews a large scale dissemination activity of information about discussions and decisions towards the staff of the randomized departments' arms will be carried out
46055279|NCT02771301|Biological|dendritic cells|Concurrent of radiotherapy and chemotherapy plus 12 cycles of dendritic cells and cytotoxic lymphocytes treatment
46055280|NCT02771067|Procedure|Fluid infusion|Fluid infusion will be performed using 6% hydroxyethyl starch. Pulse pressure variation and stroke volume will be measured before and after fluid infusion.
46055281|NCT02775123|Device|Cytosorb|A cytoadsorbent cardridge (Cytosorb) will be added to the extra-corporeal circuit (CPB).
45380574|NCT00617591|Drug|Lenalidomide|25 mg orally on days 1-21
45380575|NCT00617591|Drug|Pegylated Liposomal Doxorubicin (PLD)|40 mg/m^2 intravenously on day 1 (reduced to 30 mg/m^2 after the initial 29 patients were treated)
45380576|NCT00617591|Drug|Dexamethasone|40 mg orally on days on 1-4
45380577|NCT00865865|Procedure|Computer aided total knee arthroplasty|Use of computer aided surgery to balance soft tissue tension in total knee arthroplasty
45380578|NCT00865865|Procedure|Conventional total knee arthroplasty|Conventional method of total knee arthroplasty
45380579|NCT00864305|Drug|Gabapentin 400 mg capsules|A: Experimental Subjects received Purepac formulated products under fed conditions
45380580|NCT00864305|Drug|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
45380581|NCT00864305|Drug|Gabapentin 400 mg capsules, single dose|C: Experimental Subjects received Purepac formulated products under fasting conditions
45380582|NCT00870935|Procedure|Balloon catheter|Hysterosalpingography is performed using intrauterine balloon catheter
45380583|NCT00870935|Procedure|Cervical vacuum cup|Hysterosalpingography is performed using cervical vacuum cup
45380584|NCT00510276|Drug|Atomoxetine hydrochloride|20-50 mg, twice a day per by mouth for 12 weeks, followed by up to an additional 12 weeks
45380585|NCT00510276|Drug|Placebo|twice a day, by mouth for 12 weeks
45380586|NCT00871091|Procedure|orthodontic treatment with customized archwires|customized arch wires depending on the amount of needed tooth movement
46055282|NCT02770989|Procedure|Vimecon Laser CAI percutaneous cardiac ablation|The Vimecon Laser CAI catheter is entered through the femoral vein to access the pulmonary vein (PV) area in the heart in order to ablate the cardiac wall near the PV to create scar tissue and to isolate the PV in order to treat atrial fibrillation.
45380587|NCT00871091|Procedure|orthodontic treatment with prefabricated archwires|prefabricated archwires depending of the needed movement of the teeth
45380588|NCT00871091|Procedure|orthodontic tx w/ conventional archwires+manual adjustments|conventional archwires modified by manual adjustment, depending of needed correction
45380589|NCT00864617|Drug|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under non-fasting conditions
45380590|NCT00864617|Drug|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under non-fasting conditions
46055283|NCT02775201|Procedure|Plantaris release under ultrasound guidance|In patients diagnosed with Achilles tendinopathy the plantaris tendon will be released using a small incision at the medial ankle under ultrasound guidance by a consultant radiologist
45380591|NCT00865943|Drug|Citalopram HBr eq. 10 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
45380592|NCT00865943|Drug|CELEXATM 10 mg tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc. marketed products under fasting conditions
45380593|NCT00866021|Drug|Lopinavir/ritonavir|NRTI sparing-regimen
45380594|NCT00866021|Drug|Lopinavir/ritonavir with two nucleoside analogs|LPV/r plus 2NRTIs + PEG-INF + RBV
45380595|NCT00866099|Other|Educational Dementia training|"Tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.~Tailoring of the education programme is carried out in a three step process: 1) an educational needs analysis is carried our using a standard checklist to identify aspects of dementia care which the practice perceives as problematic for them; 2) a prescription for education is then written to address shortcomings; 3) the best forms of learning are then identified."
45380596|NCT03859193|Behavioral|Nutritional Video|A 10 - 15 minute video
46055284|NCT02775201|Procedure|Plantaris excision surgically|In patients diagnosed with Achilles tendinopathy the plantaris tendon will be excised in theatre by a consultant orthopaedic surgeon
46055285|NCT01026974|Biological|rMenB|
46055286|NCT01026974|Biological|rMenB+OMV NZ|
46055287|NCT02770911|Procedure|"without Dog Ear group"|a modified double-stapling technique with eliminating the dogears in laparoscopic anterior resection
46055288|NCT02770911|Procedure|"with Dog Ear group"|a traditional double-stapling technique without eliminating the dogears in laparoscopic anterior resection
46055289|NCT04225299|Drug|TOOKAD®|TOOKAD® -VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
46055290|NCT02775045|Other|Observation Period|8 week observational period
46055291|NCT02774967|Procedure|root coverage|Root coverage with acellular dermal matrix using two techniques: advanced positional flap ou tunneling,
46055292|NCT00897390|Drug|Saxagliptin|Tablet, Oral, 2.5 mg, Once Daily, 1 week
46055293|NCT00897390|Drug|Metformin IR (glucophage)|Tablets, Oral, 1000 mg, Once Daily, 1 week
45380597|NCT00864695|Other|Supportive care|protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject's health or function. In general, supportive care interventions are not intended to cure a disease.
45496185|NCT03252145|Device|PhysioTouch|The PhysioTouch is a hand-held device that administers negative pressure under the treatment head, and gently pulls the underlying skin and subcutaneous tissue into the suction cup. This suction produces a stretch to the skin and in the subcutaneous tissue space. This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels, and mobilizes the superficial fascia.
45380598|NCT00871247|Drug|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fed conditions
45694021|NCT01956773|Other|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
45380599|NCT00871247|Drug|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fed conditions
45380600|NCT01010412|Device|Ultrasound (Sonosite Titan T-shaped ultrasound probe)|Ultrasonography will allow direct visualization of nerves. As local anesthetic is injected, it can be seen surrounding the nerve.
45380601|NCT01010412|Device|Electrical Nerve Stimulation (Stimuplex (B Braun) needle)|
45694022|NCT00834652|Drug|Sertraline|50 mg once a day, which may be increased to 200 mg once a day
45694023|NCT00834652|Drug|Metformin|Starting dose of 500 mg daily and increasing by 500 mg every 2 weeks to a total of 2,000 mg daily
46055294|NCT00897390|Drug|Saxagliptin + Metformin IR (FDC)|Tablet, Oral, Saxagliptin 2.5 mg + metformin IR 1000 mg, Once Daily, 1 Week
46055295|NCT01034462|Drug|Levomilnacipran ER|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing. Study drug is to be given orally, in capsule form, once daily, for 8 weeks
45380602|NCT02543879|Drug|FT-1101|FT-1101 will be supplied as 5 mg, 20 mg or 100 mg capsules and will be administered per the protocol defined frequency and dose level
46055296|NCT01034462|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
46055297|NCT04176627|Device|Lung ultrasound|One-time lung ultrasound study completed on peritoneal dialysis patients at monthly clinic visit
46055298|NCT01033448|Drug|COPEGUS|COPEGUS 800 mg or 1000-1200 mg po for 24 weeks
45380603|NCT02543879|Drug|Azacitidine|Azacitidine will be administered per site's standard of care
45380604|NCT04137120|Drug|Aflibercept (BAY86-5321, Eylea)|Intravitreal injection of aflibercept as scheduled by treating physician
45380605|NCT00616655|Drug|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 1.5 mg
45380606|NCT00616655|Drug|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 0.9 mg
45380607|NCT00616655|Drug|Placebo|Placebo total daily dose 0.9 mg
45380608|NCT00510198|Device|Cardiac Compass with OptiVol Fluid Status Monitoring|Review of Cardiac Compass with OptiVol Fluid Status Monitoring
45380609|NCT00510198|Device|Standard of Care alone (clinical assessment)|Clinical assessment utilizing standard of care, alone.
45694024|NCT00834808|Drug|Tramadol HCl|One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.
45694025|NCT00850096|Other|Placebo for Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two placebo sprays administered three times daily just prior to meals for 6 weeks.
45380610|NCT00864773|Procedure|intravitreal injection with anterior paracentesis|0.1cc Aqueous humor samples were taken each time an intravitreal injection of bevacizumab (2.5 mg in 0.1 ml)
45380611|NCT01010490|Procedure|Torsional ultrasound (INFINITI, Alcon, USA)|Comparison of inta-operative efficacy and safety
45380612|NCT01010490|Procedure|Longitudinal U/S (Infiniti system, Alcon, USA)|comparison of efficacy and safety
45380613|NCT01010490|Procedure|Longitudinal U/S (LEGACY 20000, Alcon, USA)|Interrupted energy modality
45496186|NCT03252145|Other|Manual Lymph Drainage (MLD)|MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid, resulting in reductions in interstitial fluid.
45380614|NCT00871559|Drug|REGN421(SAR153192)|
45380615|NCT04127604|Behavioral|Integrated Treatment Adherence Program for Veterans (ITAP-VA)|Psychosocial support and treatment to improve treatment adherence, symptoms, and functioning.
45380616|NCT04127604|Behavioral|Safety Assessment and Follow-up Evaluation (SAFE)|Measurement-based care assessment and evaluation.
45380617|NCT05227859|Procedure|Piezocision|After anesthesia, three vertical incisions will be made (3-mm depth and 8-10 mm length) mesial and distal the upper canine as well as at an equal distance from the upper canine and 2nd premolar. The surgical procedures will be repeated after six weeks (only the mesial and distal canine incisions will be done)
45380618|NCT05227859|Device|Low-level laser|GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\point) will be applied around the upper canine in 10 sites from buccal and palatal. The middle of the extraction site will be also irradiated in 4 sites (2 buccally and 2 palatally). The LLLT will be applied 5 times in the first month of canine retraction, then every two weeks until class I canine relationship will be achieved.
45380619|NCT05227859|Device|Conventional treatment|The upper canine destalization will be done using NiTi springs. The force level will be controlled every 2 weeks. Retraction will be stopped when a class I canine relationship in both sides.
45380620|NCT05227781|Dietary Supplement|L-Citrulline|8 weeks of L-Citrulline supplementation (10 grams/day)
45380621|NCT05227781|Dietary Supplement|Placebo|8 weeks of Placebo (maltodextrin; 10 grams/day)
45496187|NCT05124002|Drug|Recombinant Human Adenovirus Type 5|H101 will be intratumorally injected 3 days before HAIC. Dosage of H101: 1 vial (5.0 × 10^11 vp) if the maximum diameters of lesion ≤ 5 cm, 2 vials (1.0 × 10^12 vp) if the maximum diameters of lesion ≤ 10 cm, 3 vials (1.5 × 10^12 vp) if the maximum diameters of lesion is > 10 cm.
45496188|NCT05124002|Drug|HAIC of FOLFOX|Oxaliplatin 50 mg + 5-FU 1.5 g + leucovorin calcium. The infusion will be continued for 2-3 days according to patients' tolerance and tumor conditions. The standard treatment for HAIC consists of 4-6 cycles, with the second cycle being 3 weeks after the end of the first HAIC cycle and the subsequent cycles being 4 weeks after the end of the previous HAIC.
45496189|NCT01661400|Drug|Metronomic Cyclophosphamide|
45496190|NCT01661400|Drug|Thalidomide|
45496191|NCT05158166|Drug|DaxibotulinumtoxinA|This is a long-acting alternative to traditional Botox A treatment.
45496192|NCT03676218|Other|Elderly cancer patients|No intervention: consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
45496193|NCT02959814|Other|QFR (observational)|QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
45694026|NCT00850096|Drug|Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two (50 IU) or four (100 IU) sprays of Nasulin (intranasal insulin spray 1%) administered three times daily just prior to meals for 6 weeks.
46055299|NCT01033448|Drug|peginterferon alfa-2a [Pegasys]|PEGASYS 180 micrograms sc once weekly for 24 weeks
45694027|NCT01939223|Drug|Regorafenib (Stivarga, BAY73-4506)|Four tablets of 40mg taken orally daily in the morning, dose of 160 mg for 21 days of treatment followed by 7 days without treatment
46055300|NCT02843724|Other|Naturopathic Care|Naturopathic diabetes care will be selected from a pre-approved menu. Participants' other health concerns will be addressed at naturopathic doctors' discretion
46055301|NCT02843724|Other|Usual (Conventional) Care|2016 Canadian Diabetes Clinical Practice Guidelines (self-management, blood-glucose-lowering, vascular protection, pharmacotherapy) will be implemented
46055302|NCT02774655|Device|Pai APP|prescribed 100 PAI weekly
46055303|NCT02774655|Device|FitBit APP|prescribed 10000 steps daily
46055304|NCT04754607|Other|Low-Level Laser Therapy|Eight target points (superior, mediolateral, inferior border of the right and left thyroid lobes, right and left sides of the isthmus) will be marked with a surgical pen by determining the thyroid borders on the skin by thyroid ultrasonography by the specialist physician. Low-level laser (28.57 J / cm2) fixed applications will be made on the thyroid gland, approximately 1 cm from each other. In practice, the patient's neck will be maintained in the extension position. Each application will last 20 seconds and the radiant energy will be 2 J, the tip of the laser will be kept in contact with the skin and upright. Duration of treatment is 6 sessions 2 days a week. The cumulative dose will be 96 J.
46055305|NCT02873390|Biological|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
46055306|NCT02770833|Other|Fish and carbohydrats with low or high GI|
46055307|NCT02770833|Other|Veal and carbohydrats with low or high GI|
45380622|NCT05227469|Behavioral|myofunctional therapy|In order to confirm that the exercises are done for a sufficient time and are done correctly, the researcher will take video recordings from the participants and examine these recordings every other day. Respondents will be contacted when errors are detected.
45380623|NCT00516048|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
45380624|NCT00866255|Device|endotracheal tube pressure measurement probe|The endotracheal tube pressure measurement probe is inserted into the endotracheal tube prior to intubation for measurement of tracheal pressure at the tip of the endotracheal tube.
46055308|NCT05335824|Other|The platelet-rich plasma (PRP)|"Twenty ml of venous blood was drawn from each patient with the use of PRP tubes that contain anticoagulant citrate dextrose. The double-spin technique was used to prepare the PRP. The injection areas were anesthetized with lidocaine 2% with epinephrine 1/80000 and left for 10 minutes. 15 units (0. 15 mL) of PRP were injected interaligamentlly in the middle, distobuccal, and distopalatal areas of the distal surface of the upper canines (5 units in each area) together with submucosal injections buccally and palatally (100 units and 50 units~, respectively)."
45380625|NCT04039997|Device|CPRMeter|teaching resuscitation with application of cpr feedback device
45380626|NCT04039997|Other|Manual chest compression|Manual chest compression
45496194|NCT03666624|Behavioral|Personalized care network|The Personalized care network intervention includes exercise training for participant with dementia and behavioral management training for addressing challenges.
45380627|NCT04040855|Other|Medication review|Multi-professional medication review
45380628|NCT00866411|Procedure|cranial electrotherapy stimulation (CES) with Alpha-Stim|three weeks of the cranial electrotherapy stimulation (CES) treatment (15 sessions of 60 minute treatments)
45380629|NCT00866411|Procedure|placebo|three weeks of placebo treatment via a double-blinded procedure so that neither the Soldier nor the study investigators will know whether the Soldier is receiving the actual treatment or placebo
45380630|NCT05227625|Behavioral|body dissatisfaction management group|"Our group is composed of 10 weekly session of 2 hours led by a psychologist trained in the management of ED and ACT therapy.~Each group will be composed of 5 to 10 people. First of all, the group will lead the participants to better know and understand the impact of BD on the symptomatology of ED by teaching current scientific knowledge on the subject. In a second step, the group will guide the patients in the acquisition of psychological skills to deal with events related to BD and to engage in actions towards the values that give meaning to their existence."
45496195|NCT03368807|Device|Continuous Glucose Monitoring|Commercially available
45694028|NCT01939223|Drug|Placebo|Four tablets taken in the morning orally daily for 21 days of treatment followed by 7 days without treatment
45694029|NCT00834886|Dietary Supplement|Melatonin|Capsules, 3 mg, once every night
45694030|NCT00834886|Other|Bright light|Bright light therapy 10.000 lux by Miljølys AS
45694031|NCT00834886|Other|Placebo red light|Red light 400 lux as placebo light
45694032|NCT00834886|Other|Placebo capsule|Capsules containing 3 mng rice flour, once every night
45694033|NCT05125289|Other|Graston technique group|Moist hot pack (10 minutes) Isometric quadriceps exercises (10 repetitions) Straight leg raise (10 repetitions) Graston technique steps 6 long strokes by the GT1 instrument on the hamstring muscle longitudinally. The Graston technique duration will be 5 minutes
45380631|NCT05227625|Behavioral|Relaxation Group|Participants will be included in a standardized relaxation program consisting of a weekly 2 hour session for 10 weeks. The group will be led by a psychologist trained in relaxation and in particular in abdominal and muscular relaxation techniques. Each group will be composed of 5 to 10 people. Initially, the therapy will lead the participants to recognize the signs of anxiety and to understand the physiological mechanisms involved. Classic techniques of anxiety management will then be introduced (cardiac coherence, abdominal and muscular relaxation, Jacobson technique, Schultz autogenic training). These techniques will be tested in session. Participants will be encouraged to practice these techniques at home.
45380632|NCT00871793|Other|Occupational therapy|Participants in this arm will receive six sessions of occupational therapy in a 5 week period.
45380633|NCT00871949|Drug|PNU-100480|100 mg oral suspension given once
45380634|NCT00871949|Drug|PNU-100480|300 mg oral suspension given once
45380635|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
45380636|NCT00871949|Drug|PNU-100480|300 mg oral suspension given once
45496196|NCT03368807|Drug|Insulin Lispro|As prescribed.
45496197|NCT05692128|Other|Hematological and chemistry tests|Laboratory tests
45496198|NCT05225129|Other|blood flow restriction exercise|blood flow restricted exercise, resistance training will be applied, corresponding to 30% of 1 maximum repetition for 8 weeks, 2 days in a week
45496199|NCT04013971|Other|Game without VR|During the AGRF biofeedback game without virtual reality (VR) participants will walk on a split-belt treadmill with a projector or screen display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game without VR for 4 minutes.
45694034|NCT05125289|Other|Active release technique group|"Moist hot pack (10 minutes)~Isometric quadriceps exercises (10 repetitions)~Straight leg raise (10 repetitions)~ART steps:~Subject lies on the plinth in prone or in side lying position with the dominant side facing upwards.~Gentle tension is applied to the hamstring muscle along the entire length while stretching the leg in prone lying or side lying positions, depending on the level of pain and tightness of muscle (5 repetitions at 5 seconds interval).~Gentle tension is also applied at the origin and insertion of the hamstring muscle until the patient feels full release."
45380637|NCT00871949|Drug|PNU-100480|35 mg oral suspension given once
45380638|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
45380639|NCT00871949|Drug|PNU-100480|100 mg oral suspension given once
45754003|NCT03927482|Behavioral|Check Your Drinking|Check Your Drinking is an online alcohol assessment that provides normative feedback on the user's drinking habits relative to his/her peers. Alcohol interventions that provide normative feedback are rated by the NIAAA Alcohol Intervention Matrix as effective and low cost, and with few administrative or structural barriers to implementation thus making it suitable for community colleges.
45754004|NCT04022408|Diagnostic Test|Liquid based cytology|Liquid based cytology
45380640|NCT00871949|Drug|PNU-100480|35 mg oral suspension given once
45380641|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
45754005|NCT04022408|Diagnostic Test|Conventional cytology|Conventional cytology
45380642|NCT00871949|Drug|PNU-100480|1000 mg oral suspension given once
45380643|NCT00871949|Drug|PNU-100480|1500 mg oral suspension given once
45380644|NCT00871949|Drug|PNU-100480|Fed conditions, 600 mg oral suspension given once
45380645|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
45380646|NCT00871949|Drug|PNU-100480|1500 mg oral suspension given once
46055309|NCT05335824|Other|The injectable platelet-rich fibrin (I-PRF) group|"Twenty ml of venous blood was drawn from each patient in this experimental group.~I-PRF was prepared with the use of 20 ml of blood drawn from the patient in dry sterile tubes without anticoagulant (quickly before coagulation starts) by following the centrifugation protocol requires one cycle only (700 RPM for 3 minutes) Injection procedures, sites, and time were similar to the PRP group."
46055310|NCT05335824|Device|The control group|NiTi closed-coil springs (American Orthodontics, Sheboygan, WI) were used to impose 150 g force from the first molar band hook to the bracket of canine on each side on 0.019*0.025-in SS archwire Patients' follow-up appointments were two weeks intervals; at each visit, the force produced by the coil was checked and readjusted when needed in order to keep it at 150-g level and the appliances were examined for any deformation or change in the position because of chewing. Canine retraction continued until achieving Class I canine relationship.
45380647|NCT00871949|Drug|PNU-100480|600 mg oral suspension given once
45380648|NCT00871949|Drug|PNU-100480|Fed conditions, 600 mg oral suspension given once
45380649|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
45380650|NCT00871949|Drug|PNU-100480|1000 mg oral suspension given once
45380651|NCT00871949|Drug|PNU-100480|600 mg oral suspension given once
45380652|NCT00871949|Drug|PNU-100480|Fed conditions, 600 mg oral suspension given once
45380653|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
45380654|NCT00865007|Drug|Monotherapy (Lopinavir/ritonavir)|NRTI sparing
45380655|NCT00865007|Drug|Monotherapy (Lopinavir/ritonavir) + ABC/3TC|NRTI sparing regimen
45380656|NCT00866489|Procedure|remote preconditioning|Remote ischemic preconditioning consist of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff is deflated.
45380657|NCT00872105|Procedure|Non-operative Treatment|Standard protocol for conservative treatment will consist of the implementation of a sling, for clavicular support and patient comfort. Pendulum or gentle Range of Motion (ROM) shoulder exercises may be implemented at any time as dictated by the attending surgeon.
45380658|NCT00872105|Procedure|Operative Treatment|"The operating surgeon will determine the positioning of the patient for surgery. ORIF of the distal clavicle fracture will be carried out as follows:~Anatomic reduction of the fracture Definitive fixation with a contoured clavicle plate and screws; a AO hook plate; a 3.5 LCDC, reconstruction, or compression plate is acceptable; a 1/3 tubular plate is not acceptable Use of bone graft is optional (iliac crest bone autograft)"
45380659|NCT00876083|Drug|Ultravist (Iopromide, BAY86-4877)|Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.
46055311|NCT02873234|Drug|Traditional Chinese Medicine|Participants are treated with TCM twice per day according to syndrome differentiation. For example, the syndrome of one participant with depression is kidney deficiency. He will take Zishui Qinggan Yin twice per day before the breakfast and dinner.
45380660|NCT05225909|Device|Endoscopic retrograde Cholangio-pancreatography (ERCP) with aScope (Single use duodenoscope|ERCP Procedure will be done using aScope. We will assess the performance of the aScope.
45380661|NCT00876161|Drug|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 5 mg, 10 mg and 20 mg.
45380662|NCT00876161|Drug|Lactose|
45380663|NCT00872417|Drug|first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT)|use the generic regimens: 3TC+NVP+D4T or 3TC+NVP+AZT to initiate the ARV therapy, after 6 months, half of the group 3TC+NVP+D4T patients switch to the the treatment of 3TC+NVP+AZT
45380664|NCT00872417|Drug|second line ARV therapy (3TC+TDF+LPV/RTV)|Use 3TC+TDF+LPV/RTV to treat those drug resistance patients, to explore the efficiency and safety of the second line ARV available in China
45496200|NCT04013971|Other|Game with VR|During the AGRF biofeedback game with virtual reality (VR) participants will walk on a split-belt treadmill with a head-mounted VR display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game with VR for 4 minutes.
45380665|NCT00872573|Device|C-Stem™ AMT Femoral Component (standard and high off-set variants)|A polished triple tapered cemented femoral component for use in total hip replacement
45496201|NCT04013971|Other|Traditional Biofeedback Interface|"For the traditional non-game biofeedback, the visual display comprises a horizontal line graph with a moveable cursor that represents the current measured value of antero-posterior ground reaction force for the targeted leg. The auditory feedback comprises an audible beep produced every time the cursor entered the target range. Participants will be exposed to the traditional biofeedback interface for 4 minutes."
46055312|NCT02873234|Drug|Antidepressants|Participants are treated with different antidepressants. The dosage, frequency and duration are determined according to guideline.
46055313|NCT02774811|Drug|Prostaglandin analogue|Topical therapy
46055314|NCT02774811|Procedure|Selective laser trabeculoplasy|Laser therapy into drainage angle
46055315|NCT02774811|Device|laser|
46055316|NCT00817050|Drug|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
46055317|NCT00817050|Drug|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
45380666|NCT00876317|Drug|Etoricoxib 60 mg|Etoricoxib 60 mg per oz per day for 14 days
45496202|NCT05179213|Drug|Azacitidine|75 mg/m2 subcutaneously on days 1-7
46055318|NCT04224831|Combination Product|Source of growth factors: autologous platelet-rich plasma (aPRP) + repetitive electromagnetic stimulation for iontophoresis|"Autologous platelet rich plasma is containing many types of growth factors (GFs) such as epithelial growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor (TGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), and insulin-like growth factor (IGF).~Repetitive high frequency electromagnetic stimulation (rEMS) creates a stimulated focus in the tissue by increasing blood flow and platelets at the capillary level. Electromagnetic stimulation along with growth factors has shown synergetic effects toward enhanced epithelial integrity and neural functions. With the addition of possible iontophoresis effects in the rEMS, the passage of the various active molecules can be augmented at the tissue level thereby increasing the widespread effect of the GFs in the damaged choroidal and outer retinal microenvironment."
46055319|NCT00816972|Drug|Desloratadine 2.5 mg|Desloratadine 2.5 mg BID
46055320|NCT00816972|Drug|Oxybutynin 2.5 mg|Oxybutynin 2.5 mg BID
46055321|NCT00816972|Drug|Placebo for Desloratadine 2.5 mg|Placebo BID
46055322|NCT00816972|Drug|Placebo for Oxybutynin 2.5 mg|Placebo BID
45380667|NCT00876317|Drug|Etoricoxib 90 mg|Etoricoxib 90 mg per oz for 14 days
45380668|NCT00866645|Drug|Intramuscular Haloperidol|1ml：5mg/ampoul the recommended dose is 10 mg per day administered. Doses of 10 mg may be administered 5mg bid with an interval longer than 4 hours for 3 days.
45380669|NCT00866645|Drug|Intramuscular Levosulpiride|2ml：50mg/ampoul the recommended dose is 100 mg per day administered. Doses of 100 mg may be administered 50mg bid with an interval longer than 4 hours for 3 days.
45380670|NCT00872651|Drug|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5%
45380671|NCT00872651|Drug|Latanoprost 0.005% / Timolol 0.5%|Latanoprost 0.005% / Timolol 0.5%
45380672|NCT00872807|Behavioral|Lifestyle counseling in groups|"The activity school in Finnmark. Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality.~They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months."
45380673|NCT00872807|Behavioral|Individual intervention|Conventional lifestyle counseling individually by single health professionals, both in hospital and in municipality.
45380674|NCT00876473|Procedure|CPAP system|"Evaluating the effects of different CPAP systems on respiratory mechanics, respiratory effort and gas-exchange~CPAP systems:~Continuous high-flow CPAP with fixed value PEEP valve~Continuous high-flow CPAP with Boussignac valve~Demand flow CPAP supplied by ventilator"
45496203|NCT05179213|Drug|Chidamide|20mg orally per week continuously
45496204|NCT03338855|Drug|Dapagliflozin|"The study consist of 5 weeks treatment period 1, 6-8 weeks wash-out period and 5 weeks treatment period 2.~The patient will be administered dapagliflozin 10 mg during Period 1 or Period 2."
45496205|NCT05499624|Device|MicroTrend System|The hands-free device measures oral mucosal carbon dioxide pressure (POMCO2) and functions outside of the body and does not require a surgical procedure or any significant deviation from standard practice to operate.
46055323|NCT02770677|Other|Modified Dantien Salee Yoga Training Program|The intervention aims to improve pulmonary function and functional fitness.
46055324|NCT02690688|Device|determination of dynamic preload variables|
46055325|NCT02774577|Other|whole body vibration training in vibrating platform in young|
46055326|NCT02774577|Other|whole body vibration training in vibrating platform in elderly|
46055327|NCT02841150|Drug|IMBRUVICA (Treatment A)|IMBRUVICA (reference treatment), 4*140 milligram (mg), capsules.
45694035|NCT05125289|Other|Proprioceptive Neuromuscular Facilitation stretching group|"Moist hot pack (10 minutes)~Isometric quadriceps exercises (10 repetitions)~Straight leg raise (10 repetitions)~PNF technique steps:~The subject is in supine position with his non-dominant leg strapped down the table while the dominant leg rests on the therapist right shoulder.~The therapist stretches the hamstring muscle until the subject first reports a mild stretch sensation; held for 7 sec by passively flexing the hip with knee fully extended, allowing no hip rotation.~Next, the subject isometrically contracts the hamstring muscle for 3 sec and then relax for 5 sec.~This sequence is repeated 5 times at a 20 second interval."
45694036|NCT00835198|Drug|Dapsone; Tretinoin|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
45694037|NCT00835198|Drug|Tretinoin|Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
45694038|NCT04636073|Device|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
45380675|NCT00876551|Procedure|Endoscopic vacuum assisted closure|"Endoscopic debridement of wound using a regular biopsy forceps.~Introduction via the nose and oral exteriorization of a silicone duodenal tube (Freka Tube, 15 Ch, Fresenius Kabi, Bad Homburg v.d. H. Germany)~Fixation of a polyurethane foam (sponge, pore size 400-600 µm, KCI, Wiesbaden Germany) to the tip of the duodenal tube with a mersilene suture (0,35mm, Johnson & Johnson, St-Stevens-Woluwe, Belgium).~Trimming of the sponge to the specific wound size.~Endoscopic placement of the sponge in the intrathoracic leak with a grasping forceps (Olympus, Germany)~Application of continuous suction of 125mmHg using vacuum pump (KCI, Wiesbaden Germany).~Sponge exchange twice a week until wound grounds are clean and closed"
45380676|NCT00872963|Biological|RTS,S/AS01E|0.5MLS of RTS,S/AS01E at 0,1,2 monthly schedule 0.5mls Rabies vaccine at 0,1,2 monthly schedule
45694039|NCT00835510|Drug|Butenafine cream 1% manufactured by Taro|Treatment applied to affected area twice daily for 7 days
45694040|NCT00835510|Drug|Lotrimin Ultra (butenafine) 1%|Treatment applied to affected area twice daily for 7 days
45694041|NCT00835510|Drug|Butenafine Vehicle manufactured by Taro|Treatment applied to affected area twice daily for 7 days
46055328|NCT02841150|Drug|Ibrutinib (Treatment B)|Ibrutinib (test treatment), 1*560 mg, tablet.
46055329|NCT04225455|Device|Glucose monitoring|"To compare the glucose monitoring CGMS Dexcom G6® with their usual self-glucose monitoring in pilots by way of assessing times achieved in safe Green flying range, in Amber flying range and in Red flying range as defined by the ARA.MED.330 diabetes protocol.~[Green: 5-15 mmol/L; Amber: 4 to <5mmol/L and >15 to 20mmol/L; Red: <4mmol/L and >20mmol/L]"
46055330|NCT02774733|Device|spirometer;Intraocular pressure;Color doppler imaging|
46055331|NCT02774499|Drug|Methadone|0.3mg/kg of methadone given preoperatively (to maximum of 30mg)
46055332|NCT02774499|Drug|Placebo|equivalent volume (5mL) of syrup given preoperatively
46055333|NCT02770443|Drug|withdrawal|withdrawal of beta blocker and ACE inhibitors
46055334|NCT02770443|Drug|standard of CARE|STANDARD OF CARE, NO WITHDRAWAL OF MEDICAL THERAPY
46055335|NCT02770053|Procedure|Foraminal enlargement|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
46055336|NCT02770209|Biological|biomimetic cartilage matrix + autologous chondrocytes|
46055337|NCT02770209|Procedure|arthroscopic debridement|
46055338|NCT02770209|Procedure|microfracture surgery|
46055339|NCT02774109|Dietary Supplement|Fish oil|Five 1000mg fish oil soft capsules per day (each capsule containing 350mg EPA and 250mg DHA) for 8 weeks
46055340|NCT02774109|Dietary Supplement|Placebo|Five 1000mg sunflower oil soft capsules per day for 8 weeks
46055341|NCT02774109|Procedure|Hotpacking|Hotpacking 15min on low back, three times a week for 8 weeks
46055342|NCT02774109|Procedure|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) 15min on low back, three times a week for 8 weeks
46055343|NCT02774031|Device|Aisys with Et control|
46055344|NCT02774031|Device|Aisys conventional|
46055345|NCT02774031|Device|Flow-i with ACG|
46055346|NCT02774031|Device|Flow-i conventional|
46055347|NCT04224909|Diagnostic Test|Video Head Impulse Test|Diagnosis of dysfunction of the semicircular canals using the vHIT
45380677|NCT05193539|Behavioral|Augmented reality and virtual reality rehabilitation|"This group underwent augmented reality and virtual reality rehabilitation with 4 different systems.~The RAPAEL Smart Glove® is a wearable sensory system that contains a single 9-axis movement and position sensor with 3 acceleration channels, 3 angular rate channels, and 3 magnetic field channels that measures wrist movements, and 5 bending sensors that measure finger movements. The RAPAEL Smart Board® is a rehabilitation system used to improve arm function by practicing gravity-compensated movements. The RehabMaster® is a game-based Kinect sensor AR rehabilitation system which uses a 3D camera to digitize patient movements and quickly analyze their range of motion, speed, motion angle, and movement cycles. rehabilitation exercise using games to encourage active arm and trunk movements and promote successful rehabilitation. The COG-Trainer® is a VR system that uses a training device synchronized with the screen through simulation."
45496206|NCT03367793|Device|Spectacles - Clinically Derived|Prescription spectacle lenses determined by clinically derived techniques. The specific techniques employed for each subject are left up to the masked examiner and are dependent upon the information needed for refraction determination, as well as ability of the participant to cooperate for testing. Measures may include autorefraction obtained pre or post dilation, retinoscopy obtained pre or post dilation, and subjective refraction obtained pre or post dilation.
45496207|NCT03367793|Device|Spectacles - Metric Technique #1 Derived|Prescription spectacle lenses determined by metric-derived objective technique #1. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Visual Strehl ratio in the spatial domain (VSX). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #1 Derived.
45496208|NCT03367793|Device|Spectacles - Metric Technique #2 Derived|Prescription spectacle lenses determined by metric-derived objective technique #2. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Pupil Fraction tessellated (PFSt). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #2 Derived.
45496209|NCT01209234|Behavioral|Standard-of-Care Education|Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home.
46055348|NCT02769663|Behavioral|questionnaires and neuropsychological assessments|
46055349|NCT02769819|Device|Flexible fiberscope|"Characteristics of patients will be assessed before induction of general anesthesia~Glottic visualization will be evaluated by direct laryngoscopy.~The endotracheal tube will be loaded onto the scope after silicon spray lubrication~Intubation will be performed with the flexible fiberscope with the patient in supine position with head and neck in neutral position~With the tip of the fiberscope in satisfactory position, the endotracheal tube will be advanced into the trachea. The scope will then be removed.~Accurate positioning of the endotracheal tube will be confirmed by capnography and lung auscultation."
46055350|NCT02774187|Drug|Sorafenib|administration of Sorafenib
46055351|NCT02774187|Procedure|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
46055352|NCT02774187|Drug|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
46055353|NCT02769897|Behavioral|Physical exercise|The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
46055354|NCT02773797|Drug|IN-DEX 1.0 mcg/kg, intranasal saline|
46055355|NCT02773797|Drug|IN-DEX 1.5 mcg/kg, intranasal saline|
46055356|NCT02773797|Drug|Placebo - Saline|
45380678|NCT05193539|Behavioral|Conventional occupational therapy|The group underwent standard ocupational therapy, such as range of motion and strengthening exercises for the affected upper extremity, table-top activities, and training for activities of daily living.
45380679|NCT00876629|Device|Pneumatic Driver|"Ten healthy volunteers will undergo MR Elastography using a pneumatic driver connected to a commercially available speaker and the stiffness of the left kidney will be measured.~The examination will be repeated on the same volunteers at least one month later and the same stiffness measurements will be performed."
45380680|NCT00617357|Device|LTM (Strattice Reconstructive Tissue Matrix)|Surgical mesh
45380681|NCT05168501|Other|Rebreathing procedure|Paired Duffin's rebreathing procedures performed two different isoxic end tidal PO2 levels (i.e., hyperoxic and hypoxic conditions) will be performed on Day 1 at 0, 2, 4, 6, and 24 hours.
45380682|NCT04039685|Other|Effects of an eight weeks aerobic exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks aerobic exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
45380683|NCT04039685|Other|Effects of an eight weeks resistance exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks resistance exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
45380684|NCT04039685|Other|Effects of an eight weeks combined (aerobic+resistance) exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks combined (aerobic+resistance) exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
45380685|NCT00876707|Device|Tecnis implant|Implant of diffractive multifocal IOL Tecnis
46055357|NCT02769741|Other|Cashews followed by Control|Participants will receive the active diet with cashew nuts as a daily snack during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the control diet at the same calorie level, but with a control snack instead of cashew nuts during Test Period II.
46055358|NCT02769741|Other|Control followed by Cashews|Participants will receive a controlled diet without cashew nuts during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the active diet at the same calorie level, but with cashew nuts as a daily snack during Test Period II.
46055359|NCT02769429|Device|Ultrasound-guided CISB|This group will receive ultrasound-guided CISB with the catheter placed on the upper trunk of the brachial plexus
45496210|NCT01209234|Drug|MRSA Decolonization|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
45496211|NCT05178745|Drug|Fluorouracil|Pharmaceutical Form: solution for injection Route of Administration: intravenous (IV), intravenous or intra-arterial infusion
45380686|NCT00876707|Device|ReSTOR implant|Implant of multifocal IOL ReSTOR
45380687|NCT00876707|Device|ReZoom implant|Implant of multifocal IOL ReZoom
45380688|NCT00876785|Other|Rye bread breakfast|A randomised, within-subject comparison design was used. Appetite (hunger, satiety and desire to eat) was rated regularly from just before breakfast at 08:00 until 16:00. Amount, type and timing of food and drink intake during the study period were standardised.
45380689|NCT00876785|Other|wheat bread based breakfast|Reference wheat bread breakfast
45380690|NCT03829475|Drug|Bezlotoxumab|This is a a fully human monoclonal antibody that binds to C. difficile toxin B, and is indicated to prevent recurrence of CDI in adults at risk for recurrent CDI (rCDI).
45380691|NCT03829475|Drug|Placebo|placebo is an infusion of normal saline.
45380692|NCT03829475|Drug|Fecal Microbiota Transplantation|FMT is an infusion of prescreened donor stool that will be administered via colonoscopy
45380693|NCT04040543|Dietary Supplement|lipid-based nutrient supplement containing adherence markers|The supplement will be provided once daily for 10 days
45380694|NCT04040543|Dietary Supplement|lipid-based nutrient supplement containing or not containing adherence markers|The product containing adherence markers will be provided once daily every other day (5 days total); the product not containing adherence markers will be provided on the intervening days for a total of 10 days.
45496212|NCT05178745|Drug|Aflibercept|Pharmaceutical Form: concentrate solution for infusion Route of Administration: IV infusion
45496213|NCT05178745|Drug|Irinotecan|Pharmaceutical Form: solution for injection Route of Administration: IV infusion
45496214|NCT04151953|Diagnostic Test|Blood sample collection|Blood sample collection for markers of myocardial injury
45496215|NCT03626220|Procedure|acupuncture|manually manipulate acupuncture at CV6 and three acupoints on each arms and legs
45496216|NCT05571241|Behavioral|Fast rehabilitation program|1-2 weeks (first post-op visit): Long thumb spica splint removed; Staples/stitches removed; Short hand-based thumb spica fitted for the patient Start Active Range of Motion Exercises (AROM) for thumb Add active assisted rang of motion exercises (AAROM) if no significant progress 6 weeks: Gradually wean off of splint during the day; wear for protection and/or more strenuous daily activities 6-8 weeks: Passive Range of Motion Exercises (PROM) (ie. stretching), if needed - (ie. No significant changes in ROM of thumb) 8-10 weeks: Resisted exercises/activities without splint on
45496217|NCT05691894|Drug|18F-FAPI|Patients will receive a tracer dose of 18F (8-10mCi) labelled FAPI
46055360|NCT02769429|Device|nerve stimulator-guided CCPVB|This group will receive landmark with nerve stimulator based needle placement and then nerve stimulator-guided CCPVB with the catheter placed on the 6th cervical spinal root
46055361|NCT02769507|Device|DC Stimulator PLUS (NeuroConn)|
46055362|NCT02773953|Device|T4PTelemonitoring|addition of a Telemonitoring unit on the CPAP line to standard care.
46055363|NCT02773953|Device|CPAP|CPAP treatment for treatment of obstructive sleep apnea syndrome
46055364|NCT02769585|Behavioral|Self-hypnosis|Self-hypnosis
45380695|NCT04040543|Dietary Supplement|lipid-based nutrient supplement not containing adherence markers|The supplement will be provided once daily for 10 days
45380696|NCT00873197|Drug|granisetron|"Sancuso® 3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days (168 hours) followed by a second patch applied to the opposite arm at 168 hours for a further 7 days (168 to 336 hours).~Kytril® (granisetron hydrochloride) 1 mg/mL; IV; 0.01 mg/kg (maximum 1 mg) administered over 30 seconds immediately following patch application on Day 1 only."
45380697|NCT00873353|Drug|capecitabine + erlotinib|"6 cycles (3 weeks each one) of :~capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks~erlotinib (Tarceva®) 150mg/day, oral. Days: every days"
45496218|NCT05691894|Drug|68Ga-FAPI|Patients will receive a tracer dose of 68Ga (2-5mCi) labelled FAPI
46055365|NCT02769585|Behavioral|CDE training|standard CDE training for an obese diabetic
46055366|NCT02773875|Device|Artificial pancreas system (Algorithm + CGM + pump)|The AP system using fault detection algorithms will determine whether insulin infusion problems are occurring and may prevent severe hyperglycemia due to its predictive nature
46055367|NCT02773719|Other|True Biofield therapy|
46055368|NCT02773719|Other|Fake Biofield therapy|
45496219|NCT05178511|Drug|Ensartinib|Ensaritinib was taken orally once 225mg, on an empty stomach or with food, until the patient developed disease progression, developed unacceptable toxicity, the investigator or subject decided to drop out, lost follow-up, initiated other antitumor therapy, or died
45496220|NCT05571163|Drug|AMG 510|Tablets
45496221|NCT05423262|Biological|TRK-950|Intravenously over 60 minutes
45380698|NCT00876941|Behavioral|Standard Brief Intervention|"Intervention: Structured, brief negotiated interview.~Intervention preparation and content: Preparation: review of ASSIST results; Content: The intervention involves 4 major parts: 1) establishing rapport and asking the subject for permission to raise the topic of drug use; 2) exploring the pros and cons of use; 3) providing feedback and assessing readiness to change; and 4) advising and negotiating a plan.~Counselor: Health Promotion Advocate, High School graduate or GED minimum Training specific to the brief intervention: Didactic and experiential; competency demonstrated by observation and/or video recordings which are content scored using a standardized form.~Contacts, Duration: One, 10-15 minutes.~Communication content delivered to primary care physician: Results of screening and BI.~Supervision: Weekly 1-hour meeting with supervisor to discuss job performance and discuss cases; biannual shadowing by supervisor."
45496222|NCT03708107|Device|MEP|MEP® will be applied with an acupuncture needle (0,30 x 25 mm). The needle will be introduced perpendicularly to the MTrP with 100 uA and then increased up to 600 uA. The current will be paused if the patient feels a burning sensation, pain or oppression, waiting up to the patient feels no discomfort. The procedure will be repeated as many times is necessary until the patient do not feel any discomfort for more than 1 minute.
45496223|NCT03708107|Other|Ischemic compression|Ischemic compression will be applied perpendicularly to the MTrP, increasing gradually the pression until the patient refers the maximum tolerable pain. This pressure will be applied for 1 minute.
45496224|NCT04110457|Procedure|spinal decompression|spinal surgery by decompression or fixation
45496225|NCT05691738|Other|Exercise Group|The exercise group will be informed about diabetes and diabetes complications. A total of 16 sessions of 8 weeks, modified otago exercises will be applied individually by the research physiotherapist.Individuals will be allowed to walk at a moderate pace for at least 30 minutes 5 days a week (home program).
45496226|NCT05691738|Other|Control Group|The control group will be informed about diabetes and diabetes complications. Individuals will be allowed to walk at a moderate pace for at least 30 minutes 5 days a week (home program)
45496227|NCT05691660|Drug|TAS3731 Dose1|Oral administration,1 day,QD
45496228|NCT05691660|Drug|TAS3731 Dose2|Oral administration,7 days,QD
45496229|NCT05691660|Drug|TAS3731 Dose3|Oral administration,7 days,BID
45496230|NCT05691660|Drug|Placebo|Oral administration, 1 day,QD
45496231|NCT05691660|Drug|Placebo|Oral administration, 7 days,QD
45496232|NCT05691660|Drug|Placebo|Oral administration, 7 days,BID
45496233|NCT03995641|Drug|marcaine and kenalog|Trigger point injection (consisting of 9 cc 0.5% Marcaine and 1 cc kenalog) may be given at time of surgery if patient is randomized to receive the injection
45496234|NCT04105231|Drug|Cannabidiol|Cannabidiol oral suspension
45496235|NCT04105231|Drug|Risperidone|Risperidone, encapsulated tablet.
45694042|NCT01954745|Drug|Cabozantinib|Cabozantinib 60 mg (free base weight) per day will be administered daily and continuously for a cycle length of 28 days. Subjects will be provided with a sufficient supply of study treatment and instructions for taking the study treatment on days without scheduled clinic visits. After fasting (with exception of water) for 2 hours, subjects will take study treatment daily with a full glass of water (minimum of 8 oz/ 240 mL) and continue to fast for 1 hour after each dose of study treatment.
45694043|NCT00835900|Drug|varenicline|variable dosing schedule
45694044|NCT00835900|Drug|placebo|placebo
45694045|NCT03838900|Device|Loop|The Loop System consists of an insulin pump (certain versions of Medtronic insulin pumps) and a Dexcom or Medtronic CGM. The system includes an iPhone with the Loop app and a RileyLink to communicate between the pump and iPhone. An Apple Watch may optionally be used with the system.
46055369|NCT02768961|Drug|sofosbuvir|"Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Sofosbuvir will be used in association with ledipasvir. In some cases, ribavirin can be added to this combination according to current guidelines"
46055370|NCT02768961|Drug|ledipasvir|"Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Ledipasvir will be used in association with sofosbuvir. In some cases, ribavirin can be added to this combination according to current guidelines"
46055371|NCT02769039|Other|No intervention. Observational studies of sleep, movement and brain imaging|Participants will be asked to visit the University for 3 baseline visits which include a screening visit & sleep study, movement tests and magnetic resonance imaging (MRI) scans. Three years later the participant will be asked to repeat the same visits.
45694046|NCT01954121|Drug|Levetiracetam|"Immediate release film-coated tablets at strengths of 250 mg and 500 mg.~Up-titration Period (Week 1 to Week 3): Levetiracetam (LEV) 250 mg twice daily (bid)~Stabilization Period and Evaluation Period (Week 3 to Week 30): LEV 500 mg bid~Down-titration Period (Week 30 up to Week 33)"
46055372|NCT02773641|Drug|Botulinum Toxin Type A|
46055373|NCT02773641|Drug|Sterile Saline Solution|
46055374|NCT02773563|Other|EUS with air insufflation|Diagnostic procedure using an echoendoscope for the study of pancreaticobiliary or gastrointestinal diseases using air insufflation
46055375|NCT02773563|Other|EUS with CO2 insufflation|Diagnostic procedure using an echoendoscope for the study of pancreaticobiliary or gastrointestinal diseases using CO2 insufflation
45380699|NCT00876941|Behavioral|Enhanced Brief Intervention|"Intervention: Less structured, motivational interview.~Intervention preparation and content: Preparation: review of ASSIST, drug consequences (SIP-D), risk behaviors, CIDI Short Form, and medical record for discussion; Content: Motivational interviewing discussing above.~Counselor: Master's level/Doctoral student.~Training specific to the brief intervention: Didactic and experiential, followed by additional work towards, and confirmation of, proficiency using audio recordings coded for motivational interviewing content.~Contacts, Duration: One plus offer of one optional booster contact, each 30-45 minutes; 2nd by telephone or in person depending on subject's preference; availability of counselor for further readiness discussions.~Communication content delivered to primary care physician: Results of screening, BI, and plan including follow-up.~Supervision: Weekly 1.5-hour meeting with supervisor with review of coded audio recordings."
45380700|NCT00876941|Behavioral|Control: Information and Feedback|Subjects randomized to the control group will not receive a BI at enrollment. But, all study subjects will receive screening and its results as part of the informed consent process (that they are at least at risk for drug use health hazards) along with a written list of resources available, including local options.
45694047|NCT01954121|Drug|Carbamazepine|"Immediate release tablets at a strength of 200 mg.~Up-titration Period (Week 1 to Week 3): Carbamazepine- Immediate Release (CBZ-IR) 200 mg once daily (qd)~Stabilization Period and Evaluation Period (Week 3 to Week 30): CBZ-IR 200 mg bid~Down-titration Period (Week 30 up to Week 33)"
45694048|NCT04635761|Behavioral|Educational Intervention|Complete AIR Program and receive the High-Risk Lung Cancer Tip Sheet
45380701|NCT00877019|Device|Sonicare elite medium brush head|
45380702|NCT00877019|Device|Sonicare elite mini brushhead|
46055376|NCT04224519|Biological|sIPV batch 1|Type I 30 DU, Type II 32 DU, Type III 45 DU
45380703|NCT00877019|Device|GABA Elmex sensitive extra soft toothbrush|
45380704|NCT00877019|Device|ADA reference toothbrush|
46055377|NCT04224519|Biological|sIPV batch 2|Type I 30 DU, Type II 32 DU, Type III 45 DU
46055378|NCT04224519|Biological|sIPV batch 3|Type I 30 DU, Type II 32 DU, Type III 45 DU
46055379|NCT02773329|Other|sensor-based interactive exercise (game-based exercise)|This intervention includes interactive game-based balance training including repetitive weight shifting and virtual obstacle crossing tasks. Wearable sensors will provide real-time visual/auditory feedback from foot and ankle position and allowed perception of motor-errors during each motor-action.
45380705|NCT00877097|Drug|Klodronate and Kliogest|
45380706|NCT00877097|Procedure|Placebo+ Kliogest|
45380707|NCT00877097|Drug|Bonefos|
45694049|NCT04635761|Behavioral|Questionnaire Administration|Ancillary studies
46055380|NCT02773329|Other|Intervention without game-based exercise|Subjects are asked to perform non-technology based foot and ankle exercises, which include body weight shifting and obstacle crossing tasks.
45380708|NCT00873431|Biological|IC47|solution/suspension for i.m. injection dosage: 30/150 mcg frequency: 3 times at Day 0, Day 42 and Day 84
45380709|NCT00877175|Drug|1% tropicamide and 2.5% phenylephrine|For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
45380710|NCT00867347|Procedure|therapeutic conventional surgery|Patients undergo radical cystectomy
46055381|NCT02768805|Biological|15 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
46055382|NCT02768805|Biological|30 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
46055383|NCT02768805|Biological|15 µg/strain of the licensed quadrivalent vaccine|Single dose of the licensed quadrivalent vaccine
45380711|NCT00867347|Radiation|radiation therapy|Patients undergo radiotherapy
46055384|NCT02773251|Drug|hyaluronic acid-carboxymethylcellulose|
46055385|NCT04224597|Diagnostic Test|ultrasonography|all participants will be determined by ultrasonography.
45380712|NCT00420927|Biological|adalimumab|Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
45380713|NCT00420927|Drug|methotrexate|Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.
45380714|NCT00420927|Biological|placebo|Placebo for adalimumab 0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
45380715|NCT00573443|Drug|dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 20 mg/ Q 10 mg, taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
45380716|NCT00573443|Drug|dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 30 mg/ Q 10 mg taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
45380717|NCT00573443|Drug|Placebo|Placebo capsules (identical in appearance to AVP-923 capsules being studied in this trial), taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
45380718|NCT01029561|Device|CPAP|Treatment with Continuous Positive Airway Pressure
45380719|NCT01029561|Behavioral|Diet|Conventional diet treatment that undergo patients in the Bariatric Surgery Program
45380720|NCT05225831|Biological|Autologous CD19/CD22 Chimeric Antigen Receptor T-cells|A single infusion of CD19 and CD22 CAR-T cells.
45380721|NCT05225831|Drug|Cyclophosphamide,Fludarabine|Given
45380722|NCT00873509|Drug|Buspirone|Buspirone liquid, 2.5 mg in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
45380723|NCT00873509|Drug|Buspirone|Buspirone liquid, 5.0 mg in 1 ml , once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
45380724|NCT00873509|Drug|Placebo|Placebo liquid, in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
45380725|NCT00873587|Procedure|Chest tube pull on inspiration|Pull chest tube on Inspiration
45380726|NCT00873587|Procedure|Expiration|Pull chest tube on Expiration
45496236|NCT05691582|Device|GRAIL|"The subjects experiment GRAIL virtual reality for three days, during which they deal with 4 different activities.~In the first activity subjects are required to ask over the treadmill in a snow environment.~in the second they are required to stand over the moving platform in a simulation of a boat pitch.~in the third they have to walk over a bridge with a slope. in the fourth the subjects are required to try so interact with virtual reality and to ski between snowman.~if it is possible, on the last day a gait analysis is executed"
45496237|NCT03557749|Diagnostic Test|Blood Sample|60 ml heparinized blood 10 ml serum
45496238|NCT03557749|Diagnostic Test|Stool Sample|pea-sized amount
45496239|NCT03557749|Diagnostic Test|Urine Sample|10 ml
45496240|NCT03557749|Diagnostic Test|Bronchoalveolar Lavage (BAL) fluid|10 ml
45496241|NCT03557749|Diagnostic Test|Gastrointestinal biopsy x 2-4|rectosigmoid site preferred
45496242|NCT03557749|Diagnostic Test|Skin biopsy|2-4 mm punch
45496243|NCT03557749|Diagnostic Test|Skin, mouth, and/or ocular swab|Involved skin, mouth, and/or ocular swab for microbiota studies
46055386|NCT02768649|Drug|RBP-7000|Sequential dosing of each cohort
46055387|NCT02768649|Drug|risperidone|All eligible subjects received a test dose of risperidone to ensure tolerability prior to dosing with RBP-7000.
46055388|NCT02773407|Drug|Azithromycin|
46055389|NCT02773407|Drug|Co-trimoxazole|
46055390|NCT02773173|Procedure|IPP in colorectal laparoscopic surgery|Deep neuromuscular blockade can only be reversed with sugammadex, so in the IPP group, it will be used as neuromuscular blocking agent and its effect will be reversed with sugammadex (4mg / kg) at the end of the surgery. During surgery: deep neuromuscular blockade (PTC 1-5), Protective ventilation strategy, Optimal position and Pre stretching as a tool to decrease intraabdominal pressure maintaining optimal workspace.
46055391|NCT02773173|Procedure|SPP in colorectal laparoscopic surgery|A depolarizing neuromuscular blocking will be used (as routine clinical practice at each center) to maintain moderate neuromuscular blockade and its effect will be reversed with anticholinesterase at the end of the surgery. During surgery: Moderate neuromuscular blockade ( TOF 2-4) , position to surgeon criteria, no prestretching and Protective ventilation. Fixed IAP (12mmHg).
46055392|NCT02768883|Behavioral|Respira Sano|The intervention is all three components: clinic + home + community.
46055393|NCT04224675|Drug|Atenolol|Captopril versus atenolol to prevent expansion rate of thoracic aortic aneurysms
45496244|NCT03557749|Diagnostic Test|Apheresis Product|Up to 10 ml of apheresis product
45380727|NCT00867425|Behavioral|Virtual Lifestyle Management|"The VLM online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program (1). VLM will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs.~Participants will be encouraged to complete 16 online, weekly lessons. The VLM curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives. The VLM lifestyle coaching team will review these entries weekly, and provide support, feedback about progress, tips on how to problem-solve around lifestyle barriers, and guidance on how to use the Keeping Track functions of VLM (e.g. keeping track of weight, fat intake, calories or physical activity)."
45380728|NCT00877253|Drug|Genexol-PM 220mg/㎡, Carboplatin 5AUC|Genexol-PM 220mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
45380729|NCT00877253|Drug|Genexol-PM 260mg/㎡, Carboplatin 5AUC|Genexol-PM 260mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
45380730|NCT00877253|Drug|Genexol-PM 300mg/㎡, Carboplatin 5AUC|Genexol-PM 300mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
45496245|NCT03557749|Diagnostic Test|Final cellular product|A second washing from the infusion bag after product and initial bag wash has infused, or up to 10 ml of final cellular product
45496246|NCT03532555|Dietary Supplement|Zinc Acetate|Zinc Acetate given with elemental zinc dose of 2mg/kg given orally only daily through 35 6/7 weeks corrected gestational age
46055394|NCT04175145|Other|Posterior spinal instrumentation|A fusion construct consisting of all pedicle screws except at uppermost instrumented vertebra. Contoured dual 6-mm stainless steel rods were used to connect the construct. Pedicle screw location and density was determined by the surgeon based on perceived curve stiffness and fusion length with an even distribution of fixation points along the construct. Pedicle screw instrumentation was performed by the free hand technique with biplanar fluoroscopic and direct screw EMG impedance testing for confirmation of placement. Reduction was via cantilever-segmental-translation maneuver in all cases.
45496247|NCT03532555|Other|No supplemental zinc|Infants will receive standard of care, which is currently no supplemental zinc
45496248|NCT01347307|Radiation|SBRT for Benign Extradural Spine Tumors|14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
45496249|NCT01347307|Radiation|SBRT for Vertebral/Paraspinal Metastases|12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
45496250|NCT03373110|Behavioral|Online Mindfulness Based Cognitive Therapy|see arm description
45496251|NCT03373110|Behavioral|Online Cognitive Behavioral Therapy|see arm description
46055395|NCT02768493|Drug|1.0 ml/kg of 0.15% ropivacaine|Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
45380731|NCT05225753|Diagnostic Test|hemoglobin serum value|post-operative anemia evaluated with hemoglobin serum value
45380732|NCT00877331|Behavioral|Brief intervention using motivational interviewing|One brief, in-person motivational interviewing session (30-45 minutes) in conjunction with the medical appointment. Plus one brief follow-up phone call one week later.
45380733|NCT00873665|Other|aerobic exercise|To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.
45496252|NCT03373110|Behavioral|Fitbit Alone|see arm description
45496253|NCT03993457|Drug|Escitalopram|Escitalopram will be started at 5 mg/day during the first week of treatment. The dose will then be increased to 10mg/day, and can be increased to 20 mg/day. Dose can be decreased to 5 mg by clinician discretion such as to increase tolerability or better manage side-effects. 5 mg will be the lowest dose allowed in the study.
45496254|NCT03993457|Drug|Bupropion|Bupropion-XL will be started at 150 mg/day and increased to 300 mg/day after one week. This dose can be increased to 450 mg/day (divided in 2 doses) at Week 2 or later. Clinicians may opt to titrate bupropion-XL in a slower fashion in cases that might increase tolerability or better manage side-effects. 150 mg will be the lowest dose allowed in the study.
45496255|NCT05571085|Other|Core Stability Exercises|Core stabilization exercises will be performed based on the program recommended by Jeffrey. Each session will take 40-50 minutes. The program consists of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period.
45380734|NCT00873665|Other|wait-list control|To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms (i.e., erectile function score, sexual functioning, urinary incontinence, and QOL) and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.
45496256|NCT05571085|Other|PNF Exercise Program|PNF exercises will consist of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period, with each session lasting 40-50 minutes.
45496257|NCT05571007|Other|True acupressure|"Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy."
45496258|NCT05571007|Other|Sham acupressure|"Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy."
45496259|NCT03348306|Device|MRI|Brain and cardiac MRI in one time with gadolinium injection.
45496260|NCT03348306|Biological|Blood sample collection|A blood sampling is also collected for hematocrit measure.
45496261|NCT05570773|Other|peer support program|Peer support: It has been suggested that peer support provides an alternative way for students to learn and makes a positive contribution to both academic and psychosocial aspects of higher education (Hogan, Fox, Barratt-See 2017). Peer academic support involves academic encouragement (support for lowering exam-related stress and motivation for lessons) and solving students' academic problems (answering questions about lessons, sharing study habits, studying together, answering questions about assignments)
45694050|NCT04634045|Behavioral|Web Based Treatment|The literature regarding the efficacy of web-based platforms for behavioral weight management interventions in pediatric populations continues to grow. Considering the continued increase in technology and internet use among youth, web-based interventions have the potential to serve as a more cost-effective and personalized approach to pediatric behavioral weight management. Extant research supports this consideration. More research that compares web-based vs. traditional delivery of acceptance-based pediatric behavioral weight management interventions is necessary to understand the utility of this platform as well as which aspects are most effective.
45496262|NCT04677439|Drug|Flumatinib|600 mg of Flumatinib orally daily for 24 months
45694051|NCT00850642|Drug|GSK2190195 100mg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
45694052|NCT00850642|Drug|Placebo|"Placebo :~2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)"
45694053|NCT03643744|Drug|Celecoxib 200mg|14 Celecoxib 200mg taken 1 in the morning and 1 in the evening.
45380735|NCT00877409|Drug|Benzoyl Peroxide 5% and Sulphur 2%|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
45380736|NCT00877409|Drug|Vehicle of Acnase|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
45496263|NCT03309072|Device|tDCS|active tDCS
45496264|NCT03309072|Device|sham tDCS|sham tDCS
45694054|NCT03643744|Drug|Placebo|14 placebo capsules taken 1 in the morning and 1 in the evening.
46055396|NCT02768493|Drug|1.5 ml/kg of 0.15% ropivacaine|Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
45380737|NCT00873899|Device|The Medtronic CareLink system (Minneapolis, MN, USA).|The Medtronic CareLink system(Minneapolis, MN, USA)includes a patient monitor plugged into a standard analog telephone connection, and a lightweight wand to communicate with the implanted device. Interrogation of the device and transmission of the data occur when the patient places the wand over the implanted device. The system uses radio frequency telemetry for wireless automatic communication. This allows for data transmission without patient intervention and enables automatic transmissions at pre-specified routine intervals as well as alert-based downloads.The system can transmit data in case of programmable conditions on diagnostic variables, arrhythmias, delivered ICD therapies, battery/lead issues, and alert the physician via phone or e-mail. The patient's information is sent to a secure Network server via the telephone connection and clinical staff can review device information.Available data are equivalent to that which can be retrieved at an in-office visit.
45380738|NCT00873977|Device|CPAP (REMstar (Respironics))|Pressure-relief CPAP treatment may reduce the sensation of breathing against high pressure without causing the upper airways to collapse and improve adherence.
45380739|NCT00874133|Procedure|Acupuncture|Acupuncture treatment for 12 weeks.
45380740|NCT00874133|Drug|Motilium|20 mg motilium thrice daily
45380741|NCT00867737|Drug|Advair HFA MDI 115/21|Two puffs from MDI twice daily for 4 weeks
45380742|NCT00867737|Drug|Symbicort 160/4.5 pMDI|"Symbicort 160/4.5 pMDI~Two puffs from MDI twice daily for 4 weeks"
45380743|NCT04551677|Biological|Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation|"Pharmaceutical form: Suspension for injection in a pre-filled syringe,~Route of administration: Intramuscular (IM)"
45380744|NCT04551677|Biological|Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation|"Pharmaceutical form: Suspension for injection in a pre-filled syringe,~Route of administration: IM"
45380745|NCT00874211|Procedure|assessment of therapy complications|By dental and medical assessments.
45380746|NCT00877643|Other|Upstream therapy|Aldosterone receptor antagonists and statins, dietary restrictions, counseling, and cardiac rehabilitation.
45380747|NCT00877643|Other|Conventional rhythm control|Usual care for atrial fibrillation and heart failure according to the present guidelines
45694055|NCT00836758|Device|Analysis with AED and manual PSG scoring|The CPAP device will be set-up at a sub-therapeutic pressure and will remain at this pressure for the entire night, if tolerated. Then the events will be analyzed with Automatic Event Detection (AED) and manual PSG scoring.
45380748|NCT00874289|Other|NGAL kit|Kit to test NGAL levels in heart failure patients
45380749|NCT04040465|Drug|Aspirin|Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.
45380750|NCT03842813|Device|DES-CRE8|Polymer-free Amphilimus™ (Sirolimus + Fatty Acid) eluting coronary stent. The absence of the polymer minimizes the risk of inflammation/thrombosis, while the propriety formulation enhances drug absorption.
45496265|NCT03625908|Device|OCT-guided PCI|Patients will receive PCI under OCT-guidance. Predefined criteria for optimization of PCI under OCT-guidance will be recommended to achieve as far as possible.
45694056|NCT00852592|Device|7000lux broad-spectrum light|dosage - 15-60minutes NOON-2PM daily
45694057|NCT00852592|Device|50lux dim red light|dosage: 15-60minutes NOON-2PM daily
46055397|NCT02768415|Drug|Apatinib|
46055398|NCT02768415|Drug|Oral Vinorelbine|
46055399|NCT02773095|Other|Novartis Access|Eight counties will be matched in pairs and randomized within each pair to either receive Novartis Access portfolio low-cost medications or to remain a control county.
46055400|NCT02768337|Drug|Afatinib|
46055401|NCT02768337|Radiation|2 Gy targeted radiotherapy|
46055402|NCT02768337|Radiation|4 Gy targeted radiotherapy|
46055403|NCT02768571|Drug|Cerebrolysin|Cerebrolysin- cerebrolysin 30 ml with 100 ml dilution/day * 21 days with rehabilitation
45380751|NCT00874445|Device|ICD/ CRT-D|Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
45380752|NCT00420849|Drug|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression, drug became commercially available or limited to 6 treatment cycles.
45694058|NCT01952015|Biological|Secukinumab|Secukinumab (AIN457) 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose).
45380753|NCT00420849|Drug|Dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4. Beginning cycle 5, a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
45380754|NCT00617279|Device|GORE PROPATEN Vascular Graft|Arterial Occlusion Bypass
45380755|NCT00617279|Procedure|Disadvantaged Autologous Vein Graft|Arterial Occlusion Bypass
45380756|NCT00877721|Device|Self Mobility Improvement in the eLderly by using the SMILING system|The effect of treatment with the SMILING system on postural stability and gait of elderly individuals will be measured using RCT cross over study design
45380757|NCT00874523|Drug|atazanavir plus raltegravir|atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks then atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks
45380758|NCT00874523|Drug|atazanavir plus raltegravir|atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks then atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks
45694059|NCT00838006|Device|heart rate variability biofeedback|Heart rate variability biofeedback, 3 session plus handheld device
45694060|NCT00838006|Device|Cognitive bias modification training|Cognitive bias modification training - 3 session plus handheld device
46055404|NCT02768571|Drug|Placebo|Placebo- saline 100 ml/day * 21 days with rehabilitation
45380759|NCT00874601|Drug|Diovan® (valsartan)|"The valsartan will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.~In those patients not achieving target level of blood pressure (more than 15% reduction of initial blood pressure or below 145 mmHg of systolic blood pressure), an additional antihypertensive drugs (diuretics, beta blockers) can be given despite of Valsartan 320 mg. If the BP is considered to be low enough, dose of valsartan can be decreased to 40 mg per day. If the administration of valsartan is judged to be inappropriate by duty doctor due to any reasons, it can be stopped and the reasons will be recorded."
45380760|NCT00874679|Drug|Levitra (Vardenafil, BAY38-9456)|Patients with diagnosis of erectile dysfunction who get vardenafil in routine treatment
45694061|NCT00838006|Device|Sham Comparator|Subjects received iPod without a study app and no additional resilience training
45694062|NCT01951703|Device|senofilcon A|Control, senfilcon A
45694063|NCT01951703|Device|senofilcon A|Test, senofilcon A
45694064|NCT00838162|Drug|TMC310911 75 mg twice daily|TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.
46055405|NCT02696889|Procedure|ROSE-1 Protocol|A bone marrow aspiration will be performed under anesthesia in preparation for a diagnostic laparoscopy for full evaluation of the pelvic anatomy. Following laparoscopy, injection of BMSCs into the right ovary will occur.
46055406|NCT02768025|Other|Traditional & Complementary Medicine treatment|Body acupuncture, Ear acupuncture and aromatic therapy
46055407|NCT02768025|Other|NRT, counselling|Nicotine Replacement Therapy, counselling
46055408|NCT02767713|Drug|Dexamethasone|Intravenous dexamethasone (0.1 mg/kg) was administered 10 hours before surgery.
46055409|NCT02767713|Other|Placebo|Normal saline (placebo) in the equal volume as active treatment was administered 10 hours before surgery.
46055410|NCT02767245|Drug|Thiamine|Thiamine IV 100 mg/day
45380761|NCT00420381|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until progressive disease
45380762|NCT01032681|Biological|EMD 521873|"Dose escalation steps:~Group 1: 0,075mg/kg - 0,15mg/kg - 0,225mg/kg - 0,3mg/kg - 0,45mg/kg - 0,6mg/kg - 0,9mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
45380763|NCT01032681|Biological|EMD 521873|"Dose escalation steps:~Group 2: CPA plus 0,6mg/kg - 0,9mg/kg~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
45380764|NCT01032681|Biological|EMD 521873|"Dose escalation steps:~Group 3: 0,9mg/kg - 1,2mg/kg - 1,5mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
45380765|NCT00874835|Device|EndoSaver™ Corneal Endothelium Delivery Instrument|Efficacy of device to maintain function and integrity of corneal endothelial cells during insertion into the eye during keratoplasty.
45380766|NCT00617201|Drug|atomoxetine|Once daily oral dosing
45380767|NCT00617201|Drug|placebo|Once daily oral dosing - matched placebo
45380768|NCT00420303|Drug|Etanercept|50 mg injection once weekly
45380769|NCT00420303|Other|Placebo|placebo
45380770|NCT03803969|Device|ConfirmRx (Insertable Cardiac Monitor)|This study is designed to characterise the safety and performance of the ConfirmRx device by assessing quality of signal attained from the device with changes in posture and physical activity at implant and 30days post procedure. The study is also intended to assess gross migrations of the device at 30days post implant.
45380771|NCT00617123|Drug|Vorapaxar 2.5 mg|Vorapaxar 2.5 mg oral tablet
45380772|NCT00617123|Drug|Placebo|matching placebo oral tablet
45380773|NCT00877955|Drug|alprazolam sublingual tablet commercial|0.5 mg sublingual tablet, single dose
45380774|NCT00877955|Drug|alprazolam sublingual tablet test|0.5 mg tablet, single dose
45380775|NCT00419757|Drug|Budesonide/formoterol (SYMBICORT) pMDI|SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily
45380776|NCT00419757|Drug|Budesonide HFA pMDI|Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily
45694065|NCT00838162|Drug|TMC310911 150 mg twice daily|TMC310911 150 mg twice daily orally (by mouth) on Days 1 to 14
45694066|NCT00838162|Drug|TMC310911 300 mg twice daily|TMC310911 300 mg twice daily orally (by mouth) on Days 1 to 14
45380777|NCT00874913|Device|measurement of ocular blood flow|measurement of ocular blood flow with a laser Doppler flowmeter
45380778|NCT00878111|Drug|NGR-hTNF|"First cohort: iv q3W 60 mcg/sqm over 120 min*~Second cohort: iv q3W 80 mcg/sqm over 120 min*~Third cohort: iv q3W 100 mcg/sqm over 120 min*~Fourth cohort: iv q3W 125 mcg/sqm over 120 min*~Fifth cohort: iv q3W 150 mcg/sqm over 120 min*~Sixth cohort: iv q3W 175 mcg/sqm over 120 min*~Seventh cohort: iv q3W 200 mcg/sqm over 120 min*~Eighth cohort: iv q3W 225 mcg/sqm over 120 min*~Ninth cohort: iv q3w 250 mcg/sqm over 120 min*~Tenth cohort: iv q3w 275 mcg/sqm over 120 min*~Eleventh cohort: iv q3w 300 mcg/sqm over 120 min*~Twelfth cohort: iv q3w 325 mcg/sqm over 120 min*~* If the first infusion is well-tolerated, the second infusion may be delivered over 90 minutes. If the 90-minute infusion is well tolerated, all subsequent infusions may be delivered over a 60-minute period."
45380779|NCT00867971|Other|Measuring intraoccular pressure|Measurement of intraoccular pressure by tonometry
45380780|NCT00434109|Drug|Sunitinib malate|Sunitinib malate (Sutent) at a dose of 37.5mg will be administered orally once daily on days 1-28 in a 42-day cycle. Treatment with Sutent will begin no sooner than seven days after the first hepatic artery embolization. Subsequent embolizations (if necessary) will be scheduled during scheduled Sutent treatment breaks. No fewer than seven days shall separate treatment with Sutent and scheduling of hepatic artery embolizations.
45380781|NCT00434109|Procedure|Hepatic Artery Embolizations|1-3 selective hepatic artery embolizations will be performed at approximately 5-week intervals, based on the extent of hepatic involvement with tumor.
45380782|NCT00875069|Other|Ethanol|Dialysis catheter lock performed after renal replacement therapy session. Lock is instilling ethanol (or placebo) in each catheter lumen for 2 minutes before being withdrawn.
45380783|NCT01029639|Procedure|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
45380784|NCT00875147|Drug|bevacizumab|Neoadjuvant chemotherapy with bevacizumab
45694067|NCT00838162|Drug|TMC310911 300 mg once daily|TMC310911 300 mg once daily orally (by mouth) on Days 1 to 14
45694068|NCT00838162|Drug|Ritonavir 100 mg twice daily|Ritonavir 100 mg twice daily orally (by mouth) on Days 1 to 14
45847377|NCT05451498|Dietary Supplement|Creatine|Participants were matched according to fat-free mass to consume a placebo, or 5-g dose of creatine monohydrate within one hour before training, or within one hour after training for 8 weeks while completing a weekly resistance training program. At each time point (before and after training), all participants co-ingested a 25-gram dose whey isolate and a 25-gram dose of carbohydrate powder along with their assigned supplement. Body composition using a 3-compartment field (3CFIELD), muscular strength (one-repetition maximum [1RM]) and endurance (repetitions to fatigue [RTF] at 80% 1RM) using bench press (BP) and back squat (SQ) exercises along with isometric mid-thigh pull (IMTP) were assessed before and after the 8-week supplementation period.
45380785|NCT01566513|Behavioral|Community Connector|The participant randomized into this arm of the study is invited to work with a person trained as a community connector, someone who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
45380786|NCT01566513|Behavioral|Peer Recovery Mentor|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
45496266|NCT03625908|Device|Angiography-guided PCI|Stent optimization using high-pressure non-compliance balloon will be highly recommend. Balloon size would not be less than the stent diameter.
45496267|NCT05570695|Behavioral|attention right training, ARTNF|In a first verum neurofeedback condition, participants will be instructed to focus attention on their right hand and the up-regulation of alpha oscillations in the right hemisphere relative to alpha oscillations in the left hemisphere will be incentivized through neurofeedback.
45496268|NCT05570695|Behavioral|attention left training, ALTNF|In a second verum neurofeedback condition, participants will be instructed to focus attention on their left hand and the down-regulation of right relative to left alpha oscillations will be incentivized.
45496269|NCT05570695|Behavioral|sham attention right training, ARTsham|During the first sham neurofeedback condition, participants will be instructed to focus attention on their right hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ARTNF for ARTsham, will be replayed (yoked feedback).
45380787|NCT01566513|Behavioral|Peer Case Manager|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
45380788|NCT05226845|Other|prescribed exercise|the therapist chooses the five exercises to do
45380789|NCT05226845|Other|chosen exercise|the patient chooses the five exercises to perform among fifteen possibilities
45380790|NCT00875225|Behavioral|DVD|Control group will receive usual care DVD from health professionals
45380791|NCT00875225|Behavioral|Intervention DVD|Intervention group will receive intervention DVD with patient stories and information from health care professionals
45380792|NCT01034943|Procedure|External fixation|Operation with external fixation and optional addition of k-wire
45380793|NCT01034943|Procedure|Volar plate|Operation with a Synthes volar two column plate (TCP)
45380794|NCT00433329|Drug|Bosentan|Oral bosentan 62.5 mg BID first 4 weeks followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated
45380795|NCT00433329|Drug|Sildenafil|Oral sildenafil 20 mg TID in patients who do not reach the 6-MWT distance threshold at Week 16
45694069|NCT00838162|Drug|Ritonavir 100 mg once daily|Ritonavir 100 mg once daily orally (by mouth) on Days 1 to 14
45694070|NCT01937351|Device|Pantheris System|Atherectomy using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries.
45694071|NCT00853606|Drug|avanafil|All subjects will initially be assigned to treatment with avanafil 100 mg. Subjects who are unable to tolerate treatment with 100 mg may undergo dose reduction to 50 mg. Subjects who tolerate avanafil 100 mg but who desire increased efficacy may request a dose increase to 200 mg.
45694072|NCT00841204|Drug|sulindac|Given orally
45380796|NCT01035021|Drug|use of rocuronium when the LMA is inserted|Anesthesia is induced with a propofol and remifentanil in both groups, however rocuronium 0.06 mg/kg is injected only in group R. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction. In group N, rocuronium is administered for the operation.
45380797|NCT01029951|Procedure|manipulation|
45380798|NCT01029951|Procedure|Mobilisation|
45380799|NCT01029951|Device|Activator instrument|
45380800|NCT00616421|Biological|MenACWY-CRM|1 injection of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly
45380801|NCT00616421|Biological|MenACWY-CRM|2 injections of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly to children 2 to 5 years of age
45496270|NCT05570695|Behavioral|sham attention left training, ALTsham|During the second sham neurofeedback condition, participants will be instructed to focus attention on their left hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ALTNF for ALTsham, will be replayed (yoked feedback).
45496271|NCT05689710|Dietary Supplement|Inositol and alpha-lactalbumin|The administration of an oral formulation based on inositol and alpha-lactalbumin (two sachets/day for 180 days)
45380802|NCT00616421|Biological|Licensed meningococcal ACWY vaccine|1 injection of the licensed meningococcal ACWY was administered intramuscularly
45380803|NCT00875303|Behavioral|Play Nicely program|The intervention was the Play Nicely program, a multimedia educational program. Permission to demonstrate the program to multiple viewers was obtained from the copyright holder. English speaking caregivers viewed the 2nd English language edition and Spanish speaking caregivers viewed the Spanish edition. In the program, there are 16 options (20 options in the Spanish version) to respond to the hypothetical situation of witnessing a young child have hurtful behavior toward another child. Caregivers in the intervention group were instructed to view 4 of the interactive options of their choosing. On average, it takes 1 minute to view one option. Parents in the control group received routine primary care with their pediatrician.
45380804|NCT00875303|Behavioral|Control|Routine primary care.
45380805|NCT05226767|Dietary Supplement|NLC-V|NLC-V
45380806|NCT00878267|Behavioral|Interview|3 step process including person to person meeting and questionnaires taking about 30 minutes.
45380807|NCT00878345|Drug|dexmedetomidine sedation protocol|Arm 1 will undergo sedation with dexmedetomidine, using 2 mcg/kg load IV over 10 minutes followed by an IV infusion of 1 mcg/kg/hr. May use versed 0.5 mg/kg IV x 1 for incomplete sedation, followed by increase of dexmedetomidine infusion to 1.5 mcg/kg/hr. Infusion will run throughout non-painful procedure (most likely MRI).
45380808|NCT00878345|Drug|pentobarbital sedation protocol|"Pentobarbital Sedation Protocol IV: 2.5 mg/kg, followed by 1.25 mg/kg as needed x2. Maintenance: May give additional 1.25 mg/kg IV x 2 if needed. Max total dose of 200 mg pentobarbital throughout sedation.~May give midazolam 0.05 mg/kg IV x 1 PRN agitation for rescue sedation."
45380809|NCT00433017|Drug|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, verteporfin was activated by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of the infusion.
45380810|NCT00433017|Drug|Ranibizumab|Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL solution for injection) administered as an intravitreal injection
45380811|NCT00433017|Drug|Placebo|As a placebo for verteporfin photodynamic therapy (for masking purposes), patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of infusion.
45496272|NCT02986789|Device|In vivo SpHb and PVi Monitoring|Pulse oximeter finger sensor that simultaneously monitors noninvasive hemoglobin (SpHb) and pleth variability index (PVi)
45496273|NCT03223428|Drug|Xermelo|This study will include patients with carcinoid syndrome who are initiating treatment with XERMELO.
45694073|NCT00841204|Other|placebo|Inactive agent
45694074|NCT00841204|Other|laboratory biomarker analysis|Correlative studies
45380812|NCT01035411|Drug|AZD9668|2 x 30 mg batch DLE494
45380813|NCT01035411|Drug|AZD9668|2 x 30 mg batch DLF497
45380814|NCT01035411|Drug|AZD9668|2 x 30 mg tablet variant 1
45496274|NCT05685498|Behavioral|Peer-led HIV self-testing among male fisherfolk in Uganda|TThe intervention is centered on the distribution of HIV self-test kits to men through their respective peer-leaders. The investigators have identified up to 18 social network groups; each group is represented by 1-2 peer-leaders who were selected during community engagement meetings. Peer-leaders have received a 3-day training in the HIV self-testing processes, communication skills, existing referral mechanisms, and basic counseling skills. After the training, each peer-leader nominated up to 20 male members (15+ years) from within their social networks who were screened for study eligibility. Eligible male social network members were administered a baseline interview and requested to go to their peer-leaders to obtain their HIV self-test kits.
45380815|NCT03726671|Other|25% Cho diet|Subjects will consume meals containing 25% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
45496275|NCT05659836|Device|Abbott SCS Systems|Patients will be implanted with Abbott spinal cord stimulation (SCS) systems (both trial and permanently-implanted systems) and provided with wearable sensors, and software applications presented on a mobile device.
45496276|NCT02777424|Drug|Prothrombin Complex Concentrate|Non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C & S
45694075|NCT00853840|Drug|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
45847378|NCT05451498|Dietary Supplement|Maltodextrin|Participants were matched according to fat-free mass to consume a placebo (maltodextrin) within one hour before training, or within one hour after training for 8 weeks while completing a weekly resistance training program. At each time point (before and after training), all participants co-ingested a 25-gram dose whey isolate and a 25-gram dose of carbohydrate powder along with their assigned supplement. Body composition using a 3-compartment field (3CFIELD), muscular strength (one-repetition maximum [1RM]) and endurance (repetitions to fatigue [RTF] at 80% 1RM) using bench press (BP) and back squat (SQ) exercises along with isometric mid-thigh pull (IMTP) were assessed before and after the 8-week supplementation period.
45847379|NCT05448300|Device|Colonoscopy with water exchange or air insufflation methods|Using computer-aided polyp detection algorithm on colonoscopy with water exchange or air insufflation methods. This computer-aided algorithm does not intervene directly the colonoscopy procedure.
45847380|NCT05444478|Procedure|Microwave ablation|only microwave ablation for tumor
45847381|NCT05444478|Drug|Lenvatinib|lenvatinib (80 mg for body no more than 60kg，120 mg for body weight >60 kg)
45380816|NCT03726671|Other|50% Cho diet|Subjects will consume meals containing 50% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
45380817|NCT03726671|Other|100% Cho diet|Subjects will consume meals containing 100% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
45380818|NCT01030029|Device|electrical auricular acupuncture|Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point [2]. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
45380819|NCT01030029|Device|P-Stim™ devices were applied without electrical stimulation and acupuncture.|Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
45380820|NCT00868127|Drug|Lapaquistat acetate|"Participants from 01-04-TL-475-008 Monotherapy Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 48 weeks."
45496277|NCT02777424|Biological|Fresh Frozen Plasma|Pooled collection of plasma from donors
45496278|NCT05360550|Drug|LSP-5415|pregnancy prevention
45694076|NCT00853840|Drug|Vardenafil|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
45694077|NCT00853840|Drug|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
45694078|NCT00853840|Drug|Placebo|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
45694079|NCT01737697|Drug|Zirconium silicate (acute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
45694080|NCT01737697|Drug|Zirconium silicate (subacute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
45380821|NCT00868127|Drug|Lapaquistat acetate and additional lipid-lowering therapy|"Participants from 01-04-TL-475-009 Atorvastatin Add-on Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current Atorvastatin therapy for up to 4 weeks.~Then, Lapaquistat 100 mg, tablets, orally, once daily and dose adjustment of Atorvastatin OR additional companion lipid-lowering therapy as needed for target LDL-C for up to 42 weeks."
45380822|NCT00868205|Dietary Supplement|Coffee consumption|3 or 5 cups of coffee daily for eight weeks
45380823|NCT00878423|Drug|AT13387|Two dosing schedules will be evaluated; twice or once weekly dosing, on three weeks out of four. The starting dose for the once weekly schedule was 10mg/m2/dose, given as one hour intravenous (IV) infusions on Days 1, 4, 8, 11, 15 and 18 of a twenty-eight day cycle. The starting dose for the twice weekly schedule, given as one hour intravenous (IV) infusions on Days 1, 8 and 15 of a twenty-eight day cycle, will be 150mg/m2/dose
45380824|NCT00878423|Drug|AT13387|Intravenous infusion over one hour on days 1, 4, 8, 11, 15 and 18, every four weeks or intravenous infusion over one hour on days 1, 8 and 15, every four weeks . Treatment may be continued indefinitively in the presence of clinical benefit
45380825|NCT05203601|Biological|SIBP-03|"Stage 1:~Six dose groups of 2, 5, 10, 15, 20 and 40 mg/kg were planned. Dose increments began at 2 mg/kg using accelerated titration. In the first dose group, after the first patient was injected with Sibp-03, if the subject developed toxicity grade ≥2（CTCAE v5.0 standard）within 21 days of initial administration，then the subject increased to 3 and the study design method in this dose level convert to 3+3. If the subject didn't develop toxicity grade ≥2, then the study of the second and next dose group can be carried out using 3+3 incremental design.~Stage 2:~Cohort 1 included patients with advanced head and neck squamous cell carcinoma and cohort 2 included patients with breast cancer. According to the results of dose escalation stage and similar drug trials, 5mg/kg and 10mg/kg dose levels were selected to enter this phase. Each cohort will be extended to include 6-8 subjects to receive this product in combination with the standard treatment study."
45496279|NCT05255874|Other|Aromatherapy|Patients in the study group will rest for 5 minutes before and after the urodynamics procedure. All patients will be asked to fill in the 'Spielberger State Anxiety Scale' before and after the urodynamic procedure. Before and after the procedure, blood pressure, heart rate, respiratory rate, peripheral oxygen saturation will be measured. Blood will be drawn for serum cortisol level. In addition to the routine treatment and care practices of the unit, aromatherapy will be applied to the patients included in the study group. Aromatherapy application will be applied to all patients by the same researcher. Aromatherapy application will be started 5 minutes before the urodynamic procedure after the patient is taken to the urodynamic room, and lavender essential oil (3 drops in 300 cc water for 5 cubic meters of room) will be used with a diffuser until the end of the procedure.
45496280|NCT03247543|Drug|Placebo|Placebo was administered once daily
45496281|NCT03247543|Drug|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
45496282|NCT03247543|Drug|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
45496283|NCT05351190|Device|Dexcom G6 CGM|rtCGM to be worn by user continuously for the duration of the 12 month study
45496284|NCT03637153|Other|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
45496285|NCT03637153|Other|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
45496286|NCT05569525|Procedure|Non-surgical periodontal therapy|Non-surgical periodontal therapy according to the full-mouth debridement protocol.
45496287|NCT01347073|Drug|HPN-100|HPN-100 is a pro-drug of PAA that combines with glutamine to provide an alternative vehicle for waste nitrogen elimination. It is a liquid with minimal taste and odor. Approximately three teaspoons of HPN-100 (~17.4 mL) delivers an equivalent amount as PBA that 40 tablets of NaPBA.
45496288|NCT05569447|Procedure|Balloon Tamponade|A tamponade device that was fashioned using an 18F red rubber catheter and Penrose drain that was cut to the approximate length of the tract and ligated proximally and distally with #0 silk.
45694081|NCT01737697|Drug|Placebo (acute phase)|Randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals for 48 hours during the acute phase.
45694082|NCT01737697|Drug|Placebo ( subacute phase)|Randomized to mimic doses of experimental drug administered once a day prior to the morning meal for 12 days during the subacute phase.
45694083|NCT00853996|Drug|acolbifene hydrochloride|Given orally
45847382|NCT05358132|Device|Pneumowave Device placement and data capture|"Participants in the acute toxicity group will be studied for a period of time during their Emergency Department attendance or in the case of PSA for the duration of their sedation and recovery period.~Usual care will be provided to the patient with additional period with Pneumowave biosensor placed onto chest and data capture for a period of time whilst patient is in the Emergency Department,"
45694084|NCT00841828|Drug|Epirubicin|
45694085|NCT00841828|Drug|Cyclophosphamide|
45694086|NCT00841828|Drug|Docetaxel|
45496289|NCT02618551|Procedure|Bronchial thermoplasty for treatment of severe asthma|"Three sessions of bronchial thermoplasty are needed to treat patients. There will be 3 to 4 weeks between each procedure.~Bronchial thermoplasty procedure is performed under general anesthesia. The medical device used in this research to achieve the thermoplasty is the Alair system (class IIb medical device ; Boston scientific)~A confocal endomicroscopy will be conducted at the first and final session of thermoplasty. This examination involves analyzing and recording the structure of bronchi microscopy through a small catheter placed on the bronchus. Photographs of the bronchi will be realized."
45496290|NCT05569057|Drug|SIM1811-03|SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors
45694087|NCT00841828|Drug|Lapatinib|
45380826|NCT05202197|Other|Smart cupboard|Development of a memory task with the help of a smart cupboard
45380827|NCT05200949|Procedure|Kidney transplant|Transplant surgery of Kidney
45847383|NCT05354466|Drug|Sugammadex injection|sugammadex as reversal agent
45380828|NCT00868283|Drug|Cerebrolysin|30 ml study drug will be given once daily by intravenous infusion for 10 consecutive days.
45380829|NCT00868283|Drug|0.9% Saline Solution|30 ml will be given once daily by intravenous infusion for 10 consecutive days.
45380830|NCT05195879|Diagnostic Test|XTR004|Single dose intravenous injection of XTR004. Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
45380831|NCT00868361|Drug|Talampanel (non-radiolabeled), [14C] Talampanel|50 mg capsule single dose
45380832|NCT04039373|Drug|BMS-986256|specified dose on specified days
45694088|NCT00841828|Drug|Trastuzumab|
45694089|NCT00855010|Drug|pioglitazone|pioglitazone 45 mg daily
45380833|NCT04039373|Drug|Mycophenolate Mofetil|specified dose on specified days
45380834|NCT00875537|Other|Capsaicin oral gel 0.025%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
45380835|NCT00875537|Other|Capsaicin oral gel 0.01%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
45380836|NCT00875693|Drug|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio.
45380837|NCT00878579|Device|PDS System|Percutaneous Dynamic Stabilization System
45694090|NCT00855010|Drug|placebo|one daily
45694091|NCT00855868|Drug|florbetapir F 18|370 MBq (10 mCi), intravenous (IV) injection, single dose
45694092|NCT00855868|Drug|[11C]-PIB|555 MBq (15 mCi), IV injection, single dose [11C]-PIB
45694093|NCT00842296|Device|RF ablation (ClosureFAST)|Segmental RF Ablation with the CLF catheter
45847384|NCT05354466|Drug|Neostigmine|neostigmine as a reversal agent
45847385|NCT05347602|Dietary Supplement|Gold Factor (Gold Nanoparticles, AuNPs)|AuNP used in the study is an aqueous suspension of clean-surfaced, faceted gold nanoparticles that have extraordinary catalytic capabilities. AuNP were 8 - 28 nm in diameter, with varying shapes from bipyramids to polyhedrons. To avoid contamination, AuNP was suspended in ultra-pure water, and were not coated with any proteins or molecules to avoid negative reactions within living tissues. This resulted in a rose-pink color due to the incident light inducing a specific resonance known as the localized surface plasmon resonance. The AuNP supplement used in this study contains elemental gold at 6 ppm. Study dosage is 1 oz per day, which is about 0.17 mg elemental gold per day.
45496291|NCT01315236|Drug|Liposomal amikacin for inhalation (LAI)|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~Administration time is approximately 13 minutes.~Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.~Subjects can continue with 84 additional days of dosing in the open label extension."
45380838|NCT00878579|Device|Fusion|Transforaminal Interbody Fusion (TLIF) with Autograft and Pedicle Screws
45380839|NCT00875771|Drug|Capecitabine+Irinotecan+Bevacizumab|"Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks~Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks~Bevacizumab: 5 mg/kg day 1, every 2 Weeks~Treatment will be given until disease progression or unacceptable toxicity."
46055411|NCT02768181|Behavioral|Nutrition-specific Behaviour change communication (BCC)|Door-to-door counseling on nutrition during pregnancy and exclusive breastfeeding from enrolment into study till birth; exclusive breastfeeding and nutrition of lactating mothers during post-natal 6 months; timely and appropriate complementary feeding with continued breastfeeding until 2 years of child's age, and nutrition of lactating mothers during post-natal 6-24 months; all counseling would be supplemented with associated issues including hygiene and sanitation, mother's sleep and rest, maternal and child healthcare seeking etc.
45380840|NCT00875849|Biological|cetuximab|
45496292|NCT01315236|Drug|placebo|"Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~Administration procedures, volume and administration time are similar to LAI.~Placebo will be administered for 84 days only during the double-blind, randomized portion of the study."
45380841|NCT00875849|Drug|cisplatin|
45380842|NCT00875849|Radiation|radiation therapy|
45380843|NCT00868595|Biological|BPX-101|Vaccine
45380844|NCT00868595|Drug|AP1903|Activating agent, infusion
45496293|NCT03730051|Drug|Gadoterate meglumine|Participants randomized into this arm will receive gadoterate meglumine contrast for their scheduled breast MRI.
45496294|NCT03730051|Drug|Gadobutrol|Participants randomized into this arm will receive gadobutrol contrast for their scheduled breast MRI.
45496295|NCT05627466|Drug|Magrolimab|Administered intravenously
45496296|NCT03232567|Biological|NasoVAX|Single ascending dose study
45380845|NCT00875927|Other|no scraping microcapsules|1, 4 grams isomalt candy containing no scraping microcapsules
45496297|NCT02477358|Procedure|Left Tooth Platelet Rich Fibrin; Right Tooth Implant Alone|All study participants will have two teeth extracted and 2 mm of root removed. Half of the subjects will have platelet rich fibrin endodontic revascularization therapy will be applied to the left tooth socket only. The right tooth is implanted alone. Each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
45496298|NCT02477358|Procedure|Right Tooth Platelet Rich Fibrin; Left Tooth Implant Alone|All study participants will have two teeth extracted and 2 mm of root removed. Half of the subjects will have platelet rich fibrin endodontic revascularization therapy to the right tooth socket only. The left tooth is implanted alone. Each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
45496299|NCT04621045|Behavioral|The Physical Activity for The Heart (PATH) intervention|The web-based Physical Activity for The Heart (PATH) intervention leverages openly accessible platforms, such as YouTube, to proffer workout videos that match the participants preferences. Currently, PATH includes over 90 workout videos vetted by a team of experts and curated on the PATH website in 3 controlled levels of intensity (beginner, intermediate, proficient) to foster gradual progression from low to high intensity PA in accordance with the FITT-VP (frequency, intensity, time, type, volume, progression) principle.
45380846|NCT00875927|Other|scraping microcapsules containing inert TCP microcapsules|1, 4 grams isomalt candy containing 2% inert TCP scraping microcapsules
45380847|NCT00875927|Other|scraping microcapsules containing Propolis|1, 4 grams, isomalt candy containing 2% Propolis scraping microcapsules
45380848|NCT00875927|Other|scraping microcapsules containing and Zinc|1, 4 grams, isomalt candy containing 2% Zinc scraping microcapsules
45380849|NCT00875927|Other|scraping microcapsules containing Propolis and Zinc|1, 4 grams, isomalt candy containing 2% Propolis and Zinc scraping microcapsules
45380850|NCT00878657|Drug|gemcitabine hydrochloride|Pre-Chemoradiation (Induction) Chemotherapy Gemcitabine will be given weekly for seven doses at a dose of 1000 mg/m2/wk (Days 1, 8, 15, 22, 29, 36, 43) unless toxicity develops. Chemoradiation gemcitabine will be given 400 mg/m2, infused over 30 minutes, within 120 minutes before radiotherapy. Post-chemoradiation chemotherapy, patients will receive two cycles of gemcitabine. A cycle will be defined as three weeks of gemcitabine at 1000 mg/m2/d, once weekly, followed by a one-week rest.
45496300|NCT04621045|Behavioral|Be Active Your Way Booklet|Be Active Your Way booklet was developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives. It simply encourages individuals to increase their PA gradually and gives them examples of things that they can do.
45496301|NCT01348490|Drug|Ruxolitinib|Ruxolitinib (INCB018424), 5 mg bid
45496302|NCT03040674|Procedure|Cell therapy|Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day
45496303|NCT03232333|Device|Biologic wound graft|Diabetic foot ulcer will be treated by grafting with MIRODERM Biologic Wound Matrix
45496304|NCT02310204|Behavioral|multidisciplinary education program|both individual and group education sessions over a 6-month period in addition to standard psoriasis care
45380851|NCT00878657|Radiation|intensity-modulated radiation therapy|"Dose escalation levels (cohorts) for this study:~Dose Level 1: GTV plus drainage areas 45 Gy, Boost GTV 50.4 Gy Dose Level 2: GTV plus drainage areas 45 Gy, Boost GTV 54.0 Gy Dose Level 3: GTV plus drainage areas 45 Gy, Boost GTV 59.4 Gy Dose Level 4: GTV plus drainage areas 45 Gy, Boost GTV 64.8 Gy Dose Level 5: GTV plus drainage areas 45 Gy, Boost GTV 70.2 Gy"
45380852|NCT00876005|Other|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 80%
45380853|NCT00876005|Other|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 30%
45496305|NCT02310204|Other|standard psoriasis care alone|
45496306|NCT04080505|Drug|SSKI- Potassium Iodide|1g/mL, 2 drops orally 3 times a day for 7 days before surgery
45496307|NCT05572411|Other|GAITRite Electronic Walkway|Participants will be asked to walk across the electronic walkway to record information relating to their gait pattern. Depending on the age and compliance of the participant, they will be asked to complete 3 passes at 3 speeds, preferred, fast and slow.
45496308|NCT05610696|Other|Low impact immersion|Consists of a sequence of shoulder, trunk and hip movements. In this modality, the aim will be to understand the physiological effects of immersion in heat water. Resisted movements (either by turbulence or by floats) or interventional maneuvers in the knee joints will not be performed. Considering the period of 5 minutes for acclimatization to the liquid environment, the program will last approximately 47 minutes.
45498231|NCT03623802|Other|Integral Movement Therapy|Protocol consists of four basic exercises, which are progressed through sessions: (I) Proprioception - sitting on an unstable surface - Swiss ball, with additional tasks with legs and arms. (II) Strength - pushing task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (III) Strength - pulling task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (IV) Lifting and carrying the loads: a) Stoop lifting. b) Squat lifting. c) Half kneeling lifting.
45694094|NCT00842608|Behavioral|Reduced exposure to anticholinergics|"Using the computerized support, physicians will be notified if they attempt to prescribe a patient a medication with anticholinergic properties and will be given a safe alternative to the drug.~Patients who are in the non-haldol arm will have their medical records manually reviewed by the study pharmacist as the computerized support is not set to differentiate between patients who can & cannot receive Haldol"
45694095|NCT00842608|Procedure|Reduced exposure to benzodiazepines|Tapering exposure to benzodiazepines by 50% over the first 48 hours after mechanical ventilation, complete stop by discharge; no benzodiazepine orders for patients not requiring mechanical ventilation
46055412|NCT02768181|Dietary Supplement|Nutrient supplement to pregnant women (PNS)|"A lipid-based micronutrient supplement (LNS) is packed in ~10g sachets. Formulation: Vegetable fat (soy), skimmed milk powder, peanuts, vitamin and mineral complex, sugar, stabilizer: fully hydrogenated vegetable fat, and antioxidant : tocopherols. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc.~Dose: 1 sachet/pregnant woman/day starting from the first counseling session (GA ~125∓15 days) continued till birth of baby. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink."
46055413|NCT02768181|Dietary Supplement|Nutrienr supplement to children 6m to 2 years|"A lipid-based micronutrient supplement (LNS) is packed in ~10g sachets. Formulation: Vegetable fat, skimmed milk powder, peanuts, sugar, vitamin and mineral complex, maltodextrin, and emulsifier: lecithin. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc. Each 20 g of LNS provide ≥4.46g LA (Linoleic Acid) and ≥0.42g ALA (α-Linolenic Acid).~Dose: 2 sachets ~(10+10=20g)/child/day from 5th completed months (181 days) to 24 completed months of child's age. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink."
45496309|NCT05610696|Other|Conventional aquatic physiotherapy|include warm-up, strengthening and calming down activities. Aquatic steppes will be used to ensure that all participants will maintain the waterline level approximately in the xiphoid appendix. For strengthening activities, the exercises must be performed at an adequate speed, which ensures a comfortable level for the activity. For this purpose, a subjective feedback will be extracted from the participants constantly. The warm-up sequence consists of six different active hip and knee movements performed at maximum range of motion and contributes to neuromuscular activation. For strengthening, each movement should be performed for 1 minute (30 seconds for each lower limb) followed by a period of 30 seconds of rest between each movement.
45380854|NCT00868673|Dietary Supplement|low fructose|"patients will receive a low fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). low fructose arm: a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of healthy fructose diet levels (less than 20 grams/day).Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done."
45380855|NCT00868673|Dietary Supplement|Normal fructose arm|patients will receive a normal fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). Normal fructose arm: participants will receive a 6 week period of normal fructose diet between 50 to 70 grams/day. Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done.
45380856|NCT00879593|Device|PtcCO2|Nocturnal assessment will be performed during the initial polysomnography (and at 6 months) with a combined PtcCO2/pulse oxymetry TOSCA500 Radiometer monitoring evaluating different physiological parameters.
45380857|NCT00879671|Dietary Supplement|lutamax (leutein)|leutein 20 mg for 3 months, then lutein 10 mg
45380858|NCT00879671|Dietary Supplement|placebo|Placebo capsules identical in taste and appearance
45380859|NCT00868829|Device|Firebird2|For the patient participated, only Firebird2 Stent will be implanted.
45380860|NCT03900221|Other|No intervention|No intervention
45380861|NCT00868907|Drug|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
45380862|NCT00868907|Drug|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
45380863|NCT00868907|Drug|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
45380864|NCT00868985|Drug|PEG 3350 plus electrolytes|Each patient was treated with PEG 3350 with electrolytes for 10 days at a dose of either one, two or three sachets per day.
45380865|NCT00868985|Drug|PEG 3350 without electrolytes|Each patient was treated with PEG 3350 for 10 days at a dose of either one, two or three sachets per day.
45380866|NCT00869063|Drug|Diclofenac Sodium Patch|Topical 1% diclofenac sodium patch, applied once daily for 7 days
45847386|NCT05347602|Dietary Supplement|Placebo|For the Placebo, water and red dye were mixed to create a placebo liquid with the same rose-pink shade as the AuNP supplement, along with flavoring that matched the AuNP supplement.
45847387|NCT05346432|Dietary Supplement|PS23|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23
45380867|NCT00869063|Drug|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active drug arm except for diclofenac sodium; applied once daily for 7 days
45496310|NCT05610696|Other|High intensity aquatic physiotherapy|In this modality subjects will perform the same sequence of exercises of the Conventional Aquatic Physiotherapy program will be respected. However the work load and speed will be adjusted to the maximum level. For strengthening, each movement should be performed for 2 minutes (1 minute for each lower limb) followed by a period of 30 seconds of rest between each movement. To guarantee the maximum effort of the participants, verbal stimuli will be constantly provided. The program will last approximately 68 minutes.
45694096|NCT00842608|Drug|Haloperidol|0.5 to 1 mg haloperidol every 8 hours via oral or parenteral route for a total of seven days or until discharge from the hospital
45694097|NCT00842608|Procedure|Usual care|May include use of typical and atypical neuroleptics, benzodiazepines, and other sedatives to manage the symptoms of delirium
45694098|NCT00856024|Biological|Peginterferon alfa-2b|PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg. The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
45694099|NCT00856024|Drug|Ribavirin|Ribavirin 250 mg. The duration of the complete treatment and the doses of ribavirin should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
45694100|NCT00856414|Biological|botulinum toxin Type A|20U, up to two injections administered intramuscularly into the glabella (2 in each side of the corrugators and 1 in the procerus)
45847388|NCT05236140|Device|Perineal electrical stimulation|Perineal electrical stimulation will be performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with perineal surface electrodes. Perineal electrical stimulation will be performed three days a week, 20 minutes a day, a total of 24 sessions for 8 weeks. The stimulation parameters are frequency at 50 Hz, a 5-10s work-rest cycle, and a 300ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100mA (according to the patient's discomfort level feedback). In this application, three surface electrodes which had 2 cm diameters were used; two electrodes symmetrically at the perianal region (medial to ischial tuberosity); and one electrode at the leg (ground-neutral electrode). Surface electrodes will be used individually for each patient. Perineal electrical stimulation sessions will be performed by an experienced urogynecology rehabilitation nurse.
45847389|NCT05144490|Other|Exercise|A single session of bodyweight exercise
45380868|NCT00869219|Drug|Nevanac|1 drop of NEVANAC at random eye
45380869|NCT00869219|Drug|Acular LS|One drop of Acular LS
45380870|NCT00878735|Behavioral|Zen meditation|Zen meditation retreat (7 days: 5 days from 5:30 to 9:30 plus one day for adaptation and the departure day). The program starts everyday at 5:30 and finish at 9:30. In silence, the volunteers perform seating and walking meditation, stretching exercises, eating and all tasks in mindfulness.
45496311|NCT03364049|Drug|MK-7162|oral tablets
45496312|NCT03364049|Biological|Pembrolizumab|IV infusion
45847390|NCT05137704|Other|No intervention|This is a non-interventional study.
45496313|NCT03636919|Other|e-BOOK|Patients will filled an e (carnet) included the questionnaire includes the Control of Allergic Rhinitis and Asthma Test (CARAT)
45496314|NCT05148156|Device|Urolift|Study intervention involves a one-time administration of Urolift in out-patient setting prior to Stereotactic body radiation therapy (SBRT).
45496315|NCT03708029|Other|Revita Allograft|Human placental allograft
45496316|NCT05348772|Drug|AmnioPul-02|Mesenchymal stem / stromal cells, MSC
45496317|NCT05681819|Drug|SHR-1707|Multiple-ascending Dose
45496318|NCT05681819|Drug|SHR-1707 placebo|Multiple-ascending Dose
45694101|NCT00843466|Other|Mild, moisturizing hand cleanser|"Hand cleanser ingredient list:~Ammonium Lauryl Sulfate, Ammonium Laureth Sulfate, Cocamide MEA, PEG-5 Cocamide Cocamidopropyl Betaine Sodium Lauroyl Sarcosinate Glycerin Petrolatum Soybean Oil Sodium Hydroxypropyl Starch Phosphate Lauric Acid Lauryl Alcohol PEG-14M Guar hydroxypropyl trimonium chloride DMDM Hydantoin; Iodopropynyl Butylcarbamate Etidronic Acid Tetrasodium EDTA Titanium Dioxide Fragrance Sodium Hydroxide Water"
45847391|NCT04971096|Dietary Supplement|PS23 live|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 30 billion CFU (colony forming units) of PS23
45847392|NCT04971096|Dietary Supplement|PS23 heat-treated|The PS23 heat-treated probiotic capsule contain 30 billion of PS23 cells.
45380871|NCT00878813|Procedure|Sampling of 15ml blood|On admission, 2 x 7.5ml blood tubes will be drawn during the first routine blood sampling
45380872|NCT00878813|Procedure|Blood-Sampling|On day 1 after intra-arterial thrombolysis, 2 x 7.5ml blood tubes on the following routine blood-sampling will be drawn.
45380873|NCT05100095|Drug|Radiation therapy|Hypofractionated radiation therapy to the primary tumor and/or lymph nodes
45380874|NCT00878891|Device|Continuous glucose monitoring for immediate correction of abnormal glycemia|Prevention of hyper and hypo glycemia
45496319|NCT05343078|Drug|Dapagliflozin 10Mg Tab|Participants will take a single-dose Dapagliflozin 10mg P.O. prior to the hemodialysis session for the single-dose pharmacokinetics protocol. In the multiple-dose protocol, Dapagliflozin 10mg P.O. will be taken daily in the morning for one week.
45496320|NCT03706235|Other|Blood draw (venipuncture)|Draw 40 mls of blood from eligible subjects. Process and ship samples to sponsor.
45496321|NCT03238963|Drug|BI 1467335|Once daily
45496322|NCT03238963|Drug|Placebo|Once daily
45496323|NCT05693298|Device|High Flow Nasal Cannula|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
45694102|NCT00856726|Drug|1-34 parathyroid infusion|1-34 parathyroid infusion at 0.055 mcg/kg/hr for 6 hours
45847393|NCT04971096|Dietary Supplement|Placebo|The placebo capsule contains microcrystalline cellulose.
45847394|NCT04880616|Drug|NBI-827104|Capsules for oral administration
45847395|NCT04880616|Drug|Placebo|Capsules matching NBI-827104 for oral administration
45496324|NCT05693298|Device|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
45496325|NCT05566015|Other|questionnaire|self-administered questionnaires as well as clinical assessment of schizophrenia symptoms and depression.
45496326|NCT03701035|Behavioral|Aerobic Training & UL Motor Training|Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if < 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
45380875|NCT00418665|Biological|AMG 531|AMG 531 will be administered by subcutaneous injection at a dose of 500 or 750 μg.
45380876|NCT00418665|Drug|Placebo|Subjects in the control group will receive placebo via subcutaneous injection.
45380877|NCT03994965|Drug|Pimavanserin 34 milligrams (MG) [Nuplazid]|Daily treatment with 34 mg per os for 6 weeks. Followed by a wash-out period up to 14 days, do to the theoretical risk of corrected QT interval (QTc) prolongation. Conventional anti-psychotic treatment will be initiated only upon normal ECG.
45380878|NCT04648059|Diagnostic Test|Blood sampling|Blood sampling will be performed to allow analyses of epigenetic markers
45380879|NCT01952067|Procedure|line-to-line reaming and cementing technique|
45380880|NCT01952067|Procedure|standard over-reaming with 2 broach sizes|
45496327|NCT03701035|Behavioral|Non-aerobic training & UL Motor Training|40 minutes non-aerobic gait & balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
45496328|NCT03337139|Behavioral|Gold Standard Behavior Therapy for Weight Loss|Group-based behavioral treatment for weight loss, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session). Participants will be asked to utilize digital monitoring devices for physical activity, weight, and diet. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
45496329|NCT03337139|Behavioral|Standard Remote Behavior Therapy for Weight Loss|Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by participant self-report. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
45496330|NCT03337139|Behavioral|Digital Data Sharing Behavior Therapy for Weight Loss|Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by the digital data that has been shared with the coach from physical activity, weight, and diet monitoring devices.
45694103|NCT00857272|Drug|PEG electrolyte lavage solution + bisacodyl - reformulation|multi dose formulation (tablet/solution) for oral administration prior to colonoscopy
45694104|NCT00857272|Drug|PEG electrolyte lavage solution + bisacodyl|multi dose preparation (tablet/solution) for oral administration prior to colonoscopy
45380881|NCT00432237|Drug|MK0974 50 mg|
45496331|NCT05439096|Other|Functional Exercise|Among Functional Exercises, cobra position is most effective in reducing pelvic pain while others are cat and fish position.Kegel exercises along with other strengthening activities for pelvic floor muscles have been accounted for in writing to favorably affect primary dysmenorrheal.
45496332|NCT05439096|Other|High Frequency Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation, best treat primary dysmenorrhea. Transcutaneous Electrical Nerve Stimulation is proposed as an incredible spasm decrease, lessening torment, decline of analgesics and improving personal satisfaction in primary dysmenorrhea patients.
45496333|NCT03683173|Behavioral|Intervention|Participants in the intervention arm may receive community events, partake in walking groups, and receive short messaging service.
45380882|NCT00432237|Drug|MK0974 150 mg|
45496334|NCT05681741|Procedure|current versus high pump flow|during each phase of randomized pump flow, arterial pressure will be increased from 40 to 90 mmHg with vasodilators and/or vasoconstrictors
45694105|NCT03696784|Biological|iC9-CAR19 T cells|iC9-CAR19 T cells will be given by a licensed healthcare provider via intravenous injection over 5-10 minutes through either a peripheral or a central line.
45694106|NCT03696784|Drug|Bendamustine|70mg/m2 IV given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion.
45694107|NCT03696784|Drug|Fludarabine|30 mg/m2 given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion
45847396|NCT04757766|Drug|in daily everyday routine practice|The treatment of patients with chronic venous disease of CEAP classes C6 will be consistent with routine clinical practice, local label for the medical use of drugs and the specific clinical situation.
46055414|NCT02767401|Device|stenting or balloon expansion|all species of drug-eluting stent ((such as Xience, Endeavor, Taxus, Excel, Firebird) implantation or balloon expansion (POBA)
46055415|NCT02767401|Drug|aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
45380883|NCT00432237|Drug|MK0974 300 mg|
45380884|NCT00432237|Drug|Comparator: Placebo|MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.
45380885|NCT00531284|Drug|Carfilzomib|Administered by intravenous (IV) bolus (2-10 minute) infusion or 30 minute infusion
45380886|NCT00531284|Drug|Dexamethasone|Administered orally or by IV infusion prior to carfilzomib
45380887|NCT01005446|Device|Encore Reverse Shoulder Prosthesis (RSP®)|The RSP is indicated for use in subjects with grossly rotator cuff deficient shoulder joints with severe arthropathy or a previously failed joint replacement with a grossly rotator cuff deficient shoulder joint.
45380888|NCT00531206|Drug|Tipranavir|
45380889|NCT00531206|Drug|Ritonavir|low dose
45380890|NCT00994994|Drug|Tranexamic Acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit in TXA group. same volume of normal saline was given in Placebo group.
45380891|NCT04000022|Device|intermittent theta burst stimulation (iTBS)|20 sessions of iTBS
45380892|NCT00999674|Other|An exercise program|The study subjects were recruited among those who responded to advertisements in outpatient clinics
45380893|NCT00999752|Drug|Nebivolol|5mg/day with increase to 10 mg/day to reach blood pressure <140/90
45496335|NCT03964363|Behavioral|Unsupervised home-based physical prehabilitation|Subsequent to screening and initial testing for frailty syndrome, participants receive an information booklet containing a selection of exercises, which allows independent prehabilitation at home.
45496336|NCT03710447|Other|HIIT + WB-EMS|"12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and whole-body electromyostimulation (WB-EMS).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~2 exercise sessions per week. Order of application: HIIT - WB-EMS. Additionally, participants receive individualized nutritional counseling."
45496337|NCT03710447|Other|WB-EMS + HIIT|"12-week supervised exercise program consisting of whole-body electromyostimulation (WB-EMS) and ergometer-based high-intensity interval training (HIIT).~WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: WB-EMS - HIIT. Additionally, participants receive individualized nutritional counseling."
45496338|NCT03710447|Other|HIIT + CST|"12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and conventional low-volume strength training(CST).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~2 exercise sessions per week. Order of application: HIIT - CST. Additionally, participants receive individualized nutritional counseling."
45496339|NCT03710447|Other|CST + HIIT|"12-week supervised exercise program consisting of conventional low-volume strength training(CST) and ergometer-based high-intensity interval training (HIIT).~CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: CST - HIIT. Additionally, participants receive individualized nutritional counseling."
45496340|NCT03710369|Drug|Placebo|The placebo pill was compounded by McDonalds Pharmacy.
45496341|NCT03710369|Drug|Sildenafil|Sildenafil from Pfizer, compounded by McDonalds Pharmacy.
45496342|NCT05681663|Other|Electroshock Wave therapy|Randomized- Controlled trial
45496343|NCT03706157|Drug|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media
45694108|NCT03696784|Drug|AP1903|"0.4 mg/kg of AP1903 as an IV infusion over 2 hrs for subjects who develop Grade 4 cytokine release syndrome (CRS) or grade ≥3 CRS that is unresponsive to standard of care interventions , subjects who develop grade ≥3 Immune effector cell-associated neurotoxicity syndrome (ICANS) that does not improve to grade ≤1 within 72 hours with standard of care interventions, and subjects with grade 4 ICANS of any duration that have evidence of cerebral edema and/or generalized convulsive status epilepticus.~Subjects in the expansion cohort who experience ≥ grade 2 CRS or ICANS that remains ≥ grade 2, twenty-four hours after an initial dose of the standard of care treatment may be part of the sub-study of rimiducid. These subjects will receive one of two assigned dose levels. DL1 and DL2 doses are 0.05 mg/kg and 0.01 mg/kg for subjects and DL1: 0.1 mg/kg and DL2: 0.01 mg/kg for subjects with ICANS."
45694109|NCT03696784|Drug|Cyclophosphamide|500 mg/m2/day administered by IV over 3 consecutive days
45694110|NCT00857506|Drug|florbetapir F 18|370 Mega Becquerel (10 mCi)
46055416|NCT02767479|Drug|rabeprazole-based regimen|This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
46055417|NCT02767479|Drug|esomeprazole^based regimen|This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
46055418|NCT02767791|Other|Acupuncture|Acupuncture
46055419|NCT02767791|Other|Auriculotherapy|Auriculotherapy
46055420|NCT02767635|Drug|Botox-Epic|injected 20 units of Botox into lateral epicondyle in Botox-Epic group
46055421|NCT02767635|Drug|Botox-Tend|injected 20 units of Botox into tender point of muscles in Botox-Tend group
45496344|NCT03706157|Drug|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
45496345|NCT03707795|Drug|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days|Participants will be given four IM injections throughout the study
45380894|NCT00999752|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg/day
45847397|NCT04720404|Behavioral|Mindfulness-Based Stress Reduction|Participants in the intervention group will follow a 4-week adapted MBSR training. The training consists of biweekly sessions of 1,5 hours. The training is structured based on the Mindfulness-Based Stress Reduction training as originally designed by John Kabat Zinn. The program includes both formal and informal meditation exercises.
45496346|NCT01312025|Procedure|conventional laparoscopic cholecystectomy|
45496347|NCT01312025|Procedure|modified laparoscopic cholecystectomy|
45496348|NCT05176535|Dietary Supplement|FertyBiotic Balance|Lactobacillus rhamnosus BPL 205, Lactobacillus plantarum BPL207 and Lactobacillus crispatus BPL209
45496349|NCT03042312|Drug|177Lu-PSMA-617|Lutetium (177Lu) -DOTA (1,4,7,10-tetra-azacyclododecane-N,N',N'',N'''-tetraacetic acid )-PSMA has three components: PSMA is the targeting vector , DOTA (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid) is a radiometal chelator and a linking group, and 177Lu is the beta emitter that upon internalization delivers radiation to the nucleus of tumor cells to cause DNA damage. The targeting vector utilizes glu-urea-lys sequence which is an inhibitor capable of binding to the domain of PSMA. These components have been previously used in human subjects and in medical research.
45496350|NCT05171231|Device|HEMOCOLLAGENE® : Sterile absorbable hemostatic sponges based on bovine collagen - class III MD|"HEMOCOLLAGENE® is an absorbable, sterile and hemostatic sponge, composed of type I undenatured, native and lyophilized bovine collagen (0.027 g per sponge).~HEMOCOLLAGENE® will be inserted into oral sites (mainly the alveoli dental) after post-extraction or post-invasive dental surgical procedure, in case of bleeding not controled by usual hemostatic method. HEMOCOLLAGENE® will be let in place and will undergo a complete and natural absorption after several weeks."
45496351|NCT03706001|Other|Psychotherapy|Psychotherapy has gained increasing acceptance as a major treatment option for mood disorders.
45847398|NCT04720404|Other|Self-help mindfulness/compassion exercises|Participants in the self-help group will receive a 4-week program with daily suggestions for mindfulness/compassion exercises of 30 minutes on a YouTube-channel. Participants can schedule the exercises themselves.
45847399|NCT04720404|Other|Support as usual|Support as usual (SAU) consists of facilities or interventions already available healthcare organisations provided to their healthcare workers (e.g. buddy-, team- and peer support system, shopping/dinner service etc.).
46055422|NCT02767635|Drug|triamcinolone acetonide (Steroid)|injected 40mg of triamcinolone acetonide into lateral epicondyle in Steroid group
46055423|NCT04224441|Drug|Chlorpromazine Pill|The experimental treatment involves the combination of chlorpromazine to the standard treatment with temozolomide solely in the adjuvant phase (after radio-chemotherapy, temozolomide for 5 days every 28, at a dose of 150-200 mg/mq for 6 cycles) of the Stupp protocol. Chlorpromazine will be administered at a dose of 50 mg/day concomitantly with the adjuvant treatment with temozolomide
45380895|NCT00530816|Drug|carfilzomib|Intravenous (IV) injection over 2 to 10 minutes twice weekly for three weeks followed by 12 days of rest.
46055424|NCT02767089|Drug|Prednisone|Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.
46055425|NCT02767089|Drug|Placebo|Placebo tablets similar to Prednisone 2.5 mg and 20 mg were supplied to make the trial doses.
46055426|NCT02767167|Other|Semi-skimmed cow's milk|430ml of semi-skimmed cow's milk / day for 12 weeks
45380896|NCT01005758|Drug|cyclophosphamide|
45380897|NCT01005758|Drug|cytarabine|
45380898|NCT01005758|Drug|dexamethasone|
45380899|NCT01005758|Drug|doxorubicin hydrochloride|
46055427|NCT04711317|Device|Nasal high flow oxygen|Pregnant women scheduled for cesarian section in general anaesthesia will be preoxygenated using nasal high flow oxygen
46055428|NCT02766855|Drug|Cysteamine|Patients were asked to use topical cysteamine 0.55% eye drops every 2 hours while awake to both eyes.
46055429|NCT04705701|Procedure|Hemodialysis|Renal replacement therapy is considered standard of care for end stage renal disease patients for clearing the blood and also helping with volume optimization, has different modalities, in our study we are using intermittent hemodialysis.
46055430|NCT02762643|Drug|DP-R213|Investigational product is prescribed to all of randomized subjects
45380900|NCT01005758|Drug|etoposide phosphate|
45380901|NCT01005758|Drug|hydrocortisone sodium succinate|
45380902|NCT01005758|Drug|imatinib mesylate|
45380903|NCT01005758|Drug|mercaptopurine|
45380904|NCT01005758|Drug|methotrexate|
45380905|NCT01005758|Drug|methylprednisolone|
45380906|NCT01005758|Drug|pegaspargase|
45380907|NCT01005758|Drug|prednisolone|
45380908|NCT01005758|Drug|prednisone|
45380909|NCT01005758|Drug|vincristine sulfate|
45380910|NCT01005758|Other|laboratory biomarker analysis|
45380911|NCT01005758|Radiation|radiation therapy|
45380912|NCT01005836|Behavioral|Cognitive behavioral therapy for youth anxiety|
45380913|NCT01005836|Other|Usual clinic care|
45380914|NCT01005836|Behavioral|Cognitive behavioral treatment for youth depression|
45380915|NCT01005992|Procedure|Fractional laser treatment|A complete treatment will consist in four laser sessions with a second-generation erbium-doped 1,550-nm fractional photothermolysis laser (Fraxel SR laser, Reliant Technologies Inc at 1-month intervals. Treatment will be delivered with a 15-mm tip and concomitant air-cooling system (Zimmer MedizinSystems, Irvine, CA). Fluence and treatment level will be registered on every session and will be adjusted according to patient tolerance.
45496352|NCT05692986|Diagnostic Test|A vaginal swab for aerobic and anaerobic cultures before antibiotic administration, 30 minutes after vaginal prep and every hour thereafter until the surgery is completed.|This is a randomized control trial that will compare chlorhexidine vaginal prep with iodine vaginal prep. Our primary outcome will be assessed using a vaginal swab test to look for aerobic and anaerobic cultures. Positive cultures will be defined as colony forming count of >5000cfu. All patients will receive preoperative antibiotics. Patients will receive a vaginal swab for aerobic and anaerobic cultures before antibiotic administration, 30 minutes after vaginal prep and every hour thereafter until the surgery was completed.
45694111|NCT00858130|Device|VeinOPlus|The Veinoplus® device electrically stimulates leg muscles via motor nerves, causing calf muscle contractions. The two electrodes are placed on the central part of the calf muscle on the back of the legs, and once the device is turned on, the length of treatment is 20 minutes. The device has a variable intensity setting which allows subjects to choose their own level and change the stimulations mid-cycle if desired. Subjects will use the device however they see fit for 2 months.
45694112|NCT01682863|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
45694113|NCT01682863|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
45694114|NCT01682863|Drug|QAB149|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI
46055431|NCT02762643|Drug|Raloxifene|Investigational product is prescribed to all of randomized subjects
46055432|NCT02762643|Drug|Cholecaliferol|Investigational product is prescribed to all of randomized subjects
45694115|NCT01682863|Drug|Placebo|To mimic QAB149
45380916|NCT01005992|Procedure|Standard scar management|The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
45380917|NCT05152472|Drug|Atezolizumab 1200 mg|(Intravenous administration)
45380918|NCT05152472|Drug|Imatinib 400 MG|(Per os)
45380919|NCT01008800|Behavioral|Social Communication|The Center-Based classroom intervention focuses on providing children with an invigorating, motivating learning environment in which emerging skills and knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement week may offer the children experiences that they would not otherwise have (Ramey & Ramey, 1998). Parent training sessions will focus on strategies aimed at improving child social engagement and communication and on topics related to autism characteristics, learning styles, interventions, and resources.
45380920|NCT01008800|Behavioral|Social communication|Parent training sessions will focus on teaching parents strategies for enhancing their child's social engagement and communication. Since parents will be using these strategies across all activities throughout the day, there is an increased likelihood of generalization. For parents of minority and underserved children, this may be the first exposure to responsive interaction strategies (Rudy & Grusec, 2001).
45380921|NCT01006070|Procedure|kyphoplasty|surgical kyphoplasty
45496353|NCT05166785|Other|DPP Tailored for Older Adults and delivered via Telehealth|Diabetes Prevention Program (DPP) Tailored for Older Adults and delivered via Telehealth (DPP-TOAT) will be composed of 16 60-minute weekly sessions followed by six 60-minute monthly support sessions
45694116|NCT02457832|Behavioral|Adapted Tango Dancing|Composed of simple steps, tango involves frequent movement initiation and cessation, multi-directional perturbations and varied rhythms. Participants focus on trunk control and stepping strategies, coordination, somatosensory awareness, attention to partner, path of movement, and aesthetics. Sessions will begin with a typical dance class warm-up consisting of breathing, limbering and postural alignment to upbeat music. Novel step elements will be introduced every class period. Those with PD will partner with an individual without PD. After novel step introduction, the instructor will present rhythmic training, which is indispensable to partnered dancing. Participants will learn 'typical' rhythms from tango and Latin dances, based upon the system of quicks (Q) and slows (S), ubiquitously used in ballroom dance training to understand the temporal relationship of movement to music.
46055433|NCT02766699|Drug|EGFR(V)-EDV-Dox|EGFR(V)-EDV-Dox using EnGeneIC EDV™ technology is a bacterially derived minicell which packages a toxic payload, Doxorubicin, into a 400 nm particle which targets specific cancer cells using bispecific antibodies (BsAb). BsAb-targeted, payload-packaged EDV nanocells only exit the leaky blood vessels associated with tumors and enter into the tumor microenvironment. The BsAb binds to the tumor cell-surface receptor, where the EDV is taken up, broken down within the cancer cell and releases the Doxorubicin. The residual EDVs that do not make it into the tumor microenvironment, are engulfed by cells of the immune system and since the EDVs are derived from bacteria, they carry potent immuno-stimulating components which appear to bypass the immuno-suppression caused by the tumor.
45380922|NCT05092802|Drug|HLX208|450mg bid po
45380923|NCT00615017|Drug|AZD9773 (CytoFab)|intravenous infusions
46055434|NCT04224363|Procedure|staining from cervical esophagus to esophagogastric junction|This group patients were given Lugol's solution staining from cervical esophagus to esophagogastric junction （downward）during chromemdoscopy.
46055435|NCT04224363|Procedure|staining from esophagogastric junction to cervical esophagus|This group patients were given Lugol's solution staining from esophagogastric junction to cervical esophagus（upward）during chromemdoscopy.
45380924|NCT00615017|Other|Placebo|Placebo
45380925|NCT05236244|Other|İntervention group|Diaphragmatic Breathing Exercises
45380926|NCT01006148|Biological|Allogenix Plus|It is a demineralized bone matrix obtained using cortical or cancellous allograft bone that is treated to remove surface lipids and then dehydrated with ethanol and ethyl esther. It is further processed leaving behind proteins, bone growth factors, and collagen. It is combined with lecithin a which is resistant to breakdown by body fluids. It contains Pro Osteon Implant 500R a naturally derived material made from a non-decorative form of coral, which is subject to a patented thermal process, which converts the coral to hydroxyapatite.
45380927|NCT01008878|Behavioral|interdisciplinary intervention|
46055436|NCT04552041|Drug|Prospecta|Oral administration.
46055437|NCT04552041|Drug|Placebo|Oral administration.
46055438|NCT04222881|Procedure|AVF anastomosis|Type of arteriovenous anastomosis
45380928|NCT01006226|Drug|64Cu-ATSM PET|2 64Cu-ATSM PET scan, one pretreatment and one 19-21 days after the first dose of bevacizumab
45380929|NCT00879047|Drug|Alcohol|Consumed orally as liquid mixed with a juice beverage, 1 g/kg formula, administered once at baseline and again at either 2 or 3 weeks
45496354|NCT05166785|Other|In-Person Diabetes Prevention Program (DPP)|Diabetes Prevention Program (DPP) is composed of 16 60-minute weekly sessions followed by six 60-minute monthly support sessions over 12 months in person approved by the Centers for Disease Control and Prevention (CDC)
45496355|NCT03360071|Drug|Allergen Immunotherapy Extract|Allergen Immunotherapy treatment mixture to be delivered subcutaneously
45496356|NCT03360071|Drug|Allergen Immunotherapy Control|Allergen Immunotherapy Control Solution to be delivered subcutaneously
45496357|NCT05692830|Drug|Alcohol|Alcohol administered orally at multiple doses and consumption speeds to test transdermal device accuracy
45496358|NCT05092776|Biological|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
45380930|NCT00879047|Drug|Alcohol placebo|Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks
45380931|NCT01008956|Biological|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injection, one dose
45380932|NCT01006304|Drug|JNJ-39439335, Placebo|
45380933|NCT03742700|Behavioral|Cigarette smoking|T-smokers were asked to smoke a cigarette of one of the popular brands (0.6mg nicotine per one cigarette) according to their everyday habits.
45380934|NCT03742700|Behavioral|E-cigarette use|E-smokers and dual users were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
45380935|NCT03742700|Behavioral|Simulation of the use of e-cigarette|The control subjects were asked to simulate the use of e-cigarettes (a device without e-liquid where aerosol was not created or inhaled).
45380936|NCT00879749|Biological|9 micrograms Nexvax2|9 micrograms, weekly intra-dermal injection, 3 week duration
45380937|NCT00879749|Biological|30 micrograms Nexvax2|30 micrograms, weekly intra-dermal injection, 3 week duration
45380938|NCT00879749|Biological|90 micrograms Nexvax2|90 micrograms, weekly intra-dermal injection, 3 week duration
45380939|NCT00879749|Biological|60 micrograms Nexvax2|60 micrograms, weekly intra-dermal injection, 3 week duration
45496359|NCT05092776|Drug|Placebo|Normal Saline (0.9% Sodium Chloride solution for subcutaneous Injection), 2 mL in the 4 mL-glass vial. The placebo will contain no active pharmaceutical ingredients.
45496360|NCT03710213|Behavioral|Text Message-based Intervention|The intervention consists of a series of educational and reminder text messages that a patient will receive in the week prior to a scheduled colonoscopy, in addition to two text messages at the time of enrollment explaining the texting program.
45847400|NCT04683900|Other|Standard of care + Mediterranean diet (intervention)|"Participants will receive a constipation management handout that is distributed regularly to patients who present with constipation symptoms at an outpatient neurology clinic. The handout recommends increasing fluids daily, as well as increasing physical activity and dietary fiber intake. Laxative medications and recommendations for usage are included.~Participants will be instructed to include the following in their diet: a) abundant use of olive oil for cooking and dressing dishes; b) consume ≥2 daily servings of vegetables; c) ≥2-3 daily serving of fruits; d) ≥3 weekly servings of legumes; e) ≥3 weekly servings of fish/seafood; f) ≥3 weekly serving of nuts/seeds; g) select white instead of red or processed meats; h) cook at least twice a week with sofrito. Limit consumption of cream, butter, processed meat, sugared beverages, industrial bakery products and desserts, and French fries or chips. For usual drinkers, the main source of alcohol should be wine."
45380940|NCT00879749|Biological|Up to 900 micrograms Nexvax2|Up to 900 micrograms, weekly intra-dermal injection, 3 week duration
45847401|NCT04683900|Other|Standard of care (control)|Participants will receive a constipation management handout that is distributed regularly to patients who present with constipation symptoms at an outpatient neurology clinic. The handout recommends increasing fluids daily, as well as increasing physical activity and dietary fiber intake. Laxative medications and recommendations for usage are included.
45496361|NCT05058924|Drug|Prophylactic low molecular weight heparin|Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight <100 kg for 6 weeks.
45380941|NCT00879749|Other|Placebo|100 microlitres 0.9% sterile sodium chloride for injection
45694117|NCT02457832|Behavioral|Behavioral Control (BC) Condition|Group health education sessions adapted to the needs of individuals with PD, about pharmacological management, nutrition, sleep disorders, cognitive deficits, bereavement coping, mobility, balance and home safety.
45496362|NCT05058924|Drug|Low molecular weight heparin and low-dose aspirin|Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight <100 kg for three weeks followed by ASA 81 mg orally daily for three weeks.
45694118|NCT02453620|Drug|Entinostat|Given PO
45694119|NCT02453620|Biological|Ipilimumab|Given IV
45694120|NCT02453620|Biological|Nivolumab|Given IV
45694121|NCT02453620|Other|Pharmacogenomic Study|Correlative studies
45694122|NCT02453620|Other|Pharmacological Study|Correlative studies
45847402|NCT04608396|Drug|AXS-05|AXS-05 taken daily for up to 52 weeks, until relapse.
45847403|NCT04608396|Drug|Placebo|Placebo taken daily for up to 52 weeks, until relapse.
45694123|NCT02417818|Device|Plasma Therapy (PlasmaDerm)|Plasma Therapy (PlasmaDerm)
45694124|NCT02417818|Device|Repetitive Plasma Therapy (repetitive PlasmaDerm)|Repetitive Plasma Therapy (Repetitive PlasmaDerm)
45694125|NCT01951625|Drug|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
45694126|NCT01951625|Drug|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
46055439|NCT02762409|Other|experimental|corresponding to surviving individuals of a hospitalization in intensive care in a department having set up the program of reduction of the discomforts collected by the patients of intensive care during a minimal period of 5 months. The program is so defined as factor of exposure and supposed protector of development of anxio-depressive disorders.These patients will have been included in the study IPREA3 in 17 centers of the interventional group of the study IPREA3 during the months of April, 2015 and October, 2015
45694127|NCT01951625|Drug|Placebo|
45380942|NCT00869297|Other|Goal Directed Fluid Administration|Intravenous Fluid will be given if SVV exceeds 13%
45380943|NCT00869297|Other|Control|Fluids titrated at discretion of anesthesiologist.
45380944|NCT00999986|Drug|cyclophosphamide|50 mg oral per day for 7 days
45380945|NCT05226611|Other|Counterstrain|Counterstrain is a hands-on OMM technique that involves shortening the muscle to resolve the dysfunctional muscle stretch reflex and holding it for 90 seconds. The patient is then brought back to a neutral position and reassessed.
45380946|NCT05181644|Device|EmoLED treatment|Treatment with the EmoLED device consists of irradiating each area of 5 cm in diameter of the lesion for 60 seconds; if the lesion is larger than 5 cm in diameter, the applications will be repeated up to cover the entire area of interest. EmoLED treatment is additional to the standard therapy for the patient.
45380947|NCT05181644|Procedure|current Standard of Care|The acral lesions will be cleansed with physiological solution, disinfected with a special device and, if necessary, a debridement will be carried out with the most appropriate method.
45694128|NCT04400890|Drug|Resveratrol|Resveratrol vs placebo given for 15 days.
45694129|NCT04400890|Dietary Supplement|Vitamin D3|Vitamin D3 100,000 IU given on day one.
45694130|NCT01936649|Drug|AdreView (Iobenguane I 123 Injection)|AdreView 10 mCi as a single i.v administration
45496363|NCT04745507|Other|Inpatient Equivalent Home Treatment|At-home psychiatric treatment by means of a multiprofessional clinic team (an equivalent to stationary psychiatric care).
45694131|NCT04351438|Device|Active Comparator: centrifuge TPE with citrate|Patients who received citrate-based anticoagulation with centrifuge TPE
45496364|NCT05051124|Behavioral|Peer Delivery of Medications|The study team will adopt a novel approach of extending beyond the use of peer support in the clinical setting and implement door-to-door peer delivery of medications within patients' communities
45496365|NCT05051124|Behavioral|Health Information Technology (HIT) Platform|To support peer delivery, the study team will use a HIT platform that performs 4 core functions: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) tracking medication refills to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data. This is an innovative use of HIT to accomplish these functions to support medication adherence.
45694132|NCT04351438|Device|Active Comparator: Filter TPE with heparin|Patients who received heparin-based anticoagulation with filter TPE
45694133|NCT04351438|Drug|Active comparator: Filter TPE with citrate|Patients who received citrate-based anticoagulation with filter TPE
45694134|NCT04330846|Procedure|Surgical resection|The type of endoscopic treatment will be initially with EBD and if a failure treatment occurred then a SEMS will be placed.
45380948|NCT05178758|Device|Virtual Reality (VR)|Patients in the intervention (VR) group will receive a series of occupational and physical therapy rehabilitation training using the VR system. All training is consists of daily activities oriented by an occupational therapist, including grasp, grip, pinch, gross, and finger-hand coordination movement. Each training will take around 1 hour for one session per day 5 times per week over a maximum of 4 weeks. The training presented a one-on-one that allowed interaction between instructor (or VR system) and participant.
45496367|NCT05681429|Drug|Lignocaine, Dexmedetomidine, Sevoflurane, Paracetamol, Parecoxib|To compare the recovery outcome of patients who undergo supratentorial craniotomy with opioid-based anaesthesia and opioid-free anaesthesia
45496368|NCT05024760|Drug|Chlorhexidine|Chlorhexidine will be inserted into the dental implant internal cavity during dental implant insertion.
45496369|NCT05024760|Drug|Hydrogen Peroxide|Hydrogen Peroxide will be inserted into the internal cavity of the dental implant during dental implant insertion.
45496370|NCT05176067|Radiation|Thoracic Three-dimensional Radiotherapy|Drug Therapy Combined With Thoracic Three-dimensional Radiotherapy
45496371|NCT03705689|Other|validation of Bitts|No intervention, observation of photographs of stool
45380949|NCT01009112|Behavioral|PTSD + IRT/CBT-I|6 weeks of prolonged exposure, 5 weeks of imagery rehearsal therapy, and 7 weeks of cognitive behavioral therapy for insomnia
45694135|NCT01720069|Drug|VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
45380950|NCT01009112|Behavioral|PTSD + Supportive Care Therapy|6 weeks of prolonged exposure + 12 weeks of supportive care therapy
45694136|NCT02337244|Device|Zimmer Persona Total Knee System|No Intervention
45694137|NCT00860314|Procedure|external electrical cardioversion (with antero-posterior electrode position)|external biphasic electrical cardioversion with step-up-protocol of 50-75-100-150-200 Joules if necessary with antero-posterior electrode position until restoration of normal sinus rhythm
45694138|NCT00860314|Procedure|external electrical cardioversion (with antero-lateral electrode position)|external biphasic electrical cardioversion with step-up protocol of 50-75-100-150-200 Joules if necessary with antero-lateral electrode position until restoration of normal sinus rhythm
45694139|NCT04135027|Other|no interventions|no interventions
45694140|NCT00890656|Drug|Cyclophosphamide (CTX)|300 mg/m^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of
45694141|NCT00890656|Drug|Vincristine|2 mg by vein (IV) weekly for 3: Days 1, 8, 15
45694142|NCT00890656|Drug|Doxorubicin|50 mg/m^2 by vein (IV) over 24 hours
45496372|NCT05331300|Drug|LASN01|Escalating doses of LASN01 will be given in different cohorts of Parts A, B and C.
45694143|NCT00890656|Drug|Decadron|80 mg by vein (IV) or by mouth (P.O.) daily days 1-4 and 15-18
45694144|NCT00890656|Drug|G-CSF|10 mcg/kg/day (rounded) by vein (IV) or under the skin (subcutaneously) within 72 ± 48 hours
45694145|NCT00890656|Drug|Methotrexate (MTX)|200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1
45694146|NCT00890656|Drug|Ara-C|3 gm/m^2 by vein (IV) over 2 hours every 12 hours for 4 doses on days 2 and 3.
45694147|NCT00890656|Drug|Pegaspargase|2,500 units/m2 by vein (IV) on day 1 of odd courses and day 5 of even courses
45694148|NCT04311112|Drug|Placebos|Placebo
45694149|NCT04311112|Drug|ZA Low dose|ZA low dose
45694150|NCT04311112|Drug|ZA high dose|ZA high dose
45694151|NCT00814138|Drug|Methotrexate|10 mg weekly for 2 weeks and then increase to 15mg for 2 weeks and then 20mg weekly until the end of the study
45694152|NCT00814138|Other|Placebo|Weekly
45694153|NCT00860938|Drug|Budesonide|After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo
45496373|NCT05331300|Drug|Placebo|Escalating doses of matching placebo will be given in different cohorts of Parts A, B and C.
45847404|NCT04561128|Drug|SHR-1819|SHR-1819 will be subcutaneously administered with different dose levels
45380951|NCT01000142|Procedure|Osteopathic Manipulative Treatment|Focused osteopathic musculoskeletal exam; paraspinal muscle inhibition and/or soft tissue kneading or stretching; rib raising and or rib mobilization; abdominal diaphragm release technique; abdominal mesenteric/colon release; thoracic inlet release technique; hip flexion/extension range of motion; shoulder range of motion with pectoral traction; cervical paraspinal muscle inhibition and/or soft tissue kneading or stretching; suboccipital release technique; specific OMT of significant somatic dysfunction (variable).
45380952|NCT01000142|Procedure|Light Touch|Focused osteopathic musculoskeletal exam; contact ribs to simulate rib raising and paraspinal muscle inhibition; contact lower rib margin to simulate abdominal diaphragm release; palpate the four quadrants of the abdomen to simulate abdominal mesenteric/colon release; contact shoulders to simulate thoracic inlet release; contact suboccipital region to simulate thoracic inlet release.
46055440|NCT02762409|Other|control|"The patients not exposed in the supposed factor protector of development of anxio-depressive disorders will be constituted by the patients estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having never operated the program of reduction of the discomforts collected by the patients of intensive care. These patients will have been included in the study IPREA3 in 17 centers of the group control some study IPREA3 during October 2014 and April, 2015"
45380953|NCT01000220|Drug|Omeprazole|
45380954|NCT01000220|Drug|Placebo|
45380955|NCT01006460|Drug|Rhodiola rosea, L|3 Capsules twice a day
45380956|NCT01006460|Drug|Rhodiola rosea, L., Eleutherococcus senticosus, Schisandra chinensis|3 capsules twice a day
45380957|NCT01006460|Drug|Panax ginseng|3 capsules twice a day
45380958|NCT01006460|Drug|Placebo - dark brown sugar|3 capsules twice a day
45380959|NCT01006694|Other|Behavioral Activation + Medication|Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
45380960|NCT01006694|Drug|Guideline Antidepressant Medication|Guideline Antidepressant Medication, following the VN National Mental Health plan.
45380961|NCT01006772|Other|Solid Ankle Foot Orthosis|Polypropylene (homopolymer) AFO with carbon fiber reinforcements is provided to experimental group patients as an adjunct therapy to conventional physical therapy.
45380962|NCT04000100|Procedure|ultrasound- guided supraclavicular brachial plexus block|"Patient lie down supine with head turned 45 degrees to the contralateral side and ipsilateral arm adducted gently by the assistant and the shoulder kept down with flexed elbow.~After sterile preparation of the skin and the ultrasound probe (12 MHz probe) were used, the brachial plexus was visualized by placing the transducer in the sagittal plane in the supraclavicular fossa behind the middle-third of the clavicle. Two distinct appearances of the brachial plexus was seen at the supraclavicular region, it either appeared as 3 hypoechoic circles with hyperechoic outer rings or as a grape like cluster of 5 to 6 hypoechoic circles, located lateral and superior to the subclavian artery between the anterior and middle scalene muscles at the lower cervical region figure"
45380963|NCT01000298|Drug|Placebo|liquid placebo medication given twice per day for 7 days
45496374|NCT04999020|Drug|Ravulizumab|Intravenous dosing will consist of a loading dose followed by maintenance doses administered every 8 weeks (q8w). The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
45496375|NCT04999020|Drug|Placebo|Intravenous dosing will consist of a loading dose followed by maintenance doses administered q8w. The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
45496376|NCT05319522|Behavioral|Acute Exercise|Participants with and without SCI will complete an arm ergometer, high-intensity interval exercise bout. The exercise bout will be performed at a relative intensity based on previously determined peak power output during an arm ergometer graded exercise test.
45380964|NCT01000298|Drug|Amoxicillin|liquid amoxicillin given twice per day for 7 days
45380965|NCT01000298|Drug|Cefdinir|liquid cefdinir given twice per day for 7 days
45380966|NCT00614939|Drug|Saxagliptin|2.5 mg once daily oral dose
45380967|NCT00614939|Drug|Placebo|Placebo
45380968|NCT01009268|Procedure|Orthogeriatric intervention|The intervention group will be transferred as soon as possible to the orthogeriatric ward, stabilised there preoperatively, and transferred back to the same ward postoperatively for further treatment and rehabilitation, while the control group will be treated in a traditional orthopaedic ward. Operative and anaesthesiologic procedures will be the same in the two groups.Clinical routines for the orthogeriatric service has been developed during the pilot phase in 2008 and 2009, and are documented in the electronic library of clinical handbooks at Department of Geriatric Medicine.
45380969|NCT05176964|Radiation|split-course HFRT|7Gy/F, d7, q3w, 5 cycles
45380970|NCT05176964|Drug|CAPOX chemotherapy|CAPOX chemotherapy will commence on day 1 for each of six cycles: oxaliplatin 130 mg/m^2 intravenous infusion on day 1,followed by capecitabine 1000 mg/m^2 administered orally twice daily on day 1 to 14 of a 21-day cycle.
45694154|NCT00862186|Behavioral|'Fatigue Facts & Fixes'|"'Fatigue Facts & Fixes' is an evidence based educational resource for adolescents with cancer. It is a bright colored laminated 8.5x11 double sided page. One side features information on cancer-related fatigue: Why am I so tired? (description of cancer-related fatigue); What causes fatigue? (contributing factors - environmental, personal/behavioral, cultural/family/other, and treatment-related); and What can help me to not be so tired? (alleviating factors - environmental, personal/behavioral, cultural/family/other, and treatment-related). The other side is a 'Do Not Disturb' sign with a pillow graphic which adolescents can use in the hospital or at home when they need some quiet time and which may also serve to attract their interest to the resource."
45694155|NCT01719757|Drug|Oxycodone/Naloxone|Twice daily
45694156|NCT01718509|Drug|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
45380971|NCT05176964|Drug|Tislelizumab|Tislelizumab 200 mg intravenous infusion on day 1 of each 21-day cycle for each of six cycles.
46055441|NCT04224207|Biological|Wharton's jelly derived mesenchymal stem cell|The mesenchymal cells that were used in this study were isolated from Wharton's jelly of the umbilical cord that was collected allogenicly from a single donor with the mother's consent. All cell preparation and cultivation procedures were conducted in a current Good Manufacturing Practice (cGMP) accredited laboratory (Onkim Stem Cell Technologies, Turkey).Cells were solubilized from cryopreservation before being made ready for injection. Average cell viability for each treatment was over 90.0% and each patient received cell numbers between 2-6x106 in a 1.5 ml saline solution .
45380972|NCT01006928|Other|Questionaire|Questionaire to mothers
45380973|NCT00869453|Other|test meal|Mixed meal containing bread, butter, beef
45380974|NCT00869453|Other|glucose|administration of a glucose meal
45380975|NCT00869453|Other|fat|administration of a lipid meal
45694157|NCT01718509|Drug|Placebo|Administered once-daily, orally, for up to 12 weeks
46055442|NCT04223895|Drug|CKD-386 Formulation 1|A single oral dose of 1 tablet under fasting conditions for each period
46055443|NCT04223895|Drug|CKD-386 Formulation 2|A single oral dose of 1 tablet under fasting conditions for each period
45380976|NCT00869453|Other|protein|administration of a protein meal
45380977|NCT00869453|Other|control|no meal
45380978|NCT01007006|Device|TMRDU|The TMRDU will assist study subjects with taking their medications as prescribed by notifying them when the next dose is due and tracking whether and when it was taken.
45380979|NCT00879827|Biological|Pediarix TM, Infanrix penta TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
45380980|NCT00879827|Biological|Hiberix TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
45380981|NCT05734352|Other|Questionnaire|Completion of the patient reported experience measurements (PREMs) questionnaire
45380982|NCT01007084|Drug|Propranolol|40 mg
45380983|NCT01007084|Drug|Propranolol ER|120 mg twice per day
45380984|NCT01007084|Drug|Sugar pills|sugar pill
45380985|NCT01000532|Device|SIELLO JT/T|Implantation of SIELLO and BPPU pacemaker leads
45380986|NCT01000532|Device|Pacemaker therapy|Pacemaker therapy
45380987|NCT01000532|Device|BPPU JT/T|Implantation of SIELLO and BPPU pacemaker leads
45380988|NCT00879281|Behavioral|Action plan|"Individualized written Action Plan to enhance self-management and early detection of an exacerbation."
45496377|NCT02949011|Drug|Baloxavir Marboxil|Tablets taken orally
45496378|NCT02949011|Drug|Placebo to Baloxavir Marboxil|Matching tablets taken orally
45496379|NCT02949011|Drug|Oseltamivir|Capsules taken orally
45694158|NCT01857934|Drug|cyclophosphamide|Given intravenously (IV)
45380989|NCT04040309|Biological|PRGF injection|Plasma rich in growth factors will be prepared following the protocol described by E. Anitua. 9 ml of patients venous blood will be taken into one tube with 3,8% sodium citrate used as an anticoagulant. The blood then will be centrifuged (PRGF Centrifuge System, Biotechnology Institute, Vitoria, Spain) at room temperature for 8 min at 1800 rpm. After centrifugation 1 ml of 2nd plasma fraction will be collected by using a pipet. To activate plasma 10% calcium chloride will be used immediately before injecting plasma into the trigger point in the masseter muscle.
45496380|NCT02949011|Drug|Placebo to Oseltamivir|Matching placebo capsules taken orally
45694159|NCT01857934|Drug|topotecan|Given IV
45496381|NCT05595954|Other|Preoperative data collection|Preoperatively, patients will be assessed with Montreal Cognitive Assessment (MoCA), Geriatric Depression Scale (GDS), Clinical Frailty Scale, 3-minute Diagnostic interview for Confusion Assessment Method-defined delirium (3D-CAM, incl. severity score), modified National Institutes of Health Stroke Scale (mNIHSS), and hand grip strength measurement (using a hand dynamometer) to establish a baseline measurement of the physical, cognitive and mental status.
45380990|NCT04040309|Drug|Lidocaine injection|1 ml 2 % Lidocaine will be injected into the trigger point in the patient's masseter muscle.
45380991|NCT00869531|Other|wholegrain|wholegrain wheat vs. refined wheat products
45380992|NCT00869531|Other|refined wheat|refined wheat products
45496382|NCT05595954|Diagnostic Test|Intraoperative NIRS|Intraoperatively, NIRS data will be collected and recorded in real-time.
45496383|NCT05595954|Diagnostic Test|Intraoperative TCD|Intraoperatively, TCD data will be collected and recorded in real-time.
45694160|NCT01857934|Biological|hu14.18K322A|Given IV
45694161|NCT01857934|Procedure|peripheral blood stem cell harvest|Following evaluation and approval by a member of the transplant staff and completion of the consent form by the participant, collection of peripheral blood stem cells (PBSC) may take place.
45847405|NCT04561128|Drug|Placebo|Placebo will be subcutaneously administered with different dose levels
45847406|NCT04095624|Behavioral|Spinal Fusion Preoperative Opioid Taper|Guided weekly opioid pain medication reduction via telephone calls prior to elective spinal fusion surgery.
45847407|NCT04095624|Other|Non-taper Control|Weekly phone calls prior to elective spinal fusion surgery, without opioid pain medication reduction recommendation or guidance.
45847408|NCT03745716|Drug|APR-246 + azacitidine|"Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
46055444|NCT04223895|Drug|D012, D326 and D337|A single oral dose of 3 tablets(D012, D326 and D337) under fasting conditions for each period
46055445|NCT04224051|Drug|Metformin|Metformin target dose 2 g daily
46055446|NCT04224051|Other|Standard care|Abdominal aortic aneurysm surveillance
45380993|NCT01000688|Drug|vildagliptin + acarbose|4 week treatment
45380994|NCT01000688|Drug|acarbose + vildagliptin|4 week treatment
45380995|NCT00879905|Drug|HSP990|
45380996|NCT01007240|Device|polyethylenimine (PEI) nanoparticles.|
45380997|NCT00879983|Drug|azithromycin (Zithromax)|"a single dose of azithromycin ER 2g~3-day regimen of azithromycin tablet 500mg"
45380998|NCT00879983|Drug|azithromycin (Zithromax)|"3-day regimen of azithromycin tablet 500mg~a single dose of azithromycin ER 2g"
45496384|NCT05595954|Diagnostic Test|Intraoperative invasive MAP|Intraoperatively, invasive arterial blood pressure data will be collected and recorded in real-time.
46055447|NCT02762487|Device|The LINX® Reflux Management System|The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
46055448|NCT04547283|Other|Usual Care|No clinical team recommendation, patients will remain in their natural choice of position
46055449|NCT04547283|Other|APPS|Clinical team guidance on prone positioning of patients
45496385|NCT05595954|Diagnostic Test|Postoperative NIRS|Postoperatively, NIRS monitoring will be continued in the ICU after the surgery until (i) endotracheal extubation, or (ii) for the first 24 hours or (iii) until emergency re-operation, whichever occurs first.
45496386|NCT05595954|Other|Postoperative data collection|Postoperatively patients will be evaluated for POD with 3D-CAM or CAM-ICU and for clinical stroke with mNIHSS. Postoperative neurocognitive disorders will be assessed using MoCA.
45496387|NCT05595954|Diagnostic Test|Collection of serum biomarker panel|The serum biomarker panel will consist of four markers of neurological injury glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), t-tau and ubiquitin-C-terminal-hydrolase-L1 (UCH-L1). Blood samples will be obtained preoperatively, after ICU admission, on postoperative day 1, 2, 6 (or hospital discharge, whichever occurs first) and between 6 and 12 weeks after surgery.
45380999|NCT01007318|Procedure|Single port laparoscopic appendectomy|Single port through the transumbilical 2-cm incision
45381000|NCT01007318|Procedure|3 port laparoscopic appendectomy|3 trocars was inserted in infraumbilical, left lower quadrant, and suprapubic area
45381001|NCT00880061|Drug|IL13-PE38QQR|
45496388|NCT05595954|Diagnostic Test|Collection of blood sample for genetic study|A blood sample for the genetic study will be obtained preoperatively.
45496389|NCT03787368|Drug|BAY1213790|Single intravenous infusion of BAY1213790 (Two different doses)
45496390|NCT03787368|Drug|0.9% sodium chloride solution|Single intravenous infusion of Placebo (0.9% sodium chloride solution)
45496391|NCT03705611|Diagnostic Test|HIV self-testing only|Partners will be asked to self-test for HIV following receipt of the test kit from their sexual contact at home or in the community. They will also get information about the partner's clinic -- an HIV testing service room dedicated to providing HIV testing, confirmatory HIV testing, and referral to HIV treatment and prevention services including couples counselling.
45496392|NCT03705611|Behavioral|HIV self-testing secondary accuracy|A monetary incentive provided conditional on clinic attendance and fulfillment of secondary accuracy procedures such as undergoing on spot finger prick rapid HIV testing
45496393|NCT05145725|Behavioral|Quality of life questionnaires|Different questionnaires to fill : SRS-22r, SF-36 score, TAPS, KIDSCREEN10
45381002|NCT00869687|Device|Poly-L-Lactic Acid Injection|0.05 mL of poly-l-lactic acid will be injected as depot at three (3) points (a total of 0.15 mL).
45496394|NCT03705533|Drug|Telmisartan|Telmisartan is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 80 mg of telmisartan.
45496395|NCT03705533|Drug|Micardis|Micardis is manufactured by Boehringer Ingelheim Ellas AE, Greece. Each tablet contains 80 mg of telmisartan.
45847409|NCT03745716|Drug|Azacitidine|"Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
46055450|NCT04540341|Other|Mulligan mobilization|Mulligan mobilization technique will be apply.
46055451|NCT04540341|Other|Core stabilization|Core stabilization technique will be apply.
46055452|NCT04540341|Other|Conventional therapy|Conventional therapy exercise will be apply.
46055453|NCT02762253|Drug|Riboflavin drops|Riboflavin drops were used every 2 minutes for 30 minutes on the cornea then exposed to 5 minutes of Ultraviolet light at an intensity of 18mW/cm2
46055454|NCT02762097|Procedure|polypectomy|. During the second visit after she consents to removal of polyp revealed on prior saline sonography, a dilatation and curettage would be performed under ultrasound guidance and after successful removal of polyp (polypectomy) saline sonography would be repeated to ensure completeness of removal.
45381003|NCT00869765|Drug|D-Cycloserine|100 mg D-cycloserine once every weekday taken 2 hours before tDCS session.
45381004|NCT00869765|Device|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
45381005|NCT00530504|Device|PROTÉGÉ™ GPS™ and PROTÉGÉ™ RX Carotid Stent Systems and SpiderFX™ Embolic Protection Device|Carotid artery stenting with distal embolic protection.
45381006|NCT00869843|Procedure|RF Ablation|
45381007|NCT00880139|Procedure|Blood sampling|Determination of cytokine plasma levels (ELISA)
45381008|NCT00880139|Procedure|Noninvasive measurement of systemic hemodynamics|performed once
45381009|NCT00880139|Procedure|Visual acuity assessment|ETDRS charts
45381010|NCT00880139|Device|Blue field entoptic technique (Blue field stimulator, BFS-2050)|performed once
45381011|NCT00880139|Procedure|Ophthalmic examination and fundus photography|7 + 1 standard fields
45381012|NCT00880139|Device|Retinal Vessel Analyzer (DVA)|Assessment of retinal vessel reactivity to stimulation with flickering light
45381013|NCT00880139|Device|High resolution optical coherence tomography (OCT)|performed once
45496396|NCT05177627|Other|Theoretical and classroom learning interventions|"aim of intervention: introduce students to the conceptual framework of fundamental of care, focus on three dimensions necessary for the delivery of high-quality fundamental care (the nurse-patient relationship; addressing different fundamental needs; and a context that supports these goals)~components and activities:~educational interventions to understand how the communication and the relationship of trust between nurse and patient are the prerequisites for high quality nursing care;~drawing attention to five essential relational elements for establishing the nurse-patient relationship (Trust; Focus; Anticipate; Know; Evaluate)~mode of delivery:~classroom lessons on philosophies and theories on communication and trust~small-group learning on realistic cases focused on fundamental needs to develop reflexivity, analytical skills, investigation~duration of the intervention: 12 hours of theoretical and classroom learning"
45694162|NCT01857934|Procedure|surgical resection|The primary tumor will be resected surgically following two initial courses of chemotherapy, if feasible. Patients who are unable to have their primary tumor resected after the initial two courses of induction chemotherapy will undergo surgery for resection of the primary tumor mass and careful lymph node staging.
45381014|NCT03999632|Other|Dietary modification with introduction of Mankai|Substituting the standard high protein, low carbohydrate preoperative shake during the preoperative liquid diet with Wolffia Globosa (Mankai) shake consisting of 16 oz of skim milk + 1 frozen cube of Wolffia Globosa (Mankai) +/- sugar substitute.
45694163|NCT01857934|Drug|cisplatin|Given IV
45694164|NCT01857934|Drug|etoposide|Given IV
45381015|NCT01007474|Device|Implantable Cardioverter-Defibrillator (ICD)|Medtronic market-released implantable cardioverter-defibrillator
45694165|NCT01857934|Drug|doxorubicin|Given IV
45847410|NCT03651336|Device|ARGOS-IO Sensor Pressure System|The ARGOS-IO Pressure sensor have been additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery in previous studies ARGOS-01 and ARGOS-02
45847411|NCT03395340|Drug|Ruxolitinib 1.5% cream|Topical formulation of ruxolitinib, a Janus kinases (JAK) 1/2 inhibitor.
45847412|NCT03395340|Drug|vehicle cream|Matching vehicle cream applied as a thin film
45847413|NCT03341676|Drug|Dexamethasone|Dexamethasone 3.3 mg/mL solution for injection
45694166|NCT01857934|Drug|vincristine|Given IV
45694167|NCT01857934|Drug|busulfan|Given IV
45694168|NCT01857934|Drug|melphalan|Given IV
45694169|NCT01857934|Biological|peripheral blood stem cell transplantation|Transplantation of previously harvested peripheral blood stem cells.
45381016|NCT01007474|Device|Implantable Pacemaker Generator (IPG)|Medtronic market-released implantable pacemaker generator
45381017|NCT01007474|Device|Implantable Loop Recorder (ILR)|Medtronic market-released implantable loop recorder
45847414|NCT03341676|Drug|Placebo|Sodium Chloride 0.9% w/v solution for injection
45847415|NCT03121716|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
45847416|NCT03121716|Drug|Gemcitabine|gemcitabine
45847417|NCT03121716|Drug|cis-platinum|cis-platinum
45381018|NCT01007474|Device|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Medtronic market-released cardiac resynchronization therapy defibrillator
45496397|NCT05177627|Other|Simulation interventions|"aim of intervention:~To develop active listening and use of non-verbal and verbal communication skills to establish a therapeutic relationship based on compassion, trust and respect; to apply the FoC conceptual framework, reflexivity and analytical skills to meet patient fundamental needs.~Students will express these goals during simulation activities with behaviours outlined by the FoC framework.~components and activities: - Implementation of communication simulation activities to develop interaction skills with patients; Implementation of simulation activities to apply the FoC conceptual framework and reflection to meet patient fundamental needs in realistic scenarios.~mode of delivery:~- simulation activities on communication and trust Use ad hoc validated scenarios to apply the FoC conceptual framework to develop reflection and meet patient fundamental needs.~duration of the intervention: 25 hours"
45496398|NCT05177627|Other|Internship interventions|"Aim of intervention: to apply active listening and non-verbal communication skills; to use the FoC conceptual framework, reflexivity, and analytical skills to meet patient fundamental needs.~Students will express these goals during simulation activities with behaviours outlined by the FoC framework.~components and activities:~- to establish effective and trusting communication with patients to demonstrate compassion and respect and to enable patients to remain calm, involved and dignified; to apply the FoC conceptual framework to meet patient fundamental needs.~mode of delivery:~attendance of clinical internship~analysis and reflections guided by the clinical preceptor on real cases using elements of FoC conceptual framework.~duration of the intervention: 150 hours of internship."
45496399|NCT05143541|Device|AEON Endostapler|Surgery with AEON Endostapler
45496400|NCT03710057|Drug|Ivabradine|A prospective, post-marketing observational study was conducted in National Institute of cardiovascular disease, Karachi-Pakistan. Total 50 patients were advised to take 5 mg Ivabradine (SIVAB) twice daily for 8 weeks.
45496401|NCT05557422|Diagnostic Test|BD OneFlow LST, and B-CLPD T1 to T4 Assays|a panel of fluorochrome-conjugated antibodies for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations on the BD FACSLyric™ flow cytometer with BD FACSuite™ Clinical application.
45496402|NCT03357731|Drug|HNO Donor|Infusion
45496403|NCT03357731|Drug|Nitroglycerin (NTG)|Infusion
45694170|NCT01857934|Biological|natural killer cell infusion|Natural killer (NK) cells obtained from a suitable donor will be given together with hu14.18K322A prior to early hematopoietic cell recovery. In the event there is not a suitable parental donor, consenting participants will receive an additional course of hu14.18K322A.
45381019|NCT01007474|Device|Implantable devices working as neurostimulators, stents, spinal/bone devices or other applications|Medtronic market-released implantable devices used as neurostimulators, stents, spinal/bone devices or for other applications
45381020|NCT00880295|Procedure|endoscopic carpal tunnel release|endoscopic surgery, which is standard of care for carpal tunnel release
45381021|NCT00880295|Procedure|open carpal tunnel release|open surgery, which is standard of care for carpal tunnel release
45694171|NCT01857934|Radiation|radiation therapy|Radiation therapy to the primary and metastatic disease sites will follow peripheral blood stem cell transplant with the exception of any patient requiring emergent radiotherapy. External beam radiotherapy will be delivered to the primary site and select metastatic and bulky nodal sites.
45694172|NCT01857934|Biological|GM-CSF|Given subcutaneously (SQ)
45381022|NCT00880373|Drug|Ibuprofen|Oral ibuprofen 800 mg three times daily for a total of 2400 mg per day for 4 days
45381023|NCT00880373|Drug|Placebo|Matching placebo three times daily for 4 days
45496404|NCT03357731|Other|Placebo|Infusion
45496405|NCT04563702|Biological|VXA-CoV2-1|non replicating Ad5 adjuvanted oral tableted vaccine
45496406|NCT05459376|Other|Exercises and dry cupping|Participants in the intervention group will receive an assessment, classification as to MDT syndrome and indication of the preferred direction of movement, whether flexion, extension or lateral displacement of the spine
45381024|NCT00880373|Drug|Diamorphine or Morphine|Diamorphine or Morphine by PCA
45381025|NCT01007630|Drug|Rasagiline|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
45381026|NCT01007630|Drug|Placebo|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
45381027|NCT05883384|Other|stool analysis , CBC, specific IgE FOR Cow milk protein allergy|apply CoMiSS and food challenge test on patient whom suspected to have cow milk protein allergy.
46055455|NCT02762097|Procedure|saline sonography|saline infusion sonography (SIS) on 8th to 11th day of menstrual cycle. On the day of admission SIS will be performed in an outpatient setting .Taking all aseptic measures a speculum will be inserted vaginally and up to 20 ml of sterile saline solution will be infused into the uterine cavity through a cervical foley's catheter of 5 french to distend the endometrial cavity. A transvaginal transducer will be used to scan the uterine cavity. In case the patient has polyps she would be offered removal under general anaesthesia on a subsequent visit as a day case procedure.
45381029|NCT05883358|Drug|Clonidine, Buprenorphine|Each patient receives rotational treatment using Buprenorphine 5cmg/hr patch; or Clonidine tablet 0.1mg 4hourly; or combined Clonidine tablet 0.1mg 4hourly + Buprenorphine 5cmg/hr patch.
45381030|NCT05883345|Diagnostic Test|Serum blood test for Helicobacter pylori immunoglobulin G, pepsinogen, and gastrin levels|Endoscopic biopsy
45381031|NCT05883332|Drug|Self-Administered Nitrous Oxide|Nitrous oxide administered at concentrations of mild sedation (20-50%)
45381032|NCT05883332|Other|Oxygen|100% oxygen at 10 Liters/minute
45381033|NCT05883319|Other|manuel therapy|approaches will be applied for 3 days / week for 6 weeks.
45381034|NCT05883319|Other|exercises|approaches will be applied for 3 days / week for 6 weeks.
45381035|NCT05883306|Drug|[14C]LXI-15028|[14C]LXI-15028
45381036|NCT05883293|Drug|Cell Free Fat Extract(CEFFE)|The subjects inhaled 2ml of CEFFE each time in a nebulized inhalation method, inhaling every 3 days, for a total of 7 inhalations
45496407|NCT03709979|Device|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
45496408|NCT03357341|Device|Mobile spirometer|Mobile spirometer will be used to measure FEV1 values weekly.
45381037|NCT05883280|Other|Binaural beats|The binaural beat audio file consists of pure tones with a frequency of 432 Hz in the left ear and 420 Hz in the right ear. It is played through headphones starting 30 minutes before the end of the surgery.
45381038|NCT05883254|Diagnostic Test|RNA Binding Protein Pumilio1 (PUM1) Expression by reverse transcriptase quantatative PCR|"Quantatative Real -Time PCR for quantification of PUM1;~The type of the recruited samples: Ethylenediamine tetra-acetic acid (EDTA) peripheral blood samples.~The method of total RNA extraction: TRIzol and TRIzol LS.~The purity and concentration of the RNA were measured using a Nano Drop 2000 instrument.~cDNA was amplified with primers using the GoScript Reverse Transcription system.~Western Blotting Assay of PUM1 protein levels"
45496409|NCT03357341|Device|Device sensor|Sensors will be attached to rescue and maintenance inhalers to measure use of rescue medication and maintenance therapy.
45496410|NCT03357341|Drug|Salbutamol|Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
46055456|NCT02762097|Drug|normal saline|Normal saline would be injected into uterine cavity to delineate defects
45496411|NCT03357341|Device|Activity monitor|Subjects will be required to wear activity monitors daily to record their physical activity.
45496412|NCT03357341|Other|electronic diary card|Electronic diary card will be completed daily by subjects in COPD cohort.
45496413|NCT03357341|Other|CAT|Subjects will be required to complete CAT monthly.
45496414|NCT03357341|Other|ACT|Subjects will be required to complete ACT monthly.
45496415|NCT05152212|Biological|LVGN7409|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
45694173|NCT01857934|Biological|G-CSF|Given subcutaneously (SQ)
46055457|NCT00746941|Drug|mefloquine|250 mg orally each day for 3 days and then weekly up to 6 months.
45381039|NCT05883215|Other|Pain catastrophizing scale|"The pain catastrophizing scale is a self-report questionnaire used to assess an individual's tendency to engage in catastrophic thinking when experiencing pain. It measures the extent to which a person magnifies, feels helpless, and feels unable to cope with pain. The scale typically consists of several items that ask individuals to rate the degree to which they experience specific thoughts or emotions related to pain catastrophizing, such as I worry all the time about whether the pain will end or I feel like I can't stand it anymore. Participants provide responses on a Likert scale indicating the intensity or frequency of their agreement with each statement. The scale helps researchers and healthcare professionals gain insights into an individual's cognitive and emotional responses to pain, which can have implications for pain management strategies and overall well-being."
45381040|NCT05883215|Other|Beck Anxiety Inventory|"Beck Anxiety Inventory (BAI), which is designed to measure the severity of anxiety symptoms in individuals. The BAI is a self-report questionnaire consisting of 21 items that assess various symptoms of anxiety, such as nervousness, fear, and physiological manifestations of anxiety. Participants rate the intensity of their symptoms over the past week on a scale ranging from 0 (not at all) to 3 (severely). The scores obtained on the BAI can help clinicians and researchers evaluate the presence and severity of anxiety symptoms, monitor changes over time, and guide treatment decisions. It is important to note that the BAI is not a diagnostic tool but rather a measure of self-reported anxiety symptoms."
45381041|NCT05883215|Other|Social Media Use Integration Scale|The Social Media Use Integration Scale (SMUIS) is a self-report measure that assesses the degree to which individuals integrate social media into their daily lives. It aims to capture the extent to which individuals incorporate social media use into various aspects of their routines, behaviors, and identity. The scale typically consists of items that assess factors such as the frequency and duration of social media use, the importance and impact of social media on personal relationships, the integration of social media into daily activities, and the emotional connection to social media.
45381042|NCT05883215|Other|Fibromyalgia Impact Questionnaire|"The Fibromyalgia Impact Questionnaire (FIQ) is a widely used self-report measure specifically designed to assess the impact of fibromyalgia on various aspects of a person's life. It is a multidimensional questionnaire that evaluates the physical functioning, social functioning, and overall well-being of individuals with fibromyalgia.~The FIQ typically consists of items that ask individuals to rate the impact of fibromyalgia on their ability to perform daily activities, such as work, household chores, and recreational activities. It also assesses the severity of fibromyalgia symptoms, including pain, fatigue, sleep disturbances, and cognitive difficulties. Additionally, the questionnaire may include items related to emotional well-being, social support, and overall quality of life."
45381043|NCT05883202|Device|Connect®|Restoration of multiple implants with a Connect® abutment between the implant and the prosthesis.
45381044|NCT05883202|Device|Multi-unit|Restoration of multiple implants with a conventional multi-unit abutment between the implant and the prosthesis.
45381045|NCT05883189|Diagnostic Test|Draw blood|Draw blood from human body and make into serum to test
45381046|NCT05883176|Drug|Bevacizumab Biosimilar QL 1101|TACE + Bevacizumab (15mg/kg, intra-arterial infusion, Q3W) for 4 cycles, followed by maintenance therapy with Bevacizumab (15mg/kg, intravenously, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.
45381047|NCT05883163|Device|Stimit Activator 1|The Stimit Activator 1 System will be used to stimulate the phrenic nerve resulting in diaphragm activation.
45496416|NCT05177549|Other|Bilateral knee examination with Lachmeter®|Bilateral knee examination with Lachmeter®. Examination repeated 3 times on each knee
45496417|NCT04900818|Drug|TJ033721|Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb)
45496418|NCT05177237|Drug|Endostar|Endostar: 210 mg (14 PCS) continuous infusion for 168h, Q3W, 4 cycles. Methylprednisolone: 80mg intravenously, once daily, for 3-5 days, gradually reduced to 10mg/ day oral maintenance dose.
45694174|NCT01857934|Drug|mesna|Given IV
45694175|NCT01857934|Drug|levetiracetam|Given IV
45694176|NCT01857934|Biological|interleukin-2|Given by continuous infusion during MRD maintenance, and SQ during induction.
45694177|NCT01857934|Drug|Isotretinoin|Given orally (PO)
45381048|NCT05883150|Drug|Nebulized Midazolam|"All the drug solutions will be freshly prepared on the day of sedation session. Depending on the dosage calculated from the weight of each child The sedative drug, the dosage will be diluted with an equal volume by adding distilled water.~The child will be seated in an upright position on the dental chair. Before placing the mask of the nebulizer, the child will be coached into proper breathing pattern"
45381049|NCT05883150|Drug|Intranasal Midazolam|All the drug solutions will be freshly prepared on the day of sedation session. Depending on the dosage calculated from the weight of each child, For children who will receive midazolam using the atomization device attached to a three-ml syringe, the child sitting reclined in knee-to-knee position. Half of the dose will be sprayed in the right nostril and the other half will be sprayed in the left nostril to double the absorptive surface area by short and quick puffs
45381050|NCT05883137|Device|Optiflow Switch|High flow nasal oxygen with the Optiflow Switch device
45381051|NCT05883124|Drug|Rivastigmine twice-weekly 9,5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
45381052|NCT05883124|Drug|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
45381053|NCT05883111|Diagnostic Test|HPV DNA methylation assay|HPV DNA methylation assay to detect HPV positivity, HPV genotype, and HPV methylation.
45496419|NCT05309772|Diagnostic Test|Basophil activation test (BAT)|"Basophils and mast cells are the key drivers of food allergic reactions and anaphylaxis to foods. The study team have developed new tests that measure the reaction of mast cells and basophils by flow cytometry following stimulation with allergen, the BAT and the MAT:~• BAT uses fresh whole blood from patients added to allergen and antibodies in a test tube. The tube containing the allergic cells are then analysed one by one to estimate how many and how much express activation markers on their surface, CD63 and CD203c.~MAT uses a human mast cell line (LAD2 cells) which are human mast cells grown in the laboratory to which patients' plasma is added in order to mimic the patients' own mast cells. Sensitised LAD2 cells are then stimulated with allergen or controls and analysed by flow cytometry to assess the expression of the activation marker CD63 on the cell surface, similar to what happens in the BAT. Results of MAT will be considered only in cases of non-responding basophils."
45381054|NCT05883098|Procedure|Wound debridement|The study's wounds will be mechanically debrided before the experimental or active comparator devices are applied. Debridation will be performed by a trained clinician using a curette. Necrotic tissue and slough will be removed during this procedure.
45381055|NCT05883098|Device|Wound closure matrix application|After wound debridement, the patients will receive the application of a wound closure matrix as dictated by their randomization allocation.
45496420|NCT05309772|Diagnostic Test|Oral food challenge (OFC)|Consumption of the food suspected of causing an allergic reaction in a medically supervised environment, starting with small amounts and progressively increasing the dose at regular intervals up to a cumulative dose corresponding to an age-appropriate portion of the food.
45496421|NCT05177081|Device|Preemptive management using home BIA monitoring system|Patients check their body composition and fluid using Home BIA system. Investigators analyze patients' body congestion status and send patient's edema status and direction of extra-diuretics usage to enrolled patients every one week.
45496422|NCT05671289|Diagnostic Test|analysis of urine volatile organic compounds|gas chromatography - mass spectrometry will be used to assess the composition of VOCs in urine samples of all participants.
45694178|NCT01857934|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
45847418|NCT02714634|Drug|Methotrexate + targeted therapy administration|"Methotrexate or leflunomide + adalimumab or~Methotrexate or leflunomide + certolizumab or~Methotrexate or leflunomide + etanercept or~Methotrexate or leflunomide + golimumab or~Methotrexate or leflunomide + infliximab or~Methotrexate or leflunomide + abatacept or~Methotrexate or leflunomide + rituximab or~Methotrexate or leflunomide + tocilizumab or~Methotrexate or leflunomide + sarilumab or~Methotrexate or leflunomide + filgotinib or~Methotrexate or leflunomide + upadacitinib or~Methotrexate or leflunomide + Tofacitinib or~Methotrexate or leflunomide + baricitinib"
45847419|NCT02714634|Drug|methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration|
45694179|NCT04547959|Device|cervical interbody cage C-CURVE|ACDF: Anterior Cervical Discectomy and Fusion with a C-CURVE cage
45694180|NCT00862810|Biological|Received HPV vaccine first|
45847420|NCT02708394|Drug|olanzapine|atypical antipsychotic
45381056|NCT05883085|Drug|Anlotinib hydrochloride|Patients receive anlotinib hydrochloride 8-12mg orally once daily on days 1-14. Courses repeat every 21 days
45847421|NCT02708394|Drug|placebo|placebo control
45847422|NCT00553800|Drug|bevacizumab|
45847423|NCT00553800|Drug|Erlotinib|
45694181|NCT00862810|Biological|Received concomitant vaccines first|
45847424|NCT02740920|Drug|Pembrolizumab|
45847425|NCT02740920|Procedure|CT Scan|
45694182|NCT00488878|Procedure|Biospecimen Collection|Patients' residual tissue samples are collected
45381057|NCT05883059|Device|Lower limb robot assisted walking training|The participants in the robot group received lower limb robot assisted walking training combined with routine rehabilitation therapy. Lower limb robot assisted walking training for 30 minutes each time, once a day, 5 times a week, for 4 consecutive weeks; Routine rehabilitation treatment includes lower limb muscle strength training, stretching training, joint range of motion training, balance training, walking training, functional electrical stimulation, etc. Routine rehabilitation treatment once a day, five times a week, for four consecutive weeks.
45381058|NCT05883059|Other|routine rehabilitation|The control group participants received routine rehabilitation, including lower limb muscle strength training, stretching training, joint range of motion training, balance training, walking training, functional electrical stimulation, etc. Routine rehabil
45381059|NCT05883046|Other|Performance-Enhancing Substances|All supplements were consumed 60 min before the isometric mid-thigh pull tests, to reach peak blood concentrations at evaluation time. Immediately after consumption, both Control and intervention participants rested in a quiet laboratory environment (Eskişehir Technical University, Laboratory of Human Athletic Performance), until the strength tests. Participants were previously informed verbally and in writing that they should abstain from caffeine consumption (any caffeine-containing beverages and foods, such as coffee or tea, energy drinks, cocoa and cocoa-containing foods, chocolate and chocolate-containing foods or caffeine-containing drugs) for at least 24 hours before
45381060|NCT05883046|Other|Placebo|20gr of maltodextrin (European origin, Alfasol®, Kimbiotek, Turkey)
45381061|NCT05883046|Other|Baseline (Control)|No supplement conditions
45694183|NCT00488878|Other|Electronic Health Record Review|Medical records are reviewed
45694184|NCT00815698|Procedure|suture|suture for mesh fixation
45381062|NCT05883033|Device|VAC|Vacuum Assisted Closure device
45381063|NCT05883020|Other|Experimental Interventions|One session per week of rSWT will be applied using the BMI-1120 SHOCK MED device (BIO-MED-INC- ITALY). The following parameters will be used: Shocks number: 1500 per muscle, will be applied over the belly of the calf muscle using the 15 mm applicator head. The pressure will be 2 bar and the frequency will be 4 Hz. Patients will receive shock wave from prone position.
45381064|NCT05883020|Other|Standard physical therapy program|Regular rehabilitation procedures consist of strengthing, stretching, facilitation and inhibitory techniques, splinting, developmental techniques, gait and balance training, and advice to parents. The duration of each session will be 1 hour, 3 times per week for 4 weeks
45381065|NCT05882994|Behavioral|rom exercise|At the beginning of the study, participants will be asked to fill out data collection tools consisting of Personal Information Form, Piper Fatigue Scale, Pittsburgh Sleep Quality Index. Data will be collected with data collection tools in the 6th and 12th weeks. Evaluation will be done. At the end of the study, rom exercises will be applied to the patients in the control group.
45381066|NCT05882981|Other|Sit and reach test|It will be used to measure the flexibility of the participants.
45381067|NCT05882981|Other|Hand grip strength measurement|Grip strength will be evaluated with a hand dynamometer in the position recommended by the American Association of Hand Therapists.
45381068|NCT05882981|Other|Back-leg-chest muscle strength measurement|An analog Back Leg-Chest dynamometer will be used to evaluate general muscle strength.
45381069|NCT05882981|Other|Functional performance|Single-leg and double-leg horizontal jump test will be used to evaluate lower extremity functional performance. The tests will be carried out according to the Eurofit test battery (Council of Europe, 1988).
45381070|NCT05882981|Other|Functional capacity|Functional capacity will be evaluated with six minute walk test according to the ATS criteria.
45381071|NCT05882968|Diagnostic Test|kidney function tests|using GFR test according to kdigo guide lines
45381072|NCT05882955|Behavioral|Recipes consumption|Participants will eat one or two recipes a day for 17 weeks
45496423|NCT04747067|Device|BIOPURE 260HF dialyzer|Dialyzer with effective surface area 2.6 m2, High-flux polyethersulfone hollow fiber with steam sterilization, myoglobin sieving coefficient (SC) 0.7, membrane cutoff 40,000 Daltons (Allmed Medical Gmbh)
45694185|NCT00815698|Procedure|no suture|no suture for mesh fixation, because we use a self-adhesive mesh
45694186|NCT00863122|Drug|lapatinib|1500 mg lapatinib by mouth per day for 10 days
45694187|NCT01604941|Drug|SPD602|50 mg/kg/day orally twice daily for 24 weeks
45694188|NCT01604785|Drug|Propofol|Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q5 minutes to a maximum of 5 doses
45694189|NCT01604785|Drug|Standard Treatment|Ketorolac, Diphenhydramine and Metoclopramide
45381073|NCT05882955|Behavioral|Hydroponic unit|Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.
45381074|NCT05882942|Dietary Supplement|Matcha green tea|This is the condition with the Matcha green tea
45381075|NCT05882942|Dietary Supplement|Placebo|This is the condition with the placebo
46055458|NCT02761863|Other|CD 74, VEGF detection|"All MPM samples will be subjected to immunohistochemistry with CD74 and VEGF antibodies.~The VEGF will be scored using a 0-3 scoring system to represent the percentage of cytoplasmic positively stained cells in the tumor portion, as follows: 0-10%, 11-30%, 31-60% and 61-100% positive staining correspond to score 0, 1, 2 and 3 respectively. Both CD74 and VEGF immunohistochemical markers will be furtherly categorized in the statistical analyses as none (0)/low (1) vs medium (2)/high expression(3).~The CD74 expression will be recorded in the tumor and the stroma semiquantitatively using the histoscore method using four representative fields with the final score resulting from the percentage of tumor cells staining positively multiplied by the staining intensity grade."
46055459|NCT04532463|Drug|Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week|To study the clinical effectiveness and safety of amphotericin B with flucytosine-fluconazole therapy for cryptococcal meningitis in patients with HIV infection.
45381078|NCT05882916|Device|HIV self-testing|Oral fluid-based HIV self-test kits for secondary distribution
45381079|NCT05882916|Behavioral|Behavioral economic 'nudges'|Salient information for men included with the self-test kit on clinic location and hours within their cluster, and pilot-tested messaging on the importance of early ART initiation, and the availability and benefits of PrEP
45381080|NCT05882903|Drug|Betamethasone Dipropionate Nasal Cream 0.0644%|Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).
45496424|NCT05646953|Other|Facial Beauty Oil|"Mode of Usage Step 1- Wash face, pat dry Step 2 - Gently massage 2-3 drops of Vasu Facial Beauty Oil over the face and neck till it gets absorbed and keep it overnight.~Step 3 - Use it for 60 days Frequency - Daily before going to bed. Route of Administration - Topical"
45694190|NCT01681849|Drug|Placebo|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
45694191|NCT01681849|Drug|Paroxetine|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
45381081|NCT05882903|Device|Pre-filled syringe and applicator device|Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
45381082|NCT05882890|Other|cranio sacral therapy|Manual treatment of 5 grams on the whole airwaysystem, the throat, the neck, the meninges, the craniel , nerve sleeves, the visceral cranium, the soft tissue in the mouth
45381083|NCT05882864|Drug|6-Gingerol|6-gingerol gel will be applied locally to the participants suffering from oral lichen planus
45381084|NCT05882864|Drug|Triamcinolone Acetonide 0.1% Oromucosal Paste|Triamcinolone Acetonide 0.1% gel will be applied locally to the participants suffering from oral lichen planus
45381085|NCT05882851|Behavioral|determination of the current nutritional status of patients|No intervention was made on the patients. Nutritional status was recorded during the treatment process. Current nutritional status and other risk factors were compared according to recovery status after treatment.
45694192|NCT01681849|Other|Positron Emission Tomography (PET) Imaging|Participants will undergo positron emission tomography (PET) imaging of the brain with O-15 radiolabelled water with exposure to traumatic scripts
45694193|NCT01681771|Behavioral|Cognitive behaviour therapy|Internet based, weekly home task and weekly feedback provided by health care professional.
45694194|NCT01681771|Behavioral|Discussion group|Internet moderated discussion group. Patients will be provided weekly question which will be used by the participant to start discuss with each others.
45694195|NCT04250350|Biological|Lebrikizumab|Subcutaneous injection
45496425|NCT03039738|Device|Vital Sync IM & VPMP (Surveillance Monitoring)|The Vital Sync™ Informatics Manager (IM) & Virtual Patient Monitoring Platform (VPMP) is an electronic medical record connectivity and remote continuous patient monitoring software solution.
45694196|NCT03839680|Procedure|Endoscopy|The endoscopy procedure uses an endoscope to examine the interior of a hollow organ or cavity of the body.
45496426|NCT03039738|Device|Telemetry Monitoring|Continuous ECG monitoring for hospitalized patients at-risk for cardiac events.
45496427|NCT05176925|Drug|Tislelizumab|Tislelizumab 200mg IV D1, Q3W
45694197|NCT03839602|Radiation|Reducing CTV|CTVs were delineated in line with tumor stage, i.e. tumor invasion.
45694198|NCT00863356|Device|2009-I-Epistaxis-1|Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis, 48 hour removal, 1 week follow-up.
45694199|NCT00005398|Other|There is no intervention|No applicable
45694200|NCT00863434|Drug|clofarabine|Given IV
45694201|NCT00863434|Drug|cytarabine|Given IV
45694202|NCT00863434|Biological|filgrastim|Given SC
45694203|NCT04228042|Drug|Infigratinib|Given PO
45694204|NCT04228042|Other|Quality-of-Life Assessment|Ancillary studies
45694205|NCT04228042|Other|Questionnaire Administration|Ancillary studies
45694206|NCT04228042|Procedure|Surgical Procedure|Undergo surgery
45381086|NCT05882838|Other|Myofascial Pain Syndrome Knowledge and Awareness Questionnaire|Myofascial Pain Syndrome Knowledge and Awareness Questionnaire is a questionnaire consisting of a total of 14 questions created by the researchers who are specialized in the field. The correct answer to each question is one point. A high score indicates a high level of knowledge and awareness, while a low score indicates a low level of awareness and knowledge.
45381087|NCT05882825|Other|Dry Needling Therapy Knowledge and Awareness Questionnaire|Dry Needling Therapy Knowledge and Awareness Questionnaire is a questionnaire consisting of a total of 14 questions created by the researchers who are specialized in the field. The correct answer to each question is one point. A high score indicates a high level of knowledge and awareness, while a low score indicates a low level of awareness and knowledge.
45381088|NCT05882799|Procedure|Ultrasound-guided dry needling|Ultrasound-guided dry needling is a minimally invasive technique that involves inserting a sterile acupuncture needle into trigger points of a muscle while monitoring the needle's progress with real-time ultrasound imaging. In this technique, a trained practitioner visualizes the piriformis muscle and the surrounding structures using an ultrasound machine, and then inserts the needle through the skin and into the muscle tissue, guided by the ultrasound image.
45381089|NCT05882799|Procedure|Blinded dry needling|Blinded dry needling is a minimally invasive technique that involves inserting a sterile acupuncture needle into trigger points of a muscle without using real-time imaging guidance. In this technique, the practitioner relies solely on their palpation skills to locate the trigger points of the piriformis muscle and inserts the needle through the skin and into the muscle tissue.
45381090|NCT05882786|Procedure|Corticosteroid injection|Subacromial injection of 40mg triamcinolone acetonide.
45381091|NCT05882786|Procedure|Dry Needling|Dry needling treatment to the supraspinatus, infraspinatus, and subscapularis muscles tendons.
45381096|NCT05882734|Drug|M1774|In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other reason. The selected dosing regimen of M1774 will be administered in all arms of Phase 2a.
45381097|NCT05882734|Drug|Cemiplimab|Cemiplimab will be administered as an intravenous infusion every 3 weeks in all arms of Phase 1b and Phase 2a until disease progression, death discontinuation criteria or any other reason.
45381098|NCT05882721|Device|Sofwave|"The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.~Other Names:~SUPERB"
45381099|NCT05882708|Drug|Ivabradine|After randomization, the starting dose of ivabradine, 5mg, is given via the gastrointestinal tract every 12 hours. Heart rate control ranged from 70 to 94 bpm. Ivabradine was maintained until 96 hours after initiation of therapy. Beyond this period, the decision to continue ivabradine is left to the discretion of the treating intensivist. During the drug intervention period, heart rate is assessed before each dose. Ivabradine is tapered or discontinued if the heart rate is lower than the target rate; If the heart rate remains ≥95 bpm after 48 hours, the dose is increased to 7.5mg. If a heart rate of 95 or more bpm recurs after discontinuation during the intervention period, treatment with ivabradine can be resumed. Furthermore, Ivabradine is also discontinued at any time in the presence of severe liver impairment, malignant arrhythmia, cardiac conduction block, allergy, the need to take drugs with potentially harmful effects of ivabradine.
45381102|NCT05882630|Drug|Surufatinib,Serplulimab,Etoposide,Carboplatin|"In dose escalation, Surufatinib will be administered orally (PO) once daily (QD) ,d1-21,q3w + Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w; 4-6 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21,q3w+Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w, 4-6 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21,q3w＋Serplulimab 4.5 mg/kg ivgtt,d1,q3w until the disease progressed."
45381103|NCT05882604|Drug|Mesna Injection|1 ml of MESNA will be injected using 20-guage needle in he upper compartment of TMJ in patient with internal derrangement.
45381104|NCT05882604|Drug|Arthrocentesis with ringer solution|Two 20-gauge needles will be placed into upper joint space as entry and exit points for washing.The arthrocentesis will be performed with 100 ml of lactated Ringer's solution to eliminate the inflammatory mediators present in the synovial fluid
45694207|NCT00815776|Device|Clayton Intra-aural Device (CID)|"The CID is a patented small, hollow, ear insert made of medical grade polymers that is custom-fit to each subject's ear. Each subject that is randomized to the CID study group will wear a pair of inserts, one in each ear. (For the purpose of this protocol, the pair of inserts will be referred to as the CID)."
45847426|NCT02747628|Drug|Placebo|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
45847427|NCT02747628|Drug|transdermal therapeutic system- nicotine.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
45847428|NCT02747628|Drug|transdermal therapeutic system- melatonin.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
45847429|NCT02748096|Procedure|Patient Specific Instrumentation|Patients will undergo a medial unicompartmental knee replacement. This knee replacement is implanted using patient specific cutting guides that have been produced based on the patient's individual anatomy (using plans from pre-operative MRI scans of the patient's knee).
45496428|NCT05176925|Drug|Sitravatinib|The starting dose of sitravatinib in this study is 70 mg, oral once daily. After receiving 2 cycles of starting dose at 70 mg once daily with sitravatinib, if patients were tolerated well with study treatment (without AEs definitely related to sitravatinib nor TRAEs leading to sitravatinib dose reduction and interruption), it is recommended to escalate sitravatinib dose to 100 mg once daily at the discretion of the investigators after discussion with patients.
45381105|NCT05882591|Procedure|Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).|Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).
45381106|NCT05882578|Other|Oncological physical exercise intervention|"An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested.~Patients will be screened and then divided in diferent groups, depending on both their cardiovascular and physical capacity.~Then they will perform 2 sessions of combined strength and endurance training per week for 16 weeks.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life."
45381107|NCT05882578|Other|Active Physical Activities intervention|"An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested Patients will be suggested to mantain active physical activities in their daily life.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life."
45381108|NCT05882539|Device|endotracheal tube material,Bite block Material|Exposure factors associated with tracheal intubation in patients that may influence the occurrence of oral mucosa pressure injurie, such as the material and fixation of the tracheal tube, the patient's own nutrition, the level of tissue perfusion and relevant treatment factors.
45381109|NCT05882526|Device|BURSTONE T-LOOP|Split mouth study one side using elastomeric power chain and other side using T loops
45381110|NCT05882513|Drug|Serplulimab and neoadjuvant therapy|"Squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1; albumin paclitaxel 260mg/m2, day1; carboplatin AUC=5, i.v, day1.~Non-squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1 ; pemetrexed 500mg/m2, day1 ; carboplatin AUC=5, i.v, day1."
45381111|NCT05882513|Procedure|surgical resection of lung cancer|radical resection of lung cancer
45381112|NCT05882500|Other|No intervention, observation|
45381113|NCT05882487|Genetic|KL002 injection solution|Neurosurgical delivery of KL002 to the brain
45381114|NCT05882474|Device|PaCO2|Level of partial pressure of carbon dioxide
45381115|NCT05882461|Behavioral|90Second Caregiver health letter|Participant receives the weekly health letter via email
45381116|NCT05882448|Procedure|laparotomy|Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion
45381117|NCT05882448|Procedure|Laparoscopy|laparoscopy with insufflation of CO2 (placement of a 3mm trocar in the left hypochondrium and insufflation of a pneumoperitoneum (carbon dioxide, pressure: 6 mmHg, flow rate: 1.5 Liter/minute) for a duration of at least 5 minutes.
45381118|NCT05882435|Other|Organization with AI|X-rays are done in the radiology department and the images are made available to emergency physicians with the AI interpretation. X-rays flagged by IA as anormal or suspicious will be reviewed without delay by the radiologist, non-flagged X-rays will be reviewed by radiologists on a delayed basis.
45381119|NCT05882409|Behavioral|Education|Education covers women's education on violence, conflict and awareness.
45381120|NCT05882396|Other|Rood's approach|Patients will receive Rood's approach includes various facilitatory and inhibitory techniques.
45381121|NCT05882396|Other|Traditional physical therapy program|Participants will be engaged in aerobic exercises and balance training, three times per week for twelve weeks.
45381122|NCT05882370|Drug|Cadonilimab|Patients were treated with TIPS plus Cadonilimab (10mg/kg, intravenously, d1, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.
45381123|NCT05882370|Procedure|transjugular intrahepatic portosystemic shunt (TIPS)|transjugular intrahepatic portosystemic shunt (TIPS)
45381124|NCT05882357|Drug|ELX/TEZ/IVA|Fixed-dose combination granules for oral administration.
45496429|NCT05147376|Drug|Curcumin mouthwash|Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
45381125|NCT05882357|Drug|IVA|Granules for oral administration
45496430|NCT05147376|Drug|Placebo mouthwash|Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
45847430|NCT02748096|Procedure|Conventional Instrumentation|Patients will undergo a medial unicompartmental knee replacement using standard conventional instruments.
45847431|NCT02754570|Drug|Pilocarpine|Pilocarpine will be administered 4 times in addition to latanoprost.
45847432|NCT02756910|Device|iThermonitor (WT701)|Continuously monitor the axillary temperature during surgery
45381126|NCT05882344|Procedure|Device Implantation- Boston Scientific, VERCISE GENUS™ system|Participants will be implanted with DBS leads bilaterally, targeting the Nucleus Basalis of Meynert. The study team will record Local Field Potentials with and without stimulation, intraoperatively. These results will help the team determine at the end of the study whether LFP desynchronization (decrease in 5-15 Hz power), or other physiological signature, can be used to predict the location that provides the most effective intervention. Finally, the team will also ascertain the safety of the procedure and NB stimulation itself.
45381127|NCT05882344|Device|DBS Stimulation - Boston Scientific, VERCISE GENUS™ system|Daily intermittent stimulation (60 Hz x 20s/min)
45381128|NCT05882331|Procedure|Extracorporeal photopheresis|ECP is initiated on study inclusion day by Therakos Cellex system, according to manufacturers' instructions. Each patient receives two ECP cycles for 2 weeks, each consisting of two sessions on consecutive days per week (alltogether four sessions), through a peripheral or central venous route. Cycles 1 and 2 are separated by 5 consecutive days. One ECP session takes ~3 hours, and is separated into 4 phases. On priming, the system performes a series of calibrations to ensure proper operation. During collection, 1500 ml of whole blood is processed to collect a concentrated buffy coat containing white blood cells, while other cells and plasma are reinfused. During the photoactive phase, a prescribed dose of 8-methoxypsoralen is added to the buffy coat, which is then circulated through ultraviolet-A photoactivation. During reinfusion phase, treated cells are automatically reinfused to the patient.
45381129|NCT05882292|Drug|ABN401|ABN401 800 mg will be administered orally once daily immediately after a meal [should be within 1 hour post-meal (fed state)] at approximately the same time each day in a 21-day cycle.
45381130|NCT05882266|Dietary Supplement|Plant Omega|A commercial plant-based omega-3 beverage consumed once daily during breakfast
45496431|NCT05681117|Other|multi-component nutrition education|"Classroom-based nutrition education 40 minutes once a week for 4 weeks~SMS Reminders SMS reminders containing healthy nutrition tips 2 times a week, 1 weekday, 1 weekend, starting with nutrition education and throughout the education (4 weeks)~Brochure Distribution Brochures prepared in accordance with the content of classroom-based nutrition education were distributed immediately after the nutrition education.~Controversial Supermarket Tour Nutrition label reading activity aimed at gaining the ability to evaluate product contents, in line with the information explained in module 4, in the supermarket tour planned to be organized once with an appropriate number of student groups (maximum 7 people) after the nutrition education"
45496432|NCT05007899|Drug|Ferrous sulfate|Alternate day dosing of ferrous sulfate
45496433|NCT05175131|Drug|Mebeverine+Simethicone|fixed-dose combination, film-coated tablets, 135 mg + 80 mg
45496434|NCT05175131|Drug|Mebeverine|Duspatalin®, coated tablets 135 mg
45496435|NCT05175131|Drug|Simethicone|Espumisan® capsules 40 mg
45496436|NCT05147142|Device|Low Intensity Focused Ultrasound|Brainsonix BX Pulsar 1002
45496437|NCT05636345|Other|pain science education|A full day of pain science education
45496438|NCT04507373|Drug|Simvastatin 40mg|40mg oral daily for 10 weeks
45496439|NCT01312337|Drug|salvage iressa|Iressa 250mg per day until progression
45496440|NCT05174897|Behavioral|emotional liberation technique|experimental group; The child, to whom an intravenous catheter will be applied, is placed on a stretcher. pain ve score fear will be evaluated before the procedure. Then, the emotional liberation technique (EFT) will be applied for 10 minutes and an intravenous catheter will be applied to evaluate the pain and fear scores during and after the procedure.
45847433|NCT02760264|Drug|Vamorolone 0.25 mg/kg/day|Oral administration of 0.25 mg/kg/day daily for 14 days.
45847434|NCT02760264|Drug|Vamorolone 0.75 mg/kg/day|Oral administration of 0.75 mg/kg/day daily for 14 days.
45381131|NCT05882266|Other|Dietary therapy only|Standard dietary therapy
45381132|NCT05882240|Other|choice of initial position|current practice of correct application and interpretation of the PLR in critical care patients
45381133|NCT05882227|Behavioral|video|The patients will receive the discharge information through the visualization of a video with discharge information extracted from the optimized hip prosthesis recovery program document; information for patients, relatives or caregivers. The video will consist of two parts: a first part where it will be explained what will happen in the next hours in the unit, the documentation that will be delivered at discharge and the pharmacological treatment. The second part will consist of a video explaining wound care at discharge, discharge recommendations, symptoms that may appear after surgery and alarm symptoms.
45381134|NCT05882227|Behavioral|Traditional information|"Patients will receive the information at discharge by means of the document entitled Optimized Hip Replacement Recovery Program; information for patients, relatives or caregivers, which will act as a control group."
45381135|NCT05882214|Dietary Supplement|β-nicotinamide Mononucleotide|After an 8-hour overnight fast, the participants ingested β-nicotinamide Mononucleotide capsules with a single morning dose of 1000mg. The purity of β-nicotinamide Mononucleotide capsules was no less than 97% according to high-performance liquid chromatography analysis.
45381136|NCT05882214|Dietary Supplement|Maltodextrin|After an 8-hour overnight fast, the participants ingested maltodextrin capsules with a single morning dose of 1000mg.
45381137|NCT05882201|Procedure|Fascia Iliaca compartment block group|"Group FICB Fascia: with the patient supine, the skin was prepped and draped with alcohol solution 70%,~. A 22-G needle will be visualized entering the fascia Lata and the FI. bupivacaine, up to 2.5mg/kg of lean body weight with a volume of injectate of .5 ml/kg up to 40 ml will be injected after aspiration beneath the fascia Lata."
45381138|NCT05882201|Procedure|Femoral nerve block group|✓ Group FNB; With the patient supine, the skin will be prepped and draped with alcohol solution 70% The nerve in the crosssection is a triangular white structure lateral to the femoral artery. Ultrasoundallows direct visualization of the needle and nerve as well as real-time monitoring of the injection of local anesthetic. An in-plane approach will be used to direct needle placement to the femoral nerve and inject after aspiration with bupivacaine, up to 2.5mg/kg of lean body weight with a volume of injectate of .5 ml/kg up to 40ml.
45847435|NCT02760264|Drug|Vamorolone 2.0 mg/kg/day|Oral administration of 2.0 mg/kg/day daily for 14 days.
45381139|NCT05882201|Procedure|General care|using ordinary technique
45381140|NCT05882123|Other|cerebral microbleeds|Whether patients with acute ischemic stroke are complicated by cerebral microbleeds
45381141|NCT05882019|Device|Breast Exam with Bexa|Breast exam with Bexa uses pressure elastography to produce a map of the breast tissue's elasticity.
45381142|NCT05882006|Other|gallstones|fellow up if the patients have gallstones
45381143|NCT05881980|Drug|Terbinafine Tablets|Terbinafine 250 mg/day
45381144|NCT05881980|Drug|Itraconazole|Itraconazole 200 mg/day
45381145|NCT05881967|Diagnostic Test|Diagnostic biomarker|Diagnostic gene for uterine sarcoma
45381146|NCT05881954|Procedure|Groin infection|Femoral artery reconstruction with tubulized pericardium patch
45381147|NCT05881941|Device|using a soundproof nebulizer with a music and a funny mask added|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
45381148|NCT05881941|Device|using a silent nebulizer with no extra attachments|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
45847436|NCT02760264|Drug|Vamorolone 6.0 mg/kg/day|Oral administration of 6 mg/kg/day daily for 14 days.
45847437|NCT02764164|Device|Intervention Active tDCS|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered directly to the brain area of interest via small electrodes. Placed over the temporoparietal junction to suppress auditory hallucinations.
45381149|NCT05881941|Device|using a routinely employed nebulizer|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
45381150|NCT05881928|Drug|Sodium Valproate 500 Mg Prolonged-Release Oral Tablet|sodium valproate tablet30 mg / kg / day , maximum 1500mg / day . LTG :
45847438|NCT02765256|Drug|Fluconazole|400mg orally once daily (Day 1-14)
45381151|NCT05881928|Drug|Lamotrigine|lamotrigine tablet 0.5 mg/kg for 2 weeks in two divided doses , increased in 0.5mg/kg/day increments every 2weeks .
45381152|NCT05881928|Device|E.E.G|device recording of brain activity. During this painless test, small sensors are attached to the scalp to pick up the electrical signals produced by the brain. These signals are recorded by a machine and are looked at by a doctoris
45381153|NCT05881915|Drug|Phenylephrine|phenylephrine infusion at rate of 0.4 mcg/Kg/min. (10 mg /1 mL) will be diluted to reach a final concentration of 10 mcg/mL
45381154|NCT05881915|Drug|Epinephrine|epinephrine infusion dose of 0.03 mcg/Kg/min. epinephrine (1mg/ 1mL ampoule) will be diluted to reach a final concentration of 10 mcg/ml.
45381155|NCT05881902|Behavioral|HEALTH FAITH MODEL GUIDED IN CANCER FREQUENTLY SEEN IN WOMEN EARLY DIAGNOSIS AND SCREENING METHODS EDUCATION|"A total of 4 home visits and 2 phone calls will be made by giving awareness training based on the Health Belief Model to the participants in the Intervention 1 group in order to eliminate the lack of information about the common female cancers in women and to increase their awareness. For 3 months, intervention 1 group will be given applications to reinforce their awareness in the education based on the Health Belief Model (for BSE and KKVM, erasable calendar magnets, booklets, phone cases and accessories themed as common cancers awareness in women as a reminder, phone call) will be made"
45381156|NCT05881902|Behavioral|STANDART CANCER EDUCATİON|The participants in the intervention 2 group will be given the standard training applied by the Ministry of Health in KETEM for women's cancers during home visits, and a total of 4 home visits and 2 SMS reminders will be made.
45381157|NCT05881889|Device|low-frequency repetitive transcranial magnetic stimulation|For patients in the rTMS group, we will first determine the intensity of the rTMS protocol by assessing the individual resting motor threshold (rMT). After determination of each individual's rMT, we will set rTMS intensity at 100% of the rMT and apply a single train of low-frequency rTMS over the DLPFS at 1 Hz for a total duration of 30 min (2000 pulses).
45381158|NCT05881889|Device|sham low-frequency repetitive transcranial magnetic stimulation|sham low-frequency repetitive transcranial magnetic stimulation
45381159|NCT05881863|Other|No intervention|This is an observational study
45496441|NCT05233787|Procedure|Tailored use of defunctioning stoma after TME|"Tailored use of defunctioning stoma after TME based on a 2-step process:~i) to perform or not a defunctioning stoma according to the personalized risk of anastomotic leakage (defunctioning stoma only if Anastomotic Failure Observed Risk Score=[2-6]), ii) to perform an early stoma closure at day 8-12, according to clinical (fever), biological (CRP level days 2 and 4 postoperatively) and radiological postoperative assessment (CT-scan with colonic contrast retrograde enema day 7-8 postoperatively)"
45381160|NCT05881850|Other|Education Program to Raise Osteoporosis Awareness|Education program prepared to increase awareness of osteoporosis will be conducted in a one-to-one education for each woman instead of group training. It is planned that the training program will consist of 3 sessions in total, to be held every 2 weeks, and each session will last approximately 40-50 minutes. In the realization of the education program, the education booklet prepared for osteoporosis awareness will also be used.
45496442|NCT05233787|Procedure|Systematic use of defunctioning stoma|Systematic use of defunctioning stoma for 2-3 months after TME, according to French national and international guidelines
45496443|NCT05232149|Drug|Orelabrutinib( lower dose)|Orelabrutinib is a white, round, uncoated tablet, will be taken lower dose QD by patients with persistent or chronic primary immune thrombocytopenia
45381161|NCT05881824|Behavioral|MDG intervention|6-month behavioral intervention aiming at weight loss and increasing adherence to the Mediterranean diet
45381162|NCT05881798|Device|Celect Platinum Vena Cava Filter|Inferior vena cava filter
45381163|NCT05881785|Biological|GR1501 low dose|3×low dose GR1501 every 2 weeks,then low dose GR1501 monthly
45496444|NCT05232149|Drug|Orelabrutinib( higher dose)|Orelabrutinib is a white, round, uncoated tablet, will be taken higher dose QD by patients with persistent or chronic primary immune thrombocytopenia
45496445|NCT05552495|Drug|CKD-386(4) F1|1 Tablet
45496446|NCT05552495|Drug|CKD-386(4) F2|1 Tablet
45496447|NCT05552495|Drug|D013, D326, D337|D013 1 Tablet, D326 1Tablet, D337 1 Tablet
45496448|NCT05229653|Drug|Ketamine|Participants in this arm will receive intravenously (IV) ketamine (0.6 mg/kg) while recovering in the post anesthesia care unit (PACU) on the day of the surgery after subject has been deemed to be stable (hemodynamically stable, awake). The study physician will administer the study intervention via an intravenous pump to deliver 0.6 mg/kg ketamine over at least 30 minutes.
45847439|NCT02765256|Drug|Vancomycin|500mg oral suspension 4 times daily (Day 1-14)
45847440|NCT02765256|Drug|Neomycin|neomycin 1000 mg orally three times daily (Days 1-3)
45847441|NCT02765256|Drug|Ciprofloxacin|ciprofloxacin 750 mg orally twice daily (Day 4-14)
45847442|NCT02765256|Drug|Polyethylene Glycol 3350|238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2
45381164|NCT05881785|Biological|GR1501 high dose|3×high dose GR1501 every 2 weeks,then high dose GR1501 monthly
45694208|NCT00815776|Device|Mouth Splint|Group 2 subjects will be assigned to the active control device, which is current standard of care therapy. The device is an intraoral flat-planed splint full coverage plastic (hard) orthotic that fits over the occlusal one-third surfaces of the dentition. The appliance is made by taking a standard wax bite registration and is made using the standard technique of taking alginate impressions of the subject's teeth, pouring dental laboratory stone into the impression and processing the acrylic appliance on the stone model. This appliance raises the plane of occlusion and provides complete contact with the opposing dentition.
45381165|NCT05881785|Biological|placebo|"Core treatment period:placebo~Maintenance treatment period: GR1501 injection"
45381166|NCT05881772|Other|Photobiomodulation|It will be applied a dose of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence MAXX, São Paulo, Brazil). For application, the patient will be positioned in a sitting position and the treatment will be performed with the fixed probe in contact with the skin at an angle of 90º, using the continuous emission mode. The therapy will be applied to the quadriceps muscle, bilaterally.
45381167|NCT05881759|Behavioral|Revised ESBA|Four intervention site staff will implement the ESBA-FFYF feeding curriculum in classes using standardized implementation protocols. Two of the four intervention sites will also participate in the Food Rx program. The control group sites will receive the existing ESBA curriculum. All program materials will be available in English and Spanish. Study participation will be maintained via weekly phone calls/text messaging by the Extension staff. For the online feeding practices content, participants will receive messages to visit the project website and watch the videos, participate in online activities, and engage in facilitated online discussions. For the Food Rx arm, participants will receive a 'Food Rx' card for bi-weekly redemption of ~30 lbs of fresh produce, plus whole grains, lean protein and low-fat dairy at a co-located Houston Food Bank food pantry. The prescription will be eligible for redemption every two weeks for 3 months, for a total of 6 redemptions.
45381168|NCT05881746|Procedure|anatomical liver resection|Based upon the segmental anatomy of the liver according to Couinaud system, anatomical resection (AR) was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these.
45381169|NCT05881746|Procedure|nonanatomical liver resection|Nonanatomical resection(NAR), known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
45381170|NCT05881733|Device|POLARx FIT cryoballoon|Patients will undergo cryoablation with the 31 mm balloon size of the POLARx FIT cryoballoon.
45381171|NCT05881707|Drug|CKD-828, D064, D702|QD, PO
45381172|NCT05881681|Behavioral|App-Delivered Mindfulness Training (MT)|Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
45381173|NCT05881668|Biological|MSC-EV|10 E10 MSC-EV particles per 100ml for a single dose. No prior HLA matching between MSC donors and recipients or liver donors
45694209|NCT00815776|Other|Exercise Group|Subjects assigned to Group 3 will be asked to track daily compliance with the protocol-specific exercise plan in their 4 week diaries. The exercise plan will consist of the following instructions: subjects will be instructed to open their jaw as far as possible, without pain and hold the jaw in that position for 5 seconds. Subjects will then close their jaw and rest 10 seconds. The exercise should be repeated exactly ten times in a row, with a 10 second rest in between each stretch. Subjects will be advised to apply a warm compress to the jaw area after completing their exercises for 10 minutes.
45694210|NCT03535636|Other|Polysomnography|Sleep architecture will be assessed by polysomnography
46055460|NCT04092361|Device|optical coherence tomography|It generates cross sectional images by analyzing the time delay and magnitude change of low coherence light as it is backscattered by ocular tissues. An infrared scanning beam is split into a sample arm and a reference arm. As the sample beam returns to the instrument it is correlated with the reference arm in order to determine distance and signal change via photodetector measurement. The resulting change in signal amplitude allows tissue differentiation by analysis of the reflective properties, which are matched to a false color scale. As the scanning beam moves across tissue, the sequential longitudinal signals, or A-scans, can be reassembled into a transverse scan yielding cross-sectional images, or B-scans, of the subject. The scans can then be analyzed in a variety of ways providing both empirical measurements (e.g. RNFL or retinal thickness/volume) and qualitative morphological information.
45381174|NCT05881655|Device|Airdoc Red Lighting Device|A medical device with ultra low lever laser irradiance of 0.6mW or 1.2mW at the surface of cornea. And the therapy lasts 3 minutes with the 4 hours or more interval of break.
45381175|NCT05881655|Device|Special Spectacles to Control Myopia|Customer designed power and fitting to each subject for all the study periods.
45381176|NCT05881642|Procedure|Prostate and seminal-sparing Cystectomy|Adopt endoscopic enucleation technology to preserve the prostate capsule and part of the urinary control support structure to help restore urinary control and erectile functions
45381177|NCT05881642|Procedure|Conventional Radical Cystoprostatectomy|According to the consensus standard program, remove the accessory tissues including the bladder,prostate and seminal vesicles
45381178|NCT05881629|Behavioral|Maternal position change to side-lying lateral with peanut ball|Participants will be assisted into a position lying on their side, specifically the same side as the fetal spine diagnosed by ultrasound. An inflated peanut ball will be positioned between the legs to open the pelvis. They will be asked to maintain the position for 60 minutes.
45381179|NCT05881629|Behavioral|Free maternal position|Participants will be asked to adopt any position of their choosing and to maintain it for 60 minutes. They will be asked to not use a peanut ball during the 60 minute study period.
45694211|NCT04209790|Radiation|Neoadjuvant chemoradiation|Intensity modulation radiation therapy (IMRT) with a simultaneous integrated boost with Fixed-gantry IMRT, helical tomotherapy, or Vesicular Modulated Arc Therapy (VMAT) can be used. All photon treatments shall be delivered with megavoltage machines of a minimum energy of 6 Megavolt (MV) photons. Selection of the appropriate photon energy(ies) should be based on optimizing the radiation dose distribution within the target volume and minimizing dose to non-target normal tissue.
45847443|NCT02765256|Drug|Promethazine|PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
45847444|NCT02765256|Drug|Fluconazole placebo|Once daily
45847445|NCT02767128|Drug|Triferic|
45381180|NCT05881616|Other|Specimen samples and baseline data collection|The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
45381181|NCT05881616|Other|Specimen samples and baseline data collection|The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
45381182|NCT05881616|Other|Specimen samples and baseline data collection|The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
45381183|NCT05881590|Other|Hybrid pulmonary rehabilitation|Technology-enabled 8-week pulmonary rehabilitation programme using the Active+me REMOTE App
45381184|NCT05881577|Other|Observational|Impact of AR on educational outcomes
45381186|NCT05881525|Biological|TC-N201 cells|T cells genetically engineered with a TCR targeting NY-ESO-1 (NY-ESO-1 TCR) that displays specific reactivity against HLA-A2+, NY-ESO-1+ target cells.
45496449|NCT05229653|Drug|Placebo|Participants in this arm will receive intravenously (IV) matching equal dose of placebo while recovering in the post anesthesia care unit (PACU) on the day of the surgery after subject has been deemed to be stable (hemodynamically stable, awake). The study physician will administer the study intervention via an intravenous pump to deliver equal volume saline over at least 30 minutes.
45381187|NCT05881525|Drug|IL-2|Following cell infusion, the patient receives intravenous IL-2. IL-2 improves the survival of TC-N201 cells after infusion.
45381188|NCT05881525|Drug|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
45381189|NCT05881525|Drug|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
45381190|NCT05881525|Drug|Nab-paclitaxel|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
45381191|NCT05881512|Device|Transcutaneous Upper Airway Stimulation Device|Multiple frequency stimulation of the hypoglossal nerve
45381192|NCT05881473|Diagnostic Test|pain assessment after clavicular fracture repair|This group includes (40) patients will have medial and lateral clavipectoral (CPB) block ultrasound guided using 20 ml Bupivacaine 0.5% for medial and lateral block equally after induction of general anesthesia.
45496450|NCT05076227|Drug|IM injection of vaccination (mRNA vaccination)|mRNA vaccination
45496451|NCT05076227|Drug|IM injection of vaccination (vector based vaccination)|vector based vaccination
45847446|NCT02767128|Drug|Fer-In-Sol|
45847447|NCT02767128|Drug|Shohl's solution|
45847448|NCT02769702|Drug|Acthar|Acthar 80 IU SC twice a week
45847449|NCT02770014|Drug|Erlotinib|
45847450|NCT02771340|Biological|ICON-1|Intravitreal injection of ICON-1
45847451|NCT02771574|Drug|Lyo avexitide|Lyophilized avexitide (Lyo avexitide) administered subcutaneously (sc)
45847452|NCT02771574|Drug|Liq avexitide|Liquid avexitide (Liq avexitide) administered subcutaneously (sc)
45847453|NCT02772432|Behavioral|Relaxation Response Resiliency Training for Parents of SPLD|
45496452|NCT04420403|Other|Manual Therapy|Cyriax's mobilization techniques will be applied as manual therapy. Before the mobilization, soft tissue mobilization techniques will be applied to relieve muscular spasm and preventing the patient' s anxiety. Bringing, manual traction, manual traction with rotation, manual traction with anterior-posterior gliding and lateral gliding mobilization techniques will be applied. Appropriate mobility techniques will be selected according to the complaints and symptoms of the patients. Cervical mobilization applications will take an average of 15-20 minutes.
45694212|NCT04209790|Drug|Drug Therapy with Temozolomide (benzolamide) (Standard of Care)|During Concomitant Radiation Therapy on the same day as the first fraction of radiotherapy. Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days. The drug will be administered orally daily during radiotherapy, as best tolerated by the patient. During weekends without radiotherapy (Saturday and Sunday), the drug will be taken in the morning. The dose will be determined using actual body surface area (BSA) as calculated in square meters at the beginning of the concomitant treatment. The BSA will be calculated from the height obtained at the pretreatment visit. Capsules of temozolomide are available in 5, 20, 100, 140, 180, and 250 mg. The daily dose will be rounded to the nearest 5 mg.
45381193|NCT05881434|Other|Emergency Department Visit Expectations Questionnaire|Patients presented with novel questionnaire designed to illicit patient's self-reported expectations across four domains (overall purpose of visit, medication intervention, imaging intervention and disposition) during check-in when arriving at the emergency department. Patients instructed to present the completed questionnaire to the treating provider.
45381194|NCT05881330|Device|ArtiAid Intra-articular Injection|Inject ArtiAid® in the affected joint at weekly interval for 5 weeks.
45381195|NCT05881317|Device|ArtiAid® Plus Intra-articular Injection|Inject ArtiAid® Plus in the affected joint at weekly interval for 3 weeks
45381196|NCT05881304|Device|Standardized research e-cigarette (SREC)|Patients will be provided with NIDA's standardized research electronic cigarette (SREC) for 8-weeks and asked to attempt to substitute the SREC for combusted cigarettes during the 8 weeks. Participants will be randomized in a 1:1 ratio to 1 of 2 conditions for 8 weeks: 1) immediate standardized research e-cigarette provision (iSREC) or 2) delayed SREC provision waitlist control (WLC). Those randomized to the iSREC group will be provided a free 8-week supply of SRECs and asked to try to switch completely to the SREC. Those in the WLC condition will receive SREC provision after an 8-week delay.
45381197|NCT05881265|Drug|Chidamide+venetoclax|Chidamide 30mg BIW x 4 weeks; Venetoclax 100mg D1, 200mg D2 and 400mg D3-28
45694213|NCT04209790|Procedure|Surgery post Radiation and Temozolomide (benzolamide)|Surgical resection of GBM will be done after radiation and Temozolomide treatment.
45694214|NCT05317234|Genetic|Whole-exome sequencing|The whole-exome sequencing will be performed via a blood sample from a patient with a diagnosis of cerebral palsy.
45694215|NCT03838822|Dietary Supplement|Cofactors|Oral administration of 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
45694216|NCT01718353|Drug|DOCETAXEL (XRP6976)|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
45847454|NCT02772666|Device|O-Glass|The new diagnostic device to distinguish relative afferent pupillary defect(RAPD).
46055461|NCT02762019|Device|Laser therapy|Treatment with K-Laser Cube3 during 4 consecutive days, with the following protocol: 660-970 nm wavelength, 3,2W mean power (6.4W pulsating at 50%), 3'51'' duration, 1-20000 Hz frequency, and 1 cm2 spot size. Laser application was performed all over the oral cavity.
45694217|NCT01718353|Drug|CABAZITAXEL (XRP6258)|Pharmaceutical form: Concentrate and solvent for solution for infusion Route of administration: Intravenous
45694218|NCT01718353|Drug|Prednisone|Pharmaceutical form: Tablet Route of administration: Oral
45381198|NCT05881239|Device|AROMHA Brain Health Test|The AROMHA Brain Health Test is a self-administered, at-home smell test developed as a potential primary screen for identifying individuals at risk for developing Alzheimer's and as a means to follow disease progression in individuals without overt cognitive symptoms. The smell test device consists of five physical smell cards and a paired web-based app that directs participants on how to sample odors and asks them questions regarding what they have smelled. The 45-minute smell test battery includes measures of odor intensity, identification, memory, and discrimination.
45381199|NCT05881213|Drug|CKD-378 (low-dose)|Quaque day (QD), PO
46055462|NCT02762019|Device|Sham therapy|Only the laser pointer movement, without laser activation, during 4 consecutive days, all over the oral cavity.
45381201|NCT05881187|Drug|Riboflavin|topical application of riboflavin followed by cross linking
45694219|NCT01716715|Drug|Cabozantinib S-malate|Given PO
45694220|NCT01716715|Other|Laboratory Biomarker Analysis|Correlative studies
45694221|NCT01716715|Drug|Paclitaxel|Given IV
45381202|NCT05881187|Drug|Antibotice.g vigamox ED Antifungal e.g Dflucan|topical application of antimicropial therapy
45381203|NCT05881187|Device|pack cross linking|TOPICAL application of cross linking after application of Riboflavin TO TREAT INFECTIOUS KERATITIS
45381204|NCT05881148|Other|Carbon sprinting spiked-shoes|Commercial Branded Carbon Spiked-Shoes, from one Trademark only to ensure generalization concerns, is used alternatively with standard carbon-free spiked-shoes, for 8 repetitions of 30m-sprint each, separated by 10 minutes rest each.
45381205|NCT05881148|Other|Standard carbon-free sprinting spiked-shoes|cf
46055463|NCT04092049|Other|lollipop|chewing lollipop for 10 minutes
45381206|NCT05881135|Drug|Citicoline|i.v. bolus administration every 12 hours for 5 days.
45381207|NCT05881135|Drug|Saline/Placebo|i.v. administered every 12 hours as a 10 ml bolus for 5 days.
45381208|NCT05881122|Behavioral|Mad Dog Dietary Consultation|The Mad Dog consultation was delivered in two parts over consecutive days. Part I entailed an accompanied trip to the participant's preferred grocery store to show the participant where selected foods could be found, how to read nutrition labels so that acceptable substitutions to the Mad Dog ingredients could be made, and how to shop for value when choices are presented. Part II of the consultation occurred in the participant's home and focused on meal preparation and kitchen accessibility, as well as a brief overview regarding the negative consequences of chronic inflammation, and the positive effects of adopting an anti-inflammatory diet. Questions and discussion were highly encouraged throughout the consultation and materials were left with the participants allowing them to easily review and reference information that was covered during the meeting. Specifically, participants were given 28 compliant recipes, additional snack ideas and shopping tips along with a consult summary.
45694222|NCT01696981|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
45694223|NCT01696981|Procedure|Sigmoidoscopy|Undergo a flexible sigmoidoscopy
45694224|NCT01696279|Drug|Lanthanum Carbonate|Lanthanum Carbonate 1500 mg to 3000 mg powder will be administered orally.
45694225|NCT01696279|Drug|Calcium Carbonate|Calcium carbonate will be administered orally at a total daily dose based on standard clinical practice. The total daily dose may be adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500 mg is reached.
45694226|NCT01681069|Dietary Supplement|IQP-VV-102|
45694227|NCT01681069|Other|Placebo|
46055464|NCT02766621|Biological|PF-06823859|Comparison of different dosages of PF-06823859 to placebo
46055465|NCT02766621|Drug|Placebo injection SC/IV|Comparison of Placebo to different doses of PF-06823859
45694228|NCT04555759|Other|2-minute walk test|The patients will do a 2-minute walk test, using their walking aids or braces
45694229|NCT01936181|Drug|Remicade (infliximab)|
46055466|NCT04091971|Drug|Ketamine|See arm description.
45694230|NCT01936181|Drug|SB2 (proposed biosimilar to infliximab)|
45847455|NCT02772666|Other|Swinging Flashlight Test|The swinging-flashlight test is used to help a practitioner identify a relative afferent pupillary defect.For an adequate test, vision must not be entirely lost. In dim room light, the examiner notes the size of the pupils. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
45847456|NCT02773758|Other|Stannous Fluoride Dentifrice|Experimental dentifrice containing 0.454%w/w stannous fluoride (1100ppm fluoride)
45847457|NCT02773758|Other|Sodium monofluorophosphate Dentifrice|Dentifrice containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride)
45381209|NCT05881109|Drug|Caspogunfin|No specific interventions were administrated. Participants receive interventions as part of routine medical care, where CAS was infused intravenously over 60 min at a loading dose of 70 mg/m2 on day 1, followed by a maintenance dose of 50 mg/m2 (maximum: 70 mg daily).
45381210|NCT05881070|Behavioral|Mobile-health self management|Mobile-health self management
45381211|NCT05881044|Other|Psychiatric interview|"Psychiatric interview which include personal identification, present history, past history and family history~Complete physical and Neurological Examination.~Mini Neuropsychiatric Interview scale. (MINI): to diagnosis psychiatric disorders~Symptom checklist 90(SCL 90)~Quality of life questionnaire.~Hamilton Depression scale.~Hamilton Anxiety scale.~Socioeconomic scale (A.El.Gilany,A.El.Wehady,and M.EL.Wasify)"
45381212|NCT05881031|Other|Home Initiation of NiPPV|Initiation of NiPPV in the home environment through the utilization of an awake NiPPV titration, oximetries, and telemonitoring.
45694231|NCT04642235|Other|Nature Nook|The Nature Nook intervention will take place on lots that already have the standard greening intervention. In addition, design elements will be added such as a simple path and benches to explicitly invite people into the space. An additional difference is the exclusive use of larger, corner lots, rather than smaller mid-block spaces, to maximize visibility.
45381213|NCT05881018|Dietary Supplement|Low glycaemic index|Diet will be supplemented with a drink containing a low glycaemic index carbohydrate
45381214|NCT05881018|Dietary Supplement|High glycaemic index|Diet will be supplemented with a drink containing a high glycaemic index carbohydrate
45381215|NCT05881018|Behavioral|Physical activity|Participants will include physical activity units
45381216|NCT05881005|Diagnostic Test|hepatic MRI|Quantification of hepatic steatosis with RMI at the diagnosis (T0) and one year after remission (T1). The percentage of patients with complete resolution of hepatic steatosis on MRI will be determined.
45496453|NCT04420403|Other|Cervical Stabilazation Exercise (CSE)|The CSE program aims to maintain a neutral spine position and activate deep cervical muscles during exercises. It is performed in stages with gradual progression according to the stages of motor learning and sensory-motor integration, namely, static, dynamic, and functional. The program will start with postural training and then the cervical bracing technique with the activation of deep neck flexors for CSE was performed. The patients will be asked to maintain a neutral spine during the exercises and throughout the day as much as possible. The difficulty and variety of exercises will be increased weekly. It will be carried out 2 days a week for 6 weeks (12 sessions) by the supervisor physiotherapist.
45381217|NCT05880992|Behavioral|Exercise|Aerobic and Strength exercises (equipment free, simple, modifiable)
45381218|NCT05880992|Dietary Supplement|Nutrition|Counselling on daily protein target of 1.2 g/kg as well as supplementation with protein shake (provided)
45381219|NCT05880992|Behavioral|Mindfulness|Deep (box) breathing completing in the morning, evening and as needed.
45381220|NCT05880979|Behavioral|Engaging Together for Healthy Relationships|A comprehensive parent-adolescent dating violence prevention intervention designed to be provider delivered within the context of a pediatric well-child visit
45381221|NCT05880979|Behavioral|Regular well child care|Participants will receive their regularly scheduled well-child care
45694232|NCT04642235|Behavioral|Nature Coach|"The Nature Coach Intervention consists of 3 components - home visit, text message follow up, and goal feedback.~Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach."
45381222|NCT05880927|Drug|Pyrotinib|Patients receive pyrotinib 400mg/day for half or one year
45381223|NCT05880901|Behavioral|After school program|The after school program are existing community-based programs that take place immediately after the regular school day (typically 3:00-6:00pm); are located in a school; are available daily throughout the academic year (Monday through Friday); and provide a combination of scheduled activities, which include a snack, homework assistance/tutoring, enrichment activities (e.g., arts and crafts, music), and opportunities for children to be physically active.
45381224|NCT05880901|Behavioral|Summer day camp|The summer day camp programs are existing camps which take place at schools from which children will be recruited. The camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks.
45381225|NCT05880875|Behavioral|Reflective Supervision Enhancement|The Reflective Supervision enhancement is a professional development series designed to train and support directors and education coordinators supervising state pre-kindergarten classrooms in using a reflective supervision approach with their staff.
45381226|NCT05880849|Drug|Choline|Eight 275mg capsules taken orally twice daily (4 capsules with breakfast & 4 capsules with dinner) x 180 days
45381227|NCT05880836|Device|nebulizer via in-line drug delivery maintaining high-flow nasal cannula oxygen|nebulized delivery of bronchodilator via in-line drug delivery maintaining high-flow nasal cannula oxygen
46055467|NCT02761707|Other|Electrical Brainstem Responses|Eye blink responses will be induced using standard stimulating electrodes employed in surface electromyography (EMG). The subjects will recline with their eyes gently closed. Sticky electrodes will be placed to the left and below the left eye. 6 different facial regions will be stimulated. The electrical stimulation will be kept constant during the test sessions. To prevent habituation, the stimuli will be delivered randomly at intervals of 45-60 sec. Four 0.2 msec pulses will be presented. In some cases, paired pulse stimulation will be performed, and a conditioning stimulus will be applied to the target facial regions at the following intervals: 10, 200, 400, 600 and 800 msec. 4 pulses will be presented at each stimulus interval with randomized interval and pulse sequences.
45381228|NCT05880836|Device|standard jet nebulization (SJN) with face mask|standard jet nebulization delivery of bronchodilator
45381229|NCT05880823|Device|Synergy cervical disc system|motion preservation disc
45381230|NCT05880810|Device|Continuous Glucose Monitor Dexcom G6 PRO|Connected to a smart phone that transmits continuous glucose monitoring data in real time to Advanced Care at Home Command Center for monitoring.
45381231|NCT05880784|Other|Reinforcement of Peer coaching and clinical audit|The goal of the proposed research study is to test the effectiveness and feasibility of an intervention to enhance peer coaching and clinic audit activities to facilitate the implementation of the Package of Essential Non- Communicable Diseases (PEN) in Nepal.
45381232|NCT05880784|Other|Continuation of usual practice without intervention|No intervention will be carried out, instead usual practice will be evaluated at the start and the end of the study period.
45381233|NCT05880745|Diagnostic Test|Nine-Hole Peg Test (NHPT)|Ataxia Rating and Rating Scale (SARA) for coordination Nine-Hole Peg Test (NHPT) and Dexterity Questionnaire-24 (DextQ-24) for manuel dexterity Beck Depression Inventory (BDI) for depression level The Fatigue Severity Scale (FSS) and Fatigue Impact Scale (FIS) for general fatigue level Static and dynamic fatigue levels for hand fatigability
45694233|NCT04642235|Other|Nature Nook + Nature Coach|The combined intervention will involve the installation of Nature Nooks to blighted vacant lots followed by the delivery of the Nature Coach intervention to people living in the immediate surrounding blocks. The intervention will be tailored to explicitly direct participants to use the Nature Nook.
45694234|NCT04641611|Other|Bicaval cannulation|Cannulation of SVC and IVC through right atrium in patients undergoing CABG. with snares applied
45694235|NCT04641611|Other|Cavoatrial cannulation|Cannulating the right atrium and Inferior vena cava with a 2-stage cannula
45694236|NCT01696045|Biological|Ipilimumab|
45694237|NCT01716169|Device|Helicoll|Helicoll Collagen I Wound Dressing
45694238|NCT01716169|Device|Standard of Care Dressings|Standard of Care wound dressings (e.g. Vaseline gauze)
45694239|NCT01935947|Drug|Azacitidine|Given SC
45694240|NCT01935947|Drug|Azacitidine|Given PO
45694241|NCT01935947|Drug|Docetaxel|Given IV
45694242|NCT01935947|Drug|Entinostat|Given PO
46055468|NCT02761707|Other|Olfactory Tests|Olfactory testing will be performed using standard tests. The University of Pennsylvania Smell Identification Test (UPSIT) assesses a subjects ability to identify odors in a forced choice format. The Snap and Sniff Threshold Test provides a threshold measure of phenyl ethyl alcohol. Short-term odor memory will be assessed using a standardized 12-item four-alternative forced-choice Odor Memory Test. This non-lexical test employs 10-, 30-, and 60-second delay intervals between the presentation of the target odorant and the first of four successively presented odors from which the target is to be selected.
45694243|NCT01935947|Drug|Gemcitabine Hydrochloride|Given IV
45694244|NCT01935947|Drug|Irinotecan Hydrochloride|Given IV
45694245|NCT01935947|Other|Laboratory Biomarker Analysis|Correlative studies
45694246|NCT01935947|Drug|Pemetrexed Disodium|Given IV
45694247|NCT04547803|Other|Standard of Care|Outpatient appointments and activities including radiologic procedures for discharging patients as standard of practice
45496454|NCT05551949|Drug|Vaginal estradiol tablets|Vaginal estradiol tablets (10mcg).
45694248|NCT04547803|Other|Video Visit|15-20 minute Video visit with an advanced practice provider (nurse practitioner or physician assistant) approximately 2-5 days after discharge.
46055469|NCT02761707|Other|Visual Deprivation|During a 2-hour visual deprivation period, subjects will wear comfortable light-tight goggles with lenses that have been blackened by flat black paint. Subjects will be given the opportunity to recline comfortable in a padded reclining chair during this time.
46055470|NCT02761707|Other|Peripheral Nerve Stimulation|Electrical stimulation will be applied to a nerve of your arm. Sticky electrode pads will also be placed on a hand muscle. You will receive electrical stimulations that lasts less than a second. The stimulations will make your muscle twitch.
46055471|NCT04019977|Other|Nurse Home Visiting Program|Brief nurse home visiting program
46055472|NCT04091815|Other|Type of anaesthesia|Two different types of anesthesia general vs combined (spinal and general)
46055473|NCT02761473|Other|skin biopsy|A skin biopsy will be obtained from a typical UP lesion in affected patients
46055474|NCT02761473|Other|blood draw|Blood will be obtained from subjects, parents and unaffected siblings
46055475|NCT02599285|Device|Fixation|Fixation of the posterior malleolus with lag-screws or plate-fixation. If syndesmosis is intra-operatively stable, no syndesmotic positioning screws will be placed.
45694249|NCT02986321|Drug|CHF6001|Dose response: Test one of 4 different doses of CHF6001
45381234|NCT05880732|Drug|Magnesium Sulfate|Magnesium sulfate (MgSO4) is an N-Methyl D-Aspartate (NMDA) receptor antagonist that has been used for postoperative analgesia and reducing both the duration and intensity of pain by preventing central sensitization in response to peripheral painful stimulus4-9.
45381235|NCT05880732|Drug|normal saline isotonic solution|only 250 ml of normal saline isotonic solution 30 minutes before induction,
45381236|NCT05880719|Other|Computer-assisted Music remediation|"These sessions of computer-assisted music remediation last 1h and are each divide in 4 parts :~15 minutes of music improvisation~20 minutes of harmony and rythm exercices~20 minutes of Lesson about the software and musical interfaces~5 minutes of debrief."
45381237|NCT05880706|Drug|BL-B01D1|Administration by intravenous infusion
45381238|NCT05880706|Drug|Osimertinib Mesylate Tablets|Osimertinib Mesylate Tablets will be administered at a fixed dose of 80mg daily.
45381239|NCT05880693|Drug|Dexmedetomidine|Group 1 received dexmedetomidine
45381240|NCT05880693|Drug|Magnesium sulfate|the group 2 received magnesium sulfate
45381241|NCT05880680|Device|SEAL Device|Using standard interventional endovascular techniques, the device is navigated via the push wire delivery system through compatible neurovascular microcatheters to the aneurysm lumen or target site. The device is positioned into its target aneurysm lumen and is electrically detached by the operator with a hand-held, battery-powered detachment handle designed specifically for the SEAL Embolization System.
45496455|NCT05541497|Drug|Varenicline Tartrate|Days 1-3: 0.5mg study pill once per day, Days 4-7: 0.5mg study pill twice per day, Weeks 2-8: 1mg study pill twice per day
45496456|NCT05541497|Drug|Placebo|Days 1-3: 0.5mg pill once per day, Days 4-7: 0.5mg pill twice per day, Weeks 2-8: 1mg pill twice per day
45694250|NCT02986321|Drug|Budesonide|active control
45694251|NCT02986321|Drug|Placebo|placebo control
45694252|NCT04554667|Behavioral|Exercise Intervention|Heavy Lifting Strength Training
45694253|NCT01618019|Dietary Supplement|Omega-3 fatty acid|5 capsules/day of either n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
45694254|NCT01618019|Dietary Supplement|Placebo|5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
45694255|NCT01593787|Drug|LCZ696|100 mg, 200 mg, 400 mg tablets.
45694256|NCT04410601|Procedure|Total thyroidectomy|DRT-diet modification, compensation strategies, oral motor exercises such as laryngeal elevation, masseters / tongue hold / exercise, bolus transition exercise; chin-down/up, head rotation, and other maneuvers with tactile stimulation.
45694257|NCT01951157|Drug|Docetaxel|Powder for solution for infusion
45694258|NCT01951157|Drug|Gemcitabine|Powder for solution for infusion
45694259|NCT01951157|Drug|Lurbinectedin (PM01183)|Powder for concentrate for solution for infusion
46055476|NCT02599285|Device|NO Fixation|Posterior malleolus will not be fixated. Syndesmotic positioning screws will be placed.
46055477|NCT02766231|Device|Physica CR|Cruciate tretaining total knee replacement
46055478|NCT02766231|Device|Physica PS|Posterior Stabilized total knee replacement
46055479|NCT02766387|Other|Evaluation of the correlation between walking speed in the 6MWT and in 2MWT, and the walking speed observed in the continuous 2km walk test and in the 10 meters walk test.|
46055480|NCT00746785|Drug|2.5 mg Olanzapine|2.5 mg
46055481|NCT00746785|Drug|5mg Olanzapine|5 mg
45381242|NCT05880667|Radiation|Adaptive Stereotactic Body Radiation|"Radiation therapy is given following generation of planning imaging at the time of simulation. A recent development has been diagnostic quality onboard imaging incorporated within radiation treatment machines. The incorporation of onboard imaging into standard practice has allowed the use Stereotactic Body Radiation (SBRT), which is a precise radiation technique that allows safe delivery of ablative radiation doses.~More recently, the development of improved technologies and software have allowed radiation plans to be generated and delivered that are specific to the anatomy of the very moment the patient is being treated. This novel ability to adjust the radiation treatment plan based upon real time imaging is termed adaptive radiation therapy. This study will utilize the novel adaptive radiation therapy technology in a patient population with technically challenging disease to deliver ablative radiation with an appropriately low toxicity rate."
45381243|NCT05880654|Procedure|Scaling & root planning|Non Surgical periodontal therapy
45381244|NCT05880589|Dietary Supplement|Milk secretory supplement group|Take 2 tablet 2 times per day for 14 days
45381245|NCT05880589|Dietary Supplement|Placebo group|Take 2 tablet 2 times per day for 14 days
46055482|NCT00746785|Drug|placebo|placebo
45496457|NCT05283954|Drug|Combination regimen: Fluoxetine, Prednisolone, Ivermectin|"Subjects will receive the following treatments:~Fluoxetine 20 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Prednisolone 25 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Ivermectin 3 mg oral tablets: Tablets started right after randomization (Day 0; 400mcg/ kg dosing), administered once a day for 05 consecutive days."
45381246|NCT05880563|Drug|[18F]-RoSMA-18-d6|[18F]-RoSMA-18-d6 will be administered intravenously by a bolus injection followed by a subsequent PET/CT-scan of the brain and the spine
45381247|NCT05880550|Other|ultrasound cavitation in addition to aerobic ex|"Ultrasonic cavitation was turned on, the program of cavitation 40 kHz was chosen, the time was adjusted at 30 minutes. The cavitational head was moved very slowly on each abdominal segment in a small circular movement for 5 minutes. After finishing the focused ultrasound of the 6 segments of the abdomen, the skin was cleaned with cotton.~in addition to that the patients will receive aerobic exercises for 40 minutes."
45381248|NCT05880550|Other|aerobic exercises.|the patients will do aerobic training for 40 minutes on a bicycle ergometer.
46055483|NCT02761551|Behavioral|Reminder notifications via autodialer|
45381250|NCT05880511|Device|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2000 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires ~ 11.5 minutes in total.
45381251|NCT05880511|Device|Augmented Reality Sensorimotor Training|Sensorimotor training is a non-invasive, non-painful procedure using augmented reality to present virtual objects which cue motor action. Augmented reality allows us to project virtual objects overlaid on the user's actual environment. The sensorimotor training task involves making movements with the head and neck such that a target crosshair presented in the centre of the glasses is moved to a virtual target that is presented in the user's environment. Participants will perform 20 minutes of sensorimotor training. The goal of augmented reality sensorimotor training is to promote goal directed actions using the head and neck.
45381252|NCT05880511|Device|Sham Repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. During the sham, participants will hear and experience the clicking from the device but will not be provided with any stimulation. The delivery of sham rTMS requires ~ 11.5 minutes in total.
46055484|NCT04515771|Behavioral|PARTNER-MH|The study intervention consists of a peer navigation program developed by the study team. The navigation program focuses on navigating VA mental health services, as well as patient engagement in mental health services and patient-provider communication. The intervention will last for 6 months, during which the participant will commit to regularly meeting with their peer specialist (interventionist). Peer navigation sessions will be guided by the specific aims of the study program, but in a way that is tailored to the participants' specific needs.
45496458|NCT05283954|Drug|Combination regimen: Albendazole, Vitamin C|"Subjects will receive the following treatments:~Vitamin C 50 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Albendazole 200 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Vitamin C 50 mg oral tablets: Tablets started right after randomization (Day 0; 130mcg/ kg dosing), administered once a day for 05 consecutive days."
46055485|NCT04090021|Drug|Esomeprazole 40mg|Use in a drug combination for H. pylori eradication
46055486|NCT04090021|Drug|Clarithromycin 500mg|Use in a drug combination for H. pylori eradication
45381253|NCT05880498|Behavioral|Mindfulness Intervention|Self-guided mindfulness training using a customized version of the Healthy Minds app
45694260|NCT01363349|Drug|CYP-1020|CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.
45694261|NCT01363349|Drug|Risperidone|
45381254|NCT05880485|Radiation|online adaptive radiotherapy|PTV with 5-10 margins covers CTV
45381255|NCT05880472|Device|Intratumoral|Comparable to CE-marked QuiremSpheres(R) outside of intended use with minor altered specification.
45381256|NCT05880459|Drug|propofol and magnesium sulphate ,propofol and nalbuphine|"The patients will be randomly divided into 2 groups by using a computer-generated randomization tableAll patients will fast from solids for 8 h and from liquids for 2 h. After arrival at preoperative area an intravenous cannula will be placed in the peripheral vein of right hand for fluid infusion and medicine administration.~All of the patients will be interviewed by the patient sedation satisfaction assessment tool (PSSI) regarding their experience 1 hour after the operation."
45381257|NCT05880433|Device|NIRS(INVOS 5100; Covidien Somanetics, Troy, MI|NIRS (Near Infrared Spectroscopy) is a non-invasive, bedside device that measures the concentration of oxygenated and deoxygenated hemoglobin in tissue, providing information about tissue oxygenation. Its working mechanism is based on the ability of light with wavelengths between 700-1000 nm to penetrate up to 8 cm into the skin and brain tissue. It offers continuous information about tissue oxygenation in different regions using probes attached to the skin. While pulse oximeters indicate arterial oxygen saturation, they are insufficient in detecting tissue-level hypoxia. Therefore, NIRS, being a painless method, is frequently used in the monitoring of newborns in the intensive care unit.
45381258|NCT05880407|Procedure|SERI osteotomy|Correction of varus deformity of the 1st Metatarsal that is stabilized with Kirschnner wire
45381259|NCT05880407|Procedure|percutaneous osteotomy according to Chevron|Correction of varus deformity by osteotomy stabilization with 2 screws inserted via dorsal percutaneous accesses to the 1st Metatarsal.
45381260|NCT05880381|Device|Virtual Reality Group|Patients allocated to the treatment group will undergo an intervention that comprises 3 weekly sessions of 60 minutes for 4 weeks with the VR prototype.
45381261|NCT05880381|Other|Control Group|The participants allocated to this group will do the formal standard care provided by the Gynecology- Obstetric service.
45381262|NCT05880368|Other|Patient partnership tools|The intervention consists of two patient partnership tools: (1) a one-page 'visit prep guide' given to relevant patients by clinic staff before seeing the primary care provider, with the intention to improve communication and shared decision-making; and (2) a series of short educational videos that clinic staff can encourage patients to watch. The interventions will be included in the workflow of the clinics during the intervention periods (i.e., clinics either do not use the intervention or use them for all relevant patients depending on study period).
45381263|NCT05880355|Drug|Dapansutrile|Oral inhibitor of NLRP3
45381264|NCT05880355|Other|Placebo|Non-active placebo
45381265|NCT05880342|Drug|Reboxetine Pill|8 mg
45381266|NCT05880342|Drug|Methylphenidate Oral Product|20 mg
45694262|NCT00867100|Drug|700 mg IV|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
45694263|NCT00867100|Drug|350 mg SC|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
46055487|NCT04090021|Drug|Metronidazole 500 mg|Use in a drug combination for H. pylori eradication
46055488|NCT04090021|Drug|Amoxicillin 1000 MG|Use in a drug combination for H. pylori eradication
46055489|NCT04090021|Drug|Levofloxacin 500mg|Use in a drug combination for H. pylori eradication
46055490|NCT04090021|Drug|Rifabutin 150 MG|Use in a drug combination for H. pylori eradication
46055491|NCT04223973|Device|Medtrum A7+ insulin Pump|Use of the Medtrum pump during 3 months in combination with a CGM
46055492|NCT04223973|Biological|Lab A1C|Measure of Lab A1C at baseline and end of study
46055493|NCT04649073|Biological|OPC-415|OPC-415 (up to 1×10^7cells/kg) On 2 days
46055494|NCT00750919|Drug|esmirtazapine|
46055495|NCT02766309|Other|Sf12-v2|structured questioner Sf-12v2, developed by Ware.et al (Ware, Kosinski, Turner-Bowker & Gandeck, 2002).
45496459|NCT02946515|Behavioral|Educational Intervention|The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.
45496460|NCT02946515|Behavioral|Wait List Control|Access to the online simulation training after the follow-up measurement visit is complete
45496461|NCT05176145|Device|VisioCyt®|"Cytological and endoscopic examination is planned as part of the usual management of patients under surveillance of Non-muscle invasive bladder cancer (NMIBC), according to the CCAFU guidelines.~Urine collection for conventional cytology and VisioCyt® test"
45496462|NCT01312415|Drug|Levobupivacaine|Patients will receive peri- and intraarticular surgical site infiltration to the knee during surgery and before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight (maximum 200mg levobupivacaine will be used if the patient's weight exceeds 100kg) plus 0.5mg epinephrine made up to 100ml with saline. An intra-articular catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. The patient will receive one further injection of 15ml of levobupivacaine 0.5% solution at 8am on the morning of the first postoperative day after which the catheter will be removed.
45496463|NCT01312415|Drug|Intrathecal morphine|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.3 mg).
45381267|NCT05880329|Diagnostic Test|Candidate POCTs for detecting UTI|POCT performance will be evaluated in participants who experience possible UTI.
45381268|NCT05880316|Behavioral|Intermittent Fasting|3:4 regime
45381269|NCT05880290|Procedure|gynaecological examination in lateral decubitus|Single group: gynaecological examination in lateral decubitus, conventional repositioning if unsuccessful
45381270|NCT05880277|Diagnostic Test|POCUS|Point of Care Ultrasound
45381271|NCT05880251|Behavioral|Operant Conditioning with Peripheral Stimulation|This is a training intervention to strengthen the weakened sensorimotor responses and reduce pain, after a limb amputation. Non-painful peripheral stimulation will be applied to elicit a response.
45381272|NCT05880251|Behavioral|Control Group with Peripheral Stimulation Only|This is a control intervention in which the non-painful peripheral stimulation will be applied, same as the operant conditioning group, but no training feedback will be provided.
45496464|NCT05143775|Procedure|Awake craniotomy|Randomly select 30 participants to implement new surgical plan, which is using a monopolar stimulator to determine positive function sites and save tumors within 5 mm of the posterior superior longitudinal fasciculus/arcuate fasciculus
45496465|NCT03036852|Drug|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet(s) administered orally once daily
45496466|NCT04979117|Device|Superb Microvascular Imaging (SMI) (Toshiba)|to determine whether there is a diagnostic value of SMI in Plantar Fasciitis and whether there is a superiority when compared Power Doppler and Color Doppler modalities.
45496467|NCT01312493|Drug|Panitumumab|Weekly panitumumab intravenously at a dosage of 2.5 mg/kg started one week prior to RT until RT is completed. No more than 8 treatments.
45381273|NCT05880238|Behavioral|Intervention group|The intervention consisted of a total of 3 modules, 20 sessions. These modules are: Module A: I explore my inner and outer world Module B: I am learning self-editing methods C module: discovering self-editing In these modules, students were trained to use sensorimotor strategies for self-regulation. The intervention program was carried out in one-hour sessions, twice a week, for a total of 10 weeks.
45381274|NCT05880238|Other|Control group|The control group will continue their education according to the preschool education curriculum.
45496468|NCT01312493|Radiation|Intensity Modulated Radiation Therapy|The dose per fraction will be 2 Gy per day. Thus, the total number of fractions will be 35. Five days a week for 7 weeks.
45496469|NCT05309837|Dietary Supplement|Polydextrose|Polydextrose-enriched food products
45496470|NCT05309837|Dietary Supplement|placebo-controlled|Control food products
46055496|NCT02761161|Drug|Mianserin|mianserin is add-on treatment to treatment as usual. Max dose 30 mg day.
45496471|NCT04313244|Biological|9vHPV vaccine|9vHPV intramuscular injection
45496472|NCT04313244|Biological|Dengue Tetravalent Vaccine (TDV)|TDV subcutaneous injection
46055497|NCT02761161|Behavioral|Imagery Rehearsal Therapy|IRT is add-on treatment to treatment as usual.
46055498|NCT04094155|Diagnostic Test|retinal vascular analysis|Retinal fundoscopy over a 3 week period in stationary patients after aneurysmatic subarachnoid hemorrhage
46055499|NCT02761395|Procedure|Al-hijamah|"Strict sterilization of selected anatomical sites.~Suction using sterile plastic disposable sucking cups~Skin scarifications (shartat mihjam): through inducing superficial (0.1 mm in depth), small (2 mm in length), multiple and evenly distributed skin incisions."
46055500|NCT02761395|Drug|Deferasirox|20-40 mg/kg/day orally
45381275|NCT05880225|Behavioral|Reciprocal Imitation Training|As a naturalistic developmental behavioral intervention (NDBI), Reciprocal Imitation Training (RIT) utilizes contingent imitation, linguistic mapping, modeling, prompting, and contingent reinforcement to train object and gesture imitation during play activities.
45381276|NCT05880225|Behavioral|music-enhanced Reciprocal Imitation Training|Music-enhanced imitation training uses music and rhythm to enhance the predictability and salience of the strategies utilized within the Reciprocal Imitation Training platform (i.e., contingent imitation, linguistic mapping, modeling, prompting, and contingent reinforcement to train object and gesture imitation during play activities).
45381277|NCT05880212|Other|Usual physiotherapy care|In Phase 1, physiotherapists will provide treatment for participants with chronic low back pain in accordance with their current standard physiotherapy practice. Physiotherapists will be free to choose the treatment approach they wish to.
45381278|NCT05880212|Other|Individualized (STOPS) physiotherapy|In Phase 3, participants will receive individualized physiotherapy in accordance with the Specific Treatment of Problems of the Spine (STOPS) approach modified for chronic low back pain. Treatment will be individualized on the basis of biopsychosocial assessment findings including dominant pain type (nociceptive, neuropathic or nociplastic), pathoanatomical subgroups (if any), and other barriers to recovery (eg. inflammation, depression, anxiety, stress, catastrophising, pain self-efficacy, and unhelpful motor control strategies). Available treatment strategies will include individualized education/advice, exercise, manual therapy, activity modification/facilitation, goal setting, motor control optimisation, cognitive-behavioural strategies, inflammation management, pain management strategies, sleep management, work management, and relaxation approaches.
45381279|NCT05880199|Device|Body surface gastric mapping device|A medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders.
45381280|NCT05880186|Dietary Supplement|Acute caffeine supplementation|To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women.
45381281|NCT05880173|Diagnostic Test|FIB4|"Diagnostic procedure :~FIB4 blood tests in medical analysis laboratories. If FIB4 positive, Non invasive spacialized evaluation (transient elastography and FibroMeter) by a specialist and if necessery liver biopsy, endoscopy and/or echography"
45381282|NCT05880160|Other|Phased withdrawal of heart failure medications|As per arm/group description
45381283|NCT05880147|Device|Consent App|Family will receive their study information and consent form in an app on a tablet
45381284|NCT05880147|Other|Traditional paper-based consent|Patient/family will receive their study information and consent on a traditional paper form
45381285|NCT05880134|Procedure|conventional posterior nerve neurectomy|"A vertical incision is made behind the posterior fontanelle. The posterior end of the posterior fontanelle is identified by palpation with an elevator. .~The mucoperiosteum is raised gently using a Cottle elevator or a suction freer elevator, after making the initial incision. Care must be taken not to injure the sphenopalatine vessel during flap elevation.~The peripheral part of the posterior nasal nerve can usually be identified just behind the incision, about 4-5 mm inferior to the sphenopalatine artery or crista ethmoidalis.~I After identifying the nerve fibres, it is cauterised using monopolar suction cautery and cut using microscissors. It is essential to carry out this procedure on both sides for effective results."
45381286|NCT05880134|Procedure|cartilage graft reinforcement after posterior nerve neurectomy|"A vertical incision is made behind the posterior fontanelle. The posterior end of the posterior fontanelle is identified by palpation with an elevator. .~The mucoperiosteum is raised gently using a Cottle elevator or a suction freer elevator, after making the initial incision. Care must be taken not to injure the sphenopalatine vessel during flap elevation.~The peripheral part of the posterior nasal nerve can usually be identified just behind the incision, about 4-5 mm inferior to the sphenopalatine artery or crista ethmoidalis.~I After identifying the nerve fibres, it is cauterised using monopolar suction cautery and cut using microscissors. It is essential to carry out this procedure on both sides for effective results.~then harvest cartilage from nasal septum and refashion it around sphenopalatine bundle to prevent nerve re-innervation~The mucoperiosteal flaps are repositioned . No nasal packing is required. Patients are discharged on the same day"
45381287|NCT05880121|Diagnostic Test|MRI|brain MRI
45381288|NCT05880108|Behavioral|12-weeks of Weight Loss|Participants will be asked to participate in a 1x/week center-based nutrition diet class, 2x/week center-based exercise classes, and 1x/week exercise session conducted on their own for 12 weeks.
45381289|NCT05880108|Behavioral|12-weeks of Weight Stability|Participants will be asked to participate in a 1x/week center-based health education class, 2x/week center-based stretching/balance classes, and 1x/week stretching/balance session conducted on their own for 12 weeks.
45496473|NCT04977947|Behavioral|Healthy Eating for My Infant|The intervention targets problem solving to overcome barriers, behavioral rehearsal and practice of healthy behaviors, promoting readiness to change, goal setting, self-monitoring, and behavioral tracking. Two standard treatment modules will be provided to each family by a study interventionist focusing on infant nutritional requirements, responsive feeding, and mealtime behaviors. Two additional treatment modules will be selected to address the unique needs articulated by each family (e.g., food insecurity, eating healthy on a limited income, emotional eating, engaging other caregivers, maternal mental health). Modules will consider the influence of maternal trauma history and mental health on feeding and eating behavior. The intervention also includes two peer counselor-led sessions during which families can discuss implementation of recommendations and barriers to change with a member of their community who can problem solve and support change.
45496474|NCT04294290|Biological|hCT-MSC infusion|This is a single site, phase I, open-label, prospective study of one intravenous infusion of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in 12 toddlers 18 to 48 months of age with autism spectrum disorder (ASD).
45381290|NCT05880095|Other|Unrestricted Mediterranean diet|Participants will received nutritional educational information to encourage their adherence to a Mediterranean dietary pattern. Neither caloric restriction nor time-eating restriction will be indicated.
45496475|NCT05155865|Device|Resynchronization with conduction system pacing|Implantation of permanent pacemaker with conduction system pacing (preferably left bundle branch) with or without defibrillator lead placement
45381291|NCT05880095|Other|Energy-reduced Mediterranean diet|Participants will follow a Mediterranean diet with a 25% caloric restriction. Participants will be provided with dietary programs, menus, shopping lists and other educational material to encourage adherence to the intervention.
45381292|NCT05880095|Other|Mediterranean diet with time-restricted eating|Participants will follow the same dietary guidelines given to MedD group, but they must to adjust their daily meals to a self-selected 10-hour eating window. This 10h eating window of their choice should be comprised between 6.00 to 20.00h. Participants will be allowed to consume water and non-caloric drinks during the fasting period (outside the 10h eating window). Participants will be advised to follow the 10h TRE during weekdays and weekends.
45847458|NCT02773836|Other|Questionnaire|Questionnaire: To evaluate the impact of the implementation of the EU Tobacco Products Directive (TPD) and Framework Convention on Tobacco Control (FCTC)
45381293|NCT05880082|Drug|Tislelizumab|Tislelizumab 200mg, Q3W, 2-4 cycles Albumin paclitaxel 240 mg/m², adjusted according to the patient Carboplatin: AUC=5 Q3W, d1 or cisplatin: 20mg/m² iv, D1-3 Q3W or Nedaplatin: 70mg d1 Q3W
45381294|NCT05880069|Other|Pathogen resistant phenotype|Drug resistant phenotype of the target pathogen under study
45381295|NCT05880056|Drug|Nerkardou 5 mg & Nerkardou 10 mg|"(Nerkardou 5 mg) Bisoprolol oral dissolved film ODF: equivalent to 5 mg of bisoprolol fumarate.~(Nerkardou 10 mg) Bisoprolol oral dissolved film ODF: equivalent to 10 mg of bisoprolol fumarate."
45496476|NCT05155865|Device|Cardiac resynchronization therapy with biventricular stimulation|Implantation of cardiac resynchronization therapy with biventricular stimulation with or without defibrillator lead placement
45381296|NCT05880030|Drug|Cholecalciferol|cholecalciferol 10000 UI
45496477|NCT05279898|Device|EEG Monitoring|Perioperative monitoring, MMGA guided by EEG for intervention group
45496478|NCT05279898|Drug|Ropivacaine|Intraoperative bilateral PIFB block with 20 mL of 0.2% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision (total of 40mL) PIFB on postoperative day 1 (provided they are extubated or getting ready to be extubated) to help with mobilization (for intervention group)
45496479|NCT05279898|Drug|Ketamine|Intraoperative infusion
45694264|NCT00867100|Drug|Placebo|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
45694265|NCT00867100|Drug|140 mg SC|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
45847459|NCT02774226|Drug|Tetrahydrobiopterin (BH4)|12 week intervention
45847460|NCT02774226|Dietary Supplement|Antioxidant Cocktail|12 week intervention
45847461|NCT02774616|Device|Ilivia ICD Family|pre-defined device programming, measurements and follow-up schedule
45847462|NCT02774616|Device|Plexa ICD lead|predefined follow-up schedule
45847463|NCT02775240|Drug|Digoxin|0.5 mg (2 x 0.25 mg) Digoxin oral dose
45847464|NCT02775240|Drug|Maribavir|200mg twice a day for 8 days
45381297|NCT05880030|Other|placebo|sunflower oil
45847465|NCT02775240|Drug|Dextromethorphan|30 mg oral dose
45847466|NCT02777268|Drug|Infacort|Multi-particulate granules
45847467|NCT02777268|Drug|Hydrocortisone|Tablet
45847468|NCT05350020|Drug|Solu-Cortef 100 MG Injection|Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial withinmarketing authorisations.
45847469|NCT05350020|Drug|Hydrocortisone 100mg/ml|Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial within marketing authorisations.
45381298|NCT05880017|Procedure|Modified ultrasound guided thoracolumbar interfascial plane (TLIP) block.|Patients will be placed in a prone position; modified ultrasound guided TLIP block will be performed using a SonoSite 2-5 MHZ Curved array (C60X) transducer. The transducer will be positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles, the probe will be moved laterally to identify longissimus (LG) and intercostalis muscles. After identifying the muscles and decontamination of the skin, the modified TLIP block will be performed under real-time ultrasound guidance using an insulated 90-mm 22G echogenic needle which will be inserted at a 15ºangle from the skin in-plane in a medial to lateral direction injecting the anesthetic locally between the longissimus and intercostalis muscles, which are easy to define using ultrasonography. After negative aspiration, injection will be in each side bilaterally in the interface between the LG and intercostalis muscles.
45381299|NCT05880017|Procedure|Conventional ultrasound guided thoracolumbar interfascial plane (TLIP) block.|Patients will be placed in a prone position; conventional ultrasound guided TLIP block will be performed using a SonoSite 2-5 MHZ Curved array (C60X) transducer. The transducer will be positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles, the probe will be moved laterally to identify the multifidus (MF) and longissimus (LG) muscles. After identifying the muscles and decontamination of the skin, the TLIP block will be performed under real-time ultrasound guidance using an insulated 90-mm 22G echogenic needle which will be inserted at a 30ºangle from the skin in-plane lateral to the medial direction through the belly of the LG toward the MF muscle. After negative aspiration, injection will be done in each side bilaterally in the interface between the MF and LG muscles.
45381300|NCT05880017|Drug|Morphine for peritoperative analgesia (control group).|Morphine based analgesia, after emergence they will receive 5mg morphine IV as a start and the rest of the first 24 hours they will receive incremental dose of intravenous morphine according to pain score.
45381301|NCT05880017|Drug|Bupivacain|As a local anesthetic will be injected in modified and conventional groups 20ml in each side.
45381302|NCT05880004|Behavioral|Support Application for Food PAntrieS (SAFPAS) - A mobile app that helps food pantries recruit, train and schedule volunteers, offer choice safely, and provides multilevel communications|The primary intervention is a mobile application (app) which supports food pantries to recruit, train and schedule volunteers; provide a safe, remote form of client choice; and provides a means of sharing real-time status information with clients, pantries, food banks, and emergency operation centers. Following formative work, user centered design, and usability testing, the SAFPAS app will be implemented in three stages, where each stage introduces new features. Pantry clients will be encouraged to download the app and learn its key features at the end of baseline data collection. During the first weeks of each stage, training of participating food pantry directors/staff and Maryland Food Bank (MFB) staff will take place - focusing on use of any new features. Initial training will be follow up by proficiency testing.
45381303|NCT05879939|Procedure|Percutaneous, repetitive phrenic nerve electrical stimulation|Phrenic nerve electrical stimulation with different stimulation intensity and frequency
45381304|NCT05879926|Drug|Ovarian Function Suppression + Aromatase Inhibitor|Aromatase inhibitor co-administered with a GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
45381305|NCT05879926|Drug|Adjuvant Chemotherapy + Ovarian Function Suppression|Adjuvant chemotherapy of investigator's choice followed by an aromatase inhibitor (AI) co-administered with an GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
45381307|NCT05879900|Other|Functional physical exercises|Functional physical exercises lasting approximately 15 minutes, for 12 weeks or 24 sessions. The exercises take place during physical education classes taught by the physical education teachers in charge of the classes. The place of intervention takes place in full-time schools in the rural area.
45381308|NCT05879900|Other|Physical Education classes|Physical Education classes according their previously planned contents.
45496480|NCT05279898|Drug|Remifentanil|Intraoperative infusion
45381309|NCT05879887|Behavioral|UPHOLDS (Utilizing Palliative Care for Heart Failure Optimized using Lay Navigators to Decrease Suffering)|UPHOLDS is a multicomponent, lay palliative care coach-led supportive care intervention designed to improve quality of life in individuals with advanced heart failure. In a series of weekly, one-on-one, 15-20 minute sessions, participants receive psychoeducation on palliative care principles (problem solving, self-care, symptom management, and advanced care planning), financial coaching (orientation to normalizing financial distress, introducing healthcare-related financial terms, exploring financial needs and steps to discussing finances in care decisions, and identifying financial resources in the health system and community), a one-time specialty palliative care outpatient clinic visit, as well as monthly follow-up.
45496481|NCT05279898|Drug|Dexmedetomidine|Intraoperative infusion
45496482|NCT05279898|Drug|Rocuronium|Intraoperative intermittent bolus
45496483|NCT05279898|Drug|Propofol|Intraoperative infusion
45496484|NCT05108909|Device|MRI, CT, and serum biomarkers|magnetic resonance image Imaging data were collected in a strong magnetic field, and collected the serum of participants.
45496485|NCT05309694|Combination Product|Paragard® T380A Intrauterine Copper Contraceptive with New Inserter|"Paragard® IUS with Investigational Inserter combines the current insertion tube and white rod to form a new pre-assembled inserter device that supports a single hand operation.~The device is used to pass the IUS through the cervical canal and into the uterine cavity and facilitates insertion of the T shaped Paragard® IUS implant into the uterus."
45381310|NCT05879848|Other|VR|virtual reality scenario synchronized with the uterine contractions
45496486|NCT05131529|Other|Taste-focused labels|"We will implement taste-focused labels on plant-based dishes in each of the 3 treatment dining halls to re-brand dishes with attributes focused on the taste of the dish (e.g., renaming a Squash with Ginger side to Aromatic Thai Curry Kabocha Squash With Zesty Ginger)."
45496487|NCT05131529|Other|Carbon impact labels|We will add labels next to all dishes served in treatment dining halls that indicate whether production of the ingredients in the dish contribute a high, moderate or low amount of carbon emissions. These labels will be absent from the same dishes served in control dining halls. Labels will be added to point-of-service signs, digital menu boards, and menu information on a mobile app.
45496488|NCT05131529|Other|Changing default menu options|We will make red meat items an opt-in (as opposed to opt-out) item across all meal stations in treatment dining halls. All menu stations will exclude red meat by default, and dining hall patrons will have to request the addition of red meat to meals. At control dining halls, red meat items will be provided by default at meal stations as normal.
45496489|NCT04784598|Other|Insoles adapted in flip-flop sandals|participants of both groups individually received a pair of customized flip-flop sandals, with or without foot pieces, covered with smooth synthetic leather
45496490|NCT05507879|Procedure|Biospecimen Collection|Undergo collection of blood samples
45496491|NCT05507879|Other|Electronic Medical Record|Review of medical records
45496492|NCT05097677|Other|Not applicable (observational study)|Not applicable (observational study)
45496493|NCT05268822|Other|Home exercise|Movement control exercise with or without specific breathing techniques
45496494|NCT05268510|Drug|Pembrolizumab|400 mg Pembrolizumab day 1 Q6W (max. 18 cycles)
45496495|NCT05268510|Drug|Olaparib|300 mg Olaparib bid. cont. day 1 to 42 (max. 16 cycles)
45496496|NCT05268510|Drug|mFOLFOX-6|Oxaliplatin 85 mg/m² 2h day 1, 15, 29 plus Leucovorin 400 mg/m² 2h day 1, 15, 29 plus 5-FU 400 mg/m² bolus, followed by 2.400 mg/m² 46h day 1, 15, 29; Q6W, 2 cycles
45496497|NCT05268510|Drug|CapOX|Oxaliplatin 130 mg/m² 2h day 1,22 plus Capecitabine 1.000 mg/m² bid. day 1-14, 22-35; Q6W, 2 cycles
45496498|NCT05042453|Device|Splentis® POP Tissue Anchoring System|Anterior cervicopexy with bilateral sacrospinous ligament fixation using Splentis
45496499|NCT04191174|Other|Hyperpolarized 129Xe MRI|Hyperpolarized 129Xe MRI to evaluate ventilation heterogeneity
45496500|NCT04191174|Other|Technegas V SPECT|Technegas V SPECT to evaluate ventilation heterogeneity
45496501|NCT04191174|Other|Sputum Induction|Sputum induction to evaluate luminal cellular inflammation
45496502|NCT05309681|Other|Epworth's sleepiness scale; unstimulated saliva sample|Unstimulated saliva sample; Epworth's sleepiness scale
45496503|NCT05309603|Other|Loaded Walking High|Walking three miles on a treadmill at a self-selected speed while wearing a backpack with weight carried high on the back
45496504|NCT05309603|Other|Loaded Walking Mid|Walking three miles on a treadmill at a self-selected speed while wearing a backpack with weight carried on the mid-back
45496505|NCT05309603|Other|Walking|Walking three miles on a treadmill at a self-selected speed
45496506|NCT05060783|Diagnostic Test|GaGnostic|Plasma
45496507|NCT05060783|Diagnostic Test|GaGnostic|Serum
45496508|NCT05060783|Diagnostic Test|GaGnostic|Urine
45496509|NCT05033717|Other|Tissue Flossing Technique|"Subjects will receive tissue-flossing intervention on bicep muscle for 30 sec to 2 min with an occlusion pressure of 100 mmHg.~After removal of flossing, participants will perform bicep strengthening exercises at an intensity of 30% of 1 RM with 6-8 rep, 4 sets for a single day and 3 days per week for 2 weeks in total."
45496510|NCT05033717|Other|Static Stretching Technique|"Subjects will perform passive static stretching exercises of bicep muscle. Each stretch will last for 30 sec at 100% of stretch intensity with 4 reps for each, 1 set per day and 3 days per week for total duration of two weeks.~After the application of static stretch, participants will perform bicep strengthening exercises at an intensity of 30% of 1 RM with 6-8 reps, 4 sets for a single day and 3 days per week for 2 weeks in total."
45496511|NCT05030597|Drug|68Ga-DOTA-FAPI|Intravenous access is pre-established. Quality control is carried out to confirm the radiochemical purity of 68Ga-DOTA-FAPI by HPLC. Intravenous administration of 68Ga-DOTA-FAPI according to 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
45381311|NCT05879822|Drug|INCB099280|Administered as specified in the treatment arm description
45381312|NCT05879809|Device|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The clinical symptoms will be evaluated before and after MT intervention.
45381313|NCT05879809|Device|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The acoustic features will be evaluated before and after MT intervention.
45381314|NCT05879809|Device|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The neuroimaging features will be evaluated before and after MT intervention.
45381315|NCT05879796|Drug|cis-platinum|chemotherapeutics
45496512|NCT05030597|Device|PET/CT|Each subject undergoes PET/CT imaging within 20-30 minutes after injection.
45496513|NCT04974515|Device|eXciteOSA|eXciteOSA is a device for improving genioglossus endurance through electrical stimulation
45381316|NCT05879796|Radiation|radiation|"External beam radiotherapy was performed using IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45-50.4 Gy;1.8-2.0 Gy/f,25 -28 f. In patients with pelvic lymph node metastasis, para-aortic lymph node metastasis, and retroperitoneal lymph node metastasis, local lesions were simultaneously boosted to 60 Gy. In FIGO stage IIIB, simultaneous or late course boost to 60 Gy was given parametrially.~Brachytherapy: High dose rate (HDR) afterloading brachytherapy was used, with a total dose of 30-40 Gy and a cumulative dose of 80-85 Gy at point A/HRCTV D90; if the tumor diameter was ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90. Brachytherapy combined with external beam radiation therapy was completed within 8 weeks."
45381317|NCT05879796|Drug|Envafolimab Injection|PD-L1 antibody
45381318|NCT05879796|Drug|Recombinant Human Endostatin Injection|angiogenesis inhibitors
45381319|NCT05879783|Diagnostic Test|Confocal laser endomicroscopy|After intravenous injection of fluorescein sodium, pCLE-based optical biopsy will be performed.
45381320|NCT05879770|Other|suture material|Some patients have had a shouldice repair with wire in the past and others with Prolene.
45381321|NCT05879705|Other|Parent intervention|Family centered, strength-based, Occupational therapy intervention program
45496514|NCT05026931|Other|Foam rolling|Group A will be treated with foam rolling effect on quadriceps, hamstring and calf muscle length. 5 min cycle ergometry, 6 min foam rolling 3 times for 30sec.For three session per week will be given atleast for 2 months.
45847470|NCT05349942|Device|Intraoral scanning and data acquisition|Intraoral scanner data acquisition, 3 scans are taken for each participant. Data will be exported from dedicated software (Planmeca, Romexis) and imported into GOM surface analysis software. Sample comparisons and sample preparation are performed here. The results are collected in excel spreadsheets and analyzed in SPSS statistical software.
45381322|NCT05879679|Behavioral|Food craving induction|Standardized craving induction procedure will be used, based on exposure to food-related images (https://www.lippc2s.fr/food-cal-pictures/). Craving intensity will be measured by visual analogic scale before and after the induction sequence.
45496515|NCT05026931|Other|Stretching exercises|Group B will be treated with stretching exercises effect on quadriceps, hamstring and calf muscle length. 5 min cycle ergometry, 6 min foam rolling 3 times for 30sec.For three session per week will be given atleast for 2 months.
45847471|NCT05349786|Other|Physical activity program|A physical activity program lasting at least 30 minutes each session was applied to HF patients in the intervention group, three days a week for three months. A pedometer was used to visualize the walking performed in the physical activity program and to record reliably. After the data obtained in the pre-test, the pedometers, which were calibrated and checked by the researchers, were delivered to the patients. At the end of each day of walking with pedometer monitoring, they were asked to record data such as the number of steps, walking hour, walking time, distance and complaints encountered during walking on the walking monitoring chart given to the patient by the researchers. Weekly phone calls and monthly home visits were made to the patients in order to determine the continuation of the medical treatment and walking program used by the patients, to increase their motivation and to detect or intervene in any situation related to the walking program.
45381323|NCT05879653|Drug|MK-3475|During the induction phase, MK-3475 200 mg will be administered as four cycles of 3-weeks regimen, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle. The treatment and maintenance phases will consist of 9 cycles of one course per 6 weeks, with MK-3475 400 mg administered on Day 1 of each course at Q6W.
45496516|NCT05477693|Biological|Experimental 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection.
45496517|NCT05477693|Biological|Control 23-valent PPV|The control vaccine was manufactured by Merck Sharp & Dohme, Ltd. Purified capsular polysaccharides from 23 Streptococcus in 0.5 mL of pneumoniae types 0.25% phenol and sodium chloride.
45381324|NCT05879653|Drug|ASG-22CE|During the induction phase, four cycles of 3-weeks regimen are administered, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle.
45496518|NCT03638843|Procedure|Gastric mucosal devitalization|Gastric mucosal devitalization is an endoscopic procedure which uses argon plasma coagulation to result in selective damage to the gastric mucosa and submucosa.
45496519|NCT04927325|Other|Set of Photos|A standardized set of photos will be taken with a tablet camera, SLR, thermal camera.
45496520|NCT05309447|Other|data collection|The study entails the collection of clinical, functional, radiological, and biomechanical data.
45381325|NCT05879653|Procedure|maximal TURBT|All participants who were not determined to have PD on imaging during the induction phase should have had a maximal TURBT performed at 13 (± 1week) weeks after the first dose of trial drug.
45381326|NCT05879653|Radiation|Radiation therapy|Radiotherapy will be initiated no later than 8 weeks after maximal TUR-BT. In this trial, a total dose of 56 Gy will be delivered using 2 Gy per dose. 40 Gy/20 fr (2 Gy/fr) to the small pelvis followed by 16 Gy /8 fr (2 Gy/fr) to the whole bladder 5 times a week for 5 consecutive days using Three-Dimensional Conformal Radiation Therapy (3D-CRT).
45381327|NCT05879640|Behavioral|Sleep education|Participants receive a handout about age appropriate sleep goals and tips for improving sleep. The handout also contains links to educational videos about sleep hygiene and the importance of sleep to healing after illness. The handout is reviewed with a clinician at bedside prior to hospital discharge.
45381328|NCT05879627|Drug|BAT8007 for injection|Intravenous infusion: once every two weeks (Q2W). The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30~120 minutes.
45381329|NCT05879614|Drug|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
45381330|NCT05879601|Other|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding.
45496521|NCT05309213|Biological|IM19 CAR-T cells|IM19 CAR-T cells will be administered at dose level:5 x 10^4 CAR+ T cells/kg,1x 10^5 CAR+ T cells/kg,3 x 10^5 CAR+ T cells/kg,1 x 10^6 CAR+ T cells/kg
45496522|NCT05309057|Dietary Supplement|Intermittent Fasting|Methods of intermittent fasting strategies, continuous energy restriction, and ad libitum diet.
45496523|NCT05438303|Drug|AZD9833|AZD9833 tablets will be administered orally once daily on Days 1 - Day 5 (Treatment Period 2) and Day 1 (Treatment Period 3) for participants recruited to Arms A and C and Day 1 for those in Arm B
45496524|NCT05438303|Drug|Midazolam|Midazolam will be administered orally as a syrup once on Day 1 of Treatment Periods 1 and 3; administered together with Omeprazole
46055501|NCT04091737|Biological|Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734|"Cryopreserved formulated autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734 in a bag for infusion~Plerixafor to mobilize hematopoietic stem cells prior to each apheresis~Single dose melphalan before administration of CSL200"
45496525|NCT05438303|Drug|Omeprazole|An Omeprazole capsule will be administered once on Day 1 of Treatment Periods 1 and 3; administered together with Midazolam
45496526|NCT05438303|Drug|Dabigatran Etexilate|A Dabigatran Etexilate capsule will be administered once on Day 1 of Treatment Periods 1 and 2
45496527|NCT05438303|Drug|Celecoxib|A Celecoxib capsule will be administered once on Day 1 of Treatment Periods 1 and 3
45381331|NCT05879601|Other|delayed orthodontic retainer delivery.|post orthodontic treatment patients will be given orthodontic retainer after 24 hours of debonding.
45381332|NCT05879588|Other|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
45381333|NCT05879588|Other|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 3 days of debonding
45381334|NCT05879562|Diagnostic Test|MoCA-Xpresso|MoCA-Xpresso is a home-based, self-administered digital cognitive screening tool, based on a tablet device.
45381335|NCT05879549|Other|Closed Chain Exercise Group|Closed Chain Exercise Group
45381336|NCT05879549|Other|Proprioceptive Exercise Group|Proprioceptive Exercise Group
45381337|NCT05879536|Drug|Tramadol-ondansetron continuous infusion|Analgesia strategy determined by routine use according to protocols, without investigator intervention.
45381338|NCT05879536|Drug|Ropivacaine via epidural catheter|Analgesia strategy determined by routine use according to protocols, without investigator intervention.
45381339|NCT05879523|Drug|HRS-1893|subcutaneous, single dose, multiple doses
45381340|NCT05879523|Drug|Placebo|subcutaneous, single dose, multiple doses
45381341|NCT05879510|Diagnostic Test|68Ga-NY104 PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration."
45381342|NCT05879497|Diagnostic Test|68Ga-NY104 PET/CT|Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration.
45381343|NCT05879471|Diagnostic Test|68Ga-NY104 PET/CT|Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration.
45847472|NCT05349708|Device|THE-FACS|Telehealth home-monitoring tablet and blood pressure cuff
45847473|NCT05349396|Drug|Eszopiclone 3mg Test Drug T-1 Coated Tablets|Participants will receive one tablet of the test formulation T-1 containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
46055502|NCT02599207|Biological|sibling umbilical cord blood|All subjects will receive a single infusion of allogeneic sibling cord blood. The first six subjects will receive cord blood cells from an HLA-matched sibling. The following 9 subjects will receive cord blood cells from an HLA-mismatched (≥3/6 match) or matched sibling. Six of the 15 subjects must be treated with haplo-identical sibling CB. Duration of study participation will be six months from the time of CB infusion.
45381345|NCT05879419|Biological|Recombinant Herpes Zoster Vaccine (RZV)|RZV comprise 50 μg of recombinant VZV glycoprotein E and the liposome-based AS01B adjuvant system (which contains 50 μg of 3-O-desacyl-4'-monophosphoryl lipid A [MPL] and 50 μg of Quillaja saponaria Molina, fraction 21 (QS21, licensed by GSK from Antigenics, a subsidiary of Agenus)). Vaccine will be administered (0.5 ml) into the deltoid muscle at inclusion and 6 weeks (two doses).
45381346|NCT05879419|Other|MTX Discontinuation|Evaluation of discontinuation of the use of methotrexate (MTX) for 2 weeks after each vaccine dose in ARD patients: patients using MTX at a stable dose for at least 12 weeks, prednisone maximum dose of 5 mg/day, in association or not with other drugs except rituximab will be consecutively evaluated at outpatient clinics regarding disease activity. Those considered to be at stable disease (at remission or low disease activity according to specific standardized disease activity indexes) will be randomized (1:1) into two arms: one that will withhold MTX for 2 weeks after each vaccine dose (MTX-withhold) and other that will maintain stable therapy (MTX-maintain).
45381347|NCT05879419|Other|MMF Discontinuation|Evaluation of discontinuation of the use of mycophenolate mofetil (MMF) for 2 weeks after each vaccine dose in ARD patients: patients using MMF at a stable dose for at least 12 weeks, prednisone maximum dose of 7.5 mg/day, not associated with other immunosuppressive therapy, will be consecutively evaluated at outpatient clinics regarding disease activity. Those considered to be at stable disease (at remission or low disease activity according to specific standardized disease activity indexes) will be randomized (1:1) into two arms: one that will withhold MMF for 2 weeks after each vaccine dose (MMF-withhold) and other that will maintain stable therapy (MMF-maintain).
45381348|NCT05879419|Other|Placebo|Patients with ARDs who received the placebo at study entry (P2). ARD patients will be randomly assigned in a 1:1 ratio, with the use of an automated Web and telephone system, to one of two subgroups: P1, patients allocated to receive vaccine right after randomization (at D0 and D42), and P2, patients allocated to receive placebo at D0 and D42. Subsequently, blindness will be broken at D84 and P2 patients will receive vaccine doses at the D84 and D126.
45381349|NCT05879419|Other|MTX maintain|MTX dose will be held stable after the two vaccine doses for comparison of vaccine immunogenicity and disease activity with the MTX-withhold group.
45381350|NCT05879419|Other|MMF maintain|MMF dose will be held stable after the two vaccine doses for comparison of vaccine immunogenicity and disease activity with the MMF-withhold group.
45496528|NCT05432141|Biological|sIPV vaccine /DTaP vaccine|All subjects received 3 doses of sIPV vaccines and 3 doses of DTaP vaccines. Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
46055503|NCT02761317|Drug|standard preparation (2L PEG-ELS)|Subjects who are randomized into group A will receive standard bowel preparation (2L PEG-ELS) on the same-day of procedure.
46055504|NCT02761317|Drug|low-volume preparation (10 mg bisacodyl plus 2L PEG-ELS)|Subjects who are randomized into group B will receive 10mg bisacodyl at 6 pm on the evening before the colonoscopy and 2L PEG-ELS on the same-day of procedure.
45381351|NCT05879406|Dietary Supplement|VitaMedica® Clear Skin Formula capsules|"After an initial screening period to determine eligibility, subjects will be randomly assigned to one of the following treatment arms: VitaMedica® Clear Skin Formula vs. Placebo for the duration of the twelve (12) week trial~Ingredients:~Vitamin A (from Betatene® Carotenoid Blend) (7,500 IU/2,250 mcg RAE) Vitamin A (from Retinyl Palmitate) (5,000 IU/1,500 mcg RAE) Vitamin C (as Ascorbic Acid) (60 mg) Vitamin E (from d-alpha-Tocopheryl Acid Succinate) (30 IU/20 mg) Zinc (from Zinc Bisglycinate Chelate) (24 mg) Selenium (from Selenium Glycinate) (48 mcg) Chromium (from Chromium Nicotinate Glycinate Chelate) (150 mcg) MSM (Methylsulfonylmethane) (200 mg) Bromelain (200 mg) Burdock (Arctium lappa) root (50 mg) Oregon Grape (Mahonia aquifolium) root (25 mg) Dandelion (Taraxacum officinale) root (50 mg) Yellow Dock Extract (Rumex crispus) root (50 mg) Hypromellose Microcrystalline cellulose Magnesium Stearate Silicon Dioxide"
45381352|NCT05879406|Other|Placebo Capsules|"After an initial screening period to determine eligibility, subjects will be randomly assigned to one of the following treatment arms: VitaMedica® Clear Skin Formula vs. Placebo for the duration of the twelve (12) week trial~Ingredients:~Magnesium Stearate (VEG) (NON-GMO) Silica (As Silicon Dioxide) Micro Cellulose (MCG) (NON-GMO)"
45381353|NCT05879380|Diagnostic Test|MRPA|patients will receive an extra MRPA, on top of the standard CTPA
45381354|NCT05879380|Diagnostic Test|CPTA|patients will receive an extra MRPA, on top of the standard CTPA
45381355|NCT05879367|Drug|Eflornithine (Dose Level 1)|Eflornithine 2.3 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
45381356|NCT05879367|Drug|Eflornithine (Dose Level 2)|Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
45381357|NCT05879367|Drug|Eflornithine (Dose Level -1)|Eflornithine 1.75 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
45381358|NCT05879367|Drug|Temozolomide|Temozolomide 150 mg/m2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule
45381359|NCT05879354|Other|Active Cycle of Breathing Techniques|Patients in the intervention group will be provided with video-guided Active Cycle of Breathing Techniques twice a day for 28 days.
45496529|NCT05432141|Biological|sIPV vaccine /Hepatitis A inactivated vaccine /MMR vaccine|All subjects will receive 1 dose of sIPV and 2 doses of hepatitis A inactivated vaccine/or 1 dose of attenuated hepatitis A vaccine and 1 dose of MMR vaccine.Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
45694266|NCT05315752|Procedure|Bariatric surgery|"Bariatric surgery includes (but is not limited to)~Gastric bypass: surgical bypass of the entire stomach, duodenum and approximately 1 m of the proximal small intestine~Sleeve: a large part of the stomach is removed laparoscopically, the open vertical edges are put back in place to leave a sleeve-like tube.~Bariatric surgery is considered a treatment option~for patients with a BMI >40 kg/m 2 , assuming the patient has previously participated successfully in a group weight management programme (weight loss >7%) or~for patients with a BMI of 35-40 kg/m 2 when the obesity is associated with type 2 diabetes or hypertension, or OAS (with CPAP therapy) or severe musculoskeletal disease"
45694267|NCT05310370|Genetic|Testing of homologous recombination deficiency|A multiple panel testing of germline and somatic genes, including BRCA1/2, and HRD score are provided for all participants.
46055505|NCT02761317|Drug|high-volume preparation (4L PEG-ELS)|Subjects who are randomized into group C will receive 2L PEG at 6 pm before the procedure and another 2L PEG-ELS on the same-day of procedure.(4L PEG)
45847474|NCT05349396|Drug|Eszopiclone 3mg Test Drug T-2 Coated Tablets|Participants will receive one tablet of the test formulation T-2 containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
46055506|NCT04019899|Dietary Supplement|control group|"2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.~600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration. If pregnancy occurs, until the 12th week of gestation."
45381360|NCT05879341|Other|High intensitiy interval training|The participants will perform HIIT at 85% of their heart rate reserve. There will be 8 cycles of high intensity with four minutes of rest intervals in between.
46055507|NCT04019899|Dietary Supplement|study group|"2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.~600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration;~600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin, 50 µg vitamin D3 as cholecalciferol (1 soft capsule/day in the evening) substitutes the previous treatment at hCG administration and lasted until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation."
45496530|NCT04868279|Behavioral|Web-Based Interactive Nurse Support Program Based on Health Promotion Model|Nursing education will be given on healthy behaviors such as nutrition, exercise, health responsibility and stress management according to the health promotion model. The researcher will make phone calls with the intervention group for 6 months (12 times in total), twice a month. During telephone interviews, individuals will be talking about the use of the website, the points that are not understood or need to be emphasized, their application of health promotion behaviors, the obstacles they experience during the application and the suggestions for this.
45496531|NCT04859231|Other|Control|Cow's milk-based formula
45496532|NCT04859231|Other|Investigational|Cow's milk-based formula with added source of enriched whey protein
45496533|NCT05308823|Procedure|Stent|The patients in this group will receive traditional treatment of IIH for 3 months in addition to venus sinus stent
45496534|NCT04804319|Other|9-days habitual diet|9-days study with habitual diet including one standardized breakfast on a single day
45496535|NCT05308745|Dietary Supplement|Yakult®|Fermented milk drink containing over 6.5×10^9 CFUs of L. casei Shirota/65 ml
45496536|NCT05308745|Dietary Supplement|Placebo|Taste, appearance, component, and number of calories are the same as Yakult®, non-fermented milk product
45496537|NCT04956809|Drug|Dapagliflozin 10Mg Tab|This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
45496538|NCT04956809|Drug|Placebo|This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
45496539|NCT04803227|Drug|Emricasan|Emricasan 25 mg BID (days 1-14). Oral (capsule) administration.
45496540|NCT04803227|Other|Placebo|Placebo BID *days 1-14). Oral (capsule) administration.
45496541|NCT04735913|Drug|Abiraterone acetate tablets|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach or after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
45381361|NCT05879328|Procedure|Liver Transplantation|Liver transplantation (LT) is an accepted surgical therapy for hepatocellular carcinoma (HCC) in patients who achieve effective and sustained tumor downstaging; in this study liver transplantation will be performed in patients undergoing a successful hepatocellular carcinoma (HCC) downstaging with the combination of atezolizumab and bevacizumab.
45496542|NCT04910867|Behavioral|Components of Genetic Counseling|"The APOL1 testing program is designed to help living donor candidates to reduce their decisional conflict and enhance their informed consent regarding living donation. This intervention component entails: (1) an artificial intelligence-based conversational agent chatbot providing foundational information about the relationship between APOL1 and kidney disease and living donor outcomes, and APOL1 testing. The chatbot helps to relieve the workload on clinicians and scale up information giving. (2) The transplant nephrologist counseling component includes discussion about the APOL1 test results and shared decision making about donation, in a culturally competent manner, so as to enhance donor candidates' informed consent for living donation."
45496543|NCT04910867|Diagnostic Test|APOL1 genetic testing|APOL1 genetic testing will be performed while live kidney donor candidates are undergoing donor evaluation to identify whether they are at elevated risk of kidney disease post-donation. This risk information is expected to better enable donor candidates to make meaningful informed decisions about donating.
45496544|NCT04910867|Other|EHR integration|APOL1 genetic test results will be integrated into the electronic health record to provide clinical decision support to transplant nephrologists in evaluating donor candidates.
45496545|NCT04906889|Drug|Dexmedetomidine Hydrochloride|dexmedetomidine iv bolus for 10 minutes followed by the infusion of 0.1-1 ug/kg/h during general anesthesia
45496546|NCT04906889|Drug|Remifentanil Hydrochloride|remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
45496547|NCT04906889|Drug|Lidocaine Hydrochloride|lidocaine iv bolus followed by the infusion of 1.5mg/kg/h during general anesthesia
45496548|NCT02945657|Drug|MM36 topical ointment, 1%|Twice daily application for 28 consecutive days
45496549|NCT05358743|Other|Probiotic group|Participants will use the probiotic product once daily (1 tablet/day) for 8 weeks
45496550|NCT05358743|Other|Placebo group|Patients will chew placebo products (blueberry tablets) once daily (1 tablet/day) for 8 weeks.
45496551|NCT05308589|Device|CPPF|Continuous Postoperative Pericardial Flush
45496552|NCT05357105|Other|Numerical Pain Scales|Patients who are about to receive regional nerve blocks will be administered a numerical pain scale (NRS) before, during and after the offset of the nerve block.
45496553|NCT04716959|Procedure|Prepectoral Prosthetic Breast Reconstruction|The prepectoral approach involves placing the tissue expander on top of the pectoralis muscle.
45496554|NCT04716959|Procedure|Subpectoral Prosthetic Breast Reconstruction|The subpectoral approach involves placing the tissue expander under the pectoralis muscle with or without acellular dermal matrix (ADM).
45496555|NCT02948777|Drug|Evolocumab|
45496556|NCT04868747|Drug|Lidocaine|The participants receive perioperative lidocaine infusion with general anesthesia for gastrectomy.
45496557|NCT04868747|Drug|normal saline|The participants receive perioperative normal slaine infusion with general anesthesia for gastrectomy.
45496558|NCT04693325|Procedure|Prolonged normothermic machine perfusion|First, a cohort of DCD kidneys (n=6) will be subjected to 1 hour of NMP and subsequently transplanted [NMP1]. Before extending the duration, secondary endpoints will be evaluated. Thereafter, the duration of NMP will be prolonged to 3 hours (n=6) [PNMP3] and consequently 6 hours (n=6) [PNMP6].
45496559|NCT04684823|Device|Patch Cap|A prescription container cap to track the dispensing of an oral dose of medication with an associated app which tracks the adherence to medication regimen.
45496560|NCT04684823|Device|Patch App|A mobile app that is used with Patch Cap to track adherence to medication regimen
45496561|NCT05357651|Drug|LB1410|anti-PD-1 and anti-TIM-3 bispecific antibody
45496562|NCT03638609|Device|Intra Aortic Balloon Pump|"Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand."
45381362|NCT05879315|Other|Fall risk prevention in hospital|All patients (hip and knee) upon admission to the Orthopedic Department of the DRS (Rizzoli Sicily Department), throughin the pre-operative setting will undergo an assessment of mobility level, dynamic stability and co-ordination: Test UP and GO, Il Four Square Step Test, Stabilometric Analysis. After admission to the DRS Rehabilitation Medicine Department, hip and knee will receive an evaluation, which is currently used, consisting of: History of fall risk through multidimensional assessment, Compilation of ICF(International Classification of Functioning, Disability and Health) and Barthel Index. The following ratings will also be added: Compiling the Morse scale, Pharmacological history, CIRS (Cumulative Illness Rating Scale)
45496563|NCT05330273|Drug|Ganaplacide|Period 1: 400 mg (4 x 100 mg tablets) for oral administration Period 2: 400 mg (4 x 100 mg tablets) for oral administration
45496564|NCT05330273|Combination Product|Lumefantrine|Period 1: 480 mg (2 x 240 mg sachets) for oral administration Period 2: 480 mg (2 x 240 mg sachets) for oral administration
45496565|NCT05330273|Drug|Efavirenz|Period 2: 600 mg (1 x 600 mg tablet) for oral administration once daily (q.d.)
45496566|NCT01312259|Other|"Changing the Interstim parameter of '' Frequency in patients with Interstitial Cystitis"|Subjects will be randomized into one of two groups. Group One will be programmed to receive 14 Hz as their frequency, while the other group (Group 2) will receive 40 Hz as their frequency for the first ninety days after surgical implantation. After three months each patient will come in to the office to have their InterStim frequency changed to the opposite frequency. After each patient has had three months to evaluate each of the two frequencies, the next step is to allow the patient to decide which setting they thought best controlled their respective symptoms. The InterStim was then programed to whichever frequency the patient chose, and this would remain for three to six months.
45496567|NCT05329259|Biological|13-valent pneumococcal conjugate vaccine|One dose of 13vPnC (0.5mL) will be administered intramuscularly.
45694268|NCT05310214|Other|Acupuncture|"Treatment with ACP will be performed by inserting sterile acupuncture needles 0.25 x 13 mm into the acupoints BL23 (Shenshu), BL25 (Dachangshu), BL40 (Weizhong), BL62 (Qixue), SI3 (Houxi) and Jiaji , for the treatment of chronic non-specific low back pain. Interventions will last one hour, and will happen twice a week for 5 weeks.~In order to increase the effectiveness of blinding for both groups, in this study the model was adopted: combined simulated control. In this case, Sham acupuncture points will be used to simulate the treatment, as follows: i) Arms: 3 cm above the lateral epicondyle of the elbow, ii) Lumbar spine: Iliac crest on the same line as the greater trochanter of the femur. Thus, in the ACP group, the placebo LACP (without dosemetry) will be applied to these 4 points together with the real treatment."
45847475|NCT05349396|Drug|Eszopiclone 3mg Reference Product Coated Tablets|Participants will receive one tablet of the Rerefence Product containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
45847476|NCT05349162|Device|Implantable cardioverter defibrillator use|Implantation of an implantable cardioverter defibrillator (epicardial or transvenous)
46055508|NCT02761239|Device|The NIM 3.0 Nerve Monitoring System|Electromyography recordings were accomplished with a pair of needle electrodes inserted through the CP muscle, which were plugged into the third and fourth channels of interface-connector box.The recurrent laryngeal nerve(RLN), vagus nerve, external branch of the superior laryngeal nerve(EBSLN) and pharyngeal plexus were stimulated with a current of 1 mA and a frequency of 4 MHz and the event threshold at 100 microV.
46055509|NCT02761083|Device|Novosyn® Quick|Eye surgery
46055510|NCT02761083|Device|Vicryl® Rapid|Eye surgery
45381363|NCT05879302|Behavioral|Kidney Offer Shared Decision Making|The intervention consists of receiving the Donor Offer Plan (DOP), reviewing a web-based educational module about donor offers including practice offer videos, followed by a discussion about the DOP with a transplant nurse coordinator.
45381364|NCT05879289|Dietary Supplement|A power supplement|A dietary supplement containing vitamins and collagen
45381365|NCT05879276|Drug|Empagliflozin 10 MG|Patients in cardiogenic shock receiving empagliflozin in addition to standard management at a dose of 10 mg per day per os (or through nasogastric tube in intubated patients) for a duration of 12 weeks.
45381366|NCT05879263|Other|INTERMITTENT ENTERAL NUTRITITION (IEN)|Administration of Enteral Nutriton (EN) by nasogastric tube in 4 bolus (24h): Duration of the infusion 1hour each shot, using an infusion pump.
45381367|NCT05879263|Other|CONTINUOS ENTERAL NUTRITITION (CEN)|Administration of Enteral Nutriton (EN) by nasogastric tube during 24 hours, using an infusion pump.
45381368|NCT05879237|Drug|Vitamin D3|Vitamin D3 ,1000 unit ,once daily, oral, for 1 month plus triple therapy
45381369|NCT05879237|Drug|Helicobacter pylori triple therapy|"Triple therapy which is: amoxcillin on 50 mg/kg/day for 2 weeks, Clarithromycin 20mg/kg/day for 2 weeks and proton pump inhibitor~3.ppi 1mg/kg/day for 1month"
45381370|NCT05879211|Behavioral|Feedback|Providers will receive detailed feedback about the timing, quality, and frequency of their goals of care communication with patients
45381371|NCT05879185|Biological|XmAb23104|XmAb23104 (10 mg/kg) intravenously on days 1 and 15 of each 28-day cycle. XmAb23104 will be administered by IV infusion at a constant rate over 1 hour.
45381372|NCT05879172|Device|electric tubular anastomotic device|"The electric tubular anastomotic device developed by Suzhou Yingtukang Medical Technology Co., Ltd. is used for colorectal end-to-end and end-to-side anastomosis. This product is suitable for open or minimally invasive colorectal cancer surgery.~Before firing the device, tissue thickness should be carefully assessed to prevent poor staling leading to leakage, inadequate hemostasis, or poor treatment."
45381373|NCT05879172|Device|traditional anastomotic device|Traditional anastomosis is used in this group. Staplers of the same brand are uniformly adopted to avoid differences between groups caused by different brands.
45381374|NCT05879146|Drug|Nirogacestat|Given by PO
45381375|NCT05879133|Behavioral|Questionnaires|Survey
45381376|NCT05879133|Other|Fit Bit|measures physical activity
45381377|NCT05879120|Drug|Pembrolizumab|Given by IV (vein)
45381378|NCT05879120|Device|Exablate MRgFUS + neoadjuvant pembolizumab|Given by IV (vein)
45381379|NCT05879068|Drug|PM8002|IV infusion
45381380|NCT05879068|Drug|Paclitaxel|IV infusion
45381381|NCT05879055|Drug|PM8002|IV infusion
45381382|NCT05879055|Drug|FOLFIRI|IV infusion
45381383|NCT05879042|Other|Static Stretching|Participants will be placed in the maximum dorsiflexion position of the ankle of the dominant side lower extremities. At this last point, it will be held in a static position for 30 seconds. A total of 10 repetitions will be done, with 5-10 seconds rest between repetitions.
45381384|NCT05879042|Other|Dynamic Stretching|Participants will be positioned by placing their hands on the edge of the standing wall. They will be asked to try to increase normal ankle motion in a controlled manner using their own body weight. The stretching position will be held for 30 seconds and a total of 10 repetitions will be done. There will be 5-10 seconds rest between repetitions.
45381385|NCT05879042|Other|PNF Stretching|For the lateral head of the gastrocnemius muscle, the dominant side lower extremities of the participants will be placed in the extension-adduction-external position. For the medial head of the gastrocnemius muscle, the dominant side lower extremities of the participants will be placed in the extension-abduction-internal rotation position. Participants will be asked to actively go as far as they can in the opposite direction from the starting position (flexion-abduction-internal rotation for the lateral head; flexion-adduction-external rotation for the medial head). When the participant returns to the starting position after reaching the final point, the practitioner will apply the hold-relax technique and will be asked to stay in this position for 10 seconds.
45381386|NCT05879042|Other|Sham stretching|Sham stretching will be applied to the calf area. While the participant is lying prone, they will wait 30 seconds in a static position without applying any stretching to the calf area before reaching the end point of the joint range of motion.
45381387|NCT05879029|Drug|Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets.|Participants in the experimental group were given Jinsang Liyan Capsule + Rabeprazole enteric-coated tablets according to the requirements, and were followed up at 4 and 8 weeks. VAS and RSI scores were used to judge the improvement degree of patients' symptoms.
45381388|NCT05879029|Drug|Jinsang Liyan Capsule placebo; Rabeprazole enteric-coated tablets.|Participants in the control group were given Jinsang Liyan Capsule placebo + Rabeprazole enteric-coated tablets according to the requirements, and were followed up at 4 and 8 weeks. VAS and RSI scores were used to judge the improvement degree of patients' symptoms.
45381389|NCT05879003|Behavioral|neuromuscular electrical stimulation|The symptomatic rotator cuff tear subjects had NMES on the two adductors.
45496568|NCT03638531|Device|Anodal tDCS|Anodal tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
46055511|NCT00746551|Drug|Ferli-6® (Continental Pharm co., ltd.)|In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.
46055512|NCT00746551|Drug|Venofer® (Vifor AG, St. Gallen, Switzerland)|Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.
46055513|NCT02766075|Behavioral|Supervised TAVR Exercise Program|Individualized exercise program designed and implemented by licensed physical therapy clinicians in three 60-minute sessions per week for four weeks. Upon randomization, subjects in the Intervention Group will undergo an initial Dynamic Gait & Balance Assessment by a licensed physical therapy clinician. The physical therapy clinician will use this assessment to design and implement an individualized STEP in three 60-minute sessions per week for four weeks. Subjects will proceed with their pre-TAVR testing in conjunction with the STEP sessions.
46055514|NCT04223817|Device|7.0 T RMI|Single 7.0 Tesla MRI of both hands in the same time
45381390|NCT05878990|Behavioral|Culturally-tailored Tobacco Treatment|Weekly telephone calls with a certified tobacco treatment specialist (CTTS) for 6 weeks. The culturally-tailored tobacco intervention content by week via telephone call with the CTTS includes among others: Reasons and Motivations for Quitting, Benefits of Quitting, Stress Management and Discussion about Environmental Influences.
45496569|NCT03638531|Device|SHAM tDCS|SHAM tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
45496570|NCT04533737|Biological|Brodalumab|Pre-filled syringe with 210 mg brodalumab in 1.5 ml solution for subcutaneous injection
45496571|NCT04533737|Other|Placebo|The placebo solution is similar to the active brodalumab solution except that it does not contain any active substance
45496572|NCT04533737|Biological|Guselkumab|Pre-filled syringe with 100 mg guselkumab in 1 ml solution for subcutaneous injection
45496573|NCT03638765|Biological|DCVax-Direct|activated, autologous dendritic cells
45496574|NCT04519853|Behavioral|Low Glycemic Load Diet|Food delivery service will provide a low glycemic load diet for 8 weeks
45496575|NCT05254847|Drug|Capecitabine combined with lenvatinib and tislelizumab|Capecitabine combined with lenvatinib and tislelizumab
45496576|NCT05249699|Drug|Isoniazid|prevent the development of tuberculosis
45496577|NCT05249699|Other|without any additional anti-tuberculosis treatment|reduce the number of Participants With Treatment-Related Adverse Events
45496578|NCT04509011|Device|Fluobeam® LX|Fluobeam®-LX is used to identify and evaluate parathyroid glands using auto-fluorescence during thyroid surgery.
45496579|NCT04491539|Behavioral|Finding Respect and Ending Stigma around HIV (FRESH)|The Finding Respect and Ending Stigma around HIV (FRESH) intervention is theoretically informed by Social Cognitive Theory (SCT) and Interpersonal Contact theory (ICT) and was specifically designed for delivery in high-stigma settings, such as Dominican Republic. FRESH was originally developed in Africa to address HIV-related stigma, and later was adapted to address intersectional stigmas experienced by sexual and gender minorities (SGM) living with HIV in the United States Deep South. To our knowledge, FRESH will be the first intervention to address intersectional stigmas experienced by men who have sex with men, transgender women, and people living with HIV in clinical settings in the Spanish-speaking Caribbean.
46055515|NCT02761005|Drug|Eradication of H. pylori|For the eradication of H. pylori, patients diagnosed to be infected with strain with mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, metronidazole 500 mg and amoxicillin 1500 mg for 1 week. Patients diagnosed to be infected with strain without mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, clarithromycin 400 mg and amoxicillin 1500 mg for 1 week.
46055516|NCT02696577|Drug|Low dose aspirin|
45381391|NCT05878990|Behavioral|Culturally-tailored Content Newsletters|Weekly newsletters covering topics such as Race and Smoking, Nicotine Replacement Therapy (NRT) Reasons and Motivations for Quitting, Benefits of Quitting and other related topics.
45381392|NCT05878990|Behavioral|Control Preference Scale|Survey to elicit preference on the decision-making interaction with healthcare provider. The survey uses a 5 point scale from 1 to 5 with 1 or 2 points representing Active Control Preference; 3 or 4 representing a Collaborative Control Preference and 5 representing a Passive Control Preference.
45381393|NCT05878990|Behavioral|Active Content Newsletter or Passive Content Newsletter|Based on the answers to the Control Preference Scale, participants will receive the appropriate weekly newsletter (active content or passive content). Newsletters are covering topics such as Race and Smoking, Nicotine Replacement Therapy (NRT) Reasons and Motivations for Quitting, Benefits of Quitting and other related topics presented in a more passive or active manner.
46055517|NCT02696577|Drug|Omega 3|
46055518|NCT00753649|Biological|Infanrix™ hexa|Intramuscular, three doses
45381394|NCT05878977|Drug|Immune checkpoint inhibitor|Identification of novel predictive and prognostic biomarkers for immunotherapy treatment response in metastatic melanoma
45381395|NCT05878964|Other|EQ-5D-5L questionnaire|Quality of life evaluation questionnaire
45381396|NCT05878964|Other|FACT-G (Functional Assessment of Cancer Therapy - General)|Quality of life evaluation questionnaire
45381397|NCT05878964|Other|FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)|Self reported evaluation of cutaneous toxicity questionnaire.
45381398|NCT05878951|Drug|OnabotulinumtoxinA|Intra-detrusor OnabotulinumtoxinA is commonly known as botox
46055519|NCT04093609|Genetic|XIST gene deletion|detection of XIST gene deletion by fluorescence in situ hybridization
45496580|NCT04751669|Dietary Supplement|Vitamin and trace elements|Dietary supplement oral route, once a day, during 14 days
45496581|NCT04751669|Dietary Supplement|Placebo|Dietary supplement (placebo) oral route, once a day, during 14 days
46055520|NCT04091425|Drug|TAK-925|TAK-925 IV infusion
45496582|NCT04640909|Other|Peripheral blood samples withdrawal|Peripheral blood samples evaluation
45381400|NCT05878925|Other|Aroma|The study intervention is an olfactory stimulation with vanilla or strawberry aroma. The aroma will be applied to the inner surface of the nCPAP mask of preterm infants using designated scent pens every 3-4 hours over a period of 12 hours. The two aromas will be applied in blocks of 5 consecutive infants (5 infants vanilla, 5 infants strawberry, and so forth).
45381401|NCT05878925|Other|Placebo|During the control intervention, identically looking placebo pens will be used to apply a colored carrier solution (without aroma) to the inner surface of the nCPAP mask of preterm infants in the same manner.
45381402|NCT05878912|Other|Diet intervention|The diet intervention delivers a weight loss program. The main component is a total diet replacement low energy diet. The intervention includes a gradual food reintroduction phase and maintenance strategies.
45381403|NCT05878834|Dietary Supplement|Beta-glucan supplement group|Take 1 capsule 1 time per day for 12 weeks.
45381404|NCT05878834|Dietary Supplement|Placebo group|Take 1 capsule 1 time per day for 12 weeks.
45496583|NCT04738019|Diagnostic Test|Medical examination or treatment.|Medical examination or treatment when delayed on-set nodule or other side effects occur due to Y-Solution filler injection.
45496584|NCT04731233|Biological|Plasma Rich in Growth Factor (PRGF) Supplementation|After rinsing the joint, the TMJ will be injected with blood plasma rich in growth factors (PRGF). PRGF supplementation which is an autologous platelet-enriched plasma obtained from patient's own blood, which after activation with calcium chloride allows the release of a pool of biologically active proteins that influence and promote a range of biological processes.
45496585|NCT04731233|Drug|Triamcinolone Acetonide|After rinsing the joint, the TMJ will be injected with 40 mg of triamcinolone acetonide with 5 mg bupivacaine.
46055521|NCT04091425|Drug|Placebo|TAK-925 placebo-matching IV infusion
46055522|NCT04223427|Procedure|Directional and single ring STN-DBS on gait|"Surgery for STN-DBS and STN-LFP recordings during gait initiation (M1): 15 days~Surgery for STN-DBS electrodes implantation~Placement of stimulation electrodes according to the usual procedure, including a MRI with contrast product~Intraoperative electrophysiological recordings~Intraoperative clinical evaluation~Intraoperative identification of the electrodes and final position with X-Ray~Post-operative 3D helical TDM without iode injection~STN-LFP recordings during gait initiation performed 3 to 5 days after surgery~Placement of the neurostimulator (5 days after surgery)~Acute testing of STN-DBS for first parameters setting programming~Follow-up of the patient with outpatient visits as usually performed in PD patients operated for STN-DBS with progressive adaptation of parameters settings using single-ring stimulation.~Directional and single ring STN-DBS on gait (M7)"
45381405|NCT05878795|Behavioral|WET-SP|WET-SP will consist of 5 treatment sessions; the first session lasting about one hour and each subsequent session lasting approximately 45 minutes. Each session will include a 30-minute written exposure exercise. The participant will be given general instructions for completing the narrative writings and specific instructions for completing the first session. Participants will be instructed to write about the same suicidal crisis during each session. The therapist will emphasize the importance of delving into their deepest emotions surrounding the suicidal crisis as well as the importance of writing detailed information about the crisis. Following writing, the therapist and the participant will process the writing experience. Subsequent sessions involve the therapist iteratively providing feedback to the patient regarding their writing from the previous session.
45381406|NCT05878795|Behavioral|TAU|TAU includes initial psychiatric stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily throughout the duration of hospitalization and have structured times for psychoeducation groups, case management, medication management, hygiene, and meals.
46055523|NCT04222491|Drug|Peanut oral immunotherapy|Peanut oral immunotherapy for peanut allergy
45381407|NCT05878756|Other|Functional Strength Training|In addition to conventional therapy, experimental group was also given functional strength training program. Functional strength training was given as home program consisting of ten tasks.The ten tasks were STS, one leg standing, weight shifting(from one side of body to other), step-ups, lateral step-ups, squatting against wall, picking an object from standing position, walking forward, walking backward and kicking the ball.
45381408|NCT05878691|Drug|GRC 54276|"Part 1a: GRC 54276 QD will be administered orally from Day 1 to Day 21 in a 21-day treatment cycle.~Part 2: GRC 54276 monotherapy therapy will commence after establishment of the MTD and/or RP2D for monotherapy arm."
45381409|NCT05878691|Drug|GRC 54276 + Pembrolizumab|"Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of pembrolizumab IV every 21 days.~Part 2: GRC 54276 in combination with pembrolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm."
45381410|NCT05878691|Drug|GRC 54276 + Atezolizumab|"Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of atezolizumab IV every 21 days.~Part 2: GRC 54276 in combination with atezolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm."
45381411|NCT05878535|Drug|Metformin|Metformin 850 mg oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. The dose can be up-titrated to 1500-2000 mg divided q8-12hr with meals in enrolled diabetic patients as a monotherapy or combined with sulfonylurea.
45381412|NCT05878535|Drug|Placebo|Placebo oral tablets. Prescribed: Once daily PO with meals and 200 mL of water.
45381413|NCT05877833|Other|Vibrancy Assessment|Additionally, important medical events that may not result in death, be life threatening, or require hospitalization may be considered SAEs when, based on appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.
45381414|NCT05877664|Drug|ZG0895 Hydrochloride for Injection|The dose escalation of ZG0895.HCl is set as 0.06, 0.12, 0.18, 0.37, 0.75, 1.50, 2.25, 3.00, and 3.75 mg/m^2 groups, subcutaneous (SC) injection once a week (QW)
45381415|NCT05877651|Biological|MASCT-I injection|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
45381416|NCT05877443|Procedure|Open system|Oxygen delivered on open system, for example high flow nasal cannula or low flow oxygen by nasal cannula or face mask
45381417|NCT05877443|Procedure|Non-invasive mechanical ventilation|Respiratory support by for example continues or bilevel positive airway pressure
45381418|NCT05877443|Procedure|Invasive mechanical ventilation|Respiratory support delivered through endotracheal tube or tracheostomy
45381419|NCT05877404|Other|Surveys|Survey on practice patterns surrounding tumor genetic testing in endometrial cancer.
45381420|NCT05877105|Other|Ventilator-associated pneumonia prevention Evidence-based practices (VAPPEBP) which consists of ten items bundle|VAP prevention EBP which consists of ten items bundle; hand hygiene, head-of-bed elevation, oral care with cetylpyridinium chloride, avoidance of oversedation, proper breathing circuit management, appropriate maintenance of endotracheal tube cuff pressure, closed system and subglottic suctioning, daily assessment for extubation, early ambulation and rehabilitation, and peptic ulcer and deep vein thrombosis (DVT) prophylaxis.
45381421|NCT05876806|Drug|Dabrafenib|Dabrafenib is a 150 mg twice daily capsule administered orally on a continuous basis
45381422|NCT05876806|Drug|Trametinib|Trametinib is a 2 mg once daily tablet administered orally on a continuous basis.
45381423|NCT05876637|Other|Left Nostril Breathing|The participants which will show cardiovascular hyper reactivity towards CPT will be divided into 2 groups having 30 participants in each group. Experimental group will receive Left Nostril Breathing(slow, deep breath taken through your left nostril while closing your right nostril with your right thumb. Then just as gently exhale long, slowly, and completely through the left nostril, just as gently. It will be done while sitting) for 10 minutes twice a day for the duration of 12 weeks. Follow up will be taken through administration Cold pressor test after every 4,8 and 12 weeks.
45381424|NCT05876637|Other|Conventional|30 participants will be recruited in conventional group which will receive simple deep breathing exercises of 3 sessions per week for the duration of 12 weeks.Follow up will be taken after every 4,8 and 12 weeks.
45381425|NCT05876273|Device|Neural-net Artificial Pancreas|NAP is a neural-net implementation of the previously tested UMPC algorithm (below).
45496586|NCT05292053|Drug|TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation|TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder)
45496587|NCT04584203|Diagnostic Test|Bedside Echocardiography|"All the intensivists performing the TTE in the involved centers fulfill the criteria of the American Society of Echocardiography and of the European Society of Intensive Care.~Medicine to be considered as experts in critical care echocardiography. Each center performs the TTE evaluation by means of the ultrasound device available in the unit equipped with the tissue Doppler imaging program and a phased array transducer of 2.5 MHz and doppler signals is recorded along with the electrocardiogram.~For the purpose of this study, the following TTE parameters are recorded from the apical 4-chamber view during each set of measurements:"
45496588|NCT04584203|Procedure|Spontaneuos breathing trial|The Spontaneous Breathing Trial will be performed accordingly to the clinical practice of the involved centers (a total support - including positive end-expiratory pressure plus pressure support equal or lower to 8 cmH20)
45496589|NCT04584203|Diagnostic Test|Bedside Echocardiography_1|Echocardiography performed within 24h from patient's admission - not optional
45496590|NCT04584203|Diagnostic Test|Bedside Echocardiography_2|Echocardiography performed within 12h from patient's spontaneous breathing trial - not optional
45496591|NCT04584203|Diagnostic Test|Bedside Echocardiography_3|Echocardiography performed at 60 +/- 12h from patient's admission - optional
45496592|NCT04584203|Diagnostic Test|Bedside Echocardiography_4|Echocardiography performed 24h after patient's estubation - optional
45496593|NCT05212181|Device|H-Man|H-Man device will be deployed to patients for onboarding and home-based training.
45496594|NCT05288621|Device|electroacupuncture|"For'four sacral points'group, Hua Tuo brand disposable acupuncture needles (size 0.40 × 100mm) and electronic needle therapy instrument SDZ-IIB will be used.Bilateral BL30 and BL35, were selected as acupoints protocol.~'Four sacral points'group consists of 8 sessions over an 4-week period after baseline(2 sessions in each week), each for 30minutes. The electroacupuncture will be set at a frequency of 2.0 Hz, continuous wave, a moderate intensity the patient can tolerate and 30 min during each treatment."
45496595|NCT05306639|Other|Rehabilitation|rehabilitation sessions using spinal magnetic stimulation or neuromodulation
45496596|NCT05207111|Drug|Revefenacin Inhalation Solution|Revefenacin Inhalation Solution, 175 mcg/3 mL following a single nebulized inhaled 175 mcg (1 x 175 mcg/3 mL) dose administered under fasting conditions.
45496597|NCT03256097|Device|XDP sound processing strategy - Period 0|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
45496598|NCT03256097|Device|XDP sound processing strategy - Period 1|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
45496599|NCT03256097|Device|VG sound processing strategy - Period 1|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
45496600|NCT03256097|Device|XDP sound processing strategy - Period 2|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
45496601|NCT03256097|Device|VG sound processing strategy - Period 2|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend
45496602|NCT03256097|Device|XDP sound processing strategy - Period 3|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
45381426|NCT05876273|Device|University of Virginia Model Predictive Control|A previously tested artificial pancreas control algorithm, based on a differential-equation model of the human metabolic system in diabetes.
45381427|NCT05876247|Other|Electromagnetic Articulography|Motion tracking sensors will track articulatory movements of the tongue, jaw and lips
45381428|NCT05876221|Drug|Cablivi|Patients with immune Thrombotic Thrombocytopenic Purpura, who have been treated with caplacizumab (Cablivi®)
45381429|NCT05876104|Behavioral|Behavioral therapy|Behavioral and supportive therapy
45381430|NCT05875506|Drug|Ozone gel|(Ozene; Premier Research Labs, lp, 3500-b Wadley pl, Austin, TX, USA. 78728) applied in dry socket
45381431|NCT05875506|Drug|doxycycline hyclate saturated chitosan dressing|doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA) applied in dry socket
45381432|NCT05875441|Drug|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
45381433|NCT05875441|Drug|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
45381434|NCT05875441|Drug|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose.
45381435|NCT05875441|Drug|Placebo|16 placebo capsules will be administered as a single dose.
45381436|NCT05875350|Procedure|Intraligamental local anesthetic injection|The intraligamental technique was administered using ligajet intraligamentary jet injector (Micro Mega Company) containing Articaine hydrochloride 4% with adrenaline 1:200000 (ArtPharma Dent, inc, Egypt)
45496603|NCT03256097|Device|VG sound processing strategy - Period 3|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend
45496604|NCT03256097|Device|Voice Track|Voice Track is a cochlear implant noise cancellation system which is designed to reduce the adverse effect of background noise on speech perception through cochlear implants
45496605|NCT05199077|Drug|GM-XANTHO|a topical applied ointment
45496606|NCT05195567|Diagnostic Test|Glucometer Test|measurement of the blood glucose concentration using the blood glucose monitor for personal use
45496607|NCT05195567|Diagnostic Test|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device
45496608|NCT04417517|Drug|evorpacept|Fusion protein that blocks CD47-SIRPalpha pathway
45496609|NCT04417517|Drug|azacitidine|Hypomethylating agent (HMA)
45496610|NCT04697381|Biological|somatropin - GH naïve pediatric cohort|somatropin 0.245 mg/kg/week
45496611|NCT04697381|Biological|somatropin - GH treated cohort|somatropin 0.084 mg/kg/week
46055524|NCT02765685|Device|brace ODRA (PROTEOR company)|Port of the orthosis ODRA during day during 12 months, Complement to their usual care. The subjects will have for instruction to wear the brace a minimum of 6 hours a day, 5 days a week, And to remove it during the rest periods in lengthened position.
46055525|NCT02765685|Other|Usual care|"The patients will benefit only from the coverage proposed usually, by their regular doctor and according to the notices of the medical and paramedical specialists taking care of this pathology (physiotherapists, orthopaedic osteopaths, sports medicine physician, surgeon, rheumatologists, rehabilitative doctors, etc.). In the absence of recommendations on the modalities of coverage of the gonarthrose and in front of diverse clinical habits, the usual said coverage can be at the same time medicinal (anti-inflammatory, painkilling, …), non-medicinal (physiotherapy, port of an orthosis, …), even surgical, according to the influencers."
45381437|NCT05874947|Device|linear measurement|Linear measurements from digital caliper ,CBCT and EOS generated digital dental models
45381438|NCT05874791|Behavioral|Goal Management training|metacognitive group intervention
45381439|NCT05874037|Drug|Fluvoxamine|Fluvoxamine is an FDA approved drug for the treatment of OCD. This trial is testing the effects of the drug on long COVID.
45381440|NCT05873816|Device|ProtEmbo - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the ProtEmbo cerebral embolic protection device.
45381441|NCT05873816|Device|Sentinel - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the Sentinel cerebral embolic protection device.
45381442|NCT05872542|Drug|Silver Diamine Fluoride (SDF)|Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply SDF to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Remove excess SDF with gauze or cotton pellets. Continue to isolate the site for up to three minutes.
45496612|NCT04697381|Biological|somatropin - adult cohort|somatropin 0.084 mg/kg/week
45496613|NCT01312571|Behavioral|Internet-based cognitive behavioural therapy (iCBT)|The Internet-based cognitive behavioural therapy (iCBT) consists of our structured self-help program lasting a total of nine active treatment weeks. This treatment program has been well evaluated and involved in several research projects.
45496614|NCT01312571|Behavioral|Internet-based computerized attention training|The Internet-based computerized attention training program lasting a total of four active treatment weeks. The treatment is consist of two training sessions per week, about 10 minutes long.
45496615|NCT04732793|Device|Hyruan ONE®|For use as a symptomatic treatment of osteoarthritis (OA) of the knee
45496616|NCT04732793|Device|Durolane®|For use as a symptomatic treatment of osteoarthritis (OA) of the knee
45496617|NCT04695977|Drug|CMP-001|Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
45496618|NCT04695977|Drug|Nivolumab|Nivolumab 360 mg IV is administered Q3W.
45496619|NCT04644965|Diagnostic Test|CombynTM Function & Spaces ECG|Multi-frequency impedance measurement to assess the muscle and fat mass
45496620|NCT04644965|Diagnostic Test|Blood Taking|Sampling of blood of the finger pad to assess liver function
45496621|NCT04644965|Diagnostic Test|Spiroergometry|Spiroergometry to assess cardiopulmonary capacity. The intensity will be raised in steps until total exhaustion. In between each step we will take blood of the ear lobe to determine the lactate level
46055526|NCT00750139|Drug|NAFT-500|topical cream 1 application every day up to 4 weeks weeks
46055527|NCT00750139|Drug|Placebo 2-weeks|placebo cream 1 application every day for up to 4 weeks
46055528|NCT00750139|Drug|Naftin 1%|topical allylamine cream applied once a day for up to 4 weeks
46055529|NCT00750139|Drug|Placebo 4-weeks|topical placebo cream applied once a day for up to 4 weeks
45381443|NCT05872542|Other|Glass Ionomer Restoration (GI)|Application of GI restoration necessitates removal of carious tissue using round bur rotating on low-speed contra and excavation of infected carious dentin. Followed by restoring the prepared cavity with glass ionomer restoration according to the manufacturer's instructions. The restoration will be checked for any high spots and occlusal interference (if any) will be corrected.
45381444|NCT05872542|Other|Sodium fluoride varnish with nano-sliver particles (NaF-AgNP)|Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply NaF-AGNP to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Continue to isolate the site for up to three minutes.
45496622|NCT04644965|Diagnostic Test|Dordel Koch Test (DKT)|Dordel Koch Test (DKT) to evaluate the motor activity. The DKT is a heterogeneous test battery for children and adolescents and consists of seven parts: lateral jumping, sit and reach, situps, long stand jump, one-legged stand, push-ups and 6-min-run
46055530|NCT04192461|Procedure|Tooth guided immediate implant placement|The technique of implant insertion consisted of a progressive preparation of the implant site using the anatomy of the root of the multi-radicular mandibular molars to be extracted as a reference and as an aid to engage the inter-radicular septum
46055531|NCT02765763|Drug|2-Minute Reveal Masque|
46055532|NCT02765763|Drug|24/7 Barrier Repair Cream|
46055533|NCT02765763|Drug|8-in-1 BioSerum|
45381449|NCT05872295|Drug|IKS014|IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent.
45381450|NCT05872269|Drug|Saroglitazar|4 Mg Oral Tablet
45381451|NCT05871086|Dietary Supplement|Coenzyme Q10|Coenzyme Q10 soft gelatin capsules daily for 3 months
45496623|NCT04644965|Diagnostic Test|Ultrasound|Ultrasound for abdominal wall muscles
45381452|NCT05871086|Other|Placebo|Placebo Capsules
45381453|NCT05871086|Drug|Standard Regimen|"Patients may be receiving any of these commonly used JIA treatments including:~Ibuprofen - 30 to 40 mg/kg/day in 3 to 4 divided doses~Diclofenac - 2 to 3 mg/kg/day in divided doses 2 to 3 times daily~Methotrexate - Initial: 10 to 15 mg/m2 once weekly; adjust gradually up to 20 to 30 mg/m2 once weekly~Leflunomide - Weight based, 10-20 mg once daily~Sulfasalazine - 30 to 50 mg/kg/day in 2 divided doses~Etanercept - 0.8 mg/kg/dose once weekly~Adalimumab - Weight based, 10-40 mg every other week"
45496624|NCT04644965|Diagnostic Test|Stance and gait analyses|Stance and gait analyses for measuring the core stability
45496625|NCT04908761|Procedure|Transmuscular quadratus lumborum block|Patients assigned to the TQL block group receive the TQL block in a supine position with the surgical site facing up before recovery of general anesthesia after surgery. For the block, 30cc of 0.375% ropivacaine is used.
45496626|NCT04908761|Procedure|Placebo|For patients assigned to the control group, 30cc of 0.9% normal saline is used for TQL block.
45496627|NCT03093155|Drug|Ixabepilone|"Ixabepilone will be administered at 20 mg/m2 intravenously days 1, 8, 15 of a 28-day cycle over one hour.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response"
46055534|NCT02765763|Drug|Null Formula 2-Minute Reveal Masque|
46055535|NCT02765763|Drug|Null Formula 24/7 Barrier Repair Cream|
46055536|NCT02765763|Drug|Null Formula 8-in-1 BioSerum|
46055537|NCT02765919|Radiation|HDR Brachytherapy of 9 Gy in 2 fractions|Two fractions of HDR brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
46055538|NCT02765919|Radiation|HDR Brachytherapy of 7 Gy in 3 fractions|Three fractions of HDR Brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
46055539|NCT02765841|Drug|Lomitapide|
46055540|NCT02760771|Other|with BAV|balloon dilation of the aortic valve prior to implantation of the THV
46055541|NCT02760771|Other|without BAV|no balloon dilation of the aortic valve prior to implantation of the THV
46055542|NCT00750061|Drug|Lithium Carbonate|"The subject start at a dosage regime of three times a day and one tablet of lithium carbonate, 250mg/table, oral administration each time for three days. The daily dose will be adjusted according to the serum lithium level and the clinical findings. Target serum lithium level is 0.6-1.2mM.~The course of medication is 6 weeks."
46055543|NCT00750061|Drug|Placebo|Matching placebo
46055544|NCT04223739|Drug|Landiolol|"Landiolol infusion with incremental doses (range from 2,5µg/kg/min to 80 µg/kg/min) with go of heart rate < 90 bpm. Doses are modified every 10 minutes if necessary.~Once heart rate goal is obtained, switch to an oral dose of Bisoprolol."
46055545|NCT04223739|Drug|Amiodarone|Amiodarone loading dose of 5-7 mg/kg in 1 hour followed by an infusion of 1 g/day until conversion to sinus rhythm. Once sinus rhythm is obtained, switch to an oral dose of 200mg/day
46055546|NCT04091269|Device|automatic adjustmen of inspiratory triger and cycling-off based on waveform and PSV with fixed Esence|The ventilators have a compunter drived funcation of automatic adjustmen of inspiratory triger and cycling-off based on waveform, IntelliCycleTM 2.0.
45496628|NCT03093155|Drug|Bevacizumab|"Bevacizumab will be administered at 10 mg/kg intravenously days 1, 15 of a 28-day cycle over one hour. Bevacizumab will be infused after ixabepilone. The first dose of bevacizumab will be administered intravenously over 90 minutes; the second dose may be administered over 60 minutes if no prior reaction to previous infusion; subsequent doses may be administered over 30 minutes if no prior reaction to previous infusion.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response."
45496629|NCT03080129|Dietary Supplement|Fresubin energy|dietary protein energy supplement
45496630|NCT04762121|Procedure|Peripheral IV|Insertion of peripheral intravenous catheter
45496631|NCT03324581|Drug|OPC-64005|OPC-64005 film coated tablets
45496632|NCT03324581|Drug|Atomoxetine|Atomoxetine gelatin capsules
45496633|NCT03324581|Drug|Placebo|OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules
45496634|NCT02943473|Drug|Ibrutinib|"Ibrutinib is a type of drug called a kinase inhibitor. Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing."
45496635|NCT03629873|Drug|Chidamide|Chidamide 30mg po d-7、-4、0、3; Carmustine 300mg/m^2 IVD d-6; Etoposide 150mg/m^2/d qd IVD d-5~-2; Cytarabine 150mg/m^2 q12h IVD d-5~-2; Cyclophosphamide 1.0g/m^2/d qd IVD d-5~-2
45496636|NCT04294043|Drug|Gallium nitrate|Study subjects will receive an infusion of gallium nitrate.
45847477|NCT05349084|Diagnostic Test|PET-cCTA-cFFR|patients presenting with stable angina and a moderate pretest likelihood for CAD who are already scheduled to undergo ICA for the clinical indication of angina will be recruited to undergo PET-cCTA-cFFR
45847478|NCT05348694|Dietary Supplement|Pendulum WBF-038|"All bacteria contained in Pendulum WBF-038 are commensal organisms that have been repeatedly documented to inhabit the human gastrointestinal tract under normal circumstances. Pendulum's WBF-038 is a proprietary formulation of the following strains: Akkermansia muciniphila, Clostridium butyricum, Clostridium beijerinckii, Anaerobutyricum hallii, Bifidobacterium infantis, plus chicory inulin and magnesium stearate. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS).~The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃."
45847479|NCT05348694|Dietary Supplement|Pendulum Placebo|Pendulum placebo capsules containing magnesium stearate
45496637|NCT05019833|Device|Signals collection|A non-CE marked embedded software will be temporarily uploaded in the implanted device, in order to enable the collection of sensors signals.
45496638|NCT03073733|Biological|human retinal progenitor cells|live suspension of 3.0 or 6.0 x 10e6 human retinal progenitor cells (hRPC) suspended in clinical grade medium injected intravitreally under local anesthesia
45496639|NCT03073733|Other|Mock injection|pressing the hub of a syringe with no needle against the eye to mimic intravitreal injection
45496640|NCT05019677|Drug|GP+PD-1+Tight|"Drug: Tislelizumab Tislelizumab 200mg IV Q3W~Other Name:~BGB-A317 Anti-PD-1 therapy~Drug: Ociperlimab Ociperlimab 900mg IV Q3W~Other Name:~BGB-A1217 Anti-TIGIT therapy~Drug: GP chemotherapy gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W"
45496641|NCT05010785|Procedure|Immediate implant placement and alveolar ridge splitting with GBR and i-PRF|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate using bone graft mixed with i-PRF
45496642|NCT05010785|Procedure|Immediate implant placement and alveolar ridge splitting with GBR|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate
45496643|NCT02899793|Drug|Pembrolizumab|Pembrolizumab 200 mg (fixed dose) IV every 3 weeks (+/- 3 days) until progression or adverse effects prohibit therapy
45496644|NCT04981145|Drug|Iguratimod Tablets|Participants are treated with Iguratimod Tablets 25 mg Twice a day for 24 weeks.
46055547|NCT02765997|Biological|Unmanipulated UCB|Unmanipulated UCB infusion given on Day 0. All patients will receive the same conditioning and immunoprophylaxis for the prevention of acute and chronic GVHD, previously demonstrated to offer the best outcomes in recipients of partially HLA matched UCB. Standard supportive care, including the use of Neupogen [G-CSF] and prophylactic anti-bacterial, protozoal, viral and fungal agents, will also be prescribed. Supportive care will be modified throughout the transplant course at the treating physician's judgement.
45496645|NCT04981145|Drug|Hydroxychloroquine Sulfate Tablets|Participants are treated with Hydroxychloroquine Sulfate Tablets 200 mg Twice a day for 24 weeks.
45496646|NCT02864147|Drug|9-valent HPV vaccine|All women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
45496647|NCT02864147|Drug|Imiquimod|At the baseline visit, this group will be instructed about the correct method of self-application of imiquimod 6.25mg as a vaginal suppository and receive a 16 week course of the drug.
45496648|NCT04258631|Drug|Hydromorphone|Given IT
45496649|NCT04258631|Procedure|Laparotomy|Undergo laparotomy
45496650|NCT04258631|Drug|Liposomal Bupivacaine|Drug
45496651|NCT04258631|Other|Questionnaire Administration|Ancillary studies
45496652|NCT02931695|Other|evaluation of QT interval duration|ECG to evaluation of QT interval duration
45496653|NCT02931695|Other|circulating sex hormones levels sample|Association between circulating sex hormones levels (progesterone, estradiol, testosterone, FSH) and QTcF duration (univariate and multivariate analysis).
45496654|NCT04877015|Device|Active Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
45496655|NCT04877015|Device|Sham Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
45496656|NCT03638063|Diagnostic Test|Adenosine Triphosphate|Adenosine Triphosphate aerosol
45496657|NCT03638063|Diagnostic Test|capsaicin|capsaicin aerosol
45496658|NCT04869371|Drug|Docetaxel injection|75 mg/m2 body surface area every 3 weeks for 6 cycles before robot assisted radical prostatectomy
45496659|NCT04869371|Drug|Triptorelin Pamoate for Injectable Suspension|15mg every 12 weeks
45496660|NCT04869371|Drug|Prednisone Acetate Tablets|5 mg oral low dose prednisone, once daily
45496661|NCT02710331|Drug|Active Dronabinol|10 mg capsule of Dronabinol will be administered orally.
45496662|NCT02710331|Drug|Placebo|Control: no alcohol, administered for ~80 minutes.
45496663|NCT02710331|Drug|Placebo|Control: Placebo pill (no active cannabinoids) administered orally.
46055548|NCT02765997|Biological|SR-1 UCB|SR-1 UCB infusion given on Day 0. All patients will receive the same conditioning and immunoprophylaxis for the prevention of acute and chronic GVHD, previously demonstrated to offer the best outcomes in recipients of partially HLA matched UCB. Standard supportive care, including the use of Neupogen [G-CSF] and prophylactic anti-bacterial, protozoal, viral and fungal agents, will also be prescribed. Supportive care will be modified throughout the transplant course at the treating physician's judgement.
46055549|NCT00916981|Procedure|percutaneous autologous preosteoblast cells implantation|percutaneously injection of preosteoblast into the nonunion under radioscopic control
45381454|NCT05870215|Other|Visit 1: Clinical exam and questionnaires|Medical history and examination, including vital signs, inhaler technique and adherence check (using prescript refills via the Dossier Santé Québec and/or calls to the community pharmacy), 5-item Asthma Control Questionnaire (ACQ-5), dyspnea rated on the modified Medical Research Council scale (mMRC), visual analog scale (VAS) for six respiratory symptoms, Pittsburgh Vocal Cord Dysfunction Index, Nijmegen Questionnaire, Hospital Anxiety and Depression Scale.
45381455|NCT05870215|Other|Visit 1: Respiratory physiology|FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
45381456|NCT05870215|Other|Visit 1: Inflammometry|Nasosorption with nasal epithelial lining fluid (NELF), nasal swab for ultrarapid SARS-CoV2 molecular test (ID NOW), nasopharyngeal swab for rapid multiplex PCR viral (BIOFIRE), nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, total and specific serum immunoglobulin E, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank), chest x-ray
45496664|NCT02710331|Drug|Active Ethanol|Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
45496665|NCT02885753|Drug|Oxaliplatin intravenous|85 mg/m² in intravenous. 1 cycle each 15 days
45496666|NCT02885753|Drug|5 FU bolus|5 fluorouracil : 400 mg/m² in bolus of 10 minutes (intravenous) following by 2400 mg/m² during 46 hours in intravenous
46055550|NCT02765607|Procedure|Heart surgery|
46055551|NCT02765295|Device|medical ultrasonic hydrogen/oxygen nebulizer (MUNHO)|The medical ultrasonic nebulizers with hydrogen/oxygen generating function (MUNHO) will be provided exclusively by the sponsor, Asclepius Meditec Inc (Shanghai, China). The MUNHO consists of a electrolytic tank which, by using direct current converted from alternating current (220 V), generates the hydrogen and oxygen gas from pure water (2:1 in volume). The MUNHO is also capable of nebulizing the water via ultrasounds with the hydrogen-oxygen mixed gas which is finally delivered to the patient's airways via the facial mask through a plastic tube. Typically, the volume of hydrogen-oxygen mixed gas is 3 liters per minute (3 L/min).
46055552|NCT02765295|Device|Medical molecular mesh oxygen generator|"medical molecular mesh oxygen generator, type: OLO-1, oxygen flow: 3L/min; Shanghai Ouliang Medical Instrument Inc., Shanghai, China; Registration No.: Shanghai Medical Instrument approval No. 20152540046.~This device has an identical appearance as compared with the MUHNO so that the patients could not readily discriminate with the MUHNO, and is also capable of displaying the actual cumulative duration of oxygen inhalation."
45496667|NCT02885753|Drug|Folinic acid|400 mg/m² in intravenous
45496668|NCT02885753|Drug|Oxaliplatin intra-arteriel|85 mg/m² in intra-arterial. 1 cycle each 15 days
45496669|NCT02885753|Drug|Panitumumab|Only for patient RAS wild: 6 mg/Kg at each cycle in intravenous
45496670|NCT02885753|Drug|Bevacizumab|5 mg/kg at each cycle in intravenous
45496671|NCT02885753|Drug|5 FU continuous|2400 mg/m² intravenously over 46 hours
45496672|NCT02885753|Drug|Irinotecan|150 mg/m² intravenous
45496673|NCT04228523|Other|Therapeutic education workshop|"Workshop on Parkinson disease drug has several educative sequences (lasting 4hours).~A first round table is organized to know the needs and issues related to drug management of patients.~The 1st educative sequence consists in knowing the different class of dopaminergic drugs and their action.~The 2nd educative sequence leads patients to understand their prescription and be aware of the needs to take pills regularly.~The 3rd educative sequence consists in learning and identifying potentials adverse effects and finds effective strategies to prevent them.~At the end, one patient explains its tips and tricks about its drug management"
46055553|NCT02765529|Procedure|Blood sampling|
45496674|NCT04228523|Other|Speaking Therapy|Speaking group is leaded by a psychologist from Centre Expert Parkinson (lasting 2 hours). This specific time is an exchange between patients with Parkinson disease who feel free to come. It is about sharing its own experience. It is a very special moment, confidential and kindly where patients don't judge themselves and speak only if they want to.
45496675|NCT03320369|Other|Elemental Diet Therapy|Elemental diet is a formula composed of amino-acids, carbohydrates, and lipids that is 100% nutritionally complete
45496676|NCT02650895|Biological|Efprezimod alfa|Recombinant fusion protein consisting of the extracellular domain of mature human CD24 linked to the human immunoglobulin G1 (IgG1) Fc domain
45496677|NCT02650895|Drug|Saline|0.9% sodium chloride
45496678|NCT04742231|Device|Hand-held dynamometer|Maximum Grip Strength will be measured using a hand-held dynamometer (K-FORCE Grip dynamometer®. Kinvent Biomequanique S.A.S, Montpellier, France) during the preoperative, intraoperative (Awake craniotomy) and postoperative period.
45496679|NCT03320057|Drug|Mifepristone|Patients will receive Mifeprex® (mifepristone) by pharmacy rather than standard care at clinic visit
45496680|NCT03320057|Other|Training on mifepristone dispensing|Pharmacists were offered a training on medication abortion and mifepristone dispensing
45496681|NCT04741139|Drug|Acetaminophen and Diphenhydramine Only Product|Using a scheduled medication regimen of diphenhydramine and acetaminophen following IVIG medication to evaluate feasibility of enrollment, medication adherence, side effects related to study medication and IVIG.
45381457|NCT05870215|Other|Visit 2: Clinical exam and questionnaires|Medical history and examination, including vital signs, symptom scores (ACQ-5, mMRC), visual analog scale (VAS) for six respiratory symptoms, Hospital Anxiety and Depression Scale, satisfaction questionnaire about point-of-care biomarker measurements, satisfaction questionnaire about point-of-care biomarker measurements: letter and email sent to treating doctor.
45496682|NCT04738409|Other|Lifestyle intervention|The purpose of the research is to evaluate the potential of a multidimensional lifestyle program for PCOS girls. The primary aim is to verify the effectiveness of a 16-week AID intervention vs. HCD (combined with PA&T), in terms of improvement in androgens level and immune-metabolic risk parameters
45496683|NCT03316547|Other|SENSE Program|Specific amounts of auditory, tactile, vestibular, kinesthetic, and visual exposure conducted daily through hospitalization. This includes specifically timed and set amounts of reading/talking/singing, cycled lighting, skin-to-skin (kangaroo) care or gentle human touch, rocking, and therapeutic exercises [passive range of motion (PROM), gentle stretching]. The intervention plan is intended to be implemented by parents when available, and by surrogates when the parents are unable to be present in the hospital. Specific amounts and timing of interventions will be tailored to the current medical status and age of each infant.
45694269|NCT05310214|Other|Laser acupuncture|"The use of LACP (808 nm wavelength, 100 mW, energy 6 J per acp point), on acupoints BL23 (Shenshu), BL25 (Dachangshu), BL40 (Weizhong), BL62 (Qixue), SI3 (Houxi) and Jiaji will be used as a treatment for nonspecific chronic low back pain. Interventions will last one hour, and will happen twice a week for 5 weeks.~Sham acupuncture points will be used to simulate the treatment, as follows: i) Arms: 3 cm above the lateral epicondyle of the elbow, ii) Lumbar spine: Iliac crest on the same line as the greater trochanter of the femur. These sham points will be inserted superficially so that the depth is sufficient to keep them fixed during the experiment, without individuals reporting the dequi."
45694270|NCT00817804|Device|Use of the V60 Mask Ventilator|The V60 Mask Ventilator used to provide noninvasive ventilation. It is compared to the patient's conventional ventilator in a cross-over study. The ventilator settings can range from CPAP to Pressure Support ventilation with values of IPAP and EPAP to match the conventional ventilation on which the patient had been placed.
45694271|NCT03839524|Drug|TG4050|Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.
45694272|NCT00818116|Device|AcrySof ReSTOR Aspheric IOL|Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL) for the replacement of cataract in the natural lens of the eye.
45694273|NCT00818272|Biological|Remicade (infliximab)|Participants with confirmed diagnosis of severe active Crohn's disease (CD) and participants suffering from fistulae who do not respond sufficiently to a complete and adequate therapy with a conventional treatment received infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of infliximab therapy with additional infusions of 5 mg/kg at week 2 and week 6 after the initial dose, followed by infusions every 8 weeks (maintenance) or if signs and symptoms of the disease recur (readministration).
45694274|NCT00868348|Drug|Ketorolac|30 mg (1 ml) infiltration combined with Intraarticular bolus injection of 120 mg (4 ml) ketorolac
45694275|NCT00868348|Drug|Saline|1 ml infiltration 4 ml intraarticular bolus injection of placebo
45694276|NCT01933919|Drug|Fluvoxamine maleate|Film-coated tablet containing 25 mg of fluvoxamine maleate
45694277|NCT01933919|Drug|Placebo|Placebo tablet matching to fluvoxamine maleate
45694278|NCT00819286|Device|SternaLock Rigid Fixation Plates|patients will have their sternum closed by rigid fixation using SternaLock Rigid Fixation Plates
46055554|NCT02760537|Behavioral|Lay Health Worker Intervention|Lay Health Worker Phone Intervention The second phase addressed phone intervention training, where LHWs who had completed the first phase and were willing to participate in the second phase learned the process for calling participants to remind them to complete a series of HBV vaccinations. The LHWs assigned to the intervention group conducted phone interventions by reminding participants about completing a series of vaccinations at Months 1, 2, and 6, and also provided accompanying resources and support.
46055555|NCT02760537|Behavioral|Placebo (a list of resources)|Those in the control group received a list of resources along with their results by mail that offered free vaccinations, such as local health departments.
45381458|NCT05870215|Other|Visit 2: Respiratory physiology|FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
45381459|NCT05870215|Other|Visit 2: Inflammometry|SARS-CoV2 Test (ID NOW), nasosorption, nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank)
45381460|NCT05870215|Other|Visit 3: e-mail|ACQ-5, peak flow measurement, and questions about the patient's asthma management.
45694279|NCT00819286|Device|wire (control)|patients will have their sternum closed using wire (stainless steel surgical wire).
45694280|NCT04640441|Other|Sit-to-stand care|"Passive range of motion(ROM) exercise of lower legs, active ROM exercise of lower legs, and sitting balance exercise, 20~30 min, once daily.~Anti-gravity ROM exercise of lower leg, resistance exercise of low leg, and sitting balance exercise, 20~30min, once daily.~Stepping exercise and sit-to-stand exercise, 20~30min, once daily."
46055556|NCT02765451|Behavioral|interventions of the Cancéropôle Nord-Ouest|"During the time defined by the randomization, the Cancéropôle Nord-Ouest offers to help to develop a clinical research activities in the centers. The various aids are : Structuring clinical research at the local level, Support (strategy, logistics, technical, Data management, methodology), a portfolio of straightforward studies ( French National Cancer Institute, cooperative groups conducting cancer clinical research, New Project), Good Clinical Practice training, Clinical research technician, Others,....."
45381461|NCT05869331|Procedure|Early mobilization|Patients randomized to nonoperative treatment have already received treatment using early mobilization in the original trial, and all fractures have been confirmed healed. Mobilization consisted of 5 repetitions of full finger extension followed by maximum finger flexion, and 5 such sets of 5 were required per day for the first 6 weeks. Buddy taping or resting splint was offered if the patient experienced difficulty, and mobilization was performed by all patients in this treatment arm.
45381462|NCT05869331|Procedure|Operative treatment|Patients randomized to operative treatment have already received treatment using open reduction and internal fixation (ORIF) with cortical screws in the original trial, and all fractures have been confirmed healed. Surgery was performed under general anaesthesia through a dorsal incision centered over the fractured metacarpal. Reduction was performed under visual inspection and fixation performed using 2 or more cortical screws (Synthes Compact Hand 2.0) as first option. At the surgeons preference fixation using plate and screw fixation was also allowed. Postoperatively patients were put in a plaster cast for two weeks and then hand therapy was initiated.
45381463|NCT05868837|Drug|Rituximab|Rituximab 1000 mg IV on RCP days 1 and 15
45381464|NCT05868837|Other|Placebo|Placebo 1000 mg IV on RCP days 1 and 15
45381465|NCT05868421|Behavioral|Support Person Coaching Call|Support person participants assigned to the intervention group will additionally receive a 1-call coaching session about 15-25 minutes in duration on how to support their Veteran smoker. The session will be delivered by research staff by phone or video call. Support persons in the intervention group and the control/no intervention group will receive existing written material resources on support strategies to stop smoking, and resources on how to stop smoking by postal mail or email.
45381466|NCT05868421|Behavioral|SP written materials|Written materials covering tips on effective supportive strategies for smoking cessation
45381467|NCT05868421|Behavioral|Written Smoking Cessation Materials|Written materials on resource and referral information for VHA and non-VHA EBCT options
45381468|NCT05866549|Other|Mindfulness-based Childbirth and Parenting Program|Mindfulness-based childbirth and parenting program will be applied to individuals in this group. The program consists of nine sessions, eight of which will take place during pregnancy. Sessions planned during pregnancy will be held once a week, lasting 8 weeks.
45381469|NCT05866536|Biological|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
45381470|NCT05866536|Biological|Saline Injection|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
46055557|NCT02760303|Behavioral|Cognitive Behavioral Therapy|Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be the thought-emotion-behavior linkages as outlined by cognitive-behavioral theory. Activities will illustrate how thoughts affect emotions and behaviors, the application of these activities to current stressors, and strategies to apply these new skills to future stressors.
45694281|NCT04381702|Procedure|Pancreatoduodenectomy|Open or laparoscopic pancreato-duodenectomy with pancreatojejunal anastomosis
45694282|NCT05317468|Other|Contraceptive Counseling|Patients will receive contraceptive counseling to review all available contraceptive methods prior to their visit with a clinician.
45694283|NCT05318170|Procedure|Laparoscopic ultra-radical lymph node debulking|Laparoscopic ultra-radical lymph node debulking using Yasargil clamps
46055558|NCT02760303|Behavioral|Mindfulness Based Stress Reduction|Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be understanding how to gain control over one's thoughts and feelings using relaxation, meditation, and other mindfulness-based techniques. Activities will focus on the instruction and practice of mindfulness techniques, such as meditation and yoga, and the application of these practices to everyday activities.
45496684|NCT02740205|Other|Algorithm for enteral nutrition support|Enteral nutrition support prescribed by the Clinical Nutrition Service under the instructions of the algorithm based on evidence
45496685|NCT02738255|Device|Varnum mouthpiece|An adhesive mouthpiece with a central opening applied during sleep
45496686|NCT04824989|Behavioral|Sleep Health in Preschoolers (SHIP)|SHIP is an 8 session home visiting intervention to reduce child sleep problems using a framework that draws from motivational interviewing and social cognitive theory, and effectively improves sleep timing, duration, and quality. Following ecological assessment of child sleep and sleep routines, feedback is provided on family strengths and challenges in the child sleep domain, with motivational interviewing to increase parent knowledge of sleep, correct misperceptions, and raise outcomes expectations. The remaining sessions are targeted modules that give tailored feedback and education, and coach the parent in setting manageable goals, identifying action steps, anticipating barriers, and supporting positive behaviors. Targets: bedtime scheduling, consistency, and routines; media use, independent sleep onset, nightmares and fears, night wakings, and early waking; sleep location, nap issues, engaging other caregivers.
45496687|NCT04824989|Behavioral|Family Check-Up (FCU)|FCU is an 8 session home visiting intervention to reduce behavior problems for children through improved parenting. Over 30 years of research establishes its efficacy in reducing behavioral and emotional problems, including in low income toddlers. Following ecological assessment of behavior management and child behavior, family receives feedback on family strengths and challenges within the behavioral domain via a motivational interviewing approach. The remaining sessions are targeted modules drawn from the Everyday Parenting curriculum, individualized based on parent goals and identified challenge areas. Each session begins by establishing a collaborative skill set, involves teaching the rationale for a skill, teaching and modeling effective use of the skill, and then role play and experiential practice to coach the parent to success. Targets can include Positive Behavior Support, Limit Setting and Monitoring, Family Routines, Communication, and Problem Solving.
45496688|NCT04824989|Behavioral|Oral Health, Child Safety, and Environmental Health Intervention (Active Control)|This intervention serves as an active control condition to ensure that observed effects are due to the intervention content, rather than to study processes, staff attention, or general support and problem solving. The intervention is designed to be comparable to SHIP and FCU in intensity, personal contact, session structure and approach, but focused on Oral Health, Child Safety, and Environmental Health, domains which should not immediately affect study outcomes.
45496689|NCT02227199|Drug|Brentuximab Vedotin|Given IV
45496690|NCT02227199|Drug|Carboplatin|Given IV
45381471|NCT05866159|Other|Kinesiotape using Rocktape®|Kinesiotape using Rocktape® on day one by a physiotherapist who has experienced more than five years. If possible, the taping will be left for seven days.
45496691|NCT02227199|Drug|Etoposide|Given IV
45496692|NCT02227199|Drug|Ifosfamide|Given IV
45496693|NCT02227199|Other|Laboratory Biomarker Analysis|Correlative studies
45496694|NCT04131647|Other|Weight Maintenance|Following a 12-week weight loss and exercise program, subjects will participate in a weight maintenance program of Heart Healthy nutrition, walking, and resistance band exercise
45496695|NCT04131647|Other|Weight Maintenance + Intermittent Fasting|Following a 12-week weight loss and exercise program, subjects will participate in a weight maintenance program of Heart Healthy nutrition, walking, resistance band exercise and intermittent fasting (2 small meals per day) one day per week for 24 weeks.
45496696|NCT04762433|Device|Kegel Exercise Pregnancy Training - app|"KEPT-app is designed to educate pregnant women on PFMT via the step-by-step training with the capability element to improve their confidence and skills (beginner, intermediate and advance skills). Pregnant women are encouraged to continue adopt the PFMT throughout pregnancy until postpartum period.~The details of the mHealth app content was developed based on the need assessment gathered from the cross-sectional study (Jaffar et al., 2020). It was conducted to identify the need of PFMT by looking at the prevalence of the UI among pregnant women and to understand their knowledge, attitude, and practices towards PFMT."
46055559|NCT02760303|Behavioral|Diabetes Support and Education|Participants will attend group therapy sessions, once a week for 9 weeks. Participants will receive diabetes education via a support group format. The focus of these sessions will be peer group social support and non-adherence diabetes education topics (e.g., emergency preparedness, smoking and diabetes).
45381472|NCT05866159|Other|Sham taping|sham taping with Rocktape®, with no tension.
45381473|NCT05864755|Drug|HAIC+Durvalumab+Tremelimumab+Bevacizumab|Tremelimumab：300mg, only once in cycle 1.Durvalumab: 1500mg, iv,q3w Bevacizumab: 15mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
45496697|NCT04752761|Behavioral|Extrambulatory digital PROMs detection|An alternative PROMs evaluation method will be used in which the questionnaire will be administered to the patient digitally (Google Forms) in an outpatient environment
45496698|NCT04108091|Drug|Treatment for TTR amyloidosis|The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if not tolerated.
46055560|NCT02765373|Drug|Exemestane|
46055561|NCT02765373|Drug|Letrozole|
46055562|NCT02765373|Drug|Anastrozole|
46055563|NCT02760615|Drug|Caffeine|Caffeine tablets
46055564|NCT02760615|Drug|Losartan|Losartan tablets
45381474|NCT05864404|Drug|remimazolam-remifentanil|In the case of remimazolam, the bolus is prepared in a 30cc syringe by mixing 0.075mg/kg and normal saline to make a total of 25mL. Inject the bolus at a rate of 150 cc/h, and measure the sedation depth every 2 to 3 minutes, stopping the infusion when the target sedation depth (RASS -1 to -2 points) is reached. Remimazolam is then infused at 0.5 to 1 mg/kg/hr to maintain the target depth of sedation until the end of the procedure. Remifentanil was infused at a rate of 1.2-7.2 mcg/kg/h.
46055565|NCT02760615|Drug|Omeprazole|Omeprazole capsules
46055566|NCT02760615|Drug|Dextromethorphan|Dextromethorphan capsules
46055567|NCT02760615|Drug|Midazolam|Midazolam syrup
46055568|NCT02760615|Drug|Vedolizumab|Vedolizumab solution for IV infusion
45496699|NCT04108091|Drug|Treatment for TTR amyloidosis|The usual adult dose is 61 mg of tafamidis orally once daily.
45496700|NCT04853147|Drug|palonosetron, dexamethasone, and fosaprepitant dissolved in 0.9% NaCl|palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, fosaprepitant 150mg dissolved in 0.9% NaCl 150ml, iv.drip,
45496701|NCT04853147|Drug|palonosetron, dexamethasone, and 0.9% NaCl|palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, 0.9% NaCl 150ml, iv.drip,
45496702|NCT03473561|Drug|Racecadotril plus ORS|"1.5 mg/kg of Racecadotril will be administered, 3 times daily, via the oral route (in addition to standard treatment i.e. oral rehydration solution).~In infants less than 9 kg: one 10 mg sachet 3 times daily. In infants from 9 kg to < 13 kg: two 10 mg sachets 3 times daily. In children from 13 kg to 27 kg: one 30 mg sachet 3 times daily. In children of more than 27 kg: two 30 mg sachets 3 times daily."
45694284|NCT01933217|Drug|Methylphenidate|
45694285|NCT01933217|Drug|Placebo|
45381475|NCT05864404|Drug|dexmedetomidine-remifentanil|In the case of dexmedetomidine, the bolus is prepared in a 30cc syringe by mixing 1.0mcg/kg and normal saline to make a total of 25mL. Inject the bolus at a rate of 150 cc/h, and measure the sedation depth every 2 to 3 minutes, stopping the infusion when the target sedation depth (RASS -1 to -2 points) is reached. Dexmedetomidine is then infused at 0.4 to 0.8 mcg/kg/h to maintain the target depth of sedation until the end of the procedure. Remifentanil was infused at a rate of 1.2-7.2 mcg/kg/h.
45381476|NCT05863637|Other|Intensive Short-Term Dynamic Psychotherapy|A dynamic and intensive psychotherapy with eight therapeutic sessions
45381477|NCT05862987|Dietary Supplement|Hydrogen rich water|Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.
45381478|NCT05862987|Dietary Supplement|Placebo|Tap water with molecular hydrogen concentration 0.0 ppm.
45496703|NCT03315689|Drug|Vehicle|Vehicle Topical Solution
45496704|NCT03315689|Drug|ATI-50002|ATI-50002 Topical Solution
46055569|NCT02760459|Drug|Dexamethasone|
45381479|NCT05862454|Drug|Magnesium|Magnesium injection therapy
45381480|NCT05860127|Behavioral|Referral for Cognitive Stimulation Therapy|Physician will review participant eligibility for CST treatment and offer referral based on clinical judgement
45381481|NCT05860127|Other|No change to Standard of Care|Participants will not receive referral from a physician. They will continue with standard of care at their site.
45496705|NCT03436901|Diagnostic Test|MRI with DWI vs CT|MRI with diffusion weighted imaging of thorax, abdomen, and pelvis without contrast agent vs. CT of thorax, abdomen, and pelvis with contrast agent
45496706|NCT03314519|Diagnostic Test|Lung ultrasonography by experienced anaesthesiologist|Use ultrasound image of lung at upper and lower lobe to detect lung collapse and compare grading of lung collapse by surgeon as gold standard
45496707|NCT03314519|Diagnostic Test|Fiberoptic bronchoscopy for double lumen tube's position|Use fiberoptic bronchoscope via double lumen tube to detect optimum position of double lumen tube and record grading of lung collapse by surgeon as gold standard
45496708|NCT04699799|Other|Present odors to participants while recording brain activity|Present odors to participants while recording brain activity
45496709|NCT01856855|Radiation|Stereotactic Body Radiation Therapy with Integrated Boost|SBRT with Integrated boost at 7.25 Gy and 8.00 Gy per fraction for five fractions
45496710|NCT04689347|Drug|Bevacizumab|Bevacizumab 5 mg/kg intravenous infusion every 2 weeks
45496711|NCT04689347|Drug|Irinotecan|irinotecan 165 mg/sqm intravenous infusion every 2 weeks
45694286|NCT01932437|Biological|ETI-204|monoclonal antibody
45694287|NCT01932437|Other|Placebo|Placebo for ETI-204
45694288|NCT01949051|Drug|Levocabastine|Intranasal aqueous 50 mcg microsuspension of levocabastine supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
45694289|NCT01949051|Drug|Placebo|Intranasal aqueous 0 mcg microsuspension supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
45694290|NCT01948193|Biological|Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine|0.5 mL, Intramuscular
45694291|NCT01694485|Biological|Abrilumab|Administered by subcutaneous injection.
45694292|NCT01694485|Drug|Placebo|Placebo matching to abrilumab administered by subcutaneous injection
46055570|NCT02760459|Drug|Normal saline solution|
46055571|NCT02765217|Drug|Lactobacillus reuteri DSM 17938|Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on efficacy.
46055572|NCT02765217|Drug|Placebo|Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on
46055573|NCT02765217|Drug|Amoxicillin-Clavulanic Acid|All study patients will received amoxicillin-clavulanic acid at the dose of 50-90 mg/kg/day.
45496712|NCT04689347|Drug|Leucovorin|leucovorin 200 mg/sqm intravenous infusion every 2 weeks
45496713|NCT04689347|Drug|5Fluorouracil|48-hours continuous intravenous infusion of 5-fluorouracil (5-FU) 3200 mg/sqm every 2 weeks
45496714|NCT04689347|Drug|Temozolomide|Oral temozolomide with progressive dose escalation at inter-patient level over days 1-5 every 28 days. (75 mg/sqm; 100 mg/sqm; 125 mg/sqm or 150 mg/sqm)
45496715|NCT03313037|Biological|Multivalent|Pneumococcal conjugate vaccine
45496716|NCT03313037|Biological|Prevnar 13|Pneumococcal conjugate vaccine
45496717|NCT03313037|Biological|PPSV23|Pneumococcal polysaccharide vaccine
45496718|NCT03313037|Other|Saline|Placebo
45496719|NCT01268579|Drug|ribavirin|The clinical intervention in this study is ribavirin therapy for approximately 14 days. Ribavirin 800 mg/day is administered in divided doses, 400 mg PO qAM and 400 mg PO qPM.
45496720|NCT04685759|Other|In-Person Exercise Protocol|Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes per in-person session.
45496721|NCT04685759|Other|Virtual Exercise Protocol|Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes each virtual session. A TheraBand (resistance band) will be provided to patients in this group to be used for resistance and flexibility training.
45496722|NCT02420795|Drug|Akt/ERK Inhibitor ONC201|Given PO
45694293|NCT01931735|Procedure|Randomized Meniscectomy|Arthroscopic meniscectomy
45694294|NCT01931735|Procedure|Randomized Lavage|Arthroscopic Lavage
45496723|NCT02420795|Other|Laboratory Biomarker Analysis|Correlative studies
45496724|NCT02420795|Other|Pharmacological Study|Correlative studies
45496725|NCT04674995|Procedure|Stent placement|All interventional procedures have been performed in the operating room with a Dumon rigid bronchoscope under general anesthesia. Neodymium-doped yttrium aluminium garnet laser photoresection was performed at 15-30 watts and pulse duration of 0.5-1.0s whenever indicated. A silicone stent was placed.
45496726|NCT02384759|Drug|aflibercept|
45496727|NCT02384759|Drug|LV5FU2|
45496728|NCT03638219|Other|Data collection about eligible patients presented to our department from 2015 to 2018. Then follow up till 2020.|Data collection, follow up and bioscore calculation at the end of study
46055574|NCT02760381|Device|NBI + Acetic Acid (AA)|Patients belonging to the Routine colonoscopy Cohort will receive NBI + Acetic Acid (AA) chromoendoscopy for optical predictions of colonic polyps.
45496729|NCT04634591|Procedure|Bariatric surgery|Bariatric surgery (Roux-en-Y gastric bypass, gastric banding, or sleeve gastrectomy) for the treatment of morbid obesity
45496730|NCT05276843|Combination Product|Qigong exercise program|Qigong is a low-impact, weight-bearing exercise characterized by gentle movements designed to dissipate force throughout the body while the subject changes poses, with well-coordinated sequences of both isometric and isotonic segmental movements in the trunk and 4 extremities.
45496731|NCT05276765|Procedure|cad/cam socket sealing abutment|Anatomically formed healing abutments that can solve many of the problems inherent to immediate posterior implant placement and to optimize the conditioning of supra implant tissue architecture enhancing the emergence profile of the final implant restoration
45496732|NCT05276765|Procedure|standard healing abutment|Standard healing abutment will be inserted after removal of cover screw after immediate implant insertion and then a muco-periosteal flap will be reflected for the primary closure of the socket and sutured around the standard healing abutment.
45496733|NCT03334175|Drug|Walnuts|1 ounce of individually wrapped, raw walnuts to be consumed daily replacing a high-refined carbohydrate food.
45496734|NCT05276687|Drug|Betadine|Wound irrigation
45496735|NCT05276687|Drug|Vancomycin|instillation in the wound
45496736|NCT04616339|Drug|PF-06882961 100 mg|"PF-06882961 100 mg will be provided in 5 different oral formulations A, B, C, D, and E. Cohort 1 is a randomized, open-label, single dose, 4-period, 4-sequence, crossover design where the first 2 periods are cross-over (Formulations A and B) and the second 2 periods are crossover (Formulations C and D).~Cohort 2 is a randomized, open-label, single dose, 2-period, 2 sequence, crossover design (Formulations A and E)"
45496737|NCT03333941|Device|ReCell® Autologous Cell Harvesting Device|RES (Regenerative Epithelial Suspension) derived from the use of the ReCell® device will be applied over skin grafts meshed more widely than conventional autografting.
45694295|NCT01931735|Procedure|Standard of Care Meniscectomy Pre-Amend|Arthroscopic meniscectomy
45694296|NCT01931735|Procedure|Standard of Care Meniscectomy Post-Amend|Arthroscopic meniscectomy
45694297|NCT01930799|Behavioral|Systematic Screening and Education Regimen|Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
45694298|NCT01947491|Drug|DFD01 Spray|
46055575|NCT02760225|Drug|89Zr-Pembrolizumab|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
45496738|NCT02942771|Drug|0.075mg/kg TT301/MW189|0.075 mg/kg IV twice daily on Days 1 through 5
45496739|NCT02942771|Drug|0.15mg/kg TT301MW189|0.15 mg/kg IV twice daily on Days 1 through 5
45496740|NCT02942771|Drug|0.25mg/kg TT301/MW189|0.25 mg/kg IV twice daily on Days 1 through 5
45496741|NCT02942771|Drug|0.30mg/kg TT301/MW189|0.30 mg/kg IV twice daily on Days 1 through 5
45496742|NCT02942771|Drug|Placebo|0.9% sodium chloride
45496743|NCT04705649|Other|Treatment de-escalation|De-escalation from standard treatment based on molecular profile
45496744|NCT05276375|Drug|Bronchipret|Bronchipret syrup (3x 5,4 ml daily) until day 14
45496745|NCT04697771|Other|Fine Motor Skills Training|Fine Motor Skills Training The sessions will be held by considering the fine motor skills training and the criteria of fidelity of the fine motor interventions suggested by Pfeiffer et al. Each goal was enriched with activities and games that improve fine motor skills and handwriting performance.
45496746|NCT05275985|Diagnostic Test|68Ga-FAPI Positron Emission Tomography-Computed Tomography|The patients with suspected pancreatic lesions were included. They underwent 68Ga-FAPI PET/CT to distinguish benign and malignant lesions, to evaluate the resectability of lesions and to detect distant metastasis. The treatment methods were decided according to the results of 68Ga-FAPI PET/CT.
45496747|NCT05275829|Other|Tele simulation|Interactive tele simulation sessions utilising web-based video-conferencing technology (WebEx platform).
45496748|NCT03036150|Drug|Dapagliflozin|10 mg or 5 mg tablets given once daily, per oral use.
45496749|NCT03036150|Drug|Placebo|Placebo matching dapagliflozin 10 mg or 5 mg
45694299|NCT01947491|Drug|Comp01 Lotion|
45694300|NCT01947491|Drug|Vehicle Lotion|
45694301|NCT01947491|Drug|Vehicle Spray|
45496750|NCT03332771|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
45496751|NCT03332771|Drug|Glimepiride|"Pharmaceutical form: capsule~Route of administration: oral"
46055576|NCT02760225|Device|89Zr-Pembrolizumab PET|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
46055577|NCT02764983|Behavioral|Driving Behavior Interview|This will be completed thrice, at baseline, post-test1 and at post-test2
45496752|NCT03332771|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
45496753|NCT03332771|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
46055578|NCT02764983|Behavioral|Fitness-to-Drive Screening Measure|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
45496754|NCT03332771|Drug|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
45496755|NCT03625830|Device|Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
45496756|NCT03625830|Device|rapid exchange PTCA -Balloon Catheter (SeQuent® Neo)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
45496757|NCT04123704|Drug|Sitravatinib|sitravatinib capsule
45496758|NCT04108104|Drug|Cyproheptadine|3-month treatment
45496759|NCT04108104|Drug|Alpress LP|3-month treatment
45496760|NCT05304468|Radiation|IMRT|Patients in experimental group received reduced dose IMRT
45496761|NCT05304468|Drug|induction chemotherapy|cisplatin-based induction chemotherapy for two cycles
45496762|NCT05304468|Drug|cisplatin concurrent chemotherapy|cisplatin 100mg/m2, for two(60Gy) or three cycles(70Gy)
45694302|NCT04638725|Other|Blood sample for genetic analysis|Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study
45694303|NCT04553575|Biological|serology|biological blood samples withdrawn at 6, 12 and 24 months
45694304|NCT01692301|Drug|LCZ696|200 mg tablet
45694305|NCT01692301|Drug|Olmesartan|20 mg and 40 mg capsules
45694306|NCT01692301|Drug|LCZ696 matching placebo|LCZ696 Matching Placebo tablet
45694307|NCT01692301|Drug|Olmesartan matching placebo|Olmesartan matching placebo capsule
45694308|NCT01692301|Drug|amlodipine|amlodipine 2.5 mg or 5 mg tablets
45694309|NCT01692301|Drug|hydrochlorothiazide|hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets
46055579|NCT02764983|Other|Clinical Driving Assessment|Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Strength. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
46055580|NCT02764983|Behavioral|Propensity for Angry Driving Scale|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
45496763|NCT03310775|Behavioral|Parent-assisted social skills training program for young adult with ASD|The subjects will participate in the treatment program weekly for a total of 16 weeks. The final visit will be made at the point four months after the completion of treatment to see long-term effects.
45496764|NCT03619434|Procedure|Femtosecond Laser|The laser will be used to make incisions in the cornea for the graft.
45496765|NCT03619434|Procedure|Trephine blade|A trephine blade will be used to make incisions in the cornea for the graft
45496766|NCT05250102|Device|Pulse oximeter sensors|Pulse oximeter reading will be compared to CO-oximeter reading.
45496767|NCT05275595|Other|Medical records review|"Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, severity of COVID-19 and associated complications, testing methods for SARS-CoV-2 virus and duration of RT-PCR positivity, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5. In patients with nephrotic syndrome, the presence of nephrotic-range proteinuria at evaluation at onset, relapse or following non-response to immunosuppression, was considered as 'relapse'.~The Patients will be followed up until discharge, death or 4weeks after diagnosis of COVID-19, whichever was earlier, until 20 January."
45496768|NCT05275595|Other|Medical records review|Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, associated complications, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5.
45496769|NCT04582799|Device|ECCO2R|Extracorporeal CO2 Removal
45496770|NCT04582799|Device|NIV|Non-invasive ventilation
45496771|NCT05248308|Device|Embozene Microspheres|"Embozene Microspheres are manufactured by Varian Medical Systems (Palo Alto, CA). These microspheres are non-resorbable hydrogel microspheres coated with polyzene-F. Embozene microspheres are approved for use in treating arteriovenous malformations, hypervascular tumors such as uterine fibroids and hepatomas, and prostatic arteries in patients with benign prostatic hyperplasia.~One of the causes of chronic pain in the setting of a knee arthroplasty may be increased blood flow to the specific area(s) of pain. The purpose of this procedure is to reduce blood flow (embolize) to specific parts of the knee which are contributing to your pain.~This procedure is performed by infusing the Embozene particles into specific knee arteries (genicular arteries) in the region of knee pain."
45496772|NCT04236245|Device|Venclose RF System|Treatment of great saphenous vein (GSV) using Venclose RF System
45496773|NCT03330119|Drug|Alternate Management|With the alternate management protocol, the pre-operative order set is the same, with the addition of a single preoperative dose of acetaminophen 1 g IV x1, gabapentin 600 mg PO x1, and ondansetron 8 mg IV x1. Post-operatively, patients receive the same ketorolac 30mg x 9 doses every 6 hours, as well as acetaminophen 975 mg every 6 hours, both given standing. These two are timed so the patient is receiving one of the two medications every 3 hours during their inpatient stay. After 9 doses of ketorolac, the patient receives 600mg of ibuprofen PO, also given standing, instead of the ketorolac. If the patient requires narcotics, they may receive them on an as needed basis. IV fluids are running at 80 cc/ hour. Patients are encouraged to ambulate, including the evening of the surgery, have their foley catheter removed 12 hours post-operatively, and can have a regular diet immediately.
45496774|NCT03330119|Drug|Control|The regular Lankenau cesarean section order set includes routine vital signs, labs, IV fluids, and fetal heart monitoring. Post standard cesarean section orders include IV fluids running at 125 cc/ hour, along with routine post-partum care. In terms of pain control, most patients receive 9 doses of 30mg of IV ketorolac every 6 hours, along with hydromorphone, oxycodone/acetaminophen, or a hydromorphone PCA, per patient or attending request.
45496775|NCT03842969|Drug|RO7234292 (RG6042)|Intrathecal injection
45496776|NCT05123274|Behavioral|Social Support Mobilization|Five main sessions and two booster sessions focused on providing accurate information about HIV medical care, increasing participants' feelings of resilience and self-worth, and mobilizing or creating social supports.
45381482|NCT05859243|Behavioral|Traditional concurrent training|The subjects will perform two sessions per week of traditional concurrent training, consisting of strength training followed by aerobic exercise over 12 weeks, with progressive intensities and training volumes. Each traditional concurrent training session will consist of specific warm-up performed on equipment for upper and lower limbs with a load of less than 30% of the training load. Then the bench press, low row, leg press, extension and knee flexion exercises will be performed. Participants will be instructed to perform the concentric phase of the movement in one second and the eccentric phase in two seconds. After strength training, aerobic training (walking outdoors or on a treadmill) will be performed with intensity based on the adapted BORG effort perception scale (ranged to 0 = minimum effort, to 10 = maximal effort).
45496777|NCT05123274|Behavioral|Individual Care Counseling|Twenty-minute individual counseling session focused on HIV medical care
45496778|NCT04731480|Drug|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
45496779|NCT04731480|Drug|Propofol|The target controlled infusion (TCI) pump will be programmed to marsh model with the target plasma site concentration of 3-µg/ml. The plasma concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
45496780|NCT04731480|Drug|Propofol|The target controlled infusion (TCI) pump will be programmed to Schneider model with the target effect site concentration of 3-µg/ml. The effect-site concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
45496781|NCT04731480|Drug|Propofol|Manual propofol administration will be done using an intravenous infusion pump to maintain a target BIS of 50 during induction and maintenance of anesthesia.
45496782|NCT03040986|Other|Laboratory Biomarker Analysis|Correlative studies
45496783|NCT03040986|Drug|Selumetinib Sulfate|Given by mouth (PO)
45381483|NCT05859243|Behavioral|Concurrent training consisting of strength training combined with dance classes|Each concurrent training session associated with dance classes will consist of the same strength training as the traditional concurrent training group, but the traditional aerobic training will be replaced by a dance class. Each dance class will consist of a 5-minute general warm-up with joint mobility exercises and dynamic stretching. Then the main part will be performed with the elaboration of choreography, lasting approximately 20 minutes. Finally, there will be a 5-minute cool-down with stretching exercises. Classes will be held in four different dance modalities, divided into four modules.
45381484|NCT05858788|Drug|SAR441566|Tablet
45381485|NCT05856981|Drug|ADU-1805|anti-SIRPα monoclonal antibody
45381486|NCT05856981|Drug|Pembrolizumab|Keytruda
45381487|NCT05856357|Drug|Sulfadoxine pyrimethamine|Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
45496784|NCT05261022|Behavioral|Love Together, Parent Together (L2P2)|Love Together Parent Together (L2P2) is a brief, low-intensity relationship intervention intended to improve the interparental relationship for parents of young children.
45496785|NCT03983382|Diagnostic Test|Left Ventricular Ejection Fraction|LVEF assessment at baseline, 6 months, and 12 months
45496786|NCT03936660|Other|Intense Education Intervention|Intervention will involve guideline-based care education.
45496787|NCT03039192|Drug|Esketamine|Intranasal esketamine solution 84 milligram (mg)
45496788|NCT03039192|Other|Placebo|Intranasal Placebo solution
45496789|NCT03039192|Other|Standard of Care|The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
45496790|NCT05222178|Drug|HMI-103|HMI-103 is an AAVHSC15 vector containing a functional copy of the human PAH gene
45496791|NCT05370612|Device|Dexcom G6 CGM|"Dexcom 6 CGM, an FDA approved device. Sensors will be placed on the abdomen per package instruction to collect continuous glucose data.~Experimental Group will wear CGM for the duration of their pregnancy.~Control Group will have CGM data collected for 10 days at enrollment and at 28-32 weeks into their pregnancy."
45496792|NCT05370612|Other|Participant Finger Stick Glucose Monitoring|Standard of care for individual participant
45496793|NCT02428842|Procedure|Tumor biopsies|Tumor biopsies will be performed before and after treatment.
45381488|NCT05854550|Device|Apreo Implant Group|One or two procedures involving placement of up to three Apreo implants in the bronchial tree of each lung.
45381489|NCT05852431|Drug|Pegozafermin|Subcutaneous injection
45381490|NCT05852431|Drug|Placebo|Subcutaneous injection
46055581|NCT02764983|Behavioral|Community Integration Questionnaire|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
45381492|NCT05851183|Drug|Vitis Vinifera seed extract medication plus lifestyle modification|Administer 150mg of Vitis Vinifera seed extract (Entelon®) orally twice a day
45381493|NCT05851183|Behavioral|Lifestyle modification|For lifestyle modifications, it is recommended to avoid sitting or standing for long periods, elevate legs closer to the height of the heart during rest, correct daily habits, and wear compression stockings during daytime hours.
45381494|NCT05851157|Drug|VX-548|Tablets for oral administration.
45381495|NCT05850988|Other|%80 Oxygen concentration|Patients will be administered %80 Oxygen for 3 minutes during preoxygenation.
45381496|NCT05850988|Other|%100 Oxygen concentration|Patients will be administered %100 Oxygen for 3 minutes during preoxygenation.
45381497|NCT05850572|Drug|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10^12 CFU/capsule) in addition to their usual antidepressant treatment. Subjects will continue to receive FMT capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
45381498|NCT05850572|Other|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antidepressant treatment. Placebo capsules contained the food probiotic Lactobacillus (10^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
45381499|NCT05850234|Biological|GC012F|GC012F is a BCMA/CD19 dual CAR product under investigation for the treatment of patients with RRMM.
45381500|NCT05849532|Device|Functional Electrical Stimulation|12-weeks of training sessions that include initial screening and clinical assessment (Week 1-2), onsite training sessions (Week 3-4), home training sessions (Week 4-8). There will also be pre (Week 1), mid (Week 7) and post-training (Week 12) assessment. Each session will consist of a 10-minute warm-up session with 5-6 stretching exercises. Warm-up will be followed by a 30 minute training session comprising of mobility, balance and walking exercises with FES. This will be followed by a cool down session for 10-minutes comprising of 5-6 muscle stretches. The participant will first watch video of the each exercise on the android tablet and then perform the exercises.
45381501|NCT05849454|Device|Messy Memories Intervention|"Messy Memories is a mobile application that allows users to self-administer exposure therapy techniques outside of the traditional psychotherapy context. Participants are asked to recall a difficult (messy) memory, which they can choose to audio record or to document in writing, including what they did, felt, thought, smelled, saw, etc. They are then asked questions about what it was like to re-experience the memory, such as what emotions were elicited (e.g., sadness, anger, fear). Next, participants are asked to process what the memory means to them. They are then instructed to listen to their recording or read their written account of the memory as often as they like, until the memory becomes easier to re-experience. They respond to processing questions each time they listen to or read about their prior difficult memory."
45381502|NCT05849103|Other|Blood Pressure Control Targets|This intervention specifies the goal blood pressure as less than 150/100 versus less than 140/90
45381503|NCT05849103|Other|Hypertension Management|This intervention specifies whether the participant has hypertension management through their obstetric clinician or through a single nurse navigator who provides feedback and modifies hypertension treatment based on blood pressure values submitted by the participant.
45381504|NCT05847985|Device|transcranial direct current stimulation (tDCS)|tDCS using electric currents to modulate underlying neurons
45381505|NCT05847790|Device|Invu monitoring belt|INVU monitoring belt used for remote NSTs
45381506|NCT05847790|Other|Standard of care|In-clinic NSTs - standard of care
45381507|NCT05847673|Behavioral|Online Smoking Cessation Intervention|Receive EQQUAL A intervention
45381508|NCT05847673|Behavioral|Online Smoking Cessation Intervention|Receive EQQUAL B intervention
45381509|NCT05847673|Other|Questionnaire Administration|Ancillary studies
45381510|NCT05847673|Other|Health Promotion and Education|Receive motivational messages and smoking cessation information via SMS text messages
46055582|NCT02764983|Behavioral|Satisfaction with Life Questionnaire|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
46055583|NCT02764983|Procedure|Driving simulator evaluation|The driving simulator evaluation uses a driving simulator with simulated drives engineered to address Veteran driving concerns such as reactions to other drivers and road conditions (e.g., debris). The simulator is used at baseline and post-tests 1 and 2. The intervention sessions (X3) also occur using simulator.
46055584|NCT02764983|Other|Focus Group Discussion Interview Guide|Focus group discussion will occur once using the interview guide
45496794|NCT02428842|Procedure|Blood sampling|Blood sampling will be performed before and after treatment.
45496795|NCT02367690|Drug|Selinexor|Topical gel
45496796|NCT02367690|Other|Standard-of-Care|Surgical debridement, sterile saline rinses, and dressing changes.
45496797|NCT02367690|Other|Vehicle Gel|Topical vehicle gel with no active ingredients.
45496798|NCT03698279|Biological|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
45496799|NCT03698279|Biological|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
45496800|NCT03698279|Biological|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
45496801|NCT03698279|Biological|Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)|Pharmaceutical form: Solution for injection Route of administration: IM
45496802|NCT03698279|Biological|FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)|Pharmaceutical form: Solution for injection Route of administration: IM
45496803|NCT03628950|Procedure|ICSSB group|At supine position with abducted limb, the probe of ultrasound will be translocated in costoclavicular space; the subclavian artery will be identified. The three cords of the brachial plexus will be visualized lateral to the artery. By using an in-plane technique and a cephalad-to-caudate direction, the block needle will be advanced until its tip will be in the middle of three cords and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected. Then at lateral decubitus position, by using in-plane technique the probe will be translocated in suprascapular fossa, lateral-to-medial direction, the block needle will be advanced until its tip in the floor of the suprascapular fossa ventral to the fascia of the supraspinatus muscle and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected .
45496804|NCT03628950|Procedure|ISB group|The probe of ultrasound will be applied in lateral side of the neck at the level of the cricoid cartilage to obtain a view of the three hypoechoic structures which represent the roots of the brachial plexus. Using an in-plane technique and a lateral to-medial direction, the block needle will be advanced until its tip will be positioned under the prevertebral fascia between the two most superficial hypoechoic structures and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected at level of C5-6 and another 10 ml of 0.25 % bupivacaine Hydrochloride will be injected at level of C7-8.
45496805|NCT05275283|Other|PEEP|6 cmH2O of PEEP
45496806|NCT01529034|Drug|USL261|
45496807|NCT05275049|Combination Product|PT plus translingual stimulation device|PoNS device will be used to deliver trans-lingual electrical stimulation. The stimulation will be delivered while the participants engages in evidence-based physiotherapy for walking and balance.
45381511|NCT05846906|Drug|Sildenafil Citrate|oral sildenafil (Respatio® 20mg )
45381512|NCT05846906|Drug|Clomiphene Citrate 50mg|used for ovionulation induct
45496808|NCT05275049|Combination Product|PT plus translingual stimulation control device|Control device will be used. Participants will wear device while engaging in evidence-based physiotherapy for walking and balance.
45381513|NCT05846074|Diagnostic Test|sweat samples and used face mask will be collected|Collection of sweat samples and used face mask will take approximately 15 minutes before or after collection for the SARS-Cov PCR test
45381514|NCT05845320|Other|ICIQ-UI SF questionnaire|validated arabic short form of ICIQ on urinary incontinence
45381515|NCT05844735|Drug|SAR441566|Tablet
45496809|NCT03036072|Other|Strict normothermia|
45496810|NCT03036072|Device|Delayed Rewarming|Use of the servo-controlled cooling blanket for delayed rewarming to target temperature.
45496811|NCT05107362|Diagnostic Test|untrained lay user performs investigational diagnostic test|Untrained lay users (parents/guardians of pediatric subjects or friends/family members of adult subjects) collect throat swab specimens and perform the investigational diagnostic test.
45496812|NCT03619512|Genetic|Whole exome sequencing.|Retrospective biological exploration of the samples, including tumoral DNA exploration.
45694310|NCT01592773|Drug|Memantine Hydrochloride (HCl)|"During the 6-week double-blind dosing titration/maintenance period, Memantine extended-release 3-mg and 6-mg capsules; oral administration. Dosing was once daily.~During open-label treatment: Memantine extended-release 3mg capsules; oral administration. The maximum target dosage was identified during the prior studies for each patient. Dosing was once daily."
45694311|NCT01930175|Drug|VAY736|
46055585|NCT04685967|Device|Glass ionomer|Equia Forte HT, GC, Tokyo, Japan
45381516|NCT05844735|Drug|Placebo|Tablet
45381517|NCT05844735|Drug|Ciprofloxacin|Tablet
45381518|NCT05844462|Drug|Tadalafil|Oral Tadalafil
45381519|NCT05844462|Drug|Placebo|Oral Placebo
45381520|NCT05844111|Drug|[14C]-BGB-11417|A single oral dose of liquid formulation
45381521|NCT05843799|Drug|ILB-202|Single i.v. infusion
45381522|NCT05843799|Drug|Placebo|Single i.v. infusion
45381523|NCT05842460|Behavioral|Nutrient warning labels|Inclusion of nutrient warning labels, which are currently mandatory in Brazil, to images of food products.
45496813|NCT03619512|Genetic|RNA sequencing|Characterization of tumor transcriptomic profile.
45496814|NCT03619512|Other|Mass spectrometry|Characterization of tumor proteomic profiles.
45694312|NCT01930175|Drug|Placebo|
45694313|NCT04124965|Drug|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
45694314|NCT01592695|Drug|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
46055586|NCT04685967|Device|Bulk-fill composite|SonicFill2, Orange, CA, USA
46055587|NCT00744757|Drug|Decitabine|Decitabine 20 mg per m^2 will be administered intravenous infusion over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
46055588|NCT02760147|Device|Pressure Support Over Support|Pressure Support Level upward by 50%, 2 hours
46055589|NCT02760147|Device|Pressure Support Under Support|Pressure Support Level downward by 50%, 2 hours
46055590|NCT02760147|Device|PEEP Over Level|PEEP Level upward by 50%, 2 hours
45496815|NCT03038880|Drug|Faricimab|Faricimab was administered via IVT injections as specified during the treatment period.
45496816|NCT03038880|Drug|Ranibizumab|Ranibizumab was administered via IVT injections as specified during the treatment period.
45496817|NCT03038880|Drug|Sham Procedure|The sham was a procedure that mimicked an IVT injection and involved the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in the faricimab treatments arms at applicable visits to maintain masking among treatment arms.
45496818|NCT01192464|Drug|autologous CAR.CD30 EBV specific-CTLs|Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection.
45496819|NCT05038644|Drug|XmAb18968 - Dose level -1|0.1 mg IV C1D1, 0.3 mg IV C1D2, then 0.4 mg IV on D8, D15, and D22 in a 28-day cycle.
45496820|NCT05038644|Drug|XmAb18968 - Dose level 0 (starting dose)|0.2 mg IV C1D1, 0.6 mg IV C1D2, then 0.8 mg IV on D8, D15, and D22 in a 28-day cycle.
45496821|NCT05038644|Drug|XmAb18968 - Dose level 1|0.25 mg IV C1D1, 0.75 mg IV C1D2, then 1.0 mg IV on D8, D15, and D22 in a 28-day cycle.
45496822|NCT05038644|Drug|XmAb18968 - Dose level 2|0.4 mg IV C1D1, 0.9 mg IV C1D2, then 1.3 mg IV on D8, D15, and D22 in a 28-day cycle.
45381524|NCT05842460|Behavioral|Nutrient and ultraprocessed warning labels|Inclusion of nutrient warning labels, which are currently mandatory in Brazil, and an experimental ultraprocessed warning label to images of food products.
45381525|NCT05841719|Other|Screening test|Capillary blood sampling by finger-prick devices and second confirmatory venous sampling when needed.
45381526|NCT05841485|Diagnostic Test|Assessment of coronary microvascular dysfunction using intracoronary pressure-temperature wire|The primary assessment method in this study is the measurement of coronary microvascular dysfunction using a pressure-temperature wire to determine coronary flow reserve (CFR) and index of microvascular resistance (IMR).
45496823|NCT05038644|Drug|XmAb18968 - Dose level 3|0.5 mg IV C1D1, 1.0 mg IV C1D2, then 1.5 mg IV on D8, D15, and D22 in a 28-day cycle.
45496824|NCT03035916|Other|Transversus abdominis plane block|Participants in this group receive ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia, 30 minutes later the surgery will be started.
45496825|NCT03035916|Other|Epidural anesthesia|Participants in the Epidural group receive a epidural block (T8-9) with 2 mL of 1.6% lidocaine as a test dose before induction. After a successful placement of epidural catheter, the block then is established with 5 mL of 0.375% ropivacaine and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.
45496826|NCT03035916|Other|control|The Control group receives standard IV-inhaled general anesthesia.
45496827|NCT01702571|Drug|Trastuzumab Emtansine|Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenously on Day 1 of a 3-week cycle every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
45496828|NCT05094570|Drug|Dupilumab Prefilled Syringe|Dupilumab 300 mg
45496829|NCT03675516|Other|No specific intervention|Usual care
45496830|NCT01637688|Dietary Supplement|Comparison of treatment with different amino acid formulas|Growth and amino acid status of a newly innovated amino acid formula (NAAF) and a commercial amino acid formula (AAF)
45694315|NCT01592695|Behavioral|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
45496831|NCT05655000|Procedure|Neonatal thymus transplantation|The donor's neonatal thymus vessels will be dissected right after the routinary partial thymectomy. These vessels will be anastomosed into the recipient's penetrating vessels within the radial forearm by using a supermicrosurgical technique. The graft will be explanted at day 14-21 after the procedure.
45496832|NCT04889040|Drug|RO7496998|275 mg tablets
45496833|NCT04889040|Drug|Placebo|Matching tablets
45496834|NCT03606486|Other|Biospecimen Collection|Undergo collection of tumor sample and blood draw
45496835|NCT03606486|Other|Laboratory Biomarker Analysis|Correlative studies
46055591|NCT02760147|Device|PEEP Under Level|PEEP Level downward by 50%, 2 hours
45496836|NCT03606486|Device|Lavage|Undergo uterine lavage
45496837|NCT03606486|Other|Pap Smear|Undergo pap smear
45496838|NCT05655078|Radiation|Proton beam therapy|5 weeks (Mon-Fri) of proton beam treatment to the hemithorax to a dose of 50Gy in 25 fractions with a boost to 60Gy for the visible tumour (gross tumour volume-GTV).
45496839|NCT01632930|Other|urinary PCA3 test using Progensa® PCA3 assay kit (Gen-Probe)|urinary PCA3 test will be performed in patients before they undergo prostate biopsy for increased serum PSA and/or abnormal digital rectal examination. Patients with negative biopsies will be definitively enrolled in the study. The physician in charge will have knowledge of PCA3 test results and will be asked to determine the subsequent follow-up taking these results into account.
45496840|NCT03231943|Drug|GSK3640254|GSK3640254 is a capsule available in 1 milligram (mg), 10 mg and 100 mg dosing strength. GSK3640254 capsule will be given via oral route during each dosing day with approximately 240 mL of water.
45496841|NCT03231943|Drug|Placebo|Placebo capsule matching to the study treatment will be given via oral route during each dosing day with approximately 240 mL of water.
45496842|NCT01578239|Drug|Octreotide LAR|"In the experimental arm, 30 mg Octreotide LAR treatment was given to the participants until the end of study for symptom control purpose, unless the participant progressed or died.~In the active comparator arm, 60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died."
45496843|NCT01578239|Drug|177Lu-DOTA0-Tyr3-Octreotate|Four administrations of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
46055592|NCT02765139|Behavioral|Engaging Men through Accountable Practice|Engaging Men through Accountable Practice aims to engage men as agents of change through structured, weekly discussions with committed groups of men. It aims to address entrenched views of gender roles and identify positive models of masculinity. The approach follows a structured series of discussions designed to explore existing understandings of masculinity and create more positive models of what it means to be a 'good' man, promoting self-reflection and pushing men to analyze and change their own power and privilege. This methodology begins with a series of discussions with women to inform men's dialogue groups, and includes continuous feedback loops with women throughout the process so that the work with men is grounded in, and accountable to, women's views and objectives.
46055593|NCT02765139|Other|Alternative intervention|Control communities will receive an alternative intervention focused on a non-gender topic of 16 weekly sessions for men only.
45381527|NCT05839210|Behavioral|LIFE-L Mediterranean Diet|Mediterranean Diet will include goals of: 4+ vegetable servings (2-4 cups) daily, 2+ fruit servings (1.5-2 cups) daily, 2+ whole grain servings daily, 1+ legume serving daily, 1+ serving nuts and seeds daily, and seafood 2 times per week. Limit or avoid highly processed foods, sugar-sweetened beverages and foods, processed meats, red meat, and alcohol.
45381528|NCT05839210|Behavioral|LIFE-L Home-Based Exercise Program|The Home-Based Exercise Program will include goals of: 150+ minutes moderate or 75+ minutes vigorous exercise per week, completed in sessions of at least 10-minute duration, including daily aerobic exercise plus two resistance-based exercise sessions per week.
45496844|NCT05274893|Drug|SYHX2011 and Abraxane®|IV infusion, 260 mg/m^2
45496845|NCT03231709|Drug|Trelagliptin|Trelagliptin tablets
45496846|NCT03231709|Drug|Alogliptin|Alogliptin tablets
45496847|NCT01220531|Biological|Cultured Thymus Tissue|Potential recipients of cultured thymus tissue are screened for eligibility. The thymus tissue (from an unrelated donor), the donor, and the donor's mother are screened for safety. Cultured thymus tissue is implanted under general anesthesia in the operating room. Cultured thymus tissue is placed into the subject's quadriceps. Two to three months post-implantation, if medically stable, subjects may undergo an allograft biopsy. Subjects undergo laboratory testing for approximately one-year post-implantation. At approximately year 2 post-implantation, subjects are contacted for data collection.
45496848|NCT01220531|Procedure|Blood Draw|
45496849|NCT01220531|Drug|Rabbit anti-thymocyte globulin|Three IV doses of 2 mg/kg RATGAM are given prior to implantation of cultured thymus tissue for immune suppression groups 2, 3, and 4. Each dose is given over 12 hours. RATGAM is usually given on days -5, -4, and -3 prior to implantation of cultured thymus tissue.
45496850|NCT01220531|Drug|Cyclosporine|Csa may be given every 8 or every 12 hours orally or IV before and after implantation of cultured thymus tissue for immune suppression groups 3 and 4. The Csa dose is dependent on T cell numbers and the target CSA trough levels. Csa is weaned as per protocol.
45694316|NCT01592695|Behavioral|Tobacco quit line referral|Participants assigned to this condition will receive a referral to their state tobacco quit line. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
45694317|NCT01592695|Drug|Nicotine replacement therapy - nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
45694318|NCT01592695|Drug|Nicotine replacement therapy - nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
46055594|NCT00917527|Drug|Atorvastatin|Atorvastatin 40mg/D for 6 weeks to improve endothelial dysfunction
45381529|NCT05839210|Behavioral|Supportive Materials|"Participants will receive an informational study notebook, an exercise reference poster and videos, a Fitbit, and three stretch bands of different intensities. Participants will also receive supportive and informational text messages or emails three (3) times per week during the study; participants can opt-out of these messages.~Participants will be requested to utilize the Fitbit app to track exercise sessions, as well as the MyFitnessPal app to track their diet. Support to set up apps will be provided by research staff. For participants who choose not to use the app, a laminated diet and exercise tracking sheet with dry erase marker will be provided, and participants will be advised to send a picture of their completed tracking sheet by text message to research staff each week."
45381530|NCT05838807|Device|Thermal Ultrasound|Participants in this group will receive thermal ultrasound treatment using a gel-coupled ultrasound probe that delivers continuous ultrasound waves at a frequency of 1 Mega Hertz. The ultrasound probe will be moved continuously over the affected wrist and hand region for 5 minutes per session, three times per week, for four weeks. The intensity of the ultrasound wave will be set at 1.0 W/cm2 applied for 5 minutes. The treatment will be administered three times per week, for four weeks.
45381531|NCT05838807|Device|Pulsed Ultrasound|Participants in this group will receive pulsed ultrasound treatment using a gel-coupled ultrasound probe that delivers pulsed ultrasound waves at a frequency of 1 Mega Hertz. The ultrasound probe will be moved continuously over the affected wrist and hand region for 15 minutes with 25% duty cycle and intensity of 1.0 W/cm2.The treatment will be administered three times per week, for four weeks.
45381532|NCT05838807|Device|Combined Ultrasound|Participants in this group will receive a combination of thermal and pulsed ultrasound treatments. The thermal ultrasound treatment will be administered first for 5 minutes, followed by the pulsed ultrasound treatment for another 15 minutes. The same parameters as described above will be used for each treatment modality. The combination treatment will be administered three times per week, for four weeks.
45381533|NCT05838807|Device|Placebo Ultrasound|Participants in this group will receive a placebo ultrasound treatment that looks and feels identical to the active ultrasound treatments, but does not deliver any therapeutic effects. The placebo treatment will be administered using the same gel-coupled ultrasound probe for 15 minutes per session, three times per week, for four weeks, with the intensity set at 0 W/cm² and the temperature maintained at room temperature.
45381534|NCT05838768|Drug|HRO761|Tablet
45381535|NCT05838768|Biological|tislelizumab|Concentrate for solution for infusion
45381536|NCT05838768|Drug|irinotecan|Concentrate for solution for infusion
45381537|NCT05838573|Drug|Metformin|Take metformin 1500mg per day
45381538|NCT05838573|Drug|Placebo|Take placebo 1500mg per day
45381539|NCT05838521|Drug|Sacituzumab govitecan|This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132).
45381540|NCT05838027|Behavioral|Cash Transfer|Participants will receive $125 every 2 weeks for 8 payments via ClinCard, for a total of $1000.
45381541|NCT05837234|Device|ULF SCS|Ultra low frequency spinal cord stimulation
45381542|NCT05835245|Procedure|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
45381543|NCT05835245|Drug|Sintilimab|a PD-1 immune check inhibitor
45381544|NCT05835245|Drug|Lenvatinib|Lenvatinib capsules
45381545|NCT05832658|Device|With EMG-Biofeedback|Once a day for a total of 15 sessions, the Mendelsohn maneuver will be performed for 15 minutes and the effortful swallow maneuver will be performed for 15 minutes with game-based emg-biofeedback.
45381546|NCT05832658|Behavioral|Without EMG-Biofeedback|Once a day for a total of 15 sessions, the Mendelsohn maneuver will be performed for 15 minutes and the effortful swallow maneuver will be performed for 15 minutes with only verbal feedback.
45381547|NCT05832658|Behavioral|Usual Care|Patient and family education will be provided by the investigator. In addition, each patient will be evaluated and oral motor exercises and thermal tactile stimulation will be given to each patient when necessary.
45496851|NCT01220531|Drug|Tacrolimus|If unable to tolerate cyclosporine, then FK506 is given. FK506 may be given every 8 or every 12 hours orally or IV before and after implantation of cultured thymus tissue. FK506 dose is dependent on T cell numbers and the target FK506 trough levels. FK506 is weaned as per protocol.
45496852|NCT01220531|Drug|Methylprednisolone or Prednisolone|Steroids IV or orally may be given before and/or after implantation of cultured thymus tissue. Steroid administration and dosage depends on T cell numbers. Steroids are weaned as per protocol.
45496853|NCT01220531|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) may be given if the T cell count remains elevated 5 days after implantation of cultured thymus tissue. If MMF is given, the dose is 15 mg/kg/dose every 8 hours IV or orally. MMF may be stopped at 35 days or continued for up to six months after implantation of cultured thymus tissue.
45496854|NCT05572099|Diagnostic Test|ExoDx Prostate|Observational only.
46055595|NCT04222179|Device|ultrathın esophagogastroduodenoscope|Place the naso-enteric tube together with the ultrathin esophagogastroduodenoscope from the same nasal cavity
46055596|NCT02597647|Biological|LAIV|Subjects underwent nasal swabs, nasopharyngeal saline wash, and nasal brushings pre, and 1-2 weeks and 4-6 weeks following intranasal administration of LAIV.
46055597|NCT02597647|Other|Saline|Subjects underwent nasal swabs, nasopharyngeal saline wash, and nasal brushings pre, and 1-2 weeks and 4-6 weeks following intranasal administration of saline nasal spray.
46055598|NCT02764905|Behavioral|intensive cognitive physical rehabilitation program|include 2 phases: a) Intensive phase: weekly 4 hour group meeting which will include computerized cognitive training, aerobic, balance and strength exercise and group discussion that will be dedicated to cognitive rehabilitation strategies development and implementation with emphasis on disease management and physical activity as well as psycho-education on various disease management aspects (medical and nutritional) b) a consolidation phase: monthly 2 hour group discussions on challenges of implementation and coping strategies.
46055599|NCT00745849|Drug|esomeprazole|40mg by mouth twice daily
46055600|NCT00745849|Drug|placebo|
45496855|NCT05255471|Drug|Olaparib|Olaparib 300 mg, film-coated tablets, twice daily PO, d1- 28 continuously
45496856|NCT05255471|Drug|Chemotherapy drug|"Platinum-based chemotherapy at the Investigator's choice among the following regimens:~Carboplatin (AUC5) plus Pegylated Liposomal Doxorubicin (PLD) 30mg/m2 on day 1 every 28 days for a maximum of 8 cycles;~Carboplatin (AUC4) plus Gemcitabine 1000mg/m2 on day 1, 8 every 21 days for a maximum of 8 cycles;~Carboplatin (AUC5) plus Paclitaxel (175mg/m2) every 21days for a maximum of 8 cycles"
45496857|NCT03241927|Biological|Pembrolizumab|Day 1 of each 3 week cycle
45496858|NCT03936751|Device|CPAP|This is the standard treatment for OSA.
45496859|NCT03936751|Device|Nasal Strips|Nasal strips were commercially available in the market for supposing treat snoring and sleep apnea but no proof that this is true. Our group previously validated nasal strips as an interesting placebo.
45496860|NCT05571865|Dietary Supplement|Probiotic|Oral administration of a probiotic
45496861|NCT03329885|Drug|BMS-986251|Escalating oral dose
45496862|NCT03329885|Other|Placebo|Escalating oral dose
45496863|NCT05255315|Behavioral|Comparative analysis comparing the morbidity of the antebrachial free flap to that of the temporal flap flap during exenteration as well as the rate of fitting patients with epithesis.|"A retrospective analysis will be performed by comparing the computerized data of patients reconstructed with a free antebrachial flap to that of patients reconstructed with a temporal muscle flap.~Another analysis, this time prospective, will be carried out by comparing the answers to the reconstruction specific questionnaires as well as the POSAS scores of patients reconstructed with either a free antebrachial flap or a temporalis muscle flap."
45496864|NCT04663841|Other|transcranial magnetic stimulation|transcranial magnetic stimulation is delivered as part of routine care and is not managed by this observational study
45694319|NCT01592695|Drug|Bupropion Sustained Release|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
46055601|NCT02759913|Procedure|Lumbar puncture|Collection of biofluids to determine the accuracy, sensitivity and specificity of a diagnostic test developed by Iron Horse Diagnostics
46055602|NCT02764827|Biological|Pollen sensitization|Skin prick test with local and imported Bermuda, Johnson and careless weed allergen extracts at concentration of 10,000, 3,000, 1,000 and 300 AU/mL and measure specific IgE levels
45381550|NCT05832255|Drug|Psilocybin, 1.5 mg|Blister packs will contain five capsules of the study drug, Psilocybin 1.5mg. Subjects will be given blister packs with weekly doses at each visit including baseline (day 1), day 8, day 15, day 21, and day 28. Weekly blister packs will contain five doses (1-2 extra capsules depending on the week) to accommodate for flexibility in scheduling. Unused and open packages will be returned to study staff at each visit after baseline.
45496865|NCT00490763|Behavioral|Survey|7 surveys at the beginning of the study and again every 6 months about diet, coping with the disease, and quality of life.
45496866|NCT02941523|Drug|NOX66|NOX66 administration
45496867|NCT02941523|Drug|Carboplatin|Carboplatin administration
45496868|NCT03666143|Drug|Sitravatinib|120 mg orally once daily in combination with tislelizumab
45496869|NCT03666143|Drug|Tislelizumab|200 mg IV once every 3 weeks
45496870|NCT03609203|Other|10 Weeks of Strength Trailing|"Week 1 (pre training session): self efficacy survey; 5-point frailty assessment*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples"
45694320|NCT01592695|Drug|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
45694321|NCT01592695|Drug|Combination pharmacotherapy - transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
45694322|NCT01592695|Drug|Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
46055603|NCT02599051|Device|Mini-arc|We will place a single incision sling at the time of surgery for stress urinary incontinence
46055604|NCT02599051|Device|Monarc|We will place a transobturator sling at the time of surgery for stress urinary incontinence
46055605|NCT02764671|Biological|10μg/0.5ml recombinant hepatitis B vaccine|5000 participants who are healthy neonates receive 10μg/0.5ml recombinant hepatitis B vaccine on day 0, 30 and 60.
46055606|NCT02759991|Drug|Hecolin|0.6ml Hecolin vaccine im. on day 0, 1 month and 6 months.
46055607|NCT02759991|Drug|Hepa-B|1ml Hepa-B vaccine im. on day 0, 1 month and 6 months.
46055608|NCT04112277|Drug|Cumulative morphine consumption|morphine equivalent [mg] 24 hours after the procedure
46055609|NCT00749203|Drug|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
46055610|NCT00749203|Drug|Ketamine|Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
46055611|NCT02764515|Drug|Kunxian Capsule|Patients in the Kunxian Capsule group will take Kunxian Capsule 0.6gm orally twice daily for 24weeks
46055612|NCT02764515|Drug|Methotrexate|the Methotrexate group will take Methotrexate 10mg orally every week for 24 weeks
45381552|NCT05828654|Behavioral|Focus Group Discussions and Semi-structured Interviews|Community representatives will be asked to participate in either 1:1 semi-structured interviews with a research staff member or to engage in focus group discussions with other community members. These interviews and discussions will gather broad perspectives on resource and training needs for community lay navigators and inform the adaptation of existing Peer Connect training materials
45381553|NCT05828654|Behavioral|Training community lay navigators|Lay navigators identified from among the recruited community representatives will be trained either in-person or virtually by research staff members in motivational interviewing and other strategies to provide psychosocial support to older socially disadvantaged adults with cancer. For community lay navigators and inform the adaptation of existing Peer Connect training materials.
46055613|NCT02598115|Other|Collaborative Pharmaceutical Care|The pharmacist performs collaborative pharmaceutical care in the ward: reconciliation of drug treatments and revision of drug prescriptions indicated on the admission drug prescription. He/she emits pharmaceutical interventions recorded on the standardized support provided by the French Society of Clinical Pharmacy. The pharmaceutical interventions are discussed during a collaborative interview.
46055614|NCT04223271|Diagnostic Test|Indicor|Handheld device with attached PPG sensor that is paired with a tablet to estimate left ventricular end diastolic pressure. Subjects will blow into the device in order to perform a standardized Valsalva maneuver for 10 seconds. The index finger will be resting in the PPG sensor during the test. Each test requires three efforts, with 45 seconds rest between efforts.
45381557|NCT05827276|Other|Life story questionnaire|Participant will receive physical therapy treatment as usual using information from Life Story Questionnaire.
45381558|NCT05826327|Drug|Esketamine|The drug esketamine will be added to the experimental group as opposed to the control group.
45381559|NCT05826327|Drug|Sufentanil|Sufentanil for labour analgesia in the control group
45381560|NCT05823116|Drug|Vancomycin Continuous Infusion|A precision drug dosing platform will be used to determine the empiric dosing regimen and the dosing parameter targeted will be an area-under-the-curve (AUC) of 500 mg⸱hr/L (range 400-600 mg⸱hr/L). The total daily dose is infused over a period of 24 hours.
45381561|NCT05823116|Drug|Vancomycin Intermittent Infusion|A precision drug dosing platform will be used to determine the empiric dosing regimen and the dosing parameter targeted will be an area-under-the-curve (AUC) of 500 mg⸱hr/L (range 400-600 mg⸱hr/L). The dose is infused at rates of 1 gram per hour in every 8, -12, or -24 hour intervals.
45381562|NCT05822635|Device|SpyGlass Discover Digital System or SpyGlass DS Direct Visualization System|Observational, prospective study for the clinical utility of the SpyGlass Discover Digital Catheter and the SpyScope DS Catheter during an intraoperative endoscopy procedure.
45381563|NCT05822219|Behavioral|COVID-19 vaccine and booster training, and importance|COVID-19 vaccine and booster information training
45381564|NCT05821959|Combination Product|AAVAnc80-hOTOF via Akouos Delivery Device|AAVAnc80-hOTOF is a sterile suspension intended to be administered via a one-time unilateral intracochlear administration using the Akouos Delivery Device.
45496871|NCT03609203|Other|Group Nutrition Discussion: week 1, week 5 and week 10|"Week 1 (pre training session): self efficacy survey; 5-point frailty assessment*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples"
45694323|NCT01592695|Drug|Combination pharmacotherapy - transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
45694324|NCT01592695|Behavioral|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
45496872|NCT00360425|Drug|ferumoxytol|
45496873|NCT00360425|Drug|moxifloxacin|
45496874|NCT00360425|Drug|placebo|
45496875|NCT02938585|Drug|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
45381565|NCT05819749|Behavioral|Diabetes Homelessness Medication Support Program in Spanish|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief diabetes education as needed.
45381566|NCT05817721|Drug|Proton pump inhibitor|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis will be divided into a PPI/Non-PPI group depending on if they concomitantly were prescribed a PPI or not
45381567|NCT05817721|Device|LAMS-implantation|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis
46055615|NCT00748969|Drug|Somatropin (DNA origin)|The study starting dose of Nutropin AQ® will be 0.48 mg/kg/week divided into daily SC injections. Nutropin AQ® will be administered by either the subject or, if unable to demonstrate competency in this, then by the guardian. To decrease the risk of increased intracranial hypertension, the dose in the first month of treatment will be decreased by 50% (0.24 mg/kg/week), and then increased to 0.48 mg/kg/week if tolerated well after 1 month.
46055616|NCT02759679|Other|Human breath samples|
46055617|NCT02764749|Dietary Supplement|cranberry (poly)phenol containing supplement|Sustained intake of 9 grams of freeze-dried cranberry powder per day (2x 4.5 grams daily over 1 month). The powder is dissolved in water and administered as a drink.
46055618|NCT02764749|Dietary Supplement|Placebo comparator: cranberry (poly)phenol deprived supplement|Sustained intake (2x 4.5 grams daily over 1 month) of a control supplement dissolved in water
46055619|NCT02759757|Other|Kinesio Taping|This is a tape that can be placed in different parts of the body using different shapes and tensions. In theory, this tape can change muscle activity.
46055620|NCT02759757|Other|Placebo|A micropore tape will be used as placebo
46055621|NCT02764437|Biological|Whole lung antigen challenge, segmental allergen challenge|Whole lung antigen challenge with housedust mite, short ragweed or cat hair allergen extracts. Segmental allergen challenge with housedust mite, short ragweed or cat hair allergen extracts.
45381571|NCT05814991|Drug|Nitroglycerin solution|Controlled hypotension will be induced (intravenous administration of nitroglycerin 2-10 µg/kg/min) 15 minutes prior to the start of mucosal detachment, and will be sustained for the osteotomy stage.
45381572|NCT05814991|Device|monitoring of cerebral oxygen saturation|NIRS-based monitoring of rSO2 has unique advantages: directly or indirectly detecting physiological changes and metabolic processes, it is easy to realize, and involves simple procedures.
45381573|NCT05814367|Drug|Blink® Tears eye drops in a multidose bottle|Control
45381574|NCT05814367|Drug|Preservative-free investigational lubricating eye drops in a Novelia® eyedropper|Test
45381575|NCT05812248|Diagnostic Test|Perioperative cardiac biomarker measurement|High-sensitivity cardiac troponin T is measured within 7 days prior to surgery and at day 1 and day 2 after surgery. N-terminal pro-B-type natriuretic peptide is measured within 7 days before surgery.
45694325|NCT01592695|Behavioral|Behavioral activation for the treatment of depression|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
45694326|NCT01592695|Behavioral|Behavioral management of post-cessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
45694327|NCT01929863|Drug|GSK2330672|GSK2330672 will be supplied as oral solution, and will be administered BID [45 mg (2 days repeat dose) and 90 mg (5 days repeat dose) in each period]
45694328|NCT01929863|Drug|Placebo|GSK2330672 matching placebo will be supplied as oral solution, and will be administered BID (7 days of dosing in each period)
46055622|NCT02759601|Drug|Tefinostat|Tefinostat is a novel type of HDACi used in cancer targeted specifically to cell of monocyte - macrophase lineage
46055623|NCT02764359|Drug|IV vancomycin|IV vancomycin for the treatment of infection. Following the vancomycin loading dose, vancomycin dosing will be at the discretion of the pharmacist and attending physician and will follow standard of care.
46055624|NCT04221867|Procedure|Stricture dilation with CRE balloon|Esophageal stricture is treated by dilation therapy.
46055625|NCT04221867|Procedure|Autologous fat grafting|Autologous fat graft is gathered and injected to stricture
46055626|NCT02759367|Other|High potassium diet|An increase in consumption of high potassium fruits and vegetables
45381581|NCT05809934|Drug|AZD2693|AZD2693 solution SC once per month
45381582|NCT05809934|Other|Placebo|Sodium chloride 0.9% solution SC once per month
45496876|NCT02938585|Drug|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
45496877|NCT00233597|Drug|ferumoxytol or oral iron|
45496878|NCT04727411|Procedure|XEN45 Gel stent|XEN Gel stent implantation either combined or as a stand-alone procedure
45496879|NCT04727411|Procedure|Trabeculectomy|XEN Gel stent implantation either combined or as a stand-alone procedure
45496880|NCT04661267|Dietary Supplement|Stem Cell Support Formula|This liquid supplement contains the following ingredients: chondroitin sulfate, glucosamine sulfate, vitamin C (ascorbic acid), curcumin and Bioperine®, resveratrol, L-carnosine, bitter melon, and vitamin D.
45496881|NCT04661267|Dietary Supplement|Placebo|The placebo comparator will look and taste similar without the active ingredients of the Stem Cell Support Formula.
45496882|NCT05571631|Other|exercise|Arm ergometer will aplied as an aerobic exercise. Combination of balance training and arm ergometer exerise program will applied.
45381583|NCT05809011|Drug|Dexamethasone|After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
45496883|NCT04282811|Drug|Venetoclax|Patients treated with venetoclax-based regimens outside clinical trials in Italy
45496884|NCT05220059|Dietary Supplement|Polyphenol extract|Single dose
45496885|NCT05220059|Dietary Supplement|Placebo|Maltodextrin
45496886|NCT03229759|Drug|Octenidine Dihydrocloride in aqueous solution|application of investigational product
45496887|NCT03229759|Other|Vehicle Control|application of vehicle control
45496888|NCT03229759|Other|Saline Control|application of placebo
46055627|NCT04594707|Drug|PRM-151 (Zinpentraxin Alfa)|"Cohort A: Participants will receive three loading doses of open-label PRM-151 on days 1, 3, and 5, then one infusion every 4 weeks (Q4W). 10 mg/kg of PRM 151 will be administered by intravenous (IV) infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks.~Cohort B: Participants previously randomized to the placebo in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. All three doses will contain PRM-151. Participants previously randomized to the treatment arm in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. One of the three doses will contain PRM-151, whereas two doses will contain placebo."
46055628|NCT02696655|Behavioral|Behavioural intervention|Behavioural intervention administered by healthcare professionals targetting multiple lifestyle behaviours
45381584|NCT05809011|Drug|Prednisone|After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
45496889|NCT05218109|Device|tVNS|transcutaneous vagus nerve stimulation
45496890|NCT05218109|Behavioral|Mindfulness|Brightmind mobile mindfulness application
45496891|NCT05218109|Device|sham tVNS|sham transcutaneous vagus nerve stimulation
45496892|NCT05218109|Other|Number Puzzle|Control number puzzle task delivered via mobile device
45496893|NCT03558191|Drug|SHR-1210|A humanized monoclonal immunoglobulin PD-1 antibody
45496894|NCT03476681|Drug|NEO-201 in combination with pembrolizumab|NEO-201 will be given intravenously every 2 weeks in combination with pembrolizumab. In each cycle subjects will receive 3 doses of NEO 201 and one dose of pembrolizumab.
45381585|NCT05806554|Device|Continuous glucose monitoring device|Continuous glucose monitoring device
45496895|NCT03620825|Other|Dehydration by sauna exposure|Participants repeatedly undergo sauna exposures until they loose 3% of their body weight.
45496896|NCT03620825|Drug|Indomethacin|Participants take indomethacin in tablet form the evening before and the morning of the visit to induce intestinal permeability
45496897|NCT01312649|Behavioral|Experimental psychology methods (computer tests)|
45496898|NCT01312727|Other|Blood and urine sample collections|phenotype and genotype analysis, biological analysis
45496899|NCT03527537|Drug|Insulin|Insulin may be administered base on glucose log values. The dosing of the insulin will be determined by the provider using typical management of gestational diabetes.
45496900|NCT03228433|Drug|TAK-418|TAK-418 Capsule.
45496901|NCT03228433|Drug|TAK-418 Placebo|TAK-418 placebo-matching capsules.
45496902|NCT04463797|Other|Square-stepping exercise|The square-stepping exercise is a low-cost indoor program to improve lower extremities fitness and cognitive function.
45496903|NCT04463797|Other|Stretching and strengthening|whole-body stretching and upper extremity strengthening
45496904|NCT03930121|Other|Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)|Two daily sessions of intensive SLT combined with tDCS of the left primary motor cortex (M1)
45496905|NCT01496118|Drug|panobinostat|Specified dose on specified days
45496906|NCT01496118|Drug|carfilzomib|Specified dose on specified days
45496907|NCT02936869|Behavioral|Performance-based monetary incentives|
45496908|NCT05083884|Other|No Intervention|This is a cross-sectional non-product related survey including peri- and post-menopausal women with moderate to severe VMS associated with menopause.
45496909|NCT04649034|Diagnostic Test|Doppler echocardiogram exam|A complete echocardiographic study will be performed at enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
45496910|NCT04649034|Diagnostic Test|Cardiac magnetic resonance|"A cardiac MR will be acquired within 10 days after the enrollment. The protocol includes the following sequences: cine mode of short axis from LV base to apex and 2-3-4 chambers. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 3 min and 10 min of the administration of a total of 0.2 mmol / kg of Prohance®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ) and sphericity index will be measured."
45496911|NCT04649034|Diagnostic Test|Brain magnetic resonance|A brain MR will be acquired within 10 days after the enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
45496912|NCT04649034|Diagnostic Test|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment.
45496913|NCT04649034|Diagnostic Test|Holter monitoring|At inclusion all patients will carry a Holter device for 24 hours to ensure absence of atrial fibrillation
45496914|NCT03606096|Biological|Boostrix IPV infant acellular Pertussis|mother is randomized to receive Boostrix ® Polio (GSK) and infant acellular pertussis
45496915|NCT03606096|Biological|Boostrix IPV infant whole Pertussis|mother is randomized to receive Boostrix ® Polio (GSK) and infant whole Pertussis
45496916|NCT03606096|Biological|TT infant acellular Pertussis|mother is randomised to receive Tetanus Toxoid and infant acellular Pertussis
45496917|NCT03606096|Biological|TT infant whole Pertussis|mother is randomised to receive Tetanus Toxoid and infant whole Pertussis
45496918|NCT03309605|Drug|ELX-02|ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug
45496919|NCT03309605|Drug|Placebo|Placebo
45381586|NCT05804435|Device|iNod™ System|The iNod™ Ultrasound Imaging System enables visualization of endobronchial lesions, peripheral lung nodules, or lung masses (referred to as lesions) using R-EBUS and performance of lung biopsy under direct R-EBUS visualization.
45381587|NCT05801757|Drug|Remimazolam|Using two different doses of remidazolam for continuous pumping to maintain anesthetic effect
45381588|NCT05801757|Drug|Propofol|propofol 2-3mg/kg/h
45496920|NCT02936635|Drug|tirasemtiv|Oral
45496921|NCT03227029|Biological|RSV ΔNS2/Δ1313/I1314L|10^6 plaque-forming units (PFU); administered as nose drops
45496922|NCT03227029|Biological|RSV 276|10^5 PFU; administered as nose drops
45496923|NCT03227029|Biological|Placebo|Isotonic diluent, administered as nose drops
45496924|NCT04544280|Drug|Xeomin Injectable Product|Intramuscular injection
45496925|NCT05571475|Other|Simulated competition|During a competition, athletes will typically compete for a reward, against opponents and in the presence of others. This will be replicated in the laboratory.
45496926|NCT03487614|Behavioral|Behavior-based parental intervention|Behavioral intervention designed to promote healthy feeding behaviors in parents of 2-5 year olds, and to modify parenting practices in a way that encourages adequate physical activity, sufficient sleep, and healthy nutrition, while limiting sedentary behaviors.
45496927|NCT03551665|Behavioral|Protective step training|Participants will undergo 2 weeks of training, in which they will be exposed to repeated slips on a treadmill. This approach is aimed at improving protective steps.
45496928|NCT05015634|Other|Active Arm|Patient develops possible cardiac symptoms, takes an ECG, BP and oxygen saturation as per their training. Patient will receive a phone call by the trial cardiologist who will have access to a high-quality ECG trace, as well as blood pressure and oxygen saturations, and coupled with the clinical history, can decide on the most appropriate course of further management. With remote follow up over the phone at 3, 6 and 9 months.
45496929|NCT05015634|Other|Control Arm|Standard routine clinical care will be carried out, with remote follow up over the phone at 3, 6 and 9 months.
45381589|NCT05801146|Drug|Botulinum Toxin Type A Injection [HG102]|Single administration, Day 0, 20 units
45381590|NCT05801146|Drug|Botulinum Toxin Type A Injection [Botox]|Single administration, Day 0, 20 units
45381591|NCT05800730|Other|refined carbohydrate breakfast|After wearing CGM on Day 1, participants will be provided with breakfast A once daily on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12. Breakfast A contains white bread (50g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
45496930|NCT05014776|Drug|Tadalafil|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Tadalafil (20 mg) will be administered orally every day on days 3-21 for cycles 1-6.
45496931|NCT05014776|Drug|Pembrolizumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on Day 1 of cycles 1-6.
45381592|NCT05800730|Other|whole grain breakfast|After wearing CGM on Day 1, participants will be provided with Breakfast B once daily on Day 5, Day 6, Day 9, Day 11. Breakfast B contains plain oats (35g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
45381593|NCT05800730|Other|energy-restricted diet|After completing the baseline data and biological sample collection, the ERD group volunteers underwent a 10-day dietary intervention from day 3 to day 12. During this period, a standard breakfast was provided to all volunteers daily by the research staff through the school cafeteria. The ERD group volunteers still had their lunch and dinner provided by the research staff through the school cafeteria to ensure their daily energy intake was controlled between 1200-1500 kcal.
45381594|NCT05800730|Other|time-restricted diet|After completing the baseline data and biological sample collection, the volunteers in the TRD group will undergo a 10-day dietary intervention from day 3 to day 12. The TRD group needs to adjust their breakfast eating time to after 10:00 am daily, and they are free to choose their own lunch and dinner according to their dietary habits but must finish their meals before 4:00 pm. During this time window, no other energy-providing foods should be consumed.
45381595|NCT05800145|Behavioral|Resource information Supplemental Nutrition Assistance Program (SNAP)|Participants randomized to the resource referral arm will receive a tailored list of information about community resources. The list will include information about local emergency food resources (e.g. local food pantries) and government programs to address FI (e.g. SNAP).
45381596|NCT05800145|Behavioral|community health worker (CHW)|Participants randomized to the CHW intervention will have an initial baseline visit scheduled at a mutually convenient location.
45381597|NCT05800145|Behavioral|medically tailored meals|Participants will receive 10 medically tailored meals delivery to their home weekly for 3 months
45381598|NCT05796479|Drug|Amlitelimab DP1|"Injection solution 1~Subcutaneous"
45381599|NCT05796479|Drug|Amlitelimab DP2|"Injection solution 2~Subcutaneous"
45496932|NCT05014776|Drug|Ipilimumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (50mg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
45496933|NCT05014776|Drug|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 [1 × 109 colony forming units (CFU) in 100ml NS] will be administered IV on Day 2 of Cycles 1-6.
45496934|NCT03329573|Drug|Paroxetine IR tablets A|Paroxetine IR tablets A will be the investigational drug. These are film coated tablets with unit dose strength of 20 milligrams (mg) and will be administered via oral route. These tablets will be manufactured in GSKT.
45381600|NCT05795647|Drug|Pentoxifylline+Tocopherol|Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening
45381601|NCT05794399|Drug|Rivaroxaban|"Intervention Group:~The patients in the intervention group will be treated with Rivaroxaban 20 mg once daily with the evening meal in patients with a CrCl >50 mL/min OR 15 mg in cases of moderate-to-severe renal impairment dose with the dosing of once daily with the evening meal in patients with a CrCl ≤50 mL/min. The patient in the intervention group will be requested for follow-up after 3 months of commencing the treatment or whenever the signs and symptoms of bleeding events are noted."
45496935|NCT03329573|Drug|Paroxetine IR tablets B|Paroxetine IR tablets B will be the reference drug. These are film coated tablets with unit dose strength of 20 mg and will be administered via oral route. These tablets will be manufactured in Mississauga.
45496936|NCT00604201|Biological|Umbilical Cord Blood|unrelated umbilical cord blood will be co-infused with haploidentical CD34-selected cells from a related donor for treatment of severe aplastic anemia and myelodysplastic syndrome.
45496937|NCT00492349|Drug|Varenicline|Varenicline 0.5mg po qd x 7 days then titrated to Varenicline 0.5mg po bid x 7 weeks
45496938|NCT00492349|Drug|Placebo|Placebo 0.5mg po qd x 7 days then titrated to Placebo 0.5mg po bid x 7 weeks
45496939|NCT03924193|Drug|Lisdexamfetamine Dimesylate|Participants randomly assigned to this arm will receive 12 weeks of LDX medication.
45496940|NCT03924193|Behavioral|Cognitive-Behavioral Therapy|Participants randomly assigned to this arm will receive 12 weeks of Cognitive-Behavioral Therapy
45496941|NCT03924193|Other|Combination LDX and Cognitive-Behavioral Therapy|Participants randomly assigned to this arm will receive 12 weeks of LDX and Cognitive-Behavioral Therapy
45496942|NCT03308825|Biological|Fluzone Quadrivalent vaccine|0.25 mL, Intramuscular
45496943|NCT03308825|Biological|Fluzone Quadrivalent vaccine|0.5 mL, Intramuscular
45496944|NCT03308825|Biological|Fluzone High-Dose vaccine|0.5 mL, Intramuscular
45496945|NCT03238417|Other|Evidence-Based Quality Improvement|Multilevel research-clinical partnership approach to supporting local strategic planning, priority setting, skill building and engagement in addressing targeted healthcare delivery problems. Launched at participating VA facilities through advance key stakeholder interviews, in-person site visits, data review (e.g., structure and environment of care, gender disparities in quality and patient experience), QI education/training, technical support (e.g., QI project and measures development), additional formative feedback from the evaluation (e.g., provider/survey measure summaries), external and internal practice facilitation, and across-EBQI site collaboration calls. Local leadership, EBQI champions and QI teams develop and implement innovation projects aimed at improving prioritized quality targets related to women Veterans' health and healthcare needs as well as facility-level structural changes needed to improve compliance with VA guidelines.
45496946|NCT04235855|Device|Endoscopic USG guided Liver biopsy|Diagnostic yield with EUS guided liver biopsy - Left lobe Bx vs combined right and left lobe or vs right lobe would be assessed.
45496947|NCT04235855|Device|Percutaneous Liver Biopsy|All liver biopsies done in the Institute as routine procedure by percutaneous route would be compared with the EUS guided biopsy in respect to safety , tissue quality and diagnostic yield .
45496948|NCT05196503|Biological|Treatment|"Experimental product: product derived from autologous blood, obtained after centrifugation.~Treatment modalities: intraoperative periradicular administration of autologous PRF."
45496949|NCT03328325|Biological|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
45496950|NCT03328325|Biological|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
45496951|NCT03476603|Drug|Irbesartan|Patients are tested for their normal prescription irbesartan medication
45496952|NCT03476525|Drug|Fluoxetine|Patients are tested for their normal prescription fluoxetine medication
46055629|NCT04221399|Drug|DWP16001|Tablets, Oral, Once daily, Single dose
45381602|NCT05794399|Drug|Warfarin|"Control Group:~The patients in the control group will be treated with Warfarin. The dose will be started with 5 mg and will be titrated based on the International Normalized Ratio (INR) which will be targeted at the range of 2.0 to 3.0. The dual antiplatelet duration will be based on the latest guidelines. The patients will be asked for frequent INR monitoring on an OPD basis until the INR is within the therapeutic range, after which patients will be asked for monthly follow-up INR reports. The patients in the control group will not be treated with heparin or low molecular weight heparin before the INR is maintained in the therapeutic range."
45381603|NCT05791201|Drug|VX-264|Allogeneic human stem cell-derived islets.
45381604|NCT05790733|Other|Standard intubation|This involves the use of 5% Xylocaine nebulizer spray and a single-use cannula. The nurse checks its expiry date and that the quantity is sufficient to practice the 7 instillations in one nostril and the other 7 in the mouth. A waiting time is respected and the installation of the NGS can begin. She will also set up a fast for 2 hours after this local anesthesia.
45694329|NCT01929863|Drug|Metformin|Metformin 850 mg will be administered BID from Run-in period till Day 7 of period 2
45694330|NCT01918085|Other|Hydrocolloid strip|An adhesive strip made of hydrocolloid adhesive
45694331|NCT01918085|Other|Strata strip|An adhesive strip made of the Strata adhesive
45694332|NCT01714687|Device|balloon sinus dilation|
45694333|NCT01714687|Other|medical therapy|
46055630|NCT04221399|Drug|DWP16001|Tablets, Oral, Once daily, Multiple dose
46055631|NCT02759445|Other|routine treatment|No intervention, only observation and describing
46055632|NCT02764125|Drug|Stalevo|levodopa/carbidopa/entacapone
46055633|NCT02764125|Drug|levodopa MR|levodopa MR/carbidopa/ODM-104
46055634|NCT02764281|Drug|MEDA|"Methotrexate, 3.0g/m2/d iv, day 1~Etoposide, 100mg/m2 iv, day 2 to day 4~Dexamethasone, 40mg/d iv, day 1 to day 4~Pegaspargase, 2500IU/m2/d im, day 4~The MEDA chemotherapy will be repeated every 3 weeks."
46055635|NCT02764281|Procedure|Auto-HSCT|Auto-HSCT will be performed with patients who responded to the initial MEDA chemotherapy with standard BEAM conditioning regimen.
46055636|NCT02764203|Other|Dark Chocolate|50g dark chocolate consumed for a period of 2 weeks
46055637|NCT02764203|Device|Wearable devices|Up to three wearable devices will be worn by the subject to measure parameters such as heart rate, blood pressure and number of steps
46055638|NCT02763969|Drug|BMS-986202|
46055639|NCT02763969|Drug|Placebo|
45496953|NCT04112693|Procedure|Esophageal biopsies during Peroral Endoscopic Myotomy (POEM)|"In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies intended for histopathological analysis will be analyzed in FFOCT before histopathological analysis. The FFOCT analysis take place for the patient inclued after than 10 november 2020.~The biopsies are taken by the gastroenterologist who performs the POEM and is assisted by an endoscopy-specialized nurse."
45496954|NCT03366467|Other|SADE|The SADE: the sensory stimuli addressed are visual and auditory, as follows: (i) Visual sensation. All ceiling fluorescent lighting are removed. The adapted lighting consisted of slow-moving, repetitive visual color effects created by a projector, in the child's visual field. (ii) Auditory stimuli include rhythmic music, which was heard via loudspeakers.
45496955|NCT03366467|Other|RDE|The RDE utilized fluorescent lighting on the ceiling, without special visual effects and without music stimulation.
45496956|NCT05039489|Drug|Antipsychotic drugs|Stable antipsychotic medication 4 weeks before and during the treatment. Chlorpromazine (CPZ) equivalent dosages were calculated for second- and first-generation antipsychotic drugs
45496957|NCT05039489|Device|cTBS（the left temporoparietal cortex as the stimulation target）|Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
45496958|NCT05039489|Device|cTBS （the left cerebellum Crus II as the stimulation target）|Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
45496959|NCT05008289|Device|Magnetic transcutaneous spinal cord stimulation|In the active group, non-invasive spinal cord stimulation will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (thoracic level T2-T3). The intensity of stimulation will represent 100% of the motor threshold, which is determined by abdominal muscle contractions, found from single pulses, gradually applied every 10 seconds until the onset of contractions. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hertz repeated at 5 Hertz. In total 1200 pulses will be applied for 3 minutes and 58 seconds.
45496960|NCT05008289|Device|Transcutaneous electrical nerve stimulation|"To create a sensation of muscle contraction and impression of active stimulation, both the placebo and active groups will be subjected to the sensory effect of transcutaneous electrical neurostimulation (TENS). The surface electrodes of TENS (model Neurodyn®️, Ibramed®️) will be placed in parallel at the height of the thoracic level T2-T3, with the following parameters: 80Hertz, 150ms, approximately at 60 miliampère.~In the placebo group, a coil will be allocated in the thoracic region T2-T3, however this coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, away from its field of view, to provide the idea from the sound stimulus that it is being stimulated."
45496961|NCT04967105|Device|Near-infrared spectroscopy|Before the induction of anesthesia, NIRS sensors were placed on both sides of the flank area that overlies the kidney to monitor renal SO2, whose alteration trends over time during operation will be recorded and evaluated in later analysis.
46055640|NCT02763969|Drug|Interferon alpha-2a recombinant|
46055641|NCT02763969|Drug|Famotidine|
45381605|NCT05790733|Other|Hypnosis|"Hypnosis is a particular psychological state marked by the functioning of the individual at a level of attention other than the ordinary state of consciousness. It can, under certain conditions, give the appearance of sleep or somnambulism without sharing all the characteristics.~As part of the treatment, hypnosis is widely used for pain control. The adverse effects reported are nil. One of its main benefits is improved patient comfort. Another benefit is the reduction of exposure to anesthetic products.~The installation of the NGS with hypnosis will be carried out according to the protocol set out in appendix 4."
45381606|NCT05790486|Behavioral|Take a Break plus Nicotine replacement therapy (NRT) Sampling|"Take a Break is an intervention in which smokers are encouraged to engage in smoking abstinence. The main element, the Break, is a two-week challenge where smokers report days they are smoke-free. The Break is preceded by a 1-week training challenge where Challenge Quizzes (ecological momentary assessments) collect information to guide the smokers during the Break. At baseline, all smokers will be provided NRT lozenges for sampling. At week 1 of the Marathon, our Tobacco Treatment Specialist will call all smokers, assess their experiences and facilitate an abstinence goal."
46055642|NCT02763969|Drug|Ustekinumab|
46055643|NCT02696187|Behavioral|KOLwebben|KOL-webben will be introduced to all people with COPD during their ordinary visits to the primary care center during a 3 months period. The introduction to KOL-webben will be tailored to each person's needs and include 1) registration of the patient at KOL-webben 2) showing and discussing specific content on KOL-webben (e.g. movies with exercises if the person needs exercise training) chosen to meet the needs of the individual 3) giving a card (A5 format) with address to KOL-webben, user information and references to chosen content on KOL-webben. All patients will also receive a pedometer.
46055644|NCT02758977|Procedure|ALPPS|For detailed information please refer to description of experimental arm
45496962|NCT04098497|Behavioral|Mobile intervention|"The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of mania, depression, medication adherence, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments."
45381607|NCT05790486|Behavioral|The Comparison|The comparison group will receive Nicotine Replacement Therapy sampling and will be balanced in all variables except the Take a Break Intervention.
45496963|NCT04045223|Other|Blood samples|Maternal blood will be taken at arrival at the delivery unit and after delivery. Furthermore, placental blood will be taken after delivery.
45496964|NCT04003961|Other|STOP- BANG Questionnaire and Epworth sleepiness scale|STOP- BANG Questionnaire and Epworth sleepiness scale will be filled in maximum 10 minutes
45496965|NCT03986957|Other|No interventions|No interventions - observational study
45496966|NCT04718441|Drug|Lumason|Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.
45496967|NCT03665545|Drug|IMA950/Poly-ICLC|IMA950 mixed with Poly-ICLC administered subcutaneously
45496968|NCT03665545|Drug|IMA950/Poly-ICLC and pembrolizumab|IMA950 mixed with Poly-ICLC administered subcutaneously in combination with pembrolizumab
45496969|NCT03305081|Device|Levonorgestrel IUD, copper IUD, etonorgestrel implant|Long-acting reversible contraception
45496970|NCT04079881|Drug|Insulin|to give pre-prandial and post-prandial insulin (will use patient insulin dose patient use at home) to patients with T1D and evaluate the response of post-prandial glucagon and post-prandial hyperglycemia.
45496971|NCT03891329|Device|Acticor/Rivacor ICDs/CRT-Ds|pre-defined device programming, measurements and follow-up schedule
45496972|NCT03891329|Device|Plexa S DX|Implantation, measurements and follow-up schedule
45496973|NCT03325673|Device|TrueTear|TrueTear Device (Intranasal Tear Neurostimulator) was used intranasally on CL wear days; it was also used on non-CL wear days if the participant chose. The number of applications was determined by participant.
45496974|NCT03325673|Device|TrueTear Sham Control|TrueTear sham device, which is not electrically active and has limited tip insertion depth, was used intranasally on CL wear days; it was also used on non-CL wear days if participant chose. The number of applications was determined by participant.
45496975|NCT03223909|Drug|PRO-087|0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate
45381608|NCT05790486|Other|Community Paramedicine Standard Plus Enhanced Implementation Program|Counties randomized to the enhanced program will receive the standard implementation program plus the following enhancements. We will engage and train local implementation champions. The EMS Implementation Champion will go through the Take a Break Intervention but will not receive NRT sampling. The local implementation champions are internal facilitators with additional knowledge and experience related to the electronic referral process. The champions will also be leaders in their county by trying to improve referrals, remind EMS personnel, and distribute feedback on the performance of the county.
45381609|NCT05790486|Other|Community Paramedicine Standard Implementation Program|In counties randomized to the standard program, we will engage EMS leaders and train local personnel. The training will be applying the Ask-Advise-Refer model and the use of an eRefer tool in EMS situations and conditions. The EMS will then engage smokers in the field or community to use the Ask-Advise-Refer training to submit electronic referrals with the eRefer tool.
45381610|NCT05790473|Diagnostic Test|Artificial Intelligence|Development of AI algorithm for early detection of fetal brain anomalies in the first trimester of pregnancy
45381611|NCT05789563|Other|Hypoxia and Smartwatch model|Breathing mixtures of O2 (14 %, 12 %, 10 %) balanced with N2 and monitoring SpO2 by one of the smartwatch models on left wrist and by pulse oximeter on left index finger.
45496976|NCT03223909|Drug|Systane Ultra|Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.
45381612|NCT05789433|Behavioral|Aerobic exercise|Moderate- to vigorous-intensity aerobic exercise
45381613|NCT05789433|Behavioral|Progressive stretching|Statistic stretching of eight major muscle groups
45381614|NCT05789368|Dietary Supplement|Placebo sachet|consume 1 sachet per day
45381615|NCT05789368|Dietary Supplement|VeCollal sachet|consume 1 sachet per day
45381616|NCT05789368|Dietary Supplement|Collagen sachet|consume 1 sachet per day
45381617|NCT05788510|Other|Pneumococcal vaccine|Investigation of vaccination status, for Pneumococcal vaccine , of patients who received anti-TNF alpha therapy
45381618|NCT05786846|Drug|Iodinated contrast agents|Patients who use iodinated contrast agents clinically
45381619|NCT05783973|Diagnostic Test|Next generation sequencing|Extract DNA from bile，tissue and tissue sample, minimum DNA amount should be over 50ng.
45496977|NCT03223909|Drug|Systane Ultra Preservative Free|Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,
45496978|NCT03733925|Drug|Golimumab|Participants will receive golimumab 50 mg SC injections at Week 0 and q4w thereafter through Week 24.
45496979|NCT03649711|Drug|Ticagrelor 90mg|Ticagrelor Pill
45496980|NCT03649711|Drug|Clopidogrel 75mg|Clopidogrel Pill and a matching placebo to conceal frequency
45496981|NCT03649711|Drug|Aspirin 81 mg|Aspirin Pill
45496982|NCT05181631|Other|Biobanking|"Collection of blood (One tube of blood 4-5 ml + One EDTA tube of blood 5 ml) will be attempted for each participant at baseline. Availability of these samples will be indicated in the e-CRF.~Samples will be collected by hospital staff and stored following regulatory conditions of conservation in CRB of Hospital Avicenne under the responsibility of Pr Marianne ZIOL. "
45496983|NCT03303521|Drug|Placebo|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days."
45496984|NCT03303521|Drug|Sodium Zirconium Cyclosilicate (ZS)|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days."
45496985|NCT03214081|Drug|Vonoprazan|Vonoprazan tablets
45496986|NCT05181397|Drug|Tocilizumab|Participants in tocilizumab group will receive intravenous 8mg/kg tocilizumab.
45496987|NCT02888171|Drug|ferric citrate|Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.
45496988|NCT02888171|Drug|ferrous sulfate|Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.
45496989|NCT02932891|Drug|DSXS topical|topical treatment
45496990|NCT04517903|Other|eye rubbing questionnaire|eye rubbing questionnaire
45496991|NCT05181319|Other|occurrence of bronchopulmonary dysplasia|We observe the incidence of bronchopulmonary dysplasia
45847480|NCT05348148|Drug|Oral Levocetirizine|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
46055645|NCT02758977|Procedure|TWO STAGE HEPATECTOMY|For detailed information please refer to description of active comparator arm
46055646|NCT02759211|Other|Backwards Walking|The Backwards Walking Group will perform backwards walking for the entire treatment intervention.
46055647|NCT02759211|Other|Forwards Walking|The Forwards Walking Group will perform forwards walking for the entire treatment intervention.
45381620|NCT05781035|Procedure|dexmedetomidine|patients will recieve moderate sedation by dexmedetomidine as study group
45496992|NCT03302975|Device|Real-time visual biofeedback during treadmill running|Real-time biofeedback of braking forces during running
45381621|NCT05781035|Procedure|general anesthesia|general anesthesia with neuromuscular blockade under controlled ventilation as control group.
45496993|NCT03212521|Drug|Glecaprevir/Pibrentasvir|Glecaprevir/pibrentasvir 100 mg/40 mg co-formulated tablets taken orally as 3 tablets once a day.
45496994|NCT05181241|Drug|Dimolegin|"Dimolegin (DD217) - enteric coated tablets 10 mg developed by PharmaDiall Ltd (Moscow), manufactured by Federal State Unitary Enterprise Research and Practical Center Pharmaceutical Protection at The Federal Medical Biological Agency (FMBA) of Russia"
45496995|NCT05181163|Diagnostic Test|swab|Swabs from site of infection will be taken
45496996|NCT03212365|Drug|Fixed dose|Participants will receive 40 mg enoxaparin twice daily
45496997|NCT03212365|Drug|Variable dose|Participants will receive 0.5mg/kg enoxaparin twice daily
45496998|NCT03487627|Behavioral|Electronic and Care Support Manager Contact|This intervention will consist of electronic and Care Support Manager (CSM) contacts with parents from the first week following their adolescent's discharge from hospitalization through the first 3 months after discharge. The electronic application content will be accessible and delivered to parents weekly. Parents will also be able to enter a keyword on their electronic device to access content and material in real time. The CSM contacts will supplement the informational content delivered electronically by providing opportunities to ask questions about the electronic application material, and by checking on progress toward treatment follow through for their youth, identifying and problem solving any difficulties and concerns, and addressing health needs of each parent.
45381622|NCT05780203|Behavioral|One session exposure treatment|One session exposure treatment during which patients will be confronted with a height-related situation.
45381623|NCT05780203|Behavioral|Sham Cognitive Bias Modification training|Sham Cognitive Bias Modification training procedure matched in format to active training but adapted to not target height-related, interpretational processing biases.
45496999|NCT03487627|Behavioral|Enhanced Treatment-as-usual (TAU)|TAU typically involves a discharge planning session by unit staff with the adolescent and their parent(s) to discuss safety monitoring and referrals for mental health services following discharge from psychiatric hospitalization. Investigators will augment this usual care by providing written materials to families outlining some of the key considerations for caring for their adolescent. These written materials will include brochures with information for parents following adolescent suicidal behavior, a listing of resources including instructions for when to call 911 or go to the emergency room, and information regarding the National Suicide Prevention Lifeline. Written materials will be provided to both the enhanced TAU participants as well as participants receiving the electronic and CSM intervention.
45497000|NCT03897673|Dietary Supplement|Early Iron|iron syrup for the first three months (84 days) and placebo syrup for the fourth month
45694334|NCT01714609|Drug|Placebo|Placebo Comparator: Placebo
46055648|NCT04660929|Biological|CT-0508|anti-HER2 CAR macrophages
46055649|NCT04660929|Biological|Pembrolizumab|anti-PD antibody
46055650|NCT04223349|Drug|JNJ-70033093|JNJ-70033093 capsules will be administered orally .
46055651|NCT04223349|Drug|Placebo|Matching placebo in capsule will be administered orally.
46055652|NCT02764047|Dietary Supplement|Probiotic|L. acidophilus 10⁹, B. lactis 10⁹
45497001|NCT03897673|Dietary Supplement|Delayed Iron|placebo syrup for the first month (28 days) and iron syrup for the second, third, and fourth months
45497002|NCT05328505|Radiation|Image-guided Radiotherapy|de-escalation radiotherapy to elective volumes + simultaneous integrated boost to PSMA avid lesions delivered in 20 fractions +/- ADT (clinical decision). The elective prostate bed and pelvic lymph node regions will receive 45 Gy. The PSMA-avid lymph node(s) will receive an SIB to 55-60 Gy and/or the PSMA-avid lesion in the prostate bed will receive an SIB to 60 Gy. Pelvic nodal treatment and ADT use will be left to the discretion of the treating physician.
45497003|NCT03273257|Drug|Riociguat|"Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.~Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability."
45497004|NCT03273257|Drug|Placebo|Placebo will be given analogue to riociguat with matching tablets.
45497005|NCT03273257|Procedure|Pulmonary endarterectomy|PEA will be performed at the end of medical treatment (Day 90)
45497006|NCT04316741|Behavioral|Snapcoach|A brief motivational interviewing-based intervention combined with health coaching via social media for 4 weeks
45497007|NCT02700035|Other|Bii-Zin-Da-De-Dah (Listening to One Another)|Bii-Zin-Da-De-Dah (Listening to One Another) is a family-centered alcohol and drug prevention program for Anishinabe communities. It was the first American Indian adaptation of the Iowa Strengthening Families Program (now called the Strengthening Families Program). This program has been developed and adapted in partnership with multiple Anishinabe communities over a span of 13 years. Bii-Zin-Da-De-Dah has been enormously popular in communities. It is currently the center piece of a National Canadian Mental Health Promotion Program funded by the Public Health Agency of Canada. Now in its third Phase, focusing on national scale-up among first nations people, it has been adapted for eight cultures and translated into French in a recent implementation in Canada.
45497008|NCT02553473|Drug|Doxycycline|
45497009|NCT02553473|Drug|Placebo|
45497010|NCT02522507|Behavioral|Empowering youth towards employment|Experimental: Empowering youth towards employment This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
45497011|NCT03637751|Behavioral|Behavioral|Trier Social Stress Test
45497012|NCT03637751|Behavioral|Control condition|In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
45497013|NCT04495673|Device|Transcranial Direct Current Stimulation (tDCS)|Participants receive 10 sessions (2 5-visit blocks of 46 minutes) of active tDCS to DLPFC (dorsolateral prefrontal cortex)
45497014|NCT04495673|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Participants receive 10 sessions (1 5-visit block of 46 minutes of active tDCS and 1 5-visit block of sham tDCS)
45497015|NCT04495673|Behavioral|Cognitive Training|Executive functioning tasks
45381624|NCT05780203|Behavioral|Active Cognitive Bias Modification training|Active Cognitive Bias Modification training targeting height-related, interpretational processing biases.
45381625|NCT05779852|Other|self-hypnosis and dressing|self-hypnosis during dressing
45497016|NCT04270877|Drug|Naltrexone Pill|Treatment with LDN for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
45694335|NCT01714609|Drug|Sorafenib|Sorafenib, 400 mg twice daily
45694336|NCT01929707|Drug|LY3050258|
45694337|NCT01929707|Drug|Placebo|
45694338|NCT01714063|Device|Pressurized Metered-Dose Inhaler|Pressurized Metered-Dose Inhaler
46055653|NCT02763657|Other|fMRI scanning|All participants are scanned while evaluating linear-order and set-inclusion reasoning problems
46055654|NCT02758821|Other|No CRP will be measured onsite|No CRP will be measured onsite
46055655|NCT02758821|Other|CRP cut-off of 20mg/L.|Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever < 20mg/L.
46055656|NCT02758821|Other|CRP cut-off of 40mg/L.|Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever < 40mg/L.
45381626|NCT05779852|Other|dressing|dressing without self-hypnosis
45381627|NCT05774704|Drug|Low curcumin group|One curcumin capsule (250 mg curcumin) after each meal, 3 times a day for 2 weeks.
45381628|NCT05774704|Drug|High curcumin group|One curcumin capsule (500 mg curcumin) after each meal, 3 times a day for 2 weeks.
45381629|NCT05774665|Drug|Omega 3|Omega-3 fatty acid enriched for eicosapentaenoic acid (EPA)
45381630|NCT05774665|Other|Placebo|Placebo consisting of soybean oil (about 54% omega-6 and 6% omega-3, but no EPA or docosahexaenoic acid (DHA)).
45497017|NCT04270877|Drug|Placebo oral tablet|Treatment with LDN-placebo for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
45497018|NCT03271307|Behavioral|Optimized PITC|Providers will receive training on the importance of HIV testing and their role in testing as part of OPD care and morning HIV testing will be offered. Providers will receive job aids on the importance of referring patients for HIV testing, and the study team will conduct regular monitoring and evaluation on PITC implementation.
45497019|NCT03271307|Diagnostic Test|Facility HIVST|HIVST will be carried out in a group setting among patients in the waiting area of OPD clinics. Eligible clients will receive education about HIV testing and a demonstration of how to use and interpret results of a self-test kit will occur in the group setting. Participants will use the HIVST kit in a group setting and will be given private settings (private room or booth) to interpret their results. Participants will disclose their results to their OPD provider if they choose. Routine linkage to confirmatory testing and ART initiation will be conducted.
45497020|NCT03271307|Diagnostic Test|Index HIVST|HIVST demonstration and distribution will be provided to HIV-positive clients in participating facilities to distribute to their partners. Partners who have a reactive HIVST test result, or are unable or unwilling to use HIVST, will be asked to present at the health facility for routine HIV testing. Routine linkage to confirmatory testing and ART initiation will be conducted.
45497021|NCT03271151|Drug|Cymbalta|"Duloxetine (Cymbalta) is a serotonin and norepinephrine dual reuptake inhibitor (SNRI) that is an effective treatment for painful diabetic neuropathy. It is approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain"
45381631|NCT05771480|Biological|Durvalumab|Participants will receive 1500 mg every 3 weeks, or every 4 weeks (in combination with chemotherapy every 3 weeks, or every 2 weeks, respectively) from cycle 1 to cycle 8 of chemotherapy. Upon completion, participants will receive 1500 mg every 4 weeks (as monotherapy)
45497022|NCT03271151|Other|Placebo|Placebo to compare outcomes against Duloxetine
45497023|NCT03245723|Procedure|Pulmonary Function Testing|Subjects will undergo Spirometry and Plethysmography
45497024|NCT03245723|Procedure|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
45497025|NCT03245723|Procedure|Positron Emission Tomography|Subjects will undergo positron emission tomography to detect images of the heart
45497026|NCT03245723|Procedure|Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
45497027|NCT02349971|Device|MR-HIFU|Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) provides precise and controlled delivery of focused ultrasound energy inside a lesion using an external applicator, without the need for a scalpel or needle
45497028|NCT05003921|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
45497029|NCT03301649|Drug|Generic Ivermectin Lotion 0.5%|Topical lotion, generic formulation of the brand product.
45497030|NCT03301649|Drug|Sklice® (Ivermectin) Lotion 0.5%|Topical lotion, brand product.
45497031|NCT03301649|Drug|Vehicle Lotion|Topical lotion, placebo. Has no active ingredient.
45497032|NCT03637439|Other|Ultrasound-guided Percutaneous Neuromodulation|It's a new intervention of sport physiotherapy. It´s an invasive technique. It is necessary an ultrasound
45497033|NCT03637439|Other|Ultrasound-guided Percutaneous Needle|Same protocol without electricity
45497034|NCT04647617|Behavioral|Quantitative weight -bearing and report exercise sign data every weekly|keep their normal live style
45497035|NCT03222973|Drug|BIIB033 (opicinumab)|Administered as specified in the treatment arm
45497036|NCT03222973|Drug|Placebo|Administered as specified in the treatment arm
45381632|NCT05771480|Drug|Gemcitabine monotherapy|Gemcitabine monotherapy as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
45381633|NCT05771480|Drug|Gemcitabine + cisplatin|Gemcitabine plus cisplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab) for WHO/ECOG PS 2 participants only
45694339|NCT01929395|Device|Supine MRI|A limitation of MRI studies of the breast is that MRI exams are performed with the patient prone and the breasts in a pendant position, which is markedly different than the position of the breast when the patient is supine on the Operating Room table. The spatial information the surgeon receives from the prone MRI about the site of the tumor in the breast is hard to mentally translate into the actual site of the tumor in the breast of a supine patient prepared for surgery.
45694340|NCT04124809|Device|laser assisted collapse|Apply 1-2 pulses of laser using the Saturn between 2 adjacent trophectoderm cells away from the inner cell mass in the blastocysts
45694341|NCT04553263|Drug|Contrave 8Mg-90Mg Extended-Release Tablet|Naltrexone HCl/Bupropion HCl is an FDA-approved weight-loss medication with efficacy via the mesolimbic dopamine system to reduce hunger and help control cravings.
45381634|NCT05771480|Drug|Gemcitabine + oxaliplatin|Gemcitabine + oxaliplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
45497037|NCT01144416|Biological|SCH 900962 / Corifollitropin alfa / Org 36286|SCH 900962 will be provided as ready-for-use prefilled syringes containing 150 μg corifollitropin alfa per 0.5 mL. On day 2 or 3 of the menstrual cycle, a single dose of 150 μg corifollitropin alfa will be administered by subcutaneous injection in the abdominal wall in the morning.
45497038|NCT01144416|Biological|RecFSH / follitropin beta|RecFSH will be provided as a ready-for-use solution in 900 IU cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of recFSH will be done in the morning by daily injections in the abdominal wall. A starting dose of 300 IU will be administered and fixed for at least 7 days.
45497039|NCT01144416|Drug|Placebo for SCH 900962|"Supplied as a pre-filled syringe containing an identical solution when~compared to SCH 900962, however without the active ingredient corifollitropin alfa. On Day 2 or 3 of the menstrual cycle (=Stimulation Day 1), a single dose of placebo SCH 900962 is to be administered in the morning by subcutaneous injection in the abdominal wall."
45381635|NCT05771480|Drug|Gemcitabine + carboplatin|Gemcitabine + carboplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
45381636|NCT05771480|Drug|Gemcitabine + cisplatin + S-1|Gemcitabine + cisplatin + S-1 as background gemcitabine-based chemotherapy every 2 weeks (i.e, 4 cycles of durvalumab)
45381637|NCT05771480|Drug|Gemcitabine + S-1|Gemcitabine + S-1 as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
45381638|NCT05771480|Drug|Gemcitabine + cisplatin + albumin-bound paclitaxel|Gemcitabine + cisplatin + albumin-bound paclitaxel as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
45694342|NCT04553263|Drug|Bupropion|Bupropion is FDA-approved and marketed both as an antidepressant agent (Wellbutrin®) and treatment for smoking cessation (Zyban®) and has shown efficacy in reducing symptoms of depression and drug craving in stimulant users. it is also a promising candidate to improve cognition function.
45694343|NCT01713283|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
45694344|NCT01713283|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
46055657|NCT04221711|Device|Repetitive pulsed magnetic stimulation|"OMNITRON ProMed is a rPMS (repetitive peripheral magnetic stimulation) device used for deep stimulation of muscles and/or neurones (outside the brain). The energy is delivered by way of a special round treatment coil, whose cover material is tested for biocompatibility.~The OMNITRON ProMed device produces a high-energy impulse field and stimulates tissue, in particular soft tissue, muscles and neurons, by means of repetitive peripheral magnetic stimulation (rPMS). Short, extremely strong magnetic fields in the microsecond range are emitted non-invasively. OMNITRON ProMed works with short-term energy emission at a peak power of up to 60 million watts and a magnetic field strength of up to 100 milliTesla.~The intensity of treatment can be set between 20 and 100 %. The device automatically adjusts the magnetic field strength and the frequency of the pulses emitted depending on the intensity selected.~For comfortable transport and application the product is compact and portable."
45694345|NCT04768075|Drug|Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody
45694346|NCT04768075|Drug|Placebo|IV infusion Simulator of Camrelizumab
46055658|NCT04221711|Procedure|Eccentric Calf Muscle Training for Achilles Tendinopathy|"Patients will be asked to stand with their full body weight on the injured leg. From an upright body position and standing with all body weight on the forefoot and the ankle joint in plantar flexion, the calf muscle is then loaded by having the patient slowly lower the heel beneath the forefoot. The calf muscle will only be loaded eccentrically, not concentric. Instead, the non-injured leg is used to get back to the start position. The first set of this exercise is performed in an upright position, followed by a second set with the knee bent to 45°. This regimen is performed 2x per day.~The patients are told to go ahead with the exercise even if they experienced pain. However, they are told to stop if the pain becomes disabling."
45694347|NCT04768075|Drug|Cisplatin|IV infusion
45694348|NCT04768075|Drug|Carboplatin|IV infusion
46055659|NCT04221633|Behavioral|Enhancing Early Engagement (E3) webinar|Webinar-based training to provide information regarding evidence-based engagement strategies (e.g., motivational interviewing, McKay's engagement model), trauma, mental health screening, and identifying evidence-based mental health treatments for children.
46055660|NCT04221633|Behavioral|Consultation for E3 training|10 consultation calls with experts in engagement, child trauma, and mental health screening to support the webinar training
46055661|NCT02758743|Drug|Acetium Lozenge|Slow-release L-Cysteine to block smoke.derived acetaldehyde in saliva thereby inhibiting the formation of harmans
45381639|NCT05769777|Drug|Amlitelimab|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous (SC)
45381640|NCT05769322|Device|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
45381644|NCT05765669|Procedure|Percutaneous transiliac - transsacral screw fixation|Surgical intervention in the form of percutaneous transiliac - transsacral screw fixation
45381645|NCT05765669|Other|Pain management and physical therapy|Non-operative management in the form of pain management and physical therapy advanced with weightbearing as tolerated
45694349|NCT04768075|Drug|Pemetrexed|IV infusion
45694350|NCT04768075|Drug|Paclitaxel|IV infusion
45497040|NCT01144416|Drug|Placebo for recFSH|Supplied as identical ready-for-use solution, but without the active ingredient, in cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of placebo-recFSH will be done by daily injections in the abdominal wall in the morning for a period of 7 days.
45497041|NCT00335777|Drug|Migranal nasal spray at 1 hour|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
45497042|NCT00335777|Drug|Migranal nasal spray at 4 hour|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
45497043|NCT04222205|Diagnostic Test|Spontaneous breathing trial (SBT) crossover sequence 1|SBTs with T-piece breathing for one hour during odd-numbered months and SBTs with inspiratory pressure augmentation for one hour during even-numbered months.
45497044|NCT04222205|Diagnostic Test|Spontaneous breathing trial (SBT) crossover sequence 2|SBTs with inspiratory pressure augmentation for one hour during odd-numbered months and SBTs with T-piece breathing for one hour during even-numbered months.
45497045|NCT04424004|Other|COVID-19 PCR and serology testing|"PCR testing: participate will conduct at-home collection and return of self-administered nasal swabs for COVID-19 polymerase chain reaction (PCR) viral testing. Saliva specimens may replace the nasal swab specimen. Specimens will be collected at baseline and every 2 weeks in conjunction with questionnaire administration.~Serology testing: The same randomized participants will also provide a blood sample for serologic testing for SARS-CoV-2 IgG antibodies. Specimens will be collected by routine venipuncture at the MURDOCK Study office in Kannapolis, NC.Specimens for serology will be collected at baseline approximately 1 month after the first questionnaire and 2 weeks after the first nasal swab collection and COVID-19 PCR testing. Specimens for serology will be collected at least bi-monthly and up to monthly thereafter through a total study duration of 6, and up to 12, months."
45497046|NCT03764137|Drug|[89Zr]Panitumumab PET-MRI|All patients entered into the study will have [89Zr]Panitumumab-PET/MRI imaging.
45497047|NCT02889809|Drug|Fluticasone furoate|Fluticasone furoate will be supplied as 50 mcg per blister dry white powder for inhalation using ELLIPTA inhaler.
45497048|NCT02889809|Drug|Placebo|Placebo will be supplied as dry white powder Lactose for inhalation using ELLIPTA inhaler.
45497049|NCT02889809|Drug|Montelukast|Montelukast will be supplied as 4 mg chewable tablet (5 year old subjects) and as 5 mg chewable tablet (>=6 year old subjects)
45497050|NCT02889809|Drug|Short Acting Beta 2 Agonist|Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.
45497051|NCT03625518|Drug|prostaglandins E2|insertion of vaginal PGE2 for up to 30 hours, up to two attempts for cervical ripening and induction
45497052|NCT03625518|Device|intracervical balloon catheter combined with pitocin|insertion of Foley catheter intra cervical and inflating the balloon with 50-60 cc of saline, with IV pitocin according to hospital protocol
45497053|NCT03469297|Device|Brown Glaucoma Implant|The Brown Glaucoma Implant (BGI) is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye. Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma.
45694351|NCT04768075|Drug|Albumin paclitaxel|IV infusion
45694352|NCT01592383|Drug|erlotinib hydrochloride|Given PO
45694353|NCT01691521|Drug|Mepolizumab IV|Mepolizumab 75 mg IV will be administered every 4 weeks with the last dose at Week 28
46055662|NCT02758743|Drug|Placebo|Placebo with no active substance will not have the effect on intervention device.
46055663|NCT02758587|Drug|Defactinib|cross reference with arm/group descriptions
46055664|NCT02758587|Drug|Pembrolizumab|cross reference with arm/group descriptions
45381646|NCT05764954|Device|NovoTTF-200T System|The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week).
45381647|NCT05764642|Drug|Lumason|Ultrasound contrast agent administered intravenously
45381648|NCT05764642|Diagnostic Test|Super-resolution ultrasound imaging|Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.
45381649|NCT05764395|Drug|Rigosertib|Given by mouth
45381650|NCT05764395|Biological|Pembrolizumab|Given by IV
45381651|NCT05764395|Procedure|Magnetic Resonance Imaging|Undergo MRI
45381652|NCT05764395|Procedure|Biospecimen Collection|Undergo blood sample collection
45381653|NCT05764395|Procedure|Biopsy|Undergo tissue biopsy
45381654|NCT05763888|Other|No drug will given|No intervention will be given to the subject
45381655|NCT05763186|Other|Sampling|Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
45694354|NCT01691521|Drug|Mepolizumab SC|Mepolizumab 100 mg SC will be administered every 4 weeks with the last dose at Week 28
46055665|NCT02763891|Other|Intervention group (Body body suspension and tilting exercises)|The body suspension and tilting exercise program (Chordata Method) involved suspending the body in the apparatus while performing tilting exercises. The Chordata apparatus consists of a steel structure with special springs and a harness specifically manufactured for practicing the Chordata Method. During the training sessions, the prescribed exercises emphasize the repetition of movements designed to promote different types of muscle contractions (concentric, eccentric, static) performed in different body positions and joint angles. Thus, when using the method, patients experience maximal functional performance beyond to the body mass centre, activating trunk antagonist muscles and motor memory evocation. Each session lasts 30 minutes.
46055666|NCT02763891|Other|Control group (global muscle stretching)|Subjects receiving submitted a global muscle stretching session twice a week for eight weeks. During this period. All participants are requested to don't engage in any additional type of exercise program or physical activity throughout the study period.
45381656|NCT05763186|Other|Sampling and rinsing|Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
45497054|NCT00972738|Drug|montelukast sodium|Montelukast 10-mg tablet orally once daily at bedtime for 2 weeks.
45497055|NCT00972738|Drug|Comparator: loratadine|Loratadine 10-mg tablet orally once daily at bedtime for 2 weeks.
45497056|NCT00972738|Drug|Comparator: Placebo|placebo tablet orally once daily at bedtime for 2 weeks
45497057|NCT03452839|Drug|Meropenem|Meropenem or injection vials to be re-constituted in a solution of NaCl 0.9%.
45497058|NCT04701281|Combination Product|Intra-arterial LIOX + Capecitabine|5 - 7 LIOX (liver isolation oxaliplatin) intra-arterial infusions over 8 weeks + capecitabine
45497059|NCT05012670|Drug|[14C]-Paxalisib Capsule|Each subject will receive a single dose 15 mg (NMT 3.5 MBq), administered orally in the fasted state with with 240 mL water.
45497060|NCT04313478|Behavioral|Low Birth Weight and Normal Weight infants|This cross-sectional study included LBW and NW infants at between 3 and 9 months of age. The levels of trunk control were investigated by using the Segmental Assessment Trunk Control (SATCo). The Alberta Infant Motor Scale (AIMS) were used for assessment of gross motor performance and identify typical and atypical motor development of infants.
45497061|NCT05180929|Device|Dual M1-tDCS|In the M1- dual tDCS montage, the anodal electrode will be placed above ipsilesional M1 and the cathode will be positioned over contralesional M1.
45497062|NCT05180929|Device|a-tDCS over contralesional PMC|In the anodal-tDCS for PMC, the anodal electrode will be placed over the contralesional PMC. The PMC is defined as being 2.5 cm anterior to the M1. The cathodal electrode will be positioned over the contralateral suborbital region
45497063|NCT05180929|Device|Sham tDCS|For sham stimulation, there is no particular electrode configuration to be followed, thus, 6 participants will receive sham stimulation with the configuration will be used in group A, and 5 participants will receive sham stimulation with the configuration will be used in group B. By pressing the sham button, the current will automatically ramped up over 10 sec. till reaching 1 mA, then it will be decreased gradually over 30 seconds till turning off the apparatus. This is to ensure the typical initial itching sensation
45497064|NCT04249830|Biological|Allogeneic Stem Cell Transplant|The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.
45497065|NCT04249830|Device|CliniMACS TCR α/β Reagent Kit and CliniMACS CD19|The CliniMACS™system can be used to selectively enrich or reduce specific cell populations based on the magnetic cell selection (MACS) technology developed by Miltenyi Biotec. Cell mixtures can be separated in a magnetic field using one or more immunomagnetic- labeled antibodies specific for the cell types of interest (e.g.TCR αβ+ T cells and CD19+ B cells from HPC(A) products).
45497066|NCT03243305|Drug|AMPHORA|non-hormonal contraceptive vaginal gel
45497067|NCT04168632|Other|OPTIMAT|The intervention was to serve a new school lunch menu plan as similar as possible to a baseline menu plan but 40% lower in greenhouse gas emissions, being nutritionally adequate and no more expensive.
45497068|NCT03882918|Drug|OV101|Each subject will be titrated to his or her maximal tolerated daily dose, up to a maximum daily dose of 15 mg at bedtime.
45381657|NCT05758571|Drug|EGCG|EGCG (high pressure liquid chromatographic purity ≥ 95%; from Ningbo Hepu Biotechnology Co., Ltd.) is dissolved in 0.9% normal saline; 10ml is inhaled by atomization three times a day.
45497069|NCT03222583|Drug|Placebo|Matching placebo tablet for oral administration
45497070|NCT03222583|Drug|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
45497071|NCT04907045|Behavioral|Health Coaching|The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.
45497072|NCT04907045|Behavioral|Practice Facilitation|In the context of a supportive relationship, a trained facilitator delivers the following interventions to clinic staff: Bolster Education, Audit and Provide Feedback, Support Plan-Do-Study-Act Cycles, Engage Others in Change.
45497073|NCT04907045|Behavioral|Standard Implementation|Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.
46055667|NCT04634955|Procedure|tranforaminal epidural injection|tranforaminal epidural injection which is performed by fluoroscopic guidance
46055668|NCT02758509|Drug|Pegylated interferon alfa-2a + Ribavirin|
46055669|NCT02758509|Drug|Pegylated interferon alfa-2a + Ribavirin + Boceprevir|
46055670|NCT02758509|Drug|Pegylated interferon alfa-2a + Ribavirin +Telaprevir|
45497074|NCT04188743|Biological|Allogenic FMT|Transplantation of fecal microbiota from a donor into a recipient
45497075|NCT04188743|Biological|Autologous FMT|Transplantation of autologous fecal microbiota
45694355|NCT01691521|Drug|IV Placebo|Normal saline (placebo) will be administered IV every 4 weeks with the last dose at Week 28
45694356|NCT01691521|Drug|SC Placebo|Normal saline (placebo) will be administered SC every 4 weeks with the last dose at Week 28
46055671|NCT02758509|Drug|Ledipasvir/Sofosbuvir|
46055672|NCT02758509|Drug|Ombitasvir/paritaprevir/ritonavir+Dasabuvir|
46055673|NCT02758509|Drug|Daclatasvir+Sofosbuvir|
46055674|NCT02758509|Drug|Simeprevir+Sofosbuvir|
46055675|NCT02763813|Device|Herbst (propulsion type oral appliance)|Oral appliance
45497076|NCT05282329|Device|Transcranial alternating Current Stimulation (tACS)-active|Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. daily tACS sessions were scheduled in a 5-day sequence for four consecutive weeks, and each session lasted 20minutes. Participants were administered 2 mA alternating current delivered with gamma frequency, delivered over the temporal lobe.
46055676|NCT02763813|Device|Retention type appliance (ORM)|
45381662|NCT05757843|Diagnostic Test|Signatera ctDNA test|All subjects will receive consolidation Durvalumab approximately every 4 weeks. Prior to the 5th cycle the first mandatory ctDNA test will be done. If it's negative and the subsequent test 4 weeks later prior to cycle 6 is negative, then Durvalumab will be stopped otherwise subject will continue consolidation durvalumab until 2 negative ctDNA analyses performed approximately 4 weeks apart or up to 1 year of consolidation per standard medical practice is complete.
45497077|NCT05282329|Device|Transcranial Alternating Current Stimulation (tACS)-sham|Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. Controls received sham stimulations with the same protocol.
45497078|NCT01314391|Genetic|mutation analysis|
45381663|NCT05756842|Dietary Supplement|Honey-based gel supplementation|70 g/day of a honey-based gel divided into 2 equal doses of 35 gr (in the morning and evening) for a total duration of 14 days
45497079|NCT01314391|Genetic|polymerase chain reaction|
45381664|NCT05756829|Other|High frequency, low touch virtual health care|Virtual visits between certified diabetes educators and patients occurring every 2 +/- 1 weeks for a total of 6 months
45381665|NCT05756166|Procedure|Biopsy|Undergo tumor biopsy
45381666|NCT05756166|Procedure|Biospecimen Collection|Undergo blood sample collection
45381667|NCT05756166|Drug|Celecoxib|Given PO
45381668|NCT05756166|Procedure|Computed Tomography|Undergo CT scan
45381669|NCT05756166|Biological|Interferon Alpha-2|Given IV
45381670|NCT05756166|Procedure|Magnetic Resonance Imaging|Undergo MRI
45497080|NCT01314391|Other|laboratory biomarker analysis|
46055677|NCT02758353|Drug|Community distribution of SP|SP delivered at both the community and facility level by trained CBHVs in three LGAs.
45381671|NCT05756166|Biological|Pembrolizumab|Given IV
45381672|NCT05756166|Drug|Rintatolimod|Given IV
45497081|NCT04180397|Drug|Furosemide|Furosemide 10 mg/ml for injection/infusion
45497082|NCT04180397|Drug|Isotonic saline|Isotonic saline used as placebo (injection/infusion)
45497083|NCT04540445|Other|Pupillary Assessment|Pupillary assessment with handheld pupillometer
45497084|NCT04174859|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Treatment dose is following the description of physicians.
45497085|NCT04629911|Device|THRIVE|Patients will receive HFNO therapy during laryngomicrosurgery. Patients will undergo a gastric ultrasound examination after HFNO therapy.
45497086|NCT03625674|Behavioral|explanation when prescribing psychoactive medicine|explanation of the pathogenesis of FD and the mechanism of psychoactive medicine
45497087|NCT03295721|Drug|HTX-011|HTX 011 (bupivacaine/meloxicam), 60 mg/1.8 mg by instillation
46055678|NCT04633005|Drug|Polypill|Polypill formulation consisting of metoprolol succinate, empagliflozin, and spironolactone.
46055679|NCT04633005|Drug|Control Rx|Typical prescriptions of guideline-directed therapies for heart failure with reduced ejection fraction.
46055680|NCT00635583|Other|Increased Dairy Consumption|"3 additional servings of dairy (two of which must be milk or yogurt)~8 oz milk~6 oz yogurt~1.5 oz cheese"
46055681|NCT02763423|Procedure|umbilical cord mesenchymal stem cell|allogeneic umbilical cord mesenchymal stem cell transplantation by intravenous injection
46055682|NCT02758275|Behavioral|Teaching: Individual (5606)|"Usual care and Teaching: Individual (5606): It consists of 6 educational sessions:~Behavior Modification (4360) Promotion of a behavior change.~Teaching Disease Process (5602) Assisting the patient to understand information related to a specific disease process.~Teaching: Prescribed Medication (5616) Preparing a patient to safely take prescribed medications and monitor for their effects.~Teaching: Prescribed Diet (5614) Preparing a patient to correctly follow a prescribed diet.~Teaching: Prescribed Exercise (5612) Preparing a patient to achieve and/or maintain a prescribed level of activity.~Coping Enhancement (5230) Assisting a patient to adapt to perceived stressors, changes, or threats that interfere with meeting life demands and roles."
45381673|NCT05755568|Other|No Intervention|As this is an observational study, no intervention will be administered.
45381674|NCT05755399|Device|Brain imaging using transcranial focused ultrasound (tFUS)|All enrolled patients will be imaged using the MRI as standard of care. The patient will additionally be imaged using the tFUS system, ICC HIFU Synthesizer. Total imaging time will be limited to 15 minutes. Following image acquisition by the ultrasound, the standard of care surgery will be performed.
45497088|NCT03295721|Drug|Saline Placebo|Saline placebo by instillation
45497089|NCT03295721|Drug|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 50 mg by injection
45497090|NCT03295721|Device|Luer-lock applicator|Applicator for instillation
45497091|NCT03295721|Device|Vial access device|Device for withdrawal of drug product
45497092|NCT00803790|Drug|alendronate sodium+vitamin D combination|A single dose tablet of 70mg alendronate sodium+5600 IU vitamin D combination tablet in one treatment period of each sequence.
45497093|NCT00803790|Drug|Comparator: alendronate|A single dose tablet of 70mg alendronate in one treatment period of each sequence.
45497094|NCT00803790|Dietary Supplement|Comparator: Vitamin D|Two tablets of 2800 IU vitamin D, totaling 5600 IU, in one treatment period of each sequence.
45497095|NCT03637985|Device|resistive exercise|resistive exercise by elastic band for 12 weeks
45497096|NCT03637985|Device|aerobic exercise in form of treadmill walking|aerobic exercise in form of treadmill walking for 12 weeks
45497097|NCT03568188|Procedure|treatment with focal HIFU|HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
45847481|NCT05348148|Drug|Combined Intranasal Mometasone Furoate with oral Levocetirizine|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
45497098|NCT03568188|Biological|PSA dosage|PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
45847482|NCT05348148|Drug|Combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
45847483|NCT05348070|Procedure|Laparoscopy/Laparotomy|All patients included in the study were operated patients.
45381675|NCT05755152|Other|polyphenol-lecithin precipitate (PLP)|Chewing gum made with material produced from patented technology to rapidly isolate polyphenols from fruit juice (PLP).
45497099|NCT03568188|Device|MRI|MRI exam will be regularly performed during patient follow up.
45497100|NCT03568188|Other|Questionnaires|Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function).
45497101|NCT03568188|Procedure|Prostatic biopsies|Prostatic biopsies will be regularly performed during patient follow up.
45381676|NCT05755152|Other|control formulation|Chewing gum made with material produced from conventional technology (e.g cranberry extract).
45847484|NCT05346120|Biological|allogeneic marrow stromal cells (MSCs)|stem cell infusion
45381677|NCT05755113|Drug|Tigilanol Tiglate|Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
45381678|NCT05753462|Drug|Phase 1, SQY51|SQY51 is administered by intravenous infusion.
45381679|NCT05753462|Drug|Phase 2a, SQY51 (cohort 1)|SQY51 is administered by intravenous infusion at dose 1
45381680|NCT05753462|Drug|Phase 2a, SQY51 (cohort 2)|SQY51 is administered by intravenous infusion at dose 2.
45497102|NCT03568188|Biological|blood test|if the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) will be performed during their follow up.
45497103|NCT03568188|Biological|urine test|if the patient decides to participate in the ancillary study, a urine test (for PCA3 test) will be performed during their follow up.
45497104|NCT00442338|Drug|montelukast sodium|Montelukast 7 mg single injection (IV bolus administration) over 2-3 minutes
45497105|NCT00442338|Drug|montelukast sodium|Montelukast 14 mg single injection (IV bolus administration) over 5 minutes
45497106|NCT00442338|Drug|aminophylline hydrate|Aminophylline 250 mg IV drip infusion over 60 minutes
45497107|NCT03506412|Drug|Entresto™ 49Mg-51 mg tablet|Entresto™ 49Mg-51 mg will be given twice daily orally for 5 weeks
45497108|NCT03420768|Drug|BMS-986263|Administered by intravenous (IV) infusion
45497109|NCT03420768|Other|Placebo|Administered by intravenous (IV) infusion
45497110|NCT03625440|Diagnostic Test|The Digit span test and PASAT with waterpipe smoking|Cognitive tests at baseline and 30minutes after waterpipe smoking
45497111|NCT03625440|Diagnostic Test|The Digit span test and PASAT without waterpipe smoking|The Digit span test and Paced Auditory Serial Addition Test (PASAT) at baseline and 30minutes later
45497112|NCT04964778|Device|SKED©|A SKED device is lightweight plastic stretcher used for moving patients through difficult terrain.
45497113|NCT04961112|Device|Cranial Electrotherapy Stimulation|Participants will receive cranial electrotherapy stimulation stimulation on one of two separate visits (within-subjects).
45497114|NCT04961112|Device|Sham Cranial Electrotherapy Stimulation|Participants will receive sham stimulation on one of two separate visits (within-subjects).
45381681|NCT05753462|Drug|Phase 2a, SQY51 (cohort 3)|SQY51 is administered by intravenous infusion at dose 3.
45381682|NCT05750329|Procedure|assisted liver transplantation combined with two-stage hepatectomy|"Stage 1 Surgery: Left Hepatectomy, Left Lateral Graft Implantation, Portal Shunt to Graft Intermediate stage: continuous monitoring of liver function indexes and liver transplant donor volume after the first stage of surgery. Until the graft size reaches 0.8% of body weight (GBWR), or 35%-45% of the standard liver volume.~Stage 2 Surgery: Residual Right Hepatectomy"
45497115|NCT02316834|Other|Laboratory Biomarker Analysis|Correlative studies
45497116|NCT02316834|Drug|BMN 673|"BMN673 given at a dose of 1 mg orally once daily.~Participants begin taking BMN 673 tablets by mouth every day, starting on the day of scheduled laparoscopy. Participants take the study drug for at least 7 days before scheduled tumor reduction surgery."
45497117|NCT02975934|Drug|Rucaparib|Rucaparib will be administered daily.
45497118|NCT02975934|Drug|Abiraterone acetate or Enzalutamide or Docetaxel|Abiraterone acetate and enzalutamide will be administered daily. Docetaxel will be administered every 3 weeks.
45497119|NCT05059158|Radiation|positron emission tomography (PET)|18-Flutemetamol PET (clinical indicated) is going to be performed at the visit.
45694357|NCT01929317|Drug|Ropinirole CR 2mg tablet|Ropinirole CR 2mg tablets will be supplied as white oval film-coated tablets.
45381683|NCT05746546|Drug|Transdermal Nicotine patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. Participants will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
45381684|NCT05741164|Procedure|Biopsy|Undergo tumor biopsy
45381685|NCT05741164|Procedure|Biospecimen Collection|Undergo blood sample collection
45381686|NCT05741164|Procedure|Computed Tomography|Undergo CT scan
45381687|NCT05741164|Biological|Pembrolizumab|Given IV
45381688|NCT05741164|Drug|Propranolol|Given PO
45381689|NCT05741164|Other|Questionnaire Administration|Ancillary studies
45497120|NCT02879136|Drug|Methylphenidate|Patient will be randomized to Methylphenidate
45497121|NCT02879136|Other|Physical Therapy|All Patients will have standard of care PT used for PD patients
45497122|NCT02879136|Drug|Atomoxetine|Patient will be randomized to Atomoxetine
45497123|NCT00250458|Drug|Comparator: Rizatriptan|One dose Rizatriptan 10 mg orally disintegrating tablet / oral lyophilisate to treat one migraine attack.
45497124|NCT00250458|Drug|Comparator: Placebo|One dose matching placebo to Rizatriptan to treat one migraine attack.
45497125|NCT01965132|Drug|Biologic or targeted synthetic DMARD|
45497126|NCT01667133|Drug|ponatinib - Phase 1|30 mg dose of ponatinib taken orally once daily for at least the first 6 patients. If no dose-limiting toxicities are observed, the next patients will receive 45 mg dose of ponatinib taken orally once daily. Once the recommended dose is confirmed, all patients may receive the recommended dose, at the investigators' discretion.
45497127|NCT01667133|Drug|ponatinib - Phase 2|Recommended dose of ponatinib as determined in the dose escalation phase. In addition, 3 patients will receive 15 mg dose once daily for 8 days for PK testing. These PK patients may be allowed to receive the recommended dose after PK testing is complete, at the investigators' discretion.
45497128|NCT05109741|Behavioral|Internet-based Psychodynamic Therapy|Internet-based Psychodynamic Therapy based on the SUBGAP model developed by Farrell Silverberg
45497129|NCT05109741|Behavioral|Internet-based Behavioral Activation|Internet-based Behavioral Activation based on the BATD-R model developed by Carl Lejuez and others.
45694358|NCT01929317|Drug|Ropinirole CR 8mg tablet|Ropinirole CR 8mg tablets will be supplied as white oval film-coated tablets.
45694359|NCT01929317|Drug|Ropinirole CR matching Placebo tablet|Ropinirole CR matching Placebo tablet tablets (containing no active ingredients) indistinguishable in appearance from Ropinirole CR 2 mg tablets.
45694360|NCT01711879|Drug|Aflibercept|Details covered in arm description
45694361|NCT04546867|Diagnostic Test|Sonographic based visualization of a pancreatic stent|As described above. All patients start with an ultasound-based approach to visualize pancreatic stents position. Depending on the findings, x-ray will be performed if no stent is visualized in the pancreatic duct or an esophagogastroduodenoscopy will be performed to remove the pancreatic stent and confirm sonographic findings if the pancreatic stent is displayed in situ.
45694362|NCT00869206|Drug|zoledronic acid|Given IV
45694363|NCT04625231|Behavioral|Educational Shared-Decision Making Tool|Patients received a short video presentation on pain management, use of over the counter medication, side effects of opioids and over-the-counter medications and ability to choose the amount of opioid pills up to the standard care amount.
45694364|NCT01689649|Drug|Topiramate|The patients will receive topiramate tablet twice daily orally up to 16 weeks.
45381690|NCT05739383|Drug|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL|Subcutaneous injection in pre-filled syringe.
45381691|NCT05739383|Drug|Placebo in 1.5ml|Matching placebo in 1.5ml solution for injection
45694365|NCT01929083|Drug|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
45381692|NCT05736731|Biological|A2B530|Autologous logic-gated Tmod CAR T-cells
45381693|NCT05736731|Diagnostic Test|xT-Onco with HLA-LOH Assay|An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
45847485|NCT05266482|Other|Personal report|In the intervention group, in addition to receiving the usual care, patients will receive personal reports on multiple time points. These reports include feedback on their PROs including reference scores of patients who previously underwent total knee replacement surgery.
45381694|NCT05735262|Device|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
45381695|NCT05735262|Device|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
45381696|NCT05735171|Procedure|GTR surgery|Gross total resection of the enhancing tumor volume
45497130|NCT03947775|Drug|9-valent HPV vaccination|Gardasil-9 is a novel, 9-valent HPV recombinant vaccine, which expands the coverage of oncogenic HPV types, with the addition of HPV types 31, 33, 45, 52, and 58 to the existing quadrivalent vaccine types. The addition of these five oncogenic types is estimated to improve cancer coverage to 90% (versus 70% for the quadrivalent vaccine) [38]. With its expanded coverage of oncogenic HPV types, its proven efficacy in primary prevention and its potential role in mitigating HGAIN recurrences.
45497131|NCT01498770|Drug|Asenapine|Asenapine prescribed as recorded in the CPRD in the UK
45497132|NCT01498770|Drug|Aripiprazole|Aripiprazole prescribed as recorded in the CPRD in the UK
45497133|NCT01498770|Drug|Quetiapine|Quetiapine prescribed as recorded in the CPRD in the UK
45497134|NCT01498770|Drug|Risperidone|Risperidone prescribed as recorded in the CPRD in the UK
45694366|NCT01929083|Drug|Placebo|Subjects will receive oral placebo two capsules once daily every evening for 7 days
45694367|NCT01929083|Drug|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
45694368|NCT01689337|Drug|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 30 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
45694369|NCT01689337|Drug|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
45694370|NCT01689337|Drug|Placebo|Placebo matched to Sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
45694371|NCT04624529|Other|Self evaluation tool|This self-evaluation tool to evaluate cognitive function, developed by the occupational therapy department, is a paperwork task with guidelines for semi-structured interpretation.
45694372|NCT01688635|Drug|LY2963016|Administered subcutaneously
45694373|NCT01688635|Drug|US Approved Lantus|Administered subcutaneously
45694374|NCT04881409|Device|Respiratory support with nasal high-flow (NHF)|Patient with AECOPD is treated with NHF.
45381697|NCT05735171|Procedure|AI-guided surgery|Supramarginal resection including high-risk areas of recurrence
45381700|NCT05733273|Other|Nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
45497135|NCT01498770|Drug|Olanzapine|Olanzapine prescribed as recorded in the CPRD in the UK
45497136|NCT01498770|Drug|Ziprasidone|Ziprasidone prescribed as recorded in the CPRD in the UK
45497137|NCT01498770|Drug|Iloperidone|Iloperidone prescribed as recorded in the CPRD in the UK
45497138|NCT01498770|Drug|Paliperidone|Paliperidone prescribed as recorded in the CPRD in the UK
45497139|NCT01498770|Drug|Lurasidone|Lurasidone prescribed as recorded in the CPRD in the UK
45497140|NCT01498770|Drug|Clozapine|Clozapine prescribed as recorded in the CPRD in the UK
45497141|NCT01498770|Drug|Amisulpride|Amisulpride prescribed as recorded in the CPRD in the UK
45497142|NCT01498770|Drug|Sertindole|Sertindole prescribed as recorded in the CPRD in the UK
45497143|NCT01498770|Drug|Zotepine|Zotepine prescribed as recorded in the CPRD in the UK
45497144|NCT00140946|Drug|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
45497145|NCT00140946|Drug|Comparator: placebo / Duration of Treatment: 16 weeks|
45497146|NCT01267812|Drug|bortezomib|Given SC or IV
45497147|NCT01267812|Biological|rituximab|Given IV
45497148|NCT01267812|Other|laboratory biomarker analysis|Correlative studies
45497149|NCT01267812|Other|immunohistochemistry staining method|Correlative studies
45497150|NCT01267812|Genetic|RNA analysis|Correlative studies
45694375|NCT04881409|Device|Respiratory support with non-invasive ventilation (NIV)|Patient with AECOPD is treated with NIV.
45847486|NCT05264688|Diagnostic Test|68Ga-FAPI-04 imaging agent|1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg) intravenously
45847487|NCT05259930|Other|Amino MP9|Name used by Nualtra for their product of BCAA
45847488|NCT05257590|Drug|Nivolumab Injection [Opdivo]|Nivolumab will be administered at 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting with Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.
45497151|NCT01267812|Genetic|gene expression analysis|Correlative studies
45497152|NCT01267812|Genetic|DNA analysis|Correlative studies
45497153|NCT01267812|Other|pharmacological study|Correlative studies
45497154|NCT01267812|Other|pharmacogenomic studies|Correlative studies
45497155|NCT01267812|Other|Questionnaire Administration|
45497156|NCT00095004|Drug|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
45847489|NCT05257590|Drug|CVM-1118|CVM-1118 will be administered 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects.
45497157|NCT00095004|Drug|Comparator: placebo / Duration of Treatment: 1 day|
45497158|NCT00967746|Drug|Etonogestrel-releasing IUS|Low dose; treatment duration of 6 months with a possible extension to 12 months
45694376|NCT01591681|Device|Pump suspension|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
45694377|NCT04871503|Device|BTL-899 Buttocks|The treatment administration phase in both study groups will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899 will be applied over the gluteal area.
45694378|NCT02986009|Behavioral|Parenting|"The parenting intervention consists of four weekly sessions, each lasting two hours. The intervention was designed according to the parenting characteristics of Chinese parents in Hong Kong. The four sessions cover: 1) response modification (stop and rest), 2) relaxation/enhancing positive moods (relax and play), 3) cognitive reframing (think), and 4) using social support (talk and share). Discussion, practice, and questions are involved in each session."
45694379|NCT02986009|Behavioral|Information|The information intervention consists of four weekly sessions, each lasting for two hours. The contents cover information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China.
45694380|NCT02985931|Other|Diagnostic imaging scans of SPECT and MRI|
45694381|NCT00891436|Drug|Fluticasone furoate nasal spray|2 sprays each nostril every morning for 2 weeks
45694382|NCT00891436|Drug|Placebo nasal spray|2 sprays each nostril every morning for 2 weeks
45694383|NCT01711645|Biological|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate|55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
45381701|NCT05733273|Other|Single leg bridge exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
45381702|NCT05733273|Other|Hamstring razor curl|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
45381704|NCT05729568|Drug|Teropavimab|Administered intravenously
45381705|NCT05729568|Drug|Zinlirvimab|Administered intravenously
45381706|NCT05729568|Drug|Lenacapavir Tablet|Administered orally
45381707|NCT05729568|Drug|Lenacapavir Injection|Administered subcutaneously
45381708|NCT05729568|Drug|Antiretroviral Therapy|Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir alafenamide, dolutegravir/abacavir lamivudine, and rilpivirine/emtricitabine/tenofovir alafenamide.
45381709|NCT05727371|Combination Product|Regen Matrix-PRP-XLHA|Single intra-articular injection at Day 0
45381710|NCT05727371|Device|Hylan G-F 20|Single intra-articular injection at Day 0
45381711|NCT05727371|Drug|Placebo|Single intra-articular injection at Day 0
45381712|NCT05727293|Other|noting|Non intervention
45497159|NCT00967746|Drug|Etonogestrel-releasing IUS|Intermediate dose; treatment duration of 6 months with a possible extension to 12 months
45497160|NCT00967746|Drug|Etonogestrel-releasing IUS|High dose; treatment duration of 6 months with a possible extension to 12 months
45497161|NCT00967746|Device|Multiload-cu 375®|Duration of 6 months with a possible extension to 12 months
45497162|NCT00092118|Drug|Montelukast|one 10 mg tablet, taken once daily at bed time for 6 weeks
45497163|NCT00092118|Drug|Comparator: Placebo|one placebo tablet, taken once daily at bed time for 6 weeks
45497164|NCT00920634|Drug|Follitropin beta|For subcutaneous or intramuscular injection, the usual dosage is 50 IU of follitropin beta (recombinant) once daily for 7 days. The dosage should be adjusted subsequently while monitoring the development of follicles (dose increase by 25 IU every 7 days if the response of the ovaries is poor) and, after confirming presence of follicles of 18 mm or larger in mean diameter by the ultrasonic tomography, ovulation is induced by the administration of a human chorionic gonadotropin preparation.
45497165|NCT05167578|Behavioral|Medication reconciliation|A pharmacist will go through all medicines physicians have prescribed, over-the-counter medicines (OTC) and food supplements one by one to assess the actual medicine used by the patient. If a pharmacist identifies medication discrepancies between physician's prescriptions and patient's self-reported use of medicine during the medication reconciliation, she/he will find out the patients' reasons for adjusting the medication.
45497166|NCT00092040|Drug|MK0217, alendronate sodium/Duration of Intervention: 12 mo|
45497167|NCT00092040|Drug|Comparator: risedronate / Duration of Intervention: 12 mo|
45381713|NCT05726409|Other|Mobile application|Participants will use the meal planner function on the mobile application to plan and cook at least 3 meals a week for 12 weeks.
45497168|NCT04925154|Behavioral|The only intervention will be the information brochure that will be given after the first questionnaire.|The information brochure will be given to both groups at the same time at 2-3 weeks after the first consultation (patients group) or after answering the first questionnaire (physicians group).
45497169|NCT05582928|Device|Neurofeedback|Neurofeedback training during which participant will be asked to change the size of a bar using different strategies to vary the parameters of its current brain's states (neurofeedback training) computed on the realtime EEG signals.
45381714|NCT05725070|Drug|212Pb-NG001|"212Pb-NG001 is a targeted alpha-emitting radiopharmaceutical conjugated to a PSMA targeting peptide.~Patients will receive an initial single 10 MBq dose IV to explore the imaging potential of 212Pb-NG001."
45497170|NCT04051008|Behavioral|Online - use of online grocery shopping platform|The Online intervention will utilize online grocery shopping (shopping at a local grocery store via online platform).
45497171|NCT04051008|Behavioral|Default - use of online grocery shopping platform with default shopping carts|The Defaults intervention, will augment the Online intervention, showing participants a default cart when they log into their online grocery shopping accounts. They will be told that their cart has been filled with items that conform to a diabetic diet and can be used to make the recipes from provided recipe cards, and that they may modify their cart as they like.
45497172|NCT04914780|Behavioral|Education|Education intervention with mobile application for 4 weeks
45694384|NCT04381546|Other|Functional Electrical Stimulation FES|Functional electrical stimulation (FES) is delivered to the quadriceps and hamstrings of the paretic limb in patients with hemiplegia. It is based on the real-time estimation of the knee angle and support phase during gait.
45694385|NCT00820534|Drug|Penciclovir|Penciclovir every 2 hours during waking hours for 96 hours
45694386|NCT00820534|Drug|Placebo|Placebo every 2 hous during waking hours for 96 hours
46055683|NCT02758197|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) course directly following medical treatment optimization. The MBSR course consists of eight weekly 2-hour sessions and one 6 hour session midway through the course and involves psychoeducation, relaxation techniques, gentle stretching (very mild form of yoga), and different forms of meditation. Participants will learn ways to better cope with their pain and the disability and distress related to it with a goal of reducing the stress response that is our body's normal reaction to pain. All sessions will be conducted by a psychologist or social worker with a minimum of 2 years of experience in chronic pain management, formal MBSR training and 2 years of experience leading MBSR groups.
45381715|NCT05719805|Drug|Mavacamten|Specified dose on specified days
46055684|NCT02758041|Device|Sebacia Microparticles|
45497173|NCT05225142|Procedure|Modified minimally invasive surgery|Surgical intervention alone
45381722|NCT05715255|Behavioral|Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C)|Participants randomized to the adaptive intervention are telephoned weekly and asked to enter by pin-pad or voice the severity of the PRO-CTCAE items on a 0-4 scale, with 0 being none and 4 being very severe. Participants are mailed the Symptom Management and Survivorship Handbook in their preferred language (English or Spanish). Survivors who rated any item at moderate or higher (2-4) will be referred by the ATSM to read the corresponding chapters in the Handbook and given a call back in 24 hours to inquire about the severity of the reported symptom, whether it has improved or worsened, and whether the participant reported it to their HCP, or the HCP has contacted the survivor. Participants that report elevated symptoms for two consecutive weeks are rerandomized to continue the ATSM alone or continue the ATSM with TIP-C added for 8 weeks. TIP-C is delivered by a masters prepared counselor with cancer expertise via weekly 30-minute phone calls using interpersonal techniques.
45381723|NCT05715255|Behavioral|Active control comparator|Survivors in the active control will receive weekly AVR assessments of PROCTCAE symptoms, and summary of these assessments will be sent securely to HCPs. Survivors will not receive the Handbook and will not be prompted by the AVR to contact HCPs unless the symptoms are severe.
45497174|NCT05225142|Procedure|Modified minimally invasive surgery with enamel matrix derivative|Surgical intervention with local application of regenerative biomaterial
45497175|NCT05225142|Procedure|Modified minimally invasive surgery with enamel matrix derivative and bone replacement graft|Surgical intervention with local application of regenerative biomaterial and bone replacement graft
45497176|NCT03261947|Drug|TAK-931|TAK-931 hard gelatin capsules
45497177|NCT05654844|Radiation|LC images|Angular and Linear Measurements were compared in mandibular symphysis region using the LC images
45694387|NCT01590433|Drug|Exenatide|Subjects will inject 5mcg of exenatide subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
45694388|NCT01590433|Drug|Placebo|Subjects will inject 5mcg of identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
45694389|NCT01590433|Behavioral|Dietary counseling|All subjects will also receive individualized dietary counseling. Subjects in the placebo group will be counseled to follow a hypocaloric diet.
45497178|NCT05654844|Radiation|CBCT images|Angular and Linear Measurements were compared in mandibular symphysis region using the CBCT images
45497179|NCT05224284|Other|BPA levels|BPA (Bisfenol A) in blood and ejaculate samples
45497180|NCT04906824|Device|great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing|VascuCel implantation in order to perform great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing
45497181|NCT05224128|Drug|Imatinib 200mg|Imatinib have to be taken 200mg/day orally for 24 weeks in a seated position with a meal or a large (at least 250 mL) glass of water
45497182|NCT05224128|Drug|Placebo|Capsules (similar appearance with imatinib) without active substance have to be taken orally for 24 weeks in a seated position with a meal or a large (at least 250 mL) glass of water
45497183|NCT04976946|Other|Comprehensive questionnaire|Multi-staged, international Delphi study that aims to establish criteria for standardised complication reporting in Urology.
45497184|NCT04949880|Device|Neurovascular Drug-Eluting Balloon Dilatation Catheter|The neurovascular drug-eluting balloon dilatation catheter consists of a tip, a drug-coated balloon, markers, a catheter and a catheter hub. The main component of the drug coating is sirolimus, and the coating is evenly distributed on the effective length surface of the balloon.
45497185|NCT04050852|Drug|Nusinersen Treatments|Antisense oligonucleotide, which targets the SMN2 pre-mRNA, particularly exon 7.
45381724|NCT05714306|Biological|PEP-DC1|PEP-DC1 vaccine comprises autologous dendritic cells pulsed with personalized peptides detected or predicted a priori (using our current integrated antigen identification methodologies).
45381725|NCT05714306|Biological|OC-DC|OC-DC vaccine is an autologous dendritic cell vaccine loaded with autologous oxidized tumor lysate.
45497186|NCT05065242|Behavioral|Cognitive Behavioural Therapy|Sleep restriction, Stimulus control, sleep hygiene and cognitive techniques to handle sleep disturbing thoughts.
45694390|NCT00820612|Drug|Indomethacin|100 mg PR once at the time of ERCP
45694391|NCT00820612|Other|Placebo suppositories|2 placebo suppositories at the time of ERCP
45694392|NCT01928927|Drug|Telmisartan|Participants received Telmisartan 40 mg daily during weeks 0-4 followed by telmisartan 80 mg daily during weeks 5-48.
45694393|NCT00871624|Drug|Dexmedetomidine|Dexmedetomidine will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
45694394|NCT00871624|Drug|Placebo|Placebo infusion will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
45694395|NCT05315518|Diagnostic Test|single-shade universal resin composite (omnichroma) with blocker( omnichroma blocker)|(OMNICHROMA BLOCKER) is indicated for preventing shade-matching interference in Class IV restorations, Masking dark dentition and dentin. In cases where there is a lack of tooth structure to bond to, (BLOCKER) works as a supplementary product to provide a lingual wall to the restoration, prevent shade-match obstruction and mask staining.
45381726|NCT05714306|Biological|PEP-DC2|PEP-DC2 comprises autologous dendritic cells pulsed with the peptides detected or predicted after vaccination with OC-DC.
45381727|NCT05714306|Drug|Low dose cyclophosphamide|Cyclophosphamide administered on D1 of each cycle, the day prior to each vaccination (Vx) at a dose of 200 mg/m2 intravenously (i.v.)
45497187|NCT04051086|Biological|Physical examination and Urine and blood samples|"Only one visit for each participant : A large majority of visits will be part of patients' usual care~Medical examination : birth, weight, gender, blood pressure, medical history~Urine and blood samples"
45497188|NCT04051086|Biological|Urine and blood samples|"Only one visit for each participant~Medical history~Urine and blood samples"
45497189|NCT05223660|Drug|Low dose KT07|A single dose of 4 capsules, followed by multiple doses on Days 8-12
45497190|NCT05223660|Drug|High dose KT07|A single dose of 6 capsules, followed by multiple doses on Days 8-12
45497191|NCT05223660|Drug|Low dose Placebo|A single dose of 4 capsules, followed by multiple doses on Days 8-12
45497192|NCT05223660|Drug|High dose Placebo|A single dose of 6 capsules, followed by multiple doses on Days 8-12
45497193|NCT03590730|Device|ICD implantation|ICD will be implanted according to current guidelines recommendations.
45497194|NCT05518968|Behavioral|Acceptance and commitment therapy|8 weekly coach-guided videoconferencing sessions and the use of a web app based on acceptance and commitment therapy
45497195|NCT03625206|Behavioral|Cognitive bias modification training|These training sessions aim to modify a selective attention bias towards threat and a tendency to interpret ambiguous situations in threatening ways
45497196|NCT03625206|Behavioral|Control training|These exercises are matched to the task demands of the modules of cognitive bias modification training
45497197|NCT04896918|Behavioral|Tobacco use|
45497198|NCT05223426|Other|Cognitive training|A cognitive training program will be individually developed for each participant based on baseline neuropsychological tests. It will include: Computerized cognitive training: this training include: the Dual-Task, the Stroop and the N-Back task. The tasks are accompanied by feedback based on the participant's responses (e.g., progress graph, feedback, etc.). In order to promote participants' learning, the level of difficulty of the tasks increased as training sessions progressed. Two sets of stimuli will be used to maximize the generalization of learning. Memory training: This training is adapted from the MEMO+ training program (Belleville et al., 2018). These sessions, also home-based, will be done through online video and are covering a variety of topics: memory (normal aging, mnemonic strategies), attention, aging, etc. Each week, participants will be asked to complete the equivalent of 6 training sessions of 15 minutes each, for a total of 1h30 per week.
45381728|NCT05713955|Device|Obsidian|To create OBSiDiAN BioMatrix, 120 ml of the the patient's blood is added to the processing unit. The Vivostat® processor unit heats, separates, centrifugates to get the plasma. Batroxobin is added. After again processing, the result is an OBSiDian syringe filled with BioMatrix Obsidian®ASG. This will be applied on the anastomosis
46055685|NCT02763501|Procedure|closure of mesenteric defects|Closure of mesenteric defects by use of non-absorbable running sutures in RCT; and according to the choice of the surgeon in the non-RCT
46055686|NCT02763501|Procedure|non-closure of mesenteric defects|Mesenteric defects are left open
46055687|NCT02763345|Device|Supporting LIFE electronic Community Case Management|The SL eCCM App is smartphone application developed to run on Android operating systems 3.0 Honeycomb and above. The SL eCCM App represents an electronic format of the WHO and UNICEFs paper-based CCM clinical decision rule, currently adopted as national policy in Malawi for assessing children presenting to village clinics with acute illness.The App includes a tap-sensitive breath counter for measuring breathing rate.
46055688|NCT02763345|Other|Standard care|
45381735|NCT05708066|Other|Lavender Aromatherapy|"Participants will have the Bioesse lavender patch placed on the chest, according to manufacturer recommendations.~After the lavender patch has been in place for 5 minutes, the same VAS anxiety questionnaire will be provided"
45381736|NCT05708066|Other|Non-scented Tab|A non-scented tab will be placed on the participant's chest, according to manufacturer recommendations. Participants in this group will only receive the initial VAS anxiety questionnaire.
45381737|NCT05706259|Dietary Supplement|Soft gelatin 200000 IU vitamin D3 capsule|Weekly single dose for 3-weeks
45381738|NCT05706259|Dietary Supplement|Orodispersible (sachet) 200000 IU vitamin D3|Weekly single dose for 3-weeks
45497199|NCT05223426|Other|Usual Care|Participants will be asked to continue the care and follow-up as usually planned with the attending cardiologist. Apart from weekly follow-ups with the research team member, no changes will be made to the participant's medical care.
45497200|NCT04897776|Device|Central Thalamic Stimulation|Stimulation of the bilateral thalamic CL is a promising approach in human patients to improve conscious arousal. To restore conscious arousal by stimulation of the thalamic intralaminar CL it is necessary to provide bilateral stimulation, placing one lead in each thalamus. Bilateral thalamic CL stimulation was shown previously to improve human conscious arousal and is based on existing research in patients with disorders of consciousness.
45497201|NCT04897776|Device|Hippocampal Stimulation|The hippocampus has been a target for brain stimulation for seizure reduction in epilepsy. While the efficacy of HC stimulation varies considerably among different studies, the surgical procedure and therapeutic electrical stimulation are well tolerated by patients, with few peri-operative complications being reported, and histopathologic analysis not revealing a difference between stimulated and non-stimulated hippocampal tissue (Han et al. 2014)
45497202|NCT04886856|Behavioral|Mindful Moms|Twelve 75 minutes weekly group sessions involving gentle yoga practices designed for pregnant women, led by experienced yoga teachers.
45497203|NCT04886856|Behavioral|Prenatal Education|Twelve 75 minutes weekly group sessions involving prenatal education (for example, what to expect during your pregnancy, during labor and delivery, and after the delivery of your child).
45381739|NCT05704374|Diagnostic Test|sympathetic stimulation maneuver (mental arithmetic test, cold pressure test)|Mental arithmetic calculation and cold pressure increase sympathetic tone. For the mental arithmetic task, the subject is asked to mentally subtract a two-digit number from a four-digit number and respond within 5 seconds. This arithmetic calculation is repeated for different numbers. This test is continued for three minutes. For the cold pressure test, subjects are asked to immerse their right hand in 2-4 degrees cold water up to the elbow and hold it in the water for three minutes. The mental arithmetic task and cold stress test will be applied simultaneously.
45381740|NCT05704374|Drug|Pregabalin 150mg|In the second phase of the experiment, 150 mg (single dose) of pregabalin will be given to FMS patients to reduce sympathetic activity and evaluate its effect on T- and H-reflexes.
45381741|NCT05704192|Procedure|TACE ± Systemic therapy|TACE: conventional TACE (cTACE) or drug-eluting beads TACE (dTACE); Systemic therapy: programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors, vascular endothelial growth factor -tyrosine kinase inhibitor (VEGF-TKI)/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.
45381742|NCT05704166|Drug|Pirfenidone/Placebo|Patients were given drugs orally one week before radiotherapy, 200mg/ time, 3 times a day in the first week; 300mg/ time 3 times daily for the second week and 400mg/ time 3 times daily for the third to eighth week. Take it after a meal.
45381743|NCT05703750|Procedure|TACE ± Systemic therapy|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE); Systemic therapy: PD-1/PD-L1 inhibitors, VEGF-TKI/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.
45497204|NCT04852848|Behavioral|Connect2Test Intervention|Brief assessment based feedback and motivational interviewing intervention
45381744|NCT05703724|Device|AI algorithm for the detection of glaucoma|The investigational device that will be used during this study is an AI algorithm embedded into an API for the detection of glaucoma developed by MONA.health
45381747|NCT05701709|Drug|SHR-A2102|SHR-A2102 was given intravenously. Patients may continue to use SHR-A2102 until disease progression or unacceptable toxicity occurs.
45497205|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|5 mg orally once daily for 20 weeks
45497206|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|10 mg orally once daily for 20 weeks
45497207|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|20 mg orally once daily for 20 weeks
45497208|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|30 mg orally once daily for 20 weeks
45497209|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|40 mg orally once daily for 20 weeks
45497210|NCT03098979|Drug|Placebo|Orally once daily for 20 weeks
45497211|NCT03625362|Dietary Supplement|Hydrogen|Hydrogen-rich water
45497212|NCT03625362|Dietary Supplement|Placebo|Tap water
45497213|NCT03625596|Dietary Supplement|L-Arginine|Acute intervention (3 hours)
45497214|NCT03625596|Dietary Supplement|Nitrate / Nitrite|Acute intervention (3 hours)
45497215|NCT03625596|Dietary Supplement|Placebo|Acute intervention (3 hours)
45497216|NCT04802304|Other|Beyond Bias Treatment|The intervention has three components: 1) a summit that includes impactful stories told to and by family planning providers that highlight the consequences of provider bias, 2) a forum for continued communication between providers, and 3) a rewards program where clinics in which providers exhibit less biased client interactions or who have improved the most towards this end will be rewarded with social recognition and a ceremony.
45497217|NCT05221944|Other|Patients had a history of antithrombotic therapy|Patients with antithrombotic drugs were identified and grouped and their medical records were reviewed.
45497218|NCT05221944|Other|Patients had no history of antithrombotic therapy|Patients had no history of antithrombotic therapy
45497219|NCT05416827|Procedure|slow-release dexamethasone implant|Epiretinal membrane eyes underwent PPV combined with Ozurdex implant
45497220|NCT04961619|Drug|dabrafenib|There is no treatment allocation. Patients administered dabrafenib by prescription that have started before inclusion of the patient into the study will be enrolled.
45497221|NCT04961619|Drug|trametinib|There is no treatment allocation. Patients administered trametinib by prescription that have started before inclusion of the patient into the study will be enrolled.
45497222|NCT05416671|Behavioral|guided narrative technique-writing|The experimental group underwent the psychological intervention of guided narrative technique-writing with the theme of teacher criticism for 20 to 30 minutes once a day for three consecutive days.
45497223|NCT05079477|Behavioral|Exposure to sugar-sweetened beverage warning labels|Graphic images of the amount of sugar (randomly assigned teaspoons, packets, or cubes) and text warning labels
45497224|NCT05079477|Behavioral|Exposure to calorie information|Calories for all beverages and foods
45497225|NCT04958421|Device|PiCSO Impulse System|After blood flow restoration, the subjects meeting all eligibility criteria will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes whereas the treatment should be continued during and post stent insertion. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
45497226|NCT04980690|Biological|IBC0966|IBC0966 is an investigational product.
45381748|NCT05696171|Procedure|Cochlear implant manual insertion|Manual insertion of the cochlear implant into the round window during the surgery
45381749|NCT05696171|Procedure|Cochlear implant robotized insertion|Robotic insertion of the cochlear implant into the round window during the surgery
45497227|NCT05076513|Drug|Niraparib|"In Phase 0, 300mg administered orally QD for 4 days prior to resection.~In the Expansion cohort/Maintenance phase, niraparib will be administered as described below:~For patients weighing <77 kg (<170 lbs) OR with a platelet count <150,000/mcL, the recommended dosage is 200 mg taken orally once daily.~For patients weighing ≥77 kg (≥170 lbs) AND a platelet count ≥150,000/ mcL, the recommended dosage is 300 mg taken orally once daily."
45497228|NCT05076513|Radiation|Radiation therapy|Participants in Arm A who move onto the Expansion cohort will receive 6-7 weeks of radiation therapy per standard of care.
45596413|NCT03531541|Device|Application of TENS|The subject's skin will be cleaned with mild soap and water. Two square self-adhesive electrodes (5x5cm) will be placed 1 cm below the olecranon of the ulna and 10 cm above the radiocarpal joint of the dominant hand, maintaining the PPT measurement region between two electrodes. Two identical TENS units will be used: an active and a placebo (Neurodyn Portable TENS, IBRAMED). The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes. Participants will be asked about the intensity of TENS every 5 minutes, and if the intensity has faded, the intensity will be increased again to a strong but comfortable level.
45497229|NCT05450094|Behavioral|Screening Only|The Screening Only intervention integrates enhancements to school-based mental health (SBMH). Each school's typical SBMH service delivery system will be enhanced with biweekly meetings of voluntary school teams (comprised of administrators, school counselors, general and special education teachers, and other school-employed mental health professionals) to 1) follow standardized evidence-based intervention decision making process to identify students with mental health risk, plan and/or refer for an evidence-based intervention, monitor intervention progress, and adjust intervention plans as needed; 2) administer teacher-rated and student self-report universal screening twice annually; 3) review screening and related school records data to identify students with mental health risk; and 4) review screening, referral, and receipt data to monitor progress of entire SBMH service delivery system.
45497230|NCT05450094|Behavioral|Enhanced Screening|The Enhanced Screening intervention involves the enhancements to school-based mental health (SBMH) of the Screening Only intervention with the addition of 3 empirically supported enhancements: 1) Voluntary school teams will review screening and service receipt data disaggregated by racial/ethnic subgroups to identify and problem solve inequities. 2) Unintentional bias training for voluntary school teams, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias. 3) Mental Health Literacy training for voluntary school teams in awareness and understanding of students' mental health well-being and need for intervention.
45497231|NCT04621266|Behavioral|Online Home-based peer support|Online Home-based peer support will be provided to support participants' breastfeeding. There will be a minimum of 2 and maximum of 3 home visits between trained peer counsellors and participants. Each session will last approximately 30 minutes.
45497232|NCT04979910|Drug|Ixekizumab|a monoclonal antibody (mAb) against interleukin 17A (IL-17A)
45497233|NCT04979910|Drug|Placebo|matching placebo
45497234|NCT01119183|Behavioral|ACOG education pamphlet on preeclampsia|The ACOG pamphlet on preeclampsia will be offered to this group
45497235|NCT01119183|Behavioral|Preeclampsia education tool|The newly created preeclampsia educational tool will be offered to this group
45497236|NCT04978818|Drug|Vaxelis|Eligible infants will be block randomized to one of two study arms.
45497237|NCT04978818|Drug|PedvaxHIB|Eligible infants will be block randomized to one of two study arms.
45497238|NCT05066919|Procedure|Open plantar fasciotomy|In the surgical treated group, the plantar fascia is defined percutaneously (medial and lateral margin). An incision is then made just distal to the heel pad medially over the plantar fascia. A resection is performed 1 cm in length with a width corresponding to 50% of the medial band. The skin is sutured with nylon/nonresorbable suture. Postoperatively, the operated foot is elevated for the first 24 hours. Then free mobilization in postoperative shoe (ProCare shoe) is allowed. The dressing is left untouched for 3-5 days, after which it can be changed to a patch. After 14 days the sutures are removed and the patient allowed using regular shoes.
45497239|NCT05066919|Other|Conservative treatment|In the conservative treatment group, patients are instructed in performing stretching exercises with plantar fascia specific stretching exercises 10 x 10 seconds, 3 times daily and high load strength training are every other day for 3 months. Each high load strength exercise consists of 3 seconds of concentric phase (lifting up with the heel) and 3 seconds of eccentric phase (lowering the heel) with 2 seconds of isometric pause (pause at maximum lifted heel). 12 repetitions max (RM) are performed, defined as the maximum (over) weight the patient can lift 12 times with full range of motion while performing the exercise correctly. 3 x 12 exercises are performed per workout. After 2 weeks, the load is while the number of repetitions is reduced to 10 RM with an increase to 4 repetitions per workout. After 4 weeks the intensity is increased to 8RM with 5 set. Patients are instructed to increase the load throughout the training period.
45497240|NCT05422482|Biological|GC1123|ICV-administered Hunterase, Idursulfase-ß
45497241|NCT05418465|Drug|Huangqi Guizhi Wuwu decoction|Huangqi Guizhi Wuwu decoction, 100ml at a time, 2 times a day. Oral administration.
45497242|NCT05418465|Drug|Dapagliflozin|Dapagliflozin, 10mg at a time, once a day. Oral administration.
45497243|NCT03261167|Drug|Botulinum toxin A (GSK1358820)|GSK1358820 is sterile, purified type A botulinum neurotoxin complex. GSK1358820 injection will contain botulinum toxin A (100 units), sodium chloride (0.9 milligrams [mg]), and human serum albumin (0.5 mg). It will be available with doses of 400 units and 240 units.
45497244|NCT03261167|Drug|Placebo|Placebo injection will contain sodium chloride (0.9 mg).
45497245|NCT05400330|Biological|LX1001|Gene therapy
45497246|NCT05416359|Drug|TQB3915 tablets|TQB3915 binds to estrogen receptors through covalent bonds, and blocks intracellular signal transmission by changing the conformation of ERα, thereby inhibiting the growth of tumor cells.
45497247|NCT05391126|Drug|Irinotecan|Usual dosing per package insert.
45497248|NCT05418309|Drug|Tislelizumab Nab paclitaxel|Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles;Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
45497249|NCT05137548|Drug|ATI-2173 50 mg|ATI-2173 is a liver-targeted phosphoramidate oral prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
45497250|NCT05137548|Drug|Tenofovir 300Mg Oral Tablet|Tenofovir is an oral nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus. It will be dosed as a tablet by mouth
45497251|NCT04545840|Device|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).
45497252|NCT04534842|Drug|SYNB1618|15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1618
45497253|NCT04534842|Drug|SYNB1934|15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1934
45497254|NCT04526093|Other|TruTrace™ verified Medical Cannabis products|With the introduction of TruTrace™ verification, cannabis products can be clearly identified. Key information, including cannabinoid and terpene compositions can be collated into a Master Strain Certificate.
45694396|NCT01710709|Drug|Aripiprazole|400mg or 300mg, intramuscular injections every 4 weeks.
45694397|NCT05318404|Dietary Supplement|Jejunostomy feeding|Maintain jejunostomy feeding till postoperative 1st visit after esophagectomy in delayed feeding group
45497255|NCT05044611|Drug|Anhydrous Amiloride Hydrochloride|"Amiloride is a blocker of ENaC that is administered patients with various disorders, such as primary or secondary hyperaldosteronism. It does not have the market authorization in the indication of lithium-induced NDI.~Dose : 5 mg Pharmaceutical form: Tablets Daily Posology : 10 mg Route of administration : oral Procedures and duration of treatment: 2 months during the double blinded phase and 10 additional months for the open label phase"
45497256|NCT05044611|Drug|Placebo|Route of administration : oral the control arm will receive a placebo twice daily during 2 months
45497257|NCT05091294|Other|Local anesthetic injection rate in spinal anesthesia|Administering intrathecal local anesthetics for all patients according to height and weight.
45497258|NCT02725853|Device|tDCS|Application of 1.5 mA tDCS for 30 minutes
45497259|NCT02725853|Device|sham tDCS|Application of sham tDCS for 30 minutes
45497260|NCT02725853|Behavioral|personalized practice|arm exercise consisting of whole arm movement within a restricted elbow range of motion
45497261|NCT02725853|Behavioral|non-personalized practice|arm exercise consisting of unrestricted whole arm movement
45497262|NCT04520178|Drug|5-Hydroxytryptophan 100 MG|100mg combined with 50mg carbidopa
45497263|NCT04520178|Drug|5-Hydroxytryptophan|50mg combined with 50mg carbidopa
45497264|NCT04520178|Drug|Carbidopa|50mg
45497265|NCT04520178|Drug|Placebo|Placebo
45497266|NCT04505891|Behavioral|Education|Kidney health education will be delivered prior to discharge by trained nurse educators.
45497267|NCT04505891|Behavioral|Education and follow-up|In patients allocated to the education and follow-up arm, education along with a a post-discharge healthcare visit from a multidisciplinary care team will be performed.
45497268|NCT04872543|Drug|ASTX727|ASTX727 will be self-administered orally by the patient on a once daily basis, days 1 through 5 of each 21-day cycle. Cycle 1 day 1 (C1D1) is defined as the first day that ASTX727 is administered.
45497269|NCT05340894|Procedure|MCKENZIE exercises|McKenzie method is popular amongst physiotherapists as a management approach for spinal pain and McKenzie exercises for LBP are beneficial treatment for increasing flexibility of spine and improving the pain with better results in pain relief
45497270|NCT05340894|Procedure|WILLIAM'S exercises|William flexion exercise is to reduce pain or soreness and provide lower trunk stability by actively developing the abdominal muscles,gluteus maximus and hamstring, passively stretching the hip flexors and lower back muscles(sacro spinalis) and to restore or improve the work balance between the postural flexor and extensor muscle groups
45497271|NCT03294941|Combination Product|HepQuant SHUNT Liver Diagnostic Kit|Serial testing over 48 weeks
45497272|NCT03632499|Other|rehabilitation|rehabilitation
45497273|NCT03098433|Drug|Liothyronine|Single dose
45497274|NCT03098433|Drug|Levothyroxine|Active comparator
45497275|NCT03098433|Drug|Placebos|Placebo
45497276|NCT05044650|Dietary Supplement|KOVIR capsule combined with background treatment|KOVIR is a hard capsule containing fine powder mixed medicinal herbs 600 mg
45694398|NCT05317546|Drug|Cannabidiol|In counterbalanced order, 35 youth (ages 16-22) will receive 600mg of cannabidiol or placebo three hours before a neuroimaging and behavioral assessment paradigm, separated by a 13-day washout period.
46055689|NCT02763267|Other|Oral glucose tolerance test|75 gram oral glucose tolerance test (fasting) at: Visit 1 (pregnant [4-14 weeks gestation] and nonpregnant women); Visit 2 (pregnant subjects only at 24-28 weeks gestation); Visit 3 (pregnant subjects only at 6-12 weeks postpartum)
46055690|NCT02762955|Biological|BCD-057|BCD-057 is biosimilar of adalimumab (produced by BIOCAD).
45497277|NCT03294317|Device|His bundle pacing|Medtronic SelectSecure SureScan MRI model 3830 lead
45497278|NCT05320926|Drug|Clopidogrel monotherapy|Patients will be randomized to stop aspirin and maintain clopidogrel after short-term DAPT.
45497279|NCT05320926|Drug|Aspirin monotherapy|Patients will be randomized to stop clopidogrel and maintain aspirin after short-term DAPT.
45497280|NCT05320926|Device|zotarolimus-eluting stent (Resolute Onyx ®)|zotarolimus-eluting stent (Resolute Onyx ®)
45497281|NCT05415891|Behavioral|Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum|The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with the study's community collaborative board, including representatives from the HIV care and advocacy communities as well as community members. The training is a whole-site training to address stigma as a barrier to accessing substance use and mental health services by persons living with HIV. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to persons living with HIV in order to reduce stigma-related barriers to mental health and substance use healthcare in Positive Impact Health Centers and increase retention in healthcare services for persons living with HIV.
45497282|NCT05415891|Device|You℞ Decision prescribing platform|The You℞ Decision prescribing platform is a mobile application that serves as a reference to quickly inform providers about the medications recommended for serious mental health disorders and naltrexone to treat AUD; the appropriate dosing regimen; and potential contraindications or interactions related to antiretroviral therapy medications or other psychiatric medication. Information for the platform is adapted from the Department of Veteran Affairs' Manual for HIV Care in Primary Care settings.
45497283|NCT05418075|Other|Psychotherapy|If the families agree to participate in the study, they are randomly assigned to a treatment group. In each of the three groups, they are treated with FBT in a weekly session. In the two comparison groups, Hometreatment or MBSR are offered in addition to FBT, with two consultations per week in each case.
46055691|NCT02762955|Biological|Humira®|Humira is the original adalimumab (produced by F. Hoffman-La Roche)
46055692|NCT02757807|Behavioral|Utilization of Serenita for Relaxation|Users to use Serenita daily and before sexual interaction in order to assess stress and reduce it
46055693|NCT04191681|Drug|Sacubitril-Valsartan|Sacubitril-valsartan at low or equivalent dose to be initiated or added to patients randomized to this arm, and titrated up every 2-4 weeks, per standard practice guidelines and label recommendations per physician's discretion.
46055694|NCT04191681|Drug|Usual care (standard-of-care) arm|Other oral vasodilator therapy to be continued or initiated to patients randomized to this arm, and titrated up every 2-4 weeks, per standard practice guidelines and label recommendations per physician's discretion.
46055695|NCT02757729|Drug|PAC-14028 cream 0.1%|Topical application
45497284|NCT04928118|Other|Evaluate the blood flow and pressure into kidneys|"Renal artery pressure and flow measures will be obtained using dedicated equipment positioned into the renal artery under fluoroscopic guidance.~A pulmonary artery catheter will be used to measure the pressure inside participant's renal vein and to collect small blood samples to measure oxygen content."
45497285|NCT04375553|Other|Aerobic exercise|Intradialytic aerobic exercise
45497286|NCT05296512|Drug|Lenvatinib|Lenvatinib is an oral capsule medication that will be taken by mouth once daily, every day of each 21-day treatment cycle. Treatment will be administered on an outpatient basis.
45497287|NCT05296512|Drug|Pembrolizumab|"Pembrolizumab will be administered intravenously (IV) on Day 1 of every 21-day treatment cycle. Treatment will be administered on an outpatient basis.~Pembrolizumab will be given up to 35 cycles (approximately 24 months). Participants who stop pembrolizumab treatment with SD or better may be eligible for up to an additional 17 cycles (approximately 12 months) of pembrolizumab treatment (Pembrolizumab Re-Treatment) if they progress after stopping pembrolizumab and while receiving lenvatinib."
46055696|NCT02757729|Drug|PAC-14028 cream 0.3%|Topical application
45497288|NCT05417997|Dietary Supplement|Kunamin®|Grape juice, seed, stem and rice extracts supplement containing KH good healthy cells (proteins)
45497289|NCT05417997|Drug|Favipiravir|Antiviral medication used to treat influenza
45497290|NCT05417997|Drug|Enoxaparin|Anticoagulant medication
45497291|NCT05417997|Drug|Lansoprazole|Treat stomach ulcers, a damaged esophagus, gastroesophageal reflux disease (GERD), and high levels of stomach acid.
45497292|NCT05417997|Drug|Paracetamol|Analgesic to treat minor aches and pains, and fever reducer.
45497293|NCT05417997|Drug|Ceftriaxone/ Clarithromycin|Inhibits the production of pneumolysin
45497294|NCT05417997|Drug|Methylprednisolone|Treat inflammation, severe allergies, flares of chronic illnesses
45497295|NCT04292574|Other|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their conditions.
45497296|NCT03292913|Behavioral|Positive Health Check|Positive Health Check (PHC) is an online intervention that delivers tailored evidence-based prevention messages to human immunodeficiency virus (HIV) positive patients through a series of brief interactive videos designed to simulate a conversation with an human immunodeficiency virus (HIV) primary care provider.
45497297|NCT03292913|Behavioral|Standard of Care|Standard of care for patients with human immunodeficiency virus (HIV) (this includes standard of care practices around antiretroviral therapy (ART) initiation, adherence and retention)
45847490|NCT05456958|Other|MRI Biofeedback|We will use state-of-the-art fMRI and neurofeedback of brain signals in order to teach patients with PTSD to self-regulate pathological brain activity that is associated with their symptoms. Indeed, feedback information is crucial for learning, where rt-fMRI-based neurofeedback makes information about brain activity accessible to our consciousness (Ros et al., 2014; Sitaram et al., 2017). It thus provides a reinforcement signal to induce personalized learning mechanisms, allowing individuals to search for appropriate cognitive strategies to voluntarily control brain activity. The feedback signal will come from activity within either the amygdala or PCC.
45847491|NCT05456958|Other|Sham-MRI Biofeedback|In the sham-control arm (N=20), individuals will receive fake neurofeedback signal, i.e., from a successful participant in one of the experimental arms.
45847492|NCT05456568|Device|LymphAssistTM Professional|An intermittent pneumatic compression (IPC) device that mimics manual lymphatic drainage. Participants use the device daily for 12 weeks alongside their usual and standard lymphoedema care
45497298|NCT04871451|Drug|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
45497299|NCT04999839|Drug|NDI-034858 study drug|Dosage Level - 1
45847493|NCT05456022|Drug|Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one|"Appearance (Color) Conforms Yellow Appearance (Form) Powder~1H NMR Spectrum Conforms to Structure Loss on Drying < 4 % _ Purity (HPLC) > 95 %"
45497300|NCT04999839|Drug|NDI-034858 study drug|Dosage Level - 2
46055697|NCT02757729|Drug|PAC-14028 cream 1.0%|Topical application
46055698|NCT02757729|Drug|PAC-14028 cream vehicle|Topical application
46055699|NCT02757651|Drug|Hydrogen Peroxide|Hydrogen Peroxide
46055700|NCT02753049|Behavioral|Peer led mHelath behavioral intervention|A trained peer adherence coach will schedule five, weekly-60 minute, 'ACCESS' sessions, delivered to participants via remote videoconferencing, using smartphones. Cognitive behavioral strategies will be employed to target beliefs about antiretroviral treatment (ART), knowledge of ART, and adherence self-efficacy.
45497301|NCT04999839|Drug|NDI-034858 study drug|Dosage Level - 3
45497302|NCT04999839|Drug|NDI-034858 study drug|Dosage Level - 4
45497303|NCT04999839|Other|Placebo|Placebo
45497304|NCT04167995|Drug|Probiotic Formula lacteal forte|Active Comparator: Patient with attention deficit hyperactive disorder patients (n=40) will receive probiotic preparation twice daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks .
45497305|NCT03704844|Other|non applicable|non applicable
45497306|NCT04005144|Drug|Binimetinib|Given PO
45497307|NCT04005144|Drug|Brigatinib|Given PO
45497308|NCT05418933|Other|Family workshop|Family workshops for 5 courses, with 6-7 families in one course. The workshops were 2 hours per session, one time per week, for a total of 6 weeks.
45497309|NCT03291587|Other|Personnel Training and Coaching Calls|"Training of Lung Cancer Screening Personnel on implementation of the US PHS Guidelines for Smoking Cessation and Performance Coaching during Implementation Phase of the Study~Each site will have a coaching team: two members of our research team including an expert in tobacco cessation and an expert in lung cancer screening. Active coaching includes six, 1-1 ½ hour video exchanges among program sites and coaching teams, once every 4-6 weeks over an 8-month implementation phase. One week prior to the call, each site will be prompted with an email to inform the coaching team of any challenges associated with implementation."
45497310|NCT03856788|Drug|Saline|40 mL sterile normal saline
45497311|NCT03856788|Drug|Bupivacaine|40 mL 0.25% bupivacaine
45497312|NCT03625284|Dietary Supplement|Placebo|Edible oil
46055701|NCT02752503|Drug|Nalmefene|
46055702|NCT04479579|Drug|Apixaban 2.5 milligram|apixaban 2.5 milligram twice daily from discharge until postoperative day 29 +/- 1 day
45497313|NCT03625284|Dietary Supplement|FucoVital|Microalgae oil extract
45497314|NCT03210961|Drug|PF-06826647 tablet|PF-06826647 tablet for oral administration
45497315|NCT03210961|Drug|PF-06826647 oral suspension|PF-06826647 suspension for oral administration (oral suspension to be administered to the 3mg starting dose cohort only)
45497316|NCT03210961|Other|Placebo oral solution/suspension|placebo oral solution for the single ascending dose, first cohort only
45497317|NCT03210961|Other|Placebo tablet|Matching placebo tablet
45497318|NCT04797078|Procedure|Transperineal biopsy|Transperineal free hand MRI-US fusion prostate biopsy
45497319|NCT04797078|Procedure|Transrectal biopsy|Transrectal MRI-US fusion prostate biopsy
45497320|NCT03638921|Drug|MEOPA|Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.
45497321|NCT05417919|Other|Solution-oriented Nursing in Violence Against Women (SONVAW)|The Personal Information Form was filled in by the students themselves before the program. İSKEBE was filled before, after the program and at the follow-up 3 months later. 3 days were determined for the program for the students in the experimental group, and the program was applied for 60 minutes a day for 6 weeks, allowing the students to participate in the program on a suitable day
45497322|NCT04792008|Biological|YQ23|Single dose of 120 mg/kg YQ23 via intravenous route will be evaluated
45381752|NCT05690594|Other|Self or straight administered questionnaire|"Self or straight administered questionnaire with 5 parts:~General questionnaire (to collect socio-demographic data)~ICIQ score to evaluate urinary continence~FLQI score to evaluate fecal continence~FSFI score to evaluate sexuality in women or IIEF-5 score to evaluate sexuality in men~SF-12 score to evaluate quality of life The questionnaire will be sent to patients by email and/or mail. Patients will be able to either complete the questionnaire alone and return it to the primary investigator, or to request a telephone interview to help them to complete the questionnaire. The questionnaire is administered only once and the estimated response time to the questionnaire is between 30 minutes and one hour."
45381753|NCT05690386|Biological|Lonapegsomatropin|Once-weekly subcutaneous injection of Lonapegsomatropin
45497323|NCT04792008|Biological|Matching placebo|Single dose of 0.9% normal saline via intravenous route as matching placebo
45497324|NCT04853667|Other|Interview|Semi-structured interview, lasting a maximum of one hour
45497325|NCT03242759|Drug|nintedanib|Drug
45497326|NCT03242759|Drug|pirfenidone|Drug
45497327|NCT04050930|Other|Mastication|Simultaneous recordings of postprandial thermogenesis (gas exchange), cardiac activity (ECG), masticatory muscle contraction (EMG), and blood collection, during alternating periods of no-mastication or mastication of natural foods or chewing gums of different hardness
45497328|NCT05180617|Behavioral|Music Therapy|Music therapy participants will interact both musically and verbally with the therapist and will be given a range of both electronic and acoustic instruments from which they can choose to play. Music therapy sessions will be based upon music improvisation, and as such participants are not required to have any previous instrument or other music experience and be invited to improvise freely using the instruments. The music therapist will accompany participants in the improvisation. This provides participants with an opportunity to connect with emotions and feelings connected to hidden psychic material. Following improvisations, the therapist and client will identify these moments of interest which can be further explored either verbally or through further improvisation. The music created within sessions will be recorded and participants can take a copy of the recordings home and it will be used in the therapeutic monitoring and analysis of sessions.
45497329|NCT05415579|Other|Traditional Chinese medicine (TCM)|TCM treatment includes Chinese herbal medicine, acupuncture, moxibustion, massage, taiji, and qigong.
45694399|NCT01617629|Biological|MUC1 Dendritic Cell Vaccine (Cvac)|"The recommended dosing regimen for CAN-003X was every 4 weeks for the first 3 doses and then every 12 weeks for 3 doses, for a total of 6 doses over 44 weeks (Regimen A, applicable to CAN-003 observational Standard of Care patients and CAN-003 Cvac patients that have progressed prior to the fourth dose of Cvac).~Participants who received more than 3 doses of Cvac in CAN-003 continued with the CAN-003 dosing schedule (Regimen B; Cvac every 4 weeks for a total of 7 doses and then every 8 weeks for 3 doses, for a total of 10 doses over approximately 48 weeks)."
45694400|NCT00874510|Behavioral|Mandatory Naps|As above, interns on extended duty overnight call shifts will be required to transfer cell phones and cross-coverage responsibilities to night float residents for a 5 hour period each night they are on call. For Year 2, interns will nap in shifts, instead of concurrently, with the first nap shift between 12am-3am and the second shift between 3am-6am
45381754|NCT05690386|Drug|Somatropin|Once-daily subcutaneous injection of Somatropin
45694401|NCT01686373|Device|Activa Dose II Real tDCS|20 minutes of 1 milliamp active tDCS per treatment day (15 total sessions)
45694402|NCT01686373|Device|Activa Dose II Sham tDCS|20 minutes of sham stimulation per treatment day (15 total sessions)
45847494|NCT05456022|Drug|Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT)|Nano QUT will prepared by PLGA-PEG nanocomposites that will be prepared by an oil-in-water (O/W) single emulsion solvent evaporation method
45847495|NCT05456022|Drug|Doxorubicin chemotherapeutic drug as a positive control|Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2
45497330|NCT03416010|Behavioral|COPE-P|"Session 1 ABCs (A=Antecedent or Activator event, B=Belief that follows the event, C=Consequence: how you feel and how you behave).~Session 2 self-esteem and positive self-talk, including ways to build self-esteem and the group provides examples of how to change unhealthy habits into healthy ones.~Session 3 stress/coping during pregnancy. Physical and emotional responses to stress are discussed along with healthy snacking and healthy ways to cope with typical stresses.~Session 4 planning, goal setting and the 4-step problem solving process. Session 5 dealing with emotions in healthy ways through positive thinking and effective communication.~Session 6 coping with stressful situations encountered during pregnancy while continuing to reinforce the thinking-feeling-behaving triangle."
45497331|NCT03656029|Drug|Cannabis|Participants will smoke as much of the cigarette as they wish
45497332|NCT03656029|Drug|Placebo|Participants will smoke a placebo cigarette
46055703|NCT02752659|Procedure|Self-measured arm circumference, therapist-measured arm-circumference, perometer-measured arm circumference|
46055704|NCT02757495|Drug|Dexmedetomidine|Single dose caudal epidural injection will be done using 25 G needle. patients of Group BD will be given dexmedetomidine (precedex 100 µg/mL parenteral preparation (Hospira ® ) 2 µg/kg in 1 ml/kg bupivacaine 0.25%,
45497335|NCT05232877|Other|SHAM tDCS|The control group will follow cognitive training with a combined sham tDCS. Intervention will last for 4-week with 3 sessions per week (12 sessions).
45497336|NCT05232877|Other|tDCS|The intervention group will follow sessions of tDCS combined with a simultaneous cognitive training on tablet
45497337|NCT03097029|Drug|Pancreatic Enzyme|All subjects will take pancreatic enzymes at a dose appropriate for their weight. Pancreatic enzymes are used to help digest fat and other nutrients.
45497338|NCT02545517|Biological|Rabipur|Subjects in all the groups received Rabipur vaccine booster dose, administered intramuscularly in the deltoid region of the non-dominant arm
45497339|NCT02545517|Procedure|Blood sampling|Blood samples were drawn from all subjects at day 1 and then at subsequent year intervals from extension study day 1 onwards.
45497340|NCT03636841|Device|medical device with CE marking (Ultravision ©)|Ultravision © is a medical device that is used during laparoscopy to reduce the discomfort caused by surgical smoke produced by the electrical section of tissue. It works by using the principle of electrostatic precipitation, that is to say it causes the precipitation of suspended smoke droplets on the organs and walls of the abdomen.
45694403|NCT03838666|Drug|Suspension of human autologous MSC 3P|Single administration of the suspension of human autologous MSC 3P in 1.5 ml on the surface of the repaired rotator cuff tendon
45694404|NCT03838432|Device|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
45694405|NCT03838354|Drug|Chidamide|Chidamide 2.5 mg po biw, every four weeks for one cycle. It will be given three cycles.
45694406|NCT03838354|Drug|Chidamide|Chidamide 5 mg po biw, every four weeks for one cycle. It will be given three cycles.
45694407|NCT01709695|Drug|Guanfacine Hydrochloride XR|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
45381755|NCT05690256|Behavioral|Resilience Clinic|A psychoeducational caregiver-child intervention based in primary care, designed to mitigate toxic stress and promote child resilience. Participants engage in 6 weekly visits in primary care using an interactive curriculum based in the evidence-based Circle of Security Parenting along with mindfulness principles.
45381756|NCT05690256|Behavioral|Enhanced primary care|In addition to usual pediatric primary care, enhanced primary care (the control condition for this study) provides navigational services to link to community resources based on screening for unmet social needs (e.g., food insecurity, housing, financial strain).
45381757|NCT05687266|Drug|Datopotamab deruxtecan|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
45381758|NCT05687266|Drug|Durvalumab|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
45381759|NCT05687266|Drug|Carboplatin|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
45381760|NCT05687266|Drug|Pembrolizumab|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle for a maximum of 35 cycles or 2 years (whichever occurs first).
45381761|NCT05687266|Drug|Cisplatin|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
45381762|NCT05687266|Drug|Pemetrexed|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
45381763|NCT05687266|Drug|Paclitaxel|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
45381764|NCT05685472|Biological|MEDI5752|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.
45381765|NCT05684796|Drug|Anticoagulation|Anticoagulation with unfractionated heparin (UFH) or low molecular weight heparin (LMWH)
45381766|NCT05684796|Device|mechanical aspiration thrombectomy|Mechanical aspiration thrombectomy with the Indigo Aspiration System.
45497341|NCT03197454|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Forty-two minutes of training on computerized exercises that targets processing speed, memory and attention.
45497342|NCT03197454|Other|Commercially available computerized training|Forty-two minutes of training on computerized, casual video games.
45694408|NCT01709695|Drug|Placebo|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
45694409|NCT05312320|Other|Information film|"Sexual activity after MI does not increase risk of recurrence or death~Sexual activity is associated with improved outcome after MI~Resuming sexual activity as normal is recommended and completely safe"
45694410|NCT05310760|Drug|Vit C|Oral vitamin C (100 mg three times daily for one week then 100 mg once daily for 1-3 months)
46055705|NCT02757183|Device|"IntelliH"|"IntelliH is a mobile health and a web-based software application that allows patients to enter their blood glucose, weight, medication, diet and other life-style data for review by their providers and monitor their health remotely."
45497343|NCT04206995|Other|Solid Phase Microextraction (SPME)|A SPME fibre is held directly above skin cancer, or healthy skin for a period of less than 30 minutes to capture VOCs. No drug will be used. This is to investigate the capability of the technique in capturing VOCs.
45847496|NCT05455866|Device|central venous catheter|collection and descriptionof central venous catheter-related complications
45847497|NCT05455788|Drug|Aminoglycoside|injection of sewing ring of prosthetic valve with aminoglycoside
45847498|NCT05455554|Diagnostic Test|Flowmet-D|Flowmet-D is a non-invasive device that measures blood flow.
45847499|NCT05455554|Diagnostic Test|ABI|ABI is the ratio of the systolic blood pressure measured at the ankle to that measured at the brachial artery and is considered the gold standard for the diagnosis of peripheral artery disease.
45381767|NCT05683483|Other|WEsleep Interventions|1) Postponing morning nursing rounds to avoid waking patients early and daily assessment of sleep quality by the nurse during morning rounds; 2) Implementing sleep promoting interventions, including optimization of medication and iv fluid timing; 3) Education for health care professionals on sleep; 4) Implementing sleep rounds and change department infrastructure; including 'sleep menu' where patients can choose from earplugs, eye masks, and warm socks. Implement blackout curtains depending on baseline light intensity.
45381768|NCT05680558|Drug|UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis|Extracorporeal Photopheresis (ECP)
45847500|NCT05455398|Procedure|Surgical treatment of round window niche enlargement via round window for inner ear drug delivery|The round window niche is surgically removed and the hormone is slowly released into the inner ear using a gelatin sponge that has absorbed the hormone in the round window
45847501|NCT05455398|Procedure|Drum chamber drug injection|Injection of drugs into the tympanic chamber through the tympanic membrane
45847502|NCT05455242|Behavioral|Habit formation|Habit formation interventions to promote context-dependent automatic behaviors to support diabetes self-management.
45847503|NCT05455164|Dietary Supplement|Isomalto Oligosaccharide|all of the subjects were given eucaloric prepared meal which contain high protein and DF (contain 25-30 gram DF and protein content between 30-40% of total macronutrient distribution range)
45847504|NCT05455086|Behavioral|Cigarette Smoking|Receive 1 puff of tobacco flavored protonated e-liquid
45847505|NCT05455086|Behavioral|Cigarette Smoking|Receive 1 puff of unflavored protonated e-liquid
45381769|NCT05680558|Device|THERAKOS® CELLEX photopheresis system|THERAKOS® CELLEX is an FDA-approved extra-corporeal photopheresis system
45381770|NCT05679557|Other|Perioperative geriatric assessment and intervention|The intervention will comprise a preoperative, thorough geriatric, multidisciplinary assessment (CGA) and tailored interventions, focused on optimizing health issues of expected importance in further course of surgery. Furthermore, postoperative ward rounds by a geriatric team will be conducted. Thus, the course of treatment for each patient will be a close interdisciplinary collaboration.
45381771|NCT05679180|Device|micropulse laser|treatment with confluent spots over the area of focal leak on the earliest phase of fundus fluorescein angiography on Navilas® system using 5% duty cycle with 100 micron spot size with 200 ms envelope. Thirty percent of threshold laser burn power was used.
45497344|NCT04206995|Other|Absorptive patch|An adsorptive patch, covering skin cancer and healthy skin sites will be applied for a period of maximum 30 minutes to capture VOCs. No drug will be used. This is to investigate the capability of the technique in capturing VOCs.
45694411|NCT05236504|Dietary Supplement|Melatonin and magnesium-containing pod|A 50-100mL hot water drink, obtained from a coffee pod machine, containing 1.9mg of melatonin and 200mg of magnesium in a powdered form, will be ingested 30 minutes before bedtime. Total duration of this intervention: 4 weeks, after which 1 week of washout will occur, before switching to the other intervention.
45497345|NCT03625128|Drug|F-18|This is an open-label study to evaluate the performance of a novel tau imaging ligand in up to 36 subjects (12 AD, 3 FTD, 3 PSP, 3 CBS, 3 VCI and 12 HV).
45694412|NCT05236504|Other|Placebo comparator|A 50-100mL hot water drink of identical taste, obtained from an identical pod with the same ingredients except melatonin and magnesium, will be ingested 30 minutes before bedtime. Total duration of this intervention: 4 weeks, after which 1 week of washout will occur, before switching to the other intervention.
45694413|NCT02150044|Device|Acclarent Tympanostomy Tube Delivery System (TTDS).|tympanostomy tube delivery system
45694414|NCT01685983|Drug|Abiraterone acetate|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.
45694415|NCT01685983|Drug|Prednisolone|Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.
45847506|NCT05455086|Behavioral|Cigarette Smoking|Receive 1 puff of tobacco flavored unprotonated cigarette
45847507|NCT05455086|Behavioral|Cigarette Smoking|Receive 1 puff of unfavored unprotonated cigarette
45847508|NCT05455086|Procedure|Computed Tomography|Undergo PET/CT
45847509|NCT05455086|Procedure|Positron Emission Tomography|Undergo PET/CT
45847510|NCT05455086|Other|Questionnaire Administration|Ancillary studies
45381772|NCT05678127|Procedure|Skin biopsy|"Two 3mm skin biopsies from the abdominal wall will be taken. One at the triggerpoint of the pain, the second one at the contralateral, non-affected side of the abdominal wall.~Lidocaine will be used for local anaesthesia of the skin, before the biopsies will be taken."
45381773|NCT05674851|Other|MRI|collection of MRI scans for mathematical model development
45381774|NCT05672251|Procedure|Biopsy|Undergo biopsy
45381775|NCT05672251|Procedure|Biospecimen Collection|Undergo collection of blood samples
45497346|NCT03625050|Procedure|Chuna + Usual care(Celecoxib and esomeprazole)|"Chuna therapy (CT), 2 sessions/week, 4 weeks (8 sessions in total) Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~CT and UC group will receive the same UC regimen."
45497347|NCT03625050|Drug|Usual care(Celecoxib and esomeprazole)|"Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp)."
45497348|NCT03257813|Drug|PRO-122|1 drop every 12 hours for 30 days of alternating treatment with 30 days
45497349|NCT03257813|Drug|Krytantek Ofteno®|1 drop every 12 hours for 30 days of alternating treatment with 30 days
45497350|NCT03210259|Drug|Humira®|Duration - 58 weeks
45497351|NCT03210259|Drug|BI 695501|Duration - 58 weeks
45497352|NCT04773678|Drug|CBP-201|CBP-201 subcutaneous (SC) injection.
45497353|NCT04773678|Drug|Placebo|Placebo subcutaneous (SC) injection.
45497354|NCT04812015|Device|transcutaneous auricular vagus nerve stimulation (taVNS) 15 minutes|Sham 60 minutes and taVNS active stimulation for 15 minutes
45497355|NCT04812015|Device|taVNS 30 minutes|Sham 45 minutes and taVNS active stimulation for 30 minutes
45497356|NCT04812015|Device|taVNS 45 minutes|Sham 30 minutes and taVNS active stimulation for 45 minutes
45497357|NCT04812015|Device|taVNS 60 minutes|Sham 15 minutes and taVNS active stimulation for 60 minutes
45497358|NCT04812015|Device|taVNS 75 minutes|Sham 0 minutes and taVNS active stimulation for 75 minutes
45497359|NCT04812015|Device|taVNS 0 minutes|Sham taVNS 75 minutes
45497360|NCT03257657|Behavioral|Observation Group participants|Women in the observation group will receive usual WIC care, plus the opportunity to meet with a WIC Registered Dietitian (RD) at the 12 week visit. Written WIC materials on lifestyle recommendations will also be given to all observation group participants at the baseline visit. The Investigators will connect with the participant prior to the 12 week visit to make an appointment to meet with the WIC RD at that time.
45497361|NCT03257657|Behavioral|Lifestyle group participants|Women in this group will receive typical WIC care plus the below described activities. The intervention will last 12 weeks.
45497362|NCT04319757|Drug|ACE1702|ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously
45497363|NCT04319757|Drug|Cyclophosphamide|Lympho-conditioning agent
45497364|NCT04319757|Drug|Fludarabine|Lympho-conditioning agent
45381776|NCT05672251|Procedure|Computed Tomography|Undergo PET/CT
45497365|NCT04576806|Other|Body temperature|Warming of administered fluid bolus
45497366|NCT04576806|Drug|Fluid bolus|Administration of fluid bolus of crystalloid of 500ml over 15 minutes
45497367|NCT04576806|Other|Room temperature|Cooling of administered fluid bolus
45497368|NCT05180461|Drug|emodepside|emodepside tablet
45497369|NCT05180461|Drug|matching placebo of emodepside|emodepside matching placebo tablet
45694416|NCT02151448|Biological|DC vaccine|Administered on Monday of each cycle: 1 intranodal ultrasound-guided injection (target dose of 3 x 10e6 cells in 0.5 mL) + 1 intradermal injection (target dose of 3 x 10e6 cells in 0.5 mL)
45381777|NCT05672251|Biological|Loncastuximab Tesirine|Given IV
45381778|NCT05672251|Biological|Mosunetuzumab|Given IV
45381779|NCT05672251|Procedure|Positron Emission Tomography|Undergo PET/CT
45381780|NCT05671510|Drug|Gotistobart|Gotistobart will be administrated through IV infusion over 60 minutes, once every 21 days in assigned dose.
45381781|NCT05671510|Drug|Docetaxel|Docetaxel will be administrated through IV infusion over 60 minutes, once every 21 days in 75mg/m2 dose.
45497370|NCT05180461|Drug|ivermectin|ivermectin tablet (overencapsulated for blinding)
45497371|NCT05180461|Drug|matching placebo of ivermectin|matching placebo of overencapsulated ivermectin tablet
45497372|NCT05229861|Behavioral|HIIT|Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants will perform five high-intensity intervals (95% HRpeak) at high pedalling rates of 80-100 rpm for 90 seconds each. Intervals are interspersed by active breaks of unloaded pedalling (20W, 60-70rpm) aimed to return to 60% HRpeak (approximately 1-1.5 min). The duration of a HIIT sessions is approximately 25 minutes.
45497373|NCT05229861|Behavioral|MCT|Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants perform continuous bicycle ergometry at moderate intensity (60% HRpeak) and 60-70 rpm for the duration of 30 minutes.
45497374|NCT05180305|Diagnostic Test|Mitomic Prostate Test|Mitomic Prostate Test
45497375|NCT05415345|Biological|Cecolin|Bivalent HPV Vaccine
45497376|NCT05415345|Biological|Hecolin|Hepatitis E vaccine
45497377|NCT05205889|Behavioral|Mobile intervention on values and goals in patients with chronic pain.|The protocol consists of 10 daily sessions, 10-20 Minutes each. After each session participants will complete daily measures. Participants will learn about values and a values based life. Further they will identify their own values and are encouraged to set a goal to pursue those values. Based on this, barriers to achieving goals are explained and a corresponding commitment will be made.
45497378|NCT03704454|Dietary Supplement|50 mg PYC and then placebo|4 weeks on PYC, then 4 weeks on placebo
45497379|NCT03704454|Dietary Supplement|100 mg PYC and then placebo|4 weeks on PYC, then 4 weeks on placebo
45381782|NCT05670782|Drug|KM-819|Participants will receive oral doses of KM-819 once-daily
45381783|NCT05670782|Drug|Placebo|Participants will receive matching placebo once-daily
45497380|NCT03704454|Dietary Supplement|Placebo and then 50 mg PYC|4 weeks on placebo, then 4 weeks on PYC
45497381|NCT03704454|Dietary Supplement|Placebo and then 100 mg PYC|4 weeks on placebo, then 4 weeks of PYC
45497382|NCT05417529|Other|music therapy intervention|"Participants did not receive premedication with midazolam 0,02 mg/kg intravenous and received music therapy intervention by a certified music therapist FAMI . Music Treatment consisted of 3 steps:~(1)30 minutes before surgery, music therapist (MTp) engaged the patient in an individual brief conversation (10 min.) to identify preferred musical genre/songs and prepared a customized playlists to listen to during induction; (2)After being monitored in the operating room, patients were prepared to listening to music ; (3)Music listening during anesthesia induction. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation"
45497383|NCT05417529|Drug|Standard Preparation|Partecipants receive premedication with midazolam 0,02 mg/kg intravenous. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation
45497384|NCT02496611|Drug|Weight loss with pharmacotherapy|Participants randomized to the drug intervention group will receive Exenatide extended-release.
45497385|NCT02496611|Drug|Weight loss without pharmacotherapy|Participants randomized to the placebo group will receive a placebo.
45497386|NCT03636295|Drug|Warfarin|Participants in both arms will be on warfarin therapy post-mechanical valve replacement as is standard, but will have different INR target ranges.
45847511|NCT05455008|Behavioral|Remotely-delivered health coaching intervention|Single-arm remotely-delivered health coaching intervention to increase physical activity and reduce sedentary behavior during pregnancy, consisting of 12 health coaching sessions.
45381784|NCT05668728|Other|Group 1: Peppering|Before injection we will palpate the muscles of trapezius, m. rhomboideus, m. levator scapula for finding painful trigger points, and we will mark the point. the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. The needle will be inserted and removed until the local twitch response disappears, at least 10 times at each point found. Afterwards, the patient will be given a standard exercise program for the neck muscles. With this method, dry needling will be applied to the patient 4 times a week, once a week.
45497387|NCT03105570|Procedure|Areola Sparing Mastectomy|A small circular incision would be made to separate nipple from breast and an additional incision directly extended from nipple or located at other part of breast such as infra-mammary fold and subaxillary area would be made to remove the total mammary parenchyma. Routine implant based or flap base reconstruction would be performed subsequentially. Nipple reconstruction is optional.
45497388|NCT04767048|Procedure|bilateral mucosectomy + tonsillectomy|Basic bilateral tongue mucosectomy assisted by robot or laser plus tonsillectomy (unilateral or bilateral at the choice of the investigator)
45497389|NCT04767048|Procedure|tonsillectomy|tonsillectomy (unilateral or bilateral at the choice of the investigator)
45497390|NCT04566666|Drug|Placebo|Placebo of SCD-044 product
45847512|NCT05453916|Drug|Nitazoxanide 500Mg Oral Tablet|patients receiving treatment with Nitazoxanide 500 mg two times daily for 14 days
45847513|NCT05453916|Drug|Rifaximin 550Mg Tab|patients receiving treatment rifaximin at a dose of 550 mg three times daily for 14 days
45497391|NCT04566666|Drug|SCD-044_Dose 1|SCD-044 tablets in Dose 1.
45497392|NCT04566666|Drug|SCD-044_Dose 2|SCD-044 tablets in Dose 2
45847514|NCT05451420|Drug|PegIFN α- 2b|"Adjuvant immunotherapy with GM-CSF and Hepatitis B vaccine~；GM-CSF（100 μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd）；Hepatitis B vaccine（Each 1.0ml/HBsAg60 μ g. Shenzhen Kangtai Biological Products Co., Ltd）"
46055706|NCT02752581|Device|Suction drain|A suction drain is used to remove excess fluid from tissues after surgery.
46055707|NCT02752581|Device|No suction drain|A suction drain is used to remove excess fluid from tissues after surgery.
45497393|NCT04566666|Drug|SCD-044_Dose 3|SCD-044 in Dose 3
45497394|NCT03237481|Drug|HTX-011|HTX 011 (bupivacaine/meloxicam), 300 mg/9 mg by instillation
45497395|NCT03237481|Drug|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 75 mg by injection
45497396|NCT03237481|Drug|Saline placebo|Saline placebo by instillation
45497397|NCT03237481|Device|Luer-lock applicator|Applicator for instillation
46055708|NCT02752347|Device|Surface EMG device|measuring the muscles activity using surface EMG device
46055709|NCT04220697|Other|electroencephalography (EEG)|recording of resting state EEG using 64 surface electrodes
46055710|NCT04220697|Other|questionnaires|Hospital Anxiety Depression Scale (HADS) Neuropathic Pain questionnaire (DN4) Brief Pain Inventory (BPI) Fatigue Assessment Scale (FAS)
45497398|NCT03237481|Device|Vial access device|Device for withdrawal of drug product
45497399|NCT03704220|Drug|Warfarin|Removal of anticoagulation with warfarin
45497400|NCT03222349|Drug|Diazepam Buccal Film|Subjects received a single DBF dose determined by age and body weight during the interictal state and during the ictal/peri-ictal period with at least 14 days washout between doses.
45497401|NCT03543553|Other|This is not an intervention study|This is not an intervention study
45497402|NCT05180071|Device|TEMA elbow system|Total elbow replacement
45497403|NCT02927925|Drug|Daratumumab|Participants will receive daratumumab 16 mg/kg as intravenous infusion.
45497404|NCT05170165|Other|Using a clinical decision software to provide specific recommendation of a medication at a certain dosage|During routine follow-up, clinicians, cardiologists, and NPs who have a scheduled visit with an enrolled patient will be offered a medication recommendation. The medication recommendation will be generated by the clinical decision support tool. The software will advise the cardiologist whether an HF medication should be initiated, discontinued, or the dosage titrated and if the patient requires labs. In addition, the software, or decision engine (DE), will be run once weekly and every time the patient has new basic metabolic panel results. If the patient is admitted to the hospital, skilled nursing facility, or inpatient rehabilitation unit, the use of DE will be placed on hold until the patient is discharged and at home.
45497405|NCT03208933|Drug|Pirfenidone|Pirfenidone 2403 mg/d capsules orally will be given in divided doses (TID) after titration period of 14 days.
45497406|NCT05168917|Diagnostic Test|LIAISON Calprotectin|Immunoassay for fecal calprotectin measurement
45497407|NCT05163951|Procedure|Trabeculectomy|trabeculectomy
45497408|NCT05163951|Procedure|SPI+GSL+GT|Peripheral iridectomy (SPI) combined with goniosynechialysis (GSL) and goniotomy (GT)
45497409|NCT02499120|Drug|palbociclib|Palbociclib will be supplied as capsules containing 75 mg, 100 mg, or 125 mg equivalents of palbociclib free base. Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.
45497410|NCT02499120|Drug|Cetuximab|Cetuximab injection for IV infusion will be provided in 100 mg/50 mL, single-use vials, and 200 mg/100 mL, single-use vials. In Japan, cetuximab will be provided in 100 mg/20 mL, single-use vials. Administered, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
45497411|NCT02499120|Drug|Placebo|"Placebo for palbociclib will be indistinguishable from the palbociclib capsules and will be supplied as capsules matching in size and color the various palbociclib formulations.~Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle."
46055711|NCT04220697|Other|high frequency electrical stimulation of the forearm skin (HFS)|HFS consists of transcutaneous electrical stimuli delivered as 42 Hz trains (pulse width: 2 ms) lasting 1 s. The trains are repeated 12 times. Each train is separated by 10 seconds.
46055712|NCT04220697|Other|cutaneous mechanical pinprick stimulation|Mechanical pinprick stimuli will be applied manually by the operator on the skin using a mechanical stimulator (maximum weight 128 mN).
46055713|NCT02757261|Device|Laser|Low-level laser therapy administrated to acupoints
46055714|NCT02757261|Device|Occlusal splint|Occlusal splint with expander
45381785|NCT05668728|Other|group 2: spin and wait|Just before the injection, painful trigger points in the bilateral muscles of trapezius, m. rhomboideus, and m. levator scapula will be identified and marked by palpation, and the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. After the dry needle is inserted at each point found, it will be spinned counterclockwise and left. Waiting time for each patient will be limited to 15 minutes. Afterwards, the patient will be given a standard exercise program for the neck muscles. With this method, dry needling will be applied to the patient 4 times a week, once a week.
46055715|NCT02757261|Device|Placebo laser|Placebo laser (Low-level laser therapy administrated to acupoints)
46055716|NCT02752425|Device|Visual feedback|Use of ultrasound echography for tongue articulatory visual feedback
46055717|NCT02757027|Drug|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
45694417|NCT02151448|Drug|Celecoxib|Administered at 200 mg, once a day orally, starting the day of the first DC vaccine through week 4/cycle 2. Participants will not take celecoxib while receiving standard of care chemotherapy as instructed by their local oncologist. Celecoxib will continue starting week 20/cycle 3 and continue until the Friday of the last day of the CKM administration, cycle 4. Administered at 400 mg, 200 mg twice a day orally, on days participants receive vaccine and CKM.
45694418|NCT02151448|Drug|Interferon Alfa-2b|Intravenous infusion over 20 minutes: doses tested in Phase 1 portion (5, 10, or 20 MU/m2) will determine the Phase 2 dose. Administered on the Tuesday of each CKM cycle.
46055718|NCT02757027|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
46055719|NCT02756871|Other|online guided self-help intervention for perfectionism|"CBT based online guided self-help intervention for perfectionism based on CBT manual for treatment of perfectionism, Cognitive Behavioural Treatment of Perfectionism by Sarah Egan, Tracy Wade, Roz Shafran and Martin Antony"
46055720|NCT04220541|Behavioral|Motor learning based exercise|Symptomatic exercise
46055721|NCT02752113|Drug|Empagliflozin and Linagliptin|Empagliflozin and Linagliptin
46055722|NCT02752113|Drug|Metformin and Insulin sc|Metformin and Insulin sc
46055723|NCT02751957|Behavioral|Early Start Denver Model|The Early Start Denver Model is an evidence based, behavioral intervention for young children who have an autism spectrum disorder. It is a behavioral treatment informed by the principles of applied behavior analysis.
46055724|NCT00745615|Drug|Laquinimod|Laquinimod tablets/capsules will be administered as per the dose and schedule specified in the respective arms.
46055725|NCT00745615|Drug|Placebo|Placebo matching to laquinimod will be administered as per the dose and schedule specified in the respective arms.
46055726|NCT02756715|Drug|propofol group|Patient will be anesthetized by using propofol infusion during operation.
46055727|NCT02756715|Drug|Desflurane group|Patient will be anesthetized by using desflurane inhalation during operation.
45497419|NCT03207763|Device|Microneedle Formulation 1|"Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The total mass of excipients delivered by placebo microneedle patch will be <1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches."
45497420|NCT03207763|Device|Microneedle Formulation 2|"Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The ratio of the excipients and excipients used will vary slightly from Formulation 1. The total mass of excipients delivered by placebo microneedle patch will be <1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches."
45497421|NCT02423772|Behavioral|Acceptance and Commitment Therapy + Mindfulness-Based Relapse Prevention + Treatment as Usual (TAU)|
45497422|NCT03220711|Device|confocal endomicroscope|"This instrument provides real-time endoscopic histology to guide endoscopic biopsy or endoscopic mucosal resection (EMR) in the patient study group during colonoscopies."
45381786|NCT05668728|Other|group 3: Peppering and spin and wait|Just before the injection, painful trigger points in the bilateral muscles of trapezius, m. rhomboideus, and m. levator scapul will be identified and marked with palpation, and the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. After the needle is inserted and removed, it will be spinned counterclockwise for 15 minutes in each patient until the local twitch response disappears, at least 10 times at each point found. Afterwards, the patient will be given a standard exercise program. With this method, dry needling will be applied to the patient 4 times a week, once a week.
45497423|NCT03220711|Drug|Fluorescein|Fluorescent dye used for imaging contrast only.
46055728|NCT02756325|Device|MRI|Imaging will be performed using a clinical whole-body MRI and a pelvic phased-array coil. No intravenous contrast will be administered. Sequences will include Diffusion weighted imaging (DWI), T2 mapping, arterial spin labeling, and spectroscopy. The acquisition is expected to take approximately one hour
46055729|NCT02756091|Other|No study-specific intervention|
46055730|NCT02756169|Other|Intervention|Three actions since pregnancy until the first year of life of the baby for helping the women with obesity to increase the probability of a successful breastfeeding.
46055731|NCT04221321|Drug|Atorvastatin 40 mg|Atorvastatin 40 mg
46055732|NCT04221321|Drug|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
46055733|NCT04221321|Drug|RAPA114|RAPA114 tablet
45381787|NCT05668221|Behavioral|Prehabilitation|Prehabilitation includes exercise prescription, cognitive function assessment and training, nutritional optimisation at least 4 weeks prior to surgery
45381788|NCT05667324|Drug|Ropivacaine|A single injection into the pterygopalatine fossa bilaterally of 0.5% ropivacaine at a dose of 20 mg (each side)
45381789|NCT05667324|Drug|Dexamethasone|Plus 4 mg dexamethasone
45381790|NCT05667324|Drug|Placebo|A single injection into the pterygopalatine fossa bilaterally of a balanced crystalloid intravenous solution (4 ml of normal saline)
45381791|NCT05667142|Drug|XEN1101|XEN1101 capsules
45381792|NCT05667142|Drug|Placebo|Placebo capsules
45381793|NCT05665595|Biological|Pembrolizumab/Vibostolimab|Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 17 administrations
45381794|NCT05665595|Biological|Pembrolizumab|Pembrolizumab 25 mg/mL administered as IV infusion for up to 17 administrations
45381795|NCT05663242|Drug|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
45381796|NCT05663242|Drug|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
45381797|NCT05662319|Drug|Fitusiran|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous (SC)
45381798|NCT05662319|Drug|Clotting factor concentrates (CFC) or bypassing agents (BPA)|"Coagulation factor VIII (ATC code: B02BD02)~Coagulation factor IX (ATC code: B02BD04)~Coagulation factor VIIa (ATC code: B02BD08)~Factor VIII inhibitor bypassing activity (ATC code: B02BD03)~Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)"
45381799|NCT05662319|Drug|Antithrombin concentrate (ATIIIC)|Antithrombin III (ATC code: B01AB02) Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)
45381800|NCT05661851|Drug|Investigational Lubricating Eye Drop in a Novelia® bottle|Investigational Product
45381801|NCT05661851|Drug|Blink® Tears eye Drops|Control Product
45381802|NCT05656521|Drug|101-PGC-005|'005 is a targeted prodrug of dexamethasone that binds to activated macrophages.
45381803|NCT05656521|Drug|Dexamethasone|Dexamethasone is a glucocorticoid commonly prescribed to treat inflammation.
45381804|NCT05655013|Drug|Zoledronate|zoledronate 5 mg
45497424|NCT04767165|Diagnostic Test|MRI|Dynamics of Bone marrow fat fraction by mDixon-quant (%)
45497425|NCT02417688|Device|Cu[64]-25%-CANF-Comb PET-MR|Single IV injection of a novel radiopharmaceutical for diagnostic imaging of atherosclerosis by PET-MR
45497426|NCT05136729|Behavioral|Self-Natural Posture Exercise training|SNPE training will be provided face-to-face or online by certified instructors. The SNPE exercise training involves the use of special belts to align and stabilize posture and joints. Up to 4 belts can be used, placed around the hips, around the thighs, below the knees, and above the ankles. Myofascial release is part of the training, which is self-performed with SNPE equipment.
45497427|NCT01568307|Drug|Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.|The choice of SSRI will be based on clinical judgement and prescribed in line with standard dosing approved by the Therapeutic Goods Administration (TGA).
45497428|NCT04766034|Behavioral|Simulated Grocery Shopping Exercise|Participants will click a link and simulate a shopping experience by selecting a week's worth of Supplemental Nutrition Assistance Program (SNAP)-eligible groceries for their household in a web-based supermarket platform
45497429|NCT03237013|Behavioral|Facial Morphing Intervention|Participants assigned to this condition were exposed to facial morphing technology that displays the progression of facial-ageing up to 72years, both with and without damage from UV exposure.
45497430|NCT03237013|Behavioral|Mindfulness Intervention|Participants assigned to this condition engaged in a self-guided mindfulness intervention audio tape. This intervention instructed participants to pay attention to the present moment, with a non-judgemental stance. For example, participants were instructed to notice their breath, thoughts, feelings, physical sensations, and to internally describe them, without passing judgement
45497431|NCT02415036|Device|Delcath Hepatic Delivery System|
45497432|NCT02415036|Drug|Melphalan|
45497433|NCT04752267|Procedure|Computed Tomography|Undergo PET/CT
45497434|NCT04752267|Drug|18F-FMAU|Given IV
45497435|NCT04752267|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
45497436|NCT04752267|Procedure|Positron Emission Tomography|Undergo PET/CT
45497437|NCT02117700|Dietary Supplement|N-acetyl cysteine 600 mg once/day|NAC 600 mg once/day + Placebo once/day for 16 weeks
45497438|NCT02117700|Dietary Supplement|N-acetyl cysteine 600mg twice/day|N-acetyl cysteine 600 mg twice/day for 16 weeks
45497439|NCT02117700|Other|Placebo twice/day|Placebo capsules twice/day for 16 weeks
45497440|NCT04864080|Behavioral|Computer game/task|N-back, COGED, PacMan game, Bandit task, Websurf task.
45381805|NCT05655013|Drug|Placebo|isotonic saline 100 mL
45381806|NCT05653271|Drug|Cyclophosphamide|Lymphodepleting agent
45497441|NCT04864080|Behavioral|Health surveys online|Health surveys to study themes like pain, sleep, depression and anxiety, and PTSD.
45497442|NCT05086263|Device|Pico G2 4k|"On this virtual reality headset, it will be loaded with an educational virtual reality mock MRI training titled Ready Teddy. This training explains the procedure to the viewer and addresses common questions that individuals often have regarding an MRI. Furthermore, using audio/visual cues, when the viewer moves their head too much in a MRI like setting they are reminded to stay still. Biofeedback training is aimed to mimic the experience of the MRI with real audio recordings of image acquisition, in order to adequately train the view to stay still in an MRI procedure."
45497443|NCT03236779|Other|dry needling|The electrotherapy equipment used (Enruf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode) (42). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3 1.5 mA for 5 seconds conveyed to the muscle will be applied.
45497444|NCT04544124|Behavioral|Contingency management|Incentives will be provided for treatment attendance over a 12-week period.
45497445|NCT03096483|Device|OEC Elite system|Adults undergoing vascular, gastrointestinal (GI), urology or pain management procedures
46055734|NCT04221243|Device|3D printed space maintainer by NextDent Ortho Rigid|Biocompatible 3D printing material
46055735|NCT04221243|Device|Conventional Band and Loop|metal space maintainer
46055736|NCT02755701|Drug|Branched-chain Amino Acid|BCAA (livact) will be administered 3 times a day during 24 weeks
46055737|NCT02755701|Drug|Placebo|Placebo will be administered in the same way
45381807|NCT05653271|Drug|Fludarabine|Lymphodepleting agent
45381808|NCT05653271|Drug|ACE1831|Allogeneic gamma delta T (gdT) cell therapy
45381809|NCT05653271|Drug|Obinutuzumab|Anti-CD20 monoclonal antibody
45381810|NCT05650086|Device|Thermalytix|One-time Thermal imaging is performed for this cohort.
45381811|NCT05646511|Radiation|SCRT|5x5 Gy: 25 Gy
45381812|NCT05646511|Drug|CAPOX|Six cycles of CAPOX capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, every 3 weeks
45381813|NCT05646511|Drug|CAPOXIRI|Six cycles of CAPOX capecitabine 800 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1 and irinotecan 200 mg/m2 intravenously on day 1, every 3 weeks)
45381814|NCT05644184|Biological|Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)|Each 0.1 mL (2 drops) dose of nOPV1 vaccine contains approximately 10^5.5, 10^6.0, or 10^6.5 CCID50.
45381815|NCT05644184|Biological|Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)|The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10^6.0 CCID50 per 0.1 mL (2 drops) dose.
45381816|NCT05644041|Drug|Gemcitabine|Gemcitabine will be administered intravesically at a dose of 2000 mg.
46055738|NCT04220931|Drug|botulinum toxin injection|injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.
46055739|NCT02751801|Other|no intervention|
46055740|NCT02755857|Drug|Lozanoc|65 mg
45497446|NCT05100277|Genetic|Oncotype DX® Assay|After surgery, tumoral tissue was used to perform Oncotype Dx®. Patients were evaluated and therapy recommendations - adjuvant chemotherapy (CT) plus hormone therapy (HT) or HT alone - were captured before and after revealing the test results. Results from TAILORx10 were used to guide decisions for or against CT for individual patients. Changes in treatment recommendations were obtained.
45694419|NCT02151448|Biological|rintatolimod|Intravenous infusion of 200 mg on Wednesday and Friday only of the CKM regimen. The protocol allows for de-escalation to 100 mg if attributable adverse effects are observed.
45847515|NCT05448222|Diagnostic Test|Diagnostic Test: gait speed; ct scan; grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
45847516|NCT05448144|Other|Collect stool and blood samples from patients|Collect stool and blood samples from patients
45381817|NCT05641207|Device|RheOx™ with the RheOx™ Catheter treated in the trial|"Eligible patients will be assigned to two sessions of treatments with RheOx~Treatment 1 is scheduled at right lung at the first treatment.~And then approximately one month later, treatment 2 is delivered to left lung at the second treatment."
46055741|NCT02755545|Drug|Product A (adapalene)|Product A applied topically to the entire face or other affected area of the skin once daily
45381818|NCT05633992|Biological|V116|Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
45381819|NCT05633992|Biological|PPSV23|Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
45497447|NCT05100277|Other|Cost|Changes in treatment costs were estimated from Pérola Byington Hospital.
45497448|NCT04763538|Other|Standard of care|Patients are treated according to the standard of care for each individual disease.
45694420|NCT01685437|Biological|AA4500|2 injections separated by approximately 24 hours to 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles
45847517|NCT05376150|Drug|XEN1101 10 mg|XEN1101 oral capsule
45847518|NCT05376150|Drug|XEN1101 20 mg|XEN1101 oral capsule
45847519|NCT05376150|Drug|Placebo|Placebo capsule
45694421|NCT00875212|Drug|calcium glycerophosphate|use of a dentifrice containing CaGP (0.13%) and no fluoride
46055742|NCT02755545|Drug|Product B (salicylic acid)|Product B applied topically to affected area of the skin 1 to 3 times daily
46055743|NCT02755389|Drug|0 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be no oxygen flowing through the cannulae in this group during the study.
45694422|NCT00875212|Drug|no active ingredient|dentifrice without calcium glycerophosphate and no fluoride
45694423|NCT00875212|Drug|fluoride|use of a dentifrice containing fluoride (1500ppm) only
45694424|NCT00875212|Drug|CAGP + fluoride|calcium glycerophosphate and fluoride dentifrice
45847520|NCT05329038|Biological|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
45847521|NCT05324124|Drug|Selpercatinib|Administered orally.
45847522|NCT05305092|Device|PET/MRI, psychobehavioral tests and questionnaires, serum biomarkers and stool sample|Neuroimaging data were collected by integrated PET/MRI machine, and collected the psychobehavioral data, the serum and stool samples of participants.
45847523|NCT05273814|Drug|Tislelizumab|Tislelizumab intravenous infusion 200mg d4
45847524|NCT05273814|Drug|Pemetrexed|Pemetrexed intravenous infusion 500mg/m2 d1
45847525|NCT05273814|Drug|Bevacizumab|Pemetrexed intravenous infusion 7.5mg/kg，d1
45497449|NCT05417373|Other|calculated radscore|The development cohort is case_control research. The validation cohort is prospective study to test the accuracy of calculated radscore based on diagonisis model.
45497450|NCT03257267|Drug|Cemiplimab|Intravenous (IV) administration every 3 weeks (Q3W)
45497451|NCT03257267|Drug|Investigator Choice (IC) Chemotherapy|"IC chemotherapy options include:~Antifolate: Pemetrexed~Topoisomerase 1 inhibitor: Topotecan or Irinotecan~Nucleoside analogue: Gemcitabine~Vinca alkaloid: Vinorelbine~The only chemotherapy treatments allowed in the control arm are any of the 5 drugs that are listed as IC options above."
45497452|NCT04543812|Drug|Ferric citrate|Ferric citrate will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
45497453|NCT04543812|Drug|Placebo|Matching placebo will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
45497454|NCT02932579|Other|Pharmacogenomic Testing|Saliva collection (5mL)
45497455|NCT02932579|Drug|Ibuprofen|400 mg
45497456|NCT02932579|Drug|hydroxycontin/acetominophen|hydroxycontin 2.5 mg, acetominophen 325 mg
45497457|NCT02932579|Drug|acetominophen|650 mg
45497458|NCT02932579|Drug|Oxycontin/acetominophen|5mg Oxycontin, 325 mg acetominophen. This will be a rescue medication is the other three pain medications do not work.
45497459|NCT03701412|Radiation|MRI|MRI brain
45497460|NCT05417295|Procedure|Inflating air into the bronchial cuff before changing position|Inflating air into the bronchial cuff before or after changing position
45497461|NCT05417295|Procedure|Inflating air into the bronchial cuff after changing position|Inflating air into the bronchial cuff after changing position
45497462|NCT03624894|Other|impression|common polyvinylsiloxane oral impression
45497463|NCT04748757|Drug|recombinant human annexin A5|recombinant human annexin A5, manufactured as SY-005
45497464|NCT04748757|Drug|Placebo|Normal saline 50 ml
45694425|NCT00875836|Drug|Buspirone|Flexible dose, up to 60 mg daily
45381820|NCT05630430|Procedure|The Effect of Volar Carbon Plate Applications on Radiation Exposure and Procedure Time in Intra-articular Radius Distal End Fractures|Surgery procedure, Although the bones are at the surgeon's disposal in plate fixation of radius distal end fractures, fluoroscopy is frequently used for reduction control. The increase in the need for scopy both directly affects the duration of the operation and causes the surgical team to be exposed to excessive radiation. Since titanium alloy plates are radiopaque, they create a superposition to the fracture line and more than one view is usually required in each plane to ensure the reduction quality during surgery. Carbon alloy plates, on the other hand, offer the advantage of faster radiological reduction control because they do not create superposition to the fracture line. In our study, in addition to the comparisons in the literature, it is aimed to investigate the effect of carbon plates on the procedure time. surgery time and exposure of radiation will be recorded at the end of the surgery
45381821|NCT05630001|Drug|Iptacopan|Treatment with iptacopan at a dose of 200 mg b.i.d. will start on the first day (Day 1) and continue for 24 weeks.
45694426|NCT00875836|Drug|Placebo|Flexible dose, up to 60 mg daily
45497465|NCT03207451|Drug|Vorapaxar|Vorapaxar is the principle study drug and will be given to all subjects.
45497466|NCT03207451|Drug|Vorapaxar and Aspirin|Subjects in groups 3 will be on Aspirin when they begin Vorapaxar therapy.
45497467|NCT03207451|Drug|Vorapaxar and Clopidogrel|Subjects in groups 2 will be on Clopidogrel when they begin Vorapaxar therapy.
45497468|NCT03207451|Drug|Vorapaxar, Aspirin, and Clopidogrel|Subjects in groups 4 will be on both Aspirin and Clopidogrel when they begin Vorapaxar therapy.
45497469|NCT03704142|Device|Sound World Solutions CS50+|Participants will be tested using the Sound World Solutions CS 50+ hearing devices.
45497470|NCT03704142|Device|Tweak Focus|Participants will be tested using the Tweak Focus hearing devices.
45497471|NCT03704142|Device|IQ Earbuds|Participants will be tested using the IQ Earbuds hearing devices.
45497472|NCT03704142|Device|Bose Hearphones|Participants will be tested using the Bose Hearphones hearing devices.
45497473|NCT05040451|Device|Carillon Mitral Contour System|"The Carillon Mitral Contour System (XE2) consists of the following components:~An implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV)~A delivery system which consists of a custom 9F delivery catheter and a handle assembly."
45497474|NCT05089123|Biological|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
45497475|NCT05089123|Biological|Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
45497476|NCT02666547|Drug|68Ga-NODAGA-RGD PET/CT|200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images acquired on all body . For glioma, images acquired centred on the skull
45497477|NCT02666547|Radiation|18F-FDG PET/CT|3.5 MBq/kg 18F-FDG will be administered i.v. and images acquired on all body
45497478|NCT02666547|Radiation|18F-FET PET/CT|200 MBq 18F-FET will be administered i.v. and images acquired centred on the skull
45497479|NCT04540770|Drug|HuL001|Anti-ENO1 monoclonal antibody
45694427|NCT05235802|Diagnostic Test|Magnetic Resonance Imaging (MRI) (including functional MRI)|"Patients will undergo magnetic resonance imaging including the following protocols:~3D T1w MPRAGE~3D T2w FLAIR SPACE~3D T2w SPACE~3D T1w PSIR (cortical visualization)~2D synthetic MRI (quantitative T1, T2, PD and myelin quantification)~Resting-state fMRI (6 min, human connectome protocol, 2 mm iso)~3D SWI~DWI b1000 32 directions and b3000 64 directions."
45694428|NCT05235802|Diagnostic Test|Blood sampling (serum/plasma preparation)|Blood will be screened for genetic modifications. Serum will be analyzed for auto-antibodies and other inflammatory and neurodegenerative biomarkers.
45694429|NCT05235802|Diagnostic Test|Cerebrospinal fluid (CSF)|CSF will be analyzed for inflammatory and neurodegenerative biomarkers.
45381822|NCT05628623|Drug|Cytarabine|Arm A: CBF-Cytarabine 3000 mg/m2 or 1500 mg/m2 IV twice daily (BID), 12 hours apart x 6 doses either on Days 1, 3, and 5 OR Days 1, 2, and 3
45381823|NCT05628623|Drug|Venetoclax|Venetoclax 100 mg daily Day 1 through Day 8 Venetoclax 400 mg orally once daily on Days 1-14 Venetoclax 400 mg orally once daily on Days 1-28
45381824|NCT05628623|Drug|CPX-351|Daunorubicin 29 mg/m2/Cytarabine 65 mg/m2 liposome IV on Days 1 and 3
45497480|NCT03671421|Procedure|ACL reconstruction - graft choice|Use of 3 different ipsilateral autograft options
45497481|NCT03703908|Drug|CCX140-B|Orally administered tablet
45497482|NCT02361125|Drug|Methylphenidate|5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue. Participants to take a maximum of 20 mg/day, for total of 28 tablets for 7 days.
45497483|NCT02361125|Behavioral|Fatigue Evaluations|Participants to have evaluation of their fatigue, ability to sleep, and will answer a set of general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment.
45497484|NCT03350503|Device|AcrySof IQ Toric A-code IOL|Intended to provide visual acuity, including astigmatism correction, over the lifetime of the cataract patient
45497485|NCT03350503|Procedure|Cataract surgery|Removal of cataractous lens and implantation of IOL
45497486|NCT03701256|Procedure|Bilateral ultrasound guided TAP bloc|In the TAP group: Bilateral ultrasound guided TAP bloc for laparoscopic gynecologic surgery
45497487|NCT03701256|Drug|Neuromuscular blockade agent: Atracurium 01mg/kg per bolus|In the TRAC group: Neuromuscular blockade agent: Atracurium 01mg/kg per bolus for maintaining muscular relaxation and immobilization during laparoscopic gynecologic surgery
45497488|NCT04780581|Drug|Dexamethasone|6 mg/24h - 10 days
45497489|NCT04780581|Drug|Methylprednisolone|250 mg/ 24h - 3 days
45497490|NCT01526135|Drug|mFolfirinox|"mFolfirinox every 14 days, 12 cycles, 24 weeks.~mFolfirinox : Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)"
45497491|NCT01526135|Drug|Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
45497492|NCT03703830|Device|Cerebellar transcranial direct current stimulation|Cerebellar transcranial direct current stimulation (ctDCS) will be applied during 25 minutes at 2 mA of intensity. Anodal electrode will be positioned 1 cm below inion and cathodal electrode at right deltoid muscle.
45694430|NCT05235802|Diagnostic Test|Clinical assessments / questionnaires|"Glasgow Outcome Scale Extended (functional outcome)~Short-Form 36 (quality of life),~EQ-5D (quality of life),~Mini-Mental State Extended (MMSE) (mental state assessment).~Barthel Index (daily living disabilities),~Montgomery-Åsberg Depression Score (MADRS-S) (level of depression)~Fatigue Severity Scale (FSS) (level of fatigue)~Other than that, neurological assessments focusing on the Unified Parkinson's Disease Rating Scale (UPDRS) will be performed."
45694431|NCT00891982|Drug|CTGel/ BPO Wash|"Benzoyl Peroxide (BPO) wash will be used once daily in the morning for 28 days~Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days."
45694432|NCT00891982|Drug|Soap Free Cleanser and CTGel|"Soap Free Cleanser will be used once daily in the morning for 28 days~Clindamycin and Tretinoin gel will be used once daily in the evening for 28 days."
45694433|NCT05312476|Drug|Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets|"Dose escalation studies:3 dose groups in total: expect 3-6 cases in each group, and dose set at 1×106/kg，3×106/kg，6×106/kg.~Dose extension study:3 cases (1 dose group)."
45497493|NCT03703830|Other|Treadmill locomotor training|The Treadmill Locomotor Training (TLT) will be performed through speed and step length progression protocol for 25 minutes and combined to ctDCS
45381825|NCT05628623|Drug|Azacitidine|Azacitidine 75 mg/m2 IV/SC on Days 1-7 OR Days 1-5 and Days 8-9 (per institutional preference)
45381826|NCT05627674|Behavioral|Usual Care|Usual care incorporates guideline awareness and brief advice.
45381827|NCT05627674|Behavioral|RiskProfile-Clin|RiskProfile-Clin incorporates standard brief advice and guideline awareness plus specific patient risk feedback using clinical factors.
45381828|NCT05627674|Behavioral|RiskProfile-Gen|RiskProfile-Gen incorporates standard brief advice and guideline awareness plus specific patient risk feedback using clinical factors and genetic factors.
45381829|NCT05622006|Behavioral|Sedentary breaks|Interrupting sitting with different frequencies of walking/jogging at moderate intensity.
45497494|NCT03703830|Device|Sham Cerebellar transcranial direct current stimulation|Sham Cerebellar transcranial direct current stimulation (ctDCS sham) will be applied during 30 seconds at 2 mA of intensity. Anodal electrode will be positioned 1 cm below inion and cathodal electrode at right deltoid muscle. However, subjects will keep the placement of electrodes for 25 minutes to ensure stimulation's masking.
45497495|NCT04697589|Dietary Supplement|Memophenol 300 mg|300 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
45497496|NCT04697589|Dietary Supplement|Memophenol 600 mg|600 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
45497497|NCT04697589|Dietary Supplement|Placebo|Colored maltodextrin
45497498|NCT03701178|Other|BioHPP PEEK|milled BioHPP PEEK in a new material can be used as a dental restoration
45847526|NCT05215080|Dietary Supplement|Organic Formula Milk|Organic formula milk is given to the infants three times a day for three months. Each serving contains 7 spoons (1 spoon contain 4,6 grams) of milk powder and 210 ml of water.
45381830|NCT05619146|Device|Motor-assisted arms and legs cycling|The participants will complete 60min of active cycling training paradigm, 5 times a week, for 12 weeks. The cycling ergometer will be used to provide motorized assistance during simultaneous arms and legs cycling to the participant while they are seated.
45381831|NCT05616923|Drug|Trametinib|Topical cream containing 0.1 mg/g trametinib
45381832|NCT05616013|Biological|Bimagrumab|Human monoclonal antibody to the activin receptor type II
45381833|NCT05616013|Drug|Semaglutide|Glucagon-like peptide-1 (GLP-1) receptor agonist
45381834|NCT05616013|Other|Bimagrumab Placebo|Placebo
45497499|NCT05417139|Other|Immunotherapy+induction chemotherapy+radiotherapy|All enrolled patients received Sintilimab (200mg, d1, q3w) + GP (gemcitabine 1000mg / m2, d1, d8 + cisplatin 80mg / m2, d1, q3w) for 4-6 cycles followed by radiotherapy of primary site and cervical metastasis, and Sintilimab (200mg, q3w) treatment was continued during and after radiotherapy until disease progression or toxicity or up to 2 years.
45497500|NCT03703752|Diagnostic Test|Multi-detector CT scan|This is a diagnostic radiological test to diagnose the IH and evaluate the clinical condition of IH
45497501|NCT03288779|Device|Theta Burst Stimulation|Transcranial magnetic stimulation with theta burst stimulation
45497502|NCT03206749|Drug|VX-150|Participants received VX-150 1500 milligram (mg) as first dose, followed by VX-150 750 mg dose every 12 hours (q12h) for 2 days.
45497503|NCT03206749|Drug|HB/APAP|Participants received HB 5 mg/APAP 325 mg every 6 hours (q6h) for 2 days.
45497504|NCT03206749|Drug|Placebo|Participants received placebo matched to VX-150 and HB/APAP for 2 days.
45497505|NCT04635969|Behavioral|Sexual Health and Development Education for Children With Intellectual Disability|Sexual Health and Development Education for Children With Intellectual Disability: It is aimed to eliminate the problems related to personal care and cleaning of children with mental retardation, to learn the symptoms of adolescence and to learn the methods of protection from abuse.
45497506|NCT04754646|Device|Split-face injection of RHA® 4 with a cannula into a single NLF.|"RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).~The brand of cannula used for injection is up to the discretion of the Treating Investigator (TI), providing the cannula is registered for use by the US FDA."
45497507|NCT04754646|Device|"Split-face injection of RHA® 4 with a needle (TSK 27G x ½) into the contralateral NLF."|"RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF)."
45497508|NCT03705923|Procedure|Bariatric surgery|laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy
45497509|NCT03255941|Drug|DMPA|The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use DMPA.
45497510|NCT03255941|Drug|Sayana Press|The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use Sayana Press
45497511|NCT03703674|Drug|GCSF|Granulocyte-colony stimulating factors (G-CSF)
45497512|NCT03705390|Drug|ILB|Administration will be weekly subcutaneous injections at a dose of 2mg/kg once per week for up to a maximum of 48 weeks
45497513|NCT04805424|Procedure|Lipo-abdominoplasty|Abdominoplasty plus liposuction
45497514|NCT04805424|Procedure|Abdominoplasty|Abdominoplasty
45694434|NCT05312398|Drug|Cetuximab|"I LINE:~- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter~II LINE:~- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line~THIRD LINE:~- Irinotecan + cetuximab~Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line"
45694435|NCT05312398|Drug|FOLFIRI|"I LINE:~- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid given concurrently with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter"
45847527|NCT05006118|Drug|Radio-labeled rodatristat ethyl 600 mg|Single dose of rodatristat ethyl 600 mg as an oral suspension containing a mixture of [12C]-rodatristat ethyl and [14C]-rodatristat ethyl to contain approximately 600 microcuries (uCi) of radioactivity
45381835|NCT05614921|Other|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block 30 ml local anesthetic each side
45381836|NCT05614921|Other|Wound infiltration|5 ml local anesthetic for each trocar side
45381837|NCT05612932|Other|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
45381838|NCT05612932|Other|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 7 days of debonding
45381839|NCT05612425|Behavioral|Safety Behavior Fading for Appearance Concerns|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.
45381840|NCT05612425|Behavioral|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress.
45497515|NCT04659993|Behavioral|Telemental Health Sessions, Support Groups and Questionnaires|Participants will complete initial online questionnaires lasting about 25-30 minutes as well as attend weekly support group meetings online. After 4 weeks, participants will complete seven online follow-up questionnaires that should take no longer than 30 minutes and again at the end of the study.
45497516|NCT03705312|Device|Transcatheter mitral valve repair|Transcatheter mitral valve repair performed using the MitraClip device
45497517|NCT03705312|Other|Guideline-directed medical therapy|Standard medical therapy for heart failure as recommended by HF guidelines
45497518|NCT03701100|Device|tDCS|tDCS
45497519|NCT04226313|Diagnostic Test|Self-sampling by Evalyn Brush|Women will perform a cervicovaginal self-sampling at their home using Evalyn Brush.
45497520|NCT04226313|Diagnostic Test|Self sampling by Evalyn Brush home or in GP´s clinic|Women will perform a cervicovaginal self-sampling at their home or the GP´s clinic using Evalyn Brush
45497521|NCT03701022|Drug|SHR1210|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes. Apatinib oral administration, 500mg per day.
45497522|NCT04221165|Drug|Opioids|Opioids will be prescribed as per institutional standards.
45497523|NCT04221165|Drug|PAiN - multimodal analgesia|PAiN: Pregabalin, Acetaminophen, Naproxen, pantoprazole magnesium
45497524|NCT03255629|Drug|glucagon|novel, stable non-aqueous glucagon formulation provided by Xeris Pharmaceuticals
45497525|NCT03255629|Device|Closed loop glucagon pump|a novel closed-loop glucagon system (CLG) incorporating a novel, stable non-aqueous glucagon formulation together with an infusion pump system (Omnipod) guided by real-time continuous glucose monitoring (Dexcom) that is triggered by a hypoglycemia alert algorithm.
45497526|NCT03031938|Drug|Investigational medical product (IMP) administered in parent study|IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen, diclofenac, administered in parent study
45497527|NCT03587571|Procedure|Surgical intervention|Open reduction and plate osteosynthesis.
45497528|NCT01143779|Drug|FLT-PET|FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
45497529|NCT03558737|Other|Nasal high-frequency jet ventilation (nHFJV)|Non-invasive high-frequency jet ventilation provided via the Bunnell Life Pulse high-frequency JET ventilator through a Rusch latex nasopharyngeal airway
45497530|NCT03558737|Other|Nasal intermittent positive pressure ventilation (NIPPV)|Non-invasive positive pressure ventilation delivered via a conventional ventilator through Hudson prongs
45497531|NCT03703596|Drug|Anlotinib Hydrochloride|Anlotinib (12mg QD PO d1-14, 21 days per cycle)
45497532|NCT03703596|Drug|Docetaxel|Docetaxel (75mg/m2 IV d1, 21 days per cycle)
45497533|NCT01137773|Drug|Insulin|All patients in the trial will have blood taken hourly for glucose analysis, regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
45497534|NCT01137773|Drug|Conventional insulin treatment|All patients in the trial will have blood taken hourly for glucose analysis , regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
45497535|NCT03700944|Other|Yoga training|Complete protocol with yoga training for a period of 8 weeks, 60 minutes, 3 times a week.
45497536|NCT03632031|Device|Oasis Extracellular Matrix|Patients will receive OASIS Extracellular Matrix according to the Instruction for Use
45497537|NCT01568385|Drug|TAK-438|
45497538|NCT03569553|Drug|AIGIV|Anthrax Immune Globulin Intravenous (Human)
45497539|NCT03700866|Procedure|Functional splinting time|Functional splinting time is the time needed for the final healing and organization of Peridontal ligament of tooth with extrusive luxation injury to reattach to the alveolus and function normally in the oral cavity
45497540|NCT04525092|Device|Online Pre-dilution Hemodiafiltration|The following parameters: maximum Blood flow rate allowed by vascular access, dialyste rate of 500 mL/min and average convective volume of >44L/session reinjected in pre-dilution mode. The dialysate composition, net ultrafiltration rate and use of anticoagulation will be prescribed according to participant's characteristics.
45497541|NCT04525092|Device|Conventional Hemodialysis|Using the following parameters: maximum Blood flow rate allowed by vascular access, dialysate rate of 500 mL/min, no convection. The dialysate composition, net ultrafiltration rate and use of anticoagulation will be prescribed according to participant's characteristics.
45497542|NCT04525092|Device|Online Post-dilution Hemodiafiltration|The following parameters: maximum Blood flow rate allowed by vascular access, dialyste rate of 500 mL/min and average convective volume of >22L/session reinjected in pre-dilution mode. The dialysate composition and net ultrafiltration rate will be prescribed according to participant's characteristics. Usage of intra-dialysis anticoagulation is mandatory.
45497543|NCT03703518|Other|Mixed reality|"This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions, using the Microsoft Hololens Roboraid game. The duration of the sessions will be 10 minutes."
45497544|NCT03703518|Other|Conventional exercise group|This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions. This program will consist on stabilisation exercises of the cervical region, in neck deep flexors and neck deep extensors muscles to provide them with strength and resistance
45497545|NCT03700710|Behavioral|Self-Guided Approach|"For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information.~From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform.~In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform."
45497546|NCT03700710|Behavioral|Dietitian-led Approach|"For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information.~From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform.~In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform.~Dietitians will access the web platform and provided personalized motivational interview phone calls on a weekly basis."
45497547|NCT03700632|Other|patch therapy|The eyes are alternatively patched for 2 hours a day in cases without a dominant eye while in cases with dominancy, the dominant eye is patched five days a week and the non-dominant eye is patched two days a week
45497548|NCT03698604|Procedure|Hysterectomy|Total Laparoscopic Hysterectomy Total Abdominal hysterectomy
45497549|NCT03698526|Device|Samsung Gear VR, Galaxy S8, Applied VR App|Virtual Reality Experience
45497550|NCT03624426|Device|Automated Somatosensory Evoked Potential device (EPAD@)|After commencement of general anesthesia and during patient positioning, stimulating sensors will be applied to patient wrists and a recording sensor is applied at base of neck posteriorly (at C5 level), forehead and the bilateral wrists. The monitoring will be continued throughout the surgery.
45497551|NCT03703362|Other|Resistance training|30 supervised training-sessions over 12 weeks
45381841|NCT05608200|Drug|Lenvatinib, sintilimab plus TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight <60kg) P.O. qd and sintilimab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
45381842|NCT05608200|Drug|Lenvatinib plus TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight <60kg) P.O. qd will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. The interruption, dose reduction and discontinuation of lenvatinib depended on the presence and severity of toxicities according to the drug directions.
45497552|NCT01568151|Behavioral|Clinic-directed intervention program|Clinic-directed intervention program: Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions including: 1)provider-directed interventions (computerized case-based education, evidence-based guidelines, ask the expert; 2)office-based systems (risk assessment forms, procedure monitoring, follow-up protocol, audit with feedback, chart reminders); and 3) waiting room materials.
45694436|NCT05312398|Drug|FOLFOX regimen|"II LINE:~- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line"
45847528|NCT04963218|Diagnostic Test|AI Algorithm to detect LVEF in ECG|A clinical decision support software as a medical device that detects whether a patient has LVEF less than or equal to 40% based upon the input of one or more ECG vectors at the point-of-care.
45847529|NCT04867044|Other|STUDY|One Hundred Fifty woman patients diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
46055744|NCT02755389|Drug|15 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 15 L/min of oxygen flowing through the cannulae in this group during the study.
46055745|NCT02755389|Drug|60 L/min oxygen via high-flow nasal cannulae|Patients will have high-flow nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 60 L/min of oxygen flowing through the cannulae in this group during the study.
45497553|NCT01568151|Behavioral|Individual Patient-Directed Program|If the subjects have not undergone colorectal cancer screening within 12 months of receiving the clinic-directed program, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
45497554|NCT03698292|Drug|Itopride|Prokinetic Drug
45497555|NCT03698292|Drug|Metoclopramide 10mg|Prokinetic Drug
45497556|NCT04615455|Drug|ASCs|ASCs expanded from healthy donors. The ASC product contains 22 million ASCs/ml.
45497557|NCT04615455|Drug|Cryostor CS10|CryoStor® CS10 freeze medium
45497558|NCT03703284|Other|Treatments to reduce intracranial pressure|Drugs such as mannitol, glycerin fructose, etc and/or surgery
45497559|NCT04614909|Drug|Pamiparib|60mg administered orally BID for 4 days prior to surgical resection
45694437|NCT05312398|Drug|Irinotecan|"III LINE:~- Irinotecan + cetuximab~Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line"
45694438|NCT01685203|Drug|ABT-450/r|Tablet; ABT-450; Capsule; ritonavir
46055746|NCT02695797|Other|IVIG|IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
46055747|NCT02695797|Drug|Prednisolone|IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
46055748|NCT02755311|Procedure|liver resection|Intraoperative ultrasound was routinely used during surgery. Anatomic resection was carried out in the form of segmentectomy or/and subsegmentectomy.In segmentectomy, the hepatic parenchyma was transacted at the intersegmental plane as described by Couinaud. If the hepatic parenchymal transaction plane needed to go beyond the intersegmental plane to achieve the desired extent of resection margin, the small portal branches supplying the liver parenchyma up to the intended transaction plane were punctured under US guidance and injected with methylthioninium chloride, and then liver subsegmentectomy was performed either alone or in combination with segmentectomy along the plane of demarcation as delineated by the injected methylthioninium chloride. Nonanatomic resection with a negative resection margin was performed when anatomical resection may cause inadequate liver remnant. Pringle's maneuver was used if necessary with a clamp/unclamp time of 10 min/5 min.
45381843|NCT05606692|Drug|Propofol 1%|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
45381844|NCT05606692|Drug|Sevoflurane/Ultane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
45381845|NCT05606614|Genetic|TSHA-102|TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one time intrathecal (IT) administration.
45381846|NCT05606237|Device|Low-level Red Light Therapy Device|The treatment device used in this study is a semi-conductor laser product (Eyerising International Pty Ltd, Melbourne, Australia), emitting low-level red-light with a wavelength of 650 ± 10 nm. Based on calculations done by the manufacturer, the device provides light at a power of 2.00 ± 0.50 mW.
45381847|NCT05603104|Drug|Clozapine|See arm description
45381848|NCT05603104|Drug|Esketamine Nasal Product|See arm description
45381849|NCT05603104|Drug|Escitalopram|See arm description
45497560|NCT04614909|Drug|Olaparib|200mg administered orally BID for 4 days prior to surgical resection
45497561|NCT04614909|Radiation|Radiation therapy|Patients in Phase 2 will receive 6-7 weeks of radiation therapy per standard of care
45497562|NCT04614909|Drug|Temozolomide|Arm A and Arm B participants after RT is completed, will receive pamiparib in combination with TMZ (newly diagnosed participants). Arm C participants will receive olaparib with TMZ.
45497563|NCT01567917|Procedure|CRC surgery|"Patients will receive surgery for the treatment of CRC as routine clinical practice. These patients will be prospectively observed for the development of VTE(Group A; Doppler US cohort vs. Group B; Simple observation cohort)~- Doppler US is not an intervention. The Doppler US is a non-invasive test (ultrasonography) for the detection of VTE"
45497564|NCT03698214|Other|reversed shock index < 1|Among patients with isolated TBI, those with an RSI < 1 had higher mortality
45694439|NCT01685203|Drug|ABT-267|Tablet
45694440|NCT01685203|Drug|Ribavirin (RBV)|Tablet
45694441|NCT01928771|Biological|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 44 inclusive.
45694442|NCT01928771|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
45497565|NCT03698214|Other|reversed shock index ≥ 1|Among patients with isolated TBI, those with an RSI ≥ 1 had lower mortality
45497566|NCT03698136|Other|Stimulation of denervated muscles|The study investigates the effect of electrical stimulation on denervated muscles in the forearm and hand regarding muscle structure and thickness. The study will be performed on tetraplegics who have either paralysed the wrist extensor, the short thumb spreader or the muscle between the thumb and index finger.The study lasts 12 weeks and consists of an ultrasound examination at the beginning and end of the study and an intermediate stimulation phase.The stimulation takes place either during an inpatient stay or at home for 12 weeks, 5 times a week 33 minutes.
46055749|NCT02755311|Procedure|transarterial chemoembolization|A microcatheter was inserted into the feeding arteries as selectively as possible through the lobar, segmental, or subsegmental arteries, dependent on the tumor distribution and hepatic functional reserve. Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin. Subsequently, chemolipiodolization was performed mixed with 5 ml of lipiodol. According to the number and size of the lesions, and liver and kidney function of the patient, the chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team. If residual flow remained after infusion of these agents, additional lipiodol was injected. Embolization was performed with absorbable gelatin sponge particles 350-560 μm in diameter.
45497567|NCT03698058|Dietary Supplement|Toddler milk|Commercially available toddler milk
45497568|NCT04613271|Drug|Favipiravir|"Assignment of Administration Group 1:~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days."
45497569|NCT04613271|Drug|Azithromycin|Azithromycin 500 mg once a day for 5 days.
45497570|NCT05415189|Other|Not relevant|This is a non-intervention cohort study
45497571|NCT03094611|Biological|Inotuzumab Ozogamicin|Given IV
45497572|NCT04395261|Diagnostic Test|Wideband Tympanometry|
45497573|NCT04601337|Procedure|Infrared Neural Stimulation|We will stimulate nerves identified for transfer or grafting over a range of simulation parameters (pulse width, spot size, energy per unit area, etc) to determine the stimulation threshold. Only portions of the nerve that are no longer functionally required will be stimulated optically. Successful INS events will be determined by visual muscle contractions. Stimulation thresholds will be determined by fitting the data to a cumulative distribution function. Stimulation sites on the nerve will be harvested and histologically examined for evidence of INS-induced damage.
45497574|NCT03631953|Drug|Trametinib|Trametinib administered at a fixed dose (1.5 mg daily)
45497575|NCT03631953|Drug|Alpelisib|A panel of 3 doses of ALPELISIB could be tested
45497576|NCT03631953|Biological|Blood sample|Therapeutic biomarkers
45694443|NCT04545229|Other|VR-based Pain Alleviation Tool (VR-PAT)|Four smart phone based virtual reality games developed by the Research Information Solutions and Innovation (RISI) at the Nationwide Children's Hospital.
45694444|NCT01589653|Drug|biphasic insulin aspart 30|Dose individually adjusted by the subjects themselves according to the titration algorithm every second week. Administered subcutaneously (s.c., under the skin) twice daily.
46055750|NCT02755311|Drug|carboplatin|Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin (Bristol-Myers Squibb, New York, NY).
46055751|NCT02755311|Drug|lipiodol|Chemolipiodolization was performed mixed with 5 ml of lipiodol (Lipiodol Ultra-Fluide; André Guerbet Laboratories, Aulnay-sous-Bois, France).
46055752|NCT02755311|Drug|epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil|The chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team.
46055753|NCT02755311|Other|absorbable gelatin sponge particles|Embolization was performed with absorbable gelatin sponge particles (Gelfoam; Hangzhou Bi-Trumed Biotech Co., Ltd., Hangzhou, Zhejiang, China) 350-560 μm in diameter.
45497577|NCT03631953|Device|MRI|A MRI with contrast will be performed before treatment start. Assessment of tumor growth.
45497578|NCT01030575|Drug|Inositol lower volume|5 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
45497579|NCT01030575|Drug|Inositol mid-level volume|20 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
45497580|NCT01030575|Drug|Inositol high volume|40 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
45497581|NCT01030575|Drug|Placebo low volume|Glucose 5% given in volumes equal to that of the comparator drug
45497582|NCT04378023|Drug|Neoadjuvant Chemo-radiotherapy|Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by concomitant oral capecitabine (825mg/m2 bid).Thereafter, gemcitabine iv (1000mg/m2) plus cisplatin iv (25mg/m2) will be administered the day 1 and 8 every 21 days until transplant.
45497583|NCT04378023|Procedure|Liver Transplantation|If no spread disease is discovered after neoadjuvant treatment, the patient will be listed for liver transplantation.
45497584|NCT04314687|Biological|Umbilical Cord Mesenchymal Stem Cells|The umbilical cord was removed from the donor and brought to cell culture facility immediately. Upon arrival, pre-sterility sample testing was performed to ensure the sample was free from contaminant. Culture processes were conducted in a laboratory room where high sterility and safety were guaranteed. Every batch of the cells was monitored by a series of quality control testing to assure the quality of the product.
45497585|NCT04314687|Biological|Conditioned Medium|Conditioned medium collected from umbilical cord mesenchymal stem cell (UC-MSC) cultured. Every batch of the conditioned medium was monitored by a series of quality control testing to assure the quality of the product.
45497586|NCT04314687|Other|Standard Therapy|Standard therapy for cerebral palsy such as physiotherapy
45497587|NCT04119843|Drug|Mangoral|800 mg manganese chloride [II] tetrahydrate, 500 mg L-alanine, and 800 IU vitamin D3
45497588|NCT04215471|Drug|PD-L1 Antibody SHR-1316|Neoadjuvant therapy with immunoreagent (PD-L1 antibody SHR-1316) for resectable oesophageal squamous cell carcinoma
45847530|NCT04867044|Other|Control|healthy woman volunteers
45847531|NCT04800510|Device|Carbon Fiber Custom Dynamic Orthosis (CDO)|The CDO will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
45381850|NCT05603104|Drug|Sertraline|See arm description
45497589|NCT04561011|Behavioral|Internet-delivered Cognitive Behavioural Therapy(ICBT)|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend ~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
45497590|NCT04065477|Behavioral|computer-based cognitive rehabilitation (CBCR)|Program designed to improve strategic cognitive domains (e.g., complex attention, working memory)
45497591|NCT04105725|Behavioral|Brief Motivational Intervention+Substance-Free Activity Session|A dialogue with the individual of their own experiences with alcohol use and related problems, as well as academic/career goals and personal interests.
45497592|NCT04105725|Other|Alcohol + Nutrition Education Session|Education on alcohol, alcohol metabolism in the body, and alcohol overdose, as well as education on food groups and recommendations for a balanced diet.
45497593|NCT04066023|Drug|C213 Microneedle System|The C213 System is a proprietary disposable patch and a reusable applicator. The zolmitriptan-coated titanium microneedle array (3 cm^2 array) is attached to a 5 cm^2 adhesive patch.
45497594|NCT04066023|Drug|Placebo|The C213 System is a proprietary disposable patch and a reusable applicator. The placebo patch is a single use, 3 cm^2 Placebo (intracutaneous microneedle) system that contains no active ingredients.
45497595|NCT03106987|Drug|Active Comparator: Olaparib tablets|"Olaparib~300mg Olaparib tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
45497596|NCT03106987|Drug|Placebo|"Placebo~300mg placebo tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
45497597|NCT02910895|Other|tumor biopsy|biopsy
45497598|NCT04971109|Drug|TPOXX|Study is based on Animal Regulatory Rule
45497599|NCT04971109|Other|TPOXX Placebo|Does not apply
45497600|NCT04947709|Behavioral|Physical Activity|The main structure of the physical activity program will focus on increasing physical activity. Physical activity will initially start at a duration of 15-30 minute bouts, and at rate of perceived exertion levels of 5-6 (somewhat hard). Over the course of the intervention, goals will be set to progress to 60 minutes of continuous physical activity, at a rate of perceived exertion level of 5-6 (somewhat hard). Participants will be instructed on the use of the ratings of the perceived exertion scale (Borg's RPE 1-10 scale). Participants will be instructed to walk, or engage in other forms of leisure-time physical activity to achieve these goals (cycling, running, swimming, etc). As the adolescent and young adults' health and fitness status improve, frequency, intensity, and session duration will be modified accordingly during weekly support calls. Moreover, goals will be responsive to the most recent week's achieved minutes and rate of perceived exertion.
45694445|NCT01589653|Drug|biphasic insulin aspart 30|Dose individually adjusted according to the directions given by the investigator. Administered subcutaneously (s.c., under the skin) twice daily.
45694446|NCT01928615|Drug|Trastuzumab - intravenous solution|Trastuzumab was supplied as a powder to be reconstituted as a solution for intravenous infusion.
45694447|NCT01928615|Drug|Trastuzumab - subcutaneous solution|Trastuzumab was supplied as a solution for subcutaneous injection.
45694448|NCT01928615|Drug|Chemotherapy|Standard chemotherapy for early breast cancer.
45381851|NCT05603104|Drug|Duloxetine|See arm description
45381852|NCT05603104|Drug|Venlafaxine|See arm description
45381853|NCT05603104|Drug|Lithium|See arm description
45381854|NCT05603104|Drug|Lamotrigine|See arm description
45381855|NCT05603104|Drug|Valproate acid|See arm description
45381856|NCT05603104|Drug|Quetiapine|See arm description
45381857|NCT05603104|Drug|Second-line Antidepressants|See arm description
45381858|NCT05603104|Drug|Second-line Antipsychotics|See arm description
45381859|NCT05603104|Drug|Ketamine Hydrochloride|See arm description
45381860|NCT05603104|Drug|Esketamine hydrochloride|See arm description
45381861|NCT05602688|Dietary Supplement|Lemon Balm Supplement|Oral 200 mg Lemon Balm supplement tablet Twice a day for three-weeks
45381862|NCT05602688|Dietary Supplement|Matched Placebo|Matched placebo tablet Twice a day for three-weeks
45381864|NCT05601336|Drug|Dapagliflozin 5 MG|SGLT2 inhibitor
45381865|NCT05601336|Drug|Metformin Hydrochloride 1000 MG|metformin
45381866|NCT05601336|Drug|Dapagliflozin/Metformin|SGLT2 inhibitor and metformin HCl extended-release
45497601|NCT02932267|Drug|Adapalene 0.3% / BPO 2.5% gel|Epiduo Forte / Tactupump gel to be applied once a daily at bed time on entire face during 16 weeks
45497602|NCT04930705|Device|Treatment with TempSure Applicator|Subjects will receive up to 5 treatments on the abdomen.
45497603|NCT03217591|Drug|IW-1973|Oral Tablet
45497604|NCT03217591|Drug|IW-1973|Oral Tablet
45497605|NCT03217591|Drug|Placebo|Oral Tablet
45497606|NCT04927195|Drug|EDP1867|EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria
45497607|NCT04927195|Drug|Placebo|Placebo oral capsule
45497608|NCT03636763|Drug|data report|"the information gliptin exposure will be reported"
45694449|NCT01589497|Drug|Rifampicin|Participants with body weight </= 50kg were administered one 450 mg tablet orally once daily. Participants with body weight >50kg were administered one 600 mg tablet orally once daily.
45694450|NCT01589497|Drug|Isoniazid|Participants were administered three 100 mg tablets or one 300 mg tablet once daily.
45497609|NCT03031782|Drug|secukinumab|secukinumab is a high-affinity fully human monoclonal anti-human antibody that targets IL-17A and neutralizes activity.
45497610|NCT03031782|Other|placebo|Matched placebo to AIN457 for use in the double blind Treatment Period 2
45497611|NCT03697902|Diagnostic Test|Ultrasonographic Measurement on Fetal cisterna magna length|"The length measurement on the fetal cisterna magna (CM) with an angle of 0° between the transducer and the axial cerebellar plane of the fetal head (midline structures will be perpendicular to the ultrasound beam). After that, CM will be measured again after moving the transducer approximately 30° towards the fetal occiput.~Measurements will be performed on the axial cerebellar plane using internal landmarks including the cavum septi pellucidi, thalamus, third ventricle, cerebral peduncles and cerebellar hemispheres.The anteroposterior measurement will be made between the posterior border of the cerebellar vermis and the internal face of the occipital bone.~All the ultrasonography examinations were performed abdominally, using 3-5 megahertz (MHz) transducers."
45497612|NCT03697824|Drug|GSK3377794|GSK3377794 is genetically engineered NY-ESO-1 Specific (c259) T cells.
45497613|NCT03697824|Drug|Pembrolizumab|Pembrolizumab will be administered at a dose of 200 mg once every 3 weeks for adults and 2 mg/kg (up to 200 mg) once every 3 weeks for children.
45497614|NCT03697824|Drug|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
45497615|NCT03697824|Drug|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
45497616|NCT03700398|Device|first OE|optical enhancement(OE)，a kind of electron straining endoscopy
45497617|NCT03700398|Device|first WLI|the routine in the clinical practice
45497618|NCT03702894|Drug|Clavamox|Clavamox, Film-coated Tablets, 875 mg + 125 mg, manufactured by Pharmtechnology LLC, Belarus
45497619|NCT03702894|Drug|Augmentin®|Augmentin®, Film-coated Tablets, 875 mg + 125 mg, marketed by GlaxoSmithKline Trading CJSC, Russia
45497620|NCT03697746|Drug|paracetamol|paracetamol 1000 mg vial
45497621|NCT03697746|Drug|Dexketoprofen Trometamol|dexketoprofen trometamol 50 mg bulb
45497622|NCT03697746|Drug|Ibuprofen|ıbuprofen 400 mg vial
45497623|NCT03216265|Other|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
45381867|NCT05600244|Procedure|PENG block Technique|A linear probe will be used. Puncture will be performed in a lateromedial direction until the needle tip reached the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, 30 ml of bupivacaine 0.25% will be injected in the plane beneath the iliopsoas muscle
45381868|NCT05600244|Procedure|Lumbar ESPB Technique|Using the out-plane technique, a 22G/80-mm block needle will be advanced until it reached the transverse process. 0.5-1 ml of the prepared local anesthetic solution, 30 ml bupivacaine 0.25% will be administered leading to hydrodissection to confirm the correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurs when administering local anesthetic . All local anesthetic will be administered to this location between the transverse process and the erector spinae muscle
45381869|NCT05600244|Procedure|Transmuscular QLB-t block Technique|A convex transducer will be placed in the transverse plane on the flank of the patient cranial to the iliac crest. The 4th lumbar vertebral transverse process, erector spinae muscles, psoas muscle, transverse abdominis muscle, internal and externa oblique muscles, and the quadratus lumborum muscle will be identified. A 15 cm 22G insulated needle will be inserted on the posterior corner of the transducer. 30 ml bupivacaine 0.25% will be administered between the quadratus lumborum and psoas muscles into the fascial plane.
45381870|NCT05599672|Behavioral|Alcohol-targeted Brief Intervention-Medication Therapy Management|Alcohol-targeted Brief Intervention-Medication Therapy Management (ABI-MTM) intervention is a pharmacy-based medication management intervention, combined with Screening, Brief Intervention, and Referral to Treatment. ABI-MTM includes 5 core elements. A common duration for medication counseling in outpatient pharmacies a single 30-45 minute session. These include a medication review, a personal medication record, a medication action plan, a brief motivational intervention, and documentation and follow up.
45497624|NCT03216265|Other|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
45497625|NCT03216265|Other|No treatment|No treatment.
45497626|NCT03697668|Drug|Imatinib|triple combination for the treatment of malaria
45497627|NCT03697668|Drug|Dihydroartemisinin-piperaquine|standard malaria treatment
45497628|NCT04387812|Device|Xtrodes home PSG system|Wireless, convenient and relies on actual recording of EMG, EOG and EEG in a home setting
45497629|NCT03700164|Other|Temperature|Water-perfused suit.
45497630|NCT03700086|Device|Disposable negative wound pressure device (PICO)|Application of a disposable negative wound pressure device for surgical site infection prevention.
45497631|NCT03700086|Device|OPsite post-op visible standard sterile dressing|Application of a standard sterile wound dressing.
45497632|NCT04050384|Device|Baby GentleStick|The Baby GentleStick is a handheld device that fits and provides vibration to an Owen Mumford Unistik3 Dual lancet. The gentle vibration occurs at 178 Hertz with a free-hanging 0.24 mm range of motion. The device may provide vibration alone and also allow for simultaneous vibration and deployment of the lancet.
45497633|NCT03700008|Diagnostic Test|Speech analysis tool|Using the speech analysis tool with recording 120 seconds of free speech and analysis of 200 content-free parameters of the speech including factor analytic process to compress the data to 5-10 core parameters.
45497634|NCT03700008|Diagnostic Test|Conventional psychological measurements|Using well known and validated psychological measurements to identify the mental state of the participants.
45497635|NCT03697434|Behavioral|Palliative Care referral|Individuals with Parkinson disease identified as having specific uncontrolled symptoms or critical events will undergo standardized referral to palliative care, who will provide supportive care. During the palliative care referral, participants and their care partners may discuss symptoms, disease burden (physical, emotion, financial, and psychological), quality of life, goals of care, and advance directive completion. Palliative care specialists may recommend interventions to manage bothersome symptoms or to improve disease burden for both participants and care partners.
45847532|NCT04784208|Diagnostic Test|Blood test for Thyroid stimulating hormone (TSH)|Blood test for Thyroid stimulating hormone (TSH)
45497636|NCT03702738|Drug|N-acetyl cysteine|NAC is listed by WHO as an essential medicine for its use in paracetamol (acetaminophen) poisoning, in which it protects against fatal liver injury. It also reduces the viscosity of sputum, thereby serving as an expectorant.
45497637|NCT03702660|Other|GIP(3-30)NH2|Peptide derived from the naturally occuring gut hormone GIP
45497638|NCT03702660|Other|Peripheral venous cannulation|Intravenous access for infusions
45497639|NCT03702660|Other|GLP-1|Peptide infusion
45497640|NCT04486950|Drug|TAK-951|TAK-951 intravenous infusion.
45497641|NCT04486950|Drug|TAK-951 Placebo|TAK-951 placebo-matching intravenous infusion.
45497642|NCT03699852|Radiation|Membracel and LED photobiomodulation|Participants were positioned so that the skin graft donor area was accessible. A light-emitting diode (LED) plate was covered with sterile transparent and waterproof film to prevent contamination when in contact with the donor area. The application was in contact, with full coverage of the surgical wound and was irradiated with radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. It is worth mentioning that the LED plate was applied in direct contact with the skin graft donor area in the immediate postoperative period and on the primary cover used (Membracel®) on the 1st, 3rd, 5th and 7th postoperative days. Coverage remained until spontaneous departure. The researcher and the participants used specific goggles for this procedure.
45497643|NCT03699852|Other|Membracel|This group did not receive LED application, remaining with the skin donor area covered by Membracel® and were evaluated under the same conditions.
45497644|NCT03697200|Other|APA|Light touch using vaccaria seeds on specific points of the ear
45497645|NCT03697200|Other|Sham APA control|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
45497646|NCT03697200|Other|Education control|Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Materials will be tailored so that they can be delivered within 15 minutes for each session
45497647|NCT04050696|Device|BQ 1.2|BQ 1.2 exposure of EMF exposure paradigm in conjunction with upper limb PT regimen
46055754|NCT04554771|Drug|Tocilizumab 20 Mg/mL Intravenous Solution|tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 of standard of care neoadjuvant chemoradiation
45497648|NCT03702582|Drug|Rivaroxaban|Anticoagulant drug that works via direct inhibition of factor Xa. FDA approved for prophylaxis against stroke in non-valvular atrial fibrillation
45694451|NCT01589497|Drug|Pyrazinamide|Participants with a body weight of 40-55 kg were administered two 500 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 500 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 500 mg tablets orally once daily.
45694452|NCT01589497|Drug|Ethambutol|Participants with a body weight of 40-55 kg were administered two 400 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 400 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 400 mg tablets orally once daily.
45694453|NCT01589497|Drug|Moxifloxacin|Participants were administered one 400 mg tablet orally once a day.
45694454|NCT01928381|Drug|AZD5213 + pregabalin|Double blind Investigational drug AZD5213 (capsules) given in combination with pregabalin (capsules)
46055755|NCT04554771|Drug|Paclitaxel|Paclitaxel 50 mg/m2 will be given intravenously on days 1, 8, 15, 22 and 29
45497649|NCT03702582|Drug|Warfarin|Anticoagulation drug that works via inhibition of vitamin K dependent clotting factors. FDA approved for prophylaxis against stroke in atrial fibrillation
45497650|NCT03697044|Procedure|Irinotecan Drug-Eluting-Bead Trans Arterial ChemoEmbolisation|Patient Registry to assess the delivery of Irinotecan loaded drug eluting beads for the treatment of colorectal liver cancer metastases.
45497651|NCT04693416|Other|Intrapersonal Stigma Reduction|Brief intervention for stigma reduction
45694455|NCT01928381|Drug|Placebo|Double blind placebo capsules to match AZD5213 and pregabalin
45694456|NCT01928381|Drug|pregabalin capsules|Double blind pregabalin capsules to match AZD5213 and placebo
46055756|NCT04554771|Drug|Carboplatin|Carboplatin AUC = 2 will be given intravenously on days 1, 8, 15, 22 and 29
46055757|NCT04554771|Radiation|External beam radiotherapy|External beam radiotherapy will be delivered to a total dose of 41.4 Gy in 23 fractions of 1.8 Gy, 5 fractions per week starting the first day of the first cycle of chemotherapy
46055758|NCT04553523|Device|Hydrus Microstent|Crescent-shaped nitinol device intended as a permanent implant to provide an outflow pathway for aqueous humor. The device is placed through the trabecular meshwork into Schlemm's canal immediately following placement of a monofocal IOL.
45497652|NCT04693416|Other|Interpersonal Stigma Reduction|Brief intervention for support persons of intrapersonal intervention participants.
45497653|NCT03699774|Drug|DS-8500a|DS-8500a is provided as three 25-mg tablets for oral administration
45497654|NCT03699774|Drug|Rosuvastatin|Rosuvastatin is provided as a 10-mg tablet for oral administration
45497655|NCT03699696|Drug|Propofol|Induction of anesthesia prior to surgery with propofol
45497656|NCT03699618|Drug|Anti-VEGF|Standard of care treatment with anti-VEGF only
45497657|NCT03699618|Other|Hemorrhage displacement + Anti-VEGF|Standard of care treatment with hemorrhage displacement (at investigators' discretion) followed by anti-VEGF injections
45497658|NCT03696966|Dietary Supplement|Portion-Controlled Meals|Increase dietary structure using portion-controlled meals (PCM)
45497659|NCT03696966|Behavioral|Low-Calorie Diet|Restrict calorie intake daily
45497660|NCT03696966|Behavioral|Intermittent Very-Low Calorie Diet|Severely restrict calorie intake intermittently
46055759|NCT04553523|Procedure|Cataract surgery|Cataract surgery performed using standard anesthesia and phacoemulsification techniques
46055760|NCT04553523|Device|Monofocal IOL|Commercially available monofocal intraocular lens as determined by the investigator
46055761|NCT02755233|Other|Pulmonary Function|Spirometry and DLCO were measured according to performance standards based on the statements from the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Values of DLCO were adjusted for the patient's current hemoglobin value, and the patients were asked to withhold cigarette smoking at least four hours before pulmonary function testing. Lung volumes and DLCO were measured with a commercial ZAN300 CO Diffusion system (nSpire Health GmbH, Oberthulba, Germany)
46055762|NCT02751723|Other|validated questionnaires|
45497661|NCT03702426|Drug|GMCSF|GMCSF 1.5mcg/Kg
45497662|NCT03702426|Drug|Norfloxacin|Tablet Norfloxacin 400 mg
45497663|NCT03696888|Behavioral|Telecoach|A skills-training web-app teaching skills for reducing problematic alcohol use.
45497664|NCT03696888|Behavioral|TeleCoach control|A web-app providing information about the health-related consequences of alcohol consumption.
45497665|NCT00265941|Drug|cetuximab|Cetuximab 400 mg/m^2 IV loading dose 5-7 days before start of radiation therapy, then 250 mg/m^2 IV weekly for 7 weeks
45497666|NCT00265941|Drug|cisplatin|Cisplatin 100 mg/m^2 IV on days 1 and 22
45497667|NCT00265941|Radiation|Accelerated Fractionation by Concomitant Boost|3DCRT 54 Gy in 30 1.8 Gy fractions over 6 weeks with boost 18 Gy in 12 1.5 Gy fractions for last 12 days, for a total of 72 Gy in 42 fractions over 6 weeks
45497668|NCT00265941|Radiation|Intensity-modulated radiation therapy|70 Gy in 35 2.0 Gy fractions over 6 weeks with 6 fractions per week (on Saturday or as second daily fraction) in 5 of the 6 weeks.
45497669|NCT04367922|Behavioral|Positive Emotion Skills Course|The skills will be delivered over approximately 6 weeks, and individuals can participate from any device and location with internet access. A week will consist of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting. Participants cannot skip ahead, and can only progress to the next lesson if they have completed the current one, but they can return to old lessons or exercises if they wish to. Skills include: positive events, capitalizing, gratitude, mindfulness, positive reappraisal, personal strengths, achievable goals, self-compassion.
45497670|NCT03696732|Other|Anxiety questionnaire|Spielberger. State-Trait Inventory questionnaire
45497671|NCT03696732|Other|VAS questionnaire|verbal numerical scale (VNS) anxiety score
45497672|NCT01568541|Drug|Regular toothpastes|One tooth brushing
45497673|NCT01568541|Drug|Children's toothpastes|One tooth brushing
45694457|NCT01928225|Biological|Human Papillomavirus vaccine|The participants receive the qHPV vaccine at entry, week 4 and week 26
46055763|NCT04549155|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.
45497674|NCT03699462|Drug|Plasma solution-A injection|The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
45497675|NCT03699462|Drug|5% Albumin|The group receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
45497676|NCT03699384|Drug|Azacitidine|AZA 75 mg/m^2 SC or IV D 1-7 28 day cycle x 1
45497677|NCT03699384|Drug|Avelumab|Avelumab 10mg/kg IV D1, D15, 28d cycle Until progression or MRD If MRD-, tx x 1 yr or go to allo SCT
45497678|NCT03702348|Other|Resistance exercise|Protocol with 5min warm-up exercise and 8 exercises that progress in positioning and resistance based on maximum repetition test. The exercises strengthen both the lower and upper limbs and are intended to simulate activities such as sitting and standing up, climbing stairs, picking up weight ...
45497679|NCT03702192|Device|novel anticoagulation protocol used in conjunction with the Berlin Heart EXCOR|novel antithrombotic management protocol
45497680|NCT03699306|Procedure|NG tube insertion method|a feeding tube called naso-gastric or NG tube were inserted through nostril inside the stomach randomly by one of three methods mentioned earlier
45497681|NCT03624738|Procedure|Procedure|"Patients with redo cardiac surgery 1: femoral artery-femoral vein cardiopulmonary bypass (CPB) in order to achieve cardiac decompression prior to sternotomy.~Patients with redo cardiac surgery 2: only conventional aortobicaval cannulation will be used"
45497682|NCT04014231|Procedure|Diagnostic Imaging|Undergo placement of single wave application
45497683|NCT04014231|Other|Laboratory Biomarker Analysis|Correlative studies
45497684|NCT05378763|Drug|Poziotinib|Poziotinib tablets
45497685|NCT05378763|Drug|Docetaxel|Docetaxel IV infusion
45497686|NCT04462302|Behavioral|Internet-based pain coping skills program|The purpose of this study is to determine if an 8-session Internet-based pain management program can help you better manage your cancer-related pain.
45497687|NCT03697590|Drug|No curettage|Standard PDT without curettage
45497688|NCT03697590|Drug|Curettage|Standard PDT
45497689|NCT05375799|Other|Clinical Observation|"This is an observational study, so there are no interventions. Data will be recruited from adult patients diagnosed with COVID-19, described in medical records, by laboratory detection of SARS-CoV-2 RNA, who used the Assisted Breathing Helmet - ELMO.~All the following predictor variables will be collected: demographic and anthropometric data; clinical characteristics of patients (comorbidities, date of onset of symptoms and initial symptoms, hospital admission, laboratory tests, chest X-ray tests, need for intubation or ICU admission); start date of ELMO use, blood gas analysis before and after the first application of ELMO and data related to its use (number of applications, number of days of therapy, total time of therapy, as well as reasons for the interruption and adverse effects )."
45497690|NCT03636997|Procedure|Draining seton|Number 1 silk suture was passed through the fistula track and tied as loose seton
45497691|NCT03636997|Procedure|Rerouting of track|The seton and fistula track were rerouted to involve the internal anal sphicnter only and spare the external sphincter
46055764|NCT02755155|Drug|Human serum albumin infusion 4%|Continuous infusion of 15mL/kg of bodyweight over 24h/day
45497692|NCT05420883|Other|Acupressure|One minute after the Nonstress test recording starts, sequential pressure will be applied to the Zhi yin (BL67) acupuncture points simultaneously for 2 minutes. The process will be repeated a second time, with a three-minute rest period. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
45694458|NCT04624061|Behavioral|Integrated HIV/HTN care model|The intervention is a multi-component intervention of combined HIV and HTN care, based on the PRECEDE framework, to continuously identify barriers and facilitators leads to better health outcomes including dual control of HIV/HTN among adults in HIV care in the intervention compared to control facilities
45694459|NCT01927757|Biological|Etanercept|Administered by subcutaneous injection
46055765|NCT02755155|Drug|Human serum albumin infusion 20%|Specify details not covered in associated Arm Description. Intermittent infusion up to 200 ml/8h/day until the plasma albumin concentration is in the range 30+3g/L
45497693|NCT05420883|Other|Halojen ışık|One minute after the start of the Nonstress test recording, halogen light stimulation will be given from the mother's abdomen over the fetal head for 10 seconds and the procedure will be repeated after 10 minutes. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
45497694|NCT05420883|Other|Control|No application will be made to the control group. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
45497695|NCT04665973|Behavioral|Therapeutic patient education : oral semi-structured interview|The physiotherapist discusses and goes through each page of the booklet and involves the patient as much as possible. He demonstrates the exercises proposed in the booklet and then ask the patient to perform them in front of him. The physiotherapist tries to identify the patient's needs and suggests different ways to ensure that the patient has different opportunities to maintain the best possible level of PA
45497696|NCT04665973|Behavioral|Therapeutic patient education : booklet (passive)|The booklet (11 pages): explains why it is important to maintain a good level of PA as part of cancer treatment and reviews the most common side effects of cancer therapy and the relative importance of PA in combating these effects (pages 2-3) ; defines PA, its modalities and possible security precautions (pages 4-5), suggests exercises to be performed oneself and a target intensity to be reached (pages 6-8), provides a roadmap to be completed oneself (pages 9-10), and outlines procedures for joining an exercise medicine group (page 11).
45497702|NCT03696654|Procedure|adenotonsillar surgery|when indicated, adenotonsillar surgery for SDB treatment
45497703|NCT05420571|Procedure|digital impression|3D printed models after digital impressions
45497704|NCT05420571|Procedure|alginate impression|Alginate impressions after plaster model infusion to make models
45497705|NCT03696420|Other|Coordinates of active plots and VIM landmarks calculation|Stimulation efficacy will be assessed by comparing, according to usual care, the clinical evaluation (FTM scale) with and without stimulation, and the four contacts of each electrode will be tested clinically, with an accelerometer and an electromyography to determine which one is the most active on tremor. Coordinates of the anatomical landmarks will be calculated on the pre-operative MRI and those of the active plots on the fusion between post-operative CT-scan and pre-operative MRI.
45497706|NCT00188695|Procedure|MRI contrast agent Combidex (ferumoxtran-10)|Combidex as an MR-lymph node contrast agent for the detection of small lymph nodes and lymph metastases.
45497707|NCT05420415|Other|CSTME|Tumor microenvironment collagen signature
45497708|NCT02937571|Drug|Carfilzomib|
45847533|NCT04782570|Device|Verum TMS|Intensity of 100% of the resting motor threshold with iTBS. 600 stimuli applied in bursts of three pulses at 50 Hz given every 200 ms. iTBS will be applied 20 times for 2 s every 10 s.
45497709|NCT02937571|Drug|Lenalidomide|
45497710|NCT02937571|Drug|Dexamethasone|
45497711|NCT03882957|Behavioral|Sustained attention|participants will complete a sustained attention task
45497712|NCT03882957|Behavioral|media multi-task|participants will complete multiple media tasks at the same time
45497713|NCT03882957|Other|Video|participants will watch a video of media tasks being completed
45497714|NCT04333290|Drug|[11C]MeDAS|PET radiotracer
45497715|NCT03201211|Biological|Blood sampling|A volume of approximately 20 mL of whole blood should be drawn from each subject, at each study visit, for antibody determination and assay validation/development.
45497716|NCT03201211|Biological|GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, PE-PilA and UspA2.|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
45497717|NCT03201211|Biological|GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2.|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
45497718|NCT03201211|Drug|Placebo|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
45497719|NCT03843723|Other|Pre-flight evaluation|All the participants receive the interventions as part of their routine medical care during their annual visit for CF follow-up. Oxygen saturation are measured by pulse oximetry. Exercise testing is performed by 6MWT and CPET. Pre-flight evaluation is performed by HAST.
45497720|NCT03727191|Other|Control Group (education, guidelines, recommendations)|Nutritional education and guidelines for the consumption of a completed shreded diet and recommendations for physical activity for one month.
45847534|NCT04782570|Device|Sham TMS|Sham stimulation with same protocol, but without magnetic stimulation
45847535|NCT04775004|Other|Bone marrow venting procedure (BMVP)|The BMVP involves creating small holes in a non-weight bearing area of the bone that does not have any important structures; the holes act as channels, which allow for flow of the participants own biologic products and stem cells from within the bone marrow.
45497721|NCT03727191|Other|Experimental Group (education, guidelines, 2 pckts diet, recommendations)|Nutritional education and guidelines for the consumption of a completed shreded diet including 2 packets of 90 grams every day and recommendations for physical activity for one month.
45497722|NCT04633837|Device|Extracellular Matrix Graft Injectable Implant|The extracellular matrix injectable implant will serve as the intervention in this study.
45694460|NCT01927757|Drug|Methotrexate|Background methotrexate at least 15 mg weekly
45694461|NCT01927367|Other|Clinical Decision Support System for AF|A web-based clinical decision support system, computerizing the Canadian AF clinical guidelines and best-practice approaches, to support primary care providers and patients in optimizing and standardizing AF care.
45694462|NCT01913639|Drug|Regorafenib|
45694463|NCT01913639|Drug|5-Fluorouracil|
45694464|NCT01913639|Drug|Leucovorin|
45497723|NCT03622437|Behavioral|Patient-led follow-up|"Patient-education, with information about signs of recurrent disease (alarm-symptoms), potential late effects, and how these can be managed.~The patients are instructed to contact a specialist nurse in case of alarm-symptoms, concerns or other problems related to the cancer disease throughout the entire follow-up period. The specialist nurse responds to the referrals, according to a standardized algorithm.~In addition, all patients receive:~CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years~Only for patients with a stoma:~- access to stoma care by specialist nurses"
45497724|NCT03622437|Other|Standard follow-up|"Patients with sphincter-preserving resection:~- outpatient visits incl. rectoscopy at 6, 12, 18, 24 and 36 months~Patients with rectal amputation and a permanent stoma:~outpatient visits at 3, 12 and 36 months~access to stoma care by specialist nurses~All patients:~CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years"
45497725|NCT04624945|Diagnostic Test|APTT CWA (Activated partial thromboplastin time clot waveform analysis), Procalcitonin and Serological/Inflammatory markers (KL-6, SPA, MIG, Presepsin)|"Primary Aim: To validate the use of APTT CWA (Activated partial thromboplastin time clot waveform analysis) and ICIS (Intensive Care Infection Score), as early sepsis markers for neurosurgical ICU patients suffering subarachnoid haemorrhage, traumatic brain injury and other intracranial haemorrhages.~Secondary Aim: To examine the evolution of CWA, immuno-parameters (KL-6, SP-A, MIG, presepsin) and various WBC (white blood cell count) activation markers over the time in relation to diagnosis of sepsis, development of positive blood cultures and mortality or recovery. Blood parameter measurements using a 3-part and 5-part differential analyser will be performed. KL-6, SP-A, MIG, presepsin are serum biomarkers - MIG (Monokine induced by gamma interferon), SP-A (Surfactant protein A), KL-6 (Krebs von den Lungen 6)."
45497726|NCT04871893|Device|multiECCO2R blood-gas exchanger|Treatment with the blood-gas exchanger multiECCO2R for CO2 removal
45497727|NCT05598879|Other|anonymized data collection during programmed surveillance clinical follow up|anonymized data entry of demographic, clinical, imaging, laboratory, cancer treatment, and cardiovascular events into a RedCap Cloud platform
45497728|NCT03540069|Behavioral|Care Group Cervical Cancer Screening Education Curriculum|a multi-modal peer education curriculum directed at a multi-level audience and aimed at motivating women to seek cervical cancer screening services.
45497729|NCT04490343|Diagnostic Test|Abdominopelvic low dose CT|Patients with urinary stones will undergo multiple computed tomography (CT) examinations
45497730|NCT03696264|Dietary Supplement|Amino acid intake|Amino acid intake will range between 0.2-3.0g/kg/d
45497731|NCT04472949|Drug|Durvalumab|Durvalumab: 1500 mg iv
45497732|NCT04472949|Drug|carboplatin|Carboplatin: AUC 5 mg/mL/min iv
45497733|NCT04472949|Drug|etoposide|Etoposide: 100 mg/m2 iv
45497734|NCT04472949|Radiation|Thoracic radiotherapy|Thoracic radiotherapy: 39 Gy in 13 fractions, starting 3-8 weeks after day 1 of last cycle of induction treatment, over 2.5 weeks Prophylactic cranial irradiation (PCI) is allowed but optional: according to local practice, starting 3-8 weeks after day 1 of last cycle of induction treatment Follow up phase Patients will be followed up for 24 months, every 8 weeks.
45497735|NCT03696186|Drug|Luminal type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
45497736|NCT03696186|Drug|Luminal type-2|Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+Prednisone (5 mg, twice daily)
46055766|NCT02751645|Procedure|Acute Normovolemic hemodilution|ANH is a technique in which a portion of the patients' own blood is removed before any surgical bleeding occurs. It is stored until the end of the operation, at which point it is returned to the patient.
46055767|NCT02754843|Device|Phonak's equivalent newly developped power BTE|
46055768|NCT02754843|Device|Equivalent competitor device|
46055769|NCT02754765|Drug|Bedaquiline|
46055770|NCT02754765|Drug|Delamanid|
46055771|NCT02754765|Drug|Clofazimine|
46055772|NCT02754765|Drug|Levofloxacin|
45497737|NCT03696186|Drug|Neuroendocrine type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
45694465|NCT01913639|Drug|Oxaliplatin|
46055773|NCT02754765|Drug|Moxifloxacin|
46055774|NCT02754765|Drug|Linezolid|
46055775|NCT02754765|Drug|Pyrazinamide|
46055776|NCT02754765|Drug|Control arm MDR-TB regimen, consistent with WHO guidelines|Control arm MDR-TB regimen, consistent WHO guidelines
46055777|NCT02751411|Device|micro-enema with Promelaxin|The intervention has a lubricating, protective action on the anus and rectum and a balanced osmotic action which elicits the evacuation reflex.
46055778|NCT02751411|Drug|Macrogol 4000|Stool softener
46055779|NCT04358289|Other|Basic antimicrobial stewardship education|Commune health center: Revision of guidelines for antibiotic prescribing for respiratory infections in primary care, Training primary healthcare doctors in the application of the new guidelines
45381871|NCT05599672|Behavioral|Standard medication counseling|Standard Medication Counseling (SMC) will be the treatment as usual condition in this study and was chosen/developed following Gold et al.'s guide for selecting control conditions in behavioral intervention studies. For the first component, all SMC participants will receive a single 5-10 minute medication information/counseling session delivered by a pharmacist, other than the study pharmacist, that possesses a similar level of education and professional licensing. The content of this session follows federal and state pharmacy requirements requiring pharmacists to: (1) offer counseling, (2) document counseling was offered, (3) offer a counseling process for patients not present (not applicable to this study given all patients must screen in person), and (4) discuss generic substitution. Following this session, in the second SMC component, participants will be emailed/mailed (according to participant preference) safety information about co-use of alcohol and opioids.
45497738|NCT03696186|Drug|Neuroendocrine type-2|Goserelin (3.75mg, once every 4 weeks)+Carboplatin (area under the curve 5 on day 1 every 3 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
45497739|NCT03696186|Drug|Atypical type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
45497740|NCT03696186|Drug|Atypical type-2|Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+ targeted therapy according to next Generation Sequencing (NGS)+ Prednisone (5 mg, twice daily), or Goserelin (3.75mg, once every 4 weeks)+Abiraterone+ Prednisone (5 mg, twice daily) if no druggable gene mutation detected.
45497741|NCT03699072|Device|DermaRep™ Wound Contact Device|Treatment of venous leg ulcers once weekly for 8 weeks along with standard of care dressings
45497742|NCT03964311|Other|Emergency Room Evaluation Tool (ER2)|Emergency Room Evaluation Tool represents a screening method that will be used at the Emergency by nurses. This tool evaluates the health conditions of all the patients who are 75 years and over.
45497743|NCT03698916|Drug|Celecoxib cream 8%|transdermal delivery of 8% Celecoxib
45497744|NCT03336333|Drug|Zanubrutinib|Administered as two 80-mg capsules by mouth twice a day (160 mg twice a day)
45497745|NCT03336333|Drug|Bendamustine|Administered intravenously (IV) at a dose of 90 mg/m2/day on the first 2 days of each cycle for 6 cycles.
45497746|NCT03336333|Drug|Rituximab|Administered intravenously (IV) at a dose of 375 mg/m2 on day 0 of cycle 1, and at a dose of 500 mg/m2 on day 1 of cycles 2 to 6.
45497747|NCT03336333|Drug|Venetoclax|400mg tablets administered orally once daily.
45497748|NCT03698838|Device|McDESPOT|MRI sequence, mcDESPOT (multicomponent driven equilibrium potential of T1 and T2) that utilizes a computer model that takes T1 and T2 sequences and derives a quantitative value for the myelin content in the myelin sheath
45497749|NCT03695952|Drug|Nivolumab or pembrolizumab|Nivolumab 3 mg/kg intravenous every 2 weeks; Pembrolizumab 200 mg intravenous every 3 weeks
45497750|NCT03695874|Other|Phase 1 : fill out 1 scale|"Patients will be asked to complete questionnaires.~Group 1: the purpose is to simplify a 75 items scale by a statistical analysis of the data collected from 400 patients. The statistical purification will allow to finalize an abbreviated scale (20-25 items).~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires."
45497751|NCT03695874|Other|Phase 2 : fill out 1 scale and 4 questionnaires|"Patients will be asked to complete questionnaires.~Group 2: the purpose is to validate the abbreviated scale by a statistical analysis of the data collected from 200 patients. The statistical validation will allow to check the consistency and correlation of the abbreviated scale with other scales: a general Quality Of Life scale (SF36), an anxiety and depression scale (HAD), a social support scale (SSQ6) and a scale of regulation emotional (CERQ) and to test and re-test to check fidelity of the abbreviated scale.~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires."
45497752|NCT04458597|Radiation|Image-guided adjuvant pelvic radiotherapy|Image-guided adjuvant pelvic radiotherapy delivered at an SBRT prescription dose of 30 Gy in 5 fractions if feasible, well-tolerated and effective for the adjuvant treatment of high-risk endometrial cancer.
45497753|NCT03695796|Diagnostic Test|biopsy-proven NAFLD patients with non-invasive tests of liver fibrosis (blood tests, elastography devices) and biobank|To evaluate and improve the non-invasive diagnosis of liver fibrosis in NAFLD and to develop the non-invasive diagnosis of NASH
46055780|NCT04358289|Other|Participatory action research group in commune health center and community|"Establish a participatory action research group~Engagement with the group through participatory action research involving problem identification, planning change strategies, implementing strategies, and evaluation"
45497754|NCT03695640|Drug|Magnesium Sulfate|Addition of magnesium sulfate as an adjuvant to levobupivacaine
45497755|NCT03695640|Procedure|continuous femoral nerve block|continuous nerve block with levobupivacaine for treatment postoperative pain
46055781|NCT04358289|Other|Antimicrobial stewardship program in hospitals|"The intervention activities in hospitals will include: training a health-worker in each of the participating hospitals to act as a facilitator or activator; forming an antibiotic stewardship group; meeting regularly and following an action-research cycle that includes problem identification, planning change strategies, implementing strategies, and evaluating strategies"
45497756|NCT04420221|Biological|Sa-5Ag half dose non-adjuvanted|1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, non-adjuvanted at Day 1, administered intramuscularly.
45497757|NCT04420221|Biological|Sa-5Ag full dose non-adjuvanted|1 dose of Sa-5Ag (5 antigens of S. aureus) full dose, non-adjuvanted at Day 1, administered intramuscularly.
45497758|NCT04420221|Biological|Sa-5Ag half dose adjuvanted|1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, adjuvanted at Day 1, administered intramuscularly.
45497759|NCT04420221|Biological|Sa-5Ag full dose adjuvanted|A series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61), administered intramuscularly.
45497760|NCT04420221|Biological|Placebo|One dose of placebo (saline solution for injection/ vial or prefilled syringe) at Day 1 for placebo groups 1 to 3 and a series of 2 doses of placebo given approximately 2 months apart (Days 1 and 61) for placebo groups 4 and 5, administered intramuscularly.
45497761|NCT03929913|Device|Transmural Systems Transcatheter Mitral Cerclage Annuloplasty (TMCA)|The Transcatheter Mitral Cerclage Annuloplasty implant has two components, with or without a coronary artery protection element, and the wishbone lock with coronary sinus and right ventricular outflow track limbs. Procedure is performed from a trans-jugular venous approach. Coronary guidewires and microcatheters are used to navigate into a coronary vein to the target capture catheter. The implant is then attached to the back end of the guidewire and pulled out of the internal jugular sheath. The position of the implant is adjusted so the coronary protection element lies directly over any underlying branch of the left coronary artery. The wishbone lock is advanced over the two limbs of the implant and the desired tension is titrated to the degree of mitral regurgitation. Coronary angiography is performed to confirm there is no coronary compression. After desired tension has been achieved, the wishbone lock is locked and the two limbs of the implant are cut with a cutter catheter.
45497762|NCT03702114|Device|auricular point detection|This device is only for auricular detection. No additional intervention will be delivered.
45497763|NCT03698760|Diagnostic Test|Olfactory test|"Olfactory test:~All fragrances tested are kept in an airtight case protected from cold and heat.~The test is done on a tablet and the data will be automatically saved. The first screen is about the administrative data, sex and age of the subject. Olfactory test: six odors among the fourteen are proposed in a randomized way."
45497764|NCT03702036|Drug|molibresib|molibresib 20 mg will be supplied for compassionate use for the identified individual subject.
45694466|NCT01913483|Drug|Bivalirudin|Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
45381872|NCT05599243|Drug|Dutasteride|The application will be made locally (spray for topical application on the scalp) Application: 1 mL (6 sprays) once a day. Each 1mL of formulation has approximately 1.5mg of Dutasteride (more precisely it would be 1.4835mg when considering density).
45497765|NCT03698682|Drug|Levofloxacin 500mg|One tablet per day for 7 days.
45847536|NCT04775004|Other|Platelet Rich Plasma (PRP)|The PRP group will have 40cc to 60cc (about 3 tablespoons) of blood drawn at the time of surgery. The blood sample will then be prepared in a centrifuge machine to collect a component of the blood called platelet rich plasma. Once appropriate concentrations of the PRP are confirmed, the PRP will be injected into the subject's knee prior to wound closure.
45847537|NCT04607616|Behavioral|Baseline sessions TAU|TAU consists of sessions lasting around one/one and a half hour ; the consultant is practicing as usual. The interventions focus on child's behavior, parent infant relationship, with moments of play with the child, advices, informations about child development and Autism.
46055782|NCT04358289|Other|Community education|Development of educational materials for the community and farmers; Disseminated of messages through posters, leaflets and local media channels
46055783|NCT02754921|Procedure|percutaneous dilatational tracheostomy using Ultra-Perc|Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ultra-Perc
46055784|NCT02754921|Procedure|Percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin|Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin
46055785|NCT02755077|Procedure|Head rotation during mask ventilation|Patient's head position is axially rotated 45 degrees to the right.
45381873|NCT05599243|Other|Placebo|Vehicle excipient
45497766|NCT03695562|Procedure|sequential drilling technique|Patient with vitamin D deficiency using sequential drilling technique
45497767|NCT03695328|Behavioral|physical activity level|
45497768|NCT03695328|Behavioral|Dietary Intake|
45694467|NCT01913483|Drug|Unfractionated Heparin|Unfractionated heparin is an anticoagulant.
45694468|NCT04415723|Other|supportive care management programme|nurse-led management programme
45694469|NCT01913405|Biological|PEGylated Recombinant factor VIII (rFVIII)|Lyophilized powder and solvent for solution for injection
45694470|NCT01927055|Drug|Droxidopa|Droxidopa at 100 mg, 200 mg, 300 mg
45694471|NCT01927055|Drug|Placebo|Placebo to match droxidopa capsules and strength designations
45694472|NCT01913327|Drug|Aripiprazole|
45497769|NCT04648098|Other|Discharge training and telephone counseling|"The discharge training was given by using different teaching methods in the form of verbal expression, demonstration, and question and answer. The care guide prepared by the researchers in line with the literature was used as a training material for stroke patients and their caregivers.The training varied according to the learning level of individuals but took an average of 40-60 minutes.~Consultation service was given to the caregivers one week after discharge and once a month for three months by telephone call."
45497770|NCT03029832|Drug|MOXR0916|MOXR0916, 300 milligram (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
45497771|NCT03029832|Drug|Atezolizumab|Atezolizumab, 1200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
45497772|NCT04412187|Diagnostic Test|[18F]-GE-180 PET|serial [18F]-GE-180 PET imaging to assess microglia activation
45497773|NCT04412187|Diagnostic Test|3T MRI|serial MR imaging (i) to determine infarct characteristics, (ii) to identify gray and white matter structures connected to the infarct, (iii) to detect incident lesions, and (iv) to quantify longitudinal changes e.g. of cortical thickness
45497774|NCT04412187|Diagnostic Test|immune cell profiling in blood|Cell-specific cytokine profiles, markers of activation, terminal differentiation as well as cytotoxicity will be assesses using flow cytometry.
45497775|NCT03695016|Behavioral|ActiveGOALs|13 week, online self-directed intervention. Once weekly sessions are based on social-cognitive theory models of behavior changes. Coaches will provide weekly feedback . Behavior tracking tools will be provided. Links to tools that support physical activity will also be provided.
45497776|NCT04391595|Drug|Abemaciclib|100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
45381874|NCT05599100|Behavioral|STAR-Caregivers Virtual Training & Follow-up (STAR-VTF)|For 6-8 weeks, caregivers will complete online training modules asynchronously. Caregivers will be instructed to complete one module per week. The content of the modules is as follows: Module 1 introduces caregivers to the behavioral treatment of dementia, realistic expectations, and effective communication; Module 2 covers the ABC (antecedents, behaviors, consequences) approach to problem-solving, including rationale and development of an ABC plan; Module 3 instructs caregivers to review the ABC plan and revise as needed; Module 4 covers pleasant events and managing negative thinking; Module 5 instructs caregivers to review the ABC plan, pleasant activities schedule, and to revise as needed; Module 6 covers coping with caregiving and maintaining gains. Each module takes about 45 minutes to complete. The modules use text, pictures, and illustrations with a voiceover presentation. Caregivers will receive the online training modules in their preferred language (English or Spanish).
45381875|NCT05597228|Behavioral|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
45497777|NCT04391595|Drug|LY3214996|400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
45497778|NCT04252638|Behavioral|Acceptance and Commitment Therapy plus Sleep Restriction|Acceptance and Commitment Therapy (ACT) is a newer form of behavioral therapy working with acceptance, and the clarification of personal values. Acceptance, in this case, means the willingness to (temporarily) experience unpleasant sensations such as sleeplessness or tiredness without attempting to control or change them. Aims are, first, to reduce suffering due to unsuccessful control attempts (such as frustration, anger, anxiety) and second, to improve processes that are typically worsened by increased control efforts (such as sleep). Clarification of values means identifying aspects of life that are perceived as rewarding and encouraging approach-behavior in valued aspects of life (instead of avoidance-behavior that is often associated with insomnia and mental disorders).
46055786|NCT00744523|Device|Mo.Ma cerebral protection device|Proximal embolic protection based on the principle endovascular clamping consisting of a catheter with two compliant balloons. Mo.Ma is designed to achieve cerebral protection by proximal blood flow blockage at the carotid bifurcation: antegrade and retrograde flow blockage are achieved by proximal balloon occlusion of the CCA and distal balloon occlusion of the ECA. Cerebral protection is established prior to the initial wire passage through the stenosis and maintained during the entire procedure. Mo.Ma provides withdrawal of embolic particles by allowing manual syringe aspiration of any micro-emboli at the end of the procedure before restoring blood flow through the stented vessel.
45381876|NCT05595083|Drug|intranasal dexmedetomidine group|patients will receive 1.5 ug/kg intranasal dexmedetomidine diluted with saline + infusion saline
45381877|NCT05595083|Drug|intravouns dexmedetomidine group|patients will receive 0.1- 0.4 ug/kg intravenous infusion dexmedetomidine + intranasal saline.
45381878|NCT05594576|Procedure|GI GENIUS™ artificial intelligence system|Device used during coloscopy for detection of colonic adenoma
45381879|NCT05594576|Procedure|ENDOCUFF VISION® endoscopic cap|Device used during coloscopy for detection of colonic adenoma
45381880|NCT05594264|Behavioral|HBPStories|A 6-week web-based study. Systolic blood pressure, diastolic blood pressure, and medication adherence will be measured at baseline and 6-weeks.
45497779|NCT04252638|Behavioral|Cognitive Behavioral Therapy including Sleep Restriction|CBT-I, the gold standard treatment for insomnia, consists of sleep education, relaxation, sleep restriction, and cognitive therapy.
45497780|NCT05598567|Other|target controlled infusion - total intravenous general anesthesia|Both interventions are subtypes of general anesthesia.
45497781|NCT05598567|Other|sevoflurane based balanced general anesthesia|Both interventions are subtypes of general anesthesia.
45497782|NCT04050228|Other|Imaging|Patient in the control arm will receive standard neoadjuvant chemotherapy and clinical monitoring as per standard of care. Patients will be imaged but no modifications to treatment will occur in this trial arm depending on response by quantitative ultrasound. Patients in the experimental arm will receive adaptive neoadjuvant chemotherapy based on quantitative ultrasound monitoring. Non-responders to neoadjuvant chemotherapy based on quantitative ultrasound will be switched to different chemotherapy or other treatments reflecting current clinical practice. The treatment option will be left to the discretion of the treating medical oncologist and the care team.
45497783|NCT03701880|Drug|Ivabradine|Ivabradine is pacemaker current I(f) inhibitor thereby slowing heart rates without exhibiting negative inotropic effect on the myocardium or altering ventricular action potential
45497784|NCT03701880|Drug|Bisoprolol|Bisoprolol is beta-blocker
45497785|NCT03692754|Drug|Atorvastatin 20mg|Atorvastatin will be given in 20 mg po qn for 1 month
45497786|NCT03692754|Drug|Atorvastatin 10mg|Atorvastatin will be given in 10 mg po qn for 1 month
45497787|NCT03692754|Drug|Dexamethasone|Dexamethasone will be given in 40mg po qd for 4 days
45497788|NCT03692598|Device|MIA, Minimally Invasive Annuloplasty Device - Surgical|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from an open surgical approach
45497789|NCT03692598|Device|MIA, Minimally Invasive Annuloplasty Device - Percutaneous|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from a percutaneous approach
45381881|NCT05592210|Other|Questionnaires|Participants will be asked to fill out the the Demographic Information Sheet, Karitane parenting confidence scale, Parental Stressor Scale: Neonatal Intensive Care Unit (PSS:NICU) and Dyadic Coping Inventory.
45694473|NCT01913327|Drug|Risperidone|Week One, Risperidone 1 mg po qd; Week Two, 2 mg po qd; Week Three, 4 mg po qd; Week Four, 6 mg po qd; Week Five (and thereafter), 8 mg po qd.
45847538|NCT04607616|Behavioral|Interactive guidance therapy|"The objective is to reinforce the identification, deciphering, interpretation, and answer to child's signals by the parent, in order to to promote a synchronous and attuned response to the child's needs.~Sessions last around one/one and a half hour. Parent plays 7-10 minutes with the child, in the presence of the therapist, with toys chosen according to the child's developmental stage. Then therapist proposes an immediate viewing of the play session. The therapist selects short moments of positive interaction. He has determined a  focus , depending on the play, previous sessions, the child's difficulties and parent's interventions. He accompanies, guides and supports the parent to describe the interaction, the alternance in play, joint attention, shared affect, in a co-construction: the parent discovers the child's and his own skills."
45847539|NCT04607616|Diagnostic Test|Developmental and diagnostic assessments|MSEL, CARS, ECAR, CIM10, DMS5, ADOS, ADIR
45847540|NCT04607616|Behavioral|Developmental assessment -Parental scales|Vineland II, IFDC, IDE
45497790|NCT03694860|Other|questionnaire|Members of European society of anaesthesiology care will obtain an electronic survey considering their clinical practice in RSI
45497791|NCT03694782|Behavioral|Food diary supply|Each participant was issued with a food supply diary to record details of their household food supply and related trips over 1-mo period. Household food supply included food purchases, food gift/donation, and potential crops from the garden. Away-from-home food consumption was not recorded. For each food purchase, participants provided details of date, place of purchase, foods purchased (name, quantity and expense incurred), and trip made (origin/where the trip started, destination/where the trip ended, and mode of transportation). When till receipts were available in grocery stores or supermarkets, participants were asked to collect them in an envelope placed at the end of the food supply diary. To facilitate data entry, all family members were encouraged to help filling out the diary.
45694474|NCT01913327|Drug|Modafinil|Single-dose 200 mg once orally, versus placebo single-dose, added-on to antipsychotic medication.
45694475|NCT01926509|Drug|MK-8892|
45847541|NCT04607616|Behavioral|Qualitative analysis|Interpretative Phenomenological Analysis. Parents' semi structured interview about the Interactive Guidance experience. Qualitative analysis of transcripts (recurrent themes, meta themes).
45847542|NCT04589286|Behavioral|Pack Health's Digital Life Coaching (DLC)|Pack Health smartphone-based DLC platform
45847543|NCT04589286|Other|Electronic Handouts|Generic wellness-related electronic handouts
45694476|NCT01926509|Drug|Placebo for MK-8892|
45694477|NCT01926119|Device|Transcranial Magnetic Stimulation|
45381884|NCT05587855|Other|E-group|Participants with Hypertension will be assigned to eCulinary medicine
45381885|NCT05580666|Drug|Azithromycin Oral Tablet|Antimicrobial therapy
45381886|NCT05580666|Drug|Placebo oral tablet|Inert ingredients
45694478|NCT01912781|Device|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of gas permeable contact lenses
45497792|NCT03694782|Behavioral|Actigraph|Participants were instructed to wear a triaxial accelerometer (wGT3X-BT or wActiSleep-BT, Actigraph, Pensacola, FL, USA) fitted with an elastic strap on right side of the hip for 9 consecutive days, except for bathing and performing activities in the water. The Actigraph was accompanied by an activity logbook in which participants were required to daily record time when awake and sleeping, and, if any, time and duration of workout or device removal
45381887|NCT05577559|Procedure|Superficial cervical plexus block|patients will receive bilateral ultrasound guided superficial cervical plexus block using 15 ml of bupivacaine 0.25% for each side.
45381888|NCT05577559|Procedure|Cervical Erector spinae block|patients will receive bilateral ultrasound guided cervical erector spinae plane block using 15 ml of bupivacaine 0.25% for each side at the level of C6.
45497793|NCT03694782|Behavioral|Questionnaire|Participants received by email a link to complete an online questionnaire about mental and social health, sensibility to food waste, and connection with nature
45497794|NCT03688308|Procedure|Arthroscopic rotator cuff repair with bone marrow aspirate concentrate|Subjects will undergo shoulder arthroscopy for rotator cuff repair using a double row technique. Subjects will also be injected with bone marrow aspirate concentrate harvested from the pelvis and centrifuged prior to injection in the shoulder (produced using the Harvest/Terumo BCT system)
45497795|NCT03688308|Procedure|Arthroscopic rotator cuff repair|Subjects will undergo shoulder arthroscopy for rotator cuff repair using a double row technique.
45497796|NCT03692520|Biological|SCT200|Recombinant Anti-EGFR Monoclonal Antibody （SCT200）
45497797|NCT04224558|Drug|Mesna|"Stem Cell Mobilization: Infused according to institutional guidelines;~Post-PBSC Infusion Conditioning: Mesna provided with Cytoxan according to institutional protocol."
45497798|NCT04224558|Drug|Cyclophosphamide|"Stem Cell Mobilization:~Cyclophosphamide (CY) infused intravenously over 1 hour: 50 mg/kg (25 mg/kg/day on 2 consecutive days)"
45381891|NCT05571943|Drug|Difamilast|Difamilast Ointment 1%
45381892|NCT05569915|Behavioral|Trauma Expressive Writing|Participants assigned to the trauma condition will write about an experience of trauma for 15 to 20 minutes per day across five consecutive days.
45381893|NCT05569915|Behavioral|Stigma Expressive Writing|Participants assigned to the stigma condition will write about an experience of stigma or bias for 15 to 20 minutes per day across five consecutive days.
45381894|NCT05569915|Behavioral|Control|Participants assigned to the control condition will write about their days for 15 to 20 minutes per day across five consecutive days. This control condition is standard across many expressive writing studies.
45381895|NCT05567406|Drug|Belumosudil|Pharmaceutical form: Tablet; Route of administration: Oral
45381897|NCT05566262|Drug|Bodewell Calming Cream|Bodewell is a non-prescription and contains 22 botanical ingredients in addition to colloidal oatmeal.
45381898|NCT05562934|Biological|Experimental drug|SC injection
45381899|NCT05562934|Other|Placebo|SC injection
45381900|NCT05560737|Behavioral|ODYSSEE-vCHAT|"ODYSSEE-vCHAT consists of:~Automated digital counselling resources (educational pages, videos, tools, and trackers)~Chatrooms available 24/7~Weekly 30-minute presentations and discussions led by a healthcare professional or patient representative~Each aspect was informed by a rotating schedule of 7 weekly self-care themes. Webcasts were recorded and streamed to our private YouTube channel, and associated hyperlinks were shared on the program. Subjects had the option of submitting photographs depicting heart-healthy lifestyles and activities (with no identifying, sensitive, or personal information) to the Gallery Wall.~Subjects were invited by email to access the resources available to them. They logged on to the program using password-protected personal accounts. Each participant's total number of logins and login time (with timestamps) were recorded. Assessments occurred online at baseline, months 4 and 8, and study completion (up to 16 months)."
45381901|NCT05557110|Drug|Blinatumomab|Reduced-intensity chemotherapy followed by Blinatumomab
45497799|NCT04224558|Drug|Filgrastim|"Stem Cell Mobilization: Filgrastim (G-CSF) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapheresis;~Post-PBSC Infusion Conditioning: Filgrastim administered intravenously 5 mcg/kg IV starting day + 5, continue until ANC of >1000/μL"
45497800|NCT04224558|Procedure|Apheresis catheter placement|Subjects will require placement of an Apheresis catheter by Intervention Radiologists on the day of collection of stem cells.
45497801|NCT04224558|Procedure|Leukapheresis|Leukapheresis will be performed on a continuous flow separator machine according to institutional guidelines to target 3-8 x 10^6 CD34+ cells/kg body weight.
45497802|NCT04224558|Drug|Fludarabine|Preparative/Conditioning Regime Fludarabine given as 30 mg/m2 per dose x 4 days, beginning on day -6.
45497803|NCT04224558|Drug|Methylprednisolone|Preparative/Conditioning Regime r-ATG pre-medication according to institutional guidelines
45497804|NCT04224558|Drug|Diphenhydramine|Preparative/Conditioning Regime r-ATG premedication according to institutional guidelines
45497805|NCT04224558|Drug|Acetaminophen|Preparative/Conditioning Regime r-ATG premedication according to institutional guidlines
45497806|NCT04224558|Drug|anti-thymocyte globulin (rabbit)|Preparative/Conditioning Regime r-ATG administered intravenously: 2.5 mg/kg/dose IV over 6 hours on specified days (day -6,-4,-2); ); total 3 doses=7.5 mg/kg.
45497807|NCT04224558|Drug|lymphocyte immune globulin|Preparative/Conditioning Regime In patients who develop severe allergic reactions to rATG (Thymoglobulin), it may be substituted by horse ATG (hATG, ATGAM, Pharmacia & Upjohn, Kalamazoo, MI). The recommended dose of hATG is 25 mg/kg/day for 3 doses.
45497808|NCT04224558|Biological|Peripheral Blood Stem Cell Infusion|PBSC (peripheral blood stem cell) infusion on day 0 as per institutional guidelines.
45497809|NCT04224558|Drug|Cytoxan|Post-PBSC Infusion Conditioning Cytoxan infused intravenously: 50mg/kg/day x 2 days. Infused over 2 hours with adequate hydration or according to institutional guidelines.
45381902|NCT05556889|Procedure|a modified auriculotemporal nerve blockade|Helix feet in front of the zygomatic arch is served as anatomy marks of auriculotemporal nerve block, and the modified auriculotemporal nerve blockade is implemented as follows: Zygomatic arch level, posterior to the superficial temporal artery, the vertical puncture depth is about 0.5 -1 cm, and 2 ml of local anesthetics are injected after withdrawing without blood.
45497810|NCT03089697|Biological|N-Rephasin® SAL200|A single dose of SAL200 (SAL-1, 3mg/kg) intravenous administration of the study drug, in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
45497811|NCT03089697|Other|Placebo|A single dose of the formulation buffer (placebo), excluding the main ingredient of the study drug in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
45497812|NCT05598411|Drug|Oral Glucocorticoids|methylprednisolone 24mg qd, 2-week duration
45381903|NCT05556889|Procedure|Traditional auriculotemporal nerve blockade|Traditional auriculotemporal nerve blockade
45497813|NCT05598411|Drug|Oral placebo|oral placebo 24mg qd, 2-week duration
45497814|NCT05598333|Drug|NAN-101|Intracoronary Infusion of NAN-101 or placebo
45497815|NCT03688230|Drug|abituzumab|1000 mg IV
45497816|NCT03688230|Combination Product|Placebo + Cetuximab + FOLFIRI|400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min
45497817|NCT03694314|Dietary Supplement|Omega-3 fatty acids|200 ml drink. The drink contains 840 mg total of omega-3 (360 mg of DHA, 240 mg of EPA, 200 mg of alpha-linolenic acid, and 40 mg of DPA).
45497818|NCT03694314|Dietary Supplement|Placebo|200 mL placebo fruit juice with no effect on the hypothesized outcome.
45497819|NCT03694236|Drug|durvalumab|"Neo-adjuvant chemoradiation period The treatment consisted of paclitaxel, carboplatin, duvalumab and radiation. The radiation treatment comprises 45Gy (total 25Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery Chest CT and/or PET CT with appropriate other diagnostic method (ex. Bronchoscopy) will be performed before surgery and type of surgery Follow-up period There is every 4 month visit with chest CT and abdominal CT is done at 1,2,5 post-op year. Other diagnostic method can be performed if indicated."
45497820|NCT04043364|Behavioral|LIVE|Learning, Innovation, Volunteers and Empowerment
45497821|NCT03692364|Device|Ceramic-on-ceramic uncemented hip arthroplasty|
45497822|NCT03692364|Device|Metal-on-polyethylene uncemented total hip arthroplasty|
45381904|NCT05556512|Drug|Tirzepatide|Administered SC
45381905|NCT05556512|Drug|Placebo|Administered SC
45497823|NCT03688152|Drug|INCB053914|"Dose Escalation: INCB053914 at the protocol-defined starting dose in combination with INCB050465, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study."
45497824|NCT03688152|Drug|INCB050465|"Dose Escalation: INCB050465 at the protocol-defined starting dose in combination with INCB053914, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study."
45497825|NCT03692286|Combination Product|Silver nanoparticle/Calcium hydroxide|Intracanal Medication composed of combined silver nanoparticles with calcium hydroxide
45497826|NCT03692286|Drug|Silver Nanoparticles in gel form|Intracanal medication composed of silver nanoparticles in gel form
45497827|NCT03692286|Drug|Calcium Hydroxide Intracanal medication|Calcium hydroxide intracanal medication
45497828|NCT05654766|Diagnostic Test|Flow cytometry|Parameters such as FSC, SSC, median fluorescence of anti CD42b, PAC-1, CD41, CD63, CD62P, as well as Annexin V fluorescence will be assessed.
45497829|NCT05654766|Diagnostic Test|Platelet aggregation and plasma coagulation|Turbodimetric platelet aggregation test, impedance platelet aggregation test. Standard plasma coagulation test (fibrinogen level, prothrombin test, thrombin time, activated partial thromboplastin time (aPTT)).
45497830|NCT03694080|Combination Product|Calcium electroporation|Patients with potentially curable colorectal rectal cancer will be treated preoperatively
45497831|NCT03624348|Behavioral|meditation|10 minute per day, 8 week digital meditation
45497832|NCT04296864|Drug|Dupilumab|monoclonal antibody
45497833|NCT04059900|Drug|STW5 (Iberogast®, BAY98-7411)|The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.
45497834|NCT04059900|Drug|Placebo|The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals
45497835|NCT04295148|Procedure|ACL Reconstruction with Semitendinosus graft|Participants will undergo Anterior Cruciate Ligament Reconstruction with Semitendinosus graft
45497836|NCT04295148|Procedure|ACL Reconstruction with Quadriceps tendon-bone graft|Participants will undergo Anterior Cruciate Ligament Reconstruction with Quadriceps tendon-bone graft
46055787|NCT02597569|Behavioral|CO-OP KT Exposure|"Patient participants who receive therapy from clinicians who have received CO-OP KT training will belong to the CO-OP KT Exposure group. Patient participants will not receive treatment that is different from the treatment being offered to patients who do not enroll in the study.~The CO-OP KT intervention is directed at the inpatient rehabilitation team. They will be trained in Cognitive Orientation to daily Occupational Performance (CO-OP) and will also receive multi-faceted knowledge translation (KT) support."
45497837|NCT03692130|Behavioral|Mindfulness, Acceptance and Commitment-Therapy|Psychotherapeutic intervention to treat depressive patients with special exercises and education to be mindful, to accept situations and behaviors and to commit with the situation or the possibility to change.
45497838|NCT03692130|Behavioral|Jacobson|Relaxation treatment in technique of Jacobson
45497839|NCT04208490|Other|HN-STAR Intervention|The Head and Neck Survivorship Tool (HN-STAR) is a web-based tool used to assist clinicians in implementing the ACS/ASCO HNC survivorship guidelines.
45497840|NCT04207944|Drug|Sulindac 400 MG|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
45497841|NCT04207944|Other|Placebo|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
45497842|NCT04203498|Drug|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Nabiximols will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
45497843|NCT04203498|Drug|Placebo|Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 microliters (μL) containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
45497844|NCT03687918|Other|Assessment of the performances of QCAD/Lyon in characterizing Gleason ≥7 cancers among contoured lesions|"Principal Objective:~To assess the performances of QCAD/Lyon (AUC and its 95% confidence interval) in characterizing Gleason ≥7 cancers among the lesions delineated on mpMRI from the Dijon University Hospital.~Secondary Objectives:~To compare the diagnostic performance (AUC) of QCAD/Lyon and of the Likert score~To compare the diagnostic performance (AUC) of QCAD/Lyon and of the PIRADS v2 score~To define the best combination of quantitative parameters in the Dijon cohort (if different from that defined in Lyon)"
45497845|NCT03691896|Dietary Supplement|Cholecalciferol 400|dose 400 UNT/day for 12 months
45497846|NCT03691896|Dietary Supplement|Cholecalciferol 800|dose 800 UNT/day for 12 months
45497847|NCT03691896|Drug|Cholecalciferol 1200|dose 1200 UNT/day for 12 months
45497848|NCT03691818|Drug|X0002 Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
45497849|NCT03691818|Drug|Ibuprofen Tablet|Ibuprofen Tab 400mg, tid.
45497850|NCT03691818|Drug|Ibuprofen Placebo Tab|Ibuprofen Placebo Tab 400mg, tid.
45497851|NCT03691818|Drug|X0002 Placebo Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
45497852|NCT03687840|Diagnostic Test|gait analysis|Computerized gait analysis system was used to 3 times to evaluate the spatio-temporal parameters of gait.
45497853|NCT03693924|Radiation|SRT-100|The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.
45497854|NCT03687606|Drug|Human Chorionic Gonadotropin|White freeze-dried cake or powder with specifications of 1000U, 2000U, 5000U.
45497855|NCT03687606|Drug|human menopausal gonadotropin|White freeze-dried cake or powder with specification of 75IU.
46055788|NCT04517253|Drug|Baricitinib|Administered orally
45497856|NCT03691740|Device|Ocular light|A light mask to which small light emitting diode(LED) lights emitting a blue or red color light will be used to deliver ocular light
45497857|NCT03691662|Drug|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months
46055789|NCT00744991|Drug|Enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression
46055790|NCT02754999|Drug|SANGUINATE™|As needed (PRN) infusions of 500 mL of SANGUINATE
46055791|NCT02751489|Other|Bain De Soliel - Solid|0.05 gm/cm2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.
46055792|NCT04090801|Drug|Topical minoxidil 5% in 90% ethanol and 5% propylene glycol|
45381908|NCT05552469|Drug|DFV890|DFV890 Single Agent
45381911|NCT05545501|Dietary Supplement|No Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with a dextrose placebo. The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
45497858|NCT03691662|Drug|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months
46055793|NCT04090801|Drug|Topical minoxidil 5% in pure ethanol alone|The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.
45497859|NCT04059978|Drug|CBD|1600mg cannabidiol, single oral dose (8 ml oily solution)
45497860|NCT04059978|Drug|Placebo|Placebo p.o, single oral dose (8 ml oily solution)
45497861|NCT04059978|Drug|Remifentanil|Remifentanil 0.1 µg/kg/min i.v. for 30 min
45497862|NCT03199963|Drug|4-OH tamoxifen|4-Hydroxytamoxifen (afimoxifene) gel
45497863|NCT03199963|Drug|Placebo|An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
45497864|NCT04547257|Device|Seraph 100|Bloodfiltration with Seraph 100
45497865|NCT03636685|Drug|Anlotinib combined with pemetrexed and carboplatin, phase I|"Non-squamous cell lung cancer, Anlotinib Plus PC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus pemetrexed and carboplatin. middle-dose groups: Anlotinib 10mg per day plus pemetrexed and carboplatin. high-dose groups: Anlotinib 12mg per day plus pemetrexed and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin"
45497866|NCT03636685|Drug|Anlotinib combined with paclitaxel and carboplatin, phase I|"Squamous cell lung cancer, Anlotinib plus TC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus paclitaxel and carboplatin. middle-dose groups: Anlotinib 10mg per day plus paclitaxel and carboplatin. high-dose groups: Anlotinib 12mg per day plus paclitaxel and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin"
45497867|NCT03636685|Drug|Anlotinib combined with pemetrexed and carboplatin, phase II|Anlotinib: established dose QD PO d1-14, pemetrexed,carboplatin, 21 days per cycle after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
45497868|NCT03636685|Drug|Anlotinib combined with paclitaxel and carboplatin, phase II|"Anlotinib :established dose QD PO d1-14, paclitaxel,carboplatin, 21 days per cycle~after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent"
45381912|NCT05545501|Dietary Supplement|High Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
45497869|NCT03788941|Procedure|left atrial appendage closure and catheter ablation|"Left atrial appendage closure (LAAC) is a treatment strategy to reduce the risk of left atrial appendage blood clots from entering the bloodstream and causing a stroke in patients with non-valvular atrial fibrillation (AF).~Catheter ablation is a procedure used to remove or terminate a faulty electrical pathway or pathological sites from sections of the hearts of those who are prone to developing cardiac arrhythmias such as atrial fibrillation, atrial flutter, supraventricular tachycardias (SVT) and Wolff-Parkinson-White syndrome (WPW syndrome). The ablation procedure can be classified by energy source: radiofrequency ablation and cryoablation."
45497870|NCT03257631|Drug|Pomalidomide|: Subjects will be administered pomalidomide on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle and will continue treatment for up to 24 cycles or until disease progression, withdrawal of consent/assent or unresolved toxicities as described in the protocol.
45497871|NCT03257631|Drug|Pomalidomide|Pomalidomide will be provided as gelatin capsules and as an oral suspension. The starting dose will be 2.6 mg/m²/day, administered on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle.
46055794|NCT04090801|Other|Placebo (Ethanol)|The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.
46055795|NCT02754609|Other|Gluten micro-challenge|From week 12 to week 24, all participants will start a gluten micro-challenge from 10mg/day for the first 2 weeks escalating over the this period to 50mg/day at the end of week 24.
46055796|NCT02754609|Other|Inadvertent gluten challenge|From week 24 to week 36, all participants will be on gluten 50mg/day and 1g twice weekly.
45694479|NCT01912781|Device|Boston Simplus multi-action solution|Commercially available solution indicated for cleaning, removing protein, rinsing, disinfecting, conditioning, storing and cushioning of fluoro silicone acrylate and silicone acrylate rigid gas permeable contact lenses
45381913|NCT05545501|Dietary Supplement|High Salt, High β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). Ketone beverage will be the β-OHB supplement produced by KetoneAid. Participants will consume 24 mL (12 grams β-OHB) of the ketone beverage three times a day (total 36 grams β-OHB).
45694480|NCT01912781|Device|Gas permeable contact lenses|Commercially available gas permeable contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days).
45694481|NCT04415879|Device|N-95 Respirator|N-95 mask will be worn as personal protective equipment during a graded exercise test
46055797|NCT02754609|Other|Moderate gluten challenge|From week 36 to week 42, all participants will be on gluten 2g/day.
45497872|NCT03883581|Drug|dextromethorphan HBr and quinidine sulfate|All eligible and enrolled study participants will be administered the study drug, Nuedexta, as recommended by their treating neurologists.The drug will be administered per the efficacy and safety protocol, with no changes in administration method or recommended dose for individuals with ALS. Prior to commencing treatment with Nuedexta, participants will undergo a comprehensive bulbar evaluation of swallowing, airway protection, speech functions, and complete validated patient-reported surveys. Following 30 days of Nuedexta treatment, participants will be e-evaluated using the same battery of assessments.
45497873|NCT03829761|Device|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of 1Hz stimulation, for a total of 1800 pulses delivered.
45497874|NCT03829761|Device|Sham transcranial magnetic stimulation|Sham transcranial magnetic stimulation (TMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of sham stimulation. Sham stimulation will imitate the active rTMS but does not have active stimulation.
45497875|NCT03824535|Procedure|Computed Tomography|Undergo PET/CT
45497876|NCT03824535|Drug|Fludeoxyglucose F-18|Given IV
45497877|NCT03824535|Drug|Fluorine F 18 L-glutamate Derivative BAY94-9392|Given IV
45497878|NCT03824535|Procedure|Positron Emission Tomography|Undergo PET/CT
45497879|NCT03113643|Drug|Azacitidine|Chemotherapy
45497880|NCT03113643|Drug|SL-401|SL-401 works by targeting leukemia cells (blasts), and also possibly by stopping or slowing the growth of cancer stem cells, which are the undeveloped cells which can develop into cancer cells.
45497881|NCT03113643|Drug|Venetoclax|Venetoclax is a BH3-mimetic. Venetoclax blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death of CLL cells. Overexpression of Bcl-2 in some lymphoid malignancies has sometimes shown to be linked with increased resistance to chemotherapy.
45497882|NCT05324397|Device|NEUROMARK System|The NEUROMARK™ System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
45497883|NCT03091491|Drug|Ipilimumab|Ipilimumab 1 mg/kg administered every 6 weeks as a 30 min IV infusion
45497884|NCT03091491|Drug|Nivolumab|Nivolumab 3 mg/kg administered every 2 weeks as a 30 min IV infusion
45497885|NCT05598255|Drug|Dexamethasone|During standard anaesthetic management: IV administration of dexamethasone (0,5mg/kg, with a maximum dose of 5mg) in both groups (caudal blockade and dorsal penile nerve block)
45497886|NCT05598255|Procedure|Caudale Blockade with levobupivacaine|Administration of levobupivacaine 0,25%0,5ml/kg through the hiatus sacralis lege artis, before incision.
45497887|NCT05598255|Procedure|Dorsal penile nerve block with levobupivacaine|Administration of levobupivacaine 0,5% 0,1ml/kg on each side of the midline as described in Hadzic's textbook of regional anaesthesia, before incision.
45497888|NCT05293353|Other|NeoKare Breast Milk Fortifier|Powdered product made from human breast milk used to increase nutritional content of mother's own breast milk
45497889|NCT04733235|Drug|Progesterone|ultrasound measurements of endometrial thickness at the end of the estrogen phase and the day of embryo transfer.
45497890|NCT05598177|Drug|dexmedetomidine|The participant will pump dexmedetomidine at the rate of 1μg/(Kg·h) for 10 minutes at the beginning of anesthesia induction, and then maintain the pump at a rate of 0.5μg/(Kg·h) during the operation.
45694482|NCT04415879|Device|Cloth Face Mask|A cloth mask will be worn as personal protective equipment during a graded exercise test
45497891|NCT05598177|Drug|Placebo|The participant will pump saline without dexmedetomidine at the same speed as group D.
45497892|NCT05292105|Device|NC Xperience|Coronary dilatation balloon catheter (non compliant)
45497893|NCT03740529|Drug|Pirtobrutinib|Oral
45497894|NCT03740529|Drug|Venetoclax|Oral
45497895|NCT03740529|Drug|Rituximab|IV
45497896|NCT03029208|Drug|Daprodustat|Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.
45497897|NCT03029208|Drug|Darbepoetin alfa|Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 20, 30, 40, 60, 80, 100 and 150 mcg.
45497898|NCT03029208|Drug|Iron therapy|Iron therapy will be administered if ferritin is <=100 ng/mL and/or TSAT is <=20%.
45497899|NCT03693534|Diagnostic Test|Clinical Pregnancy Rate|The Clinical Pregnancy, Live Birth Rate and Blastulation Rate according to the protocol of COS
45497900|NCT03687294|Device|enzyme linked immunosorbent assay (ELISA)|ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors
45497901|NCT03198715|Drug|DS1040b|DS-1040b in solution for intravenous infusion
45497902|NCT03198715|Drug|Placebo|Saline solution for intravenous infusion
45694483|NCT04415879|Diagnostic Test|Graded exercise test|No personal protective equipment during a graded exercise test
45694484|NCT01925417|Biological|RBX2660 (microbiota suspension)|
45694485|NCT01911845|Drug|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
45694486|NCT01911845|Drug|ABT-333|Tablet
45497903|NCT03693456|Other|Conjunctival Allergen Challenge|Food allergen dissolved in water will be instilled in an increasing titrated fashion into the subjects eye and response will be graded according to proprietary scales.
45497904|NCT04191330|Device|BiovitalsHF|BiovitalsHFTM is a cloud-based platform that incorporates continuous physiology data from remote vital signs monitoring devices and electronic patient reported outcome (ePRO) monitoring of subjects at-home to support GDMT dose titration for HFrEF patients.
45497905|NCT03691506|Other|Classic CIMT group|Constraint Induced Movement Therapy (CIMT) is a new treatment technique that claims to improve the arm motor ability and the functional use of a paretic arm - hand. CIMT forces the use of the affected side by restraining the unaffected side. Child with hemiplegic cerebral palsy can learn to improve the motor ability of the more affected parts of their bodies and thus cease to rely exclusively or primarily on the less affected parts.
45497906|NCT03691506|Other|Modified CIMT group|Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
45497907|NCT03687216|Procedure|HVPG-guided therapy|"The baseline HVPG measurement is performed. According to the result, patients with an HVPG over 20 mmHg will be receive transjugular intrahepatic portocaval shunt (TIPS) .~Patients with an HVPG below 20 mmHg will be treated by endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol until treatment fails."
45497908|NCT03687216|Procedure|Routing Therapy|Without HVPG measurement, patients receive endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol.
45497909|NCT05212623|Biological|quadrivalent influenza split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
45497910|NCT05212623|Biological|quadrivalent influenza split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
45497911|NCT05212623|Biological|Influenza virus split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
45497912|NCT05212623|Biological|Influenza virus split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection.
45497913|NCT03960138|Device|Intermittent Theta-burst stimulation (iTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.
45694487|NCT01911845|Drug|Ribavirin (RBV)|Tablet
45694488|NCT01925183|Drug|Pegylated interferon alpha-2a|180mcg once weekly; subcutaneous injection
45694489|NCT01925183|Drug|Ribavirin|600mg two times daily (BID) (e.g. 3x200mg at 6am, 3x200mg at 6pm) in patients ≥75kg body weight; 2x200mg at 6am and 3x200mg at 6pm in patients <75kg; orally
45694490|NCT01925183|Drug|Boceprevir|800mg three times daily (TID) (e.g. 4x200mg at 6am, 4x200mg at 2pm, 4x200mg at 10pm); orally
45497914|NCT03960138|Device|Continuous Theta-burst stimulation (cTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
45497915|NCT03691272|Device|rTMS - Real Air Film Coil|70% resting motor threshold amplitude; Frequency 10 Hz; 10 trains of 60 pulses/train (total of 600 pulses); Inter-train interval 45s.
45497916|NCT03691272|Device|rTMS - Sham Coil|A sham coil will be applied to the scalp after the resting motor threshold is determined. Patients will be able to hear the sound and feel the vibration of sham coil, but will not experience any effective stimulation.
45497917|NCT03693222|Drug|Tramadol Hydrochloride|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.
45694491|NCT01910519|Biological|H5N1 vaccine plus AS03 adjuvant|"Administered vaccine: [GlaxoSmithKline] Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus with AS03 adjuvant, administered 21 (+/- 3) days apart."
45694492|NCT01910519|Biological|H5N1 vaccine without adjuvant|"Administered vaccine: [GlaxoSmithKline] Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus without adjuvant, administered 21 (+/- 3) days apart."
45694493|NCT01910441|Drug|Vildagliptin|Vildagliptin 50 mg twice daily
45694494|NCT01910441|Drug|Glimepiride|Glimepiride 1-6 mg once daily
45694495|NCT01910441|Drug|Metformin|Metformin (1000-1500 mg daily)
45497918|NCT03693222|Drug|Morphine Sulfate|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.
45497919|NCT04059744|Device|Fun-Knee|"Portable and low cost sensors are used in the Smart Knee Sleeve. The sensor system is composed of two inclinometers and one Bluetooth transmitter.~Fun Knee™ contains total knee replacement exercises that are gamified and supported on mobile device running on Android or iOS platforms. The mobile apps is able to capture the angle a and position data from the two inclinometers on smart knee sleeve.The free-sized knee sleeve prototypes are purchased and assembled by our collaborating vendor."
45497920|NCT03693066|Other|Ozone|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
45497921|NCT03693066|Other|chlorhexidine digluconate|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
45497922|NCT03693066|Other|Control|
45497923|NCT03631641|Biological|Nivolumab|Given IV
45497924|NCT03631875|Drug|Ketamine|use a low dose 0.5 mg/kg of ketamine in coinduction with propofol in children induction anesthesia
45497925|NCT05598099|Behavioral|Concentrated cognitive behavioral therapy|A psychological intervention consisting of psychoeducation and exposure therapy with the goal of changing the tolerability and negative interpretations of post-traumatic symptoms. The treatment is tailored to the individual patient through all stages, including relapse prevention and planning how to use treatment principles in daily life
45497926|NCT03631563|Drug|Immunosuppressive Agent|ATG-Fresenius versus ATG
45497927|NCT03019653|Drug|ANX-042|The first 20 subjects will receive a dose 0.003 µg/kg/min by infusion, the next 20 subjects will receive a dose of 0.006 µg/kg/min, then the next 20 subjects will receive 0.01 µg/kg/min.
45497928|NCT03019653|Drug|Placebo|The pharmacy created a placebo for this study is sterile Dextrose (5%) solution (D5W) 0.9% Sodium Chloride for intravenous administration to match study drug.
45497929|NCT02653755|Device|Prosigna|Transcriptional profile of 50 genes used for risk stratification.
45497930|NCT05077293|Other|Best Practice Alert (BPA)|A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.
45497931|NCT05077293|Other|In-Basket Message|An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
45497932|NCT05069181|Other|Pilates mat exercises|"Pilates mat exercises: Each Pilates session will last for one hour and commence with a 10 minute warm up and finish with a 10 min cool down. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centring which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the cranio-cervical junction).~Pilates exercise program will consist of warm up exercises, main treatment program (10 level) and cooling down exercises."
45847544|NCT04504188|Device|Heart Rate Monitor Enhanced Treatment Optimization|Heart rate (HR) will be continuously monitored by the WCD. Every two weeks a report showing daily HR trends will be emailed to the healthcare provider. The healthcare provider will also receive a HR control alert if the HR exceeds a predetermined threshold for 3 days in a row.
46055798|NCT02754609|Other|Liberal diet|From week 42, all participants will be unblinded and those who have received hookworm therapy have the option to go on a liberal diet of more than 10g of gluten/day from week 42 to week 94.
46055799|NCT02754609|Other|Necator americanus-hookworm larvae L3-10|A total of 40 participants at week 0 and week 8 will have hookworms L3-10 present in 2-3 drops of water applied to their skin and then covered in a light dressing.
46055800|NCT02754609|Other|Tabasco® Sauce|Arm: Placebo Comparator: Tabasco® Sauce A total of 10 participants at week 0 and week 8 will have Tabasco® Sauce present in 2-3 drops of water applied to their skin and covered in a light dressing
45497933|NCT05069181|Other|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit, 20 min/day, 3 days/week for 12 weeks.
45497934|NCT05069181|Other|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program 3 days/week for 12 weeks
45497935|NCT01383603|Biological|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart
45497936|NCT05065203|Procedure|planned or unplanned Cesarean, operative, or non operative delivery|All types of delivery
45497937|NCT02549157|Procedure|Pelvic Floor Muscle Training|
45497938|NCT03158805|Drug|LIRAGLUTIDE|3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
45497939|NCT03158805|Other|Placebo|Placebo injection
45497940|NCT01568775|Drug|Aliskiren|All patient and subjects received single dose of aliskiren 300 mg in treatment period.
45497941|NCT03197935|Drug|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab was administered as per schedule described in respective arm.
45497942|NCT03197935|Drug|Placebo|Placebo matched to atezolizumab was administered as per schedule described in respective arm.
45497943|NCT03197935|Drug|Nab-paclitaxel|Nab-paclitaxel was administered as per schedule described in the arms.
45497944|NCT03197935|Drug|Doxorubicin|Doxorubicin was administered as per schedule described in the arms.
45497945|NCT03197935|Drug|Cyclophosphamide|Cyclophosphamide was administered as per schedule described in the arms.
45497946|NCT03197935|Drug|Filgrastim|Filgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
46055801|NCT02754609|Other|Necator americanus-hookworm larvae L3-20|A total of 40 participants at week 0 and week 8 will have hookworms L3-20 present in 2-3 drops of water applied to their skin and then covered in a light dressing.
46055802|NCT02754609|Other|Gluten free diet|From week 0 to week 12, all participants will be on a gluten free diet.
45497947|NCT03197935|Drug|Pegfilgrastim|Pegfilgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
45497948|NCT05597865|Behavioral|Economic Empowerment Intervention|Economic Empowerment Intervention comprising Financial Literacy Sessions and Youth Development Accounts
45497949|NCT05597865|Behavioral|Alcohol and Drug Use Risk Reduction Sessions|All participants in the control and treatment arm will receive Alcohol and Drug Use Risk Reduction sessions tailored for Adolescents and Youths Living with HIV.
45381914|NCT05544136|Diagnostic Test|18F-FMISO PET/CT scan|18F-FMISO PET/CT scan (only 1 injection) that occurs 5-10 treatment days after RT start
45497950|NCT01015989|Other|CARE+ Kenya brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 9 months total.
45497951|NCT01015989|Other|CARE+ Kenya computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 9 months total.
45497952|NCT04722549|Dietary Supplement|Placebo|Cellulose
45497953|NCT04722549|Dietary Supplement|Butyrate|Sodium butyrate
45381915|NCT05544136|Radiation|Chemoradiation therapy|"18F-FMISO hypoxia negative patients complete CRT with 70Gy primary tumor and 50Gy de-escalated RT dose to gross nodes (if 50Gy is has pilot efficacy, then 44Gy to gross nodes; if 44Gy has pilot efficacy, then 40Gy to gross nodes).~18F-FMISO hypoxia positive patients are taken off study and complete SOC 70Gy CRT to primary tumor and gross nodes."
45381916|NCT05544136|Drug|Carboplatin|The chemotherapy used in this protocol is the standard of care for head and neck cancer, cisplatin or carboplatin/5-Fluorouracil
45847545|NCT04404114|Diagnostic Test|Shear wave elastography to distinguish AKI from normal kidney|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
45381917|NCT05542407|Drug|Atezolizumab|10 mg/kg- 20 mg/kg Atezolizumab will be administered by intravenous, on day 1 of each 21-day cycle.
45381918|NCT05542407|Drug|ONC201|375 mg once weekly - 625 mg ONC201 will be administered orally, once or twice weekly.
45381919|NCT05541926|Behavioral|e-Connect|Implementation of the e-Connect system
45381920|NCT05541471|Drug|VX-548|Tablets for oral administration.
45847546|NCT04404114|Diagnostic Test|Shear wave elastography to distinguish AKI from CKD|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
45381921|NCT05541471|Drug|Midazolam|Syrup for oral administration.
45381922|NCT05541471|Drug|Digoxin|Tablets for oral administration.
45381923|NCT05540860|Drug|EDG-5506 Dose 1|EDG-5506 is administered orally once per day
45381924|NCT05540860|Drug|EDG-5506 Dose 2|EDG-5506 is administered orally once per day
45381925|NCT05540860|Drug|EDG-5506 Dose 3|EDG-5506 is administered orally once per day
45381926|NCT05540860|Drug|Placebo|Placebo is administered orally once per day
45497954|NCT05003427|Drug|68Ga-FAPI-04|68Ga-FAPI-04 were injected into the patients before the PET/CT scans
45381927|NCT05540522|Biological|Quadrivalent influenza modRNA vaccine|Quadrivalent influenza modRNA vaccine (single dose)
45381928|NCT05540522|Biological|Quadrivalent influenza vaccine|Licensed quadrivalent influenza vaccine (single dose)
45381929|NCT05540405|Dietary Supplement|Low-dose bitter melon|Subject will receive 1 Insumate bitter melon capsule/d (300 mg) and 1 placebo capsule/d (300 mg)
45497955|NCT04941261|Biological|middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine|Intramuscular injection of middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
45497956|NCT04941261|Biological|high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine|Intramuscular injection of high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
45497957|NCT04941261|Biological|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
45497958|NCT00335049|Device|progressive addition spectacle lens (bifocal)|Progressive addition lenses (PAL) with a +2.00 D add.
45381930|NCT05540405|Dietary Supplement|High-dose bitter melon|Subject will receive 2 Insumate bitter melon capsules/d (300 mg each)
45381931|NCT05540405|Dietary Supplement|Placebo|Subject will receive 2 placebo capsules/d (300 mg each)
45381933|NCT05531786|Drug|Pacritinib|Pacritinib will be given as 100 mg or 200 mg tablets to be taken orally twice daily (12 hours apart) on days 1-28 of a 28 day cycle. Morning and evening should be taken at approximately the same time of day.
45497959|NCT00335049|Device|Single Vision Lenses (SVLs)|Single vision spectacle lenses.
45497960|NCT01383525|Device|Direct Selective Trabeculoplasty device|Patients will be treated with a Direct Selective Trabeculoplasty (DLTP) laser. Placement of the spots is on the sclera around the limbus.
45497961|NCT05597787|Behavioral|Stigma Reduction Tools|behavioral design, contact, and social norms
45497962|NCT05597787|Behavioral|Education|education and clinical skills
45497963|NCT05597709|Procedure|Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination|Eligible participants will receive ultrasound attenuation parameter with iLivTouch, fasting blood glucose and fasting insulin determination
45497964|NCT04908969|Behavioral|Internet-delivered Cognitive Behavior Therapy for Chronic Tic Dosorder/Tourette Disorder|The treatment will be provided through a secure internet platform designed for internet-administered treatments (BASS-4). In the treatment, the patient works through modules of self-help material, each ending in a short quiz with questions about the material. The treatment is supported by a therapist through text-based communication via the platform as well as occasional phone calls when needed. The central component in the treatment is exposure and response prevention (ERP). In ERP, the patient exposes her/himself to situations that trigger premonitory urges (a type of bodily sensation that precede the tic) while practicing to resist the tic. By doing this systematically and repeatedly, the patient gradually learns how to tolerate the premonitory urges and increase the ability to control and resist doing tics. Beyond ERP the treatment consists of other components such as applied relaxation, counter-movements and interventions to decrease stressors in the patient's everyday life.
45497965|NCT05420181|Other|Short 10hr fast|Participants will fast from 11pm the night before the study day
45497966|NCT05420181|Other|Long 16h fast|Participants will fast from 5pm the night before the study day
45497967|NCT03087513|Drug|Sugammadex Injection [Bridion]|The study participants will receive 10 ml syringe containing Sugammadex (2mg/kg) in the first phase followed by Placebo 10 ml syringe containing of 0.9% of normal saline in the second phase.
45497968|NCT03087513|Drug|Placebo|The study participants will receive Placebo 10 ml syringe containing of 0.9% of normal saline in the first phase followed by 10 ml syringe containing Sugammadex (2mg/kg) in the second phase.
45497969|NCT05420103|Other|Accelerated Stroke Ambulation Program|Stroke Rehabilitation Program
45497970|NCT04868643|Device|The DIMI Renal Replacement Therapy (RRT) System|To demonstrate that the safety and efficacy of the DIMI RRT remains consistent when used In-Center by trained dialysis nurses versus in an In-Home environment by trained Care Partners and Subjects.
45497971|NCT04863885|Drug|Ipilimumab|Participants will receive Ipilimumab 3 mg/kg
45497972|NCT04863885|Drug|Nivolumab|Participants will receive Nivoumab 1mg/kg
45497973|NCT04863885|Drug|Sacituzumab govitecan|Participants will be treated at 1 of 2 dose levels of Sacituzumab govitecan, either at 8 mg/kg, 10 mg/kg, or 6 mg/kg.
45497974|NCT03631485|Other|Exposure_having children with cancer|No intervention. The exposure is having children with cancer.
45497975|NCT02917629|Other|Laboratory Biomarker Analysis|Correlative studies
45497976|NCT02917629|Drug|Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet|Given PO
45694496|NCT01923467|Behavioral|Project Quit stop smoking program|This online stop-smoking program is individually tailored to the participant's readiness to quit, smoking triggers, and many other characteristics. It has been scientifically proven to improve quit success.
45694497|NCT01923467|Drug|Nicotine patches 21 mg|Eligible participants will receive a 2-week supply of Nicoderm CQ Step 1 patches to help them be successful in their quit attempt.
45381934|NCT05530772|Device|Endoscopic necrosectomy|Initially, a tract is created between the stomach or duodenum with the walled-off pancreatic necrotic collection through placement of a stent. Then, the endosocpe is entered the necrotic cavity with CO2 insufflation, and the necrotic materials are removed with snare, grasper, or suctioning.
45497977|NCT02917629|Other|Pharmacological Study|Correlative studies
45497978|NCT02917629|Other|Placebo|Given PO
45497979|NCT05418543|Procedure|Endoscopic ultrasound with fine needle biopsy|Patients with unresectable bile duct tumors will be investigated by either CH-EUS with FNA or conventional EUS with FNA
45694498|NCT01910129|Device|gammaCore|vagal verve stimulation 3 times a day 8 hours apart
45381935|NCT05528861|Drug|Lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8
45381936|NCT05528861|Other|Placebo|Placebo
45381937|NCT05526664|Other|Genetic testing and Omics analysis|Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics
45497980|NCT03692988|Behavioral|Dignity Therapy|Dignity Therapy (DT) invites individuals with life-limiting illnesses to reflect on matters of importance to them and compiles them in a narrative document for the patient to share.
45497981|NCT05417841|Drug|Insulin Degludec and Insulin Aspart Injection|To evaluate the efficacy and safety of the IDegAsp BID in T2DM
46055803|NCT04089631|Drug|Capecitabine|6 months capecitabine, in combination with oxaliplatin 3 to 6 months capecitabine
46055804|NCT00917059|Drug|Escitalopram|Fixed dose of 10 mg per day
46055805|NCT00917059|Drug|Bupropion XL|Fixed dose of 150 mg per day
46055806|NCT02751333|Procedure|FCSEMS with Endostitch (ES)|The fixation of FCSEMS using endostitch (ES) with the OverStitchTM system to prevent migration.
46055807|NCT02751333|Procedure|FCSEMS with No Suturing (NS)|The insertion of FCSEMS with no suturing.
46055808|NCT02751333|Device|Fully Covered Self-Expanding Metal Stents (FCSEMS)|This is the stent that will be used to treat the esophageal pathology in both groups
46055809|NCT02751333|Device|EndoStitch (ES) with the OverStitchTM system|This is the device used to apply the stitches to the stent in participants randomized to stent suturing.
45497982|NCT05417841|Drug|Insulin Aspart Injection|To evaluate the efficacy and safety of the IDegAsp QD plus IAsp BID in T2DM
45497983|NCT03691194|Dietary Supplement|fresh orange juice|The fresh oranges will be bought from Sysco. They will be squeezed at the kitchen of School of Allied Health Professional with a juicer. They will either be squeezed the night before or on the same day. The juice will not be treated with additional preservatives or sugar. The brand of the juicer is Kitchen Aid. Eight ounces of fresh orange juice needs approximately two and half oranges. They will be put into 32 oz water bottles that were bought from Sysco, and then store them in the refrigerator. They will be given to the subjects every three or four days.
45497984|NCT03691194|Dietary Supplement|concentrated orange juice|The concentrated orange juice will be bought from Sysco then reconstituted. One part of concentrated orange juice needs four parts of water to reconstitute. Then, it will be measured and the reconstituted orange juice will be put into 32 oz water bottles that we bought from Sysco. They will be stored in the refrigerator. The subjects will need to get the reconstituted orange juice every three or four days.
45497985|NCT05597475|Diagnostic Test|GLP-1R PET|Beta cell function (tests) and measure for beta cell mass (PET)
45497986|NCT03691116|Behavioral|Digital Health Profile|Screening, health check-up and automatic feedback in the areas tobacco, alcohol, exercise and diet, used on a National digital platform (Stöd och Behandlingsplattformen, SoB)
45497987|NCT03691116|Behavioral|Treatment as usual|Ordinary psychological assessment and counseling.
45497988|NCT03691038|Drug|Pregabalin 75mg bid|Through the study period, Incremental protocol follows the conventional dose regimen starting pregabaline 75mg bid.
45694499|NCT01909973|Behavioral|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
45381938|NCT05525312|Procedure|"Open-lung protective ventilation strategy"|"In the open-lung group, the positive end-tidal pressure (PEEP) is titrated to match the best lung compliance. During a PEEP decrement trial, PEEP is decreased from 20 cmH2O to 4 cmH2O by steps of 2 cmH2O/minute, and the driving the transpulmonary pressure (PTP) is calculated at each level of PEEP. In the open-lung group, the targeted PEEP corresponds to the lowest driving PTP during the PEEP decrement trial, meaning the best lung compliance. Thereafter, the PEEP is set at this level and maintained until extubation."
45694500|NCT01617005|Drug|Tocilizumab|Participants will receive tocilizumab treatment according to effective official SPC. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.
45381939|NCT05525312|Procedure|"Standard protective ventilation strategy"|"In the standard group, the positive end-tidal pressure (PEEP) is arbitrarily set at 5 cmH2O, since this is the currently recommended level of PEEP, commonly used in control groups of previous clinical trials."
45381940|NCT05523674|Other|Warm-up exercise|The warm-up exercise will be performed on a treadmill.
45381941|NCT05523674|Other|Warm-up exercise with Blood Flow Restriction|The warm-up exercise will be performed on a treadmill and pressure cuffs will be used for the blood flow restriction technique.
45381943|NCT05517603|Drug|AJ201|Administered orally
45381944|NCT05517603|Drug|Placebo|Administered orally
45381945|NCT05516914|Drug|LBL-007 Injection|Initial dose - MTD; Q3W; intravenous infusion
45381946|NCT05516914|Drug|Tislelizumab Injection|Initial dose; Q3W; intravenous infusion
45381947|NCT05516914|Drug|Cisplatin Injection|Initial dose；Q3W; intravenous infusion
45381948|NCT05516914|Drug|Gemcitabine Hydrochloride for Injection|Initial dose；Q3W; intravenous infusion
45381949|NCT05516914|Drug|Docetaxel injection|Initial dose；Q3W; intravenous infusion
45497989|NCT03691038|Drug|Pregabalin 25mg, 50mg|Through the study period, Incremental protocol follows the new dose regimen starting pregabalin 25mg, 50mg
45497990|NCT03686982|Other|Active Nitrate Bar|Bar containing Nitrate, L-citrulline; epicatechin; vitamin C and glutathione
45497991|NCT03686982|Other|Placebo Bar|No active ingredients
45497992|NCT05597319|Procedure|Liver resection|Liver resection, different kind of according to pathology
45497993|NCT03690960|Procedure|electrospun TAP nanofibers|electrospun TAP loaded nanofibers containing modified triple antibiotic paste of clindamycin , ciprofloxacin and metronidazole by electrospinning process will be placed in the root canals. The access cavity will be sealed with temporary filling material
45694501|NCT01925339|Device|Test (immediate restoration)|Test (immediate restoration)
45694502|NCT01925339|Device|Control: delayed restoration|Control: delayed restoration
45694503|NCT04621877|Behavioral|Volunteer-delivered Behavioral Activation|Behavioral Activation as delivered by trained volunteers
45694504|NCT04621877|Behavioral|Master's level clinician-delivered Behavioral Activation|Behavioral Activation as delivered by trained master's level clinicians
45694505|NCT01908803|Drug|AL-60371/AL-817 otic suspension|
45694506|NCT01908803|Drug|Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension|CIPRODEX®
45381950|NCT05514054|Drug|Imlunestrant|Administered orally.
45497994|NCT03690960|Procedure|modified TAP paste|modified TAP paste will be prepared by mixing equal proportions of CIP, MET and CLIN then placed inside the root canal, access cavity will be sealed with temporary filling
45497995|NCT03683160|Other|Cognitive Augmented Mobility Program|CAMP will combine education, one-on-one cognitive strategy training, and a cardiovascular and strength-training program conducted within a group setting. It will be run as a group of up to 6 participants, facilitated by a physiotherapist and a physiotherapy assistant or kinesiologist. It consists of 2 phases with a total of 19 sessions: Intervention Preparation (3 sessions), Active Intervention (16 sessions), and Follow-Up (1 session).
45497996|NCT05594199|Behavioral|Virtual Smoking Cessation Program|"This program consists of an e-learning smoking cessation education module and a tailored email messaging program.~The e-learning module addresses the potential health benefits to quitting smoking regarding surgery or recovering from a fracture. In addition, it provides information on getting support through the process of quitting smoking based on the individual's level of smoking dependence.~Email frequency and content will vary based on the participant's score and level of motivation. Information will include the risks associated with smoking before surgery or how quitting smoking can improve recovery from a fracture injury. Additional information includes the benefits of quitting smoking and developing coping strategies during a quit attempt. Motivational emails and references to free resources for additional smoking cessation support will also be provided."
45497997|NCT03683082|Drug|Oxygen supplementation|40% FiO2 via Venturi mask
45497998|NCT03683082|Drug|Sham O2 (medical air)|Medical air supplementation via Venturi mask
45497999|NCT05590767|Procedure|Patients scheduled to undergo shoulder rotators repair surgery|Patients scheduled to undergo shoulder rotators repair surgery, and received combined general anesthesia and interscalene block
45498000|NCT03686826|Procedure|Acquisition of MEP und SSEP|Acquisition of MEP und SSEP at two different time points within 1 to 30 days
45498001|NCT03682926|Other|Electro-stimulation|Intracavitary electrostimulation with Quark medical vaginal electrode for perineal muscle strengthening protocol.
45498002|NCT03690882|Other|systematic review of medical imaging|
45498003|NCT03686748|Behavioral|Two-point discrimination training|Patients will undergo multiple sessions of two-point discrimination training.
45498004|NCT03686748|Behavioral|One-point discrimination training|Patients will undergo multiple sessions of one-point discrimination training.
45498005|NCT02927847|Drug|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d) to wear for 1 month prior to the quit date. After the quit date, both groups will wear the nicotine patch for 8 weeks (21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks).
45498006|NCT02927847|Drug|SPECTRUM Nicotine Research Cigarettes (.03 mg)|For 1 month prior to their quit date, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
45498007|NCT02927847|Behavioral|Behavioral Activation|Participants in the BA+VLNC group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of behavioral activation treatment. BA components will include activity monitoring, values assessment, activity scheduling, and social contracts.
45498008|NCT02927847|Behavioral|Supportive Counseling|Participants in the VLNC Only group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of supportive counseling and health education. Supportive counseling and health education will include empathic listening as well as informational content on topics of exercise, nutrition, sleep and relaxation.
45498009|NCT03690804|Device|Evaluation of Autonomic nervous system indices|The ECG signal, respiration rate, SpO2 and NIPΣ or ANI are recorded simultaneously on a computer with a capture card. The other indices of HRV will be analyzed offline: SDNN (standard deviation of all NN intervals), pNN30 (NN30 count divided by the total number of all NN intervals), pNN50 (NN50 count divided by the total number of all NN intervals), RMSSD (quadratic mean of successive R-R intervals), SD1 (standard deviation), SD2 (standard deviation), LF (low frequencies), HF (high frequencies), VLF (very low frequencies), SDANN (standard deviation of the averages of NN intervals in all 5 min segments of the entire recording), ratio LF/ HF, Ptot, Poincaré plot (plot points corresponding to each R-R space of a record).
45498010|NCT03682692|Drug|ACEI/CCB|benazepril 10 mg / amlodipine besylate 5 mg fixed-dose combination
45694507|NCT01908101|Drug|Eribulin Mesylate|Given IV
45694508|NCT01908101|Other|Laboratory Biomarker Analysis|Correlative studies
45694509|NCT01923389|Other|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week for 4 weeks.
45694510|NCT01923389|Drug|100 mg PF-05231023|100 mg IV infusion twice a week for 4 weeks
45694511|NCT01907087|Biological|BMN 190|30-300 mg ICV infusion administered every other week for at least 48 weeks.
45381951|NCT05514054|Drug|Tamoxifen|Administered per local approved label.
45381952|NCT05514054|Drug|Anastrozole|Administered per local approved label.
45381953|NCT05514054|Drug|Letrozole|Administered per local approved label.
45381954|NCT05514054|Drug|Exemestane|Administered per local approved label.
45381955|NCT05513027|Device|Augmented Whole-body Scanning via Magnifying PET|-Added at the end of the SOC FDG-PET/CT scan. Will take approximately 3-5 minutes longer.
45381956|NCT05513027|Device|FDG-PET/CT|-Standard of care
45381957|NCT05513027|Drug|18F- fluorodeoxyglucose|-Standard of care given with FDG-PET/CT
45381958|NCT05511922|Drug|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
45381959|NCT05505916|Drug|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
45381960|NCT05504278|Drug|pemetrexed|500mg/m^2, Q3W, day1, i.v.
45381961|NCT05504278|Drug|cis-platinum|75mg/m^2, Q3W, day1, i.v.
45381962|NCT05504278|Drug|Sintilimab|200mg, Q3W, day1, i.v.
45381963|NCT05504278|Drug|IBI351|recommended dose, po
45381964|NCT05504278|Drug|carboplatin|AUC=5, Q3W, day1, i.v.
45381965|NCT05501600|Device|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using an electric nerve stimulator.
45381966|NCT05501600|Drug|Lidocaine IV|Subjects will receive an intravenous infusion of lidocaine for about 30 minutes.
45381967|NCT05500963|Device|Transcutaneous electrical nerve stimulation|Electrical stimulation applied over selected leg muscle will activate sensory receptors that will transmit signals back into the central nervous system.
45498011|NCT03682692|Drug|ACEI/DIU|benazepril 10 mg / hydrochlorothiazide 12.5 mg fixed-dose combination
45498012|NCT02886585|Drug|Pembrolizumab|
45498013|NCT02886585|Radiation|MRI|
45498014|NCT02886585|Radiation|PET/CT|
45498015|NCT02886585|Procedure|Stereotactic Radiosurgery|
45498016|NCT01568853|Drug|Norepinephrine|Intravenously, 10 ug/min, 24 hours
45498017|NCT01568853|Procedure|Open abdomen|IAH >=20 mmHg, and ACS emerged, such as low urine and decreased FiO2 quickly.
45498018|NCT01568853|Other|enteral nutrition|500-1500 kcal/day; Nasogastric tube feeding;
45498019|NCT01568853|Other|parenteral nutrition|3000 mL parenteral nutrition fluid, intravenously.
45498020|NCT02960438|Drug|E6011|subcutaneous administration
45498021|NCT02960438|Drug|Placebo|subcutaneous administration
45498022|NCT03926052|Drug|Lisdexamfetamine Dimesylate|Participants randomly assigned to this arm will receive 12 weeks of LDX medication.
45498023|NCT03926052|Drug|Placebo|Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.
45498024|NCT03690726|Device|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation of the leg motor cortex, in combination with resistance training
45498025|NCT03690726|Other|Sham stimulation|Imitated magnetic stimulation: An active coil will be activated under the subject's head, firing down into the mattress, while an inactive coil will be held over the scalp
45498026|NCT02853591|Procedure|Pneumoinsufflator mode and setting|Patients undergoing total laparoscopic hysterectomy will be randomized to pneumoperitoneum creation by one of two modes (standard or pressure-barrier) at one of two set pressures (15mmHg or 9mmHg) for a four-armed factorial designed study.
45498027|NCT03686592|Other|Measurement of body awareness|Questionnaires+ interviews
45498028|NCT05411991|Diagnostic Test|UNa measurement after intravenous loop diuretic bolus|Sodium concentration is measured on a urine spot sample, collected 30-120 min after administration of every protocol-specified intravenous bumetanide dose.
45694512|NCT04620161|Drug|Pradigastat Tablets 20mg|20mg, once daily, oral administration
45694513|NCT04620161|Drug|Pradigastat Tablets 40mg|40mg, once daily, oral administration
45694514|NCT04620161|Drug|Pradigastat Tablets 20mg matching Placebo|once daily, oral administration
46055810|NCT02754531|Device|USG|USG used was SonoSite® M-Turbo Bothell, WA, USA, probe linear (Array HFL 38 frekuensi 6-13 MHz). Internal subglottic diameter equals external diameter of the uncuffed endotracheal tube or trachea diameter, result rounded to the smallest uncuffed endotracheal tube size.
45694515|NCT04620161|Drug|Pradigastat Tablets 40mg matching Placebo|once daily, oral administration
45694516|NCT01616771|Device|Macintosh laryngoscope|Glottis view assessment by direct visualization using Macintosh laryngoscope
45694517|NCT01616771|Device|GVL selected by weight|Glottis view assessment by GVL selected by weight which is usually selected first
46055811|NCT02754531|Other|Cole Formula|Internal diameter of the uncuffed endotracheal tube equals (age in years/4) + 4mm.
46055812|NCT00917137|Procedure|TBNA + transbronchial lung biopsy + bronchial washing|
46055813|NCT04220385|Other|Group A|Subjects will perform following exercises, Single Leg Extension, Arm and Leg Lift, Balance Bridge, Single-Leg Twist, Single Leg Reach, Sideways Leg Lift, Single Arm Stand, Torso Twists and Plank exercise with minimum one set and maximum two sets. 30 seconds will be rest time between each set. Subjects will be encouraged to increase the number of repetitions after every 2 weeks, except in Plank exercise in which holding position time will be initially 30 seconds in each set and will be encouraged to increase holding time after every 2 weeks.
46055814|NCT04220385|Other|Group B|Subjects will perform Side Bridge, Bird Dog and Beginner Curl-up exercise in the first three weeks and Side Bridge, Bird Dog and Intermediate Curl-up exercise in the last three weeks. Repetitions per set will be 5, 4, 3 in first two weeks, 7, 6, 5 in third and fourth weeks and 9, 8, 7 in last two weeks. 8-10 seconds will be holding time in each repetition. 30 seconds will be rest time between each set
45498029|NCT05411991|Drug|Intravenous acetazolamide 500 mg OD|Upfront use of intravenous acetazolamide 500 mg OD as part of the diuretic treatment, unless hypernatremia (>145 mmol/L) or metabolic acidosis (bicarbonate <22 mmol/L) is present at the moment of the scheduled administration.
45498030|NCT05411991|Drug|Intravenous bumetanide TID|An intravenous bolus of bumetanide is administered TID, with dosing according to eGFR: 2 mg for an eGFR >45 mL/min/1.73m²; 3 mg for an eGFR 30-45 mL/min/1.73m²; and 4 mg for an eGFR <30 mL/min/1.73m². At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa <80 mmol/L), a dose of 4 mg TID is used.
45498031|NCT05411991|Drug|Oral chlorthalidone OD|In case of hypernatremia (>145 mmol/L) or low eGFR (<30 mL/min/1.73m²), oral chlorthalidone 50 mg OD is added to the diuretic treatment. At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa <80 mmol/L), oral chlorthalidone is provided at a dose of 100 mg OD. Chlorthalidone is never administered in case of hypotonic hyponatremia with serum sodium concentration <135 mmol/L.
45694518|NCT01616771|Device|smaller sized GVL|Glottis view assessment by GVL which is smaller in one size than GVL selected by age
45694519|NCT01589185|Drug|KBSA301|KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.
45694520|NCT01589185|Drug|Placebo|Placebo administered as a single intravenous infusion
45498284|NCT03683706|Behavioral|LTP in My Own Way Plus|LTP in My Own Way Plus is a 12-session integrated intervention-Learning through Play in My Own Way Plus Cognitive Behaviour Therapy (CBT). LTP in My Own Way is the extension of the parent education program called 'Learning Through Play' developed by Toronto Public Health (1993) revised by The Hincks-Dellcrest Centre (2000). LTP aims for the healthy growth of young children (birth to 6 years) using the stages of development incorporating Piaget's theory of cognitive development and Bowlby's theory of attachment. The objective of this program is to strengthen parent-child attachment by encouraging parental involvement and teaching parents how to use play activities to enhance their children's development. Second component of intervention is CBT adapted from Jeanne Miranda manual (Group CBT for Depression, group leaders guide book-2006) focusing on the three areas: thoughts and your mood, activities and your mood, people interaction and your mood.
45498285|NCT03623412|Diagnostic Test|75g oral glucose tolerance test|Women with one abnormal value in the OGTT during pregnancy (minor degree of glucose intolerance) will be offered a post-partum 75g GTT (Glucose Tolerance Test), similar to that offered to women with GDM
45498286|NCT03623412|Diagnostic Test|75g GTT|post-partum GTT
45498287|NCT02830165|Other|Laboratory Biomarker Analysis|Correlative studies
45498288|NCT02830165|Other|Quality-of-Life Assessment|Ancillary studies
45498289|NCT02830165|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45498290|NCT03184987|Drug|FF/UMEC/VI 100/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
45498291|NCT03184987|Drug|FF/UMEC/VI 200/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
45498292|NCT03184987|Drug|Salbutamol|Salbutamol is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
45498293|NCT03184987|Other|ACQ-7|ACQ-7 will be used for the assessment of control status of asthma.
45498294|NCT03193333|Drug|PRO-122|Posology: 1 drop every 12 hours for 90 days
45498295|NCT03193333|Drug|Timolol eye drops|1 drop every 12 hours for 90 days
45498296|NCT03193333|Drug|Dorzolamide-Timolol Ophthalmic|1 drop every 12 hours for 90 days
45498297|NCT03193333|Drug|Brimonidine Ophthalmic Solution|1 drop every 12 hours for 90 days
45498298|NCT03193333|Other|Placebo1|1 drop of each dropper bottle every 12 hours for 90 days
45382296|NCT05090540|Device|Trancatheter Edge to Edge Repair|TEER is performed by apposing the edges of the anterior and posterior leaflet (edge-to-edge) of prolapsed MV. The patient may be under conscious sedation or general anesthesia, depending on hospital standard practice. The procedure is performed through femoral venous access and the inter-atrial septum is crossed using standard techniques. Trans-septal puncture allows MitraClip Steerable Guide Catheter (Guide) to advance so that the guide is positioned over the mitral valve. The MitraClip delivery catheter is advanced to the MitraClip device and emerges from the tip of the guide into the left atrium. The MitraClip device can now be opened and advanced through the MV in the LV. Once in the LV, it is pulled back to grasp the leaflets. Two-dimensional and/or 3-dimensional echocardiography and color Doppler are useful for evaluating the anatomical features of the mitral valve and directing the procedure until the double orifice is formed alongside evaluating residual mitral regurgitation
45382297|NCT05090540|Procedure|Mitral Valve Replacement|Mitral valve replacement is performed using mechanical or biological prosthesis while preserving the subvalvular apparatus to avoid dilation of the left ventricle over time.
45382298|NCT05090540|Procedure|Restrictive Mitral Annuloplastie|Mitral valve repair consists of a restrictive mitral annuloplasty (RMA) using a prosthetic ring
45382299|NCT05090540|Procedure|Restrictive Mitral Annuloplastie/Subvalvular Repair|RMA may be associated with the use of a subvalvular repair (SR). The SR permits the approximation or the relocation of papillary muscles which is displaced by post infarction scar formation.
45382300|NCT05090280|Drug|PF614 solution|PF614 solution is an oxycodone prodrug
45382301|NCT05090280|Drug|Naltrexone Hydrochloride|Naltrexone 50 mg has been selected to be administered on Day -1 (single dose), Day 1 (BID), and Day 2 (single-dose) to reduce opioid-related adverse effects.
45382302|NCT05090280|Drug|Nafamostat Mesylate|Maximum dose of 10 mg nafamostat co-administered with PF614 solution. Nafamostat will be dosed as an immediate-release (IR) solution or as prototype extended-release (ER) capsules.
45498299|NCT03193333|Other|Placebo 2|1 drop of each dropper bottle every 12 hours for 90 days
45498300|NCT03193333|Drug|Krytantek|Posology: 1 drop every 12 hours for 90 days
45498301|NCT03184519|Diagnostic Test|Pregnancy test|Instead of one blood sample, patients will have three blood analyses to predict pregnancy earlier after the embryo transfer.
45498302|NCT03184441|Device|Premie Pouch|The Premie Pouch is an experimental device meant to manage the development of Deformational Plagiocephaly (DP) starting immediately following birth. The Premie Pouch has a concave-shaped foam insert that will provide a resting surface for the infant's head and body that will eliminate uneven pressure on the infant's occiput while maintaining correct body alignment. Also, the posterior neck area of the infant will be supported by a fixed bridge section of the foam insert. The Premie Pouch is designed specifically for the very low birth weight (VLBW) infant.
45498303|NCT05241145|Drug|IVMED-80|Good Manufacturing Practices-grade copper (ІІ) sulfate pentahydrate (CuSO4 #5H2O MW 249.69) was dissolved in a vehicle solution comprised of a balanced salt solution (BSS) with osmolality of approximately 500 mOsm/L. Copper sulfate was concentrated to 0.15 mg/mL. The drops were manufactured on prior to the study at a compounding pharmacy in Salt Lake City, Utah.
45498304|NCT05241145|Other|Placebo|This was identical to the IVMED-80 product, but without the active ingredient, copper sulfate.
45498305|NCT05240599|Device|Exercise Training|Exercise training will be applied in sets of 10x3, 3 times a day for 8 weeks.
45554587|NCT05616429|Dietary Supplement|Standard balanced diet|"Sham standard balanced diet with dietician supervision and follow up + usual care."
45554588|NCT05616429|Other|usual care|usual care
45554589|NCT04013217|Combination Product|Eribulin ORA|Oral eribulin mesylate will be supplied as an aqueous solution and HM30181A-UK
45498306|NCT05240443|Procedure|Bariatric Surgery + Medical Management of CKD.|The intervention group will include medical management and bariatric surgery, which will consist of Roux-en-Y gastric bypass or sleeve gastrectomy performed according to local practice standards. Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of <140/90 mmHg (<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein <2mmol/L for the treatment of CKD.
45498307|NCT05240443|Other|Medical Management for CKD|Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of <140/90 mmHg (<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein <2mmol/L for the treatment of CKD.
45498308|NCT03026166|Drug|Ipilimumab|Administered by intravenous infusion
45498309|NCT03026166|Drug|Nivolumab|Administered by intravenous infusion
45498310|NCT03026166|Drug|Rovalpituzumab tesirine|Administered by intravenous infusion
45498311|NCT03345576|Device|Testosterone and LPWS|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
45498312|NCT03345576|Drug|Testosterone and standard NMES|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
45498313|NCT03573648|Drug|Avelumab|Avelumab (10 mg/kg) will be given intravenously on cycles 2 - 4, every 2 weeks.
45498314|NCT03573648|Drug|Endocrine therapy|"The endocrine therapy given will depend on menopausal status.~Premenopausal women will receive tamoxifen AND either Goserelin or Leuprolide:~Tamoxifen (20mg) will be given orally daily x 4 cycles. (Other Names: Nolvadex)~Goserelin (3.6mg) will be given subcutaneously (under the skin) on Day 1 of each cycle x 4 cycles. (Other Names: Zoladex)~Leuprolide (3.75mg) will be given intramuscularly (in the buttock, thigh, or upper arm) on Day 1 of each cycle x 4 cycles. (Other Names: Leuprorelin, Lupron, Eligard)~Postmenopausal women will receive letrozole:~- Letrozole (2.5mg) will be given orally daily each cycle x 4 cycles. (Other Names: Femara)"
45498315|NCT03573648|Drug|Palbociclib|Palbociclib (125 mg) will be given orally on days 1-21 of each cycle x 4 cycles.
45498316|NCT03569514|Drug|AIGIV|Anthrax Immune Globulin Intravenous (Human)
45498317|NCT03558828|Behavioral|Step 1: PA Monitor|The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.
45498318|NCT03558828|Behavioral|Step 1: PA Monitor + Text|"The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.~In addition, these participants will receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent."
45382303|NCT05087095|Behavioral|CALM Intervention|"The CALM intervention includes 6 individual therapy sessions, each approximately 45-60 minutes in length, delivered over 3 months. Participants will be asked to complete self-report surveys of behavioral and psychological variables surveys at the following timepoints:~Within one week before initiating the CALM intervention therapy~Within one week after its completion,~3 months after the CALM intervention is complete~After each intervention session, participants will complete a brief post-session survey to assess acceptability of CALM session components"
45498319|NCT03558828|Behavioral|Step 2: PA Monitor with Calls|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
45498320|NCT03558828|Behavioral|Step 2: PA Monitor with Meetings|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
45498321|NCT03558828|Behavioral|Step 2: PA Monitor + Texts with Calls|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
46059051|NCT04080037|Other|Quality IQ Patient Simulations|"Online patient cases designed to simulate typical patients seen in a primary care practice. In each case, providers will answer multiple-choice questions about their preferred course of action to work-up, diagnose and treat patients in the primary care setting. After each question, providers will receive evidence-based feedback, including references, on the appropriateness of each of their care decisions. Feedback will be supported with relevant reference to evidence-based guidelines, with a specific focus on the CDC opioid guidelines.~Cases will cover typical primary care patients presenting with acute and chronic pain, who may or may not be already taking opioid medication."
45382304|NCT05087095|Behavioral|Survey Administration|"Participants will be asked to complete self-report surveys of behavioral and psychological variables at the following timepoints:~Within one week before initiating the treatment as usual~Within one week after its completion,~3 months after the treatment as usual is complete"
45382312|NCT05078866|Biological|Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP|Given IM
45382313|NCT05078866|Biological|MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP|Given IM
45498322|NCT03558828|Behavioral|Step 2: PA Monitor + Texts with Meetings|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
45498323|NCT03558828|Behavioral|Step 3: PA Monitor|During Weeks 35-50, all women will receive enhanced physical activity monitors only.
45498324|NCT03683472|Behavioral|Unwinding Anxiety Phone App|"The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety"
45382314|NCT05078866|Other|Questionnaire Administration|Ancillary studies
45382315|NCT05077423|Drug|CD33*CD3 BsAb|CD33xCD3 is a bispecific monoclonal antibody, which specifically targets CD33 on the AML blasts and CD3 on the T cells
45382316|NCT05077371|Behavioral|Peer support program|The intervention will consist of 8 face-to-face peer social support sessions conducted by volunteers diagnosed with breast cancer who have finished their medical treatment (chemotherapy, radiotherapy, surgery) or who have been in a stable phase for at least two years and who are motivated to participate in this type of intervention.
45382317|NCT05075759|Behavioral|Behavioral Intervention|Receive personalized clinician-led self-management telehealth sessions
45382318|NCT05075759|Behavioral|Behavioral Intervention|Receive personalized goal setting for daily steps and activity and dietary goals
45382319|NCT05075759|Behavioral|Behavioral Intervention|Remote sessions with a health coach
45382320|NCT05075759|Other|Survey Administration|Ancillary studies
45382321|NCT05205460|Device|Home-based telehealth exercise training program|A home-based exercise mobile app will be offered combined with the heart rate sensing clothes to each participant in the group of home-based telehealth exercise training program. The mobile app provides auto-feedback of heart rate at each exercise training session through the heart rate sensing clothes and alarm function identifying individuals' appropriate exercise intensity (target heart rate) during their exercise based on their exercise prescription calculated and set up inside the app. After completing each exercise training session, the record of training time and heart rate response is simultaneously uploaded to the cloud system of the medical center through the heart rate sensing clothes. The experienced and well-trained nurse checked the cloud system data to monitor participants' adherence to exercise training. In addition, online communication is enabled using LINE software, which provided a platform for patients and researchers to interact with each other through messaging.
45382322|NCT05205460|Behavioral|Education and self-exercise|The participants will receive a exercise prescription suggestion. Then, they will maintain their routine outpatient follow-up per month and usual lifestyles with weekly reminders.
45554590|NCT03193034|Device|Cementless Total Knee Arthroplasty|Patients will undergo a primary total knee replacement using the configuration of the ATTUNE Cementless knee (CR RP)
46059052|NCT04472299|Drug|Ropivacaine 0.2% Injectable Solution|Patients in the intervention group will have ultrasound guided bilateral T3 paravertebral catheters placed prior to surgery. Prior to surgery, these patients will have 5ml of 1.5% lidocaine with 1:200,000 epinephrine injected in each catheter. Ropivacaine 0.2% will be administered via programmed intermittent bolus of 7ml every 60 minutes through each catheter during and after surgery.
46059053|NCT02583685|Drug|PR4 + LDV/SOF + ASV 4 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
45382326|NCT05065970|Drug|Felzartamab|anti-CD38+ monoclonal antibody
45382327|NCT05065970|Other|Placebo|Placebo comparator
45382330|NCT05063552|Biological|Atezolizumab|Given IV
45382331|NCT05063552|Biological|Bevacizumab|Given IV
45382332|NCT05063552|Drug|Carboplatin|Given IV
45382333|NCT05063552|Biological|Cetuximab|Given IV
45382334|NCT05063552|Drug|Cisplatin|Given IV
45382335|NCT05063552|Procedure|Computed Tomography|Undergo CT scan
45382336|NCT05063552|Drug|Docetaxel|Given IV
45382337|NCT05063552|Procedure|Echocardiography|Undergo ECHO
45382338|NCT05063552|Procedure|Magnetic Resonance Imaging|Undergo MRI
45382339|NCT05063552|Procedure|Positron Emission Tomography|Undergo PET scan
45382340|NCT05062772|Diagnostic Test|Ultrasound|Intraoperative ultrasound imaging
45382341|NCT05061134|Drug|Ceralasertib|Ceralasertib (240 mg) will be administered orally twice daily.
45382342|NCT05061134|Biological|Durvalumab|Durvalumab (1500 mg) will be administered intravenously once every 28 days for participants who weight above > 30 kgs. For participants who weigh below ≤ 30 kgs, weight-based dosing equivalent to 20 mg/kg of durvalumab will be administered.
45382343|NCT05058040|Drug|Sodium Oligomannate Capsules|Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
45498325|NCT03676920|Behavioral|Discussions of Cost App (DISCO App)|The DISCO App is an app-based and patient-focused intervention designed to improve the frequency and quality of patient-oncologist treatment cost discussions. The DISCO App allows patients to provide basic demographic information (e.g., employment status, insurance status, etc), and uses that information to provide patients with an individually-tailored list of treatment cost questions they can ask their provider.
45498326|NCT03026088|Drug|Bisoprolol|Participants received Bisoprolol orally, once daily at a dose of 1.25 milligram (mg) up to Weeks 3, and then it was up-titrated to 2.5 mg up to Week 6, 3.75 mg up to Week 10, 5 mg up to Week 14, 7.5 mg up to Week 18 and 10 mg up to Week 26.
45498327|NCT03676842|Combination Product|FLEX Dynamic Scoring Catheter with IN.PACT Admiral DCB|Treatment by the FLEX Scoring Catheter followed by an IN.PACT Admiral DCB
45498328|NCT03328884|Drug|Irinotecan Hydrochloride|"nal-IRI (nanoliposomal irinotecan, also known as MM-398 and PEP02) is irinotecan hydrochloride, (also known as CPT-11) a topoisomerase 1 inhibitor, encapsulated in a liposome drug delivery system.~nal-IRI will be administered with a fixed dose of 60 mg/m2 on D1 of a 14-day cycle in monotherapy."
45498329|NCT03678948|Device|Radiofrequency-Based Debridement|In this process, radiofrequency energy is used to excite the water molecules in a conductive medium, such as an electrolyte (saline) solution, to generate excited radicals within precisely focused plasma. The energized particles in the plasma have sufficient energy to break molecular bonds (16-18), excising or dissolving (i.e. ablating) soft tissue at relatively low temperatures (typically 40ºC to 70ºC).
45498330|NCT03678948|Device|Mechanical Debridement|Arthroscopic chondroplasty used to remove loose and damaged cartilage which minimizes synovial irritation and mechanical impingement
45498331|NCT03678792|Drug|Buprenorphine/naloxone|Participants in this group will be tapered on buprenorphine-naloxone regimen, 2mg/day
45498332|NCT03678792|Drug|Morphine|Participants in this group will be tapered on an oral morphine regimen, 30-60mg/day
45498333|NCT03678792|Drug|Tramadol|Participants in this group will be tapered on an oral morphine regimen, 50-100mg/day
45498334|NCT03683238|Dietary Supplement|Mediterranean Diet|We aim to determine the effects of the traditional Mediterranean Diet on Hidradenitis suppurativa
45498335|NCT03678714|Behavioral|Exercise Intervention|2 sessions of supervised exercise training each week for 8 consecutive weeks and 3 sessions of supervised exercise training each week for the final 4 consecutive weeks, at 57-74% heart-rate max. Each session will last approximately 60 minutes.
45498336|NCT03678714|Behavioral|Lifestyle Physical Activity|Advice and information on how to increase physical activity will be provided. Participants will be asked to monitor and track their daily physical activity using a smart-phone fitness application. The research team will gain permission to access their recorded activity.
45498337|NCT03676686|Device|Nåva Foot Cream|Nåva Foot Cream is a Medical device (EU class IIa) for the treatment of tinea pedis, heal cracks, calluses and dry feet.
45498338|NCT03321552|Procedure|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
45498339|NCT03321552|Device|LimFlow System|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
45498340|NCT03305094|Procedure|Blood pressure cuff inflation|Cuff pressure for ischemia sham is 20 mm Hg, ischemia is 200 mm Hg and reperfusion is 0 mm Hg
45498341|NCT03676608|Biological|Bee Wax Mammary Areolae|The product to be valued are mammary areolae made by hand with organic beeswax. Despite its honey aroma, it does not contain honey. The wax used for the manufacture of the areolae is operculum. This wax is used and not another because it avoids possible residues and allergies that may contain other types of waxes. The operculum wax is used as a thickener in pharmacy and cosmetic products as a fat base in ointments and creams.
45498342|NCT03676608|Other|Usual educational care|The WHO protocol for maternal lactation.
45498343|NCT03678558|Other|Cytochalasin B supplemented vitrification medium|Vitrification of human oocyte in medium supplemented with Cytochalasin B
45498344|NCT03672786|Dietary Supplement|Multicentrum|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 2 months
45498345|NCT03678480|Drug|HTD1801|HTD1801 capsules, 250mg
45498346|NCT03678480|Drug|Ursodeoxycholic Acid|UDCA capsules, 125mg
45498347|NCT03181789|Biological|p24CE1/2 pDNA Vaccine|Administered bilaterally using the Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device
45498348|NCT03181789|Biological|p55^gag pDNA Vaccine|Administered bilaterally using the TDS-IM EP device
45498349|NCT03181789|Biological|IL-12 pDNA Adjuvant|Administered bilaterally using the TDS-IM EP device
45498350|NCT03181789|Biological|Placebo|Administered bilaterally using the TDS-IM EP device
45498351|NCT03181789|Device|Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device|The TDS-IM EP device will be used to administer study product(s).
45498352|NCT03676530|Device|Pro-Tec Shin Splint Compression Wrap|EVA Foam pad compression device with Velcro straps that is placed over tibial site of pain.
45498353|NCT03117985|Other|no drug|Stopping antiretroviral therapy
45498354|NCT03678246|Procedure|Ramped position|LSFOI glottis view
45498355|NCT03678246|Procedure|Supine position|LSFOI glottis view
45498356|NCT03672708|Diagnostic Test|Cresyl violet|cresyl violet is applicated at the concentration of 0.15% via a spraying catheter to visualize cellular and tissue architecture in the pCLE
45498357|NCT03672552|Other|FFWP and Improved Oral Care|The FFWP with dental hygiene participants will have assessments for swallowing and oral health then proceed to have a dental hygienist cleaning. This intervention group will have supervised and assisted tooth brushing by nursing staff before taking plain (thin) unmodified water and between meals.
45498358|NCT03678168|Other|Throat Pack|Post rhinology surgery throat packs will be used as a control to compare against the intervention (Pharyngeal tampons)
45498359|NCT03678168|Other|Pharyngeal Tampons|Post rhinology surgery Pharyngeal Tampons will be used as an intervention to compare against the throat pack (control)
45498360|NCT03678090|Drug|tPA standard dosage|Tissue plasminogen activator 25mg dosage
45498361|NCT03678090|Drug|tPA low dosage|Tissue plasminogen activator 2.5mg
45498362|NCT03678012|Drug|Ferumoxytol/Hydrogen peroxide|1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
45498363|NCT03678012|Drug|Hydrogen Peroxide|Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
45498364|NCT03678012|Drug|Water|Sham solution (water; negative control). Each subject will use this product during one of three treatment periods in the crossover study design.
45498365|NCT03676452|Behavioral|Active@Home exergame training|The Active@Home exergame is a multicomponent, motor-cognitive training for fall prevention in elderly adults. It mainly consists of three components; strength training, balance training and cognitive training. For strength training, Tai Chi-based movements are included. For balance training, dancing is included in the Active@Home exergame. Moreover, the Active@Home exergame explicitly targets specific attentional and executive functions. The Active@Home system set up is easy and consists of an HDMI dongle (to run the application) which must be plugged into the TV and four wearable sensors (to measure the movements).
45498366|NCT03259074|Biological|Placebo|Matching placebo to AIN457 150 mg dose administered with AIN457 via pre-filled syringes
45498367|NCT03259074|Biological|GP2017 (adalimumab biosimilar)|40 mg in pre-filled syringes was administered subcutaneously
45498368|NCT03259074|Biological|AIN457 150 mg|150 mg in pre-filled syringes was administered subcutaneously
45498369|NCT03676296|Drug|Puerarin|Puerarin (90.2 mg daily) in granules (as well as excipients) taken orally for 12 weeks
45498370|NCT03676296|Drug|Placebo|Placebo in granules (with the same excipients as the puerarin supplement but without puerarin) taken orally for 12 weeks
45498371|NCT03672474|Device|Photobiomodulation REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
45498372|NCT03672474|Device|SHAM REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and not activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
45498373|NCT03672240|Drug|APL-1202|To assess the safety and pharmacokinetics of APL-1202 alone and in combination with Bacillus Calmette Guerin
45498374|NCT03676140|Drug|Albendazole on Day 1|Albendazole 400 mg oral tablet Single Dose Treatment on D1
45498375|NCT03676140|Drug|Ivermectin on Day 1|Ivermectin 200 µg/kg oral tablet Single Dose Treatment on Day 1
45498376|NCT03676140|Drug|Diethylcarbamazine on day 1|Diethylcarbamazine 6 mg/kg oral tablet Single Dose Treatment on Day 1
45498377|NCT03676140|Drug|Azithromycin on Day 1|Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 1
45498378|NCT03676140|Drug|Azithromycin on Day 8|Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 8
45498379|NCT03676062|Other|exercise|All exercises programs applied three sessions per week, totally six week.
45498380|NCT03675984|Behavioral|asymmetrical stabilization exercise|Exercise is combined to form an appropriate combination of motion (Side-lying, Bird-dog, Prone arm lift, Prone leg lift) according to the curve pattern and muscle weakness of each patient's.
45498381|NCT03677856|Procedure|Paravertebral blockade|Type of anaesthesia
45498382|NCT03677856|Procedure|Thoracic epidural block|Type of anaesthesia
45498383|NCT03504774|Drug|Cashew or Shrimp Oral Immunotherapy|All cohorts will undergo an updosing regimen starting at 5 mg allergen, with dose escalation every 2 weeks to reach a 1000 mg dose at week 28, after which they will be maintained at that dose for 24 weeks. At the conclusion of the maintenance phase (Week 52), participants will undergo DBPCFC.
45498384|NCT03677700|Other|Laser Flare Meter|Measurement of the inflammation of the operated eye and the fellow eye before the surgery and at each post-surgery visit: D7, M1, M2, M3, M6, M12
45715035|NCT01691105|Other|AD + Integrated Tobacco Order Set|"Physician will have access to:~NRT with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center"
45498385|NCT03677622|Drug|Voluven to near maximal stroke volume of the heart|Stroke volume guided fluid treatment with Voluven on the basis of restricted fluid therapy
45498386|NCT04059042|Behavioral|Music Listening|Participants will have pain threshold testing while listening to silence, music, or nature sounds.
45498387|NCT03672162|Procedure|Total abdominal hysterectomy|Each drug group undergo elective total abdominal hysterectomy with the same general anesthesia
45498388|NCT04059120|Other|Experimental group whit specific stretching|The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced with specific exercises of stretching and with it the factors that determine the syndrome of overtraining
45498389|NCT04059120|Other|Control group whit out specific stretching|The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced less than specific exercises of stretching and with it the factors that determine the syndrome of overtraining
45498390|NCT04059198|Drug|Inarigivir soproxil|Inarigivir soproxil 400 mg tablets
45498391|NCT04059198|Drug|Tenofovir alafenamide fumarate (TAF)|Tenofovir alafenamide fumarate 25 mg tablet
45498392|NCT04058964|Biological|Pegylated Recombinant Human Hyaluronidase PH20|Given SC
45715036|NCT02685072|Drug|Progesterone (200 mgs BID)|Transdermal Nicotine Patch (TNP) + Progesterone
45498393|NCT04058964|Biological|Pembrolizumab|Given IV
45382344|NCT05057923|Biological|Bacillus subtilis|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.
45382345|NCT05056506|Procedure|EPLBD|Endoscopic papillary large balloon dilation for Choledocholithiasis
45382346|NCT05056506|Procedure|ELPBD+ESD|Endoscopic papillary balloon dilation combined with limited endoscopic sphincterotomy for Choledocholithiasis
45382347|NCT05054153|Other|refined carbohydrate breakfast|After wearing CGM on Day 1, participants will be provided with breakfast A once daily on Day 2, Day 5 and Day 6. Breakfast A contains white bread (50g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
45382348|NCT05054153|Other|whole grain breakfast|After wearing CGM on Day 1, participants will be provided with Breakfast B once daily on Day 3, Day 4 and Day 7. Breakfast B contains plain oats (35g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
45382349|NCT05054153|Other|intermittent fasting|The period during Day 8 to Day 13 is intermittent fasting period. Participants will experience the moderate fasting on Day 9 and Day 12, which means their daily energy intake is expected to be controlled within 500-600 kcal limit. In these two days, participants will be provided with all three meals. Percentages of macronutrients of provided meals will follow the Recommended Dietary Health guidelines for Chinese residents. The oral glucose tolerance test (OGTT) will be conducted in the morning on Day 8 and Day 13, to test short-term impact of IF intervention on individuals' glucose tolerance. The breakfasts on Day 10 and Day 11 will be the same as that in fasting days. Other meals will be wash-out meals.
46055845|NCT05429151|Drug|Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd andcandida antigen|"Group 1: will be treated with intralesional injection of acyclovir (Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd) 250 mg acyclovir vial diluted with 3.5 ml saline to get approximately 70 mg/ml solution. During the study, the dosage of the drug and frequency of treatment were uniform in all patients. The base of each wart was injected with 0.1 ml of intralesional acyclovir (70 mg/ml) using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until the resolution of warts or for a maximum of 5 sessions~Group 2: will be treated by intralesional Candida antigen injection (candida antigen ) at a dose of 0.2 mL. injected into the largest wart using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until complete clearance of warts or for a maximum of 5 treatment sessions."
46055846|NCT04219995|Drug|methylprednisolone sodium succinate|Methylprednisolone sodium succinate will be re-constituted in simple syrup in a concentration of 80mg/mL and will be administered orally at 20mg/kg (max 1000mg) for days 1, 2, and 3 of the intervention phase of the study.
45382357|NCT05043649|Drug|Camsirubicin|The dose escalation of camsirubicin will start at 265 mg/m2, with dose increments of 50% until a Grade 2 non-hematologic toxicity is observed at which point subsequent dose escalations will be in increments of 25% until an MTD is identified in patients with ASTS.
45382360|NCT05036733|Drug|Dupilumab|"Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.~Additionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints."
45382361|NCT05035810|Behavioral|Social Incentives and Gamification to Promote Exercise|The intervention will provide social incentives and gamification to promote physical activity.
45382362|NCT05035810|Drug|Corticosteroid Injection given in A-B order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
45382363|NCT05035810|Behavioral|No Social Incentive applied|No social incentive will be applied
45498394|NCT03246906|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
45498395|NCT03246906|Drug|Cyclophosphamide|Given IV
45498396|NCT03246906|Drug|Cyclosporine|Given PO
45498397|NCT03246906|Drug|Mycophenolate Mofetil|Given PO
45498398|NCT03246906|Drug|Sirolimus|Given PO
45498399|NCT03024606|Behavioral|text messages focused on smoking cessation and pregnancy|The impact of a text-message service on smoking cessation in medically underserved, obstetric patients when added to the usual care of pharmacist-driven CBT smoking cessation program and smoking cessation pharmacotherapy with either the nicotine replacement patch or bupropion.
45498400|NCT03671928|Other|additional blood tube|sampling of an additional tube at the usual blood test to determine the glicentin level
45498401|NCT03671928|Other|additional blood sample|for le group control, another blood sample is taken outside the usual care.
45498402|NCT03675906|Other|hypoalbuminemia|hypoalbuminemia and acute kidney injury
45382364|NCT05035810|Drug|Procedure: Corticosteroid Injection given in B-A order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
45382365|NCT05032040|Biological|vudalimab|Monoclonal bispecific antibody
45498403|NCT03675828|Behavioral|Virtual Visit|The Cleveland Clinic Express Care Online application will be used in this intervention. The subjects will have a virtual consult with a clinician from the study team that will mirror an experience had at an outpatient post-discharge visit, including review of systems and medications.
45498404|NCT02864160|Behavioral|Health Coaching|Life style coaching in 3 in-person meetings and 14 phone calls; written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
45382366|NCT05030090|Behavioral|Nutritional consultant|The control group is to be consulted by the dietitian using communication software (Line) or telephone to evaluate the nutritional requirement and guide the cancer diet principles before starting the project.
45382367|NCT05030090|Dietary Supplement|Nutritional consultant + High-calorie, high-protein liquid nutrition supplement|At the beginning of the plan, the dietitian first calculates the patient's daily calorie intake and the ratio of the three macronutrients and guides the patients or their family members of the nutritional care plan group A to implement a daily diet with a concentrated high-calorie and high-protein liquid supplement (Commercial formula contains 425 kcal and 19.1 grams of protein).
45382368|NCT05030090|Combination Product|Nutritional consultant + Liquid supplement + Powdered supplement 1 and 2|At the beginning of the plan, the dietitian first calculates the patient's daily calorie intake and the ratio of the three macronutrients and guides the patients or their family members of the nutritional care plan group B to implement a daily diet with a concentrated high-calorie and high-protein liquid supplement (Commercial formula contains 425 kcal and 19.1 grams of protein). Meanwhile, nutrition care plan group B will be given powdered supplement 1 (containing β-glucan and gamma-aminobutyric acid) and nutritional products and powdered supplement 2 (contains water-soluble dietary fiber and probiotics).
45382369|NCT05029063|Drug|Rivaroxaban 10 MG|Identical comparator drug
45382370|NCT05026177|Drug|Simufilam|Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 76 weeks at a dose of 50 mg or 100 mg.
45382371|NCT05026177|Drug|Placebo|Matching placebo given b.i.d. for 76 weeks
45382372|NCT05017571|Drug|Colchicine|Colchicine 1 capsule (0.6 mg) per day
45382373|NCT05017571|Drug|Placebo|Placebo 1 capsule per day
45382374|NCT05017012|Biological|MK-3475A|MK-3475A is a fixed-dose formulation of pembrolizumab (either Conc1 or Conc2) and MK-5180 for SC administration.
45382375|NCT05017012|Biological|Pembrolizumab|Participants will receive pembrolizumab 400 mg IV.
45382376|NCT05017012|Drug|Pemetrexed|Participants may receive 500 mg/m^2 IV every 3 weeks (Q3W) Day 1 and Day 22 of Cycles 1 to 18 as background SOC treatment during the study, as applicable to their diagnosis.
45498405|NCT02864160|Behavioral|Comparison Group|Written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
45715037|NCT02685072|Drug|Placebo|TNP + Placebo
45382377|NCT05017012|Drug|Carboplatin|Participants may receive 5 mg/mL/min IV (nonsquamous) or 6 mg/mL/min IV (squamous) on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
45382378|NCT05017012|Drug|Paclitaxel|Participants may receive 200 mg/m^2 IV on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
45382379|NCT05017012|Drug|Nab-paclitaxel|Participants may receive 100 mg/m2 IV on Day 1, 8, and 15 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
45382380|NCT05017012|Drug|Axitinib|Participants may receive 5 mg orally twice daily continuously as background SOC treatment during the study, as applicable to their diagnosis.
45382381|NCT05017012|Drug|Cisplatin|Participants may receive 75 mg/m^2 IV on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
46055847|NCT04219995|Other|Placebo|The placebo used in this study will be simple syrup.
46055848|NCT02753517|Device|Hepatobiliary scintigraphy|hepatobiliary scintigraphy with functional assessment of the future remnant liver before an extended hepatectomy of 4 or more segments
46055849|NCT05428995|Device|C-MAC videolaryngoscope|Patients with anticipated difficult airway will be awake intubated with a C-MAC videolaryngoscopy
46055850|NCT05428995|Device|Airtraq videolaryngoscope.|Patients with anticipated difficult airway will be awake intubated with a Airtraq videolaryngoscopy
46055851|NCT05428605|Other|Blood sample|10 mL on lithium heparinate tubes, 10 mL on EDTA tubes.
46055852|NCT04544475|Device|Revaree|Hyaluronic Acid Vaginal Insert (Revaree). A 2g vaginal insert that contains 5mg of HLA sodium salt and a base of semi-synthetic glycerides. It is an insert that does not require an applicator and should be placed in the vagina while laying down twice weekly.
45382388|NCT05009394|Procedure|Targeted Muscle Reinnervation (TMR)|Surgical procedure used to rewire injured proximal nerves to motor nerves directly innervating an otherwise redundant target muscle.
45382389|NCT05009394|Procedure|Regenerative Peripheral Nerve Interface (RPNI)|Surgical procedure where the the nerve is split into fascicles and wrapped in free muscle grafts.
45382390|NCT05009394|Procedure|Standard neuroma treatment, neuroma excision, and muscle burying|Surgical procedure where the neuroma is excised and the nerve stump is buried in an adjacent deep muscle.
46055853|NCT04544475|Drug|Estrace|Vaginal estrogen cream, estradiol: 100mcg
45382392|NCT05003726|Procedure|non-pharmacological treatment|This is a pragmatic setting, and specific intervention is not determined prior to the study. Non-pharmacological treatment including Korean medicine, such as acupuncture, electroacupuncture and chuna, etc, will be chosen by professional physician according to the medical condition of each subject.
45382393|NCT05003726|Procedure|pharmacological treatment|This is a pragmatic setting, and specific intervention is not determined prior to the study. The pharmacological treatment will be chosen by professional physician according to the medical condition of each subject.
45382394|NCT05002868|Drug|RP12146|starting dose of 100 mg QD
45382395|NCT05001750|Drug|long term prophylactic antibiotics (Nafcillin or Doxycycline)|VRIs in patients who also receive a pre-procedural dose of antibiotics with continued dosing of antibiotics for the duration of the external ventricular drain IRB NUMBER: 2021-12680 IRB APPROVAL DATE: 06/14/2021 NOABX in EVD Study 3 (EVD).
45382396|NCT04998786|Drug|Ixazomib|Ixazomib 3 mg/day (days 1, 8, 15) cycle 1 to until progress
45382397|NCT04998786|Drug|Iberdomide|Iberdomide 1.6 mg / day (day 1 to 21) cycle 1 to until progress
45382398|NCT04998786|Drug|Dexamethasone Oral|Cycle 1 and 2 Dexaméthasone 20 mg/day on days 1, 8, 15, 22 Cycle 3 to 6 Dexamethasone 10 mg/day on days 1, 8, 15, 22
45382399|NCT04998500|Biological|Growth hormone, saline and GH receptor blockade (Pegvisomant)|This study aims to uncover physiological effects of growth hormone (GH). The intervention with GH and GH receptor blockade (Pegvisomant) will therefore be used as tools to activate a well-known physiological response. Thus, this study is not a drug trial.
45382400|NCT04992624|Drug|Placebo|"Placebo drug will be taken similarly to the THC and CBD and be matched to keep the trial blinded.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
45382401|NCT04992624|Drug|Cannabidiol (CBD)|"Epidiolex doses will be 0.37 milliliter (mL) for seven days of treatment and then 0.75 mL two times a day (b.i.d) for the remaining days of this treatment.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
45382402|NCT04992624|Drug|Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)|"Dronabinol Capsules doses will be 2.5 mg b.i.d. for seven days of treatment and then 5 mg b.i.d. for the remaining days of this treatment.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
45382403|NCT04990258|Drug|Subcutaneous infliximab CT-P13 Remsima®SC|Patients will be switched from IV infliximab into subcutaneous infliximab Remsima®SC 120 mg.
45498406|NCT03671616|Biological|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. A single dose of the IPV-Al SSI will be given to infants age 15-18 months.
45498407|NCT03675594|Device|CAD/CAM titanium denture base|metallic denture base made of titanium
45498408|NCT03675594|Device|CAD/CAM cobalt/chromium denture bases|metallic denture bases made of cobalt/chromium
45498409|NCT03675438|Other|Sub-epitheilal TCA Inlay|A TCA lenticule is placed at the sub-epithelial interface with the anterior surface of Bowmans layer
45498410|NCT03180619|Drug|TAF|Tablet administered orally once daily
45498411|NCT03669744|Other|telephone survey|a telephone survey will be conducted at 21 patients with trigeminal neuralgia resistant to usual treatments, according to the ICHD-3β criteria treating by one or more trigeminal nerve blocks at the peri operative pain management center of Limoges University Hospital between 2014 and 2018.
45498412|NCT03671538|Drug|Anlotinib|Anlotinib 12mg qd on day 1 to 14 of a 21-day cycle
45498413|NCT03671538|Drug|pemetrexed|pemetrexed 500mg/m2 on day 1 of a 21-day cycle ;
45498414|NCT03671538|Drug|Cisplatin|Cisplatin 75mg/m2 on day 1 of a 21-day cycle ;
45498415|NCT05426941|Behavioral|Music Imagery|Up to 30 participants will be randomized to receive 8 weekly Music Imagery sessions over 8-12 weeks.
45498416|NCT05426941|Behavioral|Music Listening|Up to 15 participants will be randomized to independent music listening.
45498417|NCT05420467|Drug|Docetaxel|75 mg/m2, d1, q3w,6 cycles
45498418|NCT05420467|Drug|Carboplatin|AUC 6, d1, q3w,6 cycles
45498419|NCT05420467|Drug|Trastuzumab|starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w,6 cycles
45498420|NCT05420467|Drug|Pertuzumab|starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w ,6 cycles
45498421|NCT05420467|Drug|Nab paclitaxel|220 mg/m2, d1, q3w,6 cycles
45498422|NCT05420467|Drug|Epirubicin|90 mg/m2, d1, q3w ,4 cycles ,followed by docetaxel
45498423|NCT05420467|Drug|Cyclophosphamide|600 mg/m2, d1, q3w × 4 cycles followed by docetaxel
45498424|NCT05420467|Drug|Docetaxel|100 mg/m2, d1, q3w × 4 cycles
45498425|NCT05420467|Drug|Epirubicin|90 mg/m2,d1, q2w × 4 cycles followed by nab-paclitaxel
45498426|NCT05420467|Drug|Cyclophosphamide|600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
45498427|NCT05420467|Drug|Nab paclitaxel|125 mg/m2, d1,8,15, q3w× 4 cycles
45498428|NCT05420467|Drug|Cyclophosphamide|600 mg/m2, d1, q3w × 6 cycles
45498429|NCT03671460|Biological|CD19 CAR-T cells|T cells purified from the PBMC of subjects, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.
45498430|NCT03675204|Other|No intervention|No intervention
45498431|NCT03671382|Behavioral|Communication Training Program and Patient Prompt Sheet|The intervention being delivered is a two-component intervent. First component is the Oncologist Communication Skills Training Program. This is an e-learning module teaching oncologists to recognize and respond to patient/caregiver distress, provide information including prognosis and discuss goals of care. The second component is a patient prompt sheet which will be administered to three patients of intervention arm oncologists in the waiting area at least 30 minutes before their consultation. The sheet includes structured questions for patients to ask the oncologist about diagnosis and prognosis and will prompt patients to label and express their emotions in a direct manner.
45498432|NCT02915874|Behavioral|Acceptance and Commitment Therapy|
45498433|NCT02818218|Procedure|Liver Transplant|liver transplant recipient surgery
45498434|NCT03675048|Dietary Supplement|BioGaia Protectis drops|food supplement containing the patented lactic acid bacterium Lactobacillus reuteri Protectis®/™ (L. reuteri DSM 17938).
45498435|NCT03675048|Dietary Supplement|Placebo|Contains same excipients as study drug, without the active ingredient L. Reuteri.
45498436|NCT03022578|Procedure|Laser Interstitial Thermal Therapy|Undergo LITT
45498437|NCT03022578|Drug|Lomustine|Given PO
45498438|NCT03022422|Biological|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
45498439|NCT03022422|Biological|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe for intramuscular injection
45498440|NCT03023826|Drug|LY3202626 (R-Fasting)|Administered orally
45498441|NCT03023826|Drug|LY3202626 (T1-Fasting)|Administered orally
45498442|NCT03023826|Drug|LY3202626 (T1-Fed)|Administered orally
45498443|NCT03671070|Drug|Epinephrine|IV Low dose Boluses
45498444|NCT03671070|Drug|Traditional management of shock|"Initial resuscitation: Push boluses of 20 cc/kg isotonic saline or colloid up to and over 60 cc/kg until perfusion improves or unless rales or hepatomegaly develop~Fluid refractory shock: Begin inotrope IV/IO. Use atropine/ketamine IV/IO/IM to obtain central access and airway if needed. Reverse cold shock by titrating central dopamine or, if resistant, titrate central epinephrine. Reverse warm shock by titrating central norepinephrine.~Catecholamine resistant shock: Begin hydrocortisone if at risk for absolute adrenal insufficiency."
45498445|NCT03670992|Procedure|duodenal-pancreatectomy|surgical removal of metastatic repetitions in pancreas and/or other distal sites
45498446|NCT03670758|Diagnostic Test|Protein S activity|Intravenous blood sample
45498447|NCT03674658|Drug|Propafenone|oral, TID
45498448|NCT03674580|Behavioral|Follow-up of the suicidal patients|No intervention. Follow-up of the suicidal patients
45498449|NCT03674502|Drug|ADU-1604|anti-CTLA-4 monoclonal antibody
45498450|NCT03623256|Drug|Spinal fentanyl|25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
45498451|NCT03623256|Drug|Spinal bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route.
45498452|NCT03623256|Drug|Spinal Fentanyl and Bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL), and 25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
45498453|NCT03623256|Drug|Epidural fentanyl /spinal bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route, and 100 mcg of fentanyl (2 mL) will be administered by epidural route.
45498454|NCT03674268|Diagnostic Test|Management of the Contraversive Pushing Scale|Scale of evaluation of trunk control and pushing behavior in patients with stroke.
45498455|NCT02661672|Device|Apollo Device|The Apollo system has been cleared for the controlled aspiration of soft tissue and/or fluid during endoscopically guided neurosurgery of the ventricular system.
45498456|NCT02661672|Device|Artemis Device|The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump. The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.
45382404|NCT04988399|Other|Reiki|Reiki is a wellness practice of energy healing that began in Japan and is now practiced throughout the world. The principle of Reiki is that everything in the universe consists of energy including the human body, and deviations of this energy can lead to disease (Doğan 2018). Reiki does not have a religious doctrine and is accepted by people of all backgrounds and belief systems (McManus, 2017, p. 1056). Reiki is considered by practitioners to be a great tool for stress reduction and relaxation (International Association of Reiki Practitioners). Many people use Reiki for wellness. Reiki is not a cure for a disease or illness, but it may assist the body in creating an environment to facilitate healing. According to the Center for Reiki Research, Reiki is an effective approach for reducing pain, depression, and anxiety. Tinnitus is a pain percept, and it is likely Reiki may reduce pain and anxiety in patients with tinnitus.
45498457|NCT03669510|Other|computer guided IAN lateralization surgical technique|Tthe neurosensory alterations with computer guided inferior alveolar nerve lateralization versus non guided classic technique
45498458|NCT03674190|Procedure|Anterior Lumbar Interbody Fusion|Anterior Lumbar Fusion(ALIF)
45498459|NCT03674190|Procedure|Total Disc Replacement|Total Disc Replacement
45498460|NCT03674034|Other|CTscan and MRI images|CTscan and MRI images segmented according to procedures previously developed by GRAMFC
45498461|NCT02576496|Drug|Tinostamustine|
45498462|NCT03670290|Procedure|Fascia iliaca compartment catheter|Patient will evaluate and if VAS score >3, catheter will be inserted and 30 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS>3 or patient enounce pain.
45498463|NCT03670290|Procedure|epidural catheter|Patient will evaluate and if VAS score >3, catheter will be inserted and 10 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS>3 or patient enounce pain.
45498464|NCT03670290|Procedure|patient controlled analgesia|Patient will evaluate and if VAS score >3, patient controlled analgesia pump will be set 1mg morphine/15 min lockout.
45498465|NCT03673722|Other|Foods consistent with a MDP|We aim to increase MDP by 3 points, according to a 14-point MEDAS score
45498466|NCT03673722|Other|Physical Activity|We aim to increase PA to 150 minutes moderate activity per week.
45498467|NCT03673722|Other|Control|Participants will be given generic healthy eating advice based
45498468|NCT03113760|Drug|Tadekinig alfa|Tadekinig alfa is a soluble glycoprotein of 164 amino acids produced from Chinese Hamster Ovary cell line. Tadekinig alfa is supplied as a colorless to slightly yellow, sterile solution for injection in glass vials containing sodium chloride, and 0.02M sodium phosphate buffer as excipients. It is available in a concentration of 20mg/0.5mL.
45498469|NCT03113760|Other|0.9% sodium chloride|To ensure that the treatment remains blinded for the entire study period, the placebo solutions will be supplied in identical vials and similar labelling as the active drug and will be indistinguishable in terms of their texture, color, and smell.
45382405|NCT04988295|Drug|Lazertinib|Lazertinib will be administered orally.
45382406|NCT04988295|Drug|Amivantamab|Amivantamab will be administered as an IV infusion.
45382407|NCT04988295|Drug|Pemetrexed|Pemetrexed will be administered as an IV infusion.
45498470|NCT03166735|Drug|BI 1467335|once daily
45498471|NCT03166735|Drug|Placebo|once daily
45498472|NCT03082014|Drug|Amlodipine|blood pressure lowering agent - dihydropyridine Ca2+-channel blocker
45498473|NCT03082014|Drug|Losartan|blood pressure lowering agent - angiotensin-receptor blockers
45498474|NCT03082014|Drug|Atenolol|blood pressure lowering agent - beta-blocker
45498475|NCT02750605|Device|DEB|Intervention with drug eluting balloon.
45498476|NCT02750605|Device|POBA|Intervention with old technology as comparison
45498477|NCT03673566|Device|NICU Dashboard|The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
45498478|NCT05320159|Drug|Secukinumab|Included all the patients treated with secukinumab
45498479|NCT03670212|Drug|Yohimbine Hydrochloride|54mg of yohimbine powder was encapsulated in a generic opaque capsule and swallowed with water.
45498480|NCT03670212|Drug|Hydrocortisone|10mg hydrocortisone was encapsulated in a generic opaque capsule and swallowed with water.
45715038|NCT02652208|Behavioral|Online decision aid|The Healthwise online shared decision point for Stable Chest Discomfort
45498481|NCT03670212|Drug|Lactose Monohydrate Powder|Lactose powder was encapsulated in generic opaque capsules identical to those used during the acute stress session. Lactose doses weighed the same as the acute stress session doses (54mg and 10mg, respectively).
45498482|NCT03673488|Device|TephaFlex™ mid-urethral sling|The sling is made from P4HB material. It is placed in a similar technique to standard retropubic sling procedures, but will resorb over 18-24 months post surgery.
45498483|NCT03165955|Drug|Oraxol|HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules
45498484|NCT03669978|Procedure|Creation of a bone and arterial panorama using EndoNaut® software.|"The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.~New injections of contrast product are made to control the results of the treatment.~As part of this pilot study, the assistive software and its interface will be linked and with the mobile C-arm X-ray system. Scopic images and angiograms will be retransmitted to be processed by the EndoNaut® software."
45498485|NCT05263921|Drug|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir under fasted conditions
45498486|NCT05263921|Drug|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with water under fasted conditions
45498487|NCT05263921|Drug|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with applesauce under fasted conditions
45498488|NCT05263921|Drug|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with vanilla pudding under fasted conditions
45498489|NCT05192473|Device|Pulse Intravascular Lithotripsy System|Treatment with Pulse Intravascular Lithotripsy System
45382408|NCT04988295|Drug|Carboplatin|Carboplatin will be administered as an IV infusion.
45382409|NCT04983225|Drug|Human Dental Pulp Stem Cells|Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;
45382410|NCT04983225|Other|Saline solution|Blank control: initial Basal periodontal therapy (supragingival cleansing, subgingival scaling and root planning) followed by a single local injection of normal saline.
45382411|NCT04982250|Behavioral|Formal peer PrEP referral + HIVST delivery|After a brief training, young female PrEP users will be encouraged to refer up to 4 peers to PrEP using strategies gained from the training, PrEP educational materials (i.e., brochures), HIVST kits (2 kits/peer = 8 kits total), and Kenya MOH-style referral cards.
45382412|NCT04980300|Behavioral|Expanded Intervention|Participants in the Expanded Intervention arm will receive five virtual consultation sessions, delivered by a physical therapist over 12 weeks (at Weeks 1, 2, 4, 7, and 10) and lasting approximately 45-60 minutes each. Each session will focus on lower extremity strengthening exercises, physical activity (i.e., walking), and education about knee osteoarthritis. Participants will be provided with an exercise manual, tracking log, educational manual, and a step counter. Participants will be prescribed up to 6 exercises (quadriceps, hip abductor/gluteal, hamstrings/gluteal, calf, balance) and daily walking step goals. Progression will be a joint decision by the participant and physical therapist. Education will include information on knee osteoarthritis, managing pain, being active, weight loss, dealing with setbacks, and progressing activity. The physical therapist will also discuss barriers and facilitators to meeting and progressing goals as appropriate.
45382413|NCT04980300|Behavioral|Brief Intervention|Participants in the Brief Intervention arm will receive access to a study-specific website that navigates them to a variety of web-based resources on knee osteoarthritis. Topics for the various resources include an overview of knee osteoarthritis, brief anatomy of the knee and how that is related to pain, different types of arthritis pain and how to manage it, and how to be active with arthritis. Sessions range from 20 - 70+ minutes.
45382414|NCT04976569|Device|STN-DBS stimulation pattern change|Deep brain stimulation (DBS) is an elective surgical procedure in which electrodes are implanted into certain brain areas.We use specific STN-DBS stimulation pattern to regulate sleep architecture.
45382415|NCT04975191|Behavioral|Resources|Participants will be provided a list of resources available at VCU that are intended to support student success
45498490|NCT05184673|Other|Behavioral and environmental|These are all active comparator yoga sequences
45498491|NCT03055494|Biological|Secukinumab|Secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3, and 4 was followed by monthly dosing up to Week 48
45498492|NCT03055494|Biological|Placebo|Placebo s.c. at randomization, Weeks 1, 2, 3, 4, and 8; secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
45498493|NCT03673410|Procedure|Robotic bariatric surgery - revisional|Using robotic techniques during any revesional bariatric surgery
45498494|NCT03673410|Procedure|Laparoscopic bariatric surgery - revisional|Using laparoscopic techniques during any revesional bariatric surgery
45498495|NCT02445768|Other|Cognitive multisensory rehabilitation|
45498496|NCT03673332|Drug|immune-checkpoint inhibitors therapies|All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.
45498497|NCT02914548|Drug|OPA-15406|Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.
45498498|NCT02914548|Drug|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
45498499|NCT02400216|Drug|dual cholate|test for defining disease severity
45382416|NCT04975191|Behavioral|Personalized Feedback Program (PFP)|Participants will complete an interactive online program that explores their personality-related traits to provide personalized recommendations for success
45382417|NCT04975191|Behavioral|Substance Use Feedback Program (BMI)|Participants will complete an online program based on brief motivational intervention (BMI) content/principles that explores their current substance use patterns to make personalized recommendations for success
45382418|NCT04972487|Drug|Tofersen|Administered as intrathecal bolus injection
46055854|NCT04191369|Diagnostic Test|Esophagogastroduodenoscopy|Esophogagastroduodenoscopy for the evaluation of esophageal varices, gastric varices and hypertensive gastropathy. Portal pressure gradient will be evaluated via interventional radiology as gold standard.
45498500|NCT03048084|Drug|Levetiracetam|Antiepileptic drug levetiracetam
46055855|NCT04191369|Diagnostic Test|Endoscopic ultrasound|"Endoscopic ultrasound evaluation for the presence of esophageal varices, peri and para-esophageal collateral veins, gastric varices, portal hypertensive gastropathy, azygos vein diameter, blood flow and BFVI.~Portal pressure gradient will be evaluated via interventional radiology as gold standard."
45498501|NCT03048084|Drug|Valproic Acid|Antiepileptic drug valproic acid
46055856|NCT02753673|Behavioral|qualitative interviews with patients|
45498502|NCT02329860|Drug|Apatinib|
45498503|NCT02329860|Drug|Placebo|
45498504|NCT02251548|Drug|Ibrutinib|Oral BTK inhibitor
45498505|NCT02251548|Drug|Fludarabine|IV purine analogue chemotherapy agent
45498506|NCT02251548|Drug|Cyclophosphamide|IV alkylator chemotherapy agent
45498507|NCT02251548|Drug|Rituximab|IV anti-CD20 monoclonal antibody
45498508|NCT03165721|Drug|SGI-110 (guadecitabine)|SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.
45498509|NCT02224872|Procedure|Bone marrow transplant|Day 0
45498510|NCT02224872|Drug|Thymoglobulin|0.5 mg/kg IV on Day -9 2 mg/kg IV on Days -8, -7
45498511|NCT02224872|Drug|Fludarabine|30 mg/M2 IV on days -6 to -2
45498512|NCT02224872|Drug|Cyclophosphamide|14.5 mg/kg IV on days -6, -5, 3, 4
45498513|NCT02224872|Radiation|TBI|200 cGy on day -1
45498514|NCT02224872|Drug|Mesna|40 mg/kg IV on days 3, 4
45498515|NCT02224872|Drug|Tacrolimus|For patients 18 years or older, tacrolimus will be given per institutional standards; may be increased or later changed to a PO BID schedule. Treatment to continue until Day 365 or longer if GVHD present
45498516|NCT02224872|Drug|Mycophenolic acid mofetil|15 mg/kg PO/IV TID beginning on day 5 through day 35
45498517|NCT02645851|Drug|fluid bolus|Administration of the fluid bolus if deemed clinically necessary, OR if deemed clinically necessary AND PLR-induced SV or PP changes ≥10%, depending of the Arm the patient is assigned to
45498518|NCT02645851|Device|PiCCO system (Pulsion, Germany)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Stroke Volume changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced stroke volume change is over 10%; in case stroke volume change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
45498519|NCT02645851|Device|Vascular pressure transducers (Edwards Life Science, USA)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Pulse Pressure changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced Pulse Pressure change is over 10%; in case Pulse Pressure change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
45498520|NCT02645851|Other|Passive Leg Raising test|Passive elevation of the legs of the patient, and lying down of the trunk (if patient is in the semi-recumbent position), preferably using electric bed. If not available, elevation of the legs by an assistant to a 45 degrees angle. Effects of Passive Leg Raising on Pulse Pressure or on Stroke Volume are used to assess fluid responsiveness in patients suffering from shock states.
45498521|NCT02187198|Drug|Buprenorphine|
45498522|NCT03672942|Behavioral|Communication Skills Training|Gentle start-up is one treatment technique in the Creating Healthy Relationship Program written by John Gottman, Ph.D.
45498523|NCT03672942|Behavioral|Mindfulness|Acceptance/willingness of unwanted emotions is treatment technique of Achieving Change through Value-Based Behavior (ACTV) written by Amie Zarling, Ph.D.
46055857|NCT02753673|Behavioral|questionnaires|
46055858|NCT04506645|Drug|REGN5381|Single dose REGN5381 administered via IV infusion
45382422|NCT04966104|Behavioral|ODYSSEE-vCHAT|Automated digital counselling program with social network support
45382423|NCT04965493|Drug|Pirtobrutinib|Oral
45382424|NCT04965493|Drug|Venetoclax|Oral
45382425|NCT04965493|Drug|Rituximab|Intravenous (IV)
45382426|NCT04964089|Drug|KSI-301|Intravitreal Injection
45382427|NCT04964089|Drug|Aflibercept|Intravitreal Injection
45382428|NCT04964089|Other|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
46055859|NCT04506645|Other|Placebo|Placebo matching single dose REGN 5381 administered via IV infusion
45694640|NCT05310682|Other|Data informed Platfrom for health|The DIPH promotes local data use for decision-making, priority-setting, planning and course correction at the district level by introducing a structured and collaborative process within the administration cadre. The DIPH is delivered as a package of job aids and guidelines. It involves grouping stakeholders who are brought together to deliberate on issues in a virtual platform facilitated by regular meetings. The package facilitates stakeholders' meetings in five steps: Assessment, Engagement, Definition, Planning and Follow-up. Together, these steps make up one whole cycle of the DIPH completed over four months. Each cycle looks at a specific health theme, identified in the early stages of the cycle itself. The package also includes a digital interface where everyone can regularly review data and check on progress. Note: LSHTM has exempted this study from having a sponsor, as DIPH is implemented at the health system administration level.
45382429|NCT04963075|Device|multisensory rehabilitation paradigm|"In initial (training) sessions, subjects will be exposed (and respond) to spatiotemporally congruent pairs of visual-auditory stimuli presented within their blinded field, with occasional probes of unisensory visual stimuli on both sides of space. Once recovery of visual responsiveness in the contralesional field is observed, sessions will alternate between training/testing and testing only sessions in which performance on the visual battery will be re-assessed."
45498524|NCT03672942|Behavioral|Placebo|Couples randomly assigned to this condition listen to music on headphones. This may be considered an active placebo as it is similar to a Time Out technique taught in battering interventions.
45498525|NCT02642029|Device|Excitatory TMS|Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.
45694641|NCT03216694|Diagnostic Test|Cardiopulmonary exercise testing|Aerobic fitness measured using a cycle ergometer and metabolic cart
45694642|NCT03397966|Drug|recombinant human BNP (1-32)|Subjects will receive an IV infusion of recombinant human BNP1-32 (6 mcg BNP/ml saline) for 240 minutes.
45848011|NCT05304000|Behavioral|Box Breathing|"Participants are informed they should sit down in a chair or lie down, and to get a timer. Then they are told to take the CO2 tolerance test as follows: Take 4 breaths through the nose. Then take a maximally deep breath and once your lungs are full, exhale as slowly as possible through your nose or mouth. Time how long it takes to empty your lungs; this will be your C02 discard duration. Use your discard duration to determine how long your inhales, exhales, and breath holds should be (CO2 discard time) by using this table: <20 sec = 3 - 4 sec, 25 - 45 sec = 5 - 6 sec, 50 - 75+ sec = 8 -10 sec. They are then told to inhale, hold, exhale, hold (for the duration determined by the C02 discard table) and to repeat this pattern for the entire 5 minutes. If at any point they had to strain to reach these times, they should simply reduce the duration of inhales, exhales, and breath holds. We ask participants to perform all breathing through their nose, if possible."
45855702|NCT04265365|Device|rTMS + optimal-rPMS|The optimal Repetitive peripheral magnetic stimulation (rPMS) depend on previous results to give an iTBS or cTBS. Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
45382430|NCT04961957|Device|Waterproof padding|Apply waterproof padding to allow for normal bathing and water activities
45694643|NCT03397966|Drug|normal saline (placebo)|Subjects will receive an IV infusion of normal saline for 240 minutes.
45694644|NCT03216616|Behavioral|Cognitive Behavioural Therapy|
45694645|NCT03275662|Behavioral|Dietary Fiber|
45694646|NCT03275662|Behavioral|Fermented Foods|
45715039|NCT02652208|Behavioral|Video decision aid|The Health Dialog DVD and booklet decision aid for Stable Chest Discomfort
45382431|NCT04961957|Device|Non-waterproof padding|Apply standard padding that does not allow for normal bathing and water activities
45382432|NCT04959383|Other|Low complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept low for this group.
45382433|NCT04959383|Other|Moderate complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept moderate for this group.
45498526|NCT02642029|Device|Inhibitory TMS|Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.
45498527|NCT02642029|Device|Sham TMS|Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.
45498528|NCT04058574|Device|Proprioception measurement on isokinetic dynamometer|Proprioception measurement on isokinetic dynamometer using joint position sense (JPS) and the threshold to detection of passive motion (TTDPM)
45498529|NCT04058730|Procedure|Laparoscopic Roux en Y Gastric by pass surgery|
45498530|NCT04058730|Procedure|Laparoscopic Sleeve Surgery|
45382434|NCT04959383|Other|High complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept high for this group.
45382435|NCT04959383|Other|Control Group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. This group will receive exergame balance training on Wii fit. Participants in this group will play Soccer Heading, Ski Slalom, Ski Jump, Table Tilt, Tightrope Walk, Balance Bubble, Penguin Slide and Snowboard Slalom game.
46055860|NCT05428449|Drug|GT20029 Gel|Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
45498531|NCT04058730|Other|Standard Medical Management|
45498532|NCT02639923|Procedure|Drawing of 7ml peripheral blood|puncture peripheral vein
45498533|NCT05239975|Biological|SCTV01C|intramuscular injection
45498534|NCT05239975|Biological|Comirnaty|intramuscular injection
45498535|NCT05239897|Device|Continuous theta burst stimulation (cTBS)|Patients assessed for postoperative delirium will be treated by consist of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions.
45498536|NCT05239819|Behavioral|Inspiratory muscle training|The initial training intensity of the preoperative threshold IMT trainer (DofinTM, Breathing Strength Builder, Taiwan) was moderate to high intensity (≥50% of MIP), which was according to the patient's baseline level and increased by 5-10% per week. The frequency is 25-30 minutes each time, twice a day and five days per week for at least two weeks. The participants would receive at least 10 times training sessions before surgery
46055861|NCT05428449|Drug|GT20029 Gel Placebo|Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
46055862|NCT02753361|Procedure|Ultrasound guidance|In the second arm, ultrasound will be used to guide the regional block
45498537|NCT05239819|Behavioral|Regulated care and education|Regulated care and education will be applied
45498538|NCT04969705|Drug|Dexmedetomidine|"60 Patients will be randomly divided into three equal groups:~Group A (n=20) : spinal anesthesia with Dexmedetomidine (5µg ) added to local anesthetic (bupivacaine Hcl ) (10 mg) given intrathecally .~Group B (n=20) : spinal anesthesia using local anesthetic( bupivacaine Hcl) (20 mg) combined with TAP block using Dexmedetomidine (20µg ) after the cesarean section~Group C (n=20) (controlled group ) : Spinal anesthesia using only local anesthetic (bupivacaine Hcl ) (10 mg) ."
45498539|NCT03676374|Drug|Prucalopride|Prucalopride 2mg taken once a day as add-on to PPI (2x/d)
45498540|NCT03676374|Drug|Placebo Oral Tablet|Placebo tablet taken once a day as add-on to PPI (2x/d)
45498541|NCT03178669|Drug|cobitolimod|Rectal administration
45498542|NCT03178669|Drug|Placebo|Solution manufactured to mimic cobitolimod
45498543|NCT03178201|Drug|TGR-1202|Treatment will be self-administered on an outpatient basis. Patients will take TGR-1202 800 mg, oral, one tablet daily on a continuous basis. Each cycle lasts 28 days.
45498544|NCT04833127|Behavioral|Gender-Enhanced -- Masibambane|"The intervention has components that provide PrEP information, provide information about HIV prevention and contraceptive options, prompt women to think about why they may be at risk for HIV, discuss women's sexual rights, and discuss how women can talk to their male partners about PrEP. The components are conducted by participants on their own time as well as during a real-time live interactive session with trained facilitators."
45715040|NCT04339192|Procedure|Minimally Invasive Tricuspid Surgery|minimally invasive tricuspid surgery including endoscopy-assist right minithoracotomy, vacuum-assist single femoral venous drainage without dissecting or snaring vena cava, direct right atriotomy through pericardium and the beating-heart technique.
46055863|NCT05428371|Diagnostic Test|Multiomic analyses of blood and surgical specimens|"The following items will be evaluated:~cell free dna length and integrity~presence or absence of SNPs in cfDNA and in DNA extracted from surgical samples~qualitative and quantitative evaluation of serum and surgical specimens proteome (proteomics)"
46055864|NCT04200417|Procedure|Chemoembolization|Chemoembolization will be performed via the artery (bronchial, non-bronchial systemic, or pulmonary) that shows the greatest tumor enhancement on angiography. Chemoembolization will be performed using a lipiodol / mitomycin emulsion, followed by spherical particles.
46055865|NCT04200417|Drug|Mitomycin C|Mitomycin (5mg/m^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.
45498545|NCT04833127|Behavioral|Individually accessed|The intervention includes an individually-accessed online PrEP video and South African government websites on PrEP and on contraception options
45498546|NCT02085408|Drug|Daunorubicin|Given IV
45498547|NCT02085408|Drug|Cytarabine|Given IV
45498548|NCT02085408|Drug|Clofarabine|Given IV
45498549|NCT02085408|Drug|Decitabine|Given IV
45498550|NCT02085408|Other|Observation|Undergo clinical observation
45498551|NCT02085408|Procedure|Allogeneic hematopoietic stem cell transplantation|Patients with an HLA-identical donor proceed to allogeneic stem cell transplantation.
45498552|NCT01829958|Drug|rituximab|
45694647|NCT03216304|Drug|100 mg safinamide|"Safinamide will be administered as follows:~Days 5-11: 100 mg safinamide (one Xadago® tablet), once a day~Day 12: a single dose of 100 mg safinamide (one Xadago® tablet), immediately followed by a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)~Days 13-15: 100 mg safinamide (one Xadago® tablet) once a day The medication will be orally administered in the morning, at 8:00±1h, under fasting conditions, with 240 mL (total volume) of still mineral water."
45694648|NCT03216304|Drug|20 mg rosuvastatin calcium period 1|"Rosuvastatin will be administered as follows:~- Day 1: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)"
45694649|NCT03216304|Drug|20 mg rosuvastatin calcium period 2|- Day 12: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet) immediately after the safinamide administration
45694650|NCT03216460|Device|Insulet automated glucose control system|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4Share® AP System and personalized model predictive control algorithm.
45694651|NCT03216538|Drug|AS101 1% oral solution|0.4 ml daily p.o.
45694652|NCT03216538|Drug|Placebo|0.4 ml daily p.o.
45855703|NCT04265365|Device|sham-rTMS+optimal-rPMS|The optimal Repetitive peripheral magnetic stimulation (rPMS) depend on previous results to give an iTBS or cTBS. Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
45855704|NCT04264143|Drug|Infusate with MTX110 and gadolinium|Pulses 1 and 2 will be prepared with 30, 60 or 90 uM concentration of MTX110. The infusate consists of gadolinium and MTX110 (30, 60, or 90 uM) at approximately 1:100 ratio.
45498553|NCT01829958|Drug|prednisone|
45498554|NCT01829958|Behavioral|Geriatric Assessment|
45498555|NCT03021642|Drug|Tepotinib test (Treatment Period 1)|Subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 * 500 mg tablet) in Treatment period 1 (Day 1)
45498556|NCT03021642|Drug|Tepotinib reference (Treatment Period 2)|Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 * 100 mg tablet) in Treatment period 2 (Day 22)
45498557|NCT03021642|Drug|Tepotinib reference (Treatment Period 1)|Subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 * 100 mg tablet) in Treatment period 1 (Day 1)
45498558|NCT03021642|Drug|Tepotinib test (Treatment Period 2)|Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 * 500 mg tablet) in Treatment period 2 (Day 22)
45498559|NCT01374984|Biological|VIGIV|VIGIV is licensed in US, by the FDA, for the treatment of complications of smallpox vaccinations and is available to eligible patients regardless of participation in this study.
45498560|NCT04613388|Other|Assesment of Effectiveness and side effects|Case Report forms, Quality of life questionaire
45498561|NCT01099644|Biological|131 I-8H9|Patients will be administered therapeutic dose of IP 131I-8H9 per the dose escalation regimen. 131I-8H9 pharmacokinetics will be studied by serial blood draws from indwelling venous lines. 131I-8H9 biodistribution will be studied by a single gamma camera scan about 5 days after IP injection where feasible.
45498562|NCT00867048|Drug|All licensed antiretroviral medications|In both arms, participants may be prescribed any licensed antiretroviral medication, in accordance with national treatment guidelines. The nature of the intervention is the timing of when to begin treatment with these medications, as described in the two treatment arms.
45498563|NCT00354120|Drug|Alentuzumab|Alentuzumab
45498564|NCT00354120|Drug|Globulina antilinfocitaria|Globulina antilinfocitaria
45498565|NCT04058808|Other|Weight Watchers|online or in a weekly wellbeing workshop, there is a fee of £12.95 per month, this is a healthy lifestyle programme based on food items having a point attached to them depending on the calorie, fat and sugar content. Each member has a specific number of points per day to use on their meals. The healthier foods have fewer points therefore you can eat more of them.
45694653|NCT03217396|Procedure|lumbar puncture|lumbar puncture performed to detect OCB for diagnostic purposes
45694654|NCT03218722|Drug|Pro-Thrombin Concentrate Complex|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg PCC.
45498566|NCT04058808|Other|Slimming world|online or in a weekly class, there is a fee of £5 per week. Free foods can be consumed freely are low fat healthy options, healthy extras (bread/milk/pulses) can be consumed in moderation. Higher fat, higher calorific foods have a number of SYNS attached, each person has a set number of SYNS (sins) per week to use as they wish.
45498567|NCT04058808|Other|Leeds 'One You'|a free weekly 1 hour class (run in various places across Leeds), a variety of topics are covered, from food labels to the Eat well guide. This eating plan is based on calorie counting.
45382448|NCT04948944|Device|transcranial direct current stimulation|the tDCS stimulator delivers very low (2mAmp) current with surface electrodes to the skull
45382449|NCT04946942|Behavioral|Collaborative Healthcare Encounters with Caregivers (CHEC)|CHEC is a brief checklist designed to identify family caregivers' unmet needs and concerns.
45498568|NCT04058808|Other|NHS Choices|a free on line programme that is based on restricting calories using the Eat well guide and encouraging physical activity.
45498569|NCT04058808|Other|5:2 diet|5 days of eating normal calories (2000 Female, 2500 Male) and 2 days eating restricted 500 calories (this may be amended depending on the patient).
45498570|NCT04058808|Other|Individuals own personal plan|the participant will explain in detail their own designed plan and this will be documented on the paper records.
45498571|NCT00169806|Other|videotape for mapping of renal anatomy and papillary biopsy|Subjects who enroll in this study will have their renal anatomy videotaped for mapping purposes. Stone location and characteristics will be documented as will papilla and calyces. One or more papillary biopsies will be taken for analysis.
45498572|NCT03021564|Other|cardiopulmonary resuscitation|Basic cardiopulmonary resuscitation : external electric shock, external cardiac massage, adrenaline injection ...
45498573|NCT03669900|Procedure|a minimally invasive surgery (SERI)|The SERI technique (as abbreviated to stand for simple, effective, rapid and inexpensive) was presented by several authors to be a minimally invasive technique since it presents with the same advantages as the percutaneous techniques with less tissue dissection and a need for only temporary hardware, meaning no instrumentation and surgery is performed under direct vision without fluoroscopy
45498574|NCT03023046|Drug|Cyclophosphamide|Given IV
45498575|NCT03023046|Drug|Dasatinib|Given PO
45382450|NCT04946942|Behavioral|Usual Care|Attendance at primary care appointments as usual.
45382451|NCT04945772|Biological|Gene Therapy Product-MCO-010|The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
45498576|NCT03023046|Drug|Doxorubicin|Given IV
45694655|NCT03218722|Drug|NaCl 0.9%|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg Saline solution.
45382452|NCT04945772|Procedure|Sham Injection|Sham Injection
45382453|NCT04943432|Behavioral|Behavioral Activation|8 sessions of harm reduction-focused Behavioral Activation for Substance Use
45382454|NCT04943094|Other|Urodynamic examination|A urodynamic examination is performed in all patients four to six weeks following TURBT and repeated six months later in order to obtain bladder function and possible changes.
45382455|NCT04941807|Device|Platelet-rich plasma|Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-rich plasma is injected into 8 proximal nail folds.
45498577|NCT03023046|Drug|Etoposide|Given IV
45498578|NCT03023046|Drug|Imatinib Mesylate|Given PO
45498579|NCT03023046|Other|Laboratory Biomarker Analysis|Correlative studies
45498580|NCT03023046|Drug|Prednisone|Given PO
45498581|NCT03023046|Biological|Rituximab|Given IV
45498582|NCT03023046|Drug|Vincristine Sulfate|Given IV
45498583|NCT03668262|Drug|Cis-atracurium|Different concentration of cis-atracurium
45498584|NCT03669198|Diagnostic Test|NT-Pro BNP|. AHF patients who met inclusion and exclusion criteria were randomly assigned to 2 groups, NT-pro BNP group and control group. In the NT-pro BNP group, serial NT-pro BNP levels at admission and pre-discharge was measured, the latter with the target of decrease ≥ 30% NT-pro BNP level. Randomised patients were followed during treatment up to 90 days post-discharge to assess short-term outcomes and costs.
45498585|NCT03019458|Dietary Supplement|MINGO|6 20oz sachets will be taken daily by intervention group
45498586|NCT04058340|Dietary Supplement|lactizole nebulization|Lactizole is generally recognized as safe: GRAS Flavor and Extract Manufacturers Association ( numer: 3773 ) Lactizole solution for nebulization was calculated based on dose-response curves; 150ppm was chosen as minimal effective (decreased sweet taste perception) and safety ( lack of FEV1 changes after nebulization)
45498587|NCT04058340|Other|Placebo|0.9% NaCl solution in nebulization
45498588|NCT03669120|Other|Informational Intervention|Receive advice to quit smoking and materials to promote smoking cessation
45498589|NCT03669120|Behavioral|Telephone-Based Intervention|Receive individualized text based messages
45498590|NCT04058106|Procedure|A patient who need the cerebral artery aneurysm clipping surgery|A patient who go the propofol based total intravenous anesthesia due to intraoperative neuromonitorung for unruptured cerebral artery aneurysm clipping surgery
45855705|NCT04264143|Device|Convection-Enhanced Delivery (CED)|CED is the method by which the drug are delivered to the brain under controlled pressure to the brain by targeted micro-catheters.
45382456|NCT04941807|Device|Platelet-poor plasma|Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-poor plasma is injected into 2 proximal nail folds.
45382457|NCT04941274|Drug|Abemaciclib|An initial dose of 200 mg twice daily and at an MTD dose will be administered orally every day of each 28-day cycle.
45382458|NCT04940299|Biological|Ipilimumab|Given IV
45382459|NCT04940299|Biological|Nivolumab|Given IV
45498591|NCT04058262|Other|Meditation presential|Facilitator-guided meditation in groups or individually, in 45-minute sessions twice a week for 2 weeks, in a quiet room with controlled light and temperature, and comfortable cushions and chairs.
45498592|NCT04058262|Other|Reiki|Reiki will be performed in 45-minute sessions twice a week for 2 weeks then in a quiet room with controlled brightness and temperature.
45498593|NCT04058262|Other|Meditation (app)|Mindfulness meditation guided through 10-15 minute audio using app, to be practiced daily at home.
45382460|NCT04940299|Biological|Tocilizumab|Given SC
46055866|NCT04200417|Drug|Lipiodol|Mitomycin (5mg/m^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.
45498594|NCT04058262|Other|round of conversation|The Round of Conversation will take place twice a week, lasting 45 minutes, for two weeks thereafter, at the same clinic, where women will talk about their lives, their needs, how they handle reported situations and how also your skills and preferences.
45498595|NCT05654688|Other|graston and muscle energy technique|"Graston technique (Gt) is a technique of mobilization of soft tissue using instruments which consider myofascial release instrument that has been reported to relieve pain, improve overall function, and increase range of motion.~Muscle energy technique (MET) is a term composed of various types of active muscular relaxation and stretching procedures. The two cornerstone forms of MET are reciprocal inhibition and post isometric relaxation. In theory, reciprocal inhibition takes advantage of the neurological phenomena of muscular contraction, which results in an inhibitory effect on the antagonistic muscles."
45498596|NCT03668964|Dietary Supplement|Vitamin B2|One capsule of 75 mg Vitamin B2 once a day for 4 weeks
45498597|NCT03668964|Dietary Supplement|Vitamin C|One capsule of 500 mg Vitamin C once a day for 4 weeks
45498598|NCT03668964|Dietary Supplement|Vitamin B2 + C|One capsule of of 75 mg Vitamin B2 plus 500 mg Vitamin C once a day for 4 weeks
45855706|NCT04261153|Other|Cognitive stimulation|3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days
45498599|NCT03668964|Dietary Supplement|Vitamin A|One capsule of 250 µg Vitamin A once a day for 4 weeks
45498600|NCT03668964|Dietary Supplement|Vitamin D3|One capsule of 60 µg Vitamin D3 once a day for 4 weeks
45498601|NCT03668964|Dietary Supplement|Vitamin E|One capsule of 100 mg Vitamin E once a day for 4 weeks
45498602|NCT03668964|Dietary Supplement|Placebo|One capsule of 575 mg microcrystalline cellulose once a day for 4 weeks
45498603|NCT03668886|Other|multimodal exercise program|warm-up, strengthening exercise, aerobic exercise, cool-down
45498604|NCT02923830|Other|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
45498605|NCT02923830|Drug|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
45498606|NCT03668730|Radiation|Intensity-modulated radiation therapy|Patients undergo low-dose OR standard dose IMRT based on their radiographic response to induction chemotherapy
45855707|NCT04260945|Biological|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 0.6-3×106 cells/kg.
45855708|NCT04260932|Biological|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 1-6×106 cells/kg.
46055867|NCT04200417|Drug|Embospheres|Embospheres are non-resorbable spherical microspheres (trisacryl gelatin) that are FDA-approved for embolization of hypervascular tumors.
46055868|NCT04219917|Other|Kinesio Tape|Kinesio Tape will be applied to treat the pain associated with patellar tendonitis, to treat the cause of the pain, and to treat both factors.
45855709|NCT04249557|Behavioral|exercise is medicine|a 12-week exercise classes program combined with other motivational skills, including feedback and information technology support. The whole program lasts for 1 year for each participant
46055869|NCT04219527|Procedure|Dual-target injection|"Intervention procedure: corticosteroid injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid) + 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
46055870|NCT02753439|Drug|Geistlich Bio Oss|Extraction of Impacted 3rd Molars,
45382470|NCT04937504|Behavioral|STAIR-PC Group|Skills Training in Affective and Interpersonal Regulation for Primary Care (STAIR-PC) is a face-to-face, individual, brief (5 session) therapy adapted from the STAIR program. STAIR-PC is an appropriate treatment for individuals who have experienced traumatic stressors, and addresses symptom targets by teaching skills to improve coping with emotions and strengthen interpersonal relationships.
45382471|NCT04937504|Behavioral|WebSTAIR Group|WebSTAIR is a web-based self-help program adapted from the STAIR program for individuals who have experienced traumatic stressors. WebSTAIR contains 10 self-guided interactive modules that teach skills to improve coping with emotions and strengthen interpersonal relationships.
45382474|NCT04935359|Drug|NIS793|Concentrate for solution infusion (Liquid in Vial)
45382475|NCT04935359|Drug|Nab-paclitaxel|Per locally approved formulation
45382476|NCT04935359|Drug|Gemcitabine|Per locally approved formulation
45382477|NCT04935359|Drug|Placebo|Dextrose 5% in water (D5W) solution for infusion
45382478|NCT04935138|Genetic|cfDNA analysis|sequencing data from cfDNA analysis
45382479|NCT04931355|Other|Acupuncture|The Acupuncture intervention（Zhongwan、Qihai、Guanyuan、Zhongji、Guilai、Shenshu、Ciliao、Xuehai、Sanyinjiao、Taixi.） will start on the 5th day of menstruation cycle, which will be carried out 1 time per day, at least 5 times a week, lasts for 10-15days. All operations were performed by experienced acupuncturists. After ET, both the control group and the treatment group will be treated with conventionally with no TCM intervention.
45382480|NCT04931355|Other|Western medicine|Western medicine
46055871|NCT05417061|Other|Saliva and serum sampling|"Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes.~Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis."
46055872|NCT02753205|Drug|Dexmedetomidine|infusion of dexmedetomidine 0.5ug/kg/h for 10 min and after that, infusion of dexmedetomidine 0.4ug/kg/h until the end of surgery
45382483|NCT04926831|Drug|capmatinib|150 mg and 200 mg tablets for oral administration
45382484|NCT04925934|Drug|VIB7734|VIB7734
45498607|NCT03668730|Drug|Paclitaxel liposome|Patients receive Paclitaxel liposome by 135mg/m2 with a total of two cycles.
45382485|NCT04925934|Other|Placebo|Placebo
45382486|NCT04924374|Dietary Supplement|Microbiota Transplant plus anti PD1 therapy|"Pooled fecal microbiota capsules of 1 donor selected based on their fecal abundance in Faecalibacterium prausnitzii, Bifidobacterium longum, Akkermansia muciniphila and Fusobacterium spp. after screening and metagenomic analysis of 10 donors with high-fiber diets (>30g/day).~anti PD1 therapy every 2-3 weeks"
45382487|NCT04924374|Drug|anti PD1 therapy|anti PD1 therapy every 2-3 weeks
46055873|NCT02753205|Drug|normal saline|infusion of normal saline
46055874|NCT05358561|Dietary Supplement|Flaxseed and Chia|Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of flaxseed, chia, flaxseed + chia and standart cakes
46055875|NCT04188873|Drug|Preparation Varenicline and Standard Duration Varenicline|16 weeks of varenicline starting 4 weeks pre-quit
46055876|NCT04188873|Drug|Preparation Varenicline and Extended Duration Varenicline|28 weeks of varenicline starting 4 weeks pre-quit
46055877|NCT04188873|Drug|Standard Duration Varenicline|12 weeks of varenicline
46055878|NCT04188873|Drug|Extended Duration Varenicline|24 weeks of varenicline
46055879|NCT04188873|Drug|Preparation Combination NRT and Standard Duration Combination NRT|16 weeks of nicotine patch + nicotine mini-lozenge starting 4 weeks pre-quit
45382498|NCT04918147|Drug|elotuzumab|Elotuzumab is a humanized recombinant monoclonal antibody (mAb) targeted against SLAMF7, a cell surface glycoprotein.
45382499|NCT04918147|Drug|placebo for elotuzumab|The placebo for elotuzumab is 0.9% sterile normal saline for injection.
45382500|NCT04918147|Drug|methylprednisolone|Premedication administered intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
45382501|NCT04918147|Drug|diphenhydramine|Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
45382502|NCT04918147|Drug|acetaminophen|Premedication administered orally, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
45382503|NCT04918147|Drug|famotidine|Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
45382504|NCT04918147|Drug|prednisone|Prescribed dosing with prednisone begins on the day of the first elotuzumab/placebo infusion, administered orally. The ten-week dosing taper proceeds, per protocol. Dosage in milligrams (mg).
45382505|NCT04916197|Drug|Dexmedetomidine prolonged sedation|Dexmedetomidine for 24h after patients finished endovascular thrombectomy and returned to ICU.
45382506|NCT04916197|Drug|0.9% saline|An equal dose of 0.9% saline 24h after patients finished endovascular thrombectomy and returned to ICU.
45382507|NCT04915768|Biological|CH505 TF chTrimer|Combined with adjuvants 3M-052-AF and Alum. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.
45382508|NCT04915768|Biological|3M-05-AF|Combined with CH505 TF chTrimer and Alum adjuvant. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.
45382509|NCT04915768|Biological|Aluminum hydroxide suspension|Combined with CH505 TF chTrimer and 3M-052-AF adjuvant. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle
45382510|NCT04915079|Behavioral|Promoting Resilience in Stress Management (PRISM)|"PRISM is a novel resilience resource intervention consisting of five, one-on-one sessions lasting 30-50 minutes targeting specific teachable resilience skills: stress management, problem solving, goal setting, benefit finding, and meaning making. Sessions will occur at a time convenient to the patient with the first session to occur within 1 week of enrollment either while inpatient or if the patient is discharged, in the outpatient setting in-person or by HIPPA-compliant Zoom. After completion, participants will receive weekly booster contacts (invitations to practice reviewing certain skills) until the occurrence of a planned patient-clinician conversation, facilitated and arranged by study staff during the 5th session. All participants will receive paper worksheets to practice skills between sessions, plus access to a free, digital PRISM app (available only for patients enrolled in PRISM)."
46055880|NCT04188873|Drug|Preparation Combination NRT and Extended Duration Combination NRT|28 weeks of nicotine patch + nicotine mini-lozenge starting 4 weeks pre-quit
46055881|NCT04188873|Drug|Standard Duration Combination NRT|12 weeks of nicotine patch + nicotine mini-lozenge
45382513|NCT04914182|Radiation|LASER|Laser will be applied in specific points for perineal lacerations.
45382514|NCT04914182|Radiation|CONTROL|"A control group of sham laser will create for the patients the impression that laser is being played, with the lights of the instrument of on mode turned on, without biological effects."
45382515|NCT04912531|Device|Virtual Realty using a Microsoft Hololens, Empatica HR wristband, and EEG|The investigators will use a DeepReality VR with biofeedback using a Microsoft Hololens, Empatica HR wristband and EEG. The Empatica HR wristband will measure HR and the EEG will measure alpha and theta brain waves. To monitor the physiologic data in real-time, data from the EEG and heart rate monitor will be streamed and processed in an Android Application that the investigators previously developed. During data collection, the Android app sends data via OSC to a specific IP and port, which is then collected in the game engine, Unity 3D and processed to adapt the virtual environment. Importantly, each device is inexpensive and can be sanitized and reused by multiple patients.
45382516|NCT04912531|Device|Essence Olfactory Necklace|The Essence Olfactory Necklace holds a small, lightweight 7 ml capsule that contains an essential oil. Within the capsule is a piezo electric transducer which allows us to control the release of scent via Bluetooth using a smartphone app. Each Essence Necklace will be paired with a google phone that the investigators will use to control the frequency and intensity of scent for each patient. The investigators will limit the frequency to one burst of scent every 20 seconds to avoid habituation. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water). The investigators chose lavender because in our previous studies, >97% of users enjoyed the lavender scent. The Essence Necklace is powered with a 3.7V Lithium Battery and has a battery lifetime of approximately 6 hours. The RC can easily recharge the Essence Necklace through a USB micro connector. Additionally, the Essence Necklace can be easily sanitized and reused by multiple patients.
45382517|NCT04912531|Device|Bedside Olfaction Device|The bedside olfaction device can be clipped on to the side of the patient's bed or beside table. The RC will turn on the night-time olfactory device at 7 pm and will turn off the device at 7 am. When turned on, the device releases scent once every 60 seconds. However, the frequency and intensity of the scent will be adjusted to the patient's preferences. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water).
46055882|NCT04188873|Drug|Extended Duration Combination NRT|24 weeks of nicotine patch + nicotine mini-lozenge
46055883|NCT04188873|Behavioral|Intensive Counseling|4 phone or video counseling sessions
46055884|NCT04188873|Behavioral|Minimal Counseling|2 brief phone or video counseling sessions
45382521|NCT04905914|Drug|ATRN-119|ATRN-119 is a capsule formulation that will be supplied as 50 mg and 200 mg hydroxymethyl cellulose (HPMC) capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.
46055885|NCT04219683|Procedure|Mandibular vertical height augmentation in segmental defects using combined vascularized and non-vascularized fibula flap|Using Free Fibula Flap for reconstruction of mandibular segemental defect
46055886|NCT04174677|Drug|Inebilizumab|Infusion of Inebilizumab
45382524|NCT04905082|Other|Best Practice|Receive usual care
45382525|NCT04905082|Other|Educational Intervention|View HOPE-Genomics tool after genomic test results are available
45382526|NCT04905082|Other|Educational Intervention|View HOPE-Genomics before sequencing results are available
45382527|NCT04905082|Procedure|Genomic Profile|Receive genomics test results
45382528|NCT04905082|Other|Survey Administration|Ancillary studies
45382529|NCT04902625|Drug|Naltrexone-Bupropion Combination|Naltrexone-bupropion will be added to the BOT module in the interventional arm.
46055887|NCT04174677|Drug|VIB4920|Infusion of VIB4920
46055888|NCT04174677|Drug|Inebilzumab+VIB4920|Infusion of Inebilizumab and VIB4920
45382532|NCT04897022|Drug|Pembrolizumab|Fixed dose of pembrolizumab 200mg IV q3 weeks
45382533|NCT04897022|Radiation|IMPRINT|The starting radiation dose will consist of 400cGy x5 fractions. Doses will be escalated by 100cGy per fraction (i.e. 400cGy, 500cGy, 600cGy) for a total of 3 dose levels. The MTD will be evaluated using a modified Continuous Reassessment Method. Dose limiting toxicities (DLTs) are defined as any treatment-related non-hematologic toxicity with a CTCAE v5 Grade ≥3 or grade ≥2 pneumonitis that requires use of steroids occurring after the start of IMPRINT through the first 3 months after the last fraction.
45382534|NCT04896827|Other|Conditioned pain modulation test|Conditioned pain modulation (CPM) protocol consist of evaluating pain during a heat test, before and after one conditioning stimulus (cold water bath); 3 cameras will be capturing participants' facial expressions during the tests.
46055889|NCT05277519|Device|Vibrations|Sequenced muscle vibrations during 30 min., 3 times a week during 5 weeks
46055890|NCT04496115|Behavioral|Mindfulness|Mindfulness training
45382537|NCT04888117|Procedure|Laparoscopic cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the cholecystectomy according to the surgeon's standard practice.
45382538|NCT04888117|Procedure|Robotic-assisted cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the cholecystectomy according to the surgeon's standard of care.
45382539|NCT04885985|Device|DEB catheter|"Trade name of DEB catheter: AcoArt Tulip (0.018) or AcoArt Litos (0.014)"
45382540|NCT04884737|Other|Mepilex Border Flex® (MBF) dressing|A new dressing technology (Mepilex Border Flex® (MBF)) provides increased conformability of the dressing to the skin with the ability of the dressing to move in all directions (e.g., 360-degree flexibility) with even slight body movements. Limited data exists on use of silicone foam dressings with all direction flexibility during prone surgical procedures.
46055891|NCT00635895|Other|Manual Lymph Drainage Therapy and Connective Tissue Massage|The treatment program was carried out five times a week, during a 3-week period for both Manual Lymph Drainage Therapy and Connective Tissue Massage groups
46055892|NCT05157633|Other|Controls|questionnaire food scale: HME data collection of food survey
46055893|NCT02751021|Other|pacemaker diagnostic algorithm|evaluation of the respiratory disturbance index by measurement of transthoracic impedance variation, to detect sleep apnea
45855710|NCT04248751|Device|Regeneten|A new scaffold material made of highly purified, type I collagen from bovine tendons has shown great promise as a bioinductive implant that helps induce the formation of new tendon-like tissue over the surface of partial- or full-thickness rotator cuff tears. This new graft material has the benefit of decreasing surgery time, as it takes a few minutes to put in place, while increasing healing and tendon thickness.
45382544|NCT04892303|Combination Product|Combination treatment (CXRPT) of external beam radiation (XRT) plus radioactive iodine (RAI)|To safely administer a minimum cumulative dose of external beam radiation to up 3 index tumors per patient, supplemented radiation dose delivered by radioactive iodine (RAI)
45855711|NCT04248751|Procedure|Debridement|The bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin
45498608|NCT03668730|Drug|Cisplatin|Patients receive Cisplatin by 25mg/m2 on day1-day3 with a total of two cycles as induction chemotherapy ; patients receive cisplatin by 100mg/m2 with a total of three cycles as concurrent chemotherapy.
45498609|NCT03668730|Drug|5-Fluorouracil|Patients receive 5-Fluorouracil by 3750mg/m2 civ120h with a total of three cycles.
45382550|NCT04879537|Other|Telemedical support|The nursing homes participating in the project will be equipped with telemedical equipment. This will allow teleconsultations to take place when needed. In addition, an early warning system will be introduced and, within the framework of the teleconsultation, a trained medical assistant can be sent to the care facility if necessary, who can carry out medical activities on site under a physician's delegated instructions. In addition, an electronic patient file will be introduced which can be accessed by the telemedicine physician and the general practitioner.
45382551|NCT04873934|Drug|Inclisiran|Inclisiran sodium 300 mg / 1.5 ml (equivalent to 284 mg of inclisiran)
45382552|NCT04861077|Drug|[18F]FMISO-PET with contrast-enhanced MRI|Triple negative breast cancer patients that are planning to undergo immunotherapy and consent to this study will have 3 imaging visits. Imaging visit 1 will take place before the patients start immunotherapy. Imaging Visit 2 will take place after the patient completes the 1st cycle of immunotherapy and before they start their 2nd cycle. Imaging Visit 3 will take place when the patient completes the 2nd cycle of immunotherapy and before they start the 4th cycle.
45382553|NCT04849416|Drug|LOXO-305|Administered orally.
45382554|NCT04848792|Dietary Supplement|Sulforaphane|Myrosinase-active whole broccoli sprout material
45382555|NCT04848792|Dietary Supplement|Placebo capsules|Placebo capsules
45382556|NCT04845620|Drug|ARQ-151 Active|ARQ-151 Cream 0.05% - Active
45382557|NCT04845620|Drug|ARQ-151 Vehicle|ARQ-151 Cream - Vehicle
45382558|NCT04843306|Behavioral|Biofeedback|Relaxation coaching will be used in this study.
45382559|NCT04843306|Behavioral|Active Breathing Control Technique|Active breathing control (ABC) requires patients to reproducibly perform multiple deep-inspiratory breath holds during treatment.
46055894|NCT02751021|Other|Attended cardiorespiratory sleep study|sleep study with portable monitor resulting in the apnea hypopnea index, to confirm sleep apnea diagnosis
46055895|NCT04488003|Drug|Ulixertinib|Oral, 600 mg, twice daily, for 28-days in each treatment cycle
45382562|NCT04833075|Other|blood sampling|A maximum of 13 blood samples (39 mL) will be derived from subjects on treatment. After discontinuation of ICI treatment, a maximum of 7 blood samples (21 mL) will be derived.
46055896|NCT04488003|Drug|Physician's Choice|Physician's choice will be restricted to two approved (not off-label) treatments for each tumor histology (agents targeting BRAF or MEK kinases and experimental agents are not permitted as physician choice)).
46055897|NCT02751099|Other|transplanted patients|bone biopsy, echocardiogram, blood samples
46055898|NCT02751177|Genetic|KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA|Mutation in plasma DNA vs tumor tissue
46055899|NCT02750787|Other|Nutritional Study Product|Two 220 ml servings per day
45382567|NCT04817618|Drug|Placebo|Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
45382568|NCT04817618|Drug|iptacopan|iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
46055900|NCT02750631|Other|Triple Therapy|The intervention consists of three interventions: missing a night of sleep, early morning bright lights and sleep phase advance
45382570|NCT04810078|Biological|Nivolumab and rHuPH20|Specified dose on specified days
45382571|NCT04810078|Biological|Nivolumab|Specified dose on specified days
45382572|NCT04808206|Device|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for the creation of anastomoses during laparoscopic bariatric surgery manufactured by Ezisurg Medical.
45382573|NCT04805775|Drug|Desflurane Inhalation|Subjects were randomized in a 1:1 ratio to undergo breast surgery under maintenance of anesthesia with the classical intravenous anesthetic drug propofol (reference group) or the inhaled anesthetic drug desflurane (test group).
45382574|NCT04802720|Other|Cognitive Behavioral Therapy for Cancer Caregivers (CBT-C)|"The sessions are outlined as follow:~psychoeducation, goal-setting, and describing the rationale for CBT (Session 1);~coping effectiveness training (Session 2);~identifying unhelpful cognitions and dysfunctional beliefs (Session 3);~challenging and restructuring unhelpful cognitions (Session 4);~behavioral activation within the limitations of the caregiving context (Session 5);~problem-solving (Session 6);~communication strategies and assertiveness training (Session 7);~consolidating gains, maintenance, and relapse prevention (Session 8)."
45554591|NCT05603949|Device|3D deep learning neural network system|With the consent of the patient, we will assist in the production of images of 3D defect blocks for free (3D deep learning neural network system (3D DNN) system process planning), complete the repair and reconstruction under the clinical routine surgery, and track the repair results after surgery. meet medical needs.
45554592|NCT02711306|Dietary Supplement|Glucomannan noodle|The participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks.
45554593|NCT02711306|Dietary Supplement|Placebo noodle|In the placebo noodle diet, the participants received the same amount of noodles without glucomannan for 4 weeks.
46055901|NCT05125731|Behavioral|Parental absence|Parent does not accompany the child during dental treatment
45382575|NCT04802720|Other|Emotion Regulation Therapy for Cancer Caregivers (ERT-C)|"The sessions are outlined as follow:~psychoeducation and motivation/dysregulation cue detection within caregiving contexts (Session 1);~attention regulation skills training (Sessions 1-2);~training in metacognitive skills (Sessions 3-4);~exposure to proactive living in the face of risk and loss while applying skills (Sessions 5-7);~consolidating gains, taking larger proactive steps, and relapse prevention (Session 8)."
45382576|NCT04800744|Other|Lavender peppermint elequil aromatab|Lavender peppermint elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
45382577|NCT04800744|Other|Sweet almond oil elequil aromatab|Sweet almond oil elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
45382578|NCT04798534|Behavioral|Service decentralization facilitation intervention|The intervention CHW will participate in three 60-minute intervention weekly sessions. During the intervention, CHW will be provided with the knowledge and skills to serve their MMT patients. The intervention sessions will also focus on enhancing the current service decentralization workflow so that the CHW can work with both their peer providers and their patients more efficiently. Two-times booster sessions will be offered before the 3- and 6-month survey for continued skill building for problem-solving. In addition to the group sessions, the intervention arm CHW will be encouraged to use a specially designed online platform to review the current policy and scientific findings, review their patients' treatment status, communicate with other providers, and provide instant consulting to their MMT patients. The MMT patients in the intervention condition can use the online platform to communicate with their CHW and view education materials disseminated by their MMT providers or CHW.
45382579|NCT04796324|Drug|Ixabepilone Injection|Ixabepilone 40 mg/m2 is administered as a 3-h intravenous infusion Day 1 in a 3-week cycle
45382580|NCT04796194|Combination Product|LTX-315 in combination with pembrolizumab|"Phase A Pembrolizumab will be given as 200 mg IV infusion over 30 minutes on Days 1 and 22.~Phase B Pembrolizumab will be given as 400 mg IV infusion over 30 minutes every 6 weeks starting at Day 43 (3 weeks after the last dose of pembrolizumab in Phase A) until discontinuation from the study or for a maximum of 24 months' total therapy, whichever comes first."
45382581|NCT04795817|Device|Transoral Robotic Surgery|Subjects will undergo TORS benign base of tongue resection procedures (i.e., partial glossectomy, epiglottoplasty, epiglottectomy, and/or lingual tonsillectomy) for the treatment of OSA. Concomitant non-robotic surgical procedures may also be performed as part of the subject's treatment for OSA, and can include one or more of the following: uvulopalatopharyngoplasty (UPPP), lateral pharyngoplasty, expansion sphincter pharyngoplasty, palatine tonsillectomy, or a modified uvulopalatoplasty. Nasal surgery such as septoplasty or turbinoplasty can be combined if it is needed.
45382582|NCT04776434|Device|SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB)|This study will capture data from the use of the SELUTION SLR according to its approved labelling.
46055902|NCT05125731|Behavioral|Parental visual support|The parent does not accompany the child during the dental treatment but watches behind the glass and is seen by the child.
46055903|NCT05125731|Behavioral|Parental presence|Parent accompanies the child during dental treatment
46055904|NCT02695641|Drug|1.25mg bevacizumab|Bevacizumab is a monoclonal antibody against VEGF-A. 1.25mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
45382586|NCT04760769|Drug|Tavapadon|Participants will receive Tavapadon at a dose of (5 to 15) mg QD, orally during a 58-week treatment period.
45382587|NCT04760405|Other|Tai Chi Easy|Patients will receive two 30-minute small group training sessions (Via Zoom) within 7 days of their scheduled transplant. After the training has been completed the participant will be provided with written (via manual) and electronic (DVD, MP3 file download) materials to continue with self-direct practice throughout the duration of the study.
45382588|NCT04758702|Biological|L-PRF (Leucocyte- platelet rich fibrin)|Leucocyte-Platelet rich fibrin is a high density fibrin clot. it serves as a biological healing matrix by supporting cell migration and cytokine release, expanding the range of its potential applications greatly. Patient's own blood is centrifuged using (Intra-spin) FDA approved centrifuge on 45 degrees angle on 2700 rpm for 12 minutes.
45382589|NCT04758702|Biological|H-PRF (Horizontal -platelet rich fibrin)|Platelet rich fibrin is a high density fibrin clot. it serves as a biological healing matrix by supporting cell migration and cytokine release, expanding the range of its potential applications greatly.Horizontally centrifuged platelet rich fibrin using (Bio-prf) centrifuge on 700 g force for 8 minutes. On a horizontal centrifugation, the cells separate much more efficiently throughout the entire membrane. This leads to better layer separation and also favors cells that are evenly distributed throughout the PRF clot.
45554594|NCT03528993|Other|exercise by hippotherapy device|Hippotherapy device mostly used on cerebral palsy, but we want to use hippotherapy device on patient with Hemiplegia.
45554595|NCT03528993|Other|conventional rehabilitation|Bobath exercises: Bobath is a type of physiotherapy treatment which aims to improve movement and mobility in patients with damage to their central nervous system (brain and spinal cord).
46055905|NCT02695641|Drug|2.50mg bevacizumab|Bevacizumab is a monoclonal antibody against VEGF-A. 2.50mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
46055906|NCT02695407|Other|3 days cannulation|assessment of artery stenosis after 3 days of artery cannulation
46055907|NCT02695407|Other|5 days cannulation|assessment of artery stenosis after 5 days of artery cannulation
45382590|NCT04758702|Device|Surgical stent|An essix surgical stent will be obtained using a high vacuum suction and used to protect the denuded donor site after suturing the wound. (Biostar® Scan/Biostar®V) will be used to make the stent.
45382591|NCT04755647|Drug|Nitric Oxide-Releasing Solution|Active antimicrobial
45554596|NCT03528993|Other|postural control exercises|perturbation on four directions, weight bearing exercises on standing positions
45382592|NCT04755647|Drug|Saline solution, hypotonic|Placebo
45382593|NCT04739761|Drug|Trastuzumab Deruxtecan|Participants will receive T-DXd administered using an IV bag containing 5% (w/v) dextrose injection infusion solution.
45382594|NCT04739423|Drug|CST-103, CST-107, matching placebo|CST-103 and matching placebo orange capsules; CST-107 and matching placebo white capsules
45382595|NCT04733040|Drug|MOR202|5 or 2 doses of MOR202 will be administered as an intravenous infusion
45382596|NCT04730557|Behavioral|Weight Loss|Each participant receives a calorie (kcal) prescription derived from calculations of estimated total energy expenditure (TEE) based on weight, height, sex, age, and activity level using equations developed by the Institute of Medicine [29]. Prescribed kcal levels are adjusted downward from the TEE to achieve a weekly weight loss of 1 to 2 pounds, generally a deficit of 500-1000 kcal/day. Weekly intervention sessions and activities will be delivered virtually using Microsoft Teams, Duke ZOOM or Duke Webex and led by Registered Dietitians.
45382597|NCT04718103|Biological|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.
45382598|NCT04718103|Biological|Placebo|Placebo will be administered as normal saline using a pre-filled syringe.
45382599|NCT04715438|Biological|mRNA-1273 SARS-CoV-2 vaccine from Moderna|All participants will receive two vaccinations against COVID-19 according to standard of care.
45382600|NCT04711655|Procedure|ARMA (antireflux ablation of the cardiac mucosa)|is an endoscopy in which argon gas ablation of the cardiac mucosa
45382601|NCT04711655|Procedure|upper digestive endoscopy|Quality diagnostic upper gastrointestinal endoscopy will be performed without intervention in patients assigned to this treatment arm.
45382602|NCT04711252|Drug|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally
45382603|NCT04711252|Drug|Anastrozole|Dosage formulation: Anastrozole tablets will be administered orally.
45382604|NCT04711252|Drug|Anastrozole placebo|Dosage formulation: anastrozole placebo tablets will be administrated orally.
45382605|NCT04711252|Drug|AZD9833 placebo|Dosage formulation: AZD9833 placebo tablets will be administrated orally.
45554597|NCT03193112|Drug|Agomelatine 25 MG Oral Tablet|We will treat our patients with Agomelatine tablet of 25 mg.
45855712|NCT04246008|Other|Neuromuscular training|The exercise training was developed based on assuring the correct performance of the exercise focusing in motor control.
45855713|NCT04246008|Other|Conventional strength training|The exercise training was developed based on standard strength training used in cardiac rehabiliation programmes
45382606|NCT04711252|Drug|Palbociclib|Dosage formulation: palbociclib tablets/capsules will be administered orally
45382607|NCT04711252|Drug|Luteinizing hormone-releasing hormone (LHRH) agonist|Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
45382608|NCT04707157|Drug|LY3556050|given orally
45382609|NCT04707157|Drug|Placebo|given orally
45382611|NCT04704570|Other|Exercise|Spinal stabilization exercise
45426040|NCT01615029|Drug|Part 1 (Dose Escalation): Daratumumab|Participants will receive intravenous (injection of a substance into a vein) infusion of daratumumab in an increased fashion from 2 milligram per kilogram (mg/kg) up to maximum dose of 16 mg/kg. Considering the safety and efficacy of dose in Part 1, recommended phase 2 dose (RP2D) for Part 2 of the study will be decided. A predose infusion of 10 percent (%) of the full dose of daratumumab will be administered a day before the first full infusion of the first cycle. Participants will receive 4 weekly infusions in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
45426041|NCT01615029|Drug|Part 2 (Dose Expansion): Daratumumab|Participants will receive RP2D as determined in Part 1 of the study. Participants will receive 4 weekly infusions of RP2D in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
45426042|NCT01615029|Drug|Lenalidomide|All participants (Part 1 and Part 2) will receive 25 mg lenalidomide orally (by mouth) from days 1 to 21 of each 28-day cycle until disease progression.
45554598|NCT05023161|Biological|Blood samples|Performed a 10 ml blood sample in each of the 200 patients included.
45554599|NCT03196154|Diagnostic Test|Fasting insulin level|Fasting insulin and C-peptide level measured using LCMS which is then used to calculate the insulin resistance and beta cell function using homeostasis model assessment
45554600|NCT03196154|Diagnostic Test|Plasma drug level|Plasma trough level of metformin and gliclazide will be measured using LCMS to ensure true compliance.
45855714|NCT04245644|Behavioral|use of targeted drugs such as aspirin, B-Blockers, Metformin, ACE-inhibitors, Statins|enrolled patients will be asked details regarding their daily drug use, before and after diagnosis of pancreatic cancer
45855715|NCT04238845|Drug|AQSP Administration|Three days treatment of all children with AQSP for SMC
45855716|NCT04238845|Dietary Supplement|Supplementation with Plumpy'Doz|Daily supplementation of children with Plumpy'Doz
45855717|NCT04238845|Dietary Supplement|Supplementation with Vitamin A|Single dose supplementation with Vitamin A to all children
45498610|NCT03623178|Other|Assertive Community Treatment|The intervention program is a type of very flexible community treatment. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialized in SUD treatment. The time of the intervention differs, there is no prefixed limitation but the duration of the intervention depends on the goals agreed on with the patient. The main objective of this intervention is to ensure an adherence to an addiction treatment program and establish or consolidate a stable healthcare and social network for the patient. The intervention aims to prevent service disengagement. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs.
45498611|NCT03623178|Other|Treatment As Usual|The treatment as usual is the intervention given in our outpatient addictology unit. It consists of an individual treatment program at our outpatient unit with regular appointments with psychiatrists and nurses. The patient can also take part in therapeutic groups and receive help from a psychologist for a targeted program or psychotherapy. The multidisciplinary team also comprises a social worker and an occupational therapist.
45498612|NCT03668652|Device|Focal HIFU treatment using Focal One (EDAP TMS) or TULSA-PRO (Profound Medical)|"HIFU arm:~Focal ablation of prostate cancer using HIFU Focal One or TULSA -PRO"
45498613|NCT03668652|Procedure|Radical prostatectomy|"Prostatectomy arm:~Robot assisted or open retropubic prostatectomy"
45498614|NCT03668574|Other|Aerobic exercise|Aerobic exercise that is defined as a form of exercise lasting 15 to 60 minutes continuous and intensity of 60% to 90% of maximal heart rate.
45498615|NCT03668574|Other|Placebo Group|Will be treated with pulsed 5-minute ultrasound and pulsed short-wave diathermy for 25 minutes. The devices will be used with disconnected internal cables to obtain the placebo effect
45498616|NCT03021018|Drug|Brivaracetam|"Pharmaceutical Form: Solution for infusion~Concentration: 10 mg/ml~Route of Administration: intravenous"
45498617|NCT03021018|Drug|Lorazepam|"Pharmaceutical Form: Solution for injection~Route of Administration: intravenous"
45498618|NCT03669042|Device|PhotoFix|PhotoFix Patch Implantation
45498619|NCT02509507|Drug|Talimogene Laherparepvec|Talimogene laherparepvec (T-VEC) administered by intralesional injection into liver tumors, with ultrasound/computed tomography (US/CT) guidance. Part 1: initial dose of T-VEC is 10^6 plaque forming unit (PFU)/mL up to 4mL in Cohorts 1 & 2, up to 8mL in Cohorts 3 & 4 of the Group A & Group B. The 1st cycle of T-VEC will be 21 (+3) days (from the 1st dose at 10^6 PFU/mL to the 2nd dose at 10^7 or 10^8 PFU/mL). Subsequent cycles of T-VEC will be 21 (±3) days. Max. volume of T-VEC administered at any dose is 4mL (Cohorts 1, 2, 5, and 6) or 8mL (Cohorts 3 & 4) for any individual lesion or for all lesions combined. Part 2: Initial dose of T-VEC is 10^6 PFU/mL followed by subsequent T-VEC doses at a concentration of 10^8 PFU/mL. T-VEC volume is up to 8mL based on the size of the inejected lesions. NOTE: as of Protocol Amendment 6 [dated 26 October 2021], intrahepatic injections of talimogene laherparepvec and liver biopsies are no longer performed in this study.
45382612|NCT04704570|Other|Remotely and face to face evaluation of Functional Capacity Level|Quality of life assessment (SF-36), and cognitive assessment ((Montreal Cognitive Assessment Scale (MOCA)) will be administered face to face. Functional capacity assessment tests will be administered both face-to-face and remotely. All participants will be administered both remotely and face-to-face. The order of the remote and face-to-face evaluations will be determined by the closed envelope randomization method. The remote evaluation will be done by video interview method under the direction of the researcher. During the remote evaluation, the necessary equipment for the participant will be prepared in the unit in advance. There will be a 10-30 minute rest interval between each evaluation.This application will only be applied at the beginning of the exercise program.After the 8-week program, only face-to-face evaluation will be made.
45498620|NCT02509507|Drug|Pembrolizumab|Pembrolizumab is a non-Amgen Investigational product that is manufactured by Merck. Pembrolizumab will be labeled, packaged, and distributed by Amgen (or designee) using Amgen (or designee) clinical study drug distribution procedures. Pembrolizumab is supplied as pembrolizumab 100 mg/4 mL vials (25 mg/mL) solution for IV infusion. The trial treatment will consist of a total dose of 200mg administered intravenously every 3 weeks (day 1 of each cycle) for up to 35 cycles.
45498621|NCT04807777|Drug|Ruxolitinib|Ruxolitinib will be administered orally twice daily during the entirety of each 28-day cycle.
45855718|NCT04238845|Dietary Supplement|Supplementation with Zinc|Daily supplementation with Zinc
46055908|NCT02750553|Drug|SHR0534|
46055909|NCT02750553|Drug|Placebo|
46055910|NCT02750475|Drug|Sunscreen Sport Lotion (BAY987516)|50 μl/cm*2 or 0.05 gm/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB# Y65-110)
46055911|NCT02750475|Other|Untreated Skin|This site is patched without treatment as irradiated control
45382613|NCT04699123|Drug|NC318 800 mg|NC318 will be given intravenously (IV) weekly for 8 doses and then every 2 weeks for patients receiving combination therapy treatment or weekly for patient receiving NC318 in monotherapy.
45498622|NCT03176407|Diagnostic Test|HemoPill acute|Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours. Patients undergo endoscopy within 12 hours after capsule ingestion. Afterwards, the endoscopic findings (endoscopy pictures and patient's endoscopy report) are compared to the sensor capsule data results. Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days.
45498623|NCT03175549|Drug|Apremilast|Fixed oral dose of 90 mg/d following the standard titration for a total dosing duration of 14 days.
45694656|NCT03216148|Diagnostic Test|FET-PET|All participating patients will receive a FET PET-scan parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
45694657|NCT00888628|Biological|Purified Pancreatic Islets|Islet after kidney transplant in patients with type I diabetes.
45694658|NCT00888628|Drug|Etanercept|Given as induction for islet cell transplant
45855719|NCT04237857|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
45855720|NCT04232202|Device|Er:YAG and Nd:YAG lasers|Extraction followed by Er:YAG laser degranulation, Nd:YAG laser disinfection, Er:YAG deepithelialization, Nd:YAG blood clot stabilization and photobiomodulation. The photobiomodulation step repeated on day 3, 5, and 7.
45855721|NCT04232202|Procedure|Standard extraction|Standard extraction procedure
45382614|NCT04699123|Drug|NC318 400 mg|NC318 will be given intravenously (IV) every 2 weeks.
45382615|NCT04699123|Drug|Pembrolizumab|Pembrolizumab 200 mg will be given IV every 3 weeks
45382616|NCT04698356|Behavioral|Auditory-cognitive training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed in order to train each individual at their own level and to make the task challenging. A short-term memory component was also added to the original training paradigm, to enhance the cognitive skills of our participants. To provide maximal speech-in-noise benefit for older, normal-hearing adults, a validation of our new training materials is required. The investigators will evaluate this in young, normal-hearing adults (18-30 years) by studying our outcome measure (speech reception threshold) for the different sentence-scenarios and test-retest sessions.
45382617|NCT04697264|Diagnostic Test|Blood and tissue sample collection from patients with endometrial cancer|Blood and tissue sample collection from patients undergoing surgery for endometrial cancer and blood sample collection only from patients undergoing chemotherapy for endometrial cancer
45382618|NCT04696432|Biological|Prizloncabtagene autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
45382619|NCT04688255|Behavioral|MSTEP|Aerobic exercise that is advanced weekly
45855722|NCT04228822|Other|Low carbohydrate diet|25-35% of carbohydrates from total energy intake
45855723|NCT04223037|Biological|Japanese Encephalitis Vaccine produced by IMBCAMS|Dosage form: 0.5mL/vial
45855724|NCT04223037|Biological|Japanese Encephalitis Vaccine produced by Liaoning Chenda|Dosage form: 0.5mL/vial
45382620|NCT04688255|Behavioral|Stretching|Stretching exercises that are advanced weekly
45498624|NCT03175549|Drug|Placebo|Identical placebo pills taken orally for 14 days
45498625|NCT05239429|Behavioral|Transcendental Meditation Technique|Participants receive one-on-one training on how to use Transcendental Meditation technique which is then practiced twice daily for approximately 20 minutes.
45498626|NCT03174925|Device|Siemens Acuson S3000 ultrasound system|Shear Wave Elastography
45382622|NCT04678856|Drug|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
45855725|NCT04213365|Other|Cognitive stimulation sessions coupled with Adapted Physical Activity sessions.|12 weeks of cognitive stimulation sessions coupled with APA (Adapted Physical Activity) sessions.
45382623|NCT04678856|Drug|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
45382624|NCT04677972|Drug|Ebselen|Glutathione peroxidase mimetic
45694659|NCT03215992|Device|Diffuse Optical Tomography (DOT) System|Diffuse optical tomography (DOT) is a novel imaging modality that uses low-intensity, near-infrared light to characterize tissue. As light of a specific wavelength travels through tissue, it is absorbed and scattered by different chromophores and cellular structures. Using four wavelengths of light allows the detection of four chromophores: oxyhemoglobin, deoxyhemoglobin, water and fat.
45694660|NCT03215680|Other|Climate|Hot and temperate climate
45855726|NCT04211753|Behavioral|Treatment as usual (schema therapy)|weekly group psychotherapy and bimonthly individual psychotherapy
45382625|NCT04677972|Drug|Placebo|Matching placebo containing excipients
45382628|NCT04662255|Drug|Pirtobrutinib|Oral
45382629|NCT04662255|Drug|Ibrutinib|Oral
45382630|NCT04662255|Drug|Acalabrutinib|Oral
45382631|NCT04662255|Drug|Zanubrutinib|Oral
45382632|NCT04662151|Biological|AT-100|reconstituted AT-100 for intratracheal administration
45382633|NCT04662151|Procedure|Air-sham|room air for intratracheal administration
45498627|NCT01314937|Drug|Mebendazole|Single-dose 500 mg mebendazole tablet
45498628|NCT01314937|Other|Usual care|Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
45498629|NCT04718155|Drug|Atorvastatin|will receive 40 mg atrorvastatin 2 days
45498630|NCT04718155|Other|placebo|will receive 40 mg placebo 2 days
45498631|NCT04668859|Drug|Midodrine|Oral vasoactive that is metabolized by the liver an peripheral tissues into desglymidodrine, an active metabolite. It produces arteriolar and venous constriction with a subsequent elevation in blood pressure.
45694661|NCT03838276|Procedure|AL 150 BPL100|Roux-en-Y gastric bypass with 150cm of alimentary limb and 100cm of biliopancreatic limb
45694662|NCT03838276|Procedure|AL 100 BPL 150|Roux-en-Y gastric bypass with 100cm of alimentary limb and 150cm of biliopancreatic limb
45855727|NCT04211753|Device|Mobile app|Medical device for crisis intervention
45855728|NCT04210661|Other|prediction software with spell checker|test with prediction software with spell checker
45855729|NCT04209621|Drug|Duvelisib|twice daily as tolerated until disease progression
45855730|NCT04209621|Drug|Ibrutinib|daily for the first six 28-day cycles
46055912|NCT02750241|Behavioral|Active video game-based intervention|"Attend 12 weekly group session at the UTMB Breast Health Clinic to play the active video games using Wii Fit U or Xbox 360.~Participate in self-paced home sessions~Monitor daily, weekly, and monthly steps using Wii Fit Meter~Feedback on physical activity and physical function"
46055913|NCT02750241|Behavioral|Pedometer|"Attend 3 monthly UTMB Breast Cancer Support Group Sessions~Monitor daily, weekly, and monthly steps using a pedometer (Digi-walker CW-700/701)~Feedback on physical activity and physical function"
46055914|NCT04219215|Device|100% O2 in oxygen chamber|Application of 100% O2 in an hyperbaric oxygen chamber
45382638|NCT04661748|Device|real time alarm of deviating vital signs|Intervention consists of actively alerting staff personnel if physiologic vital signs, deviates from certain thresholds
45498632|NCT04668859|Drug|Methylcellulose|Placebo will consist of inert methylcellulose
45382639|NCT04661501|Device|AlloDerm|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
45382640|NCT04661501|Device|AlloMax|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
45382641|NCT04661501|Device|DermACELL|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
45382642|NCT04661501|Device|Flex HD|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
46055915|NCT04219215|Device|21% O2 in oxygen chamber|Application of ambient air (21% O2) in an hyperbaric oxygen chamber
45498633|NCT04648969|Drug|kisspeptin 112-121|20 intravenous doses of kisspeptin 112-121 (4 different doses of kisspeptin (randomized) in 5 sets)
45498634|NCT04648969|Drug|GnRH|1 intravenous dose of GnRH
45498635|NCT04633369|Dietary Supplement|dietary fibers|during days 13-22 the participants will consume the dietary fiber according to their randomization and continue fasting. Participants will be asked to collect stool and oral samples 4 times during this period.
45498636|NCT02320201|Device|Transcutaneous Electrical Nerve Stimulator (TENS)|Electrical stimulation will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects.
45498637|NCT02299921|Other|Characterize alcohol and drug use|Characterize alcohol and drug use in patients newly admitted to the medical ICU service, who are expected to stay in the ICU for greater than 48 hours. The investigators will collect blood, exhaled breath condensate, urine and hair samples over the first 10 days of hospitalization. A select subset of subjects will have bronchoalveolar lavage (BAL) obtained.
45498638|NCT02261389|Other|Arm B, tumor markers assessment|Tumor markers assessment every three months through the study or until disease recurrence
45498639|NCT02924688|Drug|FF/UMEC/VI (100/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation once-daily [QD] in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
45498640|NCT02924688|Drug|FF/UMEC/VI (100/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
45694663|NCT03837886|Dietary Supplement|Sodium bicarbonate|The subjects should ingest 0.3g.kg of sodium bicarbonate 90 minutes before the beginning of the protocol task.
45694664|NCT03837886|Dietary Supplement|Calcium carbonate|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of Calcium Carbonate
45694665|NCT03219970|Drug|Osimertinib|80mg oral daily
45694666|NCT00889330|Drug|alcaftadine|0.25% Ophthalmic Solution, one drop in each eye at each of two visits.
45694667|NCT00889330|Drug|Placebo|Vehicle without active, one drop in each eye at each of two visits.
45694668|NCT03219580|Drug|5-Fluorouracil|50mg/ml concentration of 5-Fluorouracil to be injected intra-dermally in direct brow skin incisions
45694669|NCT03219580|Drug|Normal Saline Flush, 0.9% Injectable Solution|0.9% concentration of Normal Saline Injectable Solution to be injected intra-dermally in direct brow skin incisions
45694670|NCT03215446|Drug|maintenance of anaesthesia with propofol|
45694671|NCT03215446|Drug|maintenance of anaesthesia with sevoflurane|
45382649|NCT04657081|Drug|Decitabine and Cedazuridine (ASTX727)|Route of administration: oral in the form of a tablet
45382650|NCT04657081|Drug|Venetoclax|Route of administration: oral in the form of a tablet
45382651|NCT04652609|Other|PRESIONA|Aerobic and strength exercise combined with restricction blood flow cuffs during chemotherapy treatment
45382652|NCT04648046|Drug|Cyclophosphamide|Non-ablative conditioning with cyclophosphamide.
45382653|NCT04648046|Biological|LVgp120duoCAR-T cells, low dose|A single dose of 3 x 10^5 cells/kg LVgp120duoCAR-T cells will be infused.
45382654|NCT04648046|Biological|LVgp120duoCAR-T cells, high dose|A single dose of 1 x 10^6 cells/kg LVgp120duoCAR-T cells will be infused.
45382655|NCT04648046|Other|Analytic Treatment Interruption|HIV antiretroviral therapy medications will be paused.
45382656|NCT04648020|Drug|Clonidine HCl Mucoadhesive Buccal Tablet|100 μg of clonidine per tablet
45382657|NCT04648020|Drug|Placebo Mucoadhesive Buccal Tablet|Placebo
45382658|NCT04647396|Other|"Comprehensive Implementation of the Bundle recommended by the Kidney Disease: Improving Global Outcomes Group (KDIGO bundle)"|"Implementation of the KDIGO bundle for at least 12 hours~discontinuation of all nephrotoxic drugs when possible~optimization of volume status and hemodynamic parameters (consideration of a functional hemodynamic monitoring)~close monitoring of serum creatinine, fluid balance and urinary output~avoidance of hyperglycemia~considerations of alternatives to radiocontrast agents~discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period~avoidance of HES, gelatin, and chlorid-rich solutions"
45382659|NCT04645147|Biological|EBV gp350-Ferritin Vaccine|A 50 micrograms dose of EBV gp350-Ferritin vaccine will be administered intramuscularly for each vaccination at Days 0, 30, and 180 to all participants.
45382660|NCT04645147|Other|Matrix-M1|Each vaccine dose will consist of 50 micrograms of EBV gp350-Ferritin combined with 49 micrograms of Matrix-M1.
45382661|NCT04640623|Drug|TAR-200|TAR-200 will be administered transuretherally.
45382662|NCT04640623|Biological|Cetrelimab|Cetrelimab will be administered.
45382663|NCT04637113|Other|This is a non-interventional study|This is a non-interventional study.
46055916|NCT02749851|Device|MRI|Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy in 3 groups of human subjects: 1) non-smokers, 2) smokers, 3) individuals at high risk for adverse outcome. The objective of this work is to develop a new non-invasive clinical tool for early identification of placental dysfunction.
46055917|NCT02749851|Device|MRI - IUGR|Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy. The objective of this ancillary arm is to further test the sensitivity of placental magnetic resonance imaging to detect abnormal perfusion and oxygenation in confirmed cases of IUGR between gestational ages 28 to 36 weeks.
45382667|NCT04630145|Drug|Bedaquiline|Participants will receive BDQ tablets only/
45382668|NCT04630145|Drug|Clarithromycin|Participants will receive CAM 400 or 500 mg twice a day.
45382669|NCT04630145|Drug|Ethambutol|Participants will receive 500 to 750 mg daily (maximum daily dose of 1.0 gram [g]) or 15 mg/kg once a day.
45382670|NCT04630145|Drug|Rifampicin|Participants will receive daily dose is 450 mg (maximum 600 mg) RFP capsule once a day.
45382671|NCT04630145|Drug|Rifabutin|Participants will receive daily dose of RBT 300 mg or 150 mg capsules once a day.
45848012|NCT05304000|Behavioral|Cyclic Hyperventilation with Retention|"Participants are informed they should sit down in a chair or, if they prefer, to lie down, and to set a timer for 5 min. Then they are told to inhale deeply (ideally through their nose but if that is not possible, to inhale through their mouth) and then exhale by passively letting the air fall out from the mouth. We inform them that for sake of this protocol, that pattern of a deep inhale through the nose and passively letting the air fall out from the mouth = 1 breath.~Then they are instructed to perform 30 breaths (in and out) in this manner, and after those 30 breaths, to exhale all their air via their mouth and to calmly wait with lungs empty for 15 seconds."
45855731|NCT04207983|Combination Product|EYS606|EYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
45382674|NCT04629651|Drug|Captopril|Oral, to be administered per the dose escalation scheme.
45382675|NCT04627870|Device|drug (paclitaxel) coated balloon|use drug (paclitaxel) coated balloon catheter to treat intracranial in-stent restenosis
45382676|NCT04627870|Device|PTA balloon|use traditional PTA balloon with NMPA approval of indication for treating intracranial stenosis
45382677|NCT04626687|Device|test DCB|use paclitaxel coated coronary balloon catheters to treat SVD
45382678|NCT04626687|Device|RESTORE DCB|use paclitaxel coated coronary balloon catheters(RESTORE DCB) with NMPA approval indication for treating SVD
45498641|NCT02924688|Drug|FF/UMEC/VI (200/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
45382679|NCT04626362|Other|Cranberry juice|Cranberry juice cocktail will be provided by Ocean Spray Cranberries, Inc.
45382680|NCT04626362|Other|Placebo juice|Apple juice added with flavor and colorants will be provided by Ocean Spray Cranberries, Inc.
45382681|NCT04623398|Drug|Lithium Carbonate|The experimental drugs in this study will be lithium carbonate capsules dosed at 62.5mg, 125mg and 250mg prepared as hospital preparations for clinical trials.
45382682|NCT04623398|Drug|Placebo|Placebo
45382683|NCT04622319|Drug|DS-8201a|Administered initially as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle
45382684|NCT04622319|Drug|T-DM1|Administered initially as an intravenous (IV) infusion at a dose of 3.6 mg/kg on Day 1 of each 21-day cycle
45382685|NCT04621526|Drug|dexmedetomidine- ketamine|patients will receive combination of ketamine 1mg/kg and dexmedetomidine 0.5ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
45426043|NCT01615029|Drug|Dexamethasone|All participants (Part 1 and Part 2) will receive 40 mg (20 mg intravenously [injection of a substance into a vein]) dexamethasone once weekly. Participants older than 75 years or underweight (body mass index [BMI] less than [<] 18.5), the dexamethasone dose will be administered at a dose of 20 mg once weekly until disease progression.
45382686|NCT04621526|Drug|dexmedetomidine- propofol|patients will receive combination from 1 mg/kg propofol and dexmedetomidine 0.5ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 1 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
45498642|NCT02924688|Drug|FF/UMEC/VI (200/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
45498643|NCT02924688|Drug|FF/VI (100/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.
45498644|NCT02924688|Drug|FF/VI (200/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains VI 25 mcg in each blister.
45498645|NCT02924688|Drug|Fluticasone/salmeterol (FSC)|Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.
45498646|NCT02924688|Drug|Albuterol/salbutamol|This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
45848013|NCT05192772|Device|NPi200|Digital pupillometry performed during cardiopulmonary resuscutation (CPR) every CPR cycle end in case of not intubated patient, or every 2 minutes in case of intubated patient
45382689|NCT04617756|Drug|Patients receiving neoadjuvant therapy before radical nephrectomy|Chemotherapy using either a combination of Gemcitabine/Cisplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736) or Chemotherapy with either Gemcitibine/Carboplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736)
45382690|NCT04615650|Procedure|Surgical treatment|Surgical treatment of suprasyndesmotic ankle fractures
45382691|NCT04615650|Device|Ankle orthosis|Non-surgical treatment of suprasyndesmotic ankle fractures
45426044|NCT01606137|Drug|GW-1000-02|Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml) and cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each 100 μl actuation of the pump action spray delivered 2.7 mg THC and 2.5 mg CBD. A maximum daily exposure of 130 mg THC was specified by the UK regulatory authority authorisation.
45498647|NCT02924688|Device|ELLIPTA DPI|The ELLIPTA device will be used during the stabilization period and the treatment period. The ELLIPTA DPI is a moulded plastic two-sided device that can hold two individual blister strips which contain powder formulation for oral inhalation.
45498648|NCT02924688|Device|DISKUS DPI|The DISKUS device will be used during the run-in period. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FSC for oral inhalation.
45498649|NCT02924688|Device|METERED-DOSE INHALER (MDI)|Albuterol/salbutamol (rescue medication) will be delivered via metered-dose inhaler (MDI) will be used for reversibility testing.
45498650|NCT03668496|Drug|SHR-1210|Drug delivery cycle is 3 weeks, and in the experimental group,200 mg shr-1210 was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
45498651|NCT03668496|Drug|The placebo|in the control group,placebo was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
45848014|NCT05133882|Drug|Clifutinib Besylate|The queue 1 is divided into Induction therapy and Consolidation therapy and Maintenance treatment The queue 2 will receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs
45426045|NCT01532518|Drug|Nepadutant|Nepadutant oral solution
45498652|NCT03667092|Biological|non-drug intervention type|8 peripheral blood samples (8x5ml) will be obtained at different times ; before, during and after treatment
45498653|NCT03668418|Drug|Fluorouracil|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
45848015|NCT05093790|Drug|Ticagrelor|Specified dose on specified days
45848016|NCT05093790|Drug|BMS-986141|Specified dose on specified days
45848017|NCT05093790|Drug|Aspirin|Specified dose on specified days
45694672|NCT03215212|Other|eye mask|eye mask administered from 10 pm to 7 am
45382692|NCT04614948|Biological|Ad26.COV2.S|Ad26.COV2.S vaccine will be administered on Day 1 and Day 57 in the double-blind phase. At unblinding visit Ad26.COV2.S vaccine will be administered to participants at Day 57 who have not yet received second vaccination and in newly enrolled participants as either single dose on Day 1 or two doses on Day 1 and Day 57. Single dose of Ad26.COV2.S vaccine will also be administered to participants initially receiving placebo. Single booster dose of Ad26.COV2.S vaccine will be given to participants in the open label phase who have received only a single vaccination with Ad26.COV2.S.
45382693|NCT04614948|Other|Placebo|Placebo will be administered as IM injection on Day 1 and Day 57.
46055918|NCT04217265|Drug|Letrozole then misoprostol|total dose 5 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
46055919|NCT04217265|Drug|placebo then misoprostol|placebo tablets for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
46055920|NCT00635973|Drug|Gefitinib (Iressa)|Iressa
45382697|NCT04614194|Drug|Letrozole|Oral. Tablets should be taken at the same times every day, with or without food.
45382698|NCT04614194|Drug|Abemaciclib|Oral. Tablets should be taken at the same times every day, with or without food.
46055921|NCT02749929|Other|Low level laser therapy|The laser is an infrared (invisible) 60 mW 904 nm Irradia Midlaser
46055922|NCT02749929|Other|Placebo Low Level Laser Therapy|The placebo laser is an identical device to the active laser, made by Irradia Midlaser
45382702|NCT04604431|Other|iREACH CDS Tool|Pediatric clinicians in the intervention arm will 1) receive the iREACH education module, 2) have the iREACH CDS tool integrated into the EHR templates for use at the 4-, 6-, 9-, 12-month WCC, and 3) will be reminded by EHR-embedded prompts at the 9-month WCC to ask caregivers whether peanuts were introduced and tolerated.
45694673|NCT03215212|Other|ocean sound|Ocean sound administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm
45694674|NCT03215212|Other|ear plug|ear plug administered from 10 pm to 7 am
45382703|NCT04603781|Dietary Supplement|CBD Isolate|300 mg. daily dose of CBD Isolate Oil
45382704|NCT04603781|Dietary Supplement|Full Spectrum CBD Oil|300 mg. daily dose of CBD with full spectrum of other cannabinoids found in the hemp plant
45382705|NCT04603781|Dietary Supplement|Broad-Spectrum CBD Oil|300 mg. daily dose of CBD with a selected spectrum of other cannabinoids found in the hemp plant
45848018|NCT05037474|Procedure|TLE group|all patients underwent a transvenous lead extraction/explantation (TLE) procedure
45848019|NCT05015400|Other|Plain Water|To increase water fluid intake, an additional 1.89 L, during phase 1 of the menstrual cycle (days 1-5).
45498654|NCT03668418|Drug|Lederfolin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
45498655|NCT03668418|Drug|Oxaliplatin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
45498656|NCT03668418|Drug|Irinotecan|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
45498657|NCT03668418|Drug|Docetaxel|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
45848020|NCT04936074|Procedure|Muscle preserving selective laminectomy|Muscle-preserving selective laminectomy differ from traditional laminectomy by the spinous process split that preserves the deep extensor muscles. The bilateral facet joints are not exposed. After the laminectomy is finished the split fragments of the spinous process are sutured together so that the deep extensor muscles are restored.
45848021|NCT04936074|Procedure|Laminectomy with instrumented fusion|A traditional laminectomy is complemented with lateral mass and/or pedicle screws connected with rods.
45382706|NCT04603781|Dietary Supplement|Placebo Oil|MCT Oil with mint flavoring
45382707|NCT04603313|Other|tele-advice system|The intervention consists of setting up in each participating center an infectious disease tele-advice system available to general practitioners via a dedicated mobile telephone line.
45382708|NCT04603001|Drug|LY3410738|Oral LY3410738
45382709|NCT04603001|Drug|Venetoclax|Oral venetoclax
45382710|NCT04603001|Drug|Azacitidine|Subcutaneous or intravenous azacitidine
45382711|NCT04602962|Procedure|fertility preservation, several methods|fertility preservation using assisted reproductive techniques or not
45498658|NCT03668418|Drug|Cisplatin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
45694675|NCT03215134|Other|Self-criticism intervention|Compassion Focused Therapy (Gilbert, 2010) adapted to focus specifically on reducing self-criticism. This intervention was originally developed for a student population (Rose, McIntyre & Rimes, submitted) and is now being evaluated in a primary mental-health service.
45694676|NCT00896038|Drug|Aprepitant|Aprepitant is a neurokinin 1 receptor antagonist shown to have anti-stress actions in preclinical studies, and antidepressant efficacy in human clinical trials
45694677|NCT00896038|Drug|Placebo|Non-active placebo
46055923|NCT04920123|Device|Neuro-World|Neuro-World is a collection of six games that are developed for cognitive training that focuses on memory and attention.
45498659|NCT03668418|Drug|Epirubicin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
45382716|NCT04595747|Procedure|Biopsy|Undergo biopsy
45382717|NCT04595747|Procedure|Biospecimen Collection|Undergo blood sample collection
45382718|NCT04595747|Procedure|Computed Tomography|Undergo CT scan and PET/CT scan
45382719|NCT04595747|Procedure|Magnetic Resonance Imaging|Undergo MRI
45382720|NCT04595747|Procedure|Positron Emission Tomography|Undergo PET/CT scan
45498660|NCT03668418|Drug|Gemcitabine|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
45498661|NCT03668418|Drug|Nab paclitaxel|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
45498662|NCT03666702|Other|Upper limb physiotherapy programme|Web-based physio programme
45498663|NCT03666702|Other|Usual care|Usual physiotherapy care
45498664|NCT03011892|Drug|Ruxolitinib 0.15% Cream QD|Ruxolitinib 0.15% cream QD
45498665|NCT03011892|Drug|Ruxolitinib 0.5% Cream QD|Ruxolitinib 0.5% cream QD
45498666|NCT03011892|Drug|Ruxolitinib 1.5% Cream QD|Ruxolitinib 1.5% cream QD
45498667|NCT03011892|Drug|Ruxolitinib 1.5% Cream BID|Ruxolitinib 1.5% cream BID
45498668|NCT03011892|Drug|Triamcinolone 0.1% Cream BID|Triamcinolone 0.1% cream BID
45498669|NCT03011892|Drug|Vehicle Cream BID|Vehicle cream BID
45498670|NCT03017742|Device|Pulse Oximeter|
45498671|NCT02125513|Drug|carboplatin and paclitaxel followed by surgery|
45498672|NCT03667950|Procedure|Hyperspectral Imaging|Photos were taken with the hyperspectral camera of the gastrointestinal anastomosis.
45498673|NCT03667872|Procedure|Bilateral implantation of DBS system to Habeluna|Bilateral implantation of MRI compatible and LFP recordable DBS system to Habeluna
45498674|NCT03667794|Diagnostic Test|body plethysmography|measurement of conventional lung function parameters
45498675|NCT03667794|Diagnostic Test|impulse oscillometry|measurement of central and peripheral airway resistance
45498676|NCT03667794|Diagnostic Test|multiple breath washout|measurement of ventilation heterogeneity
45382721|NCT04595747|Drug|Rogaratinib|Given PO
45382722|NCT04594824|Other|No Intervention|no intervention
45382723|NCT04593654|Drug|Dose of tinzaparin or dalteparin|The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU
45382724|NCT04591210|Drug|Angiotensin converting enzyme inhibitor|The study recommends physicians to select an ACEi with proven benefit in cardiovascular diseases such as perindopril, ramipril or enalapril. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, including renal function, potassium assessment, and dose adjustments as appropriate.
45382725|NCT04591210|Drug|Angiotensin II Receptor Blockers|The study recommends physicians to select evidence-based ARBs such as candesartan or valsartan or losartan. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, and dose adjustments as appropriate.
45498677|NCT04575948|Drug|Moringa Oleifera|Non toxic Moringa extract with antibacterial and antiplaque effect will be used
45498678|NCT04575948|Drug|Chlorhexidine mouthwash|Commercial 0.12% chlorhexidine digluconate mouthwash twice daily (each morning and before bedtime during the 21-day study period) after intake of food. The patient will be asked to use 15 ml of mouthwash swish it for 60 sec. then expectorate.
45498679|NCT04575948|Drug|Base formula|Base formula is a negative control
45498680|NCT03667638|Combination Product|Platelet-Rich Plasma|Adding PRP to wound bed during surgical debridement
45498681|NCT03666546|Drug|Lactulose crystals 20 g|White or almost white crystalline powder. The product will be provided in sachets to be dissolved in 250 mL water.
45498682|NCT03666546|Drug|Lactulose crystals 30 g|White or almost white crystalline powder. The products will be provided in sachets to be dissolved in 250 mL water.
45498683|NCT03666546|Drug|Lactulose liquid 20 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
45498684|NCT03666546|Drug|Lactulose liquid 30 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
45498685|NCT03666546|Drug|Glucose|White crystalline powder. To standardise for 30 g glucose, 33 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
45498686|NCT03666546|Drug|Still water|250 mL still water will be used. Water from the same source will be also used to dissolve investigational and control products
45498687|NCT03012828|Drug|Moxidectin|Moxidectin is a broad spectrum macrocyclic lactone endectocide
45382726|NCT04585893|Drug|Rituximab|375 mg/m^2 administered via IV infusion weekly for four weeks. Administered via slow IV infusion, starting at 50mg/hr and increasing by 50mg/hr every 30 minutes to a maximum infusion rate of 400mg/hr.
45382727|NCT04585893|Drug|Etoposide|Subjects with high-risk disease will receive 100 mg/m^2 etoposide weekly for four weeks administered over one hour via IV infusion after completion of rituximab
45382728|NCT04583124|Other|ATENTO-B|Patients will perform therapeutic exercise and vagal activation techniques before medical treatment and will follow the usual care after medical treatment.
45382729|NCT04583124|Other|ATENTO-T|Patients will perform therapeutic exercise and vagal activation techniques throughout medical treatment and will follow the usual care after medical treatment.
45426046|NCT01489813|Drug|Genistein|30 mg of genistein supplement by mouth three times daily (PO TID).
45426047|NCT01489813|Drug|Sugar pill|Sugar pills will be taken by mouth three times daily (PO TID).
45498688|NCT03012828|Other|Placebo|
45498689|NCT03667560|Procedure|Dermacell ADM without basement membrane|Patient will be implanted with Dermacell ADM.
45498690|NCT03667560|Procedure|FlexHD|Patient will be implanted with FlexHD.
45498691|NCT03666936|Other|Social-health care intervention|Cancer survivors enrolled in the study could receive support from the Occupational Therapist and/or from the social care professionist to overcome the difficulties encounter at work or to facilitate work reintegration.
45498692|NCT04598724|Other|Surveys|Survey will be administered involving questions regarding knowledge and perception of palliative care.
45848022|NCT04933344|Other|patients having had BJI or PJI treated with daptomycin|patients having had BJI or PJI treated with daptomycin who developped an adverse event : eosinophilic pneumonia and/or elevation of CPK
45382730|NCT04581603|Behavioral|Cognitive Behavioral Therapy for Insomnia|CBT-I is conducted weekly for eight sessions during which the subjects meet individual with the study clinician for 45 minutes on the first session and for 30 minutes for sessions 2-8. Session 1 serves as an orientation and the onset of Sleep Restriction Therapy. Sessions 2 & 3 deliver the three main components that include, Sleep Restriction Therapy, Stimulus control, and Sleep Hygiene. All the sessions excluding the last two sessions are dedicated to the titration of total sleep time and to ensure patient adherence. The fifth session is used to deliver a specific form of cognitive therapy. The final session is used to engage the patient in a relapse-prevention didactic (i.e., to review how insomnia becomes chronic and strategies that abort an extended episode of insomnia). The subject will return on week 9 to complete the post-intervention visit after 8 weeks of behavioral sleep treatment.
45426048|NCT01489449|Device|Stent|bare metal stent implantation, any bare metal stent is allowed from different companies
45426049|NCT01489449|Combination Product|SeQuent(R) Please coated balloon|Angioplasty with Drug coated balloon (DCB)
45498693|NCT03010254|Device|ACRYSOF® IQ Extended Depth of Focus IOL|Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL; intended for long-term use over the lifetime of the pseudophakic subject
45848023|NCT04847544|Drug|ADX-629|ADX-629 administered orally twice daily (BID) for up to 28 days.
45426050|NCT01420874|Drug|FOLFOX6|IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, & in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.
45382731|NCT04581603|Behavioral|Sleep Hygiene Education|This non-active control arm of behavioral sleep intervention consists of psychoeducation on sleep hygiene, sleep-related disturbances, and the effects of stress on sleep that will be delivered weekly for 8 weeks, for a time duration that is identical to the CBT-I sessions. The effect of stress on sleep is a commonly used control condition in insomnia clinical trials. SHE is preferred to a monitor-only condition as it will control for contact with the therapist and elapsed time during sessions. The subject will return on week 9 to complete the post-intervention visit after 8 weeks of behavioral sleep treatment.
45382732|NCT04576507|Drug|Cannabis|Investigates two strengths of cannabis.
45382733|NCT04573517|Procedure|Amniotomy|Artificial rupture of amniotic membranes
45382734|NCT04573517|Device|Foley balloon|The Foley balloon is inserted transcervically and inflated to a volume of 60 cc. It may be spontaneously expelled or manually removed if in place for 12 hours.
45382735|NCT04573478|Drug|Atrasentan|Film-coated tablet
45382736|NCT04573478|Drug|Placebo|Film-coated tablet
45382737|NCT04567537|Device|Laser Treatment|Patients will receive three laser treatments at one-month intervals.
45382738|NCT04565535|Behavioral|Novel donor lifestyle optimisation protocol|Diet based on calorie requirement as calculated by indirect calorimetry. Daily exercise.
45382739|NCT04564027|Drug|Ceralasertib|Tablets will be administered orally
45382740|NCT04558593|Procedure|Active surveillance|Per standard of care: Imaging and blood tests every 6 months (3 first years) and annually (following years)
45382741|NCT04558593|Procedure|Surgery|Per standard of care: partial or full resection of the kidney, imaging annually
45382742|NCT04558346|Drug|Ghrelin (OXE-103)|40ug/kg twice daily by self-injection
45382743|NCT04558346|Drug|Placebo|40ug/kg twice daily by self-injection
45382744|NCT04557436|Drug|PBLTT52CAR19|gene therapy
45382745|NCT04557150|Drug|RO7425781|RO7425781 will be administered via IV/SC administration. The RP2Ds determined during Part I: Dose Escalation will be administered during Part II: Dose Expansion. RO7425781 will be administered as per the dosing schedule defined in Part I.
46055924|NCT02752971|Drug|Bupivacaine|
45382747|NCT04547946|Drug|dabrafenib + trametinib|There was no treatment allocation. Patients administered adjuvant treatment with combination therapy of Dabrafenib (Tafinlar®) and Trametinib (Mekinist®) by prescription that had started before inclusion of the patient into the study could be enrolled.
45382748|NCT04546009|Drug|Giredestrant|Giredestrant is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
45382749|NCT04546009|Drug|Giredestrant-matched Placebo|Giredestrant-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
45498694|NCT03010254|Device|ACRYSOF® IQ Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject
45382750|NCT04546009|Drug|Letrozole|Letrozole 2.5 milligrams (mg) is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
45382751|NCT04546009|Drug|Letrozole-matched Placebo|Letrozole-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
45382752|NCT04546009|Drug|Palbociclib|Palbociclib 125 mg is taken orally once per day on Days 1-21 of each 28-day treatment cycle.
45498695|NCT03010254|Procedure|Cataract surgery|IOL bilateral implantation
45848024|NCT04847544|Drug|Placebo|Placebo administered orally BID for up to 28 days.
45855732|NCT04205175|Drug|Feiba|This is a single center, open label, dose escalation study of in vivo administration of Feiba in congenital hemophilia A patients with inhibitors who are on emicizumab.
45855733|NCT04186663|Drug|Silver Diamine Fluoride|38% aqueous silver diamine fluoride [Ag(NH3)]2F, CAS RN 33040-28-7
45382753|NCT04546009|Drug|LHRH Agonist|Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
45382754|NCT04545736|Drug|Metformin hydrochloride|Metformin is commercially produced in immediate and extended release. Participants will receive an immediate release formulation of metformin of 500mg daily at study entry. This dose will be titrated up weekly in 500mg increments to reach a goal of 2000mg daily maximum. Once participants >=17 years of age reach 2000mg metformin immediate release they will switch to an extended-release formulation (1000mg twice a day by mouth). Participants >= 17 years of age that cannot tolerate 2000mg will be permitted to reduce their daily dose to a minimum of 1000mg/day. Because metformin extended release is not FDA-approved for children under the age of 17, participants under 17 will remain on the immediate release formulation. For these participants who remain on standard formulation, the maximum tolerated dose between 1000mg and 2000mg/day will be given.
45382755|NCT04542889|Diagnostic Test|Absolute coronary flow and resistance measurements|Thermodilution-based measurements of absolute coronary resistances using the FFR pressure guide (PressureWire® Certus® from St Jude Medical Abbott) and the Rayflow® microcatheter (Hexacath, Paris, France).
45382756|NCT04542889|Diagnostic Test|IMR measurement|IMR measurement by thermodilution using the St Jude pressure guide.
45382757|NCT04542824|Biological|epcoritamab (monotherapy)|Epcoritamab will be administered subcutaneously in cycles of 4 weeks (i.e. 28 days)
45855734|NCT04180267|Device|Low-magnitude High-frequency Vibration|35Hz, 0.3g, 20min/day, at least 3 times/week
46055925|NCT02752971|Drug|Sodium diclofenac|
46055926|NCT04416555|Device|Placebo comparator: VR googles and the non reality experience|parallel assignment (this arm will receive a static presentation in the same device)
46055927|NCT04416555|Device|Active Comparator: VR googles and the real VR program to enter act with and experience|Parallel assignment (this arm will receive the full immersive virtual reality experience
46055928|NCT02750007|Drug|HS-20004|
46055929|NCT02750163|Drug|paracetamol|Paracetamol will be given to febrile septic patients
46055930|NCT04217421|Drug|Allopurinol|Allopurinol powder for solution for infusion (PFI) 20 mg/kg body weight per administration will be administered early postnatally (within 45 minutes and 12 hours after the first dose), preoperatively (12 hours before surgery), intraoperatively (during surgery) and postoperatively (24 hours after surgery) to the neonate in case of a prenatal CCHD diagnosis. Allopurinol PFI will be administered only pre-, intra- and postoperatively to the neonate in case of a postnatal CCHD diagnosis.
45382758|NCT04542824|Biological|epcoritamab|Epcoritamab will be administered in combination with the respective SOC chemotherapy followed by epcoritamab monotherapy.
45382759|NCT04542824|Drug|rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone|21-day cycles
45382760|NCT04542824|Drug|gemcitabine and oxaliplatin|28-day cycles
45382761|NCT04542824|Biological|epcoritamab (maintenance)|28-day cycle for Cycle 1 and then 56-day cycle from Cycle 2 through 13
45382762|NCT04542824|Drug|rituximab and lenalidomide|28-day cycles.
45382763|NCT04542499|Drug|Tavapadon|Participants will be randomized to receive tavapadon 5 to 15 mg tablet QD orally for 27 weeks.
45382764|NCT04542499|Drug|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
46055931|NCT04217421|Drug|Mannitol|Mannitol powder for solution (PFI) placebo will be administered early postnatally (within 45 minutes and 12 hours after birth), preoperatively (12 hours before surgery), intraoperatively (during surgery), and postoperatively (24 hours after surgery) to the neonate in case of a prenatal CCHD diagnosis. Mannitol PFI-placebo will be administered only pre-, intra- and postoperatively to the neonate in case of a postnatal CCHD diagnosis.
46055932|NCT02749695|Drug|Melsmon|Placental extract Melsmon® (Japan): 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
46055933|NCT02749695|Other|Placebo|2 ml subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
45382768|NCT04535700|Drug|Pioglitazone 30 mg|Patients receive 30 mg/day of pioglitazone for the entire period they remain in hospital
45382769|NCT04535700|Other|standard of care|Patients receive the standard of care, according to the hospital protocol for patients with type 2 diabetes mellitus hospitalized.
45382770|NCT04535609|Drug|Mavodelpar|Once daily
45382771|NCT04535609|Drug|Placebo|Once daily
46055934|NCT04217187|Device|Neuromuscular Electrical Stimulation|Upper extremity neuromuscular electrical stimulation
46055935|NCT04217187|Device|Sham Electrical Stimulation|Sensory only upper extremity electrical stimulation
46055936|NCT02749773|Device|Oocyte Aspiration needle|Oocyte aspiration in women go through an IVF procedure,.
46055937|NCT04219137|Genetic|Molecular Profiling|This is a correlative study collecting biosamples to evaluate genomic characteristics and treatment outcomes of gastroesophageal adenocarcinoma.
46055938|NCT02749539|Device|Kinesio tape|Standard 2 -inches ( 5-m) Kinesio TexR tape was used for application in the experimental group
45382777|NCT04531215|Drug|ultrasound guided Retrolaminar Block|ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side
45382778|NCT04531215|Drug|ultrasound guided Erector Spinae Plane|ultrasound guided Erector Spinae Plane Block (ESPB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
45382779|NCT04526795|Drug|Cytarabine|Given IV
45382780|NCT04526795|Drug|Fludarabine|Given IV
45382781|NCT04526795|Drug|Pegcrisantaspase|Given IV
46055939|NCT02749539|Procedure|physiotherapy program|active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
46055940|NCT04219371|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
45498696|NCT04050150|Behavioral|Arm training in standing|Arm training will be provided in one hour sessions, 3 time per week for 8 weeks. In each session, you will practice functional tasks with your weaker arm and hand in standing or during walking. Practice will be scaled to match your current level of function and progressed over time as able.
45855735|NCT04179734|Drug|Bremelanotide|Melanocortin-4 receptor agonist subcutaneous injection.
46055941|NCT04217031|Other|No intervention|No intervention
45855736|NCT04179734|Drug|Placebo|Placebo subcutaenous injection.
45855737|NCT04176302|Device|Parkinson Holter|The neurologists will receive the wearable report (for medication adjustment, if any as per physician's criteria/judgement)
45855738|NCT04176302|Diagnostic Test|Motor fluctuations diary|The neurologists will receive the patient's diary report (for medication adjustment, if any as per physician's criteria/judgement).
45855739|NCT04176302|Other|Traditional clinical practice|The neurologists will receive the patient & caregiver report at the time of the visit (for medication adjustment, if any as per physician's criteria/judgement).
46055942|NCT02749461|Procedure|heel stick|Consecutive routine blood sampling heel sticks
46055943|NCT04583241|Other|Constitution of serum bank at D0|Blood samples at Day 0 (day of surgery)
46055944|NCT04583241|Other|Constitution of serum bank during follow-up|Blood samples are obtained at week 2, week 6 post-surgery, at the end of antibiotherapy and 6 months post-surgery, only for patients with staphylococcus aureus monoinfection who are follow-up during two years.
45498697|NCT03666468|Other|PlayMed|A highly immersive role-playing computer game focused on Paediatric Asthma and Seizure management
45498698|NCT03666468|Other|Online Package|Online package (OP) of NSW Health Guidelines focused on Paediatric Asthma and Seizure management
45382792|NCT04524390|Drug|Maralixibat|A small molecule inhibitor of the ileal bile acid transporter (IBAT)
45382793|NCT04524390|Other|Placebo|Identical to maralixibat except for the active drug substance
45382797|NCT04522375|Drug|FP-045|activator of aldehyde dehydrogenase
45382798|NCT04522271|Other|Resistant Starch|7.5 g resistant starch/m2 oral consumption
45382799|NCT04522271|Other|Placebo|Placebo oral consumption of food-grade cornstarch
45382800|NCT04521686|Drug|LY3410738|Oral LY3410738
45382801|NCT04521686|Drug|Gemcitabine|Intravenous gemcitabine
45498699|NCT03666468|Other|Paper Guidelines|Paper NSW Health Guideline focused on Paediatric Asthma and Seizure management
45498700|NCT03666390|Drug|Ketamine|We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
45498701|NCT03666390|Drug|Midazolam|We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
45498702|NCT03008460|Drug|Eziclen®/Izinova®|Oral solution taken the evening before the colonoscopy
45498703|NCT03008460|Drug|Klean-Prep®|Oral solution taken the evening before the colonoscopy
45498704|NCT03008070|Drug|IVA337|1200mg
45498705|NCT03008070|Drug|IVA337|800mg
45498706|NCT03008070|Drug|Placebo|Placebo to match
45498707|NCT02914236|Device|Vivaer Stylus|Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
45498708|NCT03623022|Drug|Clinical Center Reference Endotoxin (CCRE)|subjects will undergo an exposure to inhaled endotoxin through a nebulizer for approximately 10 minutes.
45498709|NCT03623022|Drug|Normal saline|subjects will undergo an exposure to inhaled normal saline through a nebulizer for approximately 10 minutes
45498710|NCT03667248|Device|Sorin Perceval ® Sutureless Valve (Sorin Group Italia Srl, 13040 Saluggia, Italy), available in different sizes (S 19-21mm, M 21-23mm, L 23-25mm, XL 25-27mm)|Sizing of the valve by preoperative CT scan of the heart and comparison of this measurement with the standard procedure (Sizing intraoperatively using the measuring devices provided by the product manufacturer)
45498711|NCT03666078|Procedure|cesarean delivery|women delivered by cesarean section
45498712|NCT03665376|Dietary Supplement|Carbohydrate drink load|Administration of 5% Dextrose orally as a carbohydrate drink load two hours before surgery and as an oral sips eight hours after the surgery.
45498713|NCT03665376|Combination Product|Enhanced Recovery After Surgery (ERAS)|The ERAS intervention consisted of exposing patients to ERAS protocol of care as described by the ERAS Society® for the entire perioperative period. However, some of these ERAS protocols were modified to our local resources and requirements.
45694678|NCT03219346|Other|oral care program|Oral care (sputum and special needs of people cleaning teeth) time for three days a week (with swallowing treatment time before), once a day, each about 10 minutes of oral care program.
45382802|NCT04521686|Drug|Cisplatin|Intravenous cisplatin
45382803|NCT04521686|Drug|Durvalumab|Intravenous durvalumab
45382804|NCT04515498|Device|CloudCath Monitoring System|The CloudCath Monitoring System will analyze effluent dialysate for changes associated with peritonitis.
45382805|NCT04512911|Procedure|Endocardial ablation|Endocardial ablation of VT
45382806|NCT04512911|Procedure|Endocardial- Epicardial ablation|Epicardial ablation of VT in addition to endocardial ablation
45382807|NCT04512911|Drug|Antiarrhythmic medications|Addition of anti arrhythmic medication or dose increase
45382808|NCT04510051|Drug|Cyclophosphamide|Given IV
45382809|NCT04510051|Drug|Fludarabine|Given IV
45382810|NCT04510051|Biological|IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Given intraventricularly
45382811|NCT04503551|Drug|PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
45382812|NCT04503551|Drug|Intravitreal Ranibizumab 0.5 mg Injection|Will be administered as per the schedule described in individual arm.
45694679|NCT03218956|Dietary Supplement|Dietary supplement: Protein intake|"Oral consumption of houly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates from a flavored liquid, fat from corn oil and protein free cookies.~The last 4 meals will in addition contain labelled labelled 13C phenylalanine."
46055945|NCT04583241|Other|ELISA assays of serum markers of bone remodeling at D0|Assessment by ELISA assays of serum markers of bone remodelling: the osteocalcin (OC), the procollagen propeptide type 1 (PINP), the cross linked telopeptide of type 1 collagen (CTX1) and the periostin at Day 0 (day of surgery)
46055946|NCT04583241|Other|ELISA assays of serum markers of bone remodeling during follow-up|Assessment by ELISA assays of serum markers of bone remodelling: the osteocalcin (OC), the procollagen propeptide type 1 (PINP), the cross linked telopeptide of type 1 collagen (CTX1) and the periostin at week 2, week 6 post-surgery, at the end of antibiotherapy and 6 months post-surgery, only for patients with staphylococcus aureus monoinfection who are follow-up during two years
45382817|NCT04492020|Drug|Ubrogepant 100 mg|For each qualifying prodrome event, 2 compressed tablets containing 50 mg of ubrogepant will be taken orally when the participant is confident that a headache will follow within 1-6 hours
45382818|NCT04492020|Drug|Placebo|For each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours
45498714|NCT03003390|Drug|Enoxaparin|The clinical nurse will give enoxaparin subcutaneously every 12 hours at the currently used starting dose of 0.75 mg/kg for children ≤2 months old or 0.5 mg/kg (maximum of 40 mg) for older children. The 1st dose will be given <24 hours after insertion of the catheter. Doses will be adjusted to target an anti-Xa level of 0.2-0.5 IU/mL.
45382819|NCT04491591|Other|Breast Reconstruction Education and Support Tool (BREASTChoice)|The tool is an interactive website and can be sent through My Chart and integrated into the electronic health record
45498715|NCT03003000|Drug|ibuprofen|
45382820|NCT04491591|Other|Attention Control Website|-(https://www.cancer.gov/types/breast/reconstruction-fact-sheet)
45382821|NCT04491591|Other|Clinician Survey|-Questions regarding opinions on shared decision-making with answers ranging from 1-7 with 1=strongly disagree or harmful to 7=strongly agree or beneficial. The higher the score the more the physician agrees with shared decision making.
45498716|NCT03003000|Drug|caffeine|
45498717|NCT03003000|Drug|placebo|
45498718|NCT03665298|Behavioral|Smartphone Application|App that helps patients find syringe exchange programs, safe way to dispose of needles, access to naloxone kits and access to free medical care and addiction treatment programs.
45498719|NCT03665220|Other|Ergonomic adjustments|The ergonomic adjustments made were based on a prior assessment of the patient's needs in this respect, using a purpose-made home inspection form .
45498720|NCT03665220|Other|Kinesiotherapy plus ergonomic adjustments|This group received, in addition to the ergonomic adjustments described above, sessions of postural orientation and kinesiotherapy (therapeutic exercises).
45498721|NCT03665220|Other|Healthcare education|This group received health education information, based on an illustrated manual with advice for patients with chronic stroke.
45694680|NCT03219112|Other|Balance rehabilitation using X-box One & Kinect|the virtual reality games (Kinect sports rivals) can be controlled with movements of the body that are registered through the kinect camera.
45694681|NCT03219190|Behavioral|LST High School Online|The proposed preventive intervention for high school PDA will (1) utilize both online e-learning modules and interactive classroom sessions to address PDA and concurrent alcohol/drug abuse; (2) positively change social norms surrounding PDA and alcohol/drug abuse; (3) challenge positive expectancies about the benefits of PDA; (4) discourage diversion of prescription medication; (5) enhance protective factors by building social, self-regulation, and relationship skills through interactive learning and behavioral rehearsal scenarios; and (6) include online booster sessions.
45694682|NCT02804074|Other|Optimization of antihypertensive treatment based on office BP|Optimization of antihypertensive treatment based on office BP
45694683|NCT02804074|Other|Optimization of antihypertensive treatment based on 24-hour ABPM|Optimization of antihypertensive treatment based on 24-hour ABPM
45694684|NCT02639260|Drug|N-acetyl D-mannosamine|dose escalation
45382826|NCT04485949|Combination Product|IGV-001 Cell Immunotherapy|IGV-001, an immunotherapeutic product that combines personalized whole tumor-derived cells with an antisense oligonucleotide (IMV-001) in implantable biodiffusion chambers.
45498722|NCT03666156|Other|No intervention|No Intervention
45694685|NCT04381234|Device|dialyzer|Asymmetric triacetate dialyzer
45694686|NCT04381234|Combination Product|hemodialysis with citrate-containing dialysate|acetate-free dialysate
45382827|NCT04485949|Combination Product|Placebo|Placebo in implantable biodiffusion chambers containing a predetermined inactive solution.
45382828|NCT04485949|Procedure|Standard of Care (SOC): Radiation Therapy|Radiation therapy administered per institutional standards.
45382829|NCT04485949|Drug|SOC: Temozolomide|Temozolomide administered orally.
45382830|NCT04484142|Drug|DS-1062a|DS-1062a will be administered as an intravenous (IV) infusion once every 3 weeks
45382831|NCT04479943|Other|MOVIN|MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.
45382832|NCT04479735|Device|Virtual Reality Goggles|Virtual reality goggles will placed at least 2 min prior to venipuncture to deteremine if it mitigates perceived anxiety or perceived pain scores.
45382833|NCT04478279|Drug|ST101|ST101 will be administered intravenously (IV), initially once per week with a flat dose on the schedule described for each study arm
45382834|NCT04478279|Drug|Temozolomide|Temozolomide
45382835|NCT04478279|Radiation|Radiation|Radiation
45382836|NCT04471428|Drug|Cabozantinib|Cabozantinib will be administered orally, once daily at a dose of 40 mg on Days 1-21 of each cycle.
45382837|NCT04471428|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
45382838|NCT04471428|Drug|Docetaxel|Docetaxel will be administered by IV infusion at a starting dose of 75mg/m2 on Day 1 of each 21-day cycle.
45382839|NCT04451044|Device|Philips SyncVision system with Philips pressure wires|Intent to use physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy
45382840|NCT04451044|Procedure|standard of care angiographically-guided PCI|Intent to use PCI standard of care angiographically-guided PCI for determining the PCI strategy
45694687|NCT04381234|Other|predilution hemodiafiltration|predilution hemodiafiltration
45694688|NCT03218644|Other|Mobility exercises|Usual treatment and exercises of cervical mobility before a mirror.
45382841|NCT04449328|Device|Computerized Mirror Therapy (CMT)|"Computerized Mirror Therapy (CMT) will be realizing by the device Intensive Visual Simulation 3 (IVS3).~The patient looks on a screen in front of him, mirroring the movements made by his hand, while attempting to perform the same movement with his other hand."
45382842|NCT04449328|Device|Tendon vibration|Transcutaneous vibrations are used. This device allows vibrations from 50 to 120 Hz with amplitude of 1 mm. This study the frequency used is 70 and 80 Hz.
45382843|NCT04445597|Other|Sampling of tissue|In all groups of participants, tissue from the nasal cavity and olfactory system will be surgically removed
46055947|NCT04583241|Other|Analysis of bacterial gene expression at D0|Assessement of bacterial gene expression on surgery residual tissue (bone tissue, joint fluid, fragment of prostheses) collected at Day 0 (day of the surgery)
46055948|NCT00636129|Behavioral|Relaxation Response + Stress Management Curriculum|Subjects will receive 8 weeks of Stress Management curriculum and guidance through 20 minute Relaxation Response with a research coordinator. They will also practice 20 minutes of Relaxation Response at home daily.
46055949|NCT04572789|Dietary Supplement|Omega-3 polyunsaturated fatty acids|All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of omega-3 PUFAs intervention (EPA, 1.8 g/day) and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
45694689|NCT03218644|Other|Proprioception exercises|proprioceptive exercises for craniocervical sensorimotor control.
45694690|NCT03218176|Device|Proximal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
45382847|NCT04439669|Device|Sham nrTMS and open phase|"Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to sham. In the following open phase stimulation the treatment targets are the right S2-contralateral M1-left S2."
45382848|NCT04439669|Device|Active nrTMS and open phase|"Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to S2. In the following open phase stimulation the treatment targets are contralateral M1 and left S2. If the patient benefited from active S2 stimulation, but the treatment effect faded in follow-up, the open phase stimulation starts with right S2."
46055950|NCT04572789|Dietary Supplement|omega-6 PUFAs|All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of placebo omega-6 PUFAs intervention and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
45694691|NCT03218176|Device|Proximal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
46055951|NCT02749383|Drug|PAC-14028 cream 0.3%|Topical application
46055952|NCT02749383|Drug|PAC-14028 cream 1.0%|Topical application
46055953|NCT02749383|Drug|PAC-14028 cream vehicle|Topical application
46055954|NCT02748993|Drug|PAC-14028 Cream 0.1%|Topical application
45382854|NCT04437225|Dietary Supplement|Low oxalate controlled Diet|Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
45382855|NCT04437225|Other|Primed, continuous intravenous infusion of 13C2-Glycolate|Participants will receive a continuous intravenous administration of carbon-13 glycolate, a naturally occurring form of glycolate, over the course of several hours until steady-state is achieved, using an IV catheter.
45382856|NCT04437225|Other|Bolus intravenous infusion of 13C2-Glycolate|Participants will receive a bolus intravenous administration of carbon-13 glycolate, a naturally occurring form of glycolate, using an IV catheter.
45382857|NCT04437225|Other|Oral bolus administration of 13C2-Glycolate|Participants will orally ingest a single dose of carbon-13 glycolate, a naturally occurring form of glycolate.
45694692|NCT03218176|Device|Distal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
45694693|NCT03218176|Device|Distal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
45694694|NCT03218176|Device|Proximal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
45694695|NCT03218176|Device|Proximal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
45694696|NCT03218176|Device|Distal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
45694697|NCT03218176|Device|Distal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
46055955|NCT02748993|Drug|PAC-14028 Cream 0.3%|Topical application
45382859|NCT04431726|Drug|Emicizumab|"Initially, all participants will receive 4 loading doses of 3 milligrams per kilogram (mg/kg) emicizumab subcutaneously (SC) once every week (QW) for 4 weeks followed by the maintenance dosing regimen 3 mg/kg emicizumab SC once every 2 weeks (Q2W) for a total of 52 weeks. Starting from Week 17 of treatment, individual participants may have their dose up-titrated to 3 mg/kg SC QW if they experience suboptimal bleeding control.~At the Week 53 clinic visit following consultation with the treating physician, parents/caregivers may elect for their child to continue with the maintenance 3-mg/kg SC Q2W dosing regimen or to switch to the maintenance 1.5-mg/kg SC QW or 6-mg/kg SC once every 4 weeks (Q4W) dosing regimen for the subsequent 7-year long-term follow-up period.~During the study, participants will be treated with emicizumab until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria specified in the protocol, whichever occurs first."
45694698|NCT04380844|Other|Beprevent|10 will become part of the intervention group. At first, they are given a series of questionnaires, later (1 day later) we stay at their home to install the Beprevent device, which will remain in their home for a period of two weeks, to finish and once the device of your home, we will proceed to pass the same questionnaires as at the beginning of the test, in order to compare results.
45694699|NCT03215290|Procedure|TCS|"The cutting surface recognized as not good cutting surface was further trans-parenchymal compressing sutured, if possible, using a hepatic needle."
45694700|NCT02537548|Other|Laboratory Biomarker Analysis|Correlative studies
45694701|NCT02537548|Procedure|Retroperitoneal Lymph Node Dissection|Undergo RPLND
45694702|NCT00897676|Drug|Exendin-(9-39)|100-500pmol/kg/min
46055956|NCT02748993|Drug|PAC-14028 Cream 1.0%|Topical application
45694703|NCT00897676|Drug|placebo|placebo (0.9% NaCl)
45694704|NCT01616459|Biological|Pneumococcal conjugate vaccine GSK2830929A|Intramuscular injection
45694705|NCT01616459|Biological|Pneumococcal conjugate vaccine GSK2830930A|Intramuscular injection
46055957|NCT02748993|Drug|PAC-14028 Cream Vehicle|Topical application
46055958|NCT04036929|Drug|Estrogen-bazedoxifene|Conjugated estrogens 0.45 mg-bazedoxifene acetate 20 mg.
46055959|NCT04036929|Drug|Placebo oral tablet|Placebo oral tablet
46055960|NCT04219293|Device|Microneedling w/ and w/o PRP|i. Split face comparison. Vertical line drawn midline nose extending upwards to hairline and downwards to jawline separating face into two equal treatment areas. The patients determined side of face will be treated with SkinPen Microneedling and PRP the other (nondetermined from randomization) will be treated with SkinPen Microneedling and glide. The patient side of face that will not use PRP will be treated first. The following settings will be used as treatment protocol. Topical anesthetic Benzocaine 20%, Lidocaine 10%, and Tetracaine 10% will be applied covering entire treatment area. The anesthetic will remain on skin for 30 minutes.
45382860|NCT04429555|Drug|Ibudilast|Ibudilast orally administered, 50 mg twice daily for 7 days.
45382861|NCT04429555|Drug|Placebo|Placebo orally administered, 50 mg twice daily for 7 days.
45382862|NCT04421378|Drug|Selinexor|Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral
45382863|NCT04421378|Drug|Temozolomide (TMZ)|Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral
45382864|NCT04421378|Drug|Lomustine (CCNU)|Dose and Formulation: 10, 40, or 100 mg; Capsule Route of Administration: Oral
45382865|NCT04421378|Radiation|Standard Fractionated Radiation therapy (RT)|Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.
45382866|NCT04421378|Drug|Bevacizumab|Dose and Formulation: 10 mg/kg; Route of Administration: Intravenous
45382867|NCT04421378|Device|TTField|Dose and Formulation: 200 kHz ≥18h/day; Route of administration: Scalp application of transducer arrays.
45382868|NCT04421378|Drug|Carmustine|Dose and Formulation: 150 or 200 mg/m^2; Route of Administration: Intravenous
45382869|NCT04419597|Device|HEMOPATCH|The treatment will be performed with the HEMOPATCH collagen patch and hemostatic PEG sealant (Baxter), applying two units of the large patch to reinforce the primary dural closure (HEMOPATCH 4.5x9cm, 1506253).
45382870|NCT04419597|Device|Standard of care|Usual clinical practice techniques for reinforcing primary dural closure.
45498723|NCT03514680|Behavioral|CIPN Assessment and Management Algorithm|The revised algorithm incorporates evidence-based CIPN assessment and management strategies and standardized CIPN/pain patient-reported outcomes measures. In terms of processes, trained study staff will administer the screening questionnaires (e.g., PRO-CTCAE, 0 - 10 numerical rating scale of worst CIPN pain intensity) to consented patients before their clinician visit (e.g., in the waiting room). Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm. Clinicians may then use the algorithm at their discretion to guide the assessment and management of their patients' CIPN symptoms
45498724|NCT04055454|Biological|MV-LASV|The MV-LASV vaccine candidate is a recombinant live attenuated viral vectored vaccine, based on the backbone of the measles Schwarz virus strain for prophylaxis of Lassa infection and will be administered in two different dose levels by intra muscular (i.m.) injection.
45694706|NCT01616459|Biological|Synflorix™|Intramuscular injection
45694707|NCT01616459|Biological|Prevnar 13™|Intramuscular injection
45694708|NCT01616459|Biological|Infanrix hexa™|Intramuscular injection
45694709|NCT03218254|Drug|Methylphenidate|Titration of MTP for treatment of fatigue
45694710|NCT03218254|Drug|Placebo|Placebo
45694711|NCT04415801|Diagnostic Test|Repeated removal and re-placement of healing and prosthetic abutments|Repeated removal and re-placement of healing and prosthetic abutments
45694712|NCT03215056|Drug|Methoxyflurane|PENTHROX 3mL inhalation vapour, liquid
45382871|NCT04414475|Drug|Selinexor|Participants will receive Selinexor oral tablets.
45694713|NCT03215056|Drug|Normal saline|Placebo
45694714|NCT04626401|Behavioral|Forearm immobilization|Two days of forearm immobilization
45694715|NCT01919801|Drug|Icatibant|Single dose of 30 mg icatibant administered within 12 hours of the onset of an acute attack of ACE-I-induced angioedema
45382872|NCT04414475|Drug|Dexamethasone|Participants will receive Dexamethasone oral tablets.
45382873|NCT04414475|Drug|Bortezomib|Participants will receive Bortezomib SC injection.
45382874|NCT04409444|Diagnostic Test|Lung Cancer Screening|The lung health check consists of a symptom questionnaire for the calculation of 6-year lung cancer risk (using the PLCOM2012 model)
45382875|NCT04409444|Diagnostic Test|Biomarkers|This will explore the role of biomarkers for the early detection of lung cancer. These include circulating nucleic acids, circulating proteins, circulating tumour cells and inflammatory markers.
45382876|NCT04408638|Drug|Obinutuzumab|Participants will receive a single dose of intravenous (IV) obinutuzumab pre-treatment 7 days prior to the first dose of glofitamab.
45382877|NCT04408638|Drug|Glofitamab|Participants will receive IV glofitamab for up to 12 cycles.
45382878|NCT04408638|Drug|Rituxumab|Participants will receive IV rituxumab on Day 1 of each cycle for up to 8 cycles.
45382879|NCT04408638|Drug|Tocilizumab|Participants will receive IV tocilizumab as needed for treatment of cytokine-release syndrome (CRS).
45694716|NCT01919801|Drug|Placebo|
45694717|NCT01919723|Drug|Ticagrelor|Ticagrelor loading dose
45382880|NCT04408638|Drug|Gemcitabine|Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.
45382881|NCT04408638|Drug|Oxaliplatin|Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.
45382882|NCT04408131|Biological|Blood sample|virological test
45382883|NCT04408131|Biological|Blood sample|serological test
45382884|NCT04404595|Biological|CT041|treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
45382885|NCT04403022|Device|Robotic Assisted Surgery|da Vinci SP Surgical System, instruments, and accessories in complex colorectal procedures such as low anterior resection procedure or right colectomy with or without total mesorectal excision
45382886|NCT04400474|Drug|Cabozantinib 40 mg|All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).
45694718|NCT01919723|Drug|Eptifibatide|i.v. infusion
45694719|NCT01919489|Drug|Liraglutide + OADs|Liraglutide subcutaneously daily
45694720|NCT01919489|Drug|Glargine + OADs|Glargine once daily subcutaneously
45694721|NCT01919411|Drug|Amoxicillin-Potassium Clavulanate|Patients in this arm will receive 500mg of Amoxicillin-Potassium Clavulanate Combination orally twice a day for 7 days after surgery.
45694722|NCT01919411|Drug|Placebo|Patients in this arm will receive 7 days of placebo after surgery.
45694723|NCT01901393|Drug|IV ibuprofen|
45694724|NCT01901393|Drug|Ketorolac|
46055961|NCT04281147|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Follow clinical administration
46055962|NCT02749071|Procedure|Laparoscopic implantation surgery|Laparoscopic surgery to implant the pulse generator and bipolar lead.
45498725|NCT04055454|Other|Placebo|A sterile physiological saline solution will be used as placebo to ensure blinding of the treatment with low dose MV-LASV and placebo within treatment group A. Additionally, the Placebo will be used as a control arm to enable comparison of treatment reactions within treatment groups B and C.
45498726|NCT03665844|Device|SmartSleep Boost On|"SmartSleep device can be configured to two different settings. SmartSleep Boost On setting provides soft audio tones during the night.~It's a non-invasive portable light weight device designed to stimulate deep slow wave sleep (SWS)."
45498727|NCT03665844|Device|SmartSleep Boost Off|SmartSleep device can be configured to two different settings. SmartSleep Boost Off provides no audio tones.
45498728|NCT04056390|Procedure|Catheter ablation using irrigated radiofrequency current ablation or cryothermal energy|Substrate ablation in terms of voltage abatement versus electrical left atrial appendage isolation.
45498729|NCT03665766|Drug|Cycloserine,Tacrolimus|
45498730|NCT03002610|Other|Pls|Text format with simple explanation of the survey topic main findings and is intended for lay audience.
45382887|NCT04398238|Combination Product|evaluation by transfusion medicine specialist|screening for anemia causes and treatment: iron/folate/vitamin B12 supplementation, Erythropoietin administration if indicated
46055963|NCT02749071|Device|EndoStim stimulation for first six months of study|Lower esophageal stimulation
46055964|NCT02749071|Device|EndoStim stimulation from Month 6 thru end of study|Lower esophageal stimulation
45382890|NCT04393389|Device|"AcoArt Orchid (0.035), AcoArt Tulip (0.018) and AcoArt Litos (0.014) percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd."|All comers Post Market Clinical Follow-up to continue the surveillance of the Acotec Drug Coated PTA Catheter AcoArt Orchid, AcoArt Tulip and AcoArt Litos in lower limb treatment
45382891|NCT04390763|Biological|NIS793|anti-TGFb antibody
45382892|NCT04390763|Biological|Spartalizumab|anti-PD-1 antibody
45382893|NCT04390763|Drug|gemcitabine|SOC chemotherapy
45498731|NCT03002610|Other|Infographics|Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
45498732|NCT03002610|Other|Scientific abstract|Scientific abstract the text written for the academic population and practitioners, with scientific abbreviations which enables experts to go into more detail about the topic.
45498733|NCT03665142|Other|Kinesio taping|Upper trapezius muscle stretching exercise with Kinesio taping (KT) was applied to the study group. KT was applied 8 times in total for 4 weeks with 2 sessions per week. Stretching exercise was done in the morning, afternoon and evening 3 times (repeated 10 times per set) every day for 4 weeks and 5 days of the week.
45498734|NCT03665142|Other|Exercise|Upper trapezius muscle stretching exercise was applied to the control group.
45694725|NCT01890707|Procedure|General Anesthesia|Administer: Fentanyl:1mcg/kg prior to induction, additional doses to maintain blood pressure and heart rate within 20% of preoperative values, Propofol:2mg/kg,succinylcholine, 0.5mg/kg,to be followed with Rocuronium if necessary,bolus: 0.4mg/kg, Sevoflurane and oxygen to be titrated to maintain BIS value of 40-60.
45498735|NCT03005106|Biological|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
45694726|NCT01890707|Procedure|Deep Sedation|IV administration of Propofol,initial rate 100ug/kg/min, titrated to maintain BIS 65-75,Fentanyl,Ketamine,1mcg/kg,0.5mg/kg,additional 10mg increments for analgesia/movement.
46055965|NCT02749071|Device|Sham EndoStim stimulation for first six months of study|"EndoStim device remains off (no stimulation delivered)"
45382894|NCT04390763|Drug|nab-paclitaxel|SOC chemotherapy
45382895|NCT04387318|Device|Multimodal training|"IMT will be performed using the POWERbreathe® Medic Plus inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. The IMT wil be performed two times per week for 8 weeks.~NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
45498736|NCT03005106|Procedure|Autograft|The current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original burn wound.
45498737|NCT03546894|Drug|Brigatinib|Brigatinib tablets.
45498738|NCT03546894|Drug|Alectinib|Alectinib capsules.
45498739|NCT03546894|Drug|Ceritinib|Ceritinib capsules.
45498740|NCT03546894|Drug|Lorlatinib|Lorlatinib capsules.
45498741|NCT03546894|Drug|Any FDA Approved ALK Inhibitors|FDA approved ALK inhibitors available for treatment.
45498742|NCT01004861|Drug|PLX3397|Capsules administered once or twice daily, continuous dosing
45498743|NCT03637361|Drug|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 5 mg, 20 mg, 60 mg, 100 mg, 150 mg or 200 mg REL-1017, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL
46055966|NCT02748915|Other|Electrophysiological and psychoacoustic tests|
46055967|NCT04218981|Drug|Antipsychotic drugs|Choose one of these antipsychotics (olanzapine, risperidone; amisulpride) for schizophrenia group
46055968|NCT04218981|Drug|Mood stabilizer|Choose lithium or valproate for bipolar disorder group
46055969|NCT04218981|Drug|Paroxetine|Patients with major depressive disorder are treated with paroxetine
46055970|NCT04218513|Drug|Compound Edaravone Injection|30 min intravenous infusion
45498744|NCT03637361|Drug|Placebo|
45498745|NCT03637673|Other|No intervention|No intervention
45382896|NCT04387318|Device|IMT + Pulmonary Rehabilitation|"IMT will be performed using the POWERbreathe® Medic Plus (POWERbreathe Medic Plus ®, SP, BR) inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. After that, load increases occurred as follows: 35% of MIP in week 3, 40% of MIP in week 4, 45% of MIP in week 5, 50% of MIP at week 6, 55% of MIP in week 7, and 60% of MIP in weeks 8.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
45382897|NCT04387318|Device|NMES + Pulmonary Rehabilitation|"NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
45382898|NCT04387318|Device|Pulmonary Rehabilitation|Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.
45382899|NCT04383158|Other|PRGF ENDORET® obtained from ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16)|ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16) is a system for obtaining plasma rich in growth factors (PRGF), which can be applied in the regeneration of bone and other connective tissues in oral surgery. PRGF is a completely autologous blood platelet concentrate that stimulates tissue regeneration due to enrichment with autologous growth factors, acting as a biological system.
45382900|NCT04382911|Drug|18F-fluoroestradiol|Patients will receive the FES tracer during a PET/MRI scan
45382901|NCT04376229|Other|Registry|Registry of cancer patients who receive proton radiation therapy
45382902|NCT04374812|Other|Exposure to registered nurses|Change in outcomes associated with a one hour per patient day increase in exposure to registered nurses
45382903|NCT04374812|Other|Exposure to nursing assistants|Change in outcomes associated with a one hour per patient day increase in exposure to nursing assistants
45382904|NCT04372238|Behavioral|RAPIDS Intervention|RAPIDS intervention combines a behavioral intervention along with hands-on training to use fentanyl test strips.
45382905|NCT04372238|Behavioral|Standard OEND|In the attention-matched control arm, participants will receive standardized overdose education and naloxone distribution (OEND) training, with attention-control visits at 1, 2, and 3 months. Participants will receive a naloxone kit after completion of the first session, and information regarding where to obtain additional naloxone at subsequent visits. They will have contact with study staff at month 6 and 12 follow-up visits to capture outcome and covariate data.
45382906|NCT04364386|Device|InPress Device|Treatment with InPress Device for Postpartum Hemorrhage
45426051|NCT01420874|Biological|EGFRBi armed ATC Infusions|Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion
45694727|NCT01900691|Device|Evolution® Esophageal Stent - Fully Covered|Placement of the Evolution® Esophageal Stent for benign or malignant strictures, fistulas, perforations or leaks with the intention of removal
45498746|NCT00038675|Drug|Imatinib Mesylate (Gleevec)|Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily
45498747|NCT02974907|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
45498748|NCT02974907|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
45498749|NCT03254459|Drug|Buprenorphine Sublingual Spray|0.5 mg Sublingual Spray
45694728|NCT01890473|Drug|Abatacept|
45694729|NCT01889069|Drug|Rituximab|Rituximab will be administered at a dose of 1400 mg SC once a month for at least 4 doses during the Induction period, and at a dose of 1400 mg SC once every two months for at least 6 doses during the Maintenance period.
45694730|NCT01889069|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per standard local practice as a part of standard chemotherapy regimen.
45498750|NCT03254459|Drug|Morphine|4 mg Intravenous Injection
45694731|NCT01889069|Drug|Vincristine|Vincristine will be administered as per standard local practice as a part of standard chemotherapy regimen.
45498751|NCT03254459|Drug|Oxycodone Hydrochloride|10 mg tablet
45694732|NCT01889069|Drug|Doxorubicin|Doxorubicin will be administered as per standard local practice as a part of standard chemotherapy regimen.
45694733|NCT01889069|Drug|Prednisone|Prednisone will be administered as per standard local practice as a part of standard chemotherapy regimen.
45694734|NCT01889069|Drug|Bendamustine|Bendamustine will be administered as per standard local practice as a part of standard chemotherapy regimen.
45715041|NCT04782258|Drug|Tolvaptan Suspension|Tolvaptan suspension will be administered orally or via feeding/nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age.
46055971|NCT04218513|Drug|Edaravone Injection|30 min intravenous infusion
46055972|NCT04218513|Drug|2-Aminoethanesulfonic Acid Injection|30 min intravenous infusion
46055973|NCT02748759|Device|CPM|15 repetitions of flexo-extensión with a commercially available CPM device (Kinetec Advanced Prima)
46055974|NCT02748759|Other|Manual mobilization|Manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist
46055975|NCT04218435|Drug|Sacubitril / Valsartan Oral Tablet|"Sacubitril/Valsartan is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.~Sacubitril/Valsartan is usually administered in conjunction with another heart failure therapies, in place of an ACE inhibitor or other ARB."
45426052|NCT01405521|Biological|Vaccine placebo (excipients only)|single oral dose,
45426053|NCT01405521|Biological|Ty21a|3 oral doses, alternate days
45715042|NCT04782258|Drug|Tolvaptan Tablets|Tolvaptan (OPC-41061) Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets.
45715043|NCT02653144|Drug|Ropivacaine|local anesthetics adjuvants. Ropivacaine 0.5% 20ml. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
46055976|NCT02748837|Drug|ERY974|
46055977|NCT02695485|Procedure|innervated sensate flap|sensory reconstruction via digital nerve repair with the donor nerve of the flap
46055978|NCT02748681|Device|Auto CPAP AirSense™ 10(Resmed)|AutoSet CPAP without telemedicine monitoring
46055979|NCT04158765|Other|DNeasy Tissue Kit (QIAGEN Inc., Mississauga, Ontario, Canada) and PCR- based assay (TRAPeze Telomerase Detection Kit; Millipore, Billerica, MA).|DNA will be extracted from sperm using the DNeasy Tissue Kit and Telomerase activity in samples will be measured using a PCR- based assay.
46055980|NCT04218669|Procedure|Roux-en-Y Hepaticojejunostomy|The common hepatic duct was cut and the duodenal side is closed by suture. The small intestine was cut off 15 cm below the ligament of Treitz. The distal end was lifted, and a 1-2 cm incision was made at the jejunal wall 4-5 cm from the jejunal stump. The anastomosis is used a 5-0 PSD Ⅱ suture, with double needles, inside-out in the jejunum and outside-in in the hepatic duct. One side of needles was used to continuely penetrate and suture the whole layer of the posterior-lateral wall of the jejunum, the posterior-lateral wall of the biliary duct, and the other side of needles was used to continuely stuere the anterior part of the anastomosis. Mucosa-to-mucosa contact should be ensured with every stitch.The anastomotic stomas were then checked for leakage. Enteric-enteric anastomosis was performed 60 cm below the site of the hepatojejunal anastomosis.
45426054|NCT01405521|Biological|M10ZH09 vaccine|single oral dose
46055981|NCT04218669|Procedure|T-tube drainage|The T-tube was placed for biliary drainage and the common bile duct was intermittently sutured with 4-0 vicryl sutures.
46055982|NCT04452045|Device|SweetDreams|SweetDreams is a mHealth adaptation of existing evidence-based sleep interventions. It is a user friendly and developmentally appropriate modularized 4-week web-based intervention available on computer, tablet or mobile phones.
46055983|NCT04138875|Drug|Rituximab|Rituximab is dosed at 375mg/m2 as an intravenous infusion. No adjustments are necessary for hepatic or renal impairment. Dosing will be done on baseline weight and height, however in patients who experience a >10% change in weight dosing will be readjusted.
46055984|NCT04138875|Drug|Brentuximab Vedotin|Brentuximab vedotin is to be given as intravenous infusion at a dose of 1.2mg/kg during induction and 1.8mg/kg with each cycle. Dose reductions to 1.2mg/kg are allowed at investigator discretion.
46055985|NCT04138875|Drug|Bendamustine|Bendamustine is to be given intravenously at a dose of 90mg/m2 on day 1 and day 2 of each high risk cycle. Dose reductions to 60mg/m2 are allowed at investigator discretion.
45382907|NCT04362618|Other|Muscle Strengthening Training|Muscle strengthening training will take place for a period of 12 weeks, in which participants will have 36 exercise sessions (18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. Muscles of the leg (i.e. quadriceps, hip ab- and adductors) will be trained at 3 set of 10 repetitions at 80% of 1RM with the use of elastic bands. 1RM will be assessed at baseline and the exercise intensity will be progressively increased by 10% of 1RM every two sessions from 50 up to 70-80 % of 1RM. Every 6 sessions, the 1RM will be reassessed and the training resistances will be adapted.
45382908|NCT04362618|Behavioral|Behavioral graded activity|Subjects will receive a behavioural treatment integrated within the concepts of operant conditioning with exercise therapy for a period of 12 weeks, in which the subjects will have maximum 36 BGA sessions (min. 13- max. 18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. The purpose of BGA is to increase the level of activities in a time-contingent manner and increase the level of physical activity in the subject's daily lives. BGA consists of 3 phases: pain education (phase 1), treatment phase in which subjects increase their level of activity gradually (phase 2) and integration of learned principles in daily live (phase 3).
45382909|NCT04360564|Other|Recurrent pregnancy loss|As described before.
45382910|NCT04336527|Behavioral|Home Treatment with Peer Support|After allocation participants receive a combination of Home Treatment by a multiprofessional team and Peer Support.
45382911|NCT04336527|Behavioral|Home Treatment without Peer Support|After allocation participants receive professional-led Home Treatment by a multiprofessional team without Peer Support (treatment as usual).
45382912|NCT04328337|Drug|Intralipid, 20% Intravenous Emulsion|Infusion of Intralipid 20%
45382913|NCT04328337|Drug|Placebos|saline 30 ml/hr for 12 hours through an IV
45382914|NCT04327609|Device|SELUTION SLR™ DEB|Subjects will receive standard high-pressure balloon angioplasty followed by local application of sirolimus with the SELUTION SLR™ 018 DEB (MedAlliance) of appropriate diameter and length to achieve full lesion coverage.
45498752|NCT03254459|Drug|Zofran|4 mg oral disintegrating tablet (ODT) or IV injection given at the investigator's discretion for nausea
45498753|NCT03620591|Drug|Lidocaine|Intraoperative administration of lidocaine
45498754|NCT03620591|Drug|Placebo|Intraoperative administration of normal saline
45498755|NCT04374305|Drug|Brigatinib|Oral daily per predetermined dosage per protocol.
45498756|NCT04374305|Drug|Neratinib|Oral daily per predetermined dosage per protocol.
45498757|NCT03637283|Procedure|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
45382915|NCT04327609|Device|Control Arm|The control arm will receive standard high-pressure balloon angioplasty of appropriate diameter and length and no further lesion treatment.
45498758|NCT03637283|Procedure|fan-shaped photocoagulation|vitreoretinal surgery combined with intraoperative fan-shaped photocoagulation
45498759|NCT04363463|Other|prone position|Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.
45498760|NCT05178953|Drug|Zinc Sulfate 220 mg Capsules|Zinc is an element that is involved in the activity of antioxidant enzymes. For example, the superoxide dismutase needs copper and zinc to function properly. Infertile men with asthenospermia receive 220 mg zinc sulfate tablets for 3 months
45694735|NCT02533180|Biological|Immunosuppression withdrawal|"Participants will initiate calcineurin inhibitor (CNI) withdrawal after at least 3 weeks of stable liver function, as documented by liver function tests (direct bilirubin, alanine aminotransferase and gamma-glutamyl transferase) separated by at least 1 week in the 3 week period prior to withdrawal.~CNI withdrawal will occur in eight 3 week intervals with each subsequent reduction based on liver function tests over the prior 3 week interval.~Participants on CNI and prednisone will undergo withdrawal from the two therapies concurrently.~If participants are weaned off the CNI successfully, they will initiate non-CNI withdrawal. The non-CNI withdrawal includes two dose reductions of approximately 50% over a 6 week period each, after which the drug will be discontinued."
45498761|NCT05178953|Drug|Pentoxifylline|Oral use of pentoxifylline is effective in treating cardiovascular disease, cerebrovascular disease, and other conditions associated with local circulatory disorders. Pentoxifylline affects blood viscosity. Infertile men with asthenospermia receive 400 mg pentoxifylline tablets for 3 months
45498762|NCT02736617|Drug|Ibrutinib|Given PO
45498763|NCT02736617|Biological|Obinutuzumab|Given IV
45498764|NCT05178719|Device|PMA-zeolite|given for a total period of 4 years
45498765|NCT03637907|Other|Not applicable - no intervention.|No intervention is performed, just a CT with a new detector and comparison with the same patients older image.
45498766|NCT05572619|Device|1st Reading|The medical team visually checks the non-contrast CT without cELVO and diagnose the large vessel occlusion.
45498767|NCT05572619|Device|2nd Reading|The medical team visually checks the non-contrast CT with assistance from the cELVO and diagnose the large vessel occlusion.
45498768|NCT04670393|Dietary Supplement|FertyBiotic Woman Plus|4g Myo-Inositol, 421 mg D-Chiro-Inositol, 400 mcg folic acid, 55 mcg selenium, 15 mcg vitamin D, 1,8 mg melatonin,2x109 Lactobacillus rhamnosus, 2x109 Lactobacillus crispatus and 2x109 Lactobacillus plantarum
45498769|NCT04670393|Other|Placebo|400 mcg folic acid
45498770|NCT05178251|Procedure|appendectomy|appendectomy for acute appendicitis
45382916|NCT04327284|Device|Immediate placement non-occlusal loading molar implant (Straumann BLX 6.5mm)|"At the screening visit, potential subjects will be informed about the protocol and all questions related to the study will be answered. Medical and dental histories will be reviewed and physical evaluations will be performed in order to rule out local or systemic factors that would compromise the outcome of the study. A detailed extra and intra oral examination will be performed. Appropriate radiographic imaging studies will be obtained prior to the surgical visit (per the protocol of the University of Kentucky, College of Dentistry) including CBCT and intraoral scans for treatment planning implant through Straumann Guided Surgery workflow.~The duration of the present study is 1 year including the baseline or surgical visit, 2-weeks postoperative visit, 12-weeks baseline for control group and postoperative evaluations at 3, and 12 months."
45382917|NCT04327284|Device|Delayed placement non-occlusal loading molar implant (Straumann BLX 5.0mm)|"At the screening visit, potential subjects will be informed about the protocol and all questions related to the study will be answered. Medical and dental histories will be reviewed and physical evaluations will be performed in order to rule out local or systemic factors that would compromise the outcome of the study. A detailed extra and intra oral examination will be performed. Appropriate radiographic imaging studies will be obtained prior to the surgical visit (per the protocol of the University of Kentucky, College of Dentistry) including CBCT and intraoral scans for treatment planning implant through Straumann Guided Surgery workflow.~The duration of the present study is 1 year including the baseline or surgical visit, 2-weeks postoperative visit, 12-weeks baseline for control group and postoperative evaluations at 3, and 12 months."
45382918|NCT04327115|Procedure|"Control strategy"|"Patients included in the control group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams."
45382919|NCT04327115|Procedure|"Intervention strategy"|"Patients included in the intervention group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams.~They will also get a physical activity program realized with a nurse or a nursing assistant, twice a day (morning and evening) for 5 days. The intervention consists of physical support with mimed instructions, the nature of which depends on the falling risk of the participant :~High falling risk : out of bed exercise (on a chair for at least 30 min)~Mild falling risk : out of bed exercise + in front of chair (The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes, on both feet or one foot)~Low falling risk : out of bed exercise + in front of chair + FTSS exercise (The participant performs a transfer activity of sitting to standing repeated 5 times, with physical assistance or not)"
45382920|NCT04319627|Drug|Rosuvastatin Calcium|Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
45382921|NCT04319627|Drug|Placebo Oral Tablet|Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
45382922|NCT04313400|Drug|1.1% w/w AMTX-100 CF3|AMTX-100 CF3, topical cream with 1.1% w/w active pharmaceutical ingredient
45382923|NCT04313400|Drug|Placebo|Topical cream manufactured to mimic AMTX-100 CF3
45382924|NCT04308395|Drug|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
45382925|NCT04307576|Drug|Omitted Doxorubicin|Omission of IV Doxorubicin
45382926|NCT04307576|Drug|Omitted Vincristine+Dexamethasone pulses|Omission of Vincristine+Dexamethasone pulses
45382927|NCT04307576|Drug|Inotuzumab Ozogamicin+Standard Maintenance Therapy|Addition of IV Inotuzumab ozogamicin before Maintenance Therapy
45382928|NCT04307576|Drug|Imatinib|p.o. Imatinib
45382929|NCT04307576|Drug|6-tioguanine+Standard Maintenance Therapy|Addition of p.o. 6-tioguanine to Standard Maintenance Therapy
45382930|NCT04307576|Drug|Blinatumomab|IV Blinatumomab
45694736|NCT04381780|Dietary Supplement|Recovery Factors|A unique porcine serum based polypeptide nutritional support
45694737|NCT03218332|Diagnostic Test|Biomarkers for detecting possible CTE invivo|Detection biomarkers for possible CTE: Imaging/blood/CSF/PET-tau/MRI/europsychological assessment
45694738|NCT03218098|Procedure|Lobectomy via UVATS|lobectomy with small skin access 4 cm
45694739|NCT03218020|Other|No intervention assigned, this is an observational study.|No intervention assigned, this is an observational study.
45694740|NCT00898222|Drug|aspirin|81 mg orally daily for two weeks
45694741|NCT01830556|Drug|Cetuximab|Group A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h Group B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
45694742|NCT03214354|Drug|Alemtuzumab|Alemtuzumab, Day -7 to -3. Dose: 0.2mg/kg/dose SC once daily x 5 days
45848025|NCT05406804|Behavioral|Olfactory stimulation|1) For the premature infants who use non-invasive ventilation, place a single layer of gauze soaked in breast milk on the air outlet of the non-invasive ventilator. When inhaling oxygen with a high-flow nasal cannula, the same measure is performed, and the breast milk and sterile gauze soaked in breast milk are replaced every 4 hours. 2) For the premature infants who withdrawn from assisted ventilation, place the breast pad near the infants' nose, and replace the breast milk pad every 4 hours. Acquisition of breast milk pads: use the same brand of breast milk pads; put the breast milk pads used between 00:00 and 07:00 every day (use time > 2 hours) into the same brand of milk storage bags, and use two left and right at the same time. 3) If the premature infants don't have any ventilation support, the breast milk stimulation method is the same as 2). This intervention will continue until premature infants discharge from hospital.
45848026|NCT05406804|Behavioral|Routine nursing care|Nursing is performed according to existing nursing practices. Nasal feeding is generally used.
45848027|NCT05406648|Other|Morus nigra concentrate|The experimental group was given 20 grams of black mulberry (morus nigra) concentrate per day for 12 weeks.
45848028|NCT05406492|Other|Residual blood|Residual blood samples(1~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).
45848029|NCT05406336|Other|Predicted uncontrolled BP status (yes/no) at follow up visit, derived using a machine learning algorithm|The investigators have created a machine learning algorithm to predict uncontrolled blood pressure (BP) status (yes/no) at a follow up visit among adults with uncontrolled BP at their current visit. The investigators will determine whether adding this information to a vignette describing a patient will increase the likelihood that a clinician will intensify antihypertensive medication treatment.
45848030|NCT05406180|Biological|VaxigripTetra inj.|Suspension for injection in a pre-filled syringe Injection intramuscular
45694743|NCT03214354|Radiation|Total Body Irradiation|TBI 300 cGy on Day -2
45694744|NCT03214354|Drug|Sirolimus|Sirolimus is used for GVHD prophylaxis
45694745|NCT03217630|Other|Fasting 2 h after clear liquid or 6h after a light meal|The fasting time for all patients is 2 h after clear liquid or 6h after a light meal, then gastric ultrasound examination is performed.
45694746|NCT03217942|Drug|NGF|Intramuscular injection
45694747|NCT03217552|Diagnostic Test|Mologic Biomarker Panel|In brief the proposed biomarkers will be measured in the laboratory of Mologic . These will initially be performed using standard lab assays (Enzyme Linked Immunosorbent Assays, ELISA). Biomarkers that show promise will then be mounted on a novel lateral flow device (under development), that could ultimately be deployed at the patients bedside.
45694748|NCT00903448|Drug|Prilosec OTC (omeprazole-magnesium)|Prilosec OTC (omeprazole-magnesium 20.6 mg) tablet to be taken with a glass of water prior to breakfast
45848031|NCT05406024|Device|Digital platform|The digital platform consists of 84 exercise sessions of progressive intensity. Each day, the tool offers 8 exercise sessions of about 5 to 10 minutes each, spaced out over an hour. One session can represent several exercises. The patient is asked to perform them daily.
46055986|NCT04124445|Procedure|Pulsed Radiofrequency Ablation|"Radiofrequency ablation, also called rhizotomy, is a nonsurgical, minimally invasive procedure that uses heat to reduce or stop the transmission of pain. Radiofrequency waves ablate, or burn, the nerve that is causing the pain, essentially eliminating the transmission of pain signals to the brain."
46055987|NCT04216641|Dietary Supplement|Adapted food intervention|Adapted food intervention
46055988|NCT04218747|Behavioral|VA 365 Demonstration Benefits|Reducing hunger 365 days a year in households with school children by transforming schools into food hubs ( free breakfast, lunch, supper, and food backpacks for the weekend) and providing nutrition education to parents.
46055989|NCT02748447|Device|Automated FiO2 adjustment|AVEA ventilator according to SpO2 target range delivers an automated FiO2
45694749|NCT00903448|Drug|Prevacid|Prevacid (15 mg lansoprazole) capsule to be taken with a glass of water prior to breakfast
45715044|NCT02653144|Drug|Dexmedetomidine|local anesthetics adjuvants. 75mcg of dexmedetomidine. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
46055990|NCT02748135|Drug|TB-403 20mg/kg|bi-weekly intravenous doses of TB-403 20mg/kg
46055991|NCT02748135|Drug|TB-403 50mg/kg|bi-weekly intravenous doses of TB-403 50mg/kg
46055992|NCT02748135|Drug|TB-403 100mg/kg|bi-weekly intravenous doses of TB-403 100mg/kg
46055993|NCT02748135|Drug|TB-403 175mg/kg|bi-weekly intravenous doses of TB-403 175mg/kg
46055994|NCT02747979|Other|hemodialysis only|hemodialysis treatment only
46055995|NCT02747979|Other|hemodialysis plus hemoperfusion(HA330)|combination of hemodialysis and hemoperfusion (HA330) treatment
46055996|NCT02747979|Other|hemodialysis plus hemoperfusion(HA130)|combination of hemodialysis and hemoperfusion (HA130) treatment
45498773|NCT03251963|Drug|Fixed Dose Enoxaparin|Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
45498774|NCT03251963|Drug|Variable Dose Enoxaparin|Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
45498775|NCT03287219|Drug|Methylene Blue MMX 25 mg modified release tablets|Methylene Blue MMX 25 mg modified release tablets administered with a full dose regimen of a 4-L PEG-based bowel cleansing preparation.
45382931|NCT04305613|Other|Chemoradiation|Patients will be treated with definitive concurrent chemoradiation with curative intent as determined by their medical and radiation oncologists. We will consider timing of initiation and discontinuation, type, and cumulative dose of platinum based chemotherapy. We will also consider dose, duration, and type of immunotherapy. Radiation therapy will be delivered via proton or proton therapy. Our primary radiation therapy dose-volume exposures are whole heart volumetric dose. As secondary exposures, we will comprehensively define radiation therapy dose parameters to the right ventricle, entire left ventricle, left ventricle segments, coronary arteries, and mean heart dose.
45382932|NCT04305496|Drug|Fulvestrant|Patients will be administered 500 mg (2 injections) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
45382933|NCT04305496|Drug|Capivasertib|400 mg BD (2 tablets of 200 mg taken twice a day = total daily dose 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
45382934|NCT04305496|Drug|Placebo|Placebo to match 400 mg BD (2 tablets of placebo to match 200 mg taken twice daily = placebo to match total daily dose of 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
45382935|NCT04302025|Drug|Alectinib|Participants will receive oral alectinib twice per day (BID)
45382936|NCT04302025|Drug|Entrectinib|Participants will receive oral entrectinib daily
45498776|NCT03286751|Drug|LY900014|Administered SC
45498777|NCT03286751|Drug|Insulin Lispro|Administered SC
45498778|NCT05572229|Drug|Teclistamab|1500 microgr/kg QW for 2 months, 3000 microgr/kg Q2W thereafter
45498779|NCT05572229|Drug|Daratumumab|1800 mg SC, QW for 8 weeks, Q2W for 16 weeks, Q4W thereafter
45498780|NCT05572229|Drug|Lenalidomide|25 mg per day 21/28
45498781|NCT03249935|Drug|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
45498782|NCT05572151|Procedure|lymph node number|Lymph nodes were harvested during surgical resection of rectal cancer
45382937|NCT04302025|Drug|Vemurafenib|Participants will receive oral vemurafenib BID
45382938|NCT04302025|Drug|Cobimetinib|Participants will receive oral cobimetinib daily
45382939|NCT04302025|Drug|Pralsetinib|Participants will receive oral pralsetinib daily
45498783|NCT03622073|Other|Misoprostol treatment by Midwife|Medical management of incomplete abortion
45498784|NCT03622073|Other|Misoprostol treatment by Doctor|Medical management of incomplete abortion
45694750|NCT01830634|Behavioral|Theraband with strengthening and stretching exercise|"Using the theraband for strengthening and stretching the upper and lower extremity muscles.~All exercises were performed by using a Theraband in the following movements: shoulder elevating and abducting, horizontal and oblique direction, plantar flexion, dorsi-flexion, inversion and eversion of ankle, knee extension and hip abduction. The stretching exercises were focused on the hamstring muscle and heel cord. Each movement was held for 5 seconds. The participants were instructed to perform 5-10 repetitions of each movements twice per day."
45382940|NCT04302025|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion
45498785|NCT03637205|Procedure|ECLS insertion|After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned. ECLS insertion should be performed preferably before revascularization
45498786|NCT03637205|Other|Revascularisation and optimal medical treatment|After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned.
45498787|NCT03285113|Device|GiMer Medical MN 1000 External Stimulator|Trial stimulator to generate pulsed ultrahigh frequency (>200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
45498788|NCT03000348|Drug|Cysteamine|Oral Cysteamine Capsule
45498789|NCT03000348|Drug|Placebo Oral Capsule|Placebo Oral Capsule
45694751|NCT00895180|Biological|olaratumab|Given IV
45694752|NCT00895180|Biological|ramucirumab|Given IV
46055997|NCT02695563|Drug|Lactoferrin|
46055998|NCT04218045|Procedure|Laparoscopic single anastomosis sleeve ileal bypass|a simple loop gastro-ileal bypass is added to the sleeve procedure.
46055999|NCT04218045|Procedure|Laparoscopic sleeve gastrectomy|Conventional sleeve gastrectomy using endoscopic stapler
46056000|NCT03838965|Device|biobeat sensor|biobeat sensor is a noninvasive sensor of the the hymodynamic measures during the childbirth and after 24 hours.
45382941|NCT04302025|Drug|SBRT|Patients will receive SBRT given concurrently starting with the first dose of atezolizumab
45382942|NCT04302025|Procedure|Resection|Participants will receive surgical resection of the primary tumor along with selected lymph nodes
45382943|NCT04302025|Drug|Chemotherapy|Participants will receive standard of care (SOC) chemotherapy as determined by the treating physician
45498790|NCT03283709|Device|Full-contour monolithic zirconia abutment crowns|Subjects with RPD abutment teeth that require surveyed crowns will have them fabricated from monolithic multi-layered zirconia
45498791|NCT03283709|Device|Conventional abutment crowns|Subjects with RPD abutment teeth that require surveyed crowns will have them fabricated from noble or high noble metals, veneered with feldspathic porcelain
45382944|NCT04302025|Drug|Divarasib|Participants in the KRAS G12C cohort will receive GDC-6036 for approximately 8 weeks until the day before surgery.
45382945|NCT04301934|Device|Mona Lisa Touch|Fractional CO2 LASER
45382946|NCT04301934|Drug|Conjugated estrogen|Current standard treatment for recurrent UTIs in postmenopausal women
45382947|NCT04301934|Drug|Estradiol|Current standard treatment for recurrent UTIs in postmenopausal women
45498792|NCT03664986|Drug|Liposomal Bupivacaine|The objective of our study is to compare the use of EXPAREL in minimizing post-operative pain after sacrospinous ligament fixation with or without concomitant procedures for pelvic organ prolapse, with or without suburethral sling. We hypothesize that pudendal nerve blockage using long-acting EXPAREL will reduce post-operative pain and potentially reduce oral narcotic consumption. It may also reduce the incidence of postoperative constipation and patient satisfaction.
45554601|NCT03996525|Device|Electrical Stimulation|"Two-Stage Facial Reanimation (Standard Practice) with electrical stimulation for one hour at 20Hz (Experimental Procedure).~Cross-Facial Nerve Graft (CFNG) immediately followed by electrical nerve stimulation proximal to the coaptation site on the donor facial nerve.~Nine-to-Twelve Months later, Free Muscle Transfer (FMT) followed by electrical nerve stimulation proximal to the coaptation site in the intraoral incision."
45694753|NCT03214042|Device|K-rod dynamic stabilization system|Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years. K-rod dynamic stabilization system was purchased from Biotech, USA, consisting of titanium alloy pedicle screw, titanium alloy line and polyether ether ketone (PEEK) shell between pedicle screw heads.
46056001|NCT03742089|Device|Bone Anchored Hearing Surgery|This is a observational study of pediatric patients undergoing bone anchored hearing surgery. The collected will be used to assess the implant stability development of the Ponto BHX implant during up to 24 months after implantation in a pediatric population undergoing BAHS. The study will also monitor the Ponto BHX implant safety and survival throughout the study period.
46059054|NCT02583685|Drug|PR4 + LDV/SOF + SMV 4 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
45382954|NCT04294199|Other|Early Range of MOtion|Groups will be compared to see if immobilization or early range of motion is better at returning to their sport after patellar dislocation.
45382955|NCT04287192|Other|Digital Bridge:Tool Intervention|Our Digital Bridge is an integration of the Care Connector and ePRO technologies that will support care transitions by: 1) inviting PCPs to access Care Connector while the patient is in hospital, allowing for asynchronous communication via the messaging feature for proactive discharge planning, 2) facilitating the inclusion of inter-professional recommendations in the discharge module (e.g. diet and mobility) typically missing from traditional physician generated discharge summaries, 3) electronic generation of PODS for use in patient-centred discharge teaching, 4) providing patients electronic access to PODS post discharge to facilitate use of information at home, 5) adoption of digital enabled goal-oriented process to engage patients and families in discharge process, and 6) providing ongoing self-management support for patients using ePRO for the vulnerable period 6 months post discharge.
45382956|NCT04281017|Drug|TIVA|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg)
45382957|NCT04281017|Drug|Balanced anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg
45382958|NCT04280003|Other|Alogenic adipose tissue-derived stem cells|Concentration of the cells: 10 million cells / ml
45382959|NCT04280003|Drug|Placebo solution|Placebo intravenous solution, same appearance stem cells solution
45382960|NCT04277546|Drug|Brazikumab Maintenance Dose|Completers in the lead-in study D5272C00001 (Legacy #3151-201-008) will receive a maintenance dose of brazikumab administered subcutaneously every 4 weeks up to Week 52 (Group A). The SC dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered.
45426059|NCT01314118|Drug|abiraterone acetate in combination with prednisone|Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
45426060|NCT01278914|Biological|Dendritic Cells (DC) prostate|
45498793|NCT03492918|Drug|Pembrolizumab|"Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart. Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.~All trial treatments will be administered on an outpatient basis. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min)."
45694754|NCT01830712|Drug|eptacog alfa (activated)|A review of retrospectively longitudinal data gathered in the routine follow-up from a subset of patients who underwent EOS in studies F7HAEM/USA/3/USA and F7HAEM/USA/4/USA (NCT01561391). Data will be compiled, analysed, and reported in aggregate form.
45694755|NCT01830868|Drug|Zonisamide tablets|The recommended initial daily dose is 50 mg in two divided doses. After one week the dose may be increased to 100 mg daily and thereafter the dose may be increased at weekly intervals, in increments of up to 100 mg. Doses of 300 mg to 500 mg per day have been shown to be effective, though some patients, especially those not taking CYP3A4 (cytochrome P450)-inducing agents, may respond to lower doses.
45382961|NCT04277546|Drug|Brazikumab Induction Dose|Participants in the lead-in study D5272C00001 (Legacy #3151-201-008) who have not responded to treatment and have met criteria for rescue treatment are considered inadequate/non-responders (Group B). In these eligible participants, IV induction dosing of brazikumab at Week 0, Week 4, and Week 8 will be administered, followed by brazikumab administered subcutaneously every 4 weeks thereafter (up to Week 52).
45382962|NCT04275791|Other|Triage|Experimental : Trauma patient orientation in a structured regional health organization, composed of trauma centers hierarchized in several levels according to their capacity to receive severe traumatized persons.
46056002|NCT04440033|Other|Baseline assessment of demographic, anthropometric and clinical characteristics|"Age~Sex~Height~Body weight~Handedness~Medication use~Blood pressure~Global cognition (Montreal Cognitive Assessment)~Fear of falling (Shortened Iconographical Falls Efficacy Scale)~History of falls (number of falls in the past month)~Time since diagnosis and symptom onset~Disease severity (UPDRS part III, Hoehn and Yahr)~Non-motor symptoms (UPDRS part I)~Motor symptoms (UPDRS part III)~Motor complications (UPDRS part IV)~Disease-dominant side (UPDRS part III)~Freezing of gait (New Freezing of Gait Questionnaire)"
45694756|NCT03213964|Biological|FATE-NK100|"FATE-NK100 Infusion (Day 0)~The FATE-NK100 product will be placed in approximately 100 cc of 5% human serum albumin.~Dose Level 1: 1 x 10^7 cells/kg IP~Dose Level 2: >1x10^7 cells/kg to ≤3x10^7 cells/kg~Dose Level 3: Complete FATE-NK100 bag (≥3 x 10^7 to ≤ 10 x 10^7 cells/kg)"
45382969|NCT04267185|Behavioral|Physical Activity Together for PwMS and their CGs (PAT-MS)|A dyadic physical activity intervention approach for PwMS and their family CGs affected by moderate-to-severe MS disability.
45382970|NCT04265768|Procedure|Soft tissue augmentation surgery with CTG|"An epithelial-connective tissue graft of approximately 2-3 mm of thickness and adequate length will be taken from the palate or retromolar region of the patient and de-epithelialized with a scalpel (ideally a thickness of 1.5-2.0mm).~The connective tissue graft (CTG) obtained will then be positioned buccally to the dental implant and sutured to the internal side of the flap so to provide soft tissue bulk at the level of the neck of the implant and simulate a root prominence for the missing tooth."
45382971|NCT04265768|Procedure|Soft tissue augmentation surgery with Fibro-Gide|Fibro-Gide will be used to obtain buccal soft tissue augmentation. Fibro-Gide will be trimmed with a scalpel and adjusted in size and thickness to better adapt to the area buccal to the implant. In particular, the graft will be shaped in order to obtain a graft of approximately 2-3 mm of thickness and adequate length. Fibro-Gide will then be sutured to the inner side of the buccal flap, before repositioning the flap and suturing it in a tension-free way.
45382972|NCT04265768|Procedure|No soft tissue augmentation|During implant placement surgery, no soft tissue augmentation will be performed
45382973|NCT04261439|Drug|NIZ985|NIZ985 injection
45382974|NCT04261439|Drug|Spartalizumab|Spartalizumab infusion
45382975|NCT04261439|Drug|Tislelizumab|Tislelizumab infusion
45694757|NCT03213964|Drug|Interleukin-2|"Interleukin-2 (begin Day 0): 6 million units three times a week for a total of 6 doses. For patients weighing less than 45 kilograms, the IL-2 will be given at 3 million units/m2 three times a week for 6 doses.~The 1st dose will be given immediately (within 30 minutes) after the FATE-NK100 cell infusion on Day 0 as an inpatient. The remaining doses will be given in an outpatient setting."
45715045|NCT02653144|Drug|Dexamethasone|local anesthetics adjuvants. 4mg dexamethasone. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
45382976|NCT04261036|Drug|Ascorbic Acid 1000 mg|1000 mg ascorbic acid (Vitamin C) for 14 days post-op after an elective gynecological surgery.
45382977|NCT04261036|Other|Placebo|Placebo pills for 14 days post-op after an elective gynecological surgery.
45498794|NCT03247673|Drug|CT-P16|CT-P16 is a biosimilar product for Avastin
45715046|NCT00118365|Other|placebo|Given orally
45382978|NCT04256707|Drug|Selinexor 100 mg|"100-mg 2 formulations:~5 × 20-mg tablets (Tablet A)~1 × 100-mg tablet (Tablet B)"
45382979|NCT04256707|Drug|Docetaxel|75 mg/m^2 IV
45382980|NCT04256707|Drug|Pembrolizumab|200 mg IV
45382981|NCT04256707|Drug|FOLFIRI|"FOLFIRI:~Irinotecan 180 mg/m^2~Leucovorin 400 mg/m^2~5-FU 400 mg/m^2 bolus~5-FU 2400 mg/m^2 IV"
45694758|NCT03214276|Dietary Supplement|Vinitrox polyphenols|Vinitrox™ (Nexira - France) is a combination of specific profile polyphenols from grape and apple. The main polyphenol classes are proanthocyanidins (as catechins, B2 dimer), phenolic acids (as chlorogenic acids, gallic acids) and anthocyanins (as malvidin-3-glucoside). It was administrated the night and the morning before the endurance test (oral administration)
45694759|NCT03214276|Dietary Supplement|Placebo|Made with maltodextrin. It was administrated the night and the morning before the endurance test (oral administration).
45382982|NCT04256707|Drug|Selinexor 40 mg|- 2 × 20-mg tablets (Tablet A)
45848032|NCT05405946|Behavioral|Computerized Cognitive Remediation Therapy|"Sessions of 45 minutes will be developed 2 times a week, for 4-5 months (performing a total of 40 sessions). The sessions will be led by an experienced clinician with psychotic patients, and trained for the management of CCRT. Each intervention session will be individualized according to the results of the evaluation tests and the computerized program itself will adapt the difficulty of the tasks according to the performance of each patient.~The cognitive remediation NeuroPersonalTrainer platform includes two rehabilitation modules: the cognition module that includes attention, memory and executive functions with different levels of complexity and the Social Cognition module which allows working on different aspects of emotional processing, theory of mind and cognitive biases through 43 tasks based on multiple multimedia materials."
45848033|NCT05405946|Other|Treatment as Usual|Patients receiving TAU include psychoeducation about the disorder, psychiatric visits, and follow-up and review of drug treatment. In addition, they make individual visits with psychology, nursing and / or social work. In all cases, patients are treated in outpatient clinics.
45848034|NCT05405712|Behavioral|Mobile Phone App|App-based peer support program, used in conjunction with standard outpatient treatment
45848035|NCT05405478|Drug|Omalizumab|subcutaneous injection every 2 or 4 weeks, depending on the pretreatment serum total IgE level and body weight
45848036|NCT05405478|Diagnostic Test|SNOT22 score|score will measure at screening; on day 1; and at weeks 4, 8, 16, and 24 (point range, 0-110)
45848037|NCT05402514|Behavioral|Digitally delivered exercise and education treatment Joint Academy|The Joint Academy® (www.jointacademy.com) program for people with subacromial shoulder pain consist of two daily distributed and progressively adaptable exercises there are delivered through the app as videos with subtitles. Patient education is provided 2-3 times per week as short lessons in the app with a quiz following the text to ensure that the information is properly understood by the patients. An individual physical therapist is assigned to each patient with compulsory telephone or video consultations at the start of the treatment, at 6 weeks and at 3 months. An asynchronous chat function with the physical therapist is available during the treatment period as well as a peer support chat.
46056003|NCT04440033|Other|Baseline assessment of demographic, anthropometric and clinical characteristics|"Age~Sex~Height~Body weight~Handedness~Medication use~Blood pressure~Global cognition (Montreal Cognitive Assessment)~Fear of falling (Shortened Iconographical Falls Efficacy Scale)~History of falls (number of falls in the past month)"
45694760|NCT03213808|Other|No intervention: analysis of health data from patients with|No intervention: analysis of health data from patients with respiratory allergies (asthma, rhinitis), skin allergies (dermatitis, urticarial, angioedema), anaphylaxis, gastrointestinal allergic conditions and ocular allergies (conjunctivitis) for the validation of the chapter allergies and hypersensitivity in the future version of the WHO CIM
46059055|NCT02583685|Drug|PR4 + LDV/SOF + ASV 6 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
45382983|NCT04256707|Drug|Selinexor 80 mg|- 4 × 20-mg tablets (Tablet A)
45382984|NCT04256707|Drug|Selinexor 60 mg|- 3× 20-mg tablets (Tablet A)
45382985|NCT04255745|Behavioral|progressive resistance training|Individual, tailored, progressive muscle strength and function intervention
45382986|NCT04255407|Device|I-ONE® therapy|I-ONE® therapy will be used in patients with bone bruise on the knee after anterior cruciate ligament (ACL) injury 15 days before and 60 days after ACL reconstruction surgery for 4 hours a day compared to a control group (no-treatment).
45382987|NCT04255407|Drug|Anti-inflammatory drug|Pain before and after ACL reconstruction will be managed with common anti-inflammatory drugs (Paracetamol)
45694761|NCT03217474|Procedure|FLDEB|The eye will be anesthetized, and femtosecond laser technology will be used to remove epithelial tissue (diameter: 8mm; depth: 100micron) that includes the loosened diseased corneal epithelial cells. Antibiotic ointments and drops will be instilled postoperatively.
45382988|NCT04254861|Procedure|Simplified Papilla Preservation Flap (SPPF) and PRGF ENDORET (PRGF ENDORET®-KMU16)|"A simplified papilla preservation flap (SPPF) will be performed. The clot phase of PRGF ENDORET (F2) will be placed in the defect, while the fibrin membrane phase (F1) will cover it.~Blood will be extracted and collected in dedicated tubes and then centrifuged. Up to 8 tubes of 9ml will be extracted. The time from the start of the extraction to the start of the centrifugation of the tubes must not exceed 4mins.~After centrifugation, the blood is separated into three components: Plasma rich in growth factors, White cells or leukocytes, red blood cells: this is the red column occupying the bottom of the tube.~Following BTI's instructions, fractioning of the centrifuged blood will be performed in order to separate Fraction 2 (F2), which contains a greater number of platelets and growth factors and will be used as a clot inside the periodontal defect from Fraction 1 (F1), which will be used as a fibrin member to cover the clot. The flaps will be repositioned and sutured."
45426061|NCT01246947|Procedure|Tricuspid valve repair|Randomized to receive Tricuspid valve repair using a rigid 3-dimensional annuloplasty ring using standard techniques, during Mitral surgery.
45848038|NCT05333952|Procedure|Pulmonary vein isolation|The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
45848039|NCT05333952|Procedure|Substrate ablation(PRISM based)|Substrate modification will be guided by waveform periodicity analysis. The User Defined Map of waveform periodicity analysis will be also created by CARTO 3 system (version 6) with and VISITAG ODP module. Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). Substrate modification based on waveform periodicity analysis will be performed by using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
45848040|NCT05276310|Biological|IMC-002|IMC-002 blocks the interaction between CD47 and SIRPα.
45848041|NCT05262738|Drug|50 Micrograms Vaginal Misoprostol (Intervention)|Subjects will undergo cervical ripening with 50 micrograms of vaginal misoprostol every 4 hours.
45848042|NCT05262738|Drug|25 Micrograms Vaginal Misoprostol (Control)|Subjects will undergo cervical ripening with 25 micrograms of vaginal misoprostol every 4 hours.
45848043|NCT05252832|Procedure|Superficial Cervical Plexus Block|Location of injection for block.
45848044|NCT05252832|Procedure|Local Infiltrate|Local infiltration location.
45848045|NCT05237466|Behavioral|RECLAIM: Reducing Clutter and Increasing Meaning|Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Each treatment session will involve a combination of motivational interviewing (MI) and sorting practice. The rationale behind the sorting practice is to develop the skill of sorting and the formation of a daily sorting routine. The MI portion of the initial session will involve an evaluation of client strengths and individual biopsychosocial goals. The initial and subsequent sessions will include a variety of MI techniques, including decisional balancing, developing discrepancy, personalized feedback, and reinforcement of responsibility of sense of self-efficacy.
45848046|NCT05237466|Behavioral|Sorting Practice|Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Clinicians will encourage participants to sort objects during each session while refraining from use of any specific cognitive or motivational therapeutic techniques. Participants will be asked to record the frequency and duration of any sorting/ discarding they did during the previous week.
45848047|NCT05233254|Behavioral|Abdominal Hollowing exercise|Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out. Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out.
45848048|NCT05178732|Dietary Supplement|Bolus ingestion of protein|Different phases of the menstrual cycle
45848049|NCT05178732|Dietary Supplement|a blend of protein and polyphenol|a blend of protein and polyphenol
45382989|NCT04254861|Procedure|Simplified Papilla Preservation Flap (SPPF) and GTR|A simplified papilla preservation flap (SPPF) will be performed. The defect will then be treated according to the guided tissue regeneration (GTR) principle (control group). A deproteinized bovine bone mineral (DBBM) graft will be placed in the defect and covered by a collagen membrane.
45382990|NCT04247451|Diagnostic Test|Metabolic profile and nutritional goals in diabetic foot surgery patients|"Nutritional intake: these data will be evaluated daily during preoperative hospitalization, at home, and during the actual hospitalization, from surgical intervention to discharge. Before the follow-up consultation, patients will keep a food diary. The dieticians will calculate intake and need.~Metabolic data: body composition using Bio electrical Impedance Analysis BIA (Nutrilab Akern) and Resting Energy Expenditure REE using indirect calorimetry (Cosmed Q NRG) will be analysed in three timepoints: preoperative, postoperative and at follow-up consultation. This measurements take maximum ten minutes and do not cause discomfort to the participants."
45382991|NCT04244929|Procedure|Total knee arthroplasty|Total knee arthroplasty using standard anterior approach.
45382992|NCT04244929|Device|Persona Medial Congruent Knee Prosthesis implantation with Posterior Cruciate Ligament retaining|Patients will be implanted with this medial pivoting knee prosthesis. Posterior Cruciate Ligament will be retained
45498795|NCT03247673|Drug|EU-approved Avastin|EU-approved Avastin
45498796|NCT03247673|Drug|US-licensed Avastin|US-licensed Avastin
45498797|NCT03665610|Drug|ozanimod|ozanimod
45498798|NCT03665532|Behavioral|Youth Engagement in Services|Brief phone coaching to enhance engagement, retention, and sustain adherence to HIV and substance use services for younger people living with HIV.
45848050|NCT05169918|Other|Core stabilization|"The progressive core stabilization exercise approach created by Kumar et al. will be used.~Stage 1; Isolation and facilitation of target muscles~Stage 2; Trunk stabilization training with increased load under static conditions~Stage 3; Development of trunk stabilization during slow controlled movement of the lumbar spine.~Stage 4 and 5; Lumbar stabilization during high speed and dexterous movements. The exercises will last 20-30 minutes in each sessions and twice a week for 10 weeks. The level of stage will be increased when the patients reach the aim of the stage where he/she is at. The duration of the each stage will change depending on the days the patients' need to achieve the aim of the level. For each level, at least four exercise is described."
45848051|NCT05169918|Other|Sensorial Discrimination Training|Training group will be participate in core stabilization exercises (as describe in Control Group). Additionally, Sensorial Discrimination Training (SDT) will be applied on the low back of the patients for 20 minutes before the 20 minutes of core stabilization exercises. SDT is defined as the ability to correctly interpret the characteristics of the stimulus made to a part of the body by the patient. It aims to reverse the cortical reorganization observed in patients with chronic pain. It consists of tactile localization and graphesthesia training, which includes determining the localization and type of stimulus and recognizing the letter/number that drawn in a body part, by the patient. The training consists of five stages progressively, each stage lasting two weeks. As the participants complete the sensory tests at each stage with 90% accuracy, the next stage will be passed. If this accuracy rate is not achieved within two weeks, the stage can be extended for one week.
45848052|NCT05083806|Device|Multispectral Optoacoustic Tomography|Non-invasive optoacoustic imaging of muscular structure
45694762|NCT03217474|Drug|Ganciclovir (GCV)|Patient will be treated with GCV orally (200mg, 3 times a day, for 14 days).
45382993|NCT04244929|Device|Persona Medial Congruent Knee Prosthesis implantation with Posterior Cruciate Ligament sacrifice|Patients will be implanted with this medial pivoting knee prosthesis. Posterior Cruciate Ligament will be sacrificed
45694763|NCT03217474|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation.
45382994|NCT04223193|Drug|Tavapadon|Participants will be randomized to receive tavapadon 5 mg QD to 15 mg QD tablet once daily orally for 27 weeks.
45694764|NCT03217318|Device|ureteral stenting with standard or modified ureteral stent|Ureteral stenting because of kidney and or ureteral stones at the iliacal vessel crossing of the ureter or proximally
45694765|NCT01830946|Other|Whey Protein|Whey protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
45382995|NCT04223193|Drug|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
45382996|NCT04219956|Other|Polyamine Deficient Diet|Diet low in polyamines: the estimated calculated dose is 20 times lower that in an usual diet
45426062|NCT01246947|Other|Mitral surgery alone|Randomized to Mitral surgery alone
45426063|NCT01221389|Drug|Human Plasma|Patients will receive either 2 units of AB+ plasma or 2 units of hydroxyethylated starch control solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
45694766|NCT01830946|Other|Combined Resistance and High-Intensity Interval training|Completed 3 d/wk for 4 wks (2 d of Resistance Training (RT) and 1 d of High-Intensity Interval Training (HITT)). RT exercises were chest press, seated row,leg press, shoulder press, leg extension, and leg curl (3 total sets: 2 sets of 10 repetitions and a 3rd set to muscular exhaustion with a load equaling 75-85% of 1-Repetition Maximum(RM)). All exercises and sets were separated by 90-120 sec of rest. HIIT training was completed on commerical cardiovascular equipment and requires subjects to rate their perceived exertion on a scale from 1 to 10 (1= resting quietly, 5= a warm-up level, 10= an all-out exertion). Subjects warmed-up for 2 min at level 5 and increased their exertion each min for 3 min until level 9 is perceived and then recover at level 6 for 1 min. This pattern was repeated 4 times, where the 4th cycle subjects increased their last min of exertion to level 10, followed by 1-min recovery at the initial warm-up level 5.
45694767|NCT01830946|Other|Casein Protein|Casein protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
45382997|NCT04218201|Behavioral|PCP brief advice|Brief advice will be delivered by the patient participant's PCP as part of the medical visit or via phone call. Before the encounter with the patient participant, PCPs will receive a brief printed summary report from the research staff. The summary advises the PCP that their patient participant screened positive for risky opioid use, lists the patient participant's screening results (TAPS Tool +/- COMM) and gives a suggested counseling script. The counseling script will include specific advice on opioid-related risks, will inform patient participants of resources to help them reduce their risk, and will include a recommendation to reduce their risk behavior.
45498799|NCT03664908|Other|Detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method).|biological detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method) in three serum samples groups, coming from SLE patients (having Lupus Nephritis or not) and in a control group.
45382998|NCT04218201|Behavioral|Video doctor|During the baseline visit with the research staff, patient participants will view a video on tablet or desktop computer that reinforces the PCP's counseling. The video is a recording of a provider delivering brief advice about opioid use that includes the same elements covered in the summary report outlined above.
45694768|NCT01831024|Device|Dignicap System|The DigniCap™ System consists of the digitized system for controlled scalp cooling (Digni C3) in conjunction with the soft, tight-fitting silicon cap (DigniCap™), the neoprene outer cap (DigniTherm™), and the liquid coolant (DigniCool). DIGNISTICK™ is prepared to log data from a treatment when inserted in the slot. DIGNICARD™ is a key card which has to be inserted in order to start a treatment.
45694769|NCT03213886|Drug|Calcifediol (Vitamin D)|"After surgical treatment, participants with vitamin D deficiency (25OHD < 30 ng/mL) will be randomly allocated to an intervention group or control group.~For the intervention group, participants will receive 16. 000 U oral Calcifediol daily for 5 days.~For the control group, participants will receive 16.000 U oral Calcifediol weekly for 5 weeks.~Both groups:~Will follow the usual hip fracture rehabilitation pathway.~25OHD serum levels will be measured after 4 weeks. Depending on the serum 25OHD level, the patients will receive different vitamin D strategies (according to the protocol) Patients will be monitored for up to 12 months after the discharge from the hospital, with 3 clinic visits at 3, 6 and 12 months (to determine serum vitamin D levels and to evaluate functional status)"
45694770|NCT01831102|Other|none- observational study|
45694771|NCT01739348|Drug|Verubecestat (Part I and Part II)|Single 12 mg verubecestat tablet once daily, taken orally
45694772|NCT01739348|Drug|Verubecestat (Part I and Part II)|Single 40 mg verubecestat tablet once daily, taken orally
45694773|NCT01739348|Drug|Verubecestat (Part I and Part II)|Single 60 or 40 mg verubecestat tablet once daily, taken orally
45694774|NCT01739348|Drug|Placebo (Part I)|Single placebo tablet matching verubecestat treatment once daily, taken orally
45694775|NCT01739348|Drug|Verubecestat (Part II)|Single 40 mg verubecestat tablet once daily, taken orally
45498800|NCT05571995|Behavioral|TRIMOSH|TRIMOSH will improve the knowledge, attitude and practice on occupational and health
45498801|NCT03622944|Procedure|Muscle Energy Technic|post isometric relaxation technics were applied to levator scapulae, trapezius, pectoralis muscles three sessions per week, totally six weeks.
45498802|NCT03622944|Procedure|Deep Friction Massage|deep friction massage was applied to cervical region included tendons, muscles and soft tissue.
45715047|NCT00118365|Drug|eflornithine|Given orally
45715048|NCT00118365|Drug|sulindac|Given orally
45715049|NCT00118365|Other|laboratory biomarker analysis|Correlative studies
45715050|NCT02695524|Other|Scapula-focused exercises|
45498803|NCT03622944|Procedure|Exercise|spinal stabilization exercise were applied three sessions in a week totally six weeks.
45694776|NCT03213730|Other|3D-MOT Neurotracker|"A predetermined number of spheres (eight) are presented in the 3D-MOT task. The spheres are all identical in shape and color. Before each trial, four spheres are highlighted, and then returned to their original color. Participants will be asked to track those four spheres for the duration of the trial (8 seconds). Spheres will be moving, bouncing, colliding, until they finally stop moving and the participant has to identify the spheres that were initially highlighted. Previous work with healthy individuals has shown that the minimum optimal number of sessions (3 blocks) necessary to induce brain plasticity and enhance other, non-trained brain functions is between 5-6. The training protocol will therefore include 6 sessions (3 blocks each), at intervals of 48 to 72 hours, over a maximum of 3 weeks."
45382999|NCT04218201|Behavioral|Telephone health coaching|All patient participants in the STOP arm will receive telephonic health coaching sessions at approximately 2- and 4-weeks post-baseline. Patient participants who may benefit from additional coaching (for example, those who do not improve or who experience clinical worsening of unhealthy opioid use) may receive additional coaching sessions (approximately 4 sessions) from the telephone health coach. Coaching is delivered from a centralized call center, by staff that receive standardized training and supervision. To the extent possible, calls will be scheduled at the patient participant's convenience (e.g., evenings, weekends).
45383000|NCT04218201|Behavioral|Nurse Care Manager (NCM) intervention|NCMs will provide health education and counseling on risk reduction, overdose prevention and self-management skills. Patient participants will be asked to participate in a baseline visit with the NCM, which will occur on the same day as the baseline research visit if possible. The NCM continues working with patients in the STOP condition throughout their 12 months of study participation. Following the initial visit with the NCM, the frequency of visits depends on patient participant needs.
45498804|NCT03247517|Drug|Placebo|Placebo was administered once daily
45694777|NCT03213730|Other|Visual Attention Intervention|The visual attention intervention will consist of the 2048 game, a single-player sliding block puzzle game of which the objective is to slide numbered tiles on a grid to combine them to create number 2048. 2048 is played on a gray 4×4 grid, with numbered tiles that slide smoothly when a player moves them using the four arrow keys. Every turn, a new tile will randomly appear in an empty spot on the board with a value of either 2 or 4.Tiles slide as far as possible in the chosen direction until they are stopped by either another tile or the edge of the grid. If two tiles of the same number collide while moving, they will merge into a tile with the total value of the two tiles that collided. Higher-scoring tiles emit a soft glow. Children will play for a time equivalent to that of the 3D-MOT.
45383002|NCT04201093|Drug|Tavapadon|Participants will be randomized to receive tavapadon 5 mg QD or 15 mg QD tablet once daily orally for 27 weeks.
45383003|NCT04201093|Drug|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
45498805|NCT03247517|Drug|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
45498806|NCT03247517|Drug|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
45498807|NCT03665454|Drug|PF-06412562|PF-06412562 is a dopamine agonist developed by Pfizer Inc. into a tablet form for oral usage. It will be provided as 5 mg tablets. Thus, to administer the 25 mg dose, 5 x 5 mg tablets will be given; and to administer the 20 mg dose, 4 x 5 mg tablets will be administered.
45498808|NCT03665454|Drug|Standard of Care Placebo|25/100 mg tablet(s) of carbidopa/levodopa will be encapsulated and administered according to the subject's home regimen.
45498809|NCT03664440|Drug|Nevirapine|Patients were randomized 1:1 to continuation arm (NVP-based regimens). Tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) remained as the backbone of the regimens.
45498810|NCT03664440|Drug|Rilpivirine|Patients were randomized 1:1 to switch arm (NVP-based regimens were switched to RPV-based regimens). Tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) remained as the backbone of the regimens.
45498811|NCT03663738|Behavioral|mobile app NOVAME|The training program is divided into 3 periods of 21 days, where each day the patient receives a new formation pill. At the end of one of these periods there will be a week of review in which the patient will receive reminders of the contents that he has already received. These pills will help the patient to acquire healthy lifestyle habits and improve the control of the disease. The length of the program is 84 days, and once completed, the patient can repeat or intensify efforts in the areas he considers and continue to have access to the virtual coach. Patients assigned to the intervention group will receive a brief structured explanation on how to use the application and its contents.
45498812|NCT03283553|Other|Checklist, MyChart, OpenNotes|1) Patient-family agenda-setting checklist, 2) Facilitated proxy registration for MyChart, and 3) Education on access to doctor's electronic visit notes.
45498813|NCT03283553|Other|Usual Care|Routine medical oncology care
45498814|NCT03664596|Dietary Supplement|Sublimated mare's milk|Supplement obtained through sublimation of mare milk, packed into one-dosage sachet (20g), and dissolved in a warm water (36 degrees of Celcius).
45498815|NCT03664596|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid in the form of 250 mg capsule.
45498816|NCT03283319|Biological|3.75 ug Panblok H7|0.5 mL recombinant Panblok H7 influenza vaccine antigen 15 ug/mL.
45498817|NCT03283319|Biological|7.5 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 30 ug/mL.
45498818|NCT03283319|Biological|15 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 60 ug/mL.
45498819|NCT03283319|Biological|MF59|0.5 mL MF59 (39 mg squalene/mL ) adjuvant.
45498820|NCT03283319|Biological|AS03|0.5 mL AS03 (42.4 mg squalene/mL ) adjuvant.
45498821|NCT03549533|Other|samples of sperm|As in the usual practice during artificial insemination a samples of sperm will be collected and analyzed.
45498822|NCT03637829|Other|Control|Water
45498823|NCT03637829|Other|White chocolate|Experimental snack treatment
45694778|NCT03217084|Drug|MI varnish GC|MI Varnish GC is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDENT. Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
45383004|NCT04199221|Behavioral|Stress Innoculation Training (SIT)|1 hour lecture that will cover the conceptualization phase and skills-training phase portions of stress inoculation training.
45383005|NCT04199221|Behavioral|Extra attempt|an extra attempt at intubating a mannequin configured at a difficulty level higher than will be used in the future scenarios
45383006|NCT04184895|Biological|ASP2390|Intradermal
45383007|NCT04184895|Biological|Placebo|Intradermal; normal saline solution
45383008|NCT04183348|Behavioral|Training Protocol n°1 first at Visit 1, then, Training Protocol n°2 at Visit 2|"During Protocol 1 (visit 1), participants of Group A will perform auditory spatial localization tasks with sensory feedback and during Protocol 2 (visit 2), they will perform auditory tasks without any notion of spatial localization. The 2 visits will be spaced at least 2 weeks (Wash-out).~The effects of each of the protocols on spatial location hearing abilities will be specifically assessed by comparing the results of the different assessments (SPHERE and Visual Discrimination Test) obtained before and after each protocol."
45426064|NCT01171898|Drug|ARN-509 (Phase 1)|ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily.
45498824|NCT03637829|Other|Dark chocolate 1|Experimental snack treatment
45498825|NCT03637829|Other|Dark chocolate 2|Experimental snack treatment
45498826|NCT03282227|Drug|M207 Microneedle System|M207 Microneedle System 3.8 mg
45498827|NCT04696835|Diagnostic Test|speech audiometry|65dB, 55dB or 75dB SPL speech audiometry
45498828|NCT05158127|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
45498829|NCT05157035|Behavioral|Mindfulness/Acceptance-Based Smartphone App (MABSA)|This is a mindfulness- and acceptance-based smartphone app. The mindfulness and acceptance exercises embedded in the app are based on the principles of Acceptance and Commitment Therapy. Participants in the intervention group will be using the app for 6 weeks. They are expected to access the meditations and mindfulness exercises within the app on a daily basis.
45498830|NCT05571605|Behavioral|Exercise|Participants randomized to this arm will exercise on a stationary bicycle.
45498831|NCT05571605|Behavioral|Stretching|Participants randomized to this arm will perform stretching and balance exercise.
45498832|NCT03240575|Drug|Tiotropium|Fixed Dose Combination
45498833|NCT03240575|Drug|Olodaterol|Fixed Dose Combination
45715051|NCT02695524|Other|Motor control exercises|
45848053|NCT05023512|Behavioral|Communication about the COVID-19 vaccination from the Massachusetts Department of Public Health|Participants will be randomized to receive one of two different versions of messages from the Massachusetts Department of Public Health. The message that participants in each experimental group receive will vary slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns about the Covid-19 vaccination.
45498834|NCT03240575|Drug|Fluticasone propionate|Fixed Dose Combination
45498835|NCT03240575|Drug|Salmeterol|Fixed Dose Combination
45848054|NCT04980066|Procedure|Sticky bone and EDTA|treatment using Sticky bone after EDTA root surface biomodification
45498836|NCT05571371|Other|Measuring inflammatory serum biomarkers|Measuring inflammatory serum biomarkers
45498837|NCT03385265|Behavioral|DIPPer Academy|The DIPPer Academy curricula will build on treatment models guided by the Health Beliefs Model (HBM) and Social Cognitive Theory (SCT). The curricula includes video microlectures, personalize progress reports, and other features delivered via the internet.
45498838|NCT03385265|Other|Standard of Care|Parents in the standard of care control group will be instructed to manage their child's T1D as recommended by the diabetes team.
45498839|NCT05571449|Procedure|Open reduction and internal fixation|Internal fixation of the fracture
45498840|NCT05571449|Procedure|Standard osteosynthesis planning|Plain radiograph and CT images are used
45498841|NCT05571449|Procedure|3-D model osteosynthesis planning|A 3D plastic model made from CT images is used
45498842|NCT03280121|Device|EsophyX ZR transoral device|TIF
45694779|NCT03217084|Drug|White varnish 3M|White varnish 3M is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. Clinpro White Varnish contains an innovative tri-calcium phosphate.Open the unit-dose package of Varnish and dispense the entire content onto the round application guide provided with the packet. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
45498843|NCT03233009|Other|Experimental Daily Defense Serum A|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
45498844|NCT03233009|Other|Experimental Daily Defense Serum C|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
45498845|NCT03233009|Other|Experimental Daily Defense Serum G|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
45498846|NCT03233009|Other|Experimental Daily Defense Serum N|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
45848055|NCT04980066|Procedure|Sticky bone|treatment using Sticky bone
45498847|NCT03233009|Other|Saline Solution Sodium Chloride|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
45498848|NCT04034225|Drug|SNS-301|Day 0, Week 3, Week 6, Week 9 then every 6 weeks (±3 days) for 6 additional doses, thereafter every 12 weeks (±3 days) up to 24 months.
45498849|NCT04034225|Drug|Pembrolizumab|Pembrolizumab (200 mg dose) IV infusion will be administered over 30 minutes every 3 weeks up to 24 months or Pembrolizumab (400 mg dose) IV will be administered over 30 minutes every 6 weeks up to 24 months.
45554602|NCT03996525|Device|Sham Treatment|"Two-Stage Facial Reanimation (Standard Practice) with sham electrical stimulation for one hour (Placebo).~Cross-Facial Nerve Graft (CFNG) followed by placement of unelectrified electrodes proximal to the coaptation site on the donor facial nerve.~Free Muscle Transfer (FMT) followed by placement of unelectrified electrodes proximal to the coaptation site in the intraoral incision."
45715052|NCT01576367|Biological|ACZ885|
45498850|NCT05571215|Device|Transcranial Direct Current Stimulation|Five sessions of tDCS will be performed following completions of baseline data collection. This will include 3 sessions during week one and 2 sessions in week 2. A tDCS unit (neuroConn Ilmenau, Germany) will be applied to the left DLPFC with participants in the sitting position for a 20 minutes of tDCS. An anodal 2.0 mA current will be applied to each participant, including a 30-second ramp up at the beginning of stimulation and a 30 second ramp down period and the end of stimulation. The left DLPFC (F3 from EEG 10/20 system) will be located using the Beam F3 measurement system. These parameters are consistent with those used in current literature on tDCS for pain. tDCS procedures will be performed by the PI (CA).
45498851|NCT05571215|Behavioral|Pain Neuroscience Education|Immediately following completion of each tDCS intervention, participants will be given a one-on-one PNE session provided also by the PT (CA), who is a licensed healthcare provider with expertise in delivery of the content. This educational session will last about 30 minutes. Initial sessions will involve discussion and questioning of participants about their own understanding of their pain and this information will be used to subsequently individualize the forthcoming educational sessions. The educational sessions will follow the content of Explain Pain, a patient booklet, and will include information on the neurophysiology of pain, pain as typical process, the transition from acute to chronic pain, neuroplasticity, central sensitization, factors that promote pain chronicity. Information will be presented verbally along with visuals on paper.
45498852|NCT03690947|Drug|Intravitreal Ranibizumab|All subjections received 3 initial Ranibizumab injections
45498853|NCT03690947|Procedure|Micropulse Laser|After 3 initial Ranibizumab injections, Micropulse Laser will be done as needed each month if macular edema persists
45498854|NCT03690947|Drug|Intravitreal Ranibizumab as needed|After 3 initial Ranibizumab injections, Ranibizumab will be injected as needed till BCVA reaches stabilization
45694780|NCT00899470|Drug|Co-administration of Saxagliptin and Metformin IR, Fasted|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions
45383009|NCT04183348|Behavioral|Training Protocol n°2 first at Visit 1, then, Training Protocol n°1 at Visit 2|"During Protocol 2 (visit 1), participants of Group B will perform auditory tasks without any notion of spatial localization and during Protocol 1 (visit 2), they will perform auditory spatial localization tasks with sensory feedback. The 2 visits will be spaced at least 2 weeks (Wash-out).~The effects of each of the protocols on spatial location hearing abilities will be specifically assessed by comparing the results of the different assessments (SPHERE and Visual Discrimination Test) obtained before and after each protocol."
46056004|NCT04440033|Other|Locomotor assessments|"First, 9 anthropometric measurements will be taken, 39 reflective markers will be placed, and a 6-min practice walking session will be conducted to familiarize participants with self-paced treadmill walking (SPTW). Thereafter, participants will partake in 7 experimental conditions in a (semi-)randomized order:~3 min standing~3 min standing while answering semi-standardized questions~3 min SPTW~3 min SPTW while answering semi-standardized questions (SPTW-Q)~3 min SPTW while verbally describing a VR environment (SPTW-VR1)~6 min SPTW in a VR environment containing freezing of gait provoking elements (SPTW-VR2)"
46056005|NCT04440033|Other|Speech assessments|"Acoustic analysis (including voice reports and formant analysis), video recording and motor speech profile (including analysis of diadochokinesis, voice, standard syllabic rate, intonation and second formant (F2)).~Spontaneous speech production will be assessed by answering semi-standardized questions based on the Aachen Aphasia Test and by describing a VR environment projected on a 180-degree cylindrical screen~The Speech Handicap Index (a 15-item self-reported questionnaire)"
46056006|NCT04440033|Other|Audiology assessments|"Otoscopy~Tympanometry~Pure tone audiometry~Otoacoustic emissions~Video Head Impuls Test~Cervical Vestibular Evoked Myogenic Potentials~Ocular Vestibular Evoked Myogenic Potentials~Oculomotor function testing~Positional testing~Static visual acuity test~Dynamic visual acuity test~Dizziness Handicap Inventory (a 25-item self-assessment inventory)"
46056007|NCT02747901|Other|KINESIOTAPING|Kinesiotaping group received kinesiotape for lymphatic correction and rectus femoris facilitation technique.
45498855|NCT01313741|Device|Shoulder arthroplasty with anchor peg glenoid|Shoulder arthroplasty with anchor peg glenoid
45498856|NCT02999178|Drug|Nintedanib|
45498857|NCT02999178|Drug|Placebo|
45498858|NCT02959190|Drug|Galcanezumab|Administered SC
45694781|NCT00899470|Drug|Saxagliptin/Metformin, Fasting|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions
45694782|NCT00899470|Drug|Co-administration of Saxagliptin and Metformin IR, Fed|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions
45694783|NCT00899470|Drug|Saxagliptin/Metformin, Fed|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions
45694784|NCT01738646|Drug|Vorinostat|
45694785|NCT01738646|Drug|Bevacizumab|
45694786|NCT03213574|Other|Control Group|Intraoperative fluids will be administer per the discretion of anesthesia provider and not per SVV data or study protocol.
45694787|NCT03213574|Other|Treatment Group|FloTrac arterial line data will be used to administer fluid bolus, based on study algorithm.
45383020|NCT04155190|Drug|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
45383021|NCT04155190|Drug|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
45498859|NCT02031614|Procedure|Phlebotomy|Withdrawal of 500 mL of whole blood.
45498860|NCT01344356|Radiation|stereotactic body radiotherapy|14-16 Gy / 1 fraction OR 18-21 Gy / 3 fractions (6-7 Gy per fraction)OR 25-45 Gy / 5 fractions (5-9 Gy per fraction)
45498861|NCT01344356|Radiation|Stereotactic body radiotherapy|8-12 Gy / 1 fraction OR 12-18 Gy / 3 fractions (4-6 Gy per fraction) OR 35-45 Gy / 5 fractions (7-9 Gy per fraction)
45498862|NCT03640130|Behavioral|Gaze-contingent text enhancement|"In different testing blocks, the efficacy of the different enhancements will be evaluated, such as inverting the text in a gaze-contingent inverted spotlight."
45498863|NCT03618992|Other|Cholesterol-containing moisturizers|Commercially-available cholesterol containing topical formulations to be applied daily to the scalp, skin, lips, eyelashes, and eyebrows. Available from Skin Actives Scientific (www.skinactives.com).
45498864|NCT03722810|Other|Intervention|"The intervention will be a structured in-depth interview with a patient with a chronic illness that has been chosen by the student's allocated GP teacher. These chronic diseases are the four conditions at the top of a list of diseases with high disability-adjusted life years (DALY) scores in Switzerland: ischaemic heart disease, low back pain, major depressive disorder and COPD.~GP teachers and students will be told that the students' intervention interviews need to be unaccompanied and at patients' own homes. The interview will be followed by a structured interview with the practice nurse and then a structured debriefing interview with the GP teacher."
45498865|NCT03722810|Other|Sham comparator|In the sham comparator, the student's allocated GP teacher will be give the student time to read a document that gives information about consultation skills, and asks questions that the student will need to discuss with the GP teacher. The document is designed to have real educational value, and to complement BIHAM's department-based consultation skills teaching.
45498866|NCT02236676|Behavioral|Nap after rehearsal trials|Behavioral
45498867|NCT03618368|Device|THERANOVA-500 dialyzer|THERANOVA-500 dialyzer is a hemofilter that enables Expanded Hemodialysis (HDx) therapy.
45498868|NCT03618368|Device|REVACLEAR-400 dialyzer|REVACLEAR-400 dialyzer is an usual hemofilter that enables conventional hemodialysis (HD).
45498869|NCT03618914|Biological|Dultavax and Vaxigrip|All the women got an influenza/DTP vaccine in order to induce acute inflammation
45383022|NCT04154332|Other|Sample collection|Blood, urine, placental samples, and the patient's vascular reactivity will be collected from each person enrolled in this study.
46056008|NCT02747901|Other|COLD THERAPY|Cold therapy group received cold packs immediately after operation and following postoperative days
46056009|NCT02747823|Biological|CBT124|1 mg/kg IV infusion
46056010|NCT02747823|Biological|EU Sourced Avastin®|1 mg/kg IV infusion
45383026|NCT04145440|Drug|MOR202|Patients will receive 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing will occur weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.
45383027|NCT04143516|Diagnostic Test|[18-F]- FDG - PET|Patients will undergo a limited non-contrast CT and first injection PET to localize the lesion
45426065|NCT01171898|Drug|ARN-509 (Phase 2)|ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
45426066|NCT01093326|Drug|Ponesimod 10 mg|Ponesimod 10 mg oral use
45498870|NCT02956460|Device|fanfilcon A|contact lens
45498871|NCT02956460|Device|senofilcon A|contact lens
45498872|NCT03618290|Diagnostic Test|Analyze plasma free fatty acid in blood|"This study is prospectively designed with the purpose of investigating potential new lipid targets and the free fatty acids as specific markers of acute brain injury.~Dynamic measurement of lipid profile in 3 consecutive samples at (I) the time intervals of admission, (II) 8 hours and (III) 24 hours after admission will give the opportunity of comparison mass-spectrometric analysis of highly complex plasma samples thus reducing variability between analyzed samples and allowing precise focusing on essential lipid target changes during stroke progression."
45498873|NCT02999100|Drug|IH Oxytocin|Oxytocin will be supplied as colourless and clear hard capsule with powder blend for inhalation with unit dose strength 400 mcg and 200 mcg. It will be administered using ROTAHALER dry powder inhaler (DPI).
45498874|NCT02999100|Drug|IM Oxytocin|Oxytocin will be supplied for solution for infusion in 1ml ampoule containing colourless and clear sterile solution with unit dose strength 5 I.U./mL, or 10 I.U./mL for IM administration
45694788|NCT01831414|Other|Water immersion at cervical level|balneotherapy session of spinal cord patients with a Water immersion at cervical level
45694789|NCT01831414|Other|Water immersion at xyphoid level|balneotherapy session of spinal cord patients with a Water immersion at xyphoid level
45426067|NCT01093326|Drug|Ponesimod 20 mg|Ponesimod 20 mg oral use
45426068|NCT01093326|Drug|Ponesimod 40 mg|Ponesimod 40 mg oral use
45498875|NCT02999100|Drug|IV Oxytocin|Oxytocin will be supplied as solution for infusion in 1ml ampoule containing colourless and clear sterile solution to be administered as a 30-second IV bolus with unit dose strength 5 I.U./mL, or 10 I.U./mL.
45694790|NCT03213340|Other|Catechin Cohort 1|- 4 capsules taken with water 1 hour prior to meal
45694791|NCT03213340|Other|Curcuminoid Cohort 2|- 2 capsules taken with water 1 hour prior to meal
46056011|NCT02747823|Biological|US Sourced Avastin®|1 mg/kg IV infusion
46059056|NCT02583685|Drug|PR4 + LDV/SOF + SMV 6 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
45383028|NCT04143516|Procedure|Thermal ablation (TA)|Standard ablation with the intent to create a radius of ablation at least 10 mm larger than the largest lesion diameter in order to achieve a minimum of 5 mm ablation margin around the tumor. Any radiographically-identified and biopsy-confirmed residual tumor will be treated on site with immediate ablation. This repeat ablation is not standard of care but will be performed as described for the initial ablation (in the same procedure session) and follow up will be resumed.
45383029|NCT04143516|Diagnostic Test|PET/CT Scan|Eligible patients will undergo PET/CT -guided thermal ablation as per standard IR guidelines. All patients will undergo PET/CT again, within approximately 6 weeks (+/- 2 weeks) of thermal ablation to evaluate for CN in the target tumor(s) or any sign of residual tissue enhancement, representing viable residual tumor and incomplete treatment.
46056012|NCT02747745|Behavioral|Four risk areas reflecting the great needs of FCGs of PWDs|The intervention involves home visits & phone calls from the case manager to the dyads, and receiving telephone calls from FCGs. The case manager will target the prioritized risk from the 4 risk areas of FCG problems and healthy behaviors. The intervention mainly consists of needs assessment and nursing education on home environment modification and safety, behavioral management and communication skills; home-based cognitive stimulation on PWD with simple mathematical practice, patient preferred leisure activities and reminiscence by old time photos, stories and toys; brief consultation on 4 risk areas related to FCG stress; and case management to refer the dyads to the hospital-based dementia centers and community resources.
46056013|NCT04217889|Other|Questionnaire|Short questionnaire that can be completed during the usual consultation.
46056014|NCT02747511|Drug|Haloperidol|
46056015|NCT02747511|Drug|Placebo|
46056016|NCT04217733|Drug|pentoxyifylline|Pentoxyifylline two times daily for 3 months
45383035|NCT04129164|Drug|VIB4920|Intravenous Dose 1.
45383036|NCT04129164|Drug|Placebo|Intravenous dose matched to VIB4920.
46056017|NCT04217733|Drug|Mebeverine|Mebeverine 3 times for 3 months
46056018|NCT04217733|Drug|ethosuximide|ethosuximide 3 times for 3 months
46056019|NCT04216875|Procedure|Best Practice Diabetes Management in Primary Care|Practice adherence to best practice guidelines treating diabetes patients in different primary care practices is shown in this before- and after observational study
46056020|NCT03363087|Device|Mapping and ablation|Ultra high density scar mapping Collection of impedance data during ablation
46056021|NCT03363087|Device|Mapping|Omnipolar mapping of left atrial scar and pulmonary vein isolation lines
45383043|NCT04095832|Procedure|Epidural anesthesia|Epidural anesthesia using standardized technique
45383044|NCT04088071|Device|Catheter ablation|Ablation RF technologies (e.g., THERMOCOOL SMARTTOUCH®, THERMOCOOL SMARTTOUCH® SF).
45383045|NCT04087629|Device|StrataCTX® gel|Gel forming flexible wound dressing for the prevention and treatment of radiation dermatitis
45383047|NCT04083365|Drug|Capecitabine|chemoradiation therapy with 825 mg/m2 twice daily capecitabine every day for 5 weeks
45383048|NCT04083365|Drug|Radiotherapy|5040 cGy radiotherapy for 5 days per week for 5 weeks
45383049|NCT04083365|Drug|Durvalumab|One week after the end of CT/RT patients will be treated with 1500 mg IV Q4W durvalumab for 3 administrations
45383055|NCT04075487|Other|Web-module for patient education and planning|Our goal is a mobile web-based application (App) that provides immediate feedback to Veterans seeking to develop their own pain self-management plan
45383056|NCT04072575|Drug|PP6M injection Dose 1|Participants will receive Dose 1 PP6M intramuscular (IM) injection at Visit 1 (Day) then once every 6 month up to 24 months.
45383057|NCT04072575|Drug|PP6M injection Dose 2|Participants will receive Dose 2 PP6M IM injection at Visit 1 (Day) then once every 6 month up to 24 months.
45383058|NCT04072068|Drug|Edoxaban|Every patient will receive every day edoxaban orally once a day. Edoxaban therapy will start after at least 5 days of lead-in with low-molecular-weight heparin, as per clinical practice. Edoxaban will be administered at dosage of 60 mg/day. In case of patients with body weight ≤60kg or with renal failure (creatinine clearance between 15 and 50 ml/min) or that are treated with P-gp inhibitors (cyclosporine, dronedarone, erythomycin, ketoconazole), dosage will be 30 mg/day. Patients will be treated for 6 up to 12 months with edoxaban, as per medical decision.
45383059|NCT04071847|Device|Deep Brain Stimulation (DBS)|Deep brain stimulation therapy involves the delivery of electrical signals to targeted structures in the brain to modulate neural circuit activity, and has been used successfully for the treatment of various types of movement disorders, including Parkinson's disease (PD), disabling or essential tremor, and dystonia
45383060|NCT04038190|Behavioral|behavioral activation|Behavioral activation (BA) is an intervention that indirectly addresses psychopathy by guiding individuals to identify goals in their lives, and encouraging individuals to engage in reinforcing activities that align with their goals (Lejuez et al, 2001). While initially used to treat depression, BA has been efficaciously applied to substance use because BA acts on the same reinforcement system common to many disorders (Daughters et al., 2018).
45383061|NCT04037358|Drug|Radium-223|Radium-223 plus SABR will be within two weeks.
45383062|NCT04037358|Radiation|stereotactic ablative radiotherapy (SABR)|SABR 1-5 fractions
45383063|NCT04036305|Drug|0.9% Sodium Chloride Injection|All participants will be injected subcutaneously with a single 0.5ml dose
45383064|NCT04036305|Drug|Lidocaine Injection 2%|All participants will be injected subcutaneously with a single 0.5ml dose
45383065|NCT04036305|Drug|Bupivacaine Injection 0.5%|All participants will be injected subcutaneously with a single 0.5ml dose
45498876|NCT02999100|Device|ROTAHALER|ROTAHALER DPI device is a high airflow resistance capsule-based inhaler. It will be used to deliver IH oxytocin
45498877|NCT02749370|Drug|Etanercept|Administered subcutaneously twice weekly for 12 weeks then once weekly for an additional 12 weeks.
45498878|NCT03622866|Device|Ultra-high pulse width stimulation|Algovita Spinal Cord Stimulation System with associated components
45498879|NCT03622866|Device|Traditional pulse width stimulation|Algovita Spinal Cord Stimulation System with associated components
45498880|NCT03619070|Other|Resistance training, LL|In LL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and low load (i.e. 30% of one repetition maximum)
45694792|NCT03213340|Other|Flavonoid Cohort 3|- ~ 1 oz. serving consumed 30 minutes before meal
45498881|NCT03619070|Other|Resistance training, HL|In HL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and high load (i.e. 80% of one repetition maximum)
45498882|NCT03619070|Other|Resistance training, HVHL|In HVHL, the postmenopausal women will be submitted to 12 weeks of Resistance training with high volume (i.e. six sets per exercise) and hig load (i.e. 80% of one maximum repetition)
45498883|NCT03619070|Other|Control group, CG|The CG groups do not will performed the exercise.
45498884|NCT03618836|Other|Microbiological and biological patterns on vaginal samples|To compare the microbiological and biological patterns between groups
45498885|NCT03618758|Drug|Paclitaxel|"Intraperitoneal application of Paclitaxel Phase 1: Dose determination of Paclitaxel (Recommended Dose) Starting from 40mg/m² upto 100mg/m² maximum~Phase 2: Intraperitoneal Paclitaxel with recommended dose"
45498886|NCT03618758|Drug|mFOLFOX6 regimen|Systemic mFOLFOX6: 5-FU(2400mg/m²), Oxaliplatin(100mg/m²), Leucovorin(100mg/m²)
45498887|NCT03435536|Other|Blood samples|Blood samples will be taken to analyze the circulating tumor DNA rate by NGS
45498888|NCT03618602|Drug|Bisthianostat|Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.
45498889|NCT03723200|Other|Fibrinogen and blood products|Fibrinogen and blood products
45498890|NCT03618212|Diagnostic Test|MRI|Skeletal MRI and pelvic and spinal MRI
45498891|NCT05001386|Biological|Blood collection for the evaluation of the anti-drugs sensitivity|The M.D investigators and the medical team identify the patients ( index cases and healthy volunteers) in a medical appointment. They inform them, collect the non-opposition right and the blood samples: 5 mL heparin tube and 5 mL dry tube for each person , one time.
45498892|NCT02031848|Other|Diet Intervention|
45498893|NCT02031848|Other|Assessments and Diet Intake|
45498894|NCT03617978|Procedure|Hemodynamics parameters|real-time evaluation of cardiac output parameters using the ICON device
45498895|NCT05384444|Other|Fasting mimicking diet|The fasting mimicking diet consists of a 5 day regimen: day 1 diet of the diet supplies ~1000 kcal (10% protein, 56% fat, 34% carbohydrate), day 2-5 are identical in formulation and provide 800 kcal (9% protein, 44% fat, 47% carbohydrate). At least 4 cyclic FMDs will be performed after operation.
45694793|NCT01716104|Drug|Afalaza|Safety and Efficacy
45694794|NCT01716104|Drug|Placebo|Safety and Efficacy
45694795|NCT03837262|Combination Product|Flash Glucose Monitoring and structured education|A feasibility study assessing the use of flash glucose sensing technology with structured education to improve glycemic outcomes in T2D adults and children
45694796|NCT03836170|Procedure|Laparoscopic cholecystectomy|A special catheter was inserted into the peritoneal cavity, and then about 2-5 liters of carbon dioxide was injected. After reaching a certain pressure, four small holes of 0.5-1.5cm were opened in the abdomen to dissect the structure of the triangle of the gallbladder. The gallbladder duct and gallbladder artery were cut off and closed, and then the entire gallbladder was removed.
45694797|NCT01831492|Device|zeolite + dolomite|Given for 12 weeks, after a 4 weeks wash- out of all supplements/drugs
45383068|NCT04030130|Behavioral|NDURE|NDURE is a theory-based, multi-level Patient Navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system- (care coordination), interpersonal- (social support), and individual- (Health Belief Model; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, improve cancer care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (~3 months).
45426069|NCT01083030|Device|Percutaneous transluminal angioplasty (PTA)|Angioplasty of superficial femoral artery (SFA)
45498896|NCT03617900|Drug|Ginger|Ginger extract is contains 100 mg/capsules. Use 2 capsules 3 times/day
45498897|NCT03617900|Drug|Placebo oral capsule|Lactose monohydrate 400 mg/capsules
45498898|NCT03617900|Drug|Paracetamol|500 mg paracetamol. use in need
45498899|NCT05384366|Drug|Neoadjuvant chemotherapy|doublet of taxane and carboplatin
45498900|NCT05572385|Behavioral|CIAT + Conventional neurorehabilitative therapy|CIAT = Constrained induced aphasia therapy
45694798|NCT01831492|Device|cellulose|given for 14 weeks
45694799|NCT03213106|Device|Transcranial Magnetic Stimulation (TMS)|Low frequency (1Hz) transcranial magnetic stimulation aimed to the dentate nucleus contralateral to the most symptomatic side.
45498901|NCT03616808|Other|Thromboelastometry-guided haemostatic treatment|Administration of blood products and/or procoagulants is based on thromboelastometric assays.
45498902|NCT03616652|Drug|Placebo|Placebo pill
45498903|NCT03616652|Other|Film sequence|The experimental group watches a film about the power of placebo effects.
45498904|NCT03616652|Other|Film sequence|The control group watches a film about sleep.
45498905|NCT03618524|Other|Lower limb hot water immersion|Participants will undergo two interventions in separate visits: lower limb hot water (42 deg C) immersion up to the (1) ankles or (2) knees.
45498906|NCT02031926|Device|Positive expiratory pressure|
45498907|NCT03607994|Device|HIRREM-SOP|HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
45498908|NCT03607994|Device|NCC|Nonspecific acoustic stimulation with randomly generated tones not linked to brain activity.
45498909|NCT03617510|Drug|Felbinac Trometamol Injection|Felbinac Trometamol Injection will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the drug was given 7 times,3 times/day,once every 8 hours. It means the drug was given 3 times on D3 and D4,once on D5.
45498910|NCT03617510|Drug|Placebos|Normal saline will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the Placebo was given 7 times,3 times/day,once every 8 hours.It means the Placebo was given 3 times on D3 and D4,once on D5.
45498911|NCT03617432|Drug|Chidamide|Chidamide 15mg orally BIW. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
45498912|NCT03617432|Drug|Cyclophosphamide|Cyclophosphamide(750mg/m2) was administered intravenously on d1. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
45498913|NCT03617432|Drug|Doxorubicin|Doxorubicin (50mg/m2)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
45498914|NCT03617432|Drug|Vincristine|Vincristine (1.4mg)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
45498915|NCT03617432|Drug|Etoposide|Etoposide (100mg/m2) was administered intravenously on d1,2,3.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
45383069|NCT04026503|Other|Live Long Walk Strong rehabilitation program|Live Long Walk Strong is a rehabilitation program that focuses on impairments known to contribute to mobility decline that are not considered standard of care in rehab and addresses behavioral change within the context of rehabilitation.
46056022|NCT03889353|Device|BCI sessions|up to 3 test sessions (D-30) to eliminate BCI illiteracy, then 10 rehabilitation sessions of 90 minutes (D1-D5 and D8-D12) - Session content : Guided training - Control of an avatar (VR, first person view) of the affected limb by motor mental imagery decoded by a brain computer interface.
46056023|NCT04171869|Other|no intervention|observational study, no intervention
45426070|NCT01083030|Combination Product|DCB|Drug Coated Balloon Angioplasty
45498916|NCT03617432|Drug|Prednisone|Prednisone (100mg)was administered by oral on d1-5.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
45498917|NCT03464916|Biological|CAR2 Anti-CD38 A2 CAR-T Cells|Autologous IV infusion; dose-escalation
45498918|NCT05058716|Diagnostic Test|blood sample|weekly blood sample - coenzym q10 levels
45498919|NCT04057950|Other|cosmetic product|Disulfure de sélénium versus placebo formula
45498920|NCT04051866|Procedure|Non-surgical periodontal treatment: Scaling and root planing (SRP)|Removal of dental plaque and dental calculus from the surface of a tooth, from the surface of a tooth apical to the gingival margin accumulated in periodontal pockets, or from the surface coronal to the gingival margin.
45498921|NCT04051866|Other|Oral hygiene instructions|Education for individual health regarding peridontal disease and its association with diabetes, as well as oral hygiene instructions that include the modified Bass technique, use of interproximal brushes and dental floss
45498922|NCT03616340|Drug|Shoulder injection|intra articular or subacromial shoulder injection
45498923|NCT03616340|Drug|knee injection|intra-articular knee injection
45694800|NCT03213106|Device|Sham Stimulation|The stimulation coil will be placed in the same spot as the TMS stimulation, but coil will not be attached to the TMS machine.
45715053|NCT02653456|Device|RA-308 Excimer Laser and DABRA Catheter|See information already included in arm description
45426071|NCT01027000|Biological|rituximab|
45498924|NCT03663660|Other|Organizational infrastructure pediatric plan (OIPP)|Restructuration of the hospital sectors with a stratification of health care into 4 levels.
45498925|NCT05035004|Device|Post exercise hot water immersion|Participants will complete 30 minutes of cycling on a lode bicycle ergometer (50% of VO2max), followed by a 10-minute transfer period and then 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C).
45426072|NCT01027000|Drug|busulfan|
45426073|NCT01027000|Drug|cyclophosphamide|
45426074|NCT01027000|Drug|fludarabine phosphate|
45426075|NCT01027000|Drug|methotrexate|
45498926|NCT05035004|Device|Exercise|Participants will complete 30 minutes of cycling on a lode bicycle ergometer (50% of VO2max).
46056024|NCT03961737|Procedure|prostate biopsies|"Before radiotherapy treatment, prostate biopsies will be performed in each patient. From these biopsies, explants will be performed. Half of these explants will be irradiated ex vivo and the other half will not receive any prior treatment.~Then the patient will receive radiotherapy. It will be reviewed 2 years after the end of radiotherapy. New prostate biopsies will be performed to evaluate the tumor response to radiotherapy and to characterize the immunohistochemical and transcriptomic profiles of non-responder patients."
46056025|NCT02747199|Device|SYNERGY stent|
46056026|NCT02747199|Device|BVS ABSORB scaffold|
46056027|NCT02746887|Other|Preterm/term cohort|
46056028|NCT02414607|Biological|Elderberry Juice|
46056029|NCT02414607|Other|Placebo|
45498927|NCT05035004|Device|Hot water immersion|Participants will complete 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C), followed by a 10-minute transfer period and then an additional 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C).
45498928|NCT02996682|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
45498929|NCT02996682|Drug|RBV|Capsules administered orally in a divided daily dose
45498930|NCT03664284|Procedure|subcutaneous disinfection|The investigators will randomize 105 patient on two arms. The control group receiving no disinfection of the subcutaneous tissue (A) and intervention group, receiving disinfection of the subcutaneous tissue (B).
45498931|NCT02873702|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsules.
45498932|NCT02873702|Drug|Lansoprazole|Lansoprazole capsules.
45498933|NCT02873702|Drug|Placebo|Dexlansoprazole placebo-matching capsules.
45498934|NCT03617120|Device|Ergonomic Brace vs hard brace|"Visit 1:~Usual check-up: standing in-brace radiograph of hard brace and doctor consultation~Pressure measurement of participant wearing their hard brace~Visit 2:~Brace Questionnaire (BrQ) for hard brace; Trunk Appearance Perception Scale (TAPS)~3D body scanning (before wearing the Ergonomic Brace)~Fitting of the Ergonomic Brace~Pressure measurement of participant wearing the Ergonomic Brace (instant)~Pressure measurement of participant wearing the Ergonomic Brace (after 2 hours)~3D body scanning (after wearing the Ergonomic Brace for 2 hours)~Brace Questionnaire (BrQ) for the Ergonomic Brace~Visit 3:~Standing in-brace radiograph of the Ergonomic Brace~Doctor consultation"
45498935|NCT03616262|Drug|Botox + Lidocaine|The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
45498936|NCT03616262|Drug|Lidocaine alone|The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
45383072|NCT04021108|Drug|Nivolumab 240 MG|Nivolumab (OpdivoTM) is a potent and highly selective humanized monoclonal antibody (mAB) designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Cancer cells are able to send a signal to the PD-1 via the PD-L1 molecule, tricking the T-cell into recognizing the cancer cell as normal. Nivolumab is designed to disrupt that signal and expose the cancer cell to the immune system. Nivolumab is given intravenously over a 60-minute period, usually every two weeks.
45498937|NCT02236754|Drug|18F-FP-DTBZ|The drug, no carrier added [18F]-FP-DTBZ, is formulated in 5% (v/v) ethanol in 0.9% sterile saline solution to produce [18F]-FP-DTBZ for injection. Subjects will receive a single i.v. administration of no more than 7.6 mCi of [18F]-FP-DTBZ for injection immediately prior to imaging. The specific activity at time of injection will less than 1.0 mCi/microgram and thus for a 7.6 mCi dose the maximal mass dose will be less than 10 microgram.
45498938|NCT02236754|Radiation|PET Scanning|Individuals will be imaged continuously (i.e. dynamically) for 2 hours.
45694801|NCT00904618|Procedure|TVT-SECUR - 'Hammock' technique|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
45694802|NCT00904618|Procedure|TVT-SECUR - 'U-Method'|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
45694803|NCT00904618|Drug|Local anesthesia (30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%).|Local anesthesia consisted of 30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%. Sedation was used in association with local anesthesia, including 1 mg of lorazepam sublingual as well as a combination of 0.5 to 2 mg intravenous (IV) of midazolam and 50 to 200 ug IV of fentanyl. Postoperative analgesia consisted of a prescription of 30 tablets of morphine 5 mg.
45694804|NCT03213028|Other|WHO Decision-Making Tool for Family Planning Clients and Providers|Contraception decision-making tool
45383073|NCT04019327|Drug|Talazoparib|"Phase I maximum tolerated dose portion:~Level 1, 2, 3 - 1 mg QD Days 1-6 Level 4, 5 - 1.25 mg QD Days 1-6 Level 6 - 1.5 mg QD Days 1-6"
45383074|NCT04019327|Drug|Temozolomide|"Phase I maximum tolerated dose portion:~Level 1 - 37.5 mg/m2 QD Days 2-8 Level 2 - 75 mg/m2 QD Days 2-8 Level 3 & 4 - 100 mg/m2 QD Days 2-8 Level 5 & 6 - 125 mg/m2 QD Days 2-8"
45383075|NCT04014413|Procedure|Fecal Microbiota Transplantation|Fecal microbiota transplantation
45498939|NCT03615950|Diagnostic Test|Bone Mineral Density (DEXA) scan|Radiologic assessment of bone mineral density in the lumbar spine. This will be performed at screening. If abnormal at screening, subjects will not be enrolled. For enrolled subjects, DEXA will be repeated at 12 months.
45383076|NCT03995108|Drug|Mavorixafor|Mavorixafor provided as 100 mg capsules.
45383077|NCT03995108|Drug|Placebo|Placebo matching to mavorixafor capsules
45383078|NCT03991052|Device|EV1000 and closed-loop system|This system will recommend when patients need fluid or not and adjust vasopressor administration automatically by the closed-loop system
45498940|NCT03615950|Diagnostic Test|Vitamin D Measurement|Measurement of 25-hydroxy vitamin D levels through the blood at baseline and 12 months. If low for age, subjects will receive dietary counseling to increase intake to recommended levels. Primary care providers of enrolled subjects will be notified of abnormal results.
45498941|NCT03615950|Diagnostic Test|Height measurement|Height will be measured at baseline and 12 months.
45498942|NCT03615950|Other|Assessment of medication compliance|Subjects enrolled in the intervention group will undergo assessment of compliance with swallowed corticosteroids prescribed by their clinical provider. This will be performed at 6 and 12 months.
45498943|NCT02911116|Drug|Ustekinumab|Subcutaneous Injection
45498944|NCT02911116|Drug|Ustekinumab|Intravenous Infusion
45498945|NCT03615872|Device|pessary use|evaluation of satisfaction of pessary use in case of symptomatic genital prolapse
45498946|NCT03664206|Diagnostic Test|MRS, conventional TMS and treshold tracking TMS|"Using~two MagStim 200 magnetic stimulator and a figure-of-eightc double 70 mm coil~SPECIAL MR Spectroscopy sequence~In addition, each group will undergo neurological examination"
45383079|NCT03991052|Device|Control group|This system will recommend when patients need fluid or not and nurses will adjust vasopressor administration as usual (standard of care)
45498947|NCT03664050|Drug|group A 2.5 mg letrozole oral tablets|2.5 mg letrozole oral tablets will be administered on the 2nd-3rd day of menses and then every day for 5 days. Treatment will be repeated for up to three cycles if the patient failed to conceive.
45498948|NCT03664050|Procedure|laparoscopic ovarian drilling|Bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.
45498949|NCT02998554|Drug|SHP640|Instill 1 drop of SHP640 (PVP-I 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
45498950|NCT02998554|Drug|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
45498951|NCT02996448|Drug|NDV-3A|A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.
45498952|NCT03663972|Behavioral|articulation therapy|children receive instruction in producing new sounds at the isolation, syllable and word level.
45498953|NCT03663972|Behavioral|phonologic treatment|children receive instruction in producing new sounds at the word level
45498954|NCT02995980|Device|Dual-Energy Contrast-Enhanced (DECE) mammography|Contrast mammography
45498955|NCT02995980|Device|digital mammography|routine digital mammography
45498956|NCT04055844|Drug|Decitabine|10 days of decitabine 20 mg/m2 IV daily; or, alternatively, per institution, physician, or patient preference on a 5-2-5 schedule with no weekend infusion. If a CR is achieved after 2 cycles using the 10-day schedule, subsequent cycles will change to a 5-day schedule.
45498957|NCT04055844|Drug|Ruxolitinib|Starting with day 1 of cycle 1 and continuing for up to 6 months after the end of the last cycle, patients will receive ruxolitinib 5 mg twice daily orally. Dose may be increased to 10 mg twice daily in cycles 2 through 4 if platelets improve to >100 x 10^9/L.
45498958|NCT04055844|Drug|Donor Lymphocyte Infusion (DLI)|DLI from the original donor will be infused within 10 days after the last dose of decitabine in each cycle.
45498959|NCT04058496|Other|Blood sampling|Five Timepoints: baseline (pre-operative), ICU admission, 4 hours after ICU admission, 8 hours after ICU admission, 48 hours after ICU admission
45554603|NCT03994497|Other|Blood samples|Blood samples the day of the surgery and 4 times during the next year. Blood samples and histological slides taken at each biopsy and if there is suspicion of rejection of the graft
45715054|NCT05744622|Other|KetacTM Universal AplicapTM|chemically cured conventional GICs
45383080|NCT03989466|Biological|Alemtuzumab|Given IV
45383081|NCT03989466|Drug|Itacitinib|Given PO
45383082|NCT03985046|Drug|Sintilimab plus Chemotherapy|Sintilimab will be administered intravenously, a fixed dose of 200 mg. Paclitaxel 135mg/m2, carboplatin AUC=5. Once every 3 weeks.
45383083|NCT03983369|Device|Low-Level Laser Therapy|The LLL used is the K-Laser Cube 3. The LLL is an athermal laser beam of low power, equipped with a placebo function (dummy imitating beam laser light, emitted by the same device but without physiological effect).
45383084|NCT03983369|Other|Placebo|Placebo
45383085|NCT03973151|Drug|HL-085|HL-085 is one MEK inhibitor.
45426076|NCT01027000|Drug|sirolimus|
45498960|NCT04055688|Device|Orbeye surgical videomicroscope|The ORBEYE surgical microscope is an FDA-cleared apparatus designed to facilitate operating procedures that involve fine nerves, blood vessels, and other small anatomic features by providing an enlarged stereoscopic visual field of the surgical site. The 4K 3D digital images of the ORBEYE microscope provide high-resolution stereoscopic images of the fine structures of tissue and blood vessels. As the surgical procedures are displayed on a large 55-inch monitor, the device is expected to reduce fatigue of the operator by eliminating the need for extensive viewing via microscope eyepieces for an extended period of time. The technology adopted in the ORBEYE was developed by Sony Olympus Medical Solutions, and its product design was handled by Olympus Medical Systems Corp. The ORBEYE is marketed by the Olympus Corporation.
45383086|NCT03970655|Drug|Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 1|Group 1 will receive 4 ml of 0.5% Bupivacaine or Ropivacaine with epinephrine in the LEFT pterygopalatine fossa
45498961|NCT04055688|Drug|5-Aminolevulinic Acid|5- aminolevulinic acid (5-ALA) is a European Medicines Agency- and Food and Drug Administration- (FDA-) approved drug that is administered to patients 2 to 4 hours before surgery and converted preferentially by tumor cells to protoporphyrrin IX (PPIX). PPIX fluoresces red when exposed to blue light. Use of 5-ALA has previously been shown to permit surgeons to obtain a more complete tumor resection, and its use has also been associated with an increased rate of progression-free survival.(3) There are currently 2 surgical microscope systems available on the market that are equipped with a 5-ALA visualization system. These visualization systems are currently classified by the FDA as Class I-exempt accessories to Class I-cleared surgical microscopes.
45498962|NCT02872142|Biological|Albutein 5%|Albutein is manufactured from human plasma. The dose of Albutein 5% for replacement following plasma removal will be calculated based on gender, weight, and the hematocrit of the participant.
45498963|NCT02872142|Procedure|Plasma Exchange|Plasma Exchange will be performed using albutein 5% as the replacement solution.
45498964|NCT04057794|Device|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by site clinician/physician/genetic counselor.
45498965|NCT04057794|Device|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by centralized genetic counseling group at Indiana University.
45498966|NCT02994654|Device|ReCell|"The ReCell-assigned treatment area will be treated as described in the product's Instructions for Use. In summary, 1ml of fluid physically covers a treatment area of 80 cm2. Each milliliter of fluid contains cells harvested from a square centimeter of thin split-thickness skin sample.~The reagents and components of the ReCell kit are used, in a scalable fashion, to facilitate disaggregation of cells from skin samples into filtered cell suspension. Areas to be harvested for skin samples are to be clean and show no evidence of surrounding cellulitis or infection. Treatment area sizes and cell suspension volumes are to be recorded."
45498967|NCT04882280|Behavioral|Light|10 hours of light exposure during the daytime, starting 2 hours after habitual wake time
45498968|NCT04055610|Device|Gait training using H-MEX exoskeleton|Participants will train 3 times a week for 10 weeks using H-MEX powered exoskeleton.
45554604|NCT03193424|Drug|Apatinib|Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .
45554605|NCT03526653|Other|exercise without visual stimuli|exercise on an ergometer or motomed in an environment without other visual stimuli
45554606|NCT03526653|Other|excercise with National Geografics|exercise on an ergometer or motomed while watching the National Geografics channel on television
45383087|NCT03970655|Drug|Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 2|Group 2 will receive 4 ml of 0.5% Bupivacaine or Ropivacaine with epinephrine in the RIGHT pterygopalatine fossa
45715055|NCT05744622|Other|KetacTM Universal AplicapTM with light cure|chemically cured conventional GICs with light curing enhancement
45715056|NCT01689857|Device|Scarclinic™ Thin|Apply Scarclinic™ Thin on the scar and dispense 4 ea.for each participant for 3 month.
45715057|NCT01689857|Device|Scarclinic™ Normal|Apply Scarclinic™ Normal on the scar and dispense 4 ea.for each participant for 3 month.
45715058|NCT03165240|Drug|BI 690517|Film-coated tablet
45715059|NCT03165240|Drug|Eplerenone|Film-coated tablet
45715060|NCT03165240|Drug|Placebo|Film-coated tablet
45848056|NCT04890366|Drug|Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
45848057|NCT04731714|Device|Rhythmic median nerve stimulation|Square-wave 200 µs pulses triggered by computer at 12 Hz, at the threshold for thumb movement (expected ~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
46056030|NCT02746731|Other|Cardiorespiratory and resistance training.|"A cardiorespiratory and resistance training program for at least 2 to 3 weeks will be conducted 3-times per week, of which two sessions will be supervised by a qualified person of the institute of physiotherapy and one session will be unsupervised and home-based.~Physiotherapy consists of one hour, moderate to intense interval training combined with muscle strength training."
46056031|NCT02746731|Other|Reference|No preoperative physical therapy training. Patients will be informed to remain physically active (as usual) until surgery.
46056032|NCT04403139|Drug|Shingrix|All participants will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the approved dose and schedule.
46056033|NCT02746653|Device|TroClose1200(TM)|Creation of access port and closure it by the same device, TroClose1200(TM)
45383088|NCT03967977|Drug|Tislelizumab|200 mg administered Intravenously (IV) as specified in the treatment arm
45383089|NCT03967977|Drug|Placebo|Tislelizumab placebo to match
45383090|NCT03967977|Drug|Cisplatin|70 mg/m2 administered IV as specified in the treatment arm
45383091|NCT03967977|Drug|Gemcitabine Hydrochloride|1000 mg/m2 administered IV as specified in the treatment arm
45383092|NCT03967977|Drug|Carboplatin|Area Under the Curve (AUC) 4.5 administered IV as specified in the treatment arm
45498969|NCT03615716|Behavioral|Multi-level Violence Prevention Intervention - Boys|Comprehensive, Multi-level Violence Prevention Intervention. The intervention consists of three components: (1) a 15-week after-school program, (2) group mentoring, and (3) community enhancement activities. Adolescents and mentors will attend a 2-hour weekly session at a community center, and will conduct up to four community enhancement activities. At the end of the program, a graduation celebration will be planned, and parents/guardians and stakeholders (e.g., coalition members) will be invited.
45498970|NCT03615716|Behavioral|Multi-level Violence Prevention Intervention - Caregivers|This is arm is measuring the Multi-level Violence Prevention Intervention that is administered to the boys, from the perspectives of their caregivers. The caregivers themselves will not receive an intervention, but their perspectives of the impact on the interventions on the boys will be examined
45498971|NCT04054284|Dietary Supplement|Antidiabetic Herbal Tea|Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
45498972|NCT04054284|Dietary Supplement|Herbal Tea|Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
46059057|NCT02583685|Drug|PR4 + LDV/SOF + ASV 8 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
46059058|NCT02583685|Drug|PR4 + LDV/SOF + SMV 8 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
45383096|NCT03963388|Other|Speech therapy|Online speech therapy, delivered by specialized speech therapists. Speech therapy will be complemented by a real-time visual feedback app (the Voice Trainer app).
45383097|NCT03962868|Procedure|Experimental procedure : ESD|ESD is a new endoscopic resection procedure that allows en-bloc resection for large superficial colorectal neoplasms. It used dedicated devices and consists in a deep submucosal dissection under the lesion after surelevation thanks to submucosal fluid injection and mucosal incision all around the lesion. The en bloc resection allows a perfect pathological analysis and a very low risk of recurrence (<1.5%)
45694805|NCT03837652|Other|Use of bone-borne palatal expander & maxillary osteotomy|Application of bone-borne palatal expander in conjunction with maxillary osteotomy for expansion of constricted maxillae
45383098|NCT03962868|Procedure|Comparison procedure: WF-piece meal EMR|WF-piece meal EMR is an older endoscopic resection technique. After surelevation of the lesion thanks to fluid submucosal injection, the precancerous lesion is resected in several pieces using a polypectomy snare. At the end of the procedure when macroscopically visible adenoma has been totally resected a snare tip coagulation of the margin of the scar is performed to destroy potential non visible residual adenoma. This procedure is quicker, safer than ESD but result in more recurrent disease (from 10 to 30% for lesions larger than 25 mm).
45383099|NCT03961815|Drug|Brazikumab Induction Dose|Participants who met criteria for early termination due to lack of efficacy (rescue treatment criteria) or who did not meet CDAI response at Week 52 in the lead-in study D5121C00001 are considered inadequate/non responders, and will receive IV induction dosing brazikumab at Week 0, Week 4, and Week 8 followed by maintenance dosing of brazikumab subcutaneously every 4 weeks thereafter up to Week 52.
45426077|NCT01027000|Drug|tacrolimus|
45426078|NCT01027000|Procedure|allogeneic stem cell transplant|
45498973|NCT04494438|Drug|Rituximab|
45498974|NCT03662490|Device|High resolution oesophageal manometry|High resolution oesophageal manometry (HRM) is the gold standard for the diagnosis of oesophageal motility disorder.
45498975|NCT04057482|Drug|D|treatment of BV with dequalinium chloride vaginal tablets
45498976|NCT04056936|Procedure|Frenotomy|To map the severity determining any possible consequences a tongue-tie may have for breastfeeding and infant nutrition we will follow-up a cohort of tongue-tied infants to register if the feeding, growth, thriving and speech of the infant/child is affected by a tongue-tie.
45498977|NCT03663426|Procedure|study group|"High dose corticoids pre-operative and 24h postoperative~Opioid free general anesthesia~Avoid opioids post-operative by continue clonidine, ketamine and lidocaine, only exceptional opioids after NSAID and paracetamol."
45498978|NCT03663426|Procedure|control|"No corticoids pre-operative.~Opioid anesthesia~Opioids post-operative after NSAID and paracetamol."
45498979|NCT03662412|Drug|Sirolimus|Oral solution of sirolimus, 2mg, once a day.
45498980|NCT03663270|Device|Hypotension probability index (HPI)|The intervention group is managed with the HPI parameter to detect and possibly prevent hypotension during anaesthesia.
45694806|NCT01839136|Procedure|Intrauterine transfer of gametes|
45694807|NCT01839136|Procedure|Intrauterine transfer of embryos|
45694808|NCT01839214|Drug|VB-201 160mg|
45694809|NCT01839214|Drug|Placebo|
45694810|NCT01839292|Device|uncovered D-type stent insertion|
45694811|NCT01839292|Device|double-layered ComVi stent insertion|
45383100|NCT03961815|Drug|Brazikumab Maintenance Dose|Responders from Lead-In study D5271C00001 who completed requirements through Week 52 and met CDAI response (CDAI score of < 150 points or CDAI reduction from Baseline of ≥ 100 points) without ongoing rescue treatment at Week 52 in the lead-in study. will receive maintenance dose of brazikumab administered subcutaneously every 4 weeks through Week 52, starting at Week 0. The subcutaneous dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered
45383101|NCT03960177|Drug|Glucarpidase|Given IV
45383102|NCT03960177|Other|Quality-of-Life Assessment|Ancillary studies
45383103|NCT03956056|Biological|Neoantigen Peptide Vaccine|• Each pool of vaccine study drug + poly IC:LC will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous (SC) injection.
45848058|NCT04731714|Device|Arrhythmic median nerve stimulation|Square-wave 200 µs pulses triggered by computer at random intervals with a mean rate of 12 Hz (as described in Morera Maiquez et al., 2020), at the threshold for thumb movement (expected ~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
45848059|NCT04723368|Device|Automated flying Drone carrying an Automated external defibrillator (AED)|Totally n=5 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over up to 14 months during daytime Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.
45848060|NCT04639674|Drug|AST-120|If no other medicines are taken usually, take AST-120 one hour after each meal with a frequency of three doses a day and one dose every administration. The drug will be taken for four weeks.
45848061|NCT04601532|Device|Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser|Catasyn™ Advanced Technology Hydrogel is a wound hydrogel that provides a moist wound environment. A moist wound environment is supportive to wound healing. SynePure™ Wound Cleanser is a non-cytotoxic wound cleanser for the removal of foreign material from epidermal and dermal wounds, burns, cuts, abrasions and minor irritations of the skin.
45848062|NCT04601532|Drug|Silver Sulfadiazine|Silver sulfadiazine, a sulfa drug, is used to prevent and treat infections in burn wounds.
45848063|NCT04520256|Behavioral|Online Behavioral Weight Loss Program|A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.
45694812|NCT01839370|Device|Closed Loop with Pramlintide|A closed-loop automated insulin management system (Adaptive Insulin Meal Supervisor- AIMS) for meals utilizing continuous glucose monitoring (CGM)and subcutaneous insulin pump and a standard pramlintide therapy will be compared to a standard pramlintide therapy alone to control glucose levels in individuals with type 1 diabetes. DiAs is controlled by the subject, with assistance from the study personnel as needed.
45694813|NCT01839448|Biological|Post-partum oral glucose tolerance test|All patients will have an oral glucose tolerance test at 4 to 12 weeks after the end of pregnancy. Study representatives will contact patients by phone to remind them of the necessity of this test, and its importance for their health.
45694814|NCT04380766|Procedure|Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer|Comparison between the pre-COVID and COVID groups of general, clinical, endoscopic and surgical outcomes
45694815|NCT04380532|Biological|V-SARS|Therapeutic vaccine formulated as a pill derived from heat-inactivated plasma from COVID-19 patients administered once-per-day to at least 20 healthy volunters for at least one month
45383104|NCT03956056|Drug|Poly ICLC|• Each pool of vaccine study drug + poly IC:LC will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous (SC) injection.
45383105|NCT03956056|Procedure|Blood for immune monitoring|-Baseline, day 1, day 22, day 50, day 78, week 25, and week 73
45383106|NCT03952351|Radiation|CT Coronary Angiography (CTCA)|CTCA scan in accordance with British Society of Cardiovascular Imaging CT guidelines
45383107|NCT03949920|Drug|Migalastat|Participants will be starting Migalastat as part of clinical care. Their initiation onto Migalastat is not determined by this study or it's protocol. Interventions as part of the study will be limited to the study investigations.
45383108|NCT03949855|Drug|Belimumab|"Belimumab is a recombinant, human, IgG1λ monoclonal antibody.~Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.~Standard Weekly dose: 200 mg. administered subcutaneously. A higher weekly dose, 400 mg weekly, per protocol and based on PK analysis, may be indicated for participants with high proteinuria."
45383109|NCT03949855|Drug|Placebo for Belimumab|"The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.~Standard weekly dose: 200 mg. administered subcutaneously. A higher weekly dose, 400 mg weekly, per protocol, may be indicated for participants with high proteinuria."
45498981|NCT02870972|Drug|BCX7353|Plasma kallikrein inhibitor
45498982|NCT02870972|Drug|Placebo|
45498983|NCT03663192|Device|strain echocardiography|strain echocardiography during septic shock
45498984|NCT03214367|Drug|LY900014|Administered SC
45383110|NCT03949855|Drug|Rituximab|"Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.~Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.~Dose: 1000 mg intravenously (IV), Week 4 and -6."
45383111|NCT03949387|Other|FES Cycling Exercise|FES cycling will use self-adhering surface electrodes (Pals Platinum, Fallbrook, CA) placed over the quadriceps, hamstrings, and gluteal muscle groups to deliver stimulation to the leg muscles.
45383112|NCT03949387|Other|Passive Leg Cycling|Passive leg cycling will not involve electrical stimulation
45383113|NCT03946423|Procedure|Bariatric Surgery with Sleeve Gastrectomy|Standard of care bariatric surgery with sleeve gastrectomy
45383114|NCT03946423|Behavioral|Lifestyle Intervention|All participants receive lifestyle intervention. The lifestyle intervention program is modeled closely after that used in the Diabetes Primary Prevention Trial and the LookAHEAD diabetes treatment studies. Intervention includes counseling sessions weekly for the first six months, twice a month during months 7-9, and monthly during months 10-12, and energy intake and exercise goal monitoring and guidance.
45383115|NCT03944538|Behavioral|Lifestyle Physical Activity|The intervention consists of two primary components: a dedicated Internet website and one-on-one video chats with a behavioral coach via Zoom. The intervention focuses on the skills, techniques, resources and strategies for becoming and staying physically active with MS, but does not provide a prescription for exercise or physical activity itself.
45383116|NCT03944538|Behavioral|General Wellness|The control condition provides an Internet website and one-on-one video chats that discuss materials about self-managing MS consequences and health indicators through methods other than physical activity.
46059059|NCT02583685|Drug|PR4 + LDV/SOF + ASV 12 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
45383119|NCT03927066|Other|Assigned Interventions|Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
45383120|NCT03924219|Other|CMV T cell Immunity Assay|Flow cytometry based assay quantifying IFN-gamma expression in T cells following CMV peptide stimulation (Viracor)
45383121|NCT03921944|Diagnostic Test|CT scan of the shoulders|studies of both operative and nonoperative shoulders
45383122|NCT03916627|Drug|cemiplimab|Administered intravenous (IV)
45383123|NCT03916627|Drug|Platinum Doublet|Administered intravenous (IV)
45383124|NCT03916627|Drug|fianlimab|Administered IV
45498985|NCT03214367|Drug|Insulin Lispro|Administered SC
45383125|NCT03912064|Drug|Ipilimumab|Ipilimumab is an antibody that acts against CTLA-4
45383126|NCT03912064|Biological|CD25hi Treg depleted DLI|Donor lymphocyte product
45498986|NCT03214367|Drug|Insulin Glargine|Administered SC
45383127|NCT03911869|Drug|encorafenib|taken orally
45383128|NCT03911869|Drug|binimetinib|taken orally
45498987|NCT03214367|Drug|Insulin Degludec|Administered SC
45498988|NCT02994108|Behavioral|txt2protect|Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination.
45498989|NCT02994108|Behavioral|Sexual Health Control|Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination.
45498990|NCT03663036|Diagnostic Test|Magnetic Resonance Imaging of the shoulder|Clinical and radiological assessments of the shoulders and the donor sites
45848064|NCT04520256|Behavioral|Virtual Reality for Behavioral Weight Loss Skills Training|This program allows participants to practice behavioral weight loss skills using an online virtual reality system accessed via a Web browser.
45498991|NCT03614000|Other|Screening Questionnaires|"Measurement tools:~Social Responsiveness Scale (SRS-2) is a validated 65-item scale for the screening of ASD that requires parents to rate the child's behaviors in the previous 6 months. The questionnaire assesses interpersonal behavior, communication and repetitive/stereotypic behavior characteristics of ASD.~The Aseba Questionnaires are validated diagnostic tools that can be filled in by the parents, teachers or children to evaluate various behavioral and emotional problems. The CBCL assesses internalizing (i.e., anxious, depressive and over-controlled) and externalizing (i.e., aggressive, hyperactive, noncompliant and under-controlled) behaviors.~The VG&O The VG&O is a questionnaire developed in Dutch that gives a subscale of parental stress (OBVL), family functioning (VGFO), education habits (VSOG) and life events (VMG). The OBVL will be used"
45498992|NCT02032160|Biological|Engerix B IM injection - 20ug|Engerix B IM injection - 20ug At 0, 1 and 6 months
45498993|NCT02032160|Biological|Fendrix IM injection - 20ug|Fendrix IM injection - 20ug At 0, 1 and 6 months
45498994|NCT03662958|Drug|Lutrate|a novel leuprolide acetate 3.75mg depot
45498995|NCT03662958|Drug|Enantone|market reference leuprolide acetate 3.75 mg depot
45383129|NCT03911453|Drug|Rucaparib|Patients will be treated with single agent rucaparib for 3wks and then proceed to surgery. Core-biopsies (at the time of diagnosis) and tumor from the surgical resection will be assessed for change in expression of PD-L1 by Immunohistochemical assay (IHC).
45383130|NCT03911128|Other|Observational|Observational study - no intervention
46056034|NCT02746497|Procedure|Acupuncture|"Acupuncture style; Western Medical Acupuncture (WMA). In WMA all types of sham (placebo) acupuncture are believed to produce a certain amount of sensory stimulation and thereby a possible therapeutic effect. In addition, other studies have shown that sham acupuncture is associated with a moderately large nonspecific effect and compared to other inert placebo intervention the effect associated with sham acupuncture might be larger. Thus we use a control group instead of a placebo group.~Needles; sterile disposable needles (Plandent) size 0.30x30mm. The needles will be inserted perpendicularly and rotated manual between finger and thumb for a few seconds to elicit de-qi. Needle retention time will be 10 minutes. Afterward the needle will be removed. Acupuncture points; CV-3, CV-4, LR-8, SP-6, SP-9. In total 8 points as LR-8, SP-6, SP-9 are given bilaterally."
45498996|NCT02032082|Other|Carbone monoxide|
45498997|NCT04057170|Other|accelerated protocol and mulligan method|manual therapy technic
45498998|NCT03615638|Other|Fall prevention program|12-week fall prevention program (including warm-up, cool-down, education, Tai Chi, and lower limb strengthening)
45498999|NCT03636737|Other|pathology associated|list of pathology associated to Pyoderma gangrenosum
45499000|NCT03662256|Other|Current Primary Care Referral Process|Children who refer hearing screening will receive the same referral method each preschool had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.
45848065|NCT04520256|Behavioral|Tailored Interactive Video Feedback|Video-recorded messages are used to provide periodic feedback on progress with weight loss, dietary change, and physical activity. Additional videos provide dietary skills training.
46056035|NCT02746419|Device|Vessix|Renal denervation using radio-ablation
46056036|NCT00636285|Drug|Placebo|Placebo
45383134|NCT03897127|Drug|Cytarabine|"Induction therapy: 200 mg/m2 i.v. (continuously) d1-7~Consolidation therapy:~Patients age 18-60 years~o Intermediate-dose cytarabine 1500 mg/m2 i.v. q12h (3 hrs) d1-3~Patients age >60 years o Intermediate-dose cytarabine 1000 mg/m2 i.v. q12h (3 hrs) d1-3"
45383135|NCT03897127|Drug|Daunorubicin|Induction therapy: 60 mg/m2 i.v. (1 hr) d1-3
45499001|NCT03662256|Other|Telemedicine Referral Process|In communities randomized to the expedited telemedicine intervention, parents of children who refer hearing screening will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children who refer screening will be transported to clinic for their appointment with adult chaperones. Parent participation will be required unless parents direct otherwise. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
45554607|NCT03526653|Other|Exercise with MemoRide|excercise on an ergometer or motomed with the interactive software program MemoRide with which participants can exercise in real life on a virtual manner
45554608|NCT03193346|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) 155U to 195U IM injections in head/neck areas.
45848066|NCT04520256|Behavioral|Tailored Intervention for Structured Physical Activity|Periodic self-assessment is used to guide selection of a physical activity goal. Home-based instructional videos are provided to help meet the selected goal.
45848067|NCT04520256|Behavioral|Skills Training for Dysregulated Eating|Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).
45848068|NCT04520256|Behavioral|Platform for Social Support & Friendly Competition|An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.
45499002|NCT03518216|Behavioral|ADAPT|Aim to Decrease Anxiety and Pain Treatment is a remotely delivered tailored treatment integrating mindfulness meditation and cognitive behavioral therapy. It consists of 6 sessions and blends pain and anxiety coping strategies. The first 2 sessions will be interactive with a trained psychological provider and the following 4 sessions will be web-based. Each web-based session will be followed by therapist support. The intervention is delivered through a HIPAA compliant video platform.
45499003|NCT03231371|Drug|Adenosine|Administration of intravenous adenosine infusion over 3 minutes (0.14 ml/kg, 3mg/ml concentration, total dose).
45499004|NCT03662880|Radiation|Cardiac Magnetic Resonance|Imaging modality used to detection thrombus in left atrium
45499005|NCT03662880|Radiation|Trans-esophageal echo|a procedure in which the ultrasound probe is inserted into the esophagus and ultrasonographic images are obtained of the heart using echo and color Doppler images.
45499006|NCT03613766|Other|Physical activity program|
45499007|NCT04057092|Dietary Supplement|Dietary Supplement INergy-FLD|INergy-FLD® is an immune modulating formula containing various ingredients including L-Arginine, whey protein isolate, and omega-6 fatty acid, aimed to attenuate excessive inflammatory responses without being immunosuppressive and to replenish nutrients that are depleted in a state of surgical stress, thereby enhancing the recovery process and decreasing the risk of infection. The volume of the beverage is 250mL per serving and patients will be asked to consume 3 servings periodically per day for 5 days prior to surgery and 5 days following surgery.
45499008|NCT03529019|Drug|Ensure Surgery Immunonutrition Shake|An FDA approved nutritional supplement. Prepackaged product designed to be administered one week prior to and one week post surgical procedures.
45499009|NCT03529019|Drug|Ensure Enlive Advanced Nutrition Shake|An FDA approved nutritional supplement. Prepackaged product designed to be administered 2 weeks prior to and 2 weeks post surgical procedure for a period of one week. .
45499010|NCT03613922|Other|Early Manual Therapy|Mulligan's Mobilization with Movement technique for radiocarpal,ulnocarpal, distal radioulnar and proximal radioulnar joints was applied.
45383136|NCT03897127|Drug|CPX-351|"Induction 1:~o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine [100 U/m²] i.v. (90 min) d1,3,5~Induction 2:~o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine [100 U/m²] i.v. (90 min) d1,3~Consolidation therapy:~o CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine [65 U/m²] i.v. (90 min) d1,3"
45499011|NCT03613922|Other|Routine Physiotherapy|Routine physiotherapy program consisted of range of motion, flexibility and strengthening exercises, and home exercise program was applied.
45499012|NCT03663114|Drug|Lenvatinib|Lenvatinib capsule
45694816|NCT00906958|Device|Nexus Flow Generator|The modified device to be assessed in this study will act in a similar way to the existing device, VPAP Auto, but utilises an improved algorithm which should maintain or enhance the effectiveness of the treatment.
45694817|NCT00906958|Device|VPAP Flow Generator 25|Exiting VPAP Auto 25 Flow Generator with A10 Algorithm
45383137|NCT03897088|Drug|PART 1: Double-blind Placebo-controlled|all eligible subjects will receive either tildrakizumab or placebo
45383138|NCT03897088|Drug|PART 2: Double-blind Active Treatment Extension|subjects initially on placebo will be switched over to receive tildrakizumab while subjects initially on tildrakizumab will continue to receive tildrakizumab as per defined schedule
45383139|NCT03896464|Procedure|Soft tissue hamstring autograft|Patients will be prescribed to receive a soft tissue hamstring autograft to for ACL reconstruction.
45499013|NCT03526679|Drug|Eribulin|lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days
45499014|NCT03526679|Drug|Lenvatinib|lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days
45499015|NCT03615092|Procedure|Root coverage with extended flap technique and acelular dermal matrix|At one side, the root coverage have been done with a extended flap technique and acellular dermal matrix and there was no cervical lesion. At the other side, the same technique was performed, but the gingival recession was associated with a noncarious cervical lesion.
45499016|NCT04056780|Other|Sample collection study|Sample collection and collection of laboratory values
45499017|NCT04844684|Other|Blood and urine collection|Blood sampling urine collections before RYGP and 1 month and 1 year after.
45499018|NCT04057404|Device|Alivecor Heart Monitor|
45499019|NCT03613688|Dietary Supplement|Deepure|Pu'erh Tea extract
45694818|NCT01832116|Drug|89Zr-MMOT0530A|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
45694819|NCT01839526|Drug|Iohexol|Evaluations of renal and cardiac function are standard-of-care in young patients with Fabry disease. This study uses the more precise iGFR measurement of renal function. No investigational drug will be administered in this study for the treatment of Fabry disease.
45694820|NCT03212872|Diagnostic Test|Endoscopy|
45694821|NCT01832194|Drug|Botox|
45383140|NCT03896464|Procedure|Quadriceps tendon autograft|Patients will be prescribed to receive a quadriceps tendon autograft to for ACL reconstruction.
45499020|NCT04057326|Drug|Oryz-Aspergillus Enzyme and Pancreatin Tablet|2 tablets/time, 3 times daily,Oral Administration.
45499021|NCT04057326|Drug|Placebo|2 tablets/time, 3 times daily,Oral Administration.
45499022|NCT04573829|Procedure|Home visit|Psychologist come once a week for the carer and three times a week for the patient
45499023|NCT04839146|Biological|ABNCoV2 Vaccine|SARS-CoV-2 vaccine
46056037|NCT00636285|Drug|BSYX-A110|BSYX-A110, Dosed intravenously, 3 mg/kg
46056038|NCT00636285|Drug|BSYX-A110|BSYX-A110, Dosed intravenously, 10 mg/kg
46056039|NCT02746185|Drug|rivaroxaban|rivaroxaban, 15 mg BD (Bis in die) for 3 weeks followed by 20mg OD (Omni die) for 9 weeks
46056040|NCT02746185|Drug|Low-molecular-weight heparin|dalteparin, 200 IU/kg OD for 4 weeks followed by 150 IU/kg OD for 8 weeks
46056041|NCT04216485|Behavioral|Intensive Lifestyle Intervention|Dietary intervention combined with healthy lifestyle counseling
46056042|NCT04216485|Behavioral|Standard Care|Standard prenatal care on diet, nutrition and physical activity
45499024|NCT04628507|Other|Spent media collection|Embryo spent culture media, otherwise discarded as per standard of care, is collected once embryos have completed in vitro culture.
45499025|NCT02870348|Biological|Alpha-1 MP|Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as alpha1-antitrypsin.
45499026|NCT03615014|Other|Filling questionnaires|Questionnaires will be submitted to patients during their visit to emergency service and 3 months later to evaluate the prevalence of Post Traumatic Stress Disorder and to identify predictive biopsychosocial factors
45499027|NCT03614936|Other|Geriatric Screening Test G8|Geriatric screening test (Oncodage-G8). The oncologist realizes it and proposes the oncological treatment which seems to him then the most adapted (treatment which can be different from that proposed after the oncological evaluation only).
45499028|NCT03614936|Other|Geriatric fragility test GERICO|"GERICO geriatric frailty test (if possible the same day as the G8 and in any case in the same week): Realized by the oncologist, it includes:~the socio-cultural evaluation scale,~the ADL autonomy questionnaire,~assessment of locomotor disorders,~nutritional assessment,~the MMSE Cognitive Function Evaluation Questionnaire,~the GDS-4 mood rating scale,~the comorbidity assessment test (Charlson Index)"
45499029|NCT03281720|Procedure|TAD|the same intervention as listed in the arm description
45499030|NCT03613610|Radiation|Radio-frequency ablation of genicular nerves|Ablation of the genicular nerves for pain relief in advanced knee osteoarthritis
45499031|NCT03239873|Biological|VARIVAX® PE34 Process|Varicella virus vaccine live manufactured with a new passage extension process (PE34)
45499032|NCT03239873|Biological|VARIVAX® 2016 Commercial Process|Varicella virus vaccine live manufactured with the 2016 commercial process
45499033|NCT03239873|Biological|M-M-R II®|Measles, Mumps, and Rubella virus vaccine live
45848069|NCT04098978|Other|Pharmacist Drug Therapy Management|Patients will be seen by pharmacist for collaborative drug therapy management.
45383141|NCT03873272|Device|Cryotherapy|Study subjects will wear NatraCure flexible socks on bilateral hands and feet. The sock will act as a mitten and covers the entire hand until past the wrist. There are 2 gel packs inserted into the sock, to provide cooling to the dorsal and frontal aspect of the hand. For the feet, the sock will cover the entire foot until above the ankle. Garments will be refrigerated for at least 3 hours at -25 to -30 Celsius prior to use. With each infusion, patients will wear the frozen garments on their hands and feet for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion. Two sets of socks will be used during each session for 45-60 minutes each to maintain a consistently low temperatures of the extremities.
45426079|NCT00980538|Drug|Etravirine|Participants will be dosed with etravirine by weight up to a maximum dose of 200 mg bid until switched to an etravirine-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.
45426080|NCT00949819|Other|Active surveillance|Serial, long term data collection and active surveillance
45499034|NCT05384210|Drug|Milnacipran|Milnacipran will be administered according to the treatment recommendations for fibromyalgia, starting with 50 mg once daily for 1 week then increasing to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 months.
45499035|NCT05384210|Drug|Gabapentin|Patients will receive gabapentin (1200 mg twice daily) as a monotherapy. Gabapentin will be administered according to the treatment recommendations for FM patients starting with 400 mg 3 times per day, then increasing the dose to 800 mg 3 times per day with a maximum dose of 2400 mg per day according to efficacy and tolerability for 3 months
45499036|NCT05384210|Drug|Combined gabapentin/milnacipran|Patients will receive combined gabapentin as group B and MLN as group A
45499037|NCT03613376|Other|Class II compression stockings|Patients in this group will use class II compression stocking continuously until next evening and then next 4 days during daytime
45499038|NCT03194672|Behavioral|Healthy Adolescent Transitions (HAT) program|"The components of the intervention are described in the arm description.~The intervention is based upon the theoretical framework of behavioral economics, which suggests that low intensity nudges can help recipients accomplish their own goals. All components of the intervention are voluntary; some participants may wish to discuss all components, while other participants may wish to discuss selected components consistent with their priorities."
45694822|NCT01832272|Procedure|Reinflation after early tourniquet deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled
45694823|NCT01832428|Other|Intra thecal transplantation of Autologous Stem Cells|Intra thecal transplantation of Autologous Stem Cells
45694824|NCT00907426|Drug|Bimatoprost 0.03% solution|Once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
45694825|NCT00907426|Drug|Vehicle solution|Once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
45694826|NCT01832662|Other|coffee|coffee, placebo enriched with polyphenols and placebo with caffeine
45694827|NCT01832662|Other|coffee polyphenols mixed with placebo|coffee polyphenols mixed with placebo
45383142|NCT03873272|Device|Compression Therapy|Study participants will wear Sigvaris Secure Arm Sleeves and Gloves on bilateral upper extremities. The sleeves and gloves provide 20-30mmHg of compression. Subjects will wear Sigvaris CompreFlex Lite compression garments on the lower extremities which includes a transition liner with a compressive foot, providing 20-30mmHg of compression on the lower leg and 15mmHg on the toes and feet. AccuTabs will be placed along the CompreFlex Lite to easily and accurately set the compression level at 20-30mmHg. With each chemotherapy infusion, patients will wear the sleeves/gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
45383143|NCT03873272|Device|Loose glove/sock|Study participants will wear a non-compressive sleeve and loosely fitting glove on bilateral arms and hands. They will also wear a non-compressive Sigvaris Basic Liner with the CompreFlex Lite loosely applied over it. The investigators will verify that no compression is applied via using an interface pressure sensor (PicoPress). The maximum level of allowed pressure for garments will be 3mmHg. If the pressure reading is greater than 3mmHg, then a larger garment size will be used. Measurements with the pressure sensor will be repeated as needed to ensure a low pressure level of less than 3mmHg. With each chemotherapy infusion, patients will wear the gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
45383144|NCT03870919|Drug|Palbociclib|"The included patients will first receive the following systemic treatment according standard of care:~Non-steroidal aromatase inhibitor (letrozole)~Palbociclib~Monthly Luteinizing hormone-releasing hormone (LHRH) analogue for non-menopausal patients only. Surgical bilateral oophorectomy is an acceptable option."
45383145|NCT03870919|Other|locoregional treatment|After normally 6 courses of systemic treatment initiation, the loco-regional treatment of the primary tumour will be performed: surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy
45383146|NCT03865290|Drug|Ondansetron 8mg|Oral Ondansetron 8 mg
45694828|NCT01832662|Other|maltodextrin enriched with caffeine|maltodextrin enriched with caffeine
45694829|NCT00908908|Drug|eribulin|Cycle 1 day 1: radio-labeled dose of 2 mg radioactive eribulin, followed by 1.4 mg/m^2 of non-radio-labeled eribulin thereafter on days 1 and 8 every 21 days.
45383147|NCT03865290|Drug|Placebo|Oral matched placebo
45694830|NCT00909064|Drug|Fondaparinux Sodium (Arixtra)|2.5 mg once per day to begin 6-8 hours after surgery and continued for 10 days.
45694831|NCT03837340|Other|CMHT|Community mental health teams (CMHTs) delivering evidence-based interventions to people with SMI, inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
45694832|NCT03837340|Other|CAU|Care as usual (CAU) usually consisting of inpatient psychiatric care or outpatient care prescribing medication.
45694833|NCT03837106|Other|Rehabilitation program|3-month rehabilitation program comprising exercise and education specific to musicians. The program will be supported by an online platform containing more than 50 exercise videos, narrated powerpoint presentations, informative videos, quizzes, and forums for communicating with a physiotherapist and for organizing group exercise sessions.
45694834|NCT01832896|Drug|Ecallantide subcutaneous dosing|For acute attacks of Hereditary Angioedema in children and adolescents, Ecallantide will be administered.
45694835|NCT03212014|Other|LSVT-BIG|LSVT BIG can be delivered by a physical or occupational therapist. Treatment is administered in 16 sessions over a single month (four individual 60 minute sessions per week). This protocol was developed specifically to address the unique movement impairments for people with Parkinson disease. The protocol is both intensive and complex, with many repetitions of core movements that are used in daily living. This type of practice is necessary to optimize learning and carryover of your better movement into everyday life!
45848070|NCT03872700|Drug|Intranasal fentanyl|Fentanyl Citrate
45848071|NCT03872700|Drug|Placebo|Sterile Water Up to 5Cc
45848072|NCT03811470|Other|Standard diabetes management model in each MMC center|Standard diabetes management model in each MMC center
45499039|NCT03614780|Behavioral|30 minutes outdoors|Participants were asked to add an additional 30 minutes of time spent outdoors during the last 5 days of participation
45499040|NCT04804592|Device|Tactile Esthesiometer Prototype|A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement
45499041|NCT04804592|Device|Liquid Jet Esthesiometer Prototype|Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement
45499042|NCT04804592|Device|Cochet Bonnet esthesiometer|A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
45499043|NCT03213509|Other|Interview (Social and Verbal Autopsy)|Verbal autopsy is a technique used to determine the cause of death by asking caregivers, friends or family members about signs and symptoms exhibited by the deceased in the period before death. This is usually done using a standardized questionnaire that collects details on signs, symptoms, complaints and any medical history or events. The cause of death, or the sequence of causes that led to death, are assigned based on the data collected by this questionnaire and on any other available information. The social autopsy tool is used in conjunction with the verbal autopsy tool to explore the non-biological factors contributing to a death, including the social, behavioural and health systems determinants of maternal and child deaths.
45499044|NCT04802798|Dietary Supplement|Fibre 1|Food derived fibre presented as a white powder
45499045|NCT04802798|Dietary Supplement|Fibre 2|Food derived fibre presented as a white powder
45848073|NCT03780426|Device|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability (Oliviero et al., 2011; Oliviero et al., 2015; Dileone et al., 2018). Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the left or right motor cortex, using a tSMS helmet (MAGmv1.0; Neurek SL, Toledo, Spain).
45499046|NCT04802798|Dietary Supplement|Placebo|Simple sugar, presented as a white powder
45499047|NCT03614702|Biological|1-dose cIPV + 2-doses bOPV (Candy)|Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
45499048|NCT03614702|Biological|1-dose sIPV + 2-doses bOPV (Candy)|Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
45499049|NCT03614702|Biological|2-doses cIPV + 1-dose bOPV (Candy)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
45499050|NCT03614702|Biological|2-doses sIPV + 1-dose bOPV (Candy)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
45499051|NCT03614702|Biological|2-doses cIPV + 1-dose tOPV (Candy)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
45499052|NCT03614702|Biological|2-doses sIPV + 1-dose tOPV (Candy)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
45848074|NCT03780426|Device|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain) of motor cortex contralateral to the stimulated hemisphere.
45383148|NCT03861676|Radiation|Focal brachytherapy with PSMA PET imaging|Focal brachytherapy with PSMA PET imaging. Focal (partial prostate gland) brachytherapy following 18F-DCFPyl PET/CT radiotracer imaging. Patients will also undergo pre-treatment transperineal mapping biopsy.
45383149|NCT03861676|Drug|(18F)DCFPyL|18F-DCFPyl PET/CT scan
45383150|NCT03851237|Drug|64Cu-DOTA-ECLIi|-The first four patients enrolled on study will undergo an additional delayed imaging time point approximately 2-6 hours following 64Cu-DOTA-ECL1i
45383151|NCT03851237|Device|PET/CT|-Standard of care
45499053|NCT03614702|Biological|1-dose cIPV + 2-doses bOPV (Liquid)|Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
45694836|NCT03212014|Other|POWER|Power Rehabilitation(PR), a new resistance training regime, can improve in power and independence level of the elderly people. The first word of PR was in brief of Produce Outcome Worthwhile for the Elderly Rehabilitation (POWER)
45694837|NCT03212014|Other|Traditional rehabilitation|traditional exercise models in currently clinical use
45383152|NCT03843359|Drug|GSK3745417|GSK3745417 will be administered.
45694838|NCT03211780|Device|General Electric LOGIQ E9 ultrasound system|Patients will be brought to the operating room in line with standard clinical practice and after esophageal exposure, but before surgical mobilization of the esophagus, shear wave vibrometry and B-mode imaging will be performed after esophageal distension with a fluid filled balloon intra-operatively.
45499054|NCT03614702|Biological|1-dose sIPV + 2-doses bOPV (Liquid)|Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
45499055|NCT03614702|Biological|2-doses cIPV + 1-dose bOPV (Liquid)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
45694839|NCT03211936|Procedure|PEEP TITRATED|After titrated peep levels, we choice this level of peep for de group (peep titrated)
45499056|NCT03614702|Biological|2-doses sIPV + 1-dose bOPV (Liquid)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
45499057|NCT03614702|Biological|2-doses cIPV + 1-dose tOPV (Liquid)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
45499058|NCT03614702|Biological|2-doses sIPV + 1-dose tOPV (Liquid)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
45499059|NCT02032394|Drug|Povidone-iodine|15 ml 10%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
45499060|NCT02032394|Drug|Chlorhexidine|15 ml .2%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
45499061|NCT02032394|Drug|Normal saline|15 ml .9%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
45499062|NCT03239483|Drug|Dapivirine gel|Dapivirine gel (0.05%); administered rectally
45499063|NCT03239483|Drug|Placebo gel|Universal HEC placebo gel; administered rectally
45499064|NCT02868554|Device|AcceleDent Aura|Patients receiving vibration therapy will be instructed to bite down on the AcceleDent mouthpiece, which vibrates at a .25 Newtons (25 grams) force level with a 30 Hertz frequency for 20 minutes per day.
45499065|NCT02868554|Device|Accelerated Invisalign therapy|Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
45499066|NCT01068912|Drug|Favipiravir|1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days
45499067|NCT01068912|Drug|Favipiravir|High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
45499068|NCT01068912|Drug|Placebo comparator|Placebo BID x 1 day, and Placebo BID x 4 days
45499069|NCT04563143|Other|Novel DBS Stimulation|Stimulation patterns will vary from the standard therapeutic approach in terms of frequency, contact location, and/or temporal pattern.
45499070|NCT03614624|Device|Comparative standard echocardiography between two devices : Vivid 9 General Electric and Epiq 7 Philips|Comparison of the various values of strain with the echograph General Electric and the electrograph Philips.
45499071|NCT03614546|Radiation|SBRT|Stereotactic Body Radiation Therapy (SBRT)
45499072|NCT03614546|Radiation|IMRT|Intensity-modulated Radiation Therapy (IMRT)
45694840|NCT03211936|Device|Use ultrasound|We make a lung ultrasound after we setup a different level of PEEP
45848075|NCT03192774|Device|Transcatheter Aortic Valve Implantation|Interventional replacement of the aortic valve
45383153|NCT03843359|Drug|Dostarlimab|Dostarlimab will be administered.
45499073|NCT03614546|Procedure|Hepatectomy|Hepatectomy
45499074|NCT03614546|Procedure|TACE|transarterial chemoembolization (TACE)
45499075|NCT03229109|Device|Spectrophon dehydration body monitor|Participants (both males and females) were assigned to physical activity (running), biosensor was attached to subject's wrist
45383154|NCT03843242|Device|Pacemaker with Fixed long AV delay|Fixed AV delay was applied in the first 3 months of pacemaker implantation according to previously proposed definition.
45383155|NCT03843242|Device|Pacemaker with VpS® algorithm on|"After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~In Vp-suppression algorhithm on group, Vp suppression algorithm of Enitra 8 DR-T pacemaker will be turned on at 3month visit after enrollment.~The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm."
45499076|NCT03614468|Other|Formula A|Formula A is to be feed as the sole source of nutrition for 52 weeks to healthy term infants.
45499077|NCT03614468|Other|Formula B|Formula B is to be feed as the sole source of nutrition for 52 weeks to healthy term infants.
45499078|NCT01314131|Behavioral|Stimulation group|"Patients living in nursing home can be enrolled in the study by giving their verbal consent. The trial lasts two weeks for each patients and it will be performed in three parts :~a cognitive and behaviour assessment : MMSE, BREF, NPI, IA~an interest questionnaire for patients. It contains 40 questions about activities.~the intervention : patients will be propose 5 activities. 4 of them are activities that patients are interested in. Each activity have to last 15 minutes and the stimulation is measured by a scale named Observational Measurement of Engagement ."
45499079|NCT03478670|Genetic|Strimvelis|Strimvelis is a CD34+ cell enriched dispersion of human autologous bone marrow derived hematopoietic stem/progenitor cells transduced with a retroviral vector containing the human ADA gene. It will be administered as an intravenous infusion once only.
45499080|NCT03614390|Behavioral|mindfulness based cognitive therapy (MBCT)|a well described and structured intervention, which is published previously. The psychoeducation materials in the MBCT will be titrated to discuss about low mood and burnout
45499081|NCT04056234|Procedure|Joint puncture|Patient requiring joint puncture for diagnostic or therapeutic reasons.
45499082|NCT05181215|Drug|Monomethyl Fumarate 190 Mg|2 x oral 95 mg capsules, delayed-release
45499083|NCT05181215|Drug|Diroximel Fumarate 462 mg|2 x 231 mg capsules, delayed-release
45694841|NCT03211936|Device|Impedance tomography|We use the impedance tomography to titrate peep levels, and acquire dates of collapse, hyperdistension and compliance.
45694842|NCT03211936|Other|Best PEEP for less collapse|After titrated PEEP levels we setup the best PEEP the according of tomography impedance
45694843|NCT03211936|Other|PEEP 4|We set the peep level after titrated peep = 4 cmH20.
45848076|NCT03137160|Biological|Ixekizumab|Injection
45848077|NCT03058614|Drug|CEUS|In subjects randomized into the CEUS arm, 2 mL of Lumason will be injected as a single dose via a nephrostomy tube at the time of postoperative renal ultrasound, following by 5 mL of normal saline flush. Subjects will be given up to one additional dose injected in the same fashion as indicated during the imaging study to confirm opacification of the ureter.
46056043|NCT05630391|Device|High-Fidelity Simulation Manikin|A high-fidelity simulator was developed to teach skills in nursing education, and it is sized to represent an adult male patient. The mannequin can be controlled using a computer program, it can breathe, and its vital signs can be monitored using a bedside monitor.
45383156|NCT03843242|Device|Pacemaker with IRSplus algorithm on|"After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~In IRS-plus algorithm on group, IRS plus algorithm of Enitra 8 DR-T pacemaker will be turned on at 3 month visit after enrollment.~The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm."
46056044|NCT05630391|Other|Education|Training for 26 nursing students who constituted the control group performed personnel protective equipment (PPE) wearing-removal practice
45383158|NCT03840291|Drug|Edoxaban|Edoxaban will be used for resolution of left atrial appendage thrombi
45383159|NCT03837626|Drug|Placebo - Cap|6 months of 1 pill a day
45383160|NCT03837626|Drug|Amiloride Pill|Max dose of 5 mg a day for 6 months
46056045|NCT05630157|Behavioral|Unplugged plus gambling component|12 units/lessons of the Unplugged prevention curriculum plus a gambling component including specific gambling contents in units 3-4-5-7-9 and a 13th unit based on probability and mathematical concepts taught through an online simulator
45383161|NCT03832595|Other|EHR-based PHM|"An EHR in-basket message will be sent to the patient's PCP which identifies the patient's high-risk CKD status and indicates that the patient will receive:~Nephrologist led electronic consultation: review of the patient's EHR with recommendations sent to the PCP every ~6 months,~Medication therapy management: PharmD led telephonic medication therapy management with the patient every ~6 months,~and Nurse led CKD patient education, every ~6-12 months~unless the PCP opts the patient out of the interventions (by responding to the EHR in-basket message and providing an opt-out reason or requesting an office consultation with nephrology)."
45383162|NCT03832595|Other|Usual Care|Patients in the usual care arm will continue to receive CKD care guided by their PCPs as per usual care practices (i.e., specialty consultation, pharmacotherapy, nurse education, etc. may be ordered by the PCP according to their usual practice).
45383163|NCT03819049|Biological|ExPEC10V|Participants will receive a single IM injection of ExPEC10V (1 of 3 doses [low or medium or high]) in Cohort 1 and ExPEC10V selected dose (based on the primary analysis results of Cohort 1) in Cohort 2 on Day 1.
45383164|NCT03819049|Biological|ExPEC4V|Participants will receive a single IM injection of ExPEC4V on Day 1.
45383165|NCT03819049|Biological|Prevnar 13|Participants will receive a single IM injection of Prevnar 13 on Day 1.
45383166|NCT03819049|Biological|Placebo|Participants will receive single IM injection of matching placebo on Day 1.
45383167|NCT03807076|Other|GIP-A|GIP-A
45383168|NCT03807076|Other|Placebo|Placebo
45383169|NCT03787966|Other|ATOPE-B|Patients will perform therapeutic exercise before medical treatment and will follow the usual care after medical treatment.
45383170|NCT03787966|Other|ATOPE-I|Patients will follow usual care before medical treatment and will perform therapeutic exercise after medical treatment.
45383171|NCT03781219|Drug|HL-085|HL-085 ( Capsule) is one MEK inhibitor.
45383172|NCT03781219|Drug|Vemurafenib|Vemurafenib ( Tablet) is BRAF inhibitor,
45383173|NCT03775187|Biological|Burosumab|
45383174|NCT03775174|Drug|Mepsevii|
45383175|NCT03773770|Drug|Triheptanoin|Liquid for oral (PO) or enteral tube administration
45383176|NCT03773237|Dietary Supplement|SMOFLipid|SMOFLipid will be given to HPN patients to assess the benefits or adverse effects compared to Intralipid.
45383177|NCT03773237|Dietary Supplement|Intralipid|Intralipid will be given to HPN patients to assess the benefits or adverse effects compared to SMOFlipid
45499084|NCT02032316|Device|Post-Ureteroscopy ADVA-Tec Uriprene™ Degradable Temporary Ureteral Stent|Renal stent placed after uncomplicated uteroscopy
45383181|NCT03755934|Biological|MEDI7352|MEDI7352
45383182|NCT03755934|Other|Placebo|Placebo
45383183|NCT03755336|Other|Administered Slip Perturbations|Slips will be administered in early, middle or late phases of stance during overground walking.
45554609|NCT03193346|Drug|placebo (sodium chloride 0.9 mg)|Placebo matching BOTOX® [Sodium chloride 0.9 mg] IM injections in head/neck areas.
45554610|NCT03118622|Device|Pentax|Intubation using Pentax video laryngoscope in Pentax group
45554611|NCT02448836|Device|dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of dTMS treatment for two weeks (4 sessions every week).
45554612|NCT02448836|Device|Sham: dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week).
45554613|NCT03118076|Drug|0.3% ropivacaine and 50 μg dexmedetomidine|Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
45554614|NCT03118076|Drug|Ropivacaine|Nerve blocks were administered with 0.3% ropivacaine.
45499085|NCT04566575|Other|trans vaginal ultrasound (TVUS)|In the TVUS, the residual myometrium is determined after surgery and the appearance of new cysts in the area of the caesarian section scar is assessed.
45499086|NCT04566575|Other|patient questionnaire|exploratory patient questionnaire regarding satisfaction after correction of isthmocele
45499087|NCT03613298|Device|HIFU (Focal One®)|Endometriosic lesion localization and HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using sonography, pelvic MRI and a transrectal sonography data. Once the pre-defined lesion will be located with Focal One device, succession of HIFU exposure will then be used to treat maximum lesion volume, excluding a security margin of 3 mm with the digestive mucosae.
45499088|NCT03661710|Other|Investigating Adherence to Standard of Care Medication and Cardiac Rehabilitation|Information from health care insurance providers on how many patients adhered to prescribed medication and how many underwent cardiac rehabilitation and how adherence influenced cardiovascular outcome will be retrieved
45499089|NCT03212261|Behavioral|3RP-Lymphoma|An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals who have recently completed treatment for lymphoma.
45499090|NCT04056702|Drug|Elexacaftor-tezacaftor-ivacaftor exposure|Once a clinical decision has been made to prescribed a patient triple combination therapy, people with CF are eligible to participate in this study.
45499091|NCT03613142|Procedure|Double tract anatomosis|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. A Roux-en-Y esophagojejunostomy (E-stomy) is performed by intracorporeal anastomosis with a circular stapler, and the jejunal stump is closed with a linear stapler. Next, side-to-side gastrojejunostomy (G-stomy), 15 cm below the E-stomy, is performed using 2 linear staplers. Finally, end-to-side jejunojejunostomy (J-stomy), 20 cm below the G-stomy, is performed by 2 linear staplers.
45499092|NCT03613142|Procedure|Esophagogastrostomy|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. Next, end-to-end or side to end esophagogastrostomy is performed with a circular stapler.
45694844|NCT01830400|Drug|Eslicarbazepine Acetate tablets|The Eslicarbazepine Acetate (ESL) Summary of Product Characteristics (SPC) recommended a starting dose of 400 mg once-daily (QD) which was increased to 800 mg QD after one or two weeks. Based on individual response, the dose was increased to 1200 mg QD. Treatment decisions were made by clinicians in agreement with the participant, and were independent of participation in the study.
45694845|NCT01830478|Drug|Lenalidomide|Lenalidomide 20 mg p.o. once daily, days 1-21 every 28 days, for 6 cycles
45383185|NCT03754725|Drug|Deferiprone pill|1000 mg of deferiprone (oral) BID (15 mg/Kg)
45383186|NCT03754725|Drug|placebo|patients will receive placebo orally
45383187|NCT03754725|Behavioral|Montreal Cognitive Assessment|Neurocognitive assessment, lower score indicates lower cognitive level
45383188|NCT03748641|Drug|Niraparib|Participants will receive niraparib 200 mg capsules once daily.
45383189|NCT03748641|Drug|Abiraterone Acetate|Participants will receive AA 1000 mg tablets once daily.
45383190|NCT03748641|Drug|Prednisone|Participants will receive prednisone 10 mg tablets daily.
45383191|NCT03748641|Drug|Placebo|Participants will receive matching placebo once daily.
45383192|NCT03748641|Drug|New Formulation of Niraparib and Abiraterone Acetate (AA)|Participants will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets once daily.
45383193|NCT03747484|Biological|Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR|Given IV
45383194|NCT03747484|Drug|Avelumab|Given IV
45383195|NCT03747484|Biological|Pembrolizumab|Given IV
45383196|NCT03747484|Biological|Interferon Gamma-1b|Given SC
45383197|NCT03745950|Drug|Olaparib Oral Capsule|- Olaparib will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
45694846|NCT01830478|Drug|Rituximab|Rituximab 375 mg/m2 intravenously, day 14 of every course for 6 cycles
45694847|NCT01833442|Behavioral|Kundalini Yoga Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
45383198|NCT03745950|Drug|Placebo oral capsule|- Placebo will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
45383199|NCT03731715|Drug|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
45383201|NCT03713632|Drug|Secukinumab|Secukinumab 300mg every 2 or every 4 weeks
45383202|NCT03713632|Drug|Placebo|Placebo 300mg every 2 or every 4 weeks
45499093|NCT03662802|Other|Neural Network Classifier|The convolutional neural network is configured to receive an electrocardiogram segment as an input and to generate an output indicative of whether the received electrocardiogram segment represents a cardiac arrhythmia. No specific features of the electrocardiogram are identified to the convolutional neural network, and the received electrocardiogram segment is not filtered, transformed, or processed prior to reception by the algorithm. The algorithm is trained in a similar manner - the electrocardiogram segments are the sole input to the convolutional neural network.
45499094|NCT03613064|Other|Socially Enhanced Transitional Care Intervention|Components: 1) Standardized social vulnerabilities assessment tool, to be developed and incorporated into admission workflows. 2) Electronic community service referrals to existing community resources (i.e. food banks, shelters, community rehab), via the Dallas IEP or other information technology platform, for material (food, housing) and psychosocial needs (mental health/drug treatment). 3) Community-based cardiovascular self-management interventions, to be developed and piloted in conjunction with #3 - e.g., customized 'heart healthy' food baskets for CHF/IHD; risk factor monitoring (i.e., weight and blood pressure measurement at food banks, shelters, churches, modeled on the barber shop hypertension intervention); and 'heart buddy' support groups for CHF and IHD at community sites.
45383203|NCT03700684|Behavioral|Lee Silverman Voice Treatment|Persons with Parkinson's disease receive sixteen hours of voice treatment over a four week period. Participants will practice the vocal exercises at home for an additional four weeks.
45383204|NCT03700684|Device|SpeechVive|Persons with Parkinson's disease wear the SpeechVive device several hours a day over an eight week period during opportunities for communication.
45499095|NCT03662100|Biological|LY3074828|Administered SC
45499096|NCT03662100|Drug|LY3074828|Administered SC
45499097|NCT03662100|Device|Auto-injector (AI)|AI to administer LY3074828
45499098|NCT03662100|Device|Prefilled syringe (PFS)|PFS to administer LY3074828
45499099|NCT03612986|Dietary Supplement|SYALOX® 300 Plus|Reduction of pain and improvement of the knee mobility in patients affected by knee osteoarthritis
45383205|NCT03700684|Behavioral|Control|Persons assigned to the non-treatment control group will not participate in voice treatment.
45383206|NCT03694808|Drug|Fluad Vaccine|single adjuvanted dose (AD) intramuscular injection
45383207|NCT03694808|Drug|Fluzone HD Vaccine|single high dose (HD) intramuscular injection
45499100|NCT03612986|Dietary Supplement|Placebo|Placebo comparator. No chemical effect expected
45499101|NCT03612440|Drug|dexmedetomidine|receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery
45499102|NCT03612440|Other|normal saline|receive matching placebo (equal volum of normal saline)
45499103|NCT03662724|Drug|Venetoclax|Registry study observing clinical and biological characteristics of patients with acute myeloid leukemia who are treated with Venetoclax.
45499104|NCT03662568|Drug|GLS4|Administered GLS4 120 mg orally three times daily in fed state
45383208|NCT03694158|Drug|Dupilumab|anti-IL4 receptor antagonist
45383209|NCT03694158|Other|Placebo|Placebo for Dupilumab (packaged/administered the same as the active drug)
45383210|NCT03691792|Behavioral|Cognitive-Behavioral Therapy (CBT-SAD)|12 group sessions over 6 weeks
45383211|NCT03691792|Other|Light Therapy|10,000-lux initiated at 30 min upon waking and adjusted per treatment algorithm, continuing for 6 weeks
45383212|NCT03690206|Drug|glepaglutide|Glucagon-Like Peptide-2 (GLP-2) analog
45383213|NCT03690206|Drug|Placebo|Placebo for glepaglutide
45383214|NCT03677973|Drug|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor
45383215|NCT03677973|Other|Placebo|Matching Placebo
45499105|NCT03662568|Drug|RTV|Administered RTV 100 mg orally three times daily in fed state
45499106|NCT03662568|Drug|ETV|Administered orally ETV 0.5 mg once daily in fasted state
45499107|NCT03662568|Drug|TDF|Administered TDF 300 mg orally once daily in fasted state
45499108|NCT03612362|Device|"Improved Injera Baking Biomass Stove"|"Replacing of the Ethiopian traditional Injera baking biomass stove with improved baking biomass stove, the well-known commercially distributed type of baking stove in Ethiopia, will be the intervention for this study. Control HHs will continue to use the traditional baking biomass stove. Concerning intervention duration, since the life span of the Ethiopian improved baking stove is about 5 years, the length of the intervention period will be one year to account for seasonal factors that have major effect on both ARI incidence & HAP level in Ethiopia as well as to maintain a balance between achieving a sufficiently long follow-up period for outcome measurements & suitably short follow-up period to decrease attrition."
45499109|NCT03661554|Biological|BCMA CAR-T Cells|The Chinese name of CAR-T cells is chimeric antigen receptor T cells. It is through gene transfection technology, so that patients with T lymphocytes can carry B cell-specific antigens, so that T lymphocytes can selectively kill B lymphocyte-derived tumor cells.
45383216|NCT03659539|Drug|PROPOFOL|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
45383217|NCT03659539|Drug|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
45383218|NCT03659136|Drug|Xentuzumab|Intravenous infusion
45383219|NCT03659136|Drug|Placebo|Intravenous infusion
45383220|NCT03659136|Drug|Everolimus|Tablet
45499110|NCT02993250|Drug|AL-335|Participants will receive AL-335 800 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
45499111|NCT02993250|Drug|Odalasvir (ODV)|Participants will receive ODV 25 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
45499112|NCT02993250|Drug|Simeprevir (SMV)|Participants will receive SMV 75 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
45499113|NCT05383898|Drug|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
45383221|NCT03659136|Drug|Exemestane|Tablet
45383222|NCT03632044|Drug|Ropivacaine|A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia
45383223|NCT03632044|Other|Sham Comparator|The subcutaneous placement of a 25 Gauge needle as a sham control after the induction of general anesthesia. Nothing will be injected.
45383224|NCT03631693|Procedure|Simplified papilla preservation flap|The simplified papilla preservation flap (SPPF) surgery is a conservative surgical procedure aimed at the preservation of the tissues between the teeth providing access for the debridement of the root surface in sites with residual pockets.
45383225|NCT03631693|Procedure|Resective periodontal flap with osseous recontouring|The Resective periodontal flap with osseous recontouring (RPFO) is a surgical procedure that achieves predictable pocket depth reduction by soft and hard tissue resection to obtain a more convenient soft and hard tissue architecture for oral hygiene.
45383226|NCT03629418|Drug|Targeted blood-pressure management|Prophylactic norepinephrine infusion is started before anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher.
45694848|NCT01833442|Behavioral|Relaxation Response Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
45694849|NCT01835782|Drug|L-Serine|
45383227|NCT03629418|Drug|Routine blood-pressure management|Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
45499114|NCT03612284|Device|contact lens insertion solution|"This contact lens solution is being tested for safety and comfort and is not an intervention. Subjects will have their scleral contact lenses filled with the test saline in the examination room and applied to their eyes. They will be monitored for symptoms and will be examined. Six to 8 hours later or whenever their lens clouding typically occurs they will return for further assessment and dispensing of solution if acceptable. subjects will use the solution for 5-9 days and return for a follow-up appointment. At each visit, subjects will complete an OSDI questionnaire and a Current Symptoms questionnaire."
45499115|NCT03661476|Behavioral|Oculo-Motor Exercises (OME)|"Oculomotor Exercises (OME); The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes."
45694850|NCT00909220|Behavioral|Behavioral Activation|Behavioral Activation included up to 16 weekly 50 minute psychotherapy sessions using BA (Addis & Martell, 2004; Martell et al., 2001, 2010). Techniques included functional analyses to identify the antecedent and consequential aspects of low mood, and interventions such as monitoring daily activities, assessing pleasure/satisfaction and competence achieved via activities, assigning tasks that induce mastery or pleasure, and reducing skill deficits. Clinicians included postdoctoral fellows in clinical psychology (n = 2) or licensed clinical psychologists (n = 2).
45694851|NCT04426695|Drug|REGN10933+REGN10987 combination therapy|Administered intravenously (IV) single dose
45694852|NCT04426695|Drug|Placebo|Placebo IV Single Dose
45383229|NCT03616821|Drug|Brazikumab|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through Week 50
45383230|NCT03616821|Drug|Placebo|Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous placebo every 4 weeks beginning on Day 71 through Week 50.
45383231|NCT03615469|Device|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
45383232|NCT03615469|Device|Neuromuscular electrical stimulation|When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt and muscle contraction is seen. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality.10,24,29-31 To assist better tolerance large electrodes (2x4) will be used and participants will also be instructed to be in a seated position with chair close to the wall so that their leg is 90-degree angle and then push against the wall to decrease any uncomfortable feeling during the contraction. 5 sessions per week for 6 weeks done independently at home, with 15 minutes per session (15 minutes per day/session, 15 seconds stimulation on, 15 seconds recovery time) to both legs. We expect the participant to develop tolerance to the treatment and thus increase the intensity of the NMES over time.
45383233|NCT03607474|Other|Questionnaires of life quality for patients|"the WhoQoL~a specific scale of Cushing's syndrome~The Beck II scale~HAD scale~Rosenberg questionnaire~Stunkard, Sorensen and Schlusinger (1983) figurines~Brief Cope scale"
45383234|NCT03607474|Other|Questionnaires of life quality for caregivers|"the WhoQoL~The Beck II scale~HAD scale"
45499116|NCT03612830|Procedure|Laparoscopy endoscopy cooperated surgery|LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy
45499117|NCT03612830|Procedure|Dan Vinchi robot endoscopy cooperated surgery|RECS resects the tumor completely by Dan Vinchi Robot with the help of the precise positioning and guidance of endoscopy
45694853|NCT01838200|Biological|Bacillus Calmette-Guérin (BCG) vaccine|BCG was to be administered as a single intralesional injection (200 µL volume) on Day 1 at varying doses depending on cohort assignment.
45383235|NCT03606499|Drug|Ustekinumab|No study treatment will be administered as a part of this study. Participants who are initiating the treatment with ustekinumab, will be observed according to standard clinical practice.
45499118|NCT03661788|Drug|Atomoxetine|14-day treatment interval: first week 40 mg atomoxetine (one pill), second week 80mg atomoxetine (two pills)
45499119|NCT03661788|Drug|Placebos|14-day treatment interval: first week one placebo pill, second week two placebo pills
45383236|NCT03606213|Biological|PENNVAX-GP|PENNVAX®-GP is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag, Pol and Env proteins.
45383237|NCT03606213|Biological|INO-6145|INO-6145 is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag and Pol proteins.
45383238|NCT03606213|Biological|INO-9012|The IL-12 DNA adjuvant (INO-9012) consists of a single plasmid containing a dual promoter system for expression of both the IL-12 p35 and p40 genes necessary for production of the active heterodimeric (p70) IL-12 protein.
45383239|NCT03606213|Device|CELLECTRA® 2000|Electroporation (EP) is a technology in which an electrical field is applied to increase the permeability of cell membranes and thereby enhance the uptake of drugs, vaccines, or other agents into target cells. This technology has been used in the last decade in both therapeutics and vaccinations. EP is currently being used to deliver cancer vaccines and therapeutics as well as in gene therapy. The expression levels are increased by as much as 3 orders of magnitude over plasmid injection alone.
45383240|NCT03605719|Drug|Carfilzomib|Given IV
45383241|NCT03605719|Drug|Dexamethasone|Given IV
45383242|NCT03605719|Biological|Nivolumab|Given IV
45383243|NCT03605719|Biological|Pelareorep|Given IV
45383244|NCT03603002|Diagnostic Test|Post-SABR Biopsy|Post-SABR Biopsy
45383245|NCT03596645|Drug|Golimumab|Participants receive subcutaneous (SC) golimumab through Week 50, where doses will be based on body surface area. After the Week 54 evaluations, at the discretion of investigator, participants benefiting from continued SC golimumab will continue to receive SC golimumab in the extension until end of study.
45383246|NCT03596645|Drug|Infliximab|Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
45499120|NCT03661398|Device|Transcatheter Mitral Valve Replacement|All eligible patients will be in the treatment arm for treatment with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System. There is no control (comparator) arm for this study.
45499121|NCT03612128|Other|control group|Children continued their traditional physiotherapy including upper limb exercises in three times a week for 8 week.
45499122|NCT03612128|Other|intervention group|Participants allocated to the experimental group completed three times a week, 8-week mirror therapy in addition to traditional physiotherapy . This protocol consisted of mirror therapy with a mirror box.
45499123|NCT03612752|Dietary Supplement|CMI-168|Dietary supplement
45499124|NCT03612752|Other|Placebo|Placebo
45499125|NCT03611660|Behavioral|Traditional Healthy Lifestyle Program|Twice weekly meetings that focus on nutrition and exercise for 12 weeks.
45499126|NCT03611660|Behavioral|Mindfulness Meditation Instruction|Participants receive six mindfulness sessions.
45499127|NCT03612674|Procedure|Standard colonoscopy|Current standard of care colonoscopy.
45499128|NCT03612674|Device|ARC Endocuff Vision|Subjects randomized to undergo a colonoscopy procedure with ARC Endocuff Vision will have this device placed on the top of the colonoscope used during their procedure.
45499129|NCT02989194|Drug|VIS410 low dose|Single intravenous fixed low dose of VIS410
45499130|NCT02989194|Drug|VIS410 high dose|Single intravenous fixed high dose of VIS410
45499131|NCT02989194|Drug|Placebo|Single intravenous infusion of placebo
45499132|NCT03612518|Behavioral|Text and Voice Messages|Participants in this study arm will periodically receive information regarding antenatal- and postnatal care and family planning services through text and voice messages from the fifth gestational month until the post-partum period of 42 days.
45694854|NCT01838200|Drug|Ipilimumab|Ipilimumab was to be administered as a 90-minute IV infusion at a dose of 3 mg/kg every 3 weeks (± 3 days) on Days 36, 57, 78, and 99.
45694855|NCT01838200|Drug|Isoniazid|Isoniazid was to be administered orally at a dose of 300 mg (3 × 100 mg tablets) every day from Days 29 through 56.
45694856|NCT01833754|Drug|Romosozumab|Administered as three 70 mg/mL prefilled syringe injections
45694857|NCT01720030|Drug|Levosimendan|Verum therapy
45694858|NCT01720030|Drug|Conventional therapy|Placebo therapy to safeguard blinding
45694859|NCT01720108|Drug|rivaroxaban and ASA|
45694860|NCT01720186|Device|PET/CT 4D imaging in a synchronized mode centered on the thorax.|
45383247|NCT03596476|Procedure|Upper gastrointestinal (GI) endoscopy|An upper gastrointestinal (GI) endoscopy will be performed at V1. Four esophageal biopsies will be taken in both the proximal and the distal esophagus.
45499133|NCT03612518|Behavioral|Interactive Phone Call|Participants in this study arm will receive information regarding antenatal- and postnatal care and family planning services through periodic interactive phone calls from the fifth gestational month until the post-partum period.
45499134|NCT03661242|Behavioral|Physical activity|Patients in shared care arm has regular combined visits with Oncologist and Clincal Exercise Physiologist (CEP). Individual physical activity plan developed by CEP for patients in shared care arm.
45499135|NCT05383820|Drug|Ketorolac|The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS).
45499136|NCT04055766|Device|DeepDoc AI-based Decision Support System|Patients are diagnosed by the DeepDoc within 24 hours of admission.
45499137|NCT04660214|Device|septotomy|endoscopic diverticulotomy
45499138|NCT03612050|Behavioral|Meaning Centered Psychotherapy|"Manualized, 3-session existential psychotherapy (30-45 minutes/session) with an optional 4th booster session. Content focuses on enhancing patients sense of meaning and purpose in life."
45499139|NCT03660774|Other|No treatment given|The participants will undergo a brief physical examination focused on neurologic function (muscle function, sensation, coordination, walking). Parents will be asked by the study team or the psychologist about their children and will complete several commonly used standard surveys about brain development, thinking, behavior, and decision making. The participants will also engage with the psychologist to evaluate development or thinking (IQ), and depending on their age they may be asked to complete one or more commonly used standard surveys about behavior and decision making.
45499140|NCT03611894|Other|radiological comparison|comparison between clinical and radiological characteristics
45499141|NCT03622554|Other|Adapted Physical Activity (APA)|12 APA sessions of 60 minutes
45499142|NCT03622554|Other|Therapeutic Patient Education (ETP)|Personalized ETP with 3 group sessions (1h30) and one at the end of the course (1h) and educational follow-up by phone at 3, 6 and 12 months
45499143|NCT02032472|Other|Measurement of Arterial Pressure|Pharmacies cooperate in measuring blood pressure of patients
45499144|NCT03611504|Device|Hemospray®|Hemospray® application
45383248|NCT03596476|Procedure|Wireless pH monitoring|Wireless pH monitoring will be performed at V1. The pH capsule will be clipped into the esophagus during the upper GI endoscopy. The esophageal pH will be recorded for 96 hours (ambulatory recording).
45694861|NCT03211468|Behavioral|Clinical intervention program to prevent eating disorders|See previous
45499145|NCT03622710|Other|Rehabilitation therapy|Subjects are trained to walk overground (control) or over WTDS (experimental) for 5 days/week over 4 week. Then they will be monthly follow-up for fall data.
45499146|NCT02954510|Drug|ferumoxytol|ferumoxytol will assess patency of coronary arteries
45499147|NCT03060330|Procedure|Modified Laparoscopic Ventral Mesh Rectopexy|This group will undergo modified laparoscopic ventral mesh rectopexy alone
45499148|NCT03060330|Procedure|Modified Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection|This group will undergo modified laparoscopic ventral mesh rectopexy combined with modified stapled trans-anal rectal resection
45499149|NCT02032784|Drug|octreotide|Octreotide 100mg subcutaneous every 8 hours for 5 days
45499150|NCT02032784|Other|No Octreotide|No drug
45499151|NCT04055376|Device|GENUS device (Active Settings)|"Participants in the experimental group will use the GENUS device configured to active settings for 60 minutes daily over 6 or 9 months. After 6 or 9 months, each participant will be given an option to continue the daily usage of the GENUS device configured to active settings for additional 6 or 9 months.~Note: Due to the COVID-19 pandemic, participants who have not yet reached the 6-month mark will have their 6 month visit postponed to 9 months."
45694862|NCT04380220|Diagnostic Test|Blood samples and processing|DSC perfusion technique at 3.0-T MRI only in MS patients
45694863|NCT01832974|Drug|IL-13-PE|IL-13-PE intravenous infusion
45694864|NCT01671735|Other|Survey|A clinical demonstration project funded by NCP will involve screening Veterans and enrolling veterans with pre-diabetes into the VA DPP program. This research project will recruit VA DPP eligible participants enrolled in the VA DPP program and Veterans enrolled in MOVE! that are VA DPP eligible as a comparison group. The research is not truly an intervention but similar to a program evaluation.
45694865|NCT01720342|Procedure|Aortic Valve Replacement surgery|Aortic Valve Replacement surgery of the native aortic valve with the Enable® aortic bioprosthesis.
45694866|NCT01671813|Drug|brentuximab vedotin|Brentuximab vedotin will be given intravenously as outlined in treatment arm.
45694867|NCT03836404|Device|Iliac crest reconstruction surgery|When autologous bone graft is needed for the treatment of non-unions or bone defects, is harvested from the pelvic iliac crest. Harvested tricortical graft blocks are used to facilitate fusion of joints (ie pubis symphysis, sacroiliac joint), to structurally support metaphyseal areas of articular impaction injuries and to fill in metaphyseal bone voids. The GreenBone device, with its inherent physical and biomimic properties, possesses similar structural properties to bone, thus, being the ideal material to be used for the treatment of the bone defect (3- 4cm) induced from the harvested tricortical iliac crest, restoring therefore the pelvic anatomy and minimising the risk of chronic pain, haematoma formation and herniation of the abdominal contents.
45383249|NCT03596476|Procedure|Post prandial esophageal High Resolution Impedance Manometry|Post prandial esophageal HRIM will be performed at V2. The recording will be started after transnasal insertion of the HRIM probe. A standardized meal will be given to the patient (Big Mac, medium portion of French fries, orange juice). The recording will be realized for one hour after the end of the meal.
45383250|NCT03596476|Procedure|pH-impedance monitoring|24-h pH-impedance monitoring on PPI will be performed at V3. A transnasal catheter will be inserted into the esophagus and the recording will be performed for 24 hours (ambulatory recording).
45383251|NCT03586739|Procedure|endovascular angioplasty using covered stents|Primary endovascular angioplasty using one or several covered stents
45694868|NCT03021291|Device|Gelesis100 (2.25 g)|Three capsules of Gelesis100, each containing a 750 mg mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.
45383252|NCT03586739|Procedure|endovascular angioplasty using bare metal stents|Primary endovascular angioplasty using one or several bare metal stents
45499152|NCT04055376|Device|GENUS device (Sham Settings)|"Participants in the control group will use the GENUS device configured to sham settings for 60 minutes daily over 6 or 9 months. After 6 or 9 months, each participant will be given an option to continue the daily usage of the GENUS device configured to active settings for additional 6 or 9 months.~Note: Due to the COVID-19 pandemic, participants who have not yet reached the 6-month mark will have their 6 month visit postponed to 9 months."
45499153|NCT03611426|Drug|rhThrombin ( Topical )|Active Substance
45499154|NCT03611426|Drug|placebo|saline solution
45499155|NCT03658824|Other|Behavioural Activation (BA)|"BA is based on the assumption that depression may be precipitated and is maintained by a reduction in healthy, adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term.~The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions."
45694869|NCT01833052|Device|TAVI (Medtronic CoreValve)|
45694870|NCT01833052|Device|Claret-Filter|
45694871|NCT03835858|Other|Respiratory physiotherapy|The protocol consists of 20 minutes of FR based on nasal washes in sitting, prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continuing to the residual volume. The physiotherapist through the the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
45694872|NCT01671969|Other|very low calorie diet|medically supervised diet
45694873|NCT03211078|Procedure|super-D ENB guided-PDT|PDT with super-D EBN localization will be given for treating the target lung lesion. Intrvenous photofrin (2mg/kg) will be given 48 hours before intervention. After localization of the tumor by ENB, a 630nm of light will be give for the lesion with the dosage of 2oo J/cm. Intravenous general anesthesia and endobronchial intubation will be performed under the whole procedure.
45383253|NCT03586739|Device|Duplex-scan|a Duplex-scan will be performed during patient follow up.
45383254|NCT03586739|Device|computerized tomography scan (CT-scan)|"a CT-scan will be performed in the event of symptoms of recurrence or restenosis as confirmatory exam according to clinical practice during patient follow up.~The CT-scan will be mandatory at 12 and 24 months if it has not been planned in the current practice follow-up."
45383255|NCT03586739|Device|digital angiography|In case CT-scan cannot be performed (e.g. occurrence of a non-preexisting contra-indication), a digital angiography will be authorised instead to confirm restenosis during patient follow-up.
45383256|NCT03586739|Other|Short Form-36 (SF-36) questionnaire|The patient will complete a quality-of-life questionnaire (SF-36 form) during their follow up.
45383257|NCT03573310|Drug|JNJ-64619178|JNJ-64619178 capsules to be administered orally.
45383258|NCT03556501|Diagnostic Test|Endoscopy|Purpose of this study is to create a prospective registry of patients with pancreatic collections and their imaging studies
45694874|NCT01833208|Other|Laboratory Biomarker Analysis|Correlative studies
45694875|NCT01833208|Radiation|Radiation Therapy|Undergo single-fraction radiation therapy
45694876|NCT03210922|Device|Miami cervical collar|Collar group is put on the Miami cervical collar.
45694877|NCT03830398|Drug|Paracetamol|The investigators apply paracetamol during a week in preoperative room 45 min before ECT
45694878|NCT03830398|Drug|Deksketoprofen trometamol|The investigators apply paracetamol during a week in preoperative room 45 min before ECT
45694879|NCT03830398|Drug|Placebo|The investigators apply placebo during a week in preoperative room 45 min before ECT
45694880|NCT04405323|Drug|Lu AG06466|hard capsules, orally, single doses
45694881|NCT04405323|Drug|Itraconazole|200 and 300 mg, capsules, orally
45383259|NCT03555669|Other|Depression Treatment|The depression treatment program combines measurement-based antidepressant treatment with PST with clinical response appropriate to the level of depressive severity. Patients scoring 0-4 on the PHQ-9, indicating no depression, receive no treatment. Patients scoring 5-9 on the PHQ-9, indicating mild depressive symptoms that likely are not a full major depressive episode, are offered PST. Patients scoring 10 or above on the PHQ-9, indicating moderate-to-severe depressive symptoms, are first offered anti-depressants. For this group, PST will be an alternative or augmentation option for those who do not tolerate or respond to antidepressant treatment. All patients' depressive severity is monitored with the option of modifying their treatment plan if their symptoms worsen or do not improve.
45383260|NCT03555422|Drug|Selinexor|Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
45499156|NCT04612868|Device|AEYE Software Device|"Eligible participants will undergo the following procedures:~Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis.~Additional photographic and OCT images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis.~All study subjects will have their pupils dilated using dilation drops."
45383261|NCT03555422|Drug|Matching placebo for selinexor|Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
45383262|NCT03553212|Radiation|tomotherapy|20-23 Gy in 2 fractions on the whole prostate gland +/- seminal vesicles and 24-27 Gy in 2 fractions as simultaneous integrated boost (SIB) on the dominant intraprostatic lesion (DIL) 2 weeks in all.
45499157|NCT03658746|Drug|two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)|Patients will receive a 14-day quadruple therapy for the H.pylori eradication. The regimen contains one proton pump inhibitor, colloidal bismuth pectin and two sensitive antibiotics determined by antimicrobial susceptibility test. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
45499158|NCT03658746|Drug|one proton pump inhibitor, colloidal bismuth pectin|All patients need these two drugs.
45383263|NCT03529422|Drug|Durvalumab|Durvalumab 1500mg IV every 3 weeks for 6 cycles
45383264|NCT03529422|Radiation|Intensity Modulated Radiotherapy Treatments|Total dose will be 60 Gray (Gy) at 2Gy per fractions for 30 fractions delivered Monday through Friday for 6 weeks
45383265|NCT03518203|Drug|Eculizumab|Eculizumab will be administered as intravenous infusion (IV) over 60 minutes. The dosage form will be 300 mg single-use vials each containing 30 mL of 10 mg/mL sterile, preservative-free solution.
45499159|NCT03658746|Drug|two antibiotics based on personal medication history(amoxicillin,levofloxacin, furazolidone)|Patients will receive a 14-day quadruple therapy according to personal medication history for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient hasn't been treated with levofloxacin previously, he will be treated with amoxicillin and levofloxacin. Otherwise, he will be treated with amoxicillin and furazolidone.
45499160|NCT02032862|Drug|Sage extract, 3400 mg , DER 1:17|
45499161|NCT03611192|Other|Multicomponent exercise|Aerobic exercise: 15~20 mins Resistance exercise: 15 mins Balance exercise: 15~20 mins Flexibility exercise: 10 mins
45499162|NCT03611192|Other|Home-program exercise|60 mins exercise
45499163|NCT02990910|Drug|Individualized opioid analgesia|(a）positive result 10μg/kg morphine; negative result 50μg/kg morphine.
45848078|NCT03058614|Diagnostic Test|Non-contrast CT scan|The CT scan performed in this study arm is regularly performed to evaluate the kidney and look for residual stones after surgery both at UCSF and around the world. It does not require contrast injection, so risks from contrast allergy or any injection are absent. A low dose protocol will be used, and therefore, subjects will be exposed to a very small amount of ionizing radiation as low as 1-2 mSv if randomized into this arm.
45383266|NCT03514108|Drug|Hydralazine Isosorbide Dinitrate|Tablet BiDil (Hydralazine 37.5 mg/ Isosorbide Dinitrate (ISDN) 20 mg) 2 tablets x 3 daily
45383267|NCT03514108|Drug|Placebo Oral Tablet|2 tablets x 3 daily
45383268|NCT03514108|Drug|Metformin Hydrochloride|Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
45383269|NCT03514108|Drug|Placebo Oral Tablet|2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
45383270|NCT03501173|Other|Standard of Care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy.
45383271|NCT03482791|Radiation|Proton beam therapy|"The daily prescription dose will be 1.8 or 2 Gy RBE (Relative Biologic Equivalence) to be delivered to the periphery of the planning target volume (PTV).~The Mevion S-250 Proton Radiation Beam Therapy System will be used."
45383272|NCT03482791|Other|Patient-Reported Outcome Measures|-Prior to start of therapy, end of chemoradiation (day of end of treatment or up to 1 week after), 8 weeks, 4, 6, 9, and 12-months following end of chemoradiation
45499164|NCT02990910|Device|conventional opioid analgesia|(b) all received 25μg/kg morphine
45499165|NCT04056000|Dietary Supplement|Caffeine|200 mg of caffeine, 60 minutes before exercise
45694882|NCT01720498|Drug|remifentanil|The effect site concentration of remifentanil
45694883|NCT01672047|Drug|Vitamin D2|25（OH）D level <12 nmol/L 50000IU/weekX12week， 12-39 nmol/L 50000IU/weekX4week then，50000IU/month， 40-75 nmol/L 50000IU/month， 75-116.75nmol/L 25000IU/month， >116.75nmol/L stopped.
45694884|NCT01833286|Procedure|TACE+RFA|TACE first, followed by RFA within 2 months
45694885|NCT01833286|Procedure|re-resection|repeat hepatectomy for recurrent small HCC
45694886|NCT01672125|Other|circumferential measurements in different upper limb positions.|circumferential measurements in different upper limb positions, in 90 degrees forward flexion and depending position
45694887|NCT01720576|Drug|REGN1033 (SAR391786)|
45694888|NCT01720576|Drug|Placebo|
45426081|NCT00935090|Device|3'-deoxy-3'-[18F]fluorothymidine|The tracer compound [F-18] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.
45848079|NCT03058614|Diagnostic Test|Capping trial|Subjects who are randomized into this study arm will undergo both nephrostomy tube capping and a low dose non-contrast CT scan on the first day after surgery. Successfully passing a capping trial is defined as the absence of fever, worsened flank pain, and leakage around the nephrostomy tube within 4 hours after capping the tube.
45383273|NCT03479541|Behavioral|Rehabilitation|"Participants will see a physiotherapist one-on-one twice per week for 2 weeks and once per week for 4 weeks for a total of 6 weeks. These sessions will consist of cardio, cervical flexion exercises and vestibule-ocular exercises for one hour. Participants will also have similar daily home exercises to complete for approximately 30 minutes. Both the one-on-one physiotherapy and home exercises will be individualized and progressive in the sense that each exercise can increase in the level of difficulty at the discretion of the physiotherapist depending on the performance of the participant.~For the group allocated to home monitoring, they will perform the vestibular exercises while wearing one wireless sensor on the head and one on the sternum. When the participant brings the sensors in to the physiotherapy session each week, the physiotherapist will examine the home data and likely make a more informed decision as to whether or not to increase the level of difficulty of the task."
45383274|NCT03473743|Drug|Erdafitinib|Participants will receive erdafitinib orally.
45383275|NCT03473743|Drug|Cetrelimab|Participants will receive cetrelimab by intravenous infusion.
45383276|NCT03473743|Drug|Cisplatin|Participants will receive cisplatin by intravenous infusion as a part of platinum chemotherapy.
45383277|NCT03473743|Drug|Carboplatin|Participants will receive carboplatin by intravenous infusion as a part of platinum chemotherapy.
45383278|NCT03469362|Procedure|Extracorporeal Urinary Diversion|Extra-corporeal urinary diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit by hand.
45499166|NCT04056000|Dietary Supplement|High-carbohdyrate breakfast|Ingestion of a high-carbohydrate breakfast 60 minutes before exercise
45499167|NCT04056000|Behavioral|60-minutes of steady state exercise|See intervention name
45499168|NCT03611348|Drug|Latanoprost|"Topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months.~To apply latanoprost solution, one drop of the solution will be distributed over 1cm2 of depigmented skin. Side effects will be recorded."
45499169|NCT03611348|Device|Microneedling|A superficial micro-needling technique will be done in millimeters according to depth of skin. The vitiliginous area and a thin surrounding rim (about 2 mm) will be subjected to micro-needling with dermapen. The depth of abrasion will be guided by the depth adjustor according to depth of skin on the affected area. This will be followed by the appearance of multiple, tiny, punctate, bleeding points
45499170|NCT04055532|Other|Neuraceq|Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
45499171|NCT04055064|Dietary Supplement|glucose control nutritional shake, nutrition education|Participants in the treatment group were educated about improving their diet by consuming more low-fat high-quality protein sources, vegetables, complex carbohydrates and less simple carbohydrates. They were also instructed to consume two servings (474 ml) of a commercially produced Glucose Control Nutritional Shake between meals throughout the day for 12 weeks or until complete healing. The supplements provided a total of 500 kilocalories, 28 grams of high-quality protein and essential vitamins and minerals.
45499172|NCT02033018|Drug|Aflibercept Injection|Aflibercept intravitreal injection
45499173|NCT03155100|Drug|Carfilzomib for Inj 60 milligram (MG)|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
45499174|NCT03155100|Drug|Elotuzumab 400 MG|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
45499175|NCT03155100|Drug|Dexamethasone|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
45499176|NCT02033096|Drug|Stannsoporfin|No intervention was administered during this observational study
45499177|NCT02033096|Drug|Placebo Control|No intervention was administered during this observational study
45848080|NCT03048240|Device|"perPDT"|"The protocol requires the realization of specific procedures in addition to the usual care.~The per-operative photodynamic therapy (perPDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery + lighting of the tumor bed by a light source (laser) at the end of resection (Prolonged surgery of 45 minutes)."
45499178|NCT02033096|Other|Phototherapy (as needed)|No intervention was administered during this observational study
45499179|NCT03661164|Procedure|corneal cross linking|Iontophoretic corneal cross linking
45499180|NCT03658590|Drug|Dexamethasone|a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously
45499181|NCT03658590|Drug|Distilled Water|a prefilled syringe with two milliliters of distilled water intravenously.
45499182|NCT03622476|Drug|concentrated FVIII|Intervention if the assessment considers that the treatment is inadequate
45499183|NCT03658434|Radiation|Palliative radiotherapy|Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer
45848081|NCT03048240|Drug|GLIOLAN|patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery
45848082|NCT02893800|Device|Locating system watch with GPS-technology|Patients using locating system watches with embedded global positioning system (GPS) technology and telephone function; Caregivers using a Smartphone with an installed application to see the current location of the patient and with the possibility to call the patient
45848083|NCT02856126|Procedure|Hepatic arterial infusion chemotherapy|
45848084|NCT02856126|Procedure|Transarterial chemoembolization|
45848085|NCT02856126|Drug|TACE regimen|infusion with lipiodol mixed with chemotherapy drugs (EADM , lobaplatin, and MMC ), and embolization with polyvinyl alcohol particles (PVA)
45383279|NCT03469362|Procedure|Intracorporal Urinary Diversion|Intracorporal Urinary Diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit using the Da Vinci robot.
45383280|NCT03469362|Device|Da Vinci Robot|Da Vinci Robotic Surgical System
45383281|NCT03466411|Drug|Guselkumab Dose 1|Guselkumab will be administered by IV infusion.
45383282|NCT03466411|Drug|Guselkumab Dose 2|Guselkumab will be administered by SC injection.
45383283|NCT03466411|Drug|Guselkumab Dose 3|Guselkumab will be administered by IV infusion.
45383284|NCT03466411|Drug|Guselkumab Dose 4|Guselkumab will be administered by IV infusion.
45383285|NCT03466411|Drug|Guselkumab Dose 5|Guselkumab will be by SC injection.
45383286|NCT03466411|Drug|Guselkumab|Guselkumab will be administered by IV infusion and SC injection.
45383287|NCT03466411|Drug|Ustekinumab|Ustekinumab will be administered by IV infusion and SC injection.
45499184|NCT03045744|Device|long-term paired associative stimulation|Paired associative stimulation (PAS) administered 3 times per week. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
45499185|NCT03227861|Drug|DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC|Participants will receive oral tablet containing D 800 mg /C 150 mg /F 200 mg /TAF 10 mg FDC once daily within 24 hours of the screening/ baseline visit.
45383288|NCT03466411|Drug|Placebo|Placebo will be administered as IV infusion.
45383289|NCT03457142|Biological|Abatacept|Given IV and SC
45383290|NCT03457142|Drug|Dexamethasone|Given PO
45383291|NCT03457142|Drug|Ixazomib Citrate|Given PO
45383292|NCT03457142|Other|Laboratory Biomarker Analysis|Correlative studies
45383293|NCT03431350|Drug|Niraparib 200 mg|Participants will receive niraparib 200 mg orally.
45383294|NCT03431350|Drug|Cetrelimab 240 mg|Participants will receive cetrelimab 240 mg IV every 2 weeks.
45383295|NCT03431350|Drug|Cetrelimab 480 mg|Participants will receive cetrelimab 480 mg IV every 4 weeks.
45383296|NCT03431350|Drug|Abiraterone acetate 1000 mg|Participants will receive AA 1000 mg orally.
45383297|NCT03431350|Drug|Prednisone 5 mg|Participants will receive prednisone 5 mg orally.
45383298|NCT03423628|Radiation|Radiation Therapy|"Arm A: 35 Gy of Intensity-modulated radiation therapy (IMRT) administered at daily fractions of 3.5 Gy over 10 fractions (2 weeks) Arm B: 30 Gy of whole brain radiation therapy (WBRT) or partial brain radiation therapy (PBRT) administered at daily fractions of 3 Gy over 10 fractions (2 weeks).~**Arm B has now closed to recruitment** Arm C: 60 Gy of intensity-modulated radiation therapy (IMRT) administered at daily fractions of 2 Gy over 30 fractions (6 weeks)"
45383299|NCT03423628|Drug|AZD1390|"AZD1390 Administered in 3 Cycles depending on arm:~Cycle 0 (arms A and C): 1 dose prior to Radiation Therapy. For optional food effect assessment in Arm A, 2 doses prior to RT under both fed and fasted conditions. *Note: the optional food effect assessment is currently not open to recruitment*.~Cycle 1 (all arms): Intermittent or continuous dosing during Radiation Therapy (except for first 2 cohorts of Arm A).~Cycle 2 (arms A and C): 2 weeks adjuvant treatment after Radiation Therapy."
45383300|NCT03419325|Genetic|CYP2C19 test|Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
45383301|NCT03419325|Diagnostic Test|P2RY12 assay|Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
45383302|NCT03418792|Other|Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography|Head & neck radiation with parotid sparing. Parotid sparing will be facilitated by avoidance of salivary ductal structures and stem cells, as identified by the pre-treatment MRI sialogram, in the radiation treatment plan.
45383303|NCT03411408|Device|HBO|"Hyperbaric oxygen is administrated in a multiplace hyperbaric chamber according to the following schedule:~Ten minutes of compression with a Fraction of inspired oxygen (FiO2) more than 90% from 152 to 253 kilopascal, 60 minutes of Fraction of inspired oxygen (FiO2) more than 90% at 253 kilopascal (three breathing cycles in oxygen for 22 minutes each, with two intervals breathing air for 2 minutes each) and 10 minutes of decompression with a Fraction of inspired oxygen (FiO2) more than 90% from 253 to 152 kilopascal."
45848086|NCT02856126|Drug|HAIC Regimen|Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
45848087|NCT02856126|Drug|Oral Sorafenib|Oral Sorafenib, 400mg, Bid
45848088|NCT02536170|Drug|L-arginine|L-arginine will be dispensed intravenously (IV) in the standard dose of 100 mg/kg three times a day until discharge from the emergency department (ED) or hospital.
45848089|NCT02536170|Drug|L-arginine Loading Dose|One loading dose of L-arginine will be dispensed intravenously (IV) at 200 mg/kg
45499186|NCT03461159|Other|Operant conditioning of H-reflexes|Spinal reflex responses will be elicited in a wrist flexor muscle using a peripheral nerve stimulator. During training trials, the size of the participant's response will be shown on a screen and the participant will be asked to decrease the size of the H-reflex response over successive trials. Responses that are below a threshold will be rewarded and those above will not.
45499187|NCT03461159|Other|Operant conditioning of motor evoked potentials|Motor evoked potentials will be elicited in a wrist flexor muscle using transcranial magnetic stimulation. During training trials, the size of the participant's response will be shown on a screen and the participant will be asked to increase the size of the MEP response over successive trials. Responses that are above a threshold will be rewarded and those below will not.
45499188|NCT03451955|Other|Gluten-free diet|Participants in the intervention group abstain from gluten for 6 months.
45499189|NCT03428945|Drug|Hydroxychloroquine|Hydroxychloroquine for oral administration, dosed by weight
45499190|NCT03428945|Drug|Placebo|Placebo tablet identical to active drug
45383304|NCT03411408|Radiation|RT|tomotherapy (within 60 minutes from completion of decompression of hyperbaric chamber) with 3-5 consecutive sessions- one fraction per day, 5 Gy / die .
45499191|NCT05181059|Diagnostic Test|Dual-layer spectral computerized tomography (DLSCT)|Contrast enhanced DLSCT scan using a 128-slice dual-layer detector (IQon Spectral CT, Philips Health Systems) will be performed. Patients will be placed in prone position during the DLSCT scan in order to improve the visualisation of breast tissue and comparability with MRI images. During the examination we will administer a nonionic low-osmolar iodinated contrast agent (Optiray©) in order to visualise tumor angiogenesis.
45499192|NCT03409289|Device|RUSH Exam|Within two hours of return of spontaneous circulation, the following elements of the RUSH exam will be performed: focused evaluation of the heart, inferior vena cava, abdomen and aorta with the addition of evaluation for DVT and ocular ultrasound.
45499193|NCT05180747|Other|Frequency of physical therapy sessions|Physical therapy sessions consisted of standard of care practice at our center of excellence i two different frequencies. All patients in both groups received 12 physical therapy sessions. Patients in the burst group received 2 physical therapy sessions per week in 6 weeks, while patients in the spaced group received 1 session every 2 weeks for 6 months.
45499194|NCT01336712|Procedure|Peripheral Blood Stem Cell Transplant|"Total Body Irradiation 1200cGy (150cGy given in 8 fractions twice a day six hours apart on days -4, -3, -2 and -1.~Fludarabine 30 mg/m^2 given once a day for 3 days on days -7, -6 and -5 Cyclophosphamide 50mg/kg given one a day on days +3 and +4"
45499195|NCT05179889|Drug|FOLFOXIRI|"Irinotecan 165 mg/m2 IV day 1, oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 48 hours) continuous infusion] 12 cycles per 2 weeks~mFOLFOX 6 [Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 week"
45499196|NCT05179889|Drug|mFOLFOX 6|Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 weeks
45694889|NCT01833364|Procedure|Implantation of the Peripheral Nerve Graft|"The preparatory surgery for harvesting the peripheral nerve graft will take place in the operating room at the time of the Stage I surgery for the DBS procedure. The nerve exposure and preparation will take approximately 15 minutes of operating time in addition to the DBS procedure which typically takes 75-90 minutes.~The implantation of the nerve graft will take place in the operating room at the end of the second stage surgery for DBS. The graft harvesting and implantation will take approximately 15 minutes in addition to the 4 hours that is needed for the DBS surgery. The subject's peripheral nerve graft will be implanted into the substantia nigra unilaterally. This is a single arm trial to assess safety and feasibility."
45694890|NCT01720654|Behavioral|EPT|Standardized partner notification counseling and provision of 5 partner treatment packets containing: Printed information on signs, symptoms, diagnosis, and treatment of gonorrhea and chlamydia as well as information on local testing/treatment resources; 400 mg Cefixime and 1g Azithromycin.
45694891|NCT00911326|Drug|Lymphoseek|Single injection of 50 micrograms Lymphoseek radiolabeled with either 0.5 mCi (for same day surgery) or 2.0 mCi (for next day surgery) of Tc 99m
45694892|NCT01833676|Drug|Sevoflurane|
45694893|NCT01833676|Drug|Desflurane|
45383305|NCT03406741|Behavioral|psychometric evaluation|Wechsler type composite scales (WISC)
45383306|NCT03406741|Behavioral|neuropsychological evaluation|Evaluation of child behavior by the Goodman questionnaire: Strengths and Difficulties Questionnaire
45499197|NCT03208127|Drug|Treatment with Direct Acting Antiviral tablet|HCV Treatment for 12 Weeks
45499198|NCT02865122|Drug|NTRA-9620|Oral daily dose
45499199|NCT02865122|Drug|Placebo|Oral daily dose
45383307|NCT03390504|Drug|Erdafitinib|Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.
45383308|NCT03390504|Drug|Vinflunine|Participants will receive vinflunine 320 mg/m^2 as a 20-minute intravenous infusion.
45383309|NCT03390504|Drug|Docetaxel|Participants will receive docetaxel 75 mg/m^2 as a 1 hour intravenous infusion.
45383310|NCT03390504|Drug|Pembrolizumab|Participants will receive pembrolizumab 200 mg as a 30-minute intravenous infusion.
45383311|NCT03390504|Device|Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)|FGFRi CTA will be used to determine molecular eligibility.
45383312|NCT03390036|Combination Product|Cingal|Hyaluronic Acid with Triamcinolone Hexacetonide
45499200|NCT05383430|Diagnostic Test|: Conners rating scale-Stanford-Binet Intelligence Scales- stuttering severity index third edition (SSI-3) .|Questionaire tests for ADHD -IQ-Stuttering severity assessment
45499201|NCT03611114|Dietary Supplement|Blood orange juice|
45383313|NCT03390036|Device|Monovisc|Hyaluronic Acid
45383314|NCT03390036|Drug|Triamcinolone Hexacetonide|Triamcinolone Hexacetonide
45383315|NCT03389685|Biological|Platelet Rich Plasma|Pure PRPII®, leukocyte-poor, platelet rich plasma
45499202|NCT03611114|Dietary Supplement|Control drink|
45499203|NCT02728388|Drug|aminolevulinic acid|"Drug: Levulan Kerastick~Drug: Topical placebo~Device: Omnilux Revive~Procedure: Photodynamic therapy~Other: Tumor growth rate measurements"
45499204|NCT05506475|Procedure|Blood samples|venous blood collected in a 5 mL EDTA tube
45848090|NCT02536170|Other|Placebo|Placebo of intravenous (IV) normal saline 1-2 ml/kg three times a day until discharge from the emergency department (ED) or hospital.
45499205|NCT02033330|Dietary Supplement|phenolics form orange peel|
45499206|NCT03941093|Drug|Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX|"Drug: Pamrevlumab is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil."
45499207|NCT03941093|Drug|Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX|"Drug: Placebo is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil."
45499208|NCT03611036|Other|Strength training|Upper limbs Strength training; done with dumbbells whose weight corresponds to 60-80% of the maximal voluntary force in abduction measured initially, during 4 weeks
45499209|NCT03611036|Other|Endurance training|Upper limbs Endurance training of the ; done with dumbbells whose weight corresponds to 30% of the maximum voluntary force in abduction measured initially, during 4 weeks
45499210|NCT03610958|Device|Epitomee Device|A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety.
45383316|NCT03389685|Other|Saline Placebo|saline solution
45499211|NCT04603157|Behavioral|Hybrid Exercise Training|Personalized exercise program completing at least 3 aerobic exercise sessions a week and receive eight supervised training sessions over the 3-months
45383317|NCT03388606|Behavioral|Growth Mindset|30 Minute interactive video
45383318|NCT03386383|Behavioral|Intervention|Individual session, physical activity tracker, online intervention
45383319|NCT03385798|Procedure|Endowrist|Anastomosis made by Endowrist
45383320|NCT03385798|Procedure|Endo-GIA|Anastomosis made by Endo-GIA
45383321|NCT03379506|Drug|EBR/GZR FDC Tablet|Participants who are 12 to <18 years of age will receive oral FDC tablets with EBR 50 mg/GZR 100 mg once daily by mouth.
45383322|NCT03379506|Drug|Placebo|Placebo tablet matched to EBR/GZR FDC tablet.
45499212|NCT05458271|Device|VCMX|A flap will be raised and VCMX will be placed in order to increase the soft tissue volume
45499213|NCT05458271|Procedure|CTG|A flap will be raised and a CTG will be harvested from the palate and placed in order to increase the soft tissue volume
45499214|NCT05453747|Other|Exercise|After evaluating the age groups and physical characteristics of the athletes under the titles of Warm-Up, Core/Balance/Reactive, Speed/Agility/Quickness, Resistance and Cool-Down, the exercise programs that differ for the athlete under these exercise types are listed with the NASM program and shared with the athletes. During the 8-week period between the 2 evaluations, it was applied 2 days a week on the team's fitness days.
45694894|NCT01720732|Behavioral|Lifeline NET|Short Version of Narrative Exposure Therapy
45694895|NCT03210844|Procedure|Surgical approaches of total hip arthroplasty|Surgical approaches of total hip arthroplasty
45848091|NCT00951366|Other|Patient Registry|The CHILD Clinic Patient Registry is an observational study designed to identify epidemiologic and genetic factors associated with chronic lung disease in former preterm infants or those with lung disease in the neonatal period.
45848092|NCT04682574|Drug|Vitamin C|mega dose is given to the selected critically ill patients
45383323|NCT03379506|Drug|Grazoprevir Oral Granules|Participants 3 to <12 years of age take grazoprevir granules 0.5 mg by mouth in a soft food vehicle at a dose not to exceed 50 mg.
45383324|NCT03379506|Drug|Elbasvir Oral Granules|Participants 3 to <12 years of age take elbasvir oral granules 1 mg by mouth in a soft food vehicle at a dose not to exceed 100 mg.
45383325|NCT03377517|Radiation|radiosurgical hypophysectomy|Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
45499215|NCT05453747|Other|Exercise 2|After evaluating the age groups and physical characteristics of the athletes under the titles of Warm-Up, Core/Balance/Reactive, Speed/Agility/Quickness, Resistance and Cool-Down, the exercise programs that differ for the athlete under these exercise types are listed with the NASM program and shared with the athletes. During the 8-week period between the 2 evaluations, it was applied 2 days a week on the team's fitness days.
45499216|NCT05432687|Diagnostic Test|evaluation of deep abdominal wall before surgery|: cough test (L guillarme) + ulstrasonography of transversus abdominis
45499217|NCT03917381|Biological|GEN1046|GEN1046 will be administered intravenously once every 21 days (in selected expansion cohorts GEN1046 will be administered intravenously once every 21 days for the first 2 cycles, and every 42 days in subsequent cycles)
45499218|NCT03917381|Biological|GEN1046 in combination with docetaxel (in a single expansion cohort)|GEN1046 and docetaxel will be administered intravenously once every 21 days
45499219|NCT03917381|Biological|GEN1046 in combination with pembrolizumab (in a separate expansion cohort)|GEN1046 and pembrolizumab will be administered intravenously once every 21 days or every 42 days, respectively
45383326|NCT03375788|Drug|Tesamorelin|Tesamorelin F4 formulation 1.4mg daily
45383327|NCT03375788|Drug|Identical Placebo|Placebo injection daily
45383328|NCT03368079|Device|Negative Pressure Suction Catheter|The negative pressure suction device to be used in the study will be a Foley catheter. The catheter will be placed through the gastrostomy tube site, directed retrograde through the esophagus, and terminating in the PES.
45499220|NCT03917381|Biological|GEN1046 in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)|GEN1046 and pembrolizumab and standard chemotherapy will be administered intravenously once every 21 days for 4 cycles, followed by treatment with GEN1046 and pembrolizumab once every 21 days
45499221|NCT03913949|Drug|APG-2575|Multiple dose cohorts, PO, every day (QD) of a 28-day cycle
45499222|NCT03913481|Procedure|Acute normovolemic hemodilution|In the ANH arm, after induction of general anesthesia, a total blood volume of at least 650 ml of blood will be drawn from a central line. The amount of volume drawn can be replaced with Ringer lactate or a similar crystalloid fluid up to a 3:1 ratio.
45499223|NCT03913481|Procedure|Standard care|Best available treatment without ANH
45499224|NCT03661944|Diagnostic Test|functional performance test|Functional performance test is to test the ability of the athletes in functional movements
45499225|NCT02864498|Drug|DS107|
45499226|NCT02864498|Drug|Placebo|
45499227|NCT03238781|Drug|Placebo|Placebo was presented in identical containers, stored/packaged the same as AMG 301. All injections were administered within 30 minutes on treatment days.
45499228|NCT03238781|Drug|AMG 301|AMG 301 was packaged in 5 mL clear glass vials containing 1 mL of 70 mg/mL of AMG 301. All injections were administered within 30 minutes on treatment days.
45499229|NCT02033408|Drug|AB (antibiotics)|"PO Vancomycin 250mgX4/d for 3 weeks~PO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks~PO Doxycycline 2mg/kg X2/d (up to 100mgX2/d) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks~Patients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug."
45499230|NCT02033408|Drug|CS (corticosteroids) Only|"methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)~PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks"
45694896|NCT04380376|Drug|Melphalan|Inhalations with low doses of Melphalan for 7-10 consequent days
45694897|NCT04380376|Other|Standard of care|the patients will receive only SOC (standard of care) treatment
45694898|NCT04380298|Drug|Ketorolac|30ml of local infiltration solution containing 60mg ropivacaine
45694899|NCT04380298|Drug|Ropivacaine|30ml of local infiltration solution containing 6mg ketorolac
45694900|NCT04380298|Drug|Epinephrine|30ml of local infiltration solution containing 0.1mg epinephrine
45694901|NCT04164849|Drug|5-aminolevulinic acid|5-aminolevulinic acid (30 mg/ml) will be added to mononuclear cells in a dose of 3 millimolar and incubated for 1 hour
45694902|NCT04164849|Procedure|Blue light photopheresis|The mononuclear cells incubated with 5-aminolevulinic acid for 1 hour will be exposed to blue light.
45694903|NCT04164849|Procedure|Transfusion|The treated cells are transferred back to the patient as a standard blood transfusion
45694904|NCT04164849|Procedure|Continuous Mononuclear Cell Collection (CMNC)|The mononuclear cells are collected using the Spectra Optia with the Continuous Mononuclear Cell Collection protocol. 90 ml of mononuclear cells will be collected and 100 ml of 0,9% saline will be added to dilute the cells before incubation with drug and photopheresis.
45383329|NCT03366844|Drug|Pembrolizumab|checkpoint inhibitor
45383330|NCT03366844|Radiation|RT Boost|The second dose of pembrolizumab will be given in conjunction with an RT boost, consisting of 8 Gy for 3 fractions.
45383331|NCT03360539|Behavioral|Nurse-Family Partnership|
45383332|NCT03349450|Biological|DPX-Survivac|DPX-Survivac Priming dose of 0.5ml on Study days 7 and 28. DPX-Survivac Booster dose of 0.1ml on Study days 84, 140, 196, 252, 308, and 364.
45694905|NCT01833910|Other|AHA CPR Anytime Video Self-Instruction Kit|CPR Training utilizing a video self-instruction kit including training video and inflatable manikin.
45694906|NCT01833910|Other|AHA CPR Anytime DVD|A CPR Training Video, originally developed as part of a kit, administered without the accompanying manikin.
45383333|NCT03349450|Biological|Pembrolizumab|Pembrolizumab 200mg administered intravenously every 3 weeks, commencing on study day 7 to a total of 18 infusions
45383334|NCT03349450|Drug|Cyclophosphamide 50mg|Cyclophosphamide 50mg twice daily by mouth, administered 7 days on / 7 days off, stating at study day 0, until study day 384
45383335|NCT03348969|Drug|Mitomycin c|Neoadjuvant Mitomycin C
45383336|NCT03344458|Drug|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
45383337|NCT03341949|Biological|Recurring blood sample|An additional tube will be collected for the assay of CD146s as part of the research
45383338|NCT03341936|Drug|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
45383339|NCT03341936|Drug|Lirilumab|Lirilumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
45383340|NCT03328702|Device|Continuous Positive Airway Pressure|Apex XT Fit CPAP Machine
45383343|NCT03318900|Biological|Aldesleukin|Given IV
45383344|NCT03318900|Drug|CD8-Positive T-Lymphocyte|Given IV
45383345|NCT03318900|Drug|Cyclophosphamide|Given IV
45383346|NCT03318900|Procedure|Leukapheresis|Undergo leukapheresis
45383347|NCT03318900|Biological|Utomilumab|Given IV
45383348|NCT03311412|Drug|Sym021|Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.
45383349|NCT03311412|Drug|Sym022|Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
45383350|NCT03311412|Drug|Sym023|Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
45848093|NCT04589364|Drug|Injection botulinum toxin A ( Dysport 100 unit or Neuronox 33.33 unit)|injection of toxin on facial muscle
45383351|NCT03310528|Behavioral|Interview questionnaire|Complete interview questionnaire regarding the composition and timing of their most recent food intake.
45383352|NCT03310528|Procedure|Gastric ultrasound exam|Gastric ultrasound exam prior to upper GI endoscopy procedure.
45383353|NCT03306446|Drug|Start adalimumab in monotherapy|Discontinuation of Adalimumab in patients who achieved deep remission
45383354|NCT03306264|Drug|ASTX727|ASTX727 is a tablet for oral administration, containing the fixed-dose combination of 100 mg cedazuridine (a cytidine deaminase inhibitor) and 35 mg decitabine, given by mouth Dailyx5 in 28-day cycles (in Cycle 1 or Cycle 2, then in Cycle 3 and beyond).
45383355|NCT03306264|Drug|Dacogen|Decitabine 20 mg/m^2 one-hour IV infusion Dailyx5 (in one 28-day cycle: either Cycle 1 or Cycle 2).
45383356|NCT03301220|Drug|Daratumumab SC: daratumumab + rHuPH20|Participants will receive daratumumab SC injection (daratumumab 1800 mg + rHuPH20 [2000 U/mL]) once weekly for Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks for Cycle 3 to Cycle 6 (Days 1 and 15), and thereafter every 4 weeks (Day 1) until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion. Each cycle is 28 days in duration.
45383357|NCT03292133|Drug|EGF816|EGF816 is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
45383358|NCT03292133|Drug|Gefitinib|Gefitinib is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
45383359|NCT03289728|Other|Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE)|"Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE), performed using standard protocol.~Patients with ≥ moderate ischemia observed by SPECT (≥ 10% of the myocardium or transient ischaemic dilatation or reduced post-stress ejection fraction (EF)) or abnormal movements of the myocardial walls observed during a stress echocardiogram (≥ 3/17 segments) will benefit from coronary angiography. Depending on the results of coronary angiography and on the coronary anatomy and other clinical and para-clinical considerations (territory of myocardial ischemia) revascularisation will be performed (REVASC). Patients with < moderate ischemia will receive medical treatment only (MT)."
45426082|NCT00861068|Drug|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 600mg/day, intake in the morning and in the evening, intake for 11 weeks
45848094|NCT04553484|Diagnostic Test|Measuring cardiovascular performance and blood flow|Measuring cardiovascular performance and blood flow
45499231|NCT02033252|Device|Acupuncture|In the acupuncture treatment group, 10 acupuncture points (bilateral LI4, TE23, ST36, unilateral EHN-1, GV23, LI20 and LI4) will be inserted with 0.20 mm in diameter x 30 mm in length disposal needles. The needle will be inserted to a depth of 10 - 30 mm, according to the points selected. The participating acupuncture doctors will manually manipulate the acupuncture needles with de-qi sensation and maintain the needles for 10 minutes with two times of manual stimulation, at the beginning and at the end.
45383360|NCT03289728|Procedure|Cornorary angioplasty|Participants randomized to the SCA group, will benefit from a coronary angiography within 24 to 72 hours after the diagnosis of NSTEMI; without any preliminary ischemia imaging.
45383361|NCT03284203|Device|SpiroPD|At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal.
45383362|NCT03283917|Biological|Daratumumab|Given IV
45383363|NCT03283917|Drug|Dexamethasone|Given IV or PO
45383364|NCT03283917|Drug|Ixazomib|Given PO
45383365|NCT03282890|Other|CHRP-BB|The CHRP-BB intervention is a theory-based, manual-guided, HIV risk reduction and PrEP adherence intervention. It is an integrated evidence-based intervention that uses a coping skills training approach to primary prevention and is delivered in a small group modality by two trained intervention facilitators using a motivational enhancement therapeutic style to address high risk drug- and sex-related HIV risk behaviors and PrEP adherence. Importantly, the CHRP-BB intervention includes specific behavioral and mHealth strategies designed and tested to accommodate difficulties stemming from moderate to severe neuro-cognitive impairment (NCI).
45383366|NCT03280836|Behavioral|Exercise|"All participants randomized to the intervention group will be asked to keep an exercise log with the date, time, average heart rate obtained from a heart rate monitor, duration of workout and stretching, and any comments regarding the workout. Participants will be instructed to bring workout logs to infusion sessions for review. Participants will also wear a Polar Heart Rate monitor (US model RS400, Polar Electro Inc., Lake Success, NY) during exercise to monitor exercise intensity.~The aerobic exercise intervention will work toward the target of 75 minutes physical activity per week at 60%-85% of baseline VO2max."
45499232|NCT03610880|Drug|TG-2349 (400 mg) plus DAG181 (200 mg)|Dosing period 1 (Day 1 to 7): TG-2349 400 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
45499233|NCT03610880|Drug|DAG181 (200 mg) plus TG-2349 (400 mg)|Dosing period 1 (Day 1 to 7): DAG181 200 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
45499234|NCT02097121|Biological|BOTOX®|Each vial of BOTOX (Botulinum Toxin Type A) purified neurotoxin complex, formulation No. 9060X contains 100 U of Clostridium botulinum toxin Type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. The study medication was to be reconstituted with 0.9% sodium chloride (preservative-free). The 10 mL of study drug was to be administered as 20 injections each of 0.5 mL. Under direct cystoscopic visualization, injections were to be distributed evenly across the detrusor wall and spaced approximately 1 cm apart. To avoid injecting the trigone, the injections were to be at least 1 cm above the trigone. The injection needle was to be inserted approximately 2 mm into the detrusor for each injection.
45499235|NCT05320445|Behavioral|Supportive Expressive Group Therapy|The SEGT is a six-module program where each session is approximately one hour, and is held twice a week over a three-week period. It is framed within social cognitive theory, whereby resilience to adversity (NMSK trauma in this instance) relies on personal enablement. Enablement serves to equip the individual with the personal resources to cultivate their self-efficacy and mastery and to select and construct environments that promote successful adaption.
45499236|NCT02033486|Device|TOBI + DBT|
45848095|NCT04519866|Other|Electroacupuncture|"Manual acupuncture (see procedures below) will be administered first to obtain the de qi sensation. After de qi is obtained, the electroacupuncture unit will be connected to 1-3 pairs of acupoints. Current intensity used will be based on the tolerance of each patient. Needles with electrical stimulation will be retained for 30 min.~Main acupoints will be Jingjin points (meridian sinews) along the Bladder meridian of Foot - Taiyang, such as Shenshuci, as well as Jingjin points (meridian sinews) at transverse process from L2 to L4, iliac crest and spinous process from S1 to S4. Secondary acupoints will also be selected based on patients' syndromes and symptoms."
45694907|NCT05384691|Drug|Luspatercept Injection|"All formally included patients will receive 1.75 mg/kg luspatercept administered subcutaneously every three weeks (on day 1 of each 21-day cycle) for a duration of 24 weeks.~Responders at the response assessment (according to HI-E) in week 25 will be further treated with 1.75 mg/kg luspatercept until loss of response for an expected maximum of 18 months."
46059060|NCT02583685|Drug|PR4 + LDV/SOF + SMV 12 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
46059061|NCT04506151|Behavioral|Sleep-Opt|12-week behavioral intervention
45694908|NCT03210610|Diagnostic Test|colchicine level measurement|levels of colchicine will be measured in FMF patients taking colchicine
45694909|NCT01720888|Other|BM-MSCs|Intracoronary implantation of bone marrow-derived mesencymal stem cells
45694910|NCT01672281|Other|vibrox- vs. resistance training|Comparison between two exercise interventions
45383367|NCT03279094|Biological|Hematopoietic stem cell transplantation|Haploidentical stem cell transplantation with pre-transplant immunosuppressive therapy
45383368|NCT03275740|Drug|PF-06755347 intravenous healthy participant|Single doses of PF-06755347 will be administered intravenously dose levels 1, 2, 3, 4, 5, and 6.
45383369|NCT03275740|Drug|Placebo intravenous healthy participant|Placebo comparator
45383370|NCT03275740|Drug|PF-06755347 subcutaneous healthy participant|single doses of PF-06755347 will be administered subcutaneously at dose levels of SC1, SC2, SC3, SC4, and SC5.
45383371|NCT03275740|Drug|Placebo subcutaneous healthy participant|placebo comparator
45383372|NCT03275740|Drug|PF-06755347 subcutaneous ITP|single doses of PF-06755347 will be administered subcutaneously at 2 dose levels tested in healthy participants
45383373|NCT03275415|Drug|budesonide|Intra-tracheal instillation of a combination of budesonide/surfactant in preterm infants with RDS to prevent BPD
45383374|NCT03275415|Drug|Saline|Intra-tracheal instillation of a combination of saline/surfactant in preterm infants with RDS to prevent BPD
45383375|NCT03269227|Radiation|Accelerated hypofractionation with Tomotherapy|"Tomotherapy TPS will be used for treatment plannings. Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.~Prescription doses:~Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for GTV.~Steroids (methylprednisolone 4 mg daily) should be used from day 1 of radiotherapy to day + 30 after the end of the treatment."
45383376|NCT03237858|Device|HeartLogic ON|Remote management of patients with CRT-D or ICD devices and the HeartLogic diagnostic feature turned OFF
45499237|NCT05298215|Biological|UB-221|UB-221 is a recombinant humanized IgG1 monoclonal antibody with neutralizing capability against soluble human IgE and CD23-bound IgE for the treatment of allergic diseases. The activity of UB-221 is directly through the high-affinity binding with soluble and membrane bound IgE. The neutralization of soluble IgE will desensitize the activation of mast cells and basophils by inhibiting IgE cross-linking and down-regulation of FcεRI (high affinity IgE receptor) expression on those cells. The binding to CD23-bound IgE may inhibit IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes.
45499238|NCT05298215|Other|sterile saline solution|sterile saline solution (0.9% NaCl) for intravenous (IV) infusion
45383377|NCT03237858|Device|HeartLogic OFF|Remote management of patients with CRT-D or ICD devices and the HeartLogic diagnostic feature turned ON
45383378|NCT03233724|Drug|Decitabine (DAC)|Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks
45499239|NCT02747420|Device|NURO TM|The lower extremity will be palpated and a needle insertion site will be identified 5 cm from the medial malleolus and posterior to the tibia. Between the posterior margin of the tibia and the soleus muscle, a 34-gauge acupuncture-like needle will be inserted 3-4 cm to the tibial nerve. A grounding pad will be placed on the bottom of the foot just below the smallest toe. An inactive grounding pad will be placed on top of the foot above the small toe to be consistent with the sham pad placement. The needle and grounding pad will be connected to the stimulator and the stimulation will be increased from 0 to 10 Milli-ampere. The needle will be taped. The electrical current will be set by the subject and the mA will be recorded. A 30 minute stimulation session will be given at 20 Hz.
45554615|NCT03117764|Device|Microfet Dynamometer|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
45694911|NCT01834066|Biological|Stem Cell|Intralesional transfer of Autologous Stem cell (MNCs) per dose. 6 doses in 3 months
45694912|NCT03152955|Drug|Ketamine|Ketamine will be applied in patient-controlled analgesia.
45694913|NCT03152955|Other|scalp nerve block|Scalp nerve block is performed for the blockade of the greater occipital, superficial cervical and lesser occipital nerves with 0.5% ropivacaine.
45694914|NCT03152955|Drug|ondansetron|Ondansetron(13ug/kg/h) is applied in patient-controlled analgesia.
45694915|NCT03152955|Drug|Sufentanil|Sufentanil(0.02ug/kg/h) is applied in patient-controlled analgesia.
45694916|NCT05620888|Behavioral|Walk behavior change: Tailored messages (TM)|"Every afternoon at the same time, the mobile application sends a message to the participants of the TM arm. The message is tailored based on the answers provided to the pre-intervention questionnaire. An example message is: you think you are not able to walk regularly when your morale is low: do not give up because physical activity is also good for the mood! The intervention is provided for 30 days."
45383379|NCT03233724|Drug|Tetrahydrouridine (THU)|Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks
45383380|NCT03233724|Drug|Pembrolizumab|200 mg intravenous (IV) once a day every Wednesday, Thursday or Friday every 3 weeks.
45383381|NCT03230734|Drug|Radium-223|Radium-223: administered at the dose of 55 kBq per kg body weight, given at 4 week intervals for 6 injections, by slow intravenous injection
45383382|NCT03230734|Drug|Docetaxel|Docetaxel: administered at the dose of 75 mg/m2 by intravenous infusion over a period of 1 hour every 3 weeks for 10 cycles. It is associated with prednisone 5 mg orally twice daily administered continuously.
45383383|NCT03229408|Drug|Salsalate|Lean PCOS Arms: Salsalate 1.5 gm PO bid; Obese PCOS Arm: Salsalate 2.0 gm PO bid
45383384|NCT03229408|Other|Placebo|Appears identical to experimental drug
45383385|NCT03223922|Radiation|whole brain radiation therapy|Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
45383386|NCT03213678|Procedure|Biospecimen Collection|Undergo blood specimen collection
45383387|NCT03213678|Procedure|Computed Tomography|Undergo CT
45383388|NCT03213678|Procedure|FDG-Positron Emission Tomography|Undergo FDG-PET
45383389|NCT03213678|Procedure|Magnetic Resonance Imaging|Undergo MRI
45383390|NCT03213678|Drug|Samotolisib|Given PO
45383391|NCT03213678|Procedure|X-Ray Imaging|Undergo x-ray
45383392|NCT03209050|Device|Central Venous Access Placement|Device inserted into the femoral vein to insert a central venous access catheter
46056046|NCT04379115|Device|Active Comparator: Active tDCS + Active TUS|"Device: Active comparator device: Active transcranial Direct Current Stimulation (tDCS). Subjects will receive 20 minutes of active tDCS. During each Active stimulation session, stimulation will be applied for the full 20 minutes.~Device: Active comparator device: Active Transcranial Ultrasound (TUS). Subjects will receive 20 minutes of active Transcranial Ultrasound (TUS). During active stimulation the (TUS) will be active for the full 20 minutes."
45383394|NCT03183570|Drug|[18F]FP-R01-MG-F2|7mCi (range 6-9mCi) [18F]FP-R01-MG-F2 will be administered
45499240|NCT02747420|Device|Sham|"A needle will be inserted into the lower extremity approximately 5 cm cephalad from the medial malleolus and posterior to the tibia. A sham needle will be used a the tibial nerve insertion site. This will stimulate needle placement without puncturing the skin. The needle will be taped in place. The grounding pad from the transcutaneous electrical nerve stimulation (TENS) unit device will be placed on the bottom of the foot below the smallest toe. Another electrode will be placed on the top of the foot above the small toe for conduction. The TENS electrode will be connected to the TENS unit, at 20 Hz (the same as the PTNS group). The unit will be turned on and the stimulation will be increased to the subject's first sensory level. The subject will sense stimulation to either the bottom of the foot or the toe. the TENS unit will be on for a 30 minute test period. The TENS unit will be removed and the needle will be discarded."
45499241|NCT03238001|Device|DCTclock|DCTclock is a quick and non-invasive test that measures cognitive function based on a computerized algorithmic analysis of the entire drawing process and output of a well-established cognitive assessment called The Clock Drawing Test (CDT).
45383395|NCT03182244|Drug|gilteritinib|oral
45499242|NCT02747108|Behavioral|Blood Test Group Intervention|Patients randomly assigned to the Blood Test Group will complete an HbA1c blood test around the time of their next primary care appointment. Following the HbA1c test, their VA primary care provider will be notified of the test result and will be provided with a detailed interpretation of the result. Trained study staff will then provide brief counseling by phone and written information by mail about their test result. The brief counseling and written information will be based on the American Diabetes Association and National Diabetes Prevention Program guidelines and will emphasize the risk of progression to type 2 diabetes mellitus and the rationale for preventive strategies, encourage aerobic exercise and a calorie-restricted diet to promote and maintain weight loss, and set a goal of achieving and sustaining a weight loss of at least 5% of body weight.
45499243|NCT02747108|Behavioral|Brochure Group Intervention|Participants will be asked to review a handout from the National Center for Health Promotion and Disease Prevention (NCP) on recommended screening tests and immunizations on or around the same date as their next primary care appointment.
45499244|NCT05256095|Behavioral|Thinking in Speech|Thinking in Speech is a therapy to help children with autism learn to cope with daily stressors and improve their communication.
45383396|NCT03182244|Drug|LoDAC (Low Dose Cytarabine)|subcutaneous (SC) or intravenous (IV) injection
45383397|NCT03182244|Drug|MEC (Mitoxantrone, Etoposide, Cytarabine)|intravenous
45383398|NCT03182244|Drug|FLAG (Granulocyte colony-stimulating factor (G-CSF), Fludarabine, Cytarabine)|intravenous
45383399|NCT03176420|Procedure|angioplasty and stenting of occluded cervical ICA|The procedure is performed under monitored anesthetic care. We will perform a thorough and complete six-vessel diagnostic angiogram to completely characterize the occlusion and presence of collaterals. A distal protection device is used unless technically can't be delivered beyond the occlusion or when the occlusion extends beyond the petrous segment of the internal carotid artery. Balloon angioplasty is performed followed by deployment of covered stents to jail the clot/organized thrombus. The carotid reconstruction is performed from the distal to the proximal segment with coronary stents that are telescoped until normal flow is encounter. The Blood pressure is managed rigorously during and after the procedure to minimize the chances of reperfusion hemorrhage.
45383400|NCT03174197|Drug|Atezolizumab|Given IV
45383401|NCT03174197|Radiation|Radiation Therapy|Undergo RT
45383402|NCT03174197|Drug|Temozolomide|Given PO
45383403|NCT03170518|Drug|Canagliflozin 100 mg|Canagliflozin 100 mg tablet will be administered orally (by mouth) once-daily.
45694917|NCT05620888|Behavioral|Walk behavior change: Non tailored messages (NTM)|"Every afternoon at the same time, the mobile application sends a message to the participants of the NTM arm. The message concerns the emotional well-being resulting from the performance of the physical activity and is not tailored. An example message is: walking regularly in the fresh air improves your mood. The intervention is provided for 30 days."
45694918|NCT01720966|Procedure|Liver resection|Liver resection performed for metastatic disease from colorectal carcinoma
45694919|NCT05382975|Behavioral|CSPAP-T|"Trauma-adapted CSPAP delivery:~Staffing support~Trauma-sensitive professional development for teachers and staff~Setting specific needs assessment and action planning"
45694920|NCT01676493|Drug|Codeine|
45694921|NCT01721434|Drug|Levosimendan|
45694922|NCT01721434|Drug|Placebo|Similar coloured placebo
45694923|NCT01721512|Other|Breastfeeding|
45383404|NCT03170518|Drug|Canagliflozin 300 mg|Canagliflozin 300 mg tablet will be administered orally once-daily.
45383405|NCT03170518|Drug|Placebo|Matching placebo tablet will be administered orally once-daily.
46056047|NCT04379115|Device|Sham Comparator: Sham tDCS + Sham TUS|"Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of sham tDCS. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of sham TUS. During sham stimulation the ultrasound will not be active for the full 20 minutes."
45694924|NCT01721512|Other|Infant formula|
45694925|NCT02563431|Device|SYSTAM - SP-ED|"Positioning in bed, wheelchair and standing with classics materials (pillow, holds, sling) on day J0 until J7 or Exit.~Daily passive mobilisation of the upper member by a therapist.~Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers)"
46059062|NCT04506151|Behavioral|Healthy Living|Healthy Living
45383407|NCT03164928|Drug|Denosumab|1mg/kg BW (up to a maximum of 60 mg) SC Q6M
45383408|NCT03164928|Other|Placebo|SC Q6M placebo
45426083|NCT00861068|Other|Placebo|Placebo tablets two times a day for 10 weeks
45499245|NCT02075671|Drug|Aminolevulinic acid topical solution 20%|Intervention used in the experimental arm only
45499246|NCT02075671|Device|Blu-U Light Therapy|Intervention used in experimental and sham arms
45499247|NCT02075671|Other|Placebo vehicle only|Intervention only includes the placebo vehicle solution
45499248|NCT02560298|Drug|Capecitabine|
45499249|NCT02560298|Drug|Carboplatin|Given IV
45499250|NCT02560298|Drug|Cisplatin|Given IV
45499251|NCT02560298|Drug|Fluorouracil|Given IV
45499252|NCT02560298|Other|Laboratory Biomarker Analysis|Correlative studies
45499253|NCT02560298|Drug|Paclitaxel|Given IV
45499254|NCT02560298|Other|Quality-of-Life Assessment|Ancillary studies
45499255|NCT02033642|Behavioral|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to: (1) educate adolescent/young adult participants and their parents in principles of good nutrition and physical activity, and (2) train parents to implement lifestyle changes at home to facilitate weight loss in their child by monitoring diet and physical activity behaviors, setting goals, providing support and reinforcement, and assessing and making changes to the home environment.
45499256|NCT02033642|Behavioral|Maintenance|The Maintenance condition in this study is a 12-session intervention designed to extend FBBI and continue to teach adolescent/young adult participants and their parents to continue practicing lifestyle behaviors, generalize healthful behaviors to new environments, find additional social and community supports, and prevent and manage relapse.
45694926|NCT02563431|Device|Ultrasling ER 15°Donjoy - 4P-ED|"Positioning in bed, wheelchair and standing with specific materials (holds, sling in external rotation and abduction) on day J0 until J7 or Exit.~A training of the patient and members of family on pathology, risk, use of material~Daily passive mobilization of the upper member by a therapist.~Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers) and active patient training for use the other side for support hemiplegic shoulder to prevent diastasis."
45694927|NCT03210532|Drug|Telmisartan + Amlodipine + Rosuvastatin|Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo
45426084|NCT00844285|Drug|Cimzia|The associated drug description is a total of two 200 mg subcutaneous injections of Cimzia to total 400 mg.
45426085|NCT00841789|Drug|Etanercept|etanercept 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
45426086|NCT00841789|Drug|Placebo|Placebo 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
45426087|NCT00711646|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
45426088|NCT00711646|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
45499257|NCT03226769|Device|TrueTear™|Intranasal application of TrueTear™ device for approximately 8 minutes at Day 0, for approximately 3 minutes at Day 7 and then daily use of TrueTear™ per participant guide.
45499258|NCT03226769|Device|Thermalon Dry Eye Compress|Application of Thermalon Dry Eye Compress at Day 0, Day 7 and daily use as per label instructions.
45499259|NCT01330615|Drug|EMLA|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
45499260|NCT01330615|Drug|Placebo|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
45499261|NCT03636529|Dietary Supplement|Tart cherry juice|Participants randomized to consume for 4-weeks either placebo beverage or single-strength tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage for 4 weeks to account for timing and order effects.
45499262|NCT03636529|Other|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
45499263|NCT03382145|Other|No intervention|No intervention
45694928|NCT03210532|Drug|Telmisartan + Amlodipine|Telmisartan + Amlodipine + Rosuvastatin placebo + Telmisartan placebo
45499264|NCT05034029|Drug|Metformin hydrochloride sustained release tablets|Oral
45383409|NCT03157713|Behavioral|Goal-Directed Financial Incentives|Patients will receive financial incentives for using a food diary, verified by entries in in the BookFactory Food Diary or another food diary, including internet/app-based diaries ($30 monthly); achieving 75 minutes of physical activity per week in first three months, as verified by a wearable fitness tracker ($20 monthly); achieving 150 minutes of physical activity per week in last three months, as verified by a wearable fitness tracker ($20 monthly); enrollment in a clinic-based or commercial weight loss program ($150 one time); and active participation in clinic-based or commercial weight loss program, as verified by the program ($60 monthly).
45383410|NCT03157713|Behavioral|Enhanced Usual Care|Patients will receive a food diary (BookFactory Food Diary), wearable fitness tracker (Fitbit), exercise and nutrition education materials (American Heart Association's Walking For Better Health and How to Eat Healthy), and referral information for intensive weight loss programs. This information will comprise these commercial and hospital-based weight loss programs that are evidence-based: Weight Watchers and Jenny Craig; the Veterans Administration's MOVE! and TeleMOVE! programs; Bellevue Hospital's Medical Weight Management Clinic and Intensive Nutritional Treatment programs; and New York University Langone Medical Center's Weight Management Program. We will also provide brief instructions on how to use the food diary and Fitbit Charge HR.
45499265|NCT05034029|Drug|Placebo|Placebo
45383411|NCT03157713|Behavioral|Outcome-based Financial Incentives|Patients will receive financial incentives for clinically significant weight loss, as confirmed at monthly weigh-ins. At 30 days, they will receive $50 if they lose ≥1.5% to <2.5% of baseline weight or $100 if they lose ≥2.5% of baseline weight. At 2 months and 3 months, they will receive $50 if they lose ≥2.5% to <5% of baseline weight or $100 if they lose ≥5% of baseline weight. At 4, 5, and 6 months, they will receive $100 if they lose ≥2.5% to <5% of baseline weight or $150 if they lose ≥5% of baseline weight. To employ the behavioral economic concept of regret aversion, patients will be given feedback at each assessment point about incentives they would have received had they achieved a loss of at least 2.5% of baseline weight.
46056048|NCT02745951|Other|Heliox|Half of the study population will be randomly assigned to receive cardioplegia enriched with a 70:30 (Helium:Oxygen) via a D100 pediatric oxygenator. The Heliox itself will need to be administered via an oxygen regulator using a low flowmeter.
46056049|NCT02745951|Other|Standard of care|The other half will be randomized to Nitrogen:Oxygen mixture. This will be done through the standard of care cardioplegia apparatus. There will be no novel interventions administered in this group.
45499266|NCT03637127|Device|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
46056050|NCT02742051|Drug|Everolimus|Neoadjuvant endocrine therapy
45383415|NCT03146962|Drug|Vitamin C|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.
45499267|NCT03637127|Device|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
45694929|NCT03210532|Drug|Telmisartan + Rosuvastatin|Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo
45694930|NCT03956277|Device|PUG|This methodology involves using ultrasound to place gastrostomy tube (g-tube itself is off the shelf).
45694931|NCT03210454|Other|Smallholder Marketing|The smallholder marketing intervention involves product purchasing (e.g., bananas, beans, goats, eggs) from smallholder farmers' associations through WFP's large procurement procedures. WFP is will also provide technical training on topics such as sustainable farming practices, quality control, and business practices.
45694932|NCT03210454|Other|Intimate Partner Violence (IPV) Prevention Training|IPV prevention training involves 24 hours of gender training (gender equality and rights, economic empowerment, gender-based violence prevention), and 8 hours of nutrition and food security training (with a focus on gender).
45694933|NCT05119413|Drug|New trio de Kligman|Once daily application in addition to the same sunscreen
45694934|NCT05119413|Drug|Trio Kligman|Once daily application in addition to the same sunscreen
45694935|NCT01834378|Behavioral|Low intensity intervention|We administer, a pedometer and the participants receive a prescription on physical exercise.
45694936|NCT01834378|Behavioral|High intensity intervention.|We schedule group sessions for changes in behavior e.g. type of physical activity to prefer, barriers for change of life style etc.
46056051|NCT02742051|Drug|Letrozole|Neoadjuvant endocrine therapy
46056052|NCT02742051|Drug|Fluorouracil|Neoadjuvant chemotherapy
46056053|NCT02742051|Drug|Epirubicin|Neoadjuvant chemotherapy
45383416|NCT03125564|Procedure|Fecal Microbiota Transplantation|Fecal microbiota transplantation
45848096|NCT04519866|Other|Manual acupuncture|"After disinfecting the acupuncture points, acupuncture will be performed with the patient lying prone. Depending on the acupuncture points, 0.25mm X 25-75 mm sterile acupuncture needle will be used. Needles will be inserted 10-50 mm and either rotating manipulation or lifting-thrusting manipulation will be used to achieve de qi (a compositional sensation including soreness, numbness, distention and heaviness).~Acupoints used will be similar to those mentioned for electroacupuncture (see above)."
45383417|NCT03125564|Procedure|Sham|Infusion of sham
45383418|NCT03125564|Procedure|Fecal and Mucosal Microbiota Assessment|To assess the fecal and mucosal microbiota before and after Fecal Microbiota Transplantation
45848097|NCT04492488|Drug|MRG002|Administrated intravenously
45383419|NCT03110978|Biological|Nivolumab|Given IV
45383420|NCT03110978|Radiation|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
45383421|NCT03089606|Diagnostic Test|FDG PET/CT scan|18F-fluorodeoxy glucose (FDG) positron emission tomography (PET) with intravenous (IV) contrast images are obtained before and at the end study treatment (pembrolizumab infusion).
45383422|NCT03089606|Diagnostic Test|C11-AMT PET scan|11C-methyl-L-tryptophan (C11-AMT) positron emission tomography (PET) images are obtained before study treatment (pembrolizumab infusion).
45848098|NCT04473924|Drug|Mycophenolate Mofetil|Body surface area-based dosing of mycophenolate
45848099|NCT04473924|Drug|Mycophenolate Mofetil|Standard (fixed) dosing of mycophenolate
45848100|NCT04426500|Drug|Bupivacain|Direct injection of 0.25% bupivacaine into surgical wounds
45848101|NCT04426500|Drug|Ultrasound-guided transversus abdominus plane block|bilateral TAP using ultrasound guidance in prostatectomies
46056054|NCT02742051|Drug|Cyclophosphamide|Neoadjuvant chemotherapy
46056055|NCT02741973|Other|Yoga|
46056056|NCT02741973|Other|School sport|
46056057|NCT02741895|Behavioral|Fitbit monitoring|Patients will be fitted with a Fitbit after surgery, which will monitor steps and active minutes for the duration of hospitalization.
46056058|NCT02741817|Drug|Aspirin|The intervention has been described previously in both arms individually. Group A will receive 20mg of soluble Aspirin and group B with 75mg of soluble Aspirin. As this is a crossover study, all patients will fall under both groups throughout the duration and be un-blinded.
46056059|NCT02745873|Drug|Ascorbic Acid|Ascorbic Acid (vitamin-c) 500 mg in tablet form was used.
45383423|NCT03089606|Drug|Pembrolizumab|200 mg Pembrolizumab IV administered over 30 minutes on day 1. Repeat every 3 weeks for 4 cycles, until progression, or subject withdrawal for other reasons
45499268|NCT02864342|Device|Arm 1: BreatheMate device with application|The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. Subjects will receive audio-visual daily reminders (beeps and flashes) on the BreatheMate Bluetooth device. The bluetooth device transmits this data to a cellular phone that is provided to all subjects in the study. Subjects in the intervention group will also receive audio-visual alerts (beeps, flashes) from the bluetooth device to take their medication.
45499269|NCT02864342|Device|Arm 2: BreatheMate device without application|"The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. The functionality of audio-visual daily reminders (beeps and flashes) is deactivated for this control group.~The BreatheMate service also includes a cellular phone that will display whether the Bluetooth monitoring device is paired and communicating with the cellular phone. The Bluetooth device will transmit data regarding medication usage to the cellular phone."
45383424|NCT03089606|Diagnostic Test|CT scan|Computerized tomography (CT) images are taken without IV contrast before the treatment (pembrolizumab infusion) and with IV contrast 3 months after the treatment start.
45383425|NCT03085810|Drug|Ocrelizumab|Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.
45383426|NCT03078452|Device|Power drill|Undergo bone marrow biopsy using power drill
45383427|NCT03078452|Device|Jamshidi needle|Undergo bone marrow biopsy using Jamshidi needle
45383428|NCT03077451|Other|Laboratory Biomarker Analysis|Correlative studies
45383429|NCT03077451|Drug|Nelfinavir Mesylate|Given PO
45499270|NCT03237065|Drug|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg)."
45383430|NCT03065725|Procedure|late FDG|In addition to regular FDG-PET/CT 60 minutes post injection, an extra scan 180 minutes post injection is made.
45383431|NCT03043794|Radiation|Stereotactic Body Radiation SBRT|Stereotactic Body Radiation to the breast to 21 Gy
45499271|NCT03237065|Drug|Ferric carboxymaltose|Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial. The dose of ferric carboxymaltose for the individual subject was 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg).
45694937|NCT03152565|Drug|Avelumab|"Autologous Dendritic Cells vaccine: A dose of ADC at days 1, 14, 28, 42 and 56 (total of 5 doses), and thereafter every 6 months until disease progression (maximum of 6 additional doses) or unacceptable toxicity.~Avelumab will be administered intravenously at a dose of 10 mg per kilogram of body weight, every 14 days until disease progression or unacceptable toxicity."
45383432|NCT03026283|Device|HeartFLow CT-FFR|Patients receiving CCTA to diagnose stable chest pain or stable angina will receive CT-FFR to estimate rate of flow through the coronary arteries. The rate of flow will be compared to the rate found on Invasive FFR (the gold standard) if the subject receives invasive FFR.
45383433|NCT02998268|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
45383434|NCT02998268|Drug|Taxol|Taxol is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.
45383435|NCT02998268|Drug|Carboplatin|Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. Carboplatin produces predominantly interstrand DNA cross-links rather than DNA -protein cross-links.
45383436|NCT02996773|Drug|Bendamustine|After transplant, given intravenously on day +4 as part of Phase Ib.
45383437|NCT02996773|Drug|Cyclophosphamide|After transplant, given intravenously on day +3 as part of Phase 1b.
45383438|NCT02994459|Other|Weight Loss|Diet-induced weight loss (obese only)
45383439|NCT02993900|Device|Image-Guided Brachytherapy|Brachytherapy will be precisely inserted with the assistance of magnetic resonance (MRI) scans
45383440|NCT02984241|Behavioral|eHealth Coping Skills Training|Access to a specialized coping skills training website
45383441|NCT02984241|Behavioral|eHealth Usual Web Care|Access to a website in which helpful information on coping that is available on the internet has been systematically collected and organized in one place for easy retrieval
45499272|NCT02620826|Procedure|Indirect pulp therapy|Decayed dentin is lined with a resin-modified glass ionomer (Vitrebond Plus)
45499273|NCT02620826|Procedure|Pulpotomy|A cervical pulpotomy is done and the radicular pulp is lined with Mineral Trioxide Aggregate
45499274|NCT05121077|Other|Training|2 types of training intervention will be applied in terminal heart failure patients supported with a left ventricular assist device.
45499275|NCT03171415|Drug|RZL-012|Subject receive a single-time injection. Multiple injections of RZL-012 are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
45499276|NCT03171415|Drug|Placebo|Subject receive a single-time injection. Multiple injections of the Placebo are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
45499277|NCT03829241|Drug|Troriluzole|100 mg capsule
45499278|NCT03829241|Drug|Placebo|Placebo matched to troriluzole
45383442|NCT02984241|Behavioral|Coach Support|Access to a professional coach by phone
45694938|NCT01721590|Drug|Tongxinluo|Tongxinluo,3 capsules/time 3times/day for 1 year
45694939|NCT01721590|Drug|placebo|3 capsules/time，3times/day for 1 year
45694940|NCT05381181|Biological|CD19-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
45694941|NCT01834456|Other|Med Complex Children Intervention|Comprehensive Care, including creating a care plan, offering and integrating developmental and behavioral care, with added care coordination in a Medical Home/Primary Care Practice
45694942|NCT03938415|Procedure|Acupuncture|Acupuncture involving the Koffman protocol (body acupuncture) for anxiety control (needles will be placed at bilateral LR-3, bilateral LI-4, GV 24.5 and GV 20) and Auricular ATP Plus (ear) for pain control (needles will be placed at points hippocampus, amygdala, hypothalamus, prefrontal cortex, Point Zero, Shen Men, vagus, insula, external genitalia). Subjects who tolerate the auricular needles will be offered replacement with ASP acupuncture needles for continued pain management post-procedure. The subjects will receive local anesthetic during the vasectomy per standardized clinic protocol.
45383443|NCT02948452|Other|fMRI|fMRI: reward task, anxiety provocation
45383444|NCT02947685|Drug|palbociclib|o Starting dose: 125 mg capsule taken orally once per day for 21 days followed by 7 days off to complete 28 day cycle. Dose reductions: 100 mg, 75 mg. allowed. Number of Cycles: until progression or unacceptable toxicity develops
45383445|NCT02947685|Drug|trastuzumab|Patients must have received a minimum of 4 and maximum of 8 cycles of induction therapy prior to randomization to Arm A or B, at which point they will continue on antiHER2 therapy and endocrine therapy, with or without palbociclib. Trastuzumab dosing will be determined based on a loading dose of 8mg trastuzumab/kg body weight for Q3WK dosing schedules or a maintenance dose of 6mg/kg trastuzumab/kg dosing weight for Q3WK dosing schedules. Loading dose will be administered on Cycle 1, Day 1.
45499279|NCT05210959|Other|The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)|The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS) is an instrument that assesses the quality and quantity of motor development opportunities available in the home for infants aged 3 to 18 months. In this study, the Turkish version of the AHEMD-IS were constructed. Also, the validity and reliability of this version were examined.
45499280|NCT05090423|Other|balance training alone|"The subjects will warm up to stretch the lower extremity for 5 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller."
45694943|NCT03938415|Other|Standardized pre-procedure medications|The clinic standardized pre-procedure medications alone (which include diazepam 5 mg by mouth (PO) x1 30 minutes prior to the procedure, an additional 5 mg PO x1 15 minutes later if desired effect is not achieved; and oxycodone/acetaminophen 5/325 mg PO x 1 30 minutes prior to the procedure. The subjects will receive local anesthetic during the vasectomy per standardized clinic protocol.
45694944|NCT03210142|Procedure|Transvenous hypoglossal nerve stimulation|Transvenous hypoglossal nerve stimulation to open upper airway.
45694945|NCT03210064|Drug|Apatinib|Apatinib Mesylate Tablets 500 mg qd po
45694946|NCT03210064|Drug|5-fluorouracil|5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
45694947|NCT00905554|Procedure|warm water irrigation|warm water irrigation during insertion phase of colonoscopy
45694948|NCT00905554|Procedure|air insufflation|air insufflation during the insertion phase of colonoscopy
45694949|NCT03215524|Biological|DCdP|Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide
45694950|NCT03215524|Biological|DCd+P|Daratumumab, Cyclophosphamide, Dexamethasone, + Pomalidomide added only at first confirmed biochemical progression
45694951|NCT01721902|Device|Autologous CD133+ Bone Marrow Stem Cells|Intra-myocardial injection of 2-3 x 10E6 CD133+ Bone Marrow Stem Cells
45694952|NCT01721902|Other|Carrier Solution|Intra-myocardial injection of carrier solution
45694953|NCT05079321|Device|Hydra-PEG|Zen™ RC scleral lenses (Hydra-PEG coated)
45694954|NCT05079321|Device|Uncoated|Zen™ RC scleral lenses (non-coated)
45694955|NCT01721980|Drug|GLPG0974|
45383446|NCT02947685|Drug|pertuzumab|Patients must have received a minimum of 4 and maximum of 8 cycles of induction therapy prior to randomization to Arm A or B, at which point they will continue on antiHER2 therapy and endocrine therapy, with or without palbociclib.Pertuzumab will be administered at a loading dose of 840 mg infusion and then at a maintenance dose of 420 mg q3wks. If patient is within 5 weeks of receiving loading dose at Cycle 1, Day 1, patient may start with maintenance dose of 420 mg.
45383447|NCT02947685|Drug|letrozole|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for letrozole oral therapy is 2.5 mg orally, once a day.
45383448|NCT02947685|Drug|Anastrozole|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for anastrozole is 1 mg orally, once a day.
45383449|NCT02947685|Drug|Exemestane|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for exemestane is 25 mg orally, once a day.
45383450|NCT02947685|Drug|Fulvestrant|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for Fulvestrant is 250 mg injections on Day 1 and Day 15 of Cycle 1, and q4weeks thereafter.
45383453|NCT02915367|Behavioral|SMS Reminders|Participants will receive daily reminders, with content and timing of their choosing, regarding their PrEP use. Participants will have the choice to later receive SMS reminders only when they forget to take their dose (as indicated by real-time adherence monitoring via WisePill).
45383454|NCT02908906|Drug|JNJ-63723283|JNJ-63723283 will be administered by IV infusion or SC injection or infusion.
45694956|NCT01721980|Drug|Placebo|
45694957|NCT05372991|Drug|CBT-009|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
45694958|NCT05372991|Drug|Vehicle|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
45694959|NCT05372991|Drug|Atropine Sulfate|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
45694960|NCT01672515|Device|RIPC group|
45694961|NCT01672515|Device|Control group|
45694962|NCT00906178|Behavioral|CyberSenga|Internet-based HIV prevention program
45694963|NCT03152721|Device|Parkinson KinetiGraph|The Parkinson Kinetigraph (PKG) is a wrist-worn accelerometer shaped as a watch. It records spontaneous movements and for every two minutes provides a bradykinesia score and a dyskinesia score. Furthermore it analysis movement for tremor-like episodes and registers the time with tremulous movements as well as time with extreme immobility suggesting sleep. The device can be programmed with drug intake times and provide a reminder signal. Intake of drug can be indicated on the device.
45694964|NCT03152721|Other|Self assessment|Administration of self assessment questionnaires are made within 2 weeks from starting a PKG recording. The assessments are Parkinson Disease Quality of life 8 question short version and the Non Motor Symptom in Parkinson Disease Questionnaire.
45694965|NCT01722058|Drug|Peptide application|
45694966|NCT01722136|Behavioral|Low Dosage|Exercise dose of 8kcal/kg/week
45694967|NCT01722136|Behavioral|High Dosage|Exercise dose of 14kcal/kg/week
45383455|NCT02879695|Procedure|Biospecimen Collection|Undergo blood sample collection
45383456|NCT02879695|Biological|Blinatumomab|Given IV
45383457|NCT02879695|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
45383458|NCT02879695|Biological|Ipilimumab|Given IV
45383459|NCT02879695|Biological|Nivolumab|Given IV
45383460|NCT02871882|Radiation|Gastric Emptying test|participants eat a standardized meal labeled with radioactive markers (99mTc DTPA [diethylenetriaminepentaacetic acid] and In111 Chloride). They have scans taken at specific times after the meal to document the rate of gastric emptying.
45383461|NCT02871882|Other|Mixed Oral Glucose Tolerance test|Participants eat a meal containing 63g glucose in 240mL (milliliters) of skim milk, 2 scrambled eggs, 50g Canadian bacon and one slice of bread. Blood samples are taken prior to and for 6 hours after the meal at specific time points.
45383462|NCT02871882|Drug|Conjugated bile acids sodium|500 mg tablets taken orally twice daily for 28 (+/- 4) days
45383463|NCT02871882|Other|Placebo|Placebo tablets taken orally twice daily for 28 (+/- 4) days
45383464|NCT02838680|Device|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
45383465|NCT02830204|Device|Mitral Valve Replacement with Sapien3|subjects with surgical MVR with Sapien3
45383466|NCT02824276|Drug|Oxycodone or morphine sulfate immediate release (MSIR)|Oxycodone or morphine sulfate immediate release (MSIR)
45694968|NCT03863379|Diagnostic Test|whole body DXA|Measurements of body composition may be used to study how lean body mass and body fat change during health and disease and have provided a research tool to study the metabolic effects of obesity and various wasting conditions. DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%.
45383467|NCT02824276|Drug|Placebo Treatment|Lactose (Appearance and Weight-matched placebo capsules)
45383468|NCT02813135|Drug|Ribociclib|
45383469|NCT02813135|Drug|Topotecan|
45383470|NCT02813135|Drug|Temozolomide|
45383471|NCT02813135|Drug|Everolimus|
45383472|NCT02813135|Drug|Adavosertib|
45383473|NCT02813135|Drug|Carboplatin|
45383474|NCT02813135|Drug|Olaparib|
45383475|NCT02813135|Drug|Irinotecan|
45383476|NCT02813135|Drug|Vistusertib|
45383477|NCT02813135|Drug|Nivolumab|
45383478|NCT02813135|Drug|Cyclophosphamide|
45383479|NCT02813135|Drug|Selumetinib|
45383480|NCT02813135|Drug|Enasidenib|
45383481|NCT02813135|Drug|Lirilumab|
45383482|NCT02813135|Drug|Fadraciclib|
45383483|NCT02813135|Drug|Cytarabine|
45383484|NCT02813135|Drug|Dexamethasone|
45383485|NCT02813135|Drug|Ceralasertib|
45383486|NCT02813135|Drug|Futibatinib|
45383487|NCT02813135|Drug|Capmatinib|
45383488|NCT02812537|Other|patients with conduct disorders|interview with a specialist
45383489|NCT02809196|Behavioral|1: Tailored SMS program implicating friend and mother|
45848102|NCT04426500|Drug|Laparoscopic-guided transversus abdominus plane block|bilateral TAP using laparoscopic guidance in prostatectomies
45499281|NCT05090423|Other|balance training and neurodynamic intervention for the common peroneal nerve|"The physical therapist will give the patient neurodynamic intervention for the common peroneal nerve, which is performed slider the nerve 2 seconds.~The slider technique is repeated 30 seconds for 4 times, each time can be take a rest 1 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller."
45848103|NCT04251546|Diagnostic Test|p2PSA|p2PSA test(for calculation of PHI)
45499282|NCT01984879|Other|Survey with structured questionnaire form for inflammatory bowel disease patient group|For patients with inflammatory bowel disease, survey with structured questionnaire form is carried out.
45499283|NCT03620461|Drug|Gemcitabine - nabpaclitaxel|efficacy and safety
45499284|NCT05056493|Other|Caremap app|The Caremap app is intended for organizing and tracking patient-reported health insights over time and sharing those trends and patient-centered goals with their providers, not for urgent/emergent clinical communication. Information shared with providers through the app will be used for clinical care at the discretion of their provider. Use of the app to share information and health insights will not replace usual, existing channels for patient-provider communication (e.g., MyChart, phone calls, email, pager, etc.).
45694969|NCT01672593|Procedure|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device. Upon injection, two components, fibrinogen and thrombin, were mixed together in the mixing reservoir and yield a gelatin-like glue. This procedure was repeated in patients up to 3 times within 14-day FG treatment period.
45694970|NCT01672593|Drug|Anti-Bacterial Agents|Antibacterial therapy was given to patients with signs of systemic sepsis or local inflammation with pain.
45694971|NCT01672593|Dietary Supplement|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition.
45694972|NCT01672593|Procedure|PRFG preparation|As described in our previous work, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage.
45694973|NCT03678831|Procedure|tissue|Adipocyte isolation from distal femoral epiphysis and subcutaneous adipose tissue at the surgery site; classical piece removal during prosthetic replacement of the knee
45694974|NCT01834534|Behavioral|CarePartners for depression|Automated telephone calls for depression monitoring and self-management support.
45383490|NCT02809196|Behavioral|2: Standardized SMS program implicating friend and mother|
45694975|NCT04764279|Dietary Supplement|OPTIFAST dietary supplement|Participants will use Optifast Nutrition Supplement as previously described
45383491|NCT02809196|Behavioral|3: Tailored SMS program implicating friend, not mother|
45383492|NCT02809196|Behavioral|4: Standardized SMS program implicating friend, not mother|
45383493|NCT02809196|Behavioral|5: Tailored SMS program implicating mother, not friend|
45383494|NCT02809196|Behavioral|6: Standardized SMS program implicating mother, not friend|
45383495|NCT02809196|Behavioral|7: Tailored SMS program not implicating mother or friend|
45499285|NCT01314781|Drug|solifenacin|solifenacin 5mg tablet once daily
45499286|NCT01314781|Procedure|PFMT and WBVT|pelvic floor muscle and whole body vibration training once a week
45848104|NCT04251546|Diagnostic Test|Ultrasonic parameters|Ultrasonic parameters(TPV)
45848105|NCT04251546|Diagnostic Test|Transperineal prostate biopsy|Transperineal prostate biopsy for confirmation of prostate cancer or benign disease
45848106|NCT04131192|Drug|Z650|250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal
45848107|NCT04131192|Drug|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle ，for 4-6 cycles
45848108|NCT04123626|Drug|QR-1123|unilateral IVT injection
45383496|NCT02809196|Behavioral|8: Standardized SMS program not implicating mother or friend|
45383497|NCT02809196|Behavioral|9: No SMS program|
45383498|NCT02800512|Procedure|Robotic sacrocolpopexy|Sacrocolpopexy is a procedure to surgically correct vaginal vault prolapse where mesh is used to hold the vagina in the correct anatomical position. Robotic assistance is a minimally invasive method to perform this abdominal procedure.
45383499|NCT02800512|Procedure|high uterosacral ligament suspension|Utilizing uterosacral ligaments to support the vaginal cuff can be performed vaginally-by passing sutures bilaterally through the uterosacral ligaments. near the level of the ischial spine. HUSLS is a vaginal minimally invasive procedure for POP.
45383500|NCT02799823|Device|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
45383501|NCT02797470|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
45383502|NCT02797470|Drug|Carmustine|300 mg/m2 on Day -6, as part of BEAM and R-BEAM regimens.
45499287|NCT04230395|Behavioral|CAP|4-session combination Motivational Enhancement Therapy and Cognitive Behavioral Therapy alcohol reduction intervention. The intervention will also include 3 booster sessions.
45499288|NCT04230395|Other|Usual Care|Provider advice to reduce alcohol use per recommended standard of clinical care, and referral to treatment as indicated
45848109|NCT04123626|Other|Sham procedure|Sham procedures (i.e. no penetration of the globe) closely mimic the active injection and serve to mask subjects to treatment assignment
45848110|NCT03925116|Other|COntraceptive pathway|alternative way of aiding patients in deciding contraception method
45848111|NCT03923868|Drug|D-0120|D-0120 monotherapy dose escalation, oral, multiple dose for up to 28 days
45499289|NCT01330693|Drug|Atomoxetine|Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children. Single dose of 0.5 mg/kg at baseline visit. Then dose adjusted in an open-label design afterwards.
45499290|NCT01330693|Drug|Sugar Pill|In-active sugar pill randomly assigned at baseline visit
45499291|NCT04377451|Drug|Metformin|"The trial will be conducted in two phases, with a dose escalation of metformin. Metformin dosing will begin at 500mg (children) and 850mg (adults) once daily for 5 days in cohort 1.~Cohort 2 will be received weight-based doses; 5 days of 1000mg (500mg twice daily) for those weighing <60kg and 5 days of 1500mg (1000mg mane, 500mg nocte) for those weighing ≥60kg"
45499292|NCT01913977|Device|Abylcap® System: blood flow (QB): 200mL/min; gas flow (QG):7L/min|Abylcap settings
45499293|NCT01913977|Device|Abylcap® System: blood flow (QB): 300mL/min; gas flow (QG):7L/min|Abylcap settings
45499294|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):7L/min|Abylcap settings
45499295|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):1.5L/min|Abylcap settings
45383503|NCT02797470|Drug|Cytarabine|100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.
45694976|NCT01834612|Device|CM1500|blood volume monitor
45694977|NCT04404621|Behavioral|Physical exercise (PE) training and computer-based brain (CBB)|18 weeks of PE and CBB.
45848112|NCT03883074|Device|hyaluronic acid with chondroitin + sulphate + magnesium trisilicate|Melt in mouth tablets (1100 mg)
45848113|NCT03883074|Device|Placebo|tablets with the same aspect of the active device
45694978|NCT03219034|Device|oral appliance - A ; washout; oral appliance B|Anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible. 1 week washout followed by anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.
45848114|NCT03708900|Drug|LCI699|osilodrostat (LCI699) is in the form of tablets for oral administration and comes in the following tablet strengths: 1 milligram (mg), 5 mg, and 10mg.
45848115|NCT03670836|Device|Dilapan|Dilapan-S® is a mechanical method for cervical ripening using rods made of a patented hydrogel Aquacryl, it is marketed in form of rods of 3 and 4 mm diameter. It is FDA approved for cervical ripening.
45848116|NCT03670836|Drug|Misoprostol|"25mcg of Misoprostol will be administered orally every 2 hours (maximum of 6 doses)~Misoprostol is a prostaglandin E1 analog approved for treatment and prevention of gastric ulcers. The use of Misoprostol appears to be safe and effective for induction of labor when used in low dose."
45848117|NCT03607656|Drug|Oxaliplatin|Oxaliplatin powder injection
45848118|NCT03607656|Drug|Capecitabine|Capecitabine tablet
45848119|NCT03607656|Other|TCM|TCM decoction orally taken twice a day for at least 3 months
45383504|NCT02797470|Drug|Etoposide|VP-16: 100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.
45383505|NCT02797470|Other|Laboratory Biomarker Analysis|Correlative studies
45383506|NCT02797470|Biological|Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
45383507|NCT02797470|Drug|Melphalan|140 mg/m2 on Day -1, as part of BEAM and R-BEAM regimens.
45383508|NCT02797470|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
45499296|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):3L/min|Abylcap settings
45499297|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):6L/min|Abylcap settings
45499298|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):8L/min|Abylcap settings
45499299|NCT01330771|Drug|hMG-HP/r-FSH|
45499300|NCT03164551|Device|GERI+ incubator|The embryo culture of consented participants were carried out in GERI+ incubator for both bright-field and dark-field time lapse monitoring until Day 3 of embryo culture. On Day 3, all embryos were reviewed firstly by GERI Assess software, using bright-field imaging. Finally the embryo(s) with the highest EEVA grade are transferred were followed up until the achievement of implantation and confirmation of pregnancy.
45848120|NCT03607656|Drug|S-1|S-1 capsule
45848121|NCT03607656|Drug|Docetaxel|Docetaxel injection
45848122|NCT03607656|Drug|5-FU|5-FU injection
45848123|NCT03449628|Dietary Supplement|L.casei DG|"(At least 24 billion live cells per capsule)~1 capsule, b.i.d. for 12 weeks"
45848124|NCT03449628|Dietary Supplement|PLACEBO|1 capsule, b.i.d. for 12 weeks
45848125|NCT03409614|Drug|REGN2810|REGN2810 plus Platinum-based doublet chemotherapy Part 1 and Part 2
45848126|NCT03409614|Drug|REGN2810/chemo/ipi|REGN2810 plus abbreviated chemotherapy plus Ipilimumab Part 1
45848127|NCT03409614|Other|Chemotherapy|Platinum-based doublet chemotherapy Part 1
45848128|NCT03409614|Drug|Placebo|Matching placebo Part 2
46056060|NCT02745639|Radiation|VMAT-SIB|Radiation dose prescribed to PTV2 was 45 Gy (1.8 Gy/fraction), five sessions weekly in 25 daily fractions. A simultaneous boost was delivered on PTV1 with a total dose of 57.5 Gy (2.3 Gy/fraction). Dose-volume histograms (DVHs) were calculated for the PTV1, PTV2 and OARs. Patients were treated only if the relative variations of the bone markers between the images were within 3 mm along the three spatial directions. Planning and delivery processes underwent to systematic independent-check procedures.
46056061|NCT02745639|Drug|XELOX|The prescribed concurrent chemotherapy consisted of oxaliplatin infusion 130 mg/m2 on days 1, 17, 35 and capecitabine 1650 mg/m2 daily (825 mg/m² twice daily, 5 days/week) over all the treatment. An adequate blood count was necessary to start each chemotherapy infusion. Adjuvant chemotherapy was recommended on patients with high risk factors at pathological examination and decision was left to medical oncologists discretion.
45848129|NCT03320382|Device|Multiple breath washout testing|Multiple breath washout testing will be completed on different devices over time
46056062|NCT05629143|Procedure|de-prescription of PPI via intermittent scheme|The patients will decrease their intake of PPIs via a de-prescription intermittent scheme. After one month, patients will stop their intake of PPI.
45499301|NCT03164551|Device|Conventional incubator|The embryo culture of consented participants were carried out in conventional incubator for culture until Day 3 of embryo culture. On Day 3 of embryo culture, all embryos are assessed using a bench-top microscope. The embryo(s) with optimal cell stage and grade were transferred and were followed up until the achievement of implantation and confirmation of pregnancy.
45499302|NCT02863328|Drug|semaglutide|Oral administration once-daily.
45499303|NCT02863328|Drug|empagliflozin|Oral administration once-daily.
45499304|NCT03040141|Drug|Low dose of VIS410|Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
45499305|NCT03040141|Drug|High dose of VIS410|Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
45499306|NCT03040141|Drug|Placebo|Single intravenous infusion of placebo in addition to oseltamivir
45499307|NCT02033564|Device|Macintosh/Miller Laryngoscope|
45499308|NCT02033564|Device|Glidescope Laryngoscope|
45499309|NCT02937701|Biological|ABP 710|Administered by intravenous infusion
45848130|NCT02767830|Behavioral|Excercise and Nutrition Program|
45848131|NCT02651844|Drug|Mifepristone|"At the time a patient enters the protocol, 14 pills will be given to the personnel responsible of giving the patient the medicine at her home (This was a special requirement from the Argentine Authorities).~Patients and personnel will sign the form each then she gets the medication and after that the signed form will be kept at the CRF file."
45848132|NCT02341716|Procedure|WA|Walk advice with Nordic Poles and best medical treatment
45848133|NCT02341716|Procedure|SET|Walk advice with Nordic Poles, best medical treatment and hospital-based supervised exercise therapy
45383514|NCT02764762|Drug|Vedolizumab|Vedolizumab intravenous infusion.
45383515|NCT02764762|Drug|Adalimumab|Adalimumab injection for subcutaneous use.
45383516|NCT02764762|Drug|Methotrexate|Methotrexate oral tablets.
45383517|NCT02732288|Dietary Supplement|melatonin|After measuring the subject's own timing of release of melatonin, subjects will be provided a dose of melatonin at 8pm to test the effects on the electrical activity of sleep, measured using electroencephalography. The same intervention will be given to healthy, non-brain injured controls.
45499310|NCT02937701|Biological|Infliximab|Administered by intravenous infusion
45499311|NCT05186623|Drug|Vedolizumab, Ustekinumab, or Tofacitinib|Drug administration and prospective follow-up for evaluating response
45499312|NCT01330849|Behavioral|ADHD Toolkit|For children allocated to the active intervention arm, teachers are trained to apply the ADHD Toolkit. Teacher will use the behaviour modification tool for 3 months. They are trained to select target behaviours causing impairment for the child and will apply a systematic approach of increased intensity of monitoring and feedback for the behaviour, including training of appropriate behaviour.
45499313|NCT01330849|Other|Waiting List Control group|Children in the control group will receive no specific intervention, but are promised that their teachers will apply the schoolkit for them after the study.
45848134|NCT02341716|Procedure|HET|Walk advice with Nordic Poles, best medical treatment and home-based supervised exercise therapy
45499314|NCT04602845|Drug|Fentanyl|50ug Fentanyl intravenously
46056063|NCT05629143|Procedure|de-prescription of PPI via on-demand scheme|The patients will decrease their intake of PPIs via a de-prescription on-demand scheme. After one month, patients will stop their intake of PPI.
45383518|NCT02712515|Procedure|Deep brain stimulation implantation surgery|Deep brain stimulation is a neuromodulatory therapy in which electrodes are implanted in deep brain structures. Electrical pulses are delivered through these electrodes to suppress pathological activity that are causing the symptoms of essential tremor or Parkinson's disease.
45383519|NCT02712515|Device|Ad-Tech Medical Instrumentation Corp. electrodes/subdural strips|Ad-Tech Medical Instrumentation Corp. electrodes are intraoperative monitoring subdural strips will be placed on the surface of the cortex (non-penetrating).
45499315|NCT04602845|Drug|Flurbiprofen|50mg Fentanyl intravenously
45499316|NCT04602845|Drug|Midazolam|2.5mg midazolam in 2ml normal saline intravenously
45383520|NCT02712515|Device|FHC Guideline 4000+ system and/or Medtronic RC+S|Brain signals will be recorded using the clinical Participants in this group with Parkinson's disease will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
45499317|NCT04602845|Drug|Remimazolam|3mg Remimazolam in 2ml normal saline intravenously
45499318|NCT01330927|Drug|VA106483|"Once daily oral dose of placebo for 2 nights~Once daily oral dose of 0.5 mg VA106483 for 2 nights~Once daily oral dose of 1 mg VA106483 for 2 nights~Once daily oral dose of 2 mg VA106483 for 2 nights~Once daily oral dose of 4 mg VA106483 for 2 nights~Placebo: as above"
45499319|NCT04966325|Drug|LC350189 200mg|Subject will receive an LC350189 200mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
45499320|NCT04966325|Drug|Placebo|Subject will receive a Placebo as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
45499321|NCT04966325|Drug|Moxifloxacin 400mg|Subject will receive a Moxifloxacin 400mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
45499322|NCT04966325|Drug|LC350189 600mg|Subject will receive an LC350189 600mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
45499323|NCT05096377|Other|ESP block|ESP block performed using ultrasound guidance. Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
45499324|NCT03169153|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
45499325|NCT03169153|Device|Senofilcon C contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
45499326|NCT03168919|Radiation|Fractionated Radiation|Standard of care fractionated radiation therapy will be given to the tumor.
45499327|NCT03168919|Drug|Temozolomide|Standard of care temozolomide will be given along with radiation therapy
45499328|NCT03168919|Device|MRI|Four MRI scan will be performed according to the protocol. The first one will be obtained before start of radiation therapy, the second MRI will be obtained after completion of 20 +/- 4 Gy, the third MRI will be obtained after completion of 40 +/- 4 Gy, and the final MRI will be obtained after completion of the radiation therapy.
45499329|NCT05089669|Other|Interactive e-book|The nasogastric tube feeding interactive e-book has a lot of elements such as text content, videos, pictures, links, and other interactive content with which the students can interact. The participants can use the interactive e-book to learn nasogastric tube feeding.
45499330|NCT05089669|Other|paper textbook|The paper textbook has text content and pictures. The participants can use the paper textbook to learn nasogastric tube feeding.
45694979|NCT03219034|Device|oral appliance - B; washout; oral appliance A|Anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs. 1-week washout followed by anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.
45694980|NCT01722370|Drug|Oxygen|
45694981|NCT01722370|Drug|Medical air equivalent|
45694982|NCT01721668|Behavioral|Music Supported Rehabilitation|Music Supported Rehabilitation -using musical exercises to improve hand and arm motor functioning.
45694983|NCT01721668|Behavioral|Conventional Upper Extremity Therapy|-GRASP (Graded Repetitive Arm Supplementary Program-developed Janice Eng, PhD, PT/OT Jocelyn Harris, PhD, OT, Andrew Dawson, MD, FRCP, Bill Miller, PhD, OT) protocol will be used to improve arm and hand function in people living with stroke.
45694984|NCT04764435|Other|Physician ownership|"The intervention or exposure is whether the dialysis facility was owned by a physician in 2017"
45694985|NCT04764435|Other|Large dialysis organization ownership|"The intervention or exposure is whether the dialysis facility was owned by a large dialysis organization in 2017"
45694986|NCT03594435|Drug|Ibudilast|targets neurotrophin signaling and neuroimmune function
45383521|NCT02701283|Device|Medtronic Transcatheter Aortic Valve Replacement Systems|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with Medtronic TAVR Systems
45694987|NCT03594435|Drug|Placebo oral capsule|matched to active drug, ibudilast
45694988|NCT01722448|Dietary Supplement|Choline|4 capsules with 480 mg choline per day
46056064|NCT05629143|Drug|Alginate|The patients will stop their intake of PPIs and use alginate. After one month, patients will stop their intake of alginates.
46056065|NCT02741739|Drug|REGN1033|
46056066|NCT02745717|Drug|Thymoglobulin|administration of ATG 3.5mg/kg/d (Thymoglobuline®, Genzyme) intravenously for 5 days
46056067|NCT02745717|Procedure|Cord blood|transfusion of one unit of at least 4/6 HLA loci matched cord blood.
45383522|NCT02701283|Device|Surgical Aortic Valve Replacement (SAVR)|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with a commercially approved surgical bioprothesis
45383523|NCT02687958|Drug|Everolimus|Maintenance therapy
45383524|NCT02659930|Drug|liposomal doxorubicin|liposomal doxorubicin IV day 1 of a 28-day cycle
45383525|NCT02659930|Drug|pomalidomide|pomalidomide once a day, days 1-21 of a 28-day cycle, at the dose levels described in dose escalation plan
45383526|NCT02657863|Procedure|Urine collection and blood draw|
46056068|NCT02745717|Drug|Cyclosporine Oral Product|administration of cyclosporine A 5mg/kg orally, and maintain the trough serum concentration between 200ng/ml to 300ng/ml.
46056069|NCT02745561|Drug|Endostatins|Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy.
46056070|NCT02745561|Drug|Oxaliplatin|Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.
46056071|NCT02745561|Radiation|Radiotherapy|Radiotherapy will be delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks.
46056072|NCT02745795|Behavioral|Motivational Interview|Three face-to-face interviews using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
46056073|NCT02745795|Behavioral|Conventional Interview|Three face-to-face interviews without using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
46056074|NCT02745483|Device|Separable clustered electrodes|patients who signed informed consent, RFA was performed using separable clustered electrodes (Octopus®) in which, inter-tine distances can be flexibly adjusted by an operator.
46056075|NCT02741583|Other|altitude rehabilitation program|altitude exposure
45383535|NCT02623712|Other|More Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
45383536|NCT02623712|Other|Less Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.
45383537|NCT02609776|Drug|Amivantamab|The first cohort of participants will receive IV infusions of Amivantamab 140 mg as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive lazertinib and Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with the administration of standard of care carboplatin and pemetrexed.
45383538|NCT02609776|Drug|Amivantamab|Participants will receive IV infusion of Amivantamab as monotherapy at RP2D regimen or in combination lazertinib at RP2CD regimen as determined in Part 1.
45383539|NCT02609776|Drug|Lazertinib|Lazertinib will be administered in combination with Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily on the 28-day Amivantamab treatment cycle.
45383540|NCT02609776|Drug|Carboplatin|Participants will receive carboplatin in combination with pemetrexed and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
45383541|NCT02609776|Drug|Pemetrexed|Participants will receive pemetrexed in combination with carboplatin and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
45383542|NCT02598661|Drug|Imetelstat|Intravenous injection.
45383543|NCT02598661|Drug|Placebo|Matching Placebo to Imetelstat will be administered.
45383544|NCT02593565|Other|Online questionnaires|Women will be asked to complete questionnaires during their pregnancy and a postpartum questionnaire.
45383545|NCT02586090|Behavioral|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
45383546|NCT02586090|Behavioral|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
45499331|NCT05080387|Other|Blood sample|Blood samples will obtained for measurement of neopterin level through ELIZA
45694989|NCT01722448|Dietary Supplement|Placebo|
45694990|NCT01834768|Drug|Eplerenone|
45694991|NCT01672671|Drug|Doxorubicin, Paclitaxel, Cisplatin|Doxorubicin 25 mg/m2, IV weekly. Number of Cycles: 8 Paclitaxel 100 mg/m2, IV weekly. Number of Cycles: 8. Cisplatin 30 mg/m2, IV weekly. Number of Cycles: 8.
45694992|NCT01722682|Biological|Human pancreatic islet transplantation|
45694993|NCT02463981|Device|real-time fMRI neurofeedback training running on Turbo Brain voyager (TBV) 3.2 (Brain Innovation, Maastricht, The Netherlands)|
45694994|NCT02459457|Drug|Paclitaxel and Cisplatin|patients get Paclitaxel and Cisplatin according to protocol
46056076|NCT02741583|Other|rehabilitation program|Rehabilitation at low altitude
46056077|NCT02741661|Other|No intervention. Observational study|No intervention
46056078|NCT03813537|Other|Phone Call|The experimental group will receive a phone call 3-days post procedure and asked questions based on the most frequent indications for readmission after colorectal surgery.
46056079|NCT02695251|Other|low AGE meal|Patients will receive a low AGE (eggs) meal
46056080|NCT02695251|Other|High AGE meal|Patients will receive a high (mixed nuggets) AGE (eggs) meal
46056081|NCT04347603|Procedure|TAVR|Femoral percutaneous aortic prosthesis (TAVR)
45383547|NCT02576431|Drug|BAY2757556 (Larotrectinib, Vitrakvi)|Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.
45383548|NCT02567669|Radiation|standard postoperative radiotherapy for breast cancer|subjects will undergo ct scans to assess muscle mass and questionnaires to assess fatigue at 4 defined time points during and after radiotherapy
45499332|NCT04108819|Dietary Supplement|Ketogenic Diet|Subjects will undergo ketogenic diet at a 2.5:1 (fat: carb + protein) ratio for a 2-week period.
45694995|NCT02459457|Drug|Paclitaxel and Fluorouracil|patients get Paclitaxel and Fluorouracil according to protocol
45848135|NCT02155452|Procedure|ALA|"Prior to surgery all patients would receive freshly prepared solution of 5-ALA, 20 mg/kg bodyweight dissolved in 100 ml of potable water orally approximately 4 hours (range 4-6 hrs) before the commencement of anesthesia induction for surgery.~The surgery would then be performed with the help of navigation. After craniotomy, the navigation software would be used to identify the selected target areas based on the preoperative images (MR as well as PET when available) and directed image-guided biopsies from these representative areas will be collected for histological evaluation"
45848136|NCT01952340|Dietary Supplement|Flaxseed|Milled flaxseed
45694996|NCT02459457|Drug|Paclitaxel and Carboplatin|patients get Paclitaxel and Carboplatin according to protocol
45694997|NCT02459457|Radiation|Radiotherapy|1.8Gy/d, d1-5/week, 34Fx
45694998|NCT01835236|Drug|Trastuzumab|"First administration (loading dose) 8 mg/kg i.v. infusion over 90 min.~- then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min."
45694999|NCT01835236|Drug|Pertuzumab|"First administration (loading dose) 840 mg i.v. infusion over 60 min.~- then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min."
45848137|NCT01952340|Dietary Supplement|Placebo|Wheat germ/wheat bran and mixed dietary oils
45848138|NCT01463670|Drug|lenalidomide|patients will begin therapy with lenalidomide 25 mg daily, 21 days out of a 28 day schedule. All patients will be evaluated monthly after every cycle. The dose will be adjusted downward in response to side effects and according to specific guidelines. Symptomatic POD occurring at any time during the study will result in removal of the patient from the study. After 2 cycles of lenalidomide, patients with at least stable disease (SD) will continue lenalidomide indefinitely until asymptomatic POD, at which time dexamethasone will be added at a dose of 40mg weekly. On the other hand, patient with asymptomatic POD after 2 cycles of lenalidomide will have dexamethasone added at a dose of 40 mg weekly. Patients with any type of POD after any cycle that includes dexamethasone will be taken off study. Patients can remain on study on lenalidomide or lenalidomide/dexamethasone indefinitely as long as they do not have POD as stated above and they tolerate the treatment.
46056082|NCT02745015|Procedure|non-surgical periodontal treatment|full-mouth scaling and root planing
46056083|NCT02741427|Other|Conventional toothpaste|The participants should brush their teeth with conventional toothpaste for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on their toothbrushes, use dental floss, but not mouth rinse.
45848139|NCT00682032|Dietary Supplement|beta-glucan|AIM 2: regimen to begin after baseline blood draw; AIM 3: regimen to begin after baseline blood draw and to be completed prior to surgery
45695000|NCT01835236|Drug|Paclitaxel|Day 1, 8 and 15; every 4 weeks for ≥4 months 90 mg/m2 i.v. infusion
45695001|NCT01835236|Drug|Vinorelbine|"First administration: Day 1 and 8 25 mg/m2 i.v. infusion~then day 1 and 8, every 3 weeks for ≥4 months 30 mg/m2 i.v. infusion"
45695002|NCT01835236|Drug|T-DM1|Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)
45695003|NCT01671891|Radiation|radiation therapy|45-55Gy
45848140|NCT00151398|Drug|lecozotan SR|"evaluation of long term therapy with 3 doses of lecozotan sr ( 2, 5, and 10 mg)administered to patients with AD who have completed week 12 evaluations in the short-term study. Patient duration is 42 weeks.~Arms include lecozotan sr 2 mg, 5mg, and 10 mg as well as donepezil."
45848141|NCT00151398|Drug|Donepezil|10 mg donepezil QD dosed up to 40 weeks
45695004|NCT01671891|Drug|capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)|radiotherapy concurrent chemotherapy(capecitabine+oxaliplatin)
45695005|NCT05025111|Device|Entia Liberty|Home monitoring device
45695006|NCT03152409|Drug|Aspirin 325mg|Participants will take intervention drug dose once a day in combination with their existing antidepressant treatment regimen.
45695007|NCT03152409|Drug|Placebo Oral Tablet|Participants will take a placebo tablet of the same size, shape, and color as the aspirin tablet.
45848142|NCT03181308|Drug|Carotuximab (TRC105)|Anti Endoglin Antibody
45848143|NCT03181308|Drug|OPDIVO|Programmed Death Receptor-1
45383555|NCT02520362|Drug|denosumab|subcutaneous injection
45383556|NCT02520362|Drug|bisphosphonate|The assessment of bisphosphonates includes branded oral bisphosphonates (eg, alendronate [Fosamax®], risedronate [Actonel®], ibandronate [Boniva®/Bonviva®] oral); generic bisphosphonates, including alendronate, neridodronate, and olpadronate; intravenous bisphosphonates including ibandronate IV, and zoledronate [Reclast®/Aclasta®].
45499333|NCT03205163|Biological|Advate (Low Dose)|Participants received a single IV low dose of Advate 25 IU/kg.
45499334|NCT03205163|Biological|Advate (High Dose)|Participants received a single IV high dose of Advate 65 IU/kg.
45499335|NCT03205163|Biological|BIVV001 (Low Dose)|Participants received single IV low dose of BIVV001 25 IU/kg.
45383557|NCT02503228|Procedure|Standard of care osteochondral and or meniscal allograft transplantation|Standard of care osteochondral and or meniscal allograft transplantation
45383558|NCT02487524|Other|Cold water test|The patients immerse their hand into cold water for a maximum of 90 seconds and report their pain intensity every 15 seconds during the test.
45383559|NCT02487524|Other|Autonomic nervous system monitoring|The autonomic nervous system is monitored during the cold water test and 15 minutes thereafter.
45383560|NCT02487524|Other|QST|Quantitative sensory testing.
45383561|NCT02478710|Drug|Aerosolized Tobramycin or Vancomycin|Tobramycin: 300 mg diluted in 5 mL of 0.9% normal saline q.12h. Vancomycin: 125 mg diluted in 5 mL 0.9% normal saline q.8h.
45383562|NCT02478710|Drug|Aerosolized Placebo|Placebo tobramycin: 5 ml 0.9% normal saline q. 12h. Placebo vancomycin: 5m 0.9% normal saline q. 8 hr.
45383563|NCT02477826|Drug|Nivolumab|
45383564|NCT02477826|Drug|Ipilimumab|
45383565|NCT02477826|Drug|Carboplatin|
45383566|NCT02477826|Drug|Cisplatin|
45383567|NCT02477826|Drug|Gemcitabine|
45499336|NCT03205163|Biological|BIVV001 (High Dose)|Participants received single IV high dose of BIVV001 65 IU/kg.
45383568|NCT02477826|Drug|Pemetrexed|
45383569|NCT02477826|Drug|Paclitaxel|
45695008|NCT03835468|Dietary Supplement|Galacto-oligosaccharides|GOS is a form of prebiotic, which enhance the growth of beneficial gut bacteria
45695009|NCT03835468|Dietary Supplement|Maltodextrin|sugar based placebo
45848144|NCT03184428|Other|Postoperative observation and survey|For postoperative Observation with a survey we ask the patients (or in case of no information the ophthalmologist) whether they had undergone a YAG-Laser-Capsulotomy after Cataract-Surgery or not.
45383570|NCT02476279|Other|Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement|
45383571|NCT02476279|Other|Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement|
45383572|NCT02455505|Behavioral|background questionnaire|
45383573|NCT02455505|Behavioral|bereavement risk screening tool|
45383574|NCT02432482|Behavioral|mobile Positively Smoke Free (mPSF)|mPSF is a targeted, intensive behavioral cessation intervention designed for HIV-infected smokers. It is guided by the Social Cognitive Theory model. It includes 8 weekly sessions of audio/video messages to users, daily text messages, and a variety of other smartphone capabilities, e.g. play-a-tune, play-a-game, phone-a-friend, call the quitline.
45383575|NCT02432482|Behavioral|Standard care|Brief advice to quit (<5 minutes) Self-help brochure Offer of nicotine patches
45383576|NCT02425865|Drug|GOLIMUMAB|Increase/ or Decrease/ Interruption Dose of Golimumab depending on Continuous Clinical Response or Relapse
45383577|NCT02425852|Drug|Azathioprine|Azathioprine alone versus Azathioprine and IFX
45383578|NCT02425852|Drug|Infliximab|
45383579|NCT02425852|Drug|Prednisolone|
45383580|NCT02425852|Drug|Hydrocortisone|
45383581|NCT02382549|Drug|BRAF inhibitor|BRAF inhibitor
45383582|NCT02382549|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
45383583|NCT02382549|Drug|MEK inhibitor|MEK Inhibitor
45383584|NCT02333188|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
45499337|NCT01781143|Device|Perform Echo at home.|A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
45383585|NCT02333188|Drug|Leucovorin Calcium|Given IV
45383586|NCT02333188|Drug|Irinotecan Hydrochloride|Given IV
45383587|NCT02333188|Drug|Fluorouracil|Given IV
45383588|NCT02333188|Other|Laboratory Biomarker Analysis|Correlative studies
45383589|NCT02330601|Procedure|endoscopic papillary large balloon dilation|For the patients in EPLBD group, a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
45383590|NCT02316106|Drug|daratumumab|16 mg/kg administered by intravenous (IV) infusion once every week in Cycle 1, every other week in Cycle 2 and Cycle 3, every 4 weeks in Cycle 4 to Cycle 7, and from Cycle 8 to Cycle 20 on Day 1 of each cycle. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).
45383591|NCT02316106|Drug|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1, and then on Day 1 of each cycle from Cycle 2 to Cycle 20, and every 8 weeks after Cycle 20. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).
45383592|NCT02316106|Drug|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1 only. Treatment cycles are 8 weeks in length.
45383593|NCT02296528|Device|Swallowing Expansion Device|"SED looks like the letter T and has a plate and a post. The plate is like the top part of the T or smooth part of the tack. The plate is attached to the cartilage or flexible connective tissue of the throat. The SED post is like the bottom part of the T with a small ring. The post permanently sticks out from the throat, like a skin piercing. The SED is made out of titanium because this metal is extremely strong and commonly used in medical devices put into the body, such as hip joints or bone plates."
45383594|NCT02282358|Drug|Mocetinostat|
45383595|NCT02259413|Behavioral|Exercise Rehabilitation|This intervention will consist of lifestyle education, home-based resistance exercise and stationary cycling during hemodialysis sessions. Duration of the intervention will be 26 weeks
45383596|NCT02248597|Drug|fludarabine phosphate|Given IV
45383597|NCT02248597|Drug|busulfan|Given IV
45383598|NCT02248597|Drug|cyclophosphamide|Given IV
45383599|NCT02248597|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo myeloablative or reduced intensity allogeneic stem cell transplant
45383600|NCT02248597|Drug|tacrolimus|
45499338|NCT03681145|Behavioral|Counselor delivered telehealth intervention|This is a technology-based counseling intervention for youth living with HIV (YLWH) focused on engagement in HIV care, mental health, and substance use challenges through text messaging and teleconferencing (telehealth). The intervention is delivered in 12 brief sessions.
45499339|NCT01759537|Device|Ankylos dental endosseous implants-Sub-crestal|Implants placed subcrestally
45499340|NCT01759537|Device|Ankylos dental endosseous implants-Epi-crestal|Implants placed Epi-crestally
45695010|NCT01830088|Behavioral|Attachment Based Family Therapy|Attachment-Based Family Therapy (ABFT) is is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors
45695011|NCT01830088|Behavioral|Enhanced Usual Care|No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
46056084|NCT02741427|Other|Whitening toothpaste|The subjects should brush teeth with whitening toothpaste containing blue pigment for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on toothbrushes, use dental floss, but not mouth rinse.
45383601|NCT02248597|Drug|mycophenolate mofetil|
45499341|NCT04859075|Other|Bifidobacterium longum 35624|1 capsule daily
45499342|NCT03204539|Drug|Wilate|Wilate® is a high-purity (i.e. 100 IU FVIII/mg total protein) pdVWF/FVIII complex concentrate.Wilate® possesses all the important features asked for in ITI, namely high purity, a very high pathogen safety profile, and an excellent protection of its FVIII by VWF - all achieved through unique, novel, and innovative techniques.
45695012|NCT01830166|Radiation|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
45383602|NCT02242760|Drug|SB204 2%|Applied topically twice daily
45383603|NCT02242760|Drug|SB204 4%|Applied topically daily
45383604|NCT02242760|Drug|Vehicle Gel|Applied topically twice and once daily
46056085|NCT02741427|Other|10% carbamide peroxide|"The subjects should dispense the bleaching gel at night into the trays (maxillary and mandibular) and to insert them to cover at least the anterior teeth for a period of 4 h per day, over a 2-week period. Both arches should be bleached at the same time. During the period of bleaching, volunteers should receive the same toothpaste used by G1, in other words, without whitening agents, to standardize their oral hygiene regimen"
46056086|NCT05629611|Device|Vi-Sealer|using Reusable device, Vi-Sealer
46056087|NCT05629611|Device|Ligasure|using Ligasure
46056088|NCT05629611|Device|Other AHD|Using other AHDs such as Thunderbeat, Harmonic scalpel, Caiman®, Enseal, etc. except Ligasure
45383605|NCT02203695|Drug|Enzalutamide|Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
45383606|NCT02203695|Radiation|SRT|Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx
45383607|NCT02177578|Drug|Temozolomide|Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).
45383608|NCT02177578|Radiation|Subventricular Zone radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"
45383609|NCT02177578|Radiation|Neural Progenitor Cell Sparing radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"
45383610|NCT02177227|Device|Attune TruMatch (TM) Patient-Specific Instrumentation|Patients to receive total knee replacement with TruMatch Patient-Specific Instrumentation
45383611|NCT02166463|Biological|Bleomycin Sulfate|Given IV or SC
45383612|NCT02166463|Drug|Brentuximab Vedotin|Given IV
45383613|NCT02166463|Drug|Cyclophosphamide|Given IV
45383614|NCT02166463|Drug|Doxorubicin Hydrochloride|Given IV
45383615|NCT02166463|Drug|Etoposide|Given IV
45383616|NCT02166463|Other|Laboratory Biomarker Analysis|Correlative studies
45383617|NCT02166463|Drug|Methylprednisolone|Given IV
45383618|NCT02166463|Other|Pharmacological Study|Correlative studies
45499343|NCT01331317|Drug|Paricalcitol|capsule, 1-2 micrograms daily for 90 days
45695013|NCT01830322|Drug|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
45695014|NCT01830322|Drug|Gemcitabine|
45695015|NCT01830322|Drug|Any non-gemcitabine chemotherapies or best supportive care|
45383619|NCT02166463|Drug|Prednisone|Given PO
45383620|NCT02166463|Other|Quality-of-Life Assessment|Ancillary studies
45383621|NCT02166463|Other|Questionnaire Administration|Ancillary studies
45383622|NCT02166463|Drug|Vincristine Sulfate|Given IV
45383623|NCT02138448|Behavioral|Interactive Preventive Health Record|The interactive preventive healthcare record (IPHR) is a patient-centered application that links patients to their clinician's record, explains information in lay language, displays tailored recommendations and educational resources, and makes preventive care actionable.
45383624|NCT02112526|Drug|Acalabrutinib|
45383625|NCT02094794|Drug|etoposide|Given IV
45383626|NCT02094794|Drug|cyclophosphamide|Given IV
45383627|NCT02094794|Radiation|total marrow irradiation|Undergo TMLI
45383628|NCT02094794|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
45383629|NCT02094794|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
45383630|NCT01994954|Other|RHO|Recorded oximetry data will be downloaded from home oximeters, analyzed, and used to assist in supplemental oxygen weaning decisions.
45383631|NCT01973881|Procedure|T1 Weighted MRI (magnetic resonance imaging)|"Enrolled subjects will have an MRI scan performed at baseline (within 1 month before beginning therapy), at the time of a scheduled bone marrow biopsy or end of treatment cycle (6 months), and after 12 months.~Please note: Patients in this study will be treated with chemotherapy as determined by the hematologist or the treatment protocol for an independent clinical trial for therapy of myelofibrosis. Treatment and monitoring will be performed under the usual standard of care that includes physical examinations, laboratory testing, and other indicated imaging examinations."
45383632|NCT01958840|Behavioral|Behavioral Activation for Depression Treatment|
45383633|NCT01958840|Behavioral|Supportive Counseling|
45499344|NCT03638947|Device|Swab and decolonization using povidone-iodine cleansing|Patient in this group will receive improved environmental cleaning and undergo surveillance using swabs and decolonization cleansing.
45695016|NCT02411253|Drug|rhIL-2|Subcutaneous injections of IL2 according to regimen A Subcutaneous injections of IL2 according to regimen B
45383634|NCT01909453|Drug|LGX818|LGX818- Orally 100 mg and 50 mg capsules
45383635|NCT01909453|Drug|MEK162|MEK162- Orally 15 mg tablets
45383636|NCT01909453|Drug|vemurafenib|Tablets in bottles or blisters 240 mg
45383637|NCT01902173|Procedure|Biopsy|Undergo a biopsy
45383638|NCT01902173|Procedure|Biospecimen Collection|Undergo blood sample collection
45383639|NCT01902173|Procedure|Computed Tomography|Undergo a CT scan
45383640|NCT01902173|Drug|Dabrafenib Mesylate|Given PO
45383641|NCT01902173|Procedure|Magnetic Resonance Imaging|Undergo MRI
45383642|NCT01902173|Drug|Trametinib Dimethyl Sulfoxide|Given PO
45383643|NCT01902173|Drug|Uprosertib|Given PO
45383644|NCT01892709|Drug|Hydromorphone|
45695017|NCT02411253|Drug|Placebo|Subcutaneous injections of Placebo according to regimen A Subcutaneous injections of Placebo according to regimen B
45695018|NCT01835314|Drug|Stiripentol|Stiripentol 5-50mg/kg/d divided twice or three times a day by mouth
45695019|NCT03150069|Other|Interview|In-person or telephone in-depth interview
45695020|NCT01722760|Procedure|measurements|
45695021|NCT03427281|Behavioral|questionnaire|questionnaire to assess the patterns of postoperative bracing use by spinal surgeons in Belgium
45695022|NCT01722838|Behavioral|B-ME Intervention|B-ME is a behavioral intervention of HIV prevention risk reduction administered in a group format during a 2.5 day retreat (19 hours) format.
45695023|NCT01835392|Procedure|Remote Ischemic Preconditioning|Lower limb ischemia/reperfusion cycles
45695024|NCT01835392|Other|Control|Sham placement of blood pressure cuff without inflation
45383645|NCT01891318|Radiation|radiosurgery|Undergo radiosurgery
45848145|NCT03187002|Device|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.
45695025|NCT01672905|Other|laboratory biomarker analysis|
45383646|NCT01891318|Procedure|therapeutic conventional surgery|Undergo surgical resection
45383647|NCT01891318|Procedure|quality-of-life assessment|Ancillary studies
45383648|NCT01873755|Behavioral|asthma physical activity intervention|School- and community-based intervention includes several components: a classroom-based physical activity program, asthma awareness week at the school, asthma education for parents and students enrolled in the study, collaboration with child's physician to ensure proper medical treatment of child's asthma asthma education for school personnel
45383649|NCT01860937|Procedure|leukapheresis or collection of PBMCs|
45383650|NCT01860937|Drug|cyclophosphamide based chemotherapy regimens|
45383651|NCT01860937|Biological|modified T cells|
45383652|NCT01858597|Diagnostic Test|biachemical detection|"Serum FGF19 and FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) and were correlated with anthropometric, metabolic, and endocrine parameters. Homeostasis model assessment (HOMA-IR) index was calculated and analysed.~Second, samples for measurement were obtained from 30 women with GDM and 35 healthy pregnant controls undergoing caesarean sections at term. mRNA and protein expression levels of FGF19/FGF21 and their co-receptor βKlotho（KLB）in placenta, rectus muscle and subcutaneous fat tissues were investigated with real-time quantitative polymerase chain reaction (qRT-PCR), western-blot and immunohistochemistry (IHC), respectively. Clinical data were collected and analysed."
45383653|NCT01806571|Drug|Cytarabine|Given IV
45383654|NCT01806571|Drug|Daunorubicin Hydrochloride|Given IV
45383655|NCT01806571|Other|Laboratory Biomarker Analysis|Correlative studies
45383656|NCT01806571|Drug|Nilotinib|Given PO
45383657|NCT01806571|Other|Pharmacological Study|Correlative studies
45383658|NCT01781728|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT 5 Gy x 5 (over 1-2 weeks)*
45383659|NCT01781728|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT 6.6 Gy x 5 (over 1-2 weeks)*
45383660|NCT01772472|Drug|trastuzumab|6 mg/kg intravenously every 3 weeks, 14 cycles
45383661|NCT01772472|Drug|trastuzumab emtansine|3.6 mg/kg intravenously every 3 weeks, 14 cycles
45383662|NCT01741311|Behavioral|3H+ (Holistic Health for HIV)|Four weekly HIV-risk reduction groups and an additional booster group held at week twelve summarizing the previous sessions' content, designed for opioid-dependent individuals living with HIV.
45848146|NCT03187002|Drug|Moderate IV Sedation|IV sedation with fentanyl and versed
45848147|NCT03187002|Other|SHAM: Transcutaneous electrical nerve stimulation (TENS)|Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding
45383663|NCT01741311|Behavioral|HHRP+ (Holistic Health Recovery Program)|12 two-hour group sessions addressing HIV risk reduction behavior and recovery for opioid-dependent individuals living with HIV.
45383664|NCT01705899|Drug|Human Pancreatic Islets|Pancreatic islet tissue suspended in 150 - 300 ml of phenol red-free CMRL-1066 Transplant Media supplemented with 4% (w/v) HSA and 16mM HEPES in a 600ml transfer pack. Heparin will be administered at 70 IU/kg recipient body weight. Administered by intra-portal vein infusion. To be administered once, however, if full graft function is not achieved, a second or third dose of Pancreatic Islets may be given within 18 months of the first transplant.
45383665|NCT01701154|Other|respiratory muscle strength training|
45383666|NCT01642641|Procedure|Non-surgical Subgingival Debridement (SD)|SD is a conservative non-surgical procedure aimed at reducing dental plaque and calculus from the tooth root usually under local anaesthesia.
45383667|NCT01642641|Procedure|Simplified Papilla Preservation Flap|The simplified papilla preservation flap is a novel conservative surgical procedure aimed at the preservation of the tissues between the teeth. It has been shown to significantly reduce pocket depth and has faster re-vascularisation of the flap, when compared with other procedures.
45383668|NCT01642641|Procedure|Resective Periodontal Flap with Osseous Recontouring (RPFO)|RPFO is a surgical procedure that involves the resection of soft and hard tissue to obtain optimum tissue architecture and pocket reduction or elimination.
45383669|NCT01639196|Other|Self-compassion writing|Participants are instructed to write about their chronic pain in a way that elicits self-compassion for 20 minutes once a week for three consecutive weeks.
45383670|NCT01639196|Other|Self-efficacy writing|Participants are instructed to write about their chronic pain in a way that elicits self-efficacy for 20 minutes once a week for three consecutive weeks.
45383671|NCT01633177|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
45695026|NCT01725646|Drug|Omacor®|Subjects in 4 g and 2 g Omacor® will take this drug
45695027|NCT01725646|Drug|Placebo|Subjects in placebo group will take this drug
45695028|NCT03293745|Behavioral|Face to Face CBT-I (F2F)|CBT-I delivered in-person by the therapist.
45695029|NCT03293745|Behavioral|Telemedicine CBT-I (TM)|CBT-I delivered via American Academy of Sleep Medicine Telemedicine video conference System by the therapist.
45695030|NCT01835704|Other|Radio-frequency dennervation of facet joint|
45695031|NCT01835704|Other|Diagnostic nerve-blocks performed under direct x-ray vision|
45695032|NCT03243669|Diagnostic Test|High-definition|High-definition colonoscopy
45695033|NCT03243669|Diagnostic Test|Virtual chromoendoscopy|Virtual chromoendoscopy
45695034|NCT03243669|Diagnostic Test|Standard|Standard colonoscopy
45695035|NCT00915148|Other|Ultrasound examination|Trans-abdominal and trans-perineal 3D ultrasound examination
45695036|NCT04937127|Behavioral|I-LEARN training|Training of psycho-behavorial disorders care in neurodegenerative diseases: including a theoretical part in e-learning and a practical part
45383672|NCT01633177|Drug|Omega-3 fatty acid (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
45383673|NCT01633177|Dietary Supplement|Vitamin D3 placebo|Vitamin D3 placebo
45383674|NCT01633177|Drug|Fish oil placebo|Fish oil placebo
45383675|NCT01607008|Other|MRI imaging|"3 total MRI imaging studies:~pre standard radiation treatment~during standard radiation treatment~post standard radiation treatment"
45383676|NCT01522976|Drug|Azacitidine|Given SC or IV
45383677|NCT01522976|Other|Laboratory Biomarker Analysis|Correlative studies
45383678|NCT01522976|Drug|Lenalidomide|Given PO
45383679|NCT01522976|Drug|Vorinostat|Given PO
45499345|NCT01722019|Device|Tulip fiber|Laser ablation with a wavelength of 1470 nanometers will be performed, in combination with a new sort of fiber: the tulip tip fiber.
45383680|NCT01517451|Radiation|Radiation Therapy|7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions)
45499346|NCT01722019|Device|VNUS closure fast|Radiofrequent ablation will be performed in combination with the catheter 'VNUS closure fast'.
45499347|NCT01666873|Procedure|patients that undergo a total knee prosthesis|
45499348|NCT01572337|Procedure|Non-invasive ventilation|Early non-invasive ventilation will be given to patients at an early stage of acute respiratory failure
45848148|NCT03187002|Other|SHAM: Moderate IV Sedation|Sham IV to ensure blinding
45499349|NCT01572337|Other|Standard care|
45695037|NCT04937127|Other|usual care|usual care
45695038|NCT01725724|Procedure|Autologous blood transfusion|Per- and postoperative transfusion of autologous salvaged blood collected with the Sangvia Blood Collection System.
45695039|NCT01725724|Procedure|Allogeneic blood transfusion|Transfusion of allogeneic blood according to the transfusion guidelines at each of the participating hospitals.
45848149|NCT03193398|Drug|BTRX-246040 oral capsule(s)|BTRX-246040 administered once daily to patients with MDD for 8 weeks
45383681|NCT01517451|Drug|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT.
45383682|NCT01415817|Other|Training session|Series of two training sessions after the first phase of study followed by monthly feedback.
45383683|NCT01409200|Drug|Antiandrogen Therapy|Given per standard of care
45383684|NCT01409200|Drug|Axitinib|Given PO
45383685|NCT01409200|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
45383686|NCT01409200|Procedure|Regional Lymph Node Dissection|Undergo pelvic lymph node dissection
45383687|NCT01290835|Radiation|Stereotactic radiotherapy delivered by CyberKnife|Adjuvant radiotherapy will be delivered using CyberKnife radiotherapy using twice daily sessions for five days for a total of ten sessions.
45383688|NCT01290835|Radiation|stereotactic radiotherapy|
45383689|NCT01204216|Biological|re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 month"
45383690|NCT01204216|Biological|Re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 months.~small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate."
45426089|NCT00702468|Drug|Sativex|containing delta-9-tetrahydrocannabinol (THC)(27 mg/ml):cannabidiol (CBD)(25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Dose: 100 µl oromucosal spray, as required for symptom relief
45499350|NCT03502681|Drug|Eribulin Mesylate|"Days 1, 15~Eribulin mesylate:~Dose level -1: 0.7mg/m^2;~Dose level 0: 1.1 mg/m^2;~Dose level +1: 1.4 mg/m^2"
45499351|NCT03502681|Drug|Avelumab|Days 1, 15 Avelumab (10mg/kg)
45499352|NCT02860130|Drug|Prismocitrate 18|Modality of CVVHDF
45499353|NCT02860130|Other|No Anticoagulation|Modality of CVVHDF
45554616|NCT03117764|Behavioral|1 minute sit to stand test|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
45554617|NCT03117764|Device|Accelerometer|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
45499354|NCT01471483|Behavioral|geriatric assessment and telephone call from nurse|The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. The patient will receive a phone call once a week by a nurse who is an expert in caring for older patients. He/she will be asking questions about symptoms, medications and support at home. Each call is designed to last less than 30 minutes.
45554618|NCT05585697|Other|None - crossectional|None - crossectional
45848150|NCT03193398|Drug|Placebo oral capsule(s)|administered once daily to patients with MDD for 8 weeks
45554619|NCT03528915|Other|Rifamycine treatment|Phone prospecting: occurrence of conjunctivitis in newborns treated with rifamycine treatment in delivery room.
45383691|NCT01204216|Behavioral|Diabetes education/diabetes medication adjustment|Between the initial 3-4 month trial period and the second infusion of biotin labeled cells approximately 8 months later,subjects will receive diabetes education from a CDE. In addition,if needed, diabetes medications may be adjusted by the study endocrinologist to improve subject's glycemic control.
45848151|NCT03194334|Behavioral|Vegetarian diet|
45383692|NCT01202305|Procedure|Lymph node biopsy|Inguinal lymph node biopsy
45383693|NCT01196312|Behavioral|Anxiety sensitivity therapy|ASTH consists of 6 sessions of individual treatment, each lasting approximately 75 minutes over 3 weeks. In general, each session consists of the following components1) psychoeducation regarding the anxiety response, with a focus on increasing awareness of the ways in which the patient interprets or evaluates that response 2) assistance in developing healthy emotion regulation strategies that can be used to increase acceptance and tolerance of the anxiety response (including associated catastrophic thoughts), as well as understanding the consequences associated with avoidance or control of anxiety 3) a minimum of 3 interoceptive exercises tailored to activate feared anxiety-related sensations and 4) daily homework assignments (i.e., daily anxiety monitoring and interoceptive exercises).
45383694|NCT01161199|Procedure|Leukapheresis|Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
45383695|NCT01107015|Device|Tailored Patient Intervention|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. Patients may provide their PCPs with printed copies of their logbooks and other information but physicians do not have access to the patient portal system. Patient action plans summarizing the patient-entered data and identifying possible self-management actions for improving their diabetes control are electronically sent to the patients every 2.5 months.
45383696|NCT01107015|Device|Patient-physician intervention|"Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a web portal where they may choose to review their patients' electronic logbooks. This is raw patient data that have not been analyzed."
45848152|NCT03194334|Dietary Supplement|creatine|1g creatine/day
45848153|NCT03194334|Dietary Supplement|Placebo|pills
45848154|NCT03194334|Dietary Supplement|Beta-alanine|0.8g beta-alanine per day
45848155|NCT03199872|Biological|RV001V|Sc injection
45848156|NCT03202134|Other|opioid free anesthesia|general anesthesia blocking reflexes without using an opioid
46056089|NCT02745093|Drug|Mifepristone|Women at 64-84 days' gestation will use the following dosing regimen: 200 µg mifepristone administered orally in the clinic on Day 1.
46056090|NCT02745093|Drug|Misoprostol|The client will then be given a total of 2400 µg misoprostol tablets to take home, and will be instructed to take 800 μg misoprostol administered sublingually 24-48 hours later at home and to administer a subsequent dose of 400 μg misoprostol sublingually every 3 hours up to a total of four further doses or until expulsion of the products of conception, whichever comes first.
46056091|NCT02741505|Device|Actigraph|Participants will be asked to wear an actigraph
46056092|NCT02745171|Other|physical therapy|Will be held 15 sessions, 2 times a week, lasting 50 minutes, a physical therapy protocol developed by the Pro-Parkinson Physiotherapy based on the Guide of the Dutch Society of Physiotherapy (Keus, 2004).
46056093|NCT05629533|Device|SimpleSense|The study is observational only. No interventions will be triggered by the SimpleSense device
46056094|NCT02745249|Behavioral|Maternal Nutrition Behavior change|
45695040|NCT01673139|Behavioral|Interval exercise|4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 3 years.
45695041|NCT01673139|Behavioral|Moderate exercise|Moderate exercise with pulse about 70% of max pulse; 3 times a week for 3 years.
45695042|NCT01673139|Behavioral|Control|Given information on recommendations for physical activity.
45695043|NCT01725880|Other|Observation|
45695044|NCT04379362|Procedure|Focal laser ablation|Focal laser ablation
45695045|NCT03153969|Device|SHOFU Beautifil II LS|Placed under manufacturer's instructions
45695046|NCT03153969|Device|3M/ESPE Filtek Supreme|Placed under manufacturer's instructions
45383697|NCT01107015|Device|Patient and PCP intervention with analyzed data|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a secure web portal where they can see their patients' electronic logbooks. PCPs are provided with data analysis reports. The PCP is reminded that all data analysis is based on patient-entered, unvalidated data. The PCP has the option to use this information and remains responsible for all treatment decisions.
45695047|NCT01706198|Drug|fluticasone furoate + vilanterol|once daily via a Novel Dry Powder Inhaler
45695048|NCT01706198|Drug|inhaled corticosteroid with or without a long acting beta2-agonist|ICS alone or in combination with a long acting bronchodilator
45383698|NCT01104350|Other|external radiation therapy with gemcitabine|"All patients will undergo daily image-guided radiation therapy with concurrent twice weekly gemcitabine chemotherapy. Radiation therapy will begin 2-4 weeks after restaging cystoscopy/fiducial marker placement.~Dose level #1: 23.4 Gy/1.8 Gy × 13 fractions (total dose 68.4 Gy)~Dose level #2: 27.0 Gy/1.8 Gy × 15 fractions (total dose 72.0 Gy)~Dose level #3: 30.6 Gy/1.8 Gy × 17 fractions (total dose 75.6 Gy)"
45383699|NCT01100892|Drug|Once-daily insulin detemir|Insulin detemir is a long-acting insulin analog. Starting dose 0.1 units/kg/day (titrated according to the results of home blood glucose monitoring).
45383700|NCT01025089|Drug|Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide|Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients who have completed the neo-adjuvant treatment regimen, who have no evidence of distant progression, and who are medically operable will proceed to surgical resection within 6 weeks of the last infusion.
45383701|NCT00999037|Drug|Sevelamer Carbonate|Daily renvela (800 mg tid with meals) x 12 weeks
45383702|NCT00999037|Other|Placebo|1 inert tablet tid x 12 weeks
45383703|NCT00921856|Other|Intracoronary acetylcholine provocation test|Intracoronary provocation of coronary spasm with acetylcholine in augmented dosages of 2 µg, 20 µg, 100 µg and 200 µg non-selectively in the LCA as well as 80 µg in the RCA. During the procedure, a 12 channel ECG will be recorded.
45383704|NCT00900471|Other|biologic sample preservation procedure|
45695049|NCT03079323|Radiation|PART-trial|Elective radiation to the para-aortic lymph nodes 45 Gy / 1.8 Gy
45695050|NCT01835860|Procedure|Prostate artery embolization|
45695051|NCT04378972|Other|curcumin, homotaurine, vitamin D3|ELISA tests on supernatants of 25 vitreous biopsies incubated with bioactive molecules at 37 ° C for 20 h. The concentration of soluble mediators was calculated from a calibration curve.
45695052|NCT04378972|Other|control|ELISA tests on supernatants of 25 vitreous biopsies. The concentration of soluble mediators was calculated from a calibration curve.
45695053|NCT04883073|Device|Use of Endo App|Use of Endo App
45695054|NCT01723150|Drug|Ciprofloxacin|
45383705|NCT00900471|Other|medical chart review|
45383706|NCT00861705|Biological|Bevacizumab|Given IV
45383707|NCT00861705|Drug|Carboplatin|Given IV
45695055|NCT01723150|Drug|Ceftriaxone|
45695056|NCT01723150|Drug|Trimethoprim/sulfamethoxazole|
45695057|NCT01723150|Drug|Ertapenem|
45695058|NCT01725958|Dietary Supplement|Nutritional supplement and protein shakes|
45695059|NCT01835938|Drug|1- Erlotinib|"Erlotinib 50 mg tablet by mouth every day for 14 days,~Erlotinib 100 mg tablet by mouth every day for 14 days,~Erlotinib 150 mg tablet by mouth every day for 14 days,"
45695060|NCT01835938|Drug|placebo|"Placebo 50 mg tablet by mouth every day for 14 days,~Placebo 100 mg tablet by mouth every day for 14 days,~Placebo 150 mg tablet by mouth every day for 14 days,"
45695061|NCT01726114|Device|Non-invasive Optical Glucose Monitor™|Test device
45695062|NCT01726114|Device|YSI blood glucose analyzer|Reference device
45383708|NCT00861705|Drug|Cyclophosphamide|Given IV
45499355|NCT01471483|Other|geriatric assessment and no call from nurse|The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. They will not receive the phone calls, questions and symptoms will be addressed directly by the doctors and nurses on the medical and surgical teams.
45499356|NCT05051605|Biological|COVID-19 Vaccine|Severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2)vaccine according to vaccine availability in the Egyptian ministry of health.
45499357|NCT04938817|Biological|coformulation pembrolizumab/quavonlimab|Intravenous (IV) infusion
45499358|NCT04938817|Drug|lenvatinib|Oral administration
45499359|NCT04938817|Biological|MK-4830|IV infusion
45499360|NCT04938817|Biological|coformulation favezelimab/pembrolizumab|IV infusion
45383709|NCT00861705|Drug|Doxorubicin Hydrochloride|Given IV
45383710|NCT00861705|Other|Laboratory Biomarker Analysis|Correlative studies
45383711|NCT00861705|Drug|Paclitaxel|Given IV
45383712|NCT00833664|Drug|Terbinafine HCl 250mg tablets|1 x 250 mg
45499361|NCT04114994|Diagnostic Test|Boston Cognitive Assessment (BoCA)|"The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.~BoCA includes eight subtests in the following domains: Memory/Immediate Recall, Memory/Delayed Recall, Executive function/ Visuospatial, Executive function/ Mental rotation, Attention, Mental math, Language/Prefrontal Synthesis, and Orientation. The maximum total score is 30. Higher score indicates better cognitive performance.~After BoCA is completed, the domain scores and total score are provided immediately. Users will also receive an email with the link to the full report with progress charts."
45499362|NCT03013543|Drug|Setmelanotide|RM-493 once daily subcutaneous injection
45499363|NCT00788671|Other|Laboratory Biomarker Analysis|Correlative studies
45499364|NCT00788671|Device|Levonorgestrel-Releasing Intrauterine System|Undergo placement of a levonorgestrel-releasing intrauterine system
45499365|NCT00788671|Other|Quality-of-Life Assessment|Ancillary studies
45499366|NCT03636373|Drug|Etanercept|Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
45499367|NCT03636373|Drug|Triamcinolone Acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
45499368|NCT01366729|Device|TheraTogs|Orthosis facilitating hemiplegic hip extensor and abductor activity. Worn daily from dressing in the morning to undressing at night. May be removed during therapy or afternoon sleep.
45383713|NCT00833664|Drug|Lamisil® 250 mg Tablets|1 x 250 mg
45383714|NCT00745355|Behavioral|Quality Of Life questionnaires|All patients who agree to participate will be interviewed using a baseline idiographic quality of life assessment prior to surgery and at approximately 6, 12, 18 and 24 months postoperatively. All patients will also be asked to respond to a questionnaire including all standard measures (closed-ended, multiple choice items) before surgery and at approximately 3, 6, 12, 18 and 24 months post-surgery.
45383715|NCT00696111|Drug|Depot Lupron followed by estrogen plus placebo|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of estrogen (2mg) plus placebo for six weeks.
45383716|NCT00696111|Drug|Depot Lupron followed by progesterone plus placebo.|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of progesterone (200mg) plus placebo for six weeks.
45383717|NCT00696111|Device|CPAP|CPAP (continuous positive airway pressure) treatment at home for six weeks.
45695063|NCT01836016|Drug|Salbutamol (Ventolin®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol was used to Group A patients for 26 weeks: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose, 200 inhalations. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
45383718|NCT00496119|Radiation|Proton Beam Therapy|70 Gy once daily at 2 CGE per fraction, no sooner than 2 weeks after last surgery to remove tumor, for between 35-39 treatments.
45383719|NCT00496119|Radiation|Photon Beam Therapy|Photon beam therapy once daily, no sooner than 2 weeks after last surgery to remove tumor, for 35-39 treatments.
45383720|NCT00380367|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent HPV vaccine (6, 11, 16, 18) given intramuscularly on Day 1, Month 2, and Month 6.
45383721|NCT00354393|Drug|Cisplatin|
45383722|NCT00354393|Drug|Methotrexate|
45383723|NCT00354393|Drug|Vinorelbine ditartrate|
45499369|NCT01366729|Device|Cane walking|All walking activities must take place with cane from waking until sleeping
45695064|NCT01836016|Drug|Formoterol (Oxis Turbuhaler®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Formoterol was used to Group B patients for 26 weeks: Formoterol (Oxis Turbuhaler®, AstraZeneca), 4.5μg/ dose, 60 inhalations. 4.5μg each time, twice daily.
45383724|NCT00354393|Procedure|Adjuvant therapy|
45499370|NCT04485325|Drug|Tofacitinib|5 mg twice daily, p.o.
45383725|NCT00354393|Procedure|Conventional surgery|
45383726|NCT00354393|Procedure|Neoadjuvant Therapy|
45383727|NCT00354393|Radiation|3-dimensional conformal radiation therapy|
45383728|NCT00354393|Radiation|Intensity-modulated radiation therapy|
45383729|NCT00224393|Drug|Enbrel|
45383730|NCT00199862|Drug|Iodine-124 labeled humanized A33 (antibody)|Patients will receive a single intravenous or intraarterial infusion of 10mg huA33, labeled with 4mCi-10mCi of 124I in 5-30ml of 5% HSA in normal saline (NS), over 5-10 minutes. On study days 2, 3, and/or 4 patients will have the option to receive up to 2g/kg of IVIG. Patients will be evaluated with 124I-huA33 positron-emission tomography (PET) with ex vivo quantitation of tumor uptake.
45383731|NCT00179387|Behavioral|Mind-Body Psychotherapy Group|Psycho-educational group
45383732|NCT00179387|Behavioral|Mind-Body Psychotherapy Group|Spiritual-Existential Group
45499371|NCT04485325|Biological|Etanercept|50 mg once per week, s.c.
45499372|NCT03610178|Other|Life-style modification, insulin therapy if needed|All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (<5.1 mmol/L fasting and <7.0 mmol/L postprandial) are not achieved insulin therapy is started
45499373|NCT03610178|Other|Life-style modification, insulin therapy if needed|All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (<5.3 mmol/L fasting and <7.8 mmol/L postprandial) are not achieved insulin therapy is started
45499374|NCT02033798|Drug|Tamsulosin|Once Daily 0.2mg per oral for 6 months
45383733|NCT00179348|Procedure|Quality-of-Life Assessment|Ancillary studies
45499375|NCT03609632|Other|Dietary Supplement: Glucose|Intake of 75g of glucose with 1g of 13C leucine pre-feeding
45383734|NCT00179348|Procedure|Yoga|Undergo a yoga-based rehabilitation program
45383735|NCT00128310|Drug|Vinorelbine|
45383736|NCT00128310|Drug|Gemcitabine|
45383737|NCT00870077|Dietary Supplement|ProWHEY 94 CFM, SponserR|3 times 20g per day
45383738|NCT04782401|Other|Ultrasound guided genicular nerve block + exercise treatment|This method was used to inject a total of 6 mL of lidocaine plus 40 mg of triamcinolone (TA) at 3 separate target sites: the superior lateral, superior medial, and inferior medial genicular nerves plus exercise treatment
45383739|NCT04782401|Device|Physical therapy + exercise treatment|Ten sessions of hotpack as a surface warmer, TENS as a analgezic current, ultrasound therapy as a deep warmer and exercise treatment.
45499376|NCT04491110|Other|Music Therapy|We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be done by using mobile telephones.
45695065|NCT01836016|Drug|Salmeterol / fluticasone (Seretide®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salmeterol / fluticasone was used to Group C patients and Group D patients for 26 weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
45695066|NCT01836016|Drug|Bufei granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of lung-qi deficiency will be given Bufei granule, twice daily for 26 weeks for lower dosage.
45383740|NCT01007708|Drug|IDP-108|Topical application once a day for 48 weeks
45499377|NCT04491110|Other|simulation with therapeutic education|Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through mobile phones.
45499378|NCT02986854|Biological|Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)|One intramuscular injection of MenACWY at Day 1.
45383741|NCT01007708|Drug|Vehicle|Topical application once a day for 48 weeks
45383742|NCT00885443|Drug|Propofol|Patients will be anesthetised according to standard induction protocols with propofol/remifentanil intravenously. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
45383743|NCT00885443|Drug|sevoflurane|Patients will be anesthetised according to standard induction protocols with sevoflurane by inhalation. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
45383744|NCT00882869|Drug|AEG35156 antisense IV infusion|Dose escalation (100, 200 and 300 mg/day) over 2 hr infusion, once weekly over 21 days (Day 1, 8, 15)
45383745|NCT00882869|Drug|Sorafenib|Sorafenib will be administered at 400 mg BID every day
45695067|NCT01836016|Drug|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmonic-splenic qi will be given Bufeijianpi granule, twice daily for 26 weeks for lower dosage.
45383746|NCT01001000|Procedure|Ultrasound (Pressure measurement)|cut-off value for non maturationg fistulas
45383747|NCT00882947|Drug|Ventavis (Iloprost, BAYQ6256)|Iloprost solution for inhalation, BAYQ6256, Synthetic Prostacyclin analog
45383748|NCT00531050|Drug|Indacaterol|Single dose of indacaterol 300μg capsule via Concept 1 inhaler device at approximately the same time in the morning (i.e. between 8am and 9am).
45383749|NCT00531050|Drug|Placebo|Single dose indacaterol matching placebo via Concept 1 device
45383750|NCT00531050|Drug|Salmeterol|Single dose salmeterol 50μg via the Diskus dry powder inhaler (DPI) in part 1 of the study. Morning single inhalational dose and an evening single inhalation dose of salmeterol 50μg via the Diskus DPI in part 2 of the study.
45383751|NCT05231018|Other|Psychotherapy|8-sessions psychotherapy
45383752|NCT00530348|Biological|Alemtuzumab|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
45426090|NCT00702468|Drug|Placebo|Contains no active drug and is delivered in 100 microlitre actuations by a pump action oromucosal spray
45383753|NCT00530348|Biological|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
45499379|NCT02887183|Drug|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) was supplied as unscored, ovaloid, film-coated oral tablets in the strengths of 24/26 mg, 49/51 mg, 97/103 mg to be taken twice daily (bid)
45499380|NCT00367003|Device|Deep Brain Stimulation|The deep brain stimulation system (consisting of a lead, extension wire, and implanted pulse generator) will be surgically implanted to stimulate the targeted area of the brain. Stimulation will be turned off for 4 weeks following implantation, then participants will use brain stimulation for 6 months. Participants will also take part in Behavioral Activation therapy during the 6 months of active stimulation. Participants will be followed for 10 years, or until the DBS device has been FDA approved, with adjustments made to the stimulator and medications as necessary.
45499381|NCT03167359|Radiation|Hypofractionated Simultaneous Integrated Boost Radiotherapy|Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment. The boost treatment will be given on the same days as the whole breast treatment. The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions.
45499382|NCT03658356|Other|Video instructions|Pregnant patient will watch her video explaining how to collect a urine sample for asymptomatic bacteriuria determination.
45499383|NCT03660462|Dietary Supplement|FeSO4 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg ferrous sulfate (58FeSO4)
45383754|NCT01001156|Other|Comparison of different breathing muscular training|Three times per week for ten weeks, thirty minutes.
45383755|NCT05733962|Device|Use of the device DBL-4pen|"During the treatment period, the patient will use~the DBL-4pen device (consisting of a software hosting the Diabeloop algorithm installed on a smartphone)~the associated device #1: Dexcom G6, Continuous Glucose Monitoring (CGM)~the associated device #2: Two Mallya caps for their rapid- and long-acting insulin pens.~The regulation algorithm hosted by DBL-4pen software recommends insulin doses to be administrated by the patient."
45383756|NCT01001312|Other|Daxor Blood Volume Analysis|Radiolabeled albumin for direct measurement of blood volume
45499384|NCT03660462|Dietary Supplement|FePO4 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg ferric phosphate (58FePO4)
45499385|NCT03660462|Dietary Supplement|HiFePO4 1 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 1 (57FePO4)
45383757|NCT01001312|Other|Clinical volume status assessment|Volume assessment based on history and physical examination
45383758|NCT03886220|Drug|Elagolix|Oral; Tablet
45499386|NCT03660462|Dietary Supplement|HiFePO4 2 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 2 (57FePO4)
45499387|NCT01331395|Other|Traditional Chinese Medicine|Active arm will receive Acupuncture with their IVF cycle.
45383759|NCT03886220|Drug|Placebo|Oral; Tablet
45383760|NCT01007864|Drug|piribedil|Oral application of piribedil at an equivalent dose of pramipexole or ropinirole according to a defined equivalence scheme (dose range 100 - 300 mg per day) for 11 weeks.
45383761|NCT01007864|Drug|pramipexole or ropinirole|continuation of pre-study treatment regimen
45383762|NCT05111366|Drug|TQB2450 injection|TQB2450 is an injection in the form of 1200mg, ivgtt, q3W.
45383763|NCT05111366|Drug|Anlotinib hydrochloride capsules|Anlotinib Hydrochloride is a capsule in the form of 8 mg,10 mg, and 12 mg, orally, once daily, 2 weeks on/1 week off.
45499388|NCT03660306|Procedure|opioid anesthesia|opioid anesthesia means using sufentanil during surgery
45499389|NCT03660306|Procedure|opioid free anesthesia|opioid free anesthesia means giving no opioids during surgery
45499390|NCT03658200|Other|FAST start software delay|Scan delay will be determined by the FAST software bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold the FAST START software calculates the delay.
45499391|NCT03658200|Other|Manual bolus tracking delay|Scan delay will be determined by the standard bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold a delay of 6 s is chosen (table movement and breath hold command) and the scan starts.
45554620|NCT03528915|Other|whithout Rifamycine treatment|Phone prospecting: occurrence of conjunctivitis in newborns did not receive eye drop treatment in delivery room according to new guidelines.
46056095|NCT04326075|Device|CPAP treatment|CPAP should be performed as soon as possible and only with a helmet, using a positive end-expiratory pressure (PEEP) between 8 and 14 cmH2O and an inspired oxygen fraction (FiO2) between 40 and 60%.
45383764|NCT01008020|Dietary Supplement|tea catechin extracts|Tea catechin extracts 540 mg/day, are consumed for 5 months.
45554621|NCT03192878|Drug|Infliximab|infliximab biosimilar
45383765|NCT01008098|Drug|escitalopram (lexapro)|0 - 4 week: 10 mg escitalopram a day 5 - 8 week: 20 mg escitalopram a day
45383766|NCT01008176|Behavioral|Sleep extension|Habitual sleep duration is extended by 60min/night over a 6-week time period.
45426091|NCT00681538|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum dose within any 24-hour interval is 12 sprays (THC 32.4 mg: CBD 30 mg)
45383767|NCT00530270|Drug|Dexamethasone|Individuals meeting entry criteria will be randomized to receive dexamethasone 0.3 mg/kg (12 mg maximum single dose). The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
45499392|NCT03660150|Other|Evaluation of health-related quality of life|Short Form-36 Medical Outcomes Survey (SF-36), and Brief Version of Burn Speciﬁc Health Scale (BSHS-B) are used for the present evaluation.
45499393|NCT03659994|Dietary Supplement|Multivitamin|Vitabeard
45383768|NCT00530270|Drug|Placebo|Individuals meeting entry criteria will be randomized to receive 0.3 mg/kg (12 mg maximum single dose) of placebo. The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
45383769|NCT01008254|Behavioral|Musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 12 months.
45383770|NCT01008254|Behavioral|Delayed musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 6 months.
45499394|NCT03659994|Dietary Supplement|Placebo|Placebo
45499395|NCT01068600|Drug|Indacaterol|Once daily via single-dose dry powder inhaler (SDDPI)
45499396|NCT01068600|Drug|Placebo to indacaterol|Once daily via SDDPI
45848157|NCT03204942|Device|PRF on DRG|RF will be performed with the patient in a prone position with mild flexion of the spine. Fluoroscopy beam positioned in an antero-posterior direction. A 10 cm RF needle 20 G with a 10 mm active tip.The needle is inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walking into the thoracic intervertebral foramen. So the location of the needle tip confirmed by sensory stimulation at 50 Hz. The point of maximum stimulation is at 0.5 V intensity and this is designated to be the location of the DRG. Slight redirection can be done to optimize the stimulation; injection of contrast reveals epidural uptake. After establishing the site for the RF, 1 ml 2% lidocaine should be injected through the needle.
45383771|NCT01008254|Other|No musical prompt|No intervention.
45383772|NCT01008332|Biological|Toleromune HDM|ToleroMune HDM dose 1x4 administrations 4 weeks apart
45383773|NCT01008332|Biological|Placebo|Placebo comparator, 1x4 administrations 4 weeks apart
45383774|NCT01008488|Drug|Antibiotic|Antibiotic according to local treatment routine against bowel pathogenesis
45499397|NCT01067976|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M 0.1mmol/kg body weight
45499398|NCT02858492|Drug|GSK2982772 60 mg|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
45499399|NCT02858492|Drug|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
45383775|NCT01001468|Drug|VB-201|Single daily dose of oral VB-201 20 mg
45383776|NCT01001468|Drug|VB-201|Single daily dose or oral VB-201 80 mg
45383777|NCT01001468|Other|Placebo|Single daily dose of oral placebo
45499400|NCT01067508|Other|Fiji Water|Participants are asked to drink one liter of this silicon-rich water daily for three months.
45499401|NCT03609554|Other|Pilates|The Pilates exercise programme was implemented over 6 weeks, with 2 sessions/week (55 minutes/session). The Pilates programme was conducted by the Physical Education teacher, who was certified in Pilates training. The Pilates programme began at the basic level, incorporating more difficult principles and exercises gradually. The sessions were divided into the warm-up (7 min), the main part (41 min), and the cool down (7 min). Tt concentrated on basic Pilates exercises involving the principal regions of the body (spine flexions, extensions and rotations; hip flexions, extensions and rotations; and shoulder abductions, adductions and rotations).
45499402|NCT01067352|Drug|Recombinant human growth hormone (r-hGH)|Recombinant human GH were administered subcutaneously (s.c) at the daily dose of 0.067 mg/kg of body weight to Group A1.
45499403|NCT02986074|Device|Paresthesia mapping lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using paresthesia mapping in the first part of the SCS trial and using the lead implanted using anatomical midline placement in the second part of the SCS trial
45848158|NCT03204942|Device|TRF on DRG|"Similar to the group of  PRF on DRG, but the types of the waves will be different as previously described"
45848159|NCT03204942|Drug|Corticosteroid injection|Similar to the previous groups, but without applying any type of Radio-frequency but just injecting steroids and local anesthetics as previously described
45848160|NCT03207438|Drug|Quetiapine 50 MG Extended Release Oral Tablet|OD
45499404|NCT02986074|Device|Anatomical midline lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using anatomical midline in the first part of the SCS trial and using the lead implanted using paresthesia mapping placement in the second part of the SCS trial
45554622|NCT03524703|Other|chewing gum|Chewing gum four times per day for 5 days, 15 minutes each time.
45554623|NCT03241940|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given CD19/CD22-CAR T cells IV
45554624|NCT03241940|Drug|Cyclophosphamide|Given IV
45383778|NCT01001624|Other|Melanil facial cream|Dosage commensurate with surface to be treated, Melanil facial cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Melanil facial cream.
45383779|NCT01001624|Other|Hydroquinone 2% cream|Dosage commensurate with surface to be treated, Hydroquinone 2% cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Hydroquinone 2% cream.
45383780|NCT01001780|Drug|Pentostatin; Cyclophosphamide; Rituximab|Pentostatin 2mg/m2 IV day+1 (up to 6 cycles) Cyclophosphamide 600mg/m2 IV day+1 (up to 6 cycles) Rituximab 375mg/m2 IV day+1 (up to 6 cycles)
45383781|NCT01001858|Other|Diagnosis and monitoring of OSA patients|The difference between the three strategies is given by the method used for OSA diagnosis (domiciliary RP or hospital PSG) and the type of monitoring carried out after initiating CPAP treatment (by physician at hospital or by a trained nurse in patient's home)
45383782|NCT01008566|Biological|Cixutumumab|Given IV
45383783|NCT01008566|Other|Laboratory Biomarker Analysis|Correlative studies
45383784|NCT01008566|Drug|Sorafenib Tosylate|Given orally
45383785|NCT01008644|Other|Water|The subjects will drink tap water for 2 hours, volume calculated according to weight: 20ml/kg/hour.
45383786|NCT01008644|Other|Saline 3%|The subjects will receive saline 3% intravenously for 2 hours, the volume calculated as 0.1 ml/kg/min
45383787|NCT05733494|Other|Administration of Clinical Assessment of Dysphagia in Neurodegeneration (CADN)|the CADN will be administrated to each patient at the enrolment
45383788|NCT05601128|Drug|CAB + RPV|At Day 1 all participants will initiate oral CAB 30 mg + RPV 25 mg once daily for at least 28 days during the Oral Phase. Participants will receive CAB LA 600 mg + RPV LA 900 mg IM injections at month 1 visit followed by CAB LA 400 mg + RPV LA 600 mg IM injections monthly at M2, M3, M4 and M5 visits. Then, starting at month 6 visit, participants will receive CAB LA 600 mg + RPV LA 900 mg IM injections every 2 months at M6, M8, M10 and M12.
45383789|NCT05593406|Device|Vibration Group|Whole body vibration for 15 minutes in squat and lunge position.
45383790|NCT05593406|Other|Control Group|NDT treatment 2 sessions per week
45383791|NCT01001936|Drug|SKI-606|
45383792|NCT03885596|Drug|CA-008|Drug: CA-008 4.2 mg reconstituted in saline
45383793|NCT03885596|Drug|Ketorolac|30 mg IV at the onset of anesthesia
45383794|NCT03885596|Drug|Acetaminophen IV|1 g at the onset of anesthesia
45383795|NCT03885596|Drug|Fentanyl|100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery
45383796|NCT03885596|Drug|Bupivacaine Hydrochloride|0.25% 30 mL (75 mg) prior to surgery
45383797|NCT03885596|Drug|Lidocaine HCl|1.5% 12 mL at the end of surgery
45383798|NCT03885596|Drug|Celecoxib|200 mg PO bid each day postoperative
45383799|NCT03885596|Drug|Acetaminophen Oral|1 g postoperative
45383800|NCT03885596|Drug|Lidocaine Hydrochloride|2% 15 mL at the end of surgery
45383801|NCT03885596|Drug|Exparel|Bupivacaine liposome injection suspension
45383802|NCT05733338|Other|Intermittent Hypoxia|The intermittent hypoxia protocol refers to four cycles of 10 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 5 days.
45383803|NCT05733338|Other|Sham Intermittent Hypoxia|The sham intermittent hypoxia protocol refers to 55 minutes normoxia inhaling, which is performed twice a day (at least 6 hours apart) in 5 days.
45383804|NCT01002092|Drug|Chemotherapy|Week 1 day 1 MTX 8 g/m2; Week 3 day 1-2 CDP 100-120 mg/m2 day 1 ADM/THP 60 mg/m2; Week 5 day 1-6 IFO 2 g/day; Week 7 rest; Week 8 surgery; Two weeks after the surgery repeat the chemotherapy cycle 3 times (6 weeks per cycle).
45383805|NCT01002092|Drug|Endostar|In each cycle, Week 1-2 day 1-14 endostar 7.5 mg/m2/day; Week 5-6 day 1-14 endostar 7.5 mg/m2/day
45383806|NCT05567510|Drug|BMS-986369|Specified dose on specified days
45383807|NCT03999866|Device|airtraq|airtraq videolaryngoscope
45383808|NCT03999866|Device|mcgrath mac x-blade|mcgarth mac videolaryngoscope
45383809|NCT03999866|Device|storz c-mac|storz c-mac videolaryngoscope
45383810|NCT03999866|Device|storz d-blade|storz d-blade video laryngoscope
45383811|NCT01002326|Behavioral|Cognitive-Behavioral Therapy|20 sessions of Cognitive-Behavioral Therapy
45383812|NCT05733182|Device|3000K Reading lamp|Reading lamp with custom-made circuitry to emit light of 3000K colour temperature
45383813|NCT05733182|Device|4500K Reading lamp|Reading lamp with custom-made circuitry to emit light of 4500K colour temperature
45383814|NCT05733182|Device|6500K Reading lamp|Reading lamp with custom-made circuitry to emit light of 6500K colour temperature
45383815|NCT01002404|Procedure|angled and straight tipped guide wire|Angled or straight tipped guide wire is used in the beginning of deep biliary cannulation in ERCP . If there is no success, other normal procedures (e.g. double wire cannulation and precut) are performed.
45383816|NCT00529100|Drug|Pemetrexed Phase 1|300 mg/m^2 IV, Days 1 and 22; intermediate dose escalation level of 400 mg/m^2 IV; then 500 mg/m^2 IV, repeated every 21 days (q 21 days) x 2 cycles
45383817|NCT00529100|Drug|Cisplatin Phase 1|"Cohorts 1-3: 25 mg/m^2 IV, Days 1-3 and 22-24 then 75 mg/m^2 IV, q21 days x 2 cycles~Cohort 4 carried into Phase 2: 20 mg/m^2 IV, Days 1-5 and 22-26 then 75 mg/m^2 IV, q21 days x 2 cycles."
45499405|NCT03658122|Behavioral|Parent-Child Care|Parent-Child Care (PC-CARE) is a 6-week parenting intervention for children aged 1-10 years and their caregivers. This behavioral intervention involves weekly behavioral assessments, teaching of new skills, in-the-moment practice using the new skills, and discussion of how to incorporate skills at home.
45848161|NCT03207438|Drug|Quetiapine Fumarate XR 150-300 mg|Dose ranged from 150 to 300mg, XR preparation, OD
45383818|NCT00529100|Procedure|Radiation Therapy|Phases 1 and 2: 61-65 Gy in 33-35 fractions
45383819|NCT00529100|Drug|Pemetrexed Phase 2|Concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m^2 IV on Days 1 and 22.
45383820|NCT00529100|Drug|Cisplatin Phase 2|Phase 2 (Cohort 4 carried over from Phase 1): 20 mg/m^2 IV, Days 1-5 and 22-26 then 75 mg/m^2 IV, q21 days x 2 cycles.
45848162|NCT03207438|Drug|Placebos|Placebo
45499406|NCT02920242|Drug|Rifaximin (Sandoz GmbH) tablet|200 mg tablet administered orally.
45499407|NCT02920242|Drug|Rifaximin (Xifaxan)|200 mg tablet administered orally
45848163|NCT03218592|Drug|Maraviroc Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
45848164|NCT03218592|Drug|Dolutegravir Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
45499408|NCT02920242|Drug|Placebo|Matching Placebo tablet administered orally
45499409|NCT02985996|Drug|Truvada|Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.
45499410|NCT02985996|Drug|Genvoya|Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.
45499411|NCT03225833|Drug|WVE-120101|WVE-120101 is a stereopure antisense oligonucleotide (ASO)
45499412|NCT03225833|Drug|Placebo|0.9% Sodium Chloride
45499413|NCT03659760|Other|Group Isolated|Eyes closed with patch and ears plugged between 24:00-06:00
45383821|NCT05467280|Other|Online HIIT Intervention|They will be given HIIT exercise video sessions twice a week for 6 months, through a mobile application where they will also be given nutritional and health advice, webinars and challenges.
45499414|NCT03659682|Drug|Semaglutide|subcutaneous, 1.0 mg, weekly, 48 months
45848165|NCT03218592|Drug|Truvada Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
45848166|NCT03219294|Drug|Vecuronium 0.1 mg/kg|Vecuronium will be administered to achieve and maintain 1 to 2 TOF contractions.
45848167|NCT03219294|Drug|Vecuronium 0.2mg/kg|Vecuronium will be administered to achieve and 0 TOF/PTC 1-2.
45383822|NCT04976660|Drug|TT-4|TT-4 orally administered QD starting at 200 mg and will be increased to 800 mg (dosing may be increased to BID, if appropriate based on emerging safety, PK or PD data).
45848168|NCT03219840|Drug|Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum|All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
45848169|NCT03219840|Drug|Xylitol only chewing gum|All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
45383823|NCT01002638|Other|TEGADERM®|It consists of the occlusive application of two Tegaderm®, a plastic dressing
45383824|NCT01002638|Procedure|Surgery|It consists of pulp reconstruction by a flap (for example palmar V-Y advancement flaps of Atazoy).
45383825|NCT05732948|Drug|autologous T cells & cyclophosphamide|This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of PD-1(programmed death 1)silent PSMA(prostate-specific membrane antigen)/PSCA(prostate stem cell antigen)targeted CAR-T administered one day after pretreatment with cyclophosphamide.
45383826|NCT03878108|Dietary Supplement|LCHF diet|low-carbohydrate, high-fat (LCHF)diet
45383827|NCT03878108|Dietary Supplement|LFHC diet|low-fat, high-carbohydrate (LFHC) diet
45383828|NCT01002716|Biological|Agrippal S1 (Influenza vaccination)|Single dose of vaccine
45499415|NCT03203447|Drug|suprachoroidal CLS-TA|suprachoroidal injection of CLS-TA
45499416|NCT03203447|Drug|suprachoroidal sham|sham suprachoroidal procedure
45499417|NCT03203447|Drug|Lucentis or Avastin|IVT anti-VEGF agent. Either a 0.5 mg intravitreal injection of Lucentis or 1.25 mg intravitreal injection of Avastin
45499418|NCT03659526|Diagnostic Test|Deformation imaging|Deformation parameters derived using myocardial velocity imaging or speckle tracking
45499419|NCT02858726|Drug|CR845 0.5 mcg/kg|IV medication delivered three times/week
45499420|NCT02858726|Drug|CR845 1 mcg/kg|IV medication delivered three times/week
45499421|NCT02858726|Drug|CR845 1.5mcg/kg|IV medication delivered three times/week
45499422|NCT02858726|Drug|Placebo|IV medication delivered three times/week
45554625|NCT03241940|Drug|Fludarabine Phosphate|Given IV
45554626|NCT03241940|Other|Laboratory Biomarker Analysis|Correlative studies
45848170|NCT03222414|Device|Non-invasive BP recording with conical Ultracheck Curve BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using conical Ultracheck Curve BP cuff
45848171|NCT03222414|Device|Non-invasive BP recording with traditional cylindrical BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using traditional cylindrical BP cuff
45848172|NCT03222414|Other|Direct invasive arterial pressure|Direct invasive arterial pressure readings will be recorded simultaneously with non-invasive measurements
45383829|NCT01002794|Procedure|Arthroscopic partial menisectomy|Standard arthroscopic partial meniscectomy, NGD 1. Carried out at Ullevaal University Hospital.
45383830|NCT01002794|Other|Supervised neuromuscular and strength training|Supervised exercise therapy in 12 weeks, both neuromuscular- and strength training.
45383831|NCT05732714|Behavioral|Healthy lifestyle behaviors around the time of surgery|Healthy lifestyle choices, such as improving diet and beginning to exercise around the time of surgery and it's influence on an individual's long term risk of developing cardiovascular disease.
45383832|NCT01002872|Drug|Lanthanum Carbonate|Randomization To either Lanthanum Carbonate 1 pill TID/Placebo 1 pill TID Day 15 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID. If phosphorus <3.5mg/dL Reduce to 1 pill BID. If Phosphorus >5.5mg/dL 1 pill with breakfast 1 pill with lunch 2 pills with dinner Day 30 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus is <3.5mg/dL Reduce to 1 pill daily. If phosphorus >5.5mg/dL 1 pill with breakfast 2 pills with lunch 2 pills with dinner Day 45 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus <3.5mg/dL stop the drug If phosphorus is >5.5mg/dL 2 pills with breakfast 2 pills with lunch 2 pills with dinner
45383833|NCT01002872|Drug|Fosrenol|Initial dose of drug will be 1500mg TID
45383834|NCT01002872|Drug|placebo|Initial dose of placebo will be 1 pill three times a day
45383835|NCT05388812|Other|Treatment As Usual Vocational Rehabilitation (TAU-VR)|TAU-VR Services may include 1) Compensated Work Therapy-Transitional Work (CWT-TW) assignment in a set-aside, minimum-wage, short-term job, typically in the VA setting (approximately 50% of the Veterans randomized to TW in past studies conducted by the investigators actually engaged in TW assignment) or 2) CWT-Community-Based Employment Services (CWT-CBES) which involves a community job search, placement in a competitive job, with limited follow-along support that typically ends after the Veteran is working in his/her first job
45383836|NCT05388812|Other|Individual Placement and Support (IPS)|The IPS model involves the following important domains: competitive employment, eligibility based on client choice of employment, integration of IPS and treatment team personalized counseling, rapid job search, systematic job development, and time-unlimited and individualized support.
45383837|NCT03999398|Procedure|Percutaneous coronary intervention (PCI)|Participants are treated with a PCI and stent implantation in a venous graft (previously implanted during the CABG operation)
45383838|NCT00529958|Procedure|Patellar Tendon|Patellar Tendon autograft
45383839|NCT00529958|Procedure|Hamstring Tendon|Quadruple Semitendinosus/Gracilis (Hamstring) Tendon Autograft
45499423|NCT03203291|Device|TPAD (Tethered Pelvic Assist Device)|Each day of intervention will include a 1-hour treadmill based intervention to promote increased loading onto the affected limb. Visual feedback will be provided and faded over the course of the 5-day training. Immediately on completion of the treadmill intervention, participants will receive an additional 5-10 minutes of overground intervention reinforcing weight shifting onto the affected limb.
45383840|NCT00529958|Procedure|Double-Bundle|Double-Bundle Semitendinosus/Gracilis (Hamstring) Tendon Autograft
45383841|NCT00529802|Drug|RAD001|take 2 tablets of RAD001 once a day by mouth (10 mg per day)
45383842|NCT05305586|Device|Splint retained by Bulk-fill flowable|Luxated teeth were splinted with bulk-fill flowable composite
45383843|NCT05305586|Device|Splint retained by Packable Composite|Luxated teeth were splinted with packable composite
45383844|NCT03742622|Behavioral|CON . control condition without exercise / rest condition|CON . Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
45383845|NCT03742622|Behavioral|EX. Condition with an acute exercise set in the middle of the morning|EX. Condition with an acute exercise set in the middle of the morning The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals
45499424|NCT03609476|Procedure|Room temperature saline instillation|Saline is used as room temperature
45499425|NCT03609476|Procedure|Warmed saline instillation|Saline is warmed to 37Celcius prior to instillation
45499426|NCT03609476|Procedure|No saline instillation|No saline is used prior to catheter removal
45499427|NCT04549610|Dietary Supplement|HMB supplementation|Group taking oral HMB supplementation in a blinded capsule form.
45499428|NCT04549610|Dietary Supplement|Placebo treatment|Group taking oral supplementation with placebo (corn starch) in a blinded capsule form.
45383846|NCT03742622|Behavioral|EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack|EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning followed by a snack that will cover the whole exercise-induced energy expenditure. They will then receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
45848173|NCT03223272|Drug|Reserpine|Open label reserpine 0.1 mg pill orally
45848174|NCT03224520|Behavioral|Recommender CTHC|Enhanced Messaging
45695068|NCT01836016|Drug|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 26 weeks for lower dosage.
45383847|NCT01003340|Behavioral|Wee Wheezers|The intervention, Wee Wheezers, modified to the needs of the targeted population will include 6 bi-weekly 1 hour educational home visits conducted by Community Health Workers at homes of children with persistent asthma
45383848|NCT04928456|Other|Osteopathic Manipulative Treatment (OMT)|Osteopathic Manipulative Treatment (OMT) involves a number of hands-on techniques that are meant to address somatic dysfunction in the body as a part of the osteopathic approach to treating patients. There will be five techniques in total used in the study treatment plan.
45383849|NCT00528866|Drug|bicalutamide|50 mg (one tablet) daily orally for 6 months, starting within 6 months after registration
45383850|NCT00528866|Drug|docetaxel|75 mg/m2 IV over 1 hour on day 1 of each cycle q21 days for 6 cycles, starting 3-6 weeks after completion of radiation therapy
45499429|NCT01068678|Drug|insulin degludec|Injected subcutaneously (under the skin) three times weekly. Dose was individually adjusted.
45499430|NCT01068678|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
45499431|NCT03202511|Drug|Probenecid Oral Tablet|Included in arm/group descriptions.
45499432|NCT03202511|Drug|Tenofovir disoproxil fumarate/Emtricitabine|Included in arm/group descriptions.
45695069|NCT01836016|Drug|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule, twice daily for 26 weeks for lower dosage.
45695070|NCT01836016|Drug|conventional medicine + TCM|Patients will be given the combination of conventional medicine (Salbutamol, Formoterol, Salmeterol / fluticasone, Salmeterol / fluticasone) and (Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule) for 26 weeks.
45499433|NCT03609710|Device|Transanal tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
45695071|NCT04551560|Other|Mental Stress|Patients will undergo a lab mental stress protocol, and a field protocol using ecological momentary assessment (EMA) to test the effects of psychological stress and negative emotion on PAP in HF patients.
45695072|NCT04378816|Other|Shared decision making support tool|Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions.A question prompt list (QPL) is a structured list of questions that serves as a prompt for patients to consider questions to ask their physician.
45848175|NCT03224520|Behavioral|Standard CTHC|Standard Messaging
45848176|NCT03224520|Other|Peer Recruitment|Tools to facilitate smokers' recruiting their peers
45499434|NCT03609710|Procedure|Left colic artery preservation|Left colic artery preservation during operation for lower rectal cancer
45499435|NCT03609710|Procedure|Anastomotic reinforcing sutures|Anastomotic reinforcing sutures during operation for lower rectal cancer
45848177|NCT03224520|Other|Standard Online Recruitment|Search Engine and Social Media Advertisements
45848178|NCT03237156|Drug|TAK-906|TAK-906 capsules.
45848179|NCT03237156|Drug|TAK-906 Placebo|Placebo capsules.
45848180|NCT03239106|Drug|Apremilast|Apremilast 30 mg BID daily
45848181|NCT03239574|Device|MightySat|MightySat - investigational pulse oximeter that will be placed on the subject's right index finger for the duration of the study
45848182|NCT03242148|Device|Toffee Nasal Pillows Mask|Participants will be placed on this intervention for a total 14 ± 5 days from Visit 2. Participants will be using the Toffee nasal pillows mask during this treatment arm.
45848183|NCT03257202|Drug|Clindamycin 1% Gel|topical clindamycin
45848184|NCT03257202|Drug|Benzoyl peroxide 5% gel|topical benzoyl peroxide
45848185|NCT03257202|Drug|BenzaClin 5%-1% Topical Gel|Topical clindamycin and benzoyl peroxide together
45848186|NCT03260790|Biological|PCV13|Single 0.5 ml dose of PCV13 administered via intramuscular injection
45499436|NCT03609710|Device|Robotic surgery|Robotic low anterior resection for rectal cancer
45499437|NCT03637049|Drug|PBI-4050 and midazolam|A single oral dose of midazolam (1 mL of 2mg/mL syrup) will be given to all subjects in Period 1 and on Day 5 of Period 2. 1200 mg of PBI-4050 (3 X 400 mg tablets) will be administered for 5 days (Day 1 to Day 5) of Period 2 and a single dose of midazolam (1 mL of 2mg/mL) on Day 5.
45848187|NCT03260790|Biological|PPSV23|Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously
45848188|NCT03261960|Drug|BLI4700|Oral bowel preparation
45848189|NCT03261960|Drug|Magnesium bowel preparation|Oral bowel preparation
45499438|NCT03636971|Drug|hyaluronic acid with mannitol|single shot injection (Ostenil Plus®, TRB Chemedica SA, CH, 1800kD)
45499439|NCT03636971|Drug|hyaluronic acid with sorbitol|single shot injection (Synolis®, Gebro-Pharma AG, CH, 2000 kD)
45499440|NCT03636971|Drug|Placebos|single shot injection of saline, same volume
45848190|NCT03273270|Radiation|transcranial magnetic stimulation|transcranial magnetic stimulation
45499441|NCT03610100|Drug|Acelarin|825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
45499442|NCT03610100|Drug|Gemcitabine|1000 mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
45499443|NCT03657966|Biological|DCVAC/OvCa|activated dendritic cells (DCVAC/OvCa) for immune maintenance after chemotherapy
45499444|NCT03657966|Drug|Standard of Care Chemotherapy|either carboplatin and gemcitabine or carboplatin and paclitaxel followed by DCVAC/OvCa
45499445|NCT03659370|Other|Fumigation|use Fumigation to increase the improvement of osteoarthritis of knee
45695073|NCT01723306|Genetic|Gene Modified T Cells|Subjects will undergo T cell leukopheresis. The collected T cells will be genetically modified, and then re-infused peripherally. IL2 will be given concomitantly for 30 days post modified T cell infusion via CADD pump.
45695074|NCT01836094|Drug|Methylene Blue (USP grade, 280mg oral)|
45695075|NCT01836094|Drug|Placebo|oral, one time
45499446|NCT03659370|Other|Acupuncture|Acupuncture
45499447|NCT03659292|Other|GEA|Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
45695076|NCT01705730|Drug|tocilizumab|Participants received tocilizumab monotherapy according to individualized physician-prescribed regimens.
45695077|NCT01726192|Procedure|Placement of a femoral catheter with the hydrolocalization technique|Placement of femoral nerve catheter with the hydrolocalization technique, using ropivacaine 0.6%
45695078|NCT01726192|Procedure|Placement of a femoral neurostimulating catheter|
45848191|NCT03273426|Procedure|Minimally-invasive biopsy|Intervention (core needle biopsy (14G) or vacuum-assisted biopsy(10G)) for complete clinical response (cCR) or near-cCR predicted by MRI.
45848192|NCT03273426|Procedure|wide excision|Surgical wide excision of the biopsied area.
45848193|NCT03274518|Device|Expanded Hemodialysis|"Intervention: Conversion from conventional HD to expanded hemodialysis por 1 month.~High cutoff with high retention onset dialyzers allow clearance of middle molecules, without reducing significantly serum concentration of albumin. It allows higher convective clearance in comparison to conventional hemodialysis, but it is unknown if such clearance is similar to online hemodiafiltration. Therefore, the aim of the present intervention is to compare this dialyzer with online hemodiafiltration"
45499448|NCT03659292|Other|PCEA|Patient-controlled epidural analgesia (0.15% ropivacaine and 0.5ug/ml sufentanil infusion) will be provided after surgery.
45554627|NCT03241940|Other|Questionnaire Administration|Ancillary studies
45554628|NCT04979949|Biological|CoronaVac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
45554629|NCT04979949|Biological|Turkovac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
45695079|NCT01836172|Drug|YJP-14|An 50% ethanolic extract of Lindera obtusiloba stems
45383851|NCT00528866|Drug|flutamide|250 mg (two 125-mg capsules) three times daily (total 750 mg) orally for 6 months, starting within 6 months after registration
45383852|NCT00528866|Drug|LHRH agonist|LHRH agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 6 months, starting within 6 weeks after registration
45383853|NCT00528866|Radiation|3-dimensional conformal radiation therapy|
45848194|NCT03274518|Device|Online Hemodiafiltration|"Intervention: Conversion from conventional HD to online Hemodiafiltration por 1 month.~Online hemodiafiltration has been associated with lower incidence of intradialytic hypotension in comparison to conventional hemodialysis."
45383854|NCT00528866|Radiation|radiation therapy|66.6 Gy (1.8 Gy per fraction, 5 days per week) to the prostate bed (IMRT or 3DCRT), starting 8 weeks after start of hormones
45383855|NCT05730920|Drug|Methadone|IV Methadone
45383856|NCT05730920|Drug|Liposomal bupivacaine (LB, Exparel)|LB and bupivacaine hydrochloride via erector spinae plane blocks
45383857|NCT03999008|Drug|Budesonide Oral|"The subjects will be included at time of the first dilation for an anastomotic stricture.~Basal physical exam and clinical evaluation (weight and height, dysphagia score, gastroesophageal reflux, feeding problems, respiratory symptoms, other symptoms).~Randomization will be conducted by centre. Because long gap esophageal atresia, high tension anastomosis and history of anastomotic leak are reported as risk factors for occurrence of anastomotic strictures, a stratification at randomization will be performed according to these criteria in each centre.~OVB or placebo will be given by the parents and started the day of the dilation at the first meal after recovering of the dilation and anesthesia.~Parents will be asked to bring the empty caps which will be counted for assessment of compliance."
45383858|NCT03999008|Drug|Placebos|Apple Sauce 5 mL+ 1 mL saline
45383859|NCT05140148|Drug|Amantadine|Amantadine is a antiviral drug and dopamine promoter that is currently approved by the FDA for the treatment of influenza A and Parkinson's Disease
45383860|NCT05140148|Drug|Placebo|placebo pills
45383861|NCT01003574|Behavioral|lifestyle modification and telephone counseling|A mailed individualized cancer treatment summary with recommendations for CV follow-up and lifestyle modification (standard care).
45695080|NCT01836328|Drug|Parenteral /oral methadone ratio 1:2|"See arm/group descriptions"
45695081|NCT01836328|Drug|Parenteral /oral methadone ratio 1:1.2|"See arm/group descriptions"
45848195|NCT03275766|Other|DLPFC facilitatory|15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
45383862|NCT01003574|Behavioral|lifestyle modification and telephone counseling|Standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
45383863|NCT01003652|Procedure|thyroidectomy|Comparison between two groups of patients. One group is operated on using harmonic Focus for haemostasis compared to a second group of patients operated on with the conventional haemostasis using tie-and-clamp technique
45383864|NCT01003730|Other|Ventilator settings|Active Comparison of three different parameters of ventilator settings. Results of arterial blood gases and cytokine levels.
45383865|NCT04000490|Other|SCARE Score|Predictive Score of acute coronary syndrome during the medical assessment of chest pain
45383866|NCT01003808|Biological|IMF-001|100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
45383867|NCT04932746|Drug|Dexmedetomidine|"Infusion syringes are supplied with a concentration of 0.25 mcg / mL (dexmedetomidine or placebo) either 80 mcg / 20 mL, 200 mcg / 50 mL, or 400 mcg / 100 mL.~It begins with infusion of 4 ml within 10 minutes and then continues infusion, depending on the child's weight, at 1.6 ml / kg / h.~All injections will be prepared randomly by a doctor who did not participate in the study, and then placed in unmarked infusion pumps, given to an anesthesiologist (more than 10 years experience in pediatric anesthesia) without knowledge of the infusion content. The randomization process is carried out via sealed envelope technique.~The injections in both groups will be stopped before the skin is closed. Both patients and anesthesiologists blinded the study drug (dexmedetomidine or placebo) by infusion of solution (dexmedetomidine or placebo). Depending on the size in ml, to ensure that there is no bias and blindness to the medical team about what the drug is."
45695082|NCT01726348|Drug|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally every 4 weeks for a period of 24 weeks. For treatment-naive and treatment-experienced adult patients with no darunavir resistance associated substitutions: Darunavir 800 mg will be administered with ritonavir 100 mg once daily with food. For treatment-experienced adult patients with at least one darunavir resistance associated substitution: Darunavir 600 mg will be administered with ritonavir 200 mg twice daily with food.
45695083|NCT01726426|Dietary Supplement|Probiotic|Each capsule Probiotics (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
45695084|NCT04379128|Other|Attentional tasks|a neuropsychological assessment of attentional task, executive task and interview is proposed to patients or normal control
45383868|NCT04932746|Drug|Placebo|The same anesthesia, the same amount of Saline solution will be administered, instead of dexmedetomidine, with the same protocol
45383869|NCT04929158|Procedure|Intravascular Ultrasound (IVUS) -guided Primary Percutaneous Intervention (PCI)|Preoperative criminal vascular assessment； The criminal vascular assessment after surgery
45499449|NCT03659292|Other|GA|General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
45499450|NCT03659292|Other|PCIA|Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
45499451|NCT03659058|Drug|silymarin|silymarin 140 three times daily
45499452|NCT03659058|Drug|Ursodeoxycholic Acid|Ursodeoxycholic Acid 500
45499453|NCT03659058|Drug|Antioxidants|Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg
45499454|NCT03659058|Drug|Colchicine|Colchicine 0.6
45499455|NCT03659058|Other|FOLLOW UP|follow up by abdominal ultrasound and fibroscan every 6 month for 1 year
45499456|NCT01331473|Procedure|Carotid Artery Stenting with Proximal Protection|Carotid artery angioplasty and stenting with proximal embolic protection provided by the GORE Neuro Protection System
45499457|NCT01331473|Procedure|Carotid Artery Stenting without Protection|Carotid artery angioplasty and stenting without cerebral embolic protection
45695085|NCT04378894|Behavioral|MOCEP|Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
45499458|NCT03658980|Behavioral|Health Education Intervention|Face-to-face health education intervention on Diabetic Retinopathy and available services at a tertiary hospital, followed by telephonic reminder at Day 7, 30 and 90.
45499459|NCT03635905|Drug|Gabapentin|Gabapentin (Neurontin®) is FDA-approved for the treatment of post-herpetic neuralgia and seizure disorder. Off-label uses include chronic refractory cough, neuropathy, hot flashes, restless leg syndrome, social anxiety disorder, and post-operative pain
45499460|NCT03635905|Drug|Placebo|Methylcellulose placebo capsule
45499461|NCT02960113|Drug|scopolamine patch|Group I (n=80): Will receive scopolamine patch placement on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery. The time of the application of the patch will be recorded, and the time of the start of the surgery will be recorded. The last time point for evaluation of patient's nausea/vomiting will be when the patient arrives to the post anesthesia care unit. A member of the research team will remove the patch from the patient and properly dispose the patch upon arrival to the post anesthesia care unit.
45499462|NCT02960113|Device|acupressure point P6|Group II (n=80): Will receive acupressure point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device will be removed from the patient in the operating room, before the patient is transported to the recovery room. Patients will receive continuous stimulation at a level that is comfortable for her prior to administration of the standardized regional anesthesia.
45499463|NCT04850365|Procedure|Hysteropexy|"Abdominal Sacral cervicopexy:~The approach involves suspending the cervix to the anterior longitudinal ligament on the sacrum using permanent sutures or polypropylene mesh.~Vaginal Sacrospinous cervicopexy:~This transvaginal extraperitoneal technique involves suspending the sacrospinous ligament to the cervix using either a dissolvable or permanent suture. The suspension is performed in a unilateral fashion."
45695086|NCT01705652|Drug|Nexrutine|Nexrutine 500mg by mouth, three times per day, given prior to surgery or prior to and during radiation treatment.
45695087|NCT01723540|Procedure|Minilaparotomy vs laparoscopy|MC-group will undergo ultrasonic dissection assisted minilaparotomy cholecystectomy ans patients in the LC-grout will undergo laparoscopic cholecystectomy
45695088|NCT01836406|Drug|Ketorolac tromethamine and remote ischemic preconditioning|Ketorolac tromethamine/ single / 1mg/kg/ intravenous administration 30 min before renal artery clamping, remote ischemic preconditioning / 200 mmHg / 5 min inflation and 10 min deflation / 3 cycles / after anesthetic induction
45383870|NCT04906928|Device|MRI|"standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), 3D STIR and 3D PSIR sequence.~3D FGAPSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 40 minutes (instead of 30 minutes)"
45383871|NCT05729204|Other|Hypertonic seawater solution|Nasal irrigations with hypertonic seawater solution
45383872|NCT00614393|Biological|dalotuzumab|IV infusion
45383873|NCT00614393|Drug|irinotecan hydrochloride|IV infusion
45383874|NCT00614393|Biological|cetuximab|IV infusion
45383875|NCT00614393|Drug|placebo|IV infusion
45383876|NCT00885521|Other|Exercise|8 week, twice weekly exercise program with endurance and upper and lower limb strength training
45383877|NCT00880529|Device|ON-Q bupivicaine administration|continuous subcutaneous bupivicaine drip
45383878|NCT00880529|Drug|IV opioid administration|Patient controlled analgesia with IV narcotics
45383879|NCT00880841|Drug|Buprenorphine / Naloxone|oral formulation of buprenorphine / naloxone
45383880|NCT04503863|Drug|NPC-22|Single administration of middle dose NPC-22
45848196|NCT03275766|Other|SMA inhibitory|1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
45848197|NCT03275766|Other|SMA facilitatory|Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli
45499464|NCT02919696|Drug|Abemaciclib|Administered orally
45499465|NCT02740452|Device|ligamys technique|Ligamys technique (device) or standard technique
45848198|NCT03275766|Other|sham TMS|Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session
45848199|NCT03278886|Drug|Low dose naltrexone|4.5 mg of low dose naltrexone taken once daily for 8 weeks
45848200|NCT03278886|Drug|Nalmefene|18 mg of nalmefene taken once daily for 8 weeks
45848201|NCT03281538|Drug|CR845|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
45848202|NCT03285984|Other|67% Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride|Toothpaste containing 67 percent (%) Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride
45848203|NCT03285984|Other|67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride|Toothpaste containing 67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride
45848204|NCT03285984|Other|62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium|Whitening Toothpaste containing 62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium
45499466|NCT02740452|Other|standard technique (anatomic reconstruction)|Ligamys technique (device) or standard technique
45499467|NCT02935673|Drug|lumicitabine|Oral administration of lumicitabine as tablet.
45383881|NCT04503863|Drug|NPC-22|Single administration of high dose NPC-22
45383882|NCT04503863|Drug|NPC-22 Placebo|Single administration of NPC-22 Placebo
45383883|NCT00883259|Drug|Metformin|850 mg twice daily
45383884|NCT00883259|Other|Placebo|Microcristallyne cellulose 1 table twice daily
45383885|NCT00885599|Drug|Herbal API|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
45383886|NCT00885599|Drug|Cepacol|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
45383887|NCT00885599|Drug|Listerine Antiseptic Mouth Rinse|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
45383888|NCT00885599|Drug|placebo mouthwash|colored water mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
45499468|NCT02935673|Drug|Placebo|Oral administration of matching placebo.
45499469|NCT03622398|Procedure|Total knee arthroplasty with HXLPE liner|Replacing arthritic knee with a metal device, and using a highly cross-linked polyethylene(HXLPE) liner in between metallic surfaces.
45499470|NCT03622398|Procedure|Total knee arthroplasty with conventional polyethylene liner|Replacing arthritic knee with a metal device, and using a conventional polyethylene liner in between metallic surfaces.
45499471|NCT03201809|Device|On-Q|0.2% Ropivicaine at 4 mL/h via On-Q catheter placed sub-pectoral
45499472|NCT03201809|Drug|Ultrasound guided pectoral nerve block|Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the Pecs 2 injection
45499473|NCT02919618|Radiation|stereotactic body radiotherapy (SBRT)|(Cardiac ablative radiotherapy)
45499474|NCT04458324|Drug|Buspirone Hydrochloride|Subjects take 30 mg buspirone HCl twice a day for 6 months.
45695089|NCT01723618|Drug|CRD007|
45695090|NCT01836484|Diagnostic Test|Diffusion-weighted MRI|
45695091|NCT01836484|Diagnostic Test|Fluorodeoxyglucose-18-PET/CT|
45695092|NCT01836484|Diagnostic Test|Fluoro-ethyl-coline-PET/CT|
45695093|NCT01836562|Biological|STEM CELL THERAPY|Intra thecal injection of autologous MNC ,Intra thecal inj.of 100 millions MNC in 3 doses at 10 days interval.
45695094|NCT01726816|Drug|Probucol 250mg/day|Probucol 250mg + Placebo
45695095|NCT01726816|Drug|Probucol 500mg/day|Probucol 500mg + Placebo
45695096|NCT01726816|Drug|Placebo|Probucol matching placebo
45848205|NCT03285984|Other|0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride|Toothpaste containing 0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride
45383889|NCT00881075|Drug|SeeMore(TM)|single dose intravenous injectable
45383890|NCT04366115|Drug|AVM0703|Single IV infusion at 10 mg/mL in normal saline over 1 hour to patients.
45383891|NCT04366115|Drug|Placebo|Single IV infusion in normal saline over 1 hour to patients.
45383892|NCT04712747|Procedure|Ophthalmological examinations|"OCT (Optical Coherence Tomography): posterior pole OCT B scan , optic nerve and posterior pole OCT Angiography~Adaptive optics (AO) : Image acquisition on the vessels at the exit of the optic nerve before the first upper temporal bifurcation OD or OG and evaluation of the photoreceptor mosaic. Adaptive optics may require dilatation of the pupil with a drop of tropicamide in the eye examined a few minutes before the examination.~Color retinophotography~Measurement of intraocular pressure~Patients with stroke : At the inclusion visit and 3 months after their stroke Control group : At the inclusion visit."
45383893|NCT04712747|Procedure|Blood pressure measurement at rest|At the inclusion visit
45383894|NCT04038125|Drug|Ozurdex Drug Implant Product|Intravitreal Ozurdex injection
45383895|NCT00881153|Drug|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)|
45383896|NCT00881153|Drug|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)|
45383897|NCT00885833|Drug|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 & -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, & -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, -6 for cord blood and on days -4, -3, -2 for bone marrow or mobilized peripheral blood)
45383898|NCT00612677|Drug|Oxaliplatin|Dose Regimen: 120 mg/m^2 on Days 1 every 21 days
45383899|NCT00612677|Drug|Pemetrexed|Dose Regimen: 500 mg/m^2 on Days 1 every 21 days
45383900|NCT04038749|Drug|Bromocriptine|Bromocriptine - on the first day of treatment (1,25 mg) with morning and evening meal and then 2,5 mg dose twice a day for two weeks (14 days)
45383901|NCT04038749|Drug|Cabergoline|Cabergoline - one dose (1 mg) on the first day after childbirth or 0.25 mg dose every 12 hours for 2 days
45383902|NCT04038749|Other|Natural methods|milk expression, cold compress, cabbage leaf compresses, mild painkiller- e.g. ibuprofen, supportive bra, sage tea.
45383903|NCT00883571|Procedure|house advancement flap group|A house flap of healthy tissue was incised to the depth of ischiorectal fat. The flap consisted of skin and subcutaneous tissue. The flap was sufficiently mobilized without undermining its fatty base containing perforating blood vessels. The flap should be loose and easily advanced into the anal canal. When the ''base'' of this house-shaped flap was advanced into the anal canal defect, it was fixed to the top of the excised area with 3/0 Vicryl sutures.
45383904|NCT00883571|Procedure|Rhomboid flap GROUP|A rhomboid flap was incised in ischeorectal fossa and was mobilized without undermining of its fatty base into the anal canal so that the tip of rhomboid flap is sutured to the top of stricured area using vicryl 3/0.
45383905|NCT00883571|Procedure|Y-V anoplasty GROUP|Y-V anoplastyis performed by making a v shaped incision in the perianal skin posteriorly starting from the lower end of the wound resultant from excision of scared area. A V-shaped flap is then dissected with preservation fatty base .The V flap is then advanced into the anal canal so that its tip is sutured to the top of structured area using vicryel 3/0.
45383906|NCT00881231|Drug|Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)|
45695097|NCT01836796|Dietary Supplement|Lactobacillus Reuteri|100 million Lactobacillus Reuteri once daily or 10 billion Lactobacillus Reuteri once daily for 12 weeks.
45848206|NCT03287310|Drug|GSK3511294|GSK3511294 will be available as a clear or opalescent, colorless or yellow to brown solution for injection at unit dose strength of 150 milligrams per milliliter (mg/mL). GSK3511294 will be diluted in 0.9% weight by volume (w/v) sodium chloride to achieve the desired concentration for administration. GSK3511294 will be administered by SC injection.
45848207|NCT03287310|Drug|Placebo|Matching Placebo will consist of 0.9% w/v sodium chloride which will be administered by the SC route.
45695098|NCT01836796|Dietary Supplement|Lactobacillus Reuteri DSM17938|Powder corresponding to 100 million or 10 billion Lactobacillus Reuteri is added to water once daily for 12 weeks.
45848208|NCT03287310|Drug|Salbutamol/albuterol|Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.
45383907|NCT00881231|Drug|Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)|
45383908|NCT00613925|Device|Pipelle de Cornier|A flexible suction cannula 23.5 cm in length with an inner diameter of 2.6 mm and an outer diameter of 3.1 mm. It has a 2.4mm diameter opening on the distal end, on one side of the cannula. It is a disposable polypropylene sheath with an inner plunger and is used for blind endometrial biopsy.
45383909|NCT00613925|Device|Explora curette|The curette has an outer diameter of 3.0 mm and is slightly more rigid. This cannula has a sharp Randall-type cutting edge on the distal end, on one side of the cannula.
45383910|NCT00881309|Drug|Tripterygium|TW 90mg/d
45383911|NCT00883649|Dietary Supplement|Hydroeye|2 Capsules BID
45383912|NCT00883649|Other|Inactive Capsule|2 Capsules BID
45383913|NCT00883727|Drug|Stem cell|IV infusion of stem cells
45383914|NCT00883727|Drug|Plasmalyte A|IV infusion
45383915|NCT00883805|Biological|Blood draw|Subjects will give blood for analysis of metal ion concentrations
45383916|NCT00883805|Radiation|X-Ray of Hip|Subject will have x-ray of hip to assessment of osteolysis
45383917|NCT00881387|Biological|rituximab|Given IV
45383918|NCT00881387|Drug|gemcitabine hydrochloride|Given IV
45383919|NCT00881387|Drug|vinorelbine ditartrate|Given IV
45383920|NCT00883883|Drug|Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)|
45383921|NCT00883883|Drug|Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)|
45383922|NCT00883961|Other|Supervised exercise|The patients will carry out a daily endurance exercise program consisting of walking on a treadmill for 30 minutes at an intensity of about 80% of the maximum heart rate under supervision from study personnel.
45383923|NCT00885989|Drug|SLV338|5 - 1000 mg IV
45383924|NCT00885989|Drug|Placebo|Placebo
45695099|NCT01726894|Device|Irreversible Electroporation|
45695100|NCT00915538|Drug|pMDI budesonide/formotrol 160/4.5 is in group 1|The asthmatic subjects will receive budesonide/formoterol pMDI 160/4.5 pMDI 2 inhalations used in conventional fashion, and have pulmonary function measured over 12 hours who are expected to show bronchodilation.
45848209|NCT03292614|Diagnostic Test|Measurements of the postoperative refraction|"The Measurements of the postoperative refraction will be performed with the following devices:~Autorefractor Keratometers:~Mod. ARK-760A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany), Mod. ARK-560A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany) KR-1W (TOPCON, Willich, Germany) KR-800s (TOPCON, Willich, Germany)~Manual Refractometer:~Eye refractometer PR 60 or PR 50 (Rodenstock, Munich),~Test device:~iTrace (TraceyTechnologies, Houston, Texas, USA),~Phoropter (Block-Optic, Model 11625B) Determination of subjective refraction for distance and near (reading distance)"
45848210|NCT03292692|Behavioral|OurRelationship|Online intervention with coach support
45499475|NCT04458324|Drug|Buspirone placebo|Subjects take a placebo tablet twice a day for 6 months.
45499476|NCT04458324|Device|Noninvasive Ventilation (NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
45499477|NCT04458324|Device|Sham Non-invasive ventilation (NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
45499478|NCT04458324|Other|Functional Electrical Stimulation Row Training (FESRT)|Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
45848211|NCT03295266|Drug|MK-3866|Single IV infusion of MK-3866 150 mg administered over 30 minutes at Hour 0 on Day 1 of treatment period.
45848212|NCT03301272|Drug|Onabotulinumtoxin A Injection|Reconstituted 10 units/0.1 mL. Administered intramuscular once
45499479|NCT02858154|Other|HFNC|All subjects will have a 3-4 hour intervention of HFNC to test effectiveness and safety for treating OSA
45499480|NCT02858154|Other|Low flow oxygen by nasal cannula|All subjects will have a 6 to 8 hours intervention during the clinically scheduled PSG of titration of oxygen by nasal cannula (standard of care) to manage sleep apnea
45499481|NCT02811432|Other|Kangaroo mother care|Skin-to-skin care (target: at least 18 hours per day)
45499482|NCT02811432|Other|Standard care|Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
45499483|NCT03657420|Drug|ABI-009|ABI-009 is an mTOR inhibitor. This pathway is believed to be overactive in multiple myeloma.
45499484|NCT03657420|Drug|Pomalidomide|Pomalidomide is an immunomodulatory agent and believed to work by affecting the growth signals that keep cancer cells alive.
45383925|NCT00886067|Drug|AZD1446|Solution, oral, single dose
45499485|NCT03657420|Drug|Dexamethasone|Dexamethasone is a steroid which is believed to kill cancer cells
45499486|NCT02684214|Behavioral|Prevention Plus +|Families will receive 6 monthly newsletters and meet with a BHC at the clinic for 30 minutes during months 1, 3, and 5. Child height and weight will be taken. Families will receive feedback about growth and the weight status of their child. The session materials will be reviewed and behavioral parenting strategies will be encouraged to aid with changing two dietary and two leisure-time activity (energy balance) behaviors of the child. The caretaker will also change the same energy balance behaviors as the child, as adult caretakers can then model healthy behaviors. The caretaker and child will be encouraged to change and self-monitor energy balance behaviors with the use of the picture-based diaries. During months 2, 4, and 6, BHCs will complete a 20-minute phone call with the caretaker. Caretakers will be asked to measure the height and weight of their child, calculate BMI and plot it on the BMI-for-age growth chart prior to the call. The BHC will provide feedback.
45499487|NCT02684214|Behavioral|Prevention Plus -|This condition will be identical to PP+ except that caretakers will not receive any energy balance behavior goals. Additionally, the caretaker will not self-monitor energy balance behaviors. The focus will be on all other behavioral parenting strategies to assist the child with making changes in the targeted behaviors.
45499488|NCT03657498|Procedure|Combined orthodontic-orthognathic treatment|combined treatment including orthodontics and orthognathic surgery
45499489|NCT03657498|Procedure|Standard orthodontic treatment|treatment with standard orthodontic procedures
45695101|NCT00915538|Device|Symbicort 160/4.5 plus Aerochamber Plus included in group 2|Symbicort 160/4.5 2 inhalations will be administered through a valved holding chamber, Aerochamber Plus, Pulmonary functions will be measured over 12 hours in asthmatic subjects who are expected to show bronchodilation.
45499490|NCT03657186|Dietary Supplement|ProbioSatys™|One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
45499491|NCT03657186|Other|Placebo|One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
45499492|NCT02985450|Biological|Engerix-B|Hepatitis B Vaccine
45499493|NCT03657030|Drug|CVN424|SAD / MAD
45499494|NCT03657030|Drug|Placebo|Placebo
45499495|NCT02908464|Device|Lumosity|A neurocognitive training program designed to enhance cognitive abilities
45499496|NCT02907216|Biological|Squarekids|Three doses administered subcutaneously in the upper arm or thigh
45695102|NCT01836874|Drug|No intervention|This is an observational study. Participants receiving topiramate 25 mg once-a-day for 1 week and later on, receiving increase dose up to 200 mg, twice-a-day, orally will be observed for 3 months.
45695103|NCT01724086|Drug|TMC647055|Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.
45383926|NCT00886067|Radiation|2-[18F]-F-A85380|iv, single dose
45383927|NCT00881543|Drug|Dipeptidyl Peptidase IV inhibitors|Dosage 100 mg each day, once a day, 2 months
45383928|NCT00881699|Behavioral|HIV Prevention Intervention - Project PRISSMA - HIV I have my eye on you|Eight weekly 2-hour HIV risk reduction intervention sessions, with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about HIV risk behaviors and safer sex options; (2) increase identification of personal risk of HIV and enhance the motivation to engage in safer sex behaviors; and (3) enhance skills to achieve safer sex, particularly negotiating safer sex, using condoms, and communicating within a relationship.
45499497|NCT02907216|Biological|Rotarix|Two doses administered orally
45383929|NCT00881699|Behavioral|Health Promotion Intervention|Eight weekly 2-hour health promotion intervention sessions with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about health issues specific to psychiatric patients, (2) increase identification of personal health risks and enhance motivation to engage in healthier behaviors, and (3) enhance skills to achieve healthier behaviors.
45499498|NCT02984982|Drug|Alirocumab SAR236553|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
45499499|NCT02984982|Drug|Atorvastatin|"Pharmaceutical form: tablet~Route of administration: oral"
45499500|NCT02984982|Drug|Rosuvastatin|"Pharmaceutical form: tablet~Route of administration: oral"
45499501|NCT02984982|Drug|Fenofibrate|"Pharmaceutical form: tablet~Route of administration: oral"
45499502|NCT02984982|Drug|Bezafibrate|"Pharmaceutical form: tablet~Route of administration: oral"
45499503|NCT02984982|Drug|Ezetimibe|"Pharmaceutical form: tablet~Route of administration: oral"
45499504|NCT02984982|Drug|Antiplatelets|"Pharmaceutical form: tablet or capsule~Route of administration: oral"
45848213|NCT03301272|Other|Placebo|0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
45848214|NCT03303144|Drug|Triferic|ferric pyrophosphate citrate
45383930|NCT04638569|Procedure|obturator nerve block|The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle. In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL. The time elapsed until the first needle insertion and local anesthetic injection is completed will be recorded as the application time.
45383931|NCT04038203|Device|Resonance Raman Spectroscopy (RPS)|RRS is a technology that utilizes vibrational spectroscopy, rather than absorbance spectroscopy, to determine the oxyhemoglobin concentration in tissues. Raman measurements for the UAC neonates will be obtained simultaneously on the right AND left lower extremity for 15 minutes daily in the first week of life.
45383932|NCT04124861|Drug|Drug free, IS monotherapy and GC combined with IS|Follow-up intervals: Every 3 months (3th, 6th, 9th, 12th, 15th, 18th month).
45383933|NCT00881777|Procedure|Radiofrequency heating of the myocardial infarct scar|Radiofrequency energy is applied to the epicardial surface of the heart using an external generator and a hand-held probe to heat myocardial infarction scar.
45499505|NCT02984982|Drug|Anticoagulants|"Pharmaceutical form: tablet or capsule~Route of administration: oral"
45499506|NCT04357158|Device|AeonoseTM|All participants will be asked to breathe into an electronic nose (eNose, the AeonoseTM, The eNose Company, Zutphen, the Netherlands) for 5 minutes during the pre-colonoscopy intake and just prior to the procedure to assess reproducibility (with >2 weeks in between).
45499507|NCT03622242|Device|Pain threshold index|In pain threshold index monitor, monitor patients' pain threshold index based on electroencephalography and adjust infusion rate of remifentanil and propofol according to pain threshold index
45499508|NCT03622242|Device|Wavelet index|In wavelet index monitor, monitor patients' wavelet index based on electroencephalography as an indicator of depth of anesthesia and adjust infusion rate of propofol according to wavelet index
45499509|NCT03656796|Other|Treadmill training with auditory cues|Participants should walk on the treadmill according to the rhythmic auditory cues (110% step frequency) for 30 min
45499510|NCT03656796|Other|Treadmill training without auditory cues|Participants should walk in comfortable speed on the treadmill for 30 min.
45554630|NCT03195920|Device|Enhanced Lithotripsy System|The Enhanced Lithotripsy System is a type of lithotripsy system comprising a console, treatment head, and Acoustic Energy Focusing material. Operation of the Enhanced Lithotripsy System entails combined action of extracorporeal insonation and Acoustic Energy Focusing material to fragment urinary stones.
45554631|NCT04467099|Other|Foot Exam Follow-Up|All participants will have a clinical assessment of their surgery foot by the study doctor.
45554632|NCT04467099|Radiation|X-ray|Standard x-ray of the foot.
45554633|NCT04467099|Other|Questionnaire|All participants will complete a questionnaire.
45554634|NCT00294320|Drug|Aldara (Imiquimod)|250mg of Imiquimod cream for application once daily 3 times per week.
45554635|NCT00294320|Other|Vehicle cream|250mg vehicle cream for application once daily 3 times per week.
45554636|NCT03526575|Drug|Zolpidem|
45695104|NCT01724086|Drug|TMC435|Type=exact number, unit=mg, number=75, form=capsule, route=oral. 1 capsule of 75 mg will be administered once daily.
45499511|NCT02258490|Biological|G-CSF mobilized CD34+ selected cells for transplantation|After screening and enrollment, donor will receive mobilization therapy with G-CSF (10 ug/Kg S/C daily x5-6 days) using standard National Marrow Donor Program guidelines. CD34+ cell selection will be performed according to procedures given in CliniMACS Operating Manual and institutional Standard Operating Procedures. If storage after CD34+ selection is necessary, product will be kept in a monitored refrigerator. During storage, leukocyte concentration should not exceed 2 x 108 cells/ml using platelet poor plasma to adjust cell concentration. If donor's plasma is not available, CliniMACS buffer will be used. Cell processing will be performed by personnel trained by Miltenyi on CliniMACS system prior to initiation of clinical product selection. After tests are performed and product passes release criteria, patient will receive final product. No conditioning regimen will be administered prior to cell infusion.
45499512|NCT03656484|Drug|Tetracycline-Metronidazole (TM) group|Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
45499513|NCT03656484|Drug|TM-Melatonin-Hyaluronic acid (TM-MHa) group|Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
45499514|NCT04309578|Drug|Trastuzumab, Capecitabine and Cisplatin|"Trastuzumab intravenous administration at a loading dose of 8 mg/kg on day 1 followed by 6 mg/kg every 3 weeks~Capecitabine oral administration at a dose of 1000 mg/m2 twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~Cisplatin intravenous administration at a dose of 80 mg/m2 on day 1"
45499515|NCT03656952|Drug|PF-06700841|a single oral dose of 200 mg PF-06700841
45499516|NCT03656952|Drug|Placebo|Placebo matching PF-06700841
45499517|NCT03656952|Drug|moxifloxacin|a single oral dose of 400 mg moxifloxacin
45499518|NCT03656406|Behavioral|Lateral decubitus positioning|After the DLT intubation, the patient is placed in lateral decubitus position
45499519|NCT03656406|Device|Cuff-manometer|The pressure of the bronchial cuff should be measured with cuff-manometer in supine position, and then measurement should be repeated after lateral positioning.
45499520|NCT02237976|Behavioral|Self-hypnosis|
45499521|NCT02237976|Behavioral|Routine practice|
45383934|NCT00881777|Procedure|Coronary Artery Bypass Grafting (CABG) surgery|A standard surgical procedure performed to relieve angina and reduce the risk of death from coronary artery disease. Arteries or veins from elsewhere in the body are grafted to the coronary arteries to bypass atherosclerotic narrowings and improve the blood supply to the coronary circulation supplying the myocardium.
45499522|NCT03656250|Diagnostic Test|PET/CT scans|(approximately 18 mSv/scan) and perform maximum two additional PET/MR scans; one immediately after the first stage of treatment and another one immediately after the second stage if the 3-month chemotherapy is given).
45499523|NCT02981472|Drug|Apixaban|Specified dose on specified days
45499524|NCT02981472|Drug|Vitamin K Antagonist (VKA)|Specified dose on specified days
45499525|NCT02981472|Drug|Low Molecular Weight Heparin (LMWH)|Specified dose on specified days
45499526|NCT03656172|Biological|Haemoglobin measure|Haemoglobin measure before and one month after standard iron treatment
45499527|NCT03656094|Drug|Pembrolizumab plus chemotherapy|Pembrolizumab plus chemotherapy
45499528|NCT03656094|Drug|Placebo plus chemotherapy|Placebo plus chemotherapy
45499529|NCT04298034|Drug|Labetalol, Nifedipine|Antihypertensive treatment that is safe and well studied in peripartum women.
45499530|NCT02982720|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously.
45383935|NCT02542475|Device|Low Field Magnetic Stimulation|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain. The field and timing parameters of the LFMS pulses, such as pulse timing, duration, frequency, and electric and magnetic field distribution and direction are different from other neurostimulation methods. LFMS electromagnetic fields are significantly weaker (< 100x) than those used in ECT and rTMS.
45383936|NCT00881855|Drug|Cefprozil 500 mg Tablets (Sandoz, GmbH)|
45383937|NCT00881855|Drug|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)|
45383938|NCT04015115|Behavioral|Youth Opioid Recovery Support service model|see arm 1 description
45499531|NCT02982720|Drug|Sylatron|Sylatron will be administered subcutaneously.
45499532|NCT03655938|Procedure|Piezocision combined minimally invasive alveolar bone regeneration|The piezocision surgery was performed two weeks after orthodontic appliance placement. The patients received local anesthesia in mandibular arch and vertical interproximal incisions were made below the interdental papillae in the midline, from the mesial aspect of each canine and in between each of the posterior lower teeth. The periostium was then released in order to create two subperiotal envelopes connecting the vertical incisions together. Thereafter, corticotomies were performed in the region of the incisions with a piezotome (Acteon, Merignac, France) and the envelopes were filled with a beta tricalcium phosphate, a resorbable biomaterial in order to thicken the buccal bone plate. Resorbable 5-0 sutures were used to close the flaps. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
45499533|NCT03656640|Drug|Gammanorm|Patients already receiving Gammanorm will be observed over the course of 2 years every 3 months. Gammanorm will be given standard of care.
45499534|NCT00849667|Drug|Farletuzumab|Farletuzumab IV infusion.
45499535|NCT00849667|Drug|Carboplatin|Carboplatin IV infusion.
45499536|NCT00849667|Drug|Taxane|Taxane (Paclitaxel or Docetaxel) IV infusion.
45499537|NCT00849667|Drug|Farletuzumab-matched placebo|Farletuzumab-matched placebo IV infusion.
45499538|NCT03201419|Drug|FE 201836|Oral solution for daily intake
45499539|NCT03201419|Drug|Desmopressin|Desmopressin Orally Disintegrating Tablet (ODT)
45499540|NCT03201419|Drug|Placebo oral solution|Manufactured to mimic experimental drug
45499541|NCT03201419|Drug|Placebo ODT|Manufactured to mimic experimental drug
45383939|NCT00881933|Other|Cyclophosphosphamide, TBI|fludarabine (30 mg/m2 once daily i.v. on days -7, -6, -5, -4, -3, & -2) (if body weight < 10 kg or if age < 1 year: 1.33 mg/kg) cyclophosphamide (60 mg/kg once daily i.v. on days -9, & -8) total body irradiation (3G on days -1)
45383940|NCT03940547|Other|Provision of flour|Infant and young child feeding education and provision of low AF porridge and groundnut flours from 6-18 months
45383941|NCT03940547|Other|Promotion of flour|Infant and young child feeding education and promotion of porridge and groundnut flours from 6-18 months
45383942|NCT03929237|Other|observe when return to school after surgery|Short written questionnaire asking when they returned to school and what accommodations, if any, the school made available for them
45383943|NCT00882011|Other|Latest generation chemotherapies for T-LBL + transplant|"Standard doses of one of the following chemotherapies:~Holzer~LSA2-L2 modified~Stanford regimen~Hyper CVAD~Sequential treatments analogous to the ones above mentioned (e.g.: GIMEMA LAL094, others)~Intensive chemotherapy, ALL-type, MRD oriented (NILG-TLL Clinical Trial)~Autologous transplant or allogeneic transplant or mini-allogeneic transplant"
45383944|NCT00884195|Behavioral|Gratitude Journaling|Participants will be asked to write down 5 things every day for which they are grateful.
45383945|NCT00884195|Behavioral|Neutral Journaling|Participants will be asked to write down 5 things every day that they noticed about being involved in a weight loss program.
45499542|NCT01331629|Other|ART-THERAPIE|8 sessions of art therapy during radiotherapy
45383946|NCT02543957|Procedure|Cholangioscopy|All patients will receive pre-procedural antibiotics per protocol. A blood culture will be drawn from patients prior to the procedure (before antibiotics administration), 5 minutes after the procedure and 30 minutes after the procedure. Patients will be followed up for 7 days after the procedure for fever and or sepsis.
45499543|NCT01764633|Biological|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
45499544|NCT01764633|Drug|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
45499545|NCT02924389|Drug|dolutegravir|Tivicay is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 50 mg of Tivicay (dolutegravir) will be taken orally once a day.
45499546|NCT02924389|Drug|Triumeq|Triumeq is a fixed-dose combination drug for the treatment of HIV/AIDS. It is a combination of 600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine. Triumeq will be taken orally once daily.
45499547|NCT02924389|Drug|Truvada|Truvada is a combination of emtriva and viread, both nucleoside analog HIV-1 reverse transcriptase inhibitors. Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. One Truvada tablet (containing 200 mg/300 mg of emtricitabine and tenofovir disoproxil fumarate) will be taken orally once daily.
45499548|NCT05440981|Device|iTind device|Cystoscopy will be performed to assess the anatomy of the bladder and prostate. The iTind device would be inserted under visual guidance into the bladder. The device will then be deployed and under visual guidance, it will be positioned at the prostatic lumen. After confirming the position of the device, cystoscopy will be withdrawn and the position will be finished.
45499549|NCT04850573|Other|equine assisted activities|Participants interact with the horse and learn how to safely handle the horse.
45499550|NCT01315093|Drug|Heparin, Low-Molecular-Weight|Heparin from start till hcg test
45499551|NCT01315093|Drug|no heparin|
45499552|NCT03235349|Drug|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
45383947|NCT00886223|Procedure|laparoscopic robot-assisted sacropexy|Repair of vaginal vault prolapse with laparoscopic sacropexy assisted by robotic surgical system (da Vinci®-System)
45383948|NCT00882089|Device|Contura catheter|Radiation therapy is delivered to a total dose of 34 Gy in 10 fractions bid over 5-7 days. Each day, the high dose rate iridium-192 brachytherapy treatments are separated by 6 hours. Each radiation treatment takes 15-30 minutes.
45383949|NCT00886301|Procedure|liver biopsy|liver biopsy
45383950|NCT02543645|Drug|Combination of Varlilumab and Atezolizumab|"Treatment cycles are 12 weeks each with varlilumab and atezolizumab administered every 3 weeks. During the treatment phase of the study, eligible patients will receive varlilumab for up to 3 cycles (with a 4th cycle possible following discussion with the Medical Monitor). There is no limit on the number of cycles of atezolizumab. Patients may be discontinued from receiving study treatment (atezolizumab or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg, or 3 mg/kg. The dose of atezolizumab is 1200 mg."
45383951|NCT02543411|Drug|Lidocaine 1%|"Intravenous administration as bolus of lidocaine 1.5 mg/kg before sedation and infusion of lidocaine 2 mg/kg/hr during sedation.~Sedation with fentanyl and propofol"
45383952|NCT02543411|Drug|Normal saline|"Intravenous administration as bolus of normal saline 0.15 mL/kg before sedation and infusion of normal saline 0.2 mL/kg/hr during sedation.~Sedation with fentanyl and propofol"
45383953|NCT02543489|Device|Flex IM rod|
45499553|NCT01331707|Device|Resolute Integrity (Zotarolimus-eluting stent)|Third generation drug-eluting stent
45499554|NCT01331707|Device|Promus Element (Everolimus-eluting stent)|Third generation drug-eluting stent
45383954|NCT00882167|Other|CineMRI|CineMRI scan of the abdomen at 1.5 Tesla.
45383955|NCT00882245|Other|Vehicle ointment|Topical vehicle cream
45383956|NCT00882245|Drug|Ointment|SRD441 Ointment
45383957|NCT02541929|Dietary Supplement|Docosahexaenoic acid|
45383958|NCT00882323|Drug|Cyclophosphamide, Fludarabine, Thymoglobulin|"cyclophosphamide (60 mg/kg once daily i.v. on days -8, -7)~fludarabine (40 mg/m2 once daily i.v. on days -6, -5, -4, -3, -2)~thymoglobulin (2.5 mg/kg once daily i.v. on days -4, -3, -2)"
45383959|NCT00884429|Procedure|Chest physiotherapy - Conventional|Percussion Postural Drainage and thorax compression
45383960|NCT00884429|Procedure|Chest physiotherapy - actual techniques|Slow prolonged expiration and clearance rhinopharynx retrograde
45383961|NCT00884429|Procedure|3-Airway suction|Airway suction
45383962|NCT00882401|Drug|Ergocalciferol (Vitamin D)|ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
45499555|NCT02956447|Drug|Kisspeptin 112-121|0.313 µg/kg IV
45499556|NCT02956447|Drug|Gonadotropin Releasing Hormone (GnRH)|0.075 ug/kg IV
45499557|NCT03235115|Device|Methafilcon A IV|Contact Lens
45499558|NCT03235115|Device|Ocufilcon B|Contact Lens
45499559|NCT03235115|Device|Omafilcon A|Contact Lens
45499560|NCT03953807|Drug|Dexamethasone Intravitreal Implant|Implant 700 μg
45499561|NCT03662711|Drug|Bronchodilator Agents|Fluticasone furoate/vilanterol
45499562|NCT03662711|Drug|Bronchodilator Agents|Tiotropium
45499563|NCT03662711|Drug|Bronchodilator Agents|Indacaterol
45499564|NCT03662711|Drug|Bronchodilator Agents|Umeclidinium/vilanterol
45499565|NCT03662711|Drug|Bronchodilator Agents|Fluticasone propionate/salmeterol
45499566|NCT03662711|Drug|Bronchodilator Agents|Beclometasone dipropionate/formoterol
45383963|NCT00882401|Drug|Placebo|Matching placebo at same dose schedule as ergocalciferol
45383964|NCT00886457|Drug|Decitabine and Pegylated Interferon-Alfa 2B|Patients will receive decitabine 3.7 mg/m2/day i.v. over 1 hour daily in 10 doses over 2 weeks elapsed time (Monday-Friday) every 28 days plus fixed dose of PEG-Intron (0, 0.5, 1.5, 3 or 6 mcg/kg PEG-Intron) weekly by subcutaneous injection in 28-day cycles .
45383965|NCT04038671|Device|Activated Carbon Cloth Dressing|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
45383966|NCT04038671|Device|Knitted Cellulose Acetate Mesh|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
45383967|NCT04038671|Device|Antimicrobial Alginate Dressing with Silver|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
45383968|NCT02543177|Procedure|coronary angiography|
45383969|NCT02543177|Procedure|ischemic precondition|four cycles of congestion and flow of blood in the arm of the patient for 5 minutes
45383970|NCT02543177|Procedure|prior kidney irrigation|
45383971|NCT02543099|Drug|policosanol|Patients will receive policosanol 20mg Qd
45499567|NCT03662711|Drug|Bronchodilator Agents|Budesonide formoterol
45499568|NCT03662711|Drug|Bronchodilator Agents|Glycopyrronium
45499569|NCT03662711|Drug|Bronchodilator Agents|Aclidinium
45499570|NCT03662711|Drug|Bronchodilator Agents|Umeclidinium
45499571|NCT03662711|Drug|Bronchodilator Agents|Formoterol
45499572|NCT03662711|Drug|Bronchodilator Agents|Indacaterol glycopyrronium
45499573|NCT03662711|Drug|Bronchodilator Agents|Salmeterol
45499574|NCT03662711|Drug|Bronchodilator Agents|Tiotropium olodaterol
45499575|NCT03662711|Drug|Bronchodilator Agents|Aclidinium/formoterol
45499576|NCT03662711|Drug|Bronchodilator Agents|Olodaterol
45499577|NCT03662711|Drug|Bronchodilator Agents|Formoterol/glycopyrronium bromide/beclometasone dipropionate
45499578|NCT03662711|Drug|Bronchodilator Agents|Fluticasone furoate/umeclidinium bromide/vilanterol
45499579|NCT02923531|Drug|X4P-001|X4P-001 will be administered as per the dose and schedule specified in the arm.
45499580|NCT02923531|Drug|Nivolumab|Nivolumab will be administered as per the dose and schedule specified in the arm.
45499581|NCT02934503|Biological|Pembrolizumab|200 mg IV fixed dose every 3 weeks until progression or for up to 2 years of therapy.
45499582|NCT02934503|Drug|Cisplatin|75 mg/m2
45499583|NCT02934503|Drug|Carboplatin|AUC 6
45499584|NCT02934503|Drug|Etoposide|IV every 3 weeks for up to 6 cycles (minimum of 4 cycles, maximum of 6).
45383972|NCT02543099|Drug|placebo|Patients will receive placebo 20mg Qd;
45499585|NCT02934503|Radiation|Radiation therapy|Thoracic radiotherapy will be given per institutional standards(dose and duration may vary for individual participants).
45499586|NCT03636217|Other|LGI-Milk Breakfast|This test meal with low glycemic index and milk were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.
45499587|NCT03636217|Other|LGI-Kefir Breakfast|In crossover design, this test meal with low glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast.
45499588|NCT03636217|Other|HGI-Kefir Breakfast|In crossover design, this test meal with high glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast and the LGI-Kefir Breakfast.
45499589|NCT04563247|Diagnostic Test|IgG SARS CoV 2 antibodies|The asymptomatic healthcare workers of high exposure COVID19 areas will be tested for IgG SARS CoV 2 antibodies
45499590|NCT02937545|Other|Medication Therapy Management|Community pharmacists will provide medication therapy management in combination with pharmacogenetic testing
45383973|NCT00882635|Drug|enoxaparin|"Enoxaparin 0.5 mg/kg IV bolus (Regardless of whether the investigator has chosen to initiate concomitant GP IIb/IIIa antagonist; provision for additional IV enoxaparin to be administered if elapsed time to PCI exceeds 2 hours (from original IV dose) - enoxaparin 0.25 mg/kg IV will be administered At the discretion of the treating physician, if sustained anticoagulation is required then enoxaparin subcutaneously will be administered - enoxaparin 1.0 mg/kg SQ q 12 hours.~Maintenance dose adjustment for renal insufficiency - creatinine clearance < 30 ml/min, sc enoxaparin should be administered at 1.0 mg / kg / q24 hours. No adjustment of IV dose is required in case of renal insufficiency"
45383974|NCT00882635|Drug|Unfractionated heparin|Unfractionated heparin 70 u/kg IV bolus (consistent with ASSENT 4 PCI) Baseline ACT will be draw at time of sheath insertion - With use of GP IIb/IIIa antagonist additional UFH will be administered to achieve an ACT of ≥200 - 250 seconds If IIb/IIIa is not utilized - additional UFH will be administered to achieve an ACT of ≥250-350 seconds At the discretion of the treating physician if sustained anticoagulation is required:UFH infusion 12/u/kg/hr IV infusion to commence
45383975|NCT02543021|Device|Virtual chromoendoscopy|Digital / virtual chromoendoscopy with FICE
45383976|NCT02543021|Procedure|Conventional chromoendoscopy|Conventional chromoendoscopy with indigo carmine dye spray
45383977|NCT02541539|Dietary Supplement|Lactobacillus casei Zhang|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
45383978|NCT02541539|Dietary Supplement|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
45383979|NCT00886847|Procedure|Lymph Node Needle Tissue Collections|Total of two lymph nodes sampled per patient. Four biopsies will be taken from each lymph node. Two with suction (FNA) and two without suction (FNC).
45383980|NCT00888641|Procedure|Hypothermia|Surround kidney in ice slush for 10 minutes after arterial clamping
45383981|NCT00609947|Device|Endeavor Zotarolimus-Eluting Coronary Stent|
45383982|NCT00609869|Drug|Lenalidomide|Lenalidomide was administered orally with escalating doses on 28-days cycles. The first cycle was administered with a starting dose of 2.5 mg daily on days 1-7, 5mg on days 8-14 and 10 mg on days 15-21, followed by seven days off. On cycle 2 and beyond lenalidomide was administered at 20 mg daily on days 1-21.
45499591|NCT02937545|Other|Pharmacogenetic testing|Community pharmacist will provide pharmacogenetic testing.
45499592|NCT03636139|Device|transcranial DC stimulation : anodal|anodal stimulation of the right dlPFC (i.e. F4) for 20 minutes
45499593|NCT03636139|Device|transcranial DC stimulation : sham|sham stimulation of the right dlPFC (i.e. F4) for 20 minutes
45499594|NCT05435131|Diagnostic Test|GCF obtaining|GCF obtaining: 2 GCF samples, 1 from the interproximal surface of 2 different teeth that bleeding on probing(-), were taken from each participant
45499595|NCT05435131|Diagnostic Test|Saliva Obtaining|Saliva obtaining: 1,5 ml unstimulated whole saliva collected from each participant
45499596|NCT05435131|Diagnostic Test|Serum obtaining|Serum obtaining : 8 ml of venous blood was collected from each participant and collecting blood centrifuged to obtain serum
45499597|NCT01314209|Drug|Dexmedetomidine|Dexmedetomidine 0.7 microg/kg/h 12-hour intravenous infusion
45499598|NCT05434429|Other|mobile application|Participants in the intervention group are able to access the intervention materials 5 days after enrollment. Two main self-guided intervention modules are available. Short-term self-guided intervention module include mainly audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation. Moreover, there based on breath relaxation exercises, craving management, and motivation to change. Long-term self-guided intervention module include CBT-based interventions, meditations, mindfulness, and journaling.
45499599|NCT04732325|Device|Spinal cord stimulation|Researchers will program the spinal cord stimulation (SCS) system to deliver, according to the randomization status of the participant, burst, kHz, tonic, and sham stimulation.
45499600|NCT05431075|Drug|Amoxicillin|Included in quadruple eradication medication.
45499601|NCT05431075|Drug|Tetracycline tid|Included in quadruple eradication medication.
45499602|NCT05431075|Drug|Tetracycline qid|Included in quadruple eradication medication.
45499603|NCT05431075|Drug|Bismuth Potassium Citrate|Included in quadruple eradication medication.
45499604|NCT05431075|Drug|Colloidal Bismuth Pectin|Included in quadruple eradication medication.
45499605|NCT05431075|Drug|Esomeprazole 20mg|Included in quadruple eradication medication.
45499606|NCT04709393|Other|FRAX+SARC-F questionnaire pre-screening|Pre-screening group participants will receive the FRAX+SARC-F questionnaire pre-screening and be notified of the preliminary estimation of their future hip fracture risk before being invited to our DXA screening and fall-risk assessment.
45499607|NCT03758417|Biological|LCAR-B38M CAR-T Cell|Participants will receive LCAR-B38M CAR-T cells as a single infusion which consists of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
45499608|NCT01329835|Behavioral|Lifestyle counseling|4 prenatal sessions based on principles of motivational interviewing and positive reinforcement
45499609|NCT01329835|Other|brochure|brochure given after randomization
45499610|NCT03636659|Drug|Amphotericin B Liposome|Manufactured for: Auromedics Pharma LLC, USA
45499611|NCT03636659|Drug|AmBisome (Amphotericin B) Liposome|Marketed by: Astellas Pharma US, Inc. USA
45499612|NCT04892173|Drug|NBTXR3|Suspension of inert, crystalline hafnium oxide particles, designed to generate oxygen free radicals to destroy cancer cells after activation by ionizing radiation.
45499613|NCT04892173|Drug|Cetuximab|Solution for infusion
45383983|NCT00609869|Drug|Rituximab|Rituximab was administered at 375 mg/m^2 intravenously on a weekly basis for the first cycle starting on day 15. Subsequent rituximab doses were administered on day one of cycle 2 and beyond, every 4 weeks. Doses were repeated on 28-day cycles until disease progression or unacceptable toxicity, but were planned for 12 cycles.
45499614|NCT04892173|Radiation|Radiation Therapy|Intensity-modulated radiation therapy (IMRT): 70 Gray in 35 fractions over a 7-week period.
45499615|NCT03199391|Device|BioWick SureLock Implant|The BioWick SureLock implant is a device for shoulder and extremity surgery, constructed of Ultra High Molecular Weight Polyethylene Suture. BioWick SureLock is uniquely designed to minimize these risks by avoiding manual tensioning with an inserter mechanism that ensures that the implant is consistently deployed below the cortex.
45499616|NCT01329913|Drug|MK-6325|Two 100 mg capsules, orally, once per day for 7 days
45848215|NCT03306420|Drug|M4112|All participants who received M4112 100,200,400,600 and 800 mg twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
45499617|NCT01329913|Drug|Placebo to MK-6325|Two 100 mg capsules, orally, once per day for 7 days
45383984|NCT00529568|Drug|eltrombopag|double-blind active treatment daily oral administation at dose of 25, 50, 75, or 100 mg
45383985|NCT00529568|Drug|placebo|double-blind matched placebo control daily oral administration
45383986|NCT00888719|Drug|CWP-0403 100mg|100mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
45499618|NCT01329913|Drug|MK-6325|Four 100 mg capsules, orally, once per day for 7 days
45499619|NCT01329913|Drug|Placebo to MK-6325|Four 100 mg capsules, orally, once per day for 7 days
45499620|NCT01329913|Drug|MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
45499621|NCT01329913|Drug|Placebo to MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
45499622|NCT01329991|Drug|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo
45499623|NCT01329991|Drug|Placebo|Matching placebo for PLX5622
45383987|NCT00888719|Drug|placebo|"Tablet not containing CWP-0403 and indistinguishable from CWP-0403 50mg, 100mg tablets.~Twice a day, 1 tablet at a time for 12 weeks"
45383988|NCT00888719|Drug|CWP-0403 50mg|50mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
45499624|NCT04532515|Device|Seal-G Surgical Sealant|"Seal-G is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis"
45499625|NCT04532515|Device|Seal-G MIST System|"Seal-G MIST is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis"
45499626|NCT03198767|Drug|LIK066|LIK066 50 mg tablets. Open-label, bulk, blister-pack.
45499627|NCT03198767|Dietary Supplement|Carbohydrate 50%|50% carbohydrate in breakfast meal
45499628|NCT03198767|Dietary Supplement|Carbohydrate 25%|25% carbohydrate in breakfast meal
45848216|NCT03308058|Behavioral|Breastfeeding computer education|Breastfeeding computer education
45499629|NCT03198767|Dietary Supplement|Carbohydrate 8%|8% carbohydrate in breakfast meal
45499630|NCT03198767|Dietary Supplement|Carbohydrate 0%|0% carbohydrate in breakfast meal
45848217|NCT03312348|Device|Infrared imaging|Infrared image image acquisition of study participants
45848218|NCT03315702|Other|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cm H2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
45499631|NCT03198767|Dietary Supplement|Psyllium|Powder 6 grams
45499632|NCT03198767|Dietary Supplement|Calcium carbonate|Liquid 1 gram (4 mL equivalent sugar free)
45499633|NCT03162055|Drug|Glycopyrronium/Formoterol Fumarate|Metered dose inhaler (MDI), contains glycopyrronium/formoterol fumarate fixed-dose combination 7.2/4.8 μg per actuation
45499634|NCT03162055|Drug|umeclidinium/vilanterol|Dry powder inhaler (DPI), Each metered dose contains umeclidinium/vilanterol 62.5/ 25μg fixed-dose combination per inhalation
45499635|NCT02927145|Biological|RH5.1/ ASO1|"The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The AS01 adjuvant system has been developed and manufactured by GlaxoSmithKline (GSK) Biologicals and is presented as a liquid solution in a monodose glass vial. AS01 is a liposome-based Adjuvant System with a specific aim to improve cell-mediated immunity."
45499636|NCT03980535|Procedure|Magnetic Resonance Imaging|Undergo MRI
45499637|NCT03980535|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
45499638|NCT03688919|Behavioral|Self-Regulation Intervention|The intervention targets Executive Functioning (EF), Emotion Regulation (ER) and Future Orientation (FO). The intervention will occur through home practice and text based reminders and mobile apps to practice techniques. For EF, youth will use the NBack intervention, a computer-based working memory training game. For ER, participants will engage in relaxation and biofeedback activities by completing activities (e.g., modulating breathing to keep heart rate) while wearing sensors. For FO, participants will envision and describe future events they are looking forward to, using concrete, vivid descriptive language. These descriptions will be audio recorded so that the participant can play back the cues at home at specified times of day (e.g., 7am and 3:30PM).
45499639|NCT01331785|Drug|Midodrine|Midodrine 2.5 mg to 10 mg three times a day to increase systolic BP above 100 mmHgor by 10 mmHg
45499640|NCT01382589|Drug|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation
45499641|NCT01382589|Device|NB-UVB|NB-UVB light therapy 3-times per week, for total of 72 treatments
45499642|NCT01381653|Other|Behavioral: HIV prevention intervention|Substance using HIV-negative young men who have sex with men who engage in sexual risk and use social networking (Facebook) will be recruited and enrolled in a brief intervention utilizing Motivational Interviewing over chat window to reduce their substance use and sexual risk. They will also evaluate their intervention experience at the end of their eight sessions and post-assessment.
45499643|NCT03671759|Behavioral|Start: On Caffeine|In this two-day block, participants will be instructed to consume caffeine for one day and avoid caffeine the next day.
45499644|NCT03671759|Behavioral|Start: Off Caffeine|In this two-day block, participants will be instructed to avoid caffeine for one day and consume caffeine the next day.
45499645|NCT01384227|Drug|Proflavine Hemisulfate|Proflavine hemisulfate 0.01% (derived from dissolving 10 mg Proflavine Hemisulfate USP in 100 ml of sterile water)
45499646|NCT01315171|Dietary Supplement|Medium chain triglycerides|4 tablespoons/day for 2 weeks
45499647|NCT04631835|Drug|HS-10352|Participants will receive single dose of HS-10352 on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
45499648|NCT04646369|Behavioral|"screening as usual"|Participants in this group will receive usual care at their pediatric primary care practice following information, psychoeducation, and referral to a mental health treatment provider
45499649|NCT04646369|Behavioral|Screening Wizard 2.0|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
45499650|NCT04646369|Behavioral|Screening Wizard 2.0 + SOVA|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment. SOVA is a peer-support website that social workers and doctors moderate on a 24 hour a day basis.
45499651|NCT01382511|Drug|Simvastatine|80 mg
45499652|NCT02888119|Device|PRISMA 3T MRI scanner (Siemens Medical Solutions)|A baseline MRI exam consisting of accelerated 3D-T1p, and T2, MRI will be performed. Longitudinal follow-up MRI exams (24 months) will be repeated on the same knee on all OA patients.
45499653|NCT03631329|Diagnostic Test|Doppler sonographic measurement|First, place a 4.5-12.0 MHz linear array transducer vertically on the neck with the probe marker facing the patient's head. A long axis B-mode image of the right common carotid artery is obtained at the lower border of the thyroid cartilage. The sample volume is then placed in the center of the lumen located approximately 2 cm proximal to the carotid bifurcation. Next, pulsed wave Doppler tracing is performed in the arterial blood flow. The cycle time using the calliper function in an ultrasonic machine is obtained by measuring the interval between heartbeats at the beginning of the Doppler blood flow upstroke and the Flow time is measured as the time from the beginning of the systolic upstroke to the dicrotic notch.
45499654|NCT03684447|Drug|Propofol|Series of 6 treatments with propofol.
45695105|NCT01724086|Drug|Ritonavir|Type=exact number, unit=mg, number=30 or 50, form=tablet or solution, route=oral. 0.375 mL or 0.625 ml (80 mg/mL) solution will be administered once daily.
45695106|NCT01724086|Drug|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. 5 to 6 (1000 or 1200 mg) tablets will be administered once daily, divided in 2 daily doses. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment 5 or 6 (depending on bodyweight) tablets of ribavirin (equivalent to 200 mg/tablet) per day, divided in 2 daily doses for an additional 12 or 36 weeks.
45848219|NCT03315780|Drug|Dulaglutide|Administered SC
45848220|NCT03315780|Drug|Placebo|Administered SC
45848221|NCT03319134|Device|active anodal HD-tDCS|1) active anodal HD-tDCS with memory task
45383989|NCT04037111|Device|Transcutaneous electrical vagus nerve stimulation|The patient received active VNS and escitalopram oxalate tablets for 2 months.When the VNS was stimulated, the two electrodes were vertically attached to the left carotid sinus at 2cm, or the auricular clip electrode was applied to the tragus.
45383990|NCT04037111|Device|Sham vagus nerve stimulation|The patient received sham VNS.When the VNS was stimulated, the two electrodes were vertically attached to the left carotid sinus at 2cm, or the auricular clip electrode was applied to the tragus.
45383991|NCT04037111|Drug|drug treatment|Escitalopram oxalate tablets should be taken orally once every morning for 2 months, each time 10-20mg
45383992|NCT00886925|Drug|Albumin|Albumin 20%. Day 0: 400-600 ml. Day 2: 200-400 ml.
45383993|NCT00886925|Drug|Sodium chloride 0.9%|Day 0: 400-600 ml. Day 2: 200-400 ml.
45383994|NCT02542709|Device|Active repetitive Transcranial Magnetic Stimulation|Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.
45383995|NCT02542709|Device|Sham repetitive Transcranial Magnetic Stimulation|Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
45848222|NCT03319134|Device|sham HD-tDCS|2) sham HD-tDCS with memory task
45383996|NCT00888797|Drug|Propranolol and Etodolac|Both study medications will be given orally for an intervention phase of 20 days as follows: 5 days prior to surgery, on the day of surgery, and 14 days postoperatively. Etodolac:800 mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery, 40 mg PO bid for the first postoperative week, 20 mg PO bid for the second postoperative week.
45383997|NCT00888875|Device|i-gel|insertion after induction of anaesthesia. Afterwards, intubation over the device fiberoptically
45383998|NCT00888875|Device|ILMA|Insertion after Induction. Insertion of tracheal tube over device
45499655|NCT03684447|Drug|Propofol|Series of 6 treatments with propofol. May be able to cross over and receive 6 additional treatments with the high dose of propofol.
45499656|NCT04505059|Procedure|Precision cardiac anesthesia|Aperi-operative anesthetic management through target-controlled infusion to accurately control the patient blood concentration, with combination of bispectral index and neuromuscular monitoring to adjust the dosage of general anesthetics.
45554637|NCT00189254|Drug|Imiquimod|No defined treatments were given during this study.
45848223|NCT03319134|Device|active cathodal HD-tDCS|3) active cathodal HD-tDCS with memory task
45848224|NCT03329352|Device|F&P Full-Face Mask|The F&P full-face mask will serve as the participant's primary PAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial full-face mask as their primary PAP therapy mask for 6 months after Visit 3.
45499657|NCT04505059|Procedure|Conventional cardiac anesthesia|The anesthesia strategy is mainly depending on the anesthesiologist's clinical experience
45499658|NCT01382433|Procedure|Magnetoencephalograph (MEG)|Brain imaging device that records the magnetic fields in the brain.
45499659|NCT01382433|Behavioral|Cambridge Neuropsychological Test Automated Battery (CANTAB).|the CANTAB is sensitive to cognitive changes caused by a wide range of Central Nervous System disorders and medication side-effects . The CANTAB uses a computer with a touch screen, and affords a rapid and non-invasive assessment of cognitive functions.
45499660|NCT01382433|Behavioral|Experimental: Scale for the Assessment of Negative Symptoms (SANS) and the Positive and Negative Syndrome Scale (PANSS)|The SANS and PANSS scales asses the presence and severity of Positive and Negative of Schizophrenia
45499661|NCT03549299|Biological|LSC2|Topical application of IMP on target eye
45499662|NCT01315327|Drug|Omega-3 Fatty Acids|Omega-3 fatty acids (derived from fish oil)
45499663|NCT01315327|Drug|Olive oil|Placebo
45499664|NCT01314599|Drug|PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion|"PM01183 Drug Product will be provided as a lyophilized powder for concentrate for solution for infusion with a strength of 1.0 mg/vial and 4.0 mg/vial.~Before use, the vials will be reconstituted with 2 ml or 8 ml of sterile water for injection to give a solution containing 0.5 mg/ml of PM01183."
45499665|NCT04243863|Drug|VNRX-7145|Part 1: one dose Part 2: 28 doses (once every 8 hour [q8h] dosing for 9 days with a single morning dose on Day 10)
45499666|NCT04243863|Drug|Placebo|Part 1: one dose Part 2: 28 doses (once every 8 hour [q8h] dosing for 9 days with a single morning dose on Day 10)
45499667|NCT02635633|Device|continuous thetaburst stimulation|On 4 consecutive days patients receive 5 cTBS trains with a 10min intertrain-interval. One cTBS train consists of 600 pulses delivered in bursts at theta frequency (200ms) during 40s. Each burst comprises 3 pulses at 50Hz. Focal stimulation occurs over the epileptogenic focus (EF), perpendicular to the local gyral geometry, using online neuronavigation. Stimulation intensity is set relative to the resting motor threshold (rMT) determined at baseline (80% rMT). Stimulation intensity is further adjusted to the coil-cortex distance at the EF with the following formula: adjusted MT% (AdjMT) = rMT + 2,7*(DEF-DM1) [DEF = distance over EF; DM1 = distance over M1]. If rMT exceeds the capacity of the stimulator output, stimulation intensity is 100% of maximal stimulator output (MSO).
45499668|NCT03197129|Other|sensory adapted waiting room|The SADE waiting room: a small waiting room (2.5mx2.5m) inside the clinic with 6 seats. A lighting column that children can touch and climb on. Auditory stimuli include rhythmic music, which is heard via loudspeakers.
45499669|NCT04217135|Drug|evidence-based medications vs. high-dose hydralazine + evidence-based medications|randomized in 1 to 1 fashion After discharge, high-dose hydralazine is maintained except any adverse effect and up-titration of other evidence-based medications to maximal tolerable dose will be done. The dose of medications is adjusted by clinical signs, especially peripheral perfusion, not only simply by blood pressure. If participant had low blood pressure (for example, systolic blood pressure less than 90 mmHg) but no sign of postural hypotension, or low cardiac output (cold limbs, decreased urine output, dizzy), the investigators will keep up-titration of medications.
45499670|NCT01337401|Drug|Cediranib|30mg once daily, oral until disease progression
45499671|NCT01337401|Drug|Placebo|30mg, once daily, oral until 24 weeks or disease progression if sooner
45499672|NCT01331863|Procedure|Airway and/or pulmonary Vessels Transplantation|Use of a stent-supported aortic allograft to prevent pneumonectomy in lung cancer SURGERY
45499673|NCT04178603|Other|Exercise, insulin infusion|Trial A: Acute one-legged exercise Trial B: Insulin infusion 4 hours after one-legged exercise
45499674|NCT01333891|Drug|Phenylephrine|Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
45499675|NCT01333891|Drug|Sodium-Nitroprusside|Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
45499676|NCT01333891|Device|Suction Cup|experimental stepwise increase of intraocular pressure while measurement of choroidal thickness suction force of 25, 50, 75, and 100 mmH
45499677|NCT01333891|Device|Goldmann applanation tonometer|intraocular pressure measurements
45499678|NCT01333891|Device|1060nm Optical coherence tomography|Optical coherence tomography is a widely used non-invasive method to image the retina and choroid. Using a 1060nm light source coupled to a commercially available OCT system (Heidelberg Engineering, Heidelberg, Germany) allows for the measurement of choroidal thickness
45695107|NCT01724086|Drug|Pegylated interferon alpha-2a (PegIFN)|Type=exact number, unit=mcg, number=180, form=solution, route=subcutaneous injection. PegIFN 0.5 mL prefilled syringe equivalent to 180 mcg will be administered as a subcutaneous (under the skin) injection as follow-up (FU) treatment for 12 or 36 weeks based on follow-up treatment principles as described in the protocol. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment with Pegylated interferon alpha-2a (PegIFN) 0.5 mL prefilled syringe equivalent to 180 mcg administered as a subcutaneous (under the skin) injection for an additional 12 or 36 weeks.
45499679|NCT04853875|Drug|Tetracycline, Metronidazole, Bismuth subcitrate|52 participants (Group A) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Tetracycline, Metronidazole, and Bismuth subcitrate
45383999|NCT00884663|Drug|Candesartan|Candesartan cilexitil tablets, 16 mg once daily
45499680|NCT04853875|Drug|Amoxicillin, Metronidazole, Clarithromycin|52 participants (Group B) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Amoxicillin, Metronidazole, and Clarithromycin
45499681|NCT03196973|Drug|DF289 plus DF277|1 vial into the affected ear twice daily for 7 days
45499682|NCT03196973|Drug|DF289|1 vial into the affected ear twice daily for 7 days
45499683|NCT03196973|Drug|DF277|1 vial into the affected ear twice daily for 7 days
45499684|NCT01333969|Procedure|Ischemic Preconditioning|In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components). In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
45384000|NCT00884663|Drug|propranolol|Propranolol hydrochloride capsules 160 mg once daily, slow release formulation
45384001|NCT00884663|Drug|placebo|placebo tablets and capsules
45695108|NCT01724086|Drug|GSK2336805|Type=exact number, unit=mg, number=30 or 60, form=tablet, route=subcutaneous injection. GSK2336805 one or two 30 mg tablet(s) taken orally (by mouth) once daily for 12 weeks.
45384002|NCT02542553|Procedure|Bilateral BAL|
45384003|NCT00887003|Drug|Bupivacaine|Low Volume, Low Dose (5cc, 5mg plain Bupivacaine)
45499685|NCT03196505|Drug|Exparel 266 MG Per 20 ML Injection|Liposomal bupivacaine 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
45384004|NCT00887003|Drug|Bupivacaine|Low Volume, High Dose (5cc, 10mg plain Bupivacaine)
45384005|NCT00887003|Drug|Bupivacaine|High Volume, Low Dose (10cc, 5mg plain Bupivacaine)
45499686|NCT03196505|Drug|Bupivacaine|60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
45499687|NCT01334047|Biological|DC-006 vaccine|Vaccine is administered every 4 weeks during the first year. Only patients that show immunological response will continue vaccination every months during the 2nd and 3rd year.
45499688|NCT01337557|Drug|Bepotastine|1.5% bid
45499689|NCT03636815|Other|physical therapy|Cardiopulmonary rehabilitation for patients who receive left ventricle assist device
45695109|NCT00913510|Device|CIC using LoFric Primo|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
45695110|NCT00913510|Drug|Anticholinergic medication|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, i.e. Drug.
45695111|NCT01727050|Device|Fibrin sealant spray|Fixation of mesh would be performed using fibrin sealant spray applied with a laparoscopic spray catheter
45695112|NCT01727050|Device|Mechanical stapling|Fixation of mesh would be performed using mechanical staplers
45384006|NCT00887003|Drug|Bupivacaine|High Volume, High Dose (10cc, 10mg plain Bupivacaine)
45384007|NCT00887003|Drug|Depo-Medrol|80mg Depo-Medrol
45384008|NCT00887081|Drug|PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin|PEG-IFN alpha2a 180 mcg weekly or PEG-IFN alpha2b 1.5 mcg/kg of body weight weekly plus ribavirin 800-1200 mg daily according to body weight.
45384009|NCT03998696|Drug|Cisplatin 40 mg/m2|Cisplatin 40 mg/m2, weekly, concurrent with Radiotherapy
45384010|NCT03998696|Drug|Cisplatin 100 mg/m2|Cisplatin 100 mg/m2, three weekly, concurrent with Radiotherapy
45384011|NCT00888953|Other|Fall risk assessment|Assessment of presence of risk factors (previous falls, self efficacy, balance and gait disorders, weakness, daily living impairment, limb pain, foot problems, dizziness, cognitive impairment, vision impairment, depression, urinary incontinence, heart disease, polimedication and consumption of neuroleptics and psychotropic medication)
45499690|NCT01337713|Other|Swedish Massage|Swedish massage, 45 minutes, 2 x per week for 6 weeks
45499691|NCT01337713|Other|Light Touch|Light touch, 45 minutes, 2 x week for 6 weeks
45499692|NCT03196349|Drug|Warfarin|Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3
45499693|NCT03196349|Drug|Apixaban 2.5 MG|Will be randomized to receive open label apixaban of 2.5 mg twice daily
45499694|NCT03196349|Drug|Rivaroxaban 10 MG|Will be randomized to receive open label rivaroxaban of 10mg daily
45499695|NCT01331941|Drug|AMG 386 + Paclitaxel|15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent.
45695113|NCT03836716|Drug|Arimoclomol|Active treatment
45384012|NCT00888953|Other|Tailored intervention|Induction of an intervention for each identified risk factor. If is possible the intervention will be directed towards the treatment of the underlying cause.
45384013|NCT04867460|Procedure|Ultrasound guided venous access|Access of the axillary vein using ultrasound guidance.
45384014|NCT00889031|Other|No Intervention|Patients with Chronic Lymphocytic Leukemia (CLL)
45384015|NCT05710952|Device|Review by Modjaw|A review by Modjaw's will be done before the braces treatment and after.
45384016|NCT04017923|Diagnostic Test|measurement of nasal tip support in different age groups.|Nasal tip resistances , were measured in all age groups with a digital Newton meter.
45384017|NCT02542787|Drug|VSN16R|Small molecule
45384018|NCT02542787|Other|Placebo|dummy tablet
45384019|NCT04847882|Behavioral|Questionnaire|Questionnaire submitted to the parents of children with cystic fibrosis aged 6 to 17 years and to controls in order to assess and compare the prevalence of sleep disorders and their main non-respiratory causes
45384020|NCT05120648|Behavioral|Biofeedback|We propose to study whether patients who complete a clinical six-session biofeedback protocol will demonstrate improvements in mental and physical health.
45384021|NCT03999086|Procedure|Intervention|We will utilize thromboelastography to discern when to transfuse blood products in the setting of multi-level spinal fusion
45384022|NCT03999086|Other|Control Group|Laboratory analysis to guide transfusion
45499696|NCT01331941|Drug|AMG 386|15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.
45499697|NCT02886715|Drug|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% applied to cover the affected areas of the face once daily for 84 +/- 4 days.
45384023|NCT00611975|Drug|Fluoxetine|Participants will begin taking 10 mg of fluoxetine, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 20 mg of fluoxetine once a day after 7 days, to be maintained until the luteal phase (start of ovulation) of menstrual cycle 3. If side effects are intolerable, the dose will be lowered to 10 mg of fluoxetine per day. Participants will undergo a total of 2 months of treatment with fluoxetine.
45384024|NCT00611975|Drug|Bupropion|Participants will begin taking 150 mg of bupropion, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 300 mg of bupropion once a day after 7 days, to be maintained until the luteal phase of menstrual cycle 3. If side effects are intolerable, the dose will be decreased to 150 mg of bupropion per day. Participants will undergo a total of 2 months of treatment with bupropion.
45384025|NCT05695352|Drug|Levonorgestrel 1.5mg|oral synthetic progesterone agonist
45384026|NCT05695352|Drug|Meloxicam 15 mg|Non steroidal autoinflammatory drug inhibiting both Cyclooxygenase -1 and -2 enzymes
45384027|NCT05695352|Other|Placebo|Each tablet contains Calcium Carbonate 1000 mg
45384028|NCT00889109|Other|Three dimensional unrestricted arm movements|The subjects will carry out three dimensional unrestricted arm movements. The subjects' movements will be recorded by optoelectronic infrared cameras and software. Assessment of smoothness parameters of subjects' movements will allow discriminating between subjects with intact or impaired proprioception.
45384029|NCT04895306|Drug|Testosterone Cypionate|Weekly intramuscular administration of testosterone at a dose of 3 mg
45499698|NCT02886715|Drug|Tazorac®|Tazorac® applied to cover the affected areas of the face once daily for 84 +/- 4 days.
45499699|NCT02886715|Drug|Placebo|Placebo (vehicle of the test product) applied to cover the affected areas of the face once daily for 84 +/- 4 days.
45499700|NCT04403737|Device|Rothman Index|The Rothman Index score will be calculated and visible to providers. Providers will be encouraged to follow a set of recommended-use protocols in response to different levels of the RI threshold.
45499701|NCT04360837|Procedure|alveolar recruitment|incremental and decremental positive end-expiratory pressure alveolar recruitment
45499702|NCT01337791|Drug|Telbivudine treatment|Two arms in this study, One is Telbivudine 600 mg by mouth daily from late pregnancy to 28 weeks of post partum. Another arm is clinical observation only without telbivudine treatment
45695114|NCT03836638|Drug|30 Units of botulinum toxin|30 Units of botulinum toxin to upper face
45695115|NCT03836638|Drug|50 Units of botulinum toxin|50 Units of botulinum toxin to upper face
45695116|NCT01727128|Drug|BKM120|
45695117|NCT01727206|Drug|Tocilizumab|
45695118|NCT01724164|Behavioral|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
45384030|NCT04895306|Drug|Placebo|Weekly intramuscular administration of Placebo
45384031|NCT02542241|Drug|Sodium Chloride [3%]|Patients in this arm will receive an intravenous infusion of 3% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
45384032|NCT02542241|Drug|Sodium Chloride [0.9%]|Patients in this arm will receive an intravenous infusion of 0.9% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
45384033|NCT04037891|Drug|rVA576|"19 Patients with moderate to severe AKC. the study includes two parts: Part 1: The first 3 patients selected for the study will be treated with the active drug in open-label.~Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial."
45384034|NCT04037891|Other|Placebo|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
46056096|NCT03797391|Drug|EMB-01|"In part 1, patients will receive intravenous infusions of EMB01 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.~In part 2, participants will receive intravenous infusion of EMB-01 at RP2D~The duration of each treatment cycle in both part 1 and part 2 is 28 days (4 weeks).~Participants may continue to receive study drug until discontinuation criteria are met."
45384035|NCT00887237|Device|CRT with triple site ventricular stimulation|CRT with triple site ventricular stimulation (2 RV leads and 1 LV lead)
45384036|NCT00887237|Device|Conventional cardiac resynchronization|Conventional cardiac resynchronization
46056097|NCT02740881|Other|Counselor Training Methods|
46056098|NCT00839254|Biological|Pneumococcal conjugate vaccine Synflorix (GSK1024850A)|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
45384037|NCT05007158|Other|procalcitonin blood test|blood samples of all participants were analyzed for procalitonin levels, using a commercially available procalitonin testing kit
45384038|NCT02541695|Biological|E. coli strain E1392-75-2A|"At study day 14, after a standardized evening meal and an overnight fast, subjects will receive a single oral dose of the attenuated diarrhoeagenic E. coli strain E1392-75-2A (dose will be either 1E10 CFU (n=22) or 5E10 CFU (n=22)). Oral challenge will occur at 10.00 AM. Under supervision of the project team, subjects will get a NaHCO3 solution (100 ml 2% NaHCO3) to neutralize the gastric acid. After 5 minutes, they get a fruit juice (100 ml) containing the attenuated diarrhoeagenic E. coli strain at the above-mentioned dose. Subjects go home, but are not allowed to drink or eat for 1 hour.~At study day 35, after a standardized evening meal and an overnight fast, all subjects will receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
45384039|NCT00889343|Drug|Sorafenib|2x200 mg filmcoated tablets BID on day 2-12 of a 14-days cycle, oral
45499703|NCT04358419|Diagnostic Test|Aspergillus specific proteins in exhaled breath condensate (EBC)|The EBC will be collected by use of the RTube(R) system which is commercially available for the purpose of collection of EBC. As the patient breathes through a mouth piece, the exhaled breath is lead through a cooling chamber where the vaporous part of the exhaled breath condenses. The investigators aim at collecting a total minimum of 3.0 mL EBC per study participant in order to have sufficient amount of protein for the subsequent analysis.
45554638|NCT03526419|Drug|Bupivacaine liposome|blood and milk samples will be obtained from those subjects after TAP block
45554639|NCT04978857|Other|autobiographic movie|viewing an autobiographic film through a virtual reality headset
46056099|NCT00839254|Biological|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|3 or 4 Intramuscular injections, depending on the age at the time of first vaccination only for children < 12 months of age at the time of first study vaccination.
46056100|NCT00839254|Biological|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections only for children >= 12 months of age at the time of first study vaccination.
45384040|NCT00889343|Drug|Placebo|2 filmcoated tablets BID, day 2-12 of a 14-days cycle, oral
46056101|NCT02740959|Drug|Astragalus Polysaccharides 500 mg|PG2 Injection 500 mg PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
46056102|NCT02740959|Drug|Astragalus Polysaccharides 250 mg|PG2 Injection 250 mg PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
45384041|NCT00889343|Drug|Oxaliplatin or Irinotecan|Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle
45384042|NCT00889343|Drug|Leucovorin|400 mg/m2 intravenous infusion on day 1 of a 14-days cycle
45384043|NCT00889343|Drug|5-Fluorouracil|400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle
46056103|NCT02745405|Other|Fat Suit|Participants wear a fat suit.
45499704|NCT04358419|Diagnostic Test|Pneumocystis jirovecii DNA in exhaled breath condensate (EBC)|The EBC will be collected by use of the RTube(R) system which is commercially available for the purpose of collection of EBC. As the patient breathes through a mouth piece, the exhaled breath is lead through a cooling chamber where the vaporous part of the exhaled breath condenses. The investigators aim at collecting a total minimum of 3.0 mL EBC per study participant in order to have sufficient amount of protein for the subsequent analysis.
45499705|NCT01334203|Drug|Ranolazine|"Subjects will be randomized to either ranolazine 500 mg twice daily up-titrated on Day 4 to 1000 mg administered orally twice a day or matching placebo for the 12 week treatment period.~Subjects receiving diltiazem or verapamil as their concomitant antianginal medication will receive ranolazine 500 mg or placebo administered orally twice a day."
45499706|NCT03085797|Drug|Mepolizumab|Mepolizumab injection 100 mg/millilitre (mL) is a clear to opalescent, colorless to pale yellow to pale brown sterile solution for SC injection in a single-use, safety syringe.
45499707|NCT03085797|Drug|Placebo|Placebo is a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe.
45499708|NCT03085797|Drug|Mometasone furoate|All participants will receive mometasone furoate usually 400 micrograms (mcg), 2 actuations (50 mcg/actuation) in each nostril twice daily. Intolerant participants will use 200g (2 actuations [50 g/actuation] in each nostril once daily).
45499709|NCT04262791|Device|Wrist Actigraphy Device|Wrist Actigraphy Device
45695119|NCT01724164|Behavioral|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
45695120|NCT01724164|Behavioral|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
46056104|NCT02745405|Other|Control Condition|Participants wear same clothing as intervention, but in their own size.
46056105|NCT02741115|Drug|Udenafil|Active drug
45384044|NCT00884819|Drug|Fenofibrate|fenofibrate 200 mg daily for 6-months
45384045|NCT00884819|Other|Placebo|Placebo match for 6 months
45384046|NCT04974398|Drug|Penpulimab|Arm A: Penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin 80 mg/m2, administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine 1000 mg/ m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), 3 weeks (21 days) per treatment cycle (Q3W), and then followed by penpulimab monotherapy as maintenance treatment, Q3W.
46056106|NCT02741115|Drug|Placebo|Matching Placebo
45384047|NCT04974398|Drug|placebo|Arm B: Placebo (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin (80 mg/m2, administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine (1000 mg/m2, on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), every 3 weeks (21 days) per treatment cycle and then followed by placebo monotherapy as maintenance treatment, Q3W. Subjects in Arm B will have the opportunity to crossover to open-label treatment with penpulimab monotherapy after radiographic disease progression.
45426092|NCT00681538|Drug|Placebo|containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colouring FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
45426093|NCT00640133|Device|Active DBS|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant. After a post-operative rest, participants will receive immediate DBS treatment throughout.
45499710|NCT04262791|Device|Sleep Headband|Sleep Headband
45499711|NCT02560597|Procedure|repetitive transcranial magnetic stimulation|"Stimulation over the epileptogenic focus using variable stimulation protocols as described in literature. This protocol may vary case by case, depending on patient characteristics and achieved effect from previous stimulation.~In absence of effect, rTMS is given on 5 consecutive days at most."
45554640|NCT02448524|Device|MiStent|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
46059063|NCT04079959|Procedure|endometrial biopsy|. Endometrial samples are obtained using a biopsy catheter as follows: the Pipette is inserted through the cervical os and advanced gently until resistance is felt. The inner piton of the device is then withdrawn to create suction, and the endometrial sample is obtained by moving the pipette up and down approximately 2-3 cm within the uterine cavity. The device is rotated 360° to ensure adequate coverage of the area.
45554641|NCT02448524|Device|TIVOLI|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
45554642|NCT02710292|Device|Delefilcon A contact lenses|
45554643|NCT02710292|Device|Narafilcon A contact lenses|
45554644|NCT03192644|Procedure|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
45554645|NCT03192644|Procedure|TACE|transarterial chemoembolization with epidoxorubicin and cisplatin and lipiodol
45499712|NCT01334281|Procedure|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top), 7 times (total of 210 ml for study) at the indicated time points: 1) enrollment, 2) anticipated midpoint of desensitization, 3) prior to transplant, 4) three months post-transplant, 5) six months post-transplant, 6) 12 months post-transplant, and 7) 24 months post-transplant.
45384048|NCT05229302|Behavioral|Reframet IT|The online intervention comprises 8 modules of cognitive behavioral therapy (CBT) delivered at schools by psychologists over 10 weeks. Contents: engagement and problem identification, emotional recognition and distress tolerance, identification of negative automatic thinking, help seeking and activity scheduling, problem solving, and cognitive restructuring, and a wrap up session. Two activities per module. Using a message board, the participant could communicate with research therapists who also check completed activities and respond with personalized messages. The face-to-face intervention comprises 4 CBT-based sessions to help the students in three aspects: i) close support and monitoring in case of an increase of symptomatology; ii) motivation to persist with the CBT; and iii) support the interaction between the students and CBT. Additionally, participants will be referred to a primary care clinic to receive treatment as usual.
45384049|NCT05229302|Behavioral|Usual care|Treatment as usual consists of identification and assisted referral to a primary care clinic where trained psychologists will assess the symptomatology and propose a course of actions, from initiation of psychotherapy to referral to a General practitioner to initiate medication if needed. Psychoterapy in primary care clinics consists of a range of 4-8 sessions twice a month. Most of the content of the psychotherapy are based on Cognitive-Behavioral Model. When needed, general practioners may suggest using medication, which normally are SSRI anditepressant (e.g., Fluoxetine, Sertraline). Medical check-up is conducted every month or every two months.
45499713|NCT01334281|Procedure|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top) twice (60 ml total for study), 8-12 weeks apart. Can be drawn during clinic visit or separate standard of care dialysis visit.
45499714|NCT01334359|Behavioral|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
45499715|NCT01569165|Procedure|cleansing teeth after topical fluoride therapy|washing with water 0, 15 or 30 min after APF treatment or cleansing teeth with cotton roll immediately following APF treatment.
45499716|NCT01569243|Other|Text messages|"Participants will receive diabetic medical care as usual.~Participants will be given an ActiHealth pedometer to measure daily activity.~In addition, they will be enrolled to receive the study text messages."
45499717|NCT01569243|Other|Usual care|"Participants will receive diabetic medical care as usual.~In addition, participants in the control group will be given an ActiHealth pedometer to measure daily activity (step counts will be used as a proxy for activity)."
45499718|NCT03157531|Device|B-Laser™ Atherectomy System|The B-Laser™ is indicated for use for atherectomy of infrainguinal stenoses
45499719|NCT04259749|Other|Flavor Ban|Only flavored tobacco products are banned
45499720|NCT04259749|Other|Menthol Ban|Mentholated products are banned
45848225|NCT03330834|Biological|CAR-T cells to treat advanced lung cancer|"Drug: fludarabine. On days -4 through -2, fludarabine (25mg/m2) will be infused for 3 consecutive days; Drug: cyclophosphamide. On days -4 through -2, cyclophosphamide (250mg/m2) will be infused for 3 consecutive days.~Patients will receive the above chemotherapy for lymphocyte-depletion followed by PD-L1 CAR-T cells."
46056107|NCT04317417|Behavioral|EMPOWER|"Participants will receive weekly material for a total of 5 weeks consisting of 1-2 days of didactic content and several days of brief, real-life skills practice and reporting taking approximately 10-15 minutes to complete. Adolescents and young adults cannot skip ahead, but they can return to old lessons or exercises if they choose. Most exercises are done in a diary format in which past responses are displayed next to their new ones, so that every time they visit that exercise they see their growing list of past positive experiences. Participants will be permitted up to 8 weeks to complete this self-guided intervention."
46056108|NCT02740803|Other|Sodium fluoride toothpaste 1,450 ppmF|
45499721|NCT04259749|Other|All flavored and mentholated products available|No bans: All tobacco products are available
45499722|NCT02535091|Drug|YKP3089|see above
45499723|NCT01382277|Drug|Rosuvastatin|Rosuvastatin 20 mg per day for 76 weeks
45499724|NCT03630939|Drug|ESR-114|ESR-114 Topical Gel
45499725|NCT03630939|Other|Placebo|Placebo Topical Gel
45499726|NCT02507791|Other|Fitbit Charge HR plus weekly phone calls to review physical activity data|Patients during weekly Healthy Kids, Healthy Weight classes will also upload their Fitbit data, which will be remotely accessed by the study team and weekly phone calls will be implemented to discuss activity
45499727|NCT01382199|Drug|Lactoferrin|
45554646|NCT03192644|Drug|epidoxorubicin and cisplatin and lipiodol|epidoxorubicin and cisplatin and lipiodol
45554647|NCT03192644|Drug|mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|oxaliplatin, calcium folinate, and 5-FU
45554648|NCT03110055|Drug|Grazoprevir/Elbasvir|anti-viral treatment for HCV
45554649|NCT03110055|Other|Medical records|Medical records of patients who underwent Transarterial Chemoembolization only, in the past.
45848226|NCT03334734|Drug|PBTZ169|Once a day for 14 days
45848227|NCT03334734|Drug|Isoniazid|Once a day for 14 days
45848228|NCT03334812|Biological|LNA043|LNA043 Single dose
45848229|NCT03334812|Biological|placebo to LNA043|placebo to LNA043 single dose
45848230|NCT03336450|Drug|SHP615|SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
45848231|NCT03336450|Drug|MHOS/SHP615|MHOS/SHP615
46056109|NCT02740803|Other|sodium monofluorophosphate toothpaste 1,450 ppmF|
45384050|NCT04846946|Behavioral|Hey, Friend|"Intervention in development. However, we will use intervention mapping and the designing for dissemination approach, informed by self-reported qualitative data, to develop the Hey, Friend modules. The mHealth intervention will include three modules that include multiple sub-topics (e.g., What is HIV?; How do I protect myself from HIV?; What is PrEP?, etc.), deliver culturally appropriate counseling content in community settings, juvenile court system, clinics, and schools; will include Motivational Interviewing components that are effective in evoking behavior change while being acceptable to adolescents and parents, and will include ongoing support through a text reminder to maximize the likelihood of initiating HIV prevention through testing and PrEP."
45384051|NCT00573131|Drug|OncoGel (Paclitaxel gel)|6.3 mg/mL tumor volume, injected into the esophagus during endoscopy, once, before starting chemoradiotherapy
45384052|NCT00573131|Drug|cisplatin|75 mg/m2 IV (in the vein) once on Day 1 and Day 29
45384053|NCT00573131|Drug|5-FU|1000 mg/m2/day, IV (in the vein) for 4 days (96 hours) for two cycles starting on Day 1 and Day 29
45384054|NCT00573131|Radiation|radiation therapy|50.4 Gy, given in 28 treatments, once per day for 5 1/2 weeks
45384055|NCT00573131|Procedure|esophageal resection|Removal of esophagus after completion of chemotherapy and radiation therapy
45384056|NCT01565018|Drug|Rotigotine PR 2.1.4|Treatment B: Rotigotine transdermal patch (2 mg/24 h [10 cm^2]). Reference; drug product PR 2.1.4. Single application of 1 patch for 24 hours.
45384057|NCT01565018|Drug|Rotigotine PR 2.2.1|Treatment A: Rotigotine transdermal patch (2 mg/24 h [10 cm^2]). Test; drug product PR 2.2.1. Single application of 1 patch for 24 hours.
45384058|NCT01565096|Drug|Metformin|Metformin 1000 mg BID
45384059|NCT01565096|Drug|Metformin|Metformin 1000 mg BID
45384060|NCT01565096|Drug|Vildagliptin|Vildagliptin 50 mg twice daily
45384061|NCT01565096|Drug|Glimepiride|Glimepiride at individual dose
45384062|NCT00887393|Other|low carbohydrate diet|1000 to 1200 kcalorie low carbohydrate diet (< 15% of total kcaloric intake)
45554650|NCT03110055|Procedure|Transarterial Chemoembolization|A minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply. Small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways.
45695121|NCT01724164|Behavioral|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
45695122|NCT01724164|Behavioral|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
45695123|NCT01724242|Drug|Vaginal DHEA|
46056110|NCT02740803|Other|stannous fluoride combined with sodium fluoride toothpaste 1,450 ppmF|
46056111|NCT02740803|Other|sodium fluoride combined sodium monofluorophosphate toothpaste 1,450 ppmF|
45384063|NCT00887393|Other|low-fat diet|1000 to 1200 kcalorie low-fat diet (30% fat, 60% carbohydrates of total kcaloric intake)
45384064|NCT00889499|Drug|Tropisetron 2 mg|Antagonist of the 5HT3 receptor.
45384065|NCT00889499|Drug|Tropisetron 5mg|Antagonist of the 5HT3 receptor.
45384066|NCT00889499|Drug|Placebo|NHCL 0,9%
45384067|NCT00889655|Drug|Golytely (polyethylene glycol)|4 L of golytely, in split dosing. If the patient has a morning colonoscopy, they will take 2 L of golytely over 2 hours the morning prior to their procedure and repeat this at 6 pm the night prior to their procedure.
45384068|NCT00889655|Drug|MiraLax (polyethylene glycol 3350)|238 gm of MiraLax mixed in 64 oz of Gatorade, to be consumed in split dosing the day prior to scheduled colonoscopy.
45384069|NCT05002946|Drug|SP-104|single oral dose
45554651|NCT02657954|Behavioral|CCT|10-week Compensatory Cognitive Training
45554652|NCT02657954|Behavioral|HCE|10-week Holistic Cognitive Education
45695124|NCT01724242|Drug|Placebo|
45384070|NCT05002946|Drug|Naltrexone Hydrochloride 50Mg Oral Tablet|single oral dose
45384071|NCT04641338|Drug|Fixed dose combination Dipyrone and Codeine|Fixed dose combination: dipyrone 1000 mg + codeine 30 mg every 6 hours if necessary.
45384072|NCT04641338|Drug|Dipyrone|use of 1000 mg dipyrone every 6 hours if necessary.
45384073|NCT04641338|Drug|Codeine|30 mg codeine every 6 hours if necessary.
45384074|NCT04635098|Drug|dexmedetomidine|All participants will be randomly assigned to receive either dexmedetomidine or saline
45384075|NCT04635098|Drug|saline|All participants will be randomly assigned to receive either dexmedetomidine or saline
45384076|NCT00521144|Drug|obatoclax mesylate|Given IV
45384077|NCT00521144|Drug|topotecan hydrochloride|Given IV
45384078|NCT00521144|Other|laboratory biomarker analysis|Correlative studies
45384079|NCT00520676|Drug|pemetrexed|500 mg/m^2, IV, q 21 days x 6 cycles maximum
45384080|NCT00520676|Drug|docetaxel|75 mg/m^2, IV, q 21 days x 6 cycles maximum
45384081|NCT00520676|Drug|carboplatin|AUC 5 mg*min/mL, IV, q 21 days x 6 cycles maximum
45384082|NCT03998852|Drug|Positron Emission Tomography (PET) with [18F]-FDOPA|Positron Emission Tomography (PET) with [18F]-FDOPA
46056112|NCT02740803|Other|Amine fluoride toothpaste 1,400 ppmF|
46056113|NCT02740803|Other|Non-fluoridated toothpaste 0 ppmF|
46056114|NCT02695017|Device|Iso inertial|
46056115|NCT02695017|Device|Conventional machine|
46056116|NCT02744859|Other|Label Condition|Labels will be presented in front of drinks. We will vary the messaging presented to the consumer.
46059064|NCT04079101|Drug|BIIB104|Administered as specified in the treatment arm.
45499728|NCT01337869|Procedure|Bascom Cleft Lift|Patients are positioned prone. The skin incision is drawn on the natal cleft, marking out the area of skin to be excised. The skin from this side of the natal cleft is then elevated. The skin on the opposite side of the cleft then is undermined to a distance required to allow primary closure of the defect away from the midline without tension. The elevated skin island is excised. The sinuses remaining in the deeper tissues are curetted thoroughly. Hemostasis is maintained. A 12F low-suction drain is sited and fat of the natal cleft then is approximated by using an absorbable suture. The wound is closed with a 3-0 polypropylene suture.The drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
45384083|NCT03998852|Drug|Positron Emission Tomography (PET) with [18F]-FEOBV|Positron Emission Tomography (PET) with [18F]-FEOBV
45384084|NCT03998852|Device|Magnetic Resonnance Imaging (MRI)|MRI protocol will be performed on the same day that the [18F]-FEOBV PET imaging, using a 3T scanner (Philips Medical System). Different types of images will be acquired.
45695125|NCT01724320|Drug|OTX008|OTX008 given daily without interruption, subcutaneously. Starting dose: 65 mg/day
46056117|NCT02740647|Drug|Amoxicillin Clavulanate|getting intra-venous1GR Amoxicillin Clavulanate 3 times a day for 5 days post surgery
45384085|NCT03998852|Other|Neuropsychological evaluation|Neuropsychological evaluation will be performed, consisting in an assessment of apathy by actigraphy (social or physical activities will be recorded during seven days) and a complementary assessment of apathy using the Lille Apathy Rating Scale (LARS)
46056118|NCT02740647|Drug|Placebo|50 ml of 0.9% sodium chloride three times a day
45695126|NCT01837030|Dietary Supplement|Ferrous sulfate|Ferrous sulfate 325mg by mouth twice daily for the duration of the 12 month follow up period
45695127|NCT01837030|Device|Capsule Endoscopy|GIVEN capsule
45695128|NCT01837108|Drug|Eplerenone|2 tabs of eplerenone 25 mg will be over-encapsulated and a fully mimicking placebo will be provided by the department of clinical pharmacy of the Radboud University Medical Centre Nijmegen
45695129|NCT01837108|Drug|Placebo|
45695130|NCT01727596|Other|taping|Briefly, the patella was manually displaced medially, and maintained in the position by Tex Tape (Kinesio Holding Corporation, Albuquerque, NM)
45695131|NCT01724398|Other|Conventional plus UC-MSC treatment|Received conventional treatment and umbilical cord mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×105/Kg, once a week, 4 times).
45848232|NCT03338556|Drug|PrEP-001|
46056119|NCT02744781|Device|Lumbar disc degeneration; LDD|All MR images, taken at 5 lumbar intervertebral disc levels from the first lumbar (L1) vertebra to the first sacral vertebra (S1), were independently evaluated by 2 experienced orthopedic specialists in a random order using a grading system for LDD assessment. Using a comprehensive grading system for LDD, discs were classified into 5 grades, as described by Pfirrman et al. This system uses characteristics of disc structure, distinction between the nucleus and annulus, MRI signal intensity, and intervertebral disc height for grading, and has been accepted as a standardized and reliable evaluation tool for assessment of MRI disc morphology.
46056120|NCT02740725|Other|Patching Therapy|Occlusion of a dominant eye with better best corrected visual acuity
46056121|NCT02740725|Device|Interactive Binocular Treatment System|Dissociation of two eyes with more foveal stimulation to the amblyopic eye
45384086|NCT04063748|Behavioral|Audiological rehabilitation|Experimental: tablet-based take-home auditory-cognitive training, which consists of phoneme tasks, words in quiet and in different types of noise
45384087|NCT04063748|Behavioral|Placebo Rehabilitation|CI-users: Placebo, tablet-based take-home psychophysical tasks, reading (non auditory)
45384088|NCT04063748|Behavioral|Passive Control|No intervention in the passive control group for HA-users.
45384089|NCT00610649|Drug|MK-8777|Orally administered capsules containing either 50 mg or 100 mg MK-8777.
45384090|NCT00610649|Drug|Placebo|Orally administered matching placebo capsules.
45384091|NCT02542085|Procedure|Laparoscopic repair|operative method
45384092|NCT02542085|Procedure|Hybrid repair|operative method
45384093|NCT00885053|Dietary Supplement|fish oil|Capsules. Approximately 1000 mg n-3 PUFA daily. One day + 6 weeks
45384094|NCT00885053|Dietary Supplement|olive oil|Capsules. Approximately 1 g olive oil daily. One day + 6 weeks
45695132|NCT01724398|Other|Conventional plus PE treatment|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times).
45695133|NCT01724398|Other|Conventional plus UC-MSC and PE therapy|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times). Meantime taken i.v umbilical cord mesenchymal stem cells transplantation slowly for 30minutes (1×105/Kg, once a week, 4 times), the first two times is taken after plasma exchange.
45384095|NCT00889733|Drug|Intraperitoneal (IP) Cisplatin|For patients who have had neoadjuvant chemotherapy followed by optimal debulking surgery they go on to receive combined IP Cisplatin and IV Paclitaxel.
45384096|NCT00887627|Drug|conivaptan hydrochloride|intravenous
45384097|NCT04037579|Other|Survey|Non-randomised survey
45384098|NCT00889811|Procedure|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min lower limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis )
45384099|NCT00887705|Behavioral|ADL training|The control group gets the standard rehabilitation programme which includes one hour ADL- training. The experimental group also gets the standard rehabilitation program, but instead of one hour they get an additional five hours ADL- training.
45384100|NCT00890123|Dietary Supplement|Omegaven-IV FO|Will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
45384101|NCT00885287|Drug|Artemether-lumefantrine (AL)|Standard treatment-dose of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria according to national treatment guidelines
45384102|NCT00923429|Procedure|Stay-active care|No other treatment than the stay-active care
45384103|NCT00923429|Procedure|Stay-active care+stretching|Stay-active care and muscle stretching at home and during physiotherapist appointments
45384104|NCT00923429|Procedure|Stay-active+stretching+manual therapy|Manual therapy in addition to stay-active care and stretching given during GP or physiotherapist appointments and matching home exercises
45384105|NCT00923429|Procedure|Stay-active+stretching+manual therapy+steroid injections|Manual therapy including steroid injection when indicated in addition to stay-active care and stretching during GP appointments (injections) and during GP or physiotherapist appointments (remaining treatment modalities)
45384106|NCT02542007|Device|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
45384107|NCT02542007|Device|sirolimus-eluting stent system|
45695134|NCT01724398|Other|Conventional treatment|Received conventional treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
45695135|NCT01724476|Drug|folate with B12|
45695136|NCT01724476|Drug|placebo|
45695137|NCT01724554|Drug|Intravitreal Aflibercept Injection|Aflibercept administered to the eye intravitreally either every month or every other month.
45848233|NCT03338556|Other|Placebo|
46056122|NCT05628909|Procedure|PPV with SO tamponade|Patients randomized into silicone oil group were received pars plana vitrectomy surgery with silicone oil tamponade and without internal limiting membrane peeling. And silicone oil tamponade was removed at least 12 months after the primary surgery with completely resolved of foveoschisis.
46056123|NCT05628909|Procedure|PPV with fovea-sparing ILMP and gas tamponade|Patients randomized into gas group 1 were received pars plana vitrectomy surgery with fovea-sparing internal limiting membrane peeling and gas tamponade.
46056124|NCT05628909|Procedure|PPV with gas tamponade|Patients randomized into gas group 2 were received pars plana vitrectomy surgery without internal limiting membrane peeling and gas tamponade.
45384108|NCT00887861|Drug|Investigational new drug, company code: BGG492|
45384109|NCT00887861|Drug|Placebo|
45384110|NCT04037267|Procedure|endoscopic intraventricular evacuation surgery|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the endoscopic intraventricular evacuation surgery group.
45384111|NCT00892541|Drug|ER OROS paliperidone|
45384112|NCT02541617|Procedure|Programming by community Neurologist|Deep Brain stimulator with be programmed by a community Neurologist
45384113|NCT02541617|Procedure|Standard of care|Deep Brain Stimulator will be programmed with at the implanting movement disorders center
45384114|NCT00890279|Drug|Cilnidipine|Cilnidipine up to 20 mg
45384115|NCT00890279|Drug|Imidapril|Imidapril up to 10 mg per day
45384116|NCT04037735|Device|ATTUNE S+ Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with ATTUNE S+ Knee Prosthesis by DePuy
45848234|NCT03606408|Drug|osilodrostat|osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint.
45848235|NCT03256968|Drug|Ataluren|ataluren
46056125|NCT05629455|Device|CareSuperb COVID-19 Antigen Home Test Kit|At home COVID-19 antigen test kit
46056126|NCT00586339|Biological|Cervarix|Intramuscular injection, 3 doses
46056127|NCT00586339|Biological|Placebo Control|Intramuscular injection, 3 doses
46059065|NCT04079101|Drug|Placebo|Administered as specified in the treatment arm.
45384117|NCT04037735|Device|PFC Sigma Knee Prosthesis by DePuy|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
45499729|NCT01337869|Procedure|Limberg Flap|Patients are positioned prone. The area to be excised is mapped-out, and the flap is designed. The area to be excised is mapped on the skin in a rhomboid form. The skin incision is deepened to the presacral fascia. Tissue is removed en bloc. After removing the rhombic excision, the Limberg fascia cutaneous flap is prepared through the right or left-side gluteus maximus fascia. The flap is fully mobilized and transposed medially to fulfill the rhombic defect without any tension. Hemosthasis is accomplished. A 12F low-suction drain is sited and wound is closed in two layers: the subcutaneous tissue with absorbable suture and the skin with 3/0 polypropylene. drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
45499730|NCT01381497|Drug|Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap)|This is an observational study and patients were prescribed this medication before study start
45499731|NCT01381497|Drug|Triptan monotherapy|This is an observational study and patients reported a previous triptan monotherapy prescription. Drugs of interested included naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, zolmitriptan
45499732|NCT04221997|Drug|sertraline|Sertraline is an antidepressant in a group of drugs called selective serotonin reuptake inhibitors (SSRIs)
45499733|NCT01384149|Device|external slt|Nd:YAG LASER SLT perilimbal above trabecular meshwork 180 degrees ,100 lasering dots
45695138|NCT01724632|Behavioral|Lifestyle Counseling|Participants receive instructions for making healthy changes to their diet and physical activity habits.
45695139|NCT01727752|Procedure|Decompression|
46059066|NCT04606771|Drug|Osimertinib + Savolitinib|"Osimertinib 80 mg oral QD~Savolitinib 300mg oral QD"
46059067|NCT04606771|Drug|Savolitinib + Placebo|"Savolitinib 300mg Oral QD~Placebo to Osimertinib 80mg oral QD"
45384118|NCT00892619|Procedure|using ILM forceps alone|Using ILM forceps to initiate and complete ILM peel
45384119|NCT00892619|Procedure|Breaking and peeling with end-grasping forceps|Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
45384120|NCT00608543|Drug|Aripiprazole|varied dose (5, 10, 15 mg qd) for 6 wks
45384121|NCT00890435|Other|questionnaire administration|
45384122|NCT00890435|Procedure|psychosocial assessment and care|
45695140|NCT03835936|Other|High frequency compression of the chest wall group|The protocol in the high frequency compression of the chest wall group device consists of the Smart Vest® application, with a fixed frequency of 13 Hz and a time of 15 minutes. The selected mode will be the normal (fixed parameters) and the pressure of 4 units (12 cm H2O). The patient remains seated on his parents, and with a cotton garment between the vest and the skin of the patient to prevent skin lesions.
45695141|NCT03835936|Other|Manual maneuvers physiotherapy group|20 minutes of manual maneuvers physiotherapy based on prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of spontaneous expiration and continues to the residual volume. The physiotherapist through the cough provoked or stimulation of the trachea gets expectoration of sputum, to be able to assess its weight.
45695142|NCT01837342|Procedure|Surgical reserction|
45695143|NCT01837342|Other|Radiological percutaneous drainage and washing drainage|
45695144|NCT03835624|Diagnostic Test|interleukin 33|serum and synovial fluid samples will be obtained from patients and serum samples from controls to measure interleukin 33 and its relative mRNA expression in peripheral blood mononuclear cells by PCR
46059068|NCT04079023|Procedure|Sleeve Gastrectomy|Subtotal vertical gastrectomy
46059069|NCT04504123|Drug|Doxycycline Hyclate|Doxycycline Hyclate capsules, USP 50 mg
46059070|NCT04504123|Drug|Placebo|Placebo
45384123|NCT02541383|Drug|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)|Part 1: 4 Cycles of Bortezomib,Thalidomide and Dexamethasone induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone consolidation
45384124|NCT02541383|Drug|Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab|Part 1: 4 Cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16mg/kg induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16 mg/kg consolidation
46059071|NCT04078633|Behavioral|Hand hygiene interventions|Interventions are commonly used physical props for handwashing and commonly used hygiene promotion activities.
45384125|NCT02541383|Drug|Daratumumab|Daratumumab 16mg/kg every 8 weeks for 2 years
45384126|NCT04036643|Radiation|PET-MRI|Hybrid PET / MRI machine for simultaneous acquisition of functional and molecular information of different natures coupled with the high anatomical resolution of MRI.
45384127|NCT04036487|Drug|Desflurane|Anesthesia is maintained by desflurane in an oxygen air mixture of 60/40%. If inadequate depth of anesthesia is observed, the end-expiratory concentration of desflurane would be increased.
45499734|NCT01384149|Device|standard slt|Nd:YAG LASER SLT gonioscopic laser treatment
45499735|NCT04451317|Other|Questionnaire, phone call|phone call and 3 questionnaires on a digital platform
45499736|NCT01381419|Drug|GSK1144814|Single dose.
45499737|NCT01381419|Drug|GSK1144814|Single dose which may be split in up to three divided doses given 2 to 3 hours apart.
45499738|NCT01381419|Drug|GSK1144814|Single dose that may be split in up to three divided doses given 2 to 3 hours apart.
45384128|NCT04036487|Drug|Propofol|Anesthesia is maintained by propofol 100-200 μg/kg/min. If inadequate depth of anesthesia is observed, the rate of propofol infusion would be increased.
45384129|NCT04036565|Behavioral|sunlight therapy|Exposed to sunlight for at least 30 minutes per day, at least 14 days of exposure duration of 4 weeks.
45384130|NCT02541149|Procedure|blood sample|
45384131|NCT05278793|Drug|Ferrous fumarate|Ferrous fumarate 200mg oral
45384132|NCT00892853|Procedure|CT of the bones|A CT scan will be performed on one arm and one leg for the purpose of acquiring images for this research study.
45384133|NCT00890669|Other|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):~treadmill training with additional body load (A1),~control condition (conventional physical therapy group) (B). and~treadmill training with additional body load again (A2).~Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
45384134|NCT00892931|Drug|Azixa|3.3 mg/m2 of Azixa administered by intravenous infusion over 2 hours once weekly for 3 consecutive weeks every 4 weeks (1 cycle = 4 weeks)
45384135|NCT05278325|Other|Telephone intervention|Two planned phone call between clinical controls
45384136|NCT04037657|Drug|HSK3486|HSK3486 was administered as a single dose over a 1 minute infusion period. There were five cohorts of six subjects per cohort (5 HSK3486:1 propofol).
45384137|NCT04037657|Drug|Propofol|Propofol, at a dose of 2.5 mg/kg, was administered as a 1 minute infusion at a constant rate via infusion pump.
45384138|NCT04037345|Biological|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10^6 cells/2mL)
45384139|NCT04037345|Biological|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10^7 cells/2mL)
45384140|NCT04037345|Biological|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10^7 cells/2mL)
45384141|NCT00893009|Drug|Theophylline|100 mg twice a day
45384142|NCT00893009|Drug|Placebo|Placebo
45384143|NCT00888095|Procedure|deep brain stimulation|electrode implantation in either STN or cZI
45384144|NCT00890747|Drug|sunitinib malate|Given PO
45384145|NCT00890747|Other|pharmacological study|Correlative studies
45384146|NCT00890747|Other|laboratory biomarker analysis|Correlative studies
45384147|NCT00888251|Other|Comprehensive weight management program|Full meal replacement, behaviorial modification, medical monitoring, exercise.
45384148|NCT00893087|Device|Triggering mode of the ventilator|10 min of each triggering mode
45499739|NCT03635827|Combination Product|NBTX-001 Xenon Inhaler|The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.
45499740|NCT03635827|Combination Product|Placebo|The placebo medical gas consists of 30% oxygen and 70% nitrogen.The dose of placebo medical gas is 10 L by volume.
46059072|NCT04465669|Device|Orsiro stents|"Percutaneous coronary intervention with implantation of either:~a Orsiro® biolimus a9 eluting coronary stent"
46059073|NCT04465669|Device|Resolute Integrity® stents|"Percutaneous coronary intervention with implantation of either:~a Resolute Integrity® zotarolimus eluting coronary stent"
45499743|NCT04530201|Device|Colli-Pee Small Volumes (10 mL) device|Women will self-collect two first-void urine samples at home the day prior to colposcopy using the new generation Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube will be prefilled with a non-toxic nucleic acid preservative including an internal process control.
46059074|NCT02584543|Biological|HEV vaccine|
45384149|NCT00893087|Device|Triggering method of the ventilator|Flow triggering
45384150|NCT00893087|Device|Triggering method of the ventilator|Pressure triggering
45384151|NCT00893087|Device|Triggering method of the ventilator|NAVA triggering
45384152|NCT02541305|Other|propioceptive program|The training program has 6 specific proprioceptive exercises, each five minutes long, which will conducted in static and dynamic positions for a period of 30 minutes. Each exercise session will include 55 minutes (15 minutes of warm-up with slow walk, mobility and stretching exercise, followed by 30 minutes of a propioceptive exercises program, and finishing with 10 minutes of cool down through stretching and relaxation exercises)
45384153|NCT02541305|Other|No propioceptive program|The control group continued to perform their daily activities without changing any habit. Geriatric revitalization program without proprioceptive exercises.
45384154|NCT04017845|Diagnostic Test|FIT|Screenees were supplied with two fecal collection devices and asked to collect two specimens from two consecutive Different Bowel Movement Samples (DBMS) or, in case of infrequent bowel movements, from the Same Bowel Movement Sample (SBMS).Instruction stressed that after collection the device must be stored in refrigerator and transported in an iced pack within no more than 48h from sampling. After checking for sampling appropriateness, the received samples were analyzed by the FOB Gold/SENTiFOB method (Sentinel Diagnostics SpA, Milan, Italy), according to the previously validated procedural platform
45426094|NCT00640133|Device|Sham DBS|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will mimic adjusting the settings of the electrical stimulation. After a post-operative rest, participants will receive DBS treatment after a delay of several months. Afterwards, all participants will receive open-label long-term DBS.
45499744|NCT01382121|Behavioral|Peer Modeling|Participants watch a video of an adolescent completing the fitness test and explaining coping mechanisms to preform the test well.
45499745|NCT01382121|Behavioral|Control|watching a video unrelated to the fitness test and self-efficacy
46059075|NCT02584543|Biological|HBV vaccine|
46059076|NCT04078165|Device|Zero-Gravity|Free-floating, suspended personal radiation protection
46059077|NCT04078165|Device|Conventional radiation protection|Standard lead shields and aprons
46059078|NCT02583763|Other|Echocardiography|During the ultrasound examinations standardized, moving sequences of the heart will be saved. Analyzes are performed off-line and analyzed by vector velocity imaging software.
46059079|NCT02583763|Procedure|Blood sample|The investigators will take a blood sample from the umbilical cord at birth and again at 7 years of age.
45384155|NCT04017845|Procedure|Precolonoscopy cleansing regimen|Laxative stimulant two days prior to the cleansing regimen involves the intake of one 10 mg tablet of bisacodyl (Dulcolax, Sanofi,UK) at 18:00 for two consecutive nights.The evening before colonoscopy cleansing started with 2 doses (at 16:00 and 20:00) of one sachet Sodium picosulphate preparations (PICOPREP, Ferring Pharmaceutical Co., Ltd., Zhongshan, China), dissolved in150 mL of cold water, followed with five 240 mL portions of clear liquids within 3 h. The third dose is taken in the morning about 5 h prior to colonoscopy, followed with at least three 240 mL portions of clear liquids no later than 2 h before colonoscopy.
45384156|NCT04017845|Procedure|Conventional Colonoscopy|With the colonoscopists completely blinded regarding the FIT results, conventional colonoscopy examinations were conducted in the Endoscopy Unit of Al-Kindy Polyclinic. According to the five levels of competency proposed by the European guidelines, this unit is assigned as level 2, with the possibility of removing polypoid and sessile lesions <25 mm, providing there is good access. For flat lesions, larger sessile and polypoid lesions, and smaller lesions with more difficult access, the lesions were documented appropriately with the patients referred to higher competent units in order to be safely and expertly removed.
45384157|NCT04017845|Diagnostic Test|Histopathological examinations of screen-detected lesions|Adenomas were classified according to the modified revised Vienna classification for the European Guidelines. Advanced adenoma was defined as the presence of one of the following features: >10 mm diameter, tubulovillous or villous structure, and high-grade neoplasia. Polypoid adenocarcinomas were reported according to the TNM classification, while colorectal cancer associated with flat and/or depressed lesions were reported as non-polypoid lesions, and further classified by the Paris classification. Pathologic results of hyperplastic polyps, sessile serrated lesions or post inflammatory polyps were considered normal findings.
45384158|NCT04017845|Drug|Tribenoside 400 mg + lidocaine 40 mg suppositories|Treatment of hemorrhoids was initiated with tribenoside 400 mg + lidocaine 40 mg suppositories, once daily for up to 2 weeks.
45384159|NCT04017845|Drug|Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment|Treatment of anal fissure was initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment applied every 12 hours, for up to six weeks.
45384160|NCT00893165|Behavioral|moderate physical activity|bed mounted cycles for physical activity for 30 min during each hemodialysis session
45384161|NCT02541773|Device|Cardiac Resynchronisation Therapy|Routine implantation of CRT - part of standard of care
45384162|NCT00891137|Biological|human myeloid progenitor cells|Single intravenous injection/infusion
45384163|NCT00520130|Biological|Rituximab|Rituximab: 375 mg/m(2) intravenous (IV), day 1 for patients with cluster of differentiation 20 (CD20)-positive disease.
45384164|NCT00520130|Drug|Cyclosporine|Cyclosporine: IV over 2 hours or orally every 12 hours on days -1 to 100, followed by a taper if graft versus host disease (GVHD) does not develop.
45384165|NCT00520130|Drug|Allogenic stem cell transplant (ASCT)|Allogenic stem cell transplant
45384166|NCT00520130|Drug|Conditioning Chemotherapy|"Fludarabine:30 mg/m(2) per day IV infusion over 30 minutes, daily. On days -6, -5, -4, and -3.~Cyclophosphamide:1200 mg/m(2) per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m(2) per day IV infusion, Daily on days 6, -5,-4, and -3"
45384167|NCT00520130|Drug|TMS|Tacrolimus: starting day -3 before transplant, given initially at 0.02 mg/kg/day CIV. Continue IV and then switch to an equivalent oral dose (when patient taking po) titrated for a goal level of 5 to 10 ng/ml; Sirolimus: given as an initial loading dose of 12 mg p.o. on day -3 pre-transplant, 4 mg starting day -2 pre-transplant and titrated for levels 3-12 ng/ml; Methotrexate 5 mg/m2 IV on days +1, +3, +6, and +11 post-transplant. Tacrolimus and sirolimus will be tapered at day +63, day +119 and day +180 post-transplant as tolerated.
45384168|NCT00520130|Drug|FLAG|Fludarabine:25 mg/m(2) per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg/m(2) IV over 4 hours,on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg/kg per day subcutaneous (SC) beginning 24 hours PRIOR to initiation of chemotherapy
45499746|NCT04095403|Other|Tarp Assisted Cooling|Body cooling utilizing a tarp and water
45499747|NCT04095403|Other|passive cooling|Supine rest.
45499748|NCT01332175|Device|Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
45499749|NCT01332175|Device|Placebo-Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
45499750|NCT01332175|Procedure|CPAP|Nightly use of Provent® versus Placebo-Provent® versus CPAP
45499751|NCT03159091|Drug|Rengalin|Oral administration.
45499752|NCT03159091|Drug|Placebo|Oral administration.
45848236|NCT03339570|Procedure|Orthopedic treatment for a proximal humeral fracture|Orthopedic treatment consisting in inmobilization of the arm in a sling for the first three weeks, followed by physical therapy.
45848237|NCT03340350|Drug|Minocycline|Minocycline capsule
45384169|NCT00520130|Drug|EPOCH-F|Fludarabine:25 mg/m(2) per day IV infusion over 30 minutes, daily on days 1-4 Etoposide :50 mg/m(2) per day continuous IV infusion over 24 hours on days 1-4 Doxorubicin:10 mg/m(2)/day CIV, days 1-4 Vincristine:0.4 mg/m(2) per day continuous IV infusion over 24 hours daily on days 1-4 Cyclophosphamide:750 mg/m(2) IV infusion over 30 minutes on day 5
45384170|NCT00520130|Biological|Alemtuzumab|Alemtuzumab:20 mg/day IV over 8 h on days 8 to 4 pre-transplant.
45384171|NCT05616182|Other|LARS ligament and bone prosthesis replacement was performed|To report the postoperative complications and limb function of patients who underwent LARS ligament and bone prosthesis replacement in Henan Cancer Hospital.
45384172|NCT00519896|Drug|sunitinib malate|Given PO
45384173|NCT03998384|Procedure|retrobulbar injection of autoserum|Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, local autoserum is injected into the retrobulbar space for the neurotrophic purpose.
45384174|NCT03998384|Procedure|retrobulbar injection of placebo|Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, normal saline (NS) is injected into the retrobulbar space as a comparison
45384175|NCT03941600|Behavioral|Community-based Exercise Intervention group (CBE)|The CBEI group will receive 36 (60-90 minute) one-on-one, formally directed exercise sessions by trained staff over 12 weeks. By the end the goal is to have the participants guiding their own regimens. Personalized sessions will be created for each participant based on their fitness goal(s) and preferences. Each session will include vitals, pain assessment, warm-up, stretching, cardiovascular, and strength exercises and cool-down. The participants will be monitored to ensure they are achieving at least 30 minutes of moderate-to-vigorous exercise 3 times a week. Activity monitors will also be worn to capture intensity data. At the end of each session, participants will describe their likes and dislike as well as what they gained and what they suggest for improvement. At the end of each session, the trainer will rate the participant's perceived participation during the session (1-6) using the Pittsburgh Rehabilitation Participation Scale.
45384176|NCT03941600|Behavioral|Exercise Education Control group (EEG)|The EEG group will complete an intervention that consists of a one-on-one, hour-long educational session orienting participants to an online resource center, the National Center on Health, Physical Activity, and Disability (NCHPAD). NCHPAD promotes health and well-being for PwD through resources such as adapted exercise videos, information on accessible fitness equipment, personalized exercise videos tailored to PwD, and an individualized 14-week exercise program. Participants will be given an overview of NCHPAD and asked to identify resources of interest on the website. Each participant will be asked to use resources on NCHPAD to engage in physical activity for 12 weeks. Each participant will receive a weekly phone call to inquire about their physical activity, exercises engaged in, RPE during exercise, and whether any resources were used.
45384177|NCT00527618|Drug|valacyclovir|valacyclovir 1000 mg orally twice daily for 12 weeks.
45384178|NCT00527618|Drug|acyclovir|acyclovir 400 mg orally twice daily for 12 weeks.
45384179|NCT04622072|Drug|XZP-5809-TT1 Tablet|Single tartrate of XZP-5809
45384180|NCT00527072|Biological|infliximab|Open-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
45384181|NCT00526994|Other|screened|Asked 4 questions on current exposure to intimate partner violence; if positive, receives referral information
45384182|NCT00526994|Behavioral|universal education|receives referral information
45384183|NCT04743128|Behavioral|Exercise|The experimental group started an exercise program to achieve 65% to 80% of the maximum heart rate by using a pulsometer that measured the heart rate in order to get to the moderate intensity activity goal. The exercise session was 60 minutes long, three times per week, completing 180 minutes per week of moderate intensity exercise, for 12 weeks in total.
45384184|NCT03833024|Drug|Micronized Purified Flavonoid Fraction|After randomization (1:1 with stratification by centre) patients will receive 1000 mg of oral MPFF (Venixxa, one 500mg tablet BID) for 6 months, in addition to their usual PTS and DVT treatment
45384185|NCT03833024|Drug|Placebo|After randomization (1:1 with stratification by centre) patients will receive an oral placebo (one tablet BID) for 6 months, in addition to their usual PTS and DVT treatment
45384186|NCT00519428|Drug|escitalopram|10mg/d increasing by 10 mg/week to a maximum of 40 mg/d if tolerated and not remitted
45384187|NCT00519428|Drug|bupropion extra long (XL)|150mg/d increasing to 300 mg/d after 1 week and 450 mg/d after 3 weeks, all increases if tolerated and not remitted
45384188|NCT00519428|Drug|escitalopram + bupropion|same dosing schedule as for monotherapy
45384189|NCT00432159|Device|Cervical TDR|Cervical total disc replacement using a DISCOVER Artificial Cervical Disc.
45384190|NCT00432159|Device|ACDF with plate|Anterior cervical discectomy followed by insertion of allograft spacer and placement of an anterior plate.
45384191|NCT00519194|Device|Epicor LP Cardiac Ablation System|Surgical ablation of permanent AF during concomitant open chest and/or open heart surgery
45384192|NCT00519194|Procedure|Surgical ablation of permanent AF|Concomitant AF ablation during mitral valve surgery
45384193|NCT02363660|Biological|GINI|
45384194|NCT00431847|Procedure|Regional Anesthesia|Subject received regional anesthesia to affected limb(s) within 72 hours of traumatic event.
45695145|NCT01727830|Other|Induced Coagulopathy by HES (Tetraspan), Gelatin (Physiogel), Gelatin balanced (Physiogel balanced)|Blood drawn from volunteers
45384195|NCT00431847|Procedure|Standard Pain Management Protocol|Intermittent dosing of analgesics and anxiolytics instituted prior to continuous intravenously dosing which was individually titrated to patient care goals.
45695146|NCT01727908|Other|Endoscopy with staining of the mucosa|Staining of the gastric mucosa with acetic acid and Indigocarmine
45695147|NCT01837420|Drug|VB-201 80mg|
45499753|NCT03196193|Procedure|Open Reduction and Internal Fixation|Fractured bone fragments are reduced and stabilized by intramedullary nail.
45499754|NCT03196193|Device|ZNN CM Asia|Reduced bone fragments are to be stabilized by Zimmer Natural Nail CM Asia System.
45499755|NCT03196193|Device|Anterior Support Screw|Experimental group will receive insertion of ACE 4.5/5.0mm cannulated lag-screw anteriorly to Zimmer Natural Nail CM Asia Lag-screw.
45499756|NCT01337947|Drug|Definity microbubbles|Definity microbubbles are used as a contrast agent to image blood flow in skeletal muscle
45384196|NCT00431067|Drug|BIBW 2992|
45384197|NCT01030107|Behavioral|Increase Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for 1 week.
45384198|NCT01030107|Behavioral|Decrease Sleep|Children are asked to decrease their sleep by approximately 1 1/2 hours/night.
45384199|NCT01030185|Device|NovaShunt's Automated Fluid Shunt implantation|The Automated Fluid Shunt (AFS) Device consists of an implantable sealed housing which contains an internally powered pump with supportive electronic components and circuits, an implantable Peritoneal Catheter, implantable Bladder Catheter and a non-implantable Charger used for wireless recharging an AFS battery and collecting data from the Device.
45384200|NCT01035489|Device|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
45384201|NCT01035489|Device|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
45499757|NCT03540563|Other|Blood draw|Blood will be drawn to assess ctDNA
45384202|NCT01030263|Other|Fluorescence-aided confocal endomicroscopy guided biopsy.|Fluorescence-aided confocal endomicroscopy guided biopsy.
45384203|NCT01030263|Other|Random four-quadrant biopsies.|Random four-quadrant biopsies.
45499758|NCT01338103|Drug|Rituximab|intravenous (IV) Rituximab 1 gramX2, every (q) 2 weeks.
45499759|NCT03369665|Drug|Mavenclad®|Subjects will receive Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
45499760|NCT01315405|Behavioral|Emotional facial expression recognition tests|"20 patients with an Idiopathic Parkinson's disease~+ 20 paired healthy volunteers (on sex, age, and education)~After inclusion, patients are evaluated two times: they are studied without medication (MED OFF) and with medication (STIM ON) in a randomized order. The 2 evaluations should be spaced out 15 days to one month (J0 and J+15d)~Healthy subjects have only one visit J0 (inclusion and emotional facial expression recognition tests are made at the same time)"
45499761|NCT03529877|Biological|allo-APZ2-EB|intravenous infusion of allo-APZ2-EB
45499762|NCT03621761|Behavioral|Telephone-based Cognitive Behavioral Therapy|"Cognitive behavioral therapy (CBT) is a behavioral-based treatment that promotes effective self-management skills, including adaptive thought processes and behaviors (i.e. coping skills). CBT also commonly teaches goal-setting and behavioral activation strategies for engaging in physical, social, and other valued activities in the context of fatigue."
45499763|NCT03621761|Drug|Modafinil|Modafinil is a safe, well-tolerated and effective wake-promoting agent (oral medication) that is FDA-approved for the treatment of fatigue related to sleep disorders. Modafinil is also one of the most commonly used medications for multiple sclerosis related fatigue in clinical practice, with doses ranging from 50 - 400 mg per day, in divided doses (once to twice daily).
45695148|NCT01837420|Drug|VB-201 160mg|
45695149|NCT01837420|Drug|Placebo|
45695150|NCT01727986|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg or 10 mg/kg iv every 4 weeks, 104 weeks
45848238|NCT03340428|Behavioral|Transition Community Adherence Club (TCAC)|A behavioral intervention targeting stigma and care challenges through care delivery, social capital through a group setting, improved job prospects through referrals and training, and substance use through referrals. Participants assigned to this group will meet at least every month in a group of 5-15 members for approximately 2 hours. During the meeting there will be facilitated group discussion, an interactive curriculum including life skills, economic skills, HIV and health, and disclosure and stigma. Individual health screening and distribution of prepackaged medications conclude the session. Individual referrals for specific services (e.g. mental health or substance use management) will be available.
45499764|NCT03221387|Device|Humidified nasal high flow with oxygen|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases.
45499765|NCT04527575|Biological|EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide). The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations spaced 21-28 days apart.
45695151|NCT01724788|Drug|FUROSEMIDE|Pharmaceutical form: Solution Route of administration: Intravenous
45695152|NCT01724788|Drug|FUROSEMIDE (HOE058)|Pharmaceutical form: Tablet Route of administration: Oral
45695153|NCT01837498|Drug|Neostigmine|At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
45695154|NCT01837498|Drug|Sugammadex|At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
45695155|NCT01705574|Drug|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally with food once daily
45499766|NCT04527575|Other|Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)|The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (43 volunteers)
45499767|NCT03318861|Genetic|KITE-585|A single infusion of KITE-585 autologous anti-BCMA CAR T cells
45499768|NCT03318861|Drug|Cyclophosphamide|Administered intravenously
45499769|NCT03318861|Drug|Fludarabine|Administered intravenously
45499770|NCT01381341|Drug|linifanib|QD on Day 1 of Periods 1 and 2
45499771|NCT01384071|Device|Unstable shoes (MBT)|Wearing unstable (MBT) shoes during 6 weeks
45499772|NCT01384071|Device|Sham intervention (Adidas shoes)|Normal stable shoes (Adidas Bigroar2)
45499773|NCT00523107|Drug|PG2|PG2 500 mg / 500 ml normal saline t.i.w. per week
45384204|NCT01035567|Procedure|Hybrid revascularization|First stage: implantation of the internal mammary artery into LAD in MIDCAB/TECAB procedure Second stage: PCI with drug eluting stents in other coronary arteries qualified for revascularization within 36 hours after surgery
45384205|NCT01035567|Procedure|Coronary Artery Bypass Grafting|Coronary artery bypass grafting with sternotomy on or off the pump at discretion of the operator.
45384206|NCT00430989|Other|Nitrous Oxide|General anaesthesia with the inclusion of Nitrous Oxide at 70%
45384207|NCT00430989|Other|No Nitrous Oxide|General anaesthesia with no use of Nitrous Oxide
45499774|NCT00523107|Drug|Placebo|500 ml normal saline t.i.w. per week
45499775|NCT01379391|Drug|Recombinant Human Thrombopoietin (rHTPO)|"Patients received allogeneic myeloablative hematopoietic stem cell transplantation with platelet count lower than 20G/L on +14 days after Allo-HSCT, met the above enrollment criteria and signed the informed consent forms are eligible subjects.~Administration method of rHuTPO: 300U/kg/d by percutaneous injection; Timing: d14 to d28 after Allo-HSCT."
45499776|NCT03183609|Other|Gluten Flour in Protein Shake|15 Grams Gluten Flour BID
45499777|NCT03183609|Other|Rice Flour in Protein Shake|15 Grams Rice Flour BID
45499778|NCT03631251|Drug|Open Placebo|Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
45695156|NCT01705574|Drug|ATV|300 mg capsule administered orally with food once daily
45384208|NCT01035645|Drug|GSK1070806|"The study drug, GSK1070806, is a humanised monoclonal antibody. Antibodies are proteins that are made by white blood cells during an immune reaction. They circulate in the blood and attach to foreign proteins called antigens in order to destroy or neutralise them.~Humanised monoclonal antibodies are a type of protein that is genetically engineered to resemble a human protein (humanised). GSK1070806 is designed to block a specific protein that exists in the body called Interleukin-18. Interleukin-18 works within the immune system, i.e. the body's defence system, which helps protect it from disease, bacteria and viruses. Interleukin-18 activates the immune system to fight infections and may also occasionally cause inflammation."
45384209|NCT00430755|Device|Computer-assisted history|"Methods The intervention was use of an expert system to acquire medical histories by direct interview of patients.~Description of the software program - The program tested in this study consisted of a data acquisition [history-taking] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees."
45499779|NCT05422599|Dietary Supplement|Lemon balm|300mg Lemon balm and Maltoxdextrin capsules Other Name: Melissa Officinalis L.
45499780|NCT05422599|Dietary Supplement|Placebo|300mg Maltodextrin capsules
45848239|NCT03341910|Drug|DFD-03 Lotion, 0.1%|DFD-03 Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
45499781|NCT04152213|Behavioral|Low GI diet|This educational session will cover information on obesity, complications of obesity, the benefit of weight loss, the glycemic index and its associated low GI diet, a food-exchange table including high- to low-GI foods, and self-decision in food choices. The dietary advice will be based on the standard food pyramid for the conventional Chinese diet as promoted by the Hong Kong Department of Health, with an emphasis on the selection of low-GI products. Practical tips will be given such as the selection of low-GI rice and rice products, the impact of cooking methods (including cooking time, cooking conditions, and cooking liquid volume) on rice GI, intervention to reduce the GI of rice, and listing low-GI food options and meal plans.
45499782|NCT03084315|Device|E-Cig Zero Nicotine|E-Cig Zero Nicotine
45499783|NCT03084315|Device|E-Cig 24mg Nicotine|E-Cig 24mg Nicotine
45499784|NCT03187301|Drug|APL-130277|APL-130277 single dose
45499785|NCT03187301|Drug|Placebo|Placebo single dose
45499786|NCT03187301|Drug|Moxifloxacin|moxifloxacin 400mg single dose
45499787|NCT01379313|Procedure|conventional I:E ratio|conventional I:E ratio of 1:2 is applied.
45499788|NCT01379313|Procedure|1:1 ratio|I:E ratio of 1:1 is applied.
45499789|NCT01379313|Procedure|2:1 group|Inverse I:E ratio of 2:1 is applied.
45499790|NCT01379313|Procedure|external PEEP|external positive end-expiratory pressure of 5 cmH2O is applied.
45499791|NCT01381263|Behavioral|Behavioural medicine treatment|The behavioural medicine treatment program will include muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis and age appropriate interventions aimed to address the emotional and behavioural processes of pain.
45499792|NCT01381263|Other|Standard treatment|Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
45554653|NCT02448602|Other|acupuncture|Patients will be treated with Shenmen(HT7), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
45695157|NCT01705574|Drug|RTV|100 mg tablet administered orally with food once daily
45695158|NCT01705574|Drug|FTC/TDF|200/300 mg tablet administered orally with food once daily
45384210|NCT00430755|Procedure|physician taken history|Convential history taking by physicians
45499793|NCT02963285|Other|Nasopharyngeal temperature probe|Nasopharyngeal temperatures will initially be recorded 30 minutes after induction of anesthesia. Nasopharyngeal probes will then be withdrawn at the designated increment for each age group and will be equilibrated for 3 minutes before the temperature is recorded. Thereafter, the nasopharyngeal withdrawal sequence will be repeated.
45499794|NCT01381185|Drug|Aspirin 200mg qd, Clopidogrel 2x75mg qd|According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd. This treatment will be given for 30 days from index event (myocardial infarction)
45499795|NCT01383837|Behavioral|STYLEnS|Multifamily group HIV/STI Prevention Intervention or Single Family Dyad (youth and a parent)
45499796|NCT01383837|Behavioral|Health Promotion|Health Promotion Intervention
45499797|NCT03977571|Procedure|Cytoreductive nephrectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach.
45499798|NCT03977571|Other|Tissue sampling|Tumor biopsies, blood, and stool specimens for translational biomarker research will be sampled at baseline and after 3 or 6 months.
45499799|NCT02946047|Drug|Ixazomib 1 MG|1 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 1 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
45499800|NCT02946047|Drug|Ixazomib 2 MG|2mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 2 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
46059080|NCT02581813|Behavioral|I.D.E.A.L. for Adolescents Study - Higher Dairy|12 weeks diet and exercise intervention characterized by higher dairy consumption (4 servings per day) and exercise 3 times per week
45499801|NCT02946047|Drug|Ixazomib 3 MG|3 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 3 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
45384211|NCT00430755|Other|Computer-assisted history taking|
45499802|NCT02946047|Drug|Ixazomib 4 MG|4 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 4 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
45499803|NCT05422287|Other|Virtual Reality Glasses|Group 1
45499804|NCT05422287|Other|Thermomechanical Stimulation Device|Group 2
45499805|NCT05421897|Drug|Dinutuximab with Chemotherapy|Rapid infusion of dinutuximab in 4 hours or less
45499806|NCT03077919|Drug|Ropivacaine|0.5% ropivacaine
45695159|NCT01705574|Drug|E/C/F/TDF Placebo|Tablet administered orally with food once daily
45695160|NCT01705574|Drug|ATV Placebo|Tablet administered orally with food once daily
45384212|NCT00518882|Drug|liraglutide|1.8 mg once daily for s.c. (under the skin) injection.
46059081|NCT02581813|Behavioral|I.D.E.A.L. for Adolescents Study - Lower Dairy|12 weeks diet and exercise intervention characterized by lower dairy consumption (0-1 serving per day) and exercise 3 times per week
45384213|NCT00518882|Drug|exenatide|10 mcg twice daily for s.c. (under the skin) injection.
45499807|NCT03077919|Drug|Sham treatment|preservative-free normal saline
45499808|NCT01377675|Other|Education|The third year internal medicine residents completed the usual curriculum for COPD and took one pretest and two posttests to validate the questions.
45499809|NCT01380951|Drug|telbivudine|telbivudine 600mg/d 96 weeks
45499810|NCT01377597|Drug|ranibizumab|
45499811|NCT03220217|Drug|Satoreotide trizoxetan 5-20μg|Positron emission tomography (PET) imaging agent
45384214|NCT00518336|Procedure|Blood sampling|Blood sampling at Visit 3, 5 and 7.
45384215|NCT00518336|Procedure|Collection of cervical specimen|Collection of cervical specimen at Visit2, 3, 4, 5, 6 and 7.
45384216|NCT00518336|Biological|Cervarix|Three doses administered intramuscularly at 0, 1 and 6 months.
45384217|NCT04587674|Device|Spinal Cord Stimulation|Lead(s) and Implant Pulse Generator
45384218|NCT00518180|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
45384219|NCT00518180|Biological|Tdap Vaccine|One dose of vaccine administered intramuscularly
45384220|NCT00518180|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
45384221|NCT02352116|Other|Additional face-to-face education|Additional teaching regarding what to expect in terms of postoperative pain, how to properly identify pain in children, and instruction on the proper administration of analgesic medications
45384222|NCT02352116|Other|Standard of care management|Current standard of care at a major U.S. teaching hospital.
45499812|NCT03220217|Drug|Satoreotide trizoxetan 30-45μg|Positron emission tomography (PET) imaging agent
45499813|NCT03204695|Device|Percutaneous LAA Closure|LAA Closure with the WaveCrest LAA Occlusion System (study device)
45499814|NCT03979391|Diagnostic Test|Tear collection and lumbar punction|Tear collection and lumbar punction will be performed in order to detect supernumerary oligoclonal bands
45499815|NCT03192137|Drug|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
45499816|NCT03192137|Other|Vehicle|Vehicle twice daily for 16 days
45499817|NCT03618095|Device|LOTUS Edge Valve System|TAVR with the LOTUS Edge Valve System
45695161|NCT01705574|Drug|RTV Placebo|Capsule administered orally with food once daily
45695162|NCT01705574|Drug|FTC/TDF Placebo|Tablet administered orally with food once daily
45695163|NCT01705574|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally with food once daily
45695164|NCT04378660|Diagnostic Test|Artificial intelligence for polyp detection|Colonoscopy enriched with artificial intelligence tool developed for polyp detection, implemented as a second observer
45695165|NCT01837576|Drug|Calcipotriol plus BDP gel in different doses|Topical , Once daily, 3 weeks
45695166|NCT04378738|Behavioral|survey|all people in the cohort
45848240|NCT03341910|Drug|Tazorac Cream, 0.1%|Tazorac Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
45384223|NCT00525902|Drug|Adalimumab|40 mg delivered every 2 weeks by subcutaneous injection
45384224|NCT00525824|Drug|Rosuvastatin (Crestor)|10mg and 20 mg
45384225|NCT00525824|Drug|Ezetimibe|10 mg
45384226|NCT00525824|Drug|Simvastatin|40mg and 80 mg
45384227|NCT02260778|Behavioral|Learning Collaborative|A learning collaborative is an established technique that uses the model for improvement to bridge the gap between what we know and what we do. Structured learning sessions and collaborative coaching are used to guide small cycles of change called Plan-Do-Study-Act (PDSA) cycles. This quality improvement intervention will help providers adopt treat-to-target practices through the structured learning collaborative.
45384228|NCT00525590|Drug|GLIADEL|Resect the tumor as completely as possible. After repeated irrigation of the decompressed area demonstrates no bleeding, and care is taken not to have any foreign material enter the ventricle, up to 8 GLIADEL wafers should be placed to cover the entire surface area of the resection cavity (if possible). Slight overlapping of wafer edges is permitted. The number of wafers will be determined by the size of the tumor resection cavity. Each GLIADEL wafer contains 7.7 mg of carmustine, resulting in a dose of 61.6 mg when 8 wafers are implanted. The GLIADEL wafer is a round white to yellow disk with flat surfaces.
45384229|NCT00430677|Drug|Corticosteroids (prednisone or prednisolone)|tablets, oral, 0.5-0.8 mg/kg, daily
45384230|NCT00430677|Drug|Abatacept|intravenous solution, injectable, 30 mg/kg, every 28 days
45384231|NCT00430677|Drug|Abatacept|intravenous solution, injectable, 10 mg/kg, every 28 days
45384232|NCT00430677|Drug|Mycophenolate mofetil (MMF)|tablets, oral, 1.5 to 2 g, daily
45384233|NCT00430677|Drug|Abatacept|intravenous solution, injectable, 10 mg/kg, every 28 days
45384234|NCT02631759|Drug|Lévétiracetam|"Levetiracetam will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~A phase of 7 days of levetiracetam 250 mg every 12 hours ( morning and evening)~Then a phase of 7 days of levetiracetam 250 mg every 24 hours (evening)."
45384235|NCT02631759|Drug|Placebo|"Placebo (NaCl 0,9%) will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~A phase of 7 days of placebo 250 mg every 12 hours ( morning and evening)~Then a phase of 7 days of placebo 250 mg every 24 hours (evening)."
45384236|NCT01035801|Drug|IN-105|Prandial Oral Insulin
45384237|NCT01035801|Drug|Insulin Lispro Injection|Insulin Lispro Injection
45384238|NCT00525512|Drug|tiotropium 18 mcg|Oral inhalation once daily of 18mcg tiotropium via handihaler
45384239|NCT00525512|Drug|Placebo|Oral inhalation of once-daily placebo matching tiotropium via handihaler
45384240|NCT03998306|Dietary Supplement|Experimental: Probiotics|"the participants will receive probiotic lozenge before falling asleep for 12 weeks.~the participants will receive dietetic and hygienic instructions"
45384241|NCT03998306|Other|No intervention|No intervention
45384242|NCT04504526|Drug|68Ga-Pentixafor|Intravenous injection of one dose of 74-148 MBq (2-4 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions by PET/CT.
45384243|NCT04501406|Drug|Pioglitazone|An insulin-sensitizer FDA-approved to treat hyperglycemia caused by type 2 diabetes.
45384244|NCT04501406|Other|Placebo|Placebo looks just like pioglitazone and is given in the same way but has no active drug in it.
45384245|NCT00517634|Drug|FP|Fluticasone Propionate 100 mcg BD
45384246|NCT00517634|Drug|SFC|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD
45384247|NCT00517634|Drug|Placebo|Matching Placebo
45499818|NCT04542785|Other|Rate control|Treatment will be provided according to current guidelines and as such the algorithm for treatment will be differentiated based on the status of left ventricular ejection fraction. For participants with reduced left ventricular ejection fraction, beta-blockers (metoprolol and bisoprolol) will be the primary therapy. Secondary therapies may include digoxin or amiodarone. For participants with preserved left ventricular ejection fraction, the primary therapy will be beta-blockers (metoprolol and bisoprolol) or non-dihydropyridine calcium-channel blockers (verapamil) with secondary therapy consisting of digoxin or amiodarone. Pacing therapies, alone or with atrioventricular node ablation, are utilised as indicated in the view of the treating physician.
45499819|NCT03287375|Drug|PIPAC|
45499820|NCT03881059|Other|BMS-986165 Placebo|Participants will receive BMS-986165 matching placebo QD
45384248|NCT02167490|Procedure|Arm 1: sentinel node biopsy|Sentinel node biopsy policy
45384249|NCT03683576|Drug|GB001|film-coated oral tablet
45384250|NCT03683576|Drug|Placebo|film-coated oral tablet
45384251|NCT03863834|Device|InModeRF|InModeRF minimally invasive treatment based on Radiofrequency-assisted lipolysis (RFAL) technology
45384252|NCT03998150|Procedure|Holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser (Asclepion MultiPulse HoPlus 110W and Lumenis pulse 100W and 120W)
45384253|NCT03998150|Procedure|Bipolar plasma kinetic enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using bipolar plasma kinetic energy (KLS Martin Maxium or Covidien Force Triad)
45384254|NCT03656666|Drug|Apremilast|Apremilast oral tablets
45384255|NCT03656666|Drug|Placebo|Placebo oral tablets
45384256|NCT00430521|Biological|Pandemic influenza vaccine (GSK1119711A)-formulation 1|2 or 3 doses, intramuscular injection, at different time points.
45384257|NCT00430521|Biological|Pandemic influenza vaccine (GSK1119711A)-formulation 2|2 or 3 doses, intramuscular injection, at different time points.
45384258|NCT01036035|Drug|Tolterodine|Comparison of different dosages of drug
45384259|NCT01036035|Drug|Pilocarpine|Comparison of different dosages of drug
45384260|NCT01036035|Drug|THVD-201|Comparison of different dosages of drug
45384261|NCT01036035|Drug|THVD-201|Comparison of different dosages of drug
45384262|NCT01036035|Drug|placebo capsule|Comparison of different dosages of drug
45384263|NCT01323699|Behavioral|Cognitive Behavioral Therapy|A modified version of existing Cognitive Behavioral Treatment and Self-management manuals.
45384264|NCT01036659|Drug|ecallantide - Kallikrein inhibitor that blocks the production of bradykinin|subcutaneous dose of 30mg of ecallantide or placebo (three 10 mg SC injections at three different sites ((arms, legs, abdomen). Injections are not to be administered at the attack location.
45384265|NCT01033149|Drug|N-acetylcysteine|N-acetylcysteine, flexible dose 1200-2400mg/day
45384266|NCT00429663|Device|reamed, interlocking intramedullary nail|Standard of care device for femur fracture repair
45384267|NCT00429663|Device|locking periarticular plate|Standard of care device for femur fractures
45384268|NCT00429585|Device|reamed, interlocking intramedullary nail|Standard of care device for tibia fracture repair; Randomized Treatment - Nail
45384269|NCT00429585|Device|locking periarticular plate|Standard of care device for tibia fracture repair; Randomized Treatment - Plate
45384270|NCT00440271|Drug|tipranavir|
45384271|NCT00440271|Drug|ritonavir|
45384272|NCT00440271|Drug|Optimized Background Regimen (OBR)|Patients received between two and four active anti-retroviral medications based on resistance testing results, as background treatment, and remained on these for the duration of the trial.
45384273|NCT00346216|Drug|celecoxib|100 to 200 mg twice daily, taken by mouth
45384274|NCT00346216|Drug|Ibuprofen|ibuprofen 600 mg to 800 mg three times daily, taken by mouth
45384275|NCT00346216|Drug|Naproxen|naproxen 375mg to 500 mg twice daily, taken by mouth
45384276|NCT01030419|Behavioral|Home-based, DVD-delivered physical activity|Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week. Additionally, they will be encouraged to add two days of aerobic activity (e.g. walking) each week.
45384277|NCT01030419|Behavioral|Usual care/Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD afer the completion of the 12-month follow-up testing.
45384278|NCT01325116|Behavioral|Educational Reminder|Personalized letters sent via post to the patient and their family physician at one, five, eight, and eleven months after their angiogram, sent on behalf of the interventional cardiologist. The patient letter provides a review of the role of each of the cardiac medications and urges long-term adherence. The language in the patient letter is simplified to a grade 6 level; this letter was tested for understanding and acceptability amongst a series of Cardiology patients.At the same time, close examination of data from Ontario indicated large stepwise declines in adherence at 30 and 60 days post-STEMI. To address this, patients will be provided an additional postcard type reminder two months post-STEMI.
45384279|NCT01051648|Drug|Intra ocular injection of triamcinolone acetonide|In all patients triamcinolone acetonide was prepared by keeping the bottle vertical to allow sedimentation of crystals thus removing the vehicle. It was then injected into the anterior chamber (2 ml with concentration 20 mg/ml) just prior to anterior vitrectomy. The direction of the tip of the needle was kept away from the corneal endothelium to minimize endothelial toxicity. Triamcinolone was removed as quickly & completely as possible after finishing anterior vitrectomy
45384280|NCT00417963|Device|Carotid Artery Stenting|placement of a bare metal stent at sites of stenosis in the carotid artery
45384281|NCT00429273|Drug|Guanfacine|Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures
45384282|NCT00429273|Drug|Methylphenidate (MPH)|Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.
45384283|NCT00359632|Drug|Zyvox - linezolid|Observation and testing in patients for whom their treating physician has determined linezolid is an appropriate therapy. Eye tests performed for subjects who have received linezolid for at least 6 weeks and matching controls who have received other antibiotics for similar types of infections.
45384284|NCT00359632|Drug|Matched control|Matched controls received an antibiotic other than linezolid for at least 6 weeks prior to baseline visit. The control group had only a baseline visit and there were no post baseline study visits.
45384285|NCT01324960|Drug|Ceplene®, IL-2, Azacitidine|Azacitidine: 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene at 0.5 mg subcutaneous twice daily and human recombinant IL-2 at 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
45384286|NCT01324960|Drug|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
45384287|NCT03989752|Device|Wearable Robotic Exoskeleton for Ambulation|16-week walking program (34 sessions) with an overground walking robotic exoskeleton guided by a certified physical therapist
45384288|NCT00417885|Drug|exemestane|25 mg, oral, daily dosing
45848241|NCT03341910|Drug|DFD-03 Vehicle Lotion 0%|Vehicle Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
45384289|NCT00417885|Drug|sunitinib malate|37.5 mg, oral, continuous dosing, daily
45384290|NCT01056250|Procedure|SILS cholangiography|intraoperative
45384291|NCT03989596|Radiation|Hypofractionated radiotherapy|"Preoperative hypofractionated 10x 3.25 Gy radiotherapy (5 consecutive days in a week, two weeks) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance with cone beam-CT or kV-portal position verification.~Radiotherapy boost 4x 4 Gy within one week in case of unresectability after 6 weeks."
45384292|NCT03989596|Other|Hyperthermia|Deep hyperthermia (Celsius TCS or BSD-2000) according to local protocol combined with radiotherapy, twice a week.
45384293|NCT01036893|Drug|prucalopride|prucalopride 2 mg oral dosing o.d. for 6 days
45384294|NCT01056406|Behavioral|Nutrition Education|Twice monthly interaction with study nutritionist (a registered dietitian) in the form of face-to-face individual nutrition counseling sessions, telephone and electronic follow-ups, option to attend group nutrition and group exercise classes.
45384295|NCT01856439|Drug|ProSavin|Long term follow up of patients who received ProSavin in a previous study
45384296|NCT01051726|Other|Aromatherapy oil|Oil consists of Clary Sage, Peppermint, Lavender and Frankincense with drops of each mixed into a carrier oil.
45384297|NCT01051726|Other|None essential oil|Baby oil
45384298|NCT04488770|Drug|GSK3882347|Capsule of 10-200mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
45384299|NCT04488770|Drug|Placebo|Matching strength placebo capsules will be provided
45384300|NCT00525044|Drug|Ambroxol|
45384301|NCT00525044|Drug|Placebo|
45384302|NCT00355342|Drug|Salmeterol 50 mcg BID|Salmeterol xinafoate 50 mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
45384303|NCT00355342|Drug|Fluticasone Propionate/Salmeterol 250/50 mcg BID|Fluticasone propionate/salmeterol xinafoate combination product 250/50mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
45384304|NCT00355342|Device|DISKUS inhaler|Each participant received study medication via the DISKUS, for one of two possible treatment groups. Each DISKUS contained 60 doses of study medication. Participants were instructed to administer medication BID (one inhalation in the morning and one inhalation in the evening) approximately 12 hours apart for 156-week treatment period.
45384305|NCT03573362|Device|ViziShot FLEX 19G needle|EBUS-TBNA using the ViziShot FLEX 19G needle
45384306|NCT03573362|Device|Vizishot 22G needle (standard)|EBUS-TBNA using the Vizishot 22G needle (standard)
45384307|NCT01051804|Other|Systane Ultra|Systane Ultra 1 to 2 drops per eye at least 4 times daily for 4 weeks
45384308|NCT01051804|Other|Optive lubricant Eye Drops|Optive Lubricant Eye Drops 1 to 2 drops per eye at least 4 times daily for 4 weeks
45384309|NCT01051882|Biological|MSC-NTF cells transplantation (IM)|In early ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia, intramuscularly into patients' clinically unaffected (or only mildly affected) upper arm biceps and triceps muscles according to a pre-designed grid. Intramuscular injections will be by a 26 gauge needle to a 1.5cm depth (ensuring that injection is into muscle and not adipose tissue). The patients will be injected at 24 sites with a total of 24 million cells
45384310|NCT01051882|Biological|MSC-NTF cells transplantation (IT)|In progressive ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia intrathecally(via a standard lumbar puncture)with a total of 60 million cells.
45384311|NCT01573754|Drug|Hydroxychloroquine|100 mg by mouth twice weekly
45384312|NCT01573754|Procedure|Phlebotomy|450 mL every 2 weeks
45384313|NCT03989674|Dietary Supplement|Anthocyanin|25% w/w anthocyanin extract obtained from black rice
45384314|NCT04678232|Behavioral|Positive Processes and Transition to Health (PATH)|See arm/group description for details regarding this intervention
45384315|NCT03986788|Other|Weightlessness|Volunteers will be studied during parabolic flight. Cerebral blood flow will be measured in different part of the brain during weightlessness ans compared to 1g and hypergravity measurements.
45384316|NCT03989830|Drug|second-line chemotherapy|choose appropriate regimen according to efficacy and adverse effects of first-line chemotherapy. q3W regimen, 6 cycles.
45384317|NCT03989830|Drug|Recombinant human endostatin|7.5mg/m2/d，continuous intravenous pumping in 2ml/h for 5 days each cycle. Endostar(d-7) begins one week before chemotherapy(d0), first 5-day-pump(d-7 to d-2, 240ml, 2ml/h). Second 5-day-pump begins two days later (d1 to d5). the rest pumps can be done in the same manner. Three 5-day-pumps can be done during one chemotherapy cycle. Endostar will be pumped 18 weeks during 6 cycles'second-line chemotherapy.
45384318|NCT03989518|Behavioral|Fear acquisition|Day 1. Participants are exposed to two different visual stimuli. One of these stimuli is paired with a mild electric shock (i.e. conditioned stimuli).
45384319|NCT03989518|Behavioral|Imaginal extinction|Day 2 (24 hours after Day 1). Participants are exposed to mental imagery of the stimuli used during fear conditioning. Imagery is prompted through different verbal instructions presented in a pseudo-randomized order. No shocks are delivered. Prior to imaginal extinction, participants receive task specific training.
45426095|NCT00634634|Drug|Sorafenib|sorafenib dose will be given at a daily dose to be determined based upon the phase of study that patient is enrolled The phase II dose of sorafenib will be determined from the phase I portion of the study.
45499821|NCT03881059|Drug|BMS-986165 Dose A|Participants will receive BMS-986165 Dose A QD.
45384320|NCT03989518|Behavioral|Reinstatement|Day 3 (48 h after day1). Participants are exposed to the same stimuli used during fear conditioning (day 1) and imaginal extinction (day 2). Two unsignaled shocks are delivered at the beginning of the experiment, prior to the presentation of the first visual stimulus. No further shocks are delivered. This procedure allows the study of long term effects of imaginal extinction.
45384321|NCT03989284|Behavioral|Community-based depression interventions|We conducted three types of community-based depression interventions such as peer counseling, social engagement, and combination.
45384322|NCT00355264|Drug|Phenoptin|5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels
45384323|NCT01054378|Procedure|M-mode ultrasonography|Evaluation of diaphragmatic movement using M-mode ultrasonography before and after stellate ganglion block with 1% lidocaine
45384324|NCT02533648|Drug|2 capsules of allopurinol 150 mg daily for 3 month|2 capsules of allopurinol 150 mg daily for 3 month
45384325|NCT02533648|Drug|2 capsules of lactose daily for 3 month|2 capsules of lactose daily for 3 month
45384326|NCT01056796|Device|CAR™ 27|Creation of a low colorectal (side or pouch low rectal) compression anastomosis in previously radiated patients
45384327|NCT02533492|Device|vicryl|wound closure with vicryl suture
45384328|NCT02533492|Device|Vicryl plus|wound closure with vicryl plus suture
45384329|NCT01056874|Drug|Digoxin|Oral Digoxin 0.25 mg single dose
45384330|NCT01056874|Drug|Digoxin|Oral Digoxin 0.25 mg single dose on Day 5
45384331|NCT01056874|Drug|Maraviroc|Oral Maraviroc 300 mg twice daily for 6 days
45384332|NCT01056952|Procedure|O2stand|Standard low flow oxygen therapy (O2stand). The patients will receive oxygen delivered through a face mask. The FiO2 will be adjusted in order to obtain a SaO2 > 90%. The FiO2 will be determined by a portable oxygen analyzer (MiniOX I; Mine Safety Appliances Co, Pittsburgh, Pa)
45384333|NCT01056952|Procedure|CPAP|o Continuous positive airway pressure (CPAP). CPAP will be set at 7.5 cmH2O. Airway humidification will be achieved by using a heated humidifier (MR640; Fisher & Paykel, Auckland, NZ). The FiO2 will be adjusted in order to obtain a SaO2 > 90%. A facial mask composed of a transparent mask and a soft inflatable will be used
45384334|NCT01056952|Procedure|Optiflow|High flow oxygen nasal therapy (Optiflow). The flow will be set at 40l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SaO2 > 90%
45384335|NCT00355030|Drug|somatropin|0.05 mg/kg/day
45384336|NCT00355030|Drug|leuprorelin|11.25 mg/3 months
45384337|NCT01057030|Drug|BMS-708163|Capsules, Oral, 125 mg, once daily, 14 days
45384338|NCT01057030|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 14 days
45384339|NCT03991546|Behavioral|Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot|Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
45384340|NCT03986632|Behavioral|Tundra Gifts|Tundra Gifts is a home-focused intervention delivered by community health workers (CHW) that focuses on promoting healthy eating and an active lifestyle among 3-5 year olds through family and community partnerships. Primary caregivers will attend monthly interactive education session, receive a monthly gift basket that includes resources and supplies to support behavior change at home and receive ongoing social support through a Facebook site.
45384341|NCT03989128|Other|Medical Chart Review|Undergo medical chart review
45384342|NCT03989128|Other|Survey Administration|Complete survey
45384343|NCT01057108|Other|FOSTRAP Chewing Gum|20 mg BID
45384344|NCT01057108|Other|FOSTRAP Chewing Gum|40 mg BID
45384345|NCT01057108|Other|FOSTRAP Chewing Gum|20 mg TID
45384346|NCT01057108|Other|FOSTRAP Chewing Gum|20 mg TID
45384347|NCT01057108|Other|Placebo chewing gum|
45384348|NCT01057186|Dietary Supplement|Alfacalcidol; phosphate.|Individual dosage form and dosage depending on phenotype and underlying cause.
45384349|NCT01057186|Drug|Sevelamer|Pills. Individual dosage depending on clinical symptoms/phenotype.
45384350|NCT03986476|Dietary Supplement|Probiotics|5x10^8 colony forming units (CFU) of each probiotic strain, two capsules per day over six weeks
45384351|NCT03986476|Other|Placebo|Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
45384352|NCT01057264|Drug|HAI Abraxane|Starting dose: 120 mg/m^2 by HAI infusion over 24 hours on Day 1 of 21 day cycle
45384353|NCT01057264|Drug|Gemcitabine|Starting dose: 600 mg/m^2 by IV on Days 1 and 8 of 21 day cycle
45384354|NCT01057264|Drug|Bevacizumab|10 mg/kg IV on Day 1 of 21 day cycle
45384355|NCT01057264|Drug|Filgrastim|5 mcg/kg subcutaneously starting at least 24 hours after Day 1 completion of chemotherapy, for 3 days.
45384356|NCT03991312|Drug|itraconazole|Participants will receive an oral solution as described in the arm description.
45384357|NCT03991312|Drug|rifampin|Participants will receive oral capsule(s) as described in the arm description.
45384358|NCT03991312|Drug|mitapivat sulfate|Participants will receive an oral tablet as described in the arm description.
45384359|NCT03988972|Device|diathermy|In women undergoing C.S, is healing power after diathermy equally to healing power after scalpel?
45384360|NCT03988972|Device|scalpel|Incisions made by the scalpel will be done by the traditional method, with proper hemostasis by application of pressure to skin blood vessels and by ligating the subcutaneous bleeders.
45384361|NCT01057342|Drug|carboplatin|AUC 6 i.v. given after paclitaxel as the second treatment on day 1 of each 3-week cycle.
45384362|NCT01057342|Drug|paclitaxel|175 mg/m2 i.v. first treatment on day 1 of each 3-week cycle.
45384363|NCT01057342|Drug|vadimezan|1800 mg/m2 i.v. following the administration of paclitaxel and carboplatin on day 1 of each 3-week cycle
45384364|NCT01054534|Procedure|Placement of interstim lead|Placement of insterstim lead using US image fusion technology
45384365|NCT01057420|Drug|oxygen inhalation|Inhalation of 80% oxygen via face mask
45384366|NCT01054612|Other|Tissue Sectioning via Electro Erosion Process|Focused RF energy can be used to produce consecutive thin sections of fresh tissue for immunohistochemical and nucleic acids analysis by electro-dissociation without thermal damage, ultimately allowing high resolution reconstruction of gene and protein expression patterns of large tissue specimens in 3D.
45384367|NCT01054690|Device|Bactiguard Infection Protection (BIP) Cathter.|
45384368|NCT01054690|Device|Silicone Urinary Catheter|
45384369|NCT01057498|Drug|RNS60|RNS60, 4ml nebulized twice daily for 15 minutes.
45384370|NCT01057498|Drug|RNS60 - single dose|RNS60, single 4 ml dose nebulized for 15 minutes
45384371|NCT03742258|Drug|Cyclophosphamide|Given IV
45384372|NCT03742258|Drug|Doxorubicin Hydrochloride|Given IV
45384373|NCT03742258|Drug|Prednisone|Given PO
45384374|NCT03742258|Biological|Rituximab|Given IV
45384375|NCT03742258|Drug|Spleen Tyrosine Kinase Inhibitor TAK-659|Given PO
45384376|NCT03742258|Drug|Vincristine Sulfate|Given IV
45384377|NCT01057576|Dietary Supplement|An alcoholic extract of Artemisia dracunculus L.|capsule, daily dosing
45384378|NCT01057576|Other|Placebo|capsule, daily dosage
45384379|NCT00354172|Biological|aldesleukin|10 Million units subcutaneous every other day on days -13 (after Natural killer cell graft), -11, -9, -7, -5, -3) If < 45 kilograms (Kg) - interleukin (IL)-2 at 5 MU/m2
45384380|NCT00354172|Biological|filgrastim|All patients will receive filgrastim (same as granulocyte-colony stimulating factor or G-CSF) 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight beginning on day +1 after umbilical cord blood (UCB) infusion. Granulocyte Colony Stimulating Factor (G-CSF) will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days and then discontinued. If the ANC decreases to <1.0 x 10^9/L, G-CSF will be reinstituted.
45384381|NCT00354172|Biological|natural killer cell (NK) therapy|All CD3 depleted cells will be given (less those required for product monitoring). The minimum size of a starting NK cell unit will be 700 million mononuclear cells before processing. NK cells (CD56+) and NK cell precursors (CD34+/CD7-, CD34+/CD7+, CD34-/CD7+) will be monitored and reported but will not serve as lot release.
45384382|NCT00354172|Drug|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna on days-18 and -17 after fludarabine. Cyclophosphamide 60 mg/kg/day intravenously (IV) x 2 days, total dose 120 mg/m2 (days -18 and -17)
45384383|NCT00354172|Drug|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -1 maintaining a level of >200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children <40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
45384384|NCT00354172|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -18 to -16)
45384385|NCT00354172|Drug|methylprednisolone|"This modification will be enacted based on the engraftment stopping rule on all subsequent patients to stop natural killer (NK) cell reaction.~Methylprednisolone bolus 1000 mg intravenously (IV) will be administered day -1 and day 0 (before umbilical cord blood transplant) to suppress natural killer (NK) cell activity before transplant. Starting cyclosporin and mycophenolate mofetil (MMF) will also contribute to suppressing residual NK cell activity."
45384386|NCT00354172|Drug|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -1. Patients~≥ 45 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses. Pediatric patient (<45 kilograms) will receive MMF at the dose of 15 mg/kg. Use intravenous (IV) route between days -1 and +5, then, if tolerated, may change to by mouth (PO) between days +6 and +30.~Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute Graft Versus Host Disease. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count [ANC] > 0.5 x 10^9 /L)."
45384387|NCT00354172|Procedure|Umbilical Cord Blood Transplantation (UCBT)|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
45384388|NCT00354172|Radiation|Total body irradiation (TBI)|"TBI 165 Gray (cGy) will be given twice daily for a total dose of 1320 cGy (days~-16 to -13)."
45384389|NCT03986242|Device|rolling|use non- vibration rolling and the total time is 20 minutes.
45384390|NCT03986242|Device|Vibration rolling|use Vibration rolling the vibration frequency is 28 Hz, and the total time is 20 minutes.
45384391|NCT03986242|Other|static stretching|static stretching and the total time is 20 minutes.
45384392|NCT00345592|Device|Dual (atrial and ventricular) implantable defibrillator|The devices automatically applies therapy (shock) for atrial fibrillation, when atrial fibrillation is confirmed.
45384393|NCT00345592|Device|Dual (atrial and ventricular) implantable defibrillator|In hospital application of anti arrhythmic therapies via the device
45695167|NCT01728142|Device|DANA Brief|The DANA Brief is a newly-developed neurocognitive test administered on a handheld computer that tests simple reaction time, procedural reaction time, code substitution, and spatial processing. The test also includes subtests for depression/distress, PTSD, and insomnia.
45695168|NCT01728142|Other|ANAM|The ANAM is a currently used test by military health care providers in evaluating cognitive performance after concussion.
45695169|NCT01837732|Other|Relational Touch|"Relational touch 15 mn  relational touch, hand touch (neck, face and head)"
45695170|NCT01837732|Other|Relational:|Relational: 10 mn verbal patient's centered exchanges
45695171|NCT04378582|Other|risk factors|This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, and other risk factors such as severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and ventilator parameters on day1 of mechanical ventilation or ICU admission as potentially association with survival
45695172|NCT01728298|Biological|SLITone ULTRA HDM immunotherapy|
45384394|NCT00345592|Device|Dual (atrial and ventricular) implantable defibrillator|Therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment
45384395|NCT01052506|Drug|BIIB033|Single, escalating doses of BIIB033 (8 cohorts IV, 1 cohort SC)
45695173|NCT01737710|Biological|Fluzone® Intradermal Vaccine|A 0.1mL single-dose, in a latex-free, pre-filled microinjection system with an ultra-fine micro-needle. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® Intradermal is approved for use in persons 18 through 64 years of age and will be purchased from Sanofi Pasteur, Inc.
45695174|NCT01737710|Biological|Fluzone® (Intramuscular) vaccine|A 0.5 mL single-dose delivered via syringe using single-dose vials. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® for intramuscular injection is approved for persons 6 months and older and will be purchased from Sanofi Pasteur, Inc.
45695175|NCT01724944|Procedure|Systematic pelvic and aortic lymphadenectomy|Pelvic lymphadenectomy dissection began at the origin of the external iliac vessels and continued caudally along the medial border of the psoas muscle, with the lower limit of the external iliac lymphadenectomy being represented by the deep inferior epigastric vessels. The lateral boundaries of lymphadenectomy were delineated superficially by the fascia covering the psoas muscle and deeply by the fascia covering the internal obturator and levator ani muscles. Lymph nodes along the external iliac vessels were removed en bloc with those adjacent to the common iliac vessels. Aortic lymphadenectomy dissection began at the aortic bifurcation by removing the superficial intercavoaortic, precaval, and preaortic nodal groups. Lymph nodes located lateral to the vena (i.e., paracaval nodal group) were separated from the vena cava, then removed en bloc. Lymph nodes behind the vena cava are removed if enlarged. Removal of the lateroaortic nodes was performed up to the level of the left renal vein.
45384396|NCT01052506|Drug|Placebo|Single dose of placebo comparator (8 cohorts IV, 1 cohort SC)
45384397|NCT03988816|Drug|Roflumilast|500Mcg Tab, once daily
45384398|NCT03988816|Drug|Placebo oral tablet|once daily
45384399|NCT00353704|Drug|pregabalin|capsule 150 mg x 1 per orally one hour before surgery
45384400|NCT00353704|Drug|Placebo|One capsule of saccharose (placebo) was administered about one hour before surgery
45384401|NCT00353704|Drug|morphine|All patients were equipped with a PCA (patient controlled analgesia) for 24 hours after surgery. The sum of morphine used was registered (milligram).
45384402|NCT03742180|Drug|intranasal dexmedetomidine|The patient will receive intranasal dexmedetomidine in a dose of 1ug.kg-1 in a volume of 1 ml was dripped into both nostrils using a 1-mL syringe, with the patients in the recumbent position plus 1ml sublingual 0.9% saline
45384403|NCT03742180|Drug|sublingual ketorolac|The patient will receive sublingual ketorolac in a dose of 0.5 mg.kg-1 in a volume of 1 ml and 1 ml intranasal saline 0.9%
45848242|NCT03341910|Drug|Tazorac Vehicle Cream 0%|Vehicle Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
46059082|NCT02583841|Procedure|Scaling and root planing|scaling and root planing as an intervention was done in patients of the test group
45384404|NCT00512252|Drug|AMD3100|
45384405|NCT00512252|Drug|Mitoxantrone|
45384406|NCT00512252|Drug|Etoposide|
45384407|NCT00512252|Drug|Cytarabine|
45384408|NCT03988894|Device|mDASHNa App|The functions of the app will include: (a) antihypertensive dietary education; (b) dietary self-assessment; (c) automatic feedback according to dietary self-assessment; (d) blood pressure monitoring; and (e) automatic feedback according to blood pressure data.
45384409|NCT00516386|Drug|RhIGF-1|35-40 mcg/k/dose twice daily SC
45384410|NCT00524420|Device|rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions at 120% motor threshold rTMS to left dorsolateral prefrontal cortex
45384411|NCT00524420|Device|Sham rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions of sham rTMS
45384412|NCT00512096|Drug|Ifosfamide|1200 mg/m^2 By Vein Over 2 Hours on Days 1-3
45384413|NCT00512096|Drug|Paclitaxel (Taxol)|175 mg/m^2 By Vein Over 3 Hours on Day 1
45384414|NCT00512096|Drug|Cisplatin|25 mg/m^2 By Vein Over 2 Hours on Days 1-3
45384415|NCT01565252|Dietary Supplement|eggs enriched Omega-3|In second stage participants will receive two Omega-3 enriched hard-boiled eggs/day at breakfast for a three weeks period for each participant.
45384416|NCT04462796|Dietary Supplement|Magnesium Citrate|Magnesium Citrate 200 mg daily
45695176|NCT04381000|Other|Exercise Group|The group follows warm up exercise (maximum 10 minutes). This consisted of combined, breathing techniques, low-impact aerobic exercises, free range of motion exercises of upper and lower limbs and spine, and coordination-based exercises of hands and feet. Breathing techniques take regular activities such as sitting, walking, and lying down. At the end of this phase, active stretching exercises of major muscles of arm, leg and trunk were performed.
45384417|NCT00524030|Drug|pregabalin 600 mg/day|pregabalin 600 mg/day (300mg BID), duration is 20 weeks.
45384418|NCT00524030|Drug|pregabalin 150 mg/day|pregabalin 150 mg/day (75mg BID), duration is 20 weeks.
45384419|NCT00523718|Drug|riluzole|50 mg PO bid, 12 weeks
45384420|NCT00523718|Drug|placebo|placebo, 1 capsule PO bid, 12 weeks
45695177|NCT04379674|Other|FACILITATION TAPING|The muscle technique, which is a kinesio tape technique, will be used in the biceps brachii muscle. Taping was done with 25% tension with Y tape from the origin to insertion of the muscle.
45384421|NCT00523640|Drug|combination of gemcitabine, capecitabine, and bevacizumab|gemcitabine 1000 mg/m^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle
45384422|NCT00345358|Biological|Synflorix|1, 2, 3 or 4 Intramuscular injections, depending on age group
45384423|NCT00345358|Biological|Infanrix IPV/Hib|4 intramuscular injections
45384424|NCT03869684|Drug|MT-0814|Randomly assigned dose
45384425|NCT03869684|Drug|Placebo|Placebo manufactured to mimic MT-0814
45384426|NCT01058746|Other|restrictive perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hour IV (8am to time of induction) during induction of Anesthesia. Maintenance IV Normosol or equivalent solution at 6 ml/kg/operative hour. Blood loss to be replaced volume: volume with colloid until transfusion criteria met. Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) at the discretion of the Anesthesiologist to maintain patient hemodynamic stability.
45384427|NCT01058746|Other|Liberal perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hr IV (8am to time of induction) of Anesthesia. Maintenance IV Normosol or equiv solution at 6 ml/kg/oper hr. At randomiz to the Liberal arm in the OR, an addit bolus of Normosol or equiv solution 1.5 ml/kg/fasted hr IV (8am to time of induction) will be given to bring the total to Normosol or equiv solution 2ml/kg/fasted hr IV (8am to time of induction). Pt will get an addit bolus of Normosol or equivalent solution 6ml/kg/oper hr. Maintenance IV Normosol or equivalent solution will then commence at 12ml/kg/operative hr with maximum of 1000 ml/operative hr. Blood loss replaced volume: with colloid, until transfusion criteria met (Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) used at the discretion of the Anes to maintain pt hemodynamic stability. Addit fluid boluses of 250ml Normosol or equivalent solution for urine output less than 1ml/kg for 2 hrs.
45384428|NCT00516074|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
45384429|NCT00516074|Drug|placebo|subcutaneous injection, volume equivalent to active, twice a day
45384430|NCT01057654|Drug|Pravastatin|Pravastatin 40 mg
45384431|NCT01057654|Drug|Lifibrol|Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
45384432|NCT00515294|Drug|Caffeinated Alcoholic Beer|Alcoholic Beer plus Caffeine Citrate powder.
45384433|NCT00515294|Other|Non-Caffeinated Alcoholic Beer|Alcoholic Non-Caffeinated Beer
45384434|NCT00515294|Drug|Caffeinated Non-Alcoholic Beer|Non-Alcoholic Beer plus Caffeine Citrate powder.
45384435|NCT00515294|Other|Non-Caffeinated, Non-Alcoholic Beer|Non-Alcoholic Beer
45384436|NCT00345046|Drug|Pred Forte|Four drops daily decreasing to once daily over four weeks.
45384437|NCT00345046|Drug|EconoPred Plus|Prednisolone Acetate four times daily decreasing to once daily over four weeks.
45384438|NCT00345046|Drug|Prednisolone Acetate|Dosed four times daily decreasing to once daily over four weeks.
45384439|NCT01055002|Biological|Blood stage parasite (BSP) inoculum|Inoculum of human red blood cells infected with falciparum malaria administered intravenously on Day 1
45384440|NCT00515216|Drug|5-fluorouracil|
45384441|NCT00515216|Drug|Oxaliplatin|
45499822|NCT03881059|Drug|BMS-986165 Dose B|Participants will receive BMS-986165 dose B QD.
45499823|NCT03881059|Drug|Ustekinumab|Participants will receive ustekinumab SQ injection QD.
45499824|NCT03881059|Other|Ustekinumab Placebo|Participants will receive ustekinumab SQ matching placebo QD
45499825|NCT01338337|Drug|Azacitidine|Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
45499826|NCT02861534|Drug|Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
45499827|NCT02861534|Drug|Placebo for vericiguat|2.5, 5.0, or 10.0 mg orally once daily
45499828|NCT02034032|Procedure|Regenexx SD|stem cell treatment
45499829|NCT02034032|Behavioral|Exercise Therapy|exercise therapy control
45499830|NCT02034188|Biological|Umbilical cord mesenchymal stem cells|
45695178|NCT04379674|Other|INHIBITION TAPING|The muscle technique, which is a kinesio tape technique, will be used in the biceps braki muscle. Taping was done with 25% tension with Y tape from the insertio to origo of the muscle.
46059083|NCT04077853|Drug|17 Hydroxyprogesterone Capronate|Intramuscular injection 250 mg
45499831|NCT03167255|Drug|NS-065/NCNP-01|Received during weekly intravenous infusions
45499832|NCT03140969|Drug|QR-110|RNA antisense oligonucleotide for intravitreal injection
45384442|NCT00515216|Drug|Leucovorin|
45384443|NCT01004978|Drug|Cisplatin|Given IV; undergo trans arterial chemoembolisation (TACE)
45384444|NCT01004978|Drug|Doxorubicin|Given IV; undergo TACE
45499833|NCT05426993|Other|Complex decongestive physiotherapy|CDT is a treatment approach consisting of manual lymph drainage, skin care, compression bandage and exercises.
45384445|NCT01004978|Drug|LC bead|Given IV; undergo TACE
45499834|NCT03083847|Drug|Chloroquine Phosphate|Chloroquine has been widely used for treatment and prophylaxis of malaria since 1946 (Most, London et al. 1984). It was the treatment of choice for uncomplicated malaria for decades because it was safe, well tolerated, affordable and highly effective for the treatment of malaria. However, increasing spread of chloroquine- resistant Pf over the last two decades has severely limited its use (Wellems 2002). Chloroquine phosphate is U.S Food and Drug Administration (FDA) approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf.
45384446|NCT01004978|Drug|Mitomycin|Given IV; undergo TACE
45499835|NCT03083847|Drug|Pyrimethamine|Pyrimethamine is a folic acid antagonist that has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide (Organization April 2013 (rev. January2014)
45499836|NCT03083847|Biological|Sanaria PfSPZ Challenge|Sanaria Inc has manufactured two strains of Sanaria PfSPZ Challenge: NF54 and 7G8. The Sanaria PfSPZ Challenge contains fully infectious PfSPZ purified from the salivary glands of Anopheles stephensi mosquitoes raised under aseptic conditions. The infectious PfSPZ are formulated in cryoprotectant to maintain potency for an extended period. Sanaria PfSPZ Challenge (NF54) is known to be susceptible to chloroquine, pyrimethamine, atovaquone, artesunate, but not mefloquine. Sanaria PfSPZ Challenge (7G8) is known to be susceptible to mefloquine, atovaquone, artemether and artesunate but not to chloroquine or pyrimethamine.
45499837|NCT01377519|Procedure|MR Guided Focused Ultrasound|This is an FDA approved noninvasive treatment for fibroids that uses highly focused ultrasound waves to damage fibroid tissue.
45384447|NCT01004978|Other|Placebo Administration|Given PO
45384448|NCT01004978|Drug|Sorafenib|Given PO
45384449|NCT00522626|Device|Maternal fetal monitoring|Simultaneous monitoring of maternal and fetal physiology
45499838|NCT01377519|Procedure|Placebo MR Guided Focused Ultrasound|This is a placebo treatment that requires a participant to undergo identical procedures as those of the actual MR Guided Focused Ultrasound procedure, but higly focused ultrasound waves are not directed at the uterine fibroid.
45499839|NCT03082677|Drug|Ixazomib|Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off).
45499840|NCT03136055|Drug|Pembrolizumab|Given Intravenously (IV)
45499841|NCT03136055|Drug|Irinotecan|Given IV
45499842|NCT03136055|Drug|Paclitaxel|Given IV
45384450|NCT00440193|Drug|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
45384451|NCT00440193|Drug|Enoxaparin followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
45384452|NCT00511472|Drug|MK-0941|"In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis (Titration Dose [TD] Days 1 to 4 of the Titration Phase 1) in 10-mg q.a.c. increments.~Titration Scheme #2 was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration on Days 1 to 4 of the Titration Phase 2."
45384453|NCT00511472|Drug|Placebo|10 mg Placebo (Pbo), 20 mg Pbo, 30 mg Pbo or 40 mg Pbo q.a.c.
45384454|NCT00511472|Drug|LANTUS insulin|LANTUS insulin dose will be similar to participant's previous dose of immediate or long-acting insulin
45384455|NCT01033305|Drug|CyCol™|Orally, once per day for 4 weeks
45499843|NCT01380873|Drug|Period I : HKB0701, Period II : HKB0701 and SLM0807, Period III : CJ30001|
45499844|NCT01380873|Drug|Period I : HKB0701 and SLM0807, Period II : CJ30001, Period III : HKB0701|
45499845|NCT01380873|Drug|Period I : CJ30001, Period II : HKB0701, Period III : HKB0701 and SLM0807|
45384456|NCT01033305|Drug|Placebo|Orally, once per day for 4 weeks
45384457|NCT01037049|Other|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy|
45384458|NCT00514904|Biological|Nimenrix|Single dose, intramuscular injection
45384459|NCT00514904|Biological|Mencevax|Single dose, subcutaneous injection
45384460|NCT03319082|Combination Product|Corneal Collagen Cross-linking|Photrexa Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5'-phosphate ophthalmic solution), and the KXL System (UV Irradiation).
45384461|NCT00440115|Behavioral|High intensity disease management|Health education mailings, 6 motivation interviews/counseling
45384462|NCT00440115|Behavioral|Low intensity disease management|Health education mailings, one motivation interview/counseling
45384463|NCT00440115|Behavioral|Comparison group|Health education mailings
45384464|NCT00440115|Drug|Bupropion|Buproprion or Nicotine Replacement Therapy
45499846|NCT03789045|Diagnostic Test|Metabolic thresholds and fat oxidation points relationship|Investigators aim to determine exercise intensity at which metabolic thresholds and fat oxidation points occur by using non-invasive breath-by-breath gas analysis during either graded treadmill or cycle ergometry test (2min stages and 1km/h or 50 W load increase) till exhaustion to determine maximal oxygen uptake (VO2max), with gases being collected at the mouth level. The strength of the relationship between AeT and at FATmax will be assessed using the Pearson product moment (r) correlation coefficient with same being done for AnT and FATmin correlation. A coefficient of determination (R2) will be used to detect the proportion of existing variance. A paired t-test will be used to asses' differences between measured variables. Bland-altman will be used to determine levels of agreement.
45384465|NCT04384328|Other|Early Support Programme in Orthophony|Early support in speech therapy lasts between 6 months and 24 months of corrected age. It includes 10 to 20 sessions depending on the child's needs. These sessions are conducted by a speech-language pathologist from the RPSOF-ASNR network, trained in the issues specific to the very premature child and the network's tools.
45384466|NCT01037205|Drug|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
45499847|NCT03287063|Other|Tumor Biopsy|Stereotactic biopsies will be performed prior to resection.
45384467|NCT01037205|Drug|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
45384468|NCT04378790|Other|Patching|Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye.
45384469|NCT04378790|Other|Glasses|Eye Glasses are created and worn by patient to improve vision
45499848|NCT05421273|Device|Spinal cord stimulation using passive recharge burst stimulation|Passive recharge burst is marked by a recharge pattern that passively compensates for charge differences.
45499849|NCT05421273|Device|Spinal cord stimulation using active recharge burst stimulation|Active recharge burst is characterized by negative pulses that directly compensate for charge differences.
45499850|NCT03221309|Other|Evaluate model of care for HCV-infected adults with on-going opioid misuse|Participants will be treated with direct-acting antivirals per standard of care and will be concomittantly be offered PreP for HIV prevention and buprenorphine for treatment of opioid-use disorder when clinically indicated
45499851|NCT01379235|Other|Pilatis exercise|12 weeks of pilatis exercise 3 times a week.
45695179|NCT04379674|Other|PLACEBO TAPING|Unlike Kinesio taping muscle technique, it was performed with horizontal taping on the muscle. The ends of the kinesio tapes will be applied tension-free without overlapping with I tape.
45695180|NCT01725022|Other|Home Care|This is the interventional arm where patients receive the transplant care in their homes.
45695181|NCT01728532|Device|Pulp Canal Sealer (Kerr)|permanent obturation of the root canal space with the aid of obturating points
45695182|NCT01728532|Device|PA0903|Sealing performed by the dentist , coronal obturation placed after the canal obturation
45848243|NCT03343080|Drug|1.8% lidocaine plus 0.76% sodium bicarbonate|At the time of intubation, the endotracheal tube cuff will be inflated with a solution containing 1.8% lidocaine plus 0.76% sodium bicarbonate until loss of air leak at a positive pressure of 20 cm of water. This solution will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
46056128|NCT02740491|Other|Remission Consultation|"At the end of adjuvant treatment (adjuvant chemotherapy and / or radiotherapy), the patient is seen by a referent oncologist and included in the study. A Remission consultation with a psychotherapist is then proposed and its purpose explained to the patient. The patient agrees or refuses take advantage of the Remission consultation; in case of refusal, the reasons are documented and further information is provided, thus giving the opportunity for the patient to benefit from further psychological counseling if desired.~If approval is given, the patient will be scheduled for the Remission consultation (duration 1 hour) . The latter includes a first phase evaluating the mental state of the patient, and then a proposal of individualized care if necessary and according to several methods, depending on the choice of the patient."
45384470|NCT00440037|Biological|AMG 531|AMG 531 will be administered by SC injection once per week from Week 1 (Day 1). The maximum permitted dose of AMG 531 is 10 μg/kg. AMG 531 will be supplied as a sterile, white, preservative-free, lyophilized powder in 5 mL glass vials containing 0.6 mg of protein per vial, and a protein concentration of 0.5 mg/mL when reconstituted with 1.2 mL of sterile water for injection.
45384471|NCT01037283|Behavioral|Interpersonal and Social Rhythm Therapy|Interpersonal and Social Rhythm Therapy delivered in two individual therapy sessions and six group therapy sessions.
45384472|NCT01033461|Dietary Supplement|calcium and probiotic|the subjects consumed for 4 weeks a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 and a bread enriched with 1 g pentacalcium phosphate per day
45384473|NCT01033461|Dietary Supplement|probiotic|the subjects consumed a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 for 4 weeks
45695183|NCT01837810|Drug|Ibuprofen|800mg every 8 hours as needed for pain
45848244|NCT03343080|Other|Air|At the time of intubation, the endotracheal tube cuff will be inflated with air until loss of air leak at a positive pressure of 20 cm of water. The air will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
45384474|NCT01033461|Other|placebo|the subjects consumed a yoghurt drink without L. paracasei LPC 37 and a bread without pentacalcium phosphate
45384475|NCT01033539|Other|Probiotic strain ATCC PTA 4659|Placebo control containing no probiotic strain of ATCC PTA 4659 High dose of ATCC PTA 4659 1*10 10 CFU/bag Low dose of ATCC PTA 4659 1*10 8 CFU/bag
45384476|NCT01037439|Device|Adaptive Servo-controlled Ventilation (ASV)|Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed
45384477|NCT01033617|Procedure|Injection of stem cells at time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells,or placebo solution containing plasma and indistinguishable will be injected in the myocardium. A total of 2.0 ml with 10-15 injections will be injected.
45499852|NCT05421117|Procedure|Laparoscopic adnexal mass extraction|Compared with open procedures, Minimally invasive surgery (MIS) is associated with faster recovery times, better patient quality of life, and lower postoperative complication rates. The removal of an adnexal mass from the abdominal cavity is performed most commonly using the suprapubic, trans umbilical (TU), or trans vaginal (TV) route.
45499853|NCT05421039|Behavioral|Exposure to unintended injuries|"After taking a verbal consent , an explanation of the study will be given to the caregivers~, those who fulfill the inclusion criteria will be enrolled in the study. Personal interviews by the researcher will be made with individuals or groups (2-4 persons) , participants will be chosen by means of systematic random sampling among visitors ؛ every 3rd or 5th child according to density and flow of attendance .~the investigator will fill the questionnaire through personal interview with the caregivers"
45499854|NCT03609398|Biological|RVF Vaccine|1.0 mL dose given SQ in upper arm
45695184|NCT04378348|Behavioral|Motivational Interview (MI)|The MI dialogue will begin with an introduction where the LDL is asked about the type of work he does and his concerns regarding dangers in his workplace. This will be followed by a decisional balance exercise where the interviewer will engage the LDL in thinking about the pros and cons of taking jobs with many dangers and jobs with less dangers. Using a figure of a traffic light, the interviewer will proceed to measure how important it is for the LDL to reduce the dangers in his work place and identify his reasons for its importance. Next, the interviewer will measure the LDL's level of confidence in his ability to reduce the dangers in his workplace.Together, they will develop a plan to reduce the dangers in the workplace. Finally, the interviewer will summarize the safety plan to the LDL and will explain that the team will return to the corner in one month to see how the implementation of his plan went and to conduct a post-test survey
45848245|NCT03345108|Device|Denture Adhesive Cream (Conventional Application)|The adhesive cream will be extruded from a pre-dosed syringe. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.05g for the maxillary and 0.60±0.05g for the mandibular dentures.
45848246|NCT03345108|Device|Denture Adhesive (Continuous Strip Application)|The adhesive cream will be extruded from a pre-dosed syringe. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.05 g for the maxillary and 0.60±0.05 g for the mandibular dentures.
45499855|NCT05353829|Drug|Methotrexate|When accepted inclusion the patient will be included in SRQ, and thereafter randomised for Methotrexate per oral or subcutaneous administration
45499856|NCT03740139|Other|The Police-Mental Health Linkage System|When, during an encounter, the police officer decides to call the number provided in the notice, the Linkage Specialist (a licensed mental health provider from the mental health service where the subject was recruited, who has access to the clinic's EMR) can provide telephonic support to the officer.
45499857|NCT04378400|Procedure|Sacrocolpopexy|Sacrocolpopexy is offered to patients with symptomatic prolapse (≥stage II) of the vaginal apex (vault or cervix). The procedure involves dissection of the promontory and the vaginal vault, suturing of two meshes to the anterior and posterior aspect of the vagina using minimally three rows of sutures on each side, and one row at the apex. Thereafter the mesh is fixed with staples to the promontory and the peritoneum closed, with staples and a running suture.
45848247|NCT03345108|Other|No Adhesive|No adhesive applied.
45848248|NCT03346902|Drug|EB-001|Injection of EB-001 into area of scarring (forehead)
45848249|NCT03346902|Drug|0.9% Sodium Chloride Injection|Injection of Saline into area of scarring (forehead)
45848250|NCT03349632|Device|verofilcon A contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
45848251|NCT03349632|Device|senofilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
46059084|NCT04502407|Radiation|Cisplatin-based Radiation Therapy|"High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive radiation dose of 50 Gy in 25 fractions over 5 cycles on Days 1, 8, 15, 22, and 29 of radiation treatment.~All other patients will receive radiation dose of 30 Gy in 15 fractions over 3 cycles on Days 1, 8 and 15 of radiation treatment."
46059085|NCT04502407|Drug|Cisplatin Chemotherapy|"High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive 5 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8, 15, 22, and 29 of radiation.~All other patients will receive 3 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8 and 15 of radiation."
45384478|NCT02562963|Biological|natural killer T cell|The eligible patients are infused with two doses of (4±0.5)x10^9 NKT cells in one course of treatment.
45384479|NCT02561559|Radiation|Lung metastasis from soft-tissue sarcoma|Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)
45384480|NCT03055611|Drug|ELOCTA|Extended half-life factor VIII product
45384481|NCT03055611|Drug|ALPROLIX|Extended half-life factor IX product
45384482|NCT01030731|Drug|Ceftobiprole|Ceftobiprole 250mg single dose over 2 hours.
45384483|NCT00417027|Procedure|Programmed Intermittent Epidural Bolus (PIEB)|A commercial pump that can be programmed to administer intermittent boluses and patient controlled boluses does not exist. Two pumps were prepared for each subject with the same epidural solution. One pump was programmed to administer the programmed intermittent epidural bolus(PIEB). The second pump was programmed to administer patient controlled epidural analgesia (PCEA)with a dose of 5 mL delivered with a lockout of every 10 minutes.
45384484|NCT00416949|Device|Patient-specific dosimetry|Patient-specific 3D-RD dosimetry was applied to the data collected
45384485|NCT03993483|Behavioral|Unilateral resistance exercise|The participants performed three sets of their unilateral resistance exercise (biceps curls and knee extensions) three times per week for 10 weeks.
45384486|NCT00416715|Drug|letrozole|Given PO
45384487|NCT00416715|Dietary Supplement|calcium carbonate|Given PO
45384488|NCT00416715|Other|laboratory biomarker analysis|Optional correlative studies
45384489|NCT00416715|Dietary Supplement|calcium citrate|Given PO
45384490|NCT00416715|Dietary Supplement|calcium glucarate|Given PO
45384491|NCT00416715|Drug|calcium gluconate|Given PO
45384492|NCT00416715|Dietary Supplement|cholecalciferol|Given PO
45384493|NCT00416715|Procedure|assessment of therapy complications|Ancillary studies
45384494|NCT00416715|Procedure|musculoskeletal complications management/prevention|Correlative studies
45384495|NCT01037517|Drug|Plerixafor|Plerixafor will be administered at 23:00 of Day -1 to experimental subjects at a dose of 240 mcg/kg subcutaneously, and possibly repeated the following day
45384496|NCT01037517|Other|Observation: Nonintervention|Nonintervention group, no drug will be given, observation only
45384497|NCT01323933|Drug|AB0024|Comparison of different dosages of drug
45695185|NCT04378348|Behavioral|Participatory Group Activity|Participants will view a figure of a pyramid representing the steps they can take to reduce the dangers in their workplace and the things that are in their control to reduce the dangers followed by pictures of dangerous work environments. They will be engaged in hazard identification and situational awareness by identifying and sharing out loud the dangers they see in the picture. Participants will also engage in problem solving by coming up with strategies they could use to reduce the dangers they identified in the picture and will measure their level of confidence in their ability to implement the strategies they have come up with, should they find themselves in a similar work situation. The group facilitator will summarize what the group has said and what they have learned during the group activity and will ask participants to voluntarily make a personal promise to take concrete steps to reduce the dangers at their work.
45848252|NCT03349632|Device|stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
45384498|NCT00406029|Drug|Preladenant|1 mg BID capsules
45384499|NCT00406029|Drug|Preladenant|2 mg BID capsules
45384500|NCT00406029|Drug|Preladenant|5 mg BID capsules
45384501|NCT00406029|Drug|Preladenant|10 mg BID capsules
45384502|NCT00406029|Drug|Placebo|BID capsules
45384503|NCT00406029|Drug|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
45384504|NCT00406029|Drug|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
45384505|NCT00514514|Drug|Everolimus|Tablet containing 0.5 mg or 0.75 mg. Dosing schedule: Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen
45384506|NCT00514514|Drug|Myfortic|"1 tablet containing 180 mg or 360 mg~Dosing schedule:~Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen) According to blood level 1440 mg/day (2 x 720 mg), if tolerated. Dose reduction possible in case of side effects (min. dose at BL2 (Month 3): 720 mg/day)"
45384507|NCT00514514|Drug|Sandimmun Optoral|1 capsule containing 10, 25, 50, or 100mg. Dosing: According to blood level
45384508|NCT00514514|Drug|Simulect®|Lyophilisate in vials with ampoules of sterile water for injection (5 ml). Dosing: 1 vial containing 20 mg lyophilisate. Dosing schedule: 2 x 20 mg to be applied as 10 sec. bolus injection, i.v. on Day 0 (2 h before transplant) and on Day 4
45384509|NCT00405639|Drug|Nesiritide|Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is >90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
45384510|NCT00405639|Drug|Placebo|Normal saline will be used for placebo.
45384511|NCT03993795|Other|A19010-W|A snus product
45384512|NCT03993795|Other|B19010-F|A snus product
45384513|NCT01030809|Other|Treatment Algorithm for Crohn's Disease|Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
45384514|NCT00439725|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients randomized to rivaroxaban will receive rivaroxaban 20 mg once-daily.
45384515|NCT00439725|Drug|Placebo|Patients allocated to placebo will receive a matching placebo tablet once daily.
45384516|NCT00521586|Biological|13 valent pneumococcal conjugate vaccine|TIV +13vPnC at dose 1 placebo at dose 2, one month after dose 1 13vPnC at year 5
45384517|NCT00521586|Biological|13 valent pneumococcal conjugate vaccine|TIV + placebo at dose 1 13vPnC at dose 2, one month after dose 1 and 13vPnC at year 5
45384518|NCT00515502|Drug|GSK573719|250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg
45384519|NCT00515502|Drug|Tiotropium|strips of five capsules, each containing 18 μg administered via dry powder inhaler
45384520|NCT03336216|Biological|Cabiralizumab|specified dose on specified days
45384521|NCT03336216|Drug|Nab-paclitaxel|specified does on specified days
45384522|NCT03336216|Drug|Onivyde|specified dose on specified days
45384523|NCT03336216|Biological|Nivolumab|specified dose on specified days
45384524|NCT03336216|Drug|Fluorouracil|specified dose on specified days
45384525|NCT03336216|Drug|Gemcitabine|specified dose on specified days
45499858|NCT03426657|Combination Product|Durvalumab + Tremelimumab + RT|Patients with an increased CD8+ tumor infiltrating immune cell density and at least clinically stable disease will receive radioimmunotherapy with the PD-L1 Inhibitor Durvalumab and the CTLA4-Inhibitor Tremelimumab (altogether 4 doses q4w including the induction dose) followed by maintenance therapy with Durvalumab (8 additional doses q4w).
45499859|NCT02858180|Drug|Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)|1 pill once daily of SOF/LDV FDC
45499860|NCT03082599|Device|Presbyopia and astigmatism correcting intraocular lens|The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.
45499861|NCT04232384|Procedure|Standard Paracentesis|The patients will be asked to lie supine for 10 minutes and no changes in posture will be allowed for this period. Abdominal paracentesis will be done either by blind technique (in case the ascites is clinically detectable) or ultrasonography guided (in cases the ascites is not clinically detectable).
45695186|NCT04378348|Behavioral|Control Condition|At control corner sites, we will recruit another 35 Latino day laborer participants.Participants in the control group will receive OSHA pamphlets with standard workplace safety and health information. During our needs assessment survey, we collected information regarding workrelated injuries. Results from this survey indicate the following 4 categories are the highest cause of injury among surveyed Latino day laborers: 1) moving heavy objects, 2) falls, 3) being struck by falling or lying objects, and 4) serious cuts. The OSHA materials that will be distributed to participants will include safety and health information regarding these four topics. Furthermore, given that the LDL are continuously exposed to the sun (e.g., at the corner while waiting for work, at work, and on their way to and from work), heat exposure will also be included in the OSHA materials.
45384526|NCT03336216|Drug|Oxaliplatin|specified dose on specified day
45848253|NCT03349632|Device|etafilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
45848254|NCT03350724|Device|episil wound dressing|Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
45848255|NCT03350724|Device|PeriAcryl90 wound dressing|PeriAcryl90 is a cyanoacrylate wound dressing.
45384527|NCT03336216|Drug|Leucovorin|Specified dose on specified days
45384528|NCT03336216|Drug|Irinotecan Hydrochloride|Specified dose on specified days
45384529|NCT03997734|Drug|AB001|single and repeated dosing
45384530|NCT03997734|Drug|oral capsule|single dose
45384531|NCT03997734|Drug|positive comparative patch|single and repeated dosing
45384532|NCT03997734|Drug|Placebos|single and repeated dosing
45384533|NCT03997890|Procedure|Cataract surgery with binocular implantation of either Symfony (ZXR00) or Symfony toric (ZXT) IOLs|After creating an initial side port incision with a 15-degree blade, 3-step clear corneal incisions were made using a 2.5 mm disposable metal blade. Sodium hyaluronate 1.0% (Healon; Abbott Medical Optics) was then injected into the anterior chamber. A continuous curvilinear capsulorrhexis, measuring 5.5 mm in diameter, was generated using a 26 gauge bent needle. After hydrodissection, phacoemulsification was done to remove nuclear fragments and aspiration of residual cortex. In all eyes, a Symfony or Symfony toric IOL was implanted in the capsular bag using a disposable implantation system. Irrigation and aspiration were performed to minimize ophthalmic viscoelastic surgical device retention at the end of surgery. The main incision and side port were sealed with stromal hydration using a balanced salt solution.
45384534|NCT03997344|Behavioral|Group nature hikes|Six group nature hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
45384535|NCT03997344|Behavioral|Group urban hikes|Six group urban hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
45426096|NCT00634634|Drug|Letrozole|Patients will take letrozole orally at a daily dose of 2.5 mg/day on Days 1 through 28
45848256|NCT03365154|Device|Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment|Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.
45848257|NCT03365154|Device|Balloon Angioplasty|Low pressure balloon angioplasty may be used following atherectomy
45848258|NCT03365778|Other|Patient Educational Intervention|Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. Then they will receive educational materials including 20 printed slides and view a 3 minute video on safety and efficacy of SLT. If patients agree to SLT, assistance in scheduling will be provided.
45695187|NCT01725100|Drug|GSK1120212B (Standard DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a standard DMSO content of theoretical 11.3%.
45695188|NCT01725100|Drug|GSK1120212B (Lower DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a lower DMSO content approximately 9.5%.
45384536|NCT01010646|Drug|IFN alfa-2b XL 27 MUI + Ribavirin|IFN alfa-2b XL 27 MUI administered once a week for 12 weeks by subcutaneous injections, in combination with weight dosed ribavirin daily administered orally in two divided doses
45384537|NCT01010646|Drug|IFN alfa-2b XL 36 MUI + Ribavirin|IFN alfa-2b XL 36 MUI administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
45384538|NCT01010646|Drug|IFN peg alfa-2b 1.5 µg/kg + Ribavirin|IFN peg alfa-2b 1.5 µg/kg administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
45384539|NCT00439647|Drug|Zoledronic acid 5 mg iv|Zoledronic acid 5 mg iv given once a year.
45384540|NCT00439647|Drug|Placebo|Placebo intravenous (i.v.) once a year
45695189|NCT01725178|Behavioral|Cognitive and Physical training|"Physical training - Three 60-minute session per week. Participants will be divided in groups of 10, supervised by physiotherapists. Physical activity combines aerobic exercises, muscle strengthening, balance improvement, joint flexibility. Once a week the session is replaced by outdoor walking; once a month by dancing.~Cognitive training - The program alternates focuses on specific functions and recreational sessions. Each session will be followed by a lesson about cognitive processes (memory, learning, attention, thought), providing tips to overcome difficulties in daily life. Sessions will focus on attention, imagination, spatial memory, categorization; memory for terms, meanings, songs, faces, names; memorization of texts; goal management."
45384541|NCT00515112|Drug|AndroGel|Androgel 1%, 10g daily
45384542|NCT00515112|Drug|placebo|placebo
45384543|NCT03034785|Device|FlexiMitt|The proposed research designs and fabricates a new technological innovation in wearable soft-sensors, called flexi-mitts, for measuring force modulation and joint angles of the hand (wrist and fingers) of toddlers.
45384544|NCT01030887|Behavioral|Exercise programme|Moderate intensity exercise
45384545|NCT03742557|Drug|Ketamine 50 MG/ML Injectable Solution, 0.5 mg/kg IV|Ketamine 0.5 mg/kg IV
45384546|NCT01324011|Behavioral|Adult diabetes family-based weight loss intervention|Participants assigned to the experimental group will begin the 2o-week weight loss intervention, while delayed intervention controls will wait until the end of this period to begin their program. The weight loss intervention includes 20 weekly group-based sessions facilitated by a registered dietitian. Each group session will last about 120 minutes and include: weight check, group sharing and problem-solving, discussion of a weight control topics (nutrition, physical activity, or behavior change), physical activity and/or taste-testing. Ten sessions will include a brief component, focused on improving family relationships for better diabetes self-care. The study weight loss goal is ≥10 pounds (minimum rate-0.5 lb/week; maximum-2 lbs/week). While the control group waits, they will receive 1 newsletter with study updates and general health or diabetes information. The delayed intervention includes 6 sessions (4 weekly + 2 bi-weekly) following the same format as the experimental group.
45384547|NCT01324089|Dietary Supplement|Resveratrol|Resveratrol 2.5 grams
45499862|NCT04232384|Procedure|Roll Over Paracentesis|Patients with ascites will be rolled over thrice in bed laterally upto 90 degrees on either side (Figure 1) and ascitic fluid sample is drawn within 1 minute of the last rollover. There will be four steps to this i.e roll over to one side at 90 degrees and then 180 degrees to the other side, then back to the first side and then back to the center (to complete three turns). This will be done after the disinfection and cleaning of the anterior abdominal wall have been done and the personnel involved in the procedure are ready for the paracentesis. The ascitic paracentesis will be initiated within one minute of the completion of the turn. One assistant will maintain a stopwatch during this period to ensure compliance with this.
45695190|NCT01837888|Device|WheelSee Training Program|WheelSee sessions will be administered by a peer-trainer, who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSee session will be tailored to the individual goals of participants, which will be identified during the start of each WheelSee session.
45848259|NCT03365778|Other|Usual Care|Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. No other guidance will be provided.
45384548|NCT01324089|Dietary Supplement|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
45384549|NCT01324089|Dietary Supplement|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
45384550|NCT00404547|Drug|Ciclesonide|Asthma Care with Alvesco
45384551|NCT00404547|Drug|Usual Care Inhaled Glucocorticosteroids|Usual asthma care and dosage as chosen by the Primary Care Physician including inhaled steroid treatment
45384552|NCT00515034|Drug|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
45384553|NCT00515034|Drug|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
45384554|NCT00515034|Drug|Doripenem|1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
45384555|NCT00515034|Drug|Doripenem|1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
45384556|NCT01012518|Device|Standard PCT|The standard technique, performed without video guidance
45499863|NCT02285192|Radiation|18F-Fluorodeoxyglucose (18F-FDG)|
45695191|NCT01725334|Procedure|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a surgical procedure involving the implantation of a thin flexible wire called a lead. This device sends mild electric signals to an area of the brain. This study targets two different areas that we believe may be responsible for negative symptoms observed in patients with schizophrenia. There are two stages to DBS: (1) Insertion of the DBS electrodes (2) The connection of these electrodes to a battery under the collarbone.
45384557|NCT01012518|Device|Video-guided PCT|PCT performed with the guidance of a camera-embedded ETT wired to a monitor
45384558|NCT04632030|Behavioral|Tobacco power wall size and tobacco products displayed|The intervention varies the size of the tobacco power wall and number of tobacco products displayed on it.
45695192|NCT04378036|Other|Neurodevelopmental Therapy|The Neurodevelopmental Therapy rehabilitation program was determined according to the children's level of gross motor function, age, gender, mental state, and preferences. Neurodevelopmental Therapy program consists of the rehabilitation of muscle tone disorders, increasing sensory-perception-motor integrity, exercises to increase limb functions and body control, stretching and strengthening exercises for muscle shortness and weakness, exercises that include movements in daily life and training activities such as standing, walking, body care.
45384559|NCT00404235|Drug|carboplatin|
45384560|NCT00404235|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
45384561|NCT00404079|Drug|Glucosamine sulphate|Oral intake of 1500 mg glucosamine sulfate(from Pharma Nord) daily for 6 months
45384562|NCT00404079|Drug|Placebo|Oral intake of 3 placebo capsules (similiar looking to the glucosamine sulfate capsules)daily for 6 months
45384563|NCT00403845|Drug|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
45384564|NCT00403845|Drug|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
45384565|NCT00403845|Drug|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
45384566|NCT00509262|Drug|Sitagliptin|Participants with moderate renal insufficiency will receive two sitagliptin 25 mg tablets orally daily; participants with severe renal insufficiency will receive one sitagliptin 25 mg tablet orally daily
45384567|NCT00509262|Drug|Glipizide|Participants will receive glipizide 2.5 mg (1/2 tablet) orally once daily up to 20 mg orally daily (10 mg twice daily)
45384568|NCT00509262|Drug|Placebo for Sitagliptin|Participants with moderate renal insufficiency will receive 2 placebo for sitagliptin tablets orally daily; participants with severe renal insufficiency will receive 1 placebo for sitagliptin tablet orally daily
45384569|NCT00509262|Drug|Placebo for Glipizide|Participants will receive 1/2 tablet of placebo for glipizide orally once daily up to 2 tablets orally twice daily
45426097|NCT00606346|Biological|Anti TNF therapy including infliximab|Treatments will be prescribed according to investigator judgement.
45426098|NCT00606346|Drug|No Biologics|Treatments will be prescribed according to investigator judgement.
45499864|NCT02285192|Device|PET/CT imaging|
45499865|NCT02285192|Device|PET/MRI imaging|
45499866|NCT05420493|Biological|CAR-T cells|Drug: CAR-T cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
45499867|NCT03609086|Other|Melatonin analysis|Measurement of 6-hydroxymelatonin
45499868|NCT02034344|Procedure|Skin biopsy|Participants with LE will have 2 adjacent 4 mm punch biopsies collected from involved and uninvolved skin at one timepoint and again from the involved skin site approximately 12 weeks later. Healthy participants will have 2 adjacent 4 mm punch biopsies taken at one timepoint.
45384570|NCT00607997|Drug|vosaroxin|Vosaroxin was administered by slow intravenous (IV) infusion or via syringe pump within 10 minutes.Patients could have completed up to 4 treatment cycles consisting of 1 or 2 induction treatment cycles and up to 2 consolidation treatment cycles. For Schedule A, an induction cycle was a minimum of 21 days during which patients received vosaroxin on Days 1, 8, and 15, followed by weekly observations until hematologic recovery for patients with aplastic marrow after the postinduction bone marrow assessment. For Schedules B and C, an induction cycle was a minimum of 15 days, during which patients received vosaroxin on Days 1 and 8 (Schedule B), or Days 1 and 4 (Schedule C), followed by the same weekly observations until hematologic recovery as for Schedule A.
45384571|NCT00509106|Drug|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours for 5 to 7 days
45384572|NCT00509106|Drug|Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours for 5 to 7 days
45384573|NCT00509106|Drug|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
45384574|NCT03997656|Behavioral|MyDiPP (Malaysia Diabetes Prevention Program)|The participants will go through 16-weekly core lessons that need to be completed within the first 24 weeks after randomisation focusing on changing dietary habits, increase physical activity and relapse prevention and 6-monthly post-core lessons focusing on maintenance of lifestyle habits and weight loss achieved during the core program.
45384575|NCT03997656|Other|usual care|standard health education from primary care providers in the clinic
45384576|NCT00607919|Drug|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 to 32 weeks
45499869|NCT02034344|Procedure|Blood collection|Blood for serum analyses will be taken from all participants. Blood for DNA analysis will only be taken from participants who consent to this separately.
45384577|NCT00607919|Drug|Placebo|oral, daily, for 16 weeks
45384578|NCT00344968|Drug|fluocinolone acetonide|0.5 mg fluocinolone acetonide intravitreal insert
45384579|NCT00344968|Drug|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
45384580|NCT00344968|Procedure|Standard of care laser photocoagulation|Laser photocoagulation
45384581|NCT02541461|Procedure|Laparoscopic gastrectomy|(1) Wedge resection, subtotal or total gastrectomy with or without lymph node dissection; (2) R0 resection; (3) Laparoscopic gastrectomy; (4) Gastroduodenal anastomosis or duodenal bypass, including Roux-en-Y or gastrojejunostomy
45384582|NCT00509028|Drug|Budesonide|Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
45499870|NCT02034344|Procedure|Urine collection|Urine will be collected from all participants.
45384583|NCT00509028|Drug|Conventional Asthma Therapy|According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
45384584|NCT01055080|Dietary Supplement|Cow's milk formula|Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
45384585|NCT00893321|Procedure|Inferior Oblique Muscle Recession and Myectomy|
45384586|NCT01012752|Biological|modified allergen extract|subcutaneous injections
45384587|NCT01012752|Biological|Placebo|subcutaneous injections
45384588|NCT00352846|Drug|Zoledronic Acid|4 mg/m^2 by vein over 30 Minutes at baseline and 6 months.
45384589|NCT00352846|Drug|Vitamin D|400 mg by mouth daily
45384590|NCT00352846|Drug|Calcium Carbonate|1200 mg by mouth daily
45384591|NCT00508872|Drug|5-Fluorouracil|400 mg/m^2 IV over 15 minutes, followed by 2400 mg/m^2 IV Over 46 Hours
45384592|NCT00508872|Drug|Bevacizumab|5 mg/kg IV Over 30-90 Minutes On Day 1 Every 14 Days
45384593|NCT00508872|Drug|Leucovorin|400 mg/m^2 IV Over 2 Hours On Day 1 Every 14 Days
45384594|NCT00508872|Drug|Oxaliplatin|85 mg/m^2 IV Over 2 Hours On Day 1 Every 14 Days
45426099|NCT00588250|Other|EmbryoGlue|G2 culture media from Vitrolife which contains hyaluronic acid
45499871|NCT02745587|Radiation|radiotherapy|high dose external beam radiotherapy limited to the prostate(bed)
45499872|NCT02691845|Behavioral|BA (brief advice)|
45499873|NCT02691845|Behavioral|SHE (supervised and home-based exercise)|
45499874|NCT02691845|Behavioral|HE (health education)|
45499875|NCT02691845|Behavioral|CBEX (cognitive-behavioral sessions focused on increasing and maintaining exercise)|
45554654|NCT02448602|Other|acupuncture|Patients in Sancai coordinated points group, will be treated with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
45695193|NCT04378036|Device|Hippotherapy Simulator|Horse Riding Simulator (HRS) device was used as a hippotherapy simulator device. HRS is a device that moves forward, backward, backward-to-back, right-to-left swing and up-and-down swing in 3 dimensions, similar to the movements of a real horse, forming an 8-shaped movement on five axes. After the children sat in the saddle section, they were first taken to the warm-up speed program for 5 minutes, then to another one of the other speed levels (gradually moved to other speed levels as appropriate for the development and tolerance of children) and finally to the warm-up speed program for 5 minutes.
45384595|NCT00508482|Other|deep needling|"Huatuo brand needle (0.35×75mm), LH202H electric stimulator, parameter is constant wave, 2/15Hz, and current intensity is the abdominal muscles shiver slightly and the patient feels trivial pain.~Once a day, five times a week, four weeks."
45695194|NCT04378192|Device|Laryngeal mask airway|Insertion of laryngeal mask airway before intubation of a morbidly obese patient
45695195|NCT04378192|Device|face mask|use of face mask before intubation of a morbidly obese patient
45695196|NCT01725412|Dietary Supplement|Thiamine 300mg PO once daily|
45695197|NCT01725412|Dietary Supplement|placebo|
45695198|NCT01725490|Drug|Metformin|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
45695199|NCT01725490|Drug|Metformin|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
45848260|NCT03365778|Other|Ophthalmologist Educational Intervention|Responses to online survey regarding beliefs and attitudes towards selective laser trabeculoplasty (SLT) before and after educational slide presentation were recorded and compared between physician specialty groups.
45384596|NCT00508482|Drug|Lactulose|20-30ml, once a day before breakfast, for the whole study except the run-in period
45384597|NCT00508482|Other|shallow needling|Huatuo brand needle (0.30×25mm). The usage of EA apparatus and treatment course were the same as deep needling group.
45384598|NCT00344500|Behavioral|Behavioral Weight Loss Program|"Patients randomized to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient~Be given a 7% weight loss goal~Be assisted in obtaining a 500 calorie reduction per day~Exercise for at least 30 min/day, at least 5 days a week~Maintain weekly food and exercise diaries~Be quizzed on their knowledge of healthy eating habits and nutrition"
45695200|NCT01725490|Drug|Placebo|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
45384599|NCT00344032|Biological|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
45384600|NCT00344032|Biological|HPV-16/18 VLP/AS04 Vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
45384601|NCT00607373|Drug|mipomersen|200 mg mipomersen administered once a week for 26 weeks as a 1 mL subcutaneous injection. Subjects weighing less than 50 kg received a lower dose of 160 mg (0.8mL) mipomersen.
45384602|NCT00607373|Drug|Placebo|1 mL subcutaneous injection once a week for 26 weeks. Subjects weighing less than 50 kg received 0.8 mL subcutaneous injection.
45695201|NCT01682876|Biological|MenACWY-CRM|The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm
45695202|NCT01725568|Device|BioMonitor|Implantable cardiac monitor
45695203|NCT01728610|Dietary Supplement|Probiotic (Active high)|Higher dose of probiotic supplement
45695204|NCT01728610|Dietary Supplement|Probiotic (Active low)|Lower dose of probiotic supplement
45695205|NCT01728610|Dietary Supplement|Placebo|Placebo
45695206|NCT03835390|Behavioral|SIMDiscovery|The SIMDiscovery program consists of nine stations that were designed to mirror the different stages of the perioperative process. The stations mirror the different stages of the surgical process and provide patients and their families with education regarding what they can anticipate during each aspect of the intervention.
45695207|NCT04553666|Drug|Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)|800mg Epigallocatechin-3-Gallate (EGCG) plus 250mg Ascorbic Acid (Vitamin C) taken one time a day for twelve weeks
45695208|NCT03834766|Drug|AMPH ER Tab 5, 10, 15 and 20 mg|Amphetamine
45384603|NCT00508404|Drug|Panitumumab|Administered by intravenous infusion
45384604|NCT00508404|Drug|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m², 5-fluorouracil infusion 2400 mg/m².
45384605|NCT00888407|Behavioral|HBV Screening - Small group educational session|Small group HBV focused discussion with HBV screening resources.
45384606|NCT00888407|Behavioral|Nutrition - Small group educational session|Small group session with diet & nutrition focused, topic related resources provided.
45384607|NCT00352690|Drug|Paclitaxel poliglumex|
45695209|NCT03834766|Drug|AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg|Placebo
45695210|NCT01838434|Drug|lenalidomide|given PO
45848261|NCT03369756|Device|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|Wound cleansing using Prontosan solution and gel
45848262|NCT03373890|Behavioral|Short Burst Interval Locomotor Treadmill Training (SBLTT)|SBLTT consists of interval training consisting of short-bursts (30 seconds) of vigorous intensity locomotor treadmill training (LTT) alternating with low to moderate intensity LTT.,
45554655|NCT02448602|Other|acupuncture|Patients in Control group, will be treated with at the junction of deltoid and biceps, needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
45384608|NCT00352690|Drug|Carboplatin|
45384609|NCT00352690|Radiation|External beam radiation therapy|
45384610|NCT00888485|Behavioral|Behavioral interventional program|Cognitive behavioral therapy intervention adapted to coronary disease patients performed in 20 group sessions during one year.
45384611|NCT03294408|Diagnostic Test|multimodal imaging|
45384612|NCT00895505|Drug|Phenprocoumon|Phenprocoumon 3 mg, tablet, INR adjusted
45384613|NCT00895505|Drug|Warfarin-Natrium|Warfarin-Natrium 5 mg, tablet, INR adjusted
45384614|NCT03988738|Other|Social Media Publications|Messages will be elaborated prior to participant enrollment. Messages will be evaluated by three experts.
45384615|NCT03268824|Device|Electroencephalogram (EEG)|Intracerebral electroencephalogram (EEG) will be analysed to quantify the intensity of epileptic discharge (the epileptogenicity index) on each electrode contact (only for children with focal epilepsy).
45384616|NCT03268824|Device|Diffusion Tensor imaging|We will perform Diffusion Tensor imaging in order to relate tractography measures to seizure recordings. Loss of connectivity (or disconnections) will be determined with diffusion tractography for each brain region. Then we will correlate the degree of epileptogenicity with the number of disconnections.
45384617|NCT03268824|Other|Language assessment|The language assessment will be adapted to the age of the child, with a predominant neuropsychological component.
45384618|NCT03502577|Biological|BCMA-specific CAR-expressing T Lymphocytes|Receive CAR T infusion
45384619|NCT03502577|Drug|Cyclophosphamide|Given IV
45384620|NCT03502577|Drug|Fludarabine|Given IV
45384621|NCT03502577|Drug|Gamma-Secretase Inhibitor LY3039478|Given PO
45384622|NCT03502577|Other|Laboratory Biomarker Analysis|Correlative studies
45695211|NCT01838434|Drug|idelalisib|given PO
45695212|NCT01838668|Drug|Placebo|Two placebo capsules orally BID
45695213|NCT01838668|Drug|dimethyl fumarate|Two dimethyl fumarate 120mg capsules orally BID
45384623|NCT03502577|Other|Pharmacokinetic Study|Correlative studies
45384624|NCT03249012|Other|Empiric use of Calcium Carbonate and Calcitriol|Empiric calcium carbonate and calcitriol repletion
45695214|NCT01728688|Other|PBSC transplantation|PBSCs were mobilized with recombinant human G-CSF at 5-10ug/kg/d for three days. then PBSCs were collected by means of apheresis. The collected PBSCs were infused into participant via hepatic artery
45695215|NCT01728688|Other|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
45695216|NCT01728766|Other|Small for gestational age at delivery|Small for gestational age at delivery. gestational age at >37 weeks by and birth weight <2500 g
45695217|NCT01728766|Other|Post-term Infant, Not Heavy-for-dates|Appropriate for gestational age at delivery. Gestational age at >37 weeks and birth weight >2800 g
45384625|NCT03249012|Other|PTH based Calcium Carbonate and Calcitriol repletion|PTH based treatment
45384626|NCT01565460|Other|Sample Collection|Sample Collection: bile and pancreatic duct brushings and fluid samples will be obtained from the pancreatic stricture during endoscopic retrograde cholangiopancreatic procedure.
45384627|NCT03477539|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
45384628|NCT03477539|Biological|Daratumumab|Given IV
45384629|NCT03477539|Drug|Lenalidomide|Given PO
45384630|NCT03194880|Device|AlereCOMBO and Alere q Detect|"The feasibility assessment will comprise of two components:~User's perspective: A questionnaire will be developed and used to assess the level of satisfaction among community health workers performing the two new tests, using a 5 point Likert scale. We will assess the training and manual, the use of the test, the user's confidence, troubleshooting and technical support components and resolving problems.~The laboratory component: For each test we will evaluate:~The percentage of assays completed~The percentage of assays incomplete (i.e. invalid result on two attempts)~Reasons for incomplete assays, e.g.~The sample could not be delivered to the strip or cartridge correctly~Invalid control~Results could not be interpreted~Others"
45384631|NCT00893477|Biological|rituximab|
45384632|NCT00893477|Biological|sargramostim|
45384633|NCT00893477|Genetic|gene expression analysis|
45384634|NCT00893477|Genetic|gene rearrangement analysis|
45384635|NCT00893477|Genetic|polymerase chain reaction|
45384636|NCT00893477|Genetic|polymorphism analysis|
45384637|NCT00893477|Other|laboratory biomarker analysis|
45384638|NCT01010724|Drug|bIAP|
45384639|NCT01010724|Drug|Placebo|
45695218|NCT04377646|Drug|Hydroxychloroquine|400 mg at day 1 and day 2, then 400 mg weekly up to 2 months
45384640|NCT00609245|Drug|Valproic Acid|The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).
45384641|NCT00609245|Drug|Placebo|Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.
45384642|NCT01010802|Drug|Erythropoietin human recombinant (EPOrh)|Administration scheme by subcutaneous via, of an EPOrh solution up to a weekly doses of 60 UI/kg for five weeks
45384643|NCT04036253|Biological|Erythropoietin alfa|Prefilled syringes of erythropoietin
45384644|NCT00343642|Drug|Active fructo-oligosaccharide|2 teaspoons of active fructo-oligosaccharides daily and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans
45384645|NCT00343642|Drug|Placebo fructo-oligosaccharide|2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily) and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans
45384646|NCT00343642|Dietary Supplement|Diet|A restrictive anti-inflammatory diet developed by the research team and 2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily)
45384647|NCT00893555|Drug|voriconazole|TDM (through level of 2-5mg/L).
45384648|NCT00893555|Drug|voriconazole (dosing according to the SPC)|No serum concentrations are determined
45384649|NCT02541071|Behavioral|Stress Film|
45384650|NCT02541071|Drug|Yohimbine|
45384651|NCT02541071|Drug|Clonidine|
45384652|NCT02541071|Drug|placebo|
45384653|NCT01058824|Drug|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
45384654|NCT01058824|Drug|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
45384655|NCT00895739|Biological|alemtuzumab|
45384656|NCT00895739|Drug|cyclosporine|
45384657|NCT01325038|Procedure|Isometric exercise|Isometric exercise several times/week for three months
45384658|NCT03988660|Diagnostic Test|Circulating fibrocytes|Peripheral blood samples were taken from the patients presented with right iliac fossa pain. Samples were collected in sodium heparin (EDTA). Circulating fibrocyte levels were determined by dual staining peripheral blood samples for CD4 and Col-1 using Fluorescence-Activated Cell Sorting (FACS) and correlated with histopathological diagnosis.
45384659|NCT03986320|Device|Keeogo™ Dermoskeleton|This device is intended for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions.
45384660|NCT03986398|Other|Infection prophylaxis|Infection prophylaxis with Urell®, cranberry fruit juice extract (vaccinium macrocarpon)
45384661|NCT03988348|Procedure|infraumbilical transverse incision|a 10 mm infraumbilical transverse incision will be done to allow trocar to be inserted without undue resistance from the skin so that the trocar will pass through the fascia and the peritoneum with ease
45384662|NCT03988348|Procedure|intraumbilical incision|right sided curved longitudinal intraumbilical incision will be performed for initial intraperitoneal access
45384663|NCT03986164|Device|Guided surgery with bovine spongious bone substitute|"A minimally traumatic extraction will be performed aiming at the preservation of tissue integrity. After this step, milling will be performed using a sequence of guides and cutters recommended by the Raptor Implacil / Bioparts (Implacil De Bortoli) system manufacturer for implant installation (Cone Morse 3.5mm from 11-13mm Implacil De Bortoli) in computer-guided surgeries.~In the spaces between the implant and the buccal bone plate will be filled with xenogene biomaterial (Geistlich Bio-Oss 0.25-1mm). Immediately after implant installation, the prosthetic component (Smart Line, Trunnion CM 3.5mm - T 1.5-3.5mm, height 4mm - Implacil De Bortoli) will be placed.~If necessary, the sutures of the surgical procedures will be performed with polygalactin 5.0 (Vycril Rapid®, Jonhson's Jonhson, São José dos Campos) and will be removed after 7 days."
45384664|NCT03986164|Device|Conventional surgery with bovine spongious bone substitute|The sequence of cutters recommended by the manufacturer for this type of surgery and installation of the same type of implant (Cone Morse due cone 3.5mm) will be adopted. The perforations of the collar for future insertion of the implants will be performed aiming the installation of the implants with its platform installed with sub-crestal position. The implant should be installed along the palatine wall to obtain primary stability, at the center of the mesio-distal width predetermined by the final restoration, with a minimum distance of 2 mm from the adjacent tooth, and 3 mm from the free gingival margin, becoming slightly palatinate (Kan et al, 2018). Immediately after installation, the prosthetic component (Smart Line, Trunnion CM 3.5mm - T 1.5-3.5mm, height 4mm) will be placed. If necessary, the sutures of the surgical procedures will be performed with polygalactin 5.0 (Vycril Rapid®, Jonhson's Jonhson, São José dos Campos) and will be removed after 7 days.
45384665|NCT03988582|Biological|EBV-specific T-cells|During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period.
45384666|NCT01058902|Drug|Aspirin 75 mg|Aspirin 75 mg
45695219|NCT04377646|Drug|Hydroxychloroquine (placebo)|1 pill at day 1 and day 2, then 1 pill weekly up to 2 months
45695220|NCT04377646|Drug|Zinc|15 mg per day up to 2 months
45695221|NCT04377646|Drug|Zinc (Placebo)|1 pill per day up to 2 months
45695222|NCT01728922|Dietary Supplement|5000IU vitamin D|Vigantol Oil
45695223|NCT01728922|Dietary Supplement|10000IU vitamin D|Vigantol Oil
45384667|NCT01058902|Other|no aspirin|nothing
45499876|NCT05336357|Device|Goal-Directed Therapy|"Patients will be monitored by the ClearSight™ System (Edwards Life Sciences, Irvine, CA, USA) in the first 24 hours, where the parameters Cardiac Index (CI), Stroke Volume (SV), Systolic Blood Pressure (SBP) and Mean Arterial Pressure (MAP) will be acquired continuously. The treatment goal will be to keep the CI greater than or equal to 2.2 L/min/m2, the SV greater than or equal to 35 mL/beat, and the SBP greater than or equal to 90 mmHg and/or the MAP greater than or equal to 70 mmHg.~If the CI is below 2.2 L/min/m2 and the SV less than 35 mL/beat, an aliquot of 500 mL of crystalloid solution will be administered; if there is not an increase by 10% in the CI and SV values, a new aliquot of 250 mL may be administered; if this 10% increase does not occur for at least 20 minutes, inotropic medications will be started, with doses titrated periodically. If the pre-established goal is not reached, it is suggested to consider transfusion of a concentrated red blood cell."
45499877|NCT03160885|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
45848263|NCT03375294|Drug|Nitrous Oxide|One hour inhalation of 50% nitrous oxide, an odorless, colorless gas FDA approved as an induction agent for dental sedation
45384668|NCT01055158|Behavioral|Telephone-based CBT|A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes. All sessions begin with a depression rating and agenda setting and end with task assignments and summaries.
45848264|NCT03377244|Behavioral|HBHS|Faith based diabetes curriculum that teaches participants to connect faith and health plus church-level policy changes that encourages participants to engage in healthy behaviors.
45384669|NCT01055158|Behavioral|Enhanced Usual Care|Participants randomized to this condition will be referred to receive in-person psychotherapy. Research study staff will help participants to set up their first appointment with a psychotherapist.
45384670|NCT00609167|Drug|bortezomib|"First 33 patients: 1.3 mg/m^2 IV Days 1, 4, 8 & 11~Remaining 30 patients: 1.5 mg/m^2 IV Days 1, 8, 15 & 22"
45384671|NCT00609167|Drug|cyclophosphamide|300mg/m^2 PO days 1, 8, 15 & 22
45384672|NCT00609167|Drug|dexamethasone|"First 33 patients: 40 mg PO Days 1-4, 9-12, 17-20~Remaining 30 patients: 40 mg PO Days 1-4, 9-12, 17-20 for cycles 1-2; Days 1, 8, 15, 22 for cycle 3+2 for cycle 3 and beyond"
45384673|NCT01055236|Drug|hydroxyzine|75 mg of hydroxyzine orally as premedication drugs at least half an hour before operation.
45384674|NCT04036955|Other|INFOSA-DEM|Caregivers in the intervention group received the INFOSA-DEM programme, together with usual care provided by the participating centres, while caregivers in the CG received usual care in the centres where the follow-up was carried out.
45384675|NCT00895973|Other|Stirrups delivery vs bed delivery|Position of legs at time of vaginal delivery (bed vs stirrups)
45384676|NCT00896129|Other|HRQOL Survey Packet|Questionnaires
45384677|NCT00606281|Drug|Aripiprazole|oral, 24mg/day
45384678|NCT00606281|Drug|placebo|oral, 0mg(4tablets)/day
45384679|NCT00506142|Drug|Marqibo® (vincristine sulfate liposomes injection)|"Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.~Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week."
45384680|NCT01010880|Drug|BKT140|BKT-140 drug substance is a highly selective CXCR4 antagonist. BKT140 will be injected S.C once at dose of 0.03, 0.1, 0.3, 0.9 mg/kg
45384681|NCT00891605|Drug|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-3 out of each 21 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
45499878|NCT03160885|Drug|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
45848265|NCT03377244|Behavioral|HBHS Policy|Church-level policy changes that encourages participants to engage in healthy behaviors.
45384682|NCT00891605|Drug|paclitaxel|"175 mg/m2 over 3 hours of paclitaxel will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
45848266|NCT03377244|Behavioral|WORD DPP|Faith based diabetes curriculum that teaches participants to connect faith and health.
45384683|NCT00891683|Drug|AEG33773 oral dosing|AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
45384684|NCT00893711|Other|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops/day for 21 days
45384685|NCT00893711|Other|Placebo|Placebo is administered in V drops once a day for 21 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
45384686|NCT00893711|Dietary Supplement|L.reuteri + Vit D|
45848267|NCT03379662|Device|Erchonia HLS Laser|The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.
45384687|NCT00893711|Dietary Supplement|Vit D placebo|
45384688|NCT00514020|Drug|fluorouracil|Given through a vein over 5 minutes and then continuously over 46 hours on days 1 and 15.
45384689|NCT00514020|Drug|leucovorin calcium|through a vein over 2 hours on days 1 and 15.
45384690|NCT00514020|Drug|oxaliplatin|500 ml D5W through a vein over 2 hours on days 1 and 15.
45384691|NCT00514020|Genetic|gene expression analysis|Blood collection
45384692|NCT00514020|Genetic|polymorphism analysis|Blood collection
45384693|NCT00514020|Genetic|protein expression analysis|Blood collection
45499879|NCT00730717|Drug|Humira|Will receive 80 mg of Humira injection at week 0 followed by 40 mg weekly Humira injection from Week 1 to Week 23
45384694|NCT00514020|Other|pharmacological study|Blood collection
45384695|NCT03570827|Drug|Androgen Suppression|Given androgen suppression therapy
45384696|NCT03570827|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
45384697|NCT03570827|Other|Quality-of-Life Assessment|Ancillary studies
45384698|NCT03570827|Other|Questionnaire Administration|Ancillary studies
45499880|NCT00730717|Drug|Humira|Will receive 40 mg Humira injection every other week from Week 0 to Week 23
45384699|NCT03560531|Drug|ZN-c5|ZN-c5 is a study drug
45384700|NCT03560531|Drug|Palbociclib|Palbociclib (IBRANCE®) is an approved drug
45848268|NCT03379662|Device|Placebo Laser|The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.
45384701|NCT00513708|Behavioral|Motivation Enhancement Therapy (MET)|"Participants assigned to this arm will receive a 60-minute MET intervention in addition to usual care while hospitalized for detoxification."
45384702|NCT00513708|Behavioral|Peer-Twelve Step Facilitation (P-TSF)|"In addition to usual care while hospitalized for detoxification, participants assigned to this arm will receive a 60-minute visit by peers who are recovering from alcoholism and who are active in 12-step oriented self-help programs."
45848269|NCT03379740|Other|E-cigarette|Subject's own e-cigarette
45384703|NCT00896207|Drug|Akt inhibitor SR13668|Given orally as a single dose
45384704|NCT00896285|Other|Large bore chest drain + NSAID based analgesic regimen|Chest tube greater than 14 French size and ibuprofen.
45384705|NCT00896285|Other|Small bore chest drain + NSAID based analgesic regimen|Chest tube less than or equal to 14 French size and ibuprofen.
45384706|NCT00896285|Other|Large bore chest drain + opiate based analgesic regimen|Chest tube greater than 14 French size and morphine.
45848270|NCT03379740|Other|P4M3-1.7%|P4M3 e-liquid concentration of 1.7% nicotine without lactic acid
45848271|NCT03379740|Other|P4M3-1.7%LA|P4M3 e-liquid concentration of 1.7% nicotine with lactic acid
45848272|NCT03379740|Other|P4M3-3%LA|P4M3 e-liquid concentration of 3% nicotine with lactic acid
45848273|NCT03379740|Other|P4M3-4%LA|P4M3 e-liquid concentration of 4% nicotine with lactic acid
45848274|NCT03390114|Behavioral|SHUTi|SHUTi consists of six, 40-minute, weekly sessions during which the intervention components of stimulus control, sleep restriction, sleep hygiene, cognitive restructuring, and relapse prevention are delivered. Each SHUTi session has the same structure: the main content, a homework screen with options, and a summary of the main points.
45848275|NCT03391986|Device|SEIRIN® Pyonex™ Acupuncture Needles|Needles will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix
45384707|NCT00896285|Other|Small bore chest drain + opiate based analgesic regimen|Chest tube less than or equal to 14 French size and morphine.
45384708|NCT00891761|Drug|Dexamethasone|16 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
45384709|NCT00891761|Drug|Dexamethasone|20 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
45384710|NCT00891761|Drug|IV casopitant (placebo)|IV casopitant (placebo) administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study day 1.
45384711|NCT00891761|Drug|IV casopitant (active)|Single-dose 90 mg IV casopitant administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study Day 1.
45384712|NCT00891761|Drug|Ondansetron|32mg IV ondansetron administered over not less than 15 minutes, with administration started and completed within the 75 minutes prior to the initiation of cisplatin therapy on study Day 1.
45384713|NCT01012830|Drug|Huperzine A|Huperzine A in 200 microgram (mcg) capsules taken twice daily for 8 weeks.
45384714|NCT04036175|Device|High-Flow Nasal Oxygen / Non-invasive ventilation / Standard oxygen|Device High Flow Nasal Oxygen: gas flow of 50L:Min and FiO2 adjusted to obtain SpO2>= 92% Device NIV: Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cmH2O and FiO2 adjusted for SpO2>= 92%
45384715|NCT02540603|Device|F&P Jupiter Full Face Mask|Investigative F&P Jupiter full face mask to be used for OSA therapy
45499881|NCT01332409|Drug|Salmeterol and Fluticasone|Administered according to the prescribing information in the locally approved label by the authorities.
45499882|NCT03181451|Drug|Ferric Maltol|To assess the pharmacokinetics and iron uptake of Ferric Maltol through measurement of serum iron, transferrin saturation (TSAT) and plasma concentrations of maltol and maltol glucuronide.
45499883|NCT03495973|Drug|Ustekinumab|Participants that are initiated on treatment with ustekinumab and are registered in Swibreg will be recruited into the cohort. All aspects of treatment and clinical management of participants will be in accordance with local clinical practice and applicable local regulations, and at the discretion of the participating physician.
45499884|NCT00480805|Drug|MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks|
45384716|NCT00513474|Drug|busulfan|Busulfan 3.2 mg/kg/day from day -7 to day -4 as standard of care for myeloablative (bone marrow depletion) conditioning at the investigator's discretion
45499885|NCT00480805|Drug|Comparator : ramipril /Duration of Treatment : 8 Weeks|
45499886|NCT00406783|Drug|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 15 days
45499887|NCT00406783|Drug|Placebo|Placebo tablet, once daily for 15 days
45384717|NCT00513474|Drug|cyclophosphamide|Cyclophosphamide as standard of care for myeloablative conditioning at the investigator's discretion
45384718|NCT00513474|Drug|cyclosporin-A|Cyclosporin-A as standard of care for GVHD prophylaxis at the investigator's discretion
45384719|NCT00513474|Drug|etoposide|Etoposide as standard of care for myeloablative conditioning at the investigator's discretion
45384720|NCT00513474|Drug|methotrexate|Methotrexate 1.5 mg/kg/day on days -3, -2, and -1 as standard of care for GVHD prophylaxis at the investigator's discretion
45384721|NCT00513474|Drug|rasburicase|Rasburicase 0.20 mg/kg intravenous infusion over 30 minutes for 5 to 7 days
45499888|NCT03179891|Drug|Diazepam Buccal Film 12.5 mg|All subjects received a single dose of DBF 12.5 mg during the interictal state and during the ictal/peri-ictal state with at least 14 days washout between the 2 treatment periods
45499889|NCT01334671|Drug|Atorvastatin|Group 1:80mg before PCI and 40mg per day after PCI for one month then 20mg per day until the end of the trial Group 2:40mg per day after PCI for one month then 20mg per day until the end of the trial Group 3:20mg per day after PCI until the end of the trial
45499890|NCT01332565|Drug|GSK1349572|50mg tablet
45384722|NCT00513474|Drug|sirolimus|Sirolimus as standard of care for GVHD prophylaxis at the investigator's discretion
45384723|NCT00513474|Drug|tacrolimus|Tacrolimus as standard of care for GVHD prophylaxis at the investigator's discretion
45384724|NCT00513474|Procedure|allogeneic hematopoietic stem cell transplantation|
45499891|NCT02973815|Behavioral|NU-HOME Intervention|The NU-HOME family intervention program consists of seven monthly group sessions, individual goal setting calls and online materials to support the sessions. The intervention focuses on promoting healthful family meals where parents and children cook and eat together, healthful home food and physical activity environments, and being active together as a family.
45384725|NCT00513474|Procedure|peripheral blood stem cell transplantation|
45384726|NCT00513474|Radiation|total-body irradiation|Total body irradiation 13.2 Gy over 8 fractions from day -7 to day - 4 for myeloablative conditioning at the investigator's discretion
45384727|NCT00513474|Drug|fludarabine|Fludarabine 40 mg/m^2/day from day -6 to day -3 as myeloablative conditioning at the investigator's discretion
45384728|NCT00513474|Drug|allopurinol|Allopurinol per institutional guidelines
45384729|NCT00891917|Dietary Supplement|Ubiquinol-10 Syrup|10 mg/kg/day in 2 divided doses for 3 months or Placebo Syrup for 3 months
45384730|NCT00891917|Dietary Supplement|syrup (placebo)|syrup looks exactly like the Ubiquinol-10 Syrup but has no active ingredients or supplementation
45384731|NCT00893867|Drug|DP-b99|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
45499892|NCT01338727|Behavioral|Breastfeeding Peer Counseling|3 Prenatal visits, daily in-hospital visits, 11 postpartum home visits.
45499893|NCT01332643|Genetic|Preimplantation Genetic Diagnosis|All embryos in the test group reaching blastocyst stage will undergo embryo biopsy of 3-10 trophectoderm cells. The cells will be analyzed by array CGH to detect the presence or not of chromosome abnormalities. The embryos will be vitrified and those classified by array CGH as normal, thawed for replacement.
45499894|NCT05185765|Other|Bread|Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.
45499895|NCT03160573|Drug|ClōSYS® Unflavored Rinse|
45499896|NCT03160573|Drug|ClōSYS® Flavored Rinse|
45499897|NCT03160573|Other|Placebo-Flavored Oral Rinse|Flavor-matched placebo rinse
45499898|NCT03160573|Other|Placebo-Unflavored Oral Rinse|Unflavored-matched placebo rinse
45499899|NCT01314677|Procedure|positron emission tomography/computed tomography (PET/CT)|Undergo FDG PET/CT
45499900|NCT01314677|Radiation|fludeoxyglucose F 18|Undergo FDG PET/CT
45499901|NCT05185687|Behavioral|First Come, First Served|"Respondents will view the following description of the plan: Tests will be sent out in the order they are requested. People who request tests the quickest will get them first, no matter where they live. People who request tests later may not get any. This strategy is also known as 'First Come, First Served.'"
45695224|NCT01728922|Other|Placebo|Placebo Oil
45384732|NCT00893867|Drug|Placebo|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
45499902|NCT05185687|Behavioral|Random|"Respondents will view the following description of the plan: People who request tests will be entered into a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live, but some people may not get any tests."
45499903|NCT05185687|Behavioral|Disadvantaged Priority & Random|"Respondents will view the following description of the plan: Because COVID-19 has hit people living in disadvantaged areas of the country harder, a proportion of tests will be sent exclusively to people in these zip codes. Planners will allocate 80% of the tests using a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live. The remaining 20% are set aside exclusively for the most disadvantaged areas, again allocated with a random drawing. Some people may not get any tests. But people living in disadvantaged areas are more likely to get them."
45384733|NCT01010958|Drug|Valproic Acid|Subjects should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 - 100 µg/mL).
45384734|NCT04036877|Other|Mood Disorder Assessment|Assess depression, anxiety, HRQOL, and financial toxicity in both bladder cancer patients and their caregivers via telephone survey
45384735|NCT00896519|Biological|rituximab|
45384736|NCT00896519|Biological|sargramostim|
45384737|NCT00896519|Drug|cyclophosphamide|
45384738|NCT00896519|Drug|doxorubicin hydrochloride|
45384739|NCT00896519|Drug|prednisone|
45384740|NCT00896519|Drug|vincristine sulfate|
45499904|NCT04470661|Diagnostic Test|Ultrasonography|"Point-of-care ultrasound:~Kidney length and echogenity,~Bladder scanning~VCI measures~Lung B lines and effusion~Cardiac measurements; EF, TAPSE, TR Vmax, Diameters, LV filling pressures"
45695225|NCT01682720|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
45695226|NCT01682720|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
45695227|NCT01682720|Drug|Placebo to match SOF|Placebo to match SOF administered orally once daily
45695228|NCT01682720|Drug|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
45695229|NCT01838902|Drug|DHA-PPQ|Participants will receive a 3 day course of DHA-PPQ
45695230|NCT01838902|Drug|PQ (0.75)|Participants will receive a single dose of PQ at 0.75mg base/kg body weight
45695231|NCT01838902|Drug|PQ (0.4)|Participants will receive a single dose of PQ at 0.4mg base/kg body weight
45695232|NCT01838902|Drug|PQ (0.2)|Participants will receive a single dose of PQ at 0.2mg base/kg body weight
45384741|NCT00896519|Genetic|gene expression analysis|
45384742|NCT00896519|Genetic|gene rearrangement analysis|
45384743|NCT00896519|Genetic|polymerase chain reaction|
45384744|NCT00896519|Other|R-CHOP regimen|
45695233|NCT03409822|Device|Masimo SpHb™ monitor|Attach the Masimo Rainbow SET® Radical-7 ™ pulse oximeter probe to the third or fourth finger and perform a Masimo SpHb ™ monitor.
45695234|NCT03401086|Other|Kinesio Taping|Kinesio Taping
45695235|NCT04553432|Device|Amniotic membrane Omnigen[TM]|17mm circular disk of processed amniotic tissue donated by mother after birth with a 6mm laser cut aperture to allow unimpeded vision https://www.nu-vision.co.uk/omnigen
45695236|NCT04553432|Device|Bandage soft Contact Lens OmniLenz[R]|18mm soft silicone-hydrogel contact lens https://www.nu-vision.co.uk/omnilenz
45695237|NCT03409510|Radiation|UVB radiation|"UVB treatment regimen:~Week 1-2: 0.85 kilo Joule/m2 twice per week Week 3-7: 0.85 kilo Joule/m2 three times per week Week 8-9: 1.4 kilo Joule/m2 three times per week"
45695238|NCT04551014|Device|Use of EverLift|Use of EverLift for submucosal injection prior to polypectomy
45384745|NCT00896519|Other|laboratory biomarker analysis|
45384746|NCT00896597|Drug|NRL972|2 mg NRL972 in 5 mL solution for injection administered as a 15-second intravenous injection on each of four occasions.
45384747|NCT00505752|Drug|AS900672-Enriched 50 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone [r-hFSH]), 50 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
45384748|NCT00505752|Drug|AS900672-Enriched 100 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 100 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
45695239|NCT04551014|Device|Without use of EverLift|Without use of EverLift for submucosal injection prior to polypectomy
45695240|NCT01729000|Other|Gloves|All staff must wear gloves for subjects that are in the experimental group.
45695241|NCT01729078|Dietary Supplement|Dietary intervention|three different diets ( high fat-low carb-low fiber/high carb-low fat - high fiber/high carb-low fat-low fiber)
45695242|NCT01714544|Drug|Cloderm Cream|
45384749|NCT00505752|Drug|AS900672-Enriched 150 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 150 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
45384750|NCT00505752|Drug|Follitropin alfa 150 international unit (IU)|Follitropin alfa (Gonal-f®) 150 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 21 (S21) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 50, 100 and 150 mcg will also receive daily dose of follitropin alfa 150 IU subcutaneously from Stimulation Day 6 (S6) up to S21. Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
45499905|NCT02736227|Drug|Tacrolimus Withdrawal and Everolimus Monotherapy|During the first month post-transplant, the subject receives everolimus (about 5-8 ng/mL) and tacrolimus with or without mycophenolic acid as part of standard of care procedures. At one month post-transplant, mycophenolic acid will be stopped and tacrolimus dosage will be reduced while continuing the dosage of everolimus. At three months post-transplant, tacrolimus dosage will be reduced by 50% of the daily dose each week. At four months post-transplant, tacrolimus will be discontinued.
45499906|NCT01334905|Drug|YM178|oral
45499907|NCT02623985|Device|Sofia|Patients who presented with sore throat will be performed throat swab and sent for Sofia for rapid test.
45499908|NCT02623985|Device|QuickVue|Patients who presented with sore throat will be performed throat swab and sent for QuickVue for rapid test.
45499909|NCT02623985|Device|Throat swab culture|Patients who presented with sore throat will be performed throat swab and sent for throat swab culture for gold standard.
45499910|NCT01334983|Behavioral|REST|Instruction in an individualized rapid easy strength training (isotonic with therabands) and pedometer-based walking programs.
45695243|NCT03401008|Other|Oral manifestations|To do the most accurate clinical and radiological state of oral manifestations in the series of prevalent acromegaly patients followed in the endocrinology service of the CHU of Clermont-Ferrand.
45695244|NCT03400696|Behavioral|Lower carbohydrate diet|Focused on limiting dietary carbohydrates, eating healthy fat and protein sources, and engaging in physical activity
45384751|NCT00505752|Drug|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, at least 1 follicle with a diameter of greater than or equal to [>=] 18 millimeter [mm], two or more additional follicles with a diameter of >= 16 mm, and Estradiol [E2] levels will approximately 150 picogram per milliliter [pg/mL] per mature follicle).
45384752|NCT01011036|Drug|clobazam|test substance
45384753|NCT01011036|Drug|clonazepam|positive control
45499911|NCT01332877|Behavioral|Enriched breakfast|high carbohydrate, high protein breakfast supplying 600 kcal as 50k% carbohydrate, 20% protein, 30% fat
45384754|NCT01011036|Drug|tolterodine|active placebo
45499912|NCT01332877|Behavioral|Control breakfast|Control breakfast providing 300 kcal, 13% carbohydrate, 40% protein, 48% fat
45695245|NCT03400696|Behavioral|Higher fiber diet|Focused on increasing dietary fiber, lowering fat intake from animal sources, and engaging in physical activity
45499913|NCT05095337|Drug|[14C]SHR1459|Patients will receive single dose of orally [14C]SHR1459 on Day 1.
45499914|NCT01335139|Biological|Sublingual immunotherapy (SLIT)|Participants randomized to receive sublingual allergen tablet immunotherapy with placebo injections.
45499915|NCT01335139|Biological|Subcutaneous immunotherapy (SCIT)|Participants randomized to receive subcutaneous injection immunotherapy with placebo tablets. Subcutaneous immunotherapy was included as a positive control.
45499916|NCT01335139|Other|Placebo|Participants randomized to double-placebo tablets and injections. This group was included as a negative control.
45848276|NCT03391986|Procedure|12 mm Plasters|"12 mm (0.5). Latex-free Adhesives will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix"
45695246|NCT03400696|Behavioral|Physical activity focused|Focused on aerobic and resistance exercise, while following dietary guidelines <https://www.choosemyplate.gov>
45695247|NCT01729234|Dietary Supplement|Nitrate|Dietary Supplement
45695248|NCT01729234|Dietary Supplement|Placebo|Dietary Supplement
45695249|NCT03409432|Drug|Brentuximab Vedotin|Given IV
45695250|NCT03409432|Other|Laboratory Biomarker Analysis|Correlative studies
45695251|NCT03409432|Drug|Lenalidomide|Given PO
45695252|NCT03409354|Behavioral|Tele-rehabilitation|There are five different categories of exercise in the rehabilitation program, which combines both physiotherapy (Category 1 to 4) and occupational therapy components (Category 5). Each tele-therapy session could cover all five categories of exercises. Progression of levels within each exercise within each category should be determined by the tele-therapist and in consultation with the participant.
45848277|NCT03392532|Device|Lotrafilcon B toric contact lenses with HYDRAGLYDE|Silicone hydrogel soft contact lenses for astigmatism
45848278|NCT03392532|Device|Lotrafilcon B toric contact lenses|Silicone hydrogel soft contact lenses for astigmatism
45848279|NCT03395808|Drug|Tramadol|IV; 50 mg given at Hours 0, 2, 4, 8 and every 4 hours thereafter, for a total of up to 43 doses
45695253|NCT03409354|Behavioral|Usual care|Usual rehabilitation care (e.g., PT, OT and ST), prescribed by rehabilitation therapists at participating centers and performed by participants at participating centers.
45695254|NCT03400462|Drug|NSAID|Nimesulide has anti-inflammatory and analgesic properties. Like other NSAIDs it inhibits the action of COX . If prostaglandins can not be further synthesized, so there is no factor able to excite local nociceptors. According to t must be taken regularly for a minimum 2 weeks to achieve appropriate blood concentration.
45695255|NCT03400462|Device|oral appliance|The stabilization appliance used in this study was a removable device for maxillary arch, made of hard acrylic. Appliance was fitted over occlusal and incisal surfaces of the teeth and precisely contacted with the teeth of opposing arch. It provided canine disocclusion of the posterior teeth during eccentric movements.
45695256|NCT03400462|Other|dry needling|Equipment: acupuncture needle 0,6*13 e.g. Dragon Medical Device, Visits schedule:( 1st visit - Day 1st , 2nd visit- 7 days after the 1st, 3rd visit- 7 days after the 2nd)
45695257|NCT01703858|Drug|BI 113608 PIB|powder for oral solution
45848280|NCT03395886|Drug|Remifentanil|The noninvasive ventilation intolerated patients was sedated by remifentanil.
45848281|NCT03395886|Drug|Dexmedetomidine|The noninvasive ventilation intolerated patients was sedated by dexmeditomidine.
45848282|NCT03396432|Device|Video Laryngoscopy for ET placement|Tracheal intubation performed with the Storz C-Mac Video Laryngoscope
45384755|NCT03601637|Drug|LUM|Fixed Dose Combination (FDC) granules (LUM/IVA).
45695258|NCT01703858|Drug|BI 113608|conventional tablet formulation
45695259|NCT01703858|Drug|BI 113608|conventional tablet formulation
45384756|NCT03601637|Drug|IVA|FDC granules (LUM/IVA).
45384757|NCT00896675|Other|proteomic profiles|blood samples analysis
45384758|NCT00896675|Other|proteomic profiles|blood samples analysis
45384759|NCT00893945|Drug|DC/AAT|Autologous dendritic cells that have been co-cultured with autologous apoptotic tumor (AAT) specimens.
45384760|NCT00893945|Drug|DC/AAT-Flu|Intradermal injection of Autologous dendritic cell vaccine (DC/AAT-Flu) after co-culture with flu-infected AAT
45695260|NCT01703858|Drug|BI 113608|conventional tablet formulation
45695261|NCT01703858|Drug|pantoprazole 40 mg STADA|film-coated tablet
45695262|NCT01703858|Drug|BI 113608|conventional tablet formulation
45848283|NCT03396432|Device|Direct Laryngoscopy for ET Placement|Tracheal Intubation performed with the Miller Blade
45848284|NCT03398928|Other|Acupuncture|Acupuncture added to usual care
45848285|NCT03400800|Drug|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
45384761|NCT00893945|Drug|DC/KLH|Intradermal injection of Autologous dendritic cell vaccine (DC/KLH) which have been co-cultured with Keyhole pimpit hemocyanin (KLH) as a positive control.
45384762|NCT00894023|Drug|Intracoronary bolus wtih ClearWay™RX catheter|Intracoronary bolus with Clearway catheter
45384763|NCT00894023|Drug|IV abciximab|IV abciximab + infusion
45848286|NCT03400800|Drug|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
45384764|NCT00892073|Drug|Diazoxide|Diazoxide will be initiated at half the dose (100 mg per day) for 2 weeks to allow the insulin sensitizing action of metformin to take effect. Dosage will be increased to 200mg daily, divided twice daily with meals for 6 months.
45384765|NCT00892073|Drug|Metformin|Metformin will be initiated at 500 mg twice daily and increased to 1000 mg twice daily over a one week period to minimize gastrointestinal side effects. the 2000mg is to be taken with meals for 6 months.
45499917|NCT05030129|Dietary Supplement|5-Hydroxytryptophan / Vitamin B6|5-hydroxytryptophan, also known as 5-HTP has a nutraceutical status and has never been approved as a drug for any indication, but as a dietary supplement has been used extensively for several disorders for many years such as in the therapy of depression, fibromyalgia, obesity, insomnia and chronic headache
45499918|NCT05030129|Drug|Ergoloid Mesylate|Ergoloid Mesylates, trade name Hydergine, is a mixture of the methanesulfonate salts of three dihydrogenated ergot alkaloids, dihydroergocristine, dihydroergocornine, and alpha- and beta-dihydroergocryptine. Ergot alkaloids are dopamine agonists which activate dopamine receptors (in the basal ganglia and other parts of the brain involved in motor function) and a prolactin inhibitor. Ergot is a strong vasoconstrictor and thus helps to reduce bleeding by narrowing of the blood vessels.
45499919|NCT05030129|Other|Placebo|Placebo capsules
45384766|NCT00894101|Drug|[F-18] FLT|10 mCi [F-18] FLT and 10 mCi [F-18] FDG will be used for PET imaging.
45384767|NCT00896831|Drug|L-ornithine-L-aspartate|L-ornithine-L-aspartate: 5 g (1 sachet) three times per day for 60 days
45384768|NCT00896831|Drug|placebo|Placebo: 5 g (1 sachet) three times per day for 60 days
45384769|NCT00896909|Genetic|gene expression analysis|
45384770|NCT00896909|Genetic|mutation analysis|
45499920|NCT01335217|Procedure|Transcutaneous Electrical Nerve Stimulator (TENS)|External trigeminal nerve stimulation (TNS) as an adjunctive treatment for adults with major depressive disorder (MDD) co- occurring with posttraumatic stress disorder (PTSD) when added onto antidepressant medications
45384771|NCT00896909|Genetic|polymerase chain reaction|
45384772|NCT00896909|Other|diagnostic laboratory biomarker analysis|
45384773|NCT02541227|Drug|Cerebrolysin|Cerebrolysin dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
45384774|NCT00896987|Drug|lamotrigine (Lamictal)|lamotrigine: titration for 8 weeks (25 mg~200 mg per 2 weeks) and maintenance for 40 weeks (200 mg)
45695263|NCT03409042|Behavioral|Caloric compensation|The investigators have adapted an established within-subject preload paradigm to assess infant's short term caloric compensation. At each studied age, the measure of caloric compensation required two visits at the laboratory on two non-consecutive days. On the first visit, the infants received a fixed amount of a food preload either low or high in energy density. The order of the two preloads was counterbalanced. After a delay (ranging from several hours in the 3-4 months old infants to 25 min in 10.5- and 14.5-month-old infants), the infants were served an ad libitum meal. Weight intakes (g) were assessed by weighing each bottle/bowl before and after consumption.
45848287|NCT03410628|Device|gammaCore|Non-invasive vagal nerve stimulator
45384775|NCT00896987|Drug|Carbamazepine (Tegretol)|Carbamazepine: titration for 8 weeks (100 mg~600 mg) and maintenance for 40 weeks (600 mg)
45384776|NCT00897065|Genetic|microarray analysis|
45848288|NCT03410862|Drug|Elderberry Extract|Thick reddish-brown liquid of Sambucus Nigra (Black Elderberry)
45848289|NCT03410862|Drug|Placebos|Thick reddish-brown liquid similar in appearance and taste to Elderberry Extract not containing elderberry
45384777|NCT00897065|Genetic|polymerase chain reaction|
45384778|NCT00897065|Genetic|protein expression analysis|
45384779|NCT00897065|Other|diagnostic laboratory biomarker analysis|
45384780|NCT00897065|Other|fluorescent antibody technique|
45384781|NCT00897065|Other|immunohistochemistry staining method|
45384782|NCT00897065|Other|immunologic technique|
45384783|NCT00897143|Genetic|microarray analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
45384784|NCT00897143|Genetic|mutation analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
45384785|NCT00897143|Other|flow cytometry|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
45384786|NCT00897143|Other|immunologic technique|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
45554656|NCT03195998|Diagnostic Test|TcB Measurement|TcB measurements will be obtained within approximately 30 minutes of the TSB being drawn before initiation of phototherapy, approximately 24 hours after the initiation of phototherapy and approximately 24 hours after completion of phototherapy. The TcB measurement will involve lightly pushing three times at each site which will yield an average transcutaneous bilirubin value. This will be calculated for the interscapular, buttock and sternal automatically by the bilirubinometer. While on phototherapy a measurement of the diapered, non-exposed buttock area will be obtained at approximately 24 hours to coincide with the standard of care serum bilirubin measurement.
45554657|NCT03528759|Diagnostic Test||phenotypic and genotypic Method
45499921|NCT05239559|Device|Bubble CPAP oxygen delivery device|"In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the nasopharynx of the baby. An underwater tube (expiratory arm) that acts as a blow off valve is interposed between the oxygen source and the baby. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the baby. The constant bubbling of gas through the blow off mechanism delivers the bubbling CPAP effect. Oxygen may be delivered by nasal prongs inserted into the nostril of child.~The system has three components:~Continuous gas flow into the circuit: The gas flow rate required to generate CPAP is usually 5-10 L/min.~A nasal interface connecting the child's airway with the circuit:~An expiratory arm with the distal end submerged in water to generate end-expiratory pressure.~The source of oxygen will be either an oxygen concentrator or cylinder, central distribution through pipelines."
45384787|NCT04035863|Device|Low level laser therapy|"For the PBM protocol, articles of interest were identified through analyses of titles and abstracts. Articles addressing PBM in experimental models or clinical trials of spinal cord injuries were included and articles not pertinent to the proposed study were excluded. Next, the selected articles were analyzed and used for the creation of an initial protocol (Table 1).~For irradiation, the individuals will be positioned comfortably in lateral decubitus on the examining table. Three points will be irradiated above the lesion level, which will be located using an imaging exam brought by the guardian on the day of the evaluation. After determining the lesion level, palpation of the transverse processes of the vertebrae will be performed. The same laser device (Laser DMC Therapy EC) will be used for both groups. For the placebo group, the device will emit sound but not light."
45384788|NCT00343252|Drug|teriparatide|20 ug/day, subcutaneous, 18 months
45384789|NCT00343252|Drug|risedronate|35 mg/once weekly, oral, 18 months
45499922|NCT03260023|Biological|TG4001|PhIb: Dose escalation PhII: Established RP2D for TG4001
45499923|NCT03260023|Drug|Avelumab|Anti PD-L1
45384790|NCT00343252|Drug|placebo|once weekly, oral, 18 months
45384791|NCT00343252|Drug|placebo|daily, subcutaneous, 18 months
45499924|NCT01338961|Procedure|Hypothermic CPB|Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC
45499925|NCT01339039|Drug|Plerixafor|Given subcutaneously once a day for 3 weeks followed by 1 week off (standard 3x3 design); MTD determined in Part 1 will be used as dose in Part 2.
45499926|NCT01339039|Drug|Plerixafor|Given subcutaneously once daily; MTD determined in Part 1 will be used as dose in Part 3.
45499927|NCT01339039|Drug|Bevacizumab|Given intravenously on days 1 and 15 (10 mg/kg) of each 28-day cycle
45499928|NCT01339039|Drug|Plerixafor|Daily administration for 5-9 days prior to surgery
45499929|NCT01339039|Procedure|Surgery|After receiving 5-9 days of Plerixafor (AMD3100) monotherapy, patients proceed to surgery. After recovering from surgery, patients will proceed to 28-day post-surgical cycles of therapy (Plerixafor at the MTD established in Part 1, 21 days on / 7 days off; bevacizumab 10 mg/kg on days 1 & 15).
45499930|NCT03176459|Drug|Exparel + Bupivacaine|EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam®.
45695264|NCT01729390|Other|Energy density and portion size feeding study|In a crossover design, adults are served breakfast and lunch, 1 day a week for 6 weeks. Breakfast is not varied across weeks. At 4 of the lunch meals, a salad first course will be served that needs to be eaten in its entirety. At these 4 meals the lunch entree will vary in energy density (100% and 133%) and portion size (100% and 133%). At the 2 lunch meals for which no first course is served, the lunch entree will be vary in energy density (100% and 133%) but be the same portion size (133%).
45695265|NCT01729468|Drug|Aspirin|Aspirin, 160 mg per day until 34 weeks of gestation
45695266|NCT01729468|Drug|Placebo|Placebo, 160 mg per day until 34 weeks of gestation
45499931|NCT03176459|Drug|Bupivacaine|Bupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.
45499932|NCT01339117|Other|Low fermentable substrate diet|Diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols.
45499933|NCT01339117|Other|High fermentable substrate diet|Diet high in fermentable oligosaccharides, disaccharides, monosaccharides and polyols
45499934|NCT01335295|Drug|Flavocoxid|Flavocoxid capsules TTD 500 mg/die or 1000 mg/die for 1 year
45499935|NCT05239481|Device|colonoscopy position identification sheet|According to the body position requirements of the left lying position during colonoscopy, the research group used ink to add the body position prompt sign on the disposable bed sheet .Through the position identification, patients can intuitively understand the position that should be used in the operation and the position that should be placed in each part of the body.
45384792|NCT00892229|Drug|Misoprostol (given buccally)|400 microgram misoprostol given buccally three hours before dilation and curettage (PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
45384793|NCT00892229|Drug|Misoprostol (given vaginally)|400 microgram misoprostol (MISOPROSTOL - PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
45384794|NCT00897221|Drug|Deferiprone oral solution 100mg/mL|Deferiprone oral solution (20 mg/kg/day)
45384795|NCT00897221|Drug|Deferiprone oral solution 100 mg/mL|Deferiprone oral solution(40mg/kg/day)
45384796|NCT02540525|Device|Ophira|The procedure will be perfomed with a single incision in anterior wall vagina
45384797|NCT02540525|Device|Transobturator sling|Safyre T Plus ® system uses two helical needles for securing an average urethral sling mesh polypropylene soft tissue below the pubic bone by means of spinal anesthesia. Short form of the sling implantation is carried out as follows: a small longitudinal incision in the anterior vaginal wall approximately 2 cm is performed at 1 cm from the urethral meatus. Takes place below minimum dissection toward the lower branch of the ischium, and with the aid of the needle obturator and perforated membrane (outside-in maneuver). After that, the sling is attached to the needle carrying the same path. Subsequently, the passage of the needle is held in contraleral side. The procedure finishes performing the adjustment of the track with the aid of Kelly forceps type.
46056129|NCT04190667|Diagnostic Test|Genomic testing|A multi-panel testing of 36 genes would be given for these patients in their peripheral blood and tumor tissues. These 36 genes include: BRCA1, BRCA2, ABRAXAS1(FAM175A）, ATM, ATR, BAP1, BARD1, BRIP1, C11ORF30（EMSY）, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCI, FANCL, MRE11A, NBN, PALB2, PPP2R2A, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RAD54B, RAD54, MLH1, MSH2, MSH6, PMS2, EPCAM, STK11, TP53, CDH1. The study would select 150 patients with pathogenic or likely pathogenic mutations in BRCA1/2 and 150 patients without these mutations to further explore the HRD status.
45384798|NCT00892307|Radiation|Dual Source Multidetector CT (DSCT) w/ Adenosine enhancement|Somatom Definition Dual Source CT Scanner Stress/Rest Image scan using weight based CT contrast dye
45384799|NCT00897299|Genetic|microarray analysis|
45384800|NCT00897299|Genetic|protein expression analysis|
45384801|NCT00897299|Other|immunohistochemistry staining method|
45384802|NCT00897299|Other|laboratory biomarker analysis|
45384803|NCT00342628|Biological|Vi-rEPA conjugate vaccine for typhoid fever|Vi-rEPA contains a 25 ug/dose of Vi (Sanofi-Pasteur Lot 130) and rEPA in 0.2 N NaCl, 10 mM phosphate PH 7.2 and 0.01% thimerosal.
45499936|NCT05239481|Device|Traditional disposable cleaning sheet|Traditional disposable cleaning sheets were used during control colonoscopy.Before the examination, the nursing staff took a unified and simple language to guide the patient.
45499937|NCT01332955|Drug|Telaprevir|"Drug : telaprevir, Tablet, Oral, 750 mg, q8h, 12 weeks if associated with atazanavir or raltegravir~Drug : telaprevir, Tablet, Oral, 1125 mg, q8h, 12 weeks if associated with efavirenz"
46056130|NCT02744547|Dietary Supplement|Spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
45384804|NCT00342628|Biological|Hib-TT|Hib-TT is Hemophilus influenzae type b-tetanus toxoid conjugate vaccine (ActHib, NDC#49281-545-05 Sanofi-Pasteur, France) in single-dose vials containing 10 ugof Hib CP conjugated to 24 ug of tetanus toxoid
45384805|NCT00342628|Biological|DTP|DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization
45384806|NCT00897377|Radiation|Radiation therapy|
45384807|NCT00897377|Drug|Temozolomide|
45384808|NCT04036019|Biological|CD20-directed CAR-T cells|Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously
45384809|NCT00505284|Drug|Placebo|Placebo tablets, once daily, for 15 weeks (taken orally).
45384810|NCT00505284|Drug|E2007 (2 mg)|Perampanel, 2 mg once daily, for 15 weeks (taken orally).
45384811|NCT00505284|Drug|E2007 (4 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).
45384812|NCT00505284|Drug|E2007 (6 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).
45384813|NCT00505284|Drug|E2007 (8 mg)|Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).
45384814|NCT00894569|Drug|paclitaxel/carboplatin|6 cycles paclitaxel 175 mg/m² and carboplatin AUC 5, repetition d22.
45384815|NCT00894569|Drug|cetuximab|cetuximab (400 mg/m² first dose, 250 mg/m² weekly) until disease progression
45499938|NCT01332955|Biological|pegIFN alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks or 72 weeks
45499939|NCT01332955|Drug|Ribavirin|(weight-based dose) Tablet, Oral, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, 48 weeks or 72 weeks
45499940|NCT05224895|Procedure|General Anesthesia in Trendelenburg position for robotic prostatectomy|in this arm, changes in preoperative and postoperative airway measurements and correlation with postoperative critical airway events will be monitored.
45499941|NCT01335373|Drug|Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)|Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.
45384816|NCT00337168|Drug|clofarabine|Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
45695267|NCT04550468|Other|Low-Carb High-Fat breakfast|Participants will receive 8 low-carb high-fat breakfast meal recipes to follow daily during 3 months.
45695268|NCT04550468|Other|"Low fat standard care control breakfast"|Participants will receive 8 low-fat breakfast meal recipes to follow daily during 3 months.
45384817|NCT00337168|Drug|cytarabine|Induction: 1g/m2/d; IV over 2 hrs; days 1-5 Re-induction (if necessary): 1g/m2/d; IV over 2 hrs; days 1-5 Consolidation: 1g/m2/d; IV over 2 hrs; days 1-4
45384818|NCT00892385|Drug|Methoxyamine|For all cycles, TMZ will be given orally for 5 days every 28 days. MX will be given as a single one-hour IV infusion every 28 days. Temozolomide will be administered within 5 minutes following the initiation of methoxyamine.
45384819|NCT00892385|Drug|Temozolomide|Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
45384820|NCT00892463|Drug|Quetiapine (Seroquel) XR|50mg/day - first 2 weeks 150mg/day - remaining 4 weeks min dose: 50mg/day max dose: 300mg/day
45499942|NCT05221463|Behavioral|Video-assisted breastfeeding training|Breastfeeding training was given to the experimental group for 3 days by means of the training material prepared by the training nurse of the hospital about breast milk and breastfeeding and routinely used by nurses in breast milk training in neonatal units. During the training, mothers were allowed to watch breast milk and breastfeeding training videos. On the third day after the training, feedback was received from the applications in the video regarding the knowledge and skills of the mother, and the mother's questions were answered.
45554658|NCT01190852|Drug|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray
45554659|NCT01190852|Drug|Azelastine mono|REF = AZE mono Azelastine Hydrochloride nasal spray (= essentially combination product formulation without any FLU; US AZE mono formulation as used in pivotal studies)
45554660|NCT01190852|Drug|Azelastine|COMP = Astelin® Nasal Spray = AZE mono Azelastine Hydrochloride nasal spray (= US marketed product)
45695269|NCT03400384|Other|Direct-to-consumer educational brochure|The intervention arm will be mailed an evidence-based, theory-driven direct-to-consumer educational brochure, highlighting the potential benefits and harms of opioids when used to treat chronic non-cancer pain.
46056131|NCT03737253|Drug|Follitropin alpha|The objective is to measure the effect of the drug according to gonadotropin receptor genotype.
46056132|NCT03737253|Drug|Menotropin|The objective is to measure the effect of the drug according to gonadotropin receptor genotype.
45384821|NCT01011114|Drug|Cinacalcet|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
45384822|NCT01011114|Drug|Placebo|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
45384823|NCT00606905|Biological|Gamimune N or Gamunex 10%|500 mg/kg administered in the follicular phase of the menstrual cycle. With conception, infusions every four weeks until 18-20 weeks of gestation.
45384824|NCT00606905|Other|normal saline|equivalent volume of normal saline
45554661|NCT02444312|Behavioral|Benefit-finding Writing Activity|Caregivers will be instructed to write about the benefits of caring, considering things such as improved social relationship, appreciation of life and loved ones, and the positive consequences with respect to these.
45695270|NCT01729546|Device|7 Blood glucose monitoring systems|
46056133|NCT02740569|Other|No intervention|Observational study. Intervention according to the clinical routines (not included in this part)
46056134|NCT00812968|Drug|Lenalidomide|Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
46056135|NCT02744703|Drug|total-etch adhesive|comparator use of total-etch adhesive
46056136|NCT02744703|Drug|CAPE-T|experimental group
46056137|NCT02744703|Drug|self-etch adhesive|comparator use of total-etch adhesive
46056138|NCT02744703|Drug|CAPE-S|experimental group
46056139|NCT02744937|Drug|Aspirin|aspirin is continued by its regular dosing
46056140|NCT05394337|Drug|Atezolizumab|Given by vein (IV)
46056141|NCT05394337|Drug|Tiragolumab|Given by vein (IV)
46056142|NCT02744625|Drug|Higher doses of vasopressor therapy for a MAP of 75 mmHg|
46056143|NCT02744625|Drug|Lower doses of vasopressor therapy for a MAP of 65 mmHg|
45384825|NCT01055392|Drug|Lithium Carbonate|lithium carbonate tablets, 150 mg to 450 mg (target serum lithium level 0.25 mEq/L - 0.5 mEq/L), divided in two doses, two years.
45384826|NCT01055392|Drug|Placebo|Identical placebo tablets were administered twice-a-day for two years.
45384827|NCT03063762|Drug|Atezolizumab|"Arms A and B Atezolizumab will be administered at a dose of 840 milligrams (mg) prior to RO6874281 administration as an intravenous (IV) infusion on Days 1, 15, 29, and once in 2 weeks from Day 29 onwards. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~Arms C and D Atezolizumab will be administered at a dose of 1200mg as it is a Q3W schedule"
45384828|NCT03063762|Drug|Bevacizumab|"Arms A and B Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) after the atezolizumab administration, and prior to RO6874281 administration as an IV infusion on Days 15, 29, and once in 2 weeks from Day 29 onwards.~In Arm D, Bevacizumab will be administered at a dose of 15mg/kg on Day 8 of Cycle 2 and on Day 8 of each consecutive cycle."
45384829|NCT03063762|Drug|RO6874281|"Arms A and B RO6874281 will be administered as an IV infusion on Days 1, 8, 15, 22, and 29, and once in 2 weeks from Day 29 onwards. Starting dose of RO6874281 will be 5 mg, and will be increased subsequently. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~In Arms C and D, RO will be administered on Q3W schedule at the dose defined in the dose escalation part"
45384830|NCT00897455|Genetic|DNA analysis|
45384831|NCT00897455|Genetic|mutation analysis|
45384832|NCT00897455|Genetic|polymorphism analysis|
45384833|NCT00897455|Other|laboratory biomarker analysis|
45384834|NCT00897455|Procedure|evaluation of cancer risk factors|
45384835|NCT03985228|Dietary Supplement|Fortified milk|Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose <0.01%), enriched in whey protein (5%) and calcium (0.24%), supplemented with unsaturated fatty acids omega-3 (DHA + EPA), vitamins (D, B12, B6, B9, E, C), prebiotics (FOS) and phyto curcuminoids (sunflower lecithin). Milk had to be associated with a packet of lyophilized and concentrated probiotics (Bifidobacteria infant-type and / or Lactobacilli), at the time of consumption. Milk and probiotics had been produced or supplied by Granarolo s.p.a.
45384836|NCT03985228|Dietary Supplement|Placebo milk|"Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose <0.01%) with standard proteins of milk (3.1%) and color additive quantum satis. Milk had to be associated with a packet of maltodextrin Food Grade, at the time of consumption. Milk and maltodextrin had been produced or supplied by Granarolo s.p.a."
45384837|NCT01058980|Procedure|Additional ablation until elimination of dormant conduction|Additional RF energy will be delivered at sites of re-conduction on the circular mapping catheter in each PV. Abolition of the dormant conduction will then be assessed by repeated injections of adenosine using the same doses previously used to reveal dormant conduction. Additional ablation as described will be performed until re-injection of adenosine shows no re-conduction in any of the PV.
45384838|NCT01058980|Procedure|No additional ablation|Presence of dormant PV conduction, no additional ablation.
45384839|NCT01058980|Procedure|Registry group|Among those who will be found not to have the presence of dormant conduction, and within each site, three-quarters of the patients will be randomly selected to be included in the registry group.
45384840|NCT01058980|Procedure|Usual medical care|Clinical follow-up will be performed according to the regular follow-up after AF ablation procedures in each of the participating centers. No data will be collected after discharge.One-fourth of the patients will be randomly selected to be included in the usual medical care group.
45384841|NCT00894725|Procedure|laparoscopic left colonic resection|laparoscopic colonic resection
45695271|NCT04376788|Biological|exchange blood transfusion from normal donor|IV method
45384842|NCT00894725|Procedure|open left colonic resection|conventional open colonic resection
45384843|NCT05278637|Drug|Aspirin|Aspirin 81mg/day x 4 weeks, Aspirin 325mg/day x 4 weeks. or Aspirin 325mg/day x 4 weeks, Aspirin 81mg/day x 4 weeks.
45384844|NCT05278637|Drug|Ticagrelor|Ticagrelor 90mg BID x 4 weeks
45384845|NCT00897533|Genetic|gene mapping|
45384846|NCT00897533|Genetic|polymorphism analysis|
45384847|NCT00897533|Other|diagnostic laboratory biomarker analysis|
45695272|NCT04376788|Biological|plasma from convalescent patients with COVID-19|IV method
45695273|NCT04376788|Drug|Methylene Blue 5 MG/ML|IV method
45695274|NCT03400228|Dietary Supplement|Probiotic|The probiotic is composed of a combination of Lactobacillus acidophilus (LA-5®) and Bifidobacterium lactis (BB-12®).
45384848|NCT00897533|Other|immunohistochemistry staining method|
45695275|NCT03400228|Dietary Supplement|Maltodextrin|Maltodextrin is a supplement feed based carbohydrate powder and tasteless.
45695276|NCT01729702|Other|blood sample collection|
45384849|NCT00897611|Procedure|DNA methylation analysis|
45384850|NCT00897611|Procedure|polymerase chain reaction|
45384851|NCT00897611|Procedure|computed tomography|
45384852|NCT00897611|Procedure|magnetic resonance imaging|
45695277|NCT03400072|Other|Unsupervised APA program|Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions.
45695278|NCT03400072|Other|Supervised APA program|Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions; in addition, patients will attend weekly supervised, hospital-based exercise sessions in groups of patients.
45695279|NCT03408496|Other|Myofascial release|Manual therapy
45695280|NCT03408496|Other|Muscle stretching|Muscle stretching
45695281|NCT03408496|Other|Control|Medical appointment
45695282|NCT03408418|Procedure|Platelet-rich fibrin|The use of autologous platelet-rich fibrin after tooth extraction to promote bone healing and alveolar ridge preservation
45695283|NCT01714310|Drug|lisdexamfetamine|Titration and open label treatment from baseline visit for 12 week study.
45695284|NCT01714310|Drug|Placebo|Initiated at end of study week 4 and continued to study week 12.
45695285|NCT01714310|Drug|fluoxetine|Initiated at end of study week 4 and continued to study week 12.
45384853|NCT00900965|Device|Electroacupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
45695286|NCT03408262|Biological|Ad4-EnvCN54|Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
45695287|NCT03408262|Biological|MVA-CN54|Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
45695288|NCT03408262|Biological|CN54gp140/MPLA|Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
45695289|NCT04377802|Diagnostic Test|molecular testing for virus RNA using RT-PCR|Serological testing will be performed using SARS-CoV-2 IgG assay kit (Abbott Diagnostics, US) to check for the immunity. The IgG serology test (200 individuals per run) will be done using ARCHITECT i2000SR system which provides the results within 60 minutes
45695290|NCT03401788|Drug|Belzutifan|120 mg once daily (three 40 mg oral tablets once daily).
45695291|NCT03408184|Drug|Lumbar paravertebral group|A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
45695292|NCT03408184|Drug|The field block group|A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
45695293|NCT01713998|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
45384854|NCT00900965|Device|Sham acupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
45384855|NCT00901043|Dietary Supplement|Walnut supplementation|Eight weeks of walnut supplementation
45384856|NCT00901043|Dietary Supplement|Ad lib diet|Eight weeks without walnut supplementation
45384857|NCT00901121|Device|Straumann BoneCeramic|Straumann BoneCeramic (500-1000 microns, 0.5g)
45384858|NCT00901121|Device|Bio-Oss|Bio-Oss spongiosa granules, size of particle 0.25-1 mm
45384859|NCT04017377|Drug|Drug: Cisplatin; nab-paclitaxel|Drug: Paclitaxel for Injection（Albumin Bound). Other Name: Ke ai li, ZhusheyongZishanchun(Baidanbai Jiehexing)
45384860|NCT02539901|Behavioral|Evaluation of the detection of non-linguistic sounds|Evaluation of the detection of non-linguistic sounds (sound room)
45384861|NCT02539901|Behavioral|Free hearing test categorization|Free hearing test categorization evaluation
45384862|NCT02539901|Behavioral|Early Social Communication Scale (ECSP)|Early Social Communication Scale (ECSP) evaluation
45384863|NCT02539901|Behavioral|psychomotor infancy development scale|
45695294|NCT03409900|Other|LPB|The LPB will be performed in a lateral position, but modified to utilize ultrasound guidance to enhance our ability to quickly and safely locate the lumbar plexus as well as to avoid unblinding with regard to the traditional landmark LPB technique. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).
45695295|NCT03409900|Other|QLB|The QLB will be performed in a lateral position in a manner consistent with the technique first described by Børglum. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).
45695296|NCT03408028|Other|Medical File consultation|Medical File consultation
45695297|NCT04549922|Drug|ISIS 721744|1.2 mL of ISIS 721744 subcutaneous once after randomization
45695298|NCT04549922|Drug|Normal Saline|1.2 mL subcutaneous
45695299|NCT03834376|Drug|Pimodivir|Pimodivir will be administered as tablets taken orally, twice daily (2 tablets of 300 milligram [mg]) over a time period of 5 days.
45499943|NCT05221463|Behavioral|The hospital's routine general breastfeeding training|The control group was given the hospital's general breastfeeding training for 3 days by means of the training material prepared by the training nurse of the hospital about breast milk and breastfeeding and used routinely by nurses in breast milk training in neonatal units, and the questions of the mother were answered. The mothers in this group performed the routine breastfeeding process and no other interventions were made.
45499944|NCT03204721|Other|Extracorporeal photophoresis (ECP)|The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient
45499945|NCT05218811|Device|Cryoablation Assisted Partial Nephrectomy|Cryoablation Assisted Partial Nephrectomy is monitored under Ultrasound guidance, A Cryoablation machine (FDA Approved Device) along with its Cryoprobes are used in the study The Cryoprobes are placed in close to the endophytic tumor margins. The tumor boundary area will undergo one freezing cycles. Tumor is excised after 5 minutes of freezing cycle. Thawing process is passive, renal defect repair is conducted during thawing process.
45499946|NCT05185219|Drug|Valerian|A natural plant
45499947|NCT01315483|Other|Weight Loss Dietary Pattern|Diet-physical activity program creating a weekly negative energy balance equivalent to 3500 kcal. Intervention groups receive PA protocol promoting the Physical Activity Guidelines and translated in step recommendations, but one of two diets with divergent dietary patterns (opposing fat and CHO content) that do not overlap >+5% in CHO and fat content. Macronutrient values reflect a 'pattern' or ratio within (LC 3:2 ratio for F:CHO; HC 1:4 ratio for F:CHO ) and between diets (LC:HC 3:1 for fat; LC:HC 1:2 for CHO). Six-week meal plans for five calorie levels available and incorporate educational material, supporting program components (e.g. self monitoring tools) and core competencies reinforcing weight loss behaviors in order to promote high levels of dietary adherence.
46056144|NCT02744625|Drug|Propofol for light sedation|Propofol for light sedation
46056145|NCT00839098|Other|Instruction Group: Power seat function usage instruction- verbal and written instruction|Subjects assigned to the Intervention Group will be assigned to an Intervention Group Clinician. The Intervention Group Clinicians will provide the same training as the Control Group Clinicians, with the addition of discussing the Veteran's activity and seating function usage data, reviewing and providing a study pamphlet and compact disk as a reference guide on use of power seat functions.
45499948|NCT01333267|Drug|Parathyroid Hormone-related Protein (1-36)|PTHrP (1-36) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
45499949|NCT01333267|Drug|parathyroid hormone (1-34)|PTH (1-34) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
45499950|NCT01333267|Drug|PTH (1-34) and PTHrP (1-36)|This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over one week in healthy African-American volunteers. The investigators plan to infuse low doses of intravenous PTHrP or PTH to determine if it leads to a sustained and progressive suppression of bone formation as occurs in humoral hypercalcemia of malignancy (HHM) or an increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally, the investigators will assess the direct influence of PTHrP and PTH on vitamin D metabolism, markers of bone turnover, and fractional excretion of calcium.
45695300|NCT01681628|Behavioral|Thought Field Therapy.|Thought Field Therapy is a meridian based therapy, where clients tap on specific parts of their body, according to a particular protocol. This does not obliterate the memory of the trauma, but relieves the associated distress.
45695301|NCT04377958|Diagnostic Test|Serum biomarker testing|Serum and sputum samples will be collected and biomarkers will be evaluated using ELISA
45695302|NCT03405220|Behavioral|Self affirmation, 10 items, written examples|"Participants will complete the 10 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
45695303|NCT03405220|Behavioral|Self affirmation, 10 items, no examples|"Participants will complete the 10 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
45695304|NCT03405220|Behavioral|Self affirmation, 10 items, imagined examples|"Participants will complete the 10 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
45384864|NCT02539901|Behavioral|"NEPSY (two domains: memory and learning and attention and executive functions)."|NEPSY evaluation
45384865|NCT00897845|Genetic|RNA analysis|
45384866|NCT00897845|Genetic|microarray analysis|
45384867|NCT00897845|Other|immunohistochemistry staining method|
45384868|NCT00897845|Other|laboratory biomarker analysis|
45384869|NCT00897923|Procedure|radionuclide imaging|
45384870|NCT00897923|Radiation|indium In 111-labeled autologous peripheral blood mononuclear cells|
45384871|NCT00897923|Radiation|indium In 111-labeled autologous polymorphonuclear leukocytes|
45384872|NCT00894881|Procedure|Gut cleaning as a preparation to colonoscopy [resting energy expenditure (REE)]|resting energy expenditure (REE).
45499951|NCT03155269|Dietary Supplement|Fortified Beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
45848290|NCT03415152|Drug|Omacor (Omega-3-acid ethyl esters)|Observational study without intervention, Omacor is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
45384873|NCT00901277|Behavioral|web intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors. This is a web-based intervention.
45384874|NCT00901277|Behavioral|nurse intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors given by the nurse via phone.
45384875|NCT04035785|Drug|Kangfu Anti-inflammatory Suppository|To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.
45384876|NCT00898079|Other|Cytology Specimen Collection Procedure|Correlative studies
45384877|NCT04035707|Drug|Rocuronium|using rocuronium as a relaxants during general anaesthesia
45384878|NCT04035707|Drug|general volatile anaesthesia|method of anaesthesia
45384879|NCT00901433|Device|Personal WheezoMeter|pulmonary sounds analyzer
45384880|NCT00898157|Other|laboratory biomarker analysis|
45384881|NCT02539745|Other|Vitamin D receptor polymorphic analysis|Vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis.
45384882|NCT02539745|Other|Serum levels of 1a, 25-Dihydroxyvitamin D3|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay.
45384883|NCT00894959|Biological|Heparin sodium Blausiegel 1|Heparin sodium Blausiegel 1 5.000 UI
45384884|NCT00894959|Biological|Heparin sodium APP|Heparin sodium APP 5.000 USP
45384885|NCT04035395|Other|Peer-led Support Group|The Viviendo Saludable pláticas (or talks) connected Salud y Vida participants living with diabetes together. These talks served as a forum for Salud y Vida participants to share their knowledge and experiences, including some that many health workers, friends, or family do not have. Viviendo Saludable helped participants develop better strategies for managing their diabetes in their daily life. The Viviendo Saludable pláticas complement and enhance the other services by helping participants create a network of emotional, social, and practical support needed to manage diabetes and stay healthy over the long term. Classes met once a week for one hour at locations central to participants' homes.
45848291|NCT03416946|Device|Visionaire|Custom cutting block using MRI to create patient specific instrumentations
45384886|NCT04035395|Other|Behavioral Health Consult|In a Behavioral Health consult, a participant meets with a counselor for one or more thorough meetings to talk about things that influence their health and well-being. A participant receiving a Behavioral Health consult receives support and is empowered with health coping skills that will allow for improved medication adherence and motivation to control their diabetes.
45384887|NCT04035395|Other|Medication Therapy Management Consult|Medication Therapy Management helps participants and their doctors make sure that their medications are working to improve their health. In a Medication Therapy Management (MTM) consult, a pharmacist gives participants a comprehensive review of all their medications and speaks with them about 1) how well their medications are working, 2) whether their medications have side effects, 3) if there might be interactions between the drugs their taking, 4) whether costs can be lowered and 5) other problems participants are having. The participant will get a written summary of this discussion, including an action plan that recommends what can be done to make the best use of their medications.
45426100|NCT00582062|Other|washings for experimental marker testing|During the laparoscopy, a small amount of a mild salt solution will be introduced to gently wash the inside of the abdomen. The fluid will be removed and sent to the laboratory for two analyses: 1) washings for cytology (routine), and 2) washings for experimental marker testing (experimental).
45848292|NCT03416946|Other|Traditional|Traditional cutting method
45848293|NCT03418662|Device|EndoRings device|Subjects randomized to undergo a colonoscopy procedure with the EndoRings device will have the device placed on the colonoscope that will be used during their procedure.
45848294|NCT03423186|Drug|SOBI003|Weekly i.v.infusion
45848295|NCT03426228|Diagnostic Test|HbA1C|"After overnight fasting, 10 ml of blood will be collected at four different timings during the IVF protocol:~At baseline (second day of the menstrual period)~Triggering phase (post-egg retrieval procedure)~Embryo transfer phase (post-transfer procedure)~Week 4 (positive bHCG)~4. Week 8 of pregnancy"
45384888|NCT04035395|Other|La Cocina Alegre/ The Happy Kitchen|The Happy Kitchen is a program where people come together to learn skills and self-sufficiency in preparing healthy, economical meals, laugh, cook, and enjoy food together. The cooking and nutrition program is an interactive 6-week series of classes, where the essential skills for healthy eating is taught and emphasis is placed on the selection and preparation of fresh, seasonal foods that are nutritious, economical, and delicious. Classes meet once a week for 1 ½ hours to cook, discuss, and learn together. All participants leave each class with recipes and groceries to practice new cooking skills.
45384889|NCT04035395|Other|Mind, Exercise, Nutrition, Do it!|MEND is a diet and exercise education program that helps families support their kids, ages 6-13, to reach a healthy weight. The program teaches adults and their children how to maintain energy and confidence throughout the day while learning how to cook healthy meals. Each program lasts 10 weeks and classes are 2 times per week. An adult must attend with the child.
45695305|NCT03405220|Behavioral|Self affirmation, 5 items, written examples|"Participants will complete a 5 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
46056146|NCT00839098|Other|Instruction and Virtual Coach Group: Power seat function usage instruction- verbal, written, and virtual coach|Subjects assigned to the Instruction & Virtual Coach Group will be assigned to an Intervention Group Clinician and will receive the same training and instructional materials as the Instruction Group. Subjects will also be instructed in use of the virtual coach system, which will be active during the in-home usage periods to provide personalized feedback. As the Virtual Coach is a dynamic intelligent system, it will adjust its coaching to the needs of the individual. For example, if the person is compliant, the Virtual Coach will give positive feedback and then gradually transition to operating quietly in the background. If a person is not fully compliant, it will alter feedback modes (e.g., verbal cues, auditory tones, visual cues) and timing to attempt to increase compliance.
45384890|NCT00901589|Dietary Supplement|marine n-3 polyunsaturated fatty acids|Four capsules daily containing 2.2 g marine n-3 polyunsaturated fatty acids in total
45384891|NCT00901589|Dietary Supplement|thistle oil|four capsules a day
45384892|NCT00901589|Dietary Supplement|marine n-3 polyunsaturated fatty acids|Four capsules daily, 2.2 g marine n-3 PUFAs in total
45384893|NCT00901589|Dietary Supplement|Thistle oil|Four capsules daily
45384894|NCT04035083|Device|Laser activated irrigation|Diode laser at 980 nm, power of 1.5W, for 5 seconds inside the canal along with sodium hypochlorite, repeated 4 times with a gap of 10 seconds in between
45384895|NCT04035083|Device|Passive ultrasonic irrigation|ultrasonic activation inside the canal for 1 min
45384896|NCT00895115|Dietary Supplement|vitamin E|Given once daily
45384897|NCT00895115|Procedure|sham intervention|No supplementation
45384898|NCT02540759|Dietary Supplement|Buglossoides oil|
45384899|NCT02540759|Dietary Supplement|High Oleic Sunflower Oil|
45384900|NCT00901745|Drug|Angiotensin II|Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.
45384901|NCT00901745|Drug|Noradrenaline infusion|Infusion of up to 480 picomol/ml of noradrenaline will be infused.
45384902|NCT02540837|Drug|Bupivacaine|Obturator nerve block
45384903|NCT02540837|Drug|Saline|Obturator nerve block with saline(placebo)
46056147|NCT02598973|Behavioral|Exercise|Aerobic walking
45695306|NCT03405220|Behavioral|Self affirmation, 5 items, no examples|"Participants will complete a 5 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
45695307|NCT03405220|Behavioral|Self affirmation, 5 items, imagined examples|"Participants will complete a 5 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
45695308|NCT03405220|Behavioral|Self affirmation, 3 items, written examples|"Participants will complete a 3 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
46056148|NCT02744469|Other|No intervention (observational study)|
45384904|NCT00898391|Other|laboratory biomarker analysis|Correlative studies
45384905|NCT00898391|Genetic|polymerase chain reaction|Correlative studies
45384906|NCT00898391|Genetic|polyacrylamide gel electrophoresis|Correlative studies
45384907|NCT00898391|Genetic|DNA analysis|Correlative studies
45384908|NCT00901823|Drug|Diazoxide choline|A single dose low dose DCCR then re-randomized to either multiple dose low dose DCCR or high dose DCCR
45384909|NCT00901823|Drug|Diazoxide choline high dose|A single dose high dose DCCR then re-randomized to either low or high multiple doses of DCCR
45384910|NCT00898469|Genetic|polymorphism analysis|
45384911|NCT00606593|Drug|ACT-078573 oral capsules at 25 and 100 mg and matching placebo|5-period, 5-treatment crossover: sequences: ABECD, BCADE, CDBEA, DECAB, EADBC DCEBA, EDACB, AEBDC, BACED, CBDAE Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
45384912|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
45426101|NCT00523003|Dietary Supplement|high protein|2.2 g protein/kg of LBM per day
45695309|NCT03405220|Behavioral|Self affirmation, 3 items, no examples|"Participants will complete a 3 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
45384913|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
45848296|NCT03429270|Device|TDOC 5Fr|A Pivotal Study to Assess the Performance, Safety and Usability of a New 5 French Air-Charged Catheter for Performing Urodynamic Studies on Pediatric Subjects
45384914|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
45384915|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
45384916|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
45384917|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
45384918|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
45384919|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
45384920|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
45384921|NCT00902057|Drug|desmopressin|single desmopressin subcutaneous injection, 1.5mcg
45384922|NCT00902057|Drug|desmopressin|single desmopressin subcutaneous injection, 3mcg
45499952|NCT03155269|Dietary Supplement|Non fortified beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Non fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
45499953|NCT02906670|Drug|Sym013|Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.
45499954|NCT01339195|Behavioral|French adaptation of NINDS-Canadian Stroke Network battery|"clinical: post-stroke neurological follow-up assessment~neuropsychological: comprising the NINDS-Canadian Stroke Network neuropsychological battery~MRI"
45848297|NCT03429348|Other|Sauna Rehabilitation|Firefighters selected for sauna rehabilitation will spend time in a sauna
45848298|NCT03430050|Drug|Progesterone|Progesterone capsule
45848299|NCT03430050|Drug|Placebo|Placebo capsule. Manufactured to mimic progesterone 200mg capsule.
45384923|NCT00902057|Drug|desmopressin|single desmopressin subcutaneous injection, 15mcg
45384924|NCT00902057|Drug|placebo|saline subcutaneous
45384925|NCT00895349|Procedure|CT Abdomen and Pelvis scan + whole body PET-CT scan|Pre-treatment scan
45384926|NCT00895349|Procedure|CT Abdomen and Pelvis scan|Pre-treatment scan
45384927|NCT00898547|Other|immunoenzyme technique|
45384928|NCT00898547|Other|laboratory biomarker analysis|
45384929|NCT04035941|Behavioral|Cycle Nation Multicomponent Intervention|"This intervention group will receive 4 elements:~Practical skills programme: a workplace-based programme covering basic cycling skills, delivered by trained 'cycle champions' - HSBC staff members.~Cycle provision scheme: participants will have the opportunity to have their own bicycles serviced or obtain a loaned bike or e-bike from local bike shops before the start of the programme.~Cycle-friendly workplace culture: all offices taking part will have a minimum of secure bike parking facilities as part of an ongoing roll-out of cycle infrastructure across HSBC UK offices.~Our Cycle Hub app: an adapted version of an existing HSBC app including route planning, goal setting and practical skills videos, as well as supportive social interaction among participants."
45384930|NCT00902135|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant together with a reminder
45499955|NCT01339351|Behavioral|Therapeutic Group by Teleconference|10 sessions
45499956|NCT01335451|Drug|AZD5213|Four increasing doses for young and two increasing doses for elderly subjects. Subject will receive single dose of AZD5213 oral solution (Day 1) and then start the once daily repeated doses from Day 3 to 12 for 10 days
45499957|NCT01335451|Drug|Placebo|Placebo solution, single dose (Day 1) and repeated dose from Day 3 to 12 for 10 days
46056149|NCT02610556|Drug|Cisplatin 2|Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles
46056150|NCT02610556|Drug|Docetaxel|Docetaxel 60 mg/m2, D1 every 3 weeks for 3 cycles
45499958|NCT01335529|Drug|Boceprevir, Peg-interferon alfa 2b and Ribavirin|"Screen period from Week-8~Standard treatment from day 0 to week 4 (W4)~Three-drug-regimen (Boceprevir introduction) from W4 to W8~HCV RNA determination at W8 determines treatment group and participation duration:~If undetectable HCV RNA at W8, it is a complete virological response: 3 drug-regimen is continued until W48, then there is a follow-up period up to W72 and SVR analysis,~If HCV RNA ≤ 1000IU/mL at W8, it is an incomplete virological response. The 3-drug-regimen is continued until W72, when another analysis is done."
45384931|NCT00902135|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant without a reminder
45848300|NCT03430206|Device|High-flow nasal cannula|While applied, the cannula will deliver high-flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 2L/kg/min with a maximum of 70L/min. This will be only for the duration of the surgery or procedure.
45384932|NCT00902135|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon)
45384933|NCT00898703|Other|flow cytometry|
45384934|NCT00898703|Other|immunoenzyme technique|
45384935|NCT00898703|Other|laboratory biomarker analysis|
45384936|NCT02539589|Behavioral|BART|BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
45384937|NCT02539589|Behavioral|Healthy Living|Healthy Living is a knowledge-based intervention that intends to provide one HIV information-only session and seven sessions on nutrition, healthy eating, body image, and exercise. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
45384938|NCT00902213|Behavioral|Physical Therapy|Each patient in this group will have physical therapy performed. The intervention will be tested for its effect on: 1) physical function outcomes (muscle strength, range of motion, endurance, gross motor skills), bone density and bone mineral content (end of therapy only); and 2) HRQL.
45384939|NCT00902213|Behavioral|Support|Visits with an Advanced Practice Nurse to support sustained motivation.
45384940|NCT02540369|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection.Muti-target Anti-VEGF agent. Dosing would be at physicians discretion.
46056151|NCT02610556|Drug|Cisplatin 1|Cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles
46056152|NCT02610556|Radiation|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
45499959|NCT01335607|Drug|Samatasvir tablet|Two samatasvir (IDX184) 50 mg tablets (100 mg single oral dose)
45499960|NCT01335607|Drug|Samatasvir capsule|Two samatasvir (IDX184) 50 mg capsules (100 mg single oral dose)
45499961|NCT02906358|Behavioral|Community-based pain self-management|
45499962|NCT02906358|Behavioral|Clinic-based pain self-management|
45499963|NCT00308347|Drug|MK0954, losartan / Duration of Treatment: mean 3.4 years|
45499964|NCT00308347|Drug|Placebo / Duration of Treatment: mean 3.4 years|
45499965|NCT02186834|Drug|Selinexor|Selinexor orally as outlined in the study treatment arm.
45499966|NCT02186834|Drug|Liposomal doxorubicin|Pegylated liposomal doxorubicin at a starting dose of 20 mb/m² as outlined in the treatment arm.
46056153|NCT02740101|Drug|oxytocin treatment|intranasal administration of oxytocin (40 IU)
46056154|NCT02740101|Drug|placebo treatment|intranasal administration of placebo (40 IU)
46056155|NCT02612116|Drug|Pulverized ticagrelor sublingually|Pulverized ticagrelor (180 mg) administered sublingually
46056156|NCT02612116|Drug|Pulverized ticagrelor orally|Pulverized ticagrelor (180 mg) administered orally
46056157|NCT02612116|Drug|Integral ticagrelor|Integral ticagrelor (180 mg) administered orally
46056158|NCT02744235|Device|Polysomnography Data|
45384941|NCT00902369|Drug|AK106-001616|Part1: Dose escalation Part2: Dose expansion
45384942|NCT00902369|Drug|Placebo|
45384943|NCT00902369|Drug|Active comparator|
45384944|NCT02540135|Other|fluorescein|fluorescein and conventional neuro-navigation
45384945|NCT02540135|Other|intraoperative MRI|conventional neuro-navigation and iMRI
45384946|NCT00905879|Drug|Gadobutrol (Gadovist, BAY86-4875)|Patients who will need to undergo contrast enhanced MRI with gadobutrol (Gadovist)
45384947|NCT02539433|Procedure|F-18-F-DOPA|F-18-F-DOPA i.v. injection of a dose of up to 8.5 mCi. PET scanning started 60-90 minutes post injection
45384948|NCT00605267|Drug|Tamoxifen|20 mg once daily oral dose
45384949|NCT00605267|Drug|Anastrazole (Arimidex)|1 mg once daily oral dose
45384950|NCT00605267|Drug|Goserelin acetate (Zoladex)|3.6mg/month depot injection
45384951|NCT02539355|Other|Diet A|12-week diet
45384952|NCT02539355|Other|Diet B|12-week Diet
45384953|NCT00902525|Drug|90Y-Ibritumomab Tiuxetan|All patients receive 2 courses of age-adjusted R-miniDHAP followed by two doses of 90Y-Ibritumomab Tiuxetan
45384954|NCT00902603|Drug|Commercial Ventavis® (iloprost)|Commercial Ventavis® (iloprost) administered via portable nebulizer (I-neb® AAD® system using the power disc-6)
45384955|NCT00902681|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
45384956|NCT00902681|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
45384957|NCT00906113|Drug|Intra-arterial injection of melphalan|Injection of 5 milligrams of melphalan into the ophthalmic artery once every 3 weeks for a total of 6 courses
45695310|NCT03405220|Behavioral|Self affirmation, 3 items, imagined examples|"Participants will complete a 3 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
45695311|NCT01728064|Drug|Placebo|Placebo capsules
45695312|NCT01728064|Drug|EPI-743 400 mg|
45695313|NCT01728064|Drug|EPI-743 200 mg|
45695314|NCT03407950|Behavioral|IPT+|Integrated Psychological Treatment and cognitive remediation and relaxation and Mindfulness : IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
45695315|NCT03407950|Behavioral|Treatment as usual|no specific therapy but same number and duration of each sessions than IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
45695316|NCT03834298|Other|Four Food Elimination Diet|Food allergens are thought to initiate eosinophilic inflammation and dietary elimination of trigger allergens is an effective treatment for EoE. Previous work demonstrates that in both children and adult EoE patients, the food antigens including cow's milk, wheat, egg, soy, peanut/tree nut and fish/shell fish, are the most common food triggers causing esophageal inflammation. Participants will be assigned to single arm treatment / intervention with a diet restricted of the four most common food allergens, milk, soy, wheat and egg, or a four food elimination diet (FFED). With the goal to optimize diet treatment, in Aim 2, eligible participants will undergo sequential food reintroductions based on protocol.
45695317|NCT03400774|Other|Stair-climbing|Short bouts of moderate intensity stair-climbing
45695318|NCT04377178|Device|Dentin grinder|After atraumatic extraction of the tooth, autogenous dentin particles are made with the help of a device - dentin grinder from the separated root and these particles are incorporated into the extraction socket
45695319|NCT04377178|Device|Bone mill|After atraumatic extraction of the tooth, autogenous dentin particles are made with the help of a device - Bone mill from the separated root and these particles are incorporated into the extraction socket
46056159|NCT02744235|Device|Jawbone UP®|
45384958|NCT00906113|Drug|Injection of melphalan into the ophthalmic artery|Injection of 5 milligrams of melphalan into the ophthalmic artery in an eye affected by retinoblastoma
45384959|NCT00906191|Drug|SAM-531|
45426102|NCT00523003|Dietary Supplement|standard protein|1.1 g protein/kg LBM/day standard protein diet
45426103|NCT00497926|Biological|Enriched Hematopoietic Stem Cell Infusion|Enriched Hematopoietic Stem Cell Infusion
45426104|NCT00497029|Drug|fluoride varnish|
45426105|NCT00497029|Behavioral|patient education|
45499967|NCT02186834|Drug|Dexamethasone|Participants will be instructed to take Dexamethasone 40 mg (10 tablets) orally once weekly with meals (ideally with breakfast to minimize insomnia). Participants older than 75 years and patients previously intolerant to 40 mg dosage will be allowed to receive 20 mg (5 tablets) once a week.
45695320|NCT01720420|Device|NobelReplace CC, NobelProcera Implant Bar|Implants titanium with conical connection, individualized titanium bar
45695321|NCT03835000|Procedure|Orthopedic surgery|before and after surgery, patient will need medical imaging to asses their conditions
45426106|NCT00456573|Procedure|tonsillectomy|medically indicated tonsillectomy in subjects with and without OAS
45426107|NCT00455351|Drug|Vorinostat|Increasing dosing, phase I
45426108|NCT00379340|Radiation|3-Dimensional Conformal Radiation Therapy|
45426109|NCT00379340|Procedure|Conventional Surgery|
45426110|NCT00379340|Drug|Cyclophosphamide|Given IV
45426111|NCT00379340|Biological|Dactinomycin|Given IV
45426112|NCT00379340|Drug|Doxorubicin Hydrochloride|Given IV
45426113|NCT00379340|Drug|Etoposide|Given IV
45426114|NCT00379340|Drug|Vincristine Sulfate Liposome|Given IV
45695322|NCT03409120|Device|Boston Scientific Vercise PC IPG with directional DBS lead|We will contrast the effects of omnidirectional versus directional STN DBS on dystonia symptoms in patients with PD.
45695323|NCT03405142|Drug|Panitumumab-IRDye800|Intravenous (IV) panitumumab-IRDye800 (50 mg) 1 to 5 days prior to surgery (lymphadenectomy). Panitumumab dose is < 1/12 of the therapeutic dose.
45695324|NCT03405142|Drug|Lymphoseek|Local, peri-tomoral injection with 2 mCi Lymphoseek (99mTc Tilmanocept) (as 4 x 0.1 mL injections of Lymphoseek solution
45695325|NCT03407872|Drug|Esketamine DPI|Participants will receive different number of consecutive Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts.
46056160|NCT02744235|Device|Fitbit Charge ®|
46056161|NCT02744079|Behavioral|Low carbohydrate diet|45 subjects will be randomized to a dietary arm consisting of a complete, prepared very low carbohydrate diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal
45384960|NCT00902759|Other|Walking Program|"Brisk walking is defined as faster than the slow walk, but not to exhaustion and not a running pace. Participants will be instructed to walk at home, at a gym or in a shopping mall for as far as possible on a level surface, wearing appropriate footwear as described in the walking booklet. (Patients may continue to walking longer if they desire and are symptom free). Participants should stop or slow down if they experience any discomfort (such as uncomfortable shortness of breath, chest pain, or body pain). The goal is to eventually walk for 90-120 minutes per week in three to four sessions. Participants will not be asked to take their pulse or to record their perceived exertion in order to simplify the program."
45384961|NCT04035317|Drug|Aesculus Hippocastanum / Horse Chestnut|Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.
45384962|NCT04035317|Drug|Placebo|Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.
45384963|NCT00902837|Drug|Oxycodone naloxone prolonged release tablets (OXN)|
45384964|NCT00902837|Drug|oxycodone prolonged release tablet|
45384965|NCT00902837|Drug|oxycodone naloxone tablet|
45384966|NCT00899015|Other|pharmacological study|
45384967|NCT00605813|Drug|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501091, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 52 weeks after the first administration."
45384968|NCT00899093|Other|Cytology Specimen Collection Procedure|Correlative studies
45384969|NCT00899093|Other|Laboratory Biomarker Analysis|Correlative studies
45499968|NCT03144687|Drug|Itacitinib|Itacitinib self-administered orally once daily .
45499969|NCT03144687|Drug|Ruxolitinib|Ruxolitinib self-administered orally at the stable dose of < 20 mg daily established before entering the study.
45499970|NCT04335890|Biological|Vaccination with IKKb matured Dendritic Cells|IKKb matured autologous monocyte derived dendritic cells loaded with RNAs; intravenous Infusion with a dose escalation starting with 7.5 mio Dendritic Cells for the first vaccination up to 30 mio cells per vaccination
46056162|NCT02744079|Behavioral|Low fat diet|20 subjects will be randomized to a dietary arm consisting of a complete, prepared low fat diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal.
46056163|NCT02744157|Behavioral|Longterm effects after a structured lifestyle program|present study was to describe a structured intervention to reduce cardiovascular risk in a clinical setting and to study the effects of the program on lifestyle habits and quality of life in individuals at risk after six months and one year.
46056164|NCT02740023|Device|Hearing Aid (Phonak Audéo V90-13)|Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90-13 will be fitted to the participants individual Hearing loss.
46056165|NCT02740023|Device|Hearing Aid (Successor of Phonak Audéo V90-13)|The successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90-13 will be fitted to the participants individual Hearing loss.
45384970|NCT00906269|Drug|Sildenafil therapy plus post-NSRRP HBO2T|Sildenafil (Viagra) 50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP hyperbaric oxygen therapy (90 minutes of 100% oxygen at 2.2ATA (equivalent to the pressure exerted at a depth of approximately 40 feet below sea level). There will be 5 or 10 treatments. The full treatment cycle will be completed within 2 weeks.
45384971|NCT00906269|Drug|Sildenafil therapy plus sham post-NSRRP HBO2T|Sildenafil (Viagra)50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP sham hyperbaric oxygen therapy - 90 minutes at 2.2ATA but instead of 100% oxygen, they will receive air administered via the oxygen hoods, as if they were being administered oxygen. Participants in this group will receive 5 or 10 sham treatment sessions. Full treatment cycle will be completed within 2 weeks.
45384972|NCT02538653|Other|Sandwich biscuit high in SDS|Consumption of the high SDS product (50g) alone with a glass of water
45384973|NCT02538653|Other|Co-extruded cereal low in SDS|Consumption of the low SDS product (48.3 g) alone with a glass of water
45384974|NCT00902915|Drug|lenalidomide plus dexamethasone|peroral application; lenalidomide dosage according to severity grade of renal failure.
45384975|NCT02538575|Other|6-minute walk test|a walk of 6 minutes repeated twice in an interval of 30 minutes
45384976|NCT02540057|Procedure|Flexor carpi radialis|Ligament reconstruction with tendon interposition completed using the flexor carpi radialis tendon
45384977|NCT02540057|Procedure|Abductor pollicis longus|Ligament reconstruction with tendon interposition completed using the abductor pollicis longus tendon
45384978|NCT00902993|Drug|AZD1446|Solution, oral single and multiple dose
45384979|NCT00902993|Drug|Placebo|Placebo
45426115|NCT00301808|Drug|Cisplatin|Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43
45426116|NCT00301808|Drug|Docetaxel|Docetaxel 75 mg/m2 on day 1 of each cycle
45426117|NCT00301808|Drug|Pemetrexed disodium|Pemetrexed 500 mg/m2 every 3 weeks on days 1, 22, and 43
45499971|NCT01624532|Biological|GC1109 or Placebo of GC1109|"Step1: Administer 0.3mL or 0.5mL or 0.1mL or placebo of GC1109 into the deltoid muscle three times every four weeks.~Step2: Administer 1.0mL of GC1109 or placebo of GC1109 into the deltoid muscle three times every four weeks, and once after 24 weeks."
45554662|NCT02444312|Behavioral|Neutral Writing Activity|The control group will be instructed to write number of things about the weather that day. Although the sentences can be as long or as short as they like, they will be encouraged to try and aim for about 3 or 4 sentences at least.
45554663|NCT02444156|Other|Indoor rowing|
46056166|NCT02739945|Procedure|Cubital tunnel release|The ulnar nerve is decompressed proximally at the intramuscular septum, decompressed more distally through the cubital tunnel and then exposed between the two heads of the flexor carpi ulnaris muscle. Care is taken to ensure that any point that might compress the ulnar nerve either proximally or distally is evaluated.
46056167|NCT00813748|Drug|Xolair|
45384980|NCT00922493|Other|inspiratory muscle training|"Protocol of inspiratory muscle training using threshold IMT®: After the MIP was measured, inspiratory muscle training was initiated. The Threshold-IMT® device of a linear pressure load produces a resistance to inspiration through the use of a flow-independent one-way valve. During expiration there is no resistance because the unidirectional valve opens, while during inspiration the valve closes, becoming hard due to the resistance of the spring. The suggested protocol was: initial load of 30% of the M24, increasing daily by 10%, with training for five minutes, twice a day, seven times a week in the period from the beginning of the weaning from the MV until the extubation of the patient.~An essential factor was the use of supplemental oxygen (O2) as needed by the patient. The patients were in DD with fowler 45º."
45384981|NCT00899171|Genetic|DNA analysis|
45384982|NCT00899171|Genetic|DNA methylation analysis|
45384983|NCT00899171|Genetic|RNA analysis|
45384984|NCT00899171|Genetic|gene expression analysis|
45384985|NCT00899171|Genetic|reverse transcriptase-polymerase chain reaction|
45384986|NCT00899171|Other|laboratory biomarker analysis|
45384987|NCT00604721|Drug|selumetinib|Given orally
45384988|NCT00604721|Other|pharmacological study|
45384989|NCT04034771|Drug|Melatonin 10 MG Oral Tablet|Melatonin tablets
45499972|NCT03608930|Device|Disposable Polypectomy Snare,JHY-SD-23-230-30-A1|The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the direction of the snare by rotating the handle as required, rotate the loop until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then inhaling the transected polyp into a trap followed by submission to the histological evaluation.
45384990|NCT04034771|Drug|Propofol|propofol amp
45384991|NCT04034771|Drug|Placebo oral tablet|sugar pill manufactured to mimic melatonin tablets
45384992|NCT00906581|Behavioral|Computer-based Problem-Solving Treatment|6 sessions of problem-solving treatment delivered via computer
45384993|NCT00899327|Genetic|DNA methylation analysis|
45384994|NCT00899327|Genetic|RNA analysis|
45384995|NCT00899327|Genetic|cytogenetic analysis|
45384996|NCT00899327|Genetic|gene expression analysis|
45384997|NCT00899327|Genetic|mutation analysis|
45384998|NCT00899327|Genetic|polymerase chain reaction|
45384999|NCT00899327|Genetic|protein expression analysis|
45385000|NCT00899327|Other|laboratory biomarker analysis|
46056168|NCT02743767|Procedure|Introducing five different treating adaptations|Immediate Bag-valve mask ventilation after administering of muscle relaxants, optimized preoxygenation, introducing of a preinterventional checklist, increased usage of video laryngoscopy and immediate hand alternately if frustrated intubation.
46056169|NCT05629299|Biological|Samples|Men will give semen, saliva, skin, urine and blood specimens
45385001|NCT00899483|Drug|Glucose potassium insulin solution|Enhanced glycaemic control in diabetics with glucose-potassium-insulin solution
45385002|NCT02539121|Device|Acupuncture|Acupuncture needles
45385003|NCT02539199|Drug|Misoprostol, modified-release pessary|Misoprostol pessary (7 ug/h) placed in vaginal fornix until labour is induced or maximum 24 hours
45385004|NCT02539199|Drug|Misoprostol, per-oral tablets|First day: 50 ug PO in every 4 hours maximum 3 times per day. Second day: 100 ug PO in every 4 hours maximum 3 times per day. Third day: 50 ug vaginally in every 4 hours maximum 3 times per day or until labour is induced.
45385005|NCT00903227|Drug|Fluticasone Evohaler pMDI|One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)
45385006|NCT00903227|Drug|Placebo|1 puff of inhaled Placebo twice a day
45385007|NCT00903227|Drug|Fluticasone Evohaler|One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg)
45385008|NCT00903227|Drug|Placebo intranasal spray|placebo intranasal spray 2 squirts each nostril once a day
45385009|NCT00903227|Drug|fluticasone propionate (Flixonase®)|intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts
45385010|NCT00605657|Drug|Valproic Acid|Oral administration of valproic acid
45385011|NCT00605657|Procedure|CT Scan|CT scans were done before and after treating the patient with valproic acid
45385012|NCT00605657|Procedure|Blood Sample|Blood samples were collected before and after the intervention to monitor blood counts and biomarkers of ALPS
45385013|NCT04034849|Radiation|Photobiomodulation|Photobiomodulation whit Low-Level Laser Therapy
45385014|NCT04034849|Radiation|Placebo|Device turned off
45385015|NCT00903305|Other|medical chart review|
45385016|NCT00903305|Other|questionnaire administration|
45385017|NCT00903305|Procedure|fatigue assessment and management|
45385018|NCT00903305|Procedure|psychosocial assessment and care|
45385019|NCT00903305|Procedure|quality-of-life assessment|
45385020|NCT00899795|Genetic|cytogenetic analysis|
45385021|NCT00899795|Genetic|fluorescence in situ hybridization|
45385022|NCT00899795|Other|flow cytometry|
45385023|NCT00899795|Procedure|biopsy|
45385024|NCT02539043|Device|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 Megahertz (MHz), and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random.
45385025|NCT02539043|Device|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 MHz, and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random . The procedure is followed by stereodynamic drainage, where it will be used a printhead comprising three ERAs (effective radiation area) of 15 Watt each time this procedure is calculated through the area (size of the area to be treated) divided by ERA (cm² head size).
45385026|NCT00903461|Biological|EGFR Antisense DNA|"Intratumoral EGFR AS injections weekly x 7 weeks (or less if there is no identifiable tumor), starting 2 weeks prior to radiation. The first EGFR AS injection must be given after cetuximab is administered. Subsequent EGFR AS injections can be given before or after cetuximab is administered. Injections will be in the primary and/or lymph nodes. One site will be injected per weekly session. If it is necessary the antisense injection can be scheduled within 1 business day of the original schedule date and then resume the original schedule~EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. The same lesion (primary tumor or lymph node) will be injected during treatment."
45385027|NCT00604565|Drug|soluble ferric pyrophosphate (SFP)|"Subjects will be randomized to undergo dialysis with either Fe-HD (dialysate containing SFP) The experimental concentrate containing SFP (Fe-HD)has 95mg of SFP per gallon, or 10.9 mg total iron per gallon (96 µg of SFP per dL or 11 µg of total iron per dL).~Control concentrate lacking SFP (C-HD) does not contain SFP (total iron = 0)"
45385028|NCT00604565|Other|placebo|Subjects will be randomized to undergo dialysis with C-HD (conventional dialysate lacking SFP)
45385029|NCT00903539|Device|SecurAcath Securement System|Subcutaneous catheter securement system
45385030|NCT00899873|Genetic|cytogenetic analysis|
45385031|NCT00899873|Other|flow cytometry|
45385032|NCT00899873|Other|fluorescence activated cell sorting|
45695326|NCT03407872|Drug|Esketamine DPI|"Participants will receive different dosing sequences of Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A of the study.~Dose: very low, low, medium, high."
45385033|NCT00899873|Other|immunoenzyme technique|
45385034|NCT00899873|Other|laboratory biomarker analysis|
45385035|NCT00899951|Drug|fentanyl citrate|
45695327|NCT03407872|Drug|Esketamine DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. There will be dose escalation between cohorts. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A and PART B of the study.~Dose: very low, low, medium, high."
45695328|NCT03407872|Drug|Placebo DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio.~In each cohort, number of placebo inhalations within a dosing sequence will correspond to number of Esketamine DPI inhalations."
45695329|NCT00016354|Drug|benzoylphenylurea|
45695330|NCT03834610|Drug|L-arginine 5 gm oral caps|oral L-arginine 5 gm daily for 8 weeks
45695331|NCT03834610|Drug|Tadalafil 10 MG|oral daily tadalafil 10mg for 8 weeks
46056170|NCT05216380|Behavioral|ActivityLink|"ActivityLink is an implementation program using:~Didactic and experiential training sessions for clinic staff to conduct referrals~Secure electronic referral webform to refer patients using their email address and phone number~Messaging sent to the patient and provider that they have been referred to a program~Clinic visual cues (flyers and paper prescription pad) to reinforce referrals~Motivational messaging and booster sessions from study staff to encourage referrals and troubleshoot"
46056171|NCT03857529|Device|transcranial direct current stimulation and electrical stimulator|"Contralaterally Controlled Functional Electrical Stimulation: An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator will be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).~Transcranial direct current stimulation (tDCS): TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration."
45385036|NCT00899951|Other|pharmacological study|
45385037|NCT00900107|Procedure|Exercise|
45385038|NCT00900185|Genetic|mutation analysis|
45385039|NCT00900185|Genetic|polymerase chain reaction|
45385040|NCT00900185|Genetic|polymorphism analysis|
45385041|NCT00900263|Genetic|cytogenetic analysis|
45385042|NCT00900263|Genetic|microarray analysis|
45385043|NCT00900263|Other|biologic sample preservation procedure|
45385044|NCT00900263|Other|laboratory biomarker analysis|
45385045|NCT00900341|Genetic|DNA analysis|
45385046|NCT00900341|Genetic|gene expression analysis|
45385047|NCT00900341|Genetic|protein expression analysis|
45385048|NCT00900341|Genetic|reverse transcriptase-polymerase chain reaction|
45385049|NCT00900341|Genetic|western blotting|
45695332|NCT03834610|Diagnostic Test|serum testosterone level|measurement of serum testosterone level
45695333|NCT03834610|Diagnostic Test|HbA1C|measurement of HbA1C levels
45695334|NCT03834610|Device|penile doppler|penile doppler to measure the degree of erection and penile vasculature
45385050|NCT00900341|Other|immunohistochemistry staining method|
45695335|NCT01681472|Drug|6R-MTHF (arfolitixorin) 200 mg/m2|i.v. bolus injection
45385051|NCT00900341|Other|laboratory biomarker analysis|
45385052|NCT05278013|Other|Dermabond|High viscosity Dermabond is a sterile, liquid topical skin adhesive containing monomeric (2-OCA) formulation and the colorant D & C Violet # 2. The product has a syrup-like in viscosity and polymerizes within minutes when applied to the skin. 2-OCA is an effective barrier against microbial penetration by Gram-positive (inc. methicillin-resistant Staphylococcus aureus) and Gram-negative motile and nonmotile species as long the as the film is intact (11-13). The high viscosity of Dermabond is intended to reduce the risk of unintended placement of the adhesive during the application process to other body parts, patient's clothing or in between the skin layers in the wound, which can result in delayed wound healing.
45385053|NCT02539979|Drug|Paracetamol|
45385054|NCT02539979|Drug|Placebo - Normal Saline|Normal Saline 100cc
45385055|NCT00906737|Device|Ankle-bot|The Ankle-bot is a piece of robotic therapy equipment for the ankle. In this study, it will be used to guide and assist the subject into ankle flexion, extension, inversion and eversion.
45385056|NCT00906737|Other|Conventional focused ankle therapy|Conventional focused ankle therapy will be performed by a physical therapist.
45385057|NCT00906893|Procedure|18F]-FMISO PET-CT|pretherapy([18F]-FMISO) positon emission tomography-computed tomography. Different acquisition protocols will be tested and a wild panel of quantification parameters issued from published studies and original ones developed by our team enable to describe [18F]-FMISO uptake will be used.
45385058|NCT00903773|Drug|telaprevir|
45385059|NCT05277701|Drug|Lazertinib|Lazertinib 240mg daily (1 cycle of 21 days) will be applied to the all patients until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. However, beyond disease progression is allowed based on the investigator's decision. Doses should be taken approximately 24 hours apart at the same time point each day before eating meal under fasting. If it is more than 12 hours after the dose time, the missed dose should not be taken, and patients should be instructed to take the next dose at the next scheduled time.
45385060|NCT00900653|Drug|Gynoflor E (low dose estriol with lactobacillus)|The medication, in the form of one vaginal tablet, is administered in the evenings for 18 days
45385061|NCT00605345|Drug|Darbepoetin alfa|As prescribed
45385062|NCT00605345|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc 4-weekly (starting dose)
45385063|NCT00903851|Drug|Lidoderm|Patients participated in an 8-week treatment period; patients at one site were to continue treatment for the entire 8 weeks while patients at two sites were to terminate treatment after 3 weeks. Commercially available Lidoderm® (lidocaine patch 5%) was provided to each patient with up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain.
45385064|NCT00900887|Drug|Ketorolac|ophthalmic presentation 5 mg/ml dosage one drop (0.25 mg) in the treated eye 3 times a day during one week
45385065|NCT00900887|Drug|Nepafenac|topic presentation 1 mg/ml dosage one drop (0.05 mg) in the treated eye 3 times a day during one week
45385066|NCT00900887|Drug|Polietilenglicol 400, propilenglicol|"ocular presentation Polietilenglicol 400 (4 mg), propilenglicol (3 mg), HP guar (1.9 mg)/1 ml~dosage: one drop (0.2 mg polietinglicol 400, 0.15 mg propilenglicol, 0.095 mg HP guar) 3 times a day during one week"
45385067|NCT02539277|Drug|Jinyebaidu granule|It is a chinese patent medicine extracted from four herbs: honeysuckle, isatis leaf, dandelion, and houttuynia cordata thunb.
45385068|NCT02539277|Drug|Fufangshuanghua granule|It is a Chinese patent medicne extracted from four herbs: honeysuckle, forsythia, radix Isatidis, andrographis paniculata.
45385069|NCT02539277|Drug|Jinyebaidu granule placebo|It is Jinyebaidu granule placebo.
45385070|NCT02539277|Drug|Fufangshuanghua granule placebo|It is Fufangshuanghua granule placebo.
45385071|NCT00904085|Drug|Oxymorphone IR|5 mg
45385072|NCT00908453|Drug|fosphenytoin|15mg/kg, 18mg/kg or 22.5mg/kg of loading doses of fosphenytoin
45385073|NCT02538497|Behavioral|The Newborn Behavioral Observation (NBO)|"The Newborn Behavioral Observation (NBO) is a flexible parental guidance methodology which takes between 20 and 40 minutes to administer. It consists of 18 neurobehavioral observations which give a profile of the infant´s behavioral repertoire along the dimensions: attentional-interactional, autonomic, motor and state organization.~The intervention group will receive 3 NBO consultations: 1) Routine care plus the NBO at the hospital within two days post-delivery; 2) Routine home visit plus the NBO by a public health nurse when the infant is 7-10 days old; and 3) NBO at the well-baby clinic when the infant is about 4 weeks old."
45426118|NCT00301808|Radiation|Radiation therapy|Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.
45426119|NCT00254670|Drug|Naltrexone|
45695336|NCT01681472|Drug|Levoleucovorin 200 mg/m2|i.v. bolus injection
45695337|NCT01681472|Drug|6R-MTHF (arfolitixorin) 60 mg/m2|i.v. bolus injection
45695338|NCT01681472|Drug|Levoleucovorin 60 mg/m2|i.v. bolus injection
45695339|NCT01040806|Behavioral|Usual care|Patients will receive their usual medical care
45695340|NCT01040806|Behavioral|Health coaching|Peer health coaches will counsel patients with diabetes
45385074|NCT02538497|Behavioral|Routine care|The control group will receive routine care. Between 7 and 10 days after birth a public health nurse routinely visits the family at home. Six weeks after birth, the mother and the infant visit the well-baby clinic
45385075|NCT04034537|Diagnostic Test|cPSTA|The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal. All enrolled patients will perform cPSTA signal recording.
45385076|NCT00907127|Behavioral|Exercise and Diet (Metabolic Fitness Program)|6 month program of diet and exercise training and support.
45385077|NCT02538731|Procedure|dilation-assisted stone extraction|
45385078|NCT02538731|Device|Spyglass Guided Laser Lithotrips|
45385079|NCT00908531|Drug|letrozole (Femara)|tablet 2.5 mg daily
45385080|NCT02538263|Device|Volume-targeted noninvasive ventilation|
45385081|NCT00904319|Other|Aquatic Power Training|Aquatic power training program with an exercise specialist 2/week for 6 weeks.
45385082|NCT00604175|Biological|Quadrivalent HPV vaccine|Quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine. All participants received the vaccine via intramuscular injection at baseline, Week 8 and Week 24.
45385083|NCT00605189|Device|Powered Suction Pump (VAC Freedom)|continuous foam based negative pressure wound therapy
45385084|NCT00605189|Device|Powered Suction Pump|continuous gauze based negative pressure wound therapy
45385085|NCT00605189|Device|MWT|moist wound therapy
45385086|NCT00904397|Drug|Lidoderm®|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
45385087|NCT00904397|Drug|Celecoxib|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
45385088|NCT02538887|Device|Radio Frequency Surgical Detection|
45385089|NCT00907205|Drug|SF1126|Dose Escalating with 3+ patients in each cohort
45385090|NCT00908765|Behavioral|Exercise|"High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.~Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks"
45385091|NCT00903071|Behavioral|Real PPL|See above arm description
45385092|NCT00903071|Behavioral|Sim PPL|See above arm description
45385093|NCT00908843|Other|Intravenous hydration with bicarbonate|Intravenous hydration with bicarbonate 1/6 M intravenous infusion (3ml/Kg/h) one hour before the administration of intravenous contrast
45385094|NCT00908843|Other|Oral hydration with Sodium solution|Oral hydration with Sodium solution (Casen solution of rehydration) in the 4 hours before of the intravenous contrast administration (75 ml/10 kg as equivalent to 0,25 g of sodium chloride /10 kg).
45385095|NCT00904475|Drug|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
45385096|NCT00904475|Drug|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
45385097|NCT00908921|Drug|GLIMEPIRIDE|Dosage of 1mg, 2mg and 4mg of AMARYL (Glimepiride)
45385098|NCT00904631|Device|Eraser device+ salicylic acid (5%)|Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
45385099|NCT00909077|Drug|Dexamethasone|Dexamethasone tablets: 40 mg/day for four days
45385100|NCT00909077|Drug|Dexamethasone and Rituximab|Dexamethasone tablets: 40 mgs/day for four days Rituximab iv 375 mg/m^2 weekly, a total of four times. Administered on day 2 (i.e. the patient has been treated with Dexamethasone for one day)
45385101|NCT00904709|Drug|tranexamic acid|After The starting dose of tranexamic acid will be 500 mg twice daily beginning the first day of menstrual flow for a total of 6 days per menstrual cycle. If after 2 days there is still menorrhagia without significant side effects the will be increased. The women will be assessed again at day 4 and 9 and dose escalation will continue until they have reached the optimal dose.The dose of tranexamic acid will be increased as follows: 1000 mg twice daily, 1000 mg three times daily, 1500 mg/1000 mg/1000 mg, 1000 mg four times daily, 1500 mg three times daily, and 1500 mg four times daily (maximum dose).Each patient will be followed for a minimum of one menstrual cycle and a maximum of 3 cycles.
45385102|NCT05277389|Other|START - Startle Adjuvant Rehabilitation Therapy|Application of startling acoustic stimuli during practice of movement task
45385103|NCT05277389|Other|Sham Control|Practice of Movement task without START
45385104|NCT00340834|Drug|Fingolimod 1.25 mg|"Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
45499973|NCT03080961|Device|VIBLOK barrier cream|VIBLOK safety and performance has not been proven yet in humans with an HSV-2 infection.
45499974|NCT01379157|Drug|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 0.5 hr infusion of 0.5 g every 6 hr of imipenem at room temperature
45695341|NCT01049152|Device|Continuous Glucose Monitoring (CGM)|CGM allocated one time for 3 days
45695342|NCT00915928|Drug|Perindopril|2,5 mg daily for 3 months
45499975|NCT01379157|Drug|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 4 hr infusion of 1 g every 8 hr of imipenem at room temperature
45695343|NCT00915928|Drug|Placebo|Placebo dayli for 3 months
45695344|NCT03407638|Other|PROUD Intervention|The PROUD intervention includes 3 strategies used to implement the MA Model: 1. Clinic leadership receives funding for a 1.0 full time equivalent NCM for 2 years after randomization and technical support for recruiting and hiring the NCM. Once hired for the study, the NCM will receive technical assistance (TA) from experts at Boston Medical Center (BMC) supported by PROUD, but NCMs will be employed and supervised by the health system. 2. Experts at BMC who originally developed and disseminated the MA Model will: provide intervention clinics with a Manual; train PROUD NCMs at BMC; and provide the ongoing TA for 2 years after randomization. 3. At least 3 primary care providers in the PROUD intervention clinic will obtain DEA waivers to prescribe buprenorphine for OUDs, if not already waivered, and work closely with the NCM to offer high quality primary care for OUDs (e.g. medication treatment with buprenorphine or naltrexone with close follow-up to maximize retention in treatment).
45385105|NCT00340834|Drug|Fingolimod 0.5 mg|"Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily."
45385106|NCT00340834|Drug|Interferon β-1a 30 µg|"Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.~Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
45499976|NCT01538966|Drug|Pegvisomant|
45695345|NCT03407404|Combination Product|Ketamine-Midazolam|Continous intravenous sedation with 36mg of Midazolam and 900mg of Ketamine mixed in 50ml syringes as long as patient still requires sedation.
45695346|NCT03407404|Combination Product|Morphine -Midazolam|Continous intravenous sedation with 54mg of Morphine Sulphate and 36mg of midazolam mixed in 50ml syringes as long as participant still requires sedation.
45695347|NCT03830086|Drug|Midazolam|Used for general anesthesia for gynecological laparoscopic procedures, together with Propofol, Sufentanil, Rocuronium, Sevoflurane
45695348|NCT03830086|Drug|Sufentanil|Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures together with Bupivacaine; and for general anesthesia for gynecological laparoscopic procedures, together with following drugs: Midazolam, Propofol, Rocuronium, Sevoflurane
45695349|NCT03830086|Drug|Propofol|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Sufentanil, Rocuronium, Sevoflurane
45695350|NCT03830086|Drug|Rocuronium|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Sevoflurane
45695351|NCT03830086|Drug|Sevoflurane|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium
45695352|NCT03830086|Drug|Bupivacaine|Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures, together with Sufentanil
46056172|NCT02610400|Combination Product|RACD|"Active malaria surveillance using rapid diagnostic test in households around passively-detected index case. RDT-positive subjects are treated per national policy, under which combination medication artemether-lumefantrine is first-line, using dosing (mg artemether / mg lumefantrine):~(i) 5-14kg patient: 20/120mg twice (8 hr apart) on day 1, 20/120mg twice (12 hr apart) on each of days 2 and 3 then stop (ii) 15-24kg patient: 40/240mg twice (8 hrs apart) on day 1, 40/240mg twice (12 hrs apart) on each of days 2 and 3 then stop (iii) 25-34kg patient: 60/360mg twice (8 hrs apart) on day 1, 60/360mg twice (12 hrs apart) on each of days 2 and 3 then stop (iv) > 34kg patient: 80/480mg twice (8 hrs apart) on day 1, 80/480mg twice (12 hrs apart) on each of days 2 and 3, then stop"
45499977|NCT01538966|Drug|Octreotide LAR|
45499978|NCT01538966|Drug|Lanreotide|
45695353|NCT03407326|Dietary Supplement|Alternative RUTF|The alternative RUTF contains oat, peanuts, sugar, milk powder, vegetable oil as well as premix containing concentrated minerals and vitamins and emulsifier.
45499979|NCT01377285|Drug|ARB|"Angiotensin II receptor antagonists ,these medicines have names that end in sartan.For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan"
45499980|NCT01377285|Drug|Pentoxifylline|This medication is used to improve the symptoms of a certain blood flow problem in the legs/arms (intermittent claudication due to occlusive artery disease)
45499981|NCT01377285|Drug|Placebo (for Pentoxifylline)|Sugar pill manufactured to mimic Pentoxifylline 400mg tablet
45499982|NCT03609242|Behavioral|STOP-HPV bundle intervention|This intervention will be the bundle (training in communication skills, with the addition of performance feedback followed by the addition of provider prompts).
45499983|NCT03609164|Procedure|Suture-bridge augmentation of single-row repair|
45385107|NCT03986554|Procedure|Videofluoroscopic swallow study|The Swallowing Systems Core laboratory is fully equipped to perform VFSS with a C-arm (OEC 9900) that is dedicated solely for research purposes. VFSS recordings will be kept to a minimum and only turned on during the execution of each swallow in all sequences. Video recording and images captured during the VFSS will be synced and saved to a secure server for data analysis. VFSS allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic movement of the hyolaryngeal complex during swallowing) cannot be visualized with any other technique. Patients will swallow only water. Aspiration (bolus into trachea) is not expected to occur during this study given that the individuals recruited will have no prior history of disease or disorder, and aspiration is uncommon in healthy individuals.
46056173|NCT02610400|Combination Product|RAVC|Focal, targeted indoor spraying with long-lasting insecticide pirimiphos-methyl or Actellic 300 CS, a World Health Organization (WHO)-approved organophosphate. Safety measures: (i) seeking advance permission to spray; (ii) temporarily removing items (utensils, water, food, pets) from the building during spray; (iii) covering all unremovable items; (iv) asking inhabitants to temporarily relocate outdoors during spray; (v) advising children remain outdoors until floors washed; and (vi) avoiding of spraying of any rooms that contain inhabitants, animals, or incorrectly removed/covered items. Actellic will be applied according to National Vector-borne Disease Control Program (NVDCP) indoor residual spraying (IRS) guidelines, using a Hudson X-pert sprayer (Hudson Manufacturing Co., Chicago, USA) at 40 mL/m-sq.
45385108|NCT03986554|Procedure|pharyngeal High Resolution Manometry|This procedure will only take place once during sequence 2 of the randomization B session. If desired, a small amount (< 0.5 mL) of topical 2% viscous lidocaine hydrochloride will be applied to the participant's nostril of choice prior to catheter insertion. The catheter will be placed through the nasal passage, oropharynx, and hypopharynx to the esophagus. Correct catheter placement will be verified with VFSS. With the catheter in place, the subject will perform 10 swallows of 10ml and is expected to take approximately 2.5 minutes. The catheter will then be removed and the subject will move on to sequence 3. Individuals have the option to decline this procedure if it is uncomfortable or difficult to tolerate.
45385109|NCT01057966|Dietary Supplement|ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength)|Single full strength dose capsule taken one time
45499984|NCT03630783|Behavioral|Combined Cognitive Bias Modification|
45695354|NCT03407326|Dietary Supplement|Standard RUTF|Standard RUTF contains peanut paste, sugar, non-fat dried milk (NFDM), vegetable oil, a premix containing concentrated minerals and vitamins, and emulsifier.
45385110|NCT01057966|Dietary Supplement|ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength)|Single half strength dose capsule taken one time
45385111|NCT01057966|Dietary Supplement|ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength)|Single, full strength dose tablet taken one time
45385112|NCT01058044|Other|"Evaluation of adherence to 3 oral anticancer treatment using a  Medication Event Monitoring System "|"Evaluation of adherence using a  Medication Event Monitoring System  (MEMS®) for oral anticancer treatment delivered by dispensary pharmacy"
45385113|NCT01058122|Procedure|Collection of adverse drug events|
45385114|NCT00603941|Drug|CS-7017|At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.30, or 0.50 mg BID. At Phase 2, CS-7017 will be administered at the recommended phase 2 dose (RP2D).
45385115|NCT00603941|Drug|Paclitaxel|Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
45385116|NCT00340678|Drug|Losartan|Treatment with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
45385117|NCT00340678|Drug|Placebo|Treatment with placebo corresponding to each dose of losartan.
45385118|NCT01055470|Drug|Diclofenac|Tab. Diclofenac 50 mg 12 hrly, orally, in morning and in evening after taking food for 3 months.
45385119|NCT01055470|Drug|Lornoxicam|Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
45385120|NCT00904787|Drug|ENMD-2076|capsule, dose escalation, taken orally, daily in 28 day cycles
45385121|NCT02533102|Drug|E7050|100 mg tablet administered orally
45695355|NCT02240212|Drug|Afuresertib|The unit dose strength is 50mg/75mg tablet. Afuresertib will be taken orally once daily continuously during trail.
45695356|NCT02240212|Drug|Paclitaxel|Paclitaxel sourced locally will be administered IV
45695357|NCT02240290|Drug|tozadenant tablet|Active substance: tozadenant Pharmaceutical form: Tablet Concentration: 240 mg Route of Administration: Oral administration
45499985|NCT03630627|Drug|SB26|SB26 administered intravenously
45499986|NCT03630627|Drug|Placebo|Placebo administered intravenously
45499987|NCT02905266|Biological|Nivolumab|-Specified dose on specified days
45499988|NCT02905266|Biological|Ipilimumab|-Specified dose on specified days
45385122|NCT00907361|Device|MRI with pacemaker or ICD|The aim of the present protocol is to prospectively determine the adverse event rate of non-thoracic MRI for patients with implanted cardiac devices by collecting pre- and post-MRI device interrogations in a multi-center registry.
45385123|NCT02533024|Other|Electromyography|All subjects will have an EMG before, during and immediately after surgery.
45499989|NCT03889899|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
45499990|NCT01380795|Biological|CTC|every two cures of a standard chemotherapy patients will be taken sample of blood to monitor CTC presence and EGFR/ K-ras status of that CTC
45695358|NCT02240290|Drug|C14-tozadenant capsule|Active substance: C14-tozadenant Pharmaceutical form: Capsule Concentration: 74 kBq (2 μCi) Route of administration: Oral administration
45385124|NCT05277311|Drug|LongShengZhi capsule|LongShengZhi capsules, orally, 5 capsules each time, three times a day.
45385125|NCT05277311|Drug|LongShengZhi capsule placebo|LongShengZhi capsules placebo, orally, 5 capsules each time, three times a day.
45385126|NCT03986008|Drug|Benaglutide|The treatment of Benaglutide lasted three months.During the first week: 0.1mg per day;During the second week: 0.14mg per day; From third week onwards, 0.2mg per day.
45385127|NCT03986008|Drug|Liraglutide|The treatment of Liraglutide lasted three months.During the first week: 0.6mg per day;During the second week: 1.2mg per day; From third week onwards, 1.8mg per day.
45385128|NCT00909233|Drug|Vardenafil, (Levitra, BAY38-9456)|Patients under daily life treatment receiving Levitra according to local drug information.
45385129|NCT03985774|Procedure|Transcarotid revascularization|The ENROUTE Transcarotid Neuroprotection System (NPS) has received CE Mark and is commercially available in the European Union. The ENROUTE Transcarotid NPS may be used in conjunction with carotid artery stent approved for revascularization in patients with carotid disease The ENROUTE Transcarotid Neuroprotection System is intended to provide transcarotid vascular access, introduction of diagnostic agents and therapeutic devices, and embolic protection during carotid artery angioplasty and stenting procedures for patients diagnosed with carotid artery stenosis
45385130|NCT00904865|Procedure|SPA cholecystectomy|SPA cholecystectomy
45385131|NCT00904865|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
45385132|NCT03986086|Drug|MPH966|RP2D tablet
45385133|NCT03986086|Drug|Placebo|MPH966 placebo table
45385134|NCT03313895|Behavioral|ACT|ACT stands for combined aerobic exercise and cognitive training.
45385135|NCT03313895|Behavioral|Cycling Only|Cycling on a recumbent stationary cycle
45385136|NCT03313895|Behavioral|Cognitive Training Only|Engage in cognitive training on a computer
45385137|NCT03313895|Behavioral|Stretching and Mental Stimulating Activities|Stretching exercises and mental stimulating activities on a computer
45385138|NCT01058200|Device|iCup|new vacuum extractor: sterile disposable plastic cup
45385139|NCT01058200|Device|reference cup|reference cup of the obstetrical ward: metallic cup
45385140|NCT00909311|Drug|ABT-450|capsules, QD, 1 dose in each cross-over period
45385141|NCT00909311|Drug|ritonavir|capsule, QD, 1 dose in each cross-over period
45385142|NCT00907595|Drug|Ramelteon|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
45499991|NCT04339998|Diagnostic Test|Point-of-Care Ultrasonography (POCUS)|"The POCUS exam of the heart will capture 2 standard views commonly used to assess general cardiac function at the point of care. The details of POCUS views and exam findings of interest are outline below:~Pulmonary POCUS Evaluation:~B lines: absent (< 3 lines), present (> 3 lines), fused~Consolidation: yes or no~a. Bilateral: yes or no~Pleural Effusion: yes or no~Other pleural abnormalities: yes or no Score each finding based on degree of abnormalities and number of sites with abnormalities~Cardiac POCUS Evaluation:~Parasternal long axis~Parasternal short axis~Qualitative LVEF: Normal, hyperdynamic, mild-moderately depressed, severely depressed~EPSS (E-point septal separation): normal (<10 mm), abnormal (>10 mm)~Left ventricular (LV) mass approximation by septal thickness~Left Ventricular Chamber Size by internal diameter at diastole"
45385143|NCT00907595|Drug|Placebo|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
45385144|NCT05277467|Other|no intervention|no intervention
45385145|NCT00907673|Device|Automatic Fluid Shunt System|Fully implantable peritoneal catheter, bladder catheter, and pump
45385146|NCT00907751|Drug|rituximab|Patients will be treated according to the recommendations of the Reference Centre for the management of thrombotic microangiopathies. Infusions of rituximab (375 mg/m2) will be added to this treatment at day 1, 4 and 15, immediately after plasma exchange sessions.
45385147|NCT00909467|Other|echocardiography, right heart catheterisation|at each patient an echocardiography will be performed at rest and during exercise. For the evaluation of exercise capacity, cardiopulmonary exercise testing and six-minute walk is performed. Right heart catheterisation is recommended to those with suspected pulmonary hypertension.
45385148|NCT00905333|Drug|Candesartan (test)|16 mg oral tablet, single dose
45499992|NCT01380717|Drug|Beta-blocker, ACE-inhibitor|Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day
45499993|NCT01380717|Drug|Calcium Channel Blockers, ACE-Inhibitor|Calcium Channel Blockers: 5-10 mg a day. ACEi: 5-10 mg a day
45499994|NCT04292652|Procedure|AAA surgery|EVAR is a mini invasive procedure to exclude aortic aneurysms with the intention to prevent rupture. Open repair is the traditional open surgical procedure for the same condition.
45499995|NCT01569399|Other|rTMS (repetitive transcranial magnetic stimulation)|Frequency (10hz) 120% motor threshold 10 sessions
45385149|NCT00905333|Drug|Felodipine (test)|5 mg oral extended release tablet, single dose
45385150|NCT00905333|Drug|Candesartan Cilexetil|16 mg oral tablet, single dose
45385151|NCT00905333|Drug|Felodipine|5 mg oral extended release tablet, single dose
45385152|NCT00907829|Drug|lidocaine|comparison of the effect of the drug to help improve finger function
45385153|NCT00907829|Device|muscle stimulator|comparison of the effect of stimulated muscle(s) on finger function
45385154|NCT00905411|Behavioral|PacDASH intervention|"Effect of the PacDASH intervention on nutrition and physical activity behavior of children.~15 months study."
45385155|NCT00336544|Drug|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
45385156|NCT00336544|Drug|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
45385157|NCT01059058|Procedure|MI Paste Plus|A trained staff member from the NW PRECEDENT dental/orthodontic office will give 3 tubes of MI Paste Plus (10% CPP-ACP + 900 ppm Fluoride paste) and instructions to the subject for home use. A pea-sized amount for each arch will be applied 2x/day for 8 weeks. Subjects will apply cream topically to the teeth with their finger or a cotton swab, spread around with their tongue, hold for 1-2 minutes, then expectorate.
45499996|NCT02982018|Device|senofilcon A with new UV blocker|Investigational Contact Lens
45499997|NCT02982018|Device|senofilcon A|J&J Marketed Contact Lens
45695359|NCT03407092|Other|ADAPT cohort|Thrombectomy with distal aspiration technique
45385158|NCT01059058|Procedure|PreviDent Fluoride Varnish|A trained staff member from the NW PRECEDENT dental/orthodontic office will provide a SINGLE application of PreviDent fluoride varnish (22,600 ppm Fluoride) to the subject. The total dosage will be 0.5 mL.
45385159|NCT01059058|Procedure|Normal Home Care|Subjects will receive non-prescription fluoride toothpaste (1100 ppm Fluoride) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate.
45385160|NCT00605033|Drug|Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484|Suboxone sublingual tablet 4 mg/1 mg - 24 mg/6 mg, daily for 28 days
45385161|NCT00605033|Drug|Subutex, Buprenorphine Hydrochloride, SCH 28444|Subutex sublingual tablet 4-24 mg, daily for 28 days
45385162|NCT03988114|Drug|Abemaciclib|Administered orally
45385163|NCT03988114|Drug|Nonsteroidal Aromatase Inhibitor (NSAI)|Letrozole administered orally or anastrozole administered orally (physician choice)
45385164|NCT00905645|Device|Silimed Gel-Filled Mammary Implant|
45499998|NCT03080493|Drug|Gabapentin 600mg|Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
45499999|NCT03080493|Drug|Placebo oral capsule|Packaged identical to gabapentin dosing
45385165|NCT00905723|Drug|estradiol|1 mg daily for 6 months
45385166|NCT00905723|Drug|isoflavone|150 mg isoflavone daily for 6 months
45385167|NCT00905723|Drug|Placebo|sugar pill daily for six months
45385168|NCT04034069|Device|Theta burst stimulation (TBS)|Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability. In the present study, real stimulation will be delivered in an intensity of 70% individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% individual resting motor threshold.
45385169|NCT04034069|Behavioral|Robot-assisted training|Fourier M2 upper limb rehabilitation robot (Fourier Intelligence Co. Ltd., Shanghai, China), will be used for upper limb proximal joints training. Fourier M2 upper limb rehab robot is an end-effector robot-assisted device. The device targets (1) flexion and extension of shoulder joint, (2) flexion and extension of elbow, (3) internal and external rotation of shoulder joint, and (4) abduction and adduction of shoulder joint, supported by tailored interactive TV games in the device. HandyRehab hand robot (Zunosaki Company Ltd., Hong Kong SAR) will be used for upper limb distal joints training. It is an exoskeleton over the hand which provides power-driven extension and grasping force to the fingers and thumb in order to assist the patient to open and close the paretic hand by means of surface electromyography-triggered from the signals through the forearm extensors and flexors.
45385170|NCT03987646|Procedure|Non-staged vestibular fresh socket therapy|a slowly resorbable membrane shield is placed above the labial plate of bone so that when the thin labial plate started its resorption process the shield remains till a complete gap fill occurred thus leading to a thicker labial plate of bone or it preserves the socket architecture until a complete bone fill occurred inside the socket
45385171|NCT00907985|Drug|Placebo|Single dose of placebo will be provided.
45385172|NCT00907985|Drug|Vofopitant|Vofopitant (GR205171) will be provided as 5 milligram single dose capsule administered orally. It will be available as swedish orange, size 0 capsules.
45385173|NCT00907985|Drug|Lamotrigine|Lamotrigine will be provided as 25 milligrams or 100 milligrams single dose dispersible tablet administered orally.
45385174|NCT03987880|Procedure|4.0 mm treatment|PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea.
45385175|NCT03987880|Procedure|3.5 mm treatment|PiXL treatment with UV irradiation in a central 3.5-mm ring-shaped zone of the cornea.
45385176|NCT01325194|Drug|liposomal cytarabine|50 mg intrathecally three times
45385177|NCT00908063|Drug|Oxycyte|A single dose of one of three dosage levels (dose escalating design), given by intravenous infusion at the rate of 15 mL/min (total duration expected to be between 5 and 20 minutes).
45385178|NCT00908063|Drug|Normal Saline|Normal saline will be administered as one of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury.
45385179|NCT00909701|Dietary Supplement|PreOP Booster|1 serving of 400 ml per study arm
45385180|NCT00909701|Dietary Supplement|PreOP (Nutricia Clinical Care, Trowbridge, UK)|1 serving of 400 ml per study arm
45385181|NCT01058278|Procedure|Selective Laser trabeculoplasty|The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye. Fifty spots are done over 180°. The maximal and total energy is written in the chart. After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used. The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.
45500000|NCT03080493|Drug|acetaminophen/codeine and ibuprofen|Over the counter analgesic medications
45500001|NCT03655626|Other|Sepsis Watch|The operational intervention comprises of a sepsis machine learning model, custom dashboard to present risk scores, and a rapid response team to monitor patients at-risk of sepsis and deliver sepsis treatment. Sepsis Watch was developed under operational management. The rapid response team will utilize information presented on the dashboard and follow a protocol that will enable them to support the primary teams of hospitalized patients.
45500002|NCT03655860|Device|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
45500003|NCT02906007|Drug|Bedaquiline|"100 mg oral tablets.~Doses will vary based on the participant's age and weight."
45500004|NCT01339910|Drug|Fludarabine and Busulfan|"(Flu/Bu)~Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)~Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4"
45500005|NCT01339910|Drug|Fludarabine and Melphalan|"(Flu/Mel)~Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)~Melphalan: 140 mg/m^2 on Day -2"
45695360|NCT03407092|Other|Stentriever Cohort|Thrombectomy with stent retriever
45385182|NCT00905801|Other|CT Perfusion|Subjects will be examined with a CTP Imaging protocol which comprises repeated CT-scans of the tumor over a period of 50 seconds following the injection of a 30cc bolus of an FDA-approved low osmolar, iodinated CT contrast agent using a 64 row-multidetector row CT unit (LightSpeed VCT, GE Healthcare, Milwaukee, WI). One scan will be acquired every 3 seconds over a 50s period at 100 kV, and 100mA tube current. With this method, a 4cm long segment of the tumor can be analyzed, and 32 images of a slice thickness of 1.25 mm reconstructed simultaneously. Images will be evaluated using standard CT blood flow software (Perfusion 2, AW, GE Health Care, Milwaukee, WI).
45385183|NCT00908219|Drug|Bevacizumab|Bevacizumab is given as an IV infusion of 15 mg/kg every three weeks for 12 weeks.
45385184|NCT00927173|Device|Brainsway H-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
45385185|NCT00927173|Device|Brainsway H-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
45385186|NCT02538185|Device|NanoJect device (DebioJect™)|The investigational device used in this study is the NanoJect™ device developed by Debiotech company.
45385187|NCT02538185|Device|Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)|The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)
45385188|NCT02538185|Device|Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)|The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
45385189|NCT02538185|Drug|Vaccin rabique Pasteur®|
45385190|NCT02538185|Drug|Placebo|Sodium Chloride (NaCl) 0,9%; B. Braun
45500006|NCT01339910|Drug|Busulfan and Fludarabine|"(Bu/Flu)~Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2~Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)"
45500007|NCT01339910|Drug|Busulfan and Cyclophosphamide|"(Bu/Cy)~Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4~Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)"
45500008|NCT01339910|Drug|Cyclophosphamide and Total Body Irradiation|"(Cy/TBI)~TBI: 1200-1420 cGy on Days -7 to -4~Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)"
45500009|NCT02647827|Other|Lifestyle management|All women will receive lifestyle management instructions at the baseline visit, before randomization. The lifestyle management involves one initial counselling session in connection with the baseline visit, which includes information about the importance of weight management, healthy diet and physical activity.
45500010|NCT02647827|Device|Acupuncture|Disposable, single-use, sterilized CE marked needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50 mm will be inserted to a depth of 15-40 mm in segmental acupuncture points located in abdominal and leg muscles, with innervations corresponding to the ovaries and the pancreas. Two sets of acupuncture points will be alternated every second treatment.
45500011|NCT02647827|Drug|Metformin|Oral metformin 500 mg three times daily, in total 1500 mg per day. To reduce gastrointestinal side-effects of metformin, the dose will be slowly escalated starting with 500 mg daily during the first week, increasing to 500 mg twice per day during the second the week, and 500 mg three times daily, morning, lunch and dinner from the third week in total 16 weeks including the 3 weeks step-up phase (i.e. 4 months).
45500012|NCT03622164|Radiation|Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck)|CTV54 includes only the ipsilateral neck, including levels 2-4 plus levels 1 and/or 5 as clinically indicated.
45500013|NCT03622164|Radiation|Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck)|CTV54 includes the entire surgical bed, including bilateral neck lymphatics at risk of harboring microscopic disease
45500014|NCT01377207|Procedure|Primary PCI|Thrombus aspiration and hystopathological analysis, Optical Coherence Tomography assessment of STEMI culprit vessel, Primary PCI with Drug Eluting Stent implantation; Repeat OCT assessment of culprit vessel at 9 monts follow-up
45500015|NCT02237066|Device|Chocolate PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using the Chocolate PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
45695361|NCT01713686|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
45385191|NCT00908297|Dietary Supplement|Coenzyme Q10|"By mouth (wafer) once daily for duration of study (8 weeks).~Dose escalation:~300 mg for two weeks~600 mg for two weeks~1200 mg for two weeks~1800 mg for final two weeks"
45385192|NCT00927329|Biological|dust mite inhalation|Nasal allergen challenge will be provided in a graded dose fashion of 0 AU, 100 AU, 500 AU, and 1000 AU separated by 20 minutes.
45385193|NCT00931541|Drug|AZD6088|Oral solution. Each subject will receive a single-dose of AZD6088.
45385194|NCT00931541|Drug|Placebo|Oral solution. Each subject will receive a single-dose of placebo.
45385195|NCT00927407|Drug|Malathion gel 0.5%|Malathion gel 0.5% applied to the scalp for 30 minutes
45385196|NCT00927407|Drug|Malathion lotion 0.5%|Malathion lotion 0.5% applied to scalp for 12 hours
45385197|NCT00339040|Biological|Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)|QHPV at week 0, 8, 24 and 96.
45385198|NCT00339040|Other|Placebo/QHPV|Placebo at week 0, 8, 24 and QHPV at week 96, 104, 120.
45385199|NCT03743519|Dietary Supplement|Cherry juice|30 mL of tart cherry juice concentrate, which will be diluted with 200 mL of water.
45385200|NCT03743519|Dietary Supplement|Placebo|Identical in taste and colour to the Cherry juice, but with no anthocyanin content
45695362|NCT01047436|Drug|Quinine|20 mg/kg intravenous quinine loading dose, followed by 10 mg/kg intravenously every 8 hours until resumption of normal oral therapy
45695363|NCT01047436|Drug|Artemether|Artemether sublingual spray 3 mg/kg at protocol specified timepoints until resumption of normal oral therapy
45695364|NCT02240446|Device|Active tDCS|2mA stimulation for 20 minutes twice a day for five consecutive days
45385201|NCT04015193|Procedure|Single-port thoracoscopic sympathicotomy (patient care)|Single-port thoracoscopic sympathicotomy will be performed as part of patient care, data will be collected of patients undergoing this procedure
45385202|NCT00931697|Drug|AD 452 (+) mefloquine|Single dose delivered as over-encapsulated tablet at ascending doses
45385203|NCT00931697|Drug|Racemic Mefloquine|Single dose delivered as over-encapsulated tablet at ascending dose
45385204|NCT00931697|Drug|Placebo|Over-encapsulated placebo to maintain blinding
45385205|NCT00927797|Drug|Cyclophosphamide, Pentostatin, Rituximab|
45385206|NCT00338962|Drug|paroxetine|paroxetine (40mg/day)
45695365|NCT02240446|Device|Sham tDCS|2mA for 30 seconds twice a day for five consecutive days
45695366|NCT03406936|Drug|Daily interruption of midazolam|daily at 7 am midazolam infusion will be stopped spontaneous breath trial will be done
45695367|NCT03406780|Biological|CAP-1002|The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
45695368|NCT03406780|Drug|Placebo|Placebo
45695369|NCT02240524|Procedure|D2 lymphadenectomy|The dissected lymph nodes were classified according to the Japanese Classification of Gastric Carcinoma, first English edition.
45695370|NCT02240524|Procedure|Systemic chemotherapy|
45695371|NCT02240524|Procedure|HIPEC|
45695372|NCT02240602|Drug|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 1.00 mg.
45385207|NCT00338962|Drug|desipramine|200 mg per day
45385208|NCT00338962|Drug|Naltrexone|50 mg per day
45385209|NCT00338962|Drug|Placebo|placebo
45385210|NCT03580655|Drug|Avapritinib|Avapritinib tablet
45385211|NCT00931775|Drug|Pindolol|Pill orally administered. 15 mg/day t.i.d.
45385212|NCT00927875|Drug|BMS-833923|Capsule, Oral, starting dose 30 mg, once daily, continuous
45385213|NCT00927875|Drug|Carboplatin|Vial, Intravenous (IV), dose to yield 5 mg/mL - min, once every 21 days, 1 day per cycle up to 4 cycles
45695373|NCT02240602|Drug|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.03 mg/kg.
45695374|NCT02240602|Drug|Oxycodone, 0.02 mg/kg dose|intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.02 mg/kg.
45500016|NCT02237066|Device|Standard PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using a standard PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
45695375|NCT03406546|Drug|Dexmedetomidine|Dexmedetomidine was used as a sedation agent with less side effect on respiratory system.
45695376|NCT03406546|Drug|Remifentanil|Remifentanil was used to prevent cough induced by bronchoscopy.
45385214|NCT00927875|Drug|Etoposide|Vial, Intravenous (IV), 100 mg/m²/dose, days 1, 2, & 3 of each 21 day cycle, 3 days per cycle for up to 4 cycles
45385215|NCT00924521|Dietary Supplement|Whole grain diet|Participants in this group will receive 6-9 servings of whole grain daily to replace the refined grains typically included in the average American diet. Number of servings will depend upon calorie assignment.
45385216|NCT00924521|Dietary Supplement|Refined grain|Participants in this group will receive only refined grains as typically consumed in the average American diet.
45385217|NCT00924599|Behavioral|Prevention of recurrent gestational diabetes through weight loss and exercise (English & Spanish)|Intervention groups will attend weekly sessions focused on healthy weight loss, healthy eating, exercise.
45385218|NCT00924599|Behavioral|Lifestyle education (English & Spanish)|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
45695377|NCT03406546|Device|Laryngeal mask|Laryngeal mask was used to ensure respiration function during general anesthesia.
45385219|NCT00924677|Procedure|radiofrequency neurotomy for genicular nerve|RF cannula was advanced percutaneously towards areas connecting the shaft to epicondyle of femur or tibia. Lidocaine (1 mL of 2%) was injected before activation of the RF generator (NeuroThermTM, Morgan automation LTD, Liss, UK). RF electrode was inserted through RF cannula. The temperature of the electrode tip was raised to 70℃ for 90 seconds by radiofrequency generator.
45385220|NCT00924677|Procedure|radiofrequency neurotomy sham therapy|The placebo (sham) group received the same procedure without activation of the RF generator.
45695378|NCT01681004|Device|iFuse Implant System|Placement of iFuse implant system via surgery
45695379|NCT01681004|Other|Non-surgical management|Medications for pain, physical therapy, SI joint injection and RF ablation
45695380|NCT01046110|Drug|insulin degludec|Injected under the skin once daily for 26 weeks. The doses will be individually adjusted.
45695381|NCT01046110|Drug|sitagliptin|Sitagliptin tablets administered orally once a day at the same time every day for 26 weeks
45695382|NCT04549688|Procedure|high-intensity focused ultrasound, HIFU|see above
45385221|NCT00568061|Drug|Nitric Oxide|Nitric oxide for inhalation
45385222|NCT00568061|Drug|Placebo|Nitrogen gas (placebo) for inhalation
45385223|NCT00931853|Drug|SENNA+CASSIA(Naturetti)|Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
45385224|NCT00931931|Biological|HSV1716|
45385225|NCT03547427|Other|Basal insulin alone|A study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at according to the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
45500017|NCT03655392|Behavioral|Individualized educational program|IG patients were submitted to three 30-minutes intervention of a individualized shortterm educational program delivered by a nurse, were given explanations about general aspects of the disease, prevention methods and about the importance and correct use of inhaled corticosteroids, with an educational video showing the use of the device
45500018|NCT03655392|Diagnostic Test|Induced sputum collection|All participants performed induced sputum collection
45500019|NCT03655392|Diagnostic Test|Spirometry|All participants performed spirometry test using a Koko spirometer. Pulmonary function was assessed by spirometry prebronchodilator, after withholding short-acting beta-agonists for ≥ 6 hours and long-acting beta-agonist for ≥ 24hours. Forced expiratory volume in one second (FEV1) % predicted was used as a proxy variable for overall lung function.
45385226|NCT03547427|Other|Basal pramlintide and reduced basal insulin|A study insulin pump containing pramlintide will be programmed to deliver pramlintide at 6:1 pramlintide:insulin ratio. Simultaneously, a study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at ~25% reduced rate from the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
45385227|NCT03547427|Other|CGM|Subjects will be instructed to initiate a Continuous Glucose Monitor (CGM) session 2-3 days prior to both the experimental and control CRU admissions.
45385228|NCT03547427|Other|Acetaminophen test|Consumption of a standardized meal mixed with added 1.5 g liquid acetaminophen
45385229|NCT03547427|Other|Insulin-induced hypoglycemia|During insulin-induced hypoglycemia admission, subjects will receive an insulin bolus(s) dosed to reach blood sugar of less than 55 mg/dL.
45385230|NCT03547427|Other|Exercise-induced hypoglycemia|During exercise-induced hypoglycemia admission, subjects participate in three 15 minute exercise bouts (45 minutes total) to lower blood sugar to less than 55 mg/dL.
45695383|NCT01713530|Drug|insulin degludec/insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration twice a day.
45385231|NCT00932087|Procedure|Blood sample|Blood sample for lipidomic study
45385232|NCT00928109|Behavioral|CBCT|Cognitive Behavioral Couples Therapy - weekly manualized couples therapy
45385233|NCT00928109|Behavioral|Family Supportive Therapy|Couples meet once a week for an hour for a period of 20 weeks for couples therapy. Family Supportive Therapy is not manualized and is the standard form of care at the UNC Eating Disorders Program
45385234|NCT00928265|Device|Endovascular treatment of intracranial aneurysm.|"Neuroform stent is used in conjunction of occlusives devices such as coils. Neuroform Stent allows the treatment of wide neck aneurysm with embolic coils. Put in front of the wide neck, it keeps the coils into the aneurysm and avoids them to fall in the parent artery, preventing coil protrusion.~Accomplishes this by providing coil support at the neck of the aneurysm"
45385235|NCT00928343|Drug|GLPG0187|Single ascending subcutaneous doses (subcutaneous solution), and single oral dose (oral solution)
45385236|NCT00928343|Drug|Placebo|Matching subcutaneous or oral placebo
45385237|NCT00338884|Drug|Sunitinib malate|Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
45385238|NCT00338806|Behavioral|Interpersonal psychotherapy for prevention with adolescents|Individual interpersonal psychotherapy with the adolescents will be conducted over 12 weeks and will include a family psychoeducation component.
45500020|NCT03655392|Diagnostic Test|Nitric oxide measure|All participants performed nitric oxide measure in three Mylar bags and measure was performed in a NOA280 Sievers equipment. For collection the patients blew in the balloons through a sterile nozzle in the equipment collector without prejudice or damage to the patient.
45695384|NCT01713530|Drug|insulin degludec|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration once daily.
46056174|NCT02610400|Combination Product|rfMDA|"Presumptive treatment, using the medication A-L, of the inhabitants of households surrounding a passively-detected index case, without incorporating a diagnostic test step. The investigators will administer A-L with dosing as follows (mg artemether / mg lumefantrine):~(i) 5-14kg patient: 20/120mg twice (8 hours apart) on day 1, 20/120mg twice (12 hours apart) on each of days 2 and 3, then stop (ii) 15-24kg patient: 40/240mg twice (8 hours apart) on day 1, 40/240mg twice (12 hours apart) on each of days 2 and 3, then stop (iii) 25-34kg patient: 60/360mg twice (8 hours apart) on day 1, 60/360mg twice (12 hours apart) on each of days 2 and 3, then stop (iv) > 34kg patient: 80/480mg twice (8 hours apart) on day 1, 80/480mg twice (12 hours apart) on each of days 2 and 3, then stop"
46056175|NCT02743611|Biological|BPX-701|autologous T cells genetically modified to express the αβ TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch
46056176|NCT02743611|Drug|Rimiducid|dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity
45385239|NCT00338806|Behavioral|Educational clinical monitoring|Educational clinical monitoring will include two individual sessions of psychoeducation on mood disorders with the adolescent followed by monthly (and if needed bimonthly) meetings with therapist. If more sessions are required, a referral will be made.
45385240|NCT03038100|Drug|Paclitaxel|Paclitaxel 175 milligrams per square meter (mg/m^2) IV infusion on Day 1 of each 21-day cycle
45385241|NCT03038100|Drug|Carboplatin|Carboplatin at a dose to achieve a target area under the curve (AUC) of 6 milligrams per milliliter*minute (mg/mL*min) on Day 1 of each 21-day cycle for a total of 6 cycles
45385242|NCT03038100|Drug|Atezolizumab|Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle
45385243|NCT03038100|Drug|Bevacizumab|Bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion as per the schedule specified in respective arms
45385244|NCT03038100|Drug|Atezolizumab Placebo|Placebo matching to atezolizumab on Day 1 of each 21-day cycle
45385245|NCT00338728|Drug|Imatinib Mesylate|Given PO
45500021|NCT03655392|Other|Questionnaires ACT, ACQ, AQLQ, BDI|All participants answered standardized questionnaires about asthma symptoms and depression: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI)
45500022|NCT03655392|Other|Symptoms Diary|All participants were instructed to note in the morning and evening before the use of routine inhaled corticosteroids, asthma symptoms (coughing, wheezing, shortness of breath, use of emergency inhaled corticosteroids) and three measures of peak expiratory flow (individual, provided to patients) and to return this completed diary at each study visit
45385246|NCT00338728|Drug|Letrozole|Given PO
45385247|NCT01059136|Drug|Spironolactone|Unique 200mg IV dose of Potassium Canrenoate followed by 25 mg daily oral dose of Spironolactone for 6 months
45385248|NCT01061242|Behavioral|Sleep promoting interventions|MICU staff will implement multi-faceted, staged sleep promoting interventions as part of a pre-existing sleep quality improvement project.
45385249|NCT03985618|Procedure|Caesarean section|Planned pre-labour Caesarean section at 38-40 weeks. For patients planning Caesarean Section, surgical planning, precise timing and method of Caesarean section is at the discretion of the most responsible care provider, as per local procedures.
45385250|NCT03985618|Procedure|Induction of Labour|Planned induction of labour at 38-40 weeks. For patients planning induction of labour, precise timing and method of induction of labour is at the discretion of the most responsible care provider, as per local procedures.
45385251|NCT03983278|Other|School Model|Free delivery of glasses at the school within two weeks after screening
45385252|NCT03983278|Other|Referral Model|After the primary screening children referred to nearby Vision Center/ secondary center for refraction and delivery of free glasses.
45500023|NCT03655392|Diagnostic Test|Peak flow measure|All participants registered three peak flow measures in the symptoms diary by morning and night before the use of routine inhaled corticosteroids. Peak flow was measured by the electronic peak flow meter (Mini-Wright).
45500024|NCT03655392|Diagnostic Test|Exhaled breath condensate air measurement|Exhaled breath condensate was collect during 15 to 20 minutes in a Turbo DECCS equipment (Medivac SRL, Italy) in a sterile buccal of the own apparatus with the aid of a nasal clip with the participant breathing normally without any effort or damage.
45500025|NCT01430390|Biological|Biological/Genetically Modified T cells|Following completion of the chemotherapy, genetically modified T cells will be given intravenously at one of 3 dose levels. After the infusion patients will be monitored clinically and with serial blood and marrow evaluations to assess toxicity, therapeutic effects, and the in-vivo survival of the genetically modified T-cells. A fixed CAR EBV-CTL dose (3x106 EBV-CTLs/kg) which has been demonstrated to be the ideal manufacturing dose allowing for multiple infusions and potential for multiple patient treatments per cell line generated will be used for all patients on this trial. Cohorts will be determined separately but cohort 3 will not begin to accrue until cohort 2 has treated three (3) patients without a DLT. Each patient is eligible for up to three (3) infusions.
45695385|NCT01713530|Drug|insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration with the main meals 2-4 times daily in accordance with local labelling.
45695386|NCT01045798|Drug|Caspofungin acetate|70 mg of caspofungin administered intravenously (IV) on Day 1 followed by 50 mg daily for at least 6 additional days (maximum duration study therapy is 14 days)
46056177|NCT05757700|Biological|19(T2)28z1xx TRAC T cell|"Participants will be treated with escalating doses of modified T cells.~Dose level -1: 3 x 10^6 Dose level 1: 10 x 10^6 Dose level 2: 30 x 10^6 Dose level 3: 100 x 10^6"
45695387|NCT01045798|Drug|Placebo|Placebo to caspofungin (normal saline) on Day 1 followed by placebo daily for at least 6 additional days (maximum duration study therapy is 14 days)
46056178|NCT02743299|Device|Handivent Ventilator|CPR with use of a turbine-driven ventilator (Handivent)
46056179|NCT00813592|Drug|SOM230B|SOM230 is an injectable somatostatin analogue. Like natural somatostatin and other somatostatin analogues (SRIFa), SOM230 exerts its pharmacological activity via binding to somatostatin receptors (sst). There are five known somatostatin receptors: sst 1, 2, 3, 4 and 5. Somatostatin receptors are expressed in different tissues under normal physiological conditions. Somatostatin analogues activate these receptors with different potencies (Schmid and Schoeffter 2004) and this activation results in a reduced cellular activity and inhibition of hormone secretion. Somatostatin receptors are strongly expressed in many solid tumors, especially in neuroendocrine tumors where hormones are excessively secreted e.g. acromegaly (Freda 2002), GEP/NET tumors (Oberg, et al 2004) and Cushing's disease.
46056180|NCT02743143|Behavioral|Exercise therapy|
46056181|NCT02743143|Other|Follow-up care as usual|
45385253|NCT03983278|Other|Referral Model + Cost Recovery|"After the screening children referred to Vision Center for refraction and delivery of free glasses with the option to purchase upgrade glasses"
45385254|NCT00336856|Drug|Cetuximab|The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
45385255|NCT00336856|Drug|Irinotecan|The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
45385256|NCT02532868|Drug|MK-0457|
45385257|NCT01059370|Procedure|bowel emptying|Bowel is emptied using Peristeen® irrigation system one day, by digital stimulation another trial day or filling the bladder with saline water on a third trial day. BP is measured by Finometer Pro®, respiration frequency by BIOPACK and skin conductivity measured by Biopack and nor-epinephrine and epinephrine are measured in plasma three times during each examination.
45385258|NCT00566501|Drug|Donepezil|Donepezil SR 23 mg once daily orally.
45385259|NCT00504894|Drug|Placebo|A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.
45385260|NCT00504894|Drug|Propofol|A low dose of propofol 0.90 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
45385261|NCT00504894|Drug|Thiopental|A low dose of thiopental 3.0 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
45385262|NCT03743441|Other|Low-level Laser Therapy|LLLT, 904 nm wavelength, 3 Joules per treatment point in accordance with World Association for Laser Therapy (WALT) guidelines.
45385263|NCT03743441|Other|Sham Low-level Laser Therapy|Same procedure as in the LLLT group with the exception of laser irradiation (0 mW mean output power).
45385264|NCT03743441|Other|Exercise therapy|Concentric and eccentric exercises with a total duration of approximately 20 minutes.
45385265|NCT03743441|Other|Cryotherapy|Twenty minutes of cryotherapy applied to the Achilles tendon.
45385266|NCT00924755|Device|Biomerix Revive™ (surgical mesh for inguinal hernia repair)|Inguinal hernia repair using a tension-free onlay patch, Lichtenstein-style.
45385267|NCT01011348|Dietary Supplement|Coenzyme Q10|100mg/day for three months
45385268|NCT01011348|Dietary Supplement|Coenzyme Q10|300mg/day for three months
45500026|NCT01430390|Drug|Cyclophosphamide-based chemotherapy|Cyclophosphamide-based chemotherapy regimen will be the preferred conditioning chemotherapy prior to CAR T cell infusion for patients with CD19+ malignancy in cohort 1. Recommended chemotherapy regimen consists of single agent Cyclophosphamide at a dose of 3000 mg/m2/dose IV over 1 hour or 1500mg/m2/dose x 2 doses given daily over 1 hour given for 2 days (patients may received reduced dose of cyclophosphamide based on the clinical status of the patient at discretion of the treating physician and with written approval by the MSKCC PI of this study). Alternative cyclophosphamide or non-cyclophosphamide-based regimens based on the clinical status of the patient, disease burden, and likely-hood of response may be used at the discretion of the treating physician with written approval by MSKCC PI of the study. Conditioning chemotherapy will not be given prior to infusions # 2 and #3.
45500027|NCT03655314|Other|NEWT|The Newborn Weight Tool (NEWT) is publicly available at www.newbornweight.org. For this intervention, NEWT will be embedded into the electronic medical record along with a flag for weight loss greater than or equal to the 75th centile of birth weight.
45385269|NCT01011348|Dietary Supplement|Placebo|Three month period
45385270|NCT00924911|Drug|GSK1322322|Four different formulations of 1000mg of GSK1322322
45385271|NCT00924911|Drug|GSK1322322|GSK1322322 1000mg
45385272|NCT00928655|Drug|acetazolamide|acetazolamide 250mg 1/0/2
45385273|NCT00928655|Procedure|nocturnal continuous positive airway pressure|continuous positive airway pressure
45500028|NCT03655314|Other|Usual care|The electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight.
46056182|NCT02739633|Drug|Genexol-PM|125 mg/m2 given intravenously over 60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
45500029|NCT03608618|Biological|MCY-M11|Intraperitoneal administration
46056183|NCT02739633|Drug|Gemcitabine|1000 mg/m2 given intravenously for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
46056184|NCT02739477|Drug|Favipiravir|"Cohort 1: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600 mg (1800 mg bid).~Cohort 2: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohort 1 results.~Cohort 3: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohorts 1 and 2 results."
46056185|NCT02739399|Drug|Phenylephrine|Intravenous administration
45385274|NCT00928655|Drug|placebo|placebo capsules
45385275|NCT03743363|Other|Exergame 2/week|virtual training 2 times a week(8 week-long)
45385276|NCT03743363|Other|Exergaming 3/week|virtual training 3 times a week(8 week-long)
45385277|NCT03743363|Other|Healthy control / Exergaming 1/week|In the first 8 week-long only control group. For the next 8 weeks, the control group will do 1 workout per week.
45385278|NCT01011426|Drug|Bisacodyl|5mg po 6 hours postoperatively, repeat in 12 hours if no flatus
45385279|NCT01011426|Drug|placebo|1 capsule po 6 hours after surgery; repeat in 12 hours if no flatus
45385280|NCT00925067|Procedure|laparoscopic (TEP) inguinal hernia repair|laparoscopic inguinal hernia repair with a standard heavyweight Marlex (control group) prosthesis or new generation lightweight VyproII and TiMesh prostheses (study group)
45385281|NCT00925067|Device|lightweight TiMesh|
45385282|NCT00925067|Device|lightweight VyproII|
45385283|NCT00925067|Device|Heavyweight Marlex|
45385284|NCT02808156|Other|unilateral upper limbs intensive training|The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.
45385285|NCT02808156|Other|bilateral upper limbs intensive training|The bimanual intensive training focuses activities that required the use of both hands.
45385286|NCT00932555|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
45385287|NCT05163288|Drug|N-Acetyl-L-Leucine|N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)
45385288|NCT05163288|Other|Placebo|Matching Placebo Sachet
45385289|NCT00928733|Device|Gastroduodenoscopy- Intraduodenal intubation|20 g ethanol diluted up to 10% in tap water
45385290|NCT01012908|Dietary Supplement|Norzyme - Bergamo|2 - 8 tablets per day.
45385291|NCT01012908|Dietary Supplement|Creon|2 - 8 tablets pet day
45385292|NCT00932711|Behavioral|Educational brochures|A locally developed educational brochure containing information about smoking cessation, influenza and pneumococcal vaccination, regular exercise, compliance with prescribed COPD therapy and recognition of symptoms, along with a goal setting questionnaire
45385293|NCT04014959|Combination Product|TMS/ fMRI Stimulation|"The study uses a modified repetitive TMS stimulation protocol. Participants receive active TMS on five separate days: a baseline TMS/ fMRI scan, three mini TMS sessions, and a final TMS/ fMRI scan.~Again, this level of stimulation is considered to be sub-threshold for that of a TMS treatment protocol."
45385294|NCT01012986|Other|Assessment of reading skills|
45385295|NCT04722575|Drug|Cobimetinib 20 MG Oral Tablet|Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.
45385296|NCT04722575|Drug|Vemurafenib 240 Mg Oral Capsule|960 (arm A) /720 (arm B) mg bid p.o. from week 1 to week 6.
45500030|NCT03608618|Drug|Cyclophosphamide|Intravenous administration for preconditioning
45500031|NCT03655158|Device|ozone device ( Ozonytron XL )|The adjustment of the ozone generator was %75 power for 30 seconds (75 ug/ml) based on manufacturer's instructions
45500032|NCT03654924|Device|Laryngeal Mask|General anaesthesia using LMA will be performed as per standard procedure. A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
45385297|NCT04722575|Drug|Atezolizumab 1200 MG in 20 ML Injection|840 mg IV for 2 cycles for Arm B and C. After surgery in all arms 1200 mg IV for 52 weeks
45385298|NCT00513240|Drug|Erythropoetin|Erythropoetin 500 units/kg IV x 3 : dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2
45385299|NCT00513240|Drug|Normal saline|"Normal saline placebo in 3 doses:dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2.~."
45385300|NCT00925145|Procedure|Single Incision Laparoscopic Appendectomy|
45385301|NCT00928811|Drug|basiliximab|Simulect 20 mg intravenously day of transplant and day 4
45385302|NCT00928811|Drug|basiliximab|Simulect (basiliximab) 20mg intravenously day of transplant and day 4 post operatively. Then Monthly administration of Simulect (basiliximab) 40 mg intravenously for one year duration.
45500033|NCT03654846|Device|EmergencyEye|EmergencyEye Smartphone App
45500034|NCT04184648|Other|no interventions|no intervention
45500035|NCT04203290|Drug|Bupivacaine|%0.25 bupivacaine solution
45500036|NCT04203290|Drug|Sevoflurane|End tidal sevoflurane concentration
45500037|NCT02237144|Other|Cash transfer|1500 taka ($18.75) per household distributed monthly
45500038|NCT02237144|Other|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
45500039|NCT02237144|Other|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
45500040|NCT02237144|Behavioral|Behavior Communication Change (BCC)|Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
46056186|NCT02742831|Behavioral|Intervention|"The intervention group will receive a 6-session intervention. The overview of the 6 sessions is as follows:~Behavioral chain analysis of episode where parent felt stressed with child and episode where things went well. Identification of sources of interpersonal support.~Stress relief techniques. Identification of short and long-term goals. Development of a detailed crisis plan.~Problem solving techniques.~Emotional regulation. Exercises to identify moods and explore connections between feelings, thoughts, and behavior.~Positive parenting, review of common and specific parenting challenges, child development, short and long-term effects of different discipline approaches.~Reflection, repeat behavioral chain analysis. Update crisis plan."
46056187|NCT02742831|Other|Control|The families in the control group will be contacted by a member of the study team 6 times in 12 weeks to approximate the frequency of contact that the intervention group receives. The study team member will check in with families on the telephone or in person and will help them connect with clinic and community resources as needed.
45385303|NCT00932867|Drug|Kinzal/Pritor (Telmisartan, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
45385304|NCT00928967|Drug|Interferon beta-1b, (Betaseron BAY86-5046)|The cohort included is described in section 8.5 (inclusion criteria)
45385305|NCT00932945|Drug|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
45385306|NCT00504426|Drug|OPC-249|1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)
45500041|NCT02981082|Drug|Dimethyl Fumarate (DMF)|Dimethyl Fumarate (DMF) is a prescription medicine used to treat relapsing multiple sclerosis.
45385307|NCT00933023|Drug|hydrocortisone|1%hydrocortisone topical once daily for 8 weeks
45385308|NCT00933023|Drug|Betamethasone|Betamethasone 0.1% topical once daily for 8weeks
45385309|NCT00933179|Drug|Gestodene/EE Patch (BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 3 cycles
46056188|NCT02743065|Device|HepaSphere with 50-75mg Doxorubicin|HepaSphere with 50-75mg Doxorubicin
46056189|NCT02742909|Drug|rhBNP|rhBNP was administered as a continuous infusion for 24 hours before or after placebo
46056190|NCT02742909|Drug|placebo|normal saline as a placebo was administered as a continuous infusion for 24 hours
46056191|NCT02742675|Drug|Bicalutamide|Given orally
46056192|NCT02742675|Drug|goserelin acetate|Given subcutaneously or as an injection
46056193|NCT02742675|Drug|flutamide|Given orally
45385310|NCT00933179|Drug|EE/Levonorgestrel (Microgynon, BAY86-4977)|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 3 cycles
45500042|NCT02981082|Drug|Placebo Oral Tablet|Sugar pill manufactured to mimic Dimethyl Fumarate (DMF)
45500043|NCT02237222|Other|Gait rehabilitation|
45500044|NCT02034266|Dietary Supplement|Omega-3 supplementation|5 mL twice daily, administered under the tongue
45500045|NCT03654612|Drug|Apatinib|Apatinib 500mg qd plus S-1 50mg bid d1-d14/28d cycle
45385311|NCT00504348|Drug|Tacrolimus|Start at the standard starting dose of 0.075mg/kg/day divided into two doses, then adjust doses based on clinical response and tolerability, but maintain whole blood trough levels between 5 to 10 ng/mL and total daily doses equal to or below 0.3mg/kg.
45500046|NCT03654534|Dietary Supplement|NutrenOpimum|NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
45385312|NCT00929045|Drug|Growth Hormone Replacement|
45385313|NCT00929123|Procedure|neural mobilization|manual therapy technique known to directly stress the median nerve
45385314|NCT00929123|Procedure|sham neural mobilization|sham technique mimicking the neural mobilization which is not specific to the median nerve
45385315|NCT00929123|Other|healthy controls|People without carpal tunnel syndrome for comparison
45385316|NCT00507546|Drug|Ramelteon|8 mg nightly
45500047|NCT01066104|Drug|Xolair placebo|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
45500048|NCT01066104|Drug|Xolair (omalizumab)|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
46056194|NCT02742675|Drug|leuprolide acetate|Given subcutaneously or as an injection
45385317|NCT00507546|Drug|Placebo|Nightly 8mg of placebo (same appearance as ramelteon)
45385318|NCT00925457|Other|No Intervention|Neither current domperidone nor current PPI
45500049|NCT02736968|Drug|Auranofin|Auranofin is a gold-containing chemical salt available as 3mg capsules
45500050|NCT02736968|Other|Placebo|Placebo
45500051|NCT02980224|Drug|OmegaD|OmegaD Softgels
45500052|NCT02980224|Drug|Placebo|Placebo Softgels
45500053|NCT03653910|Device|Airtraq|Airtraq is a kind of videolaryngoscope for intubation
45500054|NCT03653910|Device|Macintosh|Macintosh is a traditional laryngoscope for intubation
45500055|NCT03608306|Other|Resin-modified glass ionomer|enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
45500056|NCT03608306|Other|Bulk-fill glass hybrid restorative|It's a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.
45500057|NCT03654144|Drug|Dienogest|oral tablets
45500058|NCT03654144|Drug|Combined Oral Contraceptive|oral tablets
45500059|NCT03654456|Biological|OSA|The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
45385319|NCT00925457|Drug|Current Domperidone|Current domperidone at any dose, regardless of proton pump inhibitor status
45385320|NCT00925457|Drug|Current proton pump inhibitor (PPI)|Current PPI and not current dapoxetine
45385321|NCT04522674|Biological|Autologous platelet rich plasma|0.5 mL autologous platelet rich plasma into a symptomatic osteoarthritic lumbar facet to treat back pain caused by lumbar facet syndrome
45500060|NCT02591615|Drug|MK-3475|Dose frequency of Q3W, Day 1 of each cycle
45500061|NCT02591615|Drug|Carboplatin|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
46056195|NCT02742675|Drug|triptorelin|Given subcutaneously or as an injection
46056196|NCT02742675|Procedure|Definitive Treatment|surgery to remove prostate or radiation therapy to the prostate.
46056197|NCT02742753|Other|Data collection|Data will be collected retrospectively linking regional patient-level data prospectively captured in real-world clinical setting with mandatory national healthcare registries from 2004 to 2013.
46056198|NCT02742597|Behavioral|TIP / IMPACT Plus Care Coordination|The intervention will involve the patient attending an interdisciplinary team meeting, either through the Ontario Telemedicine Network's teleconferencing technology or in person, along with their caregiver(s), the referring practitioner, inter-professional (IP) teams and home care coordinators to discuss and uncover the patient's condition covering a diverse range of medical, functional and psycho-social issues and the development of a patient-centred treatment plan. The care plans are documented, shared, implemented and monitored by an assigned nurse from the program.
46056199|NCT00813358|Device|Zenith TX2® TAA Endovascular Graft|Endovascular treatment with the study device
45385322|NCT00933257|Drug|LACTIC ACID(ND)|Treatment duration 5 weeks
45385323|NCT04015271|Behavioral|Action Observation + Repetitive Task Practice|Observing a video of another person performing a functional task and physically repetitively performing the same task for upper extremity hemiparesis
45385324|NCT04015271|Behavioral|Placebo Video + Repetitive Task Practice|Observing a video of static images and physically repetitively performing functional task for upper extremity hemiparesis
45500062|NCT02591615|Drug|Paclitaxel|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
45500063|NCT02591615|Drug|Pemetrexed|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
45500064|NCT03077607|Drug|Talazoparib|Arm A: 0.5 mg oral dose Arm B: 1 mg oral dose
45500065|NCT03077607|Drug|Itraconazole|100 mg oral dose
45500066|NCT03077607|Drug|Rifampin|600 mg oral dose
45500067|NCT03608462|Device|repetitive transcranial magnetic stimulation(DLPFC)|high frequency(20Hz) repetitive transcranial magnetic stimulation on dorsolateral prefrontal cortex(DLPFC) .Duration:10 days.
45500068|NCT03608462|Device|repetitive transcranial magnetic stimulation(LPC)|high frequency(20Hz) repetitive transcranial magnetic stimulation on left parietal cortex(LPC).Duration:10 days
45385325|NCT00925613|Device|LMA Proseal|"Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then the LMA proseal is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for <12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.~If failure to insert Proseal occurs, a second attempt is made after deepening anesthesia with propofol 1mg/kg and remifentanil 0.5ug/kg IV. If failure occurs again, the patient is intubated with a tracheal tube."
45500069|NCT04215588|Device|Hemostasis Management System Plus|Hemostasis Management System Plus (Medtronic, Minneapolis, MN) is a point of care device useful in the management of heparinization during bypass. It estimates the individual heparin dose response and calculates heparin concentration (IU/ml) in whole blood.
45500070|NCT04215588|Device|Activated Coagulation Timer System Plus|The Activated Coagulation Timer System Plus device calculates the Activated Clotting Time (ACT) in seconds.
45385326|NCT00925613|Device|Tracheal tube|Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then a tracheal tube (size 7 for women, size 8 for men) is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for <12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.
45695388|NCT02240758|Procedure|confocal endomicroscopy with the CELLVIZIO® system (Mauna Kea technology)|The CELLVIZIO® system (Mauna Kea technology) will be used for confocal endomicroscopy during a surgical procedure (either open surgical approach or stereotaxic biopsy). The probe dedicated to the CELLVIZIO® system will be positioned against the surface of the brain, sequences will be acquired, and finally compared with anatomapathology exams. Two specific medications will be used as contrast agent in the study: Fluorescein FAURE 500mg/5mL IV with a maximum of two doses per patient OR 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
45385327|NCT00929279|Drug|bolus+infusion|Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen
45500071|NCT03608228|Other|Measuring electrical signals from the brain|If patients participate in this study, after the deep brain stimulator leads have been implanted, the researcher(s) will plan to measure electrical signals from the brain while patients perform hand movement tasks.
45500072|NCT03622086|Other|Foundations of Fitness Program|The Foundations of Fitness Program is a 12 week, bi-weekly community intensive lifestyle program which focuses on healthy diet, daily physical activity, self-esteem and support for individual and family behavior change, components supported by USPSTF evidence review. Class sessions, which involve both parent/caregiver and child will include structured fitness activities, hands on nutrition, cooking, shopping and meal planning and facilitated discussions about goal setting, self-monitoring, stimulus control and healthy homes and families. Content will be offered in a context that supports self-esteem and behavior change. The program was developed by the Carter Community Building Association (CCBA) in collaboration with the Dartmouth-Hitchcock Weight & Wellness Center research core.
45500073|NCT02977572|Device|Non-Invasive Ventilation|In arm description
45500074|NCT02977572|Device|Continuous Positive AirwayPressure CPAP|In arm description
45500075|NCT02746874|Procedure|Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected prior to lesioning.
45695389|NCT03406390|Procedure|Pterygium surgery|The patients were anesthetized with subconjunctival injection.Symblepharon was released and fibrotic tissue was extensively dissected to expose the sclera and corneal stroma. The subconjunctival fibrovascular tissue, including Tenon's capsule, were thoroughly removed using scissors from the sclera and medial rectus muscle at the area of the superior and inferior fornices and the nasal caruncle. A cryopreserved human amniotic membrane (Zhongshan Ophthalmic Center, China) was then placed on the entire exposed bare sclera with the epithelial side facing upward, and secured with 10-0 nylon sutures.
45695390|NCT04377256|Procedure|Ridge preservation: Tooth extration and immediat bone grafting in the socket|Following the tooth extraction, the socket is filled with a mixture of xenogenic bone and hyaluronic acid and sealed with an epithelio-connective arrested from the maxillary palate
45695391|NCT03406234|Other|No intervention.|Cross-sectional observation without interventions.
45695392|NCT02240992|Biological|PBSC|
45695393|NCT02240992|Biological|MSCs|
46056200|NCT05628753|Diagnostic Test|Lung Ultrasound (LUS)|LUS performed 30 mins prior to and 120 minutes after planned extubation with a linear high frequency probe longitudinal approach was used in all three zones Repeated third scan will be done prior to re-intubation (if required) The ultrasound total execution cut-off time expected to be less than 5 minutes
45385328|NCT00929279|Drug|abciximab bolus only regimen|Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
45385329|NCT00567593|Drug|Rosiglitazone|8mg tablet once a day for 14 days
45500076|NCT02746874|Procedure|Simulated Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected. A simulate sham lesion will be performed at each target site.
45500077|NCT04699149|Other|Transcranial magnetic stimulation|Non-invasive brain stimulation
45500078|NCT04699149|Other|Sham transcranial magnetic stimulation|Non-invasive brain stimulation
45500079|NCT02344121|Radiation|Radiation Therapy|Radiation therapy plans for cancer patients who have completed treatment.
45385330|NCT00335764|Drug|sorafenib tosylate|given orally
45385331|NCT00335764|Drug|erlotinib hydrochloride|given orally
45385332|NCT00335764|Drug|tipifarnib|given orally
45385333|NCT00335764|Drug|temsirolimus|IV administration
45385334|NCT03743285|Device|AID System|AID system
45385335|NCT03743285|Drug|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
45500080|NCT01377129|Procedure|Single bundle anterior cruciate ligament reconstruction|Single bundle anterior cruciate ligamentoplasty
45500081|NCT01377129|Procedure|Double bundle anterior cruciate ligament reconstruction|Double bundle anterior cruciate ligamentoplasty
45385336|NCT00933413|Drug|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
45500082|NCT02558075|Behavioral|MoodLifters Sessions|This program consists of 15 different sessions with a different topic for each session. These sessions will occur once a week for 15 weeks and will last approximately an hour each. These topics will be in one of five theoretically important areas: biological, cognitive, affective, behavioral and social. Each subsequent week will involve an in-depth exploration of each topic, including why it is important to mental well-being and practical ideas about how to implement positive changes into one's everyday life. Following the facilitator's brief presentation, group members will be invited to share their experiences, challenges, and provide peer support.
45385337|NCT03981562|Drug|Vit D|Patients will take an oral vitamin D supplement once a day for 6 months.
45385338|NCT03981562|Drug|Placebo Oral Tablet|Patients will take a placebo oral tablet once a day for 6 months.
45385339|NCT03981484|Biological|Prothrombin Complex Concentrate|single dose of 25 IU/kg of 4-PCC at time of enrollment
45695394|NCT02982694|Drug|Atezolizumab|Atezolizumab will be administered 1200 mg in 250 ml 0.9% NaCl IV infusion bag, on day 1 of each cycle of 21 days.
45695395|NCT02982694|Drug|Bevacizumab|Bevacizumab will be administered 7.5 ml/kg (diluted in 0.9% sodium chloride solution) on day 1 of each 21 days cycle.
45385340|NCT03981484|Biological|Whole Blood, Plasma, Packed Red Blood Cells|site's standard resuscitation protocol
45385341|NCT03983200|Device|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min, bid
45385342|NCT03983200|Drug|Mecobalamin|mecobalamine 0.5mg,tid
45695396|NCT04377568|Biological|Convalescent plasma (CP)|Participants will receive one infusion of convalescent plasma proportional to their weight (10 mL/kg), up to a maximum of 500 mL
45695397|NCT02156674|Drug|Naglazyme®|1 mg per kg of body weight administered once weekly as an intravenous infusion
45695398|NCT02241070|Behavioral|mindulness-based intervention|"A number of mindfulness techniques, including both formal and informal practices with integration in the context of Mind/Body meditation, were explored in order to cultivate moment-by-moment present awareness with non-judgmental acceptance."
45695399|NCT01712984|Biological|Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation|0.1mL, Intradermal
45695400|NCT01712984|Biological|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal|0.1mL, Intradermal
45385343|NCT00567359|Drug|Erlotinib|Oral drug taken daily around the same time. Starting dose is 150mg once daily.
45385344|NCT01063582|Other|exposure to occupational noise|We performed the measurement of occupational noise exposure through sound level meter and Dosimeter during flight operations of F-16 fighter plane.
45385345|NCT01063582|Procedure|cardiovascular valuation|Cardiovascular valuation was performed via electrocardiogram and echocardiographic techniques to correlate the changes observed during exposure to occupational noise
45385346|NCT04014725|Device|Myopia Intelligent Diagnostic System|An artificial intelligence to make diagnosis of myopia using ocular appearance images
45385347|NCT01063660|Drug|Treosulfan|14 g/m²/d day -6 to -4
45385348|NCT00933569|Drug|LACTIC ACID(ND)|treatment period: 21 consecutive days
45385349|NCT00925847|Drug|lithium|lithium LP 400mg daily po (doses were adjusted during the study to maintain targeted blood levels.)
45385350|NCT00492726|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin, 400mg, administered intravenously once daily
45385351|NCT00492726|Drug|Ertapenem intravenous|Active treatment: Ertapenem 1.0g, administered intravenously once daily
45385352|NCT00925925|Other|Cord blood collection for analysis|Cord blood will be collected from the placentas at delivery for analysis
45385353|NCT00933647|Dietary Supplement|Yerba Mate Tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
45385354|NCT00933647|Dietary Supplement|Green tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
45385355|NCT00933647|Dietary Supplement|Apple tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
45385356|NCT00933725|Other|TCM intervention|"Drug: Particle of compound Chinese herbs(produced by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.~One tablet placebo of Tibolone (provided by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China, once every two days, taken orally, for two months.~Behavioral: TCM emotion treatment: made under the guide of TCM theory, administered by qualified TCM physician, for three times in two months."
45385357|NCT00933725|Other|Western intervention|"Drug: Tibolone, (produced by Oujianong corporation, Nanjing, China), 2.5mg, once every two days, taken orally, for two months; Particle placebo of compound Chinese herbs (produced by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.~Behavioral: supportive psychotherapy, administered by qualified physician, for three times in two months."
45385358|NCT00309946|Drug|cediranib maleate|Given orally
45385359|NCT00492648|Procedure|Blood sampling for assay of persistence of immunogenicity|Two blood samples: 30 and 42 months after first vaccination
45385360|NCT00929591|Drug|cyclophosphamide|
45385361|NCT00929591|Drug|doxorubicin hydrochloride|
45385362|NCT00929591|Drug|endocrine therapy|
45385363|NCT00929591|Drug|endocrine-modulating drug therapy|
45695401|NCT01712984|Biological|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal|0.1mL, Intradermal
45695402|NCT01042678|Biological|MP0112|Single intravitreal injection of MP0112 in the study eye
46056201|NCT02742207|Other|Electrical atrial fibrillation Cardioversion|Electrical cardioversion for patients admitted for Atrial Fibrillation
46056202|NCT02742207|Other|Cardioversion|Electrical cardioversion for patients admitted for Atrial Fibrillation
46056203|NCT00812812|Drug|paroxetine 10mg tablet|1 or 2 tablet(s) once a day
45385364|NCT00929591|Drug|fluorouracil|
45385365|NCT00929591|Drug|tamoxifen citrate|
45385366|NCT00929591|Radiation|brachytherapy|
45385367|NCT00929591|Radiation|low-LET electron therapy|
45385368|NCT00929591|Radiation|low-LET photon therapy|
45385369|NCT00929591|Radiation|radiation therapy|
45695403|NCT01042600|Device|Endotracheal tube insertion|Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)
45695404|NCT01042600|Device|Laryngeal mask airway insertion|Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)
45695405|NCT04377412|Other|Pandemic control measures|Population of different countries are exposed to different pandemic control measures, and everyday lives of pregnant women are affected on different levels. Investigators will measure influence their influence on mental health.
45695406|NCT01041976|Behavioral|Adapted Motivational Interviewing (AMI)|Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
46056204|NCT00812812|Drug|paroxetine 20mg tablet|1 tablet once a day
46056205|NCT00812812|Drug|matched placebo to paroxetine 10mg|2 tablets once a day
46056206|NCT00812812|Drug|matched placebo to paroxetine 20mg|1 tablet once a day
46056207|NCT02739165|Drug|ART-123|380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy
46056208|NCT02739165|Drug|Placebo|Placebo by intravenous drip infusion in addition to standard of care steroid therapy
46056209|NCT02739243|Behavioral|Tailored group intervention (PREPARE)|
46056210|NCT02739243|Behavioral|Individual treatment as usual|
46056211|NCT02742285|Drug|Artemether + lumefantrine|A single adult dose of artemether-lumefantrine will be administered on a unique occasion together with food. Venous and capillary blood samples will be collected at 6 to 10 time points, as defined before drug administration with each volunteer.
46056212|NCT05297344|Procedure|direct pulp capping|direct pulp capping
46056213|NCT05297344|Procedure|pulpotomy|pulpotomy
46056214|NCT04190199|Other|Observational|Cross-sectional only
46056215|NCT05756608|Diagnostic Test|68Ga-FAPI and 18F-AlF-FAPI PET-MR|Hybrid Cardiac PET-MR with 68Ga-FAPI and 18F-AlF-FAPI radiotracer
45385370|NCT01063738|Dietary Supplement|Amino acid supplement|Flavoured essential amino acid supplement and glutamine dipeptide taken twice daily for 3 months
45385371|NCT01063738|Other|PEPSE|Enhanced physiotherapy programme of 3 1 hour sessions per week for 6 weeks while in hospital and once discharged home 1 supervised outpatient session of 1 hour and 2 home exercise sessions per week (PEPSE).
45500083|NCT01377051|Drug|Indacaterol maleate|Dry powered, 300 mcg, only one inhalation with 24 hours duration
45500084|NCT01377051|Drug|Placebo|Dry powered, same to study drug, only one inhalation
45500085|NCT03217175|Device|Bihormonal Bionic Pancreas|The glucagon pump will be filled with glucagon during the exercise visit
45385372|NCT01063738|Other|Intensive Care Unit (ICU) Recovery Manual|Standard self-directed 6 week rehabilitation package
45385373|NCT01063738|Dietary Supplement|Placebo nutritional supplement|Cherry flavoured low calorie and low protein placebo drink
45385374|NCT00929747|Device|Toric|Unilateral implantation of the AcrySof IQ Toric IOL
45385375|NCT00929747|Procedure|Limbal Relaxing Incision|Unilateral implantation of a AcrySof IQ (SN60WF) IOL with concomitant LRI at the time of surgery
45385376|NCT03997500|Drug|normal saline|a bolus of normal saline was given followed by normal saline infusion
45500086|NCT03217175|Device|Insulin Only Bionic Pancreas|The glucagon pump will be filled with placebo during the exercise visit, and the bionic pancreas will operate in an insulin only mode.
45500087|NCT03217175|Drug|Glucagon|Glucagon will be given according to the algorithm in the bihormonal bionic pancreas
45500088|NCT03217175|Drug|Placebo|Placebo will be given instead of glucagon according to the algorithm in the insulin-only bionic pancreas
45500089|NCT01379079|Drug|Acetylsalicylic acid|aspirin intake at bedtime
45500090|NCT01379079|Drug|Acetylsalicylic acid lysinate|aspirin intake on awakening
45500091|NCT02034968|Drug|Nimotuzumab|Nimotuzumab: 200mg,IV once a week during chemotherapy.
45695407|NCT01041976|Behavioral|Support and Education for Recovery (SER)|Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
45695408|NCT00921310|Drug|Pemetrexed|
46056216|NCT03673527|Drug|topical formulation of tacrolimus|Topical application of tacrolimus twice daily for 14 days (one dose on Day 14).
46056217|NCT04030546|Drug|Ivabradine|Ivabradine capsule
46056218|NCT04189965|Other|Validation of virtual environment and auditive stimulation with virtual reality glasses (Pilot phase)|The goal of this phase is the development of the experimental protocol in virtual reality. Virtual environment will be checked and auditive stimulation will be graduated.
46056219|NCT04189965|Other|Electrical cutaneous stimulation and auditive stimulation (Experimental phase)|This phase is the principal step of the study: during moving in virtual environment, electrical stimulation on one hand and auditive stimulation will be applied. EEG, ECG and skin conductance will be measured during conditioning phase and extinction phase (day 1, 30 minutes each phase). Behavioral measures will be done throughout the 3 sessions (day 1, day 2 and day 30)
45500092|NCT03652506|Device|regional oxymetry probe|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
45385377|NCT03997500|Drug|Norepinephrine|a bolus of norepinephrine was given followed by norepinephrine infusion
45385378|NCT00933881|Other|Determining a change in heart rate variability post delivery of the baby|Determining a change in heart rate variability post delivery of the baby
45385379|NCT01013064|Drug|HM10760A or Placebo|0.04 mcg/kg to 2.0mcg/kg once intravenously
45500093|NCT03652506|Procedure|Quadratus Lumborum block|Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
45500094|NCT03652506|Procedure|Thoracic Epidural block|Thoracic Epidural block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
45500095|NCT03607760|Device|ECMO|the patients with severe respiratory failure were supported by ECMO
45500096|NCT03607760|Device|conventional mechanical ventilation|the patients with severe respiratory failure were supported by conventional mechanical ventilation
45500097|NCT01380561|Drug|asimadoline|10mg [14]C labelled asimadoline Day 1 then 7 doses 0.5 mg asimadoline bid beginning on Day 2 and ending on Day 5.
45500098|NCT03608150|Device|Luminopia One|Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia.
45500099|NCT03608150|Device|Refractive Correction|Standard of care refractive correction (ex. spectacles)
45500100|NCT05182983|Other|Tongue images，coating on the tongue and clinical data|Take photos of the tongue of patients with gastrointestinal diseases and collect clinical information.
45695409|NCT00921310|Drug|Temsirolimus|
45695410|NCT04376710|Other|Completion of pre-pandemic survey|Surgeons will take a pre-pandemic survey to determine surgeon perceptions to telemedicine and barriers to implementation.
45385380|NCT00933959|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
45500101|NCT02522429|Device|Low Intensity Focused Ultrasound Device|Low Intensity Focused Ultrasound Pulsation (LIFUP) of thalamus (a key area for the consciousness network) will be performed during two sessions (one occurring after deep sedation is stopped and the second one occurring just before discharge). The proposed experiment will involve behavioral (i.e., CRS-R) and paramedical (i.e., MRI/fMRI and EEG) measurements just before and after each of the two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session).
45385381|NCT00933959|Behavioral|Sleep Hygiene|Treatment as usual
45385382|NCT01011660|Drug|Amlodipine, Telmisartan, Amiloride Compound , Simvastatin|Amlodipine; Telmisartan; Amiloride Compound; Simvastatin
45385383|NCT04014881|Biological|Third-generation anti-CD123 CAR-T cells|From the minimum dose, If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.
45385384|NCT04517604|Device|Magventure MagProx100 with MagOption|iTBS will be delivered utilizing the MagVentrure MagPro X100 with MagOption stimulator that includes active and placebo coils (C-B60 Butterfly coils). Only the active setting will be used.A MagVenture C-B60 coil will be used to deliver single pulse TMS to the non-dominant MC to identify the ab-ductor pollicis brevis (APB) muscle coordinates. The integrated Localite neuronavigation system will be used.
45385385|NCT04015505|Behavioral|Cognitive Behavioural Therapy for older adults: wisdom enhancement 'timeline technique'|The intervention is comprised of five one-hour sessions of structured talking therapy, where participants create a timeline of their life with significant events included. Through dialogue with the therapist and structured worksheets, participants are encouraged to reflect on events in their life to recognise and develop qualities of resilience and self-compassion. They are then asked to use 'the wisdom of their years' to develop strategies to manage difficulties they are currently facing. Participants will also be asked to complete worksheets and try out new strategies between sessions.
45385386|NCT01015248|Drug|Rituximab and Bendamustine|Rituximab 375 mg/m2 iv. day 1 Bendamustine 90 mg/m2 iv. day 1 and 2
45385387|NCT00926081|Behavioral|Supervised exercise training|A standardized supervised exercise training program
45385388|NCT00929825|Device|mechanical stimulation (Elastomers)|The instrument of mastication, sialogogue should be used 4 times a day for 10 minutes each time always after meals
45385389|NCT00929825|Procedure|TENS|transcutaneous electrical stimulation
45695411|NCT04376710|Other|Completion of survey after peak of pandemic|Surgeons will take another survey after the peak of pandemic to determine surgeon perceptions to telemedicine and barriers to implementation.
45385390|NCT01013142|Drug|MN-221 (Dose Group 1)|i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour
45385391|NCT01013142|Drug|MN-221 (Dose Group 2)|i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour
45500102|NCT02974140|Device|Cataract Refractive Suite (CRS)|Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery
45695412|NCT04376710|Other|Completion of post telemedicine encounter survey|Patients will take a post telemedicine encounter survey to determine patient perceptions to telemedicine and barriers to implementation.
45695413|NCT02241148|Drug|Acetaminophen 500mg|500 mg, tablets every 8 hours
45385392|NCT01013142|Drug|MN-221 (Dose Group 3)|i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour
45385393|NCT00934037|Procedure|320 Volume Detector Computed Tomography|Single Arm Study. All patients undergo Volume (Multidetector) CT.
45385394|NCT00934037|Other|Other: Multidetector Computed Tomography - 320 detectors|Multidetector computed tomography angiography
45385395|NCT01013220|Other|Depression Product Detailing|"two hour academic detailing of depression management products to employees with responsibility for purchasing health care benefits~technical assistance in purchasing high quality depression management products"
45385396|NCT01013220|Other|Depression HEDIS detailing|"academic detailing to employees responsible for purchasing health care benefits on how to use HEDIS indicators for depression to assure their depressed employees receive high quality care for the condition~technical assistance"
45385397|NCT04014569|Device|MPSA Algorithm|Insulin dosing will be adjusted using the MPSA Algorithm
45385398|NCT00506922|Drug|Pentostatin|"Given intravenously on days +8, +15, +22 and +30 post transplant:~Group 2 - Pentostatin 0.5 mg/m^2~Group 3 - Pentostatin 1 mg/m^2~Group 4 - Pentostatin 1.5 mg/m^2~Group 5 - Pentostatin 2 mg/m^2"
45385399|NCT00506922|Drug|Tacrolimus|Given intravenously from day -2, and will be switched to oral dosing when tolerated.
45385400|NCT00506922|Drug|Methotrexate|Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.
45385401|NCT00929903|Drug|pazopanib hydrochloride|Given orally
45385402|NCT00929903|Other|pharmacological study|Correlative studies
45385403|NCT01013298|Device|video-guided PCT|extubation and then re-intubation with the ETT-TVT, followed by video monitoring of the PCT procedure via the ETT-TVT
45500103|NCT02974140|Procedure|Standard manual technique|Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique
45500104|NCT02311725|Behavioral|aTAU + sTVi|Antidepressant treatment as usual provided by participants' primary care physician plus narrative communication, video-based intervention for improving depression in primary care patients.
45500105|NCT02311725|Behavioral|aTAU + Attention Control Videos|Antidepressant treatment as usual provided by participants' primary care physician plus videos about general mental health and well-being on the same dose and frequency as the experimental intervention.
45500106|NCT03653754|Diagnostic Test|Measurement of growth and body composition|Growth (height and body weight), and body composition were measured. For the body composition, Inbody 770 and Inbody S10 were used.
45385404|NCT00934193|Drug|Gabapentin|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
45385405|NCT00934193|Drug|Placebo|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
45385406|NCT01013376|Drug|MC-1101|MC-1101 1.0%
45385407|NCT01013376|Drug|Vehicle|Vehicle
45385408|NCT01011972|Drug|XMT-1107|6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops
45385409|NCT04014491|Procedure|Scapula control exercise|To perform arm elevation in the scapular plane, subjects will be first asked to correct scapular resting posture in sitting with EMG biofeedback. Then the subjects will be instructed to do elevation in the scapular plane, side lying external rotation and dynamic hug plus with control of the scapula by EMG feedback and verbal cues
45385410|NCT04014491|Procedure|scapular strengthening exercise|The subjects in the scapular strengthening group will be asked to perform these three exercises the same as scapula control group and with the same number of trials but without any EMG biofeedback and oral cues of movement or posture correction.
45385411|NCT04014491|Other|No intervention|No intervention
45385412|NCT01012050|Device|NV|Noninvasive ventilation coupled with nebulization(Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm)
45385413|NCT01012050|Other|NEB group|Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm
45500107|NCT02237300|Behavioral|VR based cue-exposure therapy|Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
45500108|NCT02237300|Behavioral|Additional Cognitive-behavioral treatment|Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
45500109|NCT04932005|Drug|DZD2269|Part A: A single oral dose at 5mg, 10mg, 20mg, 40mg, 80mg, 160mg. Part C: Twice daily dosing for 7 days at 10mg, 30mg, 80mg.
45695414|NCT02241148|Device|Kinesio taping|Taping will be changed every week.
45695415|NCT03405688|Procedure|Blood sampling|Extra blood samples taken for laboratory analysis
45695416|NCT01712516|Drug|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
45500110|NCT04932005|Drug|placebo|Part A: A single oral dose. Part C: Twice daily dosing for 7 days.
45500111|NCT04889495|Drug|Zirabev|Bevacizumab biosimilar
45500112|NCT02974842|Device|MAKO 7|Hysteroscopic cell sampling
45500113|NCT05083611|Other|GraMI|The intervention will last 6 weeks. Each technique lasts for 2 weeks. The first two techniques will be performed through the previously designed mobile application and the last technique will be performed through a mirror box. The patient can do it autonomously with the supervision of the principal investigator.
45500114|NCT03653676|Other|Exercise Test (CIIT)|The CIIT exercise test will consist of 8 bouts (2 minute each) of constant workload cycling with rest periods (1 minute each) in between each bout of exercise. Subjects and controls will be randomized to either a moderate intensity or vigorous intensity, defined as 50% or 70% of the maximal workload achieved on the maximal cardiopulmonary exercise test (CPET).
45695417|NCT01712516|Drug|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
45695418|NCT01712516|Drug|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
45695419|NCT01712516|Drug|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
45695420|NCT03405610|Behavioral|The Toolkit for Optimal Recovery after Injury|The Toolkit for Optimal Recovery after Injury (ToR) is a skills based mind body program that was designed to prevent the development of chronic pain and disability following an acute musculoskeletal injury (e.g., fracture). The program has 4 sessions and it is delivered via live video. Patients learn myth about recovery after injury, false and real pain alarms, the fear avoidance model and how to prevent the disability spiral, mindfulness based exercises and activity pacing.
45695421|NCT04166240|Behavioral|SAFER TRACKS Intervention|SAFER Change Package delivered using a Virtual Breakthrough Series [VBTS] Collaborative supplemented with automated surveillance data on test results.
45695422|NCT01703000|Device|Percutaneous coronary intervention (NG PROMUS)|Interventional coronary artery stenting with NG PROMUS study stent.
45695423|NCT01040728|Drug|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
45695424|NCT01040728|Drug|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
45695425|NCT01040728|Drug|Tiotropium 18 mcg|18 mcg inhaled once daily from HandiHaler
45695426|NCT01040728|Drug|Placebo (for Olodaterol (BI1744)l)|Placebo (olodaterol low and high dose) delivered by Respimat
45695427|NCT01040728|Drug|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
45695428|NCT01593020|Drug|Paclitaxel|80 mg/m2 by vein over 1 hour on Days 1, 8, and 15 of each 21-day cycle.
45695429|NCT01593020|Drug|Eribulin|1.4 mg/m2 by vein over 2-5 minutes on Days 1 and 8 of each 21-day study cycle.
45695430|NCT01593020|Drug|5-Fluorouracil|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
45695431|NCT01593020|Drug|Epirubicin|100 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
45695432|NCT01593020|Drug|Cyclophosphamide|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
45695433|NCT01593020|Drug|Doxorubicin|50 mg/m2 by vein on day 1, over 72 hour continuous infusion or intravenous bolus, for 4 cycles (21 day cycle) at preference of treating physicians.
45695434|NCT01040260|Other|Counseling|Smoking cessation counseling
45695435|NCT01040260|Behavioral|Contingency management|Use of tangible rewards for abstinence from smoking
45695436|NCT01040260|Drug|Nicotine patches|Nicotine patches
45695437|NCT02241226|Behavioral|Perfect Health Course|The Perfect Health course as taught at the Chopra Center for Wellbeing
45695438|NCT01046422|Drug|BMS-770767|Capsule, Oral, 15mg, Active, Daily, 28 days
45500115|NCT03536247|Procedure|Initial therapy with papillary balloon dilation|patients will first undergo papillary dilation
45695439|NCT01046422|Drug|BMS-770767|Capsule, Oral, 50mg, Active, Daily, 28 days
45695440|NCT01046422|Drug|BMS-770767|Capsule, Oral, 150mg, Active, Daily, 28 days
45695441|NCT01046422|Drug|BMS-770767|Capsule, Oral, 50mg BID, Active, Daily, 28 days
45695442|NCT01046422|Drug|Placebo|Capsule, Oral, 0mg, Daily, 28 days
45695443|NCT01046422|Drug|Metformin|Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days
45695444|NCT02241382|Device|Internal Electrocardioversion|Cardioversion by internal shock application via the implanted ICD
46056220|NCT05756530|Other|Affective touch paradigm|"Affective touch paradigm: experimental stimuli will include the touch of a soft cosmetic, a hand, which will be both expected to resemble affective pleasant stimulations, and a plastic stick with a rounded tip, as a control (non-affective) condition. Two speeds of stimulation will be adopted i) slow affective stimuli delivered at 3 cm/s and fast non-affective stimuli, delivered at non-optimal speed (18 cm/s). An imagery version of the task will be also administered: blindfolded participants will be asked to image the touches on their left forearm.~After each (actual or imagined) tactile stimulus, individuals will rate the experience level of pleasantness.~As part of the protocol, they will fill out two psychological questionnaires, assessing the level of social anhedonia and the amount and characteristics of the lifespan experiences of affective touch in close relationships."
46056221|NCT04030390|Behavioral|Physical Fatigue|Maximal cycling effort for 30s (Wingate modified)
46056222|NCT04030390|Behavioral|Control|time-matched task (sitting on the bike without pedalling)
46056223|NCT02739009|Drug|MOR106 single ascending doses, intravenous|
45500116|NCT03536247|Procedure|Initial therapy with intraductal lithotripsy|patients will first undergo intraductal laser or electrohydraulic lithrotripsy
45695445|NCT02241382|Device|External Electrocardioversion|Cardioversion by external shock application via a cardioverter/defibrillator.
45695446|NCT01712438|Biological|Human cl rhFVIII|
45695447|NCT03405376|Drug|Intravitreal aflibercept injection|Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion.
45695448|NCT02241460|Drug|Placebo|During the Double-Blind Treatment Period, patients randomized to placebo will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg. During the Open-Label Treatment Period, the patient will receive four weeks of Promescent (active treatment) in one-week cycles: 30 mg, 50 mg, 70 mg, and patient's self-selected dose.
45695449|NCT02241460|Drug|Promescent Lidocaine Spray|During the Double-Blind Treatment Period, patients randomized to active treatment will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg, followed by four weeks of treatment during the Open-Label Treatment Period using patient's self-selected dose.
45695450|NCT01712204|Drug|Placebo|Placebo Capsule BID for 16 Weeks
45695451|NCT01712204|Drug|AC-201|AC-201 50mg Capsule BID for 16 Weeks
45695452|NCT01712204|Drug|Febuxostat|Febuxostat 80 mg QD for 16 Weeks
45500117|NCT03172481|Drug|PRC-063 oral capsules|Daily dose
45500118|NCT03172481|Drug|Placebo oral capsules|Daily dose
45695453|NCT01592864|Drug|Stannous Fluoride|dentifice
45695454|NCT01592864|Drug|Sodium Monofluorophosphate|dentifrice
45695455|NCT01592786|Drug|Memantine Hydrochloride (HCl)|Memantine extended release 3-mg capsules; the dosages studied ranged from 3 - 15 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for up to 48 weeks.
45695456|NCT01711736|Biological|Quadrivalent influenza GSK2282512A vaccine|1 or 2 doses administered intramuscularly (IM) in deltoid muscle or anterolateral thigh on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
46056224|NCT02739009|Drug|Placebo single ascending doses, intravenous|
46056225|NCT02739009|Drug|MOR106 multiple ascending doses, intravenous|
46056226|NCT02739009|Drug|Placebo multiple intravenous administrations|
46056227|NCT05210296|Behavioral|Exercises|Therapeutic exercise will be applied to the elderly
45385414|NCT00930137|Other|isocaloric for week diet|"Consumption of the 2 experimental diets~a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal);~a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal)."
45385415|NCT01015404|Drug|Trafermin|Administered to the bone defect during flap operation
45385416|NCT00934271|Radiation|fractionated stereotactic radiotherapy|Audit of outcome
45385417|NCT00492024|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin - 400 mg once a day for 5 days
45500119|NCT03653598|Other|Atrial Fibrillation|Data collection on Atrial Fibrillation
45500120|NCT01163487|Drug|Dichloroacetate|25-50mg/kg per day; oral
45385418|NCT00492024|Drug|Placebo|Placebo - 380 mg Microcrystalline Cellulose
45385419|NCT00934427|Drug|0.9% nitroglycerin in TAM cream|0.5 g of Vascana (0.9% nitroglycerin in proprietary vehicle cream) is applied topically BID for one day before certain planned cold exposures, once just before same planned cold exposures, and, if needed, right after the start of symptoms during same planned cold exposures
45385420|NCT00934427|Drug|vehicle cream|0.5g of vehicle cream is topically administered BID for one day before certain planned cold exposures, once just before certain planned cold exposures, and, if needed, right after the start of symptoms during certain planned cold exposures
45500121|NCT01163487|Device|EF5|21 mg/kg; IV
45695457|NCT01711736|Biological|Fluarix|1 or 2 doses administered IM in deltoid muscle or anterolateral thigh, on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
46056228|NCT02738931|Drug|Dolutegravir 50 mg tablet|A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.
46056229|NCT02738931|Drug|Lamivudine 300 mg tablet|"Gray, diamond-shaped tablet, engraved GX EJ7 on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water."
46056230|NCT02738931|Drug|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
46056231|NCT02738931|Drug|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
46056232|NCT00810082|Device|ActiveStep|ActiveStep™ is a training simulator. The system uses a computer-controlled treadmill to recreate life-like dynamic balance challenges such as slipping and tripping in a safe, controlled environment.
45385421|NCT00926315|Drug|calcitriol|Post menopausal patients will receive Calcitriol 0.50 mcg PO per day for 1 month.
45500122|NCT03535545|Drug|[68Ga]CBP8|Up to 15 mCi of [68Ga]CBP8 will be administered to each subject.
46056233|NCT00810082|Other|Standard Physical Therapy for Fall Prevention|Standard physical therapy for fall prevention
46056234|NCT05208892|Procedure|SZMN block|Suprazygomatic Maxillary Nerve (SZMN) Blocks bilaterally
46056235|NCT05208892|Procedure|SZMN block with Dexmedetomidine|Suprazygomatic Maxillary Nerve (SZMN) Blocks with local anesthetic and Dexmedetomidine bilaterally
46056236|NCT02738697|Drug|Adjuvant chemotherapy|8~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery
46056237|NCT02738697|Procedure|Follow-up|Patients received just follow-up instead of adjuvant chemotherapy
46056238|NCT05199844|Device|Apple Watch|Apple Watch device measures heart rate and oxygen saturation
46056239|NCT02736747|Other|Cryotherapy|
46056240|NCT02736747|Other|Placebo|
46056241|NCT02738619|Drug|Vitamin D3|1600 UI
45385422|NCT00926315|Drug|Calcitriol|calcitriol 0.25 mcg PO bid
45385423|NCT01013454|Drug|varenicline free base patch|varenicline transdermal delivery system (6.0 mg payload [drug amount loaded in each patch]) will be applied to the upper back over a single 24 hour period
45385424|NCT00930215|Drug|D961H|Oral gelatin capsule
45385425|NCT00930215|Drug|D961H|Oral HPMC capsule
45500123|NCT03535545|Diagnostic Test|PET Imaging|All subjects will undergo PET imaging after administration of [68Ga]CBP8.
45500124|NCT02855450|Drug|rhNGF|Recombinant Human Nerve Growth Factor 180μg/ml (one 35 μl drop equals to 6.30 μg of rhNGF) reconstituted solution three times a day (TID) for 8 weeks of treatment.
45500125|NCT02855450|Drug|Vehicle|Ophthalmic Placebo solution of the same composition as the test product with the exception of rhNGF reconstituted solution times a day (TID) for 8 weeks of treatment.
45500126|NCT03477045|Dietary Supplement|Single dose fish oil|Fish oil consumed within a single high fat test meal
45500127|NCT03477045|Dietary Supplement|Repeated dose fish oil|Fish oil consumed daily for 8 weeks
45500128|NCT03477045|Dietary Supplement|single dose Camelina seed oil|camelina seed oil consumed within a single high fat test meal
45500129|NCT03477045|Dietary Supplement|repeated dose camelina seed oil|camelina seed oil consumed daily for 8 weeks
45695458|NCT01592708|Other|Antiemetic anesthesia protocol|Intervention group consisted of patients undergoing maxillary osteotomy who received an antiemetic protocol designed to provide multimodal antiemetic therapy which have been shown to help prevent and/or treat postoperative nausea, combined with the elimination of anesthetic factors that may contribute to postoperative nausea and vomiting.
45695459|NCT01042522|Biological|Bleomycin Sulfate|Given IV
45695460|NCT01042522|Drug|Carboplatin|Given IV
46056242|NCT02738619|Drug|placebo|placebo
45500130|NCT01379001|Drug|Scopolamine|Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)
45385426|NCT00926471|Behavioral|Cognitive Behavioral Therapy (CBT) Program|12 to 14 weekly sessions of individual CBT and parent training with 5 sessions of group counseling every other week
45500131|NCT01379001|Drug|Placebo|IM or PO placebo
45385427|NCT00491556|Procedure|Early Initiation of Highly Active Anti-Retroviral Therapy|Treatment: TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r. Duration: Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.
45385428|NCT00491556|Procedure|Standard Care|Progression: Subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur. Treatment: HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care. Duration: three years.
45385429|NCT04015037|Combination Product|placebo or drug|Group A and B (medicated or placebo)
45385430|NCT00926549|Device|Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)|macular cube scanning
45385431|NCT00926627|Drug|bosentan|62.5 mg tablets b.i.d. administered orally for 4 weeks followed by the maintenance dose of 125 mg b.i.d. (62.5 mg b.i.d. if body weight < 40 kg/90 lb)
45385432|NCT00926627|Drug|placebo|identical preparation as the study drug, but without the active substance, administered b.i.d.
45385433|NCT00934583|Behavioral|Image and Mood (IaM) program|A 10-week Internet-based intervention focused on (1) identifying and challenging automatic thoughts in order to improve body image and reduce negative affect, (2) developing adaptive emotion and behavior regulation skills associated with preventing disordered eating and negative affect, and (3) teaching relapse prevention skills. The program includes an online discussion group moderated by a study clinician.
45385434|NCT00934739|Drug|Thalidomide, Celebrex|Immediately after operation starts thalidomide (50) 4# per day and celecoxib (Celebrex)(200) 2# bid for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
45385435|NCT00934739|Drug|Cyclophosphamide, Dexamethasone|Immediately after operation starts cyclophosphamide (50) 1# per day and dexamethasone (0.5) 2# qd for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
45385436|NCT00930371|Other|high fat/high saturated fat diet|4 weeks 55% fat/25% saturated fat isocaloric diet
45385437|NCT00930371|Other|low fat/low saturated fat diet|4 weeks 20% fat/8% saturated fat isocaloric diet
45695461|NCT01042522|Drug|Cisplatin|Given IV
45695462|NCT01042522|Drug|Etoposide Phosphate|Given IV
46056243|NCT04016116|Drug|Pembrolizumab|Pembrolizumab IV every 3 weeks
46056244|NCT04016116|Drug|Ruxolitinib|Ruxolitinib po days 1-21
45385438|NCT01015482|Drug|Remifentanil|Remifentanil Infusion
45385439|NCT01015482|Drug|Midazolam|Midazolam Infusion
45385440|NCT03760679|Device|Laryngeal mask Supreme evaluation|Device: Laryngeal mask Supreme evaluation
45385441|NCT03760679|Device|i-gel evaluation|Device: i-gel evaluation
45385442|NCT00934817|Drug|Amaryl-M 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 1 for RT sequential group, respectively
45500132|NCT01379001|Drug|Donepezil|donepezil 5mg PO x 1
45500133|NCT02035124|Drug|BKM 120|
45500134|NCT02035124|Drug|Cabazitaxel|
45500135|NCT03172325|Drug|Adalimumab|40 mg Adalimumab every other week is administered subcutaneously to all the patients.
45500136|NCT03172325|Drug|Methotrexate|15 mg Methotrexate is weekly administered to all the patients.
45500137|NCT03172325|Drug|Folic Acid|At least 1 mg Folic acid is daily administered to all the patients.
45500138|NCT03172325|Drug|Prednisolone|7.5 mg Prednisolone is daily administered to all the patients.
45500139|NCT03653520|Drug|Diazepam|5 or 10mg
45500140|NCT03653520|Drug|Tramadol|50mg or 100mg
45500141|NCT03653520|Drug|Ondansetron|1 or two tabs
45695463|NCT01042522|Other|Laboratory Biomarker Analysis|Correlative studies
45695464|NCT01042522|Drug|Paclitaxel|Given IV
45695465|NCT01702844|Drug|Nab-Paclitaxel|Administer 2 cycles of Nab-Paclitaxel 100 mg/m2 IV on days 1 8 and 15
45695466|NCT01702532|Drug|Nicotine|Comparison of different dosage forms of nicotine
45695467|NCT02241616|Drug|Entecavir+Fuzheng Huayu+TCM Granule|The subjects will be taking 1 Entecavir tablet per day, 4 Fuzheng Huayu tablets three times a day and specific Traditional Chinese Medicine granule for 48 weeks.
45695468|NCT03400306|Drug|Veliparib, capsule|capsule; 50 mg or 100 mg
45695469|NCT03400306|Drug|Veliparib, tablet|tablet; 400 mg
45695470|NCT03400306|Drug|Carboplatin|Intravenous
45695471|NCT03400306|Drug|Paclitaxel|Intravenous
45695472|NCT03405298|Behavioral|Educational Material|Educational material is in the form of a brochure
46056245|NCT02736591|Drug|DHEA|Women will receive oral DHEA 25 mg t.d.s. 12 weeks before ICSI.
45385443|NCT00934817|Drug|Amaryl-M 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group, respectively
45385444|NCT01013532|Drug|Cilostazol|Cilostazol 100mg bid
45385445|NCT01013532|Drug|Probucol|Probucol 250mg bid
45385446|NCT01013532|Drug|Aspirin|Aspirin 100mg qd
45385447|NCT01013532|Drug|placebo of cilostazol|same shape and size of active cilostazol
45385448|NCT01013532|Drug|placebo of aspirin|same size and shape of active aspirin 100mg
45385449|NCT01013532|Device|ankle-brachial index (ABI)|measurement of ABI every years during follow up
45385450|NCT01013532|Device|intima-medial thickness (IMT)|ultrasound measured IMT of both common carotid arteries
45385451|NCT01013532|Device|new asymptomatic brain hemorrhage|asymptomatic macrobleedings or microbleedings on GRE images
45385452|NCT01013532|Device|new ischemic lesions on follow-up FLAIR images|any new ischemic lesions
45385453|NCT00934895|Drug|everolimus|Orally administered RAD001 will be initiated at 5 mg daily. Each cohort Phase I: administration will proceed based on escalation criteria. RAD001 will be given initially once every day. Doses will be adjusted per the dosing regimen for each cohort throughout the Phase I portion of the study
45385454|NCT00934895|Drug|abraxane|Doses of Abraxane will be calculated on Day 1 of each cycle using the patient's actual weight in the determination of body surface area. A variance of 5% of the calculated total dose will be allowed.
45385455|NCT01012206|Behavioral|Intervention regarding food habits and physical activity.|Children in the intervention group participated in an intervention program regarding food habits and physical activity.
45385456|NCT00926705|Drug|Dexmedetomidine and Fentanyl|Dexmedetomidine in a dose of 1 ug/kg initial dose then continuous infusion of 0.7 ug/kg/hr . Combined with Fentanyl at a dose of 2 ug/kg initially plus boluses of fentanyl to keep the patient hemodynamically stable.
45385457|NCT00926705|Drug|Fentanyl|This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
45385458|NCT00930449|Other|Cogmed Working Memory Training Program.|"This program includes a set of visual-spatial and auditory-verbal WM tasks presented via the computer (see Appendix 1 for a description of these tasks). All tasks involve: a) maintenance of simultaneous mental representations of multiple stimuli; b) unique sequencing of stimulus order in each trial; and c) progressive adaptation of difficulty level as a function of individual performance.~Training will require about 30 minutes per day, 5 days per week, for 5-6 weeks: participants are required to complete 90 WM trials on each training day. Training plans are individualized and are modified according to performance, but the typical plan includes 13 tasks, with 15 trials of 8 tasks each day."
45385459|NCT00930449|Other|Academy of Math|"This is an established evidence-based program designed to help at-risk learners (Grades K-12) develop mathematical proficiency by incorporating a mastery-learning approach to foster conceptual understanding, computational fluency, and strategic competency across 10 mathematical subject areas.~Training is will require about 30 minutes, 5 days per week, for the same duration as the WM program (5-6 weeks), with a counselor or teacher acting as the training aide."
45385460|NCT00930449|Other|Special Education/Individualized Tutoring|Students in this group will receive an additional 30 minutes daily of individualized supplemental instruction in their area of greatest academic need.
45385461|NCT00506454|Drug|Lipidose|Over the course of 2 weeks, immediately following subject's three (Monday/Wednesday/Friday (M/W/F)) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of Lipidose over a 2-hour period.
45385462|NCT00506454|Drug|Placebo|Over the course of 2 weeks, immediately following subject's three (M/W/F) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of placebo over a 2-hour period.
45385463|NCT03415139|Drug|Oral Glucose Tolerance Test (OGTT)|A standard OGTT will be performed. During OGTT 75gm of glucose will be given followed by phlebotomy.
45385464|NCT03415139|Drug|2 OGTTs with and without GLP-1 analogue|A standard OGTT will be performed and a second OGTT procedure will be repeated on a different day with GLP-1 analogue.
45695473|NCT03405298|Behavioral|Supplemental Collaborative Care|Supplemental care management consist of meeting with a behavioral health care manager over five sessions in-person or via phone call; the care manager will review patient information with the consulting psychiatrist, who can then make recommendations back to the primary care provider
45695474|NCT03405064|Drug|Oral Levonadifloxacin/Linezolid Tablet|oral levonadifloxacin (1000 mg BID) or oral linezolid (600 mg BID)
45695475|NCT03405064|Drug|Intravenous Levonadifloxacin/Linezolid Infusion|IV levonadifloxacin (800 mg BID) or IV linezolid (600 mg BID)
45695476|NCT01702454|Biological|Fluarix Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region depending on the priming status
45385465|NCT03415139|Drug|Hyperglycemic clamp procedure|During the hyperglycemic clamp procedure, D20 will given, followed by phlebotomy.
45385466|NCT01012284|Drug|TMC207|400 mg (4 tablets of 100 mg) of TMC207 will be administered as a single dose on Day 1 of the treatment period to participants of both the Panels (Panel A and Panel B)
45385467|NCT00930527|Dietary Supplement|Omega-3 Fatty Acid|4g per day for 3 weeks
45385468|NCT00934973|Drug|mebeverine|overencapsulated mebeverine 135 mg tds for 6 weeks
45385469|NCT00934973|Drug|methylcellulose|overencapsulated methylcellulose 3 tablets bd for 6 weeks
45385470|NCT00934973|Drug|placebo|overencapsulated placebo tablets 1 tds for 6 weeks
45385471|NCT00934973|Behavioral|CBT website with support|cognitive behavioral therapy with nurse telephone session and email support
45385472|NCT00934973|Behavioral|No website|No CBT website
45385473|NCT00934973|Behavioral|CBT website with minimal support|
45385474|NCT00485472|Drug|lacosamide|50 or 100mg tablet, 400mg daily, for 12 weeks
45385475|NCT00485472|Other|Placebo|50 or 100mg tablet, 400mg daily, for 12 weeks, matched to Lacosamide
45385476|NCT00930605|Drug|CHOP regimen alternate with ESHAP regimen|CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
45385477|NCT00930605|Drug|Alemtuzumab|Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5.
45385478|NCT01018836|Drug|riluzole|The first dose of Riluzole will be day 0 of study enrollment. WBRT must begin within 48 hours of the initiation of Riluzole therapy. At the completion of radiation, Riluzole should be discontinued and steroids should be tapered over the course of 1-3 weeks, at the discretion of the treating physicians.
45385479|NCT01018836|Radiation|whole-brain radiation therapy|Standard whole brain irradiation will be carried out at 250 cGy per day fractions times 15 to a total dose of 3750 cGy using a standard opposed lateral helmet field with the inferior border inclusive of C1.
45385480|NCT00935051|Other|Picture + MMPs and TIMP1 at week 0 and week 4|Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. This will allow to assess the level of MMP9, MMP13, MMP1 and TIMP1. A numeric photograph of the wound will be taken at week 0, week 4 and week 12 in order to assess wound area.
45385481|NCT04015661|Drug|Nab-paclitaxel|induction chemotherapy with nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
45385482|NCT00491400|Drug|Fenofibrate|140 mg/day for 8 weeks
45385483|NCT00491400|Drug|Atorvastatin|20 mg/day for 8 weeks
45385484|NCT04015583|Behavioral|exergaming group|Exergame is 'exercise + game'. Treadmill exercise is traiditional aerobic exercise
45385485|NCT00491322|Dietary Supplement|Ergocalciferol|Ergocalciferol 50000 international units once a week for 12 weeks
45385486|NCT00491322|Dietary Supplement|Ergocalciferol placebo|Ergocalciferol placebo once a week for 12 weeks
45385487|NCT00930683|Drug|MEDI-546|0.1 mg/kg MEDI-546 as a single IV dose
45385488|NCT00930683|Drug|MEDI-546|0.3 mg/kg MEDI-546 as a single IV dose
45385489|NCT00930683|Drug|MEDI-546|1.0 mg/kg MEDI-546 as a single IV dose
45385490|NCT00930683|Drug|MEDI-546|3.0 mg/kg MEDI-546 as a single IV dose
45385491|NCT00930683|Drug|MEDI-546|10.0 mg/kg MEDI-546 as a single IV dose
45385492|NCT00930683|Drug|MEDI-546|0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses
45500142|NCT03653520|Drug|MKO melt|1 or 2 MKO melts
45500143|NCT01378923|Behavioral|REVAMP|The Re-entry values and mindfulness program (REVAMP) is an 8 session group intervention designed for jail inmates nearing release into the community
45500144|NCT01378923|Behavioral|TAU|have access to standard jail programs and services
45385493|NCT00930683|Drug|MEDI-546|1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
45385494|NCT00930683|Drug|MEDI-546|5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
45385495|NCT00930683|Drug|MEDI-546|20.0 mg/kg MEDI-546 as a single IV dose
45385496|NCT00926861|Device|ultrasound|A-scan and B-scan ultrasound at baseline and month 6,12,24
45385497|NCT00926861|Device|OCT|Volume scans of spectralis OCT at baseline and month 6,12,24
45385498|NCT04314570|Procedure|Saphenous Nerve Block with Ropivacaine Treatment|Regional Anesthesia nerve blocks have become standard practice for several orthopedic surgeries for post-operative pain management, however concerns for compartment syndrome have prevented nerve blocks to become common practice for tibial plateau open reduction internal fixation pain management. Interestingly, saphenous nerve blocks do not cover the sciatic nerve, allowing for pain management while reducing concerns that it may possibly mask compartment syndrome. Patients will receive ropivacaine through the catheter from the start of the nerve block.
45385499|NCT04314570|Procedure|Saphenous Nerve Block with Saline Control|Regional Anesthesia nerve blocks have become standard practice for several orthopedic surgeries for post-operative pain management, however concerns for compartment syndrome have prevented nerve blocks to become common practice for tibial plateau open reduction internal fixation pain management. Interestingly, saphenous nerve blocks do not cover the sciatic nerve, allowing for pain management while reducing concerns that it may possibly mask compartment syndrome. Patients will receive a loading dose of Normal Saline through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
45500145|NCT02034734|Drug|ASP3652|oral
45385500|NCT00935129|Device|OmniPod system|Patients will be treated with the OmniPod system for 12 weeks
45385501|NCT00935129|Device|Patient's conventional pump|patients will be treated with their conventional pump for 12 weeks
45385502|NCT00930839|Drug|Niacin and aspirin|1000 mg Niacin, 325 mg aspirin
45385503|NCT00935207|Other|Pediatric Pain Diary|Pain diary designed for pediatric patients
45385504|NCT01013610|Drug|LNK-754|Escalating dose
45385505|NCT01013610|Drug|Placebo|Escalating dose
45385506|NCT00926939|Behavioral|Reinforcement for the abstinence of smoking|Participants in this intervention group will receive vouchers contingent upon a CO sample of 4ppm or less.
45385507|NCT00926939|Behavioral|Reinforcement for submission of videos with CO sample|This intervention group will receive vouchers contingent on their submission of videos of their CO breath tests.
45385508|NCT01015716|Behavioral|Intervention-group|Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention
45385509|NCT01015716|Behavioral|Control-group|Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
45385510|NCT00927017|Other|Liquorice 66 g/day|Liquorice 66 g/day for two weeks
45500146|NCT03608072|Drug|BI 690517|3 sequential dose groups
45500147|NCT03608072|Drug|Placebo|3 sequential dose groups
45554664|NCT04917159|Behavioral|ACT (Acceptance and Commitment Therapy) plus brief CHF education|The participants will identify their values and clarify their alternative behavior, exploring their thoughts and feelings, and finding ways to meet their own and their family member's needs. The rational bond between the patient and his/her family caregiver will be emphasized. In addtion, the contents of brief CHF education are based on the latest national clinical practice guideline for CHF, including symptoms monitoring, medication adherence, fluid and salt restriction, smoking cessation, alcohol consumption, and physical activity maintenance.
45695477|NCT02241694|Other|No treatment given|No treatment given. Participants are to complete a questionnaire in the study.
45695478|NCT02241772|Drug|TA-8995|
45385511|NCT00927017|Other|Liquorice 102 g/day|Liquorice 102 g/day for two weeks
45385512|NCT03997032|Dietary Supplement|Ocufolin|Ocufolin, Aprofol AG, Switzerland Dose: 1 capsule per day
45385513|NCT00930917|Device|Polyethylene cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
45385514|NCT00930917|Device|Polyethylene wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
45385515|NCT00930917|Other|conventional treatment|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
45385516|NCT01015794|Drug|ephedrine hydrochloride|single oral dose, 1mg/kg body weight
45385517|NCT01015794|Drug|ephedrine hydrochloride|single dose of 1 mg/kg body weight
45500148|NCT03630471|Behavioral|PRIDE 'Step 1' problem-solving intervention|"The PRIDE problem-solving intervention is one component of the PRIDE stepped care treatment architecture which comprises two sequential treatments of incremental intensity. 'Step 1' is a brief, first-line treatment. It is grounded in stress-coping theory, with a technical focus on practical problem-solving to modify developmentally salient stressors.~Step 1 has been designed as a 'low-intensity' intervention requiring fewer resources than conventional psychological treatments. This is achieved through a relatively brief delivery schedule (up to 5 x 20-30-minute sessions spread over approximately 3 weeks) and limited requirement for specialists. The delivery agents are lay counsellors receiving a combination of specialist and peer supervision. The counsellors offer guidance sessions to support the learning and implementation of problem-solving and complementary coping skills. Illustrated booklets are used to support learning of problem-solving concepts and skills practice at home."
45695479|NCT02241772|Drug|Placebo|
46056246|NCT02736591|Drug|Growth Hormone-Releasing Hormone|Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering
46056247|NCT02736591|Drug|Placebo 1|Women will receive an oral placebo similar to DHEA for 12 weeks before ICSI.
45385518|NCT01015872|Device|CPAP treatment|CPAP treatment is to improve airway obstruct for obstructive sleep apnea, and after 3 months' treatment, we evaluate the effects.
45385519|NCT00935363|Drug|glyburide|single oral dose
45385520|NCT00935363|Drug|glyburide + fluconazole|single dose oral glyburide single dose iv fluconazole
45385521|NCT00935363|Drug|glyburide + rifampin|single dose oral glyburide single dose iv rifampin
45385522|NCT00935363|Drug|glyburide + fluconazole + rifampin|single dose oral glyburide single dose iv fluconazole single dose iv rifampin
45385523|NCT00930995|Drug|Candesartan|16mg po daily
45385524|NCT00930995|Drug|Placebo|once daily
45385525|NCT00935441|Behavioral|case management with telemonitoring|telephone contact with a case manager, home telemonitoring equipment for blood sugar and blood pressure, home HbA1c measurement
45385526|NCT00935441|Behavioral|usual case management|telephone contact with a case manager
45385527|NCT01015950|Dietary Supplement|Plumpy'Sup|Lipid-based (vegetable oil, peanut paste, soy protein-containing) fortified nutrient supplement to provide 500 kcal/d
45385528|NCT01015950|Dietary Supplement|Local food supplement|"Local foods (millet flour, cowpea flour, sugar, vegetable oil) and a multiple micronutrient powder (Mix Me) are provide, according to the national Mali CMAM protocol when special processed foods are not available."
45385529|NCT01015950|Dietary Supplement|Misola|Locally produced, millet-soy-peanut-based fortified complementary food (Misola)
45695480|NCT02241850|Other|High intensity training|9 weeks of supervised high intensity training
45695481|NCT04413656|Other|ablation|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery , after surgery 1month, 3month, and every 3month in the first year and every 6 months in the second ).
46056248|NCT02736591|Drug|Placebo 2|Women will receive a placebo injection similar to growth hormone daily from day 6 of hMG stimulation until the day of hCG triggering.
46056249|NCT05757466|Drug|Prolgolimab|Prolgolimab monotherapy 1 mg/kg IV every 2 weeks up to a maximum of 24 cycles
45385530|NCT01015950|Dietary Supplement|SCSB|Processed, fortified, corn-soy-milk-based food blend (SCSB for malnourished children, to be supplied by the World Food Program) to provide an additional 500 kcal/day
45385531|NCT00931073|Drug|Dimebon alone|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
45695482|NCT04413656|Other|surgery|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery, after surgery 1month, 3month).
45695483|NCT03404908|Procedure|TAP (transversus abdominis plane block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375% ropivacaine administered (0.2 mL/kg).
45500149|NCT03630471|Behavioral|Enhanced usual care|There is no established mental health service provision in the collaborating schools. The control arm participants will receive an enhancement of this 'usual care' (essentially, no care) by having access to the same illustrated booklets used in the Intervention arm, albeit without any counsellor contact.
45500150|NCT04054986|Diagnostic Test|F-Var3 PET/CT|Participants will undergo up to 5 serial F-Var3 PET/CT scans within 25 minutes of the injection of 18F-Var3, 30, 60, 120 and 240 minutes after injection of the 18FVar3.
45500151|NCT04054986|Other|Blood draw|Collection of blood for research tests before the injection, 30, 60, 120 and 240 min after the injection.
45500152|NCT03653286|Other|NMES and Run|"NMESIn this exercise protocol for quadriceps strengthening using NMES, the medium-frequency alternating current (1KHz with 10% of the work cycle) 4 will be used. The total daily training time is 900sec (15min), it is expected to perform 45 contractions per training, with three workouts per week for six weeks.~RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance."
45385532|NCT00931073|Drug|Dimebon + Ketoconazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 4 during the daily administration of ketoconazole (400 mg, Day 1-11) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
45385533|NCT00931073|Drug|Dimebon + Omeprazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 5 during the daily administration of omeprazole(40 mg, Day 1-12) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
45385534|NCT01016028|Behavioral|Questionnaire|3 questionnaires to collect information about any pain and/or symptoms experienced, general well-being, and personal information such as age and marital status. One (1) will be a symptom assessment questionnaire where asked to rate symptoms on a scale of 0-10.
45385535|NCT01016028|Behavioral|Sensory Tests|Test of sensitivity to things such as cold and touch, involve feeling cold objects, feeling bumps on a rectangular board, and putting pegs into holes on a board; and marking on computerized drawings areas experience pain, numbness, and/or cold sensitivity.
45385536|NCT01016028|Behavioral|Interview|First 5 patients receiving platinum agents, taxanes, and bortezomib (15 patients total) will be asked to describe their symptoms in an open-ended, semi-structured 20-30 minute interview.
45385537|NCT00935597|Biological|MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)|Patients who have minimal residual disease or minimal volume relapse, and are at least four weeks post immunosuppression following allogeneic stem cell transplantation will receive a series of four HDC infusions (100,000 HDC/kg per infusion, one every four weeks(group 1). Those patients who have greater than minimal residual disease will receive HDC infusions, one every four weeks in conjunction with donor lymphocyte infusion (DLI) (group 2).
45385538|NCT00931151|Dietary Supplement|Postprandial metabolic and functional measures|After ingestion of a high fat meal containing the different protein sources, the subjects undergo a series of measures of endothelial dysfunction and blood and urine sampling for the assessment of proinflammatory cytokines levels and metabolomics determinations.
45385539|NCT00936689|Procedure|Selective TACE via microsphere loaded with Doxorubicin|Chemoembolization with microspheres: doxorubicin (maximum dose of 75 mg x vials of microspheres) loaded with non-reabsorbable microspheres (sulfate hydrospheres) at the dose of 2 ml per vial (definitive embolization).
45385540|NCT00936689|Procedure|Selective traditional TACE|Traditional chemoembolization: epirubicin (maximum dose of 75 mg) conjugated with Lipiodol at the maximum dose of 15 ml + Spongel.
45385541|NCT01018914|Drug|Prograf|oral
45385542|NCT01018914|Drug|Advagraf|oral
45385543|NCT01018914|Drug|Myfortic|oral
45385544|NCT01019070|Drug|BMS-650032|Capsules, Oral, 200 mg, BID, 7 Days
45385545|NCT00936767|Drug|Artemisone/Mefloquine (AmiM3)|Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
46056250|NCT05757466|Drug|Combination with prolgolimab and bendamustine|Prolgolimab 1 mg/kg IV D1,15; Bendamustine 90 mg/m2 IV D1,2, 28-day cycle, maximum of 3 cycles;
46056251|NCT02736513|Drug|AZD9291|Patients will receive AZD9291 at a dose of 80 mg once daily.
45385546|NCT00936767|Drug|Artesunate|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
45385547|NCT00931229|Drug|entecavir|All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines. The primary endpoint of this study is the incidence of HBV reactivation, defined by a greater than 10-fold increase, compared with previous nadir levels, of HBV DNA during rituximab-CHOP chemotherapy and within 1 year after completion of the last course of rituximab-CHOP chemotherapy. Patients who have HBV reactivation during the study period will receive free entecavir treatment, one of the standard treatment for chronic hepatitis B, for 48 weeks.
45385548|NCT01013688|Procedure|Cardioblate® Surgical Ablation System|Using Cardioblate® Surgical Ablation System to perform left atrial or bi-atrial radiofrequency ablation procedure during valve surgery
45385549|NCT00936923|Drug|furosemide|patients will take furosemide 60 or 120mg oral per day for 1 years .
45500153|NCT03653286|Other|Only Run|RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance.
45385550|NCT01019382|Drug|Lipidem fish oil infusion + Gemcitabine chemotherapy|500mls intravenous infusion once a week of lipidem in addition to standard starting dose of gemcitabine (1000mg/m2) Dose can be reduced if poorly tolerated
45385551|NCT04014023|Drug|DWP16001|DWP16001 tablets
45385552|NCT04014023|Drug|Placebo|DWP16001 placebo-matching tablets
45500154|NCT01208090|Drug|ACT-128800|ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
45385553|NCT03997188|Device|Hepilor|ZLC oral suspension and placebo were both started on Day 1 of RT-HeT and ended when RT was completed or at the onset of dysphagia.
45385554|NCT00935675|Drug|Escitalopram|Escitalopram 10 mg once a day
45385555|NCT01016184|Dietary Supplement|Vitamin D|Oral vitamin D 100,000 IU
45385556|NCT01016184|Dietary Supplement|Placebo|Placebo
45385557|NCT00502320|Drug|Ramelteon|one 8 mg tablet at bed for up to 4 months
45385558|NCT00502320|Drug|Placebo|one tablet at bedtime for up to 4 months
45500155|NCT01208090|Drug|Placebo|ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
45500156|NCT03085017|Device|BoneSeal|BoneSeal® is an absorbable synthetic bone hemostats that also contains of PLA, PEG and hydroxyapatite which supports bone re-growth. Product code MTJ. FDA number K142348.
45500157|NCT03085017|Device|Ostene|OSTENE is a synthetic, biodissolvable implant material that, provides immediate bone hemostasis, can be used on all bleeding bone surfaces, is completely biocompatible and water-soluble polymer, is a mechanical barrier that does not act biochemically.
45500158|NCT04210050|Device|Home noninvasive nocturnal ventilation with Breas VIVO 50 home ventilator or newer model as available, Breas Medical.|"In the usual care plus NIPPV group, those able to undergo attended PSG will be titrated with volume targeted pressure support mode, aiming to lower the baseline TcCO2 by 10 mmHg. In some cases, the CO2 cannot be lowered by that amount on a single titration, but rather will decrease over time.~For those unable to undergo lab titration (too frail, no transportation, decline/refuse), NIPPV will be initiated with empiric settings based on nighttime home CO2 tracking and daytime ABG monitoring."
45500159|NCT04210050|Diagnostic Test|Arterial blood gas (ABG) and serum bicarbonate level|Will be obtained at baseline (before randomization), then at 3, 6 and 12 months into the study
45500160|NCT04210050|Diagnostic Test|Overnight home oximetry and transcutaneous CO2 monitoring|will be conducted at 1 and 6 months into the study (for subjects in the NIPPV plus usual care group, testing will be done while using the ventilator.
45848301|NCT03433794|Behavioral|Alcohol 101 Plus (TM)|It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide information such as sex, weight, and state so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. The program provides updated BACs based upon choices about what to consume and how quickly to consume it. The intervention is highly interactive, with text, photos, videos, and narratives for fictional students with decision points where the participant chooses what the fictional student should do. It is a non-linear environment, where participants choose which sections of the website to explore.
45385559|NCT02567825|Device|Tympanostomy tube placement|As per routine care, tympanostomy tubes will be inserted under general anesthesia, using a small radial incision in the anteroinferior portion of the tympanic membrane; a Teflon® Armstrong-type tympanostomy tube will be used.
45385560|NCT02567825|Drug|Amoxicillin-Clavulanate and/or Ceftriaxone|Children randomized to nonsurgical management will receive stepwise therapy with amoxicillin-clavulanate (90/6.4 mg/kg in two divided doses for 10 days), and in the event of inadequate response, ceftriaxone (75 mg/kg intramuscularly, repeated in 48 hours), as recommended in the American Academy of Pediatrics guidelines.
45385561|NCT02567825|Drug|Ofloxacin Otic|Participants randomized to receive tympanostomy tubes will also be followed overtime for recurrences of AOM and treated with topical ofloxacin (Floxin® 0.3%, 5 mL) 5 drops into the affected ear twice daily for 10 days. Persistence of otorrhea after 7 days of treatment will be considered inadequate response, and children so affected will be prescribed empiric amoxicillin-clavulanate (90/6.4 mg/kg/day in two divided doses) followed by culture-directed therapy 48 hours later.
45385562|NCT00490776|Drug|Panobinostat|Panobinostat, 20 mg, hard gelatin capsules, orally, thrice weekly.
45385563|NCT00935753|Drug|sapropterin|oral 100mg tablets taken intact or dissolved in water or apple juice with morning meal for up to 60 days
45385564|NCT01019460|Procedure|Magnetic resonance imaging, computed tomography scanning and capsule endoscopy|All patients are examined with ileo-colonoscopy, capsule endoscopy, MRI and CT of the small bowel within 14 days. Capsule endoscopy will not be performed in patients with small bowel stenosis confirmed at ileo-colonoscopy, MRI and/or CT.
45385565|NCT00935831|Drug|GSK1278863A|50mg, 150mg
45385566|NCT00935831|Drug|Placebo|matching placebo
45500161|NCT03653130|Behavioral|Crossroads Orchestra Participatory Music Program|The intervention is a participatory music program where adults engage in music-making as members of a strings orchestra.
45500162|NCT03215771|Device|MyoPro Motion-G|The MyoPro Motion-G is an elbow-wrist-hand myoelectric orthosis.
45554665|NCT04917159|Behavioral|HE (Health Education)|The educational contents are based on the latest national clinical practice guideline for CHF. Besides the basic information on CHF education provided in intervention group, the contents of CHF education also include definition of CHF, epidemiology, diagnosis, comorbidity, and CHF treatment. ACT components are not covered.
45695484|NCT03404908|Procedure|QL (quadratus lumborum block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with a distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
45695485|NCT03404908|Drug|Ropivacaine|In both groups (TAP&QLB) 0.375% ropivacaine will be given (0.2 mL/kg)
45385567|NCT01019538|Other|Pre-flight test with supplemental oxygen|The Hypoxia-altitude simulation test, which is established in clinical practice, is compared to the gold standard of hypobaric chamber while giving supplemental gaseous oxygen without and with oxygen conserving device, and with oxygen concentrator.
45385568|NCT00566735|Drug|Razadyne|The starting dose of study medication is 4 mg twice a day
45500163|NCT03215771|Other|Motor Learning-Based Therapy|Motor learning-based (MLB) therapy included movement practice as close to normal as possible, high repetition, progression of challenge, part versus whole task practice, and knowledge of results. Treatment was customized to abilities of each subject and consisted of both MyoPro training and MLB therapy without device. Training with device was progressed using a hierarchy of challenge to increase complexity of movement. MLB therapy without device followed the same hierarchy, incorporating training of movements that could not be accomplished with the device and those that were trained with device. Movement quality was monitored and training practice was incrementally progressed as subject demonstrated improved ability to perform a given task/movement component. Subjects performed a custom home exercise program (HEP) on non-clinic days, increasing repetition as tolerated. At conclusion of in-clinic phase, individuals transitioned to a home phase where they continued to use the HEP.
45385569|NCT00566735|Drug|Placebo|4 mg, 2 times a day
45385570|NCT03653273|Other|DMT withdrawal|Group 1 (DMT withdrawal) will not undergo any disease modifying treatments (DMT).
45385571|NCT03653273|Drug|DMT continuation|Group 2 (DMT continuation) may undergo the DMT . The therapy continued in this research is the one previously established, at the same dose, not implying additional precautions for use.
45385572|NCT00936143|Drug|infliximab|100mg/bottle 5mg/kg inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
45500164|NCT04266990|Other|Planned Sweat collection|Four times a day at fixed time points (9:30, 11:30, 13:30, 15:30), a researcher will ask the volunteers to wash their hands with non-scented soap and then place a sterile cotton gauze in the palm of their non-dominant hand. After 10 minutes, the gauze will be retrieved by the researcher.
45385573|NCT00937079|Other|111In-exendin-4 imaging|90-100 megabecquerel (MBq) (30 microgram or less) 111In-exendin-4 IV once
45385574|NCT04013633|Other|Lifesaver virtual reality training|CPR training using the Lifesaver virtual reality application
45385575|NCT04013633|Other|Face-to-face training|Short face-to-face CPR training
45385576|NCT00566111|Drug|ceftriaxone|2g per day which will be administered IV via midline, 7 days a week for 4 weeks.
45500165|NCT04266990|Other|Spontaneous Sweat collection|As the patient will be under continuous monitoring, sweat and saliva samples will be also collected during and/or right after a seizure occurs if the volunteer is not holding a gauze at that time. The sweat samples will be collected by the researcher by applying a sterile gauze to the patients hands, either during or immediately following a seizure during 10 minutes.
45500166|NCT04266990|Other|Healthy volunteers sweat collection|A researcher will ask the volunteers to wash their hands with non-scented soap and then place a sterile cotton gauze in the palm of their non-dominant hand. After 10 minutes, the gauze will be retrieved by the researcher. The healthy samples will be collected on the same floor of Ghent University Hospital and as close as possible to where patients reside
45500167|NCT03636425|Other|Questionnaire administration to gather information|In the questionnaire there are questions about the training (number of kilometers traveled by runners on average, total height difference, number of training sessions per week, training ground) questions on other activities carried out (gym, bicycle, etc.) number of competitions that runners participated in the month, used footwear, musculoskeletal disorders in the last 12 months, which health professional the runner has addressed, which physiotherapy therapies did.
45500168|NCT01380483|Drug|doxycycline monohydrate|Tablets, 100 mg, single, oral dose
45500169|NCT01380483|Drug|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
45500170|NCT02745392|Drug|ZP-Zolmitriptan|ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system
45500171|NCT02745392|Drug|Placebo|Placebo patch(es) to match ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system (one or two patches)
45500172|NCT04265586|Behavioral|Education|"Sleep hygiene education is either face-to-face appointment or video-meeting with trained nurse."
45385577|NCT00566111|Drug|Saline solution|Saline solution will be administered IV via midline, 7 days a week for 4 weeks.
45695486|NCT03404908|Device|Needle|Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
45385578|NCT00937313|Other|Champagne wine intervention|Placebo-controlled randomised cross-over human trial
45385579|NCT00514046|Drug|Vandetanib|once daily continuously (28 day cycles)
45385580|NCT00937469|Behavioral|Social skills training, parental tr. and standard tr.|Social skills training will consist of 8 weeks of group treatment with weekly sessions of one and a half hours and includes role play, exercises and games as well as home work which will include the parents. At the same time the parents are participating in parental training groups,that will focus on supporting the children's social training. Both the children and the parental groups are lead by two group therapists. The intervention will be additional to the received standard treatment.
45385581|NCT00937469|Other|Standard treatment|The standard treatment consists of medical treatment, briefing, consulting and supporting conversations with a focus on securing compliance to the treatments´ and on aiding children and their families with the difficulties arising with the children's illness. Furthermore the parents participate in parental groups three times during the 8 weeks in which the experiment takes place. This group lasts 2 hours and is managed by two nurses who are attached to the ADHD- treatment group.
45385582|NCT00937625|Biological|cyclophosphamide, fludarabine, T-cells, Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks. After the first 6 patients the dose of IL-2 has been changed to an i.v. decrescendo regimen using 18 MIU/m2 infused over 6, 12 and 24 hours and then 4.5 MIU/m2 infused over 24 hours for three days.
45385583|NCT04014101|Drug|SHR-1210|SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
45385584|NCT04014101|Drug|apatinib|Apatinib is a selective VEGFR2 inhibitor.
45385585|NCT04014257|Drug|NOV1601(CHC2014)|a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A (TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
45385586|NCT00936533|Drug|Dysport® (Botulinumtoxin A (Btx A))|Single injection in patients´ soles with Btx A in one foot and sodium chloride in the other, with the possibility of a second injection after 12 weeks. The drug will be given in general anaesthesia after curettage of the focal hyperkeratoses. Only the areas with focal hyperkeratoses will be injected with 50 ul per injection.The active drug Btx A (Dysport®, solution for injection) has a concentration of 100 U/ml, and the maximum dose is 300 U per foot.
45385587|NCT00936533|Drug|Placebo|Placebo preparation without active compound, administered as the active drug.
45500173|NCT04265586|Behavioral|Web-based Cognitive Behavioural Therapy (iCBT)|iCBT is a web-based programme (7-16 weeks) designed to treat the symptoms of insomnia.
45385588|NCT04618250|Other|SOFIA model|A mandatory two day course for general practitioners assigned to the intervention group A prolonged consultation at the general practitioner Use of an individual care plan
45385589|NCT04264052|Diagnostic Test|CBE & MRI|"The diagnostic tests will be consisted by two visits.~In the first visit participants will undergo a medical history assessment and they will complete questionnaires related to the lung function (MRC Dyspnoea score, Dyspnoea-12 questionnaire, and Visual Analogue Scale). A spirometry will be performed to assess the lung function. Bronchoscopy will be performed at rest in a semi-supine position (on a reclined bed) and then during exercise on a treadmill.~In the second visit, spirometry and questionnaires will be performed prior to resting and during exercise measurements on a magnetic resonance imaging (MRI) scan.~Rest: Structural imaging of the neck and chest will be performed followed by dynamic imaging of the airways during several inspiratory and expiratory manoeuvres. No IV contrast media will be used."
45385590|NCT00564629|Drug|Intravenous acetaminophen plus oral placebo|Single dose of 1 gm IV acetaminophen
45385591|NCT00564629|Drug|Oral acetaminophen plus IV placebo|Single dose of 1 g PO APAP
45385592|NCT00564629|Biological|Reference standard endotoxin (RSE)|To subjects in both study arms: Administration of a 1 ng/kg body weight test dose of RSE to induce fever and test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
45385593|NCT00564395|Drug|Insulin Detemir mixed with RAI injection|Insulin Detemir mixed with RAI injection is given twice daily as subcutaneous injection
45385594|NCT00564395|Drug|Insulin Detemir and RAI injection|Insulin detemir and RAI are given as separate injections, twice daily as subcutaneous injection
45385595|NCT00937703|Device|placebo|paper support for glycaemia face to face visit at T4mounths
45385596|NCT00937703|Device|IVS|"patients transmit their glycaemia to the IVS, which advises them the insulin amount recommended by their physician in this situation.~Face to face visit at T4mounths plus telephone visits each 2 weeks."
45385597|NCT00937703|Device|PDAphone|Patients will receive PDA phone system. They will hace face to face visit at T4mounths and telephone visits each 2 weeks
45385598|NCT00937781|Genetic|RNA analysis|
45385599|NCT00937781|Genetic|gene expression analysis|
45385600|NCT00937781|Genetic|microarray analysis|
45385601|NCT00937781|Genetic|polymerase chain reaction|
45385602|NCT00937781|Other|immunohistochemistry staining method|
45385603|NCT00937781|Other|laboratory biomarker analysis|
45385604|NCT00939419|Other|Health workers TB care group|Patients received daily tuberculosis care in public health facilities by trained health worker during the first 8 weeks followed by self-treatment for the remaining 6 months. Patients were expected to visit public health facility every month for follow up. Supervisory support was given to TB focal persons by the respective district TB coordinators on a monthly basis. Anti-TB drugs were delivered to health institutions on a quarterly basis by district TB coordinators during supervision
45385605|NCT00939419|Other|Community health workers TB care group|Patients had daily TB care including observation of treatment by the CHWs in their villages for the second month. Thereafter, treatment was self-administered with a monthly follow up visit to a CHW home for the remaining 6 months. Technical support and anti-TB drugs were given to CHWs by the respective public health facility TB health worker every fortnight.
45385606|NCT00939419|Other|Self-administered treatment group|Patients took their medication at home for seven months after one month of daily care in public health facilities by TB health workers. They were taught by the TB health worker to collect their anti-TB drugs fortnightly and report missed daily doses. Follow up assessment and continued support was made by TB health worker on a monthly basis in their nearby health facility.
45385607|NCT04013243|Drug|Magnesium Sulfate|magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion
45385608|NCT04013243|Drug|Placebo|Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
45385609|NCT00940277|Behavioral|Group Counseling|Group counseling
45500174|NCT03622008|Drug|FEP-TAZ 4 g|FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days
45500175|NCT03622008|Other|Placebo|Placebo IV
45500176|NCT04063202|Other|Observation|The anonymous structured questionnaire will be self-administered by the participating students in the absence of their teachers in class-room settings.
45500177|NCT01378845|Drug|Tracleer|14 days 62,5 mg Bosentan p.o 140 days 125 mg Bosentan p.o
45385610|NCT03160547|Other|Usual Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI >30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
45385611|NCT03160547|Other|Higher Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI >30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
45385612|NCT00938093|Behavioral|Cognitive behavioral therapy|Participants receive 10 telephone therapy sessions and an accompanying workbook focused on cognitive-behavioral techniques for managing anxiety.
45385613|NCT00938093|Behavioral|Enhanced usual care|Participants receive written information about anxiety, referrals for treatment, and an optional letter to their primary care physician.
45385614|NCT00938171|Procedure|Local anesthesia|All patients will be then given adequate sedation with propofol and local anesthetic given by dermal infiltration in incision site and regional breast and axillary areas. The local anesthetic of choice will be 2 % lidocaine (Xylocaine) and 0.5% Bupivacaine (Marcaine) mixed with 7 % sodium bicarbonate and epinephrine (Bosmine)
45695487|NCT03404908|Drug|paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
45385615|NCT00938171|Procedure|General anesthesia|The method of general anesthesia for the GA group will be induced with fentanyl (1-2 μg/kg) and propofol (2.5 mg/kg). After placement of a laryngeal mask or endotracheal tube airway, anesthesia will be maintained with sevoflurane (end-tidal concentrations 1%-3%) in a 50% oxygen/nitrous oxide mixture.
45385616|NCT00938249|Dietary Supplement|Monascus Garlic Fermented Extract|
45385617|NCT00938249|Dietary Supplement|Placebo|
45385618|NCT05280275|Drug|Belantamab Mafodotin-Blmf|"Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder.~Blmf will be delivered as IV solution over at least 30 minutes."
45500178|NCT01378845|Drug|Prostavasin|Prostavasin 60 µg i.v, 5 days per week for 2 weeks
45385619|NCT05280275|Drug|Daratumumab|Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
45385620|NCT05280275|Drug|Lenalidomide|Lenalidomide will be administered per os.
45385621|NCT05280275|Drug|Dexamethasone|Dexamethasone will be administered intravenously or per os.
45385622|NCT00939497|Drug|Risperidone|
45385623|NCT00940355|Behavioral|Intervention pulmonary nurse|The intervention is conducted by a pulmonary nurse, directed at increasing awareness of problems in health status, and increasing motivation to engage in additional treatment, and improving health status.
45385624|NCT00940433|Procedure|open properitoneal hernia repair|suprapubic retro-inguinal approach
45385625|NCT00940433|Procedure|Lechtestien hernia repair|onlay mesh repair
45385626|NCT00940433|Procedure|Laparoscopic transperitoneal approach|intraperitoneal insufflation followed by re-exiting to the hernia site
45385627|NCT00940433|Procedure|Laparoscopic totally extraperitoneal approach|avoiding the peritoneum altogether
45385628|NCT00502242|Drug|ramipril|Capsule - initial treatment is 5 mg (active)- oral - once per day
45695488|NCT03404908|Drug|metamizole|Intravenous metamizole will be used (1.0 gram), up to 4 grams per day
45695489|NCT03404908|Drug|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
45695490|NCT03404908|Drug|Morphine|Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
45695491|NCT01702298|Drug|Sitagliptin 100 mg/simvastatin 40 mg FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks
45695492|NCT01702298|Drug|Metformin|Participants will continue pre-study dose of metformin tablet(s) >=1000 per day
45695493|NCT03404752|Drug|Peg-Filgrastim|
45385629|NCT00502242|Drug|ramipril|Capsule - initial treatment is 5 mg (placebo) - oral - once per day
45385630|NCT00938405|Drug|Colesevelam HCl|3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
45385631|NCT00938405|Drug|Placebo|Placebo: 3.75 gms/day in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
45385632|NCT00938483|Other|Nutramigen Lipil (Infant formula)|
45385633|NCT00938561|Drug|Inulin|
45385634|NCT03045653|Drug|Tamoxifen Oral Product|Tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy
45385635|NCT02991365|Other|nasal insulin|
45385636|NCT02991365|Other|placebo spray|
45385637|NCT03972137|Behavioral|Cognitive-Behavioral Smoking Cessation|Participants were provided with six individualized smoking cessation counseling sessions designed to help them prepare to quit, set a quit date, behaviorally manage early abstinence, and to resume cessation upon lapse.
45385638|NCT03972137|Behavioral|Heart Rate Variability Biofeedback (HRVB)|All participants were provided with individualized training in resonance breathing using biofeedback to help improve self-regulation.
45385639|NCT03972137|Drug|Transdermal Nicotine patch|All participants were offered up to eight weeks of transdermal nicotine patch, beginning on their quit date.
45385640|NCT00940511|Behavioral|Coordinated care|
45385641|NCT00490698|Drug|Zoledronate|4 mg IV Once Every 4 Weeks
45385642|NCT00490698|Drug|Atorvastatin|20 mg PO Daily
45385643|NCT02884271|Procedure|cardiopulmonary resuscitation|start cardiopulmonary resuscitation
45385644|NCT04492254|Drug|Enoxaparin|The treatment provided will be enoxaparin sodium 40mg/0.4 mL. All doses will be provided in pre-filled, single-dose syringes for subcutaneous injection.
45385645|NCT01013766|Drug|GSK1362885|100mg in the AM, 100mg in the PM, 50mg BID
46056252|NCT02610322|Behavioral|Whole soy replacement diet|Participants who are allocated to Whole soy group will receive a 30~40 min counseling session by an experienced nutritionist on: 1) conventional lifestyle education on metabolic syndrome (MetS); 2) The benefits of whole soy diet; 2) Practical techniques to incorporate of 4 servings of whole soy foods (equivalent to 25g soy protein) into their daily diet and reduce high saturated fat and cholesterol rich animal foods based on their prior 7-day dietary record during run-in; (3) Participants will also receive a pamphlet and an 30 min DVD which will provide practical cooking recipes with both illustration and demonstration on how to prepare whole soy foods/diet in an easy and fun way to replace fatty animal meat and dairy products
45385646|NCT01013766|Drug|GSK1362885|100mg in the PM, 100mg in the AM, 50mg BID
45385647|NCT01016340|Drug|MCS|MCS-5 Softgel 5 mg
45385648|NCT03855228|Drug|Mometasone furoate nasal spray (MFNS)|Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days.
45385649|NCT03855228|Drug|Loratadine|Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.
45385650|NCT03855228|Drug|Placebo nasal spray|Daily dose of placebo administered as a nasal spray for 15 days.
45385651|NCT03855228|Drug|Placebo tablet|Daily dose of placebo administered as an oral tablet for 15 days.
45385652|NCT04013165|Behavioral|Active control|Control group received usual care of the Community Mental Health Service, consisted of case management for high-risk older adults and referral to psychiatric services.
45385653|NCT04013165|Behavioral|Village-based intervention|"Individual-based case management was conducted both by healthy community dwellers (local committee) and Community Mental Health Service (CMHS) team based on risk-stratification for depression in older adults. Local committee-guided care was performed after matching a healthy dweller with 4-5 older neighbors included in risk groups. They visited the matched older individuals as often as possible at least once a week using a mood sticker. The CMHS team also conducted a separate case management for older adults with risk-stratified protocols; the higher the risk of suicide, the more intensive was the management, which could include frequent face-to-face visits. High-risk individuals were also referred to the psychiatric service, if deemed necessary.~Group-based program was comprised of weekly eight sessions, which were mainly consisted of programs enhancing interpersonal network and group cohesion, and were open to all community-dwelling older adults."
45385654|NCT04013477|Drug|DA-5207|DA-5207 Transdermal Delivery System
45385655|NCT04013477|Drug|Donepezil Hydrochloride|donepezil HCl 10mg QD
45500179|NCT03606122|Drug|PD P 506 A|PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm²
45385656|NCT00511238|Drug|carfilzomib|Subjects will receive carfilzomib 20 mg/m2 as an intravenous bolus over 2 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. A maximum of 12 cycles will be administered.
45385657|NCT00511238|Drug|carfilzomib|Subjects will receive carfilzomib intravenously over up to 10 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. In cycle 1, the dose is 20 mg/m2. If all doses are administered and well-tolerated over Cycle 1, beginning with Cycle 2 the dose will escalate to 27 mg/m2 cycle. A maximum of 12 cycles will be administered.
45385658|NCT00940667|Drug|Amlodipine plus Losartan|amlodipine/losartan 5/50mg q.d.
45385659|NCT00940667|Drug|Amlodipine|amlodipine 5mg q.d.
45385660|NCT04013087|Dietary Supplement|Oral feeding of Feihe Stage 1 infant formula|Oral feeding of Feihe Stage 1 infant formula for 16 weeks
45385661|NCT04013087|Dietary Supplement|Oral feeding of control Stage 1 formula|Oral feeding of control Stage 1 formula for 16 weeks (A commercially available product with comparable composition but does not contain sn-2 palmitate enriched vegetable oil as an ingredient (regular vegetable oil is used))
45385662|NCT04013087|Dietary Supplement|Breast feeding|Breast feeding of human milk for 16 weeks
45385663|NCT01019772|Biological|LBVH0101 (Hib vaccine)|
45385664|NCT01019772|Biological|Hiberix™ Vaccine|
45385665|NCT00940745|Device|Stereotactic Aspiration and Thrombolysis|"Device: YL-1 type of intracranial hematoma puncture needle YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward."
45385666|NCT00940745|Drug|conservative treatment|dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
45385667|NCT01014000|Device|Empirical group|Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
46056253|NCT02610322|Behavioral|usual diet|Participants who are assigned to the usual diet group (control group) will receive a 5~10 min conventional lifestyle education on MetS by a research staff in which the general recommendation for macronutrient composition of the control diet will be 50-60% of energy as carbohydrate, 15-20% of energy as protein, and <30% of energy as total fat.
46056254|NCT05756452|Diagnostic Test|Anamnesis and clinical evaluation|All partecipants will undergo a global echocardiographic evaluation, a 24-hour ECG Holter recording to assess HRV and blood samples collection for neurotransmitter measurements, platelet activation and reactivity evaluation and inflammatory profile assessment by proteomics analysis, inflammasome activity evaluation, NLRP3, pro-IL-18 and pro-IL-1β expression level by qPCR and epigenetic analysis.
45385668|NCT01014000|Device|Echocardiography-guided approach|Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
45385669|NCT00513500|Drug|Coartem and amoxicillin|Perform RDT and give Coartem for malaria and give amoxicillin for fast breathing
45385670|NCT00513500|Drug|Coartem|Give Coartem without RDT and refer fast breathing
45385671|NCT04607408|Biological|CH505TF gp120|HIV-1 CH505 transmitted/founder virus Env gp120 immunogen
45385672|NCT04607408|Biological|GLA-SE adjuvant|An oil-in-water stable emulsion (SE) containing the immunological adjuvant Glucopyranosyl Lipid A (GLA)
45385673|NCT04607408|Biological|Placebo|Sodium Chloride for Injection, 0.9% USP
45385674|NCT03969719|Drug|Placebo|Placebo
45385675|NCT03969719|Drug|PF-06835919|150 mg once daily
45385676|NCT03969719|Drug|PF-06835919|300 mg once daily
45695494|NCT04377022|Other|Combined Therapy (Aerobic Exercise in addition to conventional therapy)|"There are two intervention arm in the study~Combined therapy~Conventional Therapy"
46056255|NCT02738385|Behavioral|High Intensity Interval Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
45385677|NCT03998072|Other|Five session cognitive analytic therapy (CAT) consultancy|Five session consultancy with patients and care coordinators using cognitive analytic therapy
45385678|NCT00511004|Drug|Albendazole|Comparing 400 mg to 800 mg dose
45385679|NCT00511004|Drug|Diethylcarbamazine|Providing diethylcarbamazine more frequently in combination with albendazole
45385680|NCT02550197|Biological|Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016|0.5 mL, Intramuscular
45385681|NCT02550197|Biological|Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation|0.5 mL, Intramuscular
45385682|NCT02959502|Other|Receive tDCS+CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.
45695495|NCT03405532|Diagnostic Test|DM-ECC|Diabetes mellitus CPB
45695496|NCT03401710|Drug|Erythropoietin|Erythropoietin 4000 UI will be administered every other day subcutaneously
45695497|NCT02241928|Biological|Stem Cell|Intrathecal Autologous bone marrow mononuclear cell transplantation
45695498|NCT02242006|Other|serial serum sampling for quantification of drug concentration|
45695499|NCT03409978|Device|in-Motion app|mobile phone application for recording fidgety movements at home
45695500|NCT02242084|Drug|Intravenuse Alteplase|
45695501|NCT02993523|Drug|Azacitidine|Solution for subcutaneous or intravenous administration.
45695502|NCT02993523|Drug|Venetoclax|Tablet
45695503|NCT02993523|Drug|Placebo|Matching placebo tablet
45426120|NCT00204048|Behavioral|Observation (behavior)|Inpatients admitted in GenMed at the University of Chicago will be consented to participate in an inpatient interview that consists of questions related to quality of care and satisfaction. The patient will also be interviewed over the phone 30 days after discharge and will be asked questions related to current health and their satisfaction during their stay at University of Chicago.
45426121|NCT00165256|Other|Observation|Wide excision of DCIS and a minimum of 1cm histologically negative margin of breast tissue
45426122|NCT00138931|Procedure|Blood draw (genetic testing)|Blood draw (genetic testing)
45500180|NCT03606044|Device|3D-models|"The study radiologist will generate a patient-specific virtual 3D model of the participant's body from their pre-operational medical scans (CT, and MRI if available) using regulated commercial medical image analysis software, specifically Osirix MD 9.0 (Pixmeo, Geneva, Switzerland).(Rosset et al. 2004)~The CRFw checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon uses all available medical scan data, and the virtual 3D model as an adjunct, to assess the patient anatomy and plan the operation accordingly"
45500181|NCT05016219|Device|Circadian-Effective Light|Narrowband blue light
45500182|NCT05016219|Device|Rhythmic Light|40 hertz (Hz) flicker
45500183|NCT05016219|Device|Placebo Light|Narrowband red light
45500184|NCT05016219|Device|Placebo Rhythmic Light|Random flicker for placebo rhythmic effect
45500185|NCT03605888|Behavioral|Koa Family|"Koa Family is a 6-month program consisting of a whole-person lifestyle program (WPLP) combined with text messaging and social media support and a neighborhood tree planting campaign. The WPLP will bring groups of 8 to 10 mothers living in the same community together for 22 weekly 90-minute support sessions. Each session will cover a topic on whole-person living, including healthy eating, physical activity, stress reduction, coping, and well-being. Participants will receive brief text messages on their cell phones to encourage healthy lifestyle choices. Participants also will be invited to join a secret Facebook group where they can support one another in healthy lifestyle change. Finally, participants will have an opportunity to take part in a neighborhood tree planting campaign."
45500186|NCT03076515|Device|Nerivio Migra neurostimulation|transcutaneous electrical stimulation
45500187|NCT03076515|Device|Sham Nerivio Migra|electrical stimulation- shame mode
45500188|NCT03605810|Other|No Intervention|This study is the development of algorithms/models to predict eGFR values and/or classes for patients at certain time point based on entries in claims database (demographic characteristics, clinical diagnoses, procedures and drug treatments) for a general population and a variety of use-cases (AF, CAD, T2DM patients sub-populations).
45500189|NCT03605732|Behavioral|self help sleep hygiene intervention application|This intervention lasts for six weeks. The intervention is App-based and mainly consists of the most potent CBT techniques as well Health action process approach. Weekly feedback is provided by health psychologists.
45695504|NCT01701362|Drug|pregabalin|capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization
45695505|NCT01701362|Drug|placebo|capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization
45695506|NCT01673295|Drug|RTX infusions|RTX + Standard of Care
45695507|NCT01673295|Other|Standard of Care|Standard of Care only
45426123|NCT00138801|Drug|Ceftriaxone|
45426124|NCT00138801|Drug|Doxycycline|
45695508|NCT00919126|Drug|Xenon|Maintenance of anaesthesia obtained with Xenon 50% and propofol infusion adjusted to depth of anaesthesia.
45695509|NCT00919126|Drug|Xenon|Maintenance of anaesthesia obtained with Xenon 70% and propofol infusion adjusted to depth of anaesthesia.
45695510|NCT00919126|Drug|Medical Air in Oxygen|Maintenance of anaesthesia obtained with propofol infusion adjusted to depth of anaesthesia.
45695511|NCT03404440|Other|L.Reuteri|
46056256|NCT02738385|Behavioral|Moderate Intensity Interval Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
46056257|NCT04853290|Device|Ultrasound-guided peripheral venipuncture|Ultrasound-guided peripheral venipuncture performed by a proficient vascular access registered nurse. The procedure will be performed according to the standard operational protocol for ultrasound guided peripheral venipuncture instituted at the hospital where the study will be conducted. Site Rite 8 or Site Rite 5 ultrasound machines (Bard Access Systems, Inc., USA) will be used on the procedures.
46056258|NCT04853290|Device|Conventional peripheral venipuncture|Conventional peripheral venipuncture performed by the registered nurse at the clinical inpatient unit. The procedure will be performed according to the standard operational protocol for peripheral venipuncture protocol instituted in the hospital where the study will be conducted
46056259|NCT02736435|Device|Magnetic Resonance Guided High Intensity Focused Ultrasound|Direct treatment of uterine fibroids with MR-HIFU
46056260|NCT02736435|Drug|leuprolide acetate for depot suspension|Treatment of uterine fibroids with leuprolide acetate prior to MR-HIFU
46056261|NCT02738541|Drug|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
46056262|NCT02738541|Drug|PLACEBO DENTRIFICE WITHOUT PROPHOSPHATE|PLACEBO DENTRIFICE WITHOUT PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
46056263|NCT02610244|Other|Modified Cogmed Training|Comparison of outcome measures between treatment-as-usual group and Modified Cogmed Training group after 10 weeks and 3 months follow up.
45500190|NCT03605732|Other|patients education|Participants in the PE group will receive written weekly information on accurate and relevant information regarding insomnia symptoms, physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors
45695512|NCT04375540|Procedure|Upper first premolars extractions|Fixed orthodontic treatment with upper first premolars extraction and space closure using 0.019X0.025 SS AW and elastic chain.
45695513|NCT04375540|Procedure|Upper second premolars extraction|Fixed orthodontic treatment with upper second premolars extraction and space closure using 0.019X0.025 SS AW and elastic chain.
45695514|NCT03833908|Device|MAF-1217|Patients will be enrolled at screening (2 weeks before surgery), then will be randomized with a 1:1 ratio to 2 groups of 23 patients each: A. patients receiving MAF-1217 B. patients receiving just standard antibiotic therapy
45695515|NCT04375618|Drug|RhEGF|The EGF impregnated membrane will be placed upon the recession site and will be stabilized by suturing it to the lingual papillae using 4-0 absorbable sutures. The flap will be coronally advanced as far as possible to cover the membrane and will be sutured to the buccal interdental papillae with 4-0 absorbable sutures (Trulenetm, Healthium Medtech Pvt Ltd, Bangalore, India). Standard recall and maintenance regimen will be followed and subjects will be encouraged to report to the department on a monthly basis.
45695516|NCT04375618|Drug|Plain Collagen|A collagen membrane without FGF-2 will be used.
45695517|NCT01710800|Drug|Esomeprazole|
45695518|NCT01710800|Drug|placebo|
45695519|NCT03404284|Behavioral|Family planning and infant immunization service integration|The approach involved integration of services through health surveillance assistant (HSA) outreach as well as through the health facility platform. The HSAs provided door to door FP services in their designated communities as well as provided integrated FP and Immunisation services at village clinics and outreach sessions. At outreach sessions, mothers were offered both routine infant immunization and family planning services (pills, condoms, injectables plus referrals for other methods). At health facilities, mothers who sought routine infant immunization services were offered same-day family planning services and those who seek family planning services are also screened for infant immunization schedule completion / need for infant immunization services. HSAs and health facility providers were trained on FP-immunization service integration and were monitored through regular supportive supervision visits.
45695520|NCT03833986|Other|Stress management program|Nurses stress management program will be an experiential teaching program consisting of six sessions of stress management strategies for public health centers nurses. the workshop will be in a warm quite room with efficient light, temperature, and ventilation. The intervention group will receive handouts copies of the stress management program for each session at the end of the study.
45695521|NCT03404128|Other|Questionnaires|Questionnaire for patient: satisfaction regarding rechargeable DBS battery Questionnaire for neurologist: seizure frequency, satisfaction regarding rechargeable DBS battery
45695522|NCT01710020|Drug|CP-690,550|CP-690,550 10 mg oral powder for constitution
45695523|NCT03833830|Diagnostic Test|Optical Coherence Tomography angiography (OCTA)|There will be an OCTA measurement (observational study) for both groups. Group allocation will be made due to previous anti-VEGF treatments (longterm treatment group >20 injections and shortterm treatment group < 5 injections).
45695524|NCT02982850|Drug|Dabigatran|
45385683|NCT02959502|Other|Facilitate tDCS + CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will be trained to deliver tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
45695525|NCT02982850|Drug|Acetylsalicylic acid|
45695526|NCT02982850|Drug|Warfarin|
45385684|NCT01009424|Drug|R7103|escalating inhaled dose
45695527|NCT01700348|Device|Airflosser|Use of Philips Airflosser
45695528|NCT01700348|Device|Manual Floss|Active Comparator
45695529|NCT02242162|Procedure|phrenic nerves magnetic stimulations|
45695530|NCT04413890|Drug|Dinoprostone vaginal gel|Prostaglandin gel 0.5, 1 or 2 mg
45695531|NCT03404050|Other|Music and dance movement therapy|Theoretically, the intervention adopts a humanistic approach of person centred care highlighting the importance of maintaining and enhancing personhood for older people with dementia.
45695532|NCT02242240|Drug|Formoterol twice daily|
45385685|NCT00938795|Other|Uncertainty Management Intervention|Six 30-minute telephone calls with a nurse to discuss emotional and physical aspects of liver disease and awaiting liver transplant
45385686|NCT00938795|Other|Comparison Conditions for Liver Transplant|Six 30-minute telephone calls that provide structured education about liver disease.
45385687|NCT00939887|Drug|PF-04455242|Single dose of up to 30 mg PF-04455242, delivered in capsule.
45385688|NCT00938873|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|Mindfulness based cognitive therapy (MBCT) is a group psycho-educational treatment designed to reduce the risk of recurrent depression by integrating mindfulness based meditation practices with cognitive therapy techniques. MBCT comprises eight weekly two-hour group sessions with an additional one hour daily 6 days a week for meditative homework practice.
45385689|NCT00939965|Drug|isotretinoin|
45385690|NCT00939965|Genetic|DNA analysis|
45385691|NCT00939965|Genetic|polymerase chain reaction|
45500191|NCT04951635|Drug|Almonertinib|"The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met. The 2:1 ratio (Almonertinib to placebo)."
45500192|NCT04951635|Drug|Placebo Almonertinib|"The initial dose of Placebo Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met. The 2:1 ratio (Almonertinib to placebo)."
45500193|NCT03984968|Biological|CD19 CAR-T cells infusion combined with feeding T cells (FTCs)|"Phase1 study Optimal biological doses of feeding T cells identification CAR-T cells infusion combined with FTCs will be given in Philadelphia chromosome positive B-ALL patients with remission. FTCs will be administered at the dose of 5×106/kg, 3.25×106/kg or 2×106/kg two hours after ssCART-19 infusion on day 1 and once again administered at the same dose on day 8.~Phase 2 Expansion Study CAR-T cells infusion combined with FTCs at optimal biological dosage determined in Phase 1 study will be given in expanded Philadelphia chromosome positive B-ALL patients with remission. Bayesian optimal design is applied in this Phase 2 study to monitor the toxicity and efficacy at the specified interim analyses. The total expected sample sizes are 40."
45500194|NCT04884399|Drug|CMAB818|vascular endothelial growth factor (VEGF) inhibitor
45500195|NCT04884399|Drug|Lucentis®|vascular endothelial growth factor (VEGF) inhibitor
45500196|NCT03605576|Procedure|Fu's subcutaneous needling|"Fu's Subcutaneous Needle (FSN), is an innovation for the treatment of myofascial pain and trigger points. The needle is a non-injection needle, and the fact that both needles are manipulated and act on soft connective tissue.~FSN abstains from the muscle and deep fascia layers and is confined to only the subcutaneous layer where collagen fibers are most abundant. As the subcutaneous layer is poorly innervated, pain is less than other needling therapies.~FSN is also currently being used successfully to treat non-musculoskeletal conditions."
45695533|NCT02242240|Drug|Formoterol once daily|
45695534|NCT02242240|Drug|Tiotropium once daily|
45695535|NCT02242240|Drug|Placebo|
45385692|NCT00939965|Other|laboratory biomarker analysis|
45385693|NCT00939965|Other|pharmacological study|
45385694|NCT04012541|Procedure|active dental procedure|scaling and root planing
45385695|NCT04012541|Drug|post-myocardial infarction management|aspirin, clopidogrel, ticagrelor
45385696|NCT04012541|Radiation|basic periodontal examinations|panorama radiograph : full mouth periapical radiograph
45385697|NCT02877134|Drug|JNJ-64304500|Participants will receive JNJ-64304500 Subcutaneously.
45385698|NCT02877134|Drug|Placebo|Participants will receive placebo Subcutaneously.
45385699|NCT02877134|Drug|Ustekinumab|Participants will receive ustekinumab as per the dosing regimen.
45385700|NCT02726906|Behavioral|Moderate-aerobic walking|
45385701|NCT02726906|Radiation|Positron Emission Tomography (PET) scan|Radioligand that binds to proteins using a PET/CT scanner.
45385702|NCT02726906|Behavioral|Healthy living education|
45385703|NCT02726906|Device|Physical activity monitor|Wrist device that will track daily physical activity
45385704|NCT00563381|Drug|Tiotropium bromide|18 mcg/daily
45385705|NCT00563381|Drug|Salmeterol|100 mcg/daily
45385706|NCT00563381|Drug|Placebo Salmeterol|Placebo identical to Salmeterol device
45385707|NCT00563381|Drug|Placebo Tiotropium|Placebo identical to Tiotropium device
45385708|NCT00512798|Drug|PS-341 (VELCADE)|"Dose Levels PS-341 (day 1)~Level -1 0.7 mg/m2~Level 1 1.0 mg/m2~Level 2 1.0 mg/m2~Level 3 1.3 mg/m2~Level 4 1.5 mg/m2"
45385709|NCT00512798|Drug|temozolomide|"Temozolomide (day 8)~Level - 1 50 mg/m2~Level 1 50 mg/m2~Level 2 75/mg/m2~Level 3 75 mg/m2~Level 4 75 mg/m2"
45385710|NCT00512798|Other|immunoenzyme technique|Not noted
45385711|NCT00512798|Drug|PS-341 (VELCADE)|1.3 mg/m2 by IV on days 1, 4, 8, and 11 of every 21 days
45385712|NCT00512798|Drug|Temozolomide|75 mg/m2 by mouth, daily, during weeks 2-8 (42 days) of every 9-week course.
45385713|NCT03998930|Other|Clinical evaluation of consciousness by the Coma Recovery Scale Revised (CRS-R)|Paraclinical evaluation of consciousness by the brain-machine interface by measuring evoked potentials P300 auditory and vibrotactile and recording the EEG signal during a motor imaging task
45385714|NCT03743207|Other|Room temperature|These infants were fed with room temperature (22-24 °C) so that hypothesizing that they will have more feeding tolerance and therefore more co-existing morbidities.
45385715|NCT03743207|Other|Warmer temperature|Fifteen NICU mothers volunteered and expressed their milk for rapid measurement of freshly expressed breast milk. The mean (± SD) temperature of freshly expressed breast milk was found to be 33±1.5 °C in these preliminary measurements. Confirming this finding, the investigators decided to feed these infants with milk at 32 - 34 °C to examine the effects of feeding temperature and the possible comorbidities with a hypothesis that warmer feeding at the temperature of freshly expressed breast milk may be better physiologically.
45385716|NCT00940121|Drug|mirabegron|oral tablet
45385717|NCT00940121|Drug|mirabegron|IV solution
45385718|NCT00565721|Drug|Fluciclatide Injection - (AH111585 (F18))|18F labelled Cyclic RGD peptide PET agent for injection.
45500197|NCT03605576|Procedure|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (<10 Hz) with an intensity that produces motor contraction."
45500198|NCT01378767|Dietary Supplement|Krill oil supplementation|During a 21-day Daniel Fast, group one supplemented with krill oil capsules (two grams per day) while group two supplemented with a placebo (coconut oil capsules at two grams per day).
45695536|NCT03403972|Drug|Vancomycin 250Mg Capsule|Investigators will compare simavastatin pharmacokinetics before and after the vancomycin PO multiple administration.
45695537|NCT02242318|Drug|Telmisartan|
45695538|NCT02242318|Drug|Valsartan|
45385719|NCT00940979|Procedure|Application of Integuseal sealant|Microbial sealant (integuseal) applied with a sponge applicator
45695539|NCT02242318|Drug|Placebo|
45695540|NCT01700192|Biological|MK-8237 tablets|MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d.
45695541|NCT01700192|Biological|Placebo tablets|Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
45695542|NCT01700192|Drug|Rescue Medication: Self-Injectable Epinephrine|Self-injectable epinephrine (preferred dose of 0.30 mg) administered intramuscularly as needed for rescue medication.
45695543|NCT01700192|Drug|Rescue Medication: Loratadine tablets|Loratadine tablet 10 mg administered orally as needed for rescue medication.
45695544|NCT01700192|Drug|Rescue Medication: Olopatadine ophthalmic drops|Olopatadine hydrochloride ophthalmic drops 0.1% administered as needed for rescue medication.
45385720|NCT00938951|Other|Systane® Ultra|Polyethylene Glycol 400 0.4% / Propylene Glycol 0.3%
45385721|NCT04012619|Drug|Anlotinib Hydrochloride|Patients receive pemetrexed with cisplatin/carboplatin once every 3 weeks, and anlotinib (dose escalation) once daily on days 1-14.
45385722|NCT00561977|Behavioral|High Fiber Diet|high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
45385723|NCT00561977|Behavioral|low saturated fat diet|low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal/day.
45385724|NCT00561977|Behavioral|Combination diet|combination low saturated fat high fiber diet, with calorie restriction as specified.
45385725|NCT00941057|Drug|BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium|Oral, single dose, 2 mg EV + 3 mg DNG + 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
45385726|NCT00941057|Drug|BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)|Oral, single dose, 2 mg EV + 3 mg DNG washout phase between treatments: at least 7 days
45385727|NCT00941057|Drug|BAY 86-7660,levomefolate calcium|Oral, single dose, 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
45385728|NCT00561821|Drug|Esmirtazapine|one tablet daily
45385729|NCT00561821|Drug|Placebo|one tablet daily
45385730|NCT00558701|Device|Microcurrent stimulator|Microcurrent stimulation from 15-50 microamps
45385731|NCT00558701|Device|Silverlon Wound Contact Dressing|Silver coated nylon dressing FDA approved for use on donor sites in burn patients
45385732|NCT03684044|Drug|Baloxavir Marboxil|Baloxavir marboxil will be administered as a weight-based dose on Days 1 and 4. A third dose will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.
45385733|NCT03684044|Other|Placebo|Participants will receive matching placebo on Days 1, 4 and 7.
45385734|NCT01009502|Drug|sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
45385735|NCT00510692|Drug|Eicosapentanoic Acid (EPA)|2 x 500mg EPA capsules twice daily for 6 months
45500199|NCT03607604|Genetic|Next generation sequencing (NGS)|Patients will be tested for known MODY genes with specific focus on HNF1A, GCK and HNF4A genes. Furthermore, gene panel testing may be performed for any known diabetes genes.If the results are negative, WES/WGS will be performed in patients suspected of having MODY for identification of novel MODY mutations.
45500200|NCT04868721|Procedure|micro-osteoperforations|three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.
45500201|NCT03605420|Other|Family visit prior to hospital admission|Family receiving one visit prior to hospital admission for surgery
45695545|NCT01700192|Drug|Rescue Medication: Mometasone furoate nasal spray|Mometasone furoate monohydrate nasal spray 50 mcg administered intranasally as needed for rescue medication.
45695546|NCT00924118|Drug|Sodium Nitrite|Subjects assigned to sodium nitrite will receive an initial infusion of 6 nmol/min/kg for 48 hours. After the first six subjects have been enrolled (3 active drug, 3 control) and if there are no dose limiting toxicities, additional cohorts of six subjects each will be randomized to escalating doses of sodium nitrite versus control for a total of 30 subjects.
45695547|NCT03403894|Behavioral|Asking caregivers in their practice|A questionary is given to caregivers
45695548|NCT02242396|Drug|Telmisartan|
45385736|NCT00510692|Procedure|Endoscopy|Endoscopy with video and photographs at baseline and month 6.
45385737|NCT00510692|Procedure|Biopsies taken|9 biopsies taken at baseline and month 6 from the rectum of normal mucosa for analysis of apoptosis (3 biopsies), cell proliferation (3 biopsies) and mucosal fatty acid levels (3 biopsies). Two biopsies taken at baseline and month 6 from polyps for cell proliferation (1 biopsy) and apoptosis (1 biopsy).
45385738|NCT00510692|Drug|Placebo|2 x 500mg placebo capsules twice daily for 6 months
45500202|NCT03170609|Biological|Multivalent group B streptococcus vaccine|Various formulations at three dose levels
45500203|NCT03170609|Biological|Placebo|Saline Control
45695549|NCT02242396|Drug|Telmisartan hydrochlorothiazide|
45385739|NCT00335452|Drug|Clopidogrel|oral administration
45385740|NCT00335452|Drug|acetylsalicyclic acid (ASA)|oral administration
45385741|NCT00522548|Drug|Enteric coated mycophenolate sodium|Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
45500204|NCT03264404|Drug|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks until progression
45500205|NCT03264404|Drug|Azacitidine|50 mg/m2 subcutaneous daily for 5 days every 28 days
45500206|NCT03605186|Other|Chamomile oral cryotherapy|The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs). Patients are asked to swish the chamomile ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
45385742|NCT00522548|Drug|Mycophenolate mofetil|Patients in this group will receive CellCept (mycophenolate mofetil) or its generic equivalent formulation manufactured by Sandoz, in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
45500207|NCT03605186|Other|Oral cryotherapy|The plain icecubes will be prepared in the clinic with 400 mL of distilled water. Patients are asked to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
45695550|NCT03403816|Behavioral|Before School Physical Activity Program|BOKS is a before school physical activity program offered at no cost to participating families that focuses on engaging elementary and middle school students in physical activity, skill development and brief nutrition education sessions that prepare them for a day of learning. The BOKS curriculum includes 12 weeks of instruction and 40 minutes of structured kid-friendly activities that include warm-ups, skill of the week, running, relay and obstacle course activities and nutritional tips. The BOKS team provides training for BOKS leaders free of charge each month. BOKS is currently being used in more than 1,800 schools in the US and Canada.
45695551|NCT03403738|Behavioral|Bounce Back Now|web/smartphone-based intervention for disaster victims
45385743|NCT00522392|Drug|bortezomib|Given IV
45385744|NCT00522392|Drug|lenalidomide|Given PO
45385745|NCT00522392|Drug|dexamethasone|Given PO
45385746|NCT00335140|Biological|Rituximab|Rituximab is administered intravenously. The initial rate is 50 mg/hr for the first hour. If no toxicity is seen, the rate may be escalated gradually in 50 mg/hour increments at 30-minute intervals to a maximum of 300 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased gradually in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr.
45385747|NCT00335140|Drug|Cytarabine|3 g/m2/day in 500 cc D5W IV over 2 hrs. x 2 doses 24hrs. apart, Weeks 11, 14
45385748|NCT00335140|Drug|Dexamethasone|16mg (week 1) PO daily Weeks 1, 2, 3, 4, 5, 6 Taper by 4 mg/wk, weeks 2, 3, by 2 mg/wk week 4, 5, 6
45385749|NCT00335140|Drug|Leucovorin|25 mg PO/IV every 6 hrs. x 12 doses, Weeks 1, 3, 5, 7, 9 For patients with meningeal involvement additionally 10 mg PO every 12 hrs. x 8 doses, Weeks 2, 4, 6, 8, 10
45426125|NCT00113659|Dietary Supplement|Probiotic|Daily dose of ten to the tenth colony-forming units of Lactobacillus GG and 225 mg of inulin for the first 6 months of life.
45695552|NCT03403738|Behavioral|enhanced usual care|enhanced usual care with list of resources
45695553|NCT04374994|Drug|Avanafil 50 MG|Oral phosphodiesterase type 5 inhibitors
45695554|NCT04374994|Drug|Placebo oral tablet|lactose and maize starch, Egypt
45695555|NCT02242474|Drug|Anti-TNF suspended perioperatively|
45695556|NCT02242474|Drug|Anti-TNFα continued perioperatively|
45385750|NCT00335140|Drug|Methotrexate|"3.5 g/m2In 500 cc D5W + 25 mEq NaHCO3 IV over 2 hours, Weeks 1, 3, 5, 7, 9~For patients with meningeal involvement additionally:~12 mg Intrathecally, in preservative-free sterile .9NS Weeks 2, 4, 6, 8, 10 Via Ommaya or lumbar puncture"
45385751|NCT00335140|Drug|Procarbazine|100 mg/m2 PO daily x 7 days Weeks 1, 5, 9
45385752|NCT00335140|Drug|Vincristine|1.4 mg/m2 IV push, Weeks 1, 3, 5, 7, 9 2m2 (2.8 mg) dose cap
45385753|NCT04346264|Diagnostic Test|NO intervention planned due to the observational study design only a diagnostic testing|Only a diagnostic test (serum blood and antibody measurement) is planned
45385754|NCT01061320|Drug|alpha tocopherol|The patients were assigned to receive oral alpha tocopherol (525 IU) every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
45385755|NCT01061320|Drug|placebo|The patients were assigned to receive oral placebo every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
45385756|NCT01061398|Procedure|Cardiac CT Angiography|Patients randomized to CT Arm will undergo 64-slice cardiac CT angiography (single scan) in addition to the stress imaging test ordered by their physician
45385757|NCT01061398|Procedure|Stress Imaging Test (Stress Myocardial Perfusion Study or Stress Echocardiogram)|Stress imaging test as ordered by the subjects provider without option for cardiac CT angiography (no CT arm)
45385758|NCT01565408|Drug|NNC0114-0006|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks. The trial comprises dose escalation up to four dose levels. Progression to next dose will be based on safety evaluation.
45385759|NCT01565408|Drug|placebo|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks.
45385760|NCT03985306|Procedure|Inforatio technique|"We define the inforatio technique as punch biopsies taken in the periphery of the wound bed. The punch biopsies will have a diameter of two mms. The depth of the biopsies is primarily based on clinical assessment on distance to bone by assessment with a sterile wound probe and with attention to location and anatomy. The maximum depth will be 3.5 millimeters. The biopsies will be taken from one to two mms from the wound edges and with a distance of five mms between the biopsies.~Inforatio technique is applied after standard care and wound assessment."
45385761|NCT01012544|Drug|Clopidogrel|both arms of the study (patients with a history of stent thrombosis as well as patients who did not suffer from a stent thrombosis) will be given a 600 mg loading dose of clopidogrel
45385762|NCT01012700|Drug|Hiltonol (poly ICLC)|2 mg administered subcutaneously or intranasally to healthy volunteers
45385763|NCT01012778|Behavioral|Climb Up ADHD and Dyslexia Program|Using a peer mediated multimodal intervention program for ADHD and Dyslexia use Yoga, Meditation, Play therapy administered by (trained) high school volunteers
45385764|NCT01565486|Device|Ultrasonic coagulation device (Harmonic ACE® scalpel)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
45385765|NCT01565486|Device|bipolar energy sealing system (LigaSure Precise)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
45385766|NCT01565720|Drug|Isavuconazole|oral
45385767|NCT01565720|Drug|Placebo|oral
45385768|NCT01565720|Drug|Moxifloxacin|oral
45385769|NCT00309244|Drug|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
45385770|NCT00309244|Drug|70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)|BPR 70/30, which is a premix of intermediate acting and rapid acting insulin given sc
45385771|NCT00483756|Drug|Cyclosporine|Standard of care
45385772|NCT00483756|Drug|CP-690,550|CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12
45385773|NCT00483756|Drug|CP-690,550|CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12
45385774|NCT00309166|Biological|Cervarix vaccine|All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule.
45385775|NCT00309166|Biological|Engerix-B vaccine|All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule
45385776|NCT01063816|Drug|veliparib (ABT-888)|Dosing orally twice daily starting Cycle 2 Day 1- through 21 adjusted for subsequent cohorts using a continuous reassessment method.
45385777|NCT01063816|Drug|carboplatin|Carboplatin will be dosed on Day 1 of each cycle, intravenously.
45385778|NCT01063816|Drug|gemcitabine|Dosing on Days 1 and 8 of each Cycle, intravenously.
45500208|NCT01314755|Dietary Supplement|IMPACT|IMPACT (Nestlé Healthcare Nutrition, Minnetonka, MN, USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
45500209|NCT01314755|Dietary Supplement|An iso-caloric, iso-nitrogenous control feed|
45385779|NCT00501852|Drug|NVA237|single-dose dry-powder inhaler (SDDPI)
45385780|NCT00501852|Drug|Placebo|single-dose dry-powder inhaler (SDDPI)
45385781|NCT00501852|Drug|Tiotropium|Handihaler inhaler
45385782|NCT03981250|Behavioral|12-week home-based resistance exercise programme|Participants will perform 6 exercises (press-ups, squats, squat jumps, plank, upright row and seated row) for one minute, aiming for the maximum number of repetitions. Participants will perform one exercise per day, for 6 days a week, for 12 weeks.
45385783|NCT00482274|Drug|docetaxel|Docetaxel 75 mg/m2 intravenously (IV) over 60 minutes will be given on day 1 of each 21 day cycle.
45695557|NCT03403660|Other|non White coat|Postpartum patients are randomized to either arm of the study (white coat or standard scrub suit only) by location. All the obstetric physicians associated with patient's postpartum care should use or not use white coat in every single encounter with patient.
45385784|NCT03985462|Biological|very small embryonic-like stem cell|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
45385785|NCT03983122|Procedure|Laparoscopic sleeve gastrectomy|Each procedure will be completed with laparoscopy with five trocars. A 36F bougie will used to calibrate the volume of the remnant stomach. Linear gastrectomy will begin 2 cm proximal of the pylor and will continue until the gastroesophageal junction. According to the intraoperative decision and experience of the surgeon, endoscopic clips would be used to ensure hemostasis of the stapler line.
45385786|NCT00490542|Drug|ziprasidone (Geodon)|ziprasidone, geodon. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
45385787|NCT00490542|Drug|placebo|Placebo, sugar pill arm. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
45385788|NCT03982966|Dietary Supplement|Omega 3 fatty acids (fish oil) 1000 mg/day oral|Omega 3 fatty acids (fish oil) 1000 mg/day oral
45695558|NCT03833752|Diagnostic Test|Diagnostic Flexible Cystosocpy|Endoscopic Visualization of the Lower Urinary tract using either a flexible cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
45385789|NCT01016418|Dietary Supplement|Bovine colostrum powder|Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
45385790|NCT01059604|Drug|Sumatriptan|Sumatriptan
45385791|NCT01059604|Drug|Naratriptan|Naratriptan
45695559|NCT03833752|Diagnostic Test|Diagnostic Rigid Cystoscopy|Endoscopic Visualization of the Lower Urinary tract using either a rigid cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
45695560|NCT03403582|Other|Raspberries|250g frozen whole red raspberries
45695561|NCT04374916|Device|Premaquick®|Vaginal secretions are collected prior to any vaginal or endovaginal ultrasound examination to avoid false positives, with the nylon swab provided with the test (placed in the posterior fornix of the vagina for 10 seconds).Then the samples are tested with the Premaquick test. Results are obtained in 10 minutes.
45695562|NCT04374916|Device|PARTOSURE®|An immunochromatographic test wich determines the qualitative in vitro detection of placental alpha microglobulin-1 (PAMG-1) in cervico-vaginal secretions.
45695563|NCT01709864|Drug|NVA237|NVA237 (glycopyrronium bromide) as a powder for inhalation in single-dose capsules.
45385792|NCT01059604|Drug|Sumatriptan-naproxen combination|Sumatriptan-naproxen combination
45385793|NCT02532634|Drug|ramosetron, aprepitant, dexamethasone|ramosetron 0.3 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
45385794|NCT02532634|Drug|palonosetron, aprepitant, dexamethasone|palonosetron 0.25 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
45385795|NCT03981172|Behavioral|Daily snack food intake|participants consumed 60 gram portions of either low energy density or high energy density snack foods every day for two weeks.
45385796|NCT00501540|Drug|Lithium Carbonate|Lithium 300mg PO TID escalating to a lithium level of 0.8-1.2. Lithium carbonate will be administered the first week at 300 mg flat dose three times each day. A serum lithium level will be checked after 4-5 days of treatment by drawing a blood sample prior to the morning dose of lithium. Evaluate every 8 weeks.
45385797|NCT01014156|Drug|epoprostenol|titration up to 4 ng/kg/min
45385798|NCT00322348|Drug|Goserelin acetate|3.6 mg intramuscular depot injection given every 4 weeks
45385799|NCT00322348|Drug|Goserelin acetate|10.8 mg intramuscular depot injection given every 12 weeks
45385800|NCT01014234|Drug|Cyclosporins|These patients will undergo maintenance immunosuppressive treatment with cyclosporine + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
45695564|NCT01709864|Drug|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
45695565|NCT04878315|Drug|Capoten|Capoten will be administered per the treatment sequence
45695566|NCT04878315|Drug|Captopril|Captopril will be administered per the treatment sequence
45695567|NCT02242708|Behavioral|Alternative nostril breathing|The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
45848302|NCT03433794|Behavioral|Booster|Personalized feedback was emailed to participants. Content included sex-specific descriptive normative information (i.e., drinks per week typically consumed by males and females at the same institution), as well as reminders of harm reduction strategies (i.e., techniques the participant reported using in their last survey, versus techniques not used).
45848303|NCT03433794|Behavioral|Lilly for Better Health|This is an online education session directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. It was not expected to influence alcohol use.
45848304|NCT03440424|Drug|Lemborexant|oral tablet
45385801|NCT01014234|Drug|Rapamycin|These patients will undergo maintenance immunosuppressive treatment with rapamycin + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
45385802|NCT00501228|Drug|Filgrastim|5 mg/kg ID Once Daily x 1 Week
45385803|NCT00308620|Drug|chloroquine phosphate|250mg or 500mg PO (by mouth) QDay
45385804|NCT00308620|Drug|Placebo|Placebo once daily for 8 weeks
45385805|NCT01014312|Behavioral|Depression Care Management (DCM)|Depression Care Management (DCM) includes: 1. Monitoring the course of the depressive disorder; 2. Contacting the referring primary care physician (PCP) and offering information on the patients' current psychiatric status and medical complaints and the treatment recommended by published pharmacotherapy guidelines; 3. Determining the nature and extent of stressors affecting the patients' clinical status and functioning; 4. Psychoeducation concerning depression and depression treatment, working with the patient to select an appropriate treatment based on informed treatment preferences, and emphasizing treatment adherence; and 5. Supportive psychotherapy.
45385806|NCT01014312|Behavioral|Enhanced Care|Primary Care Physicians will be informed by letter from a study psychologist of the participants' depression diagnosis and of suicidal ideation when present. They will have no direct assistance regarding depression treatment, but they will be educated on guideline-based antidepressant treatment recommendations. Moreover, research assistants will use a suicide risk protocol at baseline and at all follow-up assessment periods that mandates immediate contact with PCPs by telephone or beeper in cases with significant risk.
45385807|NCT01016496|Other|action observation therapy|15 consecutive sessions of 18 minutes, plus repetition
45385808|NCT01016496|Other|repetition of gestures|15 consecutive session of visual games, plus repetition of gestures
45385809|NCT00492752|Drug|Sorafenib (Nexavar, BAY43-9006)|multikinase inhibitor; Sorafenib 400 mg (orally) twice daily
45385810|NCT00492752|Drug|Placebo|Matching placebo (orally) twice daily
45385811|NCT01016574|Device|Support Device for Prone radiation therapy (Giro-Couch)|Boost irradiation is applied to the ipsilateral breast in eight fractions of 2Gy/Fx
45385812|NCT01009658|Dietary Supplement|Monosodium glutamate|Oral intake of 2.0 g of monosodium glutamate on the examination day and 0.6 g of sodium chloride on the other examination day.
45385813|NCT01009658|Dietary Supplement|Sodium chloride|Oral intake of 0.6 g of sodium chloride on the examination day and 2.0 g of monosodium glutamate on the other examination day.
45385814|NCT00308308|Drug|Technosphere Insulin|Inhalation, 15U/30U
45385815|NCT00308308|Drug|Active comparator|sc injectable insulin
45385816|NCT00505934|Drug|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose within the following dose range, calculated on the basis of their age and weight:.~Ages ≥ 1 month to < 6 months: 14 mg/kg/day (7 mg/kg twice daily) to 42 mg/kg/day (21 mg/kg/day twice daily);~Ages ≥ 6 months to < 4 years: 20 mg/kg/day (10 mg/kg twice daily) to 60 mg/kg/day (30 mg/kg/day twice daily).~For subjects not taking levetiracetam oral solution prior to entering the study, the intravenous (IV) dosage corresponded to their age and weight as follows:~Ages ≥ 1 month to < 6 months: 14 mg/kg/day (7 mg/kg twice daily).~Ages ≥ 6 months to < 4 years: 20 mg/kg/day (10 mg/kg twice daily)."
45385817|NCT02532790|Drug|Prednisone|1.5mg/kg/d
45385818|NCT02532790|Drug|ACEI|0.2-0.3mg/kg/d
45385819|NCT03981406|Behavioral|Palliative Care|The intervention is one visit to the Fairview Clinics and Surgery Center palliative care clinic, with follow up visits as determined by the palliative care team and the patient.
45385820|NCT03981406|Behavioral|Standard of Care|Control group will receive standard of care treatment for IPF.
45385821|NCT00505778|Drug|Mesalamine Once-Daily|Mesalamine tablets, 1.6-2.4 g/day taken orally once a day for 52 weeks
45385822|NCT00505778|Drug|Mesalamine Twice-Daily|Mesalamine tablets, 1.6-2.4 g/day, taken twice daily for 52 weeks
45385823|NCT01061554|Dietary Supplement|Omega-3 oils from tri-glycerides|Single-dose administration of approximately 5 grams of omega-3 oils from triglycerides
46056264|NCT02736279|Drug|Dimethyl fumarate|Observation of impact of dimethyl fumarate treatment initiation on mood and gut microbiome over the first 6 months of therapy
46056265|NCT04851262|Behavioral|Exercise|The intervention is to be taught by fitness trainer at the participants' home at the start of each phase. The exercise progression model for older adults recommended by the American College of Sports Medicine, which emphasise gradual increments in training load and systematically alter one or more programme components, will be adopted.
45385824|NCT01061554|Dietary Supplement|Omega-3 oils from marine phospholipids|Single-dose administration of approximately 5 grams of omega-3 oils from marine phospholipids
45385825|NCT01063894|Other|breakfast cereal|breakfast cereal and milk
45385826|NCT01063894|Other|water|water
45385827|NCT01064050|Device|silicone trachea-bronchial stent Dumon (Novatech)|Bronchial desobstruction under interventional bronchoscopy, for inclusion, with the insertion of silicone stent trachea-bronchial covering the entire tumor area
45385828|NCT00308074|Drug|Aripiprazole|open-label, flexible-dosing
45385829|NCT01059838|Behavioral|sentence recognition|testing the ability for sentence recognition in quiet and in noise.
45385830|NCT03997058|Other|Auricular point pressure therapy|Use a hard and smooth pill to adhere to the center of the 0.7×0.7cm tape. Hold the puncture clip on the part of the ear which is selected, and give appropriate pressure (揉) to make the patient have heat, hemp, Swelling and painful feeling; patients with sputum press 3-5 times a day, each time 1-2 minutes per hole, and must be pressed once every 15-30 minutes before going to bed every night. Press the point pressure method (press the ear point with a fingertip and press it loosely, each interval is 0.5 seconds. It is better for the patient to feel the swelling and slightly heavy tingling, and the force should not be too heavy. Generally, each time the hole can be pressed 27 times. Each time one side of the ear is selected, the two ear points are used alternately, staying in the summer for 1-3 days, and staying in the winter for 3-7 days.It is not appropriate to have local inflammation of the auricle, frostbite or surface skin ulceration.
45385831|NCT03997058|Drug|Oral estazolam medication|The first dose was started from 0.5mg, qn, and taken at 30min-1h before going to bed. If the dose is not effective, gradually increase the amount to 2mg, qn. If the patient has drug-induced liver damage and respiratory depression, it is necessary to stop the drug immediately. Hemorrhoids avoid drinking alcohol during medication.
45385832|NCT01061632|Procedure|High intensity motor control exercise (deadlift)|12 treatment sessions over a 8 week period is planned for the high intensity motor control exercise.
45385833|NCT01061632|Procedure|Low intensity motor control exercise|12 sessions of low intensity motor control exercises over 8 weeks
45385834|NCT00500760|Drug|Cisplatin|Administered intravenously (IV; in a vein)
45385835|NCT00500760|Radiation|Standard Fractionation Radiotherapy|70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions)
45385836|NCT00500760|Drug|Panitumumab|Administered intravenously
45385837|NCT00505622|Drug|Perampanel|
45385838|NCT01009736|Dietary Supplement|tomato-soy juice|
45500210|NCT03605108|Dietary Supplement|Probiotic|"• Probiotic fomula per capsule:~2 Billion CFUs~HU36 - 30 mg~HU58 - 20 mg~Bacillus clausii -25 mg~Bacillus coagulans 10B - 35 mg~Prepro - 22 mg. The prebiotic that is to be used in the proprietary blend is a vegetable grade cellulose."
46056266|NCT00748189|Drug|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
46056267|NCT00748189|Drug|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
45385839|NCT01009736|Other|laboratory biomarker analysis|
45385840|NCT01009736|Other|pharmacological study|
45385841|NCT01009736|Procedure|therapeutic conventional surgery|
45385842|NCT03852576|Drug|KSP/QRH dimer|KSP-QRH-E3-IRDye800 (Peptide 919288G)
45385843|NCT01012856|Behavioral|Cognitive-Behavioral Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on cognitive restructuring without emotion-focused interventions
45385844|NCT01012856|Behavioral|Exposure-Based Cognitive Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on emotion-focused interventions
45385845|NCT03851094|Behavioral|Wellth app|The intervention is the use of Restful, the Wellth self-management app. There is no clinical treatment intervention, as all participants will be receiving PAP therapy per standard of care. Restful is a smartphone-based patient engagement tool that utilizes concepts from behavioral economics to help patients improve their adherence to therapy. The intervention includes a financial and social incentive reward program.
45385846|NCT01016730|Drug|Bortezomib|Given IV
45385847|NCT01016730|Other|Laboratory Biomarker Analysis|Correlative studies
45385848|NCT01016730|Other|Questionnaire Administration|Ancillary studies
45385849|NCT00505076|Drug|MK-0777|MK-0777 GEM, 8 mg BID
45385850|NCT00505076|Drug|MK-0777|MK-0777 GEM, 3 mg BID
45385851|NCT00505076|Drug|placebo|2 tablets placebo BID
45385852|NCT01012934|Drug|Alendronate Sodium Tablets, 70 mg|1 x 70 mg, single-dose fasting
45385853|NCT01012934|Drug|Fosamax Tablets, 70 mg|1 x 70 mg, single-dose fasting
45385854|NCT04334330|Drug|Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant|ER/PR positive, HER2-positive breast cancer patients with brain metastatic lesions receive palbociclib PO daily on days 1-21, combined with trastuzumab IV every three weeks, pyrotinib PO daily and fulvestrant IM every 4 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
45385855|NCT01015196|Drug|Zavedos|
45385856|NCT01015196|Drug|Cerubidine|
45385857|NCT01009892|Drug|Codeine Sulfate|Tablet
45385858|NCT00307684|Drug|double blind placebo|matching placebo tablets once daily for 4 weeks
45500211|NCT03605108|Other|Placebo|Rice flour only
45385859|NCT00307684|Drug|double blind PR OROS methylphenidate|18, 36, 54,72 or 90 mg/day once daily for 4 weeks
45385860|NCT00307684|Drug|open label PR OROS methylphenidate|Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
45385861|NCT00489918|Drug|teriparatide|Macroflux® patch applied to the abdomen for 30 minutes daily
45695568|NCT04374604|Diagnostic Test|Placental growth factor|On admission, the blood samples of consenting participants will be collected and analysed using enzyme linked immunosorbent assay technique to determine the level of PlGF (pg/ml).
45385862|NCT00489918|Drug|teriparatide|FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh
45385863|NCT01061788|Drug|AMG 479, Everolimus, Panitumumab|"Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~3-6 subjects, Study drug administered per dose level~3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3-6 subjects, Study drug administered per dose level~3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLS Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level"
45385864|NCT00307294|Drug|Thalidomide|100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg
45385865|NCT00307294|Drug|Doxil|On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days
45385866|NCT03981094|Drug|BMS-986278|suspension
45385867|NCT03981094|Drug|Pirfenidone|capsule
45385868|NCT01064128|Procedure|conventional laparoscopic hysterectomy|conventional 3 or 4 ports laparoscopic hysterectomy
45385869|NCT01064128|Procedure|SPA laparoscopic hysterectomy|single-port access laparoscopic hysterectomy
45385870|NCT03963401|Drug|PF-06700841|Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
45385871|NCT03963401|Other|Placebo|Starting after the Week 16 visit, subjects receiving placebo will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
45385872|NCT04410965|Drug|TERIFLUNOMIDE|Pharmaceutical form:tablet Route of administration: oral
45385873|NCT04012775|Biological|Insulin Humulin® NPH|4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
45385874|NCT04012775|Biological|Insulin Rinsulin® NPH|4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
45500212|NCT04904549|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series)|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection
45500213|NCT04904549|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series)|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
45500214|NCT04904549|Biological|Placebo|Pharmaceutical form: liquid. Route of administration: intramuscular administration.
45695569|NCT01706835|Drug|aldoxorubicin|
45695570|NCT01651533|Behavioral|Mental Practice Group|Patients are administered rehabilitative therapy targeting their affected arms on 3 days/week during a ten week period. Directly after the therapy session, they participate in targeted mental practice session in which they cognitively rehearse the movement that they just physically practiced.
45500215|NCT04904549|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
45500216|NCT04904549|Biological|SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
45385875|NCT00944723|Dietary Supplement|Zinc-fortified bread|Bread made with zinc-fortified wheat flour
45385876|NCT00944723|Dietary Supplement|Zinc supplement|Liquid supplement with zinc
45385877|NCT00944723|Dietary Supplement|Non-fortified bread|Daily consumption of non-fortified bread
45385878|NCT00944723|Dietary Supplement|Placebo supplement|Daily intake of placebo supplement
45385879|NCT00944801|Drug|Pegylated Liposomal Doxorubicine|In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
45385880|NCT00334282|Drug|Pazopanib|Oral pazopanib tablet 800 mg once daily continuously
45385881|NCT00334282|Drug|placebo|matching placebo (800 mg tablet) once daily
45385882|NCT03982420|Procedure|Transcarotid Revascularization (TCAR)|Carotid revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
45385883|NCT01060228|Drug|paliperidone ER|1 tablet of 500 mg once daily on Day 1 and Day 15
45385884|NCT01060228|Drug|divalproex sodium ER|2 tablets of 500 mg once daily from Days 5 through 18
45500217|NCT03605030|Device|Novel Lead Based Armboard|Novel Lead Based Armboard
45500218|NCT03605030|Device|Standard Armboard|Standard Armboard (without lead)
45385885|NCT00306670|Drug|Rituxan|Acquired Hemophilia A Patients Who Have Developed Anti-Factor VIII Antibodies
45385886|NCT00306670|Drug|prednisone|<30 mg/day
45385887|NCT00306592|Biological|BG00002 (natalizumab)|
45385888|NCT03982732|Biological|Boostrix-IPV|Receipt of Boostrix IPV at three different gestational time periods
45385889|NCT00321646|Drug|Bevacizumab|Bevacizumab (marketed as Avastin, Genentech) is an antibody to all isoforms of vascular endothelial growth factor and is the first putative anti-angiogenic agent approved by the Food and Drug Administration (FDA) for the treatment of cancer.All subjects will be treated with intravenous docetaxel and bevacizumab for 5 cycles, followed by docetaxel alone for Cycle 6. Bevacizumab will be given first, at a starting dose of 15 mg/kg. Bevacizumab will be given once every 21 days in the infusion center.
45385890|NCT00321646|Drug|Docetaxel|Docetaxel will be given intravenously once every 21 days in the infusion center. The starting dose is 70mg/square meter.
45385891|NCT03982654|Device|Bloomlife|Women use the Bloomlife sensor to collect data throughout their pregnancy. The collected data is stored locally in the device, but it is not used to provide any feedback to the patients or to the clinical team. Therefore the use of the device doesn't have an impact on clinical decision making and patients' care.
45385892|NCT00403767|Drug|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One 20 mg tablet once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years (Patients with moderate renal impairment at screening willl have a dose adaptation to rivaroxaban 15 mg, orally, once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years)
45385893|NCT00403767|Drug|Warfarin|Type=exact number, unit=mg, number=1, 2.5, or 5 mg, form=tablet, route=oral use. Number of warfarin tablets to be determined based on target INR values once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years
45500219|NCT03604952|Diagnostic Test|COPD patients|Tests performed one week before Ramadan (C), and during the second (R-2) and the fourth weeks of Ramadan (R-4)
45385894|NCT00403767|Drug|Matching placebo for Rivaroxaban arm (Warfarin placebo)|Form=tablet, route=oral. One warfarin placebo tablet taken orally once daily for up to an expected maximum treatment period of 32 months that may extend up to 4 years
45385895|NCT00403767|Drug|Matching placebo for Warfarin arm (Rivaroxaban placebo)|Form-tablet, Route=oral administration. Number of rivaroxaban placebo determined by the number of warfarin tablets taken. Duration of treatment is up to an expected maximum treatment period of 32 months that may extend up to 4 years
45385896|NCT00492284|Drug|verteporfin|Reduced-fluence Visudyne (25 J/cm2, 300 mW/cm2, 83 seconds)
45385897|NCT00492284|Drug|verteporfin|Very-low fluence Visudyne (15 J/cm2, 180 mW/cm2, 83 seconds)
45385898|NCT00492284|Drug|ranibizumab|0.5 mg intravitreal injection
45385899|NCT00492284|Drug|dexamethasone|0.5 mg intravitreal injection
45385900|NCT01013012|Drug|ramosetron with saline|Group A : saline 1 ml, ramosetron 6μg/kg
45385901|NCT01013012|Drug|ramosetron with dexamethasone|Group B : dexamethasone 4 mg, ramosetron 6μg/kg
45385902|NCT01009970|Drug|Rituximab|375 mg/m2 day 1
45385903|NCT01009970|Drug|Cyclophosphamide|750 mg/m2 day 2
45385904|NCT01009970|Drug|Vincristine|1,4 mg/m2 (max 2 mg) day 2
45385905|NCT01009970|Drug|Prednisone|40 mg/m2 day 2-6
45385906|NCT01009970|Drug|Doxorubicin|50 mg/m2 day 2
45385907|NCT01013090|Drug|Ringer's Lactate|Ringer's Lactate 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
45385908|NCT01013090|Drug|Six percent hydroxyethyl starch|Six percent hydroxyethyl starch 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
45385909|NCT01015352|Drug|Azacitidine|Azacitidine 75mg/sqm SQ per day for 5 days every 28 days
45385910|NCT01015352|Drug|Epoetin beta|"Epoetin beta : 60000U weekly SQ injections~NeoRecormon®"
45385911|NCT01043757|Behavioral|Financial incentives for increasing physical exercise|Throughout the 12-week intervention, participants will receive step goals. The step goals will increase by 250 steps per week, The intervention will last a total of 12 weeks. After each seven-day week, step goals will increase by an additional 250 steps - thus over the 12 weeks, participants will be asked to increase their daily step count by 3,000. Participants will receive financial incentives to attain these step goals; the incentive schemes differ according to intervention arm.
45385912|NCT00510458|Device|LFIT™ Femoral Heads With X3® Insert|LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert in total hip replacement
45385913|NCT03563157|Biological|Aldoxorubicin Hydrochloride|Aldoxorubicin Hydrochloride HCI
45385914|NCT03563157|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL-15N72D;IL-15RaSu/IgG1 Fe complex1]
45385915|NCT03563157|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
45385916|NCT03563157|Biological|ETBX-021|Ad5 [E1-, E2b-]-[HER2]
45385917|NCT03563157|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
45385918|NCT03563157|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1]
45500220|NCT02237378|Radiation|FDG PET scan|Following an overnight fast, subjects will be positioned in the Discovery 660 PET/VCT scanner. Following a scout scan to confirm patient positioning, low dose xray CT scan is performed for photon attenuation. A 20 minute dynamic PET scan is started simultaneously with 3 MBq/kg of N-13 ammonia to measure myocardial perfusion. Following N-13 decay,a 60 minute dynamic PET scan with 3 MBq/kg F-18- FDG to measure myocardial glucose uptake. Blood sampling for glucose and insulin will occur at pre specified time points throughout the scan.
45500221|NCT03607916|Drug|Hyperbaric prilocaine 2%|Varying dose according to sensitive response of previous subjects. All study doses of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
45385919|NCT03563157|Biological|GI-4000|RAS yeast
45385920|NCT03563157|Biological|GI-6207|CEA yeast
45385921|NCT03563157|Biological|GI-6301|Brachyury yeast
45385922|NCT03563157|Biological|haNK|haNK™, NK-92 [CD16.158V, ER IL-2]
45500222|NCT03607916|Drug|Hyperbaric prilocaine 2%|The dose of 60 mg of Hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
45500223|NCT03607916|Drug|Morphine|100µg morphine
45385923|NCT03563157|Drug|Avelumab|BAVENCIO® injection
45385924|NCT03563157|Drug|Capecitabine|XELODA® tablets
45385925|NCT03563157|Drug|Cetuximab|ERBITUX® injection
45385926|NCT03563157|Drug|Cyclophosphamide|Cyclophosphamide Capsules
45385927|NCT03563157|Drug|5-Fluorouracil|5-FU; Fluorouracil Injection
45500224|NCT04709627|Device|enFlow IV Fluid and Blood Warming System|The enFlow IV fluid/blood warming system's intended use is for warming blood, blood products and intravenous solutions prior to administration.
45500225|NCT01141712|Procedure|Autologous transplant|Participants will receive the BEAM conditioning regimen followed by autologous HCT.
45500226|NCT01141712|Drug|BCNU|Participants will receive BCNU 300 mg/m^2 Day -6
45385928|NCT03563157|Drug|Leucovorin|Leucovorin Calcium
45385929|NCT03563157|Drug|Nab-paclitaxel|ABRAXANE® for Injectable Suspension [paclitaxel protein-bound particles for injectable suspension] [albumin-bound]
45500227|NCT01141712|Drug|Etoposide|Participants will receive Etoposide 100 mg/m^2 BID Days -5 to -2
45385930|NCT03563157|Drug|Oxaliplatin|ELOXATIN® injection
45385931|NCT03563157|Drug|Regorafenib|STIVARGA® tablets
45385932|NCT03563157|Procedure|SBRT|Stereotactic body radiation therapy
45385933|NCT01010048|Drug|progesterone,tamsulosin,propantheline Bromide and nifedipine|clearance rate of stone
45385934|NCT01589055|Drug|Intravenous Nicotine|Subjects will be given an intravenous challenge dose of nicotine or placebo in a constant volume of 1 ml on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (1 ml over 1 min) has been safe in our IRB approved studies of nicotine. Most investigators have administered nicotine over 10 sec without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70kg;) should be administered first and the higher dose (2.0 mg/70kg) will be administered last.
45500228|NCT01141712|Drug|Cytarabine|Participants will receive Cytarabine 100 mg/m^2 BID Days -5 to -2
45695571|NCT01651533|Behavioral|Active Control Group|Individuals assigned to this group are administrated rehabilitative therapy targeting their affected arms in half four increments, occurring 3 days/week for 10 weeks. They also are administered an intervention in which they listen to a relaxation tape and/or tapes in which they receive instructions on exercises and information on stroke care.
45385935|NCT01013168|Procedure|Apheresis using the OncoSorb column|device is intended to specifically adsorb three soluble receptors (sTNF-R1, sTNF-R2 and sIL-2R α)
45385936|NCT01013246|Other|1-hour video game play|FIFA 2009, a football video game played on Xbox 360
45385937|NCT00414765|Drug|Aldesleukin|
45385938|NCT03997292|Drug|Alteplase|According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion.
45385939|NCT03997292|Drug|Urokinase|1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously.
45385940|NCT01013402|Drug|Human insulin|The test was performed in the morning after an overnight fasting and the patients remained supine during the procedure. Two intravenous lines in both arms were established before the procedure. Venous blood was obtained for serum glucose before regular insulin (0.1 U/kg ) is injected and 30 and 45 minutes thereafter. If adequate hypoglycemia was not achieved at this period, a second dose of regular insulin (0.05U/kg) was injected intravenously. In subjects who had not reached the aimed hypoglycemia levels, the test was performed in another day with a higher initial insulin dosage (0.2U/kg).
45385941|NCT01013402|Drug|Human Insulin|0.1U/kg IV pulse.
45385942|NCT01013480|Drug|Arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
45385943|NCT00500682|Drug|Placebo|9g /day (3 times a day)
45385944|NCT00500682|Drug|AST-120|9g /day (3 times a day)
45695572|NCT03403348|Drug|JNJ-64417184|Participants will receive JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
45695573|NCT03403348|Drug|Placebo|Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
45695574|NCT04867395|Behavioral|HELPix Care Plan|"A web application tool for CMC - Health literacy-informed, disease and medication-specific, standardized discharge instructions that will: 1) facilitate plain language provider/parent communication at hospital discharge and 2) act as stand-alone handouts that parents can use at home."
45695575|NCT02242786|Radiation|External beam radiation therapy|
45695576|NCT01673451|Drug|E2006|Part A: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 75 mg E2006 administered as capsules
45695577|NCT01673451|Drug|Placebo comparator|E2006-matched placebo (Part A and Part B); Part B: dose level to be determined based on results of Part A, administered as capsules
45695578|NCT02242864|Drug|Micardis®|
45695579|NCT02242864|Drug|MicardisPlus®|
46056268|NCT02610166|Behavioral|Game|"In addition to standard medical care, children in the experimental group will receive the Match-3 game. The game will be designed for short individual gameplay sessions (as little as a few seconds), once to three times a day, over the course of 8 weeks, involving no more than 15 minutes per day in anticipated screen time. There is no way to lose the game. Through a structured series of daily interactions, the player will learn strategies and develop decision-making abilities that will assist with management of their own JIA. The Match 3 concept (similar to the game, Bejeweled) will require the player to successfully match the treatment strategy to the JIA symptom."
45385945|NCT00500370|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
45385946|NCT00500370|Drug|placebo|subcutaneous injection (equivalent volume to active dose), twice a day
45385947|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
45385948|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
45385949|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
45385950|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
45385951|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 4.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
45385952|NCT03996798|Other|Disability Case Manager|The DCM will act as key figure between the patient, the multidisciplinary team of the revalidation centre, the employers and other back-to-work services in order to increase vocational reintegration after an incident which caused a handicap or chronic disease.
45385953|NCT03996486|Drug|BAY1093884|Drug administered via subcutaneous injections once weekly for 6 weeks (= 6 doses)
45695580|NCT01709708|Drug|Marcaine|Marcaine used as a topical local anesthetic to block the SPG by delivering Marcaine directly to the specific area of mucosa associated with the SPG.
45695581|NCT01709708|Drug|Saline|Saline
46056269|NCT02610166|Other|Usual Care|Children in usual care group receive standard medical care.
45385954|NCT01014468|Drug|Ranibizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
45385955|NCT01014468|Drug|Bevacizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
45385956|NCT03980782|Other|Music Therapy|Individualized music therapy developed playlist(s) that will be used based upon the latest Confusion Assessment Method result (hypoactive, hyperactive or no delirium) delivered twice daily.
45385957|NCT00503984|Drug|Azacitidine|Intravenous infusion over 30 minutes Days 1 - 5 of each 3 weekly cycle.
45385958|NCT00503984|Drug|Docetaxel|Intravenous infusion over 1 hour on day 6 of each 3 weekly cycle.
45385959|NCT00503984|Drug|Prednisone|Patient will receive prednisone 5mg twice a day from Day 1 to 21 of each cycle.
45385960|NCT00503984|Genetic|GADD45α methylation and expression analysis|"Peripheral blood samples from patients will be collected as described in section 8.1 (total of 4 blood samples). DNA will be isolated from serum, bisulfite treated and evaluated for methylation by bisulfite genomic sequencing.~Patients with accessible prostate tissue or metastases will undergo biopsy prior to treatment if they consent to do so."
45385961|NCT00503984|Drug|Pegfilgrastim|Growth factor support.Granulocyte-colony stimulating factor (G-CSF)
45385962|NCT00503984|Drug|Filgrastim|Growth factor support. Granulocyte-colony stimulating factor (G-CSF)
45385963|NCT03981016|Other|Biological collection|"blood samples collected at different times : Before surgery and during the post-operative visit and~frozen tumor samples and / or paraffin samples at the time of surgery and- paraffin around tumor samples at the time of surgery"
45385964|NCT03996564|Device|Battlefield Acupuncture|1-10 needles inserted in systematic nature as described by Battlefield acupuncture protocol.
45385965|NCT03996564|Drug|Acetaminophen|Acetaminophen 500mg-1000mg,
45385966|NCT03996564|Drug|Diclofenac|Diclofenac 50mg-75 mg orally
45385967|NCT03996564|Drug|Diazepam|Diazepam 5mg-10 mg intravenous or oral
45385968|NCT03996564|Drug|Hydrocodone|Hydrocodone 5mg/325mg-10mg/650mg mg
45385969|NCT03996564|Drug|Ketorolac|oral, or intramuscular Ketorolac 30mg-60 mg
45385970|NCT00565409|Drug|Etanercept|Subcutaneous (SC), 50 mg, once weekly for 88 weeks
45385971|NCT00565409|Drug|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
45385972|NCT00565409|Drug|Etanercept|Subcutaneous (SC), 25 mg, once weekly from week 36 to week 88.
45385973|NCT00565409|Drug|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
45385974|NCT00565409|Drug|Placebo|Subcutaneous (SC), once weekly from week 36 to week 88.
45385975|NCT00565409|Drug|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
45385976|NCT03980860|Other|Exercise Type|The implementation of 2 types of exercise programs to reduce body fat
45385977|NCT00394251|Drug|Adriamycin and Cytoxan (AC)|Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m^2 intravenous, plus Cytoxan 600 mg/m^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8).
46056270|NCT02736201|Device|Capacitive diathermy (T-CaRe®)|The instrumental manual therapy with the switched on capacitive diathermy electrode (IMT+ T-CaRe® on; n = 10) and the instrumental manual therapy with the switched off capacitive diathermy electrode (IMT+ T-CaRe® off; n = 10) will be bilaterally treated for 4 weeks (1 treatment per week during 10 minutes) in the lumbopelvic region.
46056271|NCT02736201|Other|Instrumental manual therapy|Bilateral longitudinal massage in the lumbar region (110 mm; 5 minutes in each side)
45385978|NCT00394251|Drug|ABI-007|260 mg/m^2 IV on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
45500229|NCT01141712|Drug|Melphalan|Participants will receive Melphalan 140 mg/m^2 Day -1
46056272|NCT02609230|Drug|ONC-201|
46056273|NCT02738307|Other|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure for 8 days after 6 days at low altitude
45385979|NCT00394251|Drug|Taxol|175 mg/m^2 intravenously (IV) on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
45426126|NCT00113659|Dietary Supplement|Placebo|Daily dose of placebo supplement containing 325mg inulin for the first 6 month of life.
45500230|NCT00145145|Biological|MAGE-3.A1 peptide and CpG 7909|
45500231|NCT05190263|Other|non-interventional retrospective epidemiological observational study|non-interventional retrospective epidemiological observational study
45500232|NCT03607448|Device|Freestyle Libre Flash Glucose Monitoring System|Subjects will wear the Abbott Sensor based FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes
45385980|NCT00394251|Drug|Bevacizumab|10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46).
45385981|NCT00394251|Drug|pegfilgrastim|6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary.
45385982|NCT02532400|Drug|Neoadjuvant endocrine therapy|Goserelin: 3.6mg, d1, hypodermic injection , q28d*7 plus exemestane: 25mg, po, qd*24w, or anastrozole: 1mg, po, qd*24w
45385983|NCT02532400|Drug|Neoadjuvant chemotherapy|Docetaxel: 75mg/m2, d1, q3w*6, Epirubicin 75mg/m2, d1, q3w*6 and Cyclophosphamide: 500mg/m2, d1, q3w*6
45385984|NCT03980704|Drug|IMPACT|Administration of oral immunostimulating oral supplement
45385985|NCT03980704|Drug|resource protein|Administration of oral high-protein oral supplement
45385986|NCT03980548|Procedure|CABG|Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI
45385987|NCT00394095|Drug|Topiramate|Oral topiramate 300-400mg/day for 12 weeks
45385988|NCT00394095|Drug|Placebo|Matched placebo to Experimental arm
46056274|NCT04028908|Diagnostic Test|radiographs in two views of the tibia|The anterior tilt angle of the tibia will be measured by two specialized radiologists according to a specific radiological angle measurement tool (PACS Sectra IDS7TM, Linköping, Sweden).
45385989|NCT00503906|Drug|Avastin|
45385990|NCT00503906|Drug|Gemcitabine|
45385991|NCT00503906|Drug|Abraxane|
45385992|NCT00305110|Drug|2 mg IV hydromorphone|
45385993|NCT03984760|Drug|Ferric Citrate|Take the capsules with meals or immediately after meals.
45385994|NCT03984760|Drug|Sevelamer Carbonate|Take the tablets with meals.
45385995|NCT01060462|Drug|Pts. w/ neutropenic fever associated w/ hematologic malignancy|Itraconazole 200 mg twice daily for 2 days for a total of 4 doses, then 200 mg once daily for 12 days. After 14 days of IV administration, itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
46056275|NCT02736045|Device|emWave|Our approach will be to test the impact of this intervention through a smartphone application, emWave software, which will be provided to all our subjects. emWave is a tool that reduces stress by allowing individuals to be less reactive, think clearly, and make good decisions, especially under pressure. Fifty medical residents with high burnout symptoms will be randomized to receive an 8-week intervention (emWave - computer based resilience training program).
45385996|NCT00491894|Drug|Oral Glycopyrrolate Liquid|Study medication is administered three times a day at 7-8 AM, 1-2 PM, and 7-8 PM by the parent/caregiver
45385997|NCT01060618|Other|Maraviroc + Trofile ESTA® (diagnose test)|The Trofile ESTA® will be performed in those patients and once the results are obtained (within one month approximately), the patients will be treated with the medication Maraviroc
45385998|NCT03984604|Drug|CHI-921|a standardized cannabis extract in sunflower oil administered in oral liquid (oil) form
46056276|NCT00913822|Drug|Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)|
46056277|NCT00913822|Drug|Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)|
45385999|NCT03984604|Drug|Placebo|Placebo is a vehicle oil will match CHI-921
45386000|NCT00491504|Drug|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray: 2 sprays (50 mcg) each nostril (total 200 mcg)
45386001|NCT00491504|Other|Placebo|Placebo: 2 sprays in each nostril
46056278|NCT05603091|Procedure|cryoablation of pulmonary veins|Procedures are guided by pressure waveforms analysis, which are obtained by connecting the internal lumen of the catheter through the lateral port of the hemostatic valve attached to the catheter, to a pressure transducer connected in turn to a heparinized saline serum bag and to the cryoablation console.
46056279|NCT02736123|Drug|Nivolumab - Arm A|Nivolumab will be given during the induction phase of the study for 6 weeks. This is followed by surgery. Then maintenance therapy (after recovery from surgery).
46056280|NCT02736123|Drug|Nivolumab + Ipilimumab - Arm B|Nivolumab + ipilimumab during the induction phase of the study for 6 weeks. This is followed by surgery (week 6-8+). Then maintenance therapy will be initiated for up to one year from study drug initial administration ((after recovery from surgery).
45386002|NCT04326452|Device|bidirectional oxygenation mouthpiece|Use of our bidirectional oxygenation mouthpiece with conventional oxygen support.
45386003|NCT01015508|Other|Very Low Energy Diet (VLED)|a VLED (Modifast) for 2 months in order to reduce body weight
45386004|NCT01015508|Other|Weight maintenance|10 months
45386005|NCT00500292|Drug|Vandetanib|once daily oral tablet two dose strengths
45386006|NCT00500292|Drug|FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid|intravenous infusion
45386007|NCT01013558|Drug|Remifentanil|0.15 microgram/kg/min continuous infusion.
45386008|NCT01013558|Drug|saline|continuous infusion
45386009|NCT01013636|Procedure|Blood sampling|"Anaplasma diagnosis test : serology and PCR~If presence of Anaplasma infection, proposition of treatment with doxycylin 200 mg once-a-day during 10 days"
45386010|NCT00499746|Drug|tramadol|oral dose, once per day
45386011|NCT00499746|Drug|placebo|oral dose, once per day
46056281|NCT02735967|Other|manual therapy|the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
45695582|NCT01673529|Drug|SB705498|1%, 3% and 5% (w/w) of SB705498 will be used in part A of the study. One dose will then be selected based on criteria explained in the protocol for use in Part B of the study.
45386012|NCT00499746|Drug|Hydromorphone|oral dose, once per day
46056282|NCT02735967|Device|diadynamic current|Through an electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF), 4 minutes long periods (LP) and 4 minute short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient.
45695583|NCT01673529|Drug|Placebo|Placebo to match SB705498 will be used in both Part A and Part B of the study.
45695584|NCT02243098|Drug|semaglutide|Administered as a subcutaneous injection (s.c., under the skin). Initiated with weekly semaglutide dosing of 0.25 mg in the first 4 weeks, 0.5 mg the next 4 weeks, and 1.0 mg in the third 4 week period.
45695585|NCT02243098|Drug|digoxin|Oral administration. Digoxin will be given as 2 single doses of 0.5 mg.
45695586|NCT02243098|Drug|atorvastatin|Oral administration. Atorvastatin will be given as 2 single doses of 40 mg.
45695587|NCT03403114|Behavioral|Questionnaire|a 15min questionnaire
45695588|NCT02845323|Drug|Nivolumab in combination with Urelumab|Two cycles of Nivolumab Two cycles of Urelumab
46056283|NCT00744055|Drug|Prazosin|prazosin (16mg/day) 2 times a day
46056284|NCT00744055|Drug|Placebo|Placebo
46056285|NCT02735811|Device|Assesment of long-term outcome of ICD patients|Evaluation during follow-up of the occurrence of complications related to ICD implantation and of death
46056286|NCT00748033|Device|Reference catheter: LoFric PVC, Nelaton 40 cm, CH 12|The subjects were first catheterized with this reference catheter.
46056287|NCT00748033|Device|LoFric POBE Hydro-Kit II, 5 seconds|An unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with sodium chloride in wetting solution, activation time 5 seconds
46056288|NCT00748033|Device|LoFric POBE Hydro-Kit II, 24 hours|An unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with sodium chloride in wetting solution, activation time 24 hours
45386013|NCT00499746|Drug|Methylphenidate|oral dose, once per day
45386014|NCT01010516|Drug|High-dose rosuvastatin|40 of rosuvastatin daily
45386015|NCT01010516|Drug|Statin plus fenofibrate|Existing statin plus micronised fenofibrate 200 mg daily
45386016|NCT01010516|Drug|Statin plus niacin ER/laropiprant|Existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
45386017|NCT01020162|Drug|Amitryptiline, gabapentin|For amitryptiline starting dose 20-30 mg at night, increasing until clinical effect. For gabapentin was the initial dose 300 mg tid with rapid increases up to 800 mg tid.
45695589|NCT02845323|Drug|Nivolumab monotherapy|Two cycles of Nivolumab alone
45695590|NCT01673607|Procedure|Biopsie liver|
45695591|NCT00920374|Biological|Fluarix™/Influsplit SSW®|single intramuscular dose on Day 0
46056289|NCT03545763|Other|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
46056290|NCT02736903|Behavioral|PennFit mobile individual intervention|PennFit (individual) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (individual) to record and monitor their own physical activity progress.
46056291|NCT02736903|Behavioral|PennFit mobile online network intervention|PennFit (online network) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (online network) to record and monitor their own physical activity progress. They could see both their own information and the profiles and activity logs of the three other women assigned to their network. In addition, they could send messages to the network through an instant chatting tool.
45386018|NCT01020162|Procedure|Resection of the ilioinguinal nerve|In general anaesthesia the nerve was identified and resected as central as possible
45386019|NCT00489216|Biological|efalizumab|"Efalizumab will be administered as a subcutaneous injection once a week for 8 weeks (total of 8 doses). First efalizumab injection will be dosed at 0.7mg/kg. Subsequent weekly injections given on days 8-50 will be dosed at~1mg/kg"
45386020|NCT01016886|Drug|perindopril OR bisoprolol OR placebo|"perindopril- oral daily titrated does from 2mg up to 8mg~bisoprolol- oral daily titrated dose from 2.5mg up to 10mg"
45386021|NCT00499590|Drug|bevasiranib|Bevasiranib (2.5mg) administered intravitreally every 8 or 12 weeks
45386022|NCT00499590|Drug|ranibizumab|Lucentis® (0.5 mg)administered intravitreally every 4 weeks.
45386023|NCT00510146|Drug|Olanzapine|5-20 mg, oral, once daily, for 24 weeks (participants randomized to olanzapine in double-blind treatment period) or 18 weeks (participants randomized to placebo in double-blind treatment period).
45386024|NCT00510146|Drug|Placebo|placebo tablets, oral, once daily at bedtime, 6 weeks
45386025|NCT04250064|Drug|Bevacizumab Injection|Additional concurrent low-dose Bevacizumab with standard EBRT
45386026|NCT04250064|Radiation|Ultra-low-dose RT|Ultra-low-dose EBRT instead of standard dose RT
45386027|NCT00480636|Drug|Fragmin (dalteparin sodium )|Month 1: dalteparin 200 IU/kg SC once daily. Months 2-6: dalteparin 150 IU/kg SC, once daily.
45386028|NCT01017198|Drug|BIIB021 and Food|Assessing the effect of food use on BIIB021
45695592|NCT03159039|Other|Conventional Physiotherapy|
45695593|NCT03159039|Other|Prolonged slow exhalation technique|Postural drainage associated with manual vibration and a mild pressure in the end of expiratory phase
45695594|NCT01673685|Device|Portable Oxygen|
45715061|NCT04123535|Device|ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS)|The ExAblate 2100 MRgFUS system (InSightec, Inc., Dallas, Texas, USA) is a noninvasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.14-16 The ExAblate combines a focused ultrasound surgery (FUS) delivery system and a conventional diagnostic 3T Magnetic Resonance (MR) scanner. The ExAblate systems provide a real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control. The ExAblate transducer device is an integrated component of the MR table
45386029|NCT01017198|Drug|BIIB0121 and Antacid|Assessing the effect of antacid use on BIIB021
45500233|NCT02034890|Drug|Hyaluronic Acid|intravesical instillation of 40 mg of hyaluronic acid in 6 specific time points: 1,2,3 and 4 weeks postoperatively (After radical cystectomy and orthotopic neobladder reconstruction) 2 and 3 months postoperatively
45386030|NCT01013948|Other|Non-Interventional|Non-Investigational Product (Survey Study)
45386031|NCT00499122|Drug|Cyclophosphamide|
45500234|NCT02015351|Drug|bevacizumab|Injection technique: After lid speculum insertion and irrigation of the conjunctiva with 5% povidone-iodine, 0,05ml of bevacizumab will be inserted through the pars plana 3.5mm to 4.0mm posterior to the surgical limbus using a 30 gauge needle. After injection, topical antibiotics will be immediately applied in the injected eye. Immunosuppression: Corticosteroids will be prescribed (1mg/Kg/d) with tapering along 5 months. Immunosuppressive drug of choice is cyclosporine (3-5mg/Kg/d). In case of contraindication to cyclosporine use, azathioprine or mycophenolate mofetil will be prescribed.
45500235|NCT03604796|Drug|Rectal Solution|Rectal acetaminophen at 15 mg/kg x 4/day for three days
45500236|NCT03604796|Drug|Intravenous Infusion|Loading dose of 15 mg/kg IV acetaminophen followed by a continuous infusion at a rate of 2.5 mg/kg/hr for 72 hours
46056292|NCT02737995|Drug|Ferric carboxymaltose infusion|Subjects with functional iron deficiency determined by the results of iron biomarker results at Visit 2 will receive a single dose of intravenous ferric carboxymaltose . The dose of Injectafer will be calculated from a modified Ganzoni equation adapted from previous heart failure clinical trials The maximum dose of Injectafer will be 750 mg. The calculated dose of Injectafer will be diluted in normal saline solution (4 mg/ml) and administered via a volumetric pump administered over 30 minutes.
46056293|NCT02738073|Drug|Control: Saline|
45386032|NCT00499122|Drug|Docetaxel|
45386033|NCT00499122|Drug|Doxorubicin|
45386034|NCT00499122|Drug|NOV 002|
46056294|NCT02738073|Drug|Tranexamic Acid|
46056295|NCT05380531|Diagnostic Test|Preoperative Genotyping|Genotype based risk prediction and personalized pain management
46056296|NCT02737761|Behavioral|Qualitative Interview and Adherence Measurements|Subjects will undergo an open-ended, semi-structured interview within two weeks of enrollment. The interview will be approximately 1 hour in length, performed by study staff who have been trained in qualitative research methods. This interview will be completed again 12 weeks later. Subjects will complete the MOS SAS, Automated Self-Administered 24-hour recall (ASA24), Life Orientation Test-Revised (LOT-R), Positive and Negative Affect Schedule (PANAS), Hospital Anxiety and Depression Scale (HADS), Kansas City Cardiomyopathy Questionnaire (KCCQ), and Medical Outcomes Study Short Form-12 (SF-12) at baseline and again at 12 weeks.
45386035|NCT01017276|Drug|ASP1585|oral
45386036|NCT00393939|Drug|Sunitinib malate|Sunitinib 37.5 mg daily by oral capsule in schedule 2/1 with Docetaxel 75 mg/m2 every 3 weeks or 37. 5 mg daily in continuous dosing (in absence of docetaxel)
46056297|NCT03967483|Drug|Indometacin|patient who are taken indomatacin for headaches and migraine
46056298|NCT00735553|Drug|Proellex|One 25 mg capsule of Proellex® and one placebo capsule orally daily for up to four months
46056299|NCT00735553|Drug|Proellex|Two 25 mg mg capsules of Proellex® orally daily for up to four months
45500237|NCT03607292|Procedure|Anterior sciatic nerve block|A straight line along the femoral catheter was drawn between the anterior superior iliac spine and the finger palpating the pubic bone, the index finger was placed over the femoral artery pulse, a line was drawn perpendicular to the femoral fold. Over the pulse of the femoral artery, a point 4-5 cm lateral. The sciatic nerve was imaged by USG along the needle route and the needle was advanced to the nerve.
45500238|NCT03607292|Procedure|Posterior sciatic nerve block|Patient was positioned laterally, with the limb to be blocked uppermost. The lower leg was straight extended and the upper extremity was bent 90° from the knee and was directed forward on the lower straight extended extremity. The patient's greater trochanter and posterior superior iliac spine were palpated and joined with a line, and a line was drawn 4 cm above the first line perpendicular to the caudal line. The USG probe was placed between the greater trochanter and the coccyx at the entry point of the needle and the needle was advanced by imaging the nerve.
45500239|NCT05134259|Device|Repetitive Transcranial Magnetic Stimulation|TMS device will deliver repetitive trains of magnetic pulses using Magstim Rapid 2 with angulated figure of eight shaped coil. The device comprised two-channel Neuro-EMG-MS digital system for determining the motor threshold of the patients that will be used for establishing the threshold intensity for stimulation. The figure of eight-shaped coil generated a magnetic field of up to 4 Tesla that penetrates the cranium, enters into the soft tissue of the brain and henceforth stimulates the motor neurons.
45500240|NCT03604484|Procedure|Tricuspid annuloplasty|Tricuspid annuloplasty
45500241|NCT02311049|Radiation|Hypofractionation|
45500242|NCT02237456|Procedure|Comparison of OCT scans|
45500243|NCT02237456|Procedure|Comparison of Intra Vascular Optical Coherence Tomography Systems for Assessment of Coronary Tissue, Stents and Scaffolds - DOCTOR Compare|
46056300|NCT00735553|Drug|Placebo|Two placebo capsules orally daily for up to four months
46056301|NCT02595775|Other|Individualized A/F report|Individualized A/F report containing 9 colonoscopy quality measures.
46056302|NCT02595775|Other|A/F report plus a high intensity intervention|E.g. Master class in colonoscopy
46056303|NCT02595775|Other|A/F report plus a low intensity intervention|E.g. Access to a video/presentation on good colonoscopy technique followed by a post presentation assessment.
46056304|NCT02595775|Other|A/F report alone|
46056305|NCT00740779|Drug|Silodosin 8 mg|Silodosin 8 mg daily
46056306|NCT00740779|Drug|Placebo|Placebo
46056307|NCT00740779|Drug|Silodosin 4 mg|Silodosin 4 mg daily
46056308|NCT00735475|Biological|CSL Limited Influenza Virus Vaccine (Afluria®)|A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
46056309|NCT00735475|Biological|US Licensed Influenza Virus Vaccine (Fluzone®)|A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
46056310|NCT01026818|Drug|Tadalafil|Administered by mouth for 9 months
46056311|NCT01026818|Drug|Placebo|Administered by mouth, daily or on demand for 9 months
46056312|NCT00735397|Drug|perampanel|Perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years
46056313|NCT03967405|Device|MolecuLight PID|Hand-held, real-time fluorescence imaging device
46056314|NCT02593747|Drug|Loratadine oral solution|Subjects received a single oral dose of 10 mg loratadine oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in any intervention period.
45500244|NCT02237534|Drug|Lanthanum carbonate|
45500245|NCT02237534|Drug|Calcium Carbonate|
45500246|NCT03607214|Other|Placebo|"Placebo nasal spray~Film Sequence"
45500247|NCT03602456|Other|Kentucky HEALTH|KY HEALTH is the modified Medicaid program including key components such as community engagement requirements, premiums and lockouts, redetermination lockouts, and the My Rewards incentive program.
45500248|NCT03607136|Other|exercise training|Aerobic exercises, strengthening exercises, flexibility training for 60min, twice a week for 12 weeks
45500249|NCT03604328|Drug|PA5108|single ocular implant, administered on day 1
46056315|NCT02593747|Drug|Loratadine (Claritin peach syrup)|Subjects received a single oral dose of 10 mg loratadine claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in any intervention period.
46056316|NCT00735007|Drug|Rebif® New Formulation (RNF) using RebiSmartTM|RNF 44 mg, 3 times a week by subcutaneous injection.
46056317|NCT04089397|Device|Light Therapy|Five weeks of light therapy, with 3 weekly sessions of 30 minutes, to be performed between 8:00 to 10:00, the days of dialysis
46056318|NCT00743509|Drug|Cyclophosphamide and Sirolimus|"The dose of cyclophosphamide will start at 200 mg (4 tablets) per day on day 1 and will be taken for 7 days every other week of a 28 day cycle.~Subjects will take 12 mg (12 tablets) of sirolimus on day 1 of treatment as a loading dose followed by 4 mg (4 tablets) daily continuously"
46056319|NCT04089319|Other|Music recording|Participants will listen to music for 45 minutes while they rest with acupuncture needles in place.
46056320|NCT04089319|Other|Mindfulness recording|Participants will listen to a recording of mindfulness for 15 minutes and then listen to music for 30 minutes while they rest with acupuncture needles in place.
46056321|NCT02595697|Behavioral|J-EMT for Toddlers with Autism|Children assigned to the J-EMT group will receive a total of 48, 1-hour direct intervention sessions over six months that will include teaching their parents to implement J-EMT procedures across daily activities.
46056322|NCT00917605|Other|Robot-assisted therapy|Patients will receive an intervention for 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The Robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany), will be used in this project. The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension (Hesse et al., 2003; Hesse et al., 2005). Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. Mode 3 is an active mode as in 2, but the paretic arm had to overcome an individually set, initially isometric resistance to allow the bilateral movement. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually.
46056323|NCT00734929|Drug|Aprepitant + Dexamethasone|Aprepitant 40 mg + Dexamethasone 10 mg
46056324|NCT00734929|Drug|Ondansetron + Dexamethasone|Ondansetron 4 mg + Dexamethasone 10 mg
46056325|NCT00734851|Drug|Docetaxel|Docetaxel 70 mg/m2 day 1 every 3 weeks for 4 cycles with prednisone 5 mg orally twice daily
46056326|NCT00734851|Drug|Sunitinib|Sunitinib 37.5 mg orally once daily for 14 days followed by 7 days off, for 4 cycles, concurrent with docetaxel and prednisone
45386037|NCT00393939|Drug|Taxotere|Docetaxel 100 mg/m2 every 3 weeks in the comparator arm
45386038|NCT00488982|Drug|Docetaxel|Docetaxel 75mg/m2 every 21 days
45386039|NCT00488982|Drug|Docetaxel and GM-CSF|Docetaxel 75mg/m2 every 21 days and GM-CSF 250mcg/m2 SQ days 15-28
45386040|NCT00488826|Biological|7-valent pneumococcal conjugate vaccine|
45386041|NCT00488826|Biological|Diptheria and tetanus toxoids and accelular pertussis vaccine (DTaP)|
45386042|NCT01017354|Drug|Hidroferol® (ES)|24000 IU vitamin D3 orally and once per month plus 300 mcg 25(OH)D orally and once per month
45386043|NCT01017354|Dietary Supplement|ViDe3 (CH)|60000 vitamin D3 orally and once per month
45386044|NCT01017354|Dietary Supplement|ViDe3 (CH)|24000 Vitamin D3 orally and once per month
45386045|NCT00393861|Drug|Bevacizumab and Oxaliplatin|Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes
45386046|NCT01020240|Behavioral|Avolition|- avolition for cesarean discomforts
45386047|NCT01020240|Behavioral|Orientation|"avolition of cesarean discomfort~physiotherapy orientation"
46056327|NCT00734851|Radiation|EBXRT|External beam radiotherapy to the prostate bed, started on day 100, after completion of chemotherapy. 66 Gy over 6-7 weeks.
45500250|NCT03606902|Procedure|Group f : Epidural catheter insertion|Infiltrate the skin with local anesthetic lidocaine approximately 1 cm lateral to the inferior aspect of the targeted spinous process , epidural needle tip is midline at the junction of the lamina and spinous process . The needle is withdrawn and advanced with the same medial angle but in small increments cephalad to the same depth. Either bone or ligamentum flavum is contacted. If bone is contacted, the needle is redirected cephalad and advanced. If bone is no longer contacted and the depth exceeds the depth previously noted, the epidural needle stilette is removed. loss-of-resistance syringe is attached to the needle Once attained, stabilize the epidural needle and thread the catheter. Secure the catheter using a sterile locking device and adherent dressings.
46056328|NCT02597413|Procedure|Catheterization|Women in this group will be systematically catheterized before leaving the delivery room.
45500251|NCT03606902|Drug|Group F: Continous epidural infusion of bupivacaine plus fentanyl|Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg /Kg Fentanyl initial bolus, then from the 1st hour continuous epidural infusion of 0.0625% bupivacaine with µ/Kg/h Fentanyl fixed for the next 5 hour during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
46056329|NCT00734617|Drug|Nicotine Patch|"Groups 1 & 3 1-21mg Nicotine patch and 1-placebo for 2 wks pre quit day and 4 wks post quit day~Groups 2 & 4 2-21mg Nicotine Patches for 2 wks pre quit day and 4 wks post quit day"
46056330|NCT00743431|Drug|Caelyx (Pegylated Lyposomal Doxorubicin)|Pegylated Lyposomal Doxorubicin, 50 mg/m2 every 4 weeks for 6 cycles.
45500252|NCT03606902|Drug|Group LF :Continous epidural infusion of decreasing doses of fentanyl plus pubivacaine|Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then continuous IV infusion of 0.0625%bupivacaine with 1 µg/Kg/h Fentanyl for the 1st hour then continuous epidural infusion of 0.0625%bupivacaine with 0.5 µg/Kg/h Fentanyl during the 2nd hour, then 0.0625%bupivacaine with 0.25 µ g/Kg/h Fentanyl for the 3rd hour then continue the same infusion volume and dose (0.0625%bupivacaine with 0.25Mg/Kg/h Fentanyl) for the next 3 hours during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
46056331|NCT05380453|Biological|Secukinumab 300 mg, s.c.|Secukinumab will be administered at a dose of 300 mg as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
46056332|NCT05380453|Drug|Placebo to match Secukinumab, s.c.|Placebo will be administered as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
46056333|NCT02737839|Other|Stepping On Education Program|
46056334|NCT02737839|Other|Home visit|
45715062|NCT02653768|Behavioral|Stepped Exercise Program|"STEP 1: Participants have access to an internet-based exercise program for knee OA.~STEP 2: Participants have access to an internet-based exercise program for knee OA plus telephone support.~STEP 3: Participants have access to an internet-based exercise program for knee OA plus in-person physical therapy visit"
45715063|NCT02653768|Behavioral|Arthritis Education|The arthritis education intervention will include bi-weekly mailings of low-literacy educational materials on a comprehensive set of topics related to OA and its management, based on established treatment guidelines.
45715064|NCT05746494|Device|tDCS|active anodal tDCS and sham tDCS
46056335|NCT02737839|Other|Patient Questionnaire|-Includes questions about demographics, activity level, performance status, falls, medication, comorbidities, hearing, vision, pain, and neuropathy
46056336|NCT02737839|Other|Mini-Balance Evaluation Systems Test|"The Mini-BESTest includes 14-items that assess balance across four domains: 1) anticipatory postural adjustments, 2) reactive postural responses, 3) sensory orientation, and 4) stability in gait. Each item is rated on a 0-2 scale with 0 indicating poor balance and 2 indicating no impairment. The total possible score on the Mini-BESTest is 28 points~Balance testing will take approximately 15 minutes."
46056337|NCT02737839|Other|GAITRite|"Gait will be assessed using the 4.87-m GAITRite~The GAITRite is a computerized mat that allows for measurement of spatiotemporal measures (e.g., gait velocity, stride length) of gait. We will measure gait in the following conditions: 1) comfortable forward, 2) fast-as-possible, and 3) dual-task. For comfortable forward, participants will be asked to walk at their self-perceived normal pace. For fast-as-possible, participants will be asked to walk as quickly and safely as possible. For dual-task, participants will be asked to walk at their comfortable pace forward while saying as many words that begin with a letter given to them just prior to the start of the trial. Participants will complete five trials of each condition. Gait testing will take approximately 15 minutes."
46056338|NCT02737839|Other|Precise measure of movement testing|We will conduct additional movement-based testing with participants wearing small, portable sensors (APDM, Inc., Portland, OR). These sensors allow for precise measurement of movement characteristics. The sensors will be worn on the outside of clothing and will be placed on the following body locations: 1) sternum, 2) low back, 3) right wrist, 4) left wrist, 5) right ankle, and 6) left ankle. The participants will wear these sensors during the following movement tasks: 1) Two Minute Walk Test, 2) Timed Up & Go, 3) Dual Timed Up & Go, 4) Stand and Walk (SAW), and 5) 360 Degree Turn test. These sensors will allow for capture of precise measures postural sway, arm swing, gait variability, and many other variables the proposed movement tasks.
46056339|NCT02737605|Drug|Intranasal Esketamine|Participants will receive 84 mg intranasal esketamine as 3 devices, each with 28 mg esketamine.
46056340|NCT02737605|Drug|Intravenous Esketamine|Participants will receive 0.8 milligram per kilogram body weight esketamine, 40 minutes, intravenous infusion.
46056341|NCT02737605|Drug|Moxifloxacin|Participants will receive 400 mg Moxifloxacin orally.
46056342|NCT02737605|Drug|Oral Placebo|Participants will receive matching placebo orally.
46056343|NCT02737605|Drug|Intravenous Placebo|Participants will receive placebo 40 minutes, intravenous infusion.
46056344|NCT02737605|Drug|Intranasal Placebo|Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).
46056345|NCT02737371|Drug|F901318 Dose level A oral|Adverse events days 1-10
46056346|NCT02737371|Drug|Placebo dose level A oral|Placebo adverse events days 1-10
46056347|NCT02737371|Drug|F901318 Dose level B oral|F901318 adverse events days 1-10
46056348|NCT02737371|Drug|Placebo dose level B oral|Placebo adverse events days 1-10
46056349|NCT02737371|Drug|F901318 Dose level C oral|F901318 adverse events days 1-10
45695595|NCT04374292|Behavioral|Family intervention|"Topics covered in each session with intervention group mothers.~Dietary and physical activity habits and their link to obesity and cardio-metabolic diseases. Children learn about healthy eating habits and health risks at home.~Food-preparation processes. Selecting and purchasing food and beverages; importance of food groups and their impact on health; importance of fruit and vegetables. Balance between food groups, source of foods, organic or industrialized. Family menu preparation.~Habits and behaviors surrounding eating processes identified as health or risk factors, such as energy density, portion-size control, controlling emotional eating.~Beverages. Water versus sugar-sweetened drinks prepared at home or purchased at the store.~Preventing the risk of cardiovascular diseases by learning healthy eating habits and practicing these habits at home.~Integration. Practicing the skills learned during the intervention in each stage of preparing food and eating"
45695596|NCT04374292|Other|Usual nutritional consultation|Control group mothers and children (n = 87) were given the usual nutritional consultation and were prescribed diets that covered their energy requirements according to their age and sex. CG mother/child pairs received information regarding food groups and portion sizes, were trained in the use of the food equivalence system to encourage variation, and were instructed on how to prepare the diet at home.
46056350|NCT02737371|Drug|Placebo Dose level C oral|Placebo adverse events days 1-10
46056351|NCT02737527|Procedure|24G intravenous route for Lumbar Sympathetic Block (LSB):|Enrolled subjects enter the operative room with a 24G intravenous route, and then non-invasive blood pressure and pulse oxygen saturation level are continuously monitored during and after the procedure.
46056352|NCT02737527|Device|15-cm Chiba needle for Lumbar Sympathetic Block (LSB)|The skin entry point is infiltrated using 1% lidocaine. A curved 21 G, 15-cm Chiba needle (Cook Inc., Bloomington, IN, USA) is then advanced toward the anterolateral edge of target vertebral body by posterolateral approach in patients with prone position.
46056353|NCT02737527|Device|Ultrasound for Lumbar Sympathetic Block (LSB)|Using Ultrasound, the L3 is identified by locating the lumbosacral junction on a paramedian sagittal scan and then counting cranially. After marking the level of L3 vertebra, the modified transverse scan through lumbar intertransverse space (ITS) is obtained with the transducer positioned 4-6 cm lateral to the mid-line at the L2-L3 intervertebral level. The needle is inserted from a lateral to medial direction using in-plane technique. The needle tip is inserted towards the anterior fascia of the psoas major muscle as close as paravertebral space.
46056354|NCT02737527|Device|Fluoroscope for Lumbar Sympathetic Block (LSB)|Briefly, fluoroscopic guided LSBs are performed at the lower third of the L2 or the upper third of the L3 vertebra. A targeted lumbar vertebral is identified by AP fluoroscopic imaging and the fluoroscopic C-arm is adjusted 25-35° laterally to avoid the transverse process over the needle pathway. After the skin infiltration, the needle is advanced toward the anterolateral edge of the target lumbar vertebra under fluoroscopic guidance using the tunnel vision technique.
46056355|NCT02737527|Drug|10 ml of 0.25% levobupivacaine injection for LSB|After excluding vascular injection with contrast media by a C-arm image intensifier on anteroposterior (AP) and lateral view, 10 ml of 0.25% levobupivacaine is injected through the Chiba needle.
46056356|NCT02737527|Procedure|Temperature measurement for Lumbar Sympathetic Block (LSB)|Temperature monitoring and measurement: skin-surface temperatures are monitored with small, adhesive thermocouple probes attached bilaterally to the plantar surface of the feet using transparent patches at 1-min intervals for a maximum of 20 min.
46056357|NCT02737527|Procedure|Postprocedure care for LSB|Adverse events such as genitofemoral nerve block, lumbar plexus block (transient unilateral leg weakness), or others are documented during and after the procedure for 30 min.
46056358|NCT00734539|Drug|fluconazole|6mg/kg IV/PO twice weekly for a total of up to 12-13 doses
46056359|NCT00734539|Drug|placebo|normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for a total of up to 12-13 doses
46056360|NCT02737137|Procedure|Manual measurement|Monitoring by ultrasound, Neurostimulation and Measurement Manual of the injection pressure of the local anesthetic
46056361|NCT02737137|Procedure|Measurement with a gauge|Monitoring by ultrasound, Neurostimulation and measurement with a gauge of the pressure of injection of the local anesthetic
46056362|NCT02737059|Drug|Naloxegol|25mg daily
46056363|NCT02737059|Drug|Codeine|30mg 4 times daily
45386048|NCT01020240|Behavioral|Guide|"avolition of cesarean discomfort~physiotherapy orientation~guide orientation"
45386049|NCT03993639|Drug|Pegfilgrastim|Single dose of SC administration
45386050|NCT04941222|Other|"With robotic seal PARO"|The PARO robot will be made available to the patient by the caregiver in charge of the patient for 5mn before a toilet and during the duration of the care (about 10mn), at the frequency of twice a week for 16 weeks
46056364|NCT02737059|Drug|codeine placebo|4 times daily (placebo will be made to match the codeine)
46056365|NCT02737059|Drug|naloxegol placebo|placebo will match naloxegol, given daily
46056366|NCT00743275|Biological|Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)|0.5 mL, intramuscular
46056367|NCT02735889|Other|No Carbonation|500 ml of beverage consisting of water + 10% glucose and no carbonation
46056368|NCT02735889|Other|Low carbonation|500 ml of beverage consisting of water + 10% glucose and low carbonation
45500253|NCT03606902|Procedure|Group L f : Epidural catheter insertion|Infiltrate the skin with local anesthetic lidocaine approximately 1 cm lateral to the inferior aspect of the targeted spinous process , epidural needle tip is midline at the junction of the lamina and spinous process . The needle is withdrawn and advanced with the same medial angle but in small increments cephalad to the same depth. Either bone or ligamentum flavum is contacted. If bone is contacted, the needle is redirected cephalad and advanced. If bone is no longer contacted and the depth exceeds the depth previously noted, the epidural needle stilette is removed. loss-of-resistance syringe is attached to the needle Once attained, stabilize the epidural needle and thread the catheter. Secure the catheter using a sterile locking device and adherent dressings.
45500254|NCT03604250|Dietary Supplement|Lifestyle plus prebiotic supplement|Research participants will be asked to wear health monitoring devices, including a continuous glucose and heart-rate monitors. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
45500255|NCT03604094|Procedure|Ultrasonographic evaluation|Right internal jugular vein will be evaluated with ultrasound for anatomical variations and dimensions
45500256|NCT03602378|Diagnostic Test|salivary cortisol|5 samples of saliva (first sample before around 22:00 and other samples the next morning, after awakening (00, 15, 30 and 60 minutes).
45695597|NCT05289063|Drug|Atorvastatin 10mg|Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
45695598|NCT05289063|Drug|Placebo|Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
46056369|NCT02735889|Other|High carbonation|500 ml of beverage consisting of water + 10% glucose and high carbonation
46056370|NCT02731911|Drug|dexamethasone intravitreal implant|Ozurdex® treatment for diabetic macular oedema as per standard of care in clinical practice.
46056371|NCT02731677|Other|Acupuncture|Acupuncture was applied on the acupoints F3 - BP6- VB34- IG4 - TA5 - C7 - PC6 - IG11 - VB20 - XIAOCHANXUE, once a week, eight sessions in the experimental group.
46056372|NCT02731599|Procedure|treadmill training with cues|20-minutes treadmill training per day, 6 times a week, for 4 weeks. Treadmill speed was previously set at 2.0 km/h and progressively increased until a maximum of 3.5 km/h, taking always into account the patients' physical abilities. All patients were evaluated at the enrolment and at the end of the 4-weeks treatment. The first evaluation consisted in one-minute walking on treadmill without the use of cues at 1.5 km/h speed, for all patients. The outcome measurements were: the average length of the right step, the average length of the left step, the coefficient of variance of both steps, and the gait cycle.
46056373|NCT00734149|Drug|Bortezomib|
46056374|NCT00734149|Drug|Melphalan|
46056375|NCT00734149|Drug|Prednisone|
45386051|NCT01040559|Drug|idarubicin|Transarterial chemoembolization (in the hepatic artery) with idarubicin 5mg or 10 mg or 15 mg or 20 mg or 25 mg injected in a solution of 2ml DC Bead (300 µm-500µm); 1 unique course
45386052|NCT03996954|Device|Alivecor recording|Alivecor recording and ECG recording from the same patient in very close temporal proximity
46056376|NCT05461677|Device|SAIRE smart walker|Participants will walk along the 10-meter walkway 5 times using the SAIRE smart walker
46056377|NCT05461677|Device|Standard 4-wheeled walker|Participants will walk along the 10-meter walkway 5 times using a standard 4-wheeled walker
46056378|NCT05461677|Other|No walking aid|Participants will walk along the 10-meter walkway 5 times without using a walking aid
46056379|NCT02731365|Device|Activa PC+S|The Activa PC+S is a newly developed Medtronic DBS implantable system and is available for use in clinical research. This system has a mechanism for both sensing of LFP and the ability to provide deep brain stimulation therapy. The sensing capabilities are controllable with data management using a clinician sensing tablet programmer that has a USB extension allowing for telemetry to an encrypted, locked computer.
46056380|NCT04089163|Biological|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal drug, flucytosine (5-fluorocytosine; 5-FC) to the anticancer drug 5-fluorouracil (5-FU) in cancer cells that have been infected by the Toca 511 vector.
46056381|NCT04089163|Drug|Toca FC (extended-release formulation of flucytosine)|Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
46056382|NCT02731443|Procedure|Epilepsy surgery|Epilepsy surgery is a procedure that removes an area of the brain where seizures originate.
46056383|NCT02731443|Procedure|Depth electrodes insertion|Depth electrodes are inserted for monitoring/mapping the subsurface levels of the brain for the surgical treatment of epilepsy.
45386053|NCT01020396|Drug|Metronidazole|Vaginal Gel, 0.75%
45386054|NCT01020396|Drug|Metronidazole|Vaginal Gel, 0.75%
45386055|NCT01014702|Device|LensAR Laser System|Use of laser for capsulotomy and lens fragmentation
45386056|NCT01014702|Device|Conventional phacoemulsification|Use of standard techniques for capsulotomy and lens fragmentation
45386057|NCT00480324|Biological|Rotarix|Two-dose oral vaccination.
45386058|NCT00480324|Biological|Placebo|Two-dose oral administration.
46056384|NCT00743197|Drug|Aspirin|Aspirin 81 mg daily
46056385|NCT00743197|Drug|Lisinopril|Lisinopril 10 mg every night
46056386|NCT00743197|Drug|Simvastatin|Simvastatin 20 mg every night
46056387|NCT00743197|Drug|Lovaza|Lovaza 1 gram daily
46056388|NCT00743197|Behavioral|Therapeutic Lifestyle Changes|Therapeutic lifestyle changes will be initiated with the assistance of a dietician, including diet counseling, exercise recommendation, and weight maintenance/weight loss.
46056389|NCT02731287|Drug|Timolol|The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
46056390|NCT02731287|Drug|Placebo|The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
46056391|NCT02595385|Device|Cell Salvage|Reinfusion of shed blood during the operation
45386059|NCT00488592|Biological|WT1:126-134|"Subjects were given 6 doses of PR1:169-177 in Montanide adjuvant and 6 doses of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals."
45386060|NCT00488592|Biological|PR1:169-177 Peptide|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
45386061|NCT00488592|Drug|GM-CSF (Sargramostim)|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
45386062|NCT00488592|Biological|Montanide adjuvant|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
45386063|NCT04244760|Behavioral|Pain assessment for verbal patients|The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical and thermal), and psychological state via the completion of questionnaires by the patient.
45386064|NCT04244760|Behavioral|Pain assessment for non-verbal patients|The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical), and psychological state via the completion of questionnaires by the parent of the patient.
45386065|NCT00488514|Drug|Combination Tablet of Treximet (sumatriptan/naproxen sodium)|Combination Tablet of Treximet(sumatriptan/naproxen sodium)
46056392|NCT02595385|Procedure|Retrograde Autologous Prime|Removal of fluid from the bypass circuit
46056393|NCT02731209|Device|urinary catheter|
46056394|NCT02735499|Drug|onabotulinum toxin A|Onabotulinum toxin A is installed into the bladder and EMDA (Electromotive Drug Application) is applied for 30 minutes
46056395|NCT02735733|Device|Cold Bakri Balloon|In the room temperature arm, the bakri balloon will be inserted through the vagina and placed inside the uterus and filled with room temperature saline. In the cold arm, the same intervention will performed, however, the bakri balloon will be filled with cold saline at 32 degrees Fahrenheit.
46056396|NCT02735655|Other|Physician's opinion|To get physician's opinion about the current global state of gastrointestinal endoscopy training programs and to identify the unmet needs and how to improve it through a web based questionnaire.
46056397|NCT02735343|Drug|Compazine|Compazine 10mg with diphenhydramine 25 mg IV
46056398|NCT02735343|Drug|Ketamine|Ketamine 0.3 mg/kg along with ondansetron 4 mg IV
46056399|NCT02730975|Drug|AA Reduced dose-normal diet (A)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined normal diet, described with specific caloric and fat content.
46056400|NCT02730975|Drug|AA reduced dose-fat diet (B)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined fat diet, described with specific caloric and fat content.
46056401|NCT02730975|Drug|AA normal dose-fasting conditions (C)|Cycles of 28 days length of AA at approved doses (1000 mg) administered in fasting conditions.
46056402|NCT00734071|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
46056403|NCT00734071|Drug|Placebo|Vortioxetine placebo-matching capsules
46056404|NCT02735265|Behavioral|Virtual reality|12 training sessions (90 minutes a time, 2 times a week) IG:45 minute of Kinect for Xbox games and 45 minute of standard treatment.
45386066|NCT00320710|Drug|Zoledronic acid|4mg IV
45500257|NCT03602378|Device|Holter Medilog AR12 Plus|Holter Medilog AR12 Plus - electrocardiogram during 5 minutes for measuring HRV
45695599|NCT05289063|Other|Continuous Positive Airway Pressure Therapy|CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP.
45695600|NCT04374526|Biological|COVID-19 Convalescent Plasma|ABO matched pathogen-inactivated CCP is transfused at a dose of 200 ml/day for 3 days (days 1, 2, and 3).
45695601|NCT05284305|Other|Pregnancy|DT with a history of concomitant or subsequent pregnancy.
45695602|NCT04374058|Other|less-frequency hemodialysis|Patients of treatment group would be evaluated quarterly
45695603|NCT02590809|Drug|Treatment BX1514M|X mg x 3 /day of BX1514M for 15 days. Dosage will be then adapted, depending on symptoms release and walk distance test results for another 15 days period.
45695604|NCT02590809|Drug|Placebo|Placebo will be given for 30 days
45695605|NCT02590809|Other|Walk distance test|Walk distance test during 6 minutes
45695606|NCT02590809|Other|Exercise echocardiography|
45695607|NCT01709318|Drug|Nomegestrol acetate (NOMAC)|Daily release of 500, 700, or 900 μg.
45695608|NCT01709318|Drug|Etonogestrel (ENG)|Daily release of 75, 100, 120 or 125 μg
45386067|NCT00320710|Drug|Placebo|Placebo to zoledronic acid
45386068|NCT00320398|Drug|Fondaparinux|
45386069|NCT00498186|Drug|Rotigotine|"Rotigotine transdermal patches once daily:~2.5cm2 (0.5mg/24 hours) 5cm2 (1mg/24 hours) 10cm2 (2mg/24 hours) 15cm2 (3mg/24 hours) 20cm2 (4mg/24 hours)"
45386070|NCT01017510|Device|Subcutaneous injection luer syringe|"Right scalp: Luer syringe.~Left scalp: syringe without a needle.~All injections will contain 0.1 ml of Depo Medrol - Methylprednisolone acetate 40 mg/2 ml.~The distance between injection locations will be 1 cm."
45386071|NCT01017510|Device|DERMOJET (a syringe without a needle)|"Right scalp: Luer syringe.~Left scalp: syringe without a needle.~All injections will contain 0.1 ml of Depo Medrol - Methylprednisolone acetate 40 mg/2 ml.~The distance between injection locations will be 1 cm."
45500258|NCT03602378|Device|Polar V800|Polar V800 with sensor - during 5 minutes for measuring HRV
45500259|NCT03602378|Device|AGE reader|for measuring Advanced Glycation End products (AGEs)
45500260|NCT03602300|Drug|Ravidasvir test formulation produced by Doppel|"To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions."
45500261|NCT03602300|Drug|Ravidasvir reference formulation produced by EEPI|"To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions."
45500262|NCT03606824|Drug|Pitavastatin and placebo|The initial dosage of pitavastatin is 2mg, and it will be regulated according to the level of LDL-C and the upper limit is 4mg.Since the investigators are blind to the arms,the fake regulation of placebo dosage will be same as the Pitavastatin and levothyroxine group.
45500263|NCT03606824|Drug|Pitavastatin and levothyroxine|The initial dosage of pitavastatin is 2mg and the initial dosage of levothyroxine is 12.5ug. The dosage of levothyroxine will be regulated according to thyroid function test every 2-3 weeks. The regulation of pitavastatin dosage is same as the monotherapy group.
45695609|NCT01709318|Drug|Ethinyl estradiol (EE)|Daily release of 15 μg
45695610|NCT01709318|Drug|Estradiol (E2)|Daily release of 300 μg
45695611|NCT02243254|Drug|high dose remifentanil|high dose remifentanil
45695612|NCT02243254|Drug|Ibuprofen|intravenous ibuprofen
45695613|NCT02243254|Drug|low dose remifentanil|low dose remifentanil
45695614|NCT03402880|Biological|Pembrolizumab|Given IV
45695615|NCT03402880|Drug|Epacadostat|Given PO
45386072|NCT00333970|Behavioral|cognitive remediation|individual cognitive training
45695616|NCT03402880|Other|Laboratory Biomarker Analysis|Correlative studies
45695617|NCT01673763|Device|Stent insertion into the main pancreatic duct|Stent insertion into the main pancreatic duct
45695618|NCT03402802|Drug|monitoring of adherence with medication|persons taking routine postoperative eye drops will have their frequency of drop taking monitored
45695619|NCT01673841|Procedure|Relative and absolute cerebral oxygen saturation (rScO2) measurements.|
45695620|NCT03402724|Other|echographic|Patients are called for an echographic evaluation in the implanting center in case of the usual care
46056405|NCT02735265|Behavioral|Standard treatment|CG: 90 minute of standard treatment. 12 training sessions (90 minutes a time, 2 times a week)
46056406|NCT02730897|Procedure|Central/Peripheral|Central versus peripheral location of the primary tumor
46056407|NCT03255915|Drug|Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)|TDF-FTC pod-IVR designed to deliver TDF at a target rate of 1 mg d-1 and FTC at a target rate of 2 mg d-1.
46056408|NCT03255915|Other|Placebo|A placebo pod-IVR containing microcrystalline cellulose pods.
45386073|NCT01017588|Device|PSU lumbar back support|wear PSU back supprt during doing rubber tapper
45500264|NCT03602222|Behavioral|Mobile web training LGBT mental health|Mobile web training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in a the mobile fashion (on the web).
45500265|NCT03602222|Behavioral|In-person training LGBT mental health|In-person training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in-person.
45500266|NCT03604016|Drug|Besifovir dipivoxil|Besifovir dipivoxil 150 mg
45386074|NCT03984526|Drug|normal saline|intravenous normal saline pretreatment at the onset of dexmedetomidine infusion
45386075|NCT03984526|Drug|atropine 0.5mg|intravenous atropine 0.5mg pretreatment at the onset of dexmedetomidine infusion
45386076|NCT03984526|Drug|ephedrine 8mg|intravenous ephedrine 8mg pretreatment at the onset of dexmedetomidine infusion
45386077|NCT01017666|Drug|BIIB014|BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d
45386078|NCT01017666|Drug|Placebo|Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d
46056409|NCT04109469|Device|Shark Screw® transplant|Application of a Shark Screw® transplant for osteosynthesis or arthrodesis in hand- or foot surgery
45386079|NCT03984370|Drug|ZP4207|Abdominal SC administration
45386080|NCT03984370|Other|Placebo (saline)|Abdominal SC administration
45386081|NCT01017744|Device|Anesthetic Conserving Device|"Ventilation in PSV with the Anesthetic Conserving Device with remifentanil~Ventilation in PSV with the Anesthetic Conserving Device with sevoflurane"
45500267|NCT03604016|Drug|L-carnitine|Besifovir dipivoxil 150 mg
45500268|NCT03604016|Drug|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg
45386082|NCT03984292|Procedure|Teaching of laparoscopic skills on a box simulator|The students shall be trained a laparoscopic simulator for a variable duration and the outcome shall be compared.
45500269|NCT03219333|Drug|Enfortumab vedotin|Intravenous (IV) infusion on days 1, 8 and 15 every 28 days
45500270|NCT03168867|Behavioral|The 3Ms Intervention|The 3 Ms is a brief e-health intervention delivered via an internet-based software application (CIAS) that incorporates principles of Motivational Interviewing. The goal of the 3 Ms intervention is to increase caregiver motivation to supervise children's daily diabetes care. The intervention consists of 3 brief sessions that are delivered at routine diabetes clinic appointments.
45500271|NCT01064622|Drug|vismodegib|Given PO
45500272|NCT01064622|Drug|gemcitabine hydrochloride|Given IV
45500273|NCT01064622|Other|hydrocortisone/placebo|Given PO
45386083|NCT01064596|Other|blood samples|patients with a fondaparinux treatment who have 4 blood samples during the 10 days following surgery
45386084|NCT03980392|Other|Multidomain intervention program|Multidomain intervention program for physical exercise, cognitive training, nutrition, vascular and metabolic risk controls, and motivation
45386085|NCT03980236|Device|Livongo-Insulia Study App|Throughout the study, participants will be asked to use the LIvongo-Insulia Study App daily to receive their basal insulin dose recommendation. Participants will need to check their before breakfast blood glucose using their Livongo meter. Then, they will need to open the Livongo-Insulia Study App and accept the uploaded blood glucose(s) from the Livongo meter. Once the appropriate information is received, participants will receive an insulin dose recommendation and should confirm once the dose has been taken. Depending on their blood glucose, participants may also receive coaching messages and coaching support from the Livongo program.
45386086|NCT00477594|Drug|mipomersen sodium|200 mg/ml, in 1 ml solution for subcutaneous injection.
45386087|NCT00475722|Behavioral|1 Healthy Eating|6 months telephone counseling
45386088|NCT00475722|Behavioral|2 Mediterranean|6 months telephone counseling
45386089|NCT00304954|Drug|Intravenous Daclizumab|Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
45386090|NCT00304954|Drug|Intravenous Infliximab|Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
45386091|NCT00304954|Other|Observation|Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.
45386092|NCT00304954|Drug|Oral Rapamycin|Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
45386093|NCT00475176|Drug|Peginterferon alfa-2a|
45386094|NCT00475176|Drug|Ribavirin|
45386095|NCT00475176|Drug|S-adenosyl methionine for Chronic Liver Disease|
45386096|NCT01062022|Behavioral|Standard of Care|Families randomized to this arm will receive the standard of care. They will be compared to the families in the FOCUS-CI arm of the study.
45386097|NCT01062022|Behavioral|FOCUS-CI|Families randomized to this arm of the study will be part of a family skill-building/resiliency training program designed to provide information and skills training
45386098|NCT01064674|Other|diagnostic procedure|Cardiovascular diagnostic standard procedure before renal transplantation using stress echocardiography and stress myocardial scintigraphy.
46056410|NCT02731053|Behavioral|Blues program|Participants will attend 6 weekly 1-hour sessions of group cognitive-behavioral therapy administered by school staff, and will do home practice between sessions and after the program individually using a web site (called the Blues App)
45386099|NCT01062100|Device|nuclear breast imaging using MBI Gamma camera|nuclear breast imaging using MBI Gamma camera in addition to MRI
45386100|NCT00414609|Drug|Aliskiren|Aliskiren was available in 75 mg tablet, 150 mg tablet
45386101|NCT00414609|Drug|placebo|Placebo tablets matching aliskiren for 36 weeks once daily in the morning for core period only.
45386102|NCT00393705|Drug|Insulin Biphasic Aspart 30/70|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
45386103|NCT00393705|Drug|insulin lispro LM|Participant adjusted dose, injected subcutaneously for 16 weeks - possibility of using instead of insulin lispro MM before evening meal if there is a risk of hypoglycemia after the dinner or high fasting glucose levels.
45386104|NCT00393705|Drug|insulin lispro MM|Participant adjusted dose, three times per day, injected subcutaneously for 16 weeks
45386105|NCT00393705|Drug|insulin lispro LM|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
45386106|NCT00303628|Drug|oxaliplatin|Given IV
45386107|NCT00303628|Drug|fluorouracil|Given IV
45386108|NCT00303628|Drug|leucovorin calcium|Given IV
45386109|NCT00303628|Drug|bevacizumab|Given IV
45386110|NCT00414453|Drug|Lidocaine patch 5%|lidocaine 5% patch; 12 hours on, 12 hours off
45386111|NCT00414453|Drug|Extended-release oxycodone|extended-release oxycodone titrating schedule
45386112|NCT00414453|Drug|Placebo extended-release oxycodone pills|placebo pills with titrating schedule
45386113|NCT00414453|Drug|Placebo lidocaine patches|used with extended release oxycodone group; used with placebo pills/placebo patches
45386114|NCT01040715|Biological|TNFa Kinoid|TNFa kinoid
45386115|NCT01040715|Biological|TNF kinoid|IM administration 2 or 3 injections within 28 days
45386116|NCT01037595|Drug|turmeric|turmeric 500 md tid orally for 8 weeks
45386117|NCT01037595|Drug|placebo|placebo 3 time orally for 8 weeks
45386118|NCT01037595|Drug|turmeric|500 mg tid orally for 8 weeks
45386119|NCT01037673|Procedure|Exercise program|A progressive program where load and complexity increases during a 3 month period. Initially PT-tutored every week and then every other week.
45386120|NCT01037673|Procedure|Movement exercises|A program with the same movements to maintain flexibility in the neck and shoulder. Initially PT-tutored every week and then every other week.
45386121|NCT01040949|Behavioral|couple-based counseling for smoking cessation plus self-help smoking cessation guide|Culturally sensitive couple-based counseling for smoking cessation plus self-help smoking cessation guide in Latino men with pregnant partners
45386122|NCT01040949|Behavioral|Guia -a self help smoking cessation guide|A culturally sensitive smoking cessation self help program for Latinos
45386123|NCT01041027|Drug|Paclitaxel|Given IV
45386124|NCT01041027|Drug|Carboplatin|Given IV
45386125|NCT01041027|Radiation|Internal Radiation Therapy|Undergo HDR brachytherapy
45386126|NCT01041027|Radiation|External Beam Radiation Therapy|Undergo EBRT
45386127|NCT01041027|Other|Laboratory Biomarker Analysis|Correlative studies
45386128|NCT00332488|Drug|Technosphere Insulin|Inhalation, 15U/30U, prandial
45386129|NCT00332488|Drug|Metformin & Secretagogues|Metformin tablets,Secretagogues supplied as any of the currently marketed brands and formulations.
45386130|NCT00332488|Drug|Technosphere Insulin & Metformin|Technosphere Insulin Inhalation Powder 15U/30U, Metformin tablets
45386131|NCT00332332|Biological|etanercept|etanercept subcutaneous injection
45386132|NCT00392925|Drug|pramlintide acetate 360 mcg|subcutaneous injection, twice a day, 360mcg
45386133|NCT00392925|Drug|metreleptin|subcutaneous injection, twice a day, 5mg
45386134|NCT00392925|Drug|placebo-pramlintide 600 uL|twice a day
45386135|NCT00392925|Drug|placebo-metreleptin 1 mL|twice a day
45386136|NCT00392925|Drug|Pramlintide acetate 180 mcg|subcutaneous injection twice a day, 180 mcg
45386137|NCT03979846|Other|Best Practice|Receive usual care
45386138|NCT03979846|Other|Computer Application|Use computer-based symptom reporting system
45386139|NCT03979846|Other|Questionnaire Administration|Ancillary studies
45386140|NCT03979846|Other|Quality-of-Life Assessment|Ancillary studies
45386141|NCT00474786|Drug|Sorafenib|Subjects randomized to arm B will take sorafenib 400 mg (2 x 200 mg tablets) PO, BID (total daily dose of 800 mg).
46056411|NCT02730741|Drug|Lcr restituo® sachet|symptomatic treatment of diarrhoea
46056412|NCT02730741|Drug|Placebo|
45386142|NCT00474786|Drug|temsirolimus (Torisel)|Subjects randomized to arm A will receive temsirolimus (Torisel) 25 mg via IV infusion once weekly. This infusion is to be administered over a 30-60 minute period. Subjects are to be pre-treated with 25-50 mg IV diphenhydramine (or comparable IV antihistamine) approximately 30 minutes before temsirolimus infusion.
45386143|NCT00392769|Drug|Cetuximab|Initial Dose = 400 mg/m^2 IV Over 120 Minutes, Followed by Weekly Infusions at 250 mg/m^2 IV Over 60 Minutes.
45386144|NCT03532893|Other|No intervention|This is a multi-center,observational, prospective, cohort study. A total of 10,000 subjects aged 40～75 without history of lung disease will be recruited and followed for 3 years. So there is no intervention in this study.
45386145|NCT01041183|Drug|intravenous ramosetron|0.3 mg IV ramosetron (group I)
45386146|NCT01041183|Drug|oral ramosetron|0.1 mg oral ramosetron (group II)
45386147|NCT01041183|Drug|oral and IV ramosetron|0.1 mg oral ramosetron plus 0.3 mg IV ramosetron (group III).
45386148|NCT01041261|Dietary Supplement|BariatrX Essentials 360 Treatment|Medical food
45386149|NCT03764943|Dietary Supplement|Impact Advanced Recovery|immunonutrition shake; nutritional supplement containing amino acids, omega-3 fatty acids, and nucleotides
45386150|NCT00319696|Drug|Bosentan 62.5 mg|Bosentan 62.5-mg oral tablets twice daily (b.i.d.) for 4 weeks (initial dose)
45386151|NCT00319696|Drug|Bosentan 125 mg|Bosentan 125-mg oral tablets administered b.i.d. (target dose)
45386152|NCT01037751|Behavioral|Interview|1-on-1 interview with study doctor or staff member, during regularly scheduled, standard of care clinic visit taking 30 minutes.
45386153|NCT01037751|Behavioral|Survey|Complete 3 Questionnaires during clinic visit, about 10 minutes to complete all.
45386154|NCT00474630|Drug|Naltrexone SR 32 mg/bupropion SR 360 mg/ day|
45386155|NCT00474630|Drug|Placebo|
45386156|NCT00474630|Behavioral|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
45386157|NCT01043835|Procedure|Laparoscopy-assisted gastrectomy|A 10-mm trocar for laparoscope was inserted below the umbilicus. Another 10-mm trocar was introduced in the left preaxillary line 2 cm below the costal margin as a major hand port，and a 5-mm trocar was placed at the contralateral site for traction. A 5-mm trocar was inserted in the left midclavicular line 2 cm above the umbilicus as an accessory port, and a 15-mm trocar also as an accessory port was placed at the contralateral site. The operator stood on the left side of the patient. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction. Dissected stomach and lymph node are collected through additional 5 cm incision at a median superior abdominal incision.
45386158|NCT01043835|Procedure|Open gastrectomy|Approximately 15~20 cm length incision is made from falciform process to periumbilical area. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction for all cases.
45386159|NCT01064752|Drug|Minocycline|100 mg po bid for 8 weeks
45386160|NCT01043913|Drug|Guarana extract|Guarana extract 50mg q12 hours for 21 days
45386161|NCT00392379|Drug|Nicotine Lozenges|Nicotine lozenges, 4 mg
45848305|NCT03444090|Procedure|Colon polypectomy|"For participants assigned into the experimental group, colon lumen is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both the insertion and withdrawal phases. Colon polyps with size <10 mm are removed as they are identified on insertion and withdrawal. Polyps with size >10 mm are removed only during withdrawal.~For participants assigned into the control group, deliberate inspection and polyp removal are performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum."
45386162|NCT00392379|Drug|Placebo lozenge|Placebo lozenge
45386163|NCT04450758|Procedure|Bridge to Surgery (stent or stoma)|The study is an observational study and patients will not be randomized. Resection is defined as upfront surgical resection, Bridge to Surgery as a two stage procedure.
45386164|NCT01037829|Other|Non-intervention observational study|Non-intervention observational study
45386165|NCT01020552|Other|Provision of PAC job aids and provider training on the use of the job aids|Facility-level intervention applied to all study facilities
45386166|NCT01038063|Drug|Artemether-lumefantrine combination|
45386167|NCT00497874|Behavioral|Computer-tailored intervention|Stage-based manual and three computer-tailored reports
45386168|NCT01043991|Drug|Darbepoetin alfa|
45386169|NCT01043991|Drug|Placebo|
45386170|NCT01044147|Behavioral|VLM-S|Online program for weight loss - standard
45386171|NCT01044147|Behavioral|VLM-M|Online program for weight loss - modulated
45386172|NCT01044147|Behavioral|OGR|Online program for weight loss - resources
45386173|NCT01020630|Drug|Sunitinib|Sunitinib will be orally administered at 25 mg once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
45386174|NCT01020630|Drug|Placebo|Placebo will be orally administered once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
45386175|NCT00403455|Drug|Paroxetine|SSRI
45386176|NCT04923282|Biological|single 1-hour IV infusion of 0.8 mg/kg recAP|Intravenous infusion
45386177|NCT04923282|Biological|single 1-hour IV infusion of 1.6 mg/kg recAP|Intravenous infusion
46056413|NCT04188951|Drug|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|Patients will receive 17 cycles of pembrolizumab via IV infusion of 200 mg over a period of 30 minutes, every 3 weeks starting no later than 90 days from the date of salvage head and neck therapy.
45386178|NCT04923282|Biological|single 1-hour IV infusion of 3.2 mg/kg recAP|Intravenous infusion
45386179|NCT04923282|Biological|1-hour infusions of 1.6 mg/kg recAP on Days 1, 2 and 3|Intravenous infusion
45386180|NCT04923282|Biological|Placebo|Intravenous infusion
45386181|NCT00318370|Drug|Farletuzumab|Weekly Farletuzumab infusions Dose dependent on dosing group
45386182|NCT00318370|Drug|Chemo Plus Far|Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
45386183|NCT03996408|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
46056414|NCT02730585|Biological|C-reactive protein measurement|All patients included in this study underwent a blood sample analysis for C-reactive protein concentrations at admission and 3 hours later.
45386184|NCT03996408|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
45386185|NCT01064908|Device|OxyMask|Novel vortex oxygen delivery mask
45386186|NCT00510068|Drug|Everolimus|A 10-mg dose of everolimus was given by continuous oral daily dosing of two 5-mg tablets.
45386187|NCT00510068|Drug|Everolimus Placebo|a 10-mg dose of matching placebo to Everolimus was given by continuous oral daily dosing of two 5-mg tablets.
45386188|NCT00509600|Drug|Etanercept|0.8 mg/kg Subcutaneously Once A Week for 90 Days
45386189|NCT04485728|Behavioral|Sleep Improvement Protocol Intervention for Hospitalized Antepartum Patients|Patients are getting sleep hygiene education and a sleep hygiene kit.
45386190|NCT04485026|Radiation|Local consolidative radiation therapy|All local consolidative radiation therapy should be delivered using hypofractionated local consolidative radiation therapy (>2 Gy per fraction). Exceptions may be approved on a case by case basis by the trial principal investigator. Three-dimensional conformal radiotherapy (3D-CRT), intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), and proton beam therapy (PBT) are all acceptable.
45386191|NCT04485026|Drug|Standard of care radiation therapy|Standard of care palliative radiotherapy to symptomatic lesions is permissible. The dose to symptomatic lesions should not exceed 30 Gy in 10 fractions. Brain metastases will be treated with standard of care CNS therapy throughout the study. This may include (but is not limited to) stereotactic radiosurgery, neurosurgical intervention, whole brain radiotherapy
45386192|NCT01014026|Other|Screening test|Two Vaginal self sampling devices and HPV test
45386193|NCT01014104|Drug|Methylprednisolone|Administration of Methylprednisolone
46056415|NCT00739297|Drug|Comparator: montelukast|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
46056416|NCT00739297|Drug|Comparator: placebo|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
46056417|NCT05430243|Drug|Empagliflozin 10 MG|once daily empagliflozin 10mg+/- diuretics
46056418|NCT05430243|Drug|Diuretics|diuretics as clinically indicated
46056419|NCT02730117|Device|Dialysis with continuous renal replacement therapy|Continuous renal replacement therapy is a form of 24-hour dialysis in the ICU
46056420|NCT02730117|Device|Mechanical ventilator|Invasive or noninvasive form of respiratory support
46056421|NCT02730117|Drug|Anti-Bacterial Agents|Antibacterial agents deemed appropriate by physicians in the ICU
46056422|NCT02730117|Drug|Vasopressors|Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
46056423|NCT05423223|Device|Paraffin Bath Therapy|Device named 'Fizyowax 1300' (Fizyomed, Turkey).
46056424|NCT05423223|Device|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
46056425|NCT02595619|Device|RRT plus ECCO2R|Patients with acute kidney injury will be treated with Renal replacement therapy associated to extracorporeal carbon dioxide removal in a single treatment
45386194|NCT01014104|Drug|Control|Normal salin injection
45386195|NCT00402987|Drug|Celecoxib|dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
45386196|NCT00402987|Drug|Celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo
45386197|NCT00402987|Drug|celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
45386198|NCT00402987|Drug|placebo|dose 1 placebo followed 6-12 hours later by dose 2 placebo
45386199|NCT01015664|Drug|temsirolimus|10, 15, or 25 mg IV over 30 minutes on Days 1, 8, 15 and 22
45386200|NCT01015664|Drug|cisplatin|75 mg/m2 IV over 60 minutes on day 1
45500274|NCT01376895|Behavioral|PROJECT POWER|POWER is a three session intervention to help Black men who have sex with men and women lead healthier lives, make informed sexual choices and reduce their chances of getting or giving HIV to their sex partners. Interventions are designed to be delivered via the internet in real time by a trained health educator. Each session will last between 1 and 2 hours. The sessions are grounded on the social learning theory and use cognitive behavioral approaches. Participants learn the multiple influences on their behavior, how to identify their triggers and then use problem solving skills to develop a safer strategy for life. The sessions use videos and games to teach the lessons; participants are also given work that they must complete between the sessions.
45500275|NCT01376895|Behavioral|Power Health|Power Health is a one session intervention designed to help Black men who have sex with men and women improve their general health. It focuses on health issues (including HIV) that affect Black men. The program consists of 1 session delivered via the internet in real time by a trained health educator and last approximately 2 hours
46056426|NCT02595463|Drug|Lidocaine|Intraoperative dose of intravenous lidocaine followed by an infusion until discharge from the initial recovery period.
45500276|NCT01380405|Behavioral|education intervention|"Individual or collective education interventions about the correct use of inhalers.~session in the management of inhalers in the collective or individual programmed.~Session individual: 2 session. 15 min for session. Session collective: 2 session. 30-40 min for session. Maximum 4 persons."
45500277|NCT04850391|Other|Mobile app|To compare changes induced by the movile app intervention among the three study groups
46056427|NCT02595463|Drug|Saline|Intraoperative dose of saline followed by an infusion until discharge from the initial recovery period.
46056428|NCT02730273|Device|Trial Nasal mask|Nasal mask for the treatment of obstructive sleep apnea (OSA)
45386201|NCT01015664|Drug|cetuximab|400 mg m2 on Day 1 of Cycle 1, then 250 mg/m2 IV over 60 minutes on Days 1, 8, 15, and 22
45386202|NCT01010594|Behavioral|dietary treatment|A standard dietary treatment except that they are advised to restrict their fruit intake.
45500278|NCT04163718|Drug|Umbralisib|800 mg Umbralisib will be self-administered on an outpatient basis. Umbralisib will be taken orally once daily within 30 minutes of a meal until removal from study. This treatment will be administered in 4 week (28-day) cycles.
45500279|NCT04171635|Radiation|Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI)|Investigators will validate hepatic QSM (hQSM) using histological examination and chemical measurement of liver iron concentration (LIC). Patients will undergo clinical MRI in Aim 1. In patients with increased LIC their liver explants will undergo MRI, pathological examination, and chemical determination of the LIC.
45500280|NCT04171635|Radiation|R2* Magnetic Resonance Imaging (MRI)|Investigators will be able to validate hQSM in measuring liver iron concentration (LIC) by comparing it to this traditional MRI technique
45386203|NCT01010594|Behavioral|dietary treatment|A standard dietary treatment.
45386204|NCT01015742|Drug|Stem cell Transplantation|"Busulfan: 3.2 mg/kg IV daily on days -7 to -4~Cyclophosphamide : 60 mg/m² daily on days -3 to -2~Rabbit Thymoglobulin 2.5mg/kg IV daily on days -3 to -2~Cyclosporin will begin on day -2 (IV or oral) for at least 180 days. Target trough level for cyclosporin is 200 ng/ml. In the absence of GVHD, Cyclosporin tapering will begin on day +90~Methyl prednisolone (1mg/kg/d IV) will begin on day -2 to +7 and then 0.5mg/kg until +14 posttransplant."
45386205|NCT00501644|Drug|Carboplatin|AUC of 5 by 1 hour IV infusion every 28 days.
45386206|NCT00501644|Drug|GM-CSF (Sargramostim)|Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy.
45386207|NCT00501644|Drug|Interferon Gamma|0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle).
45500281|NCT01378689|Other|Storytelling online video|patients with a history of chronic glucocorticoids use tell their experiences of side effects resulting from chronic use and provide advice on ways to prevent side effects
45500282|NCT03630549|Other|Standard of Care|Clinic-based HIV care
45500283|NCT03630549|Other|Village-based ART refill|Option to get ART refill and care by the village health worker
45500284|NCT04153539|Behavioral|Walking along a busy road|The intervention group will walk along a busy road and be exposed to traffic-related air pollution for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
45500285|NCT04153539|Behavioral|Walking in a traffic-free park|The control group will walk in a traffic-free park for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
46056429|NCT02593669|Procedure|Phacomulsification lens removal cataract surgery with neutral Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with neutral IOL.implantation
46056430|NCT02593669|Procedure|Phacomulsification lens removal cataract surgery with blue-blocking Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with blue-blocking IOL.implantation.
46056431|NCT02593669|Drug|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
46056432|NCT02593669|Drug|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells.
46056433|NCT02729961|Drug|Brentuximab Vedotin|Given IV
45386208|NCT03997214|Device|inspiratory muscle strength training|The experimental group received the intervention of inspiratory muscles training 5times/week for 6 weeks, 5days/ per cycle; the patients stayed in the semi-recumbent position, recorded the initial/first measurement of MIP. The trigger sensitivity was adjusted to 10% of the first recorded MIP at the start of training, then reducing the ventilator trigger sensitivity and training duration weekly.
45386209|NCT01014260|Drug|Placebo|This is a randomized double-blind clinical trial of doxycycline 20 mg bid versus 100mg bid versus placebo, given for 3 months, to be conducted at a single center (JHH).
45386210|NCT01014260|Drug|Doxycycline|Doxycycline 20 mg bid versus Doxycycline 100 mg bid versus placebo
45386211|NCT01010672|Drug|Ridaforolimus|Ridaforolimus, oral tablet, 40 mg once daily for 5 consecutive days followed by 2-day dosing holiday each week. Participants treated until discontinuation criteria, such as progressive disease or unacceptable toxicity, were met.
45386212|NCT01014338|Drug|Fosinopril|10mg od
46056434|NCT02729961|Drug|Ceritinib|Given PO
45386213|NCT01014338|Other|lactose|placebo
45386214|NCT01014416|Drug|Tolvaptan 15mg or 30mg or 60mg or Placebo|Single dose of Tolvaptan 15mg or 30mg or 60mg or Placebo per day
45386215|NCT00497796|Drug|maribavir|100mg twice a day for 14 weeks.
46056435|NCT02729961|Other|Laboratory Biomarker Analysis|Correlative studies
46056436|NCT02729961|Other|Pharmacological Study|Correlative studies
46056437|NCT02735031|Drug|Exenatide|6 weeks treatment with exenatide on top of insulin treatment
46056438|NCT02735031|Drug|Placebo|6 weeks treatment with placebo on top of insulin treatment
45386216|NCT00497796|Drug|ganciclovir|1000mg three times per day for 14 weeks.
45386217|NCT01017822|Biological|conatumumab|
45695621|NCT04548596|Diagnostic Test|Transcranial Doppler|"In this study, the investigators will primarily use the monitor mode of the Transcranial Doppler (TCD, non-invasive FDA approved device) to record cerebral blood flow velocity (CBFV) signals from the Middle Cerebral Artery and Internal Carotid Artery. TCD data and intracranial pressure (ICP) data will be collected in the following four scenarios. Each recording is up to 60 minutes in length:~External ventricular drain (EVD) closed to drainage for a 24 hour period as part of the EVD weaning protocol per standard of care (SOC): The Initial reading will be done within 4 hours of EVD closing. The second reading will be done within 4 hours of anticipated removal of EVD.~EVD closed most of the time and opened to drainage when the ICP becomes elevated per SOC~EVD with Intra-Parenchymal fiber optical ICP sensor per SOC~Intra-Parenchymal fiber optical ICP sensor per SOC"
45695622|NCT04374214|Procedure|Complete Pulpotomy using Mineral Trioxide Aggregate|Inflammed coronal pulp tissue will be removed till the canal orifices and mineral trioxide aggregate placed over the amputated pulp stump.
45695623|NCT04374214|Procedure|Complete Pulpotomy using Simvastain -alphatricalcium phosphate|Inflammed coronal pulp tissue will be removed till the canal orifices and Simvastatin -alpha tricalcium phosphate placed over the amputated pulp stump.
45695624|NCT03153345|Device|bedside respiratory muscle training|The program consisted of three sessions: (1) 10 minutes of breath stacking exercise, followed by (2) 10 minutes of inspiratory muscle training using a flow-oriented incentive spirometer and (3) 10 minutes of expiratory muscle training using Acapella vibratory PEP device.
45695625|NCT03153345|Behavioral|conventional stroke rehabilitation program|The program consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training.
45695626|NCT01673997|Drug|Metoprolol Succinate|Metoprolol Succinate ER Tablets 200 mg
45386218|NCT01017822|Drug|capecitabine|
45386219|NCT01017822|Drug|gemcitabine hydrochloride|
45386220|NCT01017822|Radiation|3-dimensional conformal radiation therapy|
45386221|NCT04449822|Procedure|Emergency surgery|Surgical decompression with colostomy with or without resection and eventual re-anastomosis.
45386222|NCT04449822|Procedure|Colonic stenting|The colonic stent placement to relieve the colonic obstruction.
45386223|NCT00496782|Drug|maraviroc|Treatment-experienced subjects on failed therapy, with HIV RNA ≥ 1000 copies/mL, are eligible who will receive a tropism assay at screening (Day -14 to 0). Subjects who are eligible will receive maraviroc added to a failing regimen from Day 1 to 14. On day 15, subjects will discontinue the current treatment regimen and begin a new OBT. Subjects with only R5 HIV will continue receiving maraviroc plus OBT. Subjects with non-R5 virus will discontinue receiving maraviroc but continue to receive the new OBT. Investigator selects OBT based on results of phenotype/genotype testing at baseline. The nominal dose for maraviroc is 300 mg BID. The maraviroc dose should be adjusted based on OBT patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
45386224|NCT00496782|Procedure|Trofile Assay and HIV RNA quantification assay|Trofile Assay and HIV RNA quantification assay
45386225|NCT01017900|Procedure|local excision|surgical excision by orthopaedic surgeon under local anesthesia
46056439|NCT02595541|Drug|milrinone|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study.
45695627|NCT04373824|Drug|Ivermectin|Ivermectin 200 to 400 mcg per kg body weight
46056440|NCT02595541|Drug|Sildenafil|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study. After baseline measurements, sildenafil (1mg/kg) administered in ICU via a nasogastric tube, to be repeated every 4 hours via a nasogastric tube or orally. Sildnafil is presented in tablet form which was dissolved in water to make a concentration of 1 mg/ml.
46056441|NCT03433911|Device|FemBloc|Treatment with FemBloc for women who desire permanent birth control (female sterilization)
46056442|NCT03433911|Procedure|Laparoscopic bilateral tubal sterilization|Laparoscopic bilateral tubal sterilization for women who desire permanent birth control (female sterilization)
46056443|NCT05548491|Drug|AZR-MD-001 ointment/semi-solid drug|ointment/semi-solid drug
46056444|NCT00739063|Drug|Tarceva|Tarceva (erlotinib hydrochloride) given alone, at 150 mg by mouth daily.
46056445|NCT01026194|Drug|Placebo / Teneli (Teneligliptin) + pio (pioglitazone)|Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
45386226|NCT01020708|Drug|mesalamine|4.0g mesalamine rectal suspension, rectally administered enema, 60ml volume, 4.0g mesalamine, once daily
45386227|NCT01020708|Drug|ALTH12-1:4|ALTH12-1:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 1.0g N-acetylcysteine
45386228|NCT01020708|Drug|ALTH12-2:4|ALTH12-2:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 2.0g N-acetylcysteine
45386229|NCT01020864|Drug|Cetuximab|Cetuximab 500 mg/m² i.v. day 1, every 2nd week
45386230|NCT01020864|Drug|Carboplatin|Carboplatin AUC = 3 i.v. day 1, every 21nd week
46056446|NCT01026194|Drug|Teneli / Teneli + pio|Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
45386231|NCT01020864|Drug|Vinorelbine|Vinorelbine 25 mg/m² i.v. day 1, every 2nd week
45386232|NCT01020942|Procedure|Electroacupuncture stimulation|According to the theory of traditional Chinese medicine, bilateral Neiguan (PC 6) acupoints were chosen and identified according to traditional anatomical localizations. Once insertion of original needles was made at the acupoints, the needle was stimulated electrically with the intensity of 2-6 mA and frequency of 2/30 Hz using the Electronic Acupuncture Treatment Instrument until the patient felt the so-called 'Teh Chi' sensation of heaviness, numbness and swelling. The pretreatment was individualized based on patients sex, age, weight and felt and given 1 time per day for 5 consecutive days before the heart valve replacement surgery．
45386233|NCT01020942|Procedure|No intervention|The control patients were only placed needles at the bilateral Neiguan (PC 6)acupoints without electric stimulus.
45386234|NCT01017978|Procedure|MRI Scan of soft tissue tumor|MRI scan will be completed at baseline (prior to start of subject's clinically ordered chemotherapy treatments.
45386235|NCT00402831|Biological|ProQuad®|Each dose (0.5 mL) contains live attenuated versions of measles virus Enders' Edmonston strain, mumps virus Jeryl Lynn™ (Level B) strain, rubella virus Wistar RA 27/3 strain, and varicella virus Oka/Merck strain.
45386236|NCT04428372|Drug|Mannitol|Hypertonic mannitol infusion
45386237|NCT04428372|Drug|0.9% saline|Normal saline 'placebo' arm
45386238|NCT03996642|Behavioral|Avatar Life Review|VoicingHan will screen-capture patient's storytelling performances as video files. Immediately before the first intervention, patients will complete an array of self-reported questionnaires to assess physical, spiritual, and psychological well-being and elicit relevant demographic and medical information. The assessments include the ESAS, FACIT-Sp subscale, and EORTC PAL 15. Subsequent administration of these questionnaires spaced 2-4 weeks apart will occur before each avatar session (pre-intervention). This will determine if intensity of the patient's symptoms have changed over the course of the intervention. Following completion of the Avatar session, a member of the research team will conduct a semi-structured, open-ended interview to assess patients' perception of intervention components and identify possible factors influencing intervention feasibility and any technical barriers.
45386239|NCT01038141|Procedure|Surgery for advanced haemorrhoidal disease|Milligan Morgan vs Recto Anal Repair
45386240|NCT03993561|Other|Treatment summary and survivorship care plan|Individually tailored counselling session will be implemented within 1 month of treatment completion.
45386241|NCT01014858|Drug|Donepezil|5mg donepezil daily for first 8 weeks and then increased to 10mg daily for the remainder of the study.
46056447|NCT03374553|Device|MINI DO636|"MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach.~For MINIject 636, there are 2 types of Delivery Tools available to implant and position the CS636 implant.~Both types of Delivery Tools are being studied in this amended study: Dual Operator Delivery Tool (DODT) and Single Operator Delivery Tool (SODT).~DODT is used in the first arm (cohort 1 - MINI DO636), SODT is used in the second arm (cohort 2 - MINI SO636)."
46056448|NCT03374553|Device|MINI SO636|"MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach.~For MINIject 636, there are 2 types of Delivery Tools available to implant and position the CS636 implant.~Both types of Delivery Tools are being studied in this amended study: Dual Operator Delivery Tool (DODT) and Single Operator Delivery Tool (SODT).~DODT is used in the first arm (cohort 1 - MINI DO636), SODT is used in the second arm (cohort 2 - MINI SO636)."
46056449|NCT02593513|Device|Daifert|
45386242|NCT00496626|Biological|Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)|Human Papillomavirus (Type 6, 11, 16, 18) Recombinant Vaccine (Gardasil®), 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
45386243|NCT00496626|Biological|Comparator: Placebo|aluminum-contained, 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
45386244|NCT01018212|Other|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the lesions auto administration three times a day during four months, being controlled by the specialist in months consultations.~The dose of 0,1 ml of cream for each cm. of surface, To the patient will be explained the technique of the application."
45386245|NCT01015014|Drug|AN3365|LP, 600 mg vial; reconstituted in Normal Saline
45386246|NCT01015014|Drug|Placebo|0.9% sodium chloride for injection
45386247|NCT04052958|Device|IMT - inspiratory muscle training|respiratory strength or indurance training with respiratory therapy device
45386248|NCT00471276|Drug|sunitinib|sunitinib (Sutent), 37.5 mg, daily dosing
45695628|NCT01676571|Drug|Lu AA21004|10 mg immediate-release (IR), one single dose, orally
45386249|NCT00470262|Drug|Fenofibrate 145mg PO QD|Subjects will be randomized to either fenofibrates or combination of both fenofibrate and pioglitazone
45695629|NCT04373980|Device|phototherapy|estimate CD4 and CD8 subsets in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
46056450|NCT02593513|Procedure|Control Group|Control - Morphological Assessment
46056451|NCT02734875|Other|Intervention|The intervention arm offers primary care providers additional information on patient risks and benefits as well as an offer of assistance with managing a patient's anticoagulation from a respected service at BWH.
45386250|NCT00470262|Drug|Pioglitazone 45 mg PO QD|Subjects will be randomized to either fenofibrate 145 mg PO QD or a combination of both fenofibrate 145 mg PO QD and pioglitazone 45 mg PO QD
45386251|NCT04034862|Drug|Treatment simplification (dolutegravir lamivudine)|Switch from 3 drug regimen (DTG/ABC/3TC) to 2 drug regimen
45386252|NCT00496470|Drug|Symbicort (budesonide/formoterol turbuhaler 320/9ug)|Symbicort (budesonide/formoterol turbuhaler 320/9ug)
45386253|NCT00496470|Drug|Spiriva (tiotropium bromide 18ug)|Spiriva (tiotropium bromide 18ug)
45386254|NCT01021176|Other|Placebo spray|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray yet no drug will be administered
45386255|NCT01021176|Drug|Diltiazem|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray Three Dilutions would be 5.5, 6.0 and 6.3 and the fourth at the filp of a coin randomly diluted.
45386256|NCT00496080|Device|Doppler-Guided Uterine Artery Occlusion Device (DUAO)|Investigational transvaginal clamp inserted one time for 6 hours.
45386257|NCT01018368|Drug|VX-770|In Period 1, subjects will receive a single oral dose of VX-770 150 mg on Day 1. In Period 2, subjects will receive a single oral dose of VX-770 150 mg on Day 6.
45386258|NCT01018368|Drug|Rifampin|In Period 2, subjects will receive a daily oral dose of rifampin 600 mg on Days 1 through 10
45386259|NCT00487578|Drug|naratriptan HCl|naratriptan 2.5mg tablet bid x 30 days OR matching placebo
45386260|NCT00495612|Drug|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
45386261|NCT00495612|Drug|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
45386262|NCT01021488|Drug|Rosuvastatin 20mg/d for 14days|Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
45500286|NCT01063764|Drug|Levetiracetam|"First Period: Dry syrup 50 %, 20 mg/kg/day or 1000 mg/day, 40 mg/kg/day or 2000 mg/day, 60 mg/kg/day or 3000 mg/day, twice daily administration Per Os (PO) for 14 weeks.~Second Period: Dry syrup 50 % or tablets (250 mg and 500 mg strengths), 20 to 60 mg/kg/day or 1000 to 3000 mg/day, twice daily administration Per Os (PO) until indication granted."
45695630|NCT01699178|Drug|Oral testosterone undecanoate|Total daily dose of T = 200 mg T (as 316 mg TU) to 600 mg T (as 948 mg TU), taken as 100 mg to 300 mg T BID
45695631|NCT01699178|Drug|Transdermal testosterone gel (AndroGel)|Total daily dose of T = 2.5 to 10 g of gel (25 mg to 100 mg T) QD
45848306|NCT03448068|Drug|Ketamine|"Ketamine 0.3 mg/kg (IBW) bolus with induction. Ketamine infusion 0.2mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~Ketamine infusion not titrated."
45386263|NCT01021488|Drug|enoxaparin only|enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
45386264|NCT00487188|Drug|Enfuvirtide|90 mg subcutaneous injection twice a day
45386265|NCT00487188|Drug|Highly active antiretroviral treatment (HAART)|An oral HAART regimen of 3-5 antiretrovirals was chosen by the physician and patient, based on the patient's prior treatment history and genotypic antiretroviral resistance testing.
45386266|NCT00509366|Drug|Cisplatin & Gemcitabine|"Squamous Cell NSCLC:~Gemcitabine 1250 mg/m2 IV over 30 minutes day 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
45386267|NCT00509366|Drug|Cisplatin & Pemetrexed|"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
45386268|NCT00509366|Drug|Docetaxel & Gemcitabine|"Squamous Cell NSCLC:~Docetaxel 75 mg/m2 IV over 60 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
45386269|NCT00509366|Drug|Pemetrexed & Gemcitabine|"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
45386270|NCT01015898|Radiation|photodynamic therapy|treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
45386271|NCT03997682|Other|Hands-Up Program|In addition to the usual care, being allocated to the intervention group would require the participant to attend an exercise and education program once their cast has been removed and they've restored some strength and function in their hand and wrist. The exercise portion of the intervention will focus on strength and balance training, with aspects of managing our distal radius fracture healing as well. The education will focus on learning about risk factors for a distal radius fracture, osteoporosis, exercise for adults, nutrition for adults and falls prevention strategies.
45386272|NCT01016054|Biological|AGS-8M4|IV infusion
45386273|NCT01016054|Drug|Pegylated liposomal doxorubicin (PLD)|IV infusion
45386274|NCT01016054|Drug|gemcitabine|IV infusion
45386275|NCT01016054|Drug|carboplatin|IV infusion
45386276|NCT00500318|Drug|Aclidinium Bromide|Aclidinium Bromide, 200μg. Once daily oral inhalation.
45386277|NCT00500318|Drug|Placebo|Dose matched placebo, once daily oral inhalation.
45386278|NCT00508820|Biological|Romiplostim|Romiplostim will be administered subcutaneously QW. Romiplostim will be manufactured and packaged and distributed using Amgen's clinical study investigational product distribution procedures. Romiplostim is presented as a lyophilized, white powder in 5.0 mL glass vials.
45386279|NCT00499694|Biological|bevacizumab|10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)
45386280|NCT00499694|Drug|satraplatin|80 mg/m(2), Orally, Days 1-5, every 35 days
45386281|NCT01014494|Device|Adaprev|Class III Medical Device
45386282|NCT00486954|Drug|Lapatinib|6 pills at 250 mg each once daily
45386283|NCT00486954|Drug|Paclitaxel|Infusion at 80 mg/m2 weekly
45386284|NCT00494676|Device|High power (57 prism diopter) peripheral prism glasses|All patients will wear two pairs of prism glasses in a crossover design: the high power peripheral prism glasses and sham peripheral prism glasses. Each pair of prism glasses will be worn for four weeks
45386285|NCT00494676|Device|Low power sham peripheral prism glasses|Low power (5 prism dioptre) prism glasses that provide only about 2 degrees of visual field expansion.
45386286|NCT04197180|Procedure|Hybrid Argon Plasma Coagulation|Argon Plasma Coagulation after water injection for local ablation
45386287|NCT00486720|Drug|vorinostat|vorinostat 400 mg by mouth (P.O.) capsules once daily (q.d.). Treatment in 21 day cycles for up to 8 cycles.
45386288|NCT00486720|Drug|vorinostat|vorinostat 200 mg by mouth (P.O.) capsules three times daily (t.i.d.). Treatment in 21 day cycles for up to 8 cycles.
45386289|NCT00486330|Drug|Buprenorphine, Tipranavir and ritonavir|After determining buprenorphine/naloxone pharmacokinetics over a 24-hour period, tipranavir/ritonavir and buprenorphine/naloxone will be coadministered for 7 days.
45386290|NCT04010682|Other|urine sample collection|no drug/devise intervention. sample collection study only
45386291|NCT01021566|Device|Combined hemoperfusion-hemodialysis|Combined hemoperfusion-hemodialysis for opiate detoxification for 3 days
45386292|NCT01021566|Drug|Methadone|On admission all patients will undergo a 3-day stabilization period. Then they will begin the 10-day methadone treatment regimen. The starting dose of methadone is determined by the mean daily dose requirement during the stabilization period and the dose will be reduced to zero at a linear rate over the 10 days treatment.
45500287|NCT04117815|Device|Paxman Scalp Cooling System|"All patients who accomplish inclusion criteria and do not exhibit any contraindication undergo scalp cooling with the following conditions:~Minimum 30 minutes pre-infusion cooling~Cooling for the duration of chemotherapy infusion~Minimum 90 minutes post-infusion cooling Scalp cooling is performed within the study group at each CT session."
45695632|NCT02243332|Device|KneeStim mobile rehabilitation assistance device|KneeStim is a neuromuscular electrical stimulation (NMES) device that integrates motion-tracking hardware like three-axis accelerometers and a real-time operating system to enable quadriceps muscle stimulation in time with user gait. It is a completely non-invasive device that looks like a light brace and fastens to the user's quadriceps and gastrocnemius muscles. The end goal of this device is to assist with muscle re-strengthening and re-education during a user's everyday activities.
45695633|NCT02285439|Drug|MEK162|• MEK162 is currently supplied as film-coated tablets in dose strength of 15 mg. The film-coated tablets consist of MEK162 drug substance, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and a commercial film coating. The original tablets are yellow to dark yellow capsule-shaped
45386293|NCT01021644|Behavioral|aerobic exercise-training|3 times per week for 6 months
45386294|NCT01021644|Behavioral|stretch exercise|3 times per week for 6 months
45386295|NCT01021722|Procedure|modified suture technique|Both internal and external anal sphincter was sutured separately end to end
45386296|NCT00486252|Other|Observational|This is a non-interventional study. Subgroups of naïve patients and patients with previous failure to beta-blockers therapy were analyzed.
45386297|NCT00494442|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
45386298|NCT00494442|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
45386299|NCT01021800|Biological|MIS|Cell infusion
45386300|NCT03851016|Behavioral|Life Story Book|Life story Book is intended to allow a person the opportunity to reminisce chronologically through their life and capture their life stories into a book.
45386301|NCT03851016|Behavioral|Usual Care|Three weeks of Usual Care with no visits from research team
45386302|NCT00493974|Drug|Zileuton|Zyflo tablets, 600 mg, 4 times a day
45386303|NCT00493974|Drug|Placebo|Placebo 4 x daily
45500288|NCT04117815|Other|Alopecia Assessments|"Patients (study group and reference group) will be assessed at the following time Points:~Baseline~at the half-way Point of the cyles~at the last CT cycle~3 months after completion of Treatment~6-9 months after treatment completion~The assesments include the following~Photographs of the head, which are evaluated using the CTCAEv4.0~Questionnaire including the NCI- PRO-CTCAE-ITEMS, EORTC QLQ-C30, EORTC QLQ-B23, Body Image Scale, PRO-CTACAEs and Hairdex questionnaire"
45848307|NCT03448068|Drug|Standard therapy|"Pre-op dexamethasone 4mg IV and midazolam 1-2mg IV Anesthesia Induction - Propofol 2-3mg/kg IV, Fentanyl 1mcg/kg IV, neuromuscular block w/succinylcholine and/or rocuronium, orotracheal intubation Anesthesia maintenance - Sevoflurane/rocuronium, fentanyl 0.5-1mcg/kg Anesthesia emergence - Acetaminophen 1g, ketorolac 30 mg IV, ondansetron 4mg IV, sugammadex 2mg/kg or 4 mg/kg dose depending on twitch Post-op anesthesia - Hydromorphone patient-controlled analgesia (PCA) 0.2 mg/8 min, acetaminophen 1 g IV Q8 around the clock (ATC) x 3 addl. doses, ketorolac 15 mg IV Q6 ATC x 3 addl. doses.~Other standard surgical post-op care"
45386304|NCT01018446|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
45386305|NCT01018524|Procedure|abdominal wall reconstruction|suture repair, mesh repair, onlay mesh reconstruction, sublay mesh reconstruction, recurrence rate
45386306|NCT01018602|Drug|vildagliptin|100 mg per day over 24 months
45386307|NCT01018602|Drug|inactive pill|1 pill per day over 24 months
45386308|NCT01018758|Drug|Palonosetron|Palonosetron will be given as an intravenous bolus at the dose of 250 micrograms over 30 seconds beginning 30 minutes before chemotherapy.
45386309|NCT00469092|Drug|biphasic insulin aspart|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
45386310|NCT00469092|Drug|insulin glargine|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
45386311|NCT00469092|Drug|metformin|Tablets, 2550 mcg. Administered once daily.
45386312|NCT00469092|Drug|glimepiride|Tablets 2 mg. 4, 6 or 8 mg administered once daily.
45386313|NCT03997110|Radiation|Short course palliative radiation.|Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.
45500289|NCT03073629|Diagnostic Test|Clinical Pathway|Patients will be evaluated and managed in a specialized cardiovascular clinic to determine the etiology of right heart failure and begin treatment.
45500290|NCT03652350|Procedure|CT-guided microwave ablation|Using thermal ablation electrode ECO-100AL6 probe target the GGN zone with the guidance performed by CT (Bright Speed Scanner )
45500291|NCT02880189|Device|Orbera Intragastric Balloon|The Orbera Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
45500292|NCT02880189|Procedure|Endoscopic Ultrasound Guided Core Liver Biopsy|
45500293|NCT04053972|Drug|Lenvatinib|oral lenvatinib after hepatectomy
45848308|NCT03453060|Drug|E-WE Thrombin- Dose 1|Participants received a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.
45848309|NCT03453060|Drug|E-WE Thrombin- Dose 2|Participants received a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.
45848310|NCT03453060|Drug|E-WE Thrombin- Dose 3|Participants received a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.
45848311|NCT03453060|Drug|E-WE Thrombin- Dose 4|Participants received a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.
45848312|NCT03453060|Other|Placebo|Participants received a single intravenous dose of placebo.
45848313|NCT03457116|Drug|Norco|20 tablets of Hydrocodone 5mg-Acetaminophen 325mg (Norco)
45848314|NCT03457116|Drug|NSAID|Ibuprofen 400mg for post-operative pain
45848315|NCT03459612|Drug|Lasmiditan|Administered orally
45848316|NCT03459612|Drug|Placebo|Administered orally
45848317|NCT03459612|Drug|Diphenhydramine|Administered orally
45848318|NCT03463512|Drug|Racecadotril plus ORS|Racecadotril plus ORS
45848319|NCT03463512|Drug|ORS|ORS
45848320|NCT03467412|Drug|FOL-005|intradermal injection
45848321|NCT03467412|Drug|Placebo|intradermal injection
45848322|NCT03468816|Device|Sensor activation (on DryMax Extra Soft)|Study profile of sensor activation
45848323|NCT03473184|Drug|Diacerein 1% ointment|Diacerein 1% ointment and vehicle ointment were applied on Day 1 at two randomly assigned skin sites on each side of the lower thoracic area of the back according to a randomization scheme. One side of the back was irradiated on Day 2, including an untreated irradiated control site, and the other side was to remain non-irradiated.
45848324|NCT03473886|Behavioral|Intervention arm: PP-MI|The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
45848325|NCT03475992|Device|Low-power microwave breast imaging system|Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump
45500294|NCT01380249|Drug|PDM08|To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12, 2.24, 3.5, 14, 28 and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or they are refractory to it.
45386314|NCT03997110|Radiation|Long course palliative treatment.|Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity
45386315|NCT00499616|Drug|carboplatin|Given IV
45386316|NCT00499616|Drug|cyclophosphamide|Given IV
45386317|NCT00499616|Drug|doxorubicin hydrochloride|Given IV
45386318|NCT00499616|Drug|etoposide|Given orally
45386319|NCT00499616|Drug|topotecan hydrochloride|Given IV
45386320|NCT00499616|Drug|Isotretinoin|Given orally
45386321|NCT00499616|Procedure|Surgery|With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.
45386322|NCT00499616|Drug|Filgrastim|Administered subcutaneously or by IV beginning 24-48 hrs after the last dose of chemotherapy & continuing daily until the ANC is greater than or equal to 1500 following the myelosuppressive nadir . Supportive care given to stimulate neutrophil recovery following chemotherapy and to shorten the duration of chemotherapy-induced neutropenia. On ANBL0531 the use of filgrastim was required for patients less than 60 days of age and was optional for other patients.
45500295|NCT04054518|Drug|Durvalumab|Durvalumab (MEDI4736) will be supplied as a 500-mg vial solution for infusion after dilution.
45500296|NCT01378611|Device|Vagus Nerve Stimulator: Neurocybernetic prothesis NCP, Cyberonics Inc., Webster, TX, USA|The study group is stimulated with the following parameters: Output current 0.25 milliampere (to be ramped up to max. 1.75 milliampere), Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off (duty cycle 10%).
45500297|NCT03652896|Procedure|anatomical liver resection|Liver resection is performed to achieve R0 resection for patients with appropriate BCLC staging, indocyanine green retention rate, Child-pugh grading and adequate liver remnant.
45386323|NCT01016210|Drug|Leuveris|IV
45500298|NCT04565847|Drug|Salbutamol 5mg/mL|Nebulized salbutamol given prior to Mannitol-Induced Cough Challenge
45848326|NCT03476850|Procedure|QL Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
45500299|NCT04565847|Drug|Sodium Chloride 0.9% Inhl 3Ml|Nebulized 0.9% saline given prior to Mannitol-Induced Cough Challenge
45500300|NCT03075891|Drug|Ivermectin 1% cream|Topical to the face, approximately one small pea size amount per facial region (right and left cheeks, forehead, chin, and nose) once a day for 12 weeks
45848327|NCT03476850|Procedure|TAP Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
45848328|NCT03477006|Biological|Whole blood|Low titer, group O, leukocyte reduced, platelet replete, cold stored whole blood
45848329|NCT03478254|Biological|Influenza vaccination|"Correct influenza vaccination status was considered in the following situation:~- Received at least one Influenza vaccine dose in the last year."
45386324|NCT01016210|Drug|Leuveris|All recruited women will be treated similarly employing the recombinant FSH and the fixed GnRH antagonist. Concomitantly, on the same day of the antagonist administration r-LH will be administered daily and continued until human chorionic gonadotropin (hCG) day.
45386325|NCT00402597|Drug|Rivaroxaban/Placebo|1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
45386326|NCT00402597|Drug|Placebo|1 placebo tablet twice daily for 6 months.
45386327|NCT00402597|Drug|Rivaroxaban|1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
45386328|NCT00402363|Drug|omega-3-acid ethyl esters|
45386329|NCT00402363|Drug|Placebo|
45386330|NCT00469014|Drug|Clofarabine|Day -6 to Day -3 for Arm 1 = 10 mg/m^2 intravenous (IV) Daily; Arm 2 = 20 mg/m^2 IV Daily; Arm 3 = 30 mg/m^2 IV Daily; Arm 4 = 40 mg/m^2 IV Daily
45386331|NCT00469014|Drug|Busulfan|"Day -6 to Day -3 for Arm 1: 30 mg/m^2 IV Daily; Arm 2: 20 mg/m^2 IV Daily; Arm 3: 10 mg/m^2 IV Daily; Arm 4: 40 mg/m^2 IV Daily.~Test dose Day -8 32 mg/ m^2 IV over 45 min, rest on Day -7."
45386332|NCT00469014|Drug|Fludarabine|Day -6 to Day -3 for Arm 1: 30 mg/m^2 IV Daily; Arm 2: 20 mg/m^2 IV Daily; Arm 3: 10 mg/m^2 IV Daily
45386333|NCT00469014|Other|Stem Cell Infusion|Day 0 stem cell infusion (Bone marrow or peripheral blood progenitor cells (PBPC))
45386334|NCT00469014|Drug|Thymoglobulin (ATG)|Day -3 to Day -1 at 0.5 mg/kg IV on Day -3; 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
45386335|NCT00469014|Drug|Filgrastim|Subcutaneous injection daily, starting 1 week after Stem Cell Transplant.
45386336|NCT00493038|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients will be administered daily a single moxifloxacin 400 mg tablet for 7 days
45386337|NCT00493038|Drug|Amoxicillin/Clavulanate|Patient will be administered daily Amoxicilline/Clavulanate 1000 mg tablets every 8 hours for 10 days
45386338|NCT01024998|Biological|AAV2-sFLT01|2 x 10^8 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
45386339|NCT01024998|Biological|AAV2-sFLT01|2 x 10^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
45386340|NCT01024998|Biological|AAV2-sFLT01|6 x 10^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
45386341|NCT01024998|Biological|AAV2-sFLT01|2 x 10^10 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
45500301|NCT03075891|Drug|Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules|1 Capsule once-daily for 12 weeks
45386342|NCT00392223|Drug|Azithromycin microspheres|Azithromycin microspheres, powder for oral suspension, 2 g a week, in unique administration PO, repeated weekly for 8 weeks and minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
45386343|NCT00392223|Drug|minocycline-placebo capsules|minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
45386344|NCT00392223|Drug|Azithromycin microspheres-placebo|Minocycline capsules, PO, 100 mg daily for 8 weeks and Azithromycin microspheres-placebo once a week for 8 weeks plus azithromycin placebo.
45386345|NCT00392223|Drug|Minocycline capsules,|Capsules, PO, 100 mg daily for 8 weeks.
45386346|NCT00402285|Dietary Supplement|lycopene supplement|
45386347|NCT00402285|Dietary Supplement|fish oil supplement|
45386348|NCT00402285|Other|Placebo|placebos for lycopene and fish oil.
45386349|NCT01038375|Behavioral|lifestyle counseling, home blood pressure monitoring|monthly telephone counseling over 6 months for intervention group no health provider initiated contact for control group
45386350|NCT03747159|Drug|Belimumab Injection|Weekly injection of belimumab prior to two infusions of rituximab with continuation of the belimumab as maintenance therapy
46056452|NCT04300712|Behavioral|Questionnaires at the start and end of the school year|Interventions will be proposed to children identified in a worrisome situation. The Strengths and Difficulties. Questionnaire will be used by teachers to score these situations. The recognition process of mental health problem and need continue with responses. Responses are supporting a graduated response process in school and facilitating external support when needed (mental health services, community supports). Early intervention is one of all responses, which involve caregivers. Responses to worrisome situations aim to improve schooling conditions, to acknowledge mental health problems or condition and the health services need for children. To evaluate the intervention, the impact supplement of SDQ and the follow-up questions will be used by the teachers and the parents of children who benefit of the intervention. The interventions will be experimented during year 2020-21. Children might benefit of them from several weeks to one year, according to their need.
46056453|NCT05416593|Behavioral|General exercise prescription (FITT)|The (1) control group (FITT) will receive a preexercise evaluation and 3 individualized training sessions based on the ACSM and FITT principles (ACSM, 2021). These are the procedures commonly used for apparently healthy individuals that start to exercise in health clubs.
45386351|NCT01324479|Drug|INC280|
45386352|NCT00413283|Biological|Romiplostim|Romiplostim is a thrombopoiesis recombinant protein that targets the thrombopoietin (TPO) receptor which results in increased platelet production.
45386353|NCT00413283|Drug|Placebo|Placebo subcutaneous injection.
45386354|NCT00413283|Drug|Gemcitabine|Intravenous infusion
45386355|NCT00413283|Drug|Carboplatin|Intravenous infusion
45386356|NCT00413283|Drug|Cisplatin|Intravenous infusion
45386357|NCT00402051|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
45386358|NCT00402051|Drug|Cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
45386359|NCT00402051|Drug|Carboplatin|Area under the concentration curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
45386360|NCT00468858|Other|Placebo|"Lyophilized, single dose vials and sterile water for~> injection; 0.5 mL dose; Vaccination schedule: 0, 6 months"
45386361|NCT00468858|Biological|T-DEN-Post-Transfection F17|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
45386362|NCT00468858|Biological|T-DEN-Post-Transfection F19|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
45386363|NCT00401973|Drug|olanzapine|5-20 milligrams (mg), oral, daily for 22 weeks.
45386364|NCT00401973|Drug|amantadine|Amantadine, 100 milligrams (mg), oral, 1 twice a day (BID). Patients who gained greater than 3 kilograms (kg) will switch to metformin. Patients who gained greater than 3 kg after switching to metformin will be switched to zonisamide.
45386365|NCT00401973|Drug|metformin|Metformin, 500 mg, oral, twice a day (BID) for 2 weeks titrated to 500mg three times a day (TID) thereafter. Patients who gain greater than 3 kilograms (kg) will be switched to amantadine. Patients who gained greater than 3 kg after switching to amantadine will be switched to zonisamide.
45386366|NCT00401973|Drug|zonisamide|Zonisamide, 100-400mg, oral, daily.
45386367|NCT00401973|Behavioral|Wellness education|weight management
45386368|NCT01038453|Dietary Supplement|Cholecalciferol 35 µg per day|"Cholecalciferol (Vitamin D3) oral 1 tablet 35 µg per day. Placebo oral 1 tablet per day. In total 35 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery."
45386369|NCT01038453|Other|placebo tablet|placebo 2 tablet, once a day,
45386370|NCT01038453|Dietary Supplement|Cholecalciferol (Vitamin D3) 70 µg|"Cholecalciferol (Vitamin D3) oral 2 tablets each containing 35 µg. In total 70 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery."
45386371|NCT00401193|Drug|Tranexamic acid tablets|3900 mg/Day
45386372|NCT00401193|Drug|Tranexamic acid tablets|1950 mg/Day
45386373|NCT00401193|Drug|Placebo tablets|
45386374|NCT00400569|Drug|Sunitinib Malate (SU011248)|For each 6 week cycle, patients will take SU011248 every day in the morning for 4 weeks followed by a 2 week rest period.
45386375|NCT03993015|Other|Help to diagnosis software|Help to diagnosis software
45386376|NCT01038531|Other|low-tidal-volume ventilation|goal tidal volume of 6 cc/kg ideal body weight
45386377|NCT01038531|Other|APRV|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
45386378|NCT00413049|Drug|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet and 1 placebo capsule matching amlodipine 5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
45386379|NCT00413049|Drug|Amlodipine 5 mg|1 amlodipine 5 mg capsule and 1 placebo tablet matching valsartan/amlodipine 80/5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
45386380|NCT03732495|Drug|Lenvatinib + Denosumab|"Lenvatinib and Denosumab will be used in the indication of their respective SmPCs.~Study treatments will be divided in fictitious cycles of 28 days. Lenvatinib and Denosumab will be administered as per investigator's decision, based on the data from their SmPC, at starting doses of 24mg once daily and 120mg once every 4 weeks, respectively. Dose modification guidelines of their respective SmPCs will apply.~Lenvatinib should be started the day after the inclusion. It will be taken every day at the same time, preferentially in the morning.~As in routine practice, all patients will be supplemented with daily doses of at least 500mg Calcium and 400IU Vitamin D, unless hypercalcemia is present.~Patients will be encouraged to maintain good oral hygiene during treatment with Denosumab.~Study drugs will be continued until a treatment discontinuation criterion is met"
45386381|NCT01041729|Drug|Atorvastatin|Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
45386382|NCT01041729|Drug|Standard Medical Treatment|"Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment."
46056454|NCT05416593|Behavioral|Affective regulation (AFFECT)|As for the (2) experimental group (AFFECT), the focus will be given to exercise intensity assessment and manipulation. The same preexercise evaluation, number of individualized sessions, and methodological approach (i.e., FITT) will be made. However, individual preferences and experiences regarding exercise intensity will be assessed in the preexercise evaluation. These will be used to select the exercise sessions' initial intensity. Moreover, intensity self-selection guidance and affective response assessments will be made throughout the session for continuous intensity adjustments (aiming for pleasurable feelings).
45386383|NCT01324245|Drug|Fenoldopam|Intravenous infusion at 0.5 mics/Kg/min for three hours
45386384|NCT00454194|Drug|pemetrexed disodium|given IV
45386385|NCT00454194|Drug|sorafenib tosylate|given orally
45848330|NCT03478254|Biological|Pneumococcal vaccination|"Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~One pneumococcal conjugate vaccine (PCV) 13 dose in the last year.~One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~One PPSV 23 dose in the last 5 years.~One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year."
45848331|NCT03478254|Biological|Hepatitis B Virus (HBV) vaccination|"Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months."
45848332|NCT03480048|Behavioral|Breastfeeding and weight loss support|The intervention is based on the Loving Support peer counseling breastfeeding model developed by the Special Supplemental Program for Women Infants and Children (WIC) with added components to promote postpartum weight loss.
45848333|NCT03485976|Drug|Ixekizumab|Treatment at the FDA-approved psoriasis dosing
45848334|NCT03486990|Drug|TIMP-GLIA|intravenous infusion.
45848335|NCT03490110|Behavioral|State regulation skill training|Participants complete seven supervised training sessions. Training sessions last 2 hours, and participants are requested to complete approximately 2.5 hours of additional skill practice over the course of each week outside of session (total ~4.5 hours per week).
45386386|NCT00412971|Drug|Hexvix|Single installation, TURB
45386387|NCT00412971|Other|Standard white light cystoscopy|
45386388|NCT00303472|Drug|Romiplostim|
45386389|NCT00468546|Drug|MabThera/Rituxan|1
45386390|NCT00468546|Drug|Methotrexate|2
45386391|NCT00468546|Other|Placebo|3
45386392|NCT00303316|Biological|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
45386393|NCT00303316|Biological|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
45386394|NCT01064986|Biological|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, bolus IV administration (~5 minutes)
45386395|NCT01064986|Biological|Endotoxin, Lipopolysaccharide, LPS /Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, continuous IV administration (Hydrocortisone 3mcg/kg/min)
45386396|NCT01064986|Biological|Placebo|Saline vehicle (placebo)
45386397|NCT01064986|Biological|Hydrocortisone|Hydrocortisone
45386398|NCT00468312|Drug|Mometasone furoate nasal spray|Two sprays (50 mcg/spray) in each nostril (200 mcg daily) in the morning
45386399|NCT00468312|Drug|Placebo|Two sprays in each nostril in the morning
45386400|NCT03980002|Drug|FCR and Ibrutinib|"Induction treatment:~Patients <65 y and without significant comorbidities are given FCR 1or 2 courses (If patients' white blood cell count <10×10^9/L after first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with FCR in 2 cylcles.~FCR： F（Fludarabine）：25mg/m2·d，d1-3； C（Cyclophosphamide）：CTX 250mg /m2·d，d1-3； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）；~Ibrutinib:420mg/d"
45386401|NCT03980002|Drug|BR and Ibrutinib|"Induction treatment:~Patients ≥65y and ≤75 y or <65 y but with comorbidities, are given BR 1or 2 courses (If patients' white blood cell count drop to below10×10^9/Lafter first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with BR in 2 cylcles. 1.BR： B（Bendamustine）：90mg/m2·d，d1-2； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）； 2. Ibrutinib: 420mg/d"
45386402|NCT03980002|Drug|Ibrutinib and Thalidomide|"Maintenance treatment:~After induction treatment, recommend ( but not mandatory) Ibrutinib or thalidomide monotherapy(according to patients preferrance) for MRD-positive patients.For MRD-negative patients, recommend ( but not mandatory) no maintenance therapy."
45386403|NCT03938220|Device|Electrical Cardiometry|Electrical cardiometry (EC) measurements: by the ICON_ hemodynamic monitor (ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). Four sensors of EC will be applied (1st: 5 cm above the base of the neck, 2nd: on the base of neck, 3rd: lower thorax at the level of the xiphoid and 4th: 5 cm below the 3rd electrode at the level of anterior axillary line). The ICON continuously displays HR, SV and CO.
45386404|NCT00331864|Drug|Ranibizumab|
45386405|NCT03984136|Behavioral|COHIV with exchange mechanism|A WeChat-based mini program has been developed to send and receive Center for Disease Control and Prevention certified online HIV results (COHIV). WeChat is the ubiquitous communication and social networking tool in China. Participants in the intervention group will receive his friend's COHIV only when the participants share their own in exchange. If the participant already has the COHIV, the system will lead the user to send his COHIV to the friend. If the participant does not have the COHIV, the system will guide him to make online appointment at the testing clinic.
45386406|NCT03984136|Behavioral|COHIV without exchange mechanism|The participants in the control group will be able to receive the friend's Center for Disease Control and Prevention certified online HIV results (COHIV) entirely at the friend's discretion without the mandatory exchange requirement. The system will also guide users on how to get an HIV test by making appointments with the MSM friendly clinics in the mini program.
45386407|NCT00331630|Drug|lapatinib ditosylate|Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
45386408|NCT00331630|Drug|paclitaxel albumin-stabilized nanoparticle formulation|30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
45386409|NCT00331552|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
45386410|NCT00331552|Drug|cyclophosphamide|Given orally
45386411|NCT00331552|Biological|trastuzumab|Given IV
45386412|NCT01062178|Drug|Definity|Definity is the contrast agent which is going to be injected in a bolus and infusion forms during the ultrasound performance.
45500302|NCT03075891|Other|Oral placebo capsules|1 Capsule once-daily for 12 weeks
45500303|NCT02013167|Drug|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV).
45695634|NCT03402646|Behavioral|Reminder module (SMS and Phone call)|Same as described under arm/group descriptions
45695635|NCT03402646|Behavioral|Photovoice|Same as described under arm/group descriptions
45695636|NCT02077959|Drug|lenalidomide|Given PO
45386413|NCT03983746|Device|core stability exercises and treadmill training exercises|Forty-five children with Down syndrome included in the study. The children aged 4-6 years, and they were equally divided randomly into three groups (A), (B) and (C). Group A received traditional physical therapy intervention strategies to facilitate the balance of participated children. Group (B) received same as the group (A), with additional core stability exercises training. Group (C) received same intervention strategies as group (A) in conjunction with a treadmill exercise program. The children's balance was evaluated using the Berg Balance Scale and the Biodex Balance System. Treatment sessions were for 60 min, thrice a week, for eight consecutive weeks.
45695637|NCT02077959|Biological|pidilizumab|Given IV
45695638|NCT02077959|Other|pharmacological study|Correlative studies
45695639|NCT02077959|Other|laboratory biomarker analysis|Correlative studies
45848336|NCT03490110|Other|Treatment-as-usual|Participants receive clinical care as usual over a matched time period.
45386414|NCT03980080|Drug|OSE-127|"mAb antagonist to CD127 receptor (or IL-7Rα)~Group 1-7~6 escalating dose level groups IV~SC"
45386415|NCT03980080|Drug|Placebo|Vehicle study drug
45386416|NCT03980080|Drug|OSE-127|"mAb antagonist to CD127 receptor (or IL-7Rα)~Group 8-9~2 escalating dose level groups IV"
45426127|NCT05795829|Device|disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument|Disposable intravascular ultrasound ablation catheters (used with an ultrasound ablation instrument) can use ultrasound energy to block sympathetic activity in the renal arteries.
45848337|NCT03495648|Behavioral|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
45426128|NCT05795803|Other|Forced isolation context|Exposure to the forced isolation context provided by the ongoing Covid-19 pandemic restrictive measures
45426129|NCT05795738|Behavioral|Chinese character-based visuomotor training program|this program includes visual-perceptual-motor play, paper-pencil activities, and ipad games using Chinese character as activity materials
45695640|NCT01683409|Drug|Baricitinib|Administered orally
45695641|NCT01683409|Drug|Placebo|Administered orally
45848338|NCT03496428|Device|Dental implant impressions- Different Techniques|Assessment of soft tissues changes with different techniques
45848339|NCT03496974|Drug|Bermekimab Monoclonal Antibody 200 mg|200 mg subcutaneous injection
45386417|NCT04320628|Device|AnaSept®|AnaSept® AnaSept® Antimicrobial Skin and Wound Cleanser is a clear liquid consisting of 0.057% sodium hypochlorite (NaOCl) in an isotonic saline. It has a broad-spectrum of antimicrobial action inhibiting the growth of Staphlyococcus aureus, Psuedomonas aeruginosa, Escherichia coli, Proteus mirabilis, Serratia marcescens, Clostridium difficile, including antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococcus faecalis (VRE), Carbapenem Resistant E.coli (CRE) and Acinetobacter baumannii, that are commonly found in wound bed as well as fungi such as Candida albicans and Aspergillus niger. However, NaOCL is non-toxic to mammalian cells.
45386418|NCT04320628|Other|NSS|NSS
45386419|NCT01065064|Procedure|RESTOR IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's AcrySof® ReSTOR® intraocular lens (IOL) for cataract patients with and without presbyopia. This innovative lens uses a revolutionary apodized diffractive technology to give patients a full range of quality vision (near, intermediate and distance) that greatly increases their independence from glasses after surgery
46056455|NCT02595307|Behavioral|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
46056456|NCT02735109|Other|photographies|cells description by taken photographies vith confocal microscope (VivaScope 3000)
45386420|NCT03983902|Procedure|Delayed cord clamping|Delayed cord clamping will occur for up to 2 minutes.
45426130|NCT05795738|Behavioral|traditional visuomotor training program|this program includes play and paper-and-pencil activities, ipad games using commercial or self-designed stuffs as activity materials
45426131|NCT05795725|Diagnostic Test|Artificial Intelligence-assisted Fecal Microbiome Testing|Next-generation sequencing of fecal samples and artificial intelligence analysis of test results
45426132|NCT05795725|Procedure|Colonoscopy|Colonoscopy procedure
45426133|NCT05795712|Other|Therapy Change from Baseline|The patient will be followed up from the point of view of therapy according to symptoms and flare-ups irrespective of systemic or peripheral eosinophil assessment
45426134|NCT05795673|Other|Peer support program (intervention phase)|"Implementation and Evaluation:~Intervention of mentor to provide peer support targeting psychosocial skills, coping and quality of life of adolescents with cystic fibrosis during the pediatric-adult transition The evaluation of the feasibility of the peer support program consists of assessing the effectiveness of its implementation in terms of its effect on the target audience, its acceptability to participants, and its implementation.~The mentor and the mentee will be in contact once a month for a minimum of 3 months and a maximum of 6 months by telephone.~The mentor will know the themes that the teenager would like to address in the context of peer support.~The mentee will complete the various questionnaires provided in the protocol to answer the primary and secondary endpoints."
45426135|NCT05795660|Biological|platelet rich plasma|platelet rich plasma injection
45426136|NCT05795634|Behavioral|Trier Social Stress Test|Acute psychosocial stress procedure; 5 minutes of public speaking and 5 minutes of mental arithmetic
45426137|NCT05795556|Other|Assessing sarcopenia and potential biomarkers of sarcopenia in fall patients|Blood test, body composition (BIA and/or DXA), balance tests (sway), handgrip strength, isometric knee extension strength, chair-rise test, gait-speed, thickness of the thigh muscles (ultrasound), screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), screening for depression (GDS-15), screening for self-rated health (EQ-5D-5L), frailty (CSHA Frailty Scale)
45426138|NCT05795543|Procedure|Subtalar Arthrodesis by Screws|Instruments: cannulated screws Steps: supine position , tournique over the thigh, using a extended lateral approach or sinus tarsi approach with joint debridement and preparation. Single-screw fixation was most often placed from posterior to anterior and double screws fixation was placed triangular pattern
45426139|NCT05795530|Procedure|cochlear implantation|surgery for bilateral hearing loss
45426140|NCT05795478|Drug|Oxycodone and Pregabalin|Oxycodone: 150mg PCIA during 3 days postoperatively Pregabalin: 150mg preoperatvely, 75mg BID for POD1~7,75mg QD for POD8~14
45426141|NCT05795478|Drug|Oxycodone and placebo capsules|Oxycodone: 150mg PCIA for 3 days postoperatively placebo capsules: same numbers as pregabalin at each time point
45426142|NCT05795478|Drug|Pregabalin and NS|Pregabalin: 150mg preoperatively, 75mg BID for POD1~7,75mg QD for POD8~14 NS: Equal volume NS for 3 days postoperatively
45426143|NCT05795478|Drug|placebo capsules and NS|placebo capsules: same numbers as pregabalin at each time point NS: Equal volume NS for 3 days postoperatively
45426144|NCT05795413|Procedure|Mastectomy with PECS blocks|Approximately half of patients recruited will receive a PECS block with Liposomal bupivacaine and half will not receive a block.
45426145|NCT05795413|Drug|Liposomal bupivacaine|All of the PECS blocks performed at this institution have liposomal lupivacaine as the anesthetic. Investigators will examine quality of recovery and pain control in patients who receive a PECS block versus those who do not receive one.
45426146|NCT05795400|Drug|Dapagliflozin 10mg Tab|10 mg tablets given once daily, per oral use
45426147|NCT05795400|Drug|Placebo|tablet of placebo drug dosed once daily
45426148|NCT05795387|Other|Video-based self-regulated training on the mental status exam|Authentic patient videos for self-regulated training as well as written e-course material, both on the mental status exam
45426149|NCT05795387|Other|E-course with written material on the mental status exam|Written material on the mental status exam
45426150|NCT05795322|Other|Sound healing with tuning forks|"Over the course of a half-hour virtual session, a specially developed triple OM track created by tuning forks was played."
45426151|NCT05795283|Drug|Citalopram i.v. and p.o|"Citalopram:~i.v.: 10 mg/die for day 1-7, 20 mg/die for day 8-14 p.o.: 20 mg/die for day 15-28"
45386421|NCT03983902|Procedure|Umbilical cord milking|Umbilical cord milking will occur milking of the 30 cm of the cord from placental site to baby, at a speed of 5 cm/second, 3 times in preterm newborns, 4 times in term newborns.
45386422|NCT03983902|Procedure|Immediate cord clamping|Immediate cord clamping will occur in 20 seconds after birth.
45386423|NCT00317356|Drug|OPC-6535(Tetomilast)|
45386424|NCT00331006|Drug|Rituximab|Rituximab by slow intravenous infusion; for participants greater than or equal to 10 kg, 375 mg per m^2 BSA weekly for 4 weeks; for participants less than 10 kg, 12.5 mg/kg weekly for 4 weeks
46056457|NCT02735109|Procedure|biopsy normal area|biopsy done to compare with abnormal area
46056458|NCT02595229|Procedure|Pronator quadratus repair|Suturing of the pronator quadratus muscle
46056459|NCT05411289|Procedure|acupressure|"Pressures were applied on three points consecutively, firstly on two points bilaterally Hugo point (LI4) and He-7 (Shenmen), then pressure was applied on sanyinjiao (SP6).~pressure was applied gradually for 30 seconds on the above mentioned points. Then this pressure was slowly intensified to the extent that the patient felt tingling, numbness, heaviness, and strain in the surrounding area."
46056460|NCT05411289|Procedure|sham acupressure|Pressures were applied on sham points consecutively
46056461|NCT04088461|Drug|Linagliptin / Metformin Oral Tablet|Linagliptin 2.5 mg + Metformin 850 mg twice daily plus a lifestyle modifications program
45386425|NCT00302458|Drug|OROS-Methylphenidate|Each dose of OROS MPH will be 72 mg which will be supplied as two 36 mg overencapsulated capsules
45386426|NCT00302458|Drug|Immediate Release Methylphenidate|Each dose of IR MPH will be 40 mg which will be supplied as two 20 mg overencapsulated capsules
45500304|NCT02013167|Drug|Standard of Care Chemotherapy|"FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen (e.g. idarubicin 10 mg/m² days 1 & 3; fludarabine 30 mg/m² days 1-5; cytarabine arabinoside 2 g/m² days 1-5). Patients > 60 years: Idarubicin 5 mg/m² day 1 & 3; fludarabine 20 mg/m² day 1-5; cytarabine arabinoside 1 g/m² day 1-5~HiDAC (high-dose cytarabine arabinoside) - based regimen ≥1 g/m²/day ± anthracycline and/or in combination with other drugs such as native Escherichia coli asparaginase, polyethylene glycol linked to asparaginase (PEG-asparaginase), vinca alkaloids, steroids, etoposide or alkylating agents~High-dose methotrexate-based regimen (HDMTX; 500 mg/m² to 3 g/m² infused up to 24 hours) in combination with native E. coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents.~Clofarabine as a single agent as recommended in the prescribing information or clofarabine-based regimens with 20 mg/m²/day for up to 5 days."
45386427|NCT00302458|Drug|Placebo|Placebo will be administered during the first part of the day, and again during the second part of the day.
45386428|NCT03982264|Procedure|ESD procedure|ESD were all performed as the standard procedure that has been widely described and used. A diluted sodium hyaluronate solution was injected submucosally. Mucosal incision and submucosal dissection were performed by using either Hook knife (Olympus Medical, Japan) or a dual-knife (Olympus Medical, Japan) . After the resection was finished, all of the visible vessels on the artificial ulcer bed were thoroughly coagulated with argon plasma coagulation to prevent postoperative bleeding.
45500305|NCT03805737|Other|Amulez and sunlight|Amulez and sun exposure for 2 hours
45500306|NCT03805737|Other|Amulez and red light treatment|Amulez and red light treatment for 10 minutes
45500307|NCT01378533|Drug|epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF|epirubicin 80mg/m2 iv d1 or divide in two days cyclophosphamide 600mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d*4cycles paclitaxel 175mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d*4cycles paclitaxel 150mg/m2 iv d1 carboplatin AUC=3 iv d2 G-CSF 3ug/kg ih d5-9 q14d*8cycles
45500308|NCT02630199|Drug|AZD6738|The starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity.
46056462|NCT04088461|Drug|Metformin|Metformin 850 mg twice daily plus lifestyle modifications program
45386429|NCT03982264|Procedure|EMR-C procedure|A transparent cap (MH-593; Olympus) was attached to the forward-viewing endoscope. After the endoscope was inserted to the rectum, the snare passed through the sheath and was looped along the inner lip of the cap. The tumor was then suctioned into the cap and the snare was pushed off and closed. After confirming the appropriate snare placement, both the tumor and the overlying mucosa were resected by electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and then the removed tumor was sent for pathological examination. Endoscopic examination then was repeated without the transparent cap in order to evaluate the wound carefully in case there was any perforation or bleeding and to ensure the absence of the residual tumor tissues. If there was spurting bleeding or active bleeding, hot forceps were usually to stop the bleeding.
45386430|NCT00391053|Biological|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
45386431|NCT00391053|Biological|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
45386432|NCT00391053|Biological|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
46056463|NCT01033136|Behavioral|Multiple Channel Exposure Therapy - Veterans|MCET-V offers individual therapy that provides psychoeducation about panic attacks and trauma and involves behavioral and cognitive exposure exercises.
45386433|NCT00391053|Biological|Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
45386434|NCT00317044|Drug|Esomeprazole|Esomeprazole 40 mg twice daily
45386435|NCT00317044|Drug|Esomeprazole|Esomeprazole 40 mg once daily
45386436|NCT00317044|Drug|Placebo|Placebo twice daily
45386437|NCT00301834|Biological|alemtuzumab|
45386438|NCT00301834|Drug|busulfan|
45386439|NCT00301834|Drug|cyclosporine|
45695642|NCT04548518|Biological|GPO Tri Fluvac vaccine|Each dose of Tri Fluvac contains a total of 45 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection. Tri Fluvac is manufactured and formulated into a multiple-dose vial vaccine (2 doses) using thimerosal at relatively low concentration as preservative (≤ 5.75 μg mercury/ dose). Each 0.5 ml dose of vaccine may contain residual amounts of ovalbumin (≤ 1.0μg), formaldehyde (≤ 100μg), tween 80 (≤ 0.9μg), triton x-100 (≤0.05μg) and gentamicin (≤0.075μg).
45386440|NCT00301834|Drug|fludarabine phosphate|
45386441|NCT00301834|Drug|methotrexate|
45386442|NCT00301834|Drug|methylprednisolone|
45386443|NCT00301834|Procedure|allogeneic bone marrow transplantation|
45386444|NCT00301834|Procedure|allogeneic hematopoietic stem cell transplantation|
45386445|NCT00301834|Procedure|peripheral blood stem cell transplantation|
45386446|NCT00301834|Procedure|umbilical cord blood transplantation|
45386447|NCT00301366|Drug|alpha-1 proteinase inhibitor (human)|60 mg/kg weekly for 20 weeks
45386448|NCT00330928|Device|Near Infrared Spectroscopy (NIRS) Imaging|Near infrared spectroscopic imaging of the coronary artery with an intravascular spectroscopy catheter.
45695643|NCT04548518|Biological|Licensed influenza vaccine|The comparator licensed influenza vaccine is a seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020
45848340|NCT03496974|Drug|Bermekimab Monoclonal Antibody 400 mg|400 mg subcutaneous injection
45848341|NCT03498300|Biological|Tdap vaccine|A single dose of Tdap vaccine at GA 27 - 36 weeks
45848342|NCT03501264|Behavioral|Online Game|LGBTQ Bullying game
45848343|NCT03501264|Behavioral|LGBTQ Resources|This group receives LGBTQ Resources
45848344|NCT03503292|Drug|Granisetron|Rapid metabolizer will receive 1mg IV Granisetron
45848345|NCT03503292|Drug|Ondansetron|Poor or normal metabolizers will receive 4mg Ondansetron IV
45386449|NCT00330928|Device|intravascular ultrasound (IVUS)|Ultrasound coronary catheter is positioned on a guidewire that has been placed in the coronary artery.Ultrasound imaging provides structural information about the vessel wall and blockages contained. It takes approximately 5 minutes to prepare, position, and to collect data with the catheter.
45386450|NCT01062334|Procedure|Peritoneal Microdialysis, CT-scan, leakage scoring|Peritoneal microdialysis CT-scan before discharge Leakage scoring daily
45386451|NCT00330616|Drug|323U66 SR|
45386452|NCT00466440|Drug|enzastaurin|1125 mg loading dose, then 500 mg po QD until disease progression, toxicity, or maximum 3 years
45386453|NCT00466440|Drug|placebo|Loading dose, then po QD until unblinding
45386454|NCT00466440|Drug|docetaxel|75 mg/m^2 IV, every 21 days, six 21-day cycles, maximum 10 cycles
45386455|NCT00466440|Drug|prednisone|5 mg po BID, six 21-day cycles
45386456|NCT00465972|Drug|Doxepin|Doxepin 10 mg po nightly x duration of study length OR Temazepam 15 mg po nightly x duration of study length OR Placebo nightly x duration of study length
45386457|NCT00465972|Drug|Temazepam|Temazepam capsule 15 mg po nightly x duration of study
45386458|NCT00465972|Drug|Placebo|Placebo capsule nightly for duration of study
45386459|NCT03926754|Drug|Mirabegron|"Study A The maximum tolerated dose up to a maximum of 300 mg per day for 26 weeks.~Study B One single dose of 300 mg at day one followed by 150 mg x 2 for 1 week (8-11 days)."
45386460|NCT00465894|Drug|Extended Release Tolterodine LA|Tolterodine LA 4 mg once daily for 52 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks
45386461|NCT00465894|Drug|Intra Vaginal Estradiol Cream|17-B estradiol cream 0.5 grams nightly for 6 weeks then two times weekly for 46 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks.
45386462|NCT00330460|Drug|Alendronate|ALN; 70 mg; oral; once weekly
45386463|NCT00330460|Drug|Denosumab|60 mg; SC; every 6 months
45426152|NCT05795283|Drug|Citalopram p.o|"Citalopram:~p.o: 10 mg/die for day 1-7, 20 mg/die for day 15-28"
45386464|NCT03979768|Other|Diabetes risk assessment service in Norwegian community pharmacies|Two pharmacists at each pharmacy were trained to perform risk assessments and counselling. During six months, pharmacy customers equal or above 45 years old, wishing to participate contacted the pharmacy staff. Participants completed a validated diabetes risk test and a background questionnaire including a validated instrument for self-rated health.
45848346|NCT03506724|Drug|Nifedipine|Nifedipine 10mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given and institution specific protocol will be performed.
45386465|NCT01062490|Drug|Treosulfan|14 g/m2/d, day -6 to -4
45386466|NCT00454116|Drug|Vandetanib|once daily oral tablet two doses
45386467|NCT00454116|Drug|FOLFIRI|Intravenous infusion
45386468|NCT00465816|Biological|Nimenrix (Meningococcal vaccine 134612)|Single dose intramuscular injection
45386469|NCT00465816|Biological|Twinrix|3-dose intramuscular injection. Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.
45386470|NCT00465738|Drug|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)"|active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins; powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 or 5.0 mL of sterile sodium chloride [NaCl] 0.9% solution without preservatives. Dilution with 2.0 or 5.0 mL resulted in a dose of 50 or 20 units per 1.0 mL.
45386471|NCT00400179|Drug|S-1/Cisplatin|"In Arm A, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth (NPO 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with approximately 8 ounces of water and prior to cisplatin infusion on Day 1.~Cisplatin 75 mg/m2 was administered as a 1- to 3-hour IV infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin."
45386472|NCT00400179|Drug|5-FU/cisplatin|In Arm B, 5-FU 1000 mg/m2/24 hours was administered CIV on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.
45386473|NCT00465270|Device|AMPLATZER PFO Occluder|patent foramen ovale closure device
45386474|NCT00465270|Other|Standard of Care - Medical Management|Medical management - aspirin alone, Coumadin alone, Clopidogrel alone, aspirin combined with dipyridamole
45386475|NCT00464568|Drug|GSK256066|
45386476|NCT00464490|Drug|Dexmedetomidine|Dexmedetomidine .5mcg/kg/hr-.7mcg/kg/hr 1hour prior to extubation. Dexmedetomidine will be titrated according to blood pressure, RASS and heart rate response and the dose will be lowered only after sedation is discontinued or markedly reduced.
45500309|NCT02630199|Drug|Paclitaxel|Paclitaxel 80mg/m2 on days 1,8, and 15 every 4 weeks
45695644|NCT02243488|Device|Irise Easy Pad & Menstrual Health Education|Reusable manufactured sanitary pad produced by Irise Uganda Limited and education sessions provided by qualified menstrual health educators
46056464|NCT01033136|Behavioral|Cognitive Processing Therapy|CPT offers individual therapy that targets trauma and PTSD symptoms via cognitive restructuring.
46056465|NCT04246983|Diagnostic Test|Opportunistic infection Ultrasound (OpUS) screening|this point-of-care ultrasound protocol will include lung ultrasound, assessment of pericardial and pleural effusions, ascites, abdominal lymphadenopathy and splenic micro abscesses, as well as a focused ultrasound of liver and kidneys.
46056466|NCT02595151|Device|CLE|The CLE procedure did not differ from that of conventional colonoscopy, except for the additional storage of pCLE images and videos in the gastric antrum.
45386477|NCT01022034|Procedure|sacral rectopexy with sutures or meshes|
45386478|NCT01022034|Procedure|full rectal mobilization from the sacrum without sacral rectopexy|
45386479|NCT03849300|Other|Aquatic walking exercise program group 1|12 week aquatic walking exercise program
45386480|NCT03849300|Other|Aquatic walking exercise program group 2|12 week aquatic walking exercise program
45386481|NCT03849300|Other|Land-based walking exercise group|12 week land-based walking exercise program
46056467|NCT02729649|Device|ArmAssist robotic training|
45386482|NCT00412893|Drug|Isavuconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
45386483|NCT00412893|Drug|Voriconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
46056468|NCT02729649|Other|Conventional therapy|
46056469|NCT02729649|Other|Extended conventional therapy|
45386484|NCT00412737|Drug|Oseltamivir|Oseltamivir 30 mg to 75 mg capsule or suspension orally once daily for 12 weeks.
45386485|NCT00412737|Drug|Placebo|Placebo matched to oseltamivir capsule or suspension orally once daily for 12 weeks.
45386486|NCT00508742|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2, 4, 6 and 12 months of age
45386487|NCT00508742|Biological|7 valent pneumococcal conjugate vaccine|1 dose at 2, 4, 6 and 12 months of age
45386488|NCT01041885|Device|INSTRUCT|INSTRUCT PolyActive scaffold implantation
45386489|NCT01041963|Drug|Enalapril|Patients with hypertension will take 20-40mg enalapril per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
45386490|NCT01041963|Drug|Enalapril plus Losartan|Patients with hypertension will take 20-40mg enalapril plus 25-50mg losartan per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
45386491|NCT01041963|Drug|Placebo|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
45386492|NCT01044225|Drug|Cetuximab|An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
45386493|NCT01044225|Drug|Cilengitide EMD 121974|A dose of 2000 mg by IV administration 2 weekly.
45386494|NCT00848757|Behavioral|Intensive Lifestyle Intervention|"Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the DPP Lifestyle Balance program, but modified for a group format and to be more culturally and linguistically appropriate for this population."
45386495|NCT00508274|Drug|lapatinib|Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets taken orally.
45386496|NCT00508274|Drug|capecitabine|Capecitabine is supplied as a biconvex, oblong, light peach and peach colored, film-coated tablets for oral administration.
45386497|NCT01038765|Behavioral|Mindfulness Based Cognitive Therapy|8-weeks group based intervention of mindfulness and cognitive behavioural techniques
45386498|NCT01038999|Biological|Peripheral blood biological tests|A group and B group will be evaluated three times, at baseline, then every 12 months during 3 years. In case of initiation or changing of antiretroviral therapy, patients will be evaluated once more. Control subjects will be only evaluated at baseline.
45386499|NCT01042041|Drug|sorafenib tosylate|Given orally
45386500|NCT01042041|Drug|doxorubicin hydrochloride|Given via transarterial/hepatic chemoembolization
45386501|NCT01042041|Drug|cisplatin|Given via transarterial/hepatic chemoembolization
45386502|NCT01042041|Drug|mitomycin C|Given via transarterial/hepatic chemoembolization
45386503|NCT01042041|Procedure|transarterial chemoembolization|
45386504|NCT01042041|Procedure|hepatic artery embolization|
45386505|NCT00499460|Dietary Supplement|garlic powder tablets|Each Garlicin tablet has a claimed allicin content of 3,200 microgram per tablet
45386506|NCT00499460|Drug|oxycodone|Single administration of three 5-mg oxycodone tablets or a 15-mg dose
45386507|NCT01010828|Procedure|Incision technique|Tri-Vector Approach retains the majority of 3 vectors of quadriceps.
45386508|NCT01010828|Procedure|Incision technique|Mini Mid-Vastus Approach
45386509|NCT00412113|Drug|Amlodipine besylate|Amlodipine besylate 5 mg
45386510|NCT00412113|Drug|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 10/20 mg
45386511|NCT00412113|Drug|Amlodipine besylate|Amlodipine besylate 10 mg
45386512|NCT00412113|Drug|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 5/20 mg
45386514|NCT01014650|Drug|GLYX-13|single IV or SC dose
45386515|NCT01014650|Drug|IV normal saline|Single IV dose of normal saline
45386516|NCT00411645|Drug|maribavir|100 mg twice daily for up to 12 weeks
45386517|NCT00411645|Other|placebo|twice daily for up to 12 weeks
45386518|NCT00490724|Drug|Nesiritide (1+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 1 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 15.4 to 35.2 mcg/kg.
45386519|NCT00490724|Drug|Nesiritide (2+0.005)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.005 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 9.2 to 31.7 mcg/kg.
45386520|NCT00490724|Drug|Nesritide (2+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (Fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (Flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 16.4 to 36.2 mcg/kg.
45386521|NCT01042197|Radiation|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
45386522|NCT01042197|Radiation|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
45386523|NCT01042197|Radiation|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
45386524|NCT01042197|Radiation|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
45386525|NCT01042197|Radiation|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
45386526|NCT01042197|Radiation|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
45386527|NCT01042197|Radiation|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
45386528|NCT01042197|Radiation|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
45386529|NCT01042197|Radiation|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
45386530|NCT01039077|Procedure|Laparoscopic gastric banding|Laparoscopic gastric banding for the treatment of morbid obesity.
45386531|NCT01039155|Drug|Azacitidine|Given IV
45386532|NCT01039155|Other|Laboratory Biomarker Analysis|Correlative studies
45386533|NCT01039155|Drug|Oxaliplatin|Given IV
45386534|NCT01039155|Other|Pharmacological Study|Correlative studies
45386535|NCT03835221|Device|methafilcon A toric contact lenses|Bilateral daily wear of methafilcon A toric contact lenses
45386536|NCT03835221|Device|fanfilcon A toric contact lenses|Bilateral daily wear of fanfilcon A toric contact lenses
45386537|NCT01039233|Drug|Bicalutamide 50 mg Tablet vs Casodex® 50 mg Tablet|
46056470|NCT00636519|Biological|Botulism Antitoxin Bivalent (Equine) Types A and B|One vial of Botulism Antitoxin Bivalent(Equine) Types A and B (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage A
46056471|NCT00636519|Biological|Botulism Antitoxin Heptavalent (Equine) Types A-G|One vial of Heptavalent Botulism Antitoxin (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage B
46056472|NCT02729883|Other|Quality-of-Life Assessment|Ancillary studies
45386538|NCT00398073|Biological|mouse gp100 plasmid DNA vaccine|
45386539|NCT00398073|Device|The Dermal PowderMed® devices|
45386540|NCT00398073|Other|intramuscularly (IM injection)|
45386541|NCT00490646|Drug|ixabepilone|"Ixabepilone 40 mg/m^2 was administered as a 3-hour I.V. continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity.~For the first cycle, ixabepilone was administered the day following the first dose of trastuzumab (in the first cycle trastuzumab was given on Day 0); in all the following cycles, ixabepilone was administered immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated."
45386542|NCT00490646|Drug|docetaxel|Docetaxel 100 mg/m^2 was administered as a 1-hour IV continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity. For the first cycle, docetaxel was administered the day following the first dose of trastuzumab (i.e. in the first cycle trastuzumab was given on Day 0); in all following cycles, docetaxel was administered immediately after trastuzumab if the preceding dose of trastuzumab was well tolerated.
45386543|NCT00490646|Drug|trastuzumab|Trastuzumab was administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle at a dose of 2 mg/kg until disease progression or unacceptable toxicity. In cycle 1, a loading dose of 4 mg/kg was administered as a 90-minute IV infusion on a day before initial administration of chemotherapy (i.e. on Day 0). Trastuzumab was given immediately prior to ixabepilone (Arm A) or docetaxel (Arm B) in all subsequent cycles as a 30-minute IV infusion if the initial dose was well tolerated.
45386544|NCT01039311|Device|Optical Coherence Tomography|Obtain OCT images.
45386545|NCT01039389|Drug|Ivabradine|bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min
46056473|NCT02729883|Other|Questionnaire Administration|Complete interviews
45386546|NCT01039389|Drug|Placebo|bid placebo
45386547|NCT04558827|Other|Low Carbohydrate Diet|Dietary choices are counseled to come primarily from lean meats, eggs, nuts, seeds, vegetables and berries.
45386548|NCT04558827|Other|Time Restricted Feeding|Participants will be asked to have 2 meals within an 8 hour period, preferably before 2pm.
45386549|NCT00388947|Device|AMS Prolapse Product|AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family
45386550|NCT03992937|Drug|Vaginal Micronized Progesterone|Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months.
45386551|NCT03992937|Device|Levonorgestrel-Intrauterine System|Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day.
45386552|NCT01039545|Drug|Diclofenac|Diclofenac retard 75mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
45386553|NCT01039545|Drug|Norfloxacin|Norfloxacin 400mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
45386554|NCT00490568|Drug|Rosiglitazone XR|Experimental drug
45386555|NCT00561353|Drug|TMC435|TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.
45386556|NCT00561353|Drug|Placebo|Placebo capsules identical in appearance to TMC435 capsules taken orally (by mouth) once daily for 28 days.
45386557|NCT00561353|Drug|Peginterferon (PegIFNα-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22
45386558|NCT00561353|Drug|Ribavirin|200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.
45386559|NCT03996746|Diagnostic Test|No intervention|No intervention
45386560|NCT04383587|Other|Serologic testing|COVID19 IgG antibody testing to be performed
45386561|NCT00859781|Drug|177Lu-J591|177Lu-J591 70 mCi/m2 on day 29 (+/- 2 days) of treatment
45426153|NCT05795270|Other|Treatment|Nocturnal ventilotherapy, positional therapy and oro-mandibular devices
46056474|NCT02729883|Procedure|Supportive Care|Receive patient navigation via the Take the Fight strategists
46056475|NCT00738673|Drug|degarelix|Starting dose of 240 mg (40 mg/mL). Maintenance doses of 80 mg (20 mg/mL).
45386562|NCT00859781|Drug|Ketoconazole|Ketoconazole at a dose of 400 mg (two 200 mg tabs) to be taken orally (preferably on an empty stomach) three times per day (total daily dose of 1200 mg)
45386563|NCT00859781|Drug|Hydrocortisone|Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)
45386564|NCT00859781|Drug|111In-J591|111In-J591 at a dose of 5 mCi on day 29 (+/- 2 days) of treatment
45386565|NCT00944957|Drug|Raltegravir for the first 2 weeks|Patient receives raltegravir and efavirenz placebo during the first 2 weeks
45386566|NCT00944957|Drug|Efavirenz for the last 2 weeks|Patient receives efavirenz and raltegravir placebo during the last 2 weeks
45386567|NCT00944957|Drug|Efavirenz for the first 2 weeks|Efavirenz and raltegravir placebo for the first 2 weeks
45386568|NCT00944957|Drug|Raltegravir for the last 2 weeks|Raltegravir and efavirenz placebo for the last 2 weeks
45386569|NCT00945113|Behavioral|One-week speech therapy group|One-week cross-district speech therapy group for older children (aged 8 to 15) who stammer
45386570|NCT00945347|Drug|Miglustat|Nasal instillation of miglustat
45386571|NCT00945347|Drug|Placebo|Nasal instillation of placebo matching in appearance with the Miglustat instillation
45500310|NCT01378455|Other|interactive computerized handwriting training program|In ICHTP group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software. The training program costs 45 min/once, three times/one week, and sustains four weeks.In traditional group, they received the training of paper-pencil activities with visual-perception and visual-motor integration skills. The training duration is as long as ICHTP group.
45386572|NCT00945425|Drug|AZD7325|oral capsule, once or twice daily, 7 days
45386573|NCT00945425|Drug|Placebo|oral capsule, once or twice daily, 7 days
45386574|NCT00560885|Device|AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
45386575|NCT00945503|Drug|GSK1018921|GSK1018921 is a GT1 recepor antagonist
45386576|NCT00945581|Other|Experimental Nutritional Powder Formula|Powder twice a day
45386577|NCT00945581|Other|Placebo comparator|Powder twice a day
45386578|NCT00941135|Other|Docetaxel+Cisplatin+5-FU+ Radiotherapy+Cetuximab|"Docetaxel:75 mg/m2/d IV Cisplatin:75 mg/m2/d IV 5-FU:750 mg/m2/d IV TPF 3 cycles every 3 weeks~Radiotherapy: Total 72 Gy in 42 fractions Cetuximab: 250 mg/m2/d Days 1, 8, 15, 22, 29, 36 and 43"
45386579|NCT00397215|Biological|Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)|intramuscular injection
45386580|NCT00397215|Biological|Fluarix|Intramuscular injection. All subjects not vaccinated with an influenza vaccine for the 2006-2007 season received Fluarix NH 2006/2007 (i.e. interpandemic GSK's influenza vaccine) at least 3 weeks before administration of the first dose of H5N1 vaccine.
45500311|NCT01378455|Other|traditional handwriting training program|The THTP group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
45848347|NCT03506724|Drug|Labetalol|Labetalol 20mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 40mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 80mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, then another medication will be chosen based on institution specific protocol.
45386581|NCT01042353|Procedure|E test|At the time of BAL collection, a rapid antibiogram will be performed by placing E-test antibiotic strips (AB Biodisk) directly onto Mueller-Hinton agar plates seeded with the BAL specimen (both by flooding and swabbing). E-test strips will be impregnated with cefoxitin, piperacillin-tazobactam, cefepime, imipenem, ciprofloxacin and amikacin. At 24 h, the E-test plates will be photographed and then examined separately by both a bacteriologist and a medical ICU physician following a consensus method. The final E-test results will be compared with the standard MIC cultures.
45386582|NCT01042353|Procedure|standard culture method|BAL samples will be cultured by standard methods and the minimal inhibitory concentration (MIC) of bacteria to the usual antibiotics will be determined using standard procedures
45386583|NCT01039623|Biological|Pandemrix® (H1N1 pandemic influenza)|vaccinated against H1N1 pandemic influenza. One group will receive the adjuvant vaccine while the other group will get intradermal antigen, without the adjuvant.
45386584|NCT01042431|Other|No Intervention|No intervention
45386585|NCT01042587|Other|exposure to bright light|Elders will be engaged in an activity period which will focus their attention in the direction of bright light, thus ensuring viewing the light source for a daily exposure of thirty minutes.
45386586|NCT01042587|Other|low luminosity red light|Low level red light should not entrain circadian rhythm and will serve as a placebo control
45386587|NCT01039701|Drug|AZD1446|capsules, oral, 3 times daily
45386588|NCT01039701|Drug|Placebo|capsules, oral, 3 times daily, 4 weeks
45386589|NCT03447951|Drug|Para-Toluenesulfonamide|A total dose of PTS100 in this study, the expected accumulated dose in the treatment duration, depends on the patient's tumour size. For each patient, up to 4 tumors, each not exceeding 8.8 cm in diameter, are selected for treatment by the joint decision of the investigator and the radiologist. The total dose is defined as the accumulated dose in treatment duration. The total dose is assigned as 30% of TTV for each patient and maximum TTV should be less than 366 cm3.
45386590|NCT03742401|Procedure|Surgery|Traditional open excisional surgery
45500312|NCT03759951|Behavioral|DoIT-1|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed once per week on non-consecutive days for 12 months.
45500313|NCT03759951|Behavioral|DoIT-2|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed twice per week on non-consecutive days for 12 months.
45386591|NCT03742401|Device|HIFU (Echopulse)|High intensity focused ultrasound (HIFU) non invasive intervention
45386592|NCT00556439|Drug|Abatacept|"Participants will receive a fixed dose of abatacept, approximating 10mg per kilogram of body weight. The following dosing rules will be followed:~Participants weighing less than 60kg will receive 500mg of abatacept.~Participants weighing 60 to 100kg will receive 750mg of abatacept.~Participants weighing more than 100kg will receive 1000mg of abatacept.~Abatacept will be administered in a 30-minute intravenous infusion on Days 1, 15, 29 (Month 1) and at Month 2. In the absence of toxicity or relapse, participants will remain on abatacept at the same dosage until randomization at Month 3. After randomization, only Group A (giant cell arteritis) and Group C (Takayasu arteritis) participants will continue on abatacept."
45386593|NCT00556439|Drug|Placebo|Placebo abatacept infusions will be given monthly after random assignment at Month 3.
45386594|NCT04012229|Genetic|BRCA mutation|The genetic testing was performed according interregional consensus (Manchester score > or = 16) on blood sample using classical chain-termination (Sanger sequencing) and multiplex ligation-dependant probe amplification to search large rearrangements.
45386595|NCT00945737|Dietary Supplement|Soy protein; 25 grams/day|Soy protein
45386596|NCT00945737|Dietary Supplement|Control protein|Milk protein
45386597|NCT04012307|Drug|Candesartan Cilexetil 32mg|Candesartan Cilexetil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 32 mg of candesartan cilexetil.
45386598|NCT04012307|Drug|Atacand® PROTECT|Atacand® PROTECT is manufactured by AstraZeneca GmbH, Germany. Each tablet contains 32 mg of candesartan cilexetil.
45386599|NCT00939263|Other|assessment of disease activity using the EEsAI|disease activity index
45500314|NCT03759951|Behavioral|DoIT-3|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed thrice per week on non-consecutive days for 12 months.
45500315|NCT03759951|Behavioral|Control|No training will be performed during a 1-year period. Participation only in measurements.
45386600|NCT00941213|Device|ultrasound scissors - Harmonic ACE|preparation with ultrasound scissors during operation
45386601|NCT00941213|Device|electroscalpel (Erbe Vio 300; Aesculap AG)|preparation with electroscalpel during operation
45386602|NCT00387465|Drug|Azacitidine 30mg/m2|Azacitidine 30mg/m2 subcutaneously (SQ)
45386603|NCT00387465|Drug|Entinostat|7mg by mouth (PO) on days 3 and 10 of each cycle
45386604|NCT00387465|Drug|Azacitidine 40mg/m2|Azacitidine 40mg/m2 SQ
45386605|NCT00945971|Other|Physical activity|The intervention group will engage in exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be used at the start and in the end of this study.
45386606|NCT01042665|Drug|latanoprost 0.005%|Active comparator
45386607|NCT01042665|Drug|Placebo|Placebo comparator
45386608|NCT03679221|Other|Data collection|telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
45386609|NCT00949949|Drug|everolimus|Given PO
45386610|NCT00949949|Drug|gemcitabine hydrochloride|Given IV
45386611|NCT00949949|Drug|cisplatin|Given IV
45426154|NCT05795244|Drug|Nivolumab|- Nivolumab 480 mg/every 4 weeks/IV infusion/6 cycles
45426155|NCT05795231|Device|Macintosh Laryngoscope Vs Video Laryngoscope|Evaluate incidence of first trial success and complications
45386612|NCT00941369|Drug|Insulin Glargine (HOE901)/NPH Insulin|"Arm 1: Subcutaneous injection of Insulin Glargine with the TactiPen® injector pen once daily at any time, but each day at the same time~Arm 2: Subcutaneous injection of Protamine Hagedorn basal insulin with the TactiPen® injector pen once or twice daily at the discretion of the treating physician~The starting dose is 10 I.U. (NPH basal insulin) resp. 10 U (insulin glargine) per day.~The dose adjustments will be based on the results of self-monitoring."
45386613|NCT01042743|Procedure|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
45386614|NCT01042743|Procedure|laparoscopic right-hemicolectomy|Conventional laparoscopic procedures
45386615|NCT00941447|Behavioral|Dietary|All participants in the investigation will receive a standard 12-week behavioral intervention with seven 30-45 minute phone interventions and education sessions. The intervention includes a reduced caloric prescription (1200-1500 kcal/day),fat gram prescription (30% or less kcals from fat) and carbohydrate gram prescription (150-190 grams).
45386616|NCT00941447|Behavioral|Physical Activity|There is a physical Activity of 150 minutes/week of moderate-intense physical activity.
45386617|NCT00941447|Behavioral|Self-Regulatory Approaches|Participants in this arm will receive extensive feedback based on their self-monitoring diary in which the researcher will be reinforced in areas that they are doing well in regarding their blood glucose and also assist in problem solving in areas that need improvement.
45386618|NCT00946049|Device|Vicryl Plus|
45386619|NCT00946049|Device|Vicryl|
45386620|NCT00946127|Procedure|Ventriculoperitoneal Shunt Placement|In the subjects who choose this arm, at the start of study- CSF (Cerebrospinal fluid ) will be shunted to peritoneum by placing a ventriculoperitoneal shunt catheter with or without shunt valves or anti-siphon device.
45386621|NCT00946127|Procedure|Endoscopic Third Ventriculostomy(ETV)|Patients who choose to undergo ETV arm would undergo a ventriculostomy at the start of study.
45386622|NCT00946205|Procedure|Laparoscopic posterior rectopexy|The rectum is mobilised down to the os coccygeus, then it is elevated cephalic and sutured with a multifilament suture to the presacral fascia just below the sacral promontory. The lateral stalks should be left intact.
45386623|NCT00946205|Procedure|Laparoscopic anterior mesh rectopexy|The peritoneum is incised over the right side of the promontory. The incision is extended in an inverted J-form along the right side of rectum and over the deepest part of the pouch of Douglas. Denonvilliers fascia is incised and the rectovaginal (women)/rectovesical (men) septum is broadly opened. A prosthetic mesh (3 x 17 cm) is sutured with nonabsorbable sutures to the ventral aspect of the rectum in the rectovaginal/rectovesical septum and to the lateral seromuscular borders of rectum and fixed upon the promontory using a stapler. The posterior fornix of vagina (women)/floor of the bladder (men) is elevated and sutured to the anterior aspect of the mesh. The incised peritoneum is then closed over the mesh.
45386624|NCT00950027|Drug|povidone iodine|oropharyngeal decontamination every 4 hours
45386625|NCT00950027|Drug|Placebo|oropharyngeal decontamination every 4 hours
45386626|NCT00941525|Drug|Latanoprost|1 eyedrop of latanoprost (0.005%) dosed once a day at 8:00pm for a 4-weeks period
45386627|NCT00456261|Drug|Pemetrexed|pemetrexed 500 mg/m2
45386628|NCT00456261|Drug|Gemcitabine|gemcitabine 1500 mg/m2
45386629|NCT00456261|Drug|Bevacizumab|bevacizumab 10mg/kg bevacizumab 15mg/kg
45386630|NCT00456261|Drug|Carboplatin|carboplatin AUC=5
45386631|NCT01042821|Procedure|partial rectal wall advancement flap|The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
45426156|NCT05795218|Device|Deep Brain Stimulation|implant and DBS therapy with the directSTIM™ DBS system
45500316|NCT04563065|Other|Exercise program|All sessions will begin with a warm-up of 7-8 minutes composed of mild movements and joint mobility of upper and lower limbs exercises. Then a central part of 35-40 minutes, four types of activities will be included (aerobic work, muscle strengthening, coordination/balance tasks, pelvic floor exercises), finally a section of flexibility, relaxation and final talk (comments and sharing) will be performed (12-15 minutes).
45386632|NCT01042821|Procedure|mucosal advancement flap|Fistulectomy, closure of internal sphincter and rectal advancement flap includes mucosa and submucosal layer sutured 1cm below the level of internal opening
45500317|NCT04563065|Other|Healthy lifestyle advise|This intervention consists of providing infographics and videos with advice on healthy habits throughout the pregnancy process. This type of content will be related to daily physical activity, food recommendations and fundamental exercises to perform during pregnancy.
45500318|NCT02588781|Drug|Pemetrexed|Alimta 500mg/m2 + NS 100ml IV infusion for 10mins Every 3weeks
45386633|NCT01042899|Behavioral|Teen Online Problem Solving (TOPS)|The TOPS program has 10 sessions that provide training in stress management, problem solving, communication, and social skills to all enrolled families, while the remaining 6 sessions address content related to the stressors and burdens of individual families. Each self-guided online session includes real adolescents talking about how TBI affected them, content regarding the skill, video clips showing adolescents and/or families modeling the skill, and exercises giving the family an opportunity to practice the skill. After the completion of the self-guided web pages, the family will meet with the therapist via videoconference; the therapist will review the exercises and help the family implement the problem-solving process with a problem or goal identified by the family.
45386634|NCT01042899|Behavioral|Teen Online Problem Solving--Teen Only (TOPS-TO)|TOPS-TO targets the same skills as TOPS and includes largely the same website and intervention content. However, it differs with respect to the extent of family involvement in the sessions. In TOPS-TO, sessions will be conducted with the child or adolescent alone, rather than with the family as whole. Parents will be given access to the TOPS-TO website content via their own password protected site so they will understand the skills that their child is learning. However, only the adolescent, and not the parents, will participate in the synchronous videoconferences with the therapist.
45386635|NCT01042899|Behavioral|Internet Resources Comparison (IRC)|Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
45386636|NCT03993405|Other|Ultrasonographic evaluation|Ultrasonographic measurement is assessment method to diagnosis of sarcopenia
45386637|NCT00387153|Drug|MPC-2130|MPC-2130 10 mg/mL administered by intravenous infusion over 1-2 hours
45500319|NCT04538573|Device|Virtual Reality Distraction|Patients in this group will be offered to use Oculus Rift goggles while undergoing the burn treatments, dressing changes and hydrotherapy to reduce pain and anxiety during treatment. The goggles will display Dreamland, a virtual reality videogame created by our team to maximize fun, diminish difficulty, and motion sickness. The system will be available 5 minutes before treatment to the patient in order to ease acclimatation to the goggles until the end of the treatment session.
45500320|NCT04538573|Drug|Standard Treatment|"Standard pharmacological care as per the unit's protocol will serve as the control for half of the duration of every treatment session. It consists of different analgesic and sedative medication used in combination in order to help patients go through the procedure. The unit's protocol includes drugs such as Morphine, Hydromorphone, Fentanyl, Clonidine, Ketamine, Midazolam and Acetaminophen.~Use of any co-interventions for pain or anxiety management (music, comforting, child life specialist or other) during this sequence will be documented."
45500321|NCT01063062|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks.
45500322|NCT01063062|Drug|Methotrexate|methotrexate as per standard of care in clinical practice.
45500323|NCT04418739|Drug|Human albumin|Intravenous human albumin given at a maximum dose of 1g/kg at skin incision which is infused at 100ml/hour
45500324|NCT01314989|Drug|Cyproheptadine|0,25mg/kg/day orally in 2 doses per day (2mg/5 ml)for 1 month
45500325|NCT01314989|Drug|Sugar pill|liquid placebo
45500326|NCT04483115|Drug|TPN171H|Tablets; Oral; Single dose
45386638|NCT00386607|Drug|Aliskiren|Aliskiren 300 mg
45500327|NCT04483115|Drug|Placebo|Tablets; Oral; Single dose
45386639|NCT00386607|Drug|Valsartan|Valsartan 320 mg
45386640|NCT00386607|Drug|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide (HCTZ) 12.5-25 mg
45386641|NCT00410163|Drug|Ofatumumab 500mg|Ofatumumab 500mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
45500328|NCT04483115|Drug|Tadalafil|Tablets; Oral; Single dose
45500329|NCT03569865|Device|Audiovisual Stimulation|A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study.
45500330|NCT04054362|Drug|Paclitaxel protein bound|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
45500331|NCT04054362|Drug|Cisplatin|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
45500332|NCT04054362|Drug|Gemcitabine|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
45500333|NCT04054362|Drug|Paricalcitol|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
45500334|NCT04467281|Drug|89Zr-DFO-daratumumab|Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
45500335|NCT04467281|Diagnostic Test|PET/CT|Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
45500336|NCT04350879|Other|Data record|Data record
45500337|NCT03652194|Other|in vitro evaluation of epithelial immune response during C. glabrata infection|"study of the expression of genes coding for different proteins involved in the RTqPCR activation cascade~study of protein expression by the Western-Blot method"
45386642|NCT00410163|Drug|Ofatumumab 1000mg|Ofatumumab 1000mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
45386643|NCT00410163|Drug|Fludarabine|Fludarabine (25 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses
45386644|NCT00410163|Drug|Cyclophosphamide|Cyclophosphamide (250 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses.
45386645|NCT03617523|Biological|Fluzone Quadrivalent vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
45386646|NCT03617523|Biological|Flublok Quadrivalent vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
45386647|NCT03617523|Biological|Fluzone High-Dose vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
45386648|NCT00409617|Biological|adalimumab|Adalimumab 40 mg Every Other Week dosing
45500338|NCT03652194|Other|study of the impact of resistance phenotype acquisition on the virulence of C. glabrata isolates|"in vitro evaluation by measuring cell invasion, cell adhesion and by determining epithelial cell cytotoxicity.~in vivo evaluation measured by a survival study on a CD-1 mouse model."
45500339|NCT04322019|Other|Data record|Data record
45386649|NCT00409617|Biological|adalimumab|Adalimumab 40 mg Every Week dosing if participant experiences a disease flare or is not responding to treatment. A disease flare is defined as an increase of 3 points or more on the HBI compared to the Baseline score and a total HBI score of 7 or higher. Non-response is defined as a decrease by fewer than 3 points in the HBI compared to Baseline.
45386650|NCT00300274|Drug|everolimus|Everolimus supplied as 0.75 mg tablets. Everolimus was also supplied in 0.25 mg and 0.5 mg tablets for dose adjustments.
45386651|NCT00300274|Drug|mycophenolate mofetil|Mycophenolate mofetil supplied as 500 mg tablets.
45386652|NCT00300274|Drug|cyclosporine|Cyclosporine reduced dose in the everolimus arms (approximately half of the standard dose) and standard dose in the mycophenolate mofetil arm.
45386653|NCT00300274|Drug|corticosteroids|Corticosteroids standard dose.
45386654|NCT01043211|Drug|Lidocaine Hydrochoride Injection, without epinephrine|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision. Immediately thereafter, lidocaine (1%, 10 mg/ml) will be administered on a standardized 0.3 ml/hr/kg (3 mg/kg/hr, maximum 200 mg/hr = 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the lidocaine infusion will be decreased by 50% to 0.15 ml/hr/kg (1.5 mg/kg/hr, maximum 100 mg/hr = 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
45500340|NCT04315467|Drug|SGM-101|A one-time infusion of SGM-101
45500341|NCT04315467|Device|Near infrared camera imaging system|Near infrared camera imaging system
45500342|NCT01785342|Other|Biosample and Imaging Collection|Collection of listed biosamples and CT imaging.
45500343|NCT01378143|Drug|OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI|OCZ103-OS is given in combination with Chemotherapy each cycle
45386655|NCT01043211|Drug|Normal Saline|A standardized 0.2 ml/kg intravenous bolus dose of preservative-free normal saline will be given after anesthetic induction but prior to skin incision. Immediately thereafter, normal saline will be administered on an equal 0.3 ml/hr/kg (maximum 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the normal saline infusion will be decreased by 50% to 0.15 ml/hr/kg (maximum 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
45386656|NCT01043211|Drug|Normal Saline|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision.
45386657|NCT01043289|Other|Light therapy|During the 5-week treatment period, subjects sit in front of a light box for 60 minutes daily after awakening, at a specified distance that provides the required light intensity.
45386658|NCT01043367|Dietary Supplement|Deprexil|One 600 mg Deprexil tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
45386659|NCT01043367|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
45386660|NCT01043445|Dietary Supplement|GPR 119 agonist, 2-oleyl glycerol|Emulgation, 50 ml. containing 2g 2OG
45386661|NCT01043445|Dietary Supplement|Oleic acid|Emulgation, 50 ml. containing 1.54g of oleic acid
45386662|NCT01043445|Dietary Supplement|Vehicle|Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
45386663|NCT00299728|Biological|NY-ESO-1 Protein Vaccine|NY-ESO-1 recombinant protein mixed with CpG 7909 and Montanide ISA-51 VG
45386664|NCT03741946|Procedure|Triangle of Sedillot identification using ultrasonography|Contralateral head rotation was done with protractor at angle 30°, 45°, and 60°. The distance and overlap ratio of IJV and CA was calculated in each angle.
45386665|NCT00396591|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg administered intravenously (IV) once every 2 weeks
45386666|NCT00316264|Biological|Motavizumab, palivizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
45386667|NCT00316264|Biological|Palivizumab, motavizumab|Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.
45386668|NCT00316264|Biological|Motavizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
45386669|NCT02532946|Behavioral|Bedsider.org counseling|Contraceptive counseling was done while women kept the computer/tablet throughout their visit to facilitate discussion of website information with their providers.
45386670|NCT00385827|Drug|Mitoxantrone|Mitoxantrone 12 mg/m^2 intravenously as a 30 minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2)
45386671|NCT00385827|Drug|Siltuximab|Siltuximab 6 mg/kg intravenously as a 2 hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year
45386672|NCT00385827|Drug|Prednisone|Prednisone 5 mg orally twice daily
45386673|NCT00498602|Biological|ACC-001 + QS-21|IM injection, ACC-001 (3ug, or 10ug, or 30ug) + QS-21 50ug at Day 1 and weeks 4, 12, 26, and 52
45386674|NCT00498602|Biological|QS-21|IM injection, QS-21 (50 ug) at Day 1 and weeks 4, 12, 26, and 52
45386675|NCT00498602|Other|Diluent: Phosphate Buffered Saline|IM injection, PBS Diluent at Day 1 and weeks 4, 12, 26, and 52
45386676|NCT00498602|Biological|ACC-001|IM injection, ACC 001 (10 ug, 30ug) at Day 1 and weeks 4, 12, 26, and 52
45386677|NCT00507728|Drug|Bupropion|Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)
45386678|NCT00507728|Drug|Varenicline|Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)
45386679|NCT00507728|Drug|Placebo|Placebo by mouth for 12 weeks.
45386680|NCT00507728|Behavioral|Smoking Cessation Counseling|Counseling over 8 months and telephone support calls.
45386681|NCT00498368|Drug|Intravenous Rituximab|"Rituximab Therapy [27 Patients]~Rituximab 1 gm IV on Treatment Day 1~Rituximab 1 gm IV on Treatment Day 15~Rituximab 1 gm IV on Treatment Day 168~Rituximab 1 gm IV on Treatment Day 182"
45695645|NCT01699022|Drug|Injection Cyclofem|"Injection Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.~Women were administered three consecutive monthly injections of Cyclofem for prevention of ovulation, and were followed until the 92nd day from the last (third) injection."
45386682|NCT00498368|Drug|ACE/ARB|ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of <130/80 millimeters of mercury (mmHg). Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACE inhibitor (ACEi) + ARB
45386683|NCT00498368|Dietary Supplement|Omega-3 Fatty Acid Fish Oil Supplement|Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day
45386684|NCT04460066|Drug|anti-PD-L1 antibody|Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
45386685|NCT04460066|Drug|albumin bound paclitaxel|Patients will receive 4 cycles of albumin bound paclitaxel 125mg/m2 on days 1, 8 every 3 weeks .
45386686|NCT04460066|Drug|cisplatin|Patients will receive 4 cycles of cisplatin 75mg/m2 on day 1 every 3 weeks.
45386687|NCT04460066|Drug|placebo|Patients will receive 4 cycles of placebo IV on day 1 every 3 weeks.
45500344|NCT05073107|Other|"Mobile Dental Application, Dental Monitoring (DM)"|"o The Test group will be required to take intra-oral videos (which will be translated into photographs) using the DM application weekly and it will be monitored by the delegated team members:~Day 0 (To be taken at the clinic)~Day 7 (To be taken in the evening after brushing teeth)~Day 14 (To be taken in the evening after brushing teeth)~Day 21(To be taken in the evening after brushing teeth)~Day 28 (To be taken before study Visit 2) There is a window period of +1 day for the intra-oral videos."
45386688|NCT04460066|Procedure|radical resection of esophageal carcinoma|Patients will receive radical resection of esophageal carcinoma after 4 cycles of chemotherapy.
45500345|NCT02973048|Drug|Hyperbaric bupivacaine|The dose of 10 mg of hyperbaric bupivacaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
45500346|NCT02973048|Drug|Hyperbaric prilocaine|The dose of 50 mg of hyperbaric prilocaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
45500347|NCT03342027|Drug|Bupropion|medication for smoking cessation
45500348|NCT03342027|Behavioral|Positively smoke free|an 8 session, tailored behavioral intervention for treating tobacco dependence
45386689|NCT00385671|Drug|duloxetine hydrochloride|Duloxetine (DLX) once daily (QD), orally (PO)
45500349|NCT03342027|Other|Brief advice to quit smoking|Standardized brief advice to quit smoking (standard of care)
45500350|NCT05028413|Behavioral|Participants Shown their Breath Alcohol Content Measurement|Each time a Breath Alcohol Content (BrAC) Measurement is taken by the research team, the participant is shown the measurement before completing the paper visual analog scale scale (the Self-Reported intoxication Survey) on their perceived fitness to drive.
45500351|NCT04110405|Behavioral|Stepped Care|This stepped care model involves three steps. Step 1 is a peer and nurse co-led 8-session group based upon BRIDGES. Step 2 is peer or nurse led 6-session individual meetings based upon Interpersonal Psychotherapy. Step 3 is primary care physician led medication treatment with Amitriptyline.
45500352|NCT04110405|Behavioral|Standard of Care plus Healthy Lifestyle|Standard outpatient care supplemented with literature on healthy lifestyles will serve as an enhanced control condition. In each clinic, non-specialty mental health care is available in the form of counseling from doctors or nurses along with psychiatric medication management. Given the difficulties faced by women in Tajikistan, ethical responsibility compels us to enhance the control condition by having nurses distribute written materials on healthy eating, physical fitness, and personal hygiene, at a reading level which will be widely accessible.
45386690|NCT00385671|Drug|pregabalin|Pregabalin (PGB) orally (PO)
45500353|NCT02932943|Drug|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
45500354|NCT02932943|Drug|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
45500355|NCT04054206|Drug|MN-166|MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.
45386691|NCT00385671|Drug|gabapentin|Stable Gabapentin (GAB) (participants will remain on the same dose of gabapentin at which they entered the study)
45500356|NCT03603938|Drug|potassium losartan|treated with bedtime or awakening doses of potassium losartan
45500357|NCT03652116|Drug|Wound infiltration by Bupivacaine|Subcutaneous and subrectal infiltration with 0.25 % Bupivacaine diluted in 20 ml normal saline before closure of the wound
45500358|NCT03652116|Drug|Wound infiltration by Pethidine|Subcutaneous and subrectal infiltration with 50 mg pethidine diluted in 20 ml normal saline before closure of the wound
45500359|NCT03603860|Device|Non-invasive monitoring|Comparing blood pressure measurement using the Biobeat non-invasive monitor to arterial line
45500360|NCT04428671|Biological|Cemiplimab|Given IV
45500361|NCT04428671|Radiation|Radiation Therapy|Undergo standard of care radiation therapy
45500362|NCT04428671|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
45500363|NCT03602144|Other|Carbohydrate|Participants will receive a carbohydrate-based breakfast beverage everyone morning for 42 days.
45386692|NCT00497198|Drug|MCI-196|Three tablets of MCI-196 500mg tablet at a time, three times daily, 12 weeks administration (dose in a day: 4500mg)
45386693|NCT00497198|Drug|Placebo of MCI-196 Tablet|Three tablets of Placebo tablet at a time, three times daily, 12 weeks administration
45386694|NCT00496964|Drug|Botulinum toxin A + exercise|Injection of 100 units Botox (Botulinum toxin type A) into the Vastus Lateralis of the study leg + 12 weeks of exercise for patellofemoral pain
45386695|NCT00496964|Drug|Placebo|Injection of 2 cc placebo containing 0.1cc sodium bicarbonate 8.4% (1meq/cc), 0.9cc normal saline and 1 cc of lidocaine into the vastus lateralis of the study leg followed by 12 weeks of exercise for patellofemoral pain syndrome
45386696|NCT04448366|Behavioral|Cognitive behavioral therapy|Patients in the CBT group will receive usual care. In addition, they will undergo one pre-surgery and six post-surgery face-to-face sessions of CBT. In the pre-surgery session, management of expectations towards surgery will be addressed. In the six post-surgery sessions, attention will be paid to psycho-education concerning the biological link between endometriosis-related pain and stress, relaxation training, cognitive stress management, and management of anxiety, catastrophizing and hypervigilance. The CBT sessions will be coordinated by a registered psychotherapist who is experienced in CBT and has knowledge about endometriosis. All CBT will be individual sessions.
45386697|NCT05076578|Device|Autologous Regeneration of Tissue (ARTTM) system|The ART Skin Harvesting System is intended to harvest full thickness skin microcolumns in a minimally invasive manner and scatter them at the recipient site. It consists of three components: (1) a non-sterile, reusable handheld device; (2) a sterile, single-patient use needle cartridge containing the needle array for harvesting skin micrografts from the patient donor site; and (3) a sterile, disposable handheld protective sleeve to cover the handheld device (figure 1). The sterile sleeve reduces contamination of the reusable handheld device and provides a sterile barrier between the non-sterile handheld device and the patient.
45500364|NCT03602144|Other|Protein|Participants will receive a protein-based breakfast beverage everyone morning for 42 days.
45500365|NCT03603782|Dietary Supplement|2.5% protein|2.5%
45500366|NCT03603782|Dietary Supplement|protein 5%|5%
45500367|NCT03603782|Dietary Supplement|protein 10%|10%
45500368|NCT03603782|Dietary Supplement|protein 15%|15%
45500369|NCT03603782|Dietary Supplement|A2: Peptamen 1.5 Vanilla without Breakfast|Peptamen withoug breakfast
45695646|NCT01670175|Drug|Sirolimus, Cyclophosphamide, Topotecan|Dosing of cyclophosphamide and topotecan will be 25 mg/m2/dose and 0.8 mg/ m2 /dose respectively for dose levels 1 and 2. Level 3 dosing will escalate cyclophosphamide to 50 mg/ m2/dose. If level 1 dosing not tolerated, patients will be enrolled in level -1 cohort with cyclophosphamide and sirolimus administered only on days 1-14. If level -1 not tolerated, patients will be enrolled in level -2 with topotecan administration limited to days 1-7.
45695647|NCT03402490|Behavioral|Motivational interviewing|
45695648|NCT01674231|Other|Grape in the form of freeze-dried whole grape powder|60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
45848348|NCT03507036|Device|Profound system|Profound system is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis. Based on the its effect on facial skin, it can be hypothesized that bipolar fractional radiofrequency will stimulate similar effect on suprapatellar skin, lifting and reducing laxity of the skin in that region. Bilateral suprapatellar regions will be identified and marked for treatment.
45386698|NCT01011062|Procedure|Hyperinsulinaemia|Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
45386699|NCT01011062|Drug|Losartan|Acute administration of losartan 200mg total prior to clamp
45386700|NCT01011062|Drug|Saline|Infusion of Saline as a volume control intervention
45386701|NCT01016366|Drug|Lu AA24493|Vials with solution for i.v. injection. 325mcg Lu AA24493 dosed 3 times per week for two weeks. Vials will be supplied in concentrations ready for injection.
45500370|NCT03603782|Dietary Supplement|B2: only breakfast (no product)|only breakfast
45500371|NCT03603782|Dietary Supplement|C2: 5% protein with breakfast|C2: 5% protein consumed with breakfast
45500372|NCT03603782|Dietary Supplement|D2: 5% protein 30 min before breakfast|D2: 5% protein consumed 30 min before breakfast
45500373|NCT01946867|Device|NBTXR3 activated by IMRT|
45500374|NCT01550315|Procedure|Pulsitile Arterial Tonometry (PAT) Protocol|"A blood pressure cuff will be placed on one upper arm (study arm; non-dominant), while the contralateral arm will serve as a control (control arm).~RH-PAT probes will be placed on one finger (finger II, III, or IV) of each hand (same finger on both hands). The fingers on either side of the one with the probe will be separated using soft sponge rings.~Continuous recording of pulsatile blood volume responses from both hands will be initiated.~After a 10-min equilibration period, the blood pressure cuff on the study arm will be inflated to 60 mm Hg above systolic pressure for 5 min. The cuff will then be deflated to induce reactive hyperemia, PAT recording will be stopped."
45695649|NCT01674231|Other|Grape powder placebo|60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
45848349|NCT03509766|Device|Histamine skin testing|skin testing using histamine
45848350|NCT03511638|Device|Bausch & Lomb DVisc40|Ophthalmic viscosurgical device
45848351|NCT03511638|Device|Alcon VISCOAT®|Ophthalmic viscosurgical device
45848352|NCT03519282|Device|comfilcon A multifocal toric lens|contact lens
45848353|NCT03519282|Device|omafilcon A Multifocal Toric Lens|contact lens
45695650|NCT02243566|Drug|MicardisPlus®|
45695651|NCT01670253|Behavioral|Group 1|"6 hour fast from all solid foods and milk beverages~2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)~Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like."
45848354|NCT03520998|Drug|GRF6019|GRF6019 for IV infusion
45848355|NCT03525210|Biological|9-valent HPV vaccine|Vaccination
45848356|NCT03532308|Drug|Fermented Soy|Two 12.5g packets/day) (~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Time can be between 4 and 10 weeks.
45848357|NCT03532308|Other|Placebo|A placebo compliment to the active intervention with identical packaging and labeling will be used.
45848358|NCT03532776|Drug|Podofilox Gel 0.5%|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
45848359|NCT03532776|Drug|Condylox Topical Gel 0.5%|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
45848360|NCT03532776|Drug|Placebo Gel|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
45848361|NCT03533244|Drug|0.1% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
45848362|NCT03533244|Drug|0.3% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
45848363|NCT03533244|Drug|Vehicle Eye Drops|One drop, three times daily to the study eye for 28 days
45500375|NCT01550315|Device|Calf Blood Flow in Reactive Hyperemia (CBF-RH)|Calf blood flow (CBF) will be determined using venous occlusion plethysmography and calibrated mercury strain-gauges during reactive hyperemia after a 5 min of ischemia of the distal limb. Strain-gauges will be applied to the widest part of the non-dominant calf (~10 cm below patella). Participants will remain quietly supine for 10 min with legs elevated on foam pads above the right atrium to achieve stable baseline measurements of CBF. The venous occlusion cuff is inflated for 4 seconds at 8 seconds intervals, while monitoring the change in resistance in the system, pressure inside the measuring cuff, and 5-10 determinations are performed
45386702|NCT01016366|Drug|Placebo|Vials with solution for i.v. injection. Placebo dosed 3 times per week for two weeks.
45386703|NCT03996980|Device|Custom-made foot orthoses Versus a flat insole|Compare the use of plantar orthoses (experimental group) with the use of a flat insoles (control group)
45386704|NCT00490490|Drug|Bexxar (tositumomab)|Tositumomab is a CD20-directed radiotherapeutic (131-iodine) monoclonal antibody indicated for the treatment of patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin's lymphoma who have progressed during or after rituximab therapy, including patients with rituximab-refractory non-Hodgkin's lymphoma. Tositumomab (standard regimen) will be administered at whole body exposure of 75 cGy.
45500376|NCT01550315|Device|Evaluation of Forearm-Mediated Dilation|The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.
45500377|NCT01330121|Other|Pharmacist Counseling|"Pharmacist Counseling includes but is not limited to:~Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic & non-glycemic goal levels Explaining the importance of compliance with medications & appointments Educating on the basics of nutrition and physical activity"
45426157|NCT05795179|Behavioral|Cold-Pressor Task (CPT)|CPT is a physiological stress task in which participants continuously submerge their hand and forearm in ice-water (0-4°C) for 3 minutes.
45500378|NCT02972658|Drug|Lanabecestat|Administered orally
45500379|NCT02853032|Device|Active repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver active repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
45500380|NCT02853032|Device|robotic arm|This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
45500381|NCT02853032|Device|Sham repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver placebo repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
45500382|NCT02232087|Drug|Salmeterol|A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
45500383|NCT02232087|Drug|fluticasone propionate|A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
45848364|NCT03541356|Combination Product|Placebo|Delivered via the I231 POD (Precision Olfactory Delivery) device
45500384|NCT03168425|Other|Tailored prescription|Participants will be prescribed an opioid tablet number based on a formula derived from inpatient opioid use
45500385|NCT03168425|Other|Control|Participants will be prescribed 30 tablets of oxycodone 5mg
45500386|NCT00004445|Procedure|Surgery|
45500387|NCT00004445|Device|IRS-8|
45500388|NCT01380015|Other|Commercially spearmint tea|Commercially available, non-selectively bred spearmint tea.
45848365|NCT03541356|Combination Product|L-dopa 35 mg|Delivered via the I231 POD (Precision Olfactory Delivery) device via one puff to one nostril
45848366|NCT03541356|Combination Product|L-dopa 70mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
45848367|NCT03541356|Combination Product|L-dopa 140 mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with four puffs, two to each nostril
45848368|NCT03541356|Combination Product|L-dopa 70mg/carbidopa 7mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
45848369|NCT03545412|Device|Microfocused ultrasound with visualization|Each subject to receive a minimum of 800 treatment lines, on two planes of treatment using the 4-4.5mm and 7-3.0mm transducer depths
45848370|NCT03546270|Behavioral|Swimming|This group completed 20-weeks of swimming
45848371|NCT03549234|Drug|Erector Spinae (single injection)|Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
45500389|NCT01380015|Other|High Rosmarinic Acid Spearmint Tea|The investigational product will be a high rosmarinic acid spearmint tea (700B) developed by the Department of Plant Agriculture, University of Guelph. Clone 700B has been selectively bred to contain a rosmarinic acid content 15-20 times greater than that of typical mint.
45500390|NCT03603704|Drug|LY3209590|Administered SC
45500391|NCT03603704|Drug|Placebo|Administered SC
45500392|NCT03652584|Other|High Protein Diet|
45500393|NCT03652584|Other|Control Diet|
45500394|NCT03330561|Drug|PRS-343|PRS-343
45500395|NCT03603626|Drug|Pregabalin 150mg|Preemptive pregabalin 150 mg administered 1 hour before surgery
45500396|NCT03603626|Drug|Placebo oral capsule|Placebo administered 1 hour before surgery
45500397|NCT03652038|Drug|TD-8236|Study drug to be administered via inhaler device
45386705|NCT00490490|Procedure|External beam radiotherapy (XRT)|Patient-specific XRT will begin within 24 hours of administration of the therapeutic dose of tositumomab. Subjects will receive local XRT to bulky sites of disease measuring at least 5 cm in at least one dimension. The size and number of fields to be treated will determined by the investigators, but will encompass the patient's most symptomatic/threatening site(s) of disease and not cumulatively include more than 25% of the active bone marrow. Subjects will be treated with the 2 x 2 Gy regimen (2 daily fractions of 2 Gy). Sites of disease previously-irradiated with 30 to 40 Gy will not be treated on this study.
45848372|NCT03549234|Drug|Paravertebral (single injection)|Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
45386706|NCT00490490|Drug|Potassium Iodide (KI)|"Potassium iodide (KI) will be administered as:~Saturated solution potassium iodide (SSKI) 4 drops orally 3-times-a-day,~Lugol's solution 20 drops orally 3-times-a-day, OR~KI tablets 130 mg orally once per day KI treatment will start at least 24 hours prior to tositumomab, and continue daily for 14 days following the last dose of tositumomab"
45386707|NCT04431830|Behavioral|Meaning-Centered Pain Coping Skills Training|The goal of this intervention is to help participants manage pain so that they can engage with what gives them a sense of meaning, purpose, and significance in life.
45386708|NCT04420364|Other|Maintenance or reduction of immunosuppression|Maintenance versus reduction of immunosuppression
45386709|NCT01014884|Other|Multidisciplinary team interventions|The multidisciplinary team will determine which intervention should be applied to the participant in the intervention group based on their health risk assessment responses as well as medication review and visual inspection of the home.
45386710|NCT01014884|Other|Multidisciplinary team bimonthly visits either in person or via telephone.|
45386711|NCT01014884|Other|Usual case management and pharmacy management as provided by the health Plan and the pharmacy benefit manager|
45386712|NCT01011140|Behavioral|Survey|10-15 minute online survey to assess palliative care physicians' attitudes, beliefs and practice patterns related to parenteral hydration at the end of life in Latin America and Spain.
45500398|NCT03652038|Drug|Placebo|Placebo to be administered via inhaler device
45500399|NCT03651960|Other|ROBOT PROTOTYPE|The intervention consists of 12 45-minute sessions of balance and gait training with a mobile and interactive robot prototype for 4 weeks.
45500400|NCT01377909|Drug|statin|daily statin orally for 48 weeks
45500401|NCT01765218|Drug|Topiramate|Infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.
45848373|NCT03557658|Drug|Bexagliflozin|Single oral dose of bexagliflozin tablet, 20 mg
45500402|NCT01765218|Drug|Placebo|A placebo identical in appearance to the active agent (topiramate)
45500403|NCT04053660|Procedure|Non-surgical periodontal treatment|Mechanical non-surgical treatment were performed
45500404|NCT01731522|Behavioral|EF condition|
45500405|NCT05463159|Other|Transcutaneous electrical nerve stimulation|All children received 30 min of conventional TENS (continuous stimulation with all parameters constant) with a frequency of 100 Hz and a pulse width of 200 µs.
45500406|NCT03222128|Device|TAVR|Implantation of the SAPIEN 3
45500407|NCT02972502|Drug|Metoclopramide|Patients receive 10 mg of intravenous (IV) metoclopramide.
45500408|NCT02972502|Drug|Haloperidol|Patients receive 2.5 mg of IV haloperidol.
45500409|NCT02972502|Other|Normal Saline|All patients receive a 1-liter bolus of normal saline (NS)
45500410|NCT02972502|Drug|Diphenhydramine|All patients receive 25 mg of intravenous (IV) diphenhydramine.
45500411|NCT05462067|Device|AT LARA IOL|EDOF IOL for treatment of cataract
45500412|NCT05462067|Device|AT LISA Tri IOL|Trifocal IOL for treatment of cataract
45848374|NCT03564444|Biological|Bivalent influenza vaccine|A single dose of bivalent vaccine (10^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1.
45848375|NCT03564444|Other|Placebo|A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
45848376|NCT03567252|Behavioral|Walking Group|Participants will walk 1 kilometer to a Farmer's Market.
45848377|NCT03569748|Device|IQOS|IQOS USE FOR 12 WEEKS
45848378|NCT03569748|Device|E-CIG|ELECTRONIC CIGARETTE FOR 12 WEEKS
45848379|NCT03572478|Drug|Rucaparib|600 mg taken by mouth twice daily.
45848380|NCT03572478|Drug|Nivolumab|480 mg given by intravenous (IV) infusion every 4 weeks.
45386713|NCT01014962|Drug|Albaconozole|Albaconozole 400 mg oral once daily for 5 days
45500413|NCT05461911|Dietary Supplement|Nutrison Advanced Cubison|(20% protein energy 100 kcal, 5.5 g protein, 0.85 g arginine, 38 mg of vitamin C and 2 mg of zinc) in a volume not exceeding 1.5 liters / day and, if necessary, to replenish nutritional needs based on the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g of protein / kg body weight / day according to the recommendations for nutritional support
45500414|NCT01569477|Behavioral|Incentives for abstinence and treatment engagement|Treatment incentives - incentives for biochemical verification visits, treatment engagement and abstinence
45386714|NCT01014962|Drug|Placebo|Placebo oral once daily for 5 days
45386715|NCT01014962|Drug|Albaconozole|Albaconozole 400 mg every 12 hours for 5 days
45386716|NCT01014962|Drug|Placebo|Placebo oral every 12 hours for 5 days
45386717|NCT01014962|Drug|Albaconozole|Albaconozole 400 mg oral every 8 hours for 5 days
45386718|NCT01014962|Drug|Placebo|Placebo oral every 8 hours for 5 days
45386719|NCT05058248|Procedure|pudendal block|general anesthesia with an intravenous analgesic protocol then oral without anesthesia regional loco
45386720|NCT05049980|Drug|Medical treatment with Mifégyne® and MisoOne®|When participants arrive for their uterine emptiness check-up, 12 days after treatment, patients will be asked to drop off the study questionnaire the same day in a box provided for this purpose in the department.
45386721|NCT05049980|Procedure|Endo-uterine aspiration|When patients arrive in hospital on the day of the surgery, participants will be asked to complete a questionnaire at home 1 week after surgery and return it to investigators.
45386722|NCT01039779|Behavioral|Exercise|Exercise will be taught every week over the 6-month intervention period at a subject's residence by instructors.
45386723|NCT05176418|Drug|Nicotine|IV nicotine infused over different delivery rates
45386724|NCT05176418|Drug|Nicotine|IV Nicotine infused over different delivery rates
45386725|NCT01016522|Dietary Supplement|KetoCal|Ketogenic Diet food via gastrostomy tube - 80% fat, 17% protein, 3% carbohydrates
45386726|NCT00385593|Drug|Symbicort (budesonide/formoterol) Turbuhaler|
45500415|NCT01569477|Behavioral|Attendance incentive|Attendance Incentives - incentives for only attending the biochemical verification visits
45500416|NCT03601988|Radiation|Concurrent chemo-radiotherapy|Experimental group receive 6 cycles of XELOX chemotherapy and concurrent chemo-radiotherapy. The radiotherapy dose of 45Gy in 25 fractions delivered by IMRT Radiotherapy
45500417|NCT03601988|Drug|Chemotherapy|Chemotherapy group receive 8 cycles of XELOX.
45500418|NCT03606590|Device|NovoTTF-100L(P) device|Patients will be treated continuously with the NovoTTF-100L(P) device. NovoTTF-100L(P) treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.
45500419|NCT03606590|Drug|Sorafenib|Sorafenib 400 mg (2 x 200 mg tablets) taken twice daily without food (at least 1 hour before or 2 hours after a meal).
45500420|NCT02971800|Drug|sodium fluorescein injection 10%|
45500421|NCT03601910|Drug|D308 10mg Tab.|D308 10mg Tab.1T single oral administration under fasting condition
45500422|NCT03601910|Drug|CKD-380 10mg Tab.|CKD-380(Dapagliflozin) 10mg Tab.1T single oral administration under fasting condition
45500423|NCT03163667|Drug|Placebo|oral tablets
45500424|NCT03163667|Drug|CB-839|oral tablets
45500425|NCT03163667|Drug|everolimus|oral tablets
45500426|NCT03651570|Device|PTSD Coach|PTSD Coach is a mobile mental health app that addresses the issue of mental health and stigma which can be used as a stand-alone education and symptom management and contains 4 modules: 1) Learn- Module, 2) Self- Assessment-Module, 3) Manage Symptoms-Module and 4) Find Support-Module.
45848381|NCT03574818|Drug|Necitumumab-Gemcitabine-Cisplatin|"Gemcitabine 1250mg/m2 IV on D1, D8~Cisplatin 75mg / m2 IV on D1~Necitumumab 800mg IV on D1, D8 (peripheral blood for effector cells and cytokine measurements prior to each cycle) Repeat cycle every 21 days up to 3 cycles."
45848382|NCT03574818|Diagnostic Test|Evaluation to determine if patient is a candidate to proceeed with surgical resection or not|Patients will be evaluated with repeat imaging studies (PET/CT or CT Chest, Abdomen, Pelvis) and will be re-evaluated for surgical resection. Patients who had progressive disease or are NOT a surgical candidate will come off the study and will be treated according to standard therapies. All patients will be followed up for 2-year disease-free survival and overall survival
45386727|NCT00385593|Drug|Conventional treatment|
45386728|NCT01015040|Drug|solifenacin succinate suspension|Oral
45386729|NCT01015040|Drug|solifenacin succinate tablet|Oral
45500427|NCT03651570|Behavioral|Game application|This control condition is important to control for distraction (attention on something pleasant or a task) and the human factor involved in usage prompting (i.e., same exposure time + contacts with personnel), since either distraction or the human contact with staff may, alone, lower anxiety
45386730|NCT04388618|Other|NHANES smell and taste tests|participants will be asked to smell 8 cards of different odors and submit your choices in a given card, and so for 3 different taste tips (salty, bitter and neutral). participants will be asked to submit his choices in a given card as well. Then participants photograph those cards and send it via WhatsApp to a given number to be collected
45386731|NCT01039857|Behavioral|Neuropsychological Therapy, cognitive behavioral therapy, solution focused therapy|
45386732|NCT01039857|Behavioral|Integrative Neuro-Psychotherapy|Neuropsychological therapy, cognitive-behavioral therapy, emotion-focused techniques, clarification and interpersonal therapy techniques
45386733|NCT00495794|Behavioral|Clinical pharmacist-based intervention|Pharmacist proactive outreach to patients systematically identified as having adherence or intensification problems; their use of tailored adherence counseling strategies; and their authorization to titrate medications according to prespecified algorithms
45386734|NCT01011296|Drug|PF-04427429|Single 0.2mg dose of intravenous infusion
45386735|NCT01011296|Drug|PF-04427429|Single 1mg dose of intravenous infusion
45386736|NCT01011296|Drug|PF-04427429|Single 3 mg dose of intravenous infusion
45386737|NCT00495170|Drug|Carboplatin|2 area under curve (AUC) by vein Weekly
45386738|NCT00495170|Radiation|Proton Radiotherapy|2 GY/fraction for 37 fractions (daily treatment, Monday to Friday, for 7.5 weeks).
45386739|NCT00495170|Drug|Paclitaxel|50 mg/m^2 by vein Weekly
45386740|NCT03853148|Behavioral|Otago|Exercise program for strength and balance
45386741|NCT03853148|Behavioral|Gentle yogic breathing|yogic breathing
45500428|NCT03603548|Drug|Envarsus|Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
45500429|NCT03603548|Drug|Advagraf|Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
45500430|NCT03651492|Behavioral|questionnaire administration|All the patients will be administered the Pittsburgh Questionnaire after completion of ABPM.
45500431|NCT03954782|Drug|Nintedanib 150 mg and 100 mg soft capsules|Nintedanib 150 mg soft capsules twice daily approximately 12 hours apart (i.e. 300 mg/day) for 12 weeks. In case of adverse reaction a dose reduction at 200 mg/day (100 mg twice daily) can be prescribe.
45500432|NCT03954782|Drug|Oral treatment of placebo soft capsule|Placebo soft capsules (identical to 150 mg and 100 mg soft capsules)
45500433|NCT01330199|Other|Pharmacokinetic Sampling|Blood plasma, Rectal, Cervical, and Vaginal Tissues and Secretions
45500434|NCT03651726|Drug|THX-110 (dronabinol plus PEA)|2.5 mg dronabinol capsules and 400 mg PEA tablets
45386742|NCT03853148|Behavioral|Behavioral Activation|Behavioral Activation incorporates daily planners and worksheets to identify and rate reinforcing behaviors and is often used in conjunction with other interventions because components of these interventions are easily incorporated into the daily planner based activities.
45386743|NCT03853148|Behavioral|Caregiver Gentle yogic breathing|yogic breathing
45500435|NCT03651726|Drug|Placebo|Sesame oil pill manufactured to mimic 2.5 mg dronabinol capsules; cellulose pill manufactured to mimic 400 mg PEA tablets
45500436|NCT01781039|Device|Hearing Aid fitting|Subjects with hfPTAs ranging from 0-55 dB HL will be recruitedwith 100 persons self-reporting difficulty HIN (> 50% of the time), and 100 persons reporting little difficulty HIN (< 50% of the time) will be randomly assigned to one of five groups (n = 200) based on enabled HA features using an online random assignment tool. Unaided HIQ and HIN assessments will be conducted in the sound field, and baseline DPOAE and CAP assessments will be measured. Subjects will be fit with binaural premium level receiver-in-the canal HAs (Phonak B90 or equivalent model at the start of the study) with 56 dB SPL gain receivers, using closed domes, and programmed to NAL-NL2 target gain, and randomly assigned to the groups.
45695652|NCT04373590|Behavioral|Decision aid|The chosen intervention is a one-page DA developed by the first author, published and fully described elsewhere (Zisman-Ilani et al., 2017; Zisman et al., 2018) for use during the psychiatric consultation to help patients and clinicians discuss relevant treatment options pertaining to antipsychotics such as medication nonadherence and self-tapering. The DA format is a simple one-page table with rows containing frequently asked questions by patients about their treatment options and the benefits, risks, and implications of differing decisions. The columns display the treatment options available for the treatment decision in question: continuing, adjusting, or discontinuing antipsychotic medications.
45848383|NCT03575754|Device|Percutaneous Ultrasound Gastrostomy|A balloon catheter is inserted into the stomach and used to appose tissue between anterior stomach and skin. Fluid fills the balloon, enabling ultrasound visualization. Then a guidewire is inserted, and pulled out through the mouth to create wire-to-wire (through and through) access. At that point, a gastrostomy tube is placed over it using over-the-wire (push) technique.
45848384|NCT03584100|Device|Tourniquet 8000|Pneumatic tourniquet with appropriate upper extremity cuff, pressure sensing, and ability to set device at 40 mmHg of pressure
45848385|NCT03593538|Drug|Metformin|Metformin capsule
45386744|NCT01011374|Drug|ranibizumab (Lucentis)|0.5 mg, administered intravitreally every 4 weeks
45848386|NCT03593538|Drug|Placebo|Sucrose filler in gel capsules
45386745|NCT04369976|Device|ARTIFICIAL GRAVITY COMBINED WITH EXERCISE|The passive control group will abstain from any exercise. Recordings of the participant's will include cardiovascular functioning cardiac output (CO), stroke volume (SV) mean arterial pressure (MAP) diastolic blood pressure (DBP), systolic blood pressure (SBP), and heart rate (HR), Electroencephalography ( EEG) as well as dynamic force and stance and muscle oxygenation. More specifically, after 6 training sessions (2 weeks), the centrifugation load will be increased and will be combined with either aerobic exercise (through an ergometer) or resistance training through elastic training bands. Functional connectivity and cortical-network features will be used by deep learning algorithms in order to define the optimal centrifuge training .
45386746|NCT00385203|Drug|AZD2171|45 mg oral tablet once daily dose
45500437|NCT03603470|Other|EOS imagery|Whole body EOS imaging in seated and standing position
45500438|NCT00107250|Drug|capecitabine|1000 mg/m2 orally twice daily (total of 2000 mg/m2 per day) for the first 14 days of a 21 day cycle for a maximum of 6-8 cycles.
45386747|NCT01043601|Drug|Inhaled PT005|inhaled, twice daily for 1 week duration
45500439|NCT00107250|Drug|carboplatin|AUC 6; IV; 30 minutes; Every 21 days for a maximum of 6-8 cycles
45500440|NCT00107250|Drug|cediranib maleate|Given daily; orally with approximately 240 ml of water whilst in an upright position
45386748|NCT01043601|Drug|Inhaled Placebo|inhaled, twice daily for 1 week duration
45386749|NCT01043601|Drug|Formoterol Fumarate 12 µg (Foradil Aerolizer)|inhaled, twice daily for 1 week duration
45386750|NCT01043679|Drug|Utapine|Efficacy and Safety of Utapine
45386751|NCT01043679|Drug|Seroquel|Efficacy and Safety of Seroquel
45500441|NCT00107250|Drug|paclitaxel|200mg/m2; IV; 3 hours; Every 21 days for a maximum of 6-8 cycles
45500442|NCT03606434|Other|Hypoxic exposure|30 minutes of intermittent hypoxia
45500443|NCT03603392|Other|Physical activity program|
45386752|NCT00408993|Drug|Duloxetine Hydrochloride|60 mg every day (QD) (morning or evening), by mouth (PO)
45500444|NCT03651258|Behavioral|Implementation of ALIJEU|"The intervention concerns the passage from the passive feed (gastric tube) to the active feed (breast, feeding bottle).~We propose to set up a pleasant moment just before his meal. This is a practical exercise of a few minutes.~The aim of this special moment is to facilitate child-adult exchanges, improve active food intake and reduce the length of hospital stay."
45500445|NCT03167411|Drug|Bexagliflozin|Bexagliflozin tablets, 20 mg
45695653|NCT01683019|Device|NeoSync EEG Synchronization Therapy|Generate low-energy sinusoidal magnetic field above the scalp with frequency equal to the subject's intrinsic alpha frequency (IAF). Treatment is 30 minutes, administered 5 days per week for 4 weeks.
45695654|NCT01683019|Device|Sham NeoSync EEG Synchronization Therapy|A device that looks and sounds similar to the active treatment, but no magnetic field is generated.
45695655|NCT03861507|Device|Prostate Brachytherapy|High dose - rate (HDR) brachytherapy
45695656|NCT02243644|Drug|7 days of albendazole 15 mg/kg/day|group A will receive 7 days of oral albendazole 15 mg/kg/day
45695657|NCT02243644|Drug|28 days of albendazole 15 mg/kg/day|group B will receive 28 days of oral albendazole 15 mg/kg/day
45695658|NCT01988883|Drug|Placebo|Locking gelatin capsules filled with microcrystalline cellulose
45386753|NCT00408993|Drug|Placebo|Placebo every day (QD), by mouth (PO)
45386754|NCT00395967|Drug|G-CSF plus plerixafor|Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) (10 µg/kg once a day) for 5 days. Patients received once daily plerixafor treatment (240 mg/kg) in the evening (10 to 11 hours prior to apheresis) for up to 3 days if peripheral blood CD34+ cell counts on Day 5 met the entry criteria. Morning doses of G-CSF (10 µg/kg) continued throughout apheresis.
45695659|NCT01988883|Drug|Modafinil|Modafinil is a wakefulness-promoting or psychostimulant drug. It will be administered as a single 200 mg oral tablet.
45695660|NCT01988883|Drug|Propranolol|Propranolol is a non-selective beta adrenergic antagonist.It will be administered as a single 20 mg oral tablet.
45695661|NCT04373278|Other|failure of reconstruction of the mandibule by free fibula flap|description of failure of reconstruction of the mandibule by free fibula flap:delay, type of bacteria involved in the failure, treatment, outcome
46056476|NCT02694627|Behavioral|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho is a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants are first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engages men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focus on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
45386755|NCT03993093|Other|CD4 cell count|CD4 cell count from treatment naive HIV patients
45500446|NCT03167411|Drug|Exenatide Injection|Byetta® (Exenatide), 10 ug, bid, subcutaneous injection
45500447|NCT02035436|Other|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
45500448|NCT02035436|Other|Control: Sedation|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
45695662|NCT04373356|Device|Resin Infiltration|"Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with a rubber dam and ICON will be applied following the manufacturer's instructions. After that, the rubber dam will be removed and 5% NaF Varnish will be applied.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison."
45695663|NCT04373356|Device|Sodium Fluoride Varnish|"Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with cotton roll and 5% NaF varnish will be applied following the manufacturer's instructions.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison."
46056477|NCT02594995|Drug|NBP|
46056478|NCT05377333|Drug|LY3457263|Administered SC.
46056479|NCT05377333|Drug|Placebo|Administered SC.
46056480|NCT05377333|Drug|Dulaglutide|Administered SC.
45500449|NCT03601754|Diagnostic Test|Treadmill/Bicycle exercise testing|"Exercise testing will be scheduled on the same day as the enrollment visit and within 30 days after post-implant visit.~The standard protocol will be typically set at an initial workload of 15Watts and go up by increments of 10 Watts every 3 minutes, as follows:~Stage 1 - 15 W Stage 2 - 25 W Stage 3 - 35 W Stage 4 - 45 W"
45386756|NCT00395733|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participant received a single intravenous injection with Gadobutrol (1.0 M) at a volume of 0.2 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.3 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
45386757|NCT00395733|Drug|Gadopentate dimeglumine (Magnevist, BAY86-4882)|Participant received a single intravenous injection with Gadopentate (0.5 M) at a volume of 0.4 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.6 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
45386758|NCT00441987|Drug|GSI-953|
45500450|NCT03606356|Drug|Onabotulinum toxin A|Cranial Subcutaneous Injections
45500451|NCT02237768|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
45386759|NCT00395343|Drug|sitagliptin phosphate|sitagliptin 100 mg tablet qd for a 24-wk treatment period.
45500452|NCT02237768|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
45500453|NCT03606278|Other|Structured debriefing assisted by video|In the structured debriefing assisted by video, the process was based on the immediate review of the video, stopping and rewinding the recording as required. The debriefing session was conducted in the debriefing room of the simulation laboratory with an assigned time of 15 minutes. Each session was developed in three phases. The first phase, descriptive, in which each participant was encouraged to recount what they had lived and experienced, clarifying how the events unfolded, verifying the appropriate decisions and the errors committed in the scenario and the ways they could have solved them and corrected them. The second phase, analytical, the participant reflected on what occurred in the scenario, commenting on how their feelings were involved in the development of the case. The third phase, application or transference, in which the group was encouraged to draw conclusions from what had occurred, realizing an application of this experience in a real-life.
45500454|NCT03606278|Other|Structured oral debriefing|In the structured oral debriefing, the process was based by the mental search of their memories of what occurred. The debriefing session was conducted in the debriefing room of the simulation laboratory with an assigned time of 15 minutes. Each session was developed in three phases. The first phase, descriptive, in which each participant was encouraged to recount what they had lived and experienced, clarifying how the events unfolded, verifying the appropriate decisions and the errors committed in the scenario and the ways they could have solved them and corrected them. The second phase, analytical, the participant reflected on what occurred in the scenario, commenting on how their feelings were involved in the development of the case. The third phase, application or transference, in which the group was encouraged to draw conclusions from what had occurred, realizing an application of this experience in a real-life.
45500455|NCT01952847|Other|Placebo|mTOR Inhibitor Patient Group: Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
45386760|NCT00395343|Drug|Comparator : placebo (unspecified)|sitagliptin 100 mg Pbo tablet qd for a 24-wk treatment period.
45500456|NCT01952847|Drug|Glutamine|mTOR Inhibitor Patient Group - Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
45386761|NCT00560573|Drug|CP-751,871|CP-751,871 at doses ranging from 6 to 20 mg/Kg on Day 1 of each 21-day cycle. CP-751,871 may be administered even after active comparators discontinuation, for a total number of 17 cycles (1 year).
45386762|NCT00560573|Drug|Cisplatin|"Cisplatin 75* mg/m2 or 80* mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycles.~* 75 mg/m2 when in combination with pemetrexed, 80 mg/m2 when in combination with gemcitabine"
45386763|NCT00560573|Drug|Gemcitabine|Gemcitabine 1250 mg/m2, IV on Days 1 and 8 of each 21-day cycle up to 6 cycles
45386764|NCT00560573|Drug|Pemetrexed|Pemetrexed 500 mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycle
45386765|NCT00950105|Drug|CPSI-2364 or placebo|Single, oral dose of CPSI-2364 or placebo
45386766|NCT00946283|Dietary Supplement|Lactobacillus rhamnosus GG|Culturelle DS (Lactobacillus GG) will be administered one capsule (10 billion live lactobacillus GG) daily with water
45386767|NCT00946361|Other|Examinations|Growth hormone stimulation testing, Protein turnover, Dexa scan, Bone age x-ray
45386768|NCT05301257|Behavioral|Intervention group SOSteniamoci|Intervention based on cognitive behavioural therapy principles and culturally adapted to Italian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
45426158|NCT05795179|Behavioral|Trier Social Stress Test (TSST)|The TSST is a psychosocial stressor that requires participants perform a short speech and solve math problems in front of 2 evaluative judges.
45426159|NCT05795179|Behavioral|Modified Non-Stress CPT|The modified non-stress CPT involves participants continuously submerging their hand and forearm in warm water for 3 minutes.
45426160|NCT05795179|Behavioral|Modified Non-Stress TSST|For the modified non-stress TSST, participants are asked to prepare for a speech that they will practice alone to themselves and complete math problems alone on a piece of scrap paper.
45386769|NCT00946439|Device|Wheel assisted running training|'Race-Runner' uses the principle of body weight reduction and wheel assisted running training. This is a three-wheel device specifically designed in the 1990s for athletic purposes. The participant is walking or running with the feet on the ground while using a triangular frame equipped with three large bicycle wheels. Support to the participant's body is provided by a regular cycle saddle, a frontal body support plate, and the steering handlebars. The vertical and horizontal distance of the saddle and frontal support from the steering handlebars are adaptable to the participant's body dimension and comfort. This equipment is commonly used in competition in Scandinavia and Central Europe
45386770|NCT00941837|Dietary Supplement|Olive Oil, Palm Olein Oil, Coconut Oil|Effect of dietary fat type in combination with high protein on plasma homocysteine levels; 5 wk each with 2 wk wash out in between
45386771|NCT00946517|Other|Questionnaires|Parenting and behavioral questionnaires
45386772|NCT00950261|Radiation|tri-weekly cisplatin|cisplatin 75mg/m2 every 3 weeks, intravenous, 3 cycles
45386773|NCT05280197|Procedure|TAP block|Transversus abdominis plane (TAP) nerve block with liposomal bupivacaine plus free bupivacaine
45386774|NCT05280197|Procedure|TAP block|Transversus abdominis plane (TAP) nerve block with normal saline
45386775|NCT05280197|Drug|liposomal bupivacaine plus free bupivacaine|TAP block using liposomal bupivacaine plus free bupivacaine
45386776|NCT05280197|Drug|normal saline|TAP block using normal saline
45386777|NCT00946595|Drug|efavirenz/emtricitabin/tenofovir|1x600/200/245 mg per day (one tablet) between W0 et W98
45386778|NCT00946595|Drug|lopinavir/ritonavir|4 x 200/50 mg (4 tablets) once a day between W0 and W98
45386779|NCT00942071|Biological|MVA-NP+M1|1. Intradermal injection at 5 x 10^7 pfu at day 0
45386780|NCT00942071|Biological|MVA-NP+M1|2.Intramuscular injection at 5 x 10^7 pfu/ml at day 0. Intramuscular injection at 2.5 x 10^8 pfu/ml at day 0
45386781|NCT00942071|Biological|MVA-NP+M1|3.Intramuscular injection at 1.5 x 10^8 pfu/ml at day 0
45386782|NCT03961529|Drug|0.3% OPA-15406 ointment|Twice daily
45386783|NCT03961529|Drug|1% OPA-15406 ointment|Twice daily
45386784|NCT00494780|Drug|Ofatumumab|ofatumumab 300mg, 500mg or 1000mg should be diluted into 1000mL pyrogen free saline and administered as an IV infusion.Duration of infusion will be approximately 4 hours.Infusions should be given every 3 weeks until a total of 6 infusions has been given
45386785|NCT00494780|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
45386786|NCT00494780|Drug|Doxorubicin|Doxorubicin : 50mg/m2 iv for 1 day, 24-48h post-ofatumumumab infusion start
45386787|NCT00494780|Drug|Vincristine|Vincristine : 1.4mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
45386788|NCT00494780|Drug|Prednisolone, Prednisone or equivalent|100mg p.o daily for 5 days, 24-48h post-ofatumumab infusion start
45386789|NCT01011452|Drug|Montelukast|1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
45386790|NCT01011452|Drug|Placebo|1 placebo capsule at study entry and a further placebo capsule at 10pm for four weeks
45386791|NCT00490022|Drug|Dihydrotestosterone (DHT) gel (0.7%)|DHT gel, 70 mg/day for one month
45500457|NCT01952847|Behavioral|Questionnaires|Questionnaire completion for mTOR Inhibitor Patient Group: At baseline, Day 1 of cycle 2 and beyond, after 6 months of chemotherapy, and at end of study visit.
45500458|NCT03597932|Device|standardized handover checklist|Following a review of relevant literatures and guidelines, a checklist consisting of the various key items necessary for giving continuing and safe intraoperative patient care was designed and validated by anesthesia residents and staff. Following 2-week to 1-month baseline data collection, each anesthesiologists and anesthesia residents in participating hospitals were asked to implement the safe-anesthesia checklist to improve practice over another 2-week to 1-month period. The checklist consists of an oral confirmation and closed-loop communication between the primary anesthesiologist and the replacement anesthesiologist. Evaluation of the effect of implementation of a standardized checklist during anesthesia care handover on patient safety during follow-up.
45500459|NCT02237846|Biological|Human umbilical cord tissue-derived mesenchymal stem cells|
45500460|NCT03601676|Other|Integration of electronic clinical decision support|Integration of an electronic clinical decision support system into the emergency department patient care workflow to assist with site-of-care decision-making for emergency department patients with acute pulmonary embolism.
45848387|NCT03610464|Drug|Amphetamine Extended Release Suspension [Dyanavel]|1 mL of study drug (AMPH EROS, 2.5 mg/mL), pharmacokinetic analysis
45848388|NCT03613818|Behavioral|eCHECKUP TO GO|eCHECKUP TO GO is a personalized normative feedback intervention intended to help participants make better choices about alcohol use by changing beliefs about alcohol, alcohol expectancies, and perceptions of peer drinking
45848389|NCT03614130|Device|LID011121 contact lens|Investigational silicone hydrogel contact lens
45386792|NCT00490022|Drug|Placebo gel|Placebo gel for one month
45386793|NCT01011530|Drug|MLN4924|Patients will be administered MLN4924 via an IV infusion. Each 21-day treatment cycle is composed of 2 weeks intermittent dosing of MLN4924 on Days 1, 4, 8 and 11, followed by a rest period of 10 days. A cohort of patients will receive a reduced first dose on Day 1, approximately half the strength of the dose received on Days 4, 8, 11 and dose will not be administered on Day 4 if the Day 1 dose is not tolerated.(Schedule A ramp-up), or continuous weekly dosing (Days 1, 8, and 15) of MLN4924 (Schedule B)
45386794|NCT00493454|Drug|Zevalin|.3 mCi IV Over 10 Minutes x 1 Day
45386795|NCT00493454|Drug|Rituximab|250 mg/m^2 IV Over 6 to 8 Hours
45386796|NCT00493454|Drug|^111 In Ibritumomab Tiuxetan|1.6 mg IV Over 10 Minutes x 1 Day
45386797|NCT00493220|Drug|SC HYLENEX and Ceftriaxone|single, subcutaneous, 150 U dose of HYLENEX; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
45386798|NCT00493220|Drug|SC Placebo and Ceftriaxone|single, subcutaneous injection of 1 mL 0.9% sodium chloride solution; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
45386799|NCT00493220|Drug|IV Ceftriaxone|single, intravenous infusion of 1 gm ceftriaxone (40 mg/mL solution administered at 0.83 mL/min over 30 minutes)
45426161|NCT05795179|Device|Functional Magnetic Resonance Imaging (fMRI)|Participants will complete the self-control task in the fMRI scanner.
46056481|NCT00811954|Drug|Emtricitabine/tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).
46056482|NCT00811954|Drug|Raltegravir|400 mg taken orally twice daily. An integrase inhibitor (INI).
45386800|NCT00950339|Drug|omeprazole, 20mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
45386801|NCT00950339|Drug|famotidine 40mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
45386802|NCT00950339|Drug|pantoprazole 40mg once daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
45500461|NCT05461833|Biological|Fecal transplantation|Preparation of flesh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of IBS patient by colonoscopy after standard bowel preparation.
45500462|NCT05461833|Drug|OTILONII BROMIDUM|OTILONII BROMIDUM , oral, 40 mg TID, 1 months of treatment
45500463|NCT05461833|Dietary Supplement|multi-strain probiotic|multi-strain probiotic, oral, 1 capsule BID for 1 month
45500464|NCT01560585|Drug|Isotretinoin|Isotretinoin 0.5 mg per kilogram body weight (rounded to nearest 10 mg) per day for 24 weeks
45695664|NCT03402412|Other|narrow-band UVB|Standard established treatment for atopic dermatitis with narrow-band UVB will be used in this study but initially only on a small amount of skin to assess what changes takes place in the skin.
45500465|NCT03603236|Diagnostic Test|preeclampsia|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
45500466|NCT03603236|Diagnostic Test|control|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
45500467|NCT05462847|Drug|Ringer acetate|8ml/kg Ringer acetate over 10 minutes
45500468|NCT01376427|Drug|Dexamethasone|Dexamethasone
45500469|NCT01376427|Drug|Methotrexate|Methotrexate
45500470|NCT01376427|Drug|Vincristine|Vincristine
45500471|NCT03601598|Drug|SHR-1210|SHR-1210 was administered 200mg iv every 2 weeks
45500472|NCT03601598|Drug|SHR6390|SHR6390 was administered 150mg or 100mg oral daily with 3 weeks on and 1 week off
45500473|NCT05462769|Device|Percutaneous vascular closure|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device
45500474|NCT05462691|Procedure|tuberosity suture|to suture or not suture the tuberosities in reverse shoulder arthroplasty because of a proximal humeral fracture
45500475|NCT03597152|Dietary Supplement|WelTract|Supplement commercially available from the sponsor containing powdered extracts from Hibiscus flowers and cranberry fruit, lactoferrin, D-mannose, and vitamins C and D
45695665|NCT01745757|Drug|Bevacizumab|Treatments received by patients in this study are prescribed in the context of standard care
45500476|NCT03597152|Dietary Supplement|Placebo|Inert placebo custom manufactured for the sponsor
45695666|NCT01745757|Drug|paclitaxel|Treatments received by patients in this study are prescribed in the context of standard care
45695667|NCT03402178|Drug|E2082|Solution (0.2 mg) or tablet (0.5 mg and 5 mg).
45695668|NCT03402178|Drug|Placebo|Solution (0.2 mg) or tablet (0.5 mg and 5 mg) matched to E2082.
45695669|NCT01709162|Biological|Ipilimumab|
45695670|NCT01709162|Drug|Chemotherapy|
45695671|NCT04764201|Drug|HIP2001|Test drug
45695672|NCT04764201|Drug|HGP2001|Reference drug
46056483|NCT00811954|Drug|Darunavir|800 mg taken orally once daily. A protease inhibitor (PI).
46056484|NCT00811954|Drug|Ritonavir|100 mg taken orally once daily. A protease inhibitor (PI).
46056485|NCT00811954|Drug|Atazanavir|300 mg taken orally once daily. A protease inhibitor (PI).
46056486|NCT00917839|Drug|lamotrigine|100 mg, once daily, 12 months
46056487|NCT02694705|Device|Continuous Positive Airway Pressure (CPAP)|CPAP provided by a portable Draeger Oxylog® 3000 plus ventilator
46056488|NCT02694705|Device|Bag-Valve-Mask (BVM)|Preoxygenation provided by BVM device, oxygen flow rate 15 l/min
46056489|NCT02694705|Device|Non-rebreather Mask (NRM)|Preoxygenation provided by NRM, oxygen flow rate 15 l/min
46056490|NCT01032200|Drug|Armodafinil|Given orally
46056491|NCT01032200|Other|placebo|Given orally
45695673|NCT02243800|Other|cholecalciferol versus placebo|
45386803|NCT00942227|Other|Physical therapy rehabilitation|Extension oriented exercises. Subjects will be instructed in a progression of extension oriented exercises for the lumbar spine
45386804|NCT00942227|Other|Physical therapy rehabilitation|Mechanical lumbar traction will be applied with subjects in prone utilizing 40-60% of subject's body weight to create a distraction force in the lumbar spine. Following traction, subjects will be instructed in a progression of extension oriented exercises and manual therapy to increase extension as described for the comparator group.
45386805|NCT01011608|Other|Medical Food Supplement|Medical Food Supplement to be given in divided portions in morning, afternoon and evening
45386806|NCT01011608|Other|standard hospital food|standard hospital diet ad. lib.
45386807|NCT00950417|Drug|Nimotuzumab|
45386808|NCT03996902|Behavioral|Tailored intervention|Brief motivational smoking intervention tailored to address smoking in the context of pain. Included a novel pain-smoking psycho education component, personalized feedback component, and elicitation of participant's pain-related goals to develop discrepancy between continued smoking and desired pain outcomes.
45386809|NCT03996902|Behavioral|Ask-Advise-Refer|The Ask-Advise-Refer intervention is commonly used in standard clinical practice.
45386810|NCT00946673|Drug|Vorinostat|Orally up to 400 mg
45386811|NCT00946673|Procedure|Radiation Therapy|Single fraction stereotactic radiotherapy - Standard of Care
45386812|NCT00394953|Drug|Darbepoetin alfa|As prescribed, iv.
45500477|NCT03075501|Behavioral|Paired|Drug conditioning is assessed by pairing drug administration with a given context.
45695674|NCT04764123|Diagnostic Test|AVNRT mapping|AV annuli mapping during AVNRT
45695675|NCT03402100|Drug|eye drops|children who received daily eye drops for myopia
45695676|NCT03906422|Device|3M Unitek 0.016 orthodontic archwire|Placement of 3M Unitek 0.016 archwire for orthodontic treatment
45695677|NCT03906422|Device|"Device: 0.016 Ormco 27oC NiTi orthodontic archwire"|"Placement of 0.016 Ormco 27oC NiTi orthodontic archwire"
45695678|NCT03906422|Device|"Device: 0.016 Ormco 35oC NiTi orthodontic archwire"|"Placement of 0.016 Ormco 35oC NiTi orthodontic archwire"
45695679|NCT01674309|Drug|FOLFORINOX|INTRAVENOUS administration
45500478|NCT03075501|Drug|Stimulant or sedative|CS+ for paired, CS0 for unpaired
45500479|NCT03075501|Drug|Placebo|CS- for paired, CS0 for unpaired
45695680|NCT02243956|Other|Flavanol rich food product|polyphenol rich test product
45500480|NCT03597074|Diagnostic Test|color Doppler Ultrasound derived RI and semi-quantitative evaluation of intra-renal vascularization|Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
45695681|NCT04764045|Drug|Ropivacaine|Injection of 1 ml Ropivacaine in all trigger points in and around scar. Injection of 1 ml saline in all trigger points in and around scar.
45695682|NCT01698554|Drug|bimatoprost formulation A solution|Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
45695683|NCT01698554|Drug|bimatoprost solution 0.03 %|Bimatoprost solution 0.03 % (LATISSE®) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
45695684|NCT01698554|Drug|vehicle of bimatoprost formulation A solution|Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
45695685|NCT01698554|Drug|vehicle of bimatoprost solution 0.03 %|Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
45695686|NCT03401944|Drug|TPN|
45695687|NCT03401944|Other|Control|
45386813|NCT00394953|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv / month, starting dose
45386814|NCT00946751|Drug|Levetiracetam Tablets, 750 mg (Sandoz Inc.)|
45386815|NCT00946751|Drug|Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)|
45386816|NCT00485732|Biological|HPV-16/18 VLP/AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
45386817|NCT00485732|Biological|Placebo|Three doses of placebo administered intramuscularly according to a 0, 1, 6-month schedule.
45386818|NCT00946829|Drug|telmisartan|
45500481|NCT03596528|Procedure|Lung biopsy|Each patient will be brought to the operating room and will undergo cryobiopsy and surgical biopsy of the lung sequentially in the same surgical stage.
45695688|NCT04404855|Other|NGS + Antibiotic Recommendation|NGS results in addition to recommended antibiotic therapy made by infectious disease pharmacist
45695689|NCT04404855|Procedure|Standard of Care treatment|Subjects will have a standard of care urine culture and prophylactic antibiotic prescribed per routine care.
45695690|NCT03401866|Diagnostic Test|DSC-MRI|"The multiple dose protocol with sequential DSC-MRI scans enables comparison of BTIP compliant and double-dose injections schemes."
45500482|NCT05462535|Drug|Amosartan Plus Tab.|Amosartan Plus Tab., Once daily administered per the locally approved product information
45500483|NCT05764317|Drug|Amlodipine 5 mg + atorvastatin 10 mg + perindopril arginine 5 mg|a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
45500484|NCT05764317|Drug|Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 5 mg|a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
45500485|NCT05764317|Drug|Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 10 mg|a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
45500486|NCT03596216|Other|PENS|This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is an invasive intervention by ultrasound and needles.
45500487|NCT03596216|Other|TENS|This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is a non-invasive intervention by self-adhesive electrodes.
45500488|NCT05461443|Dietary Supplement|Probiotic|
45500489|NCT05461365|Drug|Insulin|Gelfoam® cottonoids soaked in 40 IU of NPH insulin were placed on the nasal roof (between the nasal septum and the middle meatus) of each nostril. These remained in place for 15 minutes and were later removed. This procedure was performed in three visits one week apart. During the fourth and last visit (one week after the previous visit), olfaction was reevaluated using the measures previously described.
45500490|NCT03602846|Dietary Supplement|Medical Nutrition Therapy|Only given medical nutrition therapy.
45500491|NCT03602846|Drug|Insulin|Prescribed with rapid acting, intermediate acting, mixed or long acting insulin.
45500492|NCT03602846|Drug|Oral Antidiabetics|Prescribed with all types of oral anti-diabetics.
45500493|NCT02317991|Drug|nab-paclitaxel|nab-paclitaxel 125 mg/m^2 IV
45500494|NCT02317991|Biological|ramucirumab|Ramucirumab 8 mg/kg IV
45500495|NCT05763303|Other|educational program|interventional program consists of educational part and training part in case of agreement of participants
45500496|NCT03602768|Behavioral|Goal Management Training|Pre-recorded videos and games combine psycho-education, targeted skills training, and mindfulness practice to teach a system where participants can take control of their attention and cognitive faculties.
45500497|NCT03602768|Behavioral|Memory & Aging Program|Pre-recorded videos and activities combine psycho-education, memory strategy training, and social support to educate about normal memory change in aging, normalize the experience of participants going through it, and equip them to handle age-related memory change.
45500498|NCT03602768|Behavioral|Cambridge Brain Sciences|Commercial brain training software available for subscription to the general public and for research studies.
45500499|NCT00861549|Drug|Phencynonate hydrochloride|2mg/tablet
45500500|NCT03602690|Drug|Dolutegravir + Darunavir/ritonavir + optimized NRTI|Dolutegravir 50mg once daily Darunavir/ritonavir 600/100 twice daily Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)
45695691|NCT04763733|Other|laparoscopic splenectomy|surgical
45500501|NCT01379547|Behavioral|Procalcitonin guided antibiotics treatment algorithm|Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin measurement on day 5, 7 and 9.
45695692|NCT04376866|Drug|Toripalimab|anti-PD-1 antibody
45695693|NCT00895791|Device|AXXESS Biolimus A9-eluting bifurcation stent|implantation of stent
45848390|NCT03614130|Device|Comfilcon A contact lens|Commercially available silicone hydrogel contact lens
45848391|NCT03615534|Other|Therapeutic Lifestyle Changes|Four-week therapeutic lifestyle changes run-in period, comprising individualized moderate physical activity and total calories reduction.
45848392|NCT03615534|Other|Placebo|
45386819|NCT00489554|Biological|Synflorix|Intramuscular injection, 3 doses.
45695694|NCT00895791|Device|culotte stenting (Xience V)|implantation of stent
45848393|NCT03615534|Drug|Fenofibrate|
45848394|NCT03615534|Dietary Supplement|Wax Matrix Extended Release Niacin (WMER Niacin)|
45848395|NCT03618030|Drug|PRC-063 oral capsules|Daily dose
45386820|NCT00489554|Biological|Infanrix hexa|Intramuscular injection, 3 doses.
45386821|NCT00489554|Biological|Rotarix|Oral, 2 doses.
45386822|NCT00408681|Drug|lithium carbonate|Given orally
45386823|NCT00408681|Other|laboratory biomarker analysis|Correlative studies
45386824|NCT01040013|Procedure|Laparoscopy|Laparoscopic Left-Colectomy
45386825|NCT01040013|Procedure|left colectomy by laparotomy|PatientS will be operated by laparotomy
45386826|NCT00560417|Drug|Insulin Lispro Protamine Suspension|Administered subcutaneously once a day at bedtime
45386827|NCT00560417|Drug|Insulin Glargine|Administered subcutaneously once a day at bedtime
45386828|NCT01044927|Other|Integrated Care|Comparison of the effect of COPD education, self-management instruction, home monitoring with a Health Buddy Telemonitor, pulse oximeter, pedometer and spirometer, and enhanced communication with a study coordinator (cell phone access)
45386829|NCT01044927|Other|Standard Therapy|No intervention was made. Data measurements were taken at 0, 3, 6 and 9 months, as in the active intervention group.
45500502|NCT01379547|Behavioral|Conventional treatment|Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice.
45500503|NCT02237612|Procedure|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
45500504|NCT02237612|Other|laboratory biomarker analysis|Correlative studies
45500505|NCT02978495|Drug|Doxorubicin|Doxorrubicin 60 mg/m2 4 cycles each 21 days
45848396|NCT03618030|Drug|Placebo oral capsules|Daily dose
45386830|NCT01040091|Drug|Emtricitabine (FTC)|200 mg once a day
45500506|NCT02978495|Drug|Carboplatin|Carboplatin AUC 1,5 once a week, for 12 weeks
45500507|NCT02978495|Drug|Paclitaxel|80mg/m2 weekly for 12 weeks
45500508|NCT02978495|Drug|Cyclophosphamide|600mg/m2 4 cycles each 21 days
45500509|NCT02237690|Drug|Doxorubicin hydrochloride liposome|50mg/m2,IV on day1 of each cycle,On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation,After completion of Cycle 2 (Day 28), patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome Injection up to 4 more cycles if tolerance permits under guidance of their attending physicians.
45500510|NCT02972801|Procedure|Testicular biopsy|Testicular biopsy is performed to obtain testicular tissue for cryopreservation
45500511|NCT03601208|Diagnostic Test|Mitra|When the patients have their bloods done through venepuncture, an additional 5-10mls will be taken (one EDTA bottle for tacrolimus and one serum bottle for creatinine; and two Mitra VAMs). Patients will also have a fingerprick test and 20 microlitres of blood taken using Mitra volumetric absorptive microsampling (VAMs)
45500512|NCT04788017|Drug|Ziresovir|"Planned treatments are:~Cohort 1: 300 mg of ziresovir~Cohort 2: up to 600 mg of ziresovir~Cohort 3: up to 900 mg of ziresovir"
45500513|NCT04788017|Other|Placebo|"Planned treatments are:~Cohort 1: 300 mg of placebo~Cohort 2: up to 600 mg of placebo~Cohort 3: up to 900 mg of placebo"
45500514|NCT03601130|Device|HydroxyColl Bone Graft Substitute|The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) with the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
45500515|NCT03601130|Device|DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care)|The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) without the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
45500516|NCT02942615|Other|limit heart dose|limit heart dose: Dmean≤6Gy,V30≤20%,V10≤50%
46056492|NCT05539599|Diagnostic Test|Comprehensive evaluation|Non-ultrasound parameters: Central venous pressure, hand-grip strength evaluation, P0.1, Maximal inspiratory pressure, Blood gas analysis ultrasound parameters: Diaphragmatic displacement, thickening fraction, TFmax, E/e', Triscuspidal annular Plane Systolic Excursion, Lung score
46056493|NCT02694471|Behavioral|physical inactivity or bed rest with supervised recovery|All (older and younger) participants underwent 14 day of horizontal bed rest with all 24 hour daily activities were performed lying in a bed. Maximal one pillow was allowed. 28-day supervised recovery was performed 3 times weekly for 75 minutes/session.
45386831|NCT01040091|Drug|Tenofovir disoproxil fumarate (TDF)|300 mg once a day
45386832|NCT01040091|Drug|Efavirenz (EFV)|600 mg once a day
46056494|NCT02734563|Other|Collagen turnover|Type IV and V collagen synthesis and breakdown
45386833|NCT01040091|Drug|Truvada|200 mg emtricitabine + 300 mg TDF once a day
45386834|NCT00950495|Device|Mandibular Advancement Device (MAD)|This oral appliance keeps the mandible and the tongue in a protruded position. This results in an upper respiratory tract widening and/or reduced collapsibility of the upper airway, thereby preventing the upper airway collapse during sleep.
45386835|NCT00950495|Device|nasal CPAP|The CPAP machine delivers a stream of compressed air via a hose to a nose mask, splinting the airway (keeping it open under air pressure) so that unobstructed breathing becomes possible, reducing and/or preventing apneas and hypopneas
45386836|NCT00950495|Device|placebo|as a placebo, a thin (< 1 mm), hard acrylic-resin palatal splint with only a partial palatal coverage was used
45386837|NCT00942461|Procedure|Laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
45386838|NCT00942461|Procedure|Open colectomy|Open colectomy. Epidural anaesthesia used
45500517|NCT03600974|Procedure|Stretta|Stretta for Endoscopy-E(+),Acid-A(+),Reflux-symptom association-S(+) or lower oesophageal sphincter-L(+) group
45500518|NCT03600974|Procedure|Laparoscopic Nissen fundoplication|Laparoscopic Nissen fundoplication for E(+),A(+) or L(+) group
45500519|NCT03600974|Drug|Probiotic Agent|Probiotic Agent for I(+)G/W；Live Bacillus Licheniformis Cranules 0.5g bid； Bifidbacterium 0.63g bid
45500520|NCT03600974|Drug|PPI|PPIs for A(+),E(+)or S(+) patients: Nexium 20mg Qd/Bid;Lansoprazole 30mg Qd/Bid；omeprazole 10mg-30mg Qd-Bid;Rabeprazole 10mg Qd/Bid;Esomeprazole 20mg Qd/Bid;Pantoprazole 40mg Qd/Bid
45500521|NCT03600974|Drug|Prokinetic Motility Agents|Prokinetic Motility Agents for M(+) group; Mosapride 5mg Tid; Domperidone 10mg Tid
45500522|NCT03600974|Drug|Neuromodulators|Neuromodulators for P(+) or S(+);Flupentixol and Melitracen 1# bid;
45500523|NCT03075267|Drug|PT010 (BGF MDI) 320/14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
46056495|NCT05756374|Behavioral|OUT to IN|OUT to IN comprises 20 body-oriented biweekly 40-minute sessions facilitated by a psychomotor therapist in a pedagogical partnership with the preschool teacher. Sessions are implemented outdoors. All sessions are framed in a context of freedom and self and mutual bodily resonance, according to the following structure: First, children are invited to engage in exercise play activities. Second, children engage in ludic relaxation proposals. Finally, children are asked to reflect on their bodily experiences and express themselves through different expressive mediators. Preschool teachers also participate in a 25-hour training focused on the underlying principles of OUT to In and participate in 20 body-oriented biweekly 20-minute relaxation sessions, facilitated by a psychomotor therapist.
45386839|NCT00946907|Drug|Aspirin|3000mg/day of aspirin during the 4th first days and 2000mg/day of aspirin during the 17th following days
45386840|NCT00946907|Drug|placebo|3000mg/day of aspirin during the 4th first days and 2000mg/day of placebo during the 17th following days
45386841|NCT00942539|Drug|Midazolam|Intravenous infusion of 0.05 mg/kg of Midalolam
45386842|NCT00947063|Drug|Promethazine HCl 50 mg Tablets (Sandoz, Inc)|
45386843|NCT00947063|Drug|Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)|
45386844|NCT00942617|Drug|Aspirin|40 mg non-enteric coated ASA once daily for 21 + or - 2 days
45386845|NCT00345345|Biological|Alemtuzumab (Campath)|Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.
45500524|NCT03075267|Drug|PT010 (BGF MDI) 160/14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
45386846|NCT03968159|Drug|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
45386847|NCT03968159|Drug|Placebo|Placebo (2×placebo tablets [size- and color-matched to pimavanserin]) administered orally as a single dose once daily
45386848|NCT01045005|Other|Administration ofOxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non-harmful/non-toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
45386849|NCT01045005|Other|Administration of Oxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non-harmful/non-toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
45386850|NCT00947141|Drug|ganciclovir (start when CMV PCR >200copies / ml x2)|"Group A: Start ganciclovir when CMV PCR >200copies / ml x 2) . Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased > 3,000. If treated (and monitored) treat until <200 copies on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
45500525|NCT03075267|Drug|PT003 (GFF MDI) 14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
45500526|NCT03600896|Drug|CYT107|"Phase I: Patients will be treated with CYT107 post CBT (from 60 to 180 days), in with 1 of 3 doses below:~5 mcg/kg/dose for 3 doses~10 mcg/kg/dose for 3 doses~20 mcg/kg/dose for 3 doses~The optimal recommended dose determined in Phase I will be used to treat all patient enrolled in Phase II."
45500527|NCT03600662|Other|TriRec|Trileaflet Reconstruction of the Aortic Valve
45500528|NCT03600662|Other|Aortic valve replacement|Biological Prosthesis, Device: St. Jude Medical Trifecta GT
45500529|NCT03600584|Procedure|Modified one-layer duct-to-mucosa Pancreaticojejunostomy|After the completion of the preparation of the remnant pancreas for reconstruction was performed. Modified one-layer duct-to-mucosa Pancreaticojejunostomy was performed.
45500530|NCT03600584|Procedure|Invagination pancreaticojejunostomy|After the completion of the preparation of the remnant pancreas for reconstruction was performed. Invagination Pancreaticojejunostomy was performed.
45500531|NCT03600506|Drug|Dexmedetomidine|Patients will receive infusion of study drug intravenously 10 minutes before induction of anesthesia as 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr till the start of wound closure.
46056496|NCT05756296|Procedure|Therapeutic hypothermia|whole-body cooling to an esophageal temperature of 33.5°C initiated within the first 6 hours of life, continued for 72 hours, and then they were slowly rewarmed for moderate or severe NE
46056497|NCT03345771|Combination Product|Antimicrobial Barrier Dressing|Ionic Silver is a soft, nonwoven pad or ribbon that features the gelling benefits of Hydrofiber technology plus antimicrobial ionic silver.
45386851|NCT00947141|Other|Monitor (Treatment starts when CMV PCR >3,000 copies / ml)|"Group A: CMV viral load between 200-3,000 copies/ml (on 2 occasions). Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased > 3,000. If treated (and monitored) treat until <200 copies on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
45386852|NCT00947141|Drug|Stop treatment when 2 levels CMV PCR <3,000 copies / ml|"Group B: Viral load > 3,000 copies/ml. Participants are randomised to treat until < 3,000 copies/ml on 2 occasions or treat until <200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
45500532|NCT03600506|Drug|Placebo|Fifty ml of Placebo (normal saline) will be prepared and given intravenously by a syringe pump over 10 minutes initially and then over 1 hour till the start of wound closure.
45500533|NCT05266677|Other|blend of glycerides at certain proportions|combination of glycerides in specific proportions in a liquid oral supplement
45500534|NCT05266677|Other|glycerides used in current formulas|glycerides used in current formulas in a liquid oral supplement
45500535|NCT03593486|Device|Low-level Pulsed EMF|Low-level pulsed electromagnetic field stimulator delivered through a Helmholtz coil positioned around the participant's head and neck. Stimulation parameters are 0.032 µG at 0.89 Hz for 60 minutes.
45500536|NCT03593486|Device|Sham Stimulation|The stimulator will be placed around the participant's head and neck, but no EMF will be delivered.
46056498|NCT03345771|Device|Negative Pressure Wound Therapy (NPWT)|PICO provides suction known as negative Pressure wound Therapy (NPWT) which draws out excess fluid from a wound and protects the injured area from getting dirty to ultimately help promote healing. PICO consists of an nPwT pump connected to an absorbent gentle adhesive dressing
46056499|NCT00586105|Drug|Sorafenib (Nexavar, BAY43-9006)|400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
46056500|NCT05179954|Other|Metabolic testing|Participants will complete a metabolic testing protocol that includes intravenous infusion of stable isotope labeled tracers and blood sampling to determine lipoprotein kinetics
46056501|NCT05510427|Drug|Infigratinib|Given by PO
46056502|NCT05510427|Drug|Atezolizumab|Given by (IV) vein
45500537|NCT03593330|Other|Transitional Care Programme|These patients will receive a pre-admission overview of their surgery, an anticipated discharge date, and a pre-scheduled discharge appointment to set patient expectations for a shorter hospitalization. On the day of discharge, the patient and his or her caregiver will attend an extended discharge appointment with a TCP-trained nurse. Finally, patients will receive a surveillance phone call 48 hours after discharge.
45500538|NCT05214105|Other|Biospecimen/DNA collection and analysis|Patients will be followed longitudinally with collection of CBC and chemistries as well as research biomarkers (urine, plasma, and genomic materials).
45500539|NCT03590834|Behavioral|Center-based Intervention|"Center nutrition and physical activity policy modification to increase fruit and vegetable servings and more physical activity throughout the day~Staff training and technical assistance~Health education on healthy habits (diet, physical activity, sleep, screen time) using the Sesame Workshop Healthy Habits for Life (HHL) resource kit~Health contests~Gross motor and physical activity program~Miranos! activity cards based on children storybooks"
45500540|NCT03590834|Behavioral|Home-based Intervention|"Monthly interactive poster education sessions led by parent peer educators during child pick-up time. Held at Head Start Center. These sessions include family health challenges and take-home activities.~Three Home Visits delivered by Head Start staff. Obesity prevention goal-setting integrated into existing Head Start home visits~16 semi-monthly, Family Newsletters with stories, tips, and strategies to promote healthy habits for preschool children~Incorporating activities related to PA, nutrition and sleep into existing Head Start Center Summer Calendars"
45386853|NCT00947141|Other|Monitor (Treatment stops CMV PCR <200 copies / ml x2)|"Group B: Viral load > 3,000 copies/ml. Participants are randomised to treat until < 3,000 copies/ml on 2 occasions or treat until <200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
45500541|NCT03590834|Behavioral|Active Control|"Children will receive Head-Start-approved health education program for children: I Am Moving, I Am Learning. In addition, the investigators will deliver an early childhood literacy program to all active control children to increase buy-in and retention."
45500542|NCT03600272|Procedure|Combined spinal-epidural analgesia|Combined spinal-epidural analgesia during labor is a labor analgesia technique which reported maybe associate with a shorter labor duration compared to the traditional epidural labor analgesia.
45500543|NCT03600272|Procedure|Epidural analgesia|Epidural analgesia is a well-accepted technique using for pain relief during labor.
45500544|NCT05082597|Device|Low energy ESWT|Therapeutic sessions: 4(once a week, for 4 weeks) Total dosage: 2500 shoots over axillary cord lesion (1000 over most fibrotic area, 500 over upper arm, 500 over forearm, 500 over other area) Energy: 0.056-0.065mJ/mm2
45500545|NCT03600038|Behavioral|Experimental smoking cessation smartphone app|The experimental arm includes an intervention using a novel/experimental smartphone smoking cessation app.
45500546|NCT03600038|Behavioral|Standard of care smoking cessation smartphone app|The control intervention uses a standard of care smartphone smoking cessation app.
45500547|NCT05050617|Diagnostic Test|Point-of-care echocardiography|Subjects will undergo point-of-care echocardiography at the time of presentation/enrollment to assess for evidence of right sided heart dilation/strain.
45500548|NCT03913286|Device|Cortimo|The Cortimo comprises an implanted brain activity sensor and a wearable powered arm orthosis.
45695695|NCT01674387|Device|acupuncture|56 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral Jiaji (EX-B2) of cervical positive reaction plane (taking two pairs). Besides, bilateral Jianzhongshu (SI15) and bilateral Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
45695696|NCT01674387|Other|comprehensive treatment|Other 56 patients (the matched group) receive the comprehensive treatment, including traction and TENS therapy. Each treatment 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
45695697|NCT03401632|Other|Enteral nutrition|Enteral nutrition support
45695698|NCT03885531|Device|Total knee arthroplasty with Journey II CR Total Knee System|TKA with Journey II CR Total Knee System
45695699|NCT01698320|Drug|Placebo MDPI|Placebo MDPI (multi-dose dry powder inhaler) to match the active intervention.
45695700|NCT01698320|Drug|Albuterol MDPI|Albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation.
45695701|NCT03401554|Procedure|titanium mesh|closing the lateral window for maxillary sinus floor elevation with titanium mesh
45848397|NCT03619590|Other|Data Collection|When the pregnancy is reported prospectively, the Registry will collect registration data from the reporter through telephone interview or a short registration form. In the month of the estimated date of delivery, follow-up will be sought by telephone contact or a form mailed to the health professional. Information about maternal events throughout the pregnancy, pregnancy outcome, and neonatal health is requested. Additional follow-up is not sought from subsequent health care providers.
45848398|NCT03623334|Radiation|Image-Guided Radiation Therapy|Radiotherapy to a potent tumorcidal dose
45386854|NCT03966911|Device|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter|Continuous Glucose Monitoring and frequent sample testing
45386855|NCT03966365|Drug|PRO-122|"PRO-122. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution free of preservatives. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~Route of administration: topical ophthalmic."
45386856|NCT03966365|Drug|Krytantek Ofteno®|"- 1. Krytantek Ofteno®. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~- Route of administration: topical ophthalmic."
45386857|NCT02007239|Drug|tocilizumab|single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
45386858|NCT00375219|Drug|Omacetaxine mepesuccinate|"Induction:~1.25 mg/m^2 subcutaneously, twice daily for 14 consecutive days every 28 days until response. Patients not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study.~Maintenance:~1.25 mg/m^2 subcutaneously, twice daily for 7 consecutive days in a 28-day cycle, for up to 3 years."
45386859|NCT03965351|Drug|Probenecid|This is a cross-over pilot study where participants will receive both the study medication (probenecid), as well as a placebo to see if the study medication improves magnetic resonance parameters of systolic and diastolic dysfunction that occurs in the Fontan population.
46056503|NCT05510427|Drug|Bevacizumab|Given by (IV) vein
45386860|NCT03965351|Other|Placebo|placebo
45386861|NCT00947375|Drug|Lamictal TM|First group patients received either haloperidol deaconate 50 mg in weekly intramuscular and Lamictal TM 150-200 mg in day per so for 12 weeks.
45386862|NCT00947375|Drug|Haloperidol Decanoate|Second group patients were given haloperidol deaconate 50 mg in weekly intramuscular and placebo per os for 12 weeks.
45386863|NCT00942695|Other|1.5PD|average American diet plus 1.5 oz per day pistachios
45386864|NCT00942695|Other|3.0PD|average American diet plus 3.0 oz per day pistachios
45386865|NCT00942695|Other|control|average American diet without pistachios
45386866|NCT00947453|Drug|montelukast|montelukast 10 mg once daily for 8 weeks
45386867|NCT00554801|Procedure|Audiological testing|Subjects will take part in a battery of audiological tests meant to evaluate the function and status of the auditory system. These tests are similar to the kinds of testing carried out routinely in audiology clinics, and include behavioral tests of pure tone hearing, speech perception, and central auditory function, and electrophysiological testing of the middle ear and of the central auditory system.
45386868|NCT00942773|Drug|Voriconazole|
45386869|NCT00947687|Drug|PUR003|Twice-daily (BID) doses of PUR003 will be delivered via inhalation using a commercially available nebulizer for a total of 7 days
45386870|NCT00947687|Drug|Placebo|
45386871|NCT00943007|Device|Stealth Station|Neuronavigation based on preoperative MRI
45386872|NCT00943007|Device|PoleStar N20|Intraoperative MRI guided surgery
45386873|NCT00943085|Behavioral|Family-focused therapy|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. Ongoing medication management from a study psychiatrist will be available.
45386874|NCT00943085|Behavioral|Brief educational treatment|Thorough diagnostic assessment by a study evaluator, separate evaluation by a child psychiatrist, feedback session with parents and child, and provision of reading materials pertinent to managing childhood mood disorders. Ongoing medication management and crisis-oriented family sessions will be available as needed.
45386875|NCT04279769|Drug|CB-280|CB-280, oral capsule administered twice daily at the assigned dose level for 14 days
45386876|NCT04279769|Drug|Placebos|Placebo oral capsule administrated twice daily at the assigned dose level for 14 days
45386877|NCT04364555|Drug|Clobetasol Propionate|Klobetasol APL oral gel 0.025% is a topical steroid for rinsing the oral cavity. Manufactured by APL, Sweden.
45386878|NCT04364555|Drug|Placebo/Klobetasol APL oral gel 0.025%|Placebo/active
45386879|NCT04364555|Drug|Placebo|Placebo/placebo
45500549|NCT04856943|Procedure|Smartconsent application|Patients asigned to smartconsent group will sign informed consent through a Tablet.
45500550|NCT04856943|Other|Control group|Patient asigned to control group will sing the informed consent in papel, as it is performed in clinical practice
45500551|NCT03599336|Procedure|Reverse Total Shoulder Arthroplasty (rTSA)|Surgical management will include placement of fracture specific, cemented reverse total shoulder arthroplasty components as per standard surgical care and routine postoperative rehabilitation.
45695702|NCT03401554|Procedure|collagen membrane|closing the lateral window for maxillary sinus floor elevaion with collagen membrane
45848399|NCT03630198|Drug|Corticosteroid with lidocaine|Intralesional corticosteroid injection
46056504|NCT05757310|Biological|Anti-Thymocyte Globulin|Given IV
46056505|NCT05757310|Procedure|Biospecimen Collection|Undergo blood sample collection
46056506|NCT05757310|Procedure|Bone Marrow Aspirate|Undergo bone marrow aspirate
46056507|NCT05757310|Procedure|Bone Marrow Biopsy|Undergo bone marrow biopsy
46056508|NCT05757310|Drug|Cyclophosphamide|Given PO and IV
46056509|NCT05757310|Procedure|Haploidentical Hematopoietic Cell Transplantation|Undergo CD4+ T-cell depleted haploHCT
45386880|NCT00374907|Drug|Saxagliptin|Tablet, Oral, 5 mg, Once daily, (up to 12 weeks ST, up to 104 weeks LT)
45386881|NCT00374907|Drug|Placebo|Tablet, Oral, 0 mg, Once daily (up to 12 weeks ST)
45386882|NCT00374907|Drug|Metformin (blinded)|Tablet, Oral, 500 mg titrated to 1000 mg, Once daily (up to 104 weeks LT, starting at Week 12)
45695703|NCT01674465|Biological|Hypoxyprobe-1|Hypoxyprobe-1 is a biological marker used to detect oxygen levels in tissue;subjects will receive and intravenous solution for 20 minutes containing 500mg/m^2 two-three hours prior to their standard of care biopsy
45386883|NCT00374907|Drug|Metformin (open-label)|Tablets, Oral, 500-1500 mg, as needed (starting in LT)
45386884|NCT00374127|Drug|Marijuana blunt|Blunts were fabricated by cutting the bottom third off a Dutch Master® cigar, removing all of the cigar tobacco, and replacing it with all of the marijuana contained in a NIDA marijuana cigarette (ca. 800 mg).
45386885|NCT00374127|Drug|marijuana cigarette|Marijuana cigarettes were provided by the National Institute on Drug Abuse.
45386886|NCT01040247|Other|Embryo Transfer|In the study group embryo transfer will be performed on the day of oocyte aspiration and fertilization while in the control group it will be done 2 or 3 days later as is common practice.
45386887|NCT01045083|Drug|RO4917523|Oral single dose
45386888|NCT01045083|Drug|escitalopram|Oral single dose
45386889|NCT01045083|Drug|methylphenidate|Oral single dose
45695704|NCT03401476|Drug|Morphine Sulfate|Morphine Sulfate Tablets
45695705|NCT03884673|Drug|DTG+ 3TC|It is a simplified therapy regimen study of dolutegravir combined with lamivudine for HIV-1 infected patients in the real world of China.
45695706|NCT04376944|Other|Survey|questionnaire on their symptoms and their exposures
45695707|NCT04692597|Device|Phoenix Thera-Lase System|Low level laser therapy (LLLT) using Phoenix Thera-lase device (74 Watts, 1275 nm wavelength) for 6 minutes per affected hand.
45386890|NCT01045083|Drug|placebo|Oral single dose
45695708|NCT04692597|Device|SHAM Phoenix Thera-Lase System|Sham LLLT using the Phoenix Thera-lase device with the guide light on but without emitting laser photons for 6 minutes per affected hand.
45695709|NCT01698008|Other|Diabetes Doctor Mobile app|Diabetes Doctor is a mobile application software. The mobile phone application allows a subject to register blood glucose values obtained from their fingerstick glucose meter readings, the type and amount of insulin they are administering, any notes they would like to document, and the date and time of each entry. All data will be entered by the subject manually. The data will be submitted through encryption coded private servers and can be retrievable by a physician on a password protected website for privacy. A physician will evaluate this information to recommend a change of the subject's insulin regimen. The recommended insulin regimen will be delivered to the patient using the same website and received by the subject on the same mobile application software.
45386891|NCT01040325|Biological|TD Vaccine System|TD Vaccine System containing heat labile enterotoxin of E. coli (LT)
45386892|NCT01040325|Biological|TD Vaccine System|TD Vaccine System Containing Placebo Product
45386893|NCT01045239|Device|Micropulse 577 nm yellow diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
45386894|NCT01045239|Device|532 nm green diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
45386895|NCT01045317|Drug|PF-04776548|single intravenous or oral administration of 0.1mg PF-04776548.
45386896|NCT01045863|Drug|PF-03382792 Cohort 1|First cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
45386897|NCT01045863|Drug|PF-03382792 Cohort 2|Second cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
45386898|NCT01045863|Drug|PF-03382792|Optional cohort 3: Single oral ascending dose of PF-03382792, formulated in solution.
45386899|NCT01045863|Drug|Food Effect cohort|Single oral dose, cross-over to determine effect of food on PF-03382792 pharmacokinetics. Dose will be decided after reviewing data from the ascending dose portion.
45386900|NCT01045863|Drug|CSF cohort|Single oral dose of PF-03382792 formulated in solution. Dose will be decided after reviewing data from the ascending dose portion.
45386901|NCT03081585|Behavioral|Satiety State|Participants were scanned twice: once after a meal and once after fasting for 24 hours
45386902|NCT00553787|Drug|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
45386903|NCT00553787|Drug|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
45386904|NCT00553787|Drug|VI-0521|placebo
45386905|NCT00947843|Drug|aspirin + pregrel (Clopidogrel resinate)|
45386906|NCT00947843|Drug|aspirin + placebo|
45386907|NCT00947843|Drug|aspirin + plavix (Clopidogrel bisulfate)|
45386908|NCT00943475|Procedure|circumcision|circumcision by plastbell
45500552|NCT03599336|Other|Nonoperative Treatment|Subjects allocated to the nonoperative treatment arm will maintain sling immobilization for 3 weeks. The sling will be removed for elbow, wrist and hand range of motion (ROM), hygiene, and dressing only. At 3 weeks passive ROM in external rotation (ER) and forward elevation (FE) will be added. At 6 weeks from injury, the sling will be removed and stretching in all planes will be allowed. Use of the arm will be up to a fork/knife/toothbrush only. At 3 months from injury, strengthening will be added. Supervised physical therapy will be offered to patients for use at their discretion, as is current practice.
45500553|NCT03074331|Drug|SOF/VEL|400/100 mg FDC tablet(s) administered orally once daily
45500554|NCT03599024|Procedure|PCEA|The patients were able to control the administration of analgesics by themselves.
45500555|NCT03599024|Procedure|Non-PCEA|The patients were receiving analgesics according to the physician's prescription.
45386909|NCT00947921|Procedure|Plasty|Restrictive Annuloplasty
45386910|NCT00947921|Procedure|Prosthesis|Valve replacement
45386911|NCT00948077|Drug|Rifater and EMB|"The main difference between Treatment A and Treatment B is the time of taking drugs, so the intervention of this study belongs to a behavioral intervention.~The patients assigned randomly the Arm Treatment A on the fifth day will be switched to the Arm Treatment B on the sixth day. On the other hand, the patients assigned randomly the Arm Treatment B on the fifth day will be switched to the Arm Treatment A on the sixth day. The flow of intervention is drawn as below.~Treatment A (5th day) ---> Treatment B (6th day) ; Treatment B (5th day) ---> Treatment A (6th day)"
45500556|NCT03599024|Procedure|Total hip replacement|All patients enrolled in the study were indicated for total hip replacement surgery.
45695710|NCT04548206|Other|Pilates training|The program consisted of core-based Pilates exercises on the mat for 60 minutes.
45386912|NCT00407745|Drug|placebo|Placebo
45695711|NCT04548206|Other|control|The program consisted of progressive relaxation exercises at home.
45386913|NCT00407745|Drug|pregabalin|Pregabalin capsules taken twice daily up to 17 weeks (150-600 mg/day)
45386914|NCT00948233|Behavioral|Video Game|Educational anti-tobacco video game played on arcade-type kiosk for three 30-minute sessions, plus CD-ROM disc of game to use as needed, and series of illustrated materials to go along with computer sessions.
45500557|NCT02237924|Drug|endostar|Endostar 7.5mg / m2, 2 cycles of continuous intravenous pumping for ten days,and 2 cycles of maintenance therapy after radiotherapy
45500558|NCT02237924|Drug|DDP|DDP:100mg/m2 for 2-3 cycles
45500559|NCT02237924|Radiation|IMRT|IMRT:70-74Gy for 2-3 cycles
45500560|NCT04855227|Procedure|robotic-assisted ventral hernia repair|"Laparoscopic ventral hernia repair With the subject under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the repair. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.~Robotic-assisted ventral hernia repair With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the subject and used to complete the procedure. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care."
45695712|NCT04372810|Procedure|High Velocity Low Amplitude manipulation (HVLA)|The thrust manipulation technique was used, which consists of high speed and small amplitude manipulation. The therapeutic intervention was performed through decompressive maneuvers for the tibiotarsal joints. The choice of the place of application of the manipulation technique was delimited by the identification of the area or areas with compressive compartmental impairment and joint restriction. The use of the method depended directly on the identification of one or more regions of joint restraint.
46056510|NCT05757310|Drug|Pentostatin|Given IV
46056511|NCT05757310|Other|Questionnaire Administration|Ancillary studies
45500561|NCT02238002|Procedure|cataract surgery|The patients of both groups underwent cataract surgery
45500562|NCT04615533|Other|Frail older adults, assessment|Frail'BESTest, Clinical Frailty Scale, Mini BESTest, Berg Balance Scale, Tinnetti Balance and gait sacale
45500563|NCT04561089|Diagnostic Test|COVIDSeq Test|The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19
45500564|NCT03825302|Diagnostic Test|Methacholine challenge|Methacholine inhalation challenge will be administered to both male and females with asthma
45500565|NCT03825302|Diagnostic Test|Mannitol challenge|Mannitol inhalation challenge will be administered to both male and females with asthma
45500566|NCT04851795|Other|supervised physical exercise sessions|Participants assigned to the supervised exercise group will perform a supervised routine of approximately 30 minutes, 2 days per week (Monday and Wednesday at the Txagorritxu hospital, and Tuesday and Thursday at the Santiago hospital from 7:15 to 7:45 and from 15:15 to 15:45).
46056512|NCT02729571|Biological|MTBVAC|Live-attenuated tuberculosis vaccine
46056513|NCT02729571|Biological|BCG|Commercially available live-attenuated tuberculosis vaccine
46056514|NCT00743119|Drug|Placebo capsules|Placebo capsules
46056515|NCT00743119|Drug|Inactive marijuana (0% THC)|Inactive marijuana cigarettes (0% THC) provided by NIDA
46056516|NCT00743119|Drug|Low dose Dronabinol|Dronabinol 10mg
46056517|NCT00743119|Drug|High dose Dronabinol|Dronabinol 20mg
46056518|NCT00743119|Drug|Low THC marijuana|marijuana cigarettes (1.98% THC) provided by NIDA
46056519|NCT00743119|Drug|High THC marijuana|Marijuana cigarettes (3.56% THC) provided by NIDA
45500567|NCT04851795|Other|unsupervised physical exercise|For the non-supervised group, we will propose climbing the stairs from floor 0 to floor 7 three times during the working day and doing planks and stretching exercises outside of work. For the latter, an educational session will be given at the beginning of the study to explain how to perform them correctly.
45500568|NCT02238392|Procedure|Adenosine test|Testing dormant conduction after PVI
45500569|NCT02238392|Procedure|Termination of AF|Testing AF iducibility and ermination of
45500570|NCT02260193|Drug|AKB-6548|Starting dose 1. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
45695713|NCT04372810|Procedure|Care assessment and guidance|Evaluation and care guidelines on glycemic control and diabetic foot care.
45386915|NCT00948233|Behavioral|Pamphlet|Self-help pamphlet about stopping and avoiding tobacco use, provided by the National Institutes of Health.
45500571|NCT02260193|Drug|AKB-6548|Starting dose 2. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
45500572|NCT02260193|Drug|AKB-6548|Starting dose 3. Oral dose administered three times weekly for 16 weeks. Dose adjustment based on hemoglobin levels as defined in the protocol.
45386916|NCT00948233|Behavioral|Surveys|Computer surveys taken at 4 points throughout the study.
45386917|NCT00948467|Drug|TAK-733|"The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.~The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days."
45500573|NCT05763147|Device|Intravenous Access Device Flushing|locking and flushing the end of catheter line at the intervals of different drug treatment.
45500574|NCT03587402|Other|Transcutaneous perineal stimulation|Surface stimulation
45500575|NCT03587402|Other|Anal stimulation|Intra-cavitary stimulation
45500576|NCT02035514|Biological|Bone marrow autologous mesenchymal stem cells transplantation|
45500577|NCT04819035|Diagnostic Test|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement will be used to detect sepsis. Results will not be used to manage patients.
45500578|NCT02238236|Drug|Alesion®|Dry Syrup
45500579|NCT04306029|Other|Postpartum Family Planning Package|"Postpartum Family Planning Package, which consists of provider education on contraceptive delivery in the immediate postpartum period and promotion of the WHO MEC/PFP Compendium mobile application."
45500580|NCT02849678|Drug|Ropivacaine|0.5% Ropivacaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision. It is the local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.
45500581|NCT02849678|Drug|Lidocaine|"Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia. There are several studies to support this as listed in the references. Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use."
45500582|NCT04295577|Other|Niraparib|Niraparib - Niraparib is an oral, highly selective PARP-1 and -2 inhibitor. However, it also inhibits other members of the PARP family, including PARP 3, -4, -10, 12, -14, and -15[13].
45500583|NCT02238158|Drug|Atrovent® inhalets|
45500584|NCT02238314|Drug|Tipranavir low dose|
46056520|NCT02729493|Biological|EPCAM-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
46056521|NCT02734251|Dietary Supplement|Relora|750 mg/day
45386918|NCT03958955|Drug|Delgocitinib cream|Cream for topical application.
45386919|NCT03958955|Drug|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
45500585|NCT02238314|Drug|Tipranavir high dose|
45500586|NCT02238314|Drug|Ritonavir|
45500587|NCT02238314|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|
45500588|NCT02238314|Drug|Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)|
45848400|NCT03630198|Drug|Corticosteroid with normal saline|Intralesional corticosteroid injection
45848401|NCT03633084|Drug|RBM-007 Injectable Solution|(No additional description)
45848402|NCT03637296|Other|Critical time intervention|Care management offered by individual with experience working with individuals with serious mental illness. The care managers engage individuals before they are discharged from the hospital and work with them in the community to support linkages with medical and behavioral health care providers. Care managers provide problem-solving, advice, and support to maximize patients' engagement in care.
46056522|NCT02734251|Dietary Supplement|Placebo|
46056523|NCT04089241|Other|Contrast 3D Ultrasound|an ultrasound examination which will include a 3D reconstruction and thereafter CEUS will be performed using SONOVIEW contrast agent
46056524|NCT02610010|Drug|Cisplatin|Cisplatin 100 mg/m² every 3 weeks for 3 cycles during radiotherapy.
46056525|NCT02610010|Radiation|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
46056526|NCT02734329|Procedure|conventional laparoscopic partial nephrectomy|renal artery will be clamped during surgery.
46056527|NCT02734329|Procedure|zero ischemia laparoscopic RFA/MVA assisted tumor enucleation (TE)|
45386920|NCT00951119|Device|Resperate|device-guided breathing exercises
45386921|NCT00951119|Device|Resperate|breathing device without slowing of breathing frequency
45848403|NCT03637842|Drug|Lorcaserin|Lorcaserin XR 20mg per day
46056528|NCT02597023|Drug|MitoQ|Mitoquinone pill, 20 mg/day
46056529|NCT02597023|Drug|Placebo|Placebo pill with inert excipient, 1 time/day
45386922|NCT00464334|Biological|V950|V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.
45500589|NCT05764005|Behavioral|web-based tool (MAP- Management of Active surveillance in Prostate Cancer)|A web-based tool with modules on active surveillance education, team based active surveillance care delivery and the role of the PCP, and self-management for cancer anxiety and worry. {may need more detail}
45500590|NCT05764005|Behavioral|MUSIC website|Standard of care educational materials {add more detail}
45500591|NCT03587168|Other|the timed 360° turn test|Turning ability is assessed by using the timed 360° turn test.
45500592|NCT03587168|Other|Berg Balance Scale|Functional balance is assessed by using the Berg Balance Scale.
45500593|NCT03587168|Other|Four Square Step Test|The Four Square Step Test measures dynamic balance.
45500594|NCT03587168|Other|Functional Reach Test|The Functional Reach Test assesses limits of stability.
45500595|NCT03587168|Other|Trunk Impairment Scale|Trunk performance is assessed by using the trunk impairment scale.
45500596|NCT03587168|Other|Timed Up and Go Test|Functional mobility is assessed by using the timed up and go test.
45500597|NCT03587168|Other|Hoehn and Yahr Scale|Disease stage is assessed by the Hoehn and Yahr Scale.
45500598|NCT03587168|Other|Unified Parkinson's Disease Rating Scale|The Unified Parkinson's Disease Rating Scale assesses disease severity.
45500599|NCT03629769|Drug|Proxelan|Administration of one suppository of proxelan once a day for 30 days
45500600|NCT03589742|Device|AblaView® Ablation Catheter|The AblaView® Ablation Catheter is a regular RF ablation catheter with the same physical characteristics and the same biocompatible materials, with an 8 French (2.66 mm) sheath and 180º deflection angle. The tip of the catheter has 15 holes distributed around it where the irrigation will be delivered into the patient's blood. The front irrigation hole will deliver at the same time the infrared light for the OCR system.
45500601|NCT02238470|Drug|oral anticoagulants|Comparison of patients receiving oral anticoagulants with or without microbleeds in magnetic resonance imaging
45500602|NCT04703595|Genetic|To determine the presence of biallelic expansion of AAGGG in RFC1 in patients with chronic cough, regardless of the presence of neurological symptoms.|"To determine the presence of biallelic expansion of AAGGG in RFC1 in patients with chronic cough, regardless of the presence of neurological symptoms.~For the molecular study of the DNA sample of the patients, two techniques will be used: standard Polymerase chain reaction amplification with primers flanking the intron 2 fragment of the RFC1 gene and amplification using Repeated Primed Polymerase chain reaction in 3 independent reactions."
45715065|NCT03165084|Behavioral|Intervention arm: Person-centred interactive self-management support|"Person-centred tailored digital self-management support hypothesised to decrease HbA1c, improve other metabolic measurements, improve lifestyle habits, and increase diabetes empowerment, increase diabetes-dependent quality of life, improve illness perception, and improve eHealth literacy.~Access to the diabetes mobile application and the homepage during 16 weeks. Each individual will set personal goals for use of the digital resources."
45715066|NCT03165084|Other|Control arm|Participants will receive usual care and take part in a minimal intervention in the form of a brochure on the importance of self-management in diabetes.
45848404|NCT03637842|Drug|Placebo oral capsule|Placebo
45386923|NCT00464334|Biological|ISCOMATRIX™|ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.
45386924|NCT00464334|Biological|Placebo to V950|
45386925|NCT00951197|Other|Neuroimaging|Three successive MRI acquisitions to measure FA, MTR and T2 parameters.
45386926|NCT00951431|Drug|Esomeprazole|Esomeprazole 20mg daily for 8 weeks
45386927|NCT00951431|Drug|Placebo|Placebo in the form of study drug
45386928|NCT00299494|Drug|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
45386929|NCT00299494|Drug|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
45386930|NCT00299494|Drug|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
45386931|NCT00299494|Drug|Rituximab|rituximab 375 mg/m^2 via IV infusion on Day 1
45500603|NCT03581708|Other|lung cancer|If the patient is diagnosed with lung cancer in advanced stage, he/she will be followed up for VTE incidence
45500604|NCT04119375|Behavioral|Keheala Mobile Health Platform and Behavioral Interventions|"Keheala is a mobile health company that delivers powerful behavior change interventions from the social sciences across basic feature phones or smartphones to address the nonmedical drivers of disease, which exist away from health facilities.~The intervention includes automated reminders, remote self-verification of doses, accessible TB information and individualized follow-up."
45386932|NCT00951587|Device|PillCam™ (Capsule Endoscopy)|Medical Device
45386933|NCT00943553|Drug|decitabine Induction Chemotherapy|Arm A - 12 days (5 days of intravenous (IV) decitabine 20 mg/m^2 followed by 7 days of induction chemotherapy with IV daunorubicin 45 mg/m^2 and cytarabine 100 mg/m^2/day)
45500605|NCT04119375|Behavioral|Social and Behavior Change Communication (SBCC)|Automated reminders, remote self-verification of doses and accessible TB information. All interactions are behaviorally-informed but do not include regular adherence support/follow-up from study team members as the Keheala intervention does.
45500606|NCT04119375|Behavioral|SMS Reminder|Patients receive a single daily SMS message to take their medication.
45848405|NCT03638622|Combination Product|Photodynamic Therapy|Patients receive aminolevulinic acid (ALA) orally with orange juice in 3 fractions at 0,1,2 hours before undergoing photodynamic therapy using LED based Device on day one.
45386934|NCT00943553|Drug|Induction Chemotherapy|Arm B - 7 days (7 days of induction chemotherapy with IV daunorubicin 45 mg/m^2 and cytarabine 100 mg/m^2/day only)
45500607|NCT04119375|Other|Standard of Care|The standard-of-care protocol in Kenya includes diagnosis, the provision of medications - typically administered for a 1-2 week period at which point patients are expected to return to the clinical site - periodic on-the-ground follow-up by community health volunteers (CHVs)(at the discretion of local clinicians and CHVs) and nutritional support, as is sometimes provided.
45500608|NCT03586934|Drug|Acetaminophen|Acetaminophen Tablet
45500609|NCT03586934|Drug|Celecoxib 200mg|Celecoxib Tablet
45500610|NCT03586934|Drug|Celecoxib 400 mg|Celecoxib Tablet
45500611|NCT03586934|Drug|Ropivacaine|Ropivicaine nerve block (injection)
45500612|NCT03586934|Drug|Ketorolac|ketorolac injection
45500613|NCT03586934|Drug|Acetaminophen Injectable Product|Acetaminophen injection
45500614|NCT03586934|Drug|Oxycodone|oxycodone tablet
45386935|NCT04011917|Behavioral|Standard care|Treatment by an extended scope physiotherapist following Standard Operating Procedures.
45386936|NCT00453180|Drug|N-acetylcysteine|Capsules available in 300 mg or 600mg strength. Target dose of n-acetylcysteine will be 60mg/kg/day TID. Dosage will be increased to this target dose from week 1 to week 3 barring side effects. Dose reduction will be allowed at any time for adverse side effects. Maximum dose of n-acetylcysteine will be 4200mg/day.
45386937|NCT00453180|Drug|Placebo|Subjects randomized to placebo arm will receive placebo pill for duration of study.
45386938|NCT00943709|Biological|insulin glargine recombinant|Given subcutaneously
45386939|NCT00943709|Drug|therapeutic insulin|Given subcutaneously
45386940|NCT00948545|Other|Observational study - there is no intervention|Observational study - there is no intervention
45386941|NCT00951743|Drug|Adaptavir (monomeric DAPTA)|"Intranasal (IN) Solution: 20 mL of solution in a 20 mL polyethylene screw top vial to which a metered sprayer is adapted. Each spray releases approximately 0.1 0.12 mL.~Available strength - 0.01mg/mI (active study medication), or no mDAPTA (placebo study medication), in water containing 0.25% benzyl alcohol as preservative and 250 mM mannitol (GRAS) to achieve isotonicity.~Individuals in this study will be randomized to receive mDAPTA or placebo and be instructed to administer four metered nasal spray applications two times a day, in the morning, and in the evening, as close to 12 hours after the morning dose as practical. The planned daily dose of mDAPTA is 8 μg/day."
45500615|NCT03586934|Drug|Tramadol|Tramadol tablet
45500616|NCT03586934|Drug|Morphine Injectable Solution|Morphine Patient Controlled Analgesia
45500617|NCT03586934|Drug|hydrocodone bitartrate and acetaminophen|Norco tablet
45500618|NCT03586934|Drug|Morphine|morphine injection
46056530|NCT02610088|Drug|Dapagliflozin|Dapagliflozin 10 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by > 0.4% at 12 week, rescue therapy (sitagliptin 100 mg) can be added at investigator's discretion.
45500619|NCT03586934|Drug|Oxycodone Hydrochloride|oxycodone hydrochloride tablet
45500620|NCT03586934|Drug|Meloxicam|meloxicam tablet
45386942|NCT01065142|Procedure|Therapeutic education|Improve therapeutic education efficiency on life quality of heart failure patients in general practice
45426162|NCT05795140|Drug|Iptcaopan 200 mg|Open label, participant specific kits, hard gelatin capsules to be taken twice a day
45500621|NCT01596257|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
45500622|NCT01596257|Device|CliniMACS|
45500623|NCT02084121|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
45500624|NCT03577964|Diagnostic Test|Glucose Measurements,|Measurement of glucose Levels in bronchio alveolar secretions
45500625|NCT05762055|Device|Titan nanoLOCK interbody cage|Medtronic Titan Endoskeleton TCS zero-profile, stand-alone interbody cages with nanoLOCK osseointegrative technology
45500626|NCT05762055|Device|ACDF interbody cage|Anterior cervical discectomy and fusion (ACDF) is an alternative interbody cage system that does not employ nanoLOCK ossteointegrative technology
45500627|NCT04749017|Dietary Supplement|Experimental product consumption|Consumption of the experimental product 2 capsules daily, morning and evening (450 mg each capsule) for 60 days
45500628|NCT04749017|Other|Control product consumption|Consumption of control product of identical appearance 2 capsules daily for 60 days, morning and evening
45715067|NCT03165084|Other|External comparison group|External comparison groups in order to analyse possible Hawthorne effects.
45500629|NCT02035592|Other|Full dose blueberry|"Full dose: 26g of freeze dried blueberry powder to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
45500630|NCT02035592|Other|Half dose blueberry|"Half dose: 26g of freeze dried powder (containing 13g of freeze dried blueberry powder and 13g of placebo comparator material) to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
45500631|NCT02035592|Other|Control|"Control: 26g of placebo comparator material to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
45500632|NCT02051673|Biological|Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
45500633|NCT03586856|Device|Nasal mask interface|Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
45500634|NCT03586856|Device|Nasal prongs interface|Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
45500635|NCT05763069|Other|Home surveillance of pregnancies at risk|Offer women with pregnancies at risk home surveillance instaed of more frequent hospital out-patient visits and/or hospitalisation: cardiotocographia (CTG), patient measurements of CRP, temperature, blood pressure, and clinical signs of infection or severe forms of preeclampsia.
45500636|NCT03586154|Combination Product|Platelet rich plasma|combined platelet rich plasma and 1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
45386943|NCT00464178|Drug|Bortezomib|Bortezomib will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
45386944|NCT00560105|Device|Lung Flute|8 weeks home use, twice daily
45386945|NCT00560105|Device|Acapella|8 weeks home use, twice daily
45386946|NCT00467610|Drug|Panhematin|
45386947|NCT00316186|Drug|topotecan|Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
45386948|NCT00316186|Drug|carboplatin|Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
45386949|NCT04011761|Other|expert arbitration over discordant diagnoses made by AI diagnostic system and human doctors, respectively|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the experimental arm will be referred to an expert arbitrator for differential and decisive diagnosis and will receive treatment prescribed by the expert arbitrator.
45386950|NCT00948623|Behavioral|physical activity counseling program|
45386951|NCT00948623|Behavioral|sham counseling program|
45500637|NCT03586154|Drug|ketamine and bupivacaine injection|1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
45500638|NCT04658693|Device|Implanted Multi contact stimulating electrode and intramuscular electromyography recording electrode|See arm description
45848406|NCT03643692|Device|ARISES|The Adaptive, Real-time, Intelligent System to Enhance Self-care of chronic diseases (ARISES) project will use type 1 diabetes (T1DM) as an exemplary case study to demonstrate safety, technical proof of concept and efficacy of a novel mobile platform. Combining wearable sensors and smartphone technology, a range of biological, environmental and behavioural data will be analysed to provide real-time therapeutic and lifestyle decision support. Using Case-Based-Reasoning (CBR), the system will be adaptive and personalised with the ability to learn from previously encountered scenarios. Ultimately, ARISES aims to empower self-management of chronic illness and limit the complications associated suboptimal treatment.
45386952|NCT01065220|Drug|Testolactone undecanoate|4ml i.m.
45386953|NCT01065220|Drug|Lynestrenol|2/day
45386954|NCT01065220|Drug|Cyproterone Acetate|50mg per day
45386955|NCT01065220|Drug|Estradiol|100 microgram TTS twice a week
45386956|NCT01065220|Drug|5-alpha reductase inhibitor|1mg daily
45386957|NCT00943865|Behavioral|hypocaloric diet|patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant.
45386958|NCT00943865|Behavioral|Exercise recommendations|Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
45386959|NCT00943865|Behavioral|Pragmatic diet|Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control.
45500639|NCT03975621|Behavioral|Supportive Care|"Patient will receive the tablet, a pedometer (to track their steps) and an exercise band (to complete the exercise videos). Use of Nurse AMIE while receiving intervention phone calls from a patient navigator.~After 90 days, observation begins and the patient will be asked to continue using Nurse AMIE without a patient navigator's presence."
45500640|NCT01413815|Dietary Supplement|L-arginine|3.3 g of L-arginine capsules, oral,b.i.d for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine).
45500641|NCT01413815|Other|Placebo|3.3 g of placebo capsules/ b.i.d.; for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine)
45500642|NCT03585920|Behavioral|Expanded Corn Snack|A standard expanded snack will be used in each of the 3 arms, the content and type of fat added to the snack is varied in the two experimental arms.
45500643|NCT03968679|Radiation|Unilateral elective nodal irradiation|After injection of nanocolloid tracer submucosally around the tumor, patients undergo lymph drainage mapping (LDM) using SPECT/CT. If no contralateral drainage is visualized, the patient receives unilateral elective nodal irradiation (ENI). In case of contralateral lymph drainage, a contralateral sentinel node procedure is performed. If pathologic evaluation finds no metastasis, the patient receives unilateral ENI. If (micro/macro) metastasis are found, the patient will receive bilateral ENI.
45500644|NCT04646603|Drug|MRG-001|Subjects will receive subcutaneous MRG-001 injections.
45500645|NCT04646603|Drug|Placebo|Subjects will receive subcutaneous placebo injections.
45500646|NCT03579992|Behavioral|60-min isometric MyCI training|EMG-controlled in-lab training with arm restrained for 60 minutes per session
45500647|NCT03579992|Behavioral|90-min isometric MyCI training|EMG-controlled in-lab training with arm restrained for 90 minutes per session
45500648|NCT03579992|Behavioral|90-min movement MyCI training|EMG-controlled in-lab training without restraint for 90 minutes per session
45500649|NCT03629847|Drug|Everolimus|Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
45500650|NCT01330589|Drug|Placebo|Non-active placebo for 7 days: PO/TID
45500651|NCT01330589|Drug|St. Johns Wort|For 7 days: 300mg PO/TID
45715068|NCT03165318|Device|Pulsed Electromagnetic Field Therapy|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Field (PEMF) once a week for a total of 16 weeks.~The PEMF device produces pulsed magnetic fields at flux densities up to 1 mT peak."
45386960|NCT00943865|Behavioral|Pedometer-based fitness (10,000 steps)|Subjects were provided with pedometers and were instructed to perform at least 10,000 steps daily, diary recorded.
45386961|NCT00943865|Behavioral|Structured assisted exercise (fitness)|They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions
45500652|NCT03577886|Drug|CDX-6114|CDX-6114 will be administered as a single, oral dose solution at dose levels of 0.225, 0.75, 2.25, and 7.5 g.
45500653|NCT03577886|Drug|Placebo|Phosphate Buffer Diluent oral solution
45500654|NCT01314833|Drug|Docetaxel Cyclophosphamide|"Docetaxel 75 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~TC*6"
45500655|NCT01314833|Drug|Cyclophosphamide Fluorouracil Epirubicin Docetaxel|"1st -3rd Cycle: Fluorouracil 500 mg/m² D1 Epirubicin 100 mg/m² D1 Cyclophosphamide 500 mg/m² D1~1 cycle = 21 days~4th-6th Cycle: Docetaxel 100mg/m² D1~1 cycle = 21 days CEF*3-T*3"
45500656|NCT01314833|Drug|Epirubicin Cyclophosphamide Paclitaxel|"1st-4th Cycle: Epirubicin 90 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~5th-8th Cycle: Paclitaxel 80mg/m² D1, 8, 15~1 cycle = 21 days EC*4-P*4"
45500657|NCT05763927|Drug|Fruquintinib|Fruquintinib 5mg 2w on/1w off, 21d/cycle, totally 4 cycle.
45500658|NCT05763927|Drug|Toripalimab|Toripalimab 200mg d1, 21d/cycle, totally 4 cycle.
45715069|NCT03165318|Device|Sham Therapy|"Participants of this arm will be exposed to 10 minutes of sham therapy once a week for a total of 16 weeks.~The Sham device is identical to the PEMF device in physical appearance."
45715070|NCT01587079|Drug|PT003|PT003 MDI administered as two puffs BID for 7 days
45715071|NCT01587079|Drug|PT001|PT001 MDI administered as two puffs BID for 7 days
45715072|NCT01587079|Drug|PT005|PT005 MDI administered as two puffs BID for 7 days
45386962|NCT02532712|Drug|EC-18|EC-18 Soft-capsule (500mg/1 capsule)
45500659|NCT05763927|Radiation|Short-course radiotherapy|25 Gy in 5 fraction, d22-26.
45500660|NCT05763927|Procedure|TME|Surgical resection of the primary tumour in the rectum, 2-4weeks after the last dose of fruquintinib
45500661|NCT03579836|Drug|BEY1107|Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.
45500662|NCT03579836|Combination Product|Gemcitabine|Administer 1,000 mg/m2 of Gemcitabine intravenously for 30 minutes on Day 1, 8, 15 and 1-week-off (7days) schedule.
45386963|NCT02532712|Drug|Placebo|Placebo with same shape and size
45500663|NCT04577781|Drug|GLPG3970|GLPG3970 powder and solvent for oral solution to be reconstituted prior to use.
45500664|NCT04577781|Drug|Placebo|Placebo powder and solvent for oral solution to be reconstituted prior to use.
45500665|NCT02737826|Drug|Buprenorphine Initiation - Phase I|In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an 8 hour induction window.
45500666|NCT02737826|Drug|Gabapentin + Buprenorphine - Phase II|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to gabapentin will receive up to 1600mg gabapentin (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
45500667|NCT02737826|Drug|Placebo + Buprenorphine - Phase II|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
45500668|NCT02737826|Drug|Buprenorphine taper - Phase II|After a 2 week stabilization period where sublingual buprenorphine is titrated up to 24 mg/day and oral gabapentin/placebo is titrated up to 1600mg/day, subjects will enter a buprenorphine tapering period lasting up to 8 weeks. The suggested buprenorphine taper will be determined by stabilizing dose, but able to be altered by prescriber or participant based on symptoms.
45500669|NCT03367715|Drug|Nivolumab|study treatment on Day 1 with one dose of nivolumab 3 mg/kg
45500670|NCT03367715|Drug|Ipilimumab|study treatment on Day 1 with one dose of ipilimumab 1mg/kg
45500671|NCT03367715|Radiation|Radiation Therapy (RT)|total dose of 30 Gy, given in 5 consecutive fractions of 6 Gy each fraction.
45715073|NCT01587079|Drug|Tiotropium inhalation powder|Taken as 1 capsule containing 18 µg of Tiotropium via the Handihaler DPI for 7 days
45715074|NCT03028909|Drug|Oseltamivir|Standard of care for influenza caused by Type A strains
45386964|NCT00948701|Behavioral|Moving Forward Together 2|RTR volunteers from the ACS will be trained to offer a 12-week telephone-based PA program as a supplement to standard 12-week RTR services.
45386965|NCT01065298|Biological|stem cell transplantation|Group 1: 200 - 250 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - Hyperaque) and stem cells will be separated. Separated MNC's will be tagged with FDG-PET and injected into superior pancreatico duodenal artery and an PET scan will be done 2 hours later to see the percentage of stem cells homing in to pancreas. After 8 weeks G-CSF(10mcg/Kg/day) will be given subcutaneous for 5 days to achieve a Leucocyte count of >40,000/mm3. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide, plasma Insulin, HOMA-IR , HOMA-B ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
45386966|NCT00943943|Drug|G-CSF|10 microgram/kg subcutaneous injection based on adjusted ideal body weight and administered in the evening (prior to the Plerixafor). The 1st dose on day -1 and every other day for 7 total doses. G-CSF administration of 7 every-other-day doses will be repeated every 28 days.
45426163|NCT05795127|Procedure|First metatarsophalangeal joint arthrodesis|Surgery leadin to bony uninon in firts metatarsophalangeal joint
45500672|NCT03963063|Procedure|Goal-directed fluid therapy|"Patients in the group will follow our mini-fluid challenge test goal-directed therapy protocol, maintaining:~individualized optimised stroke volume by mini-fluid challenge first~keep mean arterial pressure ≧65 mmHg~keep systolic blood pressure ≦140 mmHg~keep cardiac index ≧ 2.5 L/min/cm2"
45500673|NCT03963063|Procedure|Non goal-directed fluid therapy|"Patients in the group will receive standard perioperative care at the discretion of care-giving anesthesiologist, maintaining:~keep mean arterial pressure ≧65 mmHg~keep systolic blood pressure ≦140 mmHg"
45500674|NCT03577808|Other|Biopsy|Patients with locally advanced rectal cancer will receive biopsy of the primary tumor before neoadjuvant chemoradiation.
45715075|NCT03028909|Drug|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered via infusion.
45715076|NCT03028909|Drug|Placebo|Salt-water solution containing no active ingredients.
45500675|NCT05762913|Other|Manual Diaphragm Release Technique|The therapist passes his fingers under the costal arch, during inspiration the therapist accompanies the movement of the ribs, while during expiration he takes his fingers deeper, increasing his pressure. The therapist progresses progressively deeper into the costal arch with each breath. The maneuver will be performed in two sets of 10 deep breaths. The diaphragm release technique will be applied in 3 sessions, with 2 days of rest in between.
45500676|NCT03585218|Biological|Inhalation of essential oils|"Intervention Inhalation of essential oils: From the T1 (2nd Cycle CT), Experimental Group Arms will undergo the inhalation of the hedonic aroma selected by them at the time of chemotherapy (among several types of aromas). It is intended that the participant, when receiving the CT, inhales the aroma phase-in and under the investigator's observation until the end of the treatment (about two hours). The inhalation of essential oils will occur using cotton rolls impregnated with the selected oil. The control group is not subject to intervention during chemotherapy treatment."
45500677|NCT01330667|Dietary Supplement|Nutramigen Infant Formula|Investigators will advise to supplement with 10cc's of extensively hydrolyzed formula immediately following each breastfeeding until TSB declines.
45386967|NCT00943943|Drug|Plerixafor|A fixed dose of 240 mcg/kg subcutaneous injection in the abdomen, calculated on ideal body weight. The 1st dose on day -1 and every other day for 7 total doses. Plerixafor administration of 7 every-other-day doses will be repeated every 28 days.
45500678|NCT04064931|Diagnostic Test|Detection of niacin and other vitamins in plasma|Detection of niacin and other vitamins in plasma
45500679|NCT03577652|Drug|Ticagrelor|Ticagrelor, 90mg, 90mg twice daily
45500680|NCT03620513|Drug|Decongestant (oxymetazoline 0.05%)|As described in arm/group
45500681|NCT03620513|Drug|Anesthesia (Lidocaine 15%)|As described in arm/group
45500682|NCT03620513|Drug|Decongestants and Anesthesia (oxymetazoline and lidocaine)|As described in arm/group
45500683|NCT03620513|Drug|Normal saline|Spray of normal saline as premedication
45500684|NCT05761899|Combination Product|Gene-Corrected Macrophages administered by bronchoscopic instillation|This study will evaluate administration of autologous bone marrow CD34+ cell-derived, CSF2RA lentiviral vector-transduced macrophages (CSF2RA gene-corrected macrophages) by bronchoscopic instillation into individual lung segments on three occasions at 2-month intervals in patients with hPAP. The target (maximum) number of cells to be administered is 778 million gene-corrected macrophages per 70 kg patient, which is equal to 11.1 million cells/kg of ideal body weight.
45500685|NCT03585062|Drug|S1,|S-1 is a combination of tegafur, gimeracil and oteracil at a molar ratio of 1:0.4:1, and is a new oral fluoropyrimidine anticancer agent shown to be effective for pancreatic cancer. cancer
45500686|NCT03585062|Drug|Paclitaxel-albumin|Paclitaxel-albumin is a drug which showed a survival benefit in Pancreatic Cancer when combined with S1
45500687|NCT05437679|Other|Blood collection|Peripheral blood will be collected from each subject at a single time point and data will be collected from a review of each subject's medical records.
45500688|NCT03854331|Behavioral|Resilience program|The resilience program consists of different modules that are based on research on mentalization, mindfulness, parent management training, improving self-control and self-efficacy, cognitive behaviour therapy, social learning theory and neuroscience. The MyResilience program is also informed by cognitive bias modification and self-control training research. These techniques have been found to be effective in improving engagement in health behaviours and reducing symptoms and negative behaviours in clinical groups
45715077|NCT02654860|Drug|Paracetamol 3%|Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery
45386968|NCT00943943|Drug|Sorafenib|"First dose will be given right after G-CSF and plerixafor injections. Drug doses will be separated by intervals of approximately 12 hours (+/-2 hours).~Dose Level 0 = 400 mg orally twice daily."
45386969|NCT00948779|Other|antibiotic education for children in an emergency care unit|Educational, Behavioral, and Organizational intervention to improve the use of oral antibiotics in children under 6 years
45386970|NCT00948779|Other|antibiotic education for children in an emergency care unit|Educational, Behavioral and Organizational intervention to improve the antipyretic therapy in children under 6 years.
45500689|NCT03584906|Procedure|DGG Harvesting approach|An epithelialized graft is harvested from the superficial palate and then extraorally de-epithelialized in order to obtain a connective tissue graft
45500690|NCT03584906|Procedure|ET harvesting approach|A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
45386971|NCT00453102|Drug|Rituximab|IV Infusion of 250mg/m² of Rituximab Within 4 hours on Days 1, 7, 8, 9 0.4 millicuries (mCi)/kilogram (kg) (14.8 megabecquerels (MBq)/kilogram (kg)) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³
45386972|NCT00453102|Drug|Ibritumomab Tiuxetan|"IV injection of Y-90 Zevalin® over 10 minutes on Days 1, 7, 8, 9:~0.4 mCi/kg (14.8 MBq/kg) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³"
45500691|NCT03584906|Procedure|TDT harvesting approach|A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
45500692|NCT03584906|Procedure|MT harvesting approach|An epithelialized graft is harvested from the maxillary tuberosity and then extraorally de-epithelialized in order to obtain a connective tissue graft
45386973|NCT00944099|Behavioral|Behavioral weight loss intervention|both conditions will receive an identical dietary prescription, low-calorie and less than 30% calories from fat and an identical physical activity goal of 200 minutes of moderate-intense physical activity per week during a 6 month behavioral weight loss program
46056531|NCT02610088|Drug|Gliclazide|Gliclazide MR 30 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by > 0.4% at 12 week, rescue therapy (gliclazide MR 30 mg) can be added at investigator's discretion.
45386974|NCT00949013|Other|immunohistochemistry staining method|
45386975|NCT00949013|Other|laboratory biomarker analysis|
45386976|NCT00299182|Drug|AMG 531|Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
45386977|NCT00299182|Drug|Rituximab|375 mg/m^2 by vein over 4-6 hour infusion day 1, each cycle.
45386978|NCT00299182|Drug|Cyclophosphamide|300 mg/m^2 by vein over 3 hours every 12 hours for 6 doses (days 2-4), Cycles 1,3, & 5.
45386979|NCT00299182|Drug|Vincristine|1.4 mg/m^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,& 5.
45386980|NCT00299182|Drug|Doxorubicin|50 mg/m^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,& 5.
45386981|NCT00299182|Drug|Dexamethasone|40 mg/day by mouth or by vein days 2-5 and 12-15, Cycles 1,3,& 5.
45386982|NCT00299182|Drug|Methotrexate|200 mg/m^2 by vein over 2 hours followed by 800 mg/m^2 over 22 hours Day 2, Cycles 2, 4 & 6.
45386983|NCT00299182|Drug|Cytarabine|3 g/m^2 by vein over 2 hours every 12 hours for 4 doses, days 3 & 4; OR,1 g/m^2 by vein over 2 hours every 12 hours for 4 doses, days 3 & 4 for patients > 60 years and for patients with serum creatinine > 1.5 mg/dL; Cycles 2,4,& 6.
45386984|NCT00299182|Drug|Placebo|Arm A: Placebo - subcutaneous injection administered on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm B: Placebo - subcutaneous injection administered on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
45386985|NCT00467142|Biological|bevacizumab|
45386986|NCT00467142|Drug|fluorouracil|
46056532|NCT02734407|Procedure|Assigned Intervention|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study as assigned intervention. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
45386987|NCT00467142|Drug|irinotecan hydrochloride|
45386988|NCT00467142|Drug|leucovorin calcium|
45500693|NCT03584906|Procedure|Root coverage procedure|A single or multiple gingival recession is treated with a coronally advanced flap and a connective tissue graft
45715078|NCT02654860|Drug|Placebo injection containing Saline solution 0.9%|Injection containing sterile solution of Saline Solution 0.9 %. Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
46056533|NCT02734407|Drug|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
45386989|NCT00467142|Genetic|polymorphism analysis|
46056534|NCT02596789|Device|"TMS Magpro®, Magventure Inc device"|
46056535|NCT02734173|Drug|ABT450r-ABT267-ABT333 +/- Ribavirin|12 week duration of HCV antiviral therapy with ABT450r-ABT267-ABT333 +/- Ribavirin
45500694|NCT05436587|Genetic|The whole-exome sequencing|Exome sequencing will be performed at the Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan and will be analyzed at Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Japan.
45695714|NCT01674543|Other|Resistance Training|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
45715079|NCT02654860|Drug|Hyperbaric Bupivacaine HCl 0.5%|NIMP, spinal anaesthetic before the surgical procedure
45715080|NCT01587001|Dietary Supplement|N-acetyl-cysteine|900mg three times daily for 8 weeks
45715081|NCT01587001|Drug|Placebo|Matching placebo three times daily for 8 weeks.
46056536|NCT05757154|Other|Diet|All intervention arms are coffee. Three different types of coffee is tested. Differences in type of bean, degree of roasting and preparation method.
45386990|NCT01065376|Procedure|the timing cabergoline administration|received 0.5 mg oral cabergoline per day for 8 days on the day of hCG
45386991|NCT01065376|Procedure|the timing cabergoline administration|received 0.5 mg oral cabergoline per day for 8 days on the day after oocyte retrieval
46056537|NCT02729337|Behavioral|ITG (In This Together)|Comprehensive, mHealth-based HIV prevention program for Ugandan adolescents 18-22 years of age.
45386992|NCT05300789|Other|Follow-up|There is no intervention. Patients are just going to be registered and oncologic follow-up data are going to be recorded.
45386993|NCT00949091|Drug|TAK-875|"Randomized, multiple ascending-dose sequence over 14 consecutive days to include the following:~TAK-875 25 mg tablets, orally~TAK-875 50 mg tablets, orally~TAK-875 100 mg tablets, orally~TAK-875 200 mg tablets, orally~TAK-875 400 mg tablets, orally~TAK-875 placebo-matching tablets, orally."
45386994|NCT00944177|Drug|Metformin HCl|
45500695|NCT03584360|Drug|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and placebo
45500696|NCT03584360|Drug|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and betamethasone
45715082|NCT02656420|Drug|Broccoli Sprout-derived Beverage|Maximum, half and one-fifth doses of broccoli sprout-derived beverage compared to placebos.
45715083|NCT02656420|Drug|Placebos|Placebo as comparison to broccoli sprout-derived beverages
46056538|NCT05297422|Procedure|Forearm surgey|Microsurgery Clinic , KAT Hospital Athens
46056539|NCT05297422|Drug|Ropivacaine|Ropivacaine
46056540|NCT05297422|Drug|Ketamine|Ketamine
45386995|NCT00553475|Drug|placebo|Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
45386996|NCT00553475|Drug|pregabalin|Dosage: 300 mg/day (150 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
45500697|NCT03584360|Drug|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and propionate de clobetasol
45500698|NCT01330745|Other|sublingual microcirculatory evaluation|TNF, ICAM, syndecan-1, heparan sulfate
45500699|NCT02809443|Biological|GLS-5700|GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
45500700|NCT03584282|Behavioral|Text Messaging|The text messaging intervention will send three text messages per day from a library. One will be a reminder to take PrEP, one will include PrEP information, and the third will have the content of the participant's choosing from categories of harm reduction messages and health information. Participants will also select the time period to receive these texts.
45500701|NCT03584282|Behavioral|Peer Navigation|The peer navigation intervention will provide support from a peer that is responsive to a participant's individualized needs. Peer support may include phone call reminders, help refilling PrEP prescriptions, transit assistance, or other referrals.
45500702|NCT01330823|Dietary Supplement|L-Carnitine|L-Carnitine, 4g/day, orally (Juice)
46056541|NCT02734095|Device|Ultrasound|Intravascular ultrasound measurements after percutaneous transluminal angioplasty and stenting in the treatment of femoropopliteal lesions.
46056542|NCT02609074|Procedure|Minimally invasive internal fixation surgeries|
45386997|NCT00553475|Drug|pregabalin|Dosage: 600 mg/day (300 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
45386998|NCT00329602|Drug|Placebo|Matching Placebo
45386999|NCT00329602|Drug|Ropinirole|Ropinirole IR 0.25mg/day to 4mg/day for RLS
45387000|NCT01060696|Drug|Mefenamic acid or Hyoscine or placebo|Mefenamic acid 500 mg. single oral use 30 minutes before SIS Hyoscine 10 mg. single oral use 30 minutes before SIS Placebo single oral use 30 minutes before SIS
45387001|NCT01065610|Drug|Oxytocin|
45387002|NCT01065610|Drug|Placebo|
45387003|NCT01062646|Behavioral|Multimodal music therapy|
45387004|NCT01062646|Behavioral|Community treatment as usual|
45387005|NCT00463866|Drug|Budesonide/formoterol|
45500703|NCT01330823|Dietary Supplement|Placebo|tartaric acid same dose like L-Carnitine as placebo
45500704|NCT03636191|Dietary Supplement|Probiotic strain|Lactobacillus
45500705|NCT03636191|Dietary Supplement|Placebo|Placebo
45500706|NCT05763771|Behavioral|Smart Phone App|Collection of data
45500707|NCT05763771|Other|NIcotine Patches|Place on the skin
45500708|NCT03579758|Drug|Capecitabine|Given PO
45500709|NCT03579758|Drug|Cisplatin|Given IV
45500710|NCT03579758|Drug|Gemcitabine|Given IV
45500711|NCT03636113|Device|Clarity RMS Electronic Sensor|The urinary foley catheter with electronic sensor will be placed within the Operating Room prior to surgery. Upon arrival to the ICU, the device will be connected to an electronic console by study coordinator. The study coordinator will weigh the urine drainage bag and record the weight every hour for 4-6 hours. The device will record urine flow on a 15 minute interval up to 6 hours
46056543|NCT02609074|Device|CPC/rhBMP-2 micro-scaffolds|
46056544|NCT02609074|Device|CPC paste|
46056545|NCT00733369|Device|PFC Sigma RP-F|An orthopaedic implant for total knee replacement with a high flexion rotating platform bearing
46056546|NCT00733369|Device|PFC Sigma RP|An orthopaedic implant for total knee replacement with a standard flexion rotating platform bearing
45387006|NCT00313846|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
45387007|NCT00313846|Drug|Placebo|Placebo to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.
45387008|NCT00949247|Biological|bevacizumab|Bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
45387009|NCT00949247|Biological|trastuzumab|Trastuzumab IV over 30-90 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
45387010|NCT00949247|Drug|carboplatin|Carboplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
45500712|NCT03577574|Procedure|retrobulbar anesthesia|2% lidocaine 4ml injected into retrobulbar space
45500713|NCT03577574|Procedure|peribulbar anesthesia|2% lidocaine 4 to 8ml injected into peribulbar space
45500714|NCT03577574|Procedure|two step anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.6 to 0.8ml subconjunctival injection
45500715|NCT01130519|Drug|Bevacizumab|Commercially available. Administered by intravenous infusion.
45500716|NCT01130519|Drug|Erlotinib|Commercially available. Administered orally.
45500717|NCT03070431|Radiation|High-precision RT 5x5 Gy in 1 week|Patients included in this study will receive a high-precision radiotherapy with 5x5 Gy in 1 week
45500718|NCT02238548|Biological|Cholera vaccination|Oral cholera vaccination on day 0 and day 14
45500719|NCT02238548|Other|Raw milk|
46056547|NCT02729415|Procedure|Stromal Vascular Fraction Cells (SVF Cells) Injection|The procedure involves the injection of stromal vascular fraction cells (SVF Cells) into the scalp. The injection will be performed once in the middle of two perpendicular sides of a 2 x 2 cm area.
45387011|NCT00949247|Drug|docetaxel|Docetaxel IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
45387012|NCT00949247|Other|laboratory biomarker analysis|Tumor tissue and bone marrow samples may be collected for further laboratory analysis.
45387013|NCT00551135|Drug|Pregabalin|150 mg BID
45387014|NCT00551135|Drug|placebo|Placebo
45387015|NCT00551135|Drug|Pregabalin|75 mg BID
45387016|NCT00551135|Drug|Pregabalin|25 mg BID
45387017|NCT00944333|Drug|Clopidogrel|300-600 loading dose 75 mg/die for 6 months
45387018|NCT00944333|Drug|Clopidogrel|300-600 loading dose 75 mg/die for 12 months
45387019|NCT01529801|Device|Osseotite Certain Tapered Group A|Osseotite Certain Tapered with different surface roughness
45387020|NCT01529801|Device|Osseotite Certain Tapered Group B|Osseotite Certain Tapered with different surface roughness
45387021|NCT01529801|Device|Osseotite Certain Tapered Group C|Osseotite Certain Tapered with different surface roughness
45387022|NCT00949481|Other|Pregnancy Test|Free pregnancy test strips will be supplied to family planning clinics
45387023|NCT00949481|Other|Job aid|"A new job-aid will be given to immunization providers that will guide them in assessing a mother's risk for pregnancy (based on LAM criteria), and guide them in making family planning referrals, including when a woman should start to use a family planning method if she wants to prevent pregnancy. The providers in immunization clinics will be asked to make such an assessment each time a woman has her baby vaccinated.~Additionally, in family planning clinics located in the same facilities as the immunization clinics, family planning providers will be trained to use and provided with the pregnancy checklist (see links for more information on the checklist)"
45387024|NCT04012385|Behavioral|lifestyle counseling|Nutritional plan and Physical activity goals
45387025|NCT00956423|Behavioral|moderate-intensity aerobic and resistance training|Individuals will complete four days of aerobic exercise of moderate intensity (60% of maximal VO2, approximated from heart rate). Duration of aerobic activity will gradually increase from weeks 1 through 4 until 180 min of aerobic exercise at the prescribed intensity is performed each week. Following aerobic exercise on two days per week, moderate-intensity resistance training will be performed using eight different resistance machines. One set of 8-12 repetitions will be performed during weeks 1-4; from week 5-on, 2 sets of 8-12 repetitions will be performed.
45387026|NCT00956423|Behavioral|low-intensity stretching|Individuals will perform supervised whole-body flexibility exercises on two days per week. Two sets of each exercise will be performed, with the duration of each stretch gradually increasing from 15 sec to 30 sec. A total of 15-20 stretches, focusing on whole-body flexibility, will be performed.
45387027|NCT00949559|Drug|EP-100|as a single agent administered intravenously twice weekly x 3 with 1 week off (total 28 days)
45848407|NCT03645954|Procedure|Femoral Nerve Block|"Procedure: Femoral Nerve Block~The femoral nerve block will be performed as described in Arms section.~Device: Ultrasound~Linear ultrasound transducer probe (Flex Focus 400 exp, bk medical, Denmark) will be used to guide the needle placement.~Device: Needle~20-gauge 50 mm Ultraplex needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform the femoral nerve block.~Drug: Local anesthetic~Bupivacaine 0.125% 20 mL will be used to perform the femoral nerve block."
46056548|NCT02729415|Procedure|Liposuction|Tissue collection involving the micro-harvest of subcutaneous adipose tissue to harvest the stromal vascular fraction cells (SVF Cells).
46056549|NCT02729415|Other|Hair Measurements|Hair measurements will be performed using a computerized handheld USB camera at baseline, 6 weeks, and months 3 and 6 after treatment.
45387028|NCT00949637|Behavioral|Scouting Nutrition and Activity Program|Intervention group will receive a curriculum based on social cognitive theory, wherein children will be taught skills in a supportive environment to improve their self efficacy and proxy efficacy toward eating healthful meals and being physically active with a parent. Troop leaders and parents will provide support, and help girls to create healthy opportunities in the home environment. Simultaneously, girls will be taught skills to improve the family mealtime environment, to bolster asking skills toward healthy behavior, to self-monitor healthy behavior, and to set goals for healthy behavior.
45387029|NCT00949637|Behavioral|Standard-care attentional control|Control troops complete usual troop meeting activities. Control troops receive equal observation time, equal pretest and posttest assessment, and equal study scrutiny.
46056550|NCT02734017|Other|pharmacist-led standardized medication review|the goal of this study is to assess the impact of the standardized medication review on the rate of readmissions and/or death at 30 days following initial hospitalization discharge.
45387030|NCT00299104|Drug|folate|Intravenous repeating dose
45387031|NCT00299104|Drug|methotrexate|Oral or parenteral repeating dose
45387032|NCT00299104|Drug|methylprednisolone|Intravenous repeating dose
45387033|NCT00299104|Drug|placebo|Intravenous repeating dose
45387034|NCT00299104|Drug|rituximab|Intravenous repeating dose
45387035|NCT03979690|Device|NISInspire-C System|The NISInspire-C System is a disposable robotic colonoscopy system that consists of a flexible slender insertion tube designed to ensure non-invasive, reliable and safe colorectal screening. It comprises of two components: NISInspire-C Console, and the NISInspire-C Disposable Colonoscope.
46056551|NCT00813124|Drug|Fludarabine|40 mg/m^2 by vein over 60 minutes on Day -5 through Day -2.
45500720|NCT01330901|Drug|Ustekinumab|Ustekinumab 90 mg given subcutaneously at weeks 0, 4, and 16
45500721|NCT03584204|Diagnostic Test|imaging|computed tomography, magnetic resosnance imaging, ultrasound
45500722|NCT02428647|Dietary Supplement|MNP|MNP containing containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate
46056552|NCT00813124|Drug|Busulfan|Busulfan administered at the dose calculated to achieve an area under curve (AUC) of 4000 µMol-min + 12% based on the pharmacokinetic studies (days -5, -4, -3, and -2).
45500723|NCT02428647|Dietary Supplement|preventive zinc supplement|7 mg zinc daily as dispersible tablet
46056553|NCT00813124|Drug|Thymoglobulin|2.5 mg/kg by vein over about 4-6 hours on Day -3 through Day -1.
46056554|NCT00813124|Drug|Azacitidine|Start cycles of 32 mg/m^2 daily as an injection under the skin once a day over 5 days in a row, starting about 5 weeks after the transplant. This may be repeated once a month for up to 4 months after the transplant.
45500724|NCT02428647|Dietary Supplement|therapeutic zinc supplement|20 mg zinc per day for 10 days during diarrhea episodes, as dispersible tablet
45500725|NCT02428647|Dietary Supplement|preventive placebo supplement|dispersible daily placebo tablet
45848408|NCT03645954|Procedure|Femoral Triangle & Adductor Canal Blocks|"Procedure: Femoral Triangle & Adductor Canal Blocks~These two blocks will be performed as described in Arms section.~Device: Ultrasound~Linear ultrasound transducer probe (Flex Focus 400 exp, bk medical, Denmark) will be used to guide the needle placement.~Device: Needle~20-gauge 100 mm Ultraplex needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform the femoral triangle block and adductor canal block.~Drug: Local anesthetic~Bupivacaine 0.125% 20 mL will be used to perform the femoral triangle block and adductor canal block (10 mL for each block)."
45500726|NCT02428647|Dietary Supplement|therapeutic placebo supplement|dispersible placebo tablet for 10 days during diarrhea episodes
45500727|NCT02428647|Dietary Supplement|placebo powder|placebo powder
45500728|NCT01071395|Drug|Amantadine|Amantadine hydrochloride 300mg daily in three divided doses
45500729|NCT01071395|Drug|Placebo|Sugar pill given 3 times daily
45500730|NCT00335816|Drug|fluorouracil|Given IV
45500731|NCT00335816|Drug|leucovorin calcium|Given IV
45500732|NCT00335816|Drug|oxaliplatin|Given IV
45500733|NCT00335816|Procedure|conventional surgery|Patients undergo surgery
45500734|NCT00335816|Radiation|radiation therapy|Patients undergo radiotherapy
45848409|NCT03647046|Device|Customized Scleral Lens|A wavefront customized scleral lens will be made for each subject and tested against a non-customized lens.
45848410|NCT03649932|Dietary Supplement|Enteral L-citrulline|"L-Citrulline as 10 % solution (100 mg/ml) will be provided to the bedside nurse by the Investigational Pediatric Pharmacy. The drug will be given via gavage feeding by bolus infusions followed by a 0.5 ml water flush twice daily (0900 and 2100). Bolus dosing will be needed due to the small volumes (0.5-1.5 ml per dose in most infants). The volume of nasogastric tubing used in preterm infants (Ameritus 4.0 Fr 50 cm) is 0.48 ml, therefore we will follow the administration with 0.5 ml of saline/water flush to ensure all the study drug is delivered to the patient.~Administration of study drug - Will be given via gavage feeding tube twice daily (0900 +/- 30 mins, 2100 +/- 30 mins). L-citrulline will be given by the bedside nurse as a bolus followed by 0.5 ml water flush. L-citrulline will be given separate from feeds to avoid any confusion.~Study drug will be started when infant has been off of TPN for at least 3 days so that IV arginine in TPN does not interfere."
45848411|NCT03655080|Radiation|Radiation therapy|Using the View Ray System
45848412|NCT03655080|Drug|nab-Paclitaxel|"Dose 15 mg/m^2~Should be administered by IV over 30 minutes"
45848413|NCT03663816|Device|experimental foot device|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in healthy people.
46056555|NCT00813124|Procedure|Stem Cell Transplant|Stem cell infusion on day 0 administered by vein after collected from donor.
46056556|NCT02733939|Device|Home monitoring kit|"The home monitoring kits notify the caregivers about potentially dangerous situations, such as when the person with dementia:~leaves the home without notice, since this might occur in a moment of disorientation;~leaves a water tap open;~forgets something on the stove;~gets out of bed during the night and doesn't come back within a certain time interval;~never goes to the bathroom in 24 hours;~never opens refrigerator door in 24 hours.~Depending on the personal choice of the study participants, the kit will also :~automatically turn on a light to help avoid a fall during the night;~alert the caregiver when the temperature in the house falls or rises excessively;~act as burglar alarm in some areas of the home."
46056557|NCT02729259|Behavioral|Virtual Reality Snowworld|The subjects will receive Virtual Reality Snowworld during their wound care procedure. The nurse will be doing their wound care.
46056558|NCT02729259|Behavioral|Virtual Reality slides of nature|The subjects will receive Virtual Reality Slides of Nature during their wound care procedure. The nurse will be doing their wound care.
46056559|NCT02729259|Behavioral|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
46056560|NCT05133700|Other|Interview or focus group discussion|There is no intervention. This is a qualitative piece of work only
46056561|NCT05133700|Other|Review of submitted medicines audit tools|There is no intervention. This is a qualitative piece of work only
45500735|NCT00335816|Other|laboratory biomarker analysis|Correlative studies
45500736|NCT00335816|Genetic|DNA analysis|Correlative studies
46056562|NCT00733291|Device|Nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
45387036|NCT03979456|Drug|Rituximab|After one year in the trial, the patients are split in the two dosing-arms described above. The dose-comparison phase continues four years.
45387037|NCT00313612|Drug|oxaliplatin|Given IV
45387038|NCT00313612|Drug|topotecan|Given IV
45387039|NCT00507416|Drug|Bortezomib|Bortezomib bolus intravenous (IV) injection
45387040|NCT00507416|Drug|Dexamethasone|Dexamethasone for oral administration
45695715|NCT01674543|Other|Concurrent Training|"The patients in this group will given a progressive concurrent training program, composed of aerobic and resistance training in the same session, twice per week (Tuesday and Thursday) for 20 weeks. Training sessions will performed at the same time of day (between 1 pm and 5 pm). the aerobic training will be conducted in Lifefitness 9700HR treadmill and the chosen exercises for resistance training focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
45695716|NCT01674543|Other|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
45387041|NCT00507416|Drug|Melphalan|Melphalan for oral administration
45387042|NCT00507416|Drug|Prednisone|Prednisone for oral administration
45695717|NCT01674699|Device|EXCOR Pediatric|Ventricular Assist Device
45848414|NCT03674970|Drug|Nicotine Film|"Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.~The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting."
45695718|NCT03859713|Behavioral|Physical Therapy|Evidence-based physical therapy provided in 8 individual sessions including patient education, exercise instruction and manual therapy.
45695719|NCT03859713|Behavioral|Cognitive Behavioral Therapy|Evidence-based cognitive behavioral therapy provided in 8 individual sessions focused on key components of CBT; 1) identifying and monitoring maladaptive cognitions, 2) developing coping strategies (e.g., distraction, relaxation, etc.), 3) setting and working towards behavioral goals, especially focused on physical activity, and 4) focusing on self-management skills and home instruction
45695720|NCT03859713|Behavioral|Mindfulness|Mindfulness is provided in 8 individual sessions. Focus of sessions is cognitive reappraisal, positive savoring and mindfulness practices.
45695721|NCT03877653|Device|Wireless neuromodulation|A needle and catheter are carefully inserted near the enervated nerve. The stimulator is then placed through the catheter close to the nerve. The proximal end of the stimulator is then sutured underneath the skin to prevent migration.
45387043|NCT00507416|Drug|Thalidomide|Thalidomide for oral administration
45695722|NCT01674777|Drug|ASP1941|oral
45848415|NCT03679494|Other|Shared decision making support tool|Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions
46056563|NCT00733291|Device|Etafilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
45387044|NCT00489476|Drug|Staccato Loxapine|
45387045|NCT00489476|Drug|Staccato Placebo|Placebo aerosol inhalation (0mg)
45387046|NCT00550745|Biological|Zoster Vaccine, Live|single 0.65 mL Zoster Vaccine, Live injection. 6 month treatment period.
45387047|NCT00550745|Biological|Comparator: placebo|single 0.65 mL Placebo injection. 6 month treatment period.
45426164|NCT05795088|Device|Continuous theta burst stimulation|Two sessions of continuous theta burst stimulation over primary motor cortex to explore synaptic plasticity in Patients with Parkinson's disease
45426165|NCT05795062|Drug|apixaban|patients treated with apixaban
45426166|NCT05795062|Drug|warfarin|patients treated with warfarin
45500737|NCT00335816|Genetic|polymerase chain reaction|Correlative studies
45500738|NCT00335816|Other|immunohistochemistry staining method|Correlative studies
45500739|NCT02970942|Drug|Semaglutide|Once daily administration of semaglutide subcutaneously (s.c., under the skin) in three different doses (0.1 mg, 0.2 mg and 0.4 mg)
45500740|NCT02970942|Drug|Placebo|Once daily administration subcutaneously ( s.c., under the skin)
45695723|NCT03876717|Drug|Colesevelam Hydrochloride|Colesevelam is a sequestrant that binds bile acids in the intestinal lumen, the bile acids are then excreted with the feces. Colesevelam is registered for treating hypercholesterolemia but it is as other sequestrants (e.g. cholestyramine and colestipol) effective against bile acid diarrhoea.
46056564|NCT00733291|Device|FID 107027 solution|Commercially marketed solution for contact lens disinfection
46056565|NCT02729181|Device|DRX9000|
45500741|NCT05433311|Other|Exercises|Neutral position training, transversus abdominis/multifidius/abdominal/back extensors strengthening exercise, bridge exercise, cat-camel exercise, lumbal extensor/hamstring/gastrosoleus/latissimus dorsi/gluteal stretching exercises
45387048|NCT05300633|Behavioral|Group-Based Community Reinforcement Approach and Family Training-Early Psychosis Intervention (CRAFT-EPI)|Behavioral therapy adapted for families of young people experiencing early psychosis delivered via telemedicine to groups following an individual orientation. Group session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, and problem solving. A happiness scale will be completed at each session. Will be provided in the context of an early psychosis intervention program that provides coordinated specialty care to 16- to 29-year-olds experiencing any diagnosis that can manifest as early psychosis.
45500742|NCT03577496|Other|Peppermint oil|A cotton ball with three drops of peppermint oil will be waved under the patient's nares.
45500743|NCT05429723|Drug|HS-10383|HS-10383 administered as one 50 mg, 150 mg, 450 mg and 900 mg tablet once daily, depending upon randomization.
45387049|NCT00949793|Device|Endomicroscope|Endomicroscopic images are taken at several positions on the tumor.
45500744|NCT05429723|Drug|HS-10383 Placebo|Placebo for HS-10383
45500745|NCT03073005|Other|Simulation-based Mastery Learning (SBML)|The SBML training group will first 1) watch the VAD video, then 2) participate in a SBML intervention using the simulator for a) driveline exit site sterile dressing changes; b) performing controller self-tests; c) changing power sources; d) troubleshooting emergent VAD-related malfunction; and e) recognizing specific signs and symptoms requiring immediate contact with the VAD team.
45387050|NCT00949871|Other|communication analysis|
45387051|NCT00949871|Other|questionnaire administration|
45387052|NCT00949871|Procedure|psychosocial assessment and care|
45387053|NCT00949871|Procedure|support group therapy|
45387054|NCT00952601|Dietary Supplement|Modified Atkins diet|Low carbohydrate diet
45387055|NCT00956735|Other|Pistachio|3.0 oz (2 servings) of roasted and salted or unsalted pistachios
45387056|NCT04216043|Dietary Supplement|RUSF skimmed milk powder|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
45500746|NCT03577340|Other|implant of cardiac device as per guidelines|Observation of performance to validate matrix
45500747|NCT03582878|Drug|Sirolimus Oral Product|Oral form of sirolimus, daily dosing to achieve target trough levels between 5-10ng/ml since 1.day of transplantation
45500748|NCT03582878|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil dosing 1g before transplantation and 1g bid afterwards
45500749|NCT01331057|Other|NEEL test|An assessment for children in French with items extracted from the NEEL test
45500750|NCT01331057|Other|ELAL test|An assessment of mother tongue with the ELAL of AVICENNE
45500751|NCT01331057|Other|Interview|For parents of children include in the study: A semi -structured interview
45500752|NCT03579524|Procedure|Erector Spinae Plane Block|At lateral decubitus with the operation site up, the vertebrae will be counted from cephalad to caudal direction until reaching T5 spinous process as the first palpable spinous process is C7. The ultrasound probe will be placed vertically 3 cm lateral to the T5 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle will be introduced from superior to inferior direction in-plane until the tip lay deep to erector spinae muscle. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread under erector spinae muscle. A total of 20 mL of 0.25% bupivacaine will be injected next.
45500753|NCT03579524|Procedure|Serratus Anterior Plane Block|At supine position with the arm abducted, the ribs will be counted in the mid-axillary line from downward upwards until the 5th ribs. The linear probe will be placed horizontally then three muscles will be identified: latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe from supero-anterior to posteroinferior. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread over serratus anterior muscles, then a total 20 ml of bupivacaine 0.25% will be injected.
45500754|NCT05763693|Drug|Azithromycin at Baseline|this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at baseline
45500755|NCT05763693|Drug|Azithromycin at Day 21|this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at the day 21 visit
45387057|NCT04216043|Dietary Supplement|RUSF milk protein concentrate and sucrose|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
45500756|NCT05763693|Other|Placebo at Baseline|this group will be randomized to receive Placebo at baseline
45387058|NCT04216043|Dietary Supplement|RUSF soy protein and whey permeate|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
45387059|NCT04216043|Dietary Supplement|RUSF soy and sucrose|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
45387060|NCT00952679|Device|Breast Lesion Localization Needles (interv)|needles to locate sln in CT monitor guided by CT
45426167|NCT05795049|Other|Stool and saliva sample collection|Stool and saliva samples collection
45500757|NCT05763693|Other|Placebo at Day 21|This group will be randomized to receive Placebo at the day 21 visit
45500758|NCT02238704|Dietary Supplement|Regimen A calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
45500759|NCT02238704|Dietary Supplement|Regimen B calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
45500760|NCT03995121|Radiation|[11C]APP311|It has been shown that [11C]APP311 (aka [11C]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.
45500761|NCT03577262|Other|[11C]-UCB-J|IV radioligand given prior to and during positron emission tomography (PET) scan
45500762|NCT01331135|Drug|sirolimus|daily administration of sirolimus in oral form starting at a dose of 1 mg/m2 and increasing to a possible 3 mg/m2.
45695724|NCT03876717|Drug|Placebo oral capsule|Inactive placebo tablets over-encapsulated with DB caps AAA
45387061|NCT04417127|Other|Integrated Community-Based (ICB) Care|The intervention will include the following components: (1) integrated care visits by clinical team occurring monthly during months 1-6 of the trial, and then quarterly for the remaining months (7-18), which include vital signs screening, consultation with a clinical officer, medication distribution (ART and other chronic and acute medications), and point- of-care (POC) laboratory testing (creatinine, blood glucose and hemoglobin A1C, and viral load as it becomes available); (2) peer support for promoting ART adherence during every monthly MF meeting; (3) referrals to facilities for emergency or acute care needs that are not feasible to address in the community. Integrated care refers to delivery of primary, HIV and NCD-related care, incorporating a focus on both chronic and acute needs.
45387062|NCT04417127|Other|Microfinance|"Group microfinance uses a client-driven model that involves community savings groups where members mobilize and manage their own savings, provide interest-bearing loans to group members, offer a limited form of financial insurance, and contribute to a social fund that is used for income-generating activities and in cases of emergency or welfare issues of group members.~For this study, group microfinance will refer to existing, active AMPATH Group Integrated Savings for Empowerment (GISE) microfinance groups with a majority of group members who are AMPATH HIV patients and have disclosed their HIV status. Groups will be considered active if the group was formed at least 6 months prior to study baseline, is consistently meeting as scheduled, and is actively engaging in saving and loaning."
46056566|NCT03964597|Diagnostic Test|Measurement of lens opacification|Measurement of OSI and ALD at inclusion and during post-IVT follow-up visits to M3, M6, and M12, +/- M18, +/- M24 and +/- M30.
45500763|NCT03577184|Drug|Metformin/Vildagliptin|Vildagliptin belongs to dipeptidyl peptidase-4 (DPP-4) inhibitor. Inhibition of dipeptidyl peptidase-4 (DPP-4) and metformin is a Biguanides.
45387063|NCT04416659|Device|Neuro-vascular access|Adjunctive device providing a conduit for retrieval device during thrombectomy
45500764|NCT02849171|Device|PET scan|
45500765|NCT02849171|Radiation|C-Choline|
45500766|NCT03888885|Behavioral|Sport Education Model|A total number of 25 lecturers participated in the 12-hour CPD workshop on Sport Education curriculum on June 2018. The content of the workshop focused on the development of a Sport Education season, the changing roles of teachers and students, the assessment of personal and social responsibility, and the application of sport education season and related pedagogies on handball, badminton, swimming and physical conditioning. The Sport Education courseware and class materials were then designed by the eligible lecturers. The intervention was lasted for 10-lesson, 1-day per week and the duration for each lesson was around 90 minutes. The specific five phases in Sport Education model of team selection, teacher-directed, pre-season, formal competition and cumulating event were included. The eligible lecturers led the lessons according to the designated course wares and lesson plans for each sport.
45500767|NCT02848664|Device|Dysphagia retraining with device|Patients used the device for 60 trials of retraining swallowing at home each day and also had the device turned on throughout the day in automatic mode to intermittently trigger every few minutes to trigger a swallow for saliva control
45500768|NCT03635879|Other|MCTprocal medical food|32 g MCTprocal (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
45500769|NCT03635879|Other|Milk/tricaprilin oil blend|154 mL of lactose-free skim milk/21 mL of tricaprilin oil blended and then mixed in 180 mL of water at Hour 0 Day 1
45500770|NCT03635879|Other|AC-1207|AC-1207 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
45500771|NCT03635879|Other|AC-1205|AC-1205 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
45500772|NCT03635879|Other|AC-1206|AC-1206 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
45500773|NCT03635879|Drug|AC-1202|AC-1202 (20 g MCT) mixed in 240 mL of water at Hour 0 Day 1
46056567|NCT05753878|Drug|HH-120 nasal spray, PartA cohort 1|A single dose of HH-120 nasal spray premixed with 1mg/ml methylene blue injection.
45500774|NCT02238860|Drug|Entacavir|Entacavir-0.5 mg ,OD,for
45500775|NCT02238860|Drug|Tenofovir|Tenofovir ,300 mg,OD,for 48 weeks
45500776|NCT01333709|Drug|Induction trichemotherapy - FOLFIRINOX regimen|A short (4 cycles) and intensive trichemotherapy combinig irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2, 5-Fu (bolus 400 mg/m2, followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered for 8 weeks (D1=D15).
45500777|NCT01333709|Other|Early tumor response evaluation by MRI volumetry|Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.
45500778|NCT01333709|Radiation|Radiochemotherapy Cap 50|RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake).
45500779|NCT01333709|Radiation|Radiochemotherapy Cap 60|RCT Cap 60 will combine radiotherapy at a dose of 60 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 6 weeks / 44 Gy in mini pelvis, and boost 16 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake)
45695725|NCT01674855|Drug|PEG-G-CSF|Prefilled syringe, 6mg/day, single dosing per cycle, for 6 cycle
46056568|NCT05753878|Drug|HH-120 nasal spray, Part A cohort 2-7|A single dose of HH-120 nasal spray.
46056569|NCT05753878|Drug|HH-120 nasal spray, Part A cohort 8-9|Two doses of HH-120 nasal spray.
46056570|NCT05753878|Drug|HH-120 nasal spray, Part B|HH-120 nasal spray, 10 times daily for 7 consecutive days.
45500780|NCT01333709|Procedure|Radical proctectomy with total mesorectal excision|The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
45500781|NCT02239172|Biological|PA83-FhCMB|
45387064|NCT00956969|Behavioral|Anger Awareness and Expression|Teaches patients to recognize, experience, and express emotions
45387065|NCT00956969|Behavioral|Relaxation Training|Teaches patients relaxation training
45500782|NCT05202717|Device|PHENIX U4+|The newly developed domestic PHENIX U4+ is relatively small in size. In addition to the smooth muscle stimulation function of the traditional therapy device, its electrical stimulation waveform setting can also stimulate the striated muscle, and adds more than 10 A3 reflex treatment options, which can inhibit Urinary reflex, resulting in symptoms related to urinary incontinence in the patient.
45500783|NCT05202717|Device|Traditional pelvic floor treatment instrument|Traditional pelvic floor treatment instrument commonly used in clinical practice
45500784|NCT02969382|Drug|SEP-363856|One SEP-363856 capsule (50 mg or 75 mg) daily for four weeks
45387066|NCT00952835|Other|regular treatment|regular treatment
46056571|NCT05753878|Other|Placebo nasal spray, Part B|Placebo nasal spray, 10 times daily for 7 consecutive days.
46056572|NCT02733783|Device|Cold dry air machine|Cold Dry Air (CDA)- nasal provocation: Compressed dry air is delivered through a transparent anaesthesia mask placed over the nose and mouth of the patients. Subjects are instructed to breath through the nose only. Exposure to CDA lasts for 15 minutes. The flow, measured by a gas flow analyzer of Dräger was set at 12,5 l/min. The temperature of the air reaching the nose is at -10° C with a relative humidity of 10%-15%.
46056573|NCT00732199|Other|1) hyperventilation via noninvasive positive pressure ventilation 2) multiple trials of episodic hypoxia|1) noninvasive hyperventilation to determine apneic threshold; 2) episodic hypoxia to determine ventilatory long term facilitation
46056574|NCT02733549|Other|LFTs|"A single 5-ml peripheral venous blood sample was collected from each participant.~Serum ALT, AST, ALP, GGT, total bilirubin, conjugated bilirubin, and albumin level, Platelet count, INR and aPTT were analyzed."
45500785|NCT02969382|Drug|Placebo - Cap|One Placebo capsule daily for 4 weeks
45500786|NCT03579368|Device|Symfony implantation|Bilateral Symfony IOL Implantation
45500787|NCT01333787|Dietary Supplement|Dietary Fiber Mixture|"During the four weeks the patients received fiber mixtures (intervention) or maltodextrine as the placebo. The fiber mixture was composed of six different types of fibers: 10.5% fructooligosaccharides, 12.5% inulin, 24% Arabic gum, 9% resistant starch, 33% Soya polysaccharide e 12% cellulose.~The dose was defined in accordance with the child's body weight: 6.3 grams of fiber supplement, which corresponds to 4.8 g of fiber, or placebo(1 table spoon) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing up to 18 kg; 12.6 grams of fiber supplement, which corresponds to 9.6 g of fiber, or placebo (2 table spoons) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing more than 18 Kg."
45500788|NCT03574922|Other|Balance exercises|Balance Exercises
45500789|NCT03574922|Other|Core Stabilization exercises|Core Stabilization exercises
45500790|NCT04869137|Drug|Lenvatinib Oral Product|20mg of Lenvatinib will be taken orally once daily
45500791|NCT04869137|Drug|Pembrolizumab|200mg of Pembrolizumab will be administered through IV infusion every 3 weeks.
45387067|NCT00957125|Drug|Epirubicin|75 mg/m2 i.v. infusion, 30 min, cycle day 1, cycles 1-6.
45387068|NCT00957125|Drug|Docetaxel|75 mg/m2 i.v. infusion, 60 min, cycles day 1, cycle 1-6.
45387069|NCT00957125|Drug|Bevacizumab|15 mg/kg, i.v. infusion, 90 min, cycle day 1, cycles 3-6 if PR or SD after cycle 2.
45426168|NCT05795049|Other|Questionnaire completion|"Questionnaire on;~demographic, ethnicity, IBS subtype, post-infection onset, previous surgeries~IBS severity score for adults~Hospital Anxiety and Depression scores for adults~Somatization score for adults~Total glucose and fructose and excess fructose, lactose, sorbitol, mannitol, oligosaccharides (Fructans and GOS) as measured by CNAQ questionnaire for adults and children~Quality of Life as measured by the PedsQL™ GI Symptoms Module~GI symptoms as measured by the PedsQL™ GI Symptoms Module~Anxiety, Depression as measured by the Pediatric PROMIS®"
45500792|NCT02239250|Device|Water filter and cookstove|"The Vestergaard Frandsen Lifestraw Family™ 2.1 is a point-of-use water treatment system.Water is poured through a 20 micron pre-filter into a 6L influent water tank.This water then filters through a 0.20 micron hollow-fiber ultrafiltration membrane into a 5.5L storage container.Water is then poured through a plastic tap, which prevents re-contamination.This system filters up to 18,000L of water.The system exceeds the WHO's highly protective standard for household water treatment technologies.The EcoZoom™ Spartan stove concentrates the combustion process while channeling airflow to completely burn the fuel provided.The stove has a ceramic combustion chamber within a steel housing, which is topped with a cast iron stove.The stove includes a rack for placing firewood and a pot skirt that improves the thermal efficiency.The cookstoves and filters will be delivered together at no cost to participating households.Households will receive instructions on how to operate these devices."
45500793|NCT00364637|Drug|Sevoflurane (Volatile Anesthetic)|
45500794|NCT00364637|Drug|Total intravenous anesthesia|
45500795|NCT03651414|Other|Clinical data collection|There will not be any experimental intervention. The study will be conducted according with normal clinical practice.
45500796|NCT00493961|Drug|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump)
45500797|NCT03077789|Procedure|TRABECULOTOMY|Evaluation of the prognosis of different surgery in congenital glaucoma
45500798|NCT00175136|Device|Maxim TKA|Operation with Total Knee Arthroplasty and either an I-beam stem or a wedge stem of the tibial component.
45426169|NCT05795036|Device|Mhealth|Using a mHealth intervention to promote physical activity in Phase III cardiac rehabilitation clients
45426170|NCT05795010|Other|MRD test|ctDNA detection based on tumor whole exon sequencing
45500799|NCT03649776|Other|Mental Health First Aid|Mental Health First Aid (MHFA) is listed in the Substance Abuse and Mental Health Services Administration's National Registry of Evidence-based Programs and Practices. The program also teaches the common risk factors and warning signs of specific types of illnesses like anxiety, depression, substance use, bipolar disorder, eating disorders, and schizophrenia. Participants are introduced to local mental health resources, national organizations, support groups, and online tools for mental health and addictions treatment and support.
45426171|NCT05794997|Drug|Propranolol or Carvedilol|Propranolol or Carvedilol claim is used as the exposure group.
45500800|NCT02589509|Behavioral|Direct-attention training using web-based BrainHQ|"BrainHQ (by Posit Science Corp.) computerized attention training using the following modules: Divided attention, Target tracker, Double Decision, Mixed Signals, and Freeze Frame."
45500801|NCT02589509|Behavioral|Goal Management Training (GMT)|A compensatory metacognitive strategy-based intervention program that teaches strategies for improving attentional control and problem solving.
45500802|NCT02903238|Drug|Duloxetine|Duloxetine Delayed-Release Capsules: 30mg/day for 1 week ; 60mg/day for the remaining time
45500803|NCT02903238|Drug|Placebo Oral Tablet|Lactose capsule
45500804|NCT01331369|Behavioral|Intensification of Care|Usual provided care plus social-psychological intervention: 6 consultation with doctors and 9 with community health workers, both oriented by protocol.
45500805|NCT01331369|Other|Usual Care|Usual care provided (medical and/or nurse consultation and medicines)
45500806|NCT03621852|Device|Endoultrasound guided FNB|EUS FNB with Aquire TM device
45500807|NCT03651024|Device|ED surgery|The surgical implant for ED treatment
45500808|NCT01329809|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|intratumoral or intravenous dosage: 10e9 pfu Intravenous: administered over 60 minutes Intratumoral: direct injection into a single liver lesion
45500809|NCT02847260|Drug|Remodulin|Treatment will be initiated whilst hospitalized at approximately 2.0 ng/kg/min with dose increments of 1- 2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate is increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min is achieved dose increments can be increased at a rate of up to 4 ng/kg/min with dose increments separated by at least 24 hours depending on tolerability. The aim is to achieve a dose rate of at least 10, 20 and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively and a dose rate by the end of week 16 that achieves pre-defined treatment goals subject to clinical response and tolerability.
45500810|NCT02872571|Drug|Intramuscular Islet Autograft|Intramuscular Islet Autograft After Extensive Pancreatectomy
46056575|NCT02728869|Biological|Heat Stable Rotavirus (HSRV) Vaccine|It is a lyophilized live attenuated pentavalent (G1-G4 and P1[8]) heat-stable rotavirus vaccine (HSRV) comprising of all the five rotavirus strains as in licensed RotaTeq® vaccine for protection against rotavirus infection
46056576|NCT02728869|Biological|Placebo for Heatstable Rotavirus vaccine|It is a lyophilized formulation comprising of all the inactive ingredients as in heat stable rotavirus vaccine without any rotavirus
46056577|NCT02728869|Biological|RotaTeq®|It is a pentavalent human-bovine (WC3) reassortant live-attenuated, oral vaccine developed by Merck Research Co., West Point, Pennsylvania, USA. This vaccine contains five live reassortant rotaviruses. Four reassortant rotaviruses express the VP7 protein (G1, G2, G3, or G4) from the human rotavirus parent strain and the attachment protein (P7[5]) from bovine rotavirus parent strain WC3. The fifth reassortant virus expresses the attachment protein (P1A[8]) from the human rotavirus parent strain and the outer capsid protein G6 from the bovine rotavirus parent strain.
46056578|NCT02594761|Biological|Hercules|Powder Concentrate for Intravenous Infusion, 150 mg/vial
46056579|NCT02594761|Biological|Herceptin EU|Powder for Concentrate for Solution for Infusion, 150 mg/vial
45426172|NCT05794997|Drug|Atenolol, Bisoprolol or Sotalol|Atenolol, Bisoprolol or Sotalol claim is used as the reference group.
45426173|NCT05794919|Drug|Calcium Hydroxybenzene Sulphonate Dispersible Tablets 0.25g|A generic product manufactured by Hainan Linheng Pharmaceutical Co., Ltd.
45426174|NCT05794919|Drug|Calcium Hydroxybenzene Sulfonate Tablets（Doxium®) 250mg|Calcium Hydroxybenzene Sulfonate Tablets（Doxium®）produced by OM pharma S.A.
45426175|NCT05794893|Behavioral|Good Behavior Game|Universal school-based intervention reinforcing prosocial behaviors and discouraging disruptive behaviors in young students.
45426176|NCT05794867|Diagnostic Test|clinical weaning criteria|Xray chest and calculation of thr rapid shallow breathing rate
45426177|NCT05794854|Other|Abdominal aerobic endurance exercise|Subjects combined treadmill running at 70% HRmax (27 minutes) with 4x4minutes (30-40% maximal strength, 1RM) of torso rotation and abdominal crunches (57 minutes), 4 days per wk for 10 weeks
46056580|NCT02594761|Biological|Herceptin US|Intravenous Infusion, 440 mg/vial
45387070|NCT04327583|Behavioral|IPPACTTO|"The coordinated experimental pharmaceutical path consists of 7 pharmaceutical interviews or consultations. One initial pharmaceutical consultation with the hospital pharmacist. Five follow-up pharmaceutical interviews with the dispensary pharmacist. One follow-up pharmaceutical consultation with hospital pharmacist.~Each pharmaceutical interview or consultation will result in the drafting of a pharmaceutical report to be sent to the other participating health professionals. At each pharmaceutical consultation or interview, the pharmacists requested perform a clinical pharmaceutical analysis of drug prescriptions; Evaluate the patient's understanding; Detect adherence problems, Identify drug related problems; Alert the oncologist and / or the attending physician."
45387071|NCT04295837|Other|ABLE|Home-based occupational therapy compensatory programme addressing activities of daily living
45387072|NCT04295837|Other|Usual Care|Standard occupational therapy
45387073|NCT00957203|Drug|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily
45387074|NCT00952913|Drug|Bosutinib|4 x 100-mg oral tablets, single dose
45500811|NCT03650946|Diagnostic Test|Ga-68 PSMA PET|Ga-68 PSMA PET
45500812|NCT01331447|Drug|exemestane|25 mg tablet
45500813|NCT03574844|Dietary Supplement|Saccharomyces cerevisiae, dose 500|Experimental arm
45500814|NCT03574844|Dietary Supplement|Saccharomyces cerevisiae, dose 1000|Experimental arm
45500815|NCT03574844|Dietary Supplement|Placebo|Placebo comparator arm
45500816|NCT03649620|Dietary Supplement|unripe Bokbunja Extract|tablet(1 tablet/d, 600 mg/d) for 12 weeks
45387075|NCT00952913|Drug|Bosutinib|4 x 100-mg oral tablets, single dose
46056581|NCT02728947|Drug|ROTIGOTINE|1 week at each dose
45387076|NCT00952913|Drug|Lansoprazole|2 x 30-mg oral tablets, single daily doses for 2 days
45387077|NCT00952991|Drug|LAF237 = vildagliptin|
45500817|NCT03649620|Dietary Supplement|Placebo|Placebo for 12 weeks
45387078|NCT00957437|Drug|AZD1305|Single Oral Dose, ER formulation 1
46056582|NCT02594605|Device|Platelet Rich Fibrin|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
46056583|NCT02594605|Device|Conventional Flap Surgery|Only Conventional Flap Surgery treatment the bone loss limitedly.
46056584|NCT02594839|Drug|Bone marrow mesenchymal stem cells|Bone marrow will be harvested in healthy donors followed by separation and cultivation of MSCs. Before infusion cells will be suspended in 400 mL saline
46056585|NCT02594839|Drug|Placebo|intravenous infusion of 400 mL saline
45387079|NCT00957437|Drug|AZD1305|ER formulation 1, bid for 5 days
45387080|NCT00957437|Drug|AZD1305|Single Oral Dose, ER formulation 2
45387081|NCT00957749|Drug|cPMP|Intravenous solution administered daily. Dose titrated from 80 μg/kg on Days 1-12 to 120 μg/kg on Days 13-34 to 160 μg/kg for days 35-90.
45387082|NCT00953303|Drug|glucocorticoid|One dose of Dexamethasone (20mg/day) followed by prednisone 1mg/kg/day with a maximum dose of 60mg/day.
45387083|NCT00953303|Drug|standard care|The patients will be given standard care such as diuretics, inotropic and/or vasodilator in acute decompensated congestive heart failure management.
45387084|NCT05300555|Drug|Rivaroxaban 20 MG Oral Tablet|After randomization, the patient will start medication (rivaroxaban 20mg per day or 15mg per day if eGFR between 30 and 50ml/min/1,73m²) within 24 hours. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
45387085|NCT05300555|Drug|Warfarin|After randomization, the patient will start medication within 24 hours. Bridge with heparin or enoxaparin is recommended. The INR target is between 2,0 and 3,0. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
45387086|NCT04010669|Drug|Somatostatin|2 amp of somatostatin at 1000ml normal saline solution in continuous 24-hour infusion for 5 days
45387087|NCT04010669|Drug|Placebo|24 hours infusion of 1000ml Normal Saline solution 0.9%
45426178|NCT05794854|Other|Control training intervention|Subjects performed treadmill running (45 minutes) at 70% HRmax 4 days per week for 10 weeks
45500818|NCT02968563|Drug|Tirabrutinib|Tablets administered orally
45500819|NCT02968563|Drug|Idelalisib|Tablets administered orally
45500820|NCT02968563|Drug|Obinutuzumab|Administered intravenously
45500821|NCT01329887|Drug|ketanserin|ketanserin administration is started and increase, guided by the effect on sublingual MFI, dosage is 0,03mg/kg/hr
45500822|NCT03579212|Device|Y-STRUT® (Hyprevention, Pessac, France)|The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
45500823|NCT01334099|Biological|CP-675,206|Intravenous infusion for one cycle (further cycles permitted as per medical assessment). Patient assigned dose of 3mg/kg, 6mg/kg, 10mg/kg, or 15mg/kg.
45500824|NCT01334099|Radiation|External local radiation therapy|One cycle of 2000cGy administered locally to one site over 5 days.
45500825|NCT03650868|Procedure|Thoracal paravertebral block|Thoracal paravertebral block will be performed before the surgery to the TPVB group.
46056586|NCT02729103|Drug|Xofigo (Radium 223 dichloride,BAY88-8223)|Retrospective claims analysis. Descriptive analyses of treatment patterns.
45387088|NCT04010591|Device|impedance measurement during urodynamic study|Impedance information is measured through the belt in the abdomen of the subject. The urodynamic test is performed from the state in which the urine of the bladder is completely emptied to the state of the bladder until the state becomes full, so the impedance measurement is measured from the state where the urine of the bladder is completely emptied to the state of the bladder until the state becomes full.
45387089|NCT04263311|Behavioral|CHW|Participants will undergo 5 group-based health education sessions on hypertension and diabetes management and provide culturally and linguistically tailored health information and resources There will be 2 one-on-one in-person meetings and up to 7 follow-up calls/meetings to engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to diabetes prevention as identified jointly by patient and CHW. Participants will develop with the CHW and receive a copy of their long-term and short-term Participant Action Plan. Referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.
45387090|NCT00957983|Drug|BGC20-1531|oral administration followed by Prostaglandin E2 infusion
45387091|NCT05299463|Diagnostic Test|Exercise Testing|"Tele-Six-minute walk test (T6MWT)~1 Minute Sit-to-stand test (STS)~2-minute symptom-limited Step test (ST)~3-metre Timed up and go test (TUG)."
45387092|NCT04243577|Device|Tele-EaT Sensors|Several iterations of a wearable surface EMG sensors patch and a wearable intra-oral lingual press device that we will develop, will be tested against commercially available wired devices. The wearable sensor patch will be an ultrathin patch with a honeycomb-inspired design that includes sEMG and strain sensors in order to capture muscle activity and thyroid movement signals from the submental area during swallows and swallow maneuvers/exercises. The wearable intra-oral device will integrate a wireless intraoral sensor system that will allow simultaneous recording of lingual pressure and movement during swallows and lingual tasks in a wireless fashion. Participants will perform standardized swallow tasks with both devices.
45387093|NCT04243577|Device|Conventional Sensors|Conventional sensors will include snap-on wired electrodes and the use of the Iowa Oral Performance Instrument as the control conditions. The same set of standardized swallow tasks will be completed with the conventional and commercially available devices as well.
45387094|NCT04214093|Drug|AZD0466|"In Arm A, AZD0466 will initially be administered IV over one hour, once weekly to the first cohort of patients. Subsequent cohorts of patients within Arm A are planned to receive sequentially higher doses.~In Arm B, intrapatient dose ramp-ups will involve beginning at a specified starting dose and weekly increasing the dose to a maximum target dose for the cohort."
45387095|NCT00452790|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
45387096|NCT00452790|Biological|7 valent pneumococcal conjugate vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
45387097|NCT00953381|Drug|5 mg ilaprazole|One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
46056587|NCT02594527|Other|Volunteer-led physical activity session|Participants will be encouraged by volunteers to walk or perform chair-based exercises during their stay in hospital
45387098|NCT00953381|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
45387099|NCT00953381|Drug|20 mg ilaprazole|Four 5-mg ilaprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
45387100|NCT00953381|Drug|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with four placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
45387101|NCT05300477|Drug|Acetazolamide|Carbonic Anhydrase Inhibitor
45387102|NCT05300477|Drug|Erythropoietin|Hormone for red blood cell
45387103|NCT00953459|Drug|sunitinib malate|
45387104|NCT00953459|Other|laboratory biomarker analysis|
45695726|NCT01674855|Drug|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 6 cycle
45695727|NCT03854799|Drug|Avelumab|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
45848416|NCT03685968|Device|Video laryngoscopes|Patients were randomized into one of the three groups through a computer generated randomization schedule. Patients in group A (N= 75) will be intubated using the GlideScope® AVL, patients in group B (N= 75) will be intubated using the King Vision Channeled VL; patients in group C (N=75) will be intubated using the King Vision Video Laryngoscope with Standard (non-channeled) Blade. Patients will only be tested with one device. All patients will be intubated using a conventional ETT.
45848417|NCT03687450|Behavioral|RISE yoga-based program|The RISE program developed by Kripalu Center for Yoga and Health includes yoga postures, mindfulness practices, meditation, breathing techniques, and education sessions about mindful approaches to daily living. The RISE program will be delivered as a 6-week yoga-based program on-site at Brigham and Women's Hospital in Boston, MA. The program will consist of six 60-90-minute weekly yoga-based RISE classes. Sessions will be lead by experienced instructors from Kripalu Center for Yoga & Health. Subjects in this arm will also be asked to participate in 5-10 minutes of daily home practice with direction from the RISE curriculum.
45848418|NCT03687684|Drug|TAK-831|TAK-831 Tablets.
45500826|NCT03579134|Device|partial overlay denture|removable appliance similar to a removable partial denture but with overlay occluslal rests covering the full occlusal surface of the remaining posterior teeth
45500827|NCT03579134|Other|fixed temporary crowns|fixed crowns made from temporary material placed to the newly altered vertical dimension
45500828|NCT01331525|Biological|Ipilimumab|This trial will investigate the addition of the anti-CTLA4 antibody ipilimumab to conventional carboplatin and etoposide chemotherapy in extensive stage small cell lung cancer.
45500829|NCT03650790|Diagnostic Test|Blood test|For serum analysis, approximately 2 cc antecubital vein venous blood serum will be taken from each patient to be studied for CTRP9 Level analysis. Adult blood will be centrifuged at 4000 rpm for 10 minutes to separate greenhouses. The obtained serum samples will be stored at -80 ° C until analysis.
45500830|NCT03792165|Other|Action observation therapy|The normal human movement will be recorded and than the patients will be watched them.
45500831|NCT03792165|Other|Exercise|Strengthening and stretching exercise programme focuses on hip and knee muscles
45500832|NCT03649542|Other|Fluidotherapy plus exercise|The Fluidotherapy® unit (ULTRA 115: Henley International, Sugar Land, Texas) is a high intensity heat modality consisting of a dry whirlpool of finely divided solid particles suspended in a heated air stream. A certified technician The cleaned the Fluidotherapy® unit per the user manual.
45500833|NCT01334177|Drug|TLR8 agonist VTX-2337|Given SC
45695728|NCT03854799|Drug|Capecitabine|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
45695729|NCT03854799|Radiation|EXTERNAL---BEAM IRRADIATION 50.4 GY|Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion.
45387105|NCT00953459|Radiation|fludeoxyglucose F 18|
45387106|NCT00953537|Drug|capecitabine|
45387107|NCT00953537|Other|laboratory biomarker analysis|
45387108|NCT00953537|Other|pharmacological study|
45387109|NCT00463788|Drug|cetuximab, cisplatin|"Subjects will receive an initial dose of cetuximab 400 milligram per square meter (mg/m^2) followed by weekly doses of 250 mg/m^2. All doses will be given by intravenous (IV) infusion.~Subjects will receive cisplatin (75 mg/m^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Administration of the Investigational Medicinal Product (IMP) will be stopped upon the first occurrence of disease progression, unacceptable toxicity or withdrawal of consent."
46056588|NCT02733705|Other|Control|normal saline IV
45500834|NCT01334177|Biological|cetuximab|Given IV
46056589|NCT02733705|Drug|Fentanyl|fentanyl 0.5 mcg/kg ideal BW
46056590|NCT02733705|Drug|propofol|propofol infusion
46056591|NCT00917917|Behavioral|Type of physical activity (resistance, endurance)|"To determine which type of physical activity is the best to reduce metabolic syndrome parameters especially abdominal circumference.~Group 1 will perform mostly resistance activities, group 2 mostly endurance activities, and Group 3 performing both activities at low level, serves as a control group for physical activities."
46056592|NCT00917917|Behavioral|Restrictive diet|All subjects will have the same restrictive diet (500- 700 kcal/d).
46056593|NCT02694939|Behavioral|STAND (Behavior Therapy + Motivational Interviewing)|Parent-teen collaborative skills based behavior therapy targeting Executive functioning and Delay Aversion in Teens
45387110|NCT00463788|Drug|cisplatin|"Subjects will receive cisplatin (75 mg/m^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Subjects have the option of receiving cetuximab plus cisplatin at progression within the first 6 cycles, or cetuximab alone at progression after the 6 cycles.~Administration of the IMP will be stopped upon the first occurrence of disease progression (except in cisplatin arm where switch to cetuximab plus cisplatin, or cetuximab alone is possible), unacceptable toxicity or withdrawal of consent."
45387111|NCT00548249|Device|Standard Bicarbonate Solution|Patients received 0 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
45500835|NCT01334177|Other|laboratory biomarker analysis|Correlative studies
45500836|NCT01334177|Other|pharmacogenomic studies|Correlative studies
45500837|NCT03578978|Other|No intervention|No intervention will be given to study subjects. Only blood will be obtained from study subjects.
45500838|NCT05285280|Diagnostic Test|Echocardiography|The echocardiography will be performed with a GE Vingmed Ultrasoundís Vivid9 (Horten, Norway). All subjects are examined with color TDI, 2-dimensional and M-mode echocardiography, conventional spectral Doppler, 2DSTE, and where possible 4D Echocardiography in the left lateral decubitus position.
45500839|NCT01329965|Drug|LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)|LPS or placebo (saline-salt water) will be injected (at approximately 7:30 am) in this catheter by a trained GCRC staff member involved with this study. Participants will not be told if they have received the drug or placebo. The LPS is a sterile solution of protein-free endotoxin which will be injected at a dose of 0.6 ng/kg body weight. Blood samples will be collected from a venous catheter for the first 12 hours and by venipuncture thereafter. Subjects will be continuously monitored by trained nursing staff for blood pressure (q 15 minutes) and body temperature (q 30 minutes), and the study will have physician oversight.
45695730|NCT00924352|Drug|Dasatinib|Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level - 1;100 mg QD,Dose Level - 2;70 mg QD.
45695731|NCT00924352|Drug|Ixabepilone|Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level - 1;12 mg/m2,Dose Level - 2;12 mg/m2.
45695732|NCT01674933|Drug|Duraphat® Fluoride Varnish|0.25 ml per application will be painted on tooth surfaces by a Childsmile trained Extended Duties Dental Nurse, currently registered with the UK General Dental Council
45695733|NCT01674933|Behavioral|treatment as usual|includes supervised toothbrushing, distribution of toothbrushes and toothpaste and oral health advice given at nursery school.
46056594|NCT02694939|Behavioral|Usual Care|Community Therapists free to deliver any therapy they feel is indicated.
46056595|NCT02597257|Drug|Lidocaine HCl|lidocaine continuous infusion
45500840|NCT03574766|Behavioral|Meditation|Daily meditation
45387112|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 5 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
45387113|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 10 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
45387114|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 12 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
45500841|NCT04098393|Drug|Busulfan 3.2 mg/kg/day|Busulfan 3.2 mg/kg/day, with dose adjustments made according to pharmacokinetic (PK) levels.
45500842|NCT04098393|Drug|Fludarabine|Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2.
45500843|NCT04098393|Drug|Melphalan|Melphalan (70mg/m2/day) administered on days -6 and -5.
45500844|NCT04098393|Drug|Antithymocyte globulin (ATG)|ATG will be given based on a dynamic nomogram based on the patient's absolute lymphocyte count at the start of conditioning and can result in 2 or 3 days of ATG administration.
45500845|NCT04098393|Drug|Busulfan 0.8 mg/kg|Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels.
45500846|NCT04098393|Procedure|Allogeneic hematopoietic cell transplantation (Allo-HCT)|Allogeneic hematopoietic cell transplantation following the conditioning regimen.
45500847|NCT03649386|Device|Heated and humidified breathing circuit on|Heated and humidified breathing circuit will be turned on.
45500848|NCT03649386|Device|Heated and humidified breathing circuit off|Heated and humidified breathing circuit will be turned off.
45500849|NCT03574688|Dietary Supplement|Water|Increased daily water intake with 1.5 Liters of water per day on top of habitual water intake.
45500850|NCT05763537|Behavioral|Standard Doula Care Plus PMAD Intervention|Doulas trained in the DONA training, and the PMAD-focused training will provide care to perinatal people.
45500851|NCT05763537|Behavioral|Standard Doula Care|Doulas trained in the DONA training will provide care to perinatal people.
45500852|NCT03649230|Drug|300mg netupitant/0.5mg palonosetron hydrochloride|Antiemetic (NK1 receptor antagonist/5-HT3 receptor antagonist)
45500853|NCT05761821|Device|Leadless pacemaker|All enrolled patients were implanted with leadless pacemaker.
45500854|NCT05762523|Biological|VAC∆6 vaccine - оnce at a dose of 10⁶ PFU|15 volunteers vaccinated once intradermally at a dose of 10⁶ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
45500855|NCT05762523|Biological|VAC∆6 vaccine - once at a dose of 10⁷ PFU|15 volunteers vaccinated once intradermally at a dose of 10⁷ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
45500856|NCT05762523|Biological|VAC∆6 vaccine - twice at a dose of 10⁶ PFU|15 volunteers vaccinated twice spaced 28 days apart, intradermally at a dose of 10⁶ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
45500857|NCT05762523|Biological|Live smallpox vaccine (Smallpox vaccine) + The OspaVir® inactivated smallpox vaccine|15 volunteers vaccinated by the two-step vaccination method: Step 1 - the first vaccination once subcutaneously with 1 dose (0.5 ml) of the inactivated smallpox vaccine OspaVir® in the area of the left shoulder 8-10 cm below the shoulder joint; Step 2 - the second vaccination once by the method of multiple puncture into the outer surface of the shoulder 8-10 cm below the shoulder joint with a live smallpox vaccine at a dose of 1x 106 PFU 7 days following the first vaccination with OspaVir®.
45500858|NCT02796261|Drug|Eflornithine|Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 week on, 1 week off schedule
45500859|NCT02796261|Drug|Lomustine|Lomustine 90 mg/m2 administered orally once every 6 weeks
45500860|NCT02796261|Drug|Lomustine|Lomustine 110 mg/m2 administered orally once every 6 weeks
45500861|NCT02904096|Device|Radiesse injectable implant and 2% lidocaine HCL|Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
45500862|NCT01569711|Procedure|Deep brain stimulation of nucleus accumbens|"Day0 : surgical placement of electrodes~M1 : stimulation of nucleus accumbens~M5 : stimulation of nucleus accumbens or associative territory of caudate nucleus (if no response observed with nucleus accumbens stimulation)"
45500863|NCT05202171|Other|Cervical Stabilization Exercise|Exercise group will be performed cervical stabilization exercise training applied with telerehabilitation and standard treatment ( preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine) for 8 weeks
45500864|NCT05202171|Other|Standard treatment|standard treatment will include preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine for 8 weeks
45387115|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 15 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
45500865|NCT03649074|Device|AKL-T01|"AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task."
45500866|NCT04079712|Drug|Cabozantinib S-malate|Given PO
45500867|NCT04079712|Biological|Ipilimumab|Given IV
45500868|NCT04079712|Biological|Nivolumab|Given IV
45695734|NCT03852693|Other|Histopathological review|Histopathological review
45695735|NCT04373044|Drug|Baricitinib|Given PO
45387116|NCT00463476|Biological|Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV)|Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right upper arm using 23 gauge needles.
45695736|NCT04373044|Drug|Hydroxychloroquine|Given PO
45387117|NCT01025466|Drug|Rivastigmine transdermal patch (Exelon patch), memantine|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
45500869|NCT05763381|Device|Photobiomodulation Therapy (PBMT)|Participants will receive PBMT with the PBM device over the course of three consecutive weeks (three treatments per week). PBM treatments will take approximately 5-10 minutes to administer at each session. Specific treatment parameters will be based on measurements of calf, ankle, and foot using pre-calculated treatment tables; participants will receive 10 J/cm2, 25W output power, and the length of the treatment will be dependent on treatment area (size). PBMT will be administered by a trained member of the study team using the LightForce® XPi therapy laser, provided by LiteCure, LLC/DJO Global (New Castle, DE). The LightForce® XPi therapy laser is an FDA cleared device for the treatment of pain. The trained team members will use the Smart Hand Piece technology, which achieves effective treatments and improves dosing accuracy by assessing the operator's speed and providing real-time visual (red - amber - green light) and sensory feedback.
45500870|NCT05763381|Device|Sham-Photobiomodualtion Therapy (Sham-PBMT)|Sham-PBM treatment time will be calculated in the same way as the PBM treatment group, with the time of treatment dependent on the size of the treatment area. The sham-PBMT will be administered by rolling the massage ball over the plantar surface of the foot and dorsal aspect of the calf in contact with the participants' skin. Because emission of photons at the selected treatment parameters may cause participants in the treatment group to feel warmth, the massage ball will be warmed in the sham-PBMT. The device will be turned on, so the red aiming beam will be visible, but the operator will not activate the switch to emit photons.
45500871|NCT04053348|Procedure|Home-based rehabilitation program using mobile app|Home-based rehabilitation program
45500872|NCT03648762|Behavioral|Aerobic Exercise Intervention|Aerobic Exercise Intervention - 12 weeks of a minimum of 3 days a week for 60 minutes of aerobic exercise
45500873|NCT03648762|Behavioral|Combined Aerobic and Strength Exercise Intervention|Combined Aerobic and Strength Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Combined Aerobic and Strength Exercise
45500874|NCT03648762|Behavioral|Inspiratory Muscle Training Exercise Intervention|Inspiratory Muscle Training Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Inspiratory Muscle Training Exercise
45500875|NCT02586675|Drug|Tamoxifen|Tamoxifen will be taken orally once daily on a continuous daily schedule (e.g., days 1-28 of each 28 day cycle).
45500876|NCT02586675|Drug|Ribociclib|"Ribociclib (LEE011) will be taken orally once daily on days 1-21 of each 28 day cycle. Days 22-28 will be a rest period from dosing with Ribociclib. In the continuous cohort, 400 mg ribociclib will be given daily (QD)."
45500877|NCT02586675|Drug|Goserelin|Goserelin will be given as an injectable subcutaneous implant on day 1 of every 28 day cycle. This will be given in pre-menopausal and peri-menopausal women.
45500878|NCT03648528|Drug|cholecalciferol|
45500879|NCT03648528|Drug|placebo|
45500880|NCT03648294|Other|adrenalectomy for primary addosteronism|All of the clinical and biological data were retrospectively compiled from the patient computerized record. The variables analyzed were: age, sex, body mass index (BMI), PAH discovery circumstances, pre- and postoperative systolic and diastolic blood pressure assessments, number of pre-hypertensive antihypertensive drug - and postoperatively, the laterality, the size and nature of the lesions, the operating time, the surgical technique used. The biological data evaluated were pre- and postoperative plasma and plasma creatinine, preoperative serum aldosterone concentrations, plasma renin activity, and preoperative aldosterone / renin ratio. Hypokalemia was defined as serum concentration below 3.5 mmol / L.
45500881|NCT05202015|Drug|MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)|MRI of the liver accoring to our institutional daily routine protocol
45387118|NCT01025466|Drug|Rivastigmine transdermal patch|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
45387119|NCT03910296|Behavioral|Acceptance & Commitment Therapy|ACT is a unique, third-wave therapy that uses metaphors and experiential exercises to encourage contact with previously avoided thoughts, feelings, and behaviors.
45426179|NCT05794841|Diagnostic Test|Tongue coating sample collection and multi-omics analysis|Tongue coating sample collection and multi-omics analysis for building a diagnostic model
45500882|NCT03648216|Behavioral|HAPA behavioural counseling|Behavioural counseling grounded in the Health Action Process Approach (HAPA; i.e., action planning and coping planning) to maximize sedentary behaviour and minimize steps taken.
45500883|NCT05201625|Diagnostic Test|real time PCR|real time PCR
45848419|NCT03687684|Drug|Placebo|TAK-831 Matching Placebo Tablets.
46056596|NCT02597257|Drug|Normal saline|Normal saline continuous infusion
45500884|NCT04053114|Other|DNA and RNA extraction from FFPE or frozen tissue sample|Next generation sequencing (NGS)
45695737|NCT04373044|Drug|Placebo Administration|Given Po
46056597|NCT02596477|Drug|Vepoloxamer|
46056598|NCT02596477|Other|5% dextrose in water|
46056599|NCT02690337|Drug|DS-1123|starting intravenous (IV) dose of 0.1 mg/kg.
45387120|NCT04857918|Behavioral|Virtual running group program|The intervention will include an eight-week virtual running group program hosted on online platforms such as Zoom and the fitness application Strava. Participants will be placed in running groups of 6 people, and each running group will have the collective goal to run/walk the distance across the province of B.C., (940 km) and will meet weekly over Zoom to socialize and discuss running topics and their progress towards the group goal. Participants will receive a t-shirt with the STRIDE logo and a phone armband for carrying their smart phone during runs and walks.
45387121|NCT04857918|Behavioral|Attention Control: Fitness Application Strava|The attention control condition will be instructed to record their exercise using the Strava application, and will be encouraged to participate in 150 minutes of moderate-to-vigorous exercise each week of the intervention.
45387122|NCT01025544|Biological|Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
45387123|NCT01025544|Biological|Hiberix (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
45387124|NCT03839940|Drug|Dexamethasone|Given as mouthwash
45387125|NCT03839940|Other|Placebo|Given as mouthwash
45387126|NCT03839940|Other|Questionnaire|Ancillary studies
45387127|NCT03839940|Other|Quality-of-Life Assessment|Ancillary studies
45387128|NCT03839940|Drug|Everolimus|Standard of care
45387129|NCT01025622|Biological|autologous highly purified CD133+ stem cells (SCs)|Intrahepatic reinfusion in cirrhotic patients
45387130|NCT03905928|Other|Nicotine Containing ECIG with tobacco flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a tobacco flavor."
45387131|NCT03905928|Other|Nicotine Containing ECIG with Strawberry Vanilla Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a strawberry vanilla flavor."
45387132|NCT03905928|Other|Placebo ECIG with Tobacco Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a tobacco flavor."
45387133|NCT03905928|Other|Placebo ECIG with Strawberry Vanilla Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a strawberry vanilla flavor."
45387134|NCT01027494|Drug|Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension|Four drops in the outer ear canal of infected ear(s) while awake 2 times per day for 7 days
46056600|NCT04089007|Device|SOmNI app|In addition to allowing users to track sleep behaviours across the four-week intervention period, the SOmNI app will also provide messaging via alerts and tips to outline the importance of sleep to health, suggest optimal sleep timing/duration, and suggest sleep promotion strategies. Daily review questions in the app will help the participants link changes in sleep behaviours to changes in health outcomes. As well, when goals related to sleep extension are met, the SOmNI rewards program awards points to the participant and these points can then be redeemed in $5 increments to a maximum of $40 for gift certificates.
45387135|NCT01025700|Drug|Cesemat|1 mg capsule per day for 21 days
45387136|NCT01027572|Device|Implantable neurostimulation system (Medtronic)|Thalamic stimulation will be performed using an implantable neurostimulation system
45695738|NCT03851991|Drug|Arbidol|oral
45387137|NCT03839628|Other|Reduced Physical Activity|Participants will reduce their level of physical activity for 2-weeks as defined as approximately 75% reduction from their baseline level of physical activity.
45387138|NCT00462462|Drug|Ethanol 96% Gel|
45387139|NCT00462462|Drug|Ethanol 98% Solution|
45387140|NCT00462384|Drug|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.
45387141|NCT00452400|Drug|BI 1744CL|
45500885|NCT03629691|Other|lung cavitation|apatinib treated patients developed lung cavitation
45500886|NCT03648138|Behavioral|Sugary drink warning labels|This information appears in the description of the study arms.
45500887|NCT03161405|Drug|TAK-906 Maleate|TAK-906 capsule
45500888|NCT03161405|Drug|Itraconazole|Itraconazole solution
45387142|NCT00462306|Procedure|Survey: Berlin questionnaire|Completion of questionnaire
45500889|NCT03648060|Device|Digital kinematic biofeedback system|The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed by the therapist and edited according to patient evolution.
45500890|NCT01813929|Drug|Metformin|Six week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention. If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily.
45500891|NCT01813929|Drug|Placebo|Six-week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.
45500892|NCT05284968|Drug|Cell injection|All subjects will be treated with cell injection
45500893|NCT03650166|Other|MyBP|This program includes online video high BP education and longitudinal, personalized assistance of home BP self-monitoring.
45500894|NCT03650166|Other|Personal BP monitor|Battery-powered BP monitor for personal use
45848420|NCT03688542|Other|Quality Circle Deprescribing Module|The Quality Circle Deprescribing Module consist of a discussion bringing together nurses, physicians and responsible pharmacist to create a local deprescribing consensus for frequently used drug classes, as well as implementation strategies for the consensus..
46056601|NCT04089007|Other|Control group|The research assistant will advise the participant to increase the amount of nighttime sleep achieved but will not give any sleep hygiene advice or instructions for moving their bedtime earlier.
45500895|NCT04059822|Other|Slow and deep breathing|Please see arm description
45500896|NCT04053738|Device|Anti-snoring bed|The mattress shape is adjusted using a custom made intelligent anti-snoring bed, which is able to detect snoring sound and change the position of the user whenever snoring occurs.
45500897|NCT05285046|Other|No intervention|No intervention
45500898|NCT01502085|Drug|Vorinostat, Lenalinomide and Dexamethasone|"Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21~* Lenalidomide dose for patients with renal impairment (CrCL<50ml/min) has be dose adjusted according to package insert~Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above"
45695739|NCT03851991|Drug|Placebos|controle
46056602|NCT02596633|Behavioral|Telephone-support Acceptance and Commitment Therapy (ACT)|Telephone-support Acceptance and Commitment Therapy (ACT): ACT self-help book and 8 telephone support calls
46056603|NCT04178811|Device|Holmium Laser Enucleation of Prostate|Use of Holmium Laser Enucleation of Prostate in management of Benign Prostatic Hyperplasia patients
46056604|NCT02596555|Drug|Dabigatran|Low molecular weight heparin for 72 hours followed by 6 months of dabigatran
46056605|NCT03328065|Other|Interviews|Semi-directed interviews, recorded and transcribed for analysis
46056606|NCT03328065|Other|Questionnaires|economic and psycho-social questionnaires
46056607|NCT00807040|Procedure|Mitral Valve Repair with Annuloplasty|The annuloplasty ring will be chosen by the surgeon. The ring is sized to the anterior leaflet and intertrigonal distance. A semi-rigid or rigid annuloplasty ring will be used, and if tethering is present, a subvalvar procedure will be performed.
45387143|NCT00461682|Drug|SB-705498|
45387144|NCT03576690|Biological|REGN3470-3471-3479|
45387145|NCT01027728|Drug|CCX 354-C|"Cohort 1: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days;~Cohort 2: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) twice daily for 14 days; and~Cohort 3: Eight subjects will be randomized to receive 200 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days."
45387146|NCT03776370|Procedure|Preserve the left colonic artery|Preservation of left colonic artery in rectal cancer surgery.
45387147|NCT03776370|Procedure|The left colonic artery is not preserved|The left colonic artery was dissected in rectal cancer surgery.
45387148|NCT01566474|Drug|Omeprazole|Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
45387149|NCT01566474|Drug|Melatonin|Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
45387150|NCT01025778|Drug|Clofarabine for remission induction|
45387151|NCT01025778|Drug|Etoposide for remission induction|
45387152|NCT01025778|Drug|Cyclophosphamide for remission induction|
45387153|NCT01025778|Drug|Clofarabine in conditioning before transplantation|
45387154|NCT01025778|Drug|Thiotepa in conditioning before transplantation|
45387155|NCT01025778|Drug|Melfalan in conditioning before transplantation|
45387156|NCT01025778|Procedure|Haploidentical transplantation of T-cell depleted graft|
45387157|NCT01025778|Procedure|Donor lymphocyte infusion|
45387158|NCT00443430|Drug|methotrexate|Methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus placebo etanercept and and placebo prednisolone
45387159|NCT00443430|Drug|methotrexate - etanercept - prednisolone arm|methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus etanercept 0.8 mg/kg given by sub cutaneous injection once per week, plus prednisolone, by mouth daily with decreasing dose tapered over 16 weeks.
45387160|NCT03898986|Biological|Live attenuated influenza vaccine (LAIV4)|LAIV4 vaccine dosage is 0.2 mL. The vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose-divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
45387161|NCT03898986|Biological|Inactivated Influenza Vaccine (IIV4)|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection.
45387162|NCT01022658|Drug|Insulin|For diabetes treatment: metformin continued with insulin (according to arms)
45500899|NCT05761353|Device|Endermologie|"Group A will receive -18 sessions by Endermologie system used to decrease postmastectomy lymphedema for group (A), three sessions per week for six weeks.~Each session was 30 minutes at the posterior thorax, upper arm, forearm and the hand.~-In addition to physical therapy program (active range of motion and elevation); hygiene and skin care"
45500900|NCT05761353|Device|Negative pressure therapy|"Group B will receive negative pressure therapy with~Pressure: 20-250 mmHg.~Total treatment period: 6weeks~A number of sessions: 3sessions/ week. Time of application : 30 min~In addition to physical therapy program (active range of motion and elevation); hygiene and skin care"
45500901|NCT04052802|Other|Fissure sealing|The materials will be applied to the demineralized fissures as stated in manufacturer's instructions
45500902|NCT03648684|Behavioral|Caffeine-Based Expectancy Challenge|Intervention to alter expectancies and encourage safe drug substitution (harm reduction plus expectancy modification)
45500903|NCT03648684|Behavioral|Placebo-Based Expectancy Challenge|Intervention to alter expectancies (expectancy modification only)
45500904|NCT03647982|Drug|Meditoxin|injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses
45500905|NCT03647982|Drug|Botox|injection of Botox into the intradermal of each contralateral upper back in equal doses
45500906|NCT03647904|Behavioral|SEMS Project|TThe intervention is a culmination of five empirically supported interventions: (1) The MS Wellness Program aimed at developing lifestyle strategies to enhance quality of living and cope with various aspects of MS; (2) The FACETS intervention, which aims to reduce fatigue and improve self-efficacy; (3) The Modified Story Memory technique, which improves new learning and memory; (4) The Speed of Processing training, which improves performance on measures of processing speed in persons with MS. Finally, the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders, a cognitive behavioral intervention, which improves psychological functioning and functional outcomes.
45500907|NCT03650010|Procedure|Total ankle replacement|total ankle prosthesis through a lateral or an anterior approach
45500908|NCT02901054|Drug|Ondansetron|A single 15-min intravenous infusion of ondansetron
45387163|NCT01025856|Other|Rich in MUFA diet -PA|The patients will follow a rich in MUFA diet without a physical activity program.
45500909|NCT03068715|Device|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator."
45500910|NCT03068715|Device|Sham TBS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
45500911|NCT03068715|Device|Open label TBS-DLPFC|"All patients will have the option to receive active, open label aTBS treatment after the 1-month mark, following the blinded phase.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device."
45500912|NCT04053036|Drug|MDMA|Participants will be given 1.5mg/kg of MDMA
45500913|NCT04053036|Drug|Placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
45500914|NCT03647670|Drug|PF-04965842|orally bioavailable small molecule that selectively inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site.
45500915|NCT03647670|Drug|Midazolam|substrate which undergoes extensive metabolism by CYP3A4 and CYP3A5 and acts as a sensitive probe for evaluating drug interaction with respect to these isoenzymes
45500916|NCT05202951|Other|questionnaires|Electronic case report form integrating questionnaires on chronic pain related to haemophilia, associated-comorbidities, sociodemographic characteristics and analgesic treatments used.
45500917|NCT02966340|Drug|Prazosin|2mg Prazosin
45500918|NCT02966340|Drug|Placebo|Placebo
45500919|NCT05761743|Diagnostic Test|Urine and Blood Test|Urine N-telopeptide and serum osteocalcin
45695740|NCT01675089|Drug|Zoledronic acid|The treatment group will receive 15-minute intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
45387164|NCT01025856|Other|high fiber/low glycemic index diet + pa|patients will follow for two months a high fibre/ low glycemic index diet with a physical activity program.
45387165|NCT01025856|Other|Rich in MUFA diet+PA|Patients will follow for two months a rich in MUFA diet with a physical activity program.
45500920|NCT05200689|Device|Kinesiotaping (KT)|"Kinesio taping will only be applied for a period of 5 days. Initial Kinesio taping will first occur one day after surgery.~It will be placed directly on the chest wall on a trigger point. Physiotherapists will be instructed to maintain a standard Tape length (To body size ratio) and tension among all patients of all KT groups. The edges of the tape must be rounded, to prevent premature peeling. The adhesive side of the tape must not be touched after removing its backing, to prevent any decrease in tape adherence. It will be applied using both I and Star applications. Star and I KT application is done directly above the main pain trigger point. This point is found via chest palpitations. The Tape will be replaced every 48 hours by the physiotherapist until the end of therapy. The tape must be placed after stretching the skin."
45500921|NCT03647748|Device|Sham Comparator|A modified device utilizing a pigtail connector to bypass active treatment.
45500922|NCT05207007|Procedure|Phacomulsification lens removal cataract surgery with Intraocular lens(IOL) implantation|Phacomulsification lens removal cataract surgery with IOL implantation in both two groups
45500923|NCT05284734|Procedure|Regional anesthesia intervention|Ultrasound-guided caudal and erector spinae blocks were administered
45387166|NCT01025856|Other|High fibre/low glycemic index diet-PA|Patients will follow for two months a high fibre/low glycemic index diet without a physical activity program.
45387167|NCT01022736|Drug|Gabapentin|Subjects will be administered gabapentin (600 mg, orally) 1 hour prior to cardiac bypass surgery, 1 hour following extubation, then every 8 hours for a total of 4 doses.
45387168|NCT01022814|Device|A disposable pad containing sensitive chemical indicators|After a urine/amniotic fluid leaking, liquid meets the diagnostic device and chemical reactions will occur in the test zones and cause a color change.
45387169|NCT01025934|Drug|Bevacizumab|
45500924|NCT05206851|Other|Manual Lymphatic Drainage and Hot Pack|"Application of hot pack for 20 minutes at low back in sitting, and then the participant will perform deep diaphragmatic breathing for 10 minutes, following these steps:~Sitting in comfortable position~One hand is placed over chest and other on abdomen.~Inhale deep through the nose.~Exhale through mouth, completely, counting back from 4 to 1. Application rotary or stationary circle over low back in side lying position, in pregnant females. A session of 20-30 minutes of Manual Lymphatic Drainage will be given biweekly.~And at the end of Manual Lymphatic Drainage application, deep breathing for 10 minutes will be performed again."
45500925|NCT05206851|Other|Hot Pack|Hot pack will be applied at low back, for 20 minutes as home based protocol.
45500926|NCT04023708|Drug|CYD-TDV Dengue Vaccine|Pharmaceutical form:Solution Route of administration: Intramuscular
45500927|NCT03067311|Behavioral|I-CAT|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life).
45500928|NCT03067311|Behavioral|Treatment as Usual|Treatment as usual defined by participant clinician at OASIS clinic.
45500929|NCT05185713|Other|This project is a clinical observational study. No additional medication or surgical interventions are performed on the subjects.|This project is a clinical observational study. No additional medication or surgical interventions are performed on the subjects.
45500930|NCT05762289|Other|Thrust Manipulation (in weight bearing and non weight bearing)|Pain and Range of cervical motion was assessed before and after manipulation in both groups.
45500931|NCT05174949|Device|Transcranial direct current stimulation (high-definition)|"Three conditions:~anodal stimulation over the ipsilesional primary motor cortex~cathodal one over the contralesional premotor cortex~Sham"
45500932|NCT05200611|Diagnostic Test|Fecal Immunochemical Test|Participants with positive fecal immunochemical test results were further examined by colonoscopy.
45500933|NCT04040673|Procedure|thyroid lobectomy|routine surgical removal of thyroid for biopsy
45500934|NCT04040673|Device|Raman spectroscopy probe measurement|The measurement of Raman spectra from the excised tissue
45500935|NCT05206461|Other|Trunk Control Measurement Scale|Trunk Control Measurement Scale, easy and simple to use, was used to evaluate trunk control
45387170|NCT01025934|Other|sham|
45387171|NCT01027962|Other|ICBT Program|Intensive Computerized Brain Training.
45387172|NCT01026090|Drug|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
45387173|NCT01026090|Drug|Placebo (for dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
46056608|NCT00807040|Procedure|Mitral Valve Replacement|Mitral valve replacement will include complete preservation of the subvalvar apparatus. The technique of preservation, choice of prosthetic valve, and technique of suture placement will be dependent on the surgeon's preference. The prosthetic valve will be tested for paravalvular leaks by using the left ventricular saline infusion test.
46056609|NCT02728713|Procedure|Cranial Manipulation|Performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
45387174|NCT01028040|Drug|AZD3043|Intravenous, single dose
45387175|NCT01028040|Drug|AZD3043|Infusion, single dose
46056610|NCT02728713|Procedure|Sham/Placebo|A laying on of hands with no actual treatment being performed.
46056611|NCT02733471|Drug|Lidocaine|
46056612|NCT02733471|Drug|Placebo|Placebo
45387176|NCT01028118|Other|Identifying experience with violence|Asking about life experience with violence and Cognitive Behavior Therapy.
45387177|NCT03891654|Diagnostic Test|Dynamic Contrast Enhanced Computed Tomography|Patients will receive DCE-CT prior to the start of standard of care, Stereotactic Body Radiation Therapy (SBRT), as well as 6 hours post administration of SBRT and 6 weeks post administration of SBRT.
45387178|NCT00460746|Drug|TMC125, Darunavir; Ritonavir|TMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
45387179|NCT01026246|Drug|Placebo|The placebo used will be normal saline (0.9 percent NaCl).
45426180|NCT05794828|Drug|Bupivacaine Injection|Bucivacaine will be administered intramuscularly according to package insert directions after first numbing the area with lidocaine subcutaneously
45387180|NCT01026246|Biological|EBA-175 RII-NG Malaria Vaccine|EBA-175 RII-NG malaria vaccine is supplied as a white, translucent, cloudy, nonparticulate liquid suspension in single-dose clear glass vials pre-mixed with Adju-Phos aluminum phosphate adjuvant. Each 2-mL vial of EBA-175 RII-NG vaccine contains: 0.7 mL (0.5 mL per dose) EBA-175 RII-NG, at the required dose concentration, 5 percent sucrose, 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant, sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride), and no preservative.
45387181|NCT01028274|Dietary Supplement|Placebo|Two capsules, twice daily with meals for 12 weeks.
45500936|NCT05206305|Device|GammaSense Stimulation device|Cognito Therapeutics GammaSense Stimulation device delivers sensory (auditory and visual) stimuli at a rate of 40 Hz to the wearer for one hour each day.
45500937|NCT05206149|Drug|Intranasal glugagon|Intranasal glucagon is administered at the dose of 3 mg. This corresponds to the administration of a single dose of Baqsimi®.
45500938|NCT05206149|Drug|Intranasal placebo|Intranasal placebo (represented by isotonic saline solution) is administered.
45500939|NCT05206071|Biological|CD19+22 CAR-T cells|Biological: CD19+22 CAR-T; Drug: Cyclophosphamide,Fludarabine;
45500940|NCT05170893|Dietary Supplement|Coenzyme Q10|Oral capsules
45500941|NCT05170893|Other|Placebo|Oral capsules
45500942|NCT03629457|Behavioral|Mindfulness and Mindful Self-Compassion|Mindfulness Based Stress Reduction (MBSR) and Mindful Self-Compassion
45387182|NCT01028274|Dietary Supplement|Investigational Product 1|Two capsules, twice daily with meals for 12 weeks.
45387183|NCT01028274|Dietary Supplement|Investigational Product 2|Two capsules, twice daily with meals for 12 weeks.
45500943|NCT05761041|Drug|Sodium Fluoride Varnish (5%)|Applied at baseline
45500944|NCT05761041|Behavioral|Motivational Interviewing|Two MI sessions: face-to-face at baseline and phone call at 3 months
45500945|NCT05761041|Drug|SDF|Applied bianually
45500946|NCT03629379|Drug|Ustekinumab|Patients will receive standard dosing of ustekinumab with a single intravenous infusion of about 6mg/kg ustekinumab at week 0, followed by ustekinumab 90mg subcutaneously every 8 weeks.
45500947|NCT03629379|Drug|Vedolizumab|Patients will receive standard dosing of vedolizumab 300mg at weeks 0, 2, 6, and 14. Patients with Crohn's disease could receive an extra infusion at week 10.
45500948|NCT03629301|Behavioral|ID-DPP group|This group will receive a 6 month long online behavioral change protocol adapted from the Diabetes Prevention Program. It includes 18 sessions, 12 delivered weekly (during the first 3 months) and 6 delivered biweekly (during the last 3 month period). A web page will be used to deliver the sessions, while the nutritional counseling will be delivered using video calls via Facebook chat. Participants will receive an hypocaloric (1200-1800 kcal, carbohydrates: 45-65%, fats: 20-35% and protein: 10-35%), personalized diet.
45387184|NCT00443118|Device|T-piece resuscitator Neopuff TM|Positive pressure ventilation will be performed with Neopuff® with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
45387185|NCT00443118|Device|Self Inflating Bag with PEEP|Positive pressure ventilation will be performed with Self Inflating Bag with PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
45387186|NCT00443118|Device|Self Inflating Bag without PEEP|Positive pressure ventilation will be performed with Self Inflating Bag without PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
45387187|NCT00460434|Device|TVT|Prophylactic TVT
45387188|NCT00460434|Other|Sham|Sham TVT
45387189|NCT01023048|Other|preimplantation diagnosis|genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia)
45500949|NCT03629301|Other|Wait-list Group|This group will only receive written information with recommendations on healthy eating. When the study has finished this group will receive a behavioral change protocol with nutritional counseling using a face-to-face format.
45500950|NCT05123079|Drug|Darigabat|Tablets
45500951|NCT05056779|Drug|Nemolizumab|Participants will receive loading dose of 60 milligram (2×30 mg) subcutaneous (SC) injection of nemolizumab at baseline. Thereafter 30 mg nemolizumab will be administered via single SC injection once in 4 week (Q4W) up to week 12.
45500952|NCT05056779|Drug|CD14152 placebo|Participants will receive loading dose of 60 mg (2×30 mg) SC injection of placebo at baseline. Thereafter 30 mg placebo will be administered via single SC injection Q4W up to week 12.
45500953|NCT05129163|Behavioral|Exercise|The group exercise training was held in each community center. The group exercise training contained aerobic exercise, complex physical fitness exercise, muscle training, and balance and coordination training.
45500954|NCT05129163|Behavioral|Nutrition activities|The intervention programs included: (a) training on-site staffs to use motivational interview techniques to communicate, to estimate participant's energy requirements, and to learn how to provide proper amounts of foods to individual elderlies, (b) nutrition grouped activities on ①know my plate, ②wholegrains, ③ drinking teas with dairy, and nuts, ④novel ways to eat fruit and vegetables, ⑤healthy breakfast ideas. In the first month, participants were intervened with the activities laid out above; in the second month, participants were intervened with qualitative discussion on elders' dietary changes; in the third month, participants were intervened with designed activities that helped break down barriers in order to establish a long-term change in dietary habits.
45500955|NCT05084157|Diagnostic Test|Echocardiography|Patients will undergo Doppler echocardiography
45500956|NCT05055999|Drug|First line EC/EP+Atezolizumab|Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 day
45500957|NCT05205837|Drug|Letrozole 2.5mg, hCG|Drug -Treatment Intramuscular injektion - Treatment
45500958|NCT05205837|Drug|Placebo|Drug - Placebo Intramuscular injektion - placebo
45387190|NCT01026558|Drug|Ceftobiprole|Ceftobiprole, 500 mg as single iv infusion over 2 hours
45387191|NCT03874416|Other|Specific rehabilitation|"Experimental rehabilitation of working memory:~3 sessions per week during 3 months, for a total 36 sessions."
45387192|NCT03874416|Other|Non-specific rehabilitation|Usual non-specific rehabilitation treatment for moderate to severe TBI in healthcare facilities: 2-3 sessions per week for 3 months.
45387193|NCT01023126|Behavioral|Group Psychotherapy|Group psychotherapy once a week, under a psychiatrist supervision
45387194|NCT00373425|Drug|Erlotinib|150 mg tablet
45387195|NCT00373425|Drug|Placebo|Placebo tablet
45387196|NCT00459342|Drug|dasatinib|Given orally
45387197|NCT03510156|Behavioral|Behavior analytic treatment|Function-based treatment
45387198|NCT00443040|Drug|Asimadoline|Asimadoline was provided in coated tablets of 1.0 mg strength. Subjects were given 3 tablets of study drug 90 minutes prior to their operation and then 3 tablets b.i.d. for up to 10 post-operative doses. Subjects randomized to receive 3.0 mg of asimadoline received three 1.0 mg asimadoline tablets at each scheduled dose, while those randomized to receive 1.0 mg of asimadoline received two placebo tablets and one 1.0 mg asimadoline tablet at each scheduled dose.
45387199|NCT00443040|Drug|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets. Subjects were given 3 tablets of placebo 90 minutes prior to their operation and then 3 placebo tablets b.i.d. for up to 10 post-operative doses.
45387200|NCT00442962|Drug|Efavirenz|600-mg tablet taken orally daily
45387201|NCT00442962|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine/300-mg tenofovir disoproxil fumarate tablet taken orally once daily
45387202|NCT03995160|Procedure|Use of closed suction drainage following total knee arthroplasty|Use of closed suction drainage following total knee arthroplasty
45387203|NCT03995160|Procedure|Abstain of using a closed suction drainage|Abstain of using a closed suction drainage following total knee arthroplasty
45387204|NCT01028508|Drug|lithium and Venlafaxine|Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
45387205|NCT01028508|Procedure|ECT|Procedure: ECT RUL ultra brief pulse ECT, 4 treatments in one month and then treatment on an as-needed basis for 5 months Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
45387206|NCT01026636|Drug|Ceftobiprole|
45500959|NCT05761665|Other|Evaluation|Kinesiophobia=Tampa scale Balance=Berg Balance Scale Falling=The Fall Activity Scale( Tinetti) Walking speed=Timed Get Up and Walk Test ,Two-Minute Walking Test Fragility=Frail Fragility Questionnaire, Clinical Fragility Scale
45500960|NCT01569789|Device|Vagus Nerve Stimulator|Voltage 2, placed on cymba concha
45500961|NCT01569789|Device|Vagus Nerve Stimulator|Voltage 2, place on the placebo area of the calf
45500962|NCT05205603|Drug|Infliximab|Infliximab, 5mg/kg at week 0,2,6 and schedule administration at every 8 weeks
45500963|NCT05205603|Drug|Vedolizumab|Vedolizumab, 300mg at week 0,2,6 and schedule administration at every 8 weeks
45387207|NCT00313300|Drug|Apixaban|Tablets, Oral, 2.5 mg, twice daily, 26 weeks
45387208|NCT00313300|Drug|Apixaban|Tablets, Oral, 10 mg, once daily, 26 weeks
45387209|NCT00313300|Drug|Placebo|Tablets, Oral, 0, twice daily, 26 weeks
45387210|NCT00313300|Drug|Apixaban|Tablets, Oral 10 mg, twice daily, 26 weeks
45387211|NCT01023282|Drug|ACR325|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
45387212|NCT01023282|Drug|Placebo|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
45387213|NCT00459186|Drug|RAD001|Daily for two weeks
45387214|NCT00459186|Drug|Docetaxel|Infusion once per cycle
45387215|NCT00459186|Drug|Prednisone|Prednisone 5 mg by mouth twice daily
45387216|NCT01026714|Drug|flurbiprofen|assessment of flurbiprofen plasmatic and capillary rates
45387217|NCT01026714|Drug|flurbiprofen, rifampicin|assessment of flurbiprofen plasmatic and capillary rates
45387218|NCT01026714|Drug|flurbiprofen + fluconazole|assessment of flurbiprofen plasmatic and capillary rates
45387219|NCT03996252|Drug|Calcipotriene 0.005% Foam|Application of calcipotriene foam in conjunction with generic efudex cream to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
45500964|NCT05205603|Drug|Mesalazine|Mesalazine, 4-6g/d, systemic and/or topical administration
45500965|NCT05043285|Biological|SCTV01C|intramuscular injection
45500966|NCT05043285|Other|Placebo|Intramuscular injection
45500967|NCT05042115|Other|Education in pain neurosciences and clinical hypnosis|Will be performed education in pain neurosciences and clinical hypnosis, in 4 sessions during 4 weeks
45500968|NCT05042115|Other|Education in pain neurosciences and clinical hypnosis plus osteopathic manipulative treatment|Will be performed education in pain neurosciences and clinical hypnosis, and only for this group will be delivered osteopathic manipulative treatment, in 4 sessions during 4 weeks
45500969|NCT05762211|Drug|Pooled allogeneic fecal microbiotherapy|Capsule for oral use
45500970|NCT05762211|Drug|Placebo|Capsule for oral use
45500971|NCT04380519|Drug|RPH-104 80 mg|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
45500972|NCT04380519|Drug|Olokizumab 64 mg|solution for subcutaneous administration 160 mg/mL, in the 2-mL glass vial (target volume 0,4 ml)
45500973|NCT04380519|Drug|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
45500974|NCT05760963|Other|Collection of datas|"Analysis lumbar echographies results by Trident ans Shamrock techniques.~Costiform processes on T12 to L5 were spotted and noted. For Trident technique, quality of image, depth of lumbar plexus and presence of vessels were noted.~Shamrock technique was performed, the projection of C line (line obtained with a probe put on the iliac crest) was noted with the invisible ink pen. Then the probe was oriented cephalically (for line >C) and caudally (line <C). For each lines, quality of image, depth of lumbar plexus and presence of vessels were also noted.~The projections of C, >C, <C on the costiform processes were noted."
45500975|NCT05004051|Other|ViTAA Analysis|Imaging Analysis Software
45500976|NCT04980573|Other|Aromatherapy|The aromatherapy intervention consists of inhaling a fragrant oil extracted from citrus peels, plant resins, and leaves.
45500977|NCT04980573|Other|Placebo|The placebo intervention consists of inhaling an oil extracted from inert plant matter.
45500978|NCT05761587|Other|Questionnaires|questionnaire including socio-demographic data, medical and family history, lifestyle, treatments, 5 questions from the Questionnaire Concis sur les Douleurs (QCD), the French version of the POMI scale, the diagnostic criteria of the DSM-V and two questions concerning anxiety associated with pain and therapeutic education.
45500979|NCT02847182|Biological|Cord Blood Infusion|
45500980|NCT02847182|Biological|Placebo|
45500981|NCT03574610|Device|Transcranial Rotating Permanent Magnet Stimulator (TRPMS)|"TRPMS is a wearable non-invasive transcranial rotating permanent magnet stimulator. It has been determined to be a Non Significant Risk device by the FDA.~The amount and frequency of therapy are prescribed by the physician, and the device is custom configured to the patient to deliver the required amount of treatment. The device does not turn on until it is time for the treatment. It consists of three main parts: Neoprene cap with microstimulator(s), stimulator console (device controller box) and the tablet with TRPMS app which activates the console. The neoprene cap prevents the microstimulator(s) from coming in direct contact with the scalp. Microstimulators deliver the magnetic stimulation to the brain based on a prescription program uploaded in the stimulator controller."
45500982|NCT03578900|Drug|Xeros|
45500983|NCT03578900|Drug|Citric Acid based Mouthwash|
45500984|NCT03576872|Other|Psychoeducational|Providing a binder of educational materials with nurse-led instruction in preparing pancreatic and colorectal cancer patients for chemotherapy
45387220|NCT03996252|Drug|Efudex 5% Topical Cream|Application of generic efudex cream in conjunction with calcipotriene foam to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
45500985|NCT02550002|Drug|Aflibercept|Intravitreal injection
45500986|NCT03574376|Drug|Bupivacaine Liposome Injection|Under ultrasound guidance, corresponding ribs will be identified. 3-5 ml of a 1.3% (13.3 mg/mL) of liposomal bupivacaine will be drawn into a syringe with a 1.5-in, 22-gauge needle. The needle will then be advanced 20° cephalad to the skin 3-4 cm lateral to midline at the level of each fractured rib, and 1-2 ribs levels above and below injury. The needle will be advanced 3 mm below the inferior margin of the rib, placing the tip in the space containing the neurovascular bundle. Following negative aspiration for blood or air, 3-5 mL of local anesthetic will be infused and the needle withdrawn. No more than 266 mg, or 20 ml, of the 1.3% (13.3 mg/mL) liposomal bupivacaine solution will be injected
45500987|NCT03574376|Drug|Bupivacaine|The anesthesia department will manage CEA. If possible, the patient will be in the sitting position. The skin will be prepped with chlorhexidine and sterilely draped. 3 mL of lidocaine 1% will be infiltrated the closest interspace to the rib fractures between T4 -T12. A Touhy needle will be inserted, the epidural space identified by loss of resistance technique. An epidural catheter will then be inserted to a depth of 12cm. 3 mL of test solution with lidocaine 1.5% with epinephrine, 1:200,000 will be injected with continuous EKG and SpO2 monitoring. Delivery of a 0.125% bupivacaine solution be continuously infused and titrated based on the patient's clinical status
45500988|NCT03576794|Drug|Leflunomide 20 mg|During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
46056613|NCT05756218|Other|nursing diagnoses - taboo game|Playing 7 weeks nursing diagnoses taboo cards
45387221|NCT00328510|Device|GTC frame|
45387222|NCT00328510|Device|Thermoplastic facemask|
45387223|NCT00328510|Radiation|Stereotactic radiation therapy|
45387224|NCT00313144|Drug|ARALAST Alpha1-Proteinase Inhibitor|Weekly ARALAST infusions for 2 years, dose and mode of administration as prescribed by the physician
45387225|NCT00459108|Drug|dasatinib|Given orally
45387226|NCT00458484|Radiation|stereotactic radiosurgery|"Series I: Radiation will be delivered in 4 fractions.~Series II: Radiation will be delivered in 3 fractions."
45500989|NCT03576794|Drug|Prednisolone|Patients in both groups will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27.
45500990|NCT02846558|Other|Frequent Patient Interaction|Weekly informational and supportive text messages will be sent to patients, encouraging adherence to the calorie restriction diet.
45387227|NCT00458484|Procedure|Renal Biopsy|At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance.
45500991|NCT02846558|Behavioral|Timing Restriction|Patients continue to follow their normal diet, but limit food intake to an 8-hour period during the day.
45387228|NCT00458484|Procedure|Serum Blood Markers|ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF.
45500992|NCT02846558|Device|LoseIt! Smartphone Application|Patients will be trained by study staff to download the LoseIt! application, and use it to log all food intake throughout the study duration. Data collected from the application will be the primary measure of adherence to dietary changes.
45500993|NCT04362813|Drug|Canakinumab|Canakinumab 450 mg for body weight 40-<60 kg, 600 mg for 60-80 kg or 750 mg for >80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
45500994|NCT04362813|Drug|Placebo|250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
45387229|NCT00328198|Biological|Alemtuzumab|"Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated). When escalation to 30 mg is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 18 weeks.~Part 1 of the study: The first 20 patients will be randomized to either Arm 1 (dose escalation) or Arm 2 (no escalation). Part 1 of the study has been completed; no additional patients will be enrolled in Part 1. An assigned review panel has reviewed the safety data from Part 1 and determined that all patients will be enrolled and treated under a no escalation schedule for Part 2 of the study."
45500995|NCT03578822|Drug|Recombinant human urokinase|Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
45500996|NCT03578822|Drug|Aspirin|Aspirin 300mg is taken orally at the beginning of thrombolysis.
45500997|NCT03578822|Drug|rhPro-UK simulation agent|Patients receive rhPro-UK simulation agent 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
45500998|NCT03578822|Drug|Aspirin simulation agent|Aspirin simulation agent 300mg is taken orally at the beginning of thrombolysis.
45500999|NCT03578744|Procedure|Conventional Flap surgery|After administering local anaesthetic a full thickness flap will be raised and reflected to expose the furcation defects. The furcation defects would then be debrided and the graft and membrane secured in position. Later the flap would be sutured back.
45501000|NCT03576638|Drug|Accordion Pill Carbidopa/Levodopa|AP 50/500 TID days 2-7
45501001|NCT03576638|Drug|Sinemet CR 25Mg-100Mg Extended-Release Tablet|25/100 1.5 pills five times/day
45501002|NCT04284657|Drug|Pravastatin|Pravastatin 40 mg QD
45695741|NCT01675245|Drug|No intervention|This is an observational study. Velcade will be administered as per the recommended regimen. (Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks)
45695742|NCT03850431|Behavioral|Social Norms + Behavioral Instructions|A letter with two types of nudges. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
45695743|NCT03850431|Behavioral|Caring + Consequences for Others + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patient. One highlights a potential negative consequence for others if the patient no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
45695744|NCT03850431|Behavioral|Caring + Consequences for Self + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patients. One highlights potential negative consequences for the patient if s/he no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
45501003|NCT04284657|Drug|sodium citrate|sodium citrate up to 30 ml TID
45848421|NCT03697122|Device|Heated Humidified Breathing Circuit and Forced Air Blanket|"Heated humidified breathing circuits (ANAPOD) will be set up and managed by respiratory therapist in standard fashion defined by the manufacturer. Temperate will be set at 41C.~Forced air warming blankets will be set at 42C for duration of rewarming."
45387230|NCT00328198|Biological|Alemtuzumab|"Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered SC at alternating injection sites 3 times per week for up to 18 weeks.~Part 2 of the study: All patients are currently being enrolled under the no escalation schedule for Part 2 of the study. All patients in Part 2 will be treated with 30mg of alemtuzumab (with no escalation period) administered SC (at alternating injection sites) 3 times per week (e.g., Monday, Wednesday, Friday) for up to 18 weeks. Alemtuzumab is to be administered in a supervised medical setting on an outpatient basis for the first three weeks, after which some study centers may allow a home administration option, with one weekly clinic visit. Under the home administration option, alemtuzumab may be administered by the patient or care giver if the patient meets conditions specified in the protocol guidelines for home administration."
45387231|NCT01322880|Behavioral|Discussion sessions|Those selected were invited to attend a 6 session course on household decision-making with their spouses. Topics included budgeting, household financial management, and negotiation skills
45387232|NCT01322880|Behavioral|Village Savings and Loans Associations|The approach developed by CARE International develops Village Savings and Loan Associations (VSLAs). A VSLA is a self-selected group of people who pool their money into a fund from which members can borrow. The money is paid back with interest, causing the fund to grow. The regular savings contributions to the Association are deposited with an end date in mind for distribution of all or part of the total funds (including interest earnings) to the individual members, usually on the basis of a formula that links payout to the amount saved. This lump sum distribution provides a large amount of money that members can then use as they want, without restriction.
45387233|NCT01028586|Drug|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 50 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
45387234|NCT01028586|Drug|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 100 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
45387235|NCT01028586|Drug|Placebo|matching placebo tablets
45387236|NCT03457350|Procedure|cervical negotiation|trial to bypass severe cervical stenosis
45387237|NCT01065688|Procedure|Roux-en Y reconstruction|surgical procedure
45387238|NCT01065688|Procedure|Billroth-I reconstruction|surgical procedure
45387239|NCT00450450|Procedure|allogeneic bone marrow transplantation|Patients undergo allogeneic BMT
45387240|NCT00450450|Other|laboratory biomarker analysis|Correlative studies
45387241|NCT00450450|Biological|filgrastim|Given IV
45387242|NCT03440892|Drug|methotrexate|folate antagonist
45387243|NCT03440892|Drug|sulfasalazine|Immunomodulatory
45387244|NCT03440892|Drug|abatacept|Targeting CTLA-4 (fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4)
45387245|NCT03440892|Drug|tocilizumab|IL-6 receptor antagonist
45387246|NCT03440892|Drug|tofacitinib/baricitinib|JAK inhibitor
45387247|NCT00442572|Drug|PEGASYS [peginterferon alfa-2a]|There were 4 treatment cycles of continuous intermittent treatment with Peginterferon alfa-2a. Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
45387248|NCT04898322|Drug|SY-005|2.5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
45387249|NCT04898322|Drug|SY-005|5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
45387250|NCT04898322|Drug|SY-005|10mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
45387251|NCT04898322|Drug|Placebo|Placebo
45387252|NCT01322958|Device|Pelvic Ultrasound|Pelvic ultrasound performed by the emergency physician
45387253|NCT01323036|Dietary Supplement|Krill oil|Krill oil:Total omega-3 fatty acids: 560-660 mg and Astaxanthin: 1800 µg
45387254|NCT01323036|Dietary Supplement|Fish Oil|Fish oil: Total omega-3 fatty acids: 560-660 mg
45387255|NCT01023360|Drug|Clopidogrel and proton pump inhibitors|"baseline detection --> clopidogrel 75 mg PO QD for 1 week --> clopidogrel 75 mg plus rabeprazole 20mg PO QD for 1 week --> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --> clopidogrel 75 mg plus pantoprazole 40mg PO QD for 1 week --> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --> clopidogrel 75 mg plus esomeprazole 40mg PO QD for 1 week -->~1 week washout --> aspirin 100mg PO QD for 1 week"
45387256|NCT01023438|Other|Strategy for assisted uptitration|Active specialist support (mail, phone) and educational material provided to assist primary care physicians in drug uptitration
45387257|NCT01023438|Other|Usual care|Usual communication strategy from cardiologist to primary care physician: uptitration advised but no active support nor educational material provided
45387258|NCT03685890|Drug|Nivolumab|One infusion of nivolumab (Opdivo®) 480mg (flat dose) in NaCl (Natriumklorid Baxter Viaflo, 9 mg/ml) during 60 minutes
45387259|NCT03685890|Procedure|Isolated limb perfusion (ILP)|Patients will be treated with ILP according to clinical routine at each separate site. The procedure is performed under general anaesthesia. The major artery and vein of the limb is catheterized, and a tourniquet is placed proximally on the limb. Continuous leakage monitoring is performed. The perfusate is heated to 40C and after ensuring steady state, melphalan (Alkeran®) at a dose of 13 mg/L (upper limb) or 10 mg/L (lower limb) is infused into the circulation during 20 minutes for a total perfusion time of 60 minutes. According to local routine tasonermin (Beromun®) will be added to the perfusate 30 minutes before the melphalan as a bolus dose of 1-4 mg.
45387260|NCT00442416|Drug|Epoetin alfa|As prescribed, SC
45387261|NCT00442416|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120-360 micrograms SC monthly, starting dose
45387262|NCT03674424|Drug|Avelumab|Chemotherapy with or without avelumab followed by surgery
45387263|NCT03674424|Procedure|cystectomy|Cystectomy 3 to 6 weeks after last administration of chemotherapy
45387264|NCT03674424|Combination Product|CG|Chemotherapy 4 cycles of 3 weeks
45848422|NCT03704376|Drug|30 ml of 0.2% ropivacaine|
45848423|NCT03704376|Drug|15 ml of 0.2% ropivacaine|
45848424|NCT03704376|Drug|100 mcg clonidine|
45387265|NCT03674424|Combination Product|DD-MVAC|Chemotherapy 4 cycles of 2 weeks
45501004|NCT03578666|Other|Massage|The intervention will be applied to both legs to a constant distal to proximal stroking rhythm. Firstly, participants will be lying in a prone position for 22 min: 1 min on the sole of the foot, 1 min on the Achilles tendon, 1 min on the soleus muscle, 3 min on the triceps muscle, 4 min on the hamstring muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings. Then they will assume a supine position for 18 min: 1 min on the sole of the foot, 3 min on the tibialis anterior and peroneus lateralis muscles and 4 min in the quadriceps, adductors and lata muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings.
45501005|NCT03578666|Other|Cold water immersion|The cold water immersion group immersed their lower limbs (ensuring that the iliac crests were fully immersed) in an ice bath filled with cooled water for 10 min. The water was maintained at a mean temperature of 10 degrees (±0.5°) by the addition of ice.
45501006|NCT01569945|Drug|Clomifen, Ethinyl Estradiol|starting on day 2 or 3 of the cycle: 1 tablet of Clomifen each day, for 5 days in a row. Dose 50mg or in subsequent cycles, 25 mg or 100 mg or 150 mg. After the 5 days of Clomifen, one tablet of Ethinyl Estradiol 50 mg per day, for 5 days in a row or until beta hCG is injected
45501007|NCT01569945|Drug|Menotropins|Starting on day 2 or 3 of the cycle, a daily subcutaneous injection of 37.5 IU or 75.0 IU
45695745|NCT03850431|Behavioral|Caring + Consequences for Others + Consequences for Self + Social Norms + Behavioral Instructions|A letter with all four types of nudges combined. One suggests that the institution cares about the patients. One highlights a potential negative consequence for others if the patient no-shows. One highlights potential negative consequences for the patient if s/he no-shows. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
45695746|NCT01697696|Drug|NVA237|NVA237 will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
45695747|NCT01697696|Drug|Long-acting beta 2-agonist (LABA)|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
45695748|NCT01697696|Drug|Placebo|Placebo to match QAB149
45695749|NCT04764903|Other|No intervention|There is no intervention in this study
45695750|NCT04404543|Drug|SYHA1807|Escalation Cohort Administration: Orally
45695751|NCT04404543|Drug|SYHA1807|Dose Expansion Cohort Administration: Orally
45695752|NCT03849807|Other|Experimental group|the intervention group will receive 4 weeks of chiropractic care along with usual care(Cognitive-Behavioral, psychosocial Therapy).
45695753|NCT03849807|Other|Control group|Participants in the group will receive usual health (Cognitive-Behavioral, psychosocial Therapy) care or wish to engage in during the course of the study as well as receiving a passive movement control intervention delivered by a chiropractor 3 times per week in the same hospital setting as the group receiving chiropractic care.
45695754|NCT01569152|Drug|MK-8457 100 mg|MK-8457 100 mg dosed orally BID
45695755|NCT01569152|Drug|Dose-Matched Placebo|Dose-matched placebo dosed orally BID
45695756|NCT01569152|Drug|Methotrexate|MTX dosed at the stable dose receive upon study entry
45695757|NCT03870009|Other|ARDS patients|"The patient will be installed on the scanner bed. Two series of tomographic sections will be acquired: one during an expiratory break, the other during an inspiratory pause.~cyclic hyperinflation measured by semi-automatic segmentation and by manual segmentation"
45695758|NCT01675557|Dietary Supplement|Vitamin D3|a single oral dose of vitamin D3
45387266|NCT03674424|Combination Product|PG|Chemotherapy 2 cycles of 4 weeks
45695759|NCT01675557|Dietary Supplement|Vitamin D2|a single oral dose of vitamin D2
45695760|NCT01675557|Dietary Supplement|Placebo|a single oral dose of placebo
45695761|NCT03028454|Dietary Supplement|Ginger Root|Capsules containing 250 mg of ginger root extract standardized to contain at least 5% gingerol compounds, as well as an additional 225 mg of regular ginger root.
45695762|NCT03028454|Dietary Supplement|Placebo|Capsules containing rice flour powder.
45387267|NCT01023594|Procedure|Pancreatic stent|Feeding tube insert at pancreatojejunostomy site as a stent. And then 1) tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall(external stent)or 2) tube is cut short (5cm length) and left in situ with fixating suture. In external stent group, tube will be removed about 1 months after operation.
45695763|NCT01675791|Biological|ALK tree AIT 0.5 DU|
45695764|NCT01675791|Biological|ALK tree AIT 1 DU|
45695765|NCT01675791|Biological|ALK tree AIT 2 DU|
45695766|NCT01675791|Biological|ALK tree AIT 4 DU|
45695767|NCT01675791|Biological|ALK tree AIT 7 DU|
45387268|NCT00441792|Drug|Etomidate|Etomidate at induction dose based on weight
45387269|NCT00441792|Drug|midazolam|Midazolam at induction dose based on weight
45695768|NCT01675791|Biological|ALK tree AIT 12 DU|
45695769|NCT01675791|Biological|ALK tree AIT Placebo|
45695770|NCT04410068|Device|WARMTAC|Randomization to one of the arms previous to surgery.
45695771|NCT04410068|Device|3M Bair Hugger|Randomization to one of the arms previous to surgery.
45695772|NCT03869307|Other|Exercise|The exercise programme includes exercises identified in literature to target scapular and rotator cuff muscles.
45695773|NCT03848325|Behavioral|Sleep deprivation|Eight hour opportunity for sleep followed by 24 hours of sleep deprivation.
45695774|NCT01675869|Behavioral|Executive Training of Attention and Metacognition (ETAM)|ETAM is an 8-week intervention involving weekly concurrent child (n=~6 per group) and parent intervention groups. The ETAM groups will be 1 hour in length (except for the first session which will be 2 hours).
45387270|NCT00312208|Drug|docetaxel, doxorubicin, cyclophosphamide|TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.
45387271|NCT00312208|Drug|Docetaxel,doxorubicin, cyclophosphamide|AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.
45426181|NCT05794763|Behavioral|Peer Led Group Intervention|A four-week dissonance-based program where individuals with body image concerns complete verbal, written, and behavioral activities. The program consists of four 60-minute sessions
46056614|NCT04189887|Behavioral|aerobic exercise (cycling)|People who perform aerobic exercise will ride on a stationary bike for 20 minutes after motor skill learning
46056615|NCT04189887|Behavioral|Implicit sequence learning|All participants will practice the serial reaction time task (SRTT) on the first day, and retention performance will be assessed immediately, on the 2nd day, and on the 7th day of study.
46056616|NCT05756140|Other|No intervention|No Control
46056617|NCT02733237|Drug|oxytocin treatment|intranasal administration of oxytocin (40 IU)
45695775|NCT01675869|Behavioral|Attention Control|Attention Control is an 8-week intervention involving weekly concurrent child (n=~6 per group) and parent groups that control for the effects of attention. The groups will be 1 hour in length (except for the first session which will be 2 hours).
45695776|NCT01675947|Drug|Sirolimus|Immunosuppressive agent. Blocks the T-lymphocyte activation and smooth muscle and endothelial cell proliferation that occurs in response to antigenic and cytokine (interleukin IL-2, IL-4 and IL-15) stimulation through either Ca2+-dependent or Ca2+-independent pathways. Sirolimus arrests cell cycle progression by direct interaction with two intracellular proteins (immunophilin FK binding protein 12 (FKBP-12) and the mammalian target of rapamycin (mTOR), a multifunctional serine-threonine kinase). In cells, sirolimus binds to FKBP-12, and the resulting sirolimus-FKBP-12 complex then binds to and inhibits mTOR.
46056618|NCT02733237|Drug|placebo treatment|intranasal administration of placebo (40 IU)
45426182|NCT05794737|Biological|Immunohistochemical staining|Staining of Colorectal Carcinoma tissue sections by monoclonal antibodies against human Inhibin Beta A by immunohistochemical procedures.
46056619|NCT04206813|Drug|Gardasil 9 2 dose regimen|a 2-dose regimen of Gardasil 9 at 0 and 6 months
46056620|NCT04206813|Drug|Gardasil 9 3 dose regimen|standard 3-dose regimen of Gardasil 9 at 0, 2, 6 months
46056621|NCT04206813|Drug|Gardasil 9 rescue dose|A rescue dose of Gardasil 9 will be given at 12 months
46056622|NCT02728323|Drug|Levobupivacaine|100 mg of Levobupivacaine by intramuscular injection, at the end of surgery
46056623|NCT02728323|Drug|Saline|20 ml of saline saline by intramuscular injection, at the end of surgery
46056624|NCT03311451|Device|C2 CryoBalloon 180° Ablation System|The C2 CryoBalloon 180° Ablation System is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal therapeutic endoscopes.
45695777|NCT01675947|Drug|Lidocaine|Lidocaine 2%
45848425|NCT03704376|Device|High-frequency linear ultrasound transducer|
46056625|NCT00811720|Drug|Placebo|as-needed use, tablets, orally, 6 months
46056626|NCT00811720|Drug|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
46056627|NCT04030156|Procedure|tonsillectomy|Tonsillectomy was performed under general anesthesia using cold dissection method.
46056628|NCT04202679|Drug|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
46056629|NCT04202679|Drug|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
46056630|NCT04202679|Drug|Moisturizers|"Pharmaceutical form:~Route of administration: Topical"
46056631|NCT04202679|Drug|Low to medium potent topical corticosteroids|"Pharmaceutical form:~Route of administration: Topical"
46056632|NCT04202679|Drug|Topical calcineurin inhibitors|"Pharmaceutical form:~Route of administration: Topical"
46056633|NCT00811642|Drug|Posaconazole|400mg BID oral suspension for 12 weeks
46056634|NCT05756062|Dietary Supplement|Highly-concentrated DHA triglyceride (Tridocosahexanoin-AOX 70%)|Daily administration of 2 capsules of the study product (1000 mg DHA triglyceride) for 3 months
46056635|NCT02609152|Drug|Continuous perfusion of esmolol|In the experimental arm of the study, a continuous perfusion of esmolol will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. At H4, the doctor in charge is free to gradually continue or stop the infusion.
45387272|NCT03979612|Genetic|inclusion of subjects in the GENEPY network|The inclusion of subjects in the GENEPY network follows the genealogical study of a case (index): relatives are identified as potentially at risk. In accordance with the recommendations, but also generally at the wish of the patients (Claes 2003), the index case is then asked to inform its relatives and to propose them to go to an oncogenetic consultation of their choice. If these people reside in the Midi Pyrenees Toulouse oncogenetic consultation is open to them. If following this consultation a mutation is identified or that their genetic risk is considered important, they are proposed to join the GENEPY network for their monitoring.
45387273|NCT00297778|Drug|Pramipexole|Dopamine agonist
45387274|NCT00297778|Other|Placebo|
45387275|NCT03848832|Drug|GWP42003-P|GWP42003-P presented as an oral solution containing cannabidiol
45387276|NCT03848832|Drug|Placebo|Matching placebo oral solution
45387277|NCT00450372|Biological|ADI-PEG-20|There will be 6 cycles planned, each consisting of 4 weeks. During each cycle subjects will receive injections on days 1, 8, 15, and 22 + 2 days. All subjects may begin treatment with 160 IU/m2 on a weekly basis.
46056636|NCT02609152|Drug|Continuous perfusion of saline|In the control arm of the study, a continuous infusion of normal saline will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. A H4, the doctor in charge is free to gradually continue or stop the infusion.
45501008|NCT05205135|Behavioral|SHARE Programme|"SHARE is Singapore's first 'Hospital-to-Home' programme to screen, identify and provide targeted interventions for caregivers at-risk of caregiver burden. Our interventions include psychosocial and emotional preparation of caregivers' mental resilience, and long-term engagement initiatives to connect caregivers into an integrated network of peers and community support services, delivered by programme facilitators and care support nurses.~Key stakeholders essential for the success of share include ward nurses and clinicians who refer caregivers to SHARE and community partners and hospital leaders.~This study seeks to recruit all of these individuals to better understand their experience of SHARE and the facilitators and barriers to its successful rollout to better evaluate the feasibility of SHARE in the hospital to home setting."
45501009|NCT03576560|Other|Retrospective Chart Review|Retrospective Chart Review
45501010|NCT03574220|Drug|Pembrolizumab|200mg IV every 21 days over 6 months
45501011|NCT03574220|Radiation|Stereotactic body radiotherapy|50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-14 days
45501012|NCT03574142|Drug|Epanova|A single dose of Epanova 4 g will be administered as 4 capsules (each containing 1 g of Epanova) followed by a 72-hour washout period in Chinese healthy subjects. Subsequently, multiple doses of Epanova 4 g will be administered once daily for 14 consecutive days.
45695778|NCT03845205|Behavioral|Integrated AUD Treatment|IAT will include computer-delivered BI in the hospital, nurse-delivered alcohol monitoring counseling at each outpatient LT follow-up visit, and at-home participation in web-based, 7-session CBT4CBT, supplemented by tailored text messages.
45695779|NCT01676025|Procedure|PRA|
45695780|NCT01676025|Procedure|LA|
45387278|NCT00450372|Other|Pharmacology Studies|tissue blocks will be obtained from the initial biopsy of melanoma. Immunohistochemical staining for ASS and RT-PCR will be performed on the tumor tissue
45426183|NCT05794724|Procedure|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
45501013|NCT04894773|Other|Imaginary Resistance Exercises|In imaginary resistance exercises, resistive force is assumed to get applied by the patient after demonstrating some resistive objects and the kind of force exerted by them.
45695781|NCT04640259|Other|Online Survey|Epidemiological Survey (approx 200 questions)
45695782|NCT02082717|Drug|potassium chloride replacement|
45695783|NCT02082717|Drug|Experimental - 4% Sodium Bicarbonate|
45695784|NCT03660189|Other|Two bag system|The two IV fluid bags have identical fluids and electrolytes, except one has 10% dextrose and the other has no dextrose. The two fluid bags run simultaneously and their rates are adjusted according to the patient's blood sugar.
45695785|NCT01569074|Drug|Fostamatinib|Fostamatinib 100mg twice daily for 12 weeks
45695786|NCT01569074|Drug|Fostamatinib|Fostamatinib 100mg twice daily for 4 weeks, followed by150mg once daily up to Week 12
45426184|NCT05794711|Procedure|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
45387279|NCT00327340|Drug|custirsen (OGX-011)/mitoxantrone|"All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to-1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21-day cycle.~Mitoxantrone was administered IV on Day 1 of each cycle at a planned dose of 12 mg/m² infused over 30 minutes.~Patients could receive a maximum of 9 cycles of treatment."
45695787|NCT01569074|Drug|Fostamatinib|Fostamatinib 75mg twice daily for 12 weeks
45387280|NCT00327340|Drug|custirsen (OGX-011)/docetaxel|"All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to -1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21 day cycle.~Docetaxel was administered IV on Day 1 of each cycle at a planned dose of 75 mg/m² infused over 60 minutes.~Patients could receive a maximum of 9 cycles of treatment."
45387281|NCT03995316|Behavioral|Treatment As Usual + MMB 2.0|Women assigned to use MMB 2.0, along with NorthShore HealthSystem's well established usual care, will be guided by the program to move sequentially through 6 sessions, one of which becomes available for use each week, while interacting with engaging activities within each session along with recommended practice activities to encourage transfer of learning and skills to everyday routines. Content is presented using text, interactions, animations, and videos. MMB includes daily tracking and charting of mood and pleasant activities as well as online access to a library, covering a range of issues of concern to pregnant women and new mothers. Integrated text messages offer both motivational messages and links to access specific portions of session content in the MMB 2.0 program. The study coordinator will also provide up to 3 supportive coaching calls to each woman in the MMB 2.0 condition. These calls complement and thus are adjunctive to the MMB 2.0 program.
45426185|NCT05794698|Procedure|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
45501014|NCT04894773|Other|Physical Resisted Exercises|In physical resistance exercises, resistive force is applied to the targeted region by using different and appropriate resistive objects.
45695788|NCT01569074|Drug|Fostamatinib|Fostamatinib 50mg twice daily for 12 weeks
45695789|NCT01569074|Drug|Placebo|Placebo twice daily for 12 weeks
45695790|NCT03842241|Device|Non-custom made foot orthoses|Foot orthoses is an orthotic devices which are used to support arch and rear-foot and put it in a good alignment.
45695791|NCT03842007|Diagnostic Test|Rectal Barostat Study|Contractions will be recorded with a balloon inserted into the rectum and inflated
45387282|NCT03995316|Behavioral|Treatment As Usual Only|NorthShore HealthSystem's treatment as usual, or usual care, has been in place since 2003. Screen positive women randomized to this condition will receive social work assessment by phone, followed by community mental health referral as indicated. Referrals will vary by need and may include psychotherapy, support groups, or psychiatry. Referrals will include consideration of geographic proximity, insurance, and acuity. Consistent with routine practice, NorthShore staff will document time spent during evaluation and in making specific referrals.
45387283|NCT00548093|Drug|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
45387284|NCT00548093|Drug|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
45501015|NCT03578588|Drug|Banapenem|Twelve healthy adult volunteers, half male and female, are enrolled and randomly assigned to three groups, B1, B2, and B3. The subjects in three groups receive three doses, 250 mg, 500 mg and 1000 mg. Each group of subjects receive single-dose test drug at different dosages in each period. The subjects are divided into two groups, C1 and C2, 12 subjects in each group, half males and half females. 250 mg group is performed first. After completion of observation and confirming that the drug can be safely tolerated, study on 500 mg group is then performed
45501016|NCT05758233|Procedure|Transversalis Fascia Plane Block, Transversus Abdominis Plane Block|Group 1: Transversalis Fascia Plane Block Group 2: Transversus Abdominis Plane Block
45501017|NCT04876677|Drug|Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium|Two inhalations bid: 4 inhalations; total daily dose of 400/24/50 μg BDP/FF/GB
45501018|NCT02966028|Drug|SNF472|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
45387285|NCT01062724|Other|Primene 10 % from Baxter|Primene solution will be calculated in g/kg/day and administered in ml/day Active Comparator: Trophamine This group of neonates will be receive the Trophamine amino acid solution from Pisa laboratories and the other arm will be receive a Primene amino acid solution (10 %) from Baxter laboratories. For infants identified, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat and daily enteral intake (ml/kg/d) of breast milk or formula will be record.
46056637|NCT02733393|Procedure|Sphenopalatine Ganglion (SPG) Block|Patients who are undergoing a thoracotomy will be informed that they may develop moderate to severe postoperative ISP and may have the option to receive an SPG block. The SPG block will be performed every three minutes for 20 minutes, 0.1mL of the 4% lidocaine will be administered through. After 20 minutes and various intervals thereafter the patient will be asked to rate their shoulder pain.
46056638|NCT02733393|Drug|lidocaine|
45501019|NCT02966028|Drug|Placebo|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
45501020|NCT03578432|Drug|Everolimus|Given PO
45501021|NCT03578432|Other|Laboratory Biomarker Analysis|Correlative studies
45501022|NCT03578432|Other|Survey Administration|Ancillary studies
45426186|NCT05794685|Procedure|adductor canal block|patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg of dexamethasone at a point anterior to the femoral artery, deep to the sartorius muscle (adductor canal block).
45695792|NCT03842007|Diagnostic Test|Fecoflowmetry|Rectum will be filled with a small amount of paste.Two thin catheters will be inserted into the anus to measure pressures and electrical activity (electromyography or EMG). Subjects will be asked to sit on a commode, contract (squeeze) your anal muscles, blow into a balloon, and expel the paste into the commode.
45501023|NCT03578354|Drug|4-aminopyridine|an oral drug to be swallowed
45501024|NCT03578354|Drug|Atenolol|an oral drug to be swallowed
45501025|NCT03578354|Other|Placebo|a masked placebo to be swallowed
45501026|NCT02239718|Procedure|2-unit cantilevered resin bonded bridge|Use one tooth as abutment tooth to replace one adjacent missing tooth
45501027|NCT02239718|Procedure|3-unit fixed movable resin bonded bridge|Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
45501028|NCT02925741|Other|Silk-Like Linens|Synthetic moisture-wicking fabric
45501029|NCT03576482|Other|Transport on foot|Patients go to operating room walking with their families and with their normal clothes
45695793|NCT03840915|Drug|Cisplatin|Cisplatin will be administered intravenously at a dose of 75 milligrams per meter square (mg/m^2) over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
46056639|NCT02733315|Behavioral|Diabetes Conversation Map Program|"The experiment group received seven DCMP-based group education sessions for seven consecutive weeks in addition to routine health education at a private room in the outpatient unit. One registered nurse who received DCMP facilitator training, from the Taiwanese Association of Diabetic Educators, served as the class facilitator. DCMP sessions were conducted using seven colored maps covering different topics, including walk with diabetes, what is diabetes?, a healthy diet and exercise, walk with insulin, diabetes complications and related risk factors, foot care for diabetes patients, and a type 1 diabetes patient in the home. Each map, a laminated 3-by-5-foot table-top visual with colorful drawings as metaphors of situations familiar to DM patients, was placed on a table with participants gathered around it. This procedure served to create mutual imagery to be shared with participants."
46056640|NCT02728011|Other|Scientific Brain Training (SBT)|Cognitive training
46056641|NCT02728011|Other|Tetris|
46056642|NCT02728167|Device|Pre-coagulation of the liver parenchyma with HIFU|6 to 10 (or more if necessary) side-to-side 40-seconde HIFU treatments
45501030|NCT02239796|Device|NeuroTrac continence stimulators|"Electrically stimulating the sacral nerve plexus modulates the L4-S3 nerve roots that control bladder function and urethral sphincter activity to eliminate inappropriate detrusor contractions while leaving the micturition reflex intact.~Transcutaneous posterior tibial nerve stimulation (TPTNS) is a technique of non-invasive retrograde electrical stimulation of the sacral plexus via the sciatic nerve. The posterior tibial nerve, a tributary of the sciatic nerve, is accessed using surface electrodes applied to the medial malleolar area. We are using NeuroTrac continence stimulators."
45387286|NCT05300243|Diagnostic Test|HPV integration test|The stratified analysis by the level of HPV DNA integration in HSIL and cervical cancer will be drawn to explore whether the status of HPV integration makes any difference in the progression of cervical cancer. The purpose of the research is to reduce the miss of cervix lesions and prove that HPV integration detection is sensitive in cervical cancer precise screening.
46056643|NCT02733003|Behavioral|Women's Health CoOp (WHC)|Participants in this group will participate in two workshops of the woman-focused intervention about HIV/STIs, sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues.
45387287|NCT05299385|Behavioral|Conventional rehabilition treatment(e.g leaflet) educated by hospital|"Active Comparator: subjects who are trained in accordance with the conventional manual treatment of Respiratory rehabilitation in the clinical institution and taking care home-based management.~The manual contents~method of the conventional rehabilitation treatment~intensity for aerobic exercise and anaerobic exercise"
45387288|NCT05299385|Device|Digital treatment based on Respiratory Rehabilitation Software|"Experimental: subjects who use the software as a home-based Digital Respiratory Rehabilitation software~It is intended for subjects who are prescribed a respiratory rehabilitation exercise to improve their physical condition. The software also helps them to do self-rehabilitation exercise."
45387289|NCT00958139|Other|Permethrin|Permethrin 0.5% treatment of clothing one time
45387290|NCT00958139|Other|Placebo|water sprayed on clothing one time
45387291|NCT04068311|Other|Geriatric Screening tools|Lean Six Sigma implementation in the Emergency Department of nurse-driven geriatric screening tools and protocols for patients with fall risk, delirium, and high risk scores.
45387292|NCT00450216|Drug|Ibuprofen/famotidine|HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks
45387293|NCT00450216|Drug|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for 24 weeks
45387294|NCT00953693|Procedure|Biopsy|Skin biopsy
45387295|NCT00953771|Drug|Danazol|Danazol 600 mg PO will be initiated with plasma exchange and corticosteroids at the time of enrollment.
45387296|NCT01566006|Drug|Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE|effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin
45501031|NCT02239796|Device|NeuroTrac continence stimulators|We are using NeuroTrac continence stimulators.
45501032|NCT02964312|Device|Nasal Implant|Latera implant placed as a standalone procedure or in conjunction with a turbinate reduction procedure in an office setting under local anesthesia.
45501033|NCT04155333|Device|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that stimulates the brain through the application of a low-intensity electrical current, typically ranging from 1 to 2 milliamps (mA), via electrodes placed on an individual's scalp. During the active stimulation sessions, 2 mA of stimulation will be applied for 30 minutes. During the sham stimulation session, 2 mA of stimulation will be applied over the course of 90 sec, the electrodes will remain in place for the 30 minute duration.
45695794|NCT03840915|Drug|Carboplatin|Carboplatin will be administered at area under the concentration-time Curve (AUC) 5 when combined with pemetrexed over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
45695795|NCT03840915|Drug|Pemetrexed|Pemetrexed will be administered intravenously at a dose of 500 mg/ m^2 over 10 minutes every 21 days.
46056644|NCT00809926|Drug|Valsartan/aliskiren|Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks
45387297|NCT05300165|Dietary Supplement|Beer|A daily beer will be consumed by the participants during a total of 6 weeks, changing every 2 weeks from alcohol-free lager beer, lager beer and dark beer
45387298|NCT00441480|Dietary Supplement|Plant sterols esters|1.6g phytosterols and 1.3g omega-3 fatty acids per day
45387299|NCT00441480|Dietary Supplement|placebo|4 gr of corn oil
45387300|NCT00958451|Drug|Paricalcitol|"Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml;~Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks."
45426187|NCT05794685|Procedure|4 in one block|patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg dexamethasone at the adductor hiatus where the descending genicular artery branches from superficial femoral artery (4 in one block).
46056645|NCT00809926|Drug|Valsartan|Valsartan (160mg) for 2 weeks followed by forced titration to Valsartan (320mg) for the remaining 6 weeks
45387301|NCT00958451|Drug|Ergocalciferol|"If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks.~If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks.~If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks."
45387302|NCT03372408|Other|Chart review|Retrospective chart review of program participation and socio-demographic & psychosocial characteristics
45387303|NCT05299307|Diagnostic Test|semen analysis and hormonal proflie|measure total prolactin and total testosterone and semen
45387304|NCT03372174|Device|Maintaining mechanical ventilation during surgery|dead space ventilation using tidal volume of 2.5 mL/kg/pbw (predicted body weight) with 5-7 cm H2O Positive end-expiratory pressure
45387305|NCT03372174|Device|Absence of mechanical ventilation during surgery|absence of mechanical ventilation (and no Positive end-expiratory pressure) by disconnecting the tracheal tube from the ventilator
45387306|NCT05352191|Drug|Beclomethasone|inhaled 800ug
45387307|NCT01028664|Device|SENSIMED Triggerfish|2-hour continuous IOP monitoring
45387308|NCT00954005|Drug|Therapy with Rituximab, Gemcitabine and Oxaliplatin|Rituximab 375 mg/m² day 0 or 1, Gemcitabine 1.000 mg/m² in 30 Min. day 1 and 15, Oxaliplatin 70 mg/m² in 120 Min. day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²), repetition at day 29 for 4 cycles
45387309|NCT01023750|Drug|Fenofibrate|Participants will give a baseline blood sample and begin the 4 week course of fenofibrate. Patients will be given a 33-day dose of 145 mg of fenofibrate to be taken by mouth once a day. All doses of fenofibrate will be purchased in one batch, prepared at the pharmacy under supervision. A study nurse will collect each patient's 33-day dose of fenofibrate from the pharmacy and dispense to the study participants in the clinics. Patients will be given instructions on how to take the medication and given a 24-hr phone number to call in case of questions or need for additional care. Each patient will receive a phone call at least 2 times during the course of the trial to monitor the progress. Our co-investigators, who are also physicians will be available in case a study participant needs additional care. If not available, study participants will be able to reach the cardiologist or endocrinologist on call through an additional phone number we will provide.
45387310|NCT05300009|Combination Product|topical methotrexate hydrogel 1% coupled with microneedling.|Microneedling will be performed on each wart for a maximum 5 lesions per patient using dermapen (Ostar rechargeable dermapen, OB-DG 03N, Ostar Beauty Sci-Tech Co, Beijing, China) supplied with 12 needles arranged in rows. The penetration depth was adjusted at 2-mm, endpoint was pinpoint bleeding and the dermapen will be held by the hand in a vertical direction on the wart. Then topical methotrexate 1% gel will be applied on the lesions every session.
45387311|NCT05300009|Other|Liquid nitrogen|"The wart is frozen for 10 to 30 seconds until a 1- to 2-mm ice ball halo surrounds the targeted area.~The sessions were performed every 2 week until complete clearance for a maximum of six sessions."
45387312|NCT05352113|Drug|SSRIs|SSRIs antidepressants will be used and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
45387313|NCT05352113|Procedure|acupuncture|This study will use the intradermal needle as an acupuncture intervention. Acupoints related to MDD will be stimulated. According to the position of the acupoints, choose a needle of φ0.20*1.5m or φ0.20*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
45387314|NCT05352113|Procedure|sham acupuncture|Sham acupuncture will use the same size, color, and material as the verum intradermal needle with a thin silicone pad in the middle instead of the needle body. The sham acupuncture will be needled on the points 1cm lateral to MDD-related acupoints. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. A total of 10 sessions will be performed for 6 weeks.
45501034|NCT05204979|Other|Vaginal Versus Sublingual misoprostol|Insertion failures of intra uterine devices and cervical problems seem to occur more often among women who have never delivered vaginally. Several studies have shown the benefit of misoprostol as a cervical ripening agent in nonpregnant women. This trial will compare the effect of vaginal versus sublingual misoprostol prior to insertion of an intrauterine device in multiparous women delivered by CS.
45387315|NCT05352113|Drug|placebo|Oral placebo mimicking SSRIs antidepressants. Once-daily for 6 weeks.
45501035|NCT03576404|Other|Patient-Centered Pharmacist Care|A comprehensive interview applying the concepts of Medication Therapy Management (MTM) and Motivational Interview (MI)
45695796|NCT03840915|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered intravenously at as dose of 100 mg/m^2 over 30 minutes in a 21 days cycle on Day 1, 8, and 15 in each cycle for 4 cycles (each cycle is 21 days).
45695797|NCT03840915|Drug|Gemcitabine|Gemcitabine will be administered intravenously at a dose of 1250 mg/m^2 over 30 minutes in a 21 days cycle on Day 1, and 8, in each cycle for 4 cycles (each cycle is 21 days).
45387316|NCT00547703|Drug|Nortriptyline|Nortriptyline 25mg capsule, orally administered, every night for 8 weeks
45387317|NCT00547703|Drug|Placebo|An identical placebo capsule containing lactose, administered orally, every night for 8 weeks
45387318|NCT00297232|Drug|Natalizumab|
45387319|NCT00954083|Behavioral|DIR/Floortime|Developmental, Individual-Difference, Relationship-Bases (DIR) focus more on relationship, social skills, and meaningful, spontaneous use of language and communication and integrated understand of human development
45387320|NCT00954083|Behavioral|Routine care|Routine care
45501036|NCT03647514|Drug|Abraxane|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
45501037|NCT03647514|Drug|Xeloda|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
45501038|NCT05759871|Other|GnRH antagonist|The GnRH antagonist in the control group (standard therapy) is administered from day 6 of FSH treatment at the dose of 0.25 mg per day until the triggering day and is injected each time immediately after the injection of FSH.
45501039|NCT02239952|Drug|Sunitinib|50 mg once daily, oral use for 14 days
45501040|NCT02239952|Drug|vandetanib|300 mg, once daily, oral use for 14 days
45501041|NCT02239952|Drug|Erlotinib|150 mg, once daily, oral use for 14 days
45501042|NCT03647436|Other|Comprehensive Geriatric Assessment. Both groups.|Evaluation of the incidence of geriatric syndromes: depression, delirium, cognitive disorders, falls, gait disturbances, urinary and fecal incontinence
45501043|NCT04089423|Device|Fujifilm SILVAMP TB LAM|Fujifilm SILVAMP TB LAM detects the presence of lipoarabinomannan (LAM) in urine with a visually read lateral flow test that uses silver amplification.
45501044|NCT03576326|Behavioral|Drawing Incentive|The Monetary Reward intervention is a drawing reward, in which participants are eligible for weekly rewards based on toothbrushing performance.
45695798|NCT03840915|Drug|Docetaxel|Docetaxel will be administered intravenously at a dose of 75 mg/m^2 over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
45695799|NCT03840915|Drug|M7824|M7824 will be administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 and pemetrexed.
45695800|NCT03840915|Drug|Carboplatin|Carboplatin will be administered at area under the concentration-time Curve (AUC) 6 when combined with nab-paclitaxel over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
45695801|NCT03840915|Drug|Carboplatin|Carboplatin will be administered at area under the concentration-time Curve (AUC) 5 when combined with gemcitabine over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
45695802|NCT03840915|Drug|M7824|M7824 will be administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 alone.
46056646|NCT05344131|Other|Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach)|Biopsychosocial approach
46056647|NCT02728245|Drug|Dienogest|Dienogest 2mg po qd
46056648|NCT02728245|Drug|Placebo drug|Placebo 1 table po qd
46056649|NCT02728245|Procedure|Surgery|conservative surgery without intent to oophorectomy
46056650|NCT05755984|Diagnostic Test|3D printed model|scan
46056651|NCT02732925|Device|Arm 2 Balloon Kyphoplasty|"Arm 2 Balloon Kyphoplasty (Medtronic LCC) and Conservative Treatment~Subjects will be blinded and randomised to Arm 2 and will undergo a general anaesthetic and undergo a balloon kyphoplasty surgical procedure. They will also be treated with conservative management.~Below is a list of the conservative management they will be managed by their Doctor:~Bisphosphonates~Pain relief~Systemic chemotherapy for Myeloma disease~Bed rest~Radiotherapy~Physiotherapy"
45387321|NCT05351957|Procedure|Dry needling|Only dry needling of the lower limbs will performed in all patients with acupunture needling
46056652|NCT02732925|Procedure|Conservative Management|"Patients recruited to Arm 1 and Arm 2 will undergo conservative management for Multiple Myeloma recommended by their Consultant Hematologist.~Concomitant treatment with bisphosphonates~Pain relief as required~Systemic chemotherapy for Myeloma disease~Bed rest~Radiotherapy~Physiotherapy"
46056653|NCT04770610|Drug|OT-101 Ophthalmic Solution|Atropine 0.01%
46056654|NCT04770610|Drug|Vehicle|Investigational Product minus active ingredient
46056655|NCT02732769|Device|GammaKnifePerfexion®|neurosurgery
46056656|NCT02732769|Device|GammaKnifeIcon®|neurosurgery
45387322|NCT05351645|Behavioral|Treatment|"Once per day for a 14-day trial period, participants in the Treatment group were assigned to read a first-person narrative about a past issue with suicidal thoughts or behaviors. These narratives each contained positive elements, such as providing details about how the author had overcome issues with suicide, suggesting that people with suicidal thought are not alone, or encouraging people with suicidal thoughts/behaviors to have hope."
45387323|NCT01062802|Drug|Atorvastatin|Atorvastatin 80mg, once a day for four weeks.
45387324|NCT01062802|Other|Placebo|Placebo given once daily for 4 weeks.
45387325|NCT00954161|Other|Helping behaviour curriculum|The objective of the helping behaviour curriculum is to sensitise participants to develop a helping reaction, and to teach participants how to deal with barriers to helping. The helping behaviour curriculum is being taught in 2hours.
45387326|NCT00954161|Other|First aid only curriculum|Two hours training on first aid for alcohol and drug incidents
45426188|NCT05794659|Biological|AST-201|i.d. (3-week interval, 3 cycles in total)
45426189|NCT05794659|Drug|Paclitaxel|3-week interval, 6 cycles in total
45426190|NCT05794659|Drug|Carboplatin|3-week interval, 6 cycles in total
45387327|NCT03982108|Procedure|Arthroscopic rotator cuff repair with knotless suture-bridge technique|"A posterior portal will be established to obtain adequate visualization and an anterior portal will be established through rotator interval as a working portal for diagnostic arthroscopy and debridement. Then additional portals will be established and preperation of tendon will be performed and a burr will be used for footprint preperation.~After determination of proper anchor locations, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the rotator cuff and will be used to create a suture bridge over the tendon. Then these limbs will be loaded to anchors which will form the lateral row without tying the suture limbs at the medial row. These lateral anchors will be inserted to adequate location, just lateral and distal to greater tuberosity with adequate suture-bridge tension over the rotator cuff."
45387328|NCT03982108|Procedure|Arthroscopic rotator cuff repair with knot-tying suture-bridge technique|After the same preparation procedure as in knotless suture-bridge technique, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the tendon and tied in a horizontal mattress suture pattern. After the establishment of medial row, suture limbs will be used to form a suture bridge over the tendon and will be loaded to lateral row anchors which then will be inserted lateral to greater tuberosity in a similar way to knotless repair technique.
45501045|NCT04739475|Procedure|Non Surgical Periodontal Therapy|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
46056657|NCT02732769|Device|Efficast®|Thermoformed mask
45387329|NCT00954317|Procedure|epidural placed low|epidural placed low
45387330|NCT00954317|Procedure|high epidural|high epidural
45387331|NCT01062880|Behavioral|self-guided internet modules|Patients are assigned at random to either unspecific (n= 1000) or individualized (n=1000) self guided internet modules.
45387332|NCT03938909|Genetic|cif mtDNA biomarker|The aim is to evaluate the role of ccf-mtDNA as a specific and early biomarker for different clinical pictures
45387333|NCT03867383|Drug|Calcium Chloride|"All included in intervention description.~1 gram of calcium chloride in total 60 milliliters normal saline"
45387334|NCT03867383|Drug|Placebo|60 milliliters normal saline
45387335|NCT05351567|Other|EDUCATIONAL PROGRAM CREATED ACCORDING TO TRANSFORMATIONAL LEARNING THEORY|EDUCATIONAL PROGRAM CREATED ACCORDING TO TRANSFORMATIONAL LEARNING THEORY FOR INFERTILITY FEMALES
45387336|NCT03855215|Diagnostic Test|ACTIM CRP Rapid Test (Medix, Biochemica)|The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI. healthcare workers can decide to follow the test results or not.
46056658|NCT02732769|Device|MRI|
46056659|NCT02690415|Procedure|Antibiotics Given|Patients who's treating physician prescribed antibiotics
45387337|NCT05351411|Other||Participants in the control group maintained their therapeutic routine and had the opportunity to take part in the combined progressive functional exercise intervention after follow-up assessments had been conducted.
45387338|NCT00954395|Other|D-dimer|D-dimer is performed at the time of anticoagulation suspension. If above or below age and gender specific cut-offs, anticoagulation is stopped and D- dimer repeated after 15, 30, 60 and 90 days.
45387339|NCT05351177|Other|Exercise Training|Either of; 8-weeks twice-weekly High-Intensity Interval Training or Same-Session Concurrent Exercise Training.
45695803|NCT03840915|Drug|Paclitaxel|Paclitaxel will be administered intravenously at a dose of 200 mg/m2 over 3 hours every 3 weeks for 4 cycles (each cycle is 21 days).
45695804|NCT03839121|Device|Cardiac Resynchronization Therapy (CRT)|Observation and documentation of CRT patients
45695805|NCT03752775|Device|Robot assisted upper limb rehabilitation|The patients in the experimental and the other arms will receive 20 session device assisted upper limb rehabilitation. In each session, a subject will conduct multi-joint coordinated upper limb motions for 1 hour.
45695806|NCT03749967|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
46056660|NCT02690415|Procedure|Antibiotics not given|Patients who's treating physician did not prescribed antibiotics
46056661|NCT02727855|Biological|Shanchol|Oral Cholera Vaccine
46056662|NCT05753722|Biological|PRTH-101|PRTH-101 is a humanized immunoglobulin gamma-1 (IgG1) monoclonal antibody
46056663|NCT05753722|Biological|Pembrolizumab|PRTH-101 in combination with Pembrolizumab
46056664|NCT02732613|Device|Laryngeal Mask Airway|If there were any conflicts of the Laryngeal Mask Airway classic size selection in slim patients by the actual or ideal body weight, size selection will based on actual body weight in Actual weight Group while ideal body weight in Ideal weight Group.
45387340|NCT00954473|Other|laboratory biomarker analysis|Correlative studies
45426191|NCT05794659|Drug|Placebo|i.d. (3-week interval, 3 cycles in total)
45426192|NCT05794659|Drug|rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)|i.d. (3-week interval, 3 cycles in total)
45426193|NCT05794646|Other|Hybrid effectiveness-implementation study type 2|Diagnosis of hepatitis C; Assessment of hepatic fibrosis; Treatment of hepatitis C; Assessment of psychological disorders and treatment or referral.
45501046|NCT03647280|Drug|Abraxane|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
45501047|NCT03647280|Drug|Epirubicin|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
45501048|NCT03576248|Device|In-phase 6 Hz prefronto-parietal tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
45501049|NCT03576248|Device|Sham prefronto-parietal tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
45501050|NCT03576248|Device|2 mA left prefrontal tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
45501051|NCT03576248|Device|Sham left prefrontal tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
45501052|NCT04721769|Procedure|Endoscopic strip craniectomy (with lateral osteotomies) with post-operative helmet therapy|Endoscopic strip craniectomy is a surgical procedure performed to remove pathologic bone of the calvarium that includes the fused suture. Lateral osteotomies, also known as barrel-stave osteotomies, are performed by some surgeons because of their perceived benefit in regard to cranial expansion. Following surgery, orthotic helmet therapy is performed in order to mold the calvarium with the goals of optimizing contour.
45501053|NCT04721769|Procedure|Endoscopic strip craniectomy (without lateral osteotomies) with post-operative helmet therapy|Endoscopic strip craniectomy is a surgical procedure performed to remove pathologic bone of the calvarium that includes the fused suture. Lateral osteotomies, also known as barrel-stave osteotomies, are performed by some surgeons because of their perceived benefit in regard to cranial expansion. Following surgery, orthotic helmet therapy is performed in order to mold the calvarium with the goals of optimizing contour.
45501054|NCT03646032|Behavioral|SAAFE|After completing the pre-game assessment, participants will be asked to play the SAAFE game for at least 30 minutes and up to 1 hour . At the conclusion of the game, participants will be provided with a post-game assessment about their perception of risk, knowledge of specific protective behaviors, and whether they plan to change behaviors.
45501055|NCT03646032|Behavioral|Control|This group will receive dating sim game (called Choices). They will also receive pamphlets that provide information on the testing location and care if they have HIV/STI.
45501056|NCT03578120|Biological|Pre-school booster vaccine|Routine vaccination with pre-school booster vaccine
45695807|NCT03748953|Drug|Ixazomib|Ixazomib Capsules
45695808|NCT04348773|Procedure|Dehydration|Dehydration of the natural tooth by tooth isolation
45695809|NCT04348773|Procedure|Rehydration|Rehydration
45695810|NCT04403685|Drug|Tocilizumab|Single-dose infusion of 8 mg/kg. Maximum dose of 800 mg.
45695811|NCT03746925|Procedure|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
46056665|NCT04736992|Other|No intervention involved|No intervention involved
45387341|NCT03814889|Device|Vibration pattern|"PHASE 1 and PHASE 2 are pilot studies not included in the clinical trial.~Phase 2b: All participants try on several wearable prototypes in our laboratory that provide vibration to the arm. Sensors or electrodes taped onto the arm and hand will sense muscle activity and record any changes during periods of vibration and periods with vibration turned off.~PHASE 3: Patients will be given a wearable device to take home. The patient will wear the device daily. At the beginning and end of the phase, arm function will be tested.~PHASE 4: This study takes 3 or 6 months. 1) If the patient gets Botox injections in their hand and arm, their arm function will be measured for three months during this standard care. 2) Next, all patients will be given a wearable device to take home. The patient will wear the device while feeling vibrations for 3 hours during the day while awake for two months. During this time and 1 month after this intervention, arm function will be tested."
45695812|NCT03746925|Procedure|SuperPATH|SuperPATH approach surgery to replace the hip.
45695813|NCT01604408|Biological|LY2495655|Administered SC
45695814|NCT01604408|Drug|Placebo|Administered SC
45695815|NCT04404231|Radiation|Delivery of infrared light to the head|Building upon the experience gathered from previous depression clinical trials, we will treat twice weekly for a total of 4-week duration consisting of 8 sessions. Each treatment will last 20 min and areas irradiated will include frontal and temporal areas bilaterally. Irradiance of 250 mW/cm2 with a fluence of 60 J/cm2.
45695816|NCT04404231|Other|No Infrared treatment|This is sham treatment. No light is actually given.
46056666|NCT02727621|Drug|Dexmedetomidine|Anesthesia will be maintained with continuous infusion of dexmedetomidine 0.5-0.7 µg/kg/h in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
45501057|NCT03646578|Other|State of anxiety|"Patient anxiety assessment by STAI-Y-A self-assessment questionnaire provided before and after pediatric interview.~The assessment is given to patients upon arrival in the hospitalization service of pregnancies and again after the pediatric interview. This pediatric interview should take place between 1 and 7 days after admission to the hospital ward.The second part includes a 6-week inclusion period with assessment of patients' state of anxiety by a STAI-Y-A self-assessment questionnaire given before and after pediatric interview associated with the delivery of a written document. on prematurity."
45501058|NCT03576170|Other|aromatherapy|aromatherapy by inhalation and/or therapeutic massage
45501059|NCT01566747|Drug|Pazopanib|Pazopanib 800mg day to be given continuously until disease progression.
45501060|NCT03621462|Device|Artificial Intelligence Dermatology Assistant (AIDA™)|The Artificial Intelligence Dermatology Assistant (AIDA™) collects conventional demoscopic images and images at various spectral bands. Following image acquisition, the AIDA™ software presents users with (1) similar lesion images from the International Skin Imaging Collaboration archive, (2) Hypodermoscopy™ images, and (3) images providing an indication of lesion depth, based on the spectral data.
45501061|NCT03578042|Drug|Losartan and amlodipine and hydrochlorothiazide|this is a fixed combination containing the 3 drugs
45501062|NCT03578042|Drug|Standard of care|any free triple combination therapy for hypertension given as 2 or 3 pills
45501063|NCT03646500|Procedure|Retrobulbar Block|Anesthetic nerve block administered in the retrobulbar space prior to transcleral diode procedure
45501064|NCT03646500|Procedure|Remifentanil|Remifentanil administered as intravenous infusion prior to transcleral diode procedure
45501065|NCT03574064|Other|Glucagon-Like Peptide-2 (GLP-2)|Glucagon-Like Peptide-2 (GLP-2) injection.
45501066|NCT03574064|Other|Glucose-dependent insulinotropic polypeptide (GIP)|Glucose-dependent insulinotropic polypeptide (GIP) injection.
45501067|NCT03574064|Other|GLP-2+GIP|GLP-2+GIP injection.
45387342|NCT03814889|Device|No vibration|These patients will wear a glove with a blinking light instead of feeling vibrations.
45387343|NCT03774485|Device|G-Tech Gutcheck Myoelectric recording device|Three G-Tech patches are placed on the abdomen of the patient to record myoelectric activity.
45387344|NCT03741101|Drug|Trametinib|treatment
45387345|NCT05350787|Biological|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
45501068|NCT03574064|Other|Placebo|Placebo injection.
45501069|NCT03918408|Combination Product|PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
45501070|NCT03573986|Biological|[18F]fluoromisonidazole|positron emitting radiopharmaceutical that has been studied in vivo in humans for measurement of regional hypoxia in a number of tumor types with positron emission tomography (PET/CT)
45695817|NCT04413578|Device|Dexcom G6|Continuous Glucose Monitor that, after applied, sends continuous glucose readings to to the patient's smartphone every 5 minutes. This allows the patients to receive more readings over a 24 hour period versus standard of care glucometer finger sticks.
45695818|NCT04413578|Device|Contour NextOne|A Standard of Care Glucometer with Bluetooth capability. The patient inserts a test strip into the device, takes a finger stick and collects a small blood sample on the tip of the strip to initiate the device to detect a glucose reading.
45387346|NCT00449670|Biological|H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)|Two doses of the GSK1562902A adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.
45501071|NCT03573986|Drug|Bevacizumab|Bevacizumab (Avastin, Genentech/Roche) is a humanized monoclonal antibody that binds to VEGF preventing its interaction with VEGFRs resulting in suppression of VEGF signaling.
45501072|NCT03573986|Radiation|positron emission tomography (PET/CT).|PET-CT Scan 1.) before start of Bevacizumab up to approximately 4 weeks and 2.) within 12-22 days of start of Bevacizumab
45501073|NCT05204433|Other|no intervention|no intervention
45501074|NCT03573674|Behavioral|CE - Cognitive Ergonomics (KERGO)|"CE Cognitive ergonomics Intervention deals with themes such as disruptions, interruptions, information overload.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method"
45695819|NCT01677429|Device|VR movie + balance challenge|Computer Assisted Rehabilitation Environment Integrated Reality System used for the challenge of balance control
45695820|NCT01677429|Device|still pictures from VR|Monitoring only still pictures from the VR scene in a loop, no balance challenge
45695821|NCT01677429|Behavioral|Cognitive Behavioral Therapy|For the treatment of panic disorder
45501075|NCT03573674|Behavioral|RS - Recovery Support (KUORMA)|"RS Recovery Support / Stress Management Intervention deals with themes such as workload management, recovery, work-family balance.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method"
45695822|NCT03658707|Other|questionnaire|Shoulder questionnaire
45501076|NCT03959592|Drug|Lutein, zeaxanthin and mesozeaxanthin|The intervention will involve supplementation with the macular carotenoids (1 pill daily with a meal containing lutein, zeaxanthin, mesozeaxanthin) for six months, to determine the effects on visual performance in glaucoma patients.
45501077|NCT03959592|Other|Placebo|This intervention involves an inert pill (1 pill daily with a meal) that contains only sunflower oil, for six months.
45501078|NCT04087395|Device|RHA®4 with new anesthetic agent|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 23 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.
45501079|NCT04087395|Device|RHA®4-Lidocaine|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 23 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
45695823|NCT01567826|Drug|standard of care lipid therapy|"Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.~Zocor, Lipitor [any dose] and Crestor [less than 40mg]"
45695824|NCT01567826|Drug|Aggressive lipid therapy|Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
45848426|NCT03711396|Behavioral|Advance Care Planning Group Visits|Pilot test the Advance Care Planning Group Visit intervention adaptations, called ENgaging in Advance Care planning Talks Group Visit intervention (ENACT Memory Group Visits), to see if it is feasible, acceptable and improves the number of people with amnestic mild cognitive impairment who complete an advance directive (a legal form that describes someone's wishes for future medical care if they are unable to make their own decisions). It will also see how ready individuals are to participate in advance care planning. The overall goal is to improve opportunities for older adults with amnestic mild cognitive impairment to receive medical care that is consistent with their values, goals, and preferences.
46056667|NCT02727621|Drug|propofol|Anesthesia will be maintained with continuous infusion of propofol 50-100 µg/kg/min in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
45387347|NCT00449670|Biological|H5N1 non-adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)|Two doses of the GSK1562902A non-adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.
45695825|NCT03744975|Drug|LCZ 696|Participants will receive Oral LCZ 696 (Entresto 97/103 mg)
45387348|NCT00449670|Biological|H5N1 adjuvanted split virus vaccine (A/Indonesia/05/2005 strain)|Booster administration at Month 6 (and a second booster dose 21 days later for the un-adjuvanted group only) with an adjuvanted split virus pandemic influenza candidate vaccine containing the strain A/Indonesia/5/2005.
45695826|NCT03744975|Drug|Placebos|Participants will receive 1oral Placebo capsule
45695827|NCT03657459|Other|Danger Signs of Heart Failure Videos|Short (under 3 minutes each) videos on (a) recognition of dyspnea, fatigue and edema and (b) self-management of each (based on diet, fluid management and activities)
45695828|NCT03657069|Device|Blossom|Undergo Implant Breast Reconstruction (IBR) with the Blossom Smart Expander Technology
45695829|NCT03657069|Other|Breast-Q -Reconstruction module (preoperative) version 2.0 satisfaction with breasts questionnaire|Ancillary studies
45695830|NCT03653481|Dietary Supplement|Oligofructose-enriched Inulin OI|Consumed as a powder, 8g/d for children <50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
45695831|NCT03653481|Dietary Supplement|Maltodextrin|Consumed as a powder, 8g/d for children <50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
45695832|NCT01696994|Other|Laboratory Biomarker Analysis|Correlative studies
46056668|NCT02608606|Drug|Tacrolimus|compared oral administration versus sublingual administration of tacrolimus.
46056669|NCT02732535|Procedure|sleeve gastrectomy , roux-en-y gastric bypass|laparoscopic sleeve gastrectomy or laparoscopic gastric bypass
45387349|NCT04011449|Device|Medtronic RC+S DBS system|Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system
45387350|NCT04010903|Diagnostic Test|assessment of biomarkers of insulin resistance|blood and urine sample collection for assays of BCAAs
46056670|NCT02727465|Other|Meningitis cases|None - blood draw only
45387351|NCT05350709|Other|mirror therapy|15 patients will be recruited to each group. Patients will receive a total of 20 sessions of treatment, 5 days a week.
45387352|NCT04010513|Behavioral|Hypnosis|Women in the hypnosis group will undergo treatment with three in-person hypnosis sessions and will be given access to hypnosis web-app for at home practice.
45387353|NCT04010513|Other|Standard of Care|Women in the usual care group will continue their usual care for BPS/IC as dictated by their physicians.
45387354|NCT05299931|Drug|Ustekinumab|dose escalation from every 8 weeks to every 4 weeks only in arm 2
45387355|NCT00954629|Drug|strontium chloride hexahydrate|Topical solution to be applied twice daily for 26 weeks. Dosage of up till 4 ml per application.
45387356|NCT00954629|Drug|Placebo|Topical solution to be applied twice daily for 26 weeks. Dosage up till 4ml per application.
45501080|NCT03573596|Drug|Dasatinib|CML patients who have failed a first stopping attempt and have used any TKI for one year will switch to dasatinib 100 mg qd for an additional 2 years before second stop attempt.
45501081|NCT03621618|Diagnostic Test|dobutamine|evaluation of effects of dobutamine on dynamic arterial elastance in cardiac failure
45501082|NCT03621618|Diagnostic Test|norepinephrine|evaluation of effects of norepinephrine on dynamic arterial elastance in sepsis
45501083|NCT04038333|Other|No intervention|This is an observational study without any interventions.
45501084|NCT03944304|Drug|Paclitaxel|Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).
45501085|NCT05204277|Other|Opalescence™ boost™ PF 40%|40% hydrogen peroxide in-office bleaching
45501086|NCT05204277|Other|Opalustre™|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste
45501087|NCT05204277|Other|MI-Paste Plus®|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème
45501088|NCT03619278|Other|HIVACAR|Participants will receive 5 vaccines of personalized RNA vaccine (HIVACAR01), 2 doses of 10-1074 antibodies and 3 doses of romidepsin
45501089|NCT03619278|Other|placebo|Participants will receive 5 vaccines of placebo of HIVACAR01, 2 doses of 10-1074 antibodies and 3 doses of romidepsin
45501090|NCT05204121|Drug|Elpida|elsulfavirine, capsules
45501091|NCT04697901|Device|Active Transcranial Direct Current Stimulation (tDCS)|"Active simulation will be applied to the right PPC. To target this region for stimulation, the anode electrode will be placed on the subject using the 10-20 EEG system as reference location (Thair et al., 2017). Stimulation intensity for all conditions will be set to 2 mA, which was chosen based on previous studies that have compared 1 mA to 2 mA and found the higher intensity produced reliable changes to performance (e.g., Moos et al., 2012). Total time of active stimulation will be the same for each group (20 minutes). Delivery times of the stimulation will vary based on Group assignment:~Group A: During pre-flight brief/checklist, for 20 minutes. Group B: First delivered at 30 minutes into flight for 10 minutes, second delivered at 60 minutes into flight for 10 minutes."
45501092|NCT04697901|Device|Sham Transcranial Direct Current Stimulation (tDCS)|"Sham simulation will be applied to the right PPC. To target this region for stimulation, the anode electrode will be placed on the subject using the 10-20 EEG system as reference location (Thair et al., 2017). Stimulation intensity for all conditions will be set to 2 mA, which was chosen based on previous studies that have compared 1 mA to 2 mA and found the higher intensity produced reliable changes to performance (e.g., Moos et al., 2012). Total time of active stimulation will be the same for each group (20 minutes). Sham stimulation will consist of active stimulation for 120s, including the ramping up to 2 mA and down to no stimulation. Delivery times of the stimulation will vary based on Group assignment:~Group A: During pre-flight brief/checklist, for 20 minutes. Group B: First delivered at 30 minutes into flight for 10 minutes, second delivered at 60 minutes into flight for 10 minutes."
45501093|NCT04671615|Drug|palbociclib|As provided in real world practice
45501094|NCT02899962|Drug|LEO 90100 aerosol foam|LEO 90100 aerosol foam twice weekly
45387357|NCT03665675|Biological|Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes|Given intravenously
45387358|NCT00296374|Drug|Rosuvastatin|10 mg oral dose administered once daily for 52 weeks
45387359|NCT00296374|Drug|Rosuvastatin|20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks
45387360|NCT00296374|Drug|Atorvastatin|40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks
45387361|NCT03839082|Other|Usual Care then FitBit|Usual care is a visit (15-20 mins) every 6-12 months. Usual care includes a Fibroscan (FDA 510(k) device).
45387362|NCT03839082|Other|FitBit then Usual Care|Intervention is tailored physical activity and nutritional counseling. Step counts are monitored by a FitBit Zip. A Fibroscan (FDA 510(k) device) is done.
45387363|NCT05350475|Radiation|Proton therapy|Patients in the experimental arm will receive proton therapy within the same dose and fraction schedule as patients receiving photon therapy, which is standard treatment.
45501095|NCT02899962|Drug|LEO 90100 aerosol foam vehicle|LEO 90100 aerosol foam vehicle twice weekly
45501096|NCT03647202|Drug|Milademetan Treatment A|Treatment A: Single oral dose of milademetan 160 mg capsules under fasted conditions
45695833|NCT01696994|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
45387364|NCT05350475|Radiation|Photon therapy|Patients in the photon arm will receive standard treatment with photon therapy.
45387365|NCT01023984|Procedure|TEM - Transanal Endoscopic Microsurgery|TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
45387366|NCT01023984|Procedure|ESD - Endoscopic Submucosal Dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
45387367|NCT05350241|Other|Split-belt treadmill training|Participants in the split-belt walking group (experimental group) performed repeated split-belt treadmill training with an error-augmentation strategy (exaggeration of the initial step-length asymmetry) for 60 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics.
45387368|NCT05350241|Other|Standard physical therapy|Participants in the control group received the standard physical therapy program. Each session lasted for 60 minutes, repeated three times a week, over 12 consecutive weeks. The program consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
45387369|NCT05304923|Procedure|Supraglottic jet oxygenation and ventilation|Supraglottic jet oxygenation and ventilation is conducted using a Wei nasal jet tube (WNJ, Well Lead Medical Co. Ltd, Guangzhou, China) which is connected to a manual jet ventilator (Well Lead Medical Co. Ltd, Guangzhou, China) via its jet port. The initial settings of SJOV are: driving pressure (DP) 15psi, respiratory rate (RR) 20 bpm, inspiratory-to-expiratory (I/E) ratio 1:2, and gas supply 100% oxygen.
45387370|NCT05304923|Procedure|Nasal cannula oxygen supply|Oxygen supplementation at 2 liters min-1 is delivered via a nasal cannula
45387371|NCT03387761|Drug|Ipilimumab|"For Cohort 1:~Day 1: Ipilimumab 3 mg/kg~Days 22: Ipilimumab 3 mg/kg~For Cohort 2a:~Day 1: Ipilimumab 3 mg/kg~Days 22: Ipilimumab 3 mg/kg~For Cohort 2b:~Day 1: Ipilimumab 1 mg/kg~Days 22: Ipilimumab 1 mg/kg"
45387372|NCT03387761|Drug|Nivolumab|"For Cohort 1:~Day 22: Nivolumab 1 mg/kg~Day 43: Nivolumab 3 mg/kg~For Cohort 2a:~Days 1 and 22: Nivolumab 1 mg/kg~Day 43: Nivolumab 3 mg/kg~For Cohort 2b:~- Days 1, 22 and 43: Nivolumab 3 mg/kg"
45387373|NCT01060774|Drug|Lidocaine|Up to 5 capsules of 2% lidocaine with epinephrine as a reinforcement drug post-operatively
45387374|NCT01060774|Drug|Bupivacaine|Up to 5 capsules of 0.5% Bupivacaine with epinephrine given post-operatively.
45387375|NCT04011059|Biological|Wharton's jelly-derived mesenchymal cells|Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSC around the infarcted zone.
45387376|NCT00954785|Device|Ankle brace|Sports Stirrup ankle brace (Aircast)
45387377|NCT00954785|Drug|Diclofenac 50 mg tds|In the diclofenac group, each subject will receive 50 mg diclofenac in the morning, at mid-day and in the evening
45387378|NCT00954785|Drug|Etoricoxib 120 mg mane|In the etoricoxib group, each subject will receive 120 mg etoricoxib in the morning, and placebo medication in the evening and at mid-day
45387379|NCT00326950|Drug|E7389|E7389 will be administered intravenously on Days 1 and 8 of a 21 day cycle. The initial dose level will be 0.7 mg/m2, with planned dose levels of 1.0, 1.4, 2.0 mg/m2.
45387380|NCT03981874|Other|telephonic interview|Telephonic interview
45387381|NCT00548717|Drug|Sirolimus|
45387382|NCT00548717|Drug|Mycophenolate mofetil|
45387383|NCT00548717|Drug|Bortezomib|
45387384|NCT00441168|Drug|adriamycin|adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4
45387385|NCT00441168|Drug|bortezomib|bortezomib: 1.3 mg/m² intravenous (IV) bolus on days 1, 4, 8, and 11
45387386|NCT00441168|Drug|dexamethasone|dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle
45387387|NCT00441168|Drug|vincristine|vincristine: 0.4mg IV push on days 1 to 4
45387388|NCT00296140|Behavioral|self management of PSD symptoms|
45387389|NCT00296140|Procedure|screening and treatment of PSD|
45387390|NCT03669432|Radiation|Intensity Modulated Radiotherapy|"The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days.~: The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the planned target volume (PTV) of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible.~The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System."
45695834|NCT01696994|Procedure|Ultrasound Imaging|Undergo TVU
45695835|NCT03743025|Drug|Dulaglutide Injection|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Dulaglutide injection: 0.75 mg/0.5 mL solution in a single-dose pen 1 to 3 days prior to surgery
45501097|NCT03647202|Drug|Milademetan Treatment B|Treatment B: Single oral dose of milademetan 160 mg capsules with a high-calorie, high-fat meal
45501098|NCT03647202|Drug|Milademetan Treatment C|Treatment C: Single oral dose of milademetan 160 mg capsules with a standard meal.
45387391|NCT03669432|Procedure|Surgery alone|This intervention is of no interest
45387392|NCT03958331|Behavioral|Automated Digital Reminders|Reminders from electronic monitors via texts or alarms/lights
45387393|NCT03958331|Behavioral|Individualized Adherence Feedback Report|Feedback report on individual adherence behaviors
45387394|NCT03958331|Behavioral|Individual Adherence Feedback Report with Social Norms|Feedback report on individual adherence behaviors compared to other adolescents with epilepsy
45387395|NCT01062958|Other|Neevo® (a medical food)|
45387396|NCT01062958|Other|Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12)|
45501099|NCT03646344|Drug|Heme Arginate 25 MG/ML|IMP - to be administered at a dose of 3mg/kg to a maximum dose of 250mg over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
45501100|NCT03646344|Drug|0.9% Sodium-chloride|Placebo - 100ml of 0.9% Sodium Chloride will be given over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
45501101|NCT03645876|Drug|SHR-1210|200mg
45501102|NCT03645876|Drug|BP102|7.5mg/kg
45501103|NCT03645876|Drug|oxaliplatin|130mg/m2
45501104|NCT03645876|Drug|capecitabine|1000mg/m2
45501105|NCT02899728|Drug|Carboplatin|Given IV
45501106|NCT02899728|Drug|Cediranib|Given PO
45501107|NCT02899728|Drug|Cediranib Maleate|Given PO
45501108|NCT02899728|Drug|Cisplatin|Given IV
45387397|NCT01566318|Behavioral|Problem-Solving Therapy|6-8 sessions over 8 weeks, with booster
45387398|NCT03956615|Other|Blood sampling and bone marrow analysis|Bone marrow sample analysis. A blood sampling of maximally 10 ml by venous puncture (serum)
45387399|NCT01028976|Dietary Supplement|Vitamin C (ascorbic acid)|1000 mg/day (two 500-mg tablets), 8 weeks
45387400|NCT01028976|Dietary Supplement|Placebo tablet|Placebo tablet (two 500-mg tablets), 8 weeks
45387401|NCT01024140|Drug|Escitalopram|Subjects were started on 5mg escitalopram. Medication was increased as tolerated in weekly 2.5, 5 or 10 mg increments, until a maximally tolerated dosage or a clinical response was achieved. The final dosage ranged from 5 to 20 mg/day.
45501109|NCT02899728|Drug|Etoposide|Given IV
45501110|NCT02899728|Drug|Olaparib|Given PO
45501111|NCT03645798|Behavioral|"Three good things therapy"|"To maintain an emphasis on the positive experience, participants were directed to record three good things that went well each day. These things could be minor, ordinary, or important. Next to each good thing, participants were required to answer the question: Why did this good thing happen?"
45695836|NCT03743025|Other|Saline Injection|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Saline injection/0.5 mL pre-drawn solution 1 to 3 days prior to surgery
45501112|NCT03645798|Behavioral|Normal psychological instruction|Normal psychological instruction is a convenient method set by the hospital. Nurses who have stress or psychological problem could find help through this intervention. It was delivered by psychologists.
45501113|NCT03646266|Drug|Rocuronium Bromide|Titration with rocuronium bromide until tidal volume 6ml/kg PBW
45501114|NCT02899338|Drug|BI695501 Prefilled syringe|
45501115|NCT02899338|Drug|BI695501Autoinjector|
45501116|NCT04052100|Other|Usual care|The standard preoperative measures will consist of a recommendation for physical activity and advice on tobacco smoking cessation and reduction of alcohol intake. In addition, patients who suffer from iron deficient anemia will receive intravenous iron and those at risk of malnutrition (Malnutrition Universal Screening Tool ≥2 (www.bapen.org.uk/pdfs/must/must_full.pdf)) or that require weight control for obesity (IMC≥30) will perform a nutrition intervention by a nutritionist.
45695837|NCT03742245|Drug|Olaparib|PARP inhibitor
45695838|NCT03742245|Drug|Vorinostat|HDAC inhibitor
45695839|NCT02986022|Behavioral|Resilience|Self-efficacy, optimism, altruism, goal setting
45695840|NCT02986022|Behavioral|Information|Information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China
45501117|NCT04052100|Other|Multimodal prehabilitation|"The experimental group will also carry out a prehabilitation program consisting in:~A. A motivational interview to reinforce the patient's motivation and generate a commitment in relation to the objectives of the program.~B. A physical activity promotion program to increase the number of daily steps of patients, measured by a wristband and a mobile App.~C. A supervised high-intensity exercise training program. D. An individualized nutritional optimization plan with dietary advice and protein supplementation (if necessary). Educational material and motivational messages will be sent through a mobile App.~F. Psychological support through weekly Mindfulness sessions (1.5 hours duration). Educational material and motivational messages will be sent through a mobile App.~E. A smoking cessation program consisting psycho-cognitive therapy combined with pharmacological treatment. Educational material and motivational messages will be sent through a mobile App."
45501118|NCT04052178|Device|rTMS active and sham|Repetitive transcranial magnetic stimulation of the pharyngeal sensory cortex.
45501119|NCT04052178|Device|PES active and sham|Intrapharyngeal electrical stimulation with a catheter delivering electrical pulses.
45501120|NCT04052178|Dietary Supplement|Capsaicin active and placebo|Capsaicin solution (TRPV1 agonist) at a concentration of 10-5M or placebo solution.
45501121|NCT03645642|Drug|Midodrine|Midodrine 5 mg thrice daily
45501122|NCT03645642|Biological|Albumin|Albumin 20g/l
45501123|NCT03645642|Drug|Diuretics|Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.
45501124|NCT05284266|Procedure|Liposuction early|Liposuction 6-9 months after inclusion
45501125|NCT05284266|Procedure|Liposuction late|Liposuction 18-21 months after inclusion
45501126|NCT05284266|Other|Standard conservative treatment|"Standard Conservative treatment consisiting of:~Physical therapy, including compression garment and exercise program, Self-care program"
45501127|NCT05284266|Other|Standard conservative treatment with Intermittent Pneumatic Compression (IPC)|Physical therapy, including compression garment and exercise program, Self-care program and Intermittent Pneumatic Compression (IPC)
45501128|NCT05284422|Procedure|Traditional Peripheral venous catheter insertion|Insertion of a short catheter in a peripheral vein with the help of visualization palpation
45501129|NCT05284422|Procedure|Ultrasound-guided insertion of a peripheral venous catheter|Insertion of a short catheter in a peripheral vein with the help of an ultrasound device
45501130|NCT03066609|Drug|Secukinumab 150 mg s.c.|150 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
45501131|NCT03066609|Drug|Secukinumab 300 mg s.c.|300 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
45695841|NCT03742167|Other|Telemedicine|The mobile, HIPAA-compliant, video-conferencing platform, Zoom Pro, will be used on tablet computers as a low-cost telemedicine platform for the intervention group. This platform uses Wi-Fi or cellular data connection for video streaming. The investigators will use the telephone communication on this platform for control scenarios, to mimic the current standard for audio-only consultation. A web-based software platform (WireCast®) will capture video recordings over a secure wireless network.
45695842|NCT04116710|Biological|HS-110 (viagenpumatucel-L)|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
46056671|NCT05755828|Biological|ASCT+CAR-T Cell Infusion|CD19 CAR-T cells were prepared from peripheral lymphocytes of NHL patients with PR after 3 to 4 courses of chemotherapy, and autologous stem cells were collected and frozen after mobilization of patient stem cells by granulocyte stimulating factor (10μg/kg/d*5d). BEAM pretreatment was performed. Autologous stem cells were injected 24 h after pretreatment, and the number of CD34+ cells was > 2*106/kg. On the 6th day after transplantation, autologous Anti-CD19 CAR T cells were transfused, and the dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. The patients were given constant intravenous drip/push infusion for 30 minutes.
46056672|NCT02727543|Other|Medisafe|"Medisafe is a smartphone application available to download for free on any iOS or Android device. Medisafe addresses non-adherence by providing alerts to patients when it is time to take their medications. Other features include the ability to allow a Medfriend to check in if a medication is not taken, weekly reports of medication adherence, and monitoring of biometric measurements"
45501132|NCT03066609|Drug|Placebo|Placebo 150 or 300 mg s.c at randomization, Weeks 1, 2, 3, 4, and 8. PASI responders at week 12 continued to receive placebo till Week 48. PASI non-responders at Week 12 received Secukinumab 300mg at Weeks 12, 13, 14, 15, 16 and every 4 weeks till Week 48
45501133|NCT03645486|Genetic|Infusion of lentiviral TYF-CGD-modified autologous stem cells|Infusion of lentiviral TYF-modified autologous stem cells at 1~10x10^6 gene-modified cells per kg body weight
45501134|NCT03646110|Procedure|Minimally invasive esophagectomy|Minimally invasive esophagectomy is a surgical procedure for esophageal resection
45501135|NCT05204043|Other|Peter Hess® sound massage|The Peter Hess® sound massage uses sound vibrations generated by therapeutic singing bowls. Peter Hess' methods act far from a traumatised area, far from the pain. It will be given on the patient's bed for 30 minutes.
45501136|NCT05204043|Other|Music relaxation Music Care®|The patient chooses his music preferences and receive the music relaxation in bed for 30 minutes.
45501137|NCT05204043|Other|Questionnaires|"State Trait Anxiety Inventory (STAI)~Pain assessment - Visual Analogic Scale (from 0 to 10)."
45501138|NCT03611790|Device|NeVa VS|mechanical dilatation
45501139|NCT05757921|Device|Perisolv (A)|Intended for cleaning periodontal pockets for both periodontitis and peri-implantitis. Softens degenerative tissue and biofilm before depuration of periodontal pockets. Does not affect healthy tissue.
45501140|NCT05757921|Other|Standard (B)|Deepened periodontal pockets to be treated are performed by subgingivally debridement. This is performed with piezoelectric ultrasound (EMS) under rinsing water and subgingival debridement with hand instrument.
45501141|NCT03946761|Device|Cancer goggle system|-The cancer goggle system is being used as a non-significant risk device
45501142|NCT02964234|Behavioral|Empowerment|Three group sessions (breast cancer education; communication; volunteerism) 1.5 hours 3 times across 3 weeks
45695843|NCT04116710|Biological|HS-130|Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig
46056673|NCT02608918|Drug|BMS-955176|
46056674|NCT02732223|Dietary Supplement|Functional treatment|Omega 3 fatty acids, plant sterols and polyphenols
46056675|NCT02732223|Dietary Supplement|Control treatment|placebo supplements
45501143|NCT02964234|Behavioral|Education|Three group sessions (breast cancer education; diet; physical activity) 1.5 hours 3 times across 3 weeks
45501144|NCT03921255|Other|Cognitive Bias Modification|There is support that CBM-I may work through the process of cognitive restructuring, and specifically, threat reappraisal. Threat appraisal is a tendency to overestimate the likelihood of harm (i.e., likelihood bias) and/or the negative consequences of anticipated harm (i.e., Clark & Beck, 2010), producing avoidance, thus interfering with effectively reappraising threat, thereby creating a vicious cycle (Beck et al., 1985; Clark & Beck, 2010). CBM-I procedures ensure that an interpretation bias is triggered by the ambiguous scenarios, and participants are then guided to solve the key word in accordance with a healthy response (Grey & Mathews, 2000). The observed effects of CBM-I may stem from active generation of benign or positive meanings in response to ambiguous situations, where threats were previously interpreted (Beadel et al., 2014).
45501145|NCT05757687|Device|Omega device|"The ProArc Medical Omega system is a prostatic reshaping device. The Omega System is comprised of two main components: Omega Delivery Device and Omega g Implant.~The delivery system uses a diathermy electrode to perform a circular and superficial incision through the urethral wall into the prostate tissue, into which the arc-shaped permanent implant is placed. The implant is made up of commonly used surgical implantable nitinol material, coated with Parylene coating. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra."
45501146|NCT03645252|Procedure|Vein interruption before any other surgical manipulation|"The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the vein first group, the lobar vein is dissected and the cartridge and anvil of a vascular cartridge stapler are placed on either side of the vein. The vein is punctured above the stapler with a 23-gauge needle and 7.5 ml of blood is drawn. Finally, the vein is cut. The intervention then proceeds in the usual manner."
45501147|NCT03645252|Procedure|Arteries interruption before vein interruption|"The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the arteries before vein group, lobar arteries are first dissected and interrupted (+/- the bronchus and inter-lobar fissures). The lobar vein is then dissected and blood sample is performed as described above."
45501148|NCT03645174|Device|Using long tube|Fiberoptic-guided intubation through LMA, using long tube
45387402|NCT03956225|Device|Systane iLux® Dry Eye System|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
45387403|NCT03956225|Device|LipiFlow® Thermal Pulsation System|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
45387404|NCT01024218|Device|NovoFine® needle 8 mm|
45387405|NCT01024218|Device|autocover needle|
45387406|NCT01027026|Other|Early discharge|The patients are discharged the same day as coronary angiography.
45501149|NCT03645174|Device|Aintree catheter|Fiberoptic-guided intubation through LMA, using Aintree catheter
45501150|NCT03773328|Biological|CK0801|CK0801 (Cord blood-derived T-regulatory cells)
45501151|NCT03645018|Diagnostic Test|diagnosis with tomosynthesis|Re-evaluation of lung nodule detection rate at 5 years in patients with early diagnosis of lung cancer
45501152|NCT03644394|Device|Implantation of IMES sensors|Surgical implantation of IMES sensors during routine surgery to improve prosthetic control
45501153|NCT05203809|Device|TempTraq temperature monitor|All participants will wear both TempTraq temperature monitor and CORE temperature monitor.
45501154|NCT03768492|Drug|Caffeine anhydrous 5% added to Lipoderm Cream Base.|Caffeine USP Anhydrous 5 gm Ethoxy Digylco Reagent 10 ml Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm
45501155|NCT03768492|Other|Lipoderm Cream Base|Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm
45501156|NCT03644940|Diagnostic Test|CustomSight|Subpopulation-specific clinical decision support (CDS) system for severe sepsis detection
46056676|NCT05755204|Drug|LA-CAB|Intramuscular LA-CAB for PrEP
46056677|NCT05755204|Drug|TDF/FTC|Oral TDF/FTC for PrEP
46056678|NCT02727309|Drug|Apatinib|Apatinib: 750 mg is administered orally daily, until disease progression or untolerable toxicity.
46056679|NCT02732379|Procedure|Lavender Aromatherapy|the two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
46056680|NCT02732379|Procedure|Rose Aromatherapy|the two drops of rose essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
46056681|NCT02732379|Procedure|Ginger Aromatherapy|the two drops of ginger essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
46056682|NCT02732379|Procedure|Placebo Aromatherapy|the two drops of pure water will be dropped into the gauze and the patient will inhale it for 5 minutes
46056683|NCT05755750|Drug|Genipin|Intratendinous genipin injection
46056684|NCT02732067|Other|anesthesia related deaths|number of anesthetized patients who died in the perioperative period inside the hospital
46056685|NCT05093062|Other|Tian Jiu Therapy|
45387407|NCT01027026|Other|Care as usual. No intervention. (Control group)|The patients are admitted and cared as usual in cardiology ward.
45387408|NCT05178329|Behavioral|Lifting exercise|Patients are instructed for a light lifting exercise after mastectomy.
45387409|NCT05178329|Behavioral|Standard exercise|Standard exercise program after mastectomy
45387410|NCT02936609|Other|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
45387411|NCT00457626|Drug|Valsartan|Extemporaneous suspension of valsartan, orally.
46056686|NCT02609932|Drug|Administration of drug (Interferon-gamma 1-b) subcutaneously|SD = group who has received a single dose of IFN-gamma (10, 25, 50, and 100 mcg/m2) given once with subsequent analysis of effects (serum IL-10, Neuropterin, and IFN levels as well as neutrophil Nox2 activity and gene expression by Affimetrics Chip analysis). One month is allowed between doses. SS = administration of four doses (50 mcg/m2) of IFN-gamma given on Monday, Wednesday Friday schedule with neutrophil or monocyte function studies performed before the first and after the fourth dose to determine steady state effects.
46056687|NCT02727231|Device|Florence D2A or similar closed loop glucose control system|Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
45387412|NCT02748707|Drug|Arm1|Drug (Celecoxib as 200mg twice daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
45387413|NCT02748707|Drug|Arm 2|Drug (ERLOTINIB 150 mg daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
45387414|NCT02748707|Drug|Arm 3|Drugs (Celecoxib 200mg twice daily and Erlotinib 150mg once daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
45387415|NCT02748707|Other|Arm 4|Patients randomized to this arm will be observed for 21 days before definitive treatment by surgery.Having a control group is ethically justifiable because the average waiting time in our hospital prior to definitive treatment is 30 days after diagnosis.
45387416|NCT05177861|Diagnostic Test|EMG|Electromyelography
45387417|NCT05175209|Diagnostic Test|EMG|Electromyelography
45387418|NCT05131061|Diagnostic Test|68Ga-Pentixafor PET/CT imaging|68Ga-Pentixafor PET/CT imaging
45387419|NCT04010279|Procedure|preoxygenation with 100% O2, fresh gas flow rate 12 L/minute|volunteers will be placed in supine position, fresh gas flow rate will be set at 12 L/min and delivered oxygen concentration will be set at 100%.
45387420|NCT05050487|Procedure|PENG block|"The PENG block is performed under US guid¬ance, . The pa¬tient is placed in the supine position a curvilinear low-fre¬quency ultrasound probe (2-5 MHz) is initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe approximately 30-45 degrees . .~The needle, usually a 22-G80-mm echogenic device, is inserted from lateral to medial with an in-plane approach to place the tip in the plane between the psoas tendon anteriorly and the pu¬bic ramus posteriorly .~After needle insertion and following negative aspiration, the local anesthetic is injected . The volume used of 20 ml of(L-bupivacaine; concentration 0,25% ) . This fascial plane appeared to continue in the hip pericapsular plane."
45387421|NCT05050487|Procedure|lumbar erector spinae plane block|"The lumbar erector spinae block is performed under US guid¬ance, after adequate skin disinfection The patient is placed in the lateral decubitus position according to the selected site of surgical intervention.~The 4th lumbar vertebral level will determined The convex USG transducer was placed at the mid-vertebral line in the sagittal plane. The transducer was shifted from the midline, 3.5-4 cm laterally to the side of the surgery to visualize the erector spinae muscle and transverse process . 0.5-1 ml of the prepared LA solution (20 ml bupivacaine 0.25%). All LA was administered to this location between the transverse process and the erector spinae muscle."
45387422|NCT02249975|Device|C2 CryoBalloon Focal Ablation System|"The C2 Focal Cryoablation Device will be used for the treatment of islands of BE in real patient care. Ablation at 10 seconds will be tested and post-ablation symptoms related to the Cryoballoon Focal Ablation will be recorded. At 12 weeks, the patient will receive a follow-up endoscopy and biopsy samples will be taken.~Biopsy samples will be evaluated for the presence of residual Barrett's Esophagus. Through evaluation of the histological results, treatment parameters for the ablation of human esophageal epithelium will be better understood.~Evaluations include, but are not limited to the following:~Device malfunctions~Adverse events~Patient Pain~Histological evaluation of treatment zone at 12 weeks for presence of residual Barrett's Esophagus."
46056688|NCT02727231|Device|CSII with CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with continuous glucose monitoring (CGM)
45387423|NCT01841957|Procedure|ISBCS|same-day cataract surgery
45387424|NCT01841957|Procedure|DSBCS|bilateral surgery delayed by 1-3 weeks amongst eyes
45387425|NCT01802567|Device|Guided Therapy- Pediatric Gene Analysis Platform|A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
45387426|NCT05014061|Drug|Adenosine|Adenosine infusion 70 µg/kg/min for 6 hours
45387427|NCT05001503|Device|Stability UO|STABILITY UO is a standalone software, based on a Bayesian model, which quantifies the risk of an individual patient developing severe oliguria (0.3mg/kg/hr for 6 hours). The model identifies at risk patients by predicting future urine output, using only previously recorded urine output values for that individual, allowing clinicians to see the predicted risk of a patient developing severe oliguria in real time.
45501157|NCT03864081|Device|Phase Signal Recorder|The Phase Signal Acquisition (PSAQ) System is a medical device system that is being developed to collect phase signals from patients to support the development and testing of machine learned algorithms. The PSAQ System consists of two components that work together to acquire and transmit the phase signals and patient specific data to a secured, cloud-based repository. The PSAQ System is comprised of: 1) the Phase Signal Recorder (PSR) which is a portable instrument, and 2) the Phase Signal Data Repository (PSDR) which is a cloud based data repository. Data collected during this study will not be used to guide treatment.
45387428|NCT04977245|Other|Mindfulness-Based Stress Reduction|Eight MBSR sessions of 1.5 hours per week
45387429|NCT04977245|Other|Self-Guided Mindfulness eCourse|Six weeks of a mindfulness ecourse, and two weeks of coping skills training led by a licensed neuropsychologist
45501158|NCT01345188|Drug|Ranexa|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
45501159|NCT01345188|Drug|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
45501160|NCT03852459|Drug|S-Ibuprofen|Topical Gel 5%
45501161|NCT03852459|Drug|Vehicle|Vehicle Gel
45501162|NCT03580902|Behavioral|CBT4CBT-Buprenorphine|Computerized, user-driven cognitive-behavioral therapy (CBT) web-based program adapted for use in office based buprenorphine treatment
45501163|NCT03580902|Drug|Buprenorphine/naloxone|Standard outpatient buprenorphine maintenance
45501164|NCT03644862|Device|etafill|Etafill is a HA formulation intended to be used in opthalmic anterior segment cataract surgery.
45501165|NCT03744390|Drug|AG-221|Subjects enrolled will receive continuous 28-day cycles of AG-221 -100 mg.
45501166|NCT03644316|Device|BandGrip skin closure device|topical skin closure device
45501167|NCT03629145|Behavioral|Live Music Therapy|Investigator will begin play live guitar and voice music.
45501168|NCT03629145|Behavioral|Recorded Music Therapy|Investigator will play recorded music.
45501169|NCT05283876|Device|Excimer light|Excimer light sessions
45501170|NCT05759715|Other|Iris Color Measurement , LF/HF Measurement|Iris Color Measurement (Photos were taken of the iris with a digital camera ) LF/ HF Measurement (Using the three-channel standard ambulatory Holter recording system)
45501171|NCT03644784|Diagnostic Test|Standardized protocol for assessing aortic regurgitation using videodensitometry|Standardized protocol for assessing aortic regurgitation using videodensitometry
45501172|NCT05283798|Device|IUD|Postpartum intra-caesarean section insertion of copper T380 versus multiload 375
45501173|NCT02896296|Drug|RBP-6000|Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose could be adjusted from 100 mg to 300 mg (or the reverse) based on the medical judgment of the investigator.
45501174|NCT03643614|Procedure|Injection of autologous regenerative cells of adipose tissue|Autologous regenerative cells of adipose tissue obtained by enzymatic digestion of lipoaspirate are injected diffusively in the submucosal plane of the rectum and vagina with a sharp 27G needle. Adipose tissue that has not been subjected to enzymatic processing is injected through the punctures on the skin into the deep layers of the rectovaginal septum by means of cannula of 1.0-1.2 mm in diameter, 70 mm in length, 0.1-0.2 ml in one retrograde pass of the cannula.
45501175|NCT05262348|Device|adaptive DBS delivered through AlphaDBS IPG System|"The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Adaptive DBS is a programming mode that provides stimulation in a closed-loop adaptive real-time fashion, using a biosignal recorded from the same macro-electrodes routinely implanted for DBS as an input variable."
45501176|NCT05262348|Device|conventional DBS delivered through AlphaDBS IPG System|The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Conventional DBS is programmed by DBS specialists.
45501177|NCT03643536|Other|12-WPEP|The 12-WPEP (week physical exercise program) was carried out in 3 sessions each 40 or 60minutes with alternate days per week during 3 months, and with an intensity between 40 to 80 percent of their VO2 max, as the AHA recommends
45387430|NCT00373113|Drug|Capecitabine|1250 mg/m^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
45387431|NCT00373113|Drug|Sunitinib malate|37.5 mg daily, continuous dosing
45387432|NCT01045941|Drug|Gemcitabine/Gemzar|Six cycles of Gemcitabine will be given. Each cycle of Gemcitabine comprises of Gemcitabine 1000 mg/m2 as a 30 minute infusion once weekly for 3 weeks with a fourth week off.
45387433|NCT01045941|Procedure|Laparoscopic Distal pancreatectomy|Laparoscopic resection of the distal pancreas
45501178|NCT03644706|Drug|ADV7103|Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances. The strength is 6.44 (± 10 %) mEq/g of ADV7103 (alkalinizing power).
45501179|NCT03644706|Drug|Placebo|"Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules to be taken by mouth.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules."
45501180|NCT03740919|Drug|LY900014|Administered SC
45387434|NCT00407511|Drug|Pregabalin|Pregabalin will be administered orally, twice a day for 12 weeks, including 4-week dose adjustment phase followed by 8-week maintenance phase. The minimum allowable pregabalin dose during the trial will be 75 mg BID (150 mg/day) and the maximum allowable dose will be 300 mg BID (600 mg/day).
45501181|NCT03740919|Drug|Insulin Lispro|Administered SC
46056689|NCT02726919|Drug|Clobazam|Following a baseline of 12 weeks patients will be started on clobazam, administered orally in b.i.d. schedule. In patients in whom seizure diaries have been kept prospectively prior to study screening visit, retrospective baseline will be accepted. Patients will be titrated up to either seizure freedom, to side effects or to 40 mg/day, whichever comes first
45387435|NCT00384189|Drug|Ciclesonide|inhaled Ciclesonide
45387436|NCT00384189|Drug|Placebo|Ciclesonide placebo-matching inhaler
45387437|NCT00384189|Drug|Salbutamol|Salbutamol inhalation powder
45387438|NCT00326716|Drug|Atazanavir + Ritonavir + Combivir|Capsules, tablets, Oral, initially ATV 300 mg + RTV 100 mg + ZDV/3TC 300/150 mg, dose escalated to ATV 400 mg + RTV 100 mg + ZDV/3TC 300/150 mg, ATV and RTV once daily, lamivudine (ZDV) / zidovudine (3TC) twice daily (BID), up to 36 weeks
45387439|NCT01063192|Drug|Gemcitabine|Arm 1: Gemcitabine alone on D1,8,15 every 28 days for 3 cycles
45387440|NCT01063192|Drug|Gemcitabine, Oxaliplatin, 5-Fluorouracil, Leucovorin (GOFL)|Arm 2: GOFL on D1, 15 every 28 days for 3 cycles(Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
45387441|NCT03983356|Other|Training program|An internet based training program will be offered to GPs. We will also offer face-to-face seminars with academic psychiatrists.
45387442|NCT03978910|Other|measurements of the accuracy of the reaching movements|Euclidian distance between final position and target
45387443|NCT03978988|Device|Carotid Stenting|emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first), and the choice of a previous angioplasty of the extracranial carotid artery lesion will be left to the interventionist discretion.
45501182|NCT03740919|Drug|Insulin Glargine|Administered SC
45501183|NCT03740919|Drug|Insulin Degludec|Administered SC
45501184|NCT01335685|Drug|Ixazomib|Ixazomib capsules
45501185|NCT01335685|Drug|Melphalan|Melphalan tablets
45501186|NCT01335685|Drug|Prednisone|Prednisone tablets
45501187|NCT01335763|Drug|Insulin glargine|10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of <=5.5mmol/L
46056690|NCT00590902|Drug|OSI-774: erlotinib, TarcevaTM|150 mg, 100 mg and 25 mg tablets
46056691|NCT02727153|Other|"Ultra E.R.A.S."|
46056692|NCT02727153|Other|Classic E.R.A.S.|
46056693|NCT05753566|Drug|Rezvilutamide|Specifications of 80 mg; orally, once a day
45387444|NCT03978988|Drug|Procedural Aspirin|After carotid stenting, an intravenous bolus of 250mg of Aspirin will be given at the end of the procedure in case of absence of complication.
45387445|NCT03978988|Drug|Dual dual antiplatelet therapy after 24-hours imaging follow-up|A dual antiplatelet therapy is administered after 24-hours imaging follow-up excluding intracranial hemorrhagic complications (the type and the dose of the dual antiplatelet therapy are left to the discretion of the local practice)
45387446|NCT03978988|Procedure|Intracranial thrombectomy|Intracranial thrombectomy is the endovascular procedure. In the experimental group, thrombectomy will be completed with a extracranial carotid stenting.
45387447|NCT01066078|Other|Echocardiography and SonR recording|
45387448|NCT01063426|Drug|High dose Atorvastatin+enoxaparin|High dose atorvastatin 80mg/day for 7days after index surgery (total knee replacement arthroplasty, TKRA). At the same time Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered.
45501188|NCT02926209|Device|Aer-O-Scope (Colonoscopy)|"Patients in the Aer-O-Scope first arm will undergo a colonoscopy with the Aer-O-Scope, removing any polyps detected, followed by a colonoscopy using a conventional colonoscope, removing any polyps not previously detected with the Aer-O-Scope."
45501189|NCT02926209|Procedure|Colonoscopy (Conventional Colonoscope)|"Patients in the conventional colonoscope first arm will undergo a colonoscopy with a conventional colonoscope, removing any polyps detected, followed by a colonoscopy using the Aer-O-Scope, removing any polyps not previously detected with the conventional colonoscope"
45501190|NCT02988895|Radiation|episcleral brachytherapy|The study intervention is an outpatient, ambulatory procedure performed under local anesthesia with anesthesia assist.
46056694|NCT05753566|Drug|Androgen deprivation therapy (ADT)|Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescription information
46056695|NCT05753566|Radiation|SRT|SRT according to standard of care (66.6-72 grays will be delivered to the bed of prostate ,~50.4 grays to the pelvis if needed)
45387449|NCT01063426|Drug|Enoxaparin|Enoxaparin 40mg SQ/day 12hr before TKRA and on day 1 to day7 after TKRA should be administered.
46056696|NCT02726841|Procedure|Open thoracoabdominal aortic repair + abdominal stenting|Thoracoabdominal aortic dissection (TAAD) repair + bare aortic stent (Djumbodis) implantation
45501191|NCT04466163|Behavioral|Schema Therapy and the Healthy Adult|The protocol 'Schematherapy and the Healthy Adult' (ST-HA, Broersen & Claassen, 2019) is a direct intervention meant to strengthen patients' healthy adult functioning by developing compassion and care for well-being in the face of (childhood) adversity.
45501192|NCT03635671|Diagnostic Test|Optical Coherence Tomography Angiography|Retinal scans will be acquired at each follow up visit
45501193|NCT04462965|Combination Product|Toripalimab|Injection,Specification 240mg/6ml, 3 mg/kg for the dose, iV, every 2 weeks a dose cycle, up to 1 year; Temozolomide: 100mg or 20mg, Every 4 weeks a dose cycle, up to 6 cycles Cisplatin: Injection, 20mg,Every 4 weeks a dose cycle, up to 6 cycles
45501194|NCT04462965|Combination Product|Temozolomide|Placebo：Injection,Specification 240mg/6ml, 3 mg/kg for the dose, iV, every 2 weeks a dose cycle, up to 1 year; Temozolomide: 100mg or 20mg, Every 4 weeks a dose cycle, up to 6 cycles Cisplatin: Injection, 20mg,Every 4 weeks a dose cycle, up to 6 cycles
45501195|NCT01339585|Device|Transcranial direct current stimulation (tDCS)|Eldith Direct Current Stimulator (NeuroConn GmbH, Germany)
45501196|NCT04004325|Drug|FT-4101|FT-4101 will be supplied as active capsules and will be administered per the protocol defined frequency and dose level.
45695844|NCT03653013|Behavioral|Usual standard of care|Participants will receive treatment and diabetes management as usual standard of care from their diabetes care team. They will also complete as part of the study visit: a pediatric quality of life scale(PedsQL,GenericScale and Diabetes Module) and diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study.
46056697|NCT02726841|Procedure|Classic thoracoabdominal aortic repair|Thoracoabdominal aortic dissection (TAAD) repair
46056698|NCT05753488|Diagnostic Test|graft function|renal transplantation
46056699|NCT05187741|Device|mobile health (mHealth)|"A message will be sent on Monday and Friday at 9:00 am for 3 months, the first day they will receive a message focused on adherence and the second day a message focused on motivation. Subsequently, a message will be sent on Mondays for 3 more months.~Reminders for appointments with your treating physician will be sent during the entire intervention period (6 months)."
45387450|NCT00548405|Biological|Alemtuzumab 12 mg|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
45387451|NCT00548405|Biological|Alemtuzumab 24 mg|Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
45387452|NCT00548405|Biological|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
45387453|NCT00958529|Dietary Supplement|Inulin Fiber Supplement|Orange juice fortified with 0, 5g, and 10g of 2 inulin products
46056700|NCT02721615|Procedure|Insertion of intra spinal sub dural pressure monitor|
45387454|NCT04919369|Biological|Atezolizumab|Given IV
45387455|NCT04919369|Drug|Tretinoin|Given PO
45501197|NCT04004325|Drug|FT-4101 placebo|FT-4101 placebo will be supplied as placebo capsule matching in size and color to all the active capsules and will be administered per the protocol defined frequency and dose level.
45501198|NCT04004325|Other|Deuterated Water|Deuterated water will be provided as individual ready-to-use, single dose bottles each containing 50 mL of deuterated water (70%).
45501199|NCT05208489|Other|there is no intervention involved in this study|there is no intervention involved in this study.
46056701|NCT02721615|Procedure|Insertion of sub dural microdialysis probe|
45501200|NCT05185063|Diagnostic Test|Point of Care blood test|The pH will be incorporated into the MIRACLE2 score in a pre-hospital setting. The patients will continue to be treated with standard of care.
45387456|NCT00958607|Behavioral|Timing it Right Stroke Family Support Person Intervention|Intervention delivered by a stroke support person (SSP) in-person during acute care & by telephone during inpatient rehabilitation and community discharge. SSP provides support, information & guidance and gives caregivers Stroke Family Support guide as a resource. SSP will have 1 contact with the caregiver during acute care and a 2nd contact during the last week of inpatient acute or rehabilitation care. The 1st contact while the caregiver is at home will occur 2-3 weeks after the stroke survivor has been discharged from inpatient care and then every four weeks until the caregiver passes the marker question. SSP will then encourage caregiver to contact them if they have any specific questions. The SSP will make one final contact about 8 weeks later
45387457|NCT00958607|Behavioral|Self-directed program|Participants in this arm of the trial will have family caregivers self-direct their use of the Timing it Right Stroke Family Support guide. The research assistant will instruct the caregivers how to self-manage their support needs by providing instruction on how to use the guide, which has an additional section regarding self-management. Caregivers will also be instructed that the guide is organized according to the phases of a stroke survivors' recovery. They will be instructed to review the information in each chapter as it becomes relevant to their current situation
45387458|NCT00958685|Dietary Supplement|ginger|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
45387459|NCT00958685|Dietary Supplement|placebo|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
45387460|NCT00958763|Behavioral|Motivational Interviewing, Single - MIS|The Motivational Interviewing Single Arm is delivered individually to participants in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
45387461|NCT00958763|Behavioral|Motivational Interviewing Group|The Motivational Interviewing Group Arm is delivered to participants in groups in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator and with the group, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
45426194|NCT05794633|Other|Acupuncture|"The patients will be recieved two days a week for 8 sessions with sterile 25*40 mm needles.Selected points are as local points, 2 painful points (ahshi point) in the shoulder region, Large intestine 4, 15, Gallbladder 21, Triple warmer 5, 14 Small intestine 9; as distant points Gallbladder 34 and Stomach 38.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks"
45501201|NCT05745207|Drug|E2086|E2086 tablets.
45501202|NCT05745207|Drug|Placebo|E2086 matched placebo tablets.
45501203|NCT01339663|Drug|cyclophosphamide|Given IV
45501204|NCT01339663|Biological|aldesleukin|Given SC
45695845|NCT03653013|Behavioral|Neuropsychological Consultation|Children and parents in Group 2 will also complete a pediatric quality of life scale (PedsQL,Generic Scale and Diabetes Module),diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study, as well as the self-report form of the BRIEF-2 if they are over age 11. Parents will also undergo a brief literacy and numeracy screening using the Wide Range Achievement Test, complete a parent report assessing their children's executive functioning skills at the start of the study (BRIEF-2) and they will fill out the Family Impact Module.
45695846|NCT03652545|Biological|TAA-T|Patients with newly diagnosed diffuse intrinsic pontine gliomas DIPGs (Group A) or recurrent, progressive, or refractory non-brainstem CNS malignancies (Group B). The goal of this cell infusion will be to initiate an immune response against brain tumors that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen)
45695847|NCT01337505|Drug|INNO-206|INNO-206 at dosages of 230, 350, and 450 mg/m2 (doxorubicin equivalents of 165, 260, and 325 mg/m2) will be administered as a 30 minute IVI on Day 1 of each cycle.
45695848|NCT03741777|Other|Clear oral fluid|clear oral fluid including water, pulp-free juice and tea or coffee without milk.
45501205|NCT01339663|Biological|autologous tumor cell vaccine|Receive T-APC via IV
45501206|NCT01339663|Other|laboratory biomarker analysis|Correlative studies
45501207|NCT01339663|Other|immunologic technique|Correlative studies
45501208|NCT01339663|Other|immunohistochemistry staining method|Correlative studies
45695849|NCT03831087|Diagnostic Test|TAVR-CMR|CMR protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.
45501209|NCT01339663|Genetic|polymerase chain reaction|Correlative studies
45501210|NCT01339663|Biological|therapeutic autologous lymphocytes|Receive adoptively transferred CD8+ antigen-specific T cell clones via IV
45501211|NCT03066999|Procedure|Cystoscopy|Patients will assign to either Group Cystoscopy (catheter placement via cystoscopy)
45501212|NCT03066999|Device|DirectVision|Patients will assign to either Group DirectVision (catheter placement via DirectVision)
45501213|NCT00092599|Drug|MK0653, ezetimibe|
45501214|NCT00092599|Drug|Comparator: ezetimibe, placebo|
45501215|NCT01335841|Device|Navigation station coupled with a 3D fluoroscopy|After randomization, patients will be operated with the conventional method either with navigation station. In the conventional method, the orthopedic surgeon based on anatomical criteria to establish its implants. It uses an image intensifier in 2D mode to monitor the implementation of the implants. In computer assisted surgery, the surgeon uses a navigation station that allows real-time flow instruments to guide its implementation of the implants. It uses an image intensifier in 3D mode on the one hand to achieve a first series of image that will be used for navigation and also to monitor the implementation of the implants.
45501216|NCT03737565|Device|Optimax stent®|Percutaneous coronary intervention with Optimax stent®
45501217|NCT02889133|Drug|Iron-dextran|Approved for clinical use: 1-gram dose IV - diluted in 500 mL, one pint normal saline.
45387462|NCT00958763|Other|Usual Care Group - UCG|The Usual Care Arm is delivered to participants in three brief time-equivalent health promotion sessions. Each session focuses on health promoting activities such as the importance of diet and exercise, need for physical and mental health assessment and enhanced coping for those afflicted with a history of drug and alcohol addiction. In addition participants receive liver health promotion education. Participants are also provided referrals to alcohol treatment programs in the community and offered the 3 series hepatitis A/B vaccine
45387463|NCT00958997|Drug|18F-FP-DTBZ (18F-AV-133)|The subjects will receive a single IV bolus of approximately 10 mCi 18F-AV-133.(Injection will contain no more than 25 µg of non-radiolabeled 19F-AV-133).
45387464|NCT00958997|Biological|Arginine-hydrochloride|A bolus injection of 5g of 10% arginine-hydrochloride will be given over a period of 1 minute.
45387465|NCT00959075|Dietary Supplement|Vitamin B1|100 mg Twice a day
45387466|NCT00959075|Dietary Supplement|Placebo|Sugar pill
45387467|NCT05299775|Diagnostic Test|World Health Organization Quality of Life -Brief -Taiwan version (WHOQOL-BREF-Taiwan version)|"WHOQOL-BREF-Taiwan version is used to measure the quality of life in HIV infected.~Wang Qi nine kinds of TCM constitution Questionnaire is used to measure the constitution of HIV infected."
45387468|NCT00295750|Drug|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days for 364 days.
45387469|NCT00295750|Drug|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days for 364 days.
45387470|NCT00295750|Drug|Leuprolide 7.5 mg|Leuprolide (Lupron Depot) 7.5mg IM (in the muscle every 28 days starting at day 0.
45387471|NCT04910321|Other|diet, physical activities, sleep|lifestyle factors
45387472|NCT04850963|Device|Transcranial direct current stimulation (Anodal tDCS) + dual-task training|"anodal tDCS 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
45695850|NCT03831087|Diagnostic Test|TAVR-CT|CT protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.
45695851|NCT03649503|Other|No intervention|
45695852|NCT03648645|Device|Self measurement of blood pressure|"Patients will perform the measurement of blood pressure at home, on a daily basis, in complying with the rule of 3 stated by the Haute Autorité de Santé (French Health Authority) : i.e. 3 consecutive measurements in the morning and in the evening, after a period of rest Measurements are performed using a blood pressure monitor Bluetooth-connected. If a threshold value is exceeded (and depending on the alert), a consultation will be scheduled (unexpected consultation) and notified to the patient."
45695853|NCT00003459|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Patients with a brain stem glioma will receive Antineoplaston therapy (Atengenal + Astugenal)
45695854|NCT03829215|Device|CAERVest cooling device|The CAERVest device will be filled and placed on the supine patient's chest immediately after return of spontaneous circulation. After admission to the emergency department, the device will be removed, when a temperature below 34°C is reached.
45387473|NCT04850963|Device|Transcranial direct current stimulation (tDCS dualsite) + dual-task traning|"tDCS dualsite 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
45501218|NCT02889133|Drug|Saline|Salt water IV - 500 mL, one pint normal saline.
45695855|NCT04763811|Other|Focus groups|discussion between participants about representations of health, dependance, fragility, and new technologies
45695856|NCT04763811|Other|Individual interviews|Discussion between the searcher and the participant about representations of captors, discretion of captors, wish about feed-backs of captors
45387474|NCT04850963|Device|Transcranial direct current stimulation sham + dual-task training|"tDCS sham 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
45695857|NCT03643107|Drug|Irofulven|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
45387475|NCT00959153|Device|LithoSpace Extracorporeal Shockwave Lithotripter|Shockwave therapy to break up kidney stones
45387476|NCT00959231|Drug|cyclophosphamide|
45387477|NCT00959231|Drug|cyclosporine|
45387478|NCT00959231|Drug|fludarabine phosphate|
45387479|NCT00959231|Drug|mycophenolate mofetil|
45387480|NCT00959231|Other|laboratory biomarker analysis|
45501219|NCT02889133|Procedure|Blood Donation|Standard process of collecting and storing blood and blood components (approximately 450 mL, or a pint of blood). Following donation, the blood will be leukoreduced, packed, and stored in AS-3 solution.
45501220|NCT02889133|Procedure|24-hour PTR|"The way the FDA determines how good blood is for transfusion is called a radioactive 51-Chromium 24-hour post-transfusion red cell recovery study. The purpose is to measure how many of the transfused red cells are still in circulation (being pumped by the heart through blood vessels) 24 hours after transfusion. In order to measure the percent of red cells that are still in circulation, a small amount of the donated blood will be radioactively labeled. This will be infused in one arm and then blood will be collected from the other arm at different time points to measure how much of the transfused red cells are still in circulation."
45848427|NCT03715452|Device|DyeVert Plus Contrast Reduction System|The DyeVert Plus System interfaces with standard manifold systems to provide real-time contrast monitoring and reduce the amount of contrast used in catheterization procedures while maintaining fluoroscopic image quality. System components include a disposable, single-use, sterile DyeVert Plus Disposable Kit that contains a Smart Syringe and DyeVert Plus Module, which is connected to a standard manifold and provides fluid pathway resistance modulation via a dedicated diversion valve. The diversion valve self-adjusts to the manual injection pressure to divert some of the contrast media into the reservoir chamber within the module. This diverted volume of contrast media does not enter the patient.
45848428|NCT03716076|Drug|Carbetocin|50 mcg or 100 mcg bolus of carbetocin
45848429|NCT03835728|Drug|Ocrelizumab|Subjects will be randomized in a 1:1 fashion to receive infusion of Ocrelizumab (2 doses at 300 mg and 1 dose at 600 mg) or matched placebo. The 2 300 mg doses will be administered at day 2 and day 14. The 600 mg dose will be administered during the 6 month visit. The drug will be administered via infusion three times throughout the trial period: after the initial screening, at two weeks from initial infusion, and at 6 months.
45387481|NCT00959231|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
45387482|NCT00959231|Procedure|umbilical cord blood transplantation|
45695858|NCT03643107|Combination Product|Prednisolone 10 mg|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
45695859|NCT02083107|Drug|Misoprostol|Comparison of different routes of administration of 400 micro gram misoprostol
45695860|NCT02083107|Other|Placebo|
45848430|NCT03835728|Drug|Saline|This will be the matching placebo used in the study.
45387483|NCT00959231|Radiation|total-body irradiation|
45387484|NCT03948581|Drug|Vedolizumab SC|Vedolizumab SC liquid.
45387485|NCT00548327|Drug|Atomoxetine|Comparison between Atomoxetine and Placebo
45501221|NCT01333423|Drug|Liposomal Doxorubicin|40 mg by vein administered over 2 -3 hours on Day 4 of a 28 day cycle.
45501222|NCT01333423|Drug|Seliciclib|Starting dose 200 mg by mouth twice daily on Days 1 - 3 of a 28 day cycle.
45501223|NCT03554187|Device|Ultrasonic periodontal Debridement, with appropriate device|Dental procedure that includes therapeutic interventions such as scaling to remove calculus and all soft deposits, root planing to eliminate subgingival calculus and smooth the tooth surface, and root débridement to eliminate subgingival biofilm and lightly mineralized deposits.
45501224|NCT03554187|Biological|Analyzes of periodontopathogenic bacteria|Collection of plaque, to analyze the bacteria in the pocket
45501225|NCT03554187|Genetic|IL1B test|susceptibility to periodontal disease (scratch swab onto the tongue) (no invasive)
45501226|NCT03554187|Biological|Salivary Sampling|Salivette to chew. To analyse salivary microbiota
45695861|NCT04403997|Procedure|Chromoendoscopy|Chromoendoscopy is an endoscopic technique used in the follow-up of inflammatory bowel disease of long evolution. Chromoendoscopy, through the application of specific dyes used directly on the intestinal mucosa, promotes the visualization of mucosal lesions.
45387486|NCT00548327|Procedure|Functional magnetic resonance imaging|Comparison between Atomoxetine and Placebo arms
45387487|NCT00548327|Procedure|Neuropsychological Testing|Comparison between Atomoxetine and Placebo arms
45501227|NCT03554187|Device|Halitosis measure|With appropriate device : halimeter
45501228|NCT01333579|Other|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation, frequency of 1Hz, once a day for ten days.
45501229|NCT00092209|Drug|MK0954A, hydrochlorothiazide (+) losartan potassium|
45501230|NCT00092209|Drug|Comparator: placebo, losartan, hydrochlorothiazide|
45387488|NCT00548327|Drug|Placebo|25 mg, 40 mg, 60 mg and 80 mg Atomoxetine Placebo
45501231|NCT04399473|Behavioral|Pain Neuroscience Education (PNE)|Participates in the experimental group will receive 15mins X 4 sessions of pain education by the eligible trained physical therapist in addition to usual care PT treatment.
45501232|NCT01339741|Dietary Supplement|Vitamin D3|Vitamin D3, oral supplement, 12 weeks
45501233|NCT01339741|Drug|Placebo|Placebo, oral route, 12 weeks
45501234|NCT05184829|Other|selective lymph node dissection|selective lymph node dissection
45501235|NCT05184829|Other|Systemic Lymph Node Dissection|Systemic Lymph Node Dissection
45501236|NCT01482195|Biological|Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus|The study is an open-label, dose-escalation, phase I clinical trial of subretinal administration of rAAV2-VMD2-hMERTK in patients with retinitis pigmentosa due to MERTK mutation.
45501237|NCT01341613|Dietary Supplement|Cardioviva™ supplement capsule|Twice per day (BID), 9 weeks
45501238|NCT01341613|Dietary Supplement|Placebo capsule|Twice per day (BID), 9 weeks
45501239|NCT00003777|Drug|amifostine trihydrate|
45501240|NCT00003777|Drug|cisplatin|
45501241|NCT00003777|Drug|fluorouracil|
45501242|NCT00003777|Procedure|surgical procedure|
45501243|NCT00003777|Radiation|radiation therapy|
45501244|NCT01339819|Drug|Dabigatran|Patients assigned to this group will receive Dabigatran
45501245|NCT01339819|Drug|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
45695862|NCT00925054|Drug|rAvPAL-PEG 0.001 mg/kg|In Part 1, the planned starting dose levels is 0.001 mg/kg
45695863|NCT00925054|Drug|rAvPAL-PEG 0.003 mg/kg|In Part 1, the planned starting dose levels is 0.003 mg/kg
45695864|NCT00925054|Drug|rAvPAL-PEG 0.01 mg/kg|In Part 1, the planned starting dose levels is 0.01 mg/kg
45695865|NCT00925054|Drug|rAvPAL-PEG 0.03 mg/kg|In Part 1, the planned starting dose levels is 0.03 mg/kg
45695866|NCT00925054|Drug|rAvPAL-PEG 0.1 mg/kg|In Part 1, the planned starting dose levels is 0.1 mg/kg
45695867|NCT02335905|Drug|Ceftaroline Fosamil|IV Ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour) for children 2 years of age - 17 years of age (inclusive). IV Ceftarloine Fosamil 10 mg/kg infused 120 (± 10) minutes q8h (± 1 hour) for children 1 years of age - less than 2 years of age (inclusive).
45501246|NCT05208255|Other|Exercise|"NEP is a multimodal exercise program including different motor coordination exercises and cognitive tasks. Exercises are progressed from simple to complex tasks. Varied equipment (such as different sized balls, rackets, tulles, exercises balls, eye bands, ropes etc.) is used during different exercises containing cross-limb movements, throwing, jumping, walking, and cognitive tasks. Although the stages of the NEP and exercise selection are the same for each participant, the use of materials or cognitive tasks selection may differ according to the age and skill of the participant. The cognitive tasks were performed by using different visual (colored cards, numbered cards etc.) or auditory cues.~Motor Imagery Program: Motor imagery (MI) is a dynamic mental state during which the representation of a given motor movement is rehearsed in working memory without overt motor output. MI training will be performed in the form of imagined NEP exercises in the last 15 minutes of the session."
45501247|NCT02963922|Drug|Liraglutide 3.0 mg|Injected subcutaneously (s.c., under the skin) once daily
45501248|NCT02963922|Drug|Placebo|Injected subcutaneously (s.c., under the skin) once daily
45501249|NCT01339975|Biological|Biological sample|"2 blood samples of 10mL + one urine sample~on pre-operative d-1/d, post-operative d1 and d5(+/-2),~one month post-operative,~at the end of the study in the absence of disease progression or at the date of recurrence or progression if the case arises."
45501250|NCT01339975|Biological|Biological sample|"2 blood samples of 10mL + one urine sample~before starting the therapy~at first therapeutic evaluation (2 or 3 months depending on the treatment chosen)~at the end of the study or at the date of disease progression."
45387489|NCT00959309|Behavioral|Strategies to decrease screen time in children|"15 minute session about the health impact of screen time in children and strategies to decrease screen time (removing televisions from the child's bedroom, budgeting screen time, providing a contingency plan for time spent not watching TV, encouraging family meal time, and implementing a one week television turn off, where children are encouraged to spend one week without watching TV/videos). Activities for the child include reading a story about television viewing (The Berenstain Bears and Too Much TV), and creating a list of non TV related activities to replace TV time. The intervention group will receive a CPS handout titled 'Promoting Good Television Habits' and a calendar with stickers for the television turn off.~Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')"
45501251|NCT01340131|Drug|CKD-828|Drug: Telmisartan 40mg + S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
45695868|NCT03827967|Biological|PalloV-CC|The PalloV-CC vaccine uses yeast cell wall particles (YCWP) to serve as an efficient vaccine delivery system as they can contain a broad range of antigenic material, they are rapidly phagocytized by antigen presenting cells, and they are inherently immunogenic. The PalloV-CC vaccine utilizes silicate-capped YCWP to deliver allogenic colon cancer tumor lysate. The vaccine will be given to subjects with resectable colon cancers neoadjuvantly shortly before surgery in order to study the effect of the vaccine on the tumor microenvironment using a well-validated immune scoring system for colon cancer and other immunologic tests.
45695869|NCT00925756|Drug|Maraviroc|Maraviroc will be given dose-adjusted to background HIV treatment (150 mg, 300 mg, or 600 mg twice daily)
45695870|NCT03736005|Other|Exposure of significant critical illness|Exposure. Observational study with all patients invited to follow-up clinic for kidney, muscle and functional assessments.
45848431|NCT03848910|Device|Investigational device - Sound Processor|"At visit 1 the subjects will complete self-reported assessments with respect to pre-study experience using precursor Sound Processor (comparator). At visit 1 the subjects will then receive the Investigational device (Sound Processor) which should be used during the following 6 weeks. At visit 3 the subjects will complete self-reported assessments regarding Investigational device and participate in audiology tests regarding both Sound Processors, comparator and Investigational device. The subject shall decide their preferred choice made by selection between Investigational device and the comparator."
45848432|NCT03861780|Drug|Project X 26ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
45848433|NCT03861780|Drug|Project X 5.1ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
45387490|NCT00959309|Behavioral|Non-Strategical Media Education|Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')
45387491|NCT04720547|Drug|Zolpidem|A nonbenzodiazepine hypnotic
45387492|NCT04720547|Other|No Treatment|The Control condition in which participants do not receive medication.
45501252|NCT01340131|Drug|Combination Therapy|"Drug: Telmisartan 40mg Tablet, Oral, Once Daily~Drug: S-amlodipine 5mg Tablet, Oral, Once Daily"
45501253|NCT00090181|Drug|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
45848434|NCT03861780|Drug|Prevantics Maxi Swabstick|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
45501254|NCT00090181|Drug|Comparator: diclofenac / Duration of Treatment: 4 weeks|
45501255|NCT05207787|Drug|HS-10365|Single or multiple dose(s) of HS-10365 daily or twice every day. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and/or unequivocal disease progression.
45501256|NCT03643380|Device|AHLeveeS System|AHLeveeS System for treatment of overactive bladder
45501257|NCT01336075|Procedure|Percutaneous radiofrequency catheter ablation|Percutaneous radiofrequency catheter ablation around the rights and lefts pulmonary veins, with complete circumferential ablation.
45501258|NCT01336075|Procedure|Mini invasive thoracoscopic radiofrequency ablation|Video-assisted thoracoscopic approach for electrical isolation of the pulmonary veins bilaterally and left atrial appendage excision or exclusion.
45501259|NCT05214261|Other|Safety and efficiency of post operative analgesia between laparoscopic-assisted TAP block and epidural analgesia|"Patients in the TAP group will be given a laparoscopic-assisted TAP block with a total of 2mg/kg of 0.25% bupivacaine in the bilateral subcostal region into four spots of the bilateral subcostal region, two on both sides of the lateral abdomen between the anterior iliac spine and lower costal arch. The TAP block is performed after the first trocar placement before the insertion of other trocars and the beginning of the surgical intervention.~In the control group epidural catheters will be placed using landmark- and loss-of-resistance techniques while the patient is on the operating table. Infusions of 4ml/h containing 0.125% levobupivacaine and 5.5 μg/mL fentanyl will be started with a CADD Solis VIP-infusion pump at the time of anesthesia induction."
45501260|NCT03644238|Diagnostic Test|Oral Glucose Tolerance Test|75g of glucose is consumed
45501261|NCT03644238|Behavioral|Inactivity|Lying or sitting down.
45501262|NCT03644238|Behavioral|Physical activity|20 minutes of fixed intensity exercise on a bicycle ergometer.
45501263|NCT03619785|Drug|Bupivacaine|Patient will be positioned supine or in the lateral decubitus position on the side contralateral to the fracture(s). A 3.5 in 20-gauge needle, extension tubing, and a 30 mL syringe loaded with 0.25% bupivacaine and 3 mL of 1% lidocaine loaded in a 5 mL syringe with a 27-gauge needle will be prepared. The ribs, teres minor, latissimus dorsi, and serratus anterior will be identified with bedside US and the site of entry marked along the lateral aspect of the 4th-5th rib. The skin will be sterilized and lidocaine placed at the site of entry. The needle will be introduced at a steep angle and advanced in-plane, under US-guidance, to the plane superficial to the serratus anterior muscle. A test dose of normal saline will confirm proper needle tip placement with opening of the intramuscular layer. Injection with aliquots of 3-5 mL after negative aspiration will continue until 30mL of 0.25% bupivacaine are administered.
45695871|NCT04372966|Device|Total hip arthroplasty|Corail Total hip arthroplasty system, Depuy. Exeter and Contemporary acetabular components, Stryker.
45695872|NCT04372654|Device|Electroducer Sleeve|The device's safety will be assessed at the radial and femoral puncture site
45695873|NCT03731013|Behavioral|Mediterranean diet (MedDiet)|Participants randomized in the Mediterranean diet group without physical activity will be instructed and supported towards adhering to principles of the Mediterranean diet, without changes in physical activity habits.
45695874|NCT03731013|Behavioral|Physical activity (PA)|Participants randomized in the group physical activity without Mediterranean diet will participate in a structured, supervised PA program to achieve 150 min of moderate PA per week, without changes in dietary habits.
45387493|NCT00959387|Drug|Induction TP chemotherapy|3 cycles of paclitaxel 175mg/m2 and cisplatin 80mg/m2 q3w. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.
45387494|NCT00959387|Radiation|Chemoradiotherapy (CRT)|Patients were treated with 2-dimensional radiation therapy planning (6MV photon beams). A combination of lateral-opposed portals, anterior and lateral wedged fields was used to treat the primary tumor and the lymph nodes. The primary tumor, macroscopically affected lymph nodes and bilateral cervical plus supraclavicular lymph chains were treated with five fractions of 2Gy per week for 5 weeks (up to a total of 50Gy). Gross tumor volume was defined as the primary gross tumor or involved node, and this measure was based on clinical, radiological and endoscopic examinations. An additional margin of 1.0cm was added to the GTV to create the CTV. A boost of five fractions of 2Gy per week for 2 additional weeks (up to a total dose of 70Gy) was prescribed to the CTV plus a margin of 1.0cm.
45387495|NCT00959465|Biological|H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)|Two injections at a 21-day interval (Days 1 and 22)
45387496|NCT04718285|Drug|Montelukast Oral Tablet|3x10 mg oral montelukast first day and other 13 days 1 x 10 mg montelukast
45387497|NCT04718285|Drug|Montelukast plus Favicovir (Favipiravir)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5 and 3x10 mg oral montelukast first day and rest of 13 days 1 x 10mg, concurrently.
45387498|NCT04718285|Drug|Favicovir (Standard Treatment)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5.
45387499|NCT05299619|Device|Tixel|a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling fast water evaporation with low thermal damage to the surrounding tissue (such as charring or ablation).
45387500|NCT00959543|Other|MRI|MRI and clinical investigation
45387501|NCT00959621|Drug|Aspirin|ASA 100 mg once daily per os
45501264|NCT03619785|Drug|Fentanyl, morphine, hydromorphone, hydrocodone, acetaminophen, ketorolac, gabapentin, ketamine, ibuprofen|Oral or IV pain medication as needed.
45501265|NCT03643302|Device|Version BF-1T26 electronic bronchoscope|Interventions involving the therapy of airway clearance and bronchoalveolar lavage by Version BF-1T26 electronic bronchoscope
45501266|NCT02881567|Drug|Daclizumab|High yield formulation
45501267|NCT02962674|Device|prostaFix System|
45501268|NCT03280797|Procedure|Blood sample|2ml blood taken into TruCulture tube
45501269|NCT05184595|Other|Carfilzomib delivered in OH only|Patients receive the whole treatment en OH.
45387502|NCT00959621|Drug|Klexane|Klexane 40 mg sc once daily (HABENOX 1 and 2), Klexane 40 mg twice daily in HABENOX 3
45387503|NCT00959621|Drug|Klexane and ASA|Klexane 40 mgx 1 sc and ASA 100 mg po
45387504|NCT04585919|Behavioral|Paired Screening Intervention|The intervention is the implementation of a paired outreach strategy to patients in need of colorectal cancer screening to offer FIT testing and to complete screening for social determinants of health. These screening activities are part of routine practice but the intervention that is being implemented is the paired outreach for both CRC screening and SDOH screening.
45387505|NCT05299541|Dietary Supplement|Food dish|"All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months~Group A - will receive a dish of food every evening by a person employed by a rescue organization for 6 months~At the end of the meal once a week~All dishes will be photographed at the end of the meal by Android camera, iPhone~A NUTRITION DAY success photo form will be completed and collected ."
45387506|NCT05299541|Diagnostic Test|Indirect calorimetric|• The patient will be measured with an indirect calorimetry device (Fitmate - COSMED Srl. Rome, Italy) to assess the nutritional requirement.
45387507|NCT05299541|Diagnostic Test|Bioimpedance|• The body composition test will be performed by the Bodystat®4000 Bioimpedance Device (BIA 4000, Bodystat, UK). .
45387508|NCT05299541|Behavioral|Questioners|"At 3 times point , in the recruit + 3 month and 6 month 3 questioners will be given:~HADS, Quality of life 36SF and FIM"
45387509|NCT05299541|Dietary Supplement|Plated food dish|"All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months Group b - will receive a food dish every evening by a person employed by a rescue organization with improved appearance of a plate for 6 months.~At the end of the meal once a week~All dishes will be photographed at the end of the meal by Android camera, iPhone~A NUTRITION DAY success photo form will be completed and collected ."
45695875|NCT03731013|Behavioral|Mediterranean diet and physical activity|The combination group (MedDiet + PA) will receive the combination of both interventions.
45387510|NCT04557995|Procedure|Erythropheresis|Draw blood from patient's vein and remove red blood cells as other components would be transfused back.
45695876|NCT04372888|Behavioral|choice decision frame|active choice for genetic testing
45695877|NCT04372888|Behavioral|opt-in decision frame|"gain frame for genetic testing"
45695878|NCT04372888|Behavioral|opt-out decision frame|"loss frame for genetic testing"
45387511|NCT00959777|Drug|DA-3031|
45387512|NCT00959777|Drug|Filgrastim|
45387513|NCT04450745|Behavioral|Exercise in hypoxia|60 minutes training program of mixed exercise in normobaric hypoxic chamber
45387514|NCT04450745|Behavioral|Exercise in normoxia|60 minutes training program of mixed exercise in regular air conditions
45387515|NCT03953183|Other|P3P-1mg|P3P-1mg (P3P product containing 1mg of nicotine.)
45387516|NCT03953183|Other|P3P-2mg|P3P-2mg (P3P product containing 2mg of nicotine.)
45387517|NCT00959855|Other|Pulmonary Rehabilitation|Sixteen, two hourly pulmonary rehabilitation sessions over an eight week period. The first hour will consist of an individualized exercise programme based on exercise field tests. The second hour will consist of an educational component. A home exercise programme of inspiratory muscle training (Threshold(R)IMT (respiratory muscle trainer re:HS730EU-001 single patient use) starting between 15% -30% of PiMax and progress weekly to 60% for 30 mins a day/ 5 dats a week with an inspiratory/expiratory ratio of 3:4. Patients will also be encouraged to walk or undertake an home exercise programme based on a Borg score of between 3 and 5 an additional 3 days a week.
45387518|NCT00961883|Biological|NYVAC-B|New York Vaccinia (NYVAC) vector for HIV-1, delivered intramuscularly by injection at a dose of 1 x 10 ^7 PFU
45387519|NCT00961883|Biological|Placebo|Sodium Chloride for injection, delivered intramuscularly
45387520|NCT00961883|Biological|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10^10 PFU
45387521|NCT00961883|Biological|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10^9 PFU
45387522|NCT00961883|Biological|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10^8 PFU
45387523|NCT00959933|Drug|Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)|
45387524|NCT00959933|Drug|Rebetol 200 Capsules (Schering Corporation, U.S.A.)|
45387525|NCT00960089|Device|LIQUICURE|Topical treatment, 1 time/day, 5 days/week
45501270|NCT05184595|Other|Carfilzomib delivered in OH and HaH combined|Patients receive the first cycle of treatment in OH. Then, they are randomized between exclusive OH treatment and combined treatment in OH and at home with HaH services.
45695879|NCT04372888|Behavioral|enhanced choice (context) decision frame|consequences of genetic testing
45695880|NCT04372888|Behavioral|enhanced choice (norms) decision frame|social norms for genetic testing
45695881|NCT04372888|Behavioral|enhanced choice (affect) decision frame|commitments for genetic testing
45695882|NCT03728985|Device|GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis|Endovascular Aortic Stent-Graft
45695883|NCT04372732|Diagnostic Test|Serum tumor autoantibody detection|All enrolled patients will be tested for ten kinds of tumor autoantibodies using peripheral blood before PD-1 bloackade treatment.
45848435|NCT03889158|Biological|Typhoid Vaccine|All participants will receive the typhoid vaccine.
45848436|NCT03889158|Dietary Supplement|Ascorbic Acid|All participants will receive ascorbic acid.
45695884|NCT02245126|Drug|3-3-4 mix|the drug mix included lidocaine, bupivacaine and water for injection
45695885|NCT02245126|Drug|4-4-2|In this group (4-4-2 group) eligible men were receiving an injection of the 4-4-2 local anesthetic mix ( composed of 4cc of parental lignocaine 2%, 4cc of parental bupivacaine 0.5% and 2cc of water for injection). This mix is given once before commencement of the surgical procedure safe male circumcision.
45695886|NCT04347382|Drug|Honey|1gm/Kg/Day
45695887|NCT04347382|Drug|Nigella Sativa / Black Cumin|80mg/Kg/day
45695888|NCT04347382|Drug|Placebos|Empty capsule with 250ml of distilled water
45848437|NCT04018794|Device|Behavioral/organizational skills intervention augmented with digital health application|Behavioral/organizational skills intervention with digital health application augmentation
45501271|NCT05213793|Diagnostic Test|multi-delay arterial spin labeling|Multi-delay arterial spin labeling is a new method to evaluate the degree of the cerebral perfusion. It can obtain three parameters including CBF,CBV and ATT without radiation,which is similar to the traditional technology. Multi-delay ASL can provide more information of the acute stroke patients.
45501272|NCT03643068|Drug|KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg|The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence [Lys-Ser-Pro-Asn-Pro-Arg-Phe] and [Gln-Arg-His-Lys-Pro-Arg-Glu] attached via a PEG3, Lys and Cys linker [PEG3]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (0.6 mg dose).
45501273|NCT03643068|Drug|KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg|The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence [Lys-Ser-Pro-Asn-Pro-Arg-Phe] and [Gln-Arg-His-Lys-Pro-Arg-Glu] attached via a PEG3, Lys and Cys linker [PEG3]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (1.8 mg dose).
45501274|NCT05184517|Drug|Oph1|0.5% CsA ophthalmic formulation, twice daily for 4 days and once on the fifth day, one eye (right).
45501275|NCT05184517|Drug|Restasis|0.05% CsA ophthalmic formulation twice daily for 4 days and once on the fifth day, one eye (right).
45387526|NCT00960167|Radiation|3DCRT or IMRT|"All enrolled patients will receive 3.5 Gy per fraction (five fractions per week) at the following levels;~Dose escalation by 7 Gy in 2 fractions to maximum of 63 Gy, as follows:~Dose Level I: 3.5 Gy for 12 fractions (42 Gy total) Dose Level II: 3.5 Gy for 14 fractions (49 Gy total) Dose Level III: 3.5 Gy for 16 fractions (56 Gy total) Dose Level VI: 3.5 Gy for 18 fractions (63 Gy total)"
45387527|NCT00962195|Dietary Supplement|purple sweet potato (PSP)-juice|Daily oral intake of 3x 125 ml of PSP-juice or control juice
45387528|NCT00960245|Drug|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)|
45387529|NCT00960245|Drug|Corgard (1 x 80 mg) Tablets (Bristol Laboratories)|
45501276|NCT05207475|Device|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 years after enrollment.
45501277|NCT03644628|Procedure|Laparoscopic repair of anterior and apical pelvic organ prolapse|Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
45387530|NCT00962273|Behavioral|Interactive computerized learning resource|"In a series of interactive scenarios, participants can see themselves in stressful work situations that could arise during an influenza pandemic and reflect on effective ways to work out personal and interpersonal difficulties."
45501278|NCT01336153|Drug|MLC601|group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month
45695889|NCT03726489|Device|Daavlin 7 series 3 panel narrow band phototherapy home units|"Daavlin 7 series 3 panel narrow band phototherapy home units (with 8-12 bulbs and a smaller, flat surface with door, measuring 21 wide, 74.5 tall, and 23.5). This unit is a class II device with a FDA 510K indication for psoriasis, vitiligo and atopic dermatitis/eczema. The unit will have a dosimetry controller, a UV sensor built in that measures the intensity of the light. This sensor will adjust the treatment time to compensate for any variation in output due to aging of the lamps or other factors"
45695890|NCT03726489|Device|narrow band phototherapy clinic units|Office based narrow band phototherapy unit (units typically have at least 24 bulbs in a surround structure
45695891|NCT04372342|Drug|nalbuphine|Nalbuphine hydrochloride has strong analgesic effect, quick effect and long time by stimulating receptor, and has partial antagonistic effect on the receptor, so the incidence of respiratory depression is low in theory.
45387531|NCT00962273|Behavioral|Didactic computerized learning resource|In a non-interactive format (i.e., a series of audio presentations with accompanying PowerPoint-type slides) participants are given information on how to handle stressful work situations that could arise during an influenza pandemic.
45387532|NCT00406653|Drug|abatacept|"Dextrose 5% in water, intravenous (IV).~Placebo on days Induction Period (IP)-1, IP-15,IP-29, IP-57;~3 mg/kg on days IP-1, IP-15,IP-29, IP-57;~~10 mg/kg on days IP-1, IP-15,IP-29, IP-57,~or 30 mg/kg on days IP-1,IP-15 and ~10 mg/kg on days IP-29, IP-57.~Induction Period 3 months~Maintenance Period 12 months"
45387533|NCT00406653|Drug|placebo|"Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months"
45387534|NCT00406653|Drug|abatacept|"~10 mg/kg, every 28 days.~Open- Label Extension Period until the drug is marketed for Crohn's Disease (CD)or the CD development program for abatacept is discontinued"
45387535|NCT03381651|Radiation|Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation|50.4Gy/28F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
45387536|NCT03381651|Radiation|Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation|41.4Gy/23F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
45501279|NCT01336153|Drug|Placebo|group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months
45501280|NCT03629067|Drug|Treatment T|Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide
45501281|NCT03629067|Drug|Treatment R|Co-administration of Fimasartan/Amlodipine and Hydrochlorothiazide
45501282|NCT05182333|Other|Examination|History taking, examination of upper limb
45695892|NCT04372342|Drug|remifentanil|remifentanil
45501283|NCT03644082|Behavioral|Luminosity Trial Memory Match|Working memory task that has users indicate whether the current symbol matches the one presented 2 symbols previously. As the user makes correct responses, the previous symbols reduce in contrast and fade int the background, ultimately disappearing, forcing the user to rely entirely on working memory to achieve success
45387537|NCT00547157|Drug|Panitumumab|Arm 2 consists of panitmumab plus RT
45501284|NCT03644082|Behavioral|Luminosity Trial Memory Matrix|The purpose id to remember the location of squares on a grid
45501285|NCT03644082|Behavioral|Luminosity Trial Famliar Faces|The purpose is to create associations between visual and verbal information
45501286|NCT03644082|Behavioral|Luminosity Trial Brain Shift|The purpose is to decide whether or not cards with numbers and letters are either even or vowels. This measures inhibition, flexibility, and monitoring response set. Also, letterfluency, category fluency, and category switching.
45387538|NCT00547157|Drug|Cisplatin|Cisplatin
45387539|NCT00960479|Drug|Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)|
45501287|NCT03644082|Behavioral|Luminosity Trial Star Search|The purpose is to visually scan several different objects and find the different object in array of pictures. This measures selective attention.
45501288|NCT03644082|Behavioral|Luminosity Trial Word Bubbles|"The purpose is to decide what suffix to use in order to complete a word whena prefix is given. The subject needs to come up with he ending of three different prefixes to complete the word.~This task measures verbal modality, deductive reasoning, integration of multiple bits of information, and flexibility of thinking."
45501289|NCT03644082|Behavioral|Luminosity Trial Color Match|The purpose is to identify whether colors and words match each other. This measures the ability to inhibit a dominant and automatic verbal response
45501290|NCT03644082|Behavioral|Luminosity Trial Ebb and Flow|Identify which direction leaves are pointing or moving depending on their color.This measures inhibition of impulsive and perseverative responding, and the ability to establish and maintain instructional set.
45501291|NCT03644082|Behavioral|Luminosity TrialChalk Board Challenge|purpose is to problem solve quantitative reasoningequationsand to decide which card is greater or if the 2 cards are equal when the math problem is solved.
45695893|NCT04372264|Drug|Paracetamol|1000 mg of paracetamol ( perfalgan 10mg/ml solutionBristol- Myers Squibb_UK) intravenous (IV) was given 70 patients,
45387540|NCT00960479|Drug|Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)|
45387541|NCT00960557|Drug|Combretastatin A1 Diphosphate (OXi4503)|OXi4503 administered IV on Days 1, 8, and 15 of each 28-day cycle.
45695894|NCT04372264|Drug|Dexketoprofen|Second Group: dexketoprofen 50 mg ( arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 70 patients,
45387542|NCT00960635|Drug|1,25-dihydroxy-vitamin D3 (calcitriol)|
45387543|NCT00960635|Drug|placebo|pill without agent
45387544|NCT00960713|Drug|Rituximab (MABTHERA® or RITUXAN®).|patients can be included in the study whatever the dosage used. Most patients will receive a classical 375 mg/m2 dose every week during four times (J0-J7-J14-J21).
45387545|NCT04009889|Dietary Supplement|capsule containing a probiotic blend of 5 different Lactobacilli|n=81 women (verum) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
45387546|NCT04009889|Other|capsule containing Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.|n=81 women (placebo) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
45387547|NCT00962351|Procedure|Total Hip Replacement|
45387548|NCT00962507|Drug|everolimus|Beginning with 5 mg every other day Monday, Wednesday or Friday for a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
45387549|NCT00962507|Drug|panobinostat|10 mg every Monday and Thursday of a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
45387550|NCT00962507|Other|laboratory biomarker analysis|Pre-study, day 1 and day 26 samples to evaluation how the study drugs work in vitro (in a test tube).
45501292|NCT03644082|Behavioral|Luminosiuty Follow that Frog|The purposeis to remember the path a red frog takes as it jump from lilypad to lily pad in a pond. This measures flexibility of thinking on a visual-motor sequencing task and working memory
45501293|NCT03644082|Behavioral|Luminosity Train of Thought|purpose is to guide specific colored trains into corresponding colored matching houses by attending to the different tracks. This measures divided attention.
45501294|NCT01340287|Dietary Supplement|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
45501295|NCT01340287|Dietary Supplement|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
45501296|NCT05207319|Other|integrated Moral Reasoning Development Intervention (MRDI)|The MRDI is comprised of 4 components that are run concurrently: moral reasoning, strategies of anger management and problem-solving and social skills.
45501297|NCT01341691|Other|chewing gum|single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days
45695895|NCT04372264|Drug|Ibuprofen|third group: 400 mg Ibuprofen (İntrafen 400 mg vial-Gen-İstanbul) intravenous (IV) was given 70 patients, which determined to be applied as a group.
45387551|NCT00962507|Other|pharmacological study|Pre-study, day 1 and day 26
45387552|NCT00960791|Device|AZD1656|Oral single dose
45387553|NCT00384033|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
45387554|NCT00384033|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|100 mg tablet, once daily dosing for 8 weeks
45387555|NCT00384033|Drug|Placebo|Matching placebo tablets and capsules, once daily dosing for 8 weeks
45387556|NCT00384033|Drug|Duloxetine 60 mg/day|60 mg capsule, once daily dosing for 8 weeks
45387557|NCT00962663|Drug|ICA-105665|Subjects randomized to receive ICA -105665 will receive 200 mg BID
45387558|NCT00962663|Drug|Ibuprofen|Subjects randomized to receive Ibuprofen will receive placebo to ICA-105665 at all scheduled dosing times on Days 1 to 4 and a single dose of 800 mg Ibuprofen on the morning of Day 4.
45387559|NCT00962663|Drug|Placebo|"Subjects randomized to receive placebo will receive placebo to ICA~-105665 at all scheduled dosing times on Days 1 to 4 and placebo to Ibuprofen on the morning of Day 4."
45501298|NCT05244486|Device|RestoreX 1-6 months (randomized phase)|Study participants are recommended utilize the device for 30-60 minutes, 5-7 days a week starting at 1 month post-prostatectomy and continuing until 6 months.
45501299|NCT05244486|Device|RestoreX 6-9 months (open label phase)|Both the treatment and control arms will be allowed to use the therapy from 6-9 months post-prostatectomy (open label phase). Only straight traction will be used (no counterbending).
45501300|NCT05213403|Diagnostic Test|Evaluation with new scoring system|"Evaluate whether patients who have received surgery in line with the developed scoring system have a better aesthetic and oncological outcomes"
45501301|NCT05213325|Diagnostic Test|Evaluation of serum levels of IL-6 and IL-8|Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits)
45501302|NCT03166371|Dietary Supplement|Liposomal Glutathione (GSH)|Two teaspoons (containing 840 mg GSH, 420 mg/tsp) liposomal GSH (ReadiSorb®) will be taken orally twice daily for a total daily dose of 1680 mg GSH/day. Liposomal GSH will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The study product will be consumed daily for 90 consecutive days after hospital discharge.
45501303|NCT03166371|Other|Placebo|Two teaspoons of placebo product will be taken orally twice daily. The placebo will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The placebo will be consumed daily for 90 consecutive days after hospital discharge.
45501304|NCT05207241|Other|provides guidance on gravitationally assisted breastfeeding|Prior to the first breastfeeding after delivery, the guidance of gravitationally assisted breastfeeding will be provided. The primary breastfeeding position is advised to be the sitting position, supplemented by the lateral position with a time ratio of 4:1. The following guidance will also be given: (1) participating women breastfeed individually without using a breast pump; (2) massage their breasts 4 times a day for 15 minutes each time; (3) breastfeeding time is scientifically matched with infant's schedule; (4) alternative breastfeed, ensuring emptying one breast within 24 hours. Doctors follow up once a month via WeChat. Participants complete the questionnaires. A breast ultrasound will be performed every three months. The infant weight will be measured and recorded 6 months after breastfeeding.
45501305|NCT02962908|Biological|FLU-v|Subcutaneous injection in the upper arm with 500 ug of FLU-v as 0.5ml suspension in 0.01M HCl and 0.01M NaOH
45387560|NCT00962819|Biological|MMR vaccine|People with no antibodies to either mumps, measles and rubella will be offered the MMR vaccine (they may choose to or choose not to receive the MMR vaccine)
45387561|NCT00961025|Drug|DA-1229|"single dose study : DA-1229 1.25,2.5,5,10,20,40,60mg~multiple dose study : DA-1229 5,10,20,40mg"
45387562|NCT00961025|Drug|Placebo|placebo
45387563|NCT00962897|Procedure|Femoral-popliteal bypass|Surgical bypass of blockage in the thigh
45387564|NCT00962897|Procedure|Stent-graft placement|Patients that underwent treatment of blockage in the thigh arteries with balloon angioplasty with stent-graft placement.
45387565|NCT00962975|Drug|peginterferon alfa-2a [Pegasys]|dosage at discretion of investigator based on standard of care (180mcg sc weekly) for up to 48 weeks
45387566|NCT01046097|Biological|Synflorix™|Intramuscular administration of three doses/two doses/one dose of primary vaccination/the booster dose/ catch-up dose(s) of Synflorix according to local prescribing information.
45387567|NCT01046175|Procedure|Air-stacking with a manual resuscitator|Stacking air into the lungs up to maximal insufflation capacity (MIC)with a manual resuscitator
45387568|NCT01046175|Procedure|Air-stacking with ventilator|Stacking air into the lungs to maximal insufflation capacity (MIC) with ventilator
45387569|NCT04009655|Other|music|music selected by musician
45387570|NCT00075387|Drug|Carboplatin|Given IA
45695896|NCT04366570|Other|clinical assessment of the shoulder and the cervical spine includes stress guideline tests|As a result of statistical processing, we are planning to obtain the most sensitive and specific tests from the clinical examination protocol
45387571|NCT00075387|Drug|Cyclophosphamide|Given IV
45387572|NCT00075387|Drug|Etoposide Phosphate|Given IV
45387573|NCT00075387|Other|Quality-of-Life Assessment|Ancillary studies
45387574|NCT00075387|Drug|Sodium Thiosulfate|Given IV
45695897|NCT02083809|Drug|intravenous oxytocin|30 units of oxytocin added to 500ml of inert IV fluid (saline, lactated ringer)
45387575|NCT00963131|Drug|antioxidants tablets|vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.
45387576|NCT00963209|Drug|tamoxifen citrate|
45387577|NCT00963209|Other|laboratory biomarker analysis|
45387578|NCT00963209|Other|pharmacological study|
45387579|NCT00963287|Drug|bascial prescription plus or minus herbs depend on symptoms|Decoction ,two times a day
45387580|NCT00961337|Biological|Trivalent inactivated influenza vaccine|one dose
45387581|NCT00963365|Drug|AZD6765|Single oral dose and single IV infusion of AZD6765
45387582|NCT00963365|Drug|AZD6765|Once-daily oral dose of AZD6765 or placebo on Day 1 and on Days 4 through 9.
45695898|NCT02083809|Drug|Intravenous Fluids and Electrolytes|500 ml of inert IV fluid
45695899|NCT02244112|Drug|Oprozomib|Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.
45695900|NCT02244112|Drug|Midazolam|Subjects will receive a single oral dose of midazolam 2 mg in Period 1 and oral midazolam 2 mg per dose in Period 2.
45695901|NCT03723681|Drug|Quizartinib|Quizartinib is provided as 20 mg tablets for oral administration
45695902|NCT04366180|Dietary Supplement|Probiotic|The probiotic group will received one capsule with Lactobacillus K8 per day (3x10^9 cfu/day) during 2 months
45695903|NCT04366180|Dietary Supplement|Control|The control group will received one placebo capsule per day during 2 months
45695904|NCT03722589|Biological|Flublok|0.5 mL intramuscular dose of Flublok
45695905|NCT03722589|Biological|Flucelvax|0.5 mL intramuscular dose of Flucelvax
45695906|NCT03722589|Biological|Fluarix|0.5 mL intramuscular dose of Fluarix
45695907|NCT03722589|Biological|Fluzone|0.5 mL intramuscular dose of Fluzone
45695908|NCT03722589|Biological|Fluzone High-Dose|0.5 mL intramuscular dose of Fluzone
45695909|NCT04372420|Drug|RhBMP-2 absorbable sponge in grade II furcation|The collagen sponge is impregnated with rhBMP-2 at a concentration of 0.5 μg/ml/1cm3 and were stored at 4°C. This rhBMP-2 impregnated collagen sponge was then dispensed at grade II furcation site
45387583|NCT00963443|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|2 Sachets of 500 mg Aspirin Complex.
45387584|NCT00963443|Drug|Pseudoephedrine|2 Sachets of 30 mg Pseudoephedrine
45387585|NCT00963443|Drug|Placebo|Matching Placebo
45387586|NCT00963521|Biological|therapeutic autologous dendritic cells|
45387587|NCT00961493|Behavioral|Acceptance based behavioral therapy|16 individual psychotherapy sessions focused on psychoeducation about anxiety, anxious responding, the function of emotions, mindfulness, and problems with efforts to constrict one's emotional experience; training in mindfulness skills; practice applying mindfulness skills in daily life, including acceptance of, rather than efforts to control, internal experience; and identification of values in areas of life and practice engaging in chosen actions.
45387588|NCT00961493|Behavioral|Applied relaxation|16 sessions of individual psychotherapy focused on psychoeducation about anxiety and anxious responding; training in multiple forms of relaxation; early cue detection; and practice applying relaxation in daily life.
45387589|NCT00961727|Other|Bedside Paediatric Early Warning System (Bedside PEWS)|The Bedside PEWS is comprised of 4 components; [1] an expert derived, multi-centre validated severity of illness score, [2] an inter-professionally developed documentation record into which the severity of illness score is embedded, [3] a series of score-matched care recommendations based on the opinions of over 280 paediatric health care professionals, and [4] an educator-developed education-implementation program.
45387590|NCT00963833|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients under daily life treatment receiving Betaferon according to local product information.
45387591|NCT00964067|Other|Exercise training|Interval training at 90% of max heart rate. Warm-up of 10-15 minutes up to 70% of HRmax, then 4 minutes of exercise at 90%. 3 minutes of active pause between the intervals. Total 45 minutes of exercise. Twice a week.
45387592|NCT00967655|Biological|panitumumab|
45387593|NCT00967655|Drug|capecitabine|
45387594|NCT00967655|Drug|irinotecan hydrochloride|
45387595|NCT00967655|Procedure|neoadjuvant therapy|
45387596|NCT00967655|Procedure|therapeutic conventional surgery|
45387597|NCT00967655|Radiation|radiation therapy|
45387598|NCT01563419|Device|Indicator magnifying window (Izumi Planning Co.)|"IZUMI PLANNING CO,.LTD.Tokyo.Japan~Material: Polypropylene with polycarbonate lens"
45387599|NCT00967733|Dietary Supplement|Flaxseed oil-Olive oil|2 or 4 gr per day alpha-linolenic acid pill and olive oil used for cooking
45387600|NCT00967733|Dietary Supplement|Olive oil-olive oil|1 gr olive oil pill and olive oil used for cooking
45387601|NCT00967733|Dietary Supplement|Flaxseed oil-sunflower oil|2 or 4 gr per day alpha linolenic acid pill and sunflower oil used for cooking
45387602|NCT00967733|Dietary Supplement|Olive oil-sunflower oil|1 gr olive oil pill and sunflower oil used for cooking
45387603|NCT00546377|Biological|filgrastim|
45387604|NCT00546377|Biological|pegfilgrastim|
45387605|NCT00546377|Biological|rituximab|
45387606|NCT00546377|Biological|sargramostim|
45387607|NCT00546377|Drug|cyclophosphamide|
45387608|NCT00546377|Drug|mitoxantrone hydrochloride|
45387609|NCT00546377|Drug|pentostatin|
45387610|NCT00546377|Genetic|fluorescence in situ hybridization|
45387611|NCT00546377|Genetic|gene rearrangement analysis|
45387612|NCT00546377|Genetic|polymerase chain reaction|
45387613|NCT00546377|Genetic|protein expression analysis|
45501306|NCT02962908|Biological|adjuvanted FLU-v|Subcutaneous injection in the upper arm with 500ug of FLU-v emulsified in 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection
45387614|NCT00546377|Other|flow cytometry|
45387615|NCT00546377|Procedure|biopsy|
45387616|NCT00967889|Genetic|gene expression analysis|
45387617|NCT00967889|Genetic|protein analysis|
45387618|NCT00967889|Other|biologic sample preservation procedure|
45387619|NCT00967889|Other|laboratory biomarker analysis|
45387620|NCT00964301|Other|Telemedicine Education|"Student Asthma Education. Each student will engage in 6 age-appropriate sessions on various aspects of asthma health.~Caregiver Asthma Education. The primary caregiver will engage in 2 asthma education sessions.~School Nurse Asthma Education. School nurses will participate in 2 sessions.~Primary Care Provider (PCP) Communication. The PCP of the intervention group participant will be notified of his/her patient's baseline asthma assessment. They will receive updates summarizing each telemedicine intervention."
45387621|NCT00964301|Other|Usual care|Participants will receive asthma care by their PCP with no education sessions or PCP communications by the research staff.
45387622|NCT00967967|Drug|Medication Mometasone furoate and desloratadine|One month treatment with both drugs
45387623|NCT00968045|Drug|Fibrinogen|Fibrinogen 2 gr in 100 ml sterile water. The infusion is given during 15 minutes
45387624|NCT00964379|Procedure|intraperitoneal or extraperitoneal colostomy|creation of colostomy
45387625|NCT00964457|Drug|cetuximab|cetuximab 500mg per meter square every second week
45387626|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
45387627|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
45387628|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
45387629|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
45387630|NCT00964691|Drug|Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
45387631|NCT00964691|Drug|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
45501307|NCT02962908|Biological|Saline|Subcutaneous injection in the upper arm with 0.5ml of saline
45501308|NCT02962908|Biological|Adjuvanted placebo|Subcutaneous injection in the upper arm with an emulsion made with 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection
45501309|NCT03642756|Device|different intra-arterial catheter size|in placebo group, patients were cannulated with 20 gauge intra-arterial catheter. In experiment groups, patients were cannulated with 22 gauge or 24 gauge intra-arterial catheter.
45501310|NCT02962284|Drug|abiraterone acetate with Methylprednisolone|YONSA 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
45501311|NCT03642600|Dietary Supplement|dietary advice plus myo-inositol and folic acid|dietary advice and lifestyle interventions and myo-inositol
45501312|NCT03642600|Drug|dietary advice plus Liraglutide Pen Injector|dietary advice and lifestyle interventions and liraglutide pen injector
45501313|NCT03642522|Device|repetitive transcranial magnetic stimulation|rTMS is a Health-Canada- and FDA-approved treatment for treatment-resistant depression (TRD), using focused magnetic field pulses to stimulate brain regions involved in emotion regulation, safely and non-invasively. rTMS can be applied at varying discharge frequencies which have differential effects on cortical excitability. At a low frequency (≤ 1Hz), rTMS reduces cortical excitability, while at frequencies greater than 1 Hz, rTMS facilitates cortical excitability3. In MDD, either high- frequency rTMS (HF-rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC) or low- frequency rTMS (LF-rTMS) applied over the right DLPFC have similar efficacy. This study utilizes low frequency rTMS to the right DLPFC.
45501314|NCT03642444|Device|Cane|Assistive walking device
45501315|NCT03642444|Device|Elasticated worn orthotic-garment|Assistive walking device -elasticated worn orthotic garment
45501316|NCT03642288|Drug|Gastrografin|Patients with CRE-induced SBO or ASBO both received GG challenge.
45695910|NCT04372420|Procedure|PLATELET RICH FIBRIN in grade II furcation|For preparation of PRF, patient's venous blood is collected into 10ml glass tube or glass-coated plastic tube and centrifuged at 2700 rpm for 12min which leads to two different layers in the test tube, the upper platelet rich fibrin and the lower RBC portion. The formed PRF clot could then be removed from the glass tube and used in grade II furcation
45387632|NCT00964769|Biological|pneumococcal polysaccharide vaccine|single intramuscular injection of 0.5 ml Pneumo23® (Sanofi-Aventis, Lyon France)
45501317|NCT03641352|Drug|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759
45501318|NCT03641352|Drug|Placebo|Placebo, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759. CKD-501 placebo will be changed to CKD-501 from extension study to EOS(end of study).
45501319|NCT03641274|Other|Case-management intervention for frequent users of the emergency department|The CM intervention to be implemented is an evidence-based practice. It consists of individualized services based on a detailed baseline evaluation using validated scales to identify all of the social and medical needs of each FUED. The CM team provides counseling and education on health care utilization, substance abuse and the social determinants of health directly to the FUEDs, using skills such as motivational interviewing and cross-cultural competences. Additionally, the CM team provides concrete services including, referral to psychiatric or substance abuse treatment, or medical services (such as a GP or medical specialist), on a case-by-case basis. Another key element of the CM intervention is to connect all health care or social service providers within the hospital or in the community, promoting continuity of care and improving the FUEDs' ability to navigate the complex health care system.
45554666|NCT04915677|Procedure|Soft tissue augmentation with subepithelial connective tissue graft (SCTG)|After local anesthesia a mesio-distal crestal incision will be performed reaching the alveolar bone. Split thickness dissection performed both buccal and palatal. Subepithelial connective tissue graft will be harvested and inserted beneath the mucoperiosteal flap and stretched buccally and lingually using a modified horizontal mattress suture. The flap margins at the crest will be adapted using single interrupted sutures in order to achieve a primary closure of the flap.
45695911|NCT04372576|Diagnostic Test|Assessment of ventilator-associated pneumonia criteria|Diagnosis of ventilator-associated pneumonia is based upon the routine daily clinical and laboratory parameters.
45695912|NCT02244190|Drug|Tipranavir|New oral solution (back up) formulation
45695913|NCT02244190|Drug|Tipranavir|
45695914|NCT02244190|Drug|Ritonavir|
45695915|NCT00954915|Biological|teplizumab|Cohorts 1-5: escalating doses of subcutaneously administered teplizumab; cohort 6: intravenous administration of maximum tolerated subcutaneous dose.
45387633|NCT00964847|Behavioral|Yoga exercise program|Subjects in the yoga exercise program participate in structured bi-weekly 1.5 hour yoga classes held at a yoga studio as well as develop a weekly hour-long home practice over the 6 months of the study.
45501320|NCT03644004|Other|frequency of diabetes mellitus, type 2, diagnosis in patients with medical history of gestational diabetes.|"Patients will be contacted by mail with sending of the information notice to ask them to participate in the study.~If they don't reply, the subjects will be called by phone by the investigator to collect their non opposition of participation at the study.~During this call, the investigator will be able to answer all the questions about the study.~The report of this telephone conversation will be register in the medical file of the patient.~Then, we will collect informatic data from the hospital concerning the patients.~After that they will be contacted by phone to answer a survey. Beside, another secure survey will be send by email to each patient's family doctor.~To finish, crossing data between those of the patients and the family doctor and anonymisation of the data."
45387634|NCT00964847|Behavioral|Blood pressure education/walking program|The program will consist of small group health education classes and a walking program. Subjects will be expected to attend a dietician-led nutrition class twice a month. On alternate weeks the subjects will be given either motivational talks about a variety of topics including weight loss, walking programs, and healthy lifestyle choices or they will be given educational DVDs or literature to read on the weeks that they are not attending a BPEP class. These subjects will all receive 12 nutrition classes and 12 motivational experiences. The subjects will also be expected to walk 6 days a week gradually increasing to 180 minutes of walking per week or 10,000 steps per day.
45501321|NCT03643926|Procedure|Arthroscopic Brostrom|Brostrom-Gould lateral ligament ankle reconstruction performed by arthroscopic view
45387635|NCT00968357|Drug|SCV-07|"SCV-07 dosage will remain the same throughout the study for each cohort. Monotherapy Lead-in Phase Treatment (SCV-07) for 4 weeks. Combination Treatment (SCV-07 and ribavirin) for 4 weeks, following Lead-in Phase. Re-treatment with peg INF and RBV will be offered in the Follow-up to patients who in the opinion of the investigator may benefit from treatment. All patients will have a total of 3 follow-up visits for safety assessments. Women of childbearing potential will be followed up monthly for approximately up to 6 months after the end of treatment visit. If pregnancy occurs within the follow-up period, it needs to be followed through 8 weeks after the end of pregnancy."
45387636|NCT00968435|Other|bevacizumab, cisplatin, cetuximab, radiation therapy|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions. A total dose of 70Gy is planned for the primary tumor site over approximately 33 treatment days. Day 1 will refer to the first day of radiation therapy. Concurrent with radiation therapy, patients will receive cisplatin (50 mg/m2 IV on Days 1, 2 and 22, 23) and bevacizumab (15 mg/kg IV on Days 1 and 22). Cetuximab will be administered according to the Bonner regimen (4),with a loading dose approximately 7 days prior to the start of radiation therapy (400 mg/m2 IV once, on approximately Day minus 7), followed by weekly cetuximab infusions (250 mg/m2 IV weekly X 7 infusions) until the completion of radiation therapy.
45387637|NCT00965003|Procedure|MRI scan|Standard of Care
45387638|NCT05253287|Drug|Growth Hormone|GH therapy will be initiated at a low dose of 2U/day and titrated slowly based on IGF-1 levels) subcutaneously for 1 year.
45501322|NCT03643926|Procedure|Open Brostrom|Brostrom-Gould lateral ligament ankle reconstruction performed by an open approach.
45501323|NCT03640884|Drug|Xueshuantong-Injection|Xueshuantong-Injection is a kind of natural compound injection extracted from Chinese herb Notoginseng. The major bioactive ingredient is panax notoginseng saponins.
45501324|NCT03641040|Diagnostic Test|Video-oculography|measure and analyze angles of ocular deviations between dominant and non-dominant eye using VOG with alternate cover.
45501325|NCT03641040|Diagnostic Test|Alternative prism cover test|measure and analyze angles of ocular deviations between dominant and non-dominant eye using APCT
45695916|NCT00926380|Drug|denosumab|denosumab: 60 mg SC every 6 months
45695917|NCT00926380|Drug|teriparatide|teriparatide: 20 mcg SC QD
45695918|NCT03827187|Other|Motor imagery based EEG-BCI|Information gathered in this study may be useful when considering diagnosis of prolonged disorder of consciousness and successful adoption of device could lead to assistive communication intervention with therapeutic benefits. Participants undergo quick assessment to test ability to engage in task, if successful this implies they are minimally conscious, have some awareness of self and memory intact to remember commands. During training participant undergoes multiple sessions whereby they are conducting two different imagined movements to move a sound across the azimuthal plane in a direction dictated by an auditory cue. Participant will receive auditory feedback on the position of the sound which acts as a reflection of how well the participant is engaged in the task in terms of performance and consistency across trials. The participant will move on to use the imagined movements to answer a series of biographical, situational, basic logic and numbers/letters questions.
45387639|NCT00968513|Behavioral|Brief Intervention|(N=475) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization
45387640|NCT00968513|Behavioral|Extended Treatment|(N=475) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.
45695919|NCT04366414|Other|hook breathing removing nose-clip|"Participants will perform 3 days per week of usual training, involving intense exercise 8 submaximes-dynamic apnoeas with 3-minute recovery between each one per session, and continuous training of free style swimming at moderate effort over 30 minutes, including warm-up, recovery between intervals and cool down.~The experimental breathing protocol consisted on to remove nose-clip previous to surface and then perform hook breathing during 20 seconds."
45695920|NCT04366414|Other|usual breathing (UB)|Participants will perform 3 days per week of usual training, involving intense exercise 8 submaximes-dynamic apnoeas with 3-minute recovery between each one per session, and continuous training of free style swimming at moderate effort over 30 minutes, including warm-up, recovery between intervals and cool down.
45387641|NCT00968513|Behavioral|Usual Care|brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
45387642|NCT00968591|Drug|Everolimus|
45387643|NCT00968903|Drug|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
45387644|NCT00969059|Drug|GW856553|GW856553 is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered 7.5mg bid, orally with food at breakfast and dinner.
45387645|NCT00969059|Drug|PLACEBO|Matching Placebo is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered orally with food at breakfast and dinner.
45387646|NCT00969137|Drug|saline|intravenous saline
45387647|NCT00969137|Drug|Nicotine|Intravenous nicotine
45387648|NCT00965315|Drug|Rosuvastatin,SFC fenofibrate|"Rosuvastatin 10 mg once daily~Rosuvastatin 5 mg + SFC fenofibrate 160 mg"
45387649|NCT00969215|Device|Lumenis fractional carbon dioxide laser|Laser resurfacing of a burn scar
45387650|NCT00969293|Drug|FOV2302 (Ecallantide)|"Single intravitreal injection into the relevant eye.~Five dose levels will be studied from 5 to 90µg and a maximum of 6 subjects will be included at each dose level.~Duration of Treatment: Single injection with 3 months follow-up."
45387651|NCT00969371|Device|posterior chamber IOL implantation|
45387652|NCT00969371|Device|Experimental TetraFlex Study IOL|TetraFlex IOL implanted
45387653|NCT00969449|Drug|Naproxen Sodium, (BAY H6689)|One dose of Naproxen sodium extended release 660 mg under fasting conditions
45695921|NCT02244268|Drug|ALNA®|
45695922|NCT04366492|Other|Prevalence of blood borne viral infections (HBV/HCV/HIV)|rapid finger prick test for HCV Ab, HBsAg and HIV and a questionnaire
45695923|NCT04365946|Procedure|Gastroscopy|Upper GI endoscopy and biopsy
45848438|NCT04096482|Device|Peregrine Drivable ENT Scope|Peregrine, developed by 3NT Medical, is a single-use disposable handheld endoscope, which is thinner and more flexible than other endoscopes. The endoscope includes a camera at its end and a working channel. The thin endoscope provides a means to visualize the nasal cavity and paranasal sinus space and to deliver irrigation to treat the sinus ostia (drainage openings) and spaces within the paranasal sinus cavities
45387654|NCT00969449|Drug|Naprelan, (BAY H6689)|One dose of Naprelan 500 mg (2 tablets) under fasting conditions
45387655|NCT00965393|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
45387656|NCT00965393|Drug|Placebo|Systemic infusion of placebo (saline)
45387657|NCT00965393|Drug|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140)
45387658|NCT00965471|Drug|cipher prescription 1|Drug granules include ginseng,RADIX NOTOGINSENG,prepared RHIZOMA PINELLIAE with alumen radix glyrrhigae calcaren once daily for 180 days
45387659|NCT00965471|Drug|cipher prescription 2|Placebo include amidon、bitter principles and diluents bases once daily for 180 days
45387660|NCT00965549|Drug|INSULIN GLARGINE (HOE901)|LANTUS®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
45387661|NCT00965549|Drug|Insulin aspart|NovoMix® 30: Suspension for injection. 100U/mL in a prefilled pen (FlexPen®)
45387662|NCT00965549|Drug|Insulin Glulisine|APIDRA®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
45387663|NCT00969527|Dietary Supplement|Oncoxin + Viusid|50 ml of Oncoxin + Viusid (Orally administered) twice a day, for 12 weeks.
45387664|NCT00969527|Dietary Supplement|Placebo|50 ml of Placebo (orally administered) twice a day, for 12 weeks.
45387665|NCT00969605|Procedure|Comparison of two different modes for weaning from mechanical ventilation|Chronic obstructive pulmonary disease patients under mechanical ventilation were randomized to adaptive or pressure support ventilation modes when they met the weaning criteria.
45387666|NCT00969683|Device|Tracheal intubation|Tracheal intubation using a Double lumen tube without a hook
45387667|NCT00969683|Device|Tracheal intubation|Tracheal intubation with a Double lumen tube with a hook
45501326|NCT03641976|Drug|A-FOLFOXIRI|"Arm I (A-FOLFOXIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV~Drug: oxaliplatin Given IV"
45501327|NCT03641976|Drug|Arm II (A-FOLFOX/A-FOLFIRI)|"Arm II (A-FOLFOX/A-FOLFIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV"
45501328|NCT01069692|Drug|SBR759A|SBR759A 6g daily
45501329|NCT01069692|Drug|SBR759A|Placebo Comparator 0g daily
45501330|NCT01069692|Drug|SBR759A|SBR759A 3g daily
45501331|NCT01069692|Drug|SBR759A|9g daily
45501332|NCT01069692|Drug|SBR759A|12g daily
45501333|NCT03621228|Device|MindfulGarden|MindfulGarden (MG) is an interactive digital technology that combines use of a smart television with sensors to intelligently generate content based on patient voice and gesture input, triggering a multi-layered visual 'garden' on-screen to arrest and de-escalate anxiety and aggression in treatment of hospitalized elderly diagnosed with hyperactive delirium.
45501334|NCT03641898|Procedure|FFR-guided PCI|After the angiographic screening for lesions with 40%-90% diameter stenosis, FFR will be performed according to standard protocol using the s5 console and PrimeWire Prestige PLUS coronary pressure wire (Volcano Corporation, San Diego, California). FFR is calculated as the ratio of mean distal intracoronary pressure measured by the pressure wire, and the mean arterial pressure measured through the coronary guiding catheter. An FFR ≤0.8 or >90% diameter stenosis should result in a treatment decision for revascularization by PCI and lesions with FFR >0.80 are defined as FNLs and should result in deferral of PCI.
45501335|NCT03641898|Diagnostic Test|Intravascular ultrasound|After the successful FFR-guided PCI, IVUS will be performed in all FNLs with the ultrasound Imaging Catheter Atlantis™ SR Pro (40 MHz, mechanical-type transducer, 3.2 F, Boston Scientific Corporation, Natick, MA, USA). Quantitative analyses of grayscale IVUS include contouring external elastic membrane (EEM) and luminal borders and the measurement of EEM cross-sectional area (CSA), luminal CSA, plaque and media CSA, plaque burdenand remodeling index. Virtual assessment of plaque is performed with iMap software (QIvus 2.0; Medis Medical Imaging Systems, Leiden, The Netherlands). Plaque components are categorized as dense calcium, necrotic core, fibrofatty, and fibrous tissue and reported as absolute area and proportion of total plaque area.
45501336|NCT01344876|Drug|OPB-51602|once daily during the treatment period
45695924|NCT03823209|Behavioral|Social Network|Leaders of social networks will be statistically determined. Over 5 small-group training sessions, these leaders will be trained to communicate to their social network members accurate information about PrEP and its availability; correct PrEP misconceptions and negative stereotypes; endorse PrEP use and its benefits; and strengthen friends' attitudes, intentions, perceived peer norms, and self-efficacy regarding PrEP as a personal HIV protective strategy.
45695925|NCT03823209|Behavioral|Brief HIV Prevention Counseling|Participants will receive brief (15-minute) counseling on how to prevent HIV infection.
45695926|NCT00870051|Device|Endurant Stent Graft|Endurant Stent Graft implantation
45695927|NCT03630315|Drug|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
45387668|NCT00965705|Behavioral|Therapy|Individual Therapy and Group Therapy
45387669|NCT00965783|Other|Restriction|Time in bed for each subject is restricted by two hours per night for 4 nights
45387670|NCT00965783|Other|Extension|Bedtime is extended by 2 hours per night for 4 nights
45387671|NCT00969839|Device|NovaLign Intramedullary Fixation System|Intramedullary fixation of broken humerus
45387672|NCT00965861|Other|Tissue Registry Study|If a patient consents to allowing the use of their tumor tissue sample(s) for testing/analysis at a future date, their name and information will be stored electronically in a registry that will be managed by SCRI. SCRI may then use the information contained in this registry (such as disease indication, demographic information, etc.) at any time in the future to select tissue samples on which to perform testing/analyses.
45501337|NCT03641586|Drug|BGB-283|
45501338|NCT05183178|Drug|Prasugrel 10 mg p.o|Prasugrel 10 mg once daily p.o. Patient >75 years of age or <60 kg will receive 5 mg prasugrel OD.
45501339|NCT05183178|Drug|Ticagrelor 90 mg|Ticagrelor 90 mg twice daily p.o.
45501340|NCT03640806|Other|PHYSICAL ACTIVITY|3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
45501341|NCT03572426|Other|genotyping all subjects|genotyping using SNaPshot genotyping method.
45501342|NCT02846324|Drug|GBT440|Capsules which contain GBT440 drug substance in Swedish orange
45501343|NCT02846324|Drug|Placebo|Placebo capsules
45501344|NCT02240342|Drug|Bone marrow transplant into ovarian artery|Bone marrow progenitors mobilized to peripheral blood, obtained by plasmapheresis and infused into the ovarian artery
45501345|NCT03576092|Diagnostic Test|Lung Ultrasound|Lung sonography will be performed on a SonoSite portable ultrasound machine with a C60e 5 - 2 MHx 30cm probe using a modified standard technique examining four lung regions; anterior mid-clavicular high and low on left and right sides, and one on each side posteriorly) in the semi-recumbent position.
45501346|NCT03161093|Drug|Fasinumab|Solution for injection in pre-filled syringe
45501347|NCT03161093|Drug|Naproxen|Pharmaceutical form: Capsule
45695928|NCT03630315|Drug|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
45695929|NCT03630315|Drug|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
45695930|NCT03630315|Drug|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
45695931|NCT03630315|Drug|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
45695932|NCT03630315|Drug|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
45695933|NCT03630315|Drug|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
45501348|NCT03161093|Drug|Fasinumab-matching placebo|Solution for injection in pre-filled syringe
45501349|NCT03161093|Drug|Naproxen-matching placebo|Capsule
45501350|NCT02847650|Drug|Placebo|
45695934|NCT00929344|Drug|Pregabalin|Two 150 mg capsules, 150 mg/am and 150 mg/pm (Total dose, 300mg/d), 12 week duration. Dose may be increased up to 600 mg/d or reduced to 150 mg/d based on subject response and tolerability.
45501351|NCT02847650|Drug|PF-06649751|
45501352|NCT03573440|Other|mindful education on eating|Mindful eating education material: mindful eating handout by move.va.gov. It includes topics such as: observe your body, do not judge yourself, notice your reaction to food and savor your food.
45501353|NCT03573284|Diagnostic Test|fractional exhaled nitric oxide(FeNO)|FeNO level was evaluated according to the American Thoracic Society (ATS)/ERS recommendations using a NIOX MINO analyzer (Aerocrine, Solna, Sweden) .Subjects were informed to deeply inhale NO-free air and immediately exhale in full via a mouthpiece at a constant flow rate (50 ml/s) for 10s.
45501354|NCT03573284|Diagnostic Test|impulse oscillometry(IOS)|The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.
45501355|NCT03576014|Biological|BD03|BD03 is to be administered intramuscularly 6 weeks and 2 weeks prior to kidney transplant and 2~4 weeks after the transplant.
45501356|NCT03575858|Device|Barrel shaped interdental brush|Barrel shaped interdental brush Size SS 0.8mm
45501357|NCT03575858|Device|Tapered interdental brush|Tapered interdental brush Size SS 0.6mm
45501358|NCT03575780|Drug|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% will be used in subjects with Clinically typical Actinic Keratosis on the face or balding scalp.
45501359|NCT01334255|Drug|iSONEP (sonepcizumab/LT1009)|Up to 3 doses of iSONEP given monthly will be administered as intravitreous injections in the ophthalmologist's office.
45501360|NCT03575624|Behavioral|Nutritional and goal-setting education, yoga|"This integrative program series, Live Well, was delivered bi-weekly from January-May 2017, by an interdisciplinary team of a registered nurse, occupational therapist/researcher, registered dietitian, and certified yoga instructor.~Session experiences were designed to build:~Sisterhood for health promotion and support, Individual and group health promotion through goal-setting, Healthy family nutrition and meal planning skills , Family integrated yoga practice"
45387673|NCT04009187|Behavioral|In-person wheelchair propulsion training program|The wheelchair propulsion (WP) intervention is based on our previous pilot work and the best available evidence on WP training. The CPGs recommend minimizing the force and frequency of pushes while using long strokes during propulsion. Each training session will include massed practice with repetitions overground. Each session is organized to limit the number of variables (i.e., long push strokes and dropping the hands down below axle) presented to the participant at one time. Propulsion Set A will focus on using longer push strokes. Propulsion Set B will focus on dropping the hand down toward the axle. Propulsion Set C will focus on both A and B.
45387674|NCT04009187|Behavioral|30-minute education session|Both groups will receive a 30-minute education session regarding the CPGs. This education session will follow the instructions provided in Rice and colleagues. (L. A. Rice et al., 2014). It consists of the importance of practicing biomechanical efficient propulsion. The material lists out the consequences and the impact of upper limb pain and injury. It provides a detailed step by step on how to propel properly. They will view the video that shows the biomechanics of efficient and inefficient propulsion.
45387675|NCT00969917|Drug|IPI-504|IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatment
45387676|NCT05246969|Other|Sepsis detection|The aim of the study was to observe whether the treating physicians were able to detect sepsis by strictly applying the recommended SOFA score.
45387677|NCT05194163|Drug|MW150|oral-delivered capsule of study drug
45387678|NCT05194163|Drug|Placebo|oral delivered capsule matched to study drug capsule
45387679|NCT00966173|Device|SciBase III Electrical Impedance Spectrometer|Following enrollment, patients will undergo measurements with SciBase III Electrical Impedance Spectrometer. Electrical impedance of the skin will be measured with a microinvasive spiked probe.
45387680|NCT00966251|Drug|CT-011|CT-011
45387681|NCT00966329|Drug|maraviroc|HAART regimen including 2 NRTI/NtRTIs plus maraviroc
45387682|NCT00966329|Drug|control group|"HAART regimen including 2 NRTI/NtRTIs plus one of the following :~1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir)~or ATV/unboosted (in a regimen without tenofovir)~or 1 NNRTI (nevirapine or efavirenz)."
45501361|NCT04606355|Diagnostic Test|Visual Acuity|autostereoscopic, monocular dynamic force choice test
45501362|NCT04606355|Diagnostic Test|stereopsis|autostereoscopic dynamic forced-choice depth perception test
45501363|NCT04606355|Diagnostic Test|Color vision|autostereoscopic forced choice monocular or binocular color vision tests
45501364|NCT03573128|Behavioral|Students with Autism Accessing General Education|With study team coach support, teacher implemented modules addressing student behavioral/academic goals.
45501365|NCT03573128|Other|Enhanced Services As Usual|Teaching staff access in-service presentations and print materials with no active study team coaching.
45501366|NCT01334333|Drug|Tacrolimus - Prograf® twice daily formulation|twice daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
45501367|NCT01334333|Drug|Tacrolimus - Advagraf® once daily formulation|once daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
45501368|NCT03573050|Drug|RIV-TDS 13.3 mg/24 h|5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
45501369|NCT03573050|Drug|Exelon® 13.3 mg/24 hours transdermal patch|5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
45501370|NCT03572894|Device|PVI and RPVI measurements|"PVI and RPVI measurements during variations of the tidal volume (Vt challenge) and a recruitment maneuver in anesthetized and mechanically ventilated patients.~T0 : Vt 6 mL/kg of predicted body weight (PBW) during 5 minutes~T1 : Vt 8 mL/Kg of PBW during 5 minutes~T2 : Vt 10 mL/kg of PBW during 5 minutes~T3 : Vt 6 mL/kg of PBW during 5 minutes~T4 : A single recruitment maneuver~Data will be recorded at each step."
45501371|NCT03575312|Drug|Enrofloxacin|dermal application, inhalation rsp. oral administration of Enrofloxacin
45501372|NCT05186441|Other|DMPFC iTBS|The intermittent theta-burst stimulation (iTBS) (i.e. two excitatory intervention paradigm) to target DMFPC can improve out-of-control behavior and decision-making model.
45387683|NCT00970229|Drug|[123I]MNI-420|Subjects will be injected with 8mCi, not to exceed 8.8 mCi (not > 10% of 8 mCi limit)of [123I]MNI-420, followed by SPECT imaging.
45387684|NCT00970385|Drug|CHOP21|"CHOP regimen:~cyclophosphamide 750 mg/m2 intravenously (IV) day 1~doxorubicin 50 mg/m2 IV day 1~vincristine 1,4 mg/m2 (maximum 2 mg) day 1~prednisone 100 mg/m2/D from D1 to D5."
45387685|NCT00970385|Drug|VIP/ABVD|"VIP regimen:~etoposide 100 mg/m2/D IV from D1 to D3~ifosfamide 1000 mg/m2/D from D1 to D5~cisplatinum 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD regimen:~doxorubicin50 mg/m2/D on D1 and D14~bleomycin 10 mg/m2/D~vinblastine 10 mg/m2/D~dacarbazine 375 mg/m2/D"
45501373|NCT05186441|Other|DLPFC iTBS|The intermittent theta-burst stimulation (iTBS) to target DLFPC (i.e. region within the executive control network) can effectively reduce craving, which is probably associated with enhancement of executive function.
45501374|NCT03572816|Device|Settner shoe|custom-made heel-unloading orthosis ('Settner shoe') in aftercare of calcaneus fractures (used according to manufacturer), certified 'CE' product with more than 10 years experience
45501375|NCT02847494|Drug|metoclopramide|metoclopramide 10mg intravenous infusion over 15 minutes
45501376|NCT02847494|Drug|Dexamethasone|dexamethasone 10mg intramuscular injection
45501377|NCT02847494|Drug|methylprednisolone acetate|methylprednislone acetate 160mg intramuscular injection
45501378|NCT02559401|Other|MRI|
45501379|NCT02559401|Other|Neurocognitive battery|
45501380|NCT03572270|Diagnostic Test|AMH test|Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
45501381|NCT03572270|Diagnostic Test|pelvic ultrasound|Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
45501382|NCT02554253|Drug|Ketamine|Ketamine used for induction
45501383|NCT02554253|Drug|Propofol|Propofol for induction
45501384|NCT02239484|Drug|Tadalafil|
45501385|NCT02239484|Drug|Tamsulosin|
45501386|NCT02239484|Drug|Tadalafil + Tamsulosin|
45501387|NCT01331759|Device|Neuropattern™|Neuropattern™ is a diagnostic tool aiming at measuring states of activity and reactivity of interfaces involved in the communication between the brain and peripheral bodily organs in stressful situations. The concept of Neuropattern™ assumes the states of the various interfaces to be describable by characteristic patterns of simultaneous activation of biological, psychological and symptomatic variables. Neuropattern™ assesses endophenotypes through the medical history, various questionnaires for the patient or study subject, analyses of saliva cortisol and the heart rate variability and derives hypotheses on recommendations for an effective and efficient treatment.These recommendations are based on evaluated medical and psychological therapeutic methods but specified through additional biopsychological understanding. This form of individualized therapy should reduce nonresponsiveness to therapy.
45695935|NCT00929344|Drug|Duloxetine|40 mg capsule, Once daily/am, 12 week duration, placebo capsule administered pm. Dose may be increased up to 60 mg/d or reduced to 20 mg/d based on subject response and tolerability.
45501388|NCT03575234|Drug|Cyclophosphamide|Given IV
45501389|NCT03575234|Biological|IRX-2|Given SC
45501390|NCT03575234|Biological|Nivolumab|Given IV
45501391|NCT03575234|Procedure|Surgery|Undergo surgery
45695936|NCT00929344|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
45501392|NCT01337531|Drug|Gonal-F, Fostimon|dosage form
45501393|NCT01337531|Drug|Gonal-F, Fostimon|injection, daily, 10-15 days
45501394|NCT03572114|Diagnostic Test|3Tesla MRI|"A previously validated multi-parameter mapping protocol sensitive to neuromelanin and iron content~Iron mapping and micro-bleed detection: QSM (quantitative susceptibility mapping), a fully flow-compensated, susceptibility-weighted gradient-echo sequence (5 minutes).~1-mm isotropic anatomical MPRAGE (magnetization-prepared rapid gradient-echo)~conventional FLAIR sequence"
45501395|NCT03572114|Behavioral|Burke-Fahn-Marsden Dystonia Rating scale|internationally standardized examination/quantification of dystonia
45501396|NCT03572114|Behavioral|MDS-United Parkinsons Disease Rating Scale, Part III|most recent, internationally standardized examination/quantification of bradykinesia / rigidity according to the Movement Disorder Society
46056702|NCT03060213|Behavioral|Fun For Wellness (FFW)|FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
45501397|NCT03572114|Behavioral|Beck Depression Inventory|internationally standardized examination to quantify traits of anxiety and depression
45501398|NCT03572114|Behavioral|MoCA: Montreal Cognitive Assessment:|internationally standardized examination to quantify cognition, frequently used in studies of dystonia and parkinsonism
45695937|NCT00929344|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
45387686|NCT00970385|Radiation|Radiotherapy consolidation|The treatment of Ann-Arbor stage I/II and stage III/IV patients with an initial bulky tumor (diameter ≥ 5 cm) was systematically completed by an irradiation plan. Forty grays were delivered (1,8 gray/day) over four weeks on the involved field.
45387687|NCT00966485|Drug|80 mg ASA dosing|
45387688|NCT00966485|Drug|500 mg ASA dosing|
45387689|NCT00966563|Drug|Mangafodipir|Administered dose: 2 µmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an intravenous (iv.) infusion over 2-5 min prior to reopening of occluded coronary artery during PCI
45387690|NCT00966563|Drug|Placebo|
45387691|NCT00970541|Dietary Supplement|Cinnamon Supplementation|1, 3, or 6g of cinnamon per day for 40 days
45387692|NCT00970541|Dietary Supplement|Placebo (wheat flour)|1, 3, or 6g of placebo per day for 40 days
45387693|NCT04083287|Other|Erector spinae plane block (Group E)|"Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
45387694|NCT04083287|Other|Interscalen brachial plexus block (Group I)|"Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
45501399|NCT04563611|Other|Turkish Get-up exercise|TG exercise, in 7 different steps (1. Starting position, 2. Supine girya lifting, 3. Elbow supported kettlebell lifting, 4. Hand supported kettlebell lifting, 5. High bridge, 6. Half above knee and lunge position, 7. Standing up) and the return of these different steps.
45501400|NCT04563611|Other|Askling L-Protocol|he protocol consists of 3 different exercises. These are exercise 1 aimed at increasing flexibility, exercise 2 providing strength and trunk / pelvis stabilization, and exercise 3 aiming at specific strengthening. Pain is not allowed to be provoked when performing the exercises.
45501401|NCT04563611|Other|Nordic hamstring exercise|To perform this exercise, participants will be asked to stand in an upright position on their knees. Hands and arms will be positioned on the chest and the individuals will be held by the physiotherapist at their heels. The individual will then be asked to lower the upper body forward as slowly as possible. Verbal commands will be given throughout the movement so that the hip and trunk smoothness is not disturbed.
45387695|NCT00970619|Device|Ekos endowave system thrombolysis|Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
45501402|NCT04563611|Other|Control Group|No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.
45501403|NCT02240420|Behavioral|Life Style Counseling (Star-Mama)|"Participants enrolled in the Star-Mama intervention group will receive 1. weekly automated phone calls with prevention-focused queries (e.g., diet, exercise, breastfeeding). 2. If a participant generates a value rated out of range, a health coach who receives daily electronic downloads of STAR-Mama responses will call the participant to coach her about the specific health issue. Participants also hear recorded narratives related to their out of range reply encouraging behavior change. 3. Call-backs enable coaches to engage patients in goals setting/action plans and providing information about community resources"
45501404|NCT04508855|Drug|Low molecular weight heparin|Switch from direct oral anticoagulants to low molecular weight heparin
45501405|NCT03575078|Drug|ARQ761, Olaparib|ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily
45695938|NCT00929344|Drug|Placebo|Matched placebo capsule administered 1 capsule am and 1 capsule pm for 12 week duration.
45501406|NCT02259842|Drug|BI 34021 FU2 solution|
45501407|NCT02259842|Drug|BI 34021 FU2 tablet|dose group 4 only
45501408|NCT02259842|Drug|Placebo|
45695939|NCT00929344|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
45387696|NCT00970697|Drug|becaplermin gel|the amount of the gel to be applied was determined based on ulcer area at inclusion and remains identical during all the treatment The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Becaplermin gel is packaged into masked 15g-tubes.
45501409|NCT02259842|Other|High fat, high calorie breakfast|only for dose groups 3 and 5
45501410|NCT03377036|Diagnostic Test|DBT+s2D|Digital breast tomosynthesis plus synthesized 2D mammograms
45501411|NCT03377036|Diagnostic Test|2D-FFDM|2D full-field digital mammography
45501412|NCT03572504|Other|critically ill children|Compare a series of measurement or size estimation techniques to the WHO standard to identify the most reliable method (s) of pediatric resuscitation.
45501413|NCT03157583|Other|NGBUV000A, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 (milligram per centimeter square of test site area) NGBUV000A (test product 1) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 1 will be applied to the test plates.
45501414|NCT03157583|Other|NGBUV000B, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000B (test product 2) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 2 will be applied to the test plates.
45501415|NCT03157583|Other|NGBUV000C, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000C (test product 3) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 3 will be applied to the test plates.
45501416|NCT03157583|Other|NGBUV000D, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000D (test product 4) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 4 will be applied to the test plates.
45501417|NCT03157583|Other|P3 Standard, (Expected SPF 16)|A total of 2.0 ± 0.05 mg/cm2 reference P3 standard will be spread at the topical test sites on the back of each participant.
45501418|NCT03157583|Other|Sunscreen formulation S2|A total of 1.3 mg/cm2 of sunscreen formulation S2 will be applied to the test plates.
45501419|NCT03157583|Other|Glycerin|A total of 1.3 mg/cm2 of glycerin will be applied to the test plates.
45501420|NCT03570710|Drug|intravenous tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
45501421|NCT03570710|Drug|Topical tranexamic acid|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
45695940|NCT03820557|Other|Educational Intervention|Undergo Decision Counseling Program
45501422|NCT03570710|Drug|Normal saline|110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
45387697|NCT00970697|Drug|Duoderm Hydrogel™|The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment. The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Hydrogel dressing is identical in appearance, color, consistency, and odor than becaplermin gel, and packaged in similar masked15g-tubes.
45695941|NCT03630159|Biological|Tisagenlecleucel|Gene modified autologous T cells
45695942|NCT03630159|Drug|Pembrolizumab|anti PD-1
45715205|NCT04544735|Behavioral|Integrated Physical Therapy and Coping Skills Training|The proposed intervention will provide pelvic health physical therapy interventions including: education about vaginal moisturizers and lubricants, low back and hip assessment and instruction in accommodations (e.g., strategies for accommodating sexual position of choice), instruction in vulvar massage, instruction and facilitation of vaginal dilator use, and pelvic floor muscle training (PFMT) and exercises. Women will be given a set of vaginal dilators. Cognitive behavioral techniques that have been successfully used by physical therapists in prior intervention studies will be integrated into the PT intervention including breathing and relaxation techniques, guided imagery, systematic desensitization, cognitive restructuring techniques and coping thoughts, and problem solving
45387698|NCT00970775|Drug|AZD2423|oral solution, single dose
46056703|NCT02726529|Behavioral|Brighter Bites|
45387699|NCT00970775|Drug|Placebo|oral solution,single dose
45387700|NCT00967031|Drug|capecitabine|
45387701|NCT00967031|Drug|lapatinib ditosylate|
45387702|NCT00967031|Other|circulating tumor cell analysis|
45387703|NCT00967031|Other|laboratory biomarker analysis|
45387704|NCT00967109|Other|Allowed drop in hemoglobin to level between 4,5-5,6 mmol/L|Transfusion with red blood cells to hemoglobin level between 4,5-5,5 mmol/L
45387705|NCT00967109|Other|Allowed drop in hemoglobin to level between 5,6-6,5 mmol/L|Transfusion with red blood cells to hemoglobin level between 5,6-6,5 mmol/L
45387706|NCT00545753|Drug|Spinosad|10 minute topical application product, following by a complete rinse off.
45387707|NCT00545753|Drug|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen
45387708|NCT00545753|Drug|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
45501423|NCT01315379|Behavioral|Prolonged Exposure Therapy|This intervention comprises 12-18 sessions of cognitive behavior therapy for PTSD with the components (a) Psychological education, (b) in vivo exposure (c) prolonged imaginal exposure, (d) cognitive restructuring (e) summary and relapse prevention.
45501424|NCT01337765|Drug|BEZ235 + MEK162|
45501425|NCT01334489|Device|Arabin Cervical Pessary|"The Arabin cervical pessary, which is CE-certified for preventing SPB (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC).~It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain."
45387709|NCT00967187|Drug|bevirimat dimeglumine|Patients will be treated with MPC-4326 200mg monotherapy for 14 days. Once the Day 15 viral load results become available, patients, who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
45387710|NCT00967187|Drug|bevirimat dimeglumine|Patients will be treated with MPC-4326, 300 mg monotherapy for 14 days. Once the Day 15 viral load results become available patients who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
45387711|NCT00970931|Drug|Chlorthalidone plus amiloride|Oral Chlorthalidone 12.5 mg plus amiloride 2.5 mg, once a day for 18 months
45387712|NCT00970931|Drug|placebo|Oral placebo once a day, for 18 months
45387713|NCT00971009|Behavioral|OPPC service|Access to a practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
45387714|NCT00971009|Behavioral|WebChoice IHCA|The additional features of WebChoice allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
45387715|NCT00971087|Device|Hologic Selenia Dimensions Digital Breast Tomosynthesis System|Subjects are enrolled from either a screening population or a biopsy population. Both groups are exposed to the same number of investigational images collected on the investigational device (Selenia Dimensions Full Field Digital Mammography System). Subject enrollment occurs at the time subjects are being imaged for their standard of care mammographic work up (either screening mammogram or scheduled biopsy). All subjects recruited in the biopsy population will be imaged on the investigational device prior to their biopsy procedure.
45715206|NCT04475315|Device|Papillary Muscle Sling|The sling is made of a Gore-Tex sheet or by using a 4 mm Gore-Tex vascular graft implanted around the base of the papillary muscles and tightened.
46056704|NCT02726529|Behavioral|CATCH|The comparison schools received training in implementing the Coordinated Approach to Child Health (CATCH) school-based health promotion program
45387716|NCT00406419|Drug|Methotrexate|Methotrexate tablet was administered orally at a dose 7.5-25 mg
45387717|NCT00406419|Drug|ocrelizumab|Ocrelizumab was administered via IV infusion at a dose specified in arm description
45387718|NCT00406419|Drug|Placebo|Matching placebo to ocrelizumab was administered via IV infusion
45387719|NCT00967265|Behavioral|Introduction seminar|The seminar will be held over two half days, each lasting 2.5 hours. Up to 30 patients can participate in each seminar. The details of the content of the program will be developed based on study one. The preliminarily plans are to give general information about the community mental health centre, the available treatment options and patients rights by presentations from health personnel and user representatives. At the end of each day, the patients will be divided into small groups mentored by health personnel were they can discuss the presentations and ask questions. In the breaks, literature and other type of information for patients will be on display. All participants will get a folder with details of the program and leaflets from patient organisations and governmental agencies.
45387720|NCT00967265|Other|Usual care|Usual care
45387721|NCT00967421|Drug|ethanol|BAC level 0.5 g/dL (drink + placebo pill). Drink with 2,4 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
45387722|NCT00967421|Drug|Ethanol|BAC level 1.0 g/dL (drink + placebo pill). Drink with 3,6 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
45387723|NCT00967421|Other|Placebo drink|Placebo drink containing no alcohol + placebo pill
45387724|NCT00971165|Drug|losartan|Oral losartan up to 100 mg daily fo 18 months
45387725|NCT00971165|Drug|Chlorthalidone plus amiloride|Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily, once a day for 18 months
45387726|NCT00971399|Drug|ramosetron|ramosetron 0.1mg q.d. SL on D1-5
45387727|NCT00971399|Drug|ondansetron|ondansetron 8mg, b.i.d SL on D1-5
45387728|NCT01049295|Dietary Supplement|oil fish|Active Comparator:640 mg oral oil fish pearls( 54% DHA, 10% EPA) 3 times a day
45387729|NCT01049295|Other|corn oil pearls|corn oil pearls 3 times a day
45387730|NCT00973505|Drug|Aromatase Inhibitor(Femara or Arimidex)|Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd
45387731|NCT00971477|Other|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via a store and forward teledermatology modality.
45387732|NCT00971477|Other|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
45387733|NCT00973583|Dietary Supplement|vitamin D|vitamin D3 400 IU daily
45387734|NCT00973583|Dietary Supplement|placebo|placebo
45387735|NCT00971711|Biological|Probiotic|The subjects will be randomized into either a 4 week or 8 week treatment period with the probiotic. The treatment will be open label. They will take 2 packets once daily.
45387736|NCT04008953|Device|ultrasonography|Intravascular volume assessment using ultrasonography, CVP and echocardiography
45387737|NCT00973661|Behavioral|Electronic tool set for counseling overweight patients|"Physicians randomized to the electronic tools arm will receive access to a tool set to aid with counseling of overweight patients. This tool set includes the following components: automatic calculation of BMI, alert for overweight status, counseling template for weight loss goal-setting, linkage to referral options, and access to relevant patient handouts. Physicians randomized to the usual care arm will not receive access to these tools, and will continue to provide their usual care for overweight patients."
45387738|NCT00973895|Biological|VRC-FLUDNA057-00-VP|DNA Vaccine Expressing H1 HA from Influenza A/California/04/2009 H1N1 Virus
45387739|NCT00972101|Radiation|Total Body Irradiation (TBI)|3 Gy of radiation on Days -7,-6, -5 and -4.
45387740|NCT00972101|Drug|Melphalan|140 mg/m^2 by vein over 30 minutes as a single dose on Day -8
45387741|NCT00972101|Drug|Thiotepa|10 mg/kg by vein over 4 hours as a single dose on Day -7
45387742|NCT00972101|Drug|Fludarabine|40 mg/m^2 by vein over about 30 minutes 1 time each day on Days -6 through -3.
46056705|NCT02721303|Dietary Supplement|3-day diet Run-in|Participants will be studied on one occasion after a 3-day diet run-in. This will be followed by a breakfast meal.
45715207|NCT04475315|Procedure|CABG surgery|Standard of care Coronary Artery Bypass Grafting (CABG) surgery will be performed to improve blood flow to the heart by bypassing the narrowed segment of a severely diseased coronary artery
45848439|NCT04096482|Device|Standard 30° 4mm Endoscope|The Standard 30° 4mm endoscopic sinus evaluation is the standard procedure that would normally be used to evaluate the condition of each participant.
45848440|NCT04138758|Drug|Tiotropium bromide + Olodaterol|Tiotropium bromide + Olodaterol
45387743|NCT00972101|Drug|Rituximab|"Regimen 1:~375 mg/m^2 may be given by vein over 4 - 6 hours on Day -9 if needed~Regimen 2:~375 mg/m^2 may be given by vein over 4 - 6 hours on Day -8 if needed"
45715208|NCT05746104|Drug|Administration of Indocyanine Green (ICG) and Visualization of Tumor|A single dose of the study drug, ICG, of less than 2 mg/kg will be administered on the day of surgery. The visualization of second window ICG for tumor will be performed approximately one to four hours after administration, depending on how long it takes for the neurosurgeon to get through the skin/skull or lamina/dura to the tumor.
46056706|NCT02721303|Procedure|fMRI|After a 3-day diet run-in, participants will undergo a functional magnetic resonance imaging procedure (fMRI). Repeat fMRI will be performed 30 minutes after the meal.
45387744|NCT00972101|Drug|Etoposide|60 mg/m^2 by vein over 1-2 hours as a single dose on Day -3.
45387745|NCT00972101|Drug|Anti-thymocyte globulin (ATG)|"Regimen 1:~1.25 and 1.75 mg/kg by vein over 4-6 hours on the Days -4 and -3.~Regimen 2:~0.5, 1.0 and 1.5 mg/kg by vein over 4-6 hours on respective Days -3, -2, and -1."
45387746|NCT00972101|Drug|Mycophenolate Mofetil (MMF)|15 mg/kg pills twice a day starting on day -3, and continued until Day 100+ after transplant (1 gram may be given by vein if necessary).
46056707|NCT02721303|Procedure|Intravenous catheter placed for blood draws|On the study day participants will present in the fasting state, have an intravenous catheter placed for blood draws and have baseline blood samples taken. Blood and appetite measures will be performed every half hour for 3 hours.
45387747|NCT00972101|Drug|Tacrolimus|0.03 mg/kg by vein Day -2 as 24 hour continuous infusion for several weeks. After stem cell transplant, tacrolimus given by mouth 2 times a day for up to 6 months.
45387748|NCT00972101|Procedure|Cord Blood Infusion|Cord blood infusion of larger portion through vein using Central Venous Catheter (CVC) on Day 0.
45387749|NCT00972101|Drug|G-CSF|5 mcg/kg day subcutaneously (may round up to the next vial) beginning on day +1 and continuing till absolute neutrophil count is > 2.5 x 10e^9/L.
45387750|NCT00972101|Procedure|Ex vivo expanded T cell Infusion|Infusion by vein of treated cord blood beginning dose of 1 x 10e^5 T cells/kg on Day 14+.
45387751|NCT00325468|Drug|AMG 162|AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
45387752|NCT00972257|Drug|treatment with dorzolamide/timolol|24-hour IOP control with the two fixed combinations
45387753|NCT00972257|Drug|treatment with brimonidine/timolol|24-hour pressure control with brimonidine/timolol
45387754|NCT03833661|Drug|M7824|Participants received an intravenous infusion of 1200 milligrams (mg) M7824 once every 2 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
45387755|NCT00311584|Drug|irinotecan hydrochloride|Given IV
45387756|NCT00311584|Drug|temozolomide|Given IV
45387757|NCT03021681|Other|autologous bronchial basal cell transplantation|the investigators obtained extraction bronchial basal cells micro tissue from 3~4 grade bronchus, then purified and selectively amplified bronchial basal cells to reserve . After a period of time, the basal lamina of the bronchial epithelial cells can be stored in the liquid nitrogen cell bank for a long time. Before applied to the patient, bronchial basal cells need to go through a series of strict examination. Then, bronchoscopy was performed again and the bronchial basal lamina suspension was injected directly into the lesion site .
45387758|NCT03992859|Procedure|Continuous serratus plane block|Peripheral nerve catheter placed by the surgeon at the end of surgery
45387759|NCT00383331|Drug|Pemetrexed|"A: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles~B: 500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
45387760|NCT00383331|Drug|Gemcitabine|"A: 1250 mg/m2, intravenous (IV) days 1 and 8, every 21 days x 6 cycles~B: 1500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
45387761|NCT03934541|Biological|MPER-656 Liposome Vaccine|Administered by intramuscular injection
45387762|NCT03934541|Biological|Placebo for MPER-656 Liposome Vaccine|Administered by intramuscular injection
45501426|NCT02842736|Device|Cerene(R) Cryotherapy Device|
45501427|NCT01307033|Drug|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
45501428|NCT01307033|Drug|MK-954H|Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily
45501429|NCT01307033|Drug|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
45501430|NCT01307033|Drug|Placebo to MK-954H|Placebo tablet to match MK-954H, once daily
45501431|NCT02844920|Device|Intrauterine ultrasound guided radio-frequency ablation|Radiofrequency ablation for the treatment of uterine fibroids
45715209|NCT02684188|Behavioral|Enhanced rural discharge and transition|While in the treating hospital, patients from small towns and rural communities are engaged in package of procedures designed to improve the transitions home, including a functional needs assessment that produces a plan that matches available rural community service providers to a patient's transitions needs and the provision of enhanced recovery supports to the patient.
46056708|NCT02721225|Dietary Supplement|Fructooligosaccharide|"A prebiotics defined as selectively fermented ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health"
46056709|NCT02721225|Dietary Supplement|Pocari-Sweat|Commercially used isotonic solution produced by Otsuka Pharmaceuticals Co. Ltd., Tokyo, Japan.
45501432|NCT04446143|Behavioral|Mindfulness meditation|Mindfulness meditation
45387763|NCT00325234|Drug|Pemetrexed|600 mg/m^2, administered intravenously (IV) every 21 days until disease progression or unacceptable toxicity.
45387764|NCT00325234|Drug|Carboplatin|AUC 5 mg*min/mL, administered IV every 21 days until disease progression or unacceptable toxicity.
45387765|NCT00325234|Drug|Gemcitabine|1200 mg/m^2 gemcitabine, administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
45387766|NCT00325234|Drug|Vinorelbine|30 mg/m^2 vinorelbine administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
45387767|NCT01063504|Drug|teriparatide|
45387768|NCT00366249|Drug|Tigecycline|150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis
45387769|NCT00366249|Drug|Ertapenem|Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).
45387770|NCT00325156|Biological|GSK Biologicals' combined DTPa-IPV/Hib vaccine|4 intramuscular injections
45387771|NCT01066234|Radiation|concurrent chemoradiotherapy|weekly paclitaxel 50mg/m2 plus weekly cisplatin 25mg/m2 5times with concurrent radiotherapy (5000rad/25fx) for 5 weeks followed by 2 cycles of 3-weekly paclitaxel (175mg/m2) plus cisplatin 80mg/m2.
45387772|NCT01066234|Drug|chemotherapy only|four cycles of 3-weekly paclitaxel (175mg/m2) and carboplatin (AUC5.5).
45387773|NCT03927911|Drug|EXPAREL and Bupivacaine|Drug: EXPAREL and Bupivacaine HCl 0.5%
45387774|NCT03927911|Drug|Standard of Care|Standard of Care
45387775|NCT00383019|Drug|Xalatan|latanoprost 0.005%, one rop once daily in evening
45387776|NCT00383019|Drug|Xalacom|latanoprost 0.005% adn timolol 0.5%, one drop, once daily
45387777|NCT00310804|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1
45387778|NCT00310804|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2
45387779|NCT00310804|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 3
45387780|NCT00310804|Biological|Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)|One single 0.5ml intramuscular injection of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).
45387781|NCT01046409|Other|Measuring collateral flow|Measuring collateral flow using pressure and/or velocity coronary wire
45387782|NCT01060852|Behavioral|Media Detective|10-lesson elementary school, media literacy education, substance use prevention program. Each lesson takes approximately 45 minutes to teach and was taught every school day for 2 weeks.
45387783|NCT00590187|Drug|Sapacitabine, Arm A|200 mg b.i.d. x 7 days every 3-4 weeks
45387784|NCT00590187|Drug|Sapacitabine, Arm B|300 mg b.i.d. x 7 days every 3 - 4 weeks
45387785|NCT00590187|Drug|Sapacitabine, Arm C|400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
45387786|NCT00590187|Drug|Sapacitabine, Arm D|200 mg b.i.d. x 7 consecutive days every 4 weeks
45387787|NCT00590187|Drug|sapacitabine, Arm E|300 mg q.d. x 7 consecutive days every 4 weeks
45501433|NCT02244398|Other|FP and HTC services|In this project, VHTs already providing family planning services are trained to offer HIV testing and counseling services (HTC).
45501434|NCT02244398|Other|FP services|VHTs in the control arm only provide family planning services
45715210|NCT01684943|Other|Multiplex pharmacokinetic profiling|
45501435|NCT04475705|Drug|propofol|intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60
45501436|NCT04475705|Drug|sevoflurane|sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60.
45501437|NCT04440761|Other|Observation only|Observation only
45715211|NCT01684943|Other|Continuous insulin monitoring|
45715212|NCT03115242|Other|Contrast injection Sonovue®|In addition to standardized assessment routine care, a contrast injection will be performed during the neck vessels doppler ultrasound.
45848441|NCT04138758|Drug|LABA/ICS|Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
45848442|NCT04323852|Drug|Vitamin D|Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery
45387788|NCT00590187|Drug|sapacitabine, Arm F|300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
45501438|NCT03569150|Other|Cultural adaptation/implementation COMFORT CC|The COMFORT Communication Curriculum (CC) will be culturally-adapted for 2 Native American reservation communities. The investigators will then implement the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities by training interdisciplinary healthcare professionals to conduct culturally-respectful and relevant Advance Care Planning. The investigators will then conduct a cluster-assigned pilot, wait-list controlled trial of the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities to evaluate feasibility, acceptability, and perceived effectiveness by comparing 30 Native Americans completing Advance Care Planning with a trained healthcare professional and 30 Native Americans receiving usual care.
45501439|NCT03158311|Drug|QVM149|Indacaterol acetate / glycopyrronium bromide / mometasone furoate
45501440|NCT03158311|Drug|Salmeterol/fluticasone plus tiotropium|Free triple arm of salmeterol / fluticasone plus tiotropium
45387789|NCT00590187|Drug|Sapacitabine, Arm G|200 mg b.i.d. x 7 consecutive days every 4 weeks
45387790|NCT00590187|Drug|Sapacitabine, Arm H|300 mg q.d. x 7 consecutive days every 4 weeks
45387791|NCT00590187|Drug|Sapacitabine, Arm I|100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks
45387792|NCT03978364|Drug|Azacitidine combined HHT|Azacitidine 75mg/m2，iH，qd×7days，HHT，3mg/m2 ivdrip qd×3 days
45501441|NCT01331915|Biological|Theravac|"Three groups with three doses (50 - 150 - 250 mcg), four times every three weeks.~Injection: intradermally and subcutaneously."
45501442|NCT02244866|Drug|Pergoveris (FSH and LH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
45501443|NCT02244866|Drug|Follitropin alpha (FSH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
45501444|NCT01334567|Drug|Tenofovir DF|Provision of tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablets, as prescribed by study investigators
45501445|NCT03570398|Other|unenhanced abdomino-pelvic CT scan|unenhanced abdomino-pelvic CT scan
45501446|NCT03570398|Other|abdominal ultrasound|abdominal ultrasound
45501447|NCT01337843|Other|Wellness Workbook|A web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase physical activity and manage stress. This is a 10 week intervention. Participants use one chapter of the workbook each week. Each chapter takes approximately 1.5 hours to complete.
45501448|NCT01337843|Other|Pain Management Print Materials|Print materials comparable to the content within Wellness Workbook
45501449|NCT05354804|Diagnostic Test|Troponin I (Siemens VTli) 0/1 hour algorithm|Patients will be investigated using the ESC 0/1 hour cTnT algorithm from ESC compared to a 0/1 hour algorithm utilizing the Siemens VTli POC instrument for cTnI.
45501450|NCT05354804|Diagnostic Test|Troponin T (Roche Diagnostics) 0/1 hour ESC algorithm|Patients will be investigated using the ESC 0/1 hour cTnT algorithm from ESC compared to a 0/1 hour algorithm utilizing the Siemens VTli POC instrument for cTnI.
45501451|NCT04398329|Drug|HTX-034|HTX-034, low dose
45387793|NCT03978364|Drug|Azacitidine regimen|Azacitidine 75mg/m2，iH，qd×7days，28 days a cycle
45501452|NCT04398329|Drug|HTX-034|HTX-034, high dose
45501453|NCT04398329|Device|Luer lock applicator|Applicator for instillation
45501454|NCT04398329|Drug|Bupivacaine HCl|Bupivacaine HCl, 50 mg
45501455|NCT05354726|Other|Assessments parameters|Demographic and Clinical Characteristics, Bone Mineral Density, Sarcopenia, Body Composition, Arterial Stiffness, Endothelial Function, Echocardiography,Pulmonary Function, Respiratory Muscle Strength, Submaximal exercise capacity, Maximal Exercise Capacity, Physical Activity Level, Hand Grip Strength, Lower Extremity Muscle Strength
45501456|NCT00449111|Drug|MK0954, losartan potassium / Duration of Treatment - 12 weeks|
45501457|NCT03568916|Drug|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
45501458|NCT03568916|Drug|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
45501459|NCT03568916|Drug|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
45501460|NCT01334645|Other|Copeptin|"Patients with hyponatremia < 135 mmol/L or troponin > 1 μg/L are released study.~Blood sampling are taken for Troponine T, myoglobin, creatin kinase and copeptine analysis and 18-lead ECG was performed after 2, 4, 6 and 12 h.~Copeptin and myoglobin are measured at the end of the patients inclusion, after to be centrifugrd end frozen at -80°C at each time point.~The treatment of patients is not modified by the study. At 90 days, clinicals and paraclinicals events are collected"
45501461|NCT01337921|Dietary Supplement|Multi-strain Probiotic|Multi-strain Synbiotic: 1.5 billion CFU of Lactobacillus acidophilus, Bifidobacterium bifidum,and Bifidobacterium lactis WITH galacto-oligosaccharide(GOS)/fructo-oligosaccharide (FOS) combination at 1g/dL (0.9g/dL GOS/ 0.1g/dL FOS)
45848443|NCT04323852|Drug|Placebo|Placebo
45501462|NCT03571880|Device|Biodex-assisted isometric strength testing|The maximum voluntary isometric and dynamic strength of back and abdominal muscles is measured using an isokinetic dynamometer (System 3, Biodex, Enraf-Nonius, New York).
45501463|NCT03635593|Drug|CBD|Participants will be randomized to CBD 10mg capsules for 12 weeks. Participants will start with 1, CBD (10mg) capsule per day and self-titrate up to 8, 10mg CBD capsules (80mg) per day as needed.
45501464|NCT03635593|Drug|CBD+THC|Participants will be randomized to CBD+THC 10mg (CBD 5mg + THC) for 12 weeks. Participants will start with 1, 10mg CBD+THC (5mg+5mg) capsule per day and self- titrate up to 8, 10mg CBD+THC (5mg+5mg) capsules to a maximum of 80mg (40mg CBD + 40mg THC) per day as needed.
45501465|NCT03635593|Other|Placebo|Participants randomized to placebo 10mg capsules for 12 weeks. Participants will start with 1, 10mg placebo capsule per day and self-titrate up to 8 10mg placebo capsules (80mg) per day.
45387794|NCT01046487|Drug|Imatinib mesylate, Cyclophosphamide (Dosing level 1 )|"CYCLE 1 (42 days):~Day 1 to 14 Imatinib mesylate : 400 mg/day, per os~Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os"
45387795|NCT01046487|Drug|Imatinib mesylate, Cyclophosphamide (Dosing level 2)|"CYCLE 1 (42 days):~Day 1 to 14 Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening)per os"
45387796|NCT01046487|Drug|Imatinib mesylate, Cyclophosphamide (Dosing level 3)|"CYCLE 1 (42 days):~Day 1 to 14 Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening)per os"
45387797|NCT01046487|Procedure|Blood sampling|"ONLY FOR CYCLE 1, at day 15 and day 28 :~11 sampling for dosing level 1 (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12 , +24 hours, cyclophosphamide + 12 hours) 10 sampling for the next dosing level (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12,cyclophosphamide + 12 hours)"
45387798|NCT01069276|Other|No intervention in this study|No intervention in this study
45387799|NCT01066390|Biological|TriMix-DC|eligible patients will undergo a leucapheresis for the preparation of autologous TriMix-DC vaccine.4 weeks after the leucapheresis patients will initiate therapeutic vaccination with the TriMix-DC vaccine by IV and ID administration. The vaccines will be administered at 4 different visits that will be separated with an interval of 2 weeks.
45387800|NCT03978286|Drug|Vortioxetine|10 mg per day
45387801|NCT03978286|Drug|Sertraline|75 mg per day
45387802|NCT03826186|Device|Traditional (loss-of-resistance technique) thoracic epidural placement|Thoracic epidurals will be administered using the traditional loss-of resistance technique.
45501466|NCT05213247|Device|electronic apparatus (visocor OM50).|Measurement of blood pressure and heart rate
45501467|NCT04373915|Behavioral|Remote Bedside Rounding|Parents of infants on the medical team utilizing remote rounding will have the opportunity to participate in rounds by video conferencing at the infant's bedside. Participation will be tracked and surveys regarding stress, satisfaction, and attachment will be completed by parents in both groups.
45501468|NCT03571490|Drug|Ropivacaine|Single shot of ropivacaine 0.325%
45501469|NCT03571490|Drug|Saline|Single shot of saline 0.9%
45501470|NCT05754801|Drug|Yunzhi Essence|Yunzhi Essence capsule
45501471|NCT05754801|Other|Placebo|Placebo capsules
45501472|NCT01331993|Drug|VIMOVO (AstraZeneca)|VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole
45501473|NCT01331993|Drug|VIMOVO (Patheon)|VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole
45501474|NCT01331993|Drug|Marketed enteric-coated naproxen formulation|Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet
45501475|NCT03424694|Radiation|HDR brachytherapy as monotherapy|
45501476|NCT01340365|Behavioral|Tai Chi Exercise|Practicing Tai Chi exercise 4 times a week for 6 months - twice in a classroom and twice independently
45501477|NCT01340365|Behavioral|Tai Chi|Usual care, individuals attend testing sessions for 6 months with testing at times 0, 3, and 6 months. Individuals in Usual Care receive 3 months of Tai Chi at the study end.
45501478|NCT01337999|Other|blood draws|5 blood draws during ovulatory menstrual cycles in premenopausal women
45501479|NCT03571412|Device|repetitive Transcranial Magnetic Stimulation|Subject will receive 5Hz LDLPFC or 5Hz DMPFC rTMS
45501480|NCT01341769|Other|Dietary Intervention|
45501481|NCT01341769|Other|Dietary Intervention|
45501482|NCT01341769|Other|Dietary Intervention|
45501483|NCT01341769|Other|Dietary Intervention|
45501484|NCT04344431|Combination Product|Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)|One session per day of HBOT in addition to the standard treatment with normobaric oxygen
45387803|NCT03826186|Device|CompuFlo thoracic epidural placement|Pressure sensing technology to consistently and accurately identify the thoracic epidural space.
45501485|NCT05709080|Other|family-professional collaboration practice model|Online instructional sessions will be conducted in two sessions for six hours (3 hours per session) for the physical therapists in the experimental group. The instructional session focus on explaining the specific strategies and process to implement the Family-professional Collaboration (four step process) Model as ( Step 1: Mutually agreed-upon goals, Step 2: Shared planning, Step 3: Shared implementation and Step 4: Shared evaluation of child and family outcomes.
45501486|NCT05184127|Drug|MIR 19 ®|Drug contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.
45501487|NCT05184127|Combination Product|Standard COVID-19 therapy|Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
45501488|NCT01338077|Drug|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 4 weeks
45501489|NCT01338077|Drug|Omeprazole|20 mg capsule, 1 capsule once daily, 4 weeks
45501490|NCT03570320|Other|Modification of opioid prescription method|Patients in the interventional arm of the study will receive post-op opioid medications in three small prescriptions as opposed to one large prescription. They may fill these prescriptions as needed.
45501491|NCT01315561|Other|acupuncture, injection|MSAT and intramuscular injections of diclofenac(NSAID)
45501492|NCT04328129|Procedure|Human biological samples|"Blood sample~Nasopharyngeal swab."
45501493|NCT01336309|Behavioral|Yoga Research Tool|We will be collecting data from a literature search, focus groups, cognitive interviews, and an online survey to build a measure for yoga researchers.
45501494|NCT03571178|Other|Physical Therapy|Physical therapy consisting of the application of hotpack, TENS and treatment ultrasound
45501495|NCT04266665|Drug|Dexmedetomidine|Dexmedetomidine 2 μg/ml will be given as bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
45501496|NCT04266665|Other|Normal saline|Equivalent doses for a solution containing 2mcg/ml of the tested drug calculating for a bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
45501497|NCT03571100|Drug|Chlorhexidine|Chlorhexidine administration prior to intravitreal injection (compared to gold standard povidine-iodine)
45501498|NCT03571100|Drug|Povidine-Iodine|Povidine iodine administration prior to intravitreal injection (compared to chlorhexidine)
45501499|NCT01338311|Drug|salbutamol|200mcg twice daily for a total of 7 doses
45501500|NCT01338311|Drug|Placebo|200mcg twice a day for a total of 7 doses (3.5 days).
45387804|NCT01069432|Other|No Intervention|No Intervention
45387805|NCT00382863|Device|HeartNet Ventricular Support System|The HeartNet Implant is placed on the epicardial surface of the heart surrounding both the left and right ventricles.
45387806|NCT00382863|Drug|Optimal Medical/Device Therapy|Optimal Medical/Device Therapy - For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of ACE inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as CRT or CRT-D for at least three months prior to study enrollment, when indicated.
45387807|NCT03933449|Biological|pembrolizumab|IV infusion
45387808|NCT03933449|Drug|paclitaxel|IV infusion
45387809|NCT03933449|Drug|docetaxel|IV infusion
45501501|NCT01336387|Drug|retinoid 9cUAB30|Given PO
45501502|NCT01336387|Other|placebo|Given PO
45387810|NCT03933449|Drug|irinotecan|IV infusion
45387811|NCT00974285|Drug|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
45387812|NCT00974285|Drug|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
45501503|NCT01336387|Other|pharmacological study|Correlative studies
45501504|NCT01336387|Other|laboratory biomarker analysis|Correlative studies
45501505|NCT01336387|Other|cancer prevention|Disease prevention
45501506|NCT01334879|Drug|ranibizumab 2.0 mg|Intravitreal ranibizumab (2.0 mg)
45501507|NCT05354492|Other|Program to Support Well-Being after Adversity|You will be asked to meet on Zoom weekly for 6 weeks with our trained program facilitators along with the other 6-10 members of the intervention group. Meetings will last approximately 75-90 minutes each, and will involve a variety of discussions and activities related to navigating the changes you may face after experiencing a difficult life event. These sessions will be audio-recorded for research purposes and to ensure that facilitators are doing a good job delivering the program.
45848444|NCT04381728|Device|Womed Leaf|Womed Leaf uterine film will be inserted immediately after the myomectomy, following per-operative hysterometry.
45387813|NCT03932045|Device|SYB Filler (SF-01)|Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
45387814|NCT03932045|Device|Ellansé M|Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
45387815|NCT00972413|Radiation|Computed Tomography|In Group I, twelve CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
45387816|NCT00972413|Radiation|Computed Tomography|In Group II , at least fifty (50) study participants, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a breast CBCT specifically designed to image the breast.
45387817|NCT00972413|Radiation|Computed Tomography|In Group III, at least 30 study subjects, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a unilateral intravenous (IV) CE CBCT of the involved breast.
45387818|NCT00387075|Procedure|[123I]β-CIT and SPECT imaging|This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, [123I]β-CIT , in a population of first-degree relatives of PD patients as a tool to establish an 'at risk' Parkinson disease cohort without motor symptoms of PD.
45387819|NCT00387075|Drug|[123I]β-CIT|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections),
45387820|NCT00974441|Drug|Divalproex Sodium|500 mg Extended Release Tablet
45387821|NCT00974441|Drug|Depakote®|500 mg Extended Release Tablet
45501508|NCT03570242|Other|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
45501509|NCT01315795|Drug|Lanreotide Autogel 90 mg and 120 mg|administration of lanreotide sc every 4 weeks (28 days)
45848445|NCT04420572|Drug|ozone injection|ozone injection will be applied in three doses (1st, 4th, 7th and 10th days) for a total of 4 doses. In ozone injection applications, 1st dose 25 gamma, 2nd dose 20 gamma, 3rd and 4th dose 15 gamma 10 cc ozone will be injected.
45387822|NCT01049451|Drug|ACTH|Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
45501510|NCT03570164|Drug|Sevoflurane|End-tidal concentration of sevoflurane is maintained at age-corrected 1.0 minimum alveolar concentration throughout the study period.
45501511|NCT03570164|Drug|Desflurane|End-tidal concentration of desflurane is maintained at age-corrected 1.0 minimum alveolar concentration throughout the study period.
45501512|NCT05181943|Device|Simpler diode laser|Non-contacting irradiation for 30 seconds on three intraoral sites repeated four times
45501513|NCT05181943|Drug|Conventional symptomatic treatment|Conventional treatment using oracure, BBC spray, miconaz three times daily
45501514|NCT01315951|Biological|Petroleum Jelly|Every patient will be instructed to wet the affected area, blot dry, and then apply petroleum jelly to the area before bedtime. This regimen is to be followed every other night until symptoms diminish. The patient should follow-up at one week, two weeks, and four weeks after treatment begins to see the outcome.
45501515|NCT01391234|Radiation|STAT RT planning and delivery workflow|"Patients will receive simulation, planning, quality assurance, and their first treatment in a single day using the STAT RT workflow.~Patients will receive a total of 1-5 fractions of high dose palliative radiation therapy via TomoTherapy consisting of 5-10 Gray per fraction.~Data will be collected to evaluate the effectiveness of our novel image co-registration techniques, CT-detector-based exit dose calculations, and infrared patient position monitoring. These novel techniques for image co-registration, radiation dose calculations, and patient position monitoring will not alter or replace standard of care techniques."
45501516|NCT05184049|Drug|Epalrestat,Mecobalamin|Epalrestat will be taken orally at a dose of 50mg 3 times a day before meals. In addition, conventional hypoglycemic and oral mecobalamin treatment 0.5mg/ time, 3 times/day, before meals.
45501517|NCT05184049|Drug|Mecobalamin|Subjects takes mecobalamin 0.5mg orally, 3 times a day.Regular hypoglycemia.
45501518|NCT01336543|Drug|Chemotherapy following concurrent Chemoradiotherapy|"NSCLC (Non-Small Cell Lung Cancer)~PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 80mg/m2 days 1-3 and 29-31)~Radiation 59.4 Gy with 2 cycles of PE~(Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~(Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles"
45848446|NCT04420572|Drug|betamethasone|1ml betamethasone will be used for steroid injection.
45848447|NCT04709484|Drug|USG-guided steroid injection|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus boIn the USG-guided group, steroid injection will be made to the area where the fascia is thickened under USG guidance. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.ne and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
45501519|NCT03570086|Diagnostic Test|diagnostic|using radiomics features from multiparametric thick-section clinical-quality brain MRI to distinguish migraineurs from health controls.
45501520|NCT01341847|Procedure|water method colonoscopy|This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of colonoscope during insertion since the scope is inserted into the anus until reach the cecum.
45501521|NCT01341847|Procedure|air method colonoscopy|This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
45501522|NCT03568370|Other|olive oil|Evaluate the effectiveness of olive oil and human milk in the prevention of nipple cracking, nipple pain and maternal satisfaction in lactating women during the first 3 days of treatment and the 7th and 10th day after delivery.
45501523|NCT03568214|Other|Exercise|The MICT will be prescribed according to two exercise intensity methods: individualized (i.e., VT1 and VT2) and standardized (i.e., HRR). The HIIT will be prescribed based on individual fitness (i.e., VO2max).
45501524|NCT03568136|Drug|Secukinumab 300 mg|Solution for injection in pre-filled syringe
45501525|NCT03568136|Drug|Placebo|Solution for injection in pre-filled syringe
45501526|NCT01336621|Drug|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum)
45501527|NCT05187481|Drug|Jianpi Huatan dispensing granule|once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
45501528|NCT05187481|Drug|Placebo granule|once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
45501529|NCT00383435|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
45501530|NCT00383435|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
45501531|NCT00383435|Drug|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
45501532|NCT00383435|Drug|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
45501533|NCT00383435|Drug|Placebo|Placebo MDI twice a day for 26 weeks
45501534|NCT01336699|Other|Placebo|Placebo comparator: 1 or 1.5 ml of sterile normal saline 0.9% added to 30 mL of 0.9% sterile normal saline, given orally.
45501535|NCT01336699|Biological|WRSs2|WRSs2 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10^3 colony-forming units (cfu) to 1x10^7 cfu.
45501536|NCT01336699|Biological|WRSs3|WRSs3 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10^3 colony-forming units (cfu) to 1x10^7 cfu.
45387823|NCT01049451|Drug|Methylprednisolone|Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months
45387824|NCT00974519|Drug|Fuzheng 3|"Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
45501537|NCT01340521|Drug|Clomiphene Citrate|0, 25, 50 or 100 milligrams daily. Will be taken orally days five through nine of the menstrual cycle.
45501538|NCT03698123|Other|Dietary Modification|Participants will be provided with meals, snacks and drinks with specific macronutrient compositions and encouraged to only eat and drink study meals, snacks and drinks and to avoid eating after 10:00 hours.
45501539|NCT01340599|Dietary Supplement|defined green tea catechin extract|Given PO
45387825|NCT00974519|Drug|Fuzheng 1|"Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
45387826|NCT00974519|Drug|Placebo|"Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
45501540|NCT01340599|Other|placebo|Given PO
45501541|NCT01340599|Other|immunohistochemistry staining method|Correlative studies
45501542|NCT01340599|Other|immunoenzyme technique|Correlative studies
45501543|NCT01340599|Other|questionnaire administration|Ancillary studies
45501544|NCT01340599|Procedure|therapeutic conventional surgery|Undergo radical prostatectomy
45501545|NCT01340599|Other|high performance liquid chromatography|Correlative studies
45501546|NCT01340599|Other|mass spectrometry|Correlative studies
45501547|NCT01335035|Drug|deferasirox|
45501548|NCT01340677|Drug|Canagliflozin, 50 mg|Type=1, unit=mg, number=50, form=tablet, route=oral use.Tablet is taken once without food during 1 of 3 treatment periods.
45501549|NCT01340677|Drug|Canagliflozin, 300 mg|Type=1, unit=mg, number=300, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
45501550|NCT01340677|Drug|Canagliflozin, 100 mg|Type=1, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
45501551|NCT05164315|Procedure|Tailored surgery|Procedure: Tailored surgery based on intraoperative local excision/biopsy
45501552|NCT05164315|Procedure|Total mesorectal excision (TME)|Procedure: Total mesorectal excision for all allocated patients
45501553|NCT01335269|Drug|BI 853520|BI 853520 once daily in a dose escalation schedule
45695943|NCT04371874|Drug|Hydrochlorothiazide, Captopril, Nitrendipine, Aspirin|The participants were grouped into a control group and a TDP group. Hypertension of patients in the control group was managed with the original protocol by doctors in village clinics. Patients in the TDP group were supplied with the TDP treatment, for whom different levels of oral administration plans to patients without drugs treatment in original protocol were: G 0 and G I, nifedipine (20mg, bid) or captopril (25mg, tid), hydrochlorothiazide (12.5mg, bid) for patients who couldn't tolerate previous drugs; G II, nifedipine (20mg, bid) plus hydrochlorothiazide (12.5mg, bid), or captopril (25mg, tid) plus hydrochlorothiazide (12.5mg, bid ), triple therapy for patients whose blood pressure did not reach target BP; G III, three drugs combination. Patients with drugs treatments in the original protocol were changed to be treated with the above antihypertension medications which were uniformly supplied by the government.
45501554|NCT05183815|Other|slow stroke massage and murrotal quran|murrotal quran and slow stroke massage
45501555|NCT01335347|Biological|ND1.1|adenovirus with the dsRNA adjuvant, dried and put into capsules
45501556|NCT01335347|Biological|Placebo control|Capsules of the same size and shape as experimental groups
45501557|NCT05164003|Drug|CORETOX®|Up to a total of 360U of the IP was allowed to be injected at three flexors; wrist, elbow and finger.
45695944|NCT03629613|Dietary Supplement|Oral antioxidant cocktail|"Oral antioxidant cocktail intake will occur after baseline measurements:~Dose 1 (immediately after baseline testing): 300 mg alpha-lipoic acid, 500 mg vitamin C, 200 IU vitamin E Dose 2 (30 minutes after Dose 1): 300 mg alpha-lipoic acid, 500 mg vitamin C, 400 IU vitamin E"
45387827|NCT01049529|Dietary Supplement|Docosahexaenoic acid|DHA have oil form. Each neonate is receiving 75 mg/kg/day of DHA in 188 uL/kg/day in two doses per day, since two days before surgery and over six days following cardiovascular surgery
45387828|NCT01049529|Dietary Supplement|Placebo|Placebo have oil form. Each neonate is receiving 188uL/kg/day of sunflower oil as placebo in two doses per day, since two days before surgery and over six days following cardiovascular surgery
45387829|NCT00972491|Procedure|Insertion of Laryngeal Mask Airway|The LMA will be inserted at 0 sec, 60 sec. and 90 sec. after induction of general anesthesia
45387830|NCT01045395|Dietary Supplement|Corn starch|90mg/d
45387831|NCT01045395|Dietary Supplement|Unique Marine Algae Concentrate (UMAC)|90mg/d
45387832|NCT01045395|Dietary Supplement|Golden brown algae|90mg/d
45387833|NCT00972569|Drug|BNP and PDE-V|low dose BNP 0.025 u/kg/min for 3 hours then 0.005ug/kg/min 45 hours PDE-V 12.5 mg 4 time points
45387834|NCT00972569|Drug|BNP|low dose BNP at 0.025 u/kg/min if tolerated then at 0.005 ug/kg/min for 45 hours
45387835|NCT01324557|Procedure|CSII and MDI|The aims of this study are to assess the potential efficacy and safety of insulin pump(MiniMed Paradigm® REAL-Time Revel™ Insulin Pump) to improve glycemic control in conjunction with continuous glucose monitoring (CGMS) for diabetic CAPD Patients.
45387836|NCT00972647|Procedure|Laser beam guidance|Using the laser centralizing beam to assist in position the body part prior to fluoroscopic imaging
45387837|NCT00974597|Device|AWBAT™-D and Mepilex® Ag dressings|Comparison of AWBAT™-D and Mepilex® Ag dressings for treatment of donor sites in burn surgery.
45387838|NCT00974753|Drug|Ketorolac 0.5%|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
45387839|NCT00974753|Other|Saline drops|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
45387840|NCT04008719|Other|Thymic history|This interview concerns mainly the nature of the previous psychiatric and psychological care
45387841|NCT04008719|Other|Evaluation of the psychiatric disorders|Mini International Neuropsychiatric Interview for the positive diagnosis of depression - under the MINI score of depression.
45501558|NCT05164003|Drug|BOTOX®|Up to a total of 360U of the comparator was allowed to be injected at three flexors; wrist, elbow and finger.
45501559|NCT05163535|Drug|VM-1500A-LAI|VM-1500A (parent drug of elsulfavirine) IM injection dosage form
45501560|NCT05163535|Other|ELPIDA®|Elsulfavirine capsules
45501561|NCT01338389|Dietary Supplement|CITICOLINE|"Oral administration of CITICOLINE:~Form: Powder for solution Dosage: 800mg per day duration: 5 years"
45501562|NCT01338389|Dietary Supplement|PLACEBO|"Oral administration of placebo:~Form: Powder for solution duration: 5 years"
45387842|NCT04008719|Other|Cognitive evaluation|They will be held consecutively to the patient's bedside interview on the same day. Some tests will be computerized, others will be in paper form.
45501563|NCT01338467|Device|EYEOP device|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP device
45501564|NCT01340755|Procedure|Transanal endoscopic surgery|Laparoscopy-assisted transanal endoscopic rectosigmoid resection
45501565|NCT04434209|Device|Subject management guided by NephroCheck® test|NephroCheck® is a device using biomarkers to identify subjects at risk of sepsis-associated acute kidney injury
45501566|NCT04434209|Other|Standard of Care|Standard of Care patient management
45501567|NCT01341925|Drug|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
45387843|NCT00974831|Other|Amino Acid Drink Mixture|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
45387844|NCT00974831|Other|Glucose drink|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
45387845|NCT00972803|Drug|pistacia Mutica extract|The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
45387846|NCT00972803|Drug|Placebo|The subjects were asked to use a placebo mouthwash twice a day for 4 days.
45387847|NCT00972803|Drug|Chlorhexidine|The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
45501568|NCT01341925|Behavioral|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
45387848|NCT02908269|Biological|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
45501569|NCT01341925|Other|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
45501570|NCT01338623|Drug|Tansulosine|capsule 0,4 mg
45387849|NCT02908269|Biological|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
45387850|NCT02908269|Biological|Fluzone High-Dose, vaccine, 2016-2017 formulation|0.5 mL, Intramuscular
45387851|NCT00974909|Device|Urgent PC neuromodulation system|Urgent PC neuromodulation system
45387852|NCT00974909|Device|Urgent PC neuromodulation system|Urgent PC neuromodulation system (sham)
45387853|NCT00974987|Radiation|BNCT(boron neutron capture therapy)|BSH(sodium borocaptate) 100mg/kg iv for one hour starting 13 hours before irradiation, and BPA(p-boronophenylalanine) 500/mg/kg iv at a speed of 200mg/kg/hr for 2 hours starting 2 hours before irradiation. During irradiation, BPA iv continues at a speed of 100mg/kg/hr.
45501571|NCT01340833|Drug|GSK2118436|Two capsules each containing 75 mg GSK2118436, followed by a single IV dose of 50 ug (no more than 7.4 kBq or 200 nCi) [14C]GSK2118436, starting 1.75 hours after the oral dose
45501572|NCT01332383|Drug|Naratriptan|
45695945|NCT03629613|Other|Baseline|No oral antioxidant cocktail intake or placebo intake will occur prior to baseline measurements
45695946|NCT04371796|Drug|Sintilimab injection|Sintilimab injection 200mg, 2cycles of treatment before surgery
45387854|NCT00974987|Radiation|XRT(X-ray radiation treatment)|After BNCT, 2Gy irradiation every day for 12 days.
45501573|NCT01338701|Procedure|Traditional Chinese Acupuncture (TCA)|An acupuncturist will examine and evaluate subjects before inserting thin, sterile stainless steel needles at specific points on their body. Patients will receive 10 treatments over a 6 week period.
45387855|NCT00974987|Drug|TMZ(temozolomide)|75mg/m2 for day1-12. After XRT, repeat the cycle of 150-200mg/m2 for 5 days and cessation for 23 days.
45387856|NCT00975065|Drug|vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)|vildagliptin 50 mg bid plus metformin 1500mg
45387857|NCT00975065|Drug|metformin 1500mg plus metformin 500mg or 1000mg (Diabex)|metformin 1500mg plus metformin 500mg or 1000mg
45501574|NCT01338701|Procedure|Auricular (Ear) Acupuncture|An acupuncturist will insert sterile stainless steel needles and an ASP ear needle into various points in subject's outer ear. The ASP is a shorter needle that will stay in the participant's ear for a few days. Patients will receive 10 treatments over a 6 week period.
45501575|NCT01338701|Other|Usual Care|Subjects do not receive acupuncture during the 6 week study time period. Instead, they continue to receive medical care for headaches and other symptoms. They can elect to receive up to 10 ear acupuncture treatments between the 6- and 12-week assessments.
45501576|NCT01340911|Drug|SRT3025|SRT3025 will be supplied as hard gelatin capsules containing either 27.4 mg (25 mg SRT3025 free base equivalent) or 274 mg (250 mg SRT3025 free base equivalent) of SRT3025 HCl monohydrate drug substance.
45501577|NCT01340911|Drug|Placebo|For placebo product, the SRT3025 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 105) to match the SRT3025 investigational product.
45501578|NCT01340989|Procedure|alteration of the insufflation gas|addition of 4% oxygen
45501579|NCT01340989|Procedure|full conditioning|"addition of 4% oxygen + 10% nitrous oxide to the peritoneum~humidification~set temperature of 32°C"
45501580|NCT01340989|Procedure|standard pneumoperitoneum|no intervention besides the use of CO2
45501581|NCT01337011|Other|autologous CD133pos stem cell application|The study aims to show efficacy of both intra-myocardial autologous CD133pos bone marrow cell application as well as intra-coronary CD133pos cell application in patients with symptomatic ischemic heart disease. In addition, efficacy between the two delivery routes will be compared.
45501582|NCT05162209|Dietary Supplement|Synbiotic|Oral sachet, for 12 weeks
45501583|NCT01342159|Procedure|Intravitreal injection|Intravitreal Injections were done under sterile conditions with topical anesthesia and insertion of a lid speculum. For the bevacizumab group, 1.25 mg (0.05 cc) bevacizumab (Avastin, made for F. Hoffmann-La Roche Ltd Basel, Switzerland by Genentech Inc., San Francisco, CA, USA) was injected intravitreally with a 30-gauge needle through the superotemporal quadrant. For the bevacizumab with triamcinolone group, in addition to intravitreal bevacizumab, 2 mg(0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally through the inferotemporal quadrant. For triamcinolone group, 2 mg (0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally.
45387858|NCT00972881|Biological|cetuximab|
45387859|NCT00972881|Drug|capecitabine|
45387860|NCT00972881|Drug|irinotecan hydrochloride|
45387861|NCT00972881|Procedure|neoadjuvant therapy|
45387862|NCT00972881|Procedure|therapeutic conventional surgery|
45387863|NCT00972881|Radiation|radiation therapy|
45387864|NCT00290758|Drug|placebo|Given orally
45387865|NCT00290758|Drug|genistein|Given orally
45387866|NCT00290758|Other|laboratory biomarker analysis|Correlative studies
45387867|NCT00975299|Drug|BAY86-4367|Cancer patients, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, PET/CT
45387868|NCT00975299|Drug|BAY86-4367|Healthy volunteers, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, whole body PET/CT for determination of effective dose., kinetics of BAY86-4367 in blood
45695947|NCT02244346|Drug|Secotex®|
45387869|NCT04008485|Device|Magnetic Electric Impedance Spectroscopy Device to predict PTB|During this phase, we will measure MIS in 100 women at high risk of PTB (Group 1) and 100 women with symptoms of PTB to confirm its predictive potential for PTB. To determine whether MIS assessment could prove a platform technique for other tests and treatments within existing antenatal care pathways for PTB, we will also assess vaginal swabs for fFN and measure cervical length (CL) by ultrasound.
45501584|NCT01342237|Drug|HDCT 1(TTC), HDCT2(MEC)|"TTC Topotecan (2 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4) Thiotepa (300 mg/m2 once daily i.v on days -8, -7, -6) Carboplatin (500 mg/m2 once daily i.v on days -5, -4, -3) (max. 700 mg/day)~MEC Melphalan (140 mg/m2 once daily i.v on day -7, 70 mg/m2 once daily i.v on day -6) Etoposide (200 mg/m2 once daily i.v on days -8, -6) Carboplatin (350 mg/m2 once daily i.v on days -8, -7, -6, -5)"
45387870|NCT01060930|Drug|Intravenous infusion of L-NMMA and Nor-epinephrine|Intravenous infusion of 3mg/kg L-NMMA (L-NG-monomethyl arginine; NO synthase inhibitor) and nor-epinephrine at 50 ng/kg/min. Each infusion to run over 15 mins and separated by 45 min to allow return to baseline. Drugs infused in a randomised order. During the study, blood pressure will be measured invasively using an intra-arterial radial artery cannula, central arterial stiffness measured using peripheral arterial tonometry and cardiac output using thoracic bioimpedance.
45387871|NCT00973037|Drug|Tamoxifen|Tamoxifen 20mg qd
45387872|NCT00973115|Drug|Simvastatin CR|
45387873|NCT00975377|Procedure|Hair clipping|Patients randomized to the hair clipping cohort will be clipped using an Allegiance 4413 hair clipper. Hair removal will occur on the day of surgery by one of the preoperative nursing staff, immediately prior to the scheduled operation.
45387874|NCT00973193|Drug|panitumumab|intravenous infusion of panitumumab, 6 mg per kg body weight, once every 14 days for a total of 42 days
45387875|NCT00975533|Device|Tantalus|The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM.
45501585|NCT01337323|Drug|Fluticasone furoate nasal spray|fluticasone furorate intranasal steroid spray
45501586|NCT03157037|Biological|Imlifidase|One dose of 0.25 mg/kg body weight imlifidase on study day 1
45501587|NCT04830943|Drug|Cerebrolysin|Cerebrolysin will be prescribed in a dose of 5 ml ampoule once daily through intramuscular injection (1ml contains 215.2 mg cerebrolysin) for five times per week, for a total of 40 treatments (for 8 weeks), after which the cycle was individually repeated according to the response of the patient to therapy for a maximum of 24 weeks
45501588|NCT01341145|Behavioral|Aerobic Exercise|12-week moderate-intensity aerobic exercise program designed in accordance with the recommended guidelines established by the American College of Sports Medicine
45695948|NCT03819309|Procedure|Ultrasound-guided transvaginal drainage|evacuation of the TOA will be done by ultrasound-guided transvaginal puncture under simple sedation or under general anesthesia if necessary
45501589|NCT01341145|Behavioral|Relaxation|12-week progressive muscle relaxation program (active control)
45387876|NCT00975533|Drug|Insulin|Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
45387877|NCT00372567|Drug|sunitinib malate|37.5 mg daily
45387878|NCT00372567|Drug|imatinib mesylate|800mg daily
45501590|NCT04429321|Drug|Nivolumab|Nivolumab 3 mg/kg IV every four weeks, first in combination with capecitabine then alone
45501591|NCT04429321|Drug|Ipilimumab|ipilimumab 1/mg/kg IV every 3 weeks x 4 cycles, in combination with Nivolumab
45501592|NCT04429321|Device|bland embolization|Lipiodol:ethanol embolization of their primary or target tumor
45501593|NCT03067610|Radiation|Intensity Modulated Radiation Therapy|The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction.
45501594|NCT03067610|Drug|chemotherapy|chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion
45501595|NCT01338935|Drug|CW 002|"For Cohort 1, subjects receive a single bolus of 0.02 mg/kg CW 002 (i.v.) and neuromuscular function will be allowed to recover spontaneously for at least 5 half-lives.~For Cohort 2, an estimated ED50 bolus dose of CW 002 (approximately 0.03 mg/kg) will be given i.v. followed by a second bolus of the same dosage*.~For Cohort 3, an estimated ED 75 bolus dose of CW 002 (approximately 0.04 mg/kg) will be given i.v. followed by a second bolus of the same dosage *.~For Cohort IV, an estimated ED 90 bolus dose of CW 002 (approximately 0.06 mg/kg) will be given i.v. followed by a second bolus of the same dosage*.~*For Cohorts 2-4, a second bolus dose will be administered following a minimum of 5 half-lives of CW002 (based on PK data from Cohort 1)."
45695949|NCT03819309|Procedure|Laparoscopy|TOA will be evacuated by coelioscopy under general anesthesia
45695950|NCT04365712|Device|Piezoelectric tool|
45695951|NCT04365712|Device|Oscillating Saw|
45695952|NCT03629223|Drug|Tepotinib TF2|Participants will receive single oral dose of Tepotinib TF2 under fasting or fed conditions in treatment period 1 or 2.
45387879|NCT04008251|Genetic|Second generation humanized CAR-T cells|Patients receive humanized CD19 CAR-T cells transduced with a lentiviral vector on days 0/1/2 in the absence of disease progression or unacceptable toxicity.
45501596|NCT01338935|Drug|CW 002|"Subjects receive an initial ascending bolus dose of CW 002 injection, and a second bolus followed by a continuous infusion initiated at the point of 25% recovery of twitch response. Infusion rate will be adjusted to maintain 97%- 99% suppression of twitch, but to avoid complete neuromuscular block. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 5- subject receives 2.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 30 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 6 - subject receives 3.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 60 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 7 - subject receives 4.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 90 min infusion of 2-10 mcg/kg/min of CW 002~Bolus doses of ED95 are determined in Part I of the study."
45387880|NCT00973271|Drug|290 mg DCCR|290 mg diazoxide choline
45387881|NCT00973271|Drug|435 mg DCCR|435 mg diazoxide choline
45501597|NCT01338935|Drug|CW 002|"In Part III, safety, intubation efficacy, and PK will be evaluated in 2 cohorts (Cohorts 8 and 9) of 6 subjects each, who will undergo endotracheal intubation at 60 or 90 seconds after a bolus dose of CW002 injection at 3 to 4 times the ED95. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 8 - subject receives 3.0x ED95 dose of CW 002, and intubation attempt is made 90 seconds post-bolus.~Cohort 9 - subject receives 4.0x ED95 dose of CW 002, and intubation attempt is made 60 seconds post-bolus."
45387882|NCT00973271|Drug|135 mg fenofibric acid|135 mg fenofibric acid
45501598|NCT04455295|Device|Transdermal Vagus Nerve Stimulation (tVNS)|Mild non-invasive transdermal electrical stimulation at the ear (0.0-1.0 mA, 0.0-30.0 Hz). Used in previous studies with no unexpected adverse events. Stimulator not considered a FDA regulated device in previous studies.
45501599|NCT03567902|Device|C-MAC videolaryngoscope intubation|C-MAC videolaryngoscope intubation
45501600|NCT03567902|Device|Direct laryngoscope intubation|Direct laryngoscope intubation
45501601|NCT05186701|Other|Kinesio Tape|"Kinesio tape was applied with mechanical correction technique having I shaped with 50-100% tension for 72 hours on both shoulders in retracted position from the anterior aspect of the acromion to the spinous process of the 10th thoracic vertebra of the both shoulders.~Conventional Physical; Therapy:~Thermotherapy (hot pack) applied for 10 minutes. Myofacial release. Active isolated unilateral stretching of pectoralis minor muscle for 30 seconds (3 set × 3 reps/day).~Strengthening of shoulder retractors (lower trapezius and rhomboids). (3 set × 15 reps/day).~Participants were asked to do exercises at home on daily basis."
45387883|NCT00973271|Drug|Placebo|Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid
45387884|NCT00973271|Drug|atorvastatin|20 mg atorvastatin
45387885|NCT00975767|Drug|MGCD265+erlotinib|MGCD265 and erlotinib administered daily
45387886|NCT00975767|Drug|MGCD265+docetaxel|MGCD265 administered daily; docetaxel administered once every 3 weeks
45387887|NCT00975845|Other|BioCleanse Tibialis tendon|Outcomes of anterior cruciate replacement will be evaluated
45387888|NCT00365547|Biological|bevacizumab|Will be given by intravenous (IV) infusion at the dose of 10 mg/kg on days 1 and 15 after topotecan administration until disease progression or for another reason.
45387889|NCT00365547|Drug|topotecan hydrochloride|Topotecan 4 mg/m^2 intravenously (IV) will be given as a 30-minute intravenous infusion on days 1, 8, and 15 with a rest on day 22. Treatment will be repeated every 28 days until disease progression or for another reason.
45387890|NCT00545441|Device|Surgisis Biodesign Anal Fistula Plug (Surgisis® AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia.
45387891|NCT00545441|Device|Flap|Advancement flap surgery is performed; no anal fistula plug is placed
45387892|NCT03991767|Other|"POP-UP electronic alert"|"Implementation of the POP-UP electronic alert for all patients with eligibility criteria"
45387893|NCT03991767|Diagnostic Test|Serology HIV|Realization of HIV serology for included patients.
45387894|NCT00976001|Other|Information, further rehabilitation, additional drugs to prevent recurrent stroke|
45387895|NCT00976001|Other|As the general practitioner wants to do|
45387896|NCT00979589|Drug|Clopidogrel|The first group will receive a 300mg loading dose (LD) of clopidogrel on the day of randomization, followed by 75 mg clopidogrel/day from Day 2 to 3 months. ASA will be given in a total dose ranging between 75 mg and 300 mg (open label) on the first day, followed by blinded 75 mg once /day from Day 2 to Day 21st. Between Day 21st and 3-month visits, ASA 75 mg will be replaced by a placebo of ASA 75 mg.
45695953|NCT03629223|Drug|Tepotinib TF3|Participants will receive single oral dose of Tepotinib TF3 under fasting or fed conditions in treatment period 1 or 2.
45387897|NCT00979589|Drug|Placebo of clopidogrel and Asprin|The second group will receive open label ASA in a total dose ranging between 75 mg and 300 mg on the first day, followed by blinded 75 mg once /day from Day 2 to 3 months. A placebo for clopidogrel will be given from the day of randomization until the 3-month visit.
45387898|NCT00294658|Procedure|thymectomy plus prednisone|The thymectomy will be performed as soon as possible after randomization.
45387899|NCT00294658|Drug|prednisone alone|Prednisone regimen will be every other day, starting at 10mg. The dose will increase by 10mg every 2 days to a target dose.
45387900|NCT00979667|Drug|Oseltamivir|75 mg twice daily for 5 days
45387901|NCT00979667|Drug|Zanamivir|10 mg twice daily for 5 days
45387902|NCT00979667|Drug|Placebo of Oseltamivir|twice daily for 5 days
45387903|NCT00976079|Device|Transcutaneous electrical nerve stimulation (TENS)|Continuous TENS use
45387904|NCT00976079|Device|Placebo TENS|Placebo TENS use
45387905|NCT03978052|Dietary Supplement|EGCG|"Participants that weight >50kg intake one oral dose in the morning for breakfast and a second dose in the afternoon in (266 + 266 mg/EGCG, 49 + 49 g of Font-up).~Participants that weight <50kg intake one oral dose in the morning for breakfast (266 mg/EGCG, 49 of Font-up"
45387906|NCT03978052|Dietary Supplement|Placebo EGCG|Participants that weight >50kg intake one oral dose in the morning for breakfast and a second dose in the afternoon in (266 + 266 mg/EGCG, 49 + 49 g of Font-up)
45387907|NCT03978052|Other|Personalized intervention|A personalized intervention include a physical activity plan,dietary intervention, mental health promotion interventions,
45501602|NCT05186701|Other|Conventional Physical Therapy|Conventional Treatment: Hot pack, Myofascial Releaase, Stretching and Strengthening with Theraband
45695954|NCT04366024|Other|other|clinical diagnosis
45695955|NCT03720717|Drug|Baclofen 10mg|Baclofen administration pre-operatively
45695956|NCT03720717|Other|Placebo|Placebo administration
45695957|NCT04376554|Drug|TBPM-PI-HBr|TBPM-PI-HBr (2 x 300mg tablets) PO q8h [±1 hour] for 10 days
45387908|NCT03978052|Other|Lifestyle recommendations|The recommendations are to balance caloric intake and physical activity to achieve and maintain a healthy body weight; consume a diet rich in vegetables and fruits;
45387909|NCT03923933|Drug|Chlorthalidone|Chlorthalidone
45387910|NCT03923933|Drug|Bumetanide|Bumetanide
45387911|NCT00372489|Drug|peginesatide|Participants received the same initial peginesatide dose as was administered at the end of the previous peginesatide treatment study (NCT00228449) in which the participant was enrolled. The median first dose at study start was 0.087 milligram per kilogram (mg/kg) with an interquartile range of 0.064 to 0.123 mg/kg. Each participant was to receive peginesatide as an injection administered intravenously once every 4 weeks for approximately 54 months in this trial.
45695958|NCT04376554|Drug|amoxicillin-clavulanate|amoxicillin-clavulanate (1 × 500mg/125mg tablet) PO q8h [±1 hour] for 10 days
45695959|NCT03627741|Drug|Triamcinolone Acetonide|A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
45695960|NCT04371718|Drug|JKB-122|JKB-122 is a TLR antagonist to immune modulate for autoimmune hepatitis
45695961|NCT04371718|Other|Placebo|A capsule has same component but active drug
45695962|NCT03712839|Other|Cognitive-functional evaluation|The participants will be evaluated with a set of tools within the context of meaningful ADL.
45848448|NCT04709484|Drug|Palpation-guided steroid injection|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus bone and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
45387912|NCT01066468|Drug|Gleevec/Glivec|
45387913|NCT00979823|Other|Early SimCare Diabetes Group|Residents in the early learning program group will participate in the learning cases before undergoing a knowledge and performance assessment. They will complete 18 learning cases, 4 assessment cases, knowledge survey, and a satisfaction survey.
45387914|NCT00979823|Other|Delayed SimCare Diabetes Group|Residents in the delayed learning program group will receive their usual diabetes training through their residency program for 8 months before completing the knowledge and performance assessment, and then will subsequently be offered the learning program. They will receive 4 assessment cases, knowledge survey, and satisfaction survey
45387915|NCT01581190|Dietary Supplement|Bananas versus 6% carbohydrate beverage|Trained cyclists (N=14) completed two 75-km cycling time trials (randomized, crossover) while ingesting BAN or CHO (0.2 g/kg carbohydrate every 15 min).
45387916|NCT00976157|Procedure|Bronchoscopy BAL|The bronchoscope was passed through endotracheal tube via a specific adaptor without topical anesthesia. The bronchoscope was introduced and wedged into the segmental bronchial orifice where pneumonia was suspected. Five aliquots of 20ml sterile saline were instilled and aspirated gently. The first aliquot was discarded and the last 4 aliquots were pooled for analysis. Part of the retrieved specimen in the first BAL fluid was sent to the laboratory immediately after collection for measurement of sTREM-1 level, the rest of sample was sent to microbiology lab for quantitative culture.
45387917|NCT00976235|Device|IMT - Implantable Miniature Telescope|Implantation of the telescope prosthesis (performed under the initial study)
45387918|NCT03977740|Other|chest PNF|Chest PNF technique includes oblique downward pressure at sternum, diagonal pressure at lower rib cage at supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on elbow.
45387919|NCT03977740|Other|Conventional|conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer
45501603|NCT03570008|Behavioral|9 days spa residential program|"After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~Sp-Ex: spa residential program including physical activity~Sp-alone: spa residential program alone~Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts."
45387920|NCT00976313|Procedure|Assessment of urinary micturition after thoracotomy|Post residual urine volume and voided volume will be assessed with Bladder Scan™ BVI 6100 (Bladder scan, Bothell, WA, USA) will be performed the day before surgery and on day 2 after surgery, with epidural analgesia within segments T2-4 to T10 21,22. Bladder sensitivity will be assessed at strong desire to void. On day 2 the bladder will be filled through the transurethral catheter till the patient signalised a strong desire to void, then the catheter will be removed and spontaneous micturition will be attempted. Voided volume and post void residual will be assessed.
45387921|NCT00976313|Other|International Prostate Symptom Score|International Prostate Symptom Score (IPSS) for assessment of lower urinary tract symptoms (LUTS) preoperatively
45387922|NCT03921047|Procedure|Biospecimen Collection|Undergo collection of blood samples
45387923|NCT03921047|Other|Laboratory Biomarker Analysis|Correlative studies
45695963|NCT04376164|Radiation|low level laser therapy|mandibular anterior teeth were irradiated by gallium aluminum arsenide semiconductor laser with 635 nm wavelength, 6.5J/cm2energy density, for 10 seconds at 10 points (0.2 J/point) on facial and lingual aspects. This protocol was started immediately after first wire insertion and then at days 3,7,14 of the first month and repeated for additional 2 months
45695964|NCT04365322|Other|Additional biological samples|Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected.
45387924|NCT00980135|Device|Sinecort cream|Application over 29 days
45387925|NCT00980135|Drug|Hydrocortison cream|Application over 29 days
45387926|NCT00980135|Other|Untreated skin|
45387927|NCT00980213|Drug|sunitinib|sunitinib 50 mg, per os, daily for 4 weeks then 2 weeks pause, duration months
45848449|NCT03541980|Drug|Acetaminophen|Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen
45387928|NCT04986527|Procedure|Chest tube suction|The chest tubes will be inserted using our institutional standard chest tube insertion tray. The chest tubes used will be our institutional standard and will range from 14 to 32Fr in size. After chest tube placement, an Atrium Oasis Dry Suction Water Seal Chest Drain (Getinge USA Sales, LLC) will be used.
45387929|NCT00980447|Biological|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 45µg three weeks apart
45387930|NCT00980447|Biological|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 90µg three weeks apart
45387931|NCT00980447|Biological|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 135µg three weeks apart
45387932|NCT00976469|Biological|H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated)|2-dose priming at a 21-day interval, intramuscular injection in either the upper arm or thigh, depending on the subject´s age
45387933|NCT00976469|Biological|Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011|Booster vaccination at Day 360 after first vaccination (only in subjects who received the 7.5 µg dose of the H1N1 pandemic influenza vaccine)
45387934|NCT00372411|Device|Robot-Assisted Therapy - MIT-MANUS System|The MIT-MANUS robot consists of four modules to train the entire upper limb: module A: shoulder-elbow; module B: anti-gravity; module C: wrist, and module D: hand-unit. Training will be given for 12 weeks and is divided into 4 consecutive blocks, with 9 training sessions per block.
45387935|NCT00372411|Other|Intensive Comparison Therapy|The intensive comparison therapy protocol being used in CSP#558 was developed and field-tested at the Burke Rehabilitation Hospital. It exposes the patient to the identical number of treatments, time, and intensity that robot treated patients will receive (12 weeks, 3 times per week). Therapy sessions can be conducted on back-to-back days if needed and on more than 3 days a week (with approval from the Study Chairman) over a treatment period of up to 14 weeks in order to complete the 36 treatment sessions. During each 1-hour session, subjects participate in therapy in four successive stages: 1) warm-up and assisted stretching; 2) active arm treatments; 3) goal-directed planar reaching, and 4) functionally based Neurodevelopment Techniques (NDT)/Bobath arm training (Bobath, 1979).
45387936|NCT00372411|Other|Usual Care|The usual chronic stroke care as delivered at each participating medical center
45554667|NCT04915677|Procedure|Soft tissue augmentation with xenogenic volume stable collagen matrix|After local anesthesia a mesio-distal crestal incision will be performed reaching the alveolar bone. Split thickness dissection performed both buccal and palatal. Xenogenic volume stable collagen matrix will be inserted beneath the mucoperiosteal flap and stretched buccally and lingually using a modified horizontal mattress suture. The flap margins at the crest will be adapted using single interrupted sutures in order to achieve a primary closure of the flap.
45387937|NCT00976625|Procedure|Aortic Valve Replacement|Surgical valve replacement of the aorta
45387938|NCT00980603|Drug|docetaxel|docetaxel 75 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
45387939|NCT00980603|Drug|docetaxel, cisplatin|docetaxel 60 mg/m2 and cisplatin 60 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
45387940|NCT00980603|Drug|docetaxel, S-1|docetaxel 60 mg/m2 IV on day 1 and S-1 30 mg/m2 bid PO on days 1-14 of each 3 week cycle until progression or unacceptable toxicity develops
45387941|NCT00955097|Drug|Definity®|Definity® injections given both pre-ablation and post-ablation
45554668|NCT02710214|Drug|Tissue Selective Estrogen Complex|Once-daily dosing of Duavee for 8 weeks.
45695965|NCT03719937|Device|weight on the anterior chest of the patient|The investigators aim at assessing whether and to what extent an artificial increase in chest wall elastance, while the patient is in the supine position, may yield a significant benefit to oxygenation. The increase in chest wall elastance will be will be achieved placing a 100 g/kg weight on the anterior chest wall of the patient while he/she is in the supine/semirecumbant position. The weights will be placed on the patients' chest for 120 minutes, and then removed. A number of measurements will be recorded before and after the procedure.
45848450|NCT03541980|Drug|Normal saline|Normal saline volume equivalent
45848451|NCT04511520|Other|Physical training program|
45848452|NCT04511520|Drug|Trimetazidine|
45848453|NCT04491240|Drug|EXO 1 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the first type.
45848454|NCT04491240|Drug|EXO 2 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10^10 of nanoparticles (exosomes) of the second type.
45387944|NCT00955175|Radiation|hypofractionated radiation therapy|Given 5 days a week for 20, 22, or 24 fractions
45387945|NCT00980759|Radiation|EFI|Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
45387946|NCT00980759|Radiation|Pelvic RT|Only Pelvic Irradiation with chemotherapy(cisplatin)
45387947|NCT00976859|Behavioral|Imagery Modification|Research via internet concerning the frequency of skin exchange and disputation of the collected information; in the guided imagery modification the therapist instructs the patient to imagine the feeling of being contaminated and the process of peeling off their former contaminated skin and the maturing of hundreds of new clean skin cells
45387948|NCT00976859|Behavioral|Waitlist control group|Patients in the wait list control group are treated after a waiting period of five weeks
45387949|NCT04011293|Biological|CNCT19|0.5 to 4 x 10^6 autologous CNCT19 transduced cells per kg body weight, with a maximum dose of 4 x 10^8 autologous CNCT19 transduced cells via intravenous infusion.
45387950|NCT03958019|Other|RESTORE II Program|Detailed in arm description
45387951|NCT00372255|Biological|Influsplit SSW® 2005/2006|Study influenza vaccine was administered intramuscularly in the non-dominant arm
45387952|NCT00977015|Drug|Treatment A|Inhaled, 750/150, single dose
45387953|NCT00977015|Drug|Treatment B|Inhaled, 750/150, single dose
45387954|NCT00274456|Drug|ABI-007|ABI-007 administered by intravenous infusion over 30 minutes at one of three different dosing levels (100, 150 or 300 mg/m^2) with a treatment cycle length of either 3 or 4 weeks depending upon treatment arm assignment.
45387955|NCT00274456|Drug|Docetaxel|Docetaxel dosed q3w at 100 mg/m^2
45387956|NCT01045629|Other|Consent form education|Randomly stratified schizophrenic patients group, some receive consent form education, the others not.
45387957|NCT01049607|Procedure|Clamp-Crush technique|The transectional line is marked and the liver capsule is cauterized. The liver parenchyma is then crushed stepwise using a regular Pèan clamp. Vessels and bile ducts are ligated or clipped. Vessels of less than 2mm diameter are coagulated with the irrigated bipolar forceps.
45387958|NCT01049607|Procedure|Stapler hepatectomy|The transectional line is marked and the liver capsule is cauterized. For subsequent transection of the hepatic parenchyma, the liver tissue is fractured with a vascular clamp in a stepwise fashion and subsequently divided with endo GIA vascular staplers.
45387959|NCT00977093|Other|Perfusion CMR for detection of coronary artery disease|Perfusion CMR is performed during adenosine infusion for vasodilation (3 minutes of 0.14mg/kg/min IV) and injection of Gd-DTPA-BMA at 0.075mmol/kg IV.
45387960|NCT00977093|Other|Perfusion cardiac magnetic resonance imaging|Perfusion CMR with Gd-DTPA-BMA to detect coronary artery disease
45695966|NCT03818217|Device|Coach Pepper group|"Robot Pepper's height is 1.20 meters and it weighs 28 kilograms. Pepper's operation time is about 12 hours.~Pepper will be called as Coach Pepper because s/he is virtually connected via web interfaces with a theratainment app including cognitive and physical training ."
45695967|NCT03818217|Device|Tablet group|The Tablet provides a theratainment app including cognitive and physical training.
45848455|NCT04491240|Drug|Placebo inhalation|Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
45848456|NCT04463004|Drug|Mavrilimumab|Treatment infusion
45848457|NCT04463004|Drug|Placebos|Placebo infusion
45387961|NCT00977249|Behavioral|support and visits|visits at weeks 0,2,4,6,9 and 12 and 12 months
45387962|NCT00977249|Drug|varenicline|
45387963|NCT00977249|Drug|placebo|
45387964|NCT01069822|Drug|AZD6765|IV solution
45387965|NCT01069822|Drug|midazolam|
45387966|NCT00977327|Device|Intraoperative MR (PoleStar N-20, Medtronics)|intraoperative imaging for resection control of intraaxial brain lesions
45387967|NCT00977327|Device|Intraoperative Ultrasound (Sonowand, Mison)|intraoperative imaging for resection control of intraaxial brain lesions
45387968|NCT03977974|Drug|LY3526318|Administered orally
45387969|NCT03977974|Drug|Placebo|Administered orally
45387970|NCT00955565|Procedure|Navigated|Subjects receive receive computer assisted placement of the sacroiliac screws. The computer assisted placement will be performed by using the BrainLab Vector Vision®Trauma Navigation Software. Two approaches will be used, the 2D navigation and 3D navigation.
45387971|NCT00955565|Procedure|Conventional|Subjects receive standard fluoroscopic placement of the sacroiliac screw.
45554669|NCT02710214|Drug|Placebo|Once-daily dosing of placebo for 8 weeks
45554670|NCT03524547|Device|J shaped stylet used for endotracheal intubation|After inserting a stylet into the endotracheal tube, the tube will be molded into a J-shape.
45554671|NCT03524547|Device|60-degrees stylet used for endotracheal intubation|After inserting a stylet into the endotracheal tube, the tube will be bent 60-degrees.
45848458|NCT04430634|Other|Myblu variant A|Use of Myblu e-cigarette with flavor A 2.4% nicotine
45848459|NCT04430634|Other|Myblu variant B|Use of Myblu e-cigarette with flavor B 3.6% nicotine
45387972|NCT03976180|Device|Stadard low-flow oxygen|In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care
45387973|NCT03976180|Device|HFNO with low FiO2 (21%-30%)|HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function
45387974|NCT03976180|Device|HFNO with intermediate FiO2 (50%)|In this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
45387975|NCT03976180|Device|HFNO with high FiO2 (100%)|In this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
45501604|NCT03570008|Behavioral|3 sessions of 10 minutes per day of physical exercise|"After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~Sp-Ex: spa residential program including physical activity~Sp-alone: spa residential program alone~Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts."
45387976|NCT00364923|Drug|Pralatrexate Injection|Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week cycle.
45387977|NCT01066702|Biological|NeoCart|implantation of an cartilagenous tissue implant derived from the patients own cells.
45387978|NCT01066702|Procedure|Microfracture|holes are created in bone at the base of the defect bed to encourage growth of tissue within the defect bed.
45387979|NCT00381849|Drug|Cystone|"Participants will take 2 pills, 2 times a day.~Each tablet of Cystone contains:~Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg."
45501605|NCT02246426|Other|Computerized plasticity-based adaptive cognitive training|Computerized plasticity-based adaptive cognitive training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
45501606|NCT02246426|Other|Commercially available computerized training|Commercially available computerized training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
45695968|NCT00926848|Behavioral|Partners Together in Health (PaTH) Intervention|Patients and partners in the PaTH experimental group participated in 18-36 exercise and 18 educational sessions in a structured cardiac rehabilitation program. Patients in the Usual care group also participated in 18-36 exercise and 18 educational sessions; partners, however, only participated in the educational sessions.
45695969|NCT03626337|Drug|Thiamine 100 MG/ML|100 mg thiamine provided as intramuscular injection
45695970|NCT02244658|Drug|rhTPO|rhTPO 1.0 μg/kg·d subcutaneously for 7~14 consecutive days
45387980|NCT00381849|Drug|Sugar Pill (Placebo)|Participants will take 2 pills, 2 times a day for 6 weeks.
45848460|NCT04430634|Other|Myblu variant C|Use of Myblu e-cigarette with flavor C 2.5% nicotine
45848461|NCT04430634|Other|Myblu variant D|Use of Myblu e-cigarette with flavor D 4.0% nicotine
45387981|NCT00273052|Drug|Carvedilol Phosphate modified release formulation|
45387982|NCT00273052|Drug|metoprolol succinate|
45387983|NCT01046721|Drug|Exenatide|single dose of 5 microg Exenatide. Subcutaneous administration
45387984|NCT01046721|Drug|Saline|subcutaneous administration of 0.9% saline solution (0.02 ml)
45387985|NCT02808351|Drug|Berberine|
45387986|NCT02535195|Dietary Supplement|Ginger supplement|
45387987|NCT02535195|Dietary Supplement|Placebo (starch)|
45387988|NCT01046799|Drug|Entecavir|Entecavir monotherapy after short-term HBIg therapy for patients transplanted for hepatitis B induced end-stage liver disease; in case of prior lamivudine treatment, tenofovir will be added to the reinfection prophylaxis
45387989|NCT00290290|Drug|chlorhexidine-alcohol|Preoperative skin preparation with scrub and paint technique
45387990|NCT00290290|Drug|Povidone-Iodine|preoperative skin preparation with scrub and paint technique
45387991|NCT01049685|Drug|First-line Antiretroviral Therapy|"Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background~Efavirenz: 01 capsules day, plus NRTI background"
45387992|NCT01580943|Drug|Chlorhexidine|Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds. These regimens are suggested by the manufacturers in the instructions
45501607|NCT00381485|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
45501608|NCT00381485|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
45387993|NCT01580943|Drug|Chlorhexidine|"All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?)."
45387994|NCT02534961|Drug|Cefazolin|Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy. Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established. Antibiotics will be changed according to the antibiotic sensitivity test of cultured microorganisms.
45387995|NCT01046955|Drug|Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab|comparison of induction therapies.
45387996|NCT00272038|Drug|Tarceva|150mg QD
45387997|NCT01047033|Behavioral|Health education|30 minutes of a health education module delivered to clients by loan officers during monthly repayment meetings, over the course of 8 months.
45387998|NCT01047033|Other|Microcredit|Small loans administered to clients through the collaborating microcredit organization, to be repaid monthly over the course of six months in the context of monthly loan group meetings.
45501609|NCT00381485|Drug|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 12 weeks
45387999|NCT01047111|Procedure|Esophagectomy|Esophagectomy Through Right Side Thoracotomy plus Midline Laparotomy Approach: Ivor-Lewis Procedure VS Esophagectomy Through Left Side Thoracotomy Approach: Sweet Procedure
45388000|NCT00271024|Drug|Naltrexone (drug)|50 mg q.d. for 13 weeks
45501610|NCT04835857|Device|ViTrack|ViTrack is a continuous non-invasive wearable blood pressure cuff.
45501611|NCT04835857|Device|Oscillometric BP Device|Oscillometric blood pressure measurement is the standard of care for measuring blood pressure in outpatient / home settings.
45388001|NCT00271024|Drug|Placebo (for Naltrexone)|Sugar pill manufactured to mimic Naltrexone tablet
45388002|NCT00381693|Drug|azacitidine|
45388003|NCT00545363|Drug|Ibandronate|Participants will receive ibandronate 150 mg QM orally for 6 months.
45388004|NCT04011215|Other|wool clothing|superfine merino wool ensembles for baby/child wear
45388005|NCT04011215|Other|standard clothing|Standard clothing refers to the clothing normally worn by the infant/child. This will not be superfine merino wool as superfine merino is not generally available for baby wear. The exact nature of the standard clothing will be recorded by investigators. From previous data we expect it to be primarily cotton.
45388006|NCT00955643|Other|oxygen|
45388007|NCT00955643|Other|other|
45501612|NCT04835857|Device|Auscultatory cuff|The auscultatory method is the gold standard for clinical blood pressure measurement. A brachial cuff is mounted and a trained healthcare provider uses a sphygmomanometer and listens for the Korotkoff sounds using a stethoscope to measure blood pressure.
45501613|NCT05183269|Device|Oncomfort virtual reality monitor (Oncomfort SA, Wavre, Belgium)|Use of the Oncomfort virtual reality monitor
45501614|NCT01335503|Dietary Supplement|AN-PEP|Endoprotease enzyme (AN-PEP)
45501615|NCT01341379|Drug|N-carbamylglutamate|N-carbamylglutamate: 200 mg/kg/day for 3 days, divided into 4 daily oral doses
45501616|NCT01332539|Other|no intervention|non-interventional study
45388008|NCT05059457|Device|Blood source: single and pooled capillary and venous blood|"A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+.~Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
45388009|NCT05059457|Device|Blood source: single capillary and venous blood|"A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+ .~Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
45388010|NCT05059457|Device|Blood source: pooled capillary and venous blood|"Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
45388011|NCT00977405|Device|Collatamp Gentamicin Implant|Collatamp Gentamicin placed into subcutaneous layer of dirty abdominal wounds
45388012|NCT00977639|Procedure|Pathwork TOO test|
45388013|NCT00981383|Dietary Supplement|Omega-3 Fatty Acid Supplement|3 capsules (3x1g) fish oil-derived concentrated ethyl esters, providing 1.9 g omega-3 fatty acids (1.2 g EPA and 0.6 g DHA, with 0.1 g other omega-3 fatty acids)
45388014|NCT00981383|Other|Placebo|3 capsules (3x1g) of 50/50 soybean/corn oil blend containing less than 0.12 g of omega-3 fatty acids with negligible EPA and DHA
45695971|NCT03718845|Behavioral|Mind-Body Medicine Curriculum|The Mind-Body Medicine curriculum consists of presentations on different mind-body techniques as well as the research supporting the use of these techniques.The mind-body technique is then practiced in a supportive small group setting. Mind-body techniques will include guided imagery, relaxation techniques, several forms of meditation, autogenic training and biofeedback.
45695972|NCT02982616|Dietary Supplement|Dodecanoic acid|The middle chain saturated fatty acid that can be widely found in daily food.
45388015|NCT00977795|Drug|5-aminolevulinic acid|oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg
45388016|NCT00977873|Dietary Supplement|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
45388017|NCT00977873|Dietary Supplement|Miglyol oil|Miglyol oil will be administered in 2-monthly bolus doses over a period of one year
45388018|NCT00977951|Drug|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
45501617|NCT04414735|Other|Extracorporeal Photopheresis|Infusion of autologous cellular products exposed to ultraviolet light (UV), in the presence of a photosensitizer. The cellular product is obtained through leucopheresis and its subsequent exposure to 8-methoxypsoralen (8-MOP) and irradiation with UV-A light.
45501618|NCT01335659|Device|Fractional flow reserve|Fractional flow reserve measured by pressure wire
45501619|NCT01335659|Device|IVUS|"intravascular ultrasound~:IVUS was performed in a standard fashion using an automated motorized pullback system (0.5mm/s) with commercially available imaging catheter"
45501620|NCT05182957|Drug|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody, 200mg i.v d1 (/21d)
45501621|NCT05182957|Drug|Lenalidomide|Lenalidomide 25mg qd po d1-d10 (/21d)
45501622|NCT05182957|Drug|Azacitidine|Azacitidine 75mg/m2 i.v d1-d7 (/21d)
45501623|NCT02840474|Biological|VRC-HIVMAB080-00-AB|VRC01LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.
45501624|NCT02840474|Biological|VRC-HIVMAB075-00-AB|VRC07-523LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.
45501625|NCT00092651|Drug|MK0653A, ezetimibe (+) simvastatin|
45695973|NCT02982616|Behavioral|Positive emotion|Positive emotion induced by facial expressions and classic music.
45695974|NCT02982616|Dietary Supplement|saline|saline
45695975|NCT02982616|Behavioral|neutral emotion|Neutral emotion induced by facial expressions and classic music.
45695976|NCT04403841|Other|patient education and self-management intervention in a low-resource setting on diabetes knowledge and levels of blood glucose control|The intervention consisted group education on type 2 diabetes, including, in addition to usual diabetes care: information on diet, exercise, drug therapy, and adherence
45695977|NCT04403841|Other|Usual diabetes care alone|Usual diabetes care was consistent with the ADA guidelines (15) and comprised standard dietary and exercise advice in addition to antidiabetes treatment
45388019|NCT00977951|Drug|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
45388020|NCT00977951|Drug|Placebo (vehicle)|Placebo administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
45388021|NCT00977951|Drug|Placebo|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
45388022|NCT00981539|Procedure|enema|"pre operative rectal enema~one adult bottle to be used rectally the night before surgery"
45388023|NCT00457392|Drug|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
45501626|NCT00092651|Drug|Comparators: simvastatin and ezetimibe|
45501627|NCT04777981|Dietary Supplement|CBDRA60 supplement|CBD is a non-psychotropic cannabinoid that has a broad spectrum of well-established anti-inflammatory and immunomodulatory effects. Red algae (Rhodophyta) are known for their potent anti-viral properties, non-toxicity and for being well tolerated in humans [15, 16]. Rhodophyta contain several sulfated polysaccharides that exhibit high antiviral activity against enveloped viruses.,
45501628|NCT04777981|Dietary Supplement|Placebo|Placebo
45501629|NCT01335737|Behavioral|aerobic training|12 weeks of aerobic training, 4 times/week
45501630|NCT01335737|Behavioral|Wait list|wait list control condition
45501631|NCT04889599|Drug|BH009 (Docetaxel injection)|75mg/m2
45388024|NCT00457392|Drug|sunitinib|Sunitinib 37.5 mg daily by oral capsules in a continuous regimen
45388025|NCT00457392|Drug|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
45388026|NCT00457392|Drug|placebo|Placebo daily by oral capsules in a continuous regimen
45388027|NCT00545051|Drug|Placebo|po monthly for 12 months
45388028|NCT00545051|Drug|ibandronate|150mg po monthly for 12 months
45388029|NCT00381615|Biological|rMenB|One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
45388030|NCT00381615|Biological|rMenB+OMV|One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
45501632|NCT04889599|Drug|Docetaxel injection|75mg/m2
45501633|NCT03567824|Drug|Magnesium L-lactate dihydrate|Magnesium L-lactate dihydrate 10 mEq extended release caplets
45501634|NCT03567824|Drug|Placebo Oral Tablet|Placebo will have the same appearance, taste, odor and mode of administration as MLD10.
45501635|NCT03476213|Procedure|Group TCI|Induction and anesthesia will be done by using Gepth model for sufentanil and Schnider effect model for propofol. Anesthetics will be aplicated using infusion pump Agilia (Fresenius Kabi). Another titration will be according to target value of entropy between 40 and 60 and surgical pleth index below 35.
45501636|NCT03476213|Procedure|Group TIVA|Induction of anesthesia will be done by titrating of propofol to the dose of 1.2 mg/kg and sufentanil 5-10 ug according to body weight, maintaining of anesthesia using continuous infusion of propofol 5 mg/ kg/hour and sufentanil 35 ug/hour to reach the target value of entropy between 40 and 60 and surgical pleth index below 35.
45501637|NCT03567746|Procedure|Underwater EMR|Polypectomy is performed under full water emersion avoiding the use of submucosal injection.
45501638|NCT03567746|Procedure|Conventional EMR|It will be performed in a 2-step procedure. First the formation of a submucosal injection underneath the polyp to create a submucosal safety cushion. Then EMR is performed with a polipectomy snare.
45501639|NCT01342627|Drug|Sorafenib|"Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to the protocol.~In case of disease progression Sorafenib administration will be discontinued."
45501640|NCT05709002|Behavioral|MASP+|mHealth (mobile app) for smoking cessation
45695978|NCT03624621|Behavioral|Functional Remediation|Functional remediation includes directed group sessions tapping into the main cognitive domains affected in depression (executive functioning, attention and memory) as well as their implication in daily living.
45695979|NCT03624621|Device|Computerized Cognitive Training (CCT)|12 add-on sessions (20-minute long) after each group session to train cognitive domains.
45388031|NCT00381615|Biological|DTaP-Hib-IPV|Intramuscular (IM) injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2, 3 and 4 months in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
45501641|NCT05709002|Behavioral|Control|A mobile app designed to assist the general population with smoking cessation.
45501642|NCT04384393|Biological|ThisCART19 cells|0.2-60 x 10^6 CAR T cells per kg body weight.
45501643|NCT03570944|Procedure|HRS, KRS|Elective HRS or KNR in adult patients, with any ERAS compliance
45388032|NCT00381615|Biological|PC7|IM injections of 3 doses of 0.5 mL each of PC7 supplied in prefilled syringe were administered at 2, 4 and 13 months of age in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
45388033|NCT00381615|Biological|MenC-CRM|MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized Men C component to be re-suspended with the saline solvent (aluminum hydroxide suspension) supplied. IM injection of 2 doses each of 0.5 mL were administered into the anterolateral area of the left thigh.
45501644|NCT01343641|Drug|MK-0677|The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck & Co, Inc.
45501645|NCT01343641|Drug|Placebo|Inactive Pill used as a comparator
45501646|NCT03155945|Drug|Olorinab|Olorinab active treatment for 8 weeks.
45501647|NCT03570866|Diagnostic Test|Positron emission tomography and computed tomography|Preoperative staging of early stage intermediate and high-risk endometrial cancer with positron emission tomography and computed tomography.
45501648|NCT03570866|Procedure|Surgical treatment|Surgical treatment of early stage intermediate and high-risk endometrial cancer by usual practice: peritoneal cytology, total abdominal hysterectomy, bilateral salpingo-oophorectomy, systematic pelvic and para-aortic lymphadenectomy.
45501649|NCT01342705|Procedure|phlebotomy|Procedure: Phlebotomy of 4 ml / kg to obtain (1 phlebotomy every 14 days) and maintain (1 phlebotomy every 3 months) a serum ferritin below 50 µg / l.
45501650|NCT03570788|Procedure|Amputation|Major amputation defined as at or above ankle
45501651|NCT01342783|Genetic|DNA analysis|
45501652|NCT01342783|Genetic|RNA analysis|
45501653|NCT01342783|Genetic|mutation analysis|
45501654|NCT01342783|Genetic|nucleic acid sequencing|
45501655|NCT01342783|Other|laboratory biomarker analysis|
45501656|NCT03569930|Drug|flavonoid-based supplements|Ingredients: soybean oil (glycine max), edible gelatin, rutin, borage seed oil (borago officinalis), pineapple dry extract (ananas sativus), glycerol, thickeners (mono and diglycerides of fatty acids), emulsifier (soy lecithin).
45388034|NCT00381615|Biological|MenC-Hib|MenC-Hib was obtained by extemporaneous mixing of powder and solvent just before injection. One dose (0.5 mL) of MenC-Hib was administered at 12 months of age as an IM injection into the anterolateral area of the thigh.
45388035|NCT00381615|Biological|MMR|IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months of age in the anterolateral area of the left thigh.
45501657|NCT03569930|Drug|Centella Complex|The components are: Centella Asiatica, Beta-glucan, Arnica, Aloe Vera, Menthol, Devil's claw, perform actions useful to alleviate the painful symptomatology, restore the tone of the venous wall, assist the treatment of microcirculatory damage.
45501658|NCT03569930|Behavioral|standard of care|diet rich in water and vegetable fibers, hygienic and anal dilator
45501659|NCT01343719|Drug|BI 661051|medium dose solution for oral administration
45501660|NCT01343719|Drug|BI 661051|medium dose solution for oral administration
45501661|NCT01343719|Drug|BI 661051|medium dose solution for oral administration
45695980|NCT03624621|Behavioral|Psychoeducation|12 sessions of psychoeducation on depression, providing information about the disease, causes, consequences and other useful data for the management of depression.
45501662|NCT01343719|Drug|BI 661051|low dose solution for oral administration
45695981|NCT03624621|Device|Online games|Participants play non-directed online games during 20 minutes after each psychoeducation grup session to make the two active intervention more similar.
45695982|NCT00929500|Behavioral|MAST program|MAST program: twice a week for 4 months
45388036|NCT00978107|Biological|MVA-FCU1, flucytosine|"TG4023: single IT injection; possibility to re-administer once,~Percutaneous IT injections, under radiological or ultrasound imaging guidance~Dose-escalating schedule of administration: 107 pfu (Cohort #1), 108 pfu (Cohort #2) and 4x108 pfu (Cohort #3),~MTD injected to up to 3 different lesions (Cohort #4)~5-FC (5-fluorocytosine)/flucytosine~Dose and dosing schedule:~Daily starting dose of 200 mg/kg; daily dose will be adjusted after measurement of 5-FC plasma concentration at steady state, which should be kept below 100 mg/L~Duration: 2 weeks.~Possible routes of administration:~PO: 500 mg tablets, qid~IV: 1% 250 mL vials, 45-minute infusions."
45388037|NCT00978185|Other|medical chart review|
45388038|NCT00978185|Other|questionnaire administration|
45501663|NCT01343719|Drug|BI 661051|low dose solution for oral administration
45501664|NCT01343719|Drug|BI 661051|low dose solution for oral administration
45388039|NCT00978185|Procedure|acupressure therapy|
45388040|NCT00978185|Procedure|quality-of-life assessment|
45501665|NCT01343719|Drug|BI 661051|high dose solution for oral administration
45501666|NCT01343719|Drug|BI 661051|high dose solution for oral administration
45501667|NCT01343719|Drug|BI 661051|low dose tablet
45695983|NCT03816111|Behavioral|TEACH-PD Training Curriculum|The TEACH-PD training modules have been developed by a core group of renal nurses from the HOME Network in conjunction with senior medical clinicians from the Australasian Kidney Trials Network, eLearning curriculum developers, consumer representatives, and education experts, in line with the International Society for Peritoneal Dialysis guidelines, utilizing modern adult learning principles and best practice eLearning techniques.
45695984|NCT03816111|Behavioral|Current standard PD training|Current PD training materials and plan
45695985|NCT00929578|Drug|Fluphenazine|Intralesional injection of Fluphenazine
45388041|NCT00978185|Procedure|sham intervention|
45388042|NCT00978185|Procedure|standard follow-up care|
45388043|NCT01029132|Drug|galantamine|8 mg/day (4 mg bid) during the first 4 weeks, up to a maximum of 24 mg/day (12 mg bid) at intervals of 4 weeks, from 16 to 24 mg/day based on the patient's tolerability
45388044|NCT00981695|Biological|MVA.HIVA|1 dose of 5 x 10^7 pfu of MVA.HIVA administered intramuscularly
45388045|NCT04008017|Diagnostic Test|Eosinophilic Cationic Protein biomarker|3 ml blood for serum sample for estimation of Eosinophilic Cationic Protein biomarker level using ELISA
45388046|NCT01049763|Drug|oseltamivir|oseltamivir 150 mg single oral dose oseltamivir 75 mg single oral dose
45388047|NCT00981773|Drug|Maraviroc|Maraviroc 150 mg bid
45388048|NCT00981773|Drug|Maraviroc|maraviroc 150 mg bid switch 12 weeks later
45388049|NCT04007549|Behavioral|Brief motivational interview on tobacco/alcohol risk reduction|"The intervention is a couple brief motivational interview (CBMI) on tobacco/alcohol risk reduction, delivered in a single session and a booster session one month later.~It is based on motivational interviewing principals (patient-centered communication, expression of empathy, develops discrepancy, deal with resistance to change, support self-efficacy and autonomy), with feedback on tobacco / alcohol consumption, information delivery and if needed referral to treatment. The intervention also specifically focuses on relational dynamics, and marital support development. This intervention will be compared with a single individual brief motivational intervention (IBMI) and a booster session one month later, only delivered to the patient; and the partner receive e-mail or postal brief advices.~All brief interventions will be carried out by the same psychologist trained and supervised for this type of intervention."
45388050|NCT00371865|Behavioral|Cognitive-behavioral therapy|8 group-administered sessions of Cognitive-Behavioral Therapy; includes relaxation, cognitive restructuring, and problem-solving
45501668|NCT01343719|Drug|Placebo|solution for administration
45501669|NCT01343719|Drug|BI 661051|medium dose tablet
45501670|NCT03569852|Behavioral|Time Restrictive Feeding|Volunteers will adhere to a form of time restrictive feeding, 16 hours fasting and 8 hours eating per day.
45501671|NCT03569852|Behavioral|Traditional Eating Pattern|Volunteers will adhere to a more traditional eating pattern, 12 hours fasted and 12 hours eating per day.
45501672|NCT01316731|Other|Single legged exercise|A single exercise bout that consists of one hour one-legged cycling on a adapted recumbent cycle ergometer at a submaximal rate. The non-exercising leg will serve as control for the exercising leg.
45501673|NCT03160703|Other|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silica|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica (RDA~58) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
45695986|NCT00929578|Drug|Placebo|Intralesional injection of placebo
45695987|NCT03615105|Radiation|Hyperfractionated total body irradiation|Hyperfractionated TBI is administered by a linear accelerator at a dose rate of <20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1,375 or 1,500 cGy) over 4 days (days -9 through -6).
45695988|NCT03615105|Drug|Thiotepa|Thiotepa 5 mg/kg IV
45695989|NCT03615105|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV
45695990|NCT03615105|Drug|Busulfan|Busulfan (adult/ped dose)
45388051|NCT00371865|Behavioral|Acceptance-based therapy|8 group-administered sessions of Acceptance-based therapy; includes mindfulness, values, and committed action
45695991|NCT03615105|Drug|Fludarabine|Fludarabine 25 mg/m2 IV
45695992|NCT03615105|Drug|Melphalan|Melphalan 70 mg/m2 IV
45388052|NCT05057585|Behavioral|Turning in bed, arm and leg exercises|Exercises (arm and leg exercises, turning in bed) were applied only to the experimental group. It was applied for 15 minutes 12-24 hours before the operation.
45388053|NCT03935867|Behavioral|C-PROFET|An expansion of the evidence-based, multi-factorial, fall prevention program PROFET (Prevention Of Falls in the Elderly Trial), developed for older adults who experienced a fall-related injury, to an at risk community-dwelling population who have not sustained a fall-related injury requiring medical intervention.
45388054|NCT01049841|Drug|perifosine + temsirolimus|The patient will take oral tablets of perifosine at a dose and frequency to be determined their height, weight and time when they enter the study as those entering early will be treated with lower dose levels (dosing frequency will vary from once a week to daily). The patient will receive an intravenous injection of temsirolimus once a week at a dose to be determined by their height, weight and time when they enter the study as those entering early will be treated with lower doses. In addition they will be asked to keep a medicine diary.
45388055|NCT00978263|Drug|metformin-based Oral Antidiabetic Drugs|
45388056|NCT00978263|Drug|Glargine|
45388057|NCT00981851|Drug|Tiotropium (Spiriva) + Salbutamol (Ventolin)|1 time inhalation of 5 mcg of Tiotropium bromide by Respimat and 400 mcg of Salbutamol by Volume Spacer. cigarette smoking
45388058|NCT00981851|Drug|placebo|1 time inhalation of placebo with the amount of puffs similar to the active comparator. cigarette smoking
45388059|NCT00978575|Drug|ferricarboxymaltose|Single dose of maximum 1000 mg ferricarboxymaltose intravenous
45695993|NCT03615105|Drug|Clofarabine|Clofarabine 20-30 mg/m2 IV
45388060|NCT00978575|Drug|Ferrosulfate|200mg daily for 12 weeks
45388061|NCT00978575|Drug|Placebo|100 mg isotonic sodium and 2 placebo tablets daily
45388062|NCT04007315|Device|SaeboGlove therapy|An individualised self-management training programme involving repetitive grasping and releasing movements over 6 weeks.
45388063|NCT04007315|Behavioral|Usual care|6-weeks of usual NHS care
45388064|NCT00981929|Drug|Tramadol|50 mg single oral dose
45388065|NCT00981929|Drug|Omeprazole, losartan, caffeine|20 mg omeprazole 25 mg losartan 200 mg caffeine
45388066|NCT00981929|Drug|Tramadol, omeprazole, losartan, caffeine|50 mg tramadol 20 mg omeprazole 25 mg losartan 200 mg caffeine
45388067|NCT00364845|Drug|Darbepoetin alfa|Starting dose was calculated at 0.75 micrograms per kilogram (μg/kg) body weight at randomization, rounded to nearest prefilled syringe dose unit. Dose was titrated incrementally. Monthly dose was initially double the every 2 week dose at time of conversion.
45388068|NCT00364845|Drug|Placebo|Prefilled syringe placebo, to match active arm
45388069|NCT00978653|Drug|allopurinol|150 mg once a day
45388070|NCT02688777|Behavioral|Backward Walking Training|Backward Walking Training will occur both on a treadmill and overground. In brief, BWTraining will consist of 20-30 minutes of step training with a Body Weight Support and Treadmill system (BWST), rest periods provided as warranted, with manual assistance provided by trainers, followed by 15 minutes of overground gait training. A 20-30 min period of actual stepping is the goal for the intervention sessions on the treadmill with rest periods as needed. Each training session may last up to 1 hour and 30 minutes including time for warm-up, stretching, and cool down. Participants will be fitted with a harness around their hips and torso, which will be attached to an overhead support system directly above the treadmill. From a stationary position, the treadmill belt will gradually be increased in speed with intervention trainers assisting participant to step backward with their paretic leg, their non-paretic leg (if needed) and at the hips for weight-shift.
45388071|NCT00982241|Dietary Supplement|water|drinking water / normal dietary fluids for oral intake
45388072|NCT00978809|Other|Epley maneuver|
45501674|NCT03160703|Other|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%)|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica (RDA~77) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
45501675|NCT03160703|Other|Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80|Participants will apply a full brush head of their dentifrice containing 1000 ppm fluoride as SMFP with moderate abrasivity (RDA~80) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
45848462|NCT04430634|Other|Myblu variant E|Use of Myblu e-cigarette with flavor E 3.6% nicotine
45848463|NCT04430634|Other|Myblu variant F|Use of Myblu e-cigarette with flavor F 2.4% nicotine
45388073|NCT00978809|Other|Semont maneuver|
45388074|NCT00978887|Other|Retorna|Dosage commensurate with surface to be treated, Retorna facial cream (Topical use), twice a day, for 4 weeks.
45388075|NCT00978887|Other|Placebo|Dosage commensurate with surface to be treated, Placebo facial cream (Topical use), twice a day, for 4 weeks
45388076|NCT04891445|Behavioral|Nursing monitoring program|A clinical pathway will be activate that allows all the necessary interventions, once the person is diagnosed, to be carried out on the same day, and a mental health nursing team will monitor the entire process.
45388077|NCT04891445|Behavioral|As usual|Referral to the family doctor for a request for follow-up by the gastroenterologist. The specialist prescribes the tests for the definitive diagnosis that will take place in other units (with their corresponding appointments). After this, the patient will return to the specialist to establish the treatment to follow. Pharmacological treatment will be dispensed at the hospital pharmacy (collected once a month until completion of treatment and confirmation of cure). This last step of the treatment will be done in a new consultation at the gastroenterology service after blood tests to verify the disappearance of the viral load.
45501676|NCT03160703|Other|Stannous fluoride (SnF2, 0.454%), RDA~120|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 with higher abrasivity (RDA~120) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
45388078|NCT04007237|Drug|shampoo with different composition|To reveal the mycological efficacy, safety, recurrence and cost-effectiveness of selenium sulfide 1.8% shampoo (SeS2) and ketoconazole 2% shampoo in the treatment of pityriasis versicolor.
45501677|NCT03569774|Procedure|One-lung ventilation with individualized PEEP|During one-lung ventilation for lung resection surgery, PEEP will be applied. After a subject's individualized PEEP (PEEP that corresponds to maximum lung compliance) is determined, the subject will receive one-lung ventilation with individualized PEEP.
45388079|NCT00293722|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
45501678|NCT03569774|Procedure|One-lung ventilation with low PEEP|Subjects will receive one-lung ventilation with low PEEP (5 cmH2O)
45501679|NCT01342861|Dietary Supplement|Addition of protein (milky food in the breakfast)|The main purpose of this study is to evaluate the efficacy of additional protein (adding milky food to the breakfast) in order to deliver an optimized protein and energy intake of 15.75 g and 559 Kcal, respectively.
45501680|NCT03567668|Procedure|mitral valvuloplasty|Commissural plication was the most commonly used technique to repair mitral insufficiency, which was selectively supplemented by a specific combination of one or more of the following procedures: cleft closure, chordal shortening, transposition or replacement, edge-to-edge repair, leaflet augmentation, or division of papillary muscles, depending on the individual etiology and anatomy.
45501681|NCT01316965|Behavioral|Multifaceted prevention program HELP(Hospital Elder Life Program)|"A. Structured geriatric consultation will be performed by geriatricians of the MGT(Mobile Geriatric Teams) before surgery, including clinical examination and geriatric assessment~B. All members of medical and nursing staffs will attend a two hours training session performed by the MGTs and HELP(Hospital Elder Life Program) will be implemented in the surgical wards~C. On a quarterly basis, all members of medical and nursing staffs and MGTs will gathered to analyze medical records of patients having experienced a postoperative delirium."
45501682|NCT01332617|Drug|Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.|"Simvastatin 80 mg PO daily starting day -2 through day 10.~Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly~Bortezomib 1.3 mg/m2/day IV bolus on days 3,6 and 10.~Bendamustine 100 mg/m2/day IV over 30 minute infusion on days 3 and 10.~Methylprednisolone 1g/m2 IV over 30 minutes on days 1 and 8."
45501683|NCT03569696|Biological|nivolumab|The treatment phase will begin 10 ± 2 weeks from completion of R- anthracycline based therapy. Cycle 1 day 1 will occur within 72 hours from enrolment. Study treatment will be continued until nivolumab discontinuation due to disease progression, unacceptable toxicity or completion of 2 years or 30 doses of therapy. Study drug nivolumab will be administered intravenously every 2 weeks as described in the investigator brochure (IB) in a dose of 240mg over 30 minutes 46 for 8 cycles and then 480mg every 4 weeks for two years (cycle 9-30)to a maximum of 30 doses whichever comes first.
45501684|NCT01343797|Other|Glycemic and insulinemic index tests of a fruit fructose syrup and a fruit fructo-oligosaccharid syrup|One test with 65,5g of fruit (apple) extract sugar syrup with high fructose content in 250mL of water One test with 108,2g of peach purified sugar syrup with high fructo-oligosaccharid content in 250mL of water Three tests with the reference : 50g of anhydrous glucose in 250mL of water
45501685|NCT00092573|Drug|MK0653, ezetimibe|
45848464|NCT04430634|Other|Myblu variant G|Use of Myblu e-cigarette with flavor G 4.0% nicotine
45848465|NCT04430634|Other|Myblu variant H|Use of Myblu e-cigarette with flavor H 3.6% nicotine
45388080|NCT01070056|Behavioral|Therapeutic Lifestyle Changes (MINT-TLC)|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension(HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
45501686|NCT00092573|Drug|Comparator: fenofibrate monotherapy|
45501687|NCT01342939|Other|Oral Glucose Tolerance Test (OGTT)|50g waterfree glucose dissolved in 300ml water consumed over 5 min.
45501688|NCT01342939|Other|iso glycaemic intravenous (iv) glucose infusion (IIGI)|20% glucose
45501689|NCT01342939|Dietary Supplement|Meal test|Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein)
45501690|NCT01342939|Other|Sitagliptin|Healthy control subject are given an acute dosage of 100mg the evening before the experimental day, and the same morning in order to increase levels of endogen incretin hormones
45501691|NCT01342939|Other|Incretin effect on sulphonyl urea treatment|Subject with MODY who are treated with sulphonyl urea are investigated without medication break prior to examination.
45848466|NCT04429932|Other|Myblu flavor A_2.4|Use of Myblu e-cigarette with flavor 1 at 2.4% nicotine
45848467|NCT04429932|Other|Myblu flavor B_2.4|Use of Myblu e-cigarette with flavor 2 at 2.4% nicotine
45848468|NCT04429932|Other|Myblu flavor C_2.4|Use of Myblu e-cigarette with flavor C at 2.4% nicotine
45848469|NCT04429932|Other|Myblu flavor D_2.4|Use of Myblu e-cigarette with flavor D at 2.4% nicotine
45848470|NCT04429932|Other|Myblu flavor E_1.2|Use of Myblu e-cigarette with flavor 1 at 1.2% nicotine
45848471|NCT04429932|Other|Myblu flavor F_1.2|Fse of Myblu e-cigarette with flavor F at 1.2% nicotine
45848472|NCT04429932|Other|Myblu flavor G_2.4|Use of Myblu e-cigarette with flavor G at 2.4% nicotine
45695994|NCT03615105|Procedure|HPC(A) stem cell allograft|All patients will receive anti-thymocyte globulin based conditioning followed by a G-CSF mobilized, peripheral blood hematopoietic progenitor cell HPC(A) product depleted of TCR-α/β+ Tlymphocytes using the CliniMACS system.
45501692|NCT03392090|Other|More Good Days video&brief questionnaire|Help patients with advanced cancer think about what a good day means to them and to help them think about questions they may have for their physicians when discussing treatments
45695995|NCT03615105|Drug|Rituximab|Rituximab 200 mg IV flat dose
45388081|NCT01070056|Behavioral|Usual Care|Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
45388082|NCT03976414|Other|eMOM|The intervention is the use of the website (eMOM), which is the electronic adaption of the program, Mind Over Matter: Healthy Bowels, Healthy Bladder (MOM), a small-group, community-based health promotion program that builds skills and self-efficacy to make behavior changes that improve urinary and bowel symptoms among older women with incontinence.
45388083|NCT00381303|Drug|darunavir|600mg bid for 48 wks
45388084|NCT00381303|Drug|ritonavir|100mg bid for 48 wks
45388085|NCT00448812|Device|Bronchial Thermoplasty with the Alair System|Treatment of airways with the Alair System (Bronchial Thermoplasty) in the PREDECESSOR STUDY (NCT00214526).
45501693|NCT04376983|Behavioral|Telerehabilitation for patients with a cardiac resynchronisation device|Using the device-measured physical activity to create tailored motivational messages and tips to the patients to increase physical activity
45501694|NCT01332695|Drug|ST101|tablets for oral administration
45501695|NCT01332695|Drug|Placebo|placebo to match
45501696|NCT03569540|Drug|Glibenclamide|Placebo-controlled; Double blind test
45695996|NCT03615105|Device|Rabbit antithymocyte globulin|Rabbit antithymocyte globulin dosing per nomogram. This dynamic nomogram is based on absolute lymphocyte count at the start of conditioning and can result in either 2 or 3 day ATG administration. If a patient requires 2 day administration the subjequent chemotherapies may be moved forward by one day at the treating physician's discretion.
45501697|NCT03569540|Other|Placebo|Amylum
45501698|NCT04376437|Drug|medical cannabis|inhalation by using a Portable Metered-Dose Cannabis Inhaler
45501699|NCT01335893|Drug|Indocyanine Green|Dose will be diluted in saline solution. This will be a single dose given before the surgery intravenously.
45501700|NCT03567278|Device|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement surgery.
45501701|NCT01339169|Drug|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response. After that, patients that have benefited from treatment may take 50 mg YF476 once daily for an additional up to 52 weeks.
45695997|NCT04371484|Other|ICD-10|A collection of ICD-10 codes used within the PMSI that relate to physical abuse.
45695998|NCT04371016|Other|Verticalization (bed)|"The use of a dedicated bed (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB) allows the verticalization of patients under sedation and mechanical ventilation up to 90°. The procedure foresees the gradual verticalization of the patients of 0°, 30°, 60° and 90° by steps of 30 minutes.~At the end of each position step (0°, 30°, 60° and 90°), measurement of end-expiratory lung impedance (EELI) and chest electrical impedance tomography (EIT) parameters, measurement of esophageal pressures, collection of ventilatory parameters on the ventilator, collection of Swan-Ganz catheter hemodynamic data, measurement of lung shunt by mixed venous and arterial blood gas analyses and measurement of end-expiratory lung volume (EELV) by the N2 washin-washout method"
45501702|NCT05251441|Dietary Supplement|Breast Milk Fortifier supplements|Current information is recommended for breast milk supplementation in premature babies. However, there is no consensus on when it will start. For breast milk supplementation, we planned to supplement one group of our patients with enteral nutrition of 50 ml/kg/day and the other group when they reached 100 ml/kg/day.
45695999|NCT03812289|Other|Quality-of-Life Assessment|Ancillary studies
45696000|NCT03812289|Other|Questionnaire Administration|Ancillary studies
45696001|NCT03812289|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45696002|NCT04371406|Drug|Hydroxychloroquine and Azithromycin|Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days AND Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days, in addition to standard of care
45388086|NCT00364689|Drug|Rifaximin|
45388087|NCT00364689|Drug|Lactulose|
45388088|NCT00364689|Other|Placebo|
45388089|NCT00545129|Drug|Tanezumab 10 mg IV|Single IV infusion of 10 mg tanezumab on Day 1. Maintained on baseline opioid regimen.
45388090|NCT00545129|Drug|IV Placebo for tanezumab|Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
45388091|NCT05279339|Other|Exercise|Upper limb exercises using an elastic band.
45388092|NCT00956111|Biological|split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 7.5μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
45388093|NCT00956111|Biological|split-virion, adjuvanted H1N1 vaccine of 15 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
45388094|NCT00956111|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
45388095|NCT00956111|Biological|split-virion, non-adjuvanted H1N1 vaccine of 30 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 30μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
45388096|NCT00956111|Biological|whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose|100 adults were assigned to receive 2 doses of 5μg whole-virion, adjuvanted H1N1 vaccine 21 days apart.
45696003|NCT04371406|Dietary Supplement|Azinc|Dietetary supplement, Azinc form and vitality®, 2 capsules per day, for 10 days, in addition to standard of care
45388097|NCT00956111|Biological|whole-virion, adjuvanted H1N1 vaccine of 10 μg per dose|100 adults were assigned to receive 2 doses of 10μg whole-virion, adjuvanted H1N1 vaccine 21 days apart. 100 elders were assigned to receive 1 doses of 10μg whole-virion, adjuvanted H1N1 vaccine
45388098|NCT00956111|Biological|placebo control|100 adults were assigned to receive 2 doses of placebo 21 days apart.
45388099|NCT00978965|Genetic|MPA SNP|Functional relevant MPA SNP will be sought in patients DNA isolated from leucocytes
45388100|NCT00982475|Procedure|Pulmonary vein isolation with radiofrequency current|Pulmonary vein isolation with radiofrequency current
45388101|NCT00979355|Device|GP-D-SPECT|The D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large PMTs. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient.
45388102|NCT00979433|Device|Bubble CPAP|Bubble CPAP will be delivered using Fischer & Paykel CPAP system with a starting flow of 6 liters/minute. CPAP will be initially started at a pressure of 5 - 6 cm H2O and fraction of inspired oxygen (FiO2) of 0.4 - 0.5. which will be adjusted to maintain oxygen saturation (SpO2) between 87 and 93%.
45388103|NCT00979433|Device|Conventional CPAP|Conventional CPAP will be delivered using Argyle CPAP (Sherwood Medical Company, Mexico) short nasal prongs with warm, humidified gas used (34-37°C) through a thermo-statically controlled humidifier, flow @ 4-8 L/min from either SLE 2000 pressure-controlled continuous flow ventilator (Specialized Laboratory Equipment, UK) or Baby log 8000 volume guarantee ventilator.
45388104|NCT00982631|Drug|Temsirolimus/PLD|This is a dose escalation study. Patients will start with temsirolimus iv once weekly. After 2 weeks, PLD therapy is added. From then on, PLD is repeated every 4 weeks. One cycle is 28 days. The DLT period is also defined within the first 28 days of combination therapy (thus the first 6 weeks of study participation). The first dose level (DL) is DL 1. Depending on toxicity, intermediate dose levels can be added. If no MTD is found in the sixth cohort, this dose level will be considered as the recommended dose (RD), being the optimal dose for both drugs in this combination. At the MTD dose level, the dose level will be expanded to a total of 12 patients.
45388105|NCT00364611|Drug|Bevacizumab|"Bevacizumab (Avastin) 15 mg/kg will be administered prior to chemotherapy on~On Day 1 of the 1st cycle over 120 minutes~On Day 1 of the 2nd cycle over 90 minutes, if no reaction on the first dose~On Day 1 of 3rd cycle over 60 minutes, if no reaction on previous doses~On Day 1 of subsequent cycles over 30 minutes, if no reaction on previous doses"
45388106|NCT00364611|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV infused over 60 minutes after completion of Bevacizumab infusion q3w
45696004|NCT03716817|Device|Tetric CAD|Resilient ceramic crowns (Tetric CAD by Ivoclar Vivadent) are placed using an adhesive bonding process including a total etch process with a universal adhesive (Adhese by Ivoclar Vivadent) and dual cured resin cement (Variolink Esthetic by Ivoclar Vivadent).
45696005|NCT04370938|Behavioral|Coping strategies video|No additional description
45696006|NCT03716739|Drug|Testosterone Cypionate 100 MG/ML|100 mg testosterone cypionate administered by intramuscular injection weekly for 12 weeks.
45696007|NCT03716739|Drug|Placebo|Placebo administered by intramuscular injection weekly for 12 weeks.
45696008|NCT03716661|Procedure|ORIF|Open Reduction Internal Fixation
45848473|NCT04429932|Other|Myblu flavor H_2.4|Use of Myblu e-cigarette with flavor H at 2.4% nicotine
45696009|NCT02245204|Drug|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
45848474|NCT04409886|Biological|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)
45848475|NCT04399980|Drug|Mavrilimumab|Treatment infusion
45848476|NCT04399980|Drug|Placebos|Placebo infusion
45848477|NCT04397094|Drug|Theracal LC|pulpotomy
45848478|NCT04397094|Drug|Formocresol|Pulpotomy
45388107|NCT00364611|Drug|Trastuzumab|"A loading dose of 8 mg/kg Trastuzumab (Herceptin) IV will be infused over 90 minutes on Day 2 of Cycle 1.~For all subsequent cycles 6 mg/kg trastuzumab will be administered on Day 1 one hour following completion of docetaxel infusion"
45388108|NCT00979511|Other|milk and exercise|"milk fortified with 1000mg calcium or low-calcium milk~weight-bearing exercise or passive exercise"
45388109|NCT00956189|Drug|amisulpride|Amisulpride dosage was increased from 200 up to a maximum of 1000 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
45388110|NCT00956189|Drug|aripiprazole|Aripiprazole dosage was increased from 5-7.5 up to a maximum of 30 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
45388111|NCT00984581|Drug|Avotermin|Intradermal injection, 5ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
45388112|NCT00984581|Drug|Avotermin|Intradermal injection, 50ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
45848479|NCT04385238|Other|This is an online survey with no intervention.|As this is an online survey about health and wellbeing, there is no intervention.
45388113|NCT00984581|Drug|Placebo|Intradermal injection, 100ul/linear cm wound margin administered on Day 0 and Day 1
45388114|NCT00956267|Drug|Letrozole|2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles
45696010|NCT03611907|Device|"Oocyte retrieval with only aspiration system SL1(Cook® Single Lumen)"|In this intervention a 17-Gauge needle is used to aspirate the follicles
45388115|NCT00956267|Procedure|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
45388116|NCT04007003|Behavioral|training in optimal insulin injection technique|the training will be delivered in person as well as through online training modules via the BD and Me(TM) platform
45501703|NCT03567200|Behavioral|Single-Arm Feasibility|Participants in each of the 8 participating groups (N=10-12 per group) are exposed to an integrated intervention program (integration of physical activity and psychosocial components). Each session is co-facilitated by a trained research staff member and a registered social worker, providing participants with the opportunity to engage in physical activity behaviours as well as discuss various psychosocial topics that are applicable to the participants interests. Physical activities include participating in group activities such as rock climbing, self-defence, yoga, etc. Psychosocial topics addressed include group discussions around cyber-bullying, sexual abuse and exploitation, gender issues, etc.
45501704|NCT01332773|Procedure|Artery first procedure|early identification of SMA to evaluate infiltration
45501705|NCT01332773|Procedure|No artery first procedure|conventional exposure and preparation (Kocher's manoeuvre) before transection of pancreatic parenchyma
45501706|NCT04371679|Other|No interventions planned|No interventions planned. Observational.
45696011|NCT03611907|Device|"Oocyte retrieval with aspiration and flushing system DL1 (Cook® EchoTip® Double Lumen)"|In this intervention a 17-Gauge needle is used to aspirate follicle, and consequently a 1 mL flush is injected and aspirated twice for each punctured follicle
45848480|NCT04383132|Device|Abdominal Binder|abdominal binder is a kind of elastic abdominal compression device
45696012|NCT04365010|Drug|Sodium Bicarbonate Ringer's Injection|For each month of the trial, participating ICUs were assigned to use either Sodium Bicarbonate Ringer's Injection or 0.9% Saline for any intravenous administration of isotonic crystalloid. ICUs were randomly assigned to use Sodium Bicarbonate Ringer's Injection during even-numbered months and 0.9% Saline during odd-numbered months, or vice versa.
45696013|NCT04365010|Drug|0.9% Sodium Chloride Injection|For each month of the trial, participating ICUs were assigned to use either Sodium Bicarbonate Ringer's Injection or 0.9% Saline for any intravenous administration of isotonic crystalloid. ICUs were randomly assigned to use Sodium Bicarbonate Ringer's Injection during even-numbered months and 0.9% Saline during odd-numbered months, or vice versa.
45388117|NCT00982709|Behavioral|Aerobic vs. Agility Training|High Intensity 4x's per week for 4 weeks with a physical therapist.
45388118|NCT04007081|Procedure|Bone Marrow Aspiration|collection of approximately 40 mL of bone marrow aspirate
45848481|NCT04335552|Other|Standard of care|Standard of care
45848482|NCT04335552|Drug|Hydroxychloroquine|Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5
45388119|NCT04007081|Diagnostic Test|Ultrasound Imaging of Salivary Glands|Salivary gland size will be measured by ultrasound.
45388120|NCT04007081|Other|Salivary Assay|Whole saliva production rates (sialometry) will be measured under unstimulated (first passive drool method) and stimulated (chewing gum) saliva collection conditions
45848483|NCT04335552|Drug|Azithromycin|Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5
45848484|NCT04321980|Drug|OP-101|Subcutaneous injection of OP-101 in healthy volunteers
45388121|NCT04007081|Other|Quality of Life Instruments|Participants will self-assess with the following Quality of Life (QoL) surveys: University of Michigan Xerostomia related quality of life scale (XeQOL), the MD Anderson Dysphagia Index (MDADI), and the VAS xerostomia questionnaire.
45388122|NCT00364533|Drug|Tapentadol IR (CG5503)|Fixed Dose 50, 75, & 100 mg BID for 3 days
45388123|NCT00364533|Drug|Placebo|Fixed Dose Matching placebo for 3 days
45388124|NCT00364533|Drug|Oxycodone HCL IR|Fixed Dose 10 mg BID for 3 days
45501707|NCT03567512|Behavioral|Smoking hygiene intervention|The Smoking Hygiene Intervention(SHI) will be delivered in six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (~20 minutes), 2 week telephone counseling (~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (~20 minutes), and 4 month telephone counseling (~20 minutes). The intervention, SHI, will address SHS exposure of children and parental quitting. It will include behavioral counseling to address health hazards of SHS for children, advice to quit smoking and to adopt a no smoking policy around children and self-help materials (related to second-hand smoking and quitting smoking).
45388125|NCT00364533|Drug|Tapentadol IR (CG5503)|Flexible Dose q4-6 hr Tapentadol IR 50 & 100 mg BID for 9 days
45388126|NCT00982787|Drug|Botanical extract from Passiflora incarnata|"Dosage form: Liquid Passiflora extract~Dosage: 10ml (equivalent of 2.2 g of dried Passiflora)~Frequency: Once/Twice a day~Duration: 11 week intervention period"
45848485|NCT04288752|Device|VR101 Lubricating Intravaginal Ring|VR101 Lubricating Intravaginal Ring is a personal lubrication device, for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity, and supplement the body's natural lubrication.
45388127|NCT00956345|Drug|nonacog beta pegol|Cohort to receive a single dose of 25U/kg nonacog beta pegol administered intravenously (into the vein)
45388128|NCT00956345|Drug|nonacog beta pegol|Cohort to receive a single dose of 50U/kg nonacog beta pegol administered intravenously (into the vein)
45388129|NCT00956345|Drug|nonacog beta pegol|Cohort to receive a single dose of 100U/kg nonacog beta pegol administered intravenously (into the vein)
45388130|NCT01047423|Drug|Simvastatin|40mg encapsulated once daily for 12 weeks
45388131|NCT01047423|Drug|Placebo|Encapsulated oral once daily for 12 weeks
45388132|NCT00984737|Drug|Insulin|"Capillary glucose measurements of Group 2 and Group 3 will be performed during hospitalization and will be treated when they are over 180mg/dl.~Short acting oral anti-diabetic drugs will be given to patients who refuse insulin injection."
45388133|NCT01047579|Drug|Rivastigmine transdermal|
45388134|NCT04006847|Drug|Eicosapentaenoic Acid|Eicosapentaenoic Acid once per day orally
45501708|NCT03567512|Behavioral|Placebo intervention|"The placebo intervention will include developmental perspective of the child at different stages of their life, advice on educational and emotional perspective of the child, discussion on the nutritional issues of the child, and self-help materials describing the child development issues.~Subjects randomized to control group will receive a placebo intervention on child development issues delivered at six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (~20 minutes), 2 week telephone counseling (~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (~20 minutes), and 4 month telephone counseling (~20 minutes)."
45501709|NCT01339325|Procedure|Cholecystectomy|"Standard laparoscopic cholecystectomy The first cannula is inserted with an open laparoscopy technique. LCs are performed with either HF or US energized dissection, standard or fundus-first gallbladder dissection, closure of the artery by ligature/clip or US, closure of cystic duct by ligature/clip.~Laparo-endoscopic single site cholecystectomy~The TriPort device is inserted at the navel site through a 15 to 25 mm incision with an open laparoscopy technique. Two working instruments are inserted (one grasper and one energised device) through the TriPort. A further 1.8 or 3 mm instrument inserted through the larger gel valve, parallel to a 5 mm dissecting instrument, is used in some cases to enhance exposure. Gallbladder dissection is accomplished either after preparation of the cystic duct and artery or with a fundus-first technique, by means of HF electrosurgery or US shears.The cystic artery is divided between clips or by US scissors. The duct is divided between clips."
45848486|NCT04288752|Device|Sham Ring|Sham rings are visually identical to VR101 Lubricating Intravaginal Rings, but no lubricating solution was added.
45848487|NCT04287036|Device|JJVC Investigational Contact Lens|TEST
45848488|NCT04287036|Device|1-DAY ACUVUE® DEFINE® Radiant Sweet™|CONTROL
45848489|NCT04284930|Drug|Depobupivacaine|surgeons receive schematic for injection of Depobupivacaine. Subjects receive an injection of 166mg depobupivacaine. Injection on either side of the suture line, injected directly into the fascia.
45388135|NCT04006847|Drug|Tyrosine kinase inhibitor|Tyrosine kinase inhibitor to be administered at subjects' pre-study dose
45388136|NCT00984893|Drug|zoledronic acid|
45388137|NCT00984893|Drug|Any oral bisphosphonates marketed in Canada|
45388138|NCT02502747|Drug|rhu G-CSF|rhu G-CSF will be administered 5 µg/kg twice daily for 5 days, subcutaneously
45388139|NCT02502747|Drug|optimal standard of care|Optimal standard of care
45388140|NCT02502747|Procedure|Myocardial Contrast Echocardiography|Myocardial Contrast Echocardiography with sulphur hexafluoride.
45388141|NCT00983021|Drug|insulin degludec/liraglutide|Single, simultaneous dose of NN9068, injected s.c. (under the skin)
45388142|NCT00983021|Drug|insulin degludec|Single, simultaneous dose of NN1250, injected s.c. (under the skin)
45388143|NCT00983021|Drug|liraglutide|Single, simultaneous dose of NN2211, injected s.c. (under the skin)
45388144|NCT00983021|Drug|placebo|Single, simultaneous dose of placebo, injected s.c. (under the skin)
45388145|NCT00984971|Drug|Tenofovir|Topical gel applied rectally
45388146|NCT00984971|Drug|HEC Placebo|Placebo gel applied rectally
45388147|NCT00984971|Drug|Open label tenofovir tablet|All participants will undergo an open label tenofovir tablet single dose administration (i.e. Tenofovir Disoproxil Fumarate 300 mg, aka Viread®)
45388148|NCT00544817|Radiation|Radiation Therapy|2 Gy/fraction, single daily fractions M-F, to 60 Gy total
45388149|NCT00544817|Drug|Temozolomide|"In Combined Modality Therapy, administered as 75 mg/m2 by mouth once daily~In follow-up systemic therapy, administered as 150 mg/m2 by mouth on days 1-5 every 28 days for 6 cycles"
45388150|NCT00544817|Drug|Sorafenib|In follow-up systemic therapy, administered as 400 mg by mouth twice daily for 6 months
45388151|NCT00983099|Drug|Neramexane|single and multiple dose, tablets, oral
45388152|NCT04661423|Other|Remote Automated Monitoring System|The patient will be monitored with conventional monitoring devices as well as the MultiSense patch.
45388153|NCT04812899|Behavioral|Parental guided self-help version of FBT-pre-recorded videos and readings from the book|"Each participant will receive a series of pre-recorded videos of parental guided self help version FBT. There will be10 videos of about 10 minutes each. The videos will include content on empowering parents to renourish their child and interrupt binge/purge behaviors. Readings will be assigned to each participant from the book Help Your Teenager Beat and Eating Disorder. There will be psychoeducational content on the dangers and medical complications of eating disorders. The readings will also contain content on coping skills for young people including relaxation, mindfulness strategies, and distress tolerance skills."
45501710|NCT03569462|Behavioral|"Mobile WeChat intervention"|Participants watch a demonstration of HIV self-testing, receive HIV self-testing kits, and receive access to a mobile application that delivers content to promote HIV self-testing and reduce HIV risk behavior
45848490|NCT04284930|Drug|OnQ pump|group 2: Surgeons receive instruction sheet with specific placement of catheter. All patients have two OnQ soaker catheters installed into abdominal donor site before donor closure.
45388154|NCT04005833|Diagnostic Test|spirometry|The lung function (FEV1) will be assessed at follow-up visits at 2 months, 12 months and 36 months after inclusion.
45388155|NCT00289978|Drug|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
45501711|NCT03569462|Behavioral|Control condition|Participants watch a demonstration of HIV self-testing and receive HIV self-testing kits.
45696014|NCT03609801|Behavioral|ACTV|"Achieving Change Through Values-Based Behavior (ACTV) - pronounced ACTIVE - is a new intervention program for domestic violence offenders. ACTV was developed as a collaboration between researchers, practitioners, and the criminal justice system in the state of Iowa (Zarling, Lawrence, Oregno, 2017). It is based on Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999), which is an evidence-based cognitive-behavioral psychotherapy. ACTV is innovative in two primary ways; first, ACTV applies the ACT model to the treatment of domestic violence, and second, ACTV is specifically designed for use in the correctional setting as part of criminal justice programming."
45848491|NCT04284930|Drug|0.25% Bupivacaine|group 3: given 0.25% bupivacaine without epinephrine between internal oblique and transverse abdominal muscle.
45848492|NCT04267770|Drug|Insulin (circadian)|Participant's own insulin adjusted to circadian infusion rates
45848493|NCT04267770|Drug|Insulin (flat rate)|Participant's own insulin set to flat basal rates
45848494|NCT04252092|Other|Sensory training|15 session,20 minutes sensory training program
45848495|NCT04252092|Other|Electrical stimulation|15 session,20 minutes electrical stimulation program
45388156|NCT00289978|Drug|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
45388157|NCT00289978|Drug|Placebo|Patients self-administered a fingolimod placebo capsule orally once daily.
45388158|NCT00983177|Drug|Colchicine|0.5 mg twice daily for 4 months
45388159|NCT00983177|Drug|lactose|lactose capsules twice daily
45388160|NCT04862897|Other|Patient-controlled admissions|Patients are allowed to admit themselves to inpatient care when needed (standard procedure, four days of inpatient care at a time, up to three times a month)
45388161|NCT00985283|Behavioral|Preventive home visit|in-home visit by a trained occupational therapist to assess older adult's living context and occupational performance and to provide recommendations for changes or continuation of behavior or context
45501712|NCT05708690|Drug|Tranexamic Acid 100 MG/ML|Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin. The binding of plasminogen to fibrin induces fibrinolysis - by occupying the necessary binding sites tranexamic acid prevents this dissolution of fibrin, thereby stabilizing the clot and preventing hemorrhage
45848496|NCT04204200|Dietary Supplement|liposomal vitamin C|The intake of liposomal vitamin C at 500 mg, in the morning and evening, one week before surgery, one during the day of surgery and lastly, during the first 21 post operation days.
45848497|NCT04204200|Dietary Supplement|standard vitamin C|The intake of traditional vitamin C with a daily intake of 500 mg in the morning and evening for 28 days (starting 7 days before the operative procedure, on the day of the surgery and ending twenty-one days after surgery).
45848498|NCT04204200|Dietary Supplement|placebo|The intake placebo was taken daily in the morning and the evening for 28 days (7 days before surgery, on the day of surgery and twenty-one days after the surgical procedure).
45696015|NCT03609801|Behavioral|The Duluth Model|The Duluth Model is based on the premise that domestic abuse happens when men believe they have the right to authority over women who are their intimate partners. The Duluth Model Men's Nonviolence Classes help men stop battering and explore the consequences of the violence for themselves, their partner and their children.
45696016|NCT02244814|Behavioral|Low Carbohydrate/Conventional|Lower-carbohydrate/conventional diet (usual care)
45388162|NCT00985283|Behavioral|minimal intervention|provision of information related to services and health promotion for older adults as a low-cost minimal alternative to the intervention
45388163|NCT03977428|Other|standard of care|No intervention, this a patient registry and is purely an observational study
45388164|NCT00983255|Drug|TR-701 FA for injection, 200 mg/vial|TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 & 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D
45501713|NCT05708690|Drug|normal saline|Normal saline is a cornerstone of intravenous solutions commonly used in the clinical setting. It is a crystalloid fluid administered via an intravenous solution. Its indications include both adult and pediatric populations as sources of hydration and electrolyte disturbances
45696017|NCT02244814|Behavioral|Choosing Healthy Options in Carbohydrate Energy|Choosing Healthy Options in Carbohydrate Energy
45696018|NCT03707691|Behavioral|Listening tests. Pitch training protocol|The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of ~20 minutes performed at home over a period of 15 weeks.
45388165|NCT00983255|Drug|TR-701 FA tablets|TR-701 FA will be given once orally as a 200 mg tablet in Part C.
45388166|NCT05279261|Procedure|The axillary approach|The approach enters from the axilla through the interval between the latissimus dorsi and subscapularis to expose the anteroinferior glenoid, neck and lateral border of the scapula with entire rotator cuff sparing and fix the fracture with screws or plates.
45388167|NCT00983333|Device|Time to Talk CARDIO website|This interactive web-based training device involves the completion of a brief survey regarding communication experiences between patients and health care professionals. The pattern of responses to the survey generates a personalized set of short instructional videos which demonstrate effective communication skills.
45388168|NCT00983411|Other|Non intentional leaks during non invasive ventilation|During NIV sessions (in awake state for both the 10 healthy and the 10 OHS subjects and during sleep only for the OHS subjects), the investigators will create several levels of non intentional leaks in a random order
45388169|NCT00988403|Dietary Supplement|Fructan - 7.5|Subjects will consume 7.5 grams of fructan
45388170|NCT00988403|Dietary Supplement|Fructan - 10|Subjects will consume 10 grams of fructan
45388171|NCT00988403|Dietary Supplement|Fructan - 12.5|Subjects will consume 12.5 grams of fructan
45388172|NCT00988403|Dietary Supplement|Fructan -- 5 grams|Subjects will consume 5 grams fructan.
45388173|NCT00988481|Drug|Topiramate|Topiramate titrated to 200mg/day over four weeks, for ten weeks
45501714|NCT01343875|Procedure|tear of the distal tendon in the biceps muscle|
45501715|NCT04851821|Drug|Quercetin|Each patient included, after signing the consent, will have a treatment for ten days: one tablet times three per day 30 minutes before the meal.
45501716|NCT03567122|Other|Internal Focus of Attention|Information already included in arm/group descriptions.
45501717|NCT03567122|Other|External Focus of Attention|Information already included in arm/group descriptions.
45501718|NCT03567122|Other|Control|Information already included in arm/group descriptions.
45696019|NCT03707691|Behavioral|visuo-spatial training protocol|The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of ~20 minutes performed at home over a period of 15 weeks.
45501719|NCT03379727|Drug|Midostaurin|Orally administered inhibitor of multiple tyrosine kinases
45501720|NCT03569384|Combination Product|Tele Rehab|The intervention group will obtain telerehabilitation
45501721|NCT01343953|Procedure|Cord Blood Transplantation|One or 2 cord blood units containing alone or both together more than 4x107 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients for acquired Severe Aplastic Anemia
45501722|NCT05140291|Other|Dry Needling|"1/2 needles will placed into defined innervation fields of the trigeminal nerve and rotated. Total time will be 5-7 minutes."
45696020|NCT03707691|Behavioral|EEG/MEG/MRI recordings.|Listening tests. EEG/MEG/MRI recordings
45696021|NCT02156908|Drug|D-serine|D-serine 60 mg/kg
45696022|NCT04763265|Biological|"Botulinum toxin A BoNT/A-DP"|To assess the efficacy of treatment with BoNT/A-DP in reducing the severity of glabellar frown lines at maximum frown.
45501723|NCT05140291|Other|Sham Dry Needling|Needle handles inside of guide tubes will be tapped in a way similar to an actual needle being set but the sham needles will be blunted.
45501724|NCT03567044|Diagnostic Test|Blood Draw|Eligible subjects will have blood draws at the following times: baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks.
45501725|NCT02247128|Drug|Aspirin + clopidogrel|
45501726|NCT02247128|Drug|Aspirin monotherapy|
45501727|NCT02247128|Drug|OAC + clopicogrel|
45501728|NCT02247128|Drug|OAC monotherapy|
45696023|NCT04763265|Biological|"Botulinum toxin A Botox Cosmetics"|To assess the efficacy of treatment with Botox Cosmetics in reducing the severity of glabellar frown lines at maximum frown.
45501729|NCT01339481|Drug|abatacept|Intravenous Infusion
45501730|NCT01344031|Drug|Akt Inhibitor MK2206|Given PO
45388174|NCT03720821|Behavioral|Cognitive Training + fMRI|"Consented subjects will be asked to participate in the study for up to five months. Patients will be consented at the Washington University Department of Anesthesiology and will be asked to complete baseline resilience, pain, and anxiety and depression questionnaires, along with cognitive tests by pencil and paper that will be administered by a member of the research team. The participants will also be required to complete a computer-based Trails-making test, Color Match test, and NCPT (Neurocognitive Performance Test) battery at baseline, and undergo a functional magnetic resonance imaging (fMRI) session.~All subjects will be asked to complete the three paper-pencil and computer-based measurements along with repeat pain questionnaire again 1-3 days after completion of training, undergo a second fMRI scan at that time, and complete the questionnaires again 3 months after the completion of training."
45696024|NCT02244970|Other|Mindfulness|Mindfulness is the awareness that emerges from paying attention to the present moment without judgment. In this study, subject in this arm will receive 7 weeks of MBI with a focus on tackling anxiety, depressed mood, and attention deficits among early psychosis participants. The elements of 7-week program included mindful-breathing, indoor and outdoor mindful-walking, mindful-eating, mindul-drawing, tree-of-life exercise and closing celebration.
45848499|NCT04179474|Drug|Ubrogepant|Oral administration of 100 mg ubrogepant tablet once daily [Intervention A=single dose and Intervention D=repeated daily dose].
45388175|NCT00983567|Other|teen web|Min web
45388176|NCT00542321|Other|Manual turn|Manual turn from side to back to side every 2 hours by nurses while patient receiving mechanical ventilation
45388177|NCT00542321|Device|kinetic therapy bed|Continuous, automated turning to a maximum of 45 degrees in the lateral positions while the patient is receiving mechanical ventilation
45388178|NCT00289900|Drug|MK-0524A|
45388179|NCT00289900|Drug|Atorvastatin|
45388180|NCT00289900|Drug|Simvastatin|
45388181|NCT01067014|Device|Baxano iO-Flex® System|Decompressive lumbar surgery using Baxano iO-Flex® System
45388182|NCT00543725|Drug|TMC278|25 mg tablet once daily for 96 weeks
45388183|NCT00543725|Drug|efavirenz|600 mg tablet once daily for 96 weeks
45388184|NCT00985361|Dietary Supplement|Vitamin D3 2000 international units daily|Vitamin D3 2000 international unit tablets once daily for 3 months
45388185|NCT00985361|Dietary Supplement|Vitamin C 500mg daily|Vitamin C 500mg tablets once daily for 3 months
45388186|NCT04006613|Other|Circuit Training|20 minutes of High Intensity Aerobic Training (HI) on treadmill: 2 minutes warm up + 4x 4 minutes HI+ 2 minutes of active recovery; 10 minutes of dynamic balance training; 10 minutes of functional strength training.
45388187|NCT04006613|Other|Usual Care|Exercises aimed at improving mobility and balance
45388188|NCT00984035|Other|urine samples (biomarkers)|Urine samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
45388189|NCT00984035|Other|blood samples (biomarkers)|blood samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
45388190|NCT00984035|Other|blood sample (DNA)|Blood sample collected for DNA analysis at anytime while on-study.
45388191|NCT00984113|Drug|Elinogrel|100 mg elinogrel b.i.d. with aspirin q.d. for 7 days and aspirin alone for 4 days (Dose of aspirin is 81 mg in the US and 100 mg in Germany)
45388192|NCT00269152|Drug|pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV), every 21 days x 4 cycles
45388193|NCT00269152|Drug|cisplatin|75 mg/m^2, intravenous (IV), every 21 days x 4 cycles
45501731|NCT01344031|Drug|Anastrozole|Given PO
45501732|NCT01344031|Drug|Fulvestrant|Given IM
45388194|NCT00269152|Drug|carboplatin|area under the curve (AUC) 5 milligrams per milliliter*minute (mg/ml*min), intravenous (IV), every 21 days x 4 cycles
45388195|NCT00988715|Biological|Pretargeted Radioimmunotherapy|Antibody-streptavidin conjugate and radiolabeled DOTA-biotin, each given IV
45388196|NCT00988715|Drug|Cyclosporine|Given IV
45388197|NCT00988715|Drug|Mycophenolate Mofetil|Given PO
45501733|NCT01344031|Other|Laboratory Biomarker Analysis|Correlative studies
45388198|NCT00988715|Radiation|Total-Body Irradiation|Undergo total-body irradiation
45388199|NCT00988715|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
45388200|NCT00988715|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
45501734|NCT01332929|Drug|Bevacizumab|"5, 10 or 15 mg/kg, IV, on day 1, 15 and 29 plus radiation therapy of the whole brain.~For level 0,1 and 2, a total dose of 30 Gy will be administered in 15 fractions of 2 Gy, from D15 to D33 with 5 fractions a week.~For level 3,a total dose of 30 Gy will be administered in 10 fractions of 3 Gy, from D15 to D26 with 5 fractions a week."
45696025|NCT02244970|Other|Psychoeducation|Participants in the psychoeducation group will receive seven weeks of psychoeducation sessions which include basic knowledge related to 1) General mental health, 2) Knowledge of psychosis, 3) Treatment and community resources, 4) Recovery and relapse prevention, 5) Healthy lifestyle, 6) Social skills training, and finally a closing celebration at week 7.
45848500|NCT04179474|Drug|Erenumab|Single dose subcutaneous (SC) injection of erenumab 140 mg [Intervention B].
45848501|NCT04179474|Drug|Galcanezumab|2 SC injections of galcanezumab 120 mg [Intervention C].
45388201|NCT00988715|Drug|Fludarabine Phosphate|Given IV
45848502|NCT04174638|Other|Motivational Interviewing and Education Based on Watson's Theory of Human Caring|The intervention group received 15 minute motivational interviewing based on Watson's Theory of Human Caring once a month for 12 weeks and one session 30 minutes education with educational booklet based on Watson's Theory of Human Caring. The intervention performed before the hemodialysis session in a separate room in the hemodialysis unit.
45501735|NCT04660279|Diagnostic Test|Dynamic Whole-Body parametric PET/CT|Dynamic whole-body PET/CT imaging protocol
45388202|NCT00988715|Other|Pharmacological Study|Correlative studies
45501736|NCT03566966|Biological|Non-organ-specific Ab positive|Antiviral administration and evaluation of SVR24 and side effects
45388203|NCT00988715|Other|Laboratory Biomarker Analysis|Correlative studies
45388204|NCT01325740|Drug|STX107|STX107 10 mg single dose po capsule, STX107 30 mg single dose po capsule, Placebo single po capsule
45388205|NCT03975166|Drug|Test Product|2 inhalations in one study period
45501737|NCT03566966|Biological|Non-organ-specific Ab negative|direct-acting antiviral agents
45501738|NCT01316029|Procedure|Okada Purifying Therapy|Each participant received a single session of Okada Purifying Therapy lasting 30 minutes or longer, administered by a voluntary certified practitioner.
45501739|NCT05185193|Device|radiofrequency|Radiofrequency of 9.50v, 218.5mA and 2.076W is applied once a day for 30 minutes, a total of 3 times
45501740|NCT05185193|Device|sham stimulation|The appearance is the same as the medical device for clinical trials, and when applied, the sound and the amount of light visible from the outside are designed to be the same as the medical device for clinical trials. The external light was the same, and only the high frequency that stimulates the dermis was blocked. The sham device was applied once a day for 30 minutes, a total of 3 times.
45501741|NCT02247986|Drug|Methylphenidate Hydrochloride|Bold signal changes by methylphenidate on DBD
45696026|NCT00004143|Drug|Campath, Chemo and/or TBI Allo SCT|Allogeneic PBSC/marrow will be collected/harvested from the donor after granulocyte colony-stimulating factor (G-CSF) priming. The allogeneic PBSCs will be infused as per current institutional practice.
45696027|NCT04364542|Procedure|Suprascapular nerve block|The patient lies supine in beach chair position with surgical drapes on. The anatomical landmarks are outlined and the infiltration spot is identified. The block is performed with 10 ml ropivacaine 0.75%.
45696028|NCT04364542|Procedure|Interscalene Nerve Block|The patient lies supine position with the head turned to the contralateral side to the block. A linear high-frequency ultrasound probe is used for identifying the roots of supraclavicular brachial plexus using the traceback technique. The block is performed with 15 ml ropivacaine 0.5%.
45696029|NCT04364542|Procedure|Arthroscopic rotator cuff repair|Conventional arthroscopic rotator cuff repair.
45388206|NCT03975166|Drug|Reference Product|2 inhalations in one study period
45388207|NCT01067092|Behavioral|Community Health Worker Intervention|A Community Health Worker makes 36 home visits to the person with diabetes over a two year period, providing diabetes education and self-management skills training. The curriculum covers recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. CHWs also deliver training in behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
45388208|NCT01067092|Behavioral|Educational Newsletter|Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
45501742|NCT05185115|Drug|Oxygen|administration of oxygen at a flow rate of 3 liters per minute, via nasal cannula throughout the hospitalization.
45501743|NCT05185115|Other|no oxygen therapy|No oxygen therapy during hospitalization
45501744|NCT03567434|Other|Alcohol vs. Placebo|Using a randomized, cross-over design, all subjects will consume evening alcohol (and a fluid-control placebo) in a dose that mimics binge drinking.
45501745|NCT04580953|Device|CardiaCareTM RR2|Treatment with CardiaCareTM RR2
45501746|NCT02248064|Device|Auto-titrating oxygen system|The auto-titrating oxygen system contains a number of components working together to produce variable oxygen flow. An oximeter measures the oxygen saturation of a patient and via Bluetooth this is relayed to a control centre in a mobile phone. This in turn regulates a flow meter which adjust oxygen flow.
45501747|NCT03569306|Device|ENB|ENB is carried out by a ENB system（LungCare, China) which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.
45388209|NCT03976024|Other|DHBN-FN arm|DHBN-FN will be evaluated by pharyngeal swab, anal and perineal. If the family accepts, the carriage of streptococcus in persons living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal, anal and perineal swab in consultation. These swabs will be made within 10 days of diagnosis of DHBN-FN of the index
45388210|NCT03976024|Other|Control arm (Erysipelas)|The carriage of streptococcus in patients with erysipelas will be evaluated by pharyngeal, anal and perineal swab on day 0 (admission).
45388211|NCT01067170|Device|Pneumatic Compression Stockings|Thigh-high pneumatic compression stockings
45388212|NCT01325818|Drug|pravastatin, rosuvastatin|"Active Comparator Intervention: Drug: pravastatin 10mg/day or 20mg/day~Active Comparator Intervention: Drug: rosuvastatin 20mg/day"
45388213|NCT00379899|Drug|cinacalcet|Low dose vitamin D with cinacalcet
45388214|NCT02535039|Drug|Methylprednisolone|Anaesthesia in giving 1 mg/kg intravenous methylprednisolone, methylprednisolone (1 mg/kg * d for application to the third day after surgery
45388215|NCT02535039|Other|Physiological saline|The same volume of physiological saline will be given in Placebo group
45388216|NCT02535117|Procedure|Laparoscopic Surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
45388217|NCT02535117|Procedure|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
45388218|NCT00371787|Device|Soft contact lens|Soft contact lens
45501748|NCT03569306|Device|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
45696030|NCT03705429|Drug|TC-H x Paclitaxel (P) + Trastuzumab(T)|chemotherapy
45388219|NCT00363129|Dietary Supplement|vitamin E|Given orally
45388220|NCT00363129|Other|placebo|Given orally
45388221|NCT00268996|Drug|SB-480848|SB-480848 is available as enteric-coated, free-base micronized tablet
45388222|NCT00268996|Drug|SB-480848 matching placebo|Placebo is available as enteric-coated, free-base micronized tablet
45388223|NCT00371397|Behavioral|Hatha Yoga Classes|Iyengar yoga, the form of hatha yoga used in this study, emphasizes the use of props to help students achieve precise postures safely and comfortably according to their particular body types and needs. The yoga activity sessions were directed by four experienced yoga teachers following a script. The poses used were (in order) Supta Baddha Konasana (Reclining Bound Angle Pose), Adho Mukha Svanasana (Downward Facing Dog), Supported Uttanasana (Intense Forward Stretch), Parsvotanasana (Intense Side Stretch Pose), Prasarita Padottanansana (Wide-Legged Forward Bend), Janu Sirsasana (Head to Knee Pose), Bharadvajasana (Simple Seated Twist Pose), Viparita Karani (Restful Inversion), Supported Setu Bandha Sarvanagasana (Bridge Pose), and Savasana (Corpse Pose). Blood draws occurred during the last two minutes of Supta Baddha Konasana (pose held 10 minutes), Viparita Karani (10 minutes), and Savasana (15 minutes).
45501749|NCT03566888|Device|Blood pressure assessment|Validation of an automated blood pressure device
45501750|NCT05708534|Drug|Belatacept|Switching from anticalcineurins to belatacept in a cohort of kidney transplant recipients seropositive for CMV
45501751|NCT03159611|Drug|Tenoten for children|Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
45501752|NCT03159611|Drug|Placebo|Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
45388224|NCT00371397|Behavioral|Movement Control|Walking on a treadmill at .5 miles per hour was used to control for general physical movement/cardiovascular expenditure because it best approximated the heart rates during the restorative yoga session. To match the lower heart rate, women also rested supine on a bed for several minutes after walking, before and after getting their blood drawn.
45388225|NCT00379587|Drug|Rituximab|Rituximab at months 3, 6, 9 and 12 post-transplant
45388226|NCT00379587|Drug|375 mg/m2 RRituximab|Rituximab 375 mg/m2 q3months
45388227|NCT00289276|Device|Fluid Status Monitoring (OptiVol™)|Thoracic Fluid Status Software downloaded on all subjects enrolled in the trial
45388228|NCT03975244|Behavioral|Exercise program|Twelve-week of semi-supervised exercise program. The exercise program will combine resistance and endurance training. Both the volume and intensity of training will start at moderate intensity, and progressively be increased at higher volumes and intensities.
45388229|NCT03977506|Diagnostic Test|On-road driving evaluation|"The data assessed during the road test from the two assessment grids (recommendations of the HAS and Test ride for investigation practical fitness to drive) :~road position, vehicle control, track management, safety distances, speed, visual behavior, traffic signs, vehicle overtaking, anticipatory reactions and capabilities adaptation, attentional skills, decision-making, communication with other road users, assessment of specific situations such as insertion on a 2x2 lane, mechanical management and general impressions."
45501753|NCT03000374|Drug|Panitumumab|Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.
45501754|NCT03000374|Drug|5Fluorouracil|Once every 14 days. Day 1: 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².
45501755|NCT03000374|Drug|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusión in 250-500 mL, over two hours, followed by 5-FU
45696031|NCT04370782|Drug|Hydroxychloroquine|Hydroxychloroquine 400mg twice a day (BID) on day 1, followed by 200mg BID for days 2-5
45501756|NCT03000374|Drug|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
45501757|NCT04323943|Device|Ankle Foot orthosis (AFO)|"The experimental protocol will require 4 visits: one inclusion visit and 3 visits for evaluations. Each visit corresponds to one condition: C-AFO, CM-AFO or NO (according to a random order).~Visit #1 will consist in a clinical evaluation and a familiarization session with the measuring devices and methodologies used in visit#2 #3 and #4.~During #2, #3 and #4 visits (14 days between each session), the subject will perform with C-AFO, CM-AFO or NO according to the random order :~5 x 15m overground at a comfortable walking speed (CWS) where EMG, ground reaction force and kinematics will be measured~6MWT where energy cost will be measured~5 x 15m overground (immediately after the 6MWT) at a comfortable walking speed"
45501758|NCT03566654|Device|remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times， two times per day. The duration of the treatment is 30+/-2days.
45501759|NCT03566654|Device|ambulatory blood pressure monitoring|A diagnostic technique for measuring blood pressure in daily life by means of automatic intermittent timing. Because ABPM has overcome the limitations of clinic blood pressure measurement, observation error and white coat effect, it can objectively reflect the actual level and fluctuation of blood pressure. Each patient of the two arms will use ABPM measure blood pressure before and after RIC or sham RIC treatment.
45388230|NCT00289198|Drug|FF|fluticasone furoate 110 μg nasal spray
45501760|NCT03566654|Device|Sham remote ischemic conditioning|Sham RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times. The duration of the treatment is 30+/-2days.
45501761|NCT03635359|Diagnostic Test|blood test|analysis of cell-free DNA in maternal plasma
45696032|NCT04370782|Drug|Azithromycin|Azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5
45696033|NCT04370782|Drug|Zinc Sulfate|Zinc sulfate 220mg once daily for 5 days
45388231|NCT00289198|Drug|Placebo|placebo nasal spray
45388232|NCT01067404|Biological|Trivalent inactivated influenza vaccine|0.25mL dose of 2009-10 trivalent inactivated influenza vaccine (TIV)
45501762|NCT03566576|Drug|Anlotinib|Anlotinib 8mg p.o. qd in first cohort (3 subjects). 10mg p.o. qd in second cohort (3 subjects). 12mg p.o. qd in third cohort (3 subjects).
45501763|NCT03566576|Drug|Pemetrexed|Pemetrexed 500mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
45388233|NCT03741712|Drug|SHR3680|Tablet. Specifications of 80mg
45388234|NCT03741712|Drug|SHR2554|Tablet. Specifications of 50mg and 200mg
45388235|NCT00363051|Drug|Everolimus 10 mg|Participants took two 5 mg tablets of Everolimus orally with a glass of water, once daily (preferably in the morning) in a fasting state or after no more than a light, fat-free meal. Dosing was to occur at the same time each day. If vomiting occurred, the vomited dose was not to be replaced.
45388236|NCT00363051|Drug|Octreotide Depot|
45388237|NCT00379353|Drug|Thalidomide|100 mg capsules orally, once a day for 14 days.
45501764|NCT03566576|Drug|Docetaxel|Docetaxel 60mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
45501765|NCT04377997|Drug|Enoxaparin|Given the established link between endothelial dysfunction and thrombosis in patients with cardiovascular disease9, 10 and the association between coagulopathy and adverse outcomes in patients with sepsis11, the association between increased coagulation activity, end-organ injury, and mortality risk may represent a modifiable risk factor among COVID-19 patients with critical illness. Therefore, we propose to conduct a randomized, open-label trial of therapeutic anticoagulation in COVID-19 patients with an elevated D-dimer to evaluate the efficacy. Most patients will receive low molecular weight heparin however, unfractionated heparin (UFH) will be administered for those with morbid obesity or moderate to severe renal dysfunction.
45501766|NCT03566498|Dietary Supplement|Immediate hydration|They will be allowed to start oral fluids immediately (within the first 2 hours post operatively) beginning with water or clear fluids (but not milk or soda containing drinks), the amounts will be according to their needs, solid food will be given gradually after tolerating the drinks and intravenous fluids will be given beside all of that and till the return of intestinal movements
45501767|NCT03566498|Dietary Supplement|Early hydration|They will receive the routine intravenous fluids and the oral fluids will be given after 8 hours post operatively and gradually, solid food will be allowed after that gradually too and the intravenous fluids will be stopped after return of intestinal movements.
45501768|NCT01336049|Drug|Nimotuzumab|Nimotuzumab 200mg/week
45696034|NCT04370782|Drug|Doxycycline|Doxycycline 200 mg once daily for 5 days
45696035|NCT03604653|Device|HIPEC|Heated chemotherapy is pumped into the abdomen and circulated for 90 minutes
45696036|NCT03604653|Drug|Mitomycin c|MMC 30mg@ T0, 10mg@T45 min
45696037|NCT03604653|Drug|CDDP 50|50mg/m2@T0
45696038|NCT03604653|Drug|CDDP 75|75mg/m2@T0
45388238|NCT00379353|Drug|Placebo|Two placebo capsules orally, once a day for 14 days.
45388239|NCT03992391|Behavioral|Suicide Prevention Intensive Outpatient Program|participation in a suicide prevention intensive outpatient program
45388240|NCT01047657|Behavioral|Low caloric diet plus orlistat and sibutramine|All subjetcs
45388241|NCT00378573|Drug|docetaxel|
45696039|NCT03604653|Drug|Doxorubicin|15mg/m2@T0
45696040|NCT04376320|Device|customised ceramic sheets (Group 1)|guided bone regeneration
45696041|NCT04376320|Combination Product|modified sausage technique (Group 2)|guided bone regeneration
45696042|NCT03704415|Procedure|Extended endoscopic sinus surgery|ESS of all sinuses
45696043|NCT03704415|Procedure|Limited endoscopic sinus surgery|Partial ethmoidectomy
45388242|NCT00378573|Drug|gemcitabine|
45388243|NCT00378573|Drug|bevacizumab|
45388244|NCT01581099|Procedure|Digestive Adaptations III surgery|
45388245|NCT02346747|Biological|Vigil|bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy
45388246|NCT02346747|Biological|Placebo|"freeze media."
45388247|NCT01047891|Drug|Sorafenib|Topotecan 1,25 mg/m²/d administered as an i.v. infusion over 30 minutes once daily on days 1-5, every 21 days and Sorafenib 400 mg orally twice daily (total daily dose 800 mg) administered
45501769|NCT04758949|Drug|FL-101|200 mg administered intravenously every 2 weeks prior to surgery.
45501770|NCT04758949|Drug|Nivolumab|240 mg administered intravenously every 2 weeks prior to surgery.
45388248|NCT02534571|Device|Endoscopic Application of a Hemostatic Powder TC-325|Endoscopic Application of a Hemostatic Powder TC-325 <=150g once
45501771|NCT04758949|Drug|Placebo|200 mg administered intravenously every 2 weeks prior to surgery.
45501772|NCT04320979|Radiation|internal mammary nodal irradiation|chest wall and supraclavicular +-axillary plus internal mammary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
45501773|NCT04320979|Radiation|no internal mammary nodal irradiation|chest wall and supraclavicular+-axillary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
45501774|NCT03564860|Procedure|Device data collection|Collection of device electrograms and 12-lead ECG during a device follow-up visit
45501775|NCT03565016|Other|no interventional study|no interventional study
45501776|NCT05708456|Other|Mobile application with symptom management|In this study, patients will be given evidence-based advice via a mobile application to manage their symptoms.
45501777|NCT01344343|Other|Accelerated surgical hip fracture repair|Accelerated hip fracture surgery defined as arrival in the operation room within 6 hours of diagnosis of a hip fracture requiring surgery
45501778|NCT03566186|Other|Phototherapy|Photobiomodulation or photobiostimulation, this technique is the application of monochromatic light that can influence cellular activity through inhibition or stimulation of chemical and biological functions.
45501779|NCT03566186|Other|Placebo|The same procedures as in the active phototherapy group was applied to the placebo group; however, the emitter was disabled. The device was emit the same sounds regardless of the programmed mode (active phototherapy).
45501780|NCT03566186|Other|Passive recovery|Participants was remain sat for passive recovery supervised by an independent therapist during the period when the other groups are received recovery strategies.
45501781|NCT01344421|Procedure|Minimally invasive approach for Periacetabular osteotomy|A peri-acetabular osteotomy is a surgery performed to correct the dysplastic acetabulum and reduce joint contact pressures and early osteoarthritis.
45501782|NCT03566030|Drug|Tenofovir disoproxil fumarate 300mg|Administered Tenofovir disoproxil fumarate 300 mg QD
45501783|NCT03566030|Drug|Tenofovir Alafenamide 25 mg|Administered Tenofovir Alafenamide 25 mg QD
45388249|NCT02534571|Device|Hemo-clipping|Hemo-clipping <=20 clips
45696044|NCT04376086|Procedure|Epidural anesthesia|Segmental epidural analgesia
45696045|NCT04376086|Procedure|general anesthesia|general anesthesia
45388250|NCT02534571|Drug|Epinephrine|epinephrine injection endoscopically <20 mls
45388251|NCT02534571|Device|thermo-coagulation|contact thermo-coagulation < = 4 pulses
45388252|NCT03831945|Biological|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is a broadly neutralizing human mAb targeted against the HIV-1CD4 binding site. As single intravenous infusion of VRC01(40 mg/kg) plus10-1074 (30mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is > or = 200 copies/mL.
45501784|NCT04312711|Diagnostic Test|3D-TOF-MRA|"The Principle of 3D-TOF-MRA is based on the flow effect of MR. In the GE sequence of MRA imaging, the effect of RF pulses makes the protons in the stationary tissue in the active layer in a saturated state, and the longitudinal magnetization disappears. When the inflow blood appears, its protons are in an unsaturated state and have a high degree of longitudinal magnetization. In this way, a clear difference is formed between saturated tissue and unsaturated flowing blood to display blood vessels. 3D-TOF-MRA is a non-invasive and safe method for diagnosing vascular diseases."
45501785|NCT03565952|Other|Cranial massage|Manual cranial therapy consisting of massage and cranial relaxing techniques, lasting 30 minutes each session approximately, for 3 weeks and one month follow-up. Manual therapy consists of a prone and supine cranial massage.
45501786|NCT03565952|Other|Control group|The control group does not receive treatment
45501787|NCT04302103|Biological|RC18 160mg|subcutaneous injection
45501788|NCT04302103|Biological|RC18 240 mg|subcutaneous injection
45696046|NCT03703167|Drug|Ibrutinib|Oral ibrutinib will be given between days 1 and 28 of each 28-day cycle and will be continued daily after completion of rituximab and lenalidomide. The starting dose of ibrutinib is 560 mg/day (dose level 1) and (dose level 2 ibrutinib: 840 mg daily).
45388253|NCT03831945|Biological|10-1074|10-1074 is a recombinant, fully human mAb of the IgG1 lambda isotype that specifically binds to the base of the V3 loop within HIV-1 envelope gp-120. A single intravenous infusion of VRC01 (40 mg/kg) plus 10-1074 (30 mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is > or = 200 copies/mL.
45388254|NCT03831945|Biological|Normal Saline Placebo|2 sequential infusions of normal saline placebo in matching volumes to antibody infusions will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is > or = 200 copies/mL.
45388255|NCT00457002|Drug|Apixaban|"Apixaban: Twice daily, 30 days~Placebo: Once daily, 6-14 days"
45388256|NCT00457002|Drug|Enoxaparin|"Enoxaparin: Once daily, 6-14 days~Placebo: Twice daily, 30 days"
45388257|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 5 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
45388258|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 10 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
45501789|NCT03565796|Behavioral|Personalized active referral plus financial incentive|Smokers will be introduced to various SC services in Hong Kong and be motivated to use the services.Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment.Smokers are informed at baseline that they will receive financial incentive (supermarket coupon HK$300) if they attend or use any of the SC services within 3-month.
45848503|NCT04152642|Device|Marketed Dry Mouth Rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
45848504|NCT04152642|Other|Water control|negative control
45848505|NCT04152642|Device|Experimental Dry Mouth Rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
45848506|NCT04150224|Drug|PBTZ169 640 mg OD|Two administrations once a day with a wash-out period: food effect
45388259|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
45388260|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 40 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
45388261|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 80 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
45388262|NCT00362115|Drug|Olmesartan|Olmesartan 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
45501790|NCT03565796|Behavioral|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
45501791|NCT03565796|Behavioral|Warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
45501792|NCT03565796|Behavioral|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
45696047|NCT03703167|Drug|Lenalidomide|Oral lenalidomide will be given between days 1 and 21 of each 28-day cycle for a maximum of 12 cycles. The starting dose of lenalidomide is 10 mg/day (dose level 1 & 2) lenalidomide: 15 mg daily (dose level 3) and lenalidomide: 20 mg daily (dose level 4).
45501793|NCT03565796|Behavioral|COSH booklet|A general smoking cessation self-help booklet
45696048|NCT03703167|Drug|Rituximab|Intravenous rituximab (500mg/m2) will be given on day 1 of all cycles (+/- 3 days), for up to 6 cycles.
45696049|NCT04375852|Diagnostic Test|Detection of autoantibodies|Blood was obtained from each patient for testing the endocrine functions and determination of a panel of autoantibodies to the following: Side-chain cleavage enzyme (SSC), Aromatic L-amino acid decarboxylase (AADC), Tryptophan hydroxylase (TPH),Tyrosine hydroxylase ( TH), 17α-hydroxylase (17α-OH), Cytochrome P450 1A2 (CYP1A2), 21-hydroxylase (21-OH), Potassium channel regulatory protein (KCNRG), Tyrosine phosphatase-like protein IA-2 (IA-2), Glutamic acid decarboxylase 65 (GAD65), NACT Leucine-Rich-Repeat-Protein 5 (NALP5), and Interleukin (IL) 22.
45696050|NCT03805659|Device|HD-tDCS|High-Dose transcranial Direct Current Stimulation
45696051|NCT03805659|Device|Sham|Sham sessions (no electric current)
45388263|NCT00362115|Drug|Placebo|Matching placebo tablets, orally, once daily for up to 8 weeks.
45388264|NCT00485264|Drug|Raltegravir poloxamer film coated tablet|Final Selected Dose: 400-mg tablet taken orally twice daily.
45388265|NCT00485264|Drug|Raltegravir chewable tablet|Final Selected Dose: Weight based dose of ~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily.
45388266|NCT00485264|Drug|Raltegravir oral granules for suspension (20 mg/mL)|Weight based dose of ~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data.
45388267|NCT00485264|Drug|Raltegravir poloxamer film coated tablet|Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants < 25 kg were switched to a weight-based dose of the chewable tablet.
45388268|NCT00293254|Drug|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
45848507|NCT04150224|Drug|PBTZ169 640 mg BiD|Twice a day fasted; 1 day of administration
45848508|NCT04150224|Drug|PBTZ169 960 mg SD|Once a day fasted
45848509|NCT04150224|Drug|PBTZ169 1280 mg SD|Once a day fasted
45848510|NCT04150224|Drug|PBTZ169 1280 mg MD|Once a day after meal, 14 doses
45848511|NCT04116684|Device|Withings Digital Blood Pressure Monitor|This is a home digital blood pressure monitor that can transmit recordings via a user's smartphone.
45848512|NCT04112160|Drug|Ketorolac|IM injection of either normal saline or Ketorolac
45848513|NCT04112160|Drug|normal saline|normal saline
45696052|NCT03603795|Drug|Eltrombopag|Eltrombopag concomitant with induction chemotherapy in patient with AML
45696053|NCT03603795|Drug|Placebo|Placebo concomitant with induction chemotherapy patients with AML
45501794|NCT04256005|Other|Exercise|Participants will complete one of two exercise conditions (50% Delta GET or 105% VO2peak).
45501795|NCT05353946|Device|Percutaneous coronary intervention (PCI)|Optimal stent expansion by IVUS-guided PCI.
45501796|NCT05085613|Behavioral|Corrective message framing and humor|The main content of the messages will be the same. Experimental conditions (arms 2-4) will additionally include consequent framing as a result of getting vaccinated (e.g. economic recovery for arm 2 and freedom for arm 3) and humor for arm 4. Participants will be randomized to view one of the four messages.
45501797|NCT03565718|Behavioral|Dietary Intervention: Restaurant|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to local vegan soul food restaurants.
45388269|NCT00293254|Drug|Comparator: placebo|Placebo p.o. b.i.d. with optimized background therapy. Treatment period of 48 weeks.
45501798|NCT03565718|Behavioral|Dietary Intervention: Standard/Grocery|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to grocery stores.
45501799|NCT01344499|Procedure|Carbon dioxide|standard pneumoperitoneum with 100% CO2
45848514|NCT04102956|Drug|Kallikrein|HUK has been approved by China's State Food and Drug Administration as a state category I new drug for the treatment of stroke patients. Based on the available evidence, HUK injection ameliorates neurological deficits and improves long-term outcomes.
45388270|NCT01018784|Drug|MORAb-009|MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle.
45848515|NCT04086576|Device|Alcohoot|Alcohoot branded smartphone-paired breathalyzer
45501800|NCT01344499|Procedure|full conditioning|Pneumoperitoneum with CO2 + 4% of oxygen + 10% nitrous oxide + 100% RH + T° 32°C
45501801|NCT01344499|Drug|Adept|instillation of 1 liter of fluid at the end of laparoscopy
45501802|NCT01344499|Drug|Ringer Lactate|instillation of 1 liter of fluid at the end of laparoscopy
45501803|NCT03565562|Other|Promotion of the e-health tool by local authorities|Local authorities participating in the trial will select a referent person who will be in charge of the implementation and follow-up of the promotion. A promotion toolkit with recommendations, posters, web banners, leaflets and ready-made messages and press articles will be provided to the local authorities.
45501804|NCT03565562|Other|Promotion of the e-health tool by local authorities and GPs|In those local authorities, GPs will participate passively to the promotion of the e-health tool, by providing posters and leaflets in their waiting rooms.
45501805|NCT05065879|Biological|COVAX|2 doses of Covid-19 vaccine
45501806|NCT01339715|Procedure|acupuncture and far-infrared ray|During experimental phase,inserting the needle of acupuncture into CV12 acupoint or using far-infrared ray to illuminate on CV12 20 minutes.
45501807|NCT05353868|Other|No intervention|No intervention
45501808|NCT01333085|Drug|carboplatin|
45501809|NCT01333085|Drug|RAD001|
45501810|NCT01333085|Drug|paclitaxel|
45696054|NCT04370314|Other|Dental prosthetics|Implant-supported crowns
45696055|NCT03803397|Biological|PV-001-DC|Patient-specific cellular therapeutic for cancer immunotherapy
45848516|NCT04086576|Device|BACtrack Mobile Pro|BACtrack Mobile Pro branded smartphone-paired breathalyzer
45848517|NCT04086576|Device|DRIVESAFE Evoc|DRIVESAFE Evoc branded smartphone-paired breathalyzer
45848518|NCT04086576|Device|BACtrack Vio|BACtrack Vio branded smartphone-paired breathalyzer
45848519|NCT04086576|Device|Drinkmate|Drinkmate branded smartphone-paired breathalyzer
45388271|NCT01047969|Drug|Adjuvant Chemotherapy|If after MRI + FDG-PET 8 weeks post CRT the patient shows no visible tumour or further regression adjuvant chemotherapy will be considered.
45388272|NCT01047969|Procedure|Surgery|If after MRI + FDG-PET 8 weeks post CRF no further regression or growth of disease occurs the patient will be referred for surgery.
45388273|NCT01019018|Device|subtenon block|subtenon block with stevens cannula
45388274|NCT01019018|Device|subtenon block|subtenon block with Olive tip cannula cannula
45388275|NCT03977350|Device|EEG monitoring|EEG monitoring under general anesthesia
45501811|NCT01344655|Drug|Atimos®|Formoterol 12 μg pMDI
45501812|NCT01344655|Drug|Serevent™|Salmeterol 25 µg pMDI
45501813|NCT01344655|Drug|Placebo|placebo
45696056|NCT04364464|Drug|Riociguat (Adempas, BAY 63-2521)|0.5 mg riociguat as an immediate-release (IR) tablet
45696057|NCT04746885|Dietary Supplement|DHA|Oral supplement
45696058|NCT04375774|Device|FFP2|Face Fit test of the FFP2 with the PortaCount® PRO+ 8038 from TSI
45696059|NCT04375774|Device|Facial mask|Face Fit test of a conventional respirator facial mask with the PortaCount® PRO+ 8038 from TSI
45696060|NCT04375774|Device|MFS|Face fit test of a MFS with the PortaCount® PRO+ 8038 from TSI
45696061|NCT03700047|Device|GAL1704|new dermal filler
45501814|NCT03565484|Drug|susceptibility guided therapy|Patients will take a gastroscopy and 2 biopsies will be attained from antrum and gastric body for H.pylori culture and antimicrobial susceptibility testing (AST). The susceptibility of amoxicillin, clarithromycin, metronidazole, levofloxacin, furazolidone and tetracycline will be tested.Then patients with positive culture will be treated with a 14-day quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, and two sensitive antibiotics determined by AST. Dose of two sensitive antibiotics are listed as follows : amoxicillin 1000mg bid, clarithromycin 500mg bid, tinidazole 500mg tid, levofloxacin 500mg qd, furazolidone 100mg bid, tetracycline 500mg qid.
45388276|NCT04498611|Diagnostic Test|contrast-enhanced breast MRI|Contrast-enhanced MRI will be performed on patients diagnosed with ductal carcinoma in-situ (DCIS) by preoperative biopsy.
45388277|NCT03975010|Drug|Buprenorphine Transdermal Patch|"This is an open-label, randomised, single-dose, 3 arms study design. Subjects will be randomised into one of 3 arms, in a 1:1:1 ratio, wearing BUP TDS 20 mg for 3 days or 40 mg for 3 days or 40 mg for 4 days. Safety follow-up will be planned at 7~9 days after patch removal.~The study patch will be applied under the cover of naltrexone to reduce opioid related side-effects. Naltrexone 50 mg will be taken orally every 12 hours, from the evening of Day 00 (13 hours prior to IMP application), until the evening of the patch removal."
45848520|NCT04086576|Device|Floome|Floome branded smartphone-paired breathalyzer
45848521|NCT04086576|Device|Intoxilyzer 240|Intoxilyzer 240 police grade breathalyzer
45501815|NCT03565484|Drug|personal medication history guided therapy|Patients will be treated with a 14-day emprical tailored quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid， colloidal bismuth pectin 200mg bid and two antibiotics based on personal medication history. If the patient doesn't have levofloxacin history, he will be treated with amoxicillin 1000mg bid plus levofloxacin 500mg bid. Otherwise, he will be treated with amoxicillin 1000mg bid and furazolidone 100mg bid.
45501816|NCT03565484|Drug|salvage treatment for failed eradication|If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, tetracycline 500mg qid and furazolidone 100mg bid.
45848522|NCT04075812|Device|Neuromuscular Stimulator|
45848523|NCT04061694|Procedure|Immediate loading, fully guided surgery and 3D printed restoration|Fully guided surgery installation of single dental implants. 3D printed restorations that were immediate loaded.
45848524|NCT04061694|Procedure|Immediate loading|Only subjected to immediate loading. Conventional procedure.
45388278|NCT01050075|Other|acupuncture therapy|acupuncture therapy
45501817|NCT01336127|Behavioral|Occupational Therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
45501818|NCT04734535|Device|HEMOBLAST™ Bellows|Intraoperative bleeding during epidural spine surgery will be treated with HEMOBLAST™ Bellows
45696062|NCT03700047|Device|Juvederm Voluma|hyaluronic acid
45848525|NCT04057248|Device|Dario Blood Glucose Monitoring System|Dario Blood Glucose Monitoring System (BGMS) with Dario App and Dario digital platform
45501819|NCT04734535|Device|absorbable gelatin sponge with thrombin|Intraoperative bleeding during epidural spine surgery will be treated with absorbable gelatin sponge with thrombin
45696063|NCT00924040|Drug|BL22 (CAT-3888)|30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
45696064|NCT03600441|Drug|Abexinostat|Abexinostat tosylate salt is formulated into an oral tablet formulation and is available in 20 mg strength.
45848526|NCT04057248|Behavioral|CDE|Certified Diabetes Educator Sessions
45696065|NCT04363996|Other|New Bioactive Restorative Material|Filling material
45696066|NCT04763031|Radiation|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
45696067|NCT04363918|Device|bioelectric stimulation|bioelectric stimulation
45848527|NCT04053270|Drug|Afamelanotide|16mg subcutaneous implant
45848528|NCT04053270|Drug|Placebo|Placebo subcutaneous implant
45848529|NCT04051710|Drug|Test Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
45848530|NCT04051710|Drug|Reference Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
45848531|NCT04051710|Drug|Placebo|Placebo Product
45388279|NCT01050075|Other|questionnaire administration|Ancillary study
45388280|NCT01050075|Other|management of therapy complications|To be determined by the treating physician
45388281|NCT04534010|Device|NACgraft|Patients requiring reconstruction of their nipple and areola have a NACgraft surgically implanted on their breasts. A NACgraft is a novel decellularized cadaveric implant derived from human nipples.
45848532|NCT04047342|Behavioral|Welcome email|Email
45848533|NCT04047342|Behavioral|Loss frame|Email
45848534|NCT04022694|Behavioral|Exposure to beverage health information|Red stop sign and avoidance message for sugar-sweetened beverages and green check mark and promotion message for non-sugar-sweetened beverage nutrition information
45388282|NCT01070134|Behavioral|Mindfulness-based Behavioural Therapy (MIBT)|"The MIBT treatment consists of weekly individual MIBT therapy (45-50 min.), together with weekly mindfulness-skills training group (1.5 hours).~The treatment is based on the cognitive model of depression, but will, based on concrete problems, draw from alternative cognitive techniques in order to treat personality-related problems and will use elements from mindfulness."
45848535|NCT04022694|Behavioral|Exposure to beverage calorie information|Calories for sugar-sweetened and non-sugar-sweetened beverages
45696068|NCT03598413|Dietary Supplement|Omega-3|200ml, pre-mixed oral nutritional supplement supplying 1.42g per bottle of EPA and DHA.
45696069|NCT01592240|Drug|PBO|Placebo Q28d
45388283|NCT01070134|Behavioral|PT (psychodynamic therapy)|"The PT treatment consists of weekly individual PT therapy (45-50 min.), together with weekly PT group therapy (1.5 hours).~The main elements of PT are the free-flowing, non-therapist guided dialogue, based on classic psychoanalytical free association. Basically, the role of the therapist is to set ground rules and organise the time, place and duration, to maintain a proper tone, and ultimately to ensure that a therapeutic process takes place using relevant interventions."
45388284|NCT01016990|Drug|valproic acid|
45388285|NCT01016990|Genetic|western blotting|
45388286|NCT01016990|Other|laboratory biomarker analysis|
45388287|NCT01016990|Other|pharmacological study|
45388288|NCT01048047|Drug|aliskiren/amlodipine|aliskiren 300 mg /amlodipine 10 mg
45388289|NCT03975946|Procedure|Rheopheresis procedure|Rheopheresis is performed using an automated monitor in a double-filtration cascade. Plasma purify from of high molecular weight proteins through a secondary filter is then returned to the patient. This technique is performed in tandem with a hemodialysis monitor.
45388290|NCT03975946|Biological|Blood Sample|Biological analysis
45388291|NCT03975946|Procedure|Shamapheresis procedure|Shamapheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient. This technique is performed in tandem with a hemodialysis monitor.
45388292|NCT01011686|Biological|ANT-SM|autologous adipose-derived stem cell
45388293|NCT01324635|Drug|Panobinostat|Given PO
45388294|NCT01324635|Radiation|Stereotactic body radiation therapy|Undergo SBRT
45501820|NCT03565406|Drug|Mocetinostat Induction Phase + Ipilimumab + Nivolumab|"Treatment Cycle 1: Mocetinostat at a dose of 90 mg PO TIW; ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles.~Treatment Cycle 2: Mocetinostat at a dose of 70 mg PO TIW ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles."
45696070|NCT01592240|Drug|200mg PF-04950615 (RN316)|PF-04950615 200 mg, Q28d
45696071|NCT01592240|Drug|300mg PF-04950615 (RN316)|PF-04950615 300 mg, Q28d
45696072|NCT01592240|Drug|PBO|Placebo, Q14d
45696073|NCT01592240|Drug|PF-04950615|PF-04950615 50mg, Q14d
45696074|NCT01592240|Drug|PF-04950615|PF-04950615 100 mg, Q14d
45696075|NCT01592240|Drug|PF-04950615|PF-04950615 150mg, Q14d
45696076|NCT04370158|Other|disease history|Clinical progression and prognosis of patients with interstitial lung diseases
45696077|NCT03594747|Drug|Tislelizumab Carboplatin Paxlitaxel|Treatment for advanced NSCLC
45696078|NCT03594747|Drug|Tislelizumab Carboplatin Nab-paxlitaxel|Treatment for advanced NSCLC
45696079|NCT03594747|Drug|Carboplatin Paclitaxel|Treatment for advanced squamous NSCLC
45388295|NCT01324635|Procedure|Quality-of-life assessment|Ancillary studies
45388296|NCT01324635|Radiation|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
45388297|NCT01017068|Drug|OME|4g/100ml) dose: п gutt tid x 1/52
45388298|NCT01017068|Drug|OME|(2g/100ml) dose: п gutt tid x 1/52
45388299|NCT01017068|Drug|OME|(1g/100ml) dose: п gutt tid x 1/52
45388300|NCT01017068|Drug|OME|(4g/100ml) dose: п gutt tid x 1/52
45388301|NCT01017068|Drug|OME|(2g/100ml) dose: п gutt tid x 1/52
45388302|NCT01017068|Drug|OME|(1g/100ml) dose: п gutt tid x 1/52
45848536|NCT04015440|Behavioral|HBMT|Individual is presented with words with some letters missing and told to complete the word.
45848537|NCT04015440|Behavioral|Other Training|Alternative to HBMT training
45848538|NCT04030104|Device|Reader Study - Imagio Ultrasound|Imagio ultrasound images to be reviewed as part of Reader study
45848539|NCT04030104|Device|Reader Study Imagio Ultrasound + Optoacoustic Imaging|Imagio Ultrasound + Optoacoustic images to be reviewed as part of Reader study
45848540|NCT04030104|Device|Mammography|Mammography as available per standard of care
45388303|NCT04178564|Behavioral|Cognitive Stimulation|"The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 60 minutes and they will be developed according to the following structure:~Welcoming to the group (5 minutes) Reality orientation therapy (10 minutes) Main activity (35 minutes) Session evaluation (10 minutes) CS sessions will be conducted in groups. The intervention sessions will include several activities based on different non-pharmacological therapies, whose effectiveness in elderly with neurocognitive disorders has been scientifically proven. Non-pharmacological therapies used encompass therapies such as musictherapy, reminiscence therapy, validation therapy, Montessori method in geriatrics, ADL training, art therapy and the computer software Rehacom."
45696080|NCT04357912|Behavioral|Activity Tracker Group|In addition to the standard of care exercise education, participants in the activity tracker group will be provided a Fitbit physical activity tracker at no cost to the participants. They will be asked to download the Fitbit application (app) to their personal smartphone device to allow them to see their own data collected by the Fitbit. They will also be asked to download the Stridekick app for the purpose of sharing their activity tracker data electronically with the study team and having the opportunity to participate in fitness challenges through the app. App accounts will be created by the participants with usernames that do not contain the participant's identifiable personal information. Optional fitness challenges will be created once per month by the study investigators, and participants will also receive a weekly message of encouragement from the study team.
45388304|NCT04170608|Device|FARAPULSE Endocardial Multi Ablation System|Ablation using the FARAPULSE Endocardial Multi Ablation System
45388305|NCT00456846|Drug|ABI-007|100 mg/m^2 ABI-007 weekly for 3 weeks followed by 1 week rest
45388306|NCT01011764|Behavioral|SKILLS vs ENGAGE|The investigators plan to contrast 2 different models for social skills groups. Each model involves 16 45-minute bi-weekly sessions, twice a week with a small group of children with ASD. Details of the 2 intervention models are described below.
45388307|NCT03324282|Drug|Avelumab|Combination of Gemcitabin-Cisplatin and avelumab given for 6 cycles (each cycle is 21 days)
45696081|NCT04357912|Behavioral|Standard of Care Group|Participants will receive standard of care exercise education.
45696082|NCT05620654|Drug|Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin|The starting dose for paclitaxel was 175 mg/m2, with escalation in 25 mg/m2 increments until the MTD was determined or the maximum dose level of 225 mg/m2 was reached. The target dose-limiting toxicity (DLT) rate was 25%, and the total sample size was 30 patients. HIPEC was delivered immediately following the debulking surgery using the closed technique with a target temperature of 43 ℃ for 90 minutes.
45388308|NCT03324282|Drug|GC|Combination of Gemcitabin-Cisplatin given for 6 cycles (each cycle is 21 days)
45388309|NCT00448344|Behavioral|Family-supported|Group receives quit kit, option for nicotine replacement therapy, and 5 telephone counseling sessions with the goal of attaining social support during the process of quitting smoking
45388310|NCT00448344|Behavioral|Standard Telephone counseling|Group receives quit kit, option for nicotine replacement therapy, and 5 standard smoking cessation telephone counseling sessions
45696083|NCT03692325|Drug|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
45848541|NCT04027218|Device|Dry heat|The application is made with two sacks of carob seeds during 7 minutes. The sacks are placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power.
45848542|NCT04027218|Device|High pressure|It will be carried out with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand (QUIRUMED) with European Conformity (CE) marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse.
45388311|NCT00484094|Drug|sirolimus|Dosage and treatment duration will be decided by physician's discretion considering patient's clinical situations
45388312|NCT01029288|Other|Diabetes Medication Choice Decision Aid|Diabetes Medication Choice cards
45388313|NCT01029288|Other|Statin Choice Decision Aid|Statin Choice Cards
45388314|NCT01029288|Other|Usual care for lipid therapy medication|Clinicians will follow their clinic's usual care practice for lipid therapy medication (statin) discussions.
45388315|NCT01029288|Other|Usual care for antihyperglycemic medication|Clinicians will follow their clinic's usual care practice for antihyperglycemic medication discussions.
45501821|NCT03565406|Drug|Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab|"De-escalation Phase 1: Mocetinostat will be administered 50 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg~De-escalation Maintenance Phase 2: Mocetinostat will be administered 40 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 0.3 mg/kg and nivolumab will be administered IV at a dose of 1 mg/kg during period"
45696084|NCT04357834|Other|Equipment with smartwatch throughout hospital stay on the general ward|Participants with confirmed SARS-CoV-2 infection or suspicion of COVID-19 will be equipped with a smartwatch and wear the device throughout the hospital stay on the general ward.
45501822|NCT01333163|Biological|Human GLP-1 (7-36) amide|2 hour IV infusion, 1,5pmol/min/kg.
45501823|NCT01333163|Biological|Isotone NaCl|2 hours IV infusion.
45696085|NCT04357522|Biological|15-Valent Pneumococcal Conjugate Vaccine|4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
45501824|NCT04734379|Drug|Fasudil|Oral fasudil 180 mg/day
45501825|NCT03565250|Other|self understanding interview|semi-structured interview designed for assessment of identity according to Damon & Hart's 7-dimension develomental model
45696086|NCT04357522|Biological|13-Valent Pneumococcal Conjugate Vaccine|4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
45501826|NCT05352620|Other|Implant assisted maxillary overdenture|For each patient, an implant assisted maxillary overdenture will be fabricated using a minimally invasive flapless surgical technique with OT-Equator and Smart Box attachment
45501827|NCT04163887|Procedure|hepatectomy|Resection colorectal liver metastases using a laparoscopic approach or an open approach.
45388316|NCT01029444|Procedure|Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment RQ levels and their insulin resistance.
45388317|NCT01024452|Device|DAWN AC|computerized dosing management system for anticoagulation clinics
45388318|NCT01024452|Device|Hamilton Nomogram|simple nomogram for warfarin maintenance dosing
45388319|NCT03995394|Other|Positive Reinforcement Text Message|"A text message comprising the words, Great job! We're so proud of you! Keep up the good work!"
45388320|NCT01029522|Drug|Atorvastatin (Lipilou)|treatment of dyslipidemia administration : PO, qod
45388321|NCT01029522|Drug|Atorvastatin (Lipitor)|treatment of dyslipidemia administration : PO, qod
45388322|NCT00447876|Biological|Botulinum toxin type A|Botulinum type A toxin (Dysport®): 200 Units injected at the root of the plantar fascia
45501828|NCT01333241|Behavioral|Lifestyle behavior interventon grop|
45501829|NCT01333241|Other|Placebo Comparator: Control group|
45501830|NCT03565094|Drug|Lu AF28996 solution|"Oral solution (0.1-0.2 mg/mL)~Following each cohort, a dosing conference will be held where tolerability, safety and preliminary PK results from the previous cohorts will be reviewed before deciding on the next doses"
45501831|NCT03565094|Drug|Lu AF28996 capsule|hard capsule orally QD: one dose lower than the highest dose level in part A
45501832|NCT01339871|Drug|Pazopanib|Starting dose 400 mg orally daily of 28 day cycle.
45501833|NCT01339871|Drug|Vorinostat|Starting dose 100 mg orally daily of 28 day cycle.
45501834|NCT01339949|Device|IRay|low voltage external beam radiosurgery
45501835|NCT01339949|Device|IRay|low voltage external beam radiosurgery
45501836|NCT04693429|Drug|Bepotastine Besilate|Bepotastine Besilate 1.5% QID (quater in die) for 7 days
45696087|NCT03801213|Device|urinary catheterization|Urinary catheterization with pain controlled
45696088|NCT03801213|Procedure|manual bladder stimulation technique|manual gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes
45696089|NCT00937378|Drug|SER120|Nasal Spray, once a day
45696090|NCT00937378|Drug|Placebo|Nasal Spray
45696091|NCT00005901|Drug|Pamidronate (Aredia)|Patients receive a dose of 1mg/kg/cycle (3-day infusion = 1 cycle)
45696092|NCT04369768|Procedure|restoration of permanent molars affected with MIH|restore MIH affected molars using direct composite or preformed metal crowns
45388323|NCT00447876|Drug|Placebo|0.9% sodium chloride: 2 ml injected at the root of the plantar fascia
45388324|NCT01029600|Procedure|Arthroscopic capsular release|Surgical division of thickened capsule in the shoulder
45388325|NCT01029600|Procedure|Distention with steroid|Intraarticular distention with steroid, saline, contrast and local anaesthetic
45388326|NCT01565772|Radiation|Proton Beam Radiation|45-55 Gy total, 1.8-2.2 Gy x 25 fractions Mon-Fri for 5 weeks
45388327|NCT01565772|Drug|Cisplatin|50 mg/m2 IV on days 1, 8 of cycles 1 and 2
45388328|NCT01565772|Drug|Etoposide|50 mg/m2 IV on days 1-5 on Cycles 1-2
45388329|NCT03995550|Drug|LEO 142397|A compound in development by LEO Pharma A/S
45388330|NCT03995550|Drug|Placebo|Placebo
45388331|NCT00456612|Procedure|CyberKnife|Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
45388332|NCT00456300|Drug|Exenatide|In each intervention arm the participant receives a different dose (1.25 or 2.5 mcg) of exenatide.
45388333|NCT00456300|Drug|Insulin|Each subject received a baseline study with insulin alone
45388334|NCT00267748|Drug|Sunitinib Malate Continuous Daily Dosing|Sunitinib malate starting dose 37.5 mg daily continuous daily regimen.
45388335|NCT00267748|Drug|Sunitinib Malate Schedule 4/2|Sunitinib malate starting dose 50 mg per day for four weeks, followed by a two week off-drug period. This six week cycle is repeated.
45388336|NCT00267202|Drug|Placebo|Doses of placebo were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
45388337|NCT00267202|Drug|Omalizumab|Doses of omalizumab were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
45388338|NCT00267202|Drug|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
45388339|NCT00267202|Drug|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
45388340|NCT01067638|Drug|Tranexamic Acid|1.0g loading dose before skin incision and continuous infusion 200 mg/h during surgery
45388341|NCT01070212|Other|soft gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
45388342|NCT01070212|Other|firm gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
45388343|NCT01070212|Other|no gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
45388344|NCT03977116|Drug|SLGT2|These patients will receive SLGT2 therapy after catheter ablation.
45388345|NCT03977116|Drug|Placebo|These patients will receive placebo therapy after catheter ablation.
45501837|NCT05353712|Other|SUCROSE|50g sweet creme composed of 14.3g vegetable fat and 35.7g sucrose.
45501838|NCT05353712|Other|CONTROL|35.7g sweet creme composed of 14.3g vegetable fat and 21.4g sucrose.
45501839|NCT05353712|Other|ARA20|42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g L-arabinose
45501840|NCT05353712|Other|ARA40|50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
45501841|NCT05353712|Other|TAG20|42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g D-tagatose
45388346|NCT01067794|Drug|Any platinum-based doublet chemotherapy|Dosage, dosage form, frequency and duration according to daily hospital practice
45388347|NCT00267046|Drug|Palifermin|180 mcg/kg 3 days prior to chemotherapy
45388348|NCT00267046|Drug|Placebo|Single dose 3 days prior to chemotherapy
45388349|NCT00267046|Drug|Adriamycin (Doxorubicin)|30 mg/m^2 IV continuous infusion for 72 hours; days 0, 1, 2 (infusion completing on day 3) (total dose = 90 mg/m^2).
45388350|NCT00267046|Drug|Ifosfamide|2.5 g/m^2 IV bolus over 3 hours, days 0,1, 2, 3 (total dose = 10 g/m^2); for patients receiving the AI Regimen.
45388351|NCT00267046|Drug|Vincristine|2 mg IV on day 0, for patients with small cell histology receiving the AI Regimen.
45696093|NCT03800199|Other|Perceptive rehabilitation|The first session will be an education session. Spinous processes will be reference line of the body and patient will lie down on cones. The therapist will ask the patient first to breathe normally and feel the pressure. This will lead the patient to relax and understand cones. Then, the patient will start with the diagrammatic breathing. After breath exercises patient will perform active exercises (include stretching, warming up and cooling down) on supervision. Exercises will include the whole body. Additional to this during the session therapist will ask about the pressure of cones and she will correct the patients' posture. At the end of all the session, the therapist will take a photo of the patients back with the aim of to document the pressure and hyperaemic areas.
45696094|NCT04369534|Drug|Clopidogrel|Adjusting clopidogrel dosage according to platelet reactivity results during 12 months after PCI
45696095|NCT04369534|Drug|Ticagrelor|Administration of standard dose of ticagrelor during 12 months after PCI
45696096|NCT03592563|Behavioral|Neuro-QoL questionnaire|Follow-up over time will continue (either in-person or over the phone) using the same questionnaires (depending on which group they are belongs to) at approximately 6-month intervals. During each follow-up, participants will be screened for any new signs, symptoms and diagnoses of neurological and/or psychiatric disorders, in order to correlate these outcomes with risk factors captured using the procedures described above.
45696097|NCT04369456|Other|blood sample|a blood sample is taken on Covid-19 kidney transplant patients with moderate symptoms
45696098|NCT03590457|Device|Airvo 2; High-Flow nasal cannula system|Noninvasive device used to deliver humidified oxygen at high flow rates up to 60 liters per minute
45696099|NCT04115306|Drug|PMD-026|Oral RSK1-4 inhibitor
45696100|NCT04363762|Behavioral|Internet-based multimodal pain program|A guided internet-based multimodal pain program for chronic TMD pain
45388352|NCT00267046|Drug|Cisplatin|120 mg/m^2 on day 0, for patients receiving the AP Regimen.
45388353|NCT00441090|Drug|Placebo|Placebo tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
45388354|NCT00441090|Drug|Avatrombopag tablets|Avatrombopag tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
45388355|NCT03305406|Other|Focus groups|Focus groups will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
45388356|NCT03305406|Other|Interviews|Interviews will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
45388357|NCT00441012|Biological|Comparator: Modified Process Vaccine|Modified process vaccine HBsAg 5 ug/0.5 mL and PRP [OMPC] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4 & 12 months of age. Duration of treatment is 11 months.
45388358|NCT00441012|Biological|Comparator: COMVAX™|COMVAX™ HBsAg 5 ug/0.5 mL and PRP [OMPC] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4, and 12 months of age. Duration of treatment is 11 months.
45388359|NCT01029678|Drug|Cisplatin IV|Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)
45388360|NCT01029678|Drug|Vinorelbine|Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36
45501842|NCT05353712|Other|TAG40|50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
45388361|NCT01029678|Radiation|Radiotherapy|66Gy, 33 fractions, 6 week
45388362|NCT01323426|Procedure|Periurethral injection|Periurethral injection of autologous muscle fibers
45388363|NCT00286468|Drug|Alogliptin and glyburide|Alogliptin 12.5 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
45388364|NCT00286468|Drug|Alogliptin and glyburide|Alogliptin 25 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
45388365|NCT00286468|Drug|Glyburide|Alogliptin placebo-matching tablets, orally, once daily and glyburide for up to 26 weeks.
45388366|NCT00507026|Drug|IV Diclofenac|IV Diclofenac q6h
45388367|NCT00507026|Drug|IV ketorolac|IV ketorolac q6h
45388368|NCT00507026|Drug|Placebo|Placebo q6h
45388369|NCT00446550|Drug|afegostat tartrate|
45388370|NCT01029756|Device|Macintosh Laryngoscope|Device used to gain a direct view of the vocal cords, to enable an endotracheal tube to be passed into the trachea at induction of anaesthesia.
45501843|NCT01336283|Other|Endurance training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
45388371|NCT01029756|Device|Pentax AWS Videolaryngoscope|Self-contained video laryngoscope with an integral colour-viewing screen mounted on the handle. A camera at the tip transmits an indirect image, which obviates the need to obtain a direct view of the vocal cords, when passing an endotracheal tube on induction of anaesthesia.
45388372|NCT01019174|Drug|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
45388373|NCT01019174|Drug|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
45501844|NCT01336283|Other|Strength training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
45388374|NCT01017224|Other|18F-FAZA|PET scan
45388375|NCT03847974|Drug|LIB003|300 mg SC Q4W
45388376|NCT01011842|Procedure|Radiotherapy|Standard of care
45388377|NCT01011842|Procedure|Align RT|Standard of care
45388378|NCT01011920|Drug|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.
45388379|NCT01011920|Drug|Ara-C|Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses
45388380|NCT01011920|Drug|Rituximab|Rituximab 375 mg/m2 conventional infusion on day - 5 & 0 every 3 weeks for a maximum of 4 cycles
45501845|NCT01336283|Other|Combined training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
45501846|NCT03916549|Device|Acupuncture|The acupuncture procedure is performed by one well trained person, 1 time per week in total of 10 weeks on the same day time. Sterile, disposable, stainless steel acupuncture needles (40x0.25 mm diameter) were inserted to corporal acupoints, with initial gentle stimulation by quick rotation of 1080°, after then leaving needle in located place for twenty minutes. Needling deep - 0.5-1 cm. If the intent was to invigorate - the needle was inserted to the flow of energy; if harmonization needed - the needle was placed perpendicular to the point flow of energy; if sedation was needed, needles were placed against to the flow of energy on channel. The selection of acupoints was based according by traditional Chinese medicine, literature findings.
45501847|NCT05353634|Diagnostic Test|Effects of mNGS on infected patients|The impact of mNGS on infected patients, including diagnostic value, drug selection, treatment prognosis, economic burden, etc.
45388381|NCT01011920|Drug|Thiotepa|ARM C: Thiotepa 30 mg/m2 (30 min. Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 & -4
45388382|NCT01011920|Radiation|radiotherapy|Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions. Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the orbits, which must be shielded after 30 Gy (after 36 Gy in the case of evident intraocular disease at diagnosis). Tumor-bed (boost or partial-brain RT) will be irradiated by 2 to 4 isocentric treatment fields based on tumor location, with all portals treated per each RT session.
45501848|NCT03564704|Drug|Dexamethasone|Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ALL-LBL protocol.
45388383|NCT01011920|Drug|BCNU|BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6
45388384|NCT01011920|Other|APBSCT|Autologous peripheral blood stem cell transplant (APBSCT)
45388385|NCT01017302|Drug|Placebo|Subcutenaous once weekly for 4 weeks
45388386|NCT01017302|Drug|Placebo|Single subcutaneous dose in week 5
45501849|NCT03564704|Drug|vincristine|Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
45501850|NCT03564704|Drug|Cyclophosphamide|CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
45696101|NCT04363762|Device|Occlusal splint|Occlusal splint, standard
45388387|NCT01017302|Drug|RO5095932|Escalating subcutaneous doses once weekly over a 4 weeks period
45388388|NCT01017302|Drug|RO5095932|Single subcutenaous dose in week 5
45388389|NCT01019330|Other|Allen's test|The Allen's test checks to make sure that radial and ulnar arteries that supply blood to the hand are not blocked. A pulse oximeter is placed on the index finger of the hand. The subject is asked to make a fist for 10 seconds.At this time, pressure is applied over the ulnar and radial arteries as to occlude (block) both of them. The pulse oximeter reading will begin to fall. Radial arterial pressure is then released. If the artery is patent (working), the pulse oximeter reading will begin to rise.
45388390|NCT01019330|Other|Distal pulses|Practitioner will check that the dorsalis pedis and posterior tibialis are palpable.
45388391|NCT03976102|Biological|DRL_RI (Proposed rituximab biosimilar)|Proposed rituximab biosimilar, 100mg and 500mg, concentrate for solution for infusion
45388392|NCT03976102|Other|MabThera®|Reference product rituximab, 100mg and 500mg, concentrate for solution for infusion
45388393|NCT00506948|Drug|Mycophenolate Mofetil (MMF)|15 mg/kg by vein or by mouth every 12 hours.
45388394|NCT00506948|Drug|Thymoglobulin|1.5 mg/kg by vein daily for 4 days
45388395|NCT00506948|Drug|Sirolimus|6 mg daily by mouth for 1 day, followed by 2 mg daily for 1 day.
45388396|NCT00506948|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
45388397|NCT00286234|Drug|omega-3 acid ethyl esters|4 q qd
45388398|NCT00286234|Drug|extended release niacin|2 g qpm
45388399|NCT00286234|Drug|placebo|omacor placebo plus niaspan placebo
45388400|NCT00286234|Drug|omega-3 acid ethyl esters|4 g qd
45501851|NCT03564704|Drug|Idarubicin|IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.
45388401|NCT00286234|Drug|combined treatment|omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm
45388402|NCT01019408|Drug|Chloroquine|Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan
45388403|NCT01067950|Procedure|Isolated Pancreas Transplant|
45388404|NCT01067950|Drug|Intensive Insulin Therapy|
45388405|NCT00445848|Biological|bevacizumab|
45388406|NCT00445848|Drug|erlotinib hydrochloride|
45501852|NCT03564704|Drug|Pegaspargase|PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.
45388407|NCT01068028|Drug|ORM-12741|Ascending multiple doses to sequential panels
45388408|NCT01068028|Drug|Placebo for ORM-12741|
45501853|NCT03564704|Drug|Adriamycin|Adriamycin will be added to Consolidation-Module of PDT-ALL-LBL protocol.
45501854|NCT03564704|Drug|Methotrexate|Methotrexate will be added to Consolidation-Module of PDT-ALL-LBL protocol.
45501855|NCT03564704|Drug|6-mercaptopurine.|Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
45501856|NCT03564704|Drug|Etoposide|VP-16 will be added to Consolidation-Module of PDT-ALL-LBL protocol.
45388409|NCT00286156|Drug|Rapamune|Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml Group 3- Standard Care
45388410|NCT00455520|Drug|CG5503|100, 150, 200, 250 mg twice daily given for up to 15 weeks
45388411|NCT00455520|Drug|placebo|matching placebo twice daily for 12 weeks
45388412|NCT03244098|Behavioral|Transition Assistance Program|TAP caregivers will receive an SCI caregiving guidebook, a 1-hour intervention session by an SCI clinician before hospital discharge, and four 1-hour telehealth clinic-to-home visits at 1, 2, 4, and 6 weeks after discharge by the same clinician
45388413|NCT00440700|Behavioral|Anxiety Self-Management, Patient preferred relaxing music|Experimental group randomized to patient-directed music intervention where subjects listened to tailored, self-selected music as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.
45388414|NCT00440700|Behavioral|Control 1: Noise-cancelling headphones|Control group: noise-canceling headphones only where subjects wear headphones as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.
45388415|NCT00440700|Behavioral|Control 2: Standard of Care|Usual ICU nursing care.
45388416|NCT01029834|Behavioral|family based lifestyle and behavioral counseling|16 group meetings
45388417|NCT01029834|Behavioral|counseling focused on the child|16 meetings
45388418|NCT00284050|Drug|Ranibizumab 0.3 mg|6 mg/ml ranibizumab solution for intravitreal injection
45388419|NCT00284050|Drug|Ranibizumab 0.5 mg|10 mg/ml ranibizumab solution for intravitreal injection
45388420|NCT00284050|Drug|Sham injection|Non-treatment control for sham intravitreal injection.
45388421|NCT00293020|Drug|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, 1200 mcg fentanyl; up to 4 times daily
45388422|NCT00377637|Drug|Mycophenolate mofetil (MMF)|Supplied as 500 mg tablets taken orally twice a day (BID). Dose specific for each arm. Dosing started at 500 mg BID for the first week, increasing by 500 mg in subsequent weeks until the final target dose was reached.
45388423|NCT00377637|Drug|Cyclophosphamide|"Intravenous cyclophosphamide (IVC) was administered every four weeks (monthly) to a total of six infusions.~Dosing was started at 0.75 g/m^2 of body surface area for the first month, with subsequent doses at 0.5-1.0 g/m^2. The target dose was 1.0 g/m^2, but doses were titrated by 0.25 g/m^2 increments to maintain nadir leukocyte count between 2500-4000/mm^3."
45388424|NCT00377637|Drug|Azathioprine|2 mg/kg/day orally, provided as 50 mg capsules to be taken after meals.
45388425|NCT00377637|Drug|Placebo to Azathioprine|Placebo capsules matching Azathioprine taken orally once a day.
45388426|NCT00377637|Drug|Placebo to Mycophenolate mofetil|Placebo tablets matching Mycophenolate mofetil taken orally twice daily.
45388427|NCT00377637|Drug|Corticosteroid|Oral prednisolone (or equivalent) starting at a dose of 0.75-1.0 mg/kg/day (maximum 60 mg/day) tapered to 10 mg/day.
45501857|NCT03564704|Drug|Cytarabine|AraC will be added to Consolidation-Module of PDT-ALL-LBL protocol.
45388428|NCT01050309|Drug|hexaminolevulinate (HAL)|Intravenous dose of HAL 0.4 mg/kg including 100 nCi (3.7 kBq) 14C infused over a one hour period. A vaginal dose HAL 150 mg including 13,9 kBq of 14C HAL will be administered for 7 hours. Following a colon cleaning, 100mg HAL enema including 14,8 kBq of 14C will be instilled for 30 minutes in colon
45388429|NCT00377403|Drug|Acetaminophen|"Symptomatic treatment:~Dose: 500mg every 4 to 6 hours for pain or fever"
45388430|NCT00377403|Drug|Amoxicillin|"Intervention drug:~Dose: 500mg tid for 10 days"
45388431|NCT00377403|Drug|Dextromethorphan hydrobromide with guaifenesin|"Symptomatic treatment:~Dose: 10mls every 4 to 6 hours for cough"
45388432|NCT00377403|Drug|Guaifenesin|"Symptomatic treatment:~Dose: 600mg every 12 hours to thin secretions"
45388433|NCT00377403|Drug|Pseudoephedrine Sustained Action|"Symptomatic treatment:~Dose: 120mg every 12 hours for nasal congestion"
45501858|NCT03564704|Procedure|Bone marrow aspiration|Bone marrow aspiration and additional tests will be performed in all module of PDT-ALL-LBL protocol.
45501859|NCT03564704|Procedure|Intrathecal injection|Intrathecal injection of chemotherapy will be performed in PDT-ALL-LBL protocol.
45501860|NCT03564704|Radiation|Radiation therapy|Radiation therapy will be performed for mediastinum and/or central nervous system leukemia/lymphoma in PDT-ALL-LBL protocol.
45696102|NCT04763187|Procedure|Tooth extraction|Tooth extraction and alveolus regeneration with autologous blood concentrate.
45501861|NCT03564704|Genetic|NGS|Next-Generation-Sequencing (NGS) will be performed in PDT-ALL-LBL protocol.
45501862|NCT03564704|Procedure|allogeneic hematopoietic stem cell transplantation|Allo-HSCT will be added to LBL patients with available donor in PDT-ALL-LBL protocol.
45501863|NCT03564704|Diagnostic Test|Flow-MRD|Flow-MRD will be added to PDT-ALL-LBL for bone marrow and cerebrospinal fluid samples.
45501864|NCT03564704|Diagnostic Test|FISH|FISH will be added to PDT-ALL-LBL for bone marrow samples.
45501865|NCT03564704|Diagnostic Test|Flow immunophenotyping|Flow immunophenotyping will be performed in PDT-ALL-LBL protocol.
45501866|NCT03564704|Diagnostic Test|Karyotyping|Karyotyping will be performed in PDT-ALL-LBL protocol.
45501867|NCT03564704|Drug|Chidamide|HDACi chidamide will be added to induction regimen, consolidation and maintenance module of PDT-ALL-LBL.
45388434|NCT00377403|Drug|Saline spray (0.65%)|"Symptomatic treatment:~Dose: 2 squeezes per nostril as needed for nasal congestion"
45388435|NCT00370149|Device|Antibiotic-impregnated Catheters (M/R)|Patients randomized to this arm will have the antibiotic-impregnated catheters inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
45388436|NCT00370149|Device|Non-impregnated Catheters (C/S)|Patients randomized to this arm will have the central venous catheter inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
45388437|NCT00292942|Drug|Intravenous Artesunate|Three doses of Intravenous Artesunate drug at 2, 4, or 8 mg/kg in diluent Phosphate Buffer (0.3 M, pH 8.1)
45388438|NCT00292942|Drug|Placebo|Mannitol (200 mg/vial) diluted in Phosphate Buffer and given IV in equivalent volume by subject's weight.
45388439|NCT01068106|Device|Nobori® (Biodegradable polymer limus-eluting stents)|due randomization biodegradable polymer limus-eluting stents will be implanted
45388440|NCT01068106|Device|Xience-V® (Permanent polymer limus-eluting stent)|due randomization permanent polymer limus-eluting stent will be implanted
45388441|NCT00483938|Drug|Pegylated-interferon Alfa-2a|Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.
45388442|NCT00483938|Drug|Ribavirin|Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.
45501868|NCT03564704|Diagnostic Test|PET-CT scan|PET-scan will be performed for T-LBL patients for MRD assessment in PDT-ALL-LBL.
45501869|NCT03564548|Drug|PPP001|Group assigned to PPP001
45501870|NCT03564548|Drug|Morphine sulfate or Hydromorphone or Oxycodone|Group assigned to morphine sulfate or hydromorphone or oxycodone
45501871|NCT03159455|Drug|BI 1467335|Duration - 28 days
45501872|NCT03159455|Drug|Placebo|Duration - 28 days
45501873|NCT05353010|Drug|Tacrolimus|Tacrolimus 5mg (1 mg * 5 capsules)
45501874|NCT05353010|Drug|IN-A001(Tegoprazan)|IN-A001 50mg(Tegoprazan 50mg* 1 tablet)
45501875|NCT05353010|Drug|IN-A001(Tegoprazan) + Tacrolimus|IN-A001 50mg(Tegoprazan 50mg*1 tablet) and Tacrolimus 5mg(1mg * 5capsules)
45501876|NCT05352854|Drug|0.5% pilocarpine eye drops|Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes
45696103|NCT04363450|Drug|Hydroxychloroquine|Hydroxychloroquine loading 400mg (2 capsules) twice 12 hours apart followed by 200mg (1 capsule) twice weekly
45388443|NCT00370071|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
45501877|NCT01841177|Drug|Milrinone|Milrinone is a potent selective phosphodiesterase (PDE) type III inhibitor which stimulates myocardial function (inotropy), causes peripheral vasodilatation (afterload reduction) and improves myocardial relaxation (lusitropy).
45501878|NCT03564782|Biological|PVSRIPO|The live, attenuated, oral (Sabin), serotype 1 poliovirus vaccine booster will be administered 1 week before PVSRIPO injection. The study drug, PVSRIPO, is the live attenuated, oral (Sabin) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site (IRES) derived from the human rhinovirus type 2 (HRV2). It will be given at a dose of 1x10^8 TCID50 (tissue culture infectious dose) directly into the breast tumor.
45501879|NCT01336361|Other|Survey|A one-time paper survey was mailed to subjects, along with a cover letter, explanation of the research study, and contact and informed consent information. A reminder postcard was sent to subjects approximately one week later, encouraging return of the completed survey.
45501880|NCT02838134|Other|Rocuronium|A bolus of 0.7 mg/kg rocuronium is administered just after tracheal intubation and then an infusion of rocuronium (0.3 to 0.4 mg/kg) is started when post-tetanic count (PTC) is more than 0 and titrated towards PTC 1-2.
45501881|NCT02838134|Other|No additional Rocuronium|No additional rocuronium is administered after tracheal intubation.
45501882|NCT03150589|Drug|SB11 (Proposed ranibizumab biosimilar)|SB11 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks
45501883|NCT03150589|Drug|Lucentis (ranibizumab)|Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
45501884|NCT05708300|Drug|Mepolizumab 100 MG [Nucala]|subcutaneous injection once a month
45501885|NCT05708378|Other|Rocker board training|Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
45388444|NCT00369915|Drug|Scopolamine|
45388445|NCT00369915|Drug|Scopolamine|
45388446|NCT01019564|Device|Complete Easy Rub Formula MPS|Multi-purpose solution
45696104|NCT04363450|Drug|Placebo|Loading dose of two placebo capsules twice 12 hours apart followed by 1 capsule twice weekly
45501886|NCT05708378|Other|Stable surface training|Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
45388447|NCT01019564|Device|Aquify MPS|Multi-purpose solution
45388448|NCT03991845|Drug|Vit D|Vit D supplementation was done
45388449|NCT01017380|Drug|Celecoxib|celecoxib 400 mg 1 cap before surgery
45388450|NCT01017380|Drug|etoricoxib|120 mg 1 tab before surgery
45388451|NCT00369681|Drug|Bleomycin|
45388452|NCT00369681|Biological|Rituximab|
45388453|NCT00369681|Drug|Dacarbazine|
45388454|NCT00369681|Drug|Doxorubicin|
45388455|NCT00369681|Drug|Vinblastine|
45388456|NCT00266812|Drug|Temozolomide and radiotherapy|Oral temozolomide 75mg/m2/day for 14 days, during radiation treatment, and later on temozolomide 100 mg/m2/day at 14 days on/14 days off, until unacceptable toxicity or evidence of disease progression for up to 6 cycles from initial treatment. Radiotherapy (as in Intervention 2).
45501887|NCT05340452|Drug|Klaribact 125mg/5ml Suspension|one single 20 mL dose (500mg) of the test drug will be administered to the volunteers
45501888|NCT05340452|Drug|Klaricid 125mg/5ml Suspension|one single 20 mL dose (500mg) of the Reference drug will be administered to the volunteers
45501889|NCT02835092|Other|Take Shape For Life Program|The Take Shape For Life (TSFL) Program group will be assigned to the Optimal Weight 5 & 1 Plan™ for weight loss. This group will have scheduled coaching sessions with a TSFL coach for the duration of the study.
45501890|NCT02835092|Other|Medifast Direct Program|The Medifast Direct Program (MEDD) group will be assigned to the Medifast Achieve™ Plan (4 & 2 & 1 Plan®) for weight loss. MEDD participants will have access to the services of the Medifast Nutrition Support Team.
45501891|NCT02835092|Other|Self-directed Control|The Self-directed Control Group will be assigned to a food-based, reduced calorie diet consistent with the 2015 Dietary Guidelines for Americans.
45696105|NCT03685149|Drug|Flecainide Pill|Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
45696106|NCT03685149|Drug|Placebo|Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
45696107|NCT04370080|Device|Silver Diamine Fluoride 38%|Dental caries arrest medication
45696108|NCT03588585|Procedure|Tension|Tension applied to catheter and taped firmly to leg.
45388457|NCT00266812|Procedure|Whole brain radiotherapy|2 regimens are allowed: a) 20 fractions of 2 Gray each, administered on days 1 to 5, 8 to 12, 15 to 19, and 22 to 26; b) 10 fractions of 3 Gray each, administered on days 1 to 5 and 8 to 12.
45388458|NCT04249544|Drug|Pramipexole|1mg of pramipexole
45388459|NCT04249544|Drug|Placebo|1mg equivalent of placebo
45696109|NCT03588585|Procedure|NO TENSION|Foley balloon will be taped loosely to the leg and not placed on tension. All other care will remain the same
45696110|NCT01591616|Drug|lidocaine and prilocaine|Appropriate dose of Oraqix based on weight will be given before tooth extraction
45388460|NCT00488774|Other|Placebo|Matching placebo for golimumab, intravenous infusion administered at Week 0
45388461|NCT00488774|Drug|Golimumab 1 mg per kg|Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0
45848543|NCT04027218|Device|Combination of dry heat and high pressure|"The application is made with two sacks of carob seeds during 7 minutes. The sacks may be placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power; according to instructions for use.~After 7 minutes, the pressure is applied with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand QUIRUMED with CE Marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse."
45848544|NCT04026750|Drug|Pitolisant|Pitolisant will be administered orally for 7 days. Patients may have their study drug dose adjusted downward if the starting dose is not tolerated.
45388462|NCT00488774|Drug|Golimumab 2 mg per kg|Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0
45501892|NCT03564392|Behavioral|Acceptance Based Behavioral Intervention|This intervention focuses on acceptance-based strategies with an emphasis on willingness to experience less pleasurable internal experiences (e.g., pleasure from eating calorically-dense foods) and aversive internal experiences (e.g., hunger, food cravings). Strategies to increase this willingness will be taught, including defusion (i.e., getting psychological distance from internal experiences to allow oneself to act independently of them). Mindful decision-making, as it relates to eating and exercise, will also be emphasized. Clarification and commitment to core values is another key component, as living life in accordance with one's values (e.g., health) makes willingness to make difficult choices worthwhile. Standard behavioral techniques for weight loss (i.e., self-monitoring, stimulus control, psychoeducation) will also be included.
45848545|NCT04020822|Device|Guardian Sensor (3)|Guardian Sensor (3) connected to Guardian Link (3) Transmitter and/or Guardian Connect Transmitter.
45388463|NCT00488774|Drug|Golimumab 4 mg per kg|Golimumab 4 mg per kg intravenous (IV) infusion at Week 0
45388464|NCT00361569|Drug|DR-2041a|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
45848546|NCT03979872|Diagnostic Test|MC1R Genetic Testing|[See arm/group descriptions]
45848547|NCT03979872|Other|Skin Cancer Education|[See arm/group descriptions]
45388465|NCT00361569|Drug|DR-2041b|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
45501893|NCT03145207|Drug|Lidocaine patch|lidocaine patch
45501894|NCT02836652|Device|HeartMate II (HMII)|Left Ventricular Assist Device
45501895|NCT02836652|Drug|Warfarin|(INR Target 2.0-2.5, median 2.25, per standard of patient care)
45848548|NCT03979872|Device|UV Photo|[See arm/group descriptions]
45848549|NCT03993210|Device|Magnetic Resonance Fingerprinting (MRF)|In MRF, multiple tissue properties are acquired simultaneously.
45388466|NCT00361569|Other|Placebo|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
45388467|NCT00361569|Other|Placebo|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
45388468|NCT01011998|Drug|Gleevec (imatinib), valproic acid|"Valproic acid: 250 mg three times per day and then adjusted according to attain a therapeutic level.~Gleevec will be continued at the dose the patient was taking at the time of entry onto the study."
45388469|NCT02158377|Device|Trabecular metal dental implants (TM)|Patients receive TM dental implants in this arm. The early stability is measured and compared to the stability of the TSV implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
45388470|NCT02158377|Device|Tapered screw-vent implants (TSV)|Patients receive TSV dental implants in this arm. The early stability is measured and compared to the stability of the TM implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
45388471|NCT01017458|Drug|MK0773|Three 25mg oral tablets MK0773 bid, for 12 weeks
45388472|NCT01017458|Drug|Comparator: testosterone enanthate|intramuscular injection 200mg testosterone enanthate q14d, for 12 weeks
45388473|NCT01017458|Drug|Comparator: placebo oral tablet|placebo oral tablet bid, for 12 weeks
45388474|NCT01017458|Drug|Comparator: placebo injection|placebo intramuscular injection q14d, for 12 weeks
45388475|NCT02534415|Drug|Periodontal dressing material|Procedure:Palatal wound area was covered with periodontal dressing material at baseline and 3rd day
45501896|NCT02836652|Drug|acetylsalicylic acid (ASA) therapy|(81mg/day)
45501897|NCT04335175|Other|None - observational study|None - observational study
45696111|NCT03681873|Diagnostic Test|Extremely Low Dose CT|Patients undergoing a clinically indicated chest CT will also undergo the extremely low dose CT
45696112|NCT00938314|Drug|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation
45696113|NCT00938314|Drug|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
45388476|NCT02534415|Drug|0.2% Hyaluronic acid gel|0.2% topical hyaluronic-acid gel was applied to palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
45501898|NCT01344811|Procedure|Telemonitoring|The Telemonitoring group will be provided the Smartphone, body composition analyzer and pedometer. They should visit the site once per every 3 months (12 weeks), and measure their body composition during study period. After measurement of body composition, the subjects should make transmit measured information through Smartphone into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote body composition and activity monitoring and individual obesity case management
45501899|NCT01344811|Other|control group|The control group will receive a weighting scale and pedometer. They should perform the same weight measurement (minimum three times a week) like the intervention group during the study, and measured results should be recorded in a diary of self body weight and the number of steps. In addition, the subjects should visit the site once per every three months (12 weeks).
45501900|NCT02836496|Drug|Mepolizumab 300 mg|Mepolizumab is available as lyophilized powder for injection reconstituted with Sterile Water for Injection, just prior to use.
45696114|NCT00938314|Drug|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
45388477|NCT02534415|Drug|0.8% Hyaluronic acid gel|0.8% topical hyaluronic-acid gel was applied palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
46056710|NCT02726607|Behavioral|HIV Infant Tracking System (HITSystem) 2.0|The HITsystem 2.0 intervention will be designed to: (1) utilize electronic prompts to notify providers and program managers when actions are required, and (2) send text messages to women's mobile phones to (a) motivate adherence to medication, (b) remind women of antenatal (ANC) appointments and medication refills, (c) prompt preparation for a hospital delivery, and (d) support early infant testing. Given advancements in the approach and protocols for care, HITSystem 2.0 will continue to engage mothers and encourage postnatal medication adherence. The researchers will design HITSystem 2.0 to integrate seamlessly into the existing HITSystem to link PMTCT and early infant diagnosis (EID) services through one coordinated system-level intervention.
45388478|NCT00488618|Drug|Cariprazine (RGH-188)|Cariprazine 3 mg - 12 mg oral administration, once per day.
45388479|NCT00488618|Drug|Placebo|Dose-matched placebo oral administration, once per day.
45501901|NCT02836496|Drug|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution
45501902|NCT02836496|Drug|Active OCS capsules (5 mg prednisolone or prednisone)|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed. Subjects with an increase in blood eosinophils above the pre-specified threshold will be instructed to start blinded OCS treatment from one of the bottles provided (active treatment) unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
45848550|NCT03993210|Device|Q-space Trajectory Imaging (QTI)|By using q-space trajectory encoding and a diffusion tensor distribution model, QTI improves the discrimination of diffusivity, shape, and orientation of diffusion microenvironments and therefore carries major potential for imaging the tumor microenvironment.
46056711|NCT02726607|Behavioral|Standard of PMTCT care|Pregnant women enrolled in PMTCT services at the control site will receive the current standard of PMTCT care and will not be enrolled in the HITSystem 2.0.
46056712|NCT02726685|Other|respiratory training.|breathing exercise.
46056713|NCT02726685|Other|sham training.|range of motion (ROM) exercise, stretching exercise or positioning exercise.
45388480|NCT01019642|Drug|cholecalciferol|4,000 IU per day during 6 months. Capsule form.
45554672|NCT03782415|Drug|MN-166|MN-166 is an anti-inflammatory/neuroprotective agent. MN-166 distributes well to the CNS (Sanftner et al. 2009) and it is a selective inhibitor of certain cyclic nucleotide phosphodiesterases (PDE) and the pro-inflammatory cytokine, macrophage migration inhibitory factor (MIF). At clinically-relevant plasma or CNS concentrations, MN-166 selectively inhibits macrophage migration inhibitory factor (MIF) (Cho et al 2010) and, secondarily, PDE3, 4 and 10 (Gibson et al 2006).
45388481|NCT01019642|Drug|placebo|no active principles given.
45388482|NCT00266656|Drug|Humatrope|According to investigator's clinical practice and guided by the approved package insert
45696115|NCT00938314|Drug|Saline Placebo|Saline SC, on Day 1, 3, and 5 of study participation, then Saline IV, on Day 7, 8, and 9 of study participation
45696116|NCT03587961|Drug|Symdeko|explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
45388483|NCT00483704|Drug|Telcagepant 140 mg|Telcagepant 140 mg tablets
45388484|NCT00483704|Drug|Talcagepant 280 mg|Telcagepant 280 mg tablets
45388485|NCT00483704|Drug|Placebo|Placebo tablets
45388486|NCT00483548|Drug|Ziprasidone|Oral capsule formulation to be administered every day for duration of patient's participation in the trial - 40 mg on Day 1; 40 mg twice a day (BID) on Day 2; Flexible BID dosing of 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 140 mg or 160 mg total daily dose from Day 3 through Week 6. Dose increases of up to 40 mg/day can occur after subject has received previous lower dose for at least 1 day.
45388487|NCT00483548|Drug|Placebo|Matching placebo oral capsules to be administered as per the instructions for the ziprasidone arm
45388488|NCT00445770|Drug|Etanercept|10 mg twice weekly, subcutaneous injection for 52 weeks
45388489|NCT00445770|Drug|Etanercept|25 mg, twice weekly, subcutaneous injection for 52 weeks
45388490|NCT00445770|Drug|Methotrexate|up to 8 mg per week, oral dosing for 52 weeks
45388491|NCT00266032|Drug|Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
45388492|NCT00266032|Drug|Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
45501903|NCT02836496|Drug|Placebo matching OCS capsules|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed.A subject who does not reach the pre-specified blood eosinophil threshold with a similar blood draw date will be selected to initiate a placebo OCS treatment in a blinded manner, unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
45848551|NCT03993210|Device|Magnetic Resonance Imaging Machine (MRI)|MRI is routinely used in gynecologic malignancies for its ability to depict the extent of disease at diagnosis providing guidance in staging and treatment planning.
45388493|NCT00266032|Drug|Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
45388494|NCT01012076|Behavioral|Active Control vs Experimental Treatment|The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning.
45388495|NCT01019798|Drug|sunitinib, docetaxel, cisplatin|"Sunitinib given 10 days within 14 days of each cycle。~Sunitinib 25 mg/day with adjust dosage according to patient's condition, but should return to 25 mg when feasible or should withdraw from this study.~Docetaxel 40-50 mg/m2, cisplatin 50 mg/m2 every 2 weeks.~Overall 12 cycles (24 weeks)"
45388496|NCT01012154|Device|Endomicroscope|Endomicroscopic images and biopsies are taken at several positions on the tumor.
45501904|NCT04213807|Biological|MAA868 Cohort 1|Subcutaneous injection: low dose
45848552|NCT03988374|Drug|Dentifrices|Dentifrice on plaque, gingivitis, and bleeding.
45388497|NCT00483002|Drug|varenicline|As prescribed by physician in usual clinical practice.
45388498|NCT00482612|Drug|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia [USP] name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
45501905|NCT04213807|Biological|MAA868 Cohort 2|Subcutaneous injection: high dose
45501906|NCT04213807|Biological|MAA868 Cohort 3|Subcutaneous injection: Dose to be determined.
46056714|NCT00590824|Drug|hu14.18-IL2|6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course followed by surgery and up to 2 additional courses of hu14.18-IL2
46056715|NCT00590824|Drug|hu14.18-IL2|Surgery followed by 3 courses of 6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course
45848553|NCT03976752|Drug|Genvoya|"Genvoya is a fixed-dose combination anti-retroviral drug containing tenofovir alafenamide (TAF), emtricitabine (FTC), elvitegravir (EVG), and cobicistat.~At the second study visit, participants will be provided with a single dose of Genvoya, and instructed to take the dose at home with documentation by digital, time-stamped photo or video. At the third study visit, which will occur 24 hours after home dosing, participants will be given another single dose of Genvoya at the clinic."
45388499|NCT00482612|Drug|Placebo|Placebo tablets containing the following excipients: hydroxypropyl cellulose, maize starch (USP name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
45388500|NCT00282568|Drug|Tacrolimus Modified Release (MR)|Oral
45388501|NCT00282568|Drug|tacrolimus|Oral
45388502|NCT02532322|Drug|IV acetaminophen|IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
45388503|NCT02532322|Drug|normal saline|normal saline 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
45388504|NCT00265564|Behavioral|Modified Seeking Safety integrated into std outpatient SUD care|The Seeking Safety treatment involves two (one hour) sessions of manualized group therapy for 12 weeks.
45388505|NCT00265564|Behavioral|Standard outpatient SUD care|"Patients assigned to standard care meet twice weekly in Recovery 1 groups, which focuses on building abstinence."
45501907|NCT04213807|Other|Placebo|Subcutaneous injection: Placebo
45501908|NCT05065099|Device|Online Treatment Recovery Assistance for Concussion in Kids (OnTRACK)|Patients and families will be provided the smartphone app on their personal mobile phone (Android, iPhone) or provided with a phone if they do not own one. The patients will view educational videos on concussion management, input their daily exertional status and weekly symptom status upon receiving pre-programmed notification prompts on their phone. Healthcare Providers will monitor symptom recovery via an HCP dashboard and make management recommendations using evidence-based algorithms regarding symptom recovery status. School personnel will monitor progress via a dashboard and provide targeted supports, they may also view educational videos on concussion management. Opportunities for communication between the HCP, parent/patient and school will be provided by the app.
45501909|NCT01344967|Drug|Zoledronic acid|Zoledronic Acid at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
45501910|NCT05250661|Other|Aqueous propolis extract|The patients gargled 4 times a day after meals and 5 ml each time. Patients were instructed to keep the propolis solution in their mouth for one minute, to touch all structures in the mouth, and not to eat or drink anything orally for one hour after spitting.
45696117|NCT04370392|Procedure|intraperitoneal local anaesthetic instillation|intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25) through the trocar at the subdiaphragmatic space in Trendelenburg's position for 5 min with intravenous infusion of 50 ml normal saline over 10 minutes.
45848554|NCT03974802|Device|somofilcon A contact lens|Contact Lens
45848555|NCT03974802|Device|fanfilcon A contact lens|Contact Lens
45848556|NCT03966924|Device|Rotational fractional resection (1.5mm Diameter Device)|Single treatment of skin resection and with and without focal lipectomy (removal of loose skin and fat)
46056716|NCT02841969|Other|Electrolysed water|Irrigation of wound using electrolysed water
45501911|NCT04176913|Drug|LUCAR-20S CAR-T cells|An Anti-CD20 Allogeneic CAR-T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell, Follicular, Mantle Cell or Small Lymphocytic Lymphoma
45501912|NCT04172467|Other|non-interventional retrospective epidemiological observational study|non-interventional retrospective epidemiological observational study
45501913|NCT03268213|Biological|Fecal Microbial Transplantation|"Fecal microbial transplant is offered as treatment option to eligible patients. Donors selected by the patients will be screened by questionnaire and by blood and stool tests for potential transmissible pathogens.~The stool filtrate will be administered in the ileum and/or cecum via colonoscopy"
46056717|NCT02841969|Other|Prontosan|Irrigation of wound using Prontosan
46056718|NCT02720913|Device|COR-KNOT|The COR-KNOT device was developed to make suture fixation faster and save operative time. With a single squeeze of the lever, the device remotely and automatically secures sutures with a titanium fastener, while also simultaneously trimming excess suture tails.
45388506|NCT01068184|Drug|AZD6553|Single or multiple oral dose
45388507|NCT01068184|Drug|Placebo|single or multiple oral dose
45388508|NCT00376623|Drug|BI 2536|Intravenous Infusion
45388509|NCT01027104|Other|Education|Firearm injury prevention anticipatory guidance curriculum
45501914|NCT05050279|Drug|Delgocitinib capsule|oral capsule
45501915|NCT05050279|Drug|Placebo capsule|oral capsule
45388510|NCT01029990|Other|Telephone arm|Midwifes at 72 antenatal care units in West region of Sweden receive lists with names and telephone numbers on women who have no record of screening during two screening rounds (6 - 10 years depending on age). The midwife will make up to ten attempts to reach each woman and is instructed to use no more than 30 minutes on this. If the midwife get in touch with the woman she will encourage participation in regular screening (run by midwives in Sweden) and help the woman to get an appointment.
46056719|NCT02720913|Procedure|Standard Suture Tying|Standard Suture Tying
45388511|NCT01029990|Other|Self-test arm|Women receive an offer to order a vaginal self test for HPV. The woman can return a coupon in a postage free envelope and she will receive a self testing kit (dry method) within a couple of days. She will return the test in another postage free envelope. A reminder will be sent to women who order a test but do not return it.
46056720|NCT05753410|Behavioral|Mindful Courage|Self-guided online intervention
45848557|NCT03965754|Behavioral|Social norms|This intervention introduces recipients to descriptive social norms specifying that a majority of their colleagues have signed up for the program, which sets a normative standard against which recipients are expected to compare themselves and to change their behavior accordingly (i.e., when they realize that their behavior is discrepant from that of relevant others). The personal testimonial from a Geisinger medical director serves as a personal exemplar intended to further enhance the effect of the social norms with an implicit indication that the intended behavior is desirable and feasible.
45848558|NCT03965754|Behavioral|Loss framing|This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction.
46056721|NCT02726217|Behavioral|CareSmarts Mobile Health Diabetes Program|Nurses from Diabetes Clinic will use a web-based enrollment form that includes the patient's mobile phone number, diabetes care plan, and preferred times for receiving messages. Participants in the program receive text messages about diabetes self-care. The contents of the messages that the participants receive are modified through software every two weeks as needed, based on their interactions with the system. Participants follow a flexible education curriculum in which they move from one topic to the next at their own pace.
46056722|NCT02726217|Behavioral|Standard of Care Reminders and Self Assessments|
46056723|NCT02720991|Drug|Mifepristone|200 mg of oral mifepristone
45388512|NCT00445692|Drug|Clarithromycin|Given Orally (PO)
45388513|NCT00445692|Drug|Dexamethasone|Given PO
45501916|NCT03074227|Other|Allogeneic faecal transplantation|"Patients will get bowel lavage through a nasoduodenal tube. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with allogeneic faecal microbiota transplantation via the nasoduodenal tube.~Faeces will be collected from a donor."
45501917|NCT03074227|Other|Autologous faecal transplantation|Patients will get bowel lavage through a nasoduodenal tube at our centre. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with autologous faecal microbiota transplantation via the nasoduodenal tube.Faeces will be collected from the patient him/herself, in which their own faeces (autologous) will be used as a placebo.
45501918|NCT01345201|Biological|OMP-18R5|IV infusion. Subjects with stable disease or a response at Day 56 will be allowed to continue until disease progression.
46056724|NCT02720991|Drug|Sublingual misoprostol|400 ug of misoprostol sublingually following mifepristone
45388514|NCT00445692|Drug|Lenalidomide|Given Orally (PO)
45501919|NCT04072861|Drug|RBT-9|intravenous administration
45501920|NCT05250349|Diagnostic Test|Echocardiography|Transthoracic echocardiography with standard measurements
45501921|NCT05250349|Diagnostic Test|Doppler sonography|Transcarotid and transcranial Doppler sonography
45501922|NCT05250349|Diagnostic Test|Neuropsychological tests|Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA)
45501923|NCT04044781|Drug|BPN14770, T2310|Subjects will be administered radio ligand T2310 and BPN14770 to determine brain occupancy of BPN14770.
45501924|NCT04044469|Behavioral|Immunization-enhancement|This group receives a standardized information text, suggesting that medical diagnostics is not very accurate. Reasons for why a serious disease is overlooked are mentioned and discussed.
45501925|NCT04044469|Behavioral|Immunization-inhibition|This group receives a standardized information text, suggesting that medical diagnostics is very accurate and that doctors are very often right in their first initial diagnostic assessments.
45501926|NCT04044469|Behavioral|Control group|This group receives no further information after watching the videotaped doctor's report.
45388515|NCT01024842|Biological|MVA.HIVconsv low dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10^8 pfu at week 0, 4 and 12.
45848559|NCT03965754|Behavioral|Email reminder|This intervention is a standard email reminder that mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding screenings.
45848560|NCT03962634|Drug|Kovanaze Nasal Spray|Intra-nasal local anesthetic
45848561|NCT03962634|Drug|Articaine Injection|Local anesthetic
45501927|NCT04634383|Device|WFMA - wireless floating microelectrode array|Wirelessly transmitted patterns of electrical stimulation will be delivered to the visual cortex of study participants to generate visual percepts.
45388516|NCT01024842|Other|Placebo low dose|Three intramuscular injections of placebo alone (200ul) at week 0, 4 and 12.
45848562|NCT03933774|Drug|Tretinoin 0.05% cream|Stieva-A Cream 0.05%, 25g, GSK
45501928|NCT01345279|Drug|cisplatin|50 mg/m2 IV cisplatin on day 1 and then every 3 weeks for 6 courses
45501929|NCT01345279|Drug|topotecan|topotecan 0.75 mg/m2 on days 1, 2, and 3. The regimen was repeated every 3 weeks for 6 courses
45501930|NCT01345279|Drug|paclitaxel|135 mg/m2 paclitaxel on day 1 and then every 3 weeks for 6 courses
45501931|NCT00577577|Drug|rhIGF-I/rhIGFBP-3|1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
45501932|NCT00577577|Drug|placebo|1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
45501933|NCT02833844|Drug|Evolocumab|Dose of subcutaneous evolocumab QM
45501934|NCT02833844|Drug|Placebo|Dose of matching placebo QM
45501935|NCT01345357|Drug|CEP-9722|CEP-9722 will be administered orally from day 2 through day 7 of each cycle beginning with cycle 2. The starting dose will be 150 mg twice daily. Following cycle 2, the dose will either be decreased to 150 mg daily or increased to 200 mg twice daily in a cohort of 3 to 4 new patients. Subsequent cycles will increase the dose by 100 mg twice daily in cohorts of 3 to 4 patients (with criteria to expand to 6 patients) to a maximum of 400 mg twice daily. Patients must receive CEP-9722 to remain in the study. Once treatment with CEP-9722 is discontinued, patients will withdraw from the study.
45501936|NCT01345357|Drug|Gemcitabine|Gemcitabine will be administered at 1250 mg/m^2 intravenously on day 1 and day 8 of each 21-day cycle. Dosage reduction may be applied on day 8 (within a cycle) or on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
45848563|NCT03933774|Drug|Placebo cream|Physiogel Daily Mositure Therapy Facial cream, 150mL, Stiefel
45388517|NCT01024842|Biological|MVA.HIVconsv high dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10^8 pfu at week 0, 4 and 12.
45388518|NCT01024842|Other|Placebo high dose|Three intramuscular injections of placebo alone (800ul) at week 0, 4 and 12.
45388519|NCT03824236|Biological|RTS,S/AS01E (SB257049)|Subjects from the P-Fx and NP-Fx groups will receive one Fx booster dose of RTS,S/AS01E at Day 1.
45388520|NCT00282412|Biological|Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
45388521|NCT00282412|Drug|Fludarabine|inhibits DNA synthesis or repair
45501937|NCT01345357|Drug|Cisplatin|Cisplatin will be administered at 75 mg/m^2 intravenously on day 1 of each cycle, after the infusion of gemcitabine. Dosage reduction may be applied on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
45501938|NCT01333631|Drug|Valproic acid|Valproic acid given concurrent with chemoradiotherapy for patients with pancreatic cancer
45388522|NCT00282412|Drug|Cyclophosphamide|Causes prevention of cell division by forming adducts with DNA
45388523|NCT00282412|Drug|Campath 1H|humanized monoclonal antibody against CD52 antigen
45388524|NCT00282412|Drug|GCSF|Hematopoietic growth factor
45388525|NCT00282412|Drug|Cyclosporins|immune suppressive drug
45388526|NCT00282412|Drug|Mycophenolate Mofetil|immune suppressive drug
45388527|NCT03976726|Device|Comparison of physcial parameters|Increasement of weight, volume expansion and decrease of density are measured.
45388528|NCT00282334|Device|Telemedical blood pressure monitoring|Measurement of home blood pressure, three times per week for three months and once a week for three months.
45848564|NCT03933618|Drug|Anastrozole 1mg|
45848565|NCT03933618|Drug|Clomiphene Citrate 25mg|
45848566|NCT03933618|Drug|Placebo - Cap|
45848567|NCT03930264|Drug|Azathioprine 50Mg Tab|tablet
45388529|NCT03974932|Drug|HTX-011|Dual-acting local anesthetic. Dose 1.
45388530|NCT03974932|Drug|Ibuprofen|NSAID.
45388531|NCT03974932|Drug|Acetaminophen|Analgesic.
45501939|NCT05014789|Device|Control-IQ technology 2.0|All subjects wearing the t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor
45501940|NCT01345435|Procedure|Telemonitoring group|The Telemonitoring group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should visit the site once per every 2 months (8 weeks), and measure their blood glucose using a provided blood glucose monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management
45501941|NCT01345435|Procedure|Telemonitoring & Telemedicine|The Telemonitoring & Telemedicine group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should measure their blood glucose using a provided blood glucose monitor twice a day during the study period. After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management. A remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring PC and then issue electronic prescriptions.
45848568|NCT03930264|Drug|Azathioprine 10mg/mL oral suspension|oral suspension
45848569|NCT03919422|Procedure|T2 paravertebral block|Ultrasound guided T2 thoracic paravertebral block is added in ICTP group. After interscalene brachial plexus block and superficial cervical plexus block have been administrated, selective 2nd thoracic nerve root(T2) will be blocked with 10 ml of 0.25% ropivacaine(naropin).
45848570|NCT03919422|Procedure|interscalene brachial plexus block and superficial cervical plexus block|An ultrasound-guided IC block using an ultrasound machine (Sonosite, USA), and an linear array probe with a sterile cover and a 22G(Gauge) block needle is performed. An in-plane approach, advancing the needle along the longitudinal axis of the ultrasound transducer and visualizing the entire shaft is employed. Twenty ml of 0.375% ropivacaine(naropin) is injected around brachial plexus and 10 ml of 0.25% ropivacaine around superficial cervical plexus.
45848571|NCT03926208|Procedure|Soak and Scrub|Betadine soak and scrub in addition to standard clorhexadine scrub (standard of care).
45848572|NCT03926208|Procedure|Clorhexadine scrub|Clorhexadine scrub (standard of care).
45848573|NCT03901092|Drug|flortaucipir F 18|No study drug will be administered.
45388532|NCT03974932|Drug|Celecoxib|NSAID.
45388533|NCT03974932|Drug|+/- Bupivacaine HCl|Local anesthetic.
45388534|NCT03974932|Device|Luer Lock Applicator|Applicator for instillation.
45696118|NCT04369378|Behavioral|Meditation app usage|Investigators will confirm eligibility of applicants, enroll participants in the study and provide an identification number for de-identification of the data, and provide a list of mental health resources to participants. Participants will then be sent a link to a Google Form for the pre-intervention survey, to be completed prior to first use of the mindfulness app. Participants will also be given access to the mindfulness app (Insight Timer), and instructed to use it for 10 min daily for 30 days. Two days before the end of the 30 day intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. Two months after the conclusion of the 30 day intervention period, participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
45696119|NCT03798327|Behavioral|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
45848574|NCT03887286|Device|Philips EPIQ 7 ultrasound machine|Standard transthoracic echocardiography
45848575|NCT03887286|Device|Philips Lumify Broadband sector array transducer|Portable hand-held ultrasound device
45388535|NCT03974932|Drug|HTX-011|Dual-acting local anesthetic. Dose 2.
45388536|NCT00282256|Drug|tacrolimus modified release (MR)|Oral
45388537|NCT00282256|Drug|tacrolimus|Oral
45388538|NCT00265330|Drug|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid .
45388539|NCT00292318|Behavioral|Biofeedback Therapy for Fecal Incontinence: A Randomized Control Study|Patients who have more than one episode per week of fecal incontinence would be enrolled and randomized into either the control group (medical counseling and exercises) or study group (biofeedback therapy, medical counseling, and sphincter exercises) for seven sessions to assist with their medical problem.
45388540|NCT00292318|Behavioral|control group|Medical counseling and ano-sphinctal exercises.
45388541|NCT00281632|Drug|GW786034|800 mg GW786034 administered orally on a daily basis.
45388542|NCT00543569|Drug|Alefacept|Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
45848576|NCT03882528|Biological|Plasmodium falciparum malaria parasite|Laboratory cultured Plasmodium falciparum strain 3D7 delivered via the bite of 5 infected mosquitoes with salivary gland scores of at least 2+ (11-100 sporozoites observed).
45848577|NCT03881670|Device|Lotrafilcon B|commercially available contact lens
45388543|NCT00543569|Drug|tacrolimus|The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
45388544|NCT00543569|Drug|basiliximab|Administered as a 20 mg bolus injection within 2 hours prior to transplantation and a 20 mg bolus injection on Day 3.
45388545|NCT00543569|Drug|mycophenolate mofetil|Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
45388546|NCT00543569|Drug|Corticosteroids|Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
45501942|NCT01345435|Other|SMBG|The subjects who are assigned in the control group will be provided blood glucose Monitor. The subjects who are assigned in the control group should perform the same blood glucose measurement same as the test group during the study, and measured results should be recorded in a diary of self blood glucose measurement. In addition, the subjects should visit the site once per every two months (8 weeks).
45388547|NCT02532166|Other|Esophageal lichen planus|White light endoscopy compared to narrow band imaging and Lugol for detection of esophageal lichen.
45388548|NCT01068574|Other|BASIC Score (Observational)|The BASIC Score will be assessed by a study staff, but there are no interventions.
45388549|NCT00984191|Radiation|99mTc-MIBI SPECT-CT|99mTc-MIBI SPECT-CT for abnormal cervical lymph node
45388550|NCT04773821|Other|Targeted biopsies|Prostate MpMRI at 12 month (after PCa focal treatment in standard care) and targeted biopsies in the presence of lesion(s) suggestive(s) of recurrence
45388551|NCT00984347|Drug|Oxytocin|"For low risk group (women at deliveries 1-5):~IV oxytocin 10IU/1000ml standard sol. starting at 2MU/MIN and augmenting 2MU every 20 min.~For high risk group (grandmultiparas [6th delivery and up] or women with a previous cesarean section)~IV oxytocin 5IU/1000ml standard sol. starting at 1MU/MIN augmenting 1MU every 20 MIN - in accordance with the department's protocol"
45388552|NCT00984347|Procedure|breast pump nipple stimulation|breast pump calibrated at lowest suction strength, operated alternately: 15 min one breast, 15 min second breast, 15 min rest
45388553|NCT00984425|Drug|Lapatinib and Sorafenib|Comparison of different dosages of two drug
45388554|NCT00984503|Drug|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor sites (3cm2) once just prior to wounding
45388555|NCT00984503|Drug|Placebo|Intradermal injection of Placebo at 100μl/cm2 of SSG donor site (3cm2) once just prior to wounding
45388556|NCT00984503|Drug|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor site once just prior to wounding, followed by topical Juvista at 100ng/200μl/cm2 after wounding and again at Day 1
45388557|NCT00984503|Drug|Placebo|Intradermal placebo at 100μl/cm2 of SSG donor site once just prior to wounding, followed by topical placebo at 200μl/cm2 after wounding and again at Day 1
45388558|NCT05596955|Drug|Buprenorphine injection|Extended release once-a-month buprenorphine injection . Study arm undergoes 2 fMRI examinations and weekly monitoring visits
45388559|NCT05596955|Drug|Naltrexone Injection|Extended release once-a-month naltrexone injection. Study arm undergoes 2 fMRI examinations and weekly monitoring visits
45388560|NCT00445458|Drug|HKI-272|
45388561|NCT00445458|Drug|Paclitaxel|
45388562|NCT00986063|Genetic|Genetic test for NVP induced rash|The genotype statuses that capable of predict the cutaneous side effects from nevirapine
45388563|NCT00986063|Other|3TC/D4T/NVP or 3TC/AZT/NVP|Standard HAART for AIDS patients in Thailand
45388564|NCT04487327|Other|Dry Needling|"The dry-needling treatment will consist of inserting a sterile needle into 2-4 muscles of the participant either at the MTrP or 2 cm away from the MTrP, but within the same muscle. To assist in the reduction of infection risk and protection of the participants, the site will be cleaned with alcohol prior to treatment and investigators performing the needling treatment will wear gloves and handle needles using aseptic technique throughout the procedure. Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique."
45388565|NCT01030068|Behavioral|Yoga|Yoga twice weekly
45388566|NCT01030068|Behavioral|Wellness|Health and wellness classes twice weekly
45388567|NCT01030068|Other|Smoking cessation therapy|Smoking cessation therapy
45388568|NCT03914417|Drug|Imiquimod 3.75% Cream|Approximately two weeks after Day 0, the entire treatment area was treated with imiquimod 3.75% cream. Subjects utilized the 2 weeks on, 2 weeks off, 2 weeks on regimen. Subjects were followed every 2 weeks during treatment (week 2, 4 and 6) and then at 4 and 8 weeks post last-imiquimod application (week 10 and 14).
45501943|NCT04611763|Drug|Flurbiprofen axetil preoperatively|give Flurbiprofen axetil 15 min before surgery
45501944|NCT04611763|Drug|Flurbiprofen axetil postoperatively|give Flurbiprofen axetil at the end of surgery
45554673|NCT03782415|Drug|Temozolomide|Temozolomide is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; and a first-line treatment for glioblastoma multiforme.
45848578|NCT03881670|Device|lotrafilcon B with Hydraluxe|commercially available contact lens
45388569|NCT00988871|Device|PICC, CICC|PICC insertion, CICC (advanced venous access with pulmonary artery catheter) insertion
45388570|NCT00986141|Procedure|Surgery|Selective Laser Trabeculoplasty for glaucoma
45388571|NCT00986141|Procedure|Selective Laser Trabeculoplasty|Glaucoma Treatment
45696120|NCT04357678|Other|Qi Gong Programme|"Warm-up: In warm up session joint activities were performed along with light stretching. Patients performed these activities with instructor's commands for 5 minutes.~Liu Zi Jue exercise: patients performed intact Liu Zi Jue exercise (form of Qigong).~This includes six healing sounds, Xu, He, Hu, Si, Chui, Xi and the Harmonized actions along with the instructor for 20 minutes. Cooling-down: After completion of Qigong, patient done gentle stretching to adjust back their breathing and this cool down session lasted for 5 minutes. Subjects received supervised training session for 30 min twice a week."
45696121|NCT04357678|Other|Short Form Sun Style Tai Chi|"Commencing Movement, Opening and closing hand, Single whip, Waving hands in the cloud, Opening and closing hands, Brush knee, Playing lute, Perry and Punch, Block and close, Pushing the mountain, Closing movement.~Participants attended two supervised 30min sessions twice a week. Participants learnt 3 to 4 forms per week and at the completion of study (which is the six week of training), they completed all 21 forms. In each training session, participants revised previous SSTC forms that they learnt earlier up to that session."
45388572|NCT05586113|Drug|10-day Tegoprazan bismuth-containing quadruple therapy|10-day Tegoprazan bismuth-containing quadruple therapy: Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
45388573|NCT00986297|Radiation|hypofractionated radiation therapy|hypofractionated radiation therapy
45388574|NCT00541385|Drug|pyronaridine artesunate|The strength of the granule formulation is 60:20 mg pyronaridine artesunate per sachet. Depending on their body weight, patients will receive between 1 to 3 pyronaridine artesunate sachets per day, for 3 consecutive days The actual dose-range covered by this regimen is 7.0:2.3 mg/kg to 13.3:4.4 mg/kg pyronaridine artesunate, which has shown to be effective and safe in the phase II studies conducted in children and adults.
45388575|NCT00541385|Drug|arthemeter lumefantrine|The strength of the tablet is 20 mg artemether and 120 mg lumefantrine. Depending on their body weight, patients will receive either 1 or 2 crushed tablets twice a day (≥5 to <15 = 1 tablet, 15 to <25 kg = 2 tablets), for 3 consecutive days.
45388576|NCT00988949|Drug|PF-04455242|Single oral 18 mg dose of PF-04455242.
45388577|NCT00988949|Drug|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
45388578|NCT00988949|Other|Placebo|Oral placebo.
45388579|NCT00988949|Drug|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
45388580|NCT00988949|Drug|PF-04455242|Single 30 mg oral dose of PF-04455242.
45501945|NCT03564314|Other|SUPPORT AKI Clinical Decision Support|Surgical units will receive a multidimensional clinical decision support intervention consisting of: (1) electronic and non-computerized tools to alert for early recognition of AKI, (2) educational program for physicians and nursing staff, (3) decision support tools with guidance on fluid therapies, medication management, investigations for AKI, and consultation with specialists.
45696122|NCT03585153|Other|Non-contrast magnetic resonance imaging|subjects lie in an MRI machine (non-contrast) for 30 minutes while we take pictures of their pancreas
45501946|NCT02959021|Behavioral|weight loss intervention - self directed|
45696123|NCT04357444|Drug|1: ILT101|Subcutaneous injections, once-daily administration for 10 consecutive days.
45848579|NCT03856320|Behavioral|Educational Video|An educational video describing obesity treatment options available in the VA.
45696124|NCT04357444|Drug|2: Placebo Comparator|placebo in Subcutaneous route
45848580|NCT03861000|Drug|[C-11]T-1650|radio-labeled drug
45848581|NCT03861000|Drug|BPN14770|selective compound
45848582|NCT03863496|Procedure|Scoliosis surgery|All patients will be implanted Medtronic CD Horizon Legacy 4.5 and 5.5 under X-ray control (C-arm), intraoperative spinal deformity surgery safety control and standard anesthetic support.
45848583|NCT03856944|Device|ReSTOR Toric|ReSTOR Toric bilateral IOL implantation
45501947|NCT02959021|Behavioral|weight loss intervention - peer coach|
45501948|NCT05329064|Biological|BNT162b2 Pfizer-BioNTech/Comirnaty|"The study will use 10mcg of BNT162b2 (Pfizer-BioNTech/Comirnaty®) for each dose.~Two doses will be given at 2 months apart between doses."
45848584|NCT03865446|Drug|Dacomitinib|anti-cancer agent
45848585|NCT03868254|Device|XEN Group|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015.
45388581|NCT00988949|Drug|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
45388582|NCT04760951|Dietary Supplement|TOTUM-070|5-g dose of TOTUM-070 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in two intakes
45501949|NCT05186935|Device|Injectable Hydrogel treatment|The Injectable Hydrogel is a single use two-component injectable and bioresorbable hydrogel intended for treatment of cartilage defects in the knee, it is a medical device, exclusively for clinical investigations. The hydrogel is mixed intraoperatively and with an open knee procedure inserted into the cartilage defect, where it crosslinks and adheres to the cartilage with the use of a primer, allowing it to stay in place during movements of the knee. The hydrogel covers the defect to prevent formation of scar tissue and to allow cartilage to regenerate. The Injectable Hydrogel will be used in combination with general instruments typically used. The different components of the Injectable Hydrogel are arranged in two boxes: Components of the Injectable Hydrogel are grouped in plastic cover bags or packaged in vial boxes.This is a performance study, with a single arm, i.e Injectable Hydrogel. Recovery is monitored.
45501950|NCT04568629|Other|Advice from the PiPS-B14 prognostic tool|"Participants were informed that prognostic advice came from the PiPS-B14 prognostic tool. PiPS-B14 is a validated prognostic algorithm that has been shown to be as accurate as an agreed multi-professional survival estimate.~Participants were further informed that in a previous study the PiPS-B14 risk categories for predicting two-week survival were as accurate as a doctor's or a nurse's prediction."
45501951|NCT04568629|Other|Advice from another clinician|"Participants were informed that prognostic advice came from another clinician.~Doctors were told that advice was from a nurse, whereas nurses or other types of HCPs were told that advice was from a doctor."
46056725|NCT04687228|Behavioral|More than Muscles (MTM)|"In session 1, the primary activities are: 1) define the ideal body type for men in our culture, 2) discuss the origin and perpetration of the ideal, 3) brainstorm the costs of pursuing the ideal, 4) participate in a verbal challenge during which participants counter the ideal message, and (5) are asked to complete three homework assignments (i.e., a letter to an adolescent boy, a behavioral challenge, and a mirror exposure assignment). In session 2, the primary activities are: 1) reviewing homework, 2) engage in role-plays to counter/discourage pursuit of the ideal, 3) discuss ways to challenge and avoid negative body talk statements, 4) list ways to resist the pressure to pursue this ideal both individually and as a group within the larger community (i.e., body activism), 5) discuss barriers to body activism and strategies to overcome those barriers, and 6) individually select an exit exercise to continue to actively challenge the appearance ideal."
45501952|NCT04973917|Procedure|respiratory support|respirators for invasive mechanical ventilation
45501953|NCT03985033|Other|leucocyte and platelet-rich fibrin (L-PRF)|The blood collected from each patient will be centrifuged immediately at 2700 rpm for 12 min to separate L-PRF.
45501954|NCT01341782|Drug|paricalcitol|
45501955|NCT01341782|Drug|maxacalcitol|
45501956|NCT01341782|Drug|paricalcitol placebo|
45501957|NCT01341782|Drug|maxacalcitol placebo|
45501958|NCT01345747|Device|laryngeal tube (VBM Medizintechnik, Sulz, Germany)|laryngeal tube suction number 3 and 4
45501959|NCT02607319|Drug|Bemiparin sodium|Bemiparin sodium 3,500 IU will be started on the evening of the same day of embryo transfer and until the day of pregnancy test. If the test is positive, Bemiparin will be discontinued by the end of the 12th week of gestation.
45501960|NCT05150509|Diagnostic Test|Oral Squamous Cell Carcinoma|To identify the association of elevated level of specific amino acids in OSCC by Liquid Chromatography Mass Spectrometry
45848586|NCT03868254|Procedure|Phacoemulsification|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015.
45848587|NCT03862482|Device|Brånemark® 2, Swede-Vent® 2, Screw-Vent® 1 (Configuration 1)|Brånemark® implant placed at sites 2 (left medial) and 5 (right distal), Swede-Vent® implant placed at sites 1 (left distal) and 4 (right medial), Screw-Vent® implant placed at site 3 (para symphysis)
45388583|NCT04760951|Dietary Supplement|Placebo|Placebo. Eight capsules per day to consume orally in two intakes
45501961|NCT02250157|Drug|Oratecan|
45501962|NCT03952429|Behavioral|Anti Alcohol App with Active Cognitive Bias|The active version includes an active form of cognitive bias modification, i.e. the user has to avoid alcohol stimuli 90% of the time, while they approach soft drinks 90% of the time.
45501963|NCT03952429|Behavioral|Inactive Cognitive Bias Modification|The control version includes an placebo form of cognitive bias modification, i.e. the users avoid and approach alcohol and softdrink stimuli for an equal number of trials.
45501964|NCT01345825|Other|Resistance training|Week 1: 2 sets x 12 repetitions at 12 RM Week 2: 3 sets of 12 repetitions with 12 RM Week 3: 3 sets of 10 repetitions with 10 RM Week 4-5: 3 sets of 10 repetitions with 10 RM Week 6: 3 sets of 8 repetitions with 8 RM Week 7: 4 sets of 8 repetitions with 8 RM Week 8: 4 sets of 8 repetitions with 8 RM
45501965|NCT01345903|Procedure|therapeutic conventional surgery|Undergo robotic-assisted surgery
45501966|NCT05063149|Drug|Broncho-Vaxom|Broncho-Vaxom is a bacterial extract comprising lyophilised fractions of 21 different inactivated bacterial strains, which are frequently causing RTI.
45501967|NCT05063149|Other|Placebo|Placebo powder from a capsule will be given, which will be indistinguishable from the active study drug.
45501968|NCT01341470|Drug|LY2495655|administered intravenously or subcutaneously
45388584|NCT05543915|Device|Active tDCS|The tDCS-MRI scan will last approximately one hour. The first 20 minutes of the MRI will not include tDCS stimulation. After 20 minutes, the tDCS device will ramp up to 2.0mA and deliver 2.0mA for 20 minutes. Then the tDCS will ramp down (30 seconds) and the final 20 minutes will be without stimulation.
45501969|NCT01341470|Drug|Placebo|administered intravenously or subcutaneously
45501970|NCT03564158|Drug|meropenem-vaborbactam|Meropenem-Vaborbactam being studied for effects on TQT
45501971|NCT03564158|Drug|Placebo|Placebo
45501972|NCT03564158|Drug|Moxifloxacin|Active Comparator
45501973|NCT02677298|Drug|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area.
45501974|NCT02677298|Drug|Placebo|Injection, sodium chloride 0.9 mg divided in five 0.1mL i.m. injections into glabellar area
45501975|NCT02677298|Drug|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area in up to 3 treatment cycles
45501976|NCT03143101|Biological|FluMist trivalent (2015-2016)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10^7±0.5 FFU of each vaccine strain.
45501977|NCT03143101|Biological|FluMist Quadrivalent (2015-2016)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10^7±0.5 FFU of each vaccine strain.
45501978|NCT03143101|Biological|FluMist Quadrivalent (2017-2018)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10^7±0.5 FFU of each vaccine strain.
45501979|NCT01345981|Drug|Lidocaine|dosage 20 mg and 40 mg
45501980|NCT00871351|Drug|Ezetimibe|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
45501981|NCT00871351|Drug|Atorvastatin|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
45501982|NCT00871351|Drug|Atorvastatin|2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)
45501983|NCT00871351|Drug|Rosuvastatin|1 tablet of 2.5 mg daily for 12 weeks (Weeks 5-16)
45501984|NCT04920331|Biological|Erenumab|140mg single intravenous administration (60 minutes)
45501985|NCT02745080|Biological|Secukinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
45501986|NCT02745080|Biological|Adalimumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
45501987|NCT01346137|Drug|Meloxicam|15 mg versus 30 mg per day P.O. for 15 days during 3 menstrual cycles
45501988|NCT04537507|Procedure|Coronary angiography|
45388585|NCT00989027|Drug|Oxytocin|Oxytocin, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
45388586|NCT00989027|Drug|Ergonovine|Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
45388587|NCT00989027|Drug|Carboprost|Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
45388588|NCT00989027|Drug|Oxytocin and Ergonovine|Oxytocin and Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
45501989|NCT00521599|Drug|Mometasone furoate dry powder inhaler|
45501990|NCT00521599|Drug|Placebo|
45501991|NCT04537039|Diagnostic Test|Frailty screening for people over 65 living at home.|The home care services will carry out the SEGA-A test.
45501992|NCT00442897|Drug|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg, tablet, once daily, 12wks(sub group:24wks)
45501993|NCT00442897|Drug|Comparator: atorvastatin|atorvastatin 10mg, tablet, once daily, 12wks(sub group:24wks)
45501994|NCT01346215|Biological|heparin sodium|5000 UI/mL
45501995|NCT01346215|Biological|heparin sodium|5000 UI/mL
45501996|NCT02834390|Drug|Quizartinib|"[Induction period, Cycle 1] Once-daily repeated oral administration Day 8 to Day 21.~[Induction period, Cycle 2] Once-daily repeated oral administration Day 6 to Day 19.~[Consolidation period] Once-daily repeated oral administration Day 6 to Day 19."
45501997|NCT02834390|Drug|Cytarabine|"[Induction period, Cycle 1] Once-daily intravenous injection of 100 mg/m^2 cytarabine on Day 1 to 7.~[Induction period, Cycle 2] Once-daily intravenous injection of 100 mg/m^2 cytarabine on Day 1 to 5.~[Consolidation period] Twice-daily intravenous injection of 3.0 g/m^2 cytarabine at 12-hour intervals on Days 1, 3, and 5."
45501998|NCT02834390|Drug|Idarubicin|"Either Idarubicin or Daunorubicin will be used [Induction period, Cycle 1] Once-daily intravenous injection of 12 mg/m^2 idarubicin on Day 1 to 3.~[Induction period, Cycle 2] Once-daily intravenous injection of 12 mg/m^2 idarubicin on Day 1 and 2."
45501999|NCT02834390|Drug|Daunorubicin|"Either Idarubicin or Daunorubicin will be used [Induction period, Cycle 1] Once-daily intravenous injection of 60mg/m^2 daunorubicin on Day 1 to 3.~[Induction period, Cycle 2] Once-daily intravenous injection of 60mg/m^2 daunorubicin on Day 1 and 2."
45502000|NCT03141151|Behavioral|COACH: Healthy Bodies|Staged intensity behavioral intervention focusing on healthy lifestyles in the context of family.
45502001|NCT03141151|Behavioral|COACH: Strong Minds|School Readiness Intervention focusing on literacy and parent skills
45502002|NCT01317433|Drug|Doxycycline|Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks.
45388589|NCT00989027|Drug|Oxytocin and Carboprost|Oxytocin and Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
45696125|NCT04369144|Other|Dynamic Scapular Recognition exercise|The intervention group received continual vertical downward correction using a standardized rigid tape. A hypoallergenic tape (Hypafix; BSN Medical GmbH, Hamburg, Germany) was used with 50% to 75% tension. Two rigid tapes were applied; the first one is placed from just superior to the midpoint of the superior border of the scapula to the level of T12 and the second tapes were placed from just superior to the superior angle of the scapula to the level of T12. The level of T12 was used as the end of both taps to increase the lever arm of the applied force and to decrease the incidence of peeling off of the tape. No tape was applied from the lateral angle of the scapula because it might impair the upward rotation of the scapula. Both taps were performed after each session and removed immediately before the next session
45696126|NCT03679689|Dietary Supplement|artificially sweetened beverages|artificially sweetened beverages restriction
45388590|NCT00265096|Biological|golimumab|50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
45502003|NCT01317433|Drug|Cetuximab|500 mg/m² IV infusion of 60 minutes every 15 days
45502004|NCT01358708|Drug|LACTEOL® 340 mg|LACTEOL® 340 mg will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
45502005|NCT01358708|Drug|PLACEBO|Matched LACTEOL® 340 mg Placebo will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
45696127|NCT04369222|Other|Observational|Maternal consumption of mild analgesics
45696128|NCT03584373|Drug|Ketorolac Oral Tablet [Toradol]|Ketorolac is a prescribed NSAID with strong analgesic activity. Ketorolac will be administered post surgery to compare pain outcomes to that of Percocet.
45696129|NCT03584373|Drug|Acetaminophen|Acetaminophen is an over-the counter pain medication that will be administered post surgery to compare pain outcomes to that of Percocet.
45696130|NCT03584373|Drug|Oxycodone Acetaminophen|Percocet is a prescribed opioid medication to manage pain. Percocet will be administered post surgery to compare pain outcomes to that of non-opioid analgesia.
45696131|NCT04363294|Diagnostic Test|PYP scan|99mTc-labeled pyrophosphate
45696132|NCT01591460|Drug|boceprevir|800 mg three times daily for 24, 32 or 44 weeks
45696133|NCT01591460|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 24, 32 or 44 weeks
46056726|NCT04687228|Behavioral|Media Advocacy (MA)|MA content generally centers on acknowledging and discussing the role the media has on shaping body image ideals. Session 1: In session 1, similar to MTM, the primary activities will include: (1) describing the ideal body for men in our culture, (2) discussing how the media impacts this ideal, with a particular focus on advertising. Following this, participants will (3) watch a video on how the media influences body image among men, and the consequences of internalizing these messages. Session 2: In session 2, content will continue by further discussion of the video showed in session 1, with participants sharing their reactions. Next, the group discusses the attainability of the ideal as well as discusses other forms of media (e.g., social media) and how it impacts body image.
45388591|NCT00265096|Biological|Placebo; golimumab|SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
45388592|NCT00265096|Biological|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
45502006|NCT01346449|Behavioral|Provide menu with visual cue and calorie information|Menu to be provided prior to placing the food order.
45502007|NCT01346449|Behavioral|Provide menu with visual cue but no calorie information|Menu to be provided prior to placing the food order.
45502008|NCT01346449|Behavioral|Provide menu with no visual cue but with calorie information|Menu to be provided prior to placing the food order.
45502009|NCT01346449|Behavioral|Provide menu with no visual cue and no calorie information|Menu to be provided prior to placing the food order.
45502010|NCT03563768|Procedure|One-stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
45502011|NCT01317511|Dietary Supplement|Protein|Protein drink
45696134|NCT01591460|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 4 weeks
45388593|NCT00986375|Behavioral|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
45848588|NCT03862482|Device|Brånemark® 1, Swede-Vent® 2, Screw-Vent® 2 (Configuration 2)|Brånemark® implant placed at site 3 (para symphysis), Swede-Vent® implant placed at sites 2 (left medial) and 5 (right distal), Screw-Vent® implant placed at sites 1 (left distal) and 4 (right medial)
45388594|NCT00986375|Behavioral|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program
45388595|NCT00986531|Drug|AZD8529|2 capsules by mouth for 3 days
45388596|NCT00986531|Drug|Placebo to match AZD8529|2 capsules by mouth for 3 days
45388597|NCT05529329|Procedure|overlay|Lithium Disilicate partial coverage of hypo-mineralized defected enamel
45388598|NCT05523947|Drug|YH32367|"Dose Escalation Part: 8 Cohorts (Dose level: 0.03, 0.75, 1.5, 3, 6, 12, 20, and 30 mg/kg). In Dose Escalation part, approximately 30 patients will be enrolled and patients are assigned to receive YH32367 at a starting dose of 0.3 mg/kg and the dose being escalated/de-escalated in adjacent dose cohorts will be up to 30 mg/kg.~Dose Expansion Part: 2 Cohorts (Cohort 1: Breast cancer, Cohort 2: Gastric cancer). Upon completion of the Dose Escalation part with the determination of MTD/RP2D, the Dose Expansion part will initiate. Dose Expansion part will consist of multiple cohorts in patients who were treated with three or more prior lines of therapy, HER2-positive breast cancer(Cohort 1); in patients who were treated with two or more prior lines of therapy, HER2-positive gastric or gastroesophageal junction adenocarcinoma(Cohort 2). Approximately 40 patients will be enrolled in each cohort. Additional cohorts may be added, taking into account available non-clinical or clinical data."
45388599|NCT00989105|Other|immunohistochemistry staining method|
45388600|NCT00989105|Other|laboratory biomarker analysis|
45696135|NCT01591460|Drug|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 24, 32 or 44 weeks
45696136|NCT01591460|Drug|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 4 weeks
45696137|NCT03584295|Device|Extracorporeal carbon dioxide removal|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R to facilitate early extubation
45848589|NCT03862482|Device|Brånemark® 2, Swede-Vent® 1, Screw-Vent® 2 (Configuration 3)|Brånemark® implant placed at sites 1 (left distal) and 4 (right medial), Swede-Vent® implant placed at site 3 (para symphysis), Screw-Vent® implant placed at sites 2 (left medial) and 5 (right distal)
45388601|NCT00989105|Other|pharmacological study|
45388602|NCT00989105|Procedure|computed tomography|
45696138|NCT03584295|Other|Conventional Care|Patient with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional Care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.
45848590|NCT03848208|Drug|cytisine|cytisine film-coated oral tablet
45848591|NCT03848208|Drug|placebo|matching placebo oral tablet
45848592|NCT03858894|Drug|DE-117 Ophthalmic Solution QD|DE-117 ophthalmic solution QD and Vehicle (no active DE-117 ingredient) QD add one drop in each eye
45848593|NCT03858894|Drug|DE-117 Ophthalmic Solution BID|DE-117 ophthalmic solution BID twice Daily (20:00 and 8:00) add one drop in each eye
45848594|NCT03856164|Drug|Tranexamic Acid|Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
45388603|NCT00989105|Procedure|magnetic resonance imaging|
45388604|NCT00989105|Procedure|single photon emission computed tomography|
45388605|NCT00989105|Radiation|technetium Tc 99m demobesin-4|
45388606|NCT02201108|Drug|Teriflunomide|Pharmaceutical form:film-coated tablet, Route of administration: oral
45388607|NCT02201108|Drug|Placebo|Pharmaceutical form:tablet, Route of administration: oral
45388608|NCT01068808|Procedure|skin prick test|skin prick test to aeroallergen
45388609|NCT00986609|Biological|MUC-1 peptide vaccine|Given subcutaneously
45696139|NCT04363216|Drug|Ascorbic Acid|Ascor® ascorbic acid 2-hour infusion daily (for 6 days), escalating dose (0.3g/kg, 0.6g/kg, 0.9g/kg).
45696140|NCT04363372|Drug|MRx-4DP0004|MRx-4DP0004 is a lyophilised formulation of a proprietary strain of bacteria.
45848595|NCT03856164|Drug|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
46056727|NCT02726373|Other|type of walking|Subjects walked either intermittently or continuously twice a week for 4 weeks, then crossed over
45388610|NCT00986609|Biological|poly ICLC|Given intramuscularly
45848596|NCT03849690|Drug|TAK-906|TAK-906 capsules.
45388611|NCT00986609|Biological|MUC1 peptide-poly-ICLC adjuvant vaccine|Receive adjuvant vaccination
45388612|NCT00986609|Other|laboratory biomarker analysis|Correlative studies
45388613|NCT00986609|Other|enzyme-linked immunosorbent assay|Correlative studies
45388614|NCT00986609|Other|flow cytometry|Correlative studies
45502012|NCT03563924|Other|"Setting up a specific care path AlloTC for management of TVE in patients with cancer"|"Setting up a specific care path AlloTC for management of TVE in patients with cancer with a specific coordination nurse within the AlloTC multidisciplinary team as a privileged interlocutor for health professionals and patients with the aim of simplifying the care pathways and ensuring a hospital-city interface organized in collaboration with the attending physician, to develop and publicize tools available for patients and caregivers (information documents, patient monitoring protocols, etc.)"
45502013|NCT03563846|Drug|RP-G28|RP-G28 is a purified galacto-oligosaccharide (GOS) product
45502014|NCT03635281|Procedure|Recruitment manoeuvers|"Recruitment manoeuvers will be performed as follow Recruitment manoeuvers~set FIO2 at 1.0~Ppeak limit at 45 cmH2O~Respiratory rate set at 6~I:E set at 1:1~Raise the VT at step of 2 ml/kg PBW until the Pplat is between 30-40 cmH2O~If the maximum VT is set without rasing the Pplat, raise PEEP~Allow three respiratory cycles with Pplat between 30 and 40 cmH2O~End of RM~The recruitment manouvers will be performed after 20 minutes of OLV. At the end of the RM, the VT will be set back to 5 ml/kg while the PEEP will be chosen according to the best static compliance with a decremental trial (from 16 cmH2O, lowering PEEP with steps of 2 cmH2O each until the best compliance is reached)."
45696141|NCT04363372|Drug|Placebo|Placebo capsules will be identical in appearance to active product.
45388615|NCT00989183|Other|Women undergoing a bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma|Women undergoing an elective bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma Age range 21-55 years old
45848597|NCT03849690|Drug|Esomeprazole|Esomeprazole capsules.
46056728|NCT02720601|Drug|Irinotecan & Capecitabine|Irinotecan will be administered at infusion room over 60 minutes. Capecitabine will be administered by the patients at home. Unless there is early progression of disease, at least two courses will be administered to each patient. Repeated courses may be given to the patients who benefit from the treatment (either complete or partial remission, or stabilization of disease)
46056729|NCT02725983|Behavioral|SPT consultation|
46056730|NCT02725983|Device|SOPROCARE®|
45388616|NCT00281320|Drug|Asenapine|Asenapine 2 mg twice daily (BID) on Days 1 and 2, 5 mg BID on Days 3 and 4, followed by 10 mg BID on Day 5 through the end of the trial (Week 6); or Asenapine 5 mg BID on Days 1 to 4 followed by 10 mg BID on Day 5 through the end of the trial (Week 6).
45388617|NCT00541307|Device|Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface|Endovascular treatment of the study lesion with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
45388618|NCT01068886|Procedure|External pancreatic stent|stent through pancreatic anastomosis
45502015|NCT03635281|Procedure|incremental PEEP|In this group the a PEEP level will be added after 20 minutes from OLV. PEEP values will be chosen according to the best static compliance with an incremental trial (i.e. starting from ZEEP, the PEEP values will be increased in step of 2 cmH2O each until the best compliance is reached
45696142|NCT04357210|Procedure|fistula tract excision and anal sphincter reconstruction|The primary fistulous tract was excised together with any secondary tracts or residual cavities. Then on of the reconstructive steps was performed
45696143|NCT03678675|Drug|Ketorolac|The intervention is a protocol of scheduled IV Ketorolac administered postoperatively.
45696144|NCT04363060|Combination Product|Azithromycin with amoxicillin/clavulanate|Patients will receive azithromycin 500 mg on day 1 followed by 250mg per day for the next four days with amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin
45696145|NCT04363060|Drug|amoxicillin/clavulanate|Patients will receive amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin
46056731|NCT00590590|Drug|Lidocaine/Diphenhydramine|semi solid, twice weekly, 4 months
46056732|NCT00590590|Drug|lidocaine|semi solid, twice weekly for 4 months
45848598|NCT03843372|Device|High flow nasal cannula|All of participants will be received one night high flow nasal cannula and another night for continuous positive airway pressure.
45848599|NCT03822078|Drug|Placebo|Administered by subcutaneous injection
46056733|NCT00590590|Drug|placebo|semi solid, twice weekly for 4 months
46056734|NCT02720367|Drug|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical system whose primary mode of action is the controlled release of gemcitabine into the bladder over an indwelling period.
45388619|NCT05502965|Other|dietary pattern|Reprocessed and intolerant foods were removed from the dietary pattern, and the food were cooked at home for experimental subjects.
45388620|NCT05502965|Other|EEN|All energy and nutrients are obtained from exclusive enteral nutrition.
45388621|NCT05003258|Device|Intravitreal injection of Dexamethasone implant|Intravitreal injection of Dexamethasone implant
45388622|NCT03975556|Behavioral|Culturally tailored food and diet advice|Puerto Rico-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
45502016|NCT01346761|Behavioral|Telephone Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor over the telephone. Counseling sessions will be audiotaped for quality control of intervention.
45388623|NCT03975556|Behavioral|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips included in the My Plate dietary recommendations
45388624|NCT05499689|Drug|Bupivacaine Hydrochloride|2.5 cc bupivacain injection will be administered by approaching the greater occipital nerve under ultrasound guidance.
45388625|NCT05499689|Other|Transcutaneous pulsed radiofrequency qurrent|Pulsed radiofrequency current will be applied through transcutaneous pads adhered over the greater occipital nerve trace on the nape.
45388626|NCT01017614|Drug|Monofer|"administered as intravenous infusions (A1)repeated weekly until total iron repletion is obtained~administered as intravenous bolus injections (A2)as repeated bolus injections weekly until total iron repletion is obtained"
45388627|NCT01017614|Drug|Iron Sulphate|200 mg daily
45388628|NCT01012232|Drug|20 mL ropivacaine 5 mg/mL|
45388629|NCT01012232|Drug|10 mL ropivacaine 10 mg/mL|
45388630|NCT03976570|Behavioral|Occupational Therapy|Occupational therapy to children with subthreshold attention deficit hyperactivity disorder
45388631|NCT01017692|Procedure|MRI|MRI of lumbar spine for subjects presenting with spinal stenosis symptoms
45388632|NCT00541229|Drug|sitagliptin phosphate|sitagliptin 100 mg tablets q.d. (once daily) for 7 days.
45388633|NCT00541229|Drug|sitagliptin phosphate|sitagliptin 200 mg tablets q.d. (once daily) for 7 days.
45388634|NCT00541229|Drug|Comparator: Placebo|sitagliptin 100 mg & 200 mg matching Placebo tablets q.d. (once daily) for 7 days.
45388635|NCT04006691|Drug|UGN-101 instillations|Treatment with UGN-101 once weekly for a total of 3-6 times; in a retrograde fashion.
45388636|NCT00481988|Device|transcranial direct current stimulation|Two damp sponges, one placed on the left side of the forehead, the other on the left arm. 0.1mA of current is passed for 20 minutes.
45388637|NCT00481988|Device|transcranial direct current stimulation|transcranial direct current stimulation delivers one milliamp of direct current, supplied by a constant current generator, the the left dorsolateral prefrontal cortex through a scalp electrode. The treatment is given for 20 minutes a day.
45502017|NCT01346761|Behavioral|In-Person Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor in person. Counseling sessions will be audiotaped for quality control of intervention.
45388638|NCT00481988|Device|transcranial direct current stimulation|one milliamp of direct current applied to the left dorsolateral prefrontal cortex through a scalp electrode
45388639|NCT00481988|Device|iomed phoresor transcranial direct current stimulation|for the sham group the current is turned off after 10 seconds
45388640|NCT00986765|Drug|Lovenox® (enoxaparin)|Injectable solution 4000 UI
45388641|NCT00986765|Drug|Aspegic ® (Aspirin)|100 mg/day
45388642|NCT02112188|Behavioral|In-depth Patient Interviews|
45388643|NCT02112188|Behavioral|Adaptation of IMCP for Chinese Immigrant Cancer Patients|
45388644|NCT02112188|Behavioral|Individual Meaning-Centered Psychotherapy for Chinese (IMCP-Ch) (For Phase 3)|The six sessions will be delivered every or every other week over a span of 6-16 weeks, depending on participant and interventionist availability. Sessions may also be delivered within 2 weeks to accommodate schedules. Sessions will take place via MSK-approved videoconferencing platforms (e.g. Zoom) or by telephone, depending on participant preference. The IMCP-Ch intervention will be delivered via telehealth in Mandarin Chinese by a bilingual interventionist or in English (for bilingual Chinese and English-speaking patients who prefer English) by an English-speaking therapist or through English-to-Mandarin Remote Simultaneous Medical Interpretation (RSMI), depending on participants' preference.
45502018|NCT01356602|Drug|Canakinumab pre-filled syringe|Canakinumab pre-filled syringe
45502019|NCT01356602|Drug|Canakinumab lyophilized powder|Canakinumab lyophilized powder
45502020|NCT01356602|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide
45388645|NCT00986843|Drug|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
45388646|NCT01012310|Drug|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 100mg PF-04531083 or placebo for 14 days.
45388647|NCT01012310|Drug|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 300mg PF-04531083 or placebo for 14 days.
45388648|NCT01012310|Drug|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 500mg PF-04531083 or placebo for 14 days.
45502021|NCT01356602|Drug|Placebo|Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide
45388649|NCT01012310|Drug|PF-04531083 or Placebo|A fourth cohort may be used to investigate alternative dosing regimens, formulations or food effects.
45388650|NCT04118270|Device|Afib 2gether TM Mobile Application|The Afib 2gether mobile app determines a patient's stroke risk through a series of questions that the patient will answer in the app.
45388651|NCT04734821|Procedure|Near Infra-Red Fluorescence Guided Surgery|ICG injection around tumor each four direction by endoscopy followed by NIR fluorescence guidance laparoscopic or robotic esophagectomy or gastrectomy
45388652|NCT01019876|Drug|Fludarabine|Fludarabine/Busulfan/Alemtuzumab
45696146|NCT01591382|Drug|Ketamine|Intravenous (IV) ketamine 0.2 mg/kg/hr for 24-48 hours postoperatively.
45388653|NCT01019876|Drug|Cyclophosphamide|Cyclophosphamide/Fludarabine/TMG
45696147|NCT01591382|Drug|Placebo|Patients who received ketamine-matching placebo were given saline infusions
45848600|NCT03822078|Biological|Denosumab|Administered by subcutaneous injection
45388654|NCT01019876|Drug|Cyclophosphamide 40|Cyclophosphamide/Fludarabine/ATG/TBI
45848601|NCT03806556|Drug|Tranexamic Acid|IV medication administered after patient meets inclusion/exclusion criteria
45848602|NCT03806556|Drug|Normal saline|IV medication administered after patient meets inclusion/exclusion criteria
45388655|NCT01019876|Drug|Cyclophosphamide 30|Cyclophosphamide /Fludarabine/TMG
45388656|NCT05463419|Biological|PIKA COVID-19 vaccine|"SARS-CoV-2 spike subunit protein (Also called Recombinant SARS-CoV-2 S-trimer protein), PIKA adjuvant."
45388657|NCT05463419|Biological|Inactivated Covid-19 vaccine|Inactivated SARS-CoV-2 virus
45388658|NCT01017770|Drug|Artesunate-amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
45388659|NCT01017770|Drug|Artemether-lumefantrine|Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing > 35 kg.
45502022|NCT01347775|Device|Inspiratory muscle training (URES HS730)|It will be set at 40% of the subjects baseline maximal inspiratory pressure and increased by 10% each week by an unblinded assistant. All subjects were trained with these devices for 8-10 breaths, 3 times a day, everyday for 6 weeks
45696148|NCT01591382|Drug|Hydromorphone PCA|Intravenous hydromorphone PCA
45696149|NCT04362904|Other|acupressure|
45696150|NCT03678441|Behavioral|BrainCheck Cognitive Assessment|Receive BrainCheck cognitive assessment
45696151|NCT03678441|Procedure|Cognitive Assessment|Receive pen and paper cognitive assessment
45696152|NCT03677817|Drug|Lidocaine|regimen of lidocaine administration of 1,5 mg/kg, IV bolus, followed by continuous infusion at 3,0 mg/kg/h
45696153|NCT03677817|Drug|NaCl 0,9%|IV bolus of NaCl 0,9%, followed by continuous infusion of NaCl 0,9%
45696154|NCT00931996|Drug|Antipsychotic|Risperidone is the first line antipsychotic followed by others per clinician choice. Flexible dosing QD x 4-6 weeks.
45848603|NCT03809052|Drug|GB1211|Hard capsules for oral use
45388660|NCT00493142|Other|Exercise|
45388661|NCT00493142|Other|Usual care|
45388662|NCT04006535|Genetic|genetic analysis|Saliva sample collection for genetic analysis
45388663|NCT05712707|Drug|BXCL501 (180 micrograms)|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
45388664|NCT05712707|Drug|BXCL501 (240 micrograms)|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
45848604|NCT03809052|Drug|Placebo|Hard capsules for oral use
45848605|NCT03812328|Drug|SelK2|I.V., single-dose
45848606|NCT03812328|Biological|Enoxaparin|SC, QD for up to 10 ± 2 days
45388665|NCT05712707|Other|Placebo|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
45696155|NCT04348305|Drug|Hydrocortisone|Continuous infusion: 200 mg (104 ml) every 24 hours, Bolus injections: 50 mg (10 ml) every 6 hours, Total treatment duration: 7 days
45696156|NCT04348305|Drug|Sodium Chloride 9mg/mL|Continuous infusion: 104 ml every 24 hours, Bolus injections: 10 ml every 6 hours, Total treatment duration: 7 days
45696157|NCT03677037|Other|Short-term MBT|Short-term mentalization-based therapy
45848607|NCT03816696|Drug|GSK3640254|GSK3640254 will be available as 100 mg capsules. Subjects will be administered GSK3640254 200 mg QD via the oral route.
45848608|NCT03816696|Drug|DTG|DTG will be available as 50 mg tablets. Subjects will be administered DTG 50 mg QD via the oral route.
45848609|NCT03815292|Drug|MMH-MAP|Oral administration
45848610|NCT03815292|Drug|Placebo|Oral administration
46056735|NCT02693769|Drug|fluticasone propionate/formoterol fumarate breath actuated inhaler|
46056736|NCT02693769|Drug|Indacaterol maleate / glycopyrronium bromide capsules|
45388666|NCT05712707|Other|Lofexidine (Positive Control)|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
45388667|NCT01017926|Drug|Triazolam|Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
45388668|NCT01017926|Drug|Triazolam|Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
45388669|NCT04005911|Device|Themography|Using a FLIR camera, a thermographic recording will be taken of the patient while breathing. Simultaneously, the research investigator will record the thoracic impedance-based respiratory rate as well as manually count respirations in one minute.
45388670|NCT00481832|Drug|Cyclophosphamide|4 gm /m² IV over 2 hours on day 8
45502023|NCT01347775|Device|Sham inspiratory muscle training (URES HS730)|Subjects in the control group underwent sham training, using the same device with the diaphragm removed, thus providing no resistance. They were not given frequency or duration but told to use the device when desired.
45502024|NCT01347853|Drug|Ketorolac tromethamine|30 mg intranasal post-surgery for up to 5 days total
45388671|NCT00481832|Drug|BCNU|"The dose of BCNU will be based on actual body weight unless the actual body weight is more than 15 kg greater than the ideal body weight in which case the adjusted ideal body weight will be used:~Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)"
45388672|NCT00481832|Drug|Etoposide|60mg/kg, IV over 4 hours on day -4 pre-transplant and for preparative regimen. The dose of etoposide for mobilization is 2 gm/ m².
45388673|NCT00481832|Drug|Filgrastim|10µg/kg sc qd starting day following cyclosphamide (or VP-16) until last day of apheresis
45388674|NCT00481832|Drug|Antithymocyte globulin|1.5 mg/kg/d, IV from day -11 to -7
45388675|NCT00481832|Drug|Cyclosporine|5mg/kgbid,variable, po or IV
45388676|NCT00481832|Drug|Mycophenolate mofetil|15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. Thereafter, beginning on day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor. Doses will be rounded up to the nearest 250 mg (capsules are 250 mg). MMF will be stopped on day +28 for matched related donors. For one antigen mismatched related or unrelated donors, the taper will begin on day +40. MMF will be tapered by 10% weekly till off, typically by day +96. If there is nausea and vomiting at any time preventing the oral administration of MMF, MMF should be administered intravenously at an equal dose. MMF dosing is based on actual body weight.
45388677|NCT00481832|Drug|Rituximab|375 mg/m2 IV (calculated based on actual body weight) on day 1 and day 7. Administered per current standard of care..
45388678|NCT00481832|Procedure|Autologous hematopoietic stem cell transplantation (auto-HSCT)|Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents
45388679|NCT00481832|Procedure|Allogeneic hematopoietic stem cell transplantation (allo-HSCT)|Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)
45388680|NCT00481832|Procedure|Total lymphoid irradiation|TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT
45502025|NCT01347853|Drug|Placebo|Intranasal post-surgery for up to 5 days total
45696158|NCT03677037|Other|Long-term MBT|Long-term mentalization-based therapy
45696159|NCT00928174|Drug|IV administration of fluorine-18 fluorocholine followed by PET/CT imaging|Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.
45696160|NCT01696214|Drug|Fluticasone 250 mg/salmeterol 50 mg|Drug: Fluticasone 250 mg/salmeterol 50 mg Participants will be assigned to a 24 week treatment with inhaled fluticasone/salmeterol or matching placebo
45388681|NCT00481832|Drug|CD34+ Cells|2 x 10e6 CD34+ cells per kg actual body weight on Day 0
45388682|NCT00481832|Drug|Solu-Medrol|1 mg/kg, Day-11 to Day-7
45388683|NCT00987077|Device|Selective Retina Therapy (SRT)|SRT (pulsed double-Q-switched Nd-YLF laser, wavelength 527 nm, t=1.7 µs, energy 100-370 μJ).
45388684|NCT05407415|Other|Kardia Mobile 6L Device|"The KardiaAL is a software analysis library intended to assess ambulatory electrocardiogram (ECG) rhythms from adult subjects. The device supports analyzing data recorded in compatible fonnats from any ambulatory ECG devices such as event recorders, or other similar devices. The library is intended to be integrated into other device software. The library is not intended for use in life supporting, or sustaining systems, or ECG monitors, or cardiac alarm, or OTC use only devices.~The KardiaAI library provides the following capabilities:~ECG noise filtering,~heart rate measurement from ECGs,~detection of noisy ECGs, and~ECG rhythm analysis for detecting the presence of normal sinus rhythm, atrial fibrillation, bradycardia, and tachycardia (when prescribed or used under the care of a physician)."
45388685|NCT04006067|Other|changing surgical gloves|All the surgical team including surgeons, surgical assists and scrub technicians replaced their outer surgical gloves with a new pair of sterile gloves just prior to abdominal closure.
45388686|NCT00481676|Drug|Omalizumab 75-375 mg|Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg of omalizumab upon reconstitution with 1.4 ml sterile water for injection.
45502026|NCT01346917|Drug|Lidocaine|Lidocaine 1mg/kg(loading dose, just before skin incision) and lidocaine(in normal saline, total 240cc) 1mg/kg/hr with ketorolac 90mg for 24hrs.
45502027|NCT01346917|Drug|Normal saline|Normal saline 5cc(loading dose, just before skin incision) and normal saline 240cc with ketorolac 90mg for 24hrs.
45502028|NCT01343017|Other|Ventilatory pattern|In group one, increased tidal volume with a adjusted apparatus dead space volume (IVT), In group two, normal tidal volume with a PEEP to 10 cmH2O applied(NVT). PETCO2 will be adjusted to maintain at 4.5 kPa, in both groups. When PETCO2 values were stable at 4.5 kPa, sevoflurane administration will be started with a vaporiser set to 3%. After 5 minutes the fresh gas flow will be adjusted to 1.0 L/min with an unchanged vaporiser setting throughout the anaesthesia period.
45388687|NCT00481676|Drug|Placebo to omalizumab|Placebo to omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg placebo to omalizumab upon reconstitution with 1.4 ml sterile water for injection.
45388688|NCT00481676|Drug|Loratadine|All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
45388689|NCT00481676|Drug|Clemastine|All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
45388690|NCT00987155|Device|Ergometry|MetamaxII Cortex ergospirometry system (Cortex Biophysik GmbH, Germany). Arm cycling ergometer (Ergomed 840L, Siemens, GermanyMonark, Sweden), Electrically braked wheelchair ergometer (VP 100, Handisoft France)
45696161|NCT01696214|Drug|Montelukast 10mg|Participants will be assigned to montelukast once a day for 24 weeks.
45388691|NCT04004975|Drug|Anlotinib|Anlotinib is a multitarget receptor tyrosine kinase inhibitor which inhibits vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived growth factor receptors (PDGFR) α/β, c-Kit, and Met.
46056737|NCT02726295|Drug|E. coli Nissle 1917(Mutaflor®)|
46056738|NCT02726295|Drug|Placebo|
46056739|NCT04044820|Drug|Standardized Prescription|"Oxycodone 5mg PO q4-6h PRN~If patient has allergy or other contraindications~Hydromorphone 1mg PO q4-6h PRN/ Tylenol #3 1-2 tablets PO q4h PRN~The number of tablets prescribed will depend on the extent of surgical trauma~0-5 pills for simple surgeries such as a trigger finger release~10 pills for carpal tunnel or Dupuytren's contracture releases~15 pills for a ganglion cyst excision or simple tendon transfer~20 pills for more complex procedures such as distal forearm ORIF or a wrist fusion."
45388692|NCT04086992|Other|Remote monitoring|Caregivers will be able to monitor blood pressure from home and upload in a cloud-based application on a hand-held tablet. In addition, this technology will administer surveys to the caregiver to assess for therapy side effects and adherence. Nurse-led telemedicine visits will also be utilized. The healthcare team will be able to monitor these parameters remotely.
45502029|NCT03563612|Device|cpap|application of cpap to the non-dependent lung, during one lung ventilation
45554674|NCT05189990|Diagnostic Test|Electrical impedance tomography|Fatty liver patients will be recruited from the Department of Medicine at Queen Mary Hospital. Gender- and age- matched control subjects will be publicly recruited. Subjects will undergo the EIT-liver scan and FibroScan®. Selected subgroups will also undergo MRI-PDFF scan. The performance characteristics of the device and with respect to Fibroscan/ MRI-PDFF for liver fat quantification will be assessed.
45554675|NCT05561205|Device|rTMS|repetitive transcranial magnetic stimulation
45696162|NCT01696214|Drug|Theophylline 400 mg|Participants will be assigned to theophylline once a day for 24 weeks
45696163|NCT01696214|Drug|ipratropium|Participants will be assigned to ipratropium 2.5 mL of 0.02% solution via mini nebulizer 3 times a day day for 24 weeks.
45848611|NCT03809910|Device|Reference MTB|Participants will brush their teeth with manual toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 1-timed minute under supervision of study staff.
45848612|NCT03809910|Device|Reference PTB|Participants will brush their teeth with power toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute under supervision of study staff.
45554676|NCT05561205|Drug|methylphenidate|methylphenidate
45554677|NCT03052517|Drug|QAW039 150 mg|One tablet of QAW039 150 mg once daily
45554678|NCT03052517|Drug|QAW039 450 mg|One tablet of QAW039 450 mg once daily
45554679|NCT03052517|Drug|Placebo|One tablet of Placebo once daily
45848613|NCT03809910|Device|Prototype PTB (Gum line mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode under supervision of study staff."
46056740|NCT02725749|Radiation|Laser|Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.
45696164|NCT02083263|Device|Bilevel|3 months
45696165|NCT02083263|Device|PEP mask|3 months
45696166|NCT04356898|Other|No intervention|No intervention
45388693|NCT05318729|Device|Vibration tool|Therapeutic mini massager for scar management, desensitization, muscle stimulation, oral stimulation and sensory re-education. Seek pain relief for sore achy muscles, tendons or bones.
45388694|NCT01020032|Other|"Individual receptive music therapy by U sequence method"|During the hospitalization, the intervention group benefited from at least 2 daily sessions of music therapy between day 0 and day 10, and continued the musicotherapy at home until day 60.
45388695|NCT05712473|Diagnostic Test|PYLARIFY|PYLARIFY PET
45388696|NCT03976804|Other|low dose CT scan|Lung cancer screening will be based on the analysis of a low dose CT scan
45388697|NCT03976804|Other|blood sample collection|establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
45502030|NCT01348009|Drug|Tesetaxel-capecitabine-cisplatin|"Phase 1: Tesetaxel orally on Day 1 of each cycle at dose of 18, 21, 24, or 27 mg/m2. If no dose-limiting toxicity, at least 3 subjects will be treated at each dose level until the maximum tolerated dose or the maximum dose of 27 mg/m2 is reached. At each tesetaxel dose level, capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1.~Phase 2: Tesetaxel orally on Day 1 of each cycle at dose determined in Phase 1. Capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1."
45502031|NCT05708222|Device|MEB-001|The study is for the development of a software medical device. The study participant will complete study specific questionnaires and undergo a routine sleep study. The medical device will not provide any treatment or interventions.
46056741|NCT02725749|Other|EXE|"Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks."
45388698|NCT03976804|Other|faecal sample collection|establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
45388699|NCT01022372|Procedure|Endometrial biopsy|For all the groups
45388700|NCT03727919|Behavioral|Exoskeleton-assisted gait training|In the experimental groups, participants are provided with 1-hour sessions of gait training with robot assistance, 4 times per week for 4 weeks. Assistance is provided by the Ekso GT (Ekso Bionics, Richmond, CA, USA), an exoskeleton consisting of fitted metal braces that supports the legs, feet, and trunk of the patient. Powered motors drive knee and hip joints in the sagittal plane to assist during standing up and walking over level surfaces. Steps are initiated if an active weight-shift towards the stance leg is performed by the patient. The provided assistance in stance and swing is adaptable to the patient's ability and can be adjusted for each leg separately.
45388701|NCT00987233|Drug|triamcinolone acetonide aqueous nasal spray (Apotex Inc.)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
45388702|NCT00987233|Drug|triamcinolone acetonide aqueous nasal spray (Nasacort® AQ)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
45388703|NCT00987233|Drug|Placebo|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
45502032|NCT03620305|Other|Description of treatment of septic pseudarthrosis|description of chirurgical 2 steps management of septic pseudarthrosis
45502033|NCT01343173|Drug|Imatinib stop|To stop imatinib after inclusion.
45502034|NCT01346995|Other|Experimental knee pain|Injection of 1 ml hypertonic saline (5.8%) into the infrapatellar fat pad
45502035|NCT01346995|Other|Non-painful control injections|Injection of isotonic saline into the infrapatellar fat pad
45502036|NCT02830880|Drug|FACBC PET-CT|Anti-3-[18F]FACBC is an investigational positron emission tomography (PET) radiotracer being studied given intravenously prior to PET scan.
45502037|NCT02830880|Other|MRI, CT, or Bone Scan|Conventional imaging such as a MRI, CT, or bone scan will be performed to correlate imaging findings.
45388704|NCT05318027|Device|ChatBot|The automated chatbot will check in with the patient on two pre-specified days between scheduled outpatient visits. The chatbot will follow pre-specified symptom algorithms and classify symptoms as requiring high, intermediate and low risk follow ups. High risk symptoms will trigger a same day nursing/physician visit or telemedicine call/video. Intermediate risk symptoms will trigger a nursing triage visit or telemedicine call/video on the next day or treatment day. Low risk symptoms will notify the treating physician to address the symptoms at the next scheduled on treatment visit (OTV). If adjustments are needed in the chat bot triage algorithms, they will be updated in real time to decrease risk for adverse patient events.
45388705|NCT04006301|Drug|JNJ-74699157|Participants will receive JNJ-74699157 orally.
45388706|NCT04715867|Drug|Rabix-VC|Rabix-VC will be locally manufactured by Incepta Vaccine Ltd
45388707|NCT04004897|Diagnostic Test|Optic nerve sheath diameter measurement|Optic nerve sheath diameter measurement is performed with a linear ultrasound probe placed over the eyelid.
45388708|NCT04377503|Drug|Tocilizumab 180 MG/ML|Tocilizumab 8 mg/kg diluted in 100 ml of saline administered in 60 minutes. The dose will be repeated after 12 hours.
45388709|NCT04377503|Drug|Methylprednisolone Sodium Succinate|Patients will receive methylprednisolone at a dose of 1.5 mg / kg / day divided into 2 daily doses for 7 days. Then they will receive 1 mg / kg / day for another 7 days. Finally 0.5 mg / kg / day until 21 days of use
45388710|NCT00987311|Dietary Supplement|1- Dairy drink containing probiotics A|1- Dairy drink containing probiotics A
45388711|NCT00987311|Dietary Supplement|2- Dairy drink containing probiotics B|2- Dairy drink containing probiotics B
45388712|NCT00987311|Dietary Supplement|3- Dairy drink without probiotics (control)|3- Dairy drink without probiotics (control)
45388713|NCT00542789|Drug|Esomeprazole|20mg once daily oral
45388714|NCT00542789|Drug|Placebo|once daily oral
45388715|NCT00464672|Biological|Influenza virus vaccine|Two intramuscular injections of the investigational influenza virus vaccine administered 4 weeks part to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
45388716|NCT00464672|Biological|Comparator influenza vaccine|Two intramuscular injections were administered 4 weeks apart to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
45388717|NCT05712239|Other|Advices|The advices will include patient's reassurance and description of possible causes of neck pain such as poor working ergonomics, common bad postures especially while using electronic devices for long periods and not adjustable sleeping pillows. Also, patient will be educated how to modify these different causes and asked to apply gentle neck range of motion exercises
45388718|NCT05712239|Other|Cervical and Scapular Stabilization Exercises|"Deep neck flexor training will be performed in neurodevelopment stages (supine at first week using pressure biofeedback unit , prone at second week, quadrupedal at third week, bipedal at fourth week).~Scapular stabilization exercises will include modified prone cobra, trapezius muscle exercise progression (3 stages), wall press and extension of the thoracic spine using foam roller. The modified prone cobra and the first stage of trapezius muscle exercise progression will be applied during the first two weeks. The second and third stages of trapezius muscle exercise will be applied during the last two weeks of our rehabilitation program. All exercises will be applied for 10 repetitions with 6-10 sec hold for 3 sets with 20 sec rest between each set. While wall press and thoracic extension exercises will be applied throughout the 4 weeks for 3 sets of 10 repetitions with 20 sec rest between each set."
45388719|NCT05712239|Other|Lumber Core Stability Program|"The program will be performed in three stages: activation, dynamic stabilization, and advanced core strengthening stages. Each stage will be applied for 4 sessions.~The activation stage will be based on the learning to activate transversus abdominis muscle from crock lying position using pressure biofeedback unit. In the dynamic stabilization stage, the patient will be instructed to slowly raise both arms in the scapular plan then return to the sides while maintaining the transversus abdominis muscle activation. Also, the patient will apply bridging exercise in this stage. The advanced core strengthening stage will include prone plank and side plank (right and left sides). All the exercises will be applied for 10 repetitions with 6-10 sec hold for 3 sets. The rest of 20 sec will be taken between each set."
45388720|NCT03996434|Drug|Gonadotropin|withholding gonadotropin administration for at least 24 hours
45388721|NCT03996434|Drug|Antagonist|Cetrorelix acetate 0.25 mg
45388722|NCT00987701|Drug|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after epidural, spinal or CSEA in cesarean section
45388723|NCT00987701|Drug|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after epidural, spinal or CSEA in cesarean section
45388724|NCT01020266|Procedure|non electroacupuncture stimulation|The same procedure as electroacupuncture except stimulation
45388725|NCT01020266|Procedure|Electroacupuncture pretreatment|According to the theory of traditional Chinese medicine, Baihui(GV20) acupoint was chosen and the acupuncture points were identified according to traditional anatomical localization. Once insertion was made at the acupuncture point, the needle was stimulated electrically with the intensity of 0.8-1.9 mA and frequency of 5/30 Hz for 30 min per day using an Electronic Acupuncture Treatment Instrument for 5 consecutive days before the heart valve replacement surgery．
45388726|NCT00987779|Drug|Gabapentin|Period I: Tablet in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
45388727|NCT00987779|Drug|Gabapentin|Period I: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Tablet in fasting state(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
45388728|NCT01020344|Procedure|Lung volume reduction surgery|Lung volume reduction surgery
45388729|NCT00987857|Procedure|2 yearly endoscopy|2 yearly endoscopy versus endoscopy at need
45388730|NCT00987857|Procedure|comparison of screening methods|2 yearly endoscopy versus endoscopy at need
45388731|NCT00987857|Procedure|diagnostic endoscopic procedure|2 yearly endoscopy versus endoscopy at need
45388732|NCT00987857|Procedure|endoscopic biopsy|2 yearly endoscopy versus endoscopy at need
45502038|NCT03141307|Behavioral|EICI Movie|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by watching a brief video.
45696167|NCT05347875|Other|ICanWALK© App.|"App containing educational and instructional videos on crutch fitting and walking with key components of these skills highlighted. App video records individual using the taught skills to enable them and their care providers to review their usage of the walking aids."
45388733|NCT00987857|Procedure|endoscopic procedure|2 yearly endoscopy versus endoscopy at need
45388734|NCT00987857|Procedure|quality-of-life assessment|QOL aims to elicit any differences in QOL between 2 yearly endoscopy versus endoscopy at need
45388735|NCT00987857|Procedure|screening method|All Barretts patients to be screened
45388736|NCT01020422|Procedure|Reduction mammaplasty|Sexual function of patients undergoing reduction mammaplasty will be assessed by the Female Sexual Function Index (FSFI) preoperatively and 3 and 6 months postoperatively.
45388737|NCT04895813|Behavioral|Education|The patient will be given pre-colonoscopy training and guidance by telephone.
45502039|NCT03141307|Behavioral|EICI App|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by exploring an educational app.
45502040|NCT03141307|Behavioral|Control|Standard of care, paper-based brochure
45696168|NCT04369300|Behavioral|Registery Data Collection|Observational Data Collection
45696169|NCT03794037|Drug|dydrgesterone 10 mg( tab)/12hs/14 days|Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup
45696170|NCT03794037|Combination Product|montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days|montelukast 10 mg(tab) once daily oral for 7 days & dydrgesterone 10 mg (tab) twice daily oral for 14 days &
45388738|NCT01018004|Other|follow-up care|
45388739|NCT01018004|Other|questionnaire administration|
45388740|NCT01018004|Procedure|quality-of-life assessment|
45388741|NCT04225286|Other|Human breast milk|Intranasal human breast milk
45388742|NCT05155319|Biological|UFluA 20 µg each antigen/dose|Low dose
45388743|NCT05155319|Biological|UFluA 60 µg each antigen/dose|High Dose
45388744|NCT05155319|Biological|Placebo|Placebo
45502041|NCT01347151|Device|The glidescope video laryngoscopy|
45502042|NCT01347151|Device|The Pentax airwayscope|
45502043|NCT01348243|Drug|disodium clodronate 200 mg/4 ml with 1% lidocaine|CLODRONATE 200 MG/4 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE EVERY OTHER WEEK
45502044|NCT01348243|Drug|Disodium clodronate 100 mg/3,3 ml with 1% lidocaine|CLODRONATE 100 MG/3,3 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE ONCE-WEEK
45696171|NCT04362358|Behavioral|Online cognitive behavioral therapy (CBT)|7 sessions of Cognitive Behavioural Therapy (CBT) online + possibility to contact the psychological hotline
45696172|NCT04362358|Behavioral|Online bibliotherapy programme|online bibliotherapy programme on the Ma Santé website Also with explanatory sheets and tools to improve stress management and the possibility of contacting the Psychological Hotline
45696173|NCT03791619|Device|Higher Cylinder Toric IOL|Symfony Toric models ZXT300 and ZXT375 IOL
45696174|NCT03791619|Device|Lower Cylinder Toric IOL|Symfony Toric model ZXT150 IOL
45696175|NCT04356508|Drug|Nivolumab|Single dose at 0.3mg/kg
45502045|NCT01347229|Device|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
45502046|NCT01348321|Drug|Levamisole|Group 1: Azithromycin 500 mg per day, three days a week plus oral levamisole 150 mg per day, two days a week. Group 2: Azithromycin 500 mg per day, three days a week. The used medications were not revealed to their physician. A questionnaire was filled for every patient and photos were taken from lesions using a digital camera at first, second and final visit.
45502047|NCT03772951|Other|Cognitive Remediation Therapy|Through computer information technology, using error-free, procedural learning, speech enhancement and a series of targeted computer programmatic cognitive correction tasks, patients can gradually improve problem solving and information processing capabilities, thereby improving their recognition function.
45502048|NCT03772951|Drug|Clozapine|the course of disease is more than 2 years, the condition is stable for more than one month
45502049|NCT01343329|Drug|Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment. The infusion rate will begin at 50 micrograms/kg/min and be adjusted to achieve heart rates between 80 and 100 beats/min with standard dosing regimens used in our Neuro intensive care unit. The infusion will be started at a rate of 0.05 milligrams/kg/min (50 micrograms/kg/min) for 5 minutes. After the 5 minutes of initial infusion, maintenance infusion may be continued at 0.05 mg/kg/min or increased stepwise (e.g. 0.1 mg/kg/min, 0.15 mg/kg/min to a maximum of 0.2 mg/kg/min) with each step being maintained for 4 or more minutes until the target heart rate is achieved.
45502050|NCT01343329|Drug|Propranolol|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
45502051|NCT01317589|Drug|fentanyl|"T = 0~start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~if necessary increase dose strong opioid with 50%~T=2 3 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%~T=3 5 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%"
45388745|NCT05146427|Device|Slow-wave enhancement|A headband that measures slow-wave activity during sleep and uses auditory stimulation to enhance slow waves using closed-loop auditory stimulation.
45388746|NCT05146427|Device|Sham device|A headband that measures slow-wave activity during sleep but has no auditory stimulation.
45502052|NCT01317589|Drug|methadone|"T = 0~start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~if necessary increase dose strong opioid with 50%~T=2 3 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%~T=3 5 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%"
45502053|NCT01347385|Procedure|Laparoscopic myomectomy with unidirectional barbed suture|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using unidirectional barbed suture material (V-Loc 180TM, CovidienTM). For patients randomized to the barbed suture arm of the trial, any secondary fibroid that is greater than 5cm intra-operatively (as measured by a laparoscopic measurement instrument) will also be closed with barbed suture material. The cut-off of 5cm will be used, since it is generally above this size when uterine defects need to be closed in multiple layers, making the barbed suture potentially useful. Any other secondary fibroids less than 5cm will be closed with traditional extracorporeal suturing in both arms of the trial, since these can usually be closed in one layer.
45502054|NCT01347385|Procedure|Traditional suture material|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using traditional extracorporeal suturing using absorbable monofilament suture material.
45388747|NCT01018160|Drug|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12 weeks
45388748|NCT01018238|Drug|NNC 0151-0000-0000|Multiple doses in the range of 0.05mg/kg to 0.30mg/kg administered subcutaneously (under the skin)
45388749|NCT01018238|Drug|placebo|Multiple doses of placebo (no active ingredients) administered subcutaneously (under the skin)
45388750|NCT03996512|Other|Early Active Controlled Motion (EACM)|Early active controlled wrist motion rehab protocol using that will allow midcarpal row motion.
45388751|NCT00473876|Drug|Metformin|Started at 500mg bd for 2 weeks. If well tolerated, increase to 1000mg bd for 14 weeks
45388752|NCT00473876|Drug|Matched Placebo (Capsules)|Similar dosing regime as active comparator
45388753|NCT03996668|Other|Thigh High Compression Stockings|Thigh high compression stockings will be placed after induction of anesthesia and intubation.
45388754|NCT01020578|Other|Plasma kinetic study|This study is done with the injection of an artificial lipid nanoemulsion doubly labeled with 14C-cholesteryl oleate and 3H-cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood samples collected in a pre established period of time in 24 hours.
45388755|NCT00463580|Drug|Infliximab|Participants will receive three infusions 5mg/kg of infliximab (at Baseline, Week 2 and Week 6)
45388756|NCT00463580|Drug|Placebo|Participants will receive three infusions of a placebo (at Baseline, Week 2 and Week 6)
45388757|NCT01020734|Biological|anti-thymocyte globulin|
45388758|NCT01020734|Drug|busulfan|
45502055|NCT01348477|Procedure|Elliptical domed mesh technique|A segment of polypropylene mesh of 10 by 15cm enters the inguinal preperitoneal space, where takes the form of a dome and is fixed by four stitches
45696176|NCT04362280|Behavioral|ReCHARGE|During their PE class, all participants (both arms) participate in an intensive lifestyle intervention with established efficacy among this population for the academic fall semester. The following semester, participants are randomized to different treatment arms. ReCHARGE increases the intensity of treatment provided in the first semester by increasing social support and addressing common barriers youth have to adhering to intervention.
45696177|NCT04362280|Behavioral|TAU|PE class as usual led by PE teacher.
45696178|NCT04362202|Other|Water-based Sequential Preparatory Approach|"The experimental training consists of a sequential and a preparatory approach aimed at enhancing dynamic postural stability. The exercises followed a specific sequence starting from a kneeling position, proceeding to a sitting position and ending with a supine position. Step exercises preparatory for gait were performed using a step and two floating aids. Gait exercises were performed first with the upper limbs placed on two floating aids and then during a dual motor task (i.e., catching a ball thrown by the therapist).~The control aquatic therapy consists of water-based exercises, in line with suggestions of the Hydrotherapy Association of Chartered Physiotherapists Guidance on Good Practice in Hydrotherapy.~These consisted of warm-up exercises, stretching exercises for the lower limbs, recruitment exercises and walking exercises during each phase of gait (single stance, swing and double stance)."
45696179|NCT04762641|Drug|ABL503|ABL503 will be administered intravenously (IV) on Day 1 and Day 15 of every 28-day cycle in the dose-escalation part. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
45696180|NCT01543087|Procedure|blood sampling|Blood sample collection at different time points
45696181|NCT01543087|Drug|bivalent rLP2086|A booster dose of bivalent rLP2086 at approximately 48 months following the final dose of the 2- or 3-dose primary bivalent rLP2086 vaccination series will be given at Visit 7.
45388759|NCT01020734|Drug|cyclophosphamide|
45388760|NCT01020734|Drug|cyclosporine|
45388761|NCT01020734|Drug|fludarabine phosphate|
45388762|NCT01020734|Drug|methotrexate|
45388763|NCT01020734|Procedure|allogeneic hematopoietic stem cell transplantation|
45388764|NCT01021046|Procedure|DALK using GCCT|Deep anterior lamellar keratoplasty (DALK) using glycerin-cryopreserved corneal tissue
45388765|NCT01021046|Procedure|DALK using FCT|Deep anterior lamellar keratoplasty (DALK) using fresh corneal tissue
45388766|NCT00540449|Drug|TMC278|25 mg tablet once daily for 96 weeks
45388767|NCT00540449|Drug|Efavirenz|600mg once daily for 96 weeks
45388768|NCT04891289|Drug|Gemcitabine|See arm for details.
45388769|NCT04891289|Drug|Oxaliplatin|See arm for details.
45388770|NCT04891289|Drug|Dexamethasone|See arm for details.
45388771|NCT04891289|Drug|Floxuridine (FUDR)|See arm for details.
45388772|NCT04891289|Device|Implanted Medical Device|Implanted hepatic arterial infusion pump by surgical oncology, to deliver HAI therapy
45388773|NCT04872023|Other|Blood and bone marrow sampling|Blood and bone marrow sampling
45388774|NCT05142527|Drug|ADM03820|ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies
45388775|NCT05142527|Other|Placebo|Placebo
45388776|NCT05137769|Behavioral|Body Scan|The body scan is a core element of mindfulness-based stress reduction. Participants will listen to a 20-minute audio guide instructing them to focus on sensations in the body, place attention on one area of the body at a time, and progressively move attention throughout areas of the body.
45388777|NCT04005131|Device|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 10 weeks
45388778|NCT04005131|Device|Robot and tDCS on-line after sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 5 weeks, followed by combined tDCS on-line and upper extremity rehabilitation robot for 5 times a week for 5 weeks
45502056|NCT02825420|Drug|trabectedin|
45502057|NCT01347463|Procedure|SCM triangle - ipsilateral nipple|draws the tract of the IJV using the SCM triangle head and the ipsilateral nipple
45388779|NCT05135117|Other|NeuroRescue Cooling Collar|Between bouts of exercise subjects will be provided cooling on the neck with the NeuroRescue Collar. The custom sized cooling collar has ice water (which is kept around 2 degrees celsius) that is circulated through a neoprene sleeve that is attached to their neck for the cooling period.
45388780|NCT05135117|Other|Ice Towel|Between bouts of exercise subjects will be provided cooling on the neck with a towel. The towel will be kept in ice water (which is kept around 2 degrees celsius) and placed around the neck of the individual during the cooling intervention period.
45388781|NCT03911843|Drug|omega-3 supplementation|Supplementation with Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months, currently underway or completed after 12 months of omega-3 administration, in 22/64 T1D children
45388782|NCT03911843|Drug|Vitamin D supplementation|Cholecalciferol 1000 IU/die
45388783|NCT04833335|Other|MRI perfusion sequence|Quantitative analysis
45388784|NCT00361335|Drug|Golimumab|2mg/kg or 4mg/kg will be administered as an IV infusion over 30 minutes
45696182|NCT04368598|Drug|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated on days 11 to 14 in the case of lack of response by day 10)
45696183|NCT04368598|Drug|Acetylcysteine|Acetylcysteine, po, 400mg tid, for 4 weeks
45696184|NCT05347641|Drug|Penpulimab|"Penpulimab + RMA regimen:~Rituximab 375 mg/m2 d0 iv Methotrexate (MTX) 3.5g/m2 drip D1 Cytarabine * (ARA-C) 1-2g/m2 q12H D2-3 iv Penpulimab 200 mg iv D5"
46056742|NCT02725749|Radiation|Laser + EXE|"Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.~Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks."
45388785|NCT00361335|Drug|Methotrexate|Active MTX capsules, filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg MTX tablet, will be administered at the same dose as before the study entry.
45696185|NCT01696058|Drug|Tiotropium|marketed product
45388786|NCT00361335|Drug|Placebo|Placebo solution will be administered through IV infusion in Group V and oral placebo capsules (sham MTX) filled with microcrystalline cellulose (Avicel PH 102) will be administered in Group II and IV.
45388787|NCT00264550|Drug|Golimumab 100 mg|Participants will receive subcutaneous (SC) injections of golimumab 100 mg every 4 weeks.
45388788|NCT00264550|Drug|Golimumab 50 mg|Participants will receive subcutaneous (SC) injections of golimumab 50 mg every 4 weeks.
45388789|NCT00264550|Drug|Methotrexate|Participants will receive methotrexate capsules weekly.
45388790|NCT00264550|Drug|Placebo injection|Participants will receive subcutaneous (SC) injections of placebo every 4 weeks.
45388791|NCT00264550|Drug|Placebo capsules|Participants will receive placebo capsules weekly
45388792|NCT04271033|Device|Carotid Artery Stenting|"Carotid artery stenting according to local clinical experience and ESC/ESVS guidelines using exclusively CGuard™, MicroNet covered stent under proximal or distal intraprocedural cerebral protection according to tailored CAS algorithm."
45388793|NCT04004507|Drug|Phentolamine Mesylate Ophthalmic Solution 1%|Topical Sterile Ophthalmic Solution
45388794|NCT04004507|Other|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
45388795|NCT01070290|Drug|ARQ 197|120 mg capsule administered twice daily
45388796|NCT01070290|Drug|Oxaliplatin, capecitabine or irinotecan|Investigator's choice or oxaliplatin, capecitabine or irinotecan
45388797|NCT05067257|Drug|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources
45696186|NCT01696058|Drug|Placebo matching Olodaterol|one dose
45696187|NCT01696058|Drug|Tiotropium|marketed product
45696188|NCT01696058|Drug|Olodaterol|one dose
45388798|NCT05067257|Drug|Placebo|Vehicle solution
45696189|NCT04368520|Dietary Supplement|Vitamin D3|800 IU Fultium-D3, cholecalciferol (Internis), given daily for 3 months
45696190|NCT04368520|Dietary Supplement|Vitamin D3|3,200 IU Fultium-D3, cholecalciferol (Internis), given daily for 3 months
45696191|NCT04368520|Other|Placebo|Hypromellose capsules, given daily for 3 months
45388799|NCT01048203|Drug|ABR-215050|1 mg ABR-215050
45388800|NCT01070368|Other|Commercial extract and in-house wheat extract|Patients with a history of wheat allergy underwent two skin test extracts, and open challenge with wheat. A blood test for specific IgE was performed in the same time.
45388801|NCT01070446|Dietary Supplement|Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1|This is a prospective, repeated measures study involving children with Cystic Fibrosis. Children will be assessed (1) before starting the choline supplement, (2) after taking the supplement for 6 months and after the supplement has been discontinued for 3 months.
45388802|NCT01050387|Dietary Supplement|Vitamin D|Vitamin D (either 400 IU vs 1000 IU) given orally each day
45388803|NCT01070524|Drug|CHF 5188 pMDI|CHF 5188: fixed combination budesonide/carmoterol
45388804|NCT01070524|Drug|Budesonide extrafine pMDI|Budesonide extrafine pMDI
45388805|NCT01070524|Drug|Seretide(r) Evohaler(r)|Seretide(r) Evohaler(r): fixed combination fluticasone/salmeterol
45388806|NCT01048359|Behavioral|Brief advice|The American College of Surgeons (ACS) recently mandated standards of care for all level I trauma centers and currently defined standards of care at the collaborating institution requires that assessment and referral are included in treatment as usual. Therefore, our treatment as usual, or BA, consists of an initial interview conducted by study staff, a recommendation to abstain from drug use, provision of educational material supporting that recommendation, referral to hospital or community treatment resources most likely to be beneficial to the patient and information about relevant community health care agencies.
45696192|NCT04762797|Other|Non|This is a retrospective study, without intervention.
45696193|NCT04762563|Other|IASTM application|IASTM application .
45696194|NCT04762563|Other|Kinesio Tape® Tex Gold)|Kinesio Tape® Tex Gold)
45388807|NCT01048359|Behavioral|Brief Intervention plus Booster|A brief drug use intervention based on motivational interviewing is provided to participants at baseline and a booster session incorporating personalized feedback is provided at one month
45388808|NCT01048359|Behavioral|Brief Intervention|A brief drug use intervention based on motivational interviewing is provided to participants at baseline
45388809|NCT05711927|Device|SNOO Smart Sleeper|"Infants will be secured in the SNOO Sleep Sack. They will be placed in the center of the SNOO Smart Sleeper. The SNOO will be powered on and will start playing white noise and rocking from side-to-side. The SNOO's movement and sound settings will automatically ramp up and down as needed in response to the infant's sensed level of fussiness or crying per the manufacturer's programming. The preemie mode will be enabled, which caps motion at level 2 out of 5."
45388810|NCT05711927|Device|Traditional bassinet|Infants will be swaddled using a standard hospital blanket. They will be placed in the center of the SNOO Smart Sleeper, but the SNOO will be left powered-off. No white noise will be played. No side-to-side rocking motions will occur.
45388811|NCT01071304|Drug|Midazolam|A single oral dose of midazolam 2 mg (1 mL of 2 mg/mL syrup) was given on Day -2 and Day 5.
45696195|NCT04356820|Other|acupressure|Data collection took about 10 to 15 minutes. Then the woman invited to the examination room was asked to pull one of the envelopes with the names of the groups. The women who pulled the acupressure envelope were given a semi-sitting position where the acupressure application can feel comfortable and the researcher can easily apply the acupressure points. Before the acupressure application, massage was applied for 30 seconds to ensure circulation. Afterwards, 90 seconds consecutive pressures were applied to the specified acupressure points in a certain order (SP 6, Li 4), taking into account the direction of the meridian. After the examination, the pain formed during the gynecological examination was evaluated by applying the Short Form-McGill Pain Questionnaire without leaving the examination room
45696196|NCT03580785|Genetic|genetic analysis|saliva is collected for DNA extraction
45696197|NCT03580785|Radiation|panoramic radiography|panoramic radiography
45696198|NCT03580785|Radiation|teleradiography|teleradiography
45388812|NCT01071304|Drug|Ridaforolimus|Ridaforolimus 40 mg (4 x 10 mg tablets) oral once daily on Days 1 through 5.
45848614|NCT03809910|Device|Prototype PTB (Combined mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode and 1-timed minute in Interdental mode under supervision of study staff."
45502058|NCT01347619|Other|Toolkit only with Web Access to Online Version|NHs in this arm will receive a letter announcing the availability of an atypical antipsychotic toolkit within the facility and online at the Qualidigm website. The letter will be sent to the NH administrator, Director of Nursing, and Medical Director of each facility by Qualidigm. It will state that the toolkit is designed to provide NH staff, including prescribers, leadership, nursing staff, and patients' families with information about the use, risks and costs of atypical antipsychotics in the NH setting.
45696199|NCT03580785|Radiation|intraoral X-rays|intraoral X-rays
45696200|NCT03580785|Radiation|CT scan of maxillary and mandible|CT scan of maxillary and mandible
46056743|NCT05071924|Behavioral|PLH Teens Original: In-person PLH programme for parents and teens by community-based workers|This in-person intervention is delivered over 14 sessions (10 joint parent and teen sessions and 4 separate parent and teen sessions).
45696201|NCT04356274|Other|Participatory System Dynamics (PSD)|Participatory system dynamics is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
45696202|NCT04356274|Other|Audit and Feedback (AF)|Audit and feedback is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing clinical care team data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
45388813|NCT01050465|Other|health information prescription|Patients randomized to the email arm will receive a health information prescription via email on a health care topic following their clinic visit. Patients randomized to the paper arm will receive a health information prescription on paper on a health care topic following their clinic visit.
45388814|NCT01069042|Drug|Enalapril|All subjects will initially receive 10mg of enalapril and be gradually titrated up to 20mg with blood pressure tolerance for 6 months.
45388815|NCT00541931|Drug|Dietary Supplement: LifePak Nano|Daily use
45502059|NCT01347619|Other|Toolkit, Periodic Audit/Feedback, Educational Messages|"Providing healthcare professionals with data about their performance (audit and feedback) may help improve their practice. It is more effective when clinicians previously agree to review their practice. We will use an adaptation of a Medicaid Utilization Report developed by AM Hamer. This report will show current atypical antipsychotic prescribing rates in the NH, with comparisons to state and national levels, and information regarding summary evidence for atypical antipsychotics from the AHRQ atypical antipsychotic CERSG. Reports will be sent to the NH administrator, Director of Nursing, and Medical Director of the facilities randomized to the moderate intensity arm on an every 4-month basis."
45696203|NCT04104763|Behavioral|study of osteofibrous dysplasia features|obtain long term follow-up in patients with osteofibrous dysplasia, to assess natural history of the disease, late results of treatment and in particular the potential and risk of progression to adamantinoma.
45696204|NCT01695746|Drug|C.E.R.A.|Participants receiving 0.6 mcg/kg of C.E.R.A. once every two weeks for correction of anemia and conversion to C.E.R.A. dose 120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks for maintenance of Hb according to local clinical practice or prescribing information will be observed.
45696205|NCT03790137|Drug|Fenfluramine Hydrochloride|Fenfluramine Hydrochloride will be supplied to the treatment group as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive their daily dose of Fenfluramine Hydrochloride in two doses (one in the morning and one in the evening). After a four week baseline, subjects that meet enrollment criteria will enter a titration period. The starting dose will be 0.2 mg/kg/day for the first 14 days. The dose will be increased every 2 weeks as tolerated by 0.2 mg/kg/day, to a maximum dose of 0.7 mg/kg/day, or a total maximum dose of 26 mg/day. The subject will remain on a dose of 0.7 mg/kg/day, 26 mg/day, or maximum tolerated daily dose through the end of the core study period.
45696206|NCT04795076|Dietary Supplement|Infant formula|Regular infant formula will be concentrated to give a calorie density of about 90 kcal/100 mL.
45848615|NCT03806790|Drug|LEO 90100 foam|Once daily topical application of foam from a can to psoriasis lesions. Dose depends on size of lesion.
45848616|NCT03806790|Drug|Dovobet® ointment|Once daily topical application of ointment from a tube to psoriasis lesions. Dose depends on size of lesion.
45388816|NCT03976492|Diagnostic Test|diagnostic of specific biomarkers|Protein and metabolic product differences will be detected from blood or lesion samples of normal population, patients with traumatic brain injury and/or non-brain injury using mass spectrometry proteomics and metabolomics analysis platform. Diagnostic markers of potential traumatic brain injury will be found, and their differential diagnostic values were discussed.
45388817|NCT04004663|Drug|PF-06651600|PF-06651600 100 milligrams (mg) will be provided in 4 different oral formulations (Treatment A,B,C,D). Participants will receive each formulation in one of 4 periods
45388818|NCT01581346|Other|Exercise intervention|Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
45388819|NCT04759313|Behavioral|Image Narrative|Each participant will take part in a 5-week program of weekly 1-hour telehealth sessions with the PI or a social work PhD student facilitator trained in the INI by the PI.
45388820|NCT00368979|Drug|Dutasteride|once daily
45388821|NCT00368979|Drug|Placebo|once daily
45388822|NCT00264238|Drug|Memantine|pharmacological dosing of memantine as adjunctive therapy for treatment-resistant obsessive-compulsive disorder
45696207|NCT04368286|Behavioral|pulmonary rehabilitation|Pulmonary rehabilitation (respiratory rehabilitation) is a comprehensive intervention based on a comprehensive patient assessment, targeted to the treatment of patients, including but not limited to exercise training, education and behavior change, aimed at improving the physical and mental health of patients with chronic respiratory diseases and promoting long-term adherence to health-enhancing behaviors.
45388823|NCT00540293|Drug|Atorvastatin|Prescription of 10/20/40mg dose atorvastatin based on the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group
45388824|NCT01070602|Procedure|anterior (more central) corneal paracentesis incision|3 corneal paracentesis incisions will be located 1 mm anterior to the limbus.
45388825|NCT01563653|Procedure|4 diagnostic tests for surgical success|Q-tip test, Bonney maneuver, TVT maneuver, clip strip test
45388826|NCT05005013|Other|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp.
45388827|NCT05005013|Other|Sham - Transcranial Direct Current Stimulation (tDCS)|The tDCS device is programmed to mimic active tDCS.
45388828|NCT05005013|Other|Mindfulness|Participants will follow an audio track for guided mindfulness during the stimulation.
45388829|NCT04727645|Other|Philips interventional MRI suite (Philips Healthcare, Best, the Netherlands)|iSuite is an an electroanatomical mapping system (EAM) designed to support real-time MRI guided interventional procedures.
45388830|NCT00375609|Drug|Betrixaban|Capsule
45388831|NCT00375609|Drug|Enoxaparin|Administered subcutaneously
45696208|NCT01694420|Drug|(FDC) ELV/COBI/FTC/TDF|Antiretroviral treatment
45696209|NCT04347148|Procedure|SNAGs Treatment|a sustained passive accessory movement (glide), i.e. SNAGs, will be applied by the physiotherapist while the participant will be asked to move actively as allowed by his/her physiological range in the direction producing his symptoms.
45696210|NCT04347148|Procedure|Sham Laser Treatment|A Laser YAG 3 Chronic (Winform Medical Engineering s.r.l., San Donà di Piave (VE), Italy), will be detuned and applied in the region of cervical spine in order to have a sham treatment
45388832|NCT04971941|Device|Dental Vibe|Use of Dental Vibe during dental anesthesia intervention
45388833|NCT01050621|Dietary Supplement|vitamin C (ascorbic acid)|ascorbic acid 1.5 g/kg body weight infused over 90 to 120 minutes two or three times weekly concurrent with standard cytotoxic chemotherapy individually selected for each patient by the treating oncologist on the basis of best current clinical practice
45502060|NCT01347619|Other|Items in Arm 2 plus Academic Detailing Program|This arm will receive the same information, toolkit, letters, and audit and feedback reports distributed to homes in the moderate-intensity arm. In addition, two visits to the NH will be scheduled by a pharmacist educator specially trained in the pharmacology of atypical antipsychotics, and communication techniques. Staff will be provided with up-to-date, unbiased information about antipsychotic use in NHs based on the AHRQ CER Review product adaptations. The educator will deliver targeted messages relevant to each stakeholder regarding roles in decision-making around the use atypical antipsychotic therapy in the NH setting. Each NH will receive up to two visits over the course of the 12-month intervention period.
45502061|NCT05708144|Diagnostic Test|ICG-SG incubation solution|The fresh excision breast cancer tissues were completely soaked in the incubation solution and performed fluorescence imaging.
45696211|NCT03580317|Other|EA+ Carbamazepine|"Acupoints selection: Si-bai(ST2), Xia-guan(ST7), Di-cang(ST4), Quan-liao(SI18), Jia-che(ST6) and A-shi-xue of affected side. He-gu(LI4) and Wai-guan(TE5) of two sides.~Operation:The needles(0.18×25 mm) will be selected to stimulate the local points with shallow row needling according to the distribution of neuropathy branch of trigeminal neuralgia.The needles(0.25×40mm) will be selected to stimulate the distal acupoints. The Xia-guan(ST7) and Quan-liao(SL18) (or Jia-che(ST6)), He-gu(LI4) and Wai-guan(SJ5) acupoints will be received EA treatment by HuaTuo SDZ-ⅡB acupoint neural stimulator. The EA parameter is 2/100 Hz, 60 minutes and the current intensity is comfortable to subjects. Carbamazepine tablets should be took orally, 0.1g each time, thrice daily."
45388834|NCT04933643|Other||
45388835|NCT00359073|Drug|montelukast|10 mg everyday
45388836|NCT00359073|Drug|placebo|like placebo
45388837|NCT03991143|Drug|ATH3G10|intravenous
45388838|NCT03991143|Drug|Placebo|intravenous
45388839|NCT03918239|Drug|SHP643|Participants will receive injection of SHP643.
45502062|NCT01343563|Procedure|Trigeminal Nerve Stimulation|External trigeminal nerve stimulation (TNS) as an adjunctive treatment added onto antidepressant medications.
45388840|NCT04699331|Device|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
45388841|NCT00368745|Drug|Pregabalin|GAD subjects on stable dose of alprazolam will be randomized to double-blind pregabalin at starting dose of 75mg twice daily. Weekly assessments of tolerability, need for rescue medication, anxiety/withdrawal symptoms will guide flexible dose titration of pregabalin at dose range between 75 and 300mg twice daily. Subjects successful in discontinuation of alprazolam while treated with pregabalin will continue to be maintained on pregabalin for 6 weeks and assessed weekly for ability to remain in the study.
45502063|NCT01348555|Drug|Bronchodilatator|
45502064|NCT01348555|Drug|Bronchodilatator|
45388842|NCT00368745|Drug|Placebo|GAD subjects on stable dose of alprazolam will be randomized to double-blind placebo matching assessments and study medication titration as detailed under the pregabalin arm description. Subjects successful in discontinuation of alprazolam while treated with placebo will continue to be maintained on placebo for 6 weeks and assessed weekly for ability to remain in the study.
45388843|NCT03235739|Drug|Naloxegol 25 MG|Oral Naloxegol 25 MG
45388844|NCT03235739|Drug|Placebo|matching oral placebo
45388845|NCT04645355|Drug|Guselkumab|All subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44
45388846|NCT05711771|Behavioral|medication therapy management|Patients receive medication therapy management within the primary care office
45388847|NCT04617587|Behavioral|Early Intervention|The early intervention (EI) is delivered during the NICU stay. It is a multisensory intervention which consists in three parts: parental training, massage therapy and visual interaction. The EI is first focused on parental training, according to PremieStart Protocol, in order to train parents to: recognize signs of infant stress and alert-available behavior through the identification of infant's behavioral states; adopt principles of graded stimulation; sustain infant's attention and respond to infant's cues; optimize interactions and avoid overwhelming infants through facilitation strategies. The program is held in eight main sessions and one additional post-discharge session. In addition, parents are trained and invited to daily promote preterm baby massage therapy and visual interaction (visual fixation/tracking and visual attention).
45696212|NCT03580317|Other|EA+Placebo|In this group, the selection, positioning and manipulation of acupoints, the frequency, duration and retaining needle time of treatment are same as EA + Carbamazepine Group; placebo, that appearance and specifications are the same as carbamazepine, are cooperated taken of dose 0.1g, thrice daily.
45696213|NCT03580317|Other|sham EA+Carbamazepine|"Selection of points and locations: the non-meridional points which are means to the points beside 5-10mm of the real acupoints (avoid the trigger point) in the EA group will be selected and needled with more shallow acupuncture (the depth of needling is about 1-2mm).~The operation of shame EA: The HuaTuo SDZ-ⅡB acupoint neural stimulator with damaged electrode wires will be selected to connect the points next to the Xia-guan(ST7) and Quan-liao (SI18) , He-gu (LI4) and Wai-guan(TE5).The frequency, intensity and retaining time will be same as EA group, The subjects can see the display screen and parameter settings of stimulator, however there is no electricity output in fact.~The dosage and frequency of oral carbamazepine tablets are same as above part."
45388848|NCT04573673|Device|PTNS de verum|The device will be set to program P-4: Frequency 20Htz, Pulse duration = 200 µs. The amplitude (Volt) will be adjusted by the patient according to the feeling.
45388849|NCT04573673|Device|PTNS placebo|The device will be set to program P-4: Frequency 20Htz, Pulse duration = 200 µs. A resistor will be incorporated in the device to block the passage of electric current
45696214|NCT03580317|Other|sham EA+Placebo|The points selection, positioning and manipulation are same as Shame EA+ Carbamazepine group，placebo are cooperated taken of dose 0.1g, thrice daily.
46056744|NCT05071924|Behavioral|PLH Teens Hybrid: Hybrid delivery for parents and teens by facilitators|The hybrid intervention delivered over 12 sessions (8 sessions delivered via WhatsApp groups to parents only and 4 sessions delivered in-person to parents and teens together).
46056745|NCT02720289|Other|Video-based social learning class|Brief child passenger safety lecture by a child passenger safety technician and viewing of a car seat video.
45388850|NCT01845597|Procedure|MAKOplasty® medial UKA|A robot guided medical Unicompartmental knee arthroplasty (UKA) is a procedure to replace only the medial tibiofemoral compartment of the knee.
45388851|NCT04188041|Other|TB Infection ECHO|A six-month virtual telementoring course regarding TB infection testing and treatment that incorporates didactics, case presentation, and discussion
45848617|NCT03805386|Drug|Physician directed opioid prescribing|Oxycodone 5mg 1-2 tablets every 4 hours as needed for pain. 30 tablets will be provided.
45388852|NCT01048437|Behavioral|Transplant education with video|1 hour standard transplant module is replaced with the Explore Transplant presentation and 20 minute video featuring transplant patients and donors
45388853|NCT01048437|Behavioral|Transplant education with speakers|1 hour standard transplant module is replaced with the Explore Transplant presentation and 3 live speakers: 1 deceased donor recipient, 1 living donor recipient and 1 living donor
45388854|NCT01050699|Drug|Dexmedetomidine|Intravenous continuous infusion will be initiated with a (optional) loading dose of 1 mcg/Kg over 10 minutes followed by a maintenance infusion of 0.5 mcg/kg/hour for 24 hours.
45388855|NCT01050699|Drug|Midazolam and Fentanyl|"Midazolam (Versed): Loading dose 2-4 mg IV bolus followed by continuous infusion at 1-7 mg/hour.~Open label aliquots for pain (Midazolam 1- 4 mg IV bolus.)~Fentanyl: Loading dose 50-200 mcg IV bolus; Continuous infusion rate 50-300 mcg/hour. Open label aliquots for pain (Fentanyl 50 - 200 mcg IV bolus.)"
45388856|NCT00454818|Genetic|MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)|MYDICAR administered by antegrade epicardial coronary artery infusion
45388857|NCT00454818|Procedure|Placebo Infusion|Saline; epicardial coronary artery infusion
45388858|NCT00454818|Genetic|MYDICAR Phase 2 (Placebo-controlled, Randomized Study)|MYDICAR administered by antegrade epicardial coronary artery infusion
45388859|NCT03992625|Device|Deep Brain Stimulation|High frequency electrical stimulation of deep brain nuclei for the treatment of movement disorders
45388860|NCT03668873|Behavioral|Sleep Parent Training|SPT provides a comprehensive intervention that teaches parents the basic concepts and practical skills to address an array of sleep problems.
45388861|NCT03668873|Behavioral|Sleep Parent Education|SPE is a structured program intended to mimic competent treatment as usual. Thus, SPE is an accepted treatment and serves as an active comparator that controls for time and attention.
45388862|NCT04552457|Behavioral|No activity restrictions|"Patients in the No activity restrictions group will be allowed to return to their normal activity immediately."
45388863|NCT04552457|Behavioral|Activity restrictions|"Patients in the Activity restrictions group will not be allowed to perform strenuous exercise or lift anything greater than 10lbs. Strenuous exercise will be defined as is any activity that requires so much exertion that one cannot have a conversation comfortably while doing it."
45388864|NCT00445224|Other|Hip Progressive Resistive Exercise|Hip Progressive Resistance Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening hip abduction ad external rotation musculature.
45388865|NCT00445224|Other|Quad Progressive Resistive Exercises|Quad Progressive Resistive Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening quadriceps musculature with straight leg raises and quadriceps isometrics.
45388866|NCT02408315|Drug|misoprostol/placebo|buccal or vaginal routes of administration/ placebo to compare methods for efficacy and safety during induction.
45388867|NCT01323114|Procedure|Laparoscopic duodenal exclusion|Laparoscopically-performed Roux-en Y intestinal bypass of the duodenum and proximal jejunum; stomach remains normal size and proximal division performed just distal to pylorus.
45388868|NCT01323114|Other|Conventional Medical Treatment|Standard of care medical treatment for type 2 diabetes to include medications and dietary management under the monitoring of the study endocrinologist.
45848618|NCT03805386|Drug|Patient directed opioid prescribing|Oxycodone 5mg amount ranging from 0 tablets to as much as 30 tablets as described in the standard of care.
45848619|NCT03802344|Drug|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream
45848620|NCT03802344|Drug|Cal/BDP combination|Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%
45848621|NCT03802344|Drug|Vehicle|Vehicle cream
46056746|NCT02720289|Other|Traditional didactic class|Child passenger safety lecture by a child passenger safety technician.
45388869|NCT01030146|Drug|NeilMed® Sinus Rinse™ System with Isotonic Saline|NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
45388870|NCT05711693|Device|Laser doppler vibrometry (LDV), heart(cordium) carotid pulse wave velocity (ccPWV)|Patients scheduled for thoracic aorta MRI will have LDV measurement of ccPWV. Both techniques will be compared
45388871|NCT05711693|Procedure|Blood pressure and heart rate measurement|"To all patients:~- blood pressure and heart rate will be measured"
45388872|NCT05711693|Device|carotid to femoral PWW measurement|"To all patients:~- carotid to femoral PWW will be measured by LDV and tonometry for comparison"
45388873|NCT05711693|Procedure|Questionnaire completion|All patients will complete a questionnaire of acceptability
45388874|NCT04005365|Drug|Propranolol|add propranolol in gastric cancer patients who need to receive preoperate chemotherapy
45388875|NCT03994926|Device|Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye|Device measures smooth eye pursuit and response to light flash after pt smokes cannabis
45388876|NCT03994926|Drug|Cannabis cigarette - 4.0% THC|smoked cannabis 4.0% THC
45388877|NCT01027182|Drug|Raltegravir|One 400mg tablet on day 1.
45388878|NCT00358917|Drug|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once-daily (QD) tablet
45388879|NCT00358917|Drug|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice-daily (BID) tablet
45388880|NCT04512209|Procedure|MRI|"Patients will undergo an MR scan before undergoing cytoreductive surgery. If neoadjuvant chemotherapy is administered, an extra MR scan is planned before the start of the neoadjuvant chemotherapy.~During surgery, tissue samples will be taken for interstitial fluid pressure (IFP) measurement, immunohistochemistry (IHC) and characterization of biophysical properties (viscoelastic properties and hydraulic conductivity)."
45388881|NCT02534259|Other|Force monitoring of external fixator struts|
45388882|NCT04571801|Diagnostic Test|Standard diagnostics|Standard diagnostics (Microbial diagnostics by means of standard culture methods + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis of sepsis / septic shock
45502065|NCT04437277|Diagnostic Test|Hepatitis C, serology|Inclusion of patients in conventional hospitalization at Saint Joseph Hospital. Each consenting patient benefits from a screening HCV serology carried out during a biological sample indicated by his state of health. In the case of positive HCV serology, an additional sample will be taken in search of viral replication. All detectable HCV PCR patients will be admitted to hepatology consultation for assessment of liver status including non-invasive methods and possible treatment according to the conditions of the Marketing Authorization and recommendations for routine clinical practice. Data on management (treatment or non-treatment and treatment outcome: prolonged virological response 12 weeks after completion of treatment) will be collected.
45502066|NCT00687986|Radiation|stereotactic radiotherapy|Either 3 fractions of 20 Gray or 5 fractions of 12 Gy
45502067|NCT00687986|Procedure|primary surgery|an anatomical surgical resection with lymph node dissection
45388883|NCT04571801|Diagnostic Test|Next Generation Sequencing (NGS)|Standard diagnostics + NGS (Microbial diagnostics using standard culture methods + Next Generation Sequencing + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis of sepsis / septic shock
45388884|NCT03990987|Other|time of receiving operation|patients were randomly divided into Day group (D group) (8：00～12：00) and Night group (N group) (18：00～22：00), Patients received propofol, remifentanil, and DEX for general anesthesia maintenance
45388885|NCT01048515|Drug|Caffeine|Caffeine capsule 6 mg/kg given 1 hour before test
45388886|NCT04004195|Drug|BAY2327949|A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)
45388887|NCT01050777|Drug|Liposomal meglumine antimoniate (Glucantime)|Liposomes containing meglumine antimoniate
45388888|NCT01050777|Drug|Liposomal meglumine antimoniate|Liposomal form of meglumine antimoniate
45388889|NCT01050777|Drug|Liposomal Paromomycin|Liposomal form of 10% Paromomycin
45388890|NCT01050777|Drug|Placebo|Placebo
45388891|NCT04099589|Drug|Toripalimab|Gemcitabine/Cisplatin plus Toripalimab
45388892|NCT01563809|Drug|FSH+LH|75 IU of LH will be given from stimulation day 1
45388893|NCT01563809|Drug|FSH+LH|75 IU of LH will be given from stimulation day 1
45388894|NCT00264004|Drug|AZD2171|30 mg & 45 mg oral tablet
45502068|NCT00306098|Drug|islets|Islet transplantation
45502069|NCT04422925|Procedure|Living Donor Hepatectomy|On living donor hepatectomy (preoperative), the first following day of surgery, 3rd day, and 7th day, blood will be taken for the measurement of S100β, NSE, and GFAP levels in the postoperative period. The plasma of the blood taken will be separated and stored at -800C. Values will be measured by the ELISA method. During the hospitalization, the delirium status of the patients will be evaluated with the delirium evaluation scale (Delirium Rating Scale-Revised - 98 Turkish version). Functional and cognitive information and other results will be collected at each follow-up point.
45502070|NCT03563378|Drug|Lactated Ringer|Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
45502071|NCT03563378|Drug|Normal saline|Patients will be administered normal saline for intraoperative fluid management.
45388895|NCT01069198|Drug|Albendazole, Iron, Zinc and Vitamin A|single oral dose of 200,000 IU Vitamin A at baseline and after six months, 35 mg and 65 oral elemental iron for subject aged <5 and >=5 years respectively everyday for two months starting from enrollment; 10 mg oral zinc for 10 consecutive days each month for 6 months; and a single 400 mg oral dose of albendazole at 3-months' intervals.
45388896|NCT01069198|Other|Placebo|Placebo
45388897|NCT00368355|Drug|Ara-C|"day-8 through day-5~3 g/m2 q 12 hours"
45388898|NCT00368355|Drug|Cyclophosphamide|"day-7 and day-6~45 mg/kg"
45388899|NCT00368355|Biological|Campath-1H|"day-3 through day-1~Dosing for children:~5 - 15kg : 3mg IV in 30ml NS~15.1 - 30kg : 5mg IV in 50ml NS~>30 kg : 10mg IV in 100ml NS~Adults will receive 10mg IV in 100ml NS"
45388900|NCT00368355|Radiation|Total Body Irradiation|"day-4 through day-1~175 cGy x 2 at 24 cGy/min"
45502072|NCT01352455|Procedure|Hemodialysis|5 days per week hemodialysis
45388901|NCT00368355|Procedure|Stem Cell Infusion|Stem cells are infused on day 0
45388902|NCT01070680|Drug|Precedex|mkg/ml,continuous infusion at rate 0.7 µg/kg/h
45502073|NCT02829944|Drug|Ropivacaine|
45502074|NCT02829944|Drug|Ketorolac|
45502075|NCT02829944|Drug|Placebo|
45388903|NCT01070680|Drug|sodium chlorid 0,9%|continuous intravenous infusion
45388904|NCT00445146|Drug|EVG|Elvitegravir (EVG) tablet administered orally once daily with food
45388905|NCT00445146|Drug|RTV|Ritonavir (RTV; /r) 100 mg capsule administered orally once daily with food
46056747|NCT05056948|Other|artificial intelligence (AI) computer assisted design (CAD)|Maxillary right first molar will be removed in the computer and will be designed by artificial intelligence system
45388906|NCT00445146|Drug|ARV regimen|The components of the ARV regimen will be selected by the investigator without input from the sponsor. The antiretroviral regimen must consist of at least 2 agents, not including the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz, nevirapine, or delavirdine; the protease inhibitors saquinavir, nelfinavir, or indinavir; or investigational agents (without sponsor approval).
45388907|NCT01581736|Drug|U100 Humulin|Infused at a rate of 80/mU/m2 surface area per minute one time over 2 hours
45388908|NCT01581736|Other|Exercise|Single episode of exercise riding a stationary bike.
45388909|NCT01030224|Drug|AZD9742|Increasing single IV infusion doses of AZD9742 given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo). Specific doses will be selected by the safety review committee
45502076|NCT03563300|Other|Wheat flour|Wheat flour will be administered once daily for 7 days
45502077|NCT03563300|Other|Placebo Comparator|Placebo will be administered blindly versus wheat flour for 7 days
45502078|NCT04014842|Device|RapidShock|Use of the Reconfirmation Analysis Mode algorithm
45502079|NCT04014530|Drug|Ataluren + Pembrolizumab|Ataluren and Pembrolizumab combination therapy
45502080|NCT03563534|Drug|Silver Diamine Fluoride|Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, and apply 38% silver diamine fluoride.
45502081|NCT03563534|Drug|Glass Ionomer|Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, apply resin modified glass ionomer.
45696215|NCT04362124|Biological|vaccine BCG|Performance evaluation of a single dose of BCG vaccine in reducing the severity of SARS-COV-2 infection compared to placebo, in healthcare personnel.
45502082|NCT02824562|Behavioral|Intervention|The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain.
45388910|NCT01030224|Drug|Placebo to match AZD9742|Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo)
45388911|NCT01030302|Drug|bortezomib|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
45388912|NCT00368277|Drug|Aliskiren|Aliskiren 150 mg and 300 mg tablets taken orally, once a day in the morning
45696216|NCT04362124|Other|Placebo|A single dose intradermal application of normal saline solution.
45696217|NCT04361968|Other|Animal-assisted placebo condition|Participants receive the same verbal information as in the Placebo condition. Additionally, participants will receive the same verbal information as in the Dog only condition.
45696218|NCT04361968|Other|Placebo condition|"Participants receive verbal information that they are receiving an analgesic cream (i.e. Antidolor, containing Lidocain), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream."
46056748|NCT02725827|Other|EmbryoGlue (Vitrolife)|A hyaluronan-enriched embryo transfer medium
45388913|NCT00368277|Drug|Ramipril|Ramipril 5 mg and 10 mg capsules taken orally, once a day in the morning
45388914|NCT00368277|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 or 25 mg capsules taken orally, once a day in the morning
45388915|NCT00368277|Drug|Amlodipine|Amlodipine 5 mg or 10 mg tablets taken orally, once a day in the morning
45388916|NCT03992547|Other|Robot-assisted Gait Training|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT enables training of automatically programmed normal gait pattern.
45388917|NCT00280150|Biological|bevacizumab|Given IV
45388918|NCT00280150|Drug|carboplatin|Given IV
45388919|NCT00280150|Drug|erlotinib hydrochloride|Given orally
45696219|NCT04361968|Other|Dog only condition|"Participants will get a therapeutic rationale for the presence of the dog. The rationale is supported in the literature and therefore not invented for the purpose of this study. Participants will be told that: Studies have shown the presence of an animal can affect pain perception because the presence and the interaction with an animal can increase our Oxytocin level. Therefore, the investigators want to examine if the presence of a dog has an impact on your pain perception. While participants have to wait for the action time of the cream they are allowed to pet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high degree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. The dog will always be lying at the same spot. Participants will still be able to see the dog."
45848622|NCT03799614|Device|RMBand lower dose|Light-weight portable device that delivers low dose vibration to the arm
45388920|NCT00280150|Drug|paclitaxel|Given IV
46056749|NCT02725827|Other|Control medium|The usual embryo transfer medium used in the study centres.
46056750|NCT05755126|Behavioral|Iatrosedation|Alleviating the anxiety of patients by iatrosedative interview and clinical encounter
46056751|NCT05755126|Behavioral|Musical Therapy|Patients were provided with headphones and a playlist to listen to the music of their choice for 10 minutes
46056752|NCT02720133|Biological|biochemical parameters|"patients will be collected for analysis of blood standard examinations such as blood glucose, electrolytes (potassium, sodium, magnesium calcium), renal function and also the blood count, platelet aggregation.~All these tests should be practice before, during and after Ramadan fasting for comparison."
45388921|NCT00280150|Radiation|3-dimensional conformal radiation therapy|Given 5 days a week for 7 weeks
45388922|NCT03990753|Diagnostic Test|esophagogastroduodenoscopy|standard esophagogastroduodenoscopy
45388923|NCT01582126|Other|Group balance training|Balance training i group with focus on core stability exercises and dual attention activities.
45388924|NCT03990675|Procedure|FNA, FNB|Endoscopic ultrasound guided fine needle aspiration, Endoscopic ultrasound guided fine needle biopsy
45388925|NCT01052571|Procedure|lumbar transforaminal epidural injections|with an injection of local anesthetic or with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
45848623|NCT03799614|Device|RMBand higher dose|Light-weight portable device that delivers higher dose vibration to the arm
45848624|NCT03796260|Drug|Entrectinib Test Formulation (F1)|Participants will receive a single oral dose of entrectinib F1 after completion of a standardized meal.
45848625|NCT03796260|Drug|Entrectinib Reference Formulation (F06)|Participants will receive a single oral dose of entrectinib F06 after completion of a standardized meal.
45848626|NCT03796182|Drug|Metformin|Commercially available metformin (GLUCOPHAGE®) as 500 mg tablets.
45848627|NCT03796182|Drug|PF-04965842|PF 04965842 100 mg tablets
45848628|NCT03779724|Other|exercises|
45388926|NCT00279916|Drug|Triamcinolone acetonide nasal spray|"Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms).~Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms)."
45388927|NCT00279916|Drug|Placebo nasal spray|"Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily.~Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily."
45388928|NCT02534337|Drug|GEMOX|gemcitabine 1000mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2. The treatment was repeated every 2 weeks until disease progression or limiting toxicity.
45848629|NCT03786744|Biological|ASD CB-MNC injection.|CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.
45848630|NCT03786744|Other|Standard therapy.|The standard therapy can include drugs, special psychology training etc.
45848631|NCT03790878|Behavioral|Mindful Breathing|Training in a mindful breathing skill that reduces emotional distress
45848632|NCT03790878|Behavioral|Habituation|An exposure procedure that reduces emotional distress through habituation
45696220|NCT04361968|Other|Control Condition|Participants in this condition will receive no intervention. All instructions will be conveyed in a standardized manner to ensure that the participant-experimenter relationship is comparable in terms of friendliness and attention across all four conditions.
45848633|NCT03790878|Behavioral|Control|No emotion regulation intervention, placebo
45848634|NCT03789474|Device|HUNTLEIGH FLOWTRON ACS900|
45848635|NCT03765996|Other|Decongestive Physiotherapy|This group received CDP, which include MLD, short-stretch bandages, lymph-reducing exercises, and skin care. MLD was applied to the anterior trunk, posterior trunk, and the base of the neck, progressing to the affected limb. Short-stretch bandages were applied in multiple layers after MLD. A low pH skin lotion was applied prior to bandaging and then stockinette was placed on the arm. The fingers and the hand were wrapped in gauze. A layer of cotton was wrapped around the arm. Bandages (6, 8 and/or 10cm) were sequentially applied in a spiral fashion around the limb with the smallest bandage starting at the hand. The most compression was at the most distal points and gradually decreased proximally. Exercises were done by patients to improve mobility and enhance lymphatic flow.
45848636|NCT03765996|Other|Decongestive Physiotherapy plus taping|This group received CDP as same protocol of active comparator. In addition, Kinesiotaping was applied to anterior and posterior axillo-axillary anastomosis and axillo-inguinal anastomosis. The tape was started on the unaffected side and strips of tape were applied so as to reach the affected side regarding anterior and posterior axillo-axillary anastomosis. For axillo-inguinal anastomosis, the tape was started in the inguinal region of the affected side and strips of tape were applied so that they reached the axillary region.
45848637|NCT03765762|Drug|GRF6019|GRF6019 for IV infusion
45848638|NCT03765762|Other|Placebo|Placebo for IV infusion
45848639|NCT03756012|Device|Algovita Spinal Cord Stimulation System|The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
45388929|NCT02534337|Drug|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1;Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
45502083|NCT02824562|Behavioral|Control|"The control group will receive treatment as usual. The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain. This standard of care allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic (e.g., opioid and other pain medication), non-pharmacologic (e.g., physical therapy, referral to psychology) approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group."
45696221|NCT04356118|Drug|Recombinant Human Endostatin|endostatin 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles .We advocate a highly individualized treatment plan according to each patients specific manifestations of the disease process.
45388930|NCT01052649|Other|Blood sampling|
45696222|NCT04356118|Drug|intrathcal methotrexate|Intrathecal chemotherapy specified dose on specified days.
45388931|NCT01325896|Drug|PEG-Intron sc injection|"This program is only open to patients with multiple myeloma who have achieved a complete or partial response after a myelosuppressive chemotherapy regimen followed by autologous stem cell infusion of peripheral blood transplant (PBSCT) as treatment intensification. These patients will be treated with PEG-Intron as maintenance therapy, to be permitted during the same concomitant administration of corticosteroids and / or bisphosphonates.~PEG-Intron: 35 mcg per week by subcutaneous injection to progression or recurrence of the disease, or for 5 years maximum.~Patients were administered PEG-Intron to a uniform dose of 15 mg initial week for 2 weeks. If this dose is tolerated, it would be gradually increased to 25 mg and then to 35 mg every 2 weeks, assuming that there is no toxicity of grade 3 or worse."
45388932|NCT01050933|Drug|250 ppm carbon monoxide|250 ppm of inhaled carbon monoxide over one hour
45388933|NCT00358527|Drug|Mometasone Furoate Nasal Spray (MFNS)|MFNS 50 mcg/spray: self-administered, two sprays per nostril (ie, 200 mcg QD), once daily (each morning), for 28 days.
45388934|NCT00358527|Other|Placebo|Matching placebo nasal spray: 2 sprays per nostril once daily for 28 days
45502084|NCT02744066|Device|NEATCAP|Neonates will be sized and fitted to wear the non-invasive novel hearing protection device over a set period of time in the NICU. Vitals will be monitored.
45502085|NCT03563456|Behavioral|structured combined exercise|A structured designed exercise consists of three times per week interval cardiorespiratory training of High Intensity Interval Training incorporates cycles of 1:4 interval and two times per week Resistance Exercise consists of nine-movement.
45502086|NCT03563456|Behavioral|cardiorespiratory exercise|Once per week continuous cardiorespiratory training of moderate intensity
45502087|NCT05066984|Other|structured, multidisciplinary and personalized post-ICU care|Structured, personalized and multidisciplinary post-ICU care tailored to patients' health problems initiated by ICU clinicians and coordinated by GPs.
45502088|NCT03563144|Drug|Gemcitabine|Gemcitabine is a type of chemotherapy medication used to interfere with the cancer cells' ability to grow and divide.
45502089|NCT03563144|Drug|Nab-paclitaxel|NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor. Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.
45502090|NCT03563144|Drug|Aldoxorubicin HCl|Albumin-binding prodrug of doxorubicin HCl
45388935|NCT00251758|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
45388936|NCT00251758|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
45388937|NCT00251758|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
45388938|NCT03974776|Biological|PF-06946860|PF-06946860 administered subcutaneously
45388939|NCT03974776|Other|Placebo|Placebo administered subcutaneously
45388940|NCT00279214|Drug|drotrecogin alfa (activated)|
45388941|NCT00262834|Drug|vorinostat|Given orally, conventional surgery to follow.
45388942|NCT00262834|Other|conventional surgery|Undergo conventional surgery
45388943|NCT05711459|Drug|Bicyclol tablets|Take Bicyclol tablets for the treatment of liver injury.
45502091|NCT03563144|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
45502092|NCT03563144|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
45502093|NCT03563144|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
45502094|NCT03563144|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
46056753|NCT02725437|Biological|Clostridium difficile Vaccine|0.5 mL intramuscular injection
45502095|NCT03563144|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1[MUC1]
46056754|NCT02725437|Biological|Placebo|0.5 mL intramuscular injection
45388944|NCT05709665|Other|Time to Decision for eCPR|We evaluate during high quality CPR the time for decision for eCPR
45388945|NCT05709119|Diagnostic Test|Quantification of human DNA retrieved and DNA fragmentation profile.|The sample will be analysed for material quality and have no impact on the patient's future care.
45502096|NCT03563144|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
45502097|NCT03563144|Biological|GI-6207|CEA yeast vaccine
46056755|NCT02720055|Other|Psychological workbook|
45388946|NCT05707715|Device|XSensor|"A pressure mapping system (X3 SENSOR PX 100:64.160.02, X-Sensor®, Calgary, Canada) was used to record the pressure distribution in mmHg of the head and shoulder section [18,19]. Pressure distribution was recorded for 1 minute for each lying position. The purpose of these measurements was to describe the pressure distribution created by the participants in the pillow and the supported areas, as well as to find out the differences that may occur between the pillows. Lower pressure values measured by the device were defined as high comfort, while more contact of the head area with the pillow was accepted as high support."
45388947|NCT04417361|Drug|Galcanezumab Prefilled Syringe|Galcanezumab will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
45388948|NCT04417361|Drug|Placebo|Placebo will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
45388949|NCT01563887|Behavioral|DD.com|Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
45388950|NCT01563887|Behavioral|DD.com + MI|Prior to starting and immediately after finishing the DiabetesDriving.com internet intervention, a one hour motivational interview will be conducted with participants. Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
46056756|NCT02720055|Other|Basic information workbook|Basic rehabilitation information that represents current practice.
46056757|NCT05335941|Drug|Pemetrexed|Given by vein (IV)
46056758|NCT05335941|Drug|Zimberelimab|Given by vein (IV)
45502098|NCT03563144|Biological|GI-6301|Brachyury yeast vaccine
46056759|NCT05335941|Drug|Etrumadenant|Given by PO
45388951|NCT04386239|Drug|Sarilumab Prefilled Syringe|Sarilumab administration must be associated with an antiviral treatment as defined by the treatment protocol suggested by the SIMET Experts group 4 and AIFA recommendations: chloroquine 500 mg 1 tablet twice daily or hydroxychloroquine 400 mg 1 tablet twice daily in the first day and then 200 mg 1 tablet twice daily.
45388952|NCT03396575|Biological|TTRNA-DC vaccines with GM-CSF|After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.
45502099|NCT03563144|Biological|haNK|NK-92 [CD16.158V, ER IL-2]
45502100|NCT03563144|Drug|Avelumab|Avelumab
45502101|NCT03563144|Drug|Bevacizumab|Bevacizumab
45502102|NCT03563144|Drug|Capecitabine|Capecitabine
45502103|NCT03563144|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
46056760|NCT02725359|Drug|Placebo|Group Placebo: will receive a placebo pill 1 hour before surgery
46056761|NCT02725359|Drug|Tizanidine|Group T: 6 mg tizanidine1 hour before surgery
46056762|NCT02725359|Drug|Bupivacaine|Group Bupivacaine will receive USG guided SCPB with %0,25 bupivacaine bilaterally 10 ml each side
45502104|NCT03563144|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
45502105|NCT03563144|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
45502106|NCT03563144|Drug|Oxaliplatin|Oxaliplatin
46056763|NCT02725359|Drug|Saline|USG guided SCPB with saline bilaterally 10 ml each side
46056764|NCT00809614|Biological|AIN457|The investigational drug, AIN457 50 mg lyophilizate vials was prepared by Novartis. Reconstitution of AIN457 with 1.2 mL SWFI produced a 47 mg/mL concentrate solution for infusion from which at least 1 mL was useable. The AIN457 concentrate was diluted in 5% glucose bags for infusion through a 0.2 micron in-line filter.
46056765|NCT00809614|Biological|Placebo|Matching placebo to AIN457
46056766|NCT04150419|Other|Group 1|Attentional training to avoid threatening, negative or pain-related information.
45388953|NCT03396575|Biological|TTRNA-xALT|During TMZ Cycle 4 and with DC vaccine #6, an infusion of T-cells will be administered to all subjects.
45388954|NCT03396575|Drug|Cyclophosphamide + Fludarabine Lymphodepletive Conditioning|Subjects in Group B, however, will receive lymphodepletion with cyclophosphamide + fludarabine after DC vaccination and prior to the intravenous infusion of ex vivo expanded tumor-reactive lymphocytes.
45388955|NCT03396575|Drug|Dose-Intensified TMZ|After chemoradiation, subjects in Group A will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. All subjects will have an additional five cycles of dose-intensified TMZ (for a total of 6 Cycles) with concurrent monthly DC vaccinations.
45388956|NCT03396575|Drug|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #6, and #8.
45696223|NCT04356118|Drug|Targeted drugs for non-small cell lung cancer|EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs .
45696224|NCT04361734|Other|Blood sampling to include Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA)|"Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.~Food Frequency Questionnaires (FFQs) and/or diet recall questionnaires to assess dietary intake.~Cardiovascular Ultrasound Scans (USS) to measure how well blood is carried around the body."
45388957|NCT03396575|Biological|Autologous Hematopoietic Stem Cells (HSC)|During Cycle 4, all patients will receive HSCs prior to xALT infusion and DC vaccine #6.
45388958|NCT04365413|Device|MSOT Device|The MSOT Device will be used to take images of the tumor and/or lymph nodes of patients with solid tumors before and after surgery to measure the margins of the tumor and/or positive lymph node.
45388959|NCT04365413|Procedure|Temperature Measurement|The temperature of the skin will be measured prior to and after MSOT imaging.
45388960|NCT04004585|Behavioral|Get Up For Your Health|"The intervention is a 4-week behaviour change intervention underpinned by the Theoretical Domains Framework (TDF) that aims to reduce sedentary behaviour. The intervention consists of one individualized face-to-face session and 3 subsequent weekly points of contact (face-to-face meetings or phone calls).~Behaviour change techniques will be provided including education, verbal persuasion, environmental restructuring and goal-setting."
45696225|NCT04361578|Diagnostic Test|Magnetic resonance elastography|All patients enrolled will receive magnetic resonance elastography of the brain.
45696226|NCT04361812|Drug|HS632|Subcutaneous injection of HS632
45696227|NCT04361812|Drug|Omalizumab (Xolair®)|Subcutaneous injection of Omalizumab Xolair®)
45696228|NCT04368208|Other|Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery|The Edinburgh questionnaire is a self questionnaire validated for postnatal depression between 4 and 6 weeks postnatal
45388961|NCT00541775|Drug|Sitagliptin|Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks.
45388962|NCT00541775|Drug|Comparator: Rosiglitazone|Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks.
45388963|NCT00541775|Drug|Comparator: Placebo|placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks.
45388964|NCT00541775|Drug|Comparator: Metformin|Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of >= 1500 mg.
45502107|NCT04835636|Behavioral|Diabetes Prevention Program|This program is a 1 year lifestyle modification program focused on reducing calories and fat calories and increasing physical activity to achieve a 7% weight loss. This study utilized the first 16 sessions (6 months) of the program
45502108|NCT05052476|Dietary Supplement|Bactecal® D Liquid|The patients will be randomized into two arms, A and B, in function of the intervention dose
45502109|NCT03831074|Device|Implantation of an intraocular lenses: iMics 1 NY-60 & NY-60G|
45502110|NCT03825224|Procedure|Diagnostic Test: Myostrain|This test measures the contraction of the heart muscle in one to three heartbeats per plane. It's a pulse sequence that produces images that reveal the underlying contraction fo the muscle of a healthy heart and associated weaknesses in case of disease.
45696229|NCT03781401|Device|Ambulatory blood pressure monitoring|
45696230|NCT04368052|Diagnostic Test|Mini Mental Test (MMT), S-100 beta, Neuron specific enolase and Glial fibrillary acidic protein|Patients undergoing liver transplantation (LTx) were measured using the Mini Mental Test (MMT) whereas simultaneous neuronal damage was evaluated through the measurement of S-100 beta (S100β), Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) levels.
45696231|NCT04355962|Drug|Sevoflurane|Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS
45696232|NCT04355962|Drug|Intravenous drug|Intravenous sedation in control group will be continued as initiated at the ICU e.g. propofol, fentanyl, midazolam, dexmedetomidine
45696233|NCT03781167|Drug|ABBV-951|solution for infusion
45696234|NCT04367662|Procedure|blood sampling|blood sampling in hospitalized patient for COVID-19 infection
45388965|NCT05361473|Device|The NeoHilda Point of care method|This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.
45388966|NCT05361473|Procedure|Traditional evaluation|Traditional way of evaluation
45388967|NCT04004117|Drug|Fentanyl citrate solution sublingual|Solution of fentanyl citrate (DIN : 02384124 / 02240434 / 02385406) will be administered sublingually by syringe. The dose is 12,5 mcg.
45388968|NCT04004117|Drug|Placebo oral liquid|Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
45696235|NCT04367584|Other|Clinical and laboratory examination|Clinical and laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
45388969|NCT01563965|Dietary Supplement|Carbohydrate plus hydrolyzed protein beverage|The study group received 400 ml (evening drink) or 200 ml (3h prior to operation drink) of a solution containing 11% de protein (pea hydrolized proptein), 89% de carbohydrates (maltodextrin 79% and saccharose 21%) e 0% of lipids (Providextra, Fresenius Kabi, São Paulo, Brasil). All the patients fasted for solids at least 6 hours from the operation
45502111|NCT03824600|Diagnostic Test|Fractional Flow Reserve Motorized Pullback|A pullback device (Volcano R 100, San Diego CA, USA), adapted to grip the coronary pressure wire (PressureWire X, St Jude Medical, Minneapolis, USA), set at a speed of 1 mm/sec to pullback the pressure-wire until the tip of the guiding catheter during continued pressure recording.
45502112|NCT04705766|Other|Urine Collection|A urine collection kit will be mailed to subjects' residence at 3 different timepoints over the course of 1 year to be returned to study team, upon which KIT score and other biomarkers will be assessed as outlined in the study design.
45502113|NCT04784624|Behavioral|Lifestyle program|The cardiometabolic and weight loss program is based on The Wellness Institute clinically validated lifestyle medicine program and will be delivered virtually using a digital platform and artificial intelligence that is supported by a health coach. The program focuses on building individual's self-efficacy, motivation and importance to make and sustain healthy choices. The 16-week program begins with a health risk assessment and a personalized wellness plan. The plan includes a personalized exercise plan and nutrition strategy. Each user will regularly check-in with their personal health coach whose role is to provide expert advice and also empower, support and help make the user accountable as they build a healthy lifestyle. Coaching includes identifying obstacles to changing behaviors and how to develop new behaviors that will become the norm.
45696236|NCT03779217|Other|screening mammography|As indicated by international guidelines authors will perform screening mammography in all asymptomatic women.
45696237|NCT03779217|Procedure|mastoplasty and breast fat excission|As indicated by guidelines, and in accordance to the breast surgery reduction criteria, the authors will practice a surgical intervention of mastoplasty. During the mastoplasty, authors will remove the breast fat tissue.
46056767|NCT04150419|Other|Group 2|Attention training for vigilance for positive emotional information.
46056768|NCT04150419|Other|Group 3 (control group)|Neutral attentional training (control group).
46056769|NCT02725281|Other|Stress ball|The patients in this group were given stress ball into their both palms 5 min before the lithotripsy and told to squeeze the ball whenever they would like until end of the process. This ball was medium hard and has been made of high quality silicon.
46056770|NCT02725281|Other|Music|The patients in this group were also listened to the music chosen by them with a headset from 5 min before until the end of lithotripsy. Types of music played for the patients were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
46056771|NCT05753254|Other|Firefighting training exercises with no fire|The participants will be performing firefighting equivalent work in a clean environment, without fire (no ambient temperature, soot or smoke).
46056772|NCT05753254|Other|Firefighting training exercises under wood fire|The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models), under wood fire conditions.
46056773|NCT05753254|Other|Firefighting training exercises under gas fire|The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models), under gas fire conditions.
46056774|NCT02725203|Behavioral|Activate|The Activate intervention consists of four nurse-led consultations in a thee-month period. In the consultations patients receive structured and comprehensive support in achieving an improved level of physical activity. The Behavior Change Wheel was used to develop the Activate intervention, and led to a selection of 17 behavior change techniques, which are integrated in the Activate intervention
46056775|NCT04674592|Other|Blood samples and biopsies|Blood samples for analysis of biomarkers of muscle damage. Muscle biopsies for histological analysis of muscle damage.
46056776|NCT02719821|Behavioral|Behavioral techniques|"Learning behavioral techniques designed to improve nighttime sleep quality and daytime activity for approximately 45-60 minutes on three occasions.~Device: Actiwatch-2 (Philips Respironics)"
45388970|NCT01563965|Other|Preoperative fasting of 8h|Conventional protocol of 8h fasting before an operation
45388971|NCT00539513|Drug|N-Acetylcysteine|3000 mg by mouth PO (1200 mg AM, 1800 mg PM), 12 weeks
45388972|NCT00539513|Drug|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 12 weeks
45388973|NCT04506047|Procedure|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
45388974|NCT02997761|Biological|Blinatumomab|Given IV
45696238|NCT04361890|Diagnostic Test|perineal ultrasound|all women will have ultrasound measurements of the bladder neck descent, of the movement of the ano-rectal angle during a Valsalva maneuver and elastographic measurement before and after PFMT. All measurement will be conducted by perineal route, with is a non invasive ultrasound route
45848640|NCT03748992|Drug|gNO|"This is a proof-of-concept study in which all subjects will be treated with gNO (i.e. no control) to see if there can be a microbiological effect by conversion to negative sputum cultures and how long that effect can be sustained following treatment.~Participants will be treated for 3 weeks (5 days per week), Monday through Friday, and followed monthly for 3 months.~The treatment period includes a physical exam, vital signs, blood tests, echocardiogram, spirometry test, sputum sample, questionnaires, and the inhalation gas treatment. During the inhalation gas treatment, participants will wear a face mask (similar to an oxygen mask) and will be given nitric oxide gas through the participants nose for three treatments with fifty minutes each time. They will then be followed up monthly during the Follow-up period with tests that include a physical exam and questionnaires."
45696239|NCT03779139|Procedure|Intrahepatic islets and islets in the omental pouch|Patients with islet harvest of >5000 islet equivalents per kg body weight will be randomized in a 1:1 ratio to 4000 IEq/kg delivered via intraportal route and the remainder implanted into a constructed omental pouch.
45696240|NCT03779139|Procedure|Intrahepatic islets alone|This is the standard of care procedure. Patients with islet harvest of >5000 islet equivalents per kg body weight will be randomized in a 1:1 ratio to all islets autotransplanted intrahepatically via the intraportal route.
45696241|NCT03779139|Other|Normal Volunteers|These individuals will undergo metabolic testing as well as islet cell function testing.
45388975|NCT02997761|Drug|Ibrutinib|Given PO
45388976|NCT04119791|Other|wild rice|30 grams of wild rice in the form salad, snack bar and soup
45388977|NCT02969915|Behavioral|Incentives|Treatment incentives are offered to HIV-positive participants for reaching treatment targets, including retention to medical follow-up, initiating antiretroviral therapy, and maintaining high adherence with antiretroviral therapy.
45388978|NCT02969915|Behavioral|Integrated Care Centers|ICCs offer key-population-oriented, vertically-integrated harm reduction, HIV testing, and HIV treatment services
45388979|NCT04003727|Device|Mcgrath Mac Videolaryngoscope|Patient's laryngoscopy will be done using McGrath Mac video laryngoscope
45388980|NCT04094441|Other|chest physiotherapy|chest physiotherapy
45388981|NCT04003883|Device|Holter ECG|A Holter ECG will be recorderd during shifts
45696242|NCT04361500|Device|Seraph 100|Seraph 100 therapy during a COVID-19 infection
45696243|NCT00705081|Drug|ezetimibe|10 mg once daily
45696244|NCT00705081|Drug|statin|
45696245|NCT04361110|Radiation|Computerized tomography scan of the abdomen|Non-specific abdominal ct´s with different phases and contrast +/-.
45696246|NCT00704769|Drug|Desloratadine (assigned by investigator as part of normal practice)|Desloratadine syrup, 2.5 mL (1.25mg) once daily for 2-5 year olds, 5 mL (2.5mg) once daily for 6-11 year olds, minimum 7 days of treatment, minimum of 2 visits
45696247|NCT00938548|Drug|Pregabalin|Pregabalin 75 mg orally
45696248|NCT00938548|Drug|Vitamin Complex (placebo)|Vitamin Complex orally
45388982|NCT00454584|Drug|CNTO 1275 45 mg|Type=exact number, number=45, unit=mg, form=injection, route=subcutaneous
45388983|NCT00454584|Drug|CNTO 1275 90 mg|Type=exact number, number=90, unit=mg, form=injection, route=subcutaneous
45388984|NCT00454584|Drug|Etanercept 50 mg|Type=exact number, number=50, unit=mg, form=injection, route=subcutaneous
45388985|NCT04221191|Drug|Dimethyl Fumarate|DMF as prescribed as standard of care.
45388986|NCT04221191|Other|PSP|PSPs is to support patient care.
45696249|NCT00932620|Drug|SIMVASTATIN 40 mg|SIMVASTATIN 40 mg/day for 3 months
45696250|NCT00932620|Drug|SIMVASTATIN/EZETIMIBE 10/10 mg|SIMVASTATIN/EZETIMIBE 10/10 mg/day for 3 months
45696251|NCT04361188|Procedure|MAC anesthesia|Patients receives DBS under monitored anesthesia care.
45388987|NCT03790644|Device|exoskeleton assist|"A powered exoskeleton describes a wearable robot designed around the shape and function of the human body with segments and joints externally coupled to those of the user. The exoskeleton includes a rigid outer frame, sensors that detect a user's desired movements, a computerized controller, motors and actuators, and lightweight batteries.~The exoskeleton is designed to be worn in the community."
45388988|NCT02540915|Other|Standard of Care - Registry|Standard of Care - Registry
45696252|NCT04361188|Procedure|AAA anesthesia|Patients receives DBS under asleep-awake-asleep anesthesia.
45388989|NCT04204343|Drug|Bupivacaine 0.7 ml/kg|Bupivacaine 0.25% 0.7 ml/kg
45502114|NCT04763720|Behavioral|Dyadic Developmental Psychotherapy|DDP involves approximately twenty sessions with the family, conducted by a trained DDP therapist. DDP is developed to treat trauma-related and attachment difficulties. DDP is not a manualized treatment but involves using a set of core communication techniques (termed PACE; Playfulness, Acceptance, Curiosity and Empathy).
45502115|NCT01338818|Drug|Ritalin LA (methylphenidate hydrochloride extended release)|Ritalin LA 20 mg or 30 mg (a racemic mixture of d- and l-thre-Methylphenidate Hydrocloride (MPH), Extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg. For 40mg dose patients took (2) Ritalin LA 20mg daily, for 60mg patients took (2) Ritalin LA 30mg daily and for 80mg patients took (2) Ritalin LA 30mg daily + (1) Ritalin LA 20mg daily for their optimal dose.
45696253|NCT00003453|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Adrenal Gland Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45388990|NCT04204343|Drug|Bupivacaine 0.5 ml/kg|Bupivacaine 0.25% 0.5 ml/kg
45388991|NCT02845271|Drug|placebo|"Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular"
45502116|NCT05310110|Drug|10% lidocaine spray|10% lidocaine spray 3 puff for the throat before induction
45502117|NCT05310110|Drug|Placebo of lidocaine spray|Normal saline spray 3 puff for the throat before induction
45502118|NCT05310110|Drug|Cisatracurium|Intravenous cisatracurium 0.12 mg/kg during induction
45696254|NCT04367818|Procedure|Peri-anal local anaesthetic infiltration|postoperative pain relieve, among pediatrics patient
45388992|NCT02845271|Drug|GZ389988|"Pharmaceutical form:suspension for injection~Route of administration: intraarticular"
45388993|NCT02845271|Drug|acetaminophen or paracetamol|"Pharmaceutical form: tablet~Route of administration: oral"
45388994|NCT02845271|Drug|fixed combination of paracetamol + codeine|"Pharmaceutical form: capsule~Route of administration: oral"
45388995|NCT02845271|Drug|fixed combination of paracetamol + tramadol hydrochloride|"Pharmaceutical form: tablet~Route of administration: oral"
45388996|NCT00445068|Drug|LBH589|
45388997|NCT02404337|Drug|Betaine|
45388998|NCT05361083|Drug|F18CETO|Injection of F18CETO or O15water followed by PET/CT
45388999|NCT02403089|Other|Tubes fund recovery blood count|Tubes fund recovery of blood counts among newborns
45696255|NCT04367818|Procedure|Caudal anaesthesia|Regional anaesthesia for postoperative pain relieve, among pediatrics patient
45696256|NCT01677273|Dietary Supplement|Hydrolyzed casein|30 g protein/supplement, 4 supplements/visit
45696257|NCT01677273|Dietary Supplement|Intact casein|30 g protein/supplement, 4 supplements/visit
45696258|NCT01677273|Dietary Supplement|Intact whey protein|30 g protein/supplement, 4 supplements/visit
45389000|NCT02403089|Other|the rest of the blood test and stool sample|blood samples on the recovery kinetics after transplant. The rest of the blood test and stool sample done as part of a routine examination.
45502119|NCT05310110|Drug|Placebo of cisatracurium|Intravenous normal saline during induction
45502120|NCT05310110|Drug|Propofol|The dosage of intravenous propofol for the first subjects was predetermined for each arm, and the dosage for the subsequent subjects would be determined according to the response of the previous subjects using the Dixon's up-and-down method with a step size of 0.25 mg/kg. If the subjects had no movement and stable hemodynamic status during and after the laryngeal mask airway (LMA) placement, the predetermined dosage of propofol for the subsequent subject would be decreased by 0.25 mg/kg. On the other hand, if the subjects had obvious movement, failure to LMA placement, and significant hemodynamic changes, the predetermined dosage of propofol for the subsequent subject would be increased by 0.25 mg/kg.
45502121|NCT02823470|Drug|LUM/IVA|LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
45389001|NCT00539279|Behavioral|Prolonged Exposure Therapy (PE)|PE is a therapy that aims to reduce PTSD symptoms via a systematic exposure to feared memories (by imaginal exposure - repeated narration about the traumatic memory) and situations (by in vivo exposure - engaging in feared but safe activities or facing feared situations).
45389002|NCT00539279|Behavioral|Relaxation Training (RT)|RT aims to teach relaxation methods in an effort to reduce anxiety. RT includes Progressive Muscle Relaxation, Imagery Rehearsal, and breathing training.
45389003|NCT05360147|Drug|Liraglutide|Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. We had fond its cognitive improvement effects in an observational study. In order to confirm the effects, the investigators conduct a randomized, controlled study.
45502122|NCT02823470|Device|activated smart device|
45502123|NCT02823470|Device|de-activated smart device|
45696259|NCT04355806|Drug|PD-1/PD-L1 inhibitors|Including nivolumab, pembrolizumab, atezolizumab, and durvalumab, et al.
45696260|NCT04355806|Biological|Inactivated trivalent influenza vaccine|Including two type A viruses, H1N1 and H3N2, and one type B virus, B/Brisbane.
45502124|NCT04697576|Biological|Ipilimumab|immune checkpoint inhibitor
45502125|NCT04697576|Biological|Nivolumab|immune checkpoint inhibitor
45502126|NCT04697576|Biological|Pembrolizumab|immune checkpoint inhibitor
45502127|NCT04697576|Biological|Quadrivalent Inactivated Influenza Vaccine|Given IM and intratumorally
45502128|NCT04697576|Procedure|Resection|Undergo surgical resection
45696261|NCT01677351|Drug|Clonidine|4 mcg.kg-1, 20 minutes before cataract surgery
45696262|NCT01677351|Drug|placebo|
45554680|NCT02708498|Behavioral|Educational Intervention|The seminar groups will be led by two experienced clinical nurses and researchers from the field of palliative care and geriatric care. The educational material consist of six themes; values in palliative care, symptom relief, dignity and a dignified death, collaborative co-creating care, support to next of kin and dialogue with older persons and next of kin about death and dying. The content of the different themes will have a common core for each nursing home but will be adjusted based on the expressed needs of each nursing home. New themes can be created related to the needs of the unique nursing home. The participants in the seminar groups will reflect together over the content of the developed binder of educational material and will relate it to their own work in order to identify areas suitable for changes and/or development.
45554681|NCT03766659|Diagnostic Test|MOSE|EUS-FNB with MOSE
45696263|NCT00938704|Drug|carboxymethylcellulose 0.5% +glycerin 0.9%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
45696264|NCT00938704|Drug|sodium hyaluronate 0.18%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
46056777|NCT00731731|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
46056778|NCT00731731|Procedure|Cognitive Assessment|Ancillary studies
46056779|NCT00731731|Other|Laboratory Biomarker Analysis|Correlative studies
45389004|NCT05360147|Drug|Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides|oral antidiabetic drugs (OADs) or insulin, except for glucagon-like peptide type 1 (GLP-1) analogues
45389005|NCT00444912|Drug|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (sc) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
45389006|NCT00444912|Drug|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥5*10^6 CD34+ cells/kg were collected.
45389007|NCT00444912|Biological|rituximab|Participants were given a weekly dose of rituximab 375mg/m2 by intravenous infusion for 1 week prior to and continuing until 2 weeks after the first dose of G-CSF.
45389008|NCT00538733|Drug|thalomid|"Cycles 1-4~• Thalidomide (50mg daily for days 1-7, thereafter 100mg daily for days 8-28 of the first 28 day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 for each subsequent cycle)"
45389009|NCT00538733|Drug|lenalidomide|"During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Lenalidomide (25 mg daily days 1-21 of every 28 day cycle)~During BiRD phase • 25mg daily days 1-21 of every 28 day cycle)~During Maintenance Phase~• 25 mg daily for days 1-21 out of a 28 day cycle"
45389010|NCT00538733|Drug|clarithromycin|"During T-BiRD Phase • Clarithromycin (500mg twice daily for each 28 day cycle)~During BiRD Phase:~• Clarithromycin (500mg twice daily for each 28 day cycle)"
45389011|NCT00538733|Drug|dexamethasone|"During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During BiRD Phase:~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During Maintenance Phase~• Dexamethasone 20 mg weekly (days 1,8, 15, 22 out of a 28 day cycle)"
45389012|NCT00444678|Drug|Cetuximab|500 mg/m2, IV every two weeks
45389013|NCT00444678|Drug|Oxaliplatin|85 mg/m2, IV, q 2 weeks
45389014|NCT00444678|Drug|Capecitabine|2500 mg, po bid x 7 days every two weeks
45389015|NCT00358449|Drug|mepolizumab|Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg), 2.5 mg/kg , or 10 mg/kg by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.
45389016|NCT00539981|Biological|FluBlok®|Dose: 0.5 mL, single dose; Route of administration: intramuscular. Recombinant Trivalent Hemagglutinin Influenza Vaccine containing 45 microgram (mcg) of each hemagglutinin derived from A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
45502129|NCT04748510|Procedure|Functionally Aligned Total Knee Arthroplasty|Femoral + tibial osteotomy planned for equal resection of femoral condyles to replicate patient anatomy. In coronal plane, distal femoral resection of 6.5mm subchondral bone from medial + lateral condyles, adjusted 1-3mm for compensation of wear. Proximal tibia, 7mm resection from subchondral bone from medial + lateral tibial plateau. Sagittal plane, resection angle determined intraoperatively to closely match native femoral flexion + tibial slope. Axial plane: posterior femoral resection 6.5mm from the subchondral bone of medial and lateral posterior condyles. Tibial rotation aligned to Akagi's line. Adjustments will be made to bony alignment to balance soft tissues within boundaries of 6° varus/3° valgus HKA alignment. Femoral component alignment limited to 6° valgus/3° varus in coronal plane. Tibial alignment limited 6° varus/3° valgus in coronal plane. Combined flexion of components limited to 10° flexion. Soft tissue release if balance within boundaries not achieved.
45554682|NCT03766659|Diagnostic Test|ROSE|EUS-FNA with ROSE
45554683|NCT03524391|Behavioral|Counselling based on yoga|Counseling sessions were given as one-on-one and group to patients based on yoga philosophy and therapy.
45696265|NCT03668379|Behavioral|Augment w/mHealth|"Non-responders to the first stage treatment of BAT alone may be re-randomized to this augmented intervention to receive text-message support in addition to the BAT intervention."
45848641|NCT03748758|Combination Product|Drug: OP0201|Drug OP0201
45554684|NCT03524391|Drug|Chemotherapy|Usual Care group had standard chemotherapy regimens
45848642|NCT03748758|Combination Product|Drug: Placebo|Placebo
46056780|NCT00731731|Drug|Temozolomide|Given PO
45389017|NCT00539981|Biological|Placebo|Dose: 0.5 mL normal saline for injection, single dose; Route of administration: intramuscular
45389018|NCT00990119|Device|Vapotherm High Flow Therapy|use of high flow nasal cannula to support oxygenation and CO2 removal by flushing the nasopharynx with warmed, humidified respiratory gas at flow rates that exceed a patient's inspiratory flow rate
46056781|NCT00731731|Drug|Vorinostat|Given PO
46056782|NCT05755048|Biological|Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)|Experimental: FS-1502 Dosage form: lyophilized powder Specification: 30 mg/vial Dose: 2.3 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip.
46056783|NCT05755048|Biological|Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)|Active Comparator: Trastuzumab Emtansine (T-DM1) Trade name: Kadcyla Dosage form: lyophilized powder Specification: 100 mg/vial Dose: 3.6 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip (this drug has been approved for marketing. Please refer to the package insert for details).
46056784|NCT02719665|Dietary Supplement|SPM Emulsion, Dose-modality|"Phase 1a Dose-Finding oral SPM administration of increasing dose (15ml, 30ml, and 60ml) by the following schedule:~Days 1 to 5: 15 ml; Days 6 to 14: Washout, no SPM administration; Days 15 to 19: 30 ml; Days 20-28: Washout, no SPM administration; Days 29-33: 60 ml"
45696266|NCT03668379|Behavioral|Maintenance|"Responders to the 1st-stage treatment of either 1. BAT or 2. BAT & mHealth will continue in maintenance mode. These participants will not receive any additional interventions during the 2nd-stage treatment."
45696267|NCT03668379|Behavioral|Switch to CBT & mHealth|"Non-responders to the 1st-stage treatment of either 1. BAT or 2. BAT & mHealth may be re-randomized to switch interventions in the form of an intensified dose of Cognitive Behavioral Therapy (CBT). CBT is eight sessions long and covers five modules that can be re-arranged to fit patient needs. Sessions will be scheduled once a week to facilitate more contact with participants. An identical text-messaged tool will be used."
45389019|NCT00990119|Device|Non-invasive positive pressure ventilation|Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress.
45389020|NCT03992157|Device|ECG telemetry|ECG telemetry (holter ECG) is a portable case - attached to the belt or around the neck - connected to 6 electrodes placed on the skin next to the heart. They are worn by patients during their stay in hospital
45389021|NCT00990197|Drug|Transdermal nicotine patch|Subjects will apply the nicotine patch on the morning of their treatment day and will keep it on for 24 hours.
45389022|NCT03992079|Procedure|ReCOVER Enhanced Recovery Protocol|The experimental group will receive preemptive pain management before surgery, an opioid-free strategy during surgery, and an opioid-sparing multimodal pain management protocol after surgery.
45389023|NCT01051011|Drug|insulin glargine|initial dose 10 international units (IU) sc daily, titrated according to the mean FPG, 24 (-52) weeks
45389024|NCT01051011|Drug|metformin|as prescribed
45389025|NCT01051011|Drug|taspoglutide|10mg sc weekly, 24 (-52) weeks
45389026|NCT01051011|Drug|taspoglutide|10mg sc weekly the 1st 4 weeks followed by 20mg sc weekly, 24 (-52) weeks
45389027|NCT05359913|Behavioral|Cervical cancer podcast for African American women|"The video podcast will deliver cervical cancer prevention messages using entertainment education and behavioral journalism, and film production techniques such as talking head video, interview, animations, & live-action skits. The research team will work closely with the production company in scripting the video vignettes and sequences, ensuring that video content reflects salient domains captured in the concept mapping research development phase of the study."
45696268|NCT03668379|Behavioral|Augment w/BAT & mHealth|"Non-responders to the BAT & mHealth intervention may be re-randomized to receive an additional dose of BAT & mHealth in the form of an additional session of BAT."
45696269|NCT00938782|Device|Sedline|
45848643|NCT03745092|Device|normobaric oxygen|Normobaric oxygen (NBO) is a routine adjuvant hyperoxygenation intervention supplied by facemask (such as Venturi mask), with one atmosphere pressure (1ATA=101.325kPa).
45389028|NCT05361005|Drug|BDB-001 injection|Intravenous injection
45389029|NCT05361005|Drug|Placebo|Intravenous injection
45389030|NCT01324791|Procedure|anti-reflux surgery|
45389031|NCT05360927|Drug|BDB-001 injection|Intravenous injection
45389032|NCT05360927|Drug|Placebo|Intravenous injection
45389033|NCT01051089|Behavioral|Lifestyle modification|Exercise and diet education
45389035|NCT01048749|Other|aquatic vertical suspension.|Subject is suspended in a warm water deep pool with two pool noodles around the subject and directly under the axilla. Five pound weights are placed on the ankle and the subject maintains this unloaded position for 15 minutes.
45389036|NCT01048749|Other|land-based supine flexion|The subject will lay supine with the legs supported by a foam wedge with hips flexed to 90 degrees and knees flexed to 65 degrees. They will maintain this unloaded position for 15 minutes.
45389037|NCT01048827|Drug|Busulfan|"1250 uMol*min (AUC to time 6 hrs)^~1400 uMol*min (AUC to time 6 hrs~1550 uMol*min (AUC to time 6 hrs)^"
45389038|NCT02023463|Drug|Enzalutamide|Given PO
45389039|NCT02023463|Drug|Goserelin acetate|Given SC
45696270|NCT03666351|Drug|Amlodipine 5mg|Amlodipine 5 mg
45696271|NCT03666351|Drug|Losartan|Losartan Potassium 50 mg
45389040|NCT02023463|Drug|Leuprolide acetate|Given IM or SC
45389041|NCT02023463|Radiation|Radiation therapy|Undergo image-guided radiation therapy
45848644|NCT03745092|Device|room air|The patient had a rest with lying, sitting or walking, did not performed with NBO intervention.
45848645|NCT03744780|Behavioral|ACT Workshop for Emotional Eating|"This is a one-day intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's (2016) brief emotional eating intervention, which was derived from Forman et al.'s (2013) Mind Your Health program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness."
45389042|NCT01302327|Drug|Exenatide|Exenatide
45389043|NCT01659749|Behavioral|Metabolic camp|To use an recreational camp setting to instruct PKU females of reproductive age how to make responsible dietary and reproductive decisions.
45389044|NCT01048983|Drug|Armodafinil|Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.
45696272|NCT03666351|Drug|Losartan and Amlodipine|Amlodipine 5 mg/Losartan Potassium 50 mg, Amlodipine 5 mg/Losartan Potassium 100 mg
45389045|NCT01048983|Drug|Bupropion|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
45389046|NCT01048983|Drug|Minocycline|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
45389047|NCT01048983|Drug|Curcumin|Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.
45389048|NCT01048983|Behavioral|Telephone Questionnaire|Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
45389049|NCT03929783|Procedure|Contrast Enhanced Digital Mammography|Undergo CEM
45389050|NCT01052805|Procedure|harvest nerve|harvest nerve from cadaveric donor and patients receiving nerve graft operation
45389051|NCT00990275|Other|ethanol|subjects will ingest 3 ounces of vodka mixed with fruit juice within 30 min.
45389052|NCT02534181|Drug|Caloric Management Protocol|Strategy based on reduction of nutritional intake and electrolyte replacement.
45389053|NCT03842033|Behavioral|PEAKmAAP|"The PEAKmAAP group will use a mobile app that will help manage asthma."
45389054|NCT03842033|Behavioral|PEAKmAAP-DS|This group will use the mobile app to help manage asthma. the primary care provider will receive monthly reports to help him/her know how the participants asthma symptoms are over time.
45389055|NCT03842033|Behavioral|NutriMap Usual Care|This group will use a non-asthma related app daily to record their daily intake of fruits and vegetables.
45389056|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C], then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D]
45389057|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 [Treatment B], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A]
45389058|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C]
45389059|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A], then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment B]
45389060|NCT03990441|Device|TENS|TENS application using the TensMed S82 (Enraf Nonius). Current parameters: balanced symmetric biphasic square waveform, continuous stimulation, frequency 80 Hz, pulse duration modulated between 250 and 290 μs, modulation time 5 seconds. Self-adhesive electrodes of 50 x 90 mm applied paravertebrally to 2 cm. of the spinous apophysis. Use of two channels with independent intensity (mA): electrodes of the first channel applied at level T10-L1 and second channel ones at level S2-S4. Maximum intensity without reaching pain, increasing the intensity throughout the application to maintain this level. Start of the intervention when the woman expresses pain. End of the intervention when neuraxial anesthesia is applied (if the woman demands it) or after delivery.
45389061|NCT03990441|Device|TENS Placebo|Same application as Intervention, but using 0,1 mA as fixed intensity on both channels.
45389062|NCT05359757|Other|Effect of Naturalistic Teaching Strategies in Children with autism spectrum disorder|"In this group, the patients will be provided with both the naturalistic therapeutic techniques the PECS Therapy.~A baseline of the kids in this group will be made using the portage guide and PECS~Incidental teaching trial, natural language paradigm, and time delay concepts will be incorporated in the therapy sessions and communication using picture cards will be made.~40 minutes session will be conducted in which 20 minutes session will be for naturalistic teaching techniques and 20 minutes will be for PECS.~This will be followed for 30 sessions"
45502130|NCT04748510|Procedure|Mechanically Aligned Total Knee Arthroplasty|Tibial and femoral osteotomies in the coronal plane will be planned perpendicular to the tibial and femoral mechanical axes respectively to achieve neutral overall alignment. Soft tissue balance will be assessed and minor adjustments to bony alignment made to balance the knees with a maximal adjustment of two degrees valgus and two degrees varus of coronal alignment from neutral. Femoral rotation will be planned to surgical epicondylar axis and adjustments to rotation made to allow equal flexion and extension balance (to within 1mm). If balance can not be achieved within these boundaries then soft tissue release will be undertaken. In the sagittal plane, 0-3° degrees of posterior tibial slope and 0-5° of femoral component flexion will be used to optimise implant sizing whilst preventing notching. In the axial plane, the tibial component aligned to Akagi's line, which connects the medial border of the patellar tendon attachment to the middle of the posterior cruciate ligament.
45502131|NCT05238584|Procedure|Partial omentectomy|Partial omentectomy: with preservation of the greater omentum at >2 cm from the gastroepiploic arcade.
45696273|NCT03666351|Drug|Amlodipine/Losartan/Chlorthalidone|Amlodipine 5 mg/Losartan Potassium 100 mg/Chlorthalidone 12.5 mg
45696274|NCT03666351|Drug|current treatment|treatment is done by maintaining the current treatment
45389063|NCT05359757|Other|PECS Therapy only|"A baseline will be developed using the portage guide and PECS.~Communication strategies using the PECS picture cards will be made~30 minutes session will be conducted~This will be followed for 30 sessions"
45389064|NCT03990597|Other|Placebo Administration|Applied topically
45389065|NCT03990597|Other|Questionnaire Administration|Ancillary studies
45696275|NCT00928642|Drug|imatinib mesylate by mouth|imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.
45848646|NCT03742440|Biological|GrafixPL PRIME|GrafixPL PRIME
45389066|NCT03990597|Drug|Wound Dressing Material|Applied StrataXRT topically
45389067|NCT01340417|Other|Measurements of melatonin levels in urine, blood, milk.|Measurements of melatonin levels in urine, blood, milk.
45389068|NCT01049061|Drug|MORAb-003|MORAb-003 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose
45389069|NCT01049139|Behavioral|1-sided messages|Supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).
45389070|NCT01049139|Behavioral|2-sided messages|Supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
45389071|NCT02533947|Behavioral|Exercise|The intervention consists of an individually tailored supervised exercise program with aerobic, strength and coordinative components.
45389072|NCT02533947|Behavioral|Control|A waitlist control group will get the intervention after 7 month of treatment as usual.
45389073|NCT00367341|Drug|escitalopram|Participants will receive treatment with escitalopram for 12 weeks.
45389074|NCT00367341|Behavioral|Cognitive Behavioral Therapy (CBT)|CBT will include 16 1 hour sessions provided over 12 weeks.
45389075|NCT01052961|Drug|Oseltamivir|oseltamivir 150 mg bd for 5 days
45389076|NCT02534025|Procedure|Ischemia preconditioining|Elavate blood pressure cuff pressure to 200
45389077|NCT00440466|Drug|epoetin alfa|Continue pre-study once weekly dose of epoetin alfa for 36 weeks
45502132|NCT04730570|Behavioral|Essential Coaching for Every Mother|Essential Coaching for Every Mother consists of 53 standardized text messages that provide evidence-based information that women should be aware of related to caring for their newborn and maternal mental health. Messages are personalized with the name of the child. Messages sent from birth to six-weeks postpartum, with two messages sent per day in the first two weeks and a daily message for weeks 3-6. The following topics covered in Essential Coaching for Every Mother include anxiety, depression, maternal self-care, postnatal follow-up, breastfeeding or formula feeding, infant concerns, cord care, well-baby care, normal development, crying, and safe sleep. Women who receive the messages will be able to self-select breastfeeding or formula feeding messages.
46056785|NCT02719665|Dietary Supplement|SPM Softgel, Dose-Modality|Phase 1b Dose-Finding oral softtel SPM administration of two different doses (2 softgel vs 4 softgel) Days 0 to 5: 2 SPM softgel; Days 6 to 21: Washout, no SPM administration; Days 22 to 26: 4 SPM softgel; Days 27-42: Washout, no SPM administration
46056786|NCT02719665|Dietary Supplement|Placebo Softgel|Days 43-47: 4 Placebo softgel; Day 48-64 Washout
45389078|NCT00440466|Drug|epoetin alfa|Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
45389079|NCT00440466|Drug|epoetin alfa|Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
45389080|NCT03992313|Other|Community-based HCV rapid test|HCV rapid tests will be done in the village
45389081|NCT03992313|Other|Facility-based HCV rapid test|HCV rapid tests will be done in the health center
45389082|NCT03992313|Other|Plasmatic HCV viral load|HCV viral load will be done in provincial hospital on plasma using GenXpert
45389083|NCT03992313|Other|DBS HCV viral load|HCV viral load will be done in Phnom Penh by DBS using Omunis kit
45389084|NCT01051167|Drug|Cetuximab|500 mg /m² cetuximab as an intravenous infusion over 120 minutes on day 1 every 2 weeks
45389085|NCT01325441|Drug|BBI608|
45389086|NCT01325441|Drug|Paclitaxel|
45389087|NCT00537485|Drug|SPM 962|transdermal application, 1 time per day
45389088|NCT00537485|Drug|placebo|transdermal application, 1 time per day
45389089|NCT00616967|Drug|carboplatin|Given IV
45389090|NCT00616967|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
45389091|NCT00616967|Drug|vorinostat|Given orally
45389092|NCT00616967|Other|placebo|Given orally
45502133|NCT04645862|Diagnostic Test|CT scans|4D CTA imaging
45389093|NCT04003571|Behavioral|Augmented Reality with Functional Electrical Stimulation group|Experimental group contains 30 minutes augmented reality combined with functional electrical stimulation training, and 30 minutes traditional physiotherapy. Augmented reality includes treadmill and balance exercise. Functional electrical stimulation applies on tibialis anterior muscle. Traditional physiotherapy includes rolling, sitting, standing, overground walking, facilitation of the paretic limbs, and so on.
45389094|NCT04003571|Behavioral|Traditional physiotherapy|Traditional physiotherapy includes treadmill and balance training for 30 minutes as well as rolling, sitting, standing, overground walking, facilitation of the paretic limbs for another 30 minutes .
45389095|NCT00989339|Drug|Twenty-four Hour TPN and Saline Infusion|Infusion of Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr.
45389096|NCT05358431|Other|Neuroimaging and electrophysiology|Brain and spinal cord MRI, transcranial magnetic stimulation; Motor Unit Number Estimation, EEG
45502134|NCT03562910|Other|HelpSteps application|Mobile or tablet-based tool that screens for social needs and refers to local agency based on needs and proximity.
45389097|NCT05401643|Other|Xemio mobile application|"The study consists in a mHealth intervention provided through the Xemio mobile application for breast cancer survivors. This application is installed in the personal smartphones of the participants after they are randomized in the mHealth intervention group. The Xemio app components are symptom tracking, up-to-date calendar of events organized by patient's organizations, virtual talks with experts, articles regarding new information of the disease, physical activity tracking, and evidence-based information regarding symptoms, non-pharmacological treatments for side effects, and information about common drugs to treat breast cancer. The participants can freely use the Xemio mobile application for a total of 12 months.~The control group does not have access to the Xemio application for the duration of the study but they are offered access to it at the completion of the intervention. The participants of both arms continued to receive the usual care from their oncology teams."
45389098|NCT05360537|Drug|Liraglutide injection|administration of liraglutide
45389099|NCT05360537|Drug|Insulin Glargine|Administration of glargine insulin
45389100|NCT00989417|Other|ACTIVATION of HOME MONITORING|Both patient groups will be followed for 27 months and will have Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
45389101|NCT00989495|Device|Brace|Wearing a Thoraco-Lumbo-Sacral-Orthosis (TLSO) for a minimum of 20 hours per day
45389102|NCT05590637|Drug|Pimavanserin|Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
45389103|NCT05590637|Drug|Quetiapine|Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
45389104|NCT00989651|Biological|Bevacizumab|Given IV
45502135|NCT03562754|Procedure|reduced systemic heparin anticoagulation|receive intermittent hemodialysis (Frésenius 4008) with blood flow at least of (200 ml/min) with double vascular access, biocompatible membrane dialyzer, low dose non fractionated heparine (5000 UI initially) and predilution with 25 mls/min dialysate
45502136|NCT03562754|Procedure|Regional Citrate Anticoagulation|intermittent hemodialysis using Prometheus System with blood flow at least of 200 ml/min with double vascular access, biocompatible membrane dialyzer
45389105|NCT00989651|Drug|Carboplatin|Given IV
45502137|NCT02259920|Drug|KUC 7483 CL, immediate release tablet|
45389106|NCT00989651|Drug|Cisplatin|Given IP
45389107|NCT00989651|Other|Laboratory Biomarker Analysis|Correlative studies
45389108|NCT00989651|Drug|Paclitaxel|Given IV or IP
45389109|NCT00989651|Drug|Veliparib|Given PO
45502138|NCT02259920|Drug|KUC 7483 CL, particulate formulation|
45502139|NCT02259920|Drug|KUC 7483 CL, solution formulation|
45502140|NCT02259920|Device|Enterion™ capsule|
45389110|NCT05590559|Drug|Morphine|Opiates
45389111|NCT05590559|Other|Ultrasound-guided erector spinae plane block|PVB
45389112|NCT05359601|Procedure|Infusion set replacement intervals|24-hour or 96-hour infusion set replacement intervals
45389113|NCT05590325|Drug|Dolutegravir|Single dose of the DTG dispersible tablet in two sequential cohorts and multiple-doses of the DTG dispersible tablet in a single cohort:
45389114|NCT00989729|Drug|Methylprednisolone|A single preoperative dosage 30 mg/kg Methylprednisolone suspended in physiological saline (100 ml in total) given intravenously as a 30 minute infusion, 2 hours before surgery.
45389115|NCT00989729|Drug|Physiological Saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
45389116|NCT00989807|Drug|Aztreonam lysine|Open-label, expanded access for Aztreonam lysine for inhalation 75 mg three times daily
45389117|NCT00990431|Procedure|Fractional carbon dioxide laser treatment|The CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA) employs disposable tips with a diameter of 7 mm and 15 mm, the smaller being used for the peri-orbital region. The laser beam is delivered through multiple deflective and refractive elements and focused to a spot size of approximately 120 µm in diameter at incidence to the skin to deposit an array of laser beams across the surface. Pulse energy varies from 5 to 70 mJ and density from 5 to 70 %. The pulse duration is 10 msec. In the present study, patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %.
45848647|NCT03730116|Drug|bisoprolol/perindopril FDC|the first and only single-pill combination of beta-blocker and ACE inhibitor
45502141|NCT04353674|Device|Control group|Patients randomized into this group will receive standard of care for COVID-19 infection
45502142|NCT04353674|Device|SLEDD with a L-MOD|Patients randomized to this group will undergo slow low efficiency daily dialysis for approximately 12 hours, 2 days in a row with a leukocyte modulatory device.
45502143|NCT01371656|Drug|levofloxacin|Given PO or IV
45848648|NCT03729960|Other|LENA recorder|The LENA recorder model# 0121 is a lightweight, pocket-size, rechargeable electronic recorder together with a mobile application to view the data and answer questionnaires
45389118|NCT00990431|Procedure|Fractional erbium:YAG laser treatment|The Er:YAG laser used in this study has a fractional handpiece (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany). By means of a microlens array the laser beam is divided into 13 x 13 small spots with 250 µm diameter each, spread over an area of 13 x 13 mm. A coverage of 5 % of the skin is achieved with a single pass. The pulse duration is 400 μsec. In this trial, we performed 4 passes (resulting in coverage of 20 % of the treated skin) with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses) to optimize thermal exposure.
45389119|NCT05590247|Behavioral|Intermittent Fasting Diet|Patients will follow the 16: 8 traditional intermittent fasting model, where they may only consume calories during 1 continuous 8-hour period of the day. Water may be consumed during fasting.
45389120|NCT01590095|Behavioral|Water quality|"Hardware: Free supplies chlorine tablets (Aquatabs; NaDCC) and a safe storage vessel to treat and store drinking water.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children < 36 months of age."
45389121|NCT01590095|Behavioral|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
45389122|NCT01590095|Behavioral|Hand washing|"Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
45389123|NCT01590095|Behavioral|Water quality, Sanitation, Hand washing (Combined WASH)|"Hardware: Free supplies Aquatabs; (NaDCC) and a safe storage vessel to treat and store drinking water. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children < 36 months of age.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.~Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
45389124|NCT01590095|Behavioral|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) delivered daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices.General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
45389125|NCT01590095|Behavioral|Nutrition, Water quality, Sanitation, Hand washing|Each of the interventions described above for Water Quality, Sanitation & Hand washing (Combined WASH) Plus the intervention described above for nutrition.
45389126|NCT05359523|Device|Ultrasonographic measurements of the trapezius and rhomboid muscle and fascia|B mode measurements Trapezius and rhomboid muscle thickness and fascial thickness measurement M mode measurements Abduction at 90 and 180 degrees Forward flexion at 90 and 180 degrees
45389127|NCT05590091|Other|Parenteral nutrition;Enteral nutrition|The intelligent nutrition management system was used to carry out standardized nutrition management of patients after hematopoietic stem cell transplantation
45389128|NCT00990587|Drug|Ciclopirox Olamine|Patients will take Ciclopirox Olamine at various doses depending on which dose level they come into the study at. Ciclopirox olamine will be administered orally as an aqueous suspension without food. The starting dose will be 5 mg/m2/day administered as a single dose daily for 5 days (one cycle). Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
45389129|NCT00988793|Procedure|Laparoscopic distal pancreatectomy|Comparison of two different types of surgery, laparoscopic versus distal pancreatectomy
45389130|NCT00988793|Procedure|Open distal pancreatectomy|Comparison of two different types of surgery, open versus laparoscopic distal pancreatectomy.
45389131|NCT00989885|Other|Questionnaire and polysomnography|Comparison of polysomnography data records and previously made questionnaire, with the Epworth Sleepiness Scale.
45389132|NCT05589779|Other|Asthma and cardiovascular disease|To know the clinical and inflammatory characteristics of patients with asthma and associated cardiovascular disease, as well as their relationship with eosinophil subtypes, biomarkers of chronic inflammation and bronchial remodeling.
45696276|NCT00928642|Drug|Gemcitabine Intravenous|Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle
45696277|NCT03665337|Behavioral|mTranS-C|MOBILE HEALTH
45696278|NCT03665337|Behavioral|Control|MOBILE HEALTH
45696279|NCT03663543|Drug|Conjugated Estrogen|Dosing of conjugated estrogen will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
45848649|NCT03729024|Device|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Primary and Fellow eyes will receive Light adjustable lens with Light delivery Device treatments
45389133|NCT05358275|Device|surgical cutting guide with piezo|3D planned lid surgery
45389134|NCT05358275|Other|control|ordinary cyst enucleation
45389135|NCT00537329|Drug|Anidulafungin|Eligible subjects will be initiated on a single loading dose of 200 mg IV anidulafungin, followed by 100 mg IV anidulafungin once daily for a minimum of 5 days but not more than 42 days.
45389136|NCT00990743|Drug|SYL040012|Administration of single and multiple doses of SYL040012 in ophthalmic drops solution
45389137|NCT05358197|Other|yoga|laughter yoga
45389138|NCT00990977|Behavioral|mindfulness based stress reduction (MBSR)|MBSR is an 8-week course covering a total of 24 contact hours where the group of patients meet with an clinical psychologist certified as mindfulness instructor. The group will train the ability of mindfulness by specific awareness improving practises (body-scan) guided meditations and soft yoga. Between group-sessions participants are recommended to practice 45 minutes daily and to go through instructions in MBSR hand-outs. Participants will be given audio-CDs containing instructions and guides to support home practice.
45389139|NCT04002869|Diagnostic Test|Immunologic, molecular, metabolomic and radiolologic diagnostic|Evaluation and development of new technologies
45389140|NCT04730843|Drug|ES102|ES102 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
45389141|NCT03897179|Device|INVSENSOR00032 and INVSENSOR00033|Investigational pulse oximeter device
45389142|NCT03905135|Drug|rhIL-15|Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a starting dose level of 1 mcg/kg/day, a second dose level of 2 mcg/kg/day, a third dose level at 3 mcg/kg/day, and a fourth dose level at 4 mcg/kg/day on days 1-5 of each of six cycles.
45389143|NCT03905135|Drug|rhIL-15|Interleukin-15 (IL-15) will be administered by continuous intravenous infusion at the maximum tolerated dose (MTD) or maximum administered dose (MAD) on days 1-5 of each of six cycles
45389144|NCT03905135|Biological|Avelumab|Avelumab (intravenous (IV) over 1 hour) will be administered at a dose of 10 mg/kg on days 8 and 22 of each of six cycles.
45389145|NCT05589311|Other|Transformative Learning principles|Transformative Learning principles are incorporated into the pain education workshop to stimulate critical reflection and critical discourse during the learning process.
45389146|NCT05589311|Other|Conventional didactic approach|The conventional didactic approach focuses on lecture-based instruction as the teaching center, emphasizing the delivery of syllabus and concept.
45389147|NCT00991055|Drug|Pioglitazone|"A total 16-week randomized, double-blind, controlled study to compare the efficacy and safety of pioglitazone 15mg once daily added to combination metformin plus sulfonylurea with those of placebo combining control group.~(4-week run in period and 12-week pioglitazone 15mg added to combination therapy of sulfonylurea plus metformin and placebo control group in patients with type 2 diabetes)"
45389148|NCT04002557|Other|No intervention|Interviews contain no intervention, purely observational.
45389149|NCT05589155|Other|Mobile health application|Intervention will be with mobile health application
45389150|NCT00991133|Drug|Clofarabine incorporated into a 5-drug regimen|Clofarabine (IV) 40mg/m2 into an intensive chemotherapy regimen of etoposide, cyclophosphamide, PEG-asparaginas, and vincristine
45389151|NCT00991211|Drug|Bendamustine|Comparison of Bendamustine + Rituximab with CHOP + Rituximab
45389152|NCT00991211|Drug|Standard chemotherapy CHOP + Ritiximab|Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy
45389153|NCT04672811|Device|Study App and Apple Watch|Study App and Apple Watch
45389154|NCT00357903|Biological|Etanercept|Adult Rheumatoid Arthritis (RA) patients on etanercept (TNFR:Fc) with well controlled arthritic symptoms will continue on the etanercept (TNFR:Fc) dose administered in their original protocol of enrollment. All other adults will receive 50 mg per week as two 25 mg subcutaneous (SC) injections at separate sites, either on the same day or 3 or 4 days apart. Pediatric patients ages 4 to 17 years will receive a 0.8 mg/kg per week dose (up to a maximum of 50 mg per week).
45389155|NCT03990519|Drug|JNJ-26366821|Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC).
45389156|NCT03990519|Drug|Placebo|Participants will receive sodium chloride injection as placebo on Day 1.
45389157|NCT01053039|Drug|Intrathecal Morphine|Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.
45696280|NCT03663543|Drug|Normal saline|Dosing of normal saline will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
45696281|NCT04361422|Drug|Isotretinoin Only Product in Oral Dose Form|assess antiviral efficacy, tolerability and safety of oral isotretinoin in the treatment of COVID-19 versus combined oral isotretinoin with standard therapy for COVID-19 versus the standard therapy alone.
45389158|NCT01053039|Drug|Intrathecal Saline|The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
45502144|NCT01354106|Device|Skin Trauma|Each participant completed received both treatment arms, the 3M Micropore and 3M Kind Removal Silicone Tape.
45696282|NCT03579615|Device|FIASP + closed loop device|Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
45696283|NCT03579615|Device|Insulin aspart (standard of care insulin) + closed loop device|Participants will be advised to maintain their usual insulin 24 hours prior to admission.
45696284|NCT03575403|Drug|Alcohol|In each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.
45389159|NCT01051245|Behavioral|Case manager counseling|Patients followed-up by case manager. Interventions based on the Chronic Care Model. Interventions are self management education, motivational interviewing, individualized counseling on non-pharmacological treatment to modify and sustain healthy lifestyle behaviours, and follow-up. Close contact with primary care physician and/or specialist by case manager, if clinical targets out of recommended standards. Pharmacological treatment not suggested, managed by personal criteria of health care professionals. Focus on targets.
45389160|NCT01051245|Other|Usual care|Usual care provided by primary care physician and/or specialist according to patients' needs and professional criteria. Includes free access to educational diabetes workshops and educational brochures.
45389161|NCT01051401|Drug|rosuvastatin|Given PO
45502145|NCT01354028|Other|Massage therapy|An overall massage time of approximately 10 minutes, administered by physical therapists. Almond oil or baby lotion that is currently used in standard care in the ACH NICU will be used to assist with ease of skin to skin contact during moderate pressure massage. Infants will receive two repetitions of 5-1minute periods of 12 strokes lasting approximately 5 seconds each described in protocol. Actigraph device is on infant's ankle to measure sleep.
45502146|NCT03065582|Other|Topical Product A|topical application sunscreen containing topical antioxidants and sunscreen filters
45502147|NCT03065582|Other|Topical Product B|topical application of product A without topical antioxidants
45502148|NCT03065582|Other|Topical Product C|Topical application of antioxidants only
45502149|NCT03065582|Other|Control|No product applied
45502150|NCT04541888|Drug|CsA Ophthalmic Gel|The CsA eye gel of 0.3 g: 0.15 mg
45502151|NCT04541888|Drug|Placebo|Placebo
45502152|NCT04541888|Drug|Hypromellose Eye Drop|Hypromellose Eye Drops of 10ml：50mg, 3 times daily, 1-2 drop
45696285|NCT03575403|Drug|Placebos|Subjects will receive placebo capsules.
45696286|NCT03575403|Drug|Duloxetine|Subjects will receive duloxetine capsules.
45696287|NCT03575403|Drug|Methylphenidate|Subjects will receive methylphenidate capsules.
45696288|NCT04367428|Biological|Administration of probiotics|Patients will receive the previously mentioned combination of probiotics before and after surgery
45696289|NCT04367272|Procedure|First Arthroplasty|First Knee
45696290|NCT04367272|Procedure|Second Arthroplasty|Second Knee
45389162|NCT01051401|Other|placebo|Given PO
45502153|NCT01354964|Drug|Vitamin D|
45502154|NCT01354964|Drug|Placebo|
45502155|NCT03562676|Other|weightlessness|parabolic flight
45389163|NCT01051401|Other|survey administration|Correlative study
45389164|NCT01051401|Procedure|management of therapy complications|
45389165|NCT03989973|Diagnostic Test|Gastroscopy|Gastroscopy
45502156|NCT02673476|Drug|ALS-008176|ALS-008176 tablets
45502157|NCT02673476|Drug|Placebo|Identical placebo tablets
45696291|NCT03553875|Drug|Memantine Hydrochloride|Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to memantine for the course of the 12-week randomized controlled trial (RCT).
45696292|NCT03553875|Drug|Placebo|Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to placebo for the course of the 12-week randomized controlled trial (RCT).
45389166|NCT01053117|Other|Protocolized approach to convert dialysis catheter to fistula|This group will be assigned an algorithm protocol in efforts to convert the central venous catheter to an arteriovenous fistula. A case manager will be assigned to follow these patients and implement the protocol
45389167|NCT00348933|Drug|Betaine|100-200 mg per kg per day by mouth with a maximum of 6 grams divided in two daily doses
45389168|NCT00348933|Drug|Creatine|200 mg per kg per day with a daily maximum of 5 grams divided in two daily doses
45389169|NCT00348933|Drug|Metafolin|0.5 mg per kg per day by mouth with a maximum of 8 milligrams divided in two daily doses
45389170|NCT00348933|Drug|Vitamin B12|1 mg by mouth per day for all weights and ages
45389171|NCT01325103|Procedure|Stem Cell Transplantation|All patients will undergo autologous bone marrow stem cell transplantation into the lesion area.
45389172|NCT01051479|Drug|C11-Choline|15 mCi 11C-choline will be administered intravenously as a bolus. The whole body emission scans will be acquired immediately following the tracer injection.
45389173|NCT01055691|Drug|Dapagliflozin/Metformin|Fixed dose combination dapagliflozin/metformin IR tablet 2.5 mg/850 mg Oral Single dose
45389174|NCT01055691|Drug|Dapagliflozin|dapagliflozin tablet 2.5 mg Oral Single dose
45389175|NCT01055691|Drug|Metformin|metformin IR tablet 850 mg Oral Single dose
45502158|NCT01354496|Drug|LY2409021 Reference Form|Administered orally
45502159|NCT01354496|Drug|LY2409021 Test-Med Formulation (medium particle size)|Administered orally
45502160|NCT01354496|Drug|LY2409021 Test-High Formulation (high particle size)|Administered orally
45502161|NCT01354496|Drug|LY2409021 Test-Low Formulation (low particle size)|Administered orally
45502162|NCT04164134|Other|blood draw|"Control samples for the Rb survivor group (adult) are already available at the VUMC for the platelet study; unselected volunteers from an anti-cancer campaign. Control samples (adult) for the EV study will be collected in a blooddrive at the Essen site.~Pediatric patients. For the pediatric Rb patients, blood draw is part of standard care (3mth-4y). The control blood samples of healthy children (12) will be drawn from healthy children, where the blood draw is already part of otherwise planned care (e.g. patients which are completely healthy besides having an unrelated problem for which surgery is required). Controls will be age-matched as much as possible."
45502163|NCT02259998|Drug|Persantin® new formulation|
45502164|NCT02259998|Drug|Persantin® commercial formulation|
45389176|NCT01055691|Drug|Dapagliflozin/Metformin|Fixed dose combination dapagliflozin/metformin IR tablet 5 mg/1000 mg Oral Single dose
45389177|NCT01055691|Drug|Dapagliflozin|dapagliflozin tablet 5 mg Oral Single dose
45389178|NCT01055691|Drug|Metformin|metformin IR tablet 1000 mg Oral Single dose
45389179|NCT02533869|Radiation|Low-dose CT|Low-dose computed tomography for suspected acute uncomplicated appendicitis
45389180|NCT02533869|Procedure|Laparoscopic appendectomy|All patients diagnosed with an uncomplicated acute appendicitis on low-dose CT-scan will undergo laparoscopic appendectomy to evaluate the sensitivity and specificity of the CT diagnosis
45502165|NCT04009460|Drug|ES101|ES101 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle.
45502166|NCT02035826|Behavioral|Behavioral Economics Intervention|Patients will receive an active intervention for 3 months followed by 3 months of observation. Incentives will be awarded at the end of the first 3 months, based on an improvement of at least 10 mg/dl in LDL relative to the patient's baseline LDL or achieving or sustaining LDL of 100, depending on baseline LDL and FRS. Adherence in all groups will be measured using Vitality GlowCaps as a recording device. Patients in all arms will be given the GlowCaps and instructions on use. Patients will receive adherence feedback electronically with daily lottery awards to match the timing of their task.
45389181|NCT03896477|Biological|Pneumosil|One single dose contains 2 μg of polysaccharide for serotypes 1, 5, 6A, 7F, 9V, 14, 19A, 19F and 23F, and 4 μg for serotype 6B formulated with aluminium phosphate as an adjuvant in an appropriate buffer
45389182|NCT03896477|Biological|Prevenar 13|One single dose contains 2.2 µg of the following pneumococcal polysaccharides serotypes - 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F - and 4.4 µg of pneumococcal polysaccharide serotype 6B, all conjugated to CRM197 and absorbed onto aluminum phosphate
45502167|NCT02035904|Drug|Levobupivacaine PCIA (Patient Controlled Intrawound Analgesia)|patient controlled infusion from the 2nd day after surgery
45502168|NCT02035904|Drug|saline|patient controlled infusion from the 2nd day after surgery
45502169|NCT02035904|Drug|Levobupivacaine continuous infusion|Continuous infusion Levobupivacaine 0,25% 5ml/h for 24 hs in all patients
45502170|NCT02035904|Device|intrawound infusion catheter|placed by surgeon at the end surgery in all patients
45502171|NCT02035904|Drug|morphine|PCA with morphine: 0,5 mg/ml bolus 1 mg lock-out 5 min max 20 mg in 4 hs - for the first 24 hs as rescue analgesia
45389183|NCT03896477|Biological|Synflorix|One single dose contains 1 μg of polysaccharide for serotypes 1, 5, 6B, 7F, 9V, 14, and 23F, and 3μg of serotypes 4, 18C, and 19F formulated with aluminum phosphate as an adjuvant.
45389184|NCT00444600|Drug|Triamcinolone Acetonide + laser|4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
45389185|NCT00444600|Drug|Ranibizumab + laser|0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
45389186|NCT00444600|Drug|Sham injection + laser|Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
45389187|NCT00444600|Drug|Ranibizumab + deferred laser|0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
45389188|NCT00537095|Drug|Vandetanib|300 mg oral once daily oral dose
45389189|NCT00537095|Other|Placebo|
45389190|NCT05357027|Biological|TC-E202 cells|T cells genetically engineered with a TCR targeting HPV16 E6 (E6 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells
45389191|NCT05357027|Drug|IL-2|Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance. IL-2 improves the survival of TC-E202 cells after infusion.
45389192|NCT05357027|Drug|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
45389193|NCT05357027|Drug|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
45502172|NCT02035904|Drug|Patrol|tramadol-paracetamol 37,5/325 mg oral fix combination-rescue analgesia from 2nd day (after morphine PCA removal)
45502173|NCT04110080|Procedure|multimodal pain management|Regional anesthesia techniques, specifically rectus sheath and transabdominal plane blocks, for pain management will be performed.
45502174|NCT04110080|Other|goal directed fluid management|Intraoperatively fluids will be administered based on hemodynamic parameters, in addition to clinical judgement.
45502175|NCT04110080|Other|preoperative carbohydrate loading|Patient's nutrition will be optimized preoperatively by administering carbohydrate drinks, and limiting fasting time.
45502176|NCT04110080|Procedure|Donor nephrectomy|All patient will have laparoscopic nephrectomy procedure with transplant surgery.
45389194|NCT01030380|Device|Slendertone Face|Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
45502177|NCT04110080|Procedure|regional anesthesia|transabdominal plane and rectus sheath nerve block
45502178|NCT03562520|Behavioral|Behavior change counseling|"Core modules: 1 psychoeducation session at week 0; 4 behavior change counseling (BCC) sessions will occur at weeks 0, 4, 8, and 12; phone calls and/or texting sessions (weeks 1-3, 5-7, 9-11, and booster calls and/or texts on weeks 16 and 20) from therapists.~Optional modules: Exercise coaching sessions; family involvement options will include participation in any aspect of the intervention; peer support options will include: group exercise classes on site, online Fitbit groups where adolescents can participate in competitions with each other and provide motivational support, and fitness support groups facilitated by registered social workers."
45502179|NCT02035982|Drug|Cholinesterase Inhibitor|"For participants randomized into the active treatment arm, they will be provided with the following study medications:~Donepezil - 5 mg or 10 mg Galantamine - 8 mg and 16 mg and 24 mg Rivastigmine - 1.5 mg and 3 mg~The type of study medication provided will depend on the type and dosage of the cholinesterase inhibitor they have been receiving for the last 3 months of their regular treatment. For example, if that have been taking Donepezil - 5 mg daily, they will continue on that same medication, dosage and frequency."
45502180|NCT02035982|Drug|Placebo|For participants randomized into the placebo intervention, placebo capsules will match capsules in the active intervention.
45502181|NCT05707832|Drug|Amphotericin B cholesteryl Sulfate Complex for Injection|Intravenous injection (IV), once a day after reaching the recommended dose of 3.0-4.0 mg/kg for treatment. Subjects will receive ABCD intravenous therapy for at least 2 weeks, and the longest course of treatment will not exceed 6 weeks.
45502182|NCT02822222|Drug|Magnesium citrate, tribasic anhydrous soft gelatin capsule|110 mg elemental magnesium/capsule
45502183|NCT02822222|Drug|Placebo soft gelatin capsule|0 mg elemental magnesium/capsule
45696293|NCT04367194|Behavioral|Neurorehabilitation|After examination of the patients, the patients undergo neurorehabilitation. We use virtual reality therapy. Patients perform a submaximal load that is monitored by a polar clock. We develop endurance, coordination, sensory integration, visual and acoustic input, vestibular training, proprioception training.
45389195|NCT00991367|Other|Cicatrix|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
45389196|NCT00991367|Other|Placebo|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
45389197|NCT00991445|Procedure|Minimal Invasive Surgery|After a 8-10 cm skin incision, a medial parapatellar capsule incision is made. The vastus medialis muscle or the rectus tendon are not incised, nor is the patella everted. The patella is merely pushed slightly aside when the bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
45389198|NCT00991445|Procedure|Conventional exposure|After a 15-20 cm midline skin incision is made, a medial parapatellar capsule incision is made. The incision is carried up through the insertion of the vastus medialis and into the rectus tendon. The patella is everted. The bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
45389199|NCT00991523|Dietary Supplement|protein|protein
45389200|NCT00991523|Dietary Supplement|placebo|placebo control
45389201|NCT00443898|Drug|terbinafine|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 48 weeks
45389202|NCT00443898|Drug|Placebo|vehicle (placebo) applied once daily for 48 weeks
45389203|NCT00443898|Drug|terbinafine|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 24 weeks
45389204|NCT00443898|Drug|Placebo|vehicle (placebo) applied once daily for 24 weeks
45389205|NCT00537017|Drug|Preladenant|5 mg BID capsules
45389206|NCT00537017|Drug|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
45696294|NCT03778515|Diagnostic Test|MRI|Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in patients with Ankylosing Spondylitis (AS).
45389207|NCT00537017|Drug|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O methyl transferase (COMT) inhibitor entacapone.
45389208|NCT05358041|Device|Robotic Bronchoscopy|Replace the Super-D EMN navigational platform with Ion Robotic bronchoscopy platform guided with shape sensing technology
45389209|NCT00348309|Drug|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
45389210|NCT00348309|Drug|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
45389211|NCT00348309|Other|Placebo|Placebo
45502184|NCT02821910|Drug|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
45696295|NCT04355416|Drug|curcumin Oral gel|application of curcumin oral gel after scaling and root planing
45696296|NCT04355416|Procedure|subgingival scaling and root planing|subgingival scaling and root planing without application of curcumin gel
45696297|NCT05620810|Behavioral|neuropsychiatric symptoms|neuropsychiatric symptoms
45696298|NCT03777813|Drug|Durvalumab|Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w) Immunotherapy in experimental arm only: Patients will received concomitantly a maximum of 12 infusions
45696299|NCT03777813|Combination Product|IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)|Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w)
45502185|NCT02821910|Drug|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
45502186|NCT02821910|Drug|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
45502187|NCT02821910|Drug|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
45696300|NCT04355494|Biological|eculizumab|Eculizumab at doses of 900-1200 mg will be administered intravenously (up to 7 doses)
45848650|NCT03728790|Device|Remote Patient Monitoring|Bluetooth-enabled blood pressure cuff to assess whether this technology helps providers collect more data regarding their patients' blood pressures in the postpartum period.
45389212|NCT00348309|Other|Donepezil|Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
45389213|NCT05581433|Other|Topical Cooling Spray|The process of cooling the area to be injected with a cooling spray before the application in order to reduce the pain.
45389214|NCT05581433|Other|Saline spray as Placebo|Application of saline spray without cooling effect to the area to be injected for placebo purposes
45389215|NCT04451837|Drug|Semaglutide|Ozempic s.c. once weekly for 6 months
45389216|NCT04451837|Drug|Dapagliflozin|Forxiga 10 mg p.o. once daily for 6 months
45389217|NCT05356871|Other|VO2max validity and reliability assesment|Reliability assessment of VO2max determination with three repeated measures for two methods.
45389218|NCT05580497|Device|Soft Wearable Robotic Knee System|Power assistance will be provided from the motor to the knee joint
45389219|NCT04003337|Other|Morpho-kinetics selection with time-lapse (Embryoscope) evaluation|Embryos in group B will be selected in blastocyst stage according to morpho-kinetics criteria before the embryo transfer
45389220|NCT05493683|Drug|Disitamab vedotin|2.0mg/kg，q2w
45389221|NCT05493683|Drug|Tislelizumab|400mg，q6w
45389222|NCT01053195|Behavioral|Lifestyle counseling|Non-diabetic high-risk subjects enrolled will be eligible for individual and/or group lifestyle counseling. The intervals of the counseling sessions depend on the glucose levels of the high-risk individuals, every three months for those having prediabetes and every six months for those with normal glucose levels but high risk score.
45502188|NCT02821910|Drug|Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|Low dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
45502189|NCT02821910|Drug|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
45389223|NCT05440487|Other|Iron chelator|There is no treatment allocation. Patients administered approved Iron chelators by prescription that have started before inclusion of the patient into the study will be enrolled.
45389224|NCT01053273|Procedure|Caudal Epidural Injection|Group I will receive caudal epidural injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution
45389225|NCT01053273|Procedure|percutaneous adhesiolysis|Group II will receive percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-particulate betamethasone.
45389226|NCT00440310|Drug|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
45389227|NCT00440310|Procedure|Percutaneous placement of device in liver metastases|Light Source placement will be conducted under placement imaging using ultrasound or CT guidance. No more than four Light Sources will be used at a single treatment session. The Light Sources may be used in a single lesion or in multiple lesions.
45389228|NCT00440310|Device|Interstitial light emitting diodes|200 J/cm per Light Source at 20 mW/cm light energy
45389229|NCT00440310|Drug|FOLFOX4 regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
45389230|NCT00440310|Drug|FOLFIRI regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan
45389231|NCT01055847|Drug|Aztreonam for Inhalation (AI)|Aztreonam for Inhalation
45389232|NCT01055847|Drug|Placebo|Saline Placebo
45389233|NCT02533791|Biological|4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)|one dose, 4×10^10vp/1ml per dose
45389234|NCT02533791|Biological|1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)|two doses, 0.8×10^11vp/1ml per dose, with one dose to each arm at the same time
45389235|NCT02533791|Biological|placebo|
45389236|NCT05426681|Drug|GlyBURIDE Oral Tablet|"Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of spinal cord injury. The dosing regimen involves an initial dose of 1.25mg followed by 11 consecutive doses of 0.625 mg every 6 hours. The total daily dose of Glyburide on Day 1, Day 2, and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.~Intervention: Drug: Glyburide"
45389237|NCT05394935|Other|High-Intensity Exercise|Acute, low-volume HIIT 12x (1min:1min) Working intensity: >85% heart rate reserve Resting intensity: Active rest
45389238|NCT05394935|Other|Moderate-Intensity Exercise|Continuous, MISS 50mins Working intensity: 50-60% heart rate reserve
45389239|NCT01055925|Device|modified polyurethane film dressing (OpSite, Smith&Nephew, London, UK)|
45696301|NCT02982460|Other|Isoinertial + eccentric exercise|A session of isionertial + eccentric exercise covers the activity, strength and endurance of scapular muscles.
45696302|NCT02982460|Other|Eccentric exercise|A session of eccentric exercise covers the strength of scapular muscles.
45696303|NCT03777735|Procedure|human bone graft screw|All patients undergo surgical treatment of osteochondral defects in the knee joint with human bone graft screws.
45389240|NCT01055925|Device|Aquacel® (ConvaTec, Skillman, NJ, USA), sodium carboxy-methylcellulose hydrocolloid polymer dressing|
45389241|NCT00440232|Drug|Frovatriptan|Frovatriptan 5.0 mg orally one time at the start of the 20 hour fast
45389242|NCT00440232|Drug|Placebo|Inert tab identical in appearance to Frovatriptan
45389243|NCT01564199|Drug|salmeterol / fluticasone propionate|100/1000 μg oral capsule
45389244|NCT02533323|Drug|gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
45389245|NCT02533323|Drug|oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
45389246|NCT02533323|Drug|pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
45389247|NCT05379959|Drug|MDMA|Participants will be given 125 mg of MDMA.
45389248|NCT05379959|Drug|Methamphetamine|Participants will be given 20 mg of MA.
45389249|NCT05379959|Drug|placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
45389250|NCT02533479|Other|Caloric restriction|three alternate days weekly along 4 weeks.
45389251|NCT05366465|Other|SMA adult patients|An online questionnaire aimed at collecting demographic and social data, and data concerning activity limitations, participation and quality of life of SMA patients from validated scales : QOLNMD, Rosenberg.
45389252|NCT05329103|Drug|PEEL-224|Lyophilized powder reconstituted with D5W
45502190|NCT03819452|Diagnostic Test|Vitamin D Level|Vitamin D level is measured upon the presentation of the case with ischemic stroke
45696304|NCT04355260|Procedure|Echocardiography-guided Radiofrequency ablation for Hypertrophic obstructive Cardiomyopathy (HOCM).|Echocardiography-guided Radiofrequency ablation for Hypertrophic obstructive Cardiomyopathy (HOCM).
45696305|NCT04347304|Dietary Supplement|Dark chocolate (20 grams) per day providing 508 mg of polyphenols|subjects will be given 21 grams of dark chocolate providing 289 mg of polyphenols per day for 12 weeks.
45696306|NCT04347304|Dietary Supplement|white chocolate (20 grams) with no polyphenols|subjects will be given 21 grams of white chocolate (0 mg polyohenols) per day for 12 weeks
45389253|NCT04791228|Device|Magnetic Resonance-Guided High Intensity Focused Ultrasound|"Magnetic resonance (MR)-guided high intensity focused ultrasound (HIFU) provides precise and controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator without the need for a scalpel or needle.~Additional therapeutic advantages of this modality include its range of bioeffects, including both high temperature tumor ablation via coagulative necrosis, and effects of lower temperature, mild hyperthermia that can help to enhance local drug delivery to tumors. Both tumor ablation and hyperthermia may be employed to potentiate the effects of chemotherapy."
45389254|NCT04791228|Drug|Lyso-thermosensitive Liposomal Doxorubicin|"LTLD combines doxorubicin with lyso-thermosensitive liposomes that can selectively deliver drug to tumors and when exposed to temperatures greater than 40°C, rapidly and locally releases doxorubicin in high concentrations from systemically administered LTLD.~If combined with hyperthermia, doxorubicin will be released in the heated tumor margins and in any areas within the tumor that were not completely ablated and increase the likelihood of complete tumor necrosis. LTLD will extend tumor cell death to the hyperthermic regions in the peri-ablation zones and minimize the possibility of incomplete ablation or tumor recurrence."
45389255|NCT05357885|Diagnostic Test|SARS-CoV-2 Antibody test|SARS-CoV-2 antibody test at Jefferson is Roche Elecsys Anti-SARS-CoV-2 immunoassays performed under FDA's Emergency Use Authorization.
45389256|NCT01031082|Procedure|Middle ear fluid, nasopharyngeal aspirate and urine sample.|Middle ear fluid, nasopharyngeal aspirate and urine sample collection.
45389257|NCT05311553|Procedure|Zona pellucida thinning|Laser-assisted hatching will be conducted using a Laser System with a 1.48-μm diode laser at 300 m W through thinning. The laser thinning will be performed by making 2-3 holes without reaching the inner membrane at a depth of60-80% of the Zona pellucida thickness.
45389258|NCT05311553|Procedure|Zona pellucida drilling|Laser-assisted hatching will be conducted using a Laser System with a 1.48-μm diode laser at 300 m W through drilling. The laser opening will be made from the outside to the inside of the Zona pellucida.
45389259|NCT01323348|Behavioral|Diabetes Education|"The intervention will consist of the following at enrollment and at each follow-up visit (but no more frequently than once every 12 weeks):~Measurement of HbA1c in office with immediate feedback~Measurement of blood pressure with immediate feedback~Assessment of retinopathy risk with immediate feedback~Personalized risk assessment reports based on current HbA1c~Brief assessment of patient understanding of key issues with immediate feedback~Supplemental diabetes management educational materials (provided at baseline only)~Feedback to primary care provider~Email reminder to study participants with email access of individualized risk assessment findings"
45389260|NCT05357807|Procedure|Standard RYGB|Roux-en-Y Gastric bypass
45389261|NCT05357807|Procedure|Extended Pouch RYGB|Roux-en-Y gastric bypass with an extended pouch
45389262|NCT05357807|Procedure|Banded extended pouch RYGB|Roux-en-Y gastric bypass with a banded extended pouch
45389263|NCT02968836|Dietary Supplement|Blend of amino acids|The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
45389264|NCT02968836|Dietary Supplement|Maltodextrin only|The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
45389265|NCT04003181|Drug|Antibiotics|Ciprofloxacin or Rifaximin for 10 days.
45389266|NCT04003181|Drug|Bile Acid Binder|Cholestyramine or Colesevelam lifelong.
45389267|NCT05286047|Dietary Supplement|Bifidobacterium longum CCFM1029|Subjects take one capsule containing Bifidobacterium longum CCFM1029 daily at bedtime.
45389268|NCT05286047|Dietary Supplement|Placebo|Subjects take one capsule containing maltodextrin daily at bedtime.
45389269|NCT04768608|Drug|PD1-PSMA-CART cells|PD1-PSMA-CART cells will be given IV at split doses
45389270|NCT01031316|Other|Nondisclosure of screening echocardiogram results|Subjects will be randomized to nondisclosure of screening echocardiogram results.
45389271|NCT01031316|Other|Disclosure of screening echocardiogram results|Subjects will be randomized to disclosure of screening echocardiogram results.
45389272|NCT00356889|Drug|erlotinib hydrochloride|Given orally, 150 mg, once daily.
45389273|NCT00356889|Biological|bevacizumab|Given IV, 5mg/kg on days 1 and 15 every cycle
45389274|NCT05186363|Drug|Chemopreventive Agent - SPAQ|Seasonal malaria chemoprevention (SMC) is a highly effective community-based intervention to prevent malaria infections in areas where the malaria burden is high and transmission occurs mainly during the rainy season. It involves administering monthly courses of sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) during this peak transmission period to those most at risk: children 3-59 months.
45502191|NCT05707910|Biological|EBV immunological agent|Low-dose group:2*10^7 Medium-dose group:5*10^7 High-dose group:2*10^8
45502192|NCT05707676|Drug|LB4330|LB4330
45502193|NCT03972956|Other|No intervention will be given to patients.|Samples are collected at the time of a scheduled surgery that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
45502194|NCT02817776|Device|THERMOCOOL SMARTTOUCH® SF catheter|Radiofrequency Ablation
45502195|NCT03138655|Drug|Vedolizumab|Vedolizumab IV infusion.
45502196|NCT02036138|Procedure|Laparoscopic Sleeve Gastrectomy|
45502197|NCT02036138|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
45389275|NCT05186363|Drug|Control Test - no drugs given|This is where children aged 3-59 months do not receive any chemoprevention drugs but do receive health promotion messages and visit from health workers similar to the chemoprevention SPAQ arm.
45389276|NCT04741308|Behavioral|cognitive behavior therapy|The CBT intervention is a 8-times group-based intervention that meets 2-3 weeks.Each session will be performed during chemotherapy and will last for 60 min, including 45 min cognitive behavior therapy and 15 min relaxation training.Our CBT intervention is designed to be conducted in groups of 3 to 6 patients led by two group facilitators. Group leaders will: guide participants relaxation training, develop a supportive group environment, encourage emotional expression, assist participants develop a sense of self-confidence, identify maladaptive coping and encourage adaptive coping responses.
45502198|NCT02036138|Drug|Advanced Medical Therapy|
45502199|NCT03562442|Behavioral|Smoking cessation|Smoking cessation with or without professional / medical support
45502200|NCT03903536|Procedure|Thrombectomy|A small procedure where surgeons make a cut in the hemorrhoid and drain the blood.
45502201|NCT03903536|Procedure|Hemorrhoidectomy|A surgery to remove the hemorrhoid, including the blood vessels and clot.
45389277|NCT05167565|Other|MRI/DTI|High resolution MRI scans will be acquired from each infant at three time points (~3, 6, and 12 months), while they are naturally asleep to measure the progressive myelination of the major brain fiber tracks, grey matter maturation, and to create generative models for source reconstruction of EEG sensor data.
45389278|NCT05167565|Other|EEG|EEG will be used to record infant brain activity during reaching and grasping actions to analyze beta activity
45389279|NCT05167565|Other|Eye Tracking|Infants will be presented with the experimental stimuli, which will consist of images of adults displaying different facial expressions and non-social images (e.g. a cross, a geometric pattern). This procedure is based on commonly used eye tracking paradigms designed to assess attention biases in infancy. Infant eye movement and position will be measured during stimuli presentation.
45389280|NCT05167565|Other|Ages and Stages Questionnaire (ASQ)|"The parents will be asked to complete the ASQ questionnaire (Developmental questionnaire).~ASQ-3 has 5 aspects: Communication, Gross motor, Fine motor, Problem solving and Personal-Social Each aspect has 6 questions, if the answer is Yes, score = 10, Sometimes = 5 and Not yet = 0. ASQ-3 average = average score of 5 aspects."
45389281|NCT05167565|Other|Infant Behavior Questionnaire Revised (IBQ-R)|"The parents will be asked to complete the IBQ-R questionnaire (Developmental questionnaire).~The 191-item instrument provides scores on 14 temperament scales which in turn cluster into 3 overarching factors: Positive Affectivity/Surgency, Negative Emotionality, and Orienting/Regulatory Capacity. Items are rated on a 7-point scale."
45389282|NCT05167565|Other|Beck Depression Inventory (BDI)|"The parents will be asked to complete the BDI questionnaire (Mental health questionnaire).~Scale is a 21-item self-reported questionnaire which measures the existence and severity of symptoms of depression. Scores for each symptom are added up to obtain the total scores for all 21 items. Total score ranges from 0-63; of which 0-8 is considered no depression, 0-13 is minimal depression, 14-19 is mild depression, 20-28 is moderate depression and 29-63 is severe depression."
45389283|NCT05167565|Other|The Brief Fear of Negative Evaluation Scale (BFNE)|"The parents will be asked to complete the BFNE questionnaire (Mental health questionnaire).~The BFNE measures anxiety associated with perceived negative evaluation. This scale is composed of 12 items describing fearful or worrying cognition. Scores from for each item are added up to obtain the total score."
45389284|NCT05167565|Other|Edinburgh Postnatal Depression Scale|"The parents will be asked to complete the Edinburgh Postnatal Depression Scale (Mental health questionnaire).~This is a set of 10 screening questions that can indicate whether a parent has symptoms that are common in women with depression and anxiety during pregnancy and in the year following the birth of a child. The total score is calculated by adding the numbers selected for each of the 10 items. If the parent's score is 10 points or above, they should speak to a health professional about those symptoms."
45389285|NCT03742323|Drug|Idelalisib|Idelalisib Dose: 100, 150, 200 or 300 mg (in four cohorts of six patients each).
45389286|NCT04715022|Drug|Ascorbic acid solution (American Regent Laboratories Inc.)|"Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min."
45389287|NCT04715022|Drug|Saline|Placebo (saline) will be administered
45389288|NCT05137691|Other|Adapted NHS weight management 1:1 programme|Adapted NHS 1:1 weight management programme with a low carbohydrate dietary focus, incorporating enhanced behaviour change via telehealth, step count and pedometer
45389289|NCT05137691|Other|NHS 1:1 weight management programme|NHS 1:1 weight management programme
45389290|NCT01031394|Other|Frequency of Aerobic/Resistance Training - 3 to 3|comparing group results based upon frequency of exercise
45389291|NCT05110079|Device|ByCross Atherectomy and Thrombectomy|"After assessment of the lesion by angiography the ByCross is advanced over a 0.035 guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage with guidewire is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the complete procedure is to achieved more than 70% opening."
45389292|NCT01031472|Drug|GSK2248761 formulation 1|100mg GSK2248761 formulation 1- fasted 100mg GSK2248761 formulation 1 - with food (moderate fat meal)
45389293|NCT01031472|Drug|GSK2248761 reference formulation|GSK2248761 100mg Gelucire reference capsule with food
45389294|NCT01031472|Drug|GSK2248761 formulation 3|100mg GSK2248761 formulation 3 fasted 100mg GSK2248761 formulation 3 with food (moderate fat meal)
45389295|NCT01031472|Drug|GSK2248761 formulation 2 or 4|100mg GSK2248761 formulation 2 or 4 - fasted 100mg GSK2248761 formulation 2 or 4 - with food (moderate fat meal)
45389296|NCT05091671|Other|Free From Pain Exercise Programme Variation 1|Includes the initial 45-minute consultation + the exercise booklet + the 12 reasons to exercise leaflets + the 12 metaphor leaflets.
45389297|NCT05091671|Other|Free From Pain Exercise Programme Variation 2|Includes the initial 45-minute consultation + the exercise booklet + the 12 reasons to exercise leaflets + the 12 metaphor leaflets, and the 12 Zoom online sessions.
45502202|NCT05707520|Drug|enteric-coated mycophenolate (MPAs)|Immunosuppression protocol with enteric-coated mycophenolate sodium
45502203|NCT05707520|Drug|None MPA|Immunosuppression protocol without enteric-coated mycophenolate sodium
45502204|NCT04412785|Drug|Cyclosporine|• The initial dose will be 9 mg/kg/day oral divided q12h. For IV, the dose will be 3mg/kg/day by continuous IV infusion.
45848651|NCT03727854|Dietary Supplement|Premeal protein enriched bar|Subjects in the intervention group will intake protein enriched bar 15 minutes before each meals (at least twice a day).
45848652|NCT03727854|Behavioral|Dietary modification|Subjects in this group will follow diabetes diet education.
45389298|NCT00356811|Drug|Lapatinib oral tablets|Lapatinib will be given as tablets contain 410 mg of lapatinib ditosylate monohydrate, equivalent to 250 mg lapatinib free base per tablet. Subjects will be given a 4 week supply of lapatinib tables and instructed to take 6 tablets daily (1500 mg daily dose) orally at the same time each day. Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent.
45389299|NCT00356811|Drug|Paclitaxel infusion|Subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle). Subjects will be treated with paclitaxel for at least 6 months, and may continue on paclitaxel at the discretion of the Investigator, or discontinued sooner if the subject has disease progression, an unacceptable toxicity or withdraws consent.
45389300|NCT05357339|Other|20% Albumin|100ml boluses 20% Albumin
45389301|NCT05357339|Other|Crystalloid|250ml bolus of crystalloid
45389302|NCT00439218|Drug|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD.
45389303|NCT05013749|Procedure|Hysterectomy|Hysterectomy: An incision will be made above the level of the placenta, delivering the newborn. Uterotonics will be administered, and spontaneous delivery of the placenta will be awaited using gentle traction. The absence of spontaneous separation of the placenta will confirm the diagnosis of PAS, the patient will undergo to hysterectomy. The complete removal of the uterus will be attempted, including the cervix, the duration of the intervention and intraoperative blood loss will be recorded, as well as the damage to organs neighboring the uterus. In this arm of the study, to hysterectomy will be performed in 100% of patients
45389304|NCT05013749|Procedure|Partial Myometrial Resection|Partial myometrial resection: The technique described by Palacios-Jaraquemada et al5. will be followed. Briefly, the uterus will be dissected to free it from the posterior wall of the bladder to the cervix. The vesico-uterine vessels will be ligated and the parametrial space will be visualized. The hysterotomy will be performed in the upper segment, immediately above the area of invasion of the myometrium. The entire invaded myometrium and the entire placenta will be removed. The uterus will repair itself in one or two layers. Intrauterine balloon tamponade will be used if indicated.
45389305|NCT01056003|Other|Endoscopy|observational endoscopy in all patients an EGD is planned anyway
45389306|NCT02533635|Dietary Supplement|A Master Ganoderma Detox Tea|A Master Ganoderma Detox Tea is consisted of GANODERMA, HERBA HOUTTUYNIAE, GLYCYRRHIZAE RADIX ET RHIZOMA and RUCTUS MOMORDICAE.
45389307|NCT01030614|Drug|Dexamethasone|intravenous dexamethasone 8 mgr before laparoscopic cholecystectomy or intravenous placebo before laparoscopic cholecystectomy
45389308|NCT01030614|Drug|placebo|One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
45389309|NCT03991689|Behavioral|solution-focused group therapy|Participants began a 90-minute solution-focused pain management group, which lasted for six weeks, and after the group ended, the questionnaire post-test was carried out, and a total of 26 participants thus completed their group journey. The group effect was evaluated by the difference between the scores of the questionnaires before and after the group.
45389310|NCT01030692|Drug|Placebo|The placebo groups will receive the same dosage throughout the study.
45389311|NCT01030692|Drug|Rivastigmine 3 mg|The 3 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-9, and 3 mg in the morning of Day 10.
45389312|NCT01030692|Drug|Huperzine A 0.4 mg|The 0.4 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-9, and 0.2 mg in the morning of day 10.
45389313|NCT01030692|Drug|Rivastigmine 6 mg|The 6 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-5, 3 mg in the morning and evening of Days 6-9, and 3 mg in the morning of Day 10.
45389314|NCT01030692|Drug|Huperzine A 0.8 mg|The 0.8 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-5, 0.4 mg in the morning and evening of Days 6-9, and 0.4 mg in the morning of Day 10.
45389315|NCT01056081|Other|Inspiratory muscle training|"The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).~The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training."
45389316|NCT04950959|Device|Hands-free, user-controlled robotic system intended to assist in the planning and advancement of an instrument during CT guided percutaneous procedures. T|The system is used for trajectory planning and is intended to assist the physician in the positioning of an instrument, such as a needle, where CT imaging is used for target trajectory planning and intraoperative tracking. The XACT ACE Robotic System uses a computerized quantitative guidance system, which provides real-time, accurate needle guidance, including advancement and steering of the needle from the entry point on the subject's body to the target point within the body.
45389317|NCT03141060|Drug|Delamanid|Administered orally; dosing will be based on participants' age and weight.
45848653|NCT03544242|Other|Control|A saline infusion will be administered during the pre-isolation and post-isolation phases.
45389318|NCT03141060|Drug|Optimized multidrug background regimen (OBR) for children with MDR-TB|Non-study prescribed OBR will vary according to local, national, and/or international guidelines for treatment of children with MDR-TB. Administered in addition to DLM for 24 weeks.
45389319|NCT01051713|Behavioral|Technology Supported|Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
45389320|NCT01051713|Behavioral|Standard|"Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the Keeping Track form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits."
45389321|NCT04922021|Drug|LEO 138559|LEO 138559 is an antibody given by injection just under the skin.
45389322|NCT04922021|Drug|LEO 138559 placebo|LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except the medical ingredient LEO 138559.
45389323|NCT03138252|Drug|Oxytocin|
45389324|NCT05021549|Device|nasal prong|apneic preoxygenation group (30 patients), will receive 10 L/ min of O2 via nasal prong during preintubation apnia
45389325|NCT04994561|Drug|Study Drugs and Nutritional Supplements|"Step 1: 500 mg of metformin and increase their dose 500 mg every 2 weeks up to 2000 mg or until tolerable.~Step 2: Once at tolerable daily metformin dose, subjects will take 140 mg of dasatinib along with 58 mg to 174 mg (based on body weight) bio-quercetin and 44.5 mg bio-fisetin. Subjects will take dasatinib, bio-quercetin and bio-fisetin for 2 consecutive days as described 4 times over one year (every 3 months) while participating on this study.~Step 3: Two weeks after the first dasatinib dose is complete, subjects will start taking daily nutritional supplements of 1,500 mg glucosamine, 600 mg nicotinamide riboside and 500 mg trans-resveratrol.~Step 4: Two weeks after starting daily supplements in Step 3, subjects will take a once weekly 6 mg dose of rapamycin.~Once subject is taking rapamycin, they will continue on this intervention for 12 months."
45389326|NCT03096366|Device|Blood flow restriction|With BFR, exercises will be performed at 30% one-rep max with the BFR cuff placed around the proximal thigh and inflated to 80% of limb occlusion pressure (avg: 150 mmHg).
45696307|NCT00928720|Device|CES device|Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
45389327|NCT03096366|Other|Physical therapy|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
45389328|NCT01030770|Drug|Ranibizumab|Single intravitreal injection of 500 micrograms of ranibizumab (0.05mls).
45389329|NCT01030770|Drug|0.9% Sodium Chloride|Single subconjunctival injection of 0.05mls of 0.9% w/v sodium chloride
45389330|NCT04941443|Drug|Methadone Pill|All participants will be given a 5mg methadone tablet to be taken immediately following the misoprostol dose.
45389331|NCT04941443|Drug|Ibuprofen|All participants will be provided additional analgesics (ibuprofen 800mg x4 tabs) available for use as needed every eight hours.
45389332|NCT01030848|Device|Total Knee Replacement (LCS rotating platform)|
45389333|NCT04876157|Diagnostic Test|Artificial intelligence-aimed point-of-care ultrasound image interpretation system|improve the sensitivity and specificity of the AI-aimed ultrasound interpretation system
45389334|NCT03994692|Device|PEEK eminoplasty|making obstacle at eminence using patient specefic PEEK device
45696308|NCT00928720|Device|sham device|The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
45696309|NCT00934024|Drug|varenicline|Participants will be treated with a standard course of varenicline, 0.5 mg 1 tablet every day for 3 days, then 0.5 mg 1 tab twice a day for four days, and 1 mg 1 tablet twice a day for three months.
45389335|NCT03994692|Procedure|autogenous onlay grafting eminoplasty|making obstacle at eminence using chin graft
45389336|NCT04868981|Drug|GST-HG141 tablets|Administrate GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
45389337|NCT04868981|Drug|Matching Placebos for GST-HG141 tablets|Administrate the placebos for GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
45389338|NCT01030926|Drug|insulin degludec|0.4 U/kg body weight injected subcutaneously (under the skin), single dose
45389339|NCT01030926|Drug|insulin glargine|0.4 U/kg body weight injected subcutaneously (under the skin), single dose
45696310|NCT04360954|Diagnostic Test|Diagnostic test|There is no intervention. This study will test deidentified archived biosamples.
45696311|NCT04361032|Drug|Tocilizumab Injection|Tocilizumab (LOC) (8mg/ kg per day) (1 injection per infusion). Only on the 1st day (D0)
45696312|NCT04361032|Drug|Deferoxamine|Deferoxamine (Desferal 500 mg, powder, and solvent for IV solution for injection)
45389340|NCT04822259|Device|JOURNEY II BCS Total Knee System|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II BCS Total Knee System
45389341|NCT04822259|Device|JOURNEY II CR Total Knee System|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II CR Total Knee System
45389342|NCT00535223|Behavioral|Group Based Exposure Therapy|GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking.
45389343|NCT00535223|Behavioral|Present Centered Group Therapy|"Present Centered Group Therapy includes psych-education about PTSD and a problem solving here and now focus."
45389344|NCT00536939|Drug|Enzastaurin|1125 milligrams (mg) loading dose on Day 1 of Cycle 1 only then 500 mg oral once daily, until disease progression
45389345|NCT00536939|Drug|Bevacizumab|10 milligrams per kilogram (mg/kg) intravenously, Days 1 and 15 every 28 days, until disease progression
45389346|NCT00536939|Drug|Paclitaxel|90 milligrams per square meter (mg/m^2), intravenously, Days 1 ,8, and 15 every 28 days until disease progression
45389347|NCT00536939|Drug|Placebo|Oral, daily, until disease progression
45389348|NCT04597697|Drug|Insulin icodec|Insulin icodec will be investigated in participants with impaired liver function and subjects with normal liver function. Administered as a single dose subcutaneously (under the skin) The study will last for about 8 weeks.
45502205|NCT03689101|Procedure|Endometrial biopsies|Endometrial biopsy was performed precisely 7 days after LH surge (LH+7)
45502206|NCT02820038|Behavioral|Medication Guides|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
45502207|NCT02820038|Behavioral|SMART Program|The investigators will determine if the effectiveness of written medication information can be increased by Gist Reasoning Training, delivered via the SMART Program, which is designed to enhance patients' ability to extract meaningful gist from complex information.
45389349|NCT03883217|Device|PDVibe2|The PDVibe2 is owned by Resonate Forward, LLC and will be loaned to Virginia Commonwealth University (VCU) for this project. The device is non-invasive, lightweight, untethered, contains a rechargeable battery, and is worn on both feet and ankles. PDVibe2 delivers vibration when activated by an easy to access switch on the device or by remote. The internal circuitry has been miniaturized, is encased in a small box, and is attached to the ankle using a soft flexible band.
45389350|NCT05355623|Procedure|Vaginal Repair|Vaginal Repair will be done either by application of sterilized (gamma irradiated) amniotic membrane or by Classical repair
45389351|NCT00347919|Drug|pazopanib (GW786034) 400 mg|400 mg administered orally once daily
45389352|NCT00347919|Drug|lapatinib (GW572016) 1500 mg|1500 mg administered orally once daily.
45389353|NCT00347919|Drug|lapatinib (GW572016) 1000 mg|1000 mg administered orally once daily
45389354|NCT00347919|Drug|pazopanib (GW786034) 800 mg|800 mg administered orally once daily
45389355|NCT03987321|Device|Infrarenal vena cava filter placement|Patients who are enrolled in this study are assigned to receive either Denali or Celect filter in the inferior vena cava. All other procedures are the same in both groups
45502208|NCT02820038|Behavioral|Drug Facts Boxes|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
45502209|NCT01348867|Other|Structured care led by a nurse consultant|"For the intervention group, patients will be followed up according to the following protocol. The structured care team consists of:~i) Diabetes Nurse Consultant to reinforce compliance; educate patients on insulin injection techniques and reinforce self-care including self blood glucose monitoring and lifestyle interventions, titration of medication.~ii) Technical Service Assistance to remind patients to take medications and/or give insulin injection, monitor blood glucose as prescribed, attend their next clinic appointment, encourage patients to report all side effects, self initiated change in regimen or concerns to diabetes nurse consultant and/or their doctors at the next follow up visit."
45502210|NCT01352611|Drug|baclofen, intrathecal|Patients will undergo a standard intrathecal baclofen trial procedure. This procedure consists of a single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
45502211|NCT01352689|Drug|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
45502212|NCT01352689|Drug|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
45502213|NCT03688399|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > intermediate > near
45502214|NCT03688399|Device|IOL implantation comparator|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > near > intermediate
45502215|NCT01357213|Drug|XOMA 3AB|Single intravenous infusion of XOMA 3AB in three cohorts at different concentrations.
45502216|NCT01357213|Other|Placebo|Normal saline 100 ml
45389356|NCT01051869|Procedure|Simple decompression|"Fracture fixation will be performed through a posterior approach, as this provides excellent visualization of the distal fragments. A triceps split will be used to expose the distal humerus. A midline incision will be made from proximally to distal onto the shaft of the ulna. Equal portions of the triceps muscle will be reflected medially and laterally, with use of sharp dissection to remove the triceps insertion from the olecranon. The ulnar nerve will be identified and protected proximal and distal to the medial epicondyle. Fracture fixation will be performed after anatomic reduction using standard fixation techniques and plate fixation on both the medial and lateral column.~In the simple ulnar nerve decompression group, no further treatment of the ulnar nerve will be undertaken."
45696313|NCT04747119|Other|muscle energy technique|the patient was supine and the therapist fix the lower limb of the affected side then ask the patient to perform isometric contraction for abductors maintained for 3-5 seconds, then the patient was instructed to stop, exhale and relax then the therapist perform further adducted the patient's knee of the affected side as a stretching exercise for Three to five repetitions of these directions were performed.
45389357|NCT01051869|Procedure|anterior subcutaneous transposition|In the anterior transposition of the ulnar nerve group, the ulnar nerve will be placed subcutaneously anterior to the medial epicondyle free from any pressure.
45389358|NCT03987087|Radiation|Radiation|"Thoracic intensity modulated radiation therapy (IMRT)~+EGFR TKI combination Thoracenteral innfusion chemotherapy or Thoracenteral infusion chemotherapy combination Systemic chemotherapy"
45389359|NCT03987087|Drug|Chemotherapy|EGFR TKI combination Thoracenteral innfusion chemotherapy or Thoracenteral infusion chemotherapy combination Systemic chemotherapy
45389360|NCT03987243|Behavioral|Structured Pressure Ulcer Prevention Education|Structured education for performance weight shift maneuvers and pressure ulcer prevention will occur during the initial visit for each subject. The education method used aligns with principles of the social cognitive theory to facilitate learning. The purpose in providing the education is to ensure all of the participants receive uniform instruction in how to perform weight shifts and to facilitate understanding of the importance of completing them as a protective measure against pressure ulcer development. Because each participant will come into the study at varying levels of understanding about pressure ulcer risk and knowledge of how to complete weight shift maneuvers, the education component is critical to ensure all participants are provided with the same information in the same way.
45389361|NCT03987243|Other|Mobile Seat Interface Pressure Mapping System (IPM)|This mobile IPM system was designed to provide visual information about seat interface pressure distribution to compensate for lack of sensation on the sitting surface. This variable will be toggled on and off between the intervention and control phases of the study. The participants will have access to the visual feedback while learning how to complete weight shift maneuvers at the initial visit and then again at home during the intervention phases (weeks 2 and 4). During the control phases (weeks 1 and 3), they will not have access to the visual feedback from the pressure map
45389362|NCT00439140|Biological|botulinum toxin Type A|Botulinum toxin Type A injection into the detrusor.
45389363|NCT00439140|Drug|Normal Saline (Placebo)|Placebo (Normal Saline) injection into the detrusor.
45389364|NCT00356421|Drug|Inhaled Human Insulin (Exubera®)|Preprandial inhaled insulin regimen and administration of insulin glargine QD
45389365|NCT00356421|Drug|Insulin lispro (Humalog)|Subcutaneous insulin regimen of pre-prandial insulin lispro and administration of insulin glargine QD.
45389366|NCT01324869|Biological|KH902|Intravitreal injection of 0.5mg/eye/time KH902
45389367|NCT03990129|Drug|Metamizole|One week treatment with metamizole (500 mg tablets, 2-2-2)
45389368|NCT01051947|Drug|Nebivolol|10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks
45502217|NCT01348945|Other|conventional ACL rehabilitation program|Conventional post-operative physical therapy exercises and rehabilitation, designed for ACL reconstruction for 6 months to 9 months.
45502218|NCT01357291|Behavioral|Recidivism Reduction Program|Assigned to the 21-module Recidivism Reduction Program
45502219|NCT01357291|Behavioral|Business-as-usual|Inmates who receive standard programming offered by New Mexico Department of Corrections prior to release.
45502220|NCT01352767|Device|InsuPad|Heating pad
45502221|NCT02819804|Drug|Dasatinib|Given PO
45848654|NCT03544242|Drug|Pre-Isolation Infusion|A nitrite infusion will be administered during the pre-isolation phase and a saline infusion will be administered during the post-isolation phase.
45389369|NCT01051947|Drug|Metoprolol|dosage prescribed prior to starting on study
45389370|NCT01052025|Drug|Curcumin|curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months
45389371|NCT00443820|Drug|terbinafine|Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks
45389372|NCT00443820|Drug|Placebo|Vehicle (placebo) once daily for 48 weeks
45502222|NCT02819804|Other|Laboratory Biomarker Analysis|Correlative studies
45502223|NCT02819804|Biological|Nivolumab|Given IV
45389373|NCT00443820|Drug|terbinafine|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks
45389374|NCT00443820|Drug|Placebo|Vehicle (placebo) once daily for 24 weeks
45502224|NCT02819804|Other|Pharmacological Study|Correlative studies
45502225|NCT02819726|Biological|SAIT101|1,000 mg i.v. of SAIT101 on Day 1 and 15. 1,000 mg i.v. of SAIT101 on week 24 and 26 for eligible patients.
45389375|NCT00438672|Drug|Placebo Injection|Injection without steroid
45389376|NCT00438672|Drug|Steroid (dexamethasone) Injection|Injection with steroid (dexamethasone)
45389377|NCT01027260|Drug|Itopride HCI 50 mg|Variable dosing
45389378|NCT01027260|Drug|Itopride HCI 100 mg|Variable dosing
45389379|NCT01027260|Drug|Placebo|Variable dosing
45389380|NCT01033968|Procedure|retina photocoagulation|Each patient had one eye treated with infrared laser (diode, 810nm wavelength) and the other eye treated with green laser (frequency-doubled solid state laser, diode-pumped, with 532-nm wavelength
45389381|NCT01034046|Other|Low Carbohydrate Diet|Low carbohydrate diet (45% carbohydrate, 35% fat and 20% protein diet) administered utilizing meal replacements.
45389382|NCT01034046|Other|Low Fat Diet|Low fat diet (60% carbohydrate, 20% fat and 20% protein diet) administered utilizing meal replacements.
45389383|NCT00438360|Drug|Cyclosporine A microemulsion|Oral soft gelatin capsules of Cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
45389384|NCT00438360|Drug|Placebo|Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
45389385|NCT00536471|Drug|Duloxetine hydrochloride|
45389386|NCT00536471|Drug|Placebo|
45389387|NCT00359619|Biological|CervarixTM|Subjects were administered three doses of HPV vaccine
45502226|NCT02819726|Biological|MabThera|1,000 mg i.v. of MabThera® on Day 1 and 15. 1,000 mg i.v. of MabThera® on week 24 and 26 for eligible patients.
45502227|NCT02819726|Biological|Rituxan|1,000 mg i.v. of Rituxan® on Day 1 and 15. 1,000 mg i.v. of Rituxan® on week 24 and 26 for eligible patients.
45696314|NCT04747119|Other|conventional selected physical therapy|"life style modification~Transcutaneous electrical nerve stimulation (TENS)~Flexibility stretching exercises to the hip flexors"
45696315|NCT04360798|Other|Unilateral Exercise Group|Exercise programs will be practiced 60 days, 2 days a week for 4 weeks. The entire exercise protocol will be carried out under the supervision of a physiotherapist. During the treatment session, participants exercises will only be done for 60 minutes with the affected lower extremities.
45696316|NCT04360798|Other|Bilateral Exercise Group|Exercise programs will be practiced 60 days, 2 days a week for 4 weeks. The entire exercise protocol will be carried out under the supervision of a physiotherapist. During the treatment session, participants will complete their exercises with both lower extremities for 30 minutes.
45389388|NCT00359619|Biological|HPV investigational vaccine GSK568893A, different formulations|Subjects were administered three doses of HPV investigational vaccine
45389389|NCT00437658|Drug|Elagolix|Provided as tablets for oral administration
45389390|NCT00437658|Drug|Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)|Provided for subcutaneous injection in a prefilled syringe, 104 mg/0.65 mL per syringe.
45389391|NCT00437658|Drug|Placebo to Elagolix|Matching placebo tablets for oral administration
45389392|NCT00437658|Drug|Placebo to DMPA-SC|Matching placebo for subcutaneous injection in a pre-filled syringe
45389393|NCT04689516|Device|Thoracic fluid content estimation|The patient will be monitored for thoracic fluid content and LUS score. The infusion will stop if TFC reaches 40 k ohm-1 or after completion of the infused volume. LUS evaluation will be done before the start and after the end of the infusion.
45389394|NCT03808415|Device|EMG-driven|The EMG signals are processed and can be visualized with visual feedback to make sure the user actively engaging throughout a therapy session.
45389395|NCT03757793|Device|FORE-SIGHT ELITE monitor|At end of surgery, one sensor of the FORE-SIGHT Elite monitor is placed on the DIEP flap or two sensors in case of bilateral DIEP flaps for monitoring perfusion and oxygen consumption in the free flap. A control sensor of the FORE-SIGHT Elite monitor placed on the abdomen where tissue is taken to perform the DIEP flap. This sensor reflects normal tissue oxygenation. Data obtained from the FORE-SIGHT Elite monitor will be compared to data obtained from physical examination, which is standard of care for flap monitoring.
45389396|NCT04002635|Drug|Letrozole|Letrozole ovulation induction
45502228|NCT02816138|Drug|Nicotine|Open-label transdermal nicotine patch
45502229|NCT02036060|Drug|docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d|Docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d in 21 day cycles.
45502230|NCT02036060|Drug|docetaxel 75 mg/m2 + prednisone 10 mg/d|Docetaxel 75 mg/m2 plus prednisone 10 mg/d in 21 day cycles.
45502231|NCT02815670|Drug|Idarucizumab|
45696317|NCT03552003|Other|Treatment for clinical practise|Prospective data collection with the aim to to develop a prognostic index for elderly patients with newly diagnosed cHL
45696318|NCT00928954|Drug|gabapentin|increasing to 1200 mg/day
45696319|NCT00928954|Drug|memantine|increasing to 40 mg/day
45696320|NCT04355026|Drug|Bromhexine Oral Tablet and/or hydroxychloroquine tablet|bromhexine 16 mg TID hydroxychloroquine 200 mg BID
45696321|NCT04762485|Biological|Humanized CD7 CAR-T cells|Split intravenous infusion of CD7 CAR-T cells [dose escalating infusion of (0.5-10)x10^6 CD7 CAR-T cells/kg
45696322|NCT04347070|Other|Phsyiotherapy|To observe if patients with COVID-19 benefice of physiothersapy, which kind and how many time
45389397|NCT04002635|Drug|estradiol valerate|hormonal replacement therapy
45389398|NCT03828747|Drug|Semorinemab|Participants will receive semorinemab every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period. Semorinemab will be administered Q4W in the OLE period.
45389399|NCT03828747|Drug|Placebo|Participants will receive placebo every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period.
45389400|NCT03828747|Drug|[18F]GTP1|[18F]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
45389401|NCT01052181|Drug|Cholecalciferol|Oral Cholecalciferol sachets 120,000 IU monthly for 1 year
45389402|NCT01052181|Drug|placebo|2 sachets monthly for an year
45389403|NCT01056237|Drug|Multi-target therapy|Tacrolimus (1-3mg/d) and mycophenolate mofetil(0.5-0.75g/d)
45389404|NCT01056237|Drug|Azathioprine|1.0-2.0mg/kg/d
45389405|NCT02533557|Device|stimuplex insulated needle|"2P2I group: nerve stimulating needle is advanced twice with the up-down direction at the different puncture site and LA is injected 15 mL at a time.~1P2I group: nerve stimulating needle is advanced twice with the up-down direction at the same puncture site and LA is injected 15 mL at a time."
45389406|NCT02533557|Drug|lidocaine mixed with epinephrine|2P2I group and 1P2I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time) with the up-down direction at the different puncture site. 1P2I group is injected LA at equally divided doses with the up-down direction at the same puncture site.
45389407|NCT03986775|Dietary Supplement|isomaltulose|replacement of sucrose with low-glycemic isomaltulose
45389408|NCT03986775|Dietary Supplement|sucrose|conventional beverage with sucrose
45389409|NCT00356265|Drug|Procedure: Regional phenylephrine arterial infusion|
45389410|NCT01056471|Other|Autologous mesenchymal stem cells from adipose tissue.|Intravenous infusion of autologous mesenchymal stem cells.Dose:4*10e6 cells/Kg.
45389411|NCT01056471|Other|Autologous mesenchymal stem cells from adipose tissue.|Intravenous infusion of autologous mesenchymal stem cells. Dose: 10e6 cells/Kg.
45389412|NCT01052259|Drug|Deoxyspergualin|100mg/vial as active substance; Deoxyspergualin at 3-5 mg/kg/day by 1-3 iv infusion will be given once a day for 5 to 7 days each cycle every month; Total cycle treatment will be 6.
45389413|NCT01056549|Drug|exenatide|In each study, the subjects will receive s.c. injection of either exenatide or matched placebo, in the Metabolic Testing Center and 2 hours prior to the start of the lipoprotein turnover study. Subjects will be blinded with regard to the treatments.
45696323|NCT04762173|Device|Online self-help intervention|Access to two online, self-guided programs available on the SilverCloud Health website.
45389414|NCT01052337|Drug|anaesthetics: sevofluorane|0.5%of sevofluorane with air
45389415|NCT00535145|Drug|Treatment as usual (TAU), Paliperidone ER|Treatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
45389416|NCT01052415|Behavioral|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
45389417|NCT01056627|Drug|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
45696324|NCT04367350|Diagnostic Test|laboratory biomarkers|creatine kinase, troponin, urine myoglobin, and autoimmune antibodies
45389418|NCT03590327|Device|Transcranial Magnetic Stimulation|rTMS
45389419|NCT03990831|Diagnostic Test|Functional near-infrared spectroscopy (fNIRS)|Functional near-infrared spectroscopy (fNIRS) measurement
45389420|NCT03562793|Behavioral|Communication and Activation in Pain to Enhance Relationships and Treat Pain with Equity (COOPERATE)|. COOPERATE seeks to improve patient activation in minority Veterans with chronic pain by focusing on two major skill sets: 1) goal clarification and prioritization, and 2) communication skills (Table 1). By understanding, clarifying, and prioritizing goals, and having the skills to communicate their goals, priorities, and preferences to providers, Veterans will gain knowledge, confidence, and skills to be actively involved in managing their chronic pain. The intervention consists of 6 total sessions delivered individually over 12 weeks: 4 sessions focused on teaching skills related to goal clarification/prioritization and communication (30-minutes each), delivered weekly for the first 4 weeks, plus 2 booster sessions (20-25 minutes each) delivered once per month for the next 2 months.
45389421|NCT03985995|Drug|CBD 800 mg p.o|cannabidiol solution 100 mg/ml 8 ml in single-dose containers for per os administration. After a washout period of at least two weeks, the treatment group will be receiving a single-dose of the placebo solution 8 ml as a second intervention.
45389422|NCT03985995|Drug|Placebo p.o|single dose of oral placebo solution 8 ml matched to the IMP. After a washout period of at least two weeks, the control intervention group will be receiving the cannabidiol solution 100 mg/ml 8 ml as a second intervention.
45389423|NCT04273061|Drug|Atezolizumab|1200 mg by intravenous infusion every 3 weeks as tolerated
45389424|NCT01053585|Drug|Baclofen|Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)
45389425|NCT01053585|Drug|Placebo|Placebo single 'dose' 90 minutes prior to study
45389426|NCT03986697|Drug|Biktarvy|Fixed dose combination preparation containing bictegravir, tenofovir alafenamide and emtricitabine
45389427|NCT01564355|Device|Steroid-eluting middle meatal spacer (Nasopore (TM) spacer impregnated with 1 cc of 40mg/mL triamcinolone liquid)|All study arms will receive bilateral Nasopore spacers impregnated with 1 cc of Triamcinolone to remain in the nasal cavity for 1 week post-operatively as per usual protocol.
45389428|NCT01564355|Drug|Post-op Oral Steroids|Post-operative oral prednisone 20 mg QD x 5 days , then 10 mg x 5 days, as per usual protocol.
45389429|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections,one month apart.
45389430|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections, one month apart.
45389431|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections, one month apart.
45389432|NCT01056705|Biological|Oral Poliomyelitis Vaccine|Oral Poliomyelitis Vaccine (OPV).3x0.5mloral, one month apart.
45696325|NCT04367350|Diagnostic Test|muscle ultrasound|Muscle echogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score)
45696326|NCT04762329|Other|Manage My Pain (MMP) digital pain app group|To evaluate the extent of patient engagement with the Manage My Pain (MMP) digital application when used in a clinical setting
45696327|NCT04367038|Other|Warm Acupressure, Cold Acupressure , Conventional Acupressure|Acupressure is non-invasive, safe and effective.
45696328|NCT04360642|Other|singing|Singing for Wellness will use an uncontrolled observational study design. Two mixed-cohort, 12-week community choirs will be delivered by experienced vocal practitioners in South Devon localities:
45696329|NCT04403451|Behavioral|True North|Love Notes, Financial Stability, Jobs
45696330|NCT03549351|Other|Measurable residual disease measured by flow cytometry|Measurable residual disease measured by flow cytometry
45848655|NCT03544242|Drug|Post-Isolation Infusion|A saline infusion will be administered during the pre-isolation phase and a nitrite infusion will be administered during the reperfusion phase.
45848656|NCT03500406|Device|RestoreX|Penile traction therapy in the straight position
45848657|NCT03500406|Other|Control|No treatment
45389433|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Salk strains).|3x0.5ml intramuscular injections, one month apart.
45389434|NCT00437268|Drug|enzastaurin|1125 milligrams (mg) loading dose, then 500 mg orally, daily, of each 21-day cycle until progressive disease
45389435|NCT00437268|Drug|irinotecan|300 milligrams per square meter (mg/m^2) intravenously on Day 1 of each 21-day cycle until progressive disease
45389436|NCT00437268|Drug|cetuximab|400 mg/m^2, intravenously on Day 1, 250 mg/m^2 on Day 8, Day 15 Cycle 1 then 250 mg/m^2, on Day 1, 8 and 15 of each cycle, intravenously 21-day cycles until progressive disease
45389437|NCT04002089|Drug|Exparel Injectable Product|bupivacaine liposome injectable suspension
45389438|NCT04002089|Drug|Bupivacaine|1.3%, 13.3 mg/mL
45389439|NCT01056783|Drug|OC000459|OC000459 100mg, twice daily, tablet
45389440|NCT01056783|Drug|Placebo|Placebo tablets to match OC000459 tablets, twice daily
45502232|NCT02037152|Behavioral|Body scan exercise|"The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. The audio content is adapted from the body scan exercises traditionally taught in evidence-based mindfulness interventions."
45502233|NCT02036918|Drug|Sipuleucel-T|
45502234|NCT02036918|Procedure|Lymph Node Biopsy|
45502235|NCT02809976|Drug|Ruxolitinib 1.5% Phosphate Cream|twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20
45502236|NCT02036372|Drug|Liraglutide|
45502237|NCT02036372|Drug|Insulin bolus|
45502238|NCT02036372|Drug|GIK infusion|continuous infusion
45502239|NCT02036528|Drug|Gentamicin Topical Gel|
45502240|NCT02036528|Drug|Ciprofloxacin|
45502241|NCT02036528|Drug|Doxycycline|
45502242|NCT02047682|Behavioral|Biopsychosocial|
45848658|NCT03423654|Other|Spatial Training|Spatial Training using a 5x5 grid
45848659|NCT03423654|Other|Letter number matching|Letter number matching
45848660|NCT03370536|Device|CardioInsight ECGI Mapping System|The CardioInsight mapping system is a noninvasive, single beat cardiac arrhythmia mapping system that provides 3D electroanatomic maps of the heart.
45848661|NCT03370536|Procedure|AF ablation|Empiric ablation (CFAE or linear ablation) is not permitted
45848662|NCT03370536|Drug|Ibutilide|Progressive doses of Ibutilide administered (0.25mg, then 0.25mg, then 0.5mg)
45848663|NCT03161964|Drug|Propranolol 80 Mg Oral Capsule, Extended Release|Propranolol capsule over-encapsulated to match placebo for blinding
45848664|NCT03161964|Drug|Placebo oral capsule|Placebo capsule over-encapsulated to match propranolol for blinding
45848665|NCT03078270|Drug|botulinum toxin A|Single treatment visit for 5 injections of botulinum toxin A, 40 units (for females) and 50 units (for males)/
45848666|NCT03078270|Other|Placebo|single treatment visit for 5 injections of normal saline
45389441|NCT04002245|Procedure|antiseptic application|The application of the antiseptic on the healthy and visibly clean skin of the bend of the elbow will be carried out for all participant
45389442|NCT01056861|Drug|Botulinum Toxin A|Not exceeding a total dose of 400 units, once every three months.
45389443|NCT05355467|Drug|Tenofovir disoproxil fumarate|Ricovir® (tenofovir disoproxil fumarate 300 mg) 1 tablet daily. The overall treatment period is 24 weeks.
45389444|NCT05355467|Other|Historical Data|Historical Data
45389445|NCT04139525|Biological|unfractionated heparin|A bolus of 30 I.U./kg at the start of hemodialysis, followed by 18 I.U./kg per every hour of hemodialysis.
45389446|NCT04139525|Biological|8% trisodium citrate|8% trisodium citrate in the dose of 150 ml/h.
45502243|NCT02047682|Behavioral|Reference|
45502244|NCT02880865|Biological|Live attenuated SA 14-14-2 Japanese Encephalitis vaccine|Single 0.5 mL dose of World Health Organization prequalified live, attenuated SA 14-14-2 JE vaccine manufactured by Chengdu Institute of Biological Products, Chengdu, China, administered by subcutaneous injection
45502245|NCT02880865|Biological|Measles, mumps, rubella vaccine|Single 0.5 mL dose of live, attenuated measles-mumps-rubella vaccine (Schwarz measles virus, RIT 4385 mumps strain, and Wistar RA 27/3 rubella virus) manufactured by GlaxoSmithKline, Inc., administered by subcutaneous injection.
45502246|NCT01352923|Other|blood test|preparation of blood platelets
45389447|NCT01058733|Other|Internet|new clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
45389448|NCT00437034|Biological|aflibercept|Given IV
45389449|NCT04081259|Drug|LY3214996|LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor that is being developed as a treatment for patients with advanced cancer. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
45389450|NCT01027338|Other|Tai chi exercise|
45389451|NCT03297281|Other|Maintenance of OAC in surgery of BPH by PVP.|The maintenance of AVK or DOACs treatment in the perioperative setting (without interruption of oral treatment).
45389452|NCT03297281|Other|Discontinuation of OAC in surgery of BPH by PVP.|The discontinuation of AVK or DOACs treatment with perioperative heparin relay during postoperative course.
45389453|NCT00337467|Drug|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg + RTV 100mg, once daily, 96 weeks
45389454|NCT03285425|Other|Natural history|Parent interview
45502247|NCT03635125|Drug|Nebivolol I|Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20 mg or Metoprolol 100mg
45502248|NCT03635125|Drug|Nebivolol II|Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20mg or Metoprolol 100mg
45696331|NCT04360408|Other|Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis|The total program consisting of three educational sessions (at Week -1, week -3 and week -5) and one booster session (week -10) over a period of 12 weeks. Participants will receive individual, face to face education during their regular HD session. Education will be provided over 30-45 minutes for the first session, 30 minutes in the next two sessions and 30-45 minutes for the booster session. The lead researcher, who is a nurse, will deliver the entire intervention to avoid information bias. The simple language will be used, and emphasis will be given on the objectives of each session.
45696332|NCT03548571|Biological|Dendritic cell immunization|Intradermal injection
45696333|NCT03548571|Drug|Adjuvant temozolomide|After a 4-week break, patients were then to receive up to six cycles of adjuvant temozolomide according to the standard 5-day schedule every 28 days at 150 mg per square meter for the first cycle and thereafter increase to 200 mg per square meter beginning with the second cycle.
45696334|NCT00939562|Drug|doxycycline monohydrate tablet|Tablet, 100 mg, Single dose
45696335|NCT00939562|Drug|doxycycline carragenate tablet|Tablet, 100 mg, Single dose
45696336|NCT03570801|Other|Expert Panel Review|There is some preliminary evidence suggesting that having a group of spinal experts review x-rays prior to treatment might provide useful information to the patient and the patients' treating physician when trying to make a decision about what type of surgery to perform.
45848667|NCT03042780|Drug|FOLFIRINOX|The FOLFIRINOX regimen consists of oxaliplatin given as a 2-hour intravenous infusion, immediately followed by leucovorin given as a 2-hour intra-venous infusion, with the addition, after 30 minutes, of irinotecan given as a 90-minute intravenous infusion. This study treatment is immediately followed by a continuous intravenous infusion of 5-Fluorouracil (5-FU) over a 46-hour period every 2 weeks.
45848668|NCT03042780|Drug|Granulocyte colony-stimulating factor (G-CSF)|The use of G-CSF will not be mandatory as primary prophylaxis, but will be allowed at investigators' discretion. If febrile neutropenia occurs, than the use of G-CSF will be mandatory after each following cycle of treatment.
45848669|NCT03017040|Device|CT scan|A CT scan of the wrist
45502249|NCT03635125|Other|Baseline Washout Phase|2 to 4 week Baseline Washout Phase
45502250|NCT01854385|Drug|Sumatriptan 100 mg|This is a single-arm, unblinded study of treatment for post-traumatic headache with the open label medication sumatriptan and is being undertaken to test necessary study instruments and procedures, establish feasibility and determine side effects in a population with complicated mild, moderate and severe TBI.
45502251|NCT02809118|Drug|AM-111 0.4 mg/ml|AM-111 0.4 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
45389455|NCT01056939|Device|Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with neurally adjusted ventilatory assist
45389456|NCT01056939|Device|Control (PC- or PRVC- ventilation), i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with PC or PRVC ventilation.
45389457|NCT03989739|Device|Da Vinci|
45389458|NCT04079855|Other|Diet composition 1|A diet with a specified macronutrient composition different from arms 2, 3, and 4.
45389459|NCT04079855|Other|Diet composition 2|A diet with a specified macronutrient composition different from arms 1, 3, and 4.
45389460|NCT04079855|Other|Diet composition 3|A diet with a specified macronutrient composition different from arms 1, 2, and 4.
45389461|NCT04079855|Other|Diet composition 4|A diet with a specified macronutrient composition different from arms 1, 2, and 3 based on the current information about the US macronutrient composition.
45389462|NCT03985085|Other|Comprehensive package of sexual and reproductive health services|"Implementation of a comprehensive sexual and reproductive health care package for female sex workers in Côte d'Ivoire, combining an HIV PrEP offer (for HIV- FSW) with early treatment of HIV+ FSW, management of HBV infection (testing, vaccination and treatment), testing and treatment of sexually transmitted infections (STIs) and their consequences, a contraception offer, a quarterly screening of pregnancies, menstrual management counselling and identification of addiction.~This healthcare package will be available both in mobile clinics organized for a quarterly follow-up (10 intervention sites, each site being visited every two weeks) and in the fixed clinic of the partner community-based NGO, at the discretion of each female participant."
45389463|NCT01057095|Genetic|RNA analysis|
45848670|NCT03017040|Device|Fluoroscopy Scan|A fluoroscopy scan of the wrist.
45848671|NCT02985840|Drug|Ondansetron|Patients receive intravenous ondansetron (4mg) followed by two 5ml normal saline flushes
45389464|NCT01057095|Genetic|gene expression analysis|
45389465|NCT01057095|Genetic|reverse transcriptase-polymerase chain reaction|
45389466|NCT01057095|Other|laboratory biomarker analysis|
45389467|NCT03778385|Other|Exercise|Submaximal exercise is performed in randomized order with the participant seated and the arm supported in an adjustable hand-arm orthosis.
45389468|NCT01058889|Device|Telemedical device|Monitoring of blood glucose,insulin dose, blood pressure, lifestyle factors with the telemedical device. Monitoring of system availability, percentage of data transfer, acceptance.
45389469|NCT00337077|Drug|eribulin mesylate|Given IV
45389470|NCT00428220|Drug|sunitinib|sunitinib
45848672|NCT02985840|Drug|Dexamethasone|Patients receive intravenous ondansetron(4mg) followed by intravenous dexamethasone (4mg), followed by a single 5ml normal saline flush
45848673|NCT02974686|Drug|Everolimus|
45389471|NCT01057329|Drug|Atomoxetine|mg according to body weight
45389472|NCT01057329|Drug|Duloxetine|30 mg / die
45389473|NCT01057329|Drug|Olanzapine|5mg 1 wwek and 10 mg from second week
45389474|NCT01057329|Drug|Aripiprazole|5 mg from week 1, 10 mg from week 2
45389475|NCT01057407|Drug|ASP1585|oral
45389476|NCT01057407|Drug|Sevelamer hydrochloride|oral
45389477|NCT01037478|Drug|Resminostat (4SC-201)|oral administration
45389478|NCT01057485|Procedure|AF ablation and AV node ablation|AF ablation and AV node ablation
45389479|NCT01057485|Procedure|AV node ablation|AV node ablation
45389480|NCT03986463|Other|Circulating tumour DNA (ctDNA)|Circulating tumour DNA (ctDNA) will be isolated from blood samples
45389481|NCT03986307|Dietary Supplement|Omega-3 polyunsaturated fatty acid supplementation|Daily supplementation with omega-3 capsules (daily for 14 weeks). Each day: 3 capsules of 1.1g
45389482|NCT03986307|Other|Resistance exercise|Resistance exercise training in both supplementation conditions (3 times per week for 12 weeks).
45389483|NCT03986307|Dietary Supplement|Placebo - appearance-matched oil supplementation|Daily supplementation with placebo capsules (daily for 14 weeks). Each day: 3 capsules of 1.1g
45389484|NCT01059045|Procedure|cryocontact therapy|cryocontact therapy of hemangioma is realized by using liquid nitrogen cooled metal devices
45389485|NCT01059045|Other|Control|No intervention
45389486|NCT02873975|Drug|LY2606368|
45389487|NCT01054131|Behavioral|peer support|A quasi-experimental, before and after study design will obtain data for planning and implementing a larger-scale study. Exposures and outcomes will be measured at baseline, 3 months (immediate post 12-week program) and 6 months (3 months post-program). Ten individuals with EIA will be recruited by brief screening interviews to ensure they meet inclusion criteria. Each pair of peer mentor and EIA participant will meet at SHSC for an initial contact. EIA participants will receive informational, emotional and appraisal support from trained peer mentors by telephone or neutral private location at a time convenient for both parties, at least once a week for 12 weeks.
45389488|NCT01057563|Device|drug (paclitaxel)-eluting balloon (DEB)|BMS implantation after lesion predilation with DEB
45389489|NCT01057563|Device|bare-metal stent (BMS)|BMS implantation
45389490|NCT01057563|Device|Drug (paclitaxel)-eluting balloon (DEB)|BMS implantation followed by post-dilation with DEB
45502252|NCT02809118|Drug|AM-111 0.8 mg/ml|AM-111 0.8 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
45848674|NCT02974686|Drug|Mycophenolic Acid|
45848675|NCT02966184|Drug|preservative free albuterol|Preservative free albuterol for nebulization
45848676|NCT02950896|Other|observational fetal heart rate monitoring|Patients will have fetal heart rate monitoring
45848677|NCT02877732|Device|EYE-SYNC eye-tracking|The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
45848678|NCT02877732|Other|SCAT-3 subtests|Following subtests of SCAT-3 will be administered to the participant: Symptom, Balance, Orientation and Immediate memory
45389491|NCT00345579|Biological|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014|3-dose intramuscular injection
45389492|NCT00345579|Biological|ActHIB|3-dose intramuscular injection
45389493|NCT00345579|Biological|Pediarix/Infanrix Penta|3-dose intramuscular injection
45389494|NCT05356559|Dietary Supplement|Intervention|12.5g (twice daily) Blue Whiting Protein Hydrolysates daily for 8 weeks
45389495|NCT05356559|Other|Control|Isocalorific Maltodextrin Citrus Flavoured Powder for 8 weeks
45389496|NCT04002323|Drug|Dolutegravir 50mg Tab|The subjects starts their ART with this drugs, once a day
45389497|NCT04002323|Drug|Lamivudine 300 mg|The subjects starts their ART with this drugs, once a day
45389498|NCT04002713|Other|ALT flap reconstruction|Patients who underwent ALT free flap reconstruction after head and neck cancer surgery.
45389499|NCT04002713|Other|AMT flap reconstruction|Patients who underwent AMT free flap reconstruction after head and neck cancer surgery.
45389500|NCT05354921|Device|Indwelling Catheter|Patients in the experimental group will receive foley catheter upon admission, aseptically. The catheter will be discontinued on the morning following surgery. At TOH most (>75%) hip fractures are treated within 48 hours of admission and 95% within 72 hours and hence the indwelling catheter is likely to stay in place for 3-4 days.
45389501|NCT05354921|Device|Intermittent Catheterization|"Patients randomized to the intermittent catheterization group will have their PVR monitored every 8 hours pre-operatively. If PVR>400 mL, an intermittent catheter will be used. If PVR> 400 mL greater than 3 times pre-operatively, an indwelling catheter will be placed the fourth time. The indwelling catheter will be removed the morning of post-op day 1.~It is expected that a small percentage of patients in either group will not have a PVR>400 mL preoperatively.~These patients will not be catheterized but will remain in the study. Post-operatively, both treatment groups will have their PVR monitored for 24 hours, or until PVR is less than 200 mL. If PVR>400 mL and the patient is not able to void further, intermittent catheterization will be done every six hours as needed. If post-operative PVR>400 mL greater than 3 times post-operatively, an indwelling catheter will be placed the fourth time."
45389502|NCT04001855|Other|Dilute vinegar (acetic acid)|Dilute vinegar baths or gauze soaks
45389503|NCT04001855|Other|Dilute bleach|Dilute bleach baths or gauze soaks
45389504|NCT00335829|Biological|bevacizumab|
45389505|NCT00335829|Drug|chemotherapy|
45389506|NCT00335829|Drug|embolization therapy|
45848679|NCT02877732|Other|DEM|Participant will be asked to read list of numbers out loud from a card
45389507|NCT00335829|Procedure|hepatic artery infusion|
45502253|NCT02809118|Other|Placebo|Placebo gel is administered with a single dose into the affected ear after topical anesthesia
45389508|NCT05339243|Other|ES 1|Two capsules orally once daily after breakfast for 84 days
45389509|NCT05339243|Other|HT ES1|Two capsules orally once daily after breakfast for 84 days
45389510|NCT05339243|Other|Placebo|Two capsules orally once daily after breakfast for 84 days
45389511|NCT02533011|Other|HBP lab test|Plasma level of Heparin Binding Protein will be evaluated on extra blood specimens already collected as part of standard of care.
45389512|NCT01057641|Procedure|Spacer|Implantation of a percutaneously implanted interspinous device (spacer)
45848680|NCT02877732|Other|Simple Reaction Time subtest of ANAM-SRT|Participants will perform Simple Reaction Time sub-test of ANAM-SRT test. They will be asked to click the mouse button every time they see an asterisk on the screen. Participants will perform ANAM-SRT 1 and ANAM-SRT 2 in this study.
45848681|NCT02877732|Other|Level of Alertnesss|Participants will answer questions. This assessment is to assess their alertness level.
45848682|NCT02808390|Drug|GED-0507-34-Levo 80 mg|GED-0507-34-Levo 80 mg BID for 8 Weeks
45389513|NCT01057641|Other|physiotherapy|physiotherapy
45389514|NCT05262257|Drug|Metformin|Take it regularly for 12 weeks
45389515|NCT05262257|Drug|Dapagliflozin|Take it regularly for 12 weeks
45389516|NCT05262257|Behavioral|Lifestyle intervention|patients did not take any hypoglycemic drugs and adopted diet, exercise and other lifestyle intervention measures to control blood sugar.
45389517|NCT03989817|Drug|Vasoactive Intestinal Peptide (VIP) and Saline|12 healthy volunteers of both genders will be included in the main study. Participants will meet twice, with at least one week in between. The main study is a double-blind, randomized, cross-over trial among placebo (sterile saline, non-active substance) and VIP. Intravenous infusion of VIP / placebo (saline) will be conducted over 120 minutes. Patients will be asked after each trial day to record headache strength, accompanying symptoms, and drug use for up to 24 post-infusion.
45389518|NCT01059123|Drug|Amoxicillin|50 mg/kg/24H ; Per Os ; 3 times/day 6 days
45389519|NCT01059123|Drug|Amoxicillin|50 mg/kg/24H in I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; Per Os ; 3 times/day up to day 14.
45389520|NCT03986385|Drug|Apatinib Capecitabine Oxaliplatin|apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
45389521|NCT03986385|Drug|Capecitabine Oxaliplatin|Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
45389522|NCT01054287|Other|Multifactorial falls prevention program|
45389523|NCT01054287|Other|No falls prevention intervention|
45389524|NCT03985137|Other|mucocutaneous sampling by swab at the balano-preputial furrow.|the sample is made by the patient
45696337|NCT04355104|Behavioral|Education|"A one hour educational session per week for 4 weeks. In a total of 4 sessions of education, the content based on LBP Clinical Practice Guidelines which recommended that education and counseling strategies for patients with low back pain.~Education session will be through video lecturing as a motivated tool of education for all subject who are in experimental group, this video will repeated the same in every educational session and will be sent for all participants.~The neuroscience education will be by the therapist using interactive slide show and hand-drawing images.~In addition to the education video, slide show, we will specify the education for every patient to give him all that he need, questions and details, mention his case on real spine to explore it and to determine the expected goal from what he need and what we have."
45389525|NCT01057719|Other|Physiotherapy|Individual tailored physiotherapy according to the Bobath concept sixty minutes each working day for four weeks
45389526|NCT00344019|Drug|Placebo Oral Tablet|placebo pre-PCI for ACS
45389527|NCT00344019|Drug|Atorvastatin 80mg|atorvastatin 80 mg pre-angio/PCI
45389528|NCT00344019|Other|Screening|Patients signed consent to be screened for eligibility for randomization to placebo vs. study drug (atorvastatin)
45389529|NCT03985059|Other|Transcranial Doppler|"Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed in the USINV, according to the usual care. In a second step, the patient will be verticalized (from 0° to 90°). HI parameters in supine position and during verticalization will be recorded continuously by placing the transcranial Doppler helmet.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the helmet."
45389530|NCT01059591|Drug|GSK424887|GSK424887 2mg, 10mg, 50mg, 100mg capsule
45389531|NCT01059591|Drug|Placebo|Placebo to match GSK424887 2mg, 10mg,50mg, 100mg capsule
45389532|NCT01059591|Radiation|PET|Each subject will undergo 3 PET scans : one at Baseline and the others following dosing with GSK424887 at approximately 2h post-dose and aproximately 24 hours post-dose
45389533|NCT00535847|Drug|Telaprevir|Tablet
45389534|NCT00535847|Drug|Ribavirin|Tablet
45389535|NCT00535847|Drug|Pegylated interferon alfa 2a|Solution for Injection
45389536|NCT03986151|Procedure|Coronary angiography +/- percutaneous coronary intervention|Comparison of the conventional radial approach with the distal radial approach (anatomical snuffbox)
45389537|NCT01059669|Other|diagnostic test|
45696338|NCT04355104|Behavioral|Standard physical therapy|Two session physical therapy per week for 4 weeks. The physical therapy will be based on patients case.
45696339|NCT03543735|Behavioral|Wisepill+SMS|This will include: 1) an in-person Wisepill orientation session to introduce the pillbox and generate relapse prevention messages that can be later delivered during non-adherent windows; 2) use of the Wisepill device during the intensive treatment program and after discharge; and 3) three forms of tailored SMS messages paired with Wisepill device use: a) supportive messages with medication compliance, b) reminder messages for early non-adherence (e.g., 1 hour late) and c) relapse-prevention messages after longer periods of non-adherence (e.g., several hours).
45696340|NCT03543735|Other|Wisepill-only|This will include: 1) an in-person Wisepill orientation session to introduce the pillbox; 2) use of the Wisepill during the intensive treatment program and after discharge.
45389538|NCT03606785|Drug|Tranexamic Acid Injection|The TA group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision
45389539|NCT03606785|Drug|placebo injection|patients will receive a placebo of 100 mL 0.9% normal saline
45389540|NCT03587753|Other|Dietary fatty acid partitioning|There is no intervention as such, just a physiological assessment of the partitioning and oxidation of two different types of dietary fatty acids
45389541|NCT03441971|Device|GORE PV1|Implantation of GORE PV1 Device for procedure to replace the pulmonary valve and reconstruct the right ventricular outflow tract (RVOT).
45389542|NCT00334893|Drug|eribulin mesylate|Given IV
45389543|NCT05356169|Drug|with or without venetoclax|Bcl-2 inhibitor
45554685|NCT02710136|Biological|Glycerinated German Cockroach Allergenic Extract|"Participants will receive escalating doses intranasally. Briefly: per protocol- Phase 1a NAC: N=10 cockroach sensitive adults with asthma will undergo nasal allergen challenge with dose escalation (up to 8 doses per protocol). Phase 1b: Phase 1a subjects will have repeat NAC with dose escalation (up to 8 doses).~Phase 2: N=25 cockroach sensitive children with asthma (ages 8 - 14 years) will undergo NAC with doses determined by Phase 1a data (e.g., symptoms and safety data)."
45389544|NCT01057797|Behavioral|Exercise-specific self-efficacy|Subjects in the experimental group will participate in a self-efficacy enhancing intervention designed to maximize (a) exercise-specific SE-UB strength training (b) self-efficacy for overcoming barriers to exercise and (c) SE-UB physical activities. The intervention incorporates strategies to maximize the primary sources of efficacy information: (a) mastery accomplishments, (b) social modeling, (c) social persuasion, (d) interpretation of physiological and affective symptoms.
45389545|NCT01057797|Behavioral|Gentle chair exercise|Gentle armchair fitness exercises will be used as a sham treatment to control for the attention that subjects receive in the two strength training groups. The armchair fitness exercises will be conducted in small groups (n=8-10 per group). Armchair exercises will include stretching of all major joints with an emphasis on the arms and shoulders, massage of muscles that can be reached from the armchair (scalp, neck, shoulders, lower back, abdomen and thighs) and imagery to promote relaxation. Each session will include: 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery for relaxation.
45389546|NCT01057797|Behavioral|upper body strength training|16 weeks of lab-based upper body strength training using 8: modified lateral pull down, shoulder shrug, upright row, overhead pull down, front raise, front pull down, triceps extension, biceps curl. Training load and volume will be increased progressing from 70% to 80% of the maximum strength training and from 2 sets of 8-10 repetitions progressing to 3 sets. Each week subjects will train twice in the lab and once at home. Home exercises will include 1 set of 15-20 repetitions: biceps curl, triceps extension, front raises, lateral raises, overhead press, chest press and one-arm dumbbell row.
45389547|NCT01059747|Other|no intervention applied|no intervention applied
45389548|NCT01057875|Other|caffeine|Starbuck's Grande Pike Roast coffee
45389549|NCT01057875|Other|No caffeine|Starbuck's Grande Pike Roast Decaffeinated Coffee
45389550|NCT05293691|Behavioral|Body, Breath & Mind|"The program Body, Breath & Mind is a minimally guided self-help program to improve mood. It contains a total of eight modules, which are to be completed in a weekly rhythm. Each module includes Qi Gong exercises, and instructions and exercises for value-based behavioral activation used in behavioral therapy for depression (Hofheinz, Heidenreich & Michalak, 2017). If possible, the entire program should be completed within a period of 8 weeks."
45389551|NCT05293691|Behavioral|Moodgym|Moodgym is an interactive training program for the prevention and reduction of depressive symptoms. It is based on the methods and techniques of cognitive behavioral therapy and includes five modules: feelings, thoughts, developing alternative thoughts, deal with stress and relationship. In addition to the modules, there is a workbook section where personal results and responses are stored. The effectiveness of the programme has been proven in clinical trials (Loebner et al., 2018).
45389552|NCT04001387|Procedure|Real-time ultrasound guided spinal anesthesia|The neuraxial US scan will be performed with the patient in the lateral position with the hip and knees flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance using dynamic needle tip positioning to administer the spinal anesthetic.
45389553|NCT00334737|Drug|Darbepoetin Alfa Injection|darbepoetin alfa injection 10 mics/kg once a week SC for 10 weeks or until 35 completed weeks
45389554|NCT00334737|Drug|erythropoietin alfa injection|Epo 400 units/kg 3 x weekly SC for 10 weeks or until 35 completed weeks gestation
45389555|NCT00334737|Drug|sham injection|sham injection other names: not applicable
45389556|NCT05347823|Diagnostic Test|Hair analysis for drug concentration|Sample collection for the determination of treatment adherence
45389557|NCT01564433|Procedure|Device: Electromechanical gait trainer|The experimental group will be subjected to 12-30 minute session (3 per week: Monday, Wednesday, Friday) of repetitive locomotor therapy on the Gait Trainer (Reha-Stim, Berlin, Germany), followed by 20 minutes of passive joint mobilization and stretching exercises. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion. While using the gait trainer, individuals are secured in a harness and positioned on two footplates, whose movements simulate stance and swing phase, with a ratio of 60% to 40% between the two phases. The body weight was initially reduced by 30% and then progressively increased.
45389558|NCT01564433|Procedure|Convetional control treatment|The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
45389559|NCT03986073|Drug|TQ-F3083 capsule 10 mg|Subjects in the low dose group administrated TQ-F3083 capsule 10mg, once daily for 12 weeks.
45502254|NCT01353001|Behavioral|Diet|Participants will be given a calorie and fat gram goal according to their initial bodyweight. The fat gram goals will be set at 20% to 30% of total caloric intake. Subject calorie and fat gram goals are as follows: Subjects weighing less than 175 pounds will receive a diet prescription of 1200 calories and 27 fat grams per day. Subjects weighing between 175 and 219 pounds will receive a diet prescription of 1500 calories and 33 fat grams per day. Subjects weighing between 220 and 249 pounds will receive a diet prescription of 1800 calories and 40 fat grams per day. Subjects weighing greater than 250 pounds will receive a diet prescription of 2100 calories and 47 fat grams per day.
45696341|NCT04359940|Diagnostic Test|Cardiac MRI|For clinical surveillance
45848683|NCT02808390|Drug|GED-0507-34-Levo 160 mg|GED-0507-34-Levo 160 mg BID for 8 Weeks
45848684|NCT02808390|Drug|Placebo|Placebo BID for 8 Weeks
45696342|NCT03542175|Drug|Rucaparib|one dose level (300 mg BID, 400 mg BID, 500 mg BID or 600 mg BID) concurrently with a 6-week course of radiotherapy and 4 additional weeks of maintenance rucaparib at the same dose level.
45696343|NCT03542175|Radiation|Radiotherapy|50 Gy in 2 Gy per fraction to the breast or chest wall with or without regional nodes plus a 10 Gy boost to the lumpectomy cavity, to a total dose of 60 Gy. A 10 Gy boost to the post-mastectomy scar is allowed at the discretion of the treating physician.
45696344|NCT04359862|Drug|Sevoflurane|25 patients sedated with Sevoflurane via inhalation, starting with 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
45389560|NCT03986073|Drug|TQ-F3083 capsule 20 mg|Subjects in the high dose group administrated TQ-F3083 capsule 20 mg, once daily for 12 weeks.
45389561|NCT03986073|Drug|TQ-F3083 blank analog capsule|Subjects administrated one TQ-F3083 blank analog capsule orally, once daily for 12 weeks.
45389562|NCT03986073|Drug|TQ-F3083 blank analog capsule|Subjects administrated two TQ-F3083 blank analog capsules orally, once daily for 12 weeks.
45389563|NCT03986073|Drug|Linagliptin blank analog tablet|Subjects administrated one Linagliptin blank analog tablet orally, once daily for 12 weeks.
45502255|NCT01353001|Behavioral|Diet Plus Aerobic Training|Participants will receive all of the components as described for the DIET group. Additionally, this group will participate in supervised progressive aerobic training 3 days per week. Participants will be required to attend 3 sessions per week where they will participate in supervised exercise sessions progressing from 60 to 180 minutes per week of moderate-intensity (3.0-6.0 METS) aerobic exercise. 180 minutes per week of exercise will meet the American College of Sports Medicine and the American Heart Association recommendations of 450-750 METS.min.wk-1.
45696345|NCT04359862|Drug|Propofol|25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
45696346|NCT04366726|Combination Product|abaloparatide-sMTS|abaloparatide 300 μg applied to the thigh for 5 minutes once daily for 29 days
45696347|NCT04354948|Behavioral|Pain (hypertonic saline)|A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
45696348|NCT04354948|Behavioral|No pain (Hypotonic saline)|A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
45696349|NCT03540927|Behavioral|PM+ for entrepreneurs|The intervention arm will receive 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement,provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 addresses a participant-selected problem using problem-solving techniques. Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.
45696350|NCT03540927|Other|Cash transfer to the Entrepreneurs|The entrepreneurs in the control arm will receive cash transfer only for their businesses.
45696351|NCT04354714|Drug|Ruxolitinib|For patients unable to swallow pills, a ruxolitinib suspension will be administered through a nasogastric/orogastric tube
45389564|NCT03986073|Drug|Linagliptin tablet|Subjects in the positive drug control group administrated one Linagliptin tablet orally, once daily for 12 weeks.
45389565|NCT05279729|Other|Mobile health application|Intervention will be with two different mobile health (mHealth) applications, Weight Watchers and Healthi app (formerly iTrackBites)
45389566|NCT03989193|Device|Computer guided alveolar ridge splitting technique|"The bone splitting technique could be performed using the piezoelectric system, calibrating the device on D1 setting and using profuse saline irrigation. The preparation sequence begins with CS3 insert until a total depth of 10mm was achieved across the entire extension of the ridge. The procedure continued with the CS1 insert and finally the CS2 insert.~The vertical bone cuts through the cortical layer: At the distal end of the horizontal split, a vertical cut will made with the high-speed bur within the vicinity of the buccal plate to start the separation, with a full vertical depth of 13 mm. Final design of the splitting cut was L-shaped split. At the distal and the mesial end of the horizontal split, a vertical cut was made with the high-speed bur for a full vertical depth of 13mm."
45389567|NCT05347199|Drug|Amisulpride Pill|Two single low doses amisulpride (100 mg); orally
45389568|NCT05347199|Drug|Placebo|two doses, orally
45389569|NCT01060137|Drug|fentanyl matrix|Fentanyl transdermal patch 12 - 25mcg/hr
45389570|NCT04001153|Other|Dental impressions|"Children will be included in this study if they already are treatment planned to receive a Hall Technique preformed metal crown (HTPMC) to manage carious lesions in primary molars. They will have a dental impression taken before and after the HTPMC placement to find out what happens with their bite after the treatment.~The dental impressions will be cast up into stone study models so that we can track the changes that happens in children's bites after placing the HTPMC (as it increases the height of children's bite when placed) and let them know what to expect after this procedure and as part of this study, additional follow-ups will be required 2, 4, 6 and 8 weeks after the HTPMC placement to allow us to track the changes in the bite at regular intervals to see when the child's bite returns to its pre-treatment state."
45389571|NCT01057953|Genetic|Blood drawn|Blood drawn for patient
45389572|NCT05346029|Behavioral|Lifestyle intervention|Resistance training and nutritional counseling
45696352|NCT04354714|Procedure|Peripheral blood draw|-Screening, Day 2, Day 4, Day 8, Day 15, and Day 29
45696353|NCT04366960|Drug|Enoxaparin|Subcutaneous enoxaparin
45696354|NCT03539445|Drug|Butylphthalide|This group will receive a 3-month regimen of Butylphthalide and Sodium Chloride Injection 100ml twice/day in the initial 14 days and Butylphthalide Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
45696355|NCT03539445|Drug|Butylphthalide Placebo|This group will receive a 3-month regimen of Butylphthalide Placebo Injection 100ml twice/day in the initial 14 days and Butylphthalide Placebo Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
45696356|NCT04360876|Drug|Dexamethasone injection|Dexamethasone intravenous 20mg daily for 5 days followed by 10mg daily for 5 days
45696357|NCT04360876|Drug|Placebos|Placebo delivered intravenously on the same dosing schedule as dexamethasone
45696358|NCT04403529|Drug|Traditional Chinese Medicine Formulation|"The prescription for breast cancer Traditional Chinese Medicine formulation is a combination of 12 herbal components and it is available in granules form to be dissolved in hot water for consumption."
45389573|NCT01058031|Behavioral|MBSR|Mindfulness Based Stress Reduction
45389574|NCT03090347|Other|Overconsumption of specific dietary nutrient|Subjects will be studied before and then after the consumption of a diet where specific nutrients are provided in excess.
45389575|NCT00991991|Genetic|gene expression analysis|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
45389576|NCT00991991|Genetic|polymerase chain reaction|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
45389577|NCT00991991|Genetic|polymorphism analysis|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
45389578|NCT00991991|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
45389579|NCT00991991|Other|medical chart review|Information about the patient's demographics (e.g., TNM staging, sex, age, and tissue collection dates) will be gathered by chart review or from the Multidisciplinary Melanoma Conference at University Hospitals tumor conference report in order to match cases.
45389580|NCT01058109|Other|calcium-rich diet|dietary calcium intake of 1500 mg/d
45389581|NCT01058109|Other|Calcium rich diet|dietary intake of 1500 mg/d from food
45389582|NCT03989583|Other|Infrared thermography|Temperature observation in foot and footwear in healthy children
45389583|NCT00427908|Biological|GSK Biolgicals' meningococcal vaccine 134612 (Nimenrix)|One intramuscular dose.
45389584|NCT00427908|Biological|Mencevax™ ACWY|One subcutaneous dose.
45389585|NCT00427908|Biological|Meningitec™|One intramuscular dose.
45389586|NCT00992069|Drug|Efavirenz (EFV)|Oral dose of 600 mg daily, taken in the evening
45389587|NCT00992069|Drug|TMC207|Single oral dose of 400 mg in the morning
45389588|NCT01060215|Procedure|Normal saline|20 cc normal saline injection into the knee joint
45389589|NCT01060293|Drug|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
45389590|NCT01060293|Drug|Low-dose furosemide|Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
45696359|NCT04403529|Drug|Placebo Formulation|"Placebo granules contains 5% prescription for breast cancer Traditional Chinese Medicine formulation and 95% filler, it is available in granules form to be dissolved in hot water for consumption."
45389591|NCT01060293|Drug|Low-dose furosemide combined with low-dose dopamine|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
45389592|NCT03988959|Procedure|resection of mucoeidermoid carcinoma|Surgical resection parotid with preservation of facial nerve
45389593|NCT05343767|Dietary Supplement|Natural Wellness Low-Glu low dose|The contents of 4 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses
45389594|NCT05343767|Dietary Supplement|Natural Wellness Low-Glu high dose|The contents of 5 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses
45389595|NCT05343767|Other|Metformin|A total dose of 2000 mg was administered per day.
45389596|NCT01054521|Procedure|Temperature-controlled RF|"The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.~For nontemperature-controlled RF, the probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF."
45389597|NCT01054521|Device|Bipolar RF|The bipolar RF probe will be inserted at the same area with TCRF. The energy used will be 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
45389598|NCT05253365|Behavioral|Memory Support System|The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment.
45389599|NCT00334113|Behavioral|TLC-PED|Telephone-Linked Care - Promoting Exercise for Diabetes (TLC-PED), a method that uses interactive voice response and speech recognition technologies, will be developed to provide individualized and personalized motivational messages using automated telephone calls for veterans with Type 2 diabetes who participate in a home based walking program.
45389600|NCT00992147|Drug|Adipocell|autologous cultured adipocytes (ANTG-adip)
45696360|NCT04354324|Drug|Radioiodine|The test group: low dosage (30mci). The control group: high dosage (100mci).
45696361|NCT04403373|Behavioral|Waitlist control|waitlist control
45696362|NCT04403373|Behavioral|Moderate-intensity walking exercise|walking exercise
45389601|NCT01060449|Other|LV stimulus intensity|"The voltage and pulse duration used for programmed LV pacing~Arm 1: LV lead low output Arm 2: LV lead high output"
45389602|NCT04001699|Other|Preoperative geriatric assessment|In addition to the usual care, patients randomized to the intervention group receive preoperative assessment conducted by an interprofessional team including geriatrician, registered nurse, physiotherapist and pharmacist. Based on the assessment, a preoperative optimization plan is constructed focusing on the treatment of the patient's chronic conditions, nutritional status, medication and physical activity.
45389603|NCT01054677|Behavioral|Educational intervention on antibiotic prescribing|Small educational group sessions with nurses and physicians, feedback on prescribing, presentation of guidelines and written materials
45389604|NCT03989037|Drug|SIBP-01|IBP-01: injection; strength: 150mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
45389605|NCT03989037|Drug|Herceptin|Herceptin: injection; strength: 440mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
45389606|NCT03989037|Drug|Docetaxel|Docetaxel: injection; dose 75mg/m2, 75mg/m2 once every 3 weeks (intravenous infusion, not less than 60 minutes, on the 1st day of each cycle), totaling 6 cycles;
45389607|NCT03989037|Drug|Carboplatin|Carboplatin: injection; dose AUC6, AUC6 once every 3 weeks (intravenous infusion, not less than 30 minutes, on the 1st day of each cycle), totaling 6 cycles;
45389608|NCT00416598|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplantation
45389609|NCT00416598|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplantation
45389610|NCT00416598|Drug|Busulfan|Given IV
45389611|NCT00416598|Drug|Cytarabine|Given IV
45389612|NCT00416598|Drug|Daunorubicin Hydrochloride|Given IV
45389613|NCT00416598|Drug|Decitabine|Given IV
45389614|NCT00416598|Drug|Etoposide|Given IV
45389615|NCT00416598|Biological|Filgrastim|Given SC
45502256|NCT01353001|Behavioral|Diet plus Resistance Training|Participants will receive all of the components as the DIET group. Participants will also participate in supervised resistance training protocol 3 days per week in the form of an individual session. The protocol will start the participants at a low volume of exercise at an intensity of 50-55% of 1-repetition maximum, and oscillate in both volume and intensity during the intervention, with a general trend toward increases in intensity as outlined in the ACSM Position Stand.
45502257|NCT01349023|Other|Energy density (ED), Energy content|Standard or reduced energy content and energy density of pre-portioned entrees
45502258|NCT02036606|Behavioral|questionary|
45696363|NCT04403373|Behavioral|Vigorous-intensity walking exercise|walking exercise
45696364|NCT05620264|Diagnostic Test|Tear Sample Probe|Samples will be collected by conjunctival lavage of the affected eye without topical anesthesia. Sterile normal saline will be infused at room temperature into the lower conjunctival sac by gently pulling down the lower eyelid and with a needle-free insulin syringe. After few seconds, the lavage fluid will be aspirated back into the same syringe without the syringe touching the conjunctiva.
45848685|NCT02774148|Drug|IV Acetaminophen|The patient will receive 1,00mg IV Acetaminophen every 8 hours until 3 doses have been received post-operatively.
45389616|NCT00416598|Other|Laboratory Biomarker Analysis|Correlative studies
45389617|NCT00416598|Other|Pharmacological Study|Correlative studies
45389618|NCT00534599|Drug|Placebo|oral
45389619|NCT00534599|Drug|quetiapine fumarate XR|oral
45389620|NCT04001465|Procedure|Volumetric methacholine challenge unmodified|Bronchoprovocation challenge performed per volumetric method
45389621|NCT04001465|Procedure|Modified volumetric methacholine challenge|Bronchoprovocation challenge performed per volumetric method modified to include use of ultrasonic spirometer fitted with vibrating mesh nebulizer
45389622|NCT00992381|Drug|PN400|500mg Naproxen and 20mg esomeprazole
45389623|NCT00992381|Drug|Naprosyn|500mg Naproxen
45389624|NCT05320913|Procedure|Pericapsular nerve group(PENG) block combined with periarticular multimodal drug injection (PMDI)|periarticular local anesthetic infiltration with 120 mg of ropivacaine, epinephrine 0.2 mg and 30 mg of ketorolac diluted with normal saline to a total volume of 40 mL. + PENG block with ropivacaine 40 mg and epinephrine 0.1 mg with normal saline to a total volume of 20 mL
45389625|NCT05320913|Procedure|isolated periarticular multimodal drug injection (PMDI)|periarticular local anesthetic infiltration with 150 mg of ropivacaine, epinephrine 0.3 mg and 30 mg of ketorolac diluted with normal saline to a total volume of 50 mL
45389626|NCT00992537|Drug|insulin degludec|Insulin degludec single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
45389627|NCT00992537|Drug|insulin degludec/insulin aspart|Insulin degludec/insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
45502259|NCT02047838|Other|Anti-mullerian hormone (AMH) level dosage.|
45502260|NCT02047838|Other|Follicle-stimulating hormone (FSH) level dosage.|
45502261|NCT02047838|Other|Antral follicle count (AFC).|
45502262|NCT01318681|Drug|cetirizine 10 mg|cetirizine 10 mg over encapsulated
45502263|NCT01318681|Drug|fluticasone furoate|nasal spray 25ug per dose
45502264|NCT01318681|Drug|placebo|a placebo nasal spray and placebo capsule are available for double dummy treatment
45502265|NCT02036684|Behavioral|Prehabilitation (PREHAB)|
45389628|NCT00992537|Drug|insulin aspart|Insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
45389629|NCT00992615|Procedure|prostate biopsy|prostate cores - 12 or 20
45389630|NCT05317715|Other|Group A, who will complete a questionnaire before receiving information about intrauterine devices|Group A will complete a questionnaire before receiving information about intrauterine devices and a demonstration of insertion/removal on a plastic dummy uterus.
45389631|NCT05317715|Other|Group B who will answer a questionnaire after having the information about the intrauterine devices|Group B will complete a questionnaire after receiving information about IUDs and a demonstration of insertion/removal on a plastic dummy uterus.
45389632|NCT00992693|Drug|Ribavirin (Virazole) Injection|"The drug is to be administered in a volume of 50-100 ml of normal saline to be infused over 30-40 minutes.~1) Loading dose: 33 mg/kg (maximum dose 2.64 g)(1 dose) 2) Followed by a dose of 16 mg/kg (max dose 1.28 g) every 6 hours for the first 4 days (15 doses) 3) Followed by a dose of 8 mg/kg (maximum dose 0.64 g) every 8 hours for the subsequent 6 days (18 doses) Ten day course of treatment with follow up between day 28 to day 60."
45389633|NCT05304065|Behavioral|SAFETY-A within usual ED Care|SAFETY-A is a single session collaborative, strengths-based, developmentally nuanced, cognitive-behavioral intervention (CBT) to increase safety and mental health treatment initiation. The therapist works with the youth and family (or significant other, SO) separately and together to build hope and reasons for living, develop a personal safety plan, increase protective supports; and increase motivation for and linkage to treatment.
45389634|NCT05304065|Behavioral|Combined SAFETY-A within usual ED Care + CLASP Therapeutic Follow-Up Contacts|COMB, includes SAFETY-A within usual ED care plus CLASP therapeutic and caring follow-up contacts designed to strengthen safety and treatment initiation and engagement. Core functions of CLASP include: building hope/reducing hopelessness; enhancing social/family support; strengthening problem-solving; and increasing treatment initiation and engagement.
45389635|NCT00992771|Drug|varenicline|up to 1mg BID for 8 weeks
45389636|NCT00992771|Drug|placebo|placebo matching varenicline, up to 1mg BID for 8 weeks
45389637|NCT00992849|Drug|Bevacizumab|Topical 10 mg/cc or subconjunctival 2.5 mg/0.1cc
45389638|NCT00993005|Other|Cicatrix|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 12 weeks.
45502266|NCT03562286|Procedure|Fetoscopy|Performing a minimally invasive procedure using a fetoscopic technique in order to access to amniotic cavity and make the endoscopic repair of the fetal neural tube defect.
45502267|NCT03604159|Drug|Buprenorphine Extended Release|XRB is available in dosage strengths of 100 mg/0.5 mL and 300 mg/1.5 mL buprenorphine. Each dose is provided in a prefilled syringe with a 19 gauge 5/8-inch needle.
45502268|NCT03604159|Drug|Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)|SLB is administered sublingually or buccally as a single daily dose. Medication should be prescribed in consideration of the frequency of visits. Provision of multiple refills is not advised in early treatment or without appropriate follow-up visits. After treatment induction and stabilization, the maintenance dose of SLB is generally in the range of 4mg/1mg buprenorphine/naloxone to 24mg/6mg buprenorphine/naloxone per day depending on the individual patient and clinical response.
45502269|NCT03686930|Drug|Cohort 1 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
45502270|NCT03686930|Drug|Cohort 2 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
45502271|NCT03686930|Drug|Cohort 3 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
45502272|NCT03686930|Drug|Placebo (for FP-045 oral solution)|Participants (cohorts 1-3) will receive FP-045 oral solution matching placebo.
45502273|NCT01353235|Drug|Prednisolone|Patients assigned to corticotherapy arm, will receive oral prednisolone 1mg/kg/j as an add on therapy for a maximum of 10 days.
45502274|NCT01353235|Drug|usual care|no drug administered
45502275|NCT02048228|Drug|genotyping guided therapy Ticagrelor, Clopidogrel|CYP2C19*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers and patients in the standard treatment group will be given 75 mg clopidogrel daily.
45502276|NCT02048228|Drug|standard therapy clopidogrel|All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
45502277|NCT01349179|Device|Metal on metal hip arthroplasty operated on 2002|The purpose of the study is to evaluate the presence of geodes acetabular and femoral with scan examination.
45389639|NCT00993005|Other|Placebo|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
45502278|NCT05701046|Procedure|Interbody fusion surgery|Interbody fusion surgery
45502279|NCT03046927|Drug|Ergocalciferol|Each subject on the experimental arm will receive one capsule of ergocalciferol per week for 2 months; and then once every 2 weeks for 10 months
45502280|NCT03046927|Other|Placebo|Each subject on the placebo arm will receive one capsule of placebo per week for 2 months; and then once every 2 weeks for 10 months
45848686|NCT02774148|Drug|PO Acetaminophen|The patient will receive 1,000mg po Acetaminophen every 8 hours.
45502281|NCT02036762|Other|Stretching Exercises|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
45502282|NCT01357369|Procedure|Phlebotomy|Blood samples will be drawn from the mother, umbilical vein and artery post delivery, and neonate with other clinical labs.
45389640|NCT00993083|Biological|MVA-NP+M1|Intramuscular injection at 1.5 x 10^8 pfu/ml at day 0
45389641|NCT04001231|Drug|Exenatide Once-Weekly Suspension|A single dose will be administered as 2.0-mg dose of exenatide onceweekly suspension via subcutaneous (SC) injection followed by blood samples be drawn for up to 168 hours after the first dose on Day 1 to assess single-dose PK for exenatide once-weekly suspension. Subsequently Patients will receive the second dose of the investigational product (IP) at Visit 6 (Day 8). Thereafter, patients will receive weekly (±1 day) doses of IP up to Visit 18 (Week 14).
45389642|NCT00993161|Device|Motriplate|Number of contact couples
45389643|NCT00993161|Device|Motriplate|Number of contact couples
45389644|NCT01913795|Other|integrated pest management|integrated pest management and environmental strategy
45502283|NCT02037308|Dietary Supplement|Bread|
45502284|NCT01349257|Drug|BDP/Formoterol|One single day treatment of CHF 1535 100/6 NEXT DPI®: CHF 1535 dry powder for inhalation (fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg per actuation) administered via the NEXT DPI® dry powder inhaler with charcoal block.
45696365|NCT03538587|Behavioral|Enhanced Mindfulness Intervention|"The 8-week EMI will consist of one initial in-person session with the participant and parent, a series of at home assignments, and two booster sessions. The psychoeducation group will be given educational material about coping with cancer."
45696366|NCT03538587|Behavioral|Psychoeducation|The psychoeducation group will be offered the opportunity to participate in the EMI 8 weeks post-baseline.
45696367|NCT04354636|Drug|Silver modified atraumatic restorative treatment|Silver diamine fluoride that will be applied during atraumatic restorative treatment
45848687|NCT02744352|Drug|20ml bolus of 0.5% ropivicaine|Local anesthetic
45389645|NCT01913795|Other|air purifier|air purifiers
45389646|NCT01913795|Other|Sham air purifier|sham air purifiers
45389647|NCT00993239|Drug|Birinapant (TL32711)|30 minute intravenous (IV) infusion administered once weekly for three consecutive weeks followed by a one week off (Cycle) repeated every 4 weeks as tolerated
45389648|NCT05297591|Other|assessment of UL function and prognostic factors|clinical assessments and questionnaires
45389649|NCT00993395|Behavioral|peer mentor-based disease management|peer mentor-based disease management focused on three domains: medical care, recovery, and social stabilization
45389650|NCT04001543|Dietary Supplement|Immunomodulating oral supplementation|Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.
45389651|NCT04001543|Dietary Supplement|Sip feed control|Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.
45696368|NCT04354636|Other|Atraumatic restorative treatment|Using atraumatic restorative treatment without applying silver diamine fluoride
45696369|NCT04354090|Drug|JY09|Subcutaneous injection
45848688|NCT02744352|Drug|0.2% of ropivacaine at 8 milliliter/hour|Local anesthetic
45389652|NCT03892889|Combination Product|Abilify MyCite®|Combination product of aripiprazole tablet embedded with sensor and wearable patch.
45389653|NCT00995189|Device|Opti-Free RepleniSH|Contact lens care solution containing polyquaternium-1 (PQT)
45389654|NCT00995189|Device|ReNu MultiPlus|Contact lens care solution containing polyhexamethylene biguanide (PHMB)
45389655|NCT00995189|Device|Contact lenses|Daily wear, frequent replacement contact lenses per participant's habitual brand and power.
45389656|NCT00993551|Procedure|primary surgery for cleft palate|Surgery completed using the Sommerlad technique
45389657|NCT00993629|Drug|pregnenolone|"Administered adjunctively to treatment as usual"
45696370|NCT04359550|Biological|Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)|Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)
45696371|NCT04359550|Other|placebo|placebo
45696372|NCT04354480|Biological|RSV Vaccine|Participants will receive single IM injection of Ad26.preF RSV based vaccine on Day 1.
45848689|NCT02745210|Diagnostic Test|13C magnetic resonance spectroscopy|acquisition of 13C MR spectroscopy in the brain
45389658|NCT00993629|Drug|placebo|adjunctive placebo
45389659|NCT00993707|Drug|CTX-100 (formerly ETX-100) (hyaluronic acid)|"3 mL of either 0.01%, 0.03% CTX-100 (formerly ETX-100), or placebo will be dispensed into the PARI LC STAR nebulizer and inhaled using the PARI Ultra II compressors.~Number of cycles: if the study drug (0.01% CTX-100 Inhalation Solution or placebo) bid is well tolerated in the first cohort, the second cohort of subjects will begin dosing with 0.03% CTX-100 Inhalation Solution or placebo in the same manner as the first cohort."
45389660|NCT01564511|Device|Gait trainer treatment|Patients will be subjected to 40 minutes of repetitive locomotor therapy on the Gait Trainer (GTI) (Reha-Stim, Berlin, Germany), followed by 10 minutes of passive joint mobilization and stretching exercises. The first 40 min session will be divided as follow: 15 min gait training; 5 minutes at rest; 15 minutes gait training; 5 minutes at rest. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion.
45389661|NCT01564511|Other|Conventional treatment|The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
45389662|NCT00473330|Drug|Ranibizumab|Sterile solution for intravitreal injection.
45389663|NCT00473330|Drug|Sham injection|
45389664|NCT00416520|Drug|MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose and 4 weeks of double blind
45389665|NCT00416520|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
45389666|NCT00416520|Drug|Another phosphate binder (Sevelamer)|Current approved dosing recommendations for 12 weeks
45389667|NCT00533429|Drug|enzastaurin|1125 milligram (mg) loading dose then 500 mg, oral, daily until disease progression
45389668|NCT00533429|Drug|pemetrexed|500 milligrams per square meter (mg/m^2), intravenously ( IV), Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles every (q) 21 days x 3 cycles
45502285|NCT03813446|Device|Device: RhythmPadBP|"Detection of heart rhythm and measurement of blood pressure~Intervention:~Patients will start by wearing a consumer SmartWatch (Huwaei SmartWatch 2, which has a CE mark) and a 60 second reading of their wrist Photoplethysmyograph (PPG) will be recorded. This will enable us to compare the PPG from the wrist with the fingertip data collected from the RhythmPadBP.~The watch will be cleaned with alcohol wipe in the same manner that the RhythmPadBP is cleaned between subjects use.~Patients will be asked to place their palms of both hands on RhythmPadBP and then the underlying heart rhythm and BP will be recorded. 12-lead ECG and BP reading will be obtained by standard devices for comparison."
45502286|NCT03589105|Drug|Ocrelizumab 300 mg|Two doses of 300 mg infusion administered 14 days apart.
45502287|NCT03589105|Drug|Ocrelizumab 600 mg|A single does of 600 mg infusion administered 24 weeks after the initial dose.
45502288|NCT03813368|Procedure|Whipples pancreatico-duodenectomy|Classic whipples and pylorus preserving
45502289|NCT02048306|Behavioral|Family-based PR program|The 12-week Family-based PR program will consist of psychoeducation for patients and family members (once a week) and exercise training for patients (3 times a week). The psychoeducation component aims to empower the family with strategies to facilitate a functional and healthy adjustment to the disease and includes educational and psychosocial support components.
45389669|NCT00533429|Drug|carboplatin|Area under the curve (AUC) 6, IV, Day 8 cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
45389670|NCT00533429|Drug|bevacizumab|15 milligrams/kilogram (mg/kg), IV, Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
45502290|NCT02048306|Behavioral|Conventional PR program|The 12-week Conventional PR program will consist of psychoeducation (once a week) and exercise training (3 times a week) for patients only.
45502291|NCT01357447|Drug|Dornase alfa|Dose: 2.5 mg solution BID via nebuliser for 2 weeks
45502292|NCT01357447|Drug|Saline|2.5 ml via nebuliser BID for 2 weeks (alternating with study drug)
45502293|NCT02048384|Drug|metformin alone (Arm A)|metformin alone
45502294|NCT02048384|Drug|metformin (Arm B)|rapamycin + metformin
45502295|NCT02048384|Drug|rapamycin (Arm B)|rapamycin + metformin
45389671|NCT00533429|Drug|Placebo|oral, daily
45389672|NCT01034124|Drug|warfarin, vitamin K, midazolam|warfarin tablet single dose (10 mg) vitamin K tablet single dose (10 mg) midazolam syrup single dose (5 mg)
45389673|NCT01034202|Drug|NNC126-0083|One of five dose levels administered subcutaneously (under the skin)
45389674|NCT01034202|Drug|Norditropin® SimpleXx®|One of two dose levels, followed by NNC126-0083, administered subcutaneously (under the skin)
45389675|NCT01034202|Drug|placebo|Placebo comparator
45389676|NCT01034202|Drug|NNC126-0083|One of three dose levels administered subcutaneously (under the skin)
45389677|NCT01034202|Drug|Norditropin® SimpleXx®|One of two dose levels, followed by placebo, administered subcutaneously (under the skin)
45502296|NCT01353391|Drug|Metformin|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
45502297|NCT01353391|Drug|Placebo Comparator|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
45502298|NCT01349335|Drug|Tolvaptan|tablet, 15 mg, Qd, for 7 days
45502299|NCT01349335|Drug|Tolvaptan|tablet, 30 mg, Qd, 7 days
45502300|NCT01349335|Drug|placebo|tablet, 30 mg, Qd, 7days.
45389678|NCT00533273|Biological|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500 0.58 mg/placebo into the cord of the affected hand in the double-blind phase. In the open-label extension phase, subjects could have received up to five additional injections of AA4500, with each injection separated by at least 30 days. Individual joints could have received up to a maximum of three AA4500 injections.
45696373|NCT04354480|Other|Placebo|Participants will receive a single IM injection of matching placebo on Day 1.
45389679|NCT03891641|Behavioral|Treadwell Tredlr|Complete treadling exercise 3x per week (15 min sessions) for 6 weeks.
45389680|NCT00995267|Behavioral|parent-child interaction/activities based on Adler's methods|"Description of the Intervention:~5 joint classroom activities (parents and children together, involving children in food choices/food preparation-sense of belonging/decision making): 1. Healthy breakfasts and 10 o'clock snacks 2. Fats and oils in the diet, cooking methods, setting limits to oily food intake. 3. Fruit and vegetables in the daily diet, adults as role models. 4. Learning about food categories & pyramid, healthy eating and growth. 5. Limiting consumption of sweets and snacks.~Workshop for Parents: Explaining nutritional needs of children; how to encourage good eating habits, how to deal with children's manipulations, providing tools to elicit change; use of food to attract parental attention; practical tools to deal with their children's eating habits/obesity/refusal to eat/chronic health problems/failure to grow; ways to prevent use of food as an answer to childhood frustrations."
45389681|NCT00339183|Drug|Panitumumab|Panitumumab was administered by IV infusion on Day 1 of each 14-day cycle, just before administration of FOLFIRI chemotherapy.
45389682|NCT00339183|Drug|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m^2, leucovorin 400 mg/m^2 racemate (or 200 mg/m^2 I-leucovorin), 5-FU bolus 400 mg/m^2, 5-FU infusion 2400 mg/m^2.
45389683|NCT02533245|Other|Home-based indiviualized exercise training program|Based on these results of the cardiopulmonary exercise test (CPET) on a cycle ergometer, an individualized training program (cycling/hiking) is prescribed by a physical therapist for 6 months (3x/week, ≥30min/session).
45389684|NCT02533245|Other|Supervised group training sessions|7 supervised group training sessions (cycling/hiking) are organized by a physiotherapist
45389685|NCT02533245|Other|Climb of the Mont Ventoux|Cycle or hike up the Mont Ventoux (25.7 km, average slope 4.5%)
45389686|NCT01058343|Biological|IFN-K|3 to 4 IM injections over 3 months
45389687|NCT01054833|Procedure|Needleless mid-urethral sling|The Needleless® sling is intended for use in women as a tension free, sub-urethral slings for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency. The Needleless sling is a macroporous, monofilament, knitted polypropylene featuring 'Pocket Positioning Anchors' which allow sling placement without needle introducers; thus eliminating a complicated aspect of the surgery (TVT/TOT) and reducing the potential for bladder injury or inguinal pain that can occur during transobturator needle passage. The Needleless sling was approved by KFDA, and now is available in worldwide including Korea.
45389688|NCT01325025|Other|High-field MRI (3 Teslas)|"anatomical location~conventional anatomical sequence T1, T2, FLAIR~diffusion tensor sequence (21 directions)~high angular resolution diffusion (HARDI) sequence~field map~reflexology T1, T2~spectroscopic imaging sequence"
45389689|NCT01325025|Other|High-field MRI (3 Teslas)|"anatomical location~conventional anatomical sequence T1, T2, FLAIR~diffusion tensor sequence (21 directions)~high angular resolution diffusion (HARDI) sequence~field map~reflexology T1, T2~spectroscopic imaging sequence"
45502301|NCT03040921|Procedure|Uterine transposition.|Surgical transposition of the uterus to the upper abdomen. After the end of radiotherapy, rectosigmoidectomy is performed and the uterus is repositioned into the pelvis.
45696374|NCT03567525|Procedure|lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels|After pelvic lymph node dissection, lymphatic vessels will be sealed by formation of a peritoneal iliac flap in which the bladder in folded over the area of lymph node dissection
45696375|NCT03567525|Procedure|Standard surgical approach|After pelvic lymph node dissection, lymphatic vessels will be sealed using the standard approach
45696376|NCT02084511|Drug|Placebo to BI 1026706 solution|Placebo to BI 1026706 solution
45696377|NCT02084511|Drug|BI 1026706|BI 1026706
45696378|NCT02084511|Drug|Placebo to BI 1026706 tablet|Placebo to BI 1026706 tablet
45696379|NCT02084511|Drug|Celecoxib|Celecoxib capsule
45389690|NCT01060605|Drug|rapamycin|Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
45389691|NCT00333801|Behavioral|Vocational Rehabilitation Program (VRP)|Vocational Rehabilitation Program (VRP) is a treatment-as-usual method using traditional train-place approaches, such as prevocational work skills training , compensated work therapy, or transitional work experience, which consists of temporary employment in a brokered-job with time-limited support from the VRP specialist
45502302|NCT03009487|Drug|Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Crestor Tab. 20mg(Rosuvastatin 20mg) and placebo of Olmesartan 40mg
45502303|NCT03009487|Drug|Olmesartan 40 mg, Rosuvastatin 20mg|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Crestor tab. 20mg(Rosuvastatin 20mg) and placebo of Sevikar Tab 10/40mg(Amlodipine/Olmesartan 10/40mg).
45696380|NCT00942448|Drug|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
45696381|NCT00942448|Drug|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
45696382|NCT00942448|Drug|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
45696383|NCT00942448|Other|Placebo s.c.|1 single injection at day of dental surgical extraction
45696384|NCT03532581|Other|Indocyanine Green Solution|Given Subcutaneous injection
45696385|NCT03532581|Procedure|Lymphangiography|Undergo lymphangiography
45696386|NCT02982148|Device|methylene blue intradermal injection|Methylene blue has been prove to be effective and safe as a blue dye for sentinel lymph node biopsy in early breast cancer patient. But it was also reported by some article that adverse skin lesions appeared after methylene blue injections for sentinel lymph node localization. But the effectiveness and safety of methylene blue intradermal injection has not yet been investigated.
45848690|NCT02679066|Device|Sugar-tong splint|Plaster immobilization including the elbow
45848691|NCT02679066|Device|Short forearm cast|Fiberglass immobilization with elbow free
45389692|NCT00333801|Behavioral|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is an evidence--based model of supported employment that emphasizes rapid job search within client preferences, community job development, placement in a competitive job, on-the-job training, time-unlimited follow-along supports, and integration of the IPS specialist within the treatment team.
45389693|NCT00532883|Drug|Hydroxyurea|HU capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
45389694|NCT00532883|Drug|Magnesium Pidolate|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg liquid (0.6 mEq/kg/day for 11 months)
45389695|NCT00532883|Other|Placebo Pills and Placebo Liquid|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
45389696|NCT00993785|Device|Costar Coronary Stent Delivery System|
45389697|NCT00993863|Drug|Placebo|single dose
45389698|NCT00993863|Drug|ADL5859 30 mg|single dose
45389699|NCT00993863|Drug|ADL5859 100 mg|single dose
45389700|NCT00993863|Drug|ADL5859 200 mg|single dose
45389701|NCT00993863|Drug|ibuprofen 400 mg|single dose
45389702|NCT00995423|Device|CoroflexTM Please|highly flexible CoroflexTM Please-Stent
45389703|NCT00995423|Device|Paclitaxel-eluting stent|Paclitaxel-eluting stent
45389704|NCT00993941|Procedure|Autologous BMSCs transplantation|10 ml autologous BMSCs(7~8log10 cells/ml) were infused to patients using interventional method via portal vein as well as conserved therapy for group B.
45389705|NCT00993941|Drug|Conserved therapy|Oral or intravenous administration
45389706|NCT00995657|Drug|Fluticasone Propionate|Inhaled Fluticasone Propionate 50mcg bid
45389707|NCT00995657|Drug|Fluticasone Propionate|Inhaled Fluticasone Propionate 250mcg bid
45389708|NCT00994097|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
45389709|NCT00994097|Drug|Cisplatin|Cisplatin: 80 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
45389710|NCT00994097|Drug|Gemcitabine|Gemcitabine: 1,250 mg/m² intravenous infusion on days 1 and 8 every 3 weeks for a maximum of 6 cycles
45389711|NCT00994097|Drug|Pemetrexed|Pemetrexed: 500 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
45389712|NCT00995735|Procedure|Cholecystectomy|Cholecystectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
45848692|NCT02590068|Drug|Zoster vaccine live|Single Zostavax vaccine, 0.65 ml dose, administered subcutaneously
45389713|NCT00995735|Procedure|Appendectomy|Appendectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
45389714|NCT04000919|Drug|5HTP|5HTP/carbidopa (50-200 mg 5-HTP/50 mg carbidopa)
45389715|NCT04000919|Drug|L-DOPA|L-DOPA/carbidopa (50-200 mg L-DOPA/50 mg carbidopa)
45389716|NCT04000919|Drug|Placebo oral tablet|Placebo
45389717|NCT04000919|Drug|Carbidopa|Carbidopa (50mg)
45848693|NCT02587650|Drug|Capmatinib|Given PO
45389718|NCT05223881|Device|13^C Spirulina Platensis Gastric Emptying Breath Test (GEBT)|After an overnight (minimum 8 hours) fast, patients are given a standardized test meal, after which they are administered the GEBT. Patients are asked to hold a glass tube in a comfortable position, take a deep breath and pause momentarily, blow gently into the tube for 5 - 10 seconds, slowly withdraw straw from tube while continuing to breath into tube, and immediately close the tube securely with the cap.
45389719|NCT05222789|Procedure|TAP|The transverse abdominal plane (TAP) block is a regional anesthesia technique performed using ultrasound that blocks the afferent nerves of the anterolateral abdominal wall, injecting local anesthetic in the fascial plane between the deep oblique and the transversus abdominis muscles.
45389720|NCT00995813|Biological|Rotarix|A rotavirus vaccine (Rotarix) will be administered in two doses, 8 weeks apart, in infants between 6 and 14 weeks of age. The standard dosage is 1 mL administered orally or per gastrostomy tube.
45389721|NCT00994253|Drug|Aliskiren|Aliskiren will be prescribed at 150mg po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 300mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily.
45389722|NCT00994253|Drug|Hydrochlorothiazide|Hydrochlorothiazide will be prescribed at 12.5 po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 25mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily
45389723|NCT00994331|Procedure|Percutaneous coronary intervention|non surgical procedure to open blocked coronary arteries
45389724|NCT00995969|Drug|placebo|1.0 g (w/w) placebo cream applied to both target lesions twice daily
45389725|NCT00995969|Drug|CT 327|1.0 g CT 327 cream will be applied to one target lesion twice daily and 1.0 g placebo cream will be applied to the remaining target lesion twice daily
45502304|NCT03009487|Drug|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg) 10/40mg, Placebo of Olmesartan Tab. 40mg and Placebo of Rosuvastatin 20mg
45848694|NCT02587650|Drug|Ceritinib|Given PO
45848695|NCT02587650|Drug|Entrectinib|Given PO
45848696|NCT02587650|Other|Laboratory Biomarker Analysis|Correlative studies
45848697|NCT02587650|Drug|Regorafenib|Given PO
45389726|NCT00994487|Other|High Energy Density Preload|Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is high in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles
46056787|NCT05753176|Behavioral|Online 1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained facilitators (i.e., registered psychotherapists, social workers, registered nurses, and/or a psychiatrist) consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. We also provide a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD.
45389727|NCT00994487|Other|Low Energy Density Preload|Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is low in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles.
45389728|NCT00996047|Genetic|cytogenetic analysis|
45389729|NCT00996047|Genetic|fluorescence in situ hybridization|
45389730|NCT00996359|Biological|Irradiated haploidentical allogeneic lymphocytes|Partially HLA-matched irradiated donor lymphocytes will be infused after total body irradiation.
45389731|NCT00996359|Radiation|total-body irradiation|100 cGy TBI
45389732|NCT00994565|Behavioral|Activity monitoring and distance counseling|The physical activity monitoring and distance counseling concept combines the use of a personal activity monitor with web-based tailored physical activity advice. Users can interactively plan and evaluate their own activity advice based on their actual PA scores and their PA preferences and goals.
45389733|NCT00354159|Device|Implantable Hemodynamic Monitor (Chronicle® IHM), and IHM in combination with single chamber ICD (Chronicle ICD)|Surgical implantation of hemodynamic device (IHM), or IHM/ICD, and intracardiac leads.
45389734|NCT00338949|Drug|Switch|Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.
45389735|NCT00338949|Drug|Control|Participants will remain taking the same medications of risperidone or olanzapine as they were before study entry.
45389736|NCT01325259|Other|neuropsychologic assessment|Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI
45389737|NCT01325259|Radiation|[18F]AV-45 PET|intravenous injection of 4 MBq/kg of [18F]AV-45
45389738|NCT01325259|Radiation|18-FDG PET|intravenous injection of 100 to 120 MBq of FDG
45389739|NCT01325259|Other|MRI|Magnetic Resonance Imaging
45389740|NCT01058499|Behavioral|Mindfulness Based Stress Reduction Program (MBSR)|Traditional eight-week MBSR Program.
45502305|NCT02048540|Biological|Bevacizumab|Bev (5 mg/kg, d1) every 3 weeks, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
45502306|NCT02048540|Drug|docetaxel oxaliplatin 5-FU CF|docetaxel, 75 mg/m2, iv, d1; oxaliplatin, 85 mg/m2, iv, d1; 5-FU, iv infusion 600 mg/m2 and iv injection 400mg/m2, d1-2; CF, 200 mg/m2, d1 and d2 each 3-week, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
45502307|NCT02048540|Procedure|Gastrectomy|
45502308|NCT01353469|Drug|Insulin human/Insuman Comb 25 (HR1799)|"Pharmaceutical form:Suspension~Route of administration: Subcutaneous"
45502309|NCT01353469|Drug|Insulin human/Novolin® 30R|"Pharmaceutical form:Suspension~Route of administration: Subcutaneous"
45502310|NCT03562208|Biological|Adult Bone Marrow Stem Cells|Autologous Bone Marrow Stem Cells Transplant
45502311|NCT03562130|Drug|Teduglutide|Daily sub cutaneous injection 0,05 mg/kg/day
45502312|NCT02050178|Drug|OMP-54F28, Nab-Paclitaxel and Gemcitabine|
46056788|NCT02719587|Procedure|Placebo|placebo drug identical except for the fish oil supplement, were only performed at baseline.
46056789|NCT02719587|Procedure|Omega-3|omega-3 PUFAs supplement, were only performed at baseline.
45502313|NCT02050256|Other|continuing medical education and electronic decision support|
45502314|NCT02050256|Other|education and electronic support|Continuing medical education and electronic decision support to General Practitioners.
45502315|NCT02037074|Drug|Drug: EVP-6308|Arms 1, 2, 3
45389741|NCT03988881|Procedure|Revascularization|PCI or CABG
45389742|NCT00332709|Drug|Letrozole|2.5 mg/day for 3 years
45389743|NCT00332709|Drug|Zoledronic acid|4 mg every 6 months
45389744|NCT03988725|Dietary Supplement|Vitamin E|Vitamin E 800 IU once daily
45389745|NCT03984279|Other|Patients with indication of interventional percutaneous diagnostic or therapeutic chest-abdomen-pelvic procedure under CT control|Not applicable, all patients with indication of interventional percutaneous diagnostic or therapeutic chest-abdomen-pelvic procedure under CT control on a period of 1 year will be taken into account
45389746|NCT03984123|Device|Brachial cuff, in order to achieve ischemic stimuli|Standard treatment with no brachial cuff inflation
45389747|NCT00332241|Drug|Aripiprazole|Tablets, Oral, 5, 10, or 15 mg, once daily, 8 weeks
45389748|NCT00332241|Drug|Placebo|Tablets, Oral, once daily, 8 weeks
45389749|NCT01054989|Biological|Fat/Inflammation effects|Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours
45389750|NCT01058577|Device|Non-invasive CGMS|A non-invasive continuous glucose monitoring device measured was applied at the wrist and measured skin glucose as an indirect measure of blood glucose every 10 min.
45502316|NCT02037074|Drug|Placebo|Arm 4
45502317|NCT02048618|Drug|GLPG0634|100 mg oral tablet, intake once daily for 20 weeks
45502318|NCT02048618|Drug|Placebo|placebo oral tablets, intake once daily for 20 weeks
45389751|NCT01058577|Procedure|Hyperglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (16.7 mmol/L) for at least 2.5h and euglycemia (5 mmol/L) for another 2.5h. A continuous somatostatin infusion was initiated after 1h to suppress endogenous insulin secretion. A glucose solution was infused to increase the blood glucose towards the hyperglycemic target level. At approximately t=3.5h the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level.
45389752|NCT03985683|Other|agility tests|In control group athletes will perform T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
45389753|NCT03985683|Dietary Supplement|Nutritional Interventional|Athletes were given 50 % carbohydrate in first 3 days and 70 % in next 3 days respectively.T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
45389754|NCT03983889|Drug|Midazolam|Midazolam is used as a common medication for sedation in all groups.
45696387|NCT02982148|Device|methylene blue subcutaneous injection|Methylene blue subcutaneous injection has become one of the standard method for sentinel lymph node biopsy for breast cancer patients. In such case, we use this method to be an active comparator for the intradermal injection group.
45696388|NCT04697758|Drug|AXT107 0.1 mg|Single intravitreal injection of AXT107 0.1 mg/eye
45389755|NCT03983889|Drug|Fentanyl|Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
46056790|NCT02719587|Procedure|SRP|Instrumentation was performed until the root surface was considered smooth and clean, according to the operator's clinical judgement.
46056791|NCT04022044|Behavioral|Observational group|
45389756|NCT03983889|Drug|Dexmedetomidine|Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
45389757|NCT03983889|Drug|Remifentanil|Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
45389758|NCT03983889|Drug|Propofol|Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
45389759|NCT00337935|Drug|Epoetin Alfa|Epoetin alfa administered at 20,000 IU subcutaneously every 2 weeks for a period of 26 weeks
45389760|NCT00337935|Other|Standard of care|
45389761|NCT00337779|Drug|Glatiramer Acetate (GA) 40 mg|Glatiramer Acetate Injection 40 mg/ml Daily subcutaneous injection for 12 months
45389762|NCT00337779|Drug|glatiramer acetate 20 mg|Glatiramer Acetate Injection 20 mg/ml Daily subcutaneous injection for 12 months
45389763|NCT03983811|Drug|Icotinib|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity
45502319|NCT02047448|Procedure|Pharmacist Counseling|The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
45502320|NCT02050412|Other|Cat fur scratch test|
45696389|NCT04697758|Drug|AXT107 0.25 mg|Single intravitreal injection of AXT107 0.25 mg/eye
46056792|NCT02719509|Procedure|Cardiac Ultrasound|
46056793|NCT02719197|Drug|AC-083|Hard gelatin capsules for oral administration formulated at a strengths of 1, 10 and 100 mg
45696390|NCT04697758|Drug|AXT107 0.5 mg|Single intravitreal injection of AXT107 0.5 mg/eye
45696391|NCT03562455|Other|VRSim 3.0|VRSim 3.0 is a virtual reality training module.
45696392|NCT03562455|Behavioral|In-Person Wheelchair Training|A therapist will be used to train power wheelchair users.
45696393|NCT05620186|Other|PROSPECT|PROficiency Based StePwise Endovascular Curricular Training
45696394|NCT04359082|Dietary Supplement|CocoaVia supplement|CocoaVia is a dietary supplement that has concentrated bioflavanols of 225 mg flavanols per pill along with 30 mg theobromine and 10 mg caffeine
46056794|NCT02719197|Drug|Placebo|Placebo capsules matching AC-083 capsules
46056795|NCT02719431|Drug|Warfarin|
46056796|NCT02719431|Drug|K-877|
46056797|NCT00806494|Drug|Fesoterodine|Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated
46056798|NCT02725125|Biological|EPCAM-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
45389764|NCT03983811|Drug|Placebo|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated placebo (D8-15) every 3 weeks, and continued placebo for 2 years or until the occurrence of disease relapse, metastasis or unacceptable toxicity
45389765|NCT03983811|Other|chemotherapy|Patients in each groups need to receive 4 cycles of platinum-based doublet chemotherapy
45389766|NCT00352755|Procedure|Surgical debulking with peritonectomy|
45389767|NCT00352755|Drug|Intraperitoneal 5FU|
45389768|NCT00352755|Drug|FOLFOX|
45389769|NCT00533897|Drug|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly, (Short Term (3 periods - 12 weeks each; Long Term)
45389770|NCT00533897|Drug|Placebo|Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)
45389771|NCT05212727|Device|Eye-tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
45696395|NCT04359082|Other|Placebo Pill|Placebo pill has no bioflavanols with 30 mg theobromine and 10 mg caffeine
46056799|NCT02719275|Behavioral|Social Media Monitoring|Retrospective analyses of social media activity prior to crisis.
45696396|NCT04359316|Drug|Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
45696397|NCT04359316|Drug|Azithromycin|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Azithromycin in COVID-19 patients.
45696398|NCT03559569|Biological|Biological samples will be done to evaluate the endothelial and leukocyte senescence.|Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.
45389772|NCT00426660|Drug|maraviroc|The nominal dose for maraviroc is 300 mg twice a day (BID). However, the dosage of maraviroc should be adjusted based on optimal background therapy (OBT) patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
45389773|NCT00426270|Drug|Octagam 10%|Octagam 10% was supplied as a ready-to-use solution in glass bottles.
45389774|NCT00330681|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
45389775|NCT00330681|Drug|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
45389776|NCT01061073|Drug|Omexel|
45389777|NCT01061073|Drug|spasfon|
45389778|NCT00329901|Biological|Meningococcal ACWY conjugate vaccine (MenACWY-CRM)|
45389779|NCT00329901|Biological|Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)|
45389780|NCT00329901|Biological|saline placebo|4.5 mg sodium chloride per 0.5 ml dose
45389781|NCT01061229|Drug|Homeopathic drug C12|Subjects in the intervention group are instructed to take five globules of the trial drug (potency C12), five times per day for a maximum of five days (5×5×5). The study medication is obtained from DHU (Germany), produced according to the Hahnemannian method. Subjects are asked to stop taking the medication, in agreement with their investigator, if they experience any of a predefined set of proving symptoms
45389782|NCT01061229|Other|Placebo|Placebo consists of pure sucrose globules (DHU, Germany) that are not potentiated nor impregnated with alcohol. The administration scheme is identical in the placebo control group to that of the intervention group.
45502321|NCT02048696|Other|Secondary prevention and cardiac rehabilitation clinic|Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
45502322|NCT02048774|Behavioral|Designation of Social Positioning|
45502323|NCT02048852|Other|Reduced Nicotine Content- Non Menthol|Switch from own brand of cigarette to a research cigarette with a Reduced Nicotine Content of 0.07mg nicotine yield without menthol.
45502324|NCT02048852|Other|Reduced Nicotine Content- Menthol|Switch from own brand of cigarette to Reduced nicotine level of each research cigarette to 0.07mg nicotine yield with Menthol
46056800|NCT02725047|Other|Cryotherapy|Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
45389783|NCT00436956|Procedure|Magnetic Resonance Imaging (DCE-MRI)|Scans evaluate tumor tissue and blood flow.
45389784|NCT00436956|Drug|AZD2171|20 mg oral daily for 28 days
45389785|NCT00436956|Drug|Prednisone|10mg orally daily in combination with AZD2171 20mg daily.
45389786|NCT01323504|Other|Music|Patient are listen music during their local care
45389787|NCT01323504|Other|no music|There are no music during the local care
45389788|NCT00329745|Biological|Rotarix™|Oral administration, 2 doses
45389789|NCT00329745|Biological|Placebo|Oral administration, 2 doses
45389790|NCT01031784|Device|holmium-166 poly lactic acid microspheres|Intra arterial administration of radioactive Holmium 166 microspheres; 600 mg with a specific activity ranging from 1260 MBq per kilo liver weight to 5040 MBq in the highest dose
45389791|NCT01031784|Device|holmium 166 microspheres|intra arterial administration of holmium 166 microsphers in the hepatic artery
45502325|NCT02048852|Other|Conventional Nicotine Content- Menthol|Allow own brand of Conventional Nicotine-Menthol Cigarette
45502326|NCT02048852|Other|Conventional Nicotine Content- Non Menthol|Switch from own cigarette to a research cigarette which contains Conventional Nicotine yield.
45502327|NCT03561974|Device|Humidification|Patients will benefit of humidification and warming of delivered gaz by non-invasive ventilation thanks humidification system.
45502328|NCT02048930|Device|Budesonide Easyhaler|
45502329|NCT02048930|Device|Budesonide dry powder inhaler|
45696399|NCT03762135|Other|Full version of the LIITah App.|Participants will download the LIITAH app. For the first 2 weeks the app. will only record presence in a restaurant and ask users to submit photos of their food. in week 3 all of the program features will be activated.
45696400|NCT03762135|Other|Partial App. (ELI and SNAP only)|Participants will download the LIITAH app. It will detect their presence in a restaurant and users will submit annotated photos of their purchases
45389792|NCT01031862|Other|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
45696401|NCT00939796|Device|Acclarent Tympanostomy Tube Delivery System|A device which provides a means to create a myringotomy with insertion of a proloaded tympanostomy tube (TT) for placement of the TT in patients indicated for such treatment for Otitis Media
45696402|NCT03558867|Drug|Metformin + Healthy diet|Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
45389793|NCT01324050|Behavioral|Internet-delivered psychodynamic therapy for depression|This intervention contains 9 text-based self-help modules. These modules contain material inspired by psychoanalytic theory about identifying reoccurring patterns in life among other things. In addition to the self-help modules, 10-15 minutes of therapist contact is given every week. In total, the intervention will last for 10 weeks.
45389794|NCT01324050|Behavioral|Internet-delivered therapist support|This intervention contains 1 text-based self-help module, which is mainly based on information on depression. In addition to this text, the participants in this group gets 10-15 minutes of therapist contact every week. In the conversation with the therapist, the participant informs the therapist about the activities during the week. This intervention is considered to be a form of support. In total, the intervention will last for 10 weeks.
45389795|NCT00436644|Drug|Lapatinib|1250 mg orally days 1 -28.
45389796|NCT00436644|Drug|Topotecan|3.2 mg/m2 IV over 30 min in 100mL D5W (5% dextrose in water) or 0.9% NS at days 1, 8 & 15.
45389797|NCT01037556|Drug|PR104|Nine pre-defined dose levels for specific subsets of subjects will be administered by IV (in the vein). PR104 will be administered initially as induction therapy followed by administration as consolidation therapy, as is typical of established treatment regimens in AML.
45389798|NCT00324987|Biological|Bevacizumab|Given IV
45389799|NCT00324987|Drug|Imatinib Mesylate|Given PO
45389800|NCT00324987|Other|Laboratory Biomarker Analysis|Correlative studies
45389801|NCT00324987|Other|Pharmacological Study|Correlative studies
45696403|NCT03558867|Drug|Metformin + Personalized diet|Metformin (1500 mg/d, Extended Release) + Algorithm-based personalized diet
46056801|NCT02725047|Other|Placebo - Sand|Sand (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sand bags, they will be fixed with an elastic bandage (compression). Also, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton) to mimic the experimental group.
46056802|NCT02719119|Procedure|monthly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation monthly.
46056803|NCT02719119|Procedure|bi-weekly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation bi-weekly.
46056804|NCT02948361|Other|QT Ultrasound Breast Scan|Subjects will be scanned on the QT Ultrasound Breast Scanner. For subjects that may have breast calcifications and/or mass(es) and/or other finding(s) on the QT scan image(s), standard imaging modalities (e.g., mammogram and HHUS) will be performed per American College of Radiology (ACR) recommendations.
46056805|NCT02719041|Other|Immunohistochemistry staining method|
46056806|NCT02718885|Dietary Supplement|Inulin|Females will ingest 2 doses of 5g/inulin for a total of 10g/inulin/day for four weeks Males will ingest 2 doses of 7.5g/inulin for a total of 15g/inulin/day for four weeks
45389802|NCT00324675|Drug|Rosiglitazone|4 mg tablets, bid, 12 months
45389803|NCT00324675|Drug|Placebo|2 tablets per day
45389804|NCT03988413|Drug|25mg|SYHA1402 25mg or Placebo 25mg
45389805|NCT03988413|Drug|50mg|SYHA1402 50mg or Placebo 50mg
45389806|NCT03988413|Drug|100mg|SYHA1402 100mg or Placebo 100mg
45389807|NCT03988413|Drug|200mg|SYHA1402 200mg or Placebo 200mg
45389808|NCT03988413|Drug|400mg|SYHA1402 400mg or Placebo 400mg
45389809|NCT03988413|Drug|800mg|SYHA1402 800mg or Placebo 800mg
45389810|NCT01055145|Drug|levofloxacin, moxifloxacin|Levofloxacin 750mg po per day for 3 months vs. Moxifloxacin 400mg po per day for 3 months
45389811|NCT00436566|Biological|trastuzumab|
45389812|NCT00436566|Drug|cyclophosphamide|
45389813|NCT00436566|Drug|doxorubicin hydrochloride|
45389814|NCT00436566|Drug|lapatinib ditosylate|
45389815|NCT00436566|Drug|paclitaxel|
45389816|NCT00436566|Genetic|gene expression analysis|
45389817|NCT00436566|Genetic|reverse transcriptase-polymerase chain reaction|
45389818|NCT00436566|Other|fluorophotometry|
45389819|NCT00436566|Other|laboratory biomarker analysis|
45389820|NCT00436566|Other|mass spectrometry|
45389821|NCT00436566|Procedure|adjuvant therapy|
45389822|NCT00436566|Procedure|quality-of-life assessment|
45389823|NCT01060683|Biological|Hemoglobin determination + NaCl 0.9% bolus|
45389824|NCT01060683|Biological|hemoglobin determination + Venofundin bolus|
45389825|NCT01060761|Behavioral|Rehabilitation program|"Patient and their relative receive three supportive, structured conversation with a trained nurse.~Patient and their relative receive 4 days Retreat Weekend with supportive talk and activities"
45389826|NCT01055301|Drug|bortezomib|
45389827|NCT01055301|Drug|cisplatin|
45389828|NCT01055301|Drug|cyclophosphamide|
45389829|NCT01055301|Drug|dexamethasone|
45389830|NCT01055301|Drug|doxorubicin hydrochloride|
45696404|NCT00939874|Drug|Raltegravir|Raltegravir tablet 400mg is taken orally, twice daily with or without food for 48 weeks.
45696405|NCT03557697|Behavioral|Standard of Care|At the end of the study the control group will be provided with the opportunity to receive counseling videos delivered via SMS
45696406|NCT03557697|Behavioral|SMS Intervention|Participants in the intervention group will receive SMS based video counseling which include both educational and SCT=-based behavioral content. In addition, participants will receive biweekly phone calls from study community health workers to review the video content and clarify questions, set goals, and problem-solve barriers to achieving the goals.
45696407|NCT04359160|Device|Orthense, Orthense, Digikare Inc. Blagnac, France|Mobile-app follow-up care, with questions and score
45696408|NCT04359160|Other|Questionnaire|Paper questionnaire follow-up, with questions and score
45389831|NCT01055301|Drug|etoposide|
45389832|NCT01055301|Drug|lenalidomide|
45389833|NCT01055301|Drug|melphalan|
45389834|NCT01055301|Drug|thalidomide|
45389835|NCT01055301|Genetic|gene expression analysis|
45389836|NCT01055301|Genetic|microarray analysis|
45389837|NCT01055301|Other|laboratory biomarker analysis|
45389838|NCT01055301|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|
45389839|NCT01055379|Drug|Rasagiline|1 mg/day for 12 weeks; orally
45389840|NCT01055379|Drug|Placebo|Once daily for 12 weeks; orally
45389841|NCT01031940|Device|macintosh laryngoscope|intubate with the macintosh laryngoscope
45502330|NCT02049008|Other|Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). The applications of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
45696409|NCT03557385|Drug|Iopamidol|"aFFR measurement with drug: Iopamidol (ISOVUE®-370). Subjects will receive an injector-based intracoronary bolus of contrast~Rate of 4 mL/sec, volume of 10 cc (left coronary system)~Rate of 3 mL/sec, volume of 6 cc (right coronary system)."
45696410|NCT03557385|Drug|adenosine|FFR measurement with drug: adenosine. Intravenous adenosine will be administered at a rate of 140 μg/kg of body weight per minute x 2 minutes
45696411|NCT03557385|Device|Navvus® Catheter|the NAVVUS RXi microcatheter will be used with a workhorse wire of the operator's choosing
45389842|NCT01031940|Device|C-MAC laryngoscope|intubate with the C-MAC laryngoscope
45389843|NCT01031940|Device|Airtraq device|intubate with the Airtraq device
45389844|NCT03988101|Drug|Rosuvastatin 20mg|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
45389845|NCT03988101|Drug|Control|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
45389846|NCT03987945|Device|left atrial appendage occlusion devices|All NVAF patients who are admitted for receiving left atrial appendage occlusion procedure, including Watchman, LAmbre, Lefort, and Leftear deveices.
45389847|NCT00352365|Drug|lenalidomide|Given orally
45389848|NCT01055535|Drug|Microplasmin|125 µg intravitreal injection
45389849|NCT03987867|Biological|CIK cell|CIK cell injection
45389850|NCT03987867|Biological|Sintilimab Injection|IBI308 injection
45389851|NCT03987867|Drug|Pemetrexed|Pemetrexed injection
45389852|NCT03987867|Drug|Liposome paclitaxel|Liposome paclitaxel injection
45389853|NCT03987867|Drug|Carboplatin|Carboplatin injection
45389854|NCT00532493|Drug|prazosin|"Subjects will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. As a further precaution, male subjects will be advised to sit on the toilet for urination at night during the first week of dose titration. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) and then titrating the dose upward gradually."
45389855|NCT00532493|Other|placebo|"sugar pill"
45389856|NCT00996515|Drug|5-azacytidine, erlotinib|Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15
45389857|NCT00996515|Drug|Erlotinib PO and Vidaza IV|Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.
45389858|NCT00994799|Drug|ranibizumab|10mg/ml intravitreal injection
45389859|NCT00994799|Radiation|macular grid-pattern laser|macular grid-pattern laser therapy
45389860|NCT00533507|Biological|Synflorix|Intramuscular injection, 3 doses.
45389861|NCT00533507|Biological|Infanrix hexa|Intramuscular injection, 3 doses.
45389862|NCT00533507|Biological|Rotarix|Oral, 2 doses.
45389863|NCT04000607|Device|Atrial Shunt|Transcatheter treatment of symptomatic left heart failure patients
45389864|NCT00996671|Drug|GSK2256098|focal adhesion kinase inhibitor given as a single dose
45389865|NCT00996671|Drug|Placebo|Placebo to be used as comparator for GSK2256098
45389866|NCT00996749|Dietary Supplement|omega-3 fatty acid|Given PO
45389867|NCT00996749|Other|bone scan|Correlative studies
45389868|NCT00996749|Other|dual x-ray absorptometry|Correlative studies
45389869|NCT00996749|Other|laboratory biomarker analysis|Correlative studies
45389870|NCT00996749|Procedure|biopsy|Correlative studies
45389871|NCT00994955|Device|selective retina therapy (SRT)|laser treatment
45389872|NCT03886493|Drug|Dupilumab|dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.
45502331|NCT02049008|Other|Sham Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. The simulations of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
45696412|NCT03557385|Device|CVi® Contrast Delivery System|The CVi® Contrast Delivery System will be used to deliver the contrast medium
46056807|NCT02718885|Dietary Supplement|Maltodextrin|Females will ingest 2 doses of 5g/maltodextrin for a total of 10g/maltodextrin/day for four weeks Males will ingest 2 doses of 7.5g/maltodextrin for a total of 15g/maltodextrin/day for four weeks
46056808|NCT02724813|Behavioral|Cognitive Orientation to Occupational Preformance (COOP)|
45389873|NCT00352053|Drug|Tenofovir DF|Tenofovir DF 300-mg tablet, administered orally, daily + OBR
45389874|NCT00352053|Drug|Placebo|Tenofovir DF Placebo administered orally, daily + OBR
45389875|NCT00995033|Biological|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
45389876|NCT00995033|Biological|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 6 doses over 6 months
46056809|NCT00806416|Drug|alendronate sodium (+) cholecalciferol|A single dose tablet of 70 mg alendronate/2800 IU (international unit) vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
45389877|NCT00995033|Drug|Varenicline|Days 0-2: 0.5 mg once daily, Days 3-6: 0.5 mg twice daily (morning and evening), Day 7- 84: 1.0 mg twice daily (morning and evening)
45389878|NCT00996905|Device|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
45389879|NCT00996905|Device|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
45389880|NCT00998855|Behavioral|Exercise|12 wk aerobic or/ resistance exercise program
45389881|NCT00997061|Drug|HYCAMTIN|Observing patients on HYCAMTIN and other drugs for SCLC.
45389882|NCT00351819|Drug|AndroGel|5g gel, applied once daily to the upper arms, upper back or shoulders.
45389883|NCT00351819|Other|Placebo|5g gel, applied once daily to the upper arms, upper back or shoulders.
45389884|NCT00998933|Drug|Testosterone gel 1.62%|5 grams applied topically to upper arms/shoulder and abdomen on Day 1
45389885|NCT00997217|Procedure|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min upper limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis or cardiopulmonary bypass)
45389886|NCT00999089|Procedure|Conventional Coronary Artery Bypass|Coronary artery bypass grafting with extracorporeal circulation and cardioplegic arrest
45389887|NCT00999089|Procedure|Off-Pump Coronary Artery Bypass|Coronary artery bypass grafting without extracorporeal circulation or global myocardial ischemia
45389888|NCT00999089|Procedure|Pump-Assisted Coronary Artery Bypass|Coronary artery bypass grafting with a beating but unloaded heart by using extracorporeal circulation
45389889|NCT00351351|Device|Cyberwand|FDA approved - dual probe intracorporeal lithotrite
45389890|NCT00351351|Device|single probe ultrasonic|FDA-approved - single probe ultrasonic
45389891|NCT00997451|Behavioral|Cognitive-behavioral self-management|Graded activity, pacing, stress reduction, low effort pleasant activities, cognitive coping skills.
45389892|NCT00997451|Behavioral|Symptom monitoring|Daily symptom via web diary
45389893|NCT03983187|Device|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min/ Bid for 1 month
45389894|NCT00999245|Other|High Demand / Low Infusion|HDLI dosing plan will administer either morphine or hydromorphone using PCA. Dosing will be based on body weight.
45389895|NCT00999245|Other|PCA Dosing Plan|LDHI dosing plan will administer either morphine ot hydromorphone using PCA. Dosing will be based on body weight.
45389896|NCT03983109|Device|EpiFaith loss of resistance detect syringe|An EpiFaith syringe will be used to detect the loss of resistance and facilitate the needle localization.
45502332|NCT02808338|Device|Philips BiPAP AutoSV Advanced System One|Auto SV Auto Servo Ventilation is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. This devices is FDA approved and will be set according to a predetermined setting.
45389897|NCT00323115|Biological|Autologous Dendritic Cell|Vaccine given by cervical lymph node injection 3 times every other week
45696413|NCT04644172|Behavioral|Speed of Processing Training|"Testing involves trainer-guided practice of computerbased video games. The games require the player to identify targets that are presented very briefly. In the first level, the player has to identify a target at the center of the screen. In the second level, the player has to identify targets at the center and edge of the screen simultaneously. In the third level, other objects, which serve as decoys, are added. SOPT is aimed at improving the fluidity of mental processing speed (not psychomotor reaction time) so that trainees can process more complex information over briefer periods of time. The training involves practice with feedback. The trainer teaches some task-specific strategies, offer suggestions, encouragement, and personalized modification of difficulty for enhancing performance. Speed and task difficulty level are tailored to trainee ability, trainees practice blocks of 16 trials with a goal of achieving performance of 10 to 12 correct trials for each training block."
45696414|NCT04644172|Behavioral|Instrumental Activities of Daily Living Shaping|In addition to training on the SOPT software, participants will train on tasks that simulate everyday activities that have important cognitive components (e.g., selecting medicine bottles from a cabinet, measuring ingredients to bake a cake, finding information online). The training will follow shaping principles. Activity periods will be divided into trials of specific length, and the performance of the participant will be measured and graphed to provide the participant with feedback on their performance. Verbal praise will be used to reward a participant for improvements in performance. The difficulty of the task will be increased in small increments as a participant gains mastery. The purpose of this component is to serve as a bridge between the SOPT training, which exercises a basic aspect of cognitiven function, and cognitive function in everyday life, which is embedded in the context of multi-part, and multidimensional tasks.
46056810|NCT00806416|Drug|Comparator: alendronate|A single dose table of 70 mg alendronate in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
46056811|NCT00806416|Dietary Supplement|Comparator: cholecalciferol (Vitamin D)|A single dose tablet of 2800 IU vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
45389898|NCT00323115|Drug|Temozolomide|Radiotherapy (RT) with concurrent temozolomide (TMZ) for 6 weeks before vaccine is SOC
45389899|NCT00323115|Procedure|Radiotherapy|RT is standard of care (SOC) post surgery
45389900|NCT00323115|Biological|Dendritic Cell Vaccine|Vaccine given cervical lymphnode injection 3 times every other week
45502333|NCT02808338|Device|Modified Philips BiPAP ASV|This Modified BiPAP ASV will be set to a predetermined setting. This is the investigational device.
45502334|NCT02808338|Device|ResMed S7 VPAP Adapt|This device is FDA approved and will be set to predetermined setting.
45502335|NCT02808338|Device|ResMed S9 VPAP Adapt|This device is FDA approved and will be set to predetermined setting.
45502336|NCT02050646|Other|Low Salt Diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
45502337|NCT02050646|Other|Liberal salt diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
46056812|NCT02724969|Behavioral|MILK or Text4Baby text message intervention|MILK text message intervention encompasses prenatal and postpartum breastfeeding support and education text messages. Text4Baby text message intervention encompasses prenatal and postpartum text messages about pregnancy, infant care, and postpartum issues.
46056813|NCT02724735|Drug|NSI-189|0 Milligrams, 40 Milligrams or 80 Milligrams administered in the acute study only
45389901|NCT00322881|Drug|Paclitaxel|
45502338|NCT02037386|Device|H-side branch stent|Implantation of H-side branch stent at coronary bifurcation stenotic lesion
45502339|NCT02049086|Behavioral|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)
45389902|NCT00322881|Drug|Carboplatin|
45389903|NCT01061307|Dietary Supplement|fortified extruded rice|fortified extruded rice (Fe, Zn and vitamin A) at the ratio 1:50 with normal rice
45389904|NCT00415194|Drug|pemetrexed|500 mg/m^2, IV, every 21 days, six 21 day cycles
45389905|NCT00415194|Drug|cisplatin|75 mg/m^2, administered IV, every 21 days, six 21 day cycles
45389906|NCT00415194|Drug|placebo|Approximately 100 mL normal saline administered IV, every 21 days, six 21 day cycles
45389907|NCT00436332|Biological|bevacizumab|
45389908|NCT00436332|Drug|erlotinib hydrochloride|
45389909|NCT01034436|Dietary Supplement|fatty acid quality and overweight|Duration 12 weeks
45389910|NCT00532259|Drug|CT-011|IV infusion of 1.5 mg/kg of CT-011 on Day 1(60 to 90 days post autologous PBSCT). Treatment was repeated every 42 days for a total of three courses with treatment visits on Days 1, 43, and 85.
45389911|NCT00322491|Drug|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
45389912|NCT01034514|Device|Real-time Position Management system|Standard of Care
45389913|NCT01034514|Device|Discovery ST multislice PET/CT scanner|Standard of Care
45389914|NCT01034514|Device|Infinia Hawkeye SPECT/CT gamma camera|Standard of Care
45389915|NCT01034514|Device|Pinnacle3 treatment planning system|Standard of Care
45389916|NCT01034514|Device|SKYLight nuclear camera|Standard of Care
45389917|NCT01034514|Drug|DTPA|1 mCi; inhalation
45389918|NCT01034514|Drug|TECHNETIUM TC 99M MAA|3 mCi; iv
45389919|NCT00999323|Device|stent implantation in coronary artery|Percuatenous Coronary Intervention with implanatation of a stent
45389920|NCT00997529|Drug|nonmyeloablative stem cell transplant|Conditioning includes cytoxan 60mg/kg/d on Days 6 & 5, total dose 120mg/kg, Fludarabine 25mg/m2/d on days -5 to -1, total dose 125mg/m2. Patients with decreased cardiac or liver function pre-transplant will have their dose of cytoxan reduced by 25% - 45 mg/kg/d for 2 days or total dose of 90mg/kg. Patients will receive G-CSF (5ug/kg) to foster engraftment. PBSC progenitors will be mobilized from donor with G-CSF 5ug/kg 2x daily starting 4 days prior to stem cell collection until a target of 5-10 x106 CD34+ cells/kg is reached. Peripheral blood progenitors will be isolated from leukaphereses obtained on Days 5 & 6 with additional collections dependent on cell yields. Peripheral blood from donors will be given to patients 1 day after cytoreduction & immunosuppression. Immunosuppression will be tapered Day +60 if no signs of GVHD. Patients with residual non-regressing disease or mixed chimerism after day 100, who are off immunosuppression & do not have signs of GVHD, will receive a DLI
45389921|NCT00997607|Biological|Ebola vaccine|4 mg of Ebola DNA plasmid vaccine, VRC-EBODNA023-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
45389922|NCT00997607|Biological|Marburg vaccine|4 mg of Marburg DNA plasmid vaccine, VRC-MARDNA025-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
45848698|NCT02514252|Drug|Fentanyl Sublingual Spray (FSS)|"Stage 1: First Pain Episode - Single dose of breakthrough opioid given from existing PCA pump equivalent to 10% of their MEDD.~Second Pain Episode - Single dose of FSS equivalent to 16-32% of MEDD. If not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum.~Third Pain Episode (at least 4 hours after second episode) - Participant required 2 breakthrough FSS doses for the last episode of breakthrough pain, or if the effective dose has not been identified, he/she will double the last administered dose. If breakthrough pain not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum).~Stage 2: If FSS successful in hospital, upon discharge, FSS used as first choice of pain medication instead of oral pain medication for pain for up to 4 weeks."
45389923|NCT00997607|Other|Placebo injection|4 mg of saline injection delivered at Weeks 0, 4, and 8
45502340|NCT02049086|Behavioral|Pain Module|The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
45502341|NCT02049242|Procedure|triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
46056814|NCT02724657|Other|Buteyko Method|Intervention will be held twice a week during 3 weeks.
45389924|NCT00322023|Drug|D-serine|D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.
45389925|NCT00322023|Drug|D-serine|
45389926|NCT00322023|Drug|D-serine|
45389927|NCT00322023|Drug|D-serine|
46056815|NCT02724891|Other|paper form|questionnaires in paper form
45389928|NCT00997685|Drug|Capecitabine plus oxaliplatin|"Xeloda: 1000mg/m2 bid, d1-14, q3w, Oxaliplatin:130mg/m2 d1, q3w,~4 pre-operative cycles, 4 post-operative cycles"
45389929|NCT00414960|Drug|Enzastaurin|500 mg po QD for 6 months
45389930|NCT00414960|Drug|Placebo|po QD for 6 months
45389931|NCT01061541|Biological|Tritanrix™-HepB low thio /|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
45389932|NCT01061541|Biological|Hib 2.5|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
45389933|NCT01061541|Biological|Tritanrix™-HepB|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
45502342|NCT02049242|Procedure|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
45502343|NCT02049320|Drug|Remifentanil|
45502344|NCT02050724|Drug|Radioactive labelling of pulmonary nodules|Application directly into a pulmonary nodule
45502345|NCT02050724|Device|CT guided radioactive labelling|CT guided puncture is a standard procedure in radiology. In this study it is used to mark pulmonary nodules for the following thoracoscopic surgery, done with a handheld-SPECT device.
45502346|NCT02050724|Device|Electromagnetic guided bronchoscopic radioactive labelling|Electromagnetic guided bronchoscopy is a standard procedure. In this study it is used to mark pulmonary nodules.
45502347|NCT02260076|Drug|PEG 400|
45715213|NCT05580432|Behavioral|Parenting with Positive Behavior Interventions|"Parenting with Positive Behavior Interventions is a 5 month packaged intervention. The curriculum and each element of the training and coaching program is described in detail below.~Each month, participants will participate in the following five activities:~Didactic Training: Participants will view a presentation~Workbook/Homework: Participants will complete a guided worksheet~Coaching Meeting - Planning: Participants will meet with a coach who is an expert in autism and behavior~Coaching - Observation/ Feedback: The coach will observe parent implementing the strategy, then provide feedback and direction regarding use of technique~Virtual Parent Community of Support Meeting: Attend parent led community support meeting to network, share experiences and information, and exchange ideas"
45502348|NCT02260076|Drug|Placebo|
45848699|NCT02514252|Behavioral|Questionnaires|Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. After Day 28, questionnaire completed over the phone about participant's opinion of research study.
45848700|NCT02514252|Behavioral|Mental Ability Tests|Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose.
45848701|NCT02514252|Behavioral|Study Diary|Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
45848702|NCT02434146|Drug|Topical Phenylephrine Solution|Given topically via spray
46056816|NCT02724891|Other|web/smartphone form|questionnaires in web/smartphone
46056817|NCT00811252|Drug|Placebo|capsules; daily; orally
45389934|NCT01061541|Biological|Hiberix™|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
45389935|NCT01061541|Biological|Unconjugated Hib vaccine (plain PRP)|One dose as intramuscular injection at 10 months of age
45389936|NCT00997763|Device|XIENCE V|everolimus-eluting stent
45389937|NCT00997763|Device|CYPHER|sirolimus-eluting stent
45389938|NCT00997841|Procedure|Point-of-Care versus conventional coagulation management|Patients are randomized to receive either point-of-care based or conventional coagulation measurements based coagulation therapy in the case of increased perioperative bleeding tendency
45389939|NCT00321789|Behavioral|spouse-assisted intervention|Couples assigned to this arm received nine monthly phone calls from a nurse. The patient created monthly goals and action plans related to diet, exercise, patient-provider communication, or medication adherence. The spouse created plans to support patient goal achievement.
46056818|NCT00811252|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
46056819|NCT00811252|Drug|Duloxetine|encapsulated tablets; daily; orally
46056820|NCT02724501|Behavioral|questionnaire|Using questionnaire to obtain patient's medical and family history of cancer.
46056821|NCT02724501|Procedure|Blood sample-DNA testing / Tumour-genetic markers|Using Samples obtained to produce summary statistics on the tumour markers
45389940|NCT00997919|Drug|MABT5102A|single SC dose
45389941|NCT00997919|Drug|MABT5102A|single IV dose
45389942|NCT00414726|Drug|NBO (Normobaric Oxygen)|High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
45848703|NCT02431494|Device|Blue light phototherapy|Blue light phototherapy (BLU-U Blue Light Photodynamic Therapy Illuminator manufactured by DUSA Pharmaceutical Inc. Wilmington, MA) At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes. The duration of each session will be approximately 20 minutes.
45389943|NCT00414726|Drug|Room Air|Room Air delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
45389944|NCT00997997|Drug|Moxifloxacin (Avelox, BAY12-8039)|400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information
45696415|NCT04644172|Behavioral|Transfer Package from CI Therapy|Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
45502349|NCT02807948|Device|Pacemaker, ICD, or CRT device|MRI Scans on SJM device implanted subjects for clinical purpose
45502350|NCT02050802|Drug|Moxifloxacin 400 mg|
45502351|NCT02050802|Drug|Macitentan 10 mg|
45502352|NCT02050802|Drug|Macitentan 30 mg|
45502353|NCT02050802|Other|Placebo|
45696416|NCT04644172|Other|Usual Care|Healthcare that is available for adults with cognitive impairment subsequent to COVID-19 in the community on a clinical basis. This includes commercially available, gamified, computerized cognitive training programs.
45848704|NCT02431494|Device|Microcurrent therapy|Microcurrent therapy (Micro Current Electro-Device w/gloves and carrying case, SKU:DSE-X1008 Classic Spa Collection) The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated. The duration of each session will be approximately 45 minutes.
45848705|NCT02431494|Device|Combination of BLP and Microcurrent|Same devices as described above. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
45848706|NCT02382588|Drug|gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
45848707|NCT02382588|Drug|Hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
45389945|NCT00998075|Drug|Esomeprazole/ASA Fixed Combination|Capsule, oral, single dose
45389946|NCT00998075|Drug|Esomeprazole - Nexium|Clinical Trial Capsule or MUPS Tablet, oral, single dose
45389947|NCT00998075|Drug|ASA|Tablet, oral, single dose
45848708|NCT02345460|Drug|Irinotecan Hydrochloride|Given IV
45848709|NCT02345460|Drug|Oxaliplatin|Given IV
45848710|NCT02345460|Drug|Leucovorin Calcium|Given IV
45848711|NCT02345460|Drug|Fluorouracil|Given IV
45389948|NCT00998153|Behavioral|Risk Reduction through Family Therapy|Component based intervention based on existing empirically supported treatments
45502354|NCT02051504|Behavioral|Incremental maximal exercise|The exercise test starts 2-4h after a standardised breakfast. After a 2-min resting period sitting on the cycle ergometer (Excalibur Sport, Lode B.V, Medical Technology, Groningen, Netherlands), the test starts at 30 watts with a 20 watts increment every 2min until exhaustion.
45502355|NCT02051504|Dietary Supplement|Oral Glucose Tolerance Test|The subjects arrive after an overnight fast and have a 75g Glucose Oral Charge.
45502356|NCT02051504|Procedure|Muscle biopsy|A sample of vastus lateralis (less than 150mg) is taken with a specific needle under local anesthesia.
45502357|NCT02051504|Procedure|Combined DLCO-DLNO|Lung carbon monoxide and nitric oxide diffusion capacities are assessed at rest in a sitting position.
45502358|NCT02051504|Procedure|Dual energy X-ray absorptiometry|Body composition is measured using dual energy X-ray absorptiometry at rest.
45848712|NCT02345460|Other|Laboratory Biomarker Analysis|Correlative studies
45848713|NCT02345772|Drug|fulvestrant 500 mg|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery.
45848714|NCT02345772|Drug|Docetaxel|Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles.
45848715|NCT02345772|Drug|Trastuzumab (H, 8mg/kg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
45389949|NCT00531947|Drug|Selegiline Transdermal System|EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
45389950|NCT00531947|Drug|Placebo|Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
45389951|NCT00998231|Biological|blood sample|Blood collections and peripheral blood mononuclear cells extraction will be operated after each evaluation and followed by RNA extraction, reverse transcription and gene expression quantification by real-time PCR.
45389952|NCT00998465|Other|24-hour blood pressure|Blood pressure is measured every 15 minutes in the daytime and every 30 minutes at night
45848716|NCT02345772|Drug|Pertuzumab (P, 840 mg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
45389953|NCT00998465|Other|Echocardiography|Standard 2-D and m-mode echocardiography with determination of dimensions, systolic, and diastolic function.
45389954|NCT00998465|Other|Inert gas rebreathing|Cardiac output, stroke volume and total peripheral resistance are tested at rest and during exercise (bicycle ergometer) using non-invasive equipment (inert gas rebreathing - Innocor)
45389955|NCT00998465|Radiation|Dexa-scan|Fat mass and fat free mass is determined with a whole body Dexa scan, and bone mineral density is tested with Dexa-scans of the lumbar spine and proximal femur.
45502359|NCT02051504|Procedure|Accelerometry over one week|The subjects wear an uniaxial accelerometer over one week to assess their usual physical activity level
45502360|NCT02051504|Other|Questionnaires|Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires
45502361|NCT02051582|Procedure|Surgeons using fluoroscopy with laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped with a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
45848717|NCT02280252|Drug|Paclitaxel|Paclitaxel (including Abraxane), 30 mg/m2 twice per week. Paclitaxel will be given IV over 1 hour, Abraxane® will be administered over 30 min, and administered on a Monday/Thursday or Tuesday/Friday schedule.
45389956|NCT00998465|Radiation|Plasma volume|The test is performed using 5 MBq technetium-labeled albumine (99mTc-albumine - Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
45502362|NCT02051582|Procedure|Surgeons using fluoroscopy without laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped without a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
45502363|NCT02051660|Behavioral|Manualized CALM intervention|Managing Cancer and Living Meaning Cancer (CALM) is a short-term individual psychotherapy for patients with advanced disease.
45502364|NCT02051660|Behavioral|Non-manualized supportive intervention.|Supportive psycho-oncological intervention.
45848718|NCT02280252|Radiation|Radiation therapy|Patients will receive a total dose of 45 Gy to the breast, axilla and supraclavicular area at 1.8 Gy/fraction, +14 Gy to the original palpable tumor at 2 Gy/fraction (total 32 fractions)
45389957|NCT00998465|Radiation|Glomerular filtration rate (GFR)|GFR and ECV are determined following injection of 3,7 MBq 51Cr-EDTA and postinjection samples three-four hours after injection.
45389958|NCT00998465|Other|Blood samples|p-glucose, p-insulin, NT-proBNP, hemoglobin, potassium, sodium, creatinine, albumine
45389959|NCT00998465|Other|Urine analyses|24-hour urine collections with determination of u-sodium, u-potassium and u-creatinine.
45389960|NCT00998465|Dietary Supplement|Diets with low and high sodium content|Participants are subjected to 5 days of low (90 mmol/day) and high (250 mmol/day) sodium intake in a randomized order before and 1 year after laparoscopic gastric bypass surgery.
45389961|NCT00998621|Other|Adherence questionnaire|Adherence questionnaire
45389962|NCT00998699|Drug|Xoma 052|Sterile solution subcutaneously administered every 4 weeks for 12 weeks
45389963|NCT00998699|Drug|Placebo|Sterile solution subcutaneously administered every 4 weeks for 12 weeks
45502365|NCT02051738|Drug|Mebendazole - fasted state (Treatment A)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fasted condition.
45696417|NCT03528213|Drug|Sodium Lactate light dose|bolus 2.5ml/kg then 0.25ml/kg/h
45696418|NCT03528213|Drug|Sodium Lactate high dose|bolus 2.5ml/kg then 0.5ml/kg/h
45696419|NCT03528213|Drug|Normal saline|normal saline at physician discretion
45696420|NCT05620030|Other|Univentricular Heart|Prevention of complications when discovered
45848719|NCT02266914|Device|Magnetic Resonance Elastography driver|A driver is required for MRE. The driver utilizes sound waves to produce vibrations. Images of these vibrations are captured with Magnetic Resonance scanner to produce images that indicate stiffness in an organ.
45848720|NCT02262000|Radiation|Image Guided Stereotactic Ablative Radiotherapy|
46056822|NCT02718729|Procedure|Laparoscopic resection for rectal cancer|Formal curative radical laparoscopic rectal resection.
45696421|NCT04601350|Drug|Remimazolam with a dose of 0.05mg/kg for induction of general anesthesia|Remimazolam with a dose of 0.05mg/kg for induction of general anesthesia
45696422|NCT04601350|Drug|Remimazolam with a dose of 0.1mg/kg for induction of general anesthesia|Remimazolam with a dose of 0.1mg/kg for induction of general anesthesia
45389964|NCT00998777|Procedure|Shoulder Strengthening|The intervention program is a 6 week shoulder and scapular stabilizer strengthening program that is performed 3 times per week. The program includes 10 exercises that are performed with Theraband rubber tubing and 2 stretches. The exercises are: shoulder flexion, Ys, Ts, Ws, IR @ 90, ER @ 90, Throwing acceleration, Throwing deceleration, dynamic hug, and low rows. The stretches include the sleeper stretch and the corner stretch.
45389965|NCT01003847|Drug|fenofibrate, fatty acid, placebo|fenofibrate 160 mg, fatty acids 2 gm, placeob 8 weeks of treatment
46056823|NCT02609854|Device|Sustained Acoustic Medicine (SAM)|Long-duration, low-intensity therapeutic ultrasound device that is self-applied and wearable, delivering treatment up to 4 hours per day.
45389966|NCT01003925|Behavioral|Standard of care for osteoarthritis treatment|Standard of care educational materials to inform patients about choices for knee pain.
45389967|NCT01003925|Behavioral|Conjoint Analysis for Osteoarthritis|Conjoint Analysis computer software to inform patients about choices for knee pain.
45389968|NCT00530855|Drug|Lacosamide|50 mg and 100 mg Lacosamide tablets taken for 50 -400 mg twice daily dosing for up to 2 years
45502366|NCT02051738|Drug|Mebendazole - fed state (Treatment B)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fed condition.
45696423|NCT04601350|Drug|Remimazolam with a dose of 0.2mg/kg for induction of general anesthesia|Remimazolam with a dose of 0.2mg/kg for induction of general anesthesia
46056824|NCT02609854|Device|Sham Device|Inactive ultrasound device
46056825|NCT05755594|Procedure|Robot-assisted Pancreaticoduodenectomy|By performing pancreaticoduodenectomy on the subject using the latest generation Da Vinci robotic surgical system and assisted by another surgeon for the entire procedure
46056826|NCT04114617|Other|Starch-thickened liquids|Thickener added in amounts required to reach slightly thick, mildly thick, moderately thick and extremely thick consistencies, as defined by the International Dysphagia Diet Standardisation Initiative flow test.
46056827|NCT04114617|Other|Xanthan-gum thickened liquids|Thickener added in amounts required to reach slightly thick, mildly thick, moderately thick and extremely thick consistencies, as defined by the International Dysphagia Diet Standardisation Initiative flow test.
46056828|NCT04114617|Combination Product|Barium concentration|Commercially available barium products diluted to different concentrations (i.e., 20% w/v, 40% w/v) through the addition of water
45389969|NCT01004237|Drug|pravastatin, valsartan, pravastatin+valsartan|pravastatin 40 mg, valsartan 160 mg 8 weeks of treatment
45389970|NCT01004315|Drug|KUC-7483|
45389971|NCT01004315|Drug|Placebo|
45696424|NCT04601350|Drug|midazolam with a dose of 0.05mg/kg for induction of general anesthesia|midazolam with a dose of 0.05mg/kg for induction of general anesthesia
46056829|NCT04029532|Device|Respiratory exchange ratio|Ask participants to supine on bed, using a ventilator hood cover upon their head. Measure respiratory exchange ratio for 15 minutes.
45389972|NCT01004315|Drug|Tolterodine|
45389973|NCT05165459|Device|Venous leg ulcer treatment with adipous SVF|The Celution® System isolates approximately maximum 30 million SVF cells per 100 mL of adipose tissue to be processed. Approximately 1-3 million cells per injection (total 8-30) will be administered locally, in the target ulcer.
45502367|NCT02050958|Drug|OXP001|
45696425|NCT03758001|Drug|IBI101|0.01 mg/kg; 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg; 15 mg/kg iv infusion day 1 of every 21 days
45696426|NCT03758001|Drug|IBI101|1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg iv infusion day 1 of every 21 days
45389974|NCT05239637|Other|Heparin stopped before ECMO decannulation|Heparin has been stopped for 1 hour before ECMO decannulation;The cannulas can be removed immediately with clots larger than 5 mm or enlarging clots in the circuit.
45389975|NCT05239637|Other|Heparin reduced after ECMO decannulation|Heparin gradually reduced within 24 hours after ECMO decannulation, If excess bleeding occured,decrease the heparin infusion rapidly or turn the heparin off immediately. Protamine can be given to reversing heparin if necessary.
45389976|NCT01004627|Procedure|Arterial and venous duplex ultrasound examination|Ultrasound mapping of all blood vessels in the upper limb of interest
45389977|NCT01004783|Genetic|DNA methylation analysis|
45389978|NCT01004783|Genetic|gene expression analysis|
45502368|NCT02050958|Drug|Ibuprofen|
45502369|NCT02037464|Dietary Supplement|Capsaicin Supplement (Cayenne by Nature's Way)|One capsule of the supplement to be taken twice daily.
45696427|NCT03758001|Drug|Sintilimab|200mg iv infusion day 1 of every 21 days
45696428|NCT05346861|Drug|Trastuzumab plus chemotherapy|Trastuzumab: 8 mg/kg loading dose followed by 6 mg/kg, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy Experimental: Pyrotinib +Trastuzumab + chemotherapy
45696429|NCT05346861|Drug|Trastuzumab in combination with pyrotinib plus chemotherapy|Pyrotinib: 400 mg po QD, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy
45696430|NCT04358614|Drug|Baricitinib 4 MG Oral Tablet|Baricitinib+antiviral therapy administration for 2 weeks
45502370|NCT02879383|Procedure|DMR Procedure|The DMR procedure consists of hydrothermal ablation of the duodenum using the Revita System
45502371|NCT02879383|Procedure|Sham Procedure|The sham procedure consists of placing the Revita Catheter into the stomach for 30 minutes and then removing it from the patient.
45696431|NCT01670409|Radiation|SMART|The PTV (planning target volume) of gross tumor will receive radiation dose of 66Gy, 2.2Gy per fraction and the PTV of subclinical disease will receive 54Gy, 1.8Gy per fraction,5 fraction per week.
45696432|NCT01670409|Drug|PF|Concurrent and adjuvant chemotherapy: Cisplatin, 80mg/m2, intravenous on day 1, 5fluorouracil 0.5/m2, intravenous on d1 to d4. Two cycles during radiation treatment on d1 and d28. Two additional cycles after radiation treatment, 4 weeks per cycle.
45696433|NCT05619562|Diagnostic Test|Device for CTC/DTC detection|The CTCs/DTCs will be detected and counted in peripheral blood, tumour draining blood and bone marrow samples.
46056830|NCT04029532|Device|Heart rate variability|Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist. Measure heart rate variability for 5 minutes.
46056831|NCT04029532|Device|Body composition|Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist and right foot. Measure body composition.
45389979|NCT01004783|Genetic|loss of heterozygosity analysis|
45389980|NCT01004783|Genetic|microarray analysis|
45389981|NCT01004783|Genetic|mutation analysis|
45389982|NCT01004783|Genetic|polymerase chain reaction|
45389983|NCT01004783|Genetic|reverse transcriptase-polymerase chain reaction|
45389984|NCT01004783|Other|laboratory biomarker analysis|
45389985|NCT01005017|Procedure|Percutaneous Radiofrequent Lesioning|One group receives PRFLSN after a positive trial block with bupivacaine, the other group receives no extra treatment besides optimal medical treatment.
45389986|NCT01005095|Dietary Supplement|Vitamin D3|Patients will be treated daily with 800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
45389987|NCT01005095|Dietary Supplement|Vitamin D3|Patients will receive 800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
45696434|NCT04761705|Drug|JV-GL1|Experimental Treatment
45696435|NCT04761705|Drug|Latanoprost 0.005% Ophthalmic Solution|Active Control
45696436|NCT04358692|Device|Aixplorer Mach30|To measure myocardial stiffness by ShearWave elastography on not beating heart
45696437|NCT04403217|Other|Individualized structured dietary plan based on MD|Participants will follow an individualized structured dietary plan based on Mediterranean diet for 12 weeks
46056832|NCT04029532|Behavioral|Eating behavior|Fill in questionnaire (Three-Factor Eating Questionnaire, revised 18-item, TFEQ-18).
45389988|NCT01005563|Other|Beef/Pork|Participants consuming diet containing 10, 20 or 30% dietary protein with beef/pork as the predominate sources of protein
45389989|NCT01005563|Other|Soy/Legumes|Participants consuming diet containing 10, 20, or 30% dietary protein with soy/legumes as the predominate sources of protein.
45389990|NCT01005641|Drug|exemestane|25 mg daily
45389991|NCT01005641|Drug|lapatinib|taken orally, daily, at dose recommended after dose finding part of study
45389992|NCT01005797|Drug|Panobinostat (LBH589), Sorafenib|Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.
45502372|NCT02049554|Other|Preconception Care Screener|
45502373|NCT02049710|Behavioral|Seventeen Days|Interactive video includes highlighting salience of active choices in sexual decision making, modeling different responses to sexual situations, cognitive rehearsal of preventive behaviors, and information about hormonal and non-hormonal contraception
45502374|NCT02049710|Behavioral|Driving Skills for Life|Interactive video includes guidance and practice for safe driving techniques, driver and car care tips, an eco-driving learning module, and interactive driving games.
45389993|NCT01006031|Drug|Pegylated interferon alfa-2a and Ribavirin|"Pegylated interferon alfa-2a (360 ug per week) plus oral Ribavirin (800 mg b.i.d.) for 48 or 72 weeks. The treatment will be discontinued for patients who did not achieve a reduction with respect to baseline of at least 0.5 log10 IU/ml in plasma RNA-HCV levels at week 4 or 2 log10 UI/ml at week 12 and will be considered as viral failures.~Duration: 48 weeks for patients reaching an undetectable plasma RNA_HCV at week12 and 72 weeks for those without a negative viremia at week 12 but a reduction of at least 2 log10 IU/ml in RNA-HCV levels."
45389994|NCT01006187|Drug|Liposomal lidocaine|4% cream; approximately one gram applied to injection site under an occlusive dressing for 20 minutes prior to injection
45696438|NCT04358926|Device|Hyperbaric oxygen therapy|8 sessions in 4 days of breathing 100% oxygen in 2.2 ATA. Each session is 60 minutes. 1 meter/minute compression/decompression
45696439|NCT04358770|Drug|Clocortolone Pivalate|Cream, 0.1%
45696440|NCT04402983|Other|Physiotherapy|Program content Respiratory exercise (chest breathing, diaphragmatic breathing, basal expansion exercises), Breath control training, Active breathing techniques cycle Light aerobic exercise Posture exercises Self walking
45389995|NCT01006187|Drug|Vapocoolant spray|medium stream spray on arm for 4-10 seconds prior to injection
45389996|NCT01006187|Other|Rubbing adjacent to the injection site|rubbing adjacent to the injection site before and during injection
45389997|NCT01006187|Other|Distraction|By means of self-selected reading material or video
45389998|NCT01006343|Other|Higher Protein (HP)|
45389999|NCT01006343|Other|Lower Protein (LP)|
45390000|NCT00530777|Drug|valacyclovir|500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
45390001|NCT00530777|Drug|placebo|oral placebo twice daily from 34 weeks gestation to 1 year postpartum
45502375|NCT01353625|Drug|CC-115|"Part A (actively recruiting): Dose level starts with 0.5mg daily by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose schedule is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity).~Part B: Optimal dose schedule is administered in 28-day cycles until disease progression."
45502376|NCT01357603|Biological|Glargine|dosage form: Subcutaneous injection
46056833|NCT04029532|Behavioral|Physical activity recall|Fill in questionnaire (Seven-days Physical Activity Recall, 7-d PAR).
46056834|NCT04029532|Behavioral|Depression|Fill in questionnaire (Mongomery-Asberg Depression Rating Scale, MADRS).
46056835|NCT04029532|Behavioral|Body image|Fill in questionnaire (multi-directional self-body relationship questionnaire (MBSRQ), figure rating scale (FRS)).
45390002|NCT01006421|Dietary Supplement|GINGKO BILOBA|MEMOREX 60 MG BID
45390003|NCT01006499|Drug|Pentoxifylline, pentaglobin|Pentaglobin 250mg/kg/d over 4 hour for three days Pentoxyfilline 6mg/kg/h over 4 hour for three days Pentaglobin 250mg/kg/d over 4 hour for three days+Pentoxyfilline 6mg/kg/h over 4 hour for three days Placebo (normal saline 5ml/kg over 4 hour for three days
45390004|NCT01006577|Procedure|side-to-end anastomosis|Low anterior resection for rectal cancer < 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon (3-5 cm long) is closed with a linear stapler. Stapling of the anastomosis is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The anastomosis is performed on the antimesenteric aspect of the descending colon. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
45390005|NCT01006577|Procedure|colon j pouch|Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling with a defined pouch limb length of 5-6 cm, which is measured intraoperatively. The stapling is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
45390006|NCT01006733|Genetic|Pharmacogenetic|The pharmacogenetic arm estimates therapeutic warfarin dose using cytochrome P 450 2C9 (CYP2C9), vitamin K epoxide reductase complex subunit 1 (VKORC1), and cytochrome P 450 4F2 (CYP4F2) genotype and clinical information. The clinical arm estimates warfarin dose from clinical information alone.
45390007|NCT01006733|Drug|Target INR 1.8|We will randomize patients to a target International Normalized Ratio (INR) of 2.5 or 1.8.
45502377|NCT02051894|Drug|Dobutamine|"Infants will receive treatment according to the preference of the responsible physician. As is common practice, dobutamine, dopamine and/or other treatments (including other cardiovascular drugs and/or volume replacement therapy with normal saline) will be administered.~If dobutamine is used we will take a maximum of two blood samples from the baby for pharmacokinetic analysis."
45502378|NCT01357681|Drug|(2)-epigallocatechin-3-gallate (EGCG)|Month 01:400 mg /day (200-0-200) Month 02:800 mg /day (400-0-400) Month 03 -12: 1200 mg /day (600-0-600)
45502379|NCT01357681|Drug|Placebo|Placebo
45502380|NCT02049788|Behavioral|low calorie/fat diet|Conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).
45696441|NCT04564300|Procedure|Training|Both groups will perform a standardized training protocol
46056836|NCT04144959|Device|Indigo Aspiration System|Indigo Aspiration System
45696442|NCT03516981|Biological|Pembrolizumab|200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
45696443|NCT03516981|Biological|Favezelimab|200 mg or 800 mg favezelimab solution for IV infusion administered Q3W
45696444|NCT03516981|Drug|Lenvatinib|20 mg lenvatinib capsules administered orally once daily
45390008|NCT01006811|Dietary Supplement|modified Atkins diet|"Modified Atkins Diet administration~Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~Fats (e.g. cream, butter, oils, ghee) encouraged.~Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~Clear carbohydrate-fluids not restricted.~Calcium and multivitamin supplementation will be provided."
45390009|NCT01006811|Other|modified Atkins diet|"Modified Atkins Diet administration~Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~Fats (e.g. cream, butter, oils, ghee) encouraged.~Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~Clear carbohydrate-fluids not restricted.~Calcium and multivitamin supplementation will be provided."
45390010|NCT01007201|Biological|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|
45390011|NCT03882047|Drug|Mometasone furoate|Mometasone furoate nasal spray, 200 mg once daily
45390012|NCT03882047|Drug|Fluticasone propionate|Fluticasone propionate nasal spray, 200 mg once daily
45390013|NCT03882047|Drug|Mometasone furoate placebo|Mometasone furoate placebo matching nasal spray, once daily
45390014|NCT03882047|Drug|Fluticasone propionate placebo|Fluticasone propionate placebo matching nasal spray, once daily
45390015|NCT01007279|Drug|ROSUVASTATIN|40 mg before procedure
45390016|NCT00530621|Drug|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily Cycle 1 (28 days), subsequent cycles 21 days, until disease progression
45390017|NCT00530621|Drug|placebo|oral, daily
45390018|NCT00530621|Drug|pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV), day 8 Cycle 1 (28 days), day 1 subsequent cycles (21 days), until disease progression
45390019|NCT01007357|Device|Body MR imaging|Body MR imaging will be performed to optimize sequences
45390020|NCT01007513|Procedure|Transvaginal ultrasound|A transvaginal ultrasound with an endocavitary probe will be done as required by the medical condition of the patient. The cervical and supracervical factors will be noted.
45390021|NCT01007513|Procedure|Vaginal secretion sampling|Vaginal secretion swab will be collected each time patient will have a transvaginal ultrasound. The sample will be centrifuged, frozen and store to be analysed at the end of the study with multiplex antibody arrays.
45390022|NCT00531479|Drug|voriconazole|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV BID plus anidulafungin placebo IV qd.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin placebo IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin placebo IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
45390023|NCT00531479|Drug|anidulafungin|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
45390024|NCT00531479|Drug|voriconazole|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
45390025|NCT04000451|Device|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
45502381|NCT02049788|Behavioral|Low glycaemic index diet|Experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
45502382|NCT02037932|Device|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
45390026|NCT04000451|Device|Oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
45502383|NCT01543633|Drug|Propofol|Propofol will be infused using a computer controlled delivery system running the program STANPUMP. Loss of consciousness will be defined as loss of response to auditory stimulus (button press).
45502384|NCT03561740|Drug|capecitabine|additional metronomic chemotherapy of capecitabine
45502385|NCT03494647|Device|Cheetah Heel Cup|The Cheetah Heel Cup is composed of a rubber waffle that cups the athlete's heel, secured in place by a neoprene sleeve.
45696445|NCT03516981|Drug|Quavonlimab|Quavonlimab solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)
45390027|NCT04000451|Drug|Conventional treatment|Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in seven days before the study
45390028|NCT03999905|Behavioral|Counseling training|Online training using Moodle.
45390029|NCT01007669|Behavioral|Physical activity and Health check|Strength training, aerobic capacity training.
45390030|NCT01007669|Behavioral|Health check only|Health check
45390031|NCT00999479|Drug|Norethindrone acetate and ethinyl estradiol tablets, USP|"Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets.~Each white tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Each white tablet also contains the following inactive ingredients: acacia, lactose, magnesium stearate, starch, confectioner's sugar, and talc."
45390032|NCT00999479|Drug|ferrous fumarate (placebo) tablets|Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets. Each brown tablet contains ferrous fumarate, microcrystalline cellulose, magnesium stearate, povidone, sodium starch glycolate, and compressible sugar. The ferrous fumarate tablets do not serve any therapeutic purpose.
45390033|NCT05121311|Diagnostic Test|NeoprediX B1 algorithm|Re-assessement of bilirubin measurements done according to standard of care of the participating center by the NeoprediX B1 algorithm
45390034|NCT01007747|Other|Geranium oil|Daily topical application over neuropathic pain
45390035|NCT05114603|Drug|HLX208|level 1:600mg po Bid level 2:900mg po Bid
45390036|NCT00999557|Drug|bimatoprost ophthalmic solution|Applied topically
45696446|NCT04525144|Drug|Tebonin Forte|Dietary supplement: Gingko biloba EGb 761
45848721|NCT02248740|Procedure|Ablation of the incompetent small saphenous vein|For each patient, the Small Saphenous Vein (SSV) will be accessed from the midcalf. After liberal use of tumescent anesthesia, ablation of the incompetent small saphenous vein will be performed. Half the patients will have this procedure performed using the Laser Ablation device and half will be performed using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
45848722|NCT02242578|Device|1 Hz rTMS|About 1,000 stimulation pulses over 20 min
45848723|NCT02242578|Device|10 Hz rTMS|About 1,000 stimulation pulses over 20 min
45390037|NCT00999557|Drug|placebo|Applied topically
45390038|NCT00999635|Device|Insole|Comparison of custom made and prefabricated insoles designed for the neuropathic diabetic foot, issued for day time wear and followed for a 6 month period
45390039|NCT01007903|Behavioral|Tai Chi exercise|12-week tai chi exercise class
45390040|NCT05260385|Drug|KC1036|KC1036 are administered orally QD or BID in 21-day cycles.
45390041|NCT01008137|Biological|H1N1 influenza A Vaccine (PANFLU.1)|H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)
45390042|NCT01008137|Biological|Trivalent Inactivated Influenza Vaccine (ANFLU)|Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
45390043|NCT00999791|Drug|Bevacizumab|
45390044|NCT00999791|Drug|Diclofenac|
45390045|NCT00999869|Drug|Botulinum toxin type A|Using concentration at 2 units per 0.1 of dilution with normal saline Injection in the first visit and follow up at 1 week, 1,2,3 and 4 months after injection
45696447|NCT05619484|Device|Smart AFO|Diagnostic ankle-foot orthosis with AFO stiffness and range of motion settings adjusted using a mobile application
45848724|NCT02140788|Drug|Metformin|
45848725|NCT02140788|Drug|Fish Oil|
45848726|NCT02133534|Drug|Atorvastatin|
45390046|NCT00999869|Drug|Triamcinolone acetonide|Using concentration at 10 mg/ml and equal amount of botulinum toxin A dilution
45390047|NCT05103527|Device|Dorsal Root Ganglion Stimulation|Stimulation at L2, L3, L4 and S1 spinal levels
45390048|NCT01000103|Device|Real rTMS|Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
45390049|NCT01000103|Device|Sham rTMS|"two TMS coils will be used: a passive one which is placed flat on top of the actively targeted region which remains unplugged and generates a continuous scalp tactile sensation, and an active one located at a prudential distance from the scalp, which will deliver active pulses and its accompanying sensations"
45390050|NCT01008215|Other|Algorithm|Warfarin Dosing algorithm (paper and electronic version)
45390051|NCT01008293|Drug|VSL#3|VSL#3 (2 capsules bid.for 2 months, Each containing 112.5 billion viable lyophilized bacteria). Each capsule contains 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacterium (B. longum, L. breve, and B. infantis), and 1 strain of Streptococcus salivarius subsp. thermophilus (designated hereafter as S. thermophilus)
45390052|NCT01008293|Drug|Lactulose|30-60 ml of lactulose per day for 2 months to ensure 2-3 soft stools.
45696448|NCT05618470|Drug|Wumeiwan Jiawei Fang|orally administered Wumeiwan Jiawei Fang prescription granules, 1 dose a day, twice a day, once for 14 days, for 42 days.
45696449|NCT05618470|Drug|botulinum toxin A|Botulinum toxin (Lanzhou Biopharmaceutical Co., LTD.) was injected into the medial side of the upper eyelid, the lateral side of the upper eyelid, the lateral side of the lower eyelid, and the temporal orbicularis oculi muscle of the lateral canthus. The botulinum toxin type A was diluted into 50IU/ML with normal saline and injected with a 1ml skin test syringe (4\ 5-gauge needle), and 2.5IU was injected into each point. A total of 1 injection.
45696450|NCT04358536|Device|CovX|Convolutional neural network for classification of COVID-19 from chest X-rays
45848727|NCT02009982|Procedure|Cardioneuroablation|Catheter Ablation of Vagal Inputs in Left Atrium
45390053|NCT01000181|Other|PET-CT with CuATSM|PET-CT with CuATSM
45390054|NCT03742817|Other|e-Cigarette|Participants will self-administer an experimenter-provided e-cigarette.
45390055|NCT03742661|Device|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
45390056|NCT01000259|Other|Laboratory Biomarker Analysis|Samples are analyzed in laboratory studies
45390057|NCT01008527|Drug|CP 870,893|Study drug will be administered open-label as an intravenous solution, followed by observation. Study drug will be supplied as a liquid intravenous solution in vials containing 10 mg/mL of CP870,893. CP 870,893 will be administered at a dosage of 0.01, 0.025 or 0.05 mg/kg at 0.24 mg/mL infused via a syringe pump over 15 minutes, or at 0.1 or 0.2 mg/kg/dose as an i.v. infusion in saline at a concentration of 0.24 mg/mL in an IV bag of up to 100 mL over 30 minutes (controlled by a volumetric pump) for not more than 30 minutes, with a 10 cc flush at the end that should be administered at the same rate as the CP 879,893 infusion.
45390058|NCT01008527|Biological|Peptides|NY-ESO-l 157-165 (165V) and gpl002 80-288 (288V) peptides each at a dose of 0.5 mg will be emulsified with Montanide ISA 51 VG and administered to all patients in the study at Weeks 1,3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53. Peptides will be administered as a total of 6 deep subcutaneous (s.c.) injections into alternating lower extremities one hour after CP 870,893 infusions.
45390059|NCT01008527|Biological|Oncovir poly IC:LC|The dosage of poly IC:LC chosen for the current trials has been used safely in over one hundred patients with central nervous system (CNS) malignancies enrolled in nitrates and bone turnover (NABT) trials. The injection of 1000 mcg will be made deeply subcutaneously into the same limb as the peptides/Montanide ISA 51 VG, at least 5 cm. proximal to the peptides vaccination site. Poly IC:LC will be administered to all patients in the study at Weeks 1, 3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53 one hour after CP 870,893 infusion.
45390060|NCT01000415|Other|Neoadjuvant chemotherapy followed by surgery|Cisplatin 50 mg/m2 (in the vein)on day 1 of each 23 day cycle plus gemcitabine 1000 mg/m2 (in the vein) on day 1 and day 8, for 3 cycles: until progression or unacceptable toxicity develops.
45390061|NCT05177783|Behavioral|Tuune health questionnaire|Participants complete the Tuune contraceptive decision aid health questionnaire.
45390062|NCT05177783|Behavioral|Control health questionnaire|Participants complete a standard physician intake health questionnaire.
45390063|NCT01008761|Drug|Azithromycin|Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
45390064|NCT01008761|Drug|Suspension Placebo|Placebo suspension will be administered on day 1 at 10mg/kg and then for the next 4 days at 5 mg/kg
45390065|NCT01008917|Drug|sorafenib with temsirolimus|Weekly intravenous temsirolimus with daily oral sorafenib
45390066|NCT01009073|Drug|ABT-263|"ABT-263 is taken orally.~Note - The dose and schedule is variable based on Arm and subject to change based on the toxicities observed."
45390067|NCT01009073|Drug|erlotinib|150 mg of erlotinib is taken orally once daily.
45390068|NCT01009073|Drug|irinotecan (3-week schedule)|"180 mg/m2 over 90 minutes, irinotecan will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
45390069|NCT01009073|Drug|irinotecan (weekly schedule)|"75 mg/m2 over 45 minutes, irinotecan will be given by intravenous infusion on Days 1 and 8 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
45390070|NCT00530075|Drug|Gusperimus|SC, 0.5mg/kg/day, consecutive 21 days administration, 1 to 2 weeks rest, 6 cycles
45390071|NCT01001117|Device|LensAR laser surgery|Use of laser for cataract surgery
45390072|NCT01001117|Device|Phaco-emulsification cataract surgery|Phaco-emulsification cataract surgery
45502386|NCT03494647|Device|The X Brace|The X Brace is composed of one thick elastic band that is wrapped around the athlete's arch of the foot. A second band is wrapped around the back of the heel, crossed under the foot, and secured to the thicker band on the bottom of the foot.
45502387|NCT02037698|Device|Pre-PCI coronary CT scan|Coronary CT scan before CTO PCI
45502388|NCT01357759|Drug|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
45502389|NCT01357759|Drug|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
45502390|NCT02053454|Drug|patisiran (ALN-TTR02)|Ascending doses administered by intravenous (IV) infusion
45502391|NCT02053454|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
45502392|NCT02052050|Other|core stability|
45502393|NCT02931097|Device|Deep brain stimulation|Stimulating deep brain electrodes and pulse generator
45502394|NCT02931097|Device|Sham stimulation|
45502395|NCT02052128|Drug|onapristone|
45502396|NCT01349413|Drug|Esomeprazole 20mg|Oral Esomeprazole 20mg daily for 8 weeks
45502397|NCT01349413|Other|Placebo|Identical looking placebo
45696451|NCT04358146|Other|Experimental Infant formula|Exclusive formula feeding with the new infant formula thickened with fibers
45390073|NCT01009151|Behavioral|Heart Self Care Tracker|Web-based home tele-monitoring system serving congestive heart failure patients at the University of Michigan Health System. The intervention consists of daily reporting via the Internet on parameters specified in clinical protocols, including weight, blood pressure, heart rate and heart failure symptoms. These protocols contain automated trigger mechanisms when certain values are exceeded to alert the provider and the patient for the need to take appropriate remedial action. The system provides links to educational material on heart failure and reminders for self-care measures.
45390074|NCT01009151|Behavioral|Heart Care Self Tracker|Web-based Home Tele-monitoring System
45390075|NCT01009229|Dietary Supplement|Low and high salt diets|High salt diet: 150mmol/d Low salt diet: 30mmol/d
45390076|NCT01001273|Other|Hyperinsulinemic Normoglycemic Clamp|The patient receives insulin intravenous infusion at 2ml units/kg/min. Dextrose 20% (D20W ®) will be titrated to maintain blood glucose between 4 - 6 mmol/L (72 - 108 mg/dl).
45390077|NCT01009307|Genetic|polymorphism analysis|
45390078|NCT01009307|Other|laboratory biomarker analysis|
45390079|NCT01009307|Other|medical chart review|
45390080|NCT03999671|Other|Educational|Traditional method of nursing care with what is done every day, with the method through the nursing process using nursing language as a nursing diagnosis, classification of nursing interventions, and nursing outcomes.
45390081|NCT03999671|Other|Maneuver control|Verify that the control and intervention group developed the assigned activities in each case.
45390082|NCT01001507|Procedure|Integrated family planning/HIV care and treatment services|Family planning services will be provided during the patient's HIV care visit.
45390083|NCT01001585|Drug|sevoflurane|During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached, which will take approximately 10 minutes.
45390084|NCT01001663|Device|FemoSeal®|Closure device for femoral artery access closure
45390085|NCT01001663|Other|Manual compression|Conventional manual compression
45390086|NCT05734157|Device|Peripheral PTA with a drug coated balloon|Peripheral artery angioplasty
45390087|NCT01001741|Other|Cell phone text message|We will use cellular text messages to remind patients of impending drug prescription refills and scheduled visits to their healthcare provider.
45696452|NCT04358146|Other|Infant formula thickened with locust bean gum|Exclusive formula feeding with the formula thickened with locust bean
45390088|NCT01001897|Drug|Misoprostol|400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
45390089|NCT01001897|Drug|Placebo|400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
45390090|NCT05734079|Other|Standard of care|A written hand out containing all information required for bowel preparation
45390091|NCT05734079|Other|Standard of care + Video call|Standard of care and in addition a video call with a professional nurse conducted via digital devices and a free software (Zoom video communication or What's app application)
45390092|NCT05734079|Other|Standard of care + Video call + Educational video film|Standard of care and in addition to a video call, an explanatory short video on bowel preparation (video film), streamed to the patient's mobile device or computer
45390093|NCT01002053|Procedure|Nerve conduction study and Ultrasound of the PTN|Nerve Conduction studies and ultrasound of PTN will be performed to the patient before the operation and 8 weeks postoperatively.
45390094|NCT05734001|Diagnostic Test|ROTEM Tests|"This group will undergo ROTEM based correction. ROTEM bcorrection will be based on the following protocol~EXTEM CT > 80 sec - FFP will be transfused at 15 ml/kg MCF < 35 mm- Platelet will be transfused at 10 ml/kg~FIBTEM MCF < 7 mm- Cryoprecipitate will be transfused at 5 ml/kg"
45390095|NCT05734001|Diagnostic Test|Conventional Haemostatic Tests|"To prevent bleeding during the procedure, one group will receive prophylactic transfusion of either FFP, Platelet or Cryoprecipitate based on the following protocol~If INR: > 2.5 FFP will be transfused at 15 ml/kg~If Platelet Count is 20,000/mm3-50,000/mm3 RDPC will be transfused at 10 ml/kg~If Fibrinogen < 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg"
45390096|NCT01002131|Device|CBCT|Cone Beam Computer Tomography. 3D-imaging Digital Volume Tomography, compared with gold standard intraoperative findings.
45390097|NCT01002209|Procedure|Hyperbaric Oxygen treatment (HBO)|"HBO treatment will be given in a monoplace chamber and will start on first postoperative day (study day 1). The HBO group will be treated with 100% oxygen at 2.5 bar for 100 min with two 10 min airbrakes (without mask).~HBO treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO/placebo treatment and who have a clearly uncomplicated postoperative course will terminate HBO/placebo treatment on the day of discharge from hospital."
45390098|NCT01002209|Procedure|Sham HBO|"HBO sham treatment will start on first postoperative day (study day 1). HBO sham treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO sham treatments and who have a clearly uncomplicated postoperative course will terminate HBO sham treatment on the day of discharge from hospital.~For patient blinding purposes, the sham group will breathe air and will be given a brief compression to 1.5 bar at the beginning of each treatment after which the chamber is slowly decompressed to 1.1, 1.2 , 1.3, or 1.4 bar corresponding to 0.23 ,0.25, 0.27, and 0.29 bar inspired oxygen. Two 10 min airbrakes will also be included."
45696453|NCT05620498|Drug|tislelizumab+lenvatinib+GMOX|tislelizumab 200mg, Q3W Lenvatinib 4mg Po QD Gemcitabine 1g/m2 Oxaliplatin 100mg/m, D1, q3W2
45696454|NCT05620498|Drug|tislelizumab+GEMOX|tislelizumab+GEMOX
45390099|NCT05064917|Diagnostic Test|Blood draw|The burden for child/parents in this study is low as it is limited to a single blood draw, which is already necessary for usual diagnostic care in about 70% of the children
45390100|NCT05061797|Dietary Supplement|Thermogenic Energy Drink - Active Study Product Formula|The Thermogenic Energy Drink is the Active Study Product (ASP). This energy drink formula combines, caffeine, guarana, Vitamins C, B3, B6, B12, Magnesium, Potassium, L-Citrulline, L-Arginine HCl, L-Glutamine, and Chlorogenic Acids from green coffee bean extract. Participants will consume an assigned amount of the beverage (355 ml), under observation. They will be monitored for the following 180 minutes with measurements of respiration for Resting Energy Expenditure (RER) and other metabolic markers as well as satiety via Visual Analog Scale (VAS).
45390101|NCT05061797|Dietary Supplement|Placebo|A carbonated soft drink with the same appearance, flavor and aroma as the active study product. Study participants will consume an assigned amount of the beverage (355 ml) under observation. They will then be monitored for the subsequent 180 minutes with measurements for respiration for Resting Energy Expenditure (RER) and other metabolic markers as well as satiety via a Visual Analog Scale (VAS).
45390102|NCT01002365|Other|Oxygen delivery|
45390103|NCT01002365|Other|Oxygen administration|
45390104|NCT01002443|Drug|Helicobacter pylori eradication|Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
45390105|NCT01002443|Drug|placebo|Omeprazole 20 mg or Rabeprazole 10 mg bid + two placebo (for antibiotics) for 7 days
45696455|NCT04468126|Other|Standard oxygen|Standard low flow oxygen therapy through facemask or non-rebreathing mask at least 10 L/min.
45848728|NCT02009982|Device|Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter|This is the device that will be used to perform the Cardioneuroablation procedure
45848729|NCT02013414|Device|3D ultrasound-guided biopsy|Patients will have a PET/CT prior to the biopsy. The CT images will be combined with the PET images for improved localization of suspicious tumors. During the biopsy, the 3-D ultrasound images will be acquired immediately before the biopsy while the patient is on the table. The ultrasound images together with the PET images will be used to guide the targeted biopsy of the prostate.
45848730|NCT02015910|Drug|Sitagliptin|Comparison of Sitagliptin a dipeptidyl-peptidase four (DPP-4) inhibitor 100mg pill with placebo comparator
45848731|NCT02015910|Drug|Placebo|Sugar pill manufactured to mimick Sitagliptin 100mg pill.
45848732|NCT01996410|Device|Acupuncture|
45390106|NCT01002599|Device|Boussignac TM CPAP|Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
45390107|NCT01002599|Device|Venturi Face Mask|Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
45390108|NCT01002677|Behavioral|Advocacy training curriculum|Day-long presentation of an advocacy training curriculum by the state's Brain Injury Association staff: One session per month for 4 consecutive months.
45390109|NCT01002677|Behavioral|Self-directed|Day-long group-based self-directed advocacy training activity: One session per month for 4 consecutive months.
45390110|NCT05733299|Device|aflo™ digital respiratory management platform|medical device, user app, clinician portal, data analytics hub
45390111|NCT05733299|Other|Standard care|Health service standard care will be continued
45390112|NCT01002833|Biological|Exposure to Plasmodium falciparum infected mosquitoes|Healthy volunteers are exposed to the bites of 5 Plasmodium falciparum infected mosquitoes
45390113|NCT01002911|Drug|Cefazolin, Bacitracin, Cefalexin|Single does of Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision, Bacitracin wash, Cefalexin 250-500 mg TID
45390114|NCT01002911|Drug|Cefazolin|Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision
45390115|NCT05059535|Drug|standard pain relievers|Knee arthroscopy will be performed ansd patients will receive standard pain relievers in confomtity with the current practice
45390116|NCT05733221|Device|3D Printed Model|3D Printed Model generated pre-operatively of the patients mandible.
45390117|NCT01003145|Biological|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|
45390118|NCT01003223|Other|Computer algorithm management of hyperphosphatemia|The PKM algorithm is a computer based program that calculates Phosphorus intake between dialysis, phosphorus reduction during dialysis treatment and daily oral phosphate binder intake compliance. Based on pre and post dialysis serum phosphorus levels, the algorithm makes recommendations in relation to dialysate calcium, oral phosphate binder use, and dietary counseling.
45390119|NCT05733065|Other|saliva sample|Adult twins will be asked to send saliva samples in a reply envelope to Maastricht University, department of Genetics and Cell Biology, where they will be frozen and stored before analysis. DNA will be extracted from the saliva using a commercially available kit according to the manufacturer's instructions.
45696456|NCT04468126|Other|High-flow nasal oxygen therapy|Humidified and heated oxygen with a gas flow at least 50 l/min through nasal cannula and inspired fraction of oxygen adjusted in order to maintain a SpO2 between 92 and 96%
45848733|NCT01980342|Drug|Efavirenz|Healthy women who are using Nexplanon will be asked to take a 2-week course of reduced-dose efavirenz (400 mg daily).
45848734|NCT01881984|Drug|Ravicti|Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day
46056837|NCT02608996|Drug|Nesiritide|This intervention is designed to determine the optimal dose range of BNP for treatment of patients with uncontrolled hypertension
46056838|NCT02608996|Drug|Placebo|For comparison to elucidate the true effect of nesiritide
45696457|NCT04456816|Drug|100 mg AP1189|100 mg AP1189 tablet
45696458|NCT04456816|Drug|Placebo|Matching placebo tablet
45715214|NCT01683383|Device|Device (servo-regulated cooling)|Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.
45390120|NCT05733065|Other|questionnaire|Along with saliva samples, adult twins, will be asked to complete a questionnaire about their health. Study subjects will be asked to self-report height and weight. Additionally, questions will focus on cardiometabolic risk, including questions about smoking, physical activities, medical diagnoses, current medications, family history of cardiometabolic disease, and for female twins an obstetric and gynaecological history, including number of pregnancies and pregnancy complications (such as gestational diabetes and pre-eclampsia). The questionnaire will take the form of a self-completed, web-based questionnaire which will be hosted by the Qualtrics platform (Qualtrics.com). This platform is supported by the University of Maastricht due to its security and privacy measures.
45390121|NCT00531011|Device|XIENCE V® Everolimus Eluting Coronary Stent System|Coronary artery placement of a drug-eluting stent
45390122|NCT00531011|Device|TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System|Coronary artery placement of a drug-eluting stent
45390123|NCT05051267|Other|Non-Pharmacological Methods|All of the applications that increase the effectiveness of drugs when used together with analgesics and provide the elimination of pain by releasing our body's natural morphine and endorphins without the use of analgesics are called non-pharmacological treatment.
45390124|NCT04000295|Drug|Apatinib|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 375 mg/d
45390125|NCT04000295|Drug|Etoposide|Subjects receive Etoposide capsule orally, d1-14, q3w, Dosage form: capsule, Strength: 50 mg/d
45390126|NCT04000295|Drug|Paclitaxel|Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, q3w, Dosage form: injectable, Strength: 80 mg/m2
45390127|NCT05732909|Dietary Supplement|D-β-hydroxybutyrate/D 1,3 butanediol monoester|Ketone monoester
45390128|NCT01003457|Other|ultrasonography|transvaginal ultrasonography of bladder wall thickness
45390129|NCT01003613|Drug|Tranilast, and Tissucol|1.0%, 0.1 ml, subconjunctival route, single dose
45390130|NCT01003613|Other|Beriplast P|0.1 ml to attach graft
45390131|NCT05732597|Procedure|Coronary angiography|A coronary angiogram is a procedure that uses X-ray imaging to see the patient's blood vessels of the heart. The test is generally done to see if there's a restriction in blood flow going to the heart.
45390132|NCT00529217|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for up to twelve weeks.
45390133|NCT05732441|Drug|Huange capsule|Huange Capsule was orally administered (Zhejiang Kangenbe Pharmaceutical Co., Ltd., specification: 0.4g×60 tablets/bottle, GuoYaoZhunZi Z20110006). Administration method: 1.6g each time, three times a day, 40min after breakfast, lunch and dinner. The treatment course was four weeks.
45390134|NCT05592977|Device|Intra-Oral Distalizing Device|The inner bow (1.2mm) is a modified version of the inner part of a conventional face bow. Two hooks were soldered onto the inner bow distal to the lateral incisor teeth regions, and U loop at 1st premolar region, and bends acting as mesial stop will be bent in front of the maxillary first molars. The anterior component of the inner bow is 3 mm free from the labial surface of anterior teeth
45390135|NCT05732363|Device|Ultrasonography|The US muscle measurement will be performed with the handheld portable Philips Lumify Sonography connected to a Samsung tablet. The measurement will take approximately 5-10 minutes. A seven-point measurement has to be performed based on the seven-site Jackson Pollock Generalized Prediction Equations for circumference and skinfold thickness measurements.6,7
45390136|NCT05732363|Radiation|Dual-energy X-ray Absorptiometry|The brand of the DXA scanner is the Hologic Discovery A, which has a weight limit of 204 kilograms. During the DXA scan, patients will be exposed to radiation, which is approximately 0.2 micro Sievert (µSv) for measuring body composition. For comparison: the average amount of background radiation per hour is approximately 0.23 µSv. The DXA body composition scan will be performed according to standard protocol by a specialized technician.
45390137|NCT00471146|Drug|AG-013736|oral administration, starting dose 5 mg twice daily [BID] every day until unacceptable toxicity or tumor progression.
45390138|NCT00471146|Drug|Gemcitabine|intravenous administration at 1,000 mg/m^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
45390139|NCT00471146|Drug|Gemcitabine|intravenous administration at 1,000 mg/m^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
45390140|NCT00471146|Drug|placebo|placebo
45390141|NCT04027556|Other|low dose CT contrast media - lean body weight|CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 450mgI/kg based on lean body weight.
45390142|NCT04027556|Other|Standard dose CT contrast media|CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 560mgI/kg based on total body weight.
45390143|NCT01021358|Drug|ABT-263|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
45390144|NCT01021358|Drug|Ketoconazole|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
45390145|NCT00469898|Drug|Carboplatin|"Carboplatin dosage calculation to be given on day 1, every 21 days:~Carboplatin (mg) = (AUC of 5) x (GFR + 25)~*up to 6 cycles at physician's discretion"
45390146|NCT00469898|Drug|irinotecan hydrochloride|"50 mg/m2 IV on days 1 and 8 every 21 days~Should be infused IV over 30- 90 minutes."
45390147|NCT01021436|Drug|Amikacin inhalation solution (BAY41-6551)|Daily dose of 800 mg of aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment 12 hour
45390148|NCT00529763|Drug|Dasatinib|Tablets, Oral, 70 mg BID (AD CML) or 100 mg QD (Chronic CML), once or twice daily dependent on disease stage, until subjects meet discontinuation (DC) criteria for study
45390149|NCT00486902|Drug|Ketamine|Ketamine 10 mg diluted to 20 mL delivered over 10 minutes via an infusion pump set at 2ml/minute
45390150|NCT00486902|Drug|Placebo|Saline 20 mL IV infusion delivered over 10 minutes via an infusion pump set at 2ml/minute
45390151|NCT05731271|Drug|TST003|IV humanized anti-GREM1 monoclonal antibody
45390152|NCT05559125|Drug|STSA-1002 Injection|Intravenous injection
45390153|NCT05559125|Drug|STSA-1005 Injection|Intravenous injection
45390154|NCT05728541|Drug|SYH2043|Patients will receive SYH2043 once everyday on day 1-21 of each 28-day cycle
45715215|NCT01683383|Other|Control (standard practice)|Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
45715216|NCT03114852|Diagnostic Test|blood collection|They will have blood tested to renal genetic diseases
45390155|NCT05725421|Procedure|Donor Radical and Partial Nephrectomy|Donor participants will undergo laparoscopic radical nephrectomy (RN) . Donor kidney then will undergo cold perfusion and ex-vivo partial nephrectomy (PN) with cold ischemia. During PN, careful inspection of tumor will be performed to ensure it is well-encapsulated. If any infiltrative features (versus well encapsulated tumor) are noted intraoperatively then transplant will not be performed. Multiple surgical margins will be sent (either frozen section or standard with priority). If final margins are positive or concerning, then transplant will not be performed. Biopsies of the tumor will be performed and sent to pathology (either frozen section or standard with priority).
45390156|NCT05725421|Procedure|Kidney Transplantation|The donor kidney will remain on ice while pathologic analysis is performed, and transplant recipient surgery is initiated (if pathologic analysis satisfactory). Cold ischemia with delay for pathology will have minimal functional impact in this setting based on extensive prior experience with renal transplantation where kidneys are routinely kept hypothermic for several hours prior to transplantation.
45390157|NCT05725421|Procedure|Laparoscopic Radical Nephrectomy|Radical nephrectomy consists of the removal of the kidney together with the perirenal fat and regional lymph nodes. The transperitoneal approach allows early control of the renal vessels.
45390158|NCT04000139|Drug|Standardized anthocyanin-rich extract|3g of anthocyanin-rich extract taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
45390159|NCT04000139|Drug|Placebo|3g of placebo taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
45390160|NCT05708729|Device|MCS surgery for CPSP|The investigational devices that will be used for the MCS surgeries are the following: the Vanta with AdaptiveStim Technology Primary cell neurostimulator or the Intellis Implantable Neurostimulator with AdaptiveStim Technology from Medtronic, Inc. (MN, USA). These implantable neurostimulators are intended to generate electrical pulses and to deliver stimulation trough one or more leads as part of a neurostimulation system for pain therapy in adults.
45390161|NCT05708729|Device|Vc-DBS surgery for CPSP|For the deep brain stimulation procedure, we will use Vercise stimulators from Boston Scientific together with the Cartesia Directional Leads or the Percept PC stimulator from Medtronic.
45390162|NCT03687827|Drug|Insulin degludec|Participants will receive insulin degludec U100 subcutaneous (s.c.) injection once daily for 36 weeks. Doses will be adjusted according to the fasting self-measured plasma glucose (SMPG) values. Participants earlier treated with one or more allowed oral antidiabetic drug(s) (OAD(s)), should continue their pre-trial OAD(s) treatment throughout the trial.
45390163|NCT03687827|Drug|Insulin glargine|Participants will receive insulin glargine U100 s.c. injection once daily for 36 weeks. Doses will be adjusted according to the fasting SMPG values. Participants earlier treated with one or more allowed OAD(s), should continue their pre-trial OAD(s) treatment throughout the trial.
45390164|NCT03999827|Other|Low Glycaemic Index Diet|Adherence to a diet which limits carbohydrate intake to 40-60 g/day, but carbohydrates must have a glycaemic index of less than 50. Fat and protein intake is encouraged, with approximately 60% of calorie intake as fat.
45390165|NCT00529529|Drug|Indacaterol 300 μg|Indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
45390166|NCT00529529|Drug|Salmeterol 50 μg|Salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
45390167|NCT00529529|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
45390168|NCT00529529|Drug|Placebo to salmeterol|Placebo to salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
45390169|NCT05698121|Device|CapriXpress|The app is a digital, tailored intervention aimed at activating patients during their waiting period between discharge from hospital and start of their cardiac rehabilitation by providing certainty and guidance. The goal of the intervention is to reach the end-goal: the start of the rehabilitation. Progression towards this end-goal is made automatically as time advances. The intervention provides guidance by providing the patient with a set of daily messages. These messages are pre-made by representatives of different disciplines within cardiac rehabilitation. The messages contain discipline-related information and suggestions as well as a perspective on peer experiences. Each day, the patient is free to choose which and the number of messages to engage with.
45390170|NCT05502107|Behavioral|PRESS Intervention|The study intervention is PRESS protocol training and educational delivered to EMS providers, followed by protocol implementation. EMS providers will be trained to screen all EMS patients for protocol eligibility and will start using the protocol at the beginning of the intervention phase. The PRESS EMS protocol includes 2 major components: 1) an evidence-based sepsis screening tool, and 2) a prehospital sepsis alert call to the receiving hospital for participants who screen positive. Upon arrival to the ED, ED providers will provide immediate medical assessment to the patient to determine whether there is concern for sepsis. If the treating provider determines there is concern for sepsis, the provider will deliver usual sepsis care per local hospital protocols, workflows, or care pathways. Sepsis treatment interventions will not be specified by this study protocol.
45390171|NCT05685953|Biological|DNA vaccine OC-007|Plasmid DNA vaccine
45390172|NCT05685953|Other|Placebo|0.9% NaCl solution
45390173|NCT05655377|Device|FitMi PD|Exercise using the motion sensing devices and a tablet computer
45390174|NCT04973111|Drug|CT-868 as SC Injection|CT-868
45390175|NCT04973111|Drug|Placebo as SC Injection|Placebo
45696459|NCT01670565|Drug|Belimumab|Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. Prior research provides a robust rationale for the investigation of belimumab in combination with MMF (Cellcept ®) for the treatment of early diffuse cutaneous systemic sclerosis.
45715217|NCT05432674|Combination Product|Digital Fall Prevention|Exercises delivered through a tablet and remote motivational calls
46056839|NCT00736957|Drug|Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)|Tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg (JNS013) one or two tablets will be given orally four times daily (maximum dose is 8 tablets per day) for 4 weeks during treatment period 1 (restrictions on concomitant treatments will be established) and for 48 weeks during treatment period 2 (permitting modifications to the concomitant drugs/therapies). The dosing interval will be of at least 4 hours.
45390176|NCT04973111|Drug|Active Comparator as SC Injection|Active Comparator
45390177|NCT05646251|Device|Heart Ultrasound|A wand is placed on the chest to use soundwaves to make a picture of the heart and shows how the muscle and valves work. This helps with device placement.
45390178|NCT00486434|Drug|SMC021 Oral Calcitonin|0.8mg SMC021 (Oral Calcitoinin) twice daily
45390179|NCT00486434|Drug|SMC021 Placebo|Placebo orally, twice daily
45390180|NCT04972019|Device|Telerehabilitation Experimental Group|"Experimental training will occur in the home. The experimental training will last 8 weeks, each week having up to 4 sessions of therapeutic game play (based on tolerance). Each session will start with vitals and subjective pain level being measured and logged.~They will wear a computer system modified with biosensors, then do motor and cognitive baselines. Subsequently, participants will play an increasing number of games, targeted at cognitive domains of executive function (primary), memory and attention. At the end of every session vitals and subjective pain will be measured and logged.~Clinical Coordinator will call homes weekly to ascertain general health and issues with participation.~At the end of week 4 and 8 participants and their caregivers in the experimental group will fill a subjective evaluation questionnaire to gauge perceived benefits and technical difficulties when using the experimental system. Questions will be scored on a 5-point Likert scale."
45390181|NCT04972019|Other|Telerehabilitation Sham Control Group|"Sham control group will train playing web games while wearing a biosensor connected to a laptop provided, showing the web games. However biosensor data will not be used to control game difficulty.~Sham group controls will start every session with vitals and subjective pain levels being measured and logged. Then participants will play the same frequency and duration of sessions, however those will consist of web games training the same domains (memory, focusing, executive function). Interaction will be through a mouse, and data will be downloaded to a server maintained by the company doing the web games. Data will then be transferred to the research team.~At the end of every session vitals and subjective pain levels will again be measured and logged.~Once a week the Clinical Coordinator will call the home to ascertain general health and determine is there were issues with that week participation."
45390182|NCT00424632|Drug|PF-03814735|1, 5, and 25 mg gelatin capsules administered orally once a day from day 1 to day 5, or from day 1 to day 10 every 3 weeks until disease progression or unacceptable toxicity.
45390183|NCT00529451|Drug|Aliskiren|Aliskiren
45390184|NCT00529451|Drug|Ramipril|comparator
45390185|NCT03876743|Other|Group 1-Knee Arthroscopy|Will have all of their post-operative prescriptions sent down to the pharmacy on the day of surgery to be collected.
45390186|NCT03876743|Other|Group 2-Knee Arthroscopy|Will have all prescriptions sent to pharmacy with the exception of an opiate prescription. Instead, they will be handed a physical paper prescription. They will be instructed to only fill the prescription if absolutely needed.
45390187|NCT03876743|Other|Group 1-ACL reconstruction|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
45390188|NCT03876743|Other|Group 2-ACL reconstruction|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
45390189|NCT05641259|Drug|LP-108|Oral administration for 21 or 28 days on a 28-day cycle
45390190|NCT05641259|Drug|Azacitidine|Subcutaneous administration for 7 days on a 28-day cycle at the dose of 75mg/m2 2-2.5h hours after LP-108.
45390191|NCT05408975|Device|Active Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
45502398|NCT01349647|Biological|vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant. Patients will receive vaccine at weeks 1, 2, 3, 9, 20, and 32. Patients will also receive one cycle of chemotherapy with etoposide and cisplatin or carboplatin at week 6.
45696460|NCT01670565|Drug|Mycophenolate Mofetil|Patients received background MMF therapy, some who were naive to MMF were titrated up to 1,000 mg twice daily and others had been receiving MMF at <2,000 mg/day for <3 months. MMF was chosen so that background therapy would be uniform and not a further source of variability in the small study.
45390192|NCT05408975|Device|Sham Transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
45390193|NCT05405387|Drug|Budesonide EC|Subjects will take 3mg of Budesonide or placebo. Dosing will begin on day prior to cell infusion and continue until Day 14 post transplant. Budesonide or placebo will be in capsule formulation. Budesonide or Placebo will be administered orally three times daily (every 8 hours ± 1 hours) with or without food.
45390194|NCT05405387|Drug|Placebo|Subjects will take 3mg of Budesonide or placebo. Dosing will begin on day prior to cell infusion and continue until Day 14 post transplant. Budesonide or placebo will be in capsule formulation. Budesonide or Placebo will be administered orally three times daily (every 8 hours ± 1 hours) with or without food.
45390195|NCT05401799|Device|BURT|Use of Barrett Upper extremity Robot (BURT) to improve strength and mobility of hemiplegic upper extremity.
45390196|NCT05401799|Procedure|Other Occupational Therapy|Standard occupational therapy sessions will be 60-90 minutes a day and are UE neuroeducation sessions are typically focused on improving strength and mobility of the hemipelagic arm.
45390197|NCT03999437|Drug|TERBINAFINE HYDROCHLORIDE (1%)|Topical liquid solution
45390198|NCT03999437|Drug|BUTENAFINE HYDROCHLORIDE (1%)|Topical liquid solution
45390199|NCT03999437|Drug|Vehicle Control|Topical liquid solution
45390200|NCT05311631|Behavioral|Breastfeeding support|"The core of the intervention is a trustful relation between the health visitor and the families based on principles of needs based communication. Health visitors will enhance parents' action competence based on breastfeeding self-efficacy, focusing on parents' wishes and needs.~The breastfeeding support includes four main messages: joint parenting task, skin-to-skin contact, frequent breastfeeding, and good positioning.~Training of health visitors includes e-learning and a two-day course with physical attendance. Supportive materials are developed including communicative support tools and a web-page providing support and knowledge when the health visitor is off hours.~All families in intervention sites accepting the health visitor program will receive the improved breastfeeding support. Families in the high-risk group are offered an intensified intervention with close follow-up by telephone in planned time-intervals, thus a higher dose of the intervention."
45390201|NCT05638217|Combination Product|Silver diamine fluoride 38% followed by Sodium fluoride varnish 5%|"1)Completely drying of the affected area 2)10 microliters of silver diamine fluoride 38% (CaviGuard®) will be placed on the affected area 3)The affected area should be immediately covered with 20 microliters of fluoride varnish 5% (CaviGuard®) 4)Repeat steps 1-3 one or two more times for large caries at intervals of at least 2 days apart 5)Follow up evaluation of treatment success visits will be conducted at 6 and 12 months from the initial treatment.~NOTE: This is a single intervention using the device registered as Caviguard® to apply both products (Silver diamine fluoride 38% followed by Sodium fluoride varnish 5% (®)) in sequence."
45848735|NCT01878786|Drug|Everolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus .
45390202|NCT05278871|Device|Constructive Shearwave Interference (CSI)|handheld ultrasound
45502399|NCT01349647|Biological|Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|"Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.~Patients will receive vaccine at weeks 1, 2, 3, 4, 8, and 16."
45502400|NCT02806232|Drug|Biltricide (racemate praziquantel) oral tablets|Biltricide (600 mg tablet) was administered to participants at a dose of 20 mg/kg in Part 1, Cohort 1 and at a dose of 40mg/kg in Part 1, Cohort 2.
45502401|NCT02806232|Drug|Racemate Praziquantel ODT|Racemate Praziquantel (PZQ) (150) mg was administered at a dose of 40 mg/kg in Part 1, Cohort 3 and at a dose of 60 mg/kg in Part 1, Cohort 4.
45502402|NCT02806232|Drug|Levo Praziquantel ODT|Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.
46056840|NCT02608294|Device|Kinesio Taping|The patient is placed on a stretcher, his ankle positioned in plantar flexion and inversion, a measure was held between Point A and B with a tape measure, right after the KT was removed from the paper and cut to the same extent. The KT was pulled to its maximum limit and measured with a tape for a second evaluator. This measure found after the maximum tensile strain represented 100% and a rule of three was applied in order to find the 35% voltage for muscle activation. After finding the measure of 35% strain in centimeters, the evaluator cut KT this measurement and the same was discarded. Finally the tape was positioned at Point A; pulled up to Point B; and fixed. This procedure was carried out with the ankle positioned in plantar flexion and inversion.
45390203|NCT05637281|Drug|Indometacin|Besides the conventional treatment, indomethacin will be given to the patients in the convention + indomethacin group.
45390204|NCT05637281|Other|conventional treatment|All enrolled patients received conventional management according to AP guidelines of International Association of Pancreatology and the Chinese Society of Gastroenterology, including goal-directed fluid resuscitation, oxygen supply even mechanical ventilation, and nutritional support if necessary.
45390205|NCT00486278|Drug|eptacog alfa (activated)|90 mcg/kg, injected i.v.
45390206|NCT00486278|Drug|vatreptacog alfa (activated)|5 mcg/kg, injected i.v.
45390207|NCT00486278|Drug|vatreptacog alfa (activated)|10 mcg/kg, injected i.v.
45390208|NCT00486278|Drug|vatreptacog alfa (activated)|20 mcg/kg, injected i.v.
45390209|NCT00486278|Drug|vatreptacog alfa (activated)|40 mcg/kg, injected i.v.
45390210|NCT00486278|Drug|vatreptacog alfa (activated)|80 mcg/kg, injected i.v.
45390211|NCT00321711|Drug|Placebo|Subjects in the control group will receive a placebo subcutaneous injection on a weekly basis during the 4 cycle treatment period.
45390212|NCT00321711|Biological|AMG 531 (Romiplostim)|AMG 531 (Romiplostim) will be administered weekly by subcutaneous injection at a dose of 500 or 750 μg during Part A and 750 μg during Part B for the 4 cycle treatment period, depending on randomization.
45390213|NCT00321711|Drug|Azacitidine|hypomethylating agent
45390214|NCT00321711|Drug|Decitabine|hypomethylating agent
45390215|NCT00486044|Drug|Simvastatin|40 mg tablet each night for one month, then 80 mg for 8 months
45390216|NCT00486044|Drug|Placebo|Matching tablet each night for 9 months
45390217|NCT01018472|Dietary Supplement|Bifidobacterium infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 4 months
45390218|NCT01018472|Other|Placebo|A dilute preparation of pregestimil formula (similar in appearance to the probiotic product)
45390219|NCT04193462|Other|Post-partum depression- Dyadic psychotherapy-|Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity. Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant. During the whole therapy-trial, the therapist will also use cognitive-behavioral approach to address the mother's perception of her infant and of herself as a mother.
45502403|NCT02908087|Drug|Victoza® (liraglutide)|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
45390220|NCT04193462|Other|Post-partum depression- Psycho-educational therapy|Mothers will receive a therapy in their homes for 8 weeks, 1.5 hours for each session by a therapist arriving at their home. Each session will address a different developmental aspects of the baby (feeding, movement, social-emotional development etc.). Therapist will ask the mother about her baby, will give information about developmental needs and expectations and will help mother to enrich child's development and deal will potential problems
45390221|NCT00351273|Drug|Doxycycline and Rifampin|doxycycline 100mg daily; rifampin 300mg daily (both for 6 months)
45390222|NCT00351273|Drug|Azithromycin and Rifampin|Azithromycin 500mg daily for 5 days and then twice weekly; Rifampin 300mg daily (both for 6 months)
45390223|NCT00351273|Drug|Placebo|Methylcellulose
45390224|NCT01018628|Drug|SRT2379|SRT2379 will be supplied as hard gelatin capsules, with each containing 25 mg or 250 mg of SRT2379 free base equivalent (31 or 310 mg of SRT2379 monosuccinate) without any additive.
45390225|NCT01018628|Drug|Placebo|For placebo product, the SRT2379 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 200) to match the SRT2379 investigational product.
45390226|NCT03996356|Other|No study intervention - observational study|This is an observational study where the comparative groups will be determined by the genetic variants (SNPs) of subjects and not an intervention, per se.
45390227|NCT00327717|Drug|Zonisamide|Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.
45390228|NCT00327717|Drug|Placebo|Patients in placebo group were titrated with placebo in the same way as in zonisamide group.
45390229|NCT03917810|Other|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
45390230|NCT03995810|Dietary Supplement|Carnosine, capsulle, 2 g/day, 8 weeks|We will administer supplemental carnosine (2 grams per day) for 8 weeks
45390231|NCT00463346|Drug|Acamprosate|Acamprosate 1998 mg tid
45390232|NCT00463346|Drug|Placebo|Placebo
45502404|NCT02908087|Drug|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
45502405|NCT01357837|Drug|Matching Placebo|2 capsules of matching placebo once a day, in the morning, for a total of 28 days
45502406|NCT01357837|Drug|GRT6005|2 capsules containing a total of 75 µg GRT6005 once a day, in the morning, for a total of 28 days
45390233|NCT01025024|Genetic|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
45390234|NCT01022528|Drug|Dexamethasone (0.1 mg/kg)|
45390235|NCT01022528|Drug|Dexamethasone (0.2 mg/kg)|
45390236|NCT01022528|Other|Saline|
45390237|NCT01025102|Drug|Naropin 0.1% cum sufentanil|20ml of Naropin 0.1% cum sufentanil 1mikrog per ml
45390238|NCT00462488|Drug|Vicinium|Intravesical administration of Vicinium
45390239|NCT01025180|Other|Procalcitonin level|"The duration of antibiotic treatment is based on PCT level:~< 0.25 ng/ml: antibiotic should be stopped~0.25 < PCT <0.5: antibiotic prescription is not recommended~> 0.5 ng/ml: antibiotic should be used"
45390240|NCT00454142|Drug|pazopanib hydrochloride|Given PO
45390241|NCT00454142|Other|pharmacological study|Correlative studies
45390242|NCT00454142|Procedure|computed tomography|Correlative studies
45390243|NCT00424476|Drug|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.
45390244|NCT00424476|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
45390245|NCT00424476|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
45390246|NCT03994536|Behavioral|A Person-Centred Transition Program to Empower Adolescents With Type 1 Diabetes in the Transition to Adulthood: the STEPSTONES-DIAB Project|Behavioral: Transition program Participants will be part of a transition program that aim to prepare them for adult life and adult care wich includes eight key components: 1. A transition coordinator; 2. Education on diabetes, treatments, health behavior, dealing with school, friends; 3. Telephone availability; 4. Information about the adult diabetes service: 5. Guidance of parents; 6. Meeting with peers: 7. A person-centered transition plan; and 8. Preparation and transfer to adult diabetes service.
45390247|NCT03994536|Other|Standard care|Participants allocated to this group will receive usual care, which includes regular follow-up visits in pediatric diabetes outpatient clinics. Usual care can vary across the two clinics, however, they all include meetings with a nurse and a physician.
45390248|NCT01037634|Drug|Oseltamivir|3 mg/kg given orally for 5 days for seasonal influenza, 7 days for 2009 H1N1 influenza (in Vietnam only), or 10 days for avian influenza, for children whose renal function is greater than or equal to 30 mL/min/1.73m2
45390249|NCT00453986|Biological|Meningococcal vaccine GSK134612|One intramuscular dose
45390250|NCT00453986|Biological|Mencevax™ACWY|One subcutaneous dose
45390251|NCT00453986|Biological|Fluarix™|One intramuscular dose
45848736|NCT01878786|Drug|Tacrolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.
45848737|NCT01878786|Drug|Mycophenolate mofetil (MMF/MPA)|Control Drug
45390252|NCT01032252|Other|Exercise intervention|"16 week exercise once a week of 60 minutes intervention by trained fall prevention instructors and a home program.~Intervention includes strength/power training, balance/gait training, behavioral aspects and perceptual and functional training."
45390253|NCT00435942|Device|Relay Thoracic Stent-Graft|implant
45390254|NCT00435942|Procedure|Open Repair|Open surgery
45390255|NCT01034748|Drug|[14C]PF00299804|Single 45 mg oral dose of radiolabelled PF-00299804
45390256|NCT01037712|Drug|Valacyclovir (ZELITREX)|2g, 8g/day, 4 a day 23 weeks maximum.
45390257|NCT01037712|Drug|Placebo|placebo
45502407|NCT01357837|Drug|GRT6005|2 capsules containing a total of 200 µg GRT6005 once a day, in the morning, for a total of 28 days
45390258|NCT00453362|Other|2-deoxy-2-[18F]fluoro-D-glucose (FDG)|FDG prepared in sterile buffered solution for intravenous injection. Dosage was based on the participant's weight not to exceed 15 mCi (millicurie).
45390259|NCT00453362|Other|3'-deoxy-3'-[18F]fluorothymidine (FLT)|FLT 7 mCi dose prepared in sterile buffered solution for intravenous injection.
45390260|NCT00453362|Drug|erlotinib HCl|Tablets taken orally 150 mg/day.
45390261|NCT00424398|Drug|Bepreve|sterile ophthalmic solution
45390262|NCT00424398|Drug|Placebo|sterile ophthalmic solution
45502408|NCT01357837|Drug|GRT6005|2 capsules containing a total of 400 µg GRT6005 once a day, in the morning, for a total of 28 days
45848738|NCT01851174|Drug|Gemcitabine|Patients will receive Gemcitabine (1,000 mg/m^2) IV over 30 minutes after nab-paclitaxel infusion
45390263|NCT00424398|Drug|Bepotastine Besilate|sterile ophthalmic solution
45390264|NCT00461786|Drug|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
45390265|NCT01021592|Drug|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
45390266|NCT01021670|Drug|Dapoxetine hydrochloride|One 30 mg tablet up to a maximum of one 60 mg tablet approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed for 12 weeks
45390267|NCT01021670|Other|Alternate care/non-dapoxetine hydrochloride treatment(s)|As prescribed or directed
45390268|NCT01025258|Behavioral|Frequent Scheduled CF clinic visits|Mandatory scheduled visit at the CF clinic every 1-2 months or sooner, if needed, for an evaluation by a a specialized CF team member such as: a pulmonary physician, a gastroenterologist, a dietitian, a clinical pharmacist
45390269|NCT01025258|Behavioral|frequent telephone calls to patients pre and post visits to the clinic|Frequent telephone calls for monitoring, educating and identifying barriers in adherence will be made by a designated CF team member such as the CF nurse or the CF clinical pharmacist.
45390270|NCT01025414|Drug|enteral nutrition|Group A - enteral feeding was started 2 to 4 hours after catheter placement via enteral tube inserted via endoscope below the Treitz's ligament into first intestinal loop (location of the tip) (Nutricial Ltd. Flocare). The initial flow rate was 10 ml/ hour, final 125 ml/ hour. Energy requirements was calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Diet: Peptisorb (Nutricia Ltd.) - oligopeptide diet well tolerated by intestines
45390271|NCT01025414|Drug|Parenteral nutrition|Parenteral nutrition was started 2 to 4 hours after venous catheter placement (standard Arrow type, the tip located 5 cm over right vestibule, the location confirmed on chest X-ray) and continued until oral diet covering at least 60% of daily caloric and protein demand. The energy requirements were calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Parenteral diets: Aminoplasmal 10%, Lipofundin LCT/MCT 10 and 20%, 40% Glucose, Tracutil (microelements and trace elements), Cernevit (vitamins), electrolytes
45390272|NCT00435162|Drug|Valsartan 0.25 mg/kg|once daily
45390273|NCT00435162|Drug|Valsartan 1.0 mg/kg|once daily
45390274|NCT00435162|Drug|Valsartan 4.0 mg/kg|once daily
45390275|NCT03836664|Drug|Timolol|Timolol is a clear solution supplied in a plastic ophthalmic dispenser.
45390276|NCT03836664|Drug|Placebo|Placebo is normal saline solution that will be supplied in container matched to Timolol container.
45390277|NCT01037868|Other|Supportive SMS text messages|Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
45390278|NCT01032408|Biological|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
45390279|NCT01032408|Biological|Begrivac®|15 ug of HA antigen; non-adjuvanted; trivalent
45502409|NCT02053532|Procedure|Positron emission tomography/magnetic resonance imaging|Positron emission tomography/magnetic resonance (PET/MR) imaging using 18-F-fluorodeoxyglucose (FDG) as radio tracer
45502410|NCT02053688|Device|Astigmatic Correction Lens (Nexis ACCL lenses)|Astigmatic refractive error correction
45502411|NCT02053688|Device|Toric Soft Contact Lenses|astigmatism correction using toric optics
45390280|NCT00350727|Drug|pazopanib|Pazopanib is a novel compound being developed for the treatment of various cancers.
45390281|NCT00350727|Drug|lapatinib|Lapatinib is a novel compound being developed for the treatment of various cancers.
45390282|NCT01032486|Drug|Rasagiline mesylate|Azilect® tablets (0.5mg or 1.0 mg) administered orally once daily
45390283|NCT01032564|Other|The elastography (elasticity imagery)|This diagnosis mean use the ultrasonography to measure the tissues answer under pressure
45390284|NCT01032642|Device|device for hysterosalpingography|a thin catheter originally designed for IUI (sperm processor cat. No. SP/PL/01, Aurangabad, India) connected to a 10 mL syringe filled with urographin 76% (Scherring, Germany) will be introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum will be loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye will be injected slowly and the procedure will be watched on the screen and x-ray films will be taken.
45502412|NCT01349725|Drug|ARRY-502|Oral; multiple dose, escalating
45502413|NCT01349725|Drug|Placebo|Oral; matching placebo
45502414|NCT02037854|Other|Nutrient formulation|
45502415|NCT01353781|Drug|AZD5363|Patients will be given AZD5363 capsules administered orally as a single dose, and then multiple twice-daily dosing following 3 to 7 days washout.
45696461|NCT01670565|Other|Placebo Infusion|Infusion of normal saline
45696462|NCT04432090|Drug|Placebo|Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)
45696463|NCT04432090|Drug|Study Medication (MBX-2982)|Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)
45696464|NCT04432090|Other|No medication for this group|This group will be studied to establish the norm of the measurement that will be performed to obtain the study outcomes.
45390285|NCT01061697|Drug|Pregabalin|At week 0, pregabalin 75mgbd will be given for 1 month. If visual analogue scale is not reduced by 50% after 1 month, pregabalin will be increased to 150mgbd for the second month
45390286|NCT00434304|Drug|Ropinirole prolonged release/extended release(PR/XR)|Subjects will take the investigational drug once daily at the same time each day, it is recommended that this is in the morning for optimal benefit. Investigational drug is taken for 52 weeks, starting on the next day of the Week 0 visit. One tablet of ropinirole PR/XR 2 mg tablets will be orally dosed as the initial dose. The dose will be titrated weekly by 2 mg/day, and increased to 8 mg/day in Week 4. From Week 5 up to 16, the dose will be increased at minimum intervals of one week between titration steps until sufficient efficacy is obtained, according to individual clinical response and tolerability (the dose may be titrated up to 16 mg/day). In Week 16 and further, treatment dose at Week 16 will be continuously administered up to Week 52. If insufficient efficacy is judged in a subject during treatment, or unable to maintain the dose due to adverse event, the treatment dose may be changed. The dose is down tapered according to the maintenance dose at Week 52 (or withdrawal).
45390287|NCT00424008|Drug|Mometasone furoate/formoterol (MF/F) MDI|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks.
45390288|NCT00424008|Drug|Fluticasone propionate/salmeterol (F/SC) DPI|Fluticasone propionate 250 mcg and salmeterol 50 mcg fixed dose combination dry powder inhaler taken twice daily for 52 weeks.
45390289|NCT03994068|Diagnostic Test|VIVO non invasive mapping|non invasive pre-procedural localization of PVC / VT origin
45390290|NCT00423930|Biological|bevacizumab|
45390291|NCT00423930|Drug|cisplatin|
45390292|NCT00423930|Procedure|conventional surgery|
45390293|NCT00423930|Radiation|intensity-modulated radiation therapy|
45390294|NCT00423852|Biological|filgrastim|
45502416|NCT03805880|Diagnostic Test|cerebral desaturation monitoring and cognitive examination|Before general anesthesia, continuous monitoring of cerebral oxygenation(rSO2) was started using an INVOS 5100 (Somaneic, Tro, MI) .Patient cognitive function was assessed using Mini-Mental State Examination (MMSE) on the day before surgery (baseline) and then after 1 day after surgery.
45502417|NCT03561662|Dietary Supplement|Alpro soya drinks|12 weeks
45502418|NCT02051036|Procedure|Moxibustion|"In the moxibustion treatment group, 5 moxibustion points (bilateral SP6, LV3 and unilateral CV4) will be heated with indirect moxibustion (KangHwa, Korea).~The moxa pillars will be removed when the patient feel hotness and require to remove them.~The moxibustion will be conducted repeatedly unless patients feel the sense of heat up to seven times per session."
45696465|NCT03088215|Device|shock-waves|Application of shock-waves (radial and focused)
45696466|NCT01675479|Device|LASIK correction of hyperopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
45390295|NCT00423852|Drug|carboplatin|
45390296|NCT00423852|Drug|ifosfamide|
45390297|NCT00423852|Drug|paclitaxel|
45390298|NCT00423852|Procedure|autologous hematopoietic stem cell transplantation|
45390299|NCT00423852|Procedure|peripheral blood stem cell transplantation|
45502419|NCT02053766|Drug|Sevoflurane|Sevoflurane up to 8% will be administered to study subjects
45502420|NCT02053766|Drug|Dexmedetomidine|Dexmedetomidine (Precedex) infusion starting at 1mcg/ kg/ hr will be administered to study subjects.
45502421|NCT02053766|Drug|Propofol|Propofol up to 50 mcg/ kg/min will be administered to study subjects.
45502422|NCT02053844|Other|lottery for tool users to win a $500 prize|Intervention group is eligible to enter a monthly lottery to win a $500 gift card if they use the tool each month.
45390300|NCT01037946|Behavioral|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
45390301|NCT00461708|Drug|Erlotinib|100 mg, PO, once per day
45390302|NCT00461708|Drug|Gemcitabine|1000 mg/m2, IV, on Days 1, 8 and 15 in 4-week cycles
45390303|NCT01032720|Procedure|Ultrasound|Ultrasound will be used to image knee joint and guide needle for intra-articular corticosteroid injection.
45390304|NCT01032720|Procedure|Sham ultrasound|Knee CS injection will be performed in the same method as the US-guided injection except that the US machine will be turned off. Study patient will be unaware of whether US machine is on or off.
45390305|NCT00327171|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 4.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level ( to 2.0 mg/kg) or 2 dose levels (to 1.0 mg/kg) in case of uncontrolled hypertension or urinary protein >3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
45390306|NCT00327171|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 2.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level (to 1.0 mg/kg) or 2 dose levels (to 0.5 mg/kg) in case of uncontrolled hypertension or urinary protein >3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
45390307|NCT01038024|Dietary Supplement|1 tablet composed of antioxidants and minerals|1 tablet daily
45502423|NCT02053844|Other|enhanced promotion of the tool to employers and members|Intervention group also receives extra promotion of the tool through mailings, employer outreach, and automated phone calls
45502424|NCT02053922|Drug|Syntocinon|Syntocinon ampoules (10 IU Oxytocin). (Novartis Pharma, Egypt) One ampoule 10 IU diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS, followed by an intravenous drip of 20 IU oxytocin in 500 ml saline over 4 hours.
45696467|NCT05613244|Other|Phone call|Patients will be asked to complete a questionnaire via a phone call
45696468|NCT01678755|Drug|ABT-126|ABT-126 Low Dose
45696469|NCT01678755|Drug|ABT-126|ABT-126 High Dose
45696470|NCT01678755|Drug|Placebo|Placebo
45696471|NCT04358380|Other|Liver injury|LFTs elevation or liver decompensation
45696472|NCT03512301|Device|CAMCI|CAMCI battery of computerized tasks
45715218|NCT05428462|Other|Psychoeducation day on borderline personality disorder|Transmission of latest knowledge on borderline personality disorder
45848739|NCT01851174|Drug|nab-Paclitaxel|Patients will receive nab-Paclitaxel (125 mg/m^2) IV over 30 minutes before Gemcitabine infusion
45715219|NCT05744388|Device|Gliderite® shape modification|The stylet will be more obtuse angle than the standard shape. The stylet will be lubricated also before being fitted inside the endotracheal tube. The blade will be introduced inside the mouth midline, the tube will be held from the upper third and introduced in the midline also sliding over the blade and introduced inside the glottis.
45715220|NCT05425498|Other|Physical activity program|12-weeks physical activity program will be applied by giving pedometer. 12 telephone sessions will be held once a week according to motivational interview techniques based on the Transtheoretical Model.
45390308|NCT03982875|Device|Alfred SmartBag|The Alfred SmartBag encompasses a pouch, a baseplate, and a hub, is intended to be used as a continuous ostomy monitoring system by tracking the volumetric filling of the pouch through integrated thermistor and capacitive sensors and potential leakage and skin irritation development through integrated thermistors in the wafer. The Alfred SmartBag system is indicated for daily use for both in-patient and out-patient settings to provide information to patient and medical professionals. The data is intended to aid patient self-management and to alert the clinical team to changes in the patient condition that may warrant specific intervention.
45390309|NCT03982719|Other|Brief protocol|This protocol consists of 4 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 4 weeks and 8 weeks post-fasciectomy. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery.
45390310|NCT03982719|Other|Intense protocol|This protocol consists of 6 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 3 weeks, 4 weeks, 6 weeks and 8 weeks after surgery. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery. Also, exercises will be performed by the patient under the supervision of the occupational therapist (supervised exercises) in each session except the first one at 0-3 days after surgery.
45390311|NCT00461630|Drug|ER niacin/laropiprant|
45390312|NCT00461630|Drug|simvastatin|40 mg simvastatin tablet orally per day as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
45390313|NCT00461630|Drug|ezetimibe/simvastatin|10 mg ezetimibe plus 40 mg simvastatin in single tablet taken once daily as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
45502425|NCT02053922|Drug|Carbetocin|Carbetocin (Ampoule 100 μg/ml) . [Pabal, Marketing Authorization Holder: Ferring GmbH (Gesellschaft mit beschränkter Haftung), Kiel ,Germany. Manufactured by DRAXIS Pharma , a division of specialty Pharmaceuticals Inc. Montreal ,Canada] ,diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS.
45502426|NCT02053922|Drug|Misoprostol|Misoprostol (200 mcg Tablet) [Misotac, Sigma Pharmaceutical Industries, SAE, Egypt] Two tablets (400 mcg) in the buccal space just after delivery of the neonate during CS.
45502427|NCT02052206|Procedure|Shoulder replacement surgery|
45848740|NCT01846182|Drug|Duloxetine|serotonin norepinephrine reuptake inhibitor
45502428|NCT02054000|Drug|Tirofiban|Intracoronary administering of Tirofiban
45848741|NCT01846182|Drug|Pregabalin|alpha-2-alpha subunit calcium channel ligand
45502429|NCT02054000|Other|Placebo|Intracoronary serum physiologic
45502430|NCT02054078|Drug|Bevacizumab|Bevacizumab200mg by intrapleural administration
45502431|NCT02054078|Drug|Pulvis talci|Pulvis talci 4g by intrapleural administration
45502432|NCT02052284|Other|Sterile water application|Nurses are trained in proper dispensing and application of water in a sterile gentle way that will minimize shear force on the skin, risk for skin injury, and the potential for spread of fecal flora.
45848742|NCT01846182|Drug|Placebo|Placebo
45390314|NCT01061853|Drug|TOPICAL SIROLIMUS (RAPAMUNE*)|APPLICATION ON THE LESIONS OF TOPICAL SIROLIMUS (RAPAMUNE*)1mg/ml bid during 3 months
45390315|NCT01061853|Drug|TOPICAL BETAMETHASONE 0.05%|APPLICATION ON THE LESIONS OF TOPICAL BETAMETHASONE (DIPROLENE*)0.05% bid during 3 months
45390316|NCT03982641|Procedure|all colorectal cancer surgical procedures|colorectal cancer surgical procedures
45390317|NCT00461552|Drug|Leptin|weight based, sub-cutaneous injection, twice daily
45390318|NCT00461552|Other|Placebo|weight based, sub-cutaneous injection, twice daily
45502433|NCT02051192|Behavioral|Parent-Led Exposure Therapy|Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
45696473|NCT04358302|Behavioral|Pillsy|"The electronic pill bottle cap, Pillsy, and its accompanying software application provides reminders to take a scheduled dosage of medication via bottle cap alerts and smartphone push notifications, text messages, and/or automated phone calls. The Pillsy application records dosing dispense date and time when the user opens the bottle. During the first 2 weeks of the trial, the electronic notifications will be disabled to determine a baseline measure of adherence. Within 1 day after Visit 2, the electronic notifications will be turned on for all participants, resulting in a series of alerts (via electronic pill bottle cap alerts and smartphone push notifications, text message, and/or automated phone calls).~The electronic pill bottle cap, Pillsy, is a commercially available device marketed to consumers. The electronic pill bottle cap does not capture or store PHI. Quick tips on how to use Pillsy can be found at https://www.pillsy.com/instructions"
45390319|NCT01325415|Drug|NKTR-118|25 mg tablet
45502434|NCT02051192|Other|Treatment As Usual|Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice. These participants may also elect to receive no treatment at all during the TAU period.
45502435|NCT02052362|Drug|ABT-450/r/ABT-267|ABT-450, ABT-267 and ritonavir
45696474|NCT01670799|Drug|Ketorolac|This is a pilot (feasibility) trial to determine the availability, concentration and racemic mixture of a clinically indicated pain medication, ketorolac, in the peritoneal cavity and the subsequent effect on free floating ovarian cancer cells in patients after cytoreductive surgery for ovarian cancer.
45390320|NCT01325415|Drug|moxifloxacin|400 mg tablet
45390321|NCT01325415|Drug|Placebo|tablet
45390322|NCT00453206|Procedure|allogeneic bone marrow transplantation|
45390323|NCT00453206|Procedure|allogeneic hematopoietic stem cell transplantation|
45390324|NCT00453206|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
45390325|NCT00453206|Procedure|peripheral blood stem cell transplantation|
45390326|NCT03900806|Behavioral|online cognitive rehabilitation|The cognitive rehabilitation program will be based on the protocol of a frequently used meta-cognitive strategy approach applied in many rehabilitation centers in the Netherlands. The program consists of several modules that can be used in a flexible way, depending on the specific individual problems and goals. Therapists have undergone additional training in issues related to cancer-related cognitive impairment and problems occupationally active cancer survivors might experience at work. In both intervention arms, participants will receive access to a secured personal webpage, where all content relevant to the treatment sessions can be obtained.
45390327|NCT03894254|Other|no intervention|This is study carried out in current practice. Patients are undergoing a medical examination in a memory center, with extensive and systematic evaluations for the study involving the following tests: IADL, DAD6, New AGGIR, NPI, and mini-Zarit) assessing the functions (autonomy, behavior and caregiver burden).
45390328|NCT03850496|Device|Revitive IX Neuromuscular Stimulation Device|Neuromuscular stimulation footplate device with a pre-programmed 30 minute varying electrical stimulation sequence.
45390329|NCT03995888|Drug|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
45502436|NCT00392327|Drug|Carboplatin|Given IV
45502437|NCT00392327|Drug|Cisplatin|Given IV
45502438|NCT00392327|Drug|Cyclophosphamide|Given IV
45696475|NCT02404935|Drug|Cetuximab|
45390330|NCT01022606|Other|Arterial sampling|Arterial pO2 (ABL5) Body Temperature (Vitalsens Cortemp) tcpO2 TCM400
45390331|NCT01022684|Other|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship between various inflammatory markers and PET imaging at the cross section setting
45390332|NCT01022840|Drug|S-Ketamine|drug
45390333|NCT01022840|Other|Placebo Comparison|saline control
45390334|NCT01025570|Drug|Gemcitabine, Bosutinib|Gemcitabine, 1000 mg/m2 on D1,8,15 over 30 mins standard infusion rate Bosutinib 400 mg, oral, once daily
45390335|NCT03983876|Drug|Adalimumab|"AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory disease"
45390336|NCT00327015|Drug|Saxagliptin|Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)
45390337|NCT00327015|Drug|Saxagliptin|Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)
45390338|NCT00327015|Drug|Metformin|Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)
45390339|NCT00327015|Drug|Placebo|Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)
45390340|NCT00327015|Drug|pioglitazone|Tablets, Oral, 15-45 mg, as needed (12 months LT)
45390341|NCT00434148|Drug|Pasireotide|
45390342|NCT03983655|Device|High Frequency Low Intensity TMS|125 hz, 10 gauss, 2 times daily for 6 monts
45390343|NCT03983499|Behavioral|Special Intervention|The components of the Special Intervention (SI) integrated design are: 1) Co-location of the clinical team; 2) Shared medical plan; 3) Clinical visits with a medical provider for management of chronic medical conditions; 4) Visits with behavioral health provider for management of psychosocial chronic conditions; 5) Care coordination; 6) Six group-health education classes and two booster sessions led by a promotora. Participants in the SI arm meet with the integrated care team in the context of a regular medical visit primarily to focus on clinical/biological aspects of the chronic medical conditions (diabetes, dyslipidemia, hypertension, obesity, etc.)
45390344|NCT01063569|Drug|Solu-Cortef (hydrocortisone)|Continuous Subcutaneous Hydrocortisone infusion via insulin pump. Doses adjusted to body surface area.
45390345|NCT01063569|Drug|Cortef (hydrocortisone)|Oral treatment 3 times a day. Weight adjusted doses.
45390346|NCT01063647|Drug|Treosulfan|10 g/m² i.v. infusion, day -6, -5, -4
45390347|NCT01063647|Drug|Treosulfan|12 g/m² i.v. infusion, day -6, -5, -4
45390348|NCT01063647|Drug|Treosulfan|14 g/m² i.v. infusion, day -6, -5, -4
45390349|NCT00468728|Drug|PAR-101/OPT-80|capsules
45390350|NCT00468728|Drug|Vancomycin|Capsules
45390351|NCT01061931|Procedure|Arctic Front® catheter vs. HD Mesh Ablator® catheter|Pulmonary vein ablation in patients with symptomatic paroxysmal atrial fibrillation using the Arctic Front® catheter versus the HD Mesh Ablator® catheter
45390352|NCT00433914|Biological|rMenB|One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
45502439|NCT00392327|Biological|Filgrastim|Given IV or SC
45502440|NCT00392327|Drug|Isotretinoin|Given PO
45502441|NCT00392327|Other|Laboratory Biomarker Analysis|Correlative studies
45502442|NCT00392327|Other|Quality-of-Life Assessment|Ancillary studies
45502443|NCT00392327|Radiation|Radiation Therapy|Undergo radiation therapy
45502444|NCT00392327|Drug|Vincristine Sulfate|Given IV
45502445|NCT03561506|Drug|Ferric carboxymaltose|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
45502446|NCT03561506|Drug|0.9% Normal Saline|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
45502447|NCT01336439|Drug|Botulinum toxin type A (Meditoxin®)|"In this study, the botulinum toxin type A (Meditoxin®)was supplied as a freeze-dried powder of 200U, and was reconstituted with 4ml of sterile saline to a concentration of 5U/0.1ml.~After pre-injection polysomnography, botulinum toxin type A was injected into each side bilaterally using a 1ml-syringe with a 29-gauge, and a 1/2-inch needle. The M group had an injection in masseter muscle. The MT group had an injection in masseter and temporal muscle. A total of 25U of botulinum toxin type A was injected into each site.~After 4 weeks, the subjects had a post-injection polysomnography."
45502448|NCT01336595|Device|Zirconium (Zirconium Genesis II)|Oxidized Zirconium femoral component of Genesis II TKR system is used.
45502449|NCT01336595|Device|Cobalt-Chrome (Cobalt Chrome Genesis II)|Cobalt Chrome Femoral Component of Genesis II TKR system is used
45390353|NCT00433914|Biological|rMenB+OMV|One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
45390354|NCT03983265|Other|Bilateral Sagittal Split Osteotomy|after BSSO condyle will be re positioned by using computer guided device
45390355|NCT00468650|Drug|sildenafil citrate|Tablets, 50mg and 100mg , Medication will be taken orally with a glass of water approximately one hour (30 min to 4 hours) before sexual activity. Subjects are to take one dose in any calendar day.Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil 100 mg PRN for the following four weeks.
45390356|NCT00423150|Drug|Temozolomide|Temozolomide capsules 150 mg/m^2 daily on a 7-day on / 7-day off schedule for each 28-day cycle, until disease progression, intolerable toxicity, or withdrawal of consent.
45390357|NCT01038102|Other|PUFA Diet|Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%).
45390358|NCT01038102|Other|SFA diet|Diet high in saturated fat (15E%)
45696476|NCT02404935|Drug|FOLFIRI and cetuximab|
45696477|NCT00943150|Device|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the abdominoplasty procedure.
45696478|NCT00943150|Procedure|Standard of Care (SOC)|The scalpel and electrocautery will be used for the abdominoplasty procedure.
45390359|NCT00433836|Drug|Valsartan|Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg.
45390360|NCT00433836|Drug|Enalapril|Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg.
45390361|NCT01038258|Procedure|PET scan after course 1 and surgery after 8 courses|PET scan and surgery
45390362|NCT01022918|Drug|Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures)|
45390363|NCT01022918|Drug|Temodal/radiotherapy|
45390364|NCT03996044|Other|Teeth brushing and flossing|All participants will be instructed to brush with dentifrice containing amine fluoride in their composition (Elmex®) and floss with dental flossing, 3 times a day after meals for 30 days.
45390365|NCT03996044|Other|Tongue scraping|Tongue scraping will be performed by the same operator on all participants. Posterior-anterior movements will be performed with the scraper over the tongue dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
45390366|NCT03996044|Radiation|Antimicrobial Photodynamic Therapy (aPDT)|One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
45390367|NCT03996044|Biological|Probiotics|Pharmacy-manipulated capsules containing strains of Lactobacillus salivarius WB21 (6.7 x 108 CFU) and xylitol (280mg) will be used. Forty-two capsules will be delivered for each patient, who should take 1 capsule 3 times a day after meals for 14 days.
45390368|NCT00433446|Biological|CNTO 328|
45390369|NCT00468104|Drug|Alteplase|25 Mg of Alteplase in 100 cc of normal saline was instilled intrapeurally for daily for three days
45390370|NCT00468104|Drug|Placebo|Placebo in 100 cc of normal saline was instilled intrapleurally daily for three days
45390371|NCT00326625|Drug|40 mg glatiramer acetate|parenteral drug
45390372|NCT00326625|Drug|Placebo|
45390373|NCT00433290|Drug|Duloxetine|duloxetine 30 mg every day (QD), by mouth (PO) for 1 week, then duloxetine 60 mg QD, PO for 6 weeks, followed by duloxetine 60 mg QD, PO for 6 weeks for responders or duloxetine 120 mg QD, PO for 6 weeks for non-responders
45390374|NCT00433290|Drug|Placebo|placebo every day (QD), by mouth (PO) for 13 weeks
45390375|NCT00467870|Drug|Testosterone Undecanoate 750 mg|
45390376|NCT00467870|Drug|Testosterone Undecanoate 1000 mg|
45390377|NCT01021904|Biological|Gardasil (VLP, HPV Quadrivalent prophylactic vaccine)|0.5cc I/M Site deltoid Lt Rt 3-dose regimen: 0, 2, 6 months
45390378|NCT01022060|Dietary Supplement|Renalof|One Renalof tablet (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
45390379|NCT01022060|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) three time a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
45390380|NCT00467558|Drug|Naltrexone|daily
45390381|NCT00467558|Drug|Sugar pill|daily
45390382|NCT00422292|Biological|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL dose, intramuscular (IM)
45390383|NCT00422292|Biological|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL dose, IM
45390384|NCT00422292|Biological|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 Ml dose, IM
45390385|NCT00422292|Biological|Measles, Mumps, Rubella and Varicella|0.5 mL dose, SC
45390386|NCT01038414|Behavioral|Extended Duration Behavioral Smoking Cessation Counseling|Subjects are randomized to one of 3 behavioral treatments: (1) Brief Duration (3 month) smoking-cessation counseling; (2) Moderate Duration (6 month) counseling; or (3) Extended Duration (12 month) counseling
45390387|NCT00452348|Drug|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
45502450|NCT01336751|Drug|Insulin glargine|solution for subcutaneous injection
45390388|NCT00452348|Drug|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
45390389|NCT00452114|Device|In-Exsufflator Cough Assist Device|
45390390|NCT00452114|Device|Active Comparator: Flutter Valve Device|Active Comparator
45390391|NCT01323062|Drug|Bavituximab|Administered 3 mg/kg weekly
45390392|NCT00320541|Drug|gemcitabine|1500 mg/m2, IV day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
45390393|NCT00320541|Drug|paclitaxel|90 mg/m2, IV, day 1, day 8 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
45390394|NCT00320541|Drug|bevacizumab|10 mg/kg, IV, day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
45390395|NCT03982563|Behavioral|Growth Mindset|Reading and writing activities designed to instill the belief that people can change.
45390396|NCT03982563|Behavioral|Gratitude|Reading and writing activities designed to practice noticing and appreciating good things in life.
45390397|NCT03982563|Behavioral|Behavioral Activation|Reading and writing activities designed to identify and schedule positive activities.
45390398|NCT03982563|Behavioral|Study Skills|Reading and writing activities designed to learn evidence-based study strategies.
45390399|NCT00320385|Drug|Lapatinib|oral lapatinib once daily
45390400|NCT00320385|Biological|Trastuzumab|IV trastuzumab 2mg/kg weekly after 4mg/kg loading dose
45390401|NCT01063725|Dietary Supplement|Femarelle|A soy based food supplement containing 322 mg of soy extract and 108 mg of flaxseed, to be taken twice daily
45390402|NCT01063725|Other|Placebo|Capsules containing 430 mg of microcrystalline cellulose, as a placebo, to be taken twice daily
45390403|NCT00326001|Device|Gold tip catheter|Radiofrquency ablation using gold tip catheter
45390404|NCT00326001|Device|Platinum-iridium tip catheter|Radiofrequency ablation using platinum-iridium tip catheter
45390405|NCT00309777|Drug|Pitavastatin|Pitavastatin once daily
45390406|NCT00309777|Drug|Simvastatin|Simvastatin once daily
45390407|NCT00309387|Dietary Supplement|Centrum|Multivitamin/mineral supplement containing US RDA levels of nutrients. 1 tablet a day for the expected duration of follow-up (on average 10 yrs).
45390408|NCT00309387|Other|Placebo|placebo tablets manufactured to mimic Centrum tablets.
45390409|NCT03982797|Biological|Instillation of IMUNO BCG Moreau RJ|Instillation in bladder will be done once per week during first six weeks after inclusion, and 3 instillations (one per week) on month three, another three on moth six and last three on month twelve .
45390410|NCT00325143|Biological|DTPa-HBV-IPV/Hib|1 intramuscular injection (3rd study vaccine dose)
45390411|NCT00325143|Biological|DTPa-IPV/Hib vaccine|3 intramuscular injections (1st, 2nd and 4th vaccine dose)
45696479|NCT03511131|Behavioral|Queer Sex Ed|Comprehensive sexual health education program condition (Informational)
45696480|NCT03511131|Behavioral|Keep It Up|Culturally/situation-relevant HIV-prevention experimental condition (Motivational/behavioral)
45696481|NCT03511131|Behavioral|Keep It Up-Control|HIV knowledge control condition, attention-matched to KIU (Informational)
45390412|NCT00319839|Drug|Abraxane|260 mg/m2 IV over 30 minutes every 3 weeks
45390413|NCT00319839|Drug|Cetuximab|Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles
45390414|NCT01062087|Drug|Bupivacaine, Lidocaine|Injection at surgical port site of 0.25% Bupivicaine, 2.5 mg/mL NaCl solution and/or application of Lidocaine HCl jelly 2% aqueous, up to 5 mL
45390415|NCT00319449|Drug|Ezetimibe|10 mg ezetimibe, orally, daily for 6 weeks, added to ongoing treatment with 10 mg atorvastatin
45390416|NCT00319449|Drug|Placebo|10 mg/day matching placebo to ezetimibe, orally, daily for 6 weeks, added to ongoing 10 mg atorvastatin
45696482|NCT03511131|Behavioral|Young Men's Health Project|Motivational enhancement video interviewing condition (Motivational/behavioral)
45696483|NCT03509025|Drug|Jointstem|JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
45696484|NCT03508245|Other|Wearable short wavelength light therapy|Wearable short wavelength (i.e., blue-green) light-emitting glasses worn for two weeks
45696485|NCT04320940|Drug|Phenobarbital Sodium Injection|The initial dose will be administered intravenously over a 30-minute period. The time period between the first and second dose of phenobarbital cannot occur within 30 minutes of the end of the first dose.
45696486|NCT03422523|Drug|Atezolizumab|Intravenous drip
45696487|NCT03422523|Drug|Rituximab|Intravenous drip/or Subcutaneous from cycle 2
45696488|NCT03422523|Drug|Gemcitabine 1000 mg|intravenous drip
45390417|NCT00319449|Drug|Atorvastatin 10 mg|10 mg/day atorvastatin, orally, (ongoing treatment in participants)
45390418|NCT00308997|Device|1-hertz Repetitive Transcranial Magnetic Stimulation|Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
45390419|NCT00308997|Device|Active 1-Hertz Repetitive transcranial magnetic stimulation|Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
45390420|NCT00308685|Drug|Albuterol|Albuterol 90mcg
45390421|NCT00308685|Drug|Placebo|Placebo
45390422|NCT01060839|Behavioral|Single session counseling|For index cases assigned to the counselling arm, a same sex counselor conducted 10-15 minutes individualized sessions. Counselors were specifically trained to deliver partner referral counselling focusing on five issues related to STI prevention and transmission: (1) risk of re-infection if partners are not treated concurrently; (2) risk of developing complications; (3) risk of further spread of infection in the community; (4) the asymptomatic nature of infection; and (5) social obligations and personal coping with an STI.
45390423|NCT01060917|Device|Non-invasive CGMS (continuous glucose monitoring system)|A non-invasive continuous glucose monitoring device measure was applied at the wrist and measure skin glucose as an indirect measure of blood glucose every 10 min.
45502451|NCT01336751|Drug|75% insulin lispro protamine suspension and 25 % insulin lispro injection|suspension for subcutaneous injection
45502452|NCT01336829|Drug|ETR/telaprevir|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
45696489|NCT03422523|Drug|Oxaliplatin 100 MG|intravenous drip
45696490|NCT02406729|Biological|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
45696491|NCT02406729|Other|Placebo|Route:subcutaneous
45696492|NCT03032536|Drug|AL-3778|AL-3778 tablets or capsules
45390424|NCT01060917|Procedure|Hyperglycemic and hypoglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (300 mg/dL) for 1.5 h, and euglycemia (100 mg/dL) for another 1.5 h. A continuous somatostatin infusion was initiated after the 2 h run-in period to suppress endogenous insulin secretion. A glucose solution was infused to increase blood glucose towards the hyperglycemic target level. At the end of the hyperglycemic level the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level. On a second study day a hypoglycemic clamp took place, where blood glucose after the run-in period of 2 h was lowered by means of intravenous insulin administration over a period of appr. 30 min to a hypoglycemic level of 45 mg/dL, where it was kept constant for appr. 30 min, after which blood glucose was raised to euglycemia (100 mg/dL) again by means of an intravenous glucose infusion and was kept there for 1.5 hours. .
45696493|NCT03032536|Drug|Entecavir|Entecavir once daily for 14 days
45390425|NCT01060917|Device|Non-invasive CGMS (GlucoDay)|The minimally-invasive glucose sensor GlucoDay, was used as a control measure
45390426|NCT03981159|Other|Physical training|Physical training for three months, twice per week (60 minutes per session).
45390427|NCT03981237|Device|Laser-activated irrigation with a pulsed Er:YAG laser|The root canals and the pulp chamber are filled with NaOCl 3%. Per canal, the laser tip is placed above the root canal entrance and activated (frequency 20 Hz, pulse energy 20 mJ and pulse length 50 μs) for 30s. TThe canal is then rinsed with NaOCl using a 27G needle, followed by a second application of laser, identical to the first.
45390428|NCT03981237|Device|Ultrasonically activated irrigation|The root canals and the pulp chamber are filled with NaOCl 3%. An Irrisafe file, driven by an ultrasonic unit according to the manufacturers' instructions, is held at 1-3 mm from WL (precurved if canal is curved) and activated for 30 s. The canal is then rinsed with NaOCl using a 27G needle. This cycle is repeated three times (i.e. 3*20s).
45390429|NCT03981237|Procedure|Orthograde root canal treatment|After rubber dam isolation and field disinfection, the pulp chamber is accessed. The root canal(s) is/are located and shaped using manual and mechanical NiTi instruments in combination with NaOCl (3%) irrigant. The canals are dried using paper points and obturated with gutta percha and epoxy resin sealer. The tooth is sealed with a temporary or permanent filling.
45390430|NCT03982251|Procedure|High frequency whole body vibration|1 single session ( 8 minutes) of whole body vibration therapy at 30 Hz
45390431|NCT03982251|Procedure|Low frequency whole body vibration|1 single session ( 12 minutes) of whole body vibration therapy at 20 Hz
45390432|NCT00317109|Biological|Tritanrix™- HepB|One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
45390433|NCT00317109|Biological|Hiberix™|One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
45390434|NCT00317109|Biological|Mencevax™ ACW|One subcutaneous dose during the booster vaccination study in subjects aged 24 to 30 months
45390435|NCT03982329|Device|navigated repetitive transcranial magnetic stimulation|
45390436|NCT03982329|Procedure|physical therapy|
45390437|NCT03981081|Drug|Prednisone|Corticosteroid treatment is taken in the morning in patients with NIV, and through the gastric tube in intubated patients
45390438|NCT03979287|Other|Interferential Current and Therapeutic Exercise Program|"The Interferential Current Program will be based on a bipolar application using the Sonopuls 692 device (Enraf Nonius, Rotterdam, The Netherlands). The current parameters will be: a) 4000Hz carrier frequency; and b) 60 Hz AMF with a modulation frequency of 90 Hz. The intensity of the current will be adapted to the sensitivity of each patient.~The Therapeutic Exercise Program will be applied by a physiotherapist and will consist of:~Ergonomic advices on reducing repetitive movements and/or maintained positions~A protocol of active physiotherapy for neck and shoulder muscles. This protocol will include: active stretching exercises; isometric muscle strengthening exercises; reeducation of the ocular and neck muscles with control retraining exercises"
45390439|NCT03979287|Other|Therapeutic Exercise Program|"The Therapeutic Exercise Program will be applied by a physiotherapist and will consist of:~Ergonomic advices on reducing repetitive movements and/or maintained positions~A protocol of active physiotherapy for neck and shoulder muscles. This protocol will include: active stretching exercises; isometric muscle strengthening exercises; reeducation of the ocular and neck muscles with control retraining exercises"
45696494|NCT03032536|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate once daily for 14 days
45390440|NCT01062243|Behavioral|Brain Injury Education|The Brain Injury Inpatient Guide for Families and Caregivers (BIIG-FACS), developed by J. Niemeier and J. Kreutzer, is a comprehensive intervention to meet the needs of family members and significant others of patients who are undergoing acute brain injury rehabilitation.
45390441|NCT03979209|Drug|Nasal Mometasone Rinse|Nasal irrigation twice a day (BID) of assigned dose.
45390442|NCT00316719|Drug|LAM group|Subjects took one LAM 100mg tablet orally once daily and one ADV placebo tablet orally once daily.
45390443|NCT00316719|Drug|ADV group|Subjects took one ADV 10mg tablet orally once daily and one LAM placebo tablet orally once daily.
45390444|NCT03979053|Device|Multiparametric MRI Scan|Patients attending the clinic will have a MRI scan added to their standard of care.
45696495|NCT03420963|Biological|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given IV
45696496|NCT03420963|Drug|Cyclophosphamide|Given IV
45696497|NCT03420963|Drug|Etoposide|Given IV
45696498|NCT03032770|Device|two-dimensional ultrasound and color Doppler|the eligible participants will be searched for signs suggestive of placenta accreta; low implantation of the gestational sac (<4cm from the external os), presence of placental lakes, Disruption of placental-myometrial interface and trophoblast overlapping a uterine scar by 2 dimensional transvaginal ultrasound and Intraplacental dilated vessels, turbulent blood flows and greatly increased periplacental vascularity by Doppler ultrasound by level II sonographer and co-investigator under his supervision using ultrasound device.
45696499|NCT05489614|Drug|Olpasiran|Participants will receive olpasiran by subcutaneous (SC) injection.
45390445|NCT01065987|Drug|Tizanidine|Tizanidine HCl Tablets 4 mg
45390446|NCT01063959|Procedure|Laparoscopic Sleeve Gastrectomy|Sleeve Gastrectomy was originally reported as the first step in an alternative two-staged procedure for the super obese patient to decrease morbidity, predominantly private pay.
45390447|NCT01063959|Procedure|Laparoscopic Gastric Bypass|Presently, the laparoscopically performed gastric bypass accounts for 80% of obesity surgery in the United States, predominantly covered by insurance.
45390448|NCT03978975|Behavioral|Food intake|"For all those session, subjects will take a standardized breakfast (570kcal) three hours before experimental session.~Control session (CON): subject will stand sited without any activity during 40 min.~Subjects will be submitted to three aquatic cycling exercise session:~session 27°C :aquatic cycling at 27°C without water jet during 40 min~session 27°C+ water jets : aquatic cycling at 27 °C with water jets during 40 min~session 18°C : aquatic cycling at 187°C without water jet during 40 min Every exercise session will be set at 70% of theorical maximal heart rate During each session, oxygen consumption and carbon dioxide production will be analysed with gas analysis system. Appetite and hunger sensation will be measured with a specific scale at different time point of each day of experimental session. Thirty minutes after the end of each experimental session subjects will have a buffet meal for lunch time."
45390449|NCT01064115|Drug|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
45390450|NCT00422058|Drug|liraglutide|Injected s.c. (under the skin) once daily
45390451|NCT00422058|Drug|orlistat|120 mg capsule. Administered thrice daily
45390452|NCT00422058|Drug|placebo|Injected s.c. (under the skin) once daily
45390453|NCT01032798|Drug|mepivacaine|One intra-oral injection at four different sessions, of the following formulations: 2% mepivacaine with 1:100,000 epinephrine, 3% mepivacaine, 2% and 3% liposome-encapsulated mepivacaine.
45390454|NCT02724540|Device|Bland Embolization|Lobar or segmental bland embolization with microspheres (50-500 microns) to 2-5 heartbeat stasis
45390455|NCT02724540|Combination Product|Transarterial chemoembolization|Lobar or segmental lipiodol transarterial chemoembolization. Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.
45390456|NCT02724540|Combination Product|Drug Eluting Beads Embolization|CLOSED - Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU.
45502453|NCT01336829|Drug|TMC278/telaprevir|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
45848743|NCT01800162|Drug|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
45390457|NCT02720952|Drug|Infacort®|dry granule formulation of hydrocortisone
45390458|NCT00413244|Drug|AndroGel 5 Grams|"Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
45390459|NCT00413244|Drug|Placebo|"Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
45390460|NCT01033032|Drug|Amrubicin|"Phase I: dose-escalating portion with the starting dose of amrubicin at 90mg/m^2 IV q21 days. Dose escalations are as follows:~DL2 - 100mg/m^2; DL3 - 110mg/m^2; and DL4 - 120mg/m^2. All cycles are q21 days~Phase II: Amrubicin will be administered at the maximum tolerated dose established in Phase I by IV every 21 days"
45848744|NCT01800162|Procedure|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
45848745|NCT01800162|Other|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring.
45848746|NCT01794936|Device|VTI Probe|The VTI 20 MHz microvascular Laparoscopic Doppler System is a blood flow detector that compensates for the loss of tactile sensation during laparoscopic procedures by eliminating misunderstandings related to surrounding vascular anatomy. The system's sterile doppler probes fit through standard 5mm ports, making it easy to use with no special training required.
45848747|NCT01756560|Drug|dexamethsone|
45848748|NCT01756560|Drug|Bupivacaine|
45848749|NCT01738698|Drug|SPD489 40mg|Oral administration of 40 mg once-daily for up to 12 weeks
45848750|NCT01738698|Drug|SPD489 100mg|Oral administration of 100 mg once-daily for up to 12 weeks
45848751|NCT01738698|Drug|SPD489 160mg|Oral administration of 160 mg once-daily for up to 12 weeks
45390461|NCT01032876|Procedure|Deep Hypothermic Circulatory Arrest|DHCA will be employed for a maximum of 60 minutes. If more time (>60 min) is needed for the arch reconstruction the surgeon will proceed with ACP, which will be continued for the rest of the operation (= DHCA+ACP).
45390462|NCT01032876|Procedure|Antegrade Cerebral Perfusion|One cannula will be advanced into the brachiocephalic/ innominate artery via the usual arterial cannulation site in the aorta ascendens. A flow of 20-25% of the maximum CPB-flow will be used, which corresponds to a flow rate of 40-50 ml/ kg/ min.
45390463|NCT01038492|Behavioral|p16 Methylation and Lung Cancer Education|"patients shown a presentation on p16 methylation and the development of lung cancer, asked to complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic details~patients given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing~a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits~patients are called again at three months and asked about any changes in their attitudes or smoking habits."
45390464|NCT00420420|Drug|MK0249|MK0249 two (2) 2.5 mg capsules quaque die (qd) for 28 day treatment period.
45390465|NCT00420420|Drug|Comparator: Placebo (unspecified)|MK0249 two (2) 2.5 mg Pbo capsules qd for a 28 day treatment period
45390466|NCT01038570|Drug|Syntocinon®/- Spray|3 sprays corresponding to 24 IU in each nostril
45390467|NCT01038570|Drug|Physiological serum (Sodium chloride)|Sodium chloride 0.9 % (0.3 ml) in each nostril
45390468|NCT00420342|Drug|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 A -Active study medication encapsulated tablet
45848752|NCT01738698|Drug|Placebo|Oral administration once-daily for 12 weeks
45390469|NCT00420342|Drug|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 B - Active study medication encapsulated tablet
45390470|NCT00420342|Drug|SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)|Active control encapsulated tablet
45390471|NCT00432744|Drug|CoenzymeQ10|CoenzymeQ10 will be given in 10 mg/kg daily up to 400 mg. Then a draw of CoQ10 troughs every three months will be performed.
45390472|NCT00432744|Drug|Placebo|Placebo will be given in 10 mg/kg daily up to 400 mg. Then a draw of placebo troughs every three months will be performed. This treatment group will be treated as the active group.
45390473|NCT01038648|Drug|Sitagliptin|100mg/day
45390474|NCT01038648|Other|life style modification at base line|Advice on physical activity, diet and drug adherence.
45390475|NCT00432666|Drug|IncobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection"
45390476|NCT00432666|Drug|Placebo|Placebo
45848753|NCT01717482|Drug|Metformin|
45848754|NCT01717482|Other|Placebo Comparator|Standard of Care Observation
45848755|NCT01702896|Drug|Interleukin-2|Interleukin-2
45848756|NCT01682928|Drug|IV/Oral Hydration and Bedrest|"Maternal BP (sitting)~Pulse Pressure~Pulse~Urine Specific Gravity BID~Fetal Heart Rate~Maternal Body Weight US Procedures~AC/EFW~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~1 Liter Water PO over 2 hours~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation~Strict I/O's~Vital signs"
45390477|NCT00451958|Drug|Degarelix 80 mg / Degarelix 80 mg|
45390478|NCT00451958|Drug|Degarelix 160 mg / Degarelix 160 mg|
45390479|NCT00451958|Drug|Leuprolide 7.5 mg / Degarelix 80 mg|
45390480|NCT00451958|Drug|Leuprolide 7.5 mg / Degarelix 160 mg|
45390481|NCT03775694|Device|dMRI Scan|Data will be collected from cases where dMRI scans were obtained as part of the subject's previous treatment.
46056841|NCT02608294|Device|Kinesio Taping Sham|The sham group received the tape applied without tension. The patient was positioned supine; the ankle was placed in a neutral position (90 degrees); and measured between Point A and Point B with a tape measure placed on the skin was performed. Once registered this measure in centimeters the evaluator cut the KT with the same measure, but without the presence of paper attached to it to ensure that there was no tension, because the KT needs a minimum voltage to be applied on paper. After measured and cut the KT, it was applied to the patient in the supine position with the ankle positioned at 90 degrees with no traction.
45390482|NCT01023152|Procedure|Automated cuff-inflator|RIPC protocol consisted of three 10-min cycles of lower limb ischemia at an inflation pressure of 250 mmHg induced by an automated cuff-inflator placed on the upper leg with an intervening 10 min of reperfusion during which the cuff was deflated.
45390483|NCT01025882|Drug|gemcitabine hydrochloride|Given IV
45390484|NCT01025882|Radiation|stereotactic body radiation therapy|Given as a single fraction
45390485|NCT01025960|Procedure|Standard Inspection Colonoscopy|The large bowel will be inspected for polyps during the withdrawal of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
45390486|NCT01025960|Procedure|Dual Inspection Colonoscopy|The large bowel will be inspected for polyps during the insertion of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
45390487|NCT01026116|Drug|Epirubicin|75 mg/m2 every-3-week for four cycles
45390488|NCT01026116|Drug|Cyclophosphamide|600 mg/m2 every-3-week for four cycles
45848757|NCT01682928|Other|Hydrotherapy|"Maternal BP (sitting)~Pulse Pressure~Pulse~Urine Specific Gravity BID~Fetal Heart Rate~Maternal Body Weight US Procedures~AC/EFW~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~o 1 hour +/- 30 minutes after submersion therapy~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~o 1 hour +/- 30 minutes after submersion therapy~AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~1 Liter Water PO over 2 hours~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation~Strict I/O's~Vital signs~HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy"
45390489|NCT01026116|Drug|Paclitaxel|175 mg/m2 every-3-week for four cycles followed by weekly paclitaxel (80 mg/m2) for 12 weeks
45390490|NCT00432276|Drug|Alogliptin|Alogliptin tablets.
45390491|NCT00432276|Drug|Pioglitazone|Pioglitazone tablets.
45502454|NCT01336829|Drug|telaprevir/ETR|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
45502455|NCT01336829|Drug|telaprevir/TMC278|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
45390492|NCT00432276|Drug|Metformin|Metformin HCl tablets (immediate-release, commercially available formulation) ≥1500 mg or maximum tolerated dose.
45390493|NCT00432276|Drug|Placebo|Matching placebo tablets.
45390494|NCT01022216|Device|Procellera™ Wound Dressing with V.A.C.® Therapy|Dressing indicated for partial and full-thickness wounds. Weekly dressing changes, more frequently if needed. Used as a primary contact layer in conjunction with NPWT.
45390495|NCT01022216|Device|V.A.C.® Therapy|Vacuum Assisted Closure device that uses controlled negative pressure, with dressing changes 1x/week.
45390496|NCT01022294|Drug|Nitrousoxide-oxygen and atmospheric air|Nitrousoxide-oxygen and atmospheric air
45502456|NCT01340183|Drug|AZD5099|IV Dose
45502457|NCT01340183|Drug|Placebo|IV Dose
45390497|NCT01022294|Drug|Atmospheric air; nitrousoxide-oxygen|Atmospheric air; nitrousoxide-oxygen
45390498|NCT01027442|Device|Mucosa-supported single-type guides|Compute generated Mucosa-supported single-type guides
45390499|NCT01027442|Device|Bone-supported guides|Computer generated, Multiple type Bone-supported guides
45390500|NCT01027442|Device|Dental Implants|Dental implants placed via conventional free-hand method
45390501|NCT01027520|Other|application of coban dressing|application of a intraoperative coban dressing with reapplications following dressing removal.
45390502|NCT01023230|Drug|DV-601|Six injections of DV-601 administered over a period of 12 weeks.
45390503|NCT01023230|Drug|Entecavir|Daily dosing starting approximately 4 weeks prior to first dose of DV-601 for one year total duration.
45390504|NCT03993990|Behavioral|individual empowerment-based intervention|Participants will receive an empowerment-based intervention individually, based on five steps (i. e. problem identification, meaning and perception clarification, intervention planning, intervention delivery, and evaluation). After the principal investigator delivers a pre-discharge assessment (i. e. the self-care behavior and self-efficacy of diabetes and diabetic foot ulcer, risk factors of foot ulcer, family support, and threat belief of participant), the plan of behavioral modification will be determined by the principal investigator and participants. The subsequent follow-up and intensifying interventions will be delivered at the following time points: three days after discharge, every weeks for one month, every two weeks for subsequent two months, and then every three months for three times.
45390505|NCT01027676|Drug|Study treatment|Gefitinib 250mg/QD plus vorinostat D1~7 & D15-21 / QD q 4weeks
45390506|NCT01027832|Drug|Piperacillin/Tazobactam for 7 days|Piperacillin/Tazobactam for 7 days
45390507|NCT00413010|Drug|pregabalin|pregabalin 150-600 mg/day flexibly dosed for the first 6 weeks and fixed dosed for the last 2 weeks of total 8 weeks of double blind study period, + concurrent GAD treatment from the open-label study period
45390508|NCT00413010|Drug|placebo|placebo + concurrent GAD treatment from the open-label study period
45390509|NCT00459290|Drug|mifepristone|
45390510|NCT00443534|Drug|SU011248|Administered orally in doses ranging from 25 to 50 mg once daily; dosing schedule and dosage depends on the patients dosing from the prior protocol
45502458|NCT02960490|Drug|E6011|subcutaneous administration
45502459|NCT02960490|Drug|Placebo|subcutaneous administration
45502460|NCT02804750|Drug|CORT125134|
45502461|NCT05184491|Drug|Naïve patients - ACO therapy|Naïve patients will receive classic triple therapy (amoxicillin, clarithromycin and lansoprazole) for 14 days
45502462|NCT05184491|Drug|Naïve patients - LNDL therapy|Naïve patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
45502463|NCT05184491|Drug|Naïve patients - MNDL therapy|Naïve patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
45502464|NCT05184491|Drug|Treatment-experienced patients- LNDL therapy|Experienced patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
45502465|NCT05184491|Drug|Treatment-experienced patients- MNDL therapy|Experienced patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
45390511|NCT00419952|Drug|Budesonide/formoterol (SYMBICORT) pMDI|Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
45390512|NCT00419952|Drug|Budesonide HFA pMDI|Budesonide HFA pMDI 160 ug x 2 actuations BID
45390513|NCT00443456|Drug|Amlodipine|Two tablets of amlodipine 5 mg, Oral administration, Once daily for 44 weeks
45390514|NCT00419562|Drug|Oral Insulin|7.5 mg oral insulin or placebo given before breakfast on a daily basis.
45390515|NCT00419562|Drug|Placebo|Placebo capsule designed to match active drug
45390516|NCT03557294|Drug|1.0mg Varenicline b.i.d.|Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
45390517|NCT03557294|Drug|0.5mg Varenicline b.i.d.|Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
45390518|NCT03557294|Drug|0.0mg placebo Varenicline b.i.d.|Product that looks like active varenicline, but contains no active ingredient
45390519|NCT03550040|Procedure|Radical prostatectomy|Surgical removal of the prostate
45390520|NCT01026350|Dietary Supplement|colostrum enriched with anti flu antibodies|each volunteer will receive six 1.2 g oral tablets (equivalent to 600 mg of bovine colostrum powder each) once a day for two weeks.
45390521|NCT01026428|Drug|Safinamide + Levodopa|Treatment A: 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
45390522|NCT01026428|Other|Placebo + Levodopa|Treatment B: Placebo matching 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
45390523|NCT00432042|Biological|ProQuad®|Participants received a 0.5 mL subcutaneous injection of ProQuad® containing the following live attenuated virus strains: measles virus Enders' Edmonston strain (≥3.00 log10 50% cell culture infectious dose [CCID]50), mumps virus Jeryl Lynn™ (Level B) strain (≥4.30 log10 CCID50), rubella virus Wistar RA 27/3 strain (≥3.00 log10 CCID50), and varicella virus Oka/Merck strain (≥3.99 log10 plaque-forming units [PFU]).
45390524|NCT00432042|Biological|Infanrix® hexa|Participants received a 0.5 mL intramuscular injection of Infanrix® hexa containing the following: diphtheria toxoid (≥30 IU), tetanus toxoid (≥40 IU), 3-component acellular pertussis (pertussis taxoid, filamentous haemagglutinin, and pertactin) (25 ug), Hepatitis B surface antigen recombinant (S protein) (10 ug), inactivated poliovirus types 1-3 (type 1: 40 D-antigen units; type 2: 8 D-antigen units; type 3: 32 D-antigen units), and Haemophilus influenzae type B (Hib) polysaccharide conjugate to tetanus toxoid (20-40 ug).
45390525|NCT00308139|Drug|exenatide, long acting release|
45390526|NCT00308139|Drug|exenatide|
45390527|NCT00459134|Dietary Supplement|ArginMax|Given orally
45390528|NCT00459134|Dietary Supplement|Placebo|Given orally
45390529|NCT00459056|Drug|Carvedilol CR + Lisinopril|Participants were given Carvedilol CR + Lisinopril for three months. Oral medication. Carvedilol CR and Lisinopril combination therapy was initiated at 20 mg and 10 mg, respectively. Patients returned one week later and doses of carvedilol CR and lisinopril were increased to 40 mg and 20 mg, respectively, depending on blood pressure.
45502466|NCT01340339|Device|Phototherapy|Fluorescent reverse phototherapy (7 white lights 5cm below the base of acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
45502467|NCT01340339|Device|Phototherapy|super LED reverse phototherapy (17 bulbs arranged in 42 x 31 cm in blue base acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
45502468|NCT05184179|Drug|Olmesartan Medoxomil|Olmesartan Medoxomil, Amoldipine Besylate, Rosuvastatin Ca
45502469|NCT02051270|Other|Descriptive study|More than 65 years old elders
45848758|NCT01683864|Drug|positive cytology with HIPEC|HIPEC with mytomycin and cisplatin
45390530|NCT00459056|Drug|Lisinopril + HCTZ|Participants were given Lisinopril + HCTZ for three months. Oral medication. Lisinopril + HCTZ combination therapy was initiated at 12.5 mg and 10 mg, respectively. Patients returned 1 week later and doses of hydrochlorothiazide and lisinopril were increased to 25 mg and 20 mg, respectively, depending on blood pressure levels.
45390531|NCT01062477|Biological|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
45390532|NCT01062477|Biological|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
45390533|NCT01062477|Biological|DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine|0.5 mL, Intramuscular (each vaccine)
45390534|NCT01026506|Dietary Supplement|conjugated linoleic acid|3 g/d of an esterified CLA preparation free of t10,c12-CLA (75% c9,t11-CLA, 87% purity) or placebo oil mixed in yoghurt for 12 weeks
45390535|NCT01323374|Drug|Droxidopa|Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
45390536|NCT01323374|Drug|Carbidopa|Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
45390537|NCT01323374|Drug|Droxidopa/carbidopa|Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
45390538|NCT01323374|Drug|Placebo|Oral, placebo TID
45848759|NCT01648296|Drug|[18F]FluorbetaOx|Fluorine 18-labeled FluorbetaOx
45390539|NCT00431964|Drug|azithromycin 250 mg tablets|"One (1) tablet three times weekly for patients who weigh 40-79 lbs~Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs"
45502470|NCT05187299|Other|observer tool|The observer tool is paper-based and is divided in columns (each column filled out for a dyad observed) with lines representing the above-described steps of learning and presented with visual incremental actions to be performed. The observer tool will only be used to reinforce learning and will not be used for summative evaluation. Instructors have already been involved in previous simulation studies performed in our center, and especially those in which an observer tool has been assessed (one study published, two manuscripts in preparation).
45502471|NCT02054312|Behavioral|Family Based Interpersonal Psychotherapy (FB-IPT)|
45696500|NCT03503799|Other|Observation|"Visit 1 Informed consent Medical history Demographics Result of EndoPredict® Test Status of menopause Disease status Tumor board decision Planned anti-tumor-therapy~Visit 2, 1 year after inclusion This visit will be documented at the study site Status of menopause Disease status Anti-tumor therapy Survival~Following visits For these visits, patients will be asked directly through the Center for Clinical Trials of the Philipps-University Marburg (KKS Marburg) via phone.~Status of Menopause Disease status Anti-tumor therapy Survival~Treatment after end of the study The patient will be treated during and after end of study by physician's choice."
45390540|NCT00431964|Drug|placebo tablets|"One (1) tablet three times weekly for patients who weigh 40-79 lbs~Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs"
45390541|NCT03531476|Behavioral|Online Chronic Pain Management Program|With the support of a study therapist, the participant will be enrolled in a 5 week self-directed pain management program. The study therapist is a registered health professional. The program will consist of 5 weeks of mindfulness training. The mindfulness training focuses on the basics of mindfulness-based interventions including body, emotions, sensations, thoughts, compassion, pain and stress management.
45390542|NCT01322906|Other|Group 1|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(2×105/Kg, once a week, 4 times).
45390543|NCT01322906|Other|Group 2|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(1×106/Kg, once a week, 4 times).
45390544|NCT01322906|Other|Group 3|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(5×106/Kg, once a week, 4 times).
45390545|NCT01028066|Other|Traditional|The control group will have access to the nutritionist to clear any doubts about the diet prescribed when went out the hospital and will be invited to attend a meeting nutrition in dialogic character at the end of 1 year to ensure fairness in action.
45390546|NCT01028066|Behavioral|Behavioral|The intervention group will go through 4 meetings of food education, to be held within the institution, with approximately 1 hour long, composed of 3 to 8 patients, who may or may not be accompanied by a relative. The first three meetings will be monthly and the fourth will be 6 months after the last one. Each meeting will be developed within the context of dialogic and participatory education, directed to the adoption of a healthy diet and prevention and control of cardiovascular risk factors. The meetings will follow the order: Investigation, Contextualization, Awareness and Strengthening the nutritional concepts, according to the didactics of educator Paulo Freire.
45390547|NCT00412854|Biological|Infanrix™/Hib|
45390548|NCT00412854|Biological|Infanrix|
45390549|NCT00412854|Biological|Hiberix|
45502472|NCT02054312|Behavioral|Client Centered Therapy (CCT)|
45502473|NCT01341509|Procedure|Flexor Hallucis Longus Tendon transfer|The flexor hallucis longus tendon was transferred during surgery for insertional achilles tendinopathy
45502474|NCT01341509|Procedure|Transfer of the Flexor Hallucis Longus Tendon|The Flexor Hallucis Longus Tendon was transferred during surgery for insertional achilles tendinopathy
45696501|NCT03032614|Drug|Carboplatin|Carboplatin is a second generation tetravalent organic platinum compound. Similar to cisplatin, carboplatin produces predominantly interstrand DNA crosslinks as opposed to DNA-protein crosslinks. Carboplatin is cell-cycle non-specific.
45696502|NCT03032614|Drug|Eribulin|Eribulin Mesylate is a synthetic halichondrin analog.
46056842|NCT04189185|Procedure|Suture fixation|The fracture is reduced. A 2.5 mm hole is drilled in the dorsal olecranon 15mm from the fracture. A suture is passed through the hole and is fixed to the triceps muscle. A second suture is fixed to the triceps muscle in a figure 8 configuration.
45390550|NCT00431496|Drug|Cinacalcet|Cinacalcet tablets
45390551|NCT00316173|Drug|topotecan|HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
45390552|NCT00316173|Drug|CARBOPLATIN|HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
45390553|NCT00412542|Drug|Thalidomide|100 mg PO (by mouth) daily for 8 weeks
45390554|NCT00412542|Drug|CPT-11|125 mg/m^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest
45390555|NCT00412542|Procedure|MRI Scan|Dynamic MRI scan with dye injection through vein, every 6 weeks
45502475|NCT01341509|Procedure|No transfer of Flexor Hallucis Longus tendon|There was no transfer of the Flexor Hallucis Longus tendon in surgery for insertional achilles tendinopathy
45502476|NCT02051348|Biological|Pylopass|Pylopass
45502477|NCT02051348|Biological|Placebo|Placebo
45390556|NCT00412542|Procedure|Quantitative Sensory Tests (QST)|QST, every 12 weeks, to check for any nerve problems that may be present before starting treatment; by touching a small machine tests are done on feeling of touch, vibration, and temperature.
45390557|NCT00316017|Drug|7.5% hypertonic saline/6% Dextran-70 (HSD)|250 cc dose given as a one-time intravenous (IV) bolus in the pre-hospital setting.
45390558|NCT00316017|Drug|7.5% hypertonic saline (HS)|250 cc dose given as a one-time IV bolus in the pre-hospital setting.
45502478|NCT02052518|Behavioral|Experimental|These participants will receive the enhanced intervention including decision support and problem solving skills in addition to the standard of care for the individuals in the Nuturing Family Network Home Visition Program
45390559|NCT00316017|Drug|0.9% normal saline|250 cc dose given as a one-time IV bolus in the pre-hospital setting.
45390560|NCT00451178|Drug|enzastaurin|1125 milligrams (mg) then 500 mg, oral, daily, six 21-day cycles or up to 3 years
45848760|NCT01608906|Drug|low dose intravenous heparin (LDIVH)|The LDIVH (experimental) group will receive a continuous heparin drip titrated to a prothrombin time (PTT) of 40-45. LDIVH subjects will have PTT tested within 24 hours prior to initiation of LDIVH. In addition, these subjects would continue to have a PTT tested every 6 hours until the PTT value falls between 40-45. All LDIVH subjects will have PTT values measured at least daily. This will continue until ICU discharge or a maximum of 28 days.
45390561|NCT00451178|Drug|rituximab|375 milligrams per square meter (mg/m^2), intravenous (IV), Day 1 every 21 days, six 21-day cycles
45390562|NCT00451178|Drug|cyclophosphamide|750 mg/m^2, IV, Day 1 every 21 days, six 21-day cycles
45390563|NCT00451178|Drug|doxorubicin|50 mg/m^2, IV, Day 1 every 21 days, six 21-day cycles
45390564|NCT00451178|Drug|vincristine|1.4 mg/m^2, IV, Day 1 every 21 days, six 21-day cycles
45502479|NCT03640962|Other|Evaluation|This cross-sectional study was conducted in 368 postmenopausal women aged between 40 and 65 years. This study was carried out in family health centers in Istanbul. Data were collected via face-to-face interviews by the researchers.
45502480|NCT02052674|Device|Vented urinary drainage system|This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
45502481|NCT02052674|Device|Non-vented urinary drainage system|This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
45502482|NCT05163834|Biological|Efgartigimod|intravenous infusion of efgartigimod
45390565|NCT00451178|Drug|prednisone|100 mg, oral, Days 1-5, six 21-day cycles
45502483|NCT05163834|Other|Placebo|intravenous infusion of placebo
45502484|NCT05163834|Biological|PNEUMOVAX 23|PNEUMOVAX 23 vaccine
45502485|NCT05182619|Procedure|ultrasound-guided stellate ganglion block|under aseptic conditions, using the ultrasound guidance, bilateral stellate ganglion block will be done using bupivacaine and betamethasone mixture, 8 ml volume will be given for each side
45848761|NCT01608906|Drug|Heparin|5000 units given subcutaneously three times a day until ICU discharge or a maximum of 28 days
45390566|NCT00450866|Biological|epothilone B|Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.
45390567|NCT01322984|Behavioral|Pictures|The participants will be exposed to pictures of faces and non-facial stimuli presented on a PC screen.
45390568|NCT01322984|Behavioral|Startle eliciting noise|Startle will be elicited by 95 dB noise, presented at different times after picture onset.
45390569|NCT01026584|Drug|Aripiprazole|6 week prospective study
45390570|NCT01023386|Drug|YM155|I.V.
45390571|NCT01026662|Procedure|Ablation and skin resurfacing|Subjects will receive treatment on the abdomen at different timepoints prior to a scheduled abdominoplasty. Following tissues excision samples of the treated tissue will be taken for analysis.
45390572|NCT01026662|Device|eMatrixCO2|
45390573|NCT01028456|Other|Light Therapy|10,000 lux / 30 minutes a day
45390574|NCT01028456|Other|100 lux|Placebo light
45390575|NCT01023464|Other|FID114657|artificial tears
45390576|NCT01023464|Other|SootheXP Emollient (Lubricant) Eye Drops|artificial tears
45390577|NCT01023542|Drug|delayed, low-dose CNI|immunosuppression
45390578|NCT01023542|Drug|BU-CNI|Immunosuppression
45390579|NCT01023542|Drug|BU-Everolimus|Immunosuppression
45390580|NCT01026740|Drug|Ceftobiprole|single intravenous (i.v.) infusion, 500 mg ceftobiprole administered over 2 hours.
45390581|NCT03848312|Behavioral|Cognitive Training|Participants will be completing a total of 45 computerized sessions.
45390582|NCT03848312|Behavioral|Computerized Cognitive Stimulation|Participants will be completing a total of 45 computerized cognitive stimulation sessions.
45502486|NCT01065012|Drug|Udenafil 50 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
45696503|NCT03032614|Drug|Veliparib|Veliparib is a potent PARP inhibitor that delays the repair of DNA damage induced by chemotherapeutics.
45848762|NCT01602198|Drug|Exelon [rivastigmine] transdermal patch|Exelon patch 1/day for six months
45390583|NCT01028534|Drug|Olmesartan and Azelnidipine|"Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, increase Olmesartan to 40mg per day for the next 3 months~Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, add Azelnidipine 16mg per day for the next 3 months~Azelnidipine 16mg per day for 3 months, and, if hypertension is not controlled, add Olmesartan 20mg per day for the next 3 months"
45390584|NCT03995342|Dietary Supplement|Inulin|Inulin 15 grams after dissolution by mouth， every morning for three months.
45390585|NCT03995342|Dietary Supplement|Maltodextrin|Placebo (maltodextrin) 15g/d，Oral administration after dissolution15g/d，Oral administration after dissolution
45502487|NCT01065012|Drug|Udenafil 100 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
45502488|NCT01065012|Drug|Udenafil 150 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
45848763|NCT01602198|Drug|Placebo transdermal patch|Placebo transdermal patch 1/day for 6 months
45390586|NCT01023698|Procedure|laser photocoagulation|Laser photocoagulation
45390587|NCT00442598|Drug|Glufosfamide|
45390588|NCT01028612|Radiation|thermal ablation with external beam radiation|thermal ablation with external beam radiation
45502489|NCT01065012|Drug|Placebo Matching 50 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
45502490|NCT01065012|Drug|Placebo Matching 100 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
45502491|NCT01065012|Drug|Placebo Matching 150 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
45502492|NCT01315691|Drug|Liposomal amikacin for inhalation|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~Administration time is approximately 13 minutes.~Liposomal amikacin for inhalation will be administered for 28 days followed by 56 days off treatment."
45502493|NCT01315691|Drug|Placebo for liposomal amikacin for inhalation|"Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~Administration procedures, volume and administration time are the same as for Arikace™.~Placebo will be administered for 28 days."
46056843|NCT05754970|Procedure|laser treated|"The second surgical stage was done after a healing period 12 ± 4 weeks (T1) where all the healing abutments were placed. Each healing abutment had repeated the two surfaces as twice follows: laser-treated/machined/ laser-treated/machined. Experimental healing abutment was removed after 30 ± 7 days, the same time as the soft tissue biopsy.~After the healing period (30 ± 7 days), before starting with the prosthetic restoration of the fixtures, an impression was taken of the small-diameter Has, and circular sections (diameter 5 mm) soft tissues around them were retrieved for analysis."
45390589|NCT00442286|Device|Rheos® Baroreflex Hypertension System|Electrical activation of the Carotid Baroreflex
45390590|NCT00441974|Drug|adefovir dipivoxil|adefovir dipivoxil once daily one tablet 10mg orally
45390591|NCT01023854|Procedure|Continuous Paravertebral block|"The paravertébral block is a peripheral block which gets an one-sided continuous analgesia by infiltration of the spinal nerves which appear from the intervertebral foramen.~Its realization consists of a draining in 2-3 cm of the thorny apophyses ( T6-T8). During the perception of the osseous contact (cross-functional process of the vertebra), the needle is redirected in cephalic direction until a loss of resistance corresponding to the passage of the upper costo-cross-functional ligament that is in the entrance to the paravertébral space. A catheter is then inserted into the paravertébral space."
45390592|NCT00441584|Biological|PegIntron (peginterferon alfa-2b)|Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
45390593|NCT00441584|Drug|Rebetol (ribavirin)|200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 48 weeks
45390594|NCT03368534|Device|Autologous Regenerative Technology (ART)|ART device with single-needle, fluid-assisted skin tissue harvesting technology.
45502494|NCT02038244|Other|Multimodal integrative medicine inpatient treatment program|
45502495|NCT05654090|Drug|cefoperazone sodium and sulbactam sodium|Pharmacokinetic study under fasting conditions
45848764|NCT01577628|Drug|Lipikar Balm AP|Daily application of Lipikar Balm AP starting at birth
45848765|NCT01550562|Device|Boston Scientific Precision Plus spinal cord stimulation therapy|Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system
45390595|NCT01028690|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475; will be delivered at a dose of 1x108 CFU of each strain. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. Will be taken daily throughout the entire study, from the day of inclusion to the final analysis at the end of follow-up after eradication therapy. Will be delivered either in a chewable tablet form
45390596|NCT01028690|Dietary Supplement|Placebo|placebo
45390597|NCT00430716|Drug|Sildenafil citrate|oral, 20 mg, tid
45390598|NCT00430716|Drug|Sildenafil citrate|oral 1 mg, tid
45390599|NCT00430716|Drug|Sildenafil citrate|oral 5 mg, tid
45390600|NCT00430716|Drug|Sildenafil citrate|oral 20 mg, tid
45390601|NCT01023932|Device|Cochlear Implants|
45390602|NCT01028768|Drug|Teduglutide|10 mg, one-time subcutaneous
45390603|NCT02648256|Other|Polymerase Chain Reaction on Oropharyngeal rinse|
45390604|NCT00441272|Drug|Pioglitazone|
45390605|NCT01038726|Other|Exercise Training|Aerobic exercise training program designed by the Cardiac Rehabilitation department
45390606|NCT01038726|Other|Cognitive Training|Based on cognitive training program Brain Fitness®
45390607|NCT01038726|Other|Flexibility Training|Non-aerobic flexibility training program designed by the Cardiac Rehabilitation department
45502496|NCT01340729|Drug|TPI 287|Starting dose of 125 mg/m2 IV via a central venous catheter (CVC) or a peripherally inserted central catheter (PICC) line over 60 minutes (+/- 10 minutes) on Days 1, 8, and 15 (+/- 2 days) of each 28 day (+/- 3 days) study cycle. The 4-week schedule composes one cycle.
45502497|NCT02052830|Behavioral|Wise Guys|Multi-session curriculum delivered in different formats that range in length from 5 to 12 weeks and topics covered include communication and masculinity, dating violence, abstinence and contraception, and sexually transmitted infections.
45502498|NCT02959866|Other|online income tool|An online tool that uses information about the patient to develop a tailored list of financial benefits that they are eligible to apply for.
45502499|NCT05183711|Behavioral|Questionnaires|The Numerical Rating Scale (range from 1-10, 1= least competency, 10 =highest competency) will be used for any anesthesia skills evaluation. (download the self-evaluating form via QR code)
45502500|NCT02054468|Drug|Single-Shot Propofol|Single-shot propofol induction dose (1.5-2.5mg/kg body mass)
45390608|NCT01038726|Other|Educational Sessions|DVD-based educational programs on history, art, and literature
45390609|NCT01566552|Drug|AMBISOME|SINGLE DOSE AMBISOME FOR TREATMENT OF VISCERAL LEISHMANIASIS
45502501|NCT02054468|Drug|30min infusion Propofol|30min of propofol infusion (4-6mg/kg/h)
45502502|NCT02054468|Drug|Remifentanil infusion|Remifentanil infusion (0.1-0.2µg/kg/min)
45390610|NCT01028924|Drug|Teduglutide|subcutaneous (SC), single dose
45390611|NCT01029002|Drug|Vitamin D|Vitamin D, ergocalciferol, 50000 IU, weekly for 12 weeks, with open label extension for another 3 months
45390612|NCT01029002|Other|Placebo|Patients randomized to this arm will receive one placebo pill once weekly.
45502503|NCT02054468|Drug|Rocuronium (0.07mg/kg/body mass)|Rocuronium (0.07mg/kg/body mass)
45502504|NCT02054468|Drug|Rocuronium (0.1mg/kg/body mass)|Rocuronium (0.1mg/kg/body mass)
45502505|NCT02054468|Drug|Rocuronium (0.15mg/kg/body mass)|Rocuronium (0.15mg/kg/body mass)
45502506|NCT02054468|Drug|Rocuronium (0.2mg/kg/body mass)|Rocuronium (0.2mg/kg/body mass)
45390613|NCT00430638|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary|olmesartan medoxomil + hydrochlorothiazide, if necessary. Oral tablets administered for once daily for 12 weeks
45390614|NCT00430638|Drug|Placebo|Oral tablets administered for once daily for 12 weeks
45390615|NCT01029080|Other|no interventions|No interventions
45390616|NCT01566110|Dietary Supplement|Gluten Free Diet|Subjects assigned to the intervention group will receive a standardized dietary education intervention that will inform subjects and family members of the effects of gluten on the gastrointestinal tract and emphasize the need to adhere to a diet that is gluten-free. This intervention will be delivered by a dietician who is trained in celiac disease and gluten free diet.
45390617|NCT03671330|Drug|Ribociclib Placebo|Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
45390618|NCT03671330|Drug|Ribociclib|Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
45502507|NCT02054468|Drug|Rocuronium (0.3mg/kg/body mass)|Rocuronium (0.3mg/kg/body mass)
45502508|NCT02054468|Drug|Rocuronium (0.45mg/kg/body mass)|Rocuronium (0.45mg/kg/body mass)
45502509|NCT01340807|Other|Specialized Functional Prosthetic Training|Each subject receives specialized functional prosthetic training
45502510|NCT03640650|Combination Product|Dropless Therapy|The Dropless will be injected, as a single administration, into the vitreous cavity during the cataract surgery.
45502511|NCT03640650|Drug|Usual Care|In order to reflect real-world clinical practice, the choice of topical ophthalmic medications as well as dosage, posology, and duration of treatment will be left to the discretion of the treating ophthalmologist.
45502512|NCT05183555|Drug|68Ga-DOTATOC PET/CT|68Ga-DOTATOC PET/CT will be recorded the following day of 18F-FDG PET/CT if patient signed the consent
45696504|NCT04182490|Biological|LMN-101|VHH-derived binding protein designed to bind and inhibit FlaA, flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, spirulina biomass
45696505|NCT04182490|Drug|Placebo|Identical appearing placebo
45390619|NCT03671330|Drug|NSAI: Letrozole or Anastrazole|"Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).~Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients past history.~For postmenopausal and PK cohorts, all patients will be on Letrozole."
45390620|NCT03671330|Drug|Letrozole|Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).
45390621|NCT03671330|Drug|Goserelin|Subcutaneous implant, 3.6mg on Day 1 of each 28 day cycle
45390622|NCT01038882|Drug|Midazolam|Sedation started by injecting a 4 ml drug bolus with midazolam (0.07-0.1 mg/kg dose). Supplemental doses of midazolam (2 mg) were administrated at an interval of >2 min to maintain conscious sedation
45390623|NCT01038882|Other|Physiological serum|We started by injecting a 4 ml drug bolus and we ad supplemental doses (2 ml) to maintain the conscious sedation
45390624|NCT00430482|Behavioral|Cognitive Behavioral Therapy|12 weekly sessions and 3 booster sessions of cognitive behavioral therapy
45390625|NCT00430482|Behavioral|Individual Counseling|12 weekly sessions and 3 booster sessions of individual counseling
45390626|NCT00449930|Drug|sitagliptin phosphate|(1) sitagliptin 100mg tablet once daily (q.d.) for a 24-wk treatment period
45390627|NCT00449930|Drug|Comparator: metformin hydrochloride|(4) Metformin 500mg tablets once daily (q.d.) for a 24-wk treatment period.
45502513|NCT03618966|Device|Neuromuscular magnetic stimulation (NMMS)|It is a non-invasive, stimulation technique that does not induce high-intensity cutaneous electric fields and does not activate skin nociceptors, thus resulting in a painless and better-tolerated procedure. rNMMS is delivered through a high-frequency magnetic stimulator connected to a conventional circular cooled coil. Magnetic stimulator is placed above the flexor muscles of the forearm. rNMMS is delivered at a 5-Hz frequency and with a 100% stimulation intensity of 100% of the maximum intensity in 140 trains of 50 stimuli. sNMMS is delivered with a sham coil producing similar acoustic sensations and mechanical skin perceptions.
45390628|NCT01033110|Behavioral|Exercise and Nutrition Education|Guided nordic walking training and 12 presentations about diet and health.
45390629|NCT01034982|Drug|AZD9668|20 mg
45390630|NCT01034982|Drug|AZD9668|60 mg
45502514|NCT05187143|Device|DENTAL IMPLANT|The study implants were 3.5, 3.75 or 4.5 mm implant diameter, Straumann® BLX implant SLActive® Roxolid® (Institut Straumann AG, Basel, Switzerland) and the abutment was a 0 °, 2.5 mm of height Straumann® Screw-retained Abutment. The length of the implants was 6, 8 and 10 mm. The 6 mm implant is only commercially available in 3.75 and 4.5 diameter.
45502515|NCT02052908|Other|Laboratory Biomarker Analysis|Correlative studies
45502516|NCT02052908|Drug|Naproxen|Given PO
45502517|NCT02052908|Other|Placebo Administration|Given PO
45502518|NCT03640572|Diagnostic Test|Bone marrow analysis to identify disseminated tumour cells|Pelleted cells from bone marrow samples were incubated with an excessive amount of lysing solution for 10 min, repeated 3-4 times to remove erythrocytes. The slides were dried, fixed with a mixture of ethanol and acetone (1 : 1 v v-1), and then stained for 30 min with A45-B/B3 monoclonal antibodies (5 μg ml-1) (Micromet GmbH, Germany), which recognise common epitopes of cytokeratins (CK) including CK 8, 18 and 19.
45390631|NCT01038960|Behavioral|Exercise training|3 months supervised interval training
45390632|NCT01039038|Radiation|curietherapy and radiotherapy|boost of curietherapy(40 Gy)and external radiotherapy (34 Gy)
45390633|NCT00449696|Device|Gel-200|Single intra-articular injection
45390634|NCT00449696|Device|Placebo|Single intra-articular injection
45502519|NCT01336985|Drug|Irinotecan|
45502520|NCT01336985|Procedure|Chemoembolization|
45502521|NCT01336985|Device|Drug-Eluting Beads|
45502522|NCT01336985|Procedure|Biopsy|
45502523|NCT03640494|Device|Optical Coherence Tomography|This is an observational study in which subjects will be imaged with optical coherence tomography (OCT). OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, optic nerve head and retinal blood vessels. The OCT devices are held above (and do not touch) the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the infant is not disturbed by the light.
45696506|NCT03032458|Drug|Pethidine|pethidine 25 mg IV bolus injection before start of session plus placebo gel then then IV infusion, so that the total dose doesn't exceed 1mg/kg
45390635|NCT01024166|Behavioral|Questionnaire and Review Session|Use PRO computer system to complete 2 questionnaires about any symptoms patient may be experiencing and their overall health, 30 minutes to complete. Review session about use of computer system and suggested changes.
45390636|NCT01024166|Behavioral|Questionnaire and Review Session|Use PRO computer system to complete 4 questionnaires about symptoms their overall health of patients, 30 minutes to complete. Review session about use of computer system and suggested changes.
45390637|NCT01566188|Dietary Supplement|omega-3 from vegetal origin|6 months of supplementation with omega-3 from vegetal origin
45390638|NCT01566188|Dietary Supplement|Placebo|6 months of supplementation with placebo
45390639|NCT01029158|Drug|Juvista (Avotermin)|250 ng, twice, intradermal injection, standard formulation
45390640|NCT01029158|Drug|RN1006 (Avotermin)|250 ng, intradermal injection, twice
45390641|NCT01029158|Drug|RN1006 (Avotermin)|205 ng, Intradermal injection, once
45390642|NCT01029158|Drug|RN1006 (Avotermin)|500ng, intradermal injection, once
45390643|NCT01029158|Drug|Juvista (Avotermin)|250 ng, intradermal injection, twice
45390644|NCT01029158|Drug|Juvista (Avotermin)|500 ng, intradermal injection, once
45390645|NCT01029158|Drug|Juvista (Avotermin)|500 ng, intradermal injection, once
45390646|NCT01029158|Drug|RN1006 (Avotermin)|500 ng, intradermal injection, twice
45390647|NCT01029158|Drug|Placebo|Placebo
45390648|NCT00441116|Drug|Dutasteride 0.5mg oral tablets|Dutasteride
45390649|NCT01029236|Other|Medifast Metabolism-boosting Beverages|Medifast metabolism-boosting beverages containing 90 mg EGCG and 100 mg caffeine.
45390650|NCT01024322|Drug|Ciprofloxicine or Vigamox or other.|Ciprofloxicine or Vigamox or other to be used qid till epithelialized.
45696507|NCT03032458|Drug|Ketorolac|ketorolac IV bolus injection before start of session plus placebo gel then 30 mg IV infusion so that total dose doesn't exceed 60 mg.
45390651|NCT01024322|Drug|Nonsteroidal (Acular, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) used up to qid for up to 5-10 days post-op
45390652|NCT01024322|Drug|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid for 8 weeks.
45390653|NCT03320642|Drug|Itacitinib|Itacitinib administered orally once daily at the protocol-defined dose.
45390654|NCT03320642|Drug|Calcineurin inhibitor|The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate, cyclosporine A/mycophenolate mofetil or tacrolimus plus post-treatment cyclophosphamide. Antithymocyte globulin may be included at the treating investigator's discretion with the tacrolimus/methotrexate or cyclosporine A/mycophenolate mofetil combinations.
45390655|NCT01566266|Drug|Amoxicillin|2 capsules of 250mg, 3 times per day during 1 week
45390656|NCT01566266|Drug|Placebo capsule|2 capsules of 250mg, 3 times per day during 1 week
45390657|NCT01024400|Biological|Non-adjuvanted A(H1N1)v influenza vaccine|15 mcg HA/0.5 ml
45390658|NCT00430248|Drug|Febuxostat|Febuxostat 40 mg, capsules, orally, once daily for up to 6 months.
45390659|NCT00430248|Drug|Febuxostat|Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
45390660|NCT00430248|Drug|Allopurinol|"Allopurinol 200 mg or 300 mg, capsules, orally, once daily for up to 6 months.~Dose is dependent on the subject's renal function. Subjects with normal renal function or mild renal impairment received 300 mg once daily; subjects with moderate renal impairment received 200 mg once daily."
45390661|NCT00449540|Device|Active Transcranial Magnetic Stimulation (TMS) Device|Transcranial Magnetic Stimulation Device treatment
45390662|NCT00449540|Device|Sham TMS Device|Simulated Sham treatment without TMS delivery
45390663|NCT01029470|Drug|Luveris|Luveris 75IU or 150IU depending on the patient conditions, subcutaneous injection, Qd, from Day 8 till hCG Day
45390664|NCT00411762|Drug|Capecitabine|
45502524|NCT01337063|Other|Mentored medication reconciliation quality improvement|"Based on expert recommendations from a recent conference on medication reconciliation sponsored by the Society of Hospital Medicine and funded by AHRQ, investigators will engage a steering committee and conduct a second conference to operationalize these recommendations into a set of best practice guidelines, standards, and tools to be adapted by each of 6 participating sites. After training mentors and developing data collection tools, a mentored quality improvement project will be conducted for 21 months, in which each site works to improve medication reconciliation using the toolkit and with mentorship in the form of two site visits and monthly phone calls."
45502525|NCT03640416|Device|Fitbit® Charge HR smart watch|The Fitbit® Charge HR is a commercial product widely used worldwide, and data from the device is sent to a secured online server and can be accessed by each user to see only data collected from his own device. Data collected from the Fitbit® Charge HR is described earlier.
45390665|NCT00411762|Drug|PHY906|
45390666|NCT00429858|Drug|S-1|S-1 is given as follows: 25 mg/m2 bid on days 1-7 and 15-21 of the cycle (28 days)
45390667|NCT00429858|Drug|gemcitabine hydrochloride|Patients will receive gemcitabine at a dose of 1,000 mg/m2 i.v. at a fixed-dose rate (FDR) infusion of 10 mg/m2/minute (100 minutes), once a week for 3 consecutive weeks, followed by one week rest. Each 4 week period is referred to as a treatment cycle
45390668|NCT01323738|Behavioral|Psychoeducation|Psychoeducation group on stress and how it relates to alcohol use, 4 sessions a 45 minutes
45390669|NCT01035216|Drug|GNKG168|GNKG168 will be administered as a 60 minute IV infusion once daily for 5 days followed by a 9 day rest period.
45390670|NCT01039116|Behavioral|High Intensity|High-intensity intervention, Experimental. Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.
45390671|NCT01039116|Behavioral|Low Intensity|Low-intensity intervention, Active comparator. Participants were provided with educational materials 4 times yearly.
45502526|NCT01337141|Other|Control|7 face-to-face visits.
45502527|NCT01337141|Device|Telecare system|5 telematic visits and 2 face-to-face visits.
45502528|NCT03640338|Device|Cold-Therapy System|After surgery, participants assigned to this group will receive the cold-therapy system to use at the hospital and during the first 2 weeks following discharge.
45390672|NCT01035294|Behavioral|mindfulness based intervention (MBI)|Eight, phone delivered, individual mindfulness sessions. Each training session will last 30 minutes (20 minutes for intervention + an additional 10 minutes for questions, answers, and for scheduling the next intervention. Patients will also receive instructions to practice at home every day, at least once a day, for at least 15 minutes. An audio CD containing guided mindfulness exercises will be given to the patient at the beginning of the study, to guide them during their home practice. The CD consists of sequences of different mindfulness techniques, consistent with the techniques learned during each session with the instructor. Each patient will record the minutes of mindfulness practice in a diary to be kept daily.
45502529|NCT05186831|Behavioral|Texting|Patients will be asked to text their BP. They will receive an automated response to their texts.
45502530|NCT05186831|Behavioral|Online patient portal|Patients will be asked to upload their BP to the online patient portal. They will receive information on how to sign up and use the patient portal. Patients can upload their BP readings daily or at the end of the study period.
45390673|NCT01035294|Behavioral|usual care|The UC group will be offered the standard care planned by the hospital, which includes the routine care provided by the electrophysiology team and other health care professionals that the patient may see over the course of the ICD experience. All patients receive a number of printed education materials and participate to support meetings for ICD patients four times a year. Being part of the standard care offered at UMass Memorial Medical Center, these meetings are offered to all patients regardless of their assignment (thus including patients assigned to the MBI arm).
45390674|NCT01035372|Dietary Supplement|dried plum powder|subjects will have 25% of their diet substituted by dried plum powder
45390675|NCT00449150|Drug|Cetrorelix 78 mg + 78 mg|
45390676|NCT00449150|Drug|Cetrorelix 78 mg + 52 mg|
45390677|NCT00449150|Drug|Placebo|
45390678|NCT00428844|Drug|daptomycin|6 mg/kg
45390679|NCT00428844|Drug|daptomycin|8 mg/kg
45390680|NCT00428844|Drug|vancomycin|1 gram
45390681|NCT00428844|Drug|teicoplanin|6 mg/kg; used only at UK sites
45502531|NCT01337375|Drug|peginterferon alfa 2a [Pegasys]|sc weekly
45848766|NCT01545648|Drug|Denosumab|"Formulation of Dosage forms~The vial presentations of denosumab contain 60 mg/mL denosumab, 17 mM sodium acetate, and 4.7% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL; or 70 mg/mL denosumab, 18 mM sodium acetate and 4.6% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.7 mL. The prefilled syringe (PFS) drug product contains denosumab at 60 mg/mL, 17 mM sodium acetate, 4.7% (w/v) sorbitol, and 0.01% (w/v) polysorbate 20, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL.~Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year~Route of administration: subcutaneous injection"
46056844|NCT02724267|Biological|131I-chTNT-1/B|29.6 MBq/kg,intravenous administration in 1 hour，1-3 course of treatment
46056845|NCT02718495|Drug|PTI-428|
45390682|NCT00428844|Drug|nafcillin|1-2 gram
45390683|NCT00428844|Drug|oxacillin|1-2 gram
45390684|NCT00428844|Drug|flucloxacillin|1-2 mg
45390685|NCT00457418|Drug|PEG-Intron|
45390686|NCT01039194|Drug|galantamine|Capsule, Oral, 8 mg (ER), once daily, Days 1-7
45390687|NCT01039194|Drug|galantamine|Capsule, Oral, 16 mg (ER), once daily, Days 8-24
45390688|NCT01039194|Drug|BMS-708163|Capsule, Oral, 125 mg, once daily, Days 15-24
45390689|NCT00449072|Other|Placebo|Placebo to TAA-AQ was administered once at the study site in each nostril during the baseline/screening period to demonstrate intranasal IP administration
45390690|NCT00449072|Other|Placebo|Placebo to TAA-AQ was administered intranasally once daily in each nostril during the double-blind period
45390691|NCT00449072|Drug|TAA-AQ, Nasacort® AQ|110 μg TAA-AQ was administered once daily intranasally (1 spray delivering 55 μg of TAA-AQ in each nostril) during the double-blind treatment period
45390692|NCT00449072|Drug|Claritin®|Participants were provided Children's Claritin® Syrup (5 mg of loratadine per 5 mL), as rescue medication for the relief of allergic rhinitis (AR) symptoms, and could be used throughout the study on an as needed basis according to the Food and Drug Administration-approved manufacturer's label
45390693|NCT00428610|Drug|LY573636-sodium|LY573636 dose is dependent on participant's height, weight, and gender and is adjusted to target a specific maximum concentration (Cmax) based on participant laboratory parameters. LY573636 is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
45390694|NCT02593656|Behavioral|High Protein|Protein-pacing throughout the day and exercise training for 12 weeks
45390695|NCT02593656|Behavioral|Normal Protein|Normal protein intake throughout the day and exercise training for 12 weeks
45390696|NCT01033188|Procedure|Single bundle|"Procedure:~Transarthroscopic technique with medial portal placement of the femoral tunnel. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus. The femoral tunnel is positioned at the anatomic foot print determined by the anatomic landmarks. The graft will be fixed with an Endobutton CL on the femur and with an Biosure PK screw in the tibia with the knee close to extension. Prior to the final fixation, the knee will be taken through flexion and extension movements.The surgery will be carried out by an experienced knee surgeon."
45502532|NCT01337375|Drug|peginterferon alfa-2a [Pegasys]|iv weekly
45502533|NCT01337375|Drug|peginterferon alfa-2a [Pegasys]|sc twice weekly
45390697|NCT01033188|Procedure|Double bundle|"Procedure:~Transarthroscopic technique. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus.Through a medial portal 2 tunnels will be anatomically placed in the foot print on the femur and the two tibial tunnels will be placed using the Smith & Nephew drill guide. The graft will be fixed with 2 Endobuttons on the femur and with 2 Biosure PK screws in the tibia. Prior to the final fixation, the knee will be taken through 20 flexion and extension movements. The PL bundle will be fixed with the knee close to ful extension. The surgery will be carried out by an experienced knee surgeon."
45390698|NCT01033266|Diagnostic Test|CPET|CPET will be done on patients with overlap syndrome before and after clinical CPAP treatment.
45390699|NCT00419094|Drug|Keppra XR|Administered as two 500 mg tablets (1000 mg) and two placebo tablets once daily for 18 weeks
45390700|NCT00419094|Drug|Keppra XR|Administered as four 500 mg tablets (2000 mg) once daily for 18 weeks
45390701|NCT00448916|Drug|Pregabalin|Orally-administered pregabalin
45390702|NCT00418938|Drug|Panitumumab|6mg/kg IV
45390703|NCT00418938|Drug|Bevacizumab|Either 5mg/kg OR 10mg/kg IV
45502534|NCT01337375|Drug|peginterferon alfa-2a [Pegasys]|iv twice weekly
45502535|NCT03635411|Dietary Supplement|Nicotinamide Riboside and Pterostilbene|Nicotinamide riboside and pterostilbene manufactured by Basis
45502536|NCT03635411|Dietary Supplement|Placebo|Sugar pill manufactured to mimic Basis supplement.
45502537|NCT02748512|Drug|FAI Insert administered using the Mk II inserter|
45848767|NCT01527942|Drug|Acetaminophen|Intravenous Acetaminophen 1,000 mg IV
46056846|NCT02718495|Drug|Placebo|
46056847|NCT04659226|Genetic|Blood sampling for microRNA testing|Blood samples will be collected and analyzed for the microRNA profile by means of microfluidic cards
46056848|NCT02724189|Device|MyPreOp assessment|MyPreOp is an online preoperative assessment programme created by a medical software company called Ultramed.
45390704|NCT00418938|Drug|Leucovorin|400mg/m^2 IV (in the vein)
45390705|NCT00418938|Drug|Irinotecan|180mg/m^2 IV (in the vein)
45390706|NCT00418938|Drug|5-Fluorouracil|400mg/m^2 bolus IV (in the vein) over 2-4 min, followed by 2400mg/m^2 continuous IV over 46 hours for the first 2 cycles, increased to 3000mg/m^2 thereafter if no significant side effects
45390707|NCT03279224|Biological|Allogenic FMT|"Fifty (50) g of screened donor feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.~2.The volume of fecal filtrate corresponding to fifty (50) g of donor stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.~3. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy."
45390708|NCT03279224|Biological|Autologous FMT|"1. Fifty (50) g of the participant's feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.~3.The volume of fecal filtrate corresponding to fifty (50) g of participant's stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.~3. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy."
45390709|NCT01029626|Procedure|Endoscopy|Realization of an upper GI endoscopy
45390710|NCT03996122|Other|fMRI|3 fMRI (TO, Month 2 and Month 6) 3 BDNF samples (TO, Month 2 and Month 6)
45390711|NCT00448760|Drug|Docetaxel|Intravenously, 25 mg/m2, over 30 minutes, 2 cycles
45390712|NCT00448760|Drug|Floxuridine|Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
45390713|NCT00448760|Drug|Leucovorin|Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
45390714|NCT00448760|Drug|Oxaliplatin|Intravenously, 85 mg/m2, over 2 hours, 2 cycles
45390715|NCT00448760|Genetic|Microarray analysis|Analysis of tumor for pathologic response to protocol therapy
45502538|NCT02748512|Drug|FAI Insert administered using the Mk I inserter|
45390716|NCT00448760|Genetic|reverse transcriptase-polymerase chain reaction|Analysis of tumor for pathologic response to protocol therapy
45502539|NCT04816799|Behavioral|Startle Adjuvant Rehabilitation Therapy (START)|Exposure to loud acoustic stimulus during training of motor task (in this case speech).
45390717|NCT00448760|Procedure|Conventional surgery|Surgical removal of tumor for correlative studies
45390718|NCT00418314|Device|Control|Empiric programming or one-time optimization using a non-IEGM method.
45390719|NCT00418314|Device|QuickOpt|Frequent optimization using QuickOpt to optimize AV/PV and VV delays.
45390720|NCT01033344|Biological|Placebo|Intradermal injection 1x8 administrations 2 weeks apart
45390721|NCT01033344|Biological|Cat-PAD|Intradermal injection 1x8 administrations 2 weeks apart
45390722|NCT01033344|Biological|Cat-PAD|Intradermal injection, 1x8 administrations 2 weeks apart, alternating active and placebo
45390723|NCT01039350|Drug|Darbepoetin alfa|Darbepoetin alfa will be initiated at a weekly (QW) subcutaneous dose of 300 mcg over 8 weeks.
45390724|NCT00448448|Device|Brace|Brace (TLSO) applied for at least 18 hours per day. Wear time measured using a temperature monitor. Clinical, radiographic, and self-report follow-up every 6 months.
45502540|NCT04875455|Device|POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation|In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.
45502541|NCT02748356|Drug|Lactobacillus|Eligible patients will undergo 1 Lactobacillus pediatric dose (Culturelle GG 10 Billion live organisms) instillation by study personnel at the study site. For the intravesicular Lactobacillus instillation, the contents of 1 Lactobacillus capsule will be mixed into sterile 0.9% saline using an age-based estimate of bladder capacity. Similar to adults, this bladder instillation will represent 10% of the estimated maximum bladder volume based on age.
45696508|NCT03032458|Drug|Xylocaine Gel|Xylocaine gel locally 15 minutes before session with 10 mg normal saline IV bolus before session then IV normal saline infusion then
45696509|NCT02245438|Drug|Tipranavir low dose|
45696510|NCT02245438|Drug|Tipranavir high dose|
45390725|NCT00448448|Other|Observation|Clinical, radiographic, and self-report follow-up every 6 months.
45390726|NCT01039506|Drug|CPT-11 based regimens|
45390727|NCT01033500|Drug|Belatacept|Belatacept 10mg/kg on Days 0, 4, 14, 28, 56, and 84 post-transplant, and then 5mg/kg every 4 weeks for the duration of the study.
45502542|NCT02052986|Other|VASCAZEN|All enrolled subjects will receive 4 capsules daily of VASCAZEN which delivers 3.0 grams of EPA and DHA
45696511|NCT02245438|Drug|Ritonavir low dose|
45696512|NCT02245438|Drug|Ritonavir high dose|
45696513|NCT02245438|Drug|Norethindrone-Ethinyl Estradiol|
45848768|NCT01527942|Drug|Placebo|Placebo - IV administration 0.9% 100 ml Sodium Chloride (NaCl)
45848769|NCT01507584|Device|SENSIMED Triggerfish|Comparison of fluctuation of Intraocular pressures with different class of drugs
45390728|NCT01033578|Other|PVIC, TACE|"PVIC：5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) were continuously infused into portal vein through tube by a infusion pump. Treatment started 2 weeks after the operation and was repeated every 4 weeks for 6 cycles.~TACE: 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles."
45390729|NCT01035450|Device|Everolimus-eluting stent|Everolimus-eluting stent
45390730|NCT01035450|Device|Sirolimus-eluting stent|Sirolimus-eluting stent
45390731|NCT01035528|Drug|insulin glargine|antidiabetic treatment with insulin glargine sc o.d. titrated to the target fasting glucose type 2 diabetes ≤110 mg/dl
45696514|NCT04761939|Combination Product|EluNIR Ridaforolimus Eluting Coronary Stent System|"The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:~Stent - a pre-mounted Cobalt Chromium (CoCr) alloy based stent - 2.25 mm Diameter and 8mm, 12mm, 15mm, 17mm, 20mm, 24mm, 28mm and 33mm length~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~Ridaforolimus drug - CAS Registry Number: 572924-54-0"
45848770|NCT01483872|Drug|NAC/Tigecycline/Heparin combination lock solution|
45848771|NCT01483872|Drug|Standard anticoagulant (Heparin or Citrate)|
45390732|NCT01035528|Drug|metformin|use of oral metformin o.d or b.d titrated up to 2000 mg daily for to the target fasting glucose ≤110 mg/dl
45390733|NCT03994458|Behavioral|Smartphone Full version application|Android smartphone experimental application include: rehabilitative self-administered evidence-based exercises (Strengthening and stretching), ergonomics, and education related to low back pain. The application includes videos, photos, text, and reminders.
45390734|NCT03994458|Behavioral|Samartphone limited version application|Android smartphone placebo application include: ineffective content that does not help in treating low back pain. The application includes only five posts in the general instruction and advises section about proper nutrition and few irrelevant reminders.
45390735|NCT01039662|Dietary Supplement|L-arabinose and indigestible dextrin|
45390736|NCT01039662|Dietary Supplement|Placebo|
45502543|NCT02054624|Behavioral|Lifestyle intervention|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by group telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
45502544|NCT02054624|Behavioral|Health education control|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by email.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help them maintain lost weight."
45502545|NCT02054624|Behavioral|Individual|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by on-on-one telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
45502546|NCT02054624|Behavioral|All Groups|All participants will receive the following: Questionnaires, height, weight, waist measurement, blood pressure, heart rate, electrocardiogram, blood sample, urine sample, urine pregnancy test (for females only), 400 meter walking test
45390737|NCT01033656|Drug|anakinra|100 mg subcutaneous injection daily
45390738|NCT01033656|Drug|comparators|po drugs, comparators
45390739|NCT03991806|Other|Obsservational|The frailty and the health adverse events of older adults will be assessed by using a questionnaire called: Association of Centre of Excellence Self-Administered questionnaire (CESAM).
45390740|NCT01039740|Drug|Mirtazapine|Mirtazapine administration for 6 weeks under therapeutic dose
45390741|NCT01036308|Dietary Supplement|pure fibre-product|The subjects consumed 25 g pure fibre-product per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
45390742|NCT01036308|Dietary Supplement|reference fibre|The subjects consumed 25 g reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood Ingredients) per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
45390743|NCT00405912|Drug|Placebo|Placebo (inactive drug) given 3 times per day
45390744|NCT00405912|Drug|St. John's Wort-900 mg/day|St. John's Wort - 300 mg tables -3 times per day
45390745|NCT00405912|Drug|St. John's Wort-1800mg/day|St. John's Wort - 600 mg tables - 3 times per day
45390746|NCT00448136|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 every 3 weeks
45390747|NCT00448136|Drug|5 FU|400mg/m2/day iv on days 1-5 every 6 weeks
45390748|NCT00448136|Drug|Streptozotocin|500mg/m2/day iv on days 1-5 every 6 weeks
45696515|NCT03032146|Procedure|Cardiac Rehabilitation|Cardiac rehabilitation is a multidisciplinary framework which focuses on improving the functioning of heart disease patients to facilitate and optimize the return to a regular routine as early as possible. The rehabilitation program provides the tools for the maintenance of a healthy lifestyle, encouraging participants to take part in recreational activities and includes extending their daily functioning.
45390749|NCT00448136|Drug|Xeloda|1000mg/m2 po bid on days 1-14 every 3 weeks
45390750|NCT00447902|Drug|tipranavir|
45390751|NCT00447902|Drug|ritonavir|
45390752|NCT00307437|Drug|Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg|Placebo at Weeks 0 and 4 and blinded SC injections of ustekinumab, 45 or 90 mg, at Weeks 12 and 16; followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
45390753|NCT00307437|Drug|Ustekinumab (CNTO 1275) 45 mg|Ustekinumab, 45 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
45390754|NCT00307437|Drug|Ustekinumab (CNTO 1275) 90 mg|Ustekinumab, 90 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
45390755|NCT03978819|Device|ANI|"ANI profiles during IPNS (bradycardia/asystole) or excessive analgesia.~During surgery continuous monitoring of ANI, HR and Remifentanil effect site concentration was done and recorded. Event markers were placed at the onset of bradycardia, asystole and the coincidence of ANI>80 + Remifentanil >6ng/mL). ANI values of 1 min before and 1 min after the event were used for analysis."
45390756|NCT00440726|Drug|Bortezomib|Intravenous on days 1, 4, 8 and 11. Dose assigned at study entry.
45502547|NCT01341041|Biological|chlorine dioxide|one time wash with 50ppm CD solution
45390757|NCT00440726|Drug|Dexamethasone|10 mg/m2/day divided BID, oral administration for 14 days.
45390758|NCT00440726|Drug|PEG-asparaginase|2500 IU/m2/day, intramuscular injection on Days 2, 8, 15 and 22
45390759|NCT00440726|Drug|Doxorubicin|60 mg/m2/day IV over 15 minutes on Day 1
45390760|NCT00440726|Drug|Cytarabine|"Given intrathecally on Day 1 of course 1 at the dose defined by age below.~30 mg for patients age 1-1.99~50 mg for patients age 2-2.99~70 mg for patients >3 years of age"
45390761|NCT00440726|Drug|Methotrexate|"Given intrathecally to all patients who are CNS 1 at study entry on Day 15 at the dose defined by age below.~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age"
45390762|NCT00440726|Drug|Vincristine|1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22.
45502548|NCT01341041|Biological|saline|one time wash with 50-100 cc normal saline
45502549|NCT02053064|Genetic|SAF-301|
45502550|NCT04805021|Other|no intervention|no intervention
45502551|NCT02053142|Drug|Acyclovir|Single dose of acyclovir 200mg was given for pk study
45502552|NCT02053142|Drug|Placebo|
45696516|NCT03087669|Device|LVAD flow velocity setting-Rounds per Minute(RPM) on HeartMate III®|Increase in LVAD RPM setting induces an actual increase in LVAD outflow to the patient.This gives the patient an increased systemic Cardiac Output(CO)
45696517|NCT03087669|Drug|MAP intervention using Noradrenalin|At a fixed RPM rate for the LVAD the Mean Arterial Pressure (MAP) is increased to preset levels of 60-70-80-90 mmHG using Noradrenalin
45696518|NCT00939952|Drug|ertapenem|500 mg IV once
45390763|NCT00440726|Drug|Triple IT Therapy|"Triple IT therapy will be given intrathecally on Day 8, 15, and 22 for patients who are CNS 2 and CNS 3 at study entry. Regimen/dosing as follows:~Methotrexate-~<2 years: 8 mg~2 - <3 y: 10 mg~3 - <9 y: 12 mg~>=9 y: 15 mg~Cytarabine:~<2 years: 16 mg~2 - <3 y: 20 mg~3 - <9 y: 24 mg~>=9 y: 30 mg~Hydrocortisone:~<2 years: 8 mg~2 - <3 y: 10 mg~3 - <9 y: 12 mg~>=9 y: 15 mg"
45502553|NCT01316471|Behavioral|Online Behavioral Intervention|The online behavioral intervention is travel-themed and participants visit 8 destinations (1 per week) designed to take 30 min each to complete. The destinations serve as an online analog for the weekly sessions used when delivering behavioral interventions face-to-face. The 8 child destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) relaxation and distraction skills, 4) school, 5) cognitive skills, 6) sleep hygiene and lifestyle, 7) staying active, and 8) relapse prevention. The eight parent destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I, 4) operant strategies II, 5) modeling, 6) sleep hygiene and lifestyle, 7) communication, and 8) relapse prevention.
45502554|NCT01316471|Other|Education: Online Patient Education|The purpose of the online patient education group is to control for time, attention, and computer usage. Children and parents will be provided with access to a modified version of the study website that will provide links to information from publicly available educational websites about pediatric chronic pain management. Children and parents will log onto the web program weekly at the same interval as the Online Behavioral Intervention group. Children and parents will be asked to view 3 links each week and then report a few details pertaining to the content of what they viewed.
45502555|NCT01316549|Drug|Fludarabine|Given as injection
45502556|NCT02054780|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|We propose using TF-CBT to address stress related problems (SRP) and reduce HIV risk behaviors. OVC lack behavioral and cognitive skills and intention necessary to use the available information and resources to prevent HIV. For example, internalizing problems are related to HIV risk through low self-efficacy, poor assertiveness skills, and reduced ability to negotiate safe sex. Given evidence on the link between abuse/trauma and elevated HIV risk, researchers have called for overlap between evidence-based mental health treatments like TF-CBT and HIV prevention programs. Some studies have found that skills-oriented interventions reduced HIV-risk behaviors among minority and troubled youths. An intervention study using CBT increased condom use and decreased high-risk sexual behaviors among runaway youths in a short-term follow-up evaluation. However, these studies were done in Western countries; their relevance to OVC in Africa is unproven.
45502557|NCT02054780|Behavioral|Psychosocial Counseling|"The curriculum Psychosocial Care and Counseling was developed for HIV Infected Children and Adolescents. The goal is to enable health care providers to provide safe supportive counseling and support services to HIV infected youth and their families. The course materials are designed to be adapted to different cultures and needs. The 14 modules cover child development, family systems, communicating with children, disclosure and adherence and legal/ethical issues. The course teaches basic counseling skills with children such as listening and play. It explores and challenges barriers to care such as caregivers' fear and reluctance to disclose an HIV positive diagnosis to a child, discussing adolescent sexuality, and practical issues such as inadequate legislation governing child rights. The curriculum was adapted for Zambia and endorsed by the MoH."
45696519|NCT02401815|Drug|PLX9486|PLX9486 will be administered per dose and schedule specified in the arm.
45696520|NCT02401815|Drug|Pexidartinib|Pexidartinib capsules will be administered per dose and schedule specified in the arm.
45696521|NCT02401815|Drug|Sunitinib|Sunitinib will be administered per dose and schedule specified in the arm.
45696522|NCT00947752|Drug|Glatiramer Acetate|Subjects received both doses once daily in a crossover fashion, for a total treatment duration of five weeks, including a one-week run-in period. Subject-reported injection pain was recorded in a daily diary.
45696523|NCT00947752|Drug|Experimental Glatiramer Acetate|GA 20 mg/0.5 mL
45696524|NCT03032692|Device|SWORD|Both arms will perform two separate sessions consisting of one exercise - shoulder flexion with elbow flexion at 90 degrees - for 4 minutes in two experimental conditions: with and without biofeedback. Group 1 will perform the exercise with biofeedback first and without biofeedback after; group 2 performed the exercise in the opposite order. The SWORD system will be used to record movement data in both sessions.
45696525|NCT03032692|Other|Exercise with biofeedback|
45390764|NCT03226808|Device|Vivacit-E Liner|All subjects enrolled will receive the Vivacit-E liner.
45390765|NCT01029938|Procedure|Covered stent|Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
45390766|NCT01029938|Procedure|Coil|Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
45390767|NCT03192722|Device|Colored near reading glasses|Participants are provided with colored near vision glasses.
45696526|NCT03032692|Other|exercise without biofeedback|
45696527|NCT03457155|Other|VS-I dosing in plasma samples|"VS-I dosing in plasma samples using ELISA protocol :~At intensive care admission time~24h after admission time~In case of FA occurrence~In case of sinusal rhythm recovery (in patients with new onset FA)"
45390768|NCT03192722|Device|Lighting as determined by LuxIQ/2 or OttLite Cobra|Participants are provided preferred lighting (either OttLite or lamp with findings from LuxIQ/2)
45390769|NCT01030016|Drug|atenolol|25 mg/day, twice a day for 6 weeks
45390770|NCT03995420|Behavioral|Virtual Reality Therapy (V-NeST)|V-NeST is a 12-session therapy using psychological intervention principles based on Cognitive Remediation and CBT partly based in Virtual Reality.
45390771|NCT03995420|Other|Treatment as Usual|multi-modal treatment consisting of different therapies defined by the treating team. These will include regular contact with a care coordinator and medication management by a psychiatrist.
45390772|NCT03996278|Other|Grafalon|None interventional study but there are two groups
45390773|NCT03994952|Device|Sway Balance Application|Participants complete the modified Balance Error Scoring System as prompted on and iPad mini. It has 5 balance stances, double limb stance, right tandem, left tandem, right single, and left single leg balance for 20 seconds each. This will only be used as measurement, not an intervention.
45390774|NCT03994952|Device|Balance Tracking Systems|This is a force platform. Center of pressure data will be measured and recorded while participants are completing the modified Balance Error Scoring System. This will only be used as measurement, not an intervention.
45502558|NCT01316627|Behavioral|Crooked Mirror Externalization Therapy|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
45696528|NCT03087747|Procedure|Percutaneous cholecystostomy|Placement of drainage catheter into gallbladder lumen in order to evacuate inflamed content.
45390775|NCT00447590|Device|LAP-BAND System|Restriction of food intake
45390776|NCT01024634|Behavioral|Endurance Exercise|8 weeks of Endurance exercise training, 3-4 times per week, 45-60 minutes perr session
45390777|NCT00447278|Drug|Atomoxetine|0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension
45390778|NCT00447278|Drug|Other standard therapy for ADHD|Any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
45390779|NCT01030094|Drug|Topiramate|This is an observational study. Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
45390780|NCT01030094|Drug|Carbamazepine|This is an observational study. Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
45390781|NCT01030094|Drug|Valproic acid|This is an observational study. Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
45390782|NCT01030094|Drug|Normal control|This is an observational study. Healthy female participants will be observed in Normal control group.
45390783|NCT01565798|Other|Copper-alloy surfaced patient care objects|Copper-alloy surfaced bed rails, over bed tray tables, chair arms, nurse call devices, laptop and computer monitor bezels, and IV poles were placed into the patient ICU rooms.
45390784|NCT01030328|Drug|Placebo|2 sugar pills by mouth once a day.
45390785|NCT01030328|Drug|TriLipix|135 mg of TriLipix + 40 mg of Atorvastatin by mouth once a day
45390786|NCT00446966|Drug|Omega Three Polyunsaturated fatty acids|2 grams orally twice daily pre-operatively and 2 grams orally daily after until primary endpoint or 14 days.
45390787|NCT01565876|Device|"Minkal- Auxiliary device to alleviate backload"|"The participants will undergo 6 days of study. The first day of the study include medical examination, maximal oxigen consumption day and anthropometric mesurments.~Then The participants will undergo heat tolerance test 5 times (in different days).~first day- without load. second day- with back load of 40% of the body weight. third day- with back load of 40% of the body weight and the Auxilairy Device. fourth day- with back load of 60% of the body weight. fifth day- with back load of 60% of the body weight and the Auxilairy Device. The rectal temperature, skin teperature and heart rate will be mesured each day and compered afterwards."
45390788|NCT00446654|Drug|CGC-11047|16.5 mg (3.3%) subconjunctival injection
45390789|NCT03162302|Diagnostic Test|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.
45390790|NCT00405756|Drug|Lenalidomide: Double-blind Induction|Double-blind Induction: the starting lenalidomide oral dosing regimen was 10 mg once daily on Days 1 through 21 of each 28 day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
45390791|NCT00405756|Drug|Melphalan|Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
45390792|NCT00405756|Drug|Prednisone|Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
45390793|NCT00405756|Drug|Aspirin|"Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms.~Double-blind maintenance: at the investigator's discretion"
45696529|NCT03032224|Procedure|Resection of the esophagus and the gastroesophageal junction|
45696530|NCT03456687|Drug|Exenatide|Exenatide will be administered through a subcutaneous injection once per week for the duration of the study (1 year).
45696531|NCT03497013|Device|Active tDCS|All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment).
45696532|NCT03497013|Device|Sham tDCS|For sham stimulation, the device was set to turn off after 30 seconds(study model).
45848772|NCT01385280|Biological|therapeutic estradiol|Given orally (PO)
45848773|NCT01385280|Drug|exemestane|Given PO
45390794|NCT00405756|Drug|Placebo|"Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles.~Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression."
45390795|NCT00405756|Drug|Lenalidomide: Double-blind Maintenance|Single-agent oral lenalidomide 10 mg once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
45390796|NCT00405756|Drug|Lenalidomide: Open-label|Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.
45390797|NCT00456092|Drug|Apremilast|Capsules for oral administration
45390798|NCT00456092|Drug|Placebo|Capsules for oral administration
45390799|NCT01040442|Other|vibration stimuli|A single physical therapist performed the intervention using a Novafon SK2‡ vibratory stimulation device at a frequency of 100 Hz and sway amplitude of 2 mm. The participants of the experimental group received vibratory stimulation, applied slowly by sliding the head of the device over the entire plantar region for ten minutes for each foot at every session. During the intervention, the participants remained in the supine position on an examination table.
45390800|NCT01030640|Other|placebo|single dose of the drug formulation
45390801|NCT01030640|Biological|tanezumab|single dose of the active drug tanezumab at a dose level of 20 mg
45390802|NCT00411450|Biological|Panitumumab|Administered by intravenous infusion
45390803|NCT00411450|Drug|FOLFIRI|Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
45390804|NCT00404820|Drug|Zoledronic acid 5 mg solution|Zoledronic acid was supplied as a concentrate of 5.33 mg zoledronic acid monohydrate in a 100 ml solution. 5.33 mg zoledronic acid monohydrate equals 5 mg zoledronic acid.
45390805|NCT00404820|Drug|Alendronate 70 mg tablets|Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal.
45390806|NCT00404820|Drug|Calcium/Vitamin D|Combined elemental calcium / vitamin D chewable tablets. Participants took 2 tablets a day, for a daily dose of calcium 1200 mg/vitamin D 800 IU.
45390807|NCT00417612|Drug|Paricalcitol|Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.
45390808|NCT00417612|Other|Placebo|Placebo sugar pill
45390809|NCT00446030|Drug|Docetaxel|"75 mg/m^2 administered IV on Day 1 for Cycles 1-6~All participants received a prophylactic steroid regimen prior to each dose of docetaxel - Dexamethasone 8 mg orally 12 hours prior to docetaxel, dexamethasone 10 mg IV just prior the docetaxel infusion and 8 mg orally 12 hours after docetaxel administration. If a participant had not taken their oral dexamethasone the evening prior to receiving docetaxel, the dose of the pre-docetaxel infusion of dexamethasone was increased from 10 mg IV to 15 mg IV. A Dexamethasone 8 mg equivalent may have been used (dexamethasone 8 mg = methylprednisolone 40 mg = prednisone 50 mg = prednisolone 50 mg)."
45390810|NCT00446030|Drug|Doxorubicin|50 mg/m^2 administered IV on Day 1 for Cycles 1-6
45390811|NCT00446030|Drug|Carboplatin|6 mg/mL/min (target area under the curve [AUC] dose) administered IV on Day 1 for Cycles 1-6
45390812|NCT00446030|Drug|Cyclophosphamide|500 mg/m^2 administered IV on Day 1 for Cycles 1-6
45390813|NCT00446030|Drug|Trastuzumab|A single loading dose of 8 mg/kg administered IV on Day 2 for Cycle 1, and 6 mg/kg administered IV on Day 1 for Cycles 2-6 and for maintenance therapy
45390814|NCT00446030|Drug|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and for maintenance therapy
45390815|NCT00411216|Other|Control exercises|saccadic eye movements against a plain background; no head movements
45502559|NCT01316627|Behavioral|Mirror Retraining Method|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
45502560|NCT03439657|Biological|HZ/su vaccine GSK1437173A|2 doses of 0.5 mL of the vaccine in a 0,2 Months schedule. Administered by intramuscular injection into the deltoid muscle of the non-dominant arm.
45390816|NCT00411216|Other|gaze stabilization exercises|adaptation and substitutin exercises encorporating retinal lsip and head movements
45696533|NCT03495375|Dietary Supplement|Treatment with a probiotic|All participants will take the probiotic once daily for 10 weeks in the form of a powder that can be spread on top of cold foods such as muesli, salad, or yogurt.
45848774|NCT01385280|Other|laboratory biomarker analysis|Correlative studies
45390817|NCT03995732|Drug|PC-SOD|PC-SOD will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
45390818|NCT03995732|Drug|placebo|Placebo will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
45390819|NCT01323816|Other|Medically directed care|There is no research directed care. Patients are treated as medically indicated.
45390820|NCT01027052|Other|Hamburger meat patty with salt|hamburger meat cooked with salt
45390821|NCT01027052|Other|Hamburger meat patty with spice blend|hamburger meat cooked with spice mixture
45390822|NCT00410514|Drug|Mirabegron|oral
45390823|NCT00410514|Drug|Placebo|oral
45390824|NCT03847610|Drug|Phenoxymethyl Penicillin|Phenoxymethylpenicillin tablets, 500mg every six hours for six doses, starting the day before study
45390825|NCT03847610|Device|Microneedle array|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.
45390826|NCT03995498|Other|Physical activity|Participants will engage in team sports exercise twice a day: from 9h:30 to 10h:30 and from 11h:00 to 12h:00.
45390827|NCT03995498|Other|FreeStyle Libre|Glucose levels will be measured by the FreeStyle Libre
45390828|NCT03995498|Other|SenseWear Armband|Energy expenditure during physical activity sessions will be measured with the SenseWear Armband.
45390829|NCT01036854|Drug|EUR-1025|orally, 24 mg, daily for 6 days
45390830|NCT01036854|Drug|EUR-1025|orally, 8 mg, twice daily over 6 consecutive days
45390831|NCT01036854|Drug|EUR-1025|orally, 8 mg, three times a day over 6 consecutive days
45390832|NCT01036854|Drug|EUR-1025|orally, 8 mg, 16 mg, 24 mg, daily, for 6 days
45390833|NCT03843632|Biological|VARIVAX™|VARIVAX™ administered by SC injection as 0.5 mL Varicella Virus Vaccine Live in sterile suspension on Day 1 (all participants) and Day 43 (adult and adolescent participants).
45390834|NCT01030796|Behavioral|Caffeine abstinence|Brief instruction on beginning and maintaining caffeine abstinence.
45390835|NCT03994718|Other|Music intervention|The music therapist will work with subjects for up to 60 minutes each session.
45390836|NCT03994718|Other|Visual arts intervention|The visual artist will work with subjects for up to 60 minutes each session.
45390837|NCT03994718|Other|Creative writing intervention|The creative writer will work with subjects for up to 60 minutes each session.
45390838|NCT00455858|Drug|insulin detemir|Treat-to-target dose titration scheme, once daily, injected s.c. (under the skin).
45390839|NCT00439556|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
45390840|NCT00439556|Biological|Anti-Thymocyte Globulin|Given IV
45390841|NCT00439556|Drug|Bortezomib|Given IV
45390842|NCT00439556|Drug|Carmustine|Given IV
45390843|NCT00439556|Drug|Cytarabine|Given IV
45390844|NCT00439556|Drug|Etoposide|Given IV
45390845|NCT00439556|Biological|Filgrastim|Given SC
45390846|NCT00439556|Drug|Melphalan|Given IV
45696534|NCT03495375|Other|Treatment with placebo|All participants will take the placebo once daily for 10 weeks.
45390847|NCT00439556|Drug|Methotrexate|Given IV
45390848|NCT00439556|Biological|Rituximab|Given IV
45696535|NCT00948298|Drug|Vitamin D|Two 50,000 IU tablets of oral Vitamin D3 will be given every 4 weeks.
45696536|NCT00948298|Drug|Placebo|Two tablets of oral placebo (microcrystalline cellulose),matching in appearance to the Vitamin D3, will be given every 4 weeks.
45696537|NCT05346783|Drug|TJO-083|Diquafosol ophthalmic sodium solution, 1 drop 3 times a day
45696538|NCT05346783|Other|Placebo (vehicle)|1 drop 6 times a day
45696539|NCT05346783|Drug|Diquafosol ophthalmic sodium solution 3%|Diquafosol ophthalmic sodium solution, 1 drop 6 times a day
45696540|NCT00948610|Drug|Remicade|Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.
45696541|NCT02245750|Device|Hysteroscopy|hysteroscopy and endometrial injury prior to the IVF/ICSI cycle
45390849|NCT00439556|Drug|Tacrolimus|Given IV and PO
45390850|NCT00410202|Drug|Entecavir|Tablets, Oral, 1mg, once daily, 100 weeks
45390851|NCT00410202|Drug|Tenofovir|Tablets, Oral, 300 mg, once daily
45390852|NCT00410202|Drug|Adefovir|Tablets, Oral, 10mg, once daily, 100 weeks
45390853|NCT00410202|Drug|Lamivudine|Tablets, Oral, 100mg, once daily, 100 weeks
45390854|NCT03802058|Drug|Nab-paclitaxel|Nab-paclitaxel 40mg/m2 for Injection weekly
45390855|NCT03802058|Drug|Carboplatin|Carboplatin AUC=2 for Injection weekly
45390856|NCT03802058|Radiation|Thoracic radiation therapy|Thoracic radiation therapy 60-66Gy/30-33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
45390857|NCT00445328|Drug|Dalteparin (Fragmin)|Dalteparin 5000 IU once daily subcutaneously for 6-14 days.
45390858|NCT00445328|Drug|Unfractionated heparin|Unfractionated heparin 5000 IU thrice daily subcutaneously for 6-14 days.
45390859|NCT00455312|Drug|Campath 1H|10, 9, 8, 7, and 6 days before transplant subjects will be given 1 dose of campath 1H given via catheter (0.2 mg/kg over 2 hours).
45390860|NCT00455312|Drug|Cyclophosphamide|7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).
45390861|NCT00455312|Drug|Fludarabine|6, 5, 4, 3, and 2 days before the transplant, 1 dose fludarabine is given via catheter (40 mg/kg IV over 1 hour)
45390862|NCT00455312|Procedure|Total Body Irradiation|1 day before the transplant one dose (200 cGy) of total body irradiation is given
45390863|NCT00455312|Procedure|Stem Cell Transplantation|Infusion of stem cells on Day 0.
45390864|NCT00455312|Drug|antithymocyte globulin|ATG (rabbit) 3 mg/kg for 3 days.
45390865|NCT00455312|Drug|Methylprednisolone|2mg/kg IV is given before each dose of antithymocyte globulin (ATG).
45390866|NCT01031030|Drug|cyclophosphamide|
45390867|NCT01031030|Drug|epirubicin hydrochloride|
45390868|NCT01031030|Drug|fluorouracil|
45390869|NCT01031030|Drug|methotrexate|
45390870|NCT01031030|Other|laboratory biomarker analysis|
45390871|NCT01031030|Procedure|adjuvant therapy|
45390872|NCT01031108|Drug|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight placebo capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
45390873|NCT01031108|Drug|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
45390874|NCT01024712|Drug|carboplatin|
45390875|NCT01024712|Drug|gefitinib|
45390876|NCT01024712|Drug|paclitaxel|
45390877|NCT01024712|Procedure|quality-of-life assessment|
45390878|NCT01031186|Drug|GSK356278|GSK356278
45390879|NCT01031186|Drug|PLACEBO|PLACEBO
45390880|NCT01323452|Drug|Entecavir|once daily
45390881|NCT03994640|Combination Product|Cannabis Cream|Topical, bilateral skin application of cannabis cream with self-massage of masseter muscles
45390882|NCT03994640|Combination Product|Placebo Cream|Topical, bilteral skin application of placebo cream with self-massage of masseter muscles
45502561|NCT03439657|Biological|Prevenar13|1 dose of 0.5 mL of the vaccine. Administered by intramuscular injection into the deltoid muscle of the dominant arm.
45502562|NCT02053220|Biological|Colo-Ad1|Oncolytic virus
45502563|NCT02056028|Procedure|Hepatic resection|
45390883|NCT00444626|Device|Dermal Gel Extra (DGE)|Dermal Gel Extra (DGE) Injectable Gel contains hyaluronic acid with lidocaine. DGE was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of DGE to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
45390884|NCT00444626|Device|Restylane|Restylane was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of Restylane to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
45390885|NCT00444626|Drug|EMLA Cream|EMLA Cream (Eutectic Mixture of Local Anesthetics) is an FDA-approved topical anesthetic comprised of 2.5% each of lidocaine/prilocaine. EMLA Cream was applied in approximately equal amounts prior to all injections of DGE and Restylane.
45502564|NCT01341743|Drug|Entecavir|patients will receive oral entecavir 1mg, daily for 104 weeks.
45390886|NCT01024790|Behavioral|Exercise group|24 week group exercise class supplemented with behavioral activation strategies
45390887|NCT01024868|Drug|Ropivacaine 0,5%|Injection of ropivacaine 0,5% 20 ml bilaterally before surgery
45390888|NCT04748120|Procedure|Operative management|Patients will undergo surgical removal of the affected organ. The initial approach will be in a minimally invasive, laparoscopic fashion. If necessary, conversion to an open operation may be performed. These patients will be treated preoperatively and postoperatively with similar antibiotic regimens, however the duration of antibiotic therapies will be dependent on factors such as intraoperative findings, resolution of laboratory abnormalities, and tolerance of oral medications.
45390889|NCT04748120|Procedure|Non-operative management|"Patients will be treated with 3 days of intravenous antibiotics followed by 7 days of oral antibiotics, as described below:~Non-penicillin allergic patients~piperacillin/tazobactam 3.375g IV every 6 hours for 3 days~amoxicillin/clavulanate 875/125mg by mouth every 12 hours for 7 days~Penicillin allergic patients~ertapenem 1g IV every 24 hours for 3 days~ciprofloxacin 500mg every 12 hours AND metronidazole 500mg every 8 hours for 7 days~Patients may be considered to have failed non-operative management (e.g. treatment failure) if they experience absence of clinical improvement, worsening abdominal pain and/or localized/diffuse peritonitis in the judgment of the treating surgeon at any point within the study window. If this occurs, then surgeons may proceed with rescue appendectomy or percutaneous drainage in the setting of appendicitis, or with placement of a percutaneous cholecystostomy tube in the setting of acute cholecystitis."
45390890|NCT03795194|Drug|ampicillin/clavulanate|FDA-approved antibiotic
45390891|NCT00404352|Drug|RNF|Single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months, or 36 months for patients enrolled in the OL extension.
45390892|NCT00404352|Drug|RNF|Single dose of RNF administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.
45502565|NCT01341743|Drug|Entecavir, Adefovir|patients in this arm will receive oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
45502566|NCT01341743|Drug|Entecavir, Adefovir|patients in this arm will receive oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
45502567|NCT02054858|Procedure|RIPC|Remote ischaemic preconditioning (RIPC) is a simple technique whereby brief periods of skeletal muscle ischaemia and reperfusion triggers a period of resistance to ischaemia-reperfusion injury in distant tissues eg. heart or kidney. In this study preconditioning will be performed Immediately prior to the patient undergoing a CT scan. A CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
45696542|NCT03032302|Dietary Supplement|Swisse Womens 50+ Ultivite Multivitamin|Single tablet taken once daily
45696543|NCT03032302|Dietary Supplement|Holland and Barrett Triple Strength Omega-3 Fish Oil|Single capsule taken once daily
45502568|NCT01341197|Other|Fecal immunochemical test, guaiac fecal occult-blood test, and Helicobacter pylori stool antigen test|
45502569|NCT01341275|Biological|hepatitis B vaccine|10 ug dose, one-time administration
45502570|NCT01341275|Biological|hepatitis B vaccine|20 ug dose, one-time administration
45502571|NCT02852161|Device|Magnet assissted capsule endoscopy|Patients due to have a clinically indicated gastroscopy will be asked to have a MACE procedure on the same day
45502572|NCT04783883|Device|Vestal DM|Battery powered non-invasive neurostimulation device (1.5mA)
45502573|NCT01353937|Drug|AMD3100 injection + rhPDGF-BB topical|drug therapy to be given for the first 2 week duration given on a daily basis initiated during the first visit (Day 0).
45502574|NCT04720001|Drug|Florbetaben F18|A single injection of 8.1mCi of florbetaben F18 will be administered by intravenous bolus injection
45848775|NCT01385280|Other|enzyme-linked immunosorbent assay|Correlative studies
45390893|NCT00404352|Drug|Placebo|Placebo was supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 mL.
45390894|NCT03994380|Drug|RhDNAse Inhalation Solution|rhDNAse 2.5 mg nebulizer daily for 4 weeks
45390895|NCT00439244|Drug|Zoledronic acid|Zoledronic acid 5.0 mg in a ready-to-infuse plastic bottle with a total fill volume of 103 mL to allow an infusion of 100 mL total volume corresponding to 5 mg of zoledronic acid.
45390896|NCT00439244|Drug|Placebo|Zoledronic acid matched placebo as a 103 mL solution of sterile water (physiologic 0.9% normal saline) to allow an infusion of 100 mL total volume in a ready-to-infuse plastic bottle
45390897|NCT00439244|Drug|Teriparatide|"Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. Each pre-filled delivery device is filled with 3.3 mL to deliver 3 mL.~Each mL contains 250 μg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetate acid, 0.10 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3.0 mg Metacresol, and water for injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4. Each cartridge pre-assembled into a pen device delivers 20 μg of teriparatide per dose each day for up to 28 days."
45390898|NCT01031342|Procedure|Early colonoscopy|Colonoscopy within 12 hours of presentation
45390899|NCT01031342|Procedure|Elective colonoscopy|Colonoscopy 36-60 hours after presentation
45390900|NCT04844762|Behavioral|Menthol cigarettes substitutes|In Phase 1, participants will complete 4 smoking sessions using a different product each session to examine each product's abuse liability.
45390901|NCT04844762|Behavioral|Usual brand menthol cigarettes and substitutes|In Phase 2, to assess uptake, changes in subjective effects, and use over time, participants will select their preferred study product from Phase 1 and be instructed to completely substitute the product for their usual brand menthol cigarette for one week.
45390902|NCT04844762|Behavioral|Menthol cigarettes substitutes and menthol cigarettes|In Phase 3, participants will complete a final in-lab visit to assess the substitutability of their preferred product from Phases 1 and 2, under simulated ban conditions using a progressive ratio task.
45390903|NCT03794024|Device|The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator|The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
45390904|NCT03794024|Device|The Axium Neurostimulator System|The Axium Neurostimulator System is indicated for spinal column stimulation via epidural and intra-spinal lead access to the dorsal root ganglion as an aid in the management of moderate to severe chronic intractable pain of the lower limbs in adult patients with Complex Regional Pain Syndrome Types I and II
45390905|NCT01323218|Drug|25 OH vitamin D|After written informed consent, patients will be randomized to receive a single dose of oral vitamin D (400 000 UI) or placebo. Subjects will undergo medical screening before randomisation into placebo or active group. Follow-up measurements will be performed at the beginning (day 0) and after 32 days of vitamin D supplementation: clinical examination, biological check up and sleep parameter evaluation. Patients will be instructed to stop using continuous positive airway pressure device for two nights before nocturnal sleep studies
45390906|NCT01323296|Other|Ferumoxytol|One dose of intravenous ferumoxytol (4 mgFe/kg body weight at a rate of up to 1 mL/sec)
45390907|NCT00438464|Drug|Finasteride|Given PO
45390908|NCT00438464|Other|Placebo|Given PO
45390909|NCT00438464|Procedure|Prostatectomy|Undergo prostatectomy
45390910|NCT00438464|Other|Laboratory biomarker analysis|Correlative studies
45390911|NCT00437294|Drug|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily, 21-day cycles until progressive disease
45390912|NCT00437294|Drug|placebo|oral, daily, 21-day cycles until progressive disease
45390913|NCT00437294|Drug|capecitabine|1250 mg/m^2, BID, days 1-14 of each 21-day cycle until progressive disease
45390914|NCT01033760|Drug|raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine|raltegravir (Isentress®): 400 mg bid. maraviroc (Celsentri®): 150 mg bid. darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
45390915|NCT01033760|Drug|darunavir; ritonavir; emtricitabine/tenofovir|darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
45390916|NCT00436982|Device|Cemented Triathlon total knee system|Orthopaedic implant
45390917|NCT00436982|Device|Duracon total knee system|Orthopaedic implant
45390918|NCT00443846|Biological|RotaTeq®|Rotavirus vaccine, live, oral, pentavalent, 2 mL solution for oral administration.
45390919|NCT00443846|Biological|NeisVac-C®|Meningiococcal Group C Polysaccharide Conjugate Vaccine Absorbed, 0.5 mL suspension for intramuscular injection.
45390920|NCT01027208|Drug|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m²
45390921|NCT03619772|Other|Bilateral|Participants will control game using EMG from both upper limbs.
45390922|NCT03619772|Other|Unilateral|Participants will control game using EMG from the more impaired upper limb.
45390923|NCT01031732|Procedure|MIS-2 THA|MIS two-incision THA
45696544|NCT04097002|Biological|ORCA-010|The investigational new drug ORCA-010 is a novel and improved oncolytic adenovirus based on the adenovirus serotype 5 (Ad5) genome. ORCA-010 replicates specifically in cancer cells and not in normal tissue cells. Its replication has been shown in a wide variety of cancer cell types, and it is not limited to prostate cancer.
45390924|NCT01031732|Procedure|MIS-WJ|MIS-Watson Jones THA
45390925|NCT01031732|Procedure|MIS-AL THA|Transgluteal approach
45390926|NCT01031732|Procedure|MIS-PL THA|Posterolateral approach
45390927|NCT02923544|Procedure|YUMI manipulator|
45390928|NCT01033838|Procedure|rectosigmoid resection|
45390929|NCT01033994|Biological|AS902330|10, 30 or 100 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30 or 100 µg intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
45848776|NCT01365156|Procedure|Extraperitoneal laparoscopic lymphadenectomy (EPLND)|Laparoscopic surgical procedure to remove and examine lymph nodes in abdomen, 7-10 days before chemoradiation treatment
45390930|NCT02911610|Device|arthroscopy + volar plate|surgery of wrist fractures with volar plate and added arthroscopy
45390931|NCT02911610|Device|Volar plate|surgery of wrist fractures with volar plate
45390932|NCT01031888|Drug|Topical insulin eye drops|Regular insulin injection diluted to 100U/ml After the day of surgery, besides topical steroid, antibiotic and mydriatics, the patient receives topical insulin eye drops every two hours, except from 10pm to 8am, until the epithelial defect is totally closed
46056849|NCT02724189|Other|Nurse led assessment|Standard practise is where patients undergo a face to face preoperative assessment led by a qualified nurse specialising in this field.
46056850|NCT04021654|Procedure|Data collection|Data collection of growth, neuromotor, sensorial, behavioral, and cognitive development.
45390933|NCT01031888|Drug|Conventional postoperative eye drops|topical steroid, antibiotic and mydriatics
45390934|NCT00436826|Drug|Cladribine|Participants were administered with cladribine tablets orally as cumulative dose.
45390935|NCT00436826|Drug|Placebo|Participants were administered with placebo orally.
45390936|NCT00436826|Drug|Interferon-beta (IFN-beta)|Participants received IFN-beta therapy (Rebif® new formulation [RNF] 44 microgram [mcg] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.
45390937|NCT00410124|Drug|RAD001|The dose of RAD001 was 10 mg/day. Patients were instructed to take two tablets (5 mg each) by mouth every day.
45390938|NCT00410124|Drug|Placebo|
45390939|NCT01036932|Drug|Granulocyte Colony Stimulating Factor|Dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
45390940|NCT01036932|Drug|Normal Saline|dose of 1ml s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
45390941|NCT00410046|Drug|Enbrel (etanercept)|Etanercept 50 mg SC injection once weekly
45390942|NCT00416624|Drug|darbepoetin alfa|
45390943|NCT00416624|Drug|epoetin alfa|
45390944|NCT00416624|Procedure|fatigue assessment and management|
45390945|NCT00416624|Procedure|quality-of-life assessment|
45390946|NCT02501954|Drug|Cisplatin|Given IV
45696545|NCT04053166|Device|individualized home-based physical activity|Subjects will have to reach a daily goal in number of steps, based on the initial evaluation, during 6 months . They will wear connected wrists, and will be contacted twice a month by phone call by an adapted physical activity to revaluate these goals.
45390947|NCT02501954|Drug|Carboplatin|Given IV
45390948|NCT02501954|Drug|Paclitaxel|Given IV
45390949|NCT02501954|Radiation|Radiation Therapy|Undergo Radiation Therapy
45390950|NCT01037504|Drug|AZD5423|Suspension for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days. Starting dose as determined from SAD study and with up to 4 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
45390951|NCT01037504|Drug|Placebo|Solution for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days.
45390952|NCT00262600|Drug|warfarin|once a day
45390953|NCT00262600|Drug|Dabigatran dose 1|twice daily
45390954|NCT00262600|Drug|Dabigatran dose 2|twice a day
46056851|NCT05294523|Procedure|Rocuronium priming dose|Add the priming dose of rocuronium after the first supramaximal stimulation data measured
46056852|NCT04640662|Biological|Platelet-Rich Plasma|Single-injection of 2 ml PRP into the lesion under ultrasound-guided
45390955|NCT00409578|Drug|Placebo|Placebo tablets and capsules. In order to adequately blind the study, patients were required to take a total of 1 tablet and 2 capsules during the first 4 weeks of the study. During the remainder of the study, patients were required to take 2 tablets and 2 capsules. Each dose was taken by mouth with water at approximately 8:00 AM with or without food.
45390956|NCT00409578|Drug|Aliskiren 300 mg|Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
45502575|NCT04720001|Device|PET|PET Scan for brain imaging
45502576|NCT02878213|Device|D700 System|Atrial Fibrillation Ablation Procedure
45502577|NCT04705883|Drug|Prasterone (DHEA), Micronized|Vaginal prasterone 6,5mg/24h first month, next 5 months 6,5mg/48h, vaginal administration.
45502578|NCT04677491|Drug|Ospemifene 60 mg|Ospemifene vs placebo
45696546|NCT04053166|Other|MRI|An MRI will be performed for each patient at the end of the study to identify IPH and other features of histological vulnerability (lipid core, fibrous cap integrity and calcifications).
46056853|NCT04640662|Biological|Prolotherapy|Single-injection of 2ml dextrose 16.5% into the lesion under ultrasound-guided
46056854|NCT02723877|Drug|PQR309|Dual phosphatidylinositol 3-kinase phosphoinositide 3-kinase/ mammalian target of rapamycin Inhibitor (= PI3K/mTOR Inhibitor)
46056855|NCT02723877|Drug|Eribulin|non.taxane microtubule dynamics inhibitor
46056856|NCT00736879|Drug|Dapagliflozin|Tablets, Oral, Once Daily, Up to 24 weeks
46056857|NCT00736879|Drug|Placebo|Tablets, Oral, Once Daily, Up to 24 weeks
45390957|NCT00409578|Drug|Valsartan 320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
45390958|NCT00409578|Drug|Aliskiren/valsartan 300/320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
45390959|NCT03884088|Other|Limits of Stability|Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
45390960|NCT03881436|Diagnostic Test|MRI with DTI sequence|"At the end of the planned sequence, but before any contrast agent injection:~Acquisition of a an additional anatomical T2 SPACE sequence~Acquisition of a tractography DTI sequence"
45390961|NCT03880500|Other|Spinal Manipulative Therapy|The patient lies in sidelying position, with the hip of the upper leg flexed to 90° and the foot of the flexed leg hooked behind the popliteal space of the downside leg. The chiropractor faces the subject at a 45°-angle, fixates the flexed knee with his own knee/thigh. The fingers of the cephalic hand reach under the patient's upper arm to contact the upside lateral surface of the superior spinous process. The fingers of the caudal hand hook down-side aspect of the spinous process, the forearm contacts the patient's buttock and thigh. The cephalic hand thrusts lateromedially and caudocranially, from upside toward downside (push). The caudal hand thrusts lateromedially in the opposing direction, from downside toward upside (pull). SMT is repeated after the patient turns to left side lying.
45390962|NCT01037322|Drug|cannabidiol|cannabidiol given in olive oil drops, 5 mg twice daily
45390963|NCT01037322|Drug|placebo in drops|olive oil containing no drug given in drops twice daily
45390964|NCT01039818|Radiation|Radioiodine|A unique dose of 200µCi of ¹³¹I/ml/24-RAIU
45390965|NCT01039818|Radiation|Radioiodine|A unique dose of 250µCi of ¹³¹I/ml/24-RAIU
45390966|NCT03827694|Diagnostic Test|Non-Invasive Testing for PIFI|galactomannan assay, fungal PCRs, cell-free next-generation DNA/RNA sequencing, RNAseq
45390967|NCT01070758|Drug|Lanreotide autogel|The dose of Lan-ATG will be calculated according to the surface area of the patient. The dose used in adults is usually 60 mg injection once a month, and we will adapt the patient's dose according to the body surface area and also according to the daily dose of Octreotide used with the pump. The starting dose will be 40 mg/m².
45390968|NCT01039896|Drug|Period I : SLM0807, Period II : HKB0701 and SLM0807|
45390969|NCT01039896|Drug|Period I : HKB0710 and SLM0807, Period II : SLM0807|
45390970|NCT00428090|Drug|Rosiglitazone|XR (extended release) oral tablets
45502579|NCT04677491|Behavioral|fMRI experiments|Participants will see sexually explicit video clips that alternate with non-sexual clips and neutral color projection and b) smell alternate pheromones with clear air and pine aroma.
45502580|NCT02053298|Drug|Timolol & Dorzolamide|Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
45696547|NCT04053166|Biological|blood sampling|Blood will be collected, to analyse monocyte phenotype by flow cytometry, blood rheology by ektacytometry, coagulation by rotational thromboelastometry (ROTEM). Plasma will be extracted from blood to assess inflammation, oxidative stress and antioxidant markers.
45696548|NCT04053166|Other|Questionnaires|sedentary, physical activity, nutrition and quality of life questionnaire will be performed fo each patient.
45390971|NCT00416312|Device|Patient-specific dosimetry|"Tumor absorbed dose calculation using patient-specific 3D-RD dosimetry software.~Patients receive dosimetric tositumomab IV over 60 minutes followed by iodine I 131 (^131I) tositumomab IV over 20 minutes on day 0. Patients undergo PET/CT scans and SPECT/CT scans on days 0; 2, 3 or 4; and 6 or 7. Patients who have acceptable biodistribution receive therapeutic tositumomab IV over 60 minutes followed by ^131I tositumomab IV over 20 minutes on approximately day 7."
45390972|NCT00416312|Device|conventional dosimetry|"Doses calculated using conventional dosimetry software.~Patients receive dosimetric rituximab IV followed by indium In 111 (^111In) ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo positron emission tomography (PET)/CT scans and single-photon emission computed tomography (SPECT)/CT scans between 2-24, 48-72, and 90-120 hours after ^111In ibritumomab tiuxetan administration. Patients who have acceptable biodistribution receive therapeutic rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes between days 7-9."
45390973|NCT01031966|Biological|MF59 adjuvanted H1N1 influenza monovalent vaccine|One/two single administration
45390974|NCT01031966|Drug|Thymosin alpha 1|1.6 mg, 3.2 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
45390975|NCT01031966|Drug|Thymosin alpha 1|1.6 mg, 6.4 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
45390976|NCT00436436|Drug|O6-benzylguanine|
45390977|NCT00436436|Drug|temozolomide|
45390978|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once daily (QD) tablet + emtricitabine (FTC) 200 mg QD + tenofovir disoproxil fumarate (TDF) 300 mg QD
45390979|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg QD soft gel capsule (SGC) + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 800/200 mg QD Tablet + FTC 200 mg QD + TDF 300 mg QD
45390980|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice daily (BID) tablet + FTC 200 mg QD + TDF 300 mg QD
45390981|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg BID SGC + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 400/100 mg BID Tablet + FTC 200 mg QD + TDF 300 mg QD
45390982|NCT00436280|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or 3 years
45696549|NCT04053166|Other|6-minute walk test|The 6-minute walk test is a simple, individualized test that measures how fast a patient walks on a flat, hard surface for 6 minutes.
45696550|NCT03995212|Drug|CR845 1.0 mg|Oral CR845 1.0 mg administered twice daily
45696551|NCT03995212|Drug|Placebo|Oral Placebo administered twice daily
45696552|NCT05430958|Drug|INO-4800|INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.
45696553|NCT05430958|Drug|INO-9112|INO-9112 will be given in at various doses (dose of 0, 0.05, 0.10, 0.20 or 0.40 mg) in combination with INO-4800.
45696554|NCT05430958|Device|CELLECTRA® 2000|Electroporation (EP) using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800.
45390983|NCT00436280|Drug|gemcitabine|1000 mg/m², IV, once, every two weeks, four to eight 2 week cycles
45390984|NCT00436280|Drug|rituximab|375 mg/m², IV, once every 2 weeks, four to eight 2 week cycles
45390985|NCT00436280|Drug|oxaliplatin|100 mg/m², IV, once every two weeks, four to eight 2 week cycles
45390986|NCT00394836|Drug|Ofatumumab|Eight weekly infusions of ofatumumab. The first infusion of 300mg ofatumunab
45390987|NCT00394836|Drug|Ofatumumab|followed by 7 weekly infusions of 1000mg ofatumumab
45390988|NCT00250588|Behavioral|Problem solving skills training|See description in Results
45390989|NCT00250588|Behavioral|Asthma care coordination|See description in Results
45390990|NCT00250588|Other|Usual Care|Usual clinical care
45390991|NCT00416078|Behavioral|caregiver website support|caregiver access to website support for 6 months embedded in one year of customary care
45390992|NCT00416078|Behavioral|caregiver brief supportive phone calls|caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
46056858|NCT02608372|Other|LD|Participants ingested 5 g of Laminaria digitata followed by 30 g of corn starch mixed with 200 mL of water.
45696556|NCT05428930|Drug|CKDB-501B|Intramuscular injection CKDB-501B
45696557|NCT05428930|Drug|Botox®50U|Intramuscular injection Botox®50U
45696558|NCT03031834|Drug|Quinapril|
46056859|NCT02608372|Other|UP|Participants ingested 5 g of Undaria pinnatifida followed by 30 g of corn starch mixed with 200 mL of water.
46056860|NCT02608372|Other|CTR|Participants ingested 30 g of corn starch and 1 g of pea protein powder mixed with 200 mL of water.
46056861|NCT02718339|Behavioral|Intensive counseling|
45390993|NCT01040598|Biological|Omalizumab|Omalizumab, an anti-IgE monoclonal antibody is dosed on the basis of subject's weight and IgE levels. It is administered as a subcutaneous injection every 2 weeks or 4 weeks based on the total dose required.
45390994|NCT01039974|Drug|GSK962040|"GSK962040. Planned doses per cohort as follows:~Cohort 1 planned dose = 10 mg; Cohort 2 to be determined based on data from Cohort 1"
45390995|NCT01039974|Drug|Ketoconazole|400 mg
45390996|NCT01032122|Drug|rituximab|induction phase: 375mg/m² qw, 4wks; followed by maintenance phase: 375mg/m², every 8 wks; duration: 2 years.
45390997|NCT01040676|Behavioral|Automated Telephone Nutrition Support|See Intervention Group description.
45390998|NCT02481674|Drug|VX15/2503|VX15/2503 (pepinemab) is a humanized IgG4 monoclonal antibody and will be administered intravenously at a dose of 20 mg/kg. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
45390999|NCT02481674|Drug|Placebo|Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
45391000|NCT03819660|Drug|Amifampridine Phosphate 10 MG Oral Tablet|Oral tablets
45391001|NCT00394524|Device|Glucommander|Glucommander is a Computer-guided Intravenous (IV) insulin infusion protocol used for glycemic control in inpatients. This algorithm directs the administration of IV insulin in response to Blood Glucose (BG) measurement at the patient's bedside. In this study, the Glucommander program was loaded into a PalmOne (Zire 31, Tungsten E2 by Palm Inc.) handheld personal digital assistant (PDA) device. During the infusion, the nurse entered BG levels into the system and the computer recommended the insulin infusion rate and a variable time to check the next glucose testing. An alarm prompted the scheduled glucose check. The insulin infusion followed the formula: Insulin/Hour = Multiplier × (BG- 60).
45391002|NCT00394524|Other|Standard insulin infusion algorithm|Standard insulin infusion Algorithm is a standard paper form insulin infusion algorithm. The algorithm is divided into four columns based on empirically determined insulin sensitivity. The first column was for the most insulin-sensitive patients, and the fourth column was for the most insulin resistant patients. The majority of patients are started in the algorithm 1 column. Insulin resistant patients, such as those receiving glucocorticoids or receiving >80 units of insulin per day as outpatients, started in the algorithm 2 column. The insulin infusion rate was determined by the patient's BG level and was measured hourly until the patient was stable and within the target range. If BG targets were not achieved and the BG had not decreased by at least 60 mg/dL in the preceding hour, the patient was moved to the next column.
45391003|NCT01032278|Other|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline, before each chemotherapy visit, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
45391004|NCT01032278|Behavioral|Questionnaires|Symptom questionnaire completion at baseline, beginning of every third cycle of chemotherapy, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
45502581|NCT04653545|Diagnostic Test|HbA1c|"Blood will be taken as per requirement for patients being admitted to hospital. A small sample will be sent to the biochemistry department for measurement of HbA1 (by HPLC method).~All patients who are diagnosed with diabetes (or known to have diabetes) will have a foot examination and retinal and renal screening and cardiovascular assessment for diabetes complications."
45502582|NCT02054936|Drug|Rivaroxaban (Xarelto)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
45391005|NCT00409344|Drug|Dexmedetomidine|A continuous infusion of dexmedetomidine will be started at a dose of 0.8mcg/kg/hr. This will continue for no longer than 24 hours. Four hours post extubation the study drug wii be discontinued using a standard tapering protocol: 0.6mcg/kg/hr for 4 hours then 0.4mcg/kg/hr for 4 hours, then 0.2 mcg/kg/hr for 4 hours and then 0.1mcg/kg/hr for 4 hours and then turned off.
45391006|NCT00409344|Other|Normal Saline|Normal Saline will be given as the placebo and will administered at 0.8mcg/kg/hr
45391007|NCT01040754|Other|Acupuncture|This study follows a standardized acupuncture protocol for OA knee pain. Approximately 6 acupuncture needles are placed in the skin of the leg for 25 minutes.
45391008|NCT00415610|Drug|nicardipine|"Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours.~Started at 5mg/h~Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour *Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued."
45391009|NCT00394212|Device|Transoral Suturing|suturing of anastomosis
45391010|NCT00394212|Other|Sham Endoscopy|suturing not performed
45391011|NCT01722812|Drug|Cromoglicate|Twice daily topical treatment for 14 days
45391012|NCT01722812|Drug|Placebo|Twice daily topical treatment for 14 days
45391013|NCT01323842|Procedure|EDTU|bedside ultrasound imaging by the treating emergency physician
45502583|NCT02054936|Drug|Warfarin (Coumadin)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
45696559|NCT02982382|Other|Manipulative Therapy|Subjects will receive techniques of High Velocity and Low Amplitude (HVLA) or grade V manipulation to the lumbar region (lumbar roll), and pain education based on the biopsychosocial approach.
46056862|NCT02718261|Drug|Pantoprazole|
45391014|NCT01032356|Device|Wrist Extension Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
45391015|NCT00250432|Drug|caspofungin acetate|Caspofungin acetate 50 mg IV infusion (diluted with 9% saline) (following a 70-mg IV loading dose on Day 1); Caspofungin acetate 150 mg IV infusion (diluted with 9% saline) administered daily, over the course of ~2 hrs. Duration of Treatment - 14-90 days.
45391016|NCT03741478|Drug|OLANZapine 2.5 MG|"Olanzapine capsules (2.5mg) will be administered with the following dosing schedules for each arm:~Metabolic arm - 5mg on Day 0, 7.5mg on Day 1, and 10mg on Day 2~Cognitive arm - 5mg on Day 0, 10mg on Day 1"
45391017|NCT03741478|Drug|Placebo|Placebo capsules visually identical to those containing olanzapine will be administered according to the same dosing schedule for each arm.
45391018|NCT03741478|Drug|Insulin Lispro 100 UNT/ML|"Intranasal insulin spray (or placebo) will be administered on day 2 for each arm.~For the metabolic arm: 40 IU of intranasal insulin lispro will be administered at timepoint 0 during the pancreatic euglycemic clamp procedure.~For the cognitive arm: 160 IU of intranasal insulin lispro will be administered at about 11 am on day 2 prior to the MRI imaging and cognitive testing procedures."
45391019|NCT03741478|Other|Saline|Placebo saline spray visually identical to the intranasal insulin spray will be administered on day 2 for each arm according the same dosing schedules.
45391020|NCT00250276|Biological|Cervarix™|GSK Biologicals' vaccine against human papillomaviruses 16 and 18.
45391021|NCT02532088|Dietary Supplement|Oil Palm Phenolics|Palm fruit derived phenolics compound
45391022|NCT02532088|Dietary Supplement|Placebo|Placebo
45391023|NCT00249808|Drug|Efalizumab - anti-CD11a recombinant human monoclonal antibody|Participants will receive efalizumab 1.0 milligram per kilogram (mg/kg) (with an initial conditioning dose of 0.7 mg/kg) once weekly by subcutaneous injection for 12 weeks (first treatment [FT]). Depending on the response at Week 12, participants could receive additional 8 to 12 weekly injections of efalizumab 1.0 mg/kg.
45391024|NCT00278512|Biological|Autologous Stem Cell Transplant|Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning
45502584|NCT02802878|Device|Hybrid Training using Electrodes and Joint Motion Sensors|"Electrodes (Sekisui Plastics Co., Tokyo, Japan) will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and on the posterior thigh over the motor points of the medial and lateral hamstrings. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM).~A joint motion sensor (Mutoh Engineering Inc., Tokyo, Japan) will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group."
45502585|NCT02802878|Device|Isokinetic Training with Isokinetic Dynamometer|Low intensity exercises completed using isokinetic dynamometer (HUMAC NORM, Computer Sports Medicine Inc. (CSMi), Stoughton, MA) in isokinetic mode at approximately 40%1 RM.
45502586|NCT04782791|Drug|Nivolumab plus SOX|The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg and oxaliplatin 130mg/m2 on day 1, and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): BSA<1.25 m2, 40mg; 1.25<BSA<1.50 m2, 50mg; BSA>1.50 m2, 60mg. Day 15 to day 21 is the rest period.
45502587|NCT04782791|Drug|Nivolumab|The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg on day 1.
45502588|NCT04782791|Procedure|Gastrectomy|A standard D2 radical laparoscopic gastrectomy according to the CSCO clinical guidelines for the diagnosis and treatment of gastric cancer is planned 3-4 weeks after the last cycle of preoperative therapy.
45502589|NCT04773197|Behavioral|Beating the Blues (BtB)|Beating the Blues (BtB) is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.
45696560|NCT02982382|Other|Pain Education|Individuals will receive pain education based in a biopsychosocial approach
45696561|NCT02982382|Other|Sham|The individuals will receive a simulation of spinal manipulation (sham) involving manual contact over lumbar region totaling 5 minutes.
45696562|NCT00944554|Drug|Varenicline|Varenicline given twice a day or five weeks.
45696563|NCT00944554|Drug|Placebo|Placebo given twice a day or five weeks.
45696564|NCT03031990|Behavioral|In-person yoga for fertility group|The participants in this group will complete the Yoga for Fertility class at Pulling Down the Moon: An Integrative Center for Fertility. This consists of a 30 minute discussion session followed by a 60 minute Vinyasa style yoga class one time a week for a total of 6 weeks. Participants must attend at least 5 out of the 6 sessions to be included in the analysis.
45696565|NCT03031990|Behavioral|Online yoga for fertility group|The participants in this group will complete an online webinar of the Yoga for Fertility class and engage in a home yoga practice with the Pulling Down the Moon Yoga DVD. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
45696566|NCT03031990|Behavioral|In person discussion only group|The participants in this group will attend an in-person 30 minute discussion session at Pulling Down the Moon. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
45696567|NCT03031756|Device|glycine powder air-polishing (Air-Flows)Perio Powder|
45696568|NCT03031756|Device|ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland)|
45696569|NCT00944710|Drug|Atropine|Weekend atropine 1%
45696570|NCT00944710|Device|Plano lens|plano lens over the sound eye
45696571|NCT00944710|Drug|Atropine|Weekend atropine 1%
45696572|NCT00945100|Device|Eye Patch|42 hours patching per week (averaging 6 hours patching daily)
45696573|NCT00945100|Device|Eye Patch|2 hours patching daily
45391025|NCT00278512|Biological|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant will be performed after conditioning
45391026|NCT00278512|Drug|Cyclophosphamide|Causes prevention of the cell division
45391027|NCT00278512|Drug|ATG (rabbit)|A rabbit polyclonal antibody to lymphocyte
45391028|NCT00278512|Drug|G-CSF|Hematopoietic growth factor
45391029|NCT00278512|Drug|Campath-1h|Humanized monoclonal antibody against CD52 antigen
45391030|NCT00278512|Drug|Fludarabine|inhibits DNA synthesis or repair
45391031|NCT00278512|Drug|Tacrolimus|immune suppressive drug
45391032|NCT00278512|Drug|Mesna|Mesna is a drug used to protect the bladder from the effects of the chemotherapy drugs
45391033|NCT03974698|Procedure|Hemiarthroplasty|Radiological features comparing the femoral stem position is measured on the postoperative x-ray. Presence of heterotopic ossification is assessed on the 12 months follow up.
45391034|NCT01072240|Drug|rituximab [Mabthera/Rituxan]|As prescribed by physician
45391035|NCT00427934|Drug|Maraviroc|300 mg (2- 150 mg tablets) are administered by mouth twice a day (BID) for 12 weeks.
45391036|NCT00427934|Drug|Maraviroc Placebo|Placebo tablets to match active drug. Two tablets are administered by mouth twice a day (BID) for 12 weeks.
45391037|NCT03974542|Behavioral|telephone outreach|The navigator should make at least five (5) attempts to reach the participants on different days (at least one (1) attempt in weekend) and different time slots (at least one (1) attempt each in am, pm and evening). If the navigator only reached voice mail after the 1-month intervention period, a standard script will be read and a contact number will be provided.
45391038|NCT00435188|Behavioral|Multi-component physical activity counseling program|A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
45391039|NCT00427778|Device|incontinence ring|"Incontinence ring fitted to patient's anatomy (by choosing appropriate size). It is worn continually for the duration of the treatment period.~Intravaginal incontinence ring placed proximally in the posterior vaginal fornix. Knob located at mid-urethra."
45391040|NCT02848196|Radiation|Stereotactic Body Radiation Therapy|The schedule will be 3 fractions of 15 Gy up to a total dose of 45 Gy delivered every day with VMAT and Flattening filter-free (FFF) beams. Image-guided systems, including CBCT, will be used for all patients.
45391041|NCT00427700|Drug|clomiphene citrate|100mg PO on days 5-9 of the menstrual cycle
45391042|NCT00427700|Drug|raloxifene|100mg PO on days 5-9 of the menstrual cycle
45391043|NCT01324076|Drug|doxorubicin-eluting beads|
45391044|NCT01324076|Drug|sorafenib tosylate|
45391045|NCT01324076|Other|laboratory biomarker analysis|
45391046|NCT01324076|Other|pharmacogenomic studies|
45391047|NCT01324076|Other|pharmacological study|
45502590|NCT04773197|Behavioral|Entertain Me Well (EMW)|Entertain Me Well (EMW) is is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.
45502591|NCT04773197|Behavioral|Coaching|A coach will spend approximately 5-10 minutes after each session with the patient to link the C-CBT content with patient's disease specific experiences and to motivate them to continue the program. They will also spend approximately 5 minutes between sessions to motivate a patient to complete assignments and to remind them about starting the next session on time.
45696574|NCT05384236|Other|kinesiology taping|To apply kinesiology taping in plantar fascia
45696575|NCT05384236|Other|taping or Low-dye taping|To apply taping or Low-dye taping in plantar fascia
46056863|NCT02718261|Drug|Saline 0.9% (matching placebo)|
45391048|NCT01324076|Procedure|quality-of-life assessment|
45391049|NCT00409188|Biological|Tecemotide (L-BLP25)|After receiving cyclophosphamide, participants will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression is documented.
45391050|NCT00409188|Drug|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before first tecemotide (L-BLP25) vaccination.
45391051|NCT00409188|Drug|Placebo|A single infusion (IV) of 0.9% Saline solution instead of cyclophosphamide but in the same calculated dose will be given three days before first placebo vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with placebo at weeks 0; 1; 2; 3; 4; 5; 6 and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at week 13, until disease progression is documented.
45391052|NCT00434954|Drug|exenatide twice daily (BID)|subcutaneous injection (5 mcg or 10 mcg), twice a day
45391053|NCT00434954|Drug|premixed insulin aspart twice daily (BID)|subcutaneous injection (titrated appropriately), twice a day
45391054|NCT00276484|Drug|atorvastatin|Atorvastatin 80 mg tablet by mouth, once a day for 6 weeks
45391055|NCT00276484|Drug|atorvastatin|Atorvastatin 40 mg by mouth, once a day for 6 weeks
45391056|NCT00276484|Drug|ezetimibe|Ezetimibe 10 mg tablets by mouth, once a day for 6 weeks.
45391057|NCT00426842|Drug|Midodrine Hydrochloride|Alpha1-agonist, exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure.
45391058|NCT00434876|Drug|Quetiapine XR|Quetiapine is a second generation antipsychotic medication, which has also recently shown to be associated with properties of mood stabilization in bipolar disorder.
45391059|NCT00434876|Drug|Placebo.|Inactive or inert pill which will be used as a comparator.
45391060|NCT01072318|Drug|Letrozole|Letrozole 2.5mg
45391061|NCT01072474|Procedure|Capnography|Capnographic monitoring
45391062|NCT01072474|Procedure|Standard monitoring|Standard monitoring
45391063|NCT00276094|Drug|Ospemifene 30 mg|1 tablet (dose 30 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
45391064|NCT00276094|Drug|Ospemifene 60 mg|1 tablet (dose 60 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
45391065|NCT00276094|Drug|Placebo|1 tablet taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
45391066|NCT00276094|Drug|Nonhormonal vaginal lubricant|Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.
45391067|NCT03975088|Procedure|Sub-macular injection of Ranibizumab|In this study, authors describe a new surgical technique for the treatment of refractory non tractional DME. The technique consists of vitrectomy with ILM peeling with subretinal injection of Ranibizumab.
45391068|NCT00276016|Drug|phenylephrine|immediate-release 12 mg capsules for oral administration
45502592|NCT01341353|Procedure|catheter ablation|circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
45502593|NCT01341353|Drug|Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists|
45502594|NCT02056106|Drug|antidepressant therapy|
45502595|NCT05183087|Diagnostic Test|3T Connectome MRI|MRI scan of structural connectivity
45502596|NCT05183087|Diagnostic Test|7 Tesla MRI|MRI scan of functional connectivity
45502597|NCT05183087|Diagnostic Test|TSPO PET|PET scan of neuroinflammation
45391069|NCT00276016|Drug|pseudoephedrine|60 mg immediate-release tablets for oral administration
45391070|NCT00276016|Drug|placebo|placebo capsules
45391071|NCT00434642|Drug|Carboplatin|Carboplatin was provided as commercially available drug.
45391072|NCT00434642|Drug|Gemcitabine|Gemcitabine was provided as commercially available drug.
45391073|NCT00434642|Drug|Bevacizumab|Bevacizumab was supplied as a clear to slightly opalescent, sterile liquid in glass vials (400 mg in 8 mL [25 mg/mL]) with a vehicle consisting of sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
45391074|NCT00434642|Drug|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody and contained sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
45391075|NCT01032434|Drug|sertraline|sertraline: 50-200mg/day
45391076|NCT01032512|Dietary Supplement|SUPPORTAN + GLUTAMINE PLUS|600 ML OF AN ENERGY DENSE DRINK PLUS 20 G GLUTAMINE POWDER (to give 900 Kcal and 80 g protein/day)
45391077|NCT01032512|Dietary Supplement|NO PREOPERATIVE NUTRITION SUPPORT|Patients will be assessed and followed, but will receive no special nutritional support before the surgical procedure
45391078|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 milligram per kilogram (mg/kg) for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
45502598|NCT05183087|Diagnostic Test|Tau PET|PET scan of tau deposition
45502599|NCT05183087|Diagnostic Test|Cognitive and Behavioral Assessments|Assessments of memory, attention, complex reasoning, mood and other cognitive/behavioral domains
45391079|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered intravenously (IV) once every 4 weeks for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
45391080|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
45502600|NCT05183087|Diagnostic Test|Blood Biomarkers|Blood-based assessments of proteomic and metabolic biomarkers of brain injury
45502601|NCT02056184|Drug|Adalimumab|
45502602|NCT01341431|Drug|bee venom|12 monthly injections of 100 micrograms(in 1 milliliter of NaCl 0.9%) of bee venom s.c.
45502603|NCT02056262|Other|Dental cavity evaluation|The dental cavities present will be evaluated using the ICDAS (International Caries Detection and Assessment System).
45391081|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
45502604|NCT02056262|Biological|Saliva sampling|A saliva sample will be harvested.
45502605|NCT02056262|Biological|Plaque sampling|Plaque samples from a healthy tooth and a tooth with a cavity will be harvested.
45502606|NCT02801396|Device|Etafilcon A Design 1 (Test 1)|
45502607|NCT02801396|Device|Etafilcon A Design 2 (Test 2)|
45502608|NCT02801396|Device|Etafilcon A (Control)|
45391082|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
45391083|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
45391084|NCT01588964|Procedure|HIPEC|surgery plus HIPEC with the closed technique(perfusion of the abdominal cavity with a solution containing oxaliplatin 460 mg/m2 in 2L/m2 heated saline at 42°C).The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
45391085|NCT00426764|Drug|Romidepsin|Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-day cycle.
45391086|NCT01032590|Behavioral|Internet weight loss intervention|Participants will be advised to login to the website twice a week during the intervention period. They will be prompted to report their weight, to review and update their reasons for weight loss, to indicate their success with implementing each of their weight loss strategies, to rate the perceived effectiveness of each weight loss strategy,and to revise or create new strategies, as needed.
45502609|NCT02800928|Drug|CERC-501|CERC-501
45391087|NCT01034150|Device|Relief band (Somatosensory stimulation)|Electrical median nerve stimulation
45391088|NCT01034150|Device|Placebo stimulation|Placebo stimulation
45391089|NCT01032668|Drug|Clopidogrel|high dose clopidogrel continuing after percutaneous coronary intervention
45391090|NCT01034228|Other|ORS + Isoleucine|ORS with Isolelucine for treatment of diarrhoeal in children
45502610|NCT02800928|Drug|Placebo|Placebo
45391091|NCT01034228|Other|ORS without Isoleucine|ORS without Isoleucine for the treatment of diarrhoea in children
45391092|NCT00434252|Drug|bevacizumab|15 mg/kg by intravenous (IV) infusion on the first day of each 3-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
45502611|NCT02056418|Dietary Supplement|enteral nutrition|enteral nutrition only (Nutrison Fibre, 20-30kcal/kg/day)
45502612|NCT02056418|Drug|corticosteroid|corticosteroid(equal dose to prednisone 0.75mg/kg/day,4 weeks)
45391093|NCT00434252|Drug|carboplatin|Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 3-week cycle, for a maximum of 10 cycles
45502613|NCT02056496|Dietary Supplement|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with low punicalagin:EA ratio (PE-1). After 2 weeks of washout, the same group will also consume the other extract with high punicalagin: EA ratio (PE-2).
45502614|NCT02056496|Dietary Supplement|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with high punicalagin:EA ratio (PE-2) after 2 weeks of washout. The same group will also consume the other extract with low punicalagin: EA ratio (PE-1).
45502615|NCT02056574|Drug|NA-1|
45502616|NCT02056574|Drug|Placebo|
45696576|NCT03031600|Diagnostic Test|Radiodilution via Daxor BVA-100|The BVA-100 measures the hematocrit and residual plasma radioactivity of each sample in a semi-automated process, and the residual radioactivity is compared from that of the pre-injection sample to determine plasma volume. The plasma volume and BVA-100-measured hematocrit are then used to calculate the red cell volume and actual blood volume. The BVA-100 is FDA approved for blood volume measurement in vivo, has a reported precision of ± 2.5%, and has demonstrated accuracy and specificity in blood volume assessment in clinical and research settings (Van, P.Y., et al., 2011, Borovka, M., et al., 2013).
45391094|NCT00434252|Drug|paclitaxel|175 mg/m^2 by IV infusion on the first day of each 3-week cycle (dose was based on patient's weight and could be adjusted for weight change)
45391095|NCT00434252|Drug|placebo|Administered by IV infusion on the first day of each 3-week cycle
45391096|NCT01032746|Other|educational intervention|
45502617|NCT02058680|Biological|PSA/IL-2/GM-CSF|"In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.~In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43."
45848777|NCT01365156|Radiation|Chemoradiation|Radiation for 5 days in a row for 5 to 5½ weeks plus Cisplatin Chemotherapy cisplatin chemotherapy by vein over about 2 hours, 1 time every week for about 6 weeks.
45848778|NCT01350258|Drug|Fludarabine|Part of the conditioning regimen
45391097|NCT01032746|Other|internet-based intervention|
45391098|NCT01032746|Procedure|evaluation of cancer risk factors|
45391099|NCT01032746|Procedure|fecal occult blood test|
45391100|NCT01032746|Procedure|screening colonoscopy|
45391101|NCT00425750|Drug|bortezomib|1.6 mg/m2 through a vein on days 1 and 8 of a 21-day cycle. The first dose is given as a single agent only on Day 1 of Cycle 1.
45502618|NCT02058758|Device|Magnetic Resonance Imaging|MRI scanning with novel acquisition, reconstruction, and/or analysis methods.
45502619|NCT02058914|Dietary Supplement|high fructose sweetened beverage|710 ml per day of a HF-sweetened beverage
45502620|NCT02058914|Dietary Supplement|High Glucose sweetened beverage|HG-sweetened beverage
45502621|NCT02055014|Drug|Liraglutide|
45502622|NCT02055014|Device|Duodenal-jejunal bypass liner - Endobarrier device|
45848779|NCT01350258|Drug|Thiotepa|Part of the conditioning regimen
45848780|NCT01350258|Radiation|Total Body Irradiation (TBI)|There is one fraction of total body irradiation (2Gy) as part of the conditioning regimen.
45391102|NCT00425750|Drug|docetaxel|40 mg/m2 through a vein on days 1 and 8 of a 21-day cycle except the first dose is held only on Day 1 of Cycle 1.
45391103|NCT00425750|Other|laboratory biomarker analysis|Tissue and blood collection.
45391104|NCT00425750|Other|pharmacological study|Blood collection.
45391105|NCT03994250|Other|Kinematic Alignment for total knee replacement surgery|Using Kinematic Alignment for total knee replacement surgery
45502623|NCT03148691|Drug|A-101|Topical Solution
45391106|NCT03994250|Other|Mechanical Alignment for total knee replacement surgery|Using mechanical alignment for total knee replacement surgery
45391107|NCT00414908|Drug|Pancrelipase delayed release capsule|24,000 unit capsule
45391108|NCT00414908|Drug|Placebo Comparator|Placebo
45391109|NCT01037582|Drug|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924, at escalating dose levels. Progression to next dose will be based on safety evaluation.
45391110|NCT01037582|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN9924, at all dose levels.
45391111|NCT01037582|Drug|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924 in one of three different concentrations. The dose will be selected based on the results of part 1.
45391112|NCT01037582|Drug|placebo|Subjects will be randomized to receive a single dose of placebo.
45391113|NCT01037582|Drug|NN9924 (s.c.)|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit
45391114|NCT01037582|Drug|NN9924 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit.
45391115|NCT00242710|Drug|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
45391116|NCT00242710|Drug|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
45391117|NCT00242710|Drug|CE 0.45 mg/MPA 1.5mg|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
45391118|NCT00242710|Other|Placebo|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
45391119|NCT00408876|Drug|Duloxetine|
45391120|NCT00408876|Drug|Placebo|
45391121|NCT00240994|Drug|Alemtuzumab|Administered intravenously over a period of 2-3 hours. Two doses total, the first will be one day before transplant and the second will be on the day following transplantation. Pre-medication with methylprednisolone, acetaminophen, and Benadryl will be administered before each dose.
45696577|NCT03031600|Diagnostic Test|Hemodilution via hematocrit measurement|Hemodilution uses the ideal blood volume and serial hematocrit measures drawn before and after administration of a known quantity of IV fluid to estimate blood volume. Ideal blood volume is calculated using the methods described by Feldschuh and colleagues (Feldschuh, J. and Y. Enson, 1977; Feldschuh, J. and S. Katz, 2007). Hematocrit is measured using the Abbot iSTAT point of care testing device and the lab. Urine output is measured in ml. The ideal blood volume, pre and post-bolus hematocrit, fluid bolus volume, and urine output will be used to calculate estimated blood volume using a mathematical model previously described by the investigators (D'Angelo, M., et al., 2015).
45391122|NCT00240994|Drug|Tacrolimus|Administered orally at a dose of 0.05-0.1 mg/kg twice daily, beginning 1-3 days following transplantation and continuing until weeks 8-12. Tacrolimus will be discontinued and a treatment regimen with sirolimus will be initiated between weeks 8-12 but some overlap with these medications is possible.
45391123|NCT00240994|Drug|Mycophenolate mofetil|Per recommendation
45391124|NCT00240994|Drug|Sirolimus|Administered by either liquid or tablet every 12 hours from month 6 until month 24. Dosage will vary throughout the treatment course.
45391125|NCT01070836|Drug|natalizumab|Administered as specified in the treatment arm
45391126|NCT00239590|Drug|Testosterone undecanoate|Licensed for androgen deficiency
45391127|NCT00433160|Drug|Teriparatide|daily, subcutaneous
45391128|NCT00433160|Drug|Placebo|daily, subcutaneous
45391129|NCT00239356|Drug|Aripiprazole|Tablets, Oral, 10 - 30 mg, once daily, greater than 52 weeks depending upon Aripiprazole approval in respective country
45391130|NCT03974386|Device|oXiris blood purification set|Continuous venovenous hemofiltration and adsorption (CVVHA) with oXiris filter for up to 72 hours if required. The filter will be replaced every 24 hours. The setting of CVVHA is as follows: blood flow rate 200 mL/min, replacement fluid rate 2000 mL/hr, pre-dilution 50% and post-dilution 50%. If continuous renal replacement therapy is indicated after 72 hours, conventional hemofiltration filters will be used.
45391131|NCT00393510|Drug|TCM|"The Decoction is taken orally, twice a day, treatment period is 24 weeks The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.~The formula consisted of 12 herbs, viz:~Radix astragali, Rhizoma atractylodis marcocephalae, Radix stephaniae tetrandrae, Radix polygoni multiflori, Radix rehmanniae, Radix smilax china, Fructus corni, Rhizoma dioscoreae, Cortex moutan, Rhizoma alismatis, Rhizoma smilacis glabrae, and Fructus schisandrae"
45391132|NCT00393510|Drug|Placebo|"Placebo taking orally, twice a day, 24 week treatment period The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.~The placebo was made with starch and colouring materials."
45391133|NCT01040910|Drug|smoking of cannabis|smoking of cannabis, 2 cigarettes a day, equivalent to about 50 mg THC
45391134|NCT01040910|Drug|smoking cigarettes with placebo|smoking cigarettes with cannabis that was chemically treated so that most active ingredients were removed
45391135|NCT00425438|Drug|Mycophenolate Mofetil|0.5 g PO BID from Day 0 to the end of Week 1, followed by 1.0 g PO BID from Weeks 2 through 24, and 0.75 g PO BID from Weeks 32 to 48
45696578|NCT00949078|Drug|omalizumab|omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE
45696579|NCT00945256|Other|Aerobic Exercise|45 minuties of treadmill walking was completed at 40% VO2 peak
45391136|NCT00425438|Drug|Corticosteroids|0.75 to 1.0 mg/kg/d PO (up to 60 kg/day) from Weeks 1 through 4; reduced by 10 mg/day every 2 weeks until dose reaches 40 mg/day, followed by a reduction of 5 mg/day every 2 weeks until dose reaches 10 mg/day up to Week 48
45391137|NCT00425438|Drug|Azathioprine|100 mg PO daily for participants with a body weight of 50 to 70 kg,150 mg PO daily for subjects with a body weight of more than 70 kg up to Week 48
45391138|NCT00425438|Drug|Cyclophosphamide|0.75 g/m^2 IV every 4 weeks from Weeks 1 through 4, and 0.5-1.0 g/m^2 to maintain a minimum WBC count of ≥ 2500 per mm^3 from Weeks 5 through 24
45391139|NCT01041066|Drug|labetalol|0.4 mg/kg labetalol intravenously 4 min before intubation
45391140|NCT01041066|Drug|nicardipine|20 ㎍/kg nicardipine intravenously 4 min before intubation
45391141|NCT01323608|Drug|Vitamin D3|Vitamin D3 will be given at the equivalent of the following doses: 400, 1000, and 2000 IU/day.
45391142|NCT01323608|Drug|Placebo|Placebo
45391143|NCT00275002|Drug|O6-benzylguanine|Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. O6-Benzylguanine, 120 mg/m^2, will be administered as a one-hour intravenous (IV) infusion, daily for 5 days. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses of therapy.
45391144|NCT00275002|Drug|temozolomide|Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. Temozolomide, 75 mg/m^2 (rounded to the nearest 5 mg, the size of the smallest capsule) will be given orally, 30 minutes following the completion of each infusion of O6-Benzylguanine. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses.
45391145|NCT00433004|Drug|Plan B (Levonorgestrel)|PP TEENS ARE RANDOMIZED TO PLAN B + ROUTINE CONTRACETIVE CARE VS. ROUTINE CARE ALONE. QUESTIONNAIRES ON HEALTH STATUS, SEXUAL HISTORY, AND CONTRACEPTIVE USE ARE COMPLETED AT STATED INTERVALS.
45391146|NCT00238264|Radiation|radiation therapy|Undergo 3D-CRT Undergo proton radiation therapy Undergo IMRT
45391147|NCT00414596|Device|DRX9000™|Device is designed to apply spinal decompressive forces.
45391148|NCT00393042|Drug|Dexmethylphenidate|10, 20, 25-30 mg.
45391149|NCT00393042|Drug|Mixed Amphetamine Salts, ER|10, 20, 25-30
45391150|NCT00393042|Drug|placebo|randomized placebo week during each 4 week period
45391151|NCT03742362|Device|MRI scans of distal radius|MRI scans to monitor the fat fraction in the bone marrow of the distal radius
45391152|NCT00392808|Biological|conjugated polysaccharide menC vaccine|Booster vaccine dose at 14 to 18 months.
45391153|NCT03766464|Diagnostic Test|Evaluation of TMD and pain sensitivity|Extra and intraoral clinical examination will be performed and the Diagnostic Criteria for Temporomandibular Disorders (DC / TMD) questionnaire will be applied. Measurements shall be bilateral in the masseter, anterior temporal and tenar muscles and the arithmetic mean between three measurements will be considered the value for each side for pain sensitivity analysis with an dynamometer.
45391154|NCT03766464|Diagnostic Test|Evaluation of SB|The presence or absence of SB will be diagnosed by Polysomnography
45391155|NCT03766464|Diagnostic Test|Evaluation of AB|A smartphone will be used, which was developed for a momentary evaluation that allows a report of the exact moment of AB and its possible associated symptoms.
45391156|NCT01041144|Behavioral|lifestyle counseling|supporting diabetes patients using Internet communication
45391157|NCT01040286|Drug|Flurbiprofen|2.0 mg
45391158|NCT01040286|Drug|Chlorhexidine|2.5mg
45391159|NCT01041222|Drug|ISIS 333611|5 arms of 12 hour infusion: Arm 1 0.15 mg, Arm 2 0.5 mg, Arm 3 1.5 mg, Arm 4 3.0 mg, matching volume of placebo
45391160|NCT01041300|Device|Magstim Rapid2 Stimulator|"Duration: Time is takes to find motor thresholds obtained with figure-8 coil using Magstim Rapid2 Stimulator (Estimated at 15 minutes).~Total Duration of device: 15 minutes"
45391161|NCT01041300|Device|Brainsway Multi-channel Stimulator|"Finding motor thresholds using the figure-8 coil and the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of leg obtained with Double Cone coil using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of leg obtained with circular coils using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of thumb obtained with circular coils on multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 1 hour).~Finding specificity of the motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 30 minutes).~Total Duration with Device: 2 hours and 30 minutes"
45391162|NCT03761550|Combination Product|pMDT(Process Implementation)|The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
45391163|NCT01041378|Drug|dexamethasone|Intravenous dexamethasone (0.5mg/kg) before incision
45391164|NCT03546192|Biological|Fluzone Quadrivalent Influenza Vaccine|0.5-mL, Intramuscular, SH 2015 formulation
45391165|NCT01043796|Other|Insecticide treated nets and wall liners|Participants will be provided a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme. Households where participants reside will be fitted with insecticide treated wall liners.
45391166|NCT01043796|Other|Insecticide treated nets alone|Participants will be provided with a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme
45391167|NCT01043952|Drug|Propofol|Propofol is used as an anesthetic drug on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
45391168|NCT01043952|Drug|Remifentanil|Remifentanil is used as analgesic drug, as a part of the total intravenous anaesthesia, on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
45502624|NCT02059226|Behavioral|cognitive behavioural therapy|Internet-based CBT
45502625|NCT02059226|Other|Internet-based resource page|Static webpage
45502626|NCT02059304|Device|Measurement of cervical length with embryo transfer catheter|
45502627|NCT03148067|Procedure|Intramedullary nailing for fracture fixation|
45391169|NCT01043952|Device|Bispectral Index Monitor|Bispectral Index Monitor (BIS monitor integrated in the IntelliVue Patient monitor MP70, Philips) is used to monitor the depth of anesthesia. The values this monitor reports are used as an aid in evaluating the response of the single patient to the administered anesthetics, and as a guide in adjusting the dosing of anesthetics. We follow the algorithm from: http://www.biseducation.com/assets.aspx?ac=1 (ASA Practice Advisory White Paper)
45502628|NCT02059382|Behavioral|ChiRunning training|
45502629|NCT02059382|Behavioral|unblinded accelerometer|
45391179|NCT03973450|Other|Registration of familial forms and associated neoplasia|Retrospective registration of associated endocrine and non-endocrine neoplasia and potential familial setting
45391180|NCT00274846|Biological|aldesleukin|10 million units three times a week for a total of 6 doses. For any subject less than 45 kilograms the IL-2 will be given at 5 million units per meter squared three times weekly for a total of 6 doses
45696580|NCT00945256|Drug|Sodium Nitroprusside|Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
45696581|NCT00945256|Dietary Supplement|Amino Acid Drink|7.5 gram Amino Acid drink
45391181|NCT00274846|Biological|therapeutic allogeneic lymphocytes|Cells infused per kg. 1.5-8.0 x 10^7/kg Total cells infused(for 70 kg. adult) 1.05 - 5.6 x 10^9
45391182|NCT00274846|Drug|cyclophosphamide|Days -5 and -4: 60 mg/kg
45391183|NCT00274846|Drug|fludarabine phosphate|Days -5 through -2: 25 mg/m^2
45391184|NCT00274846|Procedure|in vitro treated peripheral blood stem cell transplantation|Day 0 infuse natural killer cells
45391185|NCT01073722|Device|Placement of double lumen tube for one-lung ventilation|The gold standard for lung isolation is the use of a double lumen tube (DLT). A DLT is a bifurcated tube with a bronchial and a tracheal lumen.
45391186|NCT01073722|Device|Placement of EZ- Blocker for one-lung ventilation|Bronchial blockers are balloon-tipped semi-rigid catheters. Different types are available. They are not easy to put in position and frequently dislocates during repositioning of the patient or during surgical manipulation. To solve these problems, a novel type of bronchus blocker, i.e. the EZ- Blocker® is developed. The EZB is also a semi-rigid catheter but it has two distal extensions, both with an inflatable cuff and a central lumen. These improvements owe to the fact that the blocker anchors itself on the carina with the two extensions.
45391187|NCT01072708|Other|Prospective cohort with an annual follow-up|"Annualfollow-up including :~oral glucose tolerance test~dietary survey~biological evaluation~bacteriological and respiratory measures~dual-energy x-ray absorptiometry~physical activity survey"
45391188|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 1|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 1 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3-3´D4Δ30, 10^3 PFU of rDEN4Δ30)
45502630|NCT02059382|Behavioral|participation in online social network|
45502631|NCT02059382|Behavioral|participation in study website|
45502632|NCT02059382|Behavioral|Technology support for behavior change|
45502633|NCT02055170|Drug|finasteride 5mg oral daily|
45502634|NCT04552925|Other|Rehabilitation|Exercises and rehabilitation for massive rotator cuff tears
45502635|NCT02055326|Behavioral|Cognitive Behavioral Therapy for Smoking Cessation|one hour weekly for 8 weeks. Cognitive behavioral therapy for smoking cessation
45502636|NCT02055326|Behavioral|Yoga|One hour, twice weekly for 8 weeks of vinyasa yoga
45502637|NCT02055326|Behavioral|Health & Wellness|Lectures, handouts and printed materials on general health and wellness topics including healthy eating, cancer prevention and cardiovascular disease prevention.
45502638|NCT03561116|Dietary Supplement|XAN|Daily intake of a sachet containing 12 mg of XAN
45502639|NCT03561116|Dietary Supplement|Placebo|Daily intake of a sachet containing excipient
45696582|NCT00940576|Dietary Supplement|mare´s milk|oral intake of 250 ml mare's milk first, then placebo drink daily during 8 weeks of each (cross over design)
45696583|NCT00940576|Other|placebo drink|oral intake of 250 ml placebo drink first, then mare's milk daily during 8 weeks of each (cross over design)
45696584|NCT05354752|Drug|VC005 tablets|VC005 groups repeat administration for 7 days
45696585|NCT05354752|Drug|VC005 Placebo tablets|VC005 placebo groups repeat administration for 7 days
45848781|NCT01350258|Biological|Donor Lymphocyte Infusion (DLI)|Immediately following the conditioning regimen of fludarabine, thiotepa, and TBI, the patient receives a set dose of their donor's T cells (DLI), After the DLI, the donor's T cells will react with the remaining parts of the recipients immune system.
45848782|NCT01350258|Drug|Melphalan|Two days after the DLI, Melphalan will be given to eliminate the reacting T cells to avoid graft versus host disease. Non-activated T cells should not be affected by the Melphalan and remain to help fight infection.
45848783|NCT01350258|Device|Hematopoietic stem cell transplantation (HSCT)|"One day after the Melphalan ends, the patient will receive their donor's stem cells. This is the actual day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
45391189|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 2|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 2 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3-3´D4Δ30, 10^3 PFU of rDEN4Δ30-200,201)
45391190|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 3|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 3 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, 10^3 PFU of rDEN4Δ30)
45391191|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 4|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 4 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, 10^3 PFU of rDEN4Δ30-200,201)
45391192|NCT01072786|Biological|Placebo|One subcutaneous injection of a placebo containing vaccine diluent but no actual vaccine
45391193|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 5|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 5 (10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
45391194|NCT01071460|Device|FlexStent Femoropopliteal Self-Expanding Stent System|"Peri-procedural management will be no different to routine SFA/Popliteal Artery intervention Standard medical therapy~Procedural techniques will be identical to routine protocols for SFA/Popliteal Artery stenting. technique suggested:~Contralateral retrograde common femoral cross-over access or antegrade access~Target lower limb arteries fully imaged angiogram. with measurement of SFA/Popliteal Artery target lesion length and normal vessel diameter immediately above and below target lesion~Pre-stenting balloon dilatation of target lesion in all total occlusions and critical stenosis~Deployment of an appropriately sized FlexStent® to cover target lesion~Post-stent balloon dilate stent using a semi-compliant angioplasty balloon to enable accurate post-dilatation of stent to target diameter~Post stenting angiography assessing target lesion parameters, run-off vessel patency and complications"
45391195|NCT03974308|Other|Comprehensive physiotherapy including balneotherapy and filling questionaire|Three-week stay in a sanatorium with comprehensive physiotherapy including balneotherapy and three time filling questionaire.
45391196|NCT03974308|Other|Comprehensive physiotherapy without balneotherapy and filling questionaire|Two-week outpatient treatment with comprehensive physiotherapy without balneotherapy and three time filling questionaire
45391197|NCT03974308|Other|No intervention, only filling questionaire|No physiotherapy nor balneotherapy applied but three time filling questionaire
45391198|NCT03970798|Drug|Midazolam|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
45391199|NCT03970798|Drug|Caffeine|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
45391200|NCT03970798|Drug|Rosuvastatin|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
45391201|NCT03970798|Drug|KW-6356|In Period 2, Day 4-13(except Day11) a single dose of KW-6356 will be administered after breakfast, Day 11 a single dose of KW-6356 will be administered after fasting for at least 10 hours.
45696586|NCT05330182|Drug|LMN-201|"LMN-201 consists of orally delivered whole, dried, non-viable biomass of spirulina (Arthrospira platensis) grown from 4 separate strains, each of which has been engineered to express one of the following therapeutic proteins:~3 toxin-binding proteins that bind and inhibit C. difficile toxin B (TcdB), an essential virulence factor for C. difficile~1 lysozyme-like enzyme that selectively degrades the cell wall of C. difficile and causes rapid destruction of the organism"
45696587|NCT05330182|Drug|Placebo|Doses of placebo will be delivered as identical-appearing cornstarch with coloring in size 00, white, opaque, capsules.
45391202|NCT00237796|Behavioral|Cognitive Behavioral Social Skills Training (CBSST)|Thought challenging, social communication skills, and problem solving skills are trained in group therapy 2 hours per week for 9 months.
45502640|NCT04490993|Drug|APL-1202 in combination with Epirubicin|"Induction period: APL-1202 is administered for 12 consecutive weeks~Maintenance period: after 12-week drug free period, APL-1202 is administered for another12 consecutive weeks as maintenance treatment~Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months"
45696588|NCT03854032|Biological|Nivolumab|Given IV
45391203|NCT00237796|Behavioral|Goal Focused Supportive Contact (GFSC)|Active goal setting and supportive contact in group therapy 2 hours per week for 9 months.
45391204|NCT03970876|Biological|ATGC-100|Clostridium Botulinum Type A
45391205|NCT03970876|Biological|Botox®|Clostridium Botulinum Type A
45696589|NCT03854032|Biological|IDO1 Inhibitor BMS-986205|Given PO
45696590|NCT03854032|Procedure|Therapeutic Conventional Surgery|Undergo Surgery
45696591|NCT03854032|Other|Questionnaire Administration|Ancillary studies
45696592|NCT02982226|Other|ReNu Injection|ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
45391206|NCT00414440|Drug|Placebo|placebo comparator
45391207|NCT00414440|Drug|Everolimus|experimental
45391208|NCT00209560|Drug|fospropofol disodium|
45391209|NCT01073800|Drug|atorvastatin 80 mg per os daily|atorvastatin 80 mg per os daily
45391210|NCT01073800|Drug|placebo|placebo
45696593|NCT02982226|Other|Corticosteroid Injection|Corticosteroids are considered a standard of care for treatment of Plantar Fasciitis
45696594|NCT03031288|Device|A|standard bottle
45696595|NCT03031288|Device|B|vented base bottle
45696596|NCT03031522|Radiation|18F-IRS|According to experiment, 18F-IRS was non-toxic and stable in serum.
45696597|NCT03031444|Drug|Cetuximab plus FOLFIRI/FOLFOX|cetuximab was added into the routine perioperative chemotherapy(FOLFIRI/FOLFOX) to evaluate its safety and efficacy
45696598|NCT03031444|Drug|FOLFIRI/FOLFOX/CapeOX|to evaluate its safety and efficacy of routine perioperative chemotherapy(FOLFIRI/FOLFOX/CapeOX)
45696599|NCT05328700|Other|Kinesiotaping|Perform a neuromuscular bandage with kinesiotape in patients with plantar fasciitis
45696600|NCT05328700|Other|Tape|Perform a neuromuscular bandage with tape (Hipofix(R)) in patients with plantar fasciitis
45391211|NCT03971032|Procedure|Hysteroscopy|Diagnostic procedure
45391212|NCT03971032|Device|Infrared Spectroscopy|This device uses spectral absorption of the tissue taken during hysteroscopy to determine immediate diagnosis of malignancy
45391213|NCT01037660|Drug|Metformin|Metformin 1 gram per day
45391214|NCT01072864|Other|Walnuts|Consumption of 5 g of walnuts.
45391215|NCT01072864|Other|Walnuts|Consumption of 20 g of walnuts.
45391216|NCT01072864|Other|Walnuts|Consumption of 30 g of walnuts.
45391217|NCT01072864|Other|Walnuts|Consumption of 40 g of walnuts.
45391218|NCT01032824|Behavioral|Individual Telephone Counseling Intervention|10-session, 5-month HIV adherence and chronic disease self-management individual telephone counseling intervention.
45391219|NCT01032824|Other|Group Arm|10-session didactic telephone group
45391220|NCT01032824|Other|Book Arm|Book only.
45696601|NCT05320042|Device|kalifilcon A Daily Disposable Toric|kalifilcon A Daily Disposable Toric
45696602|NCT05320042|Device|Ultra for Astigmatism Contact Lenses|Ultra for Astigmatism Contact Lenses
45696603|NCT02982304|Device|Deep Brain Stimulation|Deep Brain Stimulation Electrode
45696604|NCT02980198|Biological|IFN-Kinoid|IM administration
45696605|NCT02980198|Other|Placebo|IM administration
45391221|NCT01032902|Device|In Vitro Diagnostic Device|For the detection of antibodies to HIV in serum, plasma, blood and oral fluid
45391222|NCT00236080|Drug|PROVIGIL 200 mg|PROVIGIL 200 mg/day
45391223|NCT00236080|Drug|Armodafinil 250 mg|Armodafinil 250 mg/day
45391224|NCT00236080|Drug|Armodafinil 200 mg|Armodafinil 200 mg/day
45391225|NCT00236080|Drug|Armodafinil 150 mg|Armodafinil 150 mg/day
45391226|NCT00236080|Drug|Placebo|Matching placebo tablets
45391227|NCT01033058|Drug|atorvastatin|80mg atorvastatin immediately after enrollment, emergency PCI,atorvastatin 40mg/d and other usual medication after PCI
45391228|NCT01033058|Drug|atorvastatin|No loading dose of statin after enrollment, emergency PCI, atorvastatin 20mg/d and other usual medication after PCI
45391229|NCT03973138|Drug|Ranibizumab|DME patients who were diagnosed through fundus manifestations and FFA examination were treated by intravitreal injections of ranibizumab (0.5mg Lucentis®; Genentech, South San Francisco, CA) under the pro re nata (PRN) treatment regimen. The retreatment were conducted if BCVA was reduced by 0.1 logarithm of the minimal angle of resolution (logMAR) value or more from maximum acuity or if OCT central subfield thickness was more than 300μm.
45391230|NCT01326130|Behavioral|Chronic care management 1-6|1- an interdisciplinary team in an education center working with primary care physicians and offering to referred patients a pre-determined sequence of clinical interventions over a 2-year-period; 2- a program supporting primary care physicians (continuing education, documentation and clinical guidelines, referral system to second line of care); 3- networking between actors insuring clinical information transfer required for efficient patient management.
45391231|NCT01071616|Drug|Cannabis Cigarette|
45391232|NCT03970564|Diagnostic Test|Neck ultrasound guide lymph node sampling|Neck ultrasound done first and lymph nodes larger than 5 mm that are technically feasible are sampled using fine needle aspiration and/or core needle biopsy
45391233|NCT00432380|Biological|Rotarix™|oral doses
45391234|NCT00432380|Biological|Placebo|oral dose
45391235|NCT03970486|Procedure|Dry needling|For the needle manipulation technique, the needle will be pulled in and out (sparrow pecking) and redirected in small angles (coning) for 5-10 seconds. For the in situ technique, the needles will stay (in situ) in the left and right lumbar multifidus muscles for 10 minutes after the insertion of the needle.
45391236|NCT03974074|Drug|Albumin infusion|Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after resection in 24 h for three days.
45391237|NCT01072942|Drug|Ciprofloxacin (Cipro InhaIe, BAYQ3939)|Ciprofloxacin Inhale 50 and 75 mg 2 times a day (BID) for 10 days
45391238|NCT01072942|Drug|Placebo|Placebo TID for 10 days
45696606|NCT02980198|Other|ISA 51|adjuvant
45696607|NCT05258734|Other|COVOS app|In this study, the patients in the experimental group will be followed up with the COVOS app and nursing interventions (videos, information messages) to manage their symptoms will be directed with the COVOS app.
45696608|NCT05258734|Other|Standard Care|In this study, the patients in the control group will not receive any intervention, the standard follow-up and health care provided by the family health center of the patients will continue.
45696609|NCT02980432|Other|changes in whole-body roll position and visual/haptic stimuli presented|In different whole-body roll positions subjects will be presented a luminous line or a rod in combination with a moving or stationary background. Participants will be asked to align the line or the rod along perceived direction of gravity.
45696610|NCT03031132|Behavioral|HP-Beverage Breakfast|Participants will consume high protein beverage (shake) breakfast meals each morning.
45391239|NCT01582516|Biological|delta-24-RGD adenovirus|slow continuous microinfusion in and around the brain tumor during 44 hrs.by 4 temporary placed catheters
45391240|NCT00234052|Biological|bevacizumab|5 mg/kg administered intravenously over 90 minutes on day 1 of each cycle (cycle = 3 weeks)
45696611|NCT03031132|Behavioral|HP-Solid Breakfast|Participants will consume high protein solid (traditional food items) breakfast meals each morning.
45696612|NCT03031132|Behavioral|Breakfast Skipping|Participants will skip breakfast each morning.
46056864|NCT02723721|Drug|Picato gel|apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 3 consecutive days.
46056865|NCT00806260|Drug|VI-0521|Phentermine 3.75 mg and topiramate 23 mg daily for the 1st week; Phentermine 7.5 mg and topiramate 46 mg daily for the 2nd week; Phentermine 11.25 mg and topiramate 69 mg daily for the 3rd week; Phentermine 15 mg and topiramate 92 mg daily for the 4th week
46056866|NCT00806260|Drug|Placebo|Placebo daily for 4 weeks
46056867|NCT00806260|Other|Alcohol|
46056868|NCT00806260|Other|alcohol placebo|fruit juice
46056869|NCT05283213|Diagnostic Test|Early biomarkers of acute kidney injury|"The biomarkers tested will be:~creatinine levels [pre-, post-CC, H6],~urinary TIMP2*IGFBP7 [H6],~Plasma NGAL [Pre-, Post-CC, H6].~Urinary NGAL [H6]~Plasma cystatin C [Pre-CC, Post-CEC & H6],~plasma HI [pre-, post-CC, H6],~plasma IL-6 [post-CC, H6],~uremia [pre-, post-CC, H6],~urinary DKK3 [pre-CC], These biomarkers will, if necessary, be corrected for hemodilution or dilution of urine, if any, using [pre-, post-CC, H6] protein and [pre-, post-CC, H6] creatinine, respectively."
45391241|NCT00234052|Drug|carboplatin|Administered intravenously at a dose of AUC=6 over 30 minutes on day 1 of each cycle (1 cycle = 3 weeks)
45391242|NCT00234052|Drug|pemetrexed|Administered intravenously at a dose of 500 mg/m2 over 10 minutes on day 1 of each cycle (1 cycle = 3 weeks)
45391243|NCT00408408|Biological|bevacizumab|15 mg/kg IV
45391244|NCT00408408|Drug|capecitabine|825 mg/m2 orally
45391245|NCT00408408|Drug|cyclophosphamide|600 mg/m2 IV
45391246|NCT00408408|Drug|docetaxel|100 mg/m2 IV
45391247|NCT00408408|Drug|doxorubicin hydrochloride (Adriamycin)|60 mg/m2 IV
45391248|NCT00408408|Drug|gemcitabine hydrochloride|1000 mg/m2 IV
45391249|NCT00414050|Biological|Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine given intramuscularly (IM) in 3 injections of 5 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 5 μg arm). Modified Process Hepatitis B Vaccine given IM in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 10 μg arm).
45391250|NCT00414050|Biological|Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB™ (currently licensed product) given IM in 3 Injections of 5 ug/0.5 mL each over 4 months.
45696613|NCT03031054|Procedure|Sono-guided injection with hyaluronic acid|Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2.5 ml) between carpal tunnel and median nerve
45696614|NCT03031054|Procedure|Sono-guided injection with normal saline|Sono-guided injection with 2.5cc Normal saline (0.9%) between carpal tunnel and median nerve
45696615|NCT03031366|Other|3d roadmap guidance|TIPS was established using 3d roadmap
45696616|NCT03031366|Other|conventional TIPS procedure|conventional TIPS procedure using wedged hepatic venography
45696617|NCT00945334|Drug|Neomycin|500 mg po bid for 14 days
45696618|NCT00945334|Drug|Placebo|placebo for 14 days tid
45696619|NCT00945334|Drug|Rifaximin|550 mg po tid
45391251|NCT00414050|Biological|Hepatitis B Vaccine (Recombinant)|ENGERIX-B® (currently licensed product) given IM in 3 Injections of 10 ug/0.5 mL each over 4 months
45391252|NCT03970408|Procedure|MNT1|"Participants will in supine. Arm will be position in standard MNT1. Shoulder, elbow, wrist and fingers will be maintained in the required position using a costumed splint throughout all testing.~All movements will be limited to the range where pain or other symptoms are not provoked. Passive neck flexion and rotation will be added to MNT1 and will be applied as tensioning movements at level 3. All movements will be repeated three times and an average will be calculated. Myrin goniometer will be used to assess neck flexion and rotation. The movements order will be randomized using excel random generation function. Movements will be done by a single trained therapist. The end position will be held up to 10 seconds until median nerve excursion is recorded by US. For US capturing, the transducer will be positioned perpendicularly and aligned longitudinally with the median nerve at the wrist. Assessor will be blinded to participants grouping."
45391253|NCT01034618|Dietary Supplement|Protein hydrolyzation|
45391254|NCT01419860|Procedure|Elective colon resection|In our scientific experiment, we evaluate microcirculation in colon wall and anastomosis with laser induced fluorescence videoangiography of ICG. By implementing this technique we can measure average pixel intensity of fluorescence signal in area of interest on bowel, which represents tissue perfusion in this respective part of intestinal wall.
45696620|NCT00087789|Genetic|CERE-110: Adeno-Associated Virus Delivery of NGF|CERE-110 2.0 x 10^10 vg, CERE-110 1.0 x 10^11 vg, CERE-110 2.0 x 10^11 vg
45696621|NCT03578224|Procedure|Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA)|Undergo EUS-FNA
45391255|NCT03973840|Drug|Testosterone Undecanoate|dose was given orally and allowed to reach steady state
45696622|NCT03578224|Procedure|Contrast-Enhanced Ultrasound|Undergo CEUS
45696623|NCT03578224|Procedure|Fine-Needle Aspiration|Undergo FNA
45696624|NCT03578224|Drug|Sonazoid (Perflubutane)|Sonazoid (ultrasound contrast agent) will be injected in 0.25 mL increments at 12, 3, 6, and 9 o'clock positions around the tumor using a 19 - 22 gauge needle system under EUS guidance
45696625|NCT03559114|Drug|Dalteparin|Dalteparin in prophylactic doses administered daily if screening criteria are satisfied.
45696626|NCT03559114|Drug|Saline|Saline in prophylactic doses administered daily if screening criteria are satisfied.
45391256|NCT00413972|Drug|ezetimibe with simvastatin|Ezetimibe 10 mg with Simvastatin 10 mg once daily for a total of eight weeks
45391257|NCT00413972|Drug|Ezetimibe with Simvastatin|Ezetimibe 10 mg with Simvastatin 20 mg once daily for a total of eight weeks
45391258|NCT00413972|Drug|Ezetimibe with Simvastatin|Ezetimibe 10 mg with Simvastatin 40 mg once daily for a total of eight weeks
45391259|NCT00413972|Drug|Placebo|Placebo once daily for a total of eight weeks
45391260|NCT01037738|Procedure|ACL reconstructive surgery and ACS/ Orthokin application|ACL reconstructive surgery and ACS/ Orthokin or Placebo intraarticular application on Day 0,1,6 and 10 postoperatively, regarding the Arm
45391261|NCT00259012|Drug|pantoprazole sodium enteric-coated spheroid suspension|pediatric suspension taken daily x 7 days
45391262|NCT01044108|Drug|NNC 0070-0002-0453|Administration of a single subcutaneous (under the skin) dose. Up to 7 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
45391263|NCT01044108|Drug|'2-0453|Administration of multiple subcutaneous (under the skin) doses for 10 weeks. Up to 4 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
45391264|NCT01044108|Drug|placebo|Placebo will be administered as a comparator at each dose level.
45391265|NCT01044186|Drug|ICL670|
45391266|NCT03970174|Other|Care Connector care transition module|Care Connector is an electronic interprofessional communication and collaboration tool. Its features include Physician Sign-Out, documentation, interprofessional care planner, messaging, and flow planner. The newest module is a care transition module which allows physicians to electronically generate discharge summaries as well as incorporation of allied health recommendation, but also will pull information into the PODS (Patient Oriented Discharge Summary) format designed by University Health Network. This results in a patient friendly discharge instruction sheet that can be provided to patient. The intervention arm will have access to the care transition feature, while the control wards do not.
45502641|NCT04490993|Drug|Placebo in combination with Epirubicin|"Induction period: placebo is administered for 12 consecutive weeks~Maintenance period: after 12-week drug free period, placebo is administered for another12 consecutive weeks as maintenance treatment~Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months"
45502642|NCT02055482|Drug|Molidustat (BAY85-3934)|BAY85-3934 will be titrated at the scheduled dose control visits to maintain the Hb in the target range of 10.0 to 12.0 g/dL. Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD. Treatment will be for minimum of 6 months to up to a maximum of 36 months.
45502643|NCT02055482|Biological|Darbepoetin|Darbepoetin will be administered according to the local label and titrated at the scheduled dose by intravenous injection. Treatment will be for a minimum of 6 months to up to a maximum of 36 months.
45502644|NCT04465565|Procedure|9% Sodium Chloride (NaCl) IV|9% Sodiun Chloride (NaCl) ( 20cc/kg) adminstrated intravenously
45696627|NCT03492021|Other|Diet Intervention_AP-CPT|Adequate Protein_Carbohydrate Post Therapy (AP-CPT) where protein intake will be 1 g/kg/d for the duration of the study .
45696628|NCT03492021|Other|Diet Intervention_PP-PPT|Optimal Protein_Protein Post Therapy (OP-PPT) with protein intake set at 2.0 g/kg/day for the duration of the study
45696629|NCT05198908|Other|VR group|"Women in this group will wear virtual reality glasses (15-20 minutes) until the episiotomy repair begins and ends. At the same time, the hospital protocol will be applied to this group.~Before episiotomy repair, each woman is given superficial perineal anesthesia with a 4 ml ampoule of Jetocaine (ADEKA®, lidocaine HCl 40 mg/2 mL, epinephrine 0.025 mg/2 mL). This dose is repeated if necessary."
45848784|NCT01319760|Device|Impella 2.5 support|Patients enrolled in the Impella arm will receive 24 hours of post-PCI hemodynamic support using the Impella 2.5
45848785|NCT01319760|Other|Standard of care (Control)|Standard care for STEMI patients post-PCI from ACC/AHA Guidelines
45391267|NCT01073878|Device|Athena Pelvic Muscle Trainer|The Athena PMT is a vaginally inserted electrical stimulator that induces the pelvic floor muscles to contract and relax, similar to Kegel exercises intended to strengthen the pelvic floor muscles.
45391268|NCT03993600|Diagnostic Test|Sweat test (Macroduct Sweat Collection System) and skin biopsy (Punch Biopsy)|"three groups:~Healthy volunteers~Patients with Cystic fibrosis~Heterozygous subjects"
45391269|NCT00209170|Behavioral|Beating the Blues|Beating the Blues is a computerized cognitive behavioral therapy.
45391270|NCT00209170|Drug|Escitalopram|Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It's a 10 mg pill taken once or twice daily for 6 months.
45391271|NCT00209170|Drug|Placebo|A sugar pill taken as one to two tablets daily for 6 months.
45391272|NCT01071694|Drug|Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)|Patients receiving Betaferon according to routine clinical practice
45848786|NCT01302444|Drug|Tadalafil|Tadalafil 40mg for 12 weeks
45848787|NCT01302444|Drug|Placebo|Placebo for 12 weeks
45391273|NCT00413894|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|iv monthly, with starting dose based on previous dose of epoetin alfa or beta or darbepoetin alfa
45391274|NCT03973216|Behavioral|A primary care group-based therapeutic yoga program|The intervention includes therapeutic yoga training and education sessions on benefits of yoga and effects of stress on the body.
45391275|NCT03970018|Other|Intra-peritoneal pressure|Measurement of intra-peritoneal pressure
45391276|NCT03972748|Drug|Itraconazole 200 mg|Oral Itraconazole capsules, 200 mg, twice daily, for 60 days prior to surgery with curative intent.
45391277|NCT01581814|Drug|Metformin|500 mg of Metformin per 3/die
45391278|NCT01581814|Drug|Yasmin;|1pill/day for cycles of 28 days (21 pills followed by 7 no-pill days)
45391279|NCT01581814|Drug|Metformin plus Yasmin|0.03 mg EE plus 3 mg of DRPS combined with 500 mg of metformin three times daily
45391280|NCT00407550|Drug|gemcitabine HCL|1250 mg/m^2 administered through 250 cc NS (normal saline) IV (intravenous) infusion over 30 minutes at days 1 & 8 of each cycle (21 days) x6 cycles.
45391281|NCT00407550|Drug|pemetrexed disodium|500 mg/m^2 administered through 100 mL NS IV infusion over 10 minutes at day 1 of each cycle.
45391282|NCT00407550|Drug|gemcitabine HCL|1500 mg/m^2 administered through 250 cc NS IV infusion over 30 minutes at days 1 of each cycle (14 days) x9 cycles.
45391283|NCT00209092|Drug|Docetaxel|"Sequential Therapy: Docetaxel will be given at 100 mg/m^2 Intravenously (IV)Day 1 every 3 weeks for 4 cycles.~Concurrent Therapy: Docetaxel will be given at 50 mg/m^2 IV Day 1."
45391284|NCT00209092|Drug|Capecitabine|Sequential Therapy: administration of capecitabine 1000 mg/m^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) Concurrent Therapy: capecitabine 1000 mg/m^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
45391285|NCT01073098|Other|Vascular occlusion test|Reperfusion slope after vascular occlusion test
45391286|NCT03969862|Device|NOVEOS® system|"The NOVEOS® System is a fully automated, high-throughput immunoassay platform that uses magnetic microbeads as a solid phase.~This is a partially closed system that is primarily intended for the determination of specific IgE with NOVEOS® Hycor allergens. It has the CE mark."
45391287|NCT03972982|Drug|Simplified intensive insulin therapy regimen|Short-term continuous subcutaneous insulin infusion to maitain near normoglycemica for 1 week, thereafter basal insulin and metformin were subsequently used. Wearable devices and smart apps will be used for lifestyle modification.
45391288|NCT03972982|Drug|Traditional Short-term Intensive insulin therapy|Short-term continuous subcutaneous insulin infusion will be initiate to maitain near normoglycemica for 2 weeks, then patients will be ordinarily follow-up
45391289|NCT00403494|Other|Placebo|Subjects receive matching oral Placebo twice daily for 24 weeks.
45391290|NCT00403494|Drug|Sapropterin Dihydrochloride|Subjects receive 400 mg oral sapropterin dihydrochloride twice daily for 24 weeks.
45391291|NCT00403260|Drug|Pyronaridine - artesunate|once a day for 3 days
45391292|NCT00403260|Drug|Mefloquine plus artesunate|once a day for 3 days
45391293|NCT01324362|Drug|Placebo|Twice daily dosing
45391294|NCT01324362|Drug|Placebo|Twice daily dosing
45391295|NCT01324362|Drug|FP 100mcg|Twice daily dosing
45391296|NCT01324362|Drug|FP 250mcg|Twice daily dosing
45391297|NCT01324362|Drug|FP 500mcg|Twice daily dosing
45391298|NCT01324362|Drug|FSC 100/50mcg|Twice daily dosing
45391299|NCT01324362|Drug|FSC 250/50mcg|Twice daily dosing
45391300|NCT01324362|Drug|FSC500/50mcg|Twice daily dosing
45391301|NCT00406848|Drug|duloxetine hydrochloride|Placebo for 1 week (double-blind placebo lead-in), then duloxetine 30 milligrams (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg QD orally for 11 weeks. This double-blind acute treatment phase was followed by a double-blind 12 week continuation phase during which participants either remained on 60 mg QD or were eligible for dose escalation to 120 mg QD orally based on depression symptom severity.
45391302|NCT00406848|Drug|placebo|Placebo for 13 weeks (The first week was placebo lead-in). This double-blind acute phase was followed by a double-blind 12 week continuation phase during which participants either remained on placebo or were eligible for receiving duloxetine 60 milligrams (mg) orally once daily (QD), beginning with duloxetine 30 mg QD orally for 1 week followed by duloxetine 60 mg QD orally for the remainder of the study based on depression symptom severity.
45391303|NCT00406692|Drug|Zonisamide|Week 1 (Wk1) -100 mg daily; Wk 2- 100 mg daily; Wk 3- 200 mg daily; Wk 4- 200 mg daily; Wk 5- 300 mg daily; Wk 6- 300 mg daily; Wk 7-11- 400 mg daily; Wk 12(Days 1-5) 300 mg daily; Wk 12 (Day 6-7) Week 13 (Days 1-3)- 200 mg daily; Week 13 (Days 4-7) - 100 mg daily.
45391304|NCT00004494|Drug|vasoactive intestinal peptide|
45391305|NCT00315705|Drug|clofarabine|Clofarabine 20-40 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle as the first of the three IV interventions administered. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
45391306|NCT00315705|Drug|Etoposide|Etoposide 75-100 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle following clofarabine therapy. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
45391307|NCT00315705|Drug|Cyclophosphamide|Cyclophosphamide 340-440 mg/m²/day as 30-60 minute intravenous (IV) infusion daily for 5 days of a 28 day cycle following the other two interventions. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
45391308|NCT03982017|Other|Mobile Health Technology Platform|When the participant navigates to the program, s/he will follow the directions on how to use the program, sign the terms of agreement, put in a password and begin the welcome page. The participant will receive daily prompts to complete brief questionnaires and review specialized content.
45391309|NCT03982017|Other|Usual care|Routine care at the time of hospital discharge, to be provided at the discretion of the clinicians caring for the participant.
45391310|NCT03982173|Drug|Tremelimumab|tremelimumab 75mg
45391311|NCT03982173|Drug|Durvalumab|Durvalumab 1500mg
45391312|NCT01062633|Dietary Supplement|A, erythritol|2,5 g 3 times a day
45391313|NCT01062633|Dietary Supplement|xylitol|2,5 g 3 times a day
45391314|NCT01062633|Dietary Supplement|C, sorbitol|2,5 g 3 times aday
45391315|NCT00307125|Drug|Rituximab plus immunosuppression|"Genetically engineered monoclonal antibody directed against the CD20 antigen on B cells and is known to deplete B cells when administered intravenously. Generally used in the treatment of non-Hodgkin's lymphoma~Standard immunosuppression is site-specific."
45391316|NCT00307125|Drug|Placebo plus immunosuppression|"Placebo dosing: Adult Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject <\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific."
45391317|NCT01066299|Drug|Syntocinon®|single dose of OXT (24 IU)
45391318|NCT01066299|Drug|inactive nasal spray|single dose (24 IU)
45391319|NCT00307047|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
45391320|NCT00307047|Device|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
45391321|NCT01066377|Dietary Supplement|Prebiotic and probiotic mix|The probiotic strain will be Bifidobacterium longum bv. infantis CCUG 52486 (10^8 - 10^9 live bacteria per day), which was originally isolated from healthy elderly subjects, and which has been demonstrated to have particular ecological fitness and anti-pathogenic effects in vitro. A suitable prebiotic (8g/day) will be selected on the basis of ability to promote optimal growth and survival of this probiotic (inulin, fructooligosaccharides [FOS], galactooligosaccharides[GOS] and xylooligosaccharides[XOS] will be tested).
45391322|NCT00306891|Drug|Cediranib|45 mg oral dose
45391323|NCT00306891|Drug|Cediranib 30 - 90 mg|oral tablet dose escalation
45391324|NCT00314145|Biological|ChimeriVax™-JE|0.5 mL, Subcutaneous (ChimeriVax™-JE); 1.0 mL, (Saline)
45391325|NCT00314145|Biological|JE-VAX®|0.5 mL, Subcutaneous (JE-Vax®); 1.0 mL, (Saline)
45391326|NCT00313911|Biological|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
45502645|NCT04395755|Behavioral|Generalized Anxiety Disorder-7 (GAD-7)|The GAD-7 is useful in primary care and mental health settings as a screening tool and symptom severity measure for the four most common anxiety disorders.
45391327|NCT00313911|Biological|Tritanrix-HepB/Hib|0.5 mL, Intramuscular
45391328|NCT03978507|Behavioral|Intelligent cueing|1 month use of an intelligent, wearable device that provides personalized cueing only when FOG is detected
45502646|NCT04395755|Behavioral|Patient Health Questionnaire-9 (PHQ-9)|The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.
45502647|NCT04743947|Other|No intervention; observational study|no intervention
45502648|NCT02059460|Drug|Terlipressin|Terlipressin (Glypressin®) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
45391329|NCT03978507|Behavioral|Feedback about the number of steps|Feedback about the number of steps is given in the intervention group as well as in the control group during the 1-month intervention-period.
45391330|NCT03980847|Drug|Alendronate 20 mg|The Alendronate 20 mg combined with nanocrystalline hydroxyapatite as a synthetic bone substitute for socket preservation after tooth extraction
45391331|NCT03980847|Procedure|Nanocrystal hydroxyapatite|Postextraction Sockets Preserved With Nanocrystal hydroxyapatite as a synthetic bone substitute alone as a bone graft
45391332|NCT03978195|Device|Non-invasive device for middle ear ventilation|Daily use of the device
45391333|NCT00391872|Drug|Ticagrelor|Ticagrelor (AZD6140) 90 mg twice daily dose (BD)
45391334|NCT00391872|Drug|Clopidogrel|Clopidogrel 75 mg once daily dose (ODD)
45391335|NCT00391170|Drug|Topical Dexamethasone|dexamethasone 0.01%
45391336|NCT00391170|Drug|Placebo|Placebo
45391337|NCT00402324|Drug|olanzapine|15mg, capsules, by mouth every evening, daily for minimum of one day, followed by 5-20mg, capsules, by mouth every evening, daily for remainder of study (6 weeks total).
45391338|NCT00402324|Drug|placebo|placebo, capsules, by mouth every evening, daily, for 6 weeks.
45391339|NCT00402324|Drug|divalproex|dose to maintain blood levels of 75-125 ug/mL, by mouth, twice a day, daily for 52 days (Study Period I and Study Period II).
45391340|NCT00294723|Drug|liraglutide|1.8 mg for s.c. (under the skin) injection
45391341|NCT00294723|Drug|glimepiride|8 mg capsule
45391342|NCT00294723|Drug|liraglutide|1.2 mg for s.c. (under the skin) injection
45502649|NCT02059460|Drug|placebo|
45502650|NCT02055716|Drug|Sulforadex|
45502651|NCT02055716|Drug|alpha-cyclodextrin|
45391343|NCT00294723|Drug|placebo|Glimepiride placebo, 8mg capsule
45391344|NCT00294723|Drug|placebo|Liraglutide placebo, 200 mcl
45391345|NCT00294723|Drug|placebo|Liraglutide placebo, 300 mcl
45391346|NCT00402246|Other|Remote Management|"The Remote Management method of treating patients consists of 3 components:~CareAlerts: Device alerts that are triggered by either device integrity issues or arrhythmic issues with the patient (e.g. multiple shocks delivered for a ventricular arrhythmia, more than 12 hours of atrial arrhythmias occurring in a day)~Conexus: the device feature which allows the device to wirelessly transmit information (possibly triggered by a CareAlert) to a patient monitor that is hooked up a patient's phone line~CareLink: the Medtronic system which allows device data to be transmitted from a patient's monitor through the phone line to ultimately be displayed on a secure website for viewing by the patient's physician.~The combination of these 3 components allow the patient's device to transmit information relating to either a device issue or patient issue to be viewed by a clinician without the patient having to take direct action."
45391347|NCT00402246|Other|In-Office Care|Routine in-office care
45391348|NCT00375492|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
45391349|NCT00375492|Drug|placebo|subcutaneous injection, volume equivalent to exenatide dose, twice a day
45391350|NCT00306189|Drug|100 mg AMG 162|100 mg AMG 162 (denosumab) SC every 6 months
45391351|NCT00306189|Drug|60 mg AMG 162|60 mg AMG 162 (denosumab) SC every 6 months
45391352|NCT00306189|Drug|14 mg AMG 162|14 mg AMG 162 (denosumab) SC every 6 months
45391353|NCT00306189|Drug|Placebo|Placebo SC every 6 months
45391354|NCT00312897|Drug|Omega-3 Fatty Acids|10 wk treatment period
45391355|NCT00312897|Drug|corn oil|placebo comparator
45391356|NCT00312663|Biological|Falciparum Malaria Protein 11 with AS01B adjuvant.|malaria experimental vaccine
45391357|NCT02532699|Dietary Supplement|AC mycelia|An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing either 420 mg of AC mycelia of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
45391358|NCT02532699|Dietary Supplement|Placebo|An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing 420 mg starch placebo of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
45391359|NCT00294645|Other|Transtelephonic monitoring (TTM)|TTM conducted at 2 month intervals. For patients with dual-chamber pacemakers, an in-office visit was required at 6 months (rather than TTM transmission for patients with single-chamber pacemakers). Follow-up frequency established to mimic best case standard of care when utilizing TTM for follow-up. A 12-month in-office visit completed the follow-up period.
45391360|NCT00294645|Other|Medtronic CareLink® Network|Remote pacemaker interrogation conducted at 3 month intervals. Follow-up frequency established to mimic best case standard of care when utilizing implantable cardioverter defibrillator (ICD) remote interrogation for follow-up. A 12-month in-office visit completed the follow-up period.
45391361|NCT00305877|Biological|cetuximab|Given IV
45391362|NCT00305877|Drug|gemcitabine hydrochloride|Given IV
45391363|NCT00305877|Drug|capecitabine|Given orally
45391364|NCT00305877|Radiation|radiation therapy|Undergo radiation therapy
45391365|NCT00305877|Biological|bevacizumab|Given IV
45391366|NCT00305877|Other|laboratory biomarker analysis|Correlative studies
45391367|NCT01064193|Procedure|biopsy|"The endometrium biopsy will be done as the same time as the GnRH treatment. The biopsy is realised with a Pipette de Cornier® (CDD international, PROMIDED France) following the laboratory protocol:~Apply antiseptic solution (povidone-iodine, Dakin®) on the cervix and vagina. In most cases, using Pozzi forceps is not necessary.~Insert carefully the pipelle de Cornier® in the uterus through the cervix.~Withdraw the piston to create a negative pression~Move the pipelle de cornier® in and out while twisting. Take care to no remove the pipelle form the uterus (suction lost). Twist the pipelle de Cornier® to cover an angle of 360°. Make several in and out cycle in order to collect a complete sample of the endometrium.~Withdraw the pipelle de Cornier® when filled with tissue~Reinsert internal piston to deposit sample in cup filled with a fixative."
45391368|NCT01064193|Procedure|IVF|fresh IVF-embryo transfer treated with long protocol for the controlled ovarian hyperstimulation
45391369|NCT03978273|Device|Night-time brace + virtual-brace|"Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Additionally :~They will perform 5 sessions of postural rehabilitation exercises per week (each of 30 minutes) with the virtual-brace (MD).~They will have also follow up consultations with a physiotherapist every 21 days, to evaluate treatment observance and to adapt postural exercises according to the results and difficulties encountered.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180."
45391370|NCT03978273|Other|Night-time brace only|"Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180."
45391371|NCT03981315|Diagnostic Test|Bile test|Analyze bile components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)
46056870|NCT05753020|Behavioral|CKM Jumpstart Tool|The CKM JumpStart Tool is a 1-page handout that describes the values of a patient and words that a providers can try with the patient to explore the patient' values more and to provide a values-based introduction to CKM. The values described in the CKM JumpStart Tool is based on a patient's response to a single validated question that we will ask the patient at T1, if they had to choose, do they value care directed at longevity or comfort. Using the patient's answer to the values question, study staff will generate a CKM JumpStart Tool prior to their upcoming clinic visit with their nephrologist. Study staff will inform the patient that their response to the values question will be shared with their provider prior to their next clinic visit and that their providers might bring up their values and treatment options for kidney disease, if the situation permits. We will share the CKM Jumpstart Tool with their provider and provide instruction on how to use the Tool.
45391372|NCT03981315|Diagnostic Test|Blood test|Analyze blood components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)
45391373|NCT03981315|Diagnostic Test|Gall stone study|Study of the extracted gall stones, analyzing their composition, type, etc.
45391374|NCT03981315|Diagnostic Test|Microbiological bile test|Determination of the microbiological composition of the bile
45391375|NCT01062711|Dietary Supplement|Whey or soy protein|Whey and casein are isolated milk proteins
45391376|NCT00312195|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
45391377|NCT00312195|Drug|Placebo to match BTDS|Placebo to match buprenorphine transdermal patch applied for 7-day wear.
45391378|NCT01062789|Device|Optical breath-hold control system (OBC)|The OBC system was designed to replace the IBC rubber bellows respiration sensor system that we are currently using for CT-guided lung biopsies. Unlike the IBC, the OBC is 1) unaffected by temperature changes, 2) has a linear sensitivity (for easier use and better accuracy), 3) has no pneumatic purge time when setting reference breath-hold level (reducing the chance of an inappropriate reference), 4) has no pneumatic cable that can occasionally interfere and get pinched during procedures, 5) is ambulatory (so patients can more easily familiarize themselves with the device before the procedure), 6) is capable of indicating proper fitting tension, 7) allows for easier binding (wireless pairing with other system components), and 8) is significantly less expensive (and possibly disposable).
45391379|NCT01066533|Other|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.After signed consent was given by patients,local anesthesia was applied before operative procedures. Operative procedures were performed with rubber dam placement and disinfected with 2% chlorhexidine gluconate. Class I occlusal cavities were prepared with ¼ round carbide burs under air-distilled water cooling. At the exposure site hemorrhage was controlled by sterile cotton pellets, saline and 5.25% NaOCl.In this group MTA was mixed on a slab according to manufacture's instructions.Then MTA was carried with a carrier to exposed pulp and it was packed with a slight pressure by moist cotton pellet to completely cover the exposed pulp.The cavities were sealed immediately with Fuji II glass ionomer.The teeth were then followed and extracted(8 teeth after 2 weeks and 8 teeth after 8 weeks)
45391380|NCT01066533|Other|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.All the procedure was carried the same as the other group.But NEC cement was used as pulp capping material.It was mixed with its liquid to provide a dense creamy mixture and then was applied on exposed pulp.the cavities were immediately sealed with Fuji II glass ionomer.The patients were followed and 8 teeth were extracted after 2 weeks and 8 teeth were extracted after 8 weeks.
45391381|NCT01062867|Drug|ORG25435|Intended doses: 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 mg/kg by intravenous infusion over 1 min Up to 25mg/kg by infusion over 30min
45391382|NCT02532777|Drug|Prednisone|
45391383|NCT02532777|Drug|Cyclophosphamide(CTX)|
45391384|NCT02532777|Drug|Mycophenolate mofetil(MMF)|
45502652|NCT04739735|Procedure|Dental Local Anaesthesia|lower primary molar teeth indicated for extraction will be given a local anaesthetic injection according to the random allocation to one of the two arms mentioned previously
45502653|NCT02059538|Other|Adipose tissue biopsies (omental and subcutaneous) liver|
45502654|NCT02059538|Radiation|CT-scan|
45696630|NCT05198908|Other|Skin to skin group|"For women in this group, a warm sterile operating room towel will be placed on the newborn until the episiotomy repair begins and ends, so that her naked body remains on the mother's chest.At the same time, the hospital protocol will be applied to this group.~Before episiotomy repair, each woman is given superficial perineal anesthesia with a 4 ml ampoule of Jetocaine (ADEKA®, lidocaine HCl 40 mg/2 mL, epinephrine 0.025 mg/2 mL). This dose is repeated if necessary."
46056871|NCT02718183|Other|Hydrogen Peroxide 35% (Opalescence Endo - Ultradent, USA)|bleaching teeth gel to intracameral use.
45391385|NCT02532777|Drug|Leflunomide(LEF)|
45391386|NCT02532777|Drug|Angiotensin-converting enzyme inhibitor(ACEI)|
45391387|NCT02532777|Drug|Methylprednisolone|
45391388|NCT03977805|Drug|Hetrombopag Olamine|a single oral taking
45391389|NCT01062945|Drug|Placebo|Matching administration of a placebo pill.
45502655|NCT02059538|Other|Stools sampling|
45502656|NCT02059538|Other|DNA sampling|
45502657|NCT02059538|Other|Blood sampling|
45502658|NCT02059538|Other|Urine sampling|
45502659|NCT02059538|Radiation|Dual energy X-ray absorptiometry-scan (DEXA-scan)|
45391390|NCT01062945|Drug|Doxazosin|The dose of doxazosin needed to alter the effects of cocaine is unknown and preclinical animal studies have not been conducted. Because of this, initially we will study the effects of a low dose of doxazosin (4 mg daily) compared to placebo daily. Because this class of medication needs to be titrated upward due to the potential for hypotension, treatment will begin at 1 mg and increased by 1 mg increments every three days until 4 mg is reached on day 12.
45391391|NCT01063023|Drug|Ortho Tri-Cyclen®|Tablets, Oral, 1 Tablet, once daily
45391392|NCT01063023|Drug|BMS-650032|Tablets, Oral, 600 mg, BID
45391393|NCT01063101|Other|Fucoidan (extract of Laminaria japonica)|Capsule (300 mg/capsule) - oral administration - 5 different dose levels - BID
45391394|NCT01063101|Other|Placebo|Cellulose filled capsule - oral administration - 5 different dose levels - BID
45391395|NCT00305253|Device|Non-pneumatic Anti-shock Garment (NASG)|In the Post-Intrevention phase of the study, the NASG will be used when a patient meets the study criteria.
45391396|NCT01066611|Drug|CAL-263|CAL-263 10 mg or placebo once daily for 7 days
45391397|NCT01066611|Drug|Placebo|CAL-263 10 mg or placebo once daily for 7 days
45391398|NCT01066689|Drug|MabThera|MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
45391399|NCT01066689|Drug|Physiological serum (Sodium Chloride, sodium citrate)|Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
46056872|NCT02718183|Other|carbamide peroxide 37% (Whiteness Superendo, FGM, Brazil).|bleaching teeth gel to intracameral use.
46056873|NCT00742885|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
45391402|NCT03980691|Biological|Chidamide with CAR-T or TCR-T cell therapy|HIV-1 specific therapy
45391403|NCT00293709|Drug|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
45391404|NCT01063257|Drug|Clofarabine|"The dosage of Clofarabine will be gradually augmented in a 3+3 design for each following dose level:~DL1 - 5mg/m2/d, DL2 - 7.5mg/m2/d, DL3 - 10mg/m2/d, DL4 - 12.5mg/m2/d (This dose may not be reached and is an optional dose level in case the MTD is not reached before and depending on further data from the ongoing MDS Phase IIa oral formulation trial).~The DLa will be the following:~DL1a - 2.5mg/m2/d, DL2a - 6.5mg/m2/d, DL3a - 8.5mg/m2/d, DL4a - 11.5mg/m2/d (In case of activation of the DL4 step). Dose levels 1a, 2a and 3a will be used for de-escalation."
45391405|NCT03977649|Drug|erenumab|erenumab 140 mg sc every 4 weeks
45391406|NCT03977649|Drug|placebo|placebo sc every 4 weeks
45391407|NCT01066767|Drug|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
45391408|NCT03980613|Other|Triage|Emergency telephone calls from cases and controls are replayed and analyzed for symptom descriptions indicating spontaneous subarachnoid haemorrhage.
45391409|NCT03980379|Drug|304 injection|Monoclonal antibodies, 100mg/10ml per injection
45391410|NCT03980379|Drug|rituximab injection|100mg/10ml per injection ，manufactured by Roche
45391411|NCT01064271|Drug|Risperidone|Risperidone Tablets 1 mg
45391412|NCT01066845|Drug|tadalafil|prescribed in accordance with usual clinical practice
46056874|NCT00811174|Drug|Octagam 10%|300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)
46056875|NCT02723487|Drug|Bupivacaine 0.125%|Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.125%), 0.5 ml/kg on each side.
45391413|NCT01064349|Drug|Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer|Trastuzumab or Lapatinib
45391414|NCT00311181|Device|Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D)|Patients that are indicated for an ICD or CRT-D receive one of these devices.
45391415|NCT01063491|Procedure|bypass graft angiography|
45391416|NCT00293397|Device|Drug-eluting beads loaded with doxorubicin hydrochloride|Doxorubicin eluting beads
45391417|NCT03981627|Drug|ADO09 formulation|Subcutaneous injection of ADO09 formulation
45391418|NCT03981627|Drug|NovoRapid®|Subcutaneous injection of insulin aspart
45391419|NCT01064505|Drug|QPI-1007 at various doses|Single Intravitreal Injection
45391420|NCT01069263|Other|Hyperbaric Oxygen Therapy|60 treatments (12 weeks - 5 days a week) of hyperbaric (pressure of 2 atmospheres) with 100% oxygen inhalation.
45391421|NCT01069263|Drug|DMSO|50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
45391422|NCT01067079|Other|No vaccine administered; subjects only have blood sampling for immunogenicity|No vaccine administered; subjects only have blood sampling for
45696631|NCT03087435|Device|Well-Being questionnaire|Development and validation of a tool to access residents well-being.
46056876|NCT02723487|Drug|Bupivacaine 0.25%|Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.25%), 0.5 ml/kg on each side.
45391423|NCT01069497|Other|Prevention of infections program|"The intervention mainly involves implementing urinary, respiratory and gastrointestinal infection prevention measures. Study nursing home medical coordinators will be in charge of training their own teams. For this, they will be provided with:~a slide-show of recommendations (commented by an expert),~recommendations guides (on paper and on computer) to be shown to their teams. Means will be provided to the intervention nursing homes : Hydro-alcoholic solutions, disinfectant detergent-impregnated tissues, mouth care kits, tec."
45502660|NCT01341899|Procedure|immunosuppression and stem cell transplantation|Hematopoietic stem cells were mobilized with cyclophosphamide (CY, 2.0 g/m2) and granulocyte colonystimulating factor (10 μg/kg per day) and then collected from peripheral blood by leukapheresis and cryopreserved. The cells were infused after conditioning with CY (200 mg/kg) and rabbit antithymocyte globulin (4.5 mg/kg).
45502661|NCT04292405|Device|Wearable Cardioverter Defibrillator|Use of the Wearable Cardioverter Defibrillator and AUDICOR AM to evaluate accuracy of cardiac acoustic biomarker recordings.
45502662|NCT02059616|Drug|Amlodipine 5mg|Daily oral administration for 8 weeks
45391424|NCT01064583|Other|cocoa|dissolved in water twice-daily intervention
45391425|NCT01067235|Drug|BF2.649|BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil Placebo capsules for 8 weeks
45391426|NCT01067235|Drug|BF2.649 add on Modafinil|BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil capsules at 200 mg per day for 8 weeks
45391427|NCT01069575|Biological|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
45391428|NCT01067313|Device|Dialyzer Ultraflux EMiC2|Dialysate flow rate = 40 ml/kg/h The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
45391429|NCT01067313|Device|Dialyzer Ultraflux AV1000S|Ultrafiltration flow rate = 40 ml/kg/h The blood flow rate will be adjusted to obtain a filtration fraction of 20%. Reinjection = 100% postdilution. The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
45391430|NCT00290745|Drug|letrozole|
45391431|NCT00290745|Drug|tamoxifen citrate|
45502663|NCT02059616|Drug|Amlodipine 10mg|Daily oral administration for 8 weeks
45502664|NCT02059616|Drug|Candesartan Cilexetil 8mg|Daily oral administration for 8 weeks
45502665|NCT02059616|Drug|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
45502666|NCT04724681|Device|WARD CSS|Wireless devices monitor vital signs continuously and transmit real-time data to an app that notifies clinical personnel when relevant deviations in vital signs occur This group will be monitored with standard Early Warning Score as well
45502667|NCT04356209|Other|e-PRO Intervention|"Statements of symptoms and patients' health status (PROs) will be collected via a web interface, including access and use in patients with burden symptoms.~The platform will include four items concerning 7 side effects of fibrosis of grade > 2 in breast cancer. Patients will be encouraged to evaluate on a 5-point Likert scale the frequency, the intensity and the repercussions on the daily life of some symptoms during the last 7 days, in particular on:~general pain~anxiety~sadness~texture of the treated breast~Patients will also be invited to express themselves on the severity of two other symptoms of their choice, to their worst degree, by listing and rating them on a 5-point scale ranging from None to Very severe Finally, the aesthetic impact will be evaluated by patients on a visual analogue scale (VAS) of 0 to 100mm"
45502668|NCT04356209|Drug|Pravastatin|All patients will take Pravastatin 40 mg per day (From Day 0 to Month 12).
45502669|NCT02055794|Procedure|Suturing of the perineal skin|
45502670|NCT02055794|Procedure|Closing perineal skin with surgical glue|
45391432|NCT00290745|Procedure|conventional surgery|
45391433|NCT00290745|Procedure|neoadjuvant therapy|
45391434|NCT01069653|Biological|HLA-A*2402-restricted CDCA1 and KIF20A peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
45391435|NCT03980223|Drug|Doxycycline Hyclate Delayed-Release 200 mg|200 mg of doxycycline taken by mouth after condomless sexual contact as post exposure prophylaxis (PEP)
45502671|NCT02055794|Procedure|No suturing of the perineal skin|
45502672|NCT02059694|Drug|Hyaluronidase|
45502673|NCT02059694|Other|2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20|
45502674|NCT02055872|Drug|Intravenous albumin|
45502675|NCT02055872|Drug|Normal saline|
45502676|NCT03146741|Drug|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
45502677|NCT03561038|Device|Franseen Needle|Comparing 2 needles designed for tissue acquisition
45502678|NCT03561038|Device|Fork-tip Needle|Comparing 2 needles designed for tissue acquisition
45502679|NCT02056730|Drug|calcium sensing receptor agonist|For the Regpara those taking 25 mg per day to get the default dose and the dose is adjusted according to the levels of calcium and parathyroid hormone. By adjusting the dose of 25 mg every 3 weeks for a period of 12 weeks, the drug is between 25-75 mg dose, with a maximum dose of not more than 100 mg per day (weeks 3, 6, 9).
45391436|NCT01067391|Drug|tadalafil|20 mg tablet, administered once per study protocol
45391437|NCT01067391|Drug|placebo|placebo tablet administered once per study protocol
45391438|NCT00402168|Drug|Belatacept|IV, IV Infusion, 5 mg/kg once every 28 days for one year
45391439|NCT00402168|Drug|Cyclosporine A|Tablets, Oral, Trough of 100-250 ng/mL, 2* daily for one year
45391440|NCT00402168|Drug|Tacrolimus|Tablets, Oral, Trough of 5-10 ng/mL, 2* daily for one year
45391441|NCT01064661|Dietary Supplement|Single probiotic arm of L-NCFM alone|Single probiotic of L-NCFM alone pills BID (2x10^10 cfu total bacteria per day)
45391442|NCT01064661|Dietary Supplement|Blend probiotic arm of L-NCFM and B-LBi07|Blend probiotic arm of L-NCFM and B-LBi07 pills BID (2x10^10 cfu total bacteria per day)
45391443|NCT00290589|Drug|Intramuscular methylprednisolone acetate|Intramuscular methylprednisolone acetate 160mg
45502680|NCT05162573|Drug|177Lu-PSMA-617|Dose-escalation of 177Lu-PSMA-617 (3, 6 or 9 GBq) combined with external beam radiotherapy (EBRT)
45502681|NCT05162573|Radiation|EBRT|External Beam Radiotherapy
45502682|NCT02056808|Drug|SMT C1100|Comparison of safety and pharmacokinetic of different dosages of drug
45502683|NCT02055950|Procedure|Storage of kidney in refrigerated solution|
45502684|NCT02055950|Procedure|Kidney perfused by pulsatile machine|
45502685|NCT04356755|Procedure|Adipose tissue harvest|An adipose tissue harvest (1) will be performed at D-14±1 for patient from arm ASC. Patients from placebo arm will have a sham adipose tissue harvest.
45391444|NCT00290589|Drug|Placebo|Normal saline intramuscular injection
45391445|NCT01067547|Drug|Iron Sucrose.|The total dose of iron sucrose given will be individualised by calculating their iron deficit.
45391446|NCT01067547|Drug|Iron sucrose|300mg of iron sucrose is given intravenously. Three infusions, each one week apart is given to patients with iron deficiency without anemia. For those patient with anemia, four infusions would be given.
45391447|NCT00290511|Drug|Fludarabine|25 mg/m^2 intravenous (IV) over 5-30 minutes on Days 2-4.
45391448|NCT00290511|Drug|Mitoxantrone|10 mg/m^2 IV over 5-30 minutes on Day 2.
45391449|NCT00290511|Drug|Rituximab|375 mg/m^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total).
45391450|NCT00290511|Drug|Zevalin|0.3 mCi/kg IV after 4 cycles of R-FND.
45391451|NCT00290511|Drug|Dexamethasone|20 mg by mouth (PO) or IV daily on Days 2-6.
45391452|NCT00290433|Drug|Cyclophosphamide|Cycle 1: 300 mg/m^2 by vein Over 3 Hours Twice Daily on Days 1, 2, and 3.
45391453|NCT00290433|Drug|Mesna|Cycle 1: 600 mg/m^2 by vein Continuous Infusion Over Days 1, 2, and 3.
45391454|NCT00290433|Drug|Vincristine|Cycle 1: 1.4 mg/m^2 by vein On Day 4 and 11.
45391455|NCT00290433|Drug|Methotrexate|Cycle 1 and 2: 200 mg/m^2 by vein Over 2 Hours on Day 1, followed by 800 mg/m^2 IV Over 22 Hours on Day 1.
45502686|NCT04356755|Drug|Autologous ASC|At day 0, patients will have ASC injections(3) in their ischemic DU. Patients will be followed-up for 16 weeks
45502687|NCT04356755|Drug|Placebo|At day 0, patients will have placebo injections(3) in their ischemic DU. Patients will be followed-up for 16 weeks
45502688|NCT01337219|Drug|Tobramycin|
45391456|NCT00290433|Drug|Ara-C|Cycle 1 and 2: 3 Gm/m^2 Over 2 Hours Twice Daily On Days 2 and 3.
45391457|NCT00290433|Drug|Dexamethasone|Cycle 1: 40 mg by vein or by mouth daily on Days 1-4 and 11-14.
45391458|NCT00290433|Drug|G-CSF|Cycle 1 and 2: 300 or 480 mcg subcutaneously 24 hours after end of Day 4 vincristine.
45391459|NCT00290433|Drug|Doxil|Cycle 1: 25 mg/m^2 by vein Over 1 Hour on Day 2.
45502689|NCT03560804|Drug|Olmesartan|Administration of olmesartan at starting dose and titrating in order to reach the target blood pressure.
45502690|NCT03560804|Drug|Chlorthalidone|Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.
45696632|NCT05153590|Drug|Saxenda®|"Patients will be treated with commercially available Saxenda® according to local label and to routine clinical practice at the discretion of the treating physician.~The indication is for adults who need help managing their weight based on two different body mass index (BMI) groups."
45391460|NCT04323033|Device|PERS stent|"PERS® is a cobalt-chromium stent, made of cobalt-chromium alloy with drug (Sirolimus) and biodegradable polymer controlling drug elution.~The length of the stent is selected to cover the treated lesion with a margin of 5 mm proximal and distal, while the diameter of the stent will be selected based on the QVA measurement (balloon to vessel ratio 1:1)."
45391461|NCT04323033|Device|NEPTUN C stent|Neptun C is balloon-expanding cobalt-chromium stent.
45391462|NCT00304083|Biological|filgrastim|Given subcutaneously
45391463|NCT00304083|Drug|doxorubicin hydrochloride|Given IV
45391464|NCT00304083|Drug|etoposide|Given IV
45391465|NCT00304083|Drug|ifosfamide|Given IV
45391466|NCT00304083|Procedure|conventional surgery|Patients undergo surgery
45391467|NCT00304083|Radiation|radiation therapy|Patients undergo radiotherapy
45391468|NCT00293241|Device|Managed Ventricular Pacing programmed ON/OFF|Device programming
45502691|NCT02056886|Procedure|SLN detection +/- complementary axillary lymphadenectomy|breast cancer surgery with SLN detection +/- complementary axillary lymphadenectomy Whatever the detection method used in the lab (Arm A: OSNA; Arm B: Pathological Examination; Arm C: Extemporaneous) to assess the positivity of sentinel lymph-node invasion, if negative result (no tumor invasion in the sentinel LN), a complementary lymph-node dissection is not mandatory if positive result (tumor invasion in the sentinel LN), a complementary lymph-node dissection is performed, either immediately (Arm A and C) or in a second surgical procedure (Arm B)
45502692|NCT03150719|Drug|Tezacaftor/Ivacaftor|TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
45696633|NCT03490864|Dietary Supplement|Melatonin 1 mg|Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
45696634|NCT03490864|Dietary Supplement|Placebos|Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
45696635|NCT03490864|Other|Meal Timing|Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.
45696636|NCT03490864|Other|NON Meal Timing|Subjects are instructed to maintain their habitual meal timing.
45391469|NCT01069809|Biological|AGS-004|HIV-1 Immune Therapy
45391470|NCT01069809|Biological|Placebo|Inactive Placebo Injection
45391471|NCT01067625|Device|TOGA® System|Formation of restrictive sleeve via transoral gastric stapling for treatment of obesity
45391472|NCT03977337|Procedure|Major emergency abdominal surgery|Major emergency gastrointestinal surgery performed within 72 hours of an acute admission or an acute reoperation.
45391473|NCT03977103|Biological|High dose irradiation conditioning + Treg/Tcon|High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation
45391474|NCT01069965|Drug|BGP-15 100 mg QD|Two 50 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
45391475|NCT01069965|Drug|BGP-15 100 mg BID|One 100 mg BGP-15 capsule by mouth in the morning; and one 100 mg BGP-15 capsule by mouth in the evening
45391476|NCT01069965|Drug|Placebo BID|Two Placebo capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
45391477|NCT01069965|Drug|BGP-15 200 mg QD|Two 100 mg BGP-15 capsule by mouth in the morning; and two Placebo capsule by mouth in the evening
45391478|NCT01069965|Drug|BGP-15 200 mg BID|Two 100 mg BGP-15 capsules by mouth in the morning; and two 100 mg BGP-15 capsules by mouth in the evening
45391479|NCT01069965|Drug|BGP-15 400 mg QD|Two 200 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
45696637|NCT03030898|Diagnostic Test|respiratory variation of the right internal jugular vein|respiratory variation of the right internal jugular vein vs respiratory variation of superior and inferior cava vena
45696638|NCT00089973|Drug|Ispinesib|Given intravenously at a dose of 18 milligram (mg)/ meter square (m^2).
45391480|NCT03979833|Genetic|Whole exome sequencing|DNA from CNS hemangioblastomas and normal tissue (blood) will be analysed using whole exome sequencing.
45391481|NCT01067703|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200 mm Hg, whereas the pressure has to be at least 20 mm Hg greater than the systolic arterial pressure measured via the arterial line.
45391482|NCT01067703|Procedure|Control/sham procedure (blood pressure cuff)|Sham placement of the blood pressure cuff around a dummy arm inflated to a pressure of 200 mm Hg with four cycles of 5 min inflation and 5 min deflation.
45391483|NCT01064895|Device|Benephit catheter for Targeted Renal Therapy|Local physician-specified agent delivery to the kidneys bilaterally via the renal arteries using the Benephit infusion system.
45391484|NCT00391092|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
45391485|NCT00391092|Drug|Docetaxel|100mg/m2 iv every 3 weeks
45391486|NCT00391092|Drug|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv every 3 weeks
45391487|NCT00374868|Drug|pemetrexed|"Phase 1: 300 mg/m^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles (dose escalation: 300 mg/m^2, 400 mg/m^2, and 500 mg/m^2)~Phase 2: phase 1 determined dose, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy"
45502693|NCT03150719|Drug|Ivacaftor|IVA 150 mg tablet.
45696639|NCT03030820|Procedure|Dental Cleaning|This is standard of care dental cleaning as is guided by the initial dental evaluation
45696640|NCT03030742|Other|Survey|"A survey will be administered at two time points (time of hospital discharge and 2-4 weeks postpartum) to determine:~Satisfaction with pain control 2-4 weeks postpartum~Patient-reported use of opioid medication postpartum (receipt of prescription, filling of prescription, if refill was obtained, and number of opioid pills remaining at the time of follow-up)~Patient characteristics associated with high opioid use~Methods of storage and disposal of unused opioids"
45391488|NCT00374868|Drug|cisplatin|"Phase 1: 50 mg/m^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles~Phase 2: 50 mg/m^2, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy"
45391489|NCT01044342|Drug|AZD1446|capsule; single oral dose
45391490|NCT01044342|Drug|AZD1446|capsule, single oral dose
45391491|NCT01044342|Drug|donepezil|capsule, single oral dose
45391492|NCT01044342|Drug|Placebo|capsule, single oral dose
45391493|NCT00374556|Drug|Placebo|3mg placebo capsule, once daily at bedtime
45696641|NCT04402203|Drug|Favipiravir|Favipiravir 200 mg (Favipira) tablet will be given orally. Day 1: Tablet Favipiravir 1600 mg twice daily Days 2-Days 10: Tablet Favipiravir 600 mg twice daily.
45696642|NCT04402203|Drug|Only Standard Treatment|Standard treatment included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs & the medication any patient is on due to any concomitant diseases.
45696643|NCT03030976|Drug|cyclophosphamide|Patients receive cyclophosphamide (Cy) on day -2 and day -1 to reduce B cells. The dose is 0.5g/m2/d.
45696644|NCT03030976|Drug|anti-CD19-CAR-T cells|A 2nd CAR, CD19 as target protein, 4-1BB as co-stimulator, and optimized the spatial conformation by a suitable hinge & transmembrane domain sequences. Patients infused with anti-CD19-CAR-T cells transduced with lentivirus on day 0 in the absence of disease progression or unacceptable toxicity to treatment of SLE. The dose is 1E6~1E7 CD19-CAR positive T cells. The cells infusion process may last for 30 min.
45848788|NCT01292070|Biological|Intradermal Human Fcγ1-Fel d1 fusion protein|"Part A: 7 sequential 10-fold dose increments from 0.001 BAU/mL to 1,000 BAU/mL; An 8th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of >= to 10mm.~Part B: 5 sequential 10-fold dose increments from 0.1 BAU/mL to 1,000 BAU/mL; An 6th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of >= to 10mm."
45391494|NCT00374556|Drug|Eszopiclone|3mg capsule, once daily at bedtime
45391495|NCT00290355|Biological|GSK 249553 vaccine|Intramuscular injection, 13 doses
45391496|NCT00290355|Biological|Placebo|Intramuscular administration, 13 doses
45391497|NCT03977025|Diagnostic Test|Lumbar punction|Patients will be evaluated prior to surgery with the Montreal Cognitive Assessment (MoCA) to determine the presence of cognitive impairment, and CSF samples, obtained by lumbar punction, will be analyzed by immunodetection of Aβ40, Aβ42, tau and ptau with multiplex technology
45391498|NCT01064973|Drug|arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the oral OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
45391499|NCT03741855|Device|Cloud Dx Kit with self-monitoring|Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.
45502694|NCT03150719|Drug|Placebo|Placebo matched to TEZ/IVA fixed-dose combination tablet.
45502695|NCT03150719|Drug|Placebo|Placebo matched to IVA tablet.
45696645|NCT03454425|Device|Exablate Subthalamotomy|ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
45848789|NCT01292070|Biological|Positive Control - standardized cat hair allergenic extract (CAT)|4 sequential 10-fold injections starting from 0.01 BAU/mL to 10 BAU/mL
45391500|NCT03741855|Device|Cloud Dx Kit with remote-monitoring|"Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.~A respiratory therapist (RT) will be monitoring asynchronously patient vitals and contacting them when their vitals exceed pre-determined thresholds.~The RT will also check on patients once a week irrespective of the value of the vitals."
45391501|NCT00374322|Drug|lapatinib|Lapatinib 1500 mg (6 tablets) daily for 12 months
45502696|NCT02038400|Device|KINETUBE medical Device|
45502697|NCT02038400|Device|insertion of tympanic ventilation tubes (tympanostomy)|
45502698|NCT01343927|Behavioral|Weekly yoga classes|Manualized 12-week Hatha yoga intervention developed specifically for chronic low back pain in adult populations; classes meet once each week at community-based locations.
45391502|NCT00374322|Other|placebo|6 tablets daily for 12 months
45391503|NCT00303459|Drug|bosentan|bosentan/62.5 mg tablet/b.i.d. for 4 weeks then bosentan/125 mg tablet/b.i.d.
45391504|NCT00303459|Drug|placebo|Matching bosentan placebo/b.i.d.
45391505|NCT00289887|Drug|Comparator: losartan +/- HCTZ|Placebo to losartan once daily for 4 weeks in run-in period. Then, losartan 50 mg for 4 weeks, then titrate to losartan 100 mg at Week 4, then titrate to losartan 100 mg + hydrochlorothiazide (HCTZ) 12.5 mg at Week 8, and finally titrate to losartan 100 mg + HCTZ 25 mg at Week 12. Duration of treatment is approximately 16 weeks.
45391506|NCT00289887|Drug|Comparator: Placebo|Placebo to losartan once daily for 4 weeks in run-in period. Then, placebo to losartan or losartan/HCTZ once daily for approximately 16 weeks.
45391507|NCT01325649|Procedure|total mesorectal excision / long course radiochemotherapy|long course 5-FU based radiochemotherapy before total mesorectal excision
45391508|NCT01325649|Radiation|long course 5-FU bases radiochemotherapy|
45391509|NCT01067937|Procedure|appendectomy|Randomisation will apply to the 8 participating centers as follow: During a first survey period of 6 month, the algorithm is not applied; The six following months, 4 randomised centers applied the algorithm, the others being still survey; The six last month, all centers will apply the algorithm
45502699|NCT01343927|Behavioral|Individual physical therapy treatment|12 weeks of fifteen individual physical therapy sessions divided as follows: Week 1 intake appointment; weeks 2-4 two appointments per week; weeks 5-12 one appointment per week.
45502700|NCT01343927|Behavioral|Education|"Participants given The Back Pain Helpbook and periodic newsletters addressing back pain and self care."
45502701|NCT02057120|Procedure|Kinesio Taping|Application of Kinesio (Kinesio Tex Gold ®) of black color. The tape will be applied from proximal to distal, leaving the anterosuperior iliac spine Bottom, passing over the Rectus Femoris and ending in the region of the anterior tibia tuberosity with a voltage of 25 %.
45502702|NCT02057120|Device|Kinesio Taping placebo|The volunteer who is allocated at random in the placebo group will receive an application of Kinesio transverse way the rectus femoris muscle, in order to verify a possible placebo effect of application of tape.
45502703|NCT02057354|Behavioral|Aerobic Exercise|The goal of the aerobic exercise training is to increase aerobic endurance. Walking on treadmill at moderate intensity with grade adjusted. Exercise tailored to individual ability level.
45696646|NCT03454425|Device|Sham Exablate Subthalamotomy|Sham ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
45848790|NCT01292070|Biological|Positive Control - Histamine Prick|1.0 mg/mL
45848791|NCT01292070|Biological|Negative Control - Intradermal Diluent|Saline, Albumin with Phenol (HSA) sterile diluent
45848792|NCT01284504|Drug|Celecoxib|200 mg tablet oral
45848793|NCT01284504|Other|placebo|Placebo, tab
45848794|NCT01204788|Procedure|Prophylactic White Cell Transfusion|Radiated white blood cell transfusions 2-3 times each week, or daily if infection develops
45848795|NCT01204788|Procedure|Therapeutic White Cell Transfusion|Radiated white blood cell transfusions daily only with infection (or persistent fever)
45391510|NCT00303069|Biological|V710|Single dose of V710 (at dosages of 5 μg, 30 μg, or 90 μg) intramuscularly
45391511|NCT00303069|Biological|Comparator: Placebo|Single dose of saline placebo intramuscularly
45391512|NCT01325727|Other|Brief computerized feedback|Brief computerized feedback
45391513|NCT01325727|Other|Resources only (control)|Participants randomized to the control group will discuss the option of quitting smoking, along with an information sheet, highlighting resources available to assist participants with smoking cessation, such as the Virginia Quitline (1-800 QUIT NOW) and nicotine replacement therapy.
45391514|NCT01068015|Other|behavior intervention and male circumcision|MSM in intervention arm can receive circumcision service for free, POL intervention, intensive HIV counseling and intensive condom promotion.
45391515|NCT01068093|Drug|Ezetimibe|10mg daily
45391516|NCT00401544|Drug|darbepoetin alfa|Darbepoetin alfa administered by subcutaneous injection.
45391517|NCT00401544|Drug|IV iron dextran|Administered by intravenous (IV) injection.
45391518|NCT01044420|Drug|mFOLFIRI|mFOLFIRI irinotecan 130-150mg/m2 iv d1 LV 200 mg/m2 iv 2h d1 5-FU 400 mg/m2 IV d1 5-FU 2.4-3 g/m2 CI 46-h repeat every 2 weeks
45391519|NCT00289731|Biological|TWINRIX™|Intramuscular injection, 3 doses
45391520|NCT00289731|Biological|Engerix™-B|Intramuscular injection, 3 doses
45391521|NCT00289731|Biological|HAVRIX™|Intramuscular injection, 2 doses
45391522|NCT00289731|Biological|HB VAX PRO™|Intramuscular injection, 3 doses
45391523|NCT00289731|Biological|Vaqta™|Intramuscular injection, 2 doses
45391524|NCT00289185|Biological|RTS,S/AS02D|3-dose intramuscular injection in the thigh
45848796|NCT01183416|Drug|3F8 monoclonal antibody and 13-cis-Retinoic Acid|A cycle consists of treatment with 3F8 for 5 days. GMCSF is started 5 days in advance of each 3F8 cycle. The break between end of a cycle of 3F8/GM-CSF and start of next cycle is 2-to-4-weeks through 4 cycles; subsequent breaks are ~6-8 weeks. 13-cis-retinoic acid is started after cycle 2.
45848797|NCT01169610|Drug|Varenicline|Varenicline is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 23 weeks of treatment. All subjects will receive open-label varenicline in blister packs.
45848798|NCT01166724|Drug|Sirolimus|Tacrolimus to Sirolimus
45848799|NCT01166724|Drug|Tacrolimus|dosage per trough level
45848800|NCT01151904|Drug|brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution|COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) administered as one drop in the morning and one drop in the evening in affected eye(s) for 12 weeks.
45848801|NCT01151904|Drug|latanoprost|Latanoprost administered in the affected eye(s) as prescribed by physician.
45848802|NCT01110174|Diagnostic Test|HD PET/CT|imaging
45848803|NCT01115244|Drug|Dapsone gel, 5%|ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
45848804|NCT01079598|Device|RF Ablation (ClosureRFS Stylet)|Bipolar energy radiofrequency ablation with RFS stylet
45848805|NCT01031550|Drug|isoflurane|isoflurane an anesthetic gas agent administered at specific times at a flow of 2 MAC
45391525|NCT00289185|Biological|Engerix-B®|3-dose intramuscular injection in the thigh.
45391526|NCT00289185|Biological|TETRActHib™|3-dose intramuscular injection in the thigh.
45391527|NCT03980067|Other|Virtual Reality Game|The virtual reality headset, device, and software, created by Stanford's Childhood Anxiety Reduction through Innovation and Technology (CHARIOT)program/Weightless Studio, LLC will be utilized in this study. Children in the VR intervention group will be allowed to select a distraction-based game to play with active VR content featuring interactive avatars and interactive experiences tailored to the pediatric population that allow players to do things such as control penguins sliding down a mountain while collecting pebbles for points, control puppies running in space to collect treats to the rhythm of music, and control an asteroid miner exploring an asteroid belt and collecting points based on color of asteroids collected. The game will last a minimum of 5 minutes in duration, provided participant tolerance. The participant may play longer if desired prior to receiving procedural sedation and the total length of activity played will be documented.
45391528|NCT00292461|Drug|Zonisamide|Tablet once or twice daily orally for 16 weeks
45391529|NCT00292461|Drug|Lamotrigine|Tablet once daily orally for 16 weeks
45391530|NCT03976869|Drug|AZD7594|During treatment period, AZD7594 (360 µg per day) will be administered as oral inhalation via dry powder inhaler or DPI (SD3FL inhaler).
45391531|NCT00288639|Drug|Pregabalin|"Pregabalin treatment, given as 2 divided doses, is initiated at a dose of 150 mg/day (75 mg BID).~Based on individual subject response and tolerability, the dosage may be increased to 300 mg/day after 1 week (150 mg BID given as two 75-mg capsules BID). Based on subjects individual response and tolerability, dosage can be incrementally increased further after an additional week to 600 mg/day (300 mg BID given as four 75-mg capsules BID)."
45391532|NCT01068171|Other|type of footwear|comparison of results between post-op shoe, air boot which the patient can remove ad lib and air boot whose removal can be monitored
45391533|NCT01068171|Other|collagen dressing with and without silver|silver-impregnated collagen dressing will be used for 2 weeks, then plain collagen dressing will be used for the remainder of the 6 months
45391534|NCT00390858|Drug|Deferasirox|Deferasirox in children from 1 to 18 years old was given orally once daily, 30 minutes prior to breakfast. An initial daily dose of 10 mg/kg was used during the 1-year core study. In this 4-year extension study dose modifications of ± 5 or 10 mg/kg were based on safety parameters and on increasing or decreasing Liver Iron Concentration (LIC), and serum ferritin. Deferasirox was available as 125 mg, 250 mg and 500 mg tablets.
45391535|NCT00390780|Drug|miconazole Lauriad|50 mg buccal tablet once a day for 14 days
45391536|NCT00390780|Drug|Clotrimazole|10mg troches administered Five Times a Day for 14 days
45391537|NCT00390546|Drug|Digoxin|
45391538|NCT00390546|Drug|Propranolol|
45391539|NCT00390468|Drug|Tandutinib|500 mg twice daily every day with doses taken approximately 12 hours apart, 28 day cycle.
45391540|NCT00400764|Drug|Dulanermin|Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.
45391541|NCT00400764|Drug|Rituximab|Rituximab was administered by intravenous (IV) infusion at 375 mg/m^2 weekly for up to eight doses.
45391542|NCT00302211|Drug|Inhaled Iloprost (5 μg)|iloprost inhalation solution (Ventavis) (5 μg)
45848806|NCT01031550|Drug|propofol|standard of care
45391543|NCT00302211|Drug|Inhaled Placebo|inhaled placebo
45391544|NCT00302211|Drug|Sildenafil|oral sildenafil (dosage between 60 and 300 mg/day)
45848807|NCT00986310|Drug|Fluoxetine|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
45391545|NCT00302211|Drug|Bosentan|oral bosentan (dosage between 62.5 and 125 mg BID)
45391546|NCT01045902|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
45391547|NCT01045902|Drug|Sulbactam/Ampicillin|Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid
45391548|NCT01041612|Device|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
45391549|NCT01041612|Device|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
45391550|NCT01041690|Drug|Bevacizumab|
45391551|NCT01041768|Procedure|Bariatric surgery|Biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve; Gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
45391552|NCT01041846|Drug|No intervention|This is an observational study. Patients receiving 20 mg/m2 of decitabine injection intravenously (into a vein) once daily for 5 days every 4 weeks will be observed.
45391553|NCT00288015|Biological|Bevacizumab|Bevacizumab 15 mg/kg IV infusion given on day 1 every 21 days = (1 cycle).
45391554|NCT00389064|Drug|Quetiapine XR|Quetiapine XR 50 mg tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily, in the evening for a 9-week treatment period.
45391555|NCT00389064|Drug|Placebo|Matching placebo tablets orally administered in flexible doses of 50 to 300 mg once daily, in the evening for a 9-week treatment period.
45391556|NCT01068327|Drug|gemcitabine hydrochloride|Given IV
45391557|NCT01068327|Drug|leucovorin calcium|Given IV
45391558|NCT01068327|Drug|fluorouracil|Given IV
45848808|NCT00986310|Drug|Placebo|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
45848809|NCT00907218|Drug|Varenicline (Chantix)|Upon completion of screening procedures and meeting eligibility criteria, subjects will begin taking varenicline daily until Week 6 of the study. At Week 6 they will discontinue varenicline and return one week later for their final study visit to assess return of ADHD symptomatology. Subjects will start on 0.5 mg of varenicline per day for the first week of treatment. The dose will be increased to 0.5 mg twice a day at the end of week 1 visit, and then increased to 1 mg twice a day at the end of week 2 visit, to remain at this dose until the week 6 visit. At week 6, all subjects will be openly discontinued from varenicline, to return to the office the following week for re-assessment one week off the medication. If significant adverse effects (AE) occur, the daily dose may be reduced by 0.5 to 1 mg. At subsequent visits, a higher dose may be resumed if tolerated. Maximum dose will be 2 mg daily.
45848810|NCT00895284|Procedure|Robotic hysterectomy|Robotic hysterectomy.
45391559|NCT01068327|Drug|nelfinavir mesylate|Given PO
45391560|NCT01068327|Radiation|stereotactic body radiation therapy|Undergo radiotherapy
45391561|NCT01068327|Radiation|hypofractionated radiation therapy|Undergo radiotherapy
45391562|NCT01068327|Procedure|therapeutic conventional surgery|Undergo surgery
45391563|NCT01045980|Drug|Bioimpedance and Vitamin D|Intervention subjects will undergo BIA assessment monthly for 1 year, and then every 3 months until the end of the planned 3-year study. Protocolized interventions to achieve euvolemia will occur based on the BIA result and they include sodium restriction, addition of diuretics, use of icodextrin, and additional rational changes to the PD prescription.
45391564|NCT01045980|Drug|Usual care and placebo|Usual care (not bioimpedance guided volume management) and Placebo
45391565|NCT01045980|Drug|Usual care and Vitamin D|Usual care (not bioimpedance guided volume management) and Vitamin D
45391566|NCT01045980|Device|Bioimpedance and Placebo|Bioimpedance guided volume management and Placebo
45391567|NCT00388674|Drug|entecavir|Tablets / Oral Solution, Oral, ETV = 0.5 mg - 1 mg, once daily, Investigator/Patient decision
45391568|NCT00388674|Drug|Other anti-HBV medication|Tablets / Oral Solution, Oral, depends on chosen active comparator, depends on chosen active comparator, Investigator/Patient decision
45391569|NCT00388362|Drug|Sirolimus|Patients will receive sirolimus at 2 mg/day orally with monitoring of trough drug levels weekly for 2 weeks to achieve trough drug levels 7-12 ng/ml. Along with prednisone therapy.
45391570|NCT00388362|Drug|Prednisone|Prednisone therapy will remain at the dose the patient received at the time sirolimus was begun. Withdrawal of prednisone will began after first evidence of improvement of chronic GVHD.
45391571|NCT03463980|Behavioral|Compassion meditation (CM)|CM session: 30 minute check-in regarding the participants' levels of suicidal ideation, as well as a discussion of current life stress and weekly meditation practice; a 30 minute didactic session that will describe the meditative technique introduced during the week; and a 30 minute guided meditation session. Participants are also encouraged to meditate at least 30 minutes a day.
45391572|NCT03463980|Behavioral|Support group (SG)|SG session: 90 minutes to talk about current concerns and to receive support and guidance from other group members and the leaders.
45391573|NCT01041924|Other|Carbon dioxide|2% inhaled CO2 for up to 8 hours.
45391574|NCT01041924|Other|Carbon dioxide|Up to a maximum of 2% CO2, only delivered for a maximum of up to 20 seconds per 60 seconds for 8 hours
45391575|NCT01042002|Behavioral|High intensity exercise|High intensity exercise 3xweek for minimum 6 weeks
45391576|NCT01046058|Drug|TMC435|150 mg (two 75-mg capsules) orally (by mouth) once daily for 7 days
45391577|NCT01046214|Drug|Bupropion HCl|Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
45391578|NCT01046214|Drug|Bupropion HCl|Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
45391579|NCT01324284|Drug|Lubiprostone|Lubiprostone is a chloride channel activator approved by the Food and Drug Administration for the treatment of chronic constipation. A randomized, double-blind, parallel-group, placebo-controlled study evaluating the effect of lubiprostone on gastric function showed slowed gastric emptying and increased small bowel and colonic transit time. Peak plasma concentration was shown to be around 1.14 hours, with a majority of the drug excreted in the urine within 48 hours.
45391580|NCT00387894|Drug|erlotinib hydrochloride|Tarceva will be self-administered in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
45391581|NCT03992976|Other|Online Chronic Pain Management Intervention for Teenagers|The intervention itself is currently under development. This development study is used to gather patient (teenager) insights, as well as insights from parents of these patients, which will inform the content and structure of the proposed intervention. This is done using qualitative-only techniques. Initial ideas for the intervention design mirror current clinical practices in paediatric chronic pain management. There are likely to be several different online modules, which include psychological techniques, medicine (advice), nursing (advice and guidance on non-pharmacological physical pain management), and physiotherapy (guidance for pacing and physiotherapy exercises). The intervention is intended to help teenagers employ a vast range of self-management techniques from these disciplines. Exact content is not yet refined as this is a development study.
45391582|NCT00387426|Drug|sunitinib malate|Given PO
45502704|NCT02057354|Behavioral|Non-Aerobic Exercise|The goal of this training is to improve overall muscle strength, balance and flexibility. Participants will do strength, balance and stretching exercises. Exercises tailored to individual ability level.
45502705|NCT04828187|Diagnostic Test|Comparison of the proposed artificial network with the ground truth|"Both eyes will be included for each study participant. Participants watched a 4-10-minute video in standard mesopic environmental lighting conditions at 3.5m viewing distance. Simultaneously, all blinking moves will be recorded through a web infrared camera.~The proposed system was tested on the 8 different subjects. Several metrics of blink detection and classification accuracy were calculated against the ground truth, which was generated by 3 independent experts, whose conflicts were resolved by a senior expert. Two independent blink identifications are assumed to be in agreement, if and only if there is sufficient temporal overlapping and the type of blink is the same between the DLED system and the ground truth."
45502706|NCT02057432|Device|intra-operative MRI|Patients will undergo an MRI during surgery.
45502707|NCT01344005|Other|caregiver-related intervention or procedure|
45502708|NCT01344005|Other|questionnaire administration|
45848811|NCT00895284|Procedure|Standard Hysterectomy|Standard hysterectomy.
45391583|NCT00387348|Drug|escitalopram oxalate|escitalopram oxalate 10 mg once daily for 4 weeks
45391584|NCT00387348|Drug|Placebo|one placebo pill identical in appearance to the escitalpram pill once daily
45391585|NCT03993522|Other|Symptom limited cardiopulmonary exercise test & Sub-maximal cardiopulmonary exercise test|Exercise tests on cycle ergometer for the purpose of collecting expired breath gasses
45391586|NCT03992820|Device|TENS machine|"The trial group will have the TENS to the area planned for injection for at least 30 minutes before injection of the local anaesthetic solution.~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration."
45502709|NCT01344005|Procedure|quality-of-life assessment|
45502710|NCT01344005|Procedure|radiography|
45502711|NCT02059772|Drug|ranibizumab|
45502712|NCT02059772|Procedure|micropulse diode laser|
45848812|NCT00903396|Drug|palonosetron hydrochloride|Given IV
45848813|NCT00903396|Other|placebo|Given IV
45848814|NCT00875394|Drug|sitagliptin phosphate|sitagliptin 100 mg Once a day (QD) for 24 weeks
45848815|NCT00875394|Drug|Comparator: metformin|metformin 850 mg Twice a day (BID) for 24 weeks
45848816|NCT00875394|Drug|Comparator: metformin|metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks
45848817|NCT00875394|Drug|Comparator: Antidiabetic Standard of Care|Patient can take any oral antidiabetic drug (other than metformin)
45848818|NCT00832572|Drug|Ranolazine|Ranolazine ER tablet administered orally for 6 weeks (500 mg twice a day for 3 weeks, followed by either 500 mg or 1000 mg twice a day for 3 weeks).
45391587|NCT03992820|Combination Product|EMLA cream|"The control group will have EMLA applied on the site planned for local anaesthetic injection and after 1 hour, will be removed and immediately injected with the same anaesthetic solution (this is already a procedure practised by many of the surgeons).~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration."
45391588|NCT01042080|Device|NAVA|Assisted mechanical ventilation according to the electrical activity of the diaphragm recorded with a 16-FR naso-gastric tube mounted with EMG electrodes
45391589|NCT01042080|Other|Expiratory trigger (ET)|Varying the cycling criterion according to the percentage of peak inspiratory flow
45391590|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
45391591|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
45391592|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
45391593|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
45391594|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
45391595|NCT00413660|Drug|CP-690,550|Oral tablets
45391596|NCT00413660|Other|placebo|Placebo
45391597|NCT01234532|Drug|entinostat|orally
45391598|NCT01234532|Drug|anastrozole|Given PO
45391599|NCT01234532|Other|diagnostic laboratory biomarker analysis|"Correlative studies will be performed utilizing tissue and blood. A baseline tumor biopsy is done prior to study entry or archival tissue from diagnosis may be used and a representative tumor sample is submitted at time of surgery.~Bloods are drawn for correlative sciences on day 1 and 15 of treatment prior to entinostat dosing and 30 mins post and again on day of surgery."
45391600|NCT01234532|Procedure|therapeutic conventional surgery|Lumpectomy or mastectomy will be performed follwoing day 29 of study therapy
45391601|NCT00431834|Device|Cardioblate System Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
45391602|NCT00431834|Procedure|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
45391603|NCT00431444|Drug|Raloxifene|
45391604|NCT00431444|Drug|Zoledronic acid|
45391605|NCT00431444|Drug|Placebo oral pills|
45391606|NCT00431444|Drug|Placebo intravenous (i.v.) infusion|
45391607|NCT01323686|Other|Imaging guided optimal LV lead placement|"LV lead placement guided by cardiac imaging using echocardiography, single-photon emission computed tomography, and CT to target a cardiac vein at the site of latest mechanical activation without scar tissue.~Visualization of cardiac venous anatomy is performed using cardiac CT if not contraindicated by depressed renal function (estimated glomerular filtration rate <30 ml/min) or allergy to contrast media. In that case, a coronary venogram is used."
45391608|NCT02594384|Drug|LAM-002A|25 mg capsules or 50 mg capsules
45848819|NCT00832572|Drug|Placebo|Placebo to match ranolazine administered twice a day for 6 weeks
45848820|NCT00811590|Drug|Everolimus|"Everolimus is a novel derivative of rapamycin. Everolimus has been in clinical development since 1996 as an immunosuppressant in solid organ transplantation. Since 2003, RAD001 is approved in Europe (trade name: Certican) via the Mutual Recognition Procedure (MRP) for the prevention of organ rejection in patients with renal and cardiac transplantation. Certican is also approved in Australia, South Africa, the Middle East, Central and South America, the Caribbean and some Asian countries.~Everolimus is being investigated as an anticancer agent based on its potential to act~directly on the tumor cells by inhibiting tumor cell growth and proliferation~indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell VEGF production and VEGF-induced proliferation of endothelial cells."
45848821|NCT00749658|Drug|Bupropion|Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.
45848822|NCT00749658|Drug|Varenicline|Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.
45848823|NCT00738972|Drug|valsartan|80 mg valsartan. Duration: 12 months. Tablets
45848824|NCT00738972|Drug|pravastatin|40 mg pravastatin. Duration: 12 months. Tablets
45848825|NCT00738972|Drug|simvastatin|40 mg simvastatin. Duration: 12 months. Tablets
45391609|NCT02594384|Drug|Rituximab|375 mg/m2 by vein
45391610|NCT02594384|Drug|Atezolizumab|1200 mg by vein
45391611|NCT00430352|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv every 8 weeks
45391612|NCT00287469|Biological|Hepatitis E vaccine, recombinant (Sar 56 kDa)|20mcg or rhE Sar 56 kDa/dose of 0.5 mL, aluminium hydroxide (0.5 mg/dose) and phenoxyethanol (2.5 mg/dose)
45391613|NCT00287469|Other|Placebo|PBS buffer placebo containing alum
45391614|NCT01068405|Drug|Methotrexate|Methotrexate: 10mg/week administered in one time, the same day each week (every monday for example)during 12 months
45391615|NCT01068405|Drug|Placebo|Placebo:10mg/week administered in one time, the same day each week (every monday for example)during 12 months
45502713|NCT01344083|Drug|T1210|2 drops T1210 once a day
45502714|NCT01344083|Drug|Olopatadine hydrochloride|2 drops once a day Olopatadine
45502715|NCT04039217|Drug|Biktarvy|Participants will be given two doses of the oral fixed dose combination anti-HIV medication Biktarvy (BIC/FTC/TAF) separated by 24 hours. The first dose is given in the clinic and participants are instructed to take the second dose at home, 24 hours after the first dose.
45502716|NCT02059850|Biological|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
45502717|NCT02059850|Drug|Cyclophosphamide|Given IV
45502718|NCT02059850|Other|Laboratory Biomarker Analysis|Correlative studies
45502719|NCT01342055|Drug|Apetrol ES|sequences of administered drugs
45502720|NCT02038478|Biological|Donor Stem Cell Transplantation|One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects.
45502721|NCT00982111|Drug|Pemetrexed|500 milligram per square meter (mg/m2) administered Intravenously (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles
45848826|NCT00738972|Drug|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets
45391616|NCT00429572|Drug|Fludarabine|30 mg/m^2 intravenously Daily for 5 Days
45391617|NCT00429572|Drug|Melphalan|70 mg/m^2 intravenously Daily for 2 Days
45391618|NCT00429572|Procedure|Stem Cell Infusion|Stem Cell Infusion on Day 0.
45391619|NCT00287079|Drug|Rebif®|44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks
45391620|NCT00287079|Other|No Treatment|No treatment for 96 weeks
45391621|NCT03976167|Device|Oxygen administration with Common nasal cannula|Oxygen administration during elective flexible bronchoscopy in children with high flow nasal cannula with inspired oxygen fraction 1.
45391622|NCT03976167|Device|Oxygen administration with high flow nasal cannula, device Airvo2 Fisher and Pykel|
45502722|NCT00982111|Drug|Cisplatin|75 mg/m2 administered I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles
45502723|NCT00982111|Biological|Necitumumab|800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V.
45502724|NCT05615090|Procedure|Arm I (Prepectoral),|The intervention will be delivered through a smartphone app. The app provides users with ED symptom self-monitoring, psycho-education and relapse prevention in an evidence-based CBT-E.
45502725|NCT05615090|Procedure|Arm II (Subpectoral)|The intervention will be delivered through a smartphone app. The app provides users with ED symptom self-monitoring, psycho-education and relapse prevention in an evidence-based CBT-E.
45502726|NCT02957682|Drug|Praluent (Alirocumab)|
45502727|NCT02957682|Drug|Placebo|
45502728|NCT02057822|Procedure|Cytokins assay in tears|
45502729|NCT03057951|Drug|Empagliflozin|once daily
45502730|NCT03057951|Drug|Placebo|once daily
45502731|NCT02060240|Behavioral|High Activity|The high activity group will undergo a 12 week ramped exercise protocol.
45502732|NCT02038556|Behavioral|cognitive behaviorial therapy -Insomnia|
45391623|NCT03975933|Diagnostic Test|Pregnancy test at Baseline|Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.
45391624|NCT03975933|Diagnostic Test|Free pregnancy test for the future use|We will provide a free pregnancy test in for the future use.
45391625|NCT03975933|Diagnostic Test|Pregnancy test for the future use with randomzied price|We will provide an opportunity to buy a pregnancy test for the future use with randomized price.
45391626|NCT00429494|Drug|Leuprolide Acetate|22.5 mg IM injection 2 months before transplant and 3 months post-transplant.
45391627|NCT00429494|Behavioral|Questionnaire|Questionnaires taking about 15 minutes to complete.
45391628|NCT00429494|Procedure|Hematopoietic Stem Cell Transplantation|Stem cell infusion on Day 0.
45391629|NCT00429416|Drug|L-leucyl-L-leucine Methyl Ester (LLME)|Infusion of L-leucyl-L-leucine methyl ester (LLME) treated donor white blood cells
45391630|NCT00429416|Drug|Fludarabine|Fludarabine 30 mg/m2 prior to HSCT infusion
45391631|NCT00429416|Drug|Cytarabine|Cytarabine 2gm/m2 prior to HSCT infusion
45391632|NCT00429416|Drug|Cyclophosphamide|Cyclophosphamide 1gm/m2 prior to HSCT infusion
45391633|NCT00429416|Drug|Tacrolimus|Tacrolimus given before and after HSCT infusion
45391634|NCT00429416|Drug|Mesna|Mesna 1gm/m2/day given prior to HSCT infusion.
45391635|NCT00429416|Biological|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|GM-CSF given post HSCT infusion
45502733|NCT02057900|Biological|Human embryonic stem cell-derived CD15+ Isl-1+ progenitors|Epicardial delivery of a fibrin patch embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors
45696647|NCT00949234|Drug|tenofovir + emtricitabine, lopinavir/ritonavir|"The preferred regimen will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a creatinine clearance 30-49 mL/min, dosing of Truvada is 1 tablet by mouth every other day. For patients with creatinine clearance <30 mL/min or on hemodialysis, Truvada should not be used. For intolerance to Truvada, Combivir (zidovudine 300mg/lamivudine 150mg)will be available to be taken as 1 PO BID. For highest-risk category exposures (receptive anal intercourse with a known or suspected HIV-positive source patient or in cases of suspected source drug resistance, see Schema, below) one of the following should be added to the above standard treatment, creating an expanded regimen:~Preferred: Lopinavir/ritonavir (200mg/50mg), 2 tablets orally twice daily or 4 tablets once daily"
45391636|NCT00429416|Procedure|Hematopoietic stem cell transplantation (HSCT)|CD34 selected allogeneic stem cell infusion with 5x104/kg untreated T cells
45391637|NCT00429182|Drug|Carboplatin|Target Area Under the Curve (AUC) of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.
45391638|NCT00429182|Drug|Cyclophosphamide|1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
45391639|NCT00429182|Drug|Thiotepa|120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
45391640|NCT00429182|Procedure|Stem Cell Transplant|Stem Cell Transplant on Day 0.
45391641|NCT00429104|Drug|Herceptin|4 mg/kg IV Over 90 Minutes
45391642|NCT00429104|Drug|GM-CSF|250 mcg/m^2 Subcutaneously
45502734|NCT02060318|Drug|Infliximab|The patients are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
45502735|NCT01318837|Drug|solifenacin|oral
45502736|NCT03146663|Drug|NUC-1031 500 mg|NUC-1031 500 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
45502737|NCT03146663|Drug|NUC-1031 750mg|NUC-1031 750 mg/m2 on Days 1, 8, and 15 of a 28-day cycle
45391643|NCT00429026|Drug|Fludarabine|25 mg/m^2 intravenous (IV) daily for 5 Days
45391644|NCT00429026|Drug|Melphalan|70 mg/m^2 IV Daily for 2 Days
45391645|NCT00429026|Drug|Cyclophosphamide|60 mg/kg IV Daily for 2 Days
45391646|NCT00429026|Procedure|Stem Cell Transplant|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Related Donor
45391647|NCT00301821|Biological|epratuzumab|
45391648|NCT00301821|Biological|rituximab|
45391649|NCT00301821|Drug|cyclophosphamide|
45391650|NCT00301821|Drug|doxorubicin hydrochloride|
45391651|NCT00301821|Drug|prednisone|
45391652|NCT00301821|Drug|vincristine sulfate|
45391653|NCT03976713|Drug|Bufei Yishen granule|Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks.
45502738|NCT01350037|Drug|alfentanil|Alfentanil is a potent but short-acting synthetic opioid analgesic drug, used for anaesthesia in surgery. It is an analogue of fentanyl with around 1/10 the potency of fentanyl and around 1/3 of the duration of action, but with an onset of effects 4x faster than fentanyl.It is an OP3 mu-agonist.Alfentanil is administered by the parenteral (injected) route for fast onset of effects and precise control of dosage.
45391654|NCT03976713|Drug|Placebo Bufei Yishen granule|Placebo Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks. The placebo granule consists of dextrin, bitter and 5% of the Bufei Yishen granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group.
45391655|NCT03976713|Drug|Tiotropium Bromide Powder for Inhalation|Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks.
45391656|NCT01068483|Drug|BKM120|
45391657|NCT00372996|Drug|CP-751,871|CP-751,871 given at 20 mg/kg IV on day 1 of each 21 day cycle.
45391658|NCT00372996|Drug|exemestane|Exemestane given at 25 mg orally once a day.
45391659|NCT00372996|Drug|exemestane|Exemestane given at 25 mg orally once a day. Treatment until progression or toxicity
45391660|NCT00372996|Drug|Fulvestrant|Used for salvage therapy and administered according to the local label and standard clinical practice.
45391661|NCT00399516|Device|Precision|
45391662|NCT01046292|Drug|Ginkgo biloba|The participants will be randomly allocated to either the intervention group or the placebo control group at a ratio of 1:1. After six months, GBE will be administered to all participants for another 6 months for free. The daily administered dose (taken with meals in the morning and evening) will consist of either twice-daily 1 capsule of Symfona® forte 120mg GBE or identically appearing placebo.
45696648|NCT02984787|Procedure|3D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 3D laparoscopic-assisted totalgastrectomy (3D-LTG) group, they will received 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection
45391663|NCT00399360|Drug|Metformin|Starting at 500 mg twice daily and increasing to 850 mg twice daily after 3 Months
45391664|NCT00399360|Drug|Placebo|500 mg twice daily increasing to 850 mg twice daily after 3 Months
45391665|NCT00399360|Behavioral|Lifestyle Modification|Lifestyle Modification
45391666|NCT00428948|Drug|Tolvaptan|Tolvaptan was supplied as tablets.
45391667|NCT00428948|Drug|Placebo|Placebo was supplied as tablets.
45391668|NCT00428792|Drug|Methylphenidate 20 mg long-acting capsules|
45391669|NCT01037894|Procedure|Acupuncture|Acupuncture from physiotherapist (with accredited training in acupuncture) in Shatin Hospital, three sessions per week for six weeks, and each session 30 minutes.
45391670|NCT01037894|Procedure|Conventional rehabilitation|In-patient physiotherapy, occupational therapy and speech therapy.
45391671|NCT00300885|Drug|Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel|Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
45391672|NCT00300885|Drug|Carboplatin plus Paclitaxel|Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
45391673|NCT00386334|Drug|Eszopiclone|2 mg tablet once per day in the evening
45391674|NCT00386334|Drug|Placebo|Tablet one per day in the evening.
45391675|NCT01143116|Device|"Silver-nitrate coated catheter (Catheter A)"|Catheter A releases silver ions into the urethra and urinary bladder upon catheterization.
45391676|NCT01143116|Device|"Degradable silver particle-coated catheter (Catheter B)"|Catheter B releases both silver ions and degradable silver particles into the urethra and urinary bladder upon catheterization.
45391677|NCT01037972|Behavioral|Conventional physiotherapy|3 times weekly 30 minutes of conventional physiotherapy to strengthen muscular strength and balance in the lower extremity.
45391678|NCT01037972|Behavioral|Whole body vibration|3 times weekly 30 minutes of exercises on a whole body vibration device to strengthen muscular strength and improve muscular balance in the lower extremity.
45696649|NCT02984787|Procedure|2D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 2D laparoscopic-assisted totalgastrectomy (2D-LTG) group, they will received 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection
45391679|NCT01034774|Drug|ACHN-490 Injection|ACHN-490 Injection at 15mg/kg is given either 1 or 5 consecutive days. Cohort 1 receives 5 consecutive days of treatment and Cohort 2 receives a single dose of treatment.
45391680|NCT01034774|Drug|Placebo (normal saline)|Placebo is given at the same volume as ACHN-490 Injection to maintain the blind.
45391681|NCT00428714|Drug|enzastaurin|Administered orally
45391682|NCT01033214|Device|Endovascular repair of TAA in the descending Thoracic Aorta|Usage of the TAArget thoracic stent graft for treatment of TAA in the Descending Thoracic Aorta.
45391683|NCT00292227|Drug|Rotigotine|"Rotigotine patch applied once daily for a 24-hour period.~Rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;"
45391684|NCT00292227|Other|Placebo|"Placebo patch applied once daily for a 24-hour period. Size and number of patches matching to rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;"
45502739|NCT01350037|Drug|remifentanil|Remifentanil is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high dose opioid and low dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.It is administered in the form remifentanil hydrochloride and in adults is given as an intravenous infusion in doses ranging from 0.1 microgram per kilogram per minute to 0.5 (µg/kg)/min.
45391685|NCT00292227|Drug|Moxifloxacin infusion|Moxifloxacin 400 mg/250 mL iv solution infused over 1h once either on Day 32 or on Day 39
45391686|NCT00292227|Other|Placebo infusion|Placebo saline solution 250 mL infused over 1h once either on Day 32 or on Day 39
45391687|NCT00292227|Other|Placebo infusion|Placebo saline solution 250 mL infused over 1h once on both Day 32 and on Day 39
45391688|NCT00386100|Drug|Avandamet 6 mg/1500 mg (ttd)|One 2 mg/ 500 mg capsule will be taken in the AM with the morning meal Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal
45391689|NCT00386100|Drug|Avandamet 4 mg/1000 mg (ttd)|One 2 mg/500 mg capsule will be taken in the AM with the morning meal. One 2 mg/500 mg capsule will be taken in the PM with the evening meal.
45391690|NCT00386100|Drug|Avandamet 2 mg/500 mg (ttd)|one placebo capsule will be taken in the AM with the morning meal one 2 mg/ 500 mg capsule will be taken in the PM with the evening meal.
45391691|NCT00386100|Drug|Avandamet 8 mg/ 2000 mg (ttd)|Two 2 mg/ 500 mg capsules will be taken in the AM with the morning meal. Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal.
45391692|NCT00386100|Drug|Metformin 500 mg (ttd)|One placebo capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
45391693|NCT00386100|Drug|Metformin 1000 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
45391694|NCT00386100|Drug|Metformin 1500 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsules will be taken in the PM with the evening meal.
45502740|NCT02060006|Drug|Meloxicam 7.5mg daily for 8 weeks|Meloxicam 7.5mg daily for 8 weeks
45696650|NCT03090880|Drug|Tinzaparin Sodium|Subcutaneous tinzaparin 4,500 IU once daily for six months.
45696651|NCT03490695|Other|Practice Facilitation|Community health nurses trained in implementing the evidence-based TASSH protocol will be employed as Practice Outreach Facilitators (POF) to train the CHPS community health officers to deliver TASSH. The POFs will be required to complete an intensive 12-week training course focused on adoption of TASSH protocol to identify patients at risk for uncontrolled HTN, initiate behavioral lifestyle counseling, and Refer patients to the community health centers for drug therapy. Over the course of 12 months, the POFs will provide support to their assigned CHPS zones to implement TASSH as part of routine patient care.The POFs will also work with CHPS directors to review current work flow and develop a plan of action for TASSH uptake at the CHPS zones.
45391695|NCT00386100|Drug|Metformin 2000 mg (ttd)|Two 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsule will be taken in the PM with the evening meal.
45502741|NCT01350193|Device|Manuka Honey|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
45696652|NCT03490695|Other|Usual Care|Provide Ghana's National Health Insurance, behavioral counseling and referral for care through the usual care system for 12 months.
45696653|NCT03489993|Diagnostic Test|Ang II and Ang-(1-7)|Measured in plasma and urine using radioimmunoassays.
45696654|NCT03489993|Diagnostic Test|FGF23 and klotho|Measured using ELISA's.
45391696|NCT01068561|Biological|intravitreal injection of autologous bone marrow stem cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
45391697|NCT00300495|Drug|Amiodarone|Perioperative orally administered
45391698|NCT00300495|Other|Control arm, standard care|Control
45391699|NCT01068639|Behavioral|No treatment given|No treatment given to study participants, only behaviorial patterns with respect to treatment compliance is observed.
45391700|NCT03979989|Drug|Tapentadol IR capsule|Tapentadol IR capsule containing 93 mg tapentadol hydrochloride.
45391701|NCT03979989|Drug|Omeprazole capsule|Omeprazole capsule containing 40 mg omeprazole.
45391702|NCT02532387|Other|Telephone follow-up|Prospectively enrolled subjects will have a 7- and 30-day phone call.
45391703|NCT01070199|Behavioral|liquid to liquid|"• One test session will involve presentation of a glass of clear cherry-flavored unthickened beverage (Kool-Aid, Kraft Foods Inc., White Plains, NY). This session will be referred to as the Liquid to Liquid session as the participants will be consuming a liquid and be told that the consistency in their stomach will be a liquid."
45391704|NCT01070199|Behavioral|liquid to solid|This session involves a solution of calcium chloride and a solution of sodium alginate. The participant will be instructed to pour the cherry-flavored beverage/alginate solution into the calcium chloride. The result is a solid mass. They are allowed to examine the solution to confirm the solid texture and consistency.Participants will be told that this same reaction will occur in their stomach when the session's beverage is consumed due to the effect of gastric acid on the solution. But, the participant will be consuming the same cherry-flavored beverage as in the 1st session. Thus, they will believe that their GI tract will be challenged with a solid mass, but in reality, the challenge is the same (i.e., liquid).Therefore, the only difference between the test sessions is expectation.
45391705|NCT01070199|Behavioral|solid to liquid|"• This session will involve the same dense gelatin cubes previously described, but participants will be told that the solid cubes will turn to liquid when they come into contact with the acid in their stomach. This trial will be known as Solid to Liquid. A demonstration of the Solid to Solid and Solid to Liquid phases will be shown to the participant before they consume the load. Both phases exhibited by placing two cubes into separate containers filled with similar looking clear liquids. The Solid to Solid phase container will contain cold water so the cube stays in solid form. The Solid to Liquid phase container will contain hot water that will quickly dissolve the cube into a liquid form."
45502742|NCT01350193|Other|Saline Irrigation|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
45502743|NCT03640182|Other|Health management model of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
45502744|NCT03620435|Drug|Atezolizumab|Atezolizumab (1200mg iv, every 3 weeks) administered concurrently with TMT and adjuvant for up to one year
45502745|NCT01357993|Drug|JNS001|18 mg, 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
45502746|NCT03618888|Other|Instructor-led training|The Instructor-led training contents a supervised practical training with a standard kit for training in BLS
45502747|NCT03618888|Other|Self-learning training|The self-learning training contents a standard kit for self-directed training in BLS
45502748|NCT01317017|Drug|Actimmune|"All subjects will receive one intradermal injections of 0.25ml of IFN-g (Actimmune TM 100 micrograms/0.5ml), in normal appearing skin of both normal volunteers and psoriasis patients.~Blood will be taken at baseline and day 1. A skin biopsy (6mm punch) will be taken at the injection site 24 hours later.~Patients will return at one to two weeks for suture removal.~Clinical assessments done at every visit.~Patients will also be evaluated at each visit for any adverse events."
45502749|NCT05637554|Procedure|Laparoscopic appendectomy using clipping.|Laparoscopic appendectomy using clipping to secure the base of the appendix.
45502750|NCT05637554|Procedure|Laparoscopic appendectomy using extracorporeal ligation to secure the base of the appendix.|Laparoscopic appendectomy using extracorporeal ligation to secure the base of the appendix.
45502751|NCT03640104|Behavioral|Intervention-Nutrition guidelines|Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.
45391706|NCT01070199|Behavioral|solid to solid|"Participants will be presented with dense gelatin cubes. These 1 x 1 x 1 cubes will have a solid appearance and require mastication, but is isocaloric to the beverage. However, after mastication and gastric processing, the solid rapidly breaks down into a clear fluid.However, participants will be informed that the cubes will remain the same solid consistency in their stomach. The masticatory process and stimulus form will be standardized through the use of a metronome. Participants will be required to chew the solid cube at a fixed rate prior to swallowing. Thus, adding to the cognitive impression that they are eating a solid when essentially the GI challenge will be similar to the beverage."
45391707|NCT01325571|Drug|Tacrolimus capsule|oral
45391708|NCT01325571|Drug|Placebo|oral
45391709|NCT00386022|Drug|GnRH|GnRH doses of 25, 75, 250 and 750 ng/kg will be given IV every 4 hr at baseline and after transdermal estradiol
45391710|NCT00386022|Drug|NAL-GLU GnRH antagonist|A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg before and after transdermal estradiol
45391711|NCT00386022|Drug|Estrogen patch|transdermal estrogen patches 0.05mg/day, changing the patch every 86 hr in second part of sequential study
45391712|NCT01068795|Drug|enoxaparin|enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
45391713|NCT03979755|Other|Application of questionnaires|Application of questionnaires described by telephone.
45391714|NCT01068951|Biological|Mesenchymal stem cells|Autologous transplantation of the patients own mesenchymal stem cells (approximately 2 x 106 cells/kg body weight) intravenously.
45391715|NCT00286455|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 26 weeks.
45391716|NCT00286455|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 26 weeks.
45391717|NCT00286455|Drug|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
45391718|NCT00385944|Drug|Prasugrel|Prasugrel 10-mg tablet taken orally as a daily maintenance dose for a 14-day treatment period.
45391719|NCT00385944|Drug|Clopidogrel|Clopidogrel two 75-mg tablets taken orally as a daily maintenance dose for a 14-day treatment period.
45391720|NCT01046370|Behavioral|Amygdala Retraining Program|Mind-body intervention.
45502752|NCT03640104|Behavioral|Nutrition guidelines|Nutritional recommendations based on international guidelines
45502753|NCT04686773|Biological|AZD1222|"AZD1222 (0.5 ml per dose) contains:~Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10^10 particles per dose.~Solution for intramuscular injection, supplied in vials (5 mL, up to 10 doses per vial) in a carton box."
45696655|NCT00951808|Biological|Single blood transfusion|Participants will receive a single transfusion of 7-13cc/kg packed red blood cells (RBCs) while in the hospital.
45391721|NCT00286221|Drug|PCA fentanyl|"PCA fentanyl 0.5 ug/kg with a dosing interval (lockout) of 15 minutes and a maximal permitted dosage of 4 demand doses per hour, according to their randomized preoperative assignment. The PCA pump (CADD-Solis Ambulatory Infusion Pump; Smiths Medical, Dublin, OH) had a preprogrammed dose limit of 50 ug fentanyl, and this was the maximal PCA dose permitted"
45696656|NCT00951808|Behavioral|Standard care|Participants will receive standard care for ACS while in the hospital.
45696657|NCT05097976|Drug|Methylprednisolone|21 x 4mg tablets beginning on POD 1
45696658|NCT05097976|Drug|Placebo|21 sugar tablets beginning on POD 1 with standard management
45391722|NCT00286221|Drug|PRN fentanyl|IV fentanyl 25 to 50 ug every 30 minutes PRN (the maximal routine dose permitted in our Neurosciences Critical Care Unit (NCCU))
45391723|NCT03976635|Device|Removable Mandibular Retractor|The appliance will be used 18 hours per day. It can only be removed for eating meals.
45391724|NCT03976635|Device|Bone-anchored intermaxillary traction|The patients will be instructed to wear the upper removable appliance for 18 hours per day. The elastics should be extended from the upper appliance towards the lower mini-screws.
45391725|NCT00285207|Drug|placebo|5 days of 28 day cycle for 2 cycles
45391726|NCT00285207|Drug|A007|5 days of 28 day cycle
45391727|NCT00398112|Drug|sunitinib malate|Given orally
45391728|NCT00398112|Other|pharmacological study|Correlative studies
45391729|NCT00398112|Other|laboratory biomarker analysis|Correlative studies
45391730|NCT01065129|Drug|G-CSF|
45391731|NCT01065129|Drug|Plerixafor|
45391732|NCT01065129|Drug|Azacitidine|
45391733|NCT03976791|Procedure|enlarged internal incision|enlarging the internal incision about 0.4mm
45391734|NCT03976791|Procedure|regular 2.2mm incision|2.2mm microincision coaxial phacoemulsification
45391735|NCT01042314|Drug|Donepezil|Tablets, Oral, 5 mg, Once Daily, Days 1-28
45391736|NCT01042314|Drug|BMS-708163|Capsule, Oral, 125 mg, Once Daily, Days 15-28
45391737|NCT01044654|Genetic|SB-728-T|Each infusion will be 5-30 billion ZFN modified CD4+ T-cells
45391738|NCT01065207|Biological|blood test at day one|"Epidemiological, clinical, virological, and immunological data will be collected.~Clinical events as neoplasia will be collected"
45391739|NCT01046604|Drug|Lovaza group|Patients who are scheduled for mitral valve repair surgery at least 3 weeks removed from the initial consult will be recruited to take 4 capsules of Lovaza (omega 3 fatty acids) daily, for 3 weeks prior to their surgery.
45391740|NCT00424346|Drug|Canakinumab|
45696659|NCT05092126|Behavioral|Exercise|Calculate oxygen consumption
45696660|NCT03030508|Other|No intervention|
45696661|NCT03030430|Biological|BAT1706 injection|1mg/kg, IV on day 1
45696662|NCT03030430|Biological|EU-sourced Avastin|1mg/kg, IV on day 1
45696663|NCT03030430|Biological|US-sourced Avastin|1mg/kg, IV on day 1
45696664|NCT00089661|Drug|Placebo|60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
45696665|NCT00089661|Drug|AMG 162 / Denosumab|60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
45391741|NCT00424346|Drug|Placebo|
45391742|NCT00283959|Drug|migalastat HCl|
45391743|NCT01069107|Other|Cottage Hospital Care|Care at a cottage hospital compared with care at a general hospital
45391744|NCT00372528|Drug|pregabalin (LYRICA)|150 mg up to a maximum of 600 mg per day bid or tid as required
45391745|NCT00283803|Drug|Exisulind|Oral antineoplastic agent that induces apoptosis in cancerous cells.
45391746|NCT00283803|Drug|luteinizing hormone-releasing hormone (LHRH) agonist|Hormonal therapy to suppress testosterone as a standard treatment for Prostate Cancer.
45391747|NCT00283803|Drug|Antiandrogen|Hormonal therapy used as lead in treatment with luteinizing hormone-releasing hormone (LHRH) agonist to prevent the initial rise in testosterone (testosterone flare) seen during the first dose of LHRH agonists.
45391748|NCT01044810|Drug|Efavirenz-based regimens|Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.
45391749|NCT01033370|Drug|clevidipine.|Clevidipine administered per IV infusion, starting dose of 2 mg/h (4 mL/hr) for 3 minutes & titrated to the desired BP lowering effect to SBP goal of < 120 mmHg, max infusion rate may not exceed 32 mg/h (64 mL/hr).
45391750|NCT03976089|Behavioral|Recipe 4 Success|"The Recipe 4 Success intervention consisted of 10 weekly lessons in which parents and toddlers prepared simple snacks or meals.~All Recipe 4 Success lessons started and ended with some evidence-based information for the parents about children's self-regulation skills or healthy eating habits. Most of each lesson in Recipe 4 Success was devoted to the snack or meal preparation activities. Each week, home visitors coached the parents as they worked with their toddlers to make increasingly challenging snacks and meals. During these activities, home visitors pointed out opportunities for parents to practice sensitive scaffolding strategies. At the same time, these meal and snack preparation activities allowed children to practice multiple age-appropriate self-regulation skills."
45391751|NCT03976089|Behavioral|Treatment as Usual Early Head Start|Treatment as Usual Early Head Start consisted of an evidence-based curriculum (usually Parents as Teachers) in which home visitors and parents worked with children on activities to support their physical, cognitive, and social-emotional development.
45391752|NCT01044888|Drug|Heparin|150 U/kg heparin was administered intravenously at the beginning of graft anastomosis and accepted a perioperative ACT value of around 300 s. Ten minutes after the loading dose, the ACT was measured. An ACT of 300 s or greater was considered as adequate. Then follow up ACT measurement was determined after 30 min from the previous ACT measurement. If ACT fell below the target value of 300 s, an additional dose of heparin was administered. If ACT was between 250 and 299 s, additional 2000 U of heparin was administered and if ACT was between 200 and 249 s then additional 3000 U of heparin was injected. Ten minutes after additional heparin injection, ACT was remeasured.
45391753|NCT03975777|Other|LO|Participants will perform an acute bout of low-intensity cycling (11 x 1 min intervals at ~73% of peak aerobic work rate interspersed with 1 min recovery periods)
45391754|NCT03975777|Other|HI|Participants will perform an acute bout of high-intensity cycling (8 x 1 min intervals at ~100% of peak aerobic work rate interspersed with 1 min recovery periods)
45391755|NCT03742466|Drug|Ozone|After prepping and draping the area, intracarpal injection of ozone/oxygen mixture (20 ml, 25μg/ml) will be performed under sonographic guidance
45502754|NCT04686773|Biological|rAd26-S|"Component I (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10^11 particles per dose.~Solution for intramuscular injection, supplied in vials (3 mL, 5 doses per vial) in a carton box"
46056877|NCT02717871|Device|PACK-CXL|"Local anesthesia~- Oxybuprocaine or Tetracaine, 1 drop each, applied together, every 3 minutes, total of 3 times~Abrasio - Abrasio: 1 mm around the borders of the infiltrate/ulcer~Corneal scrape~Hypo-osmolaric riboflavin solution~- Apply one drop every 2 minutes for 20 minutes~UV-A irradiation~3 mW/cm2 for 30 minutes or 9 mW/cm2 for 10 minutes, 18 mW/cm2 for 5 minutes, 30 mW/cm2 for 3 minutes all allowed (see paper Richoz et al)~Treatment diameter: use a irradiation diameter of 6 to 8 mm, keep the infiltrate/ulcus centered.~Additional postoperative treatment~Homatropin or Scopolamin, if anterior chamber reaction~Systemic NSAID/NSAR, if substantial pain~Do not use: topical or systemic steroids, topical NSAID/NSAR, paracetamol, vitamin A ointment, patching"
45502755|NCT02058056|Radiation|Irradiation: HA-PCI|25 Gy in 10 daily factions, five times a week
45391756|NCT03742466|Drug|methylprednisolone acetate|After prepping and draping the area, intracarpal injection of methylprednisolone acetate 40mg, and 40 mg lidocaine (20 ml, volume) will be performed under sonographic guidance
45391757|NCT01065285|Biological|Evaluation of vaccines against flu|evaluate efficacy and tolerance
45391758|NCT01033526|Drug|Aspirin (Acetylsalicylic acid, BAYE4465)|1-2 tablets Acetylsalicylic Acid 400 mg (in combination with Ascorbic Acid 240 mg) as needed every 4-6 hours over a maximum of 5 days
45391759|NCT01033526|Drug|Placebo|1-2 tablets matching Placebo as needed every 4-6 hours over a maximum of 5 days
45391760|NCT01038050|Drug|Ginkgo Biloba Extract (GBE)|Ginkgo Biloba Extract 40 mg 1# tid per day for 3 months(90 days)
45391761|NCT00397488|Drug|sunitinib malate|
45391762|NCT01038206|Behavioral|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV. Consistent with our prior Familias Unidas efficacy studies, all parent group sessions and all family visits will be conducted in Spanish and will take place in the evenings and on Saturdays at the school or at a community site that is preferred by the families.
45391763|NCT01581411|Drug|Tissue Plasminogen Activator|Intra-ophthalmic artery injection of 2 mg t-PA over 10 minutes followed by 10 mg t-PA over 2 hours
45391764|NCT02900664|Biological|PDR001|Powder for solution for infusion
45391765|NCT02900664|Biological|ACZ885|Solution for injection
45391766|NCT02900664|Biological|CJM112|Solution for infusion
45391767|NCT02900664|Drug|TMT212|Tablets
45391768|NCT02900664|Drug|EGF816|Tablets
45391769|NCT03975699|Other|Assessment of psychological repercussions of SCD|Quantitative relevant data culled from medical files and qualitative analysis based on data gathered from child and parent interviews, were collected in the three hospitals.
45391770|NCT01033604|Procedure|Glyaderm and split skin graft|Full thickness defects treated with Glyaderm and split skin graft.
45391771|NCT01033604|Procedure|Split skin graft alone.|Full thickness defects treated with split skin graft alone.
45391772|NCT03976557|Device|BIP CVC|Central venous access with noble metal coated CVC
45391773|NCT03976557|Device|Standard CVC|Central venous access with standard uncoated CVC
45391774|NCT01065363|Behavioral|standardized exercise program and dietary counseling|Lecture, 12 weeks Standardized exercise program, 12 weeks Dietary counseling, 12 weeks Information platform, 12 weeks
45391775|NCT01324596|Drug|Intravenous|Chemoimmunotheraphy
45391776|NCT01324596|Drug|Bortezomib|Chemoimmunotheraphy
45391777|NCT00424190|Drug|IV Vancomycin plus IV Aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
45391778|NCT00424190|Drug|Ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
45391779|NCT02859012|Drug|Axitinib|Dosing schedule: 5mg twice per day orally (4 weeks is considered as 1 cycle)
45391780|NCT02859012|Other|Observation|this group is observational ones.
45391781|NCT00428246|Drug|paricalcitol|1 mcg or 2 mcg for 4 weeks.
45391782|NCT00428246|Drug|Placebo|Placebo
45391783|NCT00274287|Drug|GM CSF|250 ug/m2 daily for 2 weeks followed by 2 weeks of rest
45391784|NCT01042626|Other|Oral peptones load|Enrolled subjects will receive 10 g Liebig meat extract diluted in 250ml of 0.9% saline
45391785|NCT02581670|Radiation|stereotactic radiation therapy (SRT)|Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach
45391786|NCT01045200|Other|Comparison of follow-up|Comparison of follow-up by nurse or surgeon after rectal cancer surgery
45391787|NCT01065441|Biological|AlloStim|Patients meeting eligibility criteria will be primed with at least three and up to nine intradermal AlloStim-TM injections at a frequency of every 2-8 days at doses between 1-4 x 10^7 cells
45391788|NCT01065441|Procedure|Cryoablation|Percutaneous cryoablation of selected tumor lesion under CT or US guidance
45391789|NCT01065441|Biological|AlloStim|intratumoral injection of AlloStim-TM into cryoablated tumor lesion at a dose of 1-6 x 10^7 cells
45391790|NCT01065441|Biological|AlloStim|intravenous AlloStim-TM at doses between 1 x 10^7 to 1 x 10^9 cells
45391791|NCT01065441|Biological|AlloStim|Intraperitoneal AlloStim-TM infusion in patients with peritoneal carcinomatosis and/or ascites
45391792|NCT01065441|Biological|AlloStim|Patients with malignant pleural effusion may receive intrapleural AlloStim-TM infusion at a dose of 5-10 x 10^7 cells.
45391793|NCT01065441|Biological|AlloStim|Patients with palpable tumors may receive alcohol ablation and intratumoral AlloStim-TM
45391794|NCT01045278|Drug|Pegylated interferon-alfa-2b and ribavirin|Pegylated interferon-alfa-2b 1.5 microg/kg subcutaneously once weekly plus weight based ribavirin 800-1200 mg PO for a variable period depending on their HCV genotype and response to treatment.
45391795|NCT01046760|Behavioral|Language Assessment|Patients underwent an assessment performed with School Performance Test, Syntactic Awareness Test and a Peabody Picture Vocabulary Test.
45391796|NCT00423800|Drug|Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)|"Powder for Solution in Redipen® (pegylated interferon alfa-2b) (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 or 48 weeks~200 mg ribavirin capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 or 48 weeks"
45391797|NCT03932708|Behavioral|CDC Core Elements of Outpatient Stewardship|The intervention is described above and includes components of leadership, action of policy and practice, tracking and reporting, and education and expertise.
45391798|NCT00405548|Drug|BNP (nesiritide)|
45391799|NCT00405548|Drug|Placebo|
45391800|NCT00405392|Drug|Ibandronate (SB743830HD)|
45391801|NCT00282243|Drug|tacrolimus modified release (MR)|Oral
45391802|NCT00282243|Drug|tacrolimus|Oral
45502756|NCT05162495|Device|BioStation T101 and TeraTube|Rapid detection of the novel SARS-CoV-2 (COVID-19) virus in breath samples.
45391803|NCT00272961|Drug|Placebo|placebo tablet once daily for 12 weeks
45391804|NCT00272961|Drug|TBC3711|10 mg tablets once daily for 10 weeks
45391805|NCT00272961|Drug|TBC3711|50 mg tablet once daily for 10 weeks
45848827|NCT00726180|Drug|trastuzumab (Herceptin®)|About 1 week (4 - 7 days) before scheduled breast surgery, consisting of lumpectomy or mastectomy, subjects will receive a dose of trastuzumab (Herceptin®). Trastuzumab will be given through an IV or port for approximately 90 minutes. During this time, subjects will be closely monitored by a chemotherapy nurse to make sure that subjects do not have a reaction to the medication. It is possible that the infusion of the medication will need to be slowed down, in which case, the time for the infusion will be longer than 90 minutes. The one dose of the trastuzumab drug will be provided by the study (not billed to insurance), but the charges to administer the drug will be billed to subjects or subjects health insurance.
45391806|NCT00272961|Drug|TBC3711|100 mg tablet once daily for 10 weeks
45502757|NCT02956278|Drug|Allopurinol|
45502758|NCT02956278|Other|Placebo|lactose placebo pill
45502759|NCT02058134|Device|cardioPAT cell saver|
45502760|NCT02060396|Drug|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily orally for 7 days.
45502761|NCT01358071|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion weekly or every 3 or 4 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
45502762|NCT01358071|Drug|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
45696666|NCT00941668|Drug|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
45391807|NCT00272961|Drug|TBC3711|200 mg tablet once daily for 10 weeks
45391808|NCT00282087|Drug|gemcitabine, docetaxel, doxorubicin|Cycles = 28 days
45502763|NCT01358071|Drug|Doxorubicin|60 mg/m² iv every 3 weeks for a maximum of 8 cycles
45391809|NCT00404924|Drug|ZD6474 (vandetanib)|once daily oral tablet
45391810|NCT00404924|Other|Best Supportive Care|standard of care
45391811|NCT00281697|Drug|Bevacizumab|The dose of bevacizumab was based on a patient's weight at baseline and remained the same throughout the study.
45391812|NCT00281697|Drug|Placebo|
45391813|NCT00281697|Drug|Standard chemotherapy|"Patients received one of the following four standard chemotherapies for metastatic breast cancer.~Taxane - Paclitaxel (Taxol) 90 mg/m^2 IV every week for 3 weeks followed by 1 week of rest; paclitaxel (Taxol) 175 mg/m^2 IV every 3 weeks, or paclitaxel protein-bound particles (Abraxane) 260 mg/m^2 IV every 3 weeks; or docetaxel (Taxotere) 75-100 mg/m^2 IV every 3 weeks.~Gemcitabine (Gemzar) 1250 mg/m^2 IV on Days 1 and 8 of each 3-week cycle.~Vinorelbine (Navelbine) 30 mg/m^2 IV every week of each 3-week cycle.~Capecitabine (Xeloda) 1000 mg/m^2 orally twice daily on Days 1-14 of each 3-week cycle."
45391814|NCT00271947|Biological|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation will be performed after conditioning regimen
45391815|NCT00232180|Drug|Eplerenone|Eplerenone administered on top of background standard heart failure therapy
45391816|NCT00280917|Drug|CF101|
45391817|NCT00280683|Drug|L-arginine|subjects will take matching 0.01 g/kg/day of L-arginine in divided doses for thre months.
45391818|NCT00280683|Drug|Placebo|Placebo tablets that match the L-arginine intervention tablets will be given for three months
45502764|NCT04827719|Drug|BST-236|Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)
45502765|NCT02058212|Drug|ascorbate 1000mg, vitamin E 400, zinc and selenium|anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) are given to half patients only before IVF , plasma level of ROS are detected before and on day of oocyte retrieval then correlated to pregnancy outcome
45502766|NCT02957136|Device|Rapid respiratory pathogen nucleic acid amplification test|Patients randomized to the rapid respiratory pathogen nucleic acid amplification test (Film Array Respiratory Panel, BioFire Diagnostics), will receive usual physician-directed care plus results from a rapid diagnostic test for 20 common respiratory pathogens. Patients will have a nasopharyngeal swab sample collected and tested during the ED episode of care with results reported in the electronic medical record (EMR) within two hours of sample collection. ED physicians will receive education regarding the rapid respiratory pathogen test prior to commencing the study. During the study, ED physicians will be free to review and interpret the respiratory pathogen test results and make treatment decisions based on their individual clinical judgment without involvement of study personnel.
45696667|NCT00941668|Drug|sodium monofluorophosphate toothpaste|Twice daily usage
45696668|NCT03488121|Behavioral|Poster|Posters contain inspirational messages and pictures highlighting the important and unique roles that patients and physicians can play in reducing unnecessary care and health care costs. These posters will be placed in physician offices.
45696669|NCT03488121|Behavioral|Thank-you Letter|Physicians will be sent thank-you letters containing changes in the rates of antibiotics and serum ferritin tests ordered since introduction of Choosing Wisely NL and a thank-you message from the NL Medical Association.
45696670|NCT05056792|Other|Isometric strength training for 8 week|Plyometric training for 8 week
45696671|NCT05056792|Other|Conventional training|Conventional training for 8 week
45391819|NCT00270855|Procedure|Arm Crank Ergometry|Use of an upper body cycle to perform exercise. 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
45391820|NCT00270855|Procedure|FES Cycle Ergometer|Use of an FES cycle ergometer to perform exercise. 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
45391821|NCT01070277|Drug|Tinidazole and Albendazole|Tinidazole 2 gr/daily for 2 days followed by Albendazole 400mg X2 /day for 7 days
45391822|NCT01070277|Drug|Placebo control|"2 placebo pills X2 /day for 2 days followed by~1 placebo Pill X2 / day for 7 days"
45391823|NCT01070355|Drug|Eicosapentaenoic acid free fatty acid|An enteric-coated preparation of 99% pure omega-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid as the free fatty acid. 500mg capsules, 2 taken twice daily for 2-6 weeks before liver resection.
45391824|NCT01070355|Drug|Placebo|2 capsules taken twice daily for 2-6 weeks before liver resection.
45391825|NCT00404768|Drug|GSK221149A|6mg/h and 12 mg/h
45391826|NCT00404768|Drug|Placebo|Matched Placebo to Drug
45391827|NCT00270231|Drug|Naltrexone|"All participants took naltrexone during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo; all study medication periods were separated by a 5-7 day washout period.~Dosing of the naltrexone was the same for all participants: Day 1: 12.5mg, Day 2: 25mg, Days 3 and 4: 50mg."
45391828|NCT00270231|Drug|Placebo|"All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.~Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule."
45391829|NCT02532309|Drug|Rosuvastatin (5mg，10mg，20mg)|Rosuvastatin dose adjusted by LDL-c level( If LDL-C>1.1mmol/L and <1.8mmol/L, administrated as 5mg/day.If LDL-C ≥1.8mmol/L, adjusted every 4 weeks as 5mg，10mg，20mg.
45391830|NCT02532309|Drug|Rosuvastatin 5mg|Rosuvastatin 5mg/day
45391831|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
45391832|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
45391833|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
45391834|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
45391835|NCT03909620|Diagnostic Test|Low-dose computed tomography of chest|Eligible subjects will undergo a single round of LDCT screening. The LDCT will be considered as positive if a solid nodule or part-solid nodule of size ≥6 mm or non-solid nodule of size ≥20 mm is identified. Evaluation of positive nodules will be performed as per existing standard recommendations
45391836|NCT00269919|Drug|Risperidone Long-Acting Injectable (RLAI)|The RLAI 25 mg or 37.5 mg or 50 mg will be administered intramuscularly depending on Investigator's discretion every 2 weeks for 2 years.
45391837|NCT01038284|Behavioral|Patient education|Pharmaceutical care of patients with PAH
45391838|NCT01038284|Other|Data collection|Clinical and biological data, treatment, medication errors and ADEs
45391839|NCT01038362|Other|NCEP Step 1 diet plus Almonds|NCEP Step 1 Diet Plus Almonds 3 oz per day for 6 weeks
45391840|NCT01038362|Other|No Almonds|NCEP Step 1 diet without almonds
45391841|NCT01065675|Other|Medication reconciliation completed by a RN, CPhT, or RPh|To determine which patients benefit the most from medication histories obtained by the RN, CPhT, or RPh. Patients will be admitted as inpatients through the ED with medication histories finalized electronically by the RN at the admitting unit.
45391842|NCT00258154|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
45391843|NCT00258154|Biological|Comparator: placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
45391844|NCT00258154|Biological|Comparator: Infanrix(tm) Hexa|3 doses of oral Infanrix(tm) Hexa on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
45391845|NCT00257920|Drug|Zemplar® injection|6 mcg QOD
45391846|NCT00257920|Drug|Hectorol® injection|3.6 mcg QOD
45391847|NCT00268983|Biological|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric dose: 450 mg Tositumomab infused over 1 hour followed by 5 mCi I 131 Tositumomab infused over 20 minutes~Therapeutic dose: 450 mg Tositumomab infused over 1 hour followed by Individualized mCi activity of I 131 Tositumomab (35 mg) infused over 20 minutes."
45391848|NCT00268983|Biological|Rituximab|Rituximab 375 mg/m2 given as an IV infusion once weekly for four weeks.
45391849|NCT01065753|Behavioral|Lifestyle Counseling|Diet control with exercise
45502767|NCT01354093|Drug|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken twice a day
45848828|NCT00704496|Drug|Pseudoephedrine|Pseudoephedrine is a 240 mg PO per day
45391850|NCT01070511|Drug|Tadalafil|Tadalafil will be administered orally on two consecutive days. The first dose-10 mg- will be administered the afternoon before the study. The second dose -20 mg-will be administered the morning of the study.
45391851|NCT01070511|Drug|Placebo|A placebo pill will be administered orally on two consecutive days. The first pill will be administered the afternoon before the study. The second pill will be administered the morning of the study.
45391852|NCT01070667|Drug|Dronedarone|400mg orally once per day for 3 months
45391853|NCT01070667|Drug|Placebo|1 tablet once per day for 3 months. The tablet will appear identical to the active dronedarone tablet.
45391854|NCT00257608|Drug|bevacizumab|Intravenous repeating dose
45391855|NCT00257608|Drug|placebo|Oral repeating dose
45391856|NCT00257608|Drug|erlotinib HCl|Oral repeating dose
45391857|NCT01073176|Other|TEAMS (Training Attention Executive and Motor Skills)|Training Executive, Attention and Motor Skills (TEAMS) is a new research program for preschool children with Attention-Deficit/Hyperactivity Disorder (ADHD) that attempts to use game-like activities and physical exercise to promote the growth of neural processes that underlie the core features of the disorder (e.g., hyperactivity, impulsivity) as well as associated areas of difficulty (e.g., socialization, motor skills). These activities are implemented at home and in supervised playgroups at no cost to families and are coupled with extensive parental education about ADHD symptoms and associated impairments.
45391858|NCT00231478|Drug|granisetron|20 micrograms intravenously (iv) 15 min prior to end of surgery
45391859|NCT00231478|Drug|granisetron|40 micrograms intravenously (iv) 15 min prior to end of surgery
45391860|NCT00413192|Drug|E7389|1.4 mg/m^2 administered as an intravenous (I.V.) bolus infusion on Days 1 and 8 of every 21 days.
45391861|NCT01038440|Dietary Supplement|Safflower Oil|One softgel consumed daily with food
45391862|NCT01038440|Dietary Supplement|EPA|Three different doses of EPA (0.5, 1.5 and 3.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
45391863|NCT01038440|Dietary Supplement|SDA|Four different doses of SDA (0.5, 1.5, 3.0 and 6.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
45391864|NCT00207142|Drug|Atazanavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
45502768|NCT01354093|Drug|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken once a day
45502769|NCT02060474|Drug|Triac|Triac is a naturally occuring T3 metabolite with similar bioactivity and receptor binding profile.
45502770|NCT04816955|Behavioral|Dietary recommendations|Dietary recommendations, with increasing additional behavioural/practical advice or no dietary recommendations
45502771|NCT03561272|Other|Smart Phone Application|Oral medication adherence phone application.
45696672|NCT03487887|Device|continuous glucose monitoring (CGM) iPro™2 Medtronic|A CGM device is to be set and take off by the diabetologist. Before the study start all diabetologist not familiar to the method will have a short education on CGM device. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating, physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing CGM.
45696673|NCT01597414|Drug|Pertuzumab + trastuzumab|"Trastuzumab: loading dose of 8 mg/kg of body weight on cycle 1, followed by a maintenance dose of 6 mg/kg every 3 weeks.~Pertuzumab: loading dose of 840 mg on cycle 1, followed by 420 mg for subsequent cycles, every 3 weeks.~if T-DM1: 3.6 mg/kg IV, every 3 weeks."
45696674|NCT01597414|Drug|Pertuzumab + trastuzumab + metronomic chemotherapy|Pertuzumab and trastuzumab will be administered as in arm A. Cyclophosphamide: daily dose of 50 mg/day. if T-DM1: as in arm A
45696675|NCT05056246|Drug|AMG 133|Solution for injection
45696676|NCT04984330|Drug|Selinexor|Selinexor will be given orally at a dose of 60mg once weekly on the first day of the week (day 1, 8, 15, and 22) for Cycle 1 and up to Cycle 12.
45848829|NCT00692094|Biological|Melatonin|0.025 mg-0.5 mg, daily given at a time when it is expected to delay the timing of the body clock.
45391865|NCT00207142|Drug|Atazanavir + Ritonavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
45391866|NCT00268905|Drug|E7389 + carboplatin AUC 5|Patients will receive E7389 before (Schedule A) or after (Schedule B) carboplatin AUC 5 infusion. E7389 will be administered as a 2-5 minute intravenous (IV) bolus infusion at a starting dose of 0.7 mg/m^2 on Days 1 and 8 every 21 days. Carboplatin 5 AUC will be administered as a 30-minute IV infusion on Day 1 every 21 days. Dose escalation will be performed in cohorts of three patients per dose level per schedule.
45391867|NCT00268905|Drug|E7389 + carboplatin AUC 6|"After MTD is reached with carboplatin AUC 5, dose escalation of E7389 in combination with carboplatin at AUC 6 will begin at one dose level below MTD, using the preferred schedule (A or B).~If carboplatin AUC 6 with E7389 is tolerated, the MTD reached will be used to enroll 20 additional patients with Stage IIIB or IV non-small cell lung cancer (NSCLC). If carboplatin AUC 6 is not tolerated, these patients will be enrolled at the MTD determined with the combination of E7389 and carboplatin AUC 5."
45502772|NCT03561272|Other|POD|Pill dispensing system that dispenses the medication, controls dispensed dosage, and confirms dispensing to patient through wireless communication back to the control center.
45502773|NCT03640260|Behavioral|breathing regulation with physical activity|The subjects will have education leaflets with breathing and oximetry level evaluation training.
45502774|NCT01354171|Device|MRI assisted TRUS guided biopsy|All subjects to have a confirmatory biopsy at one year. Those assigned ARM 1 to have a TRUS guided biopsy and those assigned to ARM 2to have a MRI assisted TRUS guided biopsy
45391868|NCT00268905|Drug|E7389+carboplatin AUC 6|In a population of patients who had generally received multiple prior chemotherapies, the eribulin MTD has been determined to be 1.1 mg/m2 in combination with carboplatin at an AUC of 6. The first-line NSCLC patients in the extension arm may tolerate a higher dose of eribulin, because they have not been exposed to the toxicity of other chemotherapies. To investigate this possibility, the dose of eribulin will be increased to 1.4 mg/m2 for subsequent patients, if the first six of these patients do not experience a DLT during their first cycle of eribulin at 1.1 mg/m2 and carboplatin at AUC 6 combination therapy. If no more than one of the first six patients experience a DLT during the first cycle with the 1.4 mg/m2 dose of eribulin, then the 1.4 mg/m2 dose will be considered the recommended dose for front-line NSCLC therapy and the remaining patients will be treated using this dose.
45391869|NCT03974997|Diagnostic Test|Determination of the circulating serum concentration of cytoquine TWEAK|Blood samples (20 ml of blood on dry tube) by venipuncture at the bend of the elbow will be made at T0, then monthly for a period of 1 year . The sera will be isolated by centrifugation and then frozen at -80 degrees Assays of the soluble form of TWEAK and TNF will be performed by ELISA blot technique developed by the team.
45391870|NCT00206518|Drug|Taxotere/Docetaxel|Taxotere
45391871|NCT00206518|Drug|Adriamycin/Cytoxan|Adriamycin/Cytoxan
45391872|NCT00206518|Drug|doxorubicin|AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.
45391873|NCT01065831|Behavioral|Motivational interviewing (MINT-TLC)|The MINT-TLC lifestyle intervention lead by lay health advisers will be compared to the health education attention control condition (CC). Twenty churches will participate in the study and each church will be randomly assigned to receive either MINT-TLC or CC. They will be compared on blood pressure reduction, physical activity levels, intake of fruits and vegetables, and weight reduction.
45391874|NCT03972904|Dietary Supplement|Light-Fat Rice® combined with Active Peptide®+ lifestyle guidance|Subjects will be given the Light-Fat Rice® combined with Active Peptide® with a lifestyle guidance to assist diabetes management. The method of taking the product has two parts: 1.Light-Fat Rice®: 80g (1 pack) per day as a staple meal replacement, used as a separate staple food or mixed with other staple foods, taking 4 weeks; 2.Active Peptide®: 20g (2 packs) per day (1 pack each morning and evening), served with 300ml of 40°C warm water each time before meals and take it for 4 weeks.
45391875|NCT03972904|Dietary Supplement|A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin + lifestyle guidance|A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin (both produced by the same manufacturer) with a lifestyle guidance will be given by the professional to assist in diabetes management. The product is taken as follows: 1.equal-energy staple food containing a small amount of dietary fiber: 80g (1 pack) per day, used as an independent staple food or mixed with other staple foods, taking for 4 weeks; 2.equal-energy maltodextrin: 20g(2 packs) per day(1 pack each morning and evening),take it with 300ml of 40°C warm water for 4 weeks.
45391876|NCT00423722|Drug|Saline|1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
45391877|NCT00423722|Drug|Saline|100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
45391878|NCT03899012|Procedure|Incisional Hernia Surgery|Verification of the accuracy in the collection of 21 selected variables in the Spanish EVEREG Incisional Hernia Surgery Registry
45391879|NCT00206440|Drug|esomeprazole|nexium
45696677|NCT04984330|Drug|Dexamethasone|Dexamethasone will be given orally at a dose of 20mg, if tolerated, or at a reduced dose if required, 30 to 60 minutes prior to selinexor for first 2 days of each week only (days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle).
45848830|NCT00692094|Biological|Melatonin|0.025 mg - 0.5 mg, daily, at a time when melatonin should advance the timing of their body clock.
45848831|NCT00692094|Biological|Melatonin|0.025 mg - 10 mg, daily, at a time when melatonin should advance the timing of their body clock.
46056878|NCT02717871|Drug|Cefazolin in combination with either tobramycin or gentamicin|"Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.~Initial empiric topical antibiotic therapy (eye drops or ocular ointment):~1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml)."
46056879|NCT02717871|Drug|Cycloplegic agents (cyclopentolate 1% eye drops)|Cycloplegic agents (cyclopentolate 1% eye drops): to decrease pain and synechia risk is at the physician discretion.
46056880|NCT02717871|Drug|Fluoroquinolones (Besifloxacin ; ciprofloxacin ; gatifloxacin ; levofloxacin ; moxifloxacin ; ofloxacin )|Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)
45391880|NCT00206440|Other|Placebo|Placebo 1 pill daily Cycle 1 Days 1-5 and Cycle 2 Days 1-5
45391881|NCT00268437|Drug|carboplatin|carboplatin is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
45391882|NCT00268437|Drug|Pemetrexed|Pemetrexed is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
45391883|NCT00268437|Procedure|conventional surgery|
45391884|NCT00268437|Procedure|neoadjuvant therapy|
45391885|NCT00268437|Radiation|radiation therapy|Radiation therapy begins day 1 and continues for 5 ½ weeks (45 Gy in 22-25 fractions of 1.8 Gy to extended field; 50.4 Gy in 28 fractions within boost field).
45391886|NCT00423488|Drug|Ezetimibe 10 mg|1 x 10-mg tablet, provided as blinded study treatment
45391887|NCT00423488|Drug|Simvastatin 20 mg|1 x 20-mg tablet, provided as open-label study treatment
45391888|NCT00423488|Drug|Ezetimibe Placebo|1 tablet matching ezetimibe 10-mg tablet, provided as blinded study treatment
45391889|NCT00423488|Drug|Simvastatin 20 mg|1 x 20-mg tablet, provided as blinded study treatment
45391890|NCT00423488|Drug|Simvastatin Placebo|1 tablet matching 20-mg simvastatin tablet, provided as blinded study treatment
45391891|NCT03969472|Drug|probiotics|apply probiotic after operation
45391892|NCT03969472|Device|Electrophysiologic Therapy|Pelvic floor electrophysiological therapy is used after surgery
45391893|NCT00404066|Drug|Lapatinib|1250 mg, tablets, oral daily during treatment with docetaxel (3-week cycles x 4 cycles)
45391894|NCT00404066|Drug|Doxorubicin|60 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with cyclophosphamide.
45391895|NCT00404066|Drug|Cyclophosphamide|600 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with doxorubicin.
45391896|NCT00404066|Drug|Docetaxel|100 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
45391897|NCT00404066|Drug|Pegfilgrastim|6 mg, subcutaneously on day 2 of all cytotoxic chemotherapy treatments.
45391898|NCT00404066|Drug|Filgrastim|300 or 480 mcg, subcutaneously on days 3 to 10 after cytotoxic chemotherapies.
45502775|NCT04668443|Other|Graphical Informed Consent (GIC)|The GIC (set of illustrations that complement the written information and consent form) will be proposed to prospective participants by researchers, systematically during the pre-test (stage 1). If the stage 1 shows no negative impact of the GIC on the consent process, the stage 2 will be implemented and the GIC will be proposed by researchers when they feel it could be beneficial for the participant.
45502776|NCT03561194|Dietary Supplement|Omegaven|After the diagnosis of PNALD is made, patients who are followed by the Neonatal Intensive Care Unit, NICU, will contact Dr. Honrubia and Dr. Swarup. Cases may also include referrals of patients with PNALD from other healthcare facilities or self-referrals. If the patient's parents or guardians agree to participate in the study, informed consent will be obtained. The history of present illness and past medical history will be reviewed with the guardian and pertinent demographic and medical information will be recorded on data collection forms. This form will be used to record all laboratory results, nutritional history, and descriptions of any liver biopsies performed.
45502777|NCT03618810|Drug|PEGCSF first level prophylactic use|6mg (≥45kg) or 3mg (<45kg) i.h. once 24h after chemotherapy in all cycles of chemotherapy
45391899|NCT00404066|Drug|Dexamethasone|8 mg, oral taken twice a day for 3 days starting 24 hours before docetaxel
45391900|NCT00404066|Drug|Trastuzumab|Loading dose 8 mg/kg, then 6 mg/kg, intravenously every 3 weeks for 1 year
45391901|NCT01581645|Device|Mobilaser|Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
45502778|NCT03618810|Drug|PEGCSF second level prophylactic use|6mg (≥45kg) or 3mg (<45kg) i.h. once 24h after chemotherapy in next cycle if FN or 4 grade neutropenia happened
45502779|NCT01354249|Dietary Supplement|whey protein plus carbohydrate drink|The CHO-P group received 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
45502780|NCT02058446|Drug|Amlodipine/Valsartan|Amlodipine/Valsartan: 5 mg/80 mg
45391902|NCT01581723|Device|Monopolar diathermy|monopolar diathermy
45391903|NCT01581723|Device|Bipolar diathermy|bipolar diathermy
45391904|NCT03993860|Dietary Supplement|Fish Powder|Dry small fish (Chisense) is roasted and ground into a powder and packed in a sachet (12g) and given to the child at 6 months up to the time the child is 12 moths old. Each month the childs anthropometric measurement are taken to monitor growth.
45391905|NCT03993860|Dietary Supplement|Sorghum powder|Dry sorghum is roasted and ground into a powder and packed in a sachet (12g) and given to the child at 6 months up to the time the child is 12 moths old. Each month the childs anthropometric measurement are taken to monitor growth.
45391906|NCT03993548|Behavioral|Wellness Element 1 - Exercise|Daily wellness element focusing on Exercise; adherence documented online daily
45391907|NCT03993548|Behavioral|Wellness Element 2 - Mindfulness|Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
45391908|NCT03993548|Behavioral|Wellness Element 3 - Sleep Hygiene|Daily wellness element focusing on sleep hygiene; adherence documented online daily
45391909|NCT03993548|Behavioral|Wellness Element 4 - Social Connectedness|Daily wellness element focusing on Social Connectedness; adherence documented online daily
45391910|NCT03993548|Behavioral|Wellness Element 5 - Nutrition|Daily wellness element focusing on Nutrition; adherence documented online daily
45391911|NCT03993548|Behavioral|Wellness Element 6 - Wellness Exercises|Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
45391912|NCT03993548|Behavioral|Wellness Element 7 - Motivational Messages|Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
45391913|NCT01038674|Drug|anti-IL-20|Anti-IL-20 injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
45391914|NCT01038674|Drug|placebo|Placebo injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
45391915|NCT00423332|Drug|Cediranib|45 mg oral tablet
45391916|NCT00423332|Drug|Cediranib Placebo|oral tablet
45391917|NCT01040468|Procedure|Roux-en-Y Gastric Bypass surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
45391918|NCT01040468|Procedure|Laparoscopic Adjustable Gastric Banding surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
45391919|NCT01040468|Behavioral|Intensive Lifestyle Modification|Intensive lifestyle modification program for weight loss. Participants randomized to this condition will receive an weekly individual treatment of 30 minutes for the first 6 months and every-other-week sessions from months 7 to 12. Treatment will be provided by a behavioral psychologist or registered dietitian following a structured curriculum used in our prior studies. During the first 4 months, participants will be prescribed a 1000-1200 kcal/d diet that provides four daily servings of meal replacement products (liquid shakes, cereals, meal bars, etc), combined with an evening dinner entree. Each serving of the meal replacement (HMR 170; Boston, MA) will provide 170 calories, with 16 g of protein, 22 g of carbohydrate, and 2 g of fat. Dinner entrees (containing at least 20 g of protein and approximately 220-260 kcal) will be consumed with a garden salad and a serving of fruit (and other vegetables allowed ad libitum throughout the day).
45391920|NCT00413036|Drug|lenalidomide|once daily oral capsule
45391921|NCT01034852|Procedure|Totally Thoracoscopic Maze|Epicardial pulmonary vein isolation with additional lesions as determined to be necessary by physician
45391922|NCT00412958|Drug|Ocriplasmin 25µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.
45391923|NCT00412958|Drug|Ocriplasmin 75µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.
45391924|NCT00412958|Drug|Ocriplasmin 125µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.
45391925|NCT00412958|Drug|Placebo|Intravitreal injection of placebo
45391926|NCT01040546|Behavioral|Individualized education|"We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into individualized health education group received consulting services provided by a doctor, nutritionist and fitness expert. The interventions were 12 sessions over 6 months."
45391927|NCT01040546|Behavioral|Grouped education|"We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into grouped health education group attended 12 sessions of group intervention over 6 months."
45502781|NCT02236650|Behavioral|Primary Care Stepping Stones Triple P (PC-SS Triple P)|PC-SS Triple P is a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
45502782|NCT02236650|Other|Treatment as Usual|Treatment as Usual for 4 weeks
45502783|NCT01354327|Dietary Supplement|Limicol|3 tablets / day during 4 months
46056881|NCT02717871|Drug|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops)|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium
45696678|NCT03030352|Behavioral|How-to Parenting Program|The How-to Parenting Program addresses all three key dimensions of optimal parenting; autonomy support, affiliation and structure. With weekly workshops, the How-to-Parenting Program optimizes learning by (1) linking group content with parents' needs, (2) facilitating awareness with perspective taking activities, (3) offering concrete parenting skills, (4) modeling the skills and providing practice in a predictable and non-judgmental environment, (5) emphasizing the importance of implementing these skills at home for long term behavioral change, and (6) offering tools (i.e., exercise booklet, skill summary) that facilitate information retention.
45848832|NCT00692094|Biological|Melatonin|0.025 mg - 20 mg, daily, at a time when the melatonin should advance the timing of the body clock.
45391928|NCT00423176|Drug|MFNS and antibiotic|MFNS BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
45391929|NCT00423176|Drug|Matching Placebo nasal spray plus antibiotic|Matching placebo nasal spray BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
45391930|NCT01040702|Drug|methylphenidate|a single doses of 10-20 mg in each one of two visits
45391931|NCT01040702|Dietary Supplement|sweetener pill|a capsule containing a sweetener pill
45391932|NCT00412880|Drug|BI 2536|Intravenous Infusion
45502784|NCT01354327|Dietary Supplement|Placebo|3 tablets / day during 4 months
45391933|NCT00268203|Biological|Iodine I 131 Tositumomab Therapeutic Regimen|Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) which has been trace-labeled with 5 mCi of Iodine-131 (dosimetric dose). Whole body counts using a gamma camera will be obtained 3 times between Days 0 and 7 following the dosimetric dose to determine a patient-specific mCi dose of Iodine-131 calculated to deliver the desired total body dose of radiation (either 65 cGy or 75 cGy). The therapeutic dose is administered 7-14 days after the dosimetric dose. Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) labeled with the patient-specific dose of Iodine-131 (median dose in previous studies was approximately 85 mCi). Patients who are obese will be dosed based upon 137% of their calculated lean body mass. Patients will be treated with thyroid blocking medication at least 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
45391934|NCT00384930|Drug|tadalafil|2.5 mg tadalafil tablet by mouth once a day for twelve weeks.
45391935|NCT00384930|Drug|tadalafil|5 mg tadalafil tablet by mouth once a day for twelve weeks.
45391936|NCT00384930|Drug|tadalafil|10 mg tadalafil tablet by mouth once a day for twelve weeks.
45391937|NCT00384930|Drug|tadalafil|20 mg tadalafil tablet by mouth once a day for twelve weeks.
45502785|NCT05160311|Drug|Optimized Medical Treatment (OMT)|Optimized Medical Drug Treatment
45502786|NCT05160311|Device|Drug Eluting Stent (DES) Coronary Angioplasty|Percutaneous Angioplasty with DES
45502787|NCT02842827|Drug|IMG-7289|LSD1 inhibitor
45696679|NCT04951102|Behavioral|Electronic Asthma Shared Decision-Making App|The electronic Asthma SDM App will ask questions related to medicine-related, non-medicine-related, and COVID-19-related concerns about patients' asthma, the patients' personal goals for asthma control and expectation for their upcoming visit, and the patients' preferred level of details and involvement in coming to a decision about their asthma treatment. They may also use the Asthma SDM app to find information about asthma, medication management, COVID-19 and COVID-19 vaccines.
45696680|NCT04951102|Behavioral|Shared Decision Making Physician Training Video|Training video to educate physicians on Shared Decision-Making and the use of Shared Decision-Making tools.
45696681|NCT04951102|Behavioral|Electronic Asthma Shared Decision-Making App- Patient Data|Data from the pre-visit electronic Asthma SDM app completed by the patients. Data includes medicine-related, non-medicine-related, and COVID-related concerns about patients' asthma, the patients' personal goals for asthma control and expectation for their upcoming visit, and the patients' preferred level of details and involvement in coming to a decision about their asthma treatment.
45696682|NCT04951102|Behavioral|Standard Care|Standard Care for asthma.
45696683|NCT03030196|Drug|Denosumab|NaCl 0.9% injection is used as placebo
45391938|NCT00384930|Drug|placebo|Placebo tablet taken by mouth one a day for twelve weeks
45391939|NCT00423098|Drug|Mycophenolate sodium|Mycophenolate sodium as administered orally for 2 weeks at 1440mg daily and then increased to 2160mg daily for 22 weeks.
45391940|NCT00423098|Drug|Prednisone|Oral prednisone or prednisone equivalent was started on Day 4 and subsequently tapered every 2 weeks according to the patient's weight.
45848833|NCT00676026|Drug|Fluoxetine|Fluoxetine 20 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
45848834|NCT00676026|Drug|Zolpidem|Zolpidem 10 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
45391941|NCT00423098|Drug|Methylprednisolone|All patients received bolus therapy with 0.5 g of intravenous Methylprednisolone per day for 3 consecutive days.
45391942|NCT01042704|Drug|Bendamustine|Bendamustine is given intravenously (into a vein or IV infusion) on days 1 and 2 of each cycle. Each bendamustine infusion will take 60 minutes
45391943|NCT01042704|Drug|Lenalidomide|Lenalidomide is taken orally (by mouth) in the morning on days 1 through 21 of each cycle.
45391944|NCT01042704|Drug|Dexamethasone|Dexamethasone is taken orally (by mouth) on days 1, 8, 15, and 22 of each cycle.
45391945|NCT01042704|Drug|Aspirin|All patients will receive enteric coated aspirin, 325 mg, QD while on study. If patient is unable to tolerate aspirin, patient should receive other types of anti-coagulation like Coumadin or low molecular weight heparin.
45391946|NCT01042704|Drug|Prophylaxis|All patients will receive prophylaxis with either an H-2 blocker or proton pump inhibitor (PPI) while on study medications. Suggested medications included ranitidine 150 mg PC BID or omeprazole 20 mg PO QD or equivalent.
45391947|NCT01042704|Drug|Antibiotic|PCP antibiotic prophylaxis with a Bactrim will be recommended. In case of history of zoster or fungal infection a prophylaxis with Acyclovir or Diflucan should be also considered.
45391948|NCT01042704|Other|Biweekly Follow Up|Vital signs (heart rate, breathing rate, blood pressure, and temperature) will be measured, and Blood tests to check CBC, Calcium, Electrolytes, serum, creatinine, and BUN. This follow up will take place at the Hillman Cancer Center, or whichever cancer center in which the subject is treated.
45391949|NCT01042704|Other|Cyclical Follow Up|At the beginning of each treatment cycle subjects will undergo a Physical exam, a Performance status check, Recording of any new symptoms or side effects and any new medications, Blood tests (including blood chemistry, organ function and indicators of disease), Urine test, and pregnancy test (if applicable).
45391950|NCT01042704|Other|Restaging|Every other cycle subjects' disease will be restaged. This will be accomplished by their treatment physician. Re-staging procedures includes a regular office visit, x-ray, and a bone marrow biopsy. Subjects will spend approximately 4 hours at the Hillman Cancer Center or the UPMC Cancer Center location where they are being treated for this re-staging.
45391951|NCT01042704|Other|Post-Treatment Follow Up|"After subjects stop receiving the study drugs, they will be followed every 3 months for the first two years, every 6 months for years 2-5, and annually thereafter. The following procedures, which are considered routine for their cancer care, will be done as part of this follow-up:~Physical exam~Performance status (check of ability to perform daily functions)~Recording of any new symptoms and any new medications being taken~Blood tests to check blood counts (numbers of red and white blood cells and platelets), blood chemistry (to check organ function), and indicators of disease (immunoglobulins)~Urine test (24hr urine)~Women who are able to have children will have a pregnancy test (4 weeks after their last dose of lenalidomide).~A check of the status of disease (includes bone marrow biopsy, skeletal survey, and blood and urine tests). Bone marrow biopsy will be done at the end of treatment, if subjects have a complete response, and their disease gets worse."
45391952|NCT00893516|Biological|CHOP + CD4|
45391953|NCT00893516|Drug|CHOP|
45391954|NCT00750698|Drug|SNDX-275|SNDX-275 (10 mg fixed dose PO Q2W) on days 1 and 15 of a 28-day cycle for up to 6 cycles
45391955|NCT00750698|Drug|erlotinib|erlotinib (150 mg PO QD) for up to six (6) 28-day cycles
45391956|NCT01046838|Drug|Sildenafil|40 mg three times daily for 9 weeks
45391957|NCT01046838|Drug|Placebo|tablet 3 times daily for 9 weeks
45391958|NCT03633240|Other|ER assessment|"To measure the effects of recommendations of ER2, the investigators will use ER users who will have an ER2 assessment without any recommendations as the referent group the older. This choice is possible because ER2 will be integrated into ER care in two steps:~The first step will be limited to its assessment component in order to learn how to use the tool.~The second step will be to follow the recommendations provided after the assessment.~Participants will follow-up during their hospitalization via a review of their chart. They will be censored when they will be discharged from the JGH or when the duration of hospitalization will exceed 31 days."
45391959|NCT01038908|Other|Isosulfan Blue (Patent Blue Dye V)|"Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe~Pre-incision: SLN is identified~Inject blue dye into patient's arm~Complete procedure (SLNB and/or ALND)"
45502788|NCT02842827|Drug|All-trans retinoic acid|Derivative of Vitamin A, differentiating agent.
45502789|NCT02058524|Biological|fecal microbiota transplantation|
45696684|NCT03029962|Behavioral|Girl2Girl|"Girl2Girl is a text messaging-based teenage pregnancy prevention program specifically for 14-18 year old LGB adolescent females. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 7 weeks long. A booster is delivered 12-weeks post-intervention end and reviews the topics covered in the intervention. Girl2Girl content is tailored based upon sexual experience (i.e., whether one is abstinent or sexually active) and whether one is same-sex or dually attracted."
45696685|NCT00265798|Drug|Sorafenib Tosylate|
45696686|NCT03035578|Drug|Morphine|Sampling blood for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
45696687|NCT03035578|Drug|Morphine|Sampling saliva for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
45696688|NCT04933942|Drug|Lomustine|Oral administration of Lomustine
45696689|NCT04933942|Drug|Romiplostim|Subcutaneous administration of Romiplostim
45696690|NCT04930822|Other|Table Top Visual Intervention|Table top visual interventions and exercises.
45391960|NCT01038908|Other|Isosulfan Blue (Patent Blue Dye V)|"Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe~Pre-incision: SLN is not identified (No localization)~Inject blue dye into breast (nothing in arm)~i. No localization: Inject blue dye into arm and perform ALND ii. Localization: Complete procedure (SLNB and/or ALND)"
45391961|NCT01042782|Drug|RAD001 and MitomycinC|"RAD001 tablets daily, 5mg, 7.5 mg or 10 mg (3 cohorts)~Mitomycin C 5 mg/m2 i.v. every 3 weeks"
45391962|NCT01038986|Biological|CureXcell|The CureXcell™ dosage form consists of an aseptically-processed activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.
45391963|NCT03375762|Other|Remote ischemic perconditioning|Five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score >0 and RACE motor item>0
45391964|NCT03375762|Other|Sham remote perconditioning|Sham five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score >0 and RACE motor item>0
45391965|NCT00411788|Drug|Rapamycin|oral rapamycin 6 mg daily
45391966|NCT00411788|Drug|Trastuzumab|Trastuzumab 4 mg/kg will be administered (intravenous) on day 1, and this will be followed by weekly dose of 2 mg/kg starting day 8.
45391967|NCT01046994|Procedure|biliopancreatic diversion|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve
45391968|NCT01046994|Drug|antidiabetics|patients are treated with conventional antidiabetic drugs according to the rules of good clinical practice
45391969|NCT01040936|Drug|Atorvastatin|patients admitted for Non-ST elevation ACS will be treated by atorvastatin 20md/d for one year
45391970|NCT01040936|Drug|Atorvastatin|patients admitted with Non-ST elevation ACS will be loaded with atorvastatin 80mg once, continued with 40mg/d for 30d, then change to 20mg/d, as a regular dose in China
45391971|NCT01041014|Behavioral|Professional medical interpreter|All treatment interpreters were certified bilingual in Spanish and English and had completed (1) at least 40 hours of training in medical terminology, ethics, patient privacy, and basic interpreting skills; and (2) an online course in protection of human subjects.
45391972|NCT01041092|Drug|raloxifene|Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
45391973|NCT01041170|Drug|THC|
45391974|NCT01041170|Drug|Rimonobant|
45391975|NCT01041170|Drug|Rimonabant|
45696691|NCT04930822|Device|Bioness Integrated Therapy System Visual Intervention|Digital visual interventions and exercises.
45696692|NCT00089583|Drug|LEXIVA (GW433908)|Fosamprenavir suspension or tablet bid
45696693|NCT00089583|Drug|Ritonavir|Ritonavir solution bid
45696694|NCT04902664|Behavioral|Patient education materials|Patients receive a text-message and email with educational materials about medical testing.
45391976|NCT01041326|Radiation|Radiation|Pre-operative Radiation to Prostate, SV, and Pelvic Lymph Nodes
45391977|NCT01041326|Procedure|Radical Prostatectomy|Patients will undergo evaluation by a surgeon for consideration of resection after completion of radiation therapy. If a surgical resection is possible, it is recommended that patients undergo surgery four to eight weeks after completion of radiation therapy. This surgical procedure will be performed by one of the standard accepted approaches.
45391978|NCT01041482|Drug|sorafenib|sorafenib 400mg twice daily
45391979|NCT00422942|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
45391980|NCT00422942|Drug|Methotrexate|10-25mg po weekly
45391981|NCT01039142|Drug|Acitretin|capsule acitretin in dose of 25 mg, 35 mg or 50 mg/ day for 12 weeks or reduction in PASI score by 75% whichever is earlier
45391982|NCT00422162|Drug|Duloxetine hydrochloride|60 mg once or twice a day, by mouth
45391983|NCT00422162|Drug|Placebo|placebo capsule by mouth
45391984|NCT00411632|Drug|Bexarotene|400 mg/m^2 by mouth daily x 28 Days
45391985|NCT00411632|Drug|Erlotinib|150 mg by mouth daily x 28 Days
45391986|NCT01039220|Biological|naso-pharyngeal swab|Selected patients will be asked to contact the clinical staff on site as soon as any influenza like symptoms appear. In the case of influenza like illness patients are requested to attend to the clinic within 24 hours for physical examination and naso-pharyngeal swab for diagnosis of A(H1N1)v infection.
45391987|NCT01039298|Procedure|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the control arm (using conventional white light approach).
45391988|NCT01039298|Procedure|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the FV arm (using FV guided the surgery margin)
45391989|NCT00422084|Drug|Pyronaridine artesunate|Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)
45391990|NCT00422084|Drug|Coartem® (artemether lumefantrine)|AL (20:120mg tablets) twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)
45391991|NCT00421928|Drug|oxycodone|10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks
45391992|NCT00421928|Drug|placebo|matching placebo twice a day (BID) during 15 weeks
45696695|NCT04902664|Behavioral|Physician peer-comparison email|Physicians receive an email with feedback on how they compare to their peers in aggregate on test ordering during annual physicals.
45696696|NCT04902664|Behavioral|Physician education materials|Physicians receive reference materials on medical test interpretation and incidental findings.
45391993|NCT00421928|Drug|tapentadol (CG5503)|50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks
45391994|NCT00383292|Drug|tasisulam|Tasisulam dose is dependent on participant's height, weight, and gender and is adjusted to target a specific Cmax based on participant laboratory parameters. Tasisulam is administered intravenously every 28 days until disease progression or other criteria for participant discontinuation are met.
45391995|NCT01042860|Dietary Supplement|Lutein|Lutein supplement, 10 mg daily
45391996|NCT01042860|Dietary Supplement|Placebo|Placebo
45502790|NCT03417583|Other|Protocol Intervention Group|For neuropsychiatric symptoms identified by the clinician, the treatment protocol, based on clinical standard of care, will be implemented. This protocol includes directions for multidisciplinary treatment of 7 neuropsychiatric symptoms: depression, apathy, anxiety, agitation/irritability, obsessive compulsive behaviors, delusions/hallucinations, and sleep dysfunction. These treatment recommendations differ according to symptom but include provision of additional information to patients and caregivers, psychotherapy/counseling, and pharmacotherapeutic treatment options including recommended agents and follow-up schedule.
45502791|NCT02058602|Other|Assessment of Idiopathic Pulmonary Fibrosis over a period of up to 6 months|Patients are receiving no treatment on this study and there is no investigational product involved.
45502792|NCT02715141|Behavioral|Collection of stool sample|Collection of stool sample prior to the scheduled surveillance colonoscopy.
45391997|NCT01047072|Drug|fludarabine phosphate|Given IV
45391998|NCT01047072|Radiation|total-body irradiation|Undergo total-body irradiation
45391999|NCT01047072|Drug|tacrolimus|Given orally
45392000|NCT01047072|Drug|mycophenolate mofetil|Given orally
45392001|NCT01047072|Biological|rituximab|Given IV
45392002|NCT01047072|Drug|cyclophosphamide|Given orally
45392003|NCT01047072|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo transplantation
45392004|NCT01047072|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
45392005|NCT01043016|Procedure|Photodynamic therapy|patient undergo Photocyanine Injection via venous infusion followed by photodynamic therapy with 670nm diobe laser 24 hours later
45392006|NCT00372060|Drug|sitagliptin phosphate|Sitagliptin (MK0431) 50 or 100 mg once daily for 52 weeks
45392007|NCT00372060|Drug|Comparator: sitagliptin phosphate (MK0431)|Sitagliptin (MK0431) 50 or 100 mg once daily for 40 weeks
45392008|NCT00372060|Drug|Comparator: pioglitazone|pioglitazone once daily for 52 weeks
45392009|NCT00372060|Drug|Comparator: placebo (unspecified)|Placebo once daily for 12 weeks
45392010|NCT00421304|Biological|Motavizumab|A single IV dose of motavizumab 30 mg/kg or 100 mg/kg will be administered on Day 0 of the study.
45502793|NCT02031666|Drug|JNJ-56021927 capsule|Participants will receive oral soft gel capsules providing a total dose of 240 mg JNJ-56021927 on Day 1.
45696697|NCT04902664|Behavioral|General visit preparation materials|Patients receive a text-message and email with general visit preparation tips.
45848835|NCT00676026|Drug|Progesterone|Progesterone 800 mg by mouth will be administered to each participant once in the follicular and luteal phases of the menstrual cycle.
45392011|NCT00421304|Other|Placebo|A single IV dose of placebo matched to motavizumab will be administered on Day 0 of the study.
45392012|NCT01043172|Drug|Gemcitabine|Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
45392013|NCT01045434|Drug|Omeprazole|Omeprazole Magnesium DR 20 mg Capsules
45392014|NCT01039454|Drug|GSK598809 Capsules|GSK598809 is being developed for the treatment of substance dependence and potentially other impulse control disorders.
45392015|NCT01039454|Drug|GSK598809 Placebo Capsules|Treatment of substance dependence and potentially other impulse control disorders.
45392016|NCT01045512|Drug|fluvastatin|40-80mg once daily
45392017|NCT01045590|Drug|titration|Patients in the glibenclamide plus placebo treatment group Patients in the glibenclamide plus placebo treatment group who have FPG < 270mg/dL after the glibenclamide 5mg om run-in will continue to receive glibenclamide 5mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of < 7%. If the HbA1c is > 7%, the dose of glibenclamide will be escalated in the following sequence: from 5mg om, to 5mg om, 2.5mg on, to 5mg bd and 7.5mg om, 5mg on, to 7.5mg bd. The maximum total daily dose will not exceed 15 mg. A downward titration of glibenclamide using the above sequence in the reverse order can be used to maintain normoglycemia at any visit. Once the target HbA1c level of < 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is > 7% for 2 subsequent visits, the patient will be withdrawn from the study.
45502794|NCT02031666|Drug|JNJ-56021927 tablet|Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.
45502795|NCT01354405|Drug|Lanreotide|120 mg every 28 days intramuscular
45502796|NCT03363035|Drug|Rivaroxaban 2.5 mg|One 2.5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
45502797|NCT03363035|Drug|Rivaroxaban 5 mg|One 5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
45502798|NCT03363035|Drug|Enoxaparin|Enoxaparin 1mg/kg twice daily SC until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
45502799|NCT02060084|Drug|a control group|the same dose of luke warm water
45502800|NCT02060084|Drug|a probiotic-supplemented group|was orally administered starting from day 2 after birth, at a dose of 0.5g (the numbers of Long Bifidobacterium, Lactobacillus acidophilus and Enterococcus faecalis in live>0.5*107CFU), twice per day, for 2 weeks
45392018|NCT01045590|Drug|titration|Patients in the glibenclamide + rosiglitazone treatment group who have FPG < 270mg/dL after the glibenclamide 5mg om run-in will receive glibenclamide 5mg om + rosiglitazone 4mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of < 7%. If the HbA1c is > 7%, the dose of glibenclamide will be escalated in a similar fashion as above. The only exception is at visit 5 when the dose of rosiglitazone is increased (see next paragraph). Once the target HbA1c level of < 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is > 7% for 2 subsequent visits, the patient will be withdrawn from the study.
45392019|NCT01047384|Procedure|acupuncture-moxibustion therapy|
45392020|NCT01047384|Procedure|Regular therapy|
45392021|NCT01043406|Device|Seizure Advisory System|Implant of Seizure Advisory System followed by data collection for algorithm training and subsequent enabling of seizure advisory indicators.
45392022|NCT01047462|Procedure|Surgery for acute perforated diverticulitis|Primary resection vs laparoscopic lavage
45392023|NCT00396630|Biological|Rotarix|Two-dose oral vaccination.
45392024|NCT00396630|Biological|Placebo|Two-dose oral administration.
45392025|NCT01043484|Drug|Bevacizumab + Capecitabine + Radiotherapy|Bevacizumab (5 mg/kg; days 1, 15 and 29) Capecitabine (825 mg/m2/12h, 5 days/w) Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
45392026|NCT01043484|Drug|Capecitabine + Radiotherapy|Capecitabine (825 mg/m2/12h, 5 days/w) and Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
45392027|NCT00396318|Drug|tenecteplase|"2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC.~Patients weighing ≥ 30 kg received 2-mL instillations of tenecteplase (i.e., 2 mg of tenecteplase). Patients weighing < 30 kg received instillations of tenecteplase equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg)."
45392028|NCT00396162|Drug|probiotic containing L.rhamnosus R0011 strain|500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks
45392029|NCT00396162|Other|Placebo|Placebo pill
45392030|NCT00381888|Drug|fondaparinux sodium|Fondaparinux, 2.5 mg subcutaneous, Days 1-28 by mouth.
45392031|NCT03992898|Other|No special intervention was suitable for this observational study|Investegators divided patients into 3 corhort according to the liver condition at enrollment (i.e. chronic liver disease, compemsated cirrhosis, decompensated cirrhosis). All patients received standard medical treatment, including nutritional supplementation; administration of human serum albumin, fresh frozen plasma, antivirus treatment and appropriate treatment for complications. No special intervention was suitable for this observational study.
45392032|NCT00267969|Drug|ustekinumab|Type = exact number, Form = solution for injection, Number = 45 and 90, Unit = mg, Route = subcutaneous (SC) administered at Weeks 0, 4 and 16. Both treatments (45 mg and 90 mg) administered every 12 weeks after Week 16 depending on clinical response.
46056882|NCT02593435|Genetic|NGS test|"To record the characteristic QC parameters and evaluate the detection performance of Next-Generation Sequencing (NGS), including coverage depth and sequence similarity, then be used to evaluate the quality of base recognition and alignment.~To know mutation characteristic spectrum of BRCA1/2."
45392033|NCT00267969|Drug|placebo|Form = solution for injection, route = SC administered at Weeks 0 and 4. At Weeks 12 and 16, placebo will be crossed over to receive ustekinumab 45 mg or 90 mg.
45392034|NCT00280293|Drug|Lamotrigine|Lamotrigine
45392035|NCT00280293|Drug|Placebo|Placebo
45392036|NCT00421148|Drug|Sugammadex 0.5 mg/kg|IV infusion
45392037|NCT00421148|Drug|Sugammadex 1 mg/kg|IV infusion
45392038|NCT00421148|Drug|Sugammadex 2 mg/kg|IV infusion
45392039|NCT00421148|Drug|Sugammadex 4 mg/kg|IV infusion
45392040|NCT00421148|Drug|Placebo|IV infusion
45392041|NCT00421148|Drug|Rocuronium bromide|IV infusion
45392042|NCT00403754|Drug|Indacaterol|In the morning, powder filled capsules inhaled using a single dose dry powder inhaler (SDDPI).
45392043|NCT00403754|Drug|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
45392044|NCT00403754|Drug|Salmeterol|Salmeterol 100 μg total dose taken on Day 1. 50 μg in the morning and 50 μg twelve hours post initial dose inhaled via Diskus®, an inhalation device for Salmeterol.
45392045|NCT00280059|Drug|Pregabalin|dose 150-600 mg/day given BID
45392046|NCT00280059|Drug|Lamotrigine|dose 100-500 mg/day given BID
45392047|NCT00403130|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
45392048|NCT00403130|Drug|Paclitaxel|Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
45392049|NCT00403130|Drug|Bevacizumab|Bevacizumab 10 mg/kg by IV infusion, days 1 and 15 in 28-day cycles
45392050|NCT00402740|Device|Xact Stent with either Emboshield Pro (Gen 5) or Emboshield (Gen 3)|All subjects will receive the Xact™ Rapid Exchange Carotid Stent System. The first 220 consecutively enrolled subjects will be treated with the investigational filter system, the Emboshield® Pro Rapid Exchange Embolic Protection System (Generation 5). The remaining subjects will be treated with the FDA approved Emboshield® BareWire™ Rapid Exchange Embolic Protection System (Generation 3).
45392051|NCT03993704|Drug|LHF-535|Oral suspension administered once daily for 14 days
45392052|NCT01039610|Drug|GSK945237|Dose detailed in Arm description
45392053|NCT01039610|Drug|Placebo|matching placebo tablet
45392054|NCT01039610|Drug|Linezolid|600 mg BID, 14 Days
45392055|NCT01039610|Drug|Moxifloxacin|40 mg single dose
46056883|NCT04030078|Other|Survey|Questionnaire-based survey
46056884|NCT02717715|Behavioral|Home base stroke rehabilitation|The intervention consists of physiotherapy exercises targeting functional and physical capacity.
45392056|NCT00581672|Behavioral|questionnaires of quality of life|Subjects will be asked to complete the MAX-PC along with additional psychosocial questionnaires which include anxiety, depression coping methods, resilience spirituality, religiosity, and quality of life measures and will take approximately one 30 to 45 minutes to complete by patient.
45392057|NCT00420290|Drug|kineret|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
45392058|NCT00420290|Drug|placebo|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
45392059|NCT00267189|Drug|Everolimus|1.5 mg bid adjusted in order to achieve a trough level between 3 and 8 ng/mL while in combination with CNI and between 6 and 12 ng/mL after CNI discontinuation
45392060|NCT00267189|Drug|Calcineurin inhibitors (CNI)|
45392061|NCT00267189|Drug|Mycophenolate acid (MPA)/ Azathioprine (AZA)|
45392062|NCT00267189|Drug|Steroids|
45392063|NCT03834350|Other|BREATHES Program|Participants will complete inhaler education using the virtual education module at the baseline visit of the study. Additionally, they will be asked to complete the lesson at least once before their 30 day follow-up visit on their personal device once they have been discharged from the hospital. At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal. A small device will be attached to track real-time medication use.
45392064|NCT03834350|Device|BREATHES SpiroPD or Propeller Health|At the time of their initial study visit, study participants may be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal. A small device will be attached to track real-time medication use.
45392065|NCT01589120|Behavioral|Video decision aid|Video decision aid of the goals of care
45392066|NCT00402116|Drug|enzastaurin|"Phase 1 - 250 mg Cohort 1 with one dose escalation allowed to 500 mg for Cohort 2, oral, daily, 6 weeks then twelve 28 day cycles~Phase 2 - Phase 1 established dose, oral, daily, 6 weeks then twelve 28 day cycles"
45696698|NCT03030040|Behavioral|The self-help book: Williams, M. & Penman, D. (2011). Mindfulness: A practical guide to finding peace in a frantic world. London: Piatkus.|Participants will be provided with a copy of the self-help book, and asked to read it and follow the activities outlined in it, over eight weeks. They will receive weekly standardized emails, to provide information about mindfulness and encouragement to engage with the self-help book.
45696699|NCT04893226|Behavioral|Time-Restricted Feeding (TRF)|Subjects will be educated about the health benefits of time-restricted feeding (TRF). Each subject in the TRF group will self-select a 10 hour (10h +/- 1hr) window aligned with their active phase during which they will consume all daily calories. Subjects will text the time of their first and last daily meals for the duration of the study.
45696700|NCT03029494|Device|stabilization splint|Hard acrylic type of splint with full coverage of occlusal surfaces of upper teeth, with a thickness of about 1.5 mm at the level of the first molar.
45696701|NCT03029494|Drug|Placebo Oral Tablet|sugar pill manufactured to mimic 1000 mg Vitamin C
45696702|NCT03029494|Device|placebo splint|Ineffectively designed oral appliance: an acrylic palatal plate will be used (without influence on occlusion, TMJ and masticatory muscles).
45696703|NCT03029494|Dietary Supplement|Vitamin C|1000 mg
45696704|NCT03087279|Behavioral|Texas I-CAN!|physically active, academic lessons in the elementary school classroom
45848836|NCT00679926|Drug|Once daily|Four tablets of lopinavir/ritonavir and one tablet of tenofovir given once daily
45848837|NCT00680316|Drug|Dornase alfa|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 16 (+/-2) days
46056885|NCT02608528|Radiation|[18F]fluoroglucose(FDG)|
46056886|NCT04088929|Drug|CBD|A water-soluble sublingual tablet containing 20 mg of cannabidiol (CBD) and 0.1 mg of a proprietary blend of terpenes.
45392067|NCT00402116|Drug|temozolomide|75 milligrams per meter squared (mg/m^2), oral, daily, 6 weeks then 200 mg/m^2, oral, daily, twelve 28 day cycles
45392068|NCT00402116|Radiation|radiation therapy|1.8-2.0 Gy x 30 fractions, 5 days/week, for 6 weeks
45392069|NCT00401960|Drug|Daptomycin|daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving for native valve enterococcal endocarditis
45392070|NCT00401726|Drug|Venlafaxine ER|
45392071|NCT00401726|Behavioral|Dialogues Time to Talk Program|
45392072|NCT00371826|Drug|Everolimus (RAD001)|
45392073|NCT00371826|Drug|Cyclosporine (Calcineurin Inhibitor (CNI))|
45392074|NCT00371826|Drug|Methylprednisone/prednisone|
45392075|NCT00371826|Drug|Mycophenolate sodium (MPA)|
45392076|NCT03993366|Combination Product|Fiasp+Pramlintide Closed-Loop System|Closed-loop insulin delivery with Fiasp insulin and pramlintide
45392077|NCT03993366|Device|Fiasp Closed-Loop System|Closed-loop insulin delivery with Fiasp insulin alone
45392078|NCT02457702|Other|Orally administered labeled glycerol|Oral administration of labeled glycerol
45392079|NCT00396084|Drug|Gatifloxacin|Gatifloxacin 400 mg/day x 7 days.
45392080|NCT00396084|Drug|Isoniazid|Isoniazid 300 mg/day x 7 days.
45392081|NCT00396084|Drug|Levofloxacin|Levofloxacin 1000 mg/day x 7 days.
45392082|NCT00396084|Drug|Linezolid|Linezolid 600 mg/day x 7 days; Linezolid 600 mg every 12 hours x 7 days.
45392083|NCT00396084|Drug|Moxifloxacin|Moxifloxacin 400 mg/day x 7 days.
45392084|NCT01043718|Behavioral|More-Intensive|The online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program. The program will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs. The program curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives.
45392085|NCT01043718|Behavioral|Less-Intensive|The participants will be provided with the information to access the online Diabetes Prevention Program (DPP) intervention materials. Following the original DPP trial, all DPP materials were placed online for the public to access. This group will receive a lifestyle counseling session and tools to facilitate their intervention.
45392086|NCT00395850|Drug|Disulfiram|Disulfiram at 0, 250, 375, or 500 mg/day for 12 weeks
45392087|NCT03283254|Behavioral|Practical Resources for Effective Postpartum Parenting|A preventive psychotherapy intervention for Postpartum Depression
45392088|NCT03283254|Behavioral|Enhanced Treatment As Usual|Psychoeducation about Postpartum Depression, referral to treatment in the community, clinical monitoring
45392089|NCT00420212|Drug|BG00012|
45392090|NCT00420212|Drug|Placebo|
45392091|NCT00401258|Drug|duloxetine|30mg oral duloxetine per day for one week, titrated up to 60mg per day at day 8, concluded by a one week taper period of 4 days of 30mg pills at the conclusion of the study, followed by 3 days on no medication (4+3 days=1 week), concluded with a post-taper follow-up appointment with a study physician.
45392092|NCT00380874|Drug|Pregabalin|150- 600 mg/day (double blind in divided doses)
45392093|NCT00380874|Drug|Placebo|Placebo
45392094|NCT00420056|Drug|PD-0332991|125 mg, oral, Days 1-21 of a 28-day cycle
45848838|NCT00680316|Drug|Placebo|2.5 mL (2.5 mg) placebo nebulized once daily for 16 (+/-2) days
45392095|NCT00411554|Drug|sitagliptin phosphate|sitagliptin 50 mg orally once daily QD. Duration of Treatment: 12 Weeks
45392096|NCT00411554|Drug|Comparator: voglibose|voglibose 0.2 mg orally three times daily TID. Duration of Treatment: 12 Weeks
45392097|NCT00400712|Behavioral|physical rehabilitation|two weeks intensive physical rehabilitation
45392098|NCT00380718|Drug|pemetrexed|"500 milligrams per square meter (mg/m2), intravenous (IV) in the first cycle. Acceptable toxicity* in cycle 1 determines dose increase to 1000 mg/m2 or dose decrease to 375 mg/m2 with unacceptable toxicity every 3 week in subsequent cycles till progression of disease.~*Toxicity acceptable if none of the following toxicities recorded at any time during Cycle 1: Platelets <50 x 10^9/L; absolute neutrophil count <1.0 x 10^9/L; Stomatitis/pharyngitis/esophagitis/diarrhea Grade >2; Skin Grade >2; Serum bilirubin >3.0 x upper limit of normal (ULN); alanine aminotransferase/aspartate aminotransferase >10 x ULN; Other non-hematologic toxicities Grade >2 (except nausea, vomiting)."
45696705|NCT03035266|Other|Blood Flow Restriction|Delfi's Personalized Tourniquet System for Blood Flow Restriction has been specifically designed to safely regulate and control tourniquet pressure. Occlusion pressures will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each subject will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions). The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between 5 minute cycles. Sets and repetitions will remain constant for each subject; however, resistance will be incrementally increased after the subject is able to complete all 75 repetitions without loss of proper form.
45848839|NCT00656916|Drug|Fluticasone Propionate|440 micrograms twice daily by oral inhalation.
45848840|NCT00629850|Device|Powerlung Performer|Inspiratory/Expiratory muscle trainer
45848841|NCT00619242|Drug|sorafenib|2 tablets with water by mouth twice a day for two weeks.
45392099|NCT01047696|Device|Plancha|locally developed chimney stove
45392100|NCT01045668|Procedure|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT
45392101|NCT01045668|Procedure|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT as well as VT substrates
45392102|NCT00380250|Drug|Lubiprostone|
45392103|NCT00380250|Drug|Placebo|
45392104|NCT00400400|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|Enteric-coated mycophenolate sodium supplied as 180 mg tablets.
45392105|NCT00400400|Drug|Mycophenolate mofetil|Mycophenolate mofetil supplied as 250 mg capsules.
45848842|NCT00601848|Drug|chemotherapy|
45696706|NCT03035266|Other|Standard rehabilitation|Standard of care for post-operative condition
45848843|NCT00601848|Drug|porfimer sodium|
45848844|NCT00601848|Other|immunohistochemistry staining method|
45848845|NCT00601848|Other|laboratory biomarker analysis|
45848846|NCT00601848|Procedure|spectroscopy|
45848847|NCT00601848|Procedure|therapeutic conventional surgery|
45848848|NCT00586716|Drug|intravenous immune globulin|0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments
45392106|NCT00400400|Drug|Placebo to mycophenolate sodium|Placebo to mycophenolate sodium matching tablets.
45392107|NCT00400400|Drug|Placebo to mycophenolate mofetil|Placebo to mycophenolate mofetil matching capsules.
45392108|NCT01041716|Other|None - Observational study|None - Observational study
45392109|NCT00395694|Drug|lamictal|anti-epileptic drug
45392110|NCT00419744|Drug|Budesonide/formoterol (SYMBICORT) pMDI|
45392111|NCT00419744|Drug|Formoterol Turbuhaler|
45392112|NCT00395538|Drug|PTH 1-34|Given twice daily by subcutaneous
45392113|NCT01047774|Dietary Supplement|Isolated soy protein|30-50g of protein powder daily for 2 weeks.
45392114|NCT01047774|Dietary Supplement|Isolated milk protein|30-50g of protein powder daily for 2 weeks.
45392115|NCT00395460|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|1,0M, intra venous injection at a dose of 0,1 ml/kg BW (= 0,1 mmol Gd/kg BW)
45392116|NCT00395460|Drug|Magnevist|0,5M, intra venous injection at a dose of 0,2 ml/kg BW (= 0,1 mmol Gd/kg BW)
45392117|NCT01047852|Procedure|Noninvasive ventilation|NIV will be delivered using a sequential mode (a minimum of 1 hour every 3 hours) immediately after extubation for a schedule period of 48 h after extubation. In between NIV courses ((NIV-free periods) O2 will be administered through nasal cannula in order to obtain a SaO2 ≥ 90%. Afterward, NIV will be withdraw and oxygen will be administered by nasal cannula
45392118|NCT00395304|Drug|fluticasone propionate + montelukast|Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)
45392119|NCT00395304|Drug|fluticasone propionate|Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)
45392120|NCT00395304|Drug|fluticasone propionate + salmeterol|Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)
45392121|NCT00395226|Drug|zinc sulfate|zinc sulfate 220 mg bis for 90 days
45392122|NCT00395226|Drug|placebo|placebo bid for 90 days
45392123|NCT01047930|Behavioral|Exercise|"Each 3-day experimental period will include one of the following conditions:~Morning exercise - subject will exercise on each of the three mornings in the sleep laboratory, starting 30 minutes after their habitual rise-time;~Evening exercise - subject will start exercise 4 hours before their habitual bedtime on each of the three evenings;~No exercise - subject will watch television or read and they will be required to remain sedentary."
45392124|NCT00394914|Drug|Pleconaril|Pleconaril nasal suspension is supplied in a bottle containing 120 actuations. Each actuation contains 1.5 mg of pleconaril.
45696707|NCT05346705|Behavioral|New individualized upper airway muscle functional training|The two groups of experimental groups were respectively performed tongue/soft palate muscle group control function training and soft palate muscle group vocal resistance training for 7 days.
45696708|NCT04832230|Other|Hearing test|"The hearing test is composed of several examinations:~pure tone audiogram~otoscopy~tympanometry~Healthy individuals: The hearing test will be performed at enrollment (Day 0). Patients: The hearing test will be performed at Day 1, Day 3, Day 7 and Day 30."
45392125|NCT00394914|Drug|Placebo to Pleconaril|Placebo nasal suspension
45392126|NCT03616860|Device|Focused Ultrasound (FUS) BBB Disruption|FUS BBB disruption involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets
45392127|NCT00366444|Drug|diclofenac potassium (XP21L)|25 mg every 6 hours
45392128|NCT00366444|Drug|Placebo|Placebo every 6 hours
45392129|NCT00365976|Drug|Eszopiclone|Eszopiclone 3 mg po nightly for duration of study blind phase.
45392130|NCT00365976|Drug|Placebo|Placebo nightly over duration of double blind study phase
45696709|NCT04832230|Other|Questionnaire about previous noise exposure|The participant will have to fill in a questionnaire about his/her previous noise exposure at enrollment (Day 0).
45696710|NCT04832230|Other|Otoacoustic emission measurement|"Healthy individuals: Otoacoustic emission will be measured at enrollment (Day 0).~Patients: Otoacoustic emission will be measured at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30."
45392131|NCT01049490|Biological|S-OIV H1N1 vaccine|Intramuscular: 15 mcg H1N1 vaccine: Control Intradermal: 3 mcg S-OIV H1N1 vaccine: Interventional
45392132|NCT00379236|Device|EUFLEXXA™|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate (molecular weight 2.4-3.6 MD); sodium chloride, 17 mg; disodium hydrogen phosphate dodecahydrate, 1.12 mg; sodium dihydrogen phosphate dihydrate, 0.1 mg; enough water for injection to make 2.0 ml. EUFLEXXA™ is supplied in 2.25 ml nominal volume, disposable prefilled glass syringes containing 2 mL of EUFLEXXA™. Only the contents of the syringe are sterile. EUFLEXXA™ is nonpyrogenic. See package insert for further details.
45392133|NCT00379236|Device|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Only the contents of the syringe are sterile.
45392134|NCT00379080|Procedure|conventional surgery|Undergo surgery
45696711|NCT04832230|Other|Electrocochleography|"Healthy individuals: Electrocochleography will be performed at enrollment (Day 0).~Patients: Electrocochleography will be performed at Day 30."
45392135|NCT00379080|Drug|tandutinib|Given orally
45392136|NCT00379080|Other|pharmacological study|Correlative studies
45392137|NCT00379080|Other|Tissue samples|Correlative studies
45392138|NCT00378534|Device|Miltenyi reagent system|Miltenyi Clinimax CD34 Reagent System for CD34 selection and delayed T cell depletion add back
45392139|NCT00378534|Drug|Fludarabine|Therapeutic
45392140|NCT00378534|Drug|Cyclosporine|Therapeutic
45392141|NCT00378534|Drug|Cyclophosphamide|Therapeutic
45392142|NCT00378534|Other|FILGRASTIM (G-CSF)|An HLA 6/6 identical family member will be co-enrolled into this study as a stem cell donor. Stem cell Donors will receive G-CSF for stem cell mobilization. The stem cell collection aspect of this protocol is not investigational.
45392143|NCT00377676|Drug|Cycloset|Usual diabetes therapy plus Cycloset
45392144|NCT00377676|Drug|Usual Diabetes Therapy plus placebo|Placebo tablet taken orally once in the morning, beginning with one tablet daily, titrated up by 1 tablet each week to a maximum of 6 tablets daily
45392145|NCT00377520|Drug|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
45392146|NCT00377364|Drug|Drug: Acetaminophen, Drug: Placebo|Acetaminophen: Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days, not exceeding 4,000 mg/day. Placebo: Participants will be given placebo(two 500 mg tablets) four times daily for 7 days
45392147|NCT03831282|Device|RD SET Neo SpO2|All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
45392148|NCT00365508|Drug|nicotine lozenge|nicotine lozenge
45392149|NCT00365508|Drug|nicotine patch|transdermal nicotine patch
45392150|NCT01048008|Drug|DM-CHOC-PEN|"DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
45392151|NCT01049568|Behavioral|Cell Phone Intervention|"Cell phone support, including reminders, assessment of barriers to adherence, problem solving and referrals conducted by an Adherence Facilitator.~Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization."
45392152|NCT00365352|Drug|XP13512 600MG|XP13512 600MG ONCE DAILY
45392153|NCT00365352|Drug|XP13512 1200MG|XP13512 1200MG ONCE DAILY
45392154|NCT00365352|Drug|PLACEBO|PLACEBO ONCE DAILY
45392155|NCT03992118|Behavioral|Parent coaching|Parents will be coached to implement behavioural strategies to address factors which are contributing to difficult mealtime behaviours and feeding challenges.
45392156|NCT01045746|Device|Stochastic resonance whole-body vibration A|over four weeks, three times a week with 5 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1.
45392157|NCT01045746|Device|Stochastic resonance whole-body vibration b|over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 5 Hz, Noise 4.
45392158|NCT00376506|Device|Neurostimulation device for dysphagia|A neurostimulation device that is surgically implanted in the swallowing muscles.
45392159|NCT00376506|Device|External vibrotactile device|A vibrotactile device that is placed on the neck during swallowing.
45696712|NCT04832230|Other|Speech audiometry in noise|"Healthy individuals: Speech audiometry in noise will performed at enrollment (Day 0).~Patients: Speech audiometry in noise will performed at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30."
45696713|NCT04832230|Other|Multi-frequency impedance measurement|"Healthy individuals: Multi-frequency impedance will be measured at enrollment (Day 0).~Patients: Multi-frequency impedance will be measured at Day 30."
45392160|NCT00410384|Drug|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
45392161|NCT00410384|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
45392162|NCT00410384|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
45392163|NCT00370032|Drug|alosetron|
45392164|NCT00410072|Drug|Entecavir|Tablets, Oral, ETV = 0.5 mg, once daily, 100 weeks
45392165|NCT00410072|Drug|Entecavir + Tenofovir|Tablets, Oral, ETV = 0.5 mg + TFV = 300 mg, once daily, 100 weeks
45392166|NCT00409838|Drug|Abatacept|Intravenous (IV) solution, - weight tiered (500 mg <60 kg); (750 mg 60-100 kg); (1 gram > 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
45392167|NCT00409838|Drug|Methotrexate|Tablets, Oral, ≥ 15 mg, weekly, 6 months
45392168|NCT00409838|Drug|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
45392169|NCT00409838|Drug|Abatacept|Solution, intravenous, 10 mg/kg, every 28 days
45392170|NCT00409838|Drug|Methotrexate|Tablets, oral, 15 mg weekly to be adjusted according to patient condition
45392171|NCT01041872|Drug|Propofol Astrazeneca plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
45392172|NCT01041872|Drug|Propofol Astrazeneca plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
45392173|NCT01041872|Drug|Propofol-lipuro B. Braun plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
45392174|NCT01041872|Drug|Propofol-lipuro B. Braun plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
45392175|NCT01041872|Drug|Propofol Fresenius plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
45392176|NCT01041872|Drug|Propofol Fresenius plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
45696714|NCT04832230|Other|Assessment of tinnitus severity|Tinnitus severity will be assessed using a visual analogic scale at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30.
45392177|NCT01041950|Procedure|Lumbar drainage|Lumbar CSF drainage is started after communication between the internal and external CSF-spaces is seen on CT.
45392178|NCT00399542|Drug|Lubiprostone|
45392179|NCT00399542|Drug|Placebo|
45392180|NCT01039766|Drug|Oxytocin|A single intranasal administration of 40 IU of oxytocin will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months.
45392181|NCT01039766|Drug|placebo - saline nasal spray|A single intranasal administration of saline will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months as the control to the oxytocin arm
45696715|NCT04832230|Biological|Blood sample collection|Healthy individuals: A blood sample will be collected at enrollment (Day 0). Patients: A blood sample will be collected at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30.
45696716|NCT03029026|Other|Baseline assessment|Baseline assessment will include clinical history, Quality of Life Questionnaire (EQ-5D/SF-12), a 6-minute-walk test, blood sampling for haematocrit, renal function, biomarkers (NT-pro-BNP and troponin), and biobanking (also for AL exclusions if scanning positive), a urine sample for biobanking (also for AL exclusions if scanning positive), as well as tests performed as the routine pre-operative work-up (clinical electrocardiogram, blood pressure to estimate global LV afterload, valvulo-arterial impedance).
45696717|NCT03029026|Procedure|Transthoracic echocardiography|"Patients will undergo a clinical transthoracic echocardiogram for the assessment of AS severity and diastolic function in line with the British Society of Echocardiography guidance. Simultaneous, optimised 2-chamber, 3-chamber and 4-chamber views will need to be recorded (over 3 cycles) for strain analysis.~Severe AS will be defined using standard echocardiography guidelines in conjunction with MDT consensus."
45696718|NCT03029026|Procedure|99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy|Scanning will use a hybrid SPECT-CT gamma camera after intravenous injection of 700 MBq of DPD (effective dose 4mSv). Acquisition technique: 5-minute (early) and then 3-hour (late) whole body planar scans, followed by SPECT-CT of the heart. Qualitative visual (Perugini) scoring of the cardiac uptake is performed from the 3-hour whole body planar images and the SPECT-CT images.
45392182|NCT00409682|Biological|Adalimumab|All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.
45392183|NCT00409682|Biological|Adalimumab|Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.
45392184|NCT00409682|Biological|Adalimumab|Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.
45392185|NCT01034930|Procedure|Insertion of dental implants|Each patient will receive 2 screw-type Straumann (Institut Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, according to a standard surgical protocol.
45392186|NCT03993782|Other|A19010-R|A snus product
45392187|NCT03993782|Other|B19010-O|A snus product
45392188|NCT01039844|Drug|LOC-paclitaxel|"Phase I Starting Dose: 100 mg/m^2 IV (intravenously) 1 hour infusion on Day 1, 8, 15, 22 and 29; and repeated every 42 days (6 weeks) per cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
45392189|NCT01042028|Drug|Everolimus, Cetuximab, Irinotecan|Cetuximab 500 mg/m² iv biweekly Irinotecan 180 mg/m² iv biweekly Everolimus in daily MDT dosage
45392190|NCT01042028|Drug|Capecitabine, Oxaliplatine|Capecitabine 1250 mg/m² bid. Oxaliplatin 70 mg/m² biweekly
45392191|NCT03993626|Drug|CXD101 in Combination With Nivolumab|HDAC inhibitor in combination with anti-PD-1 monoclonal antibody
45392192|NCT01042106|Drug|DSP-8658|Ascending doses of DSP-8658 - 2.5, 10, 20, 40 mg orally once daily
45392193|NCT01042106|Drug|Placebo|Placebo 2.5, 10, 20, 40 mg orally once daily
45392194|NCT01042184|Drug|Sequential therapy for 14 days|D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bi
45392195|NCT01042184|Drug|Sequential therapy for 10 days|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
45392196|NCT01042184|Drug|Triple therapy for 14 days|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
45392197|NCT01035008|Procedure|Endoscopic Ultrasound (EUS)|The investigators will do the standard EUS procedure. If a cyst is seen in the pancreas during EUS, the investigators will administer a special dye called fluorescein through the IV, and then use the new fiber-shaped microscope to take pictures of the lining of the cysts.
45392198|NCT00398216|Drug|DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor|
45392199|NCT00398138|Biological|WT-1 analog peptide vaccine|
45392200|NCT00398138|Biological|incomplete Freund's adjuvant|
45502801|NCT05211843|Other|Drinking water|The intervention will compare the effects of a usual serving of drinking water with the effects of a usual serving of apple juice. Both beverages will also be assessed relative to the effects of not drinking anything at all.
45696719|NCT03029026|Radiation|CT 3-5-minute post-contrast research sequences|Cardiac CT for ECV will use the dedicated cardiac CT scanner (Somatom FORCE; Siemens Medical Solutions, Germany). 3-5-minute post contrast research images will be taken at the end of the clinically indicated TAVR work-up CT.
45392201|NCT00398138|Biological|sargramostim|
45392202|NCT00398138|Genetic|polymerase chain reaction|
45392203|NCT00398138|Other|flow cytometry|
45392204|NCT00398138|Other|immunoenzyme technique|
45696720|NCT03029026|Procedure|Cardiac Magnetic Resonance|CMR will be performed using a 1.5-T Aera for standard late gadolinium enhancement, as well as T1 mapping and ECV.
45696721|NCT03029026|Procedure|Endomyocardial biopsy|Septal tissue specimens will be taken under direct vision by the surgical team using a 14-gauge coaxial needle system. Biopsies will be screened for amyloid by Congo red staining; if positive, tissue will be fully sub-typed (immunohistochemistry, mass spectrometry).
45696722|NCT03029026|Other|Follow-up assessment|1-year follow-up with clinical echocardiogram (for sAVR and TAVI patients) and/or telephone interview for all patients (if not carried out in person at the time of the echocardiogram). This will include a follow up Quality of Life Questionnaire as per baseline. If attending clinic or echocardiogram a 6-minute-walk test will also be performed.
45392205|NCT01042262|Other|Oxygen|100% Oxygen at a flow of 2 L/min
45392206|NCT01042262|Other|Placebo|No oxygen flow
45392207|NCT04566380|Drug|ONO-4538|IV infusion over 30 minutes
45392208|NCT04566380|Drug|oxaliplatin|IV infusion over 2 hours
45392209|NCT04566380|Drug|S-1|Administered orally twice daily
45392210|NCT04566380|Drug|capecitabine|Administered orally twice daily
45392211|NCT04566380|Drug|bevacizumab|IV infusion over 30 minutes
45392212|NCT00397982|Biological|Bevacizumab|Given IV
45392213|NCT00397982|Other|Laboratory Biomarker Analysis|Correlative studies
45392214|NCT00397982|Drug|Temsirolimus|Given IV
45392215|NCT00397982|Procedure|Therapeutic Conventional Surgery|Undergo tumor resection
45392216|NCT03993470|Behavioral|Short foot excercise for intrinsec muscles of the foot|to examine the effects of the SFE compared to a placebo exercise in the foot posture index after a daily period of 4 weeks.
45392217|NCT01040000|Drug|NPC-1C/NEO-102|Subjects will receive NPC-1C at a dose of 3.0 mg/kg. NPC-1C will be given intravenously (by vein) over approximately 1-6 hours, once every 2 weeks for 4 doses per course. Courses will be repeated in the absence of disease progression or unacceptable toxicity.
45502802|NCT05211843|Other|Apple juice|apple juice
45392218|NCT01035086|Dietary Supplement|fabricated food|The subjects consumed a high-fibre diet containing 25 g fibre (citrus- or lupin fibre) per day and a low-fibre diet (placebo) for four weeks each. After a one-week run-in period, each volunteer had to pass all three periods (arms) in different order with a two-week wash-out period between each.
45392219|NCT00408902|Drug|tandutinib|Given orally, 500 mg bid daily
45392220|NCT00408902|Other|laboratory biomarker analysis|Correlative studies
45392221|NCT00397514|Procedure|Congenital Heart Surgery Patients|undergoing either Biventricular (BiV) pacing or Right Ventricular (RV) Pacing
45392222|NCT03715166|Drug|Bumetanide Oral Solution|Oral Solution dosed at 0.5mg/mL Taken twice daily
45392223|NCT03715166|Drug|Placebo|Oral Solution Taken twice daily
45392224|NCT01035164|Drug|F-18 FEDAA1106 (BAY85-8101)|Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
45392225|NCT01035164|Drug|F-18 FEDAA1106 (BAY85-8101)|Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
45392226|NCT01035164|Drug|F-18 FEDAA1106 (BAY85-8101)|Healthy volunteers for whole body imaging: Single intravenous bolus injection of 185 MBq BAY85-8101, whole body PET for evaluation of effective dose, kinetics of BAY85-8101 in blood
45392227|NCT00397046|Drug|neratinib|HKI-272
45392228|NCT01042340|Other|Calogen® - an energy dense oleic acid based formula|A daily dose of 3 x 30 ml of Calogen®, strawberry flavour, distributed at the same time as the pharmaceutical prescriptions, i.e. at 7.00, 14.00 and 20.00.
45392229|NCT01035242|Behavioral|"association splitting"|"Association splitting is a cognitive intervention which aims at reducing obsessive thoughts. Association splitting is based on the so called fan effect (Anderson, 1974) and aims at reducing the strength of obsessive cognitions. For this purpose core intrusive thoughts are identified with the patient (such as cancer - illness) and the patient is encouraged to find non-OCD associations that are (semantically or phonologically) related to the OCD cognition (such as cancer - (zodiac) sign, cancer - great crab). To strengthen the novel connections, these associations are elaborated by the use of pictures, music, or smells. By enhancing OC-unrelated associations it is assumed that the influence of OC-related concepts is weakened."
45392230|NCT01035242|Behavioral|cognitive remediation|Computerized cognitive remediation (CogPack training). A fixed sequence is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with association splitting, six sessions are administered. Each session lasts approximately 45-60 minutes.
45392231|NCT01042418|Other|Effect of breakfasts with whole vs milled rye kernels on appetite|Iso-caloric portions of the three breakfast foods along with identical additional foods are tested in a cross over design
45848849|NCT00571194|Drug|pravastatin|"A single 10 mg dose of pravastatin will be administered 3 mL blood samples for pravastatin Pharmacokinetic evaluations will be collected at 0.5, 1, 2, 3, 4, 6, and 8 hours. 5 mL blood samples for pravastatin PK and laboratory evaluations will be drawn at pre-dose and 24 hours.~Vital Signs and Physical Exams will also be done throughout the study"
45392232|NCT01042574|Drug|Clevidipine butyrate|Cleviprex will be administered according to current package insert instructions, with a starting dose of 2.0mg/hr for 1.5 minutes and thereafter titrated to lower blood pressure to a target goal of 110 mmHG to 140mmHG.
45392233|NCT01042652|Drug|Raltegravir|Raltegarvir 400mg bid
45392234|NCT01040078|Biological|7.5ug H1N1 Influenza vaccine|0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
45392235|NCT01040078|Biological|15ug H1N1 vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
45392236|NCT01040078|Biological|seasonal influenza vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
45392237|NCT01035320|Drug|Ezetimibe|After a placebo only run-in period patients (two groups) are treated with simvastatin + ezetimibe and simvastatin + placebo in a cross-over trial. Ezetimibe effects on top of simvastatin will be evaluated as the primary aim; simvastatin effects compared to run-in on placebo will be evaluated as a secondary aim.
45502803|NCT03619122|Procedure|Second Examination|The colonoscopy is passed to the cecum and then withdrawn to hepatic flexure. Then, the scopy is inserted to the cecum and withdrawn to hepatic flexure again for second foreard view examination.
45848850|NCT00570258|Drug|Fulvestrant|Fulvestrant: 250 mg IM Q 4 weeks
45848851|NCT00570258|Drug|erlotinib|150 mg PO QD
45848852|NCT00570258|Drug|Fulvestrant|250 mg IM Q 4 weeks
45848853|NCT00570258|Drug|Placebo|Placebo 150 mg PO QD
45392238|NCT01042730|Drug|Pitavastatin 1 mg daily or 4 mg daily|Patients who met all inclusion criteria and did not meet exclusion criteria (1) are entered in run-in period, loading pitavastatin 1 mg/day for more than 1 month when informed consent was given. (Primary registration) After 1 month, patients who did not meet exclusion criteria(2) are randomized to take pitavastatin 1 mg/day or 4 mg/day.
45392239|NCT00396812|Drug|Rituximab|"Participants to receive an intravenous infusion of rituximab (1 gram ) fourteen days apart, at baseline (Day 0) and at Week 2.~Concomitant treatments to be administered at a dose and frequency prescribed per protocol include methotrexate (MTX) and folic or folinic acid."
45392240|NCT01566578|Drug|Human recombinant epidermal growth factor|topical
45392241|NCT01566578|Other|Placebo cream|Dermal cream without EGF
45392242|NCT01040234|Procedure|Bilateral dual TAP block|Bupivacaine 2.5 mg/ml 15 ml per injection. 4 injections per patient according to dual TAP block procedure
45392243|NCT01042886|Behavioral|PILI 'Ohana Lifestyle Program|9-month weight loss and weight loss maintenance intervention focusing on family and community resources/supports.
45392244|NCT01042886|Behavioral|Standard Behavioral Weight Loss Maintenance Program|9-month weight loss and weight loss maintenance intervention based on empirically-supported behavioral foci and strategies.
45392245|NCT00396656|Drug|Atenolol|100 mg tablets orally once a day (od) in the morning.
45392246|NCT00396656|Drug|Hydrochlorothiazide (HCTZ))|12.5 or 25 mg tablets orally once a day (od) in the morning.
45392247|NCT00396656|Drug|Valsartan|80 mg, 160 mg, or 320 mg tablets orally once a day in the morning
45392248|NCT01042964|Drug|revacept (PR-15)|single intravenous administration of revacept (PR-15), an inhibitor of platelet adhesion, in various strengths (10, 20, 40, 80, 160 mg) in healthy male volunteers.
45392249|NCT01043042|Other|No interventions will be used in this study|No interventions will be used in this study
45392250|NCT00408434|Drug|CS-7017|CS-7017 0.05mg and 1.0mg tablets
45392251|NCT00418886|Drug|Vandetanib|oral once daily tablet
45848854|NCT00568698|Drug|Hydroxyurea|
45392252|NCT00418886|Drug|Pemetrexed|intravenous infusion
45392253|NCT01043120|Drug|Barusiban|IV bolus of 20 mg for 1 minute followed by an IV infusion of 19 mg for up to 59 minutes. The maximum total duration of administration was 60 minutes.
45392254|NCT01043120|Drug|Placebo|IV bolus of saline (sodium chloride 0.9%) for 1 minute followed by an IV infusion of saline (sodium chloride 0.9%) for up to 59 minutes. Details on injection volume, infusion rates and doses are tabulated below.
45392255|NCT01043198|Genetic|Clinical examination and blood sampling for biological and genetic analysis|"Clinical examination and precise description of the phenotype (questionnaire)~Standardized screening with :~radiological (hands, feet, spine ; and renal ultrasonography)~biological (hormonal, metabolic, and basic genetic investigations (karyotype, FISH 22q11.2, Fragile X, and other depending on the clinical data))"
45392256|NCT01323764|Device|ShuntCheck test|Non-invasive, thermal dilution test for CSF shunt flow compared to radionuclide shunt patency testing
45392257|NCT01040312|Drug|CPT-11|CPT-11 blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.
45392258|NCT01040312|Drug|Platinum analogues|Platinum compounds produce changes in DNA structure, which causes cancer cell death (apoptosis). They are typically used alone or in combination with other chemotherapy drugs.
45392259|NCT01043276|Drug|Treatment A|PF-00258210 220 µg using inhaler A
45392260|NCT01043276|Drug|Treatment B|PF-00258210 220 µg using inhaler A and 450 µg PF-00610335 using inhaler A
45392261|NCT01043276|Drug|Treatment C|PF-00258210 440 µg and 450 µg PF-00610335 using inhaler A
45392262|NCT01043276|Drug|Treatment D|PF-00258210 350 µg and 450 µg PF-00610335 using inhaler A
45392263|NCT01043276|Drug|Treatment E|PF-00258210 220 µg using inhaler B
45392264|NCT01043354|Behavioral|stage-matched intervention|6 monthly tailored telephone-delivered counseling sessions of transtheoretical model-based counseling
45392265|NCT01043354|Behavioral|framing effects intervention|6 monthly telephone-delivered counseling sessions based on prospect theory
45392266|NCT01043354|Behavioral|attention placebo intervention|6 monthly counseling sessions about general health topics
45392267|NCT00418184|Dietary Supplement|Phosphatidylserine-Omega3|Phosphatidylserine-Omega3 conjugate capsules. Weeks 0-15: 300 mg/day. weeks 16-30: 150 mg/day and a 150 mg/day one year follow-up.
45848855|NCT00568698|Drug|Placebo to match hydroxyurea|
45848856|NCT00577356|Drug|Docetaxel|Docetaxel 75mg/m2 will be given intravenously every 3 weeks for four cycles.
45848857|NCT00577356|Biological|CG1940/CG8711|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
45848858|NCT00569868|Drug|Velcade|"Except for the two PCR-based genotyping assays, which will be conducted only on baseline samples, tests will be assessed at baseline, 1-3 hours after the first dose of Velcade day 1 and on day 11 of the first cycle of Velcade.~The platelet Aggregation Test will be done only if Platelet count is 100 000."
45392268|NCT00418184|Other|Colored cellulose tainted with fishy odor|as arm 1
45392269|NCT00407030|Drug|incobotulinumtoxinA (Xeomin) (240 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (240 Units)"
45392270|NCT00407030|Drug|incobotulinumtoxinA (Xeomin) (120 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (120 Units)"
45392271|NCT00407030|Drug|Placebo|Placebo
45392272|NCT00406718|Behavioral|Med-eMonitor|Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.
45392273|NCT00406718|Behavioral|PharmCAT|Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.
45392274|NCT00406718|Behavioral|Treatment as Usual|Participants receiving standard treatment will keep the Med-eMonitor™ device in their homes throughout the study but will not use its medication reminder function.
45392275|NCT01035476|Behavioral|Data Card Report|Patients received detailed report of acceptance and adherence base don data card information, with linked recommendations, to optimize use.
45392276|NCT00406640|Drug|Desvenlafaxine succinate sustained-release (DVS SR)|flexible dose of DVS 50-100 or 200 mg every day during 56 days. Extension until 6 months.
45392277|NCT00406640|Drug|Escitalopram|Flexible dose of Escitalopram 10 or 20 mg every day during 56 days. Extension until 6 months.
45392278|NCT01043510|Drug|insulin degludec|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
45392279|NCT01043510|Drug|insulin detemir|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
45392280|NCT01043588|Procedure|TURP|TransUrethral Resection of the Prostate
45392281|NCT01043588|Procedure|PVP|Photo selective Vaporization of the Prostate
45392282|NCT01043666|Drug|YM178|oral
45392283|NCT01043666|Drug|Placebo|oral
45392284|NCT01043666|Drug|tolterodine ER|oral
45392285|NCT01035554|Other|Self-Paced Programmed Instruction (SPPI)|If participants are assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials (PM) from the National Institutes of Health.
45392286|NCT01035554|Other|Home Blood Pressure Monitor|The home blood pressure monitor will allow the participant to measure their blood pressure anytime and anywhere precisely, quickly and easily on their upper arm.
45848859|NCT05600634|Procedure|Skin allotransplantation|Sentinel skin grafts from the same donor source will be carried on in the meantime of kidney transplantation for assisting to detect acute renal rejection.
45392287|NCT01035554|Other|Usual Care|Standard care
45392288|NCT01035554|Other|Printed Materials|National Institutes of Health Printed Materials on hypertension
45392289|NCT01040390|Drug|Lappa Arctium|To start with subjects will be prescribed Lappa Arctium in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
45392290|NCT00394706|Device|Impedance Threshold Device (ITD)|Use of Impedance Threshold Device (ITD)
45392291|NCT00394706|Device|Sham ITD|Sham ITD
45392292|NCT00394706|Other|Analyze early|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, an assessment of the cardiac rhythm is done to determine whether a defibrillatory shock is required.
45392293|NCT00394706|Other|Analyze later|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is given prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
45392294|NCT03572348|Procedure|Transecting anastomotic repair (tAR)|Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.
45392295|NCT03572348|Procedure|Vessel-sparing anastomotic repair (vsAR)|Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.
45696723|NCT04402047|Other|Electroacupuncture|We will apply Ashi points, Ex-UE9, SI3, and TE5. Sterile needles (0.3mm× 40mm) and SDZ-V EA apparatus will be utilized. Acupuncturists will insert needles perpendicularly into Ashi points for approximately 2-3mm until they pierce into the bone surface; acupuncturists will insert needles horizontally into Baxie points towards the wrist with a depth of 5-10mm; and acupuncturists will insert needles perpendicularly into SI3 and TE5 for approximately 5-10mm. All needles except Ashi points will be manually manipulated to achieve De qi. The needles at Baxie 1 and Baxie 4 will be connected using alligator clips from the EA apparatus. The electrical stimulation will last for 30 minutes with a continuous wave of 10 Hz and a fixed current intensity of 0.5 to 2 mA. All the needles will be retained for 30 minutes. Participants will undergo EA treatment three times per week for a total of 12 sessions in four consecutive weeks. If bilateral hands were affected, both sides will be treated.
45392296|NCT00394472|Drug|AZD3355|
45392297|NCT00419120|Biological|Autologous neo bladder construct|augmentation cystoplasty with autologous neo-bladder construct
45392298|NCT00395642|Device|Kronos LV-T, Lumax HF-T|Implanted CRT-device sends out device diagnostics (e.g. heart rate, device and lead integrity, patient activity) via CardioMessenger on daily basis. In addition, daily weight and blood pressure readings are taken; remote data are analyzed by investigational sites via the internet on a weekly basis.
45392299|NCT00395486|Drug|Rosuvastatin|10mg
45392300|NCT00395486|Drug|Atorvastatin|10mg
45392301|NCT01043744|Drug|Artemether-Lumefantrine|"Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of:~1 tablet (for patients weighing 5-14 kg)~2 tablets (for patients weighing 15-24 kg)"
45392302|NCT00395018|Drug|entecavir|Tablets, Oral, 1 mg, once daily, up to 72 weeks
45392303|NCT01036412|Drug|1% Chlorhexidine Gluconate Gel|Following two 2.5 ml 5-minute applications performed in clinic on Day 1, 2 x 5.0 ml syringes of chlorhexidine gel self-administered for one 5-minute application using the custom-made carriers carriers on week 2 (12-14 days from baseline visit study drug administration) and week 4 (12-14 days from Week 2 study drug administration).
45848860|NCT05599854|Procedure|vitrectomy and silicone oil injection|Parsplana vitrectomy and silicone oil injection
45392304|NCT01036412|Behavioral|Surveys|M. D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) questionnaire, in addition to a 2nd subjective, study-specific questionnaire administered during visit taking about 5 minutes to complete each assessment.
45392305|NCT00375518|Drug|Atorvastatin|Atorvastatin 40 mg once a day beginning 7 days before the operation. Surgical procedures will be as planned and unaffected by this study. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
45392306|NCT00375518|Drug|Placebo|Placebo given beginning 7 days before the operation. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
45392307|NCT01045772|Drug|rilonacept|160mg of rilonacept 1x/week
45392308|NCT01045928|Drug|lenalidomide|Given orally
45392309|NCT01045928|Biological|rituximab|Given IV
45392310|NCT01045928|Genetic|polymerase chain reaction|Correlative study
45392311|NCT01045928|Genetic|nucleic acid sequencing|Correlative study
45392312|NCT01045928|Genetic|polymorphism analysis|Correlative study
45392313|NCT01045928|Other|flow cytometry|Correlative study
45392314|NCT01045928|Other|laboratory biomarker analysis|Correlative study
45392315|NCT00256750|Drug|Cyclosporine (CsA)|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months (ST), 100-250 ng/mL, daily, 24 months (LT)
45392316|NCT00256750|Drug|Belatacept LI (less intensive)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
45392317|NCT00256750|Drug|Belatacept MI (more intensive)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
45392318|NCT00279201|Drug|Insulin glargine|Subcutaneous injection daily
45392319|NCT00279201|Drug|Lispro Low Mix|Subcutaneous injection twice daily.
45392320|NCT00279201|Drug|Lispro Mid Mix|Lispro Mid Mix subcutaneous injection 3 times daily.
45392321|NCT00279201|Drug|Lispro|Lispro subcutaneous injection 3 times daily.
45392322|NCT03741634|Other|Multi-sectoral agricultural intervention|Adult participants in the intervention arm receive a loan (~$175) from a well-established Kenyan bank used to get a human-powered water pump, seeds, fertilizers and, pesticides, and education in financial management and sustainable farming practices.
45392323|NCT03969394|Diagnostic Test|Medical imaging|Medical Imaging consisting of 1 MRI and 1 echocardiography at baseline
45392324|NCT03973060|Device|Concentric-eccentric muscular work|For muscular contraction, the physiotherapist carried out 12 repetitions with one minute rest between series and series, total working time of 12 minutes.
45392325|NCT03973060|Genetic|Genetic polymorphism|Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine whether the genetic makeup of individuals for the improvement of muscular work in the results of the study.
45392326|NCT03969784|Other|blood draw, tumoral biopsy tissus|Patient will have specific blood draw and part of their tumoral tissu biopsied
45392327|NCT01073956|Procedure|Medium-wave 448 kHz therapy|0.5 MHz radiofrequency for 10 minutes. At SPS insertion and bicipital groove
45392328|NCT01073956|Procedure|Ultrasonic therapy|Pulsed 1 MHz ultrasound at 2 W/cm2 for 10 minutes. At SPS insertion and bicipital-groove
45392329|NCT01073956|Procedure|Inactive electrotherapy|Inactive electrotherapy, inactive head, dosage 0 W/cm2 for 10 minutes. At SPS insertion and bicipital groove.
45502804|NCT01350349|Behavioral|Problem Adaptation Therapy (PATH)|Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
45502805|NCT01350349|Behavioral|Supportive Therapy|Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
45502806|NCT02582775|Drug|Thymoglobulin|0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2
45502807|NCT02582775|Drug|Cyclophosphamide|14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3
45392330|NCT00203476|Drug|Niacin|
45392331|NCT00203476|Drug|Colestipol|
45392332|NCT00203476|Drug|Ezetimibe|
45392333|NCT00203242|Drug|Depacon IV and Depakote ER|
45392334|NCT00200356|Drug|Edaravone|Edaravone, at 30 mg, is intravenously administered by drip over 30 minutes b.i.d., in the morning and the evening.
45392335|NCT00200356|Drug|Sodium Ozagrel|Sodium Ozagrel, at 80 mg, is intravenously administered by drip over 2 hours b.i.d., in the morning and the evening.
45392336|NCT01326052|Procedure|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
45392337|NCT01326052|Procedure|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
45392338|NCT00227344|Device|RF ablation|Catheter ablation with NAVISTAR® THERMOCOOL® Catheter in conjunction with CARTO™ EP Navigation System
45392339|NCT00227344|Drug|Antiarrhythmic drugs|Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study
45392340|NCT00227266|Drug|Valproic Acid and Levocarnitine|VPA,sprinkle cap; Levocarnitine, syrup; dosage is by weight
45392341|NCT00227266|Drug|Placebo|
45392342|NCT00256282|Drug|Vinorelbine|30 mg/m2 IV over 6-10 min every 14 days
45392343|NCT00256282|Drug|Docetaxel|40mg/m2 IV over 1 hour every 14 days
45392344|NCT00256282|Drug|Sargramostim|250 mcg/m2 subcutaneous (SQ) daily (QD) x 10 days
45392345|NCT01074112|Device|EFAST exam|Ultrasound of the heart, morisons pouch, pelvis, spleen and both lungs
45502808|NCT02582775|Drug|Fludarabine|30 mg/m2 IV over 60 minutes days -6 through day -2
45502809|NCT02582775|Radiation|Total Body Irradiation|See arm description for dosing.
45502810|NCT02582775|Procedure|Bone marrow infusion|Bone marrow infusion on Day 0
45502811|NCT02582775|Drug|Tacrolimus|Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors)
45502812|NCT02582775|Drug|Mycophenolate Mofetil|15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35
45502813|NCT02582775|Biological|Donor mesenchymal stem cell infusions|Day 60, 100 and 180 (collected during donor BM harvest for graft)
45502814|NCT02582775|Drug|Busulfan|busulfan IV over 3 hours on days -3 and -2 for HLA-mismatched BM recipients only (Arms F and G)
45502815|NCT03618732|Other|Bilateral movement-based computer training|
45502816|NCT03618732|Other|Video-directed conventional training|
45392346|NCT01074112|Device|Pelvic Ultrasound|Ultrasound view of the pelvis. including the bladder and uterus
45392347|NCT01074112|Procedure|Ultrasound Guided Vascular Access|Use of the ultrasound machine to identify a usable vein and guide the needle into the vein. After cannulation ultrasound is used to determine correct placement and identify extravasation.
45392348|NCT01074112|Device|Focused Ultrasound Scan|Use of ultrasound to identify and measure structures in the abdomen, thorax, retroperitoneum, or other necessary places.
45392349|NCT01074112|Device|Cardiac Ultrasound|Ultrasound views of the heart
45392350|NCT00266877|Drug|HKI-272|320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
45392351|NCT02532075|Other|Inspiratory Warm Up|Inspiratory muscle warm up. Inhaling against a resistance for two sets of 15 breaths using a PowerLung.
45392352|NCT02532075|Other|Expiratory Warm Up|Expiratory muscle warm up. Exhaling against a resistance for two sets of 15 breaths using a PowerLung.
45392353|NCT02532075|Other|Combination Warm Up|Combination of inspiratory and expiratory muscle warm up. One set of 15 breaths inhaling followed by one set 15 breaths exhaling.
45392354|NCT02532075|Other|Control Trial|Control Trial. No respiratory muscle warm up to act as a comparison to the other three intervention trials.
45392355|NCT00256204|Drug|Rasagiline Mesylate|tablet, 1mg once daily
45392356|NCT00256204|Drug|Rasagiline Mesylate|tablet, 2mg once daily
45392357|NCT00256204|Other|Placebo|Placebo
45392358|NCT00256126|Drug|Saizen|Subjects with TS will receive SAIZEN® as subcutaneous injection at a dose of 0.050 milligram per kilogram (mg/kg) of body weight per day (within the recommended dosage 0.045-0.050 mg/kg body weight) for a period of 1 month
45392359|NCT00256126|Drug|Saizen|Subjects with GHD will receive SAIZEN® as subcutaneous injection at a dose of 0.035 mg/kg of body weight per day (within the recommended dosage 0.025-0.035 mg/kg body weight) for a period of 1 month.
45392360|NCT03972358|Drug|Mifepristone|All participants will receive 200 mg mifepristone, to be taken orally on day 1.
45392361|NCT03972358|Drug|Misoprostol|All participants will receive 800 mcg misoprostol, to be taken buccally 24 hours after mifepristone (day 2)
45392362|NCT01073332|Dietary Supplement|Arginine antioxidant supplements|The proprietary supplement Niteworks® was manufactured by Herbalife International Inc. (Century City, California, USA). Each serving contained 5.2g L-arginine in a proprietary blend with L-citrulline, 500mg ascorbic acid, 400IU vitamin E, 400ug folic acid, 300mg L-taurine, and 10mg alpha lipoic acid in a lemon-flavored powder form. One serving of supplement powder was mixed with 8 oz of water, administered at bedtime based on the rationale that nitric oxide levels are lowest during sleep due to inactivity, lack of food and low blood pressure.
45392363|NCT01073332|Dietary Supplement|Placebo|The placebo group received a powder with all active ingredients replaced with M-100 maltodextrin.
45392364|NCT03969316|Procedure|Transversus abdominis plane block, Quadratus lumborum block|The TAP block which is one of the abdominal truncal blocks is performed with the blockage of the nerve group which innervates the anterior abdominal muscle wall layers. However, in QL block, the local anesthetic agent spreads through the abdominal wall and paravertebral space with the help of the perimuscular fascia to maintain the somatic analgesia.
45392365|NCT03972046|Drug|Talimogene laherparepvec (T-Vec)|Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection
45392366|NCT03972046|Drug|Dabrafenib (BRAF Inhibitor)|Dabrafenib (BRAF Inhibitor) 150 mg by mouth twice a day
45392367|NCT03972046|Drug|Trametinib (MEK Inhibitor)|Trametinib (MEK Inhibitor) 2 mg by mouth once a day
45392368|NCT01073488|Behavioral|Community Mobilization, HBLSS and facility improvement|Mobilization of the community, with special emphasis on pregnant women and their families, to identify resources and solutions to improve maternal and neonatal mortality, home-based life savings skills (HBLSS) for community birth attendants and facility improvement activities.
45848861|NCT05599542|Other|Solution-oriented approach|A preliminary assessment of the pregnant woman's thoughts on breastfeeding was made and the EARS (Eliciting, Amplifying, Reinforcing and Start Over) process was applied. Eliciting, Amplifying, Reinforcing and Start Over process guides the second and subsequent sessions in a sequential order. The Eliciting, Amplifying, Reinforcing and Start Over technique reminds the counselor of the basic concepts of solution-oriented approach and its explanation is as follows;
45392369|NCT01071772|Drug|insulin|There will be used individual intravenous insulin (actrapid) infusion to prevent non-intended hyperglycemia.
45392370|NCT01074346|Drug|Interferon-β-1a|Interferon-β-1a according to the standard practice
45392371|NCT03741556|Other|questionaire|a questionaire is sent to each participans
45392372|NCT03971890|Other|Dance therapy|The experimental group will receive a dance treatment.This protocol will be administered at weekly sessions of 60 minutes with a period of 2 times / week with a total of 16 sessions, distributed over a 8-week period. They will be evaluated at baseline, after the end of the last treatment session.
45392373|NCT03971890|Other|Educational group|The control group will receive an educational intervention. They will be evaluated at baseline, after the end of the last treatment session.
45392374|NCT00278889|Drug|AZD2171|oral tablet
45392375|NCT00278889|Drug|5-fluorouracil|intravenous infusion
45392376|NCT00278889|Drug|Leucovorin|intravenous infusion
45392377|NCT00278889|Drug|Oxaliplatin|intravenous infusion
45392378|NCT00278889|Drug|Bevacizumab|intravenous infusion
45392379|NCT01070745|Drug|Indomethacin|Three doses of intravenous (IV) indomethacin at 0.2 mg/kg/dose given over 30 minutes, at intervals of 12 hours
45392380|NCT01070745|Drug|Ibuprofen|10 mg/kg infused over 30 minutes, followed by two doses of 5mg/kg each at 24 hour intervals
45392381|NCT01071057|Drug|Naloxone|Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
45392382|NCT01071057|Drug|Saline/Morphine|Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
45392383|NCT00278109|Drug|cyclophosphamide|chemotherapy
45392384|NCT00278109|Drug|Doxorubicin|doxorubicin
45392385|NCT00278109|Radiation|radiation|radiation
45392386|NCT00296517|Drug|323U66 (Bupropion Hydrochloride Sustained Release)|Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
45392387|NCT00296517|Drug|Placebo|Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
45392388|NCT00224770|Drug|MIS+Cathflo Activase (drug)|MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo® through the catheter once every eight hours for up to 72 hours, in addition to best medical care.
45392389|NCT00224770|Procedure|Intraoperative stereotactic CT-Guided Endoscopic Surgery|Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative targeting arm as MISTIE arm. No rt-PA administered, and in addition to best medical care.
45392390|NCT02531776|Device|Subcutaneous insertions of needles|"Various types of needles with different designs and mechanical properties.~Five marketed needles are included: NovoFine 28G x 12 mm (Novo Nordisk A/S, Denmark), NovoFine 30G x 6 mm (Novo Nordisk A/S, Denmark), NovoFine 32G tip x 6 mm (Novo Nordisk A/S, Denmark), BD Ultra-Fine 32G x 4 mm Pentapoint (Beckton, Dickinson & Company, USA), and Terumo Nanopass 34G x 5 mm (Terumo, Japan).~Ten needles have been exclusively manufactured for this clinical trial by Hart Needles, USA. These needles vary in diameter, number of needle tip grinding, and angles of grindings.~Three needles have been modified from the original (NovoFine 32G x 6 mm) with lack of lubrication or damaged needle tip for simulations of repeated use.~No drugs are injected. Only the needle insertion is evaluated."
45392391|NCT00266409|Drug|Niravam|
45392392|NCT00266409|Drug|SSRI/SNRI|Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor
45392393|NCT00277095|Device|ProACT (Adjustable Continence Therapy)|Implantable device to reduce urinary stress incontinence
45392394|NCT00265785|Drug|pemetrexed|Pemetrexed 500 mg/m^2 intravenous (IV) over 10 min every 21 days until any of the following criteria is met: (1) Progression of disease or symptomatic deterioration; (2) Unacceptable toxicity; (3) Treatment delay ≥ 3 weeks, for any reason; (4) The patient may withdraw from the study at any time for any reason; (5) Physician's discretion.
45392395|NCT00276159|Drug|852A|Subcutaneous injection 0.6 mg/m2 2 times/week/12 weeks, may increase by 0.2 mg/m2 up to 1.2 mg/m2.
45392396|NCT02532153|Drug|Ketamine Hydrochloride|Single open-label infusions
45392397|NCT01072227|Procedure|Sample Collection|Tissue
45392398|NCT00265395|Drug|Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)|"Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks"
45392399|NCT00265395|Drug|Combination of pegylated interferon alfa-2b and ribavirin|"Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strength), subcutaneous, dose of 1.5 micrograms/kg, weekly for 72 weeks.~200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 72 weeks"
45392400|NCT01582113|Drug|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 500 mg or 250 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
45392401|NCT01582113|Other|Microcrystalline Cellulose|Microcrystalline Cellulose will be the placebo administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
45502817|NCT03150485|Device|JJVC Fitting Guides|Subjects who are habitual contact lens wearers with Presbyopic correction or Presbyopic symptoms, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guides, with either the Multifocal Contact Lens or an Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes of wear time during a 1-day visit.
45502818|NCT02060552|Drug|Diacerein|oral administration of IL-1βinhibitory
45502819|NCT02060552|Drug|Colchicine|"Colchicine is a toxic natural product and secondary metabolite, originally extracted from plants of the genus Colchicum (autumn crocus, Colchicum autumnale, also known as meadow saffron). It was used originally to treat rheumatic complaints, especially gout as the positive control"
45848862|NCT05599542|Other|Hypno-breastfeeding|A preliminary assessment was made about the pregnant woman's thoughts on breastfeeding. In the hypno-nursing philosophy, affirmation, relaxation, imagination and visualization techniques were used in order to positively affect the subconscious mind during the breastfeeding process.
45848863|NCT05599230|Drug|Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening|Patients will daily perform home spirometry and complete a respiratory symptoms score before (3 days) and during (first 14 days) ETI treatment.
45848864|NCT05573256|Behavioral|Lavender oil inhalation|Lavender oil inhalation;During the trial, the participants will be asked to practice lavender oil inhalation as follows: Every night before going to bed (21:00-24:00), the participants will drop two drops of 2% lavender essential oil on a 2x2 cm cotton gauze pad in a bowl, place it at a distance of 15-20 cm from their pillows, and breath normally for 20 minutes. The participants will be instructed to repeat this process by dripping lavender oil onto a new gauze pad every night for four weeks.
45848865|NCT05573256|Behavioral|Sleep hygiene education|Sleep hygiene education;The participants assigned to Groups 1 and 2 will receive sleep hygiene education using the sleep hygiene education brochure, which has been prepared by the researchers based on the literature concerning the improvement of general sleep quality in individuals with a stoma.
45392402|NCT00195442|Drug|Moroctocog alfa|Patients will be treated in accordance with the requirements of the labeling of ReFacto (Moroctocog alfa) in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
45392403|NCT01070823|Drug|Tysabri® (natalizumab)|Prescribed according to the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program
46056887|NCT02723253|Radiation|Radiotherapy|Radiotherapy was applied as conformal 3-D technique and was delivered with photon energies of 10 - 15 MV. The beams were delivered by an Elekta Precise Linac equipped with standard multi leaf collimators (MLC). A daily online check of isocenter position was performed using portal imaging, with set-up correction in case of displacement > 0.5 cm in any direction. Radiation dose delivered to PTV2 was 45 Gy (1.8 Gy/fraction) with a concomitant boost dose to the PTV1 of 10 Gy with accelerated fractionation at 2.2 Gy/fraction, five consecutive days for week.
45392404|NCT01071135|Drug|Quetiapine XR|Quetiapine XR (Seroquel Prolong®) extended-release tablets à 50 mg und 200 mg. Seroquel Prolong® should be administered as the only neuroleptics preferably once daily, preferably in the evening. The recommended initial dose is 200 mg/day. Patients should be titrated within a dose range of 400 - 800 mg/day depending on the response and tolerance of the individual patient. Dose increases can be made at intervals as short as 1 day and in increments of up to 200 mg/day. Seroquel Prolong® tablets should be swallowed whole and not split, chewed or crushed.
45426195|NCT05794633|Other|Placebo acupuncture|"The patients will be recieved two days a week for 8 sessions with placebo needle. Selected points are Large intestine 15 Triple warmer 14 gallbladder 21 and small intestine 9. We will use the placebo needle (blunt needle, tip obtuse, when acupuncture the feeling is similar to acupuncture needles into the skin, but it retracts instead of piercing the skin) to conduct acupuncture treatment. The retention time will be the same as those in the acupuncture group. The specialist will give the subjects verbal cues before and during the acupuncture manipulation, which further reduces the subjects' doubts about the authenticity of acupuncture in the this group. To ensure the implementation of the blinding method, all patients will be treated independently and avoid contacting with each other.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks"
45502820|NCT02060552|Drug|Febuxostat|A urate lowering drug, an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and gout
45502821|NCT01358149|Other|cocoa-based food|single intake of cocoa-based food
45696724|NCT04402047|Drug|Topical diclofenac sodium gel|The gel will be gently rubbed over the affected joints without excessive joint movement four times per day for 4 weeks and will be asked not to wash hands for one hour after application. Each hand treatment will be used in identical dispensing doses of gel (4 cm strip, approximately 2g, which was judged sufficient for approximately half the surface of each hand (200 cm2)). Dosing times should be distributed evenly over waking hours.If bilateral hands were affected, both sides will be treated.
45848866|NCT05533476|Behavioral|Multi Sensory Stimulation and Priming|In the MuSSAP intervention group, the infant wears a multisensory stimulating wristband aiming at increasing attention for the affected upper limb and readiness to initiate a goal-directed movement. Parents are instructed to present a toy to their child if the child shows attention to the affected arm and hand. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
46056888|NCT02723253|Drug|Tom-OX|The concurrent chemotherapy consisted of 15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2 and a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.
46056889|NCT04616794|Behavioral|Cognitive Engagement Group|Participants in this group will be encouraged to lead a cognitively stimulating lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to increase cognitively stimulating activities and by assisting participants outlining goals to progressively adopt a more cognitively active lifestyle.
45502822|NCT01358149|Other|cocoa-based food|Single intake of cocoa-based food
45392405|NCT03971968|Procedure|Skin replacement with artificial skin|Integra® Dermal Regeneration Template is a bilayer membrane system for skin replacement. The dermal replacement layer is made of a porous matrix of fibers of cross-linked bovine tendon collagen and glycosaminoglycan (chondroitin-6-sulfate). The epidermal substitute layer is made of thin polysiloxane (silicone) layer to control moisture loss from the wound. The silicone outer layer temporarily closes the wound to ward off infection and control fluid and heat loss. As skin cells migrate into the matrix the collagen is slowly absorbed into the body and replaced with protein that is naturally produced by the skin. In approximately 14 to 21 days, new dermal skin is produced and the silicone layer can be removed. A thin skin graft of the person's epidermis is applied to the wound area to complete the procedure. In total, the two surgical procedures are typically completed within 30 days. A person is left with flexible growing skin and minimal damage at the skin graft donor sites.
45392406|NCT00275301|Drug|olanzapine|Olanzapine 2.5mg by mouth at bedtime x2 weeks, then Olanzapine 5mg by mouth at bedtime x2 weeks, then Olanzapine 7.5mg by mouth at bedtime x4 weeks.
46056890|NCT04616794|Behavioral|Physical Activity Group|Participants in this group will be encouraged to lead a physically active lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to increase physical activities and by assisting participants outlining goals to progressively adopt a more physically active lifestyle.
46056891|NCT04616794|Behavioral|Diet Group|Participants in this group will be encouraged to adopt a healthy diet, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to change their diet and by assisting participants outlining goals to progressively adopt a Mediterranean-like diet.
45392409|NCT02531997|Behavioral|Hypnotic Relaxation Therapy|There are 3 induction scripts that build upon each other, each about 20 minutes in length. The first focuses on relaxation, feelings of wellness, wholeness, strength, and confidence. The second focuses more on body image related to sexuality, sexual desire, passion, and romanticism. The third includes suggestions from the previous inductions, but adds a behavior that the woman chooses to incorporate for the last 2 weeks of the intervention. A digital recording will be provided of the intervention content for home practice.
45392410|NCT02531997|Behavioral|Progressive Muscle Relaxation|Women will be instructed how to do progressive relaxation and will be given the opportunity to ask questions and express concerns. The research therapist will utilize a script to focus the conversation on relaxation and planning the implementation of the behavior. Participants will be given a digital recording of 4 pleasant background sounds to facilitate their relaxation practice. Home practice will be encouraged.
45392411|NCT03969238|Behavioral|Helpline|This helpline will aim to provide patients with new diagnosis of pain who are prescribed opioids, access to education, support and free behavioral technique to help manage their pain such as mindfulness exercises. For those with opioid use disorder, the helpline will offer support in the form of education about the disorder, opioid withdrawal symptoms, risks of overdoses, and a variety of services such as help reach appropriate care with MAT licensed providers, information on FDA-approved MAT and naloxone, and, in some cases, behavioral intervention to keep patients engaged in treatment. The opioid helpline will provide a central resource for direct services and a portal for community services. It will also serve as a referral resource for health-care professionals.
45392412|NCT00251745|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
45392413|NCT00251745|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
46056892|NCT04616794|Behavioral|Multimodal group|Participants assigned to this group will select which domain they wish to tackle first. Interventions are as described for the single-domain interventions.
46056893|NCT05752942|Behavioral|Student Intervention Matching System (SIMS)|"The Student Intervention Matching System (SIMS) is a pre-intervention matching assessment following the behavioral consultation model. The SIMS entails three steps to sequentially assess and then match students' individual characteristics to precise acquisition- or performance-based interventions. The 1st step corresponds to the problem identification stage in behavioral consultation. The 2nd step corresponds to the problem analysis stage of behavioral consultation.The 3rd step of SIMS corresponds to the implementation planning and evaluation stages of behavioral consultation."
45392414|NCT00251745|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
45392415|NCT00255190|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 12 months.
45392416|NCT00255190|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 12 months.
45392417|NCT03973762|Device|DR Grading with CAD|A CAD system is used to make DR grading.
45392418|NCT03973762|Other|DR Grading by expert panel|DR Grading by expert panel
45392419|NCT00359424|Drug|IV rt-PA alone|Intravenous (IV) recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy; Group one will receive the standard dose of IV rt-PA given over an hour.
45392420|NCT00359424|Other|endovascular therapy|Group two will receive a lower dose or the standard dose of IV rt-PA and then undergo an angiogram test (cerebral angiography) right after the medicine is given to check for blood clots. If a clot is not seen then no more treatment will be given. If a clot is seen, the neurointerventionalist will then choose a protocol approved endovascular treatment given directly in the brain artery that will be most effective in reopening the blocked artery. Endovascular therapy can be implemented with or without interarterial rt-PA use.
45392421|NCT03991026|Behavioral|Healthy food and Education/Cooking Classes|The intervention includes providing weekly seasonal produce and healthy foods to participants in addition to an education/cooking class that will be tailored to Diabetes Mellitus, Type II.
45502823|NCT05384886|Diagnostic Test|Polymerase chain reaction|Covid-19 genetic material detection from mouth and nose swab
45392422|NCT02535234|Device|Novel System|A Novel full Continuous Positive Airway Pressure (CPAP) system - Prototype Device, Mask + Accessories
45392423|NCT02535234|Device|Traditional System|A Traditional full Continuous Positive Airway Pressure (CPAP) system- Released Device + Accessories, Prototype Mask
45392424|NCT01049646|Drug|Angiotensin II|Infusion of a subpressor dose of angiotensin II will be give, this will be 0.5microG/min/kg. Thereafter thre ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
45392425|NCT01049646|Drug|Saline|Infusion of saline. Thereafter three ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
45392426|NCT02286414|Drug|Direct oral antocoagulant: dabigatran, rivaroxaban, apixaban|Exposure to direct oral antocoagulants : dabigatran, rivaroxaban, apixaban
45392427|NCT02286414|Drug|Vitamin K antagonist: warfarin, fluindione, acenocoumarol|Exposure to vitamin K antagonist
46056894|NCT05752942|Behavioral|group-based social skills training|In the control condition, students received an unconditionally mismatched acquisition-based intervention (group-based social skills training). We selected group-based social skills training for four reasons: (a) participating schools had already been delivering it as their treatment-as-usual, (b) it is a common intervention in US schools, (c) it is only effective for students with acquisition needs, and (d) it represents a counterfactual contrast to the treatment condition because externalizing behaviors driven by performance needs will be reduced more by performance-based interventions than acquisition-based ones.
45392428|NCT00255034|Biological|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
45392429|NCT00255034|Biological|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
45502824|NCT01350427|Dietary Supplement|Leucine supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 5.6 g of alanine
45502825|NCT01350427|Dietary Supplement|BCAA supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 2.8 g of isoleucine + 2.8 g of valine
45502826|NCT01350427|Dietary Supplement|Alanine supplementation|1 bout of resistance exercise and supplementation of 9.6 g of alanine
45502827|NCT05211765|Diagnostic Test|Superior vena cava transthoracic evaluation|The superior vena cava will be observed with a cardiac ultrasound machine, its diameter in different respiratory phases evaluated and compared with fluid response.
45502828|NCT05384574|Dietary Supplement|cholecalciferol|daily supplementation of cholecalciferol, 10 000 IU, during 14 days
46056895|NCT02717481|Device|US-CT Fusion examination|Patients will undergo an US examination using an US device with US-CT Fusion capabilities.
45502829|NCT04355585|Drug|Colchicine Tablets|1.8mg of Colchicine given over 1 hour (1.2 mg followed by 0.6 mg 1 hour later)
45696725|NCT03017560|Behavioral|Computerized cognitive treatment|Participants will engage in auditory and verbal memory exercises intended to improve verbal memory functioning. The exercises are: Elephant Memory, Words where are you?, Split words, Bird Songs, Sound check, and You've got voicemail. Participants will complete the exercises 1 hour per day, 6 days per week, for 6 weeks. The program automatically adjusts difficulty level according to individual performance. The program captures and reports all relevant data to the primary investigator, including accuracy and reaction time (speed), which will be used to measure progress.
45696726|NCT03028714|Behavioral|Technology-based nutrition education|All participants will undertake anthropometric measurements and assessments of blood pressure and blood glucose. They will be also asked to complete online questionnaires with regards to nutrition and physical activity. Participants in the intervention group will receive additional access to a website, providing information about nutrition topics including alcohol and physical activity. Through the website participants will be asked to play online quiz-games related to the nutrition topics. Each play will include game elements such as time, point collection and graphics. Participants will be asked to play the games as much as they want to improve their scores and to use the website as a reference tool.
45392430|NCT00255034|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 weeks
45392431|NCT00255034|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 48 weeks
45392432|NCT01049724|Other|Tear collection|Tear collection
45392433|NCT03991104|Drug|Oxaliplatin|Oxaliplatin (3 levels for phase I: 110 mg/m², 120 mg/m² and 130 mg/m²) is administered as a 2 h intravenous infusion in 500 mL of 5% glucose on day 1 and day 29 during the treatment course.
45502830|NCT04355585|Drug|Placebo oral tablet|Placebo given over 1 hour (first tablet followed by second tablet 1 hour later)
45696727|NCT03028168|Other|Yôga|Intervention observing respiratory frequency (RF) of 15- 20 respiratory cycles per minute (rcpm). A standardized 7-minute final relaxation .
45392434|NCT03991104|Drug|S-1 capsule|Patients received a fixed dose of S-1 with a dose of 80 mg/m2/d twice daily for 2 weeks, every 4 weeks.
45392435|NCT03991104|Radiation|Intensity modulated radiotherapy (IMRT)|The total radiation dose was set to 50.4 Gy, which was given in 28 fractions of 1.8 Gy once-daily fractions for over 5 weeks.
45392436|NCT00254566|Other|Moxifloxacin Placebo|1 capsule once daily for 5 days
45502831|NCT05189743|Procedure|Skin transplantation to heal burn injuries|"The study compare two different treatment modalities, STSG (split-thickness skin graft) versus dermis graft after excision of devitalized/necrotic tissue.~A dermatome will be used for graft harvest."
45392437|NCT00254566|Drug|Moxifloxacin|1 X 400mg capsule once daily for 5 days
45392438|NCT00254566|Other|Azithromycin SR Placebo|single dose, oral.
45392439|NCT00254566|Drug|Azithromycin SR|single dose 2.0 g oral
45392440|NCT02531854|Drug|ADXS11-001|
45392441|NCT02531854|Drug|Pemetrexed|
45392442|NCT02531542|Device|Echocardiography according to the READ method.|"Echocardiography will be performed before any therapy is initiated by a fully trained operator, according to the READ method. The results of this ultrasound will not be communicated to the clinician managing the patient in the emergency room.~A blood sample will be taken during the routine work-up for centralized evaluation of NT-proBNP levels."
45392443|NCT00358956|Drug|ZD6474 (vandetanib)|100 mg once daily oral tablet
45502832|NCT02061020|Drug|Cannabis (THC) in cigarettes of 30mg, 10mg and placebo|"Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.~Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.~Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).~Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours."
45392444|NCT01048086|Drug|Retinoic Acid|160 mg, given orally, divided BID on Days 1-4 of each cycle for 4 cycles. Each cycle will be six weeks in duration. Dose will be adjusted to 5.33 mg/kg/day divided BID for children <12 kg.
45392445|NCT01048086|Drug|Placebo|Placebo will be given in the same manner as retinoic acid in capsules that look identical.
45392446|NCT01052610|Drug|sublingual house dust mites allergen extract|Staloral 300 IR, Stallergenes, France
45392447|NCT01052610|Drug|placebo in sublingual applicator|placebo for Staloral 300 IR, Stallergenes, France
45392448|NCT03830892|Other|E-cigarette Lab Session 15 watts, 10 mg nicotine|E-cigarette paired with low nicotine, low device power
45392449|NCT03830892|Other|E-cigarette Lab Session 15 watts, 30 mg nicotine|E-cigarette paired with low nicotine, low device power
45502833|NCT02031744|Drug|erlotinib [Tarceva]|150 mg oral administration once daily
45502834|NCT02031744|Drug|Placebo|15 mg/kg intravenous administration every 3 weeks
45696728|NCT03028168|Other|Breathing technique|Intervention uses diaphragmatic breathing, observing slow respiratory frequency, between 5-8 rcpm. A standardized 7-minute final relaxation.
46056896|NCT05264727|Drug|Dextrose|Intravenous graded glucose infusion using 50% dextrose will commence at 1mg/kg/min and increase to 2 (0900), 4 (1000) and 8mg/kg/min (1100) every 60 minutes
46056897|NCT05264727|Drug|Clinisol 15%|Intravenous infusion 0.003ml/kg/min infused from 0 to 240 minutes
46056898|NCT02723097|Behavioral|3 RP|
45392450|NCT03830892|Other|E-cigarette Lab Session 30 watts, 10 mg nicotine|E-cigarette paired with low nicotine, low device power
45392451|NCT03830892|Other|E-cigarette Lab Session 30 watts, 30 mg nicotine|E-cigarette paired with low nicotine, low device power
45392452|NCT03830892|Other|Own Brand Session - E-cigarette|E-cigarette paired with own brand liquid and preferred power
45696729|NCT03028168|Other|Control group|Patients will be oriented to keep their pharmacological routine and daily activities, with no structured exercises. They will have to return to the hospital for post-testing after 8 weeks from randomization
45696730|NCT03027778|Other|Exercise|Intradialytic pedalling exercise during regular dialysis sessions (3x per week) for 4 months
45392453|NCT03830892|Other|Own Brand Session - E-cigarette/Cigarette|Own brand cigarette OR E-cigarette paired with own brand liquid and preferred power
45392454|NCT01048164|Procedure|Massage|Chair Massage
45392455|NCT01049880|Drug|Gemcitabine with escalating ascorbic acid|"Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic acid, given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbic acid per infusion Week 2: 25 grams ascorbic acid per infusion Week 3: 50 grams ascorbic acid per infusion Week 4: 75 grams ascorbic acid per infusion Week 5: 100 grams ascorbic acid per infusion~Ascorbic acid infusion dose is maintained at the level that provides a serum level of 350-400 mg/dL."
45392456|NCT00253630|Other|Laboratory Biomarker Analysis|Correlative studies
45392457|NCT00253630|Drug|Vorinostat|Given PO
45392458|NCT00358644|Drug|Decitabine|20 mg/m^2, IV on days 1-5 of each 28 day cycle; until death, progression or unacceptable toxicity develops.
45392459|NCT01324908|Procedure|extracorporeal photopheresis|Undergo ECP
45392460|NCT01324908|Other|laboratory biomarker analysis|Correlative studies
45392461|NCT01048320|Drug|Gemcitabine|"The starting dose of gemcitabine will be 400 mg/m2 on day 1 of a two-week cycle.~Gemcitabine is given on day 1 every two weeks according to the dose escalation schedule below:~Dose level -1 200mg/m2 Dose level 1 400mg/m2 Dose level 2 600mg/m2 Dose level 3 800mg/m2 Dose level 4 1000mg/m2 Dose level 5 1000mg/m2 It is administered as an intravenous infusion, the lyophilized powder being diluted in normal saline, at a fixed dose of 10 mg/m2/minute."
45392462|NCT01048320|Drug|Oxaliplatin|Oxaliplatin is given by intravenous infusion on day 2 every 2 weeks according to the dose escalation schedule below: Dose level -1 - 4 85mg/m2 Dose level 5 100mg/m2 Oxaliplatin should be diluted in 250 to 500 ml of 5% glucose solution to give a concentration not less than 0.2 mg/ml. It must be infused via a central venous line or peripheral vein over 2 hours. In the event of extravasation, administration must be discontinued immediately and the extravasation managed according to local procedures.
45696731|NCT03035110|Behavioral|Dialectical Behavioural Therapy (DBT) based skills groups|Dialectical Behavioural Therapy (DBT) involves skills that help people manage their emotions and tolerate distress. This therapy is found effective in reducing self-harm behaviour for outpatients with Borderline Personality Disorder.
45392463|NCT01048320|Drug|Imatinib|"Imatinib is given for 7 days every cycle starting 2 days before the gemcitabine is given, including administration on days 1 and 2 when gemcitabine and oxaliplatin are given, and for 3 days afterwards (i.e. days -2 to +5). It is thus given on a 7 days on and 7 days off intermittent dosing schedule. The dose will be fixed at 400 mg daily in tablet form and taken once daily with food.~Imatinib should commence either in the morning or lunchtime of day -2 and be taken at the same time daily for seven consecutive days in total."
45392464|NCT03990480|Drug|valsartan (160 mg/d)|Group I treated with valsartan (160 mg/d, n = 100)
45848867|NCT05533476|Behavioral|Intensive Usual Care (Upper Limb)|The Intensive Usual Care (Upper Limb) intervention is a more intensive (in duration and frequency) version of standard Usual Care with focus on the motor development of the affected upper extremity. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
45696732|NCT03017638|Other|Questionaire|Patients undergoing primary laparoscopic colectomy patients under general anesthesia with an additional Quadratus lumborum block (QLB ) will be asked to fill out a questionnaires detailing: numeric verbal analogue scores (VAS) and quality of recovery score(QoR) preoperatively, 24 hours, 48 hour and four weeks after surgery. Additional data will be collected: ASA physical status, demographics, intra- and post operative opiate(expressed as morphine equivalent in mg/kg) and non opiate consumption in order to assess the analgesic efficacy of QLB for primary laparoscopic colectomy. QLB will be performed as per standard routine regimens, in the operating room after induction of general anesthesia and prior to surgery.
45696733|NCT03017248|Drug|Ketamine|ketamine
45848868|NCT05522868|Drug|SB17170|SB17170 capsules, Oral administration 21days/cycle
45392465|NCT03990480|Drug|amlodipine (10 mg/d).|Group II amlodipine (10 mg/d, n = 100).
45392466|NCT01052688|Other|Maternal blood draw of 30 to 50ml|Maternal blood draw of 30 to 50mls during pregnancy. Blood may be drawn up to 5 times during the pregnancy between weeks 8 and 36 gestation.
45392467|NCT01052766|Procedure|PET/CT and BH PET/CT|First, fiducial markers will be placed and taped on the patient's lower chest/upper abdomen. This will allow for monitoring of chest motion during breathing. A BH-CT scan will then be acquired with clinical CT scan parameters used in nuclear medicine. A BH-PET scan (acquisition time: 6 min per bed position) will follow the BH-CT scan. BH-PET images will cover the whole thorax, which, on average, corresponds to 1-3 PET FOV's (~15 cm/FOV). Data for these 1-3 bed positions are acquired to cover the entire thorax. There will be no additional radiotracer injection for the BH-PET scan.
45392468|NCT00364182|Drug|Recombinant Coagulation Factor IX (BeneFIX)|100 IU/kg once weekly then crossover to 50 IU/kg twice weekly
45392469|NCT00364182|Drug|Recombinant Coagulation Factor IX (BeneFIX)|50 IU/kg twice weekly then crossover to 100 IU/kg once weekly
45392470|NCT00369486|Procedure|Focal laser photocoagulation|Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study technique)
45696734|NCT03017248|Drug|Placebos|0.9% normal saline
45696735|NCT03017248|Drug|Morphine|Morphine
45848869|NCT05403762|Other|ESENTA™ Skin Barrier Spray (ConvaTec, UK)|The skin protectant will be applied on clean and dry skin exposed to urine and stool. After application, the solvent evaporates leaving a silicone film on the skin surface.
45848870|NCT05403762|Other|Hydrophobes Basisgel DAC|The skin protectant will be applied on clean and dry skin. It contains 95% paraffin oil and creates a hydrophobic layer on the skin surface.
45848871|NCT05381376|Diagnostic Test|Hysteroscopy|Hysteroscopy for CSGE, AFS, and endometrial receptivity assessment
45848872|NCT05381376|Diagnostic Test|Ultrasonography|Ultrasonography for Uterus size and endometrial thickness
45392471|NCT00369486|Drug|40mg triamcinolone|Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
45392472|NCT00369486|Drug|20mg triamcinolone|Anterior peribulbar injection of 20 mg triamcinolone
45392473|NCT00369486|Drug|40mg triamcinolone + laser|Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
45392474|NCT00369486|Drug|20mg triamcinolone + laser|Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
45392475|NCT03992664|Other|EDUCATION|"The training program will focus on four parameters: cleanliness, hydration, protection from external stimuli, and finally early detection of skin side effects.~The re-evaluation of the skin as well as the repetition of the questionnaires will be done every week for 4 weeks."
45392476|NCT00363480|Drug|Salmeterol/Fluticasone 50/250 mcg|Participant received salmeterol/fluticasone combination 50/250 mcg using DISKUS™ powder inhalers.
45392477|NCT00363480|Drug|Salbutamol 100 mcg|This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol.
45392478|NCT00363480|Device|DISKUS™ powder inhalers|Participant received salmeterol and fluticasone using DISKUS™ powder inhalers.
45848873|NCT05356572|Device|Investigational Skin Preparation Device|Removal of hyperkeratotic skin with Investigational Skin Preparation Device
45392479|NCT03990714|Procedure|Right hemicolectomy|It is the resection of the right colon by a tumor and the reconstruction by an ileocolic anastomosis: intracorporeal or extracorporeal
45392480|NCT00223990|Biological|FMP1/AS02A|FMP1/AS02A candidate malaria vaccine
45392481|NCT00223990|Biological|RabAvert|RabAvert rabies vaccine
45392482|NCT01052922|Other|3 sample g-SENSA|Participants will be mailed to a 3 sample g-SENSA FOBT kit to complete at home and mail back to the lab for screening.
45392483|NCT01052922|Other|2 sample InSure|Participants will be mailed to a 2 sample InSure FOBT kit to complete at home and mail back to the lab for screening.
45392484|NCT01052922|Other|1 sample OC-Micron|Participants will be mailed to a 1 sample OC-MICRON FOBT kit to complete at home and mail back to the lab for screening.
45392485|NCT03990636|Drug|Metil 5-aminolevulinate|Scrubbing lip vermillion and applying the medication or placebo that is activated (or not, in case of placebo) with red light.
45502835|NCT02031744|Drug|Onartuzumab [MetMAb]|15 mg/kg intravenous administration every 3 weeks
45502836|NCT04653389|Drug|Sintilimab Injection|Sintilimab Injection is used as neoadjuvant therapy and adjuvant therapy.
45502837|NCT04653389|Drug|TACE|The first TACE and Sintilimab Injection will be initiated simultaneously.
45392486|NCT01048398|Drug|remifentanil|intervention: intravenous paracetamol 1g and remifentanil 1mg/100ml in 100ml of 0.9% saline.
45392487|NCT01048398|Drug|paracetamol|Control group: intravenous paracetamol 1g
45392488|NCT03971812|Biological|Blood sample|A blood sample of two 10 mL ethylenediaminetetraacetic (EDTA) tubes will be taken at the time of the visit. This sample will be centrifuged for isolation of peripheral blood mononuclear cells (PBMC).
45392489|NCT03990324|Procedure|Manual stretching|Manual stretching for the upper trapezius and levator scapulae muscle
45392490|NCT01073644|Drug|Sunitinib malate|sunitinib 50 mg, 4 weeks on, 2 weeks off
45502838|NCT04653389|Radiation|Radiotherapy|Use Cone Beam computor tomography(CBCT) locates the lession before the therapy.
45696736|NCT03035344|Other|Metabolome study|Metabolome study in ALL patients compared to healthy controls
45696737|NCT03034720|Behavioral|Collaborative Care|Intervention subjects will receive treatment from an MSW-trained care manager over the course of 6-months after randomization. Intervention team members will work collaboratively with primary care providers to link physical and mental health care longitudinally through outpatient follow-up and community rehabilitation. Intervention subjects and their families and collaborative team members will share information and deliberate treatment decisions with each other in order to develop an individually tailored treatment plan. Stepped, higher intensity care will be available for intervention subjects with recurrent symptoms. Stepped up care will include CBT booster sessions targeting post-concussive and related symptom comorbidity as well as psychopharmacologic assessment and treatment.
45696738|NCT03034486|Drug|D930, D565|Period 1: D565 administered 1 time for one day/ Period 2: D930 administered 3 time per day for 9 days/ Period 3: D565(1 time per day) with D930(3 time per day) administered for 9days
45392491|NCT02534922|Biological|Prolanta, a human prolactin receptor antagonist|Daily subcutaneous dosing
45392492|NCT03992586|Other|Wearing pink glasses|Wearing pink-colored lenses
45392493|NCT03992586|Other|Wearing clear glasses|Wearing clear glasses
45392494|NCT01048476|Dietary Supplement|lutein|Dietary Supplement: 20mg Lutein; daily supplementation one year
45392495|NCT01048476|Dietary Supplement|Lutein|Dietary Supplement: 10mg Lutein; daily supplementation one year
45392496|NCT01048476|Dietary Supplement|placebo|Dietary Supplement: placebo; daily supplementation one year
45392497|NCT01048476|Drug|Lutein and zeaxanthin|Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
45392498|NCT01581060|Drug|WX-554|Capsules of WX-554
45392499|NCT03990246|Other|Acid stable emulsion with solid droplets|This will be a 250 mL acid stable beverage emulsion in which the droplets are crystalline. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20% of the lipid palm stearin with 2.2% of the emulsifier sorbitan monooleate (Tween80)
45426196|NCT05794607|Other|Rehabilitation group|The intervention group will be given strength training to improve muscle strength and flexibility, and aerobic exercise training to improve exercise capacity with function.
45696739|NCT00088881|Biological|rituximab|Given IV
45696740|NCT00088881|Drug|prednisone|Given orally
45696741|NCT00088881|Drug|cyclophosphamide|Given IV
45696742|NCT00088881|Drug|doxorubicin|Given IV
45392500|NCT03990246|Other|Acid stable emulsion with liquid droplets|This will be a 250 mL acid stable beverage emulsion in which the droplets are liquid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20 % of the lipid palm olein with 2.2% of the emulsifier sorbitan monooleate (Tween80)
45392501|NCT03990246|Other|Acid unstable emulsion with solid droplets|This will be a 250 mL acid unstable beverage emulsion in which the droplets are solid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20% of the lipid palm stearin with 2.5% of the emulsifier sorbitan monostearate (Span60)
45392502|NCT03990246|Other|Acid unstable emulsion with liquid droplets|This will be a 250 mL acid unstable beverage emulsion in which the droplets are liquid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20 % of the lipid palm olein with 2.5% of the emulsifier sorbitan monostearate (Span60)
45392503|NCT03992742|Behavioral|Initial phase: personalized instant messaging (PIM)|"intervention Group participants will receive three months of personalized interaction through IM Apps (e.g. WhatsApp, WeChat). Our counsellors will trigger the conversation and encourage the participants to set a quit day. A total of pre-set 26 messages will be sent with the schedule of once daily for 1 week (the week across the quit date), 3 times a week for 4 weeks (2 weeks each before and after the week with quit date) and once a week for remaining 7 weeks. These messages covered generic information about the benefits of quitting, methods to avoid/ manage craving or withdrawal symptoms, and encouragement to quit and use SC services.~At the end of the initial phase (1-month), complete responders (quitters) will continue to receive PIM (subgroup C). Incomplete responders (smokers) will be randomized to continue PIM (subgroup B) or receive OCI (subgroup A)."
45392504|NCT03992742|Behavioral|Second phase: optional cocktail interventions (OCI)|For incomplete respondents (subgroup A) randomized to OCI, the available intervention options include multi-media messages, active referral plus financial incentive, phone counseling, family/peer support and medications (NRT). Participants will be guided by cessation counsellors at 1-month follow-up telephone survey to choose any combination of OCI based on their preference. If OCI participants cannot be followed up at 1-month, they will receive multi-media messages by default.
45392505|NCT03992742|Behavioral|Initial phase: regular instant messaging (RIM)|"Participants enrolled in the Control Group will receive regular messages via IM services (e.g. WhatsApp, WeChat) since initial contact and until 3-month after baseline with a tapering schedule: 1) Baseline to 4-week (1-month): 2 times/ week (8 in total); 2) 4-week to 12-week (2- & 3-month): 1 time/week (8 in total).~SC messages will generally include benefits of SC, encouragement on abstinence and use of SC services, tips on avoiding/ handling craving and reminder of participating in telephone follow-up. A reminder to participate in the telephone follow-up will also be sent at 1-, 2-, 3- and 6-month, making up a total of 20 messages.~At the end of the initial phase (1-month), complete responders (quitters) will continue to receive RIM (subgroup F). Incomplete responders (smokers) will be second randomized to continue RIM (subgroup E) or receive PIM (subgroup D). Those who are unable to follow up at 1-month will be considered as nonresponsive to the intervention."
45392506|NCT03992742|Behavioral|Second phase: personalized instant messaging (PIM)|"For incomplete responders allocated to PIM (subgroup D), participants will receive the same intervention as the Group A delivered at the initial stage. Participants will receive two months of personalized interaction through IM application. Please refer to Intervention Group Initial phase: personalized instant messaging (PIM) for details."
45392507|NCT03992742|Behavioral|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
45392508|NCT03992742|Behavioral|Warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
45392509|NCT03992742|Behavioral|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
45392510|NCT03992742|Behavioral|COSH booklet|A general smoking cessation self-help booklet
45392511|NCT00221104|Drug|Pravastatin|
45392512|NCT00189202|Drug|Sirolimus|Thymoglobulin induction, sirolimus and no maintenance corticosteroid
45696743|NCT00088881|Drug|vincristine|Given IV
45696744|NCT00088881|Radiation|indium In 111 ibritumomab tiuxetan|Given IV
45392513|NCT01071928|Drug|Docetaxel|Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1
45848874|NCT05356572|Device|GMDN 47102 / Electrode Skin Abrasive Pad|Removal of hyperkeratotic skin with Abrasive Pad for Skin Preparation
45392514|NCT01071928|Drug|ASA404|ASA404 (given after Docetaxel)IV 1800 mg/m2 over approximately 20 minutes on Day 1
45392515|NCT03969160|Behavioral|Imaginal exposure|Imaginal exposure to mental imagery of phobic and neutral stimuli
45392516|NCT00187486|Drug|Tarceva|Tarceva (erlotinib hydrochloride; previously referred to as OSI-774), a quinazoline, is an orally active, potent, selective inhibitor of EGFR tyrosine kinase. 100 - 300 milligrams (mg) every day (QD) orally (PO) every (q) 28 days depending on EIAED Status
45696745|NCT00088881|Radiation|radiation therapy|Undergo radiotherapy
45696746|NCT00088881|Procedure|positron emission tomography|Undergo PET scans
45696747|NCT02981914|Drug|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks for a max of 24 months, so long as there is no disease progression.
45696748|NCT02981680|Procedure|Remote Ischemic Preconditioning (RIPC)|Remote ischemic preconditioning (RIPC) is a phenomenon in which brief ischemia of one organ or tissue, provokes a protective effect that can reduce the mass of infarction caused by vessel occlusion and reperfusion.
45696749|NCT02981680|Procedure|sham-RIPC|
45392517|NCT00187486|Drug|Temodar|Temodar 200 mg/m^2/day x 5 days every 28 days
45392518|NCT00187486|Procedure|Radiation Therapy|Radiotherapy will be administered in 180 centigray(cGy)/day - 200cGy/day fractions delivered 5 days per week to a total dose of 5940cGy - 6100cGy. A total of 4500cGy will be delivered to the clinical tumor volume consisting of T2-bright edema + a 2centimeter margin, or, if no edema, the contrast enhancing lesion +2.5 centimeter margin. An additional boost of 1440cGy will be delivered to the gross tumor volume consisting of the contrast enhancing lesion + a 1 centimeter margin.
45392519|NCT00220636|Drug|Aripiprazole|Aripiprazole dose ranging from 5 to 30 mg/day, augmenting antidepressant treatment. Aripiprazole is used as an augmenting medication on an open label basis for patients on antidepressant medication who continue to have depressive symptoms. This is an open label case series in which all subjects receive aripiprazole augmentation. There is no comparator group.
45392520|NCT00362232|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening.
45392521|NCT00362232|Drug|Enoxaparin|Syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
45392522|NCT00362232|Drug|Placebo: tablet of Rivaroxaban|Placebo tablet of rivaroxaban administered once daily in the evening.
45392523|NCT00362232|Drug|Placebo: syringes of Enoxaparin|Placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
45392524|NCT03968926|Other|Arterial pressure management during circulatory support by VA-ECMO|Norepinephrine continuous infusion to maintain mean arterial pressure above 65 mmHg or at a higher level depending of the perfusion pressure targeted for the patient (mean arterial pressure between 65 and 85 mmHg)
45392525|NCT01048554|Drug|Temozolomide|Temozolomide 75mg/m2 for six continuous weeks
45392526|NCT01048554|Drug|Bevacizumab|Bevacizumab 10mg/kg every 2 weeks without interruption
45392527|NCT00219544|Drug|Pregabalin (Lyrica)|pregabalin 150mg/day (75mg BID)
45392528|NCT00219544|Drug|Pregabalin (Lyrica)|pregabalin 300 mg/day (150mg BID)
45392529|NCT00219544|Drug|Pregabalin (Lyrica)|pregabalin 600/day (300mg BID)
45392530|NCT00219544|Drug|Placebo|Placebo
45392531|NCT00357552|Drug|Emtricitabine/Tenofovir disoproxil fumarate|Once daily
45392532|NCT00357552|Drug|Lopinavir/Ritonavir|Twice daily
45392533|NCT00187096|Drug|Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2|See Detailed Description section for additional details of treatment interventions.
45392534|NCT00187096|Procedure|Natural Killer Cell Infusion|See Detailed Description section for additional details of treatment interventions.
45392535|NCT00187096|Device|CliniMACS System|See Detailed Description section for additional details of treatment interventions.
45392536|NCT00357396|Biological|graft versus host disease prophylaxis/therapy|
45696750|NCT03026452|Procedure|US-guided RFA|The investigators used percutaneously US-guided radiofrequency ablation for patients with small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
45696751|NCT03025750|Biological|IPV-Al SSI|Total of three primary injections of IPV-Al SSI, one at 2, 4 and 6 months of age
45696752|NCT03025750|Biological|IPV SSI|Total of three primary injections of IPV SSI, one at 2, 4 and 6 months of age
45696753|NCT03024892|Procedure|ICG GB|ICG was given by intra-gallbladder injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
45848875|NCT05356572|Device|UMDNS 13-230 / Biopsy punch (Dermal Curette)|Removal of hyperkeratotic skin with Disposable Dermal Curette
45848876|NCT05345184|Behavioral|Cognitive Behavioral Suicide Prevention for psychosis (CBSPp)|Cognitive and behavioral approach to suicide prevention tailored for individuals with psychosis
45392537|NCT00357396|Drug|busulfan|
45392538|NCT00357396|Drug|melphalan|
45392539|NCT00357396|Drug|thiotepa|
45392540|NCT00357396|Procedure|allogeneic bone marrow transplantation|
45392541|NCT00357396|Procedure|allogeneic hematopoietic stem cell transplantation|
45392542|NCT00357396|Procedure|peripheral blood stem cell transplantation|
45392543|NCT00186628|Procedure|Total lymphoid irradiation|Total lymphoid irradiation (TLI) administered at 80cGy for 10 days
45392544|NCT00186628|Drug|Rituximab|Rituximab 375 mg/m2 administered as an intravenous (IV) infusion once weekly for 4 doses.
45392545|NCT00186628|Drug|Anti-thymoglobulin, rabbit (ATG, rabbit ATG)|Rabbit anti-thymoglobulin (ATG) administered from Day -11 through Day -7 (5 doses) at 1.5 mg/kg/day, for a total dose of 7.5 mg/kg.
45392546|NCT00186628|Drug|Cyclosporine|Cyclosporine (CSP) administered orally at 6.25 mg/kg twice-a-day (BID) from Day -3 until through Day +56 post-peripheral blood progenitor cell (PBPC) infusion. Dose may be adjusted to maintain a therapeutic level of cyclosporine, or in response to renal insufficiency. If at Day +56, chimerism assessment demonstrates > 40% donor cells in the CD3+ lineage, and the patient is without evidence of GvHD, then cyclosporine taper will begin (6% reduction per week).
45392547|NCT00186628|Drug|Mycophenylate mofetil|Mycophenylate mofetil (MMF) will be administered at 15 mg/kg po Day 0, at 5 to 10 hours after mobilized PBPC infusion is complete
45392548|NCT00186628|Drug|Filgrastim|Filgrastim provided as needed for neutrophil support
45392549|NCT00186628|Drug|Granisetron|Granisetron administered as an anti-nausea agent (anti-emetic) at 1 mg orally 30 to 60 minutes before TLI
45392550|NCT00186628|Drug|Solumedrol|Solumedrol, an anti-inflammatory glucocorticoid containing methylprednisolone sodium succinate, administered at 1 mg/kg as a premedication for anti-thymoglobulin (ATG)
45392551|NCT00186628|Drug|Acetaminophen|Acetaminophen administered orally at 650 mg 1 hour prior to infusion of PBPC
45696754|NCT03024892|Procedure|ICG IV|ICG was given by systemic injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
45392552|NCT00186628|Drug|Diphenhydramine|Diphenhydramine administered by intravenous infusion at 50 mg 1 hour prior to infusion of PBPC
45392553|NCT00186628|Drug|Hydrocortisone|Hydrocortisone administered by intravenous infusion at 100 mg 1 hour prior to infusion of PBPC
45392554|NCT00368550|Drug|Sertraline|Sertraline (to a maximum of 200 mg/day) for 14-week treatment period
45392555|NCT00368550|Drug|Placebo|Placebo for 14-week treatment period
45392556|NCT01072162|Drug|Eltrombopag|25 mg tablet
45392557|NCT01072162|Drug|Eltrombopag|25 mg powder for oral suspension
45392558|NCT01050036|Procedure|autologous hematopoietic cell transplantation|"Autologous peripheral blood stem cell (PBSCs) harvesting~After the second cycle of high-dose ara-C(HDAC) consolidation chemotherapy~Mobilization: recombinant human G-CSF(Filgrastim) 5mcg/kg s.c. daily starting on 10 days after start of the second cycle of HDAC chemotherapy~Harvest procedure: peripheral blood mononuclear cells will be collected. Target CD34+ cell dose is over 5x10E6/kg.~Conditioning regimen for autologous HCT~Busulfan 3.2 mg/kg/day i.v. daily on days -7 to -5 (for 3 days)~Etoposide 400mg/m2/day i.v. daily on days -3 to -2 (for 2 days)~Autologous cell infusion and waiting for engraftment"
45696755|NCT03024892|Procedure|LC conventional|simple laparoscopic cholecystectomy was performed under white light image.
45696756|NCT03024892|Procedure|LC conventional and IOC|simple laparoscopic cholecystectomy was performed under white light image and intraoperaitve cholangiography guidance.
45392559|NCT03968692|Diagnostic Test|Prostate-Specific Antigen test|Prostate-Specific Antigen (PSA) test as opportunistic screening or in the presence of symptoms
45392560|NCT00368472|Drug|Perampanel|Perampanel 2 mg to 12 mg, once daily during the OLE study
45392561|NCT00357006|Drug|Estradiol|100 mcg adjunctive transdermal estradiol
45392562|NCT00357006|Drug|Estradiol|200 mcg adjunctive transdermal estradiol
45392563|NCT00357006|Other|placebo|adjunctive transdermal placebo
45392564|NCT01050114|Drug|onaBoNT-A|"onaBoNT-A will be the active formulation. Each vial of onaBoNT-A Purified Neurotoxin Complex, Formulation No. 9060X, contains: 100 units (U) of Clostridium botulinum toxin type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. One U corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. A 0.9% sterile saline (without preservative) for injection will be used as diluent for onaBoNT-A.~Each treatment session will be administered as 20 injections each of 1 mL (10U/ml), evenly distributed into the bladder."
45392565|NCT01050114|Drug|Oxybutynin ER|Oxybutynin ER in a 10 mg capsule will be taken twice a day for the course of the study.
45392566|NCT01324674|Other|Bach´s Flower Remedy|The subjects will have 4 drops 4 times per day, for approximately 8 months.
45392567|NCT01324674|Other|Placebo group|The subjects will have a solution non-drug type, 4 drops 4 times per day, for approximately 8 months
45392568|NCT01048632|Drug|Oxandrolone|2.5 mg oxandrolone tablets.Based upon the patient's body weight, the coordinator, PI or sub-PI will determine the appropriate dose of oxandrolone (0.1 mg/kg/dose twice daily via the buccal mucosa.)
45392569|NCT00165646|Drug|E3810|E3810 5mg: once daily orally for 4 weeks
45392570|NCT00165646|Drug|E3810|E3810 10mg: once daily orally for 4 weeks
45392571|NCT00165646|Drug|Placebo|Placebo: once daily orally for 4 weeks
45392572|NCT01480440|Device|Trabecular Metal Reverse Shoulder System|Trabecular Metal Reverse Shoulder System used in primary or revision total shoulder arthroplasty
45696757|NCT03024658|Other|positive end expiratory pressure (PEEP)|Positive end expiratory pressure was applied using anesthesia machine at the time of induction in the patients undergoing laparoscopic bariatric surgery
45696758|NCT00952120|Device|GSUC|Gauze-based wall suction negative pressure wound therapy
45392573|NCT01050270|Drug|Ondansetron|4mgs iv bolus
45392574|NCT01050270|Drug|acetylcysteine|100 mg/kg over 2 hours then 200mg/kg over 10 hours, followed by glucose 5% for 8 hours
45392575|NCT01050270|Drug|acetylcysteine|150 mg/kg over 15 mins 50 mg/kg over 4 hours 100 mg/kg over 16 hours
45392576|NCT03968458|Behavioral|CON|. Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
45502839|NCT05211687|Other|Smart-home for freezing of gait|"A projector, Kinect camera and computer are located 2 meters from the walking area. Participants walk nine times back and forth on the walking track, in each of three walking conditions:~Baseline: participants walk in a comfortable pace. The walking track consist a rectangle created by a white light projected on the floor. Based on in this walking condition, step width and cadence are calculated to determine the individual parameters of the cueing.~Light-stripes: The walking area consist of 4-5 white light-stripes. Space between the stripes is 110% of the participant step length. Participants are instructed to walk over the stripes.~Metronome: The walking track consist of a rectangle created by a white light projected on the floor, and in addition metronome beats are delivered by the computer. Beats frequency are 90% of the cadence. Participants are instructed to match their steps to the metronome beats.~Each walking condition up to 90 seconds."
45502840|NCT03134911|Drug|DOAC or VKA|6 months - 2 years
45696759|NCT00952120|Device|VAC|Commercially available Wound VAC negative pressure wound therapy device (KCI, Inc.)
45696760|NCT03017482|Device|Medtronic 670G|"This is an open labeled follow up of a clinical startup of a newly approved FDA closed loop insulin delivery system. It is essentially a prospective chart review of the clinically startup of a FDA closed loop system and has many elements of a quality improvement project with additional features of:~Questionnaires about the utility and impact of the device~Use of the device in children younger than the current FDA approval range"
45696761|NCT04353544|Other|delayed cord clamping|delayed cord clamping
45696762|NCT03017404|Drug|Doxorubicin Hydrochloride Liposome Injection|
45696763|NCT03017404|Drug|Cyclophosphamide|
45696764|NCT03017404|Drug|docetaxel|
45696765|NCT00953212|Drug|beta blockers|metoprolol 25mg by mouth every 6 hours
45696766|NCT00953212|Drug|amiodarone|amiodarone 600mg by mouth evening before surgery amiodarone 600mg by mouth morning of surgery amiodarone 400mg by mouth every 12 hours for 3 days postoperatively
45696767|NCT00953212|Drug|ascorbic acid|ascorbic acid 2,000mg by mouth evening before surgery ascorbic acid 2,000mg by mouth morning of surgery ascorbic acid 1,000mg by mouth every 12 hours for 5 postoperative days
45696768|NCT00953290|Device|Cutera Radio Frequency Device|Up to three treatments, one pass, dosage range of 15-60 kJ.
45696769|NCT03024190|Other|Kinesiotaping|The technique of Kinesiotaping for spastic wrists and fingers in stroke patients is performed from the proximal interphalangeal joints of all fingers acted on the extensor carpal and digital muscle groups, with an anchor at the proximal one-third forearm.
45696770|NCT03024190|Other|stretching exercise|15- min stretching exercise for upper extremity twice daily
45696771|NCT03024190|Other|OT rehabilitation program|regular rehabilitation program for 3 weeks
45696772|NCT03024268|Device|Figulla Flex Occluder (Occlutech)|Interventional closure of the iASD with an Figulla Flex Occluder (Occlutech)
45392577|NCT03968458|Behavioral|EX-30|Condition with an acute exercise set 30 minutes before lunch The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
45392578|NCT03968458|Behavioral|EX-90|condition with an acute exercise set 90 minutes before lunch. The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
45392579|NCT03992508|Device|intermittent pneumatic compression|
45392580|NCT03992508|Procedure|complex decongestive therapy|
45392581|NCT03968770|Dietary Supplement|Experimental group|Probiotic (Lactobacillus casei) once daily taken by 6 weeks.
45392582|NCT03968770|Dietary Supplement|Control group|Placebo of Probiotic once daily taken by 6 weeks.
45392583|NCT03968770|Other|Usual medical care|NSAIDs, once daily taken and promotion of a healthy lifestyle by 6 weeks.
45392584|NCT03968614|Other|Electric dry needling and conventional PT|Electrical Dry Needling, Eccentric Exercise, Stretching and Manual Therapy
45392585|NCT03968614|Other|Conventional PT|Eccentric Exercise, Stretching and Manual Therapy
45392586|NCT00367770|Drug|Tracleer®|Patients will receive up to 125 mg b.i.d. of Tracleer.
45392587|NCT00185614|Procedure|Autologous hematopoietic cell transplant (Auto-HCT)|The target cell dose is 2.6 x 10e6 CD34+ cells/kg
45392588|NCT00185614|Procedure|Allogeneic hematopoietic cell transplant (Allo-HCT)|The target cell dose is 5 x 10e6 CD34 cells/kg
45392589|NCT00185614|Drug|Cyclophosphamide|Cyclophosphamide administered intravenously (IV) at 4 mg /m² mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion
45392590|NCT00185614|Drug|Filgrastim|"Filgrastim 10 µg/kg/day to mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion (Auto-HCT)~Filgrastim 5 µg/kg/day starting 6 days after melphalan (Day 4 after Auto-HCT)~Filgrastim 16 µg/kg/day to mobilize donor peripheral blood progenitor cells (PBPC) for allogeneic transplant (Allo-HCT)"
45392591|NCT00185614|Drug|Melphalan|Melphalan 200 mg/m2 (high-dose) intravenously as conditioning for Auto-HCT
45392592|NCT00185614|Radiation|Total body irradiation (TBI)|200 centigray (cGy) total body irradiation delivered on Day 0
45392593|NCT00185614|Procedure|Cyclosporine (CSP)|Cyclosporine administered twice-daily by mouth at a dose of 6.25 mg/kg from Day -3 through Day 56
45392594|NCT00185614|Drug|Mycophenolate Mofetil (MMF)|Mycophenolate mofetil will begin at 15 mg/kg twice-daily by mouth from Day 0 to Day 27
45392595|NCT01075438|Biological|Prevenar® (7-valent pneumococcal conjugate vaccine)|"Pneumococcal vaccines (conjugate and polysaccharide)~Intramuscular Injections: 2 doses of 7-valent pneumococcal conjugate vaccine 8 weeks apart and 1 dose of pneumococcal polysaccharide vaccine 8 weeks later"
45392596|NCT01075438|Biological|Pneumovax® (pneumococcal polysaccharide vaccine)|"Pneumococcal vaccines (conjugate and polysaccharide)~Intramuscular Injections: 2 doses of 7-valent pneumococcal conjugate vaccine 8 weeks apart and 1 dose of pneumococcal polysaccharide vaccine 8 weeks later"
45392597|NCT00162370|Drug|Perflutren Lipid Microsphere Injectable Suspension|Activated DEFINITY 10ug/kg by bolus injection
45392598|NCT00361842|Drug|CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection|CPX-1 Liposome Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs irinotecan HCl and floxuridine.
46056899|NCT02722785|Behavioral|Aerobic and Resistance Exercise Training|Supervised aerobic and resistance exercise program consisting of 2 weekly sessions of approximately 60 minutes. Patients will perform a test of maximum cardio-respiratory (Watt-max test) and muscle strength (1 repetition maximum [1-RM] test) capacity. Using the patient's individual capacity score (Watt-max and 1RM), a personalized exercise program will be prescribed. After a light warm-up, patients will perform 20-30 min of aerobic interval training of stationary bicycle. Resistance training comprises 4 exercises for the major muscle groups: chest press, leg press, lateral pull, and knee extension with 3-4 sets of 8 to 15 repetitions. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load.
45392599|NCT01324752|Drug|PA21 and Losartan with Food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
45392600|NCT01324752|Drug|No PA21; Losartan with food|The maximum dose of Losartan will be 100 mg/day.
45392601|NCT01324752|Drug|PA21 with food and Losartan 2 hours later|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
45392602|NCT01050348|Drug|Atorvastatin calcium|Eligible patients will receive 80mgs of atorvastatin orally upon admission to hospital prior to percutaneous intervention of the affected artery. Dose of post-procedural statin will be at the discretion of the cardiologist.
45696773|NCT03034408|Drug|Nalmefene|
45696774|NCT03034408|Drug|Baclofen|
45696775|NCT03034408|Drug|Placebo Oral Capsule|
45696776|NCT03034252|Procedure|Patients with Liposarcoma|Evaluation of Liposarcoma treated in a single center
45696777|NCT03017092|Behavioral|Tablet-guided tobacco intervention|This intervention, as guided by a tablet computer, is a brief (20 minute) counseling intervention designed to increase motivation to quit smoking and to increase knowledge of methods of quitting.
45696778|NCT03016858|Procedure|Thoracoscopic Bullectomy Surgery|undergoing the Thoracoscopic Bullectomy Surgery
45696779|NCT03023020|Drug|Aspirin|Dosing per current guidelines and local practice
45696780|NCT03023020|Drug|P2Y12 inhibitor|Dosing per current guidelines and local practice
45696781|NCT00087555|Drug|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 4.5 g per day in divided doses, 2.25 g at bedtime and another 2.5 g two and a half to four hours later for 8 weeks.
45392603|NCT01050348|Drug|Inactive Placebo|Eligible patients will receive a placebo orally upon admission to hospital prior to percutaneous intervention of the affected artery.
45392604|NCT00361296|Biological|K562/GM-CSF cell vaccine|
45392605|NCT03990090|Drug|TG103|Administered SC
45392606|NCT03990090|Drug|Placebo|Administered SC
45392607|NCT01053390|Drug|Somatostatin|Somatostatin 3mg+NS（normal saline）60ml, a continuous intravenous infusion, q12h
45392608|NCT01053390|Drug|epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）|
45392609|NCT01048710|Other|No intervention|
45392610|NCT00356148|Drug|Ampicillin/Sulbactam|Ampicillin/Sulbactam 1 gr, once within onr hour before surgery
45392611|NCT00361218|Drug|open-label selective serotonin reuptake inhibitor (SSRI)|Duration is 8 weeks. For escitalopram, starting dose is 10mg po qd,which can be increased up to 30mg po qd per clinical discretion. For citalopram, starting dose is 20mg po qd, which can be increased up to 60mg po qd per clinical discretion.
45392612|NCT02534532|Other|AF screening|Screening of AF in an opportunistic screening program using a smartphone device/application confirmed by ECG
45392613|NCT02534688|Drug|LNG-IUS|
45392614|NCT02534688|Drug|DMPA|
45392615|NCT01049022|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single intravenous (IV) infusion of moxifloxacin administered over 60 minutes, at an initial dosage of 5 milligram per kilogram per body weight (mg/kg/BW) with dose escalation to 6 mg/kg in subjects of age 6 years (yrs) to less than or equal to (<=) 14 years.
45392616|NCT01049022|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 7 mg/kg/BW with dose escalation to 8 mg/kg in subjects of age 2 years to less than (<) 6 years; dose escalation was based on evaluations of the pharmacokinetic (PK) and safety data from the subjects in a preceding cohort.
45392617|NCT01049022|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 9 mg/kg/BW with dose escalation to 10 mg/kg in subjects of age 3 months to < 2 years; dose escalation was based on evaluations of the PK and safety data from the subjects in a preceding cohort.
45392618|NCT02534610|Drug|Etoricoxib|120 mg etoricoxib PO administered 1 h preoperative for group A; group B received 120 mg etoricoxib PO at the end of the surgery.
45392619|NCT02534610|Drug|Placebo|Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.
45392620|NCT02534298|Other|functional magnetic resonance imaging|functional magnetic resonance imaging
45392621|NCT01050426|Other|UFT, Leucovorin|UFT 300mg/m2/day in 3 equal doses and Leucovorin 90mg/day in 3 divided doses per day given daily on the days of radiotherapy only (30 days in total)
45392622|NCT01050426|Other|UFT/ Leucovorin + Cetuximab + Radiotherapy|UFT 300mg/m2 + LV 90mg/day on days of RT only (30 days in total), Cetuximab 400mg/m2 week 1, thereafter 250mg/m2 weeks 2-6
45392623|NCT01053468|Behavioral|Physical Activity Resource Kit|"The Intervention group (INT) will receive a Physical Activity Resource Kit which includes a step pedometer, a breast cancer-specific Physical Activity Guidebook (Exercise for health), a step pedometer resource (Step into survivorship), and a physical activity and step journal to record their daily step totals and daily physical activities.~Participants will be instructed to wear their pedometer for the entire duration of the study (i.e., chemotherapy duration)."
45392624|NCT01053468|Behavioral|Standard Materials|Participants in this usual care group will receive a generic physical activity leaflet from the Canadian Public Health Agency
45392625|NCT03990168|Device|Anodal tDCS|1 mA anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The tDCS stimulation will be delivered for 20 minutes on 6 intervention days.
45392626|NCT03990168|Behavioral|fluency intervention/ Delayed Auditory Feedback|Each participant complete three tasks include reading, conversation, and narration. Delayed auditory feedback will be used during these tasks. Each treatment session will take 20 minutes.
45392627|NCT03990168|Device|Sham tDCS|The anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The current of sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes on 6 intervention days.
45392628|NCT01053546|Behavioral|exercise intervention|The early exercise group will start study exercises approximately two weeks prior to the onset of XRT. The late exercise group will start study exercises one month after the completion of XRT. Participants will undergo an initial/pre-radiation and 1-, 3-, 6-, and 12 month post-radiation swallowing assessments.
45392629|NCT01053546|Other|questionnaire administration|Ancillary study
45392630|NCT01053546|Procedure|quality-of-life assessment|Ancillary study
45392631|NCT01049100|Procedure|lymphadenectomy|paraaortal and pelvic lymphadenectomy laparoscopic or open
45392632|NCT01049100|Other|Standard Staging|clinical Staging (FIGO) (examination in narcosis, biopsy, cystoscopy, rectoscopy) X-Ray Radiograph of Thorax, Ultrasound of abdomen, CT abdomen / pelvis positive, suspicious lymphnodes--> CT controlled biopsy
45392633|NCT01053624|Procedure|Tracheostomy|This protocol has been design to determine if tracheostomy performed immediately after lung operation (i.e. concomitant tracheotomy) could improve the postoperative outcome of high risk patients. We hypothesized that concomitant tracheotomy could reduce the length of mechanical ventilation and the number of respiratory complications
45392634|NCT00367458|Drug|Atorvastatin|80 mg atorvastatin oral daily
45392635|NCT00367458|Drug|Placebo|patients will be administered placebo
45502841|NCT03134911|Drug|VKA|6 months - 2 years
45392636|NCT01053702|Drug|R475|IV
45392637|NCT01053702|Drug|Placebo|Placebo
45392638|NCT01050738|Procedure|Position of catheter|Position of catheter for administration of local anestesia.
45502842|NCT04652843|Procedure|Rectosignoidoscopy|Rectosignoidoscopy for colonic biospsies collection
45502843|NCT04652843|Procedure|Coloscopy|Coloscopy for colonic biospsies collection
45502844|NCT05182593|Other|Diet moderate/high in FODMAPs|The subjects will obtain meal boxes prepared in the hospital kitchen with a moderately high FODMAP content (23 grams/day)
45392639|NCT00162136|Drug|Ixabepilone|Intravenous (IV) Infusion; 10, 20, 30, 35, 40 & 45 mg/m2, once every 21 days (1 cycle), up to 9 cycles
45502845|NCT05182593|Other|Diet low in FODMAPs|The subjects will obtain meal boxes prepared in the hospital kitchen with a low FODMAP content (<5 grams/day)
45502846|NCT02061098|Dietary Supplement|Pomegranate extract-first dose-Group A|Group A will consume 1 daily capsule of pomegranate extract for 3 weeks
45502847|NCT02061098|Dietary Supplement|Placebo-first dose-Group B|Group B will consume 1 daily capsules of placebo for 3 weeks.
46056900|NCT02722473|Biological|"NSE dosage hypothermia arm"|There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management between 33° and 37°C.
45392640|NCT00252694|Drug|candesartan|32 mg oral tablet
45502848|NCT02061098|Dietary Supplement|Pomegranate extract-first dose-Group B|After 3 weeks of washout, group B will consume 1 daily capsule of pomegranate extract for 3 weeks.
45696782|NCT00087555|Drug|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 6.0 g per night in divided doses of 3 g at bedtime and 3 g at 2.5 to 4 hours later for 8 weeks.
45696783|NCT00087555|Drug|Placebo|Placebo one of two doses matching active treatment by volume for 8 weeks.
45426197|NCT05794594|Device|3D printed personalized extendable prosthesis|3D printed personalized extendable prosthesis replacement for limb preservation in children
45502849|NCT02061098|Dietary Supplement|Placebo-first dose-Group A|After 3 weeks of washout, group A will consume 1 daily capsule of placebo for 3 weeks.
45392641|NCT00185458|Drug|LNG IUS|LNG IUS (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) HRT Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by WHO guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.
45392642|NCT03741400|Device|Neofect RAPAEL Smart Glove|The Neofect Rapael Smart Glove is a biofeedback system designed for upper extremity rehabilitation in stroke survivors. It includes a glove-shaped sensor device and a software application.
45392643|NCT03968068|Procedure|Exercise Procedure|Patients will undergo 30 minutes of light-moderate intensity leg cycling, using the Letto-2 (Motomed, UK) in the semi-supine position.
45392644|NCT03968068|Procedure|Remote Ischaemic Conditioning|Patients will undergo 4 cycles of upper limb RIC using a blood pressure cuff. Each cycle will involve inflating the blood pressure cuff to 200 mmHg for five minutes around the upper arm, followed by a period of relaxation of the cuff for a further 5 minutes. The total RIC treatment time will take 40 minutes.
45392645|NCT00185380|Drug|Levonorgestrel IUS (BAY86-5028, G04209B)|Levonorgestrel intrauterine contraception system (IUS) releasing 12 microg/24 h in vitro, to be used for three years
45392646|NCT00185380|Drug|Levonorgestrel IUS (BAY86-5028, G04209C)|Levonorgestrel intrauterine contraception system (IUS) releasing 16 microg/24 h in vitro, to be used for three years
45392647|NCT00185380|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel Intrauterine contraception system (IUS) releasing 20 microg/24 h to be used for three years
45392648|NCT01326208|Procedure|PEEP titration|PEEP is set according to the following protocols, respectively, in a randomized order: ARDSnet table, Open Lung strategy, guided by EIT
45392649|NCT01074424|Genetic|proteomic profiling|
45392650|NCT01074424|Other|laboratory biomarker analysis|
45392651|NCT03968302|Drug|ARM A Triple therapy for helicobacter pylori|The triple regimen was defined as a combination of amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
45392652|NCT03968302|Drug|ARM B Quadruple therapy for helicobacter pylori|Quadruple therapy included colloidal bismuth subcitrate 240 mg twice daily,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
45392653|NCT01077388|Behavioral|Dietician electronic support|Dietitian-delivered behavioral intervention, that uses a patient shared EMR and e-communications, will be integrated into routine healthcare and will result in improved control of modifiable CVD risk.
45392654|NCT01077466|Drug|Natalizumab|300 mg Natalizumab IV for every 4 week for 56 weeks (15 doses for every patient)
45392655|NCT00160654|Drug|Levetiracetam|"Pharmaceutical form: oral tablets~Concentration: 500 mg~Route of administration: Oral use"
45696784|NCT03016780|Other|Fecal Microbiota Transplantation|Fecal microbiota transplantation and the traditional treatments for ulcerative colitis in part 1.
45696785|NCT03016780|Other|Normal Saline|Normal saline and the traditional treatments for ulcerative colitisin in part 2.
45696786|NCT03022318|Drug|carbidopa-levodopa 25-100 mg tablets|See arm/group descriptions
45392656|NCT01582672|Drug|Standard Treatment|Standard treatment for Renal Cell Carcinoma
45392657|NCT01582672|Biological|AGS-003|Autologous Dendritic Cell product. Intradermal injections; 8 injections in the 1st year followed by quarterly boosters.
45502850|NCT02061098|Dietary Supplement|Pomegranate extract-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of pomegranate extract for 3 weeks.
45696787|NCT01677897|Drug|Metformin|Adding Metformin to Abiraterone in case of PSA-Progression
45392658|NCT00366678|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
45392659|NCT00366678|Biological|7-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
45392660|NCT00366678|Drug|Pentavac|The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).
45392661|NCT01053780|Other|Intercessory Prayer|A committed group of six people selected by the chief investigator prayed nine consecutive days for the patients in the intervention group; they were blind to the identity , the patients' first name, were given to the intercessors.
45392662|NCT01053780|Behavioral|Intercessory Prayer|A committed group of six people selected by the chief investigator prayed nine consecutive days for the patients in the intervention group; they were blind to the identity , the patients' first name, were given to the intercessors.
45392663|NCT01049178|Drug|Oral Silymarin|Dose Level 1: 1 capsules (1 cap at 140mg/cap) given three times per day for a total daily dose of 420 mg 28-days post Dose Level 1 Dose Level 2: 3 capsules (3 caps at 140mg/cap = 420 mg) given three times per day for a total daily dose of 1260 mg Day 56 (28-days post Dose Level 2) Dose Level 3: 5 capsules (5 caps at 140mg/cap = 700 mg) given three times per day for a total daily dose of 2100 mg Day 84 (28-days post Dose Level 3) We will evaluate change from baseline at each dose to determine the minimum effective dose.
45426198|NCT05794568|Device|OITcontrol app monitoring|App to monitor OIT patients
45502851|NCT02061098|Dietary Supplement|Placebo-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of placebo for 3 weeks.
45502852|NCT02061098|Dietary Supplement|Pomegranate extract-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of pomegranate extract for 3 weeks.
45502853|NCT02061098|Dietary Supplement|Placebo-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of placebo for 3 weeks.
45696788|NCT03033940|Radiation|Observational use of fluoroscopy|
45696789|NCT03483363|Drug|topical irrigation with the antibiotic bacitracin|Fractures will be irrigated with Bacitracin topical antibiotic (50,000 units) prior to closure.
45696790|NCT03483363|Drug|topical irrigation with sterile normal saline (NS)|Fractures will be irrigated with sterile normal saline prior to closure. All groups with receive standard parenteral (IV) prophylactic antibiotic.
45392664|NCT01049178|Drug|Oral Silymarin, maintenance dose|The maintenance Silymarin dose will be selected based on the dose escalation study and will be dosed PO three times daily as recommended. Silymarin will be provided as a capsule S. marianum (70-80% silymarin), along with an identical appearance placebo capsule created by our investigational pharmacyAt each visit a questionnaire regarding daily symptoms and disease control, the asthma control test (ACT) will be completed, eNO measured, urine collected, spirometry (lung function) measured, venipuncture performed for blood collection (20 mL), as well as assessment of acceptability, toxicity, and masking.
45392665|NCT01049178|Drug|Placebo|
45392666|NCT01053858|Procedure|intravitreal injection|intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection
45392667|NCT01049256|Other|carbon dioxide|sinusoidal carbon dioxide administration
45392668|NCT02534454|Behavioral|Active Retraining|
45392669|NCT02534454|Behavioral|Sham Retraining|
45392670|NCT02534454|Device|Active transcranial direct current stimulation (TDCS)|
45392671|NCT02534454|Device|Sham transcranial direct current stimulation (TDCS)|
45392672|NCT02534454|Drug|Nicotine Replacement Therapy (Habitrol)|Administration of Nicotine Replacement Therapy Patches
45392673|NCT01050972|Behavioral|Behavioral: Cognitive, Relaxation, Exercise Therapy|Behavioral: Cognitive, Relaxation, Exercise Therapy The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
45392674|NCT01051050|Behavioral|Mandatory use of surgery wiki|Mandatory participation in the surgery wiki. This will include adding to and reviewing information posted on the wiki. Contribution of an evidence-based review will be required at least once during the study period.
45392675|NCT01051050|Behavioral|Voluntary use of the surgery wiki|Voluntary participation in the surgery wiki. Participants can choose to use the information in the wiki as well as contribute to the wiki.
45392676|NCT00355368|Drug|Succinylcholine|1mg/kg iv
45696791|NCT03483363|Drug|intravenous (IV) prophylactic antibiotic|All groups with receive standard parenteral (IV) prophylactic antibiotic.
45502854|NCT01344239|Procedure|Limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
45696792|NCT03033628|Device|injection using DentalVibe comfort system|giving maxillary infiltration injection of dental local anesthesia using DentalVibe comfort system.
45696793|NCT03033628|Device|traditional dental injection|giving maxillary infiltration injection of dental local anesthesia without using DentalVibe comfort system.
45696794|NCT01677975|Procedure|FNA (fine needle aspiration)|
45696795|NCT03016702|Other|Cognitive stress tests during functional MRI|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function while undergoing fMRI.
45392677|NCT00355368|Drug|Rocuronium|0.6mg/kg iv
45392678|NCT01054014|Drug|JNJ-40346527/Placebo|Single oral dose of JNJ-40346527 (either 10, 50, 150, 300, 600, or 1000mg) or Placebo
45392679|NCT01054014|Drug|JNJ-40346527/Placebo|JNJ-40346527 once daily oral dose for 14 days (either 50, 150, 300, 500 or 750mg) or Placebo
45392680|NCT01054014|Drug|JNJ-40346527|JNJ-40346527 150mg one dose, either fasting (or with food), then after 7 days off treatment, JNJ-40346527 150mg either with food (or fasting)
45392681|NCT01054092|Drug|ipragliflozin|oral
45392682|NCT03989622|Other|evaluation of the visual field on the ground|evaluation of the visual field on the ground
45392683|NCT02534220|Device|Manual Toothbrush|Gum Delicate Post-Surgical Toothbrush, Oral-B, Procter & Gamble, Cincinnati, OH
45392684|NCT02534220|Device|Oscillating-rotating toothbrush|Triumph 5000, Oral-B, Procter & Gamble, Cincinnati, OH
45392685|NCT00360282|Drug|Rizatriptan|10 mg Rizatriptan in an unlabeled pill given once on one of two visits
45392686|NCT00360282|Other|Placebo|In an unlabeled pill given once on one of two visits.
45392687|NCT00373958|Biological|13 valent pneumococcal conjugate vaccine|1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
45392688|NCT00373958|Biological|7vPnc pneumococcal conjugate vaccine|1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
45392689|NCT00373880|Drug|Aripiprazole + Cocaine|Participants received aripiprazole (15mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
45392690|NCT00373880|Drug|Placebo + Cocaine|Placebo (0 mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
45392691|NCT00184600|Drug|biphasic insulin aspart|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
45392692|NCT00184600|Drug|insulin detemir|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
45392693|NCT00184600|Drug|insulin aspart|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, twice daily plus option for insulin detemir
45696796|NCT03016702|Other|Cognitive stress tests during gait task|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function both in sitting and while ambulating on a force sensor mat.
45696797|NCT00956020|Biological|Platelet rich fibrin matrix|Single treatment with platelet rich fibrin matrix
45696798|NCT03086733|Drug|Metformin|850 mg tablets v/o OD for first 5 days 850 mg tablets v/o BID until day 21
45392694|NCT03967756|Device|Automatic polyp detection system|When colonoscopists withdraw the colonoscopies and inspect the colons, the video streaming of colonoscopies was real-time switched to the automatic polyp detection system, which made it feasible to detect lesions in real time. When any potential polyp is detected by the system， there will be a tracing box on an adjacent monitor to locate the lesion with a simultaneous sound alarm.
45392695|NCT00265317|Drug|erlotinib|erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
45392696|NCT00265317|Drug|sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
45392697|NCT00265317|Drug|erlotinib|erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
45392698|NCT00265317|Drug|placebo|Placebo daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
45392699|NCT00373490|Drug|Vorinostat|600 mg daily (300 mg twice daily [b.i.d.]) for 3 consecutive days followed by 4 days of rest.
45392700|NCT00373490|Drug|Vorinostat|400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
45392701|NCT00251589|Drug|Vorinostat|Vorinostat 200 mg twice a day for 3 days a week.
45392702|NCT00251589|Drug|Vorinostat|Vorinostat 300 mg once a day for 3 days a week.
45392703|NCT00251589|Drug|Vorinostat|Vorinostat 300 mg twice a day for 3 days a week.
45392704|NCT00251589|Drug|Vorinostat|Vorinostat 400 mg once a day for 21 out of 28 days.
45392705|NCT00251589|Drug|erlotinib|erlotinib 150 mg once a day.
45392706|NCT00265239|Drug|edaravone|intravenous administration of 30mg Edaravone just before reperfusion therapy
45392707|NCT00350298|Biological|GS-CDA1/MDX-1388|One Intravenous dose
45392708|NCT00350298|Biological|normal saline|One Intravenous dose
45392709|NCT00159874|Drug|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 20 mg 3 times a day (tid) subjects with body weight >20 - 45 kg: 40 mg 3 times a day (tid) subjects with body weight >45 kg: 80 mg 3 times a day (tid)
45392710|NCT00159874|Drug|Sildenafil citrate|Oral,10 mg 3 times a day (tid), only subjects with body weight >20 kg
45696799|NCT03017170|Drug|Dried Cranberry|"Dried cranberry powder is not an extract of cranberries, but a full spectrum ingredient. It is comprised of a proprietary ratio of dried cranberry fruit, cranberry pomace, and cranberry seeds, each of which is a recognized food and/or dietary ingredient. One 500 mg capsule of dried cranberry powder consists of approximately 25 grams of cranberry fruit."
45696800|NCT03017170|Drug|Placebo Oral Capsule|Colored Maltodextrin: Proprietary mixture of: maltodextrin and food grade colors
45392711|NCT00159874|Drug|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 10 mg 3 times a day (tid); subjects with body weight >20 - 45 kg: 20 mg 3 times a day (tid); subjects with body weight >45 kg: 40 mg 3 times a day (tid)
45392712|NCT03966430|Procedure|damage control surgery|"Emergency surgery stage, (a) the hybrid operating room restores mesenteric vascular patency. (b) excision of the necrotic intestine (c) retention of suspicious intestinal ducts, double stoma (d) establishment of catheter thrombolysis pathway (e) apply TAC to maintain open abdominal.~ICU phase, including (a) fluid resuscitation; (b) anti-infective and organ function support therapy; (c) continued local anticoagulation, thrombolysis (d) arrange planned re-laparotomy (e) early EN.~Definitive surgical procedures, including (a) Deterministic fascia closure or further removal of the necrotic intestine. (b) Intestinal stoma care and enteral nutrition support treatment. (c) An enterostomy was performed about 6 months after the first operation."
45392713|NCT03966430|Procedure|non-damage control surgery|"The patients are diagnosed with AMI and treated for mesenteric thrombosis and ischemic bowel.~The patient retains the endoluminal catheter after the DSA was diagnosed as AMI.~After diagnosis, the operation is performed in the general operating room, and the intestinal fistula double or the anastomosis is performed according to the judgment of the surgeon.~After the operation, re-laparotomy is performed on demand."
45392714|NCT00349908|Device|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE used to treat symptomatic stenosis in intracranial arteries.
45392715|NCT00349908|Device|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE to treat wide-necked aneurysms
45392716|NCT00184054|Drug|Arsenic Trioxide (ATO)|Arsenic Trioxide .25 mg/kg/day
45392717|NCT00184054|Drug|Ascorbic Acid|Ascorbic Acid 1000 mg every other day for 25 days
45392718|NCT03989856|Device|2-0 polyglican absorbable sutures|The sutures will be performed with intracorporeal knots using 2-0 polyglican absorbable sutures (Vicryl; Ethicon Inc., New Jersey, USA). Suture is performed using needle holders for the closure of ovarian parenchyma and controlling bleeding. Bleeding from ovarian hilus will only resolve by suturing.
45392719|NCT03989856|Device|Diathermy|bipolar coagulation technique will be used to control significant bleeding (40 W current; Richard Wolf, Germany). I
45392720|NCT02533908|Drug|Fentanyl intranasal|fentanyl is applied intranasally with a MAD (mucosal atomization device) prior to the application of nitrous oxide 70% analgosedation
45696801|NCT05346549|Behavioral|High energy preload|Tests the extent to which participants reduce their food intake at a meal following ingestion of a high energy preload drink.
45696802|NCT05346549|Behavioral|Low energy preload|Tests the amount participants eat at a meal following ingestion of a low energy preload drink
45392721|NCT02533908|Drug|NaCl 0.9% intranasal|Placebo is applied intranasally with a MAD (mucosal atomization device) Prior to the application of nitrous oxide 70% analgosedation
45392722|NCT01051128|Device|Prometra Programmable Implantable Pump System|The Prometra Programmable Pump is a battery-operated, implantable, programmable infusion pump that dispenses drug solution into the intrathecal space through an implanted infusion catheter. All functions of the system (e.g., dosing) are controlled externally using a hand-held, battery-operated programmer.
45392723|NCT02533986|Dietary Supplement|Berry peel drink|
45392724|NCT02533986|Dietary Supplement|Control drink|
45392725|NCT00183430|Drug|Prazosin|Prazosin capsules 1 to 25 mg are taken orally twice per day in divided doses at 10 am and bedtime.
45392726|NCT00183430|Drug|Placebo|Placebo capsules are taken orally twice per day at 10 am and bedtime.
45392727|NCT00183430|Behavioral|Psychotherapy|All participants will undergo psychotherapy during medication treatment period.
45392728|NCT00183274|Drug|Venlafaxine XR|Six month intervention of Venlafaxine XR treatment with flexible range of 75 to 225 mg/d
45392729|NCT00183274|Drug|Placebo|six month intervention with placebo drug
45392730|NCT00183196|Drug|Naltrexone|Naltrexone (50 mg/day) plus gabapentin placebo in divided doses for the first 6weeks. Naltrexone (50 mg/day) for rest of 16-weeks
45392731|NCT00183196|Drug|Naltrexone plus Gabapentin|naltrexone (50 mg/day) for 16-weeks plus gabapentin (up to 1200 mg/day in divided doses) for the first 6 weeks
45392732|NCT00183196|Other|Inactive Placebo|Placebo
45392733|NCT00349752|Biological|certolizumab pegol 400 mg|Certolizumab pegol 400 mg provided in solution for subcutaneous injection (2 x 200 mg/mL) in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
45392734|NCT00349752|Other|Placebo|Placebo (commercially available sodium chloride 0.9% (preservative free)) provided for subcutaneous injection in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
45392735|NCT01055652|Drug|Dapagliflozin|10mg, oral, once daily
46056901|NCT02722473|Biological|"NSE dosage normothermia arm"|There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management at 37°C.
46056902|NCT02722551|Device|Transcatheter Mitral Valve Re-placement (TMVR) with the CardiAQ-Edwards™ Transcatheter Mitral Valve|Replacement of the mitral valve through a transcatheter approach
45392736|NCT01054326|Other|Exercises|
45392737|NCT00174460|Drug|Somatropin|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. Children randomized to the control group will get the possibility to continue treatment for a further year. The study will end after 2 and 3 years of observation, respectively.
45392738|NCT00174460|Other|Control Arm|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. The study will end after 2 and 3 years of observation, respectively. Children randomized to the control group will get the possibility to continue treatment for a further year.
45392739|NCT00348816|Drug|docetaxel|Docetaxel 20mg/m2/week IV every week during standard of care radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
45392740|NCT00348816|Drug|prednisone|Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
45392741|NCT00348816|Procedure|Radical prostatectomy|Radical prostatectomy as part of standard care
45392742|NCT00348816|Radiation|Radiation therapy|Doses for standard care radiation therapy: The initial target volume will be the lower pelvis followed by a boost to the prostate fossa and immediate periprostatic tissue. The initial dose will be 4500 cGy. With the final boost, the total dose will be 6840-6900 cGy. (4500/25 plus 2340/13 or 2400/12) with a total of 37 or 38 fractions.
45392743|NCT03989310|Drug|Manganese Chloride|Administered by inhalation at 0.4mg/kg twice per week in a 3-week cycle
45392744|NCT03989310|Drug|nab-paclitaxel|Administered intravenously, 200mg/d on day 1 and day 8 in a 3-week cycle
45392745|NCT03989310|Drug|Gemcitabine|Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
45392746|NCT03989310|Drug|anti-PD-1 antibody|Administered intravenously, 2-4mg/kg on day 2 in a 3-week cycle
45392747|NCT01051206|Drug|6% hydroxyethyl Stach 130/0.4|After dividing patients medicated with HES 130/0.4(maximum 33ml/kg/day) during surgery and one day after from the surgery with patients medicated with crystalloid only, compare the effect on the volume of bleeding, blood transfusion, and blood coagulation when using IV fluid.
45392748|NCT03966898|Drug|SHR6390 Tablets|SHR6390 Tablets
45392749|NCT03966898|Drug|Placebo Tablets|Placebo Tablets
45392750|NCT03966898|Drug|Letrozole or Anastrozole Tablets|Letrozole or Anastrozole Tablets
45392751|NCT03989544|Biological|Tezepelumab|Tezepelumab subcutaneous injection
45696803|NCT03033862|Device|Bioresorbable Vascular Scaffold|Bioresorbable Vascular Scaffold
45696804|NCT03033862|Device|Drug Eluting Stent|Drug Eluting Stent
46056903|NCT02722629|Procedure|FEESST|Flexible Endoscopic Evaluation of Swallowing with Sensory Testing
45392752|NCT03966196|Other|Measurements of oxygen saturation and finger pressure during deep inspiration|Measurements during deep inspiration of oxygen saturation with pulse oximeter and finger pressure with pressure cuff
45696805|NCT00086619|Drug|synthetic hPTH 1-34|Either daily treatment with self-injected hPTH 1-34 or ascending dose treatment at 6-month intervals of hPTH 1-34
45392753|NCT03987594|Procedure|Transurethral fulguration of the Hunner lesion|Hunner lesion of the bladder is fulgurated with electronic surgical device under cystoscopic inspection. For the intervention, general or spinal anesthesia is required.
45392754|NCT03987594|Procedure|Combination treatment of bladder hydrodistension and transurethral fulguration of the Hunner lesion|Prior to Hunner lesion fulguration, bladder hydrodistension is performed for 8 minutes at pressure of 80cmH2O. And then transurethral fulguration is performed on the Hunner lesion.
45392755|NCT03989700|Drug|Thiamine Mononitrate|Low dose group: thaimine mononitrate 25 mg/day per oral daily for 4 weeks High dose group: thaimine mononitrate 50 mg/day per oral daily for 4 weeks Placebo group: placebo 25 mg/day per oral daily for 4 weeks
45392756|NCT03987750|Drug|Safinamide Methanesulfonate 150mg|150 mg (free base)
45392757|NCT03987750|Drug|Safinamide Methanesulfonate 100mg|100 mg (free base)
45392758|NCT03987750|Drug|Safinamide Methanesulfonate matching placebo|placebo
45392759|NCT01055730|Other|Pulmonary rehabilitation|Structured education and supervised exercise program, lasting between 6 and 9 weeks.
45392760|NCT01051284|Radiation|Cyberknife radiation and gemcitabine|25 Gray of radiation will be given in 5 fractions using the Cyberknife Gemcitabine 1000 mg/m2 intravenously will be given once a week on days 1, 8, and 15 of every 28-day cycle for 6 cycles
45392761|NCT01051362|Drug|PLD and Carboplatin|Pegylated liposomal doxorubicin (PLD) 30 mg/m2, followed by Carboplatin AUC (area under the curve) 5, every 21 days for 4 cycles or until progression.
45392762|NCT01055808|Drug|Insulins|Individual dose and frequency and duration as determined by the treating physician
45392763|NCT00265083|Biological|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
45392764|NCT00265083|Biological|Golimumab (CNTO 148); placebo|SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg
45392765|NCT00265083|Biological|golimumab|50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
45392766|NCT03971097|Behavioral|Six Step Model of Self-Forgiveness|"The six-step model includes a workbook that applies Worthington's (2013) conceptualization of self-forgiveness and guides the practitioner and participant through the self-forgiveness process. Each step provides a framework for techniques and includes psychoeducation, interventions, and homework to be completed in between sessions. The individual sessions will not conflict with the timing or content of the unit's regular treatment schedule, thus, participation in the study will not affect a patient's ability to participate in TAU. All interventions will be done individually to ensure that participant confidentiality is respected throughout the therapeutic process."
45392767|NCT03971097|Behavioral|Treatment as Usual (TAU)|Treatment as Usual (TAU) includes four group therapy sessions facilitated by the social services team (counselors and social workers), two 12-step meetings facilitated by outside representatives of Alcoholics Anonymous (AA) and Narcotics Anonymous (NA), dietary, spirituality, medical care including vital signs and the administration of prescribed medication by the nursing staff, and individual needs assessment with a recommendation of appropriate aftercare.
45392768|NCT00264849|Drug|Omalizumab|Omalizumab administered by subcutaneous injection. The dosage received was individualized based on body weight and serum IgE level.
45392769|NCT00264849|Other|Optimized asthma therapy|Optimized asthma therapy (OAT) according to Global Initiative for Asthma (GINA) 2004 guidelines during the first 4 weeks of the run-in period of the study.
45392770|NCT01073709|Drug|Acetaminophen|
45696806|NCT00945958|Drug|SPARC0913|One drop of SPARC0913 in affected eye once daily for 24 weeks
45696807|NCT00085917|Drug|Double dose pegylated interferon with weight based Ribavirin|pegylated interferon alfa -2a 180ug/twice weekly and weight based ribavirin for 4 weeks then pegylated interferon alfa -2a 180ug/ weekly for the remainder of the treatment
45696808|NCT00085917|Drug|standard dose pegylated interferon alfa -2a and ribavirin|pegylated interferon alfa -2a 180ug weekly and weight based ribavirin for duration of the treatment
46056904|NCT00730405|Drug|Albaconazole 100mg|Albaconazole for 36 weeks
45392771|NCT03974607|Behavioral|Physical Activity Program (PAP)|A Physical Activity Program (PAP) will be carried out. Previously an initial measure will be made to know the little active adolescents. At the end of the PAF a retention measure will be carried out to know the scope and persistence of the variables analyzed. The PAF will be developed with a frequency of three weekly sessions, of 60 minutes, in the period of the intervention, with the exception of weeks in which there is a public holiday, where we will take measures to recover the class. A schedule for the sessions will be set according to the interests of the participants and will be the same for all. During the sessions, basic physical abilities and motor skills will be worked on with playful proposals focused on the improvement of physical and psychosocial parameters. They will always have the same monitor Graduate in Physical Activity and Sports Sciences, which will be responsible for developing the PAF.
45392772|NCT00211809|Behavioral|Cognitive Behavioral Therapy|standard psychiatric evaluation
45392773|NCT00211809|Drug|Venlafaxine|start dose of 37.5 mg/day and increased to a minimum of 150mg/day, generally over the first 4 weeks and then maintained at that dose for 8 weeks.
45392774|NCT01071291|Drug|Niaspan|Niaspan™
45392775|NCT01071291|Drug|Comparator: Placebo|Placebo
45392776|NCT03970941|Other|Cost evaluation|The cost for the hospital of the strategy of management will be evaluated.
45696809|NCT03416283|Behavioral|Remote Monitoring|Remote BP monitoring and medication adherence
45696810|NCT03416283|Behavioral|Remote Monitoring + Social Support|"Remote BP monitoring and medication adherence with enhanced support from a support partner (facilitated cheerleading)"
45696811|NCT03416049|Device|PEMF therapy with a high-power PEMF device|The 20 participants assigned to a high-power PEMF device will treat each Venous Stasis Leg Ulcer (VSLU) area for 10 minutes twice a day.
45696812|NCT03416049|Device|PEMF therapy with a medium PEMF power device|The 20 participants assigned to a medium-power PEMF device will treat each VSLU area for 15 minutes twice a day.
45696813|NCT03416049|Device|PEMF therapy with a low-power PEMF device|The 20 participants assigned to a low-power PEMF device will treat each VSLU area for 30 minutes twice a day.
45392777|NCT03970941|Other|Questionnaire|The quality of life of patients will be measured.
45392778|NCT01073787|Drug|Normal saline|10 ml/kg of normal saline will be administered over 30 minutes
45392779|NCT00129766|Biological|motavizumab (MEDI-524)|Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
45392780|NCT00129766|Biological|palivizumab|Palivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
45696814|NCT03416049|Device|PEMF therapy with the sham PEMF device|The 20 participants assigned to the sham PEMF device will treat each VSLU area for 15 minutes twice a day.
45696815|NCT00084747|Drug|bortezomib|
45392781|NCT00150592|Drug|SPD503 (Guanfacine HCl)|
45392782|NCT00150592|Drug|Placebo|
45392783|NCT00149890|Drug|Basiliximab|Basiliximab (10 mg) was supplied as a lyophilisate in vials with ampoules of sterile water for injection (5 mL) and had to be given of 10 mg (body weight <35 kg) or 20 mg (body weight ≥35 kg) strength.
45392784|NCT00149890|Drug|Cyclosporine/cyclosporine microemulsion|Cyclosporine/cyclosporine microemulsion had to be started with 100 mg/m²/day intravenous (i.v) (2x4h) for 7 days and was to be continued i.v. or orally from day 8 onwards as per center practice. During the 6 months treatment period Cyclosporine doses had to be adjusted according to Cyclosporine A (CsA)-trough levels.
45392785|NCT00149890|Drug|Steroid|Intravenous prednisolone (loading dose: 300 mg/m2, maximum 500 mg) had to be administered intraoperatively only in treatment arm 1 (day 0). The first dose of steroids in treatment arm 2 (day 0) had to be administered within 8 hours after reperfusion of the graft. Beginning from day 1 to day 6 doses of 15 mg/m2/day had to be given intravenously (i.v.) in both treatment arms. Then, the steroid doses (oral prednisone or its equivalent) were to be decreased from 10 mg/m²/day orally (day 7-13), to 7.5 mg/m²/day orally (day 14-30), to 4 mg/m²/day orally (until end of month 2), to 2.5 mg/m²/day orally (until end of month 3) and to 1 mg/m²/day orally (until end of month 6).
45392786|NCT00174382|Drug|Donepezil|donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks
45392787|NCT00355134|Drug|Fingolimod|Fingolimod capsules for oral administration
45392788|NCT00355134|Drug|Placebo|Matching placebo capsules for oral administration.
45392789|NCT03987516|Other|Active exercising|Patients allocated to the experimental group were included in an active exercising program adapted to each patient
45392790|NCT00171730|Drug|Pasireotide|
45392791|NCT00355056|Other|Sham Procedure|Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure). Participants completing 1 year follow-up are eligible for PFO closure with the AMPLATZER PFO Occluder.
45392792|NCT00355056|Device|AMPLATZER PFO Occluder|Patients in this arm will receive the AMPLATZER PFO Occluder device
45392793|NCT00348348|Drug|Besifloxacin|Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days
45392794|NCT00348348|Drug|Moxifloxacin solution|Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.
45392795|NCT01324986|Procedure|Laparoscopic anti-reflux surgery|
45696816|NCT04402671|Other|non-cross-linked porcine skin collagen membrane|non-cross-linked porcine skin collagen membrane used is Bioguide, Geistlisch Pharma AG, Wolhusen, Switzerland.
45696817|NCT04402671|Other|glutaraldehyde cross-linked bovine collagen membrane|glutaraldehyde cross-linked bovine collagen membrane GCLM used is RTM Collagen®, Osteogenics Biomedical, Lubbock, TX, USA.
45696818|NCT01678287|Drug|ASP1941|oral
45696819|NCT01678287|Drug|Placebo|oral
45696820|NCT01678365|Drug|ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole|
45392796|NCT03989388|Behavioral|Occupational self-analysis|"The Occupational Self-Analysis program provides participants with a space where they can learn to analyse the barriers and supports for occupational participation."
45392797|NCT03989388|Behavioral|Vocational guidance|To explore participant´s job interests and learned how to find a job and define a professional profile.
45392798|NCT03989388|Behavioral|Usual Rehabilitation|Usual rehabilitation: occupational therapy and/or physiotherapy.
45392799|NCT01054482|Drug|Pre-operative chemotherapy|Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op & Post-Op (total 4 cycles)
45392800|NCT01054482|Other|Pre-operative concurrent chemoradiation therapy|"Chemotherapy: Docetaxel 20 mg/m2 + carboplatin area under the curve = 2 on D1 and 8, q3weeks, Pre-Op & Post-Op: 2 cycles (total 4 cycles).~Concurrent thoracic radiotherapy: Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx"
45392801|NCT02534064|Dietary Supplement|CALIN+|Consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
45392802|NCT02534064|Dietary Supplement|CALIN+|Consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product intake during 8 weeks.
45392803|NCT02533830|Biological|sugarless gum|"One Stick of Sugarless Gum (Samara for food & Chocolates Product Company)S.A.E. , for 15 Minutes Every 2 hours After Surgery Tell Defecation"
45392804|NCT02533830|Other|traditional management|Traditional Management (Oral Intake of Clear Fluid Allowed After Passage of Flatus and Regular Diet With The Passage of Bowel Movement.
45696821|NCT00946270|Drug|CC-4047|0.5 mg capsules daily by mouth day 1 through day 28.
45696822|NCT00946270|Drug|Prednisone|30 mg by mouth daily during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
45696823|NCT00946270|Drug|CC-4047|3.0 mg capsules daily by mouth day 1 through 21.
45696824|NCT03478293|Device|iStent inject surgery|Micro-invasive glaucoma surgery (MIGS) to implant iStent inject
46056905|NCT00730405|Drug|Albaconazole 200mg|Albaconazole for 36 weeks
45426199|NCT05794542|Device|Cue X|Cue X is used with augmented (mixed) reality glasses. These glasses are similar to virtual reality glasses except you can see the real world around you with digital images overlain. The Cue X software is used on two existing devices, the Microsoft HoloLens and the Magic Leap.
45696825|NCT03021850|Procedure|Flexibility training with or without different thermal modalities|Flexibility training of the hamstring muscles by passive static stretching of the hamstring muscles in 10 30-second repetitions, with a 10-second pause between each repetition associated with or without short-wave heating or cryotherapy
46056906|NCT00730405|Drug|Albaconazole 400mg|Albaconazole for 36 weeks
46056907|NCT00730405|Drug|Albaconazole 400mg|Albaconazole for 24 weeks, Placebo for 12 weeks
46056908|NCT00730405|Drug|Placebo 400 mg|Placebo for 36 weeks
45392805|NCT03987438|Behavioral|Lifestyle intervention with APP|The lifestyle intervention will be launched by an APP installed in participants' private mobile phones, including health knowledge education, mental health counseling, smart diet advice, intelligent exercise guidance, and target weight management. Nutrition recommendation is conducted according to the Chinese Dietary Guide, Chinese and International Guidelines of Gestation Diabetes Management. Exercise guidance is given based on the Guidelines for National Fitness of China, Chinese and International Guidelines of Gestation Diabetes Management. Psychological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP. The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together to modify the behavioral supports individually based on the feedback of their characteristics and performance recorded in the APP.
45392806|NCT02533362|Drug|ANF-Rho|Pegylated version of recombinant human granulocyte-colony stimulating factor (G-CSF)
45392807|NCT00347958|Biological|Tetanus-diphtheria-acellular pertussis (Tdap) vaccine|0.5mL, Intramuscular (IM)
45392808|NCT00354744|Biological|dactinomycin|"Age based dosage: ≥ 1 year 0.045 mg/kg IV x 1(maximum dose 2.5 mg), < 1 year 0.025 mg/kg.~Day 1 of Weeks 35, 38, 41 and 44.~Given IV"
45392809|NCT00354744|Drug|cyclophosphamide|"Age based dosage: ≥ 3 years 1200 mg/m2, <3 years 40 mg/kg.~Day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41 and 44.~Given IV"
45392810|NCT00354744|Drug|doxorubicin hydrochloride|"Age based dosage: ≥ 1 year: 37.5mg/m²/day, < 1 year: treat with 50% doses calculated on a m2 basis. Total dose 75 mg/m².~Days 1 and 2 of weeks 7, 11, 15, 28 and 32.~Given IV"
45392811|NCT00354744|Drug|etoposide|"Age based dosage: ≥ 1 year: 100 mg/m²/day, < 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV"
45392812|NCT00354744|Drug|ifosfamide|"Age based dosage: ≥ 1 year: 1800 mg/m²/day, < 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV"
45392813|NCT00354744|Drug|irinotecan hydrochloride|"Dosage 50 mg/m2-max dose 100 mg/day.~Days 1-5 of weeks 1, 4, 20, 23, 47 and 50.~Given IV"
45392814|NCT00354744|Drug|vincristine sulfate|"Age based dosage: ≥ 3 years 1.5 mg/m2 (max dose 2 mg), ≥ 1 year and < 3 years 0.05 mg/kg (max dose 2 mg), < 1 year 0.025 mg/kg.~Days 1-5 of weeks 1, 2, 3, 4, 5, 7, 8, 11, 12, 15, 16, 20, 21, 22, 23, 24, 28, 29, 32, 33, 35, 38, 41, 42, 43, 44, 47, 48, 50, and 51.~Given IV"
45392815|NCT00354744|Procedure|conventional surgery|"Resection of the primary tumor with a surrounding envelope of normal tissue"
45392816|NCT00354744|Radiation|radiation therapy|Radiotherapy beginning at Week 20 to the primary tumor and to the metastatic sites excepting those with parameningeal tumors with intracranial extension (direct extension into the brain) and those requiring emergency radiotherapy
45392817|NCT00354744|Biological|filgrastim|"5 micrograms/kg/day (max 300 micrograms) beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/μL whichever comes last.~Given subcutaneously."
45696826|NCT03475641|Drug|Femoral nerve blockade|The femoral nerve blockade with lidocain is combined to the tumescent anesthesia.
45696827|NCT03475641|Procedure|The current standard treatment|Tumescent anesthesia.
45696828|NCT01678521|Procedure|LDL-apheresis|The acronym H.E.L.P. stands for Heparin-induced Extracorporeal Low-density-lipoprotein Precipitation. Antecubital veins served as blood access. The mean blood volume processed per session is of approximately 3000 ml.
45696829|NCT03021616|Other|energy drink|32oz of commercially available energy drink
45696830|NCT03021616|Other|Moxifloxacin 400mg|400mg moxifloxacin active control drink
45696831|NCT03021616|Other|Placebo|Placebo drink
45392818|NCT01051674|Other|High fiber vs. low-carbohydrate diets|High fiber diet involves at least 40 grams of dietary fiber or more per day for women and at least 50 grams of dietary fiber per day for men. Low-carbohydrate diet involves less than 120 grams of carbohydrate per day for both men and women.
45392819|NCT01055964|Drug|Tacrolimus|
45392820|NCT03989076|Procedure|Interscalene Brachial Plexus Block|Analgesic nerve block as part of routine care with pre- and post-block ultrasonographic imaging of the diaphragm and inferior vena cava
45392821|NCT03987204|Drug|Ivabradine|Ivabradine will be started and titrated to heart rate slowing of 20 bpm or greater, or an increase in pacing.
45392822|NCT01056042|Drug|intramuscular depot medroxyprogesterone acetate|150 mg, Intramuscular, every 3 months
45392823|NCT01056042|Drug|ethinyl estradiol 30 micrograms, gestodene 75 micrograms|one tablet orally, everyday
45392824|NCT01051830|Other|Diabetes interdisciplinary program|Diabetes consulting, rehabilitation program
45392825|NCT01056120|Device|Pro Kinetic Energy bare metal stent|PCI
45392826|NCT00373256|Drug|Sunitinib|Sunitinib 25 mg daily by oral capsules with titration up to 37.5 mg,
45392827|NCT00373256|Drug|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
45392828|NCT00373256|Drug|bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks.
45696832|NCT03021694|Dietary Supplement|Testing of micellar casein, blended micellar casein and native whey, versus native whey to determine post-ingestion aminoacidemia, glycemia, and insulinemia in young adult men|
45696833|NCT03086187|Device|Hephaistos unloading orthosis|The Hephaistos unloading orthosis greatly reduces plantarflexor muscle torque and plantarflexor muscle activation during any gait activity.
45696834|NCT02245828|Drug|QCC374|Single and multiple ascending doses of QCC374
45696835|NCT02245828|Drug|Placebo|Placebo comparator
45696836|NCT00956254|Drug|Fentanyl sublingual spray|Fentanyl was supplied in single-dose glass vials assembled into a delivery device to be used as a sublingual spray.
45392829|NCT00373256|Drug|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
45392830|NCT01324544|Drug|Buprenorphine IV|Buprenorphine IV administered via patient-controlled analgesia (PCA) pump for at least 24 hours and up to 72 hours.
45502855|NCT03618576|Procedure|Balance specific exercise|Balance specific exercise consists of total 10 days' physical therapy (PT) sessions (twice per day for 60 min) after surgery. It will be conducted with a computed posturographic system for diagnostics of balance and movement skills (Balance Master® System NeuroCom®) designed to objectively quantify balance and postural function of different origin. PT (weight-bearing, strengthening, gait training, aerobic, and functional exercises) was gradually increased based on the patient's functional level. Intensive patient education by multidisciplinary rehabilitation members was also provided.
45392831|NCT00394082|Drug|ABI-007|125 mg/m^2 of ABI-007 administered by intravenously (IV) over 30 minutes on days 1, 8 and 15 of each 28 day cycle.
45392832|NCT00394082|Drug|Bevacizumab|Bevacizumab administered once every 2 weeks (10 mg/kg) by IV infusion after ABI-007 has been given. The first dose is one Day 1, cycle 1.
45502856|NCT02061176|Procedure|Transanal Haemorrhoidal Dearterialization|
45392833|NCT00393848|Drug|Essential amino acid supplement|15g of essential amino acid in capsule form three times daily during hospitalization, continued through 6 weeks after discharge.
45392834|NCT00393848|Drug|Ketoconazole|200mg ketoconazole twice daily; started night before surgery and continued through hospitalization.
45392835|NCT00393848|Drug|Placebo|Placebo for Ketoconazole
45392836|NCT00393458|Drug|Indacaterol|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
45392837|NCT00393458|Drug|Formoterol|Formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
45392838|NCT00393458|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
45392839|NCT00393458|Drug|Placebo to formoterol|Placebo to formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
45392840|NCT01046006|Drug|Bortezomib, Rituximab, Dexamethasone|"Bortezomib as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1.~On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each 35-day cycle.~Dexamethasone IV 40 mg will be given on cycles 2 and 5 on days 1,8,15,22 Rituximab IV will be given on cycles 2 and 5, 375 mg/m2, on days 1,8,15,22 iv"
45696837|NCT03021148|Other|Questionnaire|Administration of questionnaire.
45392841|NCT01913132|Device|Negative pressure wound therapy with PICO (Smith & Nephew)|Negative wound pressure therapy
45392842|NCT01046162|Drug|Alprazolam|Single tablet
45392843|NCT01046162|Drug|Alprazolam|Single tablet
45392844|NCT00417482|Drug|risperidone|Risperidone open label flexible dose 0.25 to 3 mg daily for first 16 weeks; dose at 16 weeks then fixed for randomized trial
45848877|NCT05345184|Behavioral|Services as Usual (SAU)|Standard psychiatric and behavioral services provided at community mental health (e.g., case management, medication management)
45848878|NCT05330442|Behavioral|Written Exposure Therapy (WET)|The WET protocol for primary care settings consists of six, 30-minute sessions. The first session consists of psychoeducation of PTSD and treatment rationale. Written narratives are conducted in sessions 2-6, following specific writing instructions and 20 minutes of writing in each session.
45392845|NCT01043900|Procedure|repetitive transcranial magnetic stimulation (rTMS)|30 daily sessions: each with 40 trains of 5 seconds at 10Hz, with a 25 second inter-train interval, at an intensity of 110% of motor threshold. Site: Right Dorsolateral Prefrontal Cortex
45392846|NCT00417248|Drug|Cisplatin|Cisplatin 50 mg/m2 IV, days 1 and 8 of 28 day cycle
45392847|NCT00417248|Drug|Etoposide|Etoposide 50 mg/m2 IV, days 1-5 of 28 day cycle
45392848|NCT00417248|Procedure|Radiotherapy|Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy)
45502857|NCT02061176|Procedure|Open Haemorrhoidectomy|
45392849|NCT00417248|Drug|Sorafenib|Maintenance therapy of Sorafenib 400 mg PO BID, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 6 months
45392850|NCT01046240|Drug|Palonosetron|Palonosetron 3 mg administered SC or IV
45392851|NCT00392288|Drug|Ciclesonide|Ciclesonide MDI 40 µg BID over twelve weeks
45392852|NCT00392288|Drug|Ciclesonide|Ciclesonide MDI 80 µg BID over twelve weeks
45392853|NCT00392288|Drug|Placebo|Placebo MDI over twelve weeks
45392854|NCT00417170|Drug|Aliskiren|Aliskiren 300 mg tablets taken orally once daily
45392855|NCT00417170|Drug|Amlodipine|Amlodipine 5 mg capsule taken orally once daily
45392856|NCT00417170|Drug|Placebo Aliskiren|Placebo Aliskiren taken orally once daily.
45502858|NCT04314557|Device|Renal denervation|Spyral device. Bilateral renal denervation.
45502859|NCT02061254|Device|Cutometer|3 measures by cutometer on each area: the mean value will be the final value
45392857|NCT00417170|Drug|Placebo Amlodipine|Placebo Amlodipine taken orally once daily
45392858|NCT01046318|Drug|OPC-262|OPC-262 5 mg will be orally administered once daily fro 52 weeks.
45392859|NCT00392990|Drug|Regimen A|Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen
45392860|NCT00392990|Drug|Regimen B|Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)
45426200|NCT05794529|Other|There are no interventions in the present study|There are no interventions in the present study
45426201|NCT05794464|Procedure|Catheter ablation and/or electrical cardioversion|Catheter ablation and/or electrical cardio version are procedures intended to treat atrial fibrillation.
45426202|NCT05794425|Drug|Cyclosporine A|3-5 mg per kilogram per day.
45502860|NCT02061254|Device|High resolution ultrasonography (echography)|Cutaneous echography on the 3 areas, in order to measure skin thickness and echogenicity Measures are blinded to cutometer (by a different investigator)
45392861|NCT01046474|Behavioral|lifestyle|"Based on beliefs and behaviors of children sections of education will be delivered via classroom activities.~Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.~Children will also be stimulated to increase everyday activities such as walking and playing games at home and school. Also, activities with parents and family members such as walking around the neighborhood on weekends will be promoted."
45392862|NCT01046552|Procedure|preoperative ERCP and LC|preoperative ERCP followed by LC
45392863|NCT01046552|Procedure|Intraoperative ERCP and LC|LC and intraoperative ERCP
45392864|NCT01043978|Behavioral|Use of baby bottle nipple|Participants will be assigned to either a novel nipple or a conventional nipple to use when feeding their infants with the bottle
45392865|NCT01044134|Behavioral|Dietary counseling|Participants will receive personalized dietary counseling to promote behavior change
45392866|NCT00249873|Drug|clopidogrel (SR25990C)|oral administration (tablets)
45392867|NCT00249873|Drug|placebo|oral administration (tablets)
45392868|NCT00392210|Genetic|Voiding Trial|Post-void residual and uroflow study will be done twice
45392869|NCT01037348|Drug|ranibizumab 0.5mg|
45392870|NCT03490292|Combination Product|Avelumab combined with Chemoradiation|Co-administration of avelumab with chemoradiation in pre-operative period.
45392871|NCT03490292|Drug|Carboplatin|Weekly Carboplatin (AUC2) [intravenous infusion on days 1, 8, 15, 22, & 29]
45392872|NCT03490292|Drug|Paclitaxel|Weekly paclitaxel [intravenous infusion on days 1, 8, 15, 22, & 29]
45392873|NCT03490292|Radiation|Radiation|Radiation therapy [23 fractions, M-F, estimated completion day 35]
45392874|NCT01046630|Drug|AZD6765|single infusion
45392875|NCT01046630|Drug|Ketamine|single infusion
46056909|NCT02722707|Device|magnetic anal sphincter augmentation for fecal incontinence|Surgical placement of HUD called FENIX for female patients that have failed conservative therapy and less invasive therapies or who are not candidates for such therapies
45392876|NCT01046630|Drug|Placebo|single infusion
45392877|NCT01037426|Other|Fill out Questionnaire|"Questionnaire at time of Implantation and 12 months after pacemaker implantation to collect~History of falls and fractures during the 12 months before pacemaker implantation~Risk markers for falls based on FRAX risk calculator (age, gender, weight, height, history of previous fracture, family history of hip fracture, current smoking habits, glucocorticosteroid intake, rheumatoid arthritis, secondary osteoporosis, alcohol intake)~History of falls and fractures during the 12 months after pacemaker implantation~Medical and Arrhythmia History~Cardiovascular Events~Cardiovascular Medication~Device programming information"
45392878|NCT01046708|Drug|micronized progesterone|600mg in 3 separate doses per day
45392879|NCT01046786|Biological|Umbilical Cord Blood Mononuclear Cell|The cord blood mononuclear cells are obtained from thawed units of HLA-matched human umbilical cord blood. The cells will be slowly injected into the posterior gray matter after laminectomy and opening of the dura.
45392880|NCT01046786|Drug|Methylprednisolone|30 mg/kg methylprednisolone
45392881|NCT01046786|Drug|Lithium|oral lithium, titrated to maintain 0.6-1.0 mM serum level
45392882|NCT00391976|Drug|Tobramycin solution for inhalation 300 mg|Tobramycin solution for inhalation was supplied in 5 mL liquid-filled low-density polyethylene ampoules containing 300 mg tobramycin. Patients used a nebulizer to inhale the contents of the ampoules.
45392883|NCT00762554|Drug|Depodur|Depodur 10mg given epidurally at end of cesarean section.
45392884|NCT00762554|Drug|Depodur|Depodur 10mg given epidurally at end of cesarean section after patient received spinal bupivacaine at the beginning of the case.
45392885|NCT00762554|Drug|Fentanyl|Epidural fentanyl infusion started after spinal bupivacaine used for the cesarean section.
45392886|NCT00391898|Drug|Levodopa/carbidopa/entacapone|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa/entacapone was available in 2 oral dosage forms: 100/25/200 or 150/37.5/200 mg encapsulated tablets.
45392887|NCT00391898|Drug|Levodopa/carbidopa|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa was available in 2 oral dosage forms: One or one and one-half 100/25 mg encapsulated tablets.
45502861|NCT02061254|Device|Elastography|10 measures on the 3 areas (central measures will be doubled) Measures will be performed blinded to cutometer
45502862|NCT02061254|Procedure|Skin biopsy|Skin biopsy of 3 mm in diameter, for 30 participants, to evaluate histological fibrosis
45502863|NCT05189665|Procedure|Extraperitoneal high sacral ligament suspension surgery|The extraperitoneal high sacral ligament suspension surgery is to shorten the bilateral uterosacral ligaments .
45392888|NCT03993080|Device|Virtual reality relaxation|1-3.5 minute 360° videos
45392889|NCT01046864|Drug|5-FU|IV solution, IV bolus over 2-4 minutes, 400 mg/m², Every 14 days, Until disease progression/toxicity
45392890|NCT01046864|Drug|Leucovorin|IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
45392891|NCT01046864|Drug|5-FU|IV solution, IV infusion over 46 hours, 2400 mg/m², Every 14 days, Until disease progression/toxicity
45392892|NCT01046864|Drug|Irinotecan|IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
45392893|NCT01046864|Drug|Brivanib|Tablets, Oral, 400 - 800 mg, once daily, Until disease progression/toxicity
45392894|NCT01046864|Drug|Brivanib|Tablets, Oral, 600 - 800 mg, once daily, Until disease progression/toxicity
45392895|NCT01046864|Drug|Brivanib|Tablets, Oral, 800 mg, once daily, Until disease progression/toxicity
45392896|NCT01046942|Drug|Clopidogrel+acetylsalicylic acid|loading dose clopidogrel 300mg on second postoperative day. Thereafter 75mg clopidogrel daily for 3 months Aspirin 75mg daily, started within 24 hours after surgery
45392897|NCT01046942|Drug|acetylsalicylic acid|aspirin 75 mg daily, started 6-24 hours after surgery
45392898|NCT01049282|Biological|Antigen (Ag85B-ESAT-6)|Solution for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
45392899|NCT01049282|Biological|Antigen (Ag85B-ESAT-6) with adjuvant (IC31)|Suspension for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
45392900|NCT01049438|Drug|nasal mupirocin|twice daily for 10 days
45392901|NCT01049438|Drug|topical 3% hexachlorophene body wash|daily for 10 days
45392902|NCT01049438|Drug|oral anti-MRSA antibiotic|The choice of oral antibiotic was based on investigators choice and antibiotic susceptibility of prior MRSA isolates in a given patient
45392903|NCT01047098|Dietary Supplement|Iron|Iron as iron sulfate
45392904|NCT01047098|Dietary Supplement|Iron|Iron as iron sulfate
45392905|NCT01047098|Dietary Supplement|Placebo|Placebo capsule
45392906|NCT01047254|Drug|Elontril|flexible dose of Bupropion 150-300 mg
45392907|NCT01047254|Drug|placebo|
45392908|NCT01047410|Other|Exercise intervention|Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.
45392909|NCT01047410|Other|Exercise intervention and dietary advice|The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
45502864|NCT05189665|Procedure|Sacrospinous ligament fixation|The sacrospinous ligament fixation surgery is to open the front and back peritoneum through the vagina and shorten the bilateral uterosacral ligaments.
45502865|NCT01344395|Drug|ropivacaine and ketorolac|The RK-group receives four intra-articular injections via catheter with a total volume of 40 ml (380 mg ropivacaine and 60 mg ketorolac) combined with 4 intravenous injections of saline during 24 hours postoperatively
45502866|NCT01344395|Drug|Ketorolac|The K-group receives four intra-articular injections via catheter with a total volume of 40 ml saline combined with 4 intravenous injections of ketorolac (total 60 mg) during 24 hours postoperatively
45502867|NCT02291445|Drug|Menthae piperitae aetheroleum/peppermint oil (enteric coated capsule)|Peppermint oil capsule available as an over the counter prescription drug on the Dutch market.
45392910|NCT00391586|Drug|Erlotinib|"Erlotinib will be administered for at least 2 cycles (6 weeks) and for a maximum of 8 months.~Upon progression or intolerance to erlotinib, standard of care platinum-based chemotherapy (per the choice of the treating physician) is administered every 3 weeks. Physicians can adjust dose, schedule, or supportive care to the benefit of the patient"
45392911|NCT00391586|Drug|Platinum-based chemotherapy|Intravenous chemotherapy combination per physician discretion every 3 weeks for at least 2 cycles
45392912|NCT00391430|Drug|Sertraline|Dosage: up to 100 mg/day; Frequency: once per day; Duration: 12 weeks
45392913|NCT00391430|Behavioral|Cognitive behavioral therapy (CBT)|CBT consists of sixteen 1-hour sessions during a period of 12 weeks.
45392914|NCT00391274|Drug|pemetrexed|500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment
45392915|NCT00391274|Drug|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment
45392916|NCT00391118|Drug|enzastaurin|
45392917|NCT00391118|Drug|carboplatin|
45392918|NCT00391118|Drug|paclitaxel|
45392919|NCT00391118|Drug|placebo|
45392920|NCT00390884|Biological|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
45392921|NCT00390884|Biological|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
45392922|NCT01047488|Drug|Imipramine|Tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks
45392923|NCT01047488|Drug|Pregabalin|Capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
45392924|NCT01047488|Drug|Imipramine, pregabalin|Imipramine: tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks Pregabalin: capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
45392925|NCT01047488|Drug|Placebo|Placebo tablets to imipramine 25 mg, 3 or 1 tablet evening, daily, 5 weeks Placebo capsules to pregabalin 75 mg, 2 capsules daily, daily, 5 weeks
45392926|NCT01047566|Drug|Dronedarone|Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg twice daily for 12 weeks (+/- 5 days)
45392927|NCT01047566|Drug|Beta blocker or calcium antagonist or digoxin|Dose increase of beta blocker or calcium antagonist or digoxin
45392928|NCT00365846|Drug|Campath-1H|
45392929|NCT00264537|Drug|Placebo injections|SC injections
45392930|NCT00264537|Drug|Placebo capsules|Placebo capsules will be filled with microcrystalline cellulose (Avicel PH 102).
45392931|NCT00264537|Drug|Methotrexate capsules|Methotrexate capsules will be filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg methotrexate tablet.
45392932|NCT00264537|Biological|Golimumab 50 mg injections|SC injections
45392933|NCT00264537|Biological|Golimumab 100 mg injections|SC injections
45502868|NCT02291445|Drug|Menthae piperitae aetheroleum/peppermint oil (colon-targeted-delivery capsule)|Peppermint oil capsule with a coating developed according to the ColoPulse® technology, ensuring a pulsatile and therefore slower release in a lower part of the intestinal tract compared to Tempocol, namely in the (ileo-)colonic region.
45502869|NCT02062112|Other|Pattern of flavoring of bowel laxative|Unflavored bowel laxative versus entire bowel laxative flavored versus liberal flavoring as decided by patient
45696838|NCT03085953|Behavioral|Veteran Supportive Supervisor Training|"The family supportive supervisor behavior (FSSB) training intervention developed by Hammer and colleagues (2011) will be used as the basis for the development of the VSST intervention in the present study. In addition, we will draw on critical elements of training provided by the Employer Support of the Guard and Reserve (ESGR), information about potential mental and physical health effects of being in combat, and information to help reduce the stigma associated with returning veterans; in other words, de-clinicalizing their symptoms. Furthermore, this intervention study falls under the more general rubric of soldier resilience, but more specifically addresses both veteran and family resilience upon return from combat. The details of the training content will be researched and developed during the funded project period."
45696839|NCT03085953|Other|Waitlist Control|Control group will receive training following all measurements points to serve as a comparison group
45696840|NCT03020680|Dietary Supplement|Coenzyme Q10|To examine whether 200 mg/d ubiquinol for 14 days increase coenzyme Q10 status by a larger degree than 200 mg/d ubiquinone
45696841|NCT03086109|Other|Risk factors|Risk factors associated bone degenerative diseases
45848879|NCT05288946|Other|local segmental control and closed kinetic chain|the patients will receive Lumbar multifidus activation and Transversus abdominis activation then closed kinetic chain exercise in the form of Stand-up position on unstable surface, Closed chain lunge exercises, with the addition of hand weights, Bridge in prone position, Bridge in supine position, Lateral Bridge
46056910|NCT04129359|Behavioral|FamilieTrivsel|FamilieTrivsel is a modular internet-based low-cost and brief psychoeducation intervention based on the Robusthed (Resilience) programme (RP). Mentalisation approaches are used to increase resilience and ability to handle the challenges of life. The programme is licence free and can be used with low or high intensity and it can be combined with any other interventions. RP provides simple explanations and tools that can be used to discover, understand and regulate one's own thoughts and feelings by activating mental and physical resources and it provides examples and exercises that may promote communication about mental states between parents and the child. The content has been developed to include video-based training sessions based on different stages of pregnancy and early childrearing. RP appears suitable for use in general practice, where the GP sees young parents regularly and thus can direct patients towards components of the programme when need appears greatest.
46056911|NCT04129359|Other|enhanced care as usual|Structured assessments of maternal mental health, child neurodevelopment and parent-child interaction in routine preventive health care in general practice
45392934|NCT00371462|Behavioral|Use of PDA + support to reduce weight and pain|participants will attend the MOVE! group, record their food, activity, mood, pain, and weight daily via a PDA. Participants will be assigned a coach to help them set physical activity and calorie goals in order to produce a weight loss of .5%-1% per week on average over the course of 6 months. Participants will continue to log using the PDA during the 2nd 6-months for follow-up. They will also be asked to attend assessments at 3, 6, 9, and 12 months.
45392935|NCT00371462|Behavioral|MOVE! level 2 group weight loss counseling|Participants will attend the MOVE! group and will be asked to complete assessments at 3, 6, 9, and 12 months.
45392936|NCT00371150|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily, up to 52 weeks
45392937|NCT00264303|Drug|Levocetirizine|5mg oral capsules, once daily, 4 week duration
45392938|NCT00264303|Drug|Desloratadine|5mg oral capsules, once daily, 4 week duration
45392939|NCT01071369|Drug|Xylocaine|0.5% Xylocaine
45392940|NCT01071369|Drug|Xylocaine and Celestone|non-particulate Celestone
45392941|NCT01072305|Device|Intermittent pneumatic compression (IPC)|Intermittent pneumatic compression (sequential compression) using a cuff consisting of 12 chambers inflated sequentially from forefoot to groin with decremental inflation pressures (60-38 mmHg), pressure release after complete inflation, and reinflation after 4 seconds pause. ICP cuffs are covered with a frame and drapes for blinding purpose.
45392942|NCT01072305|Device|IPC - placebo|ICP cuffs are placed next to/between legs and covered with a frame and drapes for blinding purpose. IPC device is run fom induction of general anesthesia to closure of the skin.
45392943|NCT00370682|Biological|T-DEN F17|A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
45392944|NCT00370682|Biological|T-DEN F-19|A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
45502870|NCT01342289|Drug|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg/day IV. Days 3 and 4: 50 mg/kg/day IV.
45502871|NCT01342289|Drug|Fludarabine|Days -6, -5, -4, -3, and -2: 30 mg/m^2/day IV.
45502872|NCT01342289|Radiation|Total body irradiation|Day -1: 200 centigray in one fraction.
45392945|NCT00370682|Other|Placebo Comparator|A single dose of 0.5 mL of the placebo sterile solution of buffer identical in appearance to vaccine)was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
45392946|NCT00264147|Drug|etoricoxib|Period I: Arm 1: etoricoxib 10 mg tablet once daily. 12 weeks of treatment.
45392947|NCT00264147|Drug|etoricoxib|Period I: Arm 2: etoricoxib 30 mg tablet once daily. 12 weeks of treatment.
45392948|NCT00264147|Drug|etoricoxib|Period I: Arm 3: etoricoxib 60 mg tablet once daily. 12 weeks of treatment.
45392949|NCT00264147|Drug|etoricoxib|Period I: Arm 4: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
45392950|NCT00264147|Drug|Comparator: placebo|Period I: Arm 5: Pbo tablet once daily. 12 weeks of treatment.
45392951|NCT00264147|Drug|etoricoxib|Period II: Arm 1: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
45392952|NCT00264147|Drug|Comparator: diclofenac|Period II: Arm 2: diclofenac 75 mg tablet twice daily. 12 weeks of treatment.
45392953|NCT01044368|Other|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
45392954|NCT01044446|Drug|Icodextrin|one exchange daily
45392955|NCT01044446|Drug|glucose-based peritoneal dialysate|original exchange frequency
45392956|NCT00263757|Device|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation provides positive expiratory airway pressure and inspiratory pressure support, which is servocontrolled based on the detection of central sleep apnea.
45392957|NCT00263757|Other|Usual Care|Subjects randomized to this arm received medical management as prescribed by their cardiologist.
45392958|NCT01072383|Drug|BT061|administration of BT061 either intravenous or subcutaneous
45392959|NCT01072383|Drug|placebo treatment|administration of the end formulation buffer of BT061 without active ingredient, either subcutaneous or intravenous
45392960|NCT01072461|Behavioral|HAS Training|Robotically measured and facilitated training of the hemiparetic hand and arm in isolation, in a three dimensional haptically rendered virtual environment.
45392961|NCT01072461|Behavioral|HAT training|Robotically measured and facilitated training of the hemiparetic hand and arm as an integrated functional unit, in a three dimensional haptically rendered virtual environment
45392962|NCT01072461|Behavioral|Bimanual Training|Robotically measured and facilitated training of the hemiparetic hand and non-hemiparetic hand together, in a three dimensional haptically rendered virtual environment
45392963|NCT03970863|Diagnostic Test|Prostate Health Index|Use Prostate Health Index for the follow-up after focal therapy.
45392964|NCT03971019|Drug|statins|On the basis of dietary intervention. Simvastatin 20mg/d QN Po (half an hour before bedtime) (dosage can be adjusted according to other indicators of blood lipid level in each review), atorvastatin 10mg/d QN Po (half an hour before bedtime) (patients who can not tolerate the side effects of simvastatin can consider replacing this drug).
45392965|NCT03971019|Behavioral|Dietary intervention group (control group)|Restriction of dietary components that increase LDL-C Saturated Fatty Acids Less than 7% of total energy Dietary cholesterol < 300 mg/d Increasing Dietary Ingredients for Reducing LDL-C Phytosterol 2~3 g/d Water soluble dietary fiber 10~25 g/d total energy Adjusted to maintain ideal weight or lose weight Physical activity Maintain moderate intensity exercise and consume at least 200 kcal of calories per day
45502873|NCT01342289|Drug|Mycophenolate Mofetil|Days 5 to 35: 15 mg/kg PO three times per day; max daily dose 1 g.
45848880|NCT05288946|Other|local segmental control and open kinetic chain|the patients will receive Lumbar multifidus activation and Transversus abdominis activation then open kinetic chain in the form of Lower limb abduction, Knee extension in a supine position on a roller, Open chain exercise of the upper limb after co-contraction of transversus abdominis and multifidus.
45392966|NCT03970707|Other|Small Number of Players training protocol A|8 participants each side game (4vs4), size of pitch area 25*20 m. In total, 6 consecutive 4-minutes bouts interspersed by a 3-minutes rest between each bout will be executed.
45392967|NCT03970707|Other|Large Number of Players training protocol B|16 participants each side game (8vs8), size of pitch area 25*20 m. In total, 3 consecutive 8-minutes bouts interspersed by a 1-minutes rest between each bout will be executed.
45392968|NCT03974685|Drug|99mTc niacinamide polyethylene glycol bicyclic RGD peptide (99mTc-3PRGD2)|Single dose
45392969|NCT03970551|Other|Physical Counter-maneuver|Physical counter-maneuver targeted at minimizing the large drop in BP seen in IOH patients.
45392970|NCT03970551|Other|Stress Test|Stress test involving submerging your hand in ice water or performing mental arithmetic to increase sympathetic activity.
45392971|NCT03970551|Other|Functional Electrical Stimulation|A mild electrical stimulus to passively induce a leg muscle contraction with minimal sympathetic activation.
45392972|NCT03970473|Other|Pulmonary recruitment maneuver (PRM)- 30 cm H2O|Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 30 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
45392973|NCT03970473|Other|Pulmonary recruitment maneuver (PRM)- 15 cm H2O|Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 15 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
45392974|NCT00263211|Drug|Plavix|
45392975|NCT00263211|Drug|Aspirin|
45392976|NCT03970317|Device|Broad Band Light|Broad Band Light Device
45392977|NCT00248625|Drug|N-acetylcysteine|The study drug is administered as a continuous infusion at a dose of 150 mg/kg/day for up to 7 days following entry into the study. The infusion is discontinued at the time of death, liver transplant or discharge.
45502874|NCT01342289|Drug|Tacrolimus 60|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 60.
46056912|NCT02596399|Drug|DSTA4637S|Participants will receive DSTA4637S intravenously on Day 1.
46056913|NCT02596399|Drug|Placebo|Participants will receive placebo matched to DSTA4637S intravenously on Day 1.
45392978|NCT00248625|Drug|Placebo|Eligible children were adaptively allocated within strata defined by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive N-acetylcysteine (150 mg/kg/d) in 5% dextrose (D5W) and water or placebo consisting of an equal volume of D5W alone. Volumes were adjusted for small children. Study medications were infused over 24 hours for up to 7 consecutive days in a dedicated line without other medications. Treatment was stopped earlier than 7 days in the case of hospital discharge, liver transplantation, or death within 7 days of randomization.
45392979|NCT00262821|Drug|cisplatin|Given IV
45392980|NCT00262821|Drug|tirapazamine|Given IV
45392981|NCT00262743|Biological|Polyphenon E|"Phase I Dose Escalation:. 400 mg orally twice a day to 2000 mg orally twice a day~Phase II: 2000 mg orally twice a day"
45392982|NCT03974529|Behavioral|Intensive running|The patients who are assigned to this group will be required to finish a 90 minutes of training protocol, containing 30 minutes' warm-up stretching, and 60 minutes of supervised progressive aerobic endurance track running. The training takes place two time per week, for 24 weeks.
45392983|NCT03974529|Behavioral|Physiotherapy|The patients who are assigned to this group will be required to finish a 60 minutes of physiotherapy session. The training takes place once per week, for 24 weeks.
45392984|NCT01326117|Drug|tadalafil|7 days of Cialis for Daily Use (5mg)
45392985|NCT03970239|Drug|Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin)|"Imaging of the serotoninergic system with Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin). During this study, subjects will receive a single intravenous administration of approximately 4 Megabecquerel/kilogram (MBq/kg) of [11C]-DASB immediately prior to imaging using Positron Emission Tomography (PET). The effective dose in human body is about 2.1 milliSievert (mSv).~On a separate day, subjects will receive a single intravenous administration of approximately 3.7 MBq/kg of [18F]-altanserin for 120 minutes prior to imaging using Positron Emission Tomography (PET). The effective dose in human body is about 8.4 mSv."
45392986|NCT03970239|Drug|Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)|Imaging of the serotoninergic system with Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin). During this study, subjects will receive a single intravenous administration of approximately 3.7 Megabecquerel/kilogram (MBq/kg) of [18F]-altanserin 120 minutes prior to imaging using Positron Emission Tomography. The effective dose in human body is about 8.4 mSv.
45392987|NCT03970161|Device|routine ophthalmic examination|Routine ophthalmic examination, including slit lamp, intraocular pressure, and fundus examinations using direct or indirect ophthalmoscopy after pupil dilation and optical coherence tomography (OCT) examination. Patients with DM also underwent fundus fluorescein angiography (FFA) examination.
45392988|NCT03974295|Behavioral|Vaginal unprotected intercourse|Patients will allowed to engage in vaginal unprotected intercourse as many times as desired after 24 hours of pelvic rest after a frozen embryo transfer.
45392989|NCT00262119|Device|Pacemaker Medtronic EnRhythm|Pacemaker specific programming
45392990|NCT00170950|Drug|Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/amlodipine besylate 10/5 mg capsules for oral administration once daily.
45392991|NCT00170950|Drug|Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/amlodipine besylate 20/5 mg capsules for oral administration once daily.
45392992|NCT00170950|Drug|Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/amlodipine besylate: 40/10 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
45392993|NCT00170950|Drug|Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 20/12.5 mg capsules for oral administration once daily.
45392994|NCT00170950|Drug|Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/12.5 mg capsules for oral administration once daily.
45392995|NCT00170950|Drug|Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/25 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
45696842|NCT03020212|Drug|Oxygen|The subjects will be randomly assigned to receive or not LTOT and they will be followed for 30 months. At baseline and then at 10, 20 and 30 months, they will be clinically evaluated with arterial blood gases, pulse oximetry, echocardiography, spirometry with bronchodilator, diffusion capacity, quality of life (SGRQ), neurocognitive performance (MMSE) and six minutes walk test. The primary outcome will evaluate the ratio of occurrence of erythrocytosis or pulmonary hypertension. Secondary outcomes will be evaluated quality of life, lung function, neurocognitive performance and exercise tolerance by comparing the groups with and without LTOT.
46056914|NCT02722317|Behavioral|psychological support|psychological support was given to men by the service, the researcher didn't interfered in the intervention, just ask questions about it.
46056915|NCT04088695|Other|Video through a web page|Participants will see a video about blood donation.
46056916|NCT04088695|Other|Informative text|Participants will see a brief text about blood donation.
45392996|NCT00239577|Biological|Live attenuated tetravalent dengue vaccine|Live attenuated tetravalent dengue vaccine
46056917|NCT02722161|Drug|[14C]BI 1482694|
45392997|NCT00239577|Biological|Placebo|Placebo
45392998|NCT00262041|Biological|MenACWY-CRM conjugate vaccine, adjuvanted|
45392999|NCT00262041|Biological|MenACWY-CRM conjugate vaccine, unadjuvanted|
45393000|NCT00262041|Biological|MenACWY polysaccharide vaccine|
45393001|NCT03969849|Drug|REGN5713-5714-5715|Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
46056918|NCT02694237|Behavioral|Model|Each participant will receive an informed consent discussion with the aid of an anatomic knee model.
46056919|NCT02694237|Behavioral|Knee Anatomy Video|Each participant will hear a scripted informed consent discussion while they watch a knee anatomy video orated by an interviewer.
45393002|NCT03969849|Drug|Matching placebo|Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
45393003|NCT01071447|Other|Nurse-led clinic vs rheumatologist-led clinic|The subjects are seeing a rheumatology nurse (experimental arm)instead of a rheumatologist (active comparator arm) after six months. Subjects in both arms are seeing a rheumatologist after 12 months and have the possibility to contact the rheumatology nurse.
45393004|NCT00208767|Drug|Valsartan|Valsartan was titrated to a target dose of 320 mg orally daily
45393005|NCT00208767|Drug|Placebo|A matched placebo pill will be given orally daily.
46056920|NCT02694237|Behavioral|Verbal|Each participant will receive a verbal informed consent discussion without a visual aid.
45393006|NCT03969771|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program was developed by the University of Massachusetts Medical School.
45393007|NCT02531529|Drug|dexmedetomedine|intraoperative infusion
45393008|NCT02531529|Drug|Fentanyl|
45393009|NCT01071525|Drug|Niacin\Laropiprant|Hypercholesterolemic patients with low HDL will receive Niacin\Laropiprant
45393010|NCT03969537|Other|Telemedicine follow-up visit|Study participants will experience two telemedicine (live audio/video) visits.
45393011|NCT03969615|Device|SuperNO2VA nasal positive airway pressure devic|SuperNO2VA nasal positive airway pressure device utilizes supplemental oxygen and an adjustable pressure limiting valve to maintain upper airway latency
45393012|NCT03969615|Device|Supplemental oxygen|5lpm of supplemental oxygen
45393013|NCT01072695|Drug|GS-9256|75 mg BID x 28 days
45393014|NCT01072695|Drug|GS-9190|40 mg BID x 28 days
45393015|NCT01072695|Drug|Ribavirin|1000-1200 mg/day given BID
45393016|NCT01072695|Drug|Peginterferon alfa-2a|180 ug q week
45393017|NCT00390806|Drug|HYCAMTIN, oral capsules|topotecan oral capsules 1.1 mg/m2
45393018|NCT00390806|Radiation|Radiation|Whole brain radiation
45393019|NCT01049516|Behavioral|Prolonged Exposure Therapy - Massed|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions occur 5 days/week for two weeks.
45393020|NCT01049516|Behavioral|Prolonged Exposure Therapy - Spaced|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions 1-3 occur in the first two weeks, Sessions 4-5 occur in Weeks 3-4, and Sessions 6-10 occur in Weeks 5-10.
45393021|NCT01049516|Behavioral|Minimal Contact Control|Participants receive minimal contact for 4 weeks after randomization and thereafter are offered PE-Spaced or PE-Massed, according to their preference. Participants receive 10-15 minute phone calls once per week by the study therapist or independent evaluator in order to monitor their status and to provide support as needed.
46056921|NCT02594449|Drug|Benzalkonium Chloride Solution|To compare pharmacodynamics among the different concentrations of BCS and NS
46056922|NCT02722083|Drug|Chlorpheniramine maleate (BAY X002134)|4 mg tablet, single dose, orally
45393022|NCT01049516|Behavioral|Present-Centered Therapy|10 75-90 minute psychotherapy sessions, focused on identifying and solving day-to-day problems as they are brought up by the participants
45393023|NCT00390572|Behavioral|Sleep Specialty Consultation|The Sleep Specialty Consultation (SSC) consisted of: (1) a thorough sleep disorders evaluation accomplished via a clinician-administered structured interview designed to assess specific symptoms of global sleep disorder categories, review of a sleep history questionnaire, and review of available (CPRS) medical/psychiatric electronic records; (2) education about the specific sleep disorders diagnoses and relevant treatment recommendations provided to the patients; and (3) standardized diagnostic information and treatment recommendations provided to the participants' primary care providers.
45393024|NCT01047644|Other|Reduced port-flush schedule|3-month port-flushing
45393025|NCT00135200|Drug|Iodine I 131 Tositumomab|"The Bexxar therapeutic regimen is delivered in two sets of intravenous infusions given 7-14 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body. A trace amount of radioactive Iodine 131 attached to Tositumomab is initially given to enable physicians to evaluate the clearance of radiation from your body with gamma camera scans. Calculations made on the basis of these individualized radiation clearance rates allow the therapeutic dose (given 7-14 days after the dosimetric infusion) to be tailored for each patient. The therapeutic dose contains Tositumomab labeled with the amount of Iodine 131 tositumomab specifically calculated for you based on the scans performed following the dosimetric dose."
45393026|NCT01047722|Drug|Aspirin ingestion followed by doing a Bleeding Volume Test|Patient drinks a glass of Gatorade containing 325 mg of aspirin, then one hour later a bleeding volume test is performed.
45393027|NCT01047722|Procedure|Gatorade Placebo followed by Bleeding Volume Test.|Patient drinks a glass of Gatorade, then one hour later a bleeding volume test is performed.
45393028|NCT01047800|Behavioral|Counseling|"Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician in First and Final visits. Each session lasts for about 15 minutes with the following content:~First visit: prevalence of FGID in Hong Kong, chronicity nature of the disease, negative endoscopy result to be expected, time to answer patient's questions~Final visit : prevalence of FGID in Hong Kong (reinforcement), chronicity nature of the disease (reinforcement), explanation of the endoscopy result, management of disease via lifestyle modification, use of medication, need for further or repeated investigation, time to answer patient's questions."
45393029|NCT00390416|Drug|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin|Bevacizumab 10mg/kg day 1 IV over 30 minutes Docetaxel 40mg/m2 day 1 IV over 1 hour Leucovorin 400mg/m2 day 1 IV over 30 minutes Fluorouracil 400mg/m2 IVP day 1 Fluorouracil 1000mg/m2 IVCI x 48 hours Cisplatin 40mg/m2 day 3 IV over 30 minutes
45393030|NCT00261495|Drug|OROS hydromorphone HCl|8 to 32 mg once daily for 52 weeks (flexible dosing)
45393031|NCT00261495|Drug|Oxycodone|10, 20, or 40 mg twice a day for 52 weeks (flexible dosing)
45393032|NCT00168844|Drug|Tiotropium Inhalation Solution|
45393033|NCT00168844|Other|Placebo|
45393034|NCT00365456|Drug|Parathyroid Hormone (PTH)|Self-administered (100 μg in a volume of 71.4 μL) daily as a subcutaneous injection in the abdomen using the Preotact pen.
46056923|NCT02722083|Drug|Placebo|placebo tablet, single dose, orally
45393035|NCT00365456|Drug|Risedronate|Orally once weekly as one 35 mg tablet.
45393036|NCT01047956|Drug|Methadone; NAC|Methadone NAC
45393037|NCT01047956|Drug|Methadone|Methadone
46056924|NCT05257135|Biological|Biological collection|- Blood samples collected at different times: at inclusion and during treatment ( every 6 month)
46056925|NCT02694081|Procedure|Uncut Roux-en-Y Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
45393038|NCT03480698|Drug|Cerebrolysin|Dosage, frequency, duration and mode of administration of Cerebrolysin follow the local hospital practice in accordance with the terms of the local marketing authorization and is not amended or influenced by the study. Prescribed Cerebrolysin will be used as solution for injection/concentrate for solution for infusion.
45393039|NCT00147238|Drug|Ferumoxtran-10 (USPIO)|Intravenous infusion of 2.6 mg/kg of ferumoxtran-10
45393040|NCT00147238|Procedure|MR lymphangiography|First MRI examination before ferumoxtran-10 contrast injected and second MRI examination about 24 hours after injection of contrast agent, each MRI taking 20 minutes.
45393041|NCT02531464|Other|Supportive care|Systematic distress screening and needs assessment of family caregivers of patients with lung cancer
45393042|NCT00206427|Drug|GW572016|Lapatinib, 500 mg
45393043|NCT00206427|Drug|lapatinib|Lapatinib 500 mg PO
45393044|NCT00146848|Device|Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices|"All subjects in this trial receive the same device. For the purpose of this trial, intervention is programming mode and lower rate limit to deliver atrial support pacing in the two treatment arms, while the control arm will receive programming where limited atrial support pacing is delivered. DDD-70 and DDDR-40 are the treatment arms programmed to receive atrial support pacing and will be compared to the DDD-40 arm."
45393045|NCT00205881|Device|HiRes 90K Bionic Ear System|Cochlear implant system
45393046|NCT00365378|Biological|Comparator: HPV 16 L1 Vaccine|A 0.5 intramuscular injection given at Day 1, Month 2, and Month 6
45393047|NCT00365378|Biological|Comparator: Placebo|A 0.5 intramuscular placebo injection given at Day 1, Month 2, and Month 6
45393048|NCT00389324|Biological|Immune Globulin Intravenous (Human)|This trial was an open-label, single-sequence, study. The enrolled subjects received IGIV-C via two routes of administration (IV for 4 -5 weeks and SC for 24 weeks) in order to compare the PK variables, safety and tolerability of SC administration of IGIV-C. Certain subjects required IV IGIV-C dosing during a Run-in Phase (3 - 4 months) for steady-state conditions prior to the IV phase. Subjects received two IV infusions of IGIV (between 200 - 600 mg based on the subject's previous IgG dosing regimen, 3 to 4 weeks apart) until a steady-state was reached at which time PK profiling was performed. Subjects began weekly SC administration (1.37 times the weekly equivalency of each subject's monthly IV dose) 1 week following last IV dose and followed for a period of six months.
45393049|NCT00365300|Drug|pantoprazole|
45393050|NCT00365300|Drug|Placebo|
45393051|NCT01048034|Drug|Azacitidine|100 mg / m(2) subcutaneously day 1-5 every 4 weeks for 6 cycles. Another three cycles will be given together with epo for those not responding to the first 6 cycles of Azacitidine
45393052|NCT01048034|Drug|Erythropoetin|For those patients not responding to Azacitidine alone, the combination of Azacitidine and erythropoetin 60 000 U / week for 16 weeks will be given.
45393053|NCT02535182|Other|Blood Draw|"Lab will draw one tube of blood to be stored in 8 mL Becton Dickinson (BD) Vacutainer Cell Preparation Tube (CPT) tubes at three study time points as described in Table 4.7b. These time points include baseline, Day -2 (immediately prior to transplant, central line placement, or administration of any conditioning regimen), and Day +28.~Peripheral blood mononuclear cells (PBMCs) will be isolated from the whole blood samples collected from patients at the three designated time points (Baseline, Day -2, and Day +28). The lab will conduct western blotting on the cytosolic and membrane fractions of isolated PBMCs to determine the distribution of Rap1 in the different fractions, and the status of Rap1 prenylation in the cells."
45393054|NCT00370292|Drug|Pemetrexed - Before Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue
45393055|NCT00370292|Drug|Pemetrexed - After Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue.
45393056|NCT03992690|Device|Brain-machine Interfaces, Visuo-tactile Feedback and Assisted Locomotion, or the WANR protocol|Training integrating virtual-reality avatar driven by a brain-machine interface, with tactile feedback through patient's forearms, and assisted locomotion, for neurorehabilitation of SCI patients.
45393057|NCT03992690|Device|Training with traditional physiotherapy protocol|Stretching
45502875|NCT01342289|Drug|Tacrolimus 90|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 90.
45502876|NCT01342289|Drug|Tacrolimus 120|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 120.
45502877|NCT01342289|Biological|Bone marrow transplant|Donor stem cells infused IV on Day 0.
45393058|NCT01049672|Drug|Alfentanil|Titrated to a maximum dose of 50mg in 24 hours subcutaneously
45393059|NCT01049672|Drug|Diamorphine|Titrated to a maximum dose of 500mg in 24 hours given subcutaneously
45393060|NCT00369824|Biological|Different formulations of GSK Biologicals' HPV vaccine (580299)|Three doses of vaccine administered intramuscularly, with the second and third dose given one month and six months after the first dose respectively
45393061|NCT00369824|Biological|Menactra TM|One dose of vaccine administered intramuscularly
45393062|NCT00369824|Biological|Boostrix TM|One dose of vaccine administered intramuscularly
45393063|NCT00369668|Behavioral|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving their paretic arm at the same time as they move their non-paretic arm in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 4 times per week for 2 weeks.
45502878|NCT03134599|Device|etafilcon A|contact lens
45502879|NCT03134599|Device|methafilcon A - Interozzo|contact lens
45393064|NCT00369668|Behavioral|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 2 times per week for 2 weeks.
45393065|NCT00369668|Behavioral|Bilateral movements and sham electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Sham electrical stimulation (low level electrical stimulation that can be felt but is insufficient to trigger a muscle contraction) is provided to the paretic arm during the movement. Training period was 2 times per week for 2 weeks.
45393066|NCT01048112|Biological|Campylobacter jejuni strain CG8421|Single oral dose of Campylobacter jejuni strain CG8421 in sodium bicarbonate buffer
45393067|NCT02161874|Device|T3 with DCD tapered Prevail implant|T3 with DCD implant with Certain (internal) connection and platform-switch design
45393068|NCT02161874|Device|Nanotite Certain tapered implant|Nanotite (DCD) implant with Certain (internal) connection and non- platform-switch design
45393069|NCT01048190|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
45393070|NCT01048190|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
45393071|NCT01048190|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
45393072|NCT02076698|Procedure|AN-DBS|Electrode and one multichannel stimulator surgical time: 4 to 6 hours 3 visits of adjustment
45393073|NCT02076698|Drug|Usual treatment|usual treatment of epilepsy Vagus nerve stimulation: maintained
45393074|NCT01048268|Drug|glucose-dependent insulinotropic polypeptide|"For the first 20 min of the experiment the volunteers will receive GIP at 4 pmol/kg body weight.~For the following 40 minutes the volunteers will receive 2 pmol/kg body weight"
45393075|NCT01048268|Drug|Placebo|copy GIP infusion rates
45393076|NCT03993236|Drug|Experimental: Rosuvastatin/Ezetimibe 10|"Rosuvastatin/Ezetimibe 10/10mg~orally administered once daily for 90 days"
45393077|NCT03993236|Drug|Active Comparator: Rosuvastatin 20mg|"Rosuvastatin 20mg~orally administered once daily for 90 days"
45393078|NCT00388154|Drug|Gemcitabine|900 mg/m^2 by vein over 1 hour on Day 1 and Day 8.
45393079|NCT00388154|Drug|Cisplatin|30 mg/m^2 by vein over 1 hour on Day 1 and Day 8.
45393080|NCT00387764|Drug|pazopanib|800 mg daily dosing continously until progression
45393081|NCT02535104|Drug|Ranpirnase|Topical application by subject
45393082|NCT02535104|Drug|Vehicle|Vehicle control
45393083|NCT01580930|Behavioral|exercise training|12 weeks, 5 days of week, 40 min per session of exercise training
45393084|NCT01580930|Behavioral|sedentary time reduction|participants provided with strategies to decrease sitting
45393085|NCT01580930|Behavioral|exercsie training plus sedentary time reduction|12 weeks of exercise training (5 days a week, 40 min per session) plus given strategies for reducing sitting time
45393086|NCT01049750|Other|type 2 diabetic patients|males; type 2 diabetic patients
45393087|NCT00386360|Drug|Placebo comparator|oral weekly for one year
45393088|NCT00386360|Drug|risedronate|35 mg risedronate, once a week for one year
45393089|NCT03436940|Other|On Demand Discharge Planning (DDP)|Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team (hospital Continuity of care team) only in case of a specific request by the unit of hospitalization.
45393090|NCT03436940|Other|Routine Discharge Planning (RDP)|All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)
45393091|NCT00369278|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|Tablets for oral administration
45393092|NCT00529373|Drug|Odanacatib|50 mg tablet orally once weekly (OW)
45502880|NCT03134599|Device|methafilcon A - CVI (CooperVision)|contact lens
45393093|NCT00529373|Drug|Placebo for Odanacatib|50 mg tablet orally OW
45393094|NCT00529373|Dietary Supplement|Vitamin D3|5600 IU orally OW
45393095|NCT00529373|Dietary Supplement|Calcium carbonate|If needed. Total daily calcium intake (from both dietary and supplemental sources) will be approximately 1200 mg but not to exceed 1600 mg
45393096|NCT00369122|Biological|Bevacizumab|Given IV
45393097|NCT00369122|Drug|Cisplatin|Given IV
45393098|NCT00369122|Radiation|External Beam Radiation Therapy|Undergo EBRT
45393099|NCT00369122|Radiation|Internal Radiation Therapy|Undergo brachytherapy
45393100|NCT03687125|Drug|Tinostamustine|Participants received tinostamustine IV injection.
45393101|NCT03687125|Procedure|Autologous Stem Cell Transplant (ASCT)|Undergo autologous stem cell transplant
45393102|NCT03999203|Drug|Citric acid|Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients
45393103|NCT03999203|Device|Leicester Cough monitor|Ambulatory cough monitor to assess cough frequency over a 24 hour period
45393104|NCT03999203|Other|fractional exhaled nitric oxide testing (FeNO)|Measurement of exhaled nitric oxide to give an indication of airway inflammation
45393105|NCT03999203|Other|Patient reported outcome measures|A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)
45393106|NCT03999281|Other|Human Allograft (Theraskin)|Biologically active cryopreserved human skin allograft (Theraskin) was used on both cohorts, both diabetic foot ulcer and venous leg ulcer.
45393107|NCT05000489|Other|No intervention being administered|No intervention will be administered. Each patient will participate in a qualitative focus group discussing their beliefs/attitudes about their reproductive health and birth control
45502881|NCT02062190|Drug|resveratrol|"100mg 2x/day~1 month"
45393108|NCT04854395|Drug|Marcain 5 mg/ml|Total volumes of Marcain differs in each arm, depending on which nerve blocks the patients is randomized to receive. Sham block does not include injection of placebo saline, due to the risk of hydrodissection between the anatomical sections which may erase the isolation of the different nerve blocks. Instead the sham block include imitation of the real nerve block, including correct placement of the needle on the target for the block.
45393109|NCT05221931|Procedure|Percutaneous coronary intervention|1:1 randomization to DES (Ultimaster Tansei) or DCB (SeQuent Please, SeQuent Please NEO [B-Braun, Germany], or Agent [Boston Scientific, USA])
45393110|NCT04927247|Drug|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
45393111|NCT04927247|Drug|Placebo|Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug.
45393112|NCT05173493|Drug|Amoxicillin,Furazolidone|Amoxicillin-Furazolidone-containing quadruple group
45393113|NCT05173493|Drug|Amoxicillin,Levofloxacin|Amoxicillin-Levofloxacin-containing quadruple group
45393114|NCT05173493|Drug|Tetracycline,Furazolidone|Tetracycline-Furazolidone-containing quadruple group
45393115|NCT04907513|Other|Assessment of the Motivational State|A motivational interviewing algorithm developed in Rothschild Hospital for this study will be used. The results range between 0% (worst motivational state) to 100% (best motivational state).
45393116|NCT04886063|Drug|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
45393117|NCT05163821|Diagnostic Test|Manchester Somali Cognitive Assessment Tool|Cognitive screen for dementia
45393118|NCT05163821|Diagnostic Test|ACE-III Somali Translation|Cognitive screen for dementia
45393119|NCT03872843|Drug|Norco 5milligram-325milligram Tablet|Designated coated 7 days supply of pain medication (Norco 5 milligram-325milligram Tablet) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times per day until the stent will be removed in clinic a week later.
45393120|NCT03872843|Drug|Ibuprofen 400 MILLIGRAM in 1 TABLET ORAL TABLET, FILM COATED|Designated coated 7 days supply of pain medication (Ibuprofen 400 milligram) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times a day as needed until the stent will be removed in clinic a week later.
45393121|NCT00146770|Biological|Aldurazyme|Placebo for 26 weeks then 0.58 mg/kg Aldurazyme every week for 182 weeks
45393122|NCT00146770|Biological|Aldurazyme|0.58 mg/kg Aldurazyme every week for 208 weeks
45393123|NCT00146770|Biological|placebo|Placebo for 26 weeks
45393124|NCT03874013|Drug|MOD-4023|"MOD-4023 is a long-acting modified recombinant human growth hormone (r-hGH) which utilizes C-terminal peptide (CTP) technology. It will be provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a multi-dose disposable pre-filled PEN.~MOD-4023 will be administered as a SC injection once weekly, using a delivery device."
45393125|NCT03874013|Drug|Genotropin|"Genotropin® is dispensed in a 2-chamber cartridge. The front compartment contains recombinant somatropin, glycine, mannitol, sodium dihydrogen phosphate anhydrous and disodium phosphate anhydrous. The rear compartment contains m-Cresol and mannitol in water for injections.~A delivery device (Genotropin®) will be used for daily (evening/bedtime) SC administration of Genotropin® into the region of the upper arms, buttocks, thighs or abdomen (8 locations). Injection sites should be rotated.~Dose regimen for Genotropin®: 0.025 mg/kg/day (or 0.175 mg/kg/w divided equally to 7 injections over a week)."
45393126|NCT03967678|Dietary Supplement|Three portions per week (690g beef (raw weight)) for 5 weeks|Lunches served in Human Intervention Studies Unit
45393127|NCT04815239|Behavioral|Interpersonal and Social Rhythm Therapy (IPSRT)|Interpersonal and Social Rhythm Therapy (IPSRT) is an evidence-based treatment for BP adults that prevents or delays mood episodes by stabilizing sleep and daily routines.
45393128|NCT04815239|Behavioral|The Healthy Lifestyle Behavior Intervention (HL)|HL includes structured psychoeducational modules that aim to teach patients about health risks and help them achieve a balanced lifestyle to optimize physical and mental health.
45393129|NCT03966040|Biological|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7|36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7
45393130|NCT03966040|Biological|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7|36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7
45393131|NCT03966040|Biological|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7|36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7
45393132|NCT03966040|Biological|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14|36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14
45393133|NCT03999125|Drug|Aflibercept,|Primary therapy will be with Aflibercept. If the edema does not respond to the intervention, the patient will be treated with Ranibizumab, Dexamethasone Implant or Laser.
45393134|NCT03999125|Drug|Ranibizumab Injection|Primary therapy will be with ranibizumab. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Dexamethasone Implant or Laser.
45696843|NCT01678599|Drug|Benznidazole|All patients participating in this study will be treated with Benznidazole, 5mg/Kg/day PO BID for 60 days with a maximum daily dose of 300mg, as per routine care provided by MSF in rural communities in Aiquile. For patients > 60 kg, the total dose should be calculated (5mg/Kg x Weight x 60 days) and treatment duration should be adjusted/prolonged accordingly. This treatment is in accordance with the local recommendations from the Ministerio de Salud y Deportes de Bolivia.
45696844|NCT03445221|Dietary Supplement|IV Immunonutrition|patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 3 days before surgery.
45696845|NCT03445221|Dietary Supplement|Conventional Diet|patients will continue preoperative oral conventional diet.
45393135|NCT03999125|Drug|Ozurdex Drug Implant Product|Primary therapy will be with Ozurdex. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Ranibizumab or Laser
45696846|NCT03019822|Drug|LSD|100ug per os, single dose
45696847|NCT03019822|Drug|MDMA|125mg per os, single dose
45393136|NCT01077778|Procedure|Gadolinium-enhanced Magnetic Resonance Imaging|Gadolinium-enhanced Magnetic Resonance Imaging
45393137|NCT05092139|Device|endovascular treatment|all enrolled patients must receive endovascular treatment
45393138|NCT05085119|Procedure|Stepwise modifications of FiO2|FiO2 will be increased stepwise from 30 to 100% (40, 60 and 80%), and then decreased with the same FiO2 reverse steps.
45696848|NCT03019822|Drug|Amphetamine|40.3mg per os, single dose
45393139|NCT00168064|Drug|mechlorethamine-MCH (nitrogen mustard)|All affected areas (lesions) are to be treated once daily for twelve months with mechlorethamine-MCH (nitrogen mustard) 0.02% PG or NM 0.02% AP ointment
45393140|NCT04901507|Device|The Voutia System|Participants will wear the Voutia System oral irrigation device continuously through the day and night, removing for cleaning and if otherwise necessary, but not for time extending beyond six-eight hours.
45696849|NCT03019822|Drug|Placebo|Capsules containing mannitol looking identical to the other drugs
45393141|NCT00166114|Drug|Escitalopram|10 mg of Escitalopram, and titrated up to 20 mg of Escitalopram after day 22 of intervention
45393142|NCT00166114|Drug|Desipramine|25 mg of Desipramine for day 1-3, 50 mg of Desipramine for day 4-7, 75 mg of Desipramine for day 8-14, 100 mg of Desipramine for day 15-21. Titrated between 125 mg to 200 mg of Desipramine for day 22-56 of intervention
45393143|NCT03686969|Drug|Octanorm|Octanorm 0.5g/kg/week
45393144|NCT03686969|Other|Placebo|Placebo
45393145|NCT05035901|Other|visual-perception motor-coordination integration program|Visual-perception motor-coordination integration program (CCVPMCI) is a Chinese characteristic-based VMI-focused program involving the most Chinese-handwriting-related skills training. CCVPMCI mainly emphasizes the training role of visual-motor integration. The idea of CCVPMCI program will involve (1) visual motor integration training affiliated with visual perception and motor coordination as warm-up exercise, (2) more focus on visual spatial perception in connect with unique visual structure of Chinese characters, (3) the trace or component elements of Chinese characters as the interesting practice material and (4) appropriate challenge for learning.
45393146|NCT00145600|Drug|12 Week Stanford V Chemotherapy|12 weeks of Stanford V chemotherapy plus low-dose, involved-field RT in children
45393147|NCT00145600|Drug|4 cycles of VAMP chemotherapy|4 cycles of VAMP chemotherapy alone in patients who achieve a complete response after 2 cycles of VAMP chemotherapy. For patients that do not achieve a complete response after 2 cycles of VAMP, they will receive low low-dose involved field radiotherapy at the end of all chemotherapy.
45393148|NCT00145600|Drug|2 alternating cycles of VAMP/COP chemotherapy|2 alternating cycles of VAMP/COP chemotherapy (total 4 cycles of chemotherapy) plus low-dose, involved-field RT.
45393149|NCT00145600|Drug|3 alternating cycles of VAMP/COP chemotherapy|3 alternating cycles of VAMP/COP chemotherapy (total 6 cycles of chemotherapy) plus low-dose, involved-field RT
45393150|NCT05032781|Drug|Intra-arterial cold saline, minocycline, and magnesium|See study design
45393151|NCT00991601|Procedure|FNAC (fine needle aspiration cytology)|UL guided biopsy
45393152|NCT04003415|Device|Investigational Device: Contactless heart rate and respiratory rate monitor|Participant will be seated next to the investigational device. The device is contactless, and will measure the patient's heart rate and respiratory rate through use of radio-waves.
45393153|NCT04003415|Diagnostic Test|Heart Rate (EKG) Monitor|Participant will undergo 3-lead EKG testing to measure heart rate during testing.
45393154|NCT04003415|Diagnostic Test|Respiratory rate Monitor|Participant will have an elastic band around their chest for monitoring respiratory rate during testing.
45393155|NCT04003415|Diagnostic Test|Pulse Oximetry|Participants will wear a finger pulse oximeter during the testing for monitoring of heart rate, respiratory rate, and pulse oximetry.
45393156|NCT03968380|Other|Population survey with biological and physical measurements.|Individuals will be interviewed in their homes by trained interviewers. At a later date, in a location agreed with the study team, a sample of blood will be taken and we will measure fasting glucose, cholesterol level and creatinine. We will measure participants' height, weight, waist circumference and blood pressure. An Oral Glucose Tolerance Test (OGTT) will be performed on non-diabetic and/or non-pregnant participants.
45393157|NCT00129376|Drug|Doxorubicin|
45393158|NCT00129376|Drug|Cyclophosphamide|
45696850|NCT01678677|Biological|NTHI vaccine GSK2838500A (formulation 1)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
45696851|NCT01678677|Biological|NTHI vaccine GSK2838501A (formulation 2)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
45696852|NCT01678677|Biological|NTHI vaccine GSK2838502A (formulation 3)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
45696853|NCT01678677|Biological|NTHI vaccine GSK2838503A (formulation 4)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
45393159|NCT00129376|Drug|Docetaxel|
45393160|NCT05359289|Behavioral|Forest therapy training|Participants will experience nature-based interventions including forest hiking, horticultural therapy and green wellness activities for their mental health and physical conditions.
45393161|NCT05359289|Behavioral|Senior fitness training|The fitness program includes physics fitness of stamina, coordination and aerobic exercise in 12 weeks. Participants will join the senior fitness program including physical fitness, aerobic exercise and exercise prescription during the 12 weeks program.
45393162|NCT05359289|Behavioral|Board Games|Participants will play board games with each other.
45393163|NCT04878107|Drug|Camrelizumab|Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd
45393164|NCT04878107|Drug|Apatinib|Apatinib [Aitan® (brand name in China)], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor
45393165|NCT04878107|Drug|Docetaxel injection|"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug"
45393166|NCT04878107|Radiation|SBRT|Stereotactic body radiation therapy (SBRT) is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue. SBRT involves the use of sophisticated image guidance that pinpoints the exact three-dimensional location of a tumor so that the radiation can be more precisely delivered to cancer cells.
45393167|NCT04878107|Radiation|LDRT|low dose radation therapy
45393168|NCT03998969|Drug|Pantoprazole|Pantoprazole 40mg tablet
45393169|NCT03998969|Drug|DA-5204|DA-5204 tablet
45393170|NCT03998969|Drug|Placebo|Film-coated tablet manufactured to mimic DA-5204
45393171|NCT01564043|Behavioral|website and pedometer|use of pedometer and website
45393172|NCT04708847|Drug|GYM329|GYM329 subcutaneous injection
45393173|NCT04708847|Drug|Placebo|Placebo subcutaneous injection
45393174|NCT01564667|Behavioral|Attention Bias Modification Training Protocol|Attention Bias Modification computerized training sessions administered 2 times per week for 4 weeks making a total of 8 training sessions.
45696854|NCT01678677|Biological|NTHI vaccine GSK2838504A (formulation 5)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
45696855|NCT01678677|Biological|NTHI vaccine GSK2838505A (formulation 6)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
45696856|NCT01678677|Biological|NTHI vaccine GSK2838508A (formulation 7)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
45393175|NCT01564745|Other|Functional respiratory evaluation|Each enrolled patients has a pulmonary function test before and after extubation, and repeatedly at D1, D3, D5 (if they are always hospitalized)
45393176|NCT04658381|Genetic|Genetic analysis|Patient exome sequencing will be performed by Illumina technology on the NextSeq 550 sequencer. Briefly, the exons of the genes are selected by capture and are amplified by PCR simultaneously, in a single reaction, and then sequenced by Illumina technology. The analysis will only concern genes involved in albinism and in genetic pathologies associated with fovea plana.
45393177|NCT04658381|Procedure|Ophthalmologic exam|Standard ophthalmologic assessment (measurement of visual acuity, measurement of intraocular pressure, slit lamp examination), OCT-B scan, OCT-Angiography, Adaptive optics
45393178|NCT00129220|Drug|olanzapine|5-20 mg, oral, once daily (evening), for 6 weeks
45696857|NCT01678677|Biological|NTHI vaccine GSK2838509A (formulation 8)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
45696858|NCT01678677|Drug|Placebo comparator|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
45696859|NCT03019978|Other|PCAMS assessments|This is a longitudinal study, where data will be collected from 54 individuals who are already enrolled in Pennsylvania's ACAP program. Participants will be required to complete online assessments at baseline and then quarterly over a two-year time period.
45696860|NCT03443193|Other|Exercise training|Patients will undergo three weekly exercise training sessions with periodized high-intensity interval training and resistance training for a period of 12 weeks.
45696861|NCT03019900|Procedure|Red blood cells transfusions|The survey was designated to assess the practices of blood transfusion, specifically about the threshold and factors that can modify this threshold.
45393179|NCT00129220|Drug|haloperidol|2.5-10 mg, oral, twice daily (morning and evening), for 6 weeks.
45393180|NCT00129220|Drug|placebo|placebo, oral tablets, twice daily (morning and evening), for 3 weeks
45393181|NCT04640051|Procedure|LAAO|LAAO by use of 3D in silico simulation by FEops HEARTguide as part of the pre-procedural assessment and device size selection
45393182|NCT04638413|Behavioral|Walking (W)|Participants engage in 30 min of walking daily, for three weeks.
45393183|NCT04638413|Behavioral|Walking + PolyRules! (W+PolyRules!)|Participants alternate between 30 min of walking on half of the days and 30 min of gamified inhibitory control on the other days.
45393184|NCT03686813|Drug|Sildenafil Citrate|Oral sildenafil, 50 mg
45696862|NCT03019432|Behavioral|Observational clinical assessment|perception of verticality measures SVV and SPV; somatosensory assessment RASP
45696863|NCT00946348|Drug|Dronabinol|Dronabinol 10 mg or 15 mg
45696864|NCT00946348|Drug|Cannabis|Cannabis cigarette
45393185|NCT03686813|Drug|Placebo Oral Tablet|Placebo
45393186|NCT01074814|Drug|(will be assigned based on molecular profile and RPMA)|treatment will be assigned based on IHC< FISH, DNA microarray and RPMA results
45393187|NCT04003259|Behavioral|Lifestyle management programme|The programme consisted of 1) the initiation phase (1-3 months), 2) the establishment phase (3-6 months), and 3) the maintenance phase (7-12 months). Guidance was given altogether on 25 separate occasions with special emphasis on the motivation and education. The goal for weight loss was 5-10 %. The programme included four visits by medical doctor, an educational lecture by medical doctor and personal trainer, five sessions by registered dietician, two cooking classes by professional chef, two group discussions, and exercise as follows: personalized exercise program tailored by personal trainer, one-year gym access with four guided group sessions, and two guided group Nordic walking sessions, and three individual exercise sessions by personal trainer.
45393188|NCT00128830|Drug|Etravirine (ETR)|Participants will receive 800 mg of ETR (2 x 4 tablets of formulation TF035) twice daily and after the formulation switch they will receive 200 mg of ETR (2 x 2 tablets of formulation F060) twice daily until the participants benefitted from etravirine or it became comercially available.
45393189|NCT00128830|Drug|Nucleotide reverse transcriptase inhibitors (NRTIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
45393190|NCT00128830|Drug|Protease inhibitors (PIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
45393191|NCT00128830|Drug|Enfuvirtide (ENF)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
45393192|NCT01074892|Drug|Provera (medroxyprogesterone/progestin)|10 mg tablet, 1 tablet per day taken 10 days per month Duration is 6 months
45393193|NCT01074892|Drug|Provera (medroxyprogesterone)|10 mg per oral tablet. One tablet per day for 6 months
45393194|NCT01074892|Device|Mirena (levonorgestrel)|Inserted in the uterine cavity and kept in situ for 6 months
45393195|NCT03686033|Drug|Placebo|Participants will receive E2082-matched placebo tablets orally.
45502882|NCT05128539|Drug|JS001(Toripalimab)+JS002|"Part A: In this phase, 3 dose levels will be preliminarily set up. The dose level of Toripalimab is fixed as 240 mg, intravenous infusion, Q3W. The dose levels of JS002 are fixed at 75 mg,150 mg and 300 mg subcutaneously, and the traditional 3+3 design will be used for dose escalation with 21 days as entire treatment cycle. In addition, the period of 21 days after the first administration is defined as the DLT observation period.~Part B: Based on the data of the safety, PK and preliminary efficacy in Part A patients, the dosage will be determined for advanced tumor patients who had received at least first-line therapy in this part. Two to three groups with different tumor types will be further enrolled, and about 30 patients will be included in each group (the specific number and cohort will be adjusted according to the research progress). Toripalimab is a humanized IgG4κ mAb specific against human PD-1."
45696865|NCT00081159|Drug|Doxorubicin hydrochloride|Doxorubicin 20 mg/m^2 is administered intravenously either over 15 to 30 minutes via a peripheral line or over 24 hours via a central line on days 1, 8, and 15 every 28 days for 2 cycles.
45696866|NCT00081159|Drug|Goserelin acetate|
45393196|NCT03686033|Drug|E2082|Participants will receive E2082 tablets orally.
45393197|NCT00128206|Drug|Isoniazid|Isoniazid 900 mg twice weekly
45393198|NCT00128206|Drug|Rifampin|Rifampin 600mg once per day
45393199|NCT01075828|Drug|Cetuximab|Subjects will be treated according to the national label of cetuximab in combination with radiation therapy.
45393200|NCT01565057|Other|sedimenting meal|The active system quickly forms a sedimenting layer of small particles that contain most of the caloric content of the system. This system is made by adding finely grated cheese (particle size 0.5-2 mm) to yoghurt and consumption is followed by drinking 327 ml water.
45393201|NCT01074970|Drug|Cisplatin|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
45393202|NCT01074970|Drug|Rucaparib|Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles
45393203|NCT01074970|Drug|Cisplatin|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
45393204|NCT03685643|Behavioral|Intervention - Dating application topic|The intervention will consist of multimedia content to promote the safe usage of dating applications and raise awareness of the risks associated with dating application usage. The intervention will be delivered one-time in a classroom setting.
45393205|NCT03685643|Behavioral|Control - Health and exercise topic|The placebo control will consist of multimedia content regarding exercise and healthy living. It will be delivered once-time in a classroom setting.
45426203|NCT05794425|Biological|Umbilical cord blood & Umbilical cord derived mesenchymal stem cells|Intravenous infusion of umbilical cord blood and umbilical cord derived mesenchymal stem cells (5-8×10^7) at 1 week interval.
45502883|NCT01319071|Other|Blood sample|Extraction of blood sample from top-level athletes
45502884|NCT05601752|Genetic|Autologous genetically modified ADP-A2M4CD8 cells|Infusion of autologous genetically modified ADP-A2M4CD8 cells on Day 1
45502885|NCT05601752|Combination Product|Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 followed by nivolumab 480 mg IV at Week 4 and then every four weeks
45696867|NCT00081159|Drug|Leuprolide acetate|
45393206|NCT03968146|Procedure|Erector Spinae Plane Block|The linear multi-frequency 6-13 megahertz transducer will be used. In the prone position,under aseptic conditions, the probe will be placed in a longitudinal position 2-3 cm lateral to the vertebral column. The transverse processes of the vertebrae at (mid) level of surgery, the Erector Spinae muscle and the psoas muscle are identified. A 22 gauge echogenic needle will be inserted in an in plane technique in a cephalad to caudad direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, A test dose of 5% dextrose in water can expand the fascial plane and confirm needle-tip location prior to injection of local anaesthetic. Then, 0.5 ml/kg of bupivacaine 0.25% with 0.1 mg/kg dexamethasone and adrenaline 1 : 200000 will be injected between erector spinea muscle and transverse process, taking in consideration not exceeding the toxic dose of bupivacaine; 4 mg/kg . the same procedure will be repeated on the contralateral side.
45393207|NCT03968146|Drug|Fentanyl|patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
45393208|NCT03968146|Drug|additional Fentanyl|patients will receive another dose of fentanyl 1 µg/kg 1 minute before start of skin incision.
45393209|NCT03968146|Drug|Morphine|After end of surgery and emergence from anesthesia, patients will receive continuous intravenous morphine with 0.03 mg/kg/hr.
45393210|NCT03968146|Drug|rescue Morphine|Morphine IV will be given as rescue analgesia (20 µg/kg) in all study groups if VAS pain score more than 3. The total maximum hourly morphine is 0.75 mg/kg/hr.
45393211|NCT03968146|Drug|pethidine|After reaching maximum hourly morphine and the patient is still in pain, pethidine will be used as a rescue at 0.5 mg/kg.
45393212|NCT03968146|Drug|Ketorolac|patients will receive IV ketorolac from the postoperative second day 15 mg q 6 hours, not to exceed 5 days.
45393213|NCT03968146|Drug|Acetaminophen|patients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
45393214|NCT03966118|Drug|Avelumab|Avelumab 1mg/kg Day 1 and Day 15 of a 28-day cycle
45393215|NCT03966118|Drug|Ramucirumab|Ramucirumab 8mg/kg on Day 1 and Day 15 of a 28-day cycle
45393216|NCT03966118|Drug|Paclitaxel|Paclitaxel 80mg/m2 on Day 1, Day 8 and Day 15 of a 28-day cycle
45393217|NCT03968224|Drug|Dapagliflozin/Metformin|Two tablets of Metformin 850 mg every 12 hours will be provided in combination with Dapagliflozin 10 mg per day. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.
45393218|NCT03968224|Drug|Metformin|Two tablets of Metformin 850 mg every 12 hours will be provided. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.
45393219|NCT01075126|Drug|Depakote|
45393220|NCT01075126|Drug|Lithium|
45393221|NCT03823378|Drug|Elsubrutinib|Elsubrutinib capsule will be administered orally.
45393222|NCT03823378|Drug|Upadacitinib|Upadacitinib tablet will be administered orally.
45393223|NCT03823378|Drug|Placebo for elsubrutinib|Placebo capsule for elsubrutinib will be administered orally.
45502886|NCT03618498|Procedure|ILM flaps insertion techniques or free ILM flaps.|The ILM flap anchoring on the hole edge was inverted and covered the hole.Otherwise, temporal side ILM flap was used. However, if the risk of ILM flipping back was judged to be high, ILM insertion instead of ILM hole coverage was adopted.If the size of the ILM flaps was judged inadequate, the double ILM insertion technique was used, done by adding a piece of previously obtained free ILM flap on top of the inverted ILM tissue until they were securely in place.
45502887|NCT05109273|Procedure|Transcatheter ablation|Three-dimensional electroanatomic mapping and radiofrequency ablation with irrigated catheter
45696868|NCT00081159|Drug|Zoledronic acid|4 mg given intravenously over 15 minutes every 28 days for a total of 6 doses.
45696869|NCT00081159|Procedure|orchiectomy|
45696870|NCT00081159|Radiation|strontium chloride Sr|1 dose of strontium-89 (4 millicurie (mCi) total dose) administered intravenously on the first day of treatment
45696871|NCT03033550|Behavioral|brief negotiated mobile application|The intervention will supplement the standard of care with the following steps: (1) mobile- based brief negotiated Intervention ( BNI); (2) a customized companion communication vaccine report to be given before AFG sees provider; and (3) automated interactive Electronic Recall/Reminder Messages (Text messaging), including text messaging and access to a website which includes information about HPV, HPV Vaccine, and cervical cancer screening guideline.
45696872|NCT03033706|Procedure|Pulse pressure variation guided fluid therapy|Pulse pressure variation obtained from invasive blood pressure waveform
45393224|NCT03823378|Drug|Placebo for upadacitinib|Upadacitinib placebo tablet will be administered orally.
45393225|NCT00142792|Device|NMES device with EMG-triggered and Cyclic capabilities|All groups will use the NeuroMove NM900 stimulator. Subjects will use the stimulator as described for their group (treatment arm) for two 40-minute sessions per day, 5 days per week for 8 weeks. Surface electrodes for all three groups will be placed over the affected EDC and ECR (finger and wrist extensor) muscles.
45393226|NCT02531620|Other|Physiatry Assessment|Physiatrists are physicians who are medical experts in maximizing a patient's overall ability to function well and live independently. The Investigators are proposing your participation in an initial pilot study in order to test the question as to whether or not participation with a physiatrist and any interventions recommended by said physician would help improve a patient's postoperative recovery.
45393227|NCT02531620|Other|Routine Care|Usual care for your disease process
45393228|NCT00141778|Drug|Placebo|Matching placebo taken once a day
45393229|NCT00141778|Drug|Ramipril|Taken orally, once a day
45393230|NCT00141778|Drug|Spironolactone|Taken orally, once a day
45393231|NCT03967132|Other|Control Infant Formula|Ready to feed infant formula, feed ad libitum
45393232|NCT03967132|Other|Experimental Infant Formula|Ready to feed infant formula, feed ad libitum
45393233|NCT03967132|Other|Reference Group|Human milk, breast feeding ad libitum
45393234|NCT00127660|Behavioral|Menu: calories=yes, value pricing=no|
45393235|NCT00127660|Behavioral|Menu: calories=yes, value pricing = yes|
45393236|NCT00127660|Behavioral|Menu: calories=no, value pricing = no|
45393237|NCT01077934|Device|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
45393238|NCT03817528|Drug|ITI-007|ITI-007 (Lumateperone tosylate)dosed 40-60 mg based on efficacy/adverse events
45393239|NCT01078012|Behavioral|Trained counselling|
45393240|NCT01326520|Dietary Supplement|milk phospholipid|The patients will consume daily 250 mL of a dairy product, which is enriched with 3 g of milk phospholipids.
46056926|NCT02694081|Procedure|Billroth II Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
45393241|NCT01326520|Dietary Supplement|diary product|The patients will consume daily 250 mL of a common dairy product.
45393242|NCT01079884|Drug|esomeprazole 40 mg|40 mg daily for 4 weeks
45393243|NCT03965884|Other|Physical therapy and rehabilitation|Physical therapy and rehabilitation
45393244|NCT03965806|Behavioral|SURVEY|SURVEY
45393245|NCT01075906|Drug|colchicine sprinkle capsules|0.3 mg
45393246|NCT01075906|Drug|colchicine sprinkle capsules|0.3 mg
45393247|NCT01076062|Procedure|Induction of Labor|If cervical foley bulb placement is possible, the foley bulb will remain in place until either spontaneously removed or after 12 hrs, whichever is earlier. If placement is not possible, cervical ripening with misoprostol 25 micrograms (mcg) per vagina every 4 hrs (max of 4 total doses) will be initiated. Cervical examination will occur every 4 hr. Repeat doses of misoprostol will be given only if foley bulb placement is not possible and/or if palpably firm uterine contractions are less than 6 in 10 min in consecutive 10 min intervals. Once placement of a cervical foley bulb can be performed, oxytocin administration will begin at 2 mIU/min and increasing by 2 mIU/min every 20 min to ensure adequate contractions (maximum oxytocin infusion rate 36 mIU/min). Adequate contractions will be defined as 7 contractions in 15 min in consecutive 15 min intervals that palpate moderate to firm. Oxytocin infusion will begin not earlier than 4 hrs after the last misoprostol dose (if given).
45696873|NCT03033706|Procedure|Traditional fluid therapy|4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.
46056927|NCT02722005|Behavioral|Financial Coaching|One-to-one financial coaching focused on credit, debt, savings, and income supports.
46056928|NCT02722005|Behavioral|Access to referral to social services|Access to referral to a host of social services.
46056929|NCT02721927|Other|Syrian Refugees|Adult Syrian patients who visited the Emergency Department
45393248|NCT00115336|Drug|Intravenous Ketorolac|Intravenous ketorolac
45393249|NCT00115336|Drug|Ibuprofen|Ibuprofen, taken orally
45393250|NCT01076140|Drug|Nebivolol|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
45393251|NCT01076140|Drug|Lisinopril|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
45393252|NCT00205803|Biological|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
45393253|NCT00205803|Biological|7-Valent Pneumococcal Conjugate Vaccine (7vPnC)|
45393254|NCT01076218|Device|FreeStyle Navigator Continuous Glucose Monitoring System Version 1.5|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration.
45393255|NCT03974373|Procedure|BFP removal|The surgical procedure was performed using the technique with intrabuccal access, already consecrated in the literature (Materasso 2006). The Bichat fat ball access was made by means of a small incision no more than 3 mm in length in the soft tissue located in the lower aspect of the zygomatic counterfoot, taking care to visualize and protect with the retractor the Stensen's conduit. With the aid of blunt-tipped or hemostatic scissors dissection was performed, taking care to preserve the membrane surrounding the ball of fat. After removal of one side, pressure was removed to remove air and the procedure was started on the opposite side, after the removal of the two sides was realized simple suture with silk thread. There were no formal indications for sending the samples for anatomic and / or histological examination.
45393256|NCT00127192|Drug|sitagliptin phosphate|sitagliptin phosphate 25 mg, 50 mg, 100 mg QD, or 200 mg QD 12-weeks.
45696874|NCT03033706|Procedure|Brain tumor excision|Brain tumor excision under general anesthesia
46056930|NCT02721849|Behavioral|Yoga for adolescents|12 week hatha yoga course for adolescents
46056931|NCT02721849|Behavioral|Yoga for parents|12 week hatha yoga course
46056932|NCT05201079|Biological|MBK-01|A single dose of 4 capsules of MBK-01 (heterologous lyophilized fecal microbiota coming from healthy donors) orally.
45393257|NCT00127192|Drug|Comparator: placebo (unspecified)|placebo QD 12-weeks
45393258|NCT00205179|Drug|Novasoy|100mg/day soy isoflavones
45502888|NCT02060708|Device|HD-tDCS|HD-tDCS non-invasive brain stimulation using this same device (Soterix) has been designated a 'non-significant risk' by the US FDA.
45393259|NCT00205179|Drug|Placebo|100mg/day matching placebo
45393260|NCT03973125|Drug|conbercept|After three monthly injections of conbercept, if no effects was seen in the patients, the patients will receive rescue treatments such as photodynamic therapy (in the macular) or laser photocoagulation (outside the macular).
45393261|NCT00127036|Drug|XELOX|XELOX: Oxaliplatin 130 mg/m^2 intravenously (IV); Capecitabine 825 mg/m^2 by mouth (po)
45393262|NCT00127036|Drug|XELIRI|XELIRI: Irinotecan 240 mg/m^2 IV; Capecitabine 825 mg/m^2 by mouth (po)
45393263|NCT00127036|Drug|Bevacizumab|7.5 mg/kg intravenously (IV)
45393264|NCT00259857|Drug|Alendronate|Group-1/Year-1:Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight, for 12 months. Group-1/Year-2:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-1:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-2: Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months.
45393265|NCT02531919|Drug|Sodium Bicarbonate|Given PO
45393266|NCT01071681|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
45393267|NCT01072851|Behavioral|Multimedia Education|A four minute exposure to an educational video with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
45393268|NCT01072851|Behavioral|Print Media|Exposure to a printed brochure with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
45393269|NCT01072851|Behavioral|Usual and customary waiting room process|No specialized educational intervention to promote colorectal cancer screening or to explain the process
45502889|NCT04194606|Procedure|Use of radial artery for access for a coronary angiography or intervention|After puncture of the radial artery in either the area of the anatomical snuffbox or the lower forearm following modified Seldinger technique a sheath will be advanced and a CAG or PCI will be performed. After the procedure is finished the sheath will be withdrawn and a standard closure device will be applied to achieve hemostasis. The choice of the patients side, the sheath, the catheters and the closing device will be at the discretion of the interventionalist.
45502890|NCT05211531|Other|Measuring number of post-operative steps|Measuring the number of post-operative steps that inpatients take.
45502891|NCT01354483|Biological|Umbilical Cord Blood Mononuclear Cell|
45502892|NCT01354483|Biological|Methylprednisolone|30mg/kg i.v. methylprednisolone
45393270|NCT00203307|Drug|Olanzapine during first intervention period and placebo during second intervention period|Olanzapine (5-10 mg) daily during first intervention period, then placebo(matching)druing second intervention period (after a washout period)
45393271|NCT00203307|Drug|Placebo during first intervention period, then olanzapine during second intervention period|Placebo (matching) during first intervention period, then olanzapine (5-10 mg. daily) during the second intervention period (after a washout phase).
45502893|NCT01354483|Drug|Lithium Carbonate Tablet|6 weeks
45502894|NCT02061410|Device|Neuromuscular Electrical Stimlation (NMES)|The intervention was performed with subjects seated on a regular chair (hip and knee angles maintained at approximately 908), 3 times/week for a period of 8 weeks. NMES parameters included: rectangular biphasic symmetric current, pulse duration of 400 ms and stimulation frequency of 80 Hz.
45502895|NCT03617952|Behavioral|P3 Bio Intervention|Two types of improved biomass burning cookstoves (ACE1 and Greenway Jumbo) are offered to participants in both arms at varying prices.
45696875|NCT03033472|Drug|600 mg Clindamycin orally|600 mg Clindamycin orally 30 minutes before treatment
45696876|NCT03033472|Drug|Oral Placebo|Oral Placebo 30 minutes before treatment
46056933|NCT05201079|Drug|Dificlir|Oral administration of 200mg/12 hours of fidaxomicin for 10 days.
45393272|NCT01581801|Procedure|Gastric Bypass|"Roux-en-Y Gastric Bypass This laparoscopic operation includes the division of the stomach in two parts. A proximal, smaller pouch (20-25 cc volume), is connected to the rest of the gastrointestinal tract through a gastro-jejunal anastomosis, whereas the distal gastric pouch is left behind but excluded from the transit of food.~An entero-entero anastomosis, with a Roux-en-Y type of reconstruction, allows the bile and pancreatic juices to mix with the nutrients at about 100-150 cm from the gastro-jejunal connection."
45502896|NCT05211453|Procedure|atrioventricular node ablation|atrioventricular node ablation
45696877|NCT01679067|Procedure|colonoscopy with endoscopic biopsies|
46056934|NCT02721693|Device|Treadmill exercise test|Patients are subjected to an incremental exercise test to exhaustion on a treadmill
45393273|NCT01581801|Procedure|Sleeve Gastrectomy|Sleeve gastrectomy Laparoscopic SG involves a longitudinal resection of the stomach on the greater curvature from the antrum starting opposite of the nerve of Latarjet up to the angle of His The final gastric volume is about 100 mL.
45393274|NCT00126568|Drug|sorafenib tosylate|Given orally
45393275|NCT00114634|Dietary Supplement|Egg yolk preparation with cholesterol|Egg yolk preparation with cholesterol
45393276|NCT00114634|Dietary Supplement|Egg substitute, without cholesterol|Placebo control. Egg substitute, without cholesterol
45393277|NCT00202839|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program
45393278|NCT00202839|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program followed by 1.2 to 1.5 microgram/kg weekly for 24 weeks during the extended treatment program
45393279|NCT00202839|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program
45393280|NCT00202839|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program and for 24 weeks during the extended treatment program
45393281|NCT00201201|Other|Education Intervention|Adults aged 60 and over with hypertension were randomized to usual care and intervention groups. Both groups entered medication taking behaviors on the PEP-NG and answer questions related to knowledge and self-efficacy regarding adverse self-medication behaviors. The education intervention group received a tailored education program.
46056935|NCT02721771|Procedure|Ultrasound examination|echocardiographic diastology and bilateral B-line pattern will be assessed. Optic nerve sheath diameter will be assessed.
45393282|NCT00201201|Other|Control|Control group receiving care as usual after interfacing with the surveys on the PEP-NG
45393283|NCT00126490|Biological|Aldesleukin|Given subcutaneously
45393284|NCT00126490|Biological|Bevacizumab|Given IV
45393285|NCT00126490|Other|Laboratory Biomarker Analysis|Correlative studies
45393286|NCT00346632|Drug|KW-2449|Sequential ascending oral doses of KW-2449 given for 14 or 28 days (modified by protocol amendment to only 14 days dosing).
45502897|NCT03560726|Behavioral|Cognitive Behavioral Stress Management|Cognitive behavioral stress management is a well-established, practical intervention that combines elements of cognitive behavioral therapy with techniques designed to improve coping skills, social support, communication, and relaxation/mindfulness.
46056936|NCT00736645|Dietary Supplement|selenomethionine|Given orally
46056937|NCT00736645|Drug|finasteride|Given orally
45393287|NCT00200967|Drug|salmeterol|50 micrograms (mcg) twice per day (BID) (Serevent 50 mcg diskus, GlaxoSmithKline (GSK), North Carolina)
45393288|NCT00200967|Drug|beclomethasone HFA|240 mcg beclomethasone HFA (QVAR, Teva Pharmaceutical Industries)
45393289|NCT02533440|Procedure|EXPAREL and Local Anesthetics|Patients will receive EXPAREL and local anesthetics, as well as opioid and non-opioid analgesics prescription, (only use if needed, for post surgical pain)
45393290|NCT02533440|Procedure|Oral Opioid and Local Anesthetics|Patients will receive local anesthetics, as well as oral opioid or non-opioid analgesics, (only use if needed, for post surgical pain)
45393291|NCT02533518|Procedure|Rigid bronchoscopy with ultraviolet transmission|
45393292|NCT02533518|Other|Biopsy|
45393293|NCT01052064|Device|Transcranial Magnetic Stimulation|rTMS will be administered in one daily session during 5 consecutive days of 1 Hz, 90% of motor threshold for a total of 1500 stimuli. The stimulation will be focal over left dorsolateral-prefrontal cortex(F3, from the international 10-20 system)
45393294|NCT01052142|Biological|Lipovaxin-MM|Patients will receive three doses of Lipovaxin-MM by intravenous infusion at intervals of four weeks OR patients will receive 4 doses of Lipovaxin-MM by intravenous infusion at weekly intervals
45502898|NCT03376152|Behavioral|Electric Kettle Promotion|Provision of free electric kettles and promotional materials/information
45393295|NCT03991572|Device|repeated transcranial magnetic stimulation with real coil|repeated transcranial magnetic stimulation with real coil is a noninvasive technique to activate and modify the activity of the neurons
45393296|NCT03991572|Device|repeated transcranial magnetic stimulation with sham coil|repeated transcranial magnetic stimulation with sham coil is a placebo
45502899|NCT05211375|Procedure|Duodenojejunal bypass|Sleeve gastrectomy will be performed in the same manner as in the SG group. DJB will be performed by transection of the duodenum and bypassing 250 cm of the proximal jejunum. The handsewn suture will be used for duodenojejunal anastomosis, and the size of anastomosis will be 1.5 - 2 cm. Single anastomosis will be performed rather than Roux-en-Y fashion.
45502900|NCT05211375|Procedure|Sleeve gastrectomy|Sleeve gastrectomy will be performed using 36-38 Fr bougie. The initial stapling start point will be between 4-6 cm from the pylorus, and the last stapling will be performed at least 1 cm away from His angle. The height of the automatic stapler will be selected based on the researcher's discretion.
46056938|NCT00736645|Other|placebo|Given orally
46056939|NCT02716467|Other|intercessory prayer|Intercessory prayer will be offered by a group of six Christian people.
46056940|NCT02716467|Radiation|Radiotherapy|All participants will receive treatment by radiotherapy
46056941|NCT02716701|Behavioral|Exercise Group|
46056942|NCT02716701|Other|Control Group|
45393297|NCT01052220|Behavioral|BP education and BP self-regulation|"The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will be asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.~The PI will visit weekly with the intervention participants in the HD unit. to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done."
45393298|NCT01052220|Behavioral|Supportive Educative Nursing Intervention|BP Education, BP, salt and fluid monitoring, BP goal-setting, and reinforcement
45393299|NCT01054638|Drug|HAART Treatment|"Using pharmacy records, identify all patients with HAART dispensing during baseline & follow-up periods. For combination medications, classify person-time according to individual therapeutic components. HAART exposure classification by 1)any HAART exposure, 2)by HAART class, and 3)by specific nucleoside reverse transcriptase inhibitor exposure. Specific evaluation of fosamprenavir and amprenavir.~Subdivide person-time according to recent, past & non-use of HAART. Person-time for each patient partitioned into exposure windows of Recent use(From start of dispensing to end of days supplied plus 6 months), Past use(From end of current use to end of follow-up or new HAART dispensing following recent use), & Non-use(Time prior to first dispensing or all time for those who did not receive a dispensing).~Determine cumulative duration of exposure based on days supplied per dispensing per patient over the baseline & follow-up periods: Non-use, Less than 1 yr, 1-2 yrs, More than 2yrs."
45393300|NCT01054794|Device|Gastric mucosal stimulation|The lead is a sterile, 2mm diameter insulated wire (Temporary Transvenous Pacing Lead 6416-200cm, Medtronic, Minneapolis, MN) with 2 electrodes on the distal end. The mucosal stimulation parameters(Current:10 mA; Frequency: 14Hz; Pulse width: 330 ms; Cycle ON: 0.1 s; Cycle OFF: 5 s) are within the range used for standard permanent implanted GES (Enterra therapy) within the serosa and muscle layers of the stomach, and which has been shown to be safe, without any tissue damage.
45393301|NCT03742284|Device|SoftOx Wound Irrigation Solution|"The SoftOx Wound Irrigation Solution is a Medical device that contains a combination of hypochlorous acid and acetic acid in purified water. SWIS is primary intended for mechanical irrigation of acute wounds whereas hypochlorous acid acts as a ancillary medicinal (drug) substance with potential antimicrobial effects.~Acute wounds will be rinsed according to protocol and safety (AEs/ADEs/SAEs/SADEs) is the primary objective."
45393302|NCT00354432|Dietary Supplement|oral soy protein/isoflavones powder|Soy protein powder (20gm) orally 160 mg of total isoflavones isocaloric supplement of casein protein
45393303|NCT00354432|Drug|Venlafaxine|Patients receive oral venlafaxine 75mg.
45393304|NCT00354432|Dietary Supplement|Placebo Powder|Placebo powder (20gm casein protein) orally 0 mg of total isoflavones
45393305|NCT00354432|Drug|Placebo Pill|Patients receive oral placebo pill.
45393306|NCT00140140|Drug|ABI-007|Weekly intravenous infusions over 30 minutes.
45393307|NCT00140140|Drug|vinorelbine|Weekly intravenous infusions over 10-30 minutes, immediately after ABI-007. Vinorelbine is commercially available and was not supplied by the Sponsor.
45393308|NCT00140140|Drug|Trastuzumab|"Trastuzumab was administered to participants who had HER-2-neu positive tumors. Participants received trastuzumab by IV infusion via a vascular access device following dosing with ABI-007 and vinorelbine. During their first cycle, 4 mg/kg was administered on day 1 of that cycle as a loading dose. During subsequent weekly treatments, 2 mg/kg was administered.~Trastuzumab is commercially available and was not supplied by the Sponsor."
45393309|NCT00140140|Biological|G-CSF|"During Part 1, participants followed a dosing regimen with ABI-007 and vinorelbine without G-CSF treatment. However, G-CSF was allowed for administration as necessary in accordance with commonly accepted clinical guidelines.~In Part 2, participants started G-CSF treatment in concurrence with their ABI-007 and vinorelbine treatments. G-CSF was administered to all participants on Days 2-7 of each cycle, at a dose of 5 mcg/kg. If the participant's absolute neutrophil (ANC) count was >20,000/mm^3 on the day of anticipated chemotherapy, the site staff reduced the daily dose of G-CSF by 50% to 2.5 mcg/kg.~G-CSF is commercially available and was not supplied by the Sponsor."
45393310|NCT03966976|Device|ECG monitoring & record|This is a mobile ECG recorder that not only records short portions of ECG on one or three leads, but also stores, processes and transmits their data to facilitate the diagnosis and to confirm the occurrence of AF arrhythmia episodes by the physician.
45393311|NCT03966976|Other|Conventional follow-up|Conventional follow-up
45393312|NCT00346398|Biological|Oral mucosal immunoprophylaxis (OMIP)|OMIP consists of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL.
45393313|NCT00346398|Biological|Placebo|The placebo consists of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL.
45393314|NCT00346164|Drug|doxorubicin hydrochloride|Given IV
45393315|NCT00346164|Other|clinical observation|Patients undergo observation
45393316|NCT00346164|Procedure|therapeutic conventional surgery|Patients undergo surgery
45393317|NCT00346164|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
45393318|NCT00346164|Drug|ifosfamide|Given IV
46056943|NCT02716701|Other|wristband activity tracker|
45393319|NCT03991260|Diagnostic Test|SPECT|One single injection of 99mTc- ADAPT6, followed by gamma camera imaging directly post-injection and after 2, 4 and 6 hours.
45393320|NCT03986892|Behavioral|Physical Activity|Physical Activity
45393321|NCT01052298|Drug|Ciprofloxacin (Cipro inhale, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
45393322|NCT01052298|Drug|Ciprofloxacin (Cipro inhale, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given three times daily (tid) with a concluding single dose on 11d.
45393323|NCT01052298|Drug|Ciprofloxacin (Cipro inhale, BAYQ3939)|48.75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
45393324|NCT01052298|Drug|Placebo|Placebo inhalation powder will be given as an initial single dose inhalation on 00d.During the multiple dose phase placebo will be given twice/three-times daily with a concluding single dose on day 11d.
45393325|NCT03987048|Other|Measure of short- and long-term mortality and analysis of independent predictors of short- and long-term mortality.|"Data were collected regarding medical background, medical condition and management, both at admission and during the ICU stay. These included demographics, clinical, biological and therapeutic data.~Outcome at ICU discharge and at one year were also recorded."
45393326|NCT03986658|Device|Linear Asymmetric rTMS System|Linear Asymmetric rTMS System
45393327|NCT01052376|Device|Confocal endomicroscopy|
45393328|NCT01052454|Behavioral|Mindfulness-based stress reduction|Participants in the MBSR arm attend eight weekly classes.
45393329|NCT00114244|Drug|sorafenib tosylate|Given PO
45696878|NCT02981836|Biological|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
45393330|NCT00114244|Drug|gemcitabine hydrochloride|Given IV
45393331|NCT00114244|Other|laboratory biomarker analysis|Correlative studies
45393332|NCT01056588|Behavioral|CO-Contingent|In this 42 day condition, participants will receive monetary reinforcements contingent on submitting breath samples at CO levels indicating reductions or abstinence from smoking (4ppm).
45393333|NCT01056588|Behavioral|Control condition|In this condition, participants will receive monetary reinforcement for timely breath samples with no contingency for a specific breath CO level
45393334|NCT01058694|Behavioral|Short Message Services to Support ARV therapy adherence|Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design.
45393335|NCT02533128|Drug|Liberal blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) > 60 mmHg
45393336|NCT02533128|Drug|Tight blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) > 75 mmHg
45393337|NCT01054872|Biological|HIV-1 DNA plasmid vaccine|4 mg injection administered as 1 mL intramuscularly via Biojector in deltoid
45393338|NCT01054872|Biological|HIV-1 recombinant Ad5 vaccine|1 x 10^10 particle units (PU) administered as 1 mL intramuscularly by needle and syringe in deltoid
45393339|NCT01054950|Behavioral|Counseling|Our food allergy nurse will contact our intervention group and discuss any questions or concerns they may have regarding their child's food allergy.
45393340|NCT01054950|Behavioral|Placebo phone call|Phone call w/ no behavioral counseling
45393341|NCT01058772|Other|INDUCTION of LABOUR|Induction of labour will be performed by using dinoprostone 2 mg vaginally or dinoprostone 0.5 mg intracervically at 6-8h interval (up to 5 doses) or dinoprostone 10 mg vaginal device. Patients, in which cervical ripening does not occur (Bishop score < 7) after 5 attempts with PGE2, will be offered either oxytocin or Foley catheter induction or C-section, according to local protocols.
45393342|NCT01056666|Device|Conveen Optima is a urisheath to be used together with a collecting bag for urine|Conveen optima urisheath is intended to be used together with a collecting bag for urine and to be changed on a daily basis
45696879|NCT02981836|Biological|diluent of lyophilized vaccine|The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
45696880|NCT03033004|Device|Conventional Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes using the Polarys device. Polarys is a commercially available cryolipolitic device.
46056944|NCT02326311|Drug|imatinib|Tyrosin kinase inhibitor
46056945|NCT02326311|Drug|nilotinib|Tyrosin kinase inhibitor
46056946|NCT02326311|Drug|dasatinib|Tyrosin kinase inhibitor
46056947|NCT02716389|Other|Zebris CMS 70|
45393343|NCT01056666|Device|absorbent protection|The patient use his usual absorbent protection (same brand), and change it when needed
45393344|NCT00138658|Drug|custirsen sodium|Custirsen sodium (OGX-011) was to be infused intravenously over 2 hours on Days -7, -5, and 3 of Cycle 1 (pretreatment loading dose). OGX 011 was then to be infused for 2 hours weekly on Days 1, 8, and 15 of a 21-day cycle. Gemcitabine (GEM) was to be infused intravenously for 30 minutes on Days 1 and 8 and either cisplatin (CIS) or carboplatin (CARBO) were to be infused intravenously on Day 1 of this 21-day cycle. Patients were to receive a maximum of 6 cycles (1 cycle = 21 days)
45393345|NCT00337662|Drug|olanzapine|10-20 milligrams (mg), oral, daily, 10 weeks.
45393346|NCT00337662|Drug|risperidone|2-6 mg, oral, daily, for 10 weeks.
45393347|NCT00337662|Drug|risperidone|2-6 mg, oral, daily, 10 weeks
45393348|NCT00138424|Drug|Cidofovir|Cidofovir is a marketed product for treatment of Cytomegalovirus disease (retinitis) in human immunodeficiency virus (HIV) infected patients. It is packaged as a sterile, hypertonic aqueous solution for intravenous infusion only. Dosages: 0.25 mg/kg, 0.5 mg/kg, and 1.0 mg/kg.
45393349|NCT00138424|Drug|Placebo|The control for this study is sterile, 0.9% normal saline for intravenous use.
45393350|NCT00368966|Biological|13-valent Pneumococcal Conjugate Vaccine|
45393351|NCT00368966|Biological|7-valent Pneumococcal Conjugate Vaccine|
45393352|NCT00114166|Drug|topotecan hydrochloride|
45393353|NCT00125242|Behavioral|Semantic Feature Analysis (SFA)Training|SFA entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, personal associations, action associated with item). For some participants, treatment items were grouped according to typicality of category membership (e.g,, a robin-typical bird and penguin-atypical bird). Training of atypical items may stimulate a broader semantic activation of the category and thus, may promote greater generalization. Treatment was applied sequentially to sets of items in the context of single-subject, multiple baseline designs. In this way, replication of treatment effects could be evaluated within and across participants. Treatment was administered by certified SLPs three times per week until prescribed accuracy levels were met during nontreatment probes or a maximum number of treatment sessions was completed.
45393354|NCT03992534|Combination Product|LACTIN-V|Vaginal supplementation with L. crispatus CTV-05.
45393355|NCT00337428|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF)|GARDASIL™ (quadrivalent human papillomavirus [types 6, 11, 16, 18] virus-like particle [VLP] vaccine, referred to as qHPV vaccine) made at the current manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
45393356|NCT00337428|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF)|GARDASIL™ (quadrivalent human papillomavirus [types 6, 11, 16, 18] virus-like particle [VLP] vaccine, referred to as qHPV vaccine) made at the future manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
45393357|NCT00337428|Biological|Comparator: REPEVAX™ (Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Day 1 in a limb opposite that of quadrivalent HPV injection.
45393358|NCT00337428|Biological|Comparator: REPEVAX™ (Non-Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Month 1 in a limb opposite that of quadrivalent HPV injection.
45393359|NCT01049828|Other|No intervention|No treatment for tinnitus will occur in this study.
45393360|NCT01044524|Radiation|SLV 334|2000 mg via i.v. solution
45393361|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c.(subcutaneous) every other day
45393362|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c. every other day (for patients having received 500 mcg before)
45393363|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day
45393364|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day (for patients having received 250 mcg before)
45393365|NCT03741465|Procedure|The SFP technique|The USG, and the 5-point NRS evaluation in the SFP
45393366|NCT03741465|Procedure|The ASP technique|The USG, and the 5-point NRS evaluation in the ASP
45393367|NCT00113386|Biological|filgrastim|Consolidation chemotherapy
45393368|NCT00113386|Biological|pegfilgrastim|Consolidation chemotherapy
45393369|NCT00113386|Drug|cisplatin|
45393370|NCT00113386|Drug|docetaxel|
45393371|NCT00113386|Procedure|adjuvant therapy|
45393372|NCT00113386|Procedure|conventional surgery|
45393373|NCT00113386|Procedure|neoadjuvant therapy|
45393374|NCT00113386|Radiation|radiation therapy|
45393375|NCT00353262|Drug|Avastin|7.5mg/kg iv (cycle 3 only)
45502901|NCT03618264|Drug|Miscible liquid of dexamethasone and ropivacaine|Intervention in this study will be peri-incisional scalp infiltration with dexamethasone, ropivacaine and normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
45393376|NCT00353262|Drug|Oxaliplatin|130mg/m2 iv (cycles 1, 2 and 3)
45393377|NCT00353262|Drug|capecitabine [Xeloda]|1000mg/m2 po bid (cycles 1, 2 and 3)
45393378|NCT01056744|Device|Percutaneous coronary intervention with stent implantation|"Percutaneous coronary intervention with implantation of either:~- a XIENCE® V everolimus eluting coronary stent in one of the following sizes: 3.0 x 18 mm, 3.0 x 28 mm, 2.5 x 18 mm, 2.5 x 28 mm (DES group),~or:~- a Coroflex Blue® coronary stent postdilated with a Sequent Please® paclitaxel-eluting balloon in one of the following size combinations (stent / balloon): 3.0 x 16 mm / 3.0 x 20 mm, 3.0 x 25 mm / 3.0 x 30 mm, 2.5 x 16 mm / 2.5 x 20 mm, 2.5 x 25 mm / 2.5 x 30 mm (BMS/DEB group)"
45393379|NCT00337272|Drug|Placebo|Placebo taken 30 minutes before bedtime days 1-28 of treatment period
45393380|NCT00337272|Drug|Ramelteon|8 mgs daily for days 1-28 of treatment period
45393381|NCT00125164|Drug|rhIGF-1 (mecasermin, Tercica, Inc.)|Twice Daily Injection
45393382|NCT03985410|Drug|ETX2514|intravenous infusion
45502902|NCT03618264|Drug|Ropivacaine|Intervention in this study will be peri-incisional scalp infiltration with ropivacaine for participants who will undergo elective craniotomy. The local infiltration solution containing 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
46056948|NCT02716389|Other|3-D Bulls Eye Spirit Meter|
46056949|NCT00736489|Drug|AZD3199|Dry powder for inhalation, single dose
46056950|NCT00736489|Drug|Formoterol|Dry powder for inhalation, single dose
45393383|NCT03985410|Drug|Placebo|intravenous infusion
45393384|NCT03985410|Drug|moxifloxacin|oral tablet
45393385|NCT05126290|Other|Collection of personal and family history from CAFÉ Study participants|Personal medical and genetic history, as well as relevant information about family history, will be collected from participants in the CAFÉ Study through an online data entry system
45393386|NCT01056900|Procedure|Autologous Chondrocyte Implantation|"Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)~Directions and dosage:~Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected."
45393387|NCT03988686|Procedure|Radical prostatectomy plus standard care|To add radical prostatectomy on the basis of current standard of care for those with oligometastatic prostate cancer
45393388|NCT03988686|Drug|Standard of care for metastatic prostate cancer|androgen deprivation therapy with or without other systemic therapies based on current guidelines for metastatic prostate cancer
45393389|NCT00136318|Drug|Escitalopram|
45393390|NCT00136318|Drug|Placebo|
45393391|NCT00136318|Drug|Peginterferon alfa-2a|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with PEGinterferon-alfa2a, 180 mcg weekly. Patients with genotype 2 or 3 received PEGinterferon-alfa2a, 180 mcg weekly.
45393392|NCT00136318|Drug|Ribavirin|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with ribavirin, 1000 mg per day (body weight 75 kg) or 1200 mg per day (body weight, 75 kg). Patients with HCV genotype 2 or 3 received ribavirin, 800 mg per day for 24 weeks.
45393393|NCT03988218|Behavioral|perceptive tests|many tests are realized: a drawing of the interior of the body a heartbeat detection test an ischemia induction test many scales: Eating Attitude Test; Body Awareness Questionnaire; Body Shape Questionnaire; Hospital Anxiety and Depression; Questionnaire de Satisfaction Corporelle et de Perception Globale de Soi
45393394|NCT01058850|Biological|Rindopepimut|250 or 500 mcg; intradermal injection
45393395|NCT00136084|Drug|Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
45393396|NCT00136084|Drug|Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
45393397|NCT00364832|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of sc administration
45393398|NCT01326598|Device|V-Go™|Use of Insulin Delivery Device, V-Go, and the effect on A1C for T2DM patients in five categories of baseline oral antidiabetes drug (OAD) use with or without insulin.
45393399|NCT01326676|Drug|Polypill: Red Heart Pill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.~Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2."
45393400|NCT01326676|Drug|Usual medication|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
45393401|NCT00235755|Drug|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 3, patients will enter a 12 week maintenance phase.
45393402|NCT00235755|Drug|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 5, patients will enter a 12 week maintenance phase.
45393403|NCT00235755|Drug|Placebo|Oral tablet.
45393404|NCT01581879|Drug|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
45393405|NCT00337194|Biological|monoclonal antibody SGN-30|Given IV
45393406|NCT00337194|Other|placebo|Given IV
45502903|NCT05089617|Drug|YG1699|"YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~Drug: Placebo~Placebo is the same appearance as YG1699."
45502904|NCT03628911|Device|Tetanizing Burst Therapy|Tetanizing Burst Therapy tetanizes skeletal muscle with a brief burst of stimulation prior to ICD shock, thereby reducing muscular contraction due to the shock
46056951|NCT00736489|Drug|Placebo|Dry powder for inhalation, single dose
45393407|NCT00337194|Drug|vinorelbine tartrate|Given IV
45393408|NCT00337194|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
45393409|NCT00337194|Drug|gemcitabine hydrochloride|Given IV
45393410|NCT00337194|Other|laboratory biomarker analysis|Correlative studies
45393411|NCT00337194|Other|pharmacological study|Correlative studies
45393412|NCT03973749|Other|Low salycilate diet|Each arm of the experimental group will be exposed to low and high concentrations of dietary salycilates and urinary LTE4, FEV1, FVC, FEV1/FVC and total inspiratory nasal resistance will be measured at basal level and then two hours after each of the 3 daily meals.
45393413|NCT01074021|Drug|Nimotuzumab|"Nimotuzumab:(200mg/w,weekly, 7-8 weeks, one week before radiotherapy)~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy:~Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)"
45393414|NCT01074021|Drug|placebo plus chemoradiotherapy|"Placebo treatment:4 bottles/w,weekly, 7-8 weeks, one week before radiotherapy~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy: Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)"
45393415|NCT03969381|Radiation|diffusion weighted magnetic resonance image in lymphoma|compare between result of positron emission tomography /computed tomography and diffusion weighted imaging in followup of lymphoma
45393416|NCT01326195|Behavioral|Cognitive-Behavioral Dating Violence and HIV Prevention Group|Six, two-hour weekly sessions and one 2-hour booster session 6 weeks later with adolescent females
45393417|NCT01326195|Behavioral|Psycho-educational Dating Violence and HIV prevention group|Knowledge based intervention matched for time and attention to skills arm
45393418|NCT03985254|Other|Strength Training Group (STG)|"The strength training program will consist of applying resistance and progressive exercises for strength gain and will be based on the training principles recommended by the American College of Sport Medicine. The exercises were chosen based on a pilot study that successfully applied the protocol to 10 participants with FPD (data to be published) and other strength training studies (MASCALL et al, 2003; DISTEFANO et al, 2009; REIMAN et al, 2012; BALDON et al, 2014; SILVA et al, 2015).~Initially, the goal will be the development of neuromotor control and resistance (load <50% of the one repetition maximum test [1RM]), and in subsequent weeks the goal will be the development of muscle strength (load> 70% 1RM). In addition, the protocol will initially focus on strengthening the hip and trunk muscles and after four weeks of training, exercises for the knee muscles will be included."
45393419|NCT03985254|Other|Strength and Power Training Group (SPTG)|Participants who are allocated to this group will perform the same exercise program performed by the STG, but with the addition of exercises that emphasize power gain. As in the other group, initially, the objective will be the development of neuromotor control and resistance (load <50% of the one repetition maximum test [1RM]). However, in subsequent weeks the goal will be to develop strength (load> 70% 1RM) and muscle power (load between 40-60% 1RM).
45393420|NCT01074333|Drug|Cetuximab|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. The initial dose of Erbitux is 400 mg/m2 body surface area and the subsequent weekly doses are 250 mg/m2 each administered i.v. via in-line filtration with an infusion pump, gravity drip, or a syringe pump. The recommended infusion period for the initial dose is 120 minutes and for the subsequent weekly doses is 60 minutes with the maximum infusion rate not exceeding 5 ml/min.
45393421|NCT01058928|Other|Observation of fluid leakage around tracheal tube cuffs|One milliliter of Evans blue diluted in 3.5 mL of saline solution is carefully instilled on the top of the tracheal tube cuff. In the operating room, one hour and five hours after intubation, fiberoptic bronchoscopy was performed to detect the possible presence of blue dye in the trachea. If a blue spot was seen on the trachea caudal to the tube's tip on any occasion, leakage was confirmed and the experiment was finished.
45393422|NCT01582581|Behavioral|Telephonic CBT|Cognitive behavioral therapy, guided by computer, using the TAD protocol for treatment of Adolescent Depression, modified for delivery by a nurse or master's level clinician over the telephone in 15-18 sessions lasting 30-45 minutes at weekly intervals. Includes regular and standardized weekly monitoring by the treating clinician of depressive symptoms and factors affecting suicide risk.
45393423|NCT01582581|Behavioral|Wait List Control|Wait list control with measurement of key outcomes at baseline (week 0), and then weeks 3 and 5.
45502905|NCT03617016|Drug|Domperidone|Participants will receive domperidone tablets orally.
45502906|NCT03617016|Drug|Placebo|Participants will receive matching placebo to domperidone tablets orally.
45502907|NCT03798938|Other|plant-based diet|subjects will be placed in plant-based diet and the effect of plant-based diet to the endothelial function will be monitored
46056952|NCT02318355|Other|normal saline|Crystalloid intravenous solution
45502908|NCT05210829|Diagnostic Test|stationary and trait anxiety scale|survey
45502909|NCT02062268|Behavioral|health education & law enforcement|
46056953|NCT02318355|Other|lactated ringers|Crystalloid intravenous solution
46056954|NCT04964973|Device|Control|Post-surgical physiotherapeutic activity.
46056955|NCT04964973|Device|Experimental|Post-surgical physiotherapeutic activity with the application of the technique
46056956|NCT04964973|Device|Placebo|Post-surgical physiotherapeutic activity with the application of the non-activated technique
46056957|NCT02288637|Other|Olyset Plus LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin and the synergist piperonyl butoxide PBO as the active ingredients (AI).The LLIN can withstand repeated washing and retains efficacy over years of use
45393424|NCT01057056|Other|mind-body intervention|multi-disciplinary mind-body intervention including: breathing techniques, guided imagery, meditation, touch therapy
45393425|NCT03826914|Dietary Supplement|CardioFlex Q10|CardioFlex Q10 is a cardiovascular health supplement developed to increase collagen production, repair connective tissues, and help the body metabolize fats and protein. CardioFlex Q10 contains high amounts of lysine, proline and vitamin C, which the body requires to produce connective tissue (collagen). CardioFlex Q10 also includes additional supporting nutrients such as vitamin E, selenium, bio flavonoids, Coenzyme Q10 (Ubiqionol) and magnesium. The ingredients in CardioFlex Q10 help regulate the body's production of cholesterol, strengthen the arteries and heart, and reverse oxidation.
45393426|NCT03826914|Dietary Supplement|Placebo|Isocaloric maltodextrin placebo that looks and tastes identical to CardioFLex Q10
45393427|NCT01059006|Procedure|PresbyLASIK|PresbyLASIK essentially involves the creation of a multifocal surface able to correct any visual defect for distance while simultaneously allowing freedom from near spectacle dependency in presbyopic patients.
45393428|NCT01055340|Drug|Oxyntomodulin (OXM)|Single infusion of OXM 3.0 pmol/kg/min by IV
45393429|NCT01055340|Drug|Comparator: Oxyntomodulin (OXM)|Single infusion of OXM 0.6 pmol/kg/min by IV
45393430|NCT01055340|Drug|Comparator: Placebo [ hemaccel-containing saline]|Single Placebo infusion of hemaccel-containing saline by IV
45393431|NCT00385736|Biological|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 80 mg at Week 0, 40 mg at Week 2, and 40 mg every other week starting at Week 4.
45393432|NCT00385736|Biological|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week starting at Week 4.
46056958|NCT02288637|Other|Conventional Olyset LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin. The LLIN can withstand repeated washing and retains efficacy over years of use.
45393433|NCT00385736|Biological|placebo|Placebo for 40 mg syringe. Matching placebo for loading dose and every other week dosing. Subjects received placebo at Weeks 0, 2, 4, and 6, followed by 160 mg adalimumab at Week 8, 80 mg adalimumab at Week 10, and 40 mg adalimumab eow thereafter (prior to Amendment 3) or 40 mg adalimumab eow starting at Week 8 (after Amendment 3).
45393434|NCT03742206|Device|Parasacral Transcutaneous Electrical Stimulation|Electrical stimulation with surface electrodes on the sacral roots of S3 that produce inferior urinary tract neuromodulation.
45393435|NCT03742206|Device|Transcutaneous Posterior Tibial Nerve Stimulation|Electrical stimulation with surface electrodes through the activation of peripheral afferent nerves that produce inferior urinary tract neuromodulation
45393436|NCT01057212|Drug|ixabepilone|Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the remaining 40 patients enrolled.
45393437|NCT01057212|Drug|bevacizumab|Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks.
45393438|NCT01057290|Genetic|gene expression analysis|
45393439|NCT01057290|Genetic|protein expression analysis|
45393440|NCT01057290|Other|fluorescence activated cell sorting|
45393441|NCT01057290|Other|immunologic technique|
45393442|NCT01057290|Other|laboratory biomarker analysis|
45393443|NCT03988452|Drug|Darunavir|Antiretroviral therapy
45393444|NCT03988452|Drug|Ritonavir|Antiretroviral therapy
45393445|NCT03988452|Drug|Dolutegravir|Antiretroviral therapy
45393446|NCT03988452|Drug|Zidovudine|Antiretroviral therapy
45393447|NCT03988452|Drug|Tenofovir|Antiretroviral therapy
45393448|NCT03988452|Drug|Lamivudine|Antiretroviral therapy
45393449|NCT01048580|Drug|Perifosine|Perifosine 50 mg orally once a day (Days 1-21)
45393450|NCT01048580|Drug|Capecitabine|Capecitabine 1000 mg/m2 orally twice per day (Days 1-14)
45393451|NCT03988140|Device|Dental Implant Placement and subsequent prosthetic reabilithation|Surgeries to dental implant placement were performed. All patients received 3.5 mm diameter dental implants - surface blasted with TiO2 particles and machined collar of 1mm - in the interforaminal region of the mandible. The surgical sequence followed the protocol described by the implant company.A two stages protocol was used and the prostheses were placed at 4 months.The prosthetic retention system used in rehabilitation with overdentures was the O'ring and the capture of this component was done directly in the patient's mouth. After 7 and 14 days, the patients returned to occlusal adjustments and verification of prosthetic adaptation. The prostheses were made entirely of acrylic resin without metallic reinforcement and the antagonist of the patients were total edentulous and rehabilitated with muco-supported prostheses.
45393452|NCT01049906|Procedure|Placement of nerve block catheter|Placement of nerve block catheter with nerve stimulator and ultrasound
45393453|NCT01049906|Procedure|Placement of nerve block catheter|Placement of nerve block catheter with ultrasound only
45393454|NCT02533050|Device|CPAP treatment|Patients treated wear a face mask during sleep which is connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airway and stimulate normal breathing.
45393455|NCT00195819|Biological|adalimumab (D2E7)|Adalimumab 40 mg every other week (eow)
45393456|NCT00195819|Biological|placebo|Placebo every other week (eow)
45393457|NCT00527735|Drug|Ipilimumab|Ipilimumab, 10 mg/kg, administered as a single-dose, intravenously (IV), over 90 minutes depending on randomization every 3 weeks (up to 6 doses). Participants could receive additional maintenance ipilimumab at a dose of 10 mg/kg every 12 weeks starting 24 weeks after the first ipilimumab dose.
45393458|NCT00527735|Drug|Placebo|Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction. Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.
45393459|NCT00527735|Drug|Paclitaxel|175 mg/m^2, administered as a single IV dose over 3 hours every 3 weeks (up to 6 doses). Dose modifications (reductions as well as delays) done as per product label.
45393460|NCT00527735|Drug|Carboplatin|Area under the concentration curve (AUC)=6, administered as a single IV dose over 30 minutes every 3 weeks (up to 6 doses) as per randomization. Dose modifications (reductions as well as delays) done as per product label.
45393461|NCT03969147|Device|ManMaxAirway oropharyngeal airway adjunct|Healthy volunteers will self-place the ManMaxAirway.
45393462|NCT03969147|Device|Guedel Oropharyngeal airway adjunct|Healthy volunteers will self-place the standard Guedel OPA.
45393463|NCT03969147|Device|No airway adjunct|Healthy volunteers will have no airway adjunct in place.
45393464|NCT00336492|Biological|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42
45393465|NCT00336492|Biological|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46
45393466|NCT00336492|Biological|infliximab|infliximab - Could receive infusion of 10 mg/kg every 8 weeks up to week 42
45393467|NCT00336492|Biological|infliximab|infusion of 5mg/kg at weeks 0, 2, 6, then every 12 wks through week 42
45393468|NCT00194025|Drug|Valproate|Enrolled individuals received adjunctive, open-label valproate semisodium, initially started as valproate semisodium delayed -release 250 mg at bedtime for two weeks, then changed to valproate semisodium extended- release 500 mg at bedtime. Medication was administered on an outpatient/ambulatory basis, and adjusted as tolerated to target serum levels of 50-100 µg/mL. In cases where sedation or other side effects occurred, dosage was reduced. Valproate semisodium was prescribed in a single dose at bedtime.
45393469|NCT01057368|Behavioral|Day of intensive meditation practice|Long-term meditators practice for ~6 hours of meditation at each time point
45393470|NCT01057368|Behavioral|Mindfulness Based Stress Reduction (MBSR)|8-week class designed to enhance well-being through training in mindfulness meditation
45393471|NCT01057368|Behavioral|Health Enhancement Program (HEP)|8-week class designed to enhance well-being through training in physical activity, functional movement, music therapy, and nutrition
45393472|NCT02531685|Other|Placebo|Placebo: 0.9% Sodium Chloride injection.
45393473|NCT02531685|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700mcg of vaccine protein in a 3 ml, multi-dose.
45393474|NCT03969303|Device|Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)|OCT SCAN
45393475|NCT03969069|Device|MAPLe|Additional assessment with MAPLe
45393476|NCT00368108|Drug|2 mg perampanel|2 mg perampanel
45393477|NCT00368108|Drug|4 mg perampanel|4 mg perampanel
45393478|NCT00368108|Drug|placebo comparator|placebo comparator
45393479|NCT00364130|Device|Low magnitude mechanical stimulus|10 minute daily treatment sessions standing on the low magnitude mechanical stimulus device
45393480|NCT00364130|Device|Placebo (inactive) low magnitude mechanical stimulus|10 minute daily treatments standing on a placebo version of a low magnitude mechanical stimulus device
45393481|NCT00521339|Drug|Apremilast|20 mg PO (by mouth) twice per day (BID) for 84 days and then an additional 84 days during the optional treatment extension period. For subjects meeting the dose escalation criteria, dosage during the optional treatment extension period can be increased to 30 mg BID.
45393482|NCT01044602|Other|Laboratory evaluations, sleep study|Fasting plasma glucose, liver function tests, chem-7, HOMA-IR, HBA1C, lipid profile, indirect calorimetry.
45393483|NCT01044602|Other|Best Medical Management|Standard of care.
45393484|NCT01044602|Procedure|Roux-en-Y gastric bypass surgery|Surgical treatment.
45393485|NCT00363896|Drug|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation via the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
45393486|NCT00363896|Drug|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
45393487|NCT00527423|Drug|VEGF Trap Eye|Intravitreal injection
45393488|NCT01044680|Dietary Supplement|NUTRIOSE|17 grams of NUTRIOSE consumed twice daily for 12 weeks
45393489|NCT01044680|Dietary Supplement|Placebo|17 g maltodextrin consumed twice daily for 12 weeks
45393490|NCT00527111|Drug|Cetuximab|
45393491|NCT00527111|Drug|5-fluorouracil|
45393492|NCT00527111|Radiation|Pelvic irradiation|
45393493|NCT00336024|Drug|etoposide|Given IV
45393494|NCT00336024|Drug|cyclophosphamide|Given IV
45393495|NCT00336024|Drug|cisplatin|Given IV
45393496|NCT00336024|Biological|filgrastim|Given IV or SC
45393497|NCT00336024|Drug|carboplatin|Given IV
45393498|NCT00336024|Drug|thiotepa|Given IV
45393499|NCT00336024|Drug|methotrexate|Given IV
45393500|NCT00336024|Drug|leucovorin calcium|Given IV or orally
45393501|NCT00336024|Drug|vincristine sulfate|Given IV
45393502|NCT00336024|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous PBSC rescue
45393503|NCT00336024|Other|laboratory biomarker analysis|Correlative studies
45393504|NCT00336024|Procedure|quality-of-life assessment|Ancillary studies
45393505|NCT00384956|Drug|Azacitidine|
45393506|NCT04090697|Drug|Oxandrolone|Oxandrolone 2.5mg tabs will be suspended in multi-chain triglyceride (MCT) oil and administered buccally.
45393507|NCT00367640|Drug|100 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
45393508|NCT00367640|Drug|300 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
45393509|NCT00367640|Drug|500 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
45393510|NCT00367640|Drug|Placebo tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
45393511|NCT01325220|Drug|arbaclofen|5 mg bid
45393512|NCT01325220|Drug|arbaclofen|10 mg bid
45393513|NCT01325220|Drug|arbaclofen|10 mg tid
45393514|NCT01325220|Drug|Placebo|tid
45393515|NCT01055418|Dietary Supplement|Vitamin C|Vitamin C will be administered at a dose of 1000mg. There will be at least a 48 hour wash out period between both conditions (placebo and vitamin C), with the order dicteted by Latin square.
46056959|NCT02288637|Other|IRS|Actellic CS (Syngenta), is a microcapsule formulation of the organophosphate insecticide, pirimiphos-methyl. Microencapsulation greatly extends the compound's residual life when applied to interior walls and ceilings. Evaluation by LSHTM in experimental huts in Tanzania showed residual activity of more than a year. Parallel trials in Benin against pyrethroid-resistant mosquitoes killed more than 80% of An. gambiae for up to 10 months.
45393516|NCT00367484|Biological|Rebif® (clone 484-39)|s.c. administered Rebif®
45393517|NCT01324778|Device|OsseoSpeed TX|OsseoSpeedTM TX implants of lengths 6-17 mm
45393518|NCT01324778|Device|OsseoSpeed|OsseoSpeedTM implants of lengths 6-17 mm
45393519|NCT01057524|Device|High Frequency Chest Wall Oscillation (HFCWO)|Airway clearance using the high frequency chest wall oscillator device
45393520|NCT01057524|Other|Usual airway clearance|Airway clearance treatments using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure, manual techniques or oscillating positive expiratory pressure
45393521|NCT00526799|Drug|Sorafenib|"Phase I: Dose Escalation, Phase II: MTD~Dose level -1: 200mg po daily Dose level 1: 400mg po daily (MTD) Dose level 2: 400mg po bid"
45393522|NCT00526799|Drug|Topotecan|3.5mg/m2 weekly, 3 weeks on and one week off.
45393523|NCT01059084|Drug|Valacyclovir|1000 mg tid
45393524|NCT03992144|Drug|Amoxicillin 500 Mg|Amoxicillin 500mg an hour before tooth extraction
45393525|NCT03992144|Drug|metronidazole 400mg|400mg of metronidazole an hour before extraction
45393526|NCT03992144|Drug|metronidazol 400mg and amoxicillin 500mg|400mg metronidazole TDS, amoxicillin 500mg BD for 5 days after extraction
45502910|NCT05210751|Other|Physical and psychosocial assessments|Dual Task Test, 6 min Walking Test, the Baecke Habitual Physical Activity Questionnaire, Multidimensional Fatigue Inventory-20, Tracking Test, General Self-Efficacy Scale the Toronto Alexithymia Scale, the Revised FM Impact Questionnaire, the Social Support Scale.
45502911|NCT02031822|Procedure|US-guided Greater Occipital Nerve Injection|Medication injected around the greater occipital nerve: 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg.
46056960|NCT04964739|Behavioral|Cognitive Behavioral Therapy (CBT4CBT)|Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.
46056961|NCT02069925|Behavioral|Early Detection (ED)|This intervention consists of educational campaigns directed at patients & families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
45393527|NCT01059162|Device|Laser Assisted Non-penetrating glaucoma surgery|A layer by Layer ablation of the deep sclera (under the superficial scleral flap) to achieve functional fluid percolation of the inner eye humor without penetration.
45393528|NCT02534870|Drug|ABT-450/r/ABT-267|Tablet
45393529|NCT02534870|Drug|ABT-333|Tablet
45393530|NCT00526331|Device|Vigileo Monitor|Study Group = The monitor and routine vital sign measurements will be used to decide how much fluid to give during surgery; Control Group = Information from the monitor will be collected and compared to the information collected from participants in Study Group.
45393531|NCT00526331|Device|FloTrac Sensor|Device connected to the patient's arterial line and Vigileo monitor that measures fluid requirements during surgery.
45393532|NCT03992066|Drug|Vadadustat|oral 150 mg tablet
45393533|NCT03992066|Drug|Darbepoetin alfa|solution intravenous injection
45393534|NCT03992066|Drug|Epoetin alfa|solution for intravenous injection
45393535|NCT03992222|Device|Physical exercise programs PEP targeted on appropriate muscle strengthening devices allows|administration of a Physical exercise program for 24 weeks.The participants will be followed at the 24 and 52nd weeks.
45393536|NCT03986268|Drug|Vit D|The aim of this study is investigating pathologic response to neoadjuvant therapy if we give replacement therapy with vitamin D3 50.000 IU weekly dosage concurrent with chemotherapy in breast cancer patients.
45393537|NCT01048736|Behavioral|Exercise Only|4 d/wk of aerobic exercise
45393538|NCT01048736|Behavioral|Exercise + Diet|Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; ~4.5 kg weight loss).
45502912|NCT02060786|Drug|generic clopidogrel (Plavitor® )|
45502913|NCT02060786|Drug|original clopidogrel (Plavix® )|
45393539|NCT01048736|Behavioral|Exercise + Diet|Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; ~10.9 kg weight loss)
45393540|NCT01048814|Other|ChemoFx|Chemoresponse Marker Assay
45393541|NCT01048892|Biological|Seneca Valley virus-001|
45393542|NCT01048892|Drug|cyclophosphamide|
45393543|NCT01048892|Other|laboratory biomarker analysis|
45393544|NCT01048892|Other|pharmacological study|
45393545|NCT01259648|Drug|0.5 µg/kg remifentanil|0.5 µg/kg remifentanil is used during induction in addition to the classic induction protocol
45393546|NCT01259648|Drug|1.0 µg/kg remifentanil|1.0 µg/kg remifentanil is added to the classic induction anesthesia protocol
45393547|NCT01259648|Drug|NaCl|an equivalent volume (1 ml for 10 kg of weight) of 0.9% isotonic NaCl is injected in addition to the classic anesthesia induction protocol
45393548|NCT01048970|Other|Nutritional Assessment|Patients will receive nutritional assessment one week prior to treatment until completing two courses of chemotherapy
45393549|NCT01048970|Dietary Supplement|EPA-DHA arm|Patients will be randomized to receive two cans/day of EPA and DHA containing oral supplement one week prior to treatment until completing two courses of chemotherapy
45393550|NCT01049048|Dietary Supplement|Vitamin D3|2500 IU Vitamin D3
45393551|NCT01049048|Dietary Supplement|Placebo|No (0 IU) vitamin D3 added to cookie.
45393552|NCT01049126|Other|ChemoFx|Chemoresponse Marker Assay
45393553|NCT01044836|Biological|HD203|Injectable form
45393554|NCT00520481|Drug|IMC-A12 (Cixutumumab)|10 mg/kg i.v. infusion over 1 hour every 2 weeks or 20 mg/kg i.v. infusion over 1 hour every 3 weeks.
45393555|NCT01044992|Radiation|H215O PET|H215O PET investigations will be performed during two pharmacological conditions: OFF (e.g after 12 hours of usual dopaminergic treatment discontinuation) and ON (after an acute oral levodopa challenge) in all subjects. During each PET there will be two motor conditions: rest (no movement, hand and wrist lying on the joystick) and a right-hand movement, consisting of moving joystick in 4 four different directions avoiding sequence repetition performed at rest and during a right hand movement.
45393556|NCT01044992|Drug|Levodopa|Levodopa: the dosage of levodopa challenge will be equivalent to the first morning dose increased by 100 mg of levodopa whereas the dosage will be 200 mg in healthy subjects.
45393557|NCT00520403|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
45393558|NCT00520403|Drug|Interferon alfa-2a|3 MioIU sc escalating to 18 MioIU sc, 3 times weekly
45393559|NCT00520403|Drug|Vinblastine|0.1mg/kg iv every 3 weeks
45393560|NCT04810403|Behavioral|SOMEBODY Eating Disorder Prevention Program|Participants will receive daily activities to complete on their most frequently used social media platform for 14 consecutive days. Daily activities have been adapted from the Body Project - an intervention that has been demonstrated to reduce internalization of the thin ideal and reduce risk for eating disorders. Examples of activities to be piloted include unfollowing social media accounts the participant perceives as reinforcing the thin-ideal and posting a selfie without makeup or editing. Based on feedback from participants, the intervention may be altered to improve acceptability, feasibility, and preliminary evidence of potential efficacy.
45393561|NCT00520013|Drug|bevacizumab|
45393562|NCT00520013|Drug|erlotinib|
45393563|NCT00520013|Drug|paclitaxel|
45393564|NCT00520013|Drug|carboplatin|
45393565|NCT03998891|Other|restricted dietary salt intake|These patients after CRTd will receive a restricted dietary salt intake. To date, the salt intake will be 1500 grams daily.
45393566|NCT00519779|Dietary Supplement|omega-3 supplementation|2.5 g/day omega-3
45502914|NCT03628833|Device|Incontinence Management System|Incontinence detection device
45393567|NCT00519779|Dietary Supplement|Oral omega-3 fish oil placebo|to match experimental dosage
45393568|NCT00526097|Drug|Bisacodyl 10 mg|2 x 5 mg bisacodyl once daily
45393569|NCT00526097|Drug|Placebo|Placebo-to-match bisacodyl 10 mg (2 x 5 mg) once daily
45393570|NCT00525785|Drug|5-Fluorouracil|"2.2 Gm/m^2 By Vein Over 48 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 300 mg/m2 a day Monday through Friday, by continuous infusion during radiation through an outpatient portable pump."
45393571|NCT00525785|Drug|Folinic Acid|200 mg/m^2 by vein Over 30 Minutes On Days 1, 15, 29, and 43.
45393572|NCT00525785|Drug|Oxaliplatin|"100 mg/m^2 By Vein Over 2 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 45 mg/m^2 over 2 hours weekly for 5 weeks during radiation. (oxaliplatin should be administered on the first day of the radiation week)."
45393573|NCT00525785|Radiation|Radiotherapy|45 Gy (1.8 Gy fx/day) Monday through Friday, 12 days after the last dose of 5FU plus oxaliplatin and no later than 28 days.
45393574|NCT00525785|Procedure|Surgery|4-6 weeks after completion of chemoradiotherapy, restaged & surgical resection of the primary tumor and lymph nodes attempted.
45393575|NCT04746287|Drug|CKD-510 single dose|Investigational drug
45393576|NCT04746287|Drug|CKD-510 food effect|Investigational drug
45393577|NCT04746287|Drug|CKD-510 multiple dose|Investigational drug
45393578|NCT04746287|Drug|Placebo|Matching placebo
45393579|NCT04487561|Device|hemopatch|The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
45502915|NCT03616938|Procedure|Cardiopulmonary resuscitation|2-min cycle of cardiopulmonary resuscitation accorind to the American Heart Association 2015 guidelines
45502916|NCT02060864|Dietary Supplement|AN-PEP|Two pills are consumed in the morning with a breakfast
45502917|NCT02060864|Dietary Supplement|Placebo|
45502918|NCT03560414|Procedure|simple plasma exchange|simple plasma exchange treatment
46056962|NCT02069925|Behavioral|Usual Detection|This intervention will provide equivalent best practice care without the benefit of an early detection campaign
46056963|NCT02716233|Drug|pegaspargase 1250 IU/m2 x 2|only for ALL of standard risk and medium risk
45502919|NCT03560414|Procedure|conventional PDF treatment group|conventional PDF treatment group
46056964|NCT02716233|Drug|pegaspargase 2500 IU/m2 x 1|only for ALL of standard risk and medium risk
45393580|NCT04487561|Procedure|Aspirative drainage|The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
45393581|NCT03853733|Radiation|rectal cancer radiotherapy|Conformal three-dimensional radiotherapy to deliver to the primary tumor and the enlarged pelvic nodes a total dose of 39Gy in 13 sessions of 3Gy in 17 days.
45393582|NCT00525161|Drug|sorafenib|400 mg PO (orally) twice daily for 12 months from study enrollment or until disease progression, whichever occurs first.
45393583|NCT00135694|Drug|calcineurin inhibitor-based immunosuppression|May be cyclosporine, mycophenolate mofetil, or tacrolimus
45393584|NCT00135694|Procedure|liver transplant|Occurs at study entry
45393585|NCT00135694|Drug|corticosteroids|3-month course of corticosteroids
45393586|NCT00135694|Other|immunosuppression withdrawal|One year after transplantation, participants eligible for withdrawal are randomly assigned in a 4 to 1 ratio to immunosuppression withdrawal or to maintenance.
45393587|NCT00524459|Drug|docetaxel|
45393588|NCT00524459|Drug|pegylated liposomal doxorubicin hydrochloride|
45393589|NCT00524459|Procedure|conventional surgery|
46056965|NCT02047929|Other|Asthma Shared Decision Making (SDM) Toolkit|A potential solution to improving asthma outcomes is the use of patient-centered approaches like Shared Decision Making (SDM), In the SDM process, patients and their health care providers are engaged jointly in making decisions about medical tests and treatments. The research team for this proposal was funded by the Agency for Health Care Research and Quality to build, disseminate and evaluate a novel Asthma SDM Toolkit - The Asthma Comparative Effectiveness Study. The Toolkit development was completed in 2010 and has been in evaluation for 2 years. This study will continue to evaluate the Toolkit in a wide array of practices across NC while testing a new method of dissemination.
45393590|NCT00524459|Procedure|neoadjuvant therapy|
45393591|NCT00519623|Other|PassPort(R) Transdermal Insulin Delivery System|The PassPort(R) Transdermal Insulin Delivery System is a drug-device combination product used to create micropores in the skin to enable transdermal delivery of insulin.
45393592|NCT01076530|Drug|vorinostat|
45393593|NCT01076530|Drug|temozolomide|
45393594|NCT01076530|Other|diagnostic laboratory biomarker analysis|
45393595|NCT01076530|Other|pharmacological study|
45393596|NCT03966664|Diagnostic Test|In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.|Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.
45393597|NCT03966664|Diagnostic Test|In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood|Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.
45393598|NCT03966664|Diagnostic Test|Biomolecular analysis of plasma proteins.|Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.
45393599|NCT00519077|Drug|Gefitinib|Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
45393600|NCT03966508|Procedure|High-frequency electrical stimulation|High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be 5mA. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).
45393601|NCT00124618|Biological|cetuximab|
45393602|NCT00124618|Radiation|radiation therapy|
45502920|NCT03560414|Procedure|less plasma PDF treatment group|less plasma Plasma diafiltration treatment
45393603|NCT00124462|Device|Realigning knee brace and custom orthodic|A valgus brace, customized functional orthotic for neutral foot position and motion control footwear
45393604|NCT00124462|Device|Non realigning knee brace and flat orthodic|A neutral brace that does not have any varus/valgus angulation, control foot orthodic and shoes with flexible midsole
45393605|NCT00124072|Drug|Simvastatin 20 mg daily|Simvastatin 20 mg tablet once daily
45393606|NCT00124072|Dietary Supplement|Folic acid 2 mg + vitamin B12 1 mg daily|Folic acid 2 mg + vitamin B12 1 mg tablet once daily
45393607|NCT00124072|Drug|Simvastatin 80 mg daily|Simvastatin 80 mg tablet once daily
45393608|NCT00124072|Drug|Placebo|Placebo vitamin B12/folic acid tablet once daily
45393609|NCT02531386|Device|6 blood glucose monitoring systems for self-testing (blood glucose meters)|
45393610|NCT01080352|Drug|Ascorbic Acid (Vitamin C)|60grams of ascorbate given intravenous infusion in 1000ml sterile water.
45393611|NCT00362648|Biological|RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent|2.0 mL oral dose of RotaTeq™. 14 week treatment period
45393612|NCT00362648|Biological|Comparator: Placebo|Arm 2: Placebo. 14 week treatment period
45393613|NCT01045148|Radiation|CyberKnife Radiosurgery|High Dose 3800 cGy/4 fractions
45393614|NCT01045148|Radiation|CyberKnife Radiosurgery|Moderate Dose 3400 cGy/5 fractions
45393615|NCT00524303|Drug|Trastuzumab|4mg/kg IV loading dose followed by 2mg/kg IV weekly
45393616|NCT00524303|Drug|Paclitaxel|80mg/m2 IV weekly for 4 (21 day) cycles
45393617|NCT00524303|Drug|FEC75|5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles
45393618|NCT00524303|Drug|Lapatinib|1250 mg oral daily dose in arm 2, 750 mg oral daily dose for FEC cycles and then 1000 mg oral daily dose during the Paclitaxel cycles in arm 3
45393619|NCT04461041|Drug|Empagliflozin|Single oral tablet
45393620|NCT04461041|Drug|Placebo|Placebo tablet manufactured to mimic empagliflozin 10 mg tablet
45393621|NCT00335556|Drug|Doxorubicin Hydrochloride|Given IV
45393622|NCT00335556|Drug|Irinotecan Hydrochloride|Given IV
45393623|NCT00335556|Procedure|Conventional Surgery|Patients undergo resection
45393624|NCT00335556|Drug|Cyclophosphamide|Given IV
46056966|NCT00730327|Device|BioEnterics® Intragastric Balloon|Inflatable balloon inserted into the stomach.
45393625|NCT00335556|Drug|Etoposide|Given IV
45393626|NCT00335556|Drug|Carboplatin|Given IV
46056967|NCT00730327|Other|Behavioral modification|Low-calorie diet, food/exercise diary, eating plan, emphasis on exercise
46056968|NCT01999569|Drug|Letrozole|Letrozole administered daily through the time of ovulation.
46056969|NCT02716077|Radiation|FDG PET/CT imaging|
45393627|NCT00335556|Biological|Dactinomycin|Given IV
45393628|NCT00335556|Drug|Vincristine Sulfate|Given IV
45393629|NCT00335556|Radiation|Radiation Therapy|Undergo radiotherapy
45393630|NCT00335556|Other|Laboratory Biomarker Analysis|Correlative studies
45393631|NCT00518687|Biological|V710|0.5-mL single injection of V710 (60 µg)
45393632|NCT00518687|Biological|Placebo|0.5-mL single injection of matching placebo
45393633|NCT00134056|Drug|atrasentan hydrochloride|Given orally
45393634|NCT00134056|Drug|docetaxel|Docetaxel given IV and prednisone given orally
45393635|NCT00134056|Drug|prednisone|Docetaxel given IV and prednisone given orally
45393636|NCT00134056|Other|placebo|Given orally
45393637|NCT00518531|Drug|alendronate|Subjects will take 70 mg QW of oral alendronate for 1 year. If a subject is randomized to Treatment Sequence A they will receive alendronate for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive alendronate for 1 year in Treatment Period 1.
45393638|NCT00518531|Drug|denosumab|Subjects will receive 60 mg of denosumab Q6M SC for 1 year. If a subject is randomized to Treatment Sequence A they will receive denosumab for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive denosumab for 1 year in Treatment Period 1.
45393639|NCT00351468|Drug|eltrombopag olamine (SB-497115-GR)|Eltrombopag with starting dose of 50mg daily, max dose of 75mg daily and min dose of 25mg daily or less frequently. Modifications were given to maintain platelet count in range of 50 to 200 Gi/L.
45393640|NCT01326364|Procedure|Stereotactic body radiotherapy|Standard of Care
45393641|NCT01326364|Drug|Iodixanol|IV, calculated per patient
45393642|NCT01326364|Drug|Iohexol|IV, Calculated per patient
45393643|NCT01080430|Other|rehabilitation maneuver|rotation in the direction of the weak vestibular response, every 3-7 days over a period of a month. Each rotation lasts about 2 minutes and a total of 3-7 rotations are used per session.
45393644|NCT01326442|Other|low glycemic diet|a low glycemic diet, calorie restricted with exercise sessions 3 times per week
45393645|NCT01326442|Dietary Supplement|vitamin D omega-3|2000 IU vitamin D3 plus 1.8 g EPA + DHA per day for 16 weeks.
45393646|NCT00523991|Drug|tiotropium|Oral inhalation once daily of 18mcg tiotropium via handihaler
45393647|NCT00523991|Drug|Placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
45393648|NCT00350844|Drug|Hydroxyurea|20 mg/kg/day and dose escalating every 2 months until maximum tolerated dose.
45393649|NCT00345540|Drug|NOV-002|60 mg / mL / day / 20-23 Days
45393650|NCT00345540|Drug|Carboplatin|AUC 5 following IV bolus administration of NOV-002
45393651|NCT00335322|Drug|Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz)|Truvada (tenofovir 300mg qd + 200mg qd) once daily Efavirenz 600mg qd once daily
45393652|NCT00335322|Drug|Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily ritoanvir/atazanavir 100mg/300mg qd once daily (taken with food)
46056970|NCT04087915|Drug|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference
45393653|NCT00335322|Drug|Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily zidovudine 250mg/300mg qd (taken in two equal doses approximately 12 hours apart) Abacavir 600mg qd
45393654|NCT03986346|Device|pulsed dye laser|The scar will receive PDL 585 nm using a 7 mm spot size. First treatment will be within 1 year post injury.
45393655|NCT03986346|Other|standardized care|the scar will receive standardized care such as scar massage.
45393656|NCT01059396|Drug|propranolol|GPVH ≥ 10 mmHg - responders: propranolol.
45393657|NCT01059396|Drug|carvedilol|GPVH ≥ 10 mmHg nonresponders: carvedilol.
45393658|NCT01059396|Drug|placebo|placebo propranolol / carvedilol
45393659|NCT01057680|Dietary Supplement|creatine monohydrate|Powder, 0.1 g per day, 12 months
45393660|NCT01057680|Dietary Supplement|sugar placebo|powder, 0.1 g/day, 12 months
45393661|NCT00523367|Procedure|24 hour pH testing|24 hour pH testing will be used to screen patients
45393662|NCT01059474|Drug|transdermal DMPS|"12 hr urine mercury and creatinine levels will be measured on all volunteers prior to any treatment. The urine will be collected in acid-washed or heavy-metal-free specialty containers. Each volunteer will then receive 120 mg of transdermal DMPS, applied to the bicep area of one arm. The area of application will not exceed 2% body surface area. After dosing, urine will be collected for the next 12 hours (using the same protocol and send-out procedure) and assayed for mercury and creatinine levels.~Additionally, after dosing, an intravenous catheter will be placed in the arm of each subject for blood draws. Blood samples will be obtained at 30 minutes, 60 minutes, 90 minutes, 2 hours, 4 hours and 6 hours after application of the DMPS."
45393663|NCT01059552|Drug|vorinostat|vorinostat once daily for 12 weeks of therapy
45393664|NCT03741894|Drug|Iodoform|Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture placements for a week.
45393665|NCT03741894|Other|Wound closure using sutures|Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.
45393666|NCT03741894|Drug|Chlorhexidine|Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.
45393667|NCT03755765|Drug|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
45393668|NCT03755765|Biological|BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
45393669|NCT03755765|Other|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
45393670|NCT01061112|Drug|Flurbiprofen Control - Flurbiprofen Only|A single 50 mg flurbiprofen dose taken at the start of the study period. No other drugs administered during this study period.
45393671|NCT01061112|Drug|Flurbiprofen Inhibition - Flurbiprofen & Fluconazole|A single 50 mg flurbiprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
45393672|NCT01061112|Drug|Ketoprofen Control - Ketoprofen Only|A single 75 mg ketoprofen dose taken at the start of the study period. No other drugs administered during this study period.
45393673|NCT01061112|Drug|Ketoprofen Inhibition - Ketoprofen & Fluconazole|A single 75 mg ketoprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
45393674|NCT01061112|Drug|Tolbutamide Control - Tolbutamide Only|A single 500 mg tolbutamide dose taken at the start of the study period. No other drugs administered during this study period.
45393675|NCT01061112|Drug|Tolbutamide Inhibition - Tolbutamide & Fluconazole|A single 500 mg tolbutamide dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
45393676|NCT04780841|Drug|RDX013|RDX013 is an experimental drug that is a potassium secretagogue
45393677|NCT04780841|Drug|Placebo|Placebo treatment that looks identical to experimental treatment
45393678|NCT01061190|Drug|Propranolol|oral application of 160 mg Propranolol for 30 days
45393679|NCT00344448|Drug|Raptiva|During the first phase of the study, subjects are randomized in a double blind fashion to receive weekly subcutaneous injections of efalizumab (Raptiva) or placebo (weeks 0-12). The second 12 weeks long phase is open label with all subjects receiving weekly subcutaneous injections of efalizumab.
45393680|NCT00324168|Drug|Antibiotics|moxifloxacin 0.5% every one hour for 48 hours while awake and then every 2 hours until re-epithelialization
45393681|NCT00324168|Drug|Topical corticosteroid|prednisolone phosphate 1% with preservative four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
45696881|NCT03033004|Device|Contrast Cryolipolysis|Treatment will consist of a heat exposure of the subcutaneous fat for 10 minutes followed by 60 minutes of cold exposure and 10 minutes of heat exposure again. Cold and heat will be provided by the Polarys device. Polarys is a commercially available cryolipolitic device.
45848881|NCT05288946|Other|traditional therapy|the patients will receive exercise in the form of Sitting knee raise on gym ball to maintain stability in the presence of hip movement on a reduced base of support, abdominal slide to control action of the rectus abdominis while moving, Lying trunk curl with leg lift to strengthen upper and lower abdominals (figure 1-6), Basic superman to strengthen the spinal and hip extensors
45848882|NCT05270460|Drug|PCS12852|PCS12852 oral tablet administered once daily
45848883|NCT05270460|Drug|Placebo|Placebo comparator oral tablet administered once daily
45848884|NCT05263830|Other|Quantitative assay of GlypicanPC-3|Quantitative assay of GlypicanPC-3 in human serum is performed by direct sandwich immunoassay ( CanAg Glypican3 EIA - Fujirebio ) on microplate using two mouse monoclonal antibodies against two epitopes of the Glypican-3 core protein
45848885|NCT05164614|Combination Product|RT-102 (80 μg)|RaniPill capsule containing PTH with doses of 20 and 80 μg
45848886|NCT05164614|Drug|Forteo|A commercial formulation of PTH for SC control (20 µg)
45848887|NCT05164614|Combination Product|RT-102 (20 μg)|RaniPill capsule containing PTH with dose of 20μg
45848888|NCT05145738|Behavioral|C-Raven with avatar|Computer delivered intervention with the investigators' avatar; with linkage to community health worker.
45848889|NCT05145738|Behavioral|C-Raven without avatar|Computer delivered intervention without the investigators' avatar; with linkage to community health worker.
45393682|NCT00324168|Drug|Placebo|0.9% NaCl and preservative (same as in steroid) four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
45848890|NCT05001048|Drug|Phenylephrine Hydrochloride|Series of three incremental bolus injections to observe α1-adrenoreceptor mediated vasoconstriction.
45848891|NCT05001048|Other|Cold Pressor Test|Standardized sympathetic stressor involving submersion of the hand in ice-cold water for 3-minutes, aiming to elicit endogenous neurotransmitter release and blood pressure increases.
45393683|NCT00517829|Drug|Docetaxel|Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour
45393684|NCT00517829|Drug|cetuximab|ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
45393685|NCT00517829|Drug|oxaliplatin|Eloxatin 130 mg/m2 IV over 2 hours
45393686|NCT00343512|Drug|docetaxel|Docetaxel 75 mg/m2 IV (1-hour infusion) on day 1 of each cycle (cycle = 2 weeks) x 4 cycles
45393687|NCT00343512|Genetic|protein expression analysis|protein expression analysis
45393688|NCT00343512|Other|laboratory biomarker analysis|laboratory biomarker analysis
45393689|NCT00343512|Procedure|biopsy|biopsy
45393690|NCT00343512|Procedure|conventional surgery|conventional surgery
45393691|NCT00343512|Procedure|neoadjuvant therapy|neoadjuvant therapy
45393692|NCT00334542|Drug|simvastatin|24-28 weeks of simvastatin
45696882|NCT03033004|Device|Reperfusion Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes followed by 10 minutes of heat exposure using the Polarys device. Polarys is a commercially available cryolipolitic device.
45696883|NCT03085641|Device|Nasal high flow oxygen therapy|nHFT will be titrated during a first titration night and used at home during the night for 4 weeks consecutively
45848892|NCT05001048|Other|Isocapnic Acute Hypoxia|During low altitude assessment, participants will be exposed to isocapnic hypoxia equivalent to 3,800m to assess responses to acute exposure.
45848893|NCT05001048|Other|Hyperoxia|During high altitude assessments, participants will breathe an oxygen concentration comparable to their end-tidal values at low altitude for the assessment of the influences of acclimatization.
45848894|NCT04954638|Other|endodontic desinfection|"outcome assessment of the retreatment of endodontically treated teeth presenting chronic apical periodontitis~effectiveness of hyperpure chlorine dioxide compared with sodium hypochloride~using microbiological methods~outcome assessed by radiological method and clinical evaluation"
45848895|NCT04906200|Other|Best Practice|Receive usual care
45848896|NCT04906200|Other|Internet-Based Intervention|Receive access to YES portal
45848897|NCT04906200|Other|Survey Administration|Complete survey
45393693|NCT01059942|Other|mock handoff exposure|Attending and house-staff physicians will analyze six video scenarios using the Hand-off CEX, rating each of the dimensions of hand-off competence for both the senders and receivers of the mock hand-off.
45393694|NCT01059942|Other|Introduction of CEX tool in Actual Hand-offs|We will teach hospitalist physicians and house-staff how to utilize the Hand-off CEX in conducting their own hand-offs.
45393695|NCT00112294|Drug|Paclitaxel (Taxane)|IV, 225 mg/m^2
45393696|NCT00112294|Drug|Docetaxel (Taxane)|IV, 75 mg/m^2
45393697|NCT00112294|Drug|Carboplatin|AUC=6, q 3 weeks (6 cycles maximum)
45696884|NCT03033082|Other|Questionnaire sheets|"A- Marital satisfaction Index (MSI). Interview (Modified Arabic translation)~B- Sexual Satisfaction Scale:(SSS). The Arabic version of the sexual satisfaction scale was used.~C- International Index of Erectile Function Questionnaire (IIEF-5): For male subjects.~D- The Eysenck Personality Questionnaire (EPQ):~The Arabic version of the EPQ was used."
45848898|NCT04848870|Other|Salivary samples|collection of salivary samples from Sjögren patients on routine care in the oral medicine department.NA
45848899|NCT04810572|Dietary Supplement|Composition with Silymarin|"Volunteers will receive supplementation for 90 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30 and 90 days from the beginning of supplementation."
46056971|NCT04078035|Behavioral|Socio-evaluative speech task|5-minute speech task designed to induce physiological arousal in a laboratory setting.
46056972|NCT04078035|Behavioral|Control, Quiet Rest|5-minute quiet rest period.
46056973|NCT04073979|Device|Mistral implantation|Mistral implant is implanted in the Tricuspid valve
45393698|NCT00112294|Drug|Cetuximab|Intravenous, 400 mg/m^2, initial dose followed by 250 mg/m^2, weekly starting on Week 2
45393699|NCT00235443|Drug|lacosamide|Open-label treatment (two times per day) with film-coated tablets include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, and 600mg/day throughout individual study period.
45502921|NCT03406572|Device|HFHO Group|"Common name: humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases~Brand name: Airvo 2"
45696885|NCT03033160|Drug|Estradiol Ring|
45696886|NCT03019354|Device|high-flow nasal oxygen|Using high-flow nasal oxygen 10 L/min before anesthesia induction, then using high-flow nasal oxygen 30-50 L/min during intravenous general anesthesia.
45696887|NCT03019354|Device|Oxygen mask|Using oxygen mask with oxygen flow 10 L/min before and during intravenous general anesthesia.
45696888|NCT04348539|Other|Balance training|32 sessions will be held twice a week, with each session taking an average of 45 minutes
45696889|NCT00958282|Drug|lisdexamfetamine/Behavior Therapy|
45696890|NCT00958282|Other|placebo|
45696891|NCT03473769|Other|Vital Signs at 2 Hours|Patients vital signs assessed at 2 hours of arrival at ICU
45696892|NCT03473769|Other|Confusion Assessment method for the ICU (CAM-ICU)|patient must have altered mental status/fluctuating course and inattention, and either disorganized thinking or altered level of consciousness to be CAM positive; these features are determined by observing the patient during bedside cognitive testing.
46056974|NCT04874961|Dietary Supplement|Tensiofytol|standardized olive extract
46056975|NCT04874961|Dietary Supplement|Cholesfytol NG|combination preparation
45393700|NCT03973437|Device|Artificial inteligence associated ulcerative colitis severity scoring system|Patients in this group go through a flexible colonoscopy under the AI monitoring device. During the withdrawal process, inflammatory lesions are detected by AI-associated scoring system. Pictures are automatically captured and analyzed by the computer. The Mayo ES and UCEIS sores will be calculated and presented on a second screen, providing a reference for the physician to evaluate the disease severity and mucosal healing stage of the patient. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
45393701|NCT03973437|Device|Conventional human scoring|Patients in this group go through a conventional colonoscopy without the AI monitoring device. During the withdrawal process, physician evaluates the disease severity and mucosal healing stage of the patient according to his personal experience. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
45393702|NCT00234039|Drug|gemcitabine hydrochloride|
45502922|NCT03406572|Device|Standard O2|Standard oxygen therapy
45502923|NCT02062424|Other|DIPI|
45502924|NCT03798704|Diagnostic Test|IFA, LIAISON|Comparison of two diagnostic serological tests - IFA and LIAISON.
45502925|NCT05384418|Radiation|HDP-Tc99m bone scintigraphy|HDP-Tc99m bone scintigraphy
45502926|NCT03153137|Drug|Macitentan 10 mg|film-coated tablet; oral use
45502927|NCT03153137|Drug|Placebo|film-coated tablet; oral use
45502928|NCT03572166|Diagnostic Test|Arginine infusion|Intravenous Infusion of Arginine is given, copeptin measurement will be collected before and 60minutes after start of infusion
46056976|NCT04874961|Other|Placebo|contains excipients only
46056977|NCT02715843|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
45393703|NCT03973359|Behavioral|Hygienic recommendations|Recommendation of protective behaviours such as frequent hand washing and avoiding risky behaviours such as kissing young children on the mouth or cheeks and sharing utensils, foods etc.
45393704|NCT02531451|Drug|Ibuprofen|
45393705|NCT02531451|Drug|Acetylsalicylic acid|
45393706|NCT01073007|Drug|Simvastatin|Simvastatin 40 mgrs daily for three months.
45393707|NCT03741621|Dietary Supplement|Viscous Fibre Blend|High viscosity viscous fiber blend sprinkled on wheat and maize bran cereals(Bran Buds®; Kellogg Company)
45502929|NCT03572166|Diagnostic Test|Hypertonic saline infusion|Intravenous Infusion of hypertonic Saline is given, copeptin measurement will be collected before and once Plasma sodium rises above 149mmol/l
45502930|NCT05654558|Device|Auxiliary cantilever intrusion arches on initial archwires|"Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription. Lower first molars received double tubed bands while 2nd molars received single bondable tubes. Leveling and alignment phase then started with 0.014 inch NiTi wires engaging all teeth and synched behind 2nd molars. Two 0.017 x 0.025 TMA (Ormco) sectional wires were attached to auxiliary tubes on 1st molars with tip back bends mesial to the molars and attached with hooks distal to lateral incisors on top of basal leveling arch wire. Amount of intrusive force was measured to range between 20 and 40 grams per side. Basal leveling arches were upgraded whenever needed. All patients were assessed after 6 months of treatment."
45502931|NCT05654558|Device|Routine leveling and alignment|Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription, 1st and 2nd molars received tubes or bands according to each patient's further needs Lower arch was leveled and aligned with sequential wires starting with 14 NiTi and upgraded when needed. All patients were assessed after 6 months of treatment.
45502932|NCT03616626|Radiation|Once Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
45848900|NCT04810572|Dietary Supplement|Low-mineral composition without Silymarin|"Volunteers will receive supplementation for 90 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30 and 90 days from the beginning of supplementation."
45848901|NCT04773600|Drug|ARQ-151 Active|ARQ-151 Cream 0.15% - Active
45696893|NCT03019276|Drug|TQ-B3101|Escalating doses of TQ-B3101 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 100 mg to 500 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days .
45848902|NCT04773600|Drug|ARQ-151 Vehicle Cream|ARQ-151 Cream - Vehicle
45696894|NCT03032926|Behavioral|Open Trial|Behavioral Intervention
45696895|NCT03033316|Drug|Dexamethasone|
45696896|NCT03032848|Drug|Conjugated Estrogen|use of 1 gram per day
45848903|NCT04772742|Drug|Placebo|Placebo - solution for infusion
45393708|NCT03741621|Dietary Supplement|Psyllium|Bran Buds cereal (white bran and maize bran) with psyllium (Bran Buds® with PSY; Kellogg Company)
45393709|NCT03741621|Dietary Supplement|Wheat Bran|All Bran cereal (All Bran®; Kellogg Company)
45393710|NCT00323622|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|IM injection in the deltoid muscle
45393711|NCT00323622|Biological|Engerix™-B|IM injection in the deltoid muscle
45393712|NCT00323622|Biological|Hiberix®|IM injection in the deltoid muscle
45393713|NCT00323622|Biological|Prevnar™|IM injection in the deltoid muscle
45696897|NCT03032848|Drug|Promestriene|use of 1 gram per day
45696898|NCT03032848|Drug|Estriol|use of 1 gram per day
45696899|NCT03032848|Drug|Vaginal Moisturizer - Cream|use of 1 gram per day
45848904|NCT04772742|Drug|Eptinezumab|Eptinezumab - 100 mg, solution for infusion
45848905|NCT04723758|Device|GI Genius-assisted diagnostic colonoscopy|Participants will undergo diagnostic colonoscopy, which will be identical to the normal standard of care at the unit where they are undergoing their procedure, except that GI Genius will be turned on during the procedure.
45848906|NCT04723758|Diagnostic Test|Diagnostic Colonoscopy|Diagnostic colonoscopy will be performed as per the standard of care for the unit where the patient is having their procedure.
45848907|NCT04702386|Behavioral|Focus groups|Groups of 3 to 8 children led by the study psychologist lasting 1 hour for the 8-11-year-old children and up to 2 hours for the children of at least 12 years old, about being the child of a parent with CF
45848908|NCT04702386|Behavioral|Individual interviews|Interview led by the psychologist about being the child of a parent with CF
45848909|NCT04575090|Drug|Simvastatin|Simvastatin 40 mg daily.
45848910|NCT04409418|Device|Extended dwell catheters|EDCs are generally placed using ultrasound for guidance and are commonly placed in any of 3 veins in the arm. They can be inserted above or below the antecubital fossa (the bend of your elbow). These catheters can be left for up to 30 days and don't fail as quickly when compared to peripheral IVs.
46056978|NCT02715921|Other|Tele-exercise|
45393714|NCT00323622|Drug|sulfadoxine-pyrimethamine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
45393715|NCT00323622|Drug|amodiaquine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
45393716|NCT00189423|Device|Use of an impedance threshold device (ITD) during the performance of active compression decompression CPR (ACD-CPR)|"The ITD selectively prevents the influx of unnecessary respiratory gases into the patient during the chest wall recoil phase of CPR.~The ResQPump, a hand-held device containing a suction cup, attaches to the chest and actively compresses and actively re-expands the chest during the performance of CPR."
45393717|NCT00189423|Procedure|Standard cardiopulmonary resuscitation (S-CPR)|Conventional standard cardiopulmonary resuscitation (S-CPR)
45393718|NCT01325961|Radiation|Intensity-Modulated Radiation Therapy|
45393719|NCT00323310|Drug|gadobenate dimeglumine|A dose of 0.10 mmol/kg (i.e., 0.2 mL/kg) of 0.5 molar MultiHance was injected intravenously at a rate of 2 mL/sec as a single dose.
46056979|NCT02715687|Drug|Amiodarone|Will receive 30 days treatment with oral amniodarone of 200mg
45393720|NCT01326039|Drug|bupivacaine|perineural bupivacaine 5 mg/ml 20 ml
45393721|NCT01326039|Drug|saline|perineural isotonic saline 20 ml
45393722|NCT01057758|Drug|SIMVASTATIN|Patients will receive 60 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study ICU.
45393723|NCT01057758|Drug|PLACEBO|Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study ICU
45393724|NCT00186537|Drug|Rosiglitazone|
45393725|NCT00186537|Drug|Fenofibrate|
45393726|NCT00186537|Behavioral|Weight Loss|
45393727|NCT03968835|Other|Bacitracin|For the first 30 people, bacitracin will be applied and covered with xeroform and gauze.
45502933|NCT03616626|Radiation|Twice Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week
45502934|NCT03616626|Radiation|Whole Breast Irradiation|Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years
45502935|NCT03617484|Drug|Bortezomib|Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m^2 on days 1, 4, 8, and 11 of each 21-day cycle.
45502936|NCT03617484|Drug|Ibrutinib|Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.
45502937|NCT01344473|Device|Tooth Mousse creme (Casein Phosphopeptide)(RECALDENT)|TM is a water based creme containing RECALDENT. RECALDENT consists of CPP-AP: Casein Phosphopeptide - Amorphous Calcium Phosphate.
45393728|NCT03968835|Other|Skin Graft|For the next 30 patients, the amputated composite skin and soft tissue unit will be thinned out to become a full thickness skin graft.
45393729|NCT01073085|Behavioral|"Web-based automated coaching by e-mails"|
45393730|NCT01073085|Behavioral|Self-help guide|
45393731|NCT00517751|Device|X-STOP PEEK|Placement of X-STOP PEEK in up to two levels in the lumbar spine for patients diagnosed with moderately symptomatic lumbar spinal stenosis in accordance with current labeling instructions for use.
45393732|NCT00322842|Drug|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
45393733|NCT04726085|Drug|Indomethacin 150mg|Patients will be randomized to either received perioperative indomethacin or ibuprofen at the time of their emergent cerclage placement for 24 hours following surgery. Patient will be followed up through our electronic medical record system to determine gestational latency to evaluate if ibuprofen is inferior to indomethacin.
45393734|NCT04726085|Drug|Ibuprofen 2400mg|Patients will be randomized to either received perioperative indomethacin or ibuprofen at the time of their emergent cerclage placement for 24 hours following surgery. Patient will be followed up through our electronic medical record system to determine gestational latency to evaluate if ibuprofen is inferior to indomethacin.
45393735|NCT00255723|Drug|carboplatin|Given IV
45393736|NCT00255723|Drug|etoposide|Given IV
45393737|NCT00255723|Drug|ifosfamide|Given IV
45393738|NCT01060176|Drug|Tranexamic Acid|
45393739|NCT01060176|Drug|Saline Solution|
45393740|NCT04719845|Procedure|Endoscopic laser resection|Laser resection
45393741|NCT04719845|Procedure|Dilatation|Dilatation
45393742|NCT01071837|Drug|APG101|400mg weekly as intravenous infusion
45502938|NCT02063204|Drug|selumetinib|selumetinib 50 mg (2x25mg) administered by mouth as capsules
45502939|NCT03617406|Diagnostic Test|Volume Challenge|Addition volume challenge with passive leg raising method in LDDSE as well as administration of normal saline and dobutamine during TEE
46056980|NCT02715687|Drug|Placebo|Will receive 30 days treatment with oral placebo of 200mg
45393743|NCT01071837|Procedure|Blood drawing|Blood drawings, e.g. for safety labs, abdominal ultrasound, ECG. Re-Irradiation is not considered a study procedure, but standard of care (inclusion criterion)
45393744|NCT01057836|Behavioral|Neck endurance training|
45393745|NCT01057836|Behavioral|Stretching|
45393746|NCT04305977|Behavioral|WAVE-TW|The WAVE-TW open pilot trial of the intervention consists of 5 sessions conducted individually with each part participant. Each session lasts approximately 30-50 minutes. The first session will be the LifeSteps Adherence session that focuses on cognitive-behavioral and problem-solving techniques to promote adherence. The next four sessions will be dedicated to trauma writing.
45393747|NCT00132808|Drug|Zoledronic Acid|Zoledronic acid 5 mg intravenous
45393748|NCT00132808|Drug|Placebo|Physiologic 0.9% normal saline
45393749|NCT03983148|Behavioral|Motivational interviewing|There are 3 sessions. Each session is an about 60-minute individual motivational interviewing held by a trained registered nurse. The first session aims to develop an action plan that enables the parents to promote physical activity (PA) for their children. The second session targets to review the adherence to the action plan. The nurse will discuss the progress. In the last session, the aim is to motivate the parents promoting PA for their children in the long run. As such, the benefits of PA throughout the survivorship will be emphasized. And the nurse will work with the parents to identify the resources that can help maintain the designed action plan.
45393750|NCT03983148|Behavioral|Placebo control|"Other than usual medical care received by children, parents in this group will receive an individual, face-to-face intervention which mimics the time and attention received by those in the experimental group. The intervention includes three sessions of educational talk to parents of children with cancer on healthy diet for cancer patients, adverse effects of cancer treatment, methods to minimize adverse effects.~Subjects in both groups will receive a booklet developed by the advisory committee, which contains a various kind of physical activities specially designed for children with cancer."
45393751|NCT03741387|Other|Gain-frame questionnaire|Questionnaires focusing on the attitude of saving patients' lives were given to Rh negative blood donors in this group.
45393752|NCT03741387|Other|Loss-frame questionnaire|Questionnaires focusing on the attitude of preventing patients from death were given to Rh negative blood donors in this group.
45393753|NCT04714463|Procedure|Implant-based breast reconstruction|All types of implant based breast reconstructions
45393754|NCT04714463|Procedure|Autologous breast reconstruction|All types of autologous breast reconstructions
45393755|NCT04714463|Procedure|Combined methods|All types of breast reconstructions combining autologous and implant based techniques
45393756|NCT03982992|Drug|Blinatumomab in combination with donor lymphocyte infusion|Continuous blinatumomab infusion in combination with allogeneic donor lymphocyte infusion
45393757|NCT03695471|Biological|Pembrolizumab|Given IV
45393758|NCT01061268|Drug|No topical artificial tear|40 patients randomized to not using a topical artificial tear.
45393759|NCT01061268|Drug|Blink® Tears Lubricant Eye Drops|Blink® Tears Lubricant Eye Drops
45393760|NCT01061346|Other|40% Fat Diet, 20% Fructose Beverage|40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
45393761|NCT01061346|Other|20% Glucose Beverage|40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
46056981|NCT00742417|Biological|Albutein 5%|"18 Plasma Exchanges using Albutein 5%:~three weeks of intensive treatment with two plasma exchanges per week~six weeks of maintenance treatment with one weekly plasma exchange~three months of maintenance treatment with one plasma exchange every two weeks"
45393762|NCT01061346|Other|20% Glucose Beverage|20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein
45393763|NCT01057914|Dietary Supplement|Nutritional supplementation with a liquid formula|The patient consumes 400 kcal from a liquid supplementation formula
45393764|NCT01057914|Other|Dietary advice|The patient receives dietary advice for one hour during the hospital stay.
45393765|NCT01057914|Other|Combination of supplement and dietary advice|The patient receives dietary advice for one hour during the hospital stay and consumes 400 kcal from liquid supplementation formula for six month after discharge.
45393766|NCT00517361|Drug|carboplatin|AUC 6 in 250mL saline IV over 30 minutes
45393767|NCT00517361|Drug|bevacizumab|15mg/kg in 100mL saline IV over 60 - 90 minutes
45393768|NCT03984552|Behavioral|This was an observational study of medical devices (rapid tests) used for the HIV diagnosis in children up to 2 years|"These rapid tests are based on lateral flow immunochromatography technology, in which a nitrocellulose membrane is impregnated with the antigen of interest. The patient sample (blood, serum, plasma, oral fluid, etc.) is applied in this membrane which facilitates the interaction of antibodies in the sample with the antigens on the membrane. This reaction becomes visible to the naked eye thanks to a color developing revelator.~The entire testing process, from sample collection to result reading takes no more than 40 minutes and does not depend on laboratory facilities."
45393769|NCT03984864|Other|Exercise therapy|3-4 items from a list of 10 general exercises - intended for treatment of low back pain
45393770|NCT00516893|Biological|BG00002-E (natalizumab high titer)|
45393771|NCT01565135|Behavioral|Multimodal Vaccine Program|"Efforts will be made to collaborate with private ob/gyn offices to develop a multimodal intervention to improve patients'immunization rates. As part of the overall intervention, intervention practices will agree to 1) purchase, stock, and administer influenza, HPV, and Tdap vaccines, if not already doing so and 2) track patients' vaccination status. In addition, intervention strategies adopted by intervention settings to improve immunization rates may include:~Patient education regarding the importance of vaccination, including encouragement of vaccination for family members~Practice-based reminder/recall~Seek to decrease missed opportunities for immunization by using either or both of the following: provider prompts and/or provider education and feedback"
45393772|NCT01565213|Behavioral|CBT|group cognitive behavioural based therapy (CBT) administered by psychologists once a week for 12 weeks,
45502940|NCT01344551|Dietary Supplement|Cocoa Drink|High Flavanol (495mg) Low Flavanol (23mg) Matched for macro and micro nutrients
45393773|NCT01565213|Behavioral|MMI|group multimodal intervention (MMI) based on a protocol comprising a mix of existing group interventions and exercises borrowed from multiple techniques and therapeutic schools and administered by assistant nurses with brief training, including two sessions per week for 6 weeks.
45393774|NCT01565213|Behavioral|CAU|Care as usual by the GPs
45393775|NCT04279067|Device|BCI-FES dorsiflexion therapy|"BCI technology enables direct brain control of external devices such as assistive devices and prostheses by translating brain waves into control signals. When BCI systems are integrated with functional electrical stimulation (FES) systems, they can be used to deliver a novel physical therapy to improve movement after stroke. The automated software will analyze the data to generate and calibrate a BCI decoder. In the online phase, the subjects will perform 20-25 BCI-FES runs. In each run, subjects will follow 10 alternating epochs of 10-s long idling/dorsiflexion textual cues, and respond by either idling or attempting dorsiflexion to elicit BCI-FES mediated contractions of the TA muscle."
45393776|NCT04279067|Behavioral|Physiotherapy one hour|This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
45393777|NCT04279067|Behavioral|Physiotherapy two hours|This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
45393778|NCT04270955|Procedure|Embolization of the Middle Meningeal Artery|Using established endovascular techniques and materials patient will have a diagnostic catheter based angiogram performed on the side(s) of the brain where the subdural hematoma is present. After verifying the vascular anatomy to ensure safety of the procedure the Middle Meningeal Artery will be embolized.
45393779|NCT04270955|Procedure|Standard of care including possible surgical evacuation of subdural hematoma|Standard of care could include observation or intervention including surgical drainage of subdural hematoma by bedside drain, Subdural Evacuating Port System (SEPS), burr hole or craniotomy
45393780|NCT04171661|Biological|SASS|SASS applied on chronic skin wounds as skin graft
45393781|NCT03657641|Biological|Pembrolizumab|Given IV
45393782|NCT03657641|Drug|Regorafenib|Given PO
45393783|NCT03649841|Drug|Antiandrogen Therapy|Undergo ADT
45393784|NCT03649841|Drug|Abiraterone Acetate|Undergo Abiraterone Acetate Treatment SOC
45393785|NCT03649841|Drug|Prednisone|Undergo Prednisone Treatment SOC
45393786|NCT03649841|Radiation|Radiation Therapy|Undergo neutron radiation therapy
45393787|NCT04171115|Drug|G03-52-01|G03-52-01 administered intramuscularly
45393788|NCT04171115|Drug|Placebo|Placebo administered intramuscularly
45393789|NCT00522431|Drug|Testosterone|2% gel
45393790|NCT00185211|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
45393791|NCT00185211|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
45393792|NCT00516737|Drug|Comparator: rizatriptan benzoate|Rizatriptan 10 mg Orally Disintegrating Tablet (ODT); one dose, treatment of a single migraine attack
45393793|NCT00516737|Drug|Comparator: Placebo|Matching placebo; one dose, treatment of a single migraine attack
45393794|NCT03540485|Drug|Melatonin|Daily administration of 100 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm
45393795|NCT03540485|Other|Placebo|Daily administration of placebo orally, for 24 months between 10pm to 11pm
45393796|NCT01582035|Drug|TMC647055|type=exact number, unit=mg, number=500, form=solution, route=oral use. Panel 1: TMC647055 is to be taken twice daily at a dose of 500 mg per day for 10 days.
45393797|NCT01582035|Drug|TMC647055|type=exact number, unit= mg, number=up to macimum 1000, form=solution, route=oral use. Panel 2: TMC647055 is to be taken twice daily at a maximum dose of 1000 mg for 10 or 14 days.
45696900|NCT00080223|Drug|Pirfenidone|up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
45696901|NCT03472443|Other|acupuncture|Subjects will receive Sinew Acupuncture 2-3 times in two weeks, a total of 5 sessions. Needles will be inserted into the Sinew Acupoints on the affected wrist and forearm. Needles will be inserted along the subcutaneous level, nearly parallel to the skin, and the tip of needles pointing towards the painful spot at the radial styloid. 4-6 sinew acupoints will be used.
45696902|NCT04402359|Drug|meropenem|meropenem one gram slowly IV infusion every 8 hours for 14 days
46056982|NCT00742417|Other|Control|Control group followed the same schedule; however, they did not undergo plasma replacement (it was subjected to simulated plasma replacements)
46056983|NCT04068831|Drug|Talazoparib|1 mg talazoparib daily
46056984|NCT04068831|Drug|Avelumab|800 mg avelumab every 2 weeks
46056985|NCT00917995|Device|Polypropylene Mesh, density 25-40g/square meter|colostomy with a prophylactic hernia mesh
45393798|NCT01582035|Drug|TVR|type=exact number, unit= mg, number=1125, form=tablet, route=oral use. TVR is to be taken twice daily at a dose of 1125 mg for 10 days.
45502941|NCT03618108|Drug|Doxycycline Capsule|doxycycline capsule
45502942|NCT03618108|Drug|Azithromycin Capsule|azithromycin capsule
45502943|NCT03618108|Drug|Rifabutin Oral Capsule|rifabutin capsule
45502944|NCT03618108|Drug|Placebo oral capsule|Placebo oral capsule identical in size and form to doxycycline
45502945|NCT03618108|Drug|Placebo Oral Tablet|Placebo oral capsule identical in size and form to azithromcyin
45696903|NCT04402359|Drug|ceftazidime 2 grams and avibactam 500|received ceftazidime 2 grams and avibactam 500 mg every 8 hours for 14 days in solution for injection(sodium chloride 9 mg/mL (0.9%), sodium chloride 4.5 mg/mL, dextrose 25 mg/mL, 0.45% sodium chloride, 2.5% dextrose and/or Lactated Ringer's solution).
46056986|NCT04859517|Drug|ADG20|Single dose of ADG20
46056987|NCT04859517|Drug|Placebo|Single dose of placebo
45393799|NCT01582035|Drug|TVR|type=exact number, unit=mg, number=1125 or 1500, form=tablet, route=oral use. In panel 2: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 10 or 14 days. In panel 3: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 6 days with on day 6 a morning dose only.
45393800|NCT01582035|Drug|TVR|type= exact number, unit= mg, number=750, form=tablet, route=oral use. TVR is to be taken every 8 hours at a dose of 750 mg for 12 weeks.
45393801|NCT01582035|Drug|PegFN|type= exact number, unit= mcg, number=180, form=solution, route=subcutaneous. PegIFN is to be injected once per week for 24 or 48 weeks.
46056988|NCT02715999|Procedure|Quadratus Lumborum Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory.All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally at the posterior border of the quadratus lumborum muscle
45393802|NCT01582035|Drug|RBV|type=exact number, unit=mg, number=1000 or 1200, form=tablet, route=oral use. RBV is to be taken at 1000 or 1200 mg per day in 2 divided doses, depending on the weight for 24 or 48 weeks.
45393803|NCT00132730|Drug|MK-0873 2.5 mg|
45393804|NCT00132730|Drug|MK-0873 1.25 mg|
45393805|NCT00132730|Drug|MK-0873 0.75 mg|
45393806|NCT00132730|Drug|Placebo to MK-0873|
45393807|NCT00132730|Drug|Usual Care|
45393808|NCT02531841|Drug|Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)|"Arm A 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~Rituximab 375 mg/m²/d i.v. (d0,5)~Methotrexate 3.5 g/m² i.v. (d1)~Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~Thiotepa 30 mg/m² i.v. (d4) Consolidation 2 cycles of R-DeVIC (every 3 weeks):~Rituximab 375 mg/m²/d i.v. (d0)~Dexamethasone 40 mg/d i.v. (d1-3)~Etoposide 100 mg/m²/d i.v. (d1-3)~Ifosfamide 1500 mg/m²/d i.v. (d1-3)~Carboplatin 300 mg/m² i.v. (d1)"
45393809|NCT02531841|Drug|Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)|"4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~Rituximab 375 mg/m²/d i.v. (d0,5)~Methotrexate 3.5 g/m² i.v. (d1)~Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~Thiotepa 30 mg/m² i.v. (d4) Consolidation~High-dose chemotherapy (HDT-ASCT):~Carmustine* 400 mg/m² i.v. (d-6)~Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~Autologous Stem Cell Transplantation (d0)~* if carmustine is not available at the investigation site, busulfan can be administered instead:~Busulfan 3,2 mg/kg/d (d-8-(-7))~Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~Autologous Stem Cell Transplantation (d0)"
45393810|NCT01074411|Drug|Bortezomib|Given IP
45393811|NCT01074411|Drug|Carboplatin|Given IP
45393812|NCT01074411|Other|Laboratory Biomarker Analysis|Correlative studies
45393813|NCT01074411|Other|Pharmacological Study|Correlative studies
45393814|NCT00232557|Device|TLC-Asthma|Telephone-linked communication (TLC) designed to improve asthma self-management by enhancing compliance with preventive medication regimens
45393815|NCT00232557|Device|TLC-health education|A telephone-linked communication system (TLC) to provide general health education.
45393816|NCT03973983|Procedure|Ultrasound-guided transgluteal pudendal nerve injection (TG-PNI)|Ultrasound-guided transgluteal pudendal nerve local anesthetic injections
45393817|NCT03973983|Procedure|Finger-guided transvaginal pudendal nerve injection (TV-PNI)|Finger-guided transvaginal pudendal nerve local anesthetic injections
45393818|NCT03973047|Drug|Bremelanotide|Sterile aqueous solution for injection, provided as an autoinjector pen
45696904|NCT04402359|Device|ventilator|all patients selected to be ventilated for 14 days
45696905|NCT00088179|Drug|pexelizumab in conjunction with CABG|
45696906|NCT00959764|Drug|Oral Calcitonin Tablets|Oral Calcitonin tablets along with matching placebo intranasal spray
45393819|NCT03973047|Drug|Zofran|8 mg tablet (over-encapsulation in a capsule)
45393820|NCT03973047|Drug|Placebo|capsule
45393821|NCT00522275|Drug|lacosamide|50mg or 100 mg tablets, up to 800 mg/day given twice daily (BID) throughout the trial
45393822|NCT01074567|Drug|DMSO cocktail|intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
45393823|NCT01582659|Other|Telephone counseling|2 planned telephone counseling sessions are conducted.
45393824|NCT01582659|Other|Web access|Access to a web site with information about childhood constipation similar to the information given at the first visit to the clinic.
45696907|NCT00959764|Drug|Intranasal Calcitonin|Intranasal Calcitonin Spray
45696908|NCT00959764|Drug|Placebo tablets and placebo intranasal spray|Oral Placebo Tablets/Intranasal placebo spray
45393825|NCT00522041|Drug|Cellegesic|Cellegesic was supplied as an ointment containing 0.4% w/w nitroglycerin.
45393826|NCT00522041|Drug|Placebo|Placebo was supplied as an ointment identical to Cellegesic ointment except that it contained no nitroglycerin.
45393827|NCT03519971|Drug|Durvalumab|Durvalumab IV (intravenous infusion)
45393828|NCT03519971|Other|Placebo|Placebo IV (intravenous infusion)
45393829|NCT03519971|Drug|Cisplatin/ Etoposide|Cisplatin/ Etoposide, as per standard of care
45393830|NCT03519971|Drug|Carboplatin/ Paclitaxel|Carboplatin /Paclitaxel, as per standard of care
45393831|NCT03519971|Drug|Pemetrexed/ Cisplatin|Pemetrexed / Cisplatin, as per standard of care
45393832|NCT03519971|Drug|Pemetrexed/ Carboplatin|Pemetrexed / Carboplatin , as per standard of care
45393833|NCT03519971|Radiation|Radiation|5 fractions/ week for ~6 weeks (±3 days) (Total 60 Gy)
45393834|NCT00122980|Procedure|Red Cell Transfusions|Red Blood Cell Transfusions
45393835|NCT00122980|Procedure|Iron Chelation|Iron Chelation Therapy
45393836|NCT00122980|Drug|Hydroxyurea|Hydroxyurea
45393837|NCT00122980|Procedure|Phlebotomy|Phlebotomy
45393838|NCT04671251|Drug|AEVI-007|50 mg of AEVI-007 and will be reconstituted with 1.2 mL of water for injection.
45848911|NCT04302948|Other|HCV RNA screening|The Cepheid Xpert testing requires a fingerstick to obtain blood spots which are then tested for HCV RNA. Results available within one to two hours, facilitating counseling for patients to link to care.
45393839|NCT01080508|Other|tracheal ventilation with regular tube|Description of the pressure waveforms during tracheal ventilation
45393840|NCT01080508|Other|ventilation after intubation with special tube|Description of the pressure waveforms during esophageal ventilation
45393841|NCT03868631|Dietary Supplement|Whey protein supplement|19 g whey protein isolate (contains 2 g leucine) was consumed daily by one intervention group.
45393842|NCT03868631|Dietary Supplement|Soy protein supplement|26 g soy protein isolate (contains 2 g leucine) was consumed daily by the other intervention group.
45393843|NCT01078480|Procedure|Operation using a precontoured titanium plate and screws|Operation using a precontoured titanium plate and screws
45502946|NCT03618108|Drug|Placebo oral capsule|Placebo oral capsule identical in size and form to rifabutin
45393844|NCT01078480|Procedure|Displaced midshaft fracture of the collar bone|Displaced midshaft fracture of the collar bone treated with an arm sling
45502947|NCT03138473|Diagnostic Test|Residual SYNTAX Score|"The baseline SYNTAX score and the residual SYNTAX score (rSS) are calculated by summing up the individual scores for each lesion with a diameter stenosis ≥50% in vessels with a diameter ≥ 1.5 mm in the angiography obtained before and after the procedure. The SYNTAX algorithm of scoring is fully described elsewhere.~The modified Age, Creatinine, and Ejection Fraction (ACEF) score is calculated based on the age, creatinine clearance (CrCl) and left ventricular ejection fraction (LVEF), using the formula age/LVEF +1 point for every 10 ml/min/1.73 m2 reduction of CrCl below 60 ml/min/1.73 m2 (1 point for CrCl between 59 and 50, 2 points for CrCl between 49 and 40 and 3 points for CrCl between 39 and 30 ml/min/1.73 m2). The CrCl is calculated via the Cockroft-Gault equation using age, gender weight and serum creatinine before PCI. The baseline SYNTAX score was then multiplied by the modified ACEF score to obtain the baseline clinical SYNTAX score."
45502948|NCT03138473|Diagnostic Test|SYNTAX Revascularization Index|The SYNTAX Revascularization Index (SRI), representing the proportion of CAD burden treated by PCI, was calculated using the following formula: SRI= (1-[rSS/bSS]) ×100.
45502949|NCT02031900|Device|NvisionVLE Imaging System: NvisionVLE Imaging Console, NvisionVLE Optical Probe and Inflation Accessory Kit|The NvisionVLE Imaging System is indicated for use as an imaging tool in the evaluation of human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization.
45502950|NCT04903704|Diagnostic Test|1 Minute Sit to Stand Test|Participants are asked to stand repeatedly from a chair for one minute without the use of their arms for support. The number of completed repetitions is counted.
45502951|NCT01342601|Device|ect4allergy Nasal Spray (ANS01) and Eye Drops (AAT01)|Comparison of ANS01 and AAT01 with placebo
45696909|NCT01005706|Drug|rapamune, mycophenolate mofetil and steroid|"At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator."
45393845|NCT02536079|Drug|NeuroAiD|
45393846|NCT00340704|Drug|tamsulosin hydrochloride|oral
45393847|NCT00132496|Drug|rabeprazole sodium|administered orally and once daily to patients randomized to receive either 10 mg or 20 mg.
45502952|NCT01342601|Device|Placebo products|Nasal Spray and Eye drops without Ectoin
45502953|NCT03616548|Diagnostic Test|Endoscopic surveillance|Magnifying endoscopy under narrow band imaging system via chimney ileostomy after intestinal transplantation
45393848|NCT01080586|Drug|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
45393849|NCT03965416|Other|White Coat|We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
45393850|NCT03965416|Other|Without White Coat|We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
45393851|NCT02531230|Device|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
45393852|NCT03984630|Behavioral|Dietary Fiber Intervention|Intervention included weekly group-based phone counseling with a Registered Dietitian (RD) to encourage consumption of a high fiber diet (≥30 g/day). All women reported their body weight weekly.
45393853|NCT00231777|Drug|Comparator: MK0517|a single administration of 40 mg MK0517 by IV immediately prior to surgery
45393854|NCT00231777|Drug|Comparator: ondansetron|a single administration of 4 mg ondansetron by IV immediately prior to surgery
45393855|NCT01076842|Drug|Insulin-Levemir|Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl
45393856|NCT01076842|Drug|Exenatide-Bayetta|Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.
45393857|NCT01076842|Drug|Insulin-Levemir and Exenatide-Bayetta|Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.
45393858|NCT01076842|Device|SenseWear Pro3® armband|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the SenseWear Pro3® armband for collection of ancillary physiologic data
45393859|NCT01076842|Device|DexCom CGM|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the DexCom CGM for collection of continuous blood glucose concentrations.
45393860|NCT01060332|Other|Body Constitution Questionnaire|Body Constitution Questionnaire was a tool for the study of objective evaluation of diagnostics of Traditional Chinese Medicine. It has been well developed with good validation and consistency.
45393861|NCT01060410|Genetic|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the bio-activation and elimination of cyclophosphamide
45393862|NCT01060410|Drug|Cyclophosphamide|intravenous injection, 0.2g, once every two days
45393863|NCT01060410|Other|Pharmacokinetic analysis|laboratory analysis of concentration of cyclophosphamide and 4-OH-cyclophosphamide in plasma
45393864|NCT01061424|Behavioral|community health worker|community health worker provides home visits for education
45393865|NCT01061424|Behavioral|mailed information|information on asthma is mailed to the home on the same schedule as the other arm
45393866|NCT00231465|Drug|docetaxel (Taxotere®)|Taxotere® will be administered to patients a maximum of 2 cycles, after a maximal response is achieved, and then discontinued.
45393867|NCT00231465|Drug|ZD1839|ZD1839 will be continued until progression, or until trial closure, whichever comes first.
45393868|NCT03986112|Biological|carotid sonography and inferior vena cava sonography|Carotid and venous ultrasonography is performed in a comfortable state. Corrected blood flow after carotid ultrasound and carotid artery blood flow rate were measured. After inferior vena cava sonography, the collapsibility Index by measuring the largest and smallest diameter during the respiratory cycle will be obtained. Propofol 2 mg / kg is administered and remifentanil is maintained at 4.0 ng / mL using the Target Control System. Blood pressure and heart rate are measured at prior to induction, 1 minute after induction, immediately after intubation, and at 1, 3, 5, 7 and 10 minutes after intubation. Post-induction hypotension is considered as a decrease of 20% or more of baseline blood pressure or a mean arterial blood pressure of less than 60 mmHg. In the event of hypotension in accordance with the above definition, repeated administration of ephedrine 4 mg or phenylephrine 50 mcg is used.
45393869|NCT01061502|Device|Procellera (Bioelectric Wound Dressing)|Dressing used on one-half of the donor graft site. Dressing changes every 5-7 days, more frequently if needed
45393870|NCT01061502|Device|Opsite (Transparent Adhesive Dressing)|Semi-occlusive wound dressing placed on one-half of the skin graft donor site. Dressing change every 5-7 days, more frequently if needed.
45393871|NCT00254397|Drug|Leuprolide|A 3-month 11.25 mg sustained-release formulation will be administrated intramuscularly at time 0, and approximately 12 weeks (2 injections).
45393872|NCT00254397|Biological|GP100: 209-217(210M) Peptide|1.0 ml subcutaneous injection in extremities.
45393873|NCT00254397|Biological|MAGE-3 Peptide|1.0 ml subcutaneous injection in extremities.
45393874|NCT03972735|Other|Psychiatric interview|PANSS, MADRS, PSP, YMRS
45393875|NCT03972735|Other|Clinical, diagnostic and functional evaluation|ISMI, STORI, SERS, S-QOL, WEWMBS, BIRCHWOOD, MARS
45393876|NCT03972735|Other|neuropsychological assessment|WAIS IV, BEM 144, TMT A, TMT B, D2-R, V-LIS
45393877|NCT03972735|Other|NECT PROGRAM|Narrative Development and Cognitive Therapy (NECT) is a 12 session group-based manualized intervention combining psychoeducation, cognitive restructuring and narrative enhancement. The 2h sessions are conducted by two trained facilitators.
45393878|NCT00254163|Drug|Fludarabine|
45393879|NCT00254163|Drug|Cyclophosphamide|
45393880|NCT00254163|Drug|Rituximab|
45502954|NCT04349657|Device|Supera Peripheral Stent System treatment group|Percutaneous endovascular stenting with the Supera Peripheral Stent System
45502955|NCT04349657|Procedure|Endarterectomy treatment group|Surgical treatment through endarterectomy
45848912|NCT04234152|Other|Photo-protection|The MV solution is delivered from producing companies in amber vials. The MV will be sampled by the pharmacy technician in a syringe that is photo-protected with a white label indicating the subject study name, protocol number and the infusion rate. The MV will be transported to the unit in the same photo-protected syringe. In the neonatal unit, this syringe will be installed in the pump and connected to photo-protected extension duration.
45393881|NCT00254163|Drug|Pentostatin|
45393882|NCT03869333|Biological|Invaplex[AR-DETOX]|Detoxified Shigella flexneri 2a Artificial Invasin Complex (Invaplex[AR-Detox]) Vaccine
45393883|NCT03869333|Other|Placebo|Saline
45393884|NCT00110890|Drug|cinacalcet|Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg.
45393885|NCT00110890|Other|Standard of care|Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.
45393886|NCT00182637|Drug|bortezomib|
45502956|NCT03616392|Drug|D308, CKD-501|"D308~CKD-501: Lobeglitazone sulfate 0.5mg"
45848913|NCT04234152|Other|Standard Care|This group will receive the standard practice of PN compounding in the pharmacy followed by infusion in standard infusion kit available in Sainte-Justine's Hospital.
45848914|NCT04100772|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）|0.5mL,Intramuscular other name:PCV13i
45393887|NCT01076920|Genetic|Mesenchymal stem cells|60x106 MSCs Trans-endocardial intramyocardial injections (n=14-16)
45393888|NCT00182325|Behavioral|personalized web prenatal information|
45393889|NCT00182325|Behavioral|general web prenatal information|
45393890|NCT01076998|Other|Lubricant eye drop FID 115958D|1 drop in each eye, one time
45393891|NCT01076998|Other|Refresh PM Ointment|1 drop in each eye, one time
45393892|NCT00122278|Drug|Dexamethasone|Dexamethasone 10mg IV
45393893|NCT00122278|Other|Placebo|Placebo Dexamethasone 10mg IV
45393894|NCT00182091|Drug|Recombinant human growth hormone|Starting dose based on age, sex, and estrogen status and ranged from 3-6 mcg/kg/day. GH doses were adjusted based on IGF-1 levels to target the mid-normal range for age.
45393895|NCT00182091|Drug|Saline|To maintain study-subject blinding, doses were sham adjusted.
45393896|NCT03398135|Drug|risankizumab|subcutaneous (SC) injection
45393897|NCT03398135|Drug|placebo for risankizumab|subcutaneous (SC) injection
45393898|NCT01072071|Drug|furosemide|"Loading dose: 0,5mg/kg Start continuous infusion at a dose of 0,1mg/kg/h and titrate according to diuretic response.~Target value for diuresis = (amount of fluids administered at inclusion/kg/h) + 0.5mL/kg/h If safety check is satisfactory: increase target diuresis with 1mL/kg/h per 4h to a maximum of (amount of fluids administered at inclusion/kg/h) + 2.5mL/kg/h Maximal dose of furosemide: 0.3mg/kg/h Safety check every 4h. Furosemide is administered for 24h. If safety checks are satisfactory, additional periods of 24 can be added up to a maximum of 72h."
45393899|NCT00181155|Drug|Allopurinol|intravenous infusion of allopurinol (300mg)
45393900|NCT00181155|Drug|Placebo|intravenous infusion of 50 ml dose of 5% dextrose
45848915|NCT04100772|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL,Intramuscular other name:Prevnar
45393901|NCT00322452|Drug|Gefitinib|oral tablet
45393902|NCT00322452|Drug|Carboplatin|IV
45393903|NCT00322452|Drug|Paclitaxel|IV
45393904|NCT03968523|Procedure|Novel local infiltration technique|Local analgesic infiltration in the mesh fixation site
45393905|NCT03968523|Procedure|TAP block|TAP block technique
45393906|NCT01073241|Procedure|transurethral ventral wall of urethra-preserving enucleation of prostate|The patients' ventral wall of the prostate urethra was preserved and enucleation of prostate was performed for the left hyperplasia in the envelop.
45393907|NCT01073241|Procedure|transurethral prostatic resection|The patients' prostate was resected with the conventional Nesbit TURP
45393908|NCT00110812|Drug|IL-2|7.5 MIU injected intramuscularly; one arm uses Proleukin together with HAART of choice (protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors)
45393909|NCT00516269|Drug|Methylphenidate|18 mg by mouth daily for 2 weeks
45393910|NCT00516269|Drug|Placebo|Capsule by mouth daily for 2 weeks
45393911|NCT04642859|Behavioral|Computerized Cognitive abilities training battery for reading (CATB-R)|Specially designed Arabic computerized training program for dyslexia
45393912|NCT04639037|Device|Automated adjustment of vasopressor|The objective of this randomized controlled superiority study is to demonstrate that, in patients admitted to intensive care after a major surgery, tight control of MAP using a closed-loop system for vasopressor administration will result in MAP being more often within a MAP range of 80-90 mmHg compared to the same management without this automated closed-loop system (nurse adjustment of vasopressor administration)
45393913|NCT04639037|Device|Manual adjustment of vasopressor|Fluid and vasopressor will be delivered as standard of care (manual adjustment of both fluid and vasopressor infusion rate by the nurse)
45393914|NCT00229203|Drug|Plitidepsin|3-hour infusion every 2 weeks alone or in combination with dexamethasone
45393915|NCT03973515|Drug|glucokinase activator|PB-201 is a kind of dual and partial GKA
45393916|NCT03973515|Drug|Placebo|Placebo oral tablet
45393917|NCT00228813|Drug|Granulocyte Colony Stimulating Factor|"FILGRASTIM: G-CSF (NEUPOGEN®) is administered as a short IV infusion over 30 minutes or subcutaneously. It is given beginning on day -3 for 3 days to the donor prior to the bone marrow harvest.~Drug Information: FILGRASTIM: G-CSF (Neupogen®) Formulation: G-CSF is available as a preservative-free solution for injection in 1.0 ml and 1.6 ml vials containing 300 mcg/ml.~Administration: G-CSF 5 mcg/kg/d will be given subcutaneously or as a short I.V. infusion over 30 minutes.~Recombinant GM-CSF at the dose of 250 mcg/m2 will be given intravenously from day +7 to help white counts recovery. The drug will be diluted in NS at a concentration of at least 10 mcg/ml.~Drug Information: Sargramostim (Leukine) Formulation: 250 mcg, 500 mcg lyophlized powder for injection"
45393918|NCT00322374|Drug|Ixabepilone|Infusion, intravenous (IV), Cycle = 21 days. Dose escalation study.
45393919|NCT00322374|Drug|Epirubicin|Infusion, intravenous (IV): 75 mg/m^2. Cycle = 21 days, up to 10 cycles or cumulative dose of 800 mg/m².
45393920|NCT00174447|Drug|Ziprasidone|Dosage may subsequently be adjusted according to clinical status, only at each protocol visit and step by step between 40, 60 and 80 mg bid
45393921|NCT00321984|Drug|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for 4 weeks.
45393922|NCT00321984|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
45393923|NCT00321984|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
45393924|NCT03982758|Other|isometric handgrip exercise|Isometric session with handgrip: 4 sets of 2 minutes of contractions sustained at 30% of CVM, for each arm. The time between sets and between arms will be 1 minute rest.
45848916|NCT04043520|Drug|GnRH antagonist|GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)
45848917|NCT04043520|Drug|Estrogen Product|Estrogen patches will be worn by those randomized to the Estradiol arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).
45393925|NCT03982758|Other|isometric of the lower limbs|Isometric session for lower limbs: 4 sets with 2 minutes of contractions sustained at 30% of 1RM. The rest interval will be 1 minute rest.
45848918|NCT04043520|Drug|Placebo estradiol|Placebo patches will be worn by those randomized to the placebo arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).
45393926|NCT03984708|Other|Samples|Blood sample, skin biopsy
45393927|NCT03984708|Other|Indirect calorimetry|Measurement of energy expenditure by indirect calorimetry
45393928|NCT03984708|Other|Electrical bioimpedance|Measurement of electrical bioimpedance
45393929|NCT01060488|Other|GHRH+Arg, GHRH+Arg, ITT|GHRH+Arg repeatability test (2 tests) + comparison with one IT test
45393930|NCT01060488|Other|ITT, ITT, GHRH+Arg.|IT repeatability test (2 tests) + comparison with one GHRH+Arg test
45393931|NCT01060566|Drug|VX-770|In period 1, subjects will receive a single oral dose of midazolam (2 mg) and on Day 1 and Day 8. Subjects will receive single oral dose of rosiglitazone 4 mg and on Day2 and Day 9. Subjects will receive multiple doses of VX-770 150 mg q12h Day 3-10.
45393932|NCT01060566|Drug|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from Day 1 through the morning of Day 8. On the morning of Period 2 Day 1, subjects will receive a 400 mg loading dose of fluconazole. Thereafter, subjects will receive 200 mg fluconazole qd orally from Day 2 through Day 9.
45393933|NCT02533284|Drug|Magnesium Sulfate|preemptive US guided TAP block will be done using Bupivacaine 0.25% plus 0.5 gm MgSo4 in M group).
45393934|NCT02533284|Drug|bupevecaine|US guided TAP using Bupevecaine 0.25 %
45393935|NCT02533284|Drug|saline|US guided TAP using placebo (saline)
45393936|NCT00515099|Drug|Antithymocyte globulin|Daily 4-day escalating dose
45393937|NCT00515099|Drug|Placebo|Daily 4-day saline solution
45393938|NCT03998423|Biological|Fecal Microbiota Transplant|Double-encapsulated Fecal Microbiota Transplant Capsules
45848919|NCT04043520|Drug|Placebo GnRH antagonist|Postmenopausal women randomized to the placebo injection arm will receive two placebo drug injections of normal saline (24-week intervention)
45393939|NCT00110266|Drug|Deferasirox|20 mg/kg/day over one year in patients with MDS
45393940|NCT00174291|Drug|Somatropin|Liquid, daily to final height Maximum Dosage: 50 µg/kg/day
45393941|NCT00366548|Biological|13 valent pneumococcal conjugate vaccine with Polysorbate 80|
45393942|NCT00366548|Biological|13 valent pneumococcal conjugate vaccine without Polysorbate 80|
45848920|NCT04012008|Other|Comprehensive care|"Regular follow-up by nephrologists every 1-3 month~Multidisciplinary team consisting pharmacists, nurses, and dieticians"
45393943|NCT01074645|Drug|Tenofovir disoproxil fumarate (TDF)|Tenofovir 300mg/day for 3 month
45393944|NCT00252057|Behavioral|Re-Engineered Hospital Discharge|"The Re-engineered Hospital Discharge (Project RED) intervention provides a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call after discharge by a clinical pharmacist."
45393945|NCT00132028|Drug|vorinostat|Given orally
45848921|NCT04012008|Other|Standard care|"Regular follow-up by internists every 3 month~May consult nephrologists case-by-case"
45393946|NCT00132028|Other|laboratory biomarker analysis|Correlative studies
45393947|NCT01080664|Drug|AS703569|"Dose Escalation~Regimen 1 - 3-47 mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion~Regimen 1 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops"
45393948|NCT01080664|Drug|AS703569|"Dose Escalation Regimen 2 - 3-47 mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion Regimen 2 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops."
45393949|NCT02534948|Behavioral|Mindfulness and acceptance group therapy|The manual group intervention will be provided as per the second edition of Mindfulness and Acceptance-Based Group Therapy for Social Anxiety Disorder: A Treatment Manual developed by Fleming, and Kocovski (2014). The intervention will consist of 10 group therapy sessions. Each session will be conducted in 120 minutes. It includes therapist manual, client handouts, and is written to be used in conjunction with The Mindfulness and Acceptance Workbook for Social Anxiety and Shyness. The treatment manual can be easily adapted for individual therapy clients.
45393950|NCT03992378|Device|Low Level Transcutaneous Vagus Nerve Stimulation|Stimulation of the auricular branch of the vagus nerve at tragus of the external ear delivered by Parasym device.
45393951|NCT03992378|Device|Low Level Transcutaneous Vagus Nerve Stimulation|Stimulation of the ear lobe delivered by Parasym device.
45393952|NCT01045304|Drug|Iniparib|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45393953|NCT01045304|Drug|Gemcitabine|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45502957|NCT04894968|Diagnostic Test|Assessment of the presence of heart failure with preserved ejection fraction, according to guideline recommendations from the European Society of Cardiology 2016|"Patient will be screened for the presence of heart failure with preserved ejection fraction, according to guideline recommendations from the European Society of Cardiology 2016.~This requires patients to fulfill all of the four criteria listed below:~Symptoms of heart failure (e.g. dyspnea on extertion)~Preserved ejection fraction (Left ventricular ejection fraction ≥50%~NT-proBNP ≥125 pg/mL~Echocardiographic signs for structural heart disease or diastolic dysfunction (at least one of the criteria below)~Left atrial volume index >34 mL/m²~Left ventricular mass index ≥115 g/m² for males or ≥95 g/m² for females~E/e' ≥13~Septal e' <9 cm/s"
45393954|NCT01045304|Drug|Carboplatin|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45393955|NCT01080742|Drug|Lodoz (Combination of bisoprolol and hydrochlorothiazide)|The investigator will decide in advance the best therapeutic strategy for each subject according to current practice, regardless of the potential participation of this subject in the study.
45393956|NCT01582828|Procedure|Epicardial (surgical) ablation|"Pulmonary vein isolation with bipolar clamps and bipolar box lesion~Epicardial atrial appendage closure"
45393957|NCT01582828|Procedure|Hybrid|"Epicardial (surgical) ablation~Pulmonary vein isolation with bipolar clamps and bipolar box lesion~Epicardial atrial appendage closure~Endocardial assessment after 6-8 weeks, checking for isolation and if necessary touch up by RF ablation"
45393958|NCT03992300|Device|Clinical adjustment|Accuracy of the framework is checked in the patient mouth by tactile perception, screwing torque, Sheffield test and radiography.
45848922|NCT03582930|Combination Product|Infasurf Aero|Aerosolization of Infasurf administered to premature babies suffering from RDS. Successful administration of Infasurf by aerosolization will provide two important benefits for patients. (1) endotracheal intubation may be able to be avoided in some patients, and (2) the adverse events at instillation due to filling the airway with liquid and interrupting breathing may be diminished or abolished.
45393959|NCT00131248|Drug|Metaclopramide|
45393960|NCT00131248|Drug|Ranitidine|
45393961|NCT00131248|Drug|placebo|
45502958|NCT03615378|Dietary Supplement|5000 IU D3|Daily
45502959|NCT03615378|Dietary Supplement|1000 IU D3|Daily
45502960|NCT03615378|Dietary Supplement|Placebo|lactose/sugar tablet
45848923|NCT03472872|Drug|Ketorolac|15mg ketorolac in 100mL 0.9% normal saline IVPB 1,000mg acetaminophen in a 100ml IVPB
45848924|NCT03472872|Drug|Acetaminophen|1,000mg acetaminophen IVPB
45393962|NCT00362414|Drug|Dual Growth Factor|"10,000 IU Beta-hCG IV on days 1, 3, and 5 of study participation~30,000 IU Erythropoietin IV on days 7, 8 and 9 of study participation"
45393963|NCT01080820|Drug|CMX157|One single oral dose of CMX157 will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the CMX157 dose.
45393964|NCT01080820|Drug|Placebo|One single oral dose of placebo will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the placebo dose.
45393965|NCT01080820|Drug|Viread|One single oral dose of 300mg Viread.
45393966|NCT01080898|Other|tests|color photographs, FLUORESCEIN angiography and OCT
45393967|NCT01048346|Behavioral|Individual Placement and Support Model|Psychosocial intervention involving an employment specialist working with participants recruited into the study and assisting with employment.
45393968|NCT03964558|Drug|[14C]-acebilustat solution|Acebilustat is a novel synthetic small molecule leukotriene A4 hydrolase (LTA4H) inhibitor.
45393969|NCT02534792|Other|Revalvulation|
45393970|NCT01082770|Device|TEGO|A bung that can be attached to the end of dialysis lines that can be directly attached to the dialysis machine with minimal handling
45393971|NCT01082770|Device|Standard|Patients in this group will have a normal 'bung' placed at the end of their dialysis line, which will need to be removed by nursing staff prior to initiation of dialysis
45393972|NCT01049204|Drug|Maraviroc|Maraviroc 150 mg twice daily for 24 weeks
45393973|NCT01049204|Drug|placebo|Placebo twice daily for 24 weeks
45393974|NCT00096382|Biological|aldesleukin|high dose: 720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days (maximum 5 doses) or low dose: 250,000 IU/kg subcutaneously daily for 5 days, after a two day rest, 125,000 IU/kg subcutaneously daily for 5 days for five weeks (2 days rest per week)
45393975|NCT00096382|Biological|filgrastim|10 mcg/kg/day daily subcutaneously until neutrophil count >1x10^9/1.
45393976|NCT00096382|Biological|therapeutic tumor infiltrating lymphocytes|Lymphocytes that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient.
45393977|NCT00096382|Drug|cyclophosphamide|60 mg/kg/day x 2 days intravenously over 1 hour
45393978|NCT00096382|Drug|fludarabine phosphate|25 mg/m^2/day intravenous piggyback daily over 15-20 minutes for 5 days
45393979|NCT00096382|Radiation|radiation therapy|Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.
45393980|NCT00359294|Drug|PM00104|Intravenously over 1 hour daily for 5 days, every 3 weeks.
45393981|NCT00384332|Drug|orally-disintegrating olanzapine|5 to 20 mg (daily) orally disintegrating olanzapine for approx.8 weeks.
45393982|NCT00384332|Drug|regular olanzapine|5-20 mg. olanzapine daily for approximately 8 weeks.
45393983|NCT00096226|Drug|Induction Carboplatin|
45393984|NCT00096226|Drug|Induction Paclitaxel|
45393985|NCT00096226|Procedure|Resection|
45393986|NCT00096226|Drug|Consolidation Carboplatin|
45393987|NCT00096226|Radiation|Radiation Therapy|
45393988|NCT00096226|Drug|Consolidation Paclitaxel|
45502961|NCT03000101|Other|100% pomegranate juice|125 mL of 100% pomegranate juice twice daily for 12 weeks
45502962|NCT03000101|Other|placebo beverage|125 mL of placebo beverage twice daily for 12 weeks
45848925|NCT03466476|Device|Consensus TracPatch|Consensus TracPatch will be attached to the participant's shin approximately two inches below the knee through use of an adhesive strip similar to a standard bandage for 6 weeks after total knee arthroplasty.
45848926|NCT03301038|Drug|Rifampin|Rifampin 5 mg/kg (max 300 mg) daily for 8 weeks, followed by rifampin 10 mg/kg (max 600 mg) daily for 8 weeks.
45393989|NCT01078714|Drug|bumetanide|Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
45848927|NCT03053700|Drug|Bromonide 0.33% gel|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months.
45848928|NCT03053700|Device|Intense Pulsed Light (M22)|Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
45393990|NCT01081054|Other|Ambulatory versus hospitalisation|Patients are treated with the same antibiotic agent, the difference between the two arms is endovenous treatment for hospitalized patients for the first days till oral feeding. The ambulatory group starts directly with orally administered antibiotic treatment.
45393991|NCT03964324|Diagnostic Test|Fractioned Exhaled Nitrogen Oxide measurements|Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
45393992|NCT01078792|Other|CT pulmonary angio, blood tests|
45393993|NCT03963076|Other|nasal hypertonic spray: combination of hypertonic sea water and organic rosemary floral water with essential oils (ravintsara, geranium, eucalyptus radiata, niaouli)|One spray of nasal hypertonic spray morning and evening every day during 30 days
45393994|NCT00105508|Drug|Sarizotan|Subjects will receive sarizotan 1 milligram orally twice daily for 24 weeks.
45393995|NCT00105508|Drug|Placebo|Subjects will receive placebo matched to sarizotan orally twice daily for 24 weeks.
45502963|NCT03617250|Other|Disease Activity Score-28|Assessment of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio and their association with Disease Activity Score-28
45502964|NCT04625153|Biological|RC18 160mg|RC18 160mg is injected subcutaneously once a week for 48 times.
45502965|NCT04625153|Biological|RC18 240mg|RC18 240mg is injected subcutaneously once a week for 48 times.
45502966|NCT03616314|Device|stepping verticalization plus functional electrical stimulation|patients hospitalized in ICU are rehabilitated using 30 minutes/day of conventional physiotherapy + 30 minutes/day of verticalization using a tilt table with an integrated robotic stepping device synchronized with an electrical stimulation of the lower limbs muscles
45502967|NCT03616314|Device|stepping verticalization|patients receive 30 minutes/day of conventional physiotherapy + 30 minutes7day of verticalization using a tilt table with a robotic stepping device
45502968|NCT03616314|Other|conventional physiotherapy|patients are treated only with 60 minutes/day of conventional physiotherapy
45502969|NCT02236728|Drug|Pramipexole|
45502970|NCT01344707|Drug|4SC-202|oral administration dose escalation twice daily (bid)or three times a day (tid) continuous dosing for 21 days per cycle
45502971|NCT03615300|Diagnostic Test|serum NGAL|serum NGAL was measured at 0, 24, 48, and 72 hours after recovery of spontaneous circulation.
45393996|NCT01082848|Drug|aripiprazole|10 mg QD during 26 weeks
45393997|NCT01082848|Drug|placebo|QD during 26 weeks
45393998|NCT01082926|Biological|therapeutic allogeneic lymphocytes|Given intratumorally
45393999|NCT01082926|Biological|aldesleukin|Given intratumorally
45394000|NCT01082926|Other|laboratory biomarker analysis|Optional correlative studies
45394001|NCT01082926|Procedure|positron emission tomography|Optional correlative studies
45394002|NCT01083004|Procedure|Indocyanine green|Using indocyanine green as intraoperative dye
45394003|NCT01083004|Procedure|Brilliant blue arm|Using brilliant blue as intraoperative dye
45394004|NCT03962920|Drug|Tigecycline 50 MG|Local instillation of drug directly to the tumour tissue
45394005|NCT03962920|Other|Placebo|Local instillation of sterile water directly to the tumour tissue
45394006|NCT01078870|Drug|Lexapro|10mg/cap 1~2# QD
45394007|NCT01078870|Drug|Cymbalta|30mg/cap 30~60mg/QD
45394008|NCT01078870|Drug|Placebo|1~2#/cap QD
45394009|NCT01078948|Device|transcranial direct current stimulation (tDCS)|Delivery of mild current to specified brain regions.
45394010|NCT03965338|Diagnostic Test|fMRI|Screening
45394011|NCT00105196|Drug|Aripiprazole+ ADT|Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
45394012|NCT00105196|Drug|Placebo+ ADT|Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
45394013|NCT03820024|Behavioral|Tailored Feedback Messages|Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly. Participants on the feedback arm will receive 1 message per week during the 3-month study period.
45394014|NCT03819634|Device|Inset II with Lantern Technology|Each participant will insert the Inset II with Lantern technology and wear it for 10 days or until set failure and data will be collected on the cause of set failure. The infusion set will be used with their usual insulin pump.
45394015|NCT00104572|Drug|Androgel (Testosterone Gel)|1 mg tablet for 12 months
45394016|NCT00104572|Drug|Anastrozole (Aromatase Inhibitor)|
45394017|NCT00104572|Drug|Placebo tablet|Daily for 12 months
45394018|NCT00104572|Drug|Placebo gel|Daily for 12 months
45394019|NCT00104572|Dietary Supplement|Calcium Cardone 500mg with vitamin D 400 IU|1 tablet three times a day
45394020|NCT01083238|Drug|AZD5069|120mg single oral dose
45394021|NCT02531074|Behavioral|Mobile Application|
45394022|NCT02531074|Behavioral|Food Journal|
45394023|NCT02531074|Behavioral|Usual Care|
45394024|NCT03964168|Drug|Biologic Agent|Patients who discontinued a bioloic agent
45848929|NCT02836470|Drug|LB1148|A total of 700 mL of drug product will be administered orally as a split dose before surgery.
45394025|NCT01083394|Device|PTA|PTA using a conventional balloon
45394026|NCT01083394|Device|PTA with PEB|PTA using a paclitaxel eluting balloon
45848930|NCT02836470|Drug|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
45696910|NCT01005706|Drug|tacrolimus, sirolimus and steroid|"Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml."
45696911|NCT05346471|Device|Multimodal neuromonitoring|Multimodal neuromonitoring accounts for intraparenchymatous ICP probe, brain tissue oxygen probe and/or cerebral microdialysis device
45848931|NCT02808702|Behavioral|Cognitive-behavioral therapy|Twelve weekly sessions of individual cognitive-behavioral therapy
45848932|NCT02411526|Drug|ZX003 (Risperidone-SABER®)|ZX003 administered as a SC injection
45394027|NCT01083394|Procedure|Percutaneous Transluminal Angioplasty (PTA)|Percutaneous transluminal angioplasty with conventional balloon or paclitaxel-eluting balloon
45394028|NCT01079104|Device|Hepa Wash|"Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)"
45394029|NCT01079104|Procedure|Standard Medical Therapy|Standard of care treatment
45848933|NCT02411526|Drug|Risperdal Consta|Risperdal Consta administered as a IM injection
45394030|NCT01081444|Device|rTMS|effective and active cortical magnetic stimulations
45394031|NCT01081444|Device|Placebo rTMS|non active cortical magnetic stimulation
45394032|NCT03963934|Other|Program on a nurse-led telephone 6-month-follow-up for uncontrolled hypertensive women: a patient-tailored intervention|Implementation of personalized support: The accompaniment includes 7 telephone interviews for 6 months (understanding the antihypertensive treatment, identifying the brakes and the levers when taking medication, organizing the treatment taking, making the home blood pressure)
45394033|NCT00514943|Drug|BIBW 2992|experimental drug taken once daily orally
45394034|NCT00514943|Drug|Cetuximab|active comparator administered weekly intravenously
45394035|NCT01083550|Other|Decision aid exposure|Exposure to a computerized decision aid on adjuvant radioactive iodine treatment decision-making. The exposure is during one visit.
45394036|NCT01079260|Dietary Supplement|Standard ONS|Standard ONS
45394037|NCT01079260|Dietary Supplement|High Energy, low volume ONS|High energy, low volume ONS
45394038|NCT03864653|Behavioral|MoodGym|"MoodGym is a preexisting Internet-based CBT program that uses interactive content and character-driven narratives to help alleviate symptoms of depression and comorbid anxiety. The program also aims to improve the individual's functioning by promoting the development of skills and strategies to manage depression.~MoodGym consists of an introduction module, five structured intervention modules, and a workbook of assessments. Each MoodGym session takes place entirely on an Internet-connected tablet while in the physical co-presence of a Study Counselor, who can answer questions should they arise. Each session takes approximately one hour to complete."
45394039|NCT00103402|Drug|Alfuzosin|
45394040|NCT00103402|Drug|Placebo|
45696912|NCT01679379|Procedure|Absorbable suture group|Skin is closed with subcuticular stitches using [Polyglactin 910 absorbable, synthetic, braided suture]
45696913|NCT01679379|Procedure|Non absorbable suture group|Skin is closed with subcuticular stitches using Polypropylene non absorbable monofilament suture
45696914|NCT03410277|Other|Experimental hypoglycemia|Experimental hypoglycemia with and without MRI
45696915|NCT03085485|Drug|Ivacaftor 150 MG|Ivacaftor is a CFTR potentiator
45848934|NCT02411526|Drug|Oral Risperidone|Oral Risperidone given to ensure adequate therapeutic plasma concentrations from Risperdal Consta
45848935|NCT02400060|Behavioral|Telephone-Based Intervention|Receive text messaging
45848936|NCT02400060|Other|Survey Administration|Ancillary studies
45848937|NCT02400060|Other|Laboratory Biomarker Analysis|Correlative studies
45394041|NCT03864341|Behavioral|Referral to homelessness prevention services|Referral to Homebase homelessness prevention services offered by community-based organizations in NYC
45394042|NCT03864341|Behavioral|Substance use services|Referral to substance use services (SBIRT and peer counselor/social work contact) available at Bellevue Hospital
45394043|NCT03864341|Behavioral|Follow-up|Follow-up to assist participants in receiving homelessness prevention services
45394044|NCT01739309|Drug|Abemaciclib|Administered orally
45394045|NCT00095836|Drug|Gefitinib|Taken orally once a day for duration of benefit. Treatment is continuous until there is evidence of disease progression or unacceptable toxicity.
45394046|NCT00168831|Drug|Tiotropium Inhalation Solution|
45394047|NCT00168831|Other|Placebo|
45394048|NCT03330821|Drug|Cytarabine|Given IV
45394049|NCT03330821|Drug|Idarubicin|Given IV
45394050|NCT03330821|Other|Laboratory Biomarker Analysis|Correlative studies
45394051|NCT03330821|Drug|Pevonedistat|Given IV
45394052|NCT03330821|Other|Pharmacological Study|Correlative studies
45394053|NCT00103012|Drug|Gingko Biloba|Ginkgo Biloba 120 mg twice daily for 14 days
45394054|NCT00103012|Drug|Echinacea purpurea|Echinacea purpurea 500 mg three times daily for 14 days
45394055|NCT00103012|Drug|Panax ginseng|Panax ginseng 500 mg twice daily
45394056|NCT00512135|Drug|IncobotulinumtoxinA (Xeomin) (20 units)|Injection of a total of 20 Units incobotulinumtoxinA (Xeomin) on day one of each of up to eight cycles, reconstituted in a total injection volume of 0.5 mL administered in five equal parts of 0.1 mL to five predefined points of the glabellar area.
45394057|NCT03235505|Drug|Nicotine|Nicotine containing e-cigarettes + placebo-varenicline + Motivational Interview (MI)
45394058|NCT03235505|Drug|Varenicline Tartrate|Varenicline + Innokin Endura T20S electronic inhaler but without any nicotine content + MI
45394059|NCT03235505|Behavioral|Motivational Interview|Placebo-varenicline + Innokin ENdura T20S electronic inhaler but without any nicotine content +MI
45394060|NCT00251979|Drug|Esomeprazole|
45394061|NCT00511901|Drug|placebo|
45394062|NCT00511901|Drug|epoetin alpha|
45394063|NCT00511901|Drug|Niferex|
45394064|NCT04580147|Drug|Intravitreal aflibercept injection|Intravitreal aflibercept injection (2mg/0.05mL) at the conclusion of RRD repair surgery, at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
45394065|NCT04580147|Other|Sham control|Sham procedure at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
45394066|NCT03862625|Device|a modular adaptive seating system|
45394067|NCT03862625|Other|home exercise program for scoliosis|
45394068|NCT00163215|Drug|Somatropin|Adapted dosage based on IGF 1 level and weight Form: liquid; Dosage and Frequency: from 0.0033mg/kg/day to 0.0067 mg/kg/day; Duration: 3 years
45394069|NCT03147287|Drug|Palbociclib|Palbociclib is a drug that may stop cancer cells from growing
45848938|NCT00564876|Drug|Dasatinib|Fresh frozen tumor tissue must be available prior to initiating dasatinib. Eligible patients will receive neoadjuvant dasatinib 70 mg PO twice daily for 3 weeks followed by surgery. The surgical specimen will be evaluated for pathologic response. The second tumor sample will be obtained after 3 weeks of dasatinib therapy at the time of definitive surgical resection which will be evaluated for changes in genomic expression profiles. Patients with at least a 15% decrease or better objective response, without evidence of progression (per tumor evaluation pre-surgery) or pathologic response (as defined as ≥30% tumor necrosis or cell death) to neoadjuvant dasatinib therapy will be eligible to receive dasatinib 70 mg twice daily for 90 days after the completion of standard adjuvant therapy.
45394070|NCT03147287|Drug|Fulvestrant|Fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of cancer cells by estrogen
45394071|NCT03147287|Drug|Avelumab|Avelumab is an antibody designed to block the PD-1 pathway and helps the immune system in detecting and fighting cancer cells
45394072|NCT00228423|Drug|Clopidogrel 75 mg daily|Daily dose of 75 mg Clopidogrel
45394073|NCT00228423|Drug|water pill daily|Daily dose of water pill (placebo)
45394074|NCT00511667|Drug|MK0941|MK0941 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
45394075|NCT00511667|Drug|Comparator: Placebo|Placebo 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
45394076|NCT00227877|Behavioral|cSBA - New England, USA|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
45394077|NCT00227877|Behavioral|cSBA - Prague, CZR|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
45502972|NCT04254653|Behavioral|American Indian and Alaska Native What Can I Eat?|Participants will engage in 5 ~90 minute diabetes nutrition education classes. They will learn about healthy eating for type 2 diabetes management. Classes include didactic lesson, hands on learning activity, sharing session, mindful nutrition practice, and physical activity
45502973|NCT01344785|Procedure|Intramedullary nailing|All patients will be treated with Intramedullary nailing
45502974|NCT03136861|Biological|AIN457|anti IL-17a monoclonal antibody
45502975|NCT03136861|Drug|AIN457 Placebo|Placebo matching AIN457
45696916|NCT03085485|Drug|Placebo|placebo pills
45502976|NCT03482856|Behavioral|MNA plus CBT-I|MNA plus CBT-I includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, 6 individual sessions of CBT-I and 9 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. CBT-I is the standard evidence-based care for treating chronic primary insomnia and typically includes changing negative thoughts about sleep, sleep hygiene, sleep restriction therapy, and teaching relaxation skills. The 18 sessions will be spread over a period of 14 weeks.
45502977|NCT03482856|Behavioral|MNA alone|MNA alone includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, and 15 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. The 18 sessions will be spread over a period of 14 weeks.
45502978|NCT01342679|Drug|dasatinib|100mg QD
45502979|NCT04852926|Other|Self-administered questionnaires|"6 self-administered questionnaires (EORTC-QLQ-C30, RSE, BIS, HAD, FSFI, DAS-4) completed by the patients at every usual follow-up consultation.~1 (FSFI) or 2 (MSHQ, PEP) self-administered questionnaires completed by the partner (respectively female or male) between every usual follow-up consultation.~Follow-up usual consultations :~T0 (at inclusion) : before disease + since diagnosis~C4 (chemotherapy course n°4)~C6 (chemotherapy course n°6)~M3 (3 months after chemotherapy)~M6 (6 months after chemotherapy)~A1 (1 year after chemotherapy)~A2 (2 years after chemotherapy)"
45502980|NCT03616080|Behavioral|soccer play program|once a week for an hour of a soccer program for 8 weeks
45502981|NCT01342835|Drug|Propofol|The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
45502982|NCT03616002|Other|Hookah smoking|ad lib hookah smoking for 30 minutes in a controlled laboratory environment.
45848939|NCT00558870|Drug|Morphine|"Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain."
45848940|NCT00558870|Drug|Methadone|"1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)~Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain."
45394078|NCT04610099|Device|Banded Sleeve Gastrectomy|banded sleeve gastrectomy
45394079|NCT04610099|Device|Standard SG|Standard SG
45394080|NCT00513695|Drug|sunitinib malate|Given PO
45394081|NCT00513695|Drug|paclitaxel|Given IV
45394082|NCT00513695|Drug|doxorubicin hydrochloride|Given IV
45394083|NCT00513695|Drug|cyclophosphamide|Given PO
45394084|NCT00513695|Biological|filgrastim|Given SC
45394085|NCT00513695|Procedure|therapeutic conventional surgery|Undergo surgery
45394086|NCT00513695|Other|laboratory biomarker analysis|Correlative studies
45394087|NCT00513695|Other|flow cytometry|Correlative studies
45394088|NCT00162981|Drug|Clobazam Low Dose|5 to 10 mg/day with doses in the morning and at bedtime; orally
45394089|NCT00162981|Drug|Clobazam High Dose|5 to 40 mg/day with doses in the morning and at bedtime; orally
45502983|NCT01344863|Drug|trastuzumab [Herceptin]|600 mg subcutaneously using a single-use injection device on Day 1
45502984|NCT01344863|Drug|trastuzumab [Herceptin]|600 mg subcutaneously using a handheld syringe on Day 1
45502985|NCT01354561|Procedure|Respiratory physical therapy|Respiratory physical therapy using airway clearance techniques was conducted by a physiotherapist according to a detailed clinical evaluation of each patient, consisting of thoracic percussion, manual vibration, postural drainage, and cough stimulation.
45394090|NCT00511433|Drug|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28~for 6 consecutive 28-day menstrual cycles."
45394091|NCT00511433|Drug|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day menstrual cycles.
45394092|NCT00099268|Drug|Carbidopa/levodopa/entacapone|Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules.
45502986|NCT02666183|Behavioral|Video-C|use videoconferencing to provide personalized information aimed at enhancing self -efficacy and providing emotional support for distant caregivers of patients with advanced cancers
45502987|NCT02666183|Behavioral|Nurse Coaching|structured conversations with registered nurses aimed at providing emotional support
45394093|NCT00099268|Drug|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 12.5/50 mg and 25/100 mg capsules.
45394094|NCT00511355|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol (NOMAC-E2) Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
45394095|NCT00511355|Drug|Levonorgestrel and Ethinyl Estradiol|Levonorgestrel and Ethinyl Estradiol (LNG-EE) Tablets, 150 mcg LNG and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
45394096|NCT01083784|Drug|Use of prophylactic anticonvulsants (valproate, clonazepam)|start at hypothermia induction valproate : 30mg/kg iv loading - 8hr after - 6mg/kg q 8hr iv till 72hr clonazepam : 1mg po bit via L-tube till 72 hr
45394097|NCT01083784|Drug|Control group|Control group
45394098|NCT01083862|Behavioral|Educational Intervention - Text plus DVD/VHS|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes viewing a video program developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. They also were given a booklet on the same subject material written at a 5th grade level."
45502988|NCT02666183|Behavioral|Web-Only|Access to a website with caregiving resources, resources for distant care givers, and cancer information
45502989|NCT03316950|Device|IntraGen RF|IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.
45502990|NCT03316950|Device|DiVA|DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner.
45394099|NCT01083862|Behavioral|Educational Intervention - Text Only|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes reading a booklet developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. Subject material was written at a 5th grade level."
45394100|NCT03998345|Drug|609A|609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
45502991|NCT03316950|Device|Placebo (DIVA/IntraGen combined)|"(DIVA/IntraGen combined) IntraGen RF: IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.~DiVA: DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner."
45502992|NCT03139279|Drug|Dexmedetomidine|Dexmedetomidine 0.3 ug/kg intravenous bolus
45502993|NCT03139279|Other|Saline placebo|Intravenous saline/placebo
45502994|NCT03139279|Drug|Propofol|Propofol titrated intravenous boluses
45502995|NCT02562599|Drug|raltitrexed-cisplatin|Patients receive raltitrexed-cisplatin neoadjuvant chemotherapy every three weeks for two cycles, then receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
45502996|NCT02562599|Radiation|Intensity-modulated radiotherapy (IMRT)|Patients receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
45502997|NCT01358227|Drug|PR104|Dose escalation of PR104 to determine maximum tolerated dose for weekly administration
45502998|NCT03311958|Drug|Nivolumab, IV, 240 mg|Patients would be given an infusion of 240 mg nivolumab over 30 min
45502999|NCT02225405|Drug|Cisplatin|Given IV
45503000|NCT02225405|Drug|Docetaxel|Given IV
45503001|NCT02225405|Other|Laboratory Biomarker Analysis|Correlative studies
45503002|NCT02225405|Drug|Nintedanib|Given PO
45503003|NCT01370642|Drug|vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
45503004|NCT01370642|Drug|Placebo to vaniprevir|Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks
45394101|NCT04576637|Procedure|Neurophysiological monitoring during intubation|In the operating room patients will be connected to the anesthesia monitor and an IV line as standard clinical practice. Participants will receive oxygen and an IV infusion of 1-3 ng/ml remifentanil via TCI infusion pump to achieve mild sedation. Patients will then be connected to the neurophysiological electrodes to monitor for EEG, EMG, SSEP and MEP signals. After preparing the videolaryngoscope, anesthesia induction will be achieved with the use of IV ketamine 2mg/kg. Then the anesthesiologist will perform a clinical and ECG reading assessment to ensure that the patient is anesthetized and will be able to titrate more ketamine as needed to achieve hypnosis. A biteblock will be located to prevent teeth damage. A neurophysiological baseline recordings will then be performed by a neurophysiologist. The videolaryngoscope will then be inserted, during which a second neurophysiological testing will be performed to ensure the patients safety. Then mechanical ventilation will be initiated.
45394102|NCT00095212|Drug|1 Transdermal Testosterone (Patch)|300 micrograms twice a week
45394103|NCT00095212|Drug|2 Placebo Patch|Placebo patch (0 micrograms of testosterone) applied twice a week
45394104|NCT04606979|Device|1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)|"tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants."
45394105|NCT02999399|Other|Brussel Sprouts|Subjects are given ~150 g of Brussels sprouts once daily for 7 consecutive days.
45394106|NCT02999399|Drug|Deuterated Phenanthrene|Subjects are given 1 microgram of deuterated phenanthrene [D10]phe at baseline and after 7 days of Brussels sprout consumption. Urine is collected for 6 hours after each dose.
45394107|NCT02834975|Drug|Pembrolizumab|Pembrolizumab on Day 1 of each cycle.
45394108|NCT02834975|Drug|Paclitaxel|"NACT: Paclitaxel on Day 1 of each cycle;~ACT: Paclitaxel same as NACT OR; dose-dense option weekly per protocol."
45394109|NCT02834975|Drug|Carboplatin|Carboplatin IV on Day 1 of each cycle.
45394110|NCT02801279|Other|Conventional bilateral arm training|The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.
45394111|NCT02801279|Other|Kinect-based bilateral arm training|The conventional bilateral arm training focuses activities that required the use of both hands.
45394112|NCT02772731|Procedure|Partial mastectomy plus additional Shave Margin|"For the shave group, additional superior, inferior, medial and lateral margins will be removed, oriented, and sent for pathologic evaluation at the local site. Resection of additional anterior and posterior margins will be left to surgeon discretion, as this will depend on if skin or fascia was taken. All surgeons participating in the study will be educated on the expectation of what is considered a shave margin. A shave margin is defined as an additional segment of breast tissue taken from each of the superior, inferior, medial, and lateral aspects of the cavity, such that the entire circumference of the cavity is re-excised following this procedure. Orientation of each shaved margin will be done to mark the true margin."
45394113|NCT02772731|Procedure|Partial mastectomy|Surgeons will be instructed to close after partial mastectomy with no further excision.
45394114|NCT00120874|Behavioral|Individualized management of AD including caregiver training|Individualized management program: consists of home visits to get the patient exercising, doing enjoyable activities and cognitive stimulation, educational sessions for caregivers on coping with difficult situations and a caregiver support group to help with questions and emotional concerns.
45394115|NCT00120874|Drug|Memantine|Patients receive 10 milligrams of memantine twice daily.
45503005|NCT01370642|Biological|Peg-IFN|Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks
45696917|NCT03085251|Device|Blood glucose monitoring systems for self-testing (BGMS)|"Measurement procedure~Subjects will be asked to wash and dry their hands before the measurements.~The measurement procedure for each reagent system lot of a BGMS will be as follows:~Study personnel will collect a capillary blood sample from the subject's fingertip by skin puncture.~Duplicate measurements on the sample will be consecutively performed with 2 test meters using reagent system units from the same vial / package.~Capillary blood for measurements with all 3 test strip lots and for both comparison measurements will be taken from the same finger puncture.~The sample will be applied to the reagent system units following specifications in the manufacturer's labelling."
45503006|NCT01370642|Drug|ribavirin|Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
45696918|NCT03085407|Procedure|early cholecystectomy|cholecystectomy was done within 48 after admission
45696919|NCT03085407|Procedure|delayed cholecystectomy|cholecystectomy was done after 30 days after randomization
45394116|NCT00120406|Device|Zilver® PTX™ Drug Eluting Vascular Stent|Stenting of the Superfemoropopliteal Artery
45394117|NCT00120406|Procedure|Angioplasty|Angioplasty of the Superfemoropopliteal Artery
45503007|NCT02873208|Drug|ALKS 3831|Coated bilayer tablet containing 10 mg, 15 mg or 20 mg olanzapine and 10 mg samidorphan
45503008|NCT03138967|Drug|Rocuronium|Experimental: Sugammadex Participants to have cystoscopy with bladder tumor resection. Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.
45394118|NCT00120250|Drug|Eszopiclone|The total study duration is 8 weeks, with subjects receiving 3mg eszopiclone or placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of the alternate condition, followed by another 1 week washout.
45394119|NCT01081600|Other|Imaging with 89Zr-trastuzumab PET|Injection with 89Zr-trastuzumab and 89Zr-trastuzumab PET scan.
45394120|NCT01079338|Other|caffeine|
45394121|NCT00511199|Drug|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg~NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year)."
45394122|NCT00511199|Drug|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
45394123|NCT03964012|Biological|NmCV-5|Polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W&X (NmCV-5) is available as lyophilised powder of polysaccharide antigens A&X conjugated to tetanus toxoid and C,Y&W conjugated to C reactive material (CRM) protein. The diluent is Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.
45503009|NCT03138967|Drug|Sugammadex|Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade.
46056989|NCT02715999|Procedure|Transversus Abdominis Plane Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory. All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally between internal oblique and transversus abdominis muscles.
45503010|NCT03138967|Drug|Neostigmine|70 mcg/kg by vein to reverse the muscle relaxation.
45696920|NCT01679691|Other|epidural anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
46056990|NCT01798173|Biological|Serum, plasma and DNA samples|
45394124|NCT03964012|Biological|Menactra|Menactra is available as ready to use solution containing polysaccharide antigens A,C,Y&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine
45394125|NCT01083940|Other|Computerized reminders on hypertension intensification|Reminder generated to prompt providers to intensify therapy when patient's blood pressure remains uncontrolled
45394126|NCT01009385|Procedure|cervical epidural steroid injection|"After aseptic preparation and skin infiltration with 1% lidocaine~20-gauge Tuohy needle (Tae-Chang Industrial Co., Kongju, Korea) was inserted in the midline at the C6 - C7 level~identification of the epidural space confirmed by injection of contrast medium under fluoroscope~injection of 5 mL of solution containing 10 mg of triamcinolone acetonide suspension and 1.5 mL of 0.75% levobupivacaine hydrochloride, and 3.5 mL of physiologic saline (0.9% NaCl).~Post-procedure, patients were observed for any adverse effects and followed with a neurological examination"
45394127|NCT01009385|Procedure|epidural pressure measurement|"The stylet within the Tuohy needle is removed when the needle was placed in C6-7 ligamentum flavum under fluoroscopic true lateral view.~Identification of the epidural space and measurement of EP was performed with a closed measurement system."
45394128|NCT01084018|Behavioral|soulageTAVIE|VITaPaCS consists in a 30 minute-computer-tailored preoperative session, which is animated by a virtual nurse who guides the participant through a learning process about analgesic medication intake, pain communication, and cognitive restructuring. The information and the strategies provided are specifically tailored to the participants' profile, determined by a screening questionnaire, but also by their responses in real-time during the computer session. Two postoperative clinical reinforcements of ten minutes are also provided by the treating nurse based on the flags identified through the preoperative session.
45503011|NCT03138967|Drug|Glycopyrrolate|14 mcg/kg by vein to reverse the muscle relaxation.
45696921|NCT03470805|Drug|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until disease progression, unacceptable toxicity, withdraws from the study or closure of the study
45696922|NCT03088059|Drug|Afatinib|Afatinib 40 mg given orally, once daily, 1 cycle is 28 days
45503012|NCT01358305|Other|Protein Blend|Single intake of approximately 20 grams of total protein
45503013|NCT01547117|Radiation|Blood Volume|we will measure the amount of hemoglobin and myoglobin in the body by a procedure called CO rebreathing. One teaspoon of blood is taken before and after a small amount of CO has been absorbed into the bloodstream.
45503014|NCT01547117|Radiation|Total Blood Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 microcuries of radiation, blood samples are drawn before and 30 minutes after injection.
45696923|NCT03088059|Drug|Palbociclib|Palbociclib 125 mg given orally, once daily, 1 cycle is 28 days (21 days on treatment, then 7 days off)
45503015|NCT01547117|Procedure|Exercise Capacity Test - Bicycle|subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
45503016|NCT01547117|Procedure|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
45503017|NCT04958382|Drug|ciprofol|intravenous infusion of ciprofol at 0.12 mg/kg, followed by 0.4-1.6 mg/kg/h for maintenance
45503018|NCT04958382|Drug|medium/long chain fat emulsion injection (C8-24Ve)|at the infusion rate of 25-30 mL/h
45503019|NCT01358383|Drug|naproxen|250mg, oral dose
45848941|NCT00548886|Drug|Epinephrine|We will follow the protocol outlined by Ackerman et al. known as the Mayo protocol4 which is currently used routinely in our electrophysiology laboratory. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes and a twelve-lead electrocardiogram is obtained at time=0 minutes, 5 minutes, and 10 minutes. The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes and the electrocardiogram repeated. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes and electrocardiogram obtained. The epinephrine infusion is then discontinued and measurements are obtained at five minutes and ten minutes after stopping the epinephrine infusion. The total time of procedure will be 35 minutes.
45394129|NCT01084096|Behavioral|Increasing use of Antenatal Corticosteroids (ACS)|"Intervention clusters:~Increasing administration of ACS to pregnant women at high risk of preterm birth (HRPB) by providing health providers with kits containing dexamethasone, syringes, and instructions. Eligible women receive four injections of 6 mg dexamethasone from the kit or regimen of choice at the site.~Improving identification of women at HRPB by diffusing recommendations for ACS use to health care providers, training health care providers to identify signs of preterm labor and eligibility criteria for ACS use, providing reminders to healthcare providers on the use of the kits, and using a color-coded tape to measure uterine height to estimate gestational age in women at HRPB with unknown gestational age.~Control clusters: no specific intervention for comparison. Both intervention and control clusters: Birth attendants trained in essential newborn care of LBW infants and instructed to teach mothers how to provide care to premature infants."
45394130|NCT00384176|Drug|Cediranib|oral tablet once daily
45394131|NCT00384176|Drug|Bevacizumab|intravenous infusion
45394132|NCT00384176|Drug|5-fluorouracil ( in FOLFOX)|intravenous infusion
45394133|NCT00384176|Drug|Leucovorin (in FOLFOX)|intravenous infusion
45503020|NCT01358383|Drug|esomeprazole|20mg, oral dose
45503021|NCT03560336|Drug|Liraglutide|Patients will initiate treatment with liraglutide according to the approved label in Korea. Patients will initiate 0.6 mg daily and weekly increase the dose by 0.6 mg until reaching 3.0 mg daily. Patients will then continue to stay on 3.0 mg/day (total treatment duration: 26 weeks).
45503022|NCT04847388|Drug|Substance like alcohol, marijuana, etc.|Cohort study
45503023|NCT03136159|Device|Silver-impregnated antimicrobial dressing|All participants will receive an adherent soft silicone silver impregnated anti-microbial occlusive foam dressing after cesarean section. The dressing will stay on for up to seven days.
45503024|NCT03615768|Combination Product|Adapalene-Clindamycin Combination Gel|5mg Adapalene/50mg Clindamycin per 5g, applied nightly for 12 weeks
45503025|NCT03615768|Drug|Adapalene Gel|Differin 0.1% Gel, applied nightly for 12 weeks
45503026|NCT03615768|Drug|Clindamycin Gel|Clindamycin Phosphate 1% Gel applied twice daily for 12 weeks
45503027|NCT02061644|Other|Spinal anesthesia|Routine spinal anesthesia procedure will be made to the patients for surgical anesthesia.
45503028|NCT04178135|Drug|rLH|rLH supplement from day 1 of stimulation
45503029|NCT04178135|Drug|rLH|rLH supplement from day 6 of stimulation
45503030|NCT04958070|Other|MPS I|MPS I, symptoms of disease onset , ERT
45503031|NCT01318291|Behavioral|CCRI Group|Cognitive Coping and Relaxation Intervention (CCRI) Cognitive Coping and Relaxation Intervention (CCRI) group who will receive a packet of relaxation and stress management suggestions
46056991|NCT01798173|Procedure|Radiological exploration by CT scan or MRI|
45503032|NCT01318291|Behavioral|Control|Medical treatment alone
45503033|NCT03793400|Drug|Bevacizumab Injection|Anti-vascular endothelial growth factor (VEGF)
45503034|NCT03614988|Other|Evening Levothyroxine Administration|Bedtime levothyroxine intake, with 60-minute meal-free interval
45503035|NCT03614988|Other|Morning Levothyroxine Administration|Morning levothyroxine intake, 60 minutes before breakfast.
45503036|NCT01318369|Drug|Namisol|Single dose delta-9-tetrahydrocannabinol
45503037|NCT01318369|Drug|Diazepam|Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
45503038|NCT02061722|Radiation|PET Imaging with [18F]MNI-659|"The radioligands [11C]raclopride and [18F]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of [11C]raclopride will be 300 MBq/70 kg of body weight ± 10%.~The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
45503039|NCT01345097|Device|Total Hip Arthroplasty|Total Hip Arthroplasty
45503040|NCT01350739|Procedure|intraumbilical incision|vertical, intraumbilical incision
45503041|NCT01350739|Procedure|infraumbilical incision|incision at the inferior boarder of the umbilicus, circular
45503042|NCT03479684|Other|Gene-directed dosage of warfarin|the first day given model prediction dose * 1.5 times（<6mg）；the second day given model prediction dose；adjusted dose based on INR from the third day
45503043|NCT03479684|Other|standard dosage of warfarin|the first day given 4.5mg; adjusted dose based on INR from the second day
45503044|NCT01316003|Other|Optical coherence tomography|Optical coherence tomography
45503045|NCT01318447|Radiation|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) and delivered over 5 to 10 days.
45503046|NCT01986933|Drug|nemolizumab (CIM331)|
45503047|NCT01986933|Other|Placebo|
45503048|NCT05251103|Other|time-restricted feeding trial|The 5-day time-restricted feeding trial and the control trial. The meals of the time-restricted feeding trial were provided at 12:00, 16:00, and 20:00.
45503049|NCT03614052|Drug|Tamsulosin Hydrochloride 0.4 milligrams|Tamsulosin hydrochloride 0,4mg for 5 days before ureteroscopic treatment of urolithiasis
45503050|NCT03614052|Drug|Placebo Oral Tablet|Placebo oral tablet 1 tablet per day for 5 days before ureteroscopic treatment of urolithiasis
45503051|NCT01318525|Drug|ALF-5755|10 mg (25 ml) given in slow intravenous infusion over 10 minutes with an automatic syringe
45503052|NCT01318525|Drug|Saline solution (0.9% NaCl)|25 ml given in slow intravenous infusion over 10 minutes with an automatic syringe
45503053|NCT02062892|Drug|Everolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
45503054|NCT02062892|Drug|Sirolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
45503055|NCT04938258|Behavioral|Intensive Case Management|Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team (Psychiatry, Social Work, Nursing) during 2 months. The intervention will encompass attending weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes. This CM intervention will include referral to Hospital Clínic de Barcelona Addiction Outpatient Clinic and a personalised assessment of the medical, psychiatric and social situation of each individual by the CM team. An individualised care plan will be established and periodically reviewed by the multidisciplinary team in response to a better understanding of patient needs or to a change in patient health condition. The intervention will offer motivational interviewing psychotherapy to enhance motivation to reduce or to quit alcohol use, in crisis intervention, coordination of care, patient education and self-management support, and assistance to navigate in the healthcare system.
45503056|NCT02063360|Drug|BMS-663068|BMS-663068
45503057|NCT02063360|Drug|Darunavir (DRV)|Darunavir (DRV)
45503058|NCT02063360|Drug|Ritonavir (RTV)|Ritonavir (RTV)
45503059|NCT02063360|Drug|Etravirine (ETR)|Etravirine (ETR)
45503060|NCT01358461|Biological|Blood sampling|Blood sampling
45503061|NCT01358461|Other|ECG-Holter 24 h tape and sino-carotid stimulation test|ECG-Holter 24 h tape and sino-carotid stimulation test
45503062|NCT03614832|Drug|Ticagrelor 90 mg|half-dose ticagrelor treatment (90 mg loading dose, then 90 mg once daily) for 1 week.
45503063|NCT03614832|Drug|Clopidogrel 150 mg|double standard-dose clopidogrel treatment (150 mg loading dose, then 150 mg once daily) for 1 week.
45503064|NCT05210595|Drug|Clopidogrel 75 mg|75 mg/day as maintenance dose.
45503065|NCT05210595|Drug|Ticagrelor 60mg|In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60 twice daily after discharge or post PCI 1 week.
45503066|NCT05210595|Drug|Ticagrelor 45 mg|In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 45 twice daily after discharge or post PCI 1 week .
45394134|NCT00384176|Drug|Oxaliplatin (in FOLFOX)|intravenous infusion
45696924|NCT03088059|Drug|standard of care|Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care
45696925|NCT03088059|Drug|IPH2201|protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
45696926|NCT03088059|Drug|Durvalumab|Durvalumab 1500mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
45394135|NCT00513305|Drug|Arsenic trioxide|Arsenic trioxide will be administered intravenously (iv) at a dose of 0.25 mg/kg.
45394136|NCT00513305|Drug|Low-dose cytarabine alone|Cytarabine will be administered at a dose of 10 mg/m^2 subcutaneously (sc) twice a day (bid).
45696927|NCT03088059|Drug|Niraparib|Niraparib 300 mg given orally, once daily, 1 cycle is 28 days
45696928|NCT03088059|Drug|INCAGN01876|INCAGN01876 300 mg given intravenously over 30 minutes, once every 14 days, 1 cycle is 28 days
45696929|NCT03084549|Drug|Administration of Ropivacaïne|Administration of Ropivacaïne in the margins of the episiotomy
45394137|NCT00513071|Drug|saracatinib|Given orally
45394138|NCT00513071|Other|laboratory biomarker analysis|Correlative studies
45394139|NCT00510887|Drug|Bortezomib|Bortezomib 1.6 mg/m2 on days 1 and 8 of each 28-day cycle
45394140|NCT00510887|Drug|Rituximab|Rituximab 375 mg/m2 IV on day 1
45394141|NCT00510887|Drug|Fludarabine|Fludarabine 25 mg/m2 IV on days 1,2,3
45394142|NCT00510887|Drug|Mitoxantrone|Mitoxantrone 10 mg/m2 IV on day 2
45394143|NCT00510887|Drug|Dexamethasone|Dexamethasone 20 mg orally on days 1,2,3,4,5
45394144|NCT01012349|Drug|Association: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965)|1 tablet in an episody of headache
45394145|NCT01012349|Drug|Aspirin - Bayer|1 tablet in an episody of headache (Aspirin 500mg)
45394146|NCT01012427|Procedure|percutaneous cryoablation|All patients will have percutaneous image guided core biopsies of the treatment site and CT or MR imaging at approximately 5-7 months following the cryoablation. They will have repeat imaging every 5-7 months for a period of two years, and if there is evidence of recurrence (ablation zone increase > 5 mm or increased enhancement 15 HU), then repeat biopsy will be obtained. Imaging follow-up past the two year point will be at the discretion of the patient's physicians.
45503067|NCT01358539|Behavioral|Pain education|Patients receiving pain education
45503068|NCT03560570|Biological|Coagulation assay|Conventional coagulation assays: prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, factor II, FV, FVII, FX, FVIII, FIX, FXI, FXII, d-dimers, antithrombin, protein C, protein S Thrombin generation assay: in presence or not of soluble thrombomodulin
45394147|NCT01012505|Other|adding pad with maternal milk in hte incubator|"2 days prior to intervention - recording infants data and taking saliva cortisol adding pad with maternal milk - during 2 days - recording infants data and taking saliva cortisol.~stopping intervention and for other 2 days recording infants data and taking saliva cortisol"
45394148|NCT03997877|Other|Physical activity|Increase physical activity Balanced diet
45394149|NCT00358826|Drug|VIA-2291|oral dosing, 1 time daily for 12 or 24 weeks
45503069|NCT03560570|Other|Clinical data collection|At inclusion, we recorded clinical data about the disease (type and form of congenital disorder of glycosylation, and antecedent of microvascular event: thrombosis, stroke-like or hemorrhages)
45503070|NCT03614754|Diagnostic Test|Somatosensory evoked potentials|Stimulation of the pudendal nerve while recording at the sensory cortex.
45848942|NCT00538980|Drug|Dasatinib|Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
45394150|NCT00358826|Drug|Placebo|oral dosing, 1 time daily for 12 or 24 weeks
45503071|NCT02061800|Device|CliniMACS CD34+ Reagent System|The CliniMACS® Reagent System (Miltenyi Biotec, Germany), is a semi-automated immunomagnetic cell selection medical device that is used in vitro to select and enrich specific cell populations in a closed, sterile environment. The system is comprised of a computer controlled medical device containing a permanent magnet, a closed-system sterile tubing set containing columns coated with a ferromagnetic matrix, and a magnetic cell specific labeling reagent.
45503072|NCT02061800|Drug|Thiotepa|Standard of care: Thiotepa should be diluted in normal saline (NS) (1-5 mg/ml) and infused over 2 hrs on Days -5, -4. IV fluids should be at maintenance rate (1500 ml/m2). It is recommended that total parental nutrition not being used during Thiotepa administration as amino acid infusions may interfere with Thiotepa metabolism.
45394151|NCT04564313|Drug|Camrelizumab treatment|Camrelizumab (SHR-1210), 200mg, I.V., Q3W
45503073|NCT02061800|Drug|Cyclophosphamide|Standard of care: Cyclophosphamide (Cytoxan) should be infused over one hour. The drug can be diluted in dextrose water solvent (D5W), NS, or other solutions (250cc) to a maximum concentration of 20 mg/mL.
45503074|NCT02061800|Drug|Alemtuzumab|Standard of care: Each dose of alemtuzumab is to be diluted in D5W or NS (maximum concentration: 0.3 mg/mL) for IV infusion over two hours.
45394152|NCT01009541|Drug|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for three days.
45503075|NCT02061800|Drug|Tacrolimus|Standard of care: Tacrolimus dosing will be 0.03mg/kg/24 hours as continuous IV infusion or 0.12 mg/kg/day po divided Q8-12 hr
45394153|NCT01009541|Drug|Pregabalin controlled release, 165 mg|165 mg controlled release tablet administered once daily for three days.
45394154|NCT01009541|Drug|Pregabalin controlled release, 330 mg|330 mg controlled release tablet administered once daily for three days.
45394155|NCT01009541|Drug|Pregabalin immediate release, 150 mg|150 mg immediate release capsules administered every 12 hours for three days
45394156|NCT01052558|Device|iStent Inject (GTS400)|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery with subsequent implantation of GTS400 stents.
45394157|NCT01052558|Procedure|Cataract Surgery|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery only.
45394158|NCT00510653|Drug|Imatinib Mesylate|600 mg by mouth daily for 6 Weeks
45503076|NCT02061800|Drug|Melphalan|Standard of care: Melphalan 45mg/m2 (1.5 mg/kg IV for children <1 year of age or <10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
45503077|NCT02061800|Drug|Busulfan|Standard of care: Busulfan will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration >0.5 mg/mL), through a central venous access device over 2 hours.
45503078|NCT02061800|Drug|Fludarabine|Standard of care: Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
45503079|NCT02061800|Drug|Methylprednisolone|Standard of care: Methylprednisolone will be give IV slow infusion over 15-30 minutes.
45503080|NCT01354795|Procedure|1.EUS-FNA with or without suction|During EUS-FNA of the peri-pancreatic mass was performed, with or without self-retracting 10-mL syringe applied.
45503081|NCT01354795|Procedure|2.Pushing the stylet or injecting air|EUS-FNA specimen is expelled from a needle with pushing the stylet or injecting air into the needle
45503082|NCT01350817|Drug|Erlotinib + docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16
45503083|NCT01350817|Drug|Docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks.
45503084|NCT02063438|Procedure|Pericostal suture technique|
45503085|NCT02063438|Procedure|Intracostal suture technique|
45848943|NCT00529464|Procedure|Fluorescence Spectroscopy|Pictures of the cervix will be taken before and after the application of acetic acid. A clean probe will be placed against the cervix that sends out light and reads how much light is absorbed by the tissue.
45848944|NCT00529464|Procedure|Colposcopy|A standard colposcopy will be performed.
46056992|NCT02715531|Drug|5-FU|5-FU (400 mg/m^2) will be administered as an IV bolus, followed by 2400 mg/m^2 by continuous IV infusion over 46 (± 1) hours, q2w.
45394159|NCT04554095|Other|Clinical data collection|Respiratory parameters, analytic values, lung ultrasound and echocardiography
45394160|NCT01565525|Behavioral|Maternal focused intervention|This is a series of information given to mothers at child's well child visits (6 in all) starting at the newborn visit focused in maternal eating habits, using the mother as a potential 'agent of change' for the family and infant in modeling healthy eating habits.
45503086|NCT01986075|Behavioral|Computer-assisted behavior therapy|TES is a computer-assisted therapy program delivered via effective informational and multimedia technologies, includes 32 core interactive, multimedia modules, beginning with basic cognitive behavioral relapse prevention skills (e.g. drug refusal skills) and moving on to improving psychosocial functioning, (e.g. employment status, social relations) and HIV risk reduction.
45503087|NCT01986075|Drug|Mixed-Amphetamine Salts- Extended Release (MAS-ER)|80 mg/day of Mixed-Amphetamine Salts- Extended Release (MAS-ER) and computer -assisted CBT
45503088|NCT01986075|Drug|Placebo|Will receive computer -assisted CBT and placebo (instead of active Adderall-XR)
45503089|NCT04753710|Drug|Ocular gel|Instillation
45394161|NCT01565525|Behavioral|Ounce of Prevention|This intervention is given via a series of handouts given to mothers at their child's well visit from newborn period to one year of age, focusing on serving size and frequency and the introduction of new foods.
45394162|NCT01565681|Drug|ASP1240|infusion
45394163|NCT01565681|Drug|Placebo|infusion
45503090|NCT02061878|Drug|Bexarotene|Marketed product Targretin® soft gelatin capsule (75mg/capsule) is over-encapsulated in a size AA-el Swedish orange capsule. The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days.
45503091|NCT02061878|Drug|Placebo|The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
45503092|NCT01358617|Other|diagnostic laboratory biomarker analysis|Correlative studies
45503093|NCT00394355|Drug|mometasone furoate dry powder inhaler|400 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
45503094|NCT00394355|Drug|mometasone furoate dry powder inhaler|200 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
45696930|NCT03084549|Drug|Administration of placebo|Administration of placebo in the margins of the episiotomy
45848945|NCT00529464|Procedure|LEEP Procedure|A small heated wire loop is used to remove a cone-shaped piece of abnormal tissue. Procedure is performed on the same day as the colposcopy exam.
45394164|NCT01009697|Drug|Codeine Sulfate|15 mg, 30 mg, and 60 mg tablets
45394165|NCT00362336|Biological|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
45394166|NCT00362336|Biological|CombAct-HIB®|0.5 mL, IM
45394167|NCT00362336|Biological|Engerix B® Pediatric|0.5 mL, IM
45394168|NCT01009853|Drug|Codeine Sulfate|15 mg tablet
45394169|NCT05408273|Diagnostic Test|Blood samples and Microvascular function assessment evaluated through laser-Doppler flowmetry by the LASER speckle contrast analysis (LASCA) device|We enrolled 39 non-smokers, low CVR postmenopausal women, with less than 10 years of hypoestrogenism. Associations of 25(OH)D to adiposity, blood pressure, fasting aldosterone, insulin, glucose and lipid profile, HOMA-IR, parathormone and microvascular function, assessed by laser-Doppler flowmetry at cutaneous site, were investigated
45394170|NCT01052636|Other|Interdisciplinary intervention program|The intervention program developed for this study included three components: geriatric consultation service, rehabilitation program, and discharge-planning service.
45503095|NCT00394355|Drug|fluticasone propionate hydrofluoroalkane (HFA)|250 mcg FP HFA given twice a day via a metered-dose inhaler and a placebo tablet given once daily in the evening for 1 year
45503096|NCT00394355|Drug|montelukast|10 mg given once daily in the evening by mouth for 1 year.
45503097|NCT01822743|Procedure|Osteopathic manipulative treatment|Osteopathic compression of pterygopalatine node
45503098|NCT01822743|Procedure|sham comparator|
45503099|NCT02797808|Drug|Sertraline|Impact of sertraline on functional brain connectivity
45503100|NCT02797808|Other|No Intervention|Healthy control non-intervention
45503101|NCT01800669|Other|CHICA MLP Module|The MLP module screens families for medical-legal issues, alerts the physician to there presences and provides guidance and referral materials to help the physician resolve the issues.
45696931|NCT03082521|Behavioral|Improving the antibiotic prescribing quality|The goal is to improve the antibiotic prescribing quality of GPs in a GPC by setting up a participatory action research. The interventions will be co-designed with the GPs.
45696932|NCT04761549|Other|Adolescent Idiopathic Scoliosis|Adolescent Idiopathic Scoliosis
45696933|NCT03085719|Drug|Pembrolizumab|Keytruda is designed to restore the natural ability of the immune system to recognize and target cancer cells
45696934|NCT03085719|Radiation|Radiation|Radiation is used to shrink the cancer
45696935|NCT03080259|Behavioral|Stimulant Diversion Prevention (SDP)|provider training, patient/parent education and counseling, strategies for use by patients and parents, and treatment adjustments
45848946|NCT00519090|Drug|Imatinib|Administered orally as a single agent on a continuous daily schedule given 400 mg bid (twice daily) with food. One cycle comprised of 28 days.
45394171|NCT00506285|Drug|Methylphenidate Transdermal System (MTS)|MTS is an advanced patch product that provides methylphenidate evenly mixed with the adhesive. This formulation allows good adhesion and a wide range of dose sizes. MTS patch sizes of 12.5, 18.75, 25 and 37.5cm2 are equivalent to nominal doses over a 9-hour wear time of 10, 15, 20 and 30mg of MPH.
45503102|NCT01800669|Other|CHICA without the MLP module|Clinics in the control group will have the CHICA system, but without the MLP module. It will screen for medical-legal issues but will not provide additional guidance and referrals to help resolve them.
45503103|NCT05251025|Other|Passive sustained stretching|"The Group A received Passive Stretching Technique. Along with the Passive Stretching Technique, this group also received certain conventional treatments which included resistive exercises, gait training exercises, bridging and exercises in other functional positions were also undertaken by the included individuals.~All the exercises mentioned above were performed for 30 minutes and there was not any specific division of time for all these mentioned activities. The patients used to perform these conventional treatments and exercises on their motor control basis. The exercises were performed for 30 minutes and been done for 5 days in a week for consecutive 6 weeks."
45503104|NCT05251025|Other|Myofascial Release|The Group B received Myofascial Release Technique and along with conventional treatments. The Myofascial Release Technique for hamstrings was given to the patient in prone position. The technique was applied either by the crossed hands or thumbs. This total treatment was given for 30 minutes consecutively. After the technique the Myofascial structures were stretched and then were hold for straight 120 seconds so that the tissues get softened. The technique was given to patients with 6 repetitions and with a hold for 120 seconds. The treatment was continued for 5 days a week for straight 6 weeks.
45503105|NCT05751135|Device|Focal muscle vibration|Focal muscle vibration will be provided by a longitudinal muscle vibrator on muscles of lower limb; hamstrings, quadriceps, illiopsoas, calf, gluteus maximus and medius. Each muscle will be targeted 3 times with 30 seconds time period and keeping 10 second interval.
45394172|NCT00506285|Other|placebo patch|This patch is designed to appear identical to the actual intervention patch
45503106|NCT05751135|Procedure|Stretching|Stretching of shortened lower extremity muscle
45503107|NCT05751135|Procedure|Strengthening|Strengthening exercises for weak lower extremity muscles
45394173|NCT00506129|Drug|Fludarabine|25 mg/m^2 Given By Vein Daily for 5 Days Prior to Allogeneic Transplant.
45394174|NCT00506129|Drug|Melphalan|70 mg/m^2 Given By Vein Daily for 2 Days Prior to Allogeneic Transplant.
45394175|NCT00506129|Procedure|Allogeneic Transplant|Allogeneic transplant given by vein after completion of Fludarabine and Melphalan.
45394176|NCT00506129|Drug|Thymoglobulin|2 mg/kg/day by vein on days -3, -2 and -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
45394177|NCT00358670|Biological|infliximab|"Infliximab maintenance therapy~intravenous (IV) infusion every 8 weeks, 5 mg/kg body weight (first infusion at Week 4/Visit 2)."
45394178|NCT00358670|Biological|infliximab|"Infliximab intermittent therapy:~Paricipants will receive no infliximab treatment until the Week 26 improvement in PASI from Baseline (original Study P04271 [NCT00251641] Baseline) is reduced by more than 50%. At that time, participants will receive an infliximab infusion, 5 mg/kg body weight. Participants may receive additional infusions at 0, 2, 6, and 14 weeks after the first infusion of the cycle (ie, a maximum of 4 infusions in each infusion cycle) as needed until they respond, defined as a >=75% improvement in PASI from the original Baseline in Study P04271. Subjects will receive no further treatment until they relapse again (ie, improvement in PASI from Baseline is reduced by more than 50%), at which time participants will receive another infusion cycle of up to 4 infusions, as described above. Throughout the study, intermittent treatment infusion cycles will be repeated whenever participants relapse."
45394179|NCT01010087|Drug|Oseltamivir|standard (75 mg bid) or high-dose (225 mg bid) oseltamivir
45394180|NCT00505661|Drug|Letrozole|2.5 mg PO Once Daily
45394181|NCT00383786|Drug|NK1 Antagoist (GR205171)|
45394182|NCT00383786|Procedure|Psychophysiology (Trauma Script)|
45394183|NCT00383786|Procedure|Psychophysiology (Verbal Threat)|
45394184|NCT00383786|Procedure|Psychophysiology (Fear Conditioning)|
45394185|NCT00383786|Procedure|Psychophysiology (Affective Modulation)|
45394186|NCT00383786|Procedure|Psychophysiology (Heart rate variability)|
45394187|NCT00383786|Procedure|Lumbar Puncture|
45394188|NCT00383786|Procedure|24-hour plasma sampling|
45394189|NCT00383786|Procedure|MRI|
45394190|NCT05358977|Biological|Tisseel|Intraoperatively, the intervention side will receive topical administration of Tisseel to the blepharoplasty incision. A 2mL syringe of Tisseel product will be used as per the product monograph for an area of < 8cm2. There will be no variation in surgical counselling or technique, with the exception of the use of Tisseel in one eyelid closure. Both eyelids will otherwise receive standard blepharoplasty surgical techniques. There will be no monitoring of compliance necessary, given the Tisseel will be utilized intraoperatively.
45394191|NCT01010243|Drug|Lenalidomide, Pioglitazone, dexamethasone, treosulfan|"Phase I:lenalidomide dose ( 5 mg or 10 mg or 15 mg) will be determined for phase II on the basis of DLTs in the first 4 weeks for the phase II part.~Start Phase I part: lenalidomide 10 mg p.o. daily + pioglitazone 60 mg p.o. daily + treosulfan 250 mg p.o. bid + dexamethasone initially 40 mg p.o. d1-4 and d15-18, then 20mg d1 and d15. dexamethasone 1 mg p.o. continuously within the intervals of pulsed dexamethasone therapy"
45394192|NCT05358665|Other|mask use|long term mask use
45394193|NCT00383708|Drug|lanreotide (Autogel formulation)|120 mg administered via deep subcutaneous injection every 28 days over 28 weeks.
45394194|NCT00383708|Drug|Pegvisomant|Administered at 40 to 120 mg per week via subcutaneous injection once or twice a week over 28 weeks.
45394195|NCT00504881|Drug|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period
45394196|NCT00504881|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, Brivaracetam 20 mg/day or Brivaracetam 50 mg/day or Brivaracetam 100 mg/day or Brivaracetam 150 mg/day, in a double-blinded way for the 16-week Treatment Period
45394197|NCT00504725|Drug|Ketamine|Interventional
45503108|NCT05751135|Procedure|Positioning|Positioning of participant to maintain a good body posture
45394198|NCT00504725|Drug|0.9% saline|placebo
45394199|NCT01010321|Device|confocal microscopy|non-invasive imaging
45394200|NCT05407883|Behavioral|School traffic warden programme|Trained school traffic wardens placed at school crossing points to help children cross
45394201|NCT00383240|Drug|mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
45394202|NCT00383240|Drug|Mometasone furoate MDI (MF MDI) 200 mcg|MF 200 mcg via metered dose inhaler twice daily for 26 weeks
45394203|NCT00383240|Drug|formoterol fumarate 10 mcg|F via metered dose inhaler 10 mcg twice a day for 26 weeks
45394204|NCT00383240|Drug|Placebo|Placebo metered dose inhaler twice a day for 26 weeks
45394205|NCT05130788|Behavioral|WeChat Quit Coach|"WeChat Quit Coach intervention will be delivered via WeChat private groups for 6 weeks (<1 minute per day). During the intervention period, participants will receive a text message at a fixed point of time every day (e.g., 8:00 am). The messages are designed to build motivations and skillset to quit smoking. Participants will also receive a daily group discussion question (e.g., If you are to give one piece of advice to someone who has not made the decision to quit smoking, what would you say to his/her?), and be encouraged to respond to the question. Participants can comment on group members' responses and ask questions related to smoking and quitting either in group (so everyone in the group can see the message) or directly to the coach (so only the coach can see the message). The coach will respond to the questions within 24 hours. The PI and the RA will moderate group discussions."
45394206|NCT05130788|Behavioral|Leaflet|Participants in the control group will receive a leaflet with information about existing smoking cessation programs targeting Chinese American smokers.
45394207|NCT05130788|Drug|Optional Nicotine Replacement Therapy (NRT) Patches or Lozenges|Participants in both groups will be offered a 4-week supply of NRT patches and lozenges but not forced to use the medications. The medications are free to participants. If participants want to try or use the medications, the study team will mail the patches and lozenges (with a Chinese version of the instruction) or deliver in person.
45394208|NCT00362180|Drug|mipomersen|200 mg subcutaneous injections
45394209|NCT00362180|Drug|Placebo|subcutaneous injections
45394210|NCT00383162|Drug|Combination Product (sumatriptan succinate / naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in the second layer.
45394211|NCT00383162|Drug|Placebo|Matching placebo tablet.
45503109|NCT02796560|Drug|Brand name travoprost|Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
45848947|NCT00519090|Drug|Nilotinib (AMN107)|Administered orally as a single agent on a continuous daily schedule of 400 mg bid (2 x 200 mg twice daily) without food. Once cycle comprised of 28 days.
45394212|NCT01050140|Dietary Supplement|high sugar diet|25% of dietary energy from fructose or glucose
45394213|NCT03990584|Procedure|three irrigation activation methods|passive ultrasonic irrigation, sonic irrigation, manual dynamic irrigation
45696936|NCT03081351|Procedure|extended lymphadenectomy and nerve clearance|"The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node."
45696937|NCT03081351|Procedure|standard lymphadenectomy|The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
45696938|NCT03084861|Drug|Cord Blood Eye Drops|Eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives
45696939|NCT03084861|Drug|Conventional treatment|"Artificial tears: Lubristil ®~Therapeutic Contact lens: Air Optix Night&Day"
45696940|NCT01006252|Drug|Tasisulam-sodium|Administered intravenously on Day 1 of a 28-day cycle, until disease progression.
45696941|NCT01006252|Drug|Paclitaxel|80 mg/m^2 administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression
45394214|NCT03990584|Procedure|conventional needle irrigation|conventional needle irrigation
45394215|NCT01052792|Drug|Naproxen Sodium|Naproxen Sodium Tablets 550 mg
45696942|NCT03081897|Drug|SPRANC Block group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional anaesthesia (cervical plexus block) with an long acting local anesthetic according to clinical estimation of the treating anesthetist (about 15 ml Ropivacaine 0,75% around the carotid bifurcation, 5 ml Ropivacaine in the region of Erb´s Point of the superficial cervical plexus and 10 ml Ropivacaine at the area of skin incision on the tumor side); unilateral neck dissection.
45696943|NCT03081897|Drug|SPRANC Control group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional Patient Control Group (no Intervention planned), general anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); unilateral neck dissection.
45696944|NCT03089931|Procedure|Cervical spinal surgery|Cervical laminoplasty or anterior discectomy and fusion
45394216|NCT03990350|Other|Fecal Sample Collection|With permission from the parent/guardian, stool collected in a sterile container will be brought within 12 hours of defecation from home or the outpatient clinic to a separate clinical laboratory where feces will be collected through use of FLOQswab brush x 3 (Copan Diagnostics, Murrieta, CA) The swabs will be pre-labeled with a de-identified code reflecting patient number, sample number, and date and the sample will be placed into dry ice then transferred to a -80 degrees Celsius freezer until retrieval by the research staff for transfer to CHOP Microbiome Center.
45394217|NCT03990350|Other|Physical Activity Questionnaire|At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the Physical Activity Questionnaire (Physical Activity Questionnaire for Older Children) with the subject and parent.
45394218|NCT03990350|Other|Food Frequency Questionnaire|At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the Food Frequency Questionnaire with the subject and parent.
45394219|NCT03990350|Other|24-hour dietary recall diary|At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the 24-hour dietary recall diary with the subject and parent.
45394220|NCT01052870|Drug|Finasteride|Effect of 1 mg finasteride on women with androgenetic alopecia depending on their AR gene polymorphism (androgen sensitivity)
45394221|NCT00358436|Drug|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
45394222|NCT00358436|Drug|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
45394223|NCT01053026|Drug|olmesartan|(1) Olmesartan treatment or (2) Life modification and exercise training
45394224|NCT00383084|Behavioral|Lifestyle physical activity (LPA)|Bi-weekly, 60-minute group sessions spread over 12 weeks. Participants will receive education on how to increase their daily physical activity, goal setting, problem solving strategies to overcome barriers to being more physically active, and finding new ways to integrate short bouts of LPA into their daily lives.
45394225|NCT00383084|Behavioral|Fibromyalgia education|Participants will meet monthly for 1.5 to 2 hours for a total of 3 months. The sessions will be divided into three components: (1) education, (2) question and answer, and (3) social support.
45394226|NCT01045382|Biological|Mesenchymal stem cells|Mesenchymal stem cell injection
45394227|NCT01045382|Other|Isotonic solution|Isotonic solution injection
45394228|NCT01045538|Drug|Vorinostat, capecitabine, and cisplatin|Vorinostat 200~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1
45394229|NCT00361634|Drug|Etanercept|
45696945|NCT03084705|Device|Manumeter|A manumeter is a first-of-its-kind magnetic sensor to wirelessly detect hand and arm movement in a socially acceptable and easy to don package. The study participants will wear a small magnet as a ring, and a sensing/logging wristband detects changes in the magnetic field as the ring moves; the wristband can detect arm accelerations.
45696946|NCT02245906|Dietary Supplement|Control drink|As a control, subjects are asked to consume 300 ml control drinks containing equal amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
45503110|NCT02796560|Drug|Generic travoprost|Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
45503111|NCT01316081|Dietary Supplement|Vitamin C Vitamin E Selenvital all from Burgerstein Vitamine|"Vitamin C: 500mg Vitamin E: 400 I.U. Selenium: 50mcg~Placebo Supplements: identical appearing tablets"
45503112|NCT05735301|Procedure|Endovascular therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.Remedial measures after failed thrombectomy are permitted by pharmacologic arterial thrombolysis or intravenous infusion of antiplatelet drugs, such as tirofiban or rt-PA"
45503113|NCT05735301|Drug|Drug|Drug conservative therapy could be uesd in patients who with no indication of surgery
45503114|NCT05123027|Behavioral|Peer Intervention to Link Overdose Survivors to Treatment (PILOT) Peer|Participants will meet with the PILOT Peer consistently throughout the 6 months of study participation.
45503115|NCT05123027|Behavioral|Treatment As Usual Peer|Participants will receive recovery resources and standard of care procedures specific to the Emergency Department.
45503116|NCT02062970|Biological|blood draw|
45503117|NCT00958737|Drug|FOLFOX regimen|Given IV
45696947|NCT02245906|Dietary Supplement|Brazilian fruit peel flour|In this study, subjects are asked to consume 300 ml beverage drinks contain certain amounts of Brazilian fruit peel flour. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
45696948|NCT02245906|Dietary Supplement|Negative control drink|As a negative control, subjects are asked to consume 300 ml control drinks without containing amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
45696949|NCT03080649|Device|excavated with rotary bur|One of two identified caries lesions in the patient were randomly allocated to be excavated with rotary bur
45394230|NCT03992924|Procedure|function or imaging guided PCI|FFR may be good tools to differentiate patients with STEMI who may not need stent implantation from those who need Optical coherence tomography (OCT) can visualize the microstructure of culprit and the OCT characteristics were validated by histology
45394231|NCT00357968|Drug|Prasugrel|Administered orally
45394232|NCT00357968|Drug|Clopidogrel|Administered orally
45394233|NCT00357968|Drug|Placebo for Prasugrel|Administered orally
45394234|NCT00357968|Drug|Placebo for Clopidogrel|Administered orally
45394235|NCT03990272|Drug|AIT drops|once a day
45394236|NCT03990272|Drug|placebo drops|once a day
45394237|NCT01324934|Drug|ATG-Fresenius S|"Dosage: Single high-dose of 9 mg/kg pre-operatively, followed by 3 mg/kg/d at day +2 and +4. ATG-Fresenius treatment at Days 0, +2, and +4 is mandatory.~(In case of persisting DGF, the treatment is left to the discretion of the investigator. Treatment options include the continuation of ATG-Fresenius treatment with 3 mg/kg/d at Day +6 and if deemed necessary also at Day +8 - but without corticosteroids)."
45394238|NCT01053182|Procedure|Ivor-Lewis Esophagectomy|Esophagectomy via Right Side Thoracotomy Plus Midline Laparotomy Approach
45394239|NCT01053182|Procedure|Sweet Esophagectomy|Esophagectomy through Left Side Thoracotomy
45503118|NCT00958737|Drug|fluorouracil|Given IV
45503119|NCT00958737|Drug|leucovorin calcium|Given IV
45503120|NCT00958737|Drug|oxaliplatin|Given IV
45503121|NCT00958737|Drug|XELOX regimen|
45503122|NCT00958737|Drug|Capecitabine|oral
45503123|NCT01342991|Procedure|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given"
45503124|NCT01342991|Procedure|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given"
45503125|NCT02063048|Behavioral|Text Message Based Weight Loss Support|
45503126|NCT05007405|Other|Groups/Cohortes|Retrospective study on medical file of patients with osteoarticular infections diagnose (date of the positive bacteriological sample) between January 1, 2010 and December 31, 2020
45503127|NCT01343069|Procedure|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implementated
45503128|NCT03560492|Other|Exercises|5 sessions of exercises of 20 minutes each. Participants have to do a set of cervical, dorsal and abdominal stretching and strengthening exercises. Participants receive instructions to continue at home on a daily basis for 3 months and record compliance in a logbook.
45503129|NCT03560492|Device|Posture garment|Participants are provided with the appropriate size of a posture garment which includes thoracic and abdominal tensional bands. They are instructed to wear it 2 to 4 h per day for a 3 month period and record compliance in a logbook daily.
45503130|NCT01343147|Other|Microwave diathermy|Deep tissue heating via microwave diathermy
45503131|NCT01343147|Other|Superficial hyperthermia|Superficial heating via hot pack application
45503132|NCT05210127|Procedure|Scarf osteotomy for Hallux Valgus deformity|An experiment of foot muscle strength and activation, during gate phases after hallux valgus correction with the use of core foot system protocol
45503133|NCT01345331|Behavioral|Real stimulation VS Sham|Ear stimulation at specific points should work by stimulating a nerve called the vagus nerve. Previous research has shown that stimulating this nerve can help patients feel less pain. During any testing session, participants may receive either the real ear stimulation or a sham (placebo) treatment. The sham treatment will use the same equipment as the real treatment, but will not deliver any real stimulation to the ear. We use placebo/sham procedures in research to make sure that the study results are related to the study procedure, and not to other reasons.
45503134|NCT02062034|Drug|Ubiquinone|400mg daily of oral ubiquinone for 24 weeks
45394240|NCT00357656|Drug|Recombinant Protein-Free Factor VIII (rAHF-PFM)|"An initial loading dose will be administered intravenously over a period <= 5 minutes (maximum of infusion rate of 10 mL/minute) within 60 minutes prior to surgery dose in order to maintain a minimum target FVIII level of at least 80% of normal.~CI will start prior to surgery as soon as the loading dose has been administered, at a rate calculated according to a formula provided by the sponsor.~All study product must be administered with a syringe pump running at an infusion rate according to the dosing regimen, but always >= 0.4 mL/h."
45394241|NCT00357656|Drug|Recombinant Protein-Free Factor VIII (rAHF-PFM)|The treatment schedule for intermittent BI of rAHF-PFM will begin with the administration of the loading dose according to the dose recommendations provided by the sponsor. If required by the hemostatic challenge, additional boluses may be administered after a blood sample for FVIII determination has been drawn. All infusions of rAHF PFM will be given over a period <= 5 minutes (maximum infusion rate, 10 mL/min).
45503135|NCT02062034|Drug|Combined antioxidant therapy|(1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks
45503136|NCT02062034|Drug|Placebo|100 mg of oral placebo with identical appearance, form, size than ubiquinone and antioxidant combined therapy for 24 weeks
45503137|NCT03620357|Device|CGM|CGM Group: Dexcom G6 CGM
45503138|NCT03620357|Device|SMBG|SMBG Group: Blood Glucose Meter
45503139|NCT02063594|Drug|NCTX (PEGylated Liposomal Iodixanol Injection)|Single dose of NCTX (PEGylated Liposomal Iodixanol Injection) administered at escalating doses from 9 mg I/kg up to 110 mg I/kg
45394242|NCT00357500|Drug|celecoxib|
45394243|NCT00357500|Drug|cyclophosphamide|
45394244|NCT00357500|Drug|etoposide|
45394245|NCT00357500|Drug|fenofibrate|
45503140|NCT02063594|Drug|Saline Placebo|Single dose of 0.9% Sodium Chloride Injection, USP administered similarly and at an equivalent dose volume as the active drug
45503141|NCT00344487|Drug|Lopinavir/Ritonavir|Dosing of Kaletra will be per package insert and BID with food. A three-drug standard of care antiretroviral regimen will be used in this study. Subjects will enter the study already on an effective, virally-suppressive treatment regimen. One of these drugs will be substituted for Lopinavir/ritonavir (Kaletra®). However, the nucleoside/nucleotide backbone drugs that the subject is already on will remain the same.
45503142|NCT03789968|Drug|bictegravir/emtricitabine/tenofovir alafenamide|Treatment experienced patients with HIV infection that switched to a bictegravir/emtricitabine/tenofovir alafenamide-based ART regimen
45503143|NCT05089643|Drug|Anlotinib|Before breakfast, anlotinib hydrochloride capsule was taken on an empty stomach, once a day, 1 tablet (10mg) each time.Continuous oral administration for 2 weeks stopped for 1 week, that is, 3 weeks (21 days) as a treatment cycle, until disease progression or adverse reactions become intolerable.In case of missing medication, confirm that the time before the next medication is less than 12 hours, no refill.
45503144|NCT05089643|Drug|Capecitabine|Capecitabine tablets 1000 mg/m2, twice a day, within 30min after meals, were taken orally for 2 consecutive weeks and stopped for 1 week, i.e., 3 weeks (21 days) as a treatment cycle until disease progression or adverse reactions became intolerable.
45503145|NCT02871492|Drug|Pritelivir 5% w/w ointment|
45503146|NCT02871492|Drug|Pritelivir ointment matching placebo|
45696950|NCT03080649|Device|Er:YAG laser|One of two identified caries lesions in the patient were randomly allocated to be excavated with Er:YAG laser
45696951|NCT00959842|Drug|Lovaza|1 gram gel capsule 4 capsules per day for 8 weeks
45696952|NCT03080805|Drug|Pyrotinib Plus Capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/ m^2 BID)
45503147|NCT02871492|Drug|Zovirax® cream|
45503148|NCT05209581|Diagnostic Test|Distance Visual Acuity Examination|Best spectacle-corrected distance visual acuity of refugees/immigrants will be examined via a web-based digital visual acuity chart
45503149|NCT01345487|Other|Vegetable Protein|Vegetable protein in the form of fava beans/split peas
45503150|NCT01345487|Other|Animal protein|Protein in the form of minced pork/beef
45503151|NCT02063126|Dietary Supplement|ReConnect (NADH plus CoQ10)|"ReConnect supplementation (NADH: 20 mg/day plus CoQ10: 200mg/day) divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)~Placebo supplementation divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)"
45696953|NCT03080805|Drug|Lapatinib Plus Capecitabine|Lapatinib (1250 mg once daily)+ capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
45394246|NCT00357500|Drug|thalidomide|
45394247|NCT00357110|Drug|Fulvestrant|intramuscular injection
45394248|NCT00357110|Drug|Anastrozole|1 mg oral tablet
45394249|NCT01053260|Behavioral|LEARN Program|Participants will receive weekly counseling based on the LEARN Program for Weight Management
45503152|NCT02063126|Dietary Supplement|placebo|placebo (phosphoserine/serine plus vitamin C) supplementation divided in two daily doses (2 tablets/before brekfast and 2 tablets/before lunch)
45696954|NCT00959920|Procedure|Indwelling catheter|Indwelling bladder catheter will remain in place until time of delivery.
45696955|NCT00959920|Procedure|Intermittent straight catheterization|intermittent straight catheterization will be performed on an as needed basis until time of delivery.
45848948|NCT00506064|Drug|Melatonin|0.15 mg/kg by mouth (PO) Daily
45394250|NCT01053260|Behavioral|Contingency Management|Participants can earn chances to win prizes for losing weight and completing activities that promote weight loss.
45394251|NCT03337646|Drug|Lisdexamfetamine Dimesylate|Medication to treat ADHD
45503153|NCT04959435|Other|biological samples collection|samples of blood, faeces, saliva, dental plaque, oral mucosa, genital mucosa
45503154|NCT02032056|Dietary Supplement|Probiotic (10^9 CFU/day)|
45503155|NCT02032056|Dietary Supplement|Probiotic (10^8 CFU/day)|
45503156|NCT02032056|Other|Placebo|
45394252|NCT04467866|Behavioral|A Ride-on Car with a Standing Posture|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
45696956|NCT03018964|Procedure|Solo surgery|Solo surgery using a camera scope holder in single incision laparoscopic cholecystectomy
45696957|NCT03018964|Procedure|operation with a camera operator in SILC|conventional single incision laparoscopic cholecystectomy with a scopist
45848949|NCT00506064|Drug|Placebo|Two, three, or four starch tablet or capsules before bed
45394253|NCT04467866|Behavioral|Regular Therapy Program|The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve mobility, socialization and upper limb use in functional tasks. Each participant will have the opportunity to walk on the hallway/public space and interact with the therapist and caregivers depending on his/her motor abilities.
45848950|NCT00506064|Behavioral|Questionnaire|Sleep study surveys, two per day completed each evening, lasting 10 minutes
45848951|NCT00503880|Biological|filgrastim|subcutaneously one day prior to treatment
45394254|NCT00098722|Drug|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
45394255|NCT00098722|Drug|optimized background therapy|[OBT (3-6 drugs based on treatment history and resistance testing)]
45394256|NCT00098722|Drug|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
45394257|NCT00098722|Drug|optimized background therapy|[OBT (3-6 drugs based on treatment history and resistance testing)]
45394258|NCT00098722|Drug|optimized background therapy|[OBT (3-6 drugs based on treatment history and resistance testing)]
45394259|NCT01079416|Device|Capsule endoscopy, Esophagogastroduodenoscopy|
45394260|NCT02531152|Drug|Latanoprost|
45394261|NCT02531152|Drug|SAR366234|
45394262|NCT01084408|Device|SeQuent®Please (Paclitaxel coated balloon)|PCI of de-novo lesions
45394263|NCT01084408|Device|Taxus™Liberté™ (Paclitaxel eluting stent)|PCI of de-novo lesions
45394264|NCT01079494|Other|pharmaceutical care services|Patients treatment related problems and therapeutic needs or complains identified by clinical pharmacist and managed collaboratively by both pharmacist and the physician.
45394265|NCT00098254|Drug|BAY 43-9006 (Sorafenib)|Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
45503157|NCT03990233|Drug|BI 765063|mAb antagonist to SIRPα receptor, a myeloid checkpoint inhibitor
45503158|NCT03990233|Drug|BI 754091|mAb antagonist to PD-1 receptor, a lymphocyte T checkpoint inhibitor
45503159|NCT05591300|Diagnostic Test|Microparticles research|The absolute count of the total circulating microparticles will be carried out on the patients' plasma using the NanoSight NS300 instrument (Alphatest). Furthermore, the circulating microparticles will be stained with a combination of three monoclonal antibodies (Becton and Dickinson, NJ,USA) to detect microparticles released by the most abundant cell populations in the blood: leukocyte-derived microparticles (CD45+), endothelial-derived microparticles (CD31+), and PLT-derived microparticles (CD31+ CD41a+).
45503160|NCT05747157|Drug|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion.
45503161|NCT03615612|Other|QuickSee refractive error assessment + glasses|QuickSee refractive error assessment + glasses
45696958|NCT03089775|Drug|BBI-2000|Experimental
45696959|NCT03089775|Drug|Vehicle|Vehicle Comparator
45696960|NCT03089775|Other|Multiple treatments|BBI-2000, Vehicle, Clobetasol Propionate, No treatment
45696961|NCT04401735|Drug|Polydeoxyribonucleotides|PDRN injection to epidural space
45696962|NCT04401735|Drug|Normal saline|Normal saline
45696963|NCT01007110|Dietary Supplement|DHA|Docosahexaenoic Acid (DHA) from algal oil
45696964|NCT01007110|Other|Placebo|Placebo capsule
45848952|NCT00503880|Drug|clofarabine|single IV dose over 1 hour daily for 5 days
45848953|NCT00503880|Drug|cytarabine|subcutaneously daily for 5 days 2-4 hours following the end of the Clofarabine infusion
45848954|NCT00503880|Genetic|microarray analysis|Both standard cytogenetic testing and FISH (fluorescent in situ hybridization) are adequate to assess responses.
45848955|NCT00503880|Procedure|biopsy|bone marrow biopsy
45394266|NCT00095056|Drug|sitagliptin|One (participants with visit 1 estimated creatinine clearance <30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to <50 mL/min; not on dialysis) tablets of 25 mg Sitagliptin daily.
45394267|NCT00095056|Drug|Placebo to Sitagliptin|One (participants with visit 1 estimated creatinine clearance <30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to <50 mL/min and not on dialysis) tablets of placebo to sitagliptin 25 mg daily.
45394268|NCT00095056|Drug|glipizide|One 5 mg glipizide tablet per day. The dose of glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.
45394269|NCT00095056|Drug|Placebo to glipizide|One placebo to glipizide 5 mg tablet per day. The dose of placebo to glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.
45394270|NCT03962764|Behavioral|Responsible Fatherhood Program|24 hours of fatherhood curriculum, 6 hours of financial literacy, workforce development, and case management.
45394271|NCT00098020|Drug|Isotretinoin|
45394272|NCT00381680|Drug|vincristine sulfate|Given IV
45394273|NCT00381680|Drug|prednisone|Given PO
45394274|NCT00381680|Drug|doxorubicin hydrochloride|Given IV
45394275|NCT00381680|Drug|pegaspargase|Given IM
45503162|NCT02063750|Other|strengthening exercises using a Swiss ball|"This group performed eight muscle strengthening exercises using a Swiss ball of 65 cm diameter and dumbbells with different loads.~Each training session was 40 minutes long and was performed three times a week for 12 weeks. The exercises were performed in three sets of 12 repetitions, with an interval of one to two minutes of recovery between exercises, which alternated between upper limbs, lower limbs and abdomen. The load used was 60 % of one repetition maximum (1RM)."
45503163|NCT02063750|Other|strengthening exercises|The stretching group performed stretching exercises that targeted the same muscles trained in the IG. The participants remained in the stretched position for three sets of 30 s for each exercise. The total session time was 40 minutes.
45503164|NCT05209113|Other|Education|A self-management module was applied to the study group. This module includes informing the patient verbally and in writing about MS disease, the importance of drug compliance, and monitoring of disease symptoms.
45848956|NCT00475332|Drug|Iodine I -01 Tositumomab (Bexxar)|"Patients will be treated in two dosing phases, each phase includes two infusions. The first phase, termed dosimetric dose, involves an intravenous administration of 450 mg unlabeled tositumomab followed by an intravenous administration of 5 mCi (0.18 GBq) of I-131 tositumomab for the purpose of determining the rate of whole body clearance of radioactivity (residence time) so that the administered activity (mCi or GBq) to deliver a 75 cGy (or 65 cGy for patients with baseline platelet count from 100,000 to 149,999/mm^3) total body radiation dose can be calculated."
45394276|NCT00381680|Drug|cytarabine|Given IT or IV
45848957|NCT00475332|Procedure|External Beam Radiation Therapy|All patients are to receive 20 Gy in 10 fractions of 200 cGy to the PTV
45394277|NCT00381680|Drug|methotrexate|Given IT or IV
45394278|NCT00381680|Drug|dexamethasone|Given PO
45394279|NCT00381680|Drug|etoposide|Given IV
45394280|NCT00381680|Drug|cyclophosphamide|Given IV
45394281|NCT00381680|Drug|leucovorin calcium|Given IV or PO
45394282|NCT00381680|Biological|filgrastim|Given IV or SC
45394283|NCT00381680|Drug|asparaginase|Given IM
45394284|NCT00381680|Drug|mercaptopurine|Given PO
45394285|NCT03292250|Drug|BYL719|Patients will be instructed to take BYL719 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
45394286|NCT03292250|Drug|Poziotinib|Patients will be instructed to take BYL719 orally at a dose of 12 mg once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
45394287|NCT03292250|Drug|Nintedanib|Initial dose 200 mg twice per day orally according to study protocol.
45394288|NCT03292250|Drug|Abemaciclib|Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
45394289|NCT03292250|Drug|Durvalumab,Tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
45394290|NCT01053338|Drug|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
45394291|NCT01050374|Drug|albendazole + praziquantel|albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)
45394292|NCT01050374|Drug|mebendazole + praziquantel|mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)
45394293|NCT00360698|Drug|Insulin Glargine|One daily injection at bedtime
45394294|NCT00360698|Drug|Glimepiride|At same dosage as during the run-in period
45394295|NCT00360698|Drug|Insulin Glulisine|One bolus given before the main meal
45503165|NCT03143855|Drug|Lorcaserin|Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days
45503166|NCT03143855|Drug|Placebo|Placebo will be administered twice daily for for 5 days
45503167|NCT03615456|Procedure|Conventional thyroidectomy|Thyroid vessels are ligated with sutures and divided
45503168|NCT03615456|Procedure|Harmonic scalpel thyroidectomy|Thyroid vessels are sealed using harmonic scalpel device
45503169|NCT02878603|Biological|Caplacizumab|
45394296|NCT00360698|Drug|Metformin|At same dosage as during the run-in period
45503170|NCT02878603|Other|Standard of Care|• PE with plasma (e.g., fresh frozen plasma, solvent detergent/viral-inactivated plasma, cryosupernatant), • Corticosteroid treatment and • Use of other immunosuppressive agents (e.g., rituximab).
45503171|NCT05209191|Behavioral|Student Athlete Wellness Portal|A web-based design that illustrates various opioid misuse and diversion resistance strategies.
45503172|NCT03613974|Drug|Lidocaine|patients will receive different lidocaine concentrations
45503173|NCT01343225|Drug|atripla|once a day
45503174|NCT01343225|Drug|darunavir ritonavir raltegravir|as directed
45503175|NCT05208879|Biological|Characterization of carotenoid status and plasma levels of oxidative stress markers in patients (case group only)|"Carotenoid status will be determined by measuring plasma and erythrocyte concentrations of lutein and zeaxanthin obtained during an annual blood draw. These molecules will be analyzed by high performance liquid chromatography.~The oxidative stress markers will be measured, in the blood sample already collected, thanks to specific assay kits: Erythrocyte reduced glutathione, Superoxide dismutase (SOD), Glutathione peroxidase (GPx), Plasma and erythrocyte malondialdehyde, Plasma vitamin C, Plasma oxidized cholesterol, F2-isoprostanes.~This study does not result in any change in patient management, but requires the collection of an additional volume of blood (14 ml of study-specific blood) during the annual blood draw performed as part of routine patient follow-up."
45848958|NCT00478062|Biological|Hodgkin's antigens-GM-CSF-expressing cell vaccine|
45848959|NCT00478062|Procedure|adjuvant therapy|
45848960|NCT00470574|Biological|QS21|
45394297|NCT03990194|Drug|Leuprolide Acetate|Administration of Leptoprol implant every 3 months
45394298|NCT03990116|Procedure|Lateral|Posture lateral kangaroo care
45394299|NCT03990116|Procedure|Prone|Posture prone kangaroo care
45503176|NCT05208879|Other|Characterization, evaluation and comparison of macular pigment density|The macular pigment optical density (OD) will be determined by an additional photograph during the fundus usually performed for annual follow-up through two-wavelength autofluorescence imaging. Indeed, the measurement of the optical density consists of an additional post-examination analysis of additional retinal images obtained during the fundus performed for the patients' ophthalmologic follow-up.
45503177|NCT03614676|Procedure|Blood sample collection|Venous blood samples will be collected from the maternal subjects at Day 1 and Day 56 of the study and at delivery.
45503178|NCT03614676|Procedure|Cord blood sample collection|Collection of cord blood samples from maternal subjects will occur, at delivery
45503179|NCT03614676|Other|Maternal Diary Card|Completion of Diary Card about health by pregnant woman/ mother, from enrolment through week 6 post delivery.
45503180|NCT03614676|Procedure|Nasal Swab collection|Collection of nasal swabs from infants with potential LRTIs, from birth to 12 months of age.
45503181|NCT03614676|Other|Infant Diary Card|Completion of Diary Card about health of infant from birth to 12 months of age.
45503182|NCT01317251|Other|Dietary intervention (without dairy products)|Control diet without dairy products
45503183|NCT01317251|Other|Dietary intervention (high milk content)|Diet with a high content of milk (~1200 mg Ca/d from milk)
45503184|NCT01317251|Other|Dietary intervention (high cheese content)|Diet with a high content of cheese (~1200 mg Ca/d from cheese)
45394300|NCT01053416|Procedure|Yag laser iridotomy|the procedure will be performed by using a Yag laser. Single spot, 1 mJ power, beam aimed to an existing iris crypt
45394301|NCT02534558|Biological|miR 29a|Effects of IL-1β, miR-29a precursor or antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
45503185|NCT04739865|Drug|Psilocybin|Open label
45503186|NCT05078333|Other|dry needle|dry needling (on 3 trigger points on the bilateral trapezius muscle) will applied to the other 36 randomly selected patients with an acupuncture needle with a size of 0.25x0.25 by the PMR specialist for a total of 6 sessions twice a week for 3 weeks.
45503187|NCT05078333|Device|high intensity laser therapy|High intensity laser therapy (HILT), one of the physical therapy methods, was approved by the FDA in 2002. Its beneficial and versatile effect has been proven in the treatment of many musculoskeletal diseases. In addition to the exercise program, randomly selected 36 case patients + HILT (BTL brand 6000 series, United Kingdom), to the cervical area, for the a period of 3 week-weekdays, 15-minute period and 15 sessions (1.02 minutes for each 25 cm² painful area, analgesic phase, with an anergy 8.0 W, a dose 5 J / cm², a frequency of 25 Hz and total 125 joules) will be applied.
45848961|NCT00470574|Biological|sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine|
45848962|NCT00470574|Other|immunoenzyme technique|
45848963|NCT00470574|Other|immunologic technique|
45848964|NCT00470574|Other|laboratory biomarker analysis|
45848965|NCT00442260|Drug|DOXIL|
45848966|NCT00442260|Drug|Abraxane|
45848967|NCT00386724|Device|Precision Spinal Cord Stimulation System|Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
45503188|NCT03555708|Other|Physical Therapy|Physical therapy will be implemented three times a week with subjects over an eight week span. Each physical therapy session will last 40-minutes and will be conducted by a licensed physical therapist.
45503189|NCT04736511|Other|Star Excursion Balance Test|"The subject will be in unipodal support (only one foot on the ground) on the tested lower limb in the center of the platform. Three lines forming a Y will be arranged according to the lower limb in charge in three directions : anterior (ANT), posteromedial (PM) and posterolateral (PL). The goal is then to reach the longest distance possible in all three directions with the tip of the foot in relief before returning to the starting position. The subject will have 4 training trials per direction on each lower limb then 3 trials will be recorded in order to keep the average."
45503190|NCT04736511|Other|Single leg Drop Vertical Jump|The subject will drop from a step and land on one leg, then jump as high as possible and stabilize again on the same leg. The height of the step is 30 cm. The subject will perform 3 consecutive jumps in the strictest respect of the instructions: drop to the level of the mark on the ground and bounce as high as possible while spending a minimum of time on the ground. The subject must stabilize for 3 seconds during the second contact with the ground so that the instructions and measurements are reproducible.
45503191|NCT04736511|Other|Unplanned sidestep cutting manoeuvre|"The objective is to create an unanticipated playing situation, close to the daily actions of the subjects in the practice of handball. The subject will make sidestep cutting manœuvre in front of an opponent simulated by a dummy used during usual training.~The subject will sprint in a straight line and then at the force platform will make a rapid change of direction on the side of his shooting arm or will continue his run in a straight line. A light signal randomly will indicate to the player the direction in which he must carry out his manoeuvre. A computer reconstruction of the kinematics and dynamics (knee moment) will be performed."
45503192|NCT04736511|Other|Tendon vibration|The subject will be asked to stand, motionless in bipodal (both feet on the ground) support on a stable and unstable ground (foam). A tendon vibration (80Hz) will be randomly applied to the subject in the Achilles tendons or paravertebral muscles. This vibration will cause an alteration of proprioceptive information in the vibrated area leading to a disruption of postural balance. Thus, according to the amount of displacement of the center of pressure (CoP), the proprioceptive weighting ratio (dRPW) is calculated to deduce therefrom the weight assigned by the CNS to the various proprioceptive inputs during the postural task.
45503193|NCT05250635|Device|electronic stethoscope|It includes main machine and auscultation patch, which can stick on patient's body to collect and amplify breath sound.
45503194|NCT01370408|Drug|Palonosetron|Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
45503195|NCT01370408|Drug|ondansetron|Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
45503196|NCT01370408|Drug|Dexamethasone|Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
45503197|NCT04769388|Drug|Osimertinib|Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
45503198|NCT04769388|Drug|Pemetrexed/Carboplatin|Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
45503199|NCT01345565|Drug|human hepatocytes|"The intrahepatic site for liver cell transplantation has been associated with the best engraftment and function based on animal experiments. Several approaches for access to the portal vein will be considered. The technique used will be determined based on what is considered best for the child based on risk/benefit at the time.~We propose to attempt to infuse approximately 5-10% of the hepatic mass in order to provide improved hepatic function. Since we do not yet know from our experience so far the correct number of cells to transplant in order to improve function, we will continue to infuse hepatocytes as donors become available until the patient improves to the point where they are no longer meet the criteria for organ transplantation. The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant."
45503200|NCT03294109|Drug|Abdominal wall block with liposomal bupivicaine|Abdominal wall block with liposomal bupivicaine
45503201|NCT01345643|Other|Maintenance of hemoglobin level not less than 10g/dL|The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
45503202|NCT01345643|Other|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
45503203|NCT03517488|Biological|XmAb20717|Monoclonal bispecific antibody
45848968|NCT00386724|Device|Artisan Surgical Lead|Artisan paddle electrode is a 2 x 8 surgical lead approved for use as part of the Precision System.
45394302|NCT00380978|Procedure|combined spinal epidural analgesia|Analgesia was initiated in the early group using a standard needle-through-needle technique with intrathecal fentanyl 25 mcg and an epidural test dose of lidocaine 15 mg/ml and epinephrine 5 mcg/ml in 3ml. At the second analgesia request, the cervix was examined. Epidural analgesia was initiated with a dilute bupivicaine/fentanyl solution if the cervix was less than 4 cm. If the cervix was 4 cm or more, epidural analgesia was initiated with bupivicaine 1.25 mg/ml. If no cervical exam was performed at the second request for analgesia, the cervix was assumed to be at least 4 cm dilated. Thereafter, analgesia was maintained in all participants in the early group with patient-controlled epidural analgesia.
45503204|NCT04727931|Behavioral|Neuropsychological assessement and questionnaires|Neuropsychological assessement including memory, working memory, executive function, oral naming and speed processing tests. There are questionnaires to assess mood disorders, anxiety and cognitive reserve.
45394303|NCT00380978|Procedure|late analgesia (systemic)|Analgesia was initiated in the late group with hydromorphone 1mg intramuscularly (IM) and 1 mg intravenously (IV). If the cervix was less than 4 cm at the second analgesia request, hydromorphone analgesia was repeated. Epidural analgesia was initiated with bupivicaine 1.25 mg/ml if the cervix was 4 cm or more. At the third analgesia request, epidural analgesia was initiated regardless of cervical dilation. Thereafter, epidural analgesia was maintained with patient controlled analgesia until delivery.
45394304|NCT02534480|Drug|NGP 555|Gamma-secretase modulator for the treatment of Alzheimer's disease
45696965|NCT03019120|Drug|Vitamin D|"Subjects will undergo a cognitive evaluation using the Montreal Cognitive Assessment (MoCA) screening test and the Neurotrax computerized cognitive assessment battery.~Subjects will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months.~Levels of serum calcium will be repeated monthly (end of month 1, 2, 3).~Subjects will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~At 3-month follow-up subjects will be asked to complete the Neurotrax computerized cognitive assessment battery."
45848969|NCT00325572|Drug|oral zinc and vitamin C supplements|Each child will be provided separate suspensions containing zinc and vitamin C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
45394305|NCT00162123|Drug|Ipilimumab|Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
45394306|NCT00227721|Drug|Docetaxel|40 mg/m2, 30 minute IV infusion, Days 1 and 8, Every 21 days
45394307|NCT00227721|Drug|Gemcitabine hydrochloride|800mg/m2, 30 minute IV infusion, Days 1 and 8, every 21 days
45394308|NCT01074723|Dietary Supplement|b-cryptoxanthin and phytosterols|Fruit juices containing b-cryptoxanthin (ca. 1 mg), phytosterols (ca 1.7g) or both will be consumed for 4 weeks with a 4-week washout in between.
45394309|NCT01074801|Other|Closed-loop insulin delivery|Basal subcutaneous insulin delivery to be adjusted at 15min cycles according to the computer-based algorithm advice.
45394310|NCT01074801|Other|Standard insulin pump treatment|Subcutaneous insulin delivery to be performed based on subjects' standard treatment
45394311|NCT01074879|Dietary Supplement|Whey protein|Dietary supplement after training
45394312|NCT01074879|Dietary Supplement|Milk protein|Dietary supplement after training
45394313|NCT01074879|Dietary Supplement|Carbohydrates|Dietary supplement after training
45503205|NCT02065466|Drug|nab-paclitaxel|
45696966|NCT03080337|Other|Group Care|Participation in 12 group sessions with 6-10 women who are also pregnant and have diabetes.
45394314|NCT03972423|Other|With or wiyhout a checklist|The evaluation of the impact of the use of this Checklist will be done in comparison with the standard transmission practice
45394315|NCT00226941|Drug|Cetuximab|Cetuximab is a chimeric anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody, administered via a intravenous (IV) infusion at 400 mg/m² (initial loading dose) or 250 mg/m² (weekly dose). Dosage is based on m² of body surface area (BSA)
45394316|NCT00226941|Drug|Oxaliplatin|Oxaliplatin is a cancer medication used to treat colorectal cancer, and is administered on Days 2 and 23.
45394317|NCT00226941|Drug|Capecitabine|Capecitabine is a cancer medication, and is administered based on m² of body surface area (BSA) delivered in equivalent morning and evening doses
45394318|NCT00226941|Radiation|Radiotherapy|"Radiotherapy is administered on weekdays in 180 centigray fractions (doses), for 28 total fractions delivering a total dose of 5040 centigray (cGy)"
45394319|NCT00226941|Drug|Diphenhydramine hydrochloride (HCl)|Diphenhydramine HCl 50 mg (or equivalent) is administered as a per-medication for cetuximab
45394320|NCT01074957|Device|Incentive Spirometry|Incentive Spirometry (IS) has been used extensively in postoperative period and consists of spontaneous deep breaths through a device which provides a visual feedback to maintain a maximum insuflation
45394321|NCT01074957|Device|Breath-Stacking Technique|An one-way valve device to promote the summation of successive inspiratory volumes while expiration was avoided
45394322|NCT01074957|Other|Exercise|Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
45394323|NCT01075503|Procedure|brachial plexus block|0.5% Ropivacaine 40ml
45503206|NCT02065466|Drug|Temozolomide|
45696967|NCT00960622|Drug|Truvada|Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months
45503207|NCT02065466|Drug|Bevacizumab|
45503208|NCT01358773|Other|multidisciplinary intervention|Comparison of the polysomnography results, blood collection parameters, resting metabolic rate values, body composition variables, carotid artery thickness values, abdominal and subcutaneous fat and lung function variables baseline, middle and at the end of the one year of interdisciplinary weight loss program combined exercise training with physiotherapy, clinical, nutritional and psychological therapies.
45503209|NCT03970811|Procedure|Immediate Implants|dental implants are immediately placed after tooth extraction
45503210|NCT03970811|Procedure|temporary restoration|temporary restoration will be placed immediately after implant placement
45696968|NCT00960622|Drug|Combivir|Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months
45394324|NCT02531763|Behavioral|Social incentive intervention|Participant sign a pre-commitment pledge to try to achieve their goal. They are entered into a game with their teammate in which they have the chance to earn points and advance through levels (bronze, silver, gold, platinum). At the end, those in gold or platinum will receive a coffee mug as a reward
45503211|NCT03970811|Procedure|final restoration|final restoration (loading) will be placed 3 months postsurgical
45503212|NCT03446040|Biological|BMS-986258|Specified dose on specified days
45503213|NCT03446040|Biological|Nivolumab|Specified dose on specified days
45394325|NCT01075581|Drug|Epinephrin (Intranasal injection)|A total of 8 mL of epinephrine 1:100,000 will be injected in the lateral nasal wall, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
45394326|NCT01075581|Drug|Epinephrin (Topical administration)|An intranasal injection of saline solution, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
45394327|NCT00356408|Biological|Certolizumab pegol|"Certolizumab pegol (CDP870), an anti-tumor necrosis factor (TNF)α, humanized antibody Fab' fragment - polyethylene glycol conjugate, solution for injection, in 10 mM sodium acetate buffer and 125 mM sodium chloride, pH 4.7, supplied in 3 mL vials with a fill of 1.4 mL (an extractable volume of 1 mL corresponds to a dose of 200 mg).~Dosing is every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2."
45394328|NCT00509795|Biological|ranibizumab|Participants received a 0.5mg dose of ranibizumab via intravitreal (IVT) injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
45394329|NCT00509795|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
45394330|NCT00509795|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
45394331|NCT00509795|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year and were to receive sham injections at interim monthly visits. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
45394332|NCT05407649|Radiation|Radiotherapy Combined with GM-CSF|Patients with stable or progressing metastatic thymic epithelial tumours, with at least two distinct measurable sites of disease, were treated with concurrent radiotherapy (35 Gy in ten fractions or 60Gy in 30 fractions) to one metastatic site and granulocyte-macrophage colony-stimulating factor (125 μg/m(2) subcutaneously injected daily for 2 weeks, starting during the second week of radiotherapy).
45503214|NCT03446040|Drug|rHuPH20|Specified dose on specified days
45503215|NCT05192421|Behavioral|Wellness Education|Receive wellness education through a weekly email and web portal content.
45503216|NCT05192421|Behavioral|Exercise Videos|Receive pre-recorded exercise videos through a weekly email and web portal content.
45503217|NCT05192421|Behavioral|Livestream Classes|Receive 3 videoconference group exercise classes per week for 8 weeks.
45503218|NCT02064062|Biological|Autologous Mesenchymal Stem Cells|
45503219|NCT03963869|Other|Malaria Camps|The Govt. of India Malaria Control Programme (MCP) of Odisha provides ITNs and IRS, and trains community health workers (ASHAs) on the diagnosis and treatment of malaria, providing them with antimalarial drugs so that malaria treatment is available even in remote villages. Faced with a persistent burden of malaria in forest villages, the MCP recently introduced malaria camps (MCs) combining focused screening and treatment in villages with intensified vector control. The program includes one round of testing and treatment for the whole village population before the monsoon season, followed by one round of screening and treating of fever cases only during the monsoon season.
45503220|NCT05208801|Drug|Percutaneous injection|A sham procedure of 2 ml of 1% lidocaine injected percutaneously using the initial 25G needle for local anesthetics
45503221|NCT05208801|Drug|Morphine|Intrathecal injection of morphine 400mcg
45503222|NCT05208801|Drug|Morphine+Bupivacaine|Intrathecal injection of 5mg of 0.5% bupivacaine chloride
45503223|NCT03614598|Procedure|Insertion of LMA-UNIQUE(TM) device|LMA-UNIQUE(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
45503224|NCT03614598|Procedure|Insertion of LMA-SUPREME(TM) device|LMA-SUPREME(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
45696969|NCT00960622|Drug|Trizivir|Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)
45696970|NCT03430947|Drug|Vemurafenib|Vemurafenib (960 mg twice a day) will be taken on days 1 - 28 of each 28-day treatment cycle.
45696971|NCT03430947|Drug|Cobimetinib|Cobimetinib (60 mg once a day) will be taken on days 1 - 21 of each 28-day treatment cycle.
45394333|NCT05407337|Behavioral|Psychotherapy using Narrative Exposure Therapy (NET)|"There are four NET sessions, each lasting thirty minutes and defined in advance on a weekly basis. The first session is the one where the person concerned will establish his/her Life Line and start his/her life story with the peer mediator.~The second and third session will be the one where the person will continue his life story. Each session will begin with the mediator reading the story from the previous session, with the person concerned modifying the story if they wish.~The fourth session will also start with the reading of the story from the previous session and will finish the story if necessary. It will also be the occasion to give the printed story to the person concerned at the end of the session and have it signed by the mediator and the patient.~To prevent a possible risk of decompensation of the subject during the session, there will be a psychiatrist on site at the time of the NET to be available if the patient needs it."
45394334|NCT00165789|Drug|E2007|
45394335|NCT01564121|Drug|acid Zoledronic|Treatment with zoledronic acid will be initiated during hospitalization, the day after the removal of redundant. Intravenous injection of 4 mg. of zoledronate diluted in sodium chloride 9 / 1000 or a solution of 5% dextrose in intravenous over 15 minutes. In the absence of intolerance clinic, an infusion of zoledronic acid in the same doses and modalities will be performed in a hospital (on the occasion of a follow-up visit after surgery) at the 3rd, 6th, 9th and 12th weeks after the first, or 5 injections. )
45394336|NCT05162105|Other|Short rest (8 hour) between two consecutive shifts.|Participants will have shortened rest opportunity (8 hours) between two consecutive shifts, due to the shift work schedule.
45394337|NCT05162105|Other|16 hour rest opportunity between to consecutive shifts.|Participants will have a 16 hour rest opportunity between shifts, due to shift work schedule.
45394338|NCT03968367|Procedure|Magnetic activated sperm sorting|MACS is a technique which allows the spermatozoa with the best characteristics to be selected for use in assisted reproduction treatments. This technique removes apoptotic spermatozoa - those which will die without achieving fertilisation - and selects the healthy ones, thus increasing the possibility of pregnancy.
45503225|NCT03614598|Procedure|Insertion of I-GEL(R) device|I-GEL(R) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
45848970|NCT00325572|Other|oral Placebo|Each child will be provided separate Placebo suspensions C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
45394339|NCT00504257|Drug|Avastin|Day 1, every 21 day cycle
45394340|NCT00504257|Drug|Docetaxel|Day 1, 8, every 21 day cycle
45394341|NCT03997955|Other|Myofascial induction|Myofascial induction in plantar fascia
45394342|NCT03997955|Other|Sham myofascial induction|Sham myofascial induction in plantar fascia
45394343|NCT05407181|Other|Blood and Liver Function test|Data was collected through routine blood and liver function tests using a hematology analyzer and ELISA, respectively.
45394344|NCT00509093|Drug|imatinib mesylate|Patients will receive treatment with imatinib mesylate at a dose of 600 mg by mouth once a day for 12 months. The study dose can be split but the dose of 600 mg must be given within a 12 hour period.
45394345|NCT00509093|Genetic|gene expression analysis|Multidrug resistance genes: These studies will include: MDR1, MRP1, LRP, and BCRP. Bone marrow blocks or cut slides will be sent to Duke on the diagnostic AML samples. DNA will be eluted from the samples so that the above genes can be analyzed.
45394346|NCT00509093|Genetic|mutation analysis|FLT3 mutation analysis (on bone marrow aspirate or peripheral blood): These analyses will be performed by pathology at the time of diagnosis, at the participating institution. Samples will be analyzed for the FLT3 ITD and/or D835 mutation by PCR.
45394347|NCT00509093|Genetic|polymerase chain reaction|AF1q gene analysis (on bone marrow aspirate)
45394348|NCT00509093|Other|flow cytometry|C-kit MFI on AML samples will be calculated by using a CD45/ orthogonal light scatter gate to isolate blasts. The MFI will be calculated as the c-kit mean channel number (MCN) of the blasts/ MCN auto fluorescence.
45394349|NCT00509093|Procedure|biopsy|Diagnostic bone marrow biopsy/aspirate must be done within 3 weeks of registration documenting complete remission
45394350|NCT05407103|Other|Cold Acupressure|For the cold acupressure application, the researchers prepared pouches that were 3 cm long, 2 cm wide, and 1 cm high (3x2x1cm), and filled with cherry seeds - to retain heat for a longer time, hence the preference. Next, they fixed rubber bands to the pouches so that they stayed in place on the participants' hands during acupressure, and retain consistent pressure throughout. Lastly, the cold acupressure pouches were kept in a freezer for 40 minutes.
45394351|NCT05407103|Other|Warm Acupressure|For the warm acupressure application, the researchers prepared pouches that were 3 cm long, 2 cm wide, and 1 cm high (3x2x1cm), and filled with cherry seeds - to retain heat for a longer time, hence the preference. Next, they fixed rubber bands to the pouches so that they stayed in place on the participants' hands during acupressure, and retain consistent pressure throughout. Lastly, the warm acupressure pouches were heated in a microwave at 600 W for one minute.
45503226|NCT02064140|Drug|Rocuronium|
45503227|NCT03963011|Diagnostic Test|Bowel Ultrasound|Ultrasound imaging of the bowel
45696972|NCT00960778|Drug|nicotine patch (Nicoderm Committed Quitter (CQ), Habitrol)|Nicotine patch 21 mg every 24 hours will be utilized for the three days after the first scanning session.
45848971|NCT00333762|Device|Smart Power Assistance Module (SPAM)|Experimental Power wheelchair utilized to traverse prescribed course
45848972|NCT00333762|Device|Smart Wheelchair Component System (SWCS)|Experimental power wheelchair utilized to traverse prescribed course
45848973|NCT00145704|Drug|bisphosphonate therapy (risedronate)|Bisphosphonate therapy given to patients with growth hormone deficiency
45394352|NCT05358509|Drug|Ferric carboxymaltose|Pregnant participants randomized to intervention arm 1 will receive a single dose of ferric carboxymaltose having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.
45394353|NCT05358509|Drug|Iron isomaltoside|Pregnant participants randomized to intervention arm 1 will receive a single dose of iron isomaltoside having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.
45394354|NCT05358509|Drug|Ferric Sulfate|Pregnant participants randomized to the oral iron arm will be given 200 ferrous sulphate tablets with 60mg elemental iron each, immediately after randomization, and instructed to take two per day (one in the morning and one at night) throughout the remainder of their pregnancy.
45394355|NCT05406869|Device|Pulsed Sonic Balloon Dilatation Catheter and Pulsed Sonic Generater|Deliver Pulsed Sonic Balloon Dilatation Catheter to the target vessel prior to placing a coronary stent or others
45394356|NCT00160641|Biological|Certolizumab Pegol|"Strength and Form: 1 ml of Liquid product containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study."
45394357|NCT04544501|Behavioral|Culturally-Targeted Video|"Culturally targeted narrative video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor. With R03 funding (R03CA191543) we developed a culturally targeted narrative video for at-risk Latinas. A multidisciplinary team of researchers collaborated with filmmakers to develop the script and video. The script was informed by health behavior conceptual models, evidence-based risk communication strategies, and formative research (40 interviews with providers and at-risk Latinas). The script addressed identified knowledge gaps (e.g., incorrect belief that pap smears screen for ovarian cancer), facilitators (e.g., inform family cancer risk), barriers (e.g., emotional concerns), and cultural factors (e.g., respect). The 18-minute video illustrates the GCRA process with the story of Rosa, a Latina cancer survivor at increased risk of HBOC. Rosa learns about HBOC risk factors, overcomes barriers, and attends genetic counseling."
45394358|NCT04544501|Other|FORCE Fact Sheet|A publically available Spanish-language fact sheet about HBOC and GCRA developed by FORCE.
45394359|NCT03997331|Other|CRx Health|CRx Health is a connected health solution comprised of connected devices (InsulCheck, a Bluetooth-enabled pill bottle cap, and a Bluetooth-enabled glucometer) paired to a mobile smartphone app (CRx Health).
45394360|NCT03997331|Other|Chronicare|Chronicare is a disease management program comprising self-management data from the CRx Health solution syncing to an automated support system (Intervention Engine) and a remote care application (CRx Care) used by a team of clinicians to remotely monitor and support patients.
45394361|NCT00493025|Drug|cisplatin|Cisplatin IV
45394362|NCT00493025|Drug|gefitinib|Gefitinib IV
45394363|NCT00493025|Drug|paclitaxel|Paclitaxel IV
45394364|NCT00493025|Procedure|adjuvant therapy|Postoperative ZD1839
45394365|NCT00493025|Radiation|radiation therapy|Radiotherapy
45503228|NCT03628755|Behavioral|Digital Manipulation of Thyroid cartilage|"Digital manipulation of thyroid cartilage was applied to the anterior aspect of thyroid cartilage while using the thumb or finger and the patient was asked to speak.~prolongation of vowel is 7 to 8 seconds, voice rest after each set is 10 second.~total repetition is 60."
45394366|NCT01075113|Drug|sorafenib tosylate|Given orally
45394367|NCT01075113|Drug|vorinostat|Given orally
45394368|NCT03972267|Procedure|Free gingival graft|Free Gingival Graft removal from the palate donor area for socket preservation
45394369|NCT03972267|Device|Enamel Matrix Derivate|EMD in contact with the palate wound for 5 min. After this time, palatal area will be covered with an individualized acetate plate which will stay in position for 2 hours after the procedure
45503229|NCT03628755|Behavioral|Fluency Shaping Therapy|FST session comprised of speech techniques such as prolongation of sounds, easy onset, continuous phonation, light articulatory contact, in reading and conversation in three speaking situations (speaking with therapist, reading aloud, and free conversation Reading task was for 80 short phrases.
45394370|NCT01073319|Other|Placebo|Administration of placebo pill
45394371|NCT01073319|Drug|Rivastigmine|Participants will be randomized to rivastigmine (1.5 mg bid) for 6 days of each phase.
45394372|NCT01073319|Drug|Rivastigmine|Participants will be randomized to rivastigmine (3 mg bid) for 6 days of each phase.
45503230|NCT03628755|Behavioral|combination Group|combination group intervention of DMT + FST
45394373|NCT01073397|Behavioral|Yoga|Integral Yoga class (90 minutes per class), Once weekly for 10 weeks
45394374|NCT00160563|Drug|LEVOCETIRIZINE|5mg/mL oral drops, 0.125 mg/kg body weight, bid for 18 months
45394375|NCT00160563|Other|Placebo|Oral drops, bid for 18 months
45394376|NCT00380744|Drug|LY2189102|
45394377|NCT00380744|Drug|placebo|
45696973|NCT00960778|Other|denicotinized cigarettes (Quest 3 cigarettes)|Cigarettes that contain trace levels of nicotine (less than .05 mg per cigarette) will be utilized ad lib in the study for 4 days after the nicotine patch.
45394378|NCT01050452|Drug|albendazole|albendazole (400 mg on dose)
45394379|NCT01050452|Drug|mebendazole|mebendazole (500 mg one dose)
45394380|NCT01050452|Drug|ivermectin|ivermectin (200 microgram/kg body weight)
45394381|NCT01050452|Drug|albendazole + ivermectin|albendazole (400 mg one dose) + ivermectin (200 mg microgram/kg body weight)
45394382|NCT01050452|Drug|mebendazole + ivermectin|mebendazole (500 mg one dose) + ivermectin (200 microgram/kg body weight)
45394383|NCT00380588|Drug|gemcitabine|1000 milligrams per square meter (mg/m2), intravenous (IV)
45394384|NCT00380588|Drug|cisplatin|25 milligrams per square meter (mg/m2), intravenous (IV)
45394385|NCT00379808|Drug|montelukast|10 mg tablet (masked by capsule) daily for 1 month
45394386|NCT00379808|Drug|Placebo|1 lactose-containing capsule daily for 1 month
45696974|NCT03392649|Device|Parasym|Tragus stimulation was done using the Parasym device.
45696975|NCT03019042|Dietary Supplement|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, of which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
45394387|NCT03990038|Drug|Continuous perineural infusion of ropivacaine 0.2% 5 ml/h for 48 h|Group C receive the intervention Group U receives the placebo See arm description
45394388|NCT03990038|Drug|Extended Release Capsule|"Group C receives a placebo for extended release hydromorphone Group U receives Hydromorph Contin 3 mg PO BID~See arm description"
45696976|NCT03019042|Other|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
45696977|NCT03080571|Biological|autologous BMMNC stem cells|Autologous BMMNC injected in the ipsilateral MCA
45696978|NCT03080571|Other|standard care|
45394389|NCT01053494|Procedure|massage therapy|Undergo massage therapy
45394390|NCT01053494|Other|questionnaire administration|Ancillary studies
45394391|NCT01053494|Procedure|quality-of-life assessment|Ancillary studies
45394392|NCT01053494|Other|intervention by caregiver|Undergo massage by caregiver
45394393|NCT01053494|Procedure|standard follow-up care|Undergo standard follow-up care
45394394|NCT00355784|Other|overfeeding|overfeeding 2000kcals/day above energy requirements for 14d
45394395|NCT00355784|Drug|growth hormone treatment|growth hormone administrated for 2 weeks (dose = 1.0 mg/m2/d)
45394396|NCT01053572|Procedure|Adhesiolysis|Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
45394397|NCT02534636|Drug|BMS-986165|
45394398|NCT02534636|Drug|Interferon alpha-2a recombinant|
45394399|NCT02534636|Drug|Famotidine|
45394400|NCT02534636|Other|Placebo|
45394401|NCT01053650|Drug|Paracetamol|Clinical trial conducted in healthy volunteers, prospective, single center, randomized, open / hidden.
45394402|NCT03990740|Procedure|Corneal sampling|Corneal samples will be taken during corneal transplants for cases and orbital exenterations for controls. The mRNA (messenger ribonucleic acid) will be extracted and a retrotranscription will be made to obtain cDNA (complementary DNA). A qPCR (quantitative polymerase chain reaction) will be able to quantify the expression of alpha-SMA, MMP 1-2-3 and 9, and EMMPRIN.
45394403|NCT01053728|Drug|SAR161271|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
45394404|NCT01053728|Drug|Insulin glargine HOE901|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
45394405|NCT01050608|Device|Body worn alcohol gel dispenser|Records hand hygiene events of provider and tabulates on the group level.
45394406|NCT01050608|Drug|62% ethanol based hand cleanser|"CDC based guidelines with regard to utilization in the health care environment the nest"
45394407|NCT01050608|Behavioral|Educational component with regard to teaching CDC guidelines|12 minute education prior to deploying device for all providers.
45394408|NCT01050608|Behavioral|Provider and group feedback|Provide feedback with regard to expected hand hygiene goals to providers and reported anonymous group results based on recorded information.
45394409|NCT01053806|Drug|5-Azacytidine and Lenalidomide|Induction:5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days a cycle for 6 cycles and Lenalidomide 10mg/d orally days 6-28 every cycle for 6 cycles Consolidation: 5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days for 6 cycles Maintenance: Lenalidomide 10mg/d orally days 1-21 every cycle of 28 days for 13 cycles.
45394410|NCT00355472|Drug|KW-0761|IV administration at 4 escalating dose levels.
45394411|NCT01053884|Drug|Anidulafungin|"standard dose: 200mg/d on day 1, followed by 100mg/d from day 2 as maintenance dose.~Prophylaxis will be given until the recovery from neutropenia (ANC > 1,0 G/L without myelosupportive medications) and in cases of active fungal infection until best response, in case of fungemia for at least 2 weeks after the first negative culture."
45696979|NCT00961402|Behavioral|Wellness Control|6-month wellness control
45696980|NCT00961402|Behavioral|Exercise Intervention|6 month exercise intervention
45696981|NCT03080181|Drug|Pasireotide 0.6 MG/ML|The aim of the study was to evaluate the effect of pasireotide on β -cell and adipose function in patients with Cushing's disease (CD).
45696982|NCT03018886|Other|GHRH plus arginine test|One ug/kg GHRH [GHRH(1-29), GEREF Serono, Italy] was administered as an iv bolus at time 0 min, followed by arginine (L-arginine monohydrochloride, Braun, Melsungen, Germany) 0.5 g/kg (max 30g9 over 30 min. Blood samples were drawn at -15,0,15,30,45,60,75,90 min.
45848974|NCT00145704|Dietary Supplement|Vitamin D supplement|Vitamin D given to patients with growth hormone deficiency
45848975|NCT00145704|Dietary Supplement|Calcium|calcium supplement given to patients with growth hormone deficiency
45848976|NCT00108342|Drug|Nicotine gum - 2 mg and 4 mg|
45848977|NCT00108342|Drug|Nicotine lozenges - 2 mg and 4 mg|
45848978|NCT00108342|Drug|"Nicotine inhaler (4 mg yield) - low and high dosage by frequency of puffing"|can yield 4 mg from 10 mg device - infrequent and frequent puffing
45848979|NCT00108342|Other|Computer learning|
45394412|NCT03282266|Procedure|PADN|PADN was performed at three sites at the conjunctional area between the distal main trunk and the ostial left branch. The following ablation parameters were programmed at each point: a temperature of 45 ℃-50 ℃, energy ≤15 W, and a time of 120 seconds. The procedure would cease for 10 seconds if the patient felt intolerable chest pain during the procedure. The EKG and pressure lines (including cardiac output) were monitored and continuously recorded throughout the procedure.
45394413|NCT03282266|Procedure|Sham operation|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
45394414|NCT01050686|Procedure|insertion of subcutaneous wound drain|after the abdominal fascia is closed and before skin closure, a subcutaneous wound drain is inserted
45394415|NCT01050686|Procedure|no insertion of subcutaneous wound drain|closure of abdominal wall and skin without insertion of subcutaneous wound drain
45503231|NCT01355029|Behavioral|Stroke Caregiver Education and Support Program|4 week program offered weekly over a 4 week period. Each session is a 2 hour small group guided discussion on the topic area facilitated by 2 trained facilitators. The topics are: Program Introduction, sharing Caregiving Stories and an introduction to Self Management; Community Connections; Session 3 and 4 are chosen by the participants during session 1 from 6 possible options: Communication in your relationship; Cognition, Memory and Personhood; Dealing with your Emotions; Managing your Stress; Changing roles in your relationships and How to be Caregiver Smart?
45696983|NCT03080025|Behavioral|CBCT® (Cognitively Based Compassion-Training)|"The CBCT® (Cognitively Based Compassion-Training) as a secular approach was established as a structured protocol.~The therapeutic tools are based on systemic approaches & techniques, which contains a resource- & solution orientation and the approach of Gottman's model of healthy relationships (e.g. trust and commitment - based on that - elements like the positive perspective).~Four dyadic exercises are introduced to enhance positive reciprocity between the romantic partners (based on concepts of couple communication training):~a) Building mindful ability to talk, b) building mindful ability to listen (without reacting initially), c) appreciation in action - indulging the partner, d) noticing, how the partner is doing something good for me - gratefulness in action verbally/non-verbally. Finally, the empathy exercise has been added inspired by CBASP therapy for chronic major depression."
45696984|NCT01007656|Dietary Supplement|GD Antrodia camphorata|Three 500mg capsules per oral dose, twice daily with an interval of 12 hours for 90 days
45696985|NCT03089385|Other|Hypertension tool|An algorithm developed by staff at UHN to help manage hypertension in hemodialysis patients.
45696986|NCT03089229|Drug|HAT01H Cream|HAT01H Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
45848980|NCT00090870|Biological|PEG-interferon alfa-2b|Peg-Intron 1ug/kg Subcutaneous on day 1 and day 8 of each cycle. Each cycle is 21 days.
45848981|NCT00090870|Biological|GM-CSF|GM-CSF 250 ug/m2 subcutaneously daily from days 1-10 or each 21 day Peg-Intron cycle
45848982|NCT00090870|Drug|thalidomide|200mg daily by mouth
45848983|NCT00074724|Procedure|Coronary Artery Bypass|coronary revascularization using arterial or vein conduits
45394416|NCT03991754|Procedure|transcatheter aortic valve implantation|transcatheter aortic valve implantation
45394417|NCT00492557|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM), followed by a single 0.5 mL vaccine 13vPnC placebo, 1 month later.
45394418|NCT00492557|Biological|13vPnC + TIV|Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM, followed by a single 0.5 mL 13vPnC vaccine, 1 month later.
45394419|NCT00508391|Device|Optimized interventricular delay biventricular pacing|Lumax HF-T with optimized interventricular delay biventricular pacing
45394420|NCT01010711|Dietary Supplement|Migra 3|powder containing coenzyme q10, blueberries, black current, vitamins, magnesium,trace elements
45394421|NCT01015157|Procedure|Roux-en-Y laparoscopic gastric bypass for morbid obesity|Primary bariatric surgery. Standard laparoscopic procedure with linear stapling divising of the stomach (Echelon 60 stapler, GOLD cartridges) with or with Seamguard reinforcement
45394422|NCT01010789|Drug|Armodafinil|flexible dose 150-250mg/day
45394423|NCT01010789|Drug|Armodafinil|150-250mg/day; flexible dose
45394424|NCT01010789|Drug|Matching placebo|Placebo comparator
45394425|NCT01015235|Drug|Placebo|Subcutaneous infusion-once over 4 hours
45394426|NCT01015235|Drug|KAI-1678|Subcutaneous infusion-once over 4 hours
45394427|NCT01015235|Drug|Ketorolac Tromethamine|Active comparator, IV infusion, once
45394428|NCT00508157|Drug|Aripiprazole|Tablets, Oral, 5 to 30 mg, once daily, 16 weeks
45503232|NCT02065544|Behavioral|behavioral weight loss and exercise|Weight loss and exercise counseling
45848984|NCT00074724|Drug|Modern medical management|Therapies with evidence-based recommendations.
45848985|NCT00074724|Device|Dobutamine echocardiography|Incremental dose administration of dobutamine to elicit a contractile response of the myocardium.
45848986|NCT00074724|Drug|Optimal medical therapy|All medical interventions known to improve outcomes in patients with ischemic left ventricular dysfunction.
45848987|NCT00058188|Dietary Supplement|cholecalciferol|Given orally
45848988|NCT00058188|Drug|calcium gluconate|Given orally
45848989|NCT00058188|Drug|zoledronic acid|Given IV
45848990|NCT00003726|Biological|lepirudin|lepirudin
45394429|NCT00508157|Drug|Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)|Tablets, Oral, According to summary of product characteristics (SmPC)
45394430|NCT04331717|Device|Bead Block 300-500 um|These patients will undergo embolization with 300-500µm Bead Block particles.
45394431|NCT04331717|Behavioral|Weight Management|All participants will be enrolled in weight management through the Johns Hopkins Weight Management Center. During weeks -4 through 0, participants will be required to go to weekly visits. Weight management will include counseling on diet, exercise and behavior change. Food programs, pharmacotherapy and other procedures will not be utilized.
45394432|NCT04331717|Drug|Lupron|22.5 mg will be given as a single intramuscular or subcutaneous injection once every 12 weeks according to the standard of care for prostate cancer. If leuprolide acetate, 22.5 mg for 3-month administration is not available, a suitable substitute may be allowed upon approval by the principle investigator
45394433|NCT05108441|Other|Ultrasound and magnetic resonance imaging measurements of quadriceps femoris|In sedated critically ill children, quadriceps femoris thickness and cross sectional area will be measured with thigh bedside ultrasound, performed by two trained operators consecutively. These two measurements will also be made at the exact same location on a magnetic resonance imaging transverse view of the thigh, to allow comparing them to ultrasound measurements.
45394434|NCT01015313|Other|intensive sodium management|"dietary sodium restriction~avoiding positive sodium balance during dialysis by: aligning dialysate sodium with plasma sodium, avoiding sodium profiling, and avoiding saline solutions to treat intradialytic symptoms"
45394435|NCT00378560|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|V501; Gardasil, 0.5 ml injection in 3 dosing regimen
45394436|NCT00378560|Biological|Comparator: Placebo|Placebo 0.5 ml injection in 3 dosing regimen
45394437|NCT00508001|Drug|Vandetanib|ZD6474 300mg
45394438|NCT00508001|Drug|Vandetanib|ZD6474 100 mg
45394439|NCT00508001|Drug|Best Supportive Care|Placebo + Best Supportive Care
45394440|NCT01015391|Drug|T2|1.5mg/kg/day, PO (per oral),three times a day: until progression or unacceptable toxicity develops
45394441|NCT01015391|Drug|Azathioprine|2.5mg/kg, PO (per oral) one time a day:until progression or unacceptable toxicity develops the first month:1.5mg/kg,PO,one time a day the second month:2.0mg/kg,PO,one time a day since the third month:2.5mg/kg,PO,one time a day
45394442|NCT04544033|Diagnostic Test|interleuken 6 level measurment|Detection of IL6 level using ELISA technique.
45394443|NCT04544033|Diagnostic Test|Interleukin-6 Gene-174C detection|The genotyping of the polymorphisms in IL-6 promoter G-174C (rs1800795) will be performed using PCR-RFLP technique.
45394444|NCT01015469|Procedure|Conventional laparoscopic Roux-en-Y gastric bypass|Conventional laparoscopic Roux-en-Y gastric bypass
45394445|NCT01015469|Procedure|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring (GaBP-Ring)
45394446|NCT01010945|Drug|erlotinib|administered orally
45394447|NCT01010945|Drug|gemcitabine|administered intravenously
45394448|NCT01010945|Drug|nab-paclitaxel|administered intravenously
45503234|NCT05190627|Drug|Loratadine|Loratadine 10mg/day added to rapamycin for 12 months
45696987|NCT03089229|Drug|Vehicle Cream|Vehicle Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
45696988|NCT03089307|Device|Dornier Aries- ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
45848991|NCT02595996|Drug|Propranolol|escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day
45394449|NCT01011023|Other|Non application of nasogastric tube in the experimental group|Avoid the 5 post operative application of nasogastric tube in the experimental group vs the control group with the usual nasogastric tube
45394450|NCT00507689|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.
45394451|NCT00507689|Drug|Hepatitis B Immunoglobulin (HBIg)|HBIg was administered either intravenously or by intramuscular injection at a dose and frequency as prescribed by the investigative site protocol.
45394452|NCT00491387|Drug|Metoprolol Succinate|Once daily, oral, 12.5 mg to 200 mg, dose titrated to reduce heart rate by 20% or to less than 65 beats per minute.
45394453|NCT04539899|Other|VR+|Use of a virtual reality helmet during IUD insertion
45394454|NCT01011257|Drug|Asprin|asprin 81mg, 1 tab, twice daily OR aspirin 81mg, 2 tab, once daily
45394455|NCT01011257|Drug|Clopidogrel|clopidogrel 75 mg bid
45503235|NCT05190627|Drug|Placebo 10mg/day added to rapamycin for 12 months|Placebo in the same type of capsule than the experimental drug
45503236|NCT02064218|Drug|Anti-hypertensive drugs|
45503237|NCT01345799|Drug|TRK-170|
45503238|NCT01345799|Drug|Placebo|
45503239|NCT03614520|Other|Administration of olive oil|25 mL of extra virgin olive oil
45503240|NCT03614520|Other|Administration of red wine|150 mL or Red Wine
45394456|NCT01011491|Other|Medifast 5 & 1 Plan for weight loss and weight maintenance|Medifast's 5 & 1 Plan is a meal replacement program for weight loss that uses 5 Medifast meals and 1 self-prepared meal. The weight maintenance plan incorporates 3-5 Medifast meals as well as a certain amount of food from all other food groups.
45394457|NCT01011491|Other|Food-based diet plan for weight loss and weight maintenance|The food-based group was provided a meal plan for weight loss based on the guidelines of the USDA Food Guide Pyramid providing the same number of calories as the Medifast 5 & 1 Plan. Weight maintenance calories were calculated and participants were provided meal plans from the USDA Food Guide Pyramid.
45394458|NCT01015547|Drug|Infliximab plus methotrexate|IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
45394459|NCT01015547|Drug|Combination of DMARDs|IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly, SSZ 40mg/kg up to 2000mg daily, HCQ 5mg/kg daily. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
45394460|NCT01015547|Drug|Methotrexate alone|Oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
45503241|NCT03614520|Other|Combination of red wine and olive oil|150 mL of Red wine + 25 mL of Extra Virgin Olive oil will be administred at the same time
45394461|NCT00491075|Drug|Pemetrexed|500 mg/m^2 IV Over 10 Minutes on Day 1.
45503242|NCT03614520|Other|Water|Mineral water will be given as placebo
45503243|NCT03614520|Other|Dark beer|250 mL of IPA beer (alcohol 8.5% vol)
45503244|NCT03614520|Other|Light Beer|250 mL of blonde ale beer (alcohol 4,5% vol)
45503245|NCT03614520|Other|Alcohol free Beer|250 mL of alcohol free beer (alcohol 0.0% vol)
45503246|NCT01358851|Procedure|Cryotherapy|1-2 times during the treatment time
45503247|NCT01358851|Drug|LAS41005|once daily
45503248|NCT02065778|Biological|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in chronic stroke patients
45503249|NCT03619941|Dietary Supplement|Montmorency Tart Cherry Juice|"100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar."
45503250|NCT03619941|Dietary Supplement|Placebo|Placebo drink attempted to match for total energy content, macronutrient content, appearance and taste of Montmorency tart cherry juice.
45503251|NCT01343303|Drug|Placebo|Placebo tablet/capsule every 12 hours for 21 days
45503252|NCT01343303|Drug|JNJ-39439335|2 x 25 mg tablets once daily for 21 days
45503253|NCT01343303|Drug|Naproxen|500 mg capsule every 12 hours for 21 days
45503254|NCT01343303|Drug|JNJ-39439335|2 x 5 mg tablets once daily for 21 days
45696989|NCT03088293|Drug|Infliximab|Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
45696990|NCT03088293|Drug|Cyclophosphamide|Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
45848992|NCT03198156|Device|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
45503255|NCT03614442|Other|slopped shoulder implant|different implant design to enhance soft and hard tissue outcome
45503256|NCT04418115|Other|Acupuncture; based on Tradidtional Chinese Medicine|Acupuncture is a form of treatment that involves inserting very thin needles through a person's skin at specific points on the body, to various depths. Research suggests that it can help relieve pain, and it is used for a wide range of other complaints.
45503257|NCT01343381|Drug|Hepalean Heparin|400 units per kilogram bolus prior to initiation of CPB
45503258|NCT01343381|Drug|PPC Heparin|400 unit per kilogram bolus prior to initiation of CPB
45503259|NCT03620149|Drug|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Denosumab 120 mg, SC, on day 1 of every 12-week cycle
45503260|NCT02064686|Other|Exhaled breath temperature|
45394462|NCT00491075|Drug|Gemcitabine|1500 mg/m^2 IV Over 30 Minutes on Day 1, Immediately After Infusion of Pemetrexed.
45394463|NCT04302623|Behavioral|Yoga|Upa Yoga program consisting of physical postures, breathing techniques, chanting, and meditation.
45394464|NCT03998267|Device|Droobi|A new mobile application, specifically built for the diabetes patients in Qatar with the help of local expertise.
45394465|NCT03998267|Other|Standard of care|Standard of care including physicians, dietetics and diabetes educators support
45394466|NCT00507455|Drug|solifenacin succinate|Solifenacin succinate tablets
45394467|NCT00507455|Drug|tamsulosin hydrochloride|Tamsulosin hydrochloride Oral Control Absorption System (TOCAS) tablets
45394468|NCT00507455|Drug|Placebo to solifenacin|
45503261|NCT03614286|Diagnostic Test|culture and pcr|The swab immersed in Diamond's Modified medium culture tube and squeezed for cultivation and examined daily with a light microscope to identify T. vaginalis Samples from culture will be placed in 1 ml of a commercial PCR transport medium (AMPLICOR; Roche Diagnostic Systems, Branchburg, N.J.) and kept at 4°C until arrival at the laboratory within 4 days of collection. An equal volume of specimen diluent (AMPLICOR) was added to the sample , and the preparation was mixed, incubated at room temperature for 10 min, and stored at -70°C until tested.
45503262|NCT04369755|Other|MRI|A MRI in PTX mode will be done on healthy subject (approx. 90 min of sequences)
45394469|NCT00507455|Drug|Placebo to tamsulosin|
45394470|NCT04287569|Device|Record during endoscopy of video-endoscopy sequences and reflectance|Record of video-endoscopy sequences and reflectance, during endoscopy with biopsy.
45394471|NCT03997565|Procedure|TKR|No intervention provided, but investigation of the ability to modulate motor performance during specific and functional tasks in subjects undergoing TKR compared with healthy subjects.
45394472|NCT01013363|Other|iPod Nano digital music player|Digital music player pre-loaded with 10 playlists to be used intra-operatively by the participant randomized to the intervention group.
45394473|NCT04275713|Drug|Metformin|Metformin is an oral antidiabetic drug
45394474|NCT04275713|Drug|Cisplatin|Cisplatin 40 mg/m2 given intravenously once a week, maximum 6 cycles
45394475|NCT01011725|Drug|MK 0773|25 mg oral tablet b.i.d. MK 0773 or 100 mg oral tablet b.i.d. MK 0773, for 12 weeks
45503263|NCT01343537|Other|Neuro Monitoring|Neuro monitoring from day 4 to day 14 post subarachnoid hemorrhage for cerebral vasospasm
45503264|NCT02064374|Drug|Metformin 500 mg q12h|Metformin will be supplied as 500 mg tablet to be administered orally.
45503265|NCT02064374|Drug|Dolutegravir 50 mg q24h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken once a day in the morning in Period 2 (Total daily dose 50 mg per day for Cohort 1 only)
45503266|NCT02064374|Drug|Dolutegravir 50 mg q12h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken 50 mg tablets every 12 hours in Period 2 (Total daily dose 100 mg per day for Cohort 2 only).
45503267|NCT03614208|Behavioral|Home-care rehabilitation group (HCRG)|The exercise program consists of aerobic exercise on a stationary bike, muscular endurance training of the upper limb and stretching exercises for finger joint motion. The exercise on the stationary bike and muscular endurance training will be performed on alternate days, three times a week.
45394476|NCT01011725|Drug|Placebo|Placebo oral tablet b.i.d for 12 weeks
45394477|NCT01011803|Other|Combined speech therapy tools, measures of swallowing function|All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were [diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
45394478|NCT01013441|Biological|Infusion of CD3/CD28 stimulated T cells|Receive CD3/CD28 stimulated T cells after fludarabine or alemtuzumab based chemotherapy
45394479|NCT01011881|Other|pleural level of procalcitonin|no intervention
45394480|NCT00506831|Drug|Imatinib mesylate|100 mg orally daily increased by 100 mg/day every 2 weeks to maximum of 400 mg daily as tolerated. Treatment for 6 months total.
45394481|NCT04269551|Drug|BIVV020|Pharmaceutical form:solution for injection Route of administration: intravenous
45394482|NCT03996941|Behavioral|Harm reduction of informal PrEP use|"Users attending the study center interested in PrEP use , as well as those who could benefit from it are invited to attend an information session in which issues are touched like the effectiveness and safety of PrEP, and the characteristics of the SeguiPrEP program. This program consists of periodic clinical controls (five during the first year and four in the following period) that include: physical examination, HIV and other STI screening, control of renal functions, estimation and promotion of PrEP adherence, monitoring of adverse events associated with PrEP and counseling.~Those who decide to use PrEP or who are already using PrEP are asked to schedule an initiation visit."
45394483|NCT03996941|Other|PrEP follow up based on point of care testing|The study center has a point-of-care technology based laboratory, which allows obtaining immediate results in order to reduce the loss of follow-up.
45394484|NCT01015859|Device|Pacing mode|To determine which mode (DDD vs AAI SafeR)minimizes ventricular pacing
45394485|NCT00506753|Behavioral|MI/CBT|Motivational Interviewing followed by Cognitive Behavior Therapy
45394486|NCT00506753|Behavioral|RT/SU|Relaxation Training followed by Treatment as Usual
45394487|NCT00490919|Drug|Buprenorphine transdermal system|Buprenorphine transdermal system 10 or 20 mcg/h worn for 7 days
45394488|NCT00490919|Drug|Placebo|transdermal system (placebo) worn for 7 days
45394489|NCT01011959|Biological|REGN88|This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.
45394490|NCT00503867|Device|SIR-Spheres microspheres|SIR-Spheres Yttrium-90 microspheres
45394491|NCT01015937|Drug|Turmeric extract|turmeric 500 mg TID for 45 days
45394492|NCT01015937|Drug|Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker|maximum dosage as patient tolerated for 45 days
45394493|NCT01012193|Drug|cilostazol 100mg bid or clopidogrel 150-mg daily|Adjunctive cilostazol: cilostazol 100-mg bid +clopidogrel 75mg daily+aspirin 200mg daily High-MD clopidogrel: clopidogrel 150mg daly +aspirin 200mg daily
45394494|NCT00503399|Drug|Teriparatide|20 µg/day sc for 18 months
45394495|NCT00503399|Drug|Risedronate|35 mg/week po for 18 months
45394496|NCT00506519|Drug|Antithrombin alfa (INN name)|
45696991|NCT03089151|Behavioral|Community Garden Intervention|"The investigators will recruit 30 prospective gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. DUG randomly assigns people on each garden wait list to available plots, using a lottery. This creates a natural randomized experiment. Participants randomized to the garden intervention will receive a standardized garden resource package, which includes the following:~A garden plot in a Denver Urban Garden~Seeds and plant starts~Introductory gardening workshop~Social events including garden-specific events and garden mentoring.~The non-gardening group will remain on the DUG wait lists and will not receive these resources.~Duration of the intervention is 1 year."
45696992|NCT03084003|Dietary Supplement|Almonds|
45394497|NCT00506519|Drug|Control (Standard treatment)|
45394498|NCT00503009|Drug|fluticasone propionate/salmeterol|comparator
45394499|NCT00503009|Drug|fluticasone propionate|Comparator
45394500|NCT00503009|Drug|placebo|Placebo
45394501|NCT01016093|Drug|Zoledronic acid|Zoledronic acid 4 mg adjusted dose based on renal function IV 15-minute infusion every 3 months for a total of one year ( 4 doses ) beginning as soon as possible after randomization.
45394502|NCT01016093|Drug|Placebo|Placebo
45394503|NCT01012271|Other|MRI|MR arthrography is used to evaluate wrist abnormalities
45394504|NCT00160251|Drug|Boceprevir (BOC)|100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID
45394505|NCT00160251|Biological|PegIntron (PEG)|1.5 mcg/kg weekly subcutaneously
45394506|NCT00160251|Drug|Ribavirin (RBV)|200 mg capsules taken twice daily (BID) (total daily dose of 800-1400 mg/day, depending on weight [weight-based dosing {WBD}])
45394507|NCT01075425|Drug|bortezomib|Given IV
45394508|NCT01075425|Drug|belinostat|Given IV
45394509|NCT01075425|Other|laboratory biomarker analysis|Correlative studies
45696993|NCT03084003|Dietary Supplement|Graham crackers|
45696994|NCT03703401|Diagnostic Test|Hysterosalpingo-contrast-sonogram|A contrast ultrasound scan to examine fallopian tube pathology and blockage
45394510|NCT01075425|Genetic|western blotting|Correlative studies
45394511|NCT01075425|Other|pharmacological study|Correlative studies
45394512|NCT01075425|Other|flow cytometry|Correlative studies
45394513|NCT00506441|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose (Open-label) and 4 weeks of double blind
45394514|NCT00506441|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
45394515|NCT04190693|Drug|IMCY-0098 or placebo|Long-term follow-up
45696995|NCT01008280|Drug|baclofen|baclofen 10 mg tid
45696996|NCT01008280|Drug|placebo|placebo pill tid
45848993|NCT03198156|Device|Sham stimulation|Sham stimulation
45848994|NCT04422210|Drug|Venetoclax|Venetoclax will be administered orally at escalating doses from 200mg to 800mg as 100mg tablets as per the dosing schedules described above.
45394516|NCT00378014|Drug|everolimus|Start dose of everolimus was 1.5 mg in the morning followed by 1.5 mg in the evening. After one week, the dose was adjusted to achieve trough levels between 5-12 ng/mL. Once trough levels were above 5ng/mL, the CNI dose was reduced to 70%. At week 8 post-baseline (latest at week 16 post baseline), CNI was completely discontinued. For patients receiving Ciclosporin A (CiA) as CNI, the everolimus dosage was adjusted to achieve a trough level of 8-12 ng/mL, prior to discontinuation of CiA. After discontinuation of CNI, everolimus was maintained at a trough level of 5-12 ng/mL.
45394517|NCT00378014|Drug|basiliximab|All patients who met the eligibility criteria were treated with 2 doses of basiliximab on Day 0 (transplantation) and Day 4.
45394518|NCT00378014|Drug|CNI|Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month. Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
45394519|NCT00485303|Drug|Abiraterone acetate|Abiraterone acetate oral tablets 250 milligram (mg) each will be administered at a total dose of 1000 mg until documented disease progression or unacceptable toxicity.
45394520|NCT00485303|Drug|Prednisone|Prednisone/Prednisolone 5 mg tablet will be taken orally twice daily.
45394521|NCT00490841|Device|Herculink Elite Renal Stent System|This is a prospective, non-randomized, single arm, multi-center study to evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in patients with sub-optimal renal PTA results in de novo or restenotic renal artery lesions. Patients who satisfy the inclusion/exclusion criteria will be enrolled at sites in the United States. Patients will have follow up visits for evaluation.
45394522|NCT01018823|Drug|Ertugliflozin|Ertugliflozin oral dosing 1 mg, 5 mg, 25 mg, or 100 mg solutions/suspensions administered once daily for 14 days immediately after breakfast
45394523|NCT01018823|Drug|Placebo to Ertugliflozin|Placebo oral dosing solutions/suspensions administered once daily for 14 days immediately after breakfast
45394524|NCT01016249|Drug|Treatment 1. (5% Hypertonic saline + Epinephrine)|Nebulization of 4ml 5% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
45394525|NCT01016249|Drug|Treatment 3. (3% Hypertonic saline + Epinephrine)|Nebulization of 4ml 3% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
45394526|NCT01016249|Drug|Treatment 2. (Normal saline + Epinephrine)|Nebulization of 4ml 0.9% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
45394527|NCT00377858|Drug|Insulin lispro mid mixture (MM)|Patient specific adjusted dose, three times a day (TID), subcutaneous (SC) injection x 36 weeks
45503268|NCT05188365|Other|true acupuncture|"different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). the session (20 minutes) will repeated thrice weekly. the total duration of the study will be 60 days.~The points that will be manually acupunctured all over the body of every patient will be: SJ(3)/SJ(5)/SJ(17)/SJ(18)/SJ(19)/SJ(20)/SJ(21)/SJ(22)/GB(2)/GB(8)/GB(20)/LI(4)/LI(11)/KI(3)/SP(6)/ST(36)/REN(4)/REN(9)/REN(12)~The acupuncture points that will be electrically stimulated on the abdomen of every patient will be: bilateral Stomach 25 in addition to gallbladder 28 acupoints."
45848995|NCT04422210|Drug|Atezolizumab|Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.
45394528|NCT00377858|Drug|Insulin glargine|Patient specific adjusted dose, every day (QD), subcutaneous (SC) injection x 36 weeks
45394529|NCT00502775|Drug|fluticasone furoate, fexofenadine|
45394530|NCT00502697|Behavioral|Targeted Nurse Home Visits|Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic care. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.
45394531|NCT00502697|Other|Conventional prenatal/postpartum care|Women in this group received conventional prenatal care and postpartum clinic care.
45394532|NCT01013675|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
45394533|NCT01013675|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
45394534|NCT01018901|Other|Survey Administration|Patients complete survey
45394535|NCT01054040|Other|Portion plate given to cardiac rehabilitation patients|Patients in the experimental group will be provided with standard care (group and individual nutrition counselling) plus be provided a portion control plate
45394536|NCT01019057|Procedure|ILIF|Interlaminar lumbar instrumented fusion (ILIF™) is a compound surgical solution to spinal stenosis, combining direct neural decompression with an allograft interspinous spacer (ExtenSure® H2) to maintain the segmental distraction, and a spinous process fixation plate (Affix™) to maintain stability for eventual segmental fusion.
45394537|NCT01054118|Drug|JNJ-38431055|Liquid suspension of JNJ-38431055 administered as a single dose
45394538|NCT01054118|Drug|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose
45394539|NCT01054118|Drug|JNJ-38431055 + Sitagliptin 100 mg|Liquid suspension of JNJ-38431055 administered as a single dose, and capsule containing 100 mg of sitagliptin administered as a single dose
45394540|NCT01054118|Drug|Placebo|Placebo suspension and placebo capsule administered as single doses
45394541|NCT03997253|Other|blood and urine samples|various blood and urine samples will be collected from the recipient at D0, D7, D14, M1, M3, M6 and M12.
45394542|NCT03989726|Procedure|AF ablation|AF ablation includes pulmonary vein isolation and/or voltage and fractionation guided ablation
45394543|NCT03989804|Behavioral|Targeted follow-up|2 phone calls and 1 e-mail delivered over 6-8 weeks after enrollment aiming to help and support members to get started using the fitness center and its services.
45394544|NCT01054274|Device|novel stent|Patients undergo placement of a novel esophageal stent loaded with 125I seeds on day 1.
45394545|NCT01054274|Device|conventional covered stent|Patients undergo placement of a conventional covered stent on day 1.
45394546|NCT03989648|Other|Esmarch bandages|Esmarch bandage (also known as Esmarch's bandage for surgical haemostasis or Esmarch's tourniquet) in its modern form is a narrow (5 to 10 cm wide) soft rubber bandage that is used to expel venous blood from a limb (exsanguinate) that has had its arterial supply cut off by a tourniquet.
45394547|NCT03989648|Other|simple leg elevation|simple leg elevation 45 degree for 2 minutes is used to expel venous blood from a limb
45394548|NCT01050842|Drug|bicalutamide|Given orally
45394549|NCT01050842|Drug|raloxifene|Given orally
45394550|NCT01050842|Procedure|quality-of-life assessment|Ancillary study
45848996|NCT04422210|Drug|Carboplatin|Carboplatin will be administered via IV infusion at a dose of 5mg/mL/min as per the dosing schedules described above.
46056993|NCT02715531|Drug|Atezolizumab|Participants will receive atezolizumab in a flat dose of 1200 mg q3w (Arm A, Group E2, and Arm F) or 840 mg q2w (Arm B, Arm C, and Groups E1 and E3).
45394551|NCT02534246|Device|Ultrasound biopsy needle Echo Tip ProCore|Two passes preformed with Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) and two passes will be performed using SharkCore ultrasound biopsy needle (Medtronic [Beacon] 25 gauge) from single lesion.
45394552|NCT02534246|Device|Ultrasound biopsy needle SharkCore|
45394553|NCT00485069|Drug|ROP|Ropinirole Hydrochloride monotherapy group (ROP): Patients will receive ROP tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 mg/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. Concomitant use of L-dopa is prohibited during the study.
45394554|NCT00485069|Drug|ROP+L-Dopa|Ropinirole Hydrochloride with L-Dopa adjunct therapy group (ROP+L-Dopa): Patients will receive ropinirole hydrochloride (ROP) tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 milligrams (mg)/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. The dosing regimen of L-dopa remain unchanged from 4 weeks prior to the start of the Screening Phase throughout the study.
45394555|NCT01054352|Drug|JNJ38224342|multiple ascending oral doses (100, 250, 500, 750 mg) of JNJ 38224342 or matching placebo, administered for 14 consecutive days in healthy male or female volunteers
45394556|NCT01054352|Drug|JNJ38224342/placebo|up to four (4) additional cohorts consisting of healthy male volunteers may be added
45394557|NCT01054352|Drug|JNJ38224342/placebo|.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
45394558|NCT01054352|Drug|JNJ38224342/placebo|one of six (6) single ascending doses (25, 100, 300, 600, 1250 or 2000 mg) of JNJ 38224342 or matching placebo
45394559|NCT03989336|Drug|Manganese Chloride|Administered by inhalation at 0.4mg/kg twice per week in the first 3-week cycle, and then inhaled 0.4mg/kg twice in the first week of each 3-week cycle thereafter
45394560|NCT03989336|Drug|nab-paclitaxel|Administered intravenously, 180-220mg/m2 on day 2 in a 3-week cycle (day 1 without Manganese priming)
45394561|NCT03989336|Drug|Platinum chemotherapy|Administered intravenously, Cisplatin (60-80mg/m2) or Carboplatin (area under the curve [AUC] 4-6 mg/mL per min) on day 2 in a 3-week cycle (day 1 without Manganese priming)
45394562|NCT03989336|Drug|Sintilimab|Administered intravenously, 200mg on day 3 in a 3-week cycle (day 2 without Manganese priming)
45394563|NCT01054430|Drug|avanafil|200 mg avanafil tablets QD
45394564|NCT00355082|Drug|lamotrigine, 300 mg/day|300 mg/day
45394565|NCT00355082|Drug|lamotrigine, 250 mg/day|250 mg/day
45394566|NCT00502307|Drug|Tivozanib (AV-951)|solid oral dosage form taken daily for three weeks per one month cycle
45394567|NCT00502307|Drug|Placebo comparator|solid oral capsule containing excipients dosed daily for three weeks per month
45394568|NCT01325012|Procedure|Subgluteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the subgluteal location 1-3 cm caudad to the inferior border of the gluteus maximus muscle. After catheter placement, outcome measures will be assessed.
45848997|NCT04422210|Drug|Etoposide|Etoposide will be administered via IV infusion at a dose of 100mg/m^2 as per the dosing schedules described above.
45848998|NCT00000108|Behavioral|Exercise|
45848999|NCT00000126|Procedure|Surgery|
45849000|NCT00000132|Drug|Betaxolol|
45849001|NCT00000132|Procedure|Argon Laser Trabeculoplasty|
45849002|NCT00000138|Drug|Prednisolone Phosphate|
45849003|NCT00000138|Drug|Acyclovir|
45849004|NCT00000162|Procedure|Macular Argon Laser Photocoagulation|
45849005|NCT00000162|Procedure|Peripheral Scatter Argon Laser Photocoagulation|
45849006|NCT00000162|Procedure|Scatter Argon Laser Photocoagulation|
45849007|NCT00000174|Drug|Rivastigmine|
45849008|NCT00000192|Drug|Lamotrigine|
45849009|NCT00000198|Drug|Piracetam|
45849010|NCT00000204|Drug|Buprenorphine|
45849011|NCT00000210|Drug|Buprenorphine|
46056994|NCT02715531|Drug|Bevacizumab|Participants will receive bevacizumab at 15 mg/kg q3w (Arm A and Group F1) or 10 mg/kg q2w (Arm B).
46056995|NCT02715531|Drug|Gemcitabine|Gemcitabine will be administered according to the local prescribing information. The starting dose-level of gemcitabine (1000 mg/m^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
46056996|NCT02715531|Drug|Leucovorin|Leucovorin 200 mg/m^2 L-isomer form or 400 mg/m^2 D,L-racemic form will be administered IV over 120 (± 15) minutes, q2w.
45394569|NCT01325012|Procedure|Popliteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After Catheter placement outcome measures will be assessed.
45394570|NCT00484679|Drug|Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection
45394571|NCT00377312|Drug|Parathyroid Hormone (1-34)|PTH(1-34) IV given over a one week period
45394572|NCT00377234|Drug|Risedronate|35mg po weekly for 12 weeks
45394573|NCT00377234|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 3 months
45394574|NCT00377156|Radiation|radiation therapy|Patients undergo radiation therapy 5 days a week for 2.5 weeks
45394575|NCT00377156|Radiation|stereotactic radiosurgery|
45394576|NCT00376688|Other|Laboratory Biomarker Analysis|Correlative studies
45394577|NCT00376688|Drug|Temsirolimus|Given IV
45394578|NCT00376220|Drug|Riluzole|Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as Montgomery Asberg Depression Rating Scale (MADRS) < 12) the dose will not be increased further unless clinical symptoms recur.
45394579|NCT00376220|Other|Placebo|Initially dispensed 50mg capsules to take BID. At two weeks increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS < 12) the dose will not be increased further unless clinical symptoms recur.
45394580|NCT00375752|Drug|Letrozole|2.5 mg.tablet.
45394581|NCT00375752|Drug|Zolendronic Acid|4 mg or an adjusted dose based on renal function in 100 ml physiologic (o.9%) normal saline, (as an intravenous infusion over no less than 15 minutes)
45394582|NCT00484289|Drug|Abatacept|Vials (250 mg/vial), Intravenous, Weight-tiered dose of abatacept (equivalent to 10 mg/kg) based on their body weight at the enrollment visit; 500 mg for participants < 60 kg, 750 mg for participants 60 to 100 kg and 1,000 mg for participants > 100 kg, administered over a period of approximately 30 minutes at week 0, 2, 4 and every 4 weeks thereafter, until approved in Japan and was continued as a post-marketing study until the completion of the shift to a commercially available product.
45696997|NCT03084159|Behavioral|Education worksheet|Patients who screen positive for CKD and give written informed consent to be a part of the study will have their chart flagged for the medical assistant and provider to give the education worksheet intervention. The education worksheet has been developed to be used as an electronic tool within the Electronic Medical Record. The provider will review it with the patient during the visit. A paper copy will print out for the patient at the end of the visit.
45394583|NCT01013831|Drug|Erlotinib Hydrochloride|Given PO
45394584|NCT01013831|Other|Laboratory Biomarker Analysis|Correlative studies
45394585|NCT01013831|Other|Pharmacological Study|Correlative studies
45394586|NCT01016327|Drug|NMS-1116354|Oral daily administration for 7 consecutive days every 14 days
45394587|NCT03996629|Other|Patient education and compliance|When the patient is enrolled in the intervention group, pharmacists provide medical education about the pathophysiology, medications, lifestyle, how to prevent, recognize and take care of bleeding events, etc. Establish a medical record for every follow-up examination and remind follow-ups by message, phone every month.
45394588|NCT01013909|Drug|Bifonazole spray once daily|Application of one dose daily by means of an metered dose
45394589|NCT01013909|Drug|Bifonazole spray twice daily|Application of two dose daily by means of an metered dose
45394590|NCT01013909|Drug|Placebo|Application of one dose daily by means of an metered dose
45394591|NCT01013909|Drug|Placebo|Application of one dose daily by means of an metered dose
45394592|NCT01013909|Drug|Lamisil Once|One application of Lamisil Once
45394593|NCT03996551|Behavioral|ExeRTiOn online resource|This is a 12-week online resource, specifically designed for new kidney transplant recipients. It includes dietary advice, physical activity advice, and recognized behavior change techniques. The participant will be monitored by a specialist physiotherapist and will receive messages of encouragement a 6 weeks and 12 weeks.
45394594|NCT01013987|Drug|maraviroc|maraviroc: one 150 mg pill twice daily
45394595|NCT01013987|Drug|Raltegravir|raltegravir : one 400 mg pill twice daily
45394596|NCT01013987|Drug|Darunavir/ritonavir|"darunavir : two 300 mg pills twice daily with meal~ritonavir: one 100 mg pill twice daily with meal"
45696998|NCT04279665|Device|Virtual Reality (VR)|20 minutes of wearing a virtual reality headset with a choice of 4 environments based on their preference and another 20 minutes with a less immersive condition
45696999|NCT03088995|Diagnostic Test|Pilot study|Pilot study of HIV and viral hepatitis B and C screening in surgery
45697000|NCT03089073|Drug|Desmopressin|60μg or 120μg once daily at bedtime
45849012|NCT00000222|Drug|Buprenorphine|
45849013|NCT00000228|Drug|Buprenorphine|
45394597|NCT04150445|Behavioral|Internet treatment for overweight and obese patients|The behavioral treatment is provided via the Internet and comprises 12 modules that the patient follows for 6 months. The treatment modules include self-monitoring, goal setting, relapse prevention, psycho-education about nutrition, eating behavior, physical activity, sleep and stress management. Each module ends with one or more exercises to be completed before the next module is activated.
45394598|NCT01019213|Other|Septal pacing|Septal lead activated
45503269|NCT05188365|Other|sham acupuncture|different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). opposite to group A, in this group, the acupuncture needles will be inserted manually and very adjacent to the real location of group-A acupoints (sham acupuncture). The electrical stimulator will connected to abdominal acupoints (bilateral Stomach 25 in addition to gallbladder 28 acupoints) but it will be turned off during the sessions. the session will repeated thrice weekly. the total duration of the study will be 60 days
45503270|NCT05061251|Drug|BAY 2402234|Patients will receive 3 doses of 5mg each of BAY 2402234. Drug will be given Day 1 and Day 2 prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery.
45849014|NCT00000234|Drug|Buprenorphine|
46056997|NCT02715531|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered according to the local prescribing information. The starting dose-level of nab-paclitaxel (125 mg/m^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
45394599|NCT01019213|Other|His lead activated|His lead will be activated 80 ms before septal lead
45394600|NCT01019291|Other|Formaldehyde and NO2 (Exposure to indoor pollutants)|Exposure to indoor pollutants (Formaldehyde and NO2) in a randomized way, followed by bronchial challenge test with house dust mite extract.
45503271|NCT01351129|Drug|Formulation 1|150-mg immediate release tablet (single dose)
45503272|NCT01351129|Drug|Formulation 2|150-mg modified release capsule, short duration (single dose)
45394601|NCT01019291|Other|Placebo (Exposure to indoor pollutants)|Exposure to indoor pollutants (placebo) in a randomized way, followed by bronchial challenge test with house dust mite extract.
45394602|NCT01019447|Other|Vicryl Plus|Triclosan-coated polyglactin 910 antimicrobial sutures (Vicryl Plus)
45394603|NCT01019447|Other|Vicryl|Polyglactin 910 antimicrobial sutures (Vicryl)
45394604|NCT00490529|Biological|CpG-MCL vaccine|CpG-MCL vaccine is a vaccine prepared by co-culturing cells from the participant's mantle cell lymphoma suspension with 3 mcg/mL PF-3512676, then irradiated to 200 Gy. 1 x 10e8 CpG-MCL cells will be given as a subcutaneous injection.
45697001|NCT00963430|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly (IM) as 15 or 30 mcg dose. The 15 mcg dose will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as a single 1.0 mL injection in the deltoid muscle.
45697002|NCT03083925|Device|TIPS|Transjugular Intrahepatic Portosystemic Shunt
45715221|NCT05746026|Behavioral|Psycho-educational Program|"This program consisted of five (5) sessions during two weeks.~Session 1: introduction and basic information about Climate Change~Session 2: causes and factors that contribute to climate change by humans and nature~Session 3: explain climate change risks, describe and explain the impact of climate change on elder health and well-being.~Session 4: teaching proper behaviors that contribute the most to climate-driving emissions.~Session 5: learning how adapting and coping with climate change. Adaptation includes a range of coping actions that individuals may take, as well as psychological processes (e.g. emotion management, problem solving, and cognitive reframing responses) that influence reactions to (and preparations for) adverse impacts of climate change, including chronic environmental conditions and extreme events."
45849015|NCT00000240|Drug|Buprenorphine|
45503273|NCT01351129|Drug|Formulation 3|150-mg modified release capsule, long duration (single dose)
45503274|NCT02064452|Other|Triple P Online System|The Triple P Online System (TPOS) is an online parenting support program designed to assist parents in developing effective parenting practices for handling their children's problem behaviors. Content focuses on positive attention and praise, teaching strategies, effective discipline, antecedent strategies to avoid problems in high-risk situations, and applying these principles to specific situations. TPOS integrates 3 different levels of program intensity to meet different levels of family need, based on severity of children's behavior problems.
45849016|NCT00000246|Drug|Flumazenil|
45849017|NCT00000264|Drug|30% Nitrous oxide|
45849018|NCT00000264|Other|0.35 g/Kg ethanol|
45849019|NCT00000264|Other|0.7 g/Kg ethanol|
45849020|NCT00000264|Other|0 g/Kg ethanol|
45849021|NCT00000270|Drug|Cocaine|
45849022|NCT00000276|Drug|Bupropion|
45849023|NCT00000282|Drug|Pemoline|
45849024|NCT00000288|Drug|Cotinine fumarate|
45849025|NCT00000294|Drug|Carvedilol|
45849026|NCT00000300|Drug|LAAM|
45394605|NCT00490529|Biological|PF-3512676|PF-03152676 is a synthetic immunostimulatory, single-stranded oligodeoxynucleotide (oligo-DNA) moledule containing unmethylated cytosine and guanine (CpG) motifs. PF-03512676 acts as an agonist of human Toll-like receptor 9, leading to activation of antigen-presenting cells and a cascade of antitumor immune reactions.
45394606|NCT00490529|Procedure|Vaccine-primed T-cells|Vaccine primed T-cells are the post-vaccination leukapheresis harvest of peripheral blood mononuclear cells. Each collection is approx 1 x 10e10 CD3+ T-cells.
45394607|NCT00490529|Procedure|Autologous hematopoietic stem cell transplant (HSCT)|Regular medical procedure
45394608|NCT00490529|Drug|Rituximab|375 mg/m² by infusion
45503275|NCT02064452|Behavioral|Placebo Comparator|Enhanced Usual Community Care-Waitlist
45394609|NCT00490529|Drug|Standard induction chemotherapy|Patient-specific, regular medical care treatment as determined by treating oncologist
45394610|NCT00490529|Drug|Cyclophosphamide|Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
45503276|NCT02236884|Procedure|no-scar transanal total mesorectal excision(TME)|
45394611|NCT00490529|Drug|Filgrastim|Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
45394612|NCT00333840|Drug|imatinib mesilate|imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.
45503277|NCT01355263|Drug|iron and vitamin a|
45503278|NCT04415177|Device|EaseVRx headset with active intervention|VR software developed by AppliedVR informed by evidence-based cognitive behavioral therapy principles, biofeedback and mindfulness strategies for pain management.
45394613|NCT00333840|Drug|interferon-alpha (INF-a)|interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day.
45394614|NCT00333840|Drug|cytarabine (ARA-C)|cytarabine 20 mg/m^2/day (max 40 mg) SC for 10 days every month.
45394615|NCT00490451|Drug|LY573636-sodium|LY573636 dose is dependent on patient's height, weight, and gender to target a specific maximum concentration (Cmax). LY573636 is administered intravenously every 21 or 28 days until disease progression or other criteria for patient discontinuation are met.
45394616|NCT01019603|Drug|Tazarotene|Topical Tazarotene foam applied daily for 22 days.
45394617|NCT01019603|Drug|Tazaroc Gel|Topical tazarotene gel applied daily for 22 days.
45503279|NCT04415177|Device|EaseVRx headset without active intervention|VR software developed by AppliedVR with neutral non-interactive content.
45394618|NCT00321906|Drug|azathioprine|azathioprine 2mg/kg
45394619|NCT00321906|Drug|sirolimus|sirolimus 2-4mg daily
45394620|NCT00339144|Drug|Dasatinib|tablets, Oral, 100 mg, once daily for 4 weeks
45503280|NCT02065856|Biological|AVANZ Salsola|AVANZ Salsola
45503281|NCT03613428|Drug|Ruxolitinib|Dose escalation up to 80 mg administered orally
45503282|NCT03613428|Drug|Vincristine|1.4 mg/m2 i.v. weekly for 4 weeks
45503283|NCT03613428|Drug|Prednisone|1 mg/kg orally 5 consecutive days per week for 4 weeks.
45503284|NCT03290521|Procedure|intraperitoneal washing with saline solution|intraperitoneal washing at the end of surgery
45503285|NCT03290521|Procedure|No washing|no washing
45503286|NCT02065934|Other|cardio-pulmonary resuscitation|
45715222|NCT04739566|Drug|Dabrafenib|Given PO twice daily
45715223|NCT04739566|Drug|Trametinib|Given PO once daily
45715224|NCT05425108|Device|Binocular CP1|Binocular active projection of defocused image in the peripheral visual field
46056998|NCT02715531|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 will be administered IV over 120 (± 5) minutes q2w.
45394621|NCT00339144|Drug|Dasatinib|tablets, Oral, 150 mg, once daily, 4 weeks
45394622|NCT00339144|Drug|Dasatinib|tablets, Oral, 200 mg, once daily for 4 weeks
45394623|NCT00321828|Biological|bevacizumab|bevacizumab 5 mg/kg IV on day 1 every 14 days until excessive toxicity or disease progression
45394624|NCT00321828|Drug|fluorouracil|5-FU 400 mg/m2 IV bolus over 2-4 minutes then 2400 mg/m2 IV continuous infusion over 46 hours on day 1 every 14 days until excessive toxicity or disease progression
45503287|NCT01343615|Procedure|carotid stenting|A group of patients will be operated by endovascular technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects.
45715225|NCT05417854|Device|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes per day, 5 days per week for up to 8 weeks, in addition to standard clinical care.
45715226|NCT02694744|Drug|patiromer|8.4 g/day starting dose, administered orally
45849027|NCT00000306|Drug|Dextroamphetamine|
46056999|NCT02715531|Drug|Capecitabine|Capecitabine may be administered after 6 months at the discretion of the investigator (range of 650-1000 mg/m^2) twice daily on Days 1-4 of a 21-day cycle.
45697003|NCT03426423|Other|Behavioral smoking cessation intervention|"The intervention consists in a behavioral smoking cessation intervention combined with pharmacotherapy. The intervention is tailored it to specificities of participants based on findings from the previous phase of our study (DISCGO-MIX, Swissethics ID PB_2016-01459).~Counseling will cover topics such as assessing ambivalence and enhancing motivation with motivational interviewing methods, identifying barriers to quit, coping with cravings and intensive relapse prevention strategies. Participants will be advised to use over the counter nicotine replacement bi-therapy (NTR). A 2-week starting kit, consisting of nicotine transdermal patch and a short acting NRT (lozenge, gums, inhaler or mouth spray) will be provided to participants for free, if they wish to take NRT.~The behavioral intervention will last 30-45 minutes, and will be conducted by a research nurse using an interview guide."
45394625|NCT00321828|Drug|leucovorin|leucovorin 400 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
45394626|NCT00321828|Drug|oxaliplatin|Oxaliplatin 85 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
45394627|NCT01061580|Device|Harvest SmartPReP2 BMAC System|Injection of 10, 15, or 20 cc of BMAC
45394628|NCT00333138|Drug|FTY720|FTY720 capsule was taken orally once a day
45394629|NCT00333138|Drug|Placebo|Placebo 1.25 mg capsule was given once daily
45394630|NCT01058226|Biological|Malaria challenge (wild-type NF54 strain Plasmodium falciparum sporozoites)|Malaria sporozoite challenge with the wild-type NF54 strain of Plasmodium falciparum delivered by the bite of five infected Anopheles stephensi mosquitoes.
45394631|NCT00332202|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or maximum of 3 years
45394632|NCT00332202|Drug|placebo|oral, daily
45394633|NCT01061658|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Higher dosage of vaccine
45394634|NCT01061658|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Lower dosage of vaccine
45394635|NCT01061658|Other|Placebo|Placebo
45394636|NCT03982836|Dietary Supplement|Soluble Dietary Fibers|All 25 volunteers received, were separated for 7 days of washout, one containing maltodextrin (control), Frutooligossacharide or guar gum partially hydrolyzed in a randomized manner. As the partially hydrolyzed guar gum and fructooligosaccharide, soluble dietary fibers that present different behaviors in the body.
45394637|NCT01058382|Drug|Progesterone Vaginal Suppositories|Progesterone Vaginal Suppositories 200 mg three times daily for 10 weeks following embryo transfer
45394638|NCT01058382|Drug|Intramuscular Progesterone-in-Oil|Progesterone-in-Oil 50 mg IM once daily for 10 weeks following embryo transfer
45394639|NCT01061814|Drug|mipomersen|30 mg (cohort A), 70mg (cohort B) or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
45394640|NCT01061814|Drug|Placebo|30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
45394641|NCT01058460|Procedure|HPV-cytology co-testing|Subjects will receive HPV testing and conventional cytology testing at baseline. Follow up management will be based on both results.
46057000|NCT02715531|Drug|Cisplatin|Cisplatin will be administered as 80 mg/m^2 IV over 120 minutes q3w (Group E2).
45394642|NCT00331422|Drug|carboplatin|Carboplatin dose (milligrams (mg)) - Target Area Under the Curve (AUC) 6 x (Glomerular Filtration Rate+25) - Calvert Formula, given intravenously (IV) for 30 minutes.
45394643|NCT00331422|Drug|paclitaxel|Paclitaxel dose = 175 milligrams per meter squared (mg/m2) over 3 hours.
45394644|NCT00331422|Procedure|cytoreductive surgery|Surgery - tumor specimen collected for extreme drug resistant assay (EDR) and A1 assays for analysis
45394645|NCT00331344|Drug|mitoxantrone hydrochloride|Given IV
45394646|NCT00331344|Drug|ixabepilone|Given IV
45394647|NCT00331344|Drug|prednisone|Given orally
45394648|NCT03983928|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
45394649|NCT03983928|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
45394650|NCT01058538|Drug|L19IL2|Route: i.v. infusion (60 min) Patients will receive a minimum of 2 cycles of treatment. Each cycle is comprised of treatment on Days 1, 3 and 5 followed by a 16 days rest (1 cycle= 21 days). Patients may receive up to 4 further cycles of treatment (max. of 6 cycles in total). Patients will be initially recruited into the study in cohorts of 3 and the starting dose of L19IL2 will be 5 Mio IU IL2 equivalent. Five steps of dose escalation are planned: 5, 10, 20, 30 and 40 Mio IU IL2 equivalent). After the MTD has been established, the RD will be determined. A further 12 patients (with RCC) will receive the RD dose for a minimum of 2 cycles. For patients in the RD part of the study, patients can switch to maintenance therapy. Maintenance therapy consists of 15 Mio IU IL2 every 2 weeks. The maximum duration of the study for a patient is 12 months.
45394651|NCT00321672|Drug|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm^2 each were applied to the feet (2 per foot) for 60 minutes.
45394652|NCT00321672|Drug|0.04% capsaicin patch|Up to 4 control patches of 280 cm^2 each were applied to the feet (2 per foot) for 60 minutes.
45394653|NCT00321672|Drug|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm^2 each were applied to the feet (2 per foot) for 30 minutes.
45394654|NCT00321672|Drug|0.04% capsaicin patch|Up to 4 control patches of 280 cm^2 each were applied to the feet (2 per foot) for 30 minutes.
45394655|NCT03985566|Dietary Supplement|Fibre Grain|Healthy subjects will be provided with 30% Fibre Grain in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
46057001|NCT02715453|Other|Intervention on frailty|"Multidisciplinary team (physicians, nurses, physiotherapists, and nutritionists):~Nutritional evaluation and intervention after randomization and regularly during follow-up~Physiotherapy sessions for 3 months after randomization and home exercise program for 1 year~Psychiatrist or psychologist assistance for 1 year after discharge"
45394656|NCT03985566|Dietary Supplement|Jasmine white rice|Healthy subjects will be provided with Jasmine white rice in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
45394657|NCT00321048|Device|Active Breathing Coordinator|A SPECT scan will be used to determine if the active breathing device reduces radiation toxicities.
45394658|NCT01061970|Drug|Fispemifene|once daily for 4 weeks
45394659|NCT00330174|Drug|Acamprosate|2 333mg tablets three times daily
45394660|NCT03985488|Radiation|Radiation exposure|Radiation exposure via Eview Fluoroscopy machine.
45394661|NCT01058616|Drug|LTX-315 (Oncopore™)|5 mg/ml-70 mg/ml. Dosing will be done as transdermal injection of a calculated volume at day 1 and 8. Additionally weekly injections up to a maximum of 4 injections.
45394662|NCT00320424|Drug|Fondaparinux|
45394663|NCT02533206|Procedure|Endoscopic Polypectomy Performed in Clinic|Endoscopic polypectomy performed in clinic under local and topical anesthesia
45394664|NCT02533206|Procedure|Functional Endoscopic Sinus Surgery (FESS)|Functional Endoscopic Sinus Surgery
45394665|NCT00338286|Other|Standard supportive care (packed RBC transfusion)|Per doctor prescription
45394666|NCT00338286|Drug|epoetin alfa + packed RBC transfusion|40,000 IU SC once a week.
45394667|NCT00329784|Biological|Peanut Consumption Group|Peanut-containing snack. Children are to consume 2 g of peanut protein in three servings per week (total of 6 g) over 3 servings.
45394668|NCT00337818|Biological|Cervarix™|Three doses of vaccine according to a 0, 1, 6 month schedule (during the primary study)
45394669|NCT03981666|Other|Questionnaires|"To patients who have given their consent for the self-screening, the research assistant will propose 3 questionnaires, which will be completed in the waiting room and returned the same day:~Ad hoc questionnaire for demographics and medical data;~Insomnia Severity Index (ISI, 7 items, Savard et al., 2005);~Edmonton Symptom Assessment System (ESAS, 10 items, Visual Analogue Scale, Bruera et al. 1991) assessing comorbidities as pain, dyspnea, anxiety or depression...~The ISI scoring will be realized by the research assistant (in the research office) immediately after its completion."
45394670|NCT00329550|Biological|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
45394671|NCT00329550|Biological|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
45394672|NCT00329550|Biological|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol 400 mg at Weeks 0, 2 and 4.
45394673|NCT00375674|Drug|Sunitinib malate|sunitinib malate 50 mg PO on schedule 4/2: 4 weeks on, 2 weeks off for 1 year or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent.
46057002|NCT00811018|Drug|Sitaxsentan|Sitaxsentan 100 mg tablets once daily
45394674|NCT00375674|Other|Placebo|Placebo PO for 1 year on schedule 4/2: 4 weeks on, 2 weeks off or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent
45394675|NCT00350402|Behavioral|Respiratory muscle strength training|The Muscle Stength Training (MST)device is a mouthpiece that the participant uses to inspire against controlled resistance; Intervention involves use of this device for breathing exercises over 4 week period, 5 days a week, approximately 20 minutes/day.
45394676|NCT03991910|Drug|Placebos|the control group will be given placebo inside a capsule, so study participant won't be able to know the drug and doses inside the capsule (for masking). Placebo will be given until 5 days prior to Mitral valve replacement surgery.
45394677|NCT03991910|Drug|Ramipril 5Mg Oral Capsule|the treatment group will be given each Ramipril 2,5 mg inside a capsule as an initial dose, for 2 weeks. If there is no serious adverse effect in the observation period of 2 weeks, Ramipril 5 mg inside a capsule will be given for the next weeks until 5 days before the mitral valve surgery date. Study participant won't be able to know the drug and doses inside the capsule (for masking)
45394678|NCT01055600|Drug|eltrombopag|Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.
45503288|NCT01343615|Procedure|carotid endarterectomy|A group of patients will be operated by open technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects
45394679|NCT00320190|Drug|Imatinib|Imatinib tablets administered orally at a dose of 400 mg twice daily. Each 400- mg dose to be taken with a meal and a large glass of water.
45394680|NCT00320190|Drug|Dasatinib|Dasatinib tablets administered orally at a dose of 100 mg once daily.
45394681|NCT01050920|Biological|Blood collection|
45394682|NCT02534402|Drug|Prednisone|Administration of prednisone to determine the effect on whole blood gene expression.
45503289|NCT03613350|Diagnostic Test|Pad test|20-minutes pad test and urodynamic study (including uroflowmetry, filling and voiding cystometry, and urethral pressure profile) were conducted to every patient.
45503290|NCT02064530|Drug|Bupivacaine|21 ml 0.5 %bupivacaine is applied interfasially
45394683|NCT00320112|Behavioral|Reciprocal Diabetes Peer Support Program|participants are paired with another age-matched participation. Paired peer partners were encouraged to talk weekly using a telephone platform that recorded call frequency and duration and provided automated reminders promoting peer contact.
45394684|NCT00320112|Behavioral|Nurse Case management|patients are not paired in the NCM arm attended a 1.5 hour session to receive education on care manager services and diabetes educational materials and be assigned to a nurse care manager with whom they were encouraged to follow-up regularly.
45394685|NCT00320112|Behavioral|group outpatient counseling visits|Participants in the peer group were also offered three optional 1.5 hour patient-driven group sessions at month 1, 3, and 6
45394686|NCT03982524|Behavioral|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)
45849028|NCT00000312|Drug|M-CPP|
45394687|NCT03982524|Behavioral|Cognitive-behavioral therapy for patients with multiple somatoform symptoms|Cognitive-behavioral therapy for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)
45394688|NCT01063608|Biological|Anti-H1N1v Vaccine|Inclusion of hospital personnel in the context of the anti-H1N1v prophylaxy plan.
45394689|NCT00319956|Drug|Azithromycin|Give 10 mg/kg IV/PO daily for first 7 days, then give 5 mg/kg IV/PO daily for 35 days.
45394690|NCT00319956|Drug|Placebo|vehicle dose given daily, IV/PO, same volume that Azithromycin would be to equal 10 mg/kg for first 7 days, then 5 mg/kg for 5 weeks.
45394691|NCT01062048|Drug|Sitagliptin|Sitagliptin phosphate monohydrate 25 mg, 50 mg, or 100 mg tablet administered in general use according to the local label
45394692|NCT01062048|Drug|Sulfonylurea|Sulfonylurea administered in general use according to the local label
45394693|NCT01062048|Biological|Insulin|Insulin administered in general use according to the local label
45394694|NCT01060722|Drug|MOD-4023 (long lasting hGH)|Single subcutaneous dose of MOD-4023
45394695|NCT01060722|Drug|Placebo|Single subcutaneous dose of placebo material
45394696|NCT00349622|Drug|ceftriaxone|"Participants will be randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants will receive ceftriaxone and one third will receive placebo. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years."
45849029|NCT00000318|Drug|Buprenorphine|"Experimental Maintenance treatment with daily medication~Experimental Maintenance treatment with thrice-weekly medication"
45849030|NCT00000330|Drug|Opioid-Related Disorders|
45849031|NCT00000336|Drug|Selegiline|
45394697|NCT00349622|Other|placebo|an inactive substance
45394698|NCT03987698|Biological|SHR-1210|SHR-1210 injection
45394699|NCT03987698|Biological|CIK cells|CIK cells injection
45394700|NCT01051076|Drug|VWF/FVIII concentrates|200 IU/Kg by one or two bolus injections daily. After successful confirmation the dose will be tailed off progressively until discontinuation. Patients will be treated with a VWF/FVIII concentrates according to physician/patients preference.
45394701|NCT01325090|Drug|BOTOX|A syringe of 1 ml contain 25 Allergan units.
45394702|NCT01325090|Other|PLACEBO|The pharmacist will fill syringes in tuberculins of 1 ml with injectable solution of sodium chloride of 0,9 %.
45394703|NCT03989258|Diagnostic Test|Mammography outside official screening|Radiologic study
45394704|NCT00354614|Device|ApneaLink Sleep Screener|Device used to evaluate for the presence of OSA
45394705|NCT03989960|Procedure|LISA+SNIPPV|The LISA+SNIPPV group receives PS by the way of invasive surfactant administration technique and selects nasal synchronized intermittent positive pressure ventilation.
45394706|NCT03989960|Procedure|traditional InSurE|The traditional InSurE group receives intubation-surfactant- extubation technique and selects CPAP ventilation.
45394707|NCT00360308|Drug|Placebo|
45394708|NCT00360308|Drug|E2007|
45394709|NCT00360308|Drug|E2007|
45849032|NCT00000342|Drug|Risperidone|
45849033|NCT00000348|Drug|Dihydrexidine|
45849034|NCT00000354|Drug|Lofexidine|
45849035|NCT00000372|Drug|D-cycloserine|
45849036|NCT00000372|Drug|Glycine|
45849037|NCT00000372|Drug|Clozapine|
45849038|NCT00000372|Drug|Placebo|
45849039|NCT00000384|Behavioral|Cognitive Behavior Therapy|
45849040|NCT00000384|Behavioral|Educational Support|
45849041|NCT00000384|Drug|Sertraline|
45849042|NCT00000390|Drug|Imipramine hydrochloride|
45849043|NCT00000396|Behavioral|Patient self-care education|
45849044|NCT00000402|Drug|Calcium|
45849045|NCT00000438|Drug|naltrexone (Revia)|
45849046|NCT00000444|Drug|nicotine replacement patch|
45849047|NCT00000450|Drug|Naltrexone Tablet|
45849048|NCT00000450|Drug|Matched Placebo Tablet|
45849049|NCT00000486|Procedure|coronary artery bypass|
45849050|NCT00000510|Drug|aspirin|
45849051|NCT00000510|Drug|dipyridamole|
45849052|NCT00000510|Procedure|angioplasty, transluminal, percutaneous coronary|
45849053|NCT00000546|Behavioral|meditation|
45849054|NCT00000570|Drug|pulmonary surfactant|
45849055|NCT00000582|Drug|factor ix|
45849056|NCT00000600|Drug|Vitamin E|
45849057|NCT00000600|Drug|Vitamin C|
45849058|NCT00000630|Biological|HIVAC-1e|
45394710|NCT01054508|Drug|nicotinic acid/laropiprant|Nicotinic acid/laropiprant (1g/20mg) daily for 4 weeks, then nicotinic acid/laropiprant (2g/40mg) daily for 8 weeks.
45394711|NCT00348686|Drug|Candesartan|16 mg once daily in oral tablet form
45503291|NCT02064530|Drug|Dexmedetomidine|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied interfasially
45394712|NCT00348686|Drug|Candesartan|32 mg once daily in oral tablet form
45394713|NCT00348686|Drug|Felodipine|5 mg once daily in oral tablet form
45394714|NCT00348686|Drug|Felodipine|10 mg once daily in oral tablet form
45697004|NCT03426423|Other|Control|"Participants assigned to the control group will receive a less intensive and non-tailored intervention for smoking cessation.~For this arm the structured 3 steps AAR approach will be used:~Ask for smoking status. Advise to quit in a clear manner. Refer to external help: participants will receive a booklet with information on smoking cessation (non specific to diabetes and gender) and links to support facilities (national quitline, smoking cessation clinic, websites, self-help).~This unique intervention of 5-10 minutes will be performed by the research nurse."
45394715|NCT01055678|Drug|EF5|An infusion of EF5, a fluorinated 2-nitroimidazole, will be administered using the recommended dose of 21mg/kg one day prior to surgical procedure.
45394716|NCT01055678|Procedure|Partial or Total Mastectomy|A small tissue sample will be removed from the excised tissue and will be stored for later analysis.
45394717|NCT00360230|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|2 different formulations are tested. For each formulation, 3 different dosing schedules are tested
45849059|NCT00000630|Biological|gp160 Vaccine (MicroGeneSys)|
46057003|NCT02715297|Radiation|SRT to the resection cavity|46 Gy total dose will be delivered in 2 Gy per fraction, or 36 Gy delivered in 3 Gy per fraction, 5 fractions within 1 week. Doses will have to cover 95% of the PTV with the prescribed dose. The clinical target volume (CTV) will be defined as the resection cavity of the recurrent glioblastoma plus a margin of 5mm. A CTV to PTV margin of 1 to 3mm will be added according to technique used for immobilisation.
45394718|NCT00360230|Biological|Rabipur|3-dose intramuscular injection.
45394719|NCT03988946|Device|Transcatheter Mitral Valve Replacement via Transseptal Access|The Cephea Transseptal Mitral Valve System is intended for use in symptomatic patients with moderate to severe degenerative or functional mitral regurgitation, who are poor candidates for surgery and who are anatomically eligible for the treatment.
45394720|NCT03988712|Diagnostic Test|Colonoscopy, gastroscopy, virtual colonoscopy, CT scan|Patients referred with a suspected bowel malignancy were subjected to top and bottom endoscopic examination or a cross sectional imaging like CT scan and MRI scan.
45394721|NCT03989024|Drug|Gonadorelin|Drug: Gonadotropin-releasing Hormone. Generic name: Gonadorelin. Dosage form: 600ug. Dosage: 10ug/puls. Frequency: every 90 min. Duration: 3 months
45503292|NCT02064530|Drug|serum physiologic|21 ml serum physiologic is applied interfasially
45503293|NCT01358929|Drug|Placebo|Placebo to RO6807952
45503294|NCT01358929|Drug|RO6807952|Escalating subcutaneous dose
45503295|NCT01345877|Procedure|first degree cutaneous burn injury|application of thermode (5 x 2.5 cm) to lower leg temperature 47.0 C, 420 s
45394722|NCT03989024|Drug|Clomiphene|Drug: Clomiphene. Generic name: Clomiphene. Dosage form: 50mg. Dosage: 50mg. Frequency: once a day. Duration: 3 months
45394723|NCT03988790|Device|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
45394724|NCT03987308|Drug|Beinaglutide|Five-week Beinaglutide pump treatment group
45503296|NCT01568229|Drug|AMG 747|Three dose levels once-daily oral administration
45503297|NCT01568229|Drug|Placebo|Once-daily oral administration
45394725|NCT03987308|Drug|Insulin aspart|Five-week short-term CSII (insulin aspart) treatment group
45503298|NCT03613896|Procedure|conventional dentures|conventional dentures
45697005|NCT01009762|Biological|peptide vaccine (AFO-18)|18 Peptides (250 ug of each peptide) in Adjuvant CAF01 (= 625/125 ug DDA/TDB), i.m. injection week 0, 2, 4, 8.
45697006|NCT05688969|Other|early versus late biopsy|early (3-6 weeks) versus late (6-8 months) biopsy
45697007|NCT05688813|Procedure|Regional anesthesia intervention|Ultrasound-guided caudal and sacral erector spinae blocks were administered
45503299|NCT03613896|Procedure|3d printed denture|construction of a 3d printed denture through a recent method instead of conventional heat processing
45503300|NCT02066012|Other|dysmetabolic iron overload syndrome|
45697008|NCT01009918|Drug|Coreg CR®|Given orally
45697009|NCT01009918|Drug|lisinopril|Given orally
45697010|NCT01009918|Other|placebo|Given orally
45697011|NCT03088683|Device|Nathanson Retractor|Liver will be retracted with Nathanson retractor
45697012|NCT03088683|Device|Reveel Retractor|Liver will be retracted with Reveel retractor
45849060|NCT00000636|Drug|Isoniazid|
45849061|NCT00000636|Drug|Pyrazinamide|
45849062|NCT00000636|Drug|Pyridoxine hydrochloride|
45849063|NCT00000636|Drug|Rifampin|
45849064|NCT00000648|Drug|Penicillin G potassium|
45849065|NCT00000648|Drug|Ceftriaxone sodium|
45849066|NCT00000654|Drug|Fialuridine|
45849067|NCT00000660|Drug|Etoposide|
45849068|NCT00000702|Drug|Zidovudine|
45849069|NCT00000714|Drug|Trimetrexate glucuronate|
45849070|NCT00000714|Drug|Leucovorin calcium|
45849071|NCT00000732|Drug|Sulfamethoxazole-Trimethoprim|
45394726|NCT01051154|Dietary Supplement|Docosahexaenoic acid (DHA)|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
45394727|NCT01051154|Dietary Supplement|Placebo|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
45394728|NCT00348374|Drug|Insulin Lispro|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
45394729|NCT00348374|Drug|Exubera|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
45394730|NCT02533388|Device|Hwato Electronic Acupuncture Treatment Instrument|Thirty minutes prior to the induction of anaesthesia, the patients in the TEAS group started to receive TEAS by a stimulator (Hwato Electronic Acupuncture Treatment Instrument, model No.: SDZ-II, Suzhou Medical Appliances Co., Ltd., Suzhou, China) to the right hand, forearm and neck by an experienced acupuncturist at the Hegu (LI4), Neiguan (PC6), Lieque (LU7), Chize (LU5), Futu (LI18) and Renying (ST9) acupoints. TEAS was peformed with an alternate dense-disperse frequency of 2 and10 Hz ( 2 Hz for 10 s and 10 Hz for 5 s). The optimal intensity ranged from 6-15 mA, The stimulus continued until 5 min before the end of surgery.
45394731|NCT02533388|Device|Placebo|The patients in the Sham group were also connected to the apparatus, but electronic stimulation was not applied.
45394732|NCT01054898|Behavioral|advocacy intervention|A 12-week telephone social support and empowerment intervention consisting of empowerment training, scheduled weekly telephone calls, and 24-hour access to a hotline for abused women
45849072|NCT00000732|Drug|Zidovudine|
46057004|NCT02715063|Behavioral|High Intensity Interval|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
45394733|NCT01054898|Behavioral|usual community services|standard care for abused women in the community
45394734|NCT03742232|Drug|PEG3350|"PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.~PLENVU® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy)."
45503301|NCT05384028|Other|Nurse -led case management|This study would apply case management to the whole course management of AMI patients from admission to 6 months after discharge. Pharmacists, nutritionists, rehabilitation specialists and psychiatrists led by nurse would take the initiative to conduct individualized assessment and health guidance, and case managers would participate in the whole process of inpatient diagnosis and treatment. Coordinating multidisciplinary medical resources to jointly implement diagnosis and treatment and rehabilitation for patients can improve the quality of care.
45503302|NCT05384028|Other|Routine inpatient care and post-discharge follow-up management|Patients in the control group will receive routine inpatient care and post-discharge follow-up management
45503303|NCT01355341|Drug|HERBMED PLUS|500 mg Twice day for 6 month with lunch and dinner.
45503304|NCT03939533|Drug|CUTAQUIG|Human normal immunoglobulin
46057005|NCT02715063|Behavioral|Resistance training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
45394735|NCT03742232|Drug|Macrogol 4000|"SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.~SELG-ESSE® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy)."
45394736|NCT00353366|Biological|Rotarix|Two doses of the oral vaccine
45394737|NCT00353366|Other|Data collection|Safety evaluation: recording of adverse events by using diary cards and by non-leading questioning.
45394738|NCT03988478|Behavioral|Detoxification & psychotherapeutic support|
45697013|NCT05688657|Device|Monthly Replacement Toric Silicone Hydrogel Contact Lens A|Monthly Replacement Toric Silicone Hydrogel Contact Lens A - first period of 15 minutes
45697014|NCT05688657|Device|Daily Disposable Toric Silicone Hydrogel Contact Lens B|Daily Disposable Toric Silicone Hydrogel Contact Lens B - second period of 15 minutes
45697015|NCT04401657|Diagnostic Test|Fractional flow reserve with adenosine stress testing|ECG, FFR, and two-dimensional echocardiographic monitoring will be continued before, during and after adenosine infusion.
45697016|NCT03019198|Drug|Tranexamic Acid Injectable Solution|Intravenous 15 mg per kilogram tranexamic acid
45849073|NCT00000738|Drug|Nimodipine|
45849074|NCT00000738|Drug|Zidovudine|
45849075|NCT00000750|Drug|Zidovudine|
45849076|NCT00000756|Drug|Lymphocytes, Activated|
45394739|NCT00352664|Drug|Donepezil|5 mg once a day by mouth for 7 day cycle. After evaluation on Day 8, all participants will be offered donepezil every day for 7 days.
45394740|NCT00352664|Drug|Placebo|Placebo tablet once a day by mouth for one 7 day cycle. After evaluation on day 8, all participants offered donepezil every day for 7 days.
45394741|NCT01051232|Drug|Active|Six subjects will receive PF-00868554 (filibuvir) 100 mg under fasting condition.
45394742|NCT01051232|Drug|Placebo|Two subjects will receive the placebo under fasting condition.
45503305|NCT02066090|Device|Real acupuncture|"manual acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + electroacupuncture (middle CV6, CV12), twice a week, for 6 weeks~common approaches for the treatment of obesity used by doctors of Korean medicine in Korea today"
45503306|NCT02066090|Device|Sham acupuncture|"sham acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + placebo acupuncture without electrical stimulation (middle CV6, CV12), twice a week, for 6 weeks~sham acupuncture (0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) as control for manual acupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea)~placebo acupuncture without electrical stimulation as control for electroacupuncture (0.25mm diameter x 90mm length, stainless steel, Dongbangacupuncture Inc., Korea)"
45697017|NCT03019198|Drug|Placebo - Concentrate|
45697018|NCT04401501|Other|Manual Therapy and Exercises|Combination of physiotherapy (manual therapy) techniques and exercises for cervicogenic headache
45697019|NCT04401501|Other|Exercise|Exercises for cervicogenic headache
45697020|NCT03018808|Other|Minimal questionnaire|The minimal questionnaire is a reduced version of the medical interview and it will include questions about sociodemographic information, previous diagnosis of COPD, co-morbidities and smoking habits.
45697021|NCT03018808|Other|Medical interview|Medical interview includes medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.
45849077|NCT00000774|Biological|rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
45849078|NCT00000774|Biological|rgp120/HIV-1 SF-2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
45849079|NCT00000774|Biological|Placebo version of rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
45849080|NCT00000774|Biological|Placebo version of rgp120/HIV-1SF2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
45849081|NCT00000804|Drug|Indinavir sulfate|
45849082|NCT00000810|Drug|Delavirdine mesylate|
45394743|NCT01051232|Drug|Active|Six subjects will receive PF-00868554 (filibuvir) 300 mg under fasting condition.
45394744|NCT01051232|Drug|Placebo|Two subjects will receive the placebo under fasting condition.
45394745|NCT01051232|Drug|Active|Six subjects will receive PF-00868554 (filibuvir) 500 mg under fasting condition.
45394746|NCT01051232|Drug|Placebo|Two subjects will receive the placebo under fasting condition.
45849083|NCT00000810|Drug|Zidovudine|
45849084|NCT00000810|Drug|Didanosine|
45849085|NCT00000834|Drug|Lamivudine|
45849086|NCT00000834|Drug|Methotrexate|
45394747|NCT03991442|Drug|Fimasartan/Amlodipine|Active Comparator: a fixed dose combination of Fimasartan/Amlodipine or placebo
45394748|NCT03742310|Drug|Vitamin D|Vitamin D is essential for healthy bones, and to control the amount of calcium in our blood.It is important at every stage of life, but especially for rapidly growing infants and teenagers and for pregnant and breastfeeding women.
45394749|NCT03988556|Device|Photobiomodulation using CareMin650 at 6 Joules (curative intent)|"CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For curative treatment, the dose to be delivered has been set at 6J/cm2. If the lesions of patients included in a curative cohort are resolved before the end of the radiotherapy period, the treatment will be applied with a preventive aim and the dose will decrease from 6 to 3J/cm2."
45697022|NCT03018808|Other|CAT|The CAT is a questionnaire for COPD patients and is designed to measure the impact of COPD on a person's life over time.
45697023|NCT03018808|Procedure|Blood test|Blood samples will be collected at indicated time points
45697024|NCT03018808|Other|anthropometric measures|Anthropologic measures will be performed.
45849087|NCT00000834|Drug|Zidovudine|
45849088|NCT00000846|Biological|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
45849089|NCT00000846|Biological|HIV-1 Peptide Immunogen, Multivalent|
45849090|NCT00000852|Procedure|Allogeneic lymphocyte transfer|
45849091|NCT00000864|Drug|Abacavir sulfate|
45849092|NCT00000864|Drug|Zidovudine|
45849093|NCT00000876|Drug|CD4-IgG2|
45849094|NCT00000894|Drug|Cidofovir|
45849095|NCT00000894|Drug|Probenecid|
45849096|NCT00000894|Drug|Ganciclovir|
45849097|NCT00000912|Drug|Indinavir sulfate|
45849098|NCT00000912|Drug|Abacavir sulfate|
45849099|NCT00000912|Drug|Amprenavir|
45849100|NCT00000912|Drug|Nelfinavir mesylate|
45849101|NCT00000912|Drug|Efavirenz|
45849102|NCT00000912|Drug|Levocarnitine|
45849103|NCT00000912|Drug|Adefovir dipivoxil|
45849104|NCT00000912|Drug|Saquinavir|
45849105|NCT00000918|Drug|Indinavir sulfate|
45849106|NCT00000918|Drug|Lamivudine/Zidovudine|
45849107|NCT00000918|Drug|Ritonavir|
45849108|NCT00000918|Drug|Amprenavir|
45394750|NCT03988556|Device|Photobiomodulation using CareMin650 at 3 Joules (prophylactic intent)|"CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For prophylactic treatment, the dose to be delivered has been set at 3J/cm2. If oral mucositis or radiodermatitis occurs in a patient included in a prophylactic cohort, the lesions will be treated with a curative intent and the dose will increase from 3 to 6J/cm2."
45394751|NCT03988244|Device|HeartLight X3|Pulmonary vein isolation
45394752|NCT01055210|Device|Optimisation of VV delay|Programmed VV delay altered on device
45394753|NCT00490139|Drug|Lapatinib|Small molecule inhibitor
45394754|NCT00490139|Biological|Trastuzumab|Antibody
45394755|NCT00348140|Drug|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
45394756|NCT00348140|Drug|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
45394757|NCT00348140|Other|Placebo|Placebo
45394758|NCT01055990|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|The influenza A (H1N1) 2009 monovalent, (Split-virion)inactivated vaccine was developed by Shanghai Institute of Biological Products, and the seed virus was prepared from reassortant vaccine virus A/California/7/2009,distributed by the Centers for Disease Control and Prevention in the United States. This strain was recommended by the World Health Organization and obtained from the Chinese Food and Drug Administration.The vaccine adopted the assessment of experts, and formally accessed to the approval document number of production and new drug certificate issued by the Chinese Food and Drug Administration.
45394759|NCT01055990|Other|blood fix|The blood fix with a hemagglutination-inhibition titer of 1:80 or more than was collected from healthy persons who are inoculated with specific H1N1 vaccine
45394760|NCT01051388|Drug|Low-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 10 mg), once a day, for four weeks times three
45503307|NCT01351207|Other|Eggs|Comparison of a high saturated fat/low fiber meal alone, with eggs, and with a protein/cholesterol matched egg-free pudding
45503308|NCT05250557|Diagnostic Test|Fractional flow reserve|Physiologic assessment includes Δ FFR (lesion-specific) and FFR (vessel-specific) measurement. Δ FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).
45503309|NCT03613194|Procedure|Sampling|"After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:~Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal~Peritoneal liquid~none tumoral peritoneum~Portal blood~Peripheral blood~Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator."
45697025|NCT03018808|Other|Oximetry|Digital pulse oximeter on the index finger after five minutes rest and before receiving bronchodilator for spirometry will be used to measure the pulse arterial oximetry. The average of three measurements at 10 second intervals will be recorded. The heart rate will be provided by the pulse oximeter.
45394761|NCT01051388|Drug|High-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 20 mg Tablet once a day, for four weeks times three)
45394762|NCT01051388|Drug|Non-PPI (Gefarnate)|The mucosal defensive drug (Gefarnate 50 mg Capsule, twice a day, for four weeks times three)
46057006|NCT02715063|Behavioral|Plus: High Intensity Interval + Resistance Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
45697026|NCT03083613|Drug|Raltitrexed|Raltitrexed:3mg/m2,iv,d1, Every 3 weeks
45849109|NCT00000918|Drug|Efavirenz|
45394765|NCT00490061|Drug|Lapatinib|1500 mg po daily orally
45394766|NCT00490061|Procedure|Radiotherapy (radiation)|Standard of Care
45394767|NCT00490061|Device|G.E. Healthcare 1.5T MR, systems revision 12.0 M5|Standard of Care, used to deliver IMRT
45394768|NCT00490061|Device|DCE-MRI|A subset of patients received imaging before and after Lapatinib loading, prior to starting radiotherapy.
45394769|NCT01055366|Drug|Elazop (Azarga)|Administer one drop of ELAZOP in treated eye(s) twice a day for up to 12 weeks
45503310|NCT04519437|Drug|REGN10933+REGN10987|Administered subcutaneous (SC) every 4 weeks (Q4W)
45503311|NCT04519437|Drug|Placebo|Administered subcutaneous (SC) every 4 weeks (Q4W)
45503312|NCT02064608|Drug|AZD2014|mTOR inhibitor
45697027|NCT03083613|Drug|Paclitaxel|Paclitaxel:80mg/m2,iv,d1,d8, Every 3 weeks
45849110|NCT00000918|Drug|Saquinavir|
45849111|NCT00000918|Drug|Lamivudine|
45849112|NCT00000918|Drug|Stavudine|
45849113|NCT00000918|Drug|Zidovudine|
45849114|NCT00000918|Drug|Didanosine|
45849115|NCT00000924|Drug|Ritonavir|
45849116|NCT00000924|Drug|Nelfinavir mesylate|
45849117|NCT00000924|Drug|Nevirapine|
45849118|NCT00000924|Drug|Stavudine|
45849119|NCT00000924|Drug|Didanosine|
45394770|NCT03988322|Other|Low-dose CT screening with quantitative assessment and management of imaging biomarkers|Participants will be screened with a low-dose CT (a Philips 256-slice CT system). The CT images will be obtain according to the pre-defined CT scan protocol. This CT protocol is developed for quantitative assessment of lung nodules, COPD and coronary artery calcium. Detected lung nodules will be managed according to the European volume-based protocol, based on the volume and volume doubling time of lung nodule. COPD will be management according to the result of lung function test. The imaging biomarkers (eg., emphysema index, airway wall thickness, and coronary artery calcium ) will be quantitatively registered. In addition, a number of participants' characteristics will be collected: physical examination (weight, height, blood pressure), laboratory measurements (eg., fasting plasma glucose, total cholesterol, HDL-cholesterol). The social-demographic characteristics, risk factors of the 3 diseases, and health status of the participants will be collected through questionnaires.
45394771|NCT03988322|Other|Low-dose CT screening with visual assessment and management of imaging biomarkers|Participants will be screened with a low-dose CT (a Philips 64 MDCT system). The CT images will be obtain according to the routine CT scan protocol for lung cancer screening in the hospital. Detected lung nodules will be managed according to the diameter of the nodule based on the NCCN Clinical Practice Guideline in Oncology for Lung Cancer Screening. Detected emphysema and/or bronchial wall thickness, coronary artery calcium will be qualitatively recorded (yes/no).
45394772|NCT04140695|Drug|Tradipitant|BID
45554686|NCT04441437|Behavioral|Task-oriented training with a dynamic hand splint|In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the splint group received 1-hour task-oriented training with wearing a customized dynamic hand splint, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
46057007|NCT02715063|Other|Usual clinical care|Dietary restriction (1300-1500kcal) 50-52% carbohydrates, 33-35% fat, 15-20% protein
45394773|NCT04140695|Drug|Placebo|BID
45394774|NCT01019681|Biological|Cord blood stem cell injection|"The cord blood stem cells will be simply injected intramuscularly in the leg. 30 minutes prior to stem cell injection the patients will receive Vancomycin 1 gram IVPB x1 as a prophylactic measure. Patients will also receive Ativan 0.5 to 1 mg PO x 1 and Dilaudid 0.5 to 1 mg IV x1 to alleviate the discomfort of the procedure.~Cells will be injected by means of a 22 gauge sterile spinal needle after topical anesthesia of the injection site. The concentration will be at least 2 x 107 total nucleated cells per ml in phosphate buffered saline (PBS) with 5% human serum albumin (Baxter, Deerfield Illinois)."
45394775|NCT01019759|Procedure|pulmonary vein isolation|The off-pump beating heart ablation procedure is performed. Using a Microwave (MW) energy ablation tool (Microwave generator by Guidant), epicardial ablation line isolating the pulmonary veins are applied during open heart surgery
45394776|NCT00483119|Drug|intravenous immunoglobulin|Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles
45394777|NCT00483119|Drug|cyclophosphamide|cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration
45394778|NCT03996707|Other|Weight Bearing|Immediate protected weight bearing in a CAM walking boot following foot & ankle surgery
45394779|NCT03996707|Other|Strict non-weight bearing|Strict non weight bearing for 6 weeks following foot & ankle surgery
45394780|NCT00483041|Other|PLACEBO|Placebo administered as a single intravenous infusion
45394781|NCT00483041|Biological|MEDI528 9 mg/kg|MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
45394782|NCT01016639|Other|oxaliplatin, capecitabine, radiotherapy|
45394783|NCT00501293|Drug|Methylphenidate Transdermal System|One of 4 doses of the MTS transdermal patch over the same duration of wear for approximately 6 months
45394784|NCT01014221|Other|Acupuncture|acupuncture administered in 8 sessions over 4 weeks
45394785|NCT01014221|Drug|Prednisolone|2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
45394786|NCT00482729|Drug|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/Metformin HCl 50/500 mg tablet bid, titrating up to sitagliptin/Metformin HCl 50/1000 mg tablet over 4 weeks; for a 44-wk treatment period.
45394787|NCT00482729|Drug|metformin|metformin 500 mg tablet bid, titrating up to 1000 mg tablets bid for a 44-wk treatment period
45394788|NCT01019837|Biological|Focetria (Monovalent MF59-Adjuvanted vaccine)|Biological: Focetria (Monovalent MF59-Adjuvanted vaccine)
45394789|NCT01014299|Other|Recruitment maneuver|"Assigned interventions:~No intervention after tracheal intubation (control group)~Alveolar recruitment maneuver (RM group) immediately after intubation"
45394790|NCT01014377|Device|VascuActive|
45394791|NCT00359762|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
45394792|NCT00359762|Drug|glimepiride|oral tablet (titrated to maximally tolerated dose), once daily
45394793|NCT03988010|Drug|Amantadine Sulfate|200mg/500ml i.v. solution for infusion
45394794|NCT03988010|Drug|Placebo (for amantadine sulphate)|500 cc 0.9% sodium chloride
45697028|NCT00963508|Drug|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
45394795|NCT01055522|Drug|Arm 1: L19IL2 + Dacarbazine|"RD of L19IL2 determined in phase IIa. Induction Phase A: Intravenous (IV) infusion of L19IL2 on days 1, 3 and 5 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Induction Phase B: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Maintenance: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first"
45394796|NCT01055522|Drug|Arm 3: Dacarbazine|Dacarbazine Dosage: 1,000 mg/m2 DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first.
45503313|NCT04299997|Other|Assessment of the accuracy of the PI-RADS v2.1 score for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in the dataset of the 171 MRIs for 21 different readers.|"Ass of targeted suspect lesions~On each mpMRI,radiologist will contour lesions that were targeted at subsequent biopsy based on reports. Contours will be disclosed to readers who will assess,for each lesion:~Likert score(gut feelingie subjective ass of the likelihood that lesion is clinically significant prostate cancer(5-level scale))~PI-RADSv2, PI-RADSv2.1 score(by strictly applying the published PI-RADS criteria)~EPE score(ie the likelihood of extraprostatic extension;5-level subjective scale without predefined criteria)~Max diameter~Def of add suspect lesions Readers could define suspectadditional targets(AT);for each AT,they will provide the same criteria. It is expected that, for these suspect AT,at least one score is≥3~Ass of lobes Scores of prostate lobes will be automatically calculated based on 2 previous steps of reading. However,in lobes with no suspect lesion,readers could define whether same criteria are1or2,in peripheral zone and transition zone"
45394797|NCT01055522|Drug|ARM 2: L19IL2 + Dacarbazine|"RD of L19IL2 determined in phase IIa. Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first"
45503314|NCT03613584|Drug|Von Willebrand Factor|Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
45503315|NCT03613584|Drug|Saline Solution|Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
45503316|NCT03907943|Procedure|carotid endarterectomy|Surgical treatment of ICA stenosis.
45503317|NCT02066246|Device|AirSeal|100 patients are treated with the AirSeal insufflation and trocar system
45503318|NCT02066246|Device|Olympus UHI-3|100 patients are treated with a conventional insufflation and trocar system
45503319|NCT01359085|Drug|Pregabalin|Pregabalin 75 mg will be given orally as premedication at the night before surgery (at bedtime). Pregabalin 150 mg will be administered orally at 1h preoperatively and at 12h and 24h postoperatively.
45503320|NCT01359085|Procedure|ISBPB - interscalene brachial plexus block|ISBPB will be performed by an anesthesiology consultant experienced in performing the procedure, after the induction of GA. Block will be performed under sterile conditions by injection of 40ml 0.5% bupivacaine with epinephrine 1:100,000 to the plexus sheath through a 5-cm, 23-gauge short-beveled needle.
45503321|NCT04280523|Drug|ESR-specific PET scan|Lung ESR Density by PET: Investigators will use 18F-FES as an estrogen receptor (ESR)-specific PET tracer to determine lung ESR density. 18F-FES will be prepared according to published methods. Briefly, all subjects will be evaluated by PET imaging, using standardized protocols. Blood will be obtained just before FES injection to measure the endogenous estrogen level [estradiol (E2)], to rule out pregnancy in female patients, and some reserved for future studies of mechanism. Approximately 6 mCi (222 MBq) of 18F-FES will be administered intravenously over 1~2 minutes, with scanning initiated 1 hour after administration of the tracer. Emission scans will be performed of the chest. A multimodality computer platform (Syngo; Siemens) will be used for image review and manipulation.
45503322|NCT05384184|Procedure|Tumor /metastases removal|Tumor /metastases removal
45503323|NCT04322357|Drug|Prednisone|A 12-month treatment period with twice weekly, low-dose prednisone (dose of 0.75 mg/kg per day).
45503324|NCT04322357|Behavioral|In-home Exercise Training|For boys on current standard of care (daily glucocorticoid use), 6-months in-home, remotely supervised exercise training program involving a combination of aerobic and isometric leg strength exercises.
45697029|NCT00963508|Drug|Permethrin 1% rinse (Nix Crème)|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head head lice are still present.
45697030|NCT03088371|Drug|Bupivacaine 0.25%|For psoas sciatic block.
45697031|NCT03088371|Other|Pajunk Needle|For local anaesthesia application in psoas sciatic block
45697032|NCT03088371|Other|Portex combined spinal epidural kit|For combined spinal epidural anaesthesia
45394798|NCT03987152|Drug|Sirolimus|Daily intake of Sirolimus during Challenge and Rechallenge phase
45697033|NCT03088371|Drug|Lidocaine 1%|For psoas sciatic block.
45697034|NCT03088371|Drug|Bupivacaine 0.5%|For spinal anaesthesia in combined spinal epidural anaesthesia.
45697035|NCT03088371|Drug|Lidocaine 2 %|For psoas sciatic block in the post-operative period
45394799|NCT01056146|Behavioral|Internet-based Interacting Together Everyday: Recovery After Childhood TBI|Families in I-InTERACT will look through 10 web-sessions (like chapters) and participate in 10 family meetings focusing on education about traumatic brain injury, parenting skills, communication, behavior strategies, and stress management. Meetings will be conducted in their home using a computer hook-up with a trained therapist. Families will also be contacted two times per month by the counselor to discuss individual problems or concerns.
45394800|NCT01056146|Behavioral|Internet Resources Comparison|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
45394801|NCT02533856|Other|ETOC|Services provided to assist patients in accessing needed healthcare services after emergency department discharge such as scheduling appointments, finding new doctors, getting medications, or addressing problems with insurance coverage.
45394802|NCT00347438|Drug|Capecitabine|Capecitabine twice daily for 14 days followed by 7 days without taking drug (1 cycle). This schedule is followed for 8 cycles (about 24 weeks).
45394803|NCT03987230|Drug|Sensitive Eyes® Plus Saline Solution|Sensitive Eyes® Plus Saline Solution
45394804|NCT03987230|Other|Oust™ Demodex® Wipes™|Oust™ Demodex® Wipes™
45394805|NCT03987230|Other|I-LID N LASH PLUS® Eyelid Cleanser|I-LID N LASH PLUS® Eyelid Cleanser
45394806|NCT03987230|Other|Blephadex Lid Wipes|Blephadex Lid Wipes
45394807|NCT03987230|Other|Eye Cleanse Lid Wipes|Eye Cleanse Lid Wipes
45394808|NCT03987230|Other|Blephademodex|Blephademodex
45394809|NCT00329238|Drug|Dabigatran|Dabigatran 150 mg BID (twice daily)
45394810|NCT00329238|Drug|Warfarin|Warfarin dosed individually to maintain INR 2.0-3.0
45394811|NCT00329160|Drug|Rosuvastatin|2.5-20 mg
45394812|NCT00329160|Drug|HMG CoA inhibitor|3-hydroxy-3-methylglutaryl-coenzyme A
45394813|NCT00328926|Drug|Luveris® 75 IU|Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 75 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and estradiol [E2] levels). Total duration will be of 3 treatment cycles.
45394814|NCT00328926|Drug|Luveris® 25 IU|Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 25 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
45394815|NCT00328926|Drug|Placebo|Placebo will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
45394816|NCT00328926|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Fixed dose of recombinant human follicle stimulating hormone (r-hFSH, follitropin alfa) 75 to 150 IU will be administered subcutaneously for 7 days. After 7 days of treatment, if the subject response will suboptimal, based on follicular growth and serum E2 levels, follitropin alfa dose adjusted to maximal dose of 225 IU. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
45503325|NCT04322357|Drug|Prednisone plus exercise|Twice weekly prednisone for 6 months followed by twice weekly prednisone plus exercise for 6 months.
45503326|NCT01351285|Drug|up-and-down method to find out effective concentration of remifentanil for preventing cough|During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.
45503327|NCT05189041|Other|Aneurysmal pulsation in functional MRI|Quantify the aneurysmal pulsation in functional MRI on the patient with Ruptured Cerebral Aneurysm
45394817|NCT00328926|Drug|Recombinant human chorionic gonadotropin (r-hCG)|When the follicular response will adequate, ovulation will be triggered by a single 250 microgram subcutaneous injection of recombinant human chorionic gonadotropin (r-hCG, choriogonadotropin alfa). Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
45394818|NCT03982446|Genetic|Mutations|
45394819|NCT01063686|Device|insemination cervical cap|Primary abdominal ultrasound (US) for amniotic fluid index (AFI), Single vertical pocket, and dimensions of pocket below the presenting part. Speculum vaginal examination. In a sterile manner a cervical cap is adjusted on the cervix. the patient is kept recumbent for 6 hours. A repeat US exam is performed. The cervical cap is removed. After one hour another US is performed.
45394820|NCT00319254|Drug|SKI-606 (Bosutinib)|SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression.
45394821|NCT00319098|Biological|Adjuvanted pandemic influenza candidate vaccine|2 doses, intramuscular injection
45394822|NCT00319098|Biological|Fluarix|One intramuscular injection
45394823|NCT00319098|Biological|Placebo|One intramuscular injection
45394824|NCT00347360|Drug|lisinopril|
45394825|NCT00347360|Drug|carvedilol controlled release formulation|
45394826|NCT00319020|Drug|Bosentan|32-mg dispersible and breakable tablet. The body weight-adjusted dose of the dispersible tablet was dispersed in a teaspoon of water (not mixed with food) before being administered orally
45394827|NCT02532738|Drug|Routine Treatment of CD|The Drug including 6MP, AZA, infliximab and thalidomide
45503328|NCT02032290|Procedure|Assessment of Coronary Flow Reserve|
45394828|NCT02532738|Biological|MSC treatment 01|Injection of 3×10E6/kg of MSC
45394829|NCT02532738|Biological|MSC treatment 02|Injection of 6×10E6/kg of MSC
45394830|NCT02532738|Other|NS|Injection of NS
45394831|NCT01056224|Drug|Remifentanil|A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
45503329|NCT02032290|Procedure|Percutaneous coronary intervention|
45503330|NCT02032290|Drug|ticagrelor loading|
45503331|NCT02032290|Drug|Clopidogrel loading|
45503332|NCT01317329|Other|Clinically prescribed CPAP therapy|CPAP as prescribed by attending physician
45503333|NCT03560180|Diagnostic Test|Dutch score|leakage score (DUtch LeaKage, DULK), that consider several items (fever, heart rate, respiratory rate, urinary production, mental status, clinical conditions, signs of ileus, gastric retention, fascial dehiscence, abdominal pain, wound pain, leukocytosis, CRP, increase of urea or creatinine and nutrition status), to give a score
45503334|NCT03560180|Diagnostic Test|Serum C-reactive Protein|see study protocol
45503335|NCT03560180|Diagnostic Test|serum Procalcitonin|see study protocol
45394832|NCT03982680|Drug|Toripalimab|3mg/kg on d1 and d15 q4W*4cycles，then 3mg/kg q3w for 1 year in total
45394833|NCT03982680|Drug|Gemcitabine|1250mg/m2 on d1 and d15 q4W*4cycles
45394834|NCT03982680|Drug|5- fluorine pyrimidine|400mg/m2 intravenous injection plus 5-FU 2.4g-3.6g/m2 continuous intravenous drip for 48h on d1 and d15 q4W*4cycles
45394835|NCT00352118|Biological|filgrastim|subcutaneously on Days 5-14, repeating every 3 weeks for 2 courses.
45394836|NCT00352118|Biological|pegfilgrastim|If applicable on day 5, repeating every 3 weeks for 2 courses.
45394837|NCT00352118|Drug|cisplatin|Intravenous over 1 hour on day 1, every 3 weeks for 3 courses.
45394838|NCT00352118|Drug|docetaxel|Intravenous over 1 hour on day 1.
45394839|NCT00352118|Drug|fluorouracil|Intravenous continuously on days 1-4.
45394840|NCT00352118|Procedure|conventional surgery|As appropriate, neck dissection.
45394841|NCT00352118|Radiation|radiation therapy|60 Gy 5 days/week x 6 weeks with cisplatin
45394842|NCT01325376|Behavioral|Technology assisted health behavior|Web-based interactive program using an hpod sensor that tracks physical activity as well as biometric parameters into the iWell server and is transmitted to the internet site via the users PC. Also serves as a social networking site.
45394843|NCT01325376|Behavioral|Self directed|Receives support and encouragement with minimal contact. Receives printed lifestyle guidelines with diet and physical activity recommendations.
45394844|NCT00318474|Drug|Mycophenolate Mofetil (MMF)|Oral administration of MMF; dose based on body size (between 25mg/kg/day and 36ng/kg/day); maximum dose 1gm BID.
45394845|NCT00318474|Drug|MMF Placebo|Placebo only, oral administration
45394846|NCT00318474|Drug|ACEi|Administer same as pre-treatment regimen.
45394847|NCT00318474|Drug|FOS|Administer same as pre-treatment regimen
45394848|NCT00350870|Drug|disulfiram|250mg per day of Disulfiram plus CBT
45394849|NCT00350870|Drug|Placebo|Placebo plus CBT
45394850|NCT00350870|Behavioral|Placebo plus Contingency Management|Placebo plus Contingency Management for cocaine abstinence and medication compliance in addition to CBT
45394851|NCT00350870|Drug|Disulfiram plus Contingency Management|250mg of Disulfiram plus Contingency Management for cocaine abstinence and medication compliance plus CBT.
45394852|NCT03982290|Other|Probiotic, Lactobacillus plantarum PS128|PS128 capsules, 2 capsules per day
45394853|NCT03982290|Other|Placebo, microcrystalline cellulose|Placebo capsules, 2 capsules per day
45394854|NCT00350792|Drug|pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV), every 21 days x 6 cycles
45394855|NCT00350792|Drug|carboplatin|Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
45394856|NCT00317772|Drug|Topotecan|"Phase I Starting Dose: 2 mg/m^2 by vein Weekly Over 30 Minutes on Days 1, 8, and 15.~Phase II: MTD dose from Phase I by vein weekly on Days 1, 8, and 15."
45394857|NCT00317772|Drug|Gefitinib|"Phase I: 250 mg by mouth daily for 28 Days.~Phase II: 250 mg by mouth daily for 28 Days."
45394858|NCT02533778|Device|mechanical thrombectomy|Mechanical thrombectomy by either Penumbra system, TREVO, or Solitaire retrieval device
45394859|NCT01325298|Device|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
45394860|NCT01325298|Drug|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
45394861|NCT01325298|Device|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
45394862|NCT01325298|Drug|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
45394863|NCT01325454|Device|pleural pigtail drainage|With the guidance of chest US, 50 ml of pleural fluid was collected using a standard thoracentesis technique immediately or within 24 hr after hospitalization. When pleural effusion was multi-loculated, the fluid was aspirated from the largest loculus. Routine analyses of pleural fluid for total leukocytes, cell differentials of leukocytes, pH value, and levels of protein, glucose and LDH were performed in addition to cytological and microbiologic examination of pleural fluid.The rest of pleural fluid samples were mixed with 3.8 % sodium citrate in a 9:1 ratio of pleural fluid to citrate. The sodium citrate-mixed pleural fluid specimens were immersed in ice immediately and then centrifuged at 2,500 g for 10 minutes. The cell-free supernatants of pleural fluid were frozen at -70℃ immediately after centrifuge for later measurements. The commercially available enzyme-linked immunosorbent assay kits were used to measure the effusion levels of VEGF, IL-8 , tPA and PAI-1.
45394864|NCT00350636|Drug|Oxybutynin topical gel|1 application daily to skin for 12 weeks
45394865|NCT00350636|Other|Placebo topical gel|1 application daily to skin for 12 weeks
45394866|NCT01051544|Drug|FVIII Concentrates|Patients will be centrally randomized to receive a von Willebrand factor-free FVIII concentrate (recombinant or plasma-derived, monoclonally-purified). The choice of product brand will be based on physician / patients preferences.
45394867|NCT01051544|Drug|FVIII/VWF concentrates|Patients will be centrally randomized to receive a FVIII/VWF concentrate of 200 IU/Kg by one or two bolus injections daily.The choice of product brand will be based on physician / patients preferences.
45503336|NCT01351363|Device|Electrical pain threshold measurement|Assessment of preoperative pain threshold using electrical stimulation using a Painmatcher machine.
45503337|NCT01351363|Device|Measurement of electrical pain threshold|Measurement of preoperative electrical pain threshold and self reporting of postoperative pain scores (for 4 days) on VAS.
45503338|NCT04250571|Other|"information about No treatment group"|Participants will receive no pills and will be told that they are in the no treatment group
45503339|NCT04250571|Other|imaginary pill technique|Participants will be instructed to take an imagined pill. This instruction consists of a procedure including five steps (i.e., identifying the IP sensitive problem, building trust/belief/reality of the IP, constructing a personally meaningful IP, taking the IP, suggestions for self-administering the IP in real life, and building adherence). Participants in this group receive daily e-mail reminders.
45503340|NCT04250571|Other|open label placebo|"Participants will have the information that they are receiving inert pills (i.e. P-Dragees, containing Placebo), combined with the following scientific rationale: (a) deceptive as well as open label placebos have been found to be effective in relieving symptoms in a variety of clinical conditions namely anxiety, depression, chronic pain (the placebo effect is powerful), (b) classical conditioning are one of the possible mechanism of this effect (the body automatically responds), (c) positive expectations may help but are not necessary, (suspend disbelief), (d) compliance with these instructions are important for outcome (taking the pills faithfully is important).~Participants in this group receive daily e-mail reminders."
45394868|NCT03985670|Drug|teripalimab plus chemotherapy|teripalimab 240mg d1 paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1
45394869|NCT03985670|Drug|chemotherapy plus teripalimab|paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1 teripalimab 240mg d3
45394870|NCT01058720|Dietary Supplement|Vitamin D3|2000 IU orally once daily for 12 weeks
45394871|NCT00346268|Drug|Morphine, Parecoxib|Parecoxib 40 milligrams (mg) administered intravenously immediately post surgery, followed 20 mg every 12 hours until 48 hours post surgery, total 5 doses. Participants also received Patient-Controlled Analgesia (PCA) 1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA.
45394872|NCT00346268|Drug|Morphine, Placebo|Matching placebo administered intravenously immediately post surgery and every 12 hours until 48 hours post surgery, total 5 doses. Participants also received PCA (1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA
45394873|NCT00327444|Drug|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
45394874|NCT00327444|Drug|Placebo|Placebo was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
45394875|NCT00327444|Drug|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period.
45394876|NCT01051622|Other|Labeling Ceretec|Technetium-99m is used to radiolabel cells of interest i.e PBMC's
45394877|NCT03982134|Drug|PDR001|PDR001 is a humanized IgG4 antibody
45394878|NCT03982134|Drug|Panobinostat|Panobinostat is a Histone deacetylase inhibitor (HDACi).
45394879|NCT00337610|Drug|sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive blinded sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
45394880|NCT00337610|Drug|comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive placebo to match sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
45394881|NCT01062204|Device|Altrazeal|Sterile, odorless, crystalline white powder consisting of flakes of freeze dried HEMA and HPMA polymers. For application, the powder is distributed to the surface of the wound or burn where it forms a moist, flexible film and adheres to the surface of the wound.
45394882|NCT01062204|Device|Aquacel Ag|Textile fiber made from sodium carboxy-methylcellulose containing 1.2% silver in ionic form.
45394883|NCT01062282|Drug|Iloprost (Ventavis BAYQ6256)|Patients with pulmonary arterial hypertension, classified as New York Heart Association functional class III or IV where the treating physician has chosen Ventavis as a suitable treatment prior to inclusion into this non-interventional study. Patients should not have received prior treatment with Ventavis
45394884|NCT01324856|Procedure|Pancreatico gastro anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico gasto teremino-lateral anastomosis will be performed. The anastomosis will be done with posterior wall of the stomach. Pancreas will be mobilized at least 5 cm, two tobaco stiches will be applied on posterior wall of the stomach and hole of 2 cm will be done in the middle. Anterior wall of the stomach will be opened, for easier placement of the pancreas in to the stomach cavity. Pancreas will be entered in the stomach trough , tobacco stitches tided and just 2 or 3 stitches will be applied on the stomach mucosa and pancreatic capsule. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
45394885|NCT01324856|Procedure|Pancreaticojejuno anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico jejuno termino lateral duct to mucosa anastomosis will be performed. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
45394886|NCT03981042|Device|Monitoring|"After the anesthetic induction with sufentanil, propofol and atracurium, patients will be ventilated with mask until:~- Monitoring group: TOF ratio at the corrugator supercilli will be measured every 15 s after injection of atracurium. When TOF ratio reach 0, laryngoscopy with intubation will be performed"
45394887|NCT03985280|Device|Cooled radiofrequency|Under guidance of combined X-ray and ultrasound the nerves will be located . After local anesthetic aplication cooled RF needle will be apply in the objective position. Cooled RF will be performed for 2:30 minutes at 60 º C degrees.
45394888|NCT03985280|Drug|Intraaticular steroids and local anesthetic injections|Intraaticular steroids and local anesthetic injections
45394889|NCT01058876|Drug|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
45394890|NCT03986918|Device|Routine Total Hip Arthroplasty|Patients undergoing routine total hip arthroplasty will receive surveys regarding survivorship and outcomes.
45394891|NCT03986840|Other|Exercise training|A multicomponent exercise program
45394892|NCT03986762|Drug|Clavulanic Acid|~10 days of Clavulanic Acid
45394893|NCT01051700|Drug|GW786034|Investigational product
45394894|NCT01051700|Other|Placebo|Placebo
45394895|NCT01051934|Drug|SS1 (dsFv) PE38|
45394896|NCT01051934|Drug|Paclitaxel|
45394897|NCT01051934|Drug|Carboplatin|
45394898|NCT01051934|Drug|Bevacizumab|
45394899|NCT01056458|Other|auricular acupressure|use the tape of ear adhesive beads on shenmen and subcortical area of both ears after three meals and before bed for three minutes each area with alternating ears, twice a week to replace paste.
45394900|NCT01056458|Other|sham acupressure|use only tape without ear adhesive beads under the same ways
45394901|NCT01325168|Drug|syntocinon nasal spray|nasal oxytocin - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
45394902|NCT01325168|Drug|placebo nasal spray|nasal placebo - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
45394903|NCT00316914|Drug|calcium gluconate|Given IV
45394904|NCT00316914|Drug|magnesium sulfate|Given IV
45394905|NCT00316914|Other|placebo|Given IV
45394906|NCT01059032|Other|Using a 3 dimentional post processing filter|Using a 3 dimentional post processing filter
45394907|NCT03991676|Behavioral|Values-Based Behavioral Treatment|The values-based behavioral treatment will consist of a series of three, once-weekly weight loss workshops infused with techniques to elicit values clarification and awareness in moments of dietary decision-making, and to enhance autonomous motivation for behavior change.
45394908|NCT02532816|Dietary Supplement|Nutrient dense complementary foods|"Mothers/caregivers will receive optimized CFRs to improve children diets and fortified biscuits (3 types of biscuit) for 6 days per week (in 12 months).~Nutrition eduction for mothers/caregivers. Monthly body weight and length/height measurements"
45697036|NCT03088371|Drug|Bupivacaine 0.125 %|For combined spinal epidural in the post-operative period.
45394909|NCT00336284|Other|Home Monitoring|Home Monitoring programmed on. In-office and Home Monitoring evaluation at 3 and 15 months post ICD implant. Home Monitoring evaluation only at 6, 9, and 12 months post ICD implant.
45394910|NCT00336284|Other|In-Office Conventional Follow-up|Home Monitoring programmed off. In-office evaluations at 3, 6, 9, 12, and 15 months post ICD implant.
45394911|NCT00316602|Biological|IMVAMUNE|Subjects receiving two subcutaneous vaccinations
45394912|NCT00335972|Drug|Remifentanil|Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
45394913|NCT00335972|Drug|Dexmedetomidine|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
45394914|NCT03983304|Device|The ZELTIQ System|The EMS device will be used to perform the treatments.
45394915|NCT03983460|Drug|Dupilumab|Each single used prefilled syringe contains 300 mg of Dupilumab in 2 mL solution (150mg/mL) Dupilumab is a fully human monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signaling, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
45394916|NCT03983460|Drug|Optimized TCS treatment|Application of betamethasone valerate 0.1% (Betneval 0.1% cream), a potent topical corticosteroid, and if not active, application of clobetasol propionate 0.05% (Dermoval 0.05% cream), a very potent topical corticosteroid. TCS treatment will be associated with a personal therapeutic education for treatment optimization.
45394917|NCT03983460|Procedure|Biopsies|"Four skin biopsies (5 mm diameter) and ten microbiopsies (2 & 3 mm diameter) will be performed according the following schedule:~Day 0~a 5 mm section biopsy from a non-lesional skin~a 5 mm section biopsy from an active lesion~a 3 mm section microbiopsies from a non-lesional skin~a 3 mm section microbiopsies from an active lesion~a 2 mm section microbiopsies from a non-lesional skin~a 2 mm section microbiopsies from an active lesion~Day 28~a 5 mm section biopsy on improved/healed lesion~a 3 mm section microbiopsies on improved/healed lesion~a 2 mm section microbiopsies from non lesional skin identified at V1~a 2 mm section microbiopsies on improved/healed lesion~Day 168~a 5 mm section biopsy on improved/healed lesion~a 3 mm section microbiopsies on improved/healed lesion~a 2 mm section microbiopsies from non-lesional skin identified at V1~a 2 mm section microbiopsies on improved/healed lesion"
45394918|NCT03983460|Procedure|Skin prick-test|"Skin prick test is a method for medical diagnosis of allergy consisting in introducing a small amount of an allergen into the patient's skin. The allergen penetrates the epidermis by pricking the skin with a pin.~Skin Prick test for Derp and Derf will be performed at Day 0, preferentially on the forearms, avoiding lesional areas.~For the results interpretation, the two allergen Derp/Derf will be compared to 2 controls:~Negative control : saline solution~Positive control : histamine solution~Positive criteria of prick tests results are:~Positive control's diameter ≥ 3mm~And negative control's diameter < 3 mm~And tested allergen with wheal ≥ positive control, i.e. 3mm"
45394919|NCT03983460|Procedure|Blood sample collection|"A 50ml blood sample will be collected by venipuncture at Day 0, Day 28 and Day 168.~More specifically a 40 ml blood sample will be drawn on heparinized tubes for immunophenotyping and a 10 mL on serum blood collection tube for analysis of AD biomarkers by mass cytometry and ELISA."
45394920|NCT01056614|Drug|fludarabine phosphate|Given IV
45394921|NCT01056614|Drug|busulfan|Given IV
45394922|NCT01056614|Biological|anti-thymocyte globulin|Given IV
45394923|NCT01056614|Drug|tacrolimus|Given IV and orally
45394924|NCT01056614|Drug|methotrexate|Given IV
45394925|NCT01056614|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
45394926|NCT01056614|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
45394927|NCT01056614|Other|laboratory biomarker analysis|Correlative studies
45394928|NCT03983538|Other|Mathematical modeling to predict response to chemotherapy|Mathematical modeling using the patient's diagnostic core biopsy and baseline MRI of the breast will be used to predict the response to above therapy.
45394929|NCT00346034|Drug|Pregabalin|150 to 600mg/day
45394930|NCT00345878|Biological|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
45394931|NCT00345878|Biological|HPV-16/18 L1 VLP AS04 (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
45394932|NCT01052090|Drug|PHN121|a size 0 hard gel capsule containing 323.6 mg active ingredient, a complex mixture prepared from 5 commonly practiced botanical traditional Chinese medicines
45394933|NCT01056692|Drug|OC000459|Capsules twice daily for 15 days
45394934|NCT01056692|Drug|Placebo|Capsules twice daily for 15 days
45394935|NCT01059110|Drug|Salicylate ointment|cream, one application every night, for 90 days
45394936|NCT01059110|Drug|Imiquimod|cream, one dose of 250 mg, one application 3 times a week during 12 hours, for 90 days
45394937|NCT01059110|Drug|5-Fluoro-Uracil|cream, one application every night, during 12 hours, for 90 days
45394938|NCT01059110|Drug|Cryotherapy|2 cycles of 5 seconds after obtention of halo of white
45394939|NCT01059266|Drug|PURETHAL Grasses, 20.000 AUM/ml|subcutaneous injections of increasing doses according to the described regimen
45503341|NCT05384106|Dietary Supplement|(R)-1,3-butanediol|Avela™ (R)-1,3-butanediol is intended to induce ketosis in the general adult population. Avela™ (R)-1,3-butanediol is GRAS for use in beverages, bars, and gels
45394940|NCT03991364|Other|Constant gait speed group|The speed of the robot-assisted gait treatment is constantly applied for 5 times a week for 2 weeks.
45394941|NCT03991364|Other|Increasing gait speed group|The speed of the robot-assisted gait treatment is gradually increase for 5 times a week for 2 weeks.
45394942|NCT03985436|Behavioral|Trek for Surgical Success|Cognitive behavioral therapy for pain
45394943|NCT03985124|Behavioral|Tuning in to Kids for Teachers|This is an emotion-focused intervention for teachers giving them skills in emotion coaching children in their care and also understanding and managing their own emotions.
45503342|NCT05050565|Behavioral|Experiences of stigma and psychological flexibility in chronic pain participants|Chronic pain participants will answer questionnaires at two points in time, two weeks apart. These questionnaires ask about stigma and psychological flexibility, as well as depression, catastrophizing, pain interference, and social adjustment. The data collected is only observational and does not include any intervention.
45503343|NCT03379428|Drug|Trastuzumab|8 mg/kg loading dose (first dose), followed by 6 mg/kg every 3 weeks, administered intravenously (IV)
45394944|NCT00335738|Drug|liposomal vincristine sulfate|Given IV
45394945|NCT00335738|Drug|carboplatin|Given IV
45394946|NCT00335738|Drug|etoposide|Given IV
45394947|NCT02533076|Other|Challenge agent: capsaicin|"During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.~In ring number 1 and 2, subjects will receive a topical dose of 1000 µg/20 µL capsaicin (single-blind). Change in dermal blood flow induced by capsaicin will be measured with Laser Doppler Imaging."
45394948|NCT02533076|Other|Challenge agent: placebo|"During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.~In ring number 3, subjects will receive a topical dose of placebo (single-blind).Change in dermal blood flow induced by placebo will be measured with Laser Doppler Imaging."
45503344|NCT03379428|Drug|Ibrutinib 560 mg|560 mg by mouth daily
45503345|NCT03379428|Drug|Ibrutinib 840 mg|840 mg by mouth daily
45503346|NCT03379428|Drug|Ibrutinib 420 mg|420 mg by mouth daily
45503347|NCT03132805|Behavioral|PATHS to PAX|A universal classroom-based preventive intervention designed to prevent aggression.
45503348|NCT03132805|Behavioral|PATHS to PAX and the Incredible Years|A universal classroom-based preventive intervention in combination with an indicated preventive intervention, both of which are designed to prevent aggression.
45503349|NCT03628131|Drug|Pazopanib|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
45503350|NCT03628131|Drug|Ifosfamide|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
45394949|NCT02533076|Device|Mechanical stimulation with Von Frey filaments|Von Frey filaments will be used to measured the mechanical detection and pain threshold of the volunteers. The Von Frey filaments will be applied on the upper capsaicin spot in sequential order. The subject will be asked to indicate when he feels the application of the Von Frey filaments and when it hurts.
45394950|NCT02533076|Device|Temperature sensitivity measurement with Advanced Thermal Stimulation|Temperature sensitivity (detection and pain threshold) will be determined using Advanced Thermal stimulation. A thermode will be attached to the hand of the volunteer with a baseline temperature of 32°C. The thermode will heat up and cool down with a rate of 1°C/second and the volunteer will be asked to click on a computer mouse when he feels the change in temperature and when it hurts.
45394951|NCT01056770|Drug|smallpox vaccine CJ-50300|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
45394952|NCT03991598|Other|Exercise program|Exercise program in communities / Exercise program at home
45503351|NCT03628131|Drug|Carboplatin|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
45503352|NCT03628131|Drug|Etoposide|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
45503353|NCT02067884|Procedure|dynamic contrast-enhanced ultrasound imaging|Undergo CEUS
45394953|NCT03991520|Drug|Anakinra 100Mg/0.67Ml Inj Syringe|The study drug is100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection.
45394954|NCT03991520|Drug|Placebo|The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection
45394955|NCT01056926|Behavioral|Quit smoking|Subjects will quit smoking for 2 fMRIs, each abstinence lasting 2 days
45394956|NCT01056926|Drug|Nicotine patch|Subjects will wear a 21mg patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
45394957|NCT01056926|Drug|Placebo Patch|Subjects will wear a placebo patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
45394958|NCT01059422|Drug|Raltegravir; Abacavir/Lamivudine|Raltegravir: 400 mg twice daily Abacavir/Lamivudine fixed-dose combination: 600mg/300mg once daily
45394959|NCT02533700|Drug|CEOP/IVE/GDP chemotherapy regimen|"CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5~IVE:~Ifosfamide 2000mg/m2,ivgtt D1-D3 Epirubucin 70mg/m2, ivgtt D1 Etoposide 100mg/m2, ivgtt D1-D3~GDP:~Gemcitabine 1g/m2,ivgtt D1,D8 Cis-platinum 25mg/m2, ivgtt D1-D3 Dexamethasone 40mg, ivgtt D1-D4"
45394960|NCT02533700|Drug|CEOP chemotherapy regimen for 6 cycles|"CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses"
45394961|NCT01059500|Device|Webtool|Webtool provides the numeric PTP estimate for ACS and PE, and one of three testing recommendations. For ACS, PTP <2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5 to 5.5%: obtain a troponin I measurement at presentation and 120 minutes later, and if both are normal, no further testing; PTP >5.5%: proceed to provocative testing. For PE, PTP<2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5-10%, obtain a quantitative D-dimer and if normal, no further testing. PTP 10-20%, proceed directly to pulmonary vascular imaging, and if PTP>20% consider empiric anticoagulation with heparin if no contraindications.
45394962|NCT01052246|Drug|Fixed combination of clindamycin 1% + benzoyl peroxide 5%|Topical monotherapy with a fixed combination of 1% clindamycin and 5% benzoyl peroxide hydrating gel (Duac® Akne Gel, Stiefel Laboratorium GmbH, Offenbach, Germany). In order to provide standardized condition within the sample, the gel was applied on the whole face regardless of the lesion location. The gel was applied once per day in the evening throughout the observation period and left in place overnight.
45394963|NCT01052246|Device|Pulsed dye laser|"Patients randomized in the experimental group received two additional treatments with a pulsed dye laser using the following parameters:~Wavelength 585 nm~Energy fluence 3 J/cm2~Pulse duration 0.35 msec~Spot size 7 mm"
45394964|NCT01059578|Drug|GSK206136|GSK206136 2mg, 10mg, 50mg, 100mg capsule
45394965|NCT01059578|Drug|PLACEBO|Placebo to match 206136 2mg, 10mg, 50mg, 100mg capsule
45394966|NCT01059578|Radiation|PET|Each subject will undergo 3 PET Scans ; one at Baseline and the others following dosing with GSK206136 at approximately 2 hours post-dose and 24 hours post-dose
45394967|NCT01059656|Drug|Pazopanib|Administration of pazopanib per os 800mg/ qd during 6 months until stable response according to primary endpoint, with 3 monthly successive examinations, and for a period of study not exceeding 18 months.
45394968|NCT00334958|Drug|Placebo|For the 12-day Titration Phase, one matching placebo tablet will be administered twice daily and increased by 1 matching placebo tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 placebo tablets twice daily.
45394969|NCT00334958|Drug|Rufinamide|For the titration phase, Rufinamide will be administered orally in doses starting with 400 mg twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
45697037|NCT03083691|Drug|Nivolumab, Ipilimumab|Cohort 1: addition of ipilimumab in case of progression on nivolumab monotherapy.
45697038|NCT03083691|Drug|Nivolumab, Ipilimumab|Cohort 2: upfront combination therapy of nivolumab and ipilimumab for four cycles, followed by nivolumab monotherapy.
45697039|NCT01010854|Drug|VPA FEC100|oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)
45697040|NCT05685537|Drug|Levosimendan|Initiation of levosimendan 48 hours before surgery
45697041|NCT04279509|Procedure|Tumor Core Biopsy|"Performed up to a maximum of 3 time points - baseline upon study enrolment, at the completion of treatment, and upon disease progression.~Four to six tumour core samples will be obtained at each time point. At least two tumour cores will be sent fresh to Invitrocue Pte Ltd for generation of patient-derived organoids for drug-panel screening, at least 1-2 tumour cores at each time point will be stored in formalin and paraffin-embedded for immunohistochemistry analysis of biomarkers, while the remaining 1-2 tumour cores will be stored in liquid nitrogen for subsequent DNA, RNA and protein extraction for biomarker studies including gene expression and proteomics analyses."
45697042|NCT04279509|Procedure|Blood sampling|Germline DNA at baseline for pharmacogenetics analysis. Serial plasma samples for circulating tumour cells and biomarkers, at baseline, prior to day 1 of each cycle while on treatment, at the end of treatment (either upon disease progression or upon completion of predetermined cycles of chemotherapy).
45697043|NCT00964444|Device|Peisner device|The doctor/midwife stands on the device while the baby is delivered. The device measures how much force is exerted on the baby.
45394970|NCT01059734|Genetic|DNA analysis|
45394971|NCT01059734|Genetic|RNA analysis|
45394972|NCT01059734|Genetic|mutation analysis|
45394973|NCT01059734|Genetic|polymerase chain reaction|
45394974|NCT01059734|Genetic|polymorphism analysis|
45394975|NCT01059734|Other|laboratory biomarker analysis|
45394976|NCT03986528|Drug|Kanglaite Injection+Chemotherapy|Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy. The patients will also receive Kanglaite injection 200ml by IV infusion per day continuously for 14 days, commencing on the first day of chemotherapy.
45394977|NCT03986528|Drug|Chemotherapy|Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy.
45394978|NCT01057082|Dietary Supplement|Juven|Participants in the treatment arm will be asked to consume 2 packets of Juven drink mix each day for a period of six months.
45394979|NCT01057082|Dietary Supplement|Juven|Participants in the placebo arm will be asked to consume two packets of an orange-flavored drink mix each day for a period of six months.
45394980|NCT00326898|Other|Laboratory Biomarker Analysis|Correlative studies
45394981|NCT00326898|Other|Placebo|Given PO
45394982|NCT00326898|Other|Quality-of-Life Assessment|Ancillary studies
45394983|NCT00326898|Drug|Sorafenib Tosylate|Given PO
45394984|NCT00326898|Drug|Sunitinib Malate|Given PO
45394985|NCT01062360|Drug|Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine|Single oral dose of 1 to 2 Aspirin Complex sachets, each containing granules of 500 mg Acetylsalicylic Acid (ASA) and 30 mg Pseudoephedrine (PSE), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
45394986|NCT01062360|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of 1 to 2 sachets Acetylsalicylic Acid, each containing granules of 500 mg Acetylsalicylic Acid (ASA), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
45394987|NCT01062360|Drug|Pseudoephedrine|Single oral dose of 1 to 2 sachets Pseudoephedrine, each containing granules 30 mg Pseudoephedrine, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
45394988|NCT01062360|Drug|Placebo|Single oral dose of 1 to 2 sachets, each containing Placebo granules, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
45394989|NCT01062438|Genetic|DNA analysis|
45697044|NCT04353622|Device|Exoskeleton robot for upper extremity|"Robot-assisted Treatment Program:~10 minutes elbow flexion/extension~10 minutes forearm supination/pronation~10 minutes wrist flexion/extension~10 minutes ulnar/radial deviation~Frequency: 2/week Duration: 12 sessions (6 weeks)"
45697045|NCT04353622|Other|Conventional physiotherapy|Ferquency: 2/week Duration: 12 sessions (6weeks) Each session: 50 minutes
45394990|NCT01062438|Genetic|RNA analysis|
45394991|NCT01062438|Genetic|gene expression analysis|
45394992|NCT01062438|Genetic|gene rearrangement analysis|
45394993|NCT01062438|Genetic|mutation analysis|
45697046|NCT05685459|Other|Standard patient simulation model|Nursing students were trained with a standard patient simulation model for position and communication skills education.
45697047|NCT04400721|Drug|Erector spinae plane block with ropivacaine 3.75mg/ml|Single shot erector spinae block
45394994|NCT01062438|Other|laboratory biomarker analysis|
45394995|NCT03982056|Other|this is an observational study there are no interventions|development of an index to provide appropriate information on a person's ability to float, based on Physiological and anthropometric characteristics
45394996|NCT01063842|Drug|tramadol hydrochloride /acetaminophen|1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
45394997|NCT01063842|Drug|tramadol hydrochloride / acetaminophen and placebo|1 tablet of tramadol/acetaminophen in the morning, 1 tablet of placebo in the afternoon and evening for 3 days, then 1 tablet of tramadol/acetaminophen in the morning, evening and 1 tablet of placebo in the afternoon for 4 days, then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
45394998|NCT01063920|Drug|LT-NS001|1200 mg b.i.d. p.o. for 12 weeks
45394999|NCT01063920|Drug|Naprosyn®|500 mg b.i.d. p.o. for 12 weeks
45395000|NCT01062516|Drug|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
45503354|NCT02067884|Procedure|shear wave elastography|Undergo SWE
45697048|NCT01010932|Drug|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
45697049|NCT01010932|Other|TOF MRA|Each subject will undergo a Time of Flight Magnetic Resonance Angiography (TOF MRA)
45395001|NCT01062516|Drug|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
45395002|NCT01063998|Other|Urine Marker|Urinary KIM-1 measurements
45395003|NCT03981120|Procedure|Laser and Traditional Acupuncture|Acupuncture (traditional and laser) and photobiomodulation will be performed by a certified acupuncturist on-site with experience in reproductive health and the initial visit will include an assessment and traditional Chinese medicine (TCM) diagnosis.
45395004|NCT01062594|Other|Supervised exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
45395005|NCT01062594|Other|Role of exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
45395006|NCT01062594|Other|Supervised exercise program|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
45395007|NCT00326118|Biological|Haemophilus influenzae type b and meningococcal serogroup C (vaccine)|One intramuscular dose at 12-18 months of age
45395008|NCT00326118|Biological|Priorix™|One subcutaneous dose at 12-18 months of age
45395009|NCT00326118|Biological|Hiberix™|One intramuscular dose at 12-18 months of age.
45395010|NCT00326118|Biological|Meningitec™|One intramuscular dose at 12-18 months of age
45395011|NCT00334802|Drug|gemcitabine|"Phase 1: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles (dose escalation)~Phase 2: dose determined by phase 1"
45395012|NCT00334802|Drug|paclitaxel|"Phase 1: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles~Phase 2: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles"
45395013|NCT03985358|Other|Opioid counseling plus standard of care instructions|Same counselor (investigator on the study) will use the same counseling script at the randomization visit as well as at the visit where they come in for pre-admission testing prior to surgery (as a refresher) to counsel patients
45395014|NCT01052324|Drug|Remifentanil|After topical airway anesthesia with 10 % lidocaine in nostril and oropharyx, 1.5~2.0 mg of IV midazolam is injected. Awake nasotracheal fiberoptic intubation is performed with target-controlled infusion of remifentanil. Initial effect site concentration is 3.0 ng/ml. Smooth intubation is defined as absence of persistent cough with head elevation and defensive movement of extremities. In case of smooth intubation, effect site concentration is decreased by 0.5 ng/ml for the subsequent case. If intubation is not smooth, effect site concentration is increased by 0.5 ng/ml for the subsequent case. EC50 of remifentanil is determined using Dixon's up-and-down method.
45395015|NCT00307164|Drug|NucleomaxX|36 g sachet taken orally three times daily
45395016|NCT00307164|Drug|NucleomaxX placebo|36 g placebo sachet taken orally three times daily
45395017|NCT01059890|Drug|cefotaxime|
45395018|NCT01059890|Drug|Metronidazole|
45395019|NCT01059890|Drug|Ciprofloxacin|
45395020|NCT01059890|Drug|Fosfocine|
45395021|NCT01057160|Drug|Rizatriptan|use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic
45503355|NCT02067884|Drug|Definity, (Lipid Microspheres) Intravenous Suspension|Participant will receive contrast agent by intravenous administration
45503356|NCT02067884|Device|Philips Shear Wave Elastography|Equipment used for SWE
45849120|NCT00000936|Drug|hOKT3|Administered both during and after transplantation in IV form. Dosage determined by individual weight and given for a maximum of 14 days.
45849121|NCT00000936|Drug|Oral Cyclosporine|Administered orally as either sandimmune or neoral at a dose determined by weight. Patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day, for the duration of the study.
45395022|NCT01057238|Other|Intensive Communication System|Regular family meetings once a week, using a standard protocol
45395023|NCT03990974|Drug|postoperative antimicrobial prophylaxis|The drugs are all common antibiotics used to prevent postoperative infection in each hospital.
45395024|NCT03990974|Other|No postoperative antimicrobial prophylaxis|Patients will receive no antibiotics after hepatectomy unless necessary.
45395025|NCT03827564|Device|Intranasal Tear Neurostimulator (ITN) [TrueTear®]|The ITN applies a small electrical current to the nasal cavities to gently activate the body's natural tear production system.
45395026|NCT00307086|Drug|Bortezomib|the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous stem cell transplant
45395027|NCT00307086|Drug|Melphalan|Day -4 melphalan 100 mg/m2 intravenously over 30 minutes, Day -3 melphalan 100 mg/m2 intravenously over 30 minutes
45395028|NCT00307086|Procedure|PBSCT|PBSCT #1 Day 0 PBSCT #2 Day 0 (approx 90 days =/- 15 days after PBSCT #1)
45395029|NCT03741998|Device|Nasopharyngeal airway|THRIVE with a regular nasopharyngeal airway.
45395030|NCT01060202|Drug|No intervention|This is an observational study. Patients receiving bortezomib injection intravenously (into a vein) 1.3 mg/m2 twice a week for 21 days will be observed.
45395031|NCT01057316|Device|Formula PTX Stent - Dose 1|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
45395032|NCT01057316|Device|Formula PTX Stent - Dose 2|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
45503357|NCT01317485|Procedure|Laparoscopic lavage and drainage|"[CLOSED] The abdominal cavity is irrigated with six litres of warm saline in all four quadrants. At the end of the procedure a Douglas drain is inserted via the right lateral port.~***This part of the study was closed in 2013 on advice of the data and safety monitoring board due to safety issues"
45395033|NCT01057316|Device|Formula PTX Stent - Dose 3|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
45395034|NCT02533544|Drug|tenofovir disoproxil fumarate|
45395035|NCT01052402|Biological|H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation|Two vaccinations, 21 days apart, followed by a heterologous booster vaccination on Day 360
45395036|NCT03991208|Drug|Malarone|Malarone
45395037|NCT00325416|Drug|melphalan|(Days -4,-3,-2) 50 mg/m^2/day IV over 30 minutes (total dose 150 mg/m^2)
45697050|NCT05688423|Behavioral|SIRI Team|"Participants randomized to the intervention will receive integrated ID and SUD care (SIRI Team) both during the hospitalization and after hospital discharge for 4 months post-randomization. The intervention is based upon six general principles for treating PWID with infectious complications and is informed by harm reduction.~Medications for SUD as integral to management of infectious complications~Integration of ID and SUD care~Longitudinal care with familiar providers~Multidisciplinary care and care coordination~Tailored antibiotic options and care settings~Harm reduction"
45849122|NCT00000936|Drug|IV Cyclosporine|Administered intravenously (IV) both during and after transplantation at a dosage determined by individual age.
45395038|NCT00325416|Drug|topotecan (TPT)|"Phase I Dose Escalation: Level 1 - 20 mg/m^2; Level 2 - 30 mg/m^2; Level 4 - 54 mg/m^2; Level 5 - 72 mg/m^2; Level 6 - 96 mg/m^2; Level 7 - 127.8 mg/m^2; Level 8 - 170.1 mg/m^2~Phase II: Treatment at maximum tolerated dose (MTD)"
45395039|NCT00325416|Procedure|Autologous Stem Cell Rescue|Day 0
45395040|NCT01060280|Behavioral|Education on active management|Routine clinical practice plus education on active management.
45395041|NCT01060280|Other|Group GDS physiotherapy|Routine clinical practice (which will be substituted by Group GDS) plus education on active management.
45395042|NCT01060280|Other|Individual GDS physiotherapy|Routine clinical practice (except for usual physiotherapy, which is substituted by Group and Individual GDS) plus education on active management.
45395043|NCT01060358|Procedure|method (non-surgical) to measure neuromuscular neutral zones|
45395044|NCT00314808|Drug|Dronabinol|Oral route, 5mg PO 2x daily before and during 2 cycles of chemotherapy,2.5mg PO every night when not on chemotherapy
45395045|NCT03984734|Procedure|Pancreatoduodenectomy with antrectomy|
45395046|NCT03984734|Procedure|Pylorus-preserving pancreatoduodenectomy|
45395047|NCT01060436|Device|CPAP or BiPAP machines|Nightly use of CPAP or BiPAP at a pressure recommended by the subject's treating physician
45503358|NCT01317485|Procedure|Sigmoidectomy with primary anastomosis|[OPEN] Sigmoidectomy is done according to the guidelines of the American Society of Colon and Rectal Surgeons. The distal transsection margin has to be on the proximal rectum, the proximal margin is determined by the absence of wall thickening due to diverticulitis. The type of anastomosis is done according to the preference of the operating surgeon. A loop ileostomy can be fashioned in order to ensure faecal deviation to the discretion of the surgeon.
45503359|NCT01317485|Procedure|Sigmoidectomy with end-colostomy|[OPEN] This is a two-stage procedure with the intention to close the colostomy in a second stage. During the primary surgery, only the perforated diseased part must be resected. There is no need of having the distal transsection line on the proximal rectum.
45503360|NCT03612882|Other|Online questionnaire|Online questionnaire assessing sedentary behaviour, physical activity, subjective well-being, life satisfaction, depression, anxiety, and demographics
45503361|NCT03560024|Other|PACAP27|PACAP27 is vasodilator of cerebral vessels
45395048|NCT03981276|Other|Clinical rating scale to measure disease severity and progression|A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.
45503362|NCT03560024|Other|Placebo|Saline
45849123|NCT00000942|Drug|Nevirapine|
45849124|NCT00000948|Drug|Aldesleukin|Il-2
45849125|NCT00000948|Drug|ART|antiretroviral therapy for the treatment of HIV
45395049|NCT03981276|Diagnostic Test|Next-Gen Sequencing (NGS)|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
45395050|NCT01060514|Drug|Pazopanib|dose escalation, administered orally, daily
45395051|NCT01060514|Drug|Vinorelbine|dose escalation, IV days 1 and 8 of every cycle (cycles begin every 3 weeks)
45395052|NCT03986606|Biological|PSB205|PSB205 is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
45395053|NCT01057550|Procedure|Autologous fascial sling|Retropubic bottom up mid urethral sling made using autologous rectus sheath fascia
45395054|NCT01057550|Procedure|TVT|Standard TVT as described by Ulmsten 1996
45395055|NCT01057550|Procedure|Pelvicol|retropubic mid urethral sling made from Pelvicol
45395056|NCT01061216|Device|Intradermal insulin delivery: BD Research Catheter Set|1 unit/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered) 2 units/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered)
45503363|NCT05102643|Biological|SARS-CoV-2 DNA Vaccine|A novel vaccine developed for prophylaxis of COVID-19 based on HKU's PD-1-based DNA vaccine platform. It encodes a recombinant antigen comprising a soluble human PD-1 domain (i.e. programmed cell death protein, a member of the Cluster of Differentiation 28 (CD28) family) and the receptor binding domain (RBD) of SARS-CoV-2 (i.e. the key viral entry element).
45849126|NCT00000954|Drug|Bleomycin sulfate|
45395057|NCT01061216|Device|Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set|1 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered) 2 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered)
45395058|NCT00314574|Drug|omalizumab (Xolair)|Omalizumab (Xolair) was administered by subcutaneous (SC) injection every 2 or 4 weeks. Xolair was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that were reconstituted with Sterile Water for Injection (SWFI), USP.
45395059|NCT00314574|Drug|placebo|Placebo was administered by subcutaneous (SC) injection every 2 or 4 weeks. Placebo contained the same ingredients as the lyophilized formulation of Xolair,excluding omalizumab.
45395060|NCT00314574|Drug|corticosteroids|Minimum dose of 500 µg of fluticasone dry-powder inhaler or its equivalent ex-valve dose twice a day.
45395061|NCT00314574|Drug|long-acting beta-agonists|50 µg salmeterol twice daily or 12 µg formoterol twice daily.
45395062|NCT01064154|Drug|Carvedilol|Carvedilol Tablets 25 mg
45395063|NCT00314340|Behavioral|Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity|The first dose of the study medication was taken following collection of baseline measurements, and subsequent measurements were taken hourly thereafter. Respiration, heart rate, arterial oxygen saturation (pulse oximetry), and blood pressure were also monitored at these intervals to insure the safety of subjects.
45395064|NCT00314340|Drug|ER Morphine|
45395065|NCT00314340|Drug|hydrocodone plus acetaminophen|
45395066|NCT00314340|Drug|placebo|
45697051|NCT05688423|Behavioral|Treatment as Usual|Participants assigned to the TAU group will receive the standard treatment for their severe injection-related infection and substance use disorder at each hospital. While TAU may differ between sites, it is typically comprised of a patient being cared for primarily by a hospital medicine physician (hospitalist) with consultation by infectious diseases (ID) and either psychiatry or addiction medicine physician. If the ID or addiction teams believe post-hospitalization follow up is indicated, each service will follow local protocols for arranging post-discharge continuation of care.
45395067|NCT00306852|Procedure|Baerveldt implant|Patients will be randomized to receive a 350 mm^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)
45697052|NCT03018652|Drug|Intravenous immunoglobulin|IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
45395068|NCT00306852|Procedure|Trabeculectomy with mitomycin C|Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm^2 Baerveldt glaucoma implant
45395069|NCT00314262|Drug|Erlotinib & Celecoxib|"Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg) continuously for 6 months in the phase I portion.~Celecoxib given 400 mg orally BID continuously for 6 months."
45697053|NCT03018652|Drug|Normal Saline|5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
45395070|NCT00333866|Drug|pregabalin|600mg/day
45395071|NCT00333866|Drug|pregabalin|450mg/day
45395072|NCT00333866|Drug|pregabalin|300mg/day
45395073|NCT00333866|Drug|placebo|placebo
45395074|NCT00324740|Drug|vorinostat|Given orally
45395075|NCT00324740|Drug|isotretinoin|Given orally
45395076|NCT00333788|Biological|Certolizumab pegol (CDP870)|400 mg subcutaneous (sc) injection of Certolizumab pegol (CDP870) every 2 (Q2W) or 4 (Q4W) weeks
45503364|NCT05102643|Biological|Matching placebo|Solution for intramuscular injection
45503365|NCT01351441|Behavioral|Medication adherence consultation|Patients will be counseled in person on day 0 then telephonically every month after until day 365.
45395077|NCT00324116|Drug|pegaptanib sodium (Macugen)|0.3 MG/eye pegaptanib IB sodium by intravitreous injection given every 6 weeks for 54 weeks.
45395078|NCT00332696|Drug|Octreotide LAR|Octreotide long-acting release (LAR) 30 mg intramuscular injection.
45395079|NCT00332696|Drug|Octreotide (Immediate release)|Immediate-release Octreotide supplied in 100 µg/mL ampules.
45395080|NCT00332696|Drug|methylprednisolone|methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections).
45395081|NCT00332696|Drug|Placebo|Physiologic saline solution
45503366|NCT01351441|Other|Medication problems assessment|Patients will be asked if they are having any issues that may be attributable to their current drug therapy on a monthly basis. Any issue that is identified will be addressed by the pharmacist.
45503367|NCT01351441|Other|Beer's Criteria Assessment|The patient's drug therapy will be reviewed for Beer's criteria medications and possible alternatives will be addressed by the pharmacist if deemed appropriate.
45503368|NCT01351441|Behavioral|Health Literacy Assessment|Patients will be given a Health Literacy Assessment on day 0 and day 365 using the Realm-SF.
45503369|NCT04725474|Biological|CTL-002|monoclonal antibody
45503370|NCT02260232|Other|exercise training|
45395082|NCT00313716|Drug|recombinant human erythropoietin, rhEpo|The study design is 2x2 factorial with randomization to erythropoietin or placebo and to transfusion trigger 10 gm/dl or 7 g/dl. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (first 74 patients, Epo1 dosing regimen), and then the 24- and 48-hour doses were stopped for the remainder of the patients (remaining 126 patients, Epo2 dosing regimen).
45395083|NCT00313716|Other|placebo|an inactive substance
45395084|NCT00313170|Drug|Fulvestrant|intramuscular injection 250 mg & 500 mg
45395085|NCT00332462|Drug|Cyclosporine (Sandimmun® i.v.)|Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
45395086|NCT00332462|Drug|Cyclosporine (Sandimmun® Optoral)|Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
45395087|NCT03986450|Other|Enhanced recovery after surge(ERAS) protocol|"The components of ERAS multidisciplinary pathway concerning preoperative, operative, and postoperative period are as follows:~Preoperative care:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis~Perioperative care:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia~Postoperative care:~Application of midthoracic, epidural anesthesia/analgesia Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization"
45395088|NCT00324038|Drug|Buprenorphine|buprenorphine transdermal system 5, 10 and 20 mg
45395089|NCT00324038|Drug|Codeine paracetamol|combination tablet of codeine and paracetamol taken orally 3 or 4 times daily. Dosage form ranges from 8/500, 15/500 and 30/500
45395090|NCT03984110|Drug|Ozurdex|Intravitreal injection
45395091|NCT03984110|Drug|Eylea|Intravitreal injection
45395092|NCT00159861|Drug|Sildenafil citrate|
45395093|NCT01057628|Drug|ipragliflozin|oral
45395094|NCT01057628|Drug|placebo|oral
45395095|NCT03967821|Other|Questionnaire|Each patient complete FQoR-15 questionnaire 3 times (before surgery, on Day 1, on Day 2)
45395096|NCT00331760|Drug|cisplatin|
45395097|NCT00331760|Radiation|intensity-modulated radiation therapy|
45395098|NCT00225147|Drug|Recombinant Human C1 Inhibitor|IV
45395099|NCT00225147|Drug|placebo|saline solution
45395100|NCT00313014|Drug|Buprenorphine|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
45503371|NCT05095857|Drug|S-ketamine|S-ketamines is an NMDA-receptor antagonist with sedative and analgesic properties. It will in the present trial be given in sedative doses (2-3 mg/kg/hour) in case of clustered SDs following a dosing algorithm according to SD occurrence.
45395101|NCT00313014|Drug|Buprenorphine|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
45395102|NCT00313014|Drug|Oxycodone Immediate-Release|Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).
45395103|NCT01075659|Drug|Nicotine|Two single doses of experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period
45395104|NCT01075659|Drug|Nicotine|Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
45395105|NCT01075659|Drug|Nicotine|Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
45395106|NCT01077453|Drug|letrozole|Given orally
45395107|NCT01077453|Other|quality-of-life assessment|Ancillary studies
45395108|NCT01077453|Other|laboratory biomarker analysis|Correlative studies
45395109|NCT00157209|Biological|Tecemotide (L-BLP25)|After receiving single low dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until discontinuation from the study due to ECOG status of 4, participation in alternate trial, serious adverse event, or reasons that preclude assessment of clinical status in the opinion of the investigator, and in case of unavailability of study vaccine.
45849127|NCT00000954|Drug|Vincristine sulfate|
45395110|NCT00157209|Drug|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
45395111|NCT00157209|Other|Best Supportive Care (BSC)|The BSC will be provided at the investigator's discretion, and may include palliative radiation, psychosocial support, analgesics and nutritional support. Second-line chemotherapy is permitted when indicated for treatment of progressive disease.
45395112|NCT00312858|Biological|Comparator: VAQTA™ (Hepatitis A vaccine)|VAQTA™ 0.5 mL injection
45503372|NCT05095857|Other|Isotonic saline (placebo)|Isotonic saline has the same appearance as S-ketamine with both being clear liquids with no bubbles or other distinguishing features.
45503373|NCT01319227|Procedure|Hip replacement|Hip arthroplasty with uncemented components
45503374|NCT02067962|Biological|Blood sample|Blood sample
45849128|NCT00000954|Drug|Doxorubicin hydrochloride|
45395113|NCT00312858|Biological|Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine)|ProQuad™ 0.5 mL injection
45395114|NCT00312858|Biological|Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine)|Prevnar™ 0.5 mL injection
45395115|NCT03972189|Drug|TQ-B3101|TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.
46057008|NCT04037085|Drug|Ketamine|Subjects in the intervention arm will receive infusion dosing as noted in arm/group descriptions at the time of cord clamping. Duration of infusion will be 12 hours. Concentrations of ketamine and ketamine metabolites (nor-ketamine, NKET; and dehydro-nor-ketamine, DHNK) are measured in maternal plasma and urine as well as breastmilk. Maternal side effects, adverse events, and efficacy endpoints will be measured over the 12 hour infusion and over 15 hours after infusion discontinuation.
46057009|NCT00914056|Drug|lactulose|withdrawal of lactulose
46057010|NCT04568122|Device|Saliva test kit|Kit including tube with closed reagents using loop-mediated isothermal amplification (LAMP) assay to detect SARS-CoV-2 virus.
45503375|NCT03613272|Procedure|Subxiphoid approach extended thymectomy by VATS|Extended thymectomy performed through the subxiphoid-right VATS approach with double elevation of the sternum
45503376|NCT03613272|Procedure|Intercostal approach extended thymectomy by VATS|Extended thymectomy performed through the traditional intercostal VATS approach
45697054|NCT03387813|Device|CardioMEMS™ HF System|The CardioMEMS™ HF System is comprised of a lead-less, battery-less pressure sensor permanently implanted in the PA, which remotely transmits PA pressure measurements from the patient's home to a secure website. Healthcare professionals are able to access these measurements and associated waveforms to remotely guide individualization of medical management for their patients with chronic HF.
45697055|NCT04353700|Behavioral|Yoga group|During the in-home yoga intervention, participants performed 30 to 50 minutes of yoga postures three to five times a week for 12 weeks, including 5 minutes of warm-up exercise, 15 to 30 minutes of dynamic flow yoga postures, 10 minutes of weight barring standing postures, and 5 minutes of cool-down. These in-home sessions were a repeat of what participants learned during the first week of training session at UML. We progressively increased the intensity of the home practice sessions by adding the number of sun salutation (SS) over the 12 weeks.
45697056|NCT04353466|Procedure|quantitative chemical shift imaging (QCSI)|"Poor scores of QCSI with Fat Fraction below the cut off point of 0.3 which is considered bone at risk"
45697057|NCT04353466|Drug|Elelyso|intravenous (IV) infusions of Elelyso
45395116|NCT00312702|Biological|Falciparum Malaria Protein 11 with AS02A adjuvant|vaccine
45395117|NCT01060878|Drug|PYM50028|IMP
45395118|NCT01060878|Drug|Placebo|Matching placebo comprising identical vehicle to active doses
45503377|NCT05250479|Behavioral|Mindfulness education|44 primiparous pregnant women will receive mindfulness education
45697058|NCT03018496|Dietary Supplement|Beta-Hydroxy-Beta-Methylbutyrate|
45697059|NCT03018496|Other|Placebo|
45697060|NCT00966238|Biological|VAX125|STF2.HA1(SI) (VAX125), which is a recombinant fusion protein that consists of Salmonella typhimurium flagellin type 2 (STF2), a Toll-like receptor 5 (TLR5) ligand, fused at its C-terminus to the globular head domain of the hemagglutinin (HA) antigen of influenza A HA1 Solomon Islands (SI).
45697061|NCT01012336|Drug|Aprepitant/Ramosetron/Dexamethasone|"Aprepitant: The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3.~Ramosetron: 0.3 mg i.v. a single dose on day 1, administered over 30 seconds, 30 minutes prior to chemotherapy.~Dexamethasone: 20mg diluted in 50ml of 0.9% saline i.v. a single dose on day 1, administered over 30minutes prior to chemotherapy (taxane). Because all patients are premedicated with dexamethasone 20 mg before taxane administration, the dose of dexamethasone can not be reduced to 12 mg."
45697062|NCT00966550|Other|Tomato|Tomato with high carb/fat meal
45849129|NCT00000954|Drug|Zalcitabine|
45849130|NCT00000954|Drug|Didanosine|
45849131|NCT00000960|Drug|Zidovudine|
45395119|NCT00156819|Drug|fluticasone|fluticasone (100 microgram twice daily) treatment
45395120|NCT00156819|Drug|montelukast|Montelukast (5 or 10 mg each night).
45395121|NCT00156819|Drug|Fluticasone plus salmeterol|fluticasone (100 microgram) plus salmeterol (50 microgram) each night
45395122|NCT02532894|Device|Electronic cigarette|Inhaling e-cigarette vapor
45503378|NCT01355653|Device|thermal therapy|heat therapy device, topical, two applications, at 0-3 hours and 4-6 hours on treatment day
45503379|NCT01355653|Device|marketed heatwrap|heatwrap, topical, one time application, 8 hour duration
45503380|NCT05033223|Other|PTSD evaluation of emergency room staff 9 and 12 months after the end of second lockdown in France during COvid-19 pandemic|PCL-5 autoquestionnaire to make the PTSD diagnosis
45697063|NCT00966550|Other|Non-tomato|Non-tomato with high carb/fat meal
45849132|NCT00000984|Drug|CD4 Antigens|
45849133|NCT00000990|Drug|Zidovudine|
45849134|NCT00000996|Drug|Doxorubicin hydrochloride|
45849135|NCT00001026|Biological|gp160 Vaccine (Immuno-AG)|
45849136|NCT00001026|Biological|rgp120/HIV-1IIIB|
45849137|NCT00001026|Biological|rgp120/HIV-1MN|
45849138|NCT00001026|Biological|rgp120/HIV-1 SF-2|
45849139|NCT00001026|Biological|HIVAC-1e|
45849140|NCT00001044|Biological|Aluminum hydroxide|
45849141|NCT00001044|Biological|QS-21|
46057011|NCT02715219|Other|Asthma Education Programme|The Asthma Education Programme consists of four items. 1. Education video for Asthmatic patient adapted from Info Sehat by Bahagian Pendidikan Kesihatan Kementerian Kesihatan Malaysia which is explaining about Asthma disease, medication and patient responsibility in Asthma management. 2. Small group discussion with subject's to help them understand better in Asthma management. 3. Face to face demonstration and teaching of inhaler technique by three trained nurse in small group range of two to five subjects. At the end of the AEP subject will received a 4. Pamphlet will be obtain from Patients' Education Unit in Ampang Hospital containing vital information about Asthma disease and management. The intervention estimated will take 1 hour to 1 hour 30 minutes to be completed.
46057012|NCT02714907|Device|Cortrium C3 device|Data is read from Cortrium C3 monitor
45395123|NCT01077531|Drug|Otelixizumab|Otelixizumab injection for intravenous infusion. Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).
45395124|NCT01077531|Drug|Matching placebo|Matching placebo for intravenous infusion
45395125|NCT03825042|Dietary Supplement|A mix of bioactive natural compounds|A mix of bacopa, lycopene, astaxanthin and vitamin B12 in oral tablets
45395126|NCT03825042|Dietary Supplement|Placebo|Inactive compound in oral tablets
45395127|NCT01060956|Other|reporting of two different bacteria in urine culture|reporting of two different bacteria in urine culture
45395128|NCT01060956|Other|"reporting mixed growth on urine culture"|"reporting mixed growth on urine culture"
45395129|NCT00129987|Behavioral|Self management education|
45697064|NCT03387501|Drug|Plasma rich in growth factors (PRGF-Endoret)|Intrauterine administration of PRGF
45697065|NCT01012492|Drug|Abatacept|Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
45849142|NCT00001044|Biological|rgp120/HIV-1MN|
45849143|NCT00001056|Biological|gp160 Vaccine (Immuno-AG)|
45395130|NCT00224133|Drug|Silodosin|8 mg daily
45395131|NCT00224055|Drug|Sodium Ferric Gluconate Complex in Sucrose Injection|Sodium Ferric Gluconate Complex in Sucrose Injection (Ferrlecit®), 250 mg IV weekly for 4 weeks
45395132|NCT00224055|Drug|Ferrous sulfate tablets|ferrous sulfate, 325 mg oral, three times daily for 6 weeks
45395133|NCT00150969|Dietary Supplement|vitamin K1 (phylloquinone)|
45395134|NCT00150969|Dietary Supplement|placebo|1 pill daily
45395135|NCT03966573|Radiation|Radiographic imaging|Evaluating arthritis in knee and hip bilaterally. Evaluating axis deficiancy and leg length discrepancy.
45395136|NCT03966573|Other|Evaluating function|Test function and physical capasity
45395137|NCT03966573|Other|Forms|Forms for evaluating quality of life, pain, function
45395138|NCT00150345|Drug|voriconazole (Vfend)|voriconazole, early treatment
45503381|NCT02032368|Procedure|transarterial chemoembolization (TACE)|
45697066|NCT05688345|Drug|Remimazolam|The patient receives continuous infusion of remimazolam at a rate of 0.3-1.0 mg/kg/hr.
45697067|NCT05688345|Drug|Propofol|Patients are administered propofol at an effective site concentration of 1.0-2.5 mcg/ml through target-controlled infusion.
45697068|NCT05688345|Drug|Dexmedetomidine|The patient is administered a dose of dexmedetomidine at 1 mcg/kg for 10 minutes, followed by continuous infusion at a rate of 0.2-1.0 mcg/kg/hr.
45697069|NCT03016624|Device|OCT guided PCI|oct guided
45697070|NCT03016624|Device|Angiography guided PCI|angio guided
45395139|NCT00150345|Drug|voriconazole (Vfend)|voriconazole, deferred treatment
45395140|NCT01582737|Drug|Rivaroxaban(Xarelto, BAY59-7939)|Patients treated with Xarelto under practical manner
45395141|NCT01077609|Drug|Intermittent, sub-chronic and chronic Flixonase use|Intermittent exposure episode is a series of fewer than four sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
45503382|NCT01351519|Drug|Aminolevulinic Acid|Aminolevulinic Acid will be administered as a single oral dose of 20mg/kg given in 50ml of water three hours before surgery.
45503383|NCT03612492|Drug|Esmolol|Esmolol group (EG) will receive a bolus of esmolol 1.5mg / kg in 10 min following by continuous infusion at a rate of 0.1mg / kg / min.
45503384|NCT03612492|Drug|Lidocaine|Lidocaine (LG) group will received lidocaine bolus of 1.5mg / kg in 10 min following by continuous infusion at a rate of 1.5mg / kg / h.
45503385|NCT04970199|Device|laser application on acupoints|laser acupuncture
45503386|NCT05250401|Diagnostic Test|liver functions and thyroid functions|laboratory tests
45503387|NCT03612414|Dietary Supplement|Aqualief|Three tablets/day
45503388|NCT03612414|Dietary Supplement|Placebo|Three tablets/day
45697071|NCT03083457|Drug|Fluid resuscitation or amine administration|Fluid administration or amine administration if deemed necessary by the attending physician. Haemodynamics will be monitored through noninvasive cardiac output assessment by arterial pulse contour analysis
45849144|NCT00001062|Drug|Ganciclovir|
45849145|NCT00001068|Drug|Lamivudine|
45849146|NCT00001080|Biological|Influenza Virus Vaccine|
45849147|NCT00001080|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|
45849148|NCT00001080|Drug|Lamivudine|
45849149|NCT00001104|Drug|Zidovudine|
45849150|NCT00001110|Procedure|Bronchoalveolar lavage|
45503389|NCT01359163|Drug|etynodiol diacetate|tablet, 0.5 mg, single dose
45503390|NCT01359163|Drug|etynodiol diacetate|tablet, 0.5 mg, single dose
45503391|NCT04952493|Drug|Anlotinib hydrochloride|Anlotinib hydrochloride may stop the growth of tumor cells and improve iodine uptake.
45503392|NCT04952493|Drug|Sodium Iodide I 131|RAI treatment may shrink the tumor
45395142|NCT01077609|Drug|Intermittent, sub-chronic and chronic use of intranasal steroids other than Flixonase|Intermittent exposure episode is a series of fewer than four sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for an intranasal steroid other than Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
45503393|NCT04952493|Drug|Penpulimab|Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC.
45395143|NCT00223977|Drug|Sodium Ferric Gluconate Complex|125 mg weekly x 8 weeks
45395144|NCT00223977|Drug|Sodium Ferric Gluconate Complex|250 mg weekly x 4
45395145|NCT00223977|Drug|Oral Iron|325 mg ferrous sulfate orally three times daily x 8 weeks
45395146|NCT01326273|Procedure|Lymphopheresis|Lymphopheresis
45395147|NCT01326273|Procedure|CMV specific lymphocyte infusion|CMV specific lymphocyte infusion
45395148|NCT01326273|Procedure|Peripheral blood for CMV DNA PCR|Peripheral blood for CMV DNA PCR
45395149|NCT01326273|Procedure|Haematology/Blood chemistry|Haematology/Blood chemistry analysis, Collection of blood for ancillary laboratory tests.
45503394|NCT03730337|Drug|ONO-7475|ONO-7475 specified dose on specified days
45503395|NCT03730337|Drug|ONO-7475 + ONO-4538|ONO-7475+ONO-4538 specified dose on specified days
45503396|NCT04717674|Drug|[18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid)|[18F]FPIA radiotracer administration
45503397|NCT04717674|Procedure|PET/CT|PET/CT scan
45503398|NCT01351597|Drug|docetaxel/ oxaliplatin|"docetaxel - 75 mg/m2 with D5W250ml IV (in the vein)over 1 hr, every 3 weeks~oxaliplatine - 70 mg/m2 with D5W250ml IV (in the vein)over 2 hrs, every 3 weeks"
45503399|NCT04951245|Procedure|UC group: ultrasound-assisted CNSs guided|1ml of CNSs was subcutaneously injected into the areolar area in the upper outer quadrant of the breast. The injection site was massaged for 15 minutes to promote drainage of the tracer to the axilla. During the intraoperative ultrasound-assisted procedure, an ultrasound diagnostic system was used. Before the incision, ultrasound-guided exploration of SLNs was performed by placing the probe on the lateral border of the breast and sliding cranially along the lateral border of the pectoralis major muscle . A sterile skin marker was then used to mark the optimal site of incision over the targeted lymph nodes, and the distance from the skin to the nodes was measured by ultrasound and recorded in millimeters. Blunt dissection was carried out to identify the CNSs-stained nodes around the marked region. Ultrasonography probe was placed repeatedly in or around the wound at different angles for adequate visualization if SLNs could not be localized with further dissection.
45697072|NCT03083457|Drug|General anesthetic|Total intravenous anesthesia with a standard protocol
45697073|NCT03083457|Drug|Fluid administration|3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure
45697074|NCT03083457|Procedure|Low-tidal volume ventilation|Volume-control ventilation with tidal volume=7 ml/kg of predicted body weight for the entire surgical procedure. Respiratory rate will be set to maintain EtCO2 within a physiological range and kept unchanged for the entire duration of the study
46057013|NCT02714907|Device|Holter device|Date is read from Holter device
45395150|NCT00148941|Biological|SB213503 lot 1|SB213503 lot 1 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
45395151|NCT00148941|Biological|SB213503 lot 2|SB213503 lot 2 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
45395152|NCT00148941|Biological|SB213503 lot 3|SB213503 lot 3 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
45395153|NCT00148941|Biological|Infanrix|Infanrix vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
45395154|NCT00148941|Biological|IPOL|IPOL vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
45395155|NCT00148941|Biological|M-M-R II|M-M-R II vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
45395156|NCT01073553|Drug|Cephalexin capsules (Optocef, BAYO5448 )|Single dose of 500 mg (One 500 mg capsule)
45395157|NCT01073553|Drug|Cephalexin capsules (Keflex)|Single dose of 500 mg (Two 250 mg capsules)
45395158|NCT00148317|Drug|Bortezomib|During Induction Phase (6 cycles): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 During 21-day mobilization cycle (1 cycle): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11
45849151|NCT00001122|Drug|Nelfinavir mesylate|
45849152|NCT00001122|Drug|Efavirenz|
45395159|NCT00148317|Drug|dexamethasone|During Induction Phase (6 cycles): dexamethasone 40 mg on days 1-4, 8-11, and 15-18
45395160|NCT00148317|Drug|liposomal doxorubicin|If patients achieve less then a PR during the induction phase after 2 cycles, or less then a CR after 4 cycles: Liposomal doxorubicin was added at 30 mg/m2 on day 4 for the remaining cycles
45395161|NCT00148317|Drug|cyclophoshamide|During the 21 day mobilization phase (1 cycle): cyclophosphamide at 3 g/m2 on day 8
45395162|NCT00148317|Drug|filgrastim|During the 21 day mobilization phase (1 cycle): 10 μg/kg/day for 10 consecutive days starting 24 hours after cyclophosphamide administration on day 9
45395163|NCT01077765|Device|Eutrophill|Polyacrylamide Hydrogel
45395164|NCT00323882|Drug|MDX-010|selected dose administered IV every 3 weeks
45395165|NCT00331682|Drug|alvocidib|Given IV
45395166|NCT00331682|Drug|docetaxel|Given IV
45395167|NCT00323492|Drug|Truvada|Truvada + NNRTI or PI.
45395168|NCT00323492|Drug|Current HAART regimen|Maintain baseline regimen
45395169|NCT00331136|Drug|Pyronaridine-Artesunate|Once a day for 3 days
45395170|NCT03983798|Other|Simulation training in psychiatry|"Each participant will complete 6 hours of psychiatric simulation training, dealing with mood disorders, anxious disorders, eating disorders, borderline disorders, substance abuse and schizophrenia. Simulation training will be supplemented by brief lecture on concept map and portfolio at the beginning of the first hour.~Curriculum integration of simulation training in psychiatric course assure that each pathology studied is supplemented by a one-hour lecture and 1 to 3 hours clinical cases and MCQ training. A part of the medical students are supplemented by clinical practice ; whereas the other won't benefit from clinical practice."
45395171|NCT01057706|Other|chiropractic|spinal manipulation and mobilization
45395172|NCT01057706|Behavioral|exercise|strengthening, stretching, balance
45395173|NCT00323414|Drug|Polyunsaturated fatty acid (Opti-EPA)|Active experimental arm to patients with diabetes mellitus and non alcoholic steatohepatitis: Eicosapentaenoic acid (EPA):Docosahexaenoic acid (DHA)[360 mg EPA and 240 DHA in each capsule] 6 capsules-3 capsules by mouth 2 x per day x 48 weeks
45395174|NCT00323414|Drug|Placebo|Placebo gelcaps containing corn oil identical to the PUFA gelcaps 6 capsules-3 capsules by mouth 2x per day x 48 weeks
45395175|NCT03984032|Device|LMA Protector Cuff Pilot|Assessing the clinical performance of LMA Protector Cuff Pilot
45395176|NCT03984032|Device|LMA Supreme|Assessing the clinical performance of LMA Supreme
45395177|NCT01325324|Device|measurement of intraocular pressure|Intraocular pressure will be measured with the following devices (each 2 times)at the first and only study visit
45395178|NCT03983642|Device|Wii balance board|"Numerous video games exist to interact with the Wii Balance Board. One game that has been used in prior balance studies is Wii Fit.~On the first 4 weeks, balance training started with Soccer Heading game. The participants were asked to control their avatar by leaning to left or to the right in order to avoid the objects that were thrown towards them, and try to score the balls inside the net. The participants performed 3 sets of 5 rounds (2min each), totaling 30 min, and rested for 1 min between each set.~Table Tilt game continued for the remaining 4 weeks. Participants tried to enter balls into the holes by shifting their body weight on the balance board causing it to tilt in all directions. This game was divided into multiple levels of 30 seconds each, repeated over 30 min, with a one-minute rest interval between every 10 minutes of training. Moreover, 20 extra seconds were added each time a participant has won a level."
45395179|NCT00330668|Drug|rh IGF-1 (mecasermin)|Patients from untreated arm for prior study MS301 (NCT00125164) were randomized to a dose of either 80 or 120 mcg/kg twice daily. For patients receiving active treatment in previous study MS 301 (NCT00125164), they started on a dose of 80 or 120 mcg/kg twice daily based on the dose reached at end of the previous study. Following a protocol amendment in May 2009, all patients were switched to once daily doses of 160 µg/kg, escalated to a targeted maximum dose of 240 µg/kg.
45395180|NCT00306384|Drug|Alogliptin|Alogliptin tablets.
45395181|NCT01062750|Biological|adipose tissue derived stromal cells dosage|single administration of autologous adipose tissue derived stroma cells via intrahepatic arterial catheterization
45697075|NCT03083457|Procedure|Scheduled recruiting maneuvers|Pressure-control ventilation inspiratory pressure=10 cmH2O. Steplike 5-cmH2O-PEEP increase every 30 seconds to achieve a peep of 35 cmH2O, followed by 5-cmH2O-PEEP reduction every 30 seconds to set PEEP
45849153|NCT00001122|Drug|Stavudine|
45395182|NCT03980964|Device|Active NMES|Daily home-based, mobile-app controlled, neuromuscular electrical stimulation (NMES) therapy
45849154|NCT00001122|Drug|Didanosine|
45395183|NCT01062828|Diagnostic Test|Citrulline samples|Citrulline samples will be collected at the time of other lab work twice a week from enrollment until 40 weeks postconceptional age and once a week until 44 weeks postconceptional age (1 month corrected age) OR discharge from NICU(whichever is soonest). In subgroup developing NEC, citrulline samples will be collected twice a week from enrollment until discharge from NICU or death.
45395184|NCT01062906|Drug|Lidocaine|1.5 mg/Kg as bolus and a continuous infusion of 2mg/Kg/hr until the end of surgery (closure of the skin)
45395185|NCT01062906|Drug|Fentanyl|Fentanyl 3 mcg/Kg as bolus at the induction and a continuous infusion of normal saline (NaCl 0.9%) until the end of surgery (skin closure)
45395186|NCT00305604|Drug|sitagliptin phosphate|Once daily (q.d.) administration of sitagliptin 100 mg tablet (or 50 mg based on creatinine clearance). For up to a 24-wk treatment period.
45395187|NCT00305604|Drug|Comparator: Placebo|sitagliptin matching placebo for up to a 24-wk treatment period.
45395188|NCT03979014|Biological|Gardasill 9™ vaccine|3 doses of Gardasill 9™ vaccine 0.5 ml administered 3 times at 0, 2 and 6 month
45395189|NCT01064232|Drug|Risperidone|Risperidone Tablets 1 mg
45395190|NCT03979092|Behavioral|IP-ACLS|"Three senior consultants and 12 trainers conduct 2-day IP-ACLS training.~Pre-class activities: preparation First exposure reading on provider manual and lecturer notes about a new knowledge of ACLS to enhance self-directed learning.~Interactive lecture sessions: 10 topics Interactive lectures (15-20 minutes per topic) introduce a new knowledge, which anchor to their existing knowledge according to ACLS algorithms.~Simulation sessions: 10 sessions Skill sessions (50 minutes per session) used high-fidelity simulation mannequin in a team approach. Students learn through role-playing with different practical scenarios. Experiential learning is focused on hands-on and collaborative strategies for enhancing a deeper learning.~Debriefing: feedback and reflection Trainers provide immediate feedback and discussion throughout the scenarios. Debriefing is focused on the positive aspect and areas for improvement."
45395191|NCT03979092|Behavioral|Waitlist|Waitlist group will participate in subsequent IP-ACLS training.
45395192|NCT00501059|Drug|Aspirin (Acetylsalicylic acid, BAYE4465)|100mg enteric coated Aspirin, taken daily
45395193|NCT00501059|Drug|Placebo|Placebo, taken daily
45395194|NCT00344318|Biological|Pneumococcal conjugate vaccine GSK1024850A|3 Intramuscular injections.
45395195|NCT00344318|Biological|Prevenar|3 Intramuscular injections
45395196|NCT00344318|Biological|Tritanrix-HepB|3 Intramuscular injections
45395197|NCT00344318|Biological|Hiberix|Reconstituted with Tritanrix before injection
45395198|NCT00344318|Biological|Polio Sabin.|3 oral doses.
45395199|NCT00344318|Biological|Poliorix.|3 intramuscular injections
45395200|NCT00323258|Behavioral|oral education & written tips for remembering medications|Clinical pharmacist will review purpose of medications of interest (beta-blockers, statins, Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB), aspirin, and other anti-platelets) with the subject. A written list of tips for remembering medications will be provided and reviewed.
45395201|NCT00323258|Device|pill box|Subject is provided a pill box and briefly instructed on how to use the box.
45395202|NCT00323258|Device|pocket medication card|Subject is provided with a card that contains space for prescription and non-prescription medications. If desired the clinical pharmacist-investigator will complete the card for the subject.
45395203|NCT00323258|Behavioral|sharing information with community pharmacist|A fax is sent to the designated community pharmacy at the time of the subject's discharge from the hospital. The fax contains the subject's medications of interest, barriers to medication adherence, and physicians' contact information.
45395204|NCT00323258|Behavioral|Medication use evaluations by community pharmacist|The community pharmacist will assess use of medications of interest at time of first medication fill and by reviewing the subject's computerized medication profile at the pharmacy. Assessments occur at first visit to pharmacy, 6-weeks, 12-weeks, 18-weeks, and 24-weeks. If there are issues with any medications of interest the subject will be called. If needed, the subject's health care team will be notified.
45395205|NCT00323258|Behavioral|informing physician if patient has stopped a medication|The community pharmacist or clinical pharmacist-investigator will fax the subject's physician to notify that a medication has been stopped.
45395206|NCT00323258|Behavioral|Routine discharge counseling|Both groups received routine discharge counseling performed by the patient-care nurse.
45395207|NCT00323258|Other|Letter to physician/discharge summary|A letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations.
45395208|NCT00322868|Drug|pioglitazone|All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily.
45395209|NCT01016717|Drug|Omeprazole|All patients will be taking omeprazole (Losec, Abic Inc., Israel) tablets 40 mg QD for 30 days
45395210|NCT01016717|Drug|Pantoprazole|Pantoprazole tablets (Controloc 40, 40 mg/day, Nycomed, Perrigo Inc., Israel). All patients will take pantoprazole tablets 40 mg QD for 30 days
45395211|NCT01016795|Drug|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
45697076|NCT04348227|Behavioral|Enhanced hygiene measures|Wether or not hygiene measures dictated by the pandemic of severe acute respiratory syndrome coronavirus 19 , reduce multi drug resistant pathogens isolated in endotracheal aspirates.
46057014|NCT02714673|Drug|anticoagulation|anticoagulation refers to any long term effective anticoagulation including antivitamin K, direct oral anticoagulants. Aspirin, clopidogrel are not included
45395212|NCT01016795|Drug|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
45395213|NCT01016795|Drug|Chemotherapy plus Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
45395214|NCT04260737|Other|Decision Aid for Men with Localized Prostate Cancer|The intervention is an interactive decision aid aimed to assist newly diagnosed prostate cancer patients with their treatment management options.
45395215|NCT00343382|Drug|pilocarpine hydrochloride|Given orally
45395216|NCT00343382|Other|placebo|Given orally
45395217|NCT00481871|Drug|Pralatrexate Injection|"Intravenous (IV) push administration over 30 seconds to 5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Sequential Dosing: 10 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 15 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met."
45503400|NCT04951245|Procedure|GC group: CNSs plus ICG dual-tracer-guided|The preparation of CNSs mapping was identical to that of the UC group. 1ml of diluted ICG was subsequently injected into the areolar area in the upper outer quadrant of the breast. A NIR camera was used to visualize the subcutaneous lymph vessels and localized the SLNs. All fluorescent or black-stained lymph nodes along with any palpable suspicious nodes were removed. The remaining surgical field was reexamined to ensure complete resection of fluorescent lymph nodes.
45503401|NCT01347749|Behavioral|Mindfulness & Compassion Meditation-based Exposure Therapy|A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.
45697077|NCT00967486|Procedure|Carotid endarterectomy with routine shount|
45697078|NCT00967486|Procedure|Carotid endarterectomy with selective shunt|
45697079|NCT04348461|Drug|Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells|Two serial doses of 1.5 million adipose-tissue derived mesenchymal stem cells per kg
45697080|NCT04348617|Other|Moderate exercise|50 minutes of moderate exercise on treadmill
45697081|NCT04348617|Other|Rest|50 minutes of rest or sedentary activity
45697082|NCT01013194|Other|Human Fetal Liver Cell Transplantation|"Human Fetal Liver Cell Transplantation. Cell source: Non-purified and non-selected fetal liver cells from fetuses aborted between the 16th and 26th week of gestation.~Infusion technique: Isolation and incannulation of the femoral artery.Splenic artery infusion under radiological guidance.~Cell infusion: between 5 and 10x10^8 cells. Number of sessions: up to 2."
45849155|NCT00001128|Drug|Interleukin-12|
45395218|NCT00481871|Drug|Gemcitabine Hydrochloride|"Gemcitabine will be prepared and administered as an IV infusion as per manufacturer instructions.~Sequential Dosing: 400 mg/m2 every 2 weeks (days 2 and 16) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 600 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met."
45395219|NCT00481871|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
45395220|NCT00481871|Dietary Supplement|Folic Acid|"1 mg orally~Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate."
45849156|NCT00001128|Drug|Paromomycin sulfate|
45849157|NCT00001128|Drug|Azithromycin|
45395221|NCT00329420|Biological|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
45395222|NCT00329420|Biological|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
45395223|NCT00329420|Biological|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 400 mg at Weeks 0, 2 and 4.
45395224|NCT03983174|Procedure|Drainage seton with flap|Seton is placed around the external sphincter then mucosal advancement flap will be constructed
45395225|NCT03983174|Procedure|EAS sparing seton|Rerouting of the seton around the internal sphincter only sparing the external sphincter
45395226|NCT00329108|Drug|ziprasidone hydrochloride|Ziprasidone will be initiated at 80 mg/day on Day 1 and titrated to 120 mg/day from Day 3. From Day 7 the dosage may be adjusted on the basis of clinical status between 120 and 160 mg/day.
45395227|NCT00329108|Drug|olanzapine|Olanzapine will be started at 15 mg/day on Day 1 until Day 7. The dosage will then be adjusted on the basis of clinical status between 15 and 20 mg/day.
45395228|NCT01061294|Procedure|Advanced CustomVue™ iLASIK procedure|
45395229|NCT01061294|Device|WaveScan WaveFront® System, STAR S4 IR™ Excimer Laser System and IntraLase™ FS System|
45395230|NCT00329030|Drug|Autologous transplantation using rituxan/BEAM|Rituxan 375 mg/m2 (Day -19 and Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
45395231|NCT00329030|Drug|Autologous transplantation using Bexxar/BEAM|Bexxar dosimetric dose 5 mCi (Day -19); Bexxar therapy dose 75 cGy TBD (Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
45395232|NCT00328562|Drug|ZD1839 (Iressa)|
45503402|NCT01347749|Behavioral|Present Centered Therapy for PTSD|This 16 week, active group psychotherapy involves PTSD psychoeducation, supportive listening, and focusses on current stressors and PTSD symptoms.
45503403|NCT02793128|Drug|UGN-101 instillations|Treatment with UGN-101 once weekly for a total of 6 times; in a retrograde fashion. Patients who will demonstrate complete response (CR) will be treated with UGN-101 once monthly as a maintenance therapy for a total of 11 instillations or up to the first recurrence whichever comes first.
45395233|NCT00328562|Radiation|Thoracic Radiotherapy|
45395234|NCT00328172|Drug|Placebo|Placebo matching BI 1356
45395235|NCT00328172|Drug|BI 1356 dose 3 once daily|BI 1356 dose 3 once daily
45395236|NCT00328172|Drug|BI 1356 dose 2 once daily|BI 1356 dose 2 once daily
45395237|NCT00328172|Drug|BI 1356 dose 1 once daily|BI 1356 dose 1 once daily
45503404|NCT03612180|Drug|Metoprolol Succinate|Pharmacokinetics
45395238|NCT00328172|Drug|Metformin|Metformin
45395239|NCT01060748|Biological|ACE527|ACE527 comprises a mixture of three live, attenuated ETEC strains; ACAM2025 (CFA/I+ and LTB+), ACAM2022 (CS5+, CS6+ and LTB+), and ACAM2027 (CS1+, CS2+, CS3+ and LTB+). The vaccine is administered orally as a two-dose regimen, at 9x1010 cfu, on Days 0 and 21, in 200 ml CeraVacx buffer. The required volume of each vaccine strain, supplied as a frozen suspension, is mixed into the buffer solution prior to dosing.
45395240|NCT01060748|Biological|Placebo|Placebo
45503405|NCT04400799|Drug|Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml|daily incetion s.c. for 14 days
45395241|NCT01057784|Procedure|Bariatric surgery.|Bariatric Surgery
45395242|NCT01061372|Drug|Placebo|Placebo, orally administered once a day, 1-3 hours before bedtime for 12 weeks
45395243|NCT01061372|Drug|pregabalin|pregabalin 150 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
45395244|NCT01061372|Drug|pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
45395245|NCT00328094|Drug|continuous intravenous insulin infusion|Tight glucose control versus standard of care
45503406|NCT01359241|Procedure|closed-loop insulin delivery|Insulin delivery via subcutaneous pump, adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
45503407|NCT01359241|Drug|Usual diabetes treatment regimen|Usual non-insulin glucose lowering medications
45503408|NCT05250323|Other|observational tests in face-to-face visit|All necessary evaluations will be carried out for data collection. Also, that same day, the investigators will give the device to participants for the 7-day home assessment
45503409|NCT04697238|Device|Weight vest|A vest weighing up to a maximum of 15 kg.
45503410|NCT01347827|Device|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter)of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
45849158|NCT00001182|Procedure|current standard of care treatments|
45395246|NCT00500903|Drug|Alisertib|Alisertib (MLN8237) will be supplied in capsules of 5 or 25 mg and will be given on an empty stomach, with patients remaining nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose. Each dose will be given by mouth with 8 ounces of water for 7 to 21 consecutive days. A 14-day recovery period will follow each dosing period regardless of its duration.
45395247|NCT00295932|Biological|rituximab|Given IV
45503411|NCT01347827|Device|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter) of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
45503412|NCT05383794|Other|Observation of Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
45503413|NCT02068040|Dietary Supplement|CocoaVia|CocoaVia contains flavanols found natrually in cocoa beans. Capsules will contain 250mg of flavanol
45697083|NCT04761237|Drug|Goal-directed fluid therapy (GDET)|Compensatory dilatation was performed firstly and 5ml/kg crystal solution was added within 30min before induction of anesthesia.When SVV≥13%, infusion of colloidal solution 2ml/kg was performed 15-20 minutes.If the increase of SV was≥10% after the liquid impact and the SVV was still≥13%, the colloidal solution was used again for 2mL/kg and the infusion was maintained until the SVV < 13%.The infusion was stopped when the SVV < 10%.If the increase of SV was less than 10% or CI < 2.0L/min/m2 after infusion, dobutamine was given intravenously to observe the change of SV. If the increase of SV was greater than 10%, dobutamine could be maintained and the above fluid regimen continued.If the increase of SV was less than 10% and MAP≥65mmHg, the infusion of liquid was stopped and replaced with 4ml/kg/h infusion for maintenance.If the increase of SV was less than 10% and MAP was less than 65mmHg, the infusion was suspended.
45503414|NCT02524171|Behavioral|Moral Reconation Therapy (MRT)|MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
45503415|NCT02068196|Procedure|Blood sampling for Pre-existing immunity|Identify predictive biomarkers of long term study survivors who have substantially benefited from ipilimumab therapy
45503416|NCT02068196|Drug|Ipilimumab|
45503417|NCT03612570|Device|Nano-Pulse Stimulation Device|NPS utilizes a timed series of low energy, high voltage nanosecond (billionth of a second) pulses which are applied directly to targeted tissue using small microneedles. NPS energy induces cell signaling and the activation of cellular pathways by creating transient nanopores in cellular membranes and organelles and initiate regulated cell death.
45503418|NCT03142451|Drug|FMX103 minocycline foam 1.5%|Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
45697084|NCT03018262|Device|TMS - sub-study 1|TMS pulses will be applied to the motor hotspot of the surround muscle to identify the TMS-evoked potentials corresponding to motor surround inhibition (SI)
45697085|NCT03018262|Device|TMS - sub-study 2|TMS will be used to stimulate the motor cortex and an inhibitory region of the inferior parietal lobe
45849159|NCT00001188|Procedure|radiation therapy following surgery|
45395248|NCT00295932|Drug|bortezomib|Given IV
45395249|NCT00295932|Drug|cyclophosphamide|Given IV
45395250|NCT00295932|Drug|prednisone|Given orally
45395251|NCT01063140|Biological|Rabies Vaccine (RabAvert)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
45395252|NCT01063140|Biological|Rabies Vaccine (Imovax)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
45395253|NCT00305448|Drug|Fulvestrant|250 intramuscular injection
45395254|NCT00305448|Drug|Fulvestrant|500 mg intramuscular injection
45395255|NCT01063218|Other|Emollient - Cetaphil Advanced|Emollient - Cetaphil Advanced - to be applied twice a day for 20 weeks.
45395256|NCT03979170|Procedure|Lung tumor resection|lung tumor resection
45395257|NCT01066182|Dietary Supplement|DHA (docosahexaenoic acid)|3 x 500 mg capsules per day orally, each capsule providing 200 mg of DHA as a triglyceride. The liquid fill contains DHASCO®-S oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
45395258|NCT01066182|Dietary Supplement|Sunflower oil capsules|The placebo will consist of 3 x 500 mg capsules per day orally containing high-oleic sunflower oil. The dimensions, taste, appearance and colour will be identical to those of the DHA capsules. The shell of the capsule will be the same as the DHA capsule. The liquid fill contains high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitat and rosemary extract (flavouring).
45395259|NCT03981198|Device|Soliton Rapid Acoustic Pulse (RAP)|Treatment of legs and/or buttocks for the temporary improvement in the appearance of cellulite.
45395260|NCT03980652|Procedure|Change of gloves and sterile instruments|Change of gloves and use of separate , sterile instruments before closing the abdominal wall
45395261|NCT00305058|Drug|Morphine|0.05 mg/kg Intravenous
45395262|NCT00305058|Drug|Hydromorphone|0.0075 mg/kg intravenous
45395263|NCT01064388|Drug|AZD9742|IV infusion, 15 days
45395264|NCT01064388|Drug|Placebo|IV infusion, 15 days
45395265|NCT00295854|Drug|MN-001 BID|Eligible patients received 500 mg MN-001 bid
45395266|NCT00295854|Drug|MN-001|Eligible patients received 500 mg MN-001 once daily (qd)
45395267|NCT00295854|Drug|Placebo|Eligible patients received placebo
45395268|NCT00327470|Drug|Pegaptanib Sodium 0.3 mg|Pegaptanib Sodium dosed every 6 weeks in affected eye.
45395269|NCT03983408|Dietary Supplement|Korean Red Ginseng|Participants are provided with 2 Korean Red Ginseng extract tablets twice a day for total 24 weeks.
45395270|NCT03983408|Dietary Supplement|Placebo|Placebo tablets, made of corn starch and cellulose, are manufactured to mimic KRG tablets. Participants are parovided with 2 placebo tablets twice a day for first 12 weeks, following Korean Red Ginseng extract tablets twice a day for another 12 weeks.
45395271|NCT01061450|Drug|Simvastatin|80 mg once a day
45395272|NCT01061450|Drug|Placebo|1 pill once a day
45395273|NCT03983330|Behavioral|Brief Motivational Interviewing (i-BMI)|"The trained RA will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period. They will be given a self-help smoking cessation booklet with Hotline number.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting."
45395274|NCT03983330|Behavioral|Control|Similar to the intervention group, the trained RA will first ask the subjects about the priority of engaging in any desirable health-related lifestyle practice and to state a targeted goal in which they perceive as the easiest to achieve after completing the baseline questionnaires. In addition, the subjects will be given a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention. Subjects will be informed that they will receive follow-up telephone call at 1, 3, 6 and 12 months.
45697086|NCT03018262|Device|TMS - sub-study 3|TMS pulses will be delivered to the primary motor cortex at rest, at the onset of the motor task, or during the motor task
45395275|NCT03986294|Drug|S1 + Nal-IRI|S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an intravenous infusion on day 1 and 15. Courses of treatment will be repeated every 4 weeks.
45395276|NCT03986294|Drug|Nal-IRI+Leucovorin+5-FU|Nal-IRI 80 mg/m2 will be administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hours on days 1-3. Each cycle consists of 14 days. Courses of treatment will be repeated every 2 weeks.
45395277|NCT00322556|Drug|Immunoglobulins Intravenous (Human)|Liquid formulation; treatment schedule every 3 or 4 weeks using an individualized regimen with a dose of 0.2 - 0.8 g IgG per kg bw
45697087|NCT05684835|Procedure|Excision|All patients underwent surgery under general anesthesia and intraoperative neuromonitoring according to the preoperatively predicted NO. Using an anterior cervical approach, the tumor was delineated after identifying the relationships among the great vessels, nerves, and tumors. The NO was confirmed intraoperatively. Sharp dissection was performed meticulously to enucleate the tumor from the NO to preserve most nerve fibers.
45697088|NCT03018184|Other|MRI and Muscle Dynamometer|
45697089|NCT00968032|Device|Nit-Occlud® PFO|Transcatheter implantation of a PFO occluder (Nitinol double Umbrella)
45849160|NCT00001272|Drug|taxol|
45395278|NCT00321932|Dietary Supplement|calcium|All randomized patients (control and study drug) will take 1000 mg of calcium and 400 - 500 International Units (IU) of vitamin D orally each day, beginning as soon as possible after study enrollment. These supplements may be taken either in the morning or in the evening with food. Participants will continue taking the supplements on a daily basis until the final study visit (approximately 12 months after the transplant date).
45395279|NCT00321932|Dietary Supplement|cholecalciferol|Given orally
45395280|NCT00321932|Drug|zoledronic acid|Zoledronic acid (Zometa®) will be administered after randomization (but within 28 days prior to transplant) and at 3 and 6 months after the transplant for a total of 3 doses. The dose of Zometa will be 4 mg intravenous in 100 ml of sterile 0.9% sodium chloride, United States Pharmacopeia (USP), or 5% dextrose, USP infused over a minimum of 15 minutes for patients with a calculated creatinine clearance of ≥60 mL/min. The drug may be administered through a peripheral or a central intravenous line.
45395281|NCT01057940|Procedure|DBE PEJ placement|One time procedure with follow-up telephone call.
45395282|NCT02533310|Other|OST treatment with in-vivo spiders|Subjects are exposed to phobic stimuli with the aid of a trained psychotherapist during a session of maximum 3 hrs duration. The intensity of exposure is increased in four sequential steps, 1. learning to catch a spider with a glass and paper, 2. touching a spider, 3. letting a spider walk on your hand, 4. letting a spider walk on your body. These stages repeat with increasingly larger spiders. The goal of therapy is not absolute symptom reduction but sufficient reduction to allow the individual to expose themselves in everyday situations.
45395283|NCT02533310|Other|VR-OST treatment with virtual spiders|The VR-OST treatment introduces a virtual gamified version of OST treatment using a modern virtual reality headset. Individuals advance themselves through increasing levels of exposure intensity with the assistance of an automated virtual therapist.
45395284|NCT00326612|Drug|Midazolam|Intranasal Midazolam 0.2 mg/kg given once for seizures longer than 5 minutes.
45395285|NCT00326612|Drug|Diazepam|Rectal Diazepam (Diastat) given once for seizure greater than 5 minutes.
45395286|NCT01060826|Other|fisiologic serum|250 microgramos bolus intravenous during 3 minutes and continuous infusion for 4 hours after endoscopic procedure
45395287|NCT01060826|Drug|somatostatin, intravenous bolus|250 microgramos bolus intravenous in 3 minutes and continuous infusion for 4 hours after endoscopic
45395288|NCT01060826|Drug|somatostatin|Intravenous bolus 250 micrograms
45395289|NCT00325130|Biological|Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine|"Quadrivalent HPV vaccine was provided by the SPONSOR in single-dose vials containing a volume of 0.75 mL. The vaccine was administered as a~0.5-mL intramuscular dose at Day 1, Month 2, and Month 6."
45395290|NCT00325130|Biological|Comparator: Menactra™ (Concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Day 1
45395291|NCT00325130|Biological|Comparator: Adacel™ (Concomitant)|a single administration of 0.5 mL intramuscular injection administered in a limb opposite that of quadrivalent HPV injection at Day 1
45395292|NCT00325130|Biological|Comparator: Menactra™ (Non-concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
45395293|NCT00325130|Biological|Comparator: Adacel™|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
45395294|NCT00321854|Drug|pramipexole|
45395295|NCT03983252|Drug|[F-18]PBR06|PET radiopharmaceutical
45395296|NCT03982862|Drug|Triamcinolone|Triamcinolone 4mg diluted to 0.1 ml
45395297|NCT03982862|Drug|Lidocaine|0.1ml 2% Xylocaine
45395298|NCT03982862|Drug|Botulinum toxin A|4U Botox® diluted to 0.1 ml
45503419|NCT03142451|Drug|Vehicle foam|Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
45503420|NCT04065789|Drug|Carfilzomib|Carfilzomib on Days 1, 8, 15, of cycle numbers 1-9 and Days 1 and 15 only of cycle numbers 10-18, at a dose of 20 mg/m2 on day 1 of cycle 1; at dose of 56 mg/m2 on all subsequent once weekly dosing days. The quadruple regimen treatment will be administered for 18 cycles.
45503421|NCT04065789|Drug|Daratumumab|Daratumumab : 16 mg/Kg weekly for 8 weeks, then every 2 weeks for 16 weeks, and then every 4 weeks thereafter. The quadruple regimen treatment will be administered for 18 cycles.
45503422|NCT04065789|Drug|Lenalidomide|Lenalidomide (25 mg), administered on days 1-21 of 28-day cycle.In frail patients, Lenalidomide dose will be reduced according to 15 mg . The quadruple regimen treatment will be administered for 18 cycles.
45503423|NCT04065789|Drug|Dexamethasone|Patients will be treated with IV or oral dexamethasone (20 mg for fit and INT-FIT, 10 mg for frail), administered on Days 1-2, 8-9, 15-16, and 22-23 of each 28-day cycle for cycles 1-2 followed by weekly 20 mg dexamethasone on subsequent cycles; In frail patients, dexamethasone will be reduced to 10 mg . The quadruple regimen treatment will be administered for 18 cycles.
45503424|NCT03611478|Dietary Supplement|Probiotic formulation|Probiotic capsule
45503425|NCT03611478|Dietary Supplement|Placebo|Placebo capsule identical in taste and appearance to probiotic capsule
45697090|NCT04401345|Drug|Glycopyrrolate 0.2 MG/ML|In this group, the patients will receive glycopyrrolate 0.2 mg in 1 ml
45697091|NCT04401345|Drug|Normal saline|In this group, the patients will receive 1 ml of 0.9% normal saline
45395299|NCT01060904|Drug|brentuximab vedotin|0.6-1.2 mg/kg IV every 2 weeks
45395300|NCT01060904|Drug|doxorubicin|25 mg/m2 IV every 2 weeks
45395301|NCT01060904|Drug|vinblastine|6 mg/m2 IV every 2 weeks
45395302|NCT01060904|Drug|dacarbazine|375 mg/m2 IV every 2 weeks
45395303|NCT01060904|Drug|bleomycin|10 units/m2 IV every 2 weeks
45395304|NCT01060904|Drug|brentuximab vedotin|0.9-1.2 mg/kg IV every 2 weeks
45395305|NCT01058174|Drug|micafungin|intravenous infusion
45395306|NCT01058174|Drug|fluconazole|intravenous infusion
45395307|NCT01058174|Drug|liposomal amphotericin B|intravenous infusion
45395308|NCT01058174|Drug|caspofungin|intravenous infusion
45395309|NCT01061762|Behavioral|Stick To It|3-counseling session adherence intervention tailored for people with poor literacy skills
45395310|NCT01061762|Behavioral|Standard medication adherence counseling|3 counseling sessions for adherence improvement derived from standard behavioral approaches.
45395311|NCT01061762|Behavioral|Health Counseling|3-session of health improvement counseling to serve as an attention control.
45395312|NCT01058252|Combination Product|INVOCell, Letrozole 2.5 mg, recFSH 75 IU|"OVARIAN STIMULATION:~In previous cycles, cycle length and ovulatory status must be assessed and documented.~STEP 1: ANOVULATION by ORAL CONTRACEPTION~Place patients on monophasic low dose of oral contraceptive pills (OCP) such as Marvelon (Organon, 0.03 mg) continuously for 21 days, 22 days but no more.~Before stopping the oral contraceptive pills, perform an ultrasound to check for the absence of cysts (no cyst > 10 mm).~Give estradiol (2mg, 3 times a day) for 3 days from D21 or D22 and wait for bleeding.~STEP 2: STIMULATION and MONITORING Day one of the cycle equals the first day of bleeding (not spotting).~On Day 3 (D3), start letrozol 2.5mg (AROMEK) for 5 days (D7). LetrozolE can be pushed for 2 more days.~Start hMG or FSH (75 IU a day) on Day 3 like LetrozolE and continue for 5 to 7 days without increasing the dose. The dose of hMG OR FSH can be increased to 150 IU a day if low responder."
45395313|NCT01058252|Procedure|STEP-3: LH Suppression & Monitoring|"Baseline Day-2 Ultrasound to estimate antral follicles; Follow-up TVS scans on Day- 5,6,7,8 and 9 of the stimulated cycle. Ideally the lead follicle should be 18 mm on or around day 10 of the cycle.~• When the leading follicle reaches 14 to15 mm (D8 or D9), give Indomethacine (50 mg, 3 times a day) until the evening preceding the egg retrieval. The Indomethacine will prevent a premature ovulation.~The endometrium should be minimum 8 mm on the day of HCG (IVF-C 5000 IU x 2)~No need of LH testing, or E2 testsing during the stimulated cycle."
45395314|NCT01058252|Procedure|STEP-4: HCG Timing|"IVF-C (HCG 10000 IU) shall be injected to trigger the ovulation, when any of the following occur:~E2 level is over 150 pg/ml/per mature follicle (> 15 mm)~Domminent follicle is greater than 18 mm in mean diameter~LH Remains as Baseline, OR~The day when Urinary LH Surge is positive"
45395315|NCT01058252|Procedure|STEP-5: OPU, ET, Cancellation|"Ultrasound guided Ovum Pick-Up is performed 34-36 hours after IVF-C (HCG 10000 IU) injection.~Embryo Transfer is performed after 48-72 hours of incubation at 4-8 cell stage.~Maximum of 2 embryos are transferred, using ultrasound guided transfer.~Cancellation Criteria:~Poor patient compliance~Premature Ovulation~Premature LH Surge~Endometrium < 7 mm~Poor Follicular Development~E2 Level > 2,500 pg/ml"
45395316|NCT01058252|Procedure|INVOCell (Intravaginal Culturing)|Sperm preparation through Swim-Up or Gradient is performed 1 hour prior to the oocyte retrieval; Fill the device without air bubble. Only 100000 motile spermatozoa are added into the device; After follicle aspiration, oocyte(s) are identified in the follicular fluid and immediately placed into the device; The device is closed, placed into a protective outer rigid shell and then positioned into the vaginal cavity for 2 to 3 days; No activity restriction is required for the patient, except baths. After 2 or 3 days of incubation, the retention system and the device are removed from the vagina in sterile environment. The device is opened and the contents are observed in a sterile environment under microscope to find the embryos. The two best quality embryos are loaded into embryo transfer catheter and transferred immediately unto the uterine cavity using aseptic techniques.
45395317|NCT01058330|Other|Plyometric training program|The intervention is a year long individualized plyometric exercise training program. Examples of plyometric activities include jumping, hopping, running, and throwing. The number of plyometric exercises will increase gradually to prevent over training to a total of five lower extremity exercises and five upper extremity exercises
45395318|NCT01058408|Radiation|Intensity modulated radiotherapy|Administered daily 5 days per week
45395319|NCT01058408|Drug|RAD001|Taken orally once a day
45395320|NCT01058408|Drug|cisplatin|Administered intravenously once a week
45395321|NCT01060982|Device|Ultrasonic ablation device|One High Intensity focused ultrasound session before surgery. Use of appropriate energy for each patient
45395322|NCT01061060|Drug|Prostaglandin I2|oral
45503426|NCT02066558|Other|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass.
45503427|NCT02066558|Other|Placebo|
45503428|NCT04933773|Other|Movement artifact - knocking|60 seconds motion artifact simulation - knocking with sensors
45697092|NCT00968344|Dietary Supplement|Leucine|3-4g Leucine added to daily meals
45849161|NCT00001296|Drug|melphalan|
45395323|NCT01061060|Drug|Placebo|oral
45395324|NCT00310388|Drug|Retigabine (INN), Ezogabine (USAN)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patients receives between 600 and 1200 mg of retigabine per day. The duration will be until the completion of the trial, or until the patient withdraws from the trial.
45849162|NCT00001296|Drug|tumor necrosis factor|
45503429|NCT04933773|Other|Movement artifact - tremor|60 seconds motion artifact simulation - tremor with sensors
45503430|NCT04933773|Other|Artifact - ambient light|60 seconds artifact simulation - ambient light using sensor opening
45503431|NCT04933773|Other|Artifact - low perfusion|60 seconds artifact simulation - reduced perfusion using a cuff
45503432|NCT04933773|Other|SpO2 measurement|Two SpO2 measuring devices are active simultaneously on one hand during measurement.
45697093|NCT00968344|Dietary Supplement|Alanine|Powered amino acid
45697094|NCT03083301|Other|Medical Files data extraction|Medical Files data extraction
45697095|NCT05684679|Other|Incentive spirometer plus Chest physiotherapy|Incentive spirometer was given to IS group. However, a conventional chest physiotherapy was given to both groups in the optimal position.
45849163|NCT00001296|Drug|interferon-gamma|
45849164|NCT00001296|Procedure|hyperthermic isolated limb perfusion|
45503433|NCT01351831|Other|Rehabilitation with strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of balance-, mobility- and functional training exercises etc. In addition, the participants perform unilateral (operated leg) knee-extensions and leg presses in 2 sets for each strength training exercise, using relative loads of 12 RM (week 1), 10 RM (weeks 2-5), and 8 RM (week 6-7). All sets are performed to failure.
45395325|NCT03981770|Drug|General anesthesia|For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation.
45395326|NCT00500357|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose 13vPnC
45395327|NCT03981692|Other|Consecutive dual task|8 weeks and 2 days per week, one session 45 min. Consecutive dual task creates the idea that it may provide more workable work without creating stress while doing secondary task during dual task.
45395328|NCT03981692|Other|Integrated dual task|8 weeks and 2 days per week, one session 45 min. Integrated dual task is a proven mode of work that has positive effects on geriatrics
45395329|NCT01063556|Drug|donepezil HCl|Subjects will receive donepezil HCL 3 mg without haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg with haemodialysis.
45395330|NCT01063556|Drug|donepezil HCl|Subjects will receive donepezil HCl 3 mg with haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg without haemodialysis.
45395331|NCT03981458|Device|Hyalofemme|Gel made with hyaluronic acid to be applied vaginally to treat atrophic vaginitis.
45503434|NCT01351831|Other|Rehabilitation without strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of the same balance-, mobility- and functional training exercises etc. as used in the other experimental arm.
45503435|NCT03611634|Other|BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE|collection of saddles
45503436|NCT02064842|Drug|TMC647055|TMC647055 150 mg (1 capsule), 450 mg (3 capsules), 600 mg (4 capsules) taken orally (by mouth) once daily on Day 1 in Part 1. TMC647055 450 mg (3 capsules), and 600 mg (4 capsules) taken orally once daily on Days 1 to 7 in Part 2
45503437|NCT02064842|Drug|TMC435|TMC435 1 capsule of 75 mg, 100 mg, and 150 mg taken orally on Days 1 to 7 in Part 2
45503438|NCT02064842|Drug|Placebo|Placebo capsule once daily taken orally on Day 1 in Part 1
45503439|NCT02064842|Drug|Ritonavir (RTV)|RTV 30 mg (ie, 0.38 mL oral solution of RTV [80 mg/mL strength]) taken orally on Day 1 in Part 1 and on Days 1 to 7 in Part 2
45503440|NCT04924881|Drug|COVID Rehab Formula granules|COVID Rehab Formula granules once daily for 8 weeks
45395332|NCT03981458|Device|Ialuril|Bladder instillation of hyaluronic acid to treat recurrent UTI.
45395333|NCT01019915|Device|CRT|Insertion of CRT in patients with left bundle branch block. Assessment of skeletal muscle and infalmmatory profile
45395334|NCT04110041|Behavioral|Aerobic Exercise|Thrice-weekly aerobic exercise sessions lasting ~45 minutes, for 12 consecutive weeks.
45395335|NCT00309842|Biological|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenously(IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days.
45503441|NCT04924881|Other|Placebo granules|Placebo granules once daily for 8 weeks
45503442|NCT01355809|Drug|Inhalation gas|Inhalated gas, medicinal oxygen 100% via NIV with Fi O2 0.35, one time by random, 6 minutes
45503443|NCT01355809|Drug|Inhalation Nitrogen/Oxygen|Inhalated gas, Nitrogen/Oxygen (65%/35%), one time by random, 6 minutes
45503444|NCT01355809|Drug|Inhalation Helium/Oxygen|Inhalated gas, Helium/Oxygen (65%/35%) one time by random, 6 minutes
45697096|NCT05684679|Other|Diaphragmatic breathing exercise plus Chest physiotherapy|Diaphragmatic breathing exercise was given to DBE group. In addition, a conventional chest physiotherapy was given in the optimal position.
45395336|NCT00309842|Drug|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna (MT(S) 9006) at 10:00am, or per institutional routine, on days-7 and -6 after fludarabine. Cyclophosphamide 60mg/kg/day intravenous (IV) x 2 days, total dose 120 mg/kg (days -7 and -6) Dosing is calculated based on Actual BodyWeight (ABW) unless ABW > 30 kg above Ideal BodyWeight (IBW), in which case the dose should be computed using adjusted body weight.
45395337|NCT00309842|Drug|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of > 200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
45395338|NCT00309842|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -8 to -6);
45395339|NCT00309842|Drug|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -3. Patients ≥ 40 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).~Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg three times a day."
45395340|NCT00309842|Procedure|umbilical cord blood transplantation|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
45395341|NCT00309842|Radiation|total-body irradiation|The recommended TBI is 165 cGy given twice daily for a total dose of 1320 cGy (days -4 to -1).
45395342|NCT00325754|Device|E-Cylinder|Portable Oxygen Therapy Delivered Via An E-Cylinder Mounted On A Wheeled Cart
45395343|NCT00325754|Device|Lightweight Cylinder|Ambulatory Oxygen Therapy Delivered Via A Carbon-Wrapped Aluminum Cylinder
45395344|NCT01019993|Procedure|conventional OLV followed with IL-HFPPV|The patients' lungs were mechanically ventilated with intermittent positive pressure ventilation using fraction of inspired oxygen (FiO2) of 0.5 in air, tidal volume (VT) of 8 mL/kg, inspiratory to expiratory [I: E] ratio of 1:2.5, zero positive end-expiratory pressure (PEEP), respiratory rate (R.R) was adjusted to achieve an arterial carbon dioxide tension (PaCO2) 35-45 mm Hg and peak inspiratory pressures were limited to 35 cm H2O. After pleurotomy, OLV was initiated with the same ventilatory settings for the dependent lung. After 30 min, the non-dependent collapsed lung was ventilated using HFPPV mode (IL-HFPPV) with another identical ventilator, with an internal circuit of low compliance, using FiO2 of 0.5 in air, VT 3 mL/kg, I: E ratio <0.3 and R.R 60 breaths/min.
45395345|NCT01063790|Behavioral|Individualized Education|The intervention consists of written information in the form of a booklet, an individualized face to face education session and two telephone support calls regarding post-discharge pain management, adverse effects of analgesics and common concerns about asking for help with pain.Participants in the intervention group will also receive two telephone support calls. The purpose of the telephone support calls is to readdress the information that patients received in the booklet and to clarify concerns regarding post-operative pain management that were discussed during the individualized education session.
45395346|NCT03985982|Drug|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
45395347|NCT03985982|Drug|Placebo|injection, sodium chloride 0.9 % divided in five 0.1 mL i.m injections into the glabellar area
45395348|NCT00499889|Drug|Imatinib Mesylate|400 mg by mouth twice daily for 9 Days
45697097|NCT04761003|Device|Thoracoscopy forceps|take pleural biopsy
45395349|NCT00499889|Drug|Fludarabine (Fludara)|40 mg/m^2 by vein daily for 4 Days
45395350|NCT00499889|Drug|Busulfan|130 mg/m^2 by vein daily for 2 Days
45395351|NCT00499889|Drug|Antithymocyte Globulin (ATG)|2.5 mg/kg by vein daily for 3 Days
45395352|NCT00499889|Drug|Tacrolimus|Tacrolimus levels maintained between 5-15 ng/dl, first as continuous IV infusion, and converted to oral every 12 hour dosing as tolerated. Starting day -2 until day 180.
45395353|NCT00499889|Drug|Methotrexate|5 mg/m2 on days 1, 3, 6 and 11.
45395354|NCT00499889|Procedure|Donor lymphocyte infusion (DLI)|Infusion of lymphocytes from the original bone marrow donor by vein if relapse after >4 weeks of imatinib.
45503445|NCT03612102|Behavioral|Intensive Group Behavioral Treatment (IGBT)|IGBT is a 5-day intensive treatment program, where cognitive behavioral therapy is provided to children and their parents delivered over 6-8 hours per day over the course of 5 days.
45697098|NCT01015534|Drug|Temozolomide|
45697099|NCT01015534|Radiation|Whole brain irradiation|
45697100|NCT05688033|Radiation|dosimetric limitation of pelvic bone and peritoneal space during radiotherapy|dosimetric limitation of pelvic bone and peritoneal space during radiotherapy
45395355|NCT00499889|Procedure|Stem Cell Transplant|Infusion of donor bone marrow or blood stem cells by vein over approximately one hour on day 0.
45395356|NCT03982472|Other|transcutaneous electric stimulation|transcutaneous current with an amplitude around ten to hundred milliampere was applied topically to subjects
45697101|NCT03083145|Dietary Supplement|Whey Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
45697102|NCT03083145|Dietary Supplement|Pea Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
45503446|NCT04013139|Diagnostic Test|CPET|CPET
45503447|NCT03141905|Other|Sick-Day Protocol|Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring
45697103|NCT03083145|Behavioral|Snack Tray Choices|Items were selected from a snack tray filled with healthy and unhealthy snacks in order to determine if educational messaging influenced snack choices. Shack choices wre recorded on a check list by a third party observer.
45697104|NCT05683353|Other|None intervention|None intervention.
45697105|NCT03363945|Biological|MDR-101|Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
45697106|NCT00968890|Biological|Pandemrix (Influenza vaccine GSK2340272A)|Intramuscular injection, 2 doses
45697107|NCT00968890|Biological|Fluarix™|Intramuscular injection, 1 dose
45697108|NCT00968890|Biological|Placebo|Intramuscular injection, 1 dose
45849165|NCT00001338|Drug|FLAC chemotherapy with GM-CSF|
45697109|NCT03082833|Drug|AZD2014|AZD2014 is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
45697110|NCT03082989|Device|fractional flow reserve performed|assessing fractional flow reserve to drive revascularization
45697111|NCT03082989|Other|fractional flow reserve not performed|description of the main reasons leading the operator to not use fractional flow reserve to drive the coronary revascularization
45503448|NCT03141905|Other|Usual Care|Standard clinical care
45503449|NCT05383638|Other|Health education|Intervention is achieved through health education. Analyze the factors that may affect patients' satisfaction with primary medical services through existing data, and carry out targeted health education.
45503450|NCT02513407|Behavioral|Behavioral Dietary Intervention|Attend healthy nutritional education session
45503451|NCT02513407|Other|Educational Intervention|Attend EML educational session
45503452|NCT02513407|Behavioral|Exercise Intervention|Attend exercise educational session
45503453|NCT02513407|Behavioral|Exercise Intervention|Receive fitness tracker
45503454|NCT02513407|Other|Laboratory Biomarker Analysis|Correlative studies
45503455|NCT02513407|Other|Questionnaire Administration|Ancillary studies
45697112|NCT00970216|Drug|Telbivudine|Post-marketing observation for chronic hepatitis B patients receiving Telbivudine treatment
45697113|NCT03017950|Drug|CKD-330|
45697114|NCT03017950|Drug|D086|
45697115|NCT03017950|Drug|CKD-330 + D086|
45849166|NCT00001422|Drug|fludarabine|
45849167|NCT00001428|Drug|5-fluorouracil|
45849168|NCT00001440|Procedure|Autologous T cells|
45849169|NCT00001440|Drug|Interleukin-2|
45849170|NCT00001446|Drug|thalidomide|
45849171|NCT00001512|Drug|Id-KLH Vaccine|
45849172|NCT00001512|Drug|GM-CSF|
45849173|NCT00001572|Drug|Id-KLH Vaccine|
45849174|NCT00001572|Drug|QS-21 (Stimulation-QS-21) Drug|
45849175|NCT00001614|Drug|Chicken type II collagen|
45849176|NCT00001626|Drug|antithymocyte globulin|antithymocyte globulin
45849177|NCT00001626|Drug|cyclophosphamide|cyclophosphamide
45849178|NCT00001626|Drug|cyclosporine|cyclosporine
45503456|NCT04917315|Drug|JLP-2002 A mg|administration of JLP-2002 Participants received one vibegron A mg tablet, taken orally each morning, for 12 weeks.
45395357|NCT01058486|Behavioral|Self-Management and Motivational Interviewing|"Post hospital discharge, patients will be referred (<2 weeks) to pulmonary rehabilitation (PR) (1-2 sessions per week for 6-8 weeks). PR visits (approximately 1 hour) will include education, strengthening and endurance exercise as the patient tolerates.~A counselor (RN or RRT) and patient will meet once weekly after PR session. The counselor will assess the patient's self efficacy and knowledge of self-management principles of COPD. Based on the assessment and greatest needs identified by patient, the counselor will work with the participant to collaboratively develop a specific SM plan.Motivational interviewing techniques will be used.~Following completion of PR, the counselor will contact the patient monthly to provide clinical support on SM of COPD. To ensure consistency of intervention, we will use standardized treatment procedures and phone scripts."
45503457|NCT04917315|Drug|Placebo|administration of Placebo Participants received one placebo tablet, taken orally each morning, for 12 weeks.
45503458|NCT03612024|Behavioral|questionnaire|a standardized questionnaire was sent to all participants
45395358|NCT04252703|Procedure|Percutaneous coronary intervention (PCI)|Invasive cardiac catheterization, balloon angioplasty and intracoronary stenting.
45395359|NCT00309608|Drug|Linagliptin|Linagliptin medium dose tablet once daily
45395360|NCT00309608|Drug|Linagliptin|Linagliptin high dose tablet once daily
45503459|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
45503460|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tables|PPatients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
45503461|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
45395361|NCT00309608|Drug|Linagliptin|Linagliptin low dose tablet once daily
45395362|NCT00309608|Drug|Placebo|Placebo tablets once daily
45395363|NCT00309608|Drug|Glimepiride|Glimepiride tablets once daily
45503462|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
45697116|NCT00971620|Biological|Botulinum toxin type A|Given as an intralesional injection.
45697117|NCT00971620|Other|Placebo|Given as an intralesional injection
45395364|NCT00309452|Behavioral|Cognitive Behavioral Group Therapy|once per week
45395365|NCT00309452|Behavioral|Cognitive remediation|as needed
45849179|NCT00001680|Drug|Thalidomide|
45849180|NCT00001698|Drug|Ketorolac Rinse|
45849181|NCT00001716|Drug|Nitric Oxide|
45395366|NCT00309452|Drug|Medications|Individualized prescription of psychotropic medications including but not restricted to antipsychotic, antidepressant and mood stabilizers.
45395367|NCT00309452|Behavioral|MFG|Multi-Family psychoeducation Group based on the model published by McFarlane et al.
45395368|NCT00309452|Behavioral|Assertive case management|Meetings with an individual clinician (social work or nursing) who provides supportive psychotherapy, helps assist with vocational and educational supports.
45395369|NCT00309452|Other|Treatment as Usual in the community|Subjects randomized to this arm either return to their existing outpatient psychiatrist or, if they do not have one yet, are referred by the clinic to preferred providers in the community. The nature of the interventions provided is variable and is being monitored by the research clinic.
45395370|NCT00308750|Drug|enzastaurin|1125-1200 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression
45697118|NCT05687565|Dietary Supplement|Control group placebo|Dietary suplementation
45697119|NCT05687565|Dietary Supplement|Experimental group 1 lauric acid|Lauric acid 1.5 grams once daily
45395371|NCT00308750|Drug|pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV), once every (q) 21 days, six 21 day cycles or progressive disease
45395372|NCT00308750|Drug|docetaxel|75 mg/m^2, IV, q 21 days, six 21 day cycles or progressive disease
45395373|NCT00308750|Drug|carboplatin|Area under the curve (AUC) 6, IV, q 21 days, six 21 day cycles or progressive disease
45395374|NCT01061918|Device|Tecnis MF|20 patients in the Tecnis MF group.
45395375|NCT01061918|Device|ReSTOR|20 patients in the ReSTOR group.
45395376|NCT03985826|Other|Diagnosis of and treatment for Acute lymphoblastic leukaemia in childhood|The cohort of ALL survivors has all been diagnosed and treated for ALL in childhood
45395377|NCT03985748|Device|BAN|Inhaled bronchodilators will be delivered using an AeroEclipse® II Breath Actuated Nebuliz (BAN)
45395378|NCT03985748|Device|SN|Inhaled bronchodilators will be delivered using a Standard Nebulizer (SN)
45395379|NCT00489359|Drug|Pemetrexed - Phase 1|500, 600, 700, 800, or 900 milligrams per square meter (mg/m^2), administered intravenously (IV), every 21 days x 6 cycles, dose escalate to Maximum Tolerated Dose (MTD)
45395380|NCT00489359|Drug|Carboplatin - Phase 1|area under the concentration time curve (AUC) 5 or 6 mg/mL*min, administered intravenously (IV), every 21 days x 6 cycles, dose escalation to Maximum Tolerated Dose (MTD)
45395381|NCT00489359|Drug|Pemetrexed - Phase 2|Dose determined from Phase 1: 500 mg/m^2, administered IV, every 21 days x 6 cycles
45395382|NCT00489359|Drug|Carboplatin - Phase 2|Dose determined from Phase 1: AUC 6 mg/mL*min, administered IV, every 21 days x 6 cycles
45395383|NCT00481247|Drug|Dasatinib|Tablets, oral, dasatinib 50-140 mg once daily (QD)
45849182|NCT00001716|Drug|Nitroglycerin|
45395384|NCT00481247|Drug|Imatinib|Tablets, oral, imatinib 200-800 mg, QD
45395385|NCT04101461|Drug|Iron|PharaFerro27; Devart Lab Company, Egypt
45395386|NCT04101461|Diagnostic Test|Complete blood count|to assess the anemia
45395387|NCT04101461|Diagnostic Test|Serum ferritin|to assess the anemia
45395388|NCT04101461|Diagnostic Test|Serum hepcidin|to assess the iron abosrption
45395389|NCT04101461|Diagnostic Test|Serum Iron|to assess the anemia
45395390|NCT04101461|Diagnostic Test|Serum total iron binding capacity|to assess the anemia
45395391|NCT01020071|Procedure|pattern scanning laser iridotomy and iridoplasty|peripheral laser iridotomy and iridoplasty using pattern scanning laser technique
45395392|NCT01016951|Drug|AZD9164 Turbuhaler®|"Dry powder for inhalation via Turbuhaler, MAD. Starting dose in healthy volunteers is 400 µg with up to two dose escalations not exceeding AstraZeneca pre-defined exposure limits.~The COPD patients will receive a dose of 1000 µg."
45395393|NCT01016951|Drug|Placebo Turbuhaler®|Dry powder for inhalation via Turbuhaler, MAD
45395394|NCT01020149|Other|MR Imaging|MRI is used to evaluate nerve regeneration after traumatic transsection and nerve repair.
45849183|NCT00001812|Drug|Nystatin|
45395395|NCT01017107|Drug|Activated protein C|24 micrograms/kg/hour intravenously for 96 hours
45395396|NCT01020227|Behavioral|Integrative Therapies Intervention|Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
45395397|NCT01017185|Drug|HF10|
45395398|NCT03996863|Device|Otoband|Participants during infusion following chemotherapy will wear the Otoband set at normal power (effective) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
45395399|NCT03996863|Device|Placebo device|Participants during infusion following chemotherapy will wear the placebo device set at low power (6 decibels lower than normal power, ineffective power) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
45395400|NCT03997019|Procedure|opioid analgesia|opioid analgesia will be used with general anaesthesia
45395401|NCT03997019|Procedure|ESP block|ultrasound guided ESP Block before anaesthesia induction
45395402|NCT00480857|Drug|Docetaxel (Taxotere)|Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.
45395403|NCT00480779|Behavioral|GLB Group|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered in face-to-face groups by a trained lifestyle coach.
45395404|NCT00480779|Behavioral|GLB DVD|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered via DVD and weekly telephone contact with a trained lifestyle coach.
45697120|NCT05687565|Dietary Supplement|Experimental group 2 lauric acid|Lauric acid 3 grams once daily
45697121|NCT03384537|Combination Product|Listerine total care zero|reducing intra-oral cariogenic microorganism.
45697122|NCT03384537|Combination Product|Chlorhexidine Mouthwash (0.2%).|Chlorhexidine Mouthwash (0.2%).
45849184|NCT00001830|Drug|Th2 cells in allo HSCTT|
45849185|NCT00001830|Drug|Th2 Cells|
45849186|NCT00001842|Drug|Granulocyte colony-stimulating factor|
45849187|NCT00001842|Drug|Dexamethasone|
45849188|NCT00001848|Drug|Raloxifene|
45395405|NCT04061993|Procedure|Strength and Sensory-Motor Training|Early postoperative strength and sensory-motor training after total hip arthroplasty. Training consists of: hip muscles strengthening (focusing on abductors); hip and pelvic stabilization exercises; ankle and knee muscles strengthening (better dissipation of impact forces and femoral inner rotation control); trunk muscles strengthening (stabilization of pelvis and lumbar spine and reduction of local loading).
45395406|NCT04061993|Procedure|Current Standard Physiotherapy|Mobilisation using a walking aid (usually two crutches, rarely a walker), deep vein thrombosis (DVT) prevention exercises, lower limb range of motion exercises and isometric strengthening program
45395407|NCT00499031|Biological|Cetuximab|Given IV
45395408|NCT00498797|Drug|Zactima (vandetanib)|
45395409|NCT00498797|Drug|Docetaxel|
45395410|NCT00498797|Drug|Prednisolone|
45395411|NCT00498485|Drug|Placebo|Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
45395412|NCT00498485|Drug|Sodium Oxybate|Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
45395413|NCT01017341|Device|PSU hip protector|hip protetor
45503463|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
45697123|NCT01884922|Drug|Nilotinib|Tasigna®(nilotinib):: 50 mg, 150 mg and 200 mg capsules. Tasigna® capsules contain lactose monohydrate, crospovidone, poloxamer, colloidal silicon dioxide and magnesium. Orally; the capsules should be swallowed as a whole with water. No food should be consumed for 2 hours before the dose is taken and for at least one hour thereafter. For patients who are unable to swallow capsules, the content of each capsule may be dispersed in one teaspoon of apple sauce or compote or nonfat plain yogurt and should be taken immediately. Not more than one teaspoon of apple sauce / yogourt, and no food other than apple sauce or nonfat plain yogurt must be used.
45697124|NCT01884922|Drug|Vinblastine|"Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle.~Each 28-day cycle is repeated on Day 29/Day 1. No intra-patient doseescalation is permitted. Dose allocation will be centrally defined, based on toxicity observed in patients previously evaluated. Every new patient will be treated at the best current recommended dose, i.e. the dose associated with an estimated level of toxicity that is judged acceptable (20% DLT). At least two patients fully observed with no DLT are requested at a given dose level before dose escalation."
45697125|NCT03083223|Other|position|Subjects were placed consecutively in random order in five different positions. SaO2 and vital signs were measured at each position after 10, 25, and 40 minutes.
45697126|NCT01610908|Other|The Schroth exercises treatment|"The Schroth approach consists of 3D scoliosis-specific exercises based on sensorimotor and kinesthetic principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. To achieve this goal, Schroth exercises focus on endurance and strength training of postural muscles. Schroth exercises also aim to improve posture motor control by repeating corrective movements with progressively less feedback and less passive support.~Dosage: 5 individual 1-hour long sessions, continued with the daily 45 minutes home exercise program. In addition, patients are required to come weekly for 1-hour long group sessions over the span of 6 months."
45395414|NCT00480077|Device|Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )|OptiVol® Fluid status Monitoring with Cardiac Compass
45395415|NCT01017419|Behavioral|Counseling|Informational Counseling provided after hearing aid fitting
45395416|NCT04242329|Procedure|Surgical metastasectomy|Surgical removal of metastases aimed at R0 resection.
45395417|NCT04242329|Drug|Immunotherapy|Continued PD1-inhibitor treatment according to current treatment standards.
45395418|NCT05045261|Drug|administration of SLGN in arm C|administration of 3mg SLGN weekly for 24 weeks in arm C
45395419|NCT05045261|Drug|Discontinuation of NUC treatment in arms B and C|NUC treatment will be stopped after 28 weeks in arms B and C
45395420|NCT00498173|Drug|Atomoxetine|Available tablet strengths of atomoxetine: 5 mg, 10 mg, 25 mg, 40 mg. Week 1 participant takes 0.5 mg/kg/day, Week 2: 0.8 mg/kg/day, Week 3: 1.2 mg/kg/day. Potential exists for dose increase at Week 4 to 1.8 mg/kg/day based on clinical global impression-improvement rating at Week 4.
45395421|NCT00498173|Drug|Placebo|Placebo tablets dosages: 5 mg, 10 mg, 25 mg, 40 mg.
45849189|NCT00001854|Drug|Ribavirin|
45849190|NCT00001860|Drug|Sandostatin LAR Depot versus transsphenoidal surgery|
45849191|NCT00001866|Procedure|horizontal muscles of the eye will be cut and then reattached in the same position|
45849192|NCT00001890|Drug|Estrogen therapy|
45503464|NCT04887597|Drug|Secukinumab|The study is composed of a single arm receiving secukinumab for the duration of 6 months.
45849193|NCT00001926|Drug|O15|
45849194|NCT00001926|Device|Cadwell rTMS|
45849195|NCT00001944|Drug|Vinorelbine|
45395422|NCT04442009|Other|Group SCPB|In group SCBP, SCBP block will be performed. Patients will be administered dexketoprofen 50 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
45395423|NCT00295620|Drug|Anastrozole|1mg tablet daily
45395424|NCT01063374|Dietary Supplement|low glycemic diet instruction|
45395425|NCT01063374|Dietary Supplement|high cereal fibre diet instruction|
45715227|NCT05409430|Device|Neurothrombectomy|"The ANA 5F device is intended to be inserted, be navigated to the neurovascular anatomy inside an outer catheter and be used as a conduit for insertion and guidance of intravascular catheters and retrieval devices into a selected blood vessel. The funnel is deployed by retracting the conduit catheter and is intended, when deployed, to provide temporary vascular flow restriction.~The device is indicated for the introduction of interventional devices into the neuro vasculature, during interventions for restoring blood flow in patients experiencing acute ischemic stroke due to large vessel occlusion."
45395426|NCT01063452|Device|Truvalve|Atkinson Product Design urinary slide valve
45395427|NCT01063452|Other|Control (catheter drainage bag)|urinary catheter drainage bag
45395428|NCT03980496|Drug|Omeprazole|
45395429|NCT02532504|Other|CBT|"8 sessions of CBT based intervention called change your life with seven sheets of paper by Prof. Chris Williams. These sheets cover key skills of CBT that are;~Five Areas vicious circle~Bad thought spotter~Amazing Bad thought Busting Programme (ABTPB)~Easy 4 Step plan~Things you do that mess you up/Confidence sheet~Happy List/ Things you do that boost how you feel sheet~Planner and Review sheets"
45395430|NCT01066260|Dietary Supplement|Probiotic formulation|Twice a day for 24 days
45395431|NCT01066260|Other|Placebo|Twice a day for 24 days
45395432|NCT01064544|Procedure|light therapy with the device: EnergyLight|2 hr of light therapy during each hemodialysis session
45395433|NCT03981510|Diagnostic Test|3D-Transit|3D transit investigation consists of a small electromagnetic pill and a detector located in a belt around the waist. The pill is swallowed by the participant and the belt is worn until the pill has left the gastrointestinal tract. The method is without any pain and discomfort for the child. The child will visit the hospital the first time to ingest the capsule alongside a standardized meal, and is then free to go home and proceed with daily activities (beside hard exersize) while wearing the belt with the detector. The next day, the child will again visit the hospital to check whether or not the capsule has left the tract - this is done with a computer and software. The children ingesting two capsules will do this with a certain delay.
45395434|NCT02532426|Procedure|Muscle biopsy|The biopsy is performed on the vastus lateralis muscle at rest and 2 hours after an acute exercise, with a local anesthesia.
45395435|NCT01063530|Device|DIammine SIlver fluoride|Application of Diammine SIlver Fluoride in cervical lesions
45715228|NCT04738630|Drug|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
45395436|NCT01063530|Device|DIstilled water|Application of distilled water in cervical lesions
45395437|NCT00310440|Device|P-15 Synthetic osteoconductive bone substitute|Safety and efficacy of synthetic bone substitute used for fusion in spinal surgery
45395438|NCT00310440|Other|Autologous bone|Local autologous bone will be harvested, milled and placed into the cavity of the structural allograft ring
45395439|NCT03978390|Behavioral|behavioral priming|Priming the children with images of superheroes in order to behave desirably during the dental injection
45395440|NCT03978390|Behavioral|endowment effect|Giving the rewards to children before starting the dental treatment and telling children they can only keep it if they behave desirably during the dental procedure
45395441|NCT03978390|Behavioral|Positive reinforcement|Giving rewards to the children at the end if they cooperate desirably during the treatment
45395442|NCT00304356|Drug|Nitazoxanide|500 mg bid
45395443|NCT01066416|Procedure|Endoscopic Sinus Surgery|
45849196|NCT00001944|Drug|XR9576|
45395444|NCT01066416|Other|medical therapy|Subjects will undergo surgery 6 months after randomization
45395445|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 600mg and maintenance 150mg for 7days
45395446|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 600mg and maintenance 75mg for 7days
45395447|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 300mg and maintenance 150mg for 7days
45395448|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 300mg and maintenance 75mg for 7days
45395449|NCT00321620|Drug|zoledronic acid|Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
45395450|NCT00321620|Biological|denosumab|Q4W 120 mg denosumab SC and 4 mg zoledronic acid placebo IV over a minimum of 15 minutes
45395451|NCT00304278|Drug|Erlotinib (Tarceva)|150 mg daily X 7 weeks
45395452|NCT00304278|Drug|Intra-arterial Cisplatin (PLAT)|1 dose (150 mg/sq) per week X 4 weeks
45503465|NCT01347905|Other|Stable-isotope techniques|Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. The subjects will provide an initial blood sample (20ml) and then receive a test drink, containing 6 mg of 57Fe labeled ferrous sulphate. One hour later, 2 ml of an aqueous solution containing 100 μg 58Fe, as iron citrate in 250cc of normal saline will be infused over 50 min. Post infusion a 4ml blood sample will be taken. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
45503466|NCT04192266|Drug|Estradiol|2.0 mg of estradiol will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions (Session 2- 6)
45395453|NCT00304278|Radiation|Radiation Therapy (RAD)|5 days per week X 7 weeks
45395454|NCT03981068|Radiation|Re-irradiation|Cisplatin for all eligible patients, nimorazole for all SCC
45395455|NCT02532686|Drug|DAAOI-2|500-2000mg/d, oral, for 6 weeks
45395456|NCT02532686|Drug|placebo|oral, for 6 weeks
45395457|NCT01063946|Drug|Ombrabulin (AVE8062)|"Pharmaceutical form:concentrate solution~Route of administration: intravenous infusion"
45395458|NCT00291018|Device|Total Disc Replacement|Total Disc Replacement using ProDisc-C
45395459|NCT00291018|Device|ACDF|Anterior Cervical Discectomy and Fusion
45395460|NCT00320606|Drug|Immunosuppression Withdrawal|Gradual withdrawal of immunosuppressive medication. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.
45395461|NCT03978312|Other|Nominal consensus group|Nutrition Health Literacy Measurement Tool adaptation (NLit-UK)
45395462|NCT03978312|Other|electronic tool completion|Nutrition Health Literacy Measurement Tool validation (NLit-UK)
45395463|NCT03978312|Other|Patient Survey|Nutrition information cancer patient experience survey
45395464|NCT03978312|Other|Friends and Family Survey|Nutrition information friend and family of cancer patients experience survey
45503467|NCT04192266|Drug|Placebo oral tablet|2.0 mg placebo pills will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions ( Sessions 2-6)
45503468|NCT01370018|Biological|alpha-1-Proteinase Inhibitor|Alpha-1-Proteinase Inhibitor was delivered I.V. A patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of alpha-1-Proteinase Inhibitor. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of alpha-1-Proteinase Inhibitor for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers, and alpha-1-Proteinase Inhibitor.
45503469|NCT01359397|Drug|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab|Her2 - patients only
45503470|NCT01359397|Drug|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab|for Her2 + patients only
45503471|NCT05250245|Drug|Tolterodine Tartrate 4 MG|Tolterodine is actively being used in the treatment of over active bladder symptoms today
45503472|NCT05250245|Other|Continuous positive airway pressure therapy (CPAP)|The gold standard for the treatment of confirmed OSAS is continuous positive airway pressure (CPAP) therapy
45503473|NCT03329976|Other|measurement of visual acuity|complete ophthalmologic examination of a macular SD-OCT, a fundus of eye, evaluation of the vision of contrasts (Pelli-Robson test) and quantification of metamorphopsies (M-Charts);
45503474|NCT01347983|Drug|Tocilizumab+Methotrexate(MTX)|Tocilizumab: 8 mg/kg every 4 weeks, IV infusion Methotrexate: 10-20 mg/week
45503475|NCT02068664|Behavioral|prism adaptation treatment|Prism goggles shift the image one sees toward the left (because the thicker portion of the glass lens is on the right). This will change the perception of where the image is in space, causing the person to adapt. The after-effects of the treatment is what is important. It has been shown to make it easier for people to move in the right space (if have right neglect) or improves ability to complete other functional tasks.
45503476|NCT01359475|Procedure|Acetal crown, LD Caulk ltd, USA|Experimental trial of preformed acetal crowns for primary molars
45503477|NCT03611400|Dietary Supplement|Probiotic|This probiotic is commercially available and contains L. helveticus R0052 (0.2 x 10^9 CFU/capsule) and L. rhamnosus R0011 (3.8 x 10^9 CFU/capsule) as active ingredients and ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide, and maltodextrin as excipients.
45715229|NCT05352958|Procedure|Diaphragmatic ultrasound|duration 15 minutes, performed at M0, M3, M6 and M9
45395465|NCT01064102|Drug|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
45395466|NCT01064700|Device|Litebook Bright Light Box|Four weeks of daily exposure to bright light (3,000 lux) for 45 min/day, beginning within 60 min of arising.
45395467|NCT01064700|Device|Litebook inactivated negation ion generator (the placebo)|Four weeks of daily exposure to inactivated negative ion generator for 45 min/day, beginning within 60 min of arising
45849197|NCT00001956|Procedure|Blood draw|
45395468|NCT02532114|Drug|Enzalutamide|Given PO
45395469|NCT02532114|Other|Laboratory Biomarker Analysis|Correlative studies
45395470|NCT02532114|Drug|Niclosamide|Given PO
45395471|NCT02532114|Other|Pharmacological Study|Correlative studies
45395472|NCT00307736|Drug|5-fluorouracil|Given as a 24-hour infusion on days 1-14 of each 14-day cycle for a total of 3 cycles.
45395473|NCT00307736|Drug|bevacizumab|Given intravenously on day 1 of each 14-day cycle for a total of 3 cycles.
45395474|NCT00307736|Drug|erlotinib|Taken orally on days 1-14 of each 14-day cycle for a total of 3 cycles.
45395475|NCT00307736|Procedure|External beam radiation therapy (EBRT)|Given on days 1-5 and 8-12
45503478|NCT03611400|Dietary Supplement|Placebo|The placebo contains ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide and maltodextrin.
45503479|NCT05249933|Drug|Deyou; Beijing Tide Pharmaceutical Co, China, containing 20,000 iu pronase granules combined with 1 g NaHCO3 to maintain the intragastric PH at 6-8|Drink Deyo with 200ml warm water 25 minutes before swallowing the capsule to remove mucus in the stomach.
45395476|NCT00320528|Drug|atomoxetine|0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
45395477|NCT03979586|Other|Laser-assisted hyaluronic acid delivery|The facial skin remodeling corresponds to a request for repair treatment on the stigmas of heliodermia, irregularity of cutaneous texture, dyschromias, loss of radiance of the complexion, fine lines, as well as on the fine scars of the face for example, the finely depressed cicatrices sequellaires acne.
45395478|NCT00294762|Drug|Tarceva|oral tablet
45395479|NCT00294762|Drug|carboplatin|IV
45395480|NCT00294762|Drug|paclitaxel|IV
45503480|NCT02064998|Behavioral|Promillekoll|Smartphone app monitoring alcohol use with feedback on eBAC level.
45395481|NCT00294684|Drug|Corticosteroids|"Schedule and dosing of corticosteroids following portoenterostomy in infants with biliary atresia are listed below.~Days 1-3: Methylprednisolone, IV-4mg/kg/day, divided BID Days 4-7: Prednisolone, PO-4mg/kg/day, divided BID Week 2: 4 mg/kg/day, divided BID Week 3: 2 mg/kg/day, divided BID Week 4: 2 mg/kg/day, divided BID Week 5: 1 mg/kg/day, once a day Week 6: 1 mg/kg/day, once a day Week 7: 0.8 mg/kg/day, once a day Week 8: 0.6 mg/kg/day, once a day Week 9: 0.4 mg/kg/day, once a day Week 10: 0.2 mg/kg/day, once a day Week 11: 0.1 mg/kg/day, once a day Week 12-13: 0.1 mg/kg/day, every other day Week 14: Stop"
45395482|NCT00294684|Drug|Placebo|"Schedule and dosing of placebo following portoenterostomy in infants with biliary atresia:~Days 1-3: IV - normal saline 4 mg/kg/day, divided BID Days 4-7: PO placebo 4 mg/kg/day, divided BID Week 2: PO placebo 4 mg/kg/day, divided BID Week 3: PO placebo 2 mg/kg/day, divided BID Week 4: PO placebo 2 mg/kg/day, divided BID Week 5: PO placebo 1 mg/kg/day, once a day Week 6: PO placebo 1 mg/kg/day, once a day Week 7: PO placebo 0.8 mg/kg/day, once a day Week 8: PO placebo 0.6 mg/kg/day, once a day Week 9: PO placebo 0.4 mg/kg/day, once a day Week 10: PO placebo 0.2 mg/kg/day, once a day Week 11: PO placebo 0.1 mg/kg/day, once a day Week 12-13: PO placebo 0.1 mg/kg/day, once a day every other day Week 14: Stop"
45395483|NCT00307034|Biological|GSK Biologicals' 10-valent pneumococcal conjugate vaccine.|Intramuscular injection, 3 or 4 doses (2-4-11 or 2-3-4-11 months of age schedule).
45715230|NCT05352958|Other|Electro-physiological exploration of the diaphragm|duration between 30 and 60 minutes performed at M0
45395484|NCT00307034|Biological|Infanrix hexa.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
45395485|NCT00307034|Biological|Infanrix-IPV/Hib.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
45395486|NCT01061996|Drug|Basiliximab|Study Drug: basiliximab 40 mg, given as a short intravenous infusion Dosing Schedule: once every 4 weeks Concomitant Therapy: Oral corticosteroids (prednisone or equivalent) will be tapered during the first few months of the study participation Duration of Study Participation: The duration of individual study participation will vary.
45395487|NCT01069458|Other|The high protein diet group and the low fat diet group|The High Protein Diet Group was advised to have 25 energy percent from protein, 55 energy percent from fat, 20 energy percent from carbohydrate in the diet and the Low Fat Diet Group was advised to have 30 energy percent from fat, 20 energy percent from protein, 50 energy percent from carbohydrate in the diet.
45395488|NCT01064180|Drug|Carvedilol|Carvedilol Tablets 25 mg
45395489|NCT01069536|Drug|metoclopramide 10 mg|
45395490|NCT01069614|Device|TopClosure 3S System|
45395491|NCT03980106|Other|Reciprocal Inhibition Muscle Energy Technique|In this technique, the subject will be asked to contract antagonist muscles against a moderate resistant force provided by the therapist to inhibit the contraction of the agonist muscle.
45503481|NCT02064998|Behavioral|PartyPlanner|Smartphone-adapted web-based app for simulating an event with alcohol consumption in advance, real time monitoring of alcohol use with eBAC feedback during the event and later possibility of comparison between the plan and the event.
45503482|NCT02064998|Behavioral|TeleCoach|Smartphone app providing exercises and vignettes for reducing or abstaining from alcohol consumption.
45503483|NCT02032602|Other|Deep Dry Needling|
45503484|NCT01359553|Other|Intra-articular ultrasound imaging of knee joint during arthroscopy|
45503485|NCT01359553|Other|Non-invasive ultrasound imaging of knee|
45503486|NCT01359553|Other|Quantitative MRI imaging of knee|
45503487|NCT01359553|Other|Contrast-enhanced CT imaging of knee|
45503488|NCT02068742|Other|battery neuropsychological tests|Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
45503489|NCT02032836|Drug|lloprost(Ventavis,BAYQ6252, 20 µg/mL)|20 µg/mL iloprost nebulizer solution, inhaled with FOX nebulizer
45503490|NCT02032836|Drug|lloprost(Ventavis,BAYQ6252, 10 µg/mL)|10 µg/mL iloprost nebulizer solution, inhaled with I-Neb nebulizer
45503491|NCT01348217|Radiation|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph node"|40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
45503492|NCT01348217|Radiation|Boost|Boost 10 Gy in 5 fr, PTV = +1cm.
45715231|NCT03106194|Other|case management|
45715232|NCT05339542|Other|platelet rich plasma|derived from patient own blood
45503493|NCT01348217|Radiation|Boost|Boost 26 Gy in 13 fr, PTV = +1cm.
45503494|NCT01348217|Drug|chemotherapy: FOLFOX 4|6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
45849198|NCT00001956|Procedure|Oral surgery|
45395492|NCT03980106|Other|Post-Isometric Inhibition Muscle Energy Technique|In this technique, the subject will be asked to contract agonist muscles against a moderate resistant force provided by the therapist to inhibit the contraction of the agonist muscle.
45395493|NCT03976674|Behavioral|Cognitive Behavioural Therapy (CBT)|5 group sessions (2h30/session) before the surgery
45395494|NCT01064778|Other|Low GI|Subjects will be instructed to consume a liquid test meal with a low GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The low GI meal corn-starch as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p<0.001). The test meals will provide 25% of individual daily energy requirements.
45395495|NCT01064778|Other|High GI|Subjects will be instructed to consume a liquid test meal with a high GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The high GI meal contains corn-syrup as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p<0.001). The test meals will provide 25% of individual daily energy requirements.
45395496|NCT00320216|Drug|Ustekinumab|Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).
45395497|NCT00320216|Drug|Placebo|Patients in the placebo group will receive placebo medication.
45395498|NCT00290706|Drug|bortezomib|Bortezomib 1.6mg/m2 on days 1 and 15 of each cycle, given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
45395499|NCT00290706|Drug|gemcitabine hydrochloride|Gemcitabine dose of 800 mg/m2 over 30 minutes on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
45715233|NCT05339542|Drug|MethylPREDNISolone 40 MG|active comparative intervention
45395500|NCT03978156|Drug|Dronabinol 2.5 MG|Subjects will take dronabinol daily during 2 week dosing period separated by a one week washout period.
45395501|NCT03978156|Drug|Microcrystalline cellulose|Subjects will take placebo daily during 2 week dosing period separated by a one week washout period.
45395502|NCT03978234|Drug|AbobotulinumtoxinA 300 UNT|AbobotulinumtoxinA 300 UNT
45503495|NCT02065076|Drug|Sodium polystyrene sulfonate|
45395503|NCT01064934|Procedure|Lipid apheresis|Weekly lipid apheresis procedure for lipoprotein(a) lowering
45503496|NCT02065076|Drug|Lactose with carob gum|
45503497|NCT02465593|Drug|PEP503|The volume of PEP503 to be administered is based on the baseline tumor volume of each patient. There will be 4 dose levels in Phase Ib.
45503498|NCT02465593|Drug|5-fluorouracil|225 mg/m2 a day, 5 days/week for 5 weeks during radiotherapy period
45715234|NCT03162900|Drug|Glasdegib Therapeutic Exposure|Subjects Receive a single 150 mg dose of Glasdegib followed by ECG and PK assessments.
45715235|NCT03162900|Drug|Glasdegib Supra-therapeutic Exposure|Subjects receive a single 300 mg dose of glasdegib followed by ECG and PK assessments.
45849199|NCT00001956|Procedure|Tissue biopsy|
45849200|NCT00001968|Drug|Amprenavir|
45849201|NCT00001968|Drug|Ritonavir|
45849202|NCT00001968|Drug|Abacavir|
45849203|NCT00001968|Drug|Lamivudine|
45395504|NCT01064934|Other|Standard care|Standard care for maximum cardiovascular risk reduction (behavioural, exercise, nutrition, drugs, etc.)
45395505|NCT01066494|Drug|Amonafide + cytarabine|Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
45395506|NCT03977766|Procedure|Chemotherapy prevalidation|"Outpatient Chemotherapy prevalidation will done~with the help of a nurse, using the digital application, for cycle 2 and 3.~by the patient alone, using the digital application, for cycle 4 and 5."
45395507|NCT03977688|Device|Cytokin Adsorption|Haemadsorption with Cytokin Adsorber (Cytosorb)
45395508|NCT01069770|Drug|Sunitinib|50mg daily(4 weeks on & 2 weeks off), 2 cycles, until progression or unacceptable toxicity develops
45503499|NCT02465593|Drug|capecitabine|825 mg/m2 BID 5 days/week for 5 weeks during the radiotherapy period
45503500|NCT02465593|Procedure|surgical resection|Approximately 8 weeks after the completion of chemoradiotherapy, surgical resection of the tumor (total mesorectal excision, TME) will be performed once the tumor become resectable.
45395509|NCT00303108|Drug|Pegylated liposomal doxorubicin|30 mg/m2 IV on Day 1 of each 28 day cycle
45503501|NCT02465593|Radiation|Radiotherapy|Intensity-modulated radiation therapy (IMRT) or intensity modulated arc therapy (IMAT) of 5,000 cGy in 25 fractions (200 cGy/fraction, 5 times/week) to gross tumor and involved nodes and 4,500 cGy in 25 fractions (180 cGy/fraction, 5 times/week) to pelvis, starting at 24 hours after PEP503 injection.
45395510|NCT00303108|Drug|Carboplatin|AUC=5 on Day 1 of each 28 day cycle
45503502|NCT02068898|Drug|XS003|
45503503|NCT02068898|Drug|Tasigna|
45503504|NCT03611322|Drug|Semaglutide, 0.25 mg|Semaglutide will be administered subcutaneously (s.c., under the skin) on day 1 and 8 in the morning after an overnight fast of at least 8 hours
45503505|NCT03611322|Drug|Semaglutide, 0.5 mg|Semaglutide will be administered s.c. (under the skin) on day 15 and 22 in the morning after an overnight fast of at least 8 hours
45503506|NCT03611322|Drug|Semaglutide, 1.0 mg|Semaglutide will be administered s.c. (under the skin) on day 29 in the morning after an overnight fast of at least 8 hours
45503507|NCT03611322|Device|DV3372|DV3372 device will be used for administration of semaglutide
45503508|NCT03611322|Device|PDS290 pen-injector|PDS290 pen-injector will be used for administration of semaglutide
45503509|NCT02424019|Drug|ILUVIEN 0.19 MG|
45503510|NCT01346423|Behavioral|Interdisciplinary intervention|Interdisciplinary collaboration deals with tasks often complex which require different skills to make a wide assessment.In this study the treatment team consists of a physician, a physiotherapist and a social service worker. The main goal for the team is to make a survey of the patient's situation, in which the biomedical tradition to make a diagnosis is replaced by a disability diagnosis, with systematically identification of barriers for return to work. The conclusion of the team will be followed by a targeted rehabilitation plan. Factors assessed to be the major cause of the reduced function at work will have priority in the following rehabilitation process. One of the team members will be responsible for the further process to follow the plan to help the patient back to work, in cooperation with the patient, the workplace, the general practitioner, and NAV.
45503511|NCT01346423|Behavioral|Control Group, Brief Intervention|The brief intervention is a standardized intervention and the essential features are interview and examination by a specialist in physical medicine and rehabilitation. Patients will be given time to express their concerns and problems in daily activities. The examination is thorough with detailed feedback on findings and normal functions, and clear and consistent explanations on pain and defense mechanisms. Somatic findings will be explained.Unless pathological findings, the patient will be encouraged to physical activity.
45849204|NCT00001986|Drug|1-Octanol|
45849205|NCT00001992|Biological|rgp120/HIV-1IIIB|
45849206|NCT00001998|Drug|Nystatin|
45849207|NCT00002004|Drug|CD4 Antigens|
45395511|NCT00303108|Drug|trastuzumab|4 mg/kg on Days 1 and 15 of each cycle(loading dose of 8 mg/kg on Day 1 of Cycle 1 only)
45395512|NCT00302952|Drug|Lovastatin|Two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
45395513|NCT00302952|Drug|Placebo|Two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
45849208|NCT00002010|Drug|Fluconazole|
45849209|NCT00002016|Drug|Sevirumab|
45849210|NCT00002022|Drug|Epoetin alfa|
45849211|NCT00002028|Drug|Didanosine|
45849212|NCT00002034|Drug|Zidovudine|
45849213|NCT00002034|Drug|Ganciclovir|
45395514|NCT00302718|Behavioral|Physician-level financial incentives|Enrolled physician participants are eligible to receive financial incentives and audit and feedback reports based on their performance during a 4-month interval on the hypertension care study outcomes.
45395515|NCT00302718|Behavioral|Practice-level financial incentives|Enrolled practices (physician physicians and non-physician primary care personnel) are eligible to receive financial incentives and audit and feedback reports based on the performance of the practice during a 4-month interval on the hypertension care study outcomes.
45395516|NCT00302718|Behavioral|Physician- and practice-level financial incentives|Enrolled participants are eligible to receive financial incentives and audit and feedback reports based on performance during a 4-month interval on the hypertension care study outcomes. This arm tests the effect of combined financial incentives (physician-level incentives and practice-level incentives).
45697127|NCT01610908|Other|Global Postural Re-Education|The 6-month supervised Global Postural Re-education intervention involves active movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. These postures imply an active participation of the patient. Global Postural Re-education includes eight therapeutic postures, lying, sitting or standing, held for 15/20 min. each. Variously combinations are used during sessions chosen on based on the amount of pain, load capacity, age of the patient, and muscle chains to be stretched. Static and dynamic functions are also employed for about five minutes each sessions to use the recovered flexibility in functional activities Dosage: Weekly individual 1-hour long sessions, with daily 15 minutes home exercise program over 6 months.
45395517|NCT03976206|Biological|Very small embryonic-like stem cell|We carried out the subdermal application of VSELs with a 1-mL syringe (volume, 0.4 mL) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
45395518|NCT01069848|Device|Vedera KXS|One treatment session with Vedera KXS
45395519|NCT01066572|Drug|Lisinopril|5-10 mg Lisinopril per day for seven days, depending on blood pressure.
45395520|NCT01066572|Drug|Placebo|Matched placebo; identical tablets to Lisinopril.
45395521|NCT01066650|Device|Endeavor Resolute (Biolinx-based Zotarolimus-eluting stent)|Drug eluting Stent
45395522|NCT01066650|Device|Xience V (Everolimus-eluting stent)|Drug eluting stent
45395523|NCT00302328|Procedure|macular hole operation|macular hole surgery with either no peeling, indocyanine green (ICG) assisted peeling or trypan blue (tb) peeling
45395524|NCT01066728|Other|CO2 inhalation|Inhalation of CO2 (3% at the source, approximately 1% inhaled) with room air by nasal prongs at 0.5 l/min for 3 days
45395525|NCT01066728|Drug|Theophylline|
45395526|NCT01069926|Drug|AZD1656|Single dose oral tablet
46057015|NCT00730171|Drug|Linaclotide|Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.
45395527|NCT01070004|Other|Real driving situation|Continuous blue light exposure during driving compared to effects of coffee (2*200 mg of caffeine) and coffee placebo on 4h night-time real driving situation. Inside this arm, each volunteer will be randomly allocated and will all receive : continuous blue light exposure, coffee and coffee placebo at each driving session with at least 1 week between each condition.
45697128|NCT05687409|Drug|Entecavir 0.5 mg|Orally administered Entecavir 0.5 mg, once a day. For six months
45395528|NCT01070004|Other|Driving simulator|15 minutes of physical activity at a low intensity before driving compared to effects of coffee (2*200 mg of caffeine) and coffee placebo on 4h night-time driving simulator. Inside this arm, each volunteer will be randomly allocated and will all receive : 15 minutes of physical activity, coffee and coffee placebo at each driving session with at least 1 week between each condition.
45395529|NCT01325610|Dietary Supplement|cholecalciferol|a weekly dose of 20,000 IU of vitamin D3 will be given orally for 12 weeks.
45395530|NCT03977844|Other|Technical Assistance|"TA for Individual Programs TA uses experts to train program staff via webinars and site visits, using the same toolkits as CEP, in a train the trainer approach. TA provides a series of webinars and as needed site visits, focused in the example of depression care on team support for assessment, treatment support as appropriate with medication and/or psychotherapy, case management and educational resources and access to intervention toolkits. It also includes webinars and training toolkits for agencies on domains of social risk factors for health (financial security and housing security) as well as disaster preparedness and recovery."
45503512|NCT03610776|Device|Portion control plate|Portion control plate including demarcations and pictures for recommended amounts of main food groups (starch, protein and vegetables), 25 cm in diameter, enamel, white background.
45715236|NCT03162900|Drug|Positive Control (Moxifloxacin)|Subjects will receive a single 400 mg dose of moxifloxacin followed by ECG and PK assessments.
45849214|NCT00002040|Drug|Fluconazole|
45395531|NCT03977844|Other|Community Engagement and Planning|CEP for Coalitions CEP creates multi-sector networks to collaborate in evidence-based and community-prioritized toolkits or intervention materials. CEP supports a series of biweekly to monthly meetings to develop network and individual program capacity, prepare stakeholders as co-leads, and create a written training plan following CPPR principles [48, 64]. CEP councils consider local context, i.e., cultural assets and stakeholder input. Disaster preparedness and public health sectors will be encouraged to offer education/resources on social determinants and disasters within CEP training plans. CEP will be supported by a Learning Collaborative, meeting 2-3 times, using activities such as project examples, tabletop exercises and self-assessment to identify gaps and formulate goals for improvement.
45395532|NCT03977844|Other|Community Resources (CR)|The CR app will primarily provide informational resources and referral information relevant to the local community. We will identify resources for depression, social determinants and disaster preparedness and response within each community during planning with local stakeholders.
45697129|NCT05687409|Drug|A 10-g packet of lactulose oral solution and three capsules of probiotics|"A 10-g packet of lactulose oral solution and three capsules of probiotics (each containing > 4.2×106 CFU Clostridium butyricum and > 4.2×105 CFU Bifidobacterium longum infantis).~Participants orally administered the contents three times daily after meals. For six months."
45849215|NCT00002046|Drug|Zidovudine|
45849216|NCT00002052|Drug|Ceftriaxone sodium|
45849217|NCT00002052|Drug|Ampicillin sodium|
45849218|NCT00002052|Drug|Amoxicillin trihydrate|
45849219|NCT00002058|Drug|Clofazimine|
45503513|NCT03610776|Device|Conventional plate|Conventional plate without demarcations or images, 25 cm in diameter, enamel, white.
45503514|NCT01346579|Other|laboratory biomarker analysis|Correlative sciences
45503515|NCT03611088|Other|Kangaroo Position.|The kangaroo position - the newborn is positioned in the adult's breasts, face down, should be dressed in light clothes and wrapped in a flexible cloth.
45503516|NCT02066870|Drug|Icotinib|Icotinib is administered orally 125 mg three times per day, until disease progression or untolerated toxicity.
45849220|NCT00002064|Drug|Pyrimethamine|
45849221|NCT00002064|Drug|Clindamycin|
45697130|NCT05687409|Dietary Supplement|A 10-g packet of glucose oral solution and three capsules of starch|A 10-g packet of glucose oral solution and three capsules of starch. Participants orally administered the contents three times daily after meals. For six months.
45697131|NCT05679063|Other|Physiotherapy|A program of therapeutic exercise and education in the neurophysiology of pain will be applied to the participants of the experimental group
45697132|NCT05679063|Other|Sham, Control|Talks about healthy habits
45697133|NCT02162680|Drug|1% lidocaine|
45697134|NCT02162680|Drug|bacteriostatic normal saline (BNS)|
45849222|NCT00002070|Drug|Sargramostim|
45849223|NCT00002070|Drug|Ganciclovir|
45849224|NCT00002076|Drug|Fluconazole|
45849225|NCT00002082|Drug|Azithromycin|
45849226|NCT00002088|Drug|Saccharomyces boulardii|
45849227|NCT00002094|Drug|Atevirdine mesylate|
45849228|NCT00002100|Drug|Curdlan sulfate|
45849229|NCT00002106|Drug|Ranitidine hydrochloride|
45849230|NCT00002112|Drug|Nystatin|
45849231|NCT00002112|Drug|Fluconazole|
45849232|NCT00002118|Drug|Zalcitabine|
45849233|NCT00002124|Drug|Delavirdine mesylate|
45849234|NCT00002124|Drug|Lamivudine|
45849235|NCT00002124|Drug|Zidovudine|
45849236|NCT00002130|Drug|Vesnarinone|
45849237|NCT00002136|Drug|Tecogalan sodium|
45849238|NCT00002142|Drug|Cidofovir|
45849239|NCT00002142|Drug|Probenecid|
45849240|NCT00002148|Drug|OPC 14117|
45849241|NCT00002154|Drug|Thioctic acid|
45849242|NCT00002154|Drug|Selegiline hydrochloride|
45849243|NCT00002160|Drug|Ziconotide|
45849244|NCT00002166|Drug|Nevirapine|
45849245|NCT00002172|Biological|HIV-1 Immunogen|
45849246|NCT00002178|Drug|Ritonavir|
45849247|NCT00002178|Drug|Nelfinavir mesylate|
45849248|NCT00002178|Drug|Saquinavir|
45849249|NCT00002178|Drug|Delavirdine mesylate|
45849250|NCT00002184|Drug|Nelfinavir mesylate|
45849251|NCT00002184|Drug|Levocarnitine|
45849252|NCT00002184|Drug|Adefovir dipivoxil|
45395533|NCT03977844|Other|Community Resources + eBT|"The CR+eCBT app consists of the functionality of the CR app along with an interactive component to support CBT-informed coping with mood and stressors at the individual level. This component was developed previously by our group using participatory methods with community partners and includes interactive support to enhance social support networks, support cognitive restructuring (framed through partnered input as Catch it, Check it, Change it), and encourage pleasant activities [65]. Participants will receive text message notifications (with frequency set by participants, up to several times per day) and can either reply back to messages to explore content or click a link in the message to access the interactive mobile app."
45395534|NCT00301080|Drug|D-cycloserine|
45395535|NCT00301080|Other|Placebo|
45395536|NCT01066806|Behavioral|counseling on increasing calcium intake|The American Academy of Pediatrics recommends that adolescents ingest at least four servings of dairy food and at least 1300 mg calcium per day.
45395537|NCT01066806|Other|observation|observe normal dairy intake
45395538|NCT03977610|Drug|Ga-68 PSMA ligand|For PSMA PET/CT scan, the subject will have catheter(s) placed for intravenous administration of [68Ga]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi [68Ga]PSMA-11 and received PET/CT scan 60 minutes later. Patient will underwent two times of PSMA-11 PET/CT scans before and under androgen deprivation therapy within a 10-14 weeks interval.
45395539|NCT01066884|Drug|erlotinib [Tarceva]|150mg po daily
45395540|NCT01581216|Other|10 minute walk|Patients who walk a distance ≤ 300 meters in the 6-minute walk test will make a 10 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
45395541|NCT01581216|Other|20 minute walk|Patients who walk 300-450 meters in the 6-minute walk test will make a 20 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
45395542|NCT01581216|Other|30 minute walk|Patients who walk a distance less than 450 meters in the 6-minute walk test will make a 30 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
45849253|NCT00002184|Drug|Saquinavir|
45503517|NCT02066870|Drug|Arsenic trioxide|"Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved."
45503518|NCT05030363|Drug|ALDH enzyme supplementation|ALDH enzyme (PICOZYMEQ™)
45503519|NCT03635203|Device|CBCT|Observation of C-shaped root canal in mandibular first and second molars in Egyptian sub-population
45697135|NCT05678673|Drug|XL092|Specified doses on specified days
45697136|NCT05678673|Drug|Nivolumab|Specified doses on specified days
45849254|NCT00002184|Drug|Lamivudine|
45395543|NCT00290238|Device|Vertis Percutaneous Neuromodulation Therapy (PNT)|"Ten PNT sessions in eleven weeks~On average, one PNT session per week~Ten lumbar Safeguide electrodes (three centimeters in length) deployed per lumbar montage~Forty-five minutes of electrical stimulation for each session~Electrical stimulation parameters:~Continuous 50 Hz current~Charge-balanced, biphasic (each phase is 200 microsec), rectangular waveform~Intensity to subject's tolerance for ten minutes then increased to a mildly uncomfortable level"
45395544|NCT00290238|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|"Ten TENS sessions in eleven weeks~On average, one TENS session per week~Four 2-inch (5.1 centimeters) diameter pads applied per TENS lumbar montage~Forty-five minutes of electrical stimulation for each session~Electrical stimulation parameters:~Current at 2 Hz-low frequency~Pulse trains delivered as asymmetric, biphasic, square waveform current, with pulse width lasting 20 microsec~Intensity titrated according to subject's sensory threshold~To maintain blinding, the treating physician or clinician will check on the subject after 10 minutes and dial the channels down just prior to the point of turning off the device."
45395545|NCT02532270|Drug|phenylephrine|When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug in Group C and Group N.If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
45395546|NCT01581450|Drug|Nitrous Oxide|35%
45395547|NCT01581450|Drug|Nitrous Oxide|50%
45395548|NCT01325766|Other|Yoga|Yoga 2 sessions per week for 8 weeks
45395549|NCT03976284|Behavioral|Garden-fresh produce and exercise|The Garden-fresh produce and exercise (GFPE) health promotion intervention features 10 weekly sessions that take place after Sunday services in the Lincoln Memorial Church kitchen/meeting space. Each session includes a cooking demonstration focused on how to prepare and cook a meal composed of fiber-rich plant foods minimally processed. Each session also includes brief, didactic nutrition instruction and a 10-minute bout of physical activity.
45697137|NCT05678673|Drug|Sunitinib Malate|Specified doses on specified days
45697138|NCT02162992|Other|No intervention|Observational
45697139|NCT05687331|Procedure|knee arthrocentesis|arthrocentesis of the knee joint to gather a synovial fluid sample
45697140|NCT05687331|Procedure|venipuncture|Peripheral venipuncture to gather a blood sample
45697141|NCT05687331|Diagnostic Test|MRI-scan|MRI-scan of the knee
45697142|NCT05687331|Diagnostic Test|Physical examination|Physical examination of the injured knee
45697143|NCT05687331|Other|KOOS questionnaire|KOOS questionnaire of the injured knee
45395550|NCT00289848|Drug|sitagliptin phosphate|Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks.
45395551|NCT00289848|Drug|Comparator: placebo|placebo to match Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks
45395552|NCT00289770|Biological|Twinrix™|Intramuscular injection, 3 doses
45395553|NCT00289536|Biological|Antihemophilic factor, recombinant, manufactured protein-free|15 IU/kg rAHF-PFM
45395554|NCT00289536|Biological|Antihemophilic factor, recombinant, manufactured protein-free|30 IU/kg rAHF-PFM
45395555|NCT00289536|Biological|Antihemophilic factor, recombinant, manufactured protein-free|50 IU/kg rAHF-PFM
45395556|NCT00289458|Behavioral|exercise|A community aquatic exercise program designed for older adults to improve balance, strength and mobility to decrease the risk of falls.
45395557|NCT00289458|Behavioral|2|Same as 1 with the addition of a 1/week educational group program to improve confidence in movement, learn about fall risk and fall prevention and the rationale for the exercises to decrease fall risk.
45395558|NCT00289458|Behavioral|Control|no exercise
45395559|NCT00288912|Behavioral|Health Education|12-month intervention consisting of monthly phone calls about common health conditions and screening. Also includes written educational materials on these topics.
45395560|NCT00288912|Behavioral|Osteoarthritis Self-Management|12-month intervention consisting of monthly phone calls about topics related to self-care for osteoarthritis. Also includes written educational materials on these topics. Participants set goals and action plans, with assistance from health educator, about managing their osteoarthritis.
45395561|NCT01066962|Drug|darunavir/ritonavir QD + raltegravir BID|"darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~raltegravir 400 mg, 1 tablet twice daily (BID)"
45395562|NCT01066962|Drug|darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)|"darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~tenofovir/emtricitabine 245/200 mg, fixed dose combination, 1 tablet once daily (QD)"
45395563|NCT03977532|Other|Micro-blood sampling|capillary sampling of 40 microliters performed at the fingertip
45395564|NCT01067118|Drug|LINjeta U-100 Insulin|LINjeta U-100 Insulin will be used per the subjects normal insulin carbohydrate and insulin sensitivity factors
45395565|NCT01067118|Drug|Humalog U-100|Normal short acting insulin used in participants daily life including carbohydrate ratios and insulin sensitivity factors
45395566|NCT01067274|Drug|Vesanoid (ATRA)|45 mg/m2/day in two divided doses from D8 to D28
45395567|NCT01067274|Drug|AZACITIDINE (VIDAZA)|75 mg/m2/12h SC from D1 to D5
45395568|NCT01067274|Drug|CYTARABINE|Cytarabine : 60 mg/m2/12h SC from D1 to D5
45395569|NCT01065246|Drug|catumaxomab|4 intraperitoneal infusions within 11 days administered over 3 hours via an indwelling catheter at the following doses: 10 - 20 - 50 - 150 µg catumaxomab
45395570|NCT01325844|Procedure|Epidural anesthesia|0.5% ropivacaine infusion via epidural catheter at 5ml/hr during general anesthesia
45395571|NCT04307628|Other|Walnut|Study participants will eat 2 ounces of walnuts each day.
45395572|NCT04307628|Other|Nut-Free|Study participants will not eat nuts.
45395573|NCT01067430|Drug|Etoricoxib|Film coated tablet, 90 mg taken once a day for 14 days
45849255|NCT00002184|Drug|Stavudine|
45395574|NCT01067430|Drug|Diclofenac|Enteric coated tablet 50 mg given three times a day for 14 days
45395575|NCT00305864|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
45395576|NCT00305864|Drug|Motexafin Gadolinium|Given IV
45395577|NCT00305864|Drug|Temozolomide|Given orally
45395578|NCT00295880|Procedure|umbilical cord blood transplantation|The graft will be given by slow injection into each posterior iliac crest.
45395579|NCT01066130|Behavioral|Intensive individualized psychosocial treatment|Each person was given psychosocial treatment and support by a medical social worker a maximum of one time each week for a period of up to 2 years after inclusion. Treatment was designed by a medical social work on the basis of the individual's personal needs.
45395580|NCT01066130|Behavioral|Minimal treatment arm|Minimal social measures were provided to individuals in this arm. No treatment that included conversational therapy was given.
45395581|NCT03979196|Other|Inpatient Management|"Admission for a minimum of three days, administration of betamethasone, and clinical reassessment by obstetrician after three days. After the initial three day admission, further management will be at the discretion of their obstetrician who will continue their care and decide if further admissions are needed.~Weekly cervical length assessment will be performed until 28 weeks and patient readmission will be decided by their Obstetrician.~Post-intervention, women in both arms will receive the same standard of care (weekly clinic or inpatient follow-up appointments) and will be followed to delivery. Prior to delivery, participants will complete a patient Quality of Life survey and at delivery, primary and secondary outcomes will be collected."
45715237|NCT03162900|Other|Placebo Control|Subjects will receive placebo dose followed by ECG and PK assessments.
45849256|NCT00002184|Drug|Zidovudine|
45849257|NCT00002190|Drug|Saquinavir|
45395582|NCT03979196|Other|Outpatient Management|"Avoid heavy lifting and core exercise, avoid intercourse, weekly assessment of cervical length by ultrasound and administration of betamethasone. Patients will continue with outpatient management for the remainder of their pregnancy with no admission unless the patient develops contractions, PPROM, bleeding, or the cervix is dilated to ≥1cm.~Post-intervention, women in both arms will receive the same standard of care (weekly clinic or inpatient follow-up appointments) and will be followed to delivery. Prior to delivery, participants will complete a patient Quality of Life survey and at delivery, primary and secondary outcomes will be collected."
45395583|NCT03978962|Device|Guided Tissue Regeneration|"Covering oral-maxillofacial or a periodontal defects with the Resorbable Collagen Membrane in order to avoid epithelial cell infiltration and to promote periodontal tissues healing.~Covering alveolar bone defects after tooth-teeth extraction."
45395584|NCT01325480|Device|Cardiac Pacing|
45395585|NCT03982784|Procedure|single-injection TQLB(transmuscular quadratus lumborum block)|Inject 0.6ml/kg local anesthetics in between quadratus lumborum and psoas major under ultrasound guidance
45395586|NCT03982784|Drug|Morphine given as IPCA(intravenous patient controlled analgesia)|PCIA was initiated using a pump set to deliver boluses of 1.5-2 mg of morphine with a 5-minute lockout interval and no background infusion. The maximal permitted dosage of morphine was set at 8 mg/h.
45395587|NCT03978884|Drug|Losartan 50Mg Tab|Take 1 tab daily
45395588|NCT03978884|Drug|Losartan/Hydrochlorothiazide 50 Mg-12.5 Mg ORAL TABLET|Take 1 tab daily
45395589|NCT03978884|Drug|Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET|Take 1 tab daily
45395590|NCT03978884|Drug|Amlodipine 5mg|Take 1 tablet daily
45395591|NCT00319982|Drug|Diltiazem|Sustained release formulation titrated to a target dose of 360 mg daily, or a maximum of 5 mg/kg/day in pediatric subjects for the duration of the study period
45395592|NCT00319982|Drug|Placebo|Placebo comparator (double-blind allocation of study medication)
45395593|NCT00319592|Biological|ChimeriVax™-JE vaccine|0.5 mL, subcutaneously
45395594|NCT00319592|Biological|JE-VAX® vaccine|1.0 mL, subcutaneously
45395595|NCT00295490|Drug|Devil Claw|Dose ranging study so will elucidate dose Frequency is four times daily
45395596|NCT00295490|Drug|Placebo|Placebo has same dosing freq as for active intervention and for same time period
45395597|NCT03980990|Drug|Metformin|Continuation of Metformin
45395598|NCT03980756|Drug|AD-206 20mg|1 tablet administered before the breakfast during 7 days
45849258|NCT00002190|Drug|Lamivudine|
45395599|NCT03980756|Drug|Esomeprazole 20mg|1 tablet administered before the breakfast during 7 days
45395600|NCT03980756|Drug|AD-206 40mg|1 tablet administered before the breakfast during 7 days
45395601|NCT03980756|Drug|Esomeprazole 40mg|1 tablet administered before the breakfast during 7 days
45395602|NCT00305006|Procedure|Constraint-Induced Movement Therapy (CIMT)|90 hours
45395603|NCT00305006|Procedure|Hand-Arm Bimanual Intensive Therapy (HABIT)|90 hours
45395604|NCT01064258|Device|CPAP|CPAP at 4 cm H2O
45395605|NCT01064258|Device|autoCPAP|autoCPAP working between 4 and 15 cm H2O
45395606|NCT01064336|Drug|Eltrombopag|Eltrombopag is an orally bioavailable, small molecule thrombopoietin receptor (TPO-R) agonist for the treatment of idiopathic thrombocytopenic purpura
45395607|NCT03980444|Device|Basket of wire|(using a basket of wires3F) the helical type was passed through the four wires of the working channel of the orthoscope and routed to the proximal part of the rock, and the stone was routed to the bowl, then the stone was ducted The gasket was kept, and the probe of the pneumatic crusher also passed through the working channel and proceeded to break it down. Conditions were observed during the stomach as control group. Urethroscopic crushing was performed by a urologist in both groups under similar technical conditions. Findings during and after the completion of crushing include the success, stone retropulsion or parts larger than 3 mm, which requires secondary measures (SWL - ureter stenting, resection ureteroscopy), the duration of stone breakdown and traumatic ureteric complications in both groups it is registered
45697144|NCT05678439|Dietary Supplement|sesame extract|At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of sesame extract (sesamin 37-56mg per capsule). The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
45395608|NCT03980444|Procedure|control group, no basket|"In each group, ureteroscopy was performed using a standard F9.5 ureteroscope. After reaching the rock in group A (control), the probe of the pneumatic crusher was passed through the working channel of the ureteroscope and began crushing the rock.~During the crushing process, the minimum flow of water, flattening and the single-shot impact was used to minimize the stone's retropulsion."
45395609|NCT03980600|Device|FibDex wound dressing|Treatment of donor sites of 24 patients with the dressing Type 4 (final product i.e. FibDex) until the self-detachment of the wound dressing i.e. epithelialization
45395610|NCT03980600|Device|NFC wound dressing Types 1-3|Treatment of donor sites of 9 patients with the NFC dressing's (proto)Types 1-3 until the self-detachment of the wound dressing i.e. epithelialization
45395611|NCT03980600|Device|Suprathel (comparator)|Treatment of donor sites of 22 patients with Suprathel dressing, which was used as a reference (comparator) product, until the self-detachment of the wound dressing i.e. epithelialization
45395612|NCT03978572|Behavioral|Resistance Training|Exercise intervention designed to improve muscular strength and power
45395613|NCT03978572|Behavioral|Moderate-Intensity Continuous Cycling|Exercise intervention designed to improve cardiorespiratory fitness and muscular endurance
45697145|NCT05678439|Other|placebo|At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of placebo. The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
45849259|NCT00002190|Drug|Zidovudine|
45849260|NCT00002196|Drug|CI-1012|
45849261|NCT00002202|Drug|Indinavir sulfate|
45849262|NCT00002202|Drug|Amprenavir|
45849263|NCT00002208|Drug|Indinavir sulfate|
45849264|NCT00002208|Drug|Lamivudine|
45849265|NCT00002208|Drug|Stavudine|
45849266|NCT00002208|Drug|Zidovudine|
46057016|NCT04787835|Procedure|Forearm nerve block|Local anesthesia will be used to perform a forearm block of the median, radial, and ulnar nerves.
45395614|NCT03978572|Behavioral|High-Intensity Interval Cycling|Exercise intervention designed to improve cardiorespiratory fitness, muscular endurance, and muscular strength and power
45395615|NCT00319436|Behavioral|Mentalizing Therapy for Substance Using Mothers|This 12 session individual therapy aims to enhance maternal reflective functioning and soften harsh and distorted mental representations about the child. The intervention adopts a developmental progression based on attachment theory, supporting the mother in her parenting role and offering assistance with basic needs. Mothers are encouraged to reflect on their thoughts and feelings and how they affect behavior. The therapist assists mother's thinking about representations of herself as a parent and encourages her to explore opportunities for new understanding of her emotional needs. Therapist and mother explore representations of her child and their relationship in detail in order to understand their meaning and promote more balanced representations and affect regulation. Therapist and mother also explore child's emotional experiences underlying behavior. The goal is to support the mother in becoming more aware of her child's emotional needs.
45395616|NCT00319436|Behavioral|Standard Parent Education for Substance Using Mothers|This 12 session comparison was designed to match the experimental intervention on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.
45395617|NCT03978494|Drug|Advagraf®|Advagraf®1 mg and 5 mg prolonged-release hard capsules once daily (reference medicinal product).
45395618|NCT03978494|Drug|Generic tacrolimus|Tacrolimus 1 mg and 5 mg prolonged release hard capsules (Sandoz) once daily (test medicinal product)
45395619|NCT03978416|Behavioral|Healthy Weight for Living for Hispanics|"The Healthy Weight for Living (HWL) intervention, previously developed at the Energy Metabolism Laboratory (HNRCA), is broadly informed by the same behavior change theories as other interventions. For example, it also recognizes individual and environmental factors as potential areas to support behavior change for weight regulation, and provides practical tools for facilitating new habits. However, the HWL places greater emphasis on the role of biology in influencing eating behavior, giving a central role to hunger and food cravings as modulators of eating behavior. Therefore, HWL does not emphasize self-monitoring food intake and does not require increasing physical activity for effectiveness. The new intervention also targets autonomous motivation and prioritizes ease of implementation.~Information from focus groups and sequential pilots will be used to develop a culturally tailored prototype version of Healthy Weight for Living that is acceptable for Hispanic older adults."
45395620|NCT03980288|Drug|CAR-GPC3 T Cells|Pretreatment with fludarabine and cyclophosphamide CAR-GPC3 T Cells infusion
45395621|NCT03980678|Dietary Supplement|Mineral Rich Algae|Lithothamnion species is rich in calcium, magnesium (Mg) and 72 other trace elements absorbed from sea-water during the organisms life. Mineral-rich 'fronds' break off from the living organism, fall to the ocean floor and are harvested (AquaminF). The mineral extract in soluble form contains ~13.1% Calcium, ~1.04% Magnesium and measurable levels of 72 other trace minerals. Following or prior to a washout period (crossover intervention), participants will consume the Aquamin Soluble equivalent of 1000mg Calcium in 250 ml of orange flavored water for a 7 day loading period.
45395622|NCT03980678|Dietary Supplement|Orange flavoured water with maltodextrin as the placebo|Following or prior to a washout period (crossover intervention), participants will consume 250 ml of orange flavoured water (containing 20mg of Calcium with maltodextrin) for a 7 day period.
45395623|NCT01064492|Drug|PF-04620110|The three treatments are A) a single dose of 5 mg PIC under fasted condition; B) a single dose of 5 mg tablet under fasted condition: and C) a single dose of 5 mg tablet under fed condition.
45395624|NCT01064570|Drug|all-trans retinoic acid (ATRA)|
45395625|NCT01581164|Biological|Influenza vaccine|Influenza vaccine: Injection, post transplant
45395626|NCT01581164|Biological|Varicella vaccine|Varicella vaccine: Injection, post transplant
45395627|NCT00319046|Drug|Miglustat|Oral capsules containing miglustat 100 mg, administered three times daily (t.i.d.)
45697146|NCT00972088|Device|capsule endoscopy|The disposable, ingestible PillCam® SB2 Capsule acquires the video images during natural propulsion through the digestive system. The Capsule transmits the acquired images via digital radio frequency communication channel to the Given® Data Recorder unit located outside the body.
45849267|NCT00002214|Drug|Capravirine|
45849268|NCT00002220|Drug|Indinavir sulfate|
45849269|NCT00002220|Drug|Efavirenz|
45395628|NCT03980366|Device|Electroconvulsive Therapy (ECT)|Bilateral Electroconvulsive Therapy (ECT) to treat self-injurious behavior in adults with Autism Spectrum Disorder (ASD).
45395629|NCT03980210|Procedure|Hyperbaric oxygen therapy|"FiO2 0.21 - 1 ATA~FiO2 1 - 1 ATA~FiO2 1 - 2.5 ATA~FiO2 0.21 - 2.5 ATA~FiO2 0.21 - 1 ATA"
45395630|NCT01325402|Other|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose around 40 and 50 ug.
45395631|NCT01325402|Other|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose around 20 ug.
45395632|NCT01325402|Other|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose will be the Maximum Detective Mass established in the previous panels.
45395633|NCT03978338|Dietary Supplement|brain polypeptide solution|The experimental group will take the brain polypeptide solution 60ml per day which contains nitrogen 90mg, soybean oil ,glycerin and soybean phospholipids in 84days.
45395634|NCT03978338|Other|same package of placebo|The control group was treated with the same package of placebo 60ml per day which contains soybean oil ,glycerin and soybean phospholipids in 84 days.
45503520|NCT03611244|Device|Portable seat device devised to maintain lumbar lordosis|"The posterior lumbar spine pads are used to maintain lumbar lordosis and fix it with the shoulder strap so that the hip does not slip forward (so that it does not become a sacral sitting posture).~The seat is equipped with a 5 cm air filled villus cushion to relieve pressure on the ischial tuberosity when sitting for a long time. The portable seat device can be moved so that the DMD can sit on the device even when sitting in a wheelchair or a chair for home, school, or outdoors, so that the lumbar lordosis can be constantly maintained."
45697147|NCT05677815|Procedure|Underwent Surgery from 2019 to 2022|Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional, or local anaesthesia
45697148|NCT05672823|Procedure|Transcatheter Aortic Valve Implantation (TAVI)|Comparing different accessory access sites for TAVI: the temporary pacemaker access site and the diagnostic access site.
45395635|NCT00303602|Drug|Sublingual orally disintegrating olanzapine (SODO)|5 to 20mg dose, supplied in 5mg tablet strength, tablet should be placed under tongue for at least 60 seconds, daily for 16 weeks.
45395636|NCT00303602|Drug|Oral olanzapine|5 to 20mg dose, supplied in 5mg tablet strength, oral administration (tablets swallowed), daily for 16 weeks.
45395637|NCT03979976|Drug|Ramipril|Use of ramipril 10mg/day per 12 weeks. Telephone contact was made in the second and sixth week, to ask about possible side effects and ensure adherence
45395638|NCT00299130|Drug|Folate|A stable dose, ≥ 5 mg/week given as either a single dose or as a divided weekly dose, orally.
45697149|NCT01017250|Radiation|Stereotactic Radiosurgery (SRS)|Tumor Volume < 2.0cm receives 24 Gy in 1 fraction Tumor Volume 2.0-2.9cm receives 18 Gy in 1 faction Tumor Volume 3.0-4.9cm receives 25 Gy in 5Gy/fraction
45697150|NCT01017250|Drug|Bevacizumab|Bevacizumab (Avastin) 10 mg/kg given the day before SRS and 2 weeks after SRS
45715238|NCT04338568|Diagnostic Test|Lung ultrasound|The lung ultrasound examination consists of two-sided scanning of the anterior and lateral chest wall and is performed with patients in supine or near-to-supine position.
45849270|NCT00002220|Drug|Levocarnitine|
45849271|NCT00002220|Drug|Adefovir dipivoxil|
45395639|NCT00299130|Drug|Methotrexate|A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.
45395640|NCT00299130|Drug|Methylprednisolone|Intravenous infusion
45395641|NCT00299130|Drug|Placebo|Placebo to rituximab intravenous infusion
45395642|NCT00299130|Drug|Rituximab|Intravenous infusion
45395643|NCT00288054|Biological|cetuximab|"Cohorts 1 and 2: 400 mg/m2 (initial dose) 2 hour IV infusion on Day 1, Cycle 1 only.~250 mg/m2, 1 hour IV infusion on Days 8 , 15 and 22 during Cycle 1. 250 mg/m2 (subsequent doses), 1 hour IV infusion on Days 1, 8 , 15 and 22 during subsequent cycles."
45395644|NCT00288054|Drug|docetaxel|"Cohort 2 ONLY: 20 mg/m2 IV over 15 - 30 minutes on Days 8, 15 and 22 of Cycle 1. Concurrent with RT and cetuximab starting at Week 2.~20 mg/m2 IV over 15 - 30 minutes on Days 1, 8, 15 and 22 of Cycle 2."
45395645|NCT00288054|Radiation|radiation therapy|"Radiation therapy should begin on Day 8 of Cycle 1 and continue through the end of Cycle 2. Refer to Section 12.1 for Radiation Therapy Review.~RT prescription should be PTV (GTV + 2-cm margins on CT scan) to 6,480 cGy in 36 fractions given 5 days a week, 180 cGy per day. The dose is prescribed to the isocenter. The entire treatment should be planned prior to starting treatment to ensure that the plan meets protocol specifications."
45395646|NCT00287586|Drug|Testosterone Gel (Androgel)|7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years
45395647|NCT00287586|Drug|Placebo|Placebo-matching testosterone gel daily for 3 years
45395648|NCT03979716|Device|fMRI|fMRI examination
45715239|NCT05319808|Other|Manual therapy|Individualized treatment of manual therapy provided by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
45849272|NCT00002226|Drug|SU5416|
45849273|NCT00002232|Biological|APL 400-003|
45849274|NCT00002238|Drug|Interferon beta-1b|
45849275|NCT00002238|Drug|Zidovudine|
45503521|NCT04034355|Drug|Calmangafodipir (5 µmol/kg)|PledOx will be given to patients as an i.v. infusion, on top of mFOLFOX6 chemotherapy. PledOx is a solution in 20 mL single dose glass vials.
45503522|NCT04034355|Other|Placebo|Placebo will be administered via the same route as PledOx (i.v. infusion). Placebo is a solution in 20 mL single dose glass vials.
45503523|NCT05210699|Other|Product A|Usual Brand (UB) filtered, menthol combustible cigarette
45395649|NCT01070160|Drug|Endometrin (progesterone 100mg vaginal inserts)|once a day, 6-8 days as specified (prior to each EMBx)
45503524|NCT05210699|Other|Product B|Flavor variant P1211216 of a 1.5% nicotine ENDS product
45395650|NCT01070160|Drug|Metformin|per clinical care guidelines
45503525|NCT05210699|Other|Product C|Flavor variant P1211217 of a 2.4% nicotine ENDS product
45503526|NCT05210699|Other|Product D|Flavor variant P1211222 of a 5.0% nicotine ENDS product
45395651|NCT00287118|Drug|Efalizumab|Subjects will receive a conditioning dose of 0.7 milligram per kilogram (mg/kg) efalizumab subcutaneously on study Day 0 followed by 1.0 mg/kg efalizumab subcutaneously once a week for 23 weeks.
45395652|NCT03977298|Procedure|Chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine
45395653|NCT03977298|Procedure|CTG|CTG will be positioned in the buccal aspect of the peri-implant tissue
45395654|NCT03977220|Drug|Nab-paclitaxel combined with S-1|Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
45503527|NCT05210699|Other|Product E|Flavor variant P1213616 of a 1.5% nicotine ENDS product
45503528|NCT05210699|Other|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
45503529|NCT02066948|Other|wt loss|subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age
45503530|NCT02066948|Other|Meal Pattern|Even or skewed distribution of protein for a 16 week period of wt loss.
45503531|NCT02066948|Other|meal pattern|skew or even
45503532|NCT02066948|Dietary Supplement|even|even amount of protein distributed between each meal
45503533|NCT02066948|Dietary Supplement|skew|a skewed amount of protein is distributed between each meal
45715240|NCT05319808|Device|Telehealth exercises|A novel, remote computer based cervical joint positioning exercise and cervical kinaesthetic exercise (CKE) program. A technical consultant monitors the data from the remote exercises and inform the PTs if someone has not done their exercises in over 2 weeks during the study period so subjects can be encouraged with a friendly reminder.
45503534|NCT01317745|Other|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided be sanofi pasteur
45503535|NCT01317745|Drug|MF59 Adjuvant|Adjuvant/diluent manufactured by Novartis
45503536|NCT01317745|Biological|H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.
45503537|NCT03610932|Dietary Supplement|Vitamin C|Taken as 3 500mg capsules.
45503538|NCT03610932|Other|Placebo|Taken as 3 500mg capsules.
45503539|NCT01355965|Biological|Autologous T cells|
45503540|NCT03610620|Procedure|Vivascope 2500 ex-vivo fluorescent confocal microscope|scanned with the Vivascope 2500
45503541|NCT01346657|Drug|Nifidipine & LipoCol|The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects.
45503542|NCT01359709|Drug|Nicotine polacrilex|Participants will apply Nicoderm (14 mg) patches everyday during this study.
45503543|NCT02067026|Dietary Supplement|Aleurone|
45503544|NCT02067026|Dietary Supplement|Placebo|
45503545|NCT04158336|Drug|ZN-c3|ZN-c3 is a study drug
45849276|NCT00002244|Drug|WF10|
45849277|NCT00002250|Drug|CD4-IgG|
45395655|NCT01065402|Dietary Supplement|PPB-R-203-Based Meal|PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). Resistant starch can be regarded as a component of dietary fiber. Some forms of RS are present naturally in many foods, and average global consumption is estimated at 3-10 g/day. PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
45395656|NCT01065402|Dietary Supplement|TK9-Based Meal|TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
45395657|NCT00293202|Drug|Etanercept|Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week
45395658|NCT00293202|Drug|Placebo|Hemodialysis patients will receive Saline by subcutaneous injection twice a week
45395659|NCT00298896|Drug|SNS-595|
45395660|NCT03977376|Other|Guide of hosting|Guide of hosting with information about hospitalization to decrease anxiety
45503546|NCT01346735|Other|No intervention|
45715241|NCT05319808|Other|Non-computer based exercises|Home-exercises in the need of each subject (pragmatic approach) taught by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
45715242|NCT05317312|Drug|MR-107A-02|MR-107A-02 oral tablet
45395661|NCT00286494|Drug|Alogliptin and pioglitazone|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
45395662|NCT00286494|Drug|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
45395663|NCT00286494|Drug|Pioglitazone|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
45395664|NCT03976050|Drug|HL-085|HL-085 is a MEK inhibitor with potential indication for cancers. it will be given twice daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative anti-tumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
45395665|NCT00298740|Device|Aventis U-400 Insulin|
45715243|NCT05317312|Drug|Placebo|Placebo oral tablet
45715244|NCT05308108|Procedure|(Adeno)tonsillectomy|registration of PORC in children with OSAS after (adeno)tonsillectomy
45395666|NCT03979326|Procedure|Static stretching|Static stretching lasting 3 x 45 seconds will be performed in each of the examined women three times in different phases of the menstrual cycle: follicular, ovulatory and luteal. Before and after the intervention, a series of tests assessing the influence of stretching on biomechanical parameters will be carried out
45503547|NCT03940365|Device|Fetal Life tocometer device|The fetal life tocometer device is a uterine contraction monitor which is less expensive to manufacture than existing contraction monitor devices and which pairs with a smart device rather than a bulky output device.
45849278|NCT00002256|Drug|Zalcitabine|
45849279|NCT00002262|Drug|Tumor Necrosis Factor|
45395667|NCT03975972|Other|Occupational Therapy Based Literacy Intervention|Use of an occupational therapy-based literacy intervention that utilizes student interest to guide a prescriptive literacy intervention. Addressing reading as an occupation and making the necessary modifications to the literacy task to allows for increased engagement in the task. Increased engagement in literacy tasks, allows for opportunities to work on literacy deficit areas to address proficiency with reading ability.
45395668|NCT01067820|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 26 weeks
45395669|NCT01067820|Drug|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 26 weeks
45503548|NCT01317823|Other|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
45503549|NCT05539898|Device|ICD implantation|All included in the study will undergo ICD implantation for primary prevention of SCD
45503550|NCT02826486|Drug|BL-8040|BL-8040 subcutaneous(SC) injections
45503551|NCT02826486|Drug|Pembrolizumab|pembrolizumab will be given as a 30-minute IV infusion
45697151|NCT03082443|Other|Therapeutic group|"The group will take place in six meetings lasting one hour. At the end of the intervention, a new group will be started.~Issues related to illness, cardiopulmonary rehabilitation, aroused feelings and aspects of food education will be addressed, with the objective of improving nutritional profile, quality of life and reduction of stress level. During the meeting they will be constantly encouraged to express their feelings, doubts and exchanges of experiences.~In the first individual care (both groups) an initial consultation will be performed when the sociodemographic and anthropometric data will be collected and the instruments will be applied: Lipp Adult Stress Inventory, SF-12 Quality of Life Assessment Questionnaire and Questionnaire Of Food Frequency. After three months, all participants will be reassessed by the psychologist and nutritionist and anthropometric data will be collected and the instruments applied again."
45697152|NCT00812032|Drug|Aspirin|75 mg per day versus 75 mg twice daily and 320mg once daily
45697153|NCT00812032|Drug|aspirin|crossover study with three dosages: 75 mg once daily, 75 mg twice daily, 320 mg once daily.
45697154|NCT03400215|Diagnostic Test|Diagnostic Breast Cancer Scan|clinically indicated diagnostic breast MRI scans
45697155|NCT03400215|Diagnostic Test|Research Scan for Gradient-echo Spectroscopic Imaging (GSI)|15-min research MRI scan
45697156|NCT04352764|Diagnostic Test|CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test|The tests are being distributed under section IV.D of the current United States Food and Drug Administration (FDA) policies for diagnostic tests for coronavirus disease 2019. The test is available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Service's (HHS's) declaration that circumstances exist to justify the emergency use of in vitro diagnostics (IVDs) for the detection and/or diagnosis of the virus that causes COVID-19
45697157|NCT05687253|Drug|BX1000|IV BX1000
45849280|NCT00002268|Drug|Sevirumab|
45849281|NCT00002274|Drug|Didanosine|
45849282|NCT00002280|Drug|Didanosine|
45849283|NCT00002286|Drug|Zidovudine|
45849284|NCT00002292|Drug|Pentamidine isethionate|
45849285|NCT00002298|Drug|Ribavirin|
45849286|NCT00002304|Drug|Ketoconazole|
45849287|NCT00002304|Drug|Fluconazole|
45849288|NCT00002310|Drug|Crofelemer|
45849289|NCT00002316|Drug|Lobradimil|
45849290|NCT00002316|Drug|Amphotericin B|
45849291|NCT00002322|Drug|Atevirdine mesylate|
45849292|NCT00002322|Drug|Zidovudine|
45849293|NCT00002328|Drug|Azithromycin|
45849294|NCT00002334|Drug|Saquinavir|
45849295|NCT00002334|Drug|Zidovudine|
45849296|NCT00002334|Drug|Zalcitabine|
45849297|NCT00002340|Drug|Atovaquone|
45849298|NCT00002340|Drug|Pentamidine isethionate|
45849299|NCT00002346|Drug|Adefovir dipivoxil|
45849300|NCT00002352|Drug|Lobucavir|
45849301|NCT00002358|Drug|Sorivudine|
45849302|NCT00002364|Drug|Abacavir sulfate|
45849303|NCT00002370|Drug|Itraconazole|
45849304|NCT00002376|Drug|Indinavir sulfate|
45849305|NCT00002376|Drug|Lamivudine|
45849306|NCT00002376|Drug|Stavudine|
45849307|NCT00002376|Drug|Zidovudine|
45395670|NCT01067898|Dietary Supplement|vitamin D3 (cholecalciferol)|vitamin D3 (cholecalciferol) oil 20 000 IU/ml, oral dose of 200 000 IU or 100 000 IU (10ml or 5ml) every three months for one year.
45503552|NCT02826486|Drug|Chemotherapy of Onivyde|• IV Onivyde® followed by IV leucovorin (LV), followed by IV fluorouracil (5-FU), every 2 weeks.
45503553|NCT01359787|Drug|Mapracorat|Daily topical application
45503554|NCT01359787|Drug|Vehicle without active|Daily topical application
45503555|NCT02067260|Device|X5 HairLaser|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
45503556|NCT02067260|Device|X5 Hair Laser Sham Device|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
45395671|NCT01067898|Other|olive oil|10 ml (placebo group) or 5 ml (100 000 IU vitamin D3 group) oil per os every three months for one year
45503557|NCT03748485|Behavioral|wait and watch|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),without(wait and watch) adjuvant chemotherapy
45503558|NCT03748485|Drug|adjuvant chemotherapy|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),with adjuvant chemotherapy
45503559|NCT02825940|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg IV q3w (in 21-day cycles), except for participants with NSCLC who will be administered atezolizumab at a dose of 1200 mg IV on Day 1.
45503560|NCT02825940|Drug|Gemcitabine|Gemcitabine will be administered to participants with NSCLC at a dose of 1250 mg/m^2 on Days 1 and 8.
45503561|NCT02825940|Drug|Cisplatin|Cisplatin will be administered to participants with NSCLC at a dose of 75 mg/m^2 on Day 1.
45503562|NCT02065232|Drug|Tilmanocept|
45503563|NCT02065232|Drug|Sulfur Colloid|
45503564|NCT02304991|Drug|Liquid Peanut Extract|5000mcg/ml peanut protein
45697158|NCT05687253|Drug|Rocuronium Bromide|IV Rocuronium
45849308|NCT00002376|Drug|Didanosine|
45849309|NCT00002382|Drug|Saquinavir|
45697159|NCT05687175|Other|Questionnaire|Questionnaire administration (PDQ-M, NRS, SF-36)
45395672|NCT01067898|Dietary Supplement|calcium carbonate|1000 mg calcium per os every day for one year
45395673|NCT01065636|Behavioral|Diet + Resistance Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and resistance exercise training 3-days/week for 24 weeks.
45395674|NCT01065636|Behavioral|Diet + Aerobic Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and aerobic exercise training 3-days/week for 24 weeks
45395675|NCT01065636|Behavioral|Diet + Resistance/Aerobic Exercise|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and combined resistance/aerobic exercise training 3-days/week for 24 weeks
45395676|NCT03979248|Drug|BMS-986165|Specified dose on specified days.
45395677|NCT03979248|Drug|Rabeprazole|Specified dose on specified days.
45395678|NCT00285012|Drug|placebo|1mg (placebo) by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
45395679|NCT00285012|Drug|Varenicline Tartarate|1 mg by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
45503565|NCT02304991|Drug|Placebo Glycerin SLIT|pure glycerinated saline solution with caramel coloring to match color
45503566|NCT04870281|Device|CRT-DX|Evaluation of overall health, including heart failure and atrial fibrillation improvement, changes in physical fitness, and general quality of life.
45503567|NCT01348295|Other|Observation|No interventions are made. The purpose of the study is to find out current practices used in pediatric mechanical ventilation.
45503568|NCT02069132|Drug|Warfarin|warfarin treatment will be determined by treating physicians according to in-hospital guidelines, blindly to genotype assessment.
45503569|NCT03715985|Drug|EVAX-01-CAF09b|The personalised NPV-ds001 drug substance consists of multiple linear peptides (Pep-Ints) comprising natural L-amino acids dissolved in Dimethyl sulfoxide (DMSO) and 1 ml adjuvants (CAF09b) and 1,08 ml Tris buffer (25 ml).
45503570|NCT04852029|Other|Low dose hCG|Patients will either maintain the current dose of have an increased dose prescribed based on randomization
45503571|NCT01352065|Drug|Bosentan|tablet, 250 mg per day, twice per day, 8 weeks
45503572|NCT01352065|Drug|Ambrisentan|tablet, 10 mg per day, single per day, 8 weeks
45503573|NCT01352065|Drug|Placebo|Tablet, 10 mg per day, single per day, 8 weeks
45697160|NCT04746651|Other|Guided Self Help|Guided self help appointments with prison staff - 4x 30 minute appointments.
45697161|NCT02159872|Drug|Omacetaxine|1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.
45697162|NCT05687097|Device|Home-based sleep screening test or hospital-unattended sleep screening test|ApneaLink device will be used to assess the number of apnea and hypopnea events per hour of sleep.
45697163|NCT05687097|Device|Cardiovascular beat-to-beat monitoring|CareTaker device will be used to continuously record the participant's arterial blood pressure and heart rate during sleep.
45697164|NCT05687097|Device|ECG monitoring|Faror Bithium 180 device will be used to continuously record the participant's ECG during sleep.
45697165|NCT00417664|Drug|Dexmedetomidine|Dexmedetomidine administered as part of anesthesia in cardiac surgery patients
45697166|NCT00417664|Drug|Propofol|Propofol administered as part of anesthesia in cardiac surgery patients
45697167|NCT00417664|Drug|Midazolam|Midazolam administered as part of anesthesia in cardiac surgery patients
45849310|NCT00002388|Drug|Abacavir sulfate|
45849311|NCT00002394|Drug|Terbinafine hydrochloride|
45849312|NCT00002400|Drug|Indinavir sulfate|
45849313|NCT00002400|Drug|Delavirdine mesylate|
45395680|NCT00284934|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|
45849314|NCT00002400|Drug|Lamivudine|
45395681|NCT00284934|Drug|Tacrolimus|
45395682|NCT00284934|Drug|Corticosteroids|At a dose of at least 5 mg/day.
45395683|NCT00284856|Drug|montelukast sodium|montelukast 10 mg tablet once daily, 6 month treatment period
45395684|NCT00284856|Drug|Comparator: Placebo|fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period
45395685|NCT00284856|Drug|Comparator: fluticasone|fluticasone propionate 250 mcg twice daily, 6 month treatment period
45395686|NCT00284856|Drug|Comparator: Placebo|montelukast 10 mg Pbo tablet once daily, 6 month treatment period
45395687|NCT00298272|Biological|IDEC-C2B8 (rituximab)|Participants will receive 500 mg rituximab on Day 1 and Day 15
45395688|NCT00298272|Drug|Placebo|Participants will receive placebo on Day 1 and Day 15
45395689|NCT00298272|Drug|Methotrexate|Participants must have been treated with MTX ≥15 mg per week and ≤25 mg per week (dose may have been as low as 10 mg if unable to tolerate higher dose) for at least 12 weeks immediately prior to Day 1, at a stable dose for at least 4 weeks and was continued for the study duration.
45395690|NCT00298272|Drug|Etanercept|Participants must have been treated with etanercept at 50 mg per week (25 mg twice per week or 50 mg once per week).
45395691|NCT00298272|Drug|Adalimumab|Participants must have been treated with adalimumab at 40 mg every other week for at least 12 weeks immediately prior to Day 1.
45395692|NCT00298272|Drug|Methylprednisolone|Methylprednisolone 100 mg IV was administered by slow infusion to be completed at least 30 minutes prior to each infusion of rituximab or placebo.
45395693|NCT00298272|Dietary Supplement|Folate|All subjects also received a stable dose of folate (≥5 mg per week).
45849315|NCT00002400|Drug|Zidovudine|
45395694|NCT00283842|Drug|DVS SR|
45395695|NCT00283842|Drug|Placebo|
45395696|NCT01068054|Drug|tacrolimus|0.1% ointment,apply bid, 8 weeks
45395697|NCT01068054|Drug|cyclosporins|2% eyclosporine eye drops apply 1 drop to each eye QID
45395698|NCT03975816|Device|Analgesia nociception index|Monitor the maternity with Analgesia nociception index
45395699|NCT00298038|Drug|Rifaximin|Oral
45395700|NCT00298038|Drug|Placebo|Oral
45395701|NCT00283686|Drug|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg
45697168|NCT05687019|Combination Product|Intravesical instillations of Ialuril® Prefill|5 injections of Ialuril® Prefill on D0 or D1, D7, D14, D21 and D28 after Holmium laser surgery for prostate adenoma
45697169|NCT03400059|Device|Chordate System S211 in treatment mode|Chordate System S211 in treatment mode
45697170|NCT03400059|Device|Chordate System S211 in placebo mode|Chordate System S211 in placebo mode
45715245|NCT05291806|Other|Reference Product|This intervention is based on white rice.
45715246|NCT05291806|Other|Wholegrain product Dose A|This wholegrain intervention contains whole cereal kernels.
45395702|NCT00283686|Drug|Telmisartan|Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
45395703|NCT00283686|Drug|Placebo|Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
45715247|NCT05291806|Other|Wholegrain product Dose B|This wholegrain intervention contains whole cereal kernels.
45395704|NCT00283686|Other|Standard Blood Pressure Control|Achieve standard blood pressure control of 120-130/70-80 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
45395705|NCT00283686|Other|Low Blood Pressure Control|Achieve low blood pressure control of 95-110/60-75 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
45395706|NCT00297882|Drug|1. Artemether-Lumefantrine (AL)|Artemether-Lumefantrine(Co-Artem)=Artemether, 2mg/kg x 2(12h apart) and Lumefantrine, 12mg/kgx2 (12h apart).
45395707|NCT00297882|Drug|2. Amodiaquine-Artesunate (AQ-AS)|Amodiaquine-Artesunate (0H),D1(24H),D2(48H)= Artesunate 4mg/kg and Amodiaquine at 10mg/kg
45395708|NCT01065870|Drug|Neoadjuvant gemcitabine, capecitabine, and docetaxel|"6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.~Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.~Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment."
45395709|NCT01065870|Drug|Gemcitabine, capecitabine, docetaxel followed by radiotherapy|"6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.~Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.~Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment.~Radiotherapy should start 2 to 3 weeks after last planned dose of GTX. Gemcitabine at 750mg/M2 days 5, 12, 26, 33 along with capecitabine 1000 mg bid for 5 days darbepoetin 200ug, every 2 weeks if the hemoglobin is less than 10.5 gms/dl while undergoing radiotherapy.~Pegfiligastrim 6mg at the end of week 2 if the WBC count is less than 2500 cells/cu mm."
45554687|NCT04441437|Behavioral|Task-oriented training without a dynamic hand splint|In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the no-splint group received 1-hour task-oriented training, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
45849316|NCT00002406|Drug|Indinavir sulfate|
45849317|NCT00002412|Drug|Emivirine|
45849318|NCT00002412|Drug|Hydroxyurea|
45849319|NCT00002412|Drug|Stavudine|
45395710|NCT03975894|Biological|Serial prophylactic exchange blood transfusion (SPEBT).|"Serial prophylactic exchange blood transfusion (SPEBT) will be given via automated apheresis technology. SPEBT will be carried out on the haematology day unit or on the antenatal day unit/ward in accordance with local policies in participating units. The procedure will be carried out using standard operating procedures, by the clinical or research nurse/midwife, haematology day unit staff or specialist sickle nursing staff. Venous access will be via peripheral access if possible or by femoral line access if not.~SPEBT will be commenced between 6 and 18+0 weeks gestation. It will be repeated at 6-10 weekly intervals aiming to maintain HbS% <30%. It will continue throughout pregnancy and be stopped at the end of pregnancy.~Number of red cell units used per transfusion will depend on patient weight and pre-transfusion HbS%, but will usually be between 6 and 8 units of red cells on each occasion of exchange transfusion."
45395711|NCT00297648|Biological|Certolizumab pegol|Certolizumab pegol (CDP870) 400 mg administered subcutaneously (sc) at Weeks 0, 2 and 4 (induction doses), then every 4 weeks (Q4W) until Week 52. Investigators can escalate dosage to CDP870 400 mg 2-weekly (Q2W) at any time after Week 10 for lack of response/remission. After Week 52 patients can continue to receive treatment until study drug end, either Q4W or Q2W, according to their administration frequency at Week 52.
45395712|NCT03741816|Drug|Indirect pulp capping|Indirect pulp capping is a procedure in which a material is placed on a thin partition of remaining carious dentin that, if removed might expose the pulp.
45395713|NCT01068132|Drug|Cetuximab|cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1,
45503574|NCT02065310|Other|N2-(1-carboxyethyl)-2'deoxyguanosine (CEdG)|"Glucose and its adducts, such as HbA1c, decompose non-enzymatically to yield α-oxo-aldehydes are up to 20,000 x more reactive than the parent molecule. Amounts of an α-oxo-aldehyde, methylglyoxal (MG), are elevated up to 6-fold in patients with Type 1 dm. Quantitation of MG, but MG does form stable, irreversible adducts termed advanced glycation endproducts (AGEs) that can be measured. MG also reacts with DNA to yield primarily one stable DNA-AGE, CEdG, and suggests that measuring CEdG might allow for a direct method for assessing glycemic status and α-oxo-aldehyde burden.~Investigators have shown that CEdG levels are significantly elevated in urine and tissue of Type 1 & 2 dm animal models. DNA-AGE may correlate with the development of diabetes complications and identify patients at higher risk. Therefore, the investigators hypothesize that CEdG, a DNA-AGE, can be used as a marker of diabetes control and complications."
45395714|NCT01068132|Drug|FOLFIRI|irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
45395715|NCT00283296|Device|Endeavor|Collapsible, forward folding manual wheelchair
45395716|NCT00297492|Behavioral|Reduction Phone Counseling|Counseling of smokers to undergo gradual reduction in cigarettes per day prior to quit date. This includes 5 counseling calls: 3 calls focused on reduction prior to the quit date, 1 call two days prior to the quit date to discuss common strategies for preparing to quit, and 1 call two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges during reduction and after the quit date.
45395717|NCT00297492|Behavioral|Abrupt Phone Counseling|Counseling of smokers to set a quit date and not change cigarettes per day prior to quit date. This includes 5 counseling calls: 1 to set a quit date, 1 two days prior to the quit date to discuss common strategies for preparing to quit, and 3 after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
45395718|NCT00297492|Behavioral|Minimal Abrupt Phone Counseling|Minimal counseling to mimic intervention at a primary care office. This includes 2 counseling calls: 1 to set a quit date and 1 two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
45395719|NCT00297492|Drug|Pre-Quit Nicotine Lozenges|"2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette during reduction with one lozenge. Use additional lozenges to combat cravings to smoke."
45849320|NCT00002412|Drug|Didanosine|
45849321|NCT00002418|Drug|Emivirine|
45697171|NCT01021306|Device|Chiropractic w/Activator & Self Care|This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner. The instrument has two handles that are squeezed together until it clicks, resulting in a shallow, very quick thrust to the segment that is to be adjusted. The AMCT protocol is a structured method of chiropractic treatment that utilized a number of simple biomechanical tests in order to determine where to adjust. These tests are mostly well defined movements of body parts such as extending the head or laterally moving the mandible relative to the rest of the skull. This protocol includes treatment of the full spine and appendages as well as the area immediately around the jaw.
45849322|NCT00002418|Drug|Hydroxyurea|
45849323|NCT00002418|Drug|Nevirapine|
45395720|NCT00297492|Drug|Post-Quit Nicotine Lozenges|"2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette while abstinent with one lozenge. Use additional lozenges to combat cravings to smoke."
45503575|NCT03610854|Device|Fitness Tracker|Patients will continuously wear a commercially available fitness tracker which will collect data on physical activity (steps), pulse rate and sleep behaviour.
45503576|NCT01356043|Drug|S-amlodipine 5mg,Telmisartan 80mg|S-amlodipine 5mg and Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
45697172|NCT01021306|Device|Dental Care & Self Care|Following the dental exam, patients will have maxillary and mandibular polyvinyl siloxane impressions made. Interocclusal records will be made with a fast setting silicone using a metal tray. A commercial laboratory will then wax and heat process a clear acrylic resin splint attempting to capture the mandibular cusp tips in the occlusal plan of the splint. The splint will be adjusted to provide uniform posterior centric occlusal stops followed by evaluation for canine guidance. The splint will then be polished and home care instruction provided. Patients will be instructed to wear the splint at night and two hours per day.
45697173|NCT01021306|Other|Sham AMCT|This protocol will attempt to follow all of the procedures of the actual AMCT protocol except that when a thrust is given with the Activator instrument, the clinician will place the thumb of his left hand over the spot that would normally be adjusted. The tip of the instrument them will be placed very close to, but not touching the thumb. Consequently, the patient will feel the contact of the clinician's thumb on the spot that would be normally adjusted, and will hear the click of the instrument, but no thrust will be delivered to the patient.
45697174|NCT01021306|Other|Self-Care Only Group|Self care consists of an initial set of standard patient self performed treatments which will include jaw relaxation exercises, reduction of parafunction, thermal packs, low dose NSAIDs, passive opening stretches and suggestions for stress reduction.
45395721|NCT00297258|Drug|pazopanib|oral tablet
45395722|NCT00496769|Drug|Apixaban|Tablets, oral, 5 mg (2.5 mg in patients meeting any 2 of the following criteria: 80 years of age and older, weight of 60 kilograms or less, and a serum creatinine level of 1.5 mg/dL or higher), twice daily, up to 156 weeks
45395723|NCT00496769|Drug|Acetylsalicylic acid|Tablets, oral, 81-324 mg, once daily, up to 156 weeks
45395724|NCT01014845|Biological|hepatitis E vaccine|Intramuscularly given at 0, 1, 6m for three doses.
45395725|NCT01014845|Biological|Hepatitis B vaccine|Intramuscularly given at 0, 1, 6m for three doses.
45395726|NCT00478673|Device|NexStent Carotid Stent System (Monorail Delivery System)|Self-expanding carotid stent for treating patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization.
45395727|NCT00478673|Device|FilterWire EZ™ Embolic Protection System|Used as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
45395728|NCT01020461|Device|Accuvein|Accuvein will be used to facilitate venous blood sampling
45395729|NCT01020461|Device|Accuvein|Accuvein will be used to facilitate peripheral IV catheter placement
45395730|NCT04400591|Biological|Nonconforming Lisocabtagene Maraleucel|Nonconforming lisocabtagene maraleucel is lisocabtagene maraleucel that does not meet the commercial release specifications, however is deemed acceptable to administer as an investigational product in the Expanded Access Protocol setting.
45697175|NCT03082287|Device|Fecal Calprotectin Level|Measurement of calprotectin in feces
45395731|NCT04400357|Procedure|Robotic pancreaticoduodenectomy|Patients in this arm will undergo a pancreaticoduodenectomy with robotic-assisted techonology.
45395732|NCT04400357|Procedure|Open pancreaticoduodenectomy|Patients in this arm will undergo an open pancreaticoduodenectomy which is the standard surgical approach.
45395733|NCT00488345|Drug|Tygacil|
45395734|NCT00283062|Drug|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m^2 docetaxel administered intravenously over 1 hour on Day 1 every three weeks (q3w) for 6 cycles. The first cycle was to be administered within 8 days after randomization.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
45503577|NCT01356043|Drug|S-amlodipine 5mg|S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out(19 days)
45503578|NCT02065388|Behavioral|Standard of care dosing for warfarin|
45503579|NCT02065388|Genetic|Genotype-guided dosingTaiwan algorithm for warfarin|
45503580|NCT02065388|Genetic|Genotype-guided dosing IWPC algorithm for warfarin|
45554688|NCT03526341|Device|ReliaTack™ Articulating Reloadable Fixation Device|ReliaTack™ Articulating Reloadable Fixation Device with Deep Purchase Tacks
45554689|NCT04467645|Other|reflexology|Reflexology is the stimulation of the reflex points in the hands and feet by massage, designed to provide relaxation and relief in the body.
45554690|NCT02443844|Procedure|Transurethral Resection|Endoscopic treatment of bladder cancer
45849324|NCT00002418|Drug|Stavudine|
45554691|NCT02443844|Drug|Tamsulosin|Medical treatment for benign prostate hyperplasia
45395735|NCT00283062|Drug|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 8 days after randomization.
45503581|NCT04835415|Procedure|Bilateral retrolaminar block|in lateral position and after skin sterilization. The spine is palpated from cervical (C7) downward toT7 and point marked to identify the spinous process. The linear high frequency transducer (6-13 MHz) will be placed parasagittal plane 1 cm lateral to the midline. The needle (18 gauge) is inserted in the plane view of the ultrasound probe to target the T7 and needle is advanced from downward to upward until the needle tip contacted the lamina. After negative aspiration, a 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000) will be injected. The procedure will be repeated following the same steps on the other side.
45395736|NCT00283062|Drug|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m^2 docetaxel administered IV over 1 hour on Day 1 q3w for 6 cycles. The first cycle was to be administered within 30 days after progression was confirmed.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
45395737|NCT00283062|Drug|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed (on Day 1 of docetaxel administration).
45395738|NCT00283062|Drug|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed.
45503582|NCT04835415|Procedure|Thoracic epidural analgesia|In the lateral position, after skin sterilization, Ultrasound with high frequency linear probe (5-13 MHz). Thoracic intervertebral space (T7-8) will be identified by counting from the C7 to prominent thoracic spine (T7). The probe will be used in parasagittal plane 2 cm from midline. The probe will be directed medially to identify the dura matter at the T7-8 intervertebral space . the needle 18 gauage will be inserted in plane to target T7-8 intervertebral space ., after needle tip reached target space, loss of resistance technique then 20 ml bupivacaine 0.25% plus 5ug/ml adrenaline (1:200000) was injected after aspiration
45503583|NCT01317563|Dietary Supplement|Vitamins A, E, C & Selenium|daily dose = Vitamin A 10000 IU (beta carotene), Vitamin E 400 IU, Vitamin C 1200mg, and Selenium 300mcg.
45503584|NCT01317563|Dietary Supplement|Placebo|total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose
45395739|NCT00282984|Drug|placebo|1 mg placebo twice daily by mouth for 12 weeks
45395740|NCT00282984|Drug|Varenicline|1 mg twice daily by mouth for 12 weeks
45395741|NCT02532348|Other|Blood samples|Blood samples
45503585|NCT01359865|Procedure|Lumbar Plexus Block|lumbar plexus block followed by a general anesthetic. The lumbar plexus block will be performed by an attending anesthesiologist using ultrasound guidance (for measuring the depth of the psoas compartment) and nerve stimulation. A standardized block solution of 30 mL 0.5% ropivacaine will be injected in fractionated doses when a quadriceps muscle twitch is present to nerve stimulation at <0.50 mA. Fifteen minutes after block completion, the block's effectiveness will be evaluated with an ice test.
45395742|NCT00282438|Biological|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cells will be injected after conditioning
45395743|NCT00282438|Biological|Allogeneic stem cell transplantation|Allogeneic stem cells will be injected after conditioning
45503586|NCT02067338|Drug|1 mg morphine soak in epidural oxidized cellulose|During posterior lumbar spinal surgery , patients received 1 mg morphine-soaked in epidural oxidized cellulose.
45503587|NCT02067338|Drug|normal saline|During posterior lumbar spinal surgery , patients received NSS -soaked in epidural oxidized cellulose.
45503588|NCT01336764|Behavioral|Cognitive reappraisal and breathing retraining|They will be induced to rapidly achieve reduced autonomic arousal through use of a graphics-rich biofeedback procedure and simultaneously engage in the generation and rehearsal of cognitive reappraisal scripts under the coaching of project therapist also in the vehicle.
45503589|NCT01336764|Behavioral|Control|Unguided listening to radio/music.
45503590|NCT04801173|Combination Product|Very low calorie ketogenic diet|Dietary intervention with a very low calorie ketogenic diet, using commercial products of the Pronokal PnK® method
45503591|NCT04801173|Behavioral|Low calorie standard diet|Low calorie standard diet with no specified dietary supplement addition
45395744|NCT01065948|Device|Subcutaneous glucose monitoring device|monitor interstitial glucose level every 5 min over 4 hours
45395745|NCT00296400|Drug|Rosuvastatin|
45395746|NCT00296400|Drug|Atorvastatin|
45395747|NCT04282356|Drug|Intraperitoneal chemotherapy during surgery|During interval surgery the patient will undergo HIPEC (Cisplatin 100mg/m2, 1h 30 infusions with sodium thiosulfate renal protection). They will then receive postoperative IPC i.e intravenous and intraperitoneal administration (IV Paclitaxel, 135mg/m2 on D1, IP Carboplatin, AUC 6 on D1, and IP Paclitaxel, 60mg/m2 on D8) with at least 3 courses performed (up to 4-6 allowed).
45395748|NCT01068288|Procedure|Laparoscopic or open appendectomy|
45503592|NCT01348451|Device|surgical implantation|human spinal cord stem cell implantation in ALS patients
45395749|NCT01068288|Procedure|Expectant Management|"A consult to Interventional Radiology will be made at the time of admission to determine whether percutaneous drainage is feasible, and if it is the abscess will be drained by Interventional Radiology. Ultrasound and/or CT scan will be used to follow the abscess collections and/or phlegmons and guide the removal of drains.~For patients with a fecalith on imaging, a laparoscopic interval appendectomy will be performed 6-12 weeks following discharge from hospital. For those without a fecalith on imaging, a decision will be made by the family, with the guidance of the surgeon, whether or not to undergo a laparoscopic interval appendectomy."
45395750|NCT00296244|Drug|Steroids|Patients randomized to Control group shall be administered steroids as methylprednisolone (Solumedrol) 1000 mg IV during the anhepatic phase. Methylprednisolone will be continued according to the following taper schedule: 50 mg IV every 6 hrs on day 1; 40 mg IV every 6hrs on day 2; 30 mg IV every 6 hrs on day 3; 20 mg IV every 6 hrs on day 4; 20 mg IV every 12 hrs on day 5; and Prednisone 20 mg by mouth or Naso-gastric tube (NGT) on day 6. Prednisone shall be tapered slowly starting at 1 month post-OLT and weaned off completely by 6 months post-OLT.
45395751|NCT00296244|Drug|Basiliximab|Basiliximab shall be given as induction therapy at 20 mg IV bolus intra-operatively and on the 4th day after transplantation.
45395752|NCT00296244|Drug|Tacrolimus|Tacrolimus shall be used as the main maintenance immuno-suppressive drug. It will be given at a dose of 0.15mg/ kg/ day by mouth or through a naso-gastric tube (NGT), starting not earlier than 24 after the transplant but within 48 hrs after reperfusion. The dose shall be adjusted to achieve a trough level of 10-15 ng/ml during the first 30 days after transplantation and lowered to 5-10 ng/ml, thereafter.
45503593|NCT03423290|Device|FRED and FRED Jr|Flow Re-Direction Endoluminal Device
45503594|NCT01352143|Drug|Recombinant activated factor VII|Plasma will be spiked in vitro with recombinant activated factor VII to assess increases in thrombin generation with and without the drug
45503595|NCT01352143|Drug|Prothrombin Complex Concentrate|Plasma will be spiked in vitro with prothrombin complex concentrate to determine increases in thrombin generation with and without the drug
45697176|NCT05657613|Drug|CYP450 Cocktail and Transporter Substrates with Pacritinib|"Day 1: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, omeprazole 20 mg and metformin (transporter)~Day 3: Single oral dose of transporter substrates (digoxin 0.25 mg, rosuvastatin 5 mg)~Days 8-22: Oral doses of pacritinib 200 mg BID approximately 12 hours apart~Day 17: Single oral dose of transporter substrates (digoxin 0.25 mg and rosuvastatin 5 mg) will be coadministered with the AM dose of pacritinib 200 mg.~Day 21: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, and omeprazole 20 mg) along with transporter substrate (metformin 500 mg) will be coadministered with the AM dose of pacritinib 200 mg."
45697177|NCT05657613|Drug|Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib|"Days 1-7: Oral doses of pacritinib 200 mg BID~Days 8-14: Oral doses of pacritinib 200 mg BID, coadministered with an oral dose of bosentan 125 mg BID"
45395753|NCT00296244|Drug|Enteric-coated Mycophenolic acid (EC-MPA)|This drug may be given in combination with calcineurin inhibitors (tacrolimus) and steroids for maintenance immuno-prophylaxis to prevent rejection. They are particularly useful in recipients with renal dysfunction and neurotoxicity, when there is a need to reduce dose or delay introduction of calcineurin inhibitors. This drug is given at 720 mg PO BID for 3 months.
45395754|NCT00274716|Drug|MK0736|
45395755|NCT00274716|Drug|MK0916|
45503596|NCT02260310|Other|Weizhong and Huantiao|
45503597|NCT02260310|Other|A-shi point|
45503598|NCT05188651|Behavioral|face masks|wearing face masks
45395756|NCT00274716|Drug|Placebo|
45395757|NCT01068444|Drug|Pioglitazone|"Name: GLITOS（Pioglitazone）~Dosage form: Tablets~Dose(s): 30mg~Dosing schedule: QD~Duration: 6 months"
45395758|NCT01068444|Drug|placebo|placebo 30 mg/d for 6 months
45395759|NCT00282048|Drug|AG-013736 (axitinib)|AG-013736 5 mg twice daily [bid] continuous dosing in 28 day cycles.
45503599|NCT03709277|Behavioral|Pharmacist-Driven Intervention|The pharmacist will investigate patient assistance options for patients who cannot afford their specialty medication, reach out to prescribers when needed to address intolerance/adverse effects, improve health literacy, recommend options for forgetfulness, make every effort to reach patient, address clinical and financial barriers to unresponsiveness (lack of lab completion, not returning to clinic, etc.)
45697178|NCT05657613|Drug|Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib|"Days 1-7: Oral doses of pacritinib 200 mg BID~Days 8-14: Oral doses of pacritinib 200 mg BID, coadministered with an oral dose of fluconazole 200 mg QD."
45395760|NCT03975348|Device|High flow nasal cannula|High flow of warm and humidified oxygen/air mixture delivered through nasal cannula
45395761|NCT03975348|Device|Continuous positive airway pressure|Positive airway pressure applied through a sealed face mask
45395762|NCT03975348|Device|Facemask|Oxygen therapy through a conventional facemask
45395763|NCT03975192|Device|Percutaneous Electrical Nerve Field Stimulation|Placement of the PENFS device immediately following the last scheduled opiate dose in the PICU with active stimulation for 120 hours.
45395764|NCT00474539|Biological|13-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
45395765|NCT00474539|Biological|7-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
45395766|NCT01017809|Drug|Aprepitant|Cycle 1, day 2 to 17: Emend 80mg once daily in the morning on days 2 through 17 Cycles 2-6 (optional extension arm): same Emend dosing
45503600|NCT03559946|Device|percutaneous tibial nerve stimulation (PTNS)|The PTNS and the sham treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.
45503601|NCT03559946|Device|Sham procedure|The sham treatment, involves simulating the sensation of the PTNS needle insertion at the same location using a Steritberger placebo needle. This is a blunt tip needle which simulates the sensation of a needle prick when touched to the skin, however, the blunt tip retracts into the handle when pressed into the skin. This creates the illusion of the needle entering the skin, without breaking the skin's surface. An inactive PTNS surface electrode is also placed on the ipsilateral calcaneus. The two TENS surface electrodes, placed in the same location as the PTNS treatment, are active and deliver stimulation mimicking the sensory effects of the PTNS. However, since no electrode needles were inserted near the tibial nerve, there will be no tibial nerve stimulation
45503602|NCT01352299|Device|Macintosh Laryngoscope blade|Laryngoscopy performed with Macintosh Laryngoscope
45503603|NCT01352299|Device|MacCoy|Laryngoscopy performed with MacCoy Laryngoscope
45503604|NCT01352299|Device|Miller|Laryngoscopy performed with Miller Laryngoscope
45697179|NCT01021618|Drug|Regadenoson|Regadenoson (0.4mg/5 mL) injection during symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
45697180|NCT01021618|Other|Symptom-limited exercise|Dipyridamole (0.56 mg/kg) over 4 minutes followed by symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
45697181|NCT03082053|Drug|varlitinib|IMP
45697182|NCT03082053|Drug|capecitabine|Companion Medication
45697183|NCT01022242|Drug|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. PXL01 is formulated in a viscous solution of sodium hyaluronate. The drug product is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
45697184|NCT01022242|Drug|Placebo|Placebo is a physiological sodium chloride solution, which is clear and colourless.
45697185|NCT05686941|Other|Trans-cutaneous Laryngeal ultrasound (TLUS)|Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords
45697186|NCT05686941|Other|TLUS and simultaneous laryngoscopy|Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords with simultaneous video laryngoscopy (usual care)
45715248|NCT05291806|Other|Wholegrain product Dose A, cut kernels|This wholegrain intervention contains cut cereal kernels.
45849325|NCT00002418|Drug|Didanosine|
45849326|NCT00002424|Drug|L-756423|
45849327|NCT00002424|Drug|Indinavir sulfate|
45395767|NCT01014923|Behavioral|Teen driving intervention|Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
45395768|NCT01020539|Drug|Fludarabine|Conditioning Regimen
45395769|NCT01020539|Drug|Busulfan|Conditioning Regimen
45395770|NCT01020539|Drug|GVHD Prophylaxis|Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)
45395771|NCT01020539|Drug|Gemtuzumab Ozogamicin|Dose Escalation
45395772|NCT01020539|Drug|Anti-Thymocyte Globulin|Unrelated Donors only
45395773|NCT01020539|Drug|Isotretinoin|JMML patients only
45395774|NCT01015001|Procedure|Active rTMS x sham (placebo) rTMS|"Seventeen right-handed patients with DSM-IV TR diagnosis of schizophrenia were randomized in two groups. One arm received 20 sessions of 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).~The other arm received sham (placebo) stimulation over the LTPC for the same period of time. All patients were considered as having refractory schizophrenia and in use of at least 400mg/day of clozapine and referred auditory hallucinations."
45849328|NCT00002424|Drug|Lamivudine|
45849329|NCT00002424|Drug|Stavudine|
45395775|NCT01015001|Procedure|sham rTMS|same coil, same number of pulses but using an angled coil(90degres) over the frontotemporal region
45697187|NCT03358563|Drug|Docetaxel|Docetaxel is a commercially marketed product that has been approved by the FDA for the treatment of metastatic prostate cancer. It is also approved for the treatment of other malignant disease, such as locally advanced or metastatic breast cancer that returns after any prior chemotherapy; locally advanced or metastatic non-small cell lung cancer that recurs after prior platinum-based chemotherapy. However, the FDA does not currently approve its use in patients with localized prostate cancer but no evidence of radiographic metastases.
45849330|NCT00002430|Drug|Indinavir sulfate|
45849331|NCT00002430|Drug|Nelfinavir mesylate|
45849332|NCT00002430|Drug|Lamivudine|
45697188|NCT03358563|Drug|Degarelix|Degarelix is a leuteinizing hormone-releasing hormone (LHRH) antagonist. Degarelix is administered at an initial dose of 240 mg subcutaneously (2 separate injections of 120mg each totaling 240 mg) two weeks prior to cycle 1 day 's 1 treatment with chemotherapy. The initial dose is followed by a maintenance dose of 80mg administered subcutaneously as a single injection every 28 days at cycle 2 day 1 (+/- 7 days) and cycle 3 day 10 (+/- 7 days)
45849333|NCT00002430|Drug|Stavudine|
45849334|NCT00002436|Drug|Lamivudine|
45849335|NCT00002436|Drug|Zidovudine|
45849336|NCT00002436|Drug|Zalcitabine|
45849337|NCT00002442|Drug|Indinavir sulfate|
45395776|NCT01015001|Procedure|(1Hz) rTMS applied over the left temporoparietal cortex|20 sessions lasting 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).
45395777|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
45395778|NCT00281580|Drug|Placebo|Placebo to Telmisartan and Amlodipine once daily for eight weeks
45395779|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
45395780|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
45395781|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
45395782|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
45395783|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
45395784|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
45395785|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
45395786|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
45395787|NCT00281580|Drug|Amlodipine 5 mg|amlodipine 5g once daily for eight weeks
45395788|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
45395789|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
45395790|NCT00281580|Drug|Amlodipine 5 mg|amlodipine 5mg once daily for eight weeks
45395791|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
45395792|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
45395793|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
45395794|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
45395795|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
45395796|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
45395797|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
45395798|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
45849338|NCT00002442|Drug|Nelfinavir mesylate|
45849339|NCT00002442|Drug|Lamivudine|
45849340|NCT00002442|Drug|Stavudine|
45849341|NCT00002448|Drug|Ritonavir|
45849342|NCT00002448|Drug|Efavirenz|
45849343|NCT00002448|Drug|Saquinavir|
45849344|NCT00002454|Biological|autologous tumor cell vaccine|
45849345|NCT00002460|Drug|goserelin acetate|
45849346|NCT00002460|Drug|tamoxifen citrate|
45849347|NCT00002460|Procedure|ablative endocrine surgery|
45849348|NCT00002460|Procedure|oophorectomy|
45849349|NCT00002466|Drug|cyclophosphamide|
45849350|NCT00002466|Drug|doxorubicin hydrochloride|
45849351|NCT00002466|Drug|etoposide|
45395799|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
45395800|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
45395801|NCT00281580|Drug|Amlodipine 5 mg|amlodipine 5g once daily for two weeks
45849352|NCT00002466|Drug|ifosfamide|
45849353|NCT00002466|Drug|vincristine sulfate|
45849354|NCT00002466|Procedure|conventional surgery|
45849355|NCT00002466|Radiation|radiation therapy|
45849356|NCT00002472|Drug|cisplatin|
45849357|NCT00002472|Drug|etoposide|
45849358|NCT00002472|Procedure|conventional surgery|
45395802|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
45395803|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
45395804|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
45395805|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
45395806|NCT03997175|Other|Biodiversity powder|Biodiversity sand contained biodiversity powder that contains a highly diverse and rich microbial community but no known pathogens.
45395807|NCT03997175|Other|Placebo|Sand that looks like intervention sand but does not have high biodiversity
45395808|NCT04393181|Procedure|Heart transplantation 1|Heart transplantation will be performed according to local routines. Recipients will be transplanted with a donor heart with left ventricular dysfunction, defined as an ejection fraction less than 50% or regional hypokinesia.
45395809|NCT04393181|Procedure|Heart transplantation 2|Heart transplantation will be performed according to local routines. Recipients will be transplanted with a donor heart with normal function, according to the recommendations from The International Society for Heart and Lung Transplantation (ISHLT).
45395810|NCT01017887|Device|Airseal access port for laparoscopic surgery|The investigators will utilize this access port that is already approved by the FDA for it's intended use in laparoscopic surgery. The investigators are simply measuring the percentage of carbon dioxide in the peritoneal cavity.
45395811|NCT01017887|Device|Standard Laparoscopy ports|Prospective monitoring of CO2 levels during laparoscopic surgery with standard access ports.
45395812|NCT01020617|Dietary Supplement|Ls-33|10~10 CFU/day
45395813|NCT01017965|Device|Actimeter + blood pressure monitoring|Patients will receive an actimeter that they will wear for 3 days and an ambulatory blood pressure monitoring device that they will keep for 24 hours.
45395814|NCT00495755|Drug|Alemtuzumab (Campath)|An escalating dose given over 4 weeks
45395815|NCT01070862|Drug|Thalidomide, Dexamethasone|Thalidomide 200 mg/d for 3 months, Dexamethasone 40 mg/d D1-D4 and D14-D17 for 28d-3 cycles
45395816|NCT01070862|Drug|Vincristin , Adriamycin, Dexamethasone = VAD|Vincristin 0.4 mg/d continUous IV infusion D1-D4, Adriamycin 9 mg/m2 continuous IV infusion D1-D4, Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle
45395817|NCT01070862|Drug|Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)|Thalidomide : 200 mg/d at bedtime for 3 months , melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
45395818|NCT01070862|Drug|melphalan, endoxan, dexamethasone (MCDex)|melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
45395819|NCT01070862|Drug|Thalidomide, Dexamethasone|Thalidomide 200 mg/d on every other 3 months Dexamethasone 40 mg/d D1-D4, D30-D34,D60-D64, D90-D94
45395820|NCT00495677|Drug|PF-00232798|Solution, 20 mg. once daily, 10 days
45849359|NCT00002472|Procedure|neoadjuvant therapy|
45395821|NCT00495677|Drug|PF-00232798|Solution, 150 mg. once daily, 10 days
45395822|NCT00495677|Drug|PF-00232798|Solution, 5 mg. once daily, 10 days
45849360|NCT00002472|Radiation|radiation therapy|
45395823|NCT00495677|Drug|PF-00232798|Solution, 40 mg. once daily, 10 days
45395824|NCT00495677|Drug|PF-00232798|Solution, 300 mg. once daily, 10 days
45395825|NCT00495677|Drug|PF-00232798|Solution, 400 mg. once daily, 10 days
45395826|NCT01020851|Behavioral|tailored intervention|6 monthly telephone calls focusing on diet, medication and exercise adherence using the framework of the transtheoretical model
45395827|NCT01020851|Behavioral|attention placebo|6 monthly telephone-delivered sessions focusing on general health topics
45395828|NCT01018043|Other|Adult Cancer Patients|Tracking anemia management in Adult Cancer Patients
45395829|NCT01020929|Device|Blunt Coude|Type of needle tip
45395830|NCT01020929|Device|Quincke|Type of needle tip
45395831|NCT01020929|Device|Trucath|Type of needle tip
45395832|NCT00495521|Drug|4-Aminosalicylic acid extended release granules|Granules for oral administration will be administered as a volume equivalent to 50 mg/kg of 4-aminosalicylic acid three times daily for 2 weeks followed by 2 times daily for 2 weeks in the active arm or a comparable volume in the placebo arm
45395833|NCT00273858|Other|There is no Intervention. The study is observational.|The study is observational and the prescription follows the SmPC of etanercept.
45395834|NCT01070238|Dietary Supplement|Isomaltulose|
45395835|NCT03975426|Procedure|open reduction and internal fixation with fixation by absorbable screws|Group A received conservative therapy involving bed rest with the affected lower extremity positioned with the hip and knee in flexion to ensure minimal tension of the muscles attached to the ASIS avulsion fracture. Group B received open reduction and internal fixation with fixation by absorbable screws.
45395836|NCT01068522|Device|Parenchymal Intracranial pressure monitor|Treatment based on readings from Parenchymal intracranial pressure monitor.
45395837|NCT01068522|Other|Treatment based on clinical and imaging observations|Treatment based on clinical and imaging observations.
45395838|NCT00494507|Drug|Dichlorphenamide (double-blind)|50mg tablet; maximum dosage 400mg/day
45395839|NCT00494507|Drug|Placebo (double-blind)|Inactive substance manufactured to look like Dichlorphenamide 50mg tablet
45395840|NCT00494507|Drug|Dichlorphenamide (open-label)|50mg tablet; maximum dosage 400mg/day
45503605|NCT01352299|Device|TrueView|Laryngoscopy performed with TrueView laryngoscope
45849361|NCT00002478|Drug|etoposide|
45849362|NCT00002484|Radiation|radiation therapy|
45849363|NCT00002490|Biological|BCG vaccine|
45395841|NCT01018121|Behavioral|LAUNCH|A 6-month intervention consisting of two phases: Phase I (Intensive Intervention), 12 weekly sessions that alternated between group-based clinic sessions (parent and child concurrent groups) and individual home visits and Phase II (Maintenance), 12 weeks of every other week sessions, alternating between group sessions in-clinic and home sessions. Targeted 3 components: 1) Dietary education with age-specific caloric targets, healthy eating recommendations for children following the AAP guidelines used in the PC session; 2) Physical Activity education with age-specific activities for children and families; and 3) Parenting skills to achieve the diet and physical activity goals using behavioral management skills and parent modeling of eating and activity.
45395842|NCT01018121|Other|Pediatrician Counseling|A one time 45-minute visit with a board certified pediatrician for each family that focused on the AAP guidelines for eating and physical activity for children
45395843|NCT00292188|Drug|pregabalin|pregabalin
45849364|NCT00002490|Drug|mitomycin C|
45395844|NCT00292188|Drug|Placebo|placebo
45395845|NCT00272844|Drug|crystalline cholesterol oil-based suspension|200 mg/mL suspension of crystalline cholesterol in oil. Dosage (generally 75-300 mg/kg/day in divided doses) is based on initial cholesterol levels and regulated to increase, yet maintain, cholesterol levels no higher than normal ranges.
45395846|NCT00271596|Drug|20mg daily citalopram|a selective serotonin reuptake inhibitor (SSRI) treatment administered over 16 weeks
45395847|NCT00271596|Drug|Placebo|a daily matching placebo administered over 16 weeks
45395848|NCT01068756|Drug|Dapagliflozin|Tablets, Oral, 10 mg, 2 single oral 10 mg doses, 2 days
45395849|NCT01068756|Drug|Rifampin|Capsules, Oral, 600 mg, Once daily on days 4 to 11, 8 days
45395850|NCT01068834|Genetic|KIF6 genetic test|KIF6 carrier status with interpretation sheet provided to subject
45395851|NCT00291642|Drug|Placebo drops|"Pharmaceutical form: Drops for oral administration~Route of administration: Oral use"
45395852|NCT00291642|Drug|Placebo tablets matching to levocetirizine|"Pharmaceutical form: Tablets for oral administration~Route of administration: Oral use"
45395853|NCT00291642|Drug|Placebo tablets matching to cetirizine|"Pharmaceutical form: Tablets for oral administration~Route of administration: Oral use"
45395854|NCT00291642|Drug|Levocetirizine drops|"Pharmaceutical form: Drops for oral administration~Concentration: 5 mg/ml~Route of administration: Oral use"
45395855|NCT00291642|Drug|Levocetirizine tablets|"Pharmaceutical form: Tablets for oral administration~Concentration: 5 mg~Route of administration: Oral use"
45395856|NCT00291642|Drug|Cetirizine drops|"Pharmaceutical form: Drops for oral administration~Concentration: 10 mg/ml~Route of administration: Oral use"
45395857|NCT00291642|Drug|Cetirizine tablets|"Pharmaceutical form: Tablets for oral administration~Concentration: 10 mg~Route of administration: Oral use"
45395858|NCT01070472|Drug|Misoprostol|titrated oral misoprostol solution
45395859|NCT00280566|Drug|Placebo|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID (twice a day) for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to placebo will be tapered off the open-label ziprasidone by 20 mg BID every 2 days (in a double-blinded manner) until they are completely off ziprasidone and are on matching placebo capsules for up to 24 weeks of double-blind treatment.
45395860|NCT00280566|Drug|Ziprasidone Oral Capsule|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to ziprasidone will continue to receive the same stable treatment regimen achieved during the open-label treatment, ie, either 40 mg BID, 60 mg BID or 80 mg BID for up to 24 weeks of double-blind treatment.
45395861|NCT00270894|Drug|epirubicin|epirubicin (100 mg/m^2) every 2 weeks for 4 cycles
45395862|NCT00270894|Drug|cyclophosphamide|cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles
45849365|NCT00002490|Radiation|radiation therapy|
45849366|NCT00002496|Drug|chemotherapy|
45849367|NCT00002496|Drug|cisplatin|
45849368|NCT00002496|Drug|fluorouracil|
45849369|NCT00002496|Procedure|conventional surgery|
45849370|NCT00002496|Radiation|low-LET cobalt-60 gamma ray therapy|
45395863|NCT00270894|Drug|docetaxel|docetaxel (75 mg/m^2) every 2 weeks for 4 cycles
45395864|NCT00270894|Drug|trastuzumab|trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments
45395865|NCT01070628|Drug|Stalevo (levodopa/ carbidopa/ entacapone)|150mg, 125 mg, 100mg, 75mg of levodopa q.i.d. in 3.5 h interval
45395866|NCT01070628|Drug|Sinemet (levodopa/carbidopa)|150 or 100 mg levodopa q.i.d. in 3.5 hr interval
45395867|NCT01070940|Drug|NG-monomethyl-L-arginine (L-NMMA)|3 mg/kg IV priming dose + 2 mg/kg/hr IV infusion for 1 hour
45395868|NCT01070940|Drug|NG-monomethyl-L-arginine (L-NMMA)|6 mg/kg IV priming dose + 4 mg/kg/hr IV infusion for 1 hour
45395869|NCT01070940|Drug|NG-monomethyl-L-arginine (L-NMMA)|4.5 mg/kg IV priming dose + 3 mg/kg/hr IV infusion for 1 hour
45395870|NCT01070940|Drug|Placebo|Isotonic saline solution IV priming dose + IV infusion for 1 hour
45849371|NCT00002496|Radiation|low-LET electron therapy|
45849372|NCT00002496|Radiation|low-LET photon therapy|
45395871|NCT00317642|Drug|clofarabine (IV formulation)|clofarabine (IV formulation) infusion 40mg/m^2 / day up to 3 cycles
45395872|NCT00317642|Drug|placebo|placebo (sodium Chloride) 1-hour IV infusion
45395873|NCT00317642|Drug|cytarabine|cytarabine IV infusion 1g/m^2/day for up to 3 cycles
45503606|NCT01348529|Behavioral|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
45697189|NCT03358563|Drug|Bicalutamide|The dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
45697190|NCT03358563|Radiation|Ferumoxytol-enhanced MRI imaging|Ferumoxytol-enhanced MRI imaging will evaluate immune micro-environment in the prostate. Three subjects enrolled to the study will undergo the first ferumoxytol-enhanced MRI imaging within 21 days prior to start of hormonal therapy followed by second and final ferumoxytol-enhanced MRI at the conclusion of hormone therapy but prior to their prostatectomy.
45697191|NCT01018420|Drug|Colchicine|two 0.6 mg capsules (1.2 mg dose) followed by an additional 0.6mg capsule every hour for 6 additional doses
45697192|NCT01018420|Drug|Moxifloxacin|400 mg capsule at the 6 hour point
45697193|NCT03376971|Procedure|Biopsy|Undergo lung biopsy
45697194|NCT03376971|Other|Laboratory Biomarker Analysis|Correlative studies
45697195|NCT04401033|Behavioral|Telephonic medical visit|The patient will receive a telephonic call passing a medical visit
45697196|NCT04401033|Procedure|Gastrointestinal endoscopy|Upper or lower GI endoscopy according to clinical practice and current guidelines
45697197|NCT04401033|Procedure|Abdominal ultrasound|Diagnostic abdominal ultrasound according to the current guidelines
45849373|NCT00002502|Drug|busulfan|
45395874|NCT01064726|Drug|Ibuprofen|800 mg oral
45395875|NCT01064726|Drug|Fluticasone propionate|200 mcg intra-nasal
45395876|NCT01064726|Drug|Placebo|Placebo
45395877|NCT01064804|Drug|PF-04191834|PF-04191834. 100mg Immediate Release Tablets or oral suspension
45395878|NCT01064960|Device|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
45395879|NCT00295022|Drug|Placebo|"Pharmaceutical form: Over-encapsulated tablet~Route of administration: Oral use"
45697198|NCT05686785|Diagnostic Test|Transient elastography|Transient elastography measures liver stiffness in kPa
45697199|NCT03081975|Device|HD white light or NBI|Use of NBI or HD white light
45697200|NCT03082131|Dietary Supplement|Resistant Starch Wheat|The investigators will be testing high amylose wheat varieties developed by Arcadia Biosciences that have high levels of RS in the endosperm, the source of refined flour. Compared to regular wheat varieties with RS levels of less than 1%, Arcadia's wheat varieties contain between 16% and 34% RS.
45849374|NCT00002502|Drug|cyclophosphamide|
45849375|NCT00002502|Drug|cytarabine|
45849376|NCT00002502|Procedure|allogeneic bone marrow transplantation|
45849377|NCT00002508|Drug|carboplatin|
45849378|NCT00002508|Drug|etoposide|
45395880|NCT00295022|Drug|Montelukast|"Pharmaceutical form: Over-encapsulated tablet~Concentration: 10 mg~Route of administration: Oral use"
45395881|NCT00295022|Drug|Levocetirizine|"Pharmaceutical form: Over-encapsulated tablet~Concentration: 5 mg~Route of administration: Oral use"
45395882|NCT01062152|Drug|Ezatiostat Hydrochloride|Starting dose 2000 mg orally in divided doses twice daily (1000 mg in AM & 1000 mg in PM) x 21 days with one week off therapy in a 4-week cycle.
45395883|NCT01062152|Drug|Lenalidomide (Revlimid®)|10 mg orally per day in one AM dose x 21 days with one week off therapy in a 4-week cycle.
45395884|NCT00303446|Drug|Dutasteride|Dutasteride 0.5 mg/day
45395885|NCT00303446|Drug|Placebo|Matched placebo
45395886|NCT00316706|Biological|GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule
45395887|NCT00316706|Biological|Havrix™|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule.
45503607|NCT02069210|Other|Blood transfusion|Intraoperative blood transfusion
45503608|NCT05188573|Device|Early detection pancreatic cancer test|Blood collection and pancreatic cancer early detection testing with return of results
45697201|NCT03081819|Drug|SH003|Herbal medicine for cancer treatment
45697202|NCT00974350|Drug|SABER-Bupivacaine|Injectable Extended Release Solution; 2.5 mL SABER-Bupivacaine/Once
45697203|NCT00974350|Drug|SABER-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER-Bupivacaine/Once
45697204|NCT00974350|Drug|SABER-Placebo|Injectable Solution; 2.5 or 5.0 mL SABER-Placebo/Once
45697205|NCT05633901|Other|Educational Video|Patients will be given the link to the educational video and able to view it as many times as they want
45697206|NCT05633901|Other|Standard Counseling|Current standard of care verbal counseling from a clinic nurse
45697207|NCT05633511|Procedure|Split Mouth Design|PRF on one side of mouth and CTG on the other side of participant's mouth.
45849379|NCT00002508|Procedure|autologous bone marrow transplantation|
45849380|NCT00002508|Procedure|peripheral blood stem cell transplantation|
45849381|NCT00002526|Biological|filgrastim|
45849382|NCT00002526|Drug|doxorubicin hydrochloride|
45849383|NCT00002526|Drug|ifosfamide|
45849384|NCT00002532|Biological|filgrastim|
45849385|NCT00002532|Drug|asparaginase|
45395888|NCT03980132|Drug|Lugols Strong Iodine|5 L.I. drops / 8 hours for 10 days before surgery
45395889|NCT01065038|Drug|Anagrelide|
45395890|NCT01065038|Drug|Hydroxyurea|
45395891|NCT03980054|Drug|Pyrotinib|pyrotinib 400 mg, orally once daily for one year
45395892|NCT03980054|Drug|Placebo|placebo 400mg, orally once daily for one year
45395893|NCT02532608|Other|Acute sleep deprivation|Participants will stay awake for 36 hours
45395894|NCT00291486|Drug|Capecitabine|Capecitabine was administered orally at doses between 1000 and 1500 mg/m2/day depending on assigned dose level for 14 days per 21-day cycle. Daily doses were rounded to the nearest 150 mg.
45395895|NCT00291486|Drug|131I-huA33 (131-Iodine on humanised monoclonal antibody A33)|All patients received a dose of 5 mg huA33 conjugated to 5-8 mCi 131I. The therapy dose of 131I-huA33 comprised a constant protein dose of 10 mg/m2 huA33 regardless of dose level. The 131I-huA33 therapy dose was determined by the assigned dose level (i.e. 20, 30 or 40 mCi/m2 131I).
45395896|NCT00301964|Biological|bevacizumab|Given IV
45395897|NCT00301964|Other|laboratory biomarker analysis|Correlative studies
45395898|NCT03976986|Device|continuous-flow portable oxygen concentrator (cPOC)|SeQal Eclipse 3® on continuous-flow (SeQual,Ball Ground,GA): flow rate 2 litre per minute (lpm).
45395899|NCT03976986|Device|pulsed-flow portable oxygen concentrator (pPOC)|InogenOne G3® (Inogen,Goleta,CA) on pulsed-flow mode: setting 2 (flow rate 420 ml/min, 16.8 ml +/- 3ml per bolus at 25 rpm).
45395900|NCT01070706|Drug|Paclitaxel,Gemcitabine,Sunitinib|"To determine the MTD, only DLT occurring during the first cycle of treatment will be considered. And MTD is defined as the dose level at which at least one-third of patients experience a DLT during their first treatment course. The recommended dose level for the subsequent phase II study is defined as the preceding dose level before the MTD is attained.~If MTD is not reached, the recommended initial dose of the phase II part will be at the dose of paclitaxel 80 mg/m2 and gemcitabine 1200 mg/m2 (days 1, 8) with sunitinib 37.5 mg qd D2-D15."
45395901|NCT01581528|Genetic|gene expression analysis|
45395902|NCT01581528|Other|cell culture procedure|
45395903|NCT01581528|Other|flow cytometry|
45395904|NCT01581528|Other|laboratory biomarker analysis|
45395905|NCT01581528|Other|metabolic assessment|
45395906|NCT03978026|Behavioral|Nap|Each participant is compared to himself in 4 conditions,
46057017|NCT04787835|Procedure|Local anesthetic infiltration|Local anesthesia will be infiltrated at the site of injury
46057018|NCT02714751|Behavioral|Daily asynchronies information|
45395907|NCT00268242|Drug|Gemcitabine Hydrochloride|10 mg/m2/ min IV for 12 hours
45395908|NCT00268242|Drug|Mitoxantrone Hydrochloride|12 mg/m2/day IV (administer over 30-60 minutes) on Day 1, 2 and 3
45395909|NCT00294554|Drug|Memantine|Active memantine and placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
45395910|NCT00294554|Drug|Placebo Oral Tablet|Placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
45395911|NCT00294398|Other|ICS Prescription + Standard Asthma ED Discharge Therapy|"Subjects are given a prescription for a 30 day supply of an inhaled corticosteroid based on age:~1-4 year olds Budesonide 0.5mg via nebulizer once daily; 5-11 year olds Fluticasone propionate 44mcg 2 puffs via spacer twice daily; 12-18 year olds Fluticasone propionate 110mcg 2 puffs via spacer twice daily"
45395912|NCT00294398|Other|Standard Asthma ED Discharge Therapy|Subjects are instructed to use albuterol as needed (up to every 4 hours), may be prescribed prednisone and to follow-up with their primary doctor in 3-5 days. All view an educational video about asthma control and are provided a home nebulizer if needed.
45395913|NCT00279708|Drug|Atorvastatin|Placebo vs. Atorvastatin
45395914|NCT00279708|Other|Placebo Oral Tablet|Placebo: Sham Therapy in an oral tablet formulation
45395915|NCT03978182|Device|accelerated deep rTMS|A Magstim Rapid2 Plus1 Magnetic Stimulator connected to the Brainsway dTMS system with the H1-coil investigational device (Brainsway Ltd, Jerusalem, Israel). The coil is situated inside a helmet to achieve effective cooling during stimulation. A sham coil is also included in the same helmet. The sham coil mimics scalp sensations and the acoustic artifact of the active stimulation without inducing neuronal activation.
45395916|NCT01066442|Drug|BF2.649 (Pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
45395917|NCT01581372|Other|Pharmacist care|Pharmacist prescribing, education, drug management
45395918|NCT01069146|Procedure|Mild therapeutic hypothermia induction|Mild Therapeutic hypothermia was induced immediately after patient inclusion. Patients were cooled between 32 and 34°c (33 ± 1°C; 90 and 93°F) for 36 hours, using the automatic mode of an external water cooling blanket (Meditherm II®, Gaymar, Orchard Park, NY, USA). The machine constantly compares actual patient temperature (measured by a rectal probe) with the set point, and automatically adjusts the blanket water temperature so that the desired patient temperature is achieved. The target temperature was to be reached within eight hour following inclusion. Rewarming was only passive (blanket switched off), and paralytic agents were to be stopped when the body temperature reached back 36°C (97°F).
45395919|NCT03974958|Genetic|Tissue-library|circulating biomarkers (miRNA panel) analysis of blood samples
45395920|NCT00299702|Drug|Abilify|10-30 mg once daily for 104 weeks
45395921|NCT00299702|Drug|Risperidal Consta|25mg, 37.5mg, or 50mg every 2 weeks for 104 weeks
45395922|NCT03979898|Biological|ASTROSTEM|Intravenous injection of Autologous Adipose derived mesenchymal stem cells. Dose : 15kg below : 0.5x10^7cells/5mL 15kg ~ 25kg : 1x10^8cells/10mL 25kg over : 1.5x10^8cells/15mL
45395923|NCT00291330|Drug|dabigatran etexilate 150 mg|twice daily
45395924|NCT00291330|Drug|warfarin (INR 2-3)|prn to maintain INR (2-3)
45395925|NCT03975036|Drug|Anlotinib|Anlotinib Hydrochloride Capsules
45395926|NCT03975036|Drug|pd-1 antibody|Pembrolizumabinjection
45697208|NCT05395702|Drug|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10*7 Units per mg of protein
45395927|NCT00267150|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|Experimental
46057019|NCT02714829|Device|Inject BMP|Injection of ExcelOS-inject(beta-TCP) containing rhBMP-2.
46057020|NCT02714829|Device|ExcelOS-inject|Injection of ExcelOS-inject(beta-TCP) without rhBMP-2.
45395928|NCT03741504|Procedure|micro-osteoperforations (MOPs)|three (3) micro-osteoperforations (MOPs) in the cortical and medullar bone, distal to the upper canine. These MOPs will be at the apical, medial and gingival zone of the bone located at the distal surface of the canine in the buccal and in the palatal side. The deep of the MOPs will be at 6 mm. It is going to be done with a PROPEL
45395929|NCT01582230|Drug|Vildagliptin|Patient will receive vildagliptin 50mg twice daily (bid) in addition to their stable dose of insulin with or without metformin for 24 weeks
45395930|NCT01582230|Drug|Placebo|Patient will receive matching placebo to vildagliptin in addition to their stable dose of insulin with or without metformin for 24 weeks
45395931|NCT00278148|Drug|carboplatin|AUC2 weekly x 3 weeks
45395932|NCT00278148|Drug|Erlotinib|Daily
45395933|NCT00278148|Drug|paclitaxel|50mg/m2/weekly x 3 weeks
45503609|NCT05188573|Device|Early detection pancreatic cancer test and MRI Imaging|Blood collection and pancreatic cancer early detection testing with return of results and MRI Imaging
45697209|NCT03016546|Behavioral|BEST-maCARE|Features of the integrated BEST-maCARE intervention approach include: Integration of depression screening and linkages to HIV and mental health treatment in the context of perinatal care; A trained, clinic-based nurse (study nurse) plays a mediating role between the health system and its beneficiaries; scheduling of appointments; and, accompanying the patient as needed to initial appointments if desired, and, follow up. Low cost, mobile phone technology is used for frequent one:to:one patient contact with a health care provider (the study nurse) to facilitate continuity of care (for mental health, HIV and pregnancy across the continuum of care from prenatal through postpartum) and promotion of self-care (adherence) and retention in care with a theory-guided, empirically-supported, standardized counseling intervention that is delivered proactively by the study nurse over 18 weeks.
45395934|NCT00278148|Procedure|conventional surgery|conventional surgery
45395935|NCT00278148|Radiation|radiation therapy|150 cGy bid
45395936|NCT00299546|Drug|Placebo|SC injections
45395937|NCT00299546|Biological|Golimumab 50 mg|SC injections
45395938|NCT00299546|Biological|Golimumab 100 mg|SC injections
45395939|NCT01071018|Drug|MK2206 every other day|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 45 mg and 60 mg, once daily every other day in repeating 4 week cycles.
45395940|NCT01071018|Drug|MK2206 once weekly|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 135 mg and 200 mg, once weekly in repeating 4 week cycles.
45395941|NCT03975270|Drug|Sintilimab and Nab-paclitaxel|Sintilimab in Combination with Nab-paclitaxel in Patients with Advanced Recurrent or Metastatic HNSCC after 2 or More Prior Lines of Therapy
45395942|NCT01065116|Drug|AL Blister-packs with Instruction leaflets|AL Blister packs with instruction leaflets will be dispensed
45395943|NCT01065116|Drug|AL unit dose age specific pre-packs|Age specific colour coded Unit dose pre-packs will be used
45395944|NCT03977792|Drug|BOR15001L7|BOR15001L7 topically applied to infected area, 5 times a day, until complete healing of the infection.
45503610|NCT03726333|Drug|lorlatinib|continued daily administration of 100 mg lorlatinib
45697210|NCT03016546|Behavioral|Attention Control Condition|The control group will receive an intervention that is time and attention equivalent to the experimental condition. The attention effect that is likely with provision of a mobile phone in the experimental condition will be controlled by providing mobile phone to the control group participants and, they will receive time matched calls from the study nurse with content of the calls focused on infant and maternal nutritional health education per Indian National Guidelines. The phone will be used for delivery of the interventions and may also be used by study staff for purposes of establishing contact or to collect survey interview data if necessary. Time, date, and content of all phone contacts will be documented by the nurse and evaluated in the analysis.
45697211|NCT01023178|Drug|17beta Estradiol|Oral pill given daily at increasing doses every 6 months for 18 months.
45395945|NCT03977792|Drug|Docosanol Cream 10%|Comparator product topically applied to infected area, 5 times a day, until complete healing of the infection.
45849386|NCT00002532|Drug|cytarabine|
45395946|NCT01062542|Procedure|Blood Draw and Ultrasound|Patients will have a Blood sample taken to check hormone levels. Patients will also have an ultrasound test done to examine the ovaries. The ultrasound test is done by inserting a cylindrical probe into the vagina. The test has to be done this way to measures the ovaries accurately.
45395947|NCT01066598|Drug|Rituximab|Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d
45395948|NCT01066676|Drug|Dexibuprofen|400mg powder for oral suspension, daily dose 800mg
45395949|NCT01066676|Drug|Ibuprofen|400mg, powder for oral suspension, daily dose 1600mg
45395950|NCT01065194|Drug|Levosimendan|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus
45395951|NCT01065194|Drug|Placebo|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus.
45503611|NCT03726333|Drug|lorlatinib|continued daily administration of lorlatinib at the dose level same as Group C for the first 22 days and 100 mg QD afterwards
45395952|NCT01065272|Drug|Dexamethasone|"0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Dexamethasone with cherry flavour is also given in the first day, then 0.6 mg/kg/day for 4 days"
45395953|NCT01065272|Drug|Placebo|"0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Placebo is also given in the first day, then 0.6 mg/kg/day for 4 days"
45395954|NCT00299156|Drug|Clofarabine|Starting dose 10 mg (Group 1) or 20 mg (Group 2) as tablets once a day for 5 days in a row and repeated every 4-8 weeks. Each 4-8 week period is a cycle.
45503612|NCT03726333|Drug|lorlatinib|continued daily administration of 100 mg QD lorlatinib
45395955|NCT00277212|Drug|Lamotrigine + Aripiprazole|"Tablets, Oral, once daily, Phase 1 (all subjects) - up to 24 weeks; Phase 2 - up to 52 weeks~Lamotrigine 100-200 mg/day~Aripiprazole 10-30 mg/day"
45395956|NCT00277212|Drug|Lamotrigine + Placebo|"Tablets, Oral, once daily, Phase 2 - up to 52 weeks~Lamotrigine 100-200 mg/day~placebo 0 mg/day"
45395957|NCT02532296|Behavioral|Transition Coach (TC)|"TC reviews patient's medical record to understand current admission and the medical/psycho-social history. TC makes introductory hospital visit(s) with patient to establish rapport and to define post-discharge needs.~Starting in-house and continuing after discharge, TC helps patient set transition goals to maximize healthcare outcomes. Post-discharge, TC offers a voluntary face-to-face visit with patient along with weekly outreach calls, which are designed to assist patient with goal setting and attainment, medical system navigation; medication management; medical follow-up; transportation; use of community resources; and self-care.~Intervention lasts 30 days post-discharge; afterwards TC seeks to handoff to an outpatient care team member, to ensure continuity of care."
45395958|NCT02532296|Behavioral|Control|Receives usual hospital-based care, discharge preparation, transitional care and outpatient care.
45395959|NCT03982628|Diagnostic Test|Abdominal CT imaging|Routine abdominal CT imaging
45395960|NCT01066754|Drug|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
45503613|NCT03726333|Drug|lorlatinib|continued daily administration of lorlatinib at 50 mg QD initially and may be adjusted based on PK and safety results from the initial several patients
45503614|NCT03726333|Drug|lorlatinib|continued daily administration of lorlatinib at the dose level determined based on preliminary PK and safety results from first several patients in Group C
45503615|NCT01347125|Device|ImCardia Device|The device operates by harnessing energy expended by the left ventricle (LV) during Systole and returning it to the heart during Diastole thereby making it available to augment diastolic performance
45503616|NCT05188495|Drug|trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy|trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy； TPC:treatment of physician's choice,include taxanes，Gemcitabine, capecitabine, vinorelbine
45503617|NCT05686317|Device|Edwards APTURE transcatheter shunt system|Treatment with APTURE shunt
45503618|NCT05686317|Diagnostic Test|Sham procedure|CS angiography
45503619|NCT02069288|Drug|Fludrocortisone|50 µg of fludrocortisone per os
45503620|NCT02069288|Drug|Placebo|1 tablet of placebo per os
45697212|NCT01023178|Drug|Conjugated estrogens|Oral pill, started at a low dose taken daily, dose increased every 6 months for 18 months
45697213|NCT01023178|Drug|17Beta Estradiol - transdermal|Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months
45395961|NCT02531958|Other|Eggs|Participants will complete a 2-week washout period followed by intake of 1, 2, and 3 eggs per day for 4 weeks each.
45395962|NCT00276744|Biological|cetuximab|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
45395963|NCT00276744|Drug|capecitabine|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
45395964|NCT00276744|Drug|docetaxel|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
45503621|NCT01356121|Drug|Propofol|Propofol will be initiated with a .5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
45503622|NCT01356121|Drug|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
45503623|NCT05725161|Behavioral|Acceptance and commitment therapy (ACT)|Participants assigned to the ACT group will receive 8 weekly individual ACT sessions guided by a coach for one hour per week over 8 weeks through Zoom videoconferencing with psychoeducation materials provided.
45503624|NCT05725161|Behavioral|Wait-list control group with psychoeducation materials provided|The wait-list control group will receive care as usual with psychoeducation materials provided during the study period and receive ACT sessions after the study period ends
45503625|NCT01336608|Drug|Fluticasone Furoate/Vilanterol|Inhaled corticosteroid/long acting beta-agonist
45503626|NCT01336608|Drug|Vilanterol|Inhaled long acting beta-agonist
45503627|NCT01336608|Drug|Placebo|Placebo
45503628|NCT02069444|Procedure|Macintosh laryngoscope|intubation criterias withMacintosh laryngoscopein pediatric patients
45697214|NCT01023178|Drug|Progesterone, micronized|Given starting at 18 months
45849387|NCT00002532|Drug|daunorubicin hydrochloride|
45395965|NCT00276744|Drug|Erlotinib|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
45395966|NCT00276744|Drug|Gemcitabine|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
45395967|NCT00276744|Drug|Irinotecan|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
45697215|NCT03373851|Device|Zalviso Device|"The Zalviso device will be provided immediately before the Post anesthesia care unit (PACU) discharge. Patients will be queried every day during three postoperative days for the ability to use the device, their satisfaction, the level of pain, and the incidence of side effects. There will be no changes in usual care.~In the end of this study ward nurses carrying Zalviso patients will be asked to provide their usability and satisfaction evaluation for Zalviso device management. Physical therapist will be asked to provide their satisfaction regarding patients' ability to follow physical therapy program."
45395968|NCT00276744|Drug|mitomycin C|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
45395969|NCT00276744|Drug|rapamycin|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
45395970|NCT00276744|Procedure|conventional surgery|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
45395971|NCT00251316|Drug|Lithium Carbonate|30 mCi of 131I
45503629|NCT02069444|Procedure|Truview EVO2 laryngoscope|intubation criterias with Truview EVO2 laryngoscope in pediatric patients
45503630|NCT03872999|Other|Functional brain imaging without any contrast agent|"During the functional magnetic resonance imaging (fMRI) protocol, the subject will perform the attentional task while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (ET) = 30 ms, Repetition Time (RT) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min)."
45697216|NCT03373773|Procedure|Foley catheter removal|After reinsertion of the Foley catheter, both groups of women will be given instructions on urinary catheter and bag management, this will be done by an RN as per standard protocol. Prior to discharge, every subject from the home removal group as well as their significant other/caregiver/family member will receive a standardized education session and written and illustrated instructions on Foley catheter removal from RN, per standard protocol. They will be provided with the syringe for catheter removal, urine collection pan, and a diary to record their voiding quality and quantity. Both groups of women will have the catheter removal in 2 days.
45697217|NCT01023568|Device|Macintosh blade|Intubation with Macintosh blade laryngoscope
45395972|NCT00251316|Drug|Placebo|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
45395973|NCT02532192|Drug|Belinostat|"Dose Escalation Phase Starting Dose: 200 mg/m2/d by vein on Days 1 and 2 of a 21 day cycle.~Dose Expansion Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
45395974|NCT02532192|Drug|Rituximab|Dose Escalation and Dose Expansion Phases: 375 mg/m2 by vein on Day 2 of a 21 day cycle.
45395975|NCT02532192|Drug|Cisplatin|Dose Escalation and Dose Expansion Phases: 100 mg/m2 by vein on Day 2 of a 21 day cycle
45395976|NCT02532192|Drug|Cytarabine|"Dose Escalation Phase: 2 g/m2 by vein on Day 3 of a 21 day cycle. Two doses given every 12 hours.~Dose Expansion Phase: 2g/m2 by vein on Day 2 of a 21 day cycle. Two doses given every 12 hours."
45395977|NCT02532192|Drug|Dexamethasone|Dose Escalation and Dose Expansion Phases: 40 mg by mouth on Days 2 - 5 of a 21 day cycle.
45395978|NCT02532192|Drug|Ciprofloxacin|500 mg by mouth twice daily for 10 days.
45395979|NCT02532192|Drug|Fluconazole|100 mg by mouth daily for 10 days.
45395980|NCT00293462|Biological|sargramostim|
45395981|NCT00293462|Other|oral salt and soda mouthwash|Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily.
45395982|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 2.5 mg, QAM, Daily (6 months ST, 12 months LT)
45849388|NCT00002532|Drug|dexamethasone|
45697218|NCT01023568|Device|Glidescope|Intubation with Glidescope laryngoscope.
45395983|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 2.5 mg titrated to 5mg, QAM, Daily (6 months ST, 12 months LT)
45395984|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 5mg, QAM, Daily, (6 months ST, 12 months LT)
45395985|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 5mg QPM, Daily (6 months ST, 12 months LT)
45697219|NCT01023568|Device|Truview PCD|Intubation with Truview PCD laryngoscope.
45697220|NCT05623995|Drug|PCSK9 inhibitor|Evolocumab per every two weeks, starting at day 1 and up to week 48, added to guideline recommended statin therapy..
45697221|NCT05623995|Drug|Statin|Guideline recommended statin therapy.
45395986|NCT00316082|Drug|Placebo|Coated tablets, Oral, 0mg, Daily (6 months ST, 12 months LT)
45697222|NCT03372291|Other|Usual Care|Usual leukemia care with all the supportive care measures instituted by the leukemia team
45697223|NCT03372291|Other|Psychological intervention|Psychological intervention is focused on educating patients about leukemia and how to cope with its treatment
45697224|NCT01023724|Drug|Ketorolac Tromethamine 0.45%|Acuvail to be given 1 drop BID for one day prior to surgery and then 1 drop BID post operatively for 14 days.
45697225|NCT01023724|Drug|Bromfenac 0.09%|Drug given one drop BID for one day pre operatively and then BID for 14 days post operatively
45395987|NCT00316082|Drug|metformin|Tablets, Oral, 500-2000 mg, as needed (12 months LT)
45395988|NCT00316004|Drug|7.5% Hypertonic Saline in 6% Dextran-70 (HSD)|250 ml intravenous bolus administration of 7.5% saline/6% dextran 70 administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
45395989|NCT00316004|Drug|7.5% Hypertonic Saline (HS)|250 ml intravenous bolus administration of 7.5% hypertonic saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
45395990|NCT00316004|Drug|0.9% Normal Saline (NS)|250 ml intravenous bolus administration of 0.9% saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
45395991|NCT01066832|Drug|Paclitaxel|Paclitaxel-coated balloon (3 µg/mm2)
45395992|NCT00298766|Drug|VELCADE|"Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2~Or~Twice-weekly at: 0.7, 1.0, or 1.3 mg/m2"
45395993|NCT03979664|Device|Activapatch intellidose 2.5 using active Iontophoresis|Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
45697226|NCT00974818|Drug|Mitomycin C (MMC)|Patients randomized to this group will receive six weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water). Patients will receive three weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water) 3, 6, 12, 18, and 24 months after the induction course.
45697227|NCT00974818|Biological|Bacillus Calmette-Guerin (BCG)|Patients randomized to this group will receive six weekly cycles of 81 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline). Patients will receive three weekly cycles of 27 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline) 3, 6, 12, 18, and 24 months after the induction course.
45849389|NCT00002532|Drug|etoposide|
45849390|NCT00002532|Drug|idarubicin|
45849391|NCT00002532|Drug|ifosfamide|
45849392|NCT00002532|Drug|leucovorin calcium|
45849393|NCT00002532|Drug|methotrexate|
45849394|NCT00002532|Drug|prednisolone|
45849395|NCT00002532|Drug|vindesine|
45849396|NCT00002538|Procedure|laparoscopic surgery|
45849397|NCT00002544|Drug|docetaxel|
45849398|NCT00002544|Drug|mitoxantrone hydrochloride|
45849399|NCT00002550|Drug|cisplatin|
45503631|NCT03628521|Drug|Anlotinib，Erlotinib，IBI308，Pemetrexed，gemcitabine，carboplatin|Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice
45395994|NCT03979664|Device|Activapatch intellidose 2.5 using inactive Iontophoresis|Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Inactive medication will be used in the study. Using a syringe, 2 cc of inactive medication will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
45395995|NCT03979664|Drug|Dexamethasone|Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
45395996|NCT01325558|Biological|ALT-836 in combination with gemcitabine|Study participants will receive up to four courses of a 28-day biochemotherapy with the study drug (ALT-836) and gemcitabine. Each treatment course consists of five doses of ALT-836 (on Day 1, 4, 8, 15 and 22) and three doses of gemcitabine (Day 1, 8 and 15). Participants with persistent responses will receive additional two cycles, three doses each, of standard of care gemcitabine therapy.
45395997|NCT00315458|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied for 7-day wear.
45503632|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation A = 16 hr release formulation)
45697228|NCT04761471|Device|TI transcranial electrical stimulation|"Participants will undergo transcranial electrical stimulation, which will be delivered with low current amplitudes (<= 2 mA) established with international safety guidelines for electrical stimulation. Threshold for the current amplitude will be established by participants themselves, such that they cannot distinguish when stimulation is applied and not applied.~Duration of stimulation will not last longer than 30 minutes."
45395998|NCT00315458|Drug|Placebo transdermal patch|Placebo to match buprenorphine transdermal patch 10 or 20.
45395999|NCT01065662|Drug|temsirolimus|Given on days 1, 8, 15 and 22 of each cycle
45396000|NCT01065662|Drug|cediranib|Taken orally daily
45503633|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation A = 16 hr release formulation)
45503634|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation B = 20 hr release formulation)
45503635|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation B = 20 hr release formulation)
45396001|NCT01062620|Drug|AXL1717|Phase I study with increasing dosage and treatment duration
45396002|NCT01065740|Other|Patient education|
45396003|NCT01066910|Behavioral|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
45396004|NCT01066910|Behavioral|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
45396005|NCT01581242|Drug|Clevudine, Adefovir dipivoxil , Clevudine+Adefovir dipivoxil|Clevudine 20mg qd Days 1; Adefovir dipivoxil 10 mg qd Days 8;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 15
45503636|NCT02067494|Other|Myofascial Soft Tissue Release|Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.
45396006|NCT01581242|Drug|Clevudine; Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil|Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 1; Clevudine 20mg qd Days 8; Adefovir dipivoxil 10 mg qd Days 15;
45503637|NCT02067494|Other|Kinesio taping treatment|"Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain."
45503638|NCT01361347|Dietary Supplement|milk|milk for milk allergic children (1:25 dilution, whole milk)
45503639|NCT05697003|Drug|Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
45503640|NCT05697003|Drug|ADVAIR DISKUS 100/50|2 inhalations in one study period
45697229|NCT05395546|Other|dCBT-I|"Complete the evaluation of various scales and record a 7-day sleep diary before entering the group~Receive a 6-week treatment after enrollment, insist on using the app every day (about 5-10 minutes), and receive regular follow-up from the project doctor~Scale assessment needs to be completed at the end of treatment~One month after the end of treatment, cooperate with relevant follow-up and complete the scale evaluation"
45503641|NCT01356199|Dietary Supplement|ARTRONAT|Dietary supplement containing Glucosamine, Chondroïtine and manganese. 6 per day for 8 months.
45697230|NCT00977704|Device|Restylane and Perlane|
45396007|NCT01581242|Drug|Clevudine,Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil|Adefovir dipivoxil 10 mg qd Days 1;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 8; Clevudine 20mg qd Days 15
45396008|NCT03982238|Drug|Insulin|Continuous subcutaneous insulin infusion therapy for 1 month
45396009|NCT03982238|Drug|Metformin|Continuous subcutaneous insulin infusion plus metformin (at least1000mg/day) for 1 month
45396010|NCT03982238|Drug|Dapagliflozin|Continuous subcutaneous insulin infusion plus metformin (10mg/day) for 1 month
45396011|NCT00293384|Drug|Aprepitant|Aprepitant 80mg once daily in the morning on days 2 and 3
45396012|NCT00293384|Drug|Cyclophosphamide|Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes
45697231|NCT05395390|Behavioral|Exercise (Resistance Training|Resistance Training done both at home and on site using either dumbells or keiser pneumatic exercise machines respectively
45697232|NCT05395234|Behavioral|Cook Like A Boss Online - virtual week long cooking camp|The original Cook Like A Boss camp style intervention, was based on the Cook-Ed Model (Asher et al., 2020) and underpinned by SLT and ELT (Bandura & McClelland, 1977; Kolb, 1984). The content was developed to ensure it was age-appropriate in line with the guidelines (Dean et al., 2021a) and included co-creation. The camp was designed to introduce the children to a range of food and skills and to nurture an initial interest in cooking. The adapted online version of the camp included five daily videos of the original chef performing the recipes. Minor adaptions included the removal of cooking pasta from scratch due to equipment concerns, reordering the days, and chef suggestions around alternative equipment/ingredients to use. The five daily videos were: 1) Introduction & flatbreads; 2) Chicken Chowder; 3) Baking day; 4) Chilli non Carne; 5) Honey Chilli Chicken
45396013|NCT00293384|Drug|Dexamethasone|Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.
45849400|NCT00002550|Drug|etoposide|
45396014|NCT00293384|Drug|Granisetron hydrochloride|Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.
45396015|NCT00297830|Drug|Zoledronic acid|Drug is administered through 5 mg intravenous infusion over 20 minutes
45396016|NCT00297830|Drug|Alendronate|Alendronate 70 mg will be taken once a week in the morning at least 30-60 minutes before first meal
45396017|NCT00297830|Other|Placebo Zoledronic Acid|Infusion of placebo zoledronic acid during the first 5 weeks after transplantation
45396018|NCT00297830|Other|Placebo Alendronate|Placebo alendronate 70 mg once weekly
45396019|NCT00296816|Drug|Bevacizumab (Avastin®)|15 mg/kg bevacizumab administered intravenously (IV) over 30 to 90 minutes on Day 1 of every 3 week cycle for 12 months or until disease progression or unacceptable toxicity
45396020|NCT00296816|Drug|Docetaxel (Taxotere®)|75 mg/m^2 docetaxel was administered IV over 1 hour on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
45396021|NCT00296816|Drug|Oxaliplatin (Eloxatin®)|85 mg/m^2 Oxaliplatin was administered IV over 2 hours on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
45503642|NCT01356199|Dietary Supplement|PLACEBO|PLACEBO. 6 per day for 8 months.
45503643|NCT02067572|Other|Saline mouthwash|
45849401|NCT00002550|Procedure|conventional surgery|
45849402|NCT00002550|Radiation|radiation therapy|
45396022|NCT03977870|Other|vital status determination|consultation of national registries
45503644|NCT02067572|Other|Salvia mouthwash|
45503645|NCT03775473|Diagnostic Test|progastrin|PROCODE is an interventional study of category 2 (non-medicinal product), with a minimal risks and restrictions, involving only one blood drawn at the screening of colon cancer.
45503646|NCT02069522|Other|Standard Milk-based Formula Containing Carotenoid|Fed ad libitum
45503647|NCT02069522|Other|Investigational Milk-based Formula Containing Carotenoid|Fed ad libitum
45503648|NCT02033148|Drug|icotinib hydrochloride|Given PO
45503649|NCT02033148|Other|laboratory biomarker analysis|Correlative studies
45849403|NCT00002556|Drug|vincristine sulfate|Given IV
45849404|NCT00002556|Drug|carmustine|Given IV
45396023|NCT01066988|Other|ORB Ocular Emulsion|lubricant eye drop
45396024|NCT01066988|Other|SootheXP Emollient (Lubricant) Eye Drops|lubricant eye drop
45396025|NCT00314132|Biological|ChimeriVax-JE, Japanese Encephalitis vaccine|0.5 mL, Subcutaneous
45396026|NCT00314132|Biological|0.9% Saline|0.5 mL, Subcutaneous
45396027|NCT03977558|Behavioral|Intervention group|Isocaloric diet including ~50g canola oil
45396028|NCT03977558|Behavioral|Control group|ESC/EAS Guidelines for the management of dyslipidemias
45503650|NCT02033148|Other|pharmacological study|Correlative studies
45503651|NCT01361425|Drug|methildopa|methildopa, 1,5g/day (500mg 8/8 hours, orally)
45503652|NCT01361425|Drug|placebo|placebo 500mg 8/8h, orally
45503653|NCT02033226|Device|Amniotic Membrane|AM strongly resembles the oral mucosal basement membrane and possesses several types of laminins, which can promote regeneration, accelerate tissue adhesion, and preserve tissues, all of which play a key role in improved healing of periodontal lesions and might result in reduction in probing pocket depth (PPD) and decrease in clinical attachment loss (CAL)
45503654|NCT02033226|Device|Control group (Hydroxyapatite only)|The placebo group was treated with Hydroxyapatite graft placement only.
45503655|NCT01356355|Drug|Herbmed plus|one capsule of herbmed plus orally twice a day with meals till the ureteral stent is in situ.
45396029|NCT00097786|Drug|Valsartan 160 mg + nateglinide 60 mg|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
45503656|NCT01356355|Drug|Placebo|One capsule twice a day daily till ureteral stent in situ
45503657|NCT01356355|Drug|Tolterodine|One capsule twice a day daily till ureteral stent in situ
45396030|NCT00097786|Drug|Valsartan 160 mg + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
45396031|NCT00097786|Drug|Nateglinide 60 mg + valsartan placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
45503658|NCT02069600|Device|Continuous Positive Airway Pressure|"CPAP applies a positive pressure into the airway to avoid its collapse during sleep.~The pressure used in each patient is calculate by an auto CPAP device during 3 months. This device calculate the pressure that avoid 95% of sleep-disordered breathing"
45503659|NCT03610542|Behavioral|Triggers for anxiety|Students learn about different triggers for anxiety, what the signs and indicators of anxiety are, and identify their own triggers for anxiety
45503660|NCT03610542|Behavioral|Identifying and challenging negative thoughts|Students learn about the types of unrealistic thoughts that underpin anxiety and how anxiety can be reduced with more realistic thoughts. Students identify their own unrealistic thoughts that contribute to anxiety and what more realistic thoughts can be used.
45849405|NCT00002556|Drug|melphalan|Given PO
45503661|NCT03610542|Behavioral|Relaxation|Students are taught to relax through (1) breathing exercises, (2) progressive muscle relaxation, and (3) imagery. Student practice these techniques.
45503662|NCT03610542|Behavioral|Goal Setting|Students learn how to set goals, monitor goal progress, and check when goals have been achieved. Students then identify their own goals.
45849406|NCT00002556|Drug|cyclophosphamide|Given IV
45849407|NCT00002556|Drug|prednisone|Given PO
45849408|NCT00002556|Biological|recombinant interferon alfa-2b|Given SC
45849409|NCT00002556|Other|laboratory biomarker analysis|Correlative studies
45849410|NCT00002562|Drug|paclitaxel|
45849411|NCT00002568|Drug|cisplatin|
45849412|NCT00002568|Drug|paclitaxel|
45849413|NCT00002568|Procedure|conventional surgery|
45849414|NCT00002574|Biological|recombinant interferon alfa|
45849415|NCT00002574|Drug|omacetaxine mepesuccinate|
45849416|NCT00002580|Drug|cyclophosphamide|
45503663|NCT03610542|Behavioral|Overcoming avoidance|Students identify ways that they avoid anxiety-provoking situations (e.g., procrastinating exam study). Students develop plans for exposure to anxiety-provoking situations and learn study strategies to build confidence.
45396032|NCT00097786|Drug|Valsartan placebo + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
45396033|NCT01081756|Drug|r-hCG|r-hCG (250 mcg) injection subcutaneously (s.c.) or intramuscularly (i.m.)
45503664|NCT03634969|Drug|BMS-986224|Specified dose on specified days
45503665|NCT01356433|Drug|oral vitamin C|"cross-over study,2 arms Arm 1(50cases): is given oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.~Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months."
45503666|NCT01356433|Drug|oral vitamin C|Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
45396034|NCT01081756|Drug|Urinary-hCG|Urinary hCG (10,000 IU) injection s.c. or i.m.
45396035|NCT03965182|Drug|PEG|2 sachets of PEG will be used as the bowel prep regimen.
45503667|NCT02033460|Other|Manual Therapy and Education|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective will add to manual therapy treatment.
45503668|NCT02033460|Other|Manual Therapy|Manual therapy will consist on Traction oscillatory, Maintained traction in the craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
45503669|NCT02033460|Other|Manual therapy, Education and Exercise|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective and Craniocervical exercise will add to this arm.
45503670|NCT03691727|Drug|tirofiban hydrochloride (AGGRASTAT®)|Participants will have intravenous Aggrastat administered continuously over the course of 7 days in the setting of subarachnoid hemorrhage at least 12 hours post clinically indicated Endovascular Coil Embolization procedure.
45396036|NCT03965182|Drug|PEG plus SPMC|one sachet of PEG and one sachet will be administered as the bowel prep regimen
45396037|NCT03965182|Drug|SPMC|2 sachets will be administered as the bowel prep regimen.
45503671|NCT03691727|Diagnostic Test|MRI|Participants will undergo 2 MRIs administered within 24 hours post Coil Embolization procedure and prior to discharge to monitor for ischemic changes.
45503672|NCT03691727|Diagnostic Test|Neurological Exam|Neurological exams will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
45396038|NCT01081990|Drug|cyclobenzaprine|Cyclobenzaprine 5 mg TID for 7 days
45396039|NCT01079572|Other|in-person|Follow-up appointments will be completed in-person as per usual
45849417|NCT00002580|Drug|fluorouracil|
45849418|NCT00002580|Drug|goserelin acetate|
45396040|NCT01079572|Other|web-based|Patients who are at least 2 years following knee or hip replacement will complete a questionnaire online and routine x-rays at a PACS enabled imaging center. The patient's surgeon will receive an email from the database summarizing the patient's responses to key questions and will review the x-rays. The surgeon will determine whether the patient needs to be seen in-person.
45396041|NCT01084486|Drug|Metformin|
45396042|NCT01082146|Drug|Lurasidone|40 mg suspension, PO, for 7 days
45396043|NCT01084720|Drug|V0034 CR|
45396044|NCT00117988|Drug|tanespimycin|
45396045|NCT03963466|Drug|tranexamic acid|Oral tranexamic acid group(menstrual period>2days) 250mg bid（exclude menstrual period ）
45396046|NCT03963466|Radiation|1064-nm Q-Switched fractional laser|Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24 left side of cheek is selected to be treated with 1064-nm Q-Switched fractional laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
45396047|NCT03963466|Radiation|1064-nm Q-Switched laser|Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24 right side of cheek is selected to be treated with 1064-nm Q-Switched laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
45396048|NCT01082224|Drug|iodinated contrast dye|iodinated Radiocontrast dye for imaging enhancement
45396049|NCT01082224|Drug|motexafin gadolinium|motexafin gadolinium
45396050|NCT01082224|Other|Eovist-enhanced MRI|A sub-study introduces the Eovist contrast agent for MRI scans at the same time points as the parent policy-assessment trial.
45503673|NCT03691727|Behavioral|Questionnaires|Quality of Life in Brain Injury - Overall Scale (QOLIBRI-OS) and the Lawton Instrumental Activities of Daily Living (IADL) will be administered at 6 month and 1 year follow up visits.
45396051|NCT01084876|Drug|CT-P6|Administered every 3 weeks
45503674|NCT03691727|Diagnostic Test|Vital Signs|Vital signs which include temperature, respiration rate, blood pressure and O2 stats will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
45503675|NCT03691727|Other|Standard of Care Treatment|Participants will receive standard of care treatment and will not receive study drug.
45503676|NCT02069834|Drug|Arm 1 (intervention)|Dolutegravir 50 mg/j + Rilpivirine 25 mg/j qd orally (intake during meal)
45503677|NCT02069834|Drug|Arm 2 (control)|Continuation of existing HAART at the time of randomization
45503678|NCT01360177|Procedure|124 PET/CT imaging|Standard of Care
45697233|NCT03371667|Drug|Methotrexate|"Methotrexate 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Methotrexate will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103."
45697234|NCT03371667|Drug|Placebo|"Placebo 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Placebo will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103."
45697235|NCT01024738|Drug|Fluoride|Brush half mouth twice daily for four days.
45697236|NCT01024738|Drug|Triclosan, fluoride|Brush twice daily
45396052|NCT01084876|Drug|Herceptin|Administered every 3 weeks
45396053|NCT01084876|Drug|Paclitaxel|Administered every 3weeks
45396054|NCT00117676|Drug|TDF|300 mg tablet administered orally once daily
45697237|NCT01024738|Drug|Chlorhexidine Gluconate|Rinse mouth twice a day
45396055|NCT00117676|Drug|ADV|10 mg tablet administered orally once daily
45396056|NCT00117676|Drug|TDF placebo|Tablet administered orally once daily
45396057|NCT00117676|Drug|ADV placebo|Tablet administered orally once daily
45396058|NCT00117676|Drug|FTC/TDF|200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
45396059|NCT00251004|Drug|Everolimus|oral, bis in diem/twice a day (bid)
45396060|NCT00251004|Drug|Mycophenolic Acid (MPA)|2 oral capsules of mycophenolic acid 360mg administered bid
45396061|NCT00251004|Drug|Cyclosporine A (CsA)|CsA dose adjustments were based on CsA trough levels (C0).
45503679|NCT01360177|Drug|Na134I|25 to 150 mCi
45503680|NCT01360177|Drug|Tri-iodothyronine|75 ug/8hr x 4 weeks; oral
45503681|NCT01360177|Drug|Tri-iodothyronine|20 mg/day x 2
45503682|NCT02071940|Drug|PLX3397|PLX3397 capsules 1000mg/day as monotherapy
45503683|NCT01348685|Other|Compare the effect of solid vs. liquid forms of sugars on satiety and food intake|
45503684|NCT01348685|Other|the effect of solid vs. liquid forms of gelatin on appetite and food intake|
45503685|NCT01348685|Other|The effect of solid vs. liquid forms of whey protein on food intake|
45503686|NCT01346371|Drug|Refresh Tears 0.5% Lubricant Eye Drops|
45503687|NCT01346371|Drug|Bepreve 1.5% Ophthalmic Solution|
45849419|NCT00002580|Drug|leuprolide acetate|
45396062|NCT00251004|Drug|Basiliximab|All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.
45396063|NCT00251004|Drug|Corticosteroids|Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.
45697238|NCT05613153|Dietary Supplement|Peppermint Oil|Participants weighing more than 40 kg will receive 2 peppermint oil capsules 3 times a day. Smaller children who weigh between 30 kg and 40 kg will receive 1 capsule of peppermint oil 3 times a day. All subjects will receive 8 weeks of treatment.
45697239|NCT04279041|Procedure|root canal preparation|root canal preparation
45396064|NCT03973632|Drug|SH-1028 Tablets|200mg of SH-1028 Tablets, orally once every cycle.
45396065|NCT01325922|Procedure|DFT Testing with a 50/50% tilt|
45396066|NCT00275340|Other|Peer Support|
45396067|NCT00275262|Drug|Leuprolide acetate depot (LAD) 11.25 mg 3 Month|LAD intramuscular injection 11.25 mg, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
45396068|NCT00275262|Drug|Matched placebo|Matched placebo intramuscular injection, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
45396069|NCT00275028|Drug|cediranib maleate|Given orally
45396070|NCT01072266|Drug|INCB028060|10 mg and 50 mg capsules will be provided and dosed per the dosing schedule.
45396071|NCT01072422|Behavioral|smoking cessation|Use of trying to quit smoking instrument and quit smoking advice
45396072|NCT00471497|Drug|nilotinib|Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.
45396073|NCT00471497|Drug|imatinib|Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).
45396074|NCT01018199|Other|CRP|C-reactive protein guided antibiotic therapy plasma CRP measurement to guide the duration of antibiotic therapy
45396075|NCT01018199|Other|PCT|Procalcitonin guided antibiotic therapy plasma PCT measurement to guide the duration of antibiotic therapy
45396076|NCT04357457|Drug|Almitrine|Intravenous almitrine at a dose of 2 µg.kg-1.min-1 during 5 days
45396077|NCT04357457|Drug|Placebo|Intravenous glucose 5% during 5 days
45396078|NCT00493649|Drug|Taxotere|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
45396079|NCT00493649|Drug|Cytoxan|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
45396080|NCT00493649|Drug|Herceptin|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
45849420|NCT00002580|Drug|methotrexate|
45849421|NCT00002580|Drug|tamoxifen citrate|
45849422|NCT00002580|Procedure|conventional surgery|
45396081|NCT00471107|Device|DC brain polarization|0.08 mA/cm2
45396082|NCT01018277|Other|Mobilization (walking)|25 meters twice
45849423|NCT00002580|Procedure|laparoscopic surgery|
45849424|NCT00002580|Procedure|oophorectomy|
45849425|NCT00002580|Radiation|radiation therapy|
45849426|NCT00002586|Drug|13-cis retinoic acid|
45396083|NCT00488033|Procedure|CT Angiography|If results indicate blockage, patients will receive interventional assessment (i.e., angiography) and treatment if indicated. All patients will receive aggressive treatment for type II diabetes (hemoglobin A1C) and lipids.
45396084|NCT01021163|Drug|N-acetylcysteine, saline|Inject 100 mg/kg of N-acetylcysteine or the equivalent amount of saline for 15 minutes before the skin incision, then continuously inject 40 mg/kg/day of N-acetylcysteine or the equivalent amount of saline during the next 24 hours.
45396085|NCT01021241|Biological|Uricase-PEG 20|Intravenous infusion of Uricase-PEG 20 over one hour; no premedication
45396086|NCT01018355|Device|Percutaneous device closure of patent foramen ovale|Percutaneous device closure of patent foramen ovale
45396087|NCT01021397|Drug|rHPIV3cp45|10^5 TCID50 nasal drops
45396088|NCT01021397|Drug|rHPIV3cp45 placebo|1X-L15 nasal drops
45396089|NCT01022333|Dietary Supplement|Diindolylmethane (DIM)|300 mg per day of DIM for six weeks.
45503688|NCT01348841|Other|Systematic referral to MDWCT and comprehensive primary care|Systematic referral to, and follow up, by Multi-Disciplinary Wound Care Teams (MDWCTs), co-ordinated by the Case Manager (CM), will occur.There will be immediate referral to the MDWCT of clients with :1/ diabetic lower extremity ulcers,2/peripheral neuropathy, charcot changes,3/wound present longer than 4 mths. ,4/ Ankle Brachial Index less than 0.6, non-diabetics, and not being seen by a vascular surgeon. Subsequent referral to MDWCT will occur if less than 30% healing by week 4.
45396090|NCT00117598|Drug|Temsirolimus (CCI-779)|Temsirolimus 175 mg IV once a week for 3 weeks; followed by 75 mg IV once a week
45396091|NCT00117598|Drug|Temsirolimus (CCI-779)|Temsirolimus 175 mg IV once a week for 3 weeks; followed by 25 mg IV once a week
45396092|NCT00117598|Drug|Investigator's choice|"Any of the following single agent treatments:~Fludarabine 25 mg/m2 IV over 30 minutes daily for 5 consecutive days, every 28 days or oral administration, as appropriate.~Chlorambucil 0.1 (0.1-0.2) mg/kg PO daily for 3 to 6 weeks as required OR 0.4 (0.3 0.8) mg/kg PO every 21 to 28 days~Gemcitabine 1 gm/m2 IV over 30 minutes on days 1, 8 and 15 every 28 days or day 1 and day 8 every 21 days~Cyclophosphamide 300 (200-450) mg/m2 PO daily for 5 consecutive days every 21 to 28 days, OR 600 (400-1200) mg/m2 IV every 21 to 28 days~Cladribine 5 mg/m2 IV daily for 5 consecutive days, every 28 days for 2-6 cycles depending on response,~Etoposide 50 (50-150) mg/m2 IV daily for 3-5 days every 21 to 28 days OR 100 (50 300) mg/m2 PO daily for 3-5 days every 21 to 28 days~Prednisone 40 (20-60) mg/m2 PO daily or every other day~Dexamethasone 20(20-40) mg PO/IV daily for 5 consecutive days, every 14 - 28 day"
45396093|NCT01082302|Drug|Polyphenon E (Veregen) 15% ointment|3 times daily application on genital and perianal warts over 7 days
45396094|NCT01082302|Other|Green Tea Beverage with defined catechin content|3 times daily oral intake over 7 days
45503689|NCT02069912|Behavioral|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are culturally and health literacy adapted for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
45396095|NCT01082458|Drug|remifentanil / lidocaine|"Remifentanil TCI group : target controlled infusion of 2.0ng/ml of remifentanil on end of surgery.~Lidocaine IV group : Intravenous administration of 1.5mg/kg of lidocaine on end of surgery."
45503690|NCT01356511|Drug|Prednisone|Prednisone, po, 1 mg/kg/d, for 4 weeks.
45503691|NCT01356511|Drug|Dexamethasone|Dexamethasone, po, 40 mg/d, for 4 days.
45396096|NCT00469859|Drug|cytarabine|given IV
45396097|NCT00469859|Drug|idarubicin|Given IV
45396098|NCT00469859|Drug|lestaurtinib|Given orally
45396099|NCT03964948|Diagnostic Test|Kidney MRI|An MRI examination will be completed per research MRI protocol.
45396100|NCT01021475|Procedure|Visceral Manipulation|Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks and 4 VM visits with weekly frequency with first VM visit at day 1 of drug therapy.
45396101|NCT01021475|Drug|PPIs and/or Domperidone|Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks
45396102|NCT04265170|Device|BlastX with negative pressure therapy|Blast-X in combination with NPWT on,bacterial bio-burden in pressure ulcers assessed by Fluorescence imaging and quantitative biopsy.
45396103|NCT01021631|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hematocrit fall below 30% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 30% or higher, no additional transfusion is necessary.
45503692|NCT03685487|Procedure|decolonization|current practice : V1 : consultation to the service : nasal sample for all 5 days before surgery : order sent with decolonization procedure : nasal mupirocin, shower and mouthwash V2 : admission to the service : nasal sample for all and urine sample for decolonized patients V3 : nasal sample for all
45503693|NCT03685487|Other|compliance questionnaire|We asked if the patient has done the whole decolonization procedure
45503694|NCT02069990|Drug|Cholecalciferol|
45849427|NCT00002586|Dietary Supplement|Tocopherol|
45849428|NCT00002592|Biological|c-myb antisense oligonucleotide G4460|
45849429|NCT00002592|Biological|filgrastim|
45396104|NCT01021631|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hematocrit fall below 24% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 24% or higher, no additional transfusion is necessary.
45396105|NCT01085032|Drug|Transdermal Nicotine|Subjects in the experimental group receive six weeks of nicotine patch treatment, 24 hour dose, using a step-down algorithm. Participants who smoke greater than 10 cigarettes/day receive two weeks of 21 mg patch, followed by two weeks of 14 mg patch, and then two weeks of 7 mg patch. Participants who smoke 5-9 cigarettes per day receive four weeks of 14 mg patch, followed by two weeks of 7 mg.
45396106|NCT01085032|Drug|Placebo nicotine patch|"Subjects in the placebo condition receive an inert placebo patch matched for size, shape, color, and packaging.~The same step-down dosing algorithm as in the experimental condition is used."
45396107|NCT01018433|Behavioral|T-SIB|Treatment for self-injurious behaviors; study psychotherapy
45396108|NCT01018433|Other|Treatment as usual|Can include other psychotherapy and pharmacotherapy
45396109|NCT01021709|Device|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm = 35 cm2 & 10 x 10 cm = 100 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
45849430|NCT00002592|Drug|busulfan|
45396110|NCT01021787|Drug|Titanium dioxide|Topical cream
45396111|NCT03998111|Diagnostic Test|Oral glucose tolerance test|Participants will ingest 75 g anhydrous glucose dissolved in water and the blood responses will be measured over the following 2-hours using a venous cannula.
45396112|NCT00093808|Biological|trastuzumab|
45396113|NCT00093808|Drug|capecitabine|
45396114|NCT00093808|Drug|vinorelbine tartrate|
45396115|NCT00469079|Drug|Nicotine gum and lozenge|Nicotine replacement
45396116|NCT00469079|Other|Taboka|smokeless tobacco product
45396117|NCT00469079|Other|Camel Snus|smokeless tobacco product
45396118|NCT01326754|Drug|Artemether-lumefantrine combination|Dispersible formulation of artemether-lumefantrine at a dose of 2/12 mg/kg body weight of artemether and lumefantrine, respectively, per dose, given twice a day for 3 days
45396119|NCT01326754|Drug|Artesunate-amodiaquine combination|Co-formulated artesunate-amodiaquine at a dose of 4 mg/kg/day artesunate and 10 mg/kg/day amodiaquine once a day for 3 days
45396120|NCT01326754|Drug|Dihydroartemisinin-piperaquine|Co-formulated dihydroartemisinin-piperaquine at a dose of 4 mg/kg/day dihydroartemisinin and 18 mg/kg/day piperaquine once a day for 3 days
45396121|NCT00093496|Drug|gemcitabine hydrochloride|Given IV
45396122|NCT00093496|Drug|tanespimycin|Given IV
45396123|NCT00117286|Drug|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
45396124|NCT01589380|Drug|Fimasartan|"Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.~Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP < 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan."
45396125|NCT01589380|Drug|Placebo|Placebo was used in phase 3 clinical trial of fimasartan (NCT00922480, NCT01135212, and NCT01258673). The same placebo, which is manufactures at Boryoung pharmaceutical company, will be used in this trial. After enrollment and randomization, placebo will be administered one capsule once daily in placebo group.
45849431|NCT00002592|Drug|cyclophosphamide|
45849432|NCT00002592|Procedure|autologous bone marrow transplantation|
45849433|NCT00002592|Procedure|in vitro-treated bone marrow transplantation|
45849434|NCT00002598|Biological|recombinant interferon alfa|
45396126|NCT00265122|Drug|Ustekinumab 90 mg|one 90 mg SC injection each week for 4 weeks (Weeks 0-3 during Intervention Period 1 or Weeks 8-11 during Intervention Period 2 for Population 1 or Weeks 0-3 during Intervention Period 1 for Population 2)
45396127|NCT00265122|Drug|Ustekinumab 4.5 mg/kg|one IV infusion of 4.5 mg/kg over a period of not less than 2 hours at Week 0 in Intervention Period 1 or Week 8 in Intervention Period 2 for Population 1 or at Week 0 in Intervention Period 1 for Population 2
45396128|NCT00265122|Drug|Placebo SC|one SC injection each week for 4 weeks (Weeks 0-3 in Intervention Period 1 or Weeks 8-11 in Intervention Period 2 for Population 1 or at Weeks 0-3 in Intervention Period 1 for Population 2)
45396129|NCT00265122|Drug|Placebo IV|one IV infusion over a period of not less than 2 hours at Week 0 in Intervention Period 1 for Population 1 and Population 2 or at Week 8 in Intervention Period 2 for Population 1
45396130|NCT00116584|Drug|heliox|continuous heliox therapy
45396131|NCT00116584|Drug|oxygen|continuous oxygen therapy
45396132|NCT00096538|Drug|valganciclovir|
45849435|NCT00002598|Biological|sargramostim|
45849436|NCT00002598|Drug|cyclophosphamide|
45849437|NCT00002598|Drug|cytarabine|
45849438|NCT00002598|Drug|etoposide|
45849439|NCT00002598|Drug|methotrexate|
45849440|NCT00002598|Drug|mitoxantrone hydrochloride|
45849441|NCT00002598|Procedure|bone marrow ablation with stem cell support|
45849442|NCT00002598|Radiation|radiation therapy|
45849443|NCT00002604|Drug|O6-benzylguanine|Patients receive BG IV over 1 hour during week 1, and then BG IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
45849444|NCT00002604|Drug|carmustine|After one hour of receiving BG patients receive BCNU IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
45849445|NCT00002604|Drug|chemosensitization/potentiation therapy|
45849446|NCT00002610|Biological|dactinomycin|
45849447|NCT00002610|Biological|filgrastim|
45849448|NCT00002610|Drug|carboplatin|
45849449|NCT00002610|Drug|cyclophosphamide|
45503695|NCT01347281|Procedure|Injection of [18F]HX4|"Injection of [18F]HX4 before treatment (baseline) and after radiotherapy with 20 +/-4 Gy:~[18F]HX4 PET scans; 444 MBq (12 mCi) [18F]HX4 administrated via a bolus IV injection. Image acquisition: static scan at 240 min p.i.~Venous blood sampling: before injection of [18F]HX4 (blood hypoxia markers) Follow-up (3 months after treatment): [18F]FDG PET in treatment position"
45503696|NCT02072018|Drug|H-100|H-100 is a new compound to be applied to Peyronie's disease tissue with the intention of reducing disease symptoms.
45503697|NCT02072018|Drug|Placebo|Placebo is an established, standard compound to be applied to Peyronie's disease tissue that will have no effect on disease symptoms.
45849450|NCT00002610|Drug|doxorubicin hydrochloride|
45396133|NCT00239928|Drug|pegaptanib sodium|1 drop per dosed eye per protocol.
45396134|NCT00116428|Device|NAVISTAR® THERMOCOOL® Catheter|The Biosense Webster NAVISTAR® THERMOCOOL® Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
45396135|NCT00116428|Drug|Antiarrhythmic drug|Subjects randomized to the antiarrhythmic drug (control) arm will be prescribed to a not previously administered class I or class III antiarrhythmic drug that is currently approved in the U.S. for treating atrial fibrillation.
45396136|NCT03971448|Device|LPWB|The LPWB will be placed by clinical staff who will have been trained on the proper application of this device at the initial ED visit. At ED discharge, both populations will receive identical documentation on recommendations for weight bearing, type and frequency of analgesics, reasons to return for medical attention. The only difference will be care instructions related to the specific immobilization device. Specifically, the experimental group will be permitted to remove the LPWB as early as one week post ED visit as tolerated by the patient's symptoms.
45396137|NCT03971448|Device|AKWC|If the patient is randomised to AKWC, it will be apply by a cast technician. Children with AKWC immobilization will be provided with up to two appointments in the orthopedic clinic. In case the AKWC could not been placed at initial visit, the first will be within 72 hours of the ED visit to have the fiberglass AKWC placed. The second appointment will be for cast removal.
45396138|NCT03971214|Drug|PD-1 inhibitor JS-001|The extensive-stage SCLC patients will receive PD-1 inhibitor treatment after standard first-line chemotherapy, chest radiotherapy ± SABR for metastasis disease, and propylactic cranial irradiation untill disease progression or death.
45396139|NCT01073748|Drug|paracetamol|single dose of paracetamol 15mg/kg.
45396140|NCT00468845|Drug|pregabalin (Lyrica)|150 mg/day double blind (divided doses)
45396141|NCT00468845|Drug|pregabalin (Lyrica)|300 mg/day double blind (divided doses)
45396142|NCT00468845|Drug|matched placebo|matched placebo
45503698|NCT01347359|Behavioral|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, using a mutually agreed upon method of communication between each pair of peer mentor and EIA participant (either by telephone or face-to-face meeting at a neutral public location). The research team will pair trained peer mentors and individuals with EIA as closely as possible based on such characteristics as sex, age, working status, and specific disease/type of IA. Peer mentors will be responsible to initiate and maintain contact with individuals with EIA. Individuals with EIA and peer mentors will be asked to have contact once a week for 30 minutes during the 12-week study period. Meetings/ interactions will not be prescribed; rather they will be defined by the individual with EIA. Peer mentors will provide support based on the needs of the individual they are mentoring. As such the nature of each interaction is likely to vary among pairs and from one interaction to the next.
45849451|NCT00002610|Drug|etoposide|
45849452|NCT00002610|Drug|vincristine sulfate|IV
45849453|NCT00002610|Procedure|conventional surgery|
45849454|NCT00002610|Radiation|radiation therapy|
45849455|NCT00002616|Biological|aldesleukin|
45849456|NCT00002616|Biological|filgrastim|
45849457|NCT00002616|Drug|carboplatin|
45849458|NCT00002616|Drug|cyclophosphamide|
45849459|NCT00002616|Drug|thiotepa|
45849460|NCT00002616|Procedure|peripheral blood stem cell transplantation|
45849461|NCT00002622|Drug|talc|4 to 5 grams talc in 100 cc saline via chest tube at bedside, one time
45396143|NCT03996317|Other|Room air|Avoidance of hyperoxygenation
45503699|NCT01347359|Behavioral|Standard of care|"Standard of care is at the discretion of the treating rheumatologist. In addition to information and patient education about the underlying disease process provided at the time of diagnosis, it may include referral to allied health professionals (e.g., physiotherapist, occupational therapist, podiatrist, social worker). This may be via referral to The Arthritis Society or directly to individual practitioners. In addition, it may include referral to voluntary support programs in the community (e.g., Arthritis Self-Management Program)."
45503700|NCT02076308|Other|Electroacupuncture and physical therapy|real electroacupuncture
45396144|NCT00468299|Drug|Misoprostol and placebo|Women in this group receive 800 mcg misoprostol plus a placebo
45396145|NCT00468299|Drug|Mifepristone and misoprostol|This group receives mifepristone 200 mg orally; followed by 800 mcg misoprostol bucally
45396146|NCT01021865|Drug|Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere|"GLP-1 at a rate of 1.2 pmol/kg/min~Regadenoson as a stress agent 0.4mg IV given during MCE~Definity:0.6 ml of Definity diluted with 30ml of 0.9% saline infused by SYRINGE Infusion Pump"
45503701|NCT02076308|Other|Sham-electroacupuncture and physical therapy|Sham electroacupuncture
45503702|NCT02070068|Device|PINPOINT System|
45503703|NCT01347437|Behavioral|Positive STEPS|This intervention is given to patients in the experimental condition only. The Positive STEPS intervention-developed by our team-is based on general principles of cognitive-behavioral therapy as well as more specific principles of motivational interviewing32,33 and problem solving therapy. Informational, problem solving, and cognitive-behavioral STEPS are targeted over 5, in-person, intervention sessions with a PhD-level counselor. The intervention will also include a series of short videos related to the topics that the Positive STEPS intervention covers with participants. Participants in the experimental condition can also choose to receive text messages sent to their cell phone to remind them to take their medication.
45503704|NCT05076409|Drug|BI 425809|Period 1 and period 2
45503705|NCT05076409|Drug|fluconazole|Period 2
45503706|NCT02076386|Drug|Dolutegravir|Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
45503707|NCT01347515|Other|olive oil|"Each volunteer will be given, in random order, a single dose of 30 ml on a base of 80 g bread, of the following functional olive oils (FOO): FOO750 ppm, FOO500 ppm, which are enriched with two different amounts of broad-spectrum phenolic compounds from the virgin FOO250 ppm; all prepared at the Universitat de Lleida.~Post-ingestion the volunteers will rest for 8h in a comfortable warm room. During the run-in period of 2 weeks prior the first postprandial study and 1 week between each FOO treatment period, all subjects will undergo a 2-day pre-treatment wash-out period of a phenol-free diet (saturated fatty acids in the diet will be 10-13% of energy in an isocaloric diet). Volunteers will avoid non-essential physical activity during the 3 days prior to the treatment day."
45503708|NCT05033353|Diagnostic Test|Monitoring of regional cerebral oxygenation|Regional cerebral oxygenation was monitored using near-infrared spectroscopy (O3TM, Masimo, Irvine, CA) placed on the patient's forehead.
45503709|NCT01347593|Drug|ceftizoxime|ceftizoxime (cefizox) injection either after clamping the cord
45849462|NCT00002622|Drug|Talc|4 to 5 grams talc via insufflation through direct or video thoracoscopy, one time
45396147|NCT00468143|Drug|Adderall ® Immediate Release|Adderall Immediate release (IR) was provided as treatment for three weeks (at 15, 30 or 45 mg TID). The medication was optimized for titration.
45396148|NCT00468143|Drug|Adderall XR ®|Adderall Extended Release (XR) was provided as treatment for three weeks at (15, 30, or 45 mg QD). The medication was optimized for titration.
45396149|NCT00467831|Drug|Losartan|Losartan potassium tablet, 25 mg by mouth every night at bedtime.
45396150|NCT00467831|Drug|Zileuton|Zileuton tablet, 1200 mg by mouth twice daily.
45849463|NCT00002634|Biological|filgrastim|
45396151|NCT00467831|Drug|N-Acetylcysteine|N-acetylcysteine solution, 600 mg by mouth three times daily.
45396152|NCT00467831|Drug|Pravastatin|Pravastatin sodium tablet, 20 mg by mouth every night at bedtime.
45396153|NCT00467831|Drug|Erythromycin|Erythromycin tablet, 333 mg by mouth three times daily.
45849464|NCT00002634|Biological|monoclonal antibody 3F8|
45849465|NCT00002634|Drug|cisplatin|
45849466|NCT00002634|Drug|cyclophosphamide|
45849467|NCT00002634|Drug|doxorubicin hydrochloride|
45849468|NCT00002634|Drug|etoposide|
45849469|NCT00002634|Drug|mesna|
45849470|NCT00002634|Drug|perfosfamide|
45849471|NCT00002634|Drug|vincristine sulfate|
45396154|NCT00467753|Drug|Oxcarbazepine|Oxcarbazepine is available in a 300mg/5ml solution. Dosage will start at 150 mg (2.5ml) at night for 3 days and will be increased to 150 mg in the am and pm. For children who are able to tolerate the 150 mg BID dose, the oxcarbazepine will be increased to 300 mg at night and 150 mg in the morning for 3 days and 300 mg BID for the next week. The children will remain on this dose until week 3, at which time if they are tolerating the medication and do not have a Clinical Global Improvement Scale (CGI) of 1 (very much improved) they will be increased to 600 mg twice a day in a method similar to the above increases. After week 4, the child will remain on the same stable dose.
45396155|NCT00467753|Other|Placebo/sugar pill|Dosage similar to active drug
45849472|NCT00002634|Procedure|autologous bone marrow transplantation|
45396156|NCT01021943|Drug|spironolactone|Half of the subjects will be assigned to receive 25 mg of spironolactone for 6 months
45396157|NCT01021943|Drug|Placebo|Half of the subjects will be assigned to receive placebo for 6 months
45396158|NCT00116272|Drug|Etanercept|Pregnant women previously exposed to etanercept during the first trimester. Etanercept was not administered in this non-interventional study.
45396159|NCT01022021|Drug|Rituximab|Day 1 - rituximab, 375 mg/M2 IV (drug dosage is based on body weight)
45396160|NCT01022021|Drug|Bendamustine|Days 2 and 3 bendamustine, 90 mg/M2 IV over 30-60 minutes (drug dosage based on body weight)
45396161|NCT00467597|Drug|Levodopa (delivered intravenously)|"IV Levodopa is given from 09:00 to 11:00 am during the testing phase of the study. The IV Levodopa allows the researchers to watch one full on and off levodopa cycle while in the inpatient unit."
45396162|NCT00115804|Drug|Fluoxetine|Fluoxetine po 10-60 mg/day for 12 weeks. Fluoxetine was started at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily
45396163|NCT01085188|Behavioral|ACC|Weekly community based behavioral counseling and case management
45396164|NCT01085188|Behavioral|CM|Weekly community based prize drawing opportunities contingent upon completed verifiable pro-social activities and clean urine and breath alcohol test results
45396165|NCT01085188|Behavioral|UCC|recommendation made by discharge counselor upon leaving residential treatment to attend nearest outpatient clinic.
45396166|NCT00467519|Biological|Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)|0.5 mL, IM
45396167|NCT00467519|Biological|DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)|0.5 mL, IM
45396168|NCT00264810|Procedure|RNS® System implantation|Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
45396169|NCT00264810|Device|RNS® System responsive stimulation|The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
45396170|NCT00467363|Drug|acetylsalicylic-acid (aspirin)|81mg of low-dose aspirin plus 400micrograms of folic acid.
45396171|NCT00467363|Dietary Supplement|Folic acid|400micrograms of folic acid.
45396172|NCT03970980|Other|fraction of inspired oxygen (FIO2)|Different group receives different (70% vs. 90%) fraction of inspired oxygen (FIO2) during the surgery.
45396173|NCT00091390|Radiation|High Dose brachytherapy boost|19 Gy in two fractions (on day of placement and 6-24 hours later) before or after external beam radiotherapy, such that all study treatment occurs within 8 weeks.
45396174|NCT00091390|Radiation|External beam radiotherapy|45 Gy as 1.8 Gy five days a week for five weeks.
45396175|NCT00239226|Procedure|IAS pacing - study group|site of implant and permanent pacing
45396176|NCT00239226|Procedure|IAS pacing control group|site of implant and permanent pacing
45396177|NCT00239226|Procedure|Pacing RAA study group|site of implant and permanent pacing
45396178|NCT00239226|Procedure|Pacing RAA control group|site of implant and permanent pacing
45396179|NCT01022099|Procedure|Implantation of a Total Knee Arthroplasty|"In all patients a cemented, unconstrained, cruciate-retaining TKA with a rotating platform (ScorpioTM PCS, Stryker Orthopaedics, Mahwah, NJ) was implanted. No patellar resurfacing was performed. A medial parapatellar approach with a femur-first preparation was done in all cases.~The Stryker Navigation System, Knee Navigation Software V3.1 (Stryker Orthopaedics, Mahwah, NJ) was used for computer-assisted implantation.~The conventional implantation was performed with femoral intramedullary and tibial extramedullary standard alignment guides."
45396180|NCT01022177|Procedure|acupuncture|acupuncture of the eye in traditional chinese schematics
45396181|NCT01022255|Biological|Autologous FL vaccine|1.0 mg of vaccine subcutaneously (s.c.) on Day 1, and followed by 125 µg GM-CSF s.c. at Day 1 -4, monthly until 8th vaccination, bimonthly until 12th vaccination (month 16)
45396182|NCT00264576|Biological|Influenza Virus Vaccine|
45396183|NCT01071174|Other|Dapivirine|Vaginal ring containing 25mg dapivirine; One ring inserted every 28 days for 84 days (3 rings total)
45396184|NCT01071174|Other|Placebo|Vaginal Ring containing no drug substance
45396185|NCT00466505|Biological|cetuximab|400 mg/m2 iv week 1, then 250 mg/m2 weekly thereafter, starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
45396186|NCT00466505|Drug|celecoxib|200 mg po BID starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
45396187|NCT00466505|Genetic|proteomic profiling|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction. We will use LC-MS-MS or MALDITOF mass spectrometry.
45849473|NCT00002634|Procedure|in vitro-treated bone marrow transplantation|
45849474|NCT00002634|Radiation|low-LET cobalt-60 gamma ray therapy|
45849475|NCT00002634|Radiation|low-LET photon therapy|
45503710|NCT02076464|Behavioral|StudentBodies - Eating Disorders|The intervention is a structured, cognitive-behavioral guided self-help program, derived from manual-based cognitive-behavioral therapy. The intervention targets the core eating disorder pathology (e.g., extreme dietary restraint, overvaluation of shape and weight, binge eating, compensatory behaviors), focusing on helping users develop regular eating patterns, self-control strategies, problem-solving skills, and relapse prevention tools for maintenance of behavior change. The program includes daily symptom checklists, journal exercises and activities, and an asynchronous moderated online discussion group.
45503711|NCT01360333|Other|tap water, sodium chloride, carbohydrate rich fluid|Ingestion of three different fluids at three different occasions separated by at least one week, A, Tap water. B. Sodium Chloride. C. Carbohydrate rich fluid.
45503712|NCT02072252|Behavioral|Mobile Phone Application|Mobile phone app teaching cognitive behavioral skills
45396188|NCT00466505|Other|immunohistochemistry staining method|phospho-EGFR levels using western blots of tissue extracts and immunohistochemistry on frozen and (if no other option available, paraffinembedded tissue sections).
45396189|NCT00466505|Other|laboratory biomarker analysis|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction.
45396190|NCT00466505|Other|mass spectrometry|We will use LC-MS-MS or MALDITOF mass spectrometry. Before any tissues are received, the drug of interest is evaluated via MALDI mass spectrometry on a MDS/Sciex QStar QqTOF mass spectrometer.
45396191|NCT02531568|Drug|Warfarin|
45396192|NCT02531568|Drug|MT-3995|
45396193|NCT00467051|Drug|Carboplatin|Given IV
45503713|NCT03672227|Behavioral|Mealtime Matters Training|This training will address common issues that Head Start teachers including how to deal with picky eaters, in addition to education about the nutritional needs of pre-school aged children.
45503714|NCT01347671|Drug|GRT6005|25µg/day once daily
45503715|NCT01347671|Drug|GRT6005|75 µg/day once daily
45503716|NCT01347671|Drug|GRT6005|200 µg/day once daily
45697240|NCT05686473|Behavioral|Program of psychoeducation of parents and professionals|"The program consists of a standardized manual-based treatment package as an easily accessible treatment tool for use by professionals in the specialist health services, who have treatment responsibilities for children diagnosed with FASD in Norway.~The intervention program will last for about 2 months and includes eight sessions, including six digitally based, interactive psychoeducational sessions.~Topics will be:~General information about FASD~Intervention strategies in kindergartens/schools for children with FASD~Families living with FASD - activities of daily living~Self-regulatory deficits - how to cope~Executive functions in daily life~Social development in children with FASD~Guidance in social settings~Challenging behavior - what can be done"
45697241|NCT01024972|Drug|Dantrolene|Dantrolene 1.25mg/kg IV (includes 5% mannitol) every 6 hours x 7 days
45503717|NCT01347671|Drug|Matching Placebo|Once daily
45503718|NCT01361659|Procedure|shockwave treatment|9 treatments in 3 months
45503719|NCT03671603|Drug|Iodixanol|Iodixanol 270 mgI/ml or 320 mg I/ml injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
45503720|NCT02072330|Drug|TAK-536CCB|TAK-536CCB 20 mg/5 mg ＋Hydrochlorothiazide placebo tablets
45503721|NCT02072330|Drug|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets
45503722|NCT02072330|Drug|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets
45503723|NCT02072330|Drug|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets x2
45503724|NCT02072330|Drug|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets x2
45396194|NCT00467051|Biological|Filgrastim|Given IV or subcutaneously
45396195|NCT00467051|Drug|Ifosfamide|Given IV
45396196|NCT00467051|Other|Laboratory Biomarker Analysis|Optional correlative studies
45396197|NCT00467051|Drug|Paclitaxel|Given IV
45396198|NCT00264498|Drug|Gefitinib|oral tablet
45396199|NCT00264498|Drug|Gemcitabine|intravenous injection
45396200|NCT00264498|Drug|Carboplatin|intravenous injection
45396201|NCT00466193|Drug|zolpidem tartrate sublingual tablet|3.5 milligram zolpidem tartrate sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
45396202|NCT00466193|Drug|Placebo|Placebo sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
45503725|NCT05128643|Biological|Recombinant novel coronavirus vaccine (CHO cell)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant novel coronavirus vaccine (CHO cells).
45503726|NCT02070224|Other|Serum and urine samples collections|Serum and urine samples will be collected at baseline, 3 month, 6 month, 12 month to assess the predictive value of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 on OA progression (MRI, Clinical and radiological progression)
45697242|NCT01024972|Drug|Placebo|equiosmolar volume (5% mannitol) every 6 hours x 7 days
45697243|NCT03370809|Radiation|Brain PET/CT step|a cerebral PET/CT will be registered on the 45th minute after 18F-FDG injection and just before the whole body recording. This recording does'nt need a new injection but needs a low dose scanner
45697244|NCT05686395|Procedure|Ultrasound-guided Interscalene Block group|ultrasound guided interscalene block versus combined ultrasound guided shoulder anterior capsular block and suprascapular nerve block for arthroscopic shoulder surgery
45849476|NCT00002634|Radiation|radioisotope therapy|
45396203|NCT01072578|Drug|Dapagliflozin|Dapagliflozin tablets 5 mg, Oral Twice daily dose for 5 days (total daily dose 10 mg)
45396204|NCT01072578|Drug|Dapagliflozin|Dapagliflozin tablets, 10 mg, Oral, once daily dose for 5 days
45396205|NCT01072734|Drug|Vaccine|Influenza vaccine
45503727|NCT02070224|Other|Imaging (x-rays and MRI)|MRI will be done at baseline and 12 month and x-rays will be done at baseline
45503728|NCT03660215|Other|mediation|support throughout their care journey during the 90 days following an emergency visit. This support will be carried out by a specific staff trained in medico-social mediation
45396206|NCT03971058|Biological|IXIARO®- Japanese Encephalitis vaccine|Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
45396207|NCT01025141|Device|Skeletal anchorage (MINISCREW)|Skeletal anchorage
45396208|NCT01025141|Device|dental anchorage|dental anchorage (reference)
45396209|NCT03970668|Drug|Linagliptin 5 mg Oral Tablet|Patients received linagliptin 5mg once daily orally plus a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
45396210|NCT03970668|Drug|Insulin|Patients received a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
45396211|NCT01022411|Dietary Supplement|Brown rice/White rice|ad libitum intake of brown rice/white rice at every lunch and dinner for 16 weeks
45396212|NCT00263562|Drug|Steroid arm|Day 1: Solumedrol 15 mg/kg (maximum 1 gram) Day 2: Prednisone 2mg/kg PO BID Day 3: Prednisone 2mg/kg PO daily Day 4: Prednisone 1mg/kg PO daily Day 5: Prednisone 1mg/kg PO daily
45503729|NCT02072408|Drug|aflibercept|"Three monthly intravitreal aflibercept (2mg) injections~Five bimonthly intravitreal aflibercept (2mg) injections~Rescue treatment: Verteporfin photodynamic therapy~Loss of five ETDRS letters or one Snellen line of vision from baseline~Presence of subretinal fluid or intraretinal fluid despite three consecutive (monthly or bimonthly) aflibercept injection~Presence of active polyp on indocyanine green angiography"
45503730|NCT02076542|Behavioral|Education - Diabetes and Sports|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Sports was created. The module covers specific and detailed aspects of the topic sports such as insulin reduction, hypoglycemia awareness during physical activity, and blood glucose values prior to physical activity. With this module, a more comprehensive education of patients with specific interest is possible."
45849477|NCT00002646|Drug|fenretinide|
45396213|NCT00263562|Other|Placebo|Patients received normal saline in lieu of intravenously-administered methylprednisolone and placebo pills equal in number to the steroid pills received in the steroid arm
45396214|NCT00454181|Drug|Interferon-alpha|500 IU interferon-alpha lozenges taken 3 times per day for 24 weeks
45503731|NCT03644849|Device|CO2RE® (Syneron Candela Corp, Wayland, MA)|The intervention will include a single treatment of a lower extremity wound with ablative fractional carbon dioxide laser after MMS surgery.
45503732|NCT03644849|Other|Sham laser treatment|A physician who is not blinded will perform a sham laser treatment on blinded subjects.
45503733|NCT02070458|Drug|ixazomib|Given PO
45849478|NCT00002646|Drug|tamoxifen citrate|
45503734|NCT02070458|Drug|mitoxantrone hydrochloride|Given IV
45503735|NCT02070458|Drug|etoposide|Given IV
45849479|NCT00002652|Drug|suramin|
45849480|NCT00002658|Biological|filgrastim|
45849481|NCT00002658|Drug|amsacrine|
45849482|NCT00002658|Drug|cyclophosphamide|
45396215|NCT00454181|Other|placebo|200 mg lozenges containing anhydrous crystalline maltose taken three times per day for 24 weeks
45396216|NCT03970434|Other|Venous blood collection|Venous blood collection
45396217|NCT03970434|Other|Peripheral blood collection|Peripheral blood collection
45396218|NCT01073826|Behavioral|Sport|
45396219|NCT01073826|Drug|Tocilizumab|
45396220|NCT01073826|Drug|Sitagliptin|
45396221|NCT00237744|Device|Robotics training for shoulder elbow.|training utilizing a robot to assist with movement practice
45396222|NCT00237744|Device|Surface Functional Neuromuscular Stimulation|training utilizing FNS to assist with movement practice
45396223|NCT00237744|Other|whole arm motor learning|intervention utilizing motor learning training principles to perform part and whole task practice of meaningful everyday functional tasks.
45396224|NCT01072812|Drug|Posiphen® tartrate capsules|Capsules administered (240 mg/day) for 10 days Capsules administered (160 mg/day) for 10 days
45503736|NCT02070458|Drug|cytarabine|Given IV
45503737|NCT03131479|Drug|LIK066|LIK066 50 mg tablets taken orally once daily before breakfast for 7 days.
45503738|NCT02076854|Behavioral|Text-Message Intervention|
45503739|NCT01348997|Behavioral|Project Onward website + 16 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 16 other cancer survivors.
45849483|NCT00002658|Drug|cytarabine|
45849484|NCT00002658|Drug|daunorubicin hydrochloride|
45849485|NCT00002658|Drug|etoposide|
45849486|NCT00002658|Drug|idarubicin|
45849487|NCT00002658|Drug|mitoxantrone hydrochloride|
45849488|NCT00002658|Drug|thioguanine|
45849489|NCT00002658|Drug|tretinoin|
45849490|NCT00002658|Procedure|allogeneic bone marrow transplantation|
45849491|NCT00002658|Procedure|autologous bone marrow transplantation|
45849492|NCT00002658|Procedure|peripheral blood stem cell transplantation|
45849493|NCT00002658|Radiation|radiation therapy|
45849494|NCT00002664|Biological|edrecolomab|
45849495|NCT00002664|Biological|sargramostim|
45849496|NCT00002670|Drug|chemotherapy|
45849497|NCT00002670|Drug|cisplatin|
45503740|NCT01348997|Behavioral|Project Onward website + 8 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
45396225|NCT00237042|Behavioral|Self Management|Two 1.5-hour in-person sessions and 6 10-15-minute telephone calls delivered by a dental hygienist, trained and supervised by a clinical psychologist. Structured, manual-based treatment based on standard cognitive-behavioral pain therapies and self-management interventions for chronic TMD pain. Sessions included education about the biopsychosocial model of chronic pain, TMD etiology and treatments, and the rationale for self-management; relaxation and stress management training; discussion of the role of stress and emotions as potential factors exacerbating and maintaining TMD symptoms; instruction and practice in self-monitoring of symptoms to identify factors that might be helpful to modify through self-care methods; practice of dentist-prescribed self-care treatments; and discussion of strategies to maintain gains and prevent relapse.
45396226|NCT00237042|Behavioral|Targeted Self Management|Self management as described above. However, the intervention also included education about the potential effects of hormones on TMD pain, instructions to monitor the association of pain and other symptoms with menstrual cycle changes, and planning for times in participants' menstrual cycles when symptoms might increase. Participant contacts were timed according to each participant's menstrual cycle.
45396227|NCT00237042|Drug|20 mcg ethinyl estradiol and 100 mcg levonorgestrel|Combination pill (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months.
45396228|NCT00465647|Drug|Hydromorphone|Oral hydromorphone solution dosed every 6 hours up to 9 doses. Dose is determined based on the expected weight range for each age group.
45396229|NCT00465569|Drug|cow's milk powder|Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks
45396230|NCT00465569|Other|Placebo|
45396231|NCT00090766|Drug|valganciclovir [Valcyte]|po daily (dose based on body surface area and CrCL)
45396232|NCT01086904|Biological|inactivated non adjuvanted pandemic H1N1 vaccine|two administrations at D and D21 (15 µg HA)
45396233|NCT01082692|Biological|PENNVAX-B|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
45503741|NCT03620227|Other|Exercise|40 minutes of aerobic exercise on a treadmill, with a fixed speed of 5.5 km/h and intensity imposed by treadmill inclination until it reaches the frequency zone between 60% and 75% of the reserve heart rate.
45849498|NCT00002670|Radiation|low-LET cobalt-60 gamma ray therapy|
45396234|NCT03961828|Drug|Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]|The fifty (50) thalassemic children infected with HCV received the new direct-acting antiviral therapy in the form of Ledipasvir (90 mg)/Sofosbuvir (400 mg); (Harvoni) as a single oral tablet /day for 12 weeks Follow up of these patients was performed for 24 weeks. Re-evaluation of these children after 24 weeks from initiation of Ledipasvir/Sofosbuvir treatment was performed by repeating clinical assessment, Fibroscan of liver , laboratory investigations including quantitative HCV RNA by PCR and serum hyaluronic acid measurement.
45396235|NCT01087060|Procedure|partial or radical nephrectomy|
45396236|NCT01582984|Other|video or education session in addition to standard consent|Video added to standard consent + handout Video + education session added to standard consent + handout
45396237|NCT00465179|Drug|Sunitinib Malate|50 mg by mouth daily for 4 weeks, then 2 weeks off.
45396238|NCT00465101|Device|GreenLight HPS|Greenlight HPS laser system for treatment of BPH
45396239|NCT00084136|Drug|Atazanavir|400 mg taken orally daily
45503742|NCT03620227|Dietary Supplement|Beetroot juice|Ingestion of 350ml of concentrated beetroot juice (400mg of nitrate) 100 minutes before an exercise session.
45503743|NCT03620227|Dietary Supplement|Placebo|Ingestion of 350ml of placebo (0mg of nitrate, with the same color, taste and smell) 100 minutes before an exercise session.
45503744|NCT02072564|Other|Questionnaire|Questionnaire with 100 questions divided into different groups: general data, work, physical activity, character, hobbies, disease and diet.
45503745|NCT04984369|Drug|HLX208|HLX208 450mg bid po OR 600mg bid po OR 900mg bid po
45503746|NCT04984369|Drug|Cetuximab Injection [Erbitux]|Cetuximab 500 mg/m2 IV Q2W
45396240|NCT00084136|Drug|Didanosine (enteric-coated)|400 mg taken orally daily
45396241|NCT00084136|Drug|Efavirenz|600 mg taken orally daily
45396242|NCT00084136|Drug|Emtricitabine|200 mg taken orally daily
45503747|NCT02076932|Behavioral|Spinning|After the baseline studies, the women will perform Spinning three times a week. Two of the sessions are performed on our location by trained instructors and the third training is self-training in a local fitness center where we provide free membership. All trainings are heart rate monitored.
45503748|NCT02077010|Drug|Inhaled nebulized milrinone|inhaled nebulized milrinone 60mg/4ml
45503749|NCT01319461|Device|Hyalgan|Patients will receive intraarticular injection of 20mg /2ml /syringe Hyalgan® once a week for 5 consecutive weeks.
45503750|NCT01319461|Device|sterile normal saline|Patients will receive intraarticular injection of sterile normal saline once a week for 5 consecutive weeks.
45503751|NCT02070536|Other|sRAGE|
45503752|NCT03180749|Other|Follow up per standard of care|Patients will come in 2 years post implantation and receive standard examinations
45503753|NCT02077088|Other|galactooligosaccharide|addition of food grade GRAS (Generally Regarded As Safe) galactooligosaccharides
45503754|NCT01361815|Device|H-Coil Deep TMS in combination with SSRIs|The study group will receive DTMS treatment three times a week for four weeks in combination with SSRI medications.
45503755|NCT01349075|Radiation|TheraSphere|The target dose of TheraSphere most commonly used is 120 - 140 Gy. Standard radiation safety techniques will be used.
45697245|NCT05686395|Procedure|Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block|Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block
45849499|NCT00002670|Radiation|low-LET electron therapy|
45697246|NCT05686395|Drug|Bupivacaine|bupivacaine 0.25%.
45849500|NCT00002670|Radiation|low-LET photon therapy|
45849501|NCT00002676|Drug|carmustine|
45849502|NCT00002676|Drug|cyclophosphamide|
45849503|NCT00002676|Drug|cytarabine|
45849504|NCT00002676|Drug|dexamethasone|
45849505|NCT00002676|Drug|doxorubicin hydrochloride|
45849506|NCT00002676|Drug|methotrexate|
45849507|NCT00002676|Drug|vincristine sulfate|
45503756|NCT02072720|Drug|Bevacizumab|patients will receive bevacizumab (3mg/kg/wk) starting from the identified induction time point of VEGF expression
45503757|NCT05077007|Procedure|Percutaneous nephrolithotomy|Endoscopic stone Extraction from the kidney by making a puncture and dilate a tract direct into the kidney through muscle wall and renal parenchyma
45396243|NCT00084136|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg/300 mg taken orally once daily
45396244|NCT00084136|Drug|Lamivudine/Zidovudine|150 mg/300 mg taken orally twice daily
45396245|NCT03812380|Drug|EffCaMgCit|Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.
45697247|NCT01025830|Drug|Triomune|Stavudine (40mg) Lamivudine (150mg) Nevirapine (200mg)All twice a day
45697248|NCT01025830|Drug|Zerit/Epivir/Viramune|Stavudine (40mg) Lamivudine (150mg) and Nevirapine (200mg) All taken twice daily.
45849508|NCT00002676|Radiation|low-LET cobalt-60 gamma ray therapy|
45396246|NCT03812380|Other|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. The placebo will contain 400 units of vitamin D.
45697249|NCT03369405|Other|NO intervention, patient records review only|There is no intervention - the three study groups are created by utilizing three unique sets of search criteria for the patient records review.
45697250|NCT03081039|Drug|Carboplatin|Arm A: Carboplatin or Cisplatin every 21 days for 6 cycles. Dose based on weight.
45697251|NCT03081039|Drug|Cisplatin|Arm A: Cisplatin or Carboplatin every 21 days for 6 cycles. Dose based on weight.
45697252|NCT03081039|Drug|Gemcitabine|"Arm A: Given with either Cisplatin or Carboplatin every 21 days for 6 weeks. Dose based on individuals weight.~Arm B: Gemcitabine alone every 21 days for 6 cycles. Dose based on weight."
45396247|NCT01583140|Behavioral|Wellness control|Participants in the Wellness Control arm of the study receive a variety of print materials focused on general health topics.
45396248|NCT01583140|Behavioral|Physical Activity Intervention|Participants in the Physical Activity Intervention arm of the study receive culturally-modified, individually tailored physical activity print materials.
45849509|NCT00002676|Radiation|low-LET photon therapy|
45396249|NCT01085422|Drug|ABT-888|Subjects will be given ABT-888 on Days 1 -7 every 28 days orally and temozolomide on days 1-5 on days 1-5 every 28 days orally with ABT-888
45396250|NCT01085422|Drug|temozolomide|Subjects will be given ABT-888 40 mg twice daily on Days 1 -7 every 28 days orally and temozolomide on days 1-5 every 28 days orally with ABT-888
45396251|NCT01090570|Drug|PLX3397|Once-daily oral capsules
45503758|NCT05077007|Procedure|Extracorporeal Shock Wave Lithotripsy|Using Shock waves from outside the body targeted at a kidney stone causing the stone to fragment. The stones are broken into tiny pieces.
45503759|NCT01356745|Drug|Premixed 50% nitrous oxide and oxygen (Kalinox)|15 min inhalation dose (maximum duration of treatment of a subject)
45503760|NCT01356745|Drug|medical air|inhalation gas for inhalation use
45503761|NCT02072798|Drug|Cefuroxime|iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
45503762|NCT01361893|Other|Lifestyle Counseling|We will utilize a combination of quantitative and qualitative techniques to ascertain factors, attitudes, and beliefs of African American parents of infants less than 6 months old.
45697253|NCT01026844|Drug|erlotinib|Taken orally once a day
45697254|NCT01026844|Drug|hydroxychloroquine|Taken orally once a day
45697255|NCT04278963|Drug|YinHu QingWen Decoction|YinHu QingWen Decoction (Granula) consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The decoction granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
45697256|NCT04278963|Drug|YinHu QingWen Decoction(low dose)|This intervention is given as 10% dose of YinHu QingWen Decoction (Granula).The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
45697257|NCT04278963|Other|Chinese medicine treatment|This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days.
45697258|NCT04278963|Other|standard western medicine treatment|Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.
45697259|NCT00979732|Dietary Supplement|grape seed extract|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
45697260|NCT00979732|Dietary Supplement|grape seed extract placebo|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
45697261|NCT03368781|Device|AcQMap Imaging and Mapping System|3D Cardiac Imaging and Mapping during ablation procedures
45849510|NCT00002682|Drug|Amoxicillin|
45849511|NCT00002682|Drug|Bismuth Subsalicylate|
45849512|NCT00002682|Drug|Clarithromycin|
45849513|NCT00002682|Drug|Metronidazole Hydrochloride|
45396252|NCT01085656|Drug|OXi4503|"Two safety cohorts treating two (2) patients at a dose of 2.5 mg/m2 followed by two patients at 3.75 mg/m2 will be completed prior to beginning at the dose level of 5 mg/m2.~Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose escalations and de-escalations of 25% will be made until the maximum tolerated dose is reached.~Number of cycles: After Cycle 1, subjects who achieve stable disease (SD) or greater response may continue to receive additional cycles of treatment until either disease progression (defined as greater than 25% increase in leukemia myeloblasts in the bone marrow compared to baseline examination) or unacceptable toxicity due to the investigational agent."
45396253|NCT03961984|Procedure|Biodesign® anal fistula plug|Patient in general anesthesia and lithotomy position. Mucosa excision of the internal fistula opening is performed. The plug was prepared in 0.9% sodium chloride, and secured to the endoluminal brush by a suture with a 2-0 vicryl tie. The narrow end of the of the plug was then pulled through the internal opening into the fistula tract. The plug was pulled until it covered the whole length of the fistula and blocked the internal opening, the excess plug material coming out through the external opening. The plug was fixed at the internal opening by reabsorbable 3-0 sutures. Special attention was paid to ensuring that the plug was covered by mucosa when closing the internal opening. The excess plug material was trimmed by the external opening that was left open for drainage.
45396254|NCT03961906|Behavioral|physiotherapy|Will receive two trainings. First training in week one after baseline assessment for three consecutive days 60 min twice daily by trained physiotherapists and in week three further two days with 60min once daily.
45396255|NCT01087138|Behavioral|exercise|exercise class 3x's/week
45396256|NCT01087138|Behavioral|exercise and calcium|exercise class 3x's/week and 1500mg calcium intake
45396257|NCT00464945|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2,3,4 and 12 months of age
45396258|NCT01025219|Genetic|Collect 10 ml of Saliva for DNA extraction|After signed written informed consent, all patients and controls have clinical and neuropsychological evaluations (DIGS, WURS, BROWN, BIS, SSS and IGT) for phenotypic diagnosis and collection of saliva for DNA extraction and genotyping diagnosis.
45503763|NCT03602885|Behavioral|Usual chemotherapy education (CE)|Standard chemo education will given per hospital guideline
45503764|NCT03602885|Behavioral|Chemotherapy education intervention (CEI)|Video, booklet, and website educational materials
45396259|NCT01025297|Drug|Interleukin-7|3 dose levels: 3, 10 & 20 µg/kg. 4 administrations, 1 per week
45396260|NCT01025375|Dietary Supplement|inulin|10gram/day inulin for 13-day treatment
45396261|NCT01025375|Dietary Supplement|inulin|16gram/day inulin for 13-day treatment
45396262|NCT01025375|Dietary Supplement|placebo|16gram/day maltodextrin (placebo) for 13-day treatment
45396263|NCT00464087|Drug|Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin|
45396264|NCT00452699|Drug|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
45396265|NCT00452699|Drug|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
45396266|NCT00069784|Drug|insulin glargine (HOE901)|Cartridges for use in a pen device, each containing 3 mL of insulin glargine 100 U/mL solution for injection
45396267|NCT00069784|Drug|omega-3 polyunsaturated fatty acids (PUFA)|Gelatin capsules (containing icosapent ethyl esters 465 mg and doconexent ethyl esters 375 mg) for oral administration
45396268|NCT00069784|Drug|placebo|Matching placebo gelatin capsules (containing olive oil) for oral administration
45503765|NCT01360567|Dietary Supplement|Green tea extract|500 mg . one capsule of green tea extract, 3 times per day
45503766|NCT01360567|Dietary Supplement|Placebo|500 mg . one capsule of placebo, 3 times per day
45503767|NCT02077244|Behavioral|Follow up talks|Nurse led follow up talks at the ward and one and two months later.
45503768|NCT01361971|Procedure|Hyperbaric Oxygen Treatment|Participants will undergo 4 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere, during this time, patients will be treated with 100% Oxygen delivered via a hood system.
45503769|NCT02880761|Procedure|Assessment guiding surgery and puncture for AVF|Assessment guiding surgery and puncture for AVF. Assessing the parameters of vascular vessels during following-up and making suggestions on surgery and puncture of AVF
45396269|NCT00069784|Device|reusable pen device for insulin injection|
45396270|NCT01087216|Device|Group Laser = Arm A|Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
45503770|NCT01356823|Biological|30μg HPV|Participants would intramuscularly receive 30μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
45503771|NCT01356823|Biological|60μg HPV|Participants would intramuscularly receive 60μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
45503772|NCT01356823|Biological|90μg HPV|Participants would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
45396271|NCT01087216|Drug|Bras B : The group control|patient to accept habitual treatment of corticoid Opposite side lesions that will receive only the treatment by topical steroids
45503773|NCT01356823|Biological|Hepatitis B vaccine|Participants would intramuscularly receive 10μg of hepatitis B vaccine at 0, 1, 6 month for 3 doses.
45503774|NCT02070770|Dietary Supplement|Very low calorie diet|
45503775|NCT02070770|Other|Standard weight loss diet|
45396272|NCT03811834|Drug|Mobocertinib|Mobocertinib capsule, [14C]-Mobocertinib intravenous infusion, [14C]-Mobocertinib oral solution.
45396273|NCT01085890|Behavioral|Motivational interviewing|The intervention consisted of 2 group seminars with information on hypertension and related lifestyle factors and 2 follow-up visits in which blood pressure was measured and motivational interviewing took place. The motivational interviewing focused on lifestyle factors, including physical activity, stress, tobacco use, alcohol habits, and diet.
45396274|NCT03958084|Diagnostic Test|Straight Leg Raise|The assessment of the flexibility of the hamstring will be realized through the test of straight leg raise (SLR). The SLR is a passive test performed unilaterally.
45396275|NCT00090610|Drug|Docetaxel|"For Arm 1: 30mg/m2 mg IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression combined with carboplatin~For Arm 2: 30mg/m2 IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression followed by carboplatin"
45396276|NCT00090610|Drug|Carboplatin|"Arm 1: AUC 6 IV on Days 1 and 8, repeated every 21 days for 6 cycles or until disease progression, combined with docetaxel.~Arm 2: AUC 6 IV every 21 days for 6 cycles or until disease progression, following six cycles of treatment with docetaxel"
45396277|NCT03957772|Procedure|Extrafascial injection|Extrafascial injection of local anaesthetic under ultrasound guidance
45396278|NCT03957772|Procedure|Intrafascial injection|Intrafascial injection of local anaesthetic under ultrasound guidance
45396279|NCT01326988|Procedure|Real-time ultrasound guided spinal anesthesia|The neuraxial US scan will be performed with the patient in the sitting or lateral position with the hip and knees slightly flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance to administer the spinal anesthetic.
45396280|NCT03962296|Drug|Vitis vinifera extract|Three daily oral doses of 50mg tablets of Vitis vinifera extract(Entelon®, Hanlim Pharm, Seoul, South Korea) were administered to patients in this group
45396281|NCT03962296|Drug|Calcium Dobesilate|Three daily oral doses of 50mg tablets of Calcium Dobesilate(Doxium®, Ilsung Pharm, Seoul, South Korea) were administered to patients in this group
45396282|NCT03962296|Drug|Placebo|Placebo tablets lacked Vitis vinifera extract or calcium dobesilate, but their appearance was identical to those of the study group tablets.
45503776|NCT01349153|Behavioral|Facebook-based Messages/Website|Twelve weekly messages, a pedometer, sixteen group discussions, and access to an exercise website to promote increased physical activity.
45503777|NCT01349153|Behavioral|Facebook-based Self-help Comparison|Twelve weekly messages and a pedometer.
45396283|NCT01086046|Drug|Low molecular weight heparin|"Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days."
45396284|NCT01090648|Drug|etravirine|One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
45396285|NCT04224064|Diagnostic Test|Blood sampling|Blood samples will be performed in fasted state for the controls and the patients. A single sample will be made in healthy subjects and several samples in patients: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.
45396286|NCT03741244|Drug|apatinib|Apatinib is an oral small molecule antiangiogenic targeted drug developed in China. More and more studies found that antiangiogenic drugs have outstanding performance in treating glioma. From the perspective of clinical and molecular mechanism, the combination of Temozolomide and apatinib may have synergistic effect especially to TMZ insensitivity patients(MGMT gene promoter unmethylated) and poor prognosis (IDH1 wild type) population
45697262|NCT03353181|Device|Endoscopic scissors|Application of endoscopic cutting technique following endoscopic nasobiliary drainage in the treatment of malignant hilar biliary strictures.
45697263|NCT03353181|Device|Biliary stent|Standard placement of biliary stent
45697264|NCT05686239|Drug|RL-007|investigational study drug
45697265|NCT05686239|Drug|Placebo|placebo capsules matching the appearance and size of the active drug
45849514|NCT00002682|Drug|Omeprazole|
45849515|NCT00002682|Drug|Tetracycline Hydrochloride|
45503778|NCT03635047|Biological|AL002|Single-doses of AL002 in up to 9 dose-escalating cohorts
45503779|NCT03635047|Other|Saline Solution|Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects for HV and 10 active and 2 placebo for patients
45503780|NCT02073032|Other|No intervention, only observation|
45849516|NCT00002688|Drug|cyclosporine|
45849517|NCT00002688|Drug|etoposide|
45849518|NCT00002688|Drug|mitoxantrone hydrochloride|
45849519|NCT00002700|Drug|asparaginase|
45849520|NCT00002700|Drug|cyclophosphamide|
45849521|NCT00002700|Drug|cytarabine|
45849522|NCT00002700|Drug|daunorubicin hydrochloride|
45849523|NCT00002700|Drug|dexamethasone|
45849524|NCT00002700|Drug|doxorubicin hydrochloride|
45849525|NCT00002700|Drug|leucovorin calcium|
45396287|NCT03741244|Drug|Temozolomide|Temozolomide，alkylating agent， is the standard first-line chemotherapy of glioma.
45396288|NCT03962218|Procedure|aquatic physiotherapy|specific aquatic physiotherapy 3 times a week, for 6 weeks, including feet balance exercises (Rating of Perceived Effort (RPE)), slow walking in all directions, walking with obstacles, Ai Chi, exercises of muscular strength. Each session duration is of 40 minutes.
45396289|NCT01090726|Device|Storz videolaryngoscope|Storz videolaryngoscope being used for the actual intubation
45396290|NCT01090726|Device|Airtraq|Airtraq being used for the actual intubation
45396291|NCT00463385|Drug|Pomalidomide|
45396292|NCT00463385|Drug|Prednisone|Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.
45396293|NCT00463385|Drug|Placebo to pomalidomide|Matching pomalidomide placebo tablets
45396294|NCT00463385|Drug|Placebo to prednisone|Matching prednisone placebo tablets
45396295|NCT01022489|Device|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
45396296|NCT01022489|Device|Placebo (sham coil) treatment|Sham coil treatment
45396297|NCT00463229|Other|Interprofessional Team Approach|Subject in the second group will receive home care services from a team of professional service providers (CCAC Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist) and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
45503781|NCT04943549|Drug|Bupivacain|Patients will be placed in left lateral position. A low-frequency curved array ultrasound transducer will be used. The ultrasound transducer will be placed in a longitudinal orientation 2-3 cm lateral to the midline to identify the hyperechoic line of the transverse process. After identification of muscles superficial to the transverse process and local infiltration of anesthesia into the superficial tissues, a block needle will be inserted in a craniocaudal direction until contact will be achieved with the transverse process where the tip will lay in the interfascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle; the erector spinae muscle should be visualized, separating from the transverse process. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally. Forty minutes after the ESPB, the cutaneous sensory block will be assessed.
45503782|NCT02070848|Other|Session 1-4|Familiarization sessions to knee-extensor exercise separated by 72h recovery
45503783|NCT02070848|Other|Session 4|After the last familiarization session, 1 maximal incremental test on a bicycle, followed by 72h rest
45396298|NCT03839693|Biological|botulinum toxin, Type A|topical liniment
45503784|NCT02070848|Other|Session 5|2 maximal incremental tests of knee-extension exercise (concentric vs eccentric), separated by 3h rest.
45697266|NCT05686161|Biological|SW-BIC-213;SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
45396299|NCT03839693|Biological|Vehicle|Vehicle Formulation
45396300|NCT00068692|Radiation|Radiotherapy|Undergo external beam radiation therapy
45396301|NCT00068692|Drug|Fluorouracil|Given IV
45396302|NCT00068692|Drug|Leucovorin Calcium|Given IV
45503785|NCT04790695|Drug|Seribantumab|For the induction phase: Seribantumab 3,000 mg IV weekly for 12 weeks then Maintenance Phase: Seribantumab 3,000 mg IV infusion once every 2 weeks, initiating approximately 14 days after completion of induction phase. Dose or schedule may be adjusted at the discretion of the treating physician.
45396303|NCT00068692|Drug|Oxaliplatin|Given IV
45396304|NCT00068692|Drug|Irinotecan|Given IV
45396305|NCT00463151|Drug|rebamipide|0, 60, 150, 300mg of rebamipide per day for 6 weeks into colon
45503786|NCT02073110|Device|Percutaneous Optical Biopsy (OCT and DRS)|
45503787|NCT01356979|Procedure|Medical thoracoscopy|Performing medical thoracoscopy to diagnose pleural diseases after cytological and other investigational tests.
45503788|NCT02073188|Device|iBGStar|
45503789|NCT02073188|Device|Traditional Glucometer|
45503790|NCT01319305|Device|FinESS Sinus Treatment|balloon sinuplasty
45503791|NCT02073266|Procedure|Macular hole surgery using a 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8.|
45396306|NCT01025687|Dietary Supplement|water with noncalorie sweetener|
45396307|NCT01025687|Dietary Supplement|water with glucose|
45396308|NCT01025687|Behavioral|TV program showed while feeding|
45396309|NCT01025687|Behavioral|TV program showed while feeding|
45396310|NCT00068380|Drug|imatinib mesylate|Given orally
45849526|NCT00002700|Drug|mercaptopurine|
45849527|NCT00002700|Drug|methotrexate|
45849528|NCT00002700|Drug|mitoxantrone hydrochloride|
45396311|NCT00068380|Other|laboratory biomarker analysis|Correlative studies
45396312|NCT01087684|Procedure|Argon laser trabeculoplasty|Argon laser 600-800 mW, 0.1seconds, 50 micron spot size, 45 - 55 burns over 180 degrees of trabecular meshwork
45697267|NCT05686161|Biological|Sinopharm (BIBP);SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
45849529|NCT00002700|Drug|prednisolone|
45396313|NCT01087684|Procedure|Selective laser trabeculoplasty|Selective laser trabeculoplasty 0.7 - 0.8 mJ, 400 micron spot size, 3 nanosecond, 45 - 55 burns over 180 degrees of trabecular meshwork.
45396314|NCT00067990|Drug|Losartan 100mg|To be started within three months of transplant and continued for five years.
45396315|NCT00067990|Drug|Placebo|No treatment with continued follow-up for five years.
45396316|NCT01086436|Biological|Rotarix ™|Oral, single dose
45849530|NCT00002700|Drug|prednisone|
45396317|NCT01086436|Biological|Placebo|Oral, single dose
45849531|NCT00002700|Drug|therapeutic hydrocortisone|
45849532|NCT00002700|Drug|vincristine sulfate|
45849533|NCT00002700|Procedure|allogeneic bone marrow transplantation|
45849534|NCT00002700|Procedure|autologous bone marrow transplantation|
45396318|NCT01090804|Device|BreatheMAX breathing device|secretion clearance, breathing exercise
45396319|NCT00090220|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|qHPV intramuscular injection in three 0.5 mL doses over 6 months in the Base Study or EXT1
45396320|NCT00090220|Biological|Comparator: Placebo|Placebo intramuscular injection in three 0.5 mL doses over 6 months.
45396321|NCT00263328|Drug|Tacrolimus|Standard of care
45396322|NCT00263328|Drug|CP-690,550|CP-690,550 5 mg BID
45396323|NCT00263328|Drug|CP-690,550|CP-690,550 10 mg BID
45396324|NCT03741660|Dietary Supplement|konjac glucomannan|Konjac-mannan fiber-enriched biscuits (0.7 g/412KJ [100kcal] of glucommanan)
45396325|NCT03741660|Dietary Supplement|wheat bran|Wheat bran (hard red wheat bran) fiber enriched biscuits
45396326|NCT00262860|Drug|bortezomib|
45396327|NCT00262860|Drug|gemcitabine hydrochloride|
45396328|NCT00236184|Drug|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
45396329|NCT00236184|Other|Placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
45396330|NCT00296504|Drug|fosamprenavir (GW433908)|
45396331|NCT00296504|Drug|ritonavir|
45849535|NCT00002700|Radiation|radiation therapy|
45849536|NCT00002706|Procedure|Laparoscopic Surgery|Undergo vaginal hysterectomy and BSO via laparoscopy
45849537|NCT00002706|Other|Quality-of-Life Assessment|Ancillary studies
45849538|NCT00002706|Procedure|Therapeutic Conventional Surgery|Undergo total abdominal hysterectomy and BSO via conventional laparotomy
45849539|NCT00002718|Biological|anti-thymocyte globulin|
45849540|NCT00002718|Biological|filgrastim|
45849541|NCT00002718|Drug|cyclophosphamide|
45849542|NCT00002718|Drug|cytarabine|
45849543|NCT00002718|Drug|methylprednisolone|
45849544|NCT00002718|Drug|thiotepa|
45396332|NCT00313820|Drug|Pregabalin|Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
45697268|NCT05686161|Biological|Pfizer(BNT162b2);SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
45849545|NCT00002718|Procedure|in vitro-treated bone marrow transplantation|
45503792|NCT04755361|Behavioral|Housing Outreach Project Collaboration (HOP-C)|HOP-C has several components: HOP-C Case management is outreach-based (emphasizing community and home contacts) and participant goal-driven, providing coaching and skill building in key functional domains and assistance with navigating various systems (justice, housing, employment, health, education). The mental health component has two parts. One is a weekly, 90-minute, mental health and wellness-oriented group. The group acts, for most, as a stepped care approach, with members moving on to access individual psychotherapy as needed. Peer support is provided by youth with a history of lived experience of homelessness who have successfully achieved housing stability and progress in major life domains. Peers receive extensive training and are formally hired into these roles with their being 2-3 peers on the team.
45503793|NCT02073344|Procedure|Renal replacement therapy|intermittent hemodialysis or peritoneal dialysis
45503794|NCT02073344|Other|no intervention|no renal replacement therapy
45849546|NCT00002718|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45503795|NCT04252105|Dietary Supplement|Antioxidant|Antioxidant-rich diet (added selected types of fruits, vegetables, nuts, cereals and oils)
45849547|NCT00002718|Radiation|radiation therapy|
45849548|NCT00002730|Drug|buthionine sulfoximine|
45849549|NCT00002730|Drug|melphalan|
45849550|NCT00002742|Drug|amphotericin B deoxycholate|
45503796|NCT02073422|Device|Fractional flow reserve|Guidewire-based index of coronary artery stenosis severity measured when coronary microvascular resistance is minimised by administration of a vasodilator drug.
45503797|NCT02073422|Other|Magnetic resonance imaging|Cardiac magnetic resonance imaging at 3.0 Tesla, including perfusion MRI at rest and during pharmacological stress with intravenous adenosine (140-210 ug/kg/min).
45503798|NCT02073500|Other|Observational study.|"Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor.~HIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease."
45503799|NCT02073578|Procedure|Peroral Endoscopic Myotomy (POEM)|Endoscopy myotomy for treatment of achalasia
45503800|NCT02077322|Device|Silastic Spacer|The Silastic spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
45503801|NCT02077322|Device|Merocel Spacer|The Merocel spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
45503802|NCT02077400|Drug|Cephazolin|Cephazolin
45503803|NCT01362283|Other|Blood Sampling|Blood sampling for Fasting Plasma Glucose, Hemoglobin A1C, Cholesterols, Blood Urea Nitrogen, Creatinine
45503804|NCT02077478|Device|Remifentanil and propofol administration using TCI|
45849551|NCT00002742|Drug|nystatin|
45503805|NCT02077478|Device|Remifentanil and propofol administration using MCI|
45503806|NCT02077556|Drug|Everolimus|Everolimus: 1 mg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 3-8 ng/mL
45503807|NCT02077556|Drug|Mycophenolate mofetil|Mycophenolate mofetil: 10-15 mg/kg orally every 12 hours from post-operation day 1 (decrease 50% dose if white blood cell < 4000/mcL)
45849552|NCT00002748|Biological|gene-modified tumor cell vaccine therapy|
45849553|NCT00002748|Biological|interleukin-2 gene|
45849554|NCT00002754|Biological|monoclonal antibody Me1-14 F(ab')2|
45849555|NCT00002760|Drug|ketoconazole|400 mg PO tid for as long as treatment is effective
45849556|NCT00002760|Drug|therapeutic hydrocortisone|hydrocortisone 30 mg PO q am and 10 mg PO qhs for as long as treatment is effective
45849557|NCT00002760|Other|Withdrawal of antiandrogen therapy|no drugs given
45849558|NCT00002772|Biological|filgrastim|
45849559|NCT00002772|Drug|carboplatin|
45849560|NCT00002772|Drug|carmustine|
45849561|NCT00002772|Drug|cisplatin|
45849562|NCT00002772|Drug|cyclophosphamide|
45849563|NCT00002772|Drug|doxorubicin hydrochloride|
45849564|NCT00002772|Drug|paclitaxel|
45849565|NCT00002772|Drug|tamoxifen citrate|
45849566|NCT00002772|Drug|thiotepa|
45849567|NCT00002772|Procedure|autologous bone marrow transplantation|
45396333|NCT00313820|Drug|Placebo|Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
45849568|NCT00002772|Procedure|peripheral blood stem cell transplantation|
45396334|NCT00462761|Drug|AC220|Powder in bottle formulation supplied as 50mg or 350 mg in glass, crimped serum vials. Requires reconstitution by a pharmacist, and must be stored securely and protected from light.
45396335|NCT01065974|Behavioral|Behavior Therapy|Weight loss using CBT and continued CBT during weight loss maintenance.
45396336|NCT01065974|Dietary Supplement|Meal Replacements|Weight loss using CBT and meal replacements.
45396337|NCT01065974|Behavioral|Nutritrol|To make widespread nutritional changes to participants personal food environments.
45396338|NCT00235872|Biological|adalimumab|40 mg eow, sc
45396339|NCT00461981|Biological|TIV, Trivalent Inactivated Influenza Virus Vaccine|0.25 mL will be administered intramuscularly for each of two doses
45396340|NCT00461981|Biological|FluMist, Influenza Virus Vaccine Live|0.5 mL will be administered intranasally (approximately 0.25 mL into each nostril) for each of two doses
45396341|NCT03970122|Drug|GFB-887|IMP
45396342|NCT03970122|Drug|Placebo|Matching
45396343|NCT00296036|Dietary Supplement|pyridoxine hydrochloride|Given orally
45396344|NCT00296036|Drug|urea/lactic acid-based topical cream|Applied topically
45396345|NCT00296036|Other|placebo|Given orally or applied topically
45396346|NCT01072890|Drug|Temsirolimus, Pazopanib|Patients will be treated on an outpatient basis with both temsirolimus and pazopanib. All patients will receive temsirolimus intravenously (IV) weekly days 1, 8, 15, and 22. Patients will receive oral pazopanib on a daily basis starting day 1. Treatment will be administered on 28 day cycles. Patients will be in this study for a minimum of 8 weeks or 2 cycles.
45396347|NCT00089674|Drug|AMG 162|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
45396348|NCT00089674|Drug|Placebo|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
45396349|NCT01090882|Drug|Bupivocaine|20ml 0.25% at beginning of operation
45396350|NCT01090882|Drug|0.9% normal saline solution|20ml 0.9% NaCl
45396351|NCT04187482|Other|Exercise training|All participants with DM1 will undergo a 12-week aerobic exercise training intervention on a cycle ergometer
45396352|NCT01090960|Drug|GDC-0068|Oral repeating dose
45396353|NCT03976388|Device|Clinical Virtual Simulator|Interactive medical case delivered using touch-sensitive screens in small group sessions.
45396354|NCT03976388|Other|Small-Group Discussion|Small group discussion led by a physician.
45396355|NCT03898973|Biological|Quadrivalent inactivated influenza vaccine (IIV)|Intramuscular Injection. Participants will receive the inactivated flu vaccine into anterior quadriceps.
45396356|NCT01067066|Drug|TPI 287|Starting dose cycle 1, 90 mg/m2 by vein (IV) on Days 1, 8, 15 (+/- 1 day)
45396357|NCT01067066|Drug|Temodar (Temozolomide)|Starting dose cycle 1, 85 mg/m^2 by mouth (PO) daily, Day 1 to 5.
45849569|NCT00002772|Radiation|radiation therapy|
45849570|NCT00002778|Biological|sargramostim|
45396358|NCT01069250|Other|There are no interventions in this study|
45396359|NCT00313586|Drug|Azacitidine|Given SC
45396360|NCT00313586|Drug|Entinostat|Given PO
45849571|NCT00002778|Biological|therapeutic allogeneic lymphocytes|
45396361|NCT00313586|Other|Laboratory Biomarker Analysis|Correlative studies
45396362|NCT01069328|Drug|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 200 mg orally BID interrupted dosing
45396363|NCT01069328|Drug|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg orally BID interrupted dosing
45503808|NCT02077556|Drug|Tacrolimus|Tacrolimus: 0.05-0.075 mg/kg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 8-12 ng/mL
45849572|NCT00002778|Procedure|allogeneic bone marrow transplantation|
45849573|NCT00002778|Procedure|in vitro-treated bone marrow transplantation|
45396364|NCT01069328|Drug|Bevacizumab|Bevacizumab 2.5 mg/kg intravenously
45396365|NCT01069328|Drug|Bevacizumab|Bevacizumab 5 mg/kg intravenously
45396366|NCT01069328|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg intravenously
45396367|NCT01069328|Drug|Bevacizumab|Bevacizumab 10 mg/kg intravenously
45849574|NCT00002784|Biological|filgrastim|Filgrastim 10 mg/kg/d sc for 6 days after randomization.
46057021|NCT02593981|Dietary Supplement|Fruit/Honey drink|2 canisters of powder containing fruit/honey mix to be mixed with water and ingested twice a day for 28 days
45396368|NCT01069328|Drug|Paclitaxel|Paclitaxel 200 mg/m² intravenously
45396369|NCT01069328|Drug|Carboplatin|Carboplatin AUC 6 intravenously
45396370|NCT01067222|Drug|BF2.649|BF2.649 oral capsules at 10 or 20 or 40 mg per day
45503809|NCT02077556|Drug|Methylprednisolone|Methylprednisolone: 50 mg iv every 6 hours on post-operation day 1, 40 mg iv every 6 hours on post-operation day 2, 30 mg iv every 6 hours on post-operation day 3, 20 mg iv every 6 hours on post-operation day 4, 20 mg iv every 8 hours on post-operation day 5, 20 mg iv every 12 hours on post-operation day 6, 20 mg iv on post-operation day 7
45396371|NCT01067222|Drug|Modafinil|Modafinil oral capsules at 100 or 200 or 400 mg per day
45396372|NCT01067222|Drug|Placebo|Placebo oral capsules, 4 capsules per day
45396373|NCT00312572|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied for 7-day wear.
45396374|NCT01067300|Procedure|Transplantation of unrelated cord blood unit(s)|Myeloablative conditioning regimen includes, according to the patient age, either total body irradiation, fludarabine and cyclophosphamide with a GvHD prophylaxis based on cyclosporine A and mycophenolate, or the association busulfan, cyclophosphamide and anti-thymocyte globulin with GvHD prophylaxis being cyclosporine A and steroids.
45396375|NCT01067378|Other|Peer-led debriefing|
45396376|NCT01067378|Other|Expert instructor debriefing|
45396377|NCT00290888|Procedure|Acromioplasty|
45396378|NCT01069640|Biological|HLA-A*0201 or HLA-A*0206-restricted URLC10 peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
45396379|NCT00290732|Drug|Intraductal arm|Patients will receive PLD intraductally according to the dose escalation schema (Dose Level -1=1 mg, Dose Level 1=2 mg, Dose Level 2= 5mg, Dose Level 3=10 mg). The PLD dose will be diluted in 5% dextrose in water and will be mixed for a total volume of 5 ml. The PLD will be administered via a breast duct (i.e., intraductally) using a microcatheter
45396380|NCT00290732|Drug|Intravenous arm|Blood samples and a breast tissue biopsy collected to look at levels of doxorubincol from patients receiving intravenous pegylated liposomal doxorubin to compare to the group receiving drug intraductally.
45396381|NCT00312494|Drug|Placebo|Placebo with mood stabilizer (either lithium or divalproex)
45396382|NCT00312494|Drug|Ziprasidone|Flexible dosing, 20-40mg BID, with a mood stabilizer (either lithium or divalproex)
45396383|NCT00312494|Drug|Ziprasidone|Flexible dosing, 60-80mg BID, with a mood stabilizer (either lithium or divalproex)
45396384|NCT00312338|Drug|VIGAMOX|1 drop of VIGAMOX® ophthalmic solution 0.5% in both eyes TID for 7 days
45396385|NCT00290498|Drug|Rituximab|Arm A: Rituximab 375 mg/m² by vein on day 1, Cycle 1 and alternating cycles. Arm B: Rituximab 375 mg/m² on day 1, Cycle 2 and alternating cycles.
45396386|NCT00290498|Drug|Cyclophosphamide|"Arm A: Cyclophosphamide 300 mg/m^2 by vein (IVPB) over 3 hours every 12 hours x 6 doses on Days 2-4, Cycle 1 and alternating cycles.~Arm B: Cyclophosphamide 750 mg/m² by vein day 1"
45503810|NCT02077556|Drug|Prednisolone|Prednisolone: 20 mg orally once a day from post-operation day 8 to post-operation week 4, then titrated gradually
45503811|NCT02930941|Drug|Tranexamic Acid|TXA (100 mg/1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
45503812|NCT02930941|Drug|0.9% Sodium Chloride|0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
45849575|NCT00002784|Drug|CMF regimen|Cyclophosphamide 100 mg/m2 orally days 1 - 14, methotrexate 40 mg/m2 iv days 1 and 8, 5-fluorouracil 600 mg/m2 iv days 1 and 8. Repeat every 28 days.
45849576|NCT00002784|Drug|cyclophosphamide|For high-dose EC arm: cyclophosphamide 4 gm/m2 iv as 4 divided doses. For standard chemotherapy arm: cyclophosphamide 600 mg/m2 iv day 1 of 21-day EC cycles, and cyclophosphamide 100 mg/m2 orally on days 1-14 of 28-day CMF cycles.
45849577|NCT00002784|Drug|doxorubicin hydrochloride|Doxorubicin 60 mg/m2 iv on day 1 of 21-day cycles of AC.
45849578|NCT00002784|Drug|epirubicin hydrochloride|Epirubicin 90 mg/m2 iv on day 1 of 21-day cycles of EC.
45849579|NCT00002784|Drug|fluorouracil|5-fluorouracil 600 mg/m2 iv days 1 and 8 of 28-day cycles of CMF.
45849580|NCT00002784|Drug|mesna|MESNA (7.2 gm/m2) on days 2 and 3 of 21-day cycles of dose-intensive EC.
45849581|NCT00002784|Drug|methotrexate|Methotrexate 40 mg/m2 iv on days 1 and 8 of 28-day cycles of CMF.
45849582|NCT00002784|Drug|tamoxifen citrate|Tamoxifen 20mg daily for 5 years or until relapse.
45849583|NCT00002784|Procedure|peripheral blood stem cell transplantation|Peripheral blood progenitor cells (PBPC) infusion on day 5 of each 21-day cycle of dose-intensive EC.
45849584|NCT00002784|Radiation|low-LET electron therapy|Radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
45849585|NCT00002784|Radiation|low-LET photon therapy|radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
45849586|NCT00002790|Drug|cyclosporine|
45849587|NCT00002790|Drug|methotrexate|
45849588|NCT00002790|Drug|sirolimus|
45849589|NCT05752578|Other|Neuropsychological testing|During the session the patient will be administered the Memory for Intentions Screening Test (MIST; Raskin et al., 2010) with the purpose of investigating prospective memory ability. Then during the same meeting the following tests will be offered to the patient: Montreal Cognitive Assessment (MOCA; Nasreddine. Translation Pirani et al 2006) investigating global cognitive performance; - Interpersonal Reactivity Index (IRI; Davis, 1980;1983- Italian version edited by Bonino et al, 1998) with the purpose of assessing cognitive and affective empathy (Hot cognition); Modified Five Point Test (Ruffi et al 1987) aimed at assessing figurative fluency (Cold cognition).
45849590|NCT05752422|Device|Niraxx G1 Headband Device including sham|Exploring effect of active t-PBM delivered by Niraxx G1 Headband versus sham condition
45849591|NCT05752344|Other|Counseling|Professional Counseling is an activity that aims to improve the client's quality of life. Supporting his strengths and his ability to self-determination, Counseling offers a space for listening and reflection in which to explore difficulties, related to evolutionary processes, transition phase, states of crisis and reinforcement of the ability to choose or change.
45849592|NCT05752266|Dietary Supplement|AMILI Probiotic pills|AMILI (AMILI Pte Ltd) will analyze stool samples provided by participants, and assign each participant a type of probiotic pill from the 5 different types of probiotic pills commercially available in AMILI retail store.
45849593|NCT05752266|Dietary Supplement|Placebo pills|Placebo pills contaning maltodextrin with similar appearance to Probiotic pills will be provided to participants allocated to the Placebo Arm.
45849594|NCT05752188|Other|Multimarker approach in acute coronary syndrome|The main objective of the study is to evaluate the prognostic role of the biochemical marker sST2 in patients attending the Emergency Department of our hospital with acute chest pain with suspected acute coronary syndrome.
45849595|NCT05752110|Drug|Ketamine|0,5mg/kg single dose Ketamine (0.05ml/kg) intravenously administered
45849596|NCT05752110|Other|Saline|0.09% Saline (0.05ml/kg) intravenously administered
45396387|NCT00290498|Drug|Doxorubicin|Arm A: Doxorubicin 50 mg/m^2/day by vein over 15 minutes (12 hours after last dose of cyclophosphamide) on Day 5, Cycle 1 and alternating cycles.
45697269|NCT03368313|Device|Circaid|Circaid is a velcro compression device for the calf (Circaid Juxtalite® Lower Leg; Medi Gmbh, Bayreuth, Germany), thigh and knee (Circaid Juxtafit; Medi Gmbh, Bayreuth, Germany). The Circaid device will be applied with an average pressure of more than 40 mmHg, verified through a BPS (built-in pressure system).
45849597|NCT05751954|Radiation|Postero-anterior weight-bearing full-leg radiograph|Full leg standing X ray of the involved lower extremity (postero-anterior direction)
45396388|NCT00290498|Drug|Vincristine|"Arm A: Vincristine 1.4 mg/m^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12, Cycle 1 and alternating cycles.~Arm B: Vincristine 1.4 mg/m^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12 of each cycle."
45503813|NCT02077634|Drug|abiraterone acetate + prednisone + LHRH-therapy|Hormon therapy will go on
45697270|NCT05685927|Drug|6-months of medically assisted glycemic improvement|Administrated by the clinic at Steno Diabetes Center, Aarhus, Denmark
45697271|NCT05685927|Procedure|Bariatric surgery|Participants are examined prior to and 1 year following bariatric surgery in the Central Region, Denmark
45849598|NCT05751954|Device|Pedobarographic analysis|Foot pressure analysis during gait on pedobarographic device
45849599|NCT05751876|Drug|Dienogest|Dienogest 2mg was prescribed once per day orally
45849600|NCT05751798|Drug|OSE-279 100mg|Human IgG4 mAb against PD-1
45849601|NCT05751798|Drug|OSE-279 300mg|Human IgG4 mAb against PD-1
45849602|NCT05751798|Drug|OSE-279 500mg|Human IgG4 mAb against PD-1
45849603|NCT05751720|Drug|GIP/GLP-1a|The group will receive GLP-1 analogues (subcutaneous Tirzepatide). The dose of Tirzepatide is 0.25 mg once weekly for 4 weeks then 0.5 mg once weekly.
45849604|NCT05751564|Biological|"Ready to inject Umbilical cord-derived Mesenchymal Stromal Cell (MSC) product"|Cryopreserved thaw & inject MSC intra-articular therapy
45849605|NCT05751564|Biological|Resuspended Umbilical cord-derived Mesenchymal Stromal Cell (MSC) product|Cryopreserved resuspended MSC intra-articular therapy
45849606|NCT05751486|Biological|Toripalimab injection(subcutaneous)/JS001sc|JS001sc Q3W combination with gemcitabine and cisplatin.
45849607|NCT05751486|Biological|Toripalimab injection(subcutaneous)/JS001sc|JS001sc long period combination with gemcitabine and cisplatin.
45849608|NCT05751486|Biological|Toripalimab /JS001|JS001 IV (if applicable) .
45849609|NCT05751486|Biological|Toripalimab injection(subcutaneous)/JS001sc|Additional cohort (if applicable)
45849610|NCT05751408|Procedure|gait analysis using 3D (Vicon) and IMU (Movella)|Subjects are measured using Vicon 3D analysis, combined with IMU-sensors
46057022|NCT02593981|Dietary Supplement|Placebo|2 canisters of Placebo powder containing non-active ingredient to be mixed with water and ingested twice a day for 28 days
46057023|NCT00730015|Drug|Matching Placebo|Oral, once daily
45503814|NCT02077634|Drug|abiraterone acetate + prednisone|ormon therapy will be stopped
45503815|NCT01349309|Behavioral|Swallowing Exercise Group|"Swallowing Exercises~Perform each exercise 10 times. Do these 3 times a day. Vary the order of the exercises.~Effortful Swallow: As you swallow squeeze hard with all your muscles. (Can do with water or without)~Super Supraglottic Swallow:~Inhale and hold your breath very tightly, bearing down. Keep holding your breath and bearing down as you swallow. Cough when you are finished. (Can do with water or without)~Tongue Hold Maneuver:~Gently hold your tongue in between your front teeth and swallow your saliva.~Tongue Retraction:~Pull the back of your tongue to the back of your mouth and hold.~Mendelsohn Maneuver:~Swallow your saliva and pay attention to your neck as you swallow. Try to feel that something (your Adam's apple of voice box) lifts and lowers as you swallow. Now, when you swallow and you feel something lift as you swallow don't let it drop. Hold it with your muscles for several seconds."
45396389|NCT00290498|Drug|Dexamethasone|Arm A: Dexamethasone 40 mg by vein or by mouth daily x 4 on Days 2-5 and on days 12-15 of cycle 1 and alternating cycles.
45396390|NCT00290498|Drug|Methotrexate|Arm A: Methotrexate after finishing Rituximab, 200 mg/m2 by vein over 2 hours, then 800 mg/m2 by vein over 22 hours day 1 cycle 2.
45396391|NCT00290498|Drug|Cytarabine|Arm B: Cytarabine 3 g/m^2 by vein over 2 hours every 12 hours X 4 doses on days 3 & 4, cycle 2 and alternating cycles.
45396392|NCT00290498|Drug|Prednisone|Arm B: Prednisone 100 mg by mouth (as a pill, capsule, or tablet) once a day on Days 1-5, each cycle.
45396393|NCT01069796|Drug|Paclitaxel|80 mg/m² weekly
45503816|NCT01365403|Drug|RO4917838|Single oral dose, Day 1 of study period 1 and Day 16 of study period 2
45503817|NCT01365403|Drug|carbamazepine|multiple oral doses, Days 1-24 of study period 2
45503818|NCT01352663|Biological|Wockhardt's Insulin Analogue (Recomb)|Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.
45503819|NCT01352663|Biological|Lantus®|Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
45503820|NCT01362361|Drug|mFOLFOX6 + BIBF 1120|mFOLFOX6 + BIBF1120 (2x200 mg/d d1-d14) (repeated every 14 days)
45503821|NCT01362361|Drug|mFOLFOX6+placebo|mFOLFOX6 + placebo (2x200 mg/d d1-d14) (repeated every 14 days)
45503822|NCT02077712|Drug|intranasal dexmedetomidine|1 or 2 ug/kg of intranasal dexmedetomidine
45503823|NCT04949789|Other|Placebo without Exercise|2 Capsules to be taken 30 minutes before breakfast.
45396394|NCT01069796|Drug|Bevacizumab|10 mg/kg d1 d15
45396395|NCT01069796|Drug|Capecitabine|800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 & 3
45396396|NCT01067534|Drug|Salbutamol|Inhaler salbutamol 0,1 mg/dose - 4 doses=0,4 mg
45503824|NCT04949789|Other|Placebo with Exercise|2 Capsules to be taken 30 minutes before breakfast.
45503825|NCT04949789|Other|IP I|2 Capsules to be taken 30 minutes before breakfast.
45503826|NCT04949789|Other|IP II|2 Capsules to be taken 30 minutes before breakfast.
45503827|NCT04949789|Other|IP III|2 Capsules to be taken 30 minutes before breakfast.
45396397|NCT02532530|Device|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation.
45503828|NCT05191771|Device|Neovis Total Multi|1 drop in each eye, 4 times per day
45503829|NCT05191771|Device|Systane Balance|1 drop in each eye, 4 times per day
45503830|NCT02073734|Drug|Dexamethasone|Dexamethasone 8mg/IV
45503831|NCT02073734|Drug|Placebo|Placebo given IV
45849611|NCT05751330|Procedure|Transcatheter ablation of cardiac ganglionated plexi|"The ablative procedure involves applying radiofrequency deliveries in the two~Right atrium anatomical sites close to the two main ganglionic plexuses of the right atrium:~Inferior-posterior area (site of first ablation) corresponding to the right inferior atrial ganglion located between the inferior vena cava, coronary sinus ostium and near the atrioventricular node~Upper-posterior area (site of second ablation) corresponding to the right superior atrial ganglion located between the superior vena cava and the posterior surface of the right atrium"
45396398|NCT00451451|Drug|BG00012|
45396399|NCT00451451|Drug|Placebo|
45396400|NCT00451451|Drug|Glatiramer Acetate|
45396401|NCT01062698|Drug|Alteplase (rt-PA)/Actilyse|Injection of 0.9 mg/kg for 60min with an initial 10% bolus injection.
45396402|NCT01062698|Procedure|Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE)|Mechanic thrombectomy
45396403|NCT03976232|Device|Trans cranial Direct Current Stimulation (tDCS)|Active tDCS will be applied for 20 minutes with 2 mA intensity. Anode will be placed at left dorsolateral prefrontal cortex and cathode will be placed at the right cerebellar cortex.
45396404|NCT03976232|Other|Craniosacral therapy (CST)|Craniosacral therapy will be given to all the participants which includes release of all major diaphragm, frontal lift, parietal lift, occipital lift, CV4 and dural tube rocking.
45503832|NCT01365559|Drug|Group A: Carfilzomib & Non-IMiD Regimen|"Carfilzomib will be administered intravenously starting at a dose of 20 mg/m^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination non-IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study."
45396405|NCT03976232|Other|tDCS+ CST|This group will receive tDCS along with CST
45396406|NCT03977324|Procedure|Chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
45396407|NCT03977324|Procedure|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
45396408|NCT01069874|Dietary Supplement|Cholecalciferol (Vitamin D/Vigantol oil)|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
45396409|NCT01069874|Dietary Supplement|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Miglyol oil over a period of one year
45396410|NCT01022645|Device|Mirena (Levonorgestrel IUD)|Release of intrauterine levonorgestrel for contraception, approved for up to 5 years' use
45396411|NCT01022645|Device|Paragard (Copper IUD ) or Tubal Ligation|Copper IUD placed to provide contraception for up to 10 years
45396412|NCT01025765|Drug|Pioglitazone|Pioglitazone(30mg qd) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg).
45396413|NCT01025765|Drug|Acarbose|Acarbose (50 mg/per meal) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg).
45503833|NCT01365559|Drug|Group B: Carfilzomib & IMiD containing regimen.|"Carfilzomib will be administered intravenously starting at a dose of 20 mg/m^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study."
45503834|NCT03137537|Drug|Ivabradine|lower heart rate in heart failure patients.
45849612|NCT05751252|Drug|Ganirelix|An intra-venous cannula will be inserted and blood will be sampled at 10-min intervals for a 4-h baseline period commencing at 0800 h. Ganirelix will be then administered subcutaneously at single-dose regimen at 0.0625 mg (n = 10 women with PCOS). After Ganirelix administration sampling will continue at 10-min intervals for 4 h.
45396414|NCT01025765|Drug|Metformin|Metformin (500 mg tid) 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg). From week 13, all the subjects will receive pegylated interferon alfa plus ribavirin for 40 weeks.
45396415|NCT03773159|Biological|Blood sampling|4 citrated/PPACK tubes and 1 EDTA tube maximum
45396416|NCT03824912|Drug|Ketoconazole Cream 2%|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
45396417|NCT03824912|Drug|Ketoconazole Cream 2% (G&W Laboratories Inc.)|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
45503835|NCT03137537|Drug|Placebo Oral Tablet|Procedure prescribed to compare the active effect of a medicine.
46057024|NCT00730015|Drug|Linaclotide|Oral, once daily
45396418|NCT03824912|Drug|Placebo|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
45396419|NCT01022879|Procedure|vitrectomy|
45396420|NCT01069952|Device|Deep Brain Stimulation System|In DBS, thin wires are used to carry electric current to the parts of the brain involved in depression symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
45396421|NCT03765281|Other|Navigation|Service delivered by clinical Navigator who learns about youth and family's needs and matches to appropriate services.
45396422|NCT03765281|Other|Resource List|Extensive list of mental health and addictions resources, information, and services. Contact information and web links provided for individuals to explore and contact resources of interest.
45503836|NCT02071004|Drug|DS-1040b|IV of 6 mg given once over 30 minutes
45503837|NCT02071004|Drug|Aspirin|Dispersible tablet, 300mg & 75 mg, once daily for 5 days
45396423|NCT01062776|Biological|Dehydration|Furosemide 5 mg is given intravenously over 2 hours until approximately 2 liters of body fluid is lost.
45396424|NCT01062776|Biological|Placebo|No dehydration is induced
45396425|NCT01025921|Drug|colistin (Tadim)|500.000 units of inhaled colistin three times daily for 10 days
45396426|NCT01025921|Other|inhaled normal saline|inhalation of 2,5cc Normal Saline via nebulisation
45396427|NCT01070030|Drug|Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)|The patients were asked for 2 week run-in phase with atenolol 50 mg qd(once a day), followed by 4 schedule visits with 4-week interval until patient achieved BP goal. The maximum follow up was 16-week treatment. At visit 2, the patients started receiving Aliskiren/Amlodipine (150/5mg per day) for 4 weeks. At visit 3, if the patients did not achieve blood pressure (BP) goal, patients were up titrated to Aliskiren/Amlodipine (300/10 mg/day) for 4 weeks. At visit 4, if the patients did not achieve BP goal, HCT 12.5 mg/day was added to Aliskiren/Amlodipine/HCT (300/10/12.5 mg/day) for 4 weeks. Finally at visit 5, if the patients did not achieve BP goal, HCT was up titrated to Aliskiren/Amlodipine/HCT (300/10/25 mg/day) for 4 weeks until visit 6. Once the patients achieved BP goal at any visit, they completed the study.
45396428|NCT01025999|Other|No intervention|
45697272|NCT04279743|Dietary Supplement|omega-3 phospholipids|"The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening) (4 g/ day of phospholipids), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele."
45396429|NCT02532218|Drug|ARI-3037MO|Lipid lowering treatment Statins
45396430|NCT01022957|Genetic|genetic diagnosis|to determine the long term evolution of Nephronophthisis in terms of renal disease as well as extra-renal damages for patients having a confirmed diagnosis of NPHP1, NPHP2, NPHP3, NPHP4, NPHP5, NPHP6 or NPHP8 gene mutation
45396431|NCT00461123|Drug|Vardenafil (Levitra, BAY38-9456)|One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
45396432|NCT00461123|Drug|Placebo|One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
45396433|NCT00290342|Biological|DTPa-IPV|3 intramuscular injections
45396434|NCT00290342|Biological|DTPa|3 intramuscular injections
45396435|NCT00290342|Biological|IMOVAX Polio®|3 intramuscular injections
45396436|NCT00460811|Drug|Linaclotide Acetate|Oral, once daily
45396437|NCT00460811|Drug|Matching placebo|Oral, once daily
45396438|NCT00290186|Device|Hyperbaric Oxygen Treatment|100% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
45396439|NCT00290186|Device|Hyperbaric Air Treatment|14% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
45396440|NCT01325636|Other|Cell therapy|"Injection of specific T cell by intravenous way with a posology of 1000 to 5000 CD3 IFN γ+ / kg.~A second injection could be made at day 21"
45396441|NCT01070108|Drug|Ketamine|group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
45396442|NCT01070108|Drug|ketamine|ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
45396443|NCT01070108|Drug|ketamine|ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
45849613|NCT05751252|Drug|Ganirelix|An intra-venous cannula will be inserted and blood will be sampled at 10-min intervals for a 4-h baseline period commencing at 0800 h. Ganirelix will be then administered subcutaneously at single-dose regimen at 0.025 mg (n = 10 women with PCOS). After Ganirelix administration sampling will continue at 10-min intervals for 4 h.
45396444|NCT01067690|Drug|Indinavir in association with Vinblastina +/- Bleomicina|Treatment consists in an induction phase where daily Indinavir (800 mg x 2/die, orally) will be combined together with systemic Vinblastine (10 mg intravenously) +/- Bleomycin (15 mg intramuscularly) in cycles administered every 3 weeks. As maximal response will occur, patients will undergo 2 additional Vinblastine +/- Bleomycin (consolidation) cycles upon continuous treatment with Indinavir. This will be followed by a maintenance phase with Indinavir alone (800 mg x 3/die, orally) in responder patients.
45396445|NCT03977246|Behavioral|Open-placebo|Application of the open-placebo intervention
45396446|NCT03977246|Behavioral|Control|Application of the control session
45849614|NCT05751174|Other|pediatric patients affected by severe burns|All patients admitted to the pediatric intensive care unit affected by severe burns involving more than 10% of the body surface will be enrolled.
45396447|NCT03977480|Drug|Hemay007|Hemay007 will be orally administered.
45396448|NCT03977480|Drug|Placebo|Placebo
45396449|NCT03977090|Drug|Geptanolimab Injection|GB226 3mg/kg, q2w, iv.
45396450|NCT03977090|Drug|Fruquintinib|Fruquintinib 3 or 4 or 5mg,qd,po. 3 weeks-on, 1 week-off
45396451|NCT01067924|Behavioral|Motivational interviewing|Intervention arm will receive 2 motivational interviewing session aimed at increasing maintenance of physical activity upon the completion of a supervised exercise program. Motivational interviews will occur at the end of the structured program and at 3 months post program completion. Outcomes will be collected at 6 months post-program.
45396452|NCT00460655|Drug|GSK1358820|botulinum toxin type A
45396453|NCT00460655|Drug|Placebo|Placebo
45396454|NCT03982004|Device|Epicutaneous cryoimmunotherapy|Epicutaneous cryoimmunotherapy (EC) treatment includes liquid nitrogen cryotherapy applied for 10 seconds x 2 freeze-thaw cycles. Four treatment areas will be chosen at each treatment.
45396455|NCT03982004|Drug|Topical imiquimod|Patients will apply the cream directly over the treatment areas and can use up to one packet per day (covers approximately 5 cm x 5 cm).
45396456|NCT03982004|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion
45396457|NCT03982004|Other|Dermatologic Quality of Life Index|"10 questions about how much skin problems has affected the participant's life over the past week~The scoring of each question is as follows: very much = 3, a lot = 2, a little = 1, not at all = 0, not relevant = 0, and question #7 'prevented work or studying' = 3~The DLQI is calculated by summing the score of each question resulting in a max of 30 and min of 0. The higher the score, the more quality of life is impaired."
45396458|NCT03982004|Other|Functional Assessment of Cancer Therapy|"5 subscales (physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns)~Answers ranging from 0=Not at all to 4 = very much~Each item is rated on a 5-point Likert scale.~The higher the score on the social/family well-being and functional well-being indicate higher quality of life~The lower the score on physical well-being, emotional well-being, and additional concerns indicate higher quality of life"
45396459|NCT03982004|Drug|Intra-lesional GM-CSF|250 mcg every 2 weeks x 3 doses then every 3 weeks for 3 doses
45396460|NCT03982004|Device|Cry-AC|-Device used to give the cryoimmunotherapy
45396461|NCT03982004|Procedure|Cutaneous tumor biopsy|-Baseline, week 3 (prior to 1st dose of pembrolizumab), week 9, and at week 18. An optional biopsy can be obtained at the time of disease progression.
45503838|NCT02077790|Device|CASIA Cornea/Anterior Segment OCT SS-1000|"The SS-1000 is a three-dimensional, non-contact, non-invasive high resolution optical coherence tomography imaging device based on the principal of Swept Source OCT. The system achieves high resolution imaging of 10 μm (Axial) and 30 μm (Transverse) and high speed scanning of 30,000 A-scans per second."
45396462|NCT03982004|Procedure|Peripheral blood draw for research|-Baseline, week 3 (prior to 1st dose of pembrolizumab), week 9, and at week 18. An optional biopsy can be obtained at the time of disease progression.
45396463|NCT01062854|Other|Soft earplugs are worn during sleep study|"Subjects are asked to wear earplugs when possible for 3-5 nights prior to their baseline sleep study. On the night of their sleep study they are randomized to either wears earplugs or no earplugs groups."
45396464|NCT03981848|Other|Risk model of tumor relapse|High risk factor model of tumor relapse after liver transplantation
45396465|NCT01026155|Other|Respiratory muscle training|Respiratory muscle endurance training by means of isocapnic voluntary hyperpnoea
45396466|NCT01026233|Drug|brentuximab vedotin|1.8 mg/kg IV every 21 days
45503839|NCT05187559|Other|Standard physiotherapy|Neuromuscular exercise program with standard physiotherapy with no visual feedback
45503840|NCT05187559|Device|Biodex Balance SD and Biodex Gait Trainer|Neuromuscular exercise program with physiotherapy with visual feedback using Biodex platform
45503841|NCT03137459|Behavioral|Transtheoretical Model (TTM) of health behavior change|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report. For individuals in early stages of change for a given behavior, the feedback focuses on changing attitudes, a necessary prerequisite for changing behavior, by addressing common barriers and by reminding individuals they can engage in small steps.
45503842|NCT03137459|Other|Usual Care|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. Participants in this group will not receive any components of the TTM intervention.
45503843|NCT02071160|Drug|Melatonin|Melatonin is administered to the melatonin/hypothermia group (n=15) in a dose of 10 mg/kg daily for a total of 5 doses starting immediately at enrollment. Melatonin tablets (1 or 3 mg/tablet) (Puritan's Pride,Oakdale, NY, USA) are crushed, then dissolved in 5-10 ml of distilled water , then administered via an orogastric tube.
45503844|NCT01362673|Drug|PF-04171327|Oral single 5 mg dose as one 5 mg tablet
45503845|NCT01362673|Drug|PF-04171327|Oral single 10 mg dose as one 10 mg tablet
45503846|NCT01362673|Drug|PF-04171327|Oral single 30 mg dose as three 10 mg tablets
45503847|NCT01362673|Drug|Placebo|Oral single dose as matching placebo
45503848|NCT01362673|Drug|PF-04171327|Oral multiple 20 mg doses as two 10 mg tablets for 12 days
45503849|NCT01362673|Drug|Placebo|Oral multiple doses as matching placebo for 12 days
45849615|NCT05751096|Device|Low-intensity Focused Ultrasound (LIFU)|repeat pulse application of low intensity focused ultrasound using a single element transducer to a selected neurological target for neuromodulation.
45849616|NCT05751096|Device|Sham Low-intensity focused ultrasound (LIFU)|Sham application of LIFU.
45396467|NCT01062932|Drug|Cycloserine|Oral administration of cycloserine medication (50 mg administered prior to each exposure treatment) on Day 1, 4, 7, and 10 of the study
45396468|NCT01062932|Drug|Placebo|Oral administration of matching placebo pill on Days 1, 4, 7, and 10
45396469|NCT01026311|Drug|Coenzyme q 10|200 mg of Coenzyme q 10
45396470|NCT01026311|Drug|placebo|1 placebo q d during treatment period
45396471|NCT01063010|Drug|Bevacizumab|Administered intravenously 10 mg/kg over 90 minutes (+ 15 minutes)
45396472|NCT01063010|Drug|Placebo|Placebo administered intravenously for 90 minutes (+ 15 minutes)
45396473|NCT00460577|Drug|Formoterol fumerate|12 micrograms stat (twice if necessary). Inhaled via aerolizer
45396474|NCT00460577|Drug|fenoterol/ipratropium bromide|0.5 micrograms/0.25 milligrams (20 drops) inhaled via nebulization diluted in 3cc of 0.9% saline.
45396475|NCT01063088|Biological|Seasonal influenza vaccine (split virion, inactivated, prepared in Vero Cell cultures)|Single 0.5 mL intramuscular injection
45396476|NCT01581320|Drug|Test group|Once a month, administration of DP-R206 & placebo for 16 weeks
45396477|NCT01581320|Drug|Reference group|Once a month, administration of Bonviva & placebo for 16 weeks
45396478|NCT04909463|Device|Chest Splint|Those receiving intervention will be given the Duracore chest splint for use throughout the trial.
45396479|NCT01068236|Behavioral|Healthy lifestyle managment|Exercise, yoga, food diaries, provider consultation
45396480|NCT00289016|Drug|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
45396481|NCT00288860|Behavioral|Telephone monitoring|Three months of biweekly telephone monitoring and support
45503850|NCT02077868|Other|Usual Maintenance|Usual maintenance therapy according to local investigator's practice, e.g. treatment break, reduced treatment, continued treatment, and other
45503851|NCT02077868|Drug|MGN1703 treatment|MGN1703 will be used as single agent maintenance treatment
45503852|NCT01360957|Dietary Supplement|Black cumin water extract as a traditional medicine|to be given orally in a dosage of 30 ml trice daily for 60 days
45396482|NCT00288860|Other|Treatment-As-Usual|Outpatient mental health Treatment As Usual (psychotherapy and/or medications)
45503853|NCT04912583|Device|High tidal volume|A high tidal volume (14-16 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
45503854|NCT04912583|Device|Low tidal volume|A low tidal volume (8-10 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
45396483|NCT00288704|Drug|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. On Day 1, subjects received two injections of rilonacept (for a total of 320 mg).
45503855|NCT03131713|Drug|Acetaminophen|Acetaminophen 1000mg
45503856|NCT03534011|Procedure|Resuscitative Balloon Occlusion of the Aorta|If return of spontaneous circulation (ROSC) is not achieved after advanced cardiac life support (ACLS) is established, a REBOA catheter is inserted via the femoral artery and the aortic balloon inflated, according to a procedure described in a separate document. Ultrasound is used to limit risk related to cannulation and placement of the guidewire.
45503857|NCT03534011|Device|REBOA catheter|Catheter with a Resuscitative Balloon for Occlusion of the Aorta
45503858|NCT01361035|Other|Cancer risk communication skills training|Intervention physicians receive training in cancer risk communication and shared decision making (SDM). At the end of each visit with intervention physicians, standardized patients (SPs) reveal themselves as actors and give structured verbal feedback. After baseline SP visits, each intervention physician undergoes academic detailing with a communication expert. Intervention physicians are directed to a web-based communication skills tutorial where SP ratings are hyperlinked to key references for supplemental reading. Both study groups will receive annual reports detailing their patients' cancer screening status and aggregate ratings of their communication style.
45503859|NCT04894799|Other|Vestibular stimulation|In Vestibular Stimulation (VS) group, all participants will be given Infant Swing activity for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Infant Swing for 30 minutes and frog swing for 30 minutes for two weeks. Next 7th and 8th weeks, Infant Swing (30 minutes) and prone on frog swing feet touching the floor (30 minutes), trice a day will be applied. In 9th week, Infant swing and normal playground swing for 30,30 minutes will be given to all participants, trice a day. In Last week of intervention i.e., 10th week, all participants will be given Infant Swing for 30 minutes and standing on platform swing (30 minutes) trice a day.
45849617|NCT00002628|Biological|filgrastim|
45849618|NCT00002628|Drug|carboplatin|
45849619|NCT00002628|Drug|cyclophosphamide|
45849620|NCT00002628|Drug|mesna|
45849621|NCT00002628|Drug|paclitaxel|
45849622|NCT00002628|Procedure|peripheral blood stem cell transplantation|
45849623|NCT05751018|Drug|Pyrotinib|Pyrotinib maleate is a small molecule tyrosine kinase inhibitor that can irreversibly inhibit HER1, HER2, and HER4.
45396484|NCT00288704|Drug|Placebo|Subcutaneous injection of Placebo occurred during first 6 weeks of the study or during randomized withdrawal (weeks 15-24). On Day 1, subjects received two placebo injections.
45396485|NCT00288704|Drug|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. No loading dose was given for subjects who entered directly into the open-label.
45396486|NCT00288626|Drug|Granulocyte-colony stimulating factor (G-CSF) and prednisone|Growth factor regimen; occurs at study entry
45503860|NCT04894799|Other|Neck Control facilitation exercises|all participants will be given Neck Control facilitation exercises using Bobath Approach of low tone facilitation method, for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Neck Control facilitation exercises for 30 minutes and sitting facilitation Exercises with trunk weight shifting for 30 minutes, trice a day. Next 7th and 8th weeks, Neck Control facilitation exercises (30 minutes) and sitting facilitation exercises with trunk weight shifting and kneeling weight bearing (30 minutes), trice a day will be applied. In 9th and 10th weeks, Neck Control facilitation exercises, sitting and kneeling weight bearing and standing with trunk elongation will be given to all participants for one hour, trice a day.
45503861|NCT05191693|Procedure|ERCP|endoscopic papillary balloon dilation (EPBD) with endoscopic sphincterotomy (EST
45503862|NCT02073812|Drug|RPX7009 and RPX2014|The study is designed to enroll approximately 25 healthy subjects. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Carbavance (RPX7009/RPX2014)
45503863|NCT03514121|Biological|FPA150|A monoclonal antibody against B7-H4
45503864|NCT03514121|Biological|Pembrolizumab|An anti-PD1 antibody
45503865|NCT02930005|Drug|Meclofenamic acid|
45503866|NCT02930005|Drug|Pentosan polysulfate sodium|
45503867|NCT02074046|Biological|cancer stem cell vaccine|
45503868|NCT02071238|Behavioral|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
46057025|NCT00806026|Drug|placebo and pregabalin|following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.
45396487|NCT00288626|Drug|Carmustine, etoposide, cytarabine, and melphalan (BEAM)|High-dose chemotherapy; occurs seven or more days following collection of autologous graft
45396488|NCT00288626|Procedure|Autologous hematopoietic stem cell transplant|Occurs after growth factor regimen and collection of autologous graft
45396489|NCT01063244|Device|foley balloon only|place foley balloon only in cervix
45396490|NCT01063244|Device|foley balloon with weight attached|foley balloon with 1000cc IV bag attached
45396491|NCT00087490|Drug|linezolid|
45396492|NCT00087490|Drug|vancomycin|
45396493|NCT00087178|Drug|cyclophosphamide|Arm 1: cyclophosphamide 600 mg/m2 IV every 21 days for 4 cycles; Arm 2: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
45396494|NCT00087178|Drug|adriamycin|adriamycin 60 mg/m2 IV every 21 days for 4 cycles
45396495|NCT00087178|Drug|epirubicin|epirubicin 100 mg/m2 IV every 21 days for 6 cycles
45396496|NCT00087178|Drug|fluorouracil|fluorouracil 500 mg/m2 IV every 21 days for 6 cycles
45503869|NCT02071238|Behavioral|Group Consultation|Informed consent discussion in group-format
45503870|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
46057026|NCT00806026|Drug|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
45396497|NCT00288080|Drug|Dexamethasone|Premedication of dexamethasone prior to docetaxel, per institutional standards.
45396498|NCT00288080|Drug|Prednisone|10 mg orally per day until day 21 of the last cycle of docetaxel, beginning 28 days after the completion of RT.
45396499|NCT00288080|Drug|docetaxel|75 mg/m2 i.v. over 1 hour (on day 1 of each cycle) every 21 days for 6 cycles, beginning 28 days after the completion of RT.
46057027|NCT00806026|Drug|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
45503871|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
45503872|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
45503873|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
45503874|NCT01349387|Drug|Metformin|After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31.
45503875|NCT01365715|Procedure|Arteriography and preoperative embolization|Arteriography and transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
45503876|NCT01365715|Procedure|Arteriography|Arteriography of spinal metastasis/metastases without transcatheter arterial embolization prior to surgery.
45503877|NCT04913441|Other|Routine physical therapy|Patients in this group will get every session routine physical therapy of 30 minutes 3 times per week on alternative days for 12 weeks
45503878|NCT04913441|Other|Manual physical therapy with routine physical therapy|Patients in this group will get every session Manual physical therapy with routine physical therapy of 40 to 45 minutes 3 times per week on alternative days for 12 weeks
45503879|NCT04913441|Other|Stretching physical therapy with routine physical therapy|Patients in this group will get every session of Stretching physical therapy with routine physical therapy of 40 to 45 minutes 3 times per week on alternative days for 12 weeks
45503880|NCT01361191|Drug|R-MEGACHOP|"If PET + after third cycle: 2 cycles of R-IFE followed by PBSCT~If PET - after third cycle: 3 additional cycles of R-MegaCHOP - R-MegaCHOP: cycles every 21 days RITUXIMAB Dosage: 375mg/m2, IV, day 1 CICLOPHOSPHAMIDE Dosage: 1500 mg/m2, IV, day 1 DOXORUBICIN Dosage: 65 mg/m2, IV, day 1 VINCRISTIN: Dosage 1.4 mg/m2 (max. 2.0 mg/m2, IV, day 1 PREDNISONE Dosage: 60 mg/m2, IV, day 1-5~R-IFE: 2 cycles every 21 days:~IFOSFAMIDE Dosage: continuous perfusion of 10 gr/m2/iv during 72 hours. Therefore, 3.33 gr/m2/corporal weight 24 hours day +1, +2 and +3.~ETOPOSIDE Dosage: total 900 mg/m2, IV, which is 150 mg/m2 during 12 hours (days +1, +2 and +3)."
45503881|NCT03499613|Other|Multidisciplinary rehabilitation program|The multimodal rehabilitation program (MRP) based at the University Hospital is an intensive 3-weeks multidisciplinary rehabilitation program. Patients come daily for individual and group treatments, with a total of 100 hours of intervention during 3 weeks. The MRP includes physiotherapy treatments, aiming at improving cardio-vascular endurance, long-term physical activity adherence, proprioception, mobility and strength. Additionally, occupational therapy is mainly focussed on reassuring patients that spinal movements are safe. Finally, psychologists are involved in the MRP to discuss the meaning of LBP, the psychological implications and the patient's resources.
45503882|NCT04905173|Other|Squat-to-stand maneuver|Subjects will squat for 5 seconds and then stand. The squat-to-stand exercise will be done up to 10 times, and then immediately undergo echocardiographic imaging.
45849624|NCT05750940|Diagnostic Test|31Phosphor Magnetic Resonance Spectroscopy|Measurement of skeletal oxidative metabolism with 31phosphor magnetic resonance spectroscopy
45849625|NCT05750784|Procedure|Total knee arthroplasty using the active robotic surgical system|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
45849626|NCT05750706|Other|observation of invasive fungal infections|observation of invasive fungal infections during chemotherapy
45396500|NCT00288080|Drug|Oral antiandrogen|Oral antiandrogen of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy. Treatment is discontinued at the end of radiation therapy.
45849627|NCT05750628|Drug|INE963|oral INE963
45849628|NCT05750628|Drug|KAE609|oral KAE609
45849629|NCT05750628|Drug|SoC (Coartem)|SoC (Coartem)
45849630|NCT05750628|Drug|KLU156|oral sachet KLU156 (KAF156 + lumefantrine)
45849631|NCT05750550|Other|Instrument Assisted Soft Tissue Mobilization|With the IASTM device, application will be made over the skin to the triceps surae muscle and plantar fascia for 15 minutes. The application will be made in the prone position. Massage oil will be used to reduce tissue friction before the application.
45849632|NCT05750394|Procedure|Uterine layers closed|Uterus closed with 1, 2 or 3 layers
45849633|NCT05750394|Device|Suture Type|Barbed or smooth
45849634|NCT05750394|Procedure|Endometrium|Included or excluded
46057028|NCT00806026|Drug|Pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
46057029|NCT00806026|Drug|pramipexol|pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
46057030|NCT00806026|Drug|pramipexol|pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
46057031|NCT04026165|Drug|SEL|Tablet administered orally once daily
45503883|NCT04905173|Drug|Amyl nitrite inhalation|Subjects will inhale amyl nitrite prior to undergoing echocardiographic imaging. This is administered according to current laboratory protocol and is part of standard of care. This is an FDA-regulated drug that will be used as a control and will not be studied experimentally.
45503884|NCT04905173|Other|Valsalva|Subjects will undergo echocardiographic imaging while performing the Valsalva maneuver. This is according to current laboratory protocol and is part of standard of care.
45503885|NCT01362751|Other|No intervention|This study is an observational cohort study > no interventions
45396501|NCT00288080|Radiation|Radiation therapy|46.8 Gy, using either three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT), will be given to the regional lymphatics followed by a 25.2-28.8 Gy boost to the prostate, to bring the total dose to the prostate to 72.0-75.6 Gy. Daily prescription doses will be 1.8 Gy per day, 5 days per week x 8-8.5 weeks, beginning 8 weeks after the initiation of androgen suppression.
45396502|NCT00288080|Drug|LHRH agonist|LHRH agonist of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy, and then until 24 months from initiation of any treatment has been reached.
45396503|NCT01091038|Other|Basic Clinical Decision Support|The computerized physician order entry (CPOE) intervention provides physicians with a menu of medications from the formulary, default doses, and a range of potential doses for each medication. Physicians were required to enter dosage, route, and frequency for all orders. Also, CPOE ensured that all orders were legible and included the prescribing physician's signature. For a number of medications, the system displayed relevant laboratory results on the screen at the time of ordering. Other features included consequent orders, which are orders that should follow from other orders, and drug-allergy checking, drug-drug interaction checking, and drug-laboratory checking. This included checking for the most frequent drug allergies, about 80 carefully selected drug-drug interactions, and several drug-laboratory combinations
45396504|NCT01091038|Other|Routine Care|Routine Care
45503886|NCT01361269|Drug|Fosmidomycin and clindamycin|The study drugs will be co-administered under supervision by a study physician or nurse in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
45503887|NCT01357187|Other|Scheduled removal of posterior instrumentation with AmnioFix|
45503888|NCT01357187|Other|Scheduled removal of posterior instrumentation without AmnioFix|
45503889|NCT01362829|Other|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
45503890|NCT01349543|Biological|RSV A Memphis 37|Intranasal administration
45503891|NCT01353209|Drug|Letrozole|2.5 mg daily for twelve months
45396505|NCT01086514|Procedure|Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)|Each patient will have: Bilateral digital mammography, Bilateral Breast MRI, Bilateral Contrast Enhanced Digital Mammography. The latter examination is the only change in patient management. An additional contrast injection is involved. Results of the DE CEDM will be compared with routine digital mammography and breast MRI. The reference standard is pathology. If surgery is to be done; every attempt will be made to perform all imaging exams within 30 days.
45503892|NCT01353209|Drug|Placebo|sugar pill given daily for twelve months
45503893|NCT04700137|Other|Caring Contacts Plus Introductory Phone Call (CC+)|One introductory semi-structured caring phone conversation with a follow-up specialist to check-in, establish a personal connection, and provide resources at the 0-2 week time-point followed by 11 non-demanding, caring text or email messages sent over the course of 6 months.
45503894|NCT04700137|Other|Caring Contacts without an introductory phone call (CC)|Eleven non-demanding, caring text or email messages sent over the course of 6 months. Participants will not know or have spoken to the follow-up specialist who sends the caring messages.
45396506|NCT03957460|Other|SpHb monitoring|Subjects receive the continuous and noninvasive hemoglobin monitoring (SpHb monitoring).
45503895|NCT03637491|Drug|Avelumab|IV treatment
45503896|NCT03637491|Drug|Binimetinib|Oral treatment
45503897|NCT03637491|Drug|Talazoparib|Oral treatment
45503898|NCT01363063|Drug|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine with a lidocaine hydrochloride free formulation in one nostril and one dose of 15 mg ketorolac tromethamine containing 6% lidocaine hydrochloride in the other nostril
45503899|NCT01363063|Drug|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine containing 0% lidocaine hydrochloride into one nostril and either placebo or a single intranasal dose of 15 mg Ketorolac tromethamine containing 0%, 4% or 6% lidocaine hydrochloride into the other nostril
45503900|NCT01357265|Biological|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
45503901|NCT04550455|Drug|Cladribine Tablets|Cladribine tablets will be administered according the current package insert guidelines
45503902|NCT04250753|Other|Walking task|30 meters walking task (15 meters round trip) following by a rest period of 2 minutes. Participants are invited to perform the 30 meters walking task twice. Inertial sensors are put on each participant foot.
45503903|NCT03713463|Other|Oral Nutritional Supplement (ONS)|Per standard of care (SOC)
45503904|NCT01363141|Other|Regular AGE Diet|Regular AGE Diet
45503905|NCT01363141|Other|Low AGE Diet|One year reduction in dietary AGE intake.
45503906|NCT03675243|Diagnostic Test|sphincterometry|Sphincterometry is a method of the spincter function examination, which allows to assess the state of the anal sphincter muscle and its function
45503907|NCT01349699|Drug|iron sucrose|1.25 mg/kg iron sucrose is administered intravenously 1 hr before endotoxin administration
45503908|NCT01349699|Drug|Deferasirox|30 mg/kg deferasirox is administered orally 2 hrs before endotoxin administration.
45503909|NCT01349699|Drug|endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
45503910|NCT01349699|Drug|Placebo|"At t=-2 hrs starch is dissolved in water to serve as a placebo for exjade. It is prepared and administered orally by a research nurse that is unblinded to the protocol.~At t=-1 hrs 0.9% NaCl is administered intravenously serving as a placebo for iron sucrose. The infused volume is identical, and the syringes en tubes are blinded by aluminum foil. The administration is carried out by a research nurse that is unblinded to the protocol."
45503911|NCT01370161|Procedure|TIPS treatment|"A 8 mm Fluency stent will be used. The aim will be to reduce the portal pressure gradient (PPG) below to 12 mm Hg or 25-75% of baseline.~Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices.~After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted."
45503912|NCT01370161|Drug|Medical treatment|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (propranolol) will be started with an initial dose of 40 mg, the dose of propranolol will be increased/decreased step by step to achieve a baseline heart rate of 55 bpm, or 25% reduction of basal heart rate or up to the maximum tolerated dose of propranolol.~The second elective session of endoscopic band ligation will be performed within the first 7-14 days after the initial endoscopic treatment. The following sessions will be performed at 14 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed."
45503913|NCT03517761|Biological|Bone Marrow Concentrate treatment|While under unconscious TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate injectate. Patients will be repositioned in the prone position to then receive upper cervical injections to C0-C3 ligaments and facets.Patients will receive 2 of these treatment procedures 3 months apart.
45503914|NCT03517761|Other|Sham Control|Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia.Patients will also receive small skin punctures to the back of the neck to mimic ligament and facet injections. Patients will receive 2 of these procedure 3 months apart.
45503915|NCT01370239|Biological|Hu3S193|Patients will receive weekly intravenous doses of 20 mg/m2 of the antibody Hu3S193. The infusion will take 60 ± 10 minutes. The antibody should be diluted in 500 mL of normal saline.
45503916|NCT01801709|Genetic|intracerebral administration of AAVrh.10cuARSA|
45503917|NCT03628443|Diagnostic Test|Fibroblast Growth Factor 23|A sample of blood is tested for levels of fibroblast growth factor 23
45503918|NCT05191069|Other|Moringa Oleifera Mouthwash|15ml of the mouthwash to be used twice daily for 6 months
45503919|NCT05191069|Other|Placebo Mouthwash|15ml of the mouthwash to be used twice daily for 6 months
45503920|NCT01353443|Procedure|Optilene® Mesh Elastic|A number of patients will receive a Optilene® Mesh Elastic mesh, which may not be clinically indicated.
45503921|NCT03628365|Dietary Supplement|HMB (beta-hydroxy beta-methylbutyrate)|1.5 g, b.i.d., by the enteral route, from Day 4 to Day 30 (minimum 10 days)
45503922|NCT01365871|Procedure|anesthetics injection|Basal injection of anesthetics or basal + apical injection of anesthetics.
45503923|NCT03040661|Procedure|Ablation for atrial fibrillation.|Ablation for atrial fibrillation.
45503924|NCT05683587|Other|ballet course, strength course|Include of two phase,first phase is strength course for three months and second phase is ballet course for three months.
46057032|NCT04026165|Drug|Placebo|Tablet administered orally once daily
46057033|NCT04227093|Drug|Acetazolamide|Oral acetazolamide tablets of 250 mg taken twice daily.
45503925|NCT01349777|Drug|Pregrel®|Pregrel® 75mg daily for 12 months
45503926|NCT01349777|Drug|Plavix®|Plavix® 75mg daily for 12 months
45503927|NCT03446157|Drug|Cetuximab|Loading dose on day 1 of week 1 of 400 mg/m2 via IV over 2 hours Subsequent doses of 250 mg/m2 via IV over 1 hour weekly for 4 weeks (28 days) in combination with palbociclib
45503928|NCT03446157|Drug|Palbociclib|125 mg taken orally once daily on days 1-21, then 7 days off
45503929|NCT04240925|Device|NIMV with sigh breaths|Sigh breaths: Maximal Inspiratory pressure (IPAPmax) increased of at least 25% ( ≥ 125%) with a frequency of at least 1/200 breaths. The sigh breaths will be delivered as part of the standard NIMV protocol
45503930|NCT04240925|Device|Standard NIMV|Will be treated by standard NIMV with no sigh
45503931|NCT04700007|Drug|Capsaicin|A capsaicin patch will be applied on a 3x3 cm squared area on the volar forearm. The patch will be left in place for 24h after which it will be removed.
45503932|NCT04700007|Drug|Diphenhydramine|Diphenhydramin cream 1% (Restamine®) will be applied on a 3x3 cm squared predetermined area on the volar forearm for 24 hours.
45503933|NCT04700007|Drug|Morphine Chloride|Morphine solution (0.1mg/ml, Morphine Hydrochloride) 50 μl will be applied intradermally to the center of a predetermined area on the volar forearm by a 1 ml syringe.
45503934|NCT04700007|Drug|Isotonic saline|injections of isotonic saline (0.05 ml, 0.9%) as vehicle will be performed.
45503935|NCT04700007|Drug|Histamine|A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
45503936|NCT01349855|Drug|Insulin glargine HOE901|Pharmaceutical form:solution for injection: new formulation and marketed formulation Route of administration: subcutaneous
45503937|NCT04655079|Device|Anodal transcranial direct current stimulation (a-tDCS)|tDCS is delivered by a battery-driven constant current stimulator thought a pair of saline soaked surface sponge electrodes. The active electrode (anode) is placed on the scalp over the left dlPFC (F3) according to the 10 to 20 international electroencephalogram coordinates) and the cathode is placed over the right deltoid muscle. During real stimulation a constant current of 2mA (milli Ampere) is applied for 20 minutes.
45503938|NCT04655079|Device|Sham Condition|For the sham condition the electrode placement is the same of active tDCS but the electric current is ramped down 5 seconds after the beginning of the stimulation.
45503939|NCT01318655|Drug|NKTR-118|Tablet, Oral, Once daily
45503940|NCT01318655|Drug|Placebo|Tablet, Oral, Once daily
45503941|NCT04654533|Other|COSC|"COSC is professional development program for early childcare providers adapted from the Circle of Security-Parenting (COSP) model. It is a manualized intervention that leverages research on attachment relationships combining psycho-education with a mentalization-based approach. The model uses pre-produced video vignettes of secure and problematic caregiver-child interactions to illustrate how caregivers' may struggle in meeting children's' attachment needs.~Participants are invited to reflect on how they meet and perhaps still not meet the needs of the children in their care with a particular focus on the challenging or 'difficult' children.~The COSP manual has been translated into Danish (Cooper, Hoffman and Powel, 2020, translated by Pedersen, Kronendorf von Wowern, Lier, & Smith-Nielsen), and the additional COSC material has been translated into Danish for the purpose of this study."
45503942|NCT04317521|Device|Use of EKO Core and EKO Duo electronic stethoscopes|Listen to heart murmurs
45503943|NCT03430869|Drug|F-18 AV-45|In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. Alzheimer's disease pathology (A) was determined by measuring Aβ deposition by F-18 AV-45 PET.
45503944|NCT03430869|Drug|F-18-THK-5351|In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. All subjects will further undergo F-18-THK-5351 image study to detect underlying tau pathology. By doing this, the investigators will elucidate the neurodegenerative pathophysiology behind the link between depressive disorder and the subsequent development of dementia.
45503945|NCT01350011|Behavioral|Innovative System|In IS, they will receive motivational counseling at months 3,6,12, and 18. If they decide to quit smoking they will be offered up to 10 sessions of behavioral counseling and access to NRT (nicotine patch and gum) If they relapse on NRT, they will be offered varenicline, if it is not contraindicated.
45503946|NCT01350011|Behavioral|Standard Treatment Control (STC)|Participants will receive self help information and referrals for counseling and for pharmacological treatment.
45503947|NCT01357343|Other|Chiropractic|Spinal manipulation and active and passive therapy.
45503948|NCT01357343|Other|Acupuncture|Acupuncture needling, moxa, Tui Na and cupping.
45503949|NCT03430037|Dietary Supplement|Fisetin|Flavonoid Family
45503950|NCT03430037|Drug|Placebo oral capsule|Placebo
45503951|NCT01353599|Drug|Mometasone furoate|220mcg once daily, for eight weeks
45503952|NCT01733147|Drug|Omega-3 polyunsaturated fatty acids|3 capsules a day of Omega 3 polyunsaturated fatty acids taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal. Active drug will consist of 1200 mg of a ω3 FFA preparation containing 675 mg EPA and 300 mg DHA.
45503953|NCT01733147|Drug|Placebo|3 capsules a day of placebo (1200 mg of ethyl oleate 3 capsules a day) taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal.
45503954|NCT02961881|Drug|blinatumomab|Blinatumomab used as both continuous IV infusion and subcutaneous injection
45503955|NCT03334539|Biological|HL036 ophthalmic solution|HL036 ophthalmic solution
45503956|NCT03334539|Other|Placebo vehicle solution|Placebo vehicle solution
45503957|NCT04308707|Other|Breaking bad news skills|Communication skills analyzed by a specialized questionnaire designed from a Breaking bad news protocol developed in 2018-2019 in Barcelona.
46057034|NCT04227093|Drug|Placebo|Matching placebo tablets taken twice daily.
45503958|NCT01350089|Drug|Placebo (without alcohol, caffeine, energy drink)|(carbonated) water (volume equivalent to 46.5 g ethanol (inform of vodka (37.5%)) (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture is 500 mL.
45503959|NCT01350089|Drug|Comparator 1 (with alcohol; without caffeine and energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), (carbonated) water 250 mL, artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture 500 mL.
45503960|NCT01350089|Drug|Comparator 2 (with alcohol and caffeine; without energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), caffeine (80 mg), (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water) The final volume of the mixture is 500 mL.
45849635|NCT05750238|Other|no intervention|no intervention, survey was applied to the participants
45503961|NCT01350089|Drug|Comparator 3 (with alcohol and energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), Red Bull® Energy Drink (250 mL, without flavour mixture to optimize blinding), artificial fruit juice (21 g/L prepared with (carbonated) water).The final volume of the mixture is 500 mL.
45503962|NCT01357421|Drug|TT301|Single iv dose of TT301
45503963|NCT01357421|Drug|Placebo|Single iv dose of 0.9% sodium chloride for injection USP
45503964|NCT01350167|Procedure|Screening|"Triphasic CT of the abdomen with and without contrast every 12 months and alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years.~Ultrasound of the upper left quadrant every 6 months with alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years."
45503965|NCT03137303|Device|Spirometry at initial visit|Initial visit for the intervention group, an initial demographics form and health questionnaires. To evaluate the breathing, a pre and post broncho dilator will be performed as well as a spirometry test.
45503966|NCT03137303|Drug|Albuterol|The post broncho dilator spirometry test will be preformed after a breathing medication called Albuterol. Albuterol is used in standard practice for COPD and is commonly used during spirometry.
45503967|NCT03137303|Device|Spirometry at 12-month follow-up|At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry test and undergo the same spirometry protocol as the intervention group.
45503968|NCT03296553|Drug|Valganciclovir|The experimental group will receive Valganciclovir 900 mg twice in a day before the initiation of cART until viral load of HHV-8 is undetectable.
45503969|NCT03296553|Drug|Antiretroviral Combinations|Patients will receive standard antiretroviral treatment as recommended
45503970|NCT03131167|Drug|SHP639 (n=60)|Drug SHP639 is a 9-amino acid, synthetic, C-type natriuretic peptide (CNP) analog.
45503971|NCT03131167|Drug|Placebo Comparator (n=24)|Drug: Vehicle Ophthalmic placebo solution of the same composition as the test product.
45503972|NCT01365949|Genetic|microarray analysis|
45503973|NCT01365949|Genetic|protein analysis|
45503974|NCT01365949|Other|immunohistochemistry staining method|
45503975|NCT01365949|Other|laboratory biomarker analysis|
45503976|NCT05190913|Other|Instrumental perineal massage|In the active phase of labor, perineal massage will be performed with an instrument twice with an interval of one hour.
45503977|NCT05190913|Other|manual perineal massage|In the active phase of labor, manual perineal massage is performed twice an hour apart.
45503978|NCT01370551|Drug|Gynoflor|Vaginal tablet with lyophilised lactobacilli and 0.03 mg estriol; Once daily for 28 days then 3 times per week for 8 weeks;
45503979|NCT01363375|Procedure|Foot orthosis, footwear|flat insole, total contact insole , carbon fiber plate; general shoe and rocker sole shoe
45503980|NCT01363375|Procedure|Foot orthosis, Footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
45697273|NCT04279743|Dietary Supplement|omega-3 Triglycerides|"The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele."
45396507|NCT01091194|Other|Interval-based aerobic exercise|High intensity interval-based aerobic exercise training. Duration: 1 year. Three 8-weeks supervised periods of physical training 3 times per week. Individual training 2 times per week between these periods.
45697274|NCT03345615|Diagnostic Test|30-day ambulatory cardiac event monitor|SpiderFlash® 30-day ambulatory cardiac event monitoring will be worn upon discharge.
45396508|NCT01086592|Other|No intervention|Daily life activities
45503981|NCT01363375|Procedure|Foot orthosis, footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
45503982|NCT01370707|Drug|Metformin|1000~1500mg/day, 24weeks
45503983|NCT01370707|Drug|CJ-30001/CJ-30002|0.6/1500mg~0.9/1500mg/day, 24weeks
45503984|NCT04336735|Other|immunization app|A transplant specific immunization app will be trialed that 1) provides vaccine information and education, 2) stores vaccine records and 3) provides reminders when vaccines are due
45503985|NCT01363531|Other|Antibiotic prescription strategies|The patients enrolled will be randomized between four treatment strategies or arms. Patients randomized to delayed treatment arms or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
45503986|NCT01366105|Device|V.A.C. by K.C.I.|Negative Pressure Wound Therapy, Delivered by Vacuum Assisted Closure (KCI) across closed surgical incision at completion of surgery
45503987|NCT01363609|Drug|Liraglutide treatment 12 weeks|liraglutide will be started with a titration period of 2 weeks: week 1 0.6mg once daily, week 2 1.2mg once daily. If well tolerated, treatment will be continued for 10 more weeks in dosage of 1.8mg once daily
46057035|NCT02714517|Other|hydrotherapy|30 minutes sessions of physiotherapy exercises in heated pool (32°C), three times per week for four weeks
46057036|NCT02714517|Other|on land therapy|30 minutes sessions of physiotherapy exercises on land, three times per week for four weeks
45396509|NCT01086592|Other|Strong progressive strengthening exercises of lower limbs|Lower limb weight
45396510|NCT01086592|Other|Electrotherapy|Neuromuscular Electrical Nerve Stimulation
45396511|NCT01086592|Other|Electrotherapy+weights|Superimposed Neuromuscular Electric Nerve Stimulation
45503988|NCT01363609|Drug|insulin glargine treatment|Insulin glargine treatment consist a treatment period of 12 weeks. Treatment will start with a dosage of 10 IU once daily. Patient will self-titrate the insulin glargine dosage based on self-monitored fasting blood glucose (FBG) concentrations for the previous 3 days using the following guideline: If FBG levels are above 5.6 mmol/L (100-153 mg/dL) on 3 consecutive mornings, the daily dose is to be increased by 2 IU/day. If hypoglycemia documented by glucose concentration < 3.3 mmol/L (60 mg/dL) or requiring assistance occurs without an easily identifiable reason (skipped meal, excessive physical activity), the daily dose is to be downregulated, with -2 IU/day
45503989|NCT01363609|Drug|GLP-1 receptor antagonist|Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min. This will only be during one of the visit for the healthy lean controls and the T2DM group, and during two visits in the group with obesity planned for gastric bypass surgery
45503990|NCT01363687|Device|remote ischemic postconditioning|Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the upper limb free of arteriovenous fistula and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
45503991|NCT03060447|Drug|Vesatolimod|Tablets Administered orally
45503992|NCT03060447|Drug|Placebo|Tablets Administered orally
45503993|NCT03060447|Drug|ART|ART regimens administered in accordance with their prescribing information. The following agents are allowed as part of the ART regimen: nucleoside reverse transcriptase inhibitors, raltegravir, dolutegravir (DTG), rilpivirine, and maraviroc.
45503994|NCT04623567|Drug|Jiangtang Tiaozhi recipe|The Jiangtang Tiaozhi recipe is a combination of several Chinese herbs, which has been granted a patent (No. ZL 2013 1 0373659.7)
45503995|NCT04623567|Drug|Metformin|The metformin tablets (500mg) will be administrated.
45503996|NCT01712789|Drug|Pomalidomide|Oral Pomalidomide at the starting dose of 4 mg on Days 1-21 of a 28-day cycle
45849636|NCT05749614|Drug|Lidocaine cream|Group 1 was given 1 ml of 5% lidocaine cream on demand. They were instructed to apply the lidocaine cream evenly in a circular pattern to the glans penis without precise application to the sensitive area of the glans penis. The treatment lasted for a total of 4 weeks.
45503997|NCT01712789|Drug|Dexamethasone|Oral Low dose Dexamethasone at the starting dose of 40mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
45503998|NCT01357499|Device|blood pressure cuff|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times.
45503999|NCT01357499|Device|blood pressure cuff + electric muscle stimulator|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. In addition electrical muscle stimulation will be performed throughout the whole preconditioning cycle.
45504000|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml of aqueous)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
45504001|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml)+intravitreal injection of bevacizumab (1.25mg/0.05ml)
45504002|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
45396512|NCT01068314|Other|Repetitive arm exercise|After baseline testing and randomization, subjects in this group are instructed to perform repetitive handgrip exercise with an upper arm compression band until arm fatigue occurs. After resting 1 minute this exercise is repeated 9 times daily for 6 weeks.
45504003|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml)
45504004|NCT03387449|Device|Bimanual Arm Training|Device-based bimanual-to-unimanual training will be provided with the Bimanual Arm Trainer (BAT, Mirrored Motion Works, NC). The device provides bimanual-to-unimanual training of simultaneous shoulder external rotation and elbow extension, and independent training of pronation-supination and grasp and release of each hand. Range of motion and speed are recorded during training and feedback and motivation are provided through age-appropriate gaming modules.
45504005|NCT01350557|Other|Comprehensive care|Comprehensive care consisted of subacute care plus health-maintenance interventions to manage depressive symptoms, manage malnutrition, and prevent falls.
45504006|NCT01350557|Other|Subacute care|Subacute care included geriatric consultation, continuous rehabilitation, and discharge planning.
45504007|NCT02978781|Drug|SAGE-217|SAGE-217 Oral Solution
45504008|NCT02978781|Drug|SAGE-217|SAGE-217 Capsules
45504009|NCT02978781|Drug|Placebo|SAGE-217 matching placebo capsules
45504010|NCT04565379|Drug|NuSepin® 0.1 mg|NuSepin® 0.1 mg
45504011|NCT04565379|Drug|NuSepin® 0.2 mg|NuSepin® 0.2 mg
45504012|NCT04565379|Drug|Placebo|Normal Saline
45504013|NCT03074318|Drug|Avelumab|Given IV
45504014|NCT03074318|Drug|Trabectedin|Given IV
45504015|NCT02071316|Drug|Hexacapron( Tranexamic acid)|1. Treatment group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously with concurrent hexacapron( Tranexamic acid) I.V. every 6 hours until 72 hours and then the patient continue oral treatment 6 g /day for 7 days.
45504016|NCT02071316|Drug|esomeprazole|2. Standard of care group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously
45504017|NCT03318224|Other|none (observational study)|only assessments via questionnaires, no interventions
45504018|NCT02071472|Other|DP medication reconciliation|
45504019|NCT02071550|Device|FORESİGHT cerebral oxygen monitor and INVOS cerebral oxygen monitor|
45504020|NCT02071550|Device|FORESIGHT and INVOS monitor|
45504021|NCT02074202|Drug|18F- fluorocholine|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan.
45504022|NCT02074202|Drug|18F- fluorodeoxyglucose|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan
45504023|NCT02074280|Drug|rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
45504024|NCT02074592|Behavioral|Self assessment of ultrasound fetal biometry images|self assessment of ultrasound fetal biometry images followed by automatically generated feedback
45504025|NCT02074592|Behavioral|assessment of ultrasound fetal biometry images by expert|assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
45849637|NCT05749614|Drug|Lidocaine cream|Group 2 had a penile biological vibration threshold test performed to detect loci with a lower threshold. They were instructed to apply 1 ml of 5% lidocaine cream to the sensitive loci on the glans penis for 4 weeks.
45849638|NCT05749380|Drug|AmBisome|Reference, dose of 3 mg/kg.
45849639|NCT05749380|Drug|DKF-5122|Test, dose of 3 mg/kg
45849640|NCT05749302|Drug|Al18F-NOTA-FAPI|Al18F-NOTA-FAPI was injected into the patients before the PET/CT scans
45849641|NCT05749224|Diagnostic Test|Helkimo Index|Helkimo Index is comprised of five items, with each assessment having three possible answers, scored as 0, 1 or 5. The first item is related to the limitation in the range of jaw movement. The second item evaluates the alterations of joint function that produce deviations, sounds and/or joint locks or blockages; the third item evaluates the presence of pain when performing some movements; the fourth item evaluates muscular pain in the masticatory muscles; and the fifth item evaluates the presence of discomfort or pain in the prearticular area of the temporomandibular joint (TMJ) through palpation. From the sum of the 5 items, we identify no TMJ involvement if the score is 0, mild TMJ involvement when the score ranges from 1 to 9, moderate TMJ involvement if the score ranges between 10 and 19 and severe TMJ involvement for a score between 20 and 25.
45396513|NCT03957538|Behavioral|Virtual reality angiogram experience video|The VR video is watched via the VR headset, and describes the pre- procedural and procedural experience. Concurrent audio will be provided through earplugs to compete the patients' immersive experience. The video was written and directed by the team, and care has been taken to ensure that the same procedural information is contained within both the British Heart Foundation cardiac catheterisation video and of VR immersive video. Filming was performed within the cardiac catheterisation labs at our tertiary centre using the professional services of Orchard Media (Cardiff, UK). The investigators utilized real physicians and nurses to re-enact a typical day for a mock patient undergoing an uncomplicated procedure. There is also a short explanation of the procedure and animations explaining technical aspects of the procedure contained within the VR video.
45396514|NCT01068392|Drug|Oxaliplatin, Prednisolone|"OXALIPLATIN+PREDNISOLONE (OX-P)~D1 Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2hr~D1-5 Prednisolone 40-30-30 mg/day P.O~every 3 weeks"
45396515|NCT01086826|Drug|RT+CDDP/5-FU|RT=70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU: 800 mg/m2/day for 4 days Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy.
45396516|NCT01086826|Drug|RT+CETUXIMAB|RT= 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Cetuximab= 400 mg/m2 as first dose.Subsequent doses of 250 mg/ m2, weekly, for 7 times.
45396517|NCT01086826|Drug|INDUCTION CTx(TPF)+(RT+CDDP/5-FU)|"INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.~concomitant CTx= CDDP 20 mg/m2/day + 5-FU 800 mg/m2/day RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks)"
45396518|NCT01086826|Drug|INDUCTION CTx(TPF)+(RT+CETUXIMAB)|"INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.~RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks) CETUXIMAB= 400 mg/m2 as first dose. Subsequent doses of 250 mg/ m2, weekly, for 7 times."
45396519|NCT03741764|Device|Vivosorb|Resorbable implant device
45396520|NCT01091272|Drug|PF-04995274|Planned single PO 0.15mg, 1.5mg, 15mg doses of PF-04995274 interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
45396521|NCT01091272|Drug|PF-04995274|Planned single PO 0.5mg, 5mg, 50mg doses of PF-04995274, interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
45396522|NCT01091272|Drug|PF-04995274|Planned single PO 120mg and 210mg doses of PF-04995274
45396523|NCT01091272|Drug|PF-04995274|single PO dose of PF-04995274; dosage to be determined by safety and pharmacokinetic data
45396524|NCT00287690|Drug|Genistein|Drink taken once daily
45396525|NCT00287690|Drug|Placebo|Drink taken once daily
45697275|NCT05685849|Device|Echocardiography|Maternal and fetal echocardiography：Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of five echocardiographic examinations will be performed in the first trimester(11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester(29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
45396526|NCT01063400|Other|Observation|monitoring of physical activity for 14 days using physical activity monitoring devices along with activity diary
45697276|NCT05471349|Behavioral|Flyer and video|Participants will view a flyer and video
45396527|NCT00286754|Behavioral|SMI|Stage-matched intervention
45396528|NCT00286754|Behavioral|HEI|Health Education Intervention
45396529|NCT00286754|Behavioral|UC|Usual Care
45396530|NCT00286754|Behavioral|SMI|Stage-matched intervention
45396531|NCT00286754|Behavioral|HEI|Health Education Intervention
45504026|NCT02074670|Other|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
45504027|NCT02077946|Drug|liraglutide|No treatment given.
45504028|NCT02077946|Drug|sitagliptin|No treatment given.
45504029|NCT02078024|Drug|IVM plus ALB|
45504030|NCT02078024|Drug|IVM|
45504031|NCT03559790|Drug|tenofovir alafenamide|To evaluate of efficacy and safety in patients with TDF-TAF switch therapy
45504032|NCT02079896|Drug|Lexaptepid pegol (NOX-H94)|anti-hepcidin L-RNA-aptamer (Spiegelmer)
45504033|NCT02079896|Drug|Placebo|
45504034|NCT02079974|Drug|Pravastatin|20 mg pravastatin sodium daily for 3 months
45504035|NCT03559556|Other|CT angiography|CT angiography uses a CT scanner to produce detailed images of both blood vessels and tissues in various parts of the body. An iodine-rich contrast material (dye) is usually injected through a small catheter placed in a vein of the arm.
45504036|NCT01353755|Drug|Grass pollen specific immunotherapy|"Strength 1 (0.78μg/mL)~Strength 2 (6.25μg/mL)~Strength 3 (50μg/mL)~Strength 4 (200μg/mL)~The subcutaneous injections will be administered at intervals of 7 (+ 7 days)during up-titration. For maintenance the injection intervals are prolonged to 4 weeks (+2). The double blind treatment period is 2 years, followed by 1 year open-label treatment for patients previously treated with verum and 3 years open-label treatment for patients previously recieved placebo."
45504037|NCT01353755|Drug|Placabo|Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
45504038|NCT02080052|Device|Robot-assisted prostate biopsy|
45504039|NCT03135119|Behavioral|TF-CBT|TF-CBT is typically described as including 3 phases, each focusing on a common goal and encompassing a third of treatment (4 sessions). The first phase focuses on skills-building and includes psychoeducation, parenting skills training, relaxation skills training, affect modulation skills training, and cognitive coping skills training. The second phase involves focused gradual exposure activities, including construction of a narrative account of the child's maltreatment experiences and cognitive processing of maladaptive thoughts. The third phase emphasizes the child's mastery over environmental reminders of the maltreatment and includes sharing the trauma narrative with the caregiver, in vivo exposure to physical stimuli, and enhancing future development.
45504040|NCT03135119|Behavioral|TF-CBT+AAT|TF-CBT, as described in the other arm, with animal-assisted therapy as an adjunct intervention. During the administration of TF-CBT, a certified service dog will be in the room and the participant may elect to interact with the dog as various points throughout the sessions.
45504041|NCT02078258|Behavioral|ABMT|During a two-week period, 8 sessions of a modified dot probe task for attentional bias modification training (ABMT) condition, 8 sessions of a classic dot probe task for placebo training (PT) condition.
45504042|NCT01317953|Dietary Supplement|epigallocatechin gallate|"Starting dose green tea catechin extract EGCG 400 mg twice a day (BID) of EGCG (400 mg caps BID), second escalated dose 800 mg BID of EGCG (2x400 mg caps BID), third escalated dose 1200 mg BID of EGCG (3x400 mg),fourth escalated dose 1600 mg BID of EGCG (4x400 mg),and fifth escalated dose 2000 mg BID of EGCG (5x400 mg),"
45504043|NCT02078336|Drug|Midazolam Mylan|
45504044|NCT02078336|Drug|Lorazepam Mylan|
45504045|NCT02078336|Drug|Valium + Akineton + Dehydrobenzperidol + Atropine sulfate|
45504046|NCT01353833|Drug|Aldesleukin|0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.
45504047|NCT01350635|Biological|BM32|BM32 will be applied in sterile phosphate buffer solution. Drug will be applied in concentrations of 11,33 and 100 micrograms/ml
45504048|NCT02080130|Dietary Supplement|Saccharomyces boulardii|FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
45396532|NCT00286754|Behavioral|UC|Usual Care
45396533|NCT03976154|Other|Thoracic Epidural Catheter Fixation Techniques|"All thoracic epidurals will be placed by a regional anesthesia resident or fellow under the direct supervision of an attending anesthesiologist using a standard epidural kit and in the paramedian approach.~Epidural placement will occur preoperatively in the same manner as our current practice criterion. There will be no difference in placement of the epidural catheter between the control groups and the treatment group. After placement, catheters will be secured with either Dermabond, Mastisol, or a Grip-Lok fixation bandage, all with overlying Tegaderms."
45396534|NCT01070186|Drug|Sunitinib|50mg/day for 4 weeks
45396535|NCT01070186|Other|Tumor biopsy|Conducted prior to administration of sunitinib therapy
45396536|NCT01070186|Procedure|Nephrectomy|Nephrectomy 2-4 weeks after last dose of Sunitinib
45396537|NCT01070186|Other|Biomarkers|"Biomarker evaluation of blood prior to treatment, after 4 weeks of Sunitinib administration, and every three months for a year after surgery.~Biomarker evaluation of tissue prior to 4 week administration of Sunitinib"
45396538|NCT00066742|Drug|tirapazamine|Given IV
45504049|NCT02080130|Dietary Supplement|Probiotics combination|LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
45504050|NCT02080130|Other|Placebo|Placebo
45504051|NCT03366779|Device|6mm annular closure device|6MM Barricaid annular closure device implantation following standard lumbar discectomy
45504052|NCT03559478|Procedure|Sharp dissection with scalpel plus electrocautery to vessels|A scalpel will be used for dissection for TKA implantation. Bleeding vessels will be managed as encountered with electrocautery. Electrocautery will not be used for dissection.
45504053|NCT03559478|Procedure|Electrocautery for all dissection|Skin incision will be made with a scalpel, but all other dissection will be performed with electrocautery.
45504054|NCT03355001|Device|Monosyn® Quick|"Mucosal sutures in the facial and oral~Dermal sutures, particularly in pediatrics~Episiotomy~Circumcision"
45504055|NCT03353675|Biological|TG4010|1 dose (1x1E+08) Subcutaneous injection/week over 6 weeks then 1 dose/3 weeks
45504056|NCT03353675|Drug|Chemotherapy|"Pemetrexed/Cisplatin or Carboplatin~Pemetrexed maintenance"
45504057|NCT03353675|Drug|Nivolumab|360 mg IV administration every 3 weeks
45504058|NCT02075060|Procedure|IPOI (pre-operative)|
45396539|NCT00066742|Drug|cisplatin|Given IV
45504059|NCT02075060|Procedure|IPOP (post-operative)|
45504060|NCT01350713|Drug|povidone iodine|one local application of 10% povidone iodine ointment
45697277|NCT03345537|Other|Non interventional study|Non interventional study - only data collected and one blood sample additional
45697278|NCT03344913|Behavioral|Walking|walking 30 minutes per day, three days/week for 6 weeks with a member of study team.
45697279|NCT05457933|Drug|Dapagliflozin|Dapagliflozin 10 mg, every day before breakfast. Glargine insulin 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day
45396540|NCT00066742|Drug|etoposide|Given IV
45396541|NCT00066742|Radiation|radiation therapy|Undergo radiation therapy
45396542|NCT00066742|Other|laboratory biomarker analysis|Correlative studies
45697280|NCT05457933|Drug|Glargine|Glargine insulin; 300 Units/mL, average dose: 10-20 U/day, Insulin lispro 100 Units/mL, average dose: 10-30 U/day
45396543|NCT01093924|Behavioral|PILI 'Ohana 18-month weight loss maintenance|All participants will receive a 8 lesson 3-month weight loss intervention. They will then be randomized. Those continuing with the intervention will receive 17 more lessons delivered face-to-face or via DVD over 15 months for a total of 18 months. Each lesson lasts approximately 1 hour and helps participants integrate healthy eating and physical activity into their lifestyles. Participants will also be encouraged to attend 13 community activities during the last 13 months of the intervention.
45396544|NCT01091350|Device|Diprifusor (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
45396545|NCT01091350|Device|Orchestra (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
45504061|NCT02075216|Procedure|Myoblast Transplantation|For each patient 4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope. The suspension will be injected in the area of the external sphincter and along the posterior urethra proximal to the verumontanum, aiming to attain visual occlusion of the urethral lumen.
45504062|NCT02075216|Biological|Neonatal Cystourethroscope Injection|4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope.
45504063|NCT01318889|Drug|Dexpanthenol|5% dexpanthenol Mouth wash , three times a day, 10 cc each time
45697281|NCT03322995|Drug|First-line Chemotherapy|The first-line therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or best available standard of care.
45697282|NCT03322995|Drug|Second-line Chemotherapy|Second line therapies will be multi-agent and contain gemcitabine. Molecular profiling data from the initial endoscopic ultrasound (EUS)/ fine needle aspirate (FNA) biopsy may be used at the discretion of the treating physician.
45697283|NCT03322995|Radiation|Chemoradiation|50.4 Gy in 28 fractions.
45697284|NCT03321981|Drug|MCLA-128|full length IgG1 bispecific antibody targeting HER2 and HER3
45697285|NCT03321981|Drug|Trastuzumab|humanised IgG1 monoclonal antibody
45697286|NCT03321981|Drug|Vinorelbine|antineoplastic drug of vinca alkaloid family
45396546|NCT03956914|Other|Placebo|Placeob water 440 ml/day for 8 weeks
45504064|NCT02075294|Drug|Adefovir dipivoxil or Entecavir|"Adefovir tablet, 10mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines.~Entecavir tablet, 0.5mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines"
45504065|NCT02080208|Device|Optiflow|patients receive oxygen via high flow oxygen therapy during 20 minutes
45504066|NCT01357967|Drug|SSRI monotherapy|SSRI (paxil CR, es-citalopram, fluoxetine, sertraline) start with (paxil CR 12.5mg, es-citalopram 10mg, fluoxetine 20mg, sertraline 50mg) for 1 week up to maximal dosage, flexible dosage, usually in the morning
45504067|NCT01357967|Drug|Seroquel XR adjunctive|"Quetiapine group:~seroquel XR 50mg Day 1 --> 50mg Day 2 --> 150mg Day 3 --> 150mg Day 4 --> adjustment usually at hs but can be daytime"
45504068|NCT02075372|Other|Data registration|Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will collect data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry
45504069|NCT02870855|Drug|intrauterine injection of HCG|intrauterine injection of HCG berore blastocyst transfer
45504070|NCT02075450|Device|CPRcard|CPR Card in place during chest compressions to provide immediate visual feedback.
45504071|NCT02075450|Other|Just in Time Video|CPR Just in Time training video administered before the simulation case
45504072|NCT02075528|Drug|Paliperidone ER|9 mg/d of paliperidone ER was administered during the first 2 weeks, after which the dose was adjusted clinically
45697287|NCT03321981|Drug|Endocrine therapy|same endocrine therapy is administered as the last line of endocrine therapy
45697288|NCT05450133|Other|Systemic inflammatory index|neutrophil count x platelet count/lymphocyte count
45849642|NCT05749068|Device|CapScan intestinal sampling device|CapScan is an intestinal collection device used to characterize the regional distribution of sulfasalazine, the metabolic breakdown products of sulfasalazine, and the gut microbiota in the digestive tracts of healthy volunteers.
45396547|NCT03956914|Other|Deep sea water|Deep sea water 440 ml/day for 8 weeks
45396548|NCT00460265|Drug|ARM 2|Subjects will receive Cisplatin plus 5FU
45396549|NCT00460265|Drug|ARM 1|Subjects will receive Panitumumab plus cisplatin and 5FU
45396550|NCT03956290|Behavioral|TREAT pilot intervention|Participants will be asked to use the app and take pictures of everything they eat and drink, from the time they get up to the time they go to bed, regardless of size of meal/snacks/drink, for 2 weeks. This will generate data on their eating pattern and eating duration. Participants will be reminded through app, call or text by study staff based on personalized eating schedule. The sleep schedule will also be recorded.
45504073|NCT02075684|Procedure|Renal Biopsy|
45504074|NCT02075762|Procedure|Transbronchial biopsy|
45504075|NCT02075762|Procedure|Cryoprobe biopsy|
45504076|NCT02075762|Procedure|VATS biopsy|
45504077|NCT02078648|Biological|SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)|Within 20 minutes following the administration of the SL-701 emulsion, poly-ICLC should be administered as an IM injection in the same extremity (within 3 cm whenever possible) as was administered the SL-701 (deltoid muscle, unless contraindicated).
45504078|NCT02078648|Drug|Bevacizumab|Following the administration of SL-701 and poly-ICLC, bevacizumab will be administered IV at a dose of 10 mg/kg. Bevacizumab infusions may occur over 30, 60 or 90 minutes in accordance with institutional practices and guidelines.
45504079|NCT02078804|Procedure|Colonoscopy|20 000 individuals will be randomised to a primary screening colonoscopy and 60 000 to take a feces test for occult blood (FIT) and if positive (10% of individuals) they will be offered a follow-up colonoscopy.
45504080|NCT02080286|Behavioral|Prism Adaptation|All participants will undergo prism adaptation, a form of behavioural therapy involving reaching and pointing movements while wearing glasses that induce an optical shift.
45504081|NCT02080286|Device|Anodal tDCS|"Participants will receive 1mA anodal tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
45504082|NCT02080286|Device|Sham tDCS|"Participants will receive 1mA sham tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
45697289|NCT05450133|Other|BASDAI|Bath Ankylosing Spondylitis Disease Activity Index includes six questions which includes the following six parameters: fatigue, spinal pain, peripheral joint pain, attachment point inflammation, and duration and severity of morning stiffness. A total score, ranging from 0 to 10, was calculated according to the patients' responses to six questions, with a higher score indicating more severe illness.
45504083|NCT02080442|Other|Balance training|Training will consist of 30 minute sessions 2-3 times/week for a total of 18-24 sessions, in keeping with best practice guidelines for older adults.12 Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
45504084|NCT03137069|Drug|GDC-0853|GDC-0853 will be administered orally at dosages of 50, 150 and 200mg to participants, as per the dosing schedules described above.
45504085|NCT03137069|Drug|Placebo|Matching Placebo will be administered orally, as per the dosing schedules described above.
45504086|NCT02080520|Dietary Supplement|Nattokinase|
45504087|NCT02080520|Dietary Supplement|Placebo|
45504088|NCT02080598|Behavioral|2 cigarettes in 15 minutes|
45849643|NCT05748990|Drug|Intranasal insulin|160 IU insulin (Humalog) is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
45849644|NCT05748990|Drug|Placebo|0.9% saline is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
45849645|NCT05748912|Procedure|Therapeutic bronchoscopy for removal of mucus plugs|Research participants that meet the study inclusion criteria will undergo a research bronchoscopy to remove airway mucus plugs from 1 lung for the first 5 participants, and, if single lung mucus removal is well tolerated, on both lungs for the next 5 participants.
45849646|NCT05748756|Other|Enucleation and filling by Bone marrow aspirate|"The iliac crest is palpated along its widest part forming the iliac tubercle ( 5-6 cm posterior to the anterior superior iliac spine), then a 5 mm incision is made 3-4 cm posterior to the ASIS directly on the crest.~The needle is advanced between the outer and inner plates of the ileum for a 4-6 cm into the cancellous bone and 10 ml of bone marrow is aspirated.~Bone marrow aspirate is processed by a dual centrifugation technique."
45849647|NCT05748756|Other|Conventional enucleation only|patients were treated conventionally by enucleation and plain collagen sponge only.
45849648|NCT05748522|Other|Shoulder Mobility|t is one of the seven functional movements studied in FMS. This test requires the participant to simultaneously hold one hand behind the back (internal rotation) and the other hand behind the head (external rotation) with the fisted hands, and bring the hands as close to each other as possible in the back area. The distance measurement in cm is taken with a tape measure between 3 fingers of both hands.
45396551|NCT01094002|Other|Occupational therapy intervention|"Day 1: Physical, functional, cognitive, social, and emotional assessment. Need analysis for iatrogenic prevention, retraining in BADL and IADL, technical aids, instructions in patient mobilisation techniques, and for social and occupational motivation.~Day 2 until discharge: 45-minute sessions. Cognitive stimulation and confusional syndrome prevention, instructions to the caregivers on how to prevent complications such as immobility, delirium, falls, urinary incontinence, or pressure sores, and patient stimulation, retraining in activities of daily living.~Day of discharge: Instruction for caregivers on managing the patient's residual deficits, assessment for technical aids, recommendations for patient increased independence in ADL, and social and occupational activities."
45396552|NCT03742583|Other|Square Knot|Standard square knot
45396553|NCT03742583|Other|RHAP Knot|Reversing half-hitch alternating post knot
45396554|NCT01091506|Other|Placebo|Placebo once a day for 12 weeks
45396555|NCT01091506|Other|L-methylfolate|L-methylfolate 15mg once a day for 12 weeks
45396556|NCT01026467|Drug|cisplatin|Given IV
45396557|NCT01026467|Drug|carboplatin|Given IV
45396558|NCT01026467|Other|questionnaire administration|
45396559|NCT01094080|Other|standard infant formula|infants are fed a commercial formula
45396560|NCT01094080|Other|modified infant formula|the modified infant formula has a different protein content than the standard formula and long chain polyunsaturated fatty acids are added
45504089|NCT01350869|Device|Xience|Patients with Xience
45504090|NCT01358045|Drug|Diclofenac|Application on the lesion 2 times a day 8 weeks.
45504091|NCT01358045|Drug|Diclofenac + Calcitriol|Application on the lesion 2 times a day, both ointments, 8 weeks.
45504092|NCT01358045|Drug|Calcitriol|Application on the lesion, 2 times a day, 8 weeks.
45504093|NCT02076230|Drug|[14C] TH-302 (Label 1)|[14C]-labeled TH-302 (Label 1) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
45504094|NCT02076230|Drug|[14C] TH-302 (Label 2)|[14C]-labeled TH-302 (Label 2) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
45504095|NCT02076230|Drug|Unlabeled TH-302|Unlabeled TH-302 will be administered along with labeled TH-302 at the dose of 340 milligram per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1 of Part A, followed by recommended Phase 2 dose (RP2D) of 480 mg/m^2 as monotherapy infusion over 30 minutes on Days 8 and 15 of Part A; and on Days 1, 8 and 15 of Part B, until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow up, or death.
45504096|NCT03559712|Other|Collaborative care, Telemental health|Children who are referred to the collaborative tele-mental health care arm, Arm (1), will be given a follow-up appointment with the physician at the same primary care center who have successfully completed the pre-trial didactic program designed by Drs. Albanna and Hamoda. The trained child health physician will conduct assessments, treat and manage the patient. All while having weekly clinical supervision with the specialist.
45504097|NCT02080754|Other|effective sellick maneuver|Sellick maneuver is applied, as originally described by Sellick et al .
45504098|NCT02080754|Other|sham sellick maneuver|The operator who applied the maneuver is the only person who knows the arm inclusion of the patient. Thus, he sets his fingers as described in Sellick arms without exerting pressure on the cricoid cartilage.
45504099|NCT01354067|Behavioral|Control group|The control group receives standardized patient education four times, once every two weeks, during the eight week intervention period. Each session will last 60 minutes, consisting of information regarding anatomy, physiology, causes and mechanisms of COPD, drugs, nutrition, aids and energy saving procedures. The information is the same as for the intervention group, given at separate occasions.
45504100|NCT01354067|Behavioral|High-repetitive single limb training|The high-repetitive single limb exercise regime consists of three sessions per week during eight weeks of exercise training, giving a total number of 24 sessions at each location (Umeå and Huddinge University hospitals). The exercise sessions are supervised and conducted by a physical therapist using a group format, six to eight participants in each group. Each session will span for 60 minutes, duration of the major components are: 10 min warm-up followed by 40 minutes of single limb training and 10min cool-down. In addition this experimental group also receives four sessions of patient education once every two week.
45504101|NCT01357811|Drug|eliglustat; digoxin|repeat oral doses of 150 mg BID (or 100 mg BID if a CYP2D6 poor metabolizer) eliglustat (Day 11 to Day 17) plus singe dose of digoxin 0.25mg on Day 15
45504102|NCT01357811|Drug|digoxin|oral 0.25mg dose of digoxin (single dose) on Day 1
45849649|NCT05748522|Procedure|Diaphragmatic Breathing|"The participant will lie on his back in a comfortable position, diaphragmatic breathing will be taught first in the application group and he will be asked to do diaphragmatic breathing for 90 seconds. At the end of this period, the participant will be referred back to the evaluator physiotherapist, and the physiotherapist will evaluate the shoulder mobility again without knowing which group the participant is in.~In the participant control group, shoulder mobility will be evaluated and the practitioner will be asked to stay in a comfortable position on his back for 90 seconds next to the physiotherapist. At the end of the period, shoulder mobility will be evaluated again by the assessing physiotherapist."
45396561|NCT01094080|Other|breast milk|infants are breast fed
45396562|NCT01094158|Drug|Aramchol|100mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months
45504103|NCT02079116|Other|60 grams of fat plus water solution|"A solution composed by 60 grams of fat and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~300 mL final volume of the solution.~Time of oral ingestion inferior than 2 minutes.~60 minutes before the radiopharmaceutical injection.~12 hours fasting minimum."
45504104|NCT02079116|Other|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~300 mL final volume of the solution.~Time of oral ingestion inferior than 2 minutes.~30 minutes before the radiopharmaceutical injection.~12 hours fasting minimum."
45396563|NCT01094158|Drug|Aramchol|300 mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months
45504105|NCT01351181|Behavioral|Leaflet|Advice Leaflet
45504106|NCT01351181|Behavioral|Exercise Advice|Leaflet
45504107|NCT01351181|Behavioral|Normal Care|Normal Care
45504108|NCT02080910|Behavioral|Psychoeducation|
45504109|NCT04300985|Drug|Dexmedetomidine|Patients will start receiving dexmedetomidine 15 minutes before general anesthetic induction.
45396564|NCT01094158|Drug|Placebo|tablets packaged in bottles given orally once a day in the morning within approximately 10 minutes after breakfast
45396565|NCT01094236|Behavioral|On the Playground behavior management program|Treatment school playground supervisors were show the CD intervention. Control school playground supervisors were given a video on playground equipment safety. All school staff subjects were assessed before the intervention and 75 days following the supervisor intervention. Students were assessed before the intervention, and then 45 days and 75 days following the supervisor intervention. School Administrators were assessed before the intervention, and then 30 and 60 days after the supervisor intervention - school administrators at treatment schools had access to a treatment binder with CDs and worksheets, while the control school administrators did not.
45504110|NCT04300985|Drug|Sham treatment|Patients will start receiving saline solution infusion 15 minutes before general anesthetic induction.
45504111|NCT04300985|Drug|Magnesium Sulfate|Patient will start receiving magnesium infusion (20 mg/kg/h) 15 minutes before general anesthetic induction.
45504112|NCT02079194|Drug|P2Y12 antagonist monotherapy|
45504113|NCT02079194|Drug|aspirin plus P2Y12 antagonist|
45504114|NCT01358279|Procedure|transcranial direct current stimulation|A constant current of 2 mA intensity applied for 20 min over C3 or C4
45504115|NCT01351259|Device|Pneumatic device, cylindrical or tapered cuff|Continuous control of cuff pressure using a pneumatic device (Nosten) Cylindrical (Kimberly Clark tube) or tapered (Covidien tube) tracheal cuff
45504116|NCT01351493|Drug|Nitric Oxide|Nitric Oxide Gel, once or twice per day, 12weeks
45504117|NCT01351493|Drug|placebo|placebo Gel, once or twice per day, 12weeks
45504118|NCT02829671|Other|Clinical and biological assessment|Blood sample, clinical assessment with questionnaires
45504119|NCT01354379|Biological|NB-1008|NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.
45504120|NCT01354379|Biological|Fluzone IN|The active control is Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA).
45504121|NCT02079272|Other|Helical tomotherapy for breast cancer|"At baseline, before helical tomotherapy is performed, for each included woman will have:~measures of biomarkers of cardiac injury based on blood samples (including CRP, NT-Pro BNP, …, microparticles and miRNA)~cardiologic examination including echocardiography for measurement of strain and strain rate~a CT coronary angiogram for measurement of coronary plaque indexes~Helical tomotherapy will be performed for all women included in the cohort.~At the end of tomotherapy, follow-up will include:~measures of biomarkers: at the end of radiotherapy, 6 months and 24 months after radiotherapy~cardiologic examinations including a echocardiography 6 and 24 months after radiotherapy~A CT coronary angiogram 24 months after radiotherapy"
45504122|NCT03558698|Other|Good ventilation|Good ventilation with a low concentration of CO2
45504123|NCT03558698|Other|Ventilation CO2|CO2 High and Good ventilation
45504124|NCT03558698|Other|Poor Ventilation|Poor ventilation with high concentrations of CO2 and bio effluents
45396566|NCT01094314|Other|embryo culture medium|comparison between two types of embryo culture medium
45396567|NCT01091584|Device|distress thermometer|to apply the distress thermometer as written in the guideline written by 'Vereniging Integrale Kankercentra' title: 'Detecteren behoefte psychosociale zorg. The distress thermometer is collected from the experimental group and then discussed by a trained nurse
45504125|NCT01318187|Drug|paracetamol|1 gr
45396568|NCT00460109|Biological|denileukin diftitox|
45396569|NCT00460109|Biological|rituximab|
45396570|NCT03956212|Drug|Doxycycline 7 days|Patient will be treated with doxycycline orally, 100 mg, bid, 7 days
45396571|NCT03956212|Drug|Doxycycline 14 days|Patient will be treated with doxycycline orally, 100 mg, bid, 14 days
45396572|NCT01091740|Device|ZES resolute (Endeavor Resolute)|2nd generation drug eluting stent, which is coated with zotarolimus
45396573|NCT01091740|Device|EES (Xience)|2nd generation drug eluting stent, which is coated with everolimus
45504126|NCT01318187|Drug|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
45504127|NCT01318187|Drug|Paracetamol|1 gr intravenous
45504128|NCT01318187|Drug|Paracetamol|intravenous 1 gr
45504129|NCT01318187|Drug|Morphine|0.1 mg/kg intravenous
45504130|NCT01358435|Biological|30% Regular Insulin Human Neutral and 70%Isophane Insulin|Total Dose per subject is 0.4 IU/Kg given subcutaneously.
45504131|NCT01358435|Biological|Novolin 70/30|Total Dose per subject is 0.4IU/Kg given Subcutaneously.
45504132|NCT03558620|Procedure|mask ventilation|mask ventilation (one-handed ventilation, one-handed with an endoscopic bite block, and two-handed ventilation)
45504133|NCT01318265|Drug|Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole|Treatment 1: A single 160 mg dose of BAY73-4506. Treatment 2: Ketoconazole 400 mg once daily from Day -4 to Day 3. A single 160 mg dose of BAY73-4506 on Day 1.
45504134|NCT01354457|Drug|Epratuzumab and 90Y-Epratuzumab|Sequential injections of each product with an escalating dose for radiolabeled Epratuzumab between patients
45504135|NCT02079350|Drug|%6 HES and %4 Gelofusine|
45504136|NCT02081066|Other|cardiovascular risk factors|
45396574|NCT01094470|Device|Body weight support system on ground level|Gait training with body weight support on ground level with sessions of 45 minutes, three times a week, on alternating day during six weeks, completing a total of 18 sessions.
45396575|NCT01091818|Drug|dexmedetomidine|Dexemedethomidine is given as major sedative drug
45396576|NCT01091818|Drug|Midazolam|Midazolam is given as major sedative drug
45396577|NCT01091896|Drug|Bevacizumab|1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
45396578|NCT01091896|Drug|bevacizumab|1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
45396579|NCT00065260|Drug|Campath-1H|Campath-1H IV 10 days. Adults:10mg/day (children:0.2mg/kg/day).
45396580|NCT00065260|Drug|r-ATG|Rabbit ATG 3.5mg/kg/day for consecutive 5 days
45396581|NCT00065260|Drug|CsA|CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs.
45396582|NCT01327066|Drug|Droxidopa|600 mg, single oral dose
45396583|NCT01327066|Drug|Droxidopa|2000 mg, single oral dose
45396584|NCT01327066|Drug|Moxifloxacin|400 mg, single oral dose
45396585|NCT01327066|Drug|Placebo|Placebo matching Droxidopa or Moxifloxacin
45396586|NCT01094626|Drug|Secretin|Subjects will each undergo an S-MRI evaluation, at a dose of 0.2 ucg/kg per exam. Secretin will be administered by IV bolus injection over 1 minute followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
45396587|NCT03956134|Drug|Tapentadol Test Product 1|Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 1 contains different amounts of excipients than Tapentadol Test Product 2
45396588|NCT03956134|Drug|Tapentadol Test Product 2|Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 2 contains different amounts of excipients than Tapentadol Test Product 1
45396589|NCT03956134|Drug|Tapentadol Prolonged-release Reference Product|Tapentadol PR tablet containing 116 mg of tapentadol hydrochloride
45396590|NCT00460031|Drug|ketoconazole|400 tid
45396591|NCT00460031|Drug|lenalidomide|Lenalidomide will be administered daily at a dose of 25mg po qd on days 1-21 of the cycle.
45396592|NCT00460031|Drug|therapeutic hydrocortisone|20mg qam 10mg qhs
45396593|NCT00451217|Drug|Sugammadex|After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was to be administered
45697290|NCT05450133|Other|ASDAS-ESR|The ASDAS-ESR is deduced using formula that is chosen by the ASAS group. ASDAS-ESR is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte sedimentation rate (mm/h).
45697291|NCT05450133|Other|ASDAS-CRP|The ASDAS-CRP is deduced using formula that is chosen by the ASAS group. ASDAS-CRP is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte C-reactive protein (mg/dl).
45849650|NCT05745246|Behavioral|e-health training program|"Health letters, 44 issues of 90SecondFire Cancer health letters delivered twice a week during six months to firefighters by text or email~A problem-solving asynchronous chat room which encourages mutual support and exchange of ideas via a closed asynchronous bulletin board for peer-to-peer support~A brief 45-minute pre-recorded online course; it is intended as a summative exercise rather than providing new information."
45396594|NCT00451217|Drug|Neostigmine|After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered
45396595|NCT01023113|Procedure|PASCAL laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
45396596|NCT01023113|Procedure|Conventional laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
45396597|NCT00459953|Drug|Extended treatment|All participants receive an open label phase treatment that includes nicotine patch and cognitive behavior therapy for a period of 10 weeks. The extended treatment group received an additional 9 sessions of cognitive and behavioral skills training.
45396598|NCT00459875|Drug|sunitinib malate|
45396599|NCT00311402|Drug|Aggrenox capsule|extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule, 2 capsules twice daily
45396600|NCT00311402|Other|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg, 1 tablet once daily
45396601|NCT01026545|Drug|PF-04287881|500 mg once daily for 10 days
45396602|NCT01026545|Drug|Placebo|To match 500 mg dose once daily for 10 days
45396603|NCT01026545|Drug|PF-04287881|750 mg once daily for 10 days
45396604|NCT01026545|Drug|Placebo|To match 750 mg dose once daily for 10 days
45849651|NCT05743374|Other|Normal diet|These patients will be given advice about a normal healthy diet.
45849652|NCT05743374|Dietary Supplement|E400 elimination|Patients in the intervention group will be given advice how to eliminate E440 additives with regard to carragenan, CMC and polysorbates.
45396605|NCT01026545|Drug|PF-04287881|1100 mg once daily for 10 days
45396606|NCT01026545|Drug|Placebo|To match 1100 mg dose once daily for 10 days
45396607|NCT01026545|Drug|PF-04287881|Optional cohort with dose not greater than 1100 mg
45396608|NCT01026545|Drug|Placebo|Optional cohort to match dose not greater than 1100 mg
45396609|NCT01026545|Drug|PF-04287881|750 mg dose once daily for 10 days
45396610|NCT01026545|Drug|Placebo|To match 750 mg dose once daily for 10 days
45396611|NCT01026545|Drug|PF-04287881|1100 mg dose once daily for 10 days
45396612|NCT01026545|Drug|Placebo|To match 1100 mg dose once daily for 10 days
45697292|NCT05450133|Other|MASES|It is used to evaluate the sensitivity of enthesis points by palpation in patients with ankylosing spondylitis. Scoring is done by giving 1 point for sensitive areas and 0 points if there is no sensitivity on the fifth lumbar spinous process, bilateral first and seventh costochondral joints, iliac crystals, posterior and anterior iliac spines, attachment sites of achilles tendon to the calcaneus.
45697293|NCT05685693|Procedure|Robotic-assisted total knee arthroplasty (raTKA)|Robotic-assisted total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. The robot (ROSA Knee System, Zimmer Biomet, US) assists in planning and placement of the implants and resection sites.
45396613|NCT03996083|Other|Multicomponent exercise intervention|"Strength exercises were focused on lower limb strengthening. Individual bilateral intensities were calculated to estimate one repetition maximum (1-RM) for the leg and arm. This test was performed on the 2nd and 7th weeks of the intervention. A gradual and progressive intensity starting at 40% 1-RM and up 70% 1-RM was used. No external loads were applied to the rest of the exercises due to their complex execution technique and subsequent risk of adverse events. In these cases, training progression was achieved through volume (number of repetitions) and execution velocity increments.~Balance exercises included standing with their feet together, semi-tandem, tandem and one-legged stand positions and moving on to dynamic exercises (circuits, stepping and so on). Difficulty was increased by reducing arm and base support and by varying the type and complexity of exercises. An individualized progression was applied to each participant based on their progress throughout the intervention."
45396614|NCT03996083|Other|Walking intervention|"To comply with the walking goals, walking distance was calculated based on each participant´s performance on the 6-minute walking test and using a rule of thumb. Therefore, every participant had an itinerary to follow to comply with the minimum walking time each week. Distance rather than time was used with participants for practical reasons and the inability of most of them to measure time. Moreover, time and distance were individually adapted according to each participant´s performance on the previous week.~To ensure that participants complied with the walking goals, each of them (if they were cognitively able) was given a record sheet in which they had to write down their everyday walking routines. In addition, the caregivers were also informed about the walking routines and ensured that those participants who needed close supervision had someone to walk with and filled the sheet of those that were unable to do so."
45396615|NCT03724175|Drug|ursodiol (ursodeoxycholic acid, UDCA)|ursodiol (ursodeoxycholic acid, UDCA) 300 mg two times daily for 10 weeks for UC pouchitis patients
45396616|NCT01023191|Procedure|Percutaneous Insertion catheter|Insertion of CAPD catheter using percutaneous seldinger technique under local anaesthetic +/- sedation as required
45396617|NCT01023191|Procedure|Open insertion Catheter|Present technique of open insertion under general anaesthetic. Incision to lower abdomen and direct visualisation of catheter tip placement into pelvis.
45396618|NCT00450749|Other|placebo|Given PO
45396619|NCT00450749|Procedure|therapeutic conventional surgery|Undergo radical prostatectomy
45396620|NCT00450749|Other|laboratory biomarker analysis|Correlative studies
45396621|NCT00450749|Drug|lycopene|Given PO
45396622|NCT00292370|Drug|Open Label (OL) Paroxetine|Open-label Paroxetine
45396623|NCT00292370|Drug|Placebo|Double-blind placebo taken with OL paroxetine
45396624|NCT00292370|Drug|Quetiapine|Double-blind quetiapine taken with OL paroxetine
45396625|NCT00065182|Drug|Topotecan/Docetaxel combination|
45396626|NCT00065182|Drug|Docetaxel|
45396627|NCT01026701|Drug|bortezomib|injection into a vein 1.3 mg/m2 twice a week for 21 days
45396628|NCT01092052|Drug|NMS-1116354|Oral daily administration for 14 consecutive days followed by 7 days of rest
45396629|NCT01094860|Drug|Nelarabine|Starting dose 200 mg/m2 for 5 day continuous infusion administered via a central catheter, repeated every 28 days.
45396630|NCT01092130|Drug|Vitamin D|2000 IU vitamin D daily, for 6 weeks
45396631|NCT00064792|Drug|Simvastatin Susp.|During the simvastatin phase of the trial, therapy will be initiated at 0.5 mg/kg/day for six weeks and then increased to 1.0 mg/kg/day if adverse side effects are minimal or absent.
45396632|NCT00064792|Drug|OraPlus|During this trial and for two months prior, patients will be maintained on 150 mg/kg/day of dietary cholesterol (150 mg/ml in OraPlus) for the duration of the trial
45396633|NCT01095016|Drug|Meptin swinghaler|"Dose: 10ug/puff, 2 puffs daily~Frequency: QD (total 20ug/day)~Treatment duration: 2 days"
45396634|NCT01095016|Drug|Berotec|"Dose: 100ug/puff, 2 puffs daily~Frequency: QD (total 200ug/day)~Treatment duration: 2 days"
45396635|NCT01092286|Other|neuromuscular warm-up|neuromuscular warm-up exercises that take 20 minutes to perform
45697294|NCT05685693|Procedure|conventional total knee arthroplasty|total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. In conventional TKAs, no patient-specific instrumentation or robotic assistance is provided.
45697295|NCT01027468|Drug|Bevacizumab|intraocular bevacizumab injection
45697296|NCT05237349|Drug|Envafolimab|300mg,sc,d1,Q3W
45697297|NCT05237349|Drug|Oxaliplatin|130mg/m2, iv,d1,Q3W
45396636|NCT03956992|Other|Mouth gel|Stop using the mouth gel
45504137|NCT01351649|Behavioral|middle school physical activity intervention for girls|"Both the Girls on the Move intervention and attention control conditions will involve 2 components: face-to-face (individual) counseling sessions with a school nurse and an after-school (group) program. The intervention for the attention control group will not address physical activity. Both groups will respond to questionnaires at 0 (baseline) and 6 mos. Our Girls on the Move intervention is designed to help girls achieve physical activity recommendations (≥ 60 min. ≥ 5 days/wk.). The motivational, individually tailored counseling sessions with a school nurse and after-school physical activity club (3-5 times a wk. for 6 mos.) are designed to positively influence all cognitive and affective mediating variables of the Health Promotion Model."
45504138|NCT02079428|Other|No interventions|
45504139|NCT03062540|Drug|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
45504140|NCT03062540|Drug|Placebo SL Tablet|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
45396637|NCT00450437|Biological|MenACWY CRM|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.
45504141|NCT01351883|Dietary Supplement|ANOM|the ANOM was given 800ml per day before operation, and added from POD2 to POD 14 gradually from 400ml to 1200ml
45504142|NCT03060980|Drug|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini-pump delivering exenatide 20/60 mcg/day
45504143|NCT03060980|Drug|Empagliflozin (oral)|10 mg/day and 25 mg/day
45504144|NCT03060980|Drug|Glimepiride (oral)|1-6 mg/day
45504145|NCT01358591|Dietary Supplement|High calcium milk|High calcium milk (9 mg/kgBM)
45504146|NCT01358591|Dietary Supplement|Control|Regular Milk
45504147|NCT01358747|Drug|BEACOPPesc|
45504148|NCT01358747|Drug|BEACOPPesc - ABVD - PET2|
45504149|NCT03124459|Drug|ACE-083|Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.
45504150|NCT03124459|Drug|Placebo|Recombinant fusion protein or buffer solution
45504151|NCT02081144|Other|Smokefree TXT Program|The SmokeFreeTxt program is a library consisting of ~130 brief messages that can be proactively sent to smokers' cellphones using software developed and maintained by NCI. The message content is informed by principles of cognitive behavioral therapy. They are sent to smokers at random times of day (during normal waking hours), up to 5 messages per day.
45504152|NCT02081144|Drug|nicotine replacement patches|Subject will be given 4 weeks of Nicotine Replacement Patches, based on the amount he/she is smoking at baseline.
45504153|NCT02081144|Drug|Nicotine Replacement Gum|Subjects will be given 10 pieces of 2mg Nicotine Replacement Gum x 28 days.
45396638|NCT00450437|Biological|Meningococcal ACWY Conjugate vaccine|One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly.
45396639|NCT01095172|Drug|Rituximab|375mg/m^2, single dose given 2-4 weeks prior to transplantation
45396640|NCT01095172|Drug|Tacrolimus|dose calculated to give levels of 3-7ng/ml
45396641|NCT01095172|Drug|Mycophenylate mofetil|Mycophenylate mofetil 2g/day in divided doses
45504154|NCT02081144|Behavioral|Faxed Referral CT Smokers Quitline|A faxed referral will be sent to the CT Smokers Quitline for the subject.
45504155|NCT01351961|Biological|blood sampling|take a sample of blood, 46 ml
45504156|NCT01351961|Procedure|brain MRI and TEP cerebral|magnetic resonance imaging
45504157|NCT01351961|Other|Assessment of cognitive functions|Folstein MMSE, Mac Nair scale, Depression (GDS) scale, The Benton Visual Retention Test, Test of verbal fluency, formal and categorical, Trail Making Test, Grober et Buschke scale (RL/RI-16), Apathy Robert scale, Praxis rating Scale .
45396642|NCT01095172|Drug|Hydrocortisone|100mg hydrocortisone on the evening of the day of surgery and 2 further doses of hydrocortisone on day 1 post transplant.
45396643|NCT01095172|Drug|Prednisolone|Prednisolone 0.3mg/kg on day 2, 0.25mg/kg on day 3, 0.2mg/kg on day 4 and 0.16mg/kg on day 5. On day 6 they will receive 5mg prednisolone, and on day 7 none.
45396644|NCT01095172|Drug|Prednisolone|Reducing dose of prednisolone over at least 6 months. Subsequent steroid maintenance or withdrawal will be at the discretion of the patient's clinician.
45396645|NCT00286442|Drug|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin for up to 26 weeks.
45396646|NCT00286442|Drug|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin for up to 26 weeks.
45396647|NCT00286442|Drug|Metformin|Alogliptin placebo-matching tablets, orally, once daily and metformin for up to 26 weeks.
45396648|NCT00063934|Biological|oblimersen sodium|Given IV
45396649|NCT00063934|Drug|doxorubicin hydrochloride|Given IV
45396650|NCT00063934|Drug|docetaxel|Given IV
45504158|NCT01351961|Other|Electrocardiogram and blood pressure|Electrocardiogramm Blood pressure monitoring
45504159|NCT01351961|Procedure|Vascular explorations|Pulse wave velocity, VWF, IMT
45504160|NCT01351961|Biological|Urine sample|
45504161|NCT02083328|Dietary Supplement|Caffeine|Caffeine will be filled in gelatine capsules and administrated in a dosage of 6mg per kg body mass
45504162|NCT02083328|Dietary Supplement|Placebo (Mannitol)|Mannitol filled in gelatine capsules
45396651|NCT00063934|Biological|filgrastim|Given SC
45504163|NCT01354535|Procedure|Isolated Locked Compression Plate|A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
45504164|NCT01354535|Procedure|Cable Plating and Strut Allograft with Cerclage Wiring|The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
45504165|NCT02079506|Drug|Candesartan|
45504166|NCT02079506|Drug|Rosuvastatin|
45504167|NCT01370941|Dietary Supplement|Drug A Chymosin|Five drops of chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
45504168|NCT01370941|Dietary Supplement|Drug B: Placebo|B: Five drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
45697298|NCT05237349|Drug|S1|40mg/m2, op,bid,d1-14,Q3W
45396652|NCT00063934|Biological|pegfilgrastim|Given SC
45396653|NCT00063934|Procedure|therapeutic conventional surgery|Undergo surgical resection
45396654|NCT00063934|Other|pharmacological study|Optional correlative studies
45396655|NCT00063934|Other|laboratory biomarker analysis|Optional correlative studies
45396656|NCT03955744|Other|3D translabial ultrasound|All patients will undergo 3D translabial ultrasound with vaginal manometry
45396657|NCT00458783|Biological|Prolonged RBC storage|Transfusion with oldest available matching RBCs
45396658|NCT00458783|Biological|Short RBC storage|Transfusion with youngest available matching RBCs
45396659|NCT00063154|Drug|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
45396660|NCT01092520|Drug|Gabapentin|Day 1 - 5mg/kg/dose per os at bedtime then 5mg/kg/dose PO b.i.d x 1 day (Day 2) then on Day 3, 5mg/kg/dose PO t.i.d . x 19 days; after 7 days, if not at maximal effect may increase over 3 days to 10mg/kg/dose (Day 8: 5 mg/kg/dose q.am and midday, Day 9: 10mg/kg/dose b.i.d. + 5mg/kg/dose midday, Day 10: 10mg/kg/dose t.i.d.) Doses may be reduced if patient experiences intolerable side effects.
45396661|NCT03955588|Diagnostic Test|aCGH|
45396662|NCT03996161|Other|patient position|After the induction of anesthesia, mask ventilation is performed in the supine and semi-sitting position in a cross-over, randomized order.
45396663|NCT03955666|Biological|PRV-3279 or placebo|bi-specific antibody-based molecule
45396664|NCT00311168|Device|Intervention/treatment|"Device: VIP On~Device: VIP Off"
45396665|NCT00458705|Drug|bortezomib|
45396666|NCT00458705|Drug|dexamethasone|
45697299|NCT01027780|Behavioral|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
45396667|NCT00458705|Drug|pegylated liposomal doxorubicin hydrochloride|
45396668|NCT00458705|Drug|thalidomide|
45396669|NCT00062374|Drug|Cisplatin|Given IV
45396670|NCT00062374|Procedure|Computed Tomography|Undergo FDG and FLT PET/CT
45504169|NCT02081222|Procedure|surgery for congenital heart disease with cardiopulmonary bypass|surgery for congenital heart disease with cardiopulmonary bypass
45504170|NCT02940548|Drug|Nifedipine GITS|Nifedipine GITS 30~60mg/day for 8 weeks
45396671|NCT00062374|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET/CT
45396672|NCT00062374|Other|Fluorothymidine F-18|Undergo FLT-PET/CT
45396673|NCT00062374|Drug|Irinotecan Hydrochloride|Given IV
45504171|NCT02940548|Drug|Amlodipine besylate|Amlodipine besylate 5~10mg/day for 8 weeks
45504172|NCT01366183|Procedure|Assessment of Therapy Complications|Undergo nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment assessments
45697300|NCT05102799|Other|No intervention|No intervention
45697301|NCT05395156|Device|Transcutaneous electrical nerve stimulation (TENS)|Control group will receive TEAS on sham acupoint daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles Study group will receive TEAS on neurogenic acupoints daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles
45396674|NCT00062374|Procedure|Positron Emission Tomography|Undergo FDG and FLT PET/CT
45396675|NCT00062374|Procedure|Therapeutic Conventional Surgery|Undergo radical subtotal or total gastrectomy with lymph node dissection
45396676|NCT00288119|Device|Balloon Capsule Device|The Esophageal Sampling Device BESD-001 is a non-endoscopic balloon capsule catheter for obtaining an esophageal mucosal sample. At the distal end of the catheter there is a silicone capsule textured balloon assembly. The textured balloon is initially inverted with vacuum for patient to swallow the capsule but then is inflated with 5.6 cc of air (5 cc syringe withdrawn maximally) to a 16-18 mm diameter in order to contact the lumen of the esophagus to collect a sample. The balloon has a textured surface, which enhances the collection of the esophageal sample. Following sample collection the textured balloon is inverted back into the hollow capsule component via syringe draw vacuum in order to maximize & protect the site-specific sample collection.
45396677|NCT00288119|Procedure|Endoscopy|An upper endoscopy is a procedure used to visually examine your upper digestive system with a tiny camera on the end of a long, flexible tube.
45396678|NCT00285818|Drug|Mifepristone|Mifepristone is a glucocorticoid receptor antagonist.
45396679|NCT00285818|Drug|Placebo Oral Capsule|Placebo is a capsule without a pharmacological active ingredient
45504173|NCT01366183|Drug|Carboplatin|Undergo chemotherapy
45697302|NCT03320343|Other|MRI|3D morphological MRI and diffusion tensor imaging
45396680|NCT01323023|Behavioral|varies by project|
45396681|NCT01023347|Drug|Paclitaxel (Genexol®)|
45396682|NCT01023347|Drug|Paclitaxel loaded polymeric micelle (Genexol-PM®)|
45396683|NCT01095328|Other|screening|screening for Q-fever with a single blood sampling
45396684|NCT01023425|Drug|donepezil|from 5mg to 10mg, once a day, 12 months
45396685|NCT00285584|Drug|Bupropion|Participants initially received bupropion, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage of bupropion allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
45396686|NCT00285584|Drug|Placebo|Participants initially received placebo, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
45504174|NCT01366183|Biological|Filgrastim|Undergo chemotherapy
45504175|NCT01366183|Drug|Paclitaxel|Undergo chemotherapy
45504176|NCT01366183|Other|Pharmacological Study|Correlative studies
45504177|NCT01366183|Other|Quality-of-Life Assessment|Ancillary studies
45504178|NCT01366183|Other|Questionnaire Administration|Ancillary studies
45504179|NCT03134183|Drug|Vaginal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) vaginally 1-2 hours prior and placebo (buccal mint powder) buccally 1-2 hours prior to D&E
45504180|NCT03134183|Drug|Buccal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) ground with mint into buccal powder and placebo (two lactose tablets designed to appear similar to misoprostol) vaginally 1-2 hours prior to D&E
45504181|NCT02083484|Biological|Pembrolizumab|Each participant will receive pembrolizumab every 3 weeks for up to 2 years or until confirmed radiographic disease progression, unacceptable toxicity, confirmed positive pregnancy test, withdrawal of consent, or pembrolizumab approval in the participant's country.
45504182|NCT01354613|Drug|Dobutamine|IV administration at the initial study visit (all groups) and at the final study visit for the drug intervention arm (HFpEF group only). Administration of low-dose dobutamine at 5mcg/kg/min and 10mcg/kg/min for periods of approximately 30minutes/dose for purposes of performing a low-dose stress exam on the heart.
45396687|NCT01026857|Drug|Propionyl-L-Carnitine|PLC colon release tablet 1 g/die for 4 weeks
45396688|NCT01026857|Drug|Propionyl-L-Carnitine|PLC colon release tablet 2 g/die for 4 weeks
45396689|NCT01026857|Drug|Placebo|Placebo PLC colon release tablet 2 g/die for 4 weeks
45396690|NCT03671447|Other|ICU Usual Care|The control condition delivered at ICU is usual care.
45504183|NCT01354613|Drug|Amlodipine|Participants will be randomized to treatment with either amlodipine 5 mg daily or placebo, in double-blind fashion, 25 patients in each group. 12 week oral administration of 5mg/day, uptitrated to 10mg/day, determined by PI.
45504184|NCT01317719|Procedure|Distal Biceps Re-Insertion Surgery|Surgical Repair of the Distal Biceps Tendon
45697303|NCT05395000|Behavioral|Videos|A short video explaining briefly what type 1 diabetes is, the symptoms of hypoglycemia and the usefulness of glucagon as well as two short videos explaining how to administer glucagon, all less than 3 minutes long, will be viewed by the 2 groups for intranasal glucagon and injectable glucagon. Participants will have access to the videos for 2 weeks, approximately 3 months before the next stages of the project.
45396691|NCT03671447|Behavioral|Tele-ICU|The experimental complex intervention ERIC consists of daily tele-medicine based rounds at ICU. Tele-ICU is implemented after a blended learning program for ICU staff which will be completed prior to the site's crossover.
45396692|NCT03853655|Radiation|Post-operative adjuvant radiotherapy|"Conventional treatment planning, as well as intensity-modulated radiation therapy (IMRT) planning, would be allowed on the study with patients being stratified on the RT technique.~Treatment would be delivered on telecobalt unit (gamma-rays/linear accelerator (6MV photons). All fields would be treated daily.~Phase I: 46 Gray(Gy) in 23 fractions over 4.5 weeks Phase II: 14Gray in 7 fractions over 1.5 weeks~For IMRT, inverse planning would be done on a commercial TPS configured to deliver IMRT using 6MV photons. Patients shall be treated using the simultaneous integrated boost (SIB) technique with 5 fractions being delivered every week."
45396693|NCT03807700|Drug|Experimental Denture Adhesive|In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
45396694|NCT01583842|Drug|124I-Metaiodobenzylguanidine (MIBG) (no-carrier added)|"124I-MIBG (no-carrier added) Administration (infusion, 1-2 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (no-carrier added) Administration & PET/CT scan 6 weeks later."
45504185|NCT05189405|Device|INVOcell IVC|Embryo development in intravaginal incubation
45504186|NCT02083640|Drug|Palbociclib Formulation Reference|125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 1, which is representative of the intended commercial hard gelatin capsule.
45697304|NCT05395000|Behavioral|Simulation|An intranasal and injectable glucagon administration test on a mannequin in a simulated stress environment will be done.
45697305|NCT05395000|Behavioral|Interview|At the end of the simulation, participants will participate in a semi-structured, recorded individual interview of approximately 20 minutes to share their experience related to preferences, barriers, emotional impact, and method of teaching the use of the two glucagon formulations.
45504187|NCT02083640|Drug|Palbociclib Formulation Test|125 mg single dose of palbociclib formulation with 41 micrometer API particle size and dissolution level 1
45697306|NCT04278807|Procedure|Regional Anesthesia - Nerve Blocks|Regional Anesthesia and ultrasound-guided nerve blocks
45396695|NCT01583842|Drug|124I-MIBG (carrier added)|"124I-MIBG (carrier added) Administration (infusion, 60 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (carrier added) Administration & PET/CT scan 6 weeks later."
45396696|NCT01583842|Procedure|Positron Emission Tomography (PET) /Computerized tomography (CT)|A PET scan measures important body functions, such as metabolism. CT imaging uses special x-ray equipment, and in some cases a contrast material, to produce multiple images of the inside of the body. Combined PET/CT scans combine the processes of both a PET and CT at the same time.
45396697|NCT01092754|Procedure|MRI|contrast enhanced MRI
45396698|NCT01092754|Procedure|MRI|contrast enhanced MRI
45504188|NCT02083640|Drug|Palbociclib Formulation Test|125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 2
45504189|NCT01352039|Biological|Heparin Sodium - Eurofarma|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
45504190|NCT01352039|Biological|Heparin Sodium - APP Pharmaceuticals|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
45504191|NCT02083718|Biological|PBSC|
45504192|NCT02083718|Biological|MSCs|
45504193|NCT05189327|Other|No intervention|Non-interventional study
45504194|NCT02083796|Procedure|Shoulder impingement_TSM|A physiotherapist with 4 years of experience in manual therapy will administer the TSM targeting the middle thoracic spine of the subjects.
45504195|NCT02083796|Procedure|Asymptomatic_TSM|A physiotherapist with 4 years of experience in manual therapy administered the TSM targeting the middle thoracic spine of the subjects.
45504196|NCT02083796|Procedure|Shoulder impingement_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
45504197|NCT02083796|Procedure|Asymptomatic_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
45504198|NCT05189249|Other|No intervention performed|No intervention performed. Participants were enrolled retrospectively and medical records were accessed for data.
45504199|NCT01363921|Device|HCO 1100|Dialysis treatment with HCO1100
45504200|NCT02079818|Device|Penumbra Ruby Coil System|The Penumbra Ruby™ Coil is a new generation of detachable coils developed by Penumbra Inc. This coil system is specifically designed for the occlusion of aneurysms and vessels that is equivalent to standard platinum coils. This system consists of: an implantable Coil attached to a Detachment Pusher as well as a Detachment Handle. The Detachment Pusher is comprised of a shaft with a radiopaque positioning marker, a Distal Detachment Tip, and a pull wire. The Detachment Handle is used to detach the Coil Implant from the Detachment Pusher. The Penumbra Ruby Coil is designed for endovascular embolization in the peripheral vasculature. Intended users for this device are physicians who have received appropriate training in interventional radiology and endovascular intervention.
45504201|NCT01358903|Drug|RO5429083|Cohorts receiving multiple escalating doses iv
45504202|NCT01358903|Drug|RO5429083|Cohorts receiving 89Zr-labelled RO5429083 plus RO5429083, followed by RO5429083 until disease progression
45504203|NCT01366261|Device|semirigid thoracoscopy|thoracoscopy with semirigid instrument
45697307|NCT03275805|Other|Duration of Pavlik Harness treatment|The only intervention that varies from standard of care (12 weeks of treatment) will be the duration of bracing (for the treatment to normalization arm). Patients in both arms will have identical follow up protocols and imaging to closely monitor hip morphology.
45697308|NCT03275805|Other|12 week standard of care|The intervention for this arm will be standard treatment for this pathology.
45396699|NCT01092754|Drug|Gadoversetamide|Subjects will receive a single dose of Optimark(0.1 mmol/kg)as a bolus thru a peripheral IV line at 1-2 mL/sec followed by a saline flush during their medically necessary MRI .
45396700|NCT02530606|Procedure|Photoacoustic Imaging|Undergo PAI
45396701|NCT00291668|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 200 mg/mL~Route of Administration: Subcutaneous use"
45396702|NCT00291668|Other|Placebo|"Active Substance: isotonic sodium chloride solution~Pharmaceutical Form: Solution for injection~Concentration: 1 mL~Route of Administration: Subcutaneous use"
45396703|NCT01095406|Device|S1 ventilation|Ventilation with a O2 and CO2 controller
45396704|NCT00458393|Drug|daily TDF/FTC|daily oral medication
45396705|NCT00458393|Drug|Placebo|daily oral medication
45396706|NCT03955354|Drug|SHR1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
45396707|NCT03955354|Drug|apatinib mesylate|apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
45504204|NCT01366261|Device|rigid thoracoscopy|thoracoscopy with rigid instrument
45504205|NCT05190835|Device|Optical scanner|During the visits (Day 0 before surgery, Day 8, Day 21, Day 45, Month 3 and Month 6 after surgery), a measurement of the volume and the perimeter of the patient's two feet is carried out (operated foot and control foot). The edema is measured by a non-invasive method using an optical scanner (camera + laser scanning). The image processing software accompanying this tool has an automatic calculation of the volumes and the different perimeters of the foot. The measurement time by the scanner is less than 4 seconds.
45504206|NCT03136367|Other|Option Grid|The Option Grid(TM) encounter decision aid for early stage breast cancer surgery is a one-page, evidence-based summary of available options presented in a tabular format.
45504207|NCT03136367|Other|Picture Option Grid|The Picture Option Grid was derived from the Option Grid for early stage breast cancer. It uses the same evidence and integrates images and simpler text, thus exploiting pictorial superiority. The Picture Option Grid has been specifically designed for women of lower SES and low health literacy.
45504208|NCT04419337|Drug|Metformin plus Pioglitazone plus an SGLT2 inhibitor|Patients assigned to active group will stop their prior oral antidiabetic drugs and receive combination of metformin, pioglitazone, and an SGLT2 inhibitor (empagliflozin or dapagliflozin or canagliflozin) and dose will be adjusted by their physicians.
45504209|NCT03124381|Device|Cleanser, Acne Mask|A facial cleanser will be used twice daily (morning and evening). The light therapy mask will be used for 10 minutes in the evening after washing/drying the face.
45504210|NCT03124381|Device|Cleanser, Gel-Cream, Acne Mask|A facial cleanser will be used twice daily (morning and evening). In the evening after cleansing, the gel-cream will be applied full face and allowed to dry before the light therapy mask is used for 10 minutes.
45697309|NCT03344757|Behavioral|Cultural CBSM|The Culturally Adapted Cognitive Behavioral Stress Management (C-CBSM) Intervention is a 10 weekly in-person group program. Each session will last about 90 minutes. The meetings will give facts on stress, coping with difficult events, managing anger, social support and stress reactions. Participants will also receive information on how to practice relaxation on their own. The delivery of C-CBSM places a greater emphasis on salient sociocultural determinants of symptom burden and Health Related Quality of Life (HRQoL) in Hispanics (e.g., fatalistic attitudes, family interdependence, perceived discrimination, machismo).
45504211|NCT01359059|Drug|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
45504212|NCT01359059|Drug|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
45504213|NCT01354769|Device|CapnoStream20|The monitor used for data gathering is a CapnoStream20-multi parameter monitor
45504214|NCT01352273|Drug|MEK162 + RAF265|
45504215|NCT01352351|Behavioral|Breastfeeding promotion intervention|"Breastfeeding counseling during monthly microcredit meetings~Weekly cell phone messages about breastfeeding"
45504216|NCT05189093|Drug|Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection|"In the phase I dose escalation part:it is planned to recruit patients with relapsed/refractory advanced lymphoma, and 4 doses will be explored: 7.5mg/kg, 15mg/kg, 22.5mg/kg and 30mg/kg dose groups. once every two weeks (Q2W), every 14 days is a dosing cycle.~Recommend Phase II dose based on the results of Phase I dose escalation part."
45396708|NCT01095484|Drug|Rotigotine patch|1 patch daily for up to 48 months. Patch strength (per 24 hours): 1 mg - 8 mg based on investigator's assessment
45396709|NCT01063478|Drug|RAD001 (in addition to standard radiation and chemotherapy)|Standard radiation and chemotherapy (cisplatin and pemetrexed) + RAD001
45504217|NCT03620279|Behavioral|Magic camp intervention|Hand-arm bimanual motor skills training
45504218|NCT04006717|Device|Low Level Laser therapy|Diode laser (EPIC™ BIOLASE) with wavelength 940nm
45504219|NCT04006717|Procedure|Intra canal Cryotherapy|Irrigation with cold saline 2-4 C
45504220|NCT01371097|Other|Progressive Resistance strength training|Resistance strength training is given as circle training. The resistance is increased with regularly intervals.
45504221|NCT01371175|Biological|DNA.HIVA|0.5mg DNA.HIVA or placebo
45504222|NCT01371175|Biological|MVA.HIVA|5x10^6 pfu MVA or placebo
45504223|NCT01371175|Biological|MVA.HIVA|5x10^7 pfu MVA or placebo
45504224|NCT01371175|Biological|MVA.HIVA|2.5x10^8 pfu MVA or placebo
45504225|NCT04208815|Other|Milk Polar Lipids|Effects of the addition of 5 g of milk polar lipids to 20 g milk fat.
45396710|NCT01327144|Drug|Famciclovir|Famciclovir 500 mg- 1 tablet each 12 hours for 7 days
45504226|NCT04208815|Other|Milk Fat|Effects of the addition of 20 g milk fat.
45504227|NCT01371253|Other|Nintendo wii balance training|
45396711|NCT01327144|Drug|Aciclovir|Aciclovir 400 mg- 02 tablets each 4 hours for 7 days
45504228|NCT01371253|Other|EVA-soles|
45504229|NCT04036045|Other|Cardiac MRI|Patients will have a cardiac MRI at four time points during the study
45504230|NCT04036045|Other|Echocardiogram|Patients will have an echocardiogram at four time points during the study
45504231|NCT04036045|Other|Blood Draw|Patients will have blood drawn at four time points to analyze micro RNAs and Biomarkers before, during and after anthracycline treatment. Patients will also have one blood draw for future genetic sequencing.
45504232|NCT01371331|Drug|Tacrolimus granules|oral
45504233|NCT03972865|Other|EmbrunMan race|The EmbrunMan is a long-duration triathlon including 3.8 km of swimming, 188 km of cycling and 42.2 km of running, with a cumulative vertical drop of 4000 metres. Duration of the race varies between 10 hours and 16hours depending on the athletes' performance.
45504234|NCT01366339|Drug|Oral methylnaltrexone|
45504235|NCT01366339|Drug|Oral placebo|
45504236|NCT03133793|Drug|CoQ10|Participants will take 300 mg capsules two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
45504237|NCT03133793|Drug|D-Ribose Oral Powder|Participants will mix 15 grams D-Ribose powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
45504238|NCT03133793|Other|Placebo pills|Participants will take matched placebo pills that are 300 mg capsules, two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
45504239|NCT03133793|Other|Placebo powder|Participants will mix 15 grams placebo powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
45504240|NCT05190601|Device|uroflowmetry|Qmax(ml/s),Qav(ml/s),Volume (ml)
45504241|NCT01318421|Drug|ELND002|
45504242|NCT02747238|Device|Ultrasound|The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
45504243|NCT02747238|Procedure|No ultrasound|Palpation of anatomical landmarks is used for placement of labor analgesia
45504244|NCT02747238|Procedure|Epidural infusion|An epidural infusion will be started in both groups, regarding of the technique used for placement, and the same solution of Bupivacaine 0.0625% with 2mcg fentanyl/cc will be used in both groups
45504245|NCT03133481|Procedure|Adductor Canal Nerve Block|Adductor Canal never technique
45504246|NCT03133481|Drug|Femoral Nerve Block|Traditional technique
45396712|NCT01026935|Device|Open inguinal hernia repair|Altogether 400 patients are randomized to receive an open mesh repair with either sutured light weight mesh (38g/m2) or with a non-sutured light weight polypropylene mesh that adheres to tissues with polylactic micro hooks
45396713|NCT01566071|Other|Assessment of drive abilities|
45396714|NCT01323101|Drug|Doxycycline|Doxycycline 40mg, 100mg, 200mg tablet once daily, or no drug for 28 days.
45504247|NCT01366573|Drug|GSK1521498|GSK1521498 20 mg administered with alcohol to determine PK/PD interactions
45504248|NCT01366573|Other|Placebo|Placebo
45504249|NCT01366651|Drug|Doripenem|Type=exact number, unit=mg/kg, number=30, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to <1 year of age.
45504250|NCT01366651|Drug|Doripenem|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients <12 weeks of age.
45504251|NCT05190289|Other|Pre-existing degenerative factors of paraspinal muscles and bone mass|Pre-existing degenerative factors of paraspinal muscles, including muscle atrophy and fat infiltration; bone mass
45504252|NCT05124509|Biological|Three doses of SARS-CoV-2 BNT162b2 vaccine (observational)|Two doses of SARS-CoV-2 BNT162b2 mRNA vaccine, followed by a booster (3rd) dose of SARS-CoV-2 BNT162b2 mRNA vaccine.
45504253|NCT05124509|Biological|Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)|Two doses of CoronaVac SARS-CoV-2 inactivated vaccine, followed by a booster (3rd) dose of BNT162b2 mRNA vaccine.
45504254|NCT02864316|Drug|Nivolumab|
45504255|NCT03941509|Behavioral|Antimicrobial stewardship|Education, guidelines, communication tools and audit and feedback
45504256|NCT01364077|Drug|Ivabradine|Ivabradine 5 mg BID titrated to 7.5 mg if tolerated
45504257|NCT01364077|Drug|Placebo|Matched placebo
45504258|NCT01361399|Drug|Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain|Single oral application of a fixed combination of Aspirin and Lidocain (as one lozenge)
45504259|NCT01361399|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral application of Aspirin (as lozenge)
45504260|NCT01361399|Drug|Lidocain|Single oral application of Lidocain (as lozenge)
45504261|NCT01361399|Drug|Placebo|Single oral application of Placebo (as lozenge)
45504262|NCT05190133|Drug|UIC201602 and co-administration of UIC201601 and UIC201602|"UIC201602 4 Cap/day for 14 days~Wash out 21 days~UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days"
45697310|NCT03344757|Behavioral|Standard CBSM|The standard Cognitive Behavioral Stress Management (CBSM) Intervention is a 10 weekly in-person group program. Each session will last about 90 minutes. The meetings will give facts on stress, coping with difficult events, managing anger, social support and stress reactions. Participants will also receive information on how to practice relaxation on their own.
45396715|NCT01323101|Other|No doxycycline|
45504263|NCT05190133|Drug|UIC201601 and co-administration of UIC201601 and UIC201602|"UIC201601 4 Tab/day for 7 days~Wash out 14 days~UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days"
45504264|NCT02862600|Drug|Perhexiline|Period 1 (Weeks 1-8) and Period 2 (Weeks 9-16): dose titrated to two different plasma levels of perhexiline
45697311|NCT00980278|Procedure|Sinus lift augmentation and dental implant|transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
45697312|NCT00980278|Biological|Aastrom BRCs|sinus augmentation, BRC application, dental implant
45697313|NCT03344211|Drug|Enzalutamide|Given PO
45396716|NCT00310856|Biological|MenACWY-CRM|Subjects received the full dose (0.5 mL) of MenACWY-CRM, obtained by extemporaneous mixing of lyophilized MenA powder component and the MenCWY suspension, administered by IM injection into the anterolateral area of the right thigh.
45396717|NCT00310856|Biological|MenC-CRM|One dose (0.5 mL) of MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized MenC component and a saline solvent, administered by IM injection into the arm region.
45396718|NCT00310856|Biological|DTaP-Hib-IPV|
45396719|NCT00310856|Biological|PC7|One dose (0.5 mL) of PC7, supplied in pre-filled syringe, administered by IM injection into the anterolateral area of the left thigh.
45396720|NCT00310856|Biological|MMR|
45396721|NCT00310856|Biological|Varicella|
45504265|NCT02862600|Device|Use of bioanalytical assay to monitor plasma levels of perhexiline|The bioanalytical assay is the device under investigation. It will be used to monitor plasma levels of perhexiline. The data obtained from this analysis will be used to guide dose adjustments of perhexiline.
45504266|NCT01359137|Behavioral|Probation as usual|Routine probation with do deferred jail condition.
45504267|NCT01359137|Behavioral|Deferred Jail|Discretionary deferred jail in response to violations of probation conditions.
45504268|NCT01359137|Behavioral|Arizona's SAFE|Swift Accountable Fair Enforcement (SAFE) uses non-discretionary brief jail sanctions for probation violations.
45504269|NCT01364155|Drug|LIM-0705|
45504270|NCT01364155|Drug|Placebo capsules|
45504271|NCT05189899|Device|Virtual reality|One hemodialysis session with virtual reality and one other without it
45504272|NCT01354847|Device|Multiple electrode aggregometry analyses (Multiple Electrode Aggregometry, Multiplate(R), Verum Diagnostica, Munich, Germany)|ex vivo platelet aggregation at several intraoperative and postoperative measuring points.
45396722|NCT03995615|Procedure|scaling and root planing|"After initial clinical evaluation, supra gingival calculus removal will be done. GCF samples will be collected from the control and test groups (Baseline samples) using paper strips (ORAFLOW). ® Group III patients will undergo a through oral hygiene instructions, full mouth supra-gingival and sub- gingival scaling and root planing clinical parameters will be re-recorded 6 weeks later and a 2nd GCF samples will be collected from selected test site from each patients following periodontal intervention.~All the samples will be placed in eppendorf vials containing the buffer solution and samples will be stored at -800 c until the time of analysis by Enzyme -linked immune sorbent assay kit (ELISA) (GENX BIO) TM"
45396723|NCT03670355|Drug|Tenofovir (TFV) IVR|Contains 1.4 g TFV
45504273|NCT03767101|Behavioral|Cognitive behavioral therapy|In all three treatment arms, licensed therapists/trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. All treatments are based on individualized treatment plans for each patient. Therapists are supervized by an CBT expert therapist in the outpatient treatment center. On average every forth session is supervized. The total duration of treatment is variable, oriented on patients symptoms and treatment goals.
45504274|NCT01359527|Device|Hip Resurfacing|
45504275|NCT01359527|Device|Total Hip Arthroplasty|
45504276|NCT01354925|Drug|Insulin treatment during Ramadan|Insulin analogs will be used: Levemir and NovoMix70. The daily insulin dose will be calculated as follows: Sixty percent of the total daily dose will be used as the beginning daily dose at the first day of fasting. Sixty percent of the daily dose will be given as NovoMix70 before the Eftar (the main meal in the evening that breaks the fast). Forty percent of the amount will be given as Levemir (Early in the morning before the beginning of fasting.
45504277|NCT01354925|Drug|Standard of care|Standard of care during Ramadan according to physicians decision
45504278|NCT03812107|Other|Moderate Treatment Approach|The frequency of visits will be organized similarly as the intensive treatment arm (weekly, every 2 weeks, and every 4 weeks) but participants in this arm will be able to move more freely between these steps and are hypothesized to require fewer provider visits than the intensive treatment arm.
45396724|NCT03670355|Drug|Placebo IVR|Contains placebo
45504279|NCT03812107|Other|Intensive Treatment Approach|After stabilization on a MOUD, participants who relapse will be asked to return weekly until 2 consecutive urine drug tests are negative for opioids or other illicit drugs. Participants will then be asked to return every other week until 2 consecutive urine drug tests are negative for opioids or other illicit drugs, before being asked to return every 4 weeks. If the participant tests positive for illicit drugs while returning every other week, they will return to the beginning of the treatment plan (2 consecutive negative tests before going to every other week).
45504280|NCT02864082|Drug|PAT-001, 0.1%|PAT-001 is a topical ointment. PAT-001, 0.1% contains 0.1% of active drug.
46057037|NCT00805792|Drug|Donepezil|Study participants will be treated with donepezil orally at an initial dose of 5 mg daily for the first 4 weeks, then increased at their 30-day visit by 5 mg to a maximum dose of 10 mg daily, if tolerated. If the participant does not tolerate the 10 mg dose, they will remain on 5 mg through the course of the study.
45396725|NCT01068782|Drug|XL184|given orally as capsules
45396726|NCT03975998|Procedure|Mitral valve repair|Minimally invasive repair of severe organic mitral regurgiation
45396727|NCT01566227|Other|Questionnaire|3 surveys with 10 questions each: one before, during and after treatment
45396728|NCT02532062|Dietary Supplement|Cholecalciferol|4,000 IU, oral, once a day for one year
45396729|NCT02532062|Dietary Supplement|multivitamin|oral, once a day for one year
45396730|NCT02532062|Dietary Supplement|Placebo|oral, once a day for one year
45396731|NCT01566305|Dietary Supplement|Buttermilk without added egg-yolk|Buttermilk without added egg-yolk
45504281|NCT02864082|Drug|PAT-001, 0.2%|PAT-001 is a topical ointment. PAT-001, 0.2% contains 0.2% of active drug.
45504282|NCT02864082|Drug|Vehicle for PAT-001 0.1%|Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.1%.
45504283|NCT02864082|Drug|Vehicle for PAT-001 0.2%|Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.2%.
45504284|NCT05091281|Device|Intubation of the double lumen tube by Macintoch laryngoscope|After induction of anesthesia insertion of the double lumen tube was done by Macintosh laryngoscope
45504285|NCT05091281|Device|Intubation of the double lumen tube by Glidescope videolaryngoscope|After induction of anesthesia insertion of the double lumen tube was done by GlideScope® videolaryngoscope
45396732|NCT01566305|Dietary Supplement|Buttermilk with added egg yolk|Buttermilk with added egg yolk
45396733|NCT01566305|Dietary Supplement|Skimmed milk with added egg-yolk|Skimmed milk with added egg-yolk
45396734|NCT01566305|Dietary Supplement|Skimmed milk without added egg yolk|Skimmed milk without added egg yolk
45396735|NCT01566383|Procedure|24-hr pH monitoring|"Visit 1~The following will be done:~A medical history including review of your current drugs;~Collection of demographic information;~A manometry, before the 24-hour pH testing, to find the junction between the esophagus and stomach;~24-hour pH testing will be done~Visit 2~You will return to the clinic 24 hours after the visit 1 and the following will occur:~The catheter will be removed from your nose; and~You will return the recording device"
45396736|NCT00283712|Drug|Infliximab|Chimeric IgG monoclonal antibody that binds to TNF-alpha, generally used to treat Crohn's disease, given in a dosage of 5 mg/kg
45504286|NCT05091281|Device|Intubation of the double lumen tube by C-MAC®(D) videolaryngoscope|After induction of anesthesia insertion of the double lumen tube was done by C-MAC®(D) videolaryngoscope
45504287|NCT03556345|Drug|RC48-ADC|2.5 mg/kg IV every 2 weeks
45504288|NCT03610230|Drug|Iron Isomaltoside|Iron Isomaltoside 1000 (Monofer®) consists of iron with a tighter binding to its carbohydrate moiety with less free iron
45504289|NCT03610230|Drug|Iron sucrose|the currently most widely used intravenous iron preparation with good safety profile
45504290|NCT01359605|Drug|varespladib methyl|500 mg oral suspension
45396737|NCT00283712|Other|Placebo Comparator|Placebo administered in place of infliximab for control group
45504291|NCT01366963|Behavioral|Seated Measurements|"The following measurements will take place in a seated position:~Ruff 1 & 7 (visual search and attention processes) Trails A & B (Tests of scanning, mental flexibility and executive processes) Symbol Digit Modalities Test (SDMT)(attention and psychomotor speed) Stroop Test (naming response to certain stimuli) Verbal Fluency (COWA) Randt Wechsler Test of Adult Reading (WTAR)"
45504292|NCT01366963|Behavioral|Standing Measurements|"The following will be measured in a standing position (at least 5 minutes)~Orthostatic Vital Signs Randt Paired Words Subtest Digits Forward and Backward Alternate COWA test"
45504293|NCT01366963|Behavioral|Self-Administered Surveys|Center for Epidemiologic Studies Depression Scale (CES-D) Cognitive-Somatic Anxiety Questionnaire (CSAQ) Subjective Neurocognitive Inventory (SNI)
45504294|NCT03609684|Other|Gymnastic and Core Stabilization|People who regularly do gymnastics and also do 30-45 minutes core stabilization exercises
46057038|NCT02714127|Other|First-void urine collection|One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
45396738|NCT03981536|Drug|AP-101|Administered by intravenous infusion (IV)
45396739|NCT00048724|Biological|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg subcutaneously once weekly for 60 months
45396740|NCT00449033|Drug|Sorafenib (Nexavar, BAY43-9006)|Multikinase inhibitor, Sorafenib 400 mg po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m^2 IV, Cisplatin 75 mg/m^2 IV
45396741|NCT00449033|Drug|Placebo|Placebo 2 tablets po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m^2 IV, Cisplatin 75 mg/m^2 IV
45504295|NCT03609684|Other|Only Gymnastic Training|People can do gymnastics twice a week but can't do core stabilization exercise
45504296|NCT03609684|Other|Sedentary Group|People who are not interested in any sports and don't do any exercises
45504297|NCT05188859|Drug|Sintilimab+Anlotinib+Pemetrexed+Cisplatin|Sintilimab 200mg+Anlotinib 12mg+Pemetrexed 500mg/m²+Cisplatin 75mg/m2
45504298|NCT01367041|Procedure|vibration|Vibration frequency: 40 Hz, duration: 30+30 s, 2mm amplitude
45504299|NCT02033538|Drug|nanoparticle albumin-bound paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
45504300|NCT01364311|Dietary Supplement|Vitamac® Tag and Nacht capsules|"Vitamac® Tag und Nacht Kapseln: Dosage 1 capsule Vitamac® Tag per day ingested in the morning, 1 capsule Vitamac® Nacht per day ingested in the evening.~Vitamac® Tag: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, ginkgo biloba 10mg, Flavinoids 25mg, Fishoil 300mg, administered for 12 weeks Vitamac® Nacht: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selen 20µg, Ginkgo Biloba 10mg, Flavinoids 25mg, Alpha Lipon acid 150mg), administered for 12 weeks"
45504301|NCT01319513|Other|whey protein bolus|single dose of 25 g whey protein
45504302|NCT01319513|Other|whey protein pulses|10 2.5 g pulses of whey protein
45504303|NCT02792192|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in respective arm.
45504304|NCT02792192|Biological|Bacille Calmette-Guérin|For Cohort 1B, BCG will be administered (intravesically) at de-escalated doses. De-escalation will be allowed for up to three dose levels of BCG: full dose (50 mg), 66% of full dose, and 33% of full dose. After the MTD or MAD is determined for Cohort 1B, MTD/MAD will be used for all subsequent participants enrolled into Cohorts 1B, 2, and 3 (provided MAD or MTD is determined to be either full dose or 66% of a full BCG dose).
45396742|NCT00449033|Drug|Gemcitabine|Chemotherapy component; Gemcitabine 1250 mg/m^2 IV
45396743|NCT00449033|Drug|Cisplatin|Chemotherapy component; Cisplatin 75 mg/m^2 IV
45504305|NCT02643498|Radiation|Stereotactic Body Radiotherapy (SBRT)|
45697314|NCT03344211|Other|Laboratory Biomarker Analysis|Correlative studies
45697315|NCT03344211|Radiation|Radium Ra 223 Dichloride|Given IV
45697316|NCT04400565|Behavioral|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the Pathways to Recovery (PTR): A Strengths Recovery Self-Help Workbook (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
45396744|NCT01024127|Other|Laboratory Biomarker Analysis|Correlative studies
45504306|NCT01359683|Device|Dataq Instruments DI-158|Data Acquisition Device (connects to room instrumentation)
45504307|NCT05187949|Other|Mixed-method approach|Quantitative survey (cross-sectional design) and qualitative analysis (focus groups)
45504308|NCT03609996|Device|Panretinal Photocoagulation|Laser treatment for PDR
45504309|NCT03609996|Drug|Lucentis|Intraviteral injection
45504310|NCT05178199|Behavioral|RPSG|The RPSG program include sharing successful experience, progressive muscle relaxation (PMR), and mindfulness-based stress reduction (MBSR). The duration is at last 8 weeks and includes 1 hour per week of RPSG activities.
45504311|NCT05178199|Behavioral|AVMBM|"The duration is also at last 8 weeks and includes encouraging to use 5 minutes Audio and Video Mindfulness of Breathing Meditation (AVMBM) per week."
45504312|NCT02088008|Drug|cinidipine, valsartan|
45504313|NCT02033772|Procedure|Thoracoscopic surgery|
45504314|NCT01361789|Drug|parecoxib, valdecoxib, etoricoxib|"40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.~After retraction of parecoxib from the market:~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery"
45504315|NCT01361789|Drug|Dexamethasone|8 mg IV
45504316|NCT01361789|Drug|parecoxib, valdecoxib, parecoxib and dexamethasone|combination of both drugs
45504317|NCT05168761|Procedure|partial nephrectomy|
45504318|NCT02081612|Behavioral|Nutrition Education|12 educational weight management group session each addressing a different weight loss topic
45504319|NCT02081612|Procedure|Acupuncture|12 weight loss acupuncture session using both body and auricular points.
45396745|NCT01024205|Drug|sunitinib malate|
45396746|NCT01024205|Other|laboratory biomarker analysis|
45396747|NCT01024205|Procedure|adjuvant therapy|
45396748|NCT01024205|Procedure|neoadjuvant therapy|
45396749|NCT01024205|Procedure|therapeutic conventional surgery|
45396750|NCT00448019|Drug|Fludarabine|25 mg/m^2 IV over 30 minutes daily for 3 days
45396751|NCT00448019|Drug|Cyclophosphamide|250 mg/m^2 IV over 30 minutes daily for 3 days
45504320|NCT02964507|Drug|GSK525762|GSK525762 will be administered.
45504321|NCT02964507|Drug|Placebo|Placebo will be administered.
45504322|NCT02964507|Drug|Fulvestrant|Fulvestrant will be administered.
45504323|NCT01359761|Behavioral|Post Admission Cognitive Therapy (PACT)|Six (60-90 minutes) individual psychotherapy sessions administered over preferably 3 days of inpatient stay, up to 2 booster sessions during hospitalization, and 4 telephone booster sessions within 3-months post discharge
45504324|NCT02083874|Drug|CBD|
45504325|NCT01367197|Behavioral|exercise training|group based exercise training
45504326|NCT05188781|Drug|Pembrolizumab combined Anlotinib|Pembrolizumab 200 mg every 3 weeks, Anlotinib 12 mg/day, orally;2weeks treatment followed by 1week off
45504327|NCT02083952|Other|Swaddle Blanket|Two arms involve varying time spent in blanket
45504328|NCT01367353|Procedure|surgery or debulking surgery|surgery or debulking surgery
45504329|NCT01359839|Behavioral|Relaxation Response and Cognitive Behavioral Therapy|This is a group format which will meet once per week and teach the techniques of cognitive behavioral therapy as well as relaxation response meditation.
45504330|NCT03634735|Drug|Thiamine|Vitamine B1
45396752|NCT00448019|Drug|Rituximab|375 mg/m^2 IV on Day 1 by prolonged infusion. All subsequent doses 500 mg/m^2 IV 30-minute infusion.
45396753|NCT00448019|Drug|Bevacizumab|10 mg/Kg IV on Day 3, course 1 over 30-90 minutes
45504331|NCT03634735|Other|Placebo|Placebo tablets
45396754|NCT01024361|Device|CPAP|CPAP of 5 cm water pressure will be applied within 15 minutes after birth by Neopuff
45396755|NCT00457691|Drug|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
45396756|NCT00457691|Drug|irinotecan|180mg/m2 iv day 1 every 14 days
45504332|NCT03559322|Device|iNAP® Lite Sleep Therapy System|Class II intraoral devices for snoring and/or obstructive sleep apnea
45504333|NCT03634657|Radiation|Plain X-ray protection shield|Coronary angiography with mere X-ray protection shield
45504334|NCT03634657|Radiation|Protection shield & X-ray protective strips|Coronary angiography with X-ray protection shield & X-ray protective strips
45504335|NCT03634657|Radiation|Protection shield & protective strips & patient cut-outs|Coronary angiography with X-ray protection shield & X-ray protective strips & X-ray protection patient cut-outs
45504336|NCT04563195|Drug|tibulizumab (LY3090106)|subcutaneous injections of 300mg every 2 weeks over a period of 12 weeks
45504337|NCT02084108|Other|intervention|intervention group that will be provided, in addition, in-home multidimensional geriatric assessment with access to a 24h/7 day a week call service, and coordinated long-term follow-up.
45504338|NCT01371409|Other|continuous theta burst stimulation|80% active motor threshold, 600 pulses
46057039|NCT02714127|Other|Cervicovaginal lavage fluid collection|During colposcopy, the cervicovaginal region is rinsed for 2 minutes with 50 ml acetic acid (5%). This fluid is not discarded like it is done usually, but the remaining lavage fluid (5% acetic acid containing cervicovaginal fluid) will be collected.
45396757|NCT00457691|Drug|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
45396758|NCT00457691|Drug|sunitinib|37.5mg of blinded therapy every day for 28 days followed by 14 days of blinded therapy free period
45396759|NCT00457691|Drug|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
45396760|NCT00457691|Drug|irinotecan|180mg/m2 iv day 1 every 14 days
45396761|NCT00457691|Drug|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
45504339|NCT02084186|Other|herb-partitioned moxibustion|Ignited moxa cones are placed upon herbal cake. Herbs are smashed into powder. Every 2.8g medicine powder mix with 3g millet wine and then be pressed into herbal cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the herbal cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
45504340|NCT02084186|Other|bran-partitioned moxibustion|Ignited moxa cones are placed upon bran cake. Every 2.8g bran powder mix with 3g millet wine and then be pressed into bran cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the bran cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
45504341|NCT03170869|Device|Surefire Precision Infusion System|All patients enrolled in this protocol will receive DEB-TACE, which is the standard of care prescribed by their physician. Standard 5 Fr and 3 Fr catheters will be used to perform diagnostic angiography to map the hepatic vasculature to the tumor. Using standard technique, the target vessel feeding the tumor will be catheterized and DEB-TACE administered using the Surefire Precision catheter. The Doxorubicin dosing used in the DEB-TACE will be based upon tumor volume. DEB-TACE will be administered until the first of the following endpoints are reached: Achievement of target dose with stasis, leeching of contrast through the expandable tip and development of distal intrahepatic collaterals.
45504342|NCT02084342|Drug|tranexamic acid and sodium chloride injection|10mg/kg, IV (in the vein) for 30min, before incision. then at 1mg/kg/h, IV pump, until the surgery is over.
45504343|NCT02084342|Drug|normal saline|100ml, IV for 30min,before incision.
45504344|NCT02084342|Drug|desmopressin acetate injection|0.3μg/kg dissolved in 100ml NS，IV for 30min，before incision.
45504345|NCT03558542|Other|cardiopulmonary rehabilitation plus neurorehabilitation|Patients with stroke will undergo an accompanying structured cardiopulmonary rehabilitation program along with a neurorehabilitation program
45396762|NCT00457691|Drug|placebo|37.5mg of blinded placebo therapy every day for 28 days followed by 14 days of blinded therapy free period
45504346|NCT01371487|Drug|GSK1120212|Oral/once-daily single doses on Day 1 of Periods 1 and 2
45504347|NCT02084420|Drug|Ilaprazole|10mg 2 BID( 2 times / day), before breakfast and dinner
45504348|NCT02084420|Drug|Pantoprazole|40mg, BID(2 times / day), before breakfast and dinner
45504349|NCT01367431|Dietary Supplement|Xanthohumol|PK study with one capsule of one of the three doses randomly assigned
45504350|NCT01367509|Drug|Methylnaltrexone (MNTX)|
45396763|NCT00457301|Behavioral|HUI score card|Patients completed the HUI2 and HUI3 before the encounter with the clinician, the result was graphically represented in the HUI score card. Clinicians used the HUI score card as an extra tool to help them in the management of the patients
45396764|NCT00456755|Drug|Shi-Bi-Lin|4 weeks of treatment, dose of 1 g (two capsules), twice daily
45396765|NCT00456755|Other|Placebo|4 weeks of colormatched placebo capsules, dose of 1 g (two capsules), twice daily
45396766|NCT03820271|Other|SuperMELD|"The population of this arm will consist of patients newly enrolled in the National Liver Transplantation Waiting List for decompensated cirrhosis, whose liver function and MELD score are assessed at enrollment and then routinely reassessed at least quarterly during the waiting phase.~Patients will be followed from their listing to transplantation or discharge or death."
45396767|NCT00447005|Drug|Axitinib (AG-013736)|AG-013736 5mg twice daily [BID]
45396768|NCT01024439|Procedure|transumbilical single incision laparoscopic appendicectomy|"Patients will undergo transumbilical single incision laparoscopic appendicectomy. A single incision is made on umbilicus within the margin of umbilical skin ring. Peritoneal cavity is entered by open method and the fascia layer can be extended up to 2.5cm in length. A single incision laparoscopic device (Olympus) will be inserted. Conventional laparoscopic instruments will be used. Umbilical fascia will be closed by PDS-1 J-shape needle. Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. The umbilicus is reconstructed by interrupted 3-0 nylon by tacking the skin onto the fascia layers.~Three non-transparent dressings will be placed as if conventional laparoscopic appendicectomy has been done."
45504351|NCT02084498|Device|Automated bolus calculator|Training in Advanced Carbohydrate Counting and the use of an automated bolus calculator according to the BolusCal concept.
45504352|NCT02084498|Behavioral|Advanced Carbohydrate Counting|Training in advanced carbohydrate counting.
45504353|NCT01364545|Dietary Supplement|Ketone ester drink|Ketone drink - milligram per kilogram dose, consumed three times daily (at meal times)
45504354|NCT01364545|Dietary Supplement|Placebo (carbohydrate containing) drink|Placebo drink - containing carbohydrates, matched in calories to ketone, consumed three times daily
45504355|NCT02088086|Behavioral|BMI screening|Students in grades 3-8 will have their heights and weights measured annually at school and their BMIs calculated.
45504356|NCT02088086|Behavioral|BMI reporting|Schools will send a report home to parents that provides their child's height, weight, and BMI results.
45504357|NCT02088086|Behavioral|Fitness testing|Students in grades 5-8 will participate in five fitness assessments (curl-ups, sit-ups, push-ups, sit-and-reach, and the PACER test or mile run) annually at school.
45504358|NCT01364701|Drug|Sildenafil 100 mg|4 tablets for on demand use
45504359|NCT01364701|Drug|Tadalafil 20 mg|4 tablets on demand
45504360|NCT01364701|Drug|Combination half of maximal dose for sildenafil & tadalafil|4 tablets on demand
45504361|NCT02088242|Drug|Astaxanthin|Oral supplementation with the food supplement Astaxanthin. Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
45504362|NCT02088242|Drug|Placebo|3 capsules identical in shape, colour and size to the Astaxanthin capsules, which contain only the inactive ingredients of the same formulation.
45396769|NCT01024439|Procedure|conventional laparoscopic appendicectomy|"Patients will undergo conventional laparoscopic appendicectomy. A 10-mm subumbilical port will be inserted by open method. Two 5-mm working ports will be inserted under laparoscopic view at patient's left lower quadrant and suprapubic area. Umbilical fascia will be closed by PDS-1 J-shape needle.~Local anaesthetic agent , Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. All skin wound will be approximated with 3-0 nylon interrupted stitches and covered with non-transparent dressings."
45504363|NCT02440464|Procedure|Allogeneic HSCT|Eligible patients with a Human Leukocyte Antigen (HLA)-matched related or unrelated donor will undergo allogeneic hematopoietic stem cell transplant at Day 0. For GVHD prophylaxis, patients will be given Tacrolimus from Day -3 until at least 6 months following initiation, at an intravenous daily dose of 0.015 mg/kg. This will be combined with an intravenous administration of Methotrexate at 5 mg/m2 on Days +1, +3, +6, and +11.
45504364|NCT02440464|Drug|Fludarabine|Patients will receive conditioning treatment before and after HSCT. Fludarabine will be given at 30 mg/m2 intravenously on Day -6 through Day -3.
45504365|NCT02440464|Drug|Melphalan|Melphalan will be given at 70 mg/m2 intravenously on Days -4 and -3.
45396770|NCT01024517|Drug|GLPG0259 solution|single oral dose, GLPG0259, 50 mg oral solution
45396771|NCT01024517|Drug|GLPG0259|single oral dose, GLPG0259, 50 mg solid formulation
45504366|NCT02440464|Drug|Bortezomib|Bortezomib will be administered at 1.3 mg/m2 intravenously on Day -3.
45504367|NCT02440464|Drug|Ixazomib|Between 60 and 120 days following HSCT, patients randomized to the experimental arm will receive Ixazomib maintenance. Maintenance will begin at 3-mg oral doses on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule, following successful completion of 3 cycles at the previous dosage, for a total of 12 cycles.
45504368|NCT02440464|Drug|Placebo|Between 60 and 120 days following HSCT, patients randomized to the control group will be given 3 mg of placebo orally on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule following successful completion of 3 cycles of placebo maintenance at the 3-mg dose. This will continue for a total of 12 cycles.
45504369|NCT01367587|Drug|IV Methylnaltrexone|
45504370|NCT02088398|Drug|ACY-1215|
45504371|NCT03103321|Other|Internet-Based Intervention|"Receive Knowing your Options decision aid"
45504372|NCT03103321|Other|Internet-Based Intervention|"Receive Prostate Choice decision aid"
45504373|NCT03103321|Other|Best Practice|Undergo usual care
45504374|NCT03103321|Other|Quality-of-Life Assessment|Ancillary studies
45504375|NCT03103321|Other|Questionnaire Administration|Ancillary studies
45504376|NCT03103321|Other|Survey Administration|Ancillary studies
45504377|NCT03103321|Other|Laboratory Biomarker Analysis|Correlative studies
45504378|NCT02084576|Drug|Nepafenac|One drop in the study eye 3 times daily for 30 days
45504379|NCT02084576|Drug|Ketorolac|One drop in the study eye 4 times daily for 30 days
45504380|NCT03131453|Drug|CNP520 50mg|50 mg capsule
45504381|NCT03131453|Drug|CNP520 15mg|15 mg capsule
45504382|NCT03131453|Other|Matching placebo|Matching placebo for 15 and 50 mg capsules
45504383|NCT01364857|Genetic|search for polymorphisms of RASA1 gene|Blood sample ( 5 mL) at tne inclusion of the child DNA extraction and genetic analysis of the 24 exons of RASA1 gene after specific consent
45504384|NCT02084654|Drug|Exenatide 5 and 10 mcg 2 times a day|
45504385|NCT02084654|Drug|placebo|
45504386|NCT01367743|Drug|epinephrine perfusion|perfusion of commercial epinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
45504387|NCT01367743|Drug|norepinephrine perfusion|perfusion of commercial norepinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
45504388|NCT02084732|Drug|Sorafenib|drug
45504389|NCT02084810|Drug|activated recombinant human factor VII|"All subjects will receive one i.v. (intravenous, into the vein) injection of 90μg/kg.~Each subject will be allocated to two treatment periods separated by a wash-out period of a week."
45504390|NCT02084810|Drug|eptacog alfa (activated)|All subjects will receive one i.v. injection of 90μg/kg. Each subject will be allocated to two treatment periods separated by a wash-out period of a week.
45504391|NCT02780401|Other|Laboratory Biomarker Analysis|Correlative studies
45504392|NCT02780401|Biological|pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|Given ID
45504393|NCT02780401|Biological|Sargramostim|Given ID
45504394|NCT02533232|Drug|Minocycline|Minocycline 200mg per day
45697317|NCT05394454|Procedure|Bladder stimulation technique|The bladder stimulation technique consists of two consecutive maneuvers. In the first maneuver, the bladder is stimulated by tapping the suprapubic region for 30 seconds at a frequency of 100 touches per minute. In the second maneuver, circular massage is applied to the paravertebral region for 30 seconds. The two stimulation maneuvers will be repeated alternately for 3 minutes (180 seconds) until micturition begins.
45697318|NCT03274401|Device|Zenicor intermittent ECG device|At least two weeks of screening twice daily for atrial fibrillation using intermittent ECG recordings, and prolonged use of OAC-therapy if atrial fibrillation is detected
45504395|NCT01371799|Drug|Drug|Placebo
45504396|NCT01371799|Drug|Drug|4mg and 8mg Study drug
45504397|NCT02686814|Device|17mm MDT-2215 aortic valve bioprosthesis|
45504398|NCT03779828|Device|HOME LINK|Telemonitoring system which include web platform and connected devices.
45504399|NCT02673151|Procedure|Computed Tomography (CT) scan|PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).
45697319|NCT03274401|Device|5 day ECG patch|Selection of device for monitoring clinicians' choice
45504400|NCT02673151|Drug|68Ga-PSMA-11|68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11), administered by intravenous (IV) injection.
45504401|NCT02673151|Procedure|Positron Emission Tomography (PET)|PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).
45396774|NCT01565759|Drug|Lithium Carbonate|"The dose has been selected in order to achieve a therapeutic range of 0.6 - 0.8 mmol/L.~Dose titration Day 1: 1 capsule of 300 mg at bedtime Days 2 to 7: 1 capsule of 600 mg at bedtime Day 8: lithium serum levels will be tested and the dose will be adjusted proportionally to a target range of 0.6 - 0.8 mmol/L by increments of 150 mg or 300 mg."
45504402|NCT02436655|Procedure|surgical aortic valve replacement|open heart aortic valve replacement
45504403|NCT02082080|Other|Education|
45504404|NCT02082080|Other|Social support|
45504405|NCT02084966|Procedure|Procedure/Surgery: Transplantation: OCT of Kidney Transplant|Device: Optical Coherence Tomography of Kidney Transplant
45504406|NCT02942277|Biological|Pfs25M-EPA|The PpPfs25M and EcEPA lots, both manufactured at Walter Reed Bioproduction facility (Silver Spring, Maryland) in cGMP compliance, were used to manufacture the conjugate. PpPfs25M is a Pichia- expressed recombinant Pfs25 with a molecular mass of 18,713 Daltons.The Pfs25M- EPA was formulated as conjugated Pfs25M in 4 mM PBS to a 2X dilution of the high dose (188 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
45504407|NCT02942277|Biological|Pfs230D1M-EPA|The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM PBS to a 2X dilution of the high dose (160 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
45504408|NCT02942277|Other|AS01|AS01B adjuvant will also be provided as a single use vial by GSK, 100 microgram/mL MPL and 100microgram/mL QS21 in a liposomal formulation in a volume of 0.625 mL. One dose injected of AS01B corresponds to 50 μg QS21 and 50 μg MPL.
45504409|NCT02942277|Biological|Engerix-B|ENGERIX-B (hepatitis B vaccine; recombinant): is a sterile suspension of noninfectious hepatitis B virus surface antigen (HBsAg) for intramuscular administration. It contains purified HBsAg obtained by culturing genetically engineered Saccharomyces cerevisiae cells, which carry the surface antigen gene of the hepatitis B virus. Each 1-mL adult dose contains 20 g of HBsAg adsorbed on 0.5 mg aluminum as aluminum hydroxide. FDA approved for persons 20 years of age and older for a series of 3 doses on a 0-, 1-, 6-month schedule.
45504410|NCT02942277|Biological|Menactra|Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age
45504411|NCT02942277|Other|Normal Saline|Sterile isotonic (0.9%) normal saline will be commercially procured in the US and shipped to Mali at ambient temperature. Normal saline will be administered in a 0.5 mL dose as an intramuscular injection. Normal saline will also be used for diluting Pfs25M-EPA and Pfs230D1M-EPA prior to formulation with AS01B for the lower dose groups in Bamako, Mali.
45504412|NCT02942277|Drug|Coartem|Artemether/lumefantrine (Coartem(R)) is a licensed antimalarial in the US and Mali for treatment of uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Subjects who may have any contraindications to the use of these drugs will be excluded at screening. Coartem will be dosed with food and administered over 3 days for a total of 6 doses, as per package insert and standard adult dosing
45504413|NCT05042947|Device|double-loop clips|a new ligation method using the double-loop clips (D-L clips) technique
45396775|NCT00446849|Drug|MMX Mesalamine|MMX™ mesalamine 2.4g/day to 4.8g/day once-daily (QD) (two to four 1.2g tablets MMX™ mesalamine, dosed QD,respectively).
45396776|NCT01565837|Drug|Ipilimumab|Ipilimumab 10mg/kg administered intravenously over 90-minute period every 3 weeks for a total of four doses as tolerated. Maintenance ipilimumab (10 mg/kg intravenously every 3 months) will be administered beginning Week 24, as long as there is clinical benefit in the opinion of the investigator using immune related response criteria, and there are no novel or unexpected Grade 3 or 4 toxicities.
45504414|NCT05042947|Device|Titanium Clip|the Titanium Clip
45504415|NCT05505578|Behavioral|GamerFit Condition|Participants receive a Fitbit device, the GamerFit app on their mobile device, exergaming console and games (Nintendo Switch) (where applicable), and follow a 12-week exergaming curriculum provided by the app. Physical activity (PA) increases during the intervention up to 60 minutes/session. Other interventional aspects include weekly reminders, exercise and health related video materials, and weekly telehealth sessions with an intervention coach.
45504416|NCT05505578|Behavioral|Comparator Condition|Participants receive a Fitbit device, instructions on how to use it, and a booklet of healthy tips. They also get weekly reminders to charge, sync, and review their Fitbit data.
45697320|NCT05086107|Drug|BV100|Rifabutin for infusion
45396777|NCT01565837|Radiation|Stereotactic Ablative Radiosurgery (SART)|Definitive radiotherapy will be administered to up to 1-5 lesions using SART techniques after initial dose of ipilimumab. Radiotherapy will be timed before start of 3rd cycle of ipilimumab treatment to maximize synergy (week 6).
45396778|NCT00446459|Drug|mycophenolate mofetil (CellCept)|500mg - 1,000mg, taken PO, twice daily.
45504417|NCT01365013|Behavioral|DE-PLAN|structured group or individual educational sessions (4 to 5) on diet and physical activity, plus ongoing reminder contacts (e-mails, sms, etc) during 1 year
45504418|NCT01365013|Behavioral|Control group|Standard advice for lifestyle change
45504419|NCT02085044|Dietary Supplement|Ready-to-Used Supplement Food administration|
45504420|NCT02835963|Other|Data collection|Usual data collection
45504421|NCT03559244|Other|Dynamic compression brace|custom-fitted brace adjusts the pressure on the thoracic wall and enables lateral expansion of the thorax
45504422|NCT03559244|Other|Exercises|posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises
45504423|NCT04548375|Device|SCS|Conventional SCS implants approved through all payors(government and private) for FDA approved indications
45396779|NCT00456599|Drug|gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1, 8, and 15 of a treatment cycle.
45396780|NCT00456599|Drug|oxaliplatin|Oxaliplatin 85mg/m2 will be infused following gemcitabine over approximately 90 minutes on days 1 and 15 of a treatment cycle.
45396781|NCT00456599|Procedure|Radiation|The total dose in a three week treatment block will be 30 Gy in 2.0 Gy fractions.
45396782|NCT00456521|Drug|Naltrexone SR 32 mg/ bupropion SR 360 mg/ day|
45396783|NCT00456521|Drug|Placebo|
45504424|NCT02082236|Drug|Treatment Arm A: Sufenta®|Sufenta® intravenous (IV) (50 mcg/mL) 30 mcg infused over 1 minute
45504425|NCT02082236|Drug|Treatment B: Sufentanil SSM 30 mcg|single-dose SSM 30 mcg
45504426|NCT02082236|Drug|Treatment C: SSM 15 mcg|2 consecutive doses of SSM 15 mcg administered 20 minutes apart
45504427|NCT02082236|Drug|Treatment D: SSM 30 mcg|12 consecutive doses of SSM 30 mcg administered 1 hour apart
45504428|NCT04547673|Diagnostic Test|rigid nasal endoscopes|The endoscope is introduced through the nasal passage to observe, in sequence, the posterior nostril, superior and posterior walls of the nasopharynx, torus tubarius, pharyngeal opening of the auditory tube, and Rosenmu¨ller recess. The imaging light mode is set to conventional WLI and subsequently switch to NBI during the procedure, and representative images are collected and preserve for further analysis. All lesions, detected by either WLI or NBI, are biopsied.
45396784|NCT00456521|Behavioral|Intensive group lifestyle modification counseling|
45396785|NCT00456365|Drug|pravastatin|Pravastatin 20 mg daily (subject age 8-12 years) or 40 mg daily (subject age 13-21 years)
45504429|NCT02085122|Other|noninvasive ventilation|Ventilatory support with bilevel positive pressure was held for 30 minutes with the volunteer sitting comfortably. A fan with two pressure levels (Vivo 40 Bi-Level, General Electric Company), which was attached to the face of the individual through a face Macara ( Respironics), was initially adopted one of 15 cmH2O IPAP and EPAP was used 5 cmH2O, making admissible pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
45504430|NCT02082314|Procedure|RFA Vertebroplasty|
45504431|NCT02085200|Other|horizontal adduction stretch with scapular stabilization|Scapular is stabilized during manual horizontal adduction stretch
45504432|NCT02085200|Other|Horizontal adduction stretch without scapular stabilization|Scapula stabilization is not performed during horizontal adduction stretch
45504433|NCT03557996|Drug|Silver Diamine Fluoride|SDF will be applied with a brush
45504434|NCT03557996|Drug|Sodium Fluoride Varnish|NaF will be applied with a brush
45504435|NCT03559166|Drug|BLD-2660|Randomized to active product or placebo
45504436|NCT02088710|Behavioral|Enhanced information about endocrine therapy|Enhanced information about endocrine therapy, extending clinical routine information
45504437|NCT02085278|Device|Apollo Micro Catheter device|Detachable Tip Micro catheter
45504438|NCT03559088|Other|Migraine App|Smart phone app used to report migraine burden to the EHR.
45504439|NCT02296801|Drug|Letrozole|
45396786|NCT00456365|Drug|Placebo|Placebo daily
45396787|NCT03843047|Drug|3 mg/mL nicotine strength e-liquid|Availability of 3 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
45396788|NCT03843047|Drug|6 mg/mL nicotine strength e-liquid|Availability of 6 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
45504440|NCT02296801|Drug|palbociclib|
45396789|NCT03843047|Drug|12 mg/mL nicotine strength e-liquid|Availability of 12 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
45504441|NCT02082470|Other|follow-up care|Undergo survivorship care planning
45504442|NCT02082470|Other|active surveillance|Undergo cancer surveillance
45504443|NCT02082470|Other|questionnaire administration|Ancillary studies
45504444|NCT02085434|Behavioral|FITLINE practice-based referral program|The FITLINE practice-based referral program provides pediatric practices an easily accessible resource to help families make AAP-recommended Stage 1 lifestyle changes. The program includes a pediatric practice-based component (systems to identify overweight and obese children ages 8-12, a brief pediatric provider-delivered intervention, referral to the FITLINE counseling program, and feedback from the FITLINE nutritionist) and a parent support component(eight weekly FITLINE counseling telephone calls delivered by centrally located nutritionists). Providers receive a summary from the nutritionist of the progress made by families so they may support maintenance of an improved lifestyle, or refer for additional intervention.
45504445|NCT02859324|Drug|CC-122|
45504446|NCT02859324|Drug|Nivolumab|
45504447|NCT02085512|Procedure|Neurocognitive retraining Web Based Intervention|"Neurobehavioral training will be delivered through the web, with prompting for training tasks accomplished through daily emails that include a single integrated log-in system using a customized implementation with OneLogin. All training tasks have game-like features making them visually engaging, and motivating. The training tasks provide immediate feedback about performance, and are specifically designed to target circuitry critical for executive functioning (EF) and emotional reactivity."
45504448|NCT02085512|Other|Control, web-based tasks|No training modules
45504449|NCT01365247|Behavioral|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure|A manualized, twelve-week intervention applying cognitive-behavioral strategies and prolonged exposure (PE) techniques to address substance use and trauma related issues.
45396790|NCT03843047|Drug|24 mg/mL nicotine strength e-liquid|Availability of 24 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
45504450|NCT01365247|Behavioral|Relapse Prevention Treatment|Relapse Prevention Treatment is a cognitive-behavioral skills training approach to initiating and maintaining substance use-related goals.
45504451|NCT01365247|Behavioral|Active Monitoring Control Group|Participants meet with study staff on a weekly basis for the self-monitoring of PTSD and SUD symptoms. Visits consists of self-report assessments, urine toxicology, and a brief check-in with staff to confirm general health and safety.
45504452|NCT02085590|Biological|BCG vaccine|
45504453|NCT02085590|Biological|Lipopolysaccharide (LPS) E. Coli 1 ng/kg intravenously|
45504454|NCT02143063|Behavioral|prize contingency management on a traditional twice weekly schedule for cocaine abstinence|
45504455|NCT02143063|Behavioral|prize contingency management on a variable interval schedule for cocaine abstinence|
45504456|NCT02143063|Behavioral|standard care|
45504457|NCT02088866|Drug|Transdermal Lidocaine|The intervention will use 5% commercially available transdermal lidocaine in clinical practice for the treatment of tinnitus. This dose will be tailored to patient preference.
45504458|NCT02859246|Drug|Mucinex®|Mucinex®
45504459|NCT02088944|Drug|Infliximab|
45504460|NCT03609606|Drug|D013, D326 and D337|Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
45504461|NCT03609606|Drug|D013|Daily oral administration of 1 tablet under fasting conditions for 7 days
45504462|NCT03609606|Drug|D326 and D337|Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
45504463|NCT02073097|Drug|Carfilzomib|"Given IV, according to dose level. Cohorts begin with dose level (DL)1, escalated in standard 3+3 design to identify a recommended phase 2 dose DL (-2) 11 mg/m2 on day 1 and 2 every 21 days, cycles 1-6~DL (-1) 15 mg/m2 on days 1 and 2 every 21 days, cycles 1-6~DL (1) 20 mg/m2 days 1,2 every 21 days, cycles 1-6~DL (2) 20 mg/m2 days 1,2 of cycle 1 followed by 27 mg/m2 days 1,2 every 21 days for cycles 2-6.~DL (3) 20 mg/m2 days 1,2 of cycle 1 followed by 36 mg/m2 days 1,2 every 21 days for cycles 2-6.~DL(4) 20 mg/m2 days 1,2 of cycle 1 followed by 45 mg/m2 days 1,2 every 21 days for cycles 2-6~DL (5) 20 mg/m2 days 1,2 of cycle 1 followed by 56 mg/m2 days 1,2 every 21 days for cycles 2-6"
45504464|NCT02073097|Biological|Rituximab|Given IV (375mg/m^2)
45504465|NCT02073097|Drug|Cyclophosphamide|Given IV (750mg/m^2)
45504466|NCT02073097|Drug|Doxorubicin hydrochloride|Given IV (50mg/m^2)
45504467|NCT02073097|Drug|Vincristine sulfate|Given IV (1.4mg/m^2)
45504468|NCT02073097|Drug|Prednisone|Given PO (100mg)
45504469|NCT02073097|Drug|Pegfilgrastim|6 mg SC day 4 (every 21 days). Filgrastim 300 or 480 mcg IV/SC daily days 1-10 may be substituted if pegfilgrastim is not available. ONPROTM is also an acceptable method of administration.
45504470|NCT02073097|Drug|Acyclovir|PO (400mg)
45504471|NCT02082548|Other|Educational Intervention|This intervention will contain educational materials for both patients and providers that are specific to the needs in each participating country
45554692|NCT03754335|Procedure|Lumbar puncture|"Patient will be managed according to the current international recommendations in the Toulouse acute stroke center.~In the absence of clear recommendation in the literature headache will be treated according to our local predefined analgesic protocol: paracetamol 1g/6 h, and if the numerical scale ≥ 4 : continuous intravenous morphine starting at 1mg/h and increased per 0.5 mg/h every hour if numerical scale remains ≥ 4.~Lumbar puncture will be performed between day 3 and day 5 after subarachnoid hemorrhage onset by an independent scientist from our clinical investigator center. 30-mL CSF will be removed by LP.~Sham LP consisting in superficial skin puncture by a subcutaneous needle (27 gauge needle) during the usual procedure will be performed at the same time point."
45396791|NCT01565915|Device|Perlane-L|Perlane-L Injection in the midface
45396792|NCT01565915|Other|Non-treatment|Non-treatment Arm
45554693|NCT05498597|Drug|AMT-151|Administered intravenously
45396793|NCT01027169|Drug|safinamide|single dose of 50mg safinamide on Day 1
45396794|NCT01027169|Drug|safinamide|single dose of 50mg safinamide on Day 1
45396795|NCT01027169|Drug|safinamide|single dose of 50mg safinamide on Day 1
45504472|NCT04523298|Procedure|Non-ablative vaginal Erbium YAG laser treatment|"There are 3 visits where vaginal application of laser will be performed, with a 4-weeks interval. If needed, 3 extra laser applications can be added to the treatment (ie. with a maximum of 6 applications). Each application lasts around 15 minutes. The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia(24)) with SMOOTH mode setting, which enables non-ablative, thermal-only operation(25). The parameters are selected based on extensive preclinical and clinical studies(26,27,28).~Each laser treatment session consists of a full vaginal canal irradiation (using a 360° circular adapter), followed by additional irradiation of the prolapsed anterior wall (using a 90° angular adaptor) and concluded with irradiation of the vestibule area."
45504473|NCT04523298|Other|Pelvic floor exercises (PFE)|Standard PFE in Belgium are 9 sessions with a pelvic floor physiotherapist of choice, which can be extended by another 9 sessions, if clinically indicated. There are different strategies, though that will be on discretion of the physiotherapist. We will register the type of physiotherapy (standard (PFMT) versus assisted pelvic floor muscles training (APFMT)), number of completed sessions and duration of therapy. What is exactly done by the patient is registered as a variable.
45504474|NCT02089022|Other|Physiotherapy resources|The application of ice has been accomplished by means of a plastic bag containing 1.5 kg of crushed ice. The duration of the application was 30 minutes. The use of shortwave diathermy was performed by means of rectangular electrodes having a duration of 20 minutes.
45504475|NCT03609528|Device|CamPROBE|To be completed
45504476|NCT02082626|Drug|Eribulin mesylate|
45504477|NCT03610152|Behavioral|Hospital Policy change|Implementation of a hospital wide policy whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologist based on their clinical assessment of the patient.
45504478|NCT02921997|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
45504479|NCT02921997|Biological|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|Inactivated monovalent subvirion H3N2v vaccine containing hemagglutinin (HA) of A/Minnesota/11/2010 NYMC X-203 virus.
45504480|NCT02921997|Biological|Monovalent influenza A/H7N9 virus vaccine|Monovalent influenza A/H7N9 virus vaccine.
45504481|NCT02089100|Radiation|stereotactic body radiation therapy|
45504482|NCT02089100|Radiation|Systemic treatment|
45504483|NCT01083433|Behavioral|Diabetes related psychological counseling and education|The psychology intervention is based in part on an intervention to maintain parental support for diabetes care in adolescence which was developed by Anderson and colleagues (1999). The first session will include education to parents and children regarding the importance of sharing responsibility for treatment related tasks. The second session will include a discussion of the treatment sharing plan developed at the first visit and problems that may have occurred will be discussed. The third session will include a discussion of planning for possible future problems. Visits 1, 2, and 3 will include 30 minutes of diabetes education.
45504484|NCT01083433|Device|Continuous Glucose Monitor|Patients in the intensive diabetes clinic plus CGM group will wear the iPro after the baseline visit followed by every month for 4 months.
45504485|NCT02082704|Behavioral|SE Game on DSME|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
45504486|NCT02082704|Behavioral|SE Game on American History|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
45504487|NCT02791490|Drug|Sitagliptin|Oral tablet, 100 mg, once daily at approximately the same time each day
45504488|NCT02791490|Drug|Placebo|Oral tablet, once daily at approximately the same time each day
45504489|NCT02791490|Drug|Metformin IR|All participants will take Met-IR as background medication. Initially, they will take 1 x 500 mg tablet Met-IR b.i.d. (1000 mg/day). After randomization, all participants will be titrated to 2 x 500 mg tablets of Met-IR b.i.d. (2000 mg/day).
45504490|NCT02821143|Other|usual palliative care|Residents in the control group will receive usual palliative care usually delivered in their nursing homes , according to the habits of the healthcare team and their physician.
45504491|NCT02821143|Other|Telemedicine consultation|"Establishment of an initial multiprofessional Telemedicine consultation involving a palliative care physician and / or geriatrician, and other physician coordinator of nursing homes, health care team and if possible the patient's treating physician (patient and / or family may participate if they want to).~The aim is to define and formalize:~Aid to collection and application of advanced directives according to Leonetti Act if the resident is able to do so, or collection of confidence personal choices.~Definition of the objectives of care and patient's life and therapeutic adaptation with a focus on pain and uncomfortable symptoms.~Access to a mobile team of palliative care or geriatric hospitalization at home, a hospice network, if the patient's situation requires.~In case of medical worsening :~Possibility of access to consultations and use of emergency by tele-expertise or decision support within a maximum period of 72 hours, with the same objectives that above."
45504492|NCT01368289|Procedure|Endoscopic Mucosal Resection|Endoscopic Mucosal Resection of large sessile colonic polyps.
45554694|NCT02440100|Drug|PF-06648671|experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days
45554695|NCT02440100|Drug|Midazolam|commercial available oral solution of 2 mg midazolam as CYP3A probe substrate for drug interaction evaluation. Midazolam will be given as single dose with and without co-administration of PF-06648671
45504493|NCT02660775|Behavioral|schizophrenia|"The battery (ClaCoS) is composed by 6 tests and several scores will be recorded for each:~for emotion perception : Facial emotions recognition task (TREF)~for theory of mind : Movie for the assessment of social cognition ( MASC-VF)~for attributional bias : Ambiguous Intentions Hostility Questionnaire ( AIHQ)~for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~for empathy :Questionnaire of cognitive and affective empathy ( QCAE) for people with schizophrenia~for self assessment : Self - assessment of social cognition (ACSo)"
45396796|NCT00455741|Drug|Estradiol infusion|Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr.
45396797|NCT00455741|Drug|Progesterone infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.
45396798|NCT00445679|Drug|DVS SR|Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper
45396799|NCT00445679|Drug|Paroxetine|20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper
45396800|NCT00455429|Drug|Placebo|Matching placebo capsules to JNJ-26113100 (50 milligram [mg]) orally once daily or 100 mg orally once daily or 100 mg orally twice daily or 250 mg orally twice daily for 6 weeks.
45504494|NCT02660775|Behavioral|Autism|"The battery (ClaCoS ) is composed by 6 tests and several scores will be recorded for each:~for emotion perception : Facial emotions recognition task(TREF ): total score, score per emotion, detection levels~for theory of mind : Movie for the assessment of social cognition (MASC ) :total score, error type~for attributional bias : Ambiguous Intentions Hostility Questionnaire (AIHQ) :hostility score, attribution score, aggression score~for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~for empathy : Empathy quotient (EQ)~for self assessment : Self - assessment of social cognition ( ACSo ): total score and scores per processes"
45504495|NCT02660775|Behavioral|Healthy controls|only social cognitive measures
45504496|NCT01365325|Other|handled echocardiography in home monitoring program|home monitoring with clinical evaluations and ECG every three months and echocardiography examinations at the 6th, 12th and 18th month
45504497|NCT01365325|Other|ecg and clinical evaluation in home monitoring program|home monitoring with clinical evaluations and ECG every three months
45504498|NCT01368367|Other|Intensive exercise|Both groups, stretching exercise monitored once per week Intensive exercise group An aerobic and resisted exercise program for a minimum of three times per week for a total of approximately 60 minutes per session for six weeks. Aerobic exercise will be conducted on a treadmill, exercise bike or arm ergometer at an intensity of 80 % of VO2peak during initial assessment. For resistance exercise, the three repetition maximum (3RM) (maximum weight able to be lifted a maximum of 3 times) will be established and then resisted exercise will be commenced at 60% of the 3RM in the first week. Resisted exercise will then be progressed weekly by 5-10% by increasing the number of repetitions or the weights lifted. All resisted exercises will be done using variable resistance machines or free weights.
45504499|NCT02833935|Behavioral|Physical Activity Intervention|"The PA intervention will be delivered in a virtual face-to-face format using the secure and confidential Remote Education, Augmented Communication, Training and Supervision online video-based software. Intervention participants will receive 8 PA sessions over 2 months (1/week), following collaborator specific telephone-based PA counselling protocol. The counsellor will individually tailor her approach to each participant by understanding the participant's past and current PA experiences, motives to be physically active, salient concerns and barriers regarding PA, and physical home environment. Throughout the intervention, the PA counsellor and participants will co-construct and collaboratively adapt the intervention with the participants."
45504500|NCT02085746|Other|Defining Sexual Activity Questionnaire|
45504501|NCT04635631|Drug|talazoparib|Talazoparib will be administered orally on a continuous basis. Each cycle will consist of 28 days.
45396801|NCT00455429|Drug|JNJ-26113100 (50 mg) once daily|JNJ-26113100 (50 mg) capsules orally once daily for 6 weeks.
45396802|NCT00455429|Drug|JNJ-26113100 (100 mg) once daily|JNJ-26113100 (100 mg) capsules orally once daily for 6 weeks.
45396803|NCT00455429|Drug|JNJ-26113100 (100 mg) twice daily|JNJ-26113100 (100 mg) capsules orally twice daily for 6 weeks.
45396804|NCT00455429|Drug|JNJ-26113100 (250 mg) twice daily|JNJ-26113100 (250 mg) capsules orally twice daily for 6 weeks.
45396805|NCT00445601|Drug|gemcitabine hydrochloride|Given intravesically
45396806|NCT00445601|Other|placebo|Given intravesically
45396807|NCT00444587|Drug|Second line chemotherapy|As prescribed
45396808|NCT00444587|Drug|trastuzumab [Herceptin]|6mg/kg iv every 3 weeks
45396809|NCT00455195|Biological|alglucosidase alfa|IV infusion of 20 mg/kg; every other week (qow)
45396810|NCT00235716|Drug|dl-alpha-tocopherol|"Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E."
45504502|NCT02085824|Drug|Enoxaparin|
45504503|NCT02085824|Drug|rivaroxaban|
45504504|NCT02085824|Drug|dabigatran|
45504505|NCT04463667|Other|exercise|Collect all basic information including intrahepatic fat and fibrosis severity, and assign them to the exercise intervention group (n = 80) and the observation group (n = 20) after conditional screening.
45504506|NCT01368445|Drug|azelastine hydrochloride 0.15% Nasal Spray|1644 mcg, 2 sprays per nostril twice daily AM & PM)
45504507|NCT01368445|Drug|azelastine hydrochloride 0.15% and Placebo|822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)
45504508|NCT01368445|Drug|Azelastine 0.1%, Nasal Spray|1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM & PM)
45504509|NCT02085902|Drug|Ropivacaine|
45504510|NCT02654223|Biological|MG56 Mannosylated 500 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
45504511|NCT02654223|Biological|MG56 Mannosylated 1000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 1000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
45504512|NCT02654223|Biological|MG56 Mannosylated 3000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 3000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
45504513|NCT02654223|Biological|MG56 Mannosylated 5000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 5000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
45504514|NCT02654223|Biological|MG56 Mannosylated 500 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 mTU (Mannosylated Therapeutic Units)/ml sublingual
45504515|NCT02654223|Biological|MG56 Mannosylated 1000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 1000 mTU (Mannosylated Therapeutic Units)/ml sublingual
45504516|NCT02654223|Biological|MG56 Mannosylated 3000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 3000 mTU (Mannosylated Therapeutic Units)/ml sublingual
45504517|NCT02654223|Biological|MG56 Mannosylated 5000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 5000 mTU (Mannosylated Therapeutic Units)/ml sublingual
45504518|NCT02654223|Biological|Subcutaneous placebo|Comparison between placebo and active group
45504519|NCT02654223|Biological|Sublingual placebo|Comparison between placebo and active group
45504520|NCT01368523|Drug|nilotinib|
45504521|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 1|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
45504522|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 2|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
45504523|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 3|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
45504524|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 4|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
45504525|NCT01368601|Procedure|CPAP (Continuous airway pressure)|To evaluate if continuous positive airway pressure (CPAP) on the lung undergoing lobectomy can decrease the inflammatory response and PPC.
45504526|NCT01368679|Procedure|Endoprothesis Implantation|stent implantation in the abdominal artery using endovascular
45504527|NCT02507973|Other|Airway Pressure Release Ventilation|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that switches between high (PHigh) and low (PLow) continuous positive airway pressure while allowing spontaneous breathing at both phases. Alveolar recruitment and oxygenation occur during PHigh whereas ventilation occurs during brief releases to PLow.
45504528|NCT02507973|Other|Low Tidal Volume Ventilation|After enrollment and collection of baseline Intracranial pressure and hemodynamic status for 30 minutes the participants will undergo low tidal volume mechanical ventilation (LOTV), serving as a control mode of ventilation. LOTV is most commonly used for trauma patients with lung injury. LOTV provides oxygen in smaller amounts, without overstretching the lungs
45504529|NCT03558386|Behavioral|ePRO survey|An electronic patient reported outcomes survey will be completed by the patient.
45504530|NCT02086214|Device|Proprioceptive pressure therapy|Proprioceptive pressure therapy using a a LYCRA® compressive sleeve initially used in burn therapy : 15 to 25 mmHg.
45504531|NCT02086214|Device|Control|LYCRA® non-compressive sleeve initially used in burn therapy : < 5 mmHg.
45504532|NCT01368757|Drug|Revlimid|"Dose escalation 5mg - 10mg - 15mg - 20mg in cohorts of three patients~The first step of phase I will be 5 mg lenalidomide in a daily regimen, the next step will be 10 mg in a daily regimen, the dosis of the following steps will be increased by 5 mg each until dose limiting toxicity (DLT) is reached.~Phase II will be started at the MTD (1 dose step below DLT) and will be administered in a daily regimen."
45554696|NCT02440100|Drug|Placebo|Matching placebo which will be given as oral suspension, once a day for 14 days
45554697|NCT03524313|Diagnostic Test|End tidal carbon monoxide|"Evaluation of cardiac output estimated by transthoracic echocardiography and end tidal carbon monoxide~Evaluation of cardiac output estimated by transthoracic echocardiography and portal veinous velocity~Evaluation of femoral veinous velocity"
45504533|NCT04502121|Behavioral|EXPECT: Preoperative optimization of cardiac valve patient's expectations|The psychological, preoperative intervention follows a treatment manual. Patients get a personal intervention one day before surgery (30-40 minutes). It includes the development of an individual, subjectively perceived disease model, the treatment outcome expectations and the personalized outcome expectancy. Additionally they get two booster telephone calls 4 and 8 weeks after the surgery to recall the discussed topics and to talk about their recovery process (10-15 minutes).
45504534|NCT02082938|Device|Bracing|Twice a week, for a period of 5 weeks, before the sessions in the physiotherapy clinic the patients participating in the study were asked to walk at a self-selected speed on flat ground along a corridor 50 meters long, with the brace being used for fifteen minutes of gait retraining of the affected side.
45396811|NCT00235716|Drug|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
45504535|NCT04893187|Drug|SSS17|SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.
45504536|NCT04893187|Drug|Placebo|Matched placebo.
45504537|NCT03558308|Behavioral|Computer based cognitive rehabilitation|Computer based cognitive rehabilitation is a supplementary computerized tool for cognitive rehabilitation design to train various cognitive functions. Many programmes are available. The current study investigates the effects on two such programmes on rehabilitation of executive functions in the chronic phase after acquired brain injury.
45504538|NCT03558308|Other|Sham computerized gaming|Sham training with generally stimulating computer-games
45504539|NCT02086292|Procedure|2 ml 1% Lidocaine|
45504540|NCT02086292|Procedure|1 ml 2% Lidocaine|
45504541|NCT03558932|Diagnostic Test|pleural biopsy|diagnostic sampling
45504542|NCT02769273|Device|Percutaneous Transluminal Angioplasty|
45504543|NCT02083016|Device|Ablation guided by conventional mapping.|Substrate mapping and ablation of ventricular tachycardia.
45504544|NCT02083016|Device|Ablation guided by ultra-high density mapping with multielectrode catheter.|Substrate mapping and ablation of ventricular tachycardia.
45504545|NCT02086370|Procedure|Standard PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx.
45396812|NCT00235716|Drug|dl-alpha-tocopherol|"Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E."
45396813|NCT00235716|Drug|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
45396814|NCT00235716|Drug|Placebo|Matching placebos for dl-alpha-tocopherol and memantine.
45396815|NCT00274742|Biological|Blinatumomab (MT103)|Doses from 0.5 to 120 µg/m^2/24hours by continuous intravenous infusion
45396816|NCT03973398|Procedure|Quadratus Lumborum block|ultrasound guided Quadratus Lumborum block for postoperative pain
45396817|NCT03970044|Drug|Exenatide 2 MG|Glucagon-like peptide-1 receptor
45396818|NCT03970044|Drug|Dapagliflozin 10 MG|sodium-glucose co-transporter 2 (SGLT2) inhibitor
45396819|NCT00283400|Drug|25% human albumin|25% human albumin: after approval by the Data and Safety Monitoring Board dosage tier would be escalated to the subsequent higher level sequentially.
45396820|NCT00444275|Drug|esomeprazole (Nexium®)|"This randomized study was conducted on parallel groups and included two phases:~One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed"
45504546|NCT02086370|Procedure|Radical PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal.
45504547|NCT02083172|Device|Ultrasound Cardiac Output Monitor and 2 D-Echo|Hemodynamic measurements obtained by 2D-Echo and USCOM will be compared.
45504548|NCT05721105|Other|Quality of life assessment using questionnaires|Several quality of life questionnaires will be submitted to the patients and their parents. The questionnaires will be adapted to the age of the patients.
45504549|NCT02425644|Drug|ponesimod|film-coated tablet with 20 mg ponesimod, administered orally once daily in the morning
45504550|NCT02425644|Drug|teriflunomide|film-coated tablet with 14 mg teriflunomide, administered orally once daily in the morning
45504551|NCT02184741|Drug|GB-0998|Subjects received GB-0998 at 400 mg/kg body weight once daily for 5 days until 6 weeks and 6 days of gestation after confirmation of the gestational sac by ultrasonography.
45504552|NCT02184741|Drug|Placebo|Subjects received the same dose of saline as GB-0998 for 5 days after confirmation of the gestational sac by ultrasonography, up to 6 weeks and 6 days of gestation.
45504553|NCT02086526|Drug|Metformin|Approximately 37 patients will start metformin therapy 3 months after their visit 2. All other patients will receive metformin therapy at their visit 2.
45504554|NCT04180995|Drug|TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®)|TORIPALIMAB INJECTION(JS001 ) combined with chemotherapy, 3mg/kg, Q2W,up to 1 years of treatment.
45504555|NCT02627690|Other|islet transplanted|islet transplantation
45504556|NCT02627690|Other|non islet transplanted|no islet transplantation (for a non nephrologic reason)
45504557|NCT03558776|Dietary Supplement|linseed oil|linseed oil and defined background diet
45504558|NCT02089178|Procedure|intravenous anesthesia|total intravenous anesthesia group: propofol-remifentanil
45504559|NCT02089178|Procedure|inhalation anesthesia|inhalation anesthesia group: sevoflurane-remifentanil
45504560|NCT02089178|Drug|propofol-remifentanil|
45504561|NCT02089178|Drug|sevoflurane-remifentanil|
45504562|NCT02089256|Drug|Liraglutide|"Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated.~GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection)."
45504563|NCT02090816|Procedure|Surgery of liver and lung|Simultaneous resection of liver and right lung metastases in a single surgical session through a new approach
45504564|NCT04099329|Behavioral|Pre-game Safety Huddles|Coaches will be trained to lead Pre-game Safety Huddles by the RA with the study using a multi-media tool we have developed. Huddles will be brief (1-2 minutes) and will primarily focused on 1) encouraging concussion reporting and 2) encouraging good sportsmanship
45504565|NCT02086760|Other|Ultrasonography with oral hydration|Before, 30 min and 90 min following oral hydration
45504566|NCT02086760|Radiation|Scintigraphy|
45504567|NCT02861664|Other|Stannous fluoride (SnF2)|Dentifrice containing 0.454% weight by weight (w/w) SnF2 and 0.072% w/w NaF
45504568|NCT02861664|Other|Sodium monofluorophosphate (SMFP)|Dentifrice containing 1400 ppm fluoride as SMFP
45849653|NCT05740176|Device|Anterior Cervical Discectomy and Fusion|Anterior cervical discectomy is a surgical procedure that was developed to treat damaged cervical discs by relieving pressure on the nerve roots or on the spinal cord by removing the ruptured disc. The operation is performed by reaching the cervical spine through a small incision in the front of the neck. The soft tissues of the neck are then separated allowing for the disc to be removed. Anterior cervical discectomy has proven to be a safe and effective procedure for the treatment of degenerative disc disease. The anterior approach allows direct visualization of the entire interspace and wide decompression of the anterior aspect cervical spinal cord and nerve roots. It may be undertaken in cases of multilevel disease and interbody fusion may be performed if required
45849654|NCT05739396|Other|core stabilization|The treatment session lasted one hour with short breaks of around 10 minutes and will be conducted three times per week for twelve successive weeks
45849655|NCT05739240|Procedure|Osteosynthesis|Osteosynthesis of distal radius fractures
45849656|NCT05723484|Device|GIFT Device|The GIFT device - immune-based lateral flow test for reproductive-aged, non-pregnant in resource-limited settings attending sexual reproductive health (family planning) clinics, community health centers, hospitals, and mobile clinics. The test involves the qualitative detection of genital inflammation caused by asymptomatic STIs and BV in self- or clinician-collected lateral vaginal wall swabs, with results available in less than 20 minutes.
45849657|NCT05711784|Other|Phaseolean (White Kidney Bean Standardized Extract) 1500 mg Capsules|"Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.~Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water."
45396821|NCT00444275|Drug|Xolaam®|"This randomized study was conducted on parallel groups and included two phases:~One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed"
45396822|NCT00454805|Drug|AZD2171|Oral tablet
45396823|NCT00454805|Drug|Fulvestrant|intramuscular injection
45396824|NCT00283244|Drug|erlotinib hydrochloride|given orally
45396825|NCT00283244|Drug|gemcitabine hydrochloride|given IV
45396826|NCT03975686|Other|neuromuscual realigning exercise|neuromuscular realigning exercise
45396827|NCT00282464|Drug|Placebo|Subjects will start on placebo and remain on placebo for six weeks. All cards for the Placebo arm will be 0 mg bid.
45504569|NCT02086838|Drug|Theragran Hematinic|
45504570|NCT02086838|Drug|low molecular weight iron dextran|
45504571|NCT03978039|Drug|Chemotherapy|treatment as per standard of care
45504572|NCT03978039|Drug|Immunotherapeutic Agent|treatment as per standard of care
45504573|NCT03978039|Drug|target treatment|treatment as per standard of care
45504574|NCT03978039|Procedure|Surgery|treatment as per standard of care
45504575|NCT03978039|Radiation|Radiotherapy|treatment as per standard of care
45504576|NCT02236962|Drug|Placebo|
45504577|NCT02236962|Drug|Ephedrine, pioglitazone|
45504578|NCT04431375|Biological|Plasma Exchange|Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir [antiviral] 300mg PO once a day .
45504579|NCT04431375|Drug|Tenofovir|Tenofovir [antiviral] 300mg PO once a day .
45504580|NCT04431375|Other|Fecal Mircobiota Transplantation|FMT for 7 days
45504581|NCT02086994|Drug|misoprostol|given after the delivery of the anterior shoulder of the baby.
45504582|NCT02086994|Drug|carbetocin|given after delivery of anterior shoulder
45554698|NCT02439944|Drug|Nicotine patch|
45554699|NCT02439944|Drug|Nicotine mouthspray|
45849658|NCT05711784|Other|Phaseolean (White Kidney Bean Standardized Extract)3000 mg Capsules|"Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.~Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water."
45849659|NCT05711784|Other|Placebo (Resistant Dextrin) Capsules|Resistant dextrin is a soluble fiber, derived from wheat or corn starch and is prepared by highly controlled partial hydrolysis and repolymerization of the dextrinization process
45504583|NCT01307787|Other|experimental Fit-program|Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component. The physical exercise part consisted of a muscle exercise circuit and bicycle training,sport and aqua jogging. The educational part consisted of a weekly sixty minutes session. A multi-disciplinary group of healthcare professionals gave specialist orientated informational advice about how to handle the consequences of RA. Special attention was paid to ensure adjusting the level of each patients activity level to the participants' actual energy level. Further information was given about body sensations, sports, food and energy, pain, fatigue, emotional changes, sleeping disturbance and daily routine.
45396828|NCT00282464|Drug|Geodon (Ziprasidone)|Ziprasidone flexible dosing treatment arm (20-80 mg bid). For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
45504584|NCT01307787|Other|no intervention|waiting list control group with no intervention
45504585|NCT02089412|Drug|E2006|
45504586|NCT03557606|Procedure|Alar treatment with BMC using anterior approach|Patients with CCJ instability will undergo a bone marrow aspiration of approximately 30-60 cc. Platelet rich plasma (PRP) and platelet lysate (PL) will be derived from the bone marrow aspirate and later mixed with the bone marrow cell layer. While under TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate.
45504587|NCT05664711|Drug|Bupivacaine Injection|"Reciprocal unilateral stellate ganglion blocks, separated by at least 16 hours, will be given once per week for three weeks (for a total of 6 blocks).~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for bupivacaine or to support any other significant change in the labeling for the drug."
45504588|NCT02091050|Other|2D HDR planning|HDR planning using simple radiograph (2D)
45504589|NCT02091050|Other|3D HDR planning|HDR planning using computed tomography (3D)
45504590|NCT02087228|Device|Genesys HydroTherm Ablator|Heated water is circulated inside the uterus to destroy the lining of the uterus
45504591|NCT02087228|Device|radiofrequency energy ablation device|
45396829|NCT01068938|Device|three different perimeters: HFA, Octopus, MATRIX|visual fields
45396830|NCT03976856|Drug|GB226|Geptanolimab, 210mg，q2w，ivgtt.
45504592|NCT02089490|Device|NEVELIA® implantation|Skin substitute implantation followed by ultra-thin epidermal graft
45504593|NCT02089568|Drug|Co-Amoxiclav|Will receive 1.2g co-amoxiclav at induction
45504594|NCT02089568|Drug|Normal Saline|Placebo - 0.9% saline
45504595|NCT03284853|Drug|Netarsudil/Latanoprost 0.02%/0.005%|Topical sterile ophthalmic solution
45396831|NCT03976856|Drug|Fruquintinib|Fruquintinib, 3mg or 4mg or 5mg, qd.po. 3 weeks-on,1 week-off
45396832|NCT00273182|Device|InSync Model 8040|Subjects with sucessful implants of InSync Model 8040.
45396833|NCT00273182|Device|InSync III Model 8042|Subjects with successful implants of InSync III Model 8042
45504596|NCT03284853|Drug|GANFORT®|Topical sterile ophthalmic solution
45504597|NCT02091596|Drug|PluroGel N|Study Drug
45504598|NCT02091596|Drug|PluroGel|PluroGel Vehicle Placebo Comparator
45504599|NCT03126019|Drug|Parsaclisib|Parsaclisib tablets administered orally with water and without regard to food
45504600|NCT03557528|Procedure|Laparoscopic colorectal resection|Gruop 1: laparoscopic rectosigmoid resection with standard ligation of mesenteric artery at its origin Group 2: Laparoscopic rectosigmoid resection with low ligation of inferior mesenteric artery and its skeletonization with en bloc removal of all lymph nodes
45504601|NCT03557450|Device|PET/CT Scan|PET/CT scanning with sodium fluoride
45504602|NCT02087384|Biological|Gardasil|Intramuscular Gardasil vaccination at 0, 2 and 6 months.
45504603|NCT02087384|Drug|Placebo|injection of 0.9% saline
45849660|NCT05688228|Other|questionnaire|Female Sexual Function Index (FSFI) and self-administrative questionnaires on sexuality just after abortion and repeated at 1, 3 and 6 months
45849661|NCT05682300|Procedure|peripheral nerve block|After signing the informed consent by the patient, specific for this observational study, the peripheral regional anesthesia technique will be performed following the usual practice of the anesthesiologist responsible for the surgery. Under standard monitoring and taking into account the necessary aseptic measures, either peripheral nerve blocks (for surgeries involving extremities) or fascial blocks (for surgeries involving the chest wall, abdomen, or spine) will be performed.
45396834|NCT03976700|Drug|Bufei Jianpi granule|Bufei Jianpi granule is composed of many kinds of traditional Chinese medicine. The granule will be administered twice daily for five days a week for 104 weeks.
45396835|NCT03976700|Drug|Placebo Bufei Jianpi granule|Placebo Bufei Jianpi granule consists of dextrin, bitter and 5% of the Bufei Jianpi granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group. The placebo granule will be administered twice daily for five days a week for 104 weeks.
45396836|NCT00209274|Device|Percutaneous mitral valve repair using MitraClip implant|MitraClip Implant
45396837|NCT00209274|Procedure|Mitral valve repair or replacement surgery|Repair or replacement of mitral valve
45396838|NCT03976778|Other|Training program for family physicians on well-child care for children under-5 years|The researchers designed this intervention, which consisted of 3 repeated workshops, every workshop had held for 2 days, one day per week, the number of attendants was appropriate/workshop (10 - 15).
45849662|NCT05677698|Other|Lemon oil|Lemon oil with massage
45849663|NCT05677698|Other|peppermint oil|peppermint oil with massage
45849664|NCT05677698|Other|Almond oil|Almond oil massage
45396839|NCT03975764|Diagnostic Test|Collection of fecal sample|Analysis of fecal microbiome
45396840|NCT03841331|Drug|5 mg Serlopitant Tablets|Serlopitant Tablets
45396841|NCT03841331|Drug|Matching Placebo Tablets|Placebo Tablets
45396842|NCT01069016|Procedure|Sacral nerve modulation|For one week the sacral nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
45396843|NCT01069016|Procedure|Pudendal nerve stimulation|For one week the pudendal nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
45504604|NCT02087462|Other|Electroacupuncture (EA)|"Main acupoints: Da chang shu (BL25), Huan tiao (GB30), bilateral Jiaji point of attacked lumbar vertebra, Ashi points, modifying points according to different patterns.~Electroacupuncture: choose the dilatational wave, frequency is 2Hz/100Hz, electric current ranges from 0.1mA to 1.0mA, 30 mins per time.~Treatment frequency: 5 times per week in the first 2 weeks, 3 times per week in the 3rd and 4th week, 2 times per week in the 5th and 6th week.~Duration: 6 weeks."
45504605|NCT02087462|Other|Traction|An electric pelvis traction in supine position will be applied. The treatment frequency and duration are the same as EA.
45504606|NCT02087462|Drug|Voltaren|"Medication: 50 mg, twice per day~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
45504607|NCT02087462|Drug|Vitamin B1|"Medication: 10mg, twice per day.~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
45504608|NCT02087540|Drug|Telmisartan 80mg|
45504609|NCT02087540|Drug|Rosuvastatin 20mg|
45504610|NCT02087540|Drug|Rosuvastatin 10mg|
45504611|NCT02087540|Drug|Placebo(for Telmisartan 80mg)|
45504612|NCT02087540|Drug|Placebo(for Rosuvastatin 20mg)|
45504613|NCT02087540|Drug|Placebo(for Rosuvastatin 10mg)|
45504614|NCT03055221|Drug|Intravenous Treprostinil|Intravenous treprostinil supplied in 20-mL vials and diluted to the appropriate concentration for administration.
45504615|NCT01372033|Behavioral|Cognitive Behavioral Therapy|18 sessions of CBT, twice weekly
45504616|NCT01372033|Behavioral|Cognitive Behavioral Therapy|18 sessions with goals groups drug testing
45396844|NCT01326156|Device|Knee arthroplasty|Comparison of patellofemoral arthroplasty versus conventional total knee arthroplasty in cases of isolated patellofemoral osteoarthritis.
45396845|NCT03969966|Other|renal replacement therapy as clinically indicated|Continuous renal replacement therapy
45396846|NCT00262080|Drug|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
45396847|NCT00262080|Drug|Phosphate Buffer Saline (PBS),|given as three 1mL subcutaneous injections.
45396848|NCT01073904|Drug|Levonorgestrel Emergency Pill (BAY86-5028)|Single dose of 1.5 mg coated tablet
45504617|NCT03952923|Biological|CD19-CAR-T cells|CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
45504618|NCT05494970|Other|Accompaniment by the dental assistant.|"Inclusion visit (before radiotherapy treatment):~oral hygiene education (prevention of complications related to radiotherapy) will be provided by the dental assistant.~a written information guide on oral hygiene will be given to the patient.~the questionnaire entitled Motivation and oral hygiene behavior will be completed by the patient.~End of study visit (three months post-radiotherapy):~• The Motivation and oral hygiene behavior and the satisfaction questionnaires will be completed by the patient."
45504619|NCT03206463|Drug|4 mg Delta-9-THC|Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
45396849|NCT01073904|Drug|Postinor 2|Single dose of 1.5 mg tablet
45396850|NCT03969810|Behavioral|Rounding Summary|Written summary of rounds
45396851|NCT03973554|Other|pearl powder|natural product, support bone and joint health
45504620|NCT03206463|Drug|Placebo|Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
45849665|NCT05671146|Device|anti-gravity treadmill|participants will perform exercises with partial weight-bearing by using an anti-gravity treadmill
45396852|NCT03973554|Drug|CPP-ACP|Remineralising sugar free dental topical crème, containing bio-available calcium and phosphate
45396853|NCT03973320|Other|Chart Review|This is a chart review to determine if hypotensive neuraxial anesthesia is associated with worse outcomes in Primary Total Hip Arthroplasty patients.
45396854|NCT00282308|Drug|Rituximab|Rituximab was supplied in single-use vials.
45396855|NCT00282308|Drug|Methotrexate|
45396856|NCT00282308|Drug|Methylprednisone|Patients received methylprednisolone 100 mg intravenously before each infusion of rituximab.
45396857|NCT00282308|Biological|C. albicans|Patients received an intradermal injection of C. albicans (0.1 mL) on the volar surface of the forearm.
45396858|NCT00282308|Biological|Tetanus toxoid adsorbed booster vaccine|Patients received an intramuscular injection of the tetanus toxoid adsorbed booster vaccine (1 mg in 0.5 mL) in the deltoid muscle.
45396859|NCT00282308|Biological|23-valent pneumococcal polysaccharide vaccine|Patients received an intramuscular injection of the 23-valent pneumococcal polysaccharide vaccine (0.5 mL) in the deltoid muscle.
45396860|NCT00282308|Biological|Keyhole limpet hemocyanin|Patients received a subcutaneous injection of keyhole limpet hemocyanin (1 mg)
45396861|NCT01072968|Drug|BF2.649|1 capsule per day in the morning before the breakfast
45396862|NCT01072968|Drug|Placebo|1 capsule per day in the morning before the breakfast
45396863|NCT03969732|Drug|1. amyloid PET；2. T807 PET|"Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).~Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807 (4 x 300 seconds)"
45504621|NCT03206463|Drug|2 mg Delta-9-THC|Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
45396864|NCT03975608|Behavioral|"Adaptation of CALM"|"The therapy is built up by 3-8 sessions (duration about 45-60 min) over a period of 6 months. All dimensions are explored with every patient, but the order and extent of each dimension are adapted to the individual needs of the patient.~The sessions address the 4 dimensions of the original program designed for palliative cancer patients:~Symptom management and communication with healthcare providers~Changes in self and relations with each others~Spirituality, sense of meaning, and purpose~Thinking of the future, hope, and mortality~As an adaptation, the investigators will especially focus on two other aspects which take into account the specific symptoms and challenges in patients with ALS: (i) communication skills and (ii) emotional expression and control."
45504622|NCT02091674|Device|Hyaluronic acid|Injected gel
45504623|NCT02087618|Other|Kodro+|Kodro+ participants will utilize Kodro Solution on a tablet for 30 minutes a day for 36 weeks
45504624|NCT02087618|Other|Kodro+D|Kodro+D participants will utilize the Kodro Solution program 12-weeks post-baseline for 30 minutes per day for 24-weeks
45504625|NCT04610827|Drug|Ferrous sulfate|Guideline-recommended 3 mg/kg/day dosing
45504626|NCT01218555|Drug|Lenalidomide|Lenalidomide (10mg, 15mg, 20mg or 25mg) once daily by mouth, every day of each 28-day cycle.
45504627|NCT01218555|Drug|Everolimus|5mg or 10mg of everolimus administered once daily by mouth on a once daily continuous dosing schedule for 28 days.
45504628|NCT04503733|Drug|Q4W GMA301 IV injections (300 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
45504629|NCT04503733|Drug|Q4W GMA301 IV injections (600 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
45504630|NCT04503733|Drug|Q4W GMA301 IV injections (1000 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
45504631|NCT04503733|Drug|Q4W GMA301 IV injections (1800 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
45504632|NCT04503733|Other|Q4W placebo IV injections|Placebo is indistinguishable from GMA301.
45504633|NCT03557060|Drug|Nucala|NUCALA injections will be administered to eligible subjects with diagnosis of EGPA. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
45504634|NCT01368991|Device|Kryptonite|Osteoconductive biologic bone cement to be applied upon sternal closure
45504635|NCT01368991|Procedure|Conventional closure|conventional closure, no kryptonite applied
45697321|NCT05085015|Other|Functional Exercise Training Group|"Training will start with Stretching Training and end with stretching training. Stretching exercises targeting actively applied shoulder girdle, chest, neck, trunk, hip, front and back leg and ankle muscle groups will be given. Afterwards, it will be continued with Aerobic Exercise Training. The training will be given on the treadmill Treadmill Technogym. Afterwards, it will be continued with Strengthening Training. Strength training will consist of a strengthening program that includes the lower extremity, upper extremity, trunk and core region. Elastic bands will be used in the training. Then, balance training will be given at the end."
45504636|NCT02091830|Drug|Paracetamol and nonsteroidal antiinflammatory drug (NSAID)|
45504637|NCT02091830|Other|Physiotherapy|
45504638|NCT02091830|Drug|Cortisone Injection|
45504639|NCT02091830|Other|Others|
45504640|NCT01111305|Drug|Reslizumab|
45504641|NCT01111305|Drug|Diethylcarbamazine|
45504642|NCT01111305|Other|Placebo|
45504643|NCT05191927|Other|male|Nine preoperative predictors were identified for the nomogram: gender, age, platelet counts, TPOAb level and US signatures including maximum diameter, boundary, component, calcification and cervical lymph node enlargement.
45504644|NCT02089802|Drug|Pazopanib|
45504645|NCT04497415|Other|Video-Based intervention|Three minutes video of a nurse that shares her personal story
45504646|NCT03752307|Drug|Isoxsuprine Hydrochloride|Compounded Isoxsuprine hydrochloride capsules
45849666|NCT05671146|Other|Weight-bearing exercises for knee flexors and extensors|Stretching and strengthening exercises will be performed in a weight-bearing position
45504647|NCT03752307|Drug|Placebo|Identical microcrystalline cellulose placebo manufactured to mimic Isoxsuprine Hydrochloride 10 MG capsules
45504648|NCT03752307|Drug|Corticosteroid|This can be any accepted regimen, including daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon
45504649|NCT02087696|Drug|Tocilizumab|Tocilizumab dose 8mg/kg administered every 4 weeks during 24 weeks.
45504650|NCT03634423|Behavioral|Sweet Spot: Flexible high incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
45504651|NCT03634423|Behavioral|Sweet Spot: Flexible low incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
45504652|NCT03634423|Behavioral|Sweet Spot: Rigid high incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
45504653|NCT03634423|Behavioral|Sweet Spot: Rigid low incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
45504654|NCT03634423|Behavioral|FOTW: High incentive control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
45504655|NCT03634423|Behavioral|FOTW: Low incentive control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
45504656|NCT03634423|Behavioral|FOTW: High incentive treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
45504657|NCT03634423|Behavioral|FOTW: Low incentive treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
45849667|NCT05671146|Other|Non weight-bearing exercises for knee flexors and extensors|Stretching and strengthening exercises will be performed in a non-weight-bearing position
45504658|NCT03634423|Behavioral|Think Twice: Control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
45504659|NCT03634423|Behavioral|Think Twice: Treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
45504660|NCT03634423|Behavioral|WDR: Control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
45504661|NCT03634423|Behavioral|WDR: Treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
45504662|NCT00792831|Drug|ITF2357|Histone-Deacetylase Inhibitor
45504663|NCT00496431|Drug|histone deacetylase inhibitor (ITF2357)|50 mg b.i.d. (or every 8 hours or every 6 hours), every day
45504664|NCT03634501|Biological|Activated NK|Cell suspension
45504665|NCT02091908|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
45504666|NCT02091908|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
45504667|NCT02091908|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
45504668|NCT02091908|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
45504669|NCT03627897|Drug|Bupivacain|The erector spinae plane blocks proceed with 0,5 ml/kg of 0,25% bupivacain (Group B).
45849668|NCT05667168|Procedure|physiotherapy approach|The therapy will take place 2-3 times a week; the therapeutic unit will last 45 minutes and will be oriented towards one therapeutic approach from the above list. The total number of therapy sessions will be limited to 3 months (i.e. three months, 2-3 times a week). After completion of the 3-month therapy, a follow-up examination will be performed again by kinesiological analysis, questions about the intensity of tinnitus according to a numerical scale and quality of life by a selected questionnaire.
45396865|NCT00282152|Device|B-STN DBS|Deep brain stimulation (DBS) of both the right and left sub-thalamic nucleus (STN) is an FDA approved treatment for advanced PD. In mid- and advanced stage Parkinson's disease, using DBS in this area of the brain lessens symptoms and allows patients to take less drug to control the disease. Dosage and frequency are not applicable to the DBS. Once the DBS is placed, unless deemed necessary, it will not be removed.
45504670|NCT03627897|Drug|saline|No drugs or interventions were administered to the control group.
45504671|NCT01372111|Drug|Cisplatin|Cisplatin 35 mg/m2 IV weekly during weeks 1 through 6 of IMRT.
45697322|NCT05085015|Other|Home Exercise Training Group|Training will start with Stretching Training and end with stretching training. Stretching exercises targeting actively applied shoulder girdle, chest, neck, trunk, hip, front and back leg and ankle muscle groups will be given. Afterwards, it will be continued with Aerobic Exercise Training. They will walk at least 30 minutes, 3 days a week for 8 weeks at outdoor. Afterwards, it will be continued with Strengthening Training. Strength training will consist of a strengthening program that includes the lower extremity, upper extremity, trunk and core region. Elastic bands will be used in the training. Then, balance training will be given at the end.
45396866|NCT00282152|Drug|Optimal drug therapy|The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary. Examples of drugs used include carbidopa/levodopa, pramipexole, ropinirole, and selegiline.
45396867|NCT00281840|Biological|bevacizumab|Bevacizumab IV over 30-90 minutes once every 2 weeks for up to 1 year. Bevacizumab, which stops 8 weeks before surgery, may restart 4 weeks after surgery and continue for 9 months in the absence of disease progression or unacceptable toxicity.
45396868|NCT00281840|Drug|docetaxel|docetaxel IV over 1 hour once a week for 8 weeks
45504672|NCT01372111|Radiation|Elective Nodal Irradiation (ENI)|Low risk planning target volume (PTV) of 36 Gy at 2 Gy per fraction daily to bilateral, uninvolved neck nodal regions at risk for harboring microscopic cancer. High risk PTV will receive 70 Gy.
45504673|NCT02248532|Biological|Stem cell therapy|Bone marrow cells will be mobilized into peripheral blood by daily subcutaneous injections of G-CSF (10 µg/kg daily) and collected by leukapheresis. Positive immunomagnetic selection of CD34+ cells will be performed. Electroanatomic mapping of the left ventricle will be performed using the Biosense NOGA system (Biosense-Webster®, Diamond Bar, CA). The target area for cell delivery will be defined as the myocardial segments with unipolar voltage potentials ≥8.3 mV, bipolar amplitudes >1.9 mV, and linear shortening <6%. Intramyocardial delivery of cell suspension will be performed with the MyoStar (BiosenseWebster®, Diamond Bar, CA) injection catheter. Each patient will receive 20 injections (0.3 mL each; total volume of 6 mL). All the procedures will be repeated 6 months after baseline.
45504674|NCT05191849|Diagnostic Test|Blood sample collection|Baseline blood samples are collected before chemotherapy. Dynamic blood samples are also prospectively collected after 2~4 cycles of chemotherapy, or at the time of disease progression.
45504675|NCT02889627|Drug|Fecal microbiota suspension|The prepared microbiota suspension was infused into the participates' mid-gut or lower gut.
45697323|NCT05075109|Device|High Frequency TENS|30 minutes of high frequency TENS (100 Hz, 200 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks combined with task related training.
45697324|NCT05075109|Device|Low Frequency TENS|30 minutes of low frequency TENS (20 Hz, 0.2 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks. And combined with 30 minutes of TRT.
45849669|NCT05656794|Radiation|Radiotherapy|Standard of care radiotherapy administered as per institutional guidelines.
45396869|NCT00281840|Procedure|conventional surgery|8-10 weeks after the completion of chemoradiotherapy, patients may undergo neck dissection
45396870|NCT00281840|Radiation|radiation therapy|radiotherapy once daily, 5 days a week, for 8 weeks
45396871|NCT00281684|Drug|SB705498 400 mg|SB705498 400 mg
45396872|NCT00281684|Drug|SB705498 1000 mg|SB705498 1000 mg
45396873|NCT00281684|Drug|Placebo|Placebo
45396874|NCT00281684|Drug|Co-Codamol|Co-Codamol
45396875|NCT03975452|Radiation|Reduced radiation volumes|Patient treated with reduced radiation volumes with the exclusion of elective pelvic nodal irradiation
45504676|NCT02250404|Other|cytology specimen collection procedure|Correlative studies
45396876|NCT03976622|Biological|Blood samples|Blood samples: serum and PBMC
45396877|NCT03976622|Biological|Skin biopsies|These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.
45396878|NCT00272792|Drug|Sapropterin Dihydrochloride|Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
45396879|NCT00272792|Drug|Placebo|Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
45396880|NCT01069094|Drug|Progenta|12.5 mg, administered as a once daily oral dose for 90 days.
45396881|NCT01069094|Drug|Progenta|25 mg, administered as a once daily oral dose for 90 days.
45396882|NCT01069094|Drug|Progenta|50 mg, administered as a once daily oral dose for 90 days.
45396883|NCT01069094|Drug|Lucron Depot|3.75 mg IM monthly
45396884|NCT01069094|Drug|Placebo|Administered as a once daily oral dose for 90 days.
45396885|NCT00048568|Drug|Abatacept|Intravenous (IV) Solution, - Weight Titered (500 mg < 60 kg); (750 mg 60-100 kg), )1 gram > 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
45396886|NCT00048568|Drug|Methotrexate|Tablets, Oral, >= 15 mg, weekly, 1 year
45396887|NCT00048568|Drug|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
45396888|NCT00262002|Biological|MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation)|MenACWY-CRM conjugate vaccine formulated without adjuvant was injected IM (intramuscularly) in the anterolateral area of the right thigh.
45396889|NCT00262002|Biological|MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation)|MenACWY-CRM conjugate vaccine formulated with adjuvant was injected IM in the anterolateral area of the right thigh.
45396890|NCT00262002|Biological|MenACWY PS (MenACWY-CRM, polysaccharide vaccine)|MenACWY polysaccharide vaccine was injected in the anterolateral area of the right thigh.
45396891|NCT00262002|Biological|HBV (Hepatitis B vaccine)|Hepatitis B vaccine at 2, 4, 6 months of age administered IM in the anterolateral area of the left thigh.
45396892|NCT00262002|Biological|Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197)|Prevnar was administered IM in the anterolateral area of the left thigh.
45396893|NCT00262002|Biological|MMR (Measles, Mumps and Rubella vaccine)|MMR at 12 month of age, administered in the left arm.
45396894|NCT00262002|Biological|DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine)|DTaPHibIPV at 2, 3, 4 months of age, administered IM in the anterolateral area of the left thigh.
45396895|NCT00262002|Biological|Menjugate (Men C conjugated vaccine)|Menjugate was injected IM in the anterolateral area of the right thigh.
45396896|NCT01092988|Device|Exablate 2100|MR guided focused ultrasound
45396897|NCT03955120|Behavioral|Dayzz mobile sleep training|"The dayzz digital sleep program provides each user with relevant educational materials (depending on their sleep condition), sleep tracking, and sleep or health-related tasks or challenges pertaining to their sleep or sleep difficulties.~Each app user is matched with a sleep trainer who will communicate with them via a chat option within the dayzz app and who will support the participants with any sleep training issues or technical aspects of all app for the duration of the treatment program.~Participants receive a wrist-worn device for monitoring sleep and activity patterns, a Fitbit fitness tracker (www.fitbit.com), to be worn for the duration of the study."
45396898|NCT03955120|Other|Treatment as usual|Standard medical care for specific sleep condition
45396899|NCT01583998|Behavioral|e-MBC|antidepressant treatment
45396900|NCT01584076|Drug|Donepezil|"Oral Donepezil Daily~Initial Dosage: Donepezil 5 mg tablets will be used. 1/2 tablet (≈2.5 mg)/day for 8 to 17 year olds OR 1 tablet (5 mg)/day for ≥18 year olds.~Dosage Escalation: Donepezil may be increased by 1/2 tablet (≈2.5 mg)/day every 4 weeks if the amblyopic eye visual acuity has not improved by ≥5 letters or 1 logMAR line to a maximum dosage of 1 1/2 tablets (≈7.5 mg)/day for 8 to 17 year olds OR 2 tablets (10 mg)/day for ≥18 year olds."
45396901|NCT01584076|Other|Patching|Patching: 2 hours of daily patching will also be prescribed for 8 to 17 year olds only.
45396902|NCT03954964|Behavioral|Education on disposal of opioids|Current class curriculum including education about pain management with additional education about the disposal of opioids.
45396903|NCT03956836|Diagnostic Test|ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII|ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII at baseline (before surgery) and after 4h and 48 after surgery in 40 patients undergoing CRC
45396904|NCT01093144|Device|pelvic measurements using the LaborPro Device|pelvic measurements using the LaborPro Device,ultrasound non invasive measurements
45396905|NCT00281528|Drug|ABI-007 (Abraxane)|30 minute infusions
45396906|NCT00281528|Drug|bevacizumab|infusions
45504677|NCT02250404|Other|laboratory biomarker analysis|Correlative studies
45504678|NCT03125941|Drug|Dexamethasone|pre-operative intravenous administration
45504679|NCT02092142|Biological|Q fever Vaccine|Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105
45396907|NCT01095640|Drug|adapalene 0.3% topical gel|once a day, 84 days
45396908|NCT03955276|Other|Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician)|Biologically targeted matched treatment (chosen by treating physician)
45396909|NCT01095718|Behavioral|Errorless Learning|"Errorless learning refers to the use of feedforward instruction before actions to prevent learners from making mistakes. The therapist presents steps with the following instruction and the visual cues e.g., Here are steps that you need to do to make some coffee, please repeat them.~The therapist gives cues before the completion of each step. At each step the patient receives verbal and visual cues. Then cue cards are hidden, and the therapist asks immediately to give the answer about the step involved.~The therapist allows the participant to try finding the solution, if the answer or action is not immediately given, the participant receives a cue, and moves to the next step.~During cueing the patient will mostly receive verbal and visual cues and if necessary physical help."
45396910|NCT01095718|Behavioral|Modeling|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance.~Then the therapist asks immediately to the patient to do the steps."
45396911|NCT01095718|Behavioral|Trial and Error|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance.~Then the therapist asks immediately to the patient to do the steps."
45504680|NCT02774889|Behavioral|Stepping Online|"Stepping Online is a password-protected website with Stepping On graduates, whose groups are randomized to Stepping Online and will have access to and training in a password-protected website. The website includes:~Fall prevention tips~Fall prevention exercise videos with narrations for proper technique and safety precautions~Guest expert videos with online access to the guest expert to ask questions~Tools to set exercise goals, get reminders and track progress~Access to a fall prevention specialist for personal feedback and suggested group homework~Group discussion and messaging (one-to-one and with their fellow Stepping On workshop participants group, or with all Stepping Online participants and leaders)~Fall prevention resources"
45504681|NCT02095886|Drug|BMS-955176|BMS-955176
45504682|NCT01372579|Drug|eribulin mesylate|Given IV
45504683|NCT01372579|Drug|carboplatin|Given IV
45504684|NCT01372579|Procedure|biopsy|Correlative studies
45504685|NCT02089958|Procedure|Laparoscopic incisional hernia repair|Standardized laparoscopic incisional hernia repair with mesh
45396912|NCT00280748|Drug|pemetrexed disodium|500 mg/m2 once every 21 days up to 126 days
45396913|NCT00280748|Radiation|radiation therapy|Patients will receive cranial irradiation at 2.5 Gy per fraction, 5 days a week, for 3 weeks to a total dose of 37.5 Gy
45396914|NCT00271856|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|8 week MBSR course
45396915|NCT00271856|Behavioral|HIV-education and self-management workshop|8-week group covering a variety of educational topics about managing HIV infection.
45504686|NCT02090036|Drug|Primaquine (For artemether-lumefantrine+primaquine arm)|A 0.25 mg/kg single-dose primaquine will be administered concomitantly with the first dose of artemether-lumefantrine in all patients randomized into the artemether-lumefantrine+primaquine arm.
45504687|NCT02090036|Drug|Placebo (For artemether-lumefantrine arm)|Volume of normal saline mixed with coloured fruit juice measured based on weight bands will be given orally concomitantly with first dose of artemether-lumefantrine.
45504688|NCT03125629|Drug|F-18 FDG|Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging
45504689|NCT03125629|Drug|Ga-68-DOTA-TATE|Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging
45504690|NCT03125629|Device|Positron Emission Tomography / Computed Tomography (PET/CT) Scan|Scan using a regular medical care (IDE-exempt) Discovery 600 / 690 PET/CT scanner.
45504691|NCT03125629|Device|Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan|Scan using a NOVEL GE PET/MRI scanner.
45504692|NCT02092376|Drug|Cholecalciferol|
45504693|NCT02092376|Drug|Placebo|
45396916|NCT03975374|Drug|Tobramycin/dexamethasone opthalmic solution|To compare efficacy and safety in randomized patients recieving Tobradex versus Tobramycin/Dexamethasone opthamic Solution
45396917|NCT03975374|Drug|Tobradex Opthalmic Solution|Tobradex Opthalmic Solution
45396918|NCT01070264|Dietary Supplement|Noni Juice|This was an open label three-month intervention pilot study. Data were collected by pre and post intervention survey as well as laboratory testing. Inclusion criteria were: adults of both sexes aged 40 to 75, with a diagnosis of OA on the hip or knee by their primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz of TNJ a day
45396919|NCT01070420|Other|FFR via central venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min-1•kg-1) via Rt central femoral vein.
45396920|NCT01070420|Other|FFR via peripheral venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min-1•kg-1) via continuous peripheral vein.
45396921|NCT00061048|Biological|Alemtuzumab|Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
45396922|NCT01070498|Drug|Trichuris suis ova (TSO)|Subjects will receive TSO every other week for 3 months. The dose will depend on the age of the subject and vary between 100 and 2500 eggs. TSO will be administered orally as a suspension in single dose vials prepared by Ovamed GmbH, a company not directly involved in the study.
45396923|NCT01581398|Drug|Ypeginterferon alfa-2b|sc, qw, 24 weeks.
45396924|NCT01581398|Drug|Pegasys|sc, qw, 24 weeks.
45396925|NCT01581398|Drug|Ypeginterferon alfa-2b|sc, qw, 48 weeks.
45396926|NCT01581398|Drug|Pegasys|sc, qw, 48 weeks.
45396927|NCT03957148|Behavioral|Sugar-sweetened beverage reduction education for preschool children|Participants in the SSB-IMB program will receive 10 weeks of SSB related nutrition education at their child's preschool. Each week a different lesson pertaining to parental information, motivation, or behavioral skills related to SSBs will be presented via an interactive display board. Twice a week, two student educators will stand by display boards for two hours and deliver the lessons that will last 5-10 minutes with each parent. These displays will include an activity for parents to apply knowledge and skills learned during the short lesson. Educators will also provide parents with informational handouts pertaining to each lesson to reinforce concepts learned. Display board education is flexible, so that if a parent arrives while another parent is receiving education, the second educator can begin the lesson with the new parent. Multiple parents can participate in a lesson at the same time. Groups of 2-3 parents can review the lesson together, learning from each other.
45396928|NCT03954808|Other|Motor Imagery Training|Motor imagery training will be designed for the individual basis with standard protocols
45396929|NCT03954808|Other|Traditional physiotherapy|Traditional physiotherapy within a specific program
45396930|NCT03976544|Drug|Estradiol Valerate|Estradiol valerate will be started in the beginning of the menstrual cycle in order to induce proliferation of the endometrium.
45396931|NCT03976544|Drug|Micronized progesterone|If the endometrium is considered adequately proliferated, micronized progesterone is administered and frozen-thawed blastocyst transfer will take place on the 6th day of supplementation.
45396932|NCT00270998|Behavioral|Behavioral Therapy|Pelvic muscle training and exercises
45396933|NCT00270998|Device|Intravaginal Pessary|Intravaginal pessary
45504694|NCT02090192|Procedure|WBV training|
45504695|NCT02090192|Procedure|PRT training|
45396934|NCT00270998|Device|Pessary combined with behavioral therapy|Intravaginal pessary and behavioral therapy
45396935|NCT01070576|Other|no intervention|no intervention
45396936|NCT01070654|Procedure|40/30 recruitment manoeuvre|The ventilator will be switched to the continuous positive airway pressure (CPAP) mode and the pressure will be increased to 40 cmH20 for 30 seconds.
45396937|NCT01070654|Device|continuous positive airway pressure (CPAP)|continuous positive airway pressure (CPAP)
45396938|NCT01581632|Device|LipiScan/LipiScan IVUS|Evaluation of the coronary artery using near infrared spectroscopy using either a LipiScan catheter or a LipiScan/IVUS catheter following a clinically indicated coronary angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLA2 inhibition.
45396939|NCT03741686|Dietary Supplement|konjac glucomannan|Konjac-mannan fiber-enriched biscuits (0.5 g/412KJ [100kcal] of glucommanan)
45396940|NCT03741686|Dietary Supplement|wheat bran|Wheat bran (hard red wheat bran) fiber enriched biscuits
45396941|NCT01582334|Device|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
45396942|NCT00279812|Dietary Supplement|50ug selenium enriched yeast|Selenomethionine supplement (50ug/d Se) for 12 weeks
45396943|NCT00279812|Dietary Supplement|100ug selenium enriched yeast|Selenomethionine supplement (100ug/d Se) for 12 weeks
45396944|NCT00279812|Dietary Supplement|200ug selenium enriched yeast|Selenomethionine supplement (200ug/d Se) for 12 weeks
45504696|NCT05452928|Drug|Acyclovir 50 MG/ML|Patients are randomised to active treatment with IV acyclovir with the possibility of step-down to valacyclovir. If the treating physician prefers, initial IV treatment can be omitted and the patient can be treated with valacyclovir throughout the study period.
45504697|NCT05452928|Drug|Placebo|Placebo either in IV formulation or as tablets identical to valacyclovir tablets.
45504698|NCT03125395|Drug|LUM/IVA|Participants received LUM/IVA every q12h.
45504699|NCT00264602|Drug|Near Infrared Imaging|Dye injected into or around tumor at the time of surgery
45504700|NCT03557138|Behavioral|alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside|positron emission tomography and magnetic resonance imaging (PET/MRI) of kidneys of diabetic patients using alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Me4FDG)
45504701|NCT01369303|Drug|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
45504702|NCT03556436|Drug|YH25448 240mg|period 1: A single oral dose of YH25448 240 mg an overnight fast period 2: A single oral dose of YH25448 240 mg after a high-fat breakfast
45504703|NCT02092532|Drug|Rescue Intravitreal Aflibercept Injection|Patients can receive additional IAI treatment (Months 3, 5, 7, 9, and 11) if the re-treatment criteria are met.
45504704|NCT02092532|Procedure|Rescue Therapy with PDT, Laser or Intravitreal Steroids|Starting at Month 3, patients can receive non-anti VEGF rescue therapy (ie: PDT, laser, intravitreal steroids) if the pre-defined criteria are met.
45849670|NCT05636358|Other|Home-based hypnotherapy|The home-based hypnotherapy package contains five standard hypnosis exercises. They consist of one breathing exercise, and four visualisation exercises. Two separate sets adjusted to the child's age will be used: one for children younger than 12 years and one for children of 12 years and older. The children will be asked to listen to the exercises at least 5 times per week, for approximately 15-20 minutes per day, during a period of 3 months. A workbook will provide children and/or parents with the instructions and planning of the exercises.
45396945|NCT00279812|Dietary Supplement|Control onion|3 meals per week containing un-enriched onion (4ug/d) for 12 weeks
45396946|NCT00279812|Dietary Supplement|Enriched onion|3 meals per week containing un-enriched onion (50ug/d) for 12 weeks
45396947|NCT00279812|Other|Placebo|Placebo supplement for 12 weeks
45396948|NCT01070732|Drug|Paracetamol|All patients will receive one single dose of 1000mg paracetamol. If considered mandatory by the attending physician, similar doses may be administered latter for a maximum period of five days. The maximum allowed daily dose is 3000mg. If the attending physician believes that after the administration of at least of three doses the desired analgesic or antipyretic effect is not achieved, he may administer any other compound in his will.
45396949|NCT00207714|Drug|Golimumab|Type=exact, unit=mg/ml, number= 50 to 100 , form=powder for solution for infusion, route=sub cutaneous.
45396950|NCT00207714|Drug|MTX|Type=exact, unit=mg/ml, number= 10, form=powder for solution for infusion, route=sub cutaneous
45396951|NCT00207714|Drug|Placebo|Type=exact, unit=mg/ml, form=powder for solution for infusion, route=sub cutaneous
45396952|NCT00207714|Drug|Infliximab|Type=exact, unit=mg/ml number= 10, form=powder for solution for infusion, route=sub cutaneous
45396953|NCT00207090|Drug|ixabepilone|ixabepilone solution, intravenous, 40 mg/m2, once every 3 weeks until disease progression
45396954|NCT00207090|Drug|Rifampin|rifampin tablets, oral, 600 mg once daily, only on Days 15 to 21 of Cycle 1 and Days 1 to 7 of Cycle 2
45504705|NCT02092688|Device|novel kit for the detection of PAMG-1|The novel kit for the detection of PAMG-1 is a diagnostic device employing monoclonal antibodies that detect Placental α1 Microglobulin present in cervico-vaginal secretions manufactured by AmniSure® International, LLC, Boston, MA. The in vivo sensitivity detection threshold is 4ng/ml. During the test procedure, PAMG-1 from the sample sequentially binds to monoclonal antibody conjugated with labeled particles, then to monoclonal antibody immobilized on an insoluble carrier. The test requires a 30 second swab saturation in the vagina (a sterile speculum examination is not required), a 30 second active washing step whereby the swab just removed from the vagina is actively rotated in a solvent filled vial and lastly, a 5 minute waiting period from the time the swab is removed and the test strip is inserted if two testing lines do not appear sooner.
45504706|NCT02092766|Drug|artesunate|
45504707|NCT02092766|Drug|quinine|
45504708|NCT02090348|Drug|dimethyl fumarate|Administered as specified in the treatment arm
45504709|NCT02721069|Drug|NRL-1|
45504710|NCT02092844|Behavioral|CBT for Menopausal Insomnia (CBTMI)|Cognitive Behavioral Therapy for Menopausal Insomnia (CBTMI) includes education about sleep, sleep restriction, stimulus control, cognitive restructuring of sleep interfering thoughts, and relapse prevention; while also addressing women's beliefs about and reactions to hot flashes.
45504711|NCT00390741|Behavioral|Exercise Plus Program|Those assigned to the treatment group were visited by an exercise trainer three times a week for the first two months of the study, two times per week during months three and four, one time per week during months five and six, two times a month during months seven and eight, and one time a month during months nine through twelve. During months seven through twelve of the study the trainer contacted the participant by telephone once each week during the weeks that he or she did not go the participants' home.
45504712|NCT02093000|Drug|Bevacizumab|Participants will receive bevacizumab 7.5 milligrams per kilograms (mg/kg) intravenously according to bevacizumab summary of product characteristics/local labeling.
45504713|NCT00261807|Drug|Daptomycin 6mg/kg/day|
45504714|NCT02093078|Behavioral|CARD|"Intervention: CARD~This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay."
45504715|NCT02090504|Drug|Sodium Oxybate (SMO)|
45504716|NCT02090504|Drug|Oxazepam|
45504717|NCT01567059|Drug|tosedostat|Given PO
45504718|NCT01567059|Drug|cytarabine|Given IV
45504719|NCT01567059|Drug|decitabine|Given IV
45504720|NCT02090582|Other|Structured Palliative Care|Structured palliative care approach, defined as the gynecologic oncology team performing comprehensive symptom assessment with the Quality Data Collection Tool Palliative Care (QDACT-PC) and providing interventions based on National Comprehensive Cancer Network (NCCN) guidelines. Symptom scores above the acceptable threshold in the QDACT-PC tool that occur after two consecutive visits will automatically trigger palliative care consultation.
45504721|NCT02090582|Other|Usual Care|Usual care described as current practice by the gynecologic oncology team with referral to PC specialist at provider discretion or at the request of the patient or their families.
45504722|NCT02093156|Other|Bowel preparation instructions|The same-day preparation method was used as previously reported. Briefly, all patients were instructed to have a regular diet for breakfast and lunch, but only clear liquids for dinner on the day before the colonoscopy. They were asked to drink two bags of PEG-ELP (polyethylene glycol electrolyte powder) dissolved in 2 L of water, or 45 mL of sodium phosphate be diluted in 240 mL of cool water follow with at least 1.5 L of water at 05:00-06:00 h within 2 h on the day of colonoscopy. Patients were encouraged to drink more clear liquids after purgatives for adequate hydration before colonoscopy.
45396955|NCT03969576|Procedure|DEB-TACE|"Patients in the DEB-TACE group received a maximum dose of 4 ml of DC bead (diameter 75-500 um) loaded with a maximum dose of 150 mg of anthracyclines drugs, such as doxorubicin. The anticancer agents and the diameter of DC Bead for individual patient will be selected according to the common clinical practice of each center. Treatment endpoint consisted of stasis of flow within feeding vessel(s) or completed delivery of maximum single-session dose of 150 mg doxorubicin. TACE will be repeated on demand according to the radiological response."
45396956|NCT03969576|Procedure|cTACE|"Patients in the cTACE group were treated with anthracyclines, such as doxorubicin, in a mixture of lipiodol. Administration of the anticancer in oil emulsion was followed by injection of embolic materials such as gelfoam or PVA particles until complete stasis in segmental or subsegmental arterial branches. the tumor-feeding vessels should be superselected whenever possible. The anticancer agents for individual patient will be selected according to the common clinical practice of each center. TACE will be repeated on demand according to the radiological response."
45504723|NCT03556982|Biological|CART-123 cells|CD123-Targeted CAR-T cells are infused to patient received FC chemotherapy
45504724|NCT02090660|Other|ICG Localization with Spy thoracoscope localization|
45504725|NCT00073671|Behavioral|Cognitive-behavioral prevention program|Cognitive-behavioral prevention program includes 8 weekly and 6 monthly group sessions.
45504726|NCT00073671|Other|Usual care|Participants receive usual care
45504727|NCT02090738|Drug|Acetazolamide group|
45504728|NCT02090738|Drug|Standard regimen group|
45396957|NCT01071408|Other|Stroke prevention care program|Stroke prevention care program consists of group clinics, telephone coordination of care, and tracking of care through registries in the first 7 months after stroke or TIA presentation. A nurse practitioner will follow algorithms to adjust medications and to motivate patients to improve lifestyle habits.
45396958|NCT00059332|Drug|Magnesium Sulfate|Paramedics initiate a loading dose of 4 grams magnesium sulfate IV over 15 minutes, followed after hospital arrival by a maintenance infusion of 16 grams magnesium sulfate IV over 24 hours.
45504729|NCT02096510|Drug|Solu-Cortef|administration by pump for minimum 2 weeks
45504730|NCT02096510|Drug|Cortef|tablet treatment 2 ro 3 times per day for 14 days
45849671|NCT05628870|Drug|HRS-1358|HRS-1358 will be administered daily orally in continuous dosing over 28-day cycles.
45396959|NCT00059332|Drug|Normal Saline|Paramedics initiate a loading dose of placebo normal saline IV over 15 minutes, followed after hospital arrival by a maintenance infusion of placebo normal saline IV over 24 hours.
45396960|NCT01095952|Device|AVNS ON|Delaying the AV-node by stimulating the parasympathetic nerves innervating the AV-node with high frequency burst pacing during the refractory period of the ventricle using a standard atrial lead at a septal position.
45396961|NCT01096030|Drug|Regorafenib (Stivarga, BAY73-4506)|160 mg oral once daily BAY 73-4506 for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off)
45396962|NCT00233454|Drug|Midostaurin|Midostaurin is a broad-spectrum protein kinase inhibitor, acting on conventional PKC isoforms (α, β, γ); PDFRβ; VEGFR2; Syk; PKCη; Flk-1; Flt3; Cdk1/B; PKA; c-Kit; c-Fgr; c-Src; VEGFR1; and EGFR
45396963|NCT00047320|Drug|carboplatin|Given IV
45396964|NCT00047320|Drug|etoposide|Given IV
45396965|NCT00047320|Drug|ifosfamide|Given IV
45396966|NCT00047320|Drug|thiotepa|Given IV
45396967|NCT00047320|Procedure|adjuvant therapy|
45396968|NCT00047320|Procedure|conventional surgery|
45396969|NCT00047320|Procedure|neoadjuvant therapy|
45396970|NCT00047320|Procedure|peripheral blood stem cell transplantation|
45396971|NCT00047320|Radiation|radiation therapy|craniospinal irradiation
45396972|NCT00233064|Biological|Lyophilized Palivizumab|Patients will receive 15 mg/kg of lyophilized palivizumab administered intramuscularly every 30 days for a total of 5 injections.
45396973|NCT00233064|Biological|Liquid Palivizumab|Patients will receive 15 mg/kg of liquid palivizumab administered intramuscularly every 30 days for a total of 5 injections.
45396974|NCT03973242|Device|Dual focus with narrow band imaging|dual focus mode for imaging magnification + narrow band imaging for the enhancement of mucosal vascularity and irregularity
45396975|NCT03954730|Other|Eccentric Training|First session will be performed 24 hours after pre-training tests i.e. on 4th post- operative day and subsequent sessions will be performed with lapse of 48 hours. During pre-testing, weight for the eccentric training will be determined using Standardized Brzycki formulas for lower limb. Participants will perform one set of 10 repetitions with selected weight. Intensity will be increased every week by decreasing the time of performance. Volume will be increased by increasing one set after two weeks. Eccentric training will be performed in sitting position on dynamic constant external resistance equipment.After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
45396976|NCT03954730|Other|Active Release Technique|Isometric Quadriceps' contractions against therapist's resistance lasting for 10 seconds will be performed by the patient in inner range of knee extension and after relaxing; actively perform maximum full knee flexion. Patient will perform extension at knee joint again; when reaches the innermost range, therapist will apply pressure on deep fascia either through knuckles/fingers or forearm in the direction towards the hip joint and patient is asked to perform knee flexion simultaneously. The procedure is applied onto vastus lateralis, rectus femoris and vastus intermedialis thrice in a session. After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
45396977|NCT03973086|Dietary Supplement|Citrus flavonone-O-glycosides- LD|Low Dose of 200 mg
45396978|NCT03973086|Dietary Supplement|Citrus flavonone-O-glycosides- HD|High Dose of 400 mg
45396979|NCT03973086|Dietary Supplement|Placebo|Placebo (Microcrystalline Cellulose) of 400 mg
45396980|NCT01071486|Drug|Hematological Stem Cell Transplantation|Oral or Intravenous Busulfan as part of the preparative protocol for transplantation
45396981|NCT00268892|Drug|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
45396982|NCT00268892|Drug|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
45396983|NCT00268892|Drug|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
45504731|NCT05218317|Diagnostic Test|in-vivo Corneal Confocal Microscopy|All study subjects underwent IVCM (Rostock Cornea Module, Heidelberg Retinal Tomograph III; Heidelberg Engineering, Germany). Before the examination, two drops of topical anesthetic with proparacaine hydrochloride (Alcaine 0.5%, Alcon-Couvreur, Belgium) were applied to both eyes. A carbomer-based gel (Viscotears 0.2%; Dr. Gerhard Mann, Chem.- Pharm. Fabrik, Germany) was used as the coupling agent between the cornea and the applanating cap of IVCM. For correctly positioning the central cornea, all subjects were asked to fixate a determined fixation point and controlled with the device camera. All scans were performed in approximately 5 minutes for each eye by a single experienced ophthalmologist, masked from the subject's disease status.
45396984|NCT00206076|Drug|mycophenolate mofetil|mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
45396985|NCT00206076|Drug|mycophenolate mofetil|mycophenolate mofetil monotherapy
45396986|NCT03974490|Other|Rhythmic auditory stimulation|Rhythmic auditory stimulation 3 times in a week, and 2 hours of physiotherapy 6 days in a week.
45396987|NCT01073046|Device|Naso-Gastric/Jejunal Tube|Silastic Naso-Gastric/Jejunal Tube (Rusch® distributed by Teleflex Medical Srl)
45396988|NCT00278954|Biological|Gammaplex (Intravenous immunoglobulin)|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously for 12 months.
45504732|NCT03556280|Device|GammaSense Stimulation System (Active Settings)|Proprietary auditory and visual sensory stimulation device.
45396989|NCT03973008|Radiation|Adjuvant Chemoradiotherapy|DT 45Gy/25F/5W, using IMRT technology, synchronous tegio single drug chemotherapy
45396990|NCT03973008|Drug|Adjuvant Chemotherapy|Oxalis 130mg/m2 intravenous drip on day 1, tegio 80-120 mg daily, twice, half an hour after breakfast and dinner, for 14 consecutive days
45396991|NCT00278564|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
45504733|NCT03556280|Device|GammaSense Stimulation System (Sham Settings)|Proprietary auditory and visual sensory stimulation device.
45396992|NCT00278564|Drug|Cyclophosphamide|
45396993|NCT00278564|Drug|Mesna|
45396994|NCT00278564|Drug|ATG(rabbit)|
45396995|NCT00278564|Drug|Methylprednisolone|
45396996|NCT00278564|Drug|G-CSF|
45396997|NCT00278564|Drug|Rituxan|
45396998|NCT01071564|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
45396999|NCT01071564|Other|Laboratory Biomarker Analysis|Correlative studies
45397000|NCT01071564|Other|Pharmacogenomic Study|Correlative studies
45504734|NCT03555656|Behavioral|Repeated intervention|Repetition twice a year of a 2-h group session educating patients at foot hygiene and ulcer prevention
45397001|NCT01071564|Other|Pharmacological Study|Correlative studies
45504735|NCT03555656|Behavioral|Single session|Single 2-h group session educating patients at foot hygiene and ulcer prevention
45397002|NCT01071564|Drug|Vismodegib|Given PO
45397003|NCT03975296|Procedure|preoperative single-shot TMQLB|"The patient is placed in the lateral position. The curved probe of Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
45397004|NCT03975296|Procedure|preoperative single-shot TPVB|The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The curve probe of ultrasound scanner is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine is injected into the paravertebral space of T10.
45397005|NCT03975296|Drug|patient controlled intravenous analgesia(PCIA)|at the end of surgery, patient is administered a PCIA with morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.
45504736|NCT02093468|Drug|MST-188|
45504737|NCT02093468|Drug|Saline|
45504738|NCT03507855|Other|Reduced noise|All activity will cease when the patient enters the operating room and nonessential personnel will be removed. Ambient lighting will be reduced and communication devices muted.
45504739|NCT03507855|Other|Normal|No change in the normal operating room environment.
45504740|NCT02093546|Procedure|Biospecimen Collection|Undergo collection of blood and tumor
45504741|NCT03441555|Drug|Venetoclax|tablet, oral
45504742|NCT03441555|Drug|Alvocidib|Intravenous
45504743|NCT02098772|Drug|Custodiol-N|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
45504744|NCT02098772|Drug|Custodiol|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
45504745|NCT03357081|Drug|CEUS or Contrast enhanced Ultrasound|Real time contrast enhanced ultrasound with Lumason. CEUS or Contrast enhanced Ultrasound
45504746|NCT02093780|Behavioral|Alberta Anti-inflammatory diet|Patients randomized to Alberta Anti-inflammatory diet will follow a strict menu plan designed by certified dietitian for 6 months.
45504747|NCT02093780|Behavioral|Canada's Food Guide Diet|Patients randomized to Canada's Food Guide diet will receive counseling by certified dietitian for 6 months and will design their own diet following Canada's Food Guide.
45504748|NCT03346239|Behavioral|Gaze Contingent Music Reward Therapy|Feedback according to participants' viewing patterns, in order to modify their attention.
45504749|NCT03346239|Drug|Escitalopram|10-20 mg of Escitalopram
45504750|NCT03346239|Behavioral|Waitlist|Participants will wait for 12 weeks while in touch with the clinic, then receive GC-MRT for 8 weeks.
45504751|NCT05216289|Dietary Supplement|Probiac|Oral probiotic composed of Lactobacillus acidophilus, Bifidobacterium lactis, vitamins and minerals - Exímia Probiac® (EP), in combination with 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
45504752|NCT05216289|Other|Placebo|Placebo + 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
45504753|NCT02098928|Behavioral|Hand-acupuncture|Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
45504754|NCT02098928|Device|Electrico-acupuncture|Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
45849672|NCT05625516|Device|Bilateral external torque device|"The External Torque Device was developed, which allows bilateral stressing of the syndesmosis by external rotation. Both lower legs are stabilized by a special knee brace (the fibula remains free to float) or by the hip joints, which are end rotated on both sides, while an external rotation force of maximum 7.5Nm (or up to the respective pain threshold) can be set on both sides using torque newton meters. If no load is possible - which the examination of the syndesmosis generally does not allow - an intra-articular local anesthesia with 5ml ropivacaine 2mg/ml can be performed under sterile conditions after the patient's consent."
45397006|NCT03974256|Other|Training in the use of the automaton|2 days training on automaton use
45397007|NCT01073124|Procedure|Saline Load Test|Intraarticular injection of dilute methylene blue dye (1 ml per 500 ml normal saline) or normal saline into the knee joint through a lateral suprapatellar injection site. Maximum injection of 180 ml.
45397008|NCT00268346|Drug|ZD1839|ZD1839 treatment will be taken once a day PO, every day about the same time
45397009|NCT00203892|Biological|modified CEA peptide (10mcg)|Vaccine contained the modified CEA peptide (10mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
45397010|NCT00203892|Biological|modified CEA peptide (100mcg)|Vaccine contained the modified CEA peptide (100mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
45397011|NCT00203892|Biological|modified CEA peptide (1000mcg)|Vaccine contained the modified CEA peptide (1000mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
45397012|NCT00250718|Drug|Vincristine|Vincristine should be administered intravenously through a freely-running IV.
45504755|NCT02995551|Procedure|Arthroscopic meniscal repair or resection|Arthroscopic meniscal repair or resection following standard procedures.
45504756|NCT02995551|Behavioral|Exercise and education|A 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear combined with patient education teaching the participants about their disease and how to manage it through exercise and in their daily life.
45504757|NCT03556124|Device|Active - HD tDCS|Non-invasive neuromodulation using HD electrodes placed on the scalp to deliver a constant, low current at 2 mA.
45504758|NCT03556124|Device|Sham - HD tDCS|Sham neuromodulation using HD electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
45504759|NCT03556124|Device|Active - Conventional tDCS|Non-invasive neuromodulation using standard 7 cm x 5 cm electrodes placed on the scalp to deliver a constant, low current at 2 mA.
45397013|NCT00250718|Drug|VP-16|The VP-16 is optional for the first cycle if the patient has delays in obtaining the drug.
45397014|NCT00250718|Drug|Rituximab|"The total amount of rituximab needed for a patient's entire infusions (one course) will be determined at study entry. A single dose of 375 mg/m2 will be based upon the patient's actual body surface area calculated during the baseline evaluation. The dose level of rituximab will not be adjusted.~Patients will only receive rituximab if their tumors are CD20 positive CLL or NHL.~Rituximab will only be administered to patients if they have previously had less than 8 doses. If a patient is treated with rituxan they should have at least 4 doses"
45397015|NCT00250718|Drug|Dexamethasone|Dexamethasone will be administered at 200mg q 14 days. Dexamethasone should be administered over a 1 hour infusion.
45397016|NCT00250718|Drug|Levofloxacin|Levofloxacin will be administered at 500 mg PO qd.
45397017|NCT00276614|Drug|bortezomib|
45397018|NCT00276458|Drug|Comparator: atorvastatin|Atorvastatin 40mg tablet po qd (by mouth, once a day) for 6 weeks
45397019|NCT00276458|Drug|Comparator: Placebo|Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day). for 6 weeks
45397020|NCT00276458|Drug|Comparator: ezetimibe|Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day). for 6 weeks.
45397021|NCT00276458|Drug|Comparator: Placebo.|Atorvastatin 40mg Pbo tablets po qd (by mouth, once a day). for 6 weeks.
45397022|NCT00276380|Drug|EGb761|EGb761 (Tanakan) 40 mg tablets (2 tablets t.i.d. (3 times a day)) 240 mg/day for 6 months.
45397023|NCT00276380|Drug|Placebo|Placebo 40 mg tablets (2 tablets t.i.d.) 240 mg/day for 6 months.
45397024|NCT00276380|Drug|Acetylsalicylic acid|Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.
45397025|NCT03975218|Other|Patients With Stroke|In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
45397026|NCT02531984|Drug|Azithromycin|
45397027|NCT00267956|Drug|CNTO 1275 63 mg|The patients will receive 90 mg (or 63 mg after filtration) subcutaneous injection on Weeks 0, 1, 2, and 3; Placebo subcutaneous injection on Weeks 12 and 16.
45397028|NCT00267956|Drug|Placebo|The patients will receive placebo subcutaneous injection on Weeks 0, 1, 2, and 3; At weeks 12 and 16 the patients will receive CNTo1275 90 mg (or 63 mg after filtration) subcutaneous injection
45397029|NCT01072292|Behavioral|CBT-I|CBT-I is a six week program designed to improve sleep quality in people with COPD.
45397030|NCT00267488|Drug|topotecan|
45397031|NCT01073696|Drug|granisetron IV|IV
45397032|NCT01073696|Drug|granisetron patch|patch
45397033|NCT00046930|Biological|filgrastim|250 μg/m2/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to > 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
45397034|NCT00046930|Biological|sargramostim|5 μg/kg/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to > 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
45397035|NCT00046930|Drug|cytarabine|100 mg/m²/day by continuous intravenous infusion for 7 days (days 1-7).
45397036|NCT00046930|Drug|daunorubicin hydrochloride|45 mg/m²/day by 10 - 15 minute intravenous infusion for 3 days (days 1, 2, and 3).
45397037|NCT00046930|Drug|zosuquidar trihydrochloride|"Zosuquidar 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3."
45397038|NCT00046930|Drug|Placebo|"Placebo 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3. Placebo consisted of a 1:1000 dilution of Infuvite, appropriately colored."
45397039|NCT00058552|Drug|Pertuzumab (rhuMAb 2C4)|
45397040|NCT03954496|Device|transcranial direct current stimulation|This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.
45397041|NCT03954496|Behavioral|Intensive upper extremity motor training|This training is administered one-on-one with an occupational therapist. Activities will be focused on skills the participant wants to regain.
45397042|NCT01093768|Drug|Oxytocin|
45397043|NCT01093768|Drug|Vasopressin|
45397044|NCT03954418|Dietary Supplement|Acesulfame K, cyclamate, saccharine, aspartame|Intervention group receives a combination of multiple artificial sweeteners
45397045|NCT03954340|Device|iRemember Neurofeedback (NFB)|"Neurofeedback (NFB) is a treatment technique based on learning with operant conditioning, in which a feedback (or a reward) is given in proportion with the desired physiological activity in order to improve cognition and/or behavior. This research will focus on EEG-NF where electrical activity measured with EEG serves as the physiological activity to be influenced.~EEG-NFB has been successfully used as a clinical tool for over 40 years treating various disorders from Autism , ADHD , Epilepsy , OCD and depression Electroencephalography (EEG) equipment is used to measure the electrical activity representing the neuronal activity of different parts of the brain.~During the treatment, electrode(s) are placed in predetermined location. Audio and visual rewards are given when the activity is measured to be within the desired frequency range."
45397046|NCT01096108|Behavioral|Standard contest (1 month)|Smoking abstinence, 1 prize award (month 1)
45849673|NCT05625282|Procedure|Weil osteotomy|Open, oblique, distal osteotomy of the metatarsal bone, with screw fixation.
45849674|NCT05625282|Procedure|Plantar plate repair|Plantar plate reconstruction at metatarsophalangeal area, using sutures.
45397047|NCT01096108|Behavioral|Motivational and Problem-Solving|Counseling phone calls
45397048|NCT01096108|Behavioral|Extended Contests|Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
45397049|NCT03954028|Procedure|Gingival Punch Biopsy after healing of Gingival Soft Tissue Augmentation|Patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. The autogenous connective tissue (CTG) graft material will be randomized to apply to one half, and commercial acellular dermal matrix (ADM) materials will be used in the opposite half. After 3 months of healing, a gingival punch biopsy will be performed in both sides to collect the tissues for analysis.
45397050|NCT00044512|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)
45397051|NCT03956524|Biological|EuTCV|Single 0.5 mL dose of TCV of EuBiologics co., Ltd.
45397052|NCT03956524|Biological|Typbar-TCV™|Single 0.5 mL dose of TCV of Bharat Biotech
45397053|NCT03956524|Biological|Typhim Vi®|Single 0.5 mL dose of Vi capsular polysaccharide vaccine of Sanofi Pasteur
45397054|NCT03953638|Diagnostic Test|Next Generation Sequencing|To provide rapid etiological diagnosis of patients by means of next-generation sequencing.
45397055|NCT03805438|Drug|Chloroprocaine Hcl 3% Inj|"Initial Patient (A#X) 45mg (1.5mL) of Chloroprocaine 3% (Nesacaine - Fresenius Kabi), will be drawn up into a 3 ml syringe (a 1 ml 'TB syringe' will be used to aspirate the drug in aliquots to ensure accuracy). The following additive will be added: 10 mcg (0.2ml) of fentanyl (50 mcg/ml) 0.3 ml of sterile 0.9% sodium chloride Thus the total volume in the syringe will be 2 ml. Study drugs will be prepared by one anesthesiologist (un-blinded) and administered by another anesthesiologist (blinded).~Subsequent Patient (A#X+1) The dose of Chloroprocaine 3% based on outcome from prior subject and calculations mentioned previously will be added to 10 mcg (0.2ml) of fentanyl (50 mcg/ml). Sterile 0.9% sodium chloride will be added until the total volume in the syringe is 2 ml."
45397056|NCT01584154|Procedure|cryoablation|cryoablation with an 8mm-tip catheter
45397057|NCT01584154|Procedure|radiofrequency ablation|radiofrequency ablation with a 4mm-tip catheter
45397058|NCT01096264|Other|SSI and SphygmoCor® evaluations|"SSI evaluation need Aixplorer vascular ultrasound machine (available in our department) with 8 MHz linear array probe applied on the carotid and femoral artery.~SphygmoCor® evaluation used pressure captors on carotid and femoral sites to record the intra-arterial pressure wave time delay after QRS wave. After distance calculation between the two sites, Aortic PWV can be derived."
45397059|NCT01096420|Procedure|acupuncture|"Each patient had a fixed and classic acupuncture points Ex-HN-3,BL-2,GB-20,EX-HN-5 bilaterally in their 24 sessions.~Acupuncture consisted of 24 sessions of 30 min duration, administrated over 12 weeks (two sessions per week).~Sterile disposable and steel needle (3210) were used .~The needles were manipulated by rotation methods to produce a characteristic sensation know as De Qi."
45397060|NCT01096420|Drug|topiramate|"The patients were submitted to the topiramate treatment also for 12 consecutive weeks.~The study phase consists of a 4-week titration and a 8-week maintenance period.~All dosages of topiramate will be initiated at 25 mg/d hs and increased by 25 mg/d weekly to a maximum of 100 mg/day (or to the maximal tolerated dose).~Study drug was administered daily in equally divided twice daily doses."
45397061|NCT01096888|Behavioral|Enhanced WIC Program|Applying an internet based weight loss intervention to participants in the WIC program to enhance weight loss post partum.
45397062|NCT03953716|Device|low level light therapy|Start using low level light therapy after the menstrual period, once a day, every 20 minutes * 5 days ( one treatment cycle), start the next course at intervals of 2 days until the next menstruation
45397063|NCT03953716|Drug|DING KUN DAN|DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) *3 menstrual cycle
45397064|NCT03953716|Drug|Simulated drug of DING KUN DAN|Simulated drug of DING KUN DAN，3.5g BID for 10 days (starting 3-5 days before menstruation) *3 menstrual cycle
45397065|NCT03953716|Drug|Marvelon|Marvelon 1 pill QD*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) *3 menstrual cycle
45697325|NCT05075109|Other|Task Related Training|"Each session of TRT would include:~1. postural control, 2. shoulder mobilization, 3. weight bearing exercises 4. Functional activities that will comprise of simple tasks to more advanced movement patterns as follows:~Reaching activities~Forward supported reach with cane on tabletop~Reaching against gravity~Reaching overhead with active wrist/hand movements~Dynamic reaching to target e.g. catch a ball~Grasping, holding and release~Grasp, hold and release objects with gravity minimized~Pick up and move/release small objects on table~Pick up and move/release large objects without proximal support~Incorporate pinch grips in hold and release including stacking, lifting and overhead activity~Upper limb ADL~Brushing hair, putting on scarf~Opening bottles, turning off water tap~Writing, drawing~Folding of towels, hanging towels and setting table~Self-feeding"
45397066|NCT01096498|Drug|Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|Single dose of one 0.75 mg coated tablet
45697326|NCT01029730|Drug|Bendamustine|Bendamustine: 90 mg/m2 Days 1 and 2 of 6, 28-day cycles
45697327|NCT01029730|Drug|Bortezomib|Bortezomib: 1.6 mg/m2 given IV on Day 1, Day 8, and Day 15 of 6, 28-day cycles
45397067|NCT01096498|Drug|Levonorgestrel (Postday)|Single dose of one 0.75 mg tablet
45397068|NCT01096576|Drug|balapiravir [RO4588161]|sequential cohorts receiving doses orally twice daily for 5 days
45504760|NCT03556124|Device|Sham - Conventional tDCS|Sham neuromodulation using standard 7 cm x 5 cm electrodes electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
45504761|NCT02820753|Behavioral|EHR + (Text or Portal)|"Per protocol analysis:~Patients who received the initial 6 weeks of SMS messaging continuously, or logged on to the patient portal and completed at least one survey."
45504762|NCT03556046|Diagnostic Test|89Zr-Girentuximab|Single diagnostic injection on Day 0, followed by diagnostic scans on Days 3 and 7±1, as well as the whole body dosimetric imaging on Days 0, 1, 3 and 7±1
45504763|NCT05218161|Drug|Dexmedetomidine alone|All the patients in group DA will be sedated using dexmedetomidine 1mcg/kg IV bolus, followed by 0.3-0.7mcg/kg/h infusion to maintain Ramsay sedation score ≥4 during assisted ventilation.
45504764|NCT02861586|Biological|MV-CHIK low dose|recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection, 5xE4 (± 0.5 log) TCID50/dose
45397069|NCT01096576|Drug|placebo|orally twice daily for 5 days
45397070|NCT01097122|Procedure|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups
45397071|NCT00147537|Drug|CP-751,871|"Phase 2 Arm A:~CP-751,871 20 mg/kg IV over 2.5 hours up to 17 cycles"
45397072|NCT00147537|Drug|paclitaxel|"Phase 2 Arm A:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles~Phase 2 Arm B:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles"
45397073|NCT00147537|Drug|carboplatin|"Phase 2 Arm A:~Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles~Phase 2 Arm B:~Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles"
45397074|NCT00147537|Drug|CP-751,871|Phase 1b Dose Escalation/Expansion: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles) Phase 1b Erlotinib Extension: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles)
45849675|NCT05624112|Drug|Dupilumab|Dupilumab solution in a pre-filled syringe for Subcutaneous injection
45397075|NCT00147537|Drug|paclitaxel|Phase 1b Dose Escalation/Expansion: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles) Phase 1b Erlotinib Extension: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles)
45397076|NCT00147537|Drug|carboplatin|Phase 1b Dose Escalation/Expansion: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles) Phase 1b Erlotinib Extension: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles)
45397077|NCT00147537|Drug|erlotinib|Phase 1b Erlotinib Extension: erlotinib 150 mg/day orally every day (up to 17 cycles)
45397078|NCT01326507|Biological|Dosage de l'h-FABP|Dosage de l'h-FABP
45397079|NCT00222729|Drug|Pemetrexed|500 mg/m2 day 1 q 21 days
45397080|NCT00222729|Drug|Bevacizumab|15 mg/kg IV q 21 days following pemetrexed
45397081|NCT00147225|Drug|AMG 531|"Beginning with Cycle 2, administered in one of two schedules, either on day after chemotherapy and 2 days later (study cycle) or on day -5 (pre dose) and on day after chemotherapy (post dose) or combination of pre/post days of 21-28 day treatment cycle. Combination if Optimal biological dose (OBD) not reached, additional treatment at 10 mcg/kg dose level, with AMG 531 administered on day -5 (pre dose) and on day after chemotherapy (post dose).~1, 3, or 10 mcg/kg given as injection under the skin (subcutaneous)"
45397082|NCT00147225|Drug|Carboplatin|AUC=11; Cycle 1 chemotherapy alone then 3 weeks later, in Cycle 2, same dose of chemotherapy followed by AMG 531.
45397083|NCT00147225|Drug|Adriamycin|75-90 mg/m^2 IV
45504765|NCT02861586|Biological|MV-CHIK high dose|recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection; 5xE5 (± 0.5 log) TCID50/dose
45504766|NCT02861586|Biological|Priorix®|lyophilized mixed preparation containing the attenuated Schwarz measles virus strain, the RIT 4385 strain of mumps virus (derived from the Jeryl Lynn strain) and the Wistar RA 27/3 rubella virus strain. Powder and solvent for suspension for injection
45504767|NCT02861586|Biological|physiological saline solution|sterile physiological saline solution 0.9% used as placebo
45504768|NCT02096822|Behavioral|Facilitated tucking + non-nutritive sucking|
45504769|NCT02096822|Other|non-nutritive sucking|
45504770|NCT05217771|Other|High tone power therapy group|patients in this group will receive High tone power therapy from 30 to 60 minutes, 3 session /week for 4 weeks with total sessions at least l0 sessions and self-stretch for hand and shoulder.
45504771|NCT02094014|Behavioral|Normal Auditory Feedback|Participants will produce sentences under normal speaking conditions, able to hear their own speech.
45397084|NCT00147225|Drug|Ifosfamide|10 gm/m^2 IV; OR, High dose ifosfamide = 14 gm/m^2.
45397085|NCT00222105|Drug|Doxil|Doxil 40 mg/m2 IV day 1
45397086|NCT00222105|Drug|Thalidomide|50-100 mg day 1-28
45397087|NCT00222105|Drug|Dexamethasone|Dexamethasone 40 mg day 1-4 and 15-18
45397088|NCT00146757|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|100 U/kg every week
45504772|NCT02094014|Behavioral|Masked Auditory Feedback|Participants will produce sentences while listening to speech-shaped noise at 85 decibels (sound pressure level) to mask ability to hear their own speech.
45504773|NCT02094014|Behavioral|Altered Auditory Feedback|Participants will produce sentences while listening to their speech shifted up one octave and delayed.
45504774|NCT02099162|Device|coronary stents|e.g. Sirolimus eluting stent, Paclitaxel-eluting stent, Zotarolimus-eluting stent, Everolimus-eluting stent, Biolimus eluting stent, EPC(endothelial progenitor cell) Capture stent, etc
45397089|NCT00146757|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|200 U/kg every week (Week 26 onwards)
45397090|NCT00267098|Device|Cardiac Resynchronization Therapy (CRT)|Biventricular pacing
45397091|NCT00267098|Device|Cardiac Resynchronization Therapy (CRT)|Right ventricular pacing
45504775|NCT02099240|Drug|oral antibiotics|intravenous antibiotics with early switch to oral antibiotics, antibiotic type will be dependent on bacteria type
45504776|NCT02099240|Procedure|intravenous antibiotics|intravenous antibiotics for the full duration of therapy, antibiotic type will be dependent on bacteria type
45504777|NCT02384421|Device|Adaptive DBS (Activa PC+S Neurostimulator)|
45504778|NCT02384421|Device|Continuous DBS (Activa PC+S Neurostimulator)|
45504779|NCT03610074|Other|Mint Ice Cube|Application in patient's mouth of 3 mint ice cubes
45504780|NCT03610074|Procedure|Blood test|Additional blood test 5 min after mint ice cubes application
45504781|NCT03610074|Other|Patient's questioning|Patient's questioning before mint ice cubes application and at 5 min, 1h, 2h, 4h, 12h and 24h from mint ice cubes application
45504782|NCT05215977|Drug|MW031|"The active ingredient of MW031 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU"
45504783|NCT05215977|Drug|Placebo|"subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU"
45504784|NCT02034084|Procedure|left radial approach|Coronary diagnostic procedures performed through left radial approach
45697328|NCT01029730|Drug|Rituximab|Rituximab, Cycle 1: 375 mg/m2 given IV on Day 1, Day 8, and Day 15 Rituximab, Cycles 2-6: 375 mg/m2 given IV on Day 1
45397092|NCT00247676|Drug|Sunitinib (SU011248)|Sunitinib 50 mg by oral capsule, daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
45397093|NCT01073774|Behavioral|Side by side|
45397094|NCT01073774|Behavioral|couples control condition|
45504785|NCT02034084|Procedure|Right radial approach|coronary diagnostic procedures performed through right radial approach
45504786|NCT05215899|Other|MINDFULNESS-BASED YOGA AND MEDITATION|The application was carried out by the researcher who had completed mindfulness-based yoga and meditation training.
45504787|NCT03609450|Behavioral|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action plan during Week 7. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
45504788|NCT03609450|Behavioral|Low-Dose Comparator|Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, and discussion. They are also given a list of leading community, online, print, and smartphone mindfulness resources. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
45697329|NCT03315975|Biological|Inactivated influenza vaccine|One dose of quadrivalent inactivated influenza vaccine
45397095|NCT00267020|Drug|enzastaurin|1200 milligrams (mg) loading dose then 500 mg, orally, daily, six 28-day cycles
45397096|NCT00267020|Drug|gemcitabine|1000 milligrams/square meter (mg/m^2), intravenously on Days 1, 8 and 15 per cycle, six 28-day cycles
45397097|NCT03975062|Drug|dabigatran etexilate|150 mg twice daily (BID)
45697330|NCT05552235|Device|Elbow SOFT 300|15 patients will be included in this group and will used the medical device ElbowSOFT 300 during sport practice (at least 2 sport sessions per week), for 6 weeks.
45697331|NCT05552235|Other|Control group|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device), for at least 2 sport sessions per week during 6 weeks.
45397098|NCT03970772|Drug|Glucagon Injection|Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using mini-dose glucagon when their BG in range 40-69 mg/dl according a prescribed protocol.
45504789|NCT05383248|Behavioral|High Reward - High Variance|Computerized reward learning task designed to increase reward responsiveness
45504790|NCT05383248|Behavioral|High Reward - Low Variance|Computerized reward learning task designed to have minimal effect on reward responsiveness
45504791|NCT02245230|Drug|Angiotensin (1-7)|Angiotensin (1-7) is a peptide produced by the body. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 20 ng/kg/min.
45504792|NCT02245230|Drug|Trimethaphan|Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
45504793|NCT02245230|Drug|Phenylephrine|Phenylephrine is an alpha 1-adrenergic agonist. It will be administered as an acute intravenous infusion to restore blood pressure following trimethaphan with doses ranging from 0.1 to 0.5 ug/kg/min.
45504794|NCT05215743|Drug|Antioxidant formula|Active therapy
45504795|NCT05215743|Drug|Dextrose 5% in water|Placebo
45504796|NCT02099396|Drug|Docetaxel+lobaplatin|
45504797|NCT02099396|Drug|Gemcitabine+lobaplatin|
45504798|NCT05215665|Drug|GEMOX Regimen|Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W
45849676|NCT05623254|Other|no comparator - TAU (Treatment-as-usual)|"Learning the ability in mindfulness practice by specific measure (FFMQ) changes in FIVE FACET MINDFULNESS QUESTIONNAIRE (FFMQ) compared to baseline): this questionnaire measures the mindfulness ability of patients before and after the APP application (minimum score 113.7-low mindfulness ability=worse outcome ; maximum score 144.3-high mindfulness ability=better outcome) [Time Frame: At Three-six months]~Introduction of the mindfulness program during a preliminary face-to-face session to patients and caregivers~TAU Weekly mindfulness sessions delivered on-line for patients and caregivers (a specific platform for on-line sessions will be used)"
45397099|NCT03970772|Other|Glucose Tablets|Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using glucose tablets when their BG in range 40-69 mg/dl according a prescribed protocol.
45397100|NCT03970928|Device|PVI|A pulse oximetry probe which transfers data to the monitor with software able to calculate PVI data. The monitor automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor.
45504799|NCT05215665|Drug|Lenvatinib|8/12mg PO QD continuously
45697334|NCT05066997|Drug|Active treatment arm: OCS-01 (dexamethasone)|The interventional drug OCS-01 eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit
45849677|NCT05612022|Procedure|AVF creation|AVF is surgically created in the forearm by an anastomosis between a vein and an artery
45397101|NCT03970850|Diagnostic Test|NeuMoDx CT/NG Assay|NeuMoDx CT/NG Assay as implemented on NeuMoDx 288 Molecular System and NeuMoDx 96 Molecular System
45504800|NCT05215665|Drug|Toripalimab|240mg IV d1 Q3W
45504801|NCT02094092|Other|ProTectis drops (five drops per day) for 21 days|
45504802|NCT02094092|Other|Placebo drops (five drops per day) for 21 days|
45504803|NCT03627663|Behavioral|Dialectic Behavior Therapy - Skills System|Treatment with Dialectical Behavior therapy adapted for cognitively challenged individuals
45504804|NCT02099474|Other|Study of pharmacokinetic properties of raltegravir during the 3rd trimester of pregnancy|Introduction of a catheter for performing 5 blood samples in pregnant women infected by HIV-1, before the raltegravir intake, 0.5, 3, 8 and 12 hours after the intake at each of two visits (between 30 and 37 weeks of amenorrhea, and 4 to 6 weeks after delivery)
45504805|NCT02250638|Other|CA 19-9 Assay|Physicians use the CA 19-9 test results to manage their patients
45504806|NCT05667753|Behavioral|MINISTOP 3.0|MINISTOP 3.0 is a behavioral changed program with the overall aim to promote healthier lifestyle behaviors (i.e., diet, physical activity, and sedentary behavior) among 2.5/3-year old children. The MINISTOP 3.0 program consists of features such as information, monitoring, and feedback (dietary variables, physical activity, and screen time) and is built around 13 themes over a 6-month period.
45504807|NCT02250716|Procedure|cryotherapy|cryotherapy for cervical intraepithelial neoplasia in HIV infected women vs control arm of standard of care (repeat pap smear in 1 year)
45504808|NCT05217147|Other|Obtaining blood samples|Blood samples were obtained at time of diagnosis and will be analyzed for the levels of biomarker candidate molecules.
45504809|NCT03555500|Other|Non fasting|Non fasting group is allowed for clear fluids and food up to the time of the procedure.
45697335|NCT05066997|Drug|Vehicle|The vehicle drug (placebo) eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit
45697336|NCT05345535|Other|Trampoline exercise|45 minutes of exercises that includes upper and lower extremity movements a trampoline with music
45697337|NCT05345535|Other|Walking|45 minutes of moderate tempo walking
45697338|NCT03273621|Procedure|Bariatic surgery|One of two different types of surgery: sleeve gastrectomy and Roux-en-Y gastric by-pass.
45504810|NCT05217069|Drug|5-FU|400 mg/m2 (i.v. bolus) 2400 mg/m2 (i.v. 46h)
45504811|NCT05217069|Drug|Folinic Acid|400mg/m2
45504812|NCT05217069|Drug|Irinotecan|180 mg/m2
45504813|NCT05217069|Drug|Cetuximab|400 mg/m2 i.v. 120min initial dose 250 mg/m2 i.v. 60min q 1w
45504814|NCT05217069|Drug|Avelumab|10mg/kg IV (day 1 q2w)
45504815|NCT02096978|Procedure|Preparing the osteotomy to accept a standard implant device|Preparing the osteotomy with one of two randomly assigned protocols
45504816|NCT05209737|Procedure|Trendelenburg position|A 10-degree head-down position will be used in this group
45504817|NCT05209737|Procedure|Semirecumbent position|A 30-degree head-up position will be used in this group
45504818|NCT02291523|Biological|Fecal Microbial Transplant|Fecal Transplant via Colonoscopy.
45504819|NCT02250170|Drug|OPB-111077|Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on & 3 days-off (21 days=1cycle)
45504820|NCT02065635|Procedure|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
45504821|NCT02065635|Procedure|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
45504822|NCT02097368|Procedure|tongue strength measurement|tongue strength measurement
45504823|NCT02097368|Procedure|respiratory function measurement|respiratory function measurement
45504824|NCT02097368|Procedure|swallowing tests|swallowing tests
45504825|NCT02097368|Other|Magnetic resonance imaging|Magnetic resonance imaging
45504826|NCT05425784|Device|Lumoral treatment|The investigational Lumoral treatment -device provides a constant and repeatable application which can be done at home and is easily available. All subjects in the study group will receive their own Lumoral treatment -device and Lumorinse-mouth rinse tablets for the complete duration of the study.
45504827|NCT05425784|Other|Standard oral hygiene self care|Both groups shall be given oral and written instructions for twice-daily standard oral hygiene self-care.
45504828|NCT03556748|Other|whole-body electromyostimulation|WB-EMS training is performed 2x/week for a total of 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
45504829|NCT02094248|Drug|TPO|rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000U/ml, s.c injection
45504830|NCT02094248|Drug|control|Normal saline，1ml/day, s.c injection
45697339|NCT05025033|Drug|PD-1 antibody, paclitaxel or irinotecan, Apatinib mesylate|PD-1 antibody 200mg intravenous drip every 3 weeks; Apatinib 250mg/day; Chemotherapy: Irinotecan 150mg/m2, intravenous drip every 2 weeks, or Paclitaxel 150mg/m2, intravenous drip, once every 3 weeks.
45697340|NCT00980746|Drug|Eslicarbazepine acetate|Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.
45849678|NCT05612022|Procedure|AVG creation|Surgery is done using an artificial plastic tube that connects an artery to a vein
45849679|NCT05605548|Dietary Supplement|MitoQ|MitoQ is a mitochondrial targeted antioxidant that can be obtained over-the-counter.
45397102|NCT03970850|Diagnostic Test|FDA-cleared NAATs|Testing swabs and urine specimen from both male and female subjects on the FDA-cleared NAATs
45397103|NCT00242216|Drug|ritonavir-boosted atazanavir|100 mg ritonavir plus 300 mg atazanavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
45397104|NCT00242216|Drug|ritonavir-boosted fosamprenavir|100 mg ritonavir plus 1,400 mg fosamprenavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
45397105|NCT00240110|Drug|Valproate|Valproate with dose titration to achieve blood levels within the therapeutic range
45397106|NCT00240110|Drug|Placebo|Control arm
45397107|NCT00240110|Drug|Lithium Carbonate|All participants were started and stabilized on lithium carbonate as a standard treatment for bipolar disorder
45397108|NCT00239720|Drug|hOKT3gamma1(Ala-Ala)|Escalating dose given IV over 5 days (1mg, 2mg, 4mg on days 3-5) of each 28 day cycle
45504831|NCT02250248|Biological|AttraX Putty|
45504832|NCT02250248|Other|Iliac Crest Bone Graft (ICBG)|
45504833|NCT02099942|Device|V8 Balloon Aortic Valvuloplasty (BAV) Catheter|"The V8 device can be used for BAV as follows:~as stand-alone intervention~as a bridge to transcatheter aortic valve replacement (TAVR)~as a bridge to surgical aortic valve replacement (SAVR)~as an intraprocedural predilatation prior to TAVR"
45697341|NCT00980746|Drug|Placebo|oral route
45849680|NCT05605548|Other|Placebo|"A look-alike inactive substance, a sugar pill"
45504834|NCT02100020|Other|Direct Referral to physical activity|Participants randomized to the Direct Referral to Physical Activity Arm will be provided with a referral to a physical activity program in their community and will be closely monitored in this program for 16 wks.
45504835|NCT02097446|Device|Guardix-FL|
45504836|NCT02097446|Device|Interceed|
45504837|NCT02097524|Drug|Sarilumab|
45504838|NCT02097524|Drug|Tocilizumab|
45504839|NCT03628053|Biological|Tisagenlecleucel|autologous cellular immunotherapy product
45504840|NCT03628053|Drug|Blinatumomab|bispecific CD19-directed CD3 T-cell engager
45504841|NCT03628053|Drug|Inotuzumab|CD22-directed antibody-drug conjugate
45504842|NCT02100176|Other|Multidisciplinary intensive rehabilitation treatment|The first session comprises cardiovascular warm-up activities, relaxation exercises, muscle-stretching exercises, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in supine position. The second session comprises exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill plus. The last session is a session of occupational therapy aimed to improve autonomy in daily living activities.
45504843|NCT02100176|Drug|Rotigotine|Rotigotine 2-8 mg/24 h
45504844|NCT02250482|Biological|Optivate® (Human Coagulation Factor VIII)|
45849681|NCT05595876|Procedure|stent retriever thrombectomy|The technique used should be in accordance with the device IFU (instructions for use). A large bore access guide catheter possible is mandatory. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE (european compliance)-marked stent retriever device is then deployed across the occlusion. A contact aspiration large bore catheter can be used in association with the stent retriever. A minimum of 3 attempts with Stent retriever should be performed. A revascularization score will be recorded after each device attempt.
46057040|NCT03985852|Other|Patient Directed Standard of Care|The pre-test genetic counseling visit will be conducted through access to an automated genetics education assistant accessed through the patient portal. The automated approach will address all the components of the pre-test counseling and contains content designed by the genetic counselors at the University of Utah and NYU. Patients will have the option to contact genetic counselors through the patient portal, by phone, or in person but this will not be required. All results will be reviewed by a genetic counselor. Negative results will be returned by the automated genetics education assistant. Genetic counselors will return results for pathogenic variants and variants of uncertain significance via phone.
45397109|NCT00239720|Drug|Placebo|Intravenous dose of placebo given over 5 days of each 28 day cycle
45397110|NCT02532140|Drug|WCK 5107 250 mg to 2000 mg|
45397111|NCT02532140|Drug|Cefepime 2000 mg|
45397112|NCT02532140|Drug|WCK 5107 1000/2000 mg with Cefepime 2000 mg combination|
45397113|NCT02532140|Drug|Placebo|
45397114|NCT00266864|Drug|Testosterone Transdermal System (Androderm 5 mg patch)|Testosterone Transdermal System (Androderm 5 mg patch)
45397115|NCT00266708|Drug|Risedronate|risedronate 35 mg weekly
45397116|NCT00266708|Drug|Placebo|Risedronate Placebo 35 mg weekly
45397117|NCT00266630|Drug|olanzapine|oral, daily
45397118|NCT00266630|Drug|lithium|Dose adjusted according to local package insert
45397119|NCT00266630|Drug|valproate|Dose adjusted according to local package insert
45397120|NCT00266630|Drug|carbamazepine|Dose adjusted according to local package insert
45397121|NCT02531672|Drug|11C-choline|
45397122|NCT02531672|Device|PET/CT Scan|
45397123|NCT00129129|Biological|GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine|Primary phase: 3 IM doses Booster phase: 1 IM dose
45397124|NCT00129129|Biological|ActHIB|Primary phase: 3 IM doses Booster phase: 1 IM dose
45397125|NCT00129129|Biological|Pediarix|Primary phase: 3 IM doses
45397126|NCT00129129|Biological|Prevnar|Primary phase: 3 IM doses Booster phase: 1 IM dose
45397127|NCT00129129|Biological|Menomune|Primary phase: 1 SC dose
45397128|NCT00221403|Drug|Risperidone oral solution|liquid, BID dosing.
45397129|NCT00221403|Drug|Valproate Oral Solution|liquid, BID dosing.
45397130|NCT00221403|Other|Placebo|liquid, BID dosing.
45397131|NCT00145977|Drug|Alendronate|alendronate 70 mg once weekly
45397132|NCT00145977|Dietary Supplement|Calcium Citrate|600 mg of calcium citrate
45397133|NCT00145977|Dietary Supplement|Vitamin D|500 mg of Vitamin D consumed with the evening meal.
45397134|NCT00238238|Biological|rituximab|Given IV
45397135|NCT00238238|Drug|lenalidomide|Given orally
45397136|NCT03970460|Device|Primary TKA with cemented modular metal-backed tibial implant|Tibial implant will be done with a cemented implant
45397137|NCT03970460|Device|Primary TKA with uncemented trabecular metal|Tibial implant will be done with a uncemented implant
45397138|NCT03970148|Procedure|Nd: YAG laser|Before treatment an optical coherence tomography (OCT) scan of the macula is performed to monitor possible macular oedema. After application of anesthetic and midriatics drops, the patient is positioned on the chin and forhead support (ND: YAG laser). Then, a contact lens (panfundoscope) is filled with methylcellulose and placed on the cornea. The laser is focused on the opacity that is to be treated and the first laser stamp of an initial power of 3 mJ is applied. The measured direct effect will guide in further adjustment of the laser beam power to achieve the desired effect. After treatment, a single drop of corticosteroid is applied to the patient and an ocular patch is applied. On follow up days an OCT scan of the macula is performed to monitor possible side effects.
45397139|NCT01073852|Drug|Placebo|Placebo pill, 1 pill orally twice daily for 9 weeks.
45397140|NCT01073852|Drug|Hydroxychloroquine|Patients will be taking hydroxychloroquine 200mg orally twice/daily.
45397141|NCT01071122|Drug|Nifedipine (Adalat, BAYA1040) and Valsartan|Combination treatment with nifedipine GITS 30mg and valsartan 80mg, Once daily
45397142|NCT01071122|Drug|Nifedipine (Adalat, BAYA1040)|Nifedipine 60mg, Once daily
45397143|NCT01071122|Drug|Valsartan|Valsartan 160mg, Once daily
45397144|NCT03973190|Procedure|Immediate alveolar regeneration after exodontia|The extractions will be performed under local anesthesia, without making a mucoperiosteal flap, making an intraassucular incision and using appropriate periotomes, elevators and forcépes, minimizing the surgical trauma of surrounding tissues. Thorough curettage of the alveolus will be performed at the time of extraction to ensure removal of all granulation tissue and stimulate bleeding from the bone base, to form blood clot and promote healing. The sutures will be removed after 7 days of surgery, except for patients in group 3, in which sutures will not be made.
45397145|NCT03973190|Procedure|installation of dental implant and collection of biological material|The material was collected for histological analysis, extracted with trephine drill of 2.0 mm in diameter. Samples were removed before the incision. A linear incision was then made on the alveolar ridge in the region and flap detachment. The initial insertion of the implant was performed using the contra-angle at 30 rpm, the final insertion of the implant was performed with manual torque wrench, where the insertion torque was measured and the value was tabulated, not exceeding 60 N. cm. The component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. The prosthetic component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. the tabulated values and the incision was sutured.
45504845|NCT01377753|Device|Visualase Thermal Therapy System|Used for performing Laser Induced Thermal Therapy to destroy malignant or unwanted tissue by delivering laser energy sufficient to cause coagulation and necrosis of the tissue.
45849682|NCT05595876|Procedure|contact aspiration thrombectomy|A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch microwire inside is then introduced into a large-bore aspiration catheter and this construct is introduced into the long sheath as a unit. A large bore balloon guide catheter has to be placed into the cervical internal carotid artery. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. Once thrombus will be close to the aspiration catheter, then the system will carefully removed as a unit under continuous aspiration.
45849683|NCT05588388|Drug|Bevacizumab|Addition of Bevacizumab to current standard of care treatment (atezolizumab, carboplatin and etoposide) followed by maintenance Bevacizumab plus Atezolizumab for patients with ES-SCLC with LM
46057041|NCT03960424|Other|Comprehensive Outpatient Management|Patients receiving comprehensive outpatient management experience typical care received in the outpatient setting.
46057042|NCT03960424|Behavioral|Diabetes Telemonitoring|Diabetes Telehealth Management (DTM), based on the 2018 ADA Standards for T2D, uses smart devices to share information between patients, caregivers, and clinicians.
45397146|NCT03973190|Device|ISQ analysis|The prosthetic component already installed. On it is adapted the SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden). According to the manufacturer, the device generates a series of signals with different frequencies in Hertz (Hz) and these values are immediately converted to ISQ (Implantation Stability Coefficient), providing fast and accurate monitoring. The calibration is performed on the buccal and palatal surfaces of the intermediaries, that is, each implant was submitted to 2 readings. The readings were captured and tabulated for further analysis. were repeated at intervals of 7 to 10 days, 30 days and 60 days, for evaluation of SSI in the period of osseointegration. With the objective of not subjecting the implant to torque and torque during this period and to avoid interfering with the osseointegration process, the micro-pillars were covered with the micro-pillar protection screws with digital pressure only.
45397147|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|One oral dose of new formula Aspirin Prototype 1 under fasting conditions
45397148|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|One oral dose of new formula Aspirin Prototype 2 under fasting conditions
45397149|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|One oral dose of Aspirin Plain Tablet under fasting conditions
45397150|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|One oral dose of Aspirin Dry Granules under fasting conditions
45397151|NCT00128661|Biological|human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine|Three doses of Cervarix vaccine administered on a 0, 1, 6-month schedule
45397152|NCT00128661|Biological|hepatitis A inactivated virus vaccine|Three doses of Havrix vaccine administered on a 0, 1, 6-month schedule
45397153|NCT03975140|Procedure|Hypersensitive acupoint group|The first five acupoints in the sensitization sequence were pressed using the traditional Chinese medicine acupoint pressing technique, and each acupoint was pressed for two minutes.
45397154|NCT03975140|Procedure|Hyposensitive acupoint group|The last five acupoints in the sensitization sequence were pressed using the traditional Chinese medicine acupoint pressing technique, and each acupoint was pressed for two minutes.
45397155|NCT01072760|Procedure|K wire|Mallet finger treatment
45397156|NCT00145509|Drug|Asenapine|Asenapine 5 or 10 mg twice daily (BID) sublingually for 40 weeks
45397157|NCT00145509|Drug|Placebo|Fast-dissolving tablet; twice daily (BID) sublingually for 40 weeks
45397158|NCT03965871|Drug|Esketamine DPI - low dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
45397159|NCT03965871|Drug|Esketamine DPI - medium dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
45397160|NCT03965871|Drug|Esketamine DPI - high dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
45397161|NCT03965871|Drug|Placebo DPI|Placebo DPI is to be administered via dry powder inhaler.
45397162|NCT03965949|Drug|Hormone Replacement cycle 1|Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)
45397163|NCT03965949|Drug|Hormone Replacement cycle 2|Hormone Replacement cycle with GnRHa suppression
45397164|NCT00220779|Drug|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|
45697342|NCT05424783|Other|Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate|The Genomic Prostate Score is a 17 gene relative expression assay used to predict the presence of adverse pathologic findings at radical prostatectomy. This test is used to determine appropriateness for active surveillance. Prostate MRI is a prostate imaging test that has been shown to improve the detection of clinically significant prostate cancer using a PI-RADS scoring system. It relies on T2-weighted imaging, diffusion weighted imaging, dynamic contrast enhancement, and apparent diffusion coefficient to differentiate prostate cancer from normal prostate parenchyma and prostatitis.
45697343|NCT02984631|Procedure|Preventing pulm HTN during exercise|Balloon catheter is inflated within the IVC to maintain pulmonary pressures during exercise.
45397165|NCT00220779|Drug|Albumin (Human) 25%, United States Pharmacopeia (USP)|
45397166|NCT00207740|Drug|CNTO148|Type=exact type, unit=mg, number=50, 75, 100, 150, 200 and 300, form=injection, route=subcutaneous. Every 4 weeks partciapnts will receive injections in 4 parallel treatment arms
45397167|NCT00207740|Drug|Placebo|Type=exact type, unit=mg, form=injection, route=subcutaneous. Placebo will be given from from Week 0 through Week 52.
45397168|NCT00265382|Drug|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid.
45397169|NCT03969602|Behavioral|Cognitive-behavioral Therapy|The biopsychosocial approach of CBT focuses on the complex interaction between psychological, social and biological factors. The biopsychosocial model assumes that health problems are hardly ever limited to just one domain of human experience but by multiple domains of human experience. CBT helps patients understand thoughts and feelings that influence behaviors. It consists of a cognitive aspect and a behavioral aspect. The cognitive aspect is based on Becks cognitive model: the way that individuals perceive a situation is more closely connected to their reaction than the situation itself. A person's cognition has impact on their mood and emotions, their bodily reactions and their behavior. The second part of cognitive behavior therapy focuses on the actual behaviors that are contributing to the problem. The goal of CBT is to identify maladaptive thoughts and change them into more realistic and constructive thoughts to modify feelings and behavior and thereby the experience of pain.
45397170|NCT03969602|Other|Biomedical and surgery-specific education|Biomedical and surgery-specific education preoperatively and an exercise manual postoperatively.
45397171|NCT03974984|Procedure|Colon Resection|All patients undergo laparoscopic colon cancer resection.
45397172|NCT03974984|Procedure|Epidural anesthesia|Epidural inserted preoperatively and kept for 1 day postoperatively
45397173|NCT03974984|Drug|NSAID|NSAID administered according to standard operating procedure postoperatively
45397174|NCT00206726|Drug|Alemtuzumab plus Fludarabine|Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days
45397175|NCT00237692|Behavioral|Nurse Behavioral intervention with Home BP Telemonitoring|Nurse-administered behavior intervention
45697344|NCT05201157|Other|acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points exposed. The most preferred points ST36, LI4 and SP6 were selected from the points reported to affect lactation by reviewing the literature on the points to be compressed. Acupressure will be applied to points (bidirectional, right and left) for 2 minutes for a total of 6 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it will be moved to the other point in the symmetrical region and the application will be made without interruption. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch
45697345|NCT05201157|Other|Control Group|No application will be made. The mothers in this group will fill in the Visual Similarity Scale for Fatigue twice, once between 8-12 hours post-op and once on the post-op 2nd day.
45697346|NCT00981214|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) Microtabs contained in a capsule will be administered orally from Day 5 to Day 11 at an enzyme dose based on investigator's discretion, in dose stabilization period or the content of the capsule will be allowed to sprinkle on food, where necessary, followed by stabilized dose from Day 12 to Day 18 in treatment period, up to a maximum total dose of 10,000 lipase units per kilogram body weight per day (unit/kg/day).
45697347|NCT03308877|Behavioral|BMI|Four 45-minute, brief motivational sessions for substance use
45397176|NCT00237692|Behavioral|Nurse Medication Management with Home BP Telemonitoring|Nurse administer medication management according to hypertension decision support
45697348|NCT03308877|Behavioral|Stadard Care (SC)|Standard procedures at pretrial program + assessement
45697349|NCT03308565|Biological|Autologous, Adipose derived Mesenchymal Stem Cells|The mesenchymal stem cells will be collected and expanded from the subjects adipose tissue.
45697350|NCT01031134|Behavioral|Shared Decision Making|Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.
45697351|NCT01031134|Other|Usual Care|Usual Care reflects the standard of care in primary care practice: following physician recommendation for treatment. Physicians will recommend some form of depression treatment. This may take the form of an antidepressant prescription or psychotherapy referral. The physician will encourage patients to telephone with any questions. Following the treatment recommendation provided to the patient, the physician will provide care as usual.
45697352|NCT05415657|Drug|Denosumab|Denosumab 60 mg per 6 month were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
45697353|NCT05415657|Drug|Placebo|Equal volume of saline (0.9%) as placebo Q6M were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
45849684|NCT05581212|Other|Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack|Combined active case-finding, treatment and prevention of TB amongst HH contacts of TB cases, associated with initiation of standard of care (SOC) treatment in active TB cases and initiation of TB preventive therapy in those contacts without active TB, based on free screening. This intervention will be compared to the standard of care available in the country.
45849685|NCT05574582|Procedure|Graft reconstruction and internal fixation with compression screw|Patients suffering from scaphoid nonunion are treated surgically by debridement, graft reconstruction and internal fixation with compression screw
45397177|NCT00237692|Behavioral|Nurse Combined intervention with Home BP Telemonitoring|Combination of the nurse administered tailored behavioral & medication management
45397178|NCT00237458|Drug|Lacosamide|"Dosage: Lacosamide up to 400 mg/day;~Dosage form: Film-coated tablets;~Dosage Frequency and Duration: Two times per day; 9.5 years"
45397179|NCT01581788|Drug|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
45397180|NCT03973346|Other|Risk screening tool exposure|Risk screening tool is available to providers
45397181|NCT00265148|Drug|Rosiglitazone|Extended Release Tablets
45849686|NCT05563818|Other|WinterLight Mobile Phone Speech Analysis|N/A- observational study
45504846|NCT03556670|Behavioral|Total Worker Health|The intervention combines organizational and individual level strategies. Participants will be given access to pedal stands, health and safety messaging, and other environmental modifications. Intervention activities that participants could be asked to complete include: computer based training, goal setting and behavioral self-monitoring, scripted team-based health and safety discussions, and team competitions with pedal stands. Supervisor participants could additionally be asked to complete additional computer based training, goal setting and behavioral self-monitoring of supportive behaviors, and inter-supervisor observations. The intervention is six-months in duration.
45504847|NCT03556670|Other|Control|Usual practice control
45504848|NCT02250560|Biological|Replenine®-VF (High Purity Factor IX)|
45504849|NCT05197647|Other|Patients with symptomatic COVID-19 disease not requiring hospitalization.|Patients with symptomatic COVID-19 disease not requiring hospitalization.
45504850|NCT02094482|Device|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate.|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate
45504851|NCT05194761|Drug|Normal saline|Using normal saline nebulization in neonates postextubation
45504852|NCT02094560|Drug|CAP7.1|CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase
45504853|NCT03627975|Procedure|Conservative treatment|"The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, prevention and treatment of secondary epilepsy, the control of intracranial hypertension, and the corresponding symptomatic and neurotrophic treatment.~In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) will be performed according to the procedures described by Matsushima.~In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) by pass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And the STA may not be preserved."
45849687|NCT05557032|Procedure|cardiopulmonary resuscitation|pulse checks during cardiopulmonary resuscitation
45849688|NCT05544162|Dietary Supplement|Nutrition supplement - Ensure shakes|Ensure shakes will be take up to 3 times a day throughout hospitalization and for 4 weeks after discharge.
45397182|NCT00265148|Other|Placebo|Placebo dummy to match
45397183|NCT01072838|Radiation|APBI (Dose Escalation)|"Accelerated, hypofractionated partial breast radiotherapy.~3 dose schemes followed for 6 months each."
45397184|NCT01072838|Device|Contura MLB Breast Brachytherapy Catheter|
45397185|NCT03973424|Behavioral|Simple|Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, use a simplified form of tracking only high-calorie, high-fat foods in the study smartphone app, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
45397186|NCT03973424|Behavioral|Standard|Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, track calorie intake, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
45397187|NCT00043186|Drug|Placebo|Placebo subcutaneous injection
45397188|NCT00043186|Drug|Denosumab|Denosumab for subcutaneous injection
45504854|NCT05194605|Other|Prediction model|We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with osteosarcoma.
45504855|NCT05189145|Drug|estradiol valerate|8mg orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle then assess by ultrasound
45397189|NCT00043186|Drug|Alendronate|Alendronate 70 mg tablets
45504856|NCT05189145|Other|Hormonal monitoring progesterone, estradiol, luteinizing hormone|Serum Progesterone, estrogen & LH measured on day 13 after priming endometrium with 8mg estradiol valerate on a daily basis beginning as early as the first day of menstrual cycle.
45504857|NCT05189145|Diagnostic Test|transvaginal ultrasound examination|Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation
45504858|NCT05189145|Drug|Progesterone 400 Mg Vaginal Suppository|Progesterone supplements given in form of daily two vaginal prontogest suppositories400 mg each
45849689|NCT05543850|Device|Bi-hormonal closed-loop control|During bi-hormonal closed-loop control insulin and glucagon are administered to the developed closed-loop algorithm. Aditionally, patients will wear a blinded Dexcom G6 for data collection during the closed loop period.
45849690|NCT05543850|Device|Open-loop control|During open-loop control the patients will use their usual diabetes therapy. Aditionally, patients will wear a blinded Dexcom G6 for data collection during the open loop period.
45849691|NCT05538624|Drug|AVB-001 (Dose Escalation Phase)|One of four ascending doses of AVB-001 planned for IP, single dose administration in each dose level cohort of the Dose Escalation Phase (Part 1).
45397190|NCT00041470|Drug|Paclitaxel|50 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
45397191|NCT00041470|Drug|Vinorelbine|20 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
45397192|NCT00041470|Drug|Herceptin|4 mg/kg IV loading dose day 1 of first week followed by 2 mg/kg IV maintenance dose on each subsequent week. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
45504859|NCT05189145|Other|Hormonal monitoring progesterone and estradiol|Measuring the serum Progesterone & Estradiol in the early morning on the day of embryo transfer an progesterone supplementation adjusted as follows: Group II A: If P4 levels < 5ng/dl, one 100 mg intramuscular injection daily added, Group II B: If P4 levels 5-10ng/dl, dydrogesterone three times daily added. Group II C: If P4 levels >10ng, continued on 400 mg prontogest suppositories twice daily
45504860|NCT05189145|Drug|Progesterone|group II A: 100 mg intramuscular injection daily Group II B: If P4 levels 5-10ng/dl dydrogesterone added
45397193|NCT00041470|Drug|Filgrastim|5 mcg/kg daily including the day of IV chemotherapy. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
45397194|NCT03953950|Drug|Spironolactone|Spironolactone Starting dose: 25 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep< 140/90 mmHg, but avoid hypotension <90/60 mmHg), and serum potassium level (<5.5 milliequivalent /liter)
45397195|NCT03953950|Drug|Losartan|Losartan Starting dose: 50 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep< 140/90 mmHg, but avoid hypotension <90/60 mmHg), and serum potassium level (<5.5 milliequivalent /liter)
45397196|NCT00206102|Drug|quetiapine fumarate|flexible dose oral
45397197|NCT00206102|Drug|risperidone|flexible dose oral
45504861|NCT02097836|Device|Targeted Training|Custom training devices were imported from The Movement Centre for research purposes. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body.
45504862|NCT03555812|Other|Pelvic inclination measurement|Measurement of pelvic inclination per ultrasound
45504863|NCT05423366|Device|Extracorporeal Shock Wave Therapy (ESWT)|The ESWT device is product of Elettronica Pagani, Italy.
45504864|NCT05186571|Biological|Pfizer-BioNTech mRNA COVID-19 vaccination|Vaccination in children 5-11 years of age
45504865|NCT05223309|Other|Usinf thick loose sutures in seton techingues|"All patients were informed about doing fistulectomy and thick silk Seton suture placement for three months by excising the extrasphincteric part and putting the Seton suture to the intersphincteric part. Then, the second stage of operation includes the excision of the changing low type tract in which the silk Seton placed. We decrease the time of Seton placement in this study for three months to reduce the annoying symptoms of the patients. Therefore, the patient admitted to the operation theater after obtaining written consent. Most of the patients anesthetized by spinal anesthesia. In the operation theater, the patient assumed a lithotomy position~. After that, the injection of a solution, which is a mixture of methylene blue dye and hydrogen peroxide into the external opening of the fistula, was done to find the internal opening. The exit of color dye or bubbles achieved to localized of inner opening from it after using intraoperative proctoscopy examination."
45504866|NCT02097914|Behavioral|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
45504867|NCT05150847|Other|Oxygenation|Oxygenation will be calculated as PaO2/ FiO2 ratio.Static compliance will be calculated as tidal volume divided driving pressure.The potential for lung recruitment will be assessed by means of the R/I ratio (10).
45504868|NCT02094950|Procedure|Acupuncture|
45504869|NCT04967079|Drug|Trametinib|Trametinib 2 mg given orally, once daily
45504870|NCT04967079|Drug|Anlotinib|Anlotinib capsules given orally, dose ranging from 8 mg to 12 mg once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21). The initial dose is 8 mg, QD, PO, taken for the first 14 days of each 21-day cycle. If no patients developed DLT in the first treatment cycle, the 10 mg dose was explored. If 1 of 3 patients had a DLT, 3 more patients would need to be included for evaluation at this dose. If >1 out of 3 patients in a given dose group develops DLT, it is suggested that a lower dose group can be explored. If no DLT occurred at the 10 mg dose, the 12 mg dose was explored.
45849692|NCT05538624|Drug|AVB-001 (Dose Expansion Phase)|The MTD/RP2D as determined in the Dose Escalation Phase will be further evaluated in the Dose Expansion Phase.
45849693|NCT05529654|Device|Impella 5.5 with SmartAssist|For subjects enrolled in the Trial, the Impella 5.5 will be placed intra-operatively during the index cardiac surgical procedure
45397198|NCT03954262|Behavioral|observation of propofol ANS response|received an induction bolus or TCI infusion of propofol
45397199|NCT00041080|Drug|tamoxifen citrate|Given orally
45397200|NCT00041080|Drug|thalidomide|Given orally
45397201|NCT00041080|Other|laboratory biomarker analysis|Correlative studies
45849694|NCT05523414|Behavioral|SKY|The SKY intervention will be administered in-person over three sessions spread over three consecutive days by qualified instructors. Participants will then be followed up over eight weeks' time, where they will be given the option to attend daily 45-60 minute breathwork sessions, again, guided by experienced instructors. Participants will be required to log whether or not they practiced for each day in the eight-week period. They will also receive a phone call reminding them about the practice intermittently during the 8-week follow-up period.
45397202|NCT00205712|Drug|Ketamine|Ketamine without dexmedetomidine
45397203|NCT00205712|Drug|Dexmedetomidine|Ketamine plus dexmedetomidine
45397204|NCT01097200|Device|Elevate mesh|The correction of the prolapse can be made by this new technique.
45397205|NCT01097200|Device|Sacrocolpopexy|Attach a mesh between the vagina and the promontorium.
45397206|NCT03953404|Diagnostic Test|SPLA2-IIA|bedside blood test
45397207|NCT03953794|Device|Fitbit Charge 3|Smart watch monitoring activity and movement, heart rate, sleep, and more
45397208|NCT03969524|Device|MRI|Patients will undergo magnetic resonance imaging (MRI) at baseline (T0) (before NAC) and after the 2nd cycle of neoadjuvant chemotherapy(T2). Histopathological examination (gold standard) of the surgical specimen will be done for each patient and Compared to the results of MRI.
45397209|NCT03969758|Drug|Ciprofloxacin|will receive tablet Ciprofloxacin (500 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and <5 cm respectively.
45504871|NCT03555734|Other|Dietary pulses or legumes|Dietary pulses (dried beans, dried peas, chickpeas, lentils). If no data available specifically for dietary pulses than legumes will be assessed as the exposure (includes pulses, soybeans, peanuts, fresh peas, fresh beans).
45397210|NCT03969758|Drug|Cefixime|will receive tablet Cefixime (200 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and <5 cm respectively.
45504872|NCT03890601|Biological|blood sample|"A single 15 mL blood draw is planned for this study, as follow:~10 mL citrated tube (2 tubes) for APTT, PT, D-Dimers, LA, aCL, aβ2GP1, aβ2GP1-dm1 and TGA~5 mL EDTA tube for blood count~During a follow up visit, a 5 ml citrated tube and a 5 mL EDTA tube are collected from each patient for their routine laboratory evaluation. One additional citrated tube will be required to measure thrombin generation and aβ2GP1-dm1."
45504873|NCT03120949|Drug|Olokizumab 64 mg SC q4w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS).PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
45504874|NCT03120949|Drug|Olokizumab 64 mg SC q2w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS). PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
45504875|NCT03120949|Drug|Concomitant treatment|"Methotrexate 15 to 25 mg/week (or ≥ 10 mg/week if there was documented intolerance to higher doses). (Subject maintained their stable dose and route (oral, SC, or IM) during the core study and for ≥ 12 additional weeks of OLE.)~Folic acid ≥ 5 mg per week or equivalent"
45504876|NCT03556592|Drug|Tralokinumab|Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
45397211|NCT03974672|Procedure|Re-laparotomy|
45397212|NCT00203294|Drug|lidocaine, bupivicaine and saline|lidocaine, bupivicaine and saline-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
45397213|NCT00203294|Drug|lidocaine plus bupivicaine plus triamcinolone (steroid)|lidocaine, bupivicaine and triamcinolone (steroid)-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
45397214|NCT01326182|Behavioral|MAADRE|Group-based intervention combining asthma education and CBT for depressive symptoms
45397215|NCT01326182|Behavioral|MAAS|Group-based intervention including asthma education and education regarding general child health
45397216|NCT01074086|Drug|RAD 001|RAD 001 in steps of 3 patients from 10mg in day 1 and day 7 to 50 mg
45397217|NCT01074320|Other|Other|Observational study
45397218|NCT02531828|Device|Application of dressings for surgical correction.|Dressing for surgical correction
45397219|NCT02531828|Device|POLYSHAFT®|
45504877|NCT03556592|Drug|Caffeine|1x 100 mg tablet
45504878|NCT03556592|Drug|Warfarin|2x 5 mg tablets
45504879|NCT03556592|Drug|Omeprazole|1x 20 mg capsule
45504880|NCT03556592|Drug|Metoprolol|1x 100 mg tablet
45504881|NCT03556592|Drug|Midazolam Hydrochloride|1 mL of 2 mg/mL oral solution/syrup
45504882|NCT05070117|Behavioral|Exercise training|Study participants perform resistance/strength exercises 2-3 times per week for one hour, for one year.
45504883|NCT02095028|Behavioral|Dietary and lifestyle intervention|participants in the intervention group were provided with an individualized dietary intake protocol. Patients received a diet of not fewer than 1500 calories per day in the first trimester and not fewer than 1800 calories per day after 13wks of gestation.
45504884|NCT04964193|Drug|Elzsa film-coated tablet|Administered with 240 mL of water
45504885|NCT04964193|Drug|Diane-35 Sugar-coated tablet|Administered with 240 mL of water
45504886|NCT02095262|Other|reactive auditory training|
45504887|NCT02095262|Other|Interactive auditory training|
45504888|NCT04814199|Other|Algorithm|Patients will have a printed algorithm to follow while they are in labour with an epidural for pain management.
46057043|NCT04020250|Device|Echocardiography|"Echocardiographic parameters:~Tricuspid annulus plane systolic excursion (TAPSE) Tricuspid regurgitation peak gradient (TRPG)"
46057044|NCT04777929|Other|test Phthalates, estrogen and progesterone|test mothers Phthalates in their urine, and test estrogen and progesterone receptor in placental tissue
45397220|NCT00264290|Drug|Valganciclovir|900mg PO qd x 8 weeks followed by 4 weeks of observation on background antiretroviral (ARV) regimen alone.
45397221|NCT00264290|Drug|Placebo|Placebo designed to resemble Valganciclovir
45397222|NCT00234494|Drug|Cisplatin|Cisplatin 70 mg/m2, day 1
45397223|NCT00234494|Drug|Gemcitabine|Gemcitabine 1250 mg/m2, day 1 and 8
45397224|NCT00234494|Drug|Bevacizumab|Bevacizumab 15mg/kg, day 1
45397225|NCT00234104|Drug|OPC-41061(Tolvaptan)|
46057045|NCT04764591|Other|Lateral sagittal approach|Lateral sagittal approach for ultrasound guided infraclavicular brachial plexus block
45397226|NCT01582568|Drug|Certolizumab|Certolizumab 200mg-400mg subcutaneous every 2 weeks for 8 weeks.
45397227|NCT00263666|Biological|Rotarix|Oral vaccination
45397228|NCT00263666|Biological|Placebo|Oral administration
45397229|NCT00263666|Biological|Tritanrix-HB+Hib|Concomitant routine vaccination, IM administration
45397230|NCT00263666|Biological|Polio Sabin|Oral administration, concomitant routine vaccination
45397231|NCT00195338|Drug|etanercept|
45397232|NCT00039130|Biological|filgrastim|5 ug/kg/day sub Q injection day 7 until ANC>5000/ul courses II-VII
45397233|NCT00039130|Biological|rituximab|Day 8 course II 50 mg/sq m IV infusion: d 8 course IV & VI 375mg/sq m IV Day 10 course II: 325 mg/sq m IV infusion Day 12 course II: 375 mg/sq m IV infusion
45397234|NCT00039130|Drug|cyclophosphamide|200 mg/sq m/day IV infusion over 5-15 min days 1-5, courses I, III, V, VII
45397235|NCT00039130|Drug|cytarabine|1 g/sq m/day IV infusion Days 4 & 5, courses II, IV, VI
45397236|NCT00039130|Drug|dexamethasone|10mg/sq m PO or IV Days 1-5 courses II-VII
45397237|NCT00039130|Drug|doxorubicin hydrochloride|25 mg/sq m/day IV infusion Days 4 & 5 courses III,V, VII
45397238|NCT00039130|Drug|etoposide|80 mg/sq m/day IV infusion Days 4 & 5 courses II, IV, VI
45397239|NCT00039130|Drug|ifosfamide|800 mg/sq m/day IV infusion Days 1-5 courses II, IV, VI
45397240|NCT00039130|Drug|leucovorin calcium|25mg/sq m IV infusion over 15 min then 10 mg IV q 6 hrs until serum MTX <10nM, courses II-VII
45397241|NCT00039130|Drug|methotrexate|1.5 g/sq m IV infusion Day 1 courses II-VII
45397242|NCT00039130|Drug|prednisone|60 mg/sq m PO/day Days 1-7 course I
45397243|NCT00039130|Drug|vincristine sulfate|2 mg IV push Day 1 courses II-VII
45504889|NCT02100488|Device|Closed-loop insulin infusion system|"Each subject will undergo two Open-loop and two Closed-loop meal tests, each one at 1-2 week intervals, thus completing the 4 experiments in about 6 weeks. The day of the experiment, a standard mixed meal test containing 60 g of carbohydrates (CHO), will be administered. On two occasions, patients will receive in a randomized order the standard insulin bolus based on the individual insulin to CHO ratio (First arm, Open-loop study). On the other two occasions they will receive a Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study). Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
46057046|NCT04764591|Other|Costoclavicular approach|Costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
45397244|NCT00039130|Drug|Allopurinol|300 mg/day PO Days 1-14, course I
45397245|NCT01096654|Other|Ct-scan or adrenal vein sampling|Patients will be randomized to undergo either adrenal CT-scanning or AVS (with pre-AVS adrenal CT-scanning for phlebography). The result of either of these tests will determine the course of action: adrenalectomy for adenoma or MRAs for bilateral hyperplasia.
45397246|NCT00035932|Drug|Atazanavir + ritonavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
45397247|NCT00035932|Drug|Atazanavir + saquinavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
45397248|NCT00035932|Drug|Lopinavir/ritonavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
45397249|NCT03953248|Drug|L-Carnitine|
45397250|NCT02530372|Device|UriCap-F|non-invasive urine collection device for women
45397251|NCT03953326|Behavioral|HeartPhone app|Evaluative conditioning (temporally distributed micro-doses presented upon activation of smartphone screen)
45397252|NCT03953326|Drug|Acetylcholine|Endothelium-dependent vasodilation is tested with the localized delivery of the neurotransmitter
45397253|NCT03953326|Drug|Sodium Nitroprusside|Endothelium-independent vasodilation is tested with the localized delivery of the nitric oxide donor
45397254|NCT03953326|Drug|L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester|This nitric oxide inhibitor is continuously given during the localized delivery of the endothelium-dependent agonist acetycholine.
45397255|NCT01097278|Dietary Supplement|cholecalciferol|Given orally
45397256|NCT01097278|Other|placebo|Given orally
45397257|NCT01096732|Drug|GDC-0449|Gelatine capsules of 150mg.Taken O.D. for 14 days.
45397258|NCT01097356|Dietary Supplement|probiotic drinkers|HPV+, LSIL patients in this arm will drink the probiotic study drink for a period of 6 months
45397259|NCT01100788|Dietary Supplement|Short chain fructo-oligosaccharide (scFOS) 5 g|"Dietary Supplement: scFOS 5 g~Novel fiber administered in two 5 g doses--the first in a beverage and the second in a solid chew."
45397260|NCT01100788|Other|Placebo|Treatment without scFOS fiber
45397261|NCT01100788|Dietary Supplement|Short chain fructooligosaccharide (scFOS) 8 g|Novel fiber administered in two 8 g doses--the first in a beverage and the second in a solid chew.
45397262|NCT01097434|Device|Biodegradable polymer limus-eluting stents|due randomization biodegradable polymer limus-eluting stents will be implanted
45397263|NCT01097434|Device|Permanent polymer limus-eluting stent|due randomization permanent polymer limus-eluting stent will be implanted
45849695|NCT05523414|Behavioral|Health Enhancement Program|Participants will undergo Health Enhancement Program (HEP) training, that will comprise different modules including music, active body movements, contemplation, and nature walk among others. The number of hours of training will be the same as for the SKY participants. These participants will be encouraged to daily perform one or more of these activities during the follow-up period, and record how frequently they engage in these activities each week. They will also receive a phone call reminding them about the practice intermittently during the 8-week follow-up period. An experienced instructor will administer the components of the HEP training.
45397264|NCT00022516|Drug|Cyclophosphamide|50 mg/day orally continuously for 1 year
45397265|NCT00022516|Drug|Methotrexate|2.5 mg twice/day orally days 1 and 2 of every week for 1 year
45397266|NCT03953092|Drug|YG1699|YG1699 at Multiple Doses
45397267|NCT03953092|Drug|Placebos|Placebos
45504890|NCT02100488|Other|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin to carbohydrate ratio. Commercial insulin infusion systems and continuous glucose monitoring devices will be used.
45504891|NCT03627819|Dietary Supplement|Plant sterol-enriched margarine|Margarine enriched with plant sterol esters
45504892|NCT03627819|Dietary Supplement|Plant stanol-enriched margarine|Margarine enriched with plant stanol esters
45504893|NCT03627819|Dietary Supplement|Control margarine|Margarine without any addition
45504894|NCT02100566|Behavioral|Counseling (Care giver burden focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on care giver burden as the reason for adoption of the AD.
45504895|NCT02100566|Behavioral|Counseling (patient autonomy focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on patient autonomy (control) as the reason for adoption of the AD.
45504896|NCT05655819|Drug|Glutamine|5 gram powder, one rounded teaspoon, dissolved in 8 ounces of water or juice prior to drinking) taken orally three times per day
45504897|NCT05655819|Drug|Placebo|Lactose powder dissolved in 8 ounces of water or juice prior to drinking, taken orally three times per day. Looks exactly like the study drug, but it contains no active ingredient.
45504898|NCT02095418|Drug|Mycophenolate mofetil, Corticosteroids|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1500mg/day*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (2 weeks)
45504899|NCT02095418|Drug|Corticosteroids, Mycophenolate mofetil|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1000mg/day*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (3 month±2weeks)
45504900|NCT03627585|Device|Personalised programming|Reprogramming protocol already test in an observation cohort will be utilised which will direct physiologists to consider pacemaker mode, base rate, utilisation of rate response, hysteresis, sleep and rest rates as well as lead outputs.
45504901|NCT04865497|Biological|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
45504902|NCT04865497|Biological|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
45504903|NCT04865497|Biological|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg adjuvant-free S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
45849696|NCT05516628|Procedure|Surgical Resection|Resection of Primary Hepatocellular Cancer Tumour.
45849697|NCT05516628|Drug|Adjuvant Atezolizumab-Bevacizumab Therapy|Patient receives adjuvant Atezolizumab plus Bevacizumab every 3-weekly for a year following resection of hepatocellular cancer tumour.
45397268|NCT01097512|Drug|AS703569/gemcitabine|"Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
45397269|NCT01097512|Drug|AS703569/gemcitabine|"AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
45397270|NCT01100866|Dietary Supplement|POMELLA™ (pomegranate extract)|in a capsule form, 2 x 500mg once daily
45397271|NCT01100866|Other|Placebo|placebo capsules
45504904|NCT04865497|Biological|Haemophilus b Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg Haemophilus b Conjugate Vaccine.
45504905|NCT05665725|Procedure|Biospecimen Collection|Undergo blood sample collection
45849698|NCT05497674|Drug|Rongliflozin|oral administration, single dose on Day 1 and Day 11
45849699|NCT05497674|Drug|Rifampin|QD for 10 days
45397272|NCT01097590|Device|Active TLA Gut™ column|Five consecutive treatment sessions. The therapy will be administrated every second day.
45397273|NCT01097590|Device|Placebo|Five consecutive treatment sessions. The placebo therapy will be administrated every second day.
45397274|NCT00033514|Biological|trastuzumab|Day 1 4mg/kg IV 2 mg/kg IV weekly.
45397275|NCT00033514|Drug|erlotinib hydrochloride|100 mg daily on Course 1 Day 2. After three weeks patients who have not experienced specific adverse events, dose will be escalated to 150 mg daily. Patients who have experienced specific adverse events dose will remain 100 mg daily or dose reduced as necessary per protocol.
45397276|NCT00006916|Biological|bleomycin|
45397277|NCT00006916|Device|Ommaya reservoir|
45397278|NCT00006916|Radiation|radiation therapy|60.0 Gy/30 fractions x 2.0 Gy. For the first 46 Gy/23 fractions the treatment volume should include the volume of contrast-enhancing lesion and surrounding edema on pre-operative CT/MRI scan plus a 2 centimeter margin. If no edema is present, the margin should be 2.5 cm. After 46.0 Gy, the tumor volume should include the contrast-enhancing lesion (without edema) on the pre-surgery MRI/CT scan plus a 2.5 centimeter margin.
45397279|NCT03952936|Other|Vestibular Rehabilitation|standard vestibular rehabilitation with gaze stability, balance training, habituation tailored to the subject
45504906|NCT05665725|Procedure|Computed Tomography|Undergo CT scan
45504907|NCT05665725|Procedure|Positron Emission Tomography|Undergo PET scan
45504908|NCT05665725|Biological|Siltuximab|Given IV
45504909|NCT02098148|Drug|Xenon|
45504910|NCT02098148|Drug|Placebo|
45504911|NCT01369381|Procedure|Endotracheal intubation|Study patients undergo endotracheal intubation using both a conventional direct laryngoscope (Macintosh) and an alternative indirect laryngoscope (Airtraq). The order of intubation (Macintosh then Airtraq--or--Airtraq then Macintosh) is randomized.
45504912|NCT03889119|Radiation|Stereotactic Body Radiation Therapy (SBRT) radiation for prostate cancer utilizing the Elekta Versa or Agility System.|SBRT uses advanced imaging techniques to deliver targeted radiation to a tumor. The Elekta Versa and Agility Systems are approved by the Food and Drug Association (FDA) for SBRT treatment of cancer.
45504913|NCT02098382|Device|Dilapan-S|Dilapan-S synthetic osmotic dilator for cervical ripening prior to labor induction
45504914|NCT04889469|Procedure|Breast reduction|Procedure to remove excess fat, tissue and skin from the breasts.
45504915|NCT05168527|Drug|Fruquintinib,Albumin Paclitaxel,Gemcitabine|The study will mainly explore the safety and tolerability of fixed-dose level of Fruquintinib (4 mg, continuous medication for 3 weeks and withdrawal for 1 week) combined with fixed-dose level of albumin paclitaxel and gemcitabine. The fixed dose of Fruquintinib is 4 mg, with a treatment cycle every 28 days. A 28-day observation window was used to explore the side effects of fruquintinib in the combined treatment of pancreatic cancer patients with liver metastases. Evaluable patients will be assessed for DLT within 28 days after the first administration of the study drug. The 24 patients enrolled in the follow-up group will mainly evaluate the initial efficacy of furquintinib combined with albumin paclitaxel and gemcitabine as the first-line standard treatment for patients with metastatic pancreatic cancer.
45504916|NCT02095496|Device|Intellivent-ASV|12 hours of mechanical ventilation with intellivent-ASV
45504917|NCT02095496|Device|Conventional ventilation|12 hours of mechanical ventilation with pressure support ventilation
45504918|NCT01372657|Other|biometry calculation|
45504919|NCT02098460|Drug|Atorvastatin, Probucol, Cilostazol|
45504920|NCT05166031|Biological|bOPV and nOPV2|Approximately 265 subjects will receive 2 doses of bOPV, nOPV2 or bOPV + nOPV2 per arm separated by 28 days between doses.
45397280|NCT03952858|Other|Telerehabilitation Group|The telerehabilitation Group receives physiotherapy supervised exercises on-line. The Community Center Group receives the traditionel training offer in the municipality Center for older people.
45397281|NCT02530138|Dietary Supplement|synbiotic|2 symbiotics capsules per day for 28 weeks
45397282|NCT02530138|Dietary Supplement|Placebo|2 placebo capsules per day for 28 weeks
45397283|NCT02529982|Dietary Supplement|Curcumin|
45397284|NCT02529982|Dietary Supplement|Placebo|
45504921|NCT02095574|Drug|[14C]ABT-199 (GDC-0199)|[14C]ABT-199 will be administered as a single oral administration
45504922|NCT04856319|Procedure|Dental implant placement|Insertion of not more than two dental implants at the same area
45504923|NCT04856319|Drug|Antibiotic prophylaxis|Per-os 2g amoxicillin+clavulanic acid will be administered one hour prior to the surgery
45504924|NCT04856319|Other|Placebo|Per-os placebo (inert polysaccharide) will be administered one hour prior to the surgery
45504925|NCT03555344|Other|Mantra Chikitsa|Specific Mantra were given to chants for 15 mins and resting in the impact of chants for following 15 mins.
45504926|NCT05150119|Diagnostic Test|Evaluation of Synovial IL-6 in diabetic patients with gonarthrosis|To evaluate if there is a linear positive correlation between plasma glycated hemoglobin concentration HbA1c and synovial IL-6 in diabetic patients
45504927|NCT02095730|Drug|Epithelium-On Riboflavin|Riboflavin 0.1% Phosphate Sodium solution with Benzalkonium Chloride Preservative
45504928|NCT02095730|Drug|Epithelium-Off Riboflavin|Riboflavin 0.1% Phosphate Sodium solution
45504929|NCT02095730|Device|UV Light - Continuous Beam|5 minutes of constant UV exposure to saturated cornea
45504930|NCT02095730|Device|UV Pulsed Beam|5 minutes of UV exposure to saturated cornea, alternating 1 minute of treatment with 1 minute rest for a total time of 10 minutes
45504931|NCT04781283|Device|measurement of endothelial cell density by specular microscopy|"During this first appointment (T0), in addition to the usual treatment, measurement of the endothelial cell density by specular microscopy will be carried out on the affected eye (basal cell density). To overcome the variability linked to the machine, three consecutive measurements will be taken; the average of the three measurements will be used.~As part of his post-operative follow-up, the patient will be reviewed at one month, one year, two years, three years, four years and five years after the operation. During these consultations and as part of the research, a new determination of the cell density (3 consecutive measurements) by specular microscopy of the operated eye and an evaluation of the position of the XEN implant will be carried out each time. ® by OCT scan for patients having undergone this surgery."
45504932|NCT04769739|Other|CO2|using CO2 insufflation to help insertion
45504933|NCT04769739|Other|Water|using water instead of traditional gas to help insertion
45504934|NCT04769739|Other|50% saline|using 50% saline solution instead of traditional gas to help insertion
45849700|NCT05497674|Drug|Rongliflozin|oral administration, single dose on Day 1 and Day 6
45504935|NCT04769739|Other|25% saline|using 25% saline solution instead of traditional gas to help insertion
45504936|NCT05138731|Other|treatments according guidelines|different group intervened with different treatment following guidelines/consensuses accordingly
45504937|NCT05406284|Procedure|double kissing nano culotte stenting|patients with true coronary bifurcation lesion treating with double kissing nano culotte stunting technique
45504938|NCT01369459|Behavioral|MIP Protocol|We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
45504939|NCT02102438|Drug|Trastuzumab|"Trastuzumab (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg) will be given concomitantly with chemotherapy.~After completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles."
45504940|NCT02102438|Drug|Weekly Paclitaxel|Weekly paclitaxel at 80mg/m2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
45504941|NCT02102438|Drug|Carboplatin|Carboplatin at an Area Under the Curve (AUC) of 2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
45504942|NCT05442710|Biological|ARTICE|Extracorporal treatment with purified granulocyte concentrate
45504943|NCT05222217|Device|Gatekeeper|Six polyacrylonitrile prostheses (THD Gatekeeper™ Delivery System, THD SpA, Correggio, Italy) were implanted under 3D-EUS control through a 5mm perianal incision at 1, 3, 5, 7, 9 and 11 o'clock in lithotomy position, and located in the upper-middle intersphincteric space of the anal canal, using a specifically designed system.
45849701|NCT05497674|Drug|Probenecid|twice a day, for 5 days
45849702|NCT05485740|Other|cognitive multisensory rehabilitation|sensorimotor rehabilitation approach, in which the patient is asked to solve sensory discrimination exercises with closed eyes or to solve multisensory discrimination exercises, e.g., by comparing feeling shapes with seeing shapes.
45849703|NCT05485740|Other|the selected exercise program|Upper Extremity Range of motion (ROM) exercises Passive Prolonged Stretching and positioning Weight-bearing exercise
45849704|NCT05461326|Procedure|Quad tendon|quadriceps tendon autograft
45849705|NCT05461326|Procedure|BTB|patellar tendon autograft
45504944|NCT04156789|Diagnostic Test|Home sleep apnea testing|Sarcoidosis patients and control subjects will undergo one night of home sleep apnea testing using ApnoeaLinkTM Plus device (ResMed Corporation, Poway, Calif). The device records the patient's nasal respiratory pressure signal as a surrogate of nasal flow, respiratory movements by a thoracic impedance belt, and finger pulse oximetry. The results of the sleep study will be scored automatically with dedicated software (ResMed Corporation, Poway, Calif), and manually reviewed to ensure data accuracy.
45504945|NCT05222061|Device|Drug coated balloon for the side brunch|Intervention is explained in group description
45504946|NCT05222061|Device|Conventional balloon for the side brunch|Intervention is explained in group description
45504947|NCT02098616|Drug|DCV/ASV/BMS-791325|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day
45849706|NCT05437926|Device|Arrhythmia Analysis Software (software) which runs on a mobile application (Huawei Phone) and uses input from a wearable device (smart watch or smart band).|Subjects with or without cardiac arrhythmias and of light skin tone (melanin index <150) or dark skin tone (melanin index >350). Subjects will be divided based on their heart rhythm in three groups: approximately 1/3 with normal sinus rhythm, 1/3 with atrial fibrillation and 1/3 with premature beats
45397285|NCT00454649|Drug|Axitinib + Paclitaxel + Carboplatin (Cohort 1)|Axitinib (AG-013736) 1 milligram (mg) tablet orally twice daily (BID) as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel [200 milligram/square meter (mg/m^2)] 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target area under the concentration-time curve (AUC) of 6.0 milligram*minute/milliliter (mg*min/mL) on Day 1 of Cycle 1 and all subsequent cycles.
45504948|NCT02098616|Drug|DCV/ASV/BMS-791325 + RBV|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day
45504949|NCT05108077|Biological|cytokine-induced killer cells|Autologous cytokine-induced killer cells injected intravenously
45504950|NCT05108077|Other|Standard treatment according to the Clinical protocols|Standard treatment of bladder/renal cancer according to the Clinical protocols
45504951|NCT04952805|Drug|MAD0004J08|MAD0004J08 is a human monoclonal Antibody (mAb), 2.5 mL 2R vial available in two dose: 100 mg and 400 mg. The pharmaceutical form is solution for intramuscular injection.
45504952|NCT04952805|Other|Placebo|Placebo matching to MAD0004J08, 2.5 mL 2R vial. The pharmaceutical form is solution for intramuscular injection.
45504953|NCT01372267|Behavioral|Psychoeducation for substance abuse|This active control provides detailed educational information about substance use and chronic pain to those enrolled.
45504954|NCT01372267|Behavioral|CBT for pain in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and pain.
45504955|NCT02098694|Other|Physiotherapy follow-up|"Physiotherapy consultation every 4 months containing assessment of the spine and its mobility, including axial joints, assessment of the patients activity profile.~Instruction in home-exercises and recommendations for optimization of activity profile. Information regarding the disease and the importance of physical activity and exercise."
45504956|NCT04134013|Dietary Supplement|Combination: Nutrition AND Chiropractic Adjustment|LBP chiropractic adjustment per protocol, nutrition counseling/ 4 Nutrient offerings (Vitamin Booster, Shake + 2 other offerings)
45504957|NCT04134013|Other|Chiropractic Adjustment: Spinal Manipulation Therapy|LBP chiropractic adjustment per protocol
45397286|NCT00454649|Drug|Axitinib + Paclitaxel + Carboplatin (Cohort 2)|Axitinib (AG-013736) 3 tablets of 1 mg orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
45504958|NCT02102516|Drug|SPRIX(intranasal ketorolac tromethamine)|"Dose: Subjects weighing 3.0 kg received 3.15 mg (1 spray/1 nostril), subjects weighing 5.1 - 10.0 kg received 5.25 mg (1 spray/1 nostril), subjects weighing 10.1 - 15.4 kg received 10.5 mg (1 spray/1 nostril), subjects weighing 15.5 - 31.7 kg received 15.75 mg (1 spray/1 nostril), and subjects weighing >=31.8 kg received 31.5 mg (1 spray/2 nostrils).~Duration of Treatment: Subjects received a dose of SPRIX every 6 hours from the day of surgery until the morning of post-operative Day 2. Dosing may have resumed after final PK assessment of the morning of post-operative Day 3 until post-operative Day 4. A follow-up phone interview took place 14 days after the final dose of study drug."
45697354|NCT03016234|Drug|Desflurane|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with pentothal sodium inj (thiopental sodium 0.53g) 5-6mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with 50% oxygen-air-4~7% desflurane inhalation and intravenous remifentanil continous infusion (effect site concentration 3-6ng/mL) during operation. Desflurane concentration is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
45849707|NCT05437068|Other|Oral Nutritional Supplement (ONS)|ONS plus dietary counseling
46057047|NCT00590044|Drug|insulin glargine+ glulisine|Daily insulin glargine + glulisine before meals
45504959|NCT04714047|Other|Progressive Resistance Training and no booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of PRT with exercises targeting the muscles of the hip and knee joints; leg press, hip extension, hip abduction, hip flexion and knee extension. The progression will be in line with guidelines provided by the American College of Sports Medicine. The intensity will follow repetition maximum (RM) targets, from 12 RM for the first week towards 8 RM for the last weeks.~After the 12 weeks, this group consists of patients who are randomized to receive no further treatment. For the following 9 months, these patients are given a membership to a fitness center where they are encouraged to continue the same exercise regime."
45397287|NCT00454649|Drug|Axitinib + Paclitaxel + Carboplatin (Cohort 3)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
45397288|NCT00454649|Drug|Axitinib + Paclitaxel (Cohort 4)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 25 of Cycle 1 (28 days) and then without interruption from Day 3 for Cycle 2 (28 days) and all subsequent cycles (28 days). Paclitaxel (90 mg/m^2) 60-minute infusion on Day 1, 8, and 15 of each cycle.
45504960|NCT04714047|Other|Progressive Resistance Training and booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of PRT with exercises targeting the muscles of the hip and knee joints; leg press, hip extension, hip abduction, hip flexion and knee extension. The progression will be in line with guidelines provided by the American College of Sports Medicine. The intensity will follow repetition maximum (RM) targets, from 12 RM for the first week towards 8 RM for the last weeks.~After the 12 weeks, this group consists of patients who are randomized to receive 4 booster sessions (at 1, 3, 5 and 7 months after termination of the initial 12 week intervention). Additionally, for the following 9 months, these patients are given a membership to a fitness center where they are encouraged to continue the same exercise regime without supervision."
45504961|NCT04714047|Other|Neuromuscular exercise and no booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of NEMEX training with exercises focused on stability, postural function, postural orientation, lower extremity muscle strength, and functional exercises. Progression is made when an exercise is performed with good sensorimotor control and good quality of the performance and with minimal exertion and adequate control of the movement.~After the 12 weeks, this group consists of patients who are randomized to receive no further treatment. For the following 9 months, these patients are given equipment and encouraged to continue the same exercise regime at home without supervision."
45697355|NCT03016234|Drug|Propofol|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with fresofol MCT 1% inj (1% propofol) 1.5-2.5mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with intravenous fresofol MCT 2% inj (2% propofol, effect site concentration 2.5-5μg/mL) and remifentanil (effect site concentration 3-6ng/mL) continous infusion. Effect site concentration of propofol is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
45697356|NCT03695679|Behavioral|Interactive computer-based intervention|"There are 4 components of the Interactive computer-based intervention(ICBI) which will be delivered in 3 phases:~Perceived Susceptibility and Perceived Severity~Perceived Benefits and Perceived Barriers~Cue to Action~Self-Efficacy~In addition, a discussion forum will be created to handle questions from the participants. Also, there will be an email address for enquiries if the participants need any support or if they want to seek further enquiry/ clarification after reading the web-based information."
45697357|NCT04353388|Diagnostic Test|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement will be used to detect sepsis. Results will not be used to manage patients.
45397289|NCT00454649|Drug|Axitinib + Docetaxel + Carboplatin (Cohort 4a)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Docetaxel (75 mg/m^2) 60-minute infusion on Day 1 of every cycle. Carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
45397290|NCT00454649|Drug|Axitinib + Docetaxel (Cohort 5)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1. Axitinib (AG-013736) 5 mg oral tablet BID administered from Day 3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Docetaxel (100 mg/m^2) 60-minute infusion on Day 1 of each cycle.
45504962|NCT04714047|Other|Neuromuscular exercise and booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of NEMEX training with exercises focused on stability, postural function, postural orientation, lower extremity muscle strength, and functional exercises. Progression is made when an exercise is performed with good sensorimotor control and good quality of the performance and with minimal exertion and adequate control of the movement.~After the 12 weeks, this group consists of patients who are randomized to receive 4 booster sessions (at 1, 3, 5 and 7 months after termination of the initial 12 week intervention). Additionally, for the following 9 months, these patients are given equipment and encouraged to continue the same exercise regime at home."
45504963|NCT04952467|Drug|14C-XEN1101|Subjects will receive a single oral administration of a capsule containing 20 mg XEN1101
45504964|NCT02106182|Drug|Silodosin|
45504965|NCT02106182|Other|Laboratory tests|"Subject's overall health state will be evaluated by clinical laboratory tests.~Serum chemistry test: Creatinine, Blood Urea Nitrogen(BUN), Aspartate aminotransferase(AST), Alanine aminotransferase(ALT) Urinalysis: Urine Specific Gravity, Urine pH, Urine Protein, Urine Glucose, Urine Ketone, Urine Bilirubin, Urine Urobilinogen, Urine Nitrite, Urine Occult Blood(OB), Urine Red Blood Cell(RBC), Urine White Blood Cell(WBC) Immunoassay: Prostate Specific Antigen(PSA)"
45504966|NCT02106182|Other|3-days voiding diary|3-day voiding diaries will be distributed on Visits 1, 2 and 3. Subjects will record incidence of nocturia during 3 days on the diaries within 7 days of Visits 2 (baseline), 3 and 4. The average will be used to confirm the change in incidence of nocturia (at baseline, results from within 1 week from screening may be used but will be excluded for subjects needing wash-out period).
45504967|NCT02106182|Other|12 weeks|
45504968|NCT01369693|Procedure|Buccal administration of nicotine|Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes
45504969|NCT03554642|Device|Walkbot|Walkbot is a Robot Assisted Gait Training System. This system is designed to maximize muscle strength, range of joint motion, and gait function while participants engage in a virtual reality game.
45504970|NCT03554642|Behavioral|Physical Therapy|30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).
45504971|NCT04663503|Other|Exercise program|Depending on the age, there will be two components of the exercise program completed by the patients. The first component will be strengthening exercises. The second component will be endurance activities. This will be administered by the physical therapist
45504972|NCT02102594|Drug|Bortezomib|Bortezomib will be subcutaneously applicated in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
45504973|NCT03124537|Behavioral|App Experimental condition|This group were given the app to 1) count their steps, 2) add walks to their daily schedules, 3) create maps of their walking routes, and 4) text friends to invite them for a walk. Participants are asked to set a daily step goal and they can see how many steps they've taken each day since using the app. 2) There is an interface where participants can create maps based on walking routes. 3) They will also have the option to use a daily schedule to plan certain times in the day that they can walk. 4) The social feature gives participants the option to message friends, co-workers, or neighbors in one's contact list to invite them for a walk. They were also asked to respond to two questions twice a day about their mood and energy levels.
45504974|NCT03124537|Behavioral|App Condition Control|This group received the app with the first component, the ability to count steps and set daily step goals. This group will also be able to track walks to see the time, distance, and steps of each walk, but not see these walks displayed as a map. This group will monitor their daily steps over a one-month period, and will be asked to use the app as much as possible. They were also asked to respond to two questions twice a day about their mood and energy levels.
45504975|NCT04946877|Diagnostic Test|IQ assessment using Wechsler intelligence scale for children third edition (WISC-III)|IQ assessment using Wechsler intelligence scale for children third edition (WISC-III): is consists of several subtests, each classified into a verbal or performance scale .
45397291|NCT00454649|Drug|Axitinib + Capecitabine (Cohort 6)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1000 mg/m^2) orally BID from Day 1 to Day 14 of each cycle.
45397292|NCT00454649|Drug|Axitinib + Capecitabine (Cohort 7)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1250 mg/m^2) orally BID from Day 1 to Day 14 of each cycle.
45697358|NCT01031914|Device|Paced Breathing|The Paced Breathing (PB) feature(when activated) will work to relax the user and help them fall asleep by encouraging them to take deep slow breaths until they reach 10 breaths (or less) per minute. The feature will also detect when the subject has fallen asleep so the Continuous Positive Airway Pressur (CPAP) device will automatically switch from PB mode to regular CPAP mode.
45397293|NCT00454649|Drug|Axitinib + Gemcitabine + Cisplatin (Cohort 8)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Gemcitabine (1250 mg/m^2) 30-minute infusion on Day 1 and Day 8 of Cycle 1 and all subsequent cycles followed by cisplatin (80 mg/m^2) infusion on Day 1 of each cycle.
45397294|NCT00454649|Drug|Axitinib + Pemetrexed + Cisplatin (Cohort 9)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Pemetrexed (500 mg/m^2) 10-minute infusion followed by cisplatin (75 mg/m^2) infusion on Day 1 of each cycle.
45397295|NCT00454571|Drug|pazopanib hydrochloride|Given PO
45397296|NCT00454571|Drug|leuprolide acetate|
45397297|NCT00454571|Drug|goserelin acetate|
45397298|NCT01323257|Drug|erythromycin|500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
45397299|NCT01323257|Drug|Ritonavir|100 mg tablet once daily for 7 days (Trt E, F)
45504976|NCT02102672|Drug|Trimetazidine|
45504977|NCT05361590|Device|Lumoral device|The Lumoral treatment -device is a CE-marked antibacterial home-use device for the treatment and prevention of oral diseases caused by bacteria. It is used in combination with a CE-marked mouth rinse called Lumorinse.
45504978|NCT01369771|Drug|Tafluprost 0.0015%|Eye Drops, Solution. Topical Use. One single-unit dose pipet of 0.3 ml solution including 0.0015 mg/ ml of Tafluprost once daily in the affected eye(s)for 12 months.
45504979|NCT03554564|Behavioral|VOICE/Fitbit|During the VOICE (intervention) phase, participants will use the digital health platform plus Fitbit walking activity tracking for a total of five weeks (one week run-in phase plus four week study phase)
45504980|NCT03554564|Other|Daily self-reported exercise adherence|During usual care, patients will self-report on a daily basis if they met the walking exercise goal consistent with instructions from their clinician. Self-report will be recorded as a daily categorical (yes/no) variable.
45397300|NCT01323257|Drug|TMC435|150 mg capsule once daily for 7 days (Trt A, C, D)
45504981|NCT02106260|Drug|CLS003|
45504982|NCT05221905|Drug|BEET IT - Concentrate Beet root juice|Beet It Sport (James White Drinks, Ltd.) each containing 400mg of inorganic nitrate (~6.5 mmol) will be consumed twice daily (totalling ~13 mmol of inorganic nitrate per day) for at least 2 days prior to testing visits, as well as 2 hours prior to testing visits.
45504983|NCT05221905|Drug|BEET IT - Concentrate Beet root juice (nitrate depleted)|Beet It Sport (James White Drinks, Ltd.) each containing 0mg of inorganic nitrate (~0 mmol) will be consumed twice daily (totalling ~0 mmol of inorganic nitrate per day) for at least 2 days prior to testing visits, as well as 2 hours prior to testing visits. It is provided by the same company that produces the concentrated beet root juice shots (James White Drinks) but the placebo version is nitrate-depleted.
45504984|NCT02106338|Other|Placebo|Placebo capsules have the same inert components as CRS3123; 2 subjects randomized in each cohorts recieve 200mg, 400mg; and 600mg, or 100mg are planned respectively given orally every 12 hours for 10 days
45504985|NCT02106338|Drug|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, formulated in 100 and 200 mg capsules; 8 subjects randomized in Cohorts A through C receive doses of 200 mg, 400 mg; and 600 mg or 100mg are planned respectively given orally every 12 hours for 10 days.
45504986|NCT04806217|Other|Theory of Mind|Patients will be submitted to different neuropsychological tests used in routine and the non-verbal false belief task through in the Theory of Mind
45504987|NCT02101346|Dietary Supplement|Mixed High Fat Diet|Healthy, Round 1
45504988|NCT02101346|Dietary Supplement|Saturated fat diet|Healthy, Round 1 Healthy, Round 2
45504989|NCT02101346|Dietary Supplement|Monounsaturated fat diet|Healthy, Round 1
45504990|NCT02101346|Dietary Supplement|Polyunsaturated fat diet|Healthy, Round 1
45504991|NCT02101346|Dietary Supplement|Triolein 13C|Healthy, Round 2
45504992|NCT02101346|Dietary Supplement|Low fat|Healthy, Round 1
45504993|NCT04728139|Diagnostic Test|glypican 3|Assessment of glypican 3 presence in colorectal cancer patients using ELISA
45697359|NCT05404893|Diagnostic Test|Fecal calprotectin measurement|Stool samples will be collected and fecal calprotectin levels will be measured using an enzymatic immunoassay kit.
45697360|NCT02167204|Procedure|Computed Tomography|Undergo 18F-FLT PET/CT
45397301|NCT01323257|Drug|Darunavir|2 x 400 mg tablet once daily for 7 days (Trt E, F)
45697361|NCT02167204|Radiation|Fluorothymidine F-18|Undergo 18F-FLT PET/CT
45397302|NCT01323257|Drug|TMC435|50 mg capsule once daily for 7 days (Trt F)
45397303|NCT01323257|Drug|erythromycin|500 mg tablets three times a day for 7 days (Trt C)
45397304|NCT03837743|Drug|DUR-928 Topical Solution|Topical solution containing active drug
45397305|NCT03837743|Drug|Vehicle Topical Solution|Topical solution containing no active drug
45397306|NCT01323335|Drug|IV Uric Acid|
45397307|NCT01323335|Drug|IV Rasburicase|
45397308|NCT03836729|Drug|Tenofovir alafenamide/emtricitabine|TAF/FTC will be available as 25/200 milligrams (mg) tablet. Subjects will be administered TAF/FTC 25/200 mg QD via the oral route.
45397309|NCT03836729|Drug|GSK3640254|GSK3640254 will be available as 100 mg capsule. Subjects will be administered GSK3640254 200 mg capsule QD via the oral route.
45397310|NCT01027481|Drug|Lucentis|intravitreally administration of 0.05 ml Lucentis
45397311|NCT00443729|Drug|Comparator: raltegravir|raltegravir 400 milligram (mg) by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
45397312|NCT00443729|Drug|Comparator: placebo|lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
45697362|NCT02167204|Procedure|Positron Emission Tomography|Undergo 18F-FLT PET/CT
45697363|NCT05404737|Other|transthoracic echocardiography (TTE)|In order to evaluate the interchangeability of RV-LSF, a TTE will be performed just after the placement of general anesthesia, when the patient is under mechanical ventilation
45504994|NCT05221671|Other|information leaflet|Leaflets prepared to inform about anesthesia and endoscopic procedure will be given to both parents and pediatric patients. A standard leaflet has been prepared for parents. Two leaflets have been prepared for children under the age of 12 and for adolescent patients over the age of 12. Unlike routine hospital information forms, all leaflets designed and prepared as a cartoon book. It is narrated using photographs of the materials and toys in the endoscopy room. It was predicted that there would be a difference between the groups who read and did not read this information leaflet in terms of anxiety levels and anesthesia knowledge levels.
45397313|NCT00443729|Drug|Comparator: lopinavir (+) ritonavir|lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment
45697364|NCT05404737|Other|transoesophageal echocardiography (TEE).|During cardiopulmonary bypass surgery patients is monitored by a TEE as recommended.
45397314|NCT00443729|Drug|Comparator: placebo|raltegravir 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
45397315|NCT00443651|Drug|Rituximab|Rituximab was supplied as a concentrate for IV administration at a concentration of 10 mg/mL in 500 mg (50 mL) single-use vials.
45397316|NCT00443651|Drug|Anti-inflammatory drugs|Each rituximab infusion was preceded by methylprednisolone 100 mg IV. Use of stable doses of oral corticosteroids was permitted (≤ 10 mg of prednisone or equivalent per day) as were stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs).
45697365|NCT04992429|Procedure|SphinkeeperTM|The SphinkeeperTM includes up to 10 self-expandable prostheses, which get inserted into the intersphincteric place. They are made of inert Hyexpan (polyacrylonitrile)
45697366|NCT05538585|Drug|Galicaftor|Oral
45397317|NCT01027637|Other|5 mm vessel clips|evenly placed vessel clips placed at surgery and tracked by ultrasound
45397318|NCT03616067|Drug|Botox® injection|Botox® injection in salivary glands will be performed one month after inclusion. It will be performed with one injection point per gland (parotids and submandibulars)
45397319|NCT03616067|Drug|Scopoderm® patches arm|Scopoderm® patches will be initiated one month after inclusion. The patches will be renewed every 3 days, alternating behind each ear.
45397320|NCT01027247|Device|Ologen TM|
45397321|NCT03607799|Behavioral|Dietary Intervention|Individualized diet advice will be developed for each participant by a dietitian familiar with South Asian foods.
45397322|NCT03607799|Behavioral|Control|Control group participants will be provided with PDFs, website links to encourage healthy eating, physical activity, and other lifestyle factors during pregnancy. They will also receive weekly text messages aimed at increasing walking.
45397323|NCT01027715|Other|EEG monitoring and treatment of EEG seizures|Seizures will prompt treatment with loading doses of phenobarbital (20mg/kg), fosphenytoin (20mg/kg),and midazolam (0.05mg/kg bolus and .15mg/kg/hr infusion tapered over 48 hours)in that order for persisting seizures.
45697367|NCT05538585|Drug|Navocaftor|Oral
45397324|NCT01027325|Other|Dietary Intervention|Starch digestibility and carbohydrate quantity
45397325|NCT03029195|Device|Nasoalveolar molding therapy|Presurgical infant orthopedics
45397326|NCT03567473|Drug|Oral dexamethasone|Two doses of oral dexamethasone, 0.6 mg/kg (maximum single dose 10 mg). One at the time of emergency department enrolment immediately prior to first nebulized treatment and one at approximately 24 hour later
45397327|NCT03567473|Drug|Nebulized Epinephrine|Two nebulized treatments of 3 mL 1:1000 epinephrine 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment
45397328|NCT03567473|Drug|Oral placebo|Two doses of oral placebo, 0.6 mL/kg (maximum single dose 10 mL). One at the time of emergency department enrolment immediately prior to nebulized treatment and one at approximately 24 hour later . Oral placebo at Canadian sites is composed of OraBlendTM and in New Zealand and Australian sites will be a compounded solution.
45397329|NCT03567473|Drug|Nebulized normal saline|Two nebulized treatments of 3 mL of normal saline 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment
45697368|NCT00982072|Drug|tacrolimus|tacrolimus0.05mg/kg bd (levels 6-12ng/ml)
45697369|NCT00982072|Drug|prednisolone|Prednisolone 1mg/kg maximum 60mg od
45697370|NCT05537571|Drug|SLN360|SLN360 is a double-stranded small interfering ribonucleic acid (siRNA) targeting LPA messenger RNA (mRNA)
45697371|NCT05537571|Drug|Placebo|Sodium chloride, solution for injection
45697372|NCT05343195|Other|Task-oriented exercise|Task-oriented exercise program for patients after total hip replacement.
45697373|NCT05343195|Other|Control|Control intervention: conventional physiotherapy after hip replacement
45697374|NCT01899053|Drug|TAK-228|TAK-228 Capsules
45697375|NCT01899053|Drug|TAK-117|TAK-117 Capsules
45697376|NCT05396235|Biological|MT-3921|Solution for infusion; Intravenous (IV)
45504995|NCT05221515|Behavioral|Anger can go!|"The intervention Anger Can Go! was designed to treat anger regulation problems in autistic children aged 8 to 13 years old. The intervention consists of nine sessions of 60 minutes and is divided in four phases. Phase 1: psycho-education, affect-education and measuring anger with an anger-thermometer. This is a self-report scale presented as the drawing of a thermometer, that allows the child to indicate his level of anger, as linked to specific bodily and behavioral representations on a scale from 0 to 3. Phase 2: making a functional behavior assessment (FBA) and taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts. Phase 3: taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts, shifting attention away from aversive stimuli, to cope with the stress of the anger provoking situation. Phase 4: creating solutions to cope with an anger provoking situation."
45504996|NCT05221515|Behavioral|Parent psycho-education|Three psycho-educational parent group sessions (take place before the children's sessions in intervention group). Parents meet with other parents and a therapist to learn about the nature of their Expressed Emotion (EE) and how it relates to the child's aggressive behavior.
45504997|NCT01369927|Biological|Shigella Sonnei O-SPC/rBRU|
45397330|NCT03567473|Drug|MDI Epinephrine|Two doses of Epinephrine given by MDI plus spacer at 625 mcg (5 actuations of 125mcg) 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment.
45504998|NCT02101502|Other|Questioner|Obstetrics and gynecology health problems questionnaire for patients Educational effectiveness special questionnaire for medical staffs Institutional capacity special questionnaire for institution employees
45504999|NCT03121261|Drug|levobupivacaine|Comparing: 0.5% levobupivacaine 15 milligrams (mg) , 0.015% clonidine 50 micrograms (mcg) and 40% glucose 0.5 milliliters (ml) with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml
45505000|NCT03121261|Drug|clonidine|Comparing: 0.5% levobupivacaine 15 mg , 0.015% clonidine 50 mcg and 40% glucose 0.5 ml with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml
45505001|NCT02101580|Drug|ADI-PEG 20|
45505002|NCT05648019|Biological|Anti-CD19 CAR T-cells|A target per-protocol dose of vi able CD19 CAR transduced T-cells will consist of a single infusion of 0.2 to 5.0 x 10e6 lentiviral-transduced viable 41BB-CD19 CAR T-cells per kg body weight.
45697377|NCT05396235|Biological|Placebo|Solution for infusion; Intravenous (IV)
45697378|NCT05532423|Drug|Beetroot Juice - Active|Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This juice will be the active juice, meaning it has the high nitrate content that is of interest. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
45697379|NCT05532423|Drug|beetroot juice - Placebo|Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This drink will be the placebo drink, which means all of the nitrate has been extracted, however it tastes and smells the same as the active drink. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
45697380|NCT01032694|Drug|Azithromycin SR|Azithromycin SR, 2.0 g PO x 1 dose for treatment period
45397331|NCT03567473|Drug|MDI placebo|Two doses of inhaled placebo given by MDI plus spacer, 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment.
45397332|NCT00443261|Drug|Azacitidine|SC azacitidine
45397333|NCT00443261|Drug|Cisplatin|cisplatin 75 mg/m^2 day 8 every 28 days
45397334|NCT00439517|Drug|UFOX + Cetuximab|"Cetuximab infusion (400 mg/m^2 on day 1 of cycle 1 and 250 mg/m^2 at each subsequent day 1, as well as on days 8, 15 and 22)~Oxaliplatin infusion (85mg/m^2) on days 1 and 15 (every 2 weeks)~Oral UFT® (250mg/m^2 tegafur + 560 mg/m^2 uracil in 3 daily doses rounded to the nearest number of whole capsules) on days 1-21~Oral Folinic Acid (90 mg in 3 daily divided doses) on days 1-21"
45697381|NCT01032694|Drug|Amoxiclav|Amoxiclav 1000 x twice daily, 10 days duration
45697382|NCT04975581|Biological|Allograft Patch|Rotator Cuff repair with Allograft Patch (Graftjacket Now)
45697383|NCT05525949|Device|VIVID Brain|Participants receive visual perceptual training using the VIVID Brain software.
45397335|NCT00439517|Drug|FOLFOX4 + Cetuximab|"Cetuximab infusion (400 mg/m^2 on day 1 of cycle 1 and 250 mg/m^2 at each subsequent day 1, as well as on days 8, 15 and 22)~Oxaliplatin infusion (85 mg/m^2) on days 1 and 15 (every 2 weeks)~5-FU bolus + infusions (400 mg/m^2) on days 1, 2, 15 and 16~Folinic Acid infusions (200 mg/m^2) on days 1, 2, 15 and 16"
45505003|NCT02106416|Procedure|PET/MRI|Simultaneous PET/MRI (3T system)
45505004|NCT05365087|Procedure|Transoral Fundoplication and Sleeve Gastrectomy|Transoral Fundoplication procedure completed prior to Sleeve Gastrectomy
45505005|NCT05365087|Procedure|Gastric Bypass|Laparoscopic Roux-en-Y gastric bypass
45505006|NCT01372345|Drug|CIPRO®XR|Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
45505007|NCT04249323|Drug|CORT113176 Lipid Capsule Formulation|CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration
45505008|NCT04249323|Drug|Placebo matching CORT113176 Lipid Capsule Formulation|Placebo matching CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration
45505009|NCT04249323|Drug|Prednisone|Prednisone standard release tablets 1 x 20 mg plus 1 x 5 mg for oral administration
45505010|NCT02102750|Drug|Preservative free tafluprost opthalmic solution|0.0015% eye drops q.d, in both eyes for 7 to 9 days
45505011|NCT01372735|Radiation|neoadjuvant short course IMRT|neoadjuvant short course intensity-modulated radiotherapy, single dose 5 Gy, total dose 25 Gy (5x5 schedule) to primary tumor and regional lymph nodes
45505012|NCT01372735|Radiation|IORT|intraoperative radiation therapy during resection, 15 Gy (to 90% isodose) to tumor bed
45505013|NCT04227327|Drug|Abemaciclib|Abemaciclib will be administered orally at 150 mg twice daily
45397336|NCT01031147|Other|Examination|3D-TOF-MRA was performed for suspected patients to detect intracranial aneurysm, and subsequently underwent digital subtraction angiography
45397337|NCT01031225|Drug|STA 9090|STA-9090 IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
45505014|NCT04227327|Drug|Aromatase Inhibitors|Letrozole 2,5 mg daily or Anastrozole 1 mg daily
45505015|NCT02102828|Device|extended compression|Home use of extended compression therapy and aspirin
45505016|NCT02102828|Other|Aspirin|standard therapy of aspirin
45505017|NCT05228119|Biological|Oncolytic Virus Injection(RT-01)|Intravenous injection with or without intratumoral injection of a single dose of RT-01 and intravenous infusion of Nivolumab
45505018|NCT02101658|Other|clinic-based weight measurements|
45505019|NCT01372423|Drug|Lubiprostone|24 mcg capsules
45505020|NCT01372423|Drug|Placebo|24 mcg capsules
45505021|NCT02102906|Procedure|Transcranial magnetic stimulation|Single pulse TMS - 20 pulses at 120% motor threshold. Using the Magstim rapid 2 stimulator, which has a CE mark and will be used within the indications specified by the CE mark.
45505022|NCT04218357|Drug|Probenecid|safety
45505023|NCT04218357|Drug|Matching placebo|Placebo
45397338|NCT01028105|Other|Preoperative MRSA screening|MRSA preoperative screening and post operative infection rate, 30 days post operative
45397339|NCT01028261|Drug|ZGN-433|Subjects will receive placebo or ZGN-433 twice weekly over 6 weeks treatment period for a total of 12 doses. A range of doses will be evaluated.
45505024|NCT02102984|Device|covered biliary stents|endoscopic placement of covered biliary stents
45505025|NCT02102984|Device|uncovered biliary stents|endoscopic placement of uncovered biliary stents
45505026|NCT02101814|Procedure|Roux-en-Y gastric bypass (bariatric surgery)|
45505027|NCT01375933|Biological|NicVAX Vaccine|NicVAX Vaccine given 6 times over 6 months
45505028|NCT02106650|Drug|Folotyn and Leucovorin|
45505029|NCT02106650|Drug|Folic Acid|Folic acid (1.0 mg PO QD) is to be initiated at least 10 days prior to Folotyn administration, or per the USPI for Folotyn.
45505030|NCT02106650|Drug|Vitamin B12|Vitamin B12 (1 mg IM) is to be administered within 10 weeks prior to initiation of Folotyn and can be administered during Screening. Subsequent vitamin B12 injections may be given the same day as treatment with Folotyn and patients are to receive vitamin B12 every 8 to 10 weeks while treated with Folotyn.
45505031|NCT05221437|Other|antibiotic prescription|
45505032|NCT01376011|Dietary Supplement|quercetin/placebo|Quercetin 500mg once per day versus placebo
45505033|NCT04033107|Drug|Vitamin C|Participants will receive intravenous Vitamin C injection (dose: 1.5g/kg, D1-3, every 2 weeks), treatment termination when the disease progress is confirmed.
45505034|NCT04033107|Drug|Metformin|Participants will orally take metformin 4g daily.
45505035|NCT02106806|Dietary Supplement|Zinc|35 mg of elemental zinc twice daily for 16 weeks
45505036|NCT02106806|Other|Placebo|One capsule, twice daily for 16 weeks
45505037|NCT02966119|Drug|Clopidogrel or Aspirin and/or Dypyridamole|"The physician will prescribe on this antiplatelet agent if the patient is randomized in the arm  restart"
45505038|NCT05707299|Procedure|Intradermal acupuncture|"Procedure/Surgery: Bilateral Fengchi（GB20）and Qiuxu（GB40） will be stimulated. According to the position of the acupoints, the needle of φ0.20*1.5mm will be chosen. After acupuncture point localization and routine disinfection, all subjects will receive the acupuncture in the same order, and follow the steps of resting- stimulating-preparing-stimulating-resting to complete the acupuncture operation alternately.Before acupuncture, rest for 60s as the baseline period, and then stimulate the bilateral Fengchi（GB20） for 2 mins. After stopping stimulation, wait for fNIRS to return to the resting level (i.e., the preparation period), then stimulate the bilateral Qiuxu（GB40） for another 2 mins, and stop the near-infrared scanning when the image of fNIRS returns to the resting level."
45505039|NCT02103296|Procedure|Drawing admission labs from cord blood|
45505040|NCT02103296|Procedure|Drawing admission labs from infant blood|
45505041|NCT02956759|Procedure|Pan-retinal photocoagulation laser treatment|PRP initially consists of 1200 - 1600 burns given over 2-3 sessions and separated by2-3weeks by 532-argon laser machine.
45397340|NCT02943083|Behavioral|Relaxation Exercise|Groups receiving the intervention will be asked to engage in the relaxation protocol every day. Participants will be asked to continue practicing the relaxation protocol for the remainder of their pregnancy. Participants will be instructed to listen to the 7 minute guided muscle relaxation tape and engage in the 3 minute abdominal touch routine in the presence of the scent stick. Participants will be provided with a scent stick of their selected scent to take home. For the duration of the study, participants will be loaned standard headphones and an iPod Touch that contains only the guided progressive muscle relaxation audio recording to facilitate this at-home protocol.
45397341|NCT01031303|Biological|DTacP-IPV combined vaccine (TETRAXIM™)|0.5 mL, Intramuscular
45397342|NCT04726709|Behavioral|Poised for Parkinson's|Lecture, demonstration, activities, and supplemental materials designed to improve self-awareness, situational awareness, and ability to make good choices for physical and emotional self-care, moment-to-moment.
45397343|NCT01028339|Drug|Hypertonic saline|2 mL/kg of 7.5% hypertonic saline associated to hydroxyethyl starch
45397344|NCT01028339|Drug|Mannitol|Mannitol
45397345|NCT01028417|Device|Platinum microcoil|Coil Name: Vortx-18, Diamond Shape, Boston Scientific, Cork, Ireland; Coil Description: 80 mm long, fibre coated 0.018 inch diameter platinum microcoil
45505042|NCT02101892|Drug|Amitriptyline|per os, daily, evening
45505043|NCT02101892|Drug|placebo|per os, daily, evening
45505044|NCT03634111|Procedure|TAP block|TAP block was performed under guidance with 0.25% ropivacaine 20 ml each side.
45505045|NCT03634111|Drug|Morphine|Single dose was 1 mg. The locked time was 6 minutes. The limited dose was 40 mg/ 4 giờ.
45505046|NCT03634111|Drug|Ropivacaine|Ropivacaine 0.25% 20 ml each side
45505047|NCT02102048|Drug|Atazanavir|
45397346|NCT04700501|Other|Enjoy Your Bump - CBT life skills learning programme|Antenatal use of an online Cognitive Behavioural Therapy life skills learning programme to improve maternal feelings of anxiety and low mood.
45397347|NCT04695119|Other|Exposure is septic shock (defined according to Sepsis-III) and standard treatment according to departmental protocols.|Collection of data, biomarker and echocardiography analysis will be centralized and blinded. Assessment of endpoints will be blinded.
45397348|NCT01031459|Drug|Betaseron (Interferon beta-1b, BAY86-5046)|Telephone survey of all patients.
45505048|NCT02102126|Procedure|Renal denervation|
45505049|NCT03118297|Drug|Ulipristal Acetate|Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
45505050|NCT03118297|Drug|Placebo oral capsule|Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
45505051|NCT02250794|Drug|metformin and sitagliptin|metformin 750 mg PO twice daily
45505052|NCT02250794|Drug|insulin glargine and insulin lispro|insulin glargine given once daily
45505053|NCT02250794|Drug|metformin and sitagliptin|sitagliptin 100 mg PO once daily
45505054|NCT02250794|Drug|insulin glargine and insulin lispro|insulin lispro given three times daily with meals
45505055|NCT02103374|Drug|Atrovent + Bricanyl or Atrovent + Ventoline|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks
45505056|NCT02103374|Drug|Placebo|1 capsule lactose during 48 weeks
45505057|NCT01374061|Device|Classical intubation|Classical intubation
45505058|NCT01374061|Device|GLIDESCOPE|GLIDESCOPE intubation
45505059|NCT03555188|Drug|Ondansetron|Ondansetron is a highly selective receptor antagonist (5-HT3RA)
45697384|NCT05525949|Other|No-treatment Control|No-treatment is administered during control period.
45397349|NCT03495791|Other|YouTube Video|Educational Video
45397350|NCT00438815|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
45397351|NCT00438659|Drug|mometasone furoate|Applied to treatment area
45397352|NCT00438659|Other|placebo|Applied to treatment area
45397353|NCT01028495|Drug|RX-0201 plus Gemcitabine|RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off. Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.
45397354|NCT00437645|Drug|Valsartan 160 mg capsules|
45397355|NCT00437645|Drug|Amlodipine 5 mg capsules|
45397356|NCT00437645|Drug|placebo|capsules
45505060|NCT05658783|Other|Hot water foot bath|Keeping keep in 42oC (42 Degrees Celsius) hot water for 20 minutes
45505061|NCT02103452|Procedure|Ovarian and endometrial samples|Ovarian and endometrial samples were evaluated by hematoxlin &amp;eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE
45505062|NCT03967587|Device|Neosense Umbilical Catheter|The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
45505063|NCT02250950|Behavioral|MI and SDT Exercise Group|The intervention group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor trained in MI and SDT. This individual will lead group discussions and will have the participants exercise together.
45505064|NCT02250950|Behavioral|Non-MI and SDT Exercise Group|This group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor who was not trained in MI and SDT. This individual will lead a regular exercise class.
45505065|NCT05707221|Other|cleaning removable acrylic appliance with denture brush and chlorhexidine toothpaste|mechanical cleaning of removable appliance by the patient for 7 days before bedtime for one minute
45505066|NCT05707221|Other|cleaning removable acrylic appliance with cleansing tablet|chemical cleaning by patient for 7 days with cleansing tablet
45697385|NCT04957095|Drug|Inbrija|Inbrija will be administered to Parkinson's disease patients only. Patients will receive 2 capsules (84 mg) of medication.
45397357|NCT03995147|Drug|Pembrolizumab|"Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks in combination with R-CHOP for 6 cycles.~Participants that respond to the combination regiment will continue to receive pembrolizumab 200 mg IV every 3 weeks for additional 35 cycles (2 years)."
45397358|NCT03995147|Drug|R-CHOP Protocol|R-CHOP chemo-immunotherapy will be administered in combination with Pembrolizumab
45397359|NCT03477383|Diagnostic Test|donor-derived cell-free DNA (dd-cfDNA)|Measurement of dd-cfDNA and comparison against grade of rejection as measured by endomyocardial biopsy, taken simultaneously
45397360|NCT03465371|Other|CSC OnDemand Training Intervention|"Level 1: Readiness~Online readiness tool~Level 2: Core Knowledge~Week 1-self-paced core curriculum, totaling 8 hours of instruction~Level 3: Going Deeper~Week 2-instructor-led, role-specific, and advanced topics, totaling 12 hours of instruction~Level 4: Sustainability~9 months of online community of practice support; a discussion forum; open office hours with experts; multisite case conferencing; access to online materials"
45397361|NCT03465371|Other|InPerson Intervention|"Level 1: Readiness~Telephone conversations with program leaders to determine structures, roles, staffing, recruitment~Level 2: Core Knowledge~1 day of in-person training on FEP basics and CSC components~Level 3: Going Deeper~1.5 days of in-person training on how the team works, followed by breakout sessions by role~Level 4: Sustainability~9 months of monthly implementation coaching calls with team leads; monthly telephone case conferences; monthly care coordination calls split out by role"
45397362|NCT03465371|Other|Virtual InPerson Intervention|"Level 1: Readiness~Telephone conversations with program leaders to determine structures, roles, staffing, recruitment~Level 2: Core Knowledge~1 day of virtual (via Zoom) in-person training on FEP basics and CSC components~Level 3: Going Deeper~1.5 days of virtual (via Zoom) in-person training on how the team works, followed by breakout sessions by role~Level 4: Sustainability~9 months of monthly implementation coaching calls with team leads; monthly telephone case conferences; monthly care coordination calls split out by role"
45397363|NCT00437489|Drug|Inhaled Human Insulin (Exubera)|Initial dose (mg) as per weight based formula = 0.05 x body weight (kg) TID
45397364|NCT00437489|Drug|Inhaled Human Insulin (Exubera)|Initial dose of 1mg TID of inhaled human insulin
45397365|NCT01028573|Drug|PEG-ELS (Golytely)|4L consumed evening before colonoscopy
45397366|NCT01028573|Drug|PEG-ELS (Golytely)|2L consumed on the evening before and 2L consumed on the morning of Colonoscopy
45697386|NCT04957095|Other|Subcortical Stimulation|Subcortical simulation of the deep brain stimulation surgery target site will be applied by clinically placed deep brain stimulation electrodes at the previously determined therapeutic setting
45697387|NCT05391945|Diagnostic Test|polysomnography|Patient will be assessed by home Polysomnography(PSG), one night, Pulmonary function tests, including respiratory muscle strength, and comprehensive biological assessment of thyroid function.
45505067|NCT05707221|Other|combination of mechanical and chemical cleaning|cleaning the appliance with denture brush and CHX toothpaste followed by the cleansing tablet
45505068|NCT02103530|Other|FLT PET/CT|All PET/CT scans were performed using a hybrid PET/CT scanner (Gemini TF 64 with Astonish TF, Philips). F-18 FLT (2.96 MBq/kg) in 2-5 mL of normal saline was injected intravenously. One hour after FLT injection, CT began at the vertex and progressed to the upper thigh (120 kVp, 100 mA and 4 mm slice thickness). PET emission data were acquired immediately for 1 min at each bed position followed. The CT data were used for attenuation correction. Images were reconstructed using a standard ordered-subset expectation maximization algorithm with 3 iterations and 33 subsets.
45697388|NCT01032850|Drug|Sorafenib & Capecitabine|Intervention: Sorafenib twice a day by mouth (400mg), Capecitabine twice a day by mouth (850mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.
46057048|NCT00590044|Drug|NPH + Regular insulin|Split-mixed NPH + Regular insulin twice daily
45397367|NCT01028573|Drug|Miralax mixed with Gatorade|238g of PEG-3350 (Miralax) mixed with 2L of Gatorade consumed on the evening before colonoscopy
45397368|NCT01028573|Drug|Miralax|1L of PEG-3350 + Gatorade consumed on the evening before and 1L of PEG-3350 + Gatorade consumed on the morning of Colonoscopy
45397369|NCT04683575|Drug|Selenium Yeast|oral medication
45397370|NCT04683575|Drug|Placebo|oral medication
45397371|NCT03439631|Other|Patient satisfaction questionnaire|Patient satisfaction questionnaire
45397372|NCT01031615|Behavioral|Child and Family Traumatic Stress Interv (CFTSI)|4 sessions involving both the target child and a parent/caregiver
45397373|NCT01031615|Behavioral|Psychoeducational Comparison|4 individually focused sessions including psychoeducation and relaxation.
45397374|NCT04681625|Behavioral|Pelvic floor muscle training (PFMT) with suppressive urgency technique|"Pelvic floor muscle training with suppressive urgency technique:~Education about proper urination training in the period without pathological urgency.~Education about conscious urgency suppression through PFMT - suppressive urgency technique.~Education on the principle and effect of PFMT.~Exercises of varying intensity of pelvic floor muscles in different positions.~Exercises to relax the pelvic floor muscles. Exercise 5 times a week for 20-30 minutes a day."
45397375|NCT00442559|Drug|montelukast sodium|Montelukast 4/5 mg tablet (oral chewable), once daily, 12 weeks to up to 12 months
45397376|NCT00442559|Drug|inhaled corticosteroid|Inhaled corticosteroid solution, 1-4 puffs daily, 12 weeks to up to 12 months
45505069|NCT05220969|Genetic|Total Genotype Risk Score|A total genotype risk score has been generated based on the results of previously observed genetic association studies
46057049|NCT04227015|Drug|CTA101|CTA101 UCAR-T cell injection by intravenous infusion
45505070|NCT02251028|Behavioral|Value-based cognitive-behavioral therapy|The intervention is a manualized program specifically tailored for prevention of disability and psychological distress after whiplash injuries. The intervention is delivered by two trained clinical psychologists og consists of 10 weekly one-hour individual sessions.
45505071|NCT03117361|Drug|plitidepsin|Patients received plitidepsin as a 3-hour i.v. infusion at a dose of 5 mg/m2 on Days 1 and 15 every Four Weeks.
45505072|NCT03117361|Drug|Bortezomib|BTZ as a 3-5 second bolus s.c. injection at a dose of 1.3 mg/m2 on Days 1, 4, 8 and 11 every four weeks
46057050|NCT02714361|Dietary Supplement|Vitamin D3 supplement|1500 IU (37.5 mcg) Vitamin D3 capsules daily over 8 weeks (56 days)
45397377|NCT01031693|Device|Transcranial Magnetic Stimulation|daily sessions for 5 days
45397378|NCT01323491|Drug|Nicotine replacement therapy|Nicorette® TX tape 10mg, 15mg, 25mg Nicorette® microtab 2mg Nicorette® inhaler 10mg Nicorette® chewing gum 2 mg, 4mg freshfruit, freshmint, mint, whitemint
45397379|NCT00441701|Drug|Navarixin 1 mg|Navarixin 1 mg capsules
45397380|NCT00441701|Drug|Navarixin 10 mg|Navarixin 10 mg capsules
45397381|NCT00441701|Drug|Placebo to match navarixin|Placebo to navarixin capsules
45397382|NCT00441701|Drug|Rescue medication|Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief
45397383|NCT00441545|Drug|Fosrenol (Lanthanum Carbonate)|The starting dose is a total daily dose of 2250mg of Fosrenol (Lanthanum carbonate) to a maximum dose of 3000mg daily. Chewable tablets will be administered orally with meals in 750mg and 1000mg strength tablets.
45397384|NCT00441545|Drug|Sevelamer hydrochloride|The starting dose is a total daily dose of 4800mg of sevelamer hydrochloride up to a maximum of 6400 mg daily. Sevelamer hydrochloride 800mg tablets, administered orally with meals.
45397385|NCT03995381|Other|Decision aids|Shared decision making with decision aids
45397386|NCT01031849|Drug|Kaletra|Each tablet of Kaletra contains 200 mg of Lopinavir and 50mg of ritonavir. The patients will take two tablets of Kaletra bid.
45397387|NCT00436553|Drug|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, verteporfin was activated by light application of 50 J/cm^2 (Standard Fluence rate) or 25 J/cm^2 (Reduced Fluence rate) to the study eye, begun 15 minutes after the start of the infusion.
45397388|NCT00436553|Drug|Ranibizumab|Ranibizumab 0.5 mg administered as an intravitreal injection.
45397389|NCT00436553|Drug|Verteporfin Placebo|To maintain masking, as a placebo for verteporfin photodynamic therapy, patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of infusion.
45505073|NCT03117361|Drug|Dexamethasone|DXM orally at a dose of 40 mg/day on Days 1, 8, 15 and 22 every four weeks
45505074|NCT05707143|Other|home based stabilization exercises|3 times per day with 10 repetitions and holding time will be 5-10 sec
45505075|NCT05707143|Other|kegel exercises|3 times per day with 10 repetitions and holding time will be 5-10 sec
45505076|NCT01368614|Device|AVAPS-AE Mode of Therapy|AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.
46057051|NCT02714361|Other|Placebo|65% olive oil capsules daily over 8 weeks (56 days)
46057052|NCT04741581|Dietary Supplement|ThickenUp® Gel Express|Thickening gel
45397390|NCT00436553|Drug|Ranibizumab Placebo|To maintain masking, patients in the combination groups received sham intravitreal injections whenever retreatment with active Ranibizumab was not warranted based on the retreatment algorithm.
45397391|NCT00441467|Drug|Glufosfamide|5000 mg/m2 of glufosfamide on Day 1 of each three-week cycle for up to 6 cycles.
45505077|NCT01368614|Device|Respironics OnmiLab BiPAP S mode|Currently cleared Non-Invasive Ventilation (NIV) therapy modality
45505078|NCT01368614|Device|Respironics OmniLab Advanced CPAP mode|Currently cleared NIV therapy modality
45505079|NCT05220891|Other|Paracentesis|Paracentesis from ascitic patient
45505080|NCT05219305|Device|Dental Implant Placement|Placement in an edentulous site that was previously bone grafted in the prior study.
45505081|NCT05707065|Other|core strengthening exercises|The core muscles training includes transverse abdominis, multifidus, paraspinals, quadratus lumborum, and obliques.
45505082|NCT05707065|Other|Proprioceptive Neuromuscular Facilitation|lower limb PNF technique along with conventional treatment i.e., Rhythmic initiation, slow reversal, stabilizing reversal, and combination of isotones.
45505083|NCT02102360|Device|Anorganic Bovine Bone|used to improve periodontal regenerative procedures.
45505084|NCT02102360|Device|Enamel Matrix Derivative|used to improve periodontal regenerative procedures.
45505085|NCT05101681|Diagnostic Test|Teledentistry|Teledentistry using mobile photographs
45505086|NCT03555110|Behavioral|Personality Factor Battery Test (PFB Test)|Psychological instrument built for personality evaluation from the model of the Five Great Factors (FGF), that includes the following dimensions: Neuroticism, Extroversion, Socialization, Effort / Commitment), focusing on the component of the aspects of Neuroticism.
45505087|NCT03555110|Behavioral|Eye Movement Desensitization and Reprocessing Therapy (EMDR)|"It is a psychotherapeutic approach effective on treatment for trauma and post-traumatic stress disorder. It is an intervention that allows the desensitization of negative emotions from traumatic experiences.This therapy modifies memories that have been processed non-adaptively and become painful and dysfunctional memories. During the procedure, the patient is encouraged to move the eyes from side to side, associating these movements with a target situation, previously defined at the beginning of the session. The ocular movements can be replaced by tactile or sonorous stimuli. The series of stimuli must continue until the memory of the traumatic event can be reprocessed adaptively, that is, without the emotional, negative or painful process associated with that memory."
45505088|NCT05083273|Other|Cohorte|Completion of a socio-demographic, professional, medical and personal questionnaire
45505089|NCT02110004|Procedure|Ablation procedure|The primary purpose of the First-In-Man clinical investigation is to assess the Picasso NAV Catheter's ability to collect intra-cardiac signals within the desired chambers (atrial and/or ventricle) in the heart for the analysis of complex arrhythmias.
45505090|NCT02110004|Device|Picasso NAV Catheter|
45505091|NCT05082337|Device|SAVVY guidewire|The SAVVY guidewire will be used for rapid pacing runs, valve delivery and for left ventricular pressure measurements pre- and post-THV deployment
45505092|NCT03053427|Drug|Placebo|Oral administration
45697389|NCT04399707|Device|Transcutaneous electrical nerve stimulation (TENS) unit|Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
45397392|NCT01028729|Drug|Endostar|7.5mg/m2/day, iv, from day 1 to day 14
45397393|NCT01028729|Drug|Gemcitabine-Cisplatin chemotherapy|Gemcitabine 1000 mg/m2, iv, on day 1, 8 Cisplatin 80mg/m2, iv, on day 1, 2, 3
45397394|NCT03357419|Drug|Cephalexin|"The subjects will be randomized, at the operation day, to one of two treatment groups:~group 1: prophylactic antibiotic~group 2: placebo oral capsule~Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses."
45505093|NCT03053427|Drug|Gabapentin enacarbil|Oral administration
45505094|NCT02107118|Biological|ARM 1: AdMSC: adipose stem cells|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. Cells are returned to the study doctor for installation into the subject every 2 weeks for 3 months.
45505095|NCT02107118|Other|ARM 2: Placebo|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
45505096|NCT05081089|Drug|Artemether-lumefantrine|Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered according to weight as per manufacturer guidelines.
45505097|NCT05081089|Drug|Primaquine Phosphate|The single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer.
45505098|NCT05081089|Drug|Sulphadoxine-pyrimethamine with amodiaquine|Sulfadoxine/pyrimethamine tablets contain 500mg sulfadoxine and 25mg pyrimethamine. Amodiaquine tablets contain 150mg amodiaquine (as hydrochloride). Tablets will be administered according to weight as per manufacturer guidelines.
45697390|NCT04399707|Device|Placebo transcutaneous electrical nerve stimulation (TENS) unit|Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
45697391|NCT05390944|Drug|IMP4297(20mg)|Single oral dose of IMP4297 administered under fasting conditions 5*20 mg capsules in first intervention period and 10*10 mg capsules in second intervention period (after washout period: at least 7 days)
45505099|NCT05081089|Drug|Tafenoquine|100mg tafenoquine tablets are prepared into a 1mg/mL solution in water. Solution will be given according to weight as indicated per treatment arm in 5kg bands.
45397395|NCT03357419|Drug|Placebo oral capsule|"The subjects will be randomized, at the operation day, to one of two treatment groups:~group 1: prophylactic antibiotic~group 2: placebo~Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses."
45397396|NCT01031927|Drug|N-methyl glycine|staring from 500mg/day, increased by 500mg biweekly, up to maximin of 2000mg/day
45505100|NCT03555032|Drug|Talimogene laherparepvec (T-VEC)|One dose of 1 x 106 PFU/mL. Two doses of 1 x 108 PFU/mL. Given by intra-tumoural (i.t.) injection.
45505101|NCT03554408|Drug|10-1074-LS|Subcutaneous injection of 10-1074-LS
45505102|NCT03554408|Drug|10-1074-LS|Intravenous infusion of 10-1074-LS
45505103|NCT03554408|Drug|3BNC117-LS|Subcutaneous injection of 3BNC117-LS
45505104|NCT03554408|Drug|3BNC117-LS|Intravenous infusion of 3BNC117-LS
45505105|NCT05220579|Device|"Exposure to TOR device"|"Specific wave spectrum is directed by the TOR device to human tissues affected by the SARS-CoV-2 virus in order to disrupt its activity."
45505106|NCT05220579|Device|"Exposure to switched off TOR device"|"The TOR device has screened indicators on the front panel. The device was switched on / off by a medical monitor without the participation of medical personnel and investigators."
45505107|NCT02103686|Drug|Lyrica|
45505108|NCT02103686|Drug|Experimental drug|sustained release formulation of pregabalin
45505109|NCT02103686|Dietary Supplement|High fat meal|
45505110|NCT02103686|Dietary Supplement|fasted|
45505111|NCT05677581|Other|iodine nutrition status|iodine nutrition status
45505112|NCT01372969|Drug|Cx601|Suspension of adult expanded allogenic adipose-derived stem cells (eASCs) at a doses of 20 million cells and 40 million cells.
45505113|NCT02110082|Biological|Urelumab|
45505114|NCT02110082|Biological|Cetuximab|
45397397|NCT01028807|Other|Early feeding|after 24 hours fasting period, with good abdominal conditions (once flatus passage of bowel movements without abdominal distention, vomiting, nausea or ileus) the oral fluids during 24 hours and then advanced to a regular diet as tolerated.
45397398|NCT01028807|Other|5 day fasting|Obligatory 5-day fasting because it was the therapeutic gold standard at our hospital and our country. Both groups without NGT and antiemetic drug. 5-day antibiotic regimen, ranitidine and appropriate analgesics were used. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
45397399|NCT01028885|Procedure|radiation therapy treatment planning/simulation|
45505115|NCT05706831|Other|Combinatory effect of music stimulation and neurostimulation|music
45505116|NCT05063929|Other|Fruit (2 cup eq)|participants will receive 2 cup eq fruits
45505117|NCT05063929|Other|Fruit restriction (1/2 cup eq)|participants will receive 1/2 cups eq fruits
45505118|NCT02103764|Drug|Desogestrel|Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
45505119|NCT02103764|Drug|Medroxyprogesterone acetate|Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
45397400|NCT01028885|Procedure|intensity-modulated radiation therapy|
45397401|NCT01028885|Procedure|image-guided radiation therapy|
45397402|NCT01028885|Procedure|magnetic resonance imaging|
45505120|NCT05011201|Device|Dual Joint Visual Feedback without Scoring|Participants will walk on the treadmill while given instantaneous anterior and posterior foot position and immediate scoring information using the DJVF interface. A pediatric physical therapist will provide (1) verbal encouragement and redirection of attention to the task as needed (2) verbal cueing to assist if difficulty in interpreting the feedback and appropriate modification is noted.
45505121|NCT05011201|Device|Dual Joint Visual Feedback with Scoring|Participants will walk on the treadmill using the same DJFB with additional visual cumulative scoring on their performance. A pediatric physical therapist will provide (1) verbal encouragement and redirection of attention to the task as needed (2) verbal cueing to assist if difficulty in interpreting the feedback and appropriate modification is noted.
45505122|NCT02110316|Other|Dosage form of voriconazole|Instead of an oral dose of voriconazole, patients receive one intravenous dose of voriconazole (in the same dose as the oral dose).
45505123|NCT05625087|Drug|Alpelisib|Alpelisib 300 mg once daily + fulvestrant 500 mg every 28 days
45505124|NCT05625087|Drug|Ribociclib|Ribocilcib 600 mg once daily 3 weeks on/1 week off + fulvestrant 500 mg every 28 days
45505125|NCT02103842|Drug|Omega-3 fatty acids|
45505126|NCT05220267|Drug|Anlotinib plus Sintilimab|Anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle).Sintilimab was administered intravenously (200mg once every 3weeks).
45505127|NCT02110394|Other|bendamustine|Routine practice
45505128|NCT02110394|Other|rituximab|Routine practice
45505129|NCT02373241|Drug|Losartan|Standard dosing
45505130|NCT02373241|Drug|Losartan|Experimental dosing
45505131|NCT03052959|Behavioral|Immediate Intervention|The 'BETTER' prevention practitioner intervention involves assessment of a person's current participation, or lack of participation, among domains of evidence-based chronic disease prevention and surveillance (CDPS) actions. The assessment is followed several days later by a supportive meeting with a prevention practitioner nurse, using principles of shared decision making and health coaching, to establish goals for accomplishing CDPS activities of the individual's choice during the subsequent six months to develop personal goals and targets for participating in CDPS actions during the following six months. In BETTER HEALTH: DURHAM, the prevention practitioner nurse will be a public health nurse from the Durham Region Health Department.
45505132|NCT03052959|Other|Wait List Intervention|The control arm will receive the prevention practitioner intervention 6 months after the intervention arm. Their outcomes will not be assessed in the study.
45505133|NCT02107430|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa arm post radiotherapy
45505134|NCT02107430|Radiation|Standard radiotherapy|radiotherapy
45505135|NCT05059639|Other|Almond|Consume 2 ounces of almond daily for 8 weeks
45505136|NCT05059639|Other|Pretzel|Consume comparative amount of pretzel daily for 8 weeks
45505137|NCT05706675|Procedure|Non surgical periodontal therapy|Manual root planning+Ultrasonic subgingival debridement
45505138|NCT03120013|Device|Anodal cerebellar and cathodal spinal tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
45505139|NCT03120013|Device|Sham cerebellar and sham spinal tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
45505140|NCT05656131|Drug|Fluzoparib|Arms A will be treated with fluzoparib alone
45505141|NCT05656131|Drug|Fluzoparib+Camrelizumab|Arms B will be treated with fluzoparib in combination with camrelizumab
45505142|NCT02110472|Device|Corneal inlay|Presbia Flexivue Microlens implantation in corneal pocket created in nondominant eyes of emmetropic presbyopes.
45505143|NCT05220189|Diagnostic Test|EarlyTect® Bladder Cancer test|A highly accurate and sensitive real-time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE-qMSP) for measuring PENK methylation in urine DNA to detect bladder cancer in hematuria patients.
45505144|NCT01373047|Biological|anti-CEA 2nd generation designer T cells|Three infusions of gene-modified T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach.
45505145|NCT02103998|Drug|thryoid hormone T4 + oral potassium iodide (KI) for 42 days|Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
45505146|NCT02103998|Drug|D5W - 5% dextrose water|Equivalent volume of infusion as study drug
45505147|NCT05220111|Procedure|Cardiac surgical operation (valve, aorta, coronary arteries)|Quality of life assessment using EQ-5D-3L
45505148|NCT01941589|Drug|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone|maximal oral 5-ASA+/-topical 5-ASA+IV corticosteroids
45505149|NCT01941589|Drug|corticosteroids only|IV corticosteroids only
45505150|NCT02110550|Other|IPS.emmax endocrown|
45697392|NCT05390944|Drug|IMP4297(10mg)|Single oral dose of IMP4297 administered under fasting conditions 10*10 mg capsules in first intervention period and 5*20 mg capsules in second intervention period (after washout period: at least 7 days)
45697393|NCT04911309|Other|functional exercise training|12 weeks functional exercise training twice per week, each session lasting 60 min
45697394|NCT04911309|Other|standard therapy / treatment|12 weeks standard therapy / treatment
45505151|NCT02110628|Procedure|Roux-en-Y anastomosis|Roux-en-Y anastomosis
45505152|NCT02110628|Procedure|Roux-en-Y+Pouch anastomosis|Roux-en-Y+Pouch anastomosis
45505153|NCT02107664|Radiation|Palliative RT for bone cancer pain|
45505154|NCT01845649|Drug|WC3011 Estradiol Vaginal Cream|Daily for 14 days followed by 3 times per week for 10 weeks
45505155|NCT01845649|Drug|Vehicle|Daily for 14 days followed by 3 times per week for 10 weeks
45505156|NCT03554252|Other|Frequencies|Results are presented as natural frequencies (e.g. the drug was effective for 1 out of 10 people) while side effects are presented as percentages (e.g. 40% participants experienced severe side effects)
45697395|NCT04909437|Dietary Supplement|Mycobiotic|2 sachet/day, 21 days, oral
45697396|NCT04909437|Dietary Supplement|Placebo|2 sachet/day, 21 days, oral
45505157|NCT03554252|Other|Percentages|Results are presented as percentages (e.g. the drug was effective for 10% of people) while side effects are presented as natural frequencies (e.g. 4 out of 10 participants experienced severe side effects)
45505158|NCT01345929|Drug|CXA-201|CXA-201 IV infusion (1500mg q8) for 7 days
45505159|NCT01345929|Drug|Levofloxacin|Levofloxacin IV infusion (750mg qd) for 7 days
45505160|NCT02107742|Procedure|Normal speed lidocaine injection|30 seconds
45505161|NCT02107742|Procedure|Slow lidocaine injection|speed 45 seconds
45505162|NCT02107742|Procedure|Fast lidocaine injection|speed 15 seconds
45505163|NCT01825291|Procedure|CPAP treatment|
45505164|NCT02250872|Drug|Gemigliptin|Gemigliptin 100mg in 2 divided doses plus cisplatin
45505165|NCT02250872|Drug|Placebo|100mg in 2 divided doses plus cisplatin
45505166|NCT02250872|Drug|Cisplatin|All patients will receive intravenous cisplatin
45505167|NCT01374139|Drug|Bosutinib|5 clinical 100 mg tablets and 100 mg capsules, 500 mg, single dose, 2x2 crossover under fed condition
45505168|NCT01374139|Drug|Bosutinib|4 commercial 100 mg tablets, 400 mg, single dose, 2x2 crossover under fed/fast condition
45505169|NCT03817983|Diagnostic Test|MRE review for axSpA|Screening for evidence of axSpA on the MRE scan of patients with Crohn's disease followed by clinical and MRI assessment
45505170|NCT02107820|Behavioral|Bladder Training (BT)|All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
45505171|NCT02107820|Device|Percutaneous Tibial Nerve stimulation|"A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each."
45505172|NCT02110784|Drug|Eurartesim tablets|dosage bands: 24 to <36 kg body weight: 2 tablets a day for three consecutive days 36 to <75 kg body weight: 3 tablets a day for three consecutive days 75 to 100 kg body weight: 4 tablets a day for three consecutive days
45505173|NCT04988425|Drug|TNFα Monoclonal Antibody|Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery.
45505174|NCT04988425|Drug|Methylprednisolone|Injection of 500mg of methylprednisolone immediately after admission before surgery.
45397403|NCT01028885|Procedure|computed tomography|
45505175|NCT04988425|Drug|Saline|Injection of the same volume of saline immediately after admission before surgery
45697397|NCT01032928|Behavioral|Respiratory-Swallow Phase training|Patients were presented with visually guided respiratory feedback to train optimal respiratory-swallow coordination patterns.
45397404|NCT01032005|Other|double fortified salt|Refined salt of particle size < 1 mm iodized with potassium iodate (KIO3) at a concentration of 30 µg I/g salt at the factory will be purchased and blended with encapsulated Ferrous Fumarate premix containing 15% iron. Premix to salt ratio of 1 to 150 will be used to arrive at 1000 ppm elemental iron in the final product.
45397405|NCT03331289|Drug|Placebo|Placebo will be administered to 20 subjects after a 3 hour tracer equilibration period
45397406|NCT03331289|Drug|Exenatide|Exenatide will be administered to 20 subjects after a 3 hour tracer equilibration period
45397407|NCT03331289|Drug|Dapagliflozin|Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period
45397408|NCT03331289|Drug|Exenatide and Dapagliflozin|Exenatide and Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period
45397409|NCT01032083|Drug|Citalopram|Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
45397410|NCT01032083|Drug|Placebo|Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
45397411|NCT00436163|Drug|Peginterferon alfa-2a|180 mcg subcutaneously once per week for 48 weeks.
45397412|NCT01028963|Drug|Placebo|Placebo capsules once daily
45397413|NCT01028963|Drug|pioglitazone|pioglitazone 30 mg tablet once daily
45397414|NCT01028963|Drug|CCX140-B|CCX140-B capsules once daily (Group C)
45397415|NCT01028963|Drug|CCX140-B|CCX140-B capsules once daily (Group D)
45397416|NCT01029041|Other|Strengthening Exercises|Exercises that aim the improvement of muscular strength of arms and legs
45397417|NCT01029041|Other|Stretching exercises|Exercises that aim the improvement of muscular flexibility of arms, legs and spine
45397418|NCT00006604|Drug|ATV|Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
45397419|NCT00006604|Drug|Ritonavir|Administered as 100 mg capsules or oral solution.
45397420|NCT03951376|Behavioral|UPRIGHT intervention|The UPRIGHT intervention design consists of two different phases consecutively implemented in two school years: intensive phase and follow-up phase. During the intensive phase, all stakeholders are trained in the UPRIGHT WELL-BEING FOR US programme (18 skills). The follow-up phase (WELL-BEING FOR ALL) intends not only to maintain the effect of the intensive training in youths, but also to boost the positive mental health atmosphere created in the whole school. To do so, different collective activities will be organized at school level such as celebration of thematic days, activities with the community, and outdoor/indoor activities.
45505176|NCT03553784|Other|Group delivered Low Intensity Cognitive Behavioural Therapy|The intervention is group-delivered, low-intensity CBT similar to that used in IAPT (Improving Access to Psychological Therapies) Services in England. This intervention is already being offered as part of standard care at the Intervention site, and will not be altered by the study protocol, other than the requirement to complete a few more questionnaires. The intervention group meets weekly for eight weeks, and is facilitated by a clinical psychologist, a psychological well-being practitioner and a clinical nurse specialist from the medical oncology team. Content of the intervention is broad CBT, combining aspects of second-wave CBT, with elements of Narrative Therapy and ACT.
45505177|NCT03554096|Dietary Supplement|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
45505178|NCT02104154|Device|Samsung LABGEO PT10 Hepatic Panel|
45505179|NCT02110862|Other|Transittime. Defecography|
45505180|NCT01343901|Drug|Bevacizumab|Participants with mCRC and having exclusively liver or liver and lung metastases who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases as per treating physician's discretion will be observed. All concomitant medications as used in routine clinical practice are allowed.
45505181|NCT02110940|Other|Neurodynamic mobilization exercise|"The mobilization exercise is conducted with 10 repetitions for each action, the action is hold for 5 seconds when subjects had the stretch feeling. The series of exercise is told to perform 2 sets a day, daily practice.~Subjects' conditions will be reviewed at the end of 4th and 8th week. An exercise log book will be provided for each subject to record down the compliance of the exercise."
45505182|NCT02110940|Other|Conservative Physiotherapy|The control group is assigned to received conventional treatment in the physiotherapy department with the standard rehabilitation protocol consisted of electrotherapy for pain relief, strengthening exercise to increase the strength of the thigh
45505183|NCT02104232|Behavioral|THPP-I|
45505184|NCT02104232|Behavioral|EUC|
45505185|NCT02104466|Procedure|Acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. The initial acupuncture treatment will include a one-on-one diagnostic interview with one of the study acupuncturists for up to 30 minutes, followed by administration of acupuncture needles retained for 20-40 minutes. For subsequent group acupuncture treatments, participants will have a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Eight to twelve needles will be administered in acupuncture points selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
45505186|NCT05617521|Device|Abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)|Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device
45397421|NCT00006478|Biological|autologous tumor cell vaccine|
45397422|NCT00006478|Biological|keyhole limpet hemocyanin|
45397423|NCT00006478|Biological|sargramostim|
45397424|NCT00006478|Procedure|adjuvant therapy|
45397425|NCT01097902|Drug|Ibuprofen|800 mg oral one time only
45397426|NCT01097902|Drug|Placebo tablet|Placebo tablet oral one time only
45397427|NCT00436007|Biological|GSK 257049|GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine
45397428|NCT00436007|Biological|Tritanrix™ HepB/Hib|GSK Biologicals' re-constituted diphtheria, tetanus, pertussis, hepatitis B vaccine (Tritanrix™ HepB) and Haemophilus influenzae type B vaccine (Hiberix™)
45397429|NCT00436007|Biological|Rouvax™|Aventis Pasteur's attenuated measles vaccine.
45505187|NCT05617521|Device|Loose abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)|Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device. It will be loosened just prior the procedure.
45505188|NCT04862858|Other|Educational Intervention|The educational intervention will involve guideline-based treatment recommendation information for providers via fax/mail and phone and provide resources via mail and phone for patients to learn more about ways to reduce their cardiovascular risk.
45505189|NCT02104622|Device|ReWalk Rehabilitation 2.0|
45505190|NCT05219643|Device|NAVA|Nava level is set to maintain the target tidal volume: 6-10ml / kg (pbw). The trigger sensitivity is 0.5uv. The expiratory trigger sensitivity: the built-in software of the ventilator is set to 70% of the peak value of diaphragm electrical activity.
45505191|NCT05219643|Device|PSV|According to the doctor's experience, maintain the target tidal volume: 6-10ml / kg (pbw); trigger sensitivity: 1.5-2l/min, expiratory trigger sensitivity: 30% inspiratory peak flow rate.
45505192|NCT02108132|Biological|Cellular therapy|bone marrow derived mesenchymal stem cells for normal subjects will be separated and induced to adopt the hepatocyte phenotype then injected through the portal vein to hemophilia patients
45505193|NCT02108132|Biological|cellular therapy|Allogenic bone marrow derived MSCs will be isolated and subjected to induction of hepatic phenotype. After proof of in vitro secretion of albumin and factor 8 from the cell population. It will be injected into the portal vein via the spleen
45505194|NCT05706363|Procedure|Quadriceps graft|Using quadriceps graft as new medial patellofemoral ligament graft. Fixated with suture anchor
45397430|NCT00436007|Biological|Stamaril™|Aventis Pasteur's attenuated yellow fever vaccine.
45505195|NCT02108210|Drug|Anakinra|
45505196|NCT02108210|Drug|Placebo|
45505197|NCT03053271|Drug|ATR-101|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks at the same dose level being used at the completion of the open-label dose-escalation period.
45505198|NCT03053271|Drug|Placebo|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks with placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
45397431|NCT00436007|Biological|Polio Sabin™|GSK Biologicals' oral polio virus vaccine
45505199|NCT02104700|Drug|Rilpivirine/Emtricitabine/Tenofovir|Rilpivirine 25mg/Emtricitiabine 200mg/Tenofovir 300mg FDC qday
45505200|NCT02104778|Drug|Dexamethasone|In dexamethasone group, dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
45505201|NCT02104778|Drug|Epinephrine|Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block
45397432|NCT01032317|Device|Radiofrequency Catheter Ablation|The Biosense Webster EZ Steer ThermoCool NAV Diagnostic / Ablation Deflectable Tip Catheter with Contact Force Sensing Capability is designed to facilitate electrophysiological mapping and transmit radiofrequency current as well as provide a real-time measurement of contact force.
45505202|NCT05205681|Diagnostic Test|Pre-operative imaging|Use of pre-operative imaging or the diagnosis of acute appendicitis
45505203|NCT02104856|Device|Alair System (Bronchial Thermoplasty)|
45505204|NCT05606835|Other|Postural stability assessment|The Biodex Balance System SD (BDS) (Biodex Medical Systems Inc., Shirley, New York, USA) assesses postural stability (PS). Both static PS (SPS) and dynamic PS (DPS) will be assessed. In the DPS assessment, the platform can be tilted 20° in any direction. For static measurement, participants will be asked to stand barefoot on the platform, stand on one leg, keep the knees in 20-30° flexion. Meanwhile the contralateral knee will be asked to keep in 90° flexion, and stabilize their feet until the end of the test. Upon completion of the SPS assessment, the DPS assessment will be performed. The difficulty level of the DPS test will accepted as 4. For both SPS and the DPS assessment, the test consists of 3 trials of 20 seconds each with a 10-second break between trials.
45697398|NCT04278261|Procedure|Focal therapy(high-frequency irreversible electroporation)|High-frequency irreversible electroporation will be performed via the perineum with the guidance of ultrasound under general anaesthesia to the patient with localized prostate cancer
45697399|NCT04278261|Procedure|laparoscopic radical prostatectomy|Laparoscopic radical prostatectomy
45697400|NCT00983242|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 8am on Day 1 after an overnight fast of at least 10 hours.
45397433|NCT01029197|Behavioral|CBT and exposure therapy for PTSD|The CBT intervention will be administered twice weekly in group therapy sessions for 7 weeks, and then twice weekly individual sessions for 4 weeks.
45397434|NCT01029197|Other|Treatment as Usual|Participants in the treatment as usual condition will receive their usual services at the community clinic where they receive mental health and substance abuse services
45397435|NCT01032395|Biological|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
45397436|NCT01032395|Biological|Fluad®|15 ug of HA antigen; adjuvanted; trivalent
45397437|NCT01032395|Biological|Begrivac®|15 ug of antigen; non-adjuvanted; trivalent
45397438|NCT00435461|Drug|Fluticasone furoate and fexofenadine|Fluticasone furoate and fexofenadine
45397439|NCT00006436|Biological|Rituximab|2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5
45397440|NCT00006436|Biological|Filgrastim|Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle
45849708|NCT05435508|Other|Pain Neuroscience Education|A total of 1 PNE sessions (Neuroscience pain education) will be carried out, in addition medical treatment similar to control group (Usual care). The PNE sessions will be conducted by an experienced PNE certified proffesional in 35 minute face-to-face sessions. In PNE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
45849709|NCT05435508|Other|Usual care|The control group (Usual care) is treated with pre-anesthetic assessment + usual treatment, management for analgesic medication pre, during and post hysterectomy. Depending on the medical needs and criteria of patients´s care physician.
45849710|NCT05435352|Procedure|Core needle biopsy|An additional core needle biopsy is taken to run the Pear Bio test. Test results are not used to inform treatment. Approved neoadjuvant therapy regimens are given to the patient as per standard of care to observe response.
45397441|NCT00006436|Drug|EPOCH|combination chemotheray: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles
45505205|NCT05606835|Other|Frontal plan prjection angle|Frontal Plan Projection Angle (FPPA) is calculated as the angle between the thigh segment and the trunk segment based on the postural image, considering the position of the thigh and tibia. The FPPA will be evaluated using the Spark motion Pro™ application (2D). Before measurement, markers will be placed bilaterally at the SIAS, at the midpoint of the femoral condyles, and at the midpoint of the ankle bones. Participants will stand on the floor barefoot and arms crossed over the chest. Subjects will be asked to squat in a controlled manner and perform a 60° knee bend without losing balance before returning to the starting position. Test will be performed by using single leg squat test. The one-legged squat will be performed for 5 seconds at a standard pace with the researcher acting as the counter. Degrees smaller than 165 will be accepted as increase in knee valgus.
45849711|NCT05416944|Other|Personalized blood pressure management|Personalized blood pressure management: Intraoperative mean arterial pressure will be maintained at least at the mean nighttime mean arterial pressure (assessed using preoperative automated blood pressure monitoring) with a minimum mean arterial pressure of 65 mmHg, and maximum mean arterial pressure of 110 mmHg.
45849712|NCT05408910|Drug|Rifaximin 550 MG Oral Tablet [XIFAXAN]|Participants in this arm will receive Rifaximin 550 mg three times daily for 14 days.
45849713|NCT05408910|Drug|Placebo|Participants in this arm will receive placebo three times daily for 14 days.
45849714|NCT05403372|Device|PAS-C System|The InterShunt PAS-C System is a transcatheter system that creates a shunt by excising tissue from the interatrial septum resulting in a left to right atrial shunt that off-loads elevated left atrial pressure, potentially reducing symptoms and improving quality of life. The PAS-C System does not require a permanent implant to maintain patency of the interatrial shunt.
45397442|NCT01097980|Drug|Trazodone|50 mg/d trazodone was upwardly titrated to 100 mg/d over one week and then maintained
45397443|NCT01097980|Drug|Placebo|Placebo
45397444|NCT01029275|Drug|Pre-treatment with octreotide|Pre-treatment with octreotide
45397445|NCT01098058|Other|CBT plus treatment as usual|16 one-hour therapy sessions taking place over 42 weeks in addition to usual medical follow-up appointments
45397446|NCT01098058|Other|Treatment as usual|Treatment as usual appointments at the Adult ADHD Service - typically one 30-minute appointment every three to six months
45397447|NCT03994445|Behavioral|Mobile Phone-Based Intervention|"We propose our intervention based on social cognitive behavior theories and the stages of the change model.~The program will be carried out using the word Mettle, it will help ex-smokers stay off cigarettes through advices generated to promote the health from religious concepts and culture perspectives ."
45505206|NCT05606835|Other|Foot and Ankle Ability Measure|The Foot and Ankle Ailability Measure (FAAM) is used to assess the self-reported overall functional level of patients with leg, foot, and ankle musculoskeletal injuries and conditions. It consists of 1) activities of daily living [ADL] and 2) sports [S] and can be scored from 0 to 100%. In the FAAM, there are 29 items that are scored from 0 to 4. There are 21 items related to various functional activities under the subtitle activities of daily living, and 8 items related to various activities related to participation in sports under the subtitle sports. Standardized response options are answered on five-point likert scales ranging from 0 (I cannot) to 4 (no difficulty). Point totals between 0 and 84 for the ADL subtitle and between 0 and 32 for the Sports subtitle are converted to percentage points.
45505207|NCT05606835|Other|Navicular Drop Test|The navicular drop test (NDT) is a clinical method for assessing the mobility of the medial longitudinal arch (MLA). The extent of navicular subsidence is assessed to determine the flexibility of the MLA and the position of the navicular with and without transfer of body weight. To assess navicular drop, the subtalar joint will be positioned in neutral position and the height of the navicular will be measured in non-weight bearing position. Then the measurement will be repeated in weightbearing position. The height difference between the two measurements in sitting and standing is recorded as the NDT value. Values more than 10mm is accepted as pathological.
45505208|NCT05606835|Other|Calcaneotibial Angle Measurement|Measurement of the calcaneotibial angle (CTA) is one of the methods used in the evaluation of the foot and ankle. By measuring this angle, it is assessed whether the ankle problems are related to the hindfoot. In the CTA measurement, the angle between the vertical axis of the calcaneus and the longitudinal axis of the achilles tendon is measured in the standing and prone positions, and the differences will be recorded. Values more than 8 degrees is accepted as calcaneal valgus.
45505209|NCT05606835|Other|Tibial Torsion Angle|Tibial torsion is a rotational deformity which can be measured between the long axis of the tibia and the transmalleolar axes. This measurement can be used to determine the extent to foot malalignment is due to bone torsion. Measurement will be done by a goniometer. Participants will be asked to lie prone and will be positioned with the knee joint in 90° flexion and the ankle joint in a neutral position. Normal alignment is 20 degrees external rotation. Any increase or decrease accepted as pathological.
45397448|NCT01029431|Device|AirQ Intubating Laryngeal Airway|After induction of anaesthesia in each child, either a PLMA or an Air-Q® ILA of the weight-appropriate size will be inserted & the evaluation described below will be conducted. The first LMA will then be removed & the other device inserted & assessed. The order in which the LMA devices are inserted will be determined using block randomisation, with random block sizes, after recruitment & before induction of anesthesia. The anesthesiologist will insert the LMAs using the manufacturer's recommended technique, & inflate the cuff to the manufacturer's recommended intracuff pressure of 60 cm H2O. Intracuff pressure will be measured with a digital pressure cuff monitor.
45397449|NCT00434759|Behavioral|cognitive therapy|changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
45397450|NCT00434759|Behavioral|stepped care program based on cognitive therapy|starting with a digital-video-disk-based (DVD-based) self-help module (8 Sessions) followed by face-to-face-therapy including 8 or 16 sessions depending on remission status; including: changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
45397451|NCT01029509|Drug|OPB 31121|Starting dose of 200 mg (two 100 mg tablets) twice a day for 21 days followed by 7 days of rest.
45697401|NCT00983242|Drug|Verapamil HCl ER|One 240 mg verapamil HCl ER tablet taken at 8am on Days 15-18 without regard to meals and along with colchicine at 8am on Day 19 after an overnight fast of at least 10 hours.
45697402|NCT00983242|Drug|Colchicine|A single dose of 0.6 mg colchicine administered along with verapamil HCL ER at 8 am on Day 19 after an overnight fast of at least 10 hours.
45397452|NCT04829903|Drug|Dulaglutide|Dulaglutide injections
45397453|NCT04829903|Drug|Liraglutide|Liraglutide injections
45397454|NCT01032551|Behavioral|Vascular Access Decision Aid|The intervention group will receive a PtDA addressing vascular access for CA procedures. The PtDA is a brief lay summary that outlines, the purpose of the PtDA, a description of both femoral and radial approaches for CA procedures, what to expect from both approaches, the known risks/benefits of each access site (including a grading of the evidence), and a short assessment of the patients values. The values assessment is included in the PtDA as a means to help guide the patient through the decision making process. This section will ask the patient to explicitly state which features, risks, and benefits of each approach are important to them.
45397455|NCT00440999|Drug|Pyronaridine artesunate|
45505210|NCT05606835|Other|Femoral internal and external rotation measurement|Accurate assessment of hip joint range of motion (ROM) is an important component in the overall clinical evaluation of lower extremity injuries, particularly those of the hip and groin. The expected hip rotational range of motion for internal rotation (IR) is 45°, and for external rotation (ER) is 0° to 45°. In this study, a smartphone-based inclinometer will be used to measure femoral IR and ER. The inclinometer will be placed vertically so that the top edge is just below the tibial tuberosity and the bottom edge is pointed at the midpoint of the medial and lateral malleoli.
45505211|NCT02108366|Drug|Celecoxib|Celecoxib 200mg daily
45505212|NCT02108366|Drug|Oseltamivir|Oseltamivir 75mg bid
45397456|NCT00440999|Drug|Chloroquine|
45397457|NCT00434213|Drug|Daytrana|Methylphenidate Transdermal System (MTS)
45397458|NCT01029743|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Daily dose, a treatment duration of 5 weeks for patients undergoing major hip surgery and a treatment duration of 2 weeks for patients undergoing major knee surgery are recommended
45505213|NCT02108366|Drug|Placebo|Placebo capsule identical in appearance to celecoxib capsule, containing corn starch
45505214|NCT05602233|Other|Exercise|The training will be given for 6 weeks, 3 times a week for 20 minutes. This phased balance training program is based on the participant's ability to maintain a single limb posture while performing balance activities. The program includes: 1) hop to stabilization, 2) hop to stabilization and reach, 3) hop to stabilization box drill, 4) progressive single-limb stance balance activities with eyes open, and 5) progressive single-limb stance activities with eyes closed. Participants will be followed up with a physiotherapist and will be able to proceed to the next stage of the test after completing the previous level without errors.
45505215|NCT05602233|Other|STARS (Sensory-Targeted Ankle Rehabilitation Strategies)|STARS includes; joint mobilization, plantar massage and triceps surae stretching. The training will be given for 6 weeks, 3 times a week for 5 minutes.
45505216|NCT02104934|Procedure|Adductor Canal Block|
45505217|NCT05706207|Drug|HB0030 injection|0.03 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
45505218|NCT05706207|Drug|HB0030 injection|0.3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
45505219|NCT05706207|Drug|HB0030 injection|1 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
45505220|NCT05706207|Drug|HB0030 injection|3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
45505221|NCT05706207|Drug|HB0030 injection|10 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
45505222|NCT05706207|Drug|HB0030 injection|20 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
45505223|NCT05706207|Drug|HB0030 injection|30 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
45505224|NCT05706207|Drug|HB0030 injection|40 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
45505225|NCT02105090|Drug|Anesthetics, Local|
45505226|NCT02105090|Drug|Sodium Chloride 0.9%|
45505227|NCT03627273|Diagnostic Test|6 minutes walking test with walker|to walk during 6 minutes with walker
45505228|NCT03627273|Diagnostic Test|6 minutes walking test|to walk during 6 minutes with walker
45505229|NCT02111330|Drug|PBF-509|
45505230|NCT02111330|Drug|Placebo|
45505231|NCT02105168|Procedure|Blood sample|Optional
45397459|NCT01029743|Drug|Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)|Daily dose, dosage frequency and duration will be decided by physicians
45397460|NCT01032785|Device|no interventions|no interventions
45397461|NCT01029821|Drug|Low-Molecular-Weight Heparin|Isolated Ankle Fracture Single planned operation
45397462|NCT00006184|Drug|Myeloma Immunoglobulin Idiotype Vaccine|3 subcutaneous (SC) injections of myeloma protein within 10 weeks before stem cell collection the first (week 0), second (week 2), and third injection (week 6) with Id-KLH (0.5 mg SC day 1)
45505232|NCT02105168|Procedure|Tumorous biopsy|Optional
45505233|NCT02105168|Procedure|Healthy material sample|Optional
45697403|NCT04278105|Device|HD-tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.
45697404|NCT04278105|Device|Sham HD-tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
45505234|NCT03553628|Other|Chlorhexidine, Propolis and Clove Oil mouthwash|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash
45505235|NCT03553628|Other|Chlorhexidine mouthwash|Chlorhexidine HCL 0.12% mouthwash
45505236|NCT02111486|Other|breakfast|
45505237|NCT02111720|Behavioral|Maybe, Maybe Not|The goals of session one are to introduce participants to the intervention, to assess current decision context, to assist in the clarification of participant values, and to encourage the participant to set specific goals for disclosure decision-making. The goals for session two are to explore the participants' motivations to disclose or not to disclose and the potential costs and rewards of both disclosing and not disclosing. The goals for session three are to guide participants through disclosure decision making, and to support comfort/acceptance with decisions made. The goal of session four is to support the decision-making process. The booster session is used to reinforce the effects of the intervention through continued discussion of disclosure decisions in the preceding months, strategies used in disclosing, and rewards and costs of decision-making.
45505238|NCT02111720|Behavioral|Comprehensive Risk Counseling and Services|CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients.
45505239|NCT02111954|Diagnostic Test|1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9|Each patient will have two PET/CT
45505240|NCT03553550|Other|biospecimen collection|Peripheral blood collection Archival tissue collection
45505241|NCT02112032|Drug|MK-3475|This is a dose escalation study to determine the serious and non-serious adverse events that occur as the dose increases.
45505242|NCT02112032|Drug|Peginterferon alfa-2b|This is a dose escalation study to determine the serious and non-serious adverse events that occur from the combination of Peginterferon and MK-3475 as the doses increase.
45397463|NCT00006184|Drug|Bortezomib|Induction chemotherapy: 1.3 mg/m^2 bolus intravenous injection twice weekly for 2 weeks (days 1, 4, 8, 11) followed by 10 day rest period (day 12-21)
45505243|NCT01343823|Drug|ecallantide 60 mg|Administered as two 3 mL SC injections, each containing 30 mg ecallantide
45505244|NCT01343823|Drug|ecallantide 30 mg|Administered as one 3 mL SC injection containing 30 mg ecallantide
45505245|NCT01343823|Drug|ecallantide 10 mg|Administered as one 3 mL SC injection containing 10 mg ecallantide.
45505246|NCT01343823|Drug|placebo|Administered as two SC 3 mL injections
45505247|NCT01343823|Drug|placebo match for 30 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 30 mg ecallantide arm.
45505248|NCT01343823|Drug|placebo match for 10 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 10 mg ecallantide arm.
45505249|NCT02108678|Behavioral|ACT-ME|1 hour discussion about migraine education (ME) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). Migraine education covers topics including migraine symptoms, triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
45505250|NCT02108678|Behavioral|Migraine Education Only|6 hour discussion of migraine education only (MEO). This will involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine.
45505251|NCT02251184|Drug|Aggrenox|
45505252|NCT02251184|Drug|Dipyridamole|
45505253|NCT02251184|Drug|Aspirin|
45697405|NCT04278105|Other|Upper extremity rehabilitation|Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
45697406|NCT03266055|Dietary Supplement|50 g of blueberry powder, taken daily for 8 weeks|Subjects will consume blueberry powder during 8 weeks to test the possible effects of blueberries on gut microbiota composition and on metabolic syndrome parameters.
45397464|NCT00006184|Drug|Cyclophosphamide|Induction chemotherapy: 600 mg/m^2 day 4 Transplant: 1200 mg/m^2 intravenous x 4 days (days -6, -5, -4, -3)
45397465|NCT00006184|Drug|Cyclosporine|Transplant: 2 mg/kg intravenous every 12 hours continuous intravenous or by mouth (PO) until day + 180
45397466|NCT00006184|Drug|Doxorubicin hydrochloride|Induction chemotherapy: 10 mg/m^2 day continuous intravenous (CIV) days 1-3
45697407|NCT03266055|Dietary Supplement|50g of placebo blueberry powder, taken daily for 8 weeks|Subjects will consume blueberry placebo powder to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatment (blueberry powder).
45397467|NCT00006184|Drug|Etoposide|Induction chemotherapy: 50 mg/m^2 day continuous intravenous days 1-3
45397468|NCT00006184|Drug|Fludarabine phosphate|Induction chemotherapy: 25 mg/m^2 day intravenous days 1-3 Transplant: 30 mg/m^2 day x 4 days (days -6, -5, -4, -3 )
45397469|NCT00006184|Drug|Prednisone|60 mg/m^2 day 1-4
45397470|NCT00006184|Drug|Vincristine Sulfate|Induction chemotherapy: 0.5 mg/m^2 day continuous intravenous days 1-3
45397471|NCT00006184|Drug|Methotrexate|Transplant: 5 mg/m^2 intravenous on days +1, +3, +6, +11
45397472|NCT00006184|Biological|GMCSF (granulocyte macrophage colony stimulating factor)|250 mcg/m^2 subcutaneously every day, days 1-4
45397473|NCT00006184|Biological|GCSF (granulocyte colony stimulating factor)|10 mcg/kg per day subcutaneously daily from day 5 until absolute neutrophil count (ANC) > 1000/ul x 2 days
45397474|NCT00434057|Device|MelaFind(R)|Biopsy ratio comparison
45397475|NCT01098136|Other|Chiropractic|Manual treatment of musculoskeletal complaints
45505254|NCT02251184|Drug|Lansoprazole|
45505255|NCT05706051|Other|posturography|posturography will be performed when diagnosis of ARHL, in need of hearing aid fitting, is done and after information and written approval from patient. Posturography is performed later when hearing aid fitting and 3months after hearing aid use
45505256|NCT02108756|Drug|L-pantoprazole sodium|2 injection L-pantoprazole sodium (40mg), Bid
45505257|NCT02108756|Drug|Panmeilu|An injection Panmeilu (80 mg) + 1 branch placebo, Bid;
45397476|NCT01098136|Other|Conventional medical intervention|Medical, physiotherapy
45505258|NCT05596461|Device|Transcranial magnetic stimulation|Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of cognitive impairment of affective disorder was left Dorsolateral prefrontal CORTEX (DLPFC) . The left lateral DLPFC and the primary visual Cortex (V1) both play important roles in cognitive process. The regions with the strongest functional connection between V1 and DLPFC were selected as the stimulation targets.
45505259|NCT05596461|Device|Transcranial direct current stimulation|Targeted multi-channel tDCS based on individualized simulation scale can be combined with individualized simulation modeling optimization, and based on individual MRI information, through quantitative evaluation and intelligent algorithms to achieve stimulation parameter optimization, reduce the stimulation dose to non-target target areas, and improve target brain stimulation The treatment targeting and aggregation of the area can realize personalized and precise treatment.
45505260|NCT02108834|Procedure|nerve block|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.5% ropivacaine in Group 1
45505261|NCT02108834|Procedure|placebo|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.9% saline in Group 2.
45505262|NCT05547399|Drug|Zanubrutinib|Administered orally as a tablet or capsule
45505263|NCT02109068|Behavioral|Weight Loss Counseling- Phone|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
45697408|NCT04278027|Behavioral|Cognitive Remediation Therapy|"CIRCuiTS is a web-based computerised CR therapy, delivered by a therapist but supplemented with independent sessions to facilitate massed practice. It targets metacognition, particularly strategy use, in addition to providing massed practice of basic cognitive functions. The therapist facilitates motivation, metacognitive and strategy development and generalisation of learning by encouraging the participant to learn about and regulate their cognitive performance and to transfer this learning to meet real-world goals. Therapists provide additional scaffolding for CR tasks to ensure consistent successful performance. Independent sessions involve carrying out cognitive tasks allocated by the therapist to ensure scaffolded learning (Reeder et al.2017)"
45697409|NCT00984334|Drug|Naloxone SR 5 mg capsules|
45697410|NCT00984334|Drug|Placebo|
45697411|NCT00984334|Drug|Naloxone SR 10 mg capsules|
45697412|NCT00984334|Drug|Naloxone SR 20mg capsules|
45697413|NCT00984334|Drug|Naloxone SR 2.5 mg capsules|
45397477|NCT01098136|Other|Conventional and alternative intervention|Medical and alternative methods for treatment of pelvic pain syndromes
45397478|NCT00433199|Drug|Testosterone (T) Gel 1.62%|Testosterone gel 1.62% contains 1.62% testosterone gel as active ingredient.
45397479|NCT00433199|Drug|Placebo|Placebo Control
45697414|NCT02168062|Behavioral|Behavioral Dietary Intervention|Receive individualized nutrition counseling
45697415|NCT02168062|Other|Counseling|Receive individualized symptom management service counseling
45697416|NCT02168062|Other|Educational Intervention|Review educational modules
45697417|NCT02168062|Behavioral|Exercise Intervention|Receive individualized exercise counseling
45697418|NCT02168062|Drug|Goserelin Acetate|Given SC
45697419|NCT02168062|Other|Laboratory Biomarker Analysis|Correlative studies
45397480|NCT03950986|Other|Modified clinical reminders|Clinical reminders for the vaccines of interest will be bundled into a single reminder, and other changes made to streamline the design and reduce provider burden. Other changes include an immunization dashboard that relays a patient's vaccination status and talking points for providers to use in their dialogues with patients.
45397481|NCT03226379|Other|DREAMM|"4 DREAMM interventions to reduce HIV-related meningoencephalitis mortality once access to essential diagnostic tests and medicines:~Health system strengthening~Delivery of a co-designed education program tailored to frontline healthcare workers~Implementation of an algorithm for HIV-related meningoencephalitis~Infectious diseases/AHD mentorship and laboratory capacity building"
45397482|NCT01030055|Drug|TKI258 (dovitinib)|bioavailability (anhydrate capsules) food (monohydrae capsules)
45397483|NCT00006046|Biological|monoclonal antibody hu3S193|
45505264|NCT02109068|Behavioral|Weight Loss Counseling- In-Person|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
45505265|NCT02109146|Drug|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization should be used in the experimental group
45505266|NCT02109146|Other|No intervention No Transcatheter Arterial Chemoembolization|
45505267|NCT03553862|Behavioral|collaborative care|The intervention arm will receive collaborative care from a team of healthcare professionals that consists of pharmacist, physicians, nurses and dietitians. Patients in the intervention group will also receive clinical interventions carried out by the pharmacist.nurses and dietitians as well as a pharmacist.
45505268|NCT01318083|Drug|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
45505269|NCT01318083|Drug|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
45505270|NCT01318083|Drug|Glimepiride|Glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
45505271|NCT02109224|Drug|Ibrutinib|Given PO
45505272|NCT02109224|Other|Laboratory Biomarker Analysis|Correlative studies
45505273|NCT02109224|Other|Pharmacological Study|Correlative studies
45505274|NCT03554876|Device|Multi-Im Machined transepithelial component.|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM machined transepithelial component is connected to the implant.
45505275|NCT03554876|Device|Multi-Im Nanogolden transepithelial component|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Nanogolden transepithelial component is connected to the implant.
45505276|NCT03554876|Device|Multi-Im Ti-Golden transepithelial component|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Ti-Golden transepithelial component is connected to the implant.
45505277|NCT02109302|Procedure|Blood sample|
45505278|NCT02109302|Procedure|Skin biopsy|
45505279|NCT02109302|Other|Questionnaire|
45505280|NCT05705895|Procedure|CENTRAL VENOUS CATHETER CARE PROTOCOL|"Catheter care is provided in line with the CVC care protocol developed by the researcher:~For subsequent catheter care, a transparent sterile catheter cover impregnated with 2% chlorhexidine gluconate will be used.~The entry point of the catheter will be wiped with a disposable sterile skin cleaning applicator containing 2% Chlorhexidine Gluconate and 70% Isopropyl Alcohol, which will be provided by the researchers, and wait for it to dry.~Vein valve/needleless connector will be used.~Effective manual disinfection of needle-free connectors (hubs) will be ensured before each intervention.~Needle-free connectors will be replaced every 96 hours at the latest.~If necessary, the catheter lumen will be washed with a disposable, positive-pressure sterile washing system containing 10 ccs 0.9% sodium chloride to be provided by the investigators.~Pulsatile give stop give stop technique will be used in the washing process."
45505281|NCT05192187|Other|Cross-sectional self-report (questionnaires)|"participants in this group will be ask to complete questionnaires on one occasion (i.e., cross-sectional investigation). The questionnaires will consist of a self-developed questionnaire and standard questionnaires. The main aspects of the self-developed questionnaires are~perceived harmfulness of activities (selection of PHODA-SeV)~cognitions about lifting and pain~reasons for avoidance behaviour (lifting)~Standardised questionnaires include~NRS for pain~TSK-11~FABQ~RMDQ"
45397484|NCT03994991|Device|active TMS|Transcranial magnetic stimulation
45697420|NCT02168062|Drug|Leuprolide Acetate|Given SC or IM
45697421|NCT02168062|Other|Quality-of-Life Assessment|Ancillary studies
45697422|NCT02168062|Drug|Triptorelin Pamoate|Given IM
45397485|NCT03994991|Device|sham TMS|Sham transcranial magnetic stimulation
45505282|NCT02105402|Behavioral|PROMPT|The PROMPT approach utilizes a motor-speech hierarchy (MSH) to guide speech language pathologists (SLP) in selecting speech movement goals for treatment. PROMPT treatment generally proceeds systematically in a bottom-up fashion starting with the lowest subsystem in the hierarchy where a child has control issues. Furthermore, in the PROMPT approach specific techniques are used to stimulate sensory input that are assumed to facilitate the formation of sensory-motor pathways required for the acquisition and accurate production of speech movement patterns. As the speech motor behaviors are established, the clinician reduces the number of cues and the frequency and immediacy of feedback and practices transfer and generalization activities.
45505283|NCT05545137|Drug|Pivmecillinam hydrochloride tablets|400mg tablet
45505284|NCT05545137|Drug|Fosfomycin Tromethamine Granules|3g/pack
45505285|NCT02112110|Drug|BMS-791325|
45505286|NCT02112110|Drug|[13C]-BMS-791325|
45505287|NCT02105480|Device|Computer aided auscultation (CAA)|
45505288|NCT02105714|Procedure|Stool culturing for pathogenic bacteria|
45505289|NCT02105714|Procedure|Kato-Katz technique|
45505290|NCT02105714|Procedure|Baermann technique|
45505291|NCT02105714|Device|Mini-FLOTAC|
45505292|NCT02105714|Device|Crypto/Giardia Duo Strip|
45505293|NCT02105714|Procedure|Formalin-ether concentration technique|
45505294|NCT02105714|Device|CCA RDT|
45505295|NCT02105714|Procedure|Koga agar plate culture|
45505296|NCT02105714|Procedure|Kinyoun staining|
45505297|NCT02105714|Device|Multiplex PCR|
45505298|NCT02105714|Procedure|Metagenomics analysis|
45505299|NCT05540067|Behavioral|Acceptance-Based Behavior Therapy (ABBT)|In the first session, the interventionist will introduce the concept of acceptance and its possible benefits in the context of life values and participant-identified challenges related to the COVID-19 pandemic, mental health, and social support. Interventionists will help participants identify potential challenges to acceptance. At the second session, participants will practice acceptance-based coping skills and a social support behavioral plan will be developed. These discussions will help the participant clarify how best to align their values with decisions on how to manage their mental health and social support in the context of the COVID-19 pandemic.
45505300|NCT05540067|Other|Treatment-as-Usual (TAU)|TAU includes brief mental health screening, consultation with providers, and referrals to psychotherapy and/or psychiatric medication.
45397486|NCT03994757|Behavioral|MRBI|The activities content is designed according to the children's daily routine and goals. It mainly involves bathing activities, eating activities, dressing activities, game activities, social and communication activities, and according to the needs of parents. In the treatment room, after the therapist and parents discuss the intervention methods and suggestions, they will demonstrate the intervention strategies and methods, and let the parents practice the practice, and the therapist will guide them. After discussing with parents, the therapist will give parents a homework related to children's daily routine, let the parents implement at home, and discuss with parents and record before each intervention.
45505301|NCT02112266|Other|Mail support|between post treatment and follow up two groups: one with unspecific mail support every 2 weeks one without
45505302|NCT02112266|Other|no mail support|follow-up without mail support
45505303|NCT05538039|Other|Distract with play dough|Distract with play dough
45505304|NCT05538039|Other|Distract with play kaleidoscope|Distract with play kaleidoscope
45505305|NCT05538039|Other|Control group|Routine nursing care
45505306|NCT02109380|Behavioral|Bed rest|
45505307|NCT05535855|Drug|CD19 Directed CAR T Cell|The UCD19 CAR T cells are developed through transfection of autologous peripheral blood mononuclear cells with a lentivirus carrying the DNA that encodes a short chain fragment variable region (scFv) derived from an anti-CD19 monoclonal antibody, among other elements.
45505308|NCT02109536|Device|Magnetic endoscopic imager.|recognizing loop type accuracy of loop type detection methods of loop reduction assessed by type
45697423|NCT05334459|Radiation|radiotherapy|"Oligometastatic disease (defined here as 5 or fewer sites of metastatic disease involving 3 or fewer organ systems)~Primary tumor biopsy, Metastatic site biopsy (Bone, liver, etc) (if there is, based on institutional practice)~o ER / PR /Her2 /Ki67 study)~Collection of CTC.~Radiotherapy (RT) to the primary breast tumor (Hypo fractionated)~All patients will receive the standard of care treatment with CDK4/6 inhibitor + AI for 6 months (at least 26 weeks).~o Denosumab, Biphosphonate for bone metastasis~RT to metastatic side (if visible). Continue Systemic therapy~12 months, patients will have LRT surgery (BCS/mastectomy + LN evaluation; SLNB+ALND) + RT (based on the institutional practice). Collect CTC and ER/PR/Her 2 in the final specimen~ST will be continued until progression and/or unmanageable toxicity.~Radiologic evaluation every 3-6-month based on institutional practice."
45397487|NCT03994757|Behavioral|Control|Traditional treatment was directly performed for children in the treatment room by the therapist. The activity content was designed according to the children's goals. After each end of treatment, therapist will give parents a homework related to traditional treatments, let the parents perform at home, and know the parents' performance at home and record before each treatment begins.
45397488|NCT01098448|Other|scaling and root planing|scaling and root planing as a single therapy
45397489|NCT01098448|Drug|local tetracycline|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets >5mm
45505309|NCT02105792|Drug|second- or third-line glucose-lowering diabetes treatment|Observation of response and disease progression following clinician's addition of a glucose-lowering diabetes therapy (Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone) to existing therapy.
45505310|NCT03817515|Drug|ABI-009|Sirolimus Albumin-bound Nanoparticles
45397490|NCT01098448|Drug|systemic metronidazole and amoxicillin|systemic metronidazole (250 mg tid x 14) and amoxicillin (500 mg bid x 14
45397491|NCT01098448|Other|surgery|periodontal surgery in residual pockets of >4mm
45397492|NCT01098448|Drug|local antibiotics and systemic metronidazole and amoxicillin|1.7 mg/tooth tetracycline fiber plus metronidazole (250 mg tid x14d)and amoxicillin (500 mg bid x 14d)
45397493|NCT01098448|Other|local tetracycline and periodontal surgery|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets >5mm and periodontal surgery in residual pockets of >4mm
45397494|NCT01098448|Other|periodontal surgery and systemic metronidazole and amoxicillin|surgery in residual pockets >4mm and metronidazole (250mg tidx14d) and amoxicillin (500mg bidx14d)
45397495|NCT01098448|Other|surgery, local tetracycline, systemic metronidazole and amoxicillin|periodontal surgery in residual pockets >4mm, tetracycline ibers releasing approximately 1.7 mg/tooth in pockets >5mm, systemic metronidazlo (250mg tidx14d) and amoxicillin (500 mg bidx14d)
45397496|NCT01098526|Drug|GSK1349572|GSK1349572 is an experimental drug under development for the treatment of HIV. It is in the class of integrase inhibitors.
45397497|NCT01098526|Drug|Efavirenz|Efavirenz is a drug that has been approved by the FDA for the treatment of HIV. It is in the class of non-nucleoside reverse trancriptase inhibitors.
45397498|NCT01030211|Procedure|Platelet transfusion|4 units of platelets for patients with platelet count <20x10^3/uL
45397499|NCT01030211|Other|Supportive care|Supportive care includes symptomatic treatment, fluid therapy and monitoring of full blood count and blood pressure
45397500|NCT01030367|Drug|PETN, ISDN|Oral dosing of organic nitrates PETN 2x 80mg per day ISDN 2x40mg per day
45397501|NCT01032941|Drug|Probiotic|Patients in this group will be given the probiotic VSL#3 2 packets BID for a total of 8 weeks.
45397502|NCT00005908|Drug|Docetaxel - Dose A|Dose A-Cohort 1 Docetaxel 75 mg/m^2 intravenous day 1
45397503|NCT00005908|Drug|Anastrozole|1 mg orally daily for five years
45397504|NCT00005908|Drug|cyclophosphamide|600 mg/m^2 will be diluted in 100 mL 0.9% normal saline (NS) and administered intravenously over 30 minutes on day 1
45397505|NCT00005908|Drug|Docetaxel - Dose B|Dose B - Cohort 2 Docetaxel 60 mg/m^2 intravenous day 1
45397506|NCT00005908|Drug|Doxorubicin hydrochloride|60 mg/m^2 will be administered as a slow intravenous push on day 1
45397507|NCT00005908|Drug|Tamoxifen Citrate|20 mg/day orally for five years
45397508|NCT00005908|Drug|Capecitabine - Dose B|Dose B - Cohort 2 capecitabine 937.5 mg/m^2 orally twice daily day 2-15
45397509|NCT00005908|Drug|Capecitabine - Dose A|capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles
45397510|NCT00432965|Device|Moist Wound Therapy|Moist Wound Therapy (Standard of Care)
45505311|NCT02112344|Radiation|IMRT|
45505312|NCT05622045|Behavioral|Voice data|Recorded response to a question about their participation in a weight loss study.
45505313|NCT02105870|Drug|Abciximab|This drug will be administered intracoronary before percutaneous coronary intervention.
45697424|NCT05373615|Drug|Cefiderocol|After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
45397511|NCT00432965|Device|VAC Therapy|VAC Therapy
45397512|NCT01098604|Device|32mm ceramic head group|we performed THA using 32mm ceramic head in this group.
45397513|NCT01098604|Device|28mm ceramic head group|we performed THA using 28mm ceramic head in this group.
45397514|NCT00440297|Biological|Comparator: modified process hepatitis B vaccine|Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
45397515|NCT00440297|Biological|Comparator: ENGERIX-B™|ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
45397516|NCT00432809|Procedure|Gastric bypass|Roux-en-Y gastric bypass
45397517|NCT00432809|Procedure|Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy
45397518|NCT00431951|Drug|ST-246|250 mg, 400 mg or 800 mg capsules given once daily for 21 days
45397519|NCT00431951|Drug|Placebo|Capsules to match experimental drug
45397520|NCT00004978|Drug|Recombinant interleukin-2 (rIL-2)|Recombinant interleukin-2 at a dose of 7.5 MIU given twice daily subcutaneously for 5 consecutive days every 8 weeks for at least 3 cycles.
45397521|NCT01030601|Drug|Dexamethasone sodium phosphate|0.5mg in 0.05cc of Dexamethasone from a 10mg/ml vial
45505314|NCT02112422|Drug|Control|The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
45505315|NCT02112422|Drug|Intervention|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR.
45505316|NCT02251340|Behavioral|Eczema Care Plan|
45505317|NCT02109614|Drug|Extended release Niacin|Arm will be taking 1500-2000mg of niacin daily to see if lipoprotein(a) levels are lowered and aortic stenosis does not increase.
45505318|NCT02109614|Drug|Placebo Comparator|Placebo Comparator arm will be taking 1500mg of the placebo daily
45505319|NCT05646147|Device|Maximal Systolic Acceleration|Reliability of the maximal systolic acceleration
45505320|NCT02109692|Other|blood sample|dosage of miRNA
45505321|NCT05705583|Other|Other: Blood and Urine Collection|Blood and Urine Collection
45505322|NCT02106026|Other|Preventive education|The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures.
45505323|NCT05165979|Other|Hospitalization due to COVID-19|Hospitalization due to COVID-19
45397522|NCT01030679|Drug|CKD-501 0.5mg|0.5 mg/tablet, orally, 1 tablet once daily for 8 weeks
45397523|NCT01030679|Drug|CKD-501 1mg|1 mg/tablet, orally, 1 tablet once daily for 8 weeks
45397524|NCT01030679|Drug|CKD-501 2mg|2 mg/tablet, orally, 1 tablet once daily for 8 weeks
45397525|NCT01030679|Drug|Placebo|orally, 1 tablet once daily for 8 weeks
45397526|NCT00430937|Drug|Daptomycin|4 mg/kg intravenous once daily
45397527|NCT00430937|Drug|Vancomycin|1 g intravenous twice daily
45397528|NCT00430937|Drug|Teicoplanin|400 mg intravenous once daily following a loading dose of 400 mg administered at 0, 12, 24 hours on day one.
45397529|NCT01101412|Drug|Edetate Calcium Disodium|Given through CVC or PVC.
45397530|NCT01101412|Drug|Ethanol|Given through CVC or PVC
45397531|NCT01101412|Drug|Trimethoprim-sulfamethoxazole|Given through CVC or PVC
45397532|NCT01101412|Other|Hypertonic Saline|Given through CVC or PVC
45505324|NCT05159115|Other|Low-FODMAP diet|4 weeks of a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs)
45505325|NCT05159115|Other|Starch- and Sucrose Reduced Diet (SSRD)|4 weeks of a diet low in starch and sucrose
45505326|NCT05504421|Other|Sustainability education in nursing to be given with two different teaching methods|Sustainability education in nursing to be given with two different teaching methods (cooperative learning versus traditional learning) and the effects of two different teaching methods on the sustainability knowledge, attitude and skill acquisition of nursing students will be compared.
45505327|NCT02251418|Device|Extracorporeal shockwave therapy|
45505328|NCT02112500|Biological|Mesenchymal Stem Cell|Mesenchymal stem cells will be intravenously infused. Mesenchymal stem cells will be cultured and extracted from the bone marrow of the patients.
45505329|NCT05644899|Procedure|Interlaminar ultrasound-assisted intrathecal administration of nusinersen|All procedures were performed with patients either seated or placed in a lateral decubitus. After skin disinfection with 2% chlorhexidine in 70% alcohol, using a convex array, the L3-4 or L4-5 intervertebral space was identified and a left paramedian sagittal oblique view was obtained; the probe was rotated 90° into a transverse orientation, centered on the neuraxial midline, and moved in either the cephalad or caudal direction to obtain a transverse interlaminar view; the intersection between the two markings of the spinal midline and interspinous space was identified as the spinal entry point of the needle. After local anesthesia (LA) with lidocaine 2%, a 25-gauge non-traumatic 90 mm Whitacre spinal needle or a traumatic 90 mm Quincke spinal needle was used to access the subarachnoid space. After confirmation of cerebrospinal fluid (CSF) flow, 5 mL of CSF were removed. Subsequently, nusinersen was administered intrathecally over 1-3 min.
45505330|NCT05644899|Procedure|Landmark-based intrathecal administration of nusinersen|All procedures were performed with patients placed in their most comfortable position (either seated or placed in a lateral decubitus). After skin disinfection with 2% chlorhexidine in 70% alcohol, conventional palpation of the superior aspect of iliac crest was performed and the palpated intercristal line was assumed to cross the spine at L4 vertebral body or L4-L5 interspace. The skin was marked with horizontal and vertical lines at the L3-L4 or L2-L3 interspaces and was referred as entry point of the needle. The procedure was then completed in the same fashion as for US-assisted technique.
45505331|NCT02106104|Drug|Linagliptin 5 mg QD (N=24)|Linagliptin 5 mg will be taken orally, once daily for 8 weeks
45505332|NCT02106104|Drug|Glimepiride 1 mg QD (N=24)|Glimepiride 1 mg will be taken orally, once daily for 8 weeks
45505333|NCT02113670|Other|SUI 1|instillation of 50ml of air into the urinary bladder before the urodynamic test
45505334|NCT02109926|Other|Phone interview and blood test|Subjects will be interviewed about environmental, domestic and occupational exposures during several periods of life Two blood samples will be collected at enrollment to study genetic polymorphisms
45505335|NCT02113748|Other|Downhill walking training|Walk on a treadmill with a negative inclination.
45505336|NCT02113748|Other|Conventional walking training|Walk on a treadmill without inclination. Possible to progress training intensity with positive inclinations
45505337|NCT05703867|Device|Active microcurrent therapy|Non-invasive transpalpebral microcurrent therapy delivery to the upper and lower eyelids
45505338|NCT02113826|Drug|Pazopanib|Pazopanib 800mg qd daily for 4 weeks = 1 cycle
45505339|NCT02118974|Procedure|Hysterectomy|Hysterectomy
45505340|NCT02112656|Drug|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
45505341|NCT02112656|Drug|Dummy infusion|Sodium Chloride 0.9% or 5% Dextrose (D5W), Single 30 minute intravenous infusion
45505342|NCT01376323|Drug|GSK256073 1mg|GSK256073 1mg capsule
45505343|NCT01376323|Drug|GSK256073 5mg|GSK256073 5mg capsule
45505344|NCT01376323|Drug|GSK256073 10mg|GSK256073 10mg capsule
45505345|NCT01376323|Drug|GSK256073 25mg|GSK256073 25mg capsule
45505346|NCT01376323|Drug|Placebo|placebo capsule
45505347|NCT01376323|Drug|Sitagliptin 100mg|Sitagliptin 100mg capsule
45505348|NCT02113904|Drug|Adalimumab|6 injections (one every 15 days during 3 months)
45505349|NCT05703633|Other|uDCD treatment|Thrombolytic treatment/prevention ex-vivo to kidneys procured from patients after circulatory arrest
45505350|NCT02119052|Drug|octeotride|
45397533|NCT00004888|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
45697425|NCT03304587|Diagnostic Test|Polysomnography (PSG)|Sleep patterns will be measured by in-lab PSG following a standardized protocol. 10mm silver/silver chloride electroencephalogram (EEG) and electromyography (EMG) electrodes and 11mm silver/silver chloride electroculography (EOG) electrodes will be connected to a Nihon Kohden system, 912 model (Nihon Kohden, Irvine, CA). A standard sleep montage following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed. Data will be visually scored by a polysomnographer blind to study conditions following the American Academy of Sleep Medicine (AASM) Manual.
45397534|NCT00004888|Drug|docetaxel|Given IV
45397535|NCT00004888|Biological|trastuzumab|Given IV
45397536|NCT00004888|Other|laboratory biomarker analysis|Correlative studies
45505351|NCT02119052|Drug|placebo|
45505352|NCT05462223|Combination Product|Alucent Vessel Restoration System for AVF|"Alucent Vessel Restoration System for AVF (VRS-AVF) consists of the following components:~VRS 10-8-10 Dimer Coated Balloon Catheter for AVF~VRS Light Fiber~VRS Light Source"
45505353|NCT02119130|Device|QGIT|Seven pairs of clinics will be included in this study. One clinic in each pair will be selected by a computerized randomization program to be the standard of care arm (TST only) and the other will be in the QGIT arm.
45505354|NCT05459805|Drug|traditional chinese medicine Xuanfei-Zhike formula|200ml, bid, for 8 weeks
45505355|NCT05459805|Drug|inhaled corticosteroids (ICS) and long-acting β2-agonist (LABA)|one suction, q12h, for 8 weeks
45505356|NCT02119208|Behavioral|Intensity and timing of exercise|
45505357|NCT02113982|Drug|SL-401|
45505358|NCT05438979|Dietary Supplement|Placebo|Placebo for comparison to CFB
45505359|NCT05438979|Dietary Supplement|Calcium Fructoborate|216mg CFB
45505360|NCT02112812|Drug|Eradication therapy for H.pylori infection|Patients who were positive for H.pylori infection received an eradication therapy consisting of oral esomeprazole 40 md daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
45505361|NCT02112812|Drug|Eradication of Helcobacter Pylori|Patients who are positive on urea breath test are given eradication therapy for 14 days, Eradication therapy includes esomeprazole 40mg daily, clarithromycin 500mg bd, amoxicillin 1g bd
45505362|NCT02112812|Drug|Eradication therapy for Helicobacter pylori|
45505363|NCT05432115|Drug|Tetracyclin|Amoxicillin 1000mg bid +Tetracycline 500mg tid/qid +Bismuth+Esomeprazole 40mg bid
45505364|NCT02114528|Drug|Antiarrhythmic Drug Therapy|Either one or more of the following antiarrhythmic drugs: sotalol, mexiletine, procainamide, or amiodarone.
45505365|NCT02114528|Procedure|Catheter ablation|Ventricular tachycardia catheter ablation.
45505366|NCT04975321|Device|Nu Smile Zirconia crown|Placement of an anterior primary crown restoration
45505367|NCT04975321|Device|Nu Smile Pre Veneered crown|Placement of an anterior primary crown restoration
45505368|NCT04975321|Device|Composite strip crown|Placement of an anterior primary crown restoration
45505369|NCT02112890|Other|Data collection|Data of the selected subjects (through structured questionnaires and interviews) and stored serum samples obtained from the ENSANUT 2012. A subset database will be designed by the NIPH for the purpose of this study. Extracted data and laboratory results of the selected subjects will be captured in the study database.
45505370|NCT05410587|Device|Fracture Monitor (implantable device class III)|Femoral fracture fixation (bridge plating aiming at secondary bone healing) using a locking plate with an attached investigational Fracture Monitor T1.
45505371|NCT02112968|Procedure|Proscan|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
45505372|NCT02112968|Procedure|Zyoptix|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
45397537|NCT03951220|Other|Diffusion Weighted Magnetic Resonance Imaging (DWMRI)|Using the expertise of the Oxford Centre For Clinical Magnetic Resonance Research (OCMR) for imaging protocol development, and the new Fine Structural Analysis (FSA, Osteotronix Ltd, formerly Acuitas Medical) bone density quantification MRI method (Rafferty et al 2016), we will test a single protocol which combines three emerging experimental imaging sequences into a simple, non-invasive whole body imaging protocol to quantify disease burden and bone disease. To our knowledge, this has never been done before; if shown to be feasible, such a method would have two important applications: to precisely guide commissioned therapies in the clinic, so improving patient management; and as an exciting, novel research tool for the longitudinal combined assessment of tumour burden and cancer-induced bone disease in response to therapy.
45397538|NCT03951220|Other|DXA scan|Used to assess bone density
45397539|NCT03951220|Other|Bloods and urine|Samples will be taken to assess bone biomarkers
45397540|NCT00004732|Procedure|Carotid Endarterectomy (CEA)|CEA involves a neck incision and physical removal of the plaque from the inside of the carotid artery.
45397541|NCT00004732|Device|Carotid Artery Stenting (CAS)|CAS involves insertion of a catheter or tube into an artery in the groin and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open. Participants randomized to this arm of the trial were treated using the RX Acculink Carotid Stent with or without the RX Accunet Embolic Protection Device.
45505373|NCT02112968|Procedure|Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
45505374|NCT03627117|Drug|Verum|Single vape of 0.25mL of CBD e-Liquid containing: 5% CBD (low-temperature extracted Cannabidiol from Cannabis sativa L., purity 99%), Glycerine (vegetable), Propylene glycol, water
45505375|NCT03627117|Drug|Placebo|Single vape of 0.25ml e-liquid La Baronne Jaune, BORDO2.
45505376|NCT02113046|Procedure|pancreatico-jejunal anastomosis|
45505377|NCT02113046|Procedure|traditional anastomosis|
45505378|NCT02113202|Drug|Bevacizumab-IRDye800CW|Intravenous administration of a 4.5 mg, 10 mg or 25 mg of Bevacizumab-IRDye800CW 3 days prior to the fluorescence endoscopy procedure.
45505379|NCT02113202|Device|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope, which is used for the surveillance endoscopy procedure.
45505380|NCT04889755|Behavioral|SibACCESS|The primary goal of the SibACCESS program is to increase siblings' exposure to and opportunity to process cancer-related cues to decrease onset or intensification of posttraumatic stress. The program is focused on siblings, with a brief parent education component. Parents will receive psychoeducation and brief skills training to support siblings enrolled in the program. Siblings will participate in 7 group sessions and one individual session in which they will learn skills and strategies to confront information about cancer and tolerate uncomfortable thoughts and feelings related to cancer, and thereby reduce avoidance of cancer-related emotions.
45505381|NCT05074641|Other|Direct myofascial release treatment|Myofascial Release will be applied with Forearm and/or ulnar border of the palm. Deep Pressure will be applied and glided medially towards the base of the neck and/ or towards the upper scapular region
45505382|NCT05074641|Other|Bowen therapy|Thumb of the therapist will be placed on the top of the targeted muscle. The skin will be carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb will be flattened in the medial direction, when this happened the muscle would plop or respond in some way.
45505383|NCT01376401|Drug|Bendamustine|
45505384|NCT01376401|Drug|Velcade|
45505385|NCT01376401|Drug|Prednisone|
45505386|NCT02119364|Other|Working memory training|The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30-45 minutes and the family has 6 weeks to complete the training. Each session consists of 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.
45505387|NCT05611983|Behavioral|sensory relearning|feasibility of early sensory relearning
45505388|NCT02119520|Drug|Platelet rich fibrin +Atorvastatin|
45505389|NCT02119520|Drug|Platelet rich fibrin|
45505390|NCT02119520|Procedure|open flap debridement|
45505391|NCT02114762|Procedure|Balloon dilation of the Eustachian tube|Insert a balloon into one Eaustachian tube and inflate it for up to one minute. The balloon is then removed.
45505392|NCT00263731|Other|13-C-glucose|"10 grams of 13-C-glucose intravenously, as a 30-minute piggyback infusion, 2 to 6 hours prior to scheduled surgical resection of primary lung cancer."
45505393|NCT05609877|Procedure|NONA-LISA|The staff will perform Less Invasive Surfactant Administration using the standard pre- and post-procedure care including non-pharmacological treatment. The patients will not receive pharmacological analgesic treatment routinely.
45505394|NCT02119754|Drug|Plurogel PN|
45505395|NCT03961789|Other|patients undergoing opioid replacement therapy|patients undergoing opioid replacement therapy
45505396|NCT02119832|Device|Endovasccular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
45505397|NCT01376479|Biological|INV21 Low Dose|Inactivated EV71 vaccine containing whole viral particles of EV71 formulated with aluminum hydroxide.
45849715|NCT05400486|Other|Therapeutic exercise|1.Movements of flexion, extension, inclinations, and rotations of the cervical region at maximum amplitude and without load. 2.Neural mobilization of the cervical nerve roots. 3.Contraction of the deep muscles of the flexors, extensors, and rotators of the cervical region without performing spinal movements, using the movement of the eyes to aid in the accomplishment of these exercises. 4.Isometric contraction of the flexor muscles, inclinators, and rotators against manual resistance of the physiotherapist. 5.Isometric contraction of the cervical extensors of the cervical region against gravity. 6.Contraction of the flexor muscles, extensors, and incliners of the cervical region against the resistance of elastic bands.
45505398|NCT01376479|Biological|INV21 High Dose|Inactivated EV71 vaccine consisting of whole viral particles of EV71 formulated with aluminum hydroxide.
45505399|NCT01376479|Biological|Placebo|Phosphate Buffered Saline (PBS)
45505400|NCT03552614|Device|Upper limb robot-assisted rehabilitation|"Upper limb robot-assisted rehabilitation is performed with Armeo®Spring. It is a passive exoskeleton with five degrees of freedom that guarantees passive arm weight support with springs.~The treatment was composed by 45 minutes of robotic training (5 times a week for 4 weeks) during which patients performed a customized pull of exergames."
45849716|NCT05400486|Other|Therapeutic exercise group + high frequency TENS|TENS (Endophasys® - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda) will be applied to the cervical region through 4 silicon-carbon electrodes measuring 4 x 4 cm, with a water-based gel to reduce the impedance at the interface electrode skin. Thus, TENS will be applied with a rectangular, biphasic, and symmetrical pulse, with a pulse width of 100 µm, and a frequency of 100 Hz, at the maximum tolerated sensitive threshold, for 30 minutes (VANCE et al., 2012).
45397542|NCT01098760|Drug|Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment|Orally taken Sorafenib tablets of 400mg (2x200mg) twice daily (bid) in a continuous schedule. - For patients in Nerisone subgroup: additionally prophylactic use of Nerisone Fatty Ointment (1 g of Nerisone contains 1 mg (0.1%) diflucortolone valerate) cream for hands and feet, twice daily for 3 weeks - For patients in Neribas subgroup: additionally prophylactic use of Neribas Fatty Ointment (non-corticosteroid containing) cream for hands and feet, twice daily for 3 weeks
45397543|NCT03950830|Drug|Disulfiram|Disulfiram 400mg daily, continuously
45397544|NCT03952390|Other|control|
45397545|NCT03952390|Other|sepsis|
45397546|NCT00430781|Drug|pazopanib (GW786034)|
45397547|NCT00430781|Drug|lapatinib (GW572016)|
45397548|NCT01033097|Drug|DNK333 5 mg|5 mg oral
45397549|NCT01033097|Drug|Placebo to 5 mg|5 mg placebo oral
45505401|NCT03552614|Other|physiotherapy|Patients undergo 45-minute treatment sessions 5 times a week for 4 weeks of physiotherapy, focused on gross and fine motor ability to promote independence in daily activities, and it is customized on patients' need.
45505402|NCT04854343|Diagnostic Test|Secretory leukocyte protease inhibitor (SLPI) in prostate cancer|"7 ml of peripheral blood and a urine sample for the determination of SLPI concentration. Blood samples will be promptly processed to obtain sera; both sera and urine will be stored at -80°C in the laboratory. The levels of SLPI in the serum and in the urine will be quantitated by an ELISA assay by using the Human SLPI Quantikine ELISA Kit. SLPI level will be measured at diagnosis and during the follow-up (3, 9, 15 months and in case of progression).~Immunohistochemistry protocol for SLPI immunostaining to investigate SLPI levels prostate tissue"
45397550|NCT01033097|Drug|DNK333 25 mg|25 mg oral
45697426|NCT03304587|Diagnostic Test|Rectal thermistor 400 Series|Nocturnal core body temperature will be measured using a rectal thermistor 400 series manufactured by YSI (Yellow Springs, OH, USA) inserted up to a depth of 7 cm. and taped in place. The thermistor will be connected to a Model 4600 thermometer (YSI, Yellow Springs, OH, USA) that will be interfaced with the PSG via cabling. Core temperature readings will be continuously monitored and recorded every 5 minutes during the all-night sleep studies.
45697427|NCT03304587|Other|Bright blue-green light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
45397551|NCT01033097|Drug|Placebo to 25 mg|25 mg placebo oral
45397552|NCT01033097|Drug|DNK333 100 mg|100 mg oral
45397553|NCT01033097|Drug|Placebo to 100 mg|100 mg placebo oral
45397554|NCT01033097|Drug|Betamethasone 4 mg|4 mg oral
45397555|NCT01033097|Drug|DNK333 1mg|1 mg oral
45397556|NCT01033097|Drug|Placebo to 1mg|1 mg placebo oral
45397557|NCT03035123|Behavioral|Therapeutic education|Interventional arm
45397558|NCT01323725|Behavioral|Team-based financial incentives|Team-based financial incentives for smoking cessation at 6 month post-quit date.
45397559|NCT01033721|Drug|Palomid 529|comparison of different dosages of drug
45397560|NCT00429299|Drug|lapatinib|Arm B 1250mg/d PO Arm C 750mg/d PO
45397561|NCT00429299|Biological|trastuzumab|First dose 4mg/kg in 60mins, then weekly 2mg/kg in 30 mins
45505403|NCT04854343|Diagnostic Test|Determination of molecular alterations|The presence of ETS translocation (or of ETS overexpression) will be tested on bioptic samples in each patient as for routine diagnostic procedures. First, ERG overexpression will be investigated by ERG immunostaining. The samples negative for ERG immunostaining will be studied for TMPRSS2-ERG translocation either by in situ FISH or by a translocation-specific RT-PCR. Next, the biopsies negative for TMPRSS2-ERG will be tested for the overexpression of other ETS proteins (ETV1, ETV4, ETV5 and for others rarely occurring ETS). When possible, it will be determined the status of pTEN gene, the tumor suppressor most frequently lost in prostate patients. The patients negative for the overexpression of the ETS proteins will be tested for SPINK1.
45505404|NCT04854343|Diagnostic Test|Secretory leukocyte protease inhibitor (SLPI) Healthy|"SLPI level will be measured also in the serum and in the urine from controls (patients with BPH and healthy subjects).~7 ml of peripheral blood and a urine sample for the determination of SLPI concentration. Blood samples will be promptly processed to obtain sera; both sera and urine will be stored at -80°C in the laboratory. The levels of SLPI in the serum and in the urine will be quantitated by an ELISA assay by using the Human SLPI Quantikine ELISA Kit."
45505405|NCT05695053|Device|Low Level Laser Therapy|Low level laser therapy could provide energy to trigger cell differentiation.
45505406|NCT05695053|Other|Placebo|Placebo
45505407|NCT02119910|Behavioral|Technology Supported Manual|
45505408|NCT05693337|Device|Forward Looking Infrared Radar (FLIR) thermal imaging|The FLIR camera will collect temperature recordings pre-procedure and 5 minutes post-procedure, which will be used to calculate a delta T to assess achievement of a successful sympathetic block.
45505409|NCT02113280|Procedure|Arthroscopy|Patients to receive knee arthroscopy and meniscal debridement
45505410|NCT02113280|Procedure|Physiotherapy|Outpatient standardised physiotherapy regime with focus on exercise therapy
45505411|NCT05522127|Other|Colonoscopy|Colonoscopy
45505412|NCT05522127|Other|Sedoanalgesia|Ketamine, fentanil, midazolam, propofol
45505413|NCT02113358|Drug|Intravenous colloid bolus with Voluven|
45505414|NCT04854187|Device|N95 Mask/Indoor air purifier: Including sham|Participants will be using indoor air purifier and N95 mask (control arm with sham filters). The effect will be studied on blood pressure and blood glucose levels.
45505415|NCT03769142|Procedure|All monitoring|All monitoring (TCD, BIS, NIRS) are collected from the healthy side, contralateral to the interventional side
45397562|NCT00429299|Drug|paclitaxel|80mg/sqm 1 hour infusion for 12 weeks
45397563|NCT00429299|Drug|fluorouracil|600mg/sqm iv day 1 q21 days for four coursess
45397564|NCT00429299|Drug|epidoxorubicin|75mg/sqm iv day 1 q21 days for four courses
45505416|NCT02114840|Procedure|Pronator quadratus preservation after volar plate fixation in wrist fractures|Pronator quadratus preservation after volar plate fixation in wrist fractures
45505417|NCT02114840|Procedure|Pronator quadratus repair after volar plate fixation in wrist fractures|Pronator quadratus repair after volar plate fixation in wrist fractures
45505418|NCT02114840|Procedure|Pronator quadratus nonrepair after volar plate fixation in wrist fractures|Pronator quadratus nonrepair after volar plate fixation in wrist fractures
45505419|NCT05311527|Device|Urolift|Urolift Implant
45505420|NCT05311527|Radiation|SABR|Stereotactic Body Radiation Therapy for prostate cancer
45505421|NCT04878055|Drug|Reparixin|2 tablets of Reparixin (600 mg each), for the total of three daily administrations (6 tablets daily).
45505422|NCT04878055|Other|Placebo|Matched placebo, i.e. 2 tablets for the total of three daily administrations (6 tablets daily).
45505423|NCT05305365|Drug|QBS72S|QBS72S 12mg/m2 injection given intravenous once a month.
45397565|NCT00429299|Drug|cyclophosphamide|600mg/sqm day 1 q21 days for four courses
45397566|NCT01033799|Other|Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
45397567|NCT01033799|Other|Non fermented dairy product (control)|
45397568|NCT01033877|Biological|TdaP vaccine SSI|1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: >= 20 I.U. tetanus toxoid (T), >=2 I.U. diphtheria toxoid (d), 20 microgram pertussis toxoid (aP)
45397569|NCT01033877|Biological|Td vaccine SSI|1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: >= 20 I.U. tetanus toxoid (T), >=2 I.U. diphtheria toxoid (d)
45397570|NCT00428597|Drug|sunitinib malate|"sunitinib malate oral starting dose 37.5 mg daily (continuous dosing).~Dose may be decreased to 25 mg daily in case of adverse events.~It may be increased to 50 mg daily if no response is seen after 8 weeks on treatment.~Dosing to continue until unacceptable toxicity, progression of disease, death, or study termination."
45505424|NCT01376713|Biological|Ofatumumab|Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks
45505425|NCT01376713|Biological|Ofatumumab plus Dacarbazine|"Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks.~Dacarbazine administered q4w at a dose of 1000mg/m2, 4 days before next administration of Ofatumumab for 24 weeks."
45505426|NCT05286567|Drug|RGRN-305|Heat shock protein 90 inhibitor
45505427|NCT05286567|Drug|Placebo|Placebo (blinded)
45697428|NCT03304587|Other|Dim red light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
45397571|NCT00428597|Drug|Placebo|Placebo to match sunitinib taken daily (oral) on the same schedule as active agent below.
45397572|NCT01033955|Drug|Rosuvastatin|Loading dose: 40 mg (day 1) Maintenance dose: 20 mg (days 2-14)
45397573|NCT01033955|Drug|Placebo|identical appearing encapsulated placebo.
45397574|NCT00428441|Drug|Warfarin|tablets, based on INR levels, according to D-dimer levels
45505428|NCT03728179|Combination Product|Low dose irradiation + Nivolumab + Ipilimumab or Cyclophosphamide + Aspirin/Celecoxib|"Low Dose Radiation (RT): RT will be administered as single fractions every 2 weeks (Q2W) from cycle C0 to cycle C4. RT will be delivered to a number of metastatic deposits visible by PET/CT, at the PI's discretion.~Cyclophosphamide: 200mg/m2 will be administered as intravenous infusion (IV) Q2W from cycle C0 to C4.~Nivolumab: 240 mg will be administered as IV Q2W from cycle C1 to C4.~Ipilimumab: 1mg/kg will be administered as IV every 6 weeks (Q6W) from cycle C1 to C4~Aspirin: 300mg will be administered orally daily from cycle C1 to C4. All subjects will receive mandatory gastric prophylaxis with an oral H2 antagonist.~Celecoxib: 200mg will be administered orally twice a day from cycle C1 to C4.~At the end of cycle C4, patients eligible for maintenance will be treated with nivolumab at 240mg Q2W until progression or excessive toxicity; celecoxib will be maintained if the drug is well tolerated"
45505429|NCT02114918|Behavioral|Attention Modification Program|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word. Thus, although there will be no specific instruction to direct attention away from the threat word, on all trials, the position of the neutral word will indicate the position of the probe."
45397575|NCT01033175|Procedure|maximal cardiopulmonary exercise testing|Cardiopulmonary exercise testing (CPET) will be performed on a cyclic ergometer with continuous monitoring of a 12-lead electrocardiogram, heart rate and blood pressure. While breathing with a mask, the patients will perform a ramp protocol which includes 2-minutes free pedaling and progressive increase of power by 10, 15 or 20 watts/minute; power size will be selected after considering the patient' s daily activity and parameters of pulmonary function. CPET will be performed until exhaustion, unless the subjects reveal symptoms or signs indicating the exercise should stop (e.g. severe breathlessness).
45397576|NCT01033175|Procedure|peripheral blood samples|Peripheral venous blood samples will be collected again in the morning after a fasting period of ≥12 hours. After immediate centrifugation, aliquots will be stored at -75˚C until analysis. Inflammatory markers and erythropoietin will be analyzed by flow cytometry and by enzyme-linked immunosorbent assay, using commercially available kits.
45397577|NCT01033253|Behavioral|Health in Motion|Students interacted with the 30-minute program through a series of Transtheoretical Model (TTM) based assessments and tailored feedback messages. A full TTM intervention was delivered for physical activity, in which each of the appropriate constructs of the TTM based on stage of change was addressed. Optimally tailored interventions were delivered for fruit and vegetable consumption and limited TV viewing. These interventions offered feedback on the most important TTM constructs based on stage of change for each behavior. Multimedia components, including audio, video, and animations helped to capture students' interest.
45397578|NCT02488967|Drug|Carboplatin|Given IV
45397579|NCT02488967|Drug|Cyclophosphamide|Given IV
45397580|NCT02488967|Drug|Doxorubicin Hydrochloride|Given IV
45505430|NCT02114918|Behavioral|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threatening material. In this case, the probe randomly replaces the threat or neutral word."
45505431|NCT03626961|Other|readmission|Readmission after 48 hours
45397581|NCT02488967|Other|Laboratory Biomarker Analysis|Correlative studies
45505432|NCT03626961|Other|discharge|Discharge
45697429|NCT03304587|Diagnostic Test|Digital foot candle datalogging light meter|"On 2 random days during the 2-week bright light treatment, ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter (Extech Instruments, Waltham, MA) Model SDL400. The 7.1 x 2.9 x 1.0 light meter (12.21 oz) has the capacity to measure up to 10,000 footcandles (accuracy: ± 4% reading). The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck."
45397582|NCT02488967|Drug|Paclitaxel|Given IV
45397583|NCT00144339|Drug|tiotropium|
45397584|NCT00144339|Drug|placebo|
45397585|NCT03967665|Drug|N-acetyl-L-cysteine|NAC 400 mg three times per day from -14D pre-HSCT to +2 months post-HSCT
45397586|NCT02531607|Other|blood and bile|20ml of blood will be obtained from consented participants. 5ml of bile will be collected during the endoscopic procedure.
45397587|NCT00144027|Behavioral|Antipsychotic medication adherence intervention|The medication adherence intervention will include using a computer to complete a brief set of questions related to medication adherence before mental health clinic visits.
45397588|NCT00127803|Biological|Placebo (vaccine diluent)|0.5 mL, intramuscular (IM) on Days 0, 28, and 56, respectively.
45397589|NCT00127803|Biological|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
45397590|NCT00127803|Biological|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
45397591|NCT00127803|Biological|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
45697430|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue|8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue. PROMIS-Fatigue was developed based on rigorous methodologies. The psychometric properties have been established across chronic illnesses including cancer.
45397592|NCT03967431|Other|Narrative Enhancement and Cognitive Therapy (NECT)|Narrative Enhancement and Cognitive Therapy includes two introduction meetings, three psychoeducation meetings, seven cognitive restructuring meetings, seven narrative enhancement meetings and one summing up meeting.
45397593|NCT03967509|Behavioral|Comet|
45397594|NCT01077999|Drug|Carboplatin|Carboplatin AUC = 2 , weekly.
45397595|NCT01077999|Drug|Paclitaxel|Paclitaxel 50 mg/m2, weekly
45505433|NCT05108493|Other|Dry needling|Three sessions dry needling of lateral epicondyle region, once per week with disposable acupuncture needles (0.25x25mm).
45697431|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance|8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances. Validity was supported by moderate to high correlations with the existing scales, e.g. PSQI, Epworth Sleepiness Scale (ESS). The scores significantly differed participants with and without sleep disorders.
45697432|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression|8 items with 5-point rating scales (1=never to 5=always) measuring affective and cognitive manifestations of depressive mood. Higher scores indicate worse depression. In a sample of depressed outpatients, PROMIS-Depression showed greater reliability when compared to the CES-D and the Patient Health Questionnaire (PHQ-9). Convergent validity with the CES-D and PHQ-9 was supported by strong correlations, ranged 0.72 to 0.84
45697433|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function|8 items with 5-point rating scales measuring the individual's ability to complete daily activities. Higher scores indicate worse functioning. Validity was tested in 1,415 adults with diverse clinical conditions. The PROMIS Physical Function scores corresponded to the expected positive or negative changes in the individual's physical function.
45697434|NCT03304587|Other|Pittsburgh Sleep Quality Index (PSQI)|19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance. A global PSQI score greater than 5 was found to have a sensitivity of 89.6% and a specificity of 86.5% in differentiating good and poor sleepers.
45697435|NCT03304587|Other|Center for Epidemiological Studies - Depression|20-item self-report instrument commonly used to measure depressive symptoms in cancer patients. Each item is rated on a 4-point rating scale (0=rarely or none of the time to 3=all of the time) describing the frequency of occurrence during the past week. Score can range from 0-60, with higher scores indicating more depressive symptoms.
45397596|NCT01077999|Drug|panitumumab|panitumumab: 6mg/kg in weeks 1-3-5.
45397597|NCT01077999|Radiation|radiotherapy|A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
45397598|NCT00127413|Behavioral|Cognitive Behavioral Therapy - Pain|Pain treatment
45397599|NCT00127413|Behavioral|Cognitive Behavioral Therapy-Integrated|Integrated treatment
45397600|NCT00127413|Behavioral|Cognitive Processing Therapy - PTSD|Cognitive processing therapy
45397601|NCT00127413|Behavioral|Treat as Usual|Treatment as usual
45397602|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^7 CFU in 10 mL phosphate-buffered saline
45397603|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^8 CFU in 10 mL phosphate-buffered saline
45397604|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^9 CFU in 10 mL phosphate-buffered saline
45397605|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^10 CFU in 10 mL phosphate-buffered saline
45397606|NCT03971565|Biological|Blood sample 5 milliliter|The blood of the patients will be collected during their hospitalization of the hematology department participating in the research
45397607|NCT01037465|Drug|N-acetylcysteine|N-acetylcysteine
45397608|NCT01037465|Drug|Placebo|Placebo
45397609|NCT03971331|Device|PAC catheter and critical care ultrasound examination|Patients in study group were placed the PAC and performed critical care ultrasound(CCUS) to monitor the pathophysiological changes of the lung and the hemodynamics immediately
45397610|NCT01582425|Drug|Isavuconazole|oral
45397611|NCT01582425|Drug|Methadone|oral
45397612|NCT00143403|Drug|Irinotecan + 5 FU + folinic acid|irinotecan 180 mg/m2 folinic acid 400 mg/m2 (DL) followed by 5 FU bolus 400 mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
45505434|NCT05108493|Other|Home exercise program|All participants will start the home exercise program during the study period consisting of range of motion exercises for wrist flexion, extension, ulnar and radial deviation, elbow flexion and extensor; forearm supinator, and pronator muscles; stretching exercises. Eccentric strengthening of the wrist flexor extensors, ulnar and radial deviation, forearm pronation, supination, and strengthening exercise training will be given to the elbow extensors and flexors. Progressive strengthening exercises will be added to the program. The exercise program will be terminated with stretching exercises. The exercises will be performed for 10 repetitions 2 times a day, stay in each position for 10 seconds, and rest for 30 seconds between periods. Both groups will be advised to continue the exercise program for 12 weeks.
45505435|NCT03725293|Device|Angiodynamics BioFlo Midline Catheter|Placement of Angiodynamics BioFlo Midline Catheter.
45505436|NCT03725293|Device|Teleflex Arrowg+ard Blue Advanced Midline Catheter|Placement of Teleflex Arrowg+ard Blue Advanced Midline Catheter.
45505437|NCT01368536|Drug|Valturna|Valturna (aliskiren 150 mg/valsartan 160 mg) tablet
45505438|NCT01368536|Drug|Amlodipine|Amlodipine 5 mg and 10 mg capsule
45505439|NCT01368536|Drug|Chlorthalidone|Chlorthalidone 15 mg and 25 mg capsule
45505440|NCT01368536|Drug|Placebo of Valturna Tablet|Matching placebo of valturna tablet
45505441|NCT01368536|Drug|Placebo Capsule|Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule
45505442|NCT05103735|Drug|Propofol|awake neurosurgery under propofol-remifentanil sedation
45397613|NCT00143403|Drug|Folinic Acid + 5 FU|folinic acid 400 mg/m2(DL) followed by bolus 5 FU 400mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
45397614|NCT00220701|Drug|Lexapro (escitalopram)|antidepressant drug selective serotonin reuptake inhibitor (SSRI)
45397615|NCT00127101|Drug|vorinostat|Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.
45505443|NCT03051165|Device|Hypoglossal Nerve Stimulation Treatment Withdrawal|After 90 days of hypoglossal nerve stimulation (HGNS), therapy will be discontinued for 30 days before being reactivated.
45397616|NCT00127101|Drug|Comparator: bexarotene|Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.
45397617|NCT03967119|Device|Patient monitoring|Arterial blood pressure, pulse oxygen saturation, and cardiac output/stroke volume are monitored with invasive arterial catheter, pulse oxymetry, and esophageal doppler in all participants. Some dynamic variables including SVV and PPV are automatically calculated in each monitor. PWV is manually calculated in a printed plethysmographic waveform. Plethysmographic waveform amplitude (PW) is measured on a beat-to-beat basis as the vertical distance between peaks and preceding valley troughs in the waveform. The maximum PW (PWmax) and minimum PW (PWmin) are determined manually over the same respiratory cycle, and PWV is calculated. PWV=(PWmax-PWmin)/[(PWmax+PWmin)/2].
45397618|NCT00126555|Drug|Gefitinib|Oral Gefitinib induction therapy given daily for 2 months at 250 mg/day, once a day for 30 days (1 cycle = 30 days) with at least 2 cycles of treatment (60 days) given. After 2 months evaluate for clinical response (15 days) and resectability (60 days). If after 15 days with no tumor response, daily dose doubled (500 mg), and discontinuation if tumor progression.
45397619|NCT00126555|Radiation|Radiotherapy|Undergo radiation therapy treatments once a day Monday through Friday for about 7 weeks. Each treatment takes about 15 minutes.
45505444|NCT01319929|Drug|LY2828360|Administered orally
45505445|NCT01319929|Drug|Placebo|Administered orally
45505446|NCT03553316|Drug|PK101-002|-(Single) PK101-002
45505447|NCT03553316|Combination Product|PK101|-(Combination) PK101-001, PK101-002
45505448|NCT04194099|Device|20 Hz rTMS (Brain)|Higher frequency (>5 Hz) trains increase cortical excitability.
45505449|NCT04194099|Device|iTBS rTMS (Brain)|Intermittent theta burst stimulation (iTBS) is a newer rTMS approach.
45505450|NCT04194099|Device|Anode tsDCS (Spinal)|Anodal tsDCS increased the spinal reflex amplitude, as well as corticospinal excitability.
45397620|NCT00126555|Procedure|Conventional surgery|Undergo surgery
45397621|NCT00126555|Other|laboratory biomarker analysis|Correlative studies
45397622|NCT00004228|Drug|asparaginase|Given IV
45397623|NCT00004228|Drug|cyclophosphamide|Given IV
45397624|NCT00004228|Drug|cytarabine|Given IV
45505451|NCT04194099|Device|20 Hz current square-wave pulses (Spinal)|Higher frequency (>5 Hz) of current increase cortical excitability.
45505452|NCT04194099|Device|iTBS (Spinal)|Intermittent theta-burst stimulation (iTBS) is a newer approach. it may increase corticospinal excitability.
45505453|NCT04194099|Device|sham|with sham stimulation on brain and spinal.
45505454|NCT03552458|Drug|Lactobacillus Reuteri Oral Solution [BioGaia]|BioGaia Lactobacillus Reuteri drops
45505455|NCT03552458|Drug|Placebos|Placebo will be identical in physical appearance and color to the study agent and will be made by the manufacturer
45505456|NCT03633565|Drug|Sildenafil (Phosphodiesterase inhibitors)|tablet 25mg
45505457|NCT03633565|Drug|Prednisolone (Steroids)|tablet 20 mg
45505458|NCT03633565|Procedure|Mesenchymal stem cell transplantation|stem cell transplantation intramuscular
45505459|NCT02120066|Procedure|Vitrectomy for submacular hemorrhage|
45397625|NCT00004228|Drug|daunorubicin hydrochloride|Given IV
45397626|NCT00004228|Drug|dexamethasone|Given IV
45397627|NCT00004228|Drug|doxorubicin hydrochloride|Given IV
45397628|NCT00004228|Drug|leucovorin calcium|Given IV
45397629|NCT00004228|Drug|mercaptopurine|Given IV
45397630|NCT00004228|Drug|methotrexate|Given IV
45505460|NCT02120066|Drug|subretinal injection of tissue-plasminogen activator|
45505461|NCT02120144|Other|Observation & imagination|It is a combination of an observation phase followed by an immediate imagination phase of a straight gait with an imposed cadency.
45505462|NCT02120144|Other|Reading|"A 10 minutes reading phase of François Mauriac's Therese Desqueyroux on a computer"
45505463|NCT01373359|Drug|Misoprostol|400 µg sublingual misoprostol
45505464|NCT01373359|Drug|Oxytocin|10 IU IM
45505465|NCT03620071|Other|GoalKeeper|Mobile-health communication tool for parents of children with medical complexity
45505466|NCT03620071|Other|Standard Care|Standard Clinical Care
45697436|NCT03304587|Other|Montreal Cognitive Assessment (MoCA)|The MoCA is highly sensitive for screening patient with mild cognitive impairment. The MoCA is a 30-point scale with 7 cognitive subtests: visuo-executive, naming, attention, language, abstraction, delayed recall, and orientation. It scores from 0 to 30, where higher scores indicate better cognition and a score below 26 indicates cognitive impairment. The MoCA is highly sensitive for screening patient with mild cognitive impairment.
45697437|NCT03304587|Other|European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30)|The EORTC QLQ-C30 consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life during the past week.
45397631|NCT00004228|Drug|prednisone|Given IV
45697438|NCT03304587|Other|Daily Log|-A log where the participants will indicate date, wake time, sleep time answer 3 questions regarding the previous nights sleep (answers range from 1=not at all to 5=very much), have an area to indicate if naps occurred during the day, and 2 questions about fatigue & sleepiness (answers ranging from 0=no fatigue/sleepiness to 10=worst fatigue/sleepiness
45849717|NCT05400486|Other|Therapeutic exercise group + Interferential|In sequence, the interferential current will be applied. Through the Endophasys® device - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda). Four electrodes (8x5 cm), two upper and two lower (forming a square) will be positioned around the center of the neck. The electrodes will be positioned crosswise, following the parameters: 4KHz (carrier frequency), 1/1 second (Sweep Mode), 60 Hz Amplitude of frequency modulation (AMF), 30 Hz (Delta AMF), automatic vector mode, with intensity at the motor threshold of sensation, lasting 30 minutes (Albornoz-Cabello et al., 2019).
45397632|NCT00004228|Drug|thioguanine|Given PO
45397633|NCT00004228|Drug|vincristine sulfate|Given IV
45397634|NCT00004228|Radiation|radiation therapy|
45397635|NCT01101568|Drug|Simvastatin|Simvastatin 40mg (single dose) on Days 1 and 10.
45397636|NCT01101568|Drug|Rosuvastatin|Rosuvastatin 10mg (single dose) on Days 3 and 12.
45397637|NCT01101568|Drug|GSK1292263|GSK1292263 300mg BID Days 6 to 14.
45397638|NCT01098838|Drug|LCL161|
45397639|NCT01098916|Radiation|Home X-rays|X-rays examinations performed at home
45397640|NCT01098916|Radiation|X-rays in hospital|
45397641|NCT01087840|Drug|Raltegravir|"Drug: Raltegravir tablet 400mg is taken orally, twice daily with or without food for 28 days along with Tenofovir disoproxil fumarate/emtricitabine 300mg/200mg 1 tablet taken orally once daily with or without food for 28 days.~Arms: Raltegravir/Truvada Other Names: Isentress/Truvada"
45397642|NCT01098994|Dietary Supplement|Vitamin E|Daily administration of 400 IU natural d-alpha tocopherol acetate for 8 weeks
45397643|NCT01098994|Other|Dummy pills|Daily placebo administration for 8 weeks
45397644|NCT01099072|Drug|Methylphenidate+placebo|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)+ Placebo
45505467|NCT02123186|Other|newborn screening test for SMA|Routine newborn screening dried blood spots sample is used to test if missing 2 copies of SMN1 gene.
45505468|NCT03110185|Device|EEG|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
45505469|NCT03110185|Device|fcDOT|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
45505470|NCT03110185|Device|fcMRI|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
45505471|NCT02123264|Drug|Zoledronic acid|Zoledronic acid: 5 mg/year x 2 years
45505472|NCT04132869|Behavioral|Sports Readiness Intervention|Sixth graders will participate in a 6 month after-school program in which each daily session will last 90 minutes, 60 minutes of which will be moderate to vigorous physical activity. Two sports tracks will be offered during each 8-week season, and children will choose which they prefer. Coaches will be trained through a one day capacity building session and will receive online training throughout the program. Coaches will integrate sports readiness/physical activity programming, nutrition and healthy eating, and social emotional learning into the program with a focus on habit formation. A text-based platform will be utilized to encourage habits learned in the active portion of the program during June and July as well as on weekends during the intervention. Parents will be sent fliers weekly summarizing concepts addressed, and will be invited to cooking classes to watch students compete.
45505473|NCT02251964|Drug|Rituximab|2 times 1000mg dose at 14 days interval treatment
45505474|NCT02251964|Radiation|Zr-89-rituximab immuno PET/CT|Immuno labeled PET/CT of the lungs
45505475|NCT04739995|Drug|Low-dose naltrexone|4.5 mg LDN/day for 1 year
45505476|NCT04059393|Other|Internet-Based Intervention|Complete web-based legacy intervention
45505477|NCT04059393|Other|Best Practice|Receive standard of care
45505478|NCT04059393|Other|Quality-of-Life Assessment|Ancillary studies
45505479|NCT04059393|Other|Questionnaire Administration|Ancillary studies
45505480|NCT02120612|Other|Naloxone Education Intervention|"The Naloxone Education Intervention is a curriculum that has been adapted from New York State Department of Health's, Opioid Overdose Prevention program for non-medical responders."
45505481|NCT01374295|Other|video|watch a 3 minute video
45505482|NCT01374295|Other|standard education|Receives standard verbal education from healthcare provider
45505483|NCT02115152|Drug|fluorouracil|
45505484|NCT02115152|Drug|capecitabine|
45505485|NCT02115152|Drug|cyclophosphamide|
45505486|NCT02115152|Drug|Epirubicin|
45505487|NCT04680871|Device|In-Ear Sensor|The device will passively monitor participants' biometrics
45505488|NCT02115230|Procedure|Renal denervation + medical therapy|Renal denervation + medical therapy Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure
45505489|NCT04657861|Drug|APRIL CAR-T cells|Each subject receive APRIL CAR T-cells by intravenous infusion
45505490|NCT02115464|Drug|Metformin plus Chemo-radiotherapy|Metformin 2000 mg a day for 12 months plus cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
45505491|NCT02115464|Radiation|Chemo-radiotherapy|Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
45505492|NCT04054167|Drug|Low Dose Radiation Therapy|Undergo ultra low dose radiation
45505493|NCT02858076|Drug|2-mg Intravitreous Aflibercept Injection|Soluble decoy receptor fusion protein that has a high binding affinity to all isoforms of VEGF as well as to placental growth factor.
45397645|NCT01099072|Drug|methylphenidate+carnitine|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)+ Carnitine 500-1500 mg/day (depending on weight )
45397646|NCT00003526|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Cancer of Unknown Primary Origin will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45397647|NCT00195260|Drug|bosutinib|Dose levels evaluated 50mg, 100mg, 200mg, 300mg, 400mg, 500mg and 600mg. 500mg was identified as MTD, however due to GI toxicities at that dose, 400mg was selected as the RP2D. Drug was administered as long as tolerable and disease under study did not worsen.
45505494|NCT02858076|Procedure|Prompt Vitrectomy Plus Panretinal Photocoagulation|Surgical removal of the vitreous gel and associated hemorrhage, concurrent delivery of panretinal endolaser
45505495|NCT02115620|Other|Telemedicine|Daily updates on symptoms, weight, vital signs, and relevant labs will be communicated by phone with cardiology nurses at Providence Heart Clinic. Concerning changes in symptoms or signs will trigger a telemedicine clinic visit with a HF specialist using remote video/audio, virtual stethoscope technology, and VZ Cloud managed hosting. The consult will include a virtual face-face interview and physical examination between patient and HF clinician using Cisco Yabber Video, Littman e-stethoscope, and Verizon managed hosting. Medication changes, laboratory testing, additional virtual visits, or in-person clinic visits can be arranged as appropriate.
45505496|NCT01319695|Drug|corifollitropin alfa|100 microg for a group of women weighing <or=60 kg and 150 microg for a group of women weighing >60 kg
45505497|NCT01319695|Drug|recombinant follicle stimulating hormone (FSH)|150-300 IU of the drug daily from day 2 of the menstrual cycle until more than 2 follicles are >18mm
45505498|NCT05064111|Diagnostic Test|TRUS biopsy|The biopsy procedure will be completed using an FDA-approved ultrasound machine with the addition of an investigational (non-FDA approved) image fusion software.
45505499|NCT01373437|Device|Ultrasonography (Sonosite )|Sonosite MICROMAXXTM with linear probe L38e/10-5 MHz
45505500|NCT02123342|Behavioral|Exercise programme plus SMS reminders|Participants will receive SMS reminders for their myPAtHS exercise programme compared to the other group where participants will only receive the myPAtHS exercise programme.
45505501|NCT04042467|Behavioral|Greenlight Plus|Families randomized to the Greenlight Plus arm will receive a HIT intervention starting at the newborn clinic visit. During the newborn visit, these families will receive basic instructions on how to access the Greenlight technology platform, which includes the iOTA text-messaging application and a website (usable on desktop or mobile platform). Families will receive text messages and goal-setting over the first 2 years of the child's life.
45505502|NCT04042467|Behavioral|Greenlight|All residents and families seen in the participating clinics will receive the basic Greenlight materials.
45505503|NCT04594759|Drug|Isotretinoin|Participants will be getting isotretinoin (1-1.5 mg/kg/week)
45397648|NCT00195260|Drug|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
45397649|NCT00195260|Drug|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
45397650|NCT00195260|Drug|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
45505504|NCT02123420|Device|Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Sweden)|"Both sites received tapered implants with an anodised surface, one site received: Nobel Replace Tapered Groovy PS implant; (Nobel Biocare, Goteborg, Sweden), with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (PS group), the contralateral site received Nobel Replace Tapered Groovy implant with Replace Select connection with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (RP group).~Healing abutments were connected to implants at the same time of surgery , then flaps were sutured with Vicryl 4.0 sutures (Vicryl, Ethicon J&J International, St-Stevens-Woluwe, Belgium)."
45505505|NCT02123498|Drug|Omeprazole|40mg, to be taken once daily by mouth, 30-60 minutes before meals, for at least 6 weeks
45505506|NCT02123498|Drug|Ranitidine|300mg, to be taken once daily by mouth, before bedtime, for at least 6 weeks
45505507|NCT02123498|Drug|Pantoprazole|40mg, to be taken twice daily by mouth, 30-60 minutes before meals, for at least 6 weeks. (Alternative intervention if participant cannot tolerate omeprazole, is on an anticoagulant medication, or if on medication contraindicated for omeprazole and ranitidine)
45505508|NCT02123498|Procedure|24-Hour Diagnostic pH-Probe Test|Participants will undergo a routine clinical 24-hour diagnostic pH-probe test to assess quantitative measures for laryngopharyngeal reflux.
45505509|NCT02123498|Procedure|Laryngoscopy|Participants will undergo routine clinical laryngoscopy to assess presence of laryngopharyngeal reflux.
45505510|NCT02237040|Procedure|Mandibular manipulation technique|patients are treated with The mandibular manipulation technique reported by Farrar, which was an effective treatment method to reset the physiological positional relationship between condyle and disc.Then patients are told to persist in mouth opening training at home everyday. The mouth opening training is performed as follow: patients are told to try to close his mouth in intercuspal position at first, then open their mouth as wide as possible(the reference maximal mouth opening is as wide as the mouth opening after treatment in last time), then close back to the intercuspal position again.
45505511|NCT02115776|Drug|Amoxicillin-Potassium Clavulanate|Administer Amoxicillin-Potassium Clavulanate following endotracheal intubation prior to single tooth-extraction
45505512|NCT02115776|Drug|Amoxicillin|Administer Amoxicillin following endotracheal intubation prior to single tooth-extraction
45505513|NCT02115776|Drug|Chlorhexidine|Administer Chlorhexidine Digluconate following endotracheal intubation prior to single tooth extraction
45505514|NCT02856282|Drug|Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Aqueous suspension of 0.05% micronised fluticasone propionate.Each actuation contains 50 micrograms of fluticasone propionate
45505515|NCT05231421|Behavioral|Focus Group|Each focus group will consist of 5-10 participants. They will first introduce to each other and be asked to keep information shared during the session private. The moderator will initiate some questions for the group to discuss. Prompt and follow-up questions will be asked. There is no right or wrong answer for each question and no sensitive questions will be asked. The conversations during the focus group discussion will be recorded. The group will be debriefed about the purpose of the study and have a chance to ask any questions about the study if they have. The focus group discussion for each session will last about 60-90 minutes.
45397651|NCT00031486|Drug|Valacyclovir|Valacyclovir is a L-valyl ester of acyclovir. Valacyclovir is provided in 500 mg tablets, 4 tablets (500 mg tablets) 3 times a day (every 8 hours) for 90 days.
45505516|NCT02115854|Other|labial biopsy|
45505517|NCT02115932|Other|Strength & Balance Training|Subjects will be guided through 8 weeks (1 hour per week) of home-based strength and balance training sessions. During each session, a trainer will guide subjects to perform muscle strengthening, range of motion, static balance, dynamic balance and endurance exercises, after an initial warm up. They will also be given advice on continuing such training as well as daily walking for the rest of the week.
45505518|NCT03959319|Other|Movement Pattern Training|Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
45505519|NCT03959319|Other|Manual Therapy|Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
45505520|NCT02123654|Drug|Daclatasvir|
45505521|NCT02123654|Drug|Asunaprevir|
45505522|NCT02123654|Drug|DCV 3DAA|
45505523|NCT02123654|Other|Placebo for DCV 3DAA|
45505524|NCT02123654|Other|Placebo for Daclatasvir|
45505525|NCT02123654|Other|Placebo for Asunaprevir|
45505526|NCT03609138|Device|Spinal Hardware|Pedicle screws and patient specific rods
45849718|NCT05400252|Behavioral|Omnis Salutis|Omnis Salutis is a Veteran-targeted, Whole Health program for mental health care settings and teaches Veterans the skills to identify and communicate their Whole Health goals to providers and social supports
45397652|NCT00031486|Drug|Placebo|Placebo (identical to active drug in appearance) 500 mg tablets, 4 tablets 3 times daily for 90 days.
45397653|NCT01099150|Dietary Supplement|Dark chocolate enriched in flavan-3-ols and procyanidins|Acute consumption (within 15 minutes) of 60 g of chocolate containing ~900 mg of total flavan-3-ols and procyanidins.
45505527|NCT03949491|Procedure|3D medical models|Using 3D medical models of the abdomen, a virtual plan will assist reconstruction to clearly define and 3D model the normal and aberrant vascular anatomy of the donor site in order to decrease both operative time and dissection time. This will also allow for the proposal of incision lines to match the corresponding volumetric analysis of the transposed tissue in order to facilitate the creation of a patient specific tailored flap, which will improve the aesthetic outcomes, decrease donor site complications and improve patient satisfaction
45505528|NCT03930381|Other|ASTHMAXcel App|ASTHMAXcel includes interactive games, educational videos, quizzes and personalized feedback to teach different aspects of asthma management.
45505529|NCT02116010|Drug|E. coli Phages cocktail|Use of Pherecydes Pharma Phages cocktail to treat respectively E. coli burn wound infection
45397654|NCT01099150|Dietary Supplement|Standard dark chocolate|Acute consumption (within 15 minutes) of 60 g of chocolate containing ~400 mg total flavan-3-ols and procyanidins.
45397655|NCT01099150|Dietary Supplement|White chocolate|Acute consumption (within 15 minutes) of 60 g of white chocolate containing no flavan-3-ols and procyanidins.
45397656|NCT00003508|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with advanced mesothelioma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.hourly interEach infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45397657|NCT01088074|Device|Histoacryl Tissue Adhesive|
45397658|NCT01088074|Device|Dermabond|
45397659|NCT01088074|Device|Staples|
45397660|NCT01088074|Device|Monocryl 4-0|
45397661|NCT03952000|Behavioral|Exercise|A 60 minute walk at 60% maximal oxygen uptake.
45505530|NCT02116010|Drug|Standard of care : Silver Sulfadiazine|Use of Standard of care : Silver Sulfadiazine, to treat E. coli or P. aeruginosa infected burn wound
45505531|NCT02116010|Drug|P. Aeruginosa, Phages cocktail|Use of Pherecydes Pharma Phages cocktail to treat P. aeruginosa burn wound infection
45505532|NCT03609294|Drug|Treatment A (Fimasartan, Linagliptin)|Co-administration of Fimasartan and Linagliptin
45505533|NCT03609294|Drug|Treatment B (Fimasartan/Linagliptin)|Fixed Dose Combination of Fimasartan 120 mg/Linagliptin 5 mg
45697439|NCT04352920|Other|Experimental group|PHYSIUM System® provides standardized negative pressure massage for 15 minutes with the analgesic program and 15 minutes with the trigger points program at 80 millibars with eight adjustable arms both in the entire muscle and in muscle fibrosis.
45397662|NCT03951922|Behavioral|Horticultural activity|Therapeutic horticulture activities are plant-related activities that include but not limited to digging, watering, planting, weeding, trimming, fertilizing, mulching, harvesting, learning about organic farming, and exploring options to incorporate horticulture into daily activities
45397663|NCT03961594|Other|expansion volémique|cardiac output, VVP, VVE, blood pressure, Eadyn, EtCO2 will be measured before and after ELJP. In the event of an increase of more than 10% in cardiac output during the ELJP, patients will receive a volume expansion of 500ml of balanced crystalloids. The same measurements will be repeated immediately at the end of the volume expansion and 20 minutes after the end of the infusion. Patients with a 15% increase in cardiac output at the end of volume expansion will be classified as responders.
45505534|NCT05214495|Drug|topical oral Omega-3 hydrogel|Topical oral Omega-3 hydrogel prepared from fish oil
45505535|NCT05214495|Drug|conventional preventive treatment|"topical treatment including antifungal agents, anti-inflammatory mouthwash, sodium bicarbonate mouthwash.~Topical anesthetics agent, topical analgesic gel as well as systemic analgesics (if needed)"
45505536|NCT03608904|Other|Music listening|Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
45505537|NCT03608904|Other|Spoken word (language) listening|Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
45505538|NCT03551990|Procedure|whole-body electromyostimulation WB-EMS|Patients of the WB-EMS group will perform whole-body electromyostimulation (WB-EMS) training sessions twice a week over a period of 8 weeks. To allow muscle recovery a break of at least 2 days between the sessions will be scheduled. To adapt the patients to the WB-EMS intervention, the training duration will be gradually increased (week 1, 12 min; increase of 2 min/week; week 5-8, 20 min). WB-EMS training sessions will include light physical exercises according to a video tutorial and individually supervised by certified physio therapists.
45505539|NCT03907917|Device|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
45697440|NCT05387356|Other|prone position|thirty-one patients who had a positive test result for SARS-CoV-2 RNA through nasopharyngeal swab and underwent three subsequent prone positions for 16 hours will be enrolled the study. Medical datas of the patients will be obtained from patients' files which are strictly filled during pandemic. Prone position indication of intensive care unit (ICU) is in case of severe ARDS with PaO2/FiO2 <150 despite a PEEP >10 cmH2O.
45397664|NCT02530060|Drug|Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC|Fixed dose combination tablet contains 25 milligram (mg) of Rilpivirine, 300 mg of Tenofovir Disoproxil Fumarate (TDF) and 200 mg of Emtricitabine (FTC).
45397665|NCT01101646|Drug|rabeprazole sodium|four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
45505540|NCT01917552|Drug|capecitabine|capecitabine 1250 milligram (mg) / m² po bid (D1-14)
45505541|NCT02120690|Device|Trigeminal nerve stimulation|10-day TNS interventional protocol over an 10-day follow-up. Subjects will have electrodes (Superior Silver 1.25-in. diameter) placed on their foreheads to stimulate the V1 branches of the trigeminal nerve bilaterally for approximately 30 minutes each day. Current was adjusted to maintain comfortable but perceptible levels of stimulation
45505542|NCT02120768|Procedure|barrier resection/1cm resection|"For Arm Barrier resection, if a recurrence occurs, patients would be assigned to 1cm resection for their recurrent sarcomas; For Arm 1cm resection, if a recurrence occurs, patients would be assigned to barrier resection for their recurrent sarcomas."
45505543|NCT01873326|Drug|Paclitaxel|
45505544|NCT01873326|Drug|Ifosfamide|
45505545|NCT01873326|Drug|Cisplatin|
45505546|NCT01873326|Drug|Mesna|
45505547|NCT01873326|Drug|Bleomycin|
45505548|NCT01873326|Drug|Etoposide|
45397666|NCT01101646|Drug|rabeprazole sodium|two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)
45697441|NCT01888367|Drug|DFA-02 Antibiotic Gel|
45397667|NCT01101646|Drug|rabeprazole sodium|four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
45397668|NCT02530216|Other|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|"AEGIS (Automated Evaluation of Gastrointestinal Symptoms) guides patients through questionnaires to measure symptom attributes including the timing, severity, frequency, location, quality, and character of their gastrointestinal (GI) symptoms, along with relevant comorbidities, family history, and alarm features. This information is transformed into a history of present illness (HPI) written in language familiar to clinicians. AEGIS also supports both the clinician and patient with an individualized education prescription which guides the patient through a library of multi-media educational materials on GI symptoms, conditions, and treatments. The prescription is created by the portal based on each patient's unique AEGIS fingerprint."
45505549|NCT02120846|Other|Flywheel leg-press resistance exercise|
45697442|NCT01888367|Drug|DFA-02 Placebo Gel|
45505550|NCT03833817|Behavioral|Talking about Cancer (TAC)|The TAC intervention is a six session intervention designed to teach the techniques of distress tolerance and communication skills in order to assist patients and their caregivers in discussing the patients' prognoses.
45505551|NCT02116088|Behavioral|Teacher Coaching|
45505552|NCT01261728|Drug|Gemcitabine and Cisplatin|Patients will receive four cycles of GC administered every 21 days. Gemcitabine 1,000 mg/m2 and Cisplatin 35 mg/m2 will be administered intravenously on days 1 and 8. A total of four cycles of therapy will be administered at 21 day intervals followed by radical nephroureterectomy or distal ureterectomy.
45505553|NCT05022771|Drug|PMG1015 Dose 1|Dose level 1 of PMG1015
45505554|NCT05022771|Drug|PMG1015 Dose 2|Dose level 2 of PMG1015
45505555|NCT05022771|Drug|PMG1015 Dose 3|Dose level 3 of PMG1015
45505556|NCT05022771|Drug|PMG1015 Dose 4|Dose level 4 of PMG1015
45505557|NCT05022771|Drug|PMG1015 Dose 5|Dose level 5 of PMG1015
45505558|NCT05022771|Drug|PMG1015 Dose 6|Dose level 6 of PMG1015
45505559|NCT05022771|Drug|Placebo|Placebo to match
45505560|NCT05022771|Drug|PMG1015 Dose 7|Dose level 7 of PMG1015
45505561|NCT02116400|Other|Interview|All patients are interviewed at the BEC. Questionnaires and scores are administered. See endpoints.
45505562|NCT02116400|Other|Neuropsychological testing|Neuropsychological tests are administered (requires computer use). See endpoints.
45505563|NCT02116400|Biological|Serum concentration of lithium or sodium divalproate.|Venous blood is drawn and tested for serum concentration of lithium or sodium divalproate.
45505564|NCT02732184|Drug|Co-ArgI-PEG modified human arginase I|
45849719|NCT05400252|Behavioral|Health and Wellness|Health & Wellness is an educational wellness intervention
45849720|NCT05386680|Genetic|OAV101|Single intrathecal administration of OAV101 at a dose of 1.2 x 10^14 vector genomes
45849721|NCT05377164|Behavioral|food choices|Analysis of lymphocytes isolated from the peripheral blood of participants who had been on vegetarian, ketogenic or normal mixed diet for at least one year will be performed.
45505565|NCT02121080|Drug|REGN2222(SAR438584)|
45505566|NCT02121080|Drug|placebo|
45505567|NCT03608592|Biological|umbilical cord derived mesenchymal stem cells (UCMSCs) suspension|Clinical grade human umbilical cord derived mesenchymal stem cells (passage 3-5) suspension are provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University. Cells are made of suspension packages (60million cells in 100ml normal saline per bag) and infused intravenously in 2 hours.
45505568|NCT03608592|Biological|normal saline|A bag of 100ml clinical grade normal saline are also provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University.
45505569|NCT03552302|Behavioral|Yoga|"Yoga stretch warm-up exercise for 15 minutes.~Five kinds of yoga correction method for 30 minutes (abdominal breathing, throat breathing, wind box breathing, nasal alternating breathing, buzzing breathing).~Great rest for 15 minutes"
45505570|NCT03827265|Device|repetitive transcranial magnetic stimulation (rTMS)|A rTMS system is an electromagnetic device that non-invasively delivers a rapidly pulsed magnetic field to the cerebral cortex in order to activate neurons within a limited volume without inducing a seizure. The device is intended to be used to treat patients meeting clinical criteria for MDD as defined in the Diagnostic and Statistical Manual of Mental Illnesses, Fourth Edition (DSM-IV). This guidance is issued in conjunction with a Federal Register notice announcing the classification of rTMS systems for the treatment of MDD.
45505571|NCT02720718|Device|Stratafix|
45505572|NCT02720718|Device|Vicryl|
45505573|NCT02123732|Dietary Supplement|DbXell|
45505574|NCT02123732|Dietary Supplement|Placebo|
45505575|NCT04059588|Drug|2141 V-11|intratumoral injection of 2141-V11
45505576|NCT02123810|Other|CPR|Simulated cardiac arrest on a manikin Chest Compression CPR for 6 minutes
45397669|NCT01101724|Behavioral|Mandated Rest, Intervention|"In addition to CDC based discharge instructions, the intervention group will receive instructions with strict activity restriction explicitly stating No return to school and No Physical Activity for the next five days. Patients and parents in the intervention group will be provided school and work excuses for the five days post-injury."
45397670|NCT01584700|Procedure|Renal Artery Denervation|Radiofrequency ablation of the renal artery sympathetic outflow tract.
45397671|NCT01101802|Drug|Mycophenolate mofetil|Arm 1 patients were given 1 gm bd mycophenolate mofetil for 8 weeks, The mycophenolate was dispensed as 500mg tablets.
45397672|NCT01101802|Drug|sugar pill|Arm 2 patients were given 2 sugar pills bd for 8 weeks
45397673|NCT01099228|Other|131-I MIBG and 111-In pentetreotide|Subjects will receive 131I MIBG and 111In pentetreotide(surrogate for Y90-DOTATOC)
45397674|NCT01099228|Other|131-I MIBG and In-111 DOTATATE|131I MIBG and In-111 DOTATATE (surrogate for 177Lu DOTATATE)
45505577|NCT03119701|Drug|Interferon Beta-1A|Lyophilisate for solution for injection.
45397675|NCT00003472|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a recurrent/progressive Oligodendroglioma will receive Antineoplaston therapy (Atengenal + Astugenal).
45397676|NCT01099306|Other|Pharmaceutical care services|Patients' metabolic components were assessed and managed collaboratively by focused care plan designed by the clinical pharmacist and approved by the physician.Pharmacist emphasized the change in lifestyle, particularly weight loss and physical activity as a first line therapy for at least 3 months, patients were started on drug therapy when needed as recommended by clinical guidelines.
45397677|NCT01088152|Behavioral|Celiac school|Structured education of adult celiac patients at 10 sessions.
45397678|NCT01088152|Behavioral|Usual care of celiac disease women|Written information corresponding to that offered when seeking medical advice for well treated celiac disease in the primary care.
45505578|NCT03119701|Drug|Placebo|Lyophilisate for solution for injection as placebo.
45505579|NCT03717129|Drug|Genvoya Oral dose|Single Genvoya oral dose directly observed
45505580|NCT03717129|Drug|Genvoya Crushed Dose|Single Genvoya crushed tablet in water directly observed
45505581|NCT03551912|Procedure|Surgery|All patients coming for elective surgery
45505582|NCT02116478|Procedure|surgical proximal medial gastrocnemius recession|proximal medial gastrocnemius recession
45505583|NCT02123888|Radiation|Cone Beam Computed Tomography|Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy
45697443|NCT05386732|Device|Micro needling|All patients were treated with a 16 needle, 3mm, 33-gauge surgical grade stainless steel needle cartridge. The operator began treatment using a depth of (1mm) and a frequency setting of 4 (corresponding to 120 Hz). Needle depth and frequency was adjusted until pin-point bleeding occured, the minimum and maximum depth used to create pinpoint bleeding was recorded. The operator began treatment using a minimum depth of 1mm and a frequency setting of 4 (corresponding to 120 Hz). Needle depth and frequency was adjusted until pin-point bleeding occurred.
45397679|NCT01099384|Behavioral|Written self-help materials|Written materials to help adolescents stop tobacco use
45505584|NCT03627039|Drug|SGLT2|All SGLT2 medications approved prior to 2017 will be included (Canagliflozin, empagliflozin, dapagliflozin (all doses, all of the medications are oral)
45697444|NCT00988000|Other|telephone consultation|alternative to face to face consultation for new referrals
45397680|NCT01099384|Behavioral|Group behavioral counseling|group behavioral counseling (2 day weekend program)
45397681|NCT01088230|Other|Botox®|the treatment group will receive a one time injection of Botox® at the wrist flexors and pronators of the affected arm. Each subject will receive a standard dose of 150 units total, 50u each to the flexor carpi radialis and flexor carpi ulnaris, and 25u each for the pronator teres and pronator quadratus muscle groups.
45397682|NCT01088230|Other|saline solution|the control group will receive a one time injection of salt water in the flexor carpi radialis and flexor carpi ulnaris, and the pronator teres and pronator quadratus muscle groups.
45505585|NCT03627039|Drug|Metformin|Metformin is the main comparator of interest. In a secondary analysis GLP1 will be the comparator
45505586|NCT01374373|Biological|Epoetin alfa|Epoetin alfa 40.000-60.000 IU/week subcutaneously that will be controlled and up or down titrated every 2 weeks according to the currently approved prescription guidance for a total of 12 weeks of treatment with Co administration of oral ferrous sulfate 200mg BID and oral folic acid 5mg QD
45505587|NCT02116556|Drug|Prednisone|Prednisone PO 40mg/day or IV equivalent dosage for 30 days. Patients not responding at 7 days (e.g. Lille Model ≥ 0.45) treatment with Prednisone will be suspended.
45505588|NCT02116556|Drug|Rifaximin|Rifaximin PO 1200 mg/day for 90 days
45505589|NCT05006937|Procedure|Dusting|Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.
45505590|NCT05006937|Procedure|Basket extraction|Basket extraction is when a small wire basket is used to remove stone fragments.
45505591|NCT04593823|Combination Product|Furoscix Infusor|Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.
45697445|NCT00988000|Other|No intervention|no alternative to face to face consultation
45697446|NCT05343117|Drug|Palbociclib based-therapy as initial endocrine therapy|Palbociclib + aromatase inhibitor/fulvestrant (initial endocrine therapy)
45397683|NCT01099462|Drug|Ibuprofen|Ibuprofen (10mg/kg BW) will be given orally if the temperature on presentation is higher than 38.0OC according to the decision of the attending physician.
45397684|NCT01088308|Procedure|High rate atrial and vetricular stimulation|The right atria and ventricle of the subject will be electrically stimulated at high rate mimicking tachycardia episodes using electrodes placed in the right atria and ventricle.
45397685|NCT01088308|Procedure|Ventricular Tachycardia induction|A programmed electrical stimulation protocol will be performed using an electrode placed in the right ventricle.
45397686|NCT01099540|Drug|Pazopanib|Pazopanib 800 mg qd daily
45397687|NCT00003298|Drug|cisplatin|Cisplatin was administered as part of the neoadjuvant regimen. It was given at a dose of 75 mg/m² via IV over approximately one hour, on day 1 of each cycle. Three cycles were given.
45397688|NCT00003298|Drug|fluorouracil|Postoperative regimen 5-FU, along with Leucovorin, was given by IV bolus, with 5-FU given immediately after the Leucovorin
45397689|NCT00003298|Drug|leucovorin calcium|Both 5-FU and Leucovorin will be given via IV bolus, with Leucovorin given immediately before 5-FU.
45397690|NCT00003298|Drug|paclitaxel|Paclitaxel was administered as part of the neoadjuvant regimen. It was given at a dose of 175 mg/m² as a 3 hour continuous intravenous infusion on day 1. Three cycles were given.
45397691|NCT00003298|Procedure|surgery|"The surgical procedure performed involved a radical subtotal or total gastrectomy.~A complete surgical resection was required"
45397692|NCT00003298|Radiation|radiation therapy|Concomitant chemotherapy and radiation therapy course: 5-FU 400 mg/m²/day + Leucovorin 20 mg/m²/day on days 1-4 of week one and days 1-3 of week 5 of XRT. Combined chemotherapy and radiation therapy were to begin 4 weeks after day 1 of the initial course of chemotherapy
45397693|NCT01327456|Behavioral|Self-Management Intervention|patients will participate in a 1-on-1 interactive intervention, delivered by a trained research assistant targeting self-management skills (e.g. inhaler use, use of an action plan), smoking cessation, and exercise/pulmonary rehabilitation. All participants will return 2-4 weeks after the intervention for a follow-up assessment of inhaler technique use, COPD-related knowledge, and time spent in self-management.
45397694|NCT01099696|Dietary Supplement|B. infantis 35624|B. infantis 35624 in white capsules
45397695|NCT01099696|Dietary Supplement|placebo|white placebo capsules
45397696|NCT03961282|Other|Doorway Width Test|The first test consists of Doorway Width. Standard level is a doorway width of 30 inches; Enhanced is doorway width of 36 inches; Co-design allows the participant to adjust the width anywhere from 26 to 48 inches.
45397697|NCT03961282|Other|Door Frame Color Test|The second test consists of Door Frame Color. Standard level is same color (hue) as light-color wall; Enhanced level is same hue but of higher color intensity for contrast; Co-design allows the participant to adjust the color intensity range from lowest (same as wall) to highest intensity (stronger contrast than in Enhanced).
45397698|NCT03950908|Other|Single bite biopsy technique|During biopsy collection one specimen will be retrieved during a single passage of the biopsy forceps.
45397699|NCT03950908|Other|Double bite biopsy technique|During biopsy collection two specimens will be retrieved during a single passage of the biopsy forceps.
45397700|NCT03951844|Device|BRIDGE/EMPATIA exoskeleton|The participant wears the exoskeleton on his/her left arm, and he/she controls it by means of a joystick or vocal commands.
45397701|NCT03960970|Drug|Azithromycin 500 mg|Additional IV Azithromycin 500 mg to Standard Prophylaxis
45397702|NCT03960970|Drug|Mefoxin 2g|Standard Prophylaxis
45397703|NCT00002842|Drug|floxuridine|Starting dose of 0.2 mg/kg/day for 14 consecutive days.
45397704|NCT00002842|Drug|fluorouracil|300 mg/m2/day by intravenous bolus 24 hours apart for 5 consecutive days.
45397705|NCT00002842|Drug|leucovorin calcium|500 mg/m2/day by continuous intravenous infusion beginning 24 hours prior to the first dose of 5-FU and continuing until 12 hours following the last dose of 5-FU.
45397706|NCT00002842|Procedure|adjuvant therapy|Chemotherapy given after hepatic resection
45397707|NCT00002842|Procedure|conventional surgery|Hepatic resection
45505592|NCT03608631|Drug|Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA|Given IV
45505593|NCT03634345|Drug|Period 1 - Day 1: PF-04965842 administered|Period 1: Single administration of 100 mg PF 04965842.
45505594|NCT03634345|Drug|Period 2: Cohort 1: Fluvoxamine & PF-04965842|Cohort 1: Period 2: Administration of fluvoxamine from Day 1 to Day 9 and PF-04965842 on Day 8.
45505595|NCT03634345|Drug|Period 2: Cohort 2: Fluconazole & PF-04965842|Cohort 2: Period 2: Administration of fluconazole from Day 1 to Day 7 and PF-04965842 on Day 5.
45505596|NCT02116634|Biological|mesenchymal stem cell|intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
45505597|NCT04991649|Behavioral|Acceptance and Commitment Therapy-based Asthma Management Training Program|In addition to the routine pediatric asthma outpatient service as received with the TAU group, participants in the ACT group will additionally receive a two-weekly 2-hour Positive Parenting Program (Triple-P) and a four-weekly 2-hour ACT program (a total of six weekly sessions, 6-8 parents per group). The Triple-P aims to increase parental self-regulation and positive parenting practices to promote child cooperation, lead to consistent discipline and promote routines in childhood asthma management. On the other hand, The ACT sessions foster parents' psychological flexibility to cultivate non-judgmental acceptance of difficult parenting experiences, be mindful in daily parenting, develop an observer-self, and promote commitment to one's values.
45505598|NCT04991649|Behavioral|Treatment-as-usual Group|Participants in the treatment-as-usual (TAU) group will receive routine pediatric asthma outpatient services. These services include regular follow-up appointments once every 3-6 months for reviewing the child's health conditions by pediatricians, refilling medications and asthma education (1.5-2 hours every 3-4 weeks) by Advanced Practice Nurse specialized in pediatric respiratory care, and referrals to community care/welfare services by psychiatrist/medical social worker for parental training in ADHD care.
45505599|NCT02906137|Other|Peripheral blood and intestinal biopsies will be collected|Blood draw and intestinal biopsies
45505600|NCT02121314|Drug|intravenous administration of 1st line TB drugs, day 1|TB drugs IV on day 1 for calculation of bioavailability while fasting or fed
45505601|NCT04987359|Behavioral|Multimodal Lifestyle Program|The multimodal lifestyle program will utilize intensive behavioral therapy with structured exercise training and nutritional counseling.
45505602|NCT05760859|Other|Initial cue|"Symptom volunteered by the patient"
45505603|NCT03553238|Drug|Chidamide|Chidamide will be administrated at a dose of 10mg/day in PDT-ETP-ALL protocol.
45505604|NCT03553238|Drug|Dexamethasone|Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ETP-ALL protocol.
45505605|NCT03553238|Drug|vincristine|Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
45505606|NCT03553238|Drug|Cyclophosphamide|CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
45505607|NCT03553238|Drug|Idarubicin|IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
45397708|NCT01099930|Other|immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT),|"Stem Cell Mobilization with Cyclophosphamide 4.5 gm/m2 and rhGCSF 10 ug/kg/d x 10 day.~Stem Cell Collection with Cobe Spectra Stem Cell Purification with Miltenyi CliniMACS Stem Cell Transplant Conditioning with Busulphan 9.6 mg/kg iv, Cyclophosphamide 200 mg/kg iv, rabbit ATG 5 mg/kg iv followed by CD34 selected autologous hematopoietic stem cell transplant"
45397709|NCT01099930|Other|Standard Therapy|Patient will receive standard therapy as decided upon by their treating neurologist.
45397710|NCT03950596|Other|Acute resistant load exercises|"Leg bench and leg press acute resistant load exercises~Leg-bench and leg-press acute resistant load exercises"
45697447|NCT05343117|Drug|Palbociclib based-therapy after chemotherapy|Palbociclib + aromatase inhibitor/fulvestrant (after chemotherapy)
45697448|NCT05340322|Device|Colposcopy using pocket colpscope and thermocoagulator|If HPV+, visualization with pocket colposcope and treatment with thermocoagulator
45697449|NCT01898195|Drug|Varenicline|Varenicline will be provided for three months.
45697450|NCT01898195|Behavioral|Text Message|Text messages will be developed twice daily for three months
45697451|NCT01898195|Behavioral|Adherence Behavioral Therapy|Seven Adherence Behavioral Therapy sessions will given over a three month period
45397711|NCT03950596|Behavioral|Background Questionnaire|Background questionnaire will be filled out by participants
45397712|NCT03950596|Other|Pain Questionnaire|Pain questionnaire regarding pain in the knee during previous 3 months
45397713|NCT03950596|Genetic|DNA and RNA test|DNA and RNA tests will be sent to a genetic laboratory for analysis
45397714|NCT03950596|Diagnostic Test|Ultrasound|Ultrasound of the knee joint and the quadriceps muscle and the pica tendon
45397715|NCT03950596|Diagnostic Test|Percutaneous Needle Core Biopsy|Core Biopsy will be taken from the quadriceps femoris muscle
45397716|NCT01100008|Procedure|Magnetic resonance imaging (MRI)|MRI cardiac and pulmonary with gadolinium
45505608|NCT03553238|Drug|Pegaspargase|PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
45505609|NCT03553238|Drug|Adriamycin|Adriamycin will be added to Consolidation-Module of PDT-ETP-ALL protocol.
45505610|NCT03553238|Drug|Methotrexate|Methotrexate will be added to consolidation module of PDT-ETP-ALL protocol.
45505611|NCT03553238|Drug|6-Mercaptopurine|Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
45505612|NCT03553238|Drug|Etoposide|VP-16 will be added to Consolidation-Module of PDT-ETP-ALL protocol.
45697452|NCT04348071|Drug|Ruxolitinib|Participants will receive 10 mg ruxolitinib twice daily.
45697453|NCT05242666|Diagnostic Test|3T MR Imaging of the cervical spinal cord|Patients will undergo either Magnetic Resonance Imaging of the Spinal Cord
45505613|NCT03553238|Drug|Cytarabine|AraC will be added to Consolidation-Module of PDT-ETP-ALL protocol.
45397717|NCT01584310|Other|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
45397718|NCT01584310|Other|No STAMP using|No intervention
45397719|NCT03951688|Other|Experimental-Multi-modal exercise program|"Each home-based session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking.~Finally, participants are instructed to walk at their usual pace for at least 10 minutes."
45397720|NCT00143247|Drug|Exubera® (inhaled insulin)|Treatment of type 1 and type 2 diabetes with short-acting insulin
45397721|NCT00125853|Drug|Nebivolol|Nebivolol 2.5mg daily
45397722|NCT00125853|Drug|Atenolol|Atenolol 25mg daily
45397723|NCT00219141|Drug|Aliskiren 150/300 mg|Aliskiren 150 mg tablets
45397724|NCT00219141|Drug|Losartan 50/100 mg|Losartan 50 or 100 mg capsules
45397725|NCT00219141|Drug|Aliskiren placebo|Aliskiren 150 mg placebo tablet
45397726|NCT00219141|Drug|Losartan 50/100 mg placebo|Losartan 50/100 mg placebo capsules
45397727|NCT03971487|Behavioral|Psychosis and cognitive assessments|Administration of MINI, PANSS and Quality of Living scales
45397728|NCT03971487|Behavioral|Physical and neuro-cognitive evaluations|Physical, neurological and cognitive evaluations.
45397729|NCT03971487|Diagnostic Test|Safety labs and electrocardiogram|Metabolic panel, CBC and differential, urinalysis, ECG, recreational drugs. CD19+ B-cell count.
45505614|NCT03553238|Procedure|Bone marrow aspiration|Bone marrow aspiration and additional tests will be performed in all module of PDT-ETP-ALL protocol.
45505615|NCT03553238|Procedure|Intrathecal injection|Intrathecal injection chemotherapy will be performed in PDT-ETP-ALL protocol.
45697454|NCT05242666|Other|Positron Emission Tomography using [11C]PIB|Patients will undergo combination MRI/PET using a [11C]PIB radiotracer
45697455|NCT05242666|Other|3T MR Imaging of the Brain|3T MR Imaging of the Brain
45397730|NCT03971487|Biological|Ocrelizumab infusion|Two IV infusions of 300 mg of ocrelizumab 2 weeks apart
45397731|NCT00142935|Behavioral|Pre-release Initiation of MMT|Participants assigned to arm 1 will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
45397732|NCT00142935|Behavioral|Post Release Initiation of MMT.|Participants assigned to Arm 2 will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
45397733|NCT00142935|Behavioral|Standard of Care Plus|Participants assigned to Arm 3 will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
45397734|NCT03967041|Diagnostic Test|radiological defined sarcopenia|Evaluation for sarcopaenia was performed via calculating psoas cross-sectional area at level of L3 and normalising for height
45697456|NCT05242666|Other|7T MR Imaging of the Spinal Cord|7T MR Imaging of the Spinal Cord
45397735|NCT00233948|Drug|nelfinavir mesylate|Given orally
45397736|NCT00233948|Procedure|biopsy|Correlative studies
45397737|NCT00233948|Other|laboratory biomarker analysis|Correlative studies
45397738|NCT00233948|Other|pharmacological study|Correlative studies
45397739|NCT00233948|Genetic|gene expression analysis|Correlative studies
45397740|NCT00233948|Genetic|western blotting|Correlative studies
45505616|NCT03553238|Radiation|Radiation therapy|Radiation therapy will be performed for mediastinum and/or central nervous system leukemia in PDT-ETP-ALL protocol.
45505617|NCT03553238|Genetic|NGS|Next-Generation-Sequencing (NGS) will be performed in PDT-ETP-ALL protocol.
45505618|NCT03553238|Procedure|allogeneic hematopoietic stem cell transplantation|Allo-HSCT will be performed for patients with available donor in PDT-ETP-ALL protocol.
45505619|NCT03553238|Diagnostic Test|Flow-MRD|Flow-MRD will be added to PDT-ETP-ALL for bone marrow and cerebrospinal fluid samples.
45505620|NCT03553238|Diagnostic Test|FISH|FISH will be performed in PDT-ETP-ALL for bone marrow samples.
45505621|NCT03553238|Diagnostic Test|Flow immunophenotyping|Flow immunophenotyping will be performed in PDT-ETP-ALL protocol.
45505622|NCT03553238|Diagnostic Test|Karyotyping|Karyotyping will be performed in PDT-ETP-ALL protocol.
45849722|NCT05370300|Diagnostic Test|Blood test|Proprietary immunogenomic signature from peripheral blood CD14 and CD2 cells.
45505623|NCT04980027|Drug|Insulin glargine (U300)|Pharmaceutical form:Solution for injection in a prefilled pen Route of administration: Subcutaneous
45505624|NCT01373593|Drug|lidocaine|
45505625|NCT01373593|Drug|Placebo|
45505626|NCT04956549|Behavioral|Physical activity program|Supervised group sessions will be held twice per week for approximately 52 weeks. Each physical activity session will last slightly approximately 80 minutes and will consist of aerobic, strength, flexibility, and balance training. The 80 minutes of activity consists of a 5 minute warm-up, 45 minutes of aerobic training, 15 minutes of strength training, 10 minutes of balance training, and a 5 minute cool-down. The physical activity group will target 150 minutes of moderate to vigorous aerobic physical activity and two days of strength training, consistent with the current physical activity recommendations.
45505627|NCT04956549|Behavioral|Successful Aging|The successful aging group will be based on a low-intensity activity program and a healthy aging educational component. Sessions will be approximately 60 minutes in duration and will occur once per week for the first 6 months and then every other week for the remainder 6 months of the study. The physical activities will include stretching, balance training, flexibility, relaxation, and practicing activities of daily living. The successful aging education component will cover topics including avoiding scams, fall prevention, living wills, and dementia awareness.
45505628|NCT04611477|Other|Rice Hulk|Placebo
45505629|NCT04611477|Other|Synbiotic365 Ver 5|Active Comparator
45505630|NCT04611477|Other|Synbiotic365 Ver 7|Active Comparator
45505631|NCT02116712|Drug|Saracatinib|Saracatinib is escalated as follows: Three dose levels will be administered for 1 month each: 50 mg, 125 mg and 175 mg. Three subjects will be treated at the lowest daily dose of 50 mg. If no subject experiences DLT (dose limiting toxicity), the dose level is escalated to 125 mg/day for the next cohort of 3 different subjects and so on to next dose.
45505632|NCT04611087|Behavioral|Discussion|Attend focus groups
45505633|NCT04611087|Other|Interview|Attend interviews
45505634|NCT04611087|Other|Survey Administration|Ancillary studies
45397741|NCT00233948|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
45505635|NCT02116790|Drug|Naproxen|Subjects will take one 250mg Naproxen capsule
45505636|NCT02116790|Drug|Sinemet|Subjects will take one 12.5mg/50mg Sinemet.
45505637|NCT02116790|Drug|Sinemet|Subjects will take one 25mg/100mg Sinemet.
45505638|NCT02116790|Drug|Placebo|Subjects will take two placebos.
45505639|NCT03592641|Drug|Savolitinib|Given PO
45505640|NCT04675489|Other|Procedure: Vivity Toric IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's Vivity Toric Extended Vision intraocular lens (IOL) for cataract patients. This innovative lens is an extended depth of focus IOL that has been reported to result in fewer visual disturbances than diffractive IOLs.
45505641|NCT04935021|Drug|ATTR-CM|Current treatment
45397742|NCT00233948|Other|immunoenzyme technique|Correlative studies
45397743|NCT00233480|Drug|atorvastatin|atorvastatin 10mg PO QD
45505642|NCT02859961|Drug|PRO 140 (350 mg)|PRO 140 350 mg (175 mg/mL) SC injection per week
45505643|NCT02859961|Drug|PRO 140 (525 mg)|PRO 140 525 mg (175 mg/mL) SC injection per week
45505644|NCT02859961|Drug|PRO 140 (700 mg)|PRO 140 700 mg (175 mg/mL) SC injection per week
45505645|NCT02124200|Device|EGO/CE4, 9mg nicotine|
45505646|NCT02124278|Drug|PUL-042 Inhalation Solution|
45505647|NCT04503993|Other|Hepatitis B surface antigen, Hepatitis B core antibody, and Hepatitis B surface antibody|The hepatitis B tests are released into the electronic medical charts of at-risk patients who have never been screened for chronic hepatitis B using population health tools.
45697457|NCT03696927|Device|Active Powered Prosthesis (APEX) for Spinal Cord Injury|The Active Powered Prosthesis (APEX) is a proof-of-concept shoulder-elbow-wrist device intended to provide non-invasive active powered robotic assistive movement to upper extremities. Focus group participants will control the APEX device on a test manikin and provide feedback on the device design and function.
45397744|NCT00233480|Drug|placebo|matched placebo Qd x 3 months
45397745|NCT01072994|Dietary Supplement|Fish Oil|Differential proportional doses of DHA versus DHA and EPA
45397746|NCT03801928|Drug|Inflectra|The study plans to recruit 300 subjects in the United States and Canada initiating or switching to treatment with INFLECTRA over an 8 month period. The decision to start INFLECTRA will be entirely a clinical decision made by the participating physician irrespective of this study.
45697458|NCT01897727|Drug|Spironolactone|
45397747|NCT02530918|Drug|DS-7080a|1.0, 2.0, or 4.0 mg administered by a 50 μL intravitreal (IVT) injection of solution
45397748|NCT02530918|Drug|Ranibizumab|0.3 mg or 0.5 mg administered by a 50 μL IVT injection of solution
45397749|NCT01584622|Device|CADence System|Non-invasive detection of > or equal to 50% stenosis in any of the major coronary arteries.
45397750|NCT03950518|Drug|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules, 12mg/d
45397751|NCT03950518|Drug|Arginine hydrochloride|AHC,12mg/d AH,40g/d
45397752|NCT03950518|Drug|levamisole|AHC,12mg/d AH,40mg/d LM,150mg/d
45397753|NCT01102036|Other|Cultura L casei F19, acidophilus La5 , B lactis Bb 12|2 weeks consumption,250 ml/day
45397754|NCT01102036|Other|Yoghurt without probiotics|Yoghurt without probiotics
45397755|NCT01100164|Drug|Eszopiclone|Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
45505648|NCT02116868|Device|Pupillometry guided analgesia (PP)|Analgesia is guided by pupillary reflex provided by the pupillometer (AlgiScan). The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed (Tailored remifentanil controlled infusion). Administration of antihypertensive drugs or vasopressors is also guided.
45505649|NCT02116868|Drug|Tailored remifentanil controlled infusion|The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed
45697459|NCT01897727|Drug|BP medication uptitration|antihypertensive medication added or uptitrated following standard of care
45697460|NCT04352998|Dietary Supplement|One dose pre-workout condition|one dose of a multi-ingredient pre-workout supplement
45697461|NCT04352998|Dietary Supplement|Two dose pre-workout condition|two doses of a multi-ingredient pre-workout supplement
45397756|NCT01100164|Drug|Zopiclone|Zopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
45397757|NCT03950284|Device|immediate loading with all on four technique in FFF|All cases will undergo surgery under local regional anesthesia. Injection of local anaesthesia (Articaine 4% and 1:100000 epinephrine) for regional infiltration. Sequential drilling then insertion of the dental implant fixtures and abutments on which the prefabricated temporary prosthesis will be fixed.
45397758|NCT01102114|Biological|NicVAX Vaccine|NicVAX vaccine given 6 times over 6 months
45397759|NCT01102114|Biological|Placebo Vaccine|Placebo vaccine given 6 times over 6 months
45397760|NCT01327222|Drug|Bevacizumab|1.25 mg intravitreal bevacizumab
45505650|NCT02116868|Drug|Tailored antihypertensive drug administration|Administration of antihypertensive drugs or vasopressors is guided by the results of the pupillary reflex.
45397761|NCT03950362|Drug|Avelumab|Administration of Avelumab 10mg/kg Infuse IV over 30-minutes: 1 cycle 5 days before External Beam RadioTherapy, then every 21 days x 8 cycles (6 months)
45397762|NCT03950362|Device|Radiotherapy|60-66 Gy in 30-33 Fractions (2 Gy/fractions) given to the whole bladder
45505651|NCT02679781|Drug|oral midazolam|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
45505652|NCT02679781|Drug|nasal midazolam|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
45505653|NCT03551834|Other|Conventional scleral patch graft glaucoma implantation|conventional AGV implantation by using scleral patch graft to cover the tube and prevent tube exposure
45505654|NCT03551834|Other|New surgical method (short tunnel small flap technique)|a novel technique named short tunnel small flap (STSF) by tunneling the sclera to pass the AGV tube without using scleral patch graft.
45505655|NCT03633877|Device|DuraporeTM and Hy-Tape®|Medical tapes
45505656|NCT02124356|Other|Evaluation of functional performance|
45505657|NCT04475133|Other|Ultrasound guided percutaneous neuromodulation|It is a technique that consists in the electrical stimulation of peripheral nerve trunks, inserting an acupuncture needle in its path and using it as an electrode to apply electrical current
45505658|NCT02251730|Behavioral|Smoking cessation|Refer for smoking cessation
45505659|NCT04473963|Device|Ablamap Software|Subjects will receive cardiac ablation guided by the Ablamap software. The software will identify atrial fibrillation sources to help guide ablation therapy in patients with persistent atrial fibrillation. Subjects will undergo a cardioversion post ablation, as necessary.
45505660|NCT02121548|Behavioral|CHW Outreach and HPV Self-sampling|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes. Women who are randomized to this arm will also include information on the alternative screening method. They will be told that cervical self-sampling is an alternative screening technique for the Pap smear and they will be offered the choice of having the HPV screen done during that home visit or have a Pap Smear at the participating FQHC.
45505661|NCT02121548|Behavioral|CHW Outreach|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes.
45505662|NCT02121704|Device|Magnetic Endoscope Imaging (Scope Guide)|
45505663|NCT04373031|Drug|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.
45505664|NCT04373031|Drug|IRX 2|IRX-2, is a cell-derived biologic with multiple active cytokine components that acts on multiple cell types of the immune system including T cells, dendritic cells and natural killer cells.
45697462|NCT04352998|Dietary Supplement|Placebo condition|one dose of a placebo
45697463|NCT04883619|Other|Placebo|Placebo will be administered intravenously.
45849723|NCT05360628|Drug|D-0120 in combination with Allopurinol|noted above
45397763|NCT00263588|Drug|lapatinib|tyrosine kinase inhibitor
45397764|NCT00213135|Drug|Cladribine 5.25 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.
45397765|NCT00213135|Drug|Cladribine 3.5 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 48, and 52 and placebo matched to cladribine tablet will be administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
45397766|NCT00213135|Other|Placebo|Placebo matched to cladribine tablet will be administered over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.
45397767|NCT00077974|Drug|SU011248|50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity
45397768|NCT00124917|Radiation|Radiation|Areas of pathologically confirmed malignancy will undergo dose escalation as described below. Areas of image abnormality that could not be biopsied or were without definite pathologic evidence of malignancy will be given intermediate doses. The remainder of the prostate gland will receive standard dose (as per the Radiation Therapy Oncology Group (RTOG) 9406 study) 7560 centigray (cGy) in 180 cGy daily fractions.[1]
45397769|NCT03967353|Behavioral|New management mode intervention|"Patients in routine treatment group use TB assistant APP. Medical staff strengthen health promotion of the patients,including, infection control, doctor-patient communication, etc."
45397770|NCT01100398|Procedure|possible liver biopsy and serum collection|All patients with a positive ultrasound for hepatic steatosis offered a liver biopsy after obtaining fasting blood work that included a complete blood count, coagulation studies, liver function tests, fasting lipid panel, glucose and insulin. Patients with a negative ultrasound for fatty liver are not referred for liver biopsy and are considered as completed study patients. Serum is also stored for adipokine and cytokine analysis. A study investigator using a 14g Bard Monopty biopsy gun performs the liver biopsy.
45397771|NCT01102348|Other|PEP-uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) were made available to all nurses, in bedside manuals and on the local intranet
45505665|NCT02116946|Biological|Platelet Rich Plasma (PRP)|Injection of Leukocyte-rich or Leukocyte-poor Platelet Rich Plasma prepared by the Angel cPRP System along with a 12 week exercise program for treatment of patients with patellar tendinopathy.
45505666|NCT02116946|Other|Saline + exercise|Peritendinous saline injection plus 12 week exercise program.
45397772|NCT00141921|Drug|Etanercept|Open-label at a dose of 0.8 mg/kg (up to an intended dose of 50 mg) given once weekly by subcutaneous injection
45397773|NCT00029146|Procedure|extracranial-intracranial bypass surgery|Surgical anastomosis of a superficial temporal artery branch to a middle cerebral artery branch through a small craniectomy plus best current practice medical therapy
45397774|NCT00029146|Drug|best medical therapy|best current practice medical therapy
45505667|NCT02624869|Biological|Evolocumab|Administered by subcutaneous injection
45505668|NCT03553160|Other|Frequent Self-Weighing|Were given scales to weigh themselves daily. Change in weight was measured at the beginning and end of the two year observation period.
45505669|NCT02121782|Biological|Quadrivalent influenza vaccine|GC3110A, 0.5ml, intramuscular, a single dosing at Day 1
45505670|NCT02121782|Biological|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
45505671|NCT04877457|Drug|Ocrelizumab|The first course of ocrelizumab will be administered as two 300 mg infusions at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given as a single 600 mg infusion at Weeks 24 and 48.
45505672|NCT04877457|Other|Placebo|Placebo will be administered at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given at Weeks 24 and 48.
45505673|NCT02117102|Other|Bladder and lumbar stimulation technic|
45505674|NCT04656847|Drug|in daily everyday routine practice|patients with HTN and CAD treated with the the single pill combination bisoprolol/perindopril for 12 weeks in the daily clinical practice Retrospective screening and evaluation of patient's eligibility to inclusion/ exclusion criteria for entering the study allows mitigating a potential risk of deliberative medicine administration within the observational program.
45505675|NCT03553082|Drug|Sevoflurane|Fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance
45697464|NCT04883619|Drug|Nipocalimab|Nipocalimab dose 1 and dose 2 will be administered intravenously.
45397775|NCT01079793|Drug|ixabepilone|
45697465|NCT04883619|Drug|Standard-of-care treatment|Standard-of-care treatment including MMF or MPA and glucocorticoids will be administered intravenously through Week 52.
45697466|NCT05593744|Other|no intervention|This is an observational study so not involved intervention
45697467|NCT01897493|Drug|Evacetrapib|Administered orally
45697468|NCT01897493|Drug|Digoxin|Administered orally
45397776|NCT01079793|Procedure|adjuvant therapy|
45397777|NCT01079793|Radiation|intensity-modulated radiation therapy|
45397778|NCT03950206|Other|Indocyanine green angiography|Intravenous ICG (PULSION Medical Systems SE, Feldkirchen, Germany) will be used for the intraoperative evaluation of ureteral vascularization. Twenty-five milligrams of indocyanine green will be diluted in 10 ml of soluble water, and a bolus of 0.25 mg/Kg will be injected through a peripheral vein. During laparoscopy, a NIR camera-head (KARL STORZ Gesellschaft Mit Beschränkter Haftung&amp; Co., Tuttlingen, Germany) will be used to visualize the ureteral vascularization.
45397779|NCT01088620|Drug|Panitumumab|"Panitumumab 9 mg/kg BW will be administered IV every 3 weeks (q3w) for a maximum of four cycles.~In case of CR, PR or SD status at the end of the combination treatment, a panitumumab single drug treatment, consisting of 9 mg/kg BW administered every 3 weeks, will be performed until detection of disease progression."
45505676|NCT03553082|Drug|Propofol|Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance
45505677|NCT03318393|Drug|Bivalirudin|Continuous infusion
45505678|NCT03318393|Drug|Unfractionated heparin|Continuous infusion
45505679|NCT02117180|Other|FODMAP's diet|The safety and efficacy of a low FODMAP diet will be evaluated in a convenience sample of children with functional gastrointestinal disorders, over a 6 week intervention period.
45505680|NCT04289961|Diagnostic Test|Portal vein sampling|During Endoscopic UltraSound guided-Fine Needle Aspitation (EUS-FNA) a curvilinear echoendoscope is advanced to the distal stomach or duodenal bulb to provide a window of access to a branch of the PV. After verifying venous flow by Doppler signal, a 19-gauge EUS-FNA needle is advanced transhepatically into the portal vein branch. With the needle in the portal vein, the stylet is removed and negative-pressure suction is applied to aspirate blood. A transhepatic approach for portal vein branch access is an absolute requirement of this technique in order to minimize the risk of bleeding. The puncture site is monitored under EUS for complications.
45505681|NCT04622527|Other|Random assigned paradigm viewing order|Participants experience the paradigm in a random order
45697469|NCT04881903|Behavioral|Mobile Intervention for Suicidal Thoughts (MIST)|This is an interpretation bias modification intervention that is designed to target cognitive factors that contribute to suicide risk. Participants will be instructed to complete at least 5 treatment sessions per week for a period of 4 weeks. Each session takes approximately 10 minutes.
45505682|NCT02117258|Drug|Z-360|Gemcitabine (1,000 mg/m^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while Z-360 (60, 120 or 240 mg) will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
45505683|NCT02117258|Drug|Placebo|Gemcitabine (1,000 mg/m^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while placebo will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
45397780|NCT01088620|Drug|Pemetrexed|Pemetrexed 500 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
45397781|NCT01088620|Drug|Cisplatin|Cisplatin 75 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
45505684|NCT03110029|Drug|Efinaconazole 10% Topical Application Solution [JUBLIA]|Topical efinaconazole 10% solution (Jublia)
45397782|NCT00026494|Drug|temozolomide|
45397783|NCT00026494|Drug|vinorelbine tartrate|
45505685|NCT03110029|Other|Application of Nail Polish|Application of Nail Polish
45505686|NCT04051749|Procedure|Noncardiac Vascular Surgery|Noncardiac Vascular Surgery
45505687|NCT02122016|Device|SmartCare|Ventilator with a SmartCare module that is capable of performing a computer-driven weaning trial taking into account patients lung mechanics and exaled CO2.
45397784|NCT03950128|Behavioral|Mindfulness-Based Skills Training (MBST)|"This intervention teaches students mindfulness-based skills to help manage their emotions when resolving conflict with their partners. The skills followed the ABCDE acronym. ABCDE stands for awareness, breathing, checking in with your feelings and thoughts, describing your experience, and expressing what you want to change. Students learned about the skills and had opportunities to practice them as well."
45397785|NCT03950128|Behavioral|Psychoeducational|This intervention is based on the Love is Not Abuse (LINA) Curriculum (Liz Claiborne Education Development Center (n.d.)). It was adapted to be given over the course of three 50-minute sessions. The selected materials covered (a) what dating abuse is, (b) the pattern of abuse and, (c) technology and dating abuse. The curriculum is interactive and includes handouts, activities, and discussion.
45397786|NCT03950050|Drug|Ambroxol|"Ambroxol Hydrochloride therapy will be dosed up to 600 mg/day divided to twice a day starting 150 mg for the first month, 300 mg for the following month and 600 mg for the following month.~The study was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations."
45505688|NCT02122016|Other|Conventional weaning protocol|A conventional weaning protocol performed by physiotherapist with a daily weaning screen and a spontaneous breathing trial
45505689|NCT04858815|Behavioral|yogic breathing|participation in yogic breathing
45505690|NCT02122094|Behavioral|Sexual Health Promotion Intervention|The seven core modules are 1) the Importance of Sexual Health, 2) Sexual Diversity, 3) HIV and other STIs, 4) Behavioral Risk and Risk Reduction, 5) Alcohol and Drugs, 6) Stigma and 7) Health Seeking Practices. The five optional modules are 1) HIV Treatment and Adherence, 2) Stress Reduction, 3) HIV Status Disclosure, 4) MSM/Gay Disclosure, and 5) Other Sexual Health Concerns
45505691|NCT02117336|Drug|P1446A-05|"The study have dose escalation phase, followed by a dose extension phase.~Dose escalation phase: five Dose Levels will be evaluated in the 'dose escalation' phase. The Dose Levels selected are 50 mg (Dose Level 1), 75 mg (Dose Level 2), 125 mg (Dose Level 3), 200 mg (Dose Level 4) and 275 mg (Dose Level 5), once daily. If required, a 25 mg once daily dose (Dose Level -1) will also be studied. For Dose Levels 1, 2 and 3 there will be 2- dosing periods: Single Dose and Continuous Dose. At least 3-patients will be enrolled at each Dose Level. Dosing regimens planned for Dose Level 4 and 5 are 200 and 275 mg once daily. In the continuous dose period, patients will receive P1446A-05 on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.~Dose Extension Phase: Up to a total of 14 patients will be treated at the MTD of P1446A-05, determined in the dose escalation phase, until the occurrence of disease progression or unacceptable toxicity or death."
45697470|NCT04881903|Behavioral|Mobile Intervention for Reducing Anger (MIRA)|This is an interpretation bias modification intervention that is designed to target hostile interpretation bias. Participants will be instructed to complete at least 5 treatment sessions per week for a period of 4 weeks. Each session takes approximately 10 minutes.
45697471|NCT04353076|Other|Simulated heatwave exposure|Young and older adults (no cooling) are exposed to a 9-hour simulated exposure.
45697472|NCT04353076|Other|Simulated heatwave exposure with mid-day cooling|Older adults (cooling) are exposed to a 9-hour simulated exposure with mid-day ambient cooling.
45697473|NCT03264027|Drug|Carbon dioxide|Carbon dioxide will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
45849724|NCT05326932|Procedure|Mechanical thrombectomy|Subjects in intervention group will receive MT as soon as possible. Investigators and clinicians should strive to reduce delays of pre-surgery procedure and follow the local standard guideline of MT during the operation and perioperative period. All CFDA approved devices are allowed in this trial. Angioplasty and stent placement can be performed at the discretion of the physicians. Base on site experience, the randomization-operation start period should be within 60 minutes.
45849725|NCT05326308|Drug|Zanubrutinib|according to the Summary of Product Characteristics (SmPC).
45849726|NCT05315232|Other|survey and interview|qualitative assessment
45849727|NCT05312112|Drug|Venetoclax|Observational study of venetoclax in AML
45849728|NCT05312112|Drug|Gilteritinib|Observational study of gilteritinib in AML
45397787|NCT01100476|Device|Endovascular Diagnostic Procedures|Patients underwent a percutaneous diagnostic procedure utilizing a 5F procedural sheath in the common femoral artery
45397788|NCT01102504|Drug|Placebo|Placebo
45397789|NCT01102504|Dietary Supplement|Ateronon|Tomato extract containing 28 mg lycopene/ day
45397790|NCT01088698|Radiation|UVB-311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
45397791|NCT01088776|Dietary Supplement|n-3 Fatty Acid supplement|"Children will be prescribed 1600-1800 mg EPA + DHA per m2 Body Surface Area, to a maximum of the upper limit of the age-appropriate range recommended by Health Canada.~Each n-3FA gel capsule (1000 mg) will contain 400 mg EPA and 200 mg DHA derived from the oil of wild anchovies and sardines. A smaller gel capsule (500 mg; 200 mg EPA + 100 mg DHA) will be available for children unable to swallow large solid medication and a flavored liquid formulation, containing a similar proportion of EPA + DHA (2200 mg fish oil concentrate from anchovies and sardines, 750 mg EPA, 375 mg DHA per ½ teaspoon), will be available for use in toddlers and older children unable to swallow gel capsules."
45505692|NCT05551533|Other|Kampung Care App|Please refer to the previous session
45505693|NCT03552146|Drug|Propofol|Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
45505694|NCT03552146|Drug|Dexmedetomidine|Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
45505695|NCT01374763|Drug|Oxycodone|Prolonged-release oxycodone 10-30 mg twice daily
45505696|NCT01374763|Drug|Prolonged-release oxycodone/naloxone|Prolonged-release oxycodone/naloxone 10-30 mg twice daily
45505697|NCT02747004|Drug|Abemaciclib|Administered orally
45505698|NCT02747004|Drug|Tamoxifen|Administered orally
45505699|NCT02747004|Drug|Prophylactic Loperamide|Administered orally
45505700|NCT02117492|Procedure|Cuff Closure|Closure of the vaginal cuff following hysterectomy.
45505701|NCT04826367|Other|Telerehabilitation-based relaxation exercise group (EG)|the participants in this group will perform the relaxation exercises thrice a week, for 6 weeks.
45505702|NCT04454515|Drug|Dexmedetomidine|Dexmedetomidine is an α2 receptor agonist with sedative and analgesic properties. In previous reports, dexmedetomidine improves smoothness of postoperative recovery and reduces intraoperatory imflammatory responses. As patients receiving breast surgeries are especially vulnerable to postoperative nausea/ vomiting, the dosage of narcotics and associated complications were concerned for not only comfortness but also postoperative oral intake and discharge.
45505703|NCT04454515|Drug|placebo|normal saline infusion
45505704|NCT02340403|Procedure|NMR Spectroscopy|
45505705|NCT02122250|Behavioral|Interactive web-based materials|Interactive web-based materials for self-management of diabetes
45505706|NCT02122250|Behavioral|Static web-based materials|Static web-based materials
45505707|NCT03608514|Drug|Experimental|Patients in this arm of the study will receive intravenous infusion (IVi) terlipressin by rate 1-2µg/kg/min.
45505710|NCT03551756|Other|Biomarker Assessment|Exploratory Biomarker Analysis for cardiac patients versus healthy adults
45505711|NCT04207749|Device|LID015385 contact lenses|Investigational soft contact lenses
45505712|NCT04207749|Device|Comfilcon A contact lenses|Commercially available soft contact lenses
45505713|NCT04207749|Device|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
45505714|NCT02237274|Other|High altitude exposition|High altitude exposition
45505715|NCT02117726|Drug|Dexmedetomidine,midazolam|
45505716|NCT02117726|Drug|Propofol,midazolam|
45505717|NCT04125342|Device|Preventive Conditioned NIV Therapy after planned extubation|Conditioned NIV during 48 hours following extubation.
45697474|NCT03264027|Drug|Ambient air|Ambient air will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
45505718|NCT04125342|Device|Preventive HFOT after planned extubation|HFOT set according to patients tolerance during 48 hours following extubation
45505719|NCT04571281|Diagnostic Test|capillary lactate measurements|In this study capillary lactate will be measured every 10 minute during CPR.
45505720|NCT03551678|Device|Active feedback gait retraining|The device measures pressure/force under the lateral side of the foot and activates vibration if loading crosses a set threshold. The location of the vibration is customized for each subject to achieve maximal sensitivity.
45505721|NCT02733432|Drug|CD101 Vaginal Gel (3%)|CD101 Vaginal Gel (3%) intravaginally applied topical gel on Days 1 and 2
45505722|NCT02733432|Drug|CD101 External gel (1%)|CD101 external gel (1%) applied topically twice daily over 72 hours as needed
45397792|NCT01088776|Dietary Supplement|Placebo|The placebo, identical in opaque appearance and citrus-flavored taste, will contain a 50:50 blend of soybean and corn oil for both gel capsule (2 sizes) and liquid formulations.
45397793|NCT00023764|Drug|bortezomib|Given IV
45397794|NCT01088854|Device|CPAP|unique session of 30-minute of continuous airway positive pressure
45397795|NCT03961126|Drug|Injection of autologous fatty tissue associated with autologous platelet-rich plasma.|Patients will receive 2 separate infiltrations for three months by intra and subdermal injection of autologous fatty tissue (20cc) associated with autologous platelet-rich plasma (4cc) in each half vulvar.
45505723|NCT02733432|Drug|CD101 Vaginal Ointment (6%)|CD101 vaginal ointment (6%) intravaginally applied topical ointment on Day 1
45697475|NCT03264027|Drug|Argon fulguration|The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).
45505724|NCT02733432|Drug|CD101 External ointment (1%)|CD101 external ointment (1%) applied topically twice daily over 72 hours as needed
45505725|NCT02733432|Drug|Fluconazole|oral fluconazole (150mg) on Day 1
45505726|NCT03634189|Drug|Cannabidiol|Patients with ACC/AHA stage A-C will receive 5 mg/kg to a maximum tolerated dose of 25 mg/kg PO BID of Cannabidiol
45697476|NCT04415411|Other|Nursing care based on the Theory of Human Caring|Planned nursing care based on 10 caritas processes of Theory of Human Caring.
45505727|NCT02117804|Other|Early Screen for Discharge Planning|This screen is completed by a study coordinator within 24 hours of patient admission to the hospital. The screen measures four variables available from routine hospital admission clinical data (walking limitation, age, living alone prior to admission, and level of disability) that exhibit high sensitivity and specificity (AUC's were .82 and.84) in identifying patients who should receive targeted attention from a DP expert.
45505728|NCT03043365|Drug|control fish oil|4 capsules, 3 times a day after meals
45505729|NCT03043365|Drug|LCMUFA-rich saury oil|4 capsules, 3 times a day after meals
45505730|NCT03608046|Drug|Avelumab|Avelumab will be administered at a fixed dose of 10 mg/kg once every 2- week
45505731|NCT03608046|Drug|Cetuximab Injection|Cetuximab will be administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3 and irinotecan administered every 2 weeks (180 mg/m2).
45505732|NCT03608046|Drug|Irinotecan|Irinotecan will be administered every 2 weeks (180 mg/m2)
45505733|NCT02122484|Drug|Colchicine|colchicine p.os 0.5 mg bid for two days before undergoing elective CABG surgery and eight days after the operation
45849729|NCT05296278|Drug|IBI-322 Plus Lenvatinib and Platinum|IBI-322 combined with Lenvatinib (8mg/Kg) plus platinum based chemotherapy ivgtt, every 21 days until disease progression
45505734|NCT04051515|Other|Intradialysis exercise training|Combined exercise, aerobic and resistance training, implemented by nursing staff
45505735|NCT04051515|Other|Home-based exercise training|Combined exercise, aerobic and resistance training, implemented independently home
45505736|NCT02251574|Other|Low Calorie Diet|Weight management program designed around a low calorie diet.
45505737|NCT02251574|Other|Very Low Calorie Diet|Weight management program designed around a very low calorie diet.
45505738|NCT02251574|Other|Standard Care|Care provided that would normally be given to people meeting eligibility criteria for this study.
45397796|NCT03961126|Drug|Corticosteroids (clobetasol 0.05%)|Patients will receive a maintenance treatment of topical therapy with corticosteroids (clobetasol 0.05%) that will be administered by usual clinical practice.
45397797|NCT03949816|Other|medical consultation: different doctor-patient-centered style of communication|Different doctor-patient communication
45397798|NCT03949816|Other|information letter / no medical consultation|In the control treatment participants receive all information about the herbal medical product in an information letter but have no contacted with the simulated doctor.
45397799|NCT01584778|Other|eosinophil cationic protein|Serum eosinophil cationic protein levels
45505739|NCT03108157|Procedure|Endometrial scratch|Patients included in the study group will be performed an endometrial scratch with Pipelle Cournier 3 to 4 weeks before embryo transfer.
45505740|NCT03608124|Behavioral|Behavior management techniques|Pediatric dentists will be questionnaired regarding their adopted behavior management techniques for pediatric patients
45505741|NCT04051437|Procedure|Plasma exchange|During each plasma exchange session 3-4lt (1.2-1.3 times of plasma volume) of plasma will be exchanged with fresh frozen plasma and 5% albumin. Plasma exchange session will be done on an alternate day to a maximum of 5 procedures. PLEX will be discontinued if the patients Shows sustained clinical improvement, Receive liver transplantation, Refuses further PLEX session No improvement in clinical condition Intolerant to PLEX procedure
45697477|NCT01887353|Drug|Ranolazine|Patients will take ranolazine 1000 mg tablets twice daily
45697478|NCT01887353|Drug|Placebo|Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.
45697479|NCT05352711|Device|active assisted exercise and with fully immersive Head-Mounted Display virtual reality ( Oculus Quest virtual reality (VR) headset with hand con|VR is mainly created by generating visual effects through head-mounted display (HMD) systems. An HMD is a device worn on the head or as part of a helmet with a built-in display and lenses, allowing the user to experience the virtual world with the help of a wide viewing angle, head and hand movements tracking as well as objects interacting by controllers.
45505742|NCT04051437|Drug|Standard medical treatment|The consented patients will receive standard medical treatment which includes adequate nutrition (35-45 Kcal/Kg with 1.5gm/Kg protein) diuretics, anti HE measures, appropriate antibiotics for infections,tablet entecavir 0.5 mg once daily for hepatitis B, and steroids for autoimmune hepatitis.
45505743|NCT02122874|Device|Percutaneous Neurostimulation (PENS) of dermatome T7|The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
45505744|NCT02122874|Other|1200 Kcal diet|
45505745|NCT03619993|Device|On-body injector|Medical device for subcutaneous injection of a supportive medicine (Pegfilgrastim) automatically after 27 hours after application of device.
45505746|NCT03619993|Device|Pre-filled syringe|For subcutaneous injection of a supportive medicine (Pegfilgrastim).
45505747|NCT02124590|Other|Acute Exercise|Repeated isometric leg exercises at varying intensities for up to twelve minutes per bout. Leg exercises will target the quadriceps muscles.
45505748|NCT02124590|Other|Acute Exercise|Aerobic exercise session on a bike at 50% of peak VO2 for 30 minutes.
45505749|NCT02124668|Drug|Enzalutamide|oral
45505750|NCT02117960|Dietary Supplement|Omega-3|4 cap 1 g Omega-3 per day for 2 months
45505751|NCT02117960|Dietary Supplement|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
45505752|NCT03606018|Drug|Insulin Lispro Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
45505753|NCT03606018|Drug|Humalog® Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
45505754|NCT01373749|Drug|NO inhalation|NO inhalation was performed as the only treatment for PPHN during the whole course.
45505755|NCT01373749|Drug|NO inhalation continued with sildenafil|NO inhalation was performed as the primary treatment for PPHN in the first 48 hours, NO inhalation will be replaced by sildenafil after 48 hours of therapy.
45505756|NCT02035254|Other|Web-based Wellness Program|Web-based educational modules and physical activity and/or health weight challenges
45505757|NCT01374997|Other|micromethod from samples taken from blood spots on filter paper|a blood test to measure the level of alpha-galactosidase A activity by micromethod from samples taken from blood spots on filter paper
45505758|NCT03551600|Procedure|Near-infrared spectroscopy (NIRS)|NIRS analyzes regional oxygen saturations (rSO2)
45505759|NCT04505605|Other|Blood samples|A blood sample will be collected on a dry tube with 5mL separating gel on each enrolled patients. Those will be made depending on the patients hospitalization.
45505760|NCT02118116|Other|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training is a 2-day, 14-hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The ASIST program has five learning sections: 1) Preparing - Sets the tone, norms, and expectations of the workshop; 2) Connecting - allows participants to explore their own attitudes towards suicide and creates an understanding of the impact that attitudes have on the intervention process. 3) Understanding - Describes the intervention needs of a person at risk. 4) Assisting - Presents a model for suicide intervention. 5) Networking - Generates information about resources in the local community.
45397800|NCT00189488|Drug|Palifermin|Administered as an intravenous (IV) bolus.
45397801|NCT00189488|Drug|Placebo|Administered as an intravenous (IV) bolus.
45505761|NCT03607968|Procedure|The novel anterior TVM surgeries|A novel transvaginal mesh (TVM) surgery fro women with pelvic organ prolapse (POP) had been reported. Chang TC, Hsiao SM, Chen CH, Wu WY, Lin HH. Clinical outcomes and urodynamic effects of tailored transvaginal mesh surgery for pelvic organ prolapse. Biomed Res Int http;//dx.doi.org/10.1155/2015/191258.
45505762|NCT05760625|Diagnostic Test|analysis BDNF|We analysed consentration of BDNF in venous blood of patient with primary headache
45505763|NCT02034786|Procedure|Adipose tissue collection|"Only the patients selected for the Test Group will go through the procedure. The adipose tissue collection will occur in an elective surgery liposuction, in patients who meet the inclusion criteria, after signing the informed consent form. Thus, the material that would be disposed after surgery will be donated to the study.~The material for the study will be collected by the tumescent liposuction technique, which involves the removal of subcutaneous fat under local anesthesia."
45505764|NCT02034786|Biological|Transdermal injection|Transdermal injection of the filler agent composed of mesenchymal stem cells derived from autologous adipose tissue associated with hyaluronic acid.
45505765|NCT02034786|Procedure|Transdermal injection|Transdermal injection of hyaluronic acid only.
45505766|NCT04045795|Drug|isatuximab SAR650984 IV|"Pharmaceutical form: solution~Route of administration: intravenous"
45505767|NCT04045795|Drug|pomalidomide|"Pharmaceutical form: tablet~Route of administration: oral"
45505768|NCT04045795|Drug|dexamethasone|"Pharmaceutical form: tablet~Route of administration: oral"
45505769|NCT04045795|Drug|isatuximab SAR650984 SC|"Pharmaceutical form: solution~Route of administration: subcutaneous"
45397802|NCT00189488|Other|Conditioning Regimen|"Each participant received 1 of the following conditioning regimens:~Cyclophosphamide (Cy) / total body irradiation (TBI) with and without etoposide (VP-16)~TBI/VP-16~Melphalan (Mel)/TBI (TBI regimens must include fully ablative doses ie > 1100 cGy; sequence of chemotherapy/radiation (CT/RT) flexible)~Busulfan (Bu)/Cy~Bu/Mel (non-TBI but fully ablative regimens/doses [Mel dose > 140 mg/m^2])~Fludarabine (Flu)/Mel (non-TBI but fully ablative regimens/doses [Mel dose > 140 mg/m^2])"
45505770|NCT04045795|Device|Investigational injector device|Subcutaneous administration
45505771|NCT03605940|Combination Product|Methoxsalen + ECP device|2 sessions per week during 4 weeks and 1 session per week during 8 weeks
45505772|NCT03605940|Drug|Corticosteroids|2 mg/kg/day
45505773|NCT02124980|Behavioral|Recovery Line|
45849730|NCT05288868|Other|Educational Intervention: online didactic lecture and educational simulation activity|"The didactic was created by the research team and provides information on Autism Spectrum Disorder (ASD) and an approach to taking vital signs in these children. The didactic will be pre-recorded and sent by email to employee study participants. The didactic will last about 10 minutes.~The simulation activity will have the premise of a child with ASD and their caregiver at clinic visit. The employee participant will be asked to take vital signs on the patient. The caregiver will be played by an actor and the child will be played by a mannequin. An iterative script will be used by the actor during the scenario. The simulation will last about 20 minutes and will be followed by a 10 minute debrief."
45849731|NCT05269758|Behavioral|activity-based resistance training of ingestive skills (ACT-ING-program)|The ACT-ING program is based on a task-oriented approach within motor behavior theories and combines resistance training principles with goal-directed and task-specific swallowing exercises in eating and drinking activities through a client-centered procedure informed by self-determination theory.
45397803|NCT00189488|Procedure|Allogeneic stem cell transplant|Allogeneic marrow/peripheral blood progenitor cell transplantation
45397804|NCT00189488|Drug|Methotrexate|
45397805|NCT03974906|Other|Applying goal-directed fluid therapy by continuous hemodynamic monitoring system (LiDCO）|Applying continuous hemodynamic monitoring system ( LiDCO) to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.
45397806|NCT03969290|Device|Verofilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
45505774|NCT03605472|Other|cervical ultrasound|cervical ultrasound will be realized by a endocinologist trained in the cervical ultrasound
45505775|NCT02125058|Procedure|Transcutaneous sutures|Conventional excision followed by subcutaneous sutrues and transcutaneous sutures
45505776|NCT02125058|Procedure|Intracutaneous sutures|Conventional excision followed by subcutaneous sutrues and intracutaneous sutures
45505777|NCT04421131|Device|Pocket colposcope/Mobile phone camera|The Pocket colposcope or mobile phone camera will be used to capture magnified digital images of the cervix
45697480|NCT05352711|Other|active assisted range of motion exercise|Patients were treated active assisted ROM physical therapy 2 sessions per week for 4 weeks.
45397807|NCT03969290|Device|Etafilcon A contact lenses|Daily disposable contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
45397808|NCT00233402|Drug|Hexvix|Single Instillation, Transurethral Resection of the Bladder
45505778|NCT04421131|Other|mIVAA|A mobile-phone-based telemedicine platform that enables remote consultation with an expert colposcopist
45697481|NCT00988156|Drug|Eslicarbazepine acetate (BIA 2-093)|"Part I - 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~The recommended target dose of double-blind study treatment will be 20mg/kg/day.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
45849732|NCT05268432|Procedure|Surgery with intraoperative imaging|laparoscopic, robot-assisted or other intraoperative imaging (ultrasound, CT, MRI)
45397809|NCT00233402|Procedure|Standard white light cystoscopy|
45397810|NCT00233324|Drug|Surfactant|Intubation and administration of surfactant by 1 hour of age.
45505779|NCT03607734|Drug|Amoxicillin|"A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:~50mg amoxicillin (10% total dose)~250mg amoxicillin (50% total dose)~200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available."
45505780|NCT02118272|Device|Physica KR|
45505781|NCT04167345|Drug|VX-814|Tablet for oral administration.
45505782|NCT04167345|Drug|Placebo|Placebo matched to VX-814 for oral administration.
45505783|NCT03605316|Procedure|Deep brain stimulation (DBS)|Neurosurgical treatment by stereotactic implantation of electrodes in the brain that affects the functioning of subcortical neuronal circuits
45505784|NCT01375153|Drug|BNP|3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours
45505785|NCT01375153|Drug|0.9% NaCl|0.9% NaCl administered as a continuous intravenous infusion during four hours
45505786|NCT02035488|Drug|Tobramycin|Tobramycin dry powder 30 mg inhalation per dose; Dose escalation: 30-60-120 and 240 mg, each one time. One dose per week.
45505787|NCT05196997|Other|Mobility and Functional Assessments|"The first evaluation was made on the day the patient was discharged from the intensive care unit. DEMMI, Bartel Index, Katz Activities of Daily Living Rating Scale and MRC Muscle Strength Test were performed to the patient, respectively.~De-Morton Mobility assessment for test-retest reliability was performed again on the 1st day of the patient's service."
45505788|NCT03602430|Drug|Cholecalciferol|Native vitamin D dose of 200IU to be given once per month to hemodialysis patients
45397811|NCT00233324|Device|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure/Positive End Expiratory Pressure (CPAP/PEEP) begun in the delivery room and continuing in the NICU
45397812|NCT00233324|Drug|Supplemental oxygen with target saturation of 85 to 89%|Supplemental oxygen in the range of 85% to 89% until the infant is no longer requiring ventilatory support or oxygen
45397813|NCT00233324|Drug|Supplemental oxygen with target saturation of 91 to 95%|Supplemental oxygen in the range of 91% to 95% until the infant is no longer requiring ventilatory support or oxygen.
45397814|NCT00023452|Drug|RPT + INH once weekly for 3 months given by DOT|"Rifapentine (RPT) 900 mg once-weekly x 12 doses (3 months) for persons > 50.0 kg. For persons < 50.0 kg, the following doses will be given (Weight/Dose): 10.0-14.0 kg / 300 mg; 14.1-25.0 kg / 450 mg; 25.1-32.0 kg / 600 mg; 32.1-50.0 kg / 750 mg.~PLUS~Isoniazid (INH) 15 mg/kg (rounded up to nearest 50 or 100 mg; 900 mg max) once weekly x 12 doses if > 12 years old. INH 25 mg/kg (round up to nearest 50 or 100 mg; 900 mg max) if 2-11 years old.~Therapy will be given by Directly Observed Therapy (DOT)."
45397815|NCT00023452|Drug|Isoniazid (INH) daily for 9 months|Isoniazid (INH) 5 mg/kg (rounded up to nearest 50 or 100 mg; 300 mg max) daily x 270 doses (9 months) For children age 2 - 11, INH 10-15 mg/kg (round up to nearest 50 or 100 mg; 300 mg max) will be given.
45505789|NCT03602430|Drug|Placebo|A Placebo ampule will be given to hemodialysis patients once per month with their standard treatment for 3 months period. Same color, odor and size, only without the active constituent.
45505790|NCT03626103|Behavioral|+ Brief ED Intervention (BI)|Brief ED Intervention (BI): A 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant
45505791|NCT03626103|Behavioral|+ Text|Text: 8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills. Those that do not show improvement in mood after 7 days will be randomized into LiveText.
45505792|NCT05196841|Behavioral|Anastatica Hierochuntica|During the sampling process, the researcher inquired through women who apply for pregnancy follow-up and contacted the mothers who had some inclusion criteria. Also, the researcher outlined the research plan and objectives. The participants were assessed based on the eligibility criteria and, if they were eligible and willing to participate in the study.
45505793|NCT02126852|Device|Acceleromyography (AMG, one-dimensionally)|Neuromuscular monitoring
45505794|NCT02126852|Device|Acceleromyography (AMG, three-dimensionally)|Neuromuscular monitoring
45505795|NCT02126852|Device|Electromyography (EMG)|Neuromuscular monitoring
45505796|NCT03605238|Biological|Corticosteroids & tanCART19/20|Twelve days of high-dose IV methylprednisolone (1000mg×3 days, 500mg×3 days, 240mg×3 days, 120mg×3 days) before anti-CD19/20 CAR T cells infusion. The dose is 1E5~2E6 anti-CD19/20-CAR positive T cells. The cells infusion process may last for 30 min.
45505797|NCT02455479|Biological|dAd5GNE Vaccine|dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
45505798|NCT02455479|Biological|Placebo|dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
45505799|NCT02252120|Device|Supreme|
45505800|NCT02252120|Device|Laryngeal Tube|
45505801|NCT04165941|Biological|DRI cell therapy|Drug Resistant Immunotherapy with gamma delta modified T cells to be resistance to temozolomide will be infused into the surgical cavity following the completion of standard concurrent radiation and chemotherapy with temozolomide.
45505802|NCT03605160|Procedure|traditional polish|After phacoemulsification and I/A, switch to polish mode and use I/A instrument to remove the RLFs visible on the posterior capsule before injection of viscoelastic agent. IOP: 55mmHg; Aspiration: 0-10; Vacuum: 0-20. The standard for stopping polish is that the RLFs can no longer be absorbed by the side holes on the I/A instrument in this mode, or there are no discernible RLFs on the posterior capsule. If RLFs on the posterior capsular are found after IOL implantation, polish to remove them after the removal of viscoelastic agents.
45697482|NCT00988156|Drug|Eslicarbazepine acetate|"Part I: 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
45697483|NCT02160730|Drug|R-roscovitine|See Arm Description
45397816|NCT03974516|Drug|Careseng 1370|Careseng 1370 should be taken around 1 hour before meal.
45397817|NCT03972878|Other|control snack|dry fruit snack (200 kcal) + 250 ml water
45397818|NCT03972878|Other|control cream|commercial spreadable cocoa and hazelnut cream (200 kcal)+ 250 ml water
45397819|NCT03972878|Other|cream version 1|commercial spreadable cocoa and hazelnut cream (200 kcal), version 1+ 250 ml water
45397820|NCT03972878|Other|cream version 2|commercial spreadable cocoa and hazelnut cream (200 kcal), version 2+ 250 ml water
45397821|NCT03972878|Other|cream version 3|commercial spreadable cocoa and hazelnut cream (200 kcal), version 3+ 250 ml water
45397822|NCT03972878|Other|control chocolate bar|commercial chocolate bar (200 kcal)+ 250 ml water
45397823|NCT03972878|Other|chocolate bar version 1|commercial chocolate bar (200 kcal), version 1+ 250 ml water
45397824|NCT01073072|Procedure|Conventional technique|Conventional technique to repair potentially contaminated incisional or abdominal wall hernias
45397825|NCT01073072|Procedure|Technique Tutomesh®|Technique of abdominal wall reconstruction or hernia repair strengthened by Tutomesh® in potentially contaminated environment.
45397826|NCT01088932|Drug|SRX246|capsules
45397827|NCT03969056|Behavioral|Artificial Intelligence (AI) Activity|The intervention provides participants with an automated and personalized daily step goal intervention involving a sophisticated activity analytics algorithm using advanced statistics and machine learning.
45505803|NCT03605160|Procedure|fluid-jet|After phacoemulsification and I/A, inject viscoelastic agent and implant IOL without polish. Use I/A instrument to remove viscoelastic agent. A 27G irrigating syringe was used, and the RLFs on the posterior capsule were gently aligned to make a fluid-jet basically parallel to the iris. The liquid pressure of 50-120 mmHg is produced. The standard for stopping in this mode is that the RLFs can no longer be washed down from the capsule, or there are no discernible RLFs on the posterior capsule.
45697484|NCT03329313|Drug|Lowering sodium concentration dialysate|Concentration of sodium in dialysate at 140 mmol/l
45697485|NCT03329313|Drug|Highing sodium concentration dialysate|Concentration of sodium in dialysate at 145 mmol/l
45397828|NCT03969056|Behavioral|10,000 steps|The intervention provides participants with an automated daily 10,000 step goal intervention
45397829|NCT01100554|Device|Sleep endoscopy|Conscious sedation will be done under intravenous propofol infusion. The sedative level would be monitored and adjusted accord to the Bispectral Index monitor. After the adequate sedative level is achieved, a bronchoscopy (Olympus, BF) was inserted from the right nostril. The velopharynx, oropharynx, larynx, and hypopharynx obstructions were evaluated.
45697486|NCT01896869|Drug|Ipilimumab|3 mg/kg administered IV (10mg/kg if treatment started prior to protocol v 6.3)
45849733|NCT05266170|Device|aerobic and anaerobic exercises|"[aerobic]~Aerobic treadmill walking program without EX1~Aerobic treadmill walking program with EX1~High-intensity interval exercise (HIIT) program with EX1~[anaerobic]~1. Fitness exercise program with EX1"
45397830|NCT03961048|Drug|Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution bilaterally|Variable initial post-operative dose of 10cc to 40cc bilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours bilaterally.
45697487|NCT01896869|Biological|Vaccine|5x10^8 cells administered in 6 intradermal injections
45397831|NCT03961048|Drug|Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution unilaterally|Variable initial post-operative dose of 10cc to 40cc unilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours unilaterally.
45397832|NCT01100632|Dietary Supplement|Ginseng, vitamins, minerals|2 capsules per day
45397833|NCT01100632|Other|Placebo - Gelatin capsule|2 capsules per day
45397834|NCT03949426|Drug|KPG-818|KPG-818 Capsules (1 mg, 5 mg and 20 mg) for oral administration is the drug substance powder filled in capsule (PIC) dosage form. KPG-818 Capsules and placebo capsules are packaged in HDPE bottle capped with HDPE cap.
45697488|NCT01896869|Drug|FOLFIRINOX|Standard of care FOLFIRINOX may be modified according to the patient's known tolerability. Acceptable modified options could include 5-FU alone, capecitabine, FOLFOX, FOLFIRI, or FOLFIRINOX on a 21 day cycle.
45697489|NCT03329001|Drug|Niraparib Tablet|Niraparib tablet formulation
45697490|NCT03329001|Drug|Niraparib Capsule|Niraparib capsule formulation
45697491|NCT04872465|Device|TBS|We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day. After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses).
45505804|NCT02260544|Drug|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.
45505805|NCT05470647|Biological|Interleukin-4 receptor responders 1|Interleukin-4 receptor was injected subcutaneously.
45505806|NCT05470647|Biological|Interleukin-4 receptor responders 2|Interleukin-4 receptor was injected subcutaneously.
45505807|NCT05470647|Biological|Placebo|Placebo was injected subcutaneously.
45505808|NCT03552848|Biological|MSC|MSC at a dose of 1000000 cells per kilogram of body weight will be given intravenously once every 4 days for 4 times
45505809|NCT04409665|Drug|Ketamine|Patient will be sedated using Ketamine 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
45397835|NCT03949348|Procedure|Mid-urethral sling placement using autologous rectus fascia|Mid-urethral sling placement using autologous rectus fascia
45397836|NCT03949348|Procedure|Mid-urethral sling placement using synthetic mesh|Mid-urethral sling placement using synthetic mesh
45505810|NCT04409665|Drug|Glucose|Patient will be sedated using Glucose 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
45505811|NCT02854800|Drug|varenicline|Participants followed the schedule of dosing that is specified on the label: 0.5 mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84).
45505812|NCT03552770|Drug|Bevacizumab|pro-re-nata repeated single or combined intra-vitreous injection of bevacizumab
45697492|NCT04872465|Device|sham|Participants will receive sham (placebo) TBS treatment the same as experimental group
45397837|NCT03949582|Other|Test food containing different types of dietary protein|"The test foods will be (in six study visits):~Soy mince/soup Chicken mince/soup Quorn mince/soup Soy mince/soup with guar gum Chicken mince/soup with guar gum Quorn mince/soup with guar gum"
45397838|NCT00022672|Drug|trastuzumab (Herceptin®)|4mg/kg iv loading dose, followed by 2mg/kg iv weekly
45397839|NCT00022672|Drug|anastrazole (Arimidex®)|1 mg tablet taken orally daily
45397840|NCT05626036|Device|Arthrex Tightrope|High-tensile strength suture syndesmosis repair
45397841|NCT05626036|Device|Synthes Fibulink|High-tensile strength suture syndesmosis repair
45397842|NCT00076804|Behavioral|Directly Observed Therapy|Use of a patient nominated peer supporter who will observe the morning dose of ARVs
45397843|NCT00141453|Drug|olmesartan medoxomil|Tablets 10, 20, or 40 mg
45397844|NCT00141453|Drug|Placebo Tablets|Matching placebo tablets
45397845|NCT00076570|Drug|Sirolimus|
45505813|NCT01373827|Device|VASERShape MC1|Use of the VASERShape MC1 device as part of routine practice
45505814|NCT04091295|Drug|DeltaRex-G|Intravenous infusions of DeltaRex-G for treatment of advanced pancreatic cancer and sarcoma that have failed standard therapies
45505815|NCT02118350|Behavioral|Mat Pilates Training|Mat Pilates training performed two times at week for 16 weeks.
45505816|NCT05196139|Other|retrospective study|vitrectomy performed in case of submacular bleeding
45505817|NCT02125214|Device|Target Controlled Infusion system (Orchestra Base Primea, Fresenius, France)|Intravenous induction with propofol using the pharmacokinetic model by Schnider et al. The initial cerebral concentration will be 0.5 µg ml-1, which will be increased stepwise by 1.0 µg ml-1 until 2.5 µg ml-1, and then by 0.5 µg ml-1 until loss of consciousness
45505818|NCT01375231|Procedure|Measured Resection of patellofemoral joint|The goal is to remove an amount of bone from the patella so that when reconstructed, the composite thickness of the entire prosthetic patellofemoral joint is recreated
45505819|NCT01375231|Procedure|Measured resection of patella|The thickness of the anterior condyle is not considered in this measurement. The goal is to restore the composite thickness of the patella only.
45697493|NCT01896557|Drug|omeprazole|Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.
45697494|NCT01896557|Drug|Ranitidine|Influence of ranitidine on clopidogrel pharmacodynamics will be evaluated.
45697495|NCT01896557|Drug|Clopidogrel|Clopidogrel added to ASA therapy at the first medical visit, Open label 75 mg once a day will be given to all individuals as part of the protocol (since main outcome of interest is clopidogrel effect. Actual comparison arms are double blind ranitidine and omeprazole
45697496|NCT02160808|Drug|Secretin|Drug to stimulate pancreatic secretion
45697497|NCT02160808|Drug|Placebo|
45697498|NCT05492799|Drug|AX 250|biweekly infusion by intracerebroventricular (ICV) infusion
45397846|NCT00076570|Drug|Tacrolimus|
45397847|NCT01079871|Other|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
45397848|NCT03966963|Behavioral|Eye Movement Desensitization Reprocessing (EMDR)|Trauma-Focused Therapy
45505820|NCT02035098|Other|the Pac-IFicO programme|The Pac-IFicO programme is a complex interventions with multiple components. It includes focus group with ward professionals for identifying possible local obstacles to optimal pain control, informative material for the patients, an educational programs performed through guides from the wards, and an organisational intervention to the ward.
45505821|NCT04394923|Procedure|Modification of the pulmonary vein ablation line|The ablation line previously drawn will be modified regarding the esophageal print position in order to avoid RF application within the red layer of the esophageal print.
45505822|NCT04394923|Procedure|Regular PVI ablation|Blinded to the esophageal position based on the type of AF, closer to the ostium for paroxysmal AF and wider for persistent AF
45505823|NCT02125370|Other|Qualitative and survey|
45505824|NCT03605082|Drug|UCB0107|"Pharmaceutical form: solution for infusion~Route of administration: intravenous use"
45505825|NCT03605082|Other|Placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous use"
45397849|NCT00124449|Drug|Abatacept|"solution, intravenous injection, monthly, 169 days~weight based:~<60 kg = 500 mg~60 to 100 kg = 750 mg~>100 kg = 1 g"
45505826|NCT02126930|Other|Pharma consult|Upon hospital discharge, patients randomized to the experimental arm will have a pharmaceutical consultation concerning their anti-infectious treatment.
45505827|NCT02126930|Other|Routine care|Patients randomized to this arm will receive care in the habitual manner.
45505828|NCT03602274|Diagnostic Test|Hepatic function monitoring|AST, ALT, GGT, AP, Bilirubin
45505829|NCT03602274|Diagnostic Test|Nutritional status assesment|PINI, MNA nutritional assessment, PG-SGA assessment, anthropometric measurements
45505830|NCT03602274|Other|Biomarker research sampling|Blood collection for proteomic, genetic, metabolomic and microRNA transcriptomic profiling
45505831|NCT02118506|Other|Physical practice|"The control group underwent familiarization of gait phases using cards with gait phases and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases. Then, they were submitted to a physical gait training. They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
45505832|NCT02118506|Other|Mental and physical practice|"The experimental group underwent familiarization of gait phases using cards with gait phases, mental practice of gait and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Then, they were submitted to a mental training of gait. They imagined the gait steps per 400 repetitions. While imagining, they verbalized the gait phases.~Finally, they were submitted to a physical gait training. They executed 400 steps.~They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
45505833|NCT05376384|Diagnostic Test|ultrasound parameters|Annotation of ultrasonographic features of ovarian cyst. The parts examined are size, laterality, content, margins, and color score.
45505834|NCT05376384|Procedure|intraoperative parameters|Annotation of intraoperative features of ovarian cyst. The characteristics under review are: surgeon experience, previous surgery, adhesions, and uterine manipulator use
45505835|NCT02127008|Procedure|Resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was resected.
45505836|NCT02127008|Procedure|No resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was not resected.
45505837|NCT05195905|Device|PMEG|All devices that will be modified in this study protocol are commercially available in the United States. The commercially available endografts will be used to construct a fenestrated/branched device for this intervention.
45505838|NCT02127164|Device|"Veraflo device, Dakin's solution"|Veraflo device will be installed on the wound to create negative pressure after surgery. Dakin's solution will be instilled through this device into the wound at the regular intervals.
45505839|NCT02931539|Drug|Maribavir|Maribavir 400 milligrams (mg) (2x200 mg tablets) will be administered twice daily for 8 weeks.
45505840|NCT02931539|Drug|Ganciclovir|Ganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
45505841|NCT02931539|Drug|Valganciclovir|Valganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
45697499|NCT01886105|Drug|Sm-EDTMP|"Subjects receive a tracer infusion of Samarium-153 EDTMP at 1 mCi/kg. 3D dosimetry using SPECT images are obtained post tracer infusion to determine the distribution of dose delivered to the tumor and surrounding normal tissues. Tracer activity will be applied to development of the external beam radiation (EBT) planning. Second treatment infusion of Samarium will then be implemented. Maximum activity administered will be 30 mCi/kg."
45697500|NCT01886105|Other|Autologous Stem Cell Infusion|"Administered 14 days after Treatment infusion of Samarium-153 EDTMP."
45397850|NCT00124449|Drug|placebo|solution, intravenous injection, 0 mg, monthly, 169 days
45397851|NCT00076336|Drug|Telbivudine|600mg/day oral tablet for 104 weeks
45397852|NCT00076336|Drug|Lamivudine|100mg/day oral tablet for 104 weeks
45397853|NCT00076336|Drug|Placebo|Telbivudine matching placebo or lamivudine matching placebo tablet.
45397854|NCT05626504|Device|Pipeline Embolization Device with Vantage Technology|Flow-diverter device occludes aneurysms through endoluminal reconstruction and remodelling of the parent artery.
45397855|NCT00185588|Drug|Vatalanib|Vatalanib 250 mg PO Q12 hours x 7 days, 8th day forward 500 mg PO Q12 hours
45505842|NCT02931539|Drug|Foscarnet|Foscarnet as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
45505843|NCT02931539|Drug|Cidofovir|Cidofovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
45505844|NCT03602196|Other|Perineal ultrasound assessment|"women were assessed in lithotomy position with an empty bladder at rest, perineal contraction and Valsalva maneuver using a linear translabial probe. We measure the distance between symphysis and ano-rectal angle. In the same position we investigate the levator ani viscoelastic properties using shear wave elastography at rest, Valsalva maneuver and maximal contraction. During the same examination, we assess the viscoelastic properties of the external anal sphincter using shear wave elastography for the 3 conditions: rest, Valsalva, contraction.~This pelvic floor muscles assessment is performed for each of the three planned visits~For the ancillary study on non pregnant women: viscoelastic properties of levator ani are assessed at rest, stretch and contraction using shear wave elastography.~This pelvic floor muscle assessment is performed for each of the two planned visit in the ancillary study."
45505845|NCT03602196|Other|Peripheral muscles assessment|"The visco elastic properties of the biceps brachii muscle and the gastrocnemius medialis muscle are assessed rest, stretch and maximal contraction using shear wave elastography.~This peripheral muscle assessment is perform for each of the three planned visits.~For the ancillary study on non pregnant women: viscoelastic properties of biceps brachii and gastrocnemius medialis muscles are assessed at rest, stretch and contraction using shear wave elastography.~This peripheral muscles ultrasound assessment is performed for each of the two planned visit in the ancillary study."
45505846|NCT03602196|Other|Clinical pelvic floor assessment|"Women undergo a pelvic floor assessment using the Pelvic organ prolapse quantification system. Such an assessment is performed for each of the three planned visits.~Women included in the ancillary study are not involved with this examination"
45505847|NCT02125448|Device|MRI and PET-CT|
45505848|NCT05195671|Other|Review|Reviewing all protocols
45505849|NCT02125526|Device|Intra-aortic balloon pump|The intra-aortic balloon pump is placed in the descending thoracic aorta and inflates and deflates in synchrony with the cardiac cycle, providing diastolic augmentation and improving coronary blood flow, while deflating before systole, providing afterload and workload reduction for the myocardium.
45697501|NCT01886105|Radiation|External Beam Radiotherapy|"The radiotherapy portion of the combined plan will be delivered according to the judgement of the treating radiation oncologist. The total dose to be used will be modified based on surrounding tissue tolerances as evidenced by Samarium infusion and SPECT image planning.~After the treatment infusion, SPECT scans will again be performed to confirm the total dose delivered and subsequently adjust the EBT portion of the treatment plan, as necessary."
45697502|NCT03327909|Behavioral|TAKE vs. HOLD|All participants will be told to take once daily antihypertensive medications at night. Timing of other antihypertensive medication administration will differ depending on whether the participant is randomized to the TAKE or HOLD arm.
45849734|NCT05259462|Behavioral|Intervention|Participants will utilize low-cost, consumer available head-mounted displays to meet with peers and coaches online. The program will last 4 weeks and include 2 x 1-hour sessions per week of supervised peer-to-peer gaming. The coaches will utilize behavioral change and mindfulness techniques to promote autonomy, competence, and relatedness through a respectful, cohesive, and positive atmosphere. These strategies will be framed by the Self-Determination Theory and learned from the National Center on Health, Physical Activity, and Disability (NCHPAD) mindfulness coaching workshops. Some of the mindfulness-based strategies will include guided breathing focused exercises, body scanning, meditation, and acceptance of social anxiety and shyness
45849735|NCT05257746|Procedure|Rectal resection|Open or minimally invasive rectal resection with total mesorectal excision
45849736|NCT05251428|Procedure|Excision of the A1 pulley|Participants will undergo excision of the A1 pulley. Wounds will then be irrigated and closed in the standard fashion.
45397856|NCT00185588|Drug|Gemcitabine|850 mg/m2
45397857|NCT01074398|Genetic|gene expression analysis|
45397858|NCT01074398|Genetic|polymorphism analysis|
45397859|NCT01074398|Genetic|protein expression analysis|
45397860|NCT01074398|Other|immunohistochemistry staining method|
45505850|NCT05195593|Device|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
45505851|NCT03602118|Drug|Phenobarbital Sodium Injection|Phenobarbitone Inj, Phenobarbitone SOD, Phenobarbitone Sodium
45505852|NCT02131142|Device|BioFreedom drug coated coronary stent|Placement of a BioFreedom drug coated stent in a narrow coronary artery
45505853|NCT01375309|Dietary Supplement|Bifidobacterium bifidum supplementation|Bifidobacterium bifidum supplementation wiht approximately 2.5*10to9th bacteria per day
45505854|NCT01375309|Dietary Supplement|Placebo contains dextrin|0.5 of dextrin
45697503|NCT00989014|Drug|CD07805/47|0.5% Topical Gel
45397861|NCT01074398|Other|laboratory biomarker analysis|
45397862|NCT01074476|Dietary Supplement|Glucosamine sulphate|750mg glucosamine sulphate (oral tablets), twice per day for 3 months
45397863|NCT01074476|Other|Placebo|Placebo tablets, twice per day for 3 months
45397864|NCT00232544|Device|Telecommunications system|The telecommunications system is designed to improve patient adherence with prescribed positive airway pressure.
45397865|NCT00232544|Other|TLC-Control|A TLC system for providing general health education
45397866|NCT03974126|Other|40 grams of starch|40 grams of starch in form of white bread to be consumed within 15 minutes
45397867|NCT03974126|Other|80 grams of starch|80 grams of starch in form of white bread to be consumed within 15 minutes
45697504|NCT00989014|Drug|CD07805/47|0.18% Topical Gel
45697505|NCT00989014|Drug|CD07805/47|0.07% Topical Gel
45397868|NCT00231842|Drug|Ifosfamide|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg/IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
45397869|NCT00231842|Device|Radiation Therapy|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg /IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
45397870|NCT00231842|Drug|Cisplatin|dosage is 20 mg/m2/day for 5 days, ever 3 weeks.
45397871|NCT01073150|Drug|Tea Tree Oil|Tea Tree Oil shampoo 0.25% and ointment 5% daily and Tea Tree Oil oily solution 50% once a week for six weeks
45397872|NCT00076102|Drug|Pirfenidone|Pirfenidone orally as capsules three times a day approximately every 8 hours for cycles of 28 days with no rest period between cycles (28 day treatment cycles); 500 mg/m^2 every 8 hours (1500 mg/m2/day).
45397873|NCT03968588|Drug|Tacrolimus(reduced), Mycophenolate mofetil(standard)|tacrolimus target trough blood level: 3~8ng/mL MMF dose: 1.5~2g/d
45397874|NCT03968588|Drug|Tacrolimus(standard), Mycophenolate mofetil(reduced)|tacrolimus target trough blood level: 5~15ng/mL MMF dose: 0.5~1g/d
45397875|NCT05625880|Device|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place
45397876|NCT03974282|Behavioral|Psychological task|Participants will complete a psychological task that evokes antisocially- and prosocially-motivated empathic responding
45397877|NCT01582646|Drug|Terbutaline sustained release 5 mg|Terbutaline 10mg oral per day (5 mg twice a day) during 28 days
45397878|NCT03741452|Other|transversalis fascia plane block|patient controlled analgesia devices with tramadol
45397879|NCT00231062|Device|Sinuplasty|
45397880|NCT03974360|Drug|AMG 334|100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
45397881|NCT00184028|Drug|Taxotere|Taxotere is given at 60 mg/m2 as a 1-hour intravenous infusion.
45397882|NCT00184028|Drug|Oxaliplatin|Oxaliplatin will be administered intravenously over 2 hours at a rate of 10mg/m2/min. on day 1 every 3 weeks.
45397883|NCT00183872|Drug|irinotecan, docetaxel|docetaxel 30 mg/m2 IV infusion days 1 and 8, with irinotecan 65 mg/m2 IV infusion on days 1 and 8.
45397884|NCT03815175|Device|XIENCE|Subjects who received XIENCE family stent systems will be included.
45397885|NCT03815175|Drug|DAPT (aspirin and/or P2Y12 receptor inhibitor)|"1-month clear subjects (pooled from Xience 28 USA study and Xience 28 Global study) will receive 1 month of DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for > 7 consecutive days and will discontinue P2Y12 receptor inhibitor as early as 28 days and will continue with aspirin monotherapy through 12-month follow-up."
45397886|NCT01076127|Behavioral|Ketllebell training|Kettlebell training 3 x 20 min a week for 8 weeks
45397887|NCT01076127|Behavioral|Control|Receives a health examination before and after the intervention period, and are advised to stay active.
45697506|NCT00989014|Drug|CD07805/47 placebo|Vehicle Topical Gel
45697507|NCT05095012|Other|Pediatric Acute Care Concussion Clinical Pathway|MD assessment will be partially standardized to assess for patients at higher risk of becoming persistently symptomatic. These patients scoring as 'high risk' will be referred to one of three specialty clinics. High risk is defined as scoring 9 or higher out of 12 on the 5P score.
45849737|NCT05251428|Procedure|Incision of the A1 pulley in the standard fashion|Participants will undergo incision of the A1 pulley in the standard fashion. Wounds will then be irrigated and closed in the standard fashion.
45397888|NCT01080027|Drug|Rebif® New Formulation|The recommended dose of Rebif® is 22 or 44 μg administered three times per week by subcutaneous injection.
45397889|NCT00262028|Biological|MenACWY-CRM Vaccine|
45397890|NCT00262028|Biological|MenACWY-PS Vaccine|
45397891|NCT00183248|Drug|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous (IV) infusion on Days 0 and 4
45397892|NCT00183248|Drug|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 0 until withdrawal or end of the study
45397893|NCT00183248|Drug|Sirolimus|Immunosuppressant; oral daily dose starting between Months 4 and 6 post-transplant until withdrawal or end of the study
45697508|NCT03262779|Biological|combination nivolumab and ipilimumab|Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, with ipilimumab 1 mg/kg administered IV every 6 weeks.
45697509|NCT05593120|Diagnostic Test|CT-FFR|"In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis 30%-90% data in at least one major epicardial vessel will be referred for CT-FFR. In patients in whom CT-FFR analysis is performed, FFR will be derived for all vessels. CT-FFR will be evaluated in a blinded fashion with a Coarse-to-Fine Subpixel algorithm for lumen contour. The data derived from this test will determine their management strategy."
45697510|NCT05593120|Diagnostic Test|Routine care|All patients in the routine care group will be assessed according to their current conventional pathways that are based upon routine practice in Wuhan Asia Heart Hospital. The trial will encourage the routine and standard assessment and management of all patients (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance).
45697511|NCT03262467|Procedure|Aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun)|In patients with aneurysm of native vascular access indicated for surgical treatment, aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun) wil be performed.
45697512|NCT00990964|Device|Attain Success Lead|Attain Success Lead
45849738|NCT05248854|Other|Sensorimotor exercise training|The program included side stepping, tandem walking, perturbation exercise, overcoming mini obstacles, walking different surfaces and traditional hip and knee exercise. Participants applied these exercise as home program between postoperative second weeks and 8th weeks, 3-5 day /week , 20 25 min every session.
45397894|NCT00183248|Drug|Tacrolimus|Immunosuppressant; daily dose starting Day 1 until withdrawal or end of the study
45397895|NCT00183248|Procedure|Donor bone marrow stem cell infusion|2 doses of kidney donor's bone marrow stem cells by IV infusion on Day 5 and sometime between Months 4 and 6
45397896|NCT00183248|Procedure|Kidney transplant|Occurs at study entry
45397897|NCT00183170|Drug|Alcohol|Participants report for their first dosing night where they receive several alcohol/beer drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose. Participants return in a week for the 2nd session and receive placebo drinks. Participants are breath-tested after completing their placebo drinks.
45397898|NCT00183170|Other|Placebo|Participants report for their first night where they receive several placebo drinks. Participants are breath-tested after completing their placebo drinks. Participants return in a week for the 2nd session and receive alcohol drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose.
45849739|NCT05248854|Other|Core stabilization exercise training|Core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research.core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research
45397899|NCT00230282|Drug|Alemtuzumab|3 to 30 mg, IV
45397900|NCT00230282|Drug|Fludarabine|[(2R,3R,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)- 3,4-dihydroxy-oxolan-2-yl]methoxyphosphonic acid
45849740|NCT05244174|Device|Pancreatic stent|Insertion of a pancreatic stent during ERCP to improve pancreatic secretion
45397901|NCT00230282|Drug|Cytoxan|(RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
45849741|NCT05241522|Diagnostic Test|Tc-99m-Tilmanocept|Administration of 3 different doses of Tc-99m-Tilmanocept prior to SPECT-CT imaging of the kidney in order to determine the safety and efficacy of tilmanocept imaging for differentiating diabetic kidney disease from other causes of kidney disease.
45505855|NCT03604848|Drug|WHO-approved MDR-TB regimen|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, >70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, >70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily All treatment is taken daily.
45505856|NCT03604848|Drug|NGS-guided regimen: Regimen A|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, >70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, >70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily All treatment is taken daily.
45849742|NCT05235750|Behavioral|Self-affirmation writing|Writing with a focus on self-affirmation at the time following a diagnosis of an advanced cancer
45849743|NCT05226858|Diagnostic Test|Transesophageal echocardiography (TEE)|Sensitivity and specificity of TEE in identification of BTAI
45505857|NCT03604848|Drug|NGS-guided regimen: Regimen B|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, >70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, >70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily All treatment is taken daily.
45505858|NCT03604848|Drug|NGS-guided regimen: Regimen C|"Based on the drug susceptibility test results, the resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as linezolid, clofazimine or ethambutol.~The dose of linezolid, clofazimine or ethambutol as follows:~Linezolid: 600 mg daily, clofazamine: 33-50kg 50 mg daily, 51-70kg 100 daily, >70kg 100 mg daily; ethambutol: 33-50kg 800 mg daily, 51-70kg 800 daily, >70kg 1200 mg daily;"
45505859|NCT02125682|Drug|atovastatin 10 mg/day|patients will receive 10 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 80 mg daily for 8 weeks
45505860|NCT02125682|Drug|Atorvastatin 80 mg/day|patients will receive 80 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 10 mg daily for 8 weeks
45849744|NCT05218668|Drug|Fasudil (WP-0512)|Oral fasudil up to 240 mg/day
45397902|NCT00261950|Drug|Sensipar (Cinacalcet HCl)|All enrolled subjects receive study medication at a starting dose of 30 mg cinacalcet once daily beginning on day 1. Possible sequential doses are 30 mg, 60mg, 90mg, 120mg, 180 mg taken once daily. During the study, dose adjustment (dose increase/decrease/withholding) is based upon iPTH, serum calcium, and subject safety information. Subjects swallowed tablets whole without biting or chewing. Subjects were dispensed investigational product every 4 weeks starting from Day 1 through to Week 48.
45397903|NCT01071434|Procedure|MR Imaging|
45397904|NCT00230048|Behavioral|Brief computer-delivered intervention|Brief (20-minute) computer delivered intervention, plus two subsequent non-tailored mailings.
45397905|NCT00229658|Drug|pramlintide acetate|Subcutaneous injection prior to each major meal
45397906|NCT00182078|Drug|Placebo|The placebo was administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the placebo was tapered at a rate of 25mg every 3 days until it was discontinued.
45505861|NCT03602040|Behavioral|PISICC|"PISICC consists of:~Standard disease-specific information leaflet~Personalised lifestyle consideration form~1-hour group session with up to 10 participants facilitated by the PhD student who is also an experienced cardiac genetic nurse. This will include discussions of 2 scenarios (communicating with clinicians and communicating with family) and a question and answer session based on the personalised lifestyle consideration form Components a) and b) will be given to the patient after the baseline assessment and there will be an interval of 2 weeks before the participants attend for component c)."
45505862|NCT03551444|Drug|Administration of DAA-based treatment|"Antiviral therapy and treatment duration (12/24 weeks) will be indicated in each patient according to the viral genotype/subtype and the severity of liver disease, in accordance with the EASL Recommendations on Treatment of Hepatitis C 2016.~HCV-RNA quantification will be assessed by real-time PCR, with a limit of detection (LOD) of15 IU/mL.~During antiviral treatment, follow-up of the Patients will be monthly by clinical and laboratory evaluation.~Virological response to DAA-based treatment will be assessed by quantitative HCV-RNA at the end of treatment (EOT) and at 4 and 12 weeks after the EOT, to confirm sustained virological response (SVR).~SVR12 is defined as undetectable HCV-RNA at week 12 after the EOT.~Virological failures and early discontinuations of therapy due to adverse events will be also registered."
45505863|NCT03604770|Other|Survey & Food Diary|Patients will be provided with a 8 question patient survey to complete and return, as well as a food diary that they will complete over a 3 day period to assess their average caloric intake.
45505864|NCT02125760|Other|Inspiratory Muscle Training (IMT)|Sham IMT at a fixed workload of 10 cmH2O. 5 sets of 10 repetitions, twice a day, 7 days per week, for 4 weeks.
45505865|NCT02125760|Other|High-intensity IMT|High Intensity IMT. The training load is the maximum inspiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), twice a day.
45505866|NCT05760391|Radiation|Radiotherapy|IMRT or SABR for patients with ESCC.
45505867|NCT03604614|Drug|Hyperthermic Intraperitoneal Chemotherapy|The investigators use Paclitaxel as peritoneal hyperthermic perfusion chemotherapy drugs，75mg/m2 for the first time，50mg/m2 for the second time and third time.The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area <1.25m2 40mg/time, 1.25-1.50m2 50mg/time, >1.50m2 60mg/time.
45505868|NCT03604614|Drug|Without Hyperthermic Intraperitoneal Chemotherapy|The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area <1.25m2 40mg/time, 1.25-1.50m2 50mg/time, >1.50m2 60mg/time.
45505869|NCT01361945|Drug|AUY922|AUY 922 is given intravenously weekly; letrozole and lapatinib are given orally
45505870|NCT03601962|Dietary Supplement|Aqualief|400mg oral mucoadesive tablets
45505871|NCT03601962|Other|Placebo|400mg Placebo oral mucoadesive tablets
45505872|NCT02127242|Procedure|ureteroscopic air-pressure ballistic lithotripsy|In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
45505873|NCT02237430|Device|MynxGrip|Closure device for femoral artery access closure
45697513|NCT03299751|Biological|Diagnostic performances of biomarkers combination|"A blood sample of 400µL will be drawn at inclusion, when neonatal sepsis is suspected, at the same time of a venipuncture prescribed for standard care.~The dosage of 11 biomarkers will be performed in a central laboratory. The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patients), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results.~The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patientsconfirmed infection, refuted infection), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results."
45697514|NCT05022394|Biological|Nivolumab|Given IV
45697515|NCT05022394|Drug|Sapanisertib|Given PO
45849745|NCT05211882|Other|Immediate ENABLE nurse coaching, on top of usual care|Participants in the intervention arm will start on the ENABLE program at point of randomization
45397907|NCT00182078|Drug|Sertraline|The drugs were administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the medication was tapered at a rate of 25mg every 3 days until it was discontinued.
45397908|NCT03968510|Procedure|parathyroidectomy|routine parathyroidectomy will be done for the treatment of adenoma
45397909|NCT00181844|Drug|lamotrigine|Open-label, flexible-dose, BID treatment of lamotrigine (Lamictal). For children <12 years, dosing began at 0.35 mg/kg/day, divided in 2 doses, rounded down to nearest 5mg, to be increased weekly depending on response and tolerability to maintenance dose of 5-15 mg/kg/day (maximum 400 mg/day in 2 divided doses). For children ≥12 years, dose began at 25 mg/day in 1 dose, to be increased weekly depending on response and tolerability to maintenance dose of 300-500 mg/day in 2 divided doses.
45397910|NCT00181766|Drug|Strattera (atomoxetine)|Up to maximum of 1.2mg atomoxetine/kg PO QD, or 120 mg atomoxetine PO QD (whichever is less).
45397911|NCT00180674|Drug|Warfarin|
45397912|NCT01074632|Drug|Lurasidone HCl|
45397913|NCT00076024|Drug|Placebo|5 mg twice daily [bid] continuous dosing
45397914|NCT00076024|Drug|Docetaxel|Standard of care drug administration
45397915|NCT00076024|Drug|AG-013736 (axitinib)|5mg twice daily [bid] continuous dosing
45397916|NCT00076024|Drug|Docetaxel|Standard of care drug administration
45505874|NCT02237430|Other|Manual compression|Conventional manual compression
45505875|NCT02546999|Drug|botox|The agent will be given only once at point zero in the time scheme for the project.
45505876|NCT02546999|Drug|placebo|The agent will be given only once at point zero in the time scheme for the project.
45505877|NCT02131220|Drug|Prourokinase|20mg intracoronary bolus infusion using selective catheter during PCI
45505878|NCT02131220|Drug|Tirofiban|10ug/kg intracoronary bolus infusion using selective catheter during PCI
45505879|NCT02131220|Drug|normal saline|intracoronary bolus infusion using selective catheter during PCI
45505880|NCT05195203|Drug|HS-10353|Single or multiple dose(s) of HS-10353
45505881|NCT05195203|Drug|Placebo|Single or multiple dose(s) of placebo
45505882|NCT03601884|Behavioral|Optimal Health Program|The Optimal Health Program (OHP) is a self-management psychosocial program that promotes patients to be actively involved in their own healthcare and overall well-being. Sessions include Optimal Health, I-CAN-DO Model, Medication & Metabolic Monitoring, Collaborative & Strategies, Change enhancement, Visioning & Goal Setting and Maintain Well-being.
45505883|NCT03601884|Other|Treatment as Usual|"Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
45505884|NCT03550664|Device|Monitoring of neuromuscular transmission|Monitoring of neuromuscular transmission will be done by TOFScan (IdMed, Marseille, France). This device is CE marked, and is used routinely in daily clinical practice. Prior to induction of anesthesia, the TOFScan is placed on a patient's hand and the two stimulation electrodes (ECG electrodes) are placed at the level of the ulnar nerve at the wrist. After induction of anesthesia and before administration of a curare, the TOFScan is calibrated according to the manufacturer's instructions. The TOFScan is placed in automatic mode, it will then automatically adapt its mode of stimulation to the depth of the curarization. The TOFScan measurements will be recorded on a PC connected to the TOFScan.
45849746|NCT05211882|Other|Usual Care|Participants on wait-list will continue on usual care and only start ENABLE 6 months after randomization.
45505885|NCT04042077|Drug|Delafloxacin|Powder for solution for infusion 300 mg or tablet 450 mg, BID, for 5 to 14 days
45505886|NCT04042077|Drug|Vancomycin|Powder for solution for infusion 15mg/kg, BID, for 5 to 14 days
45505887|NCT04042077|Drug|Linezolid|Solution for infusion or tablet, 600 mg BID, for 5 to 14 days
45505888|NCT04042077|Drug|Piperacillin/Tazobactam|Powder for solution for infusion 4/0.5 g, TID, for 5 to 14 days
45505889|NCT04042077|Drug|Tigecycline|Powder for solution for infusion 50 mg, TID, for 5 to 14 days
45505890|NCT03557359|Drug|Nivolumab|Nivolumab (Opdivo®) is a human monoclonal antibody (HuMAb; immunoglobulin G4 (IgG4)- S228P) that targets the PD-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.
45849747|NCT05199246|Device|Lower-limb powered dermoskeleton|Patients and healthy subjects will wear the movement assistance device to perform different standardised physical evaluations.
45849748|NCT05182164|Drug|Association of pembrolizumab + cabozantinib|"A treatment cycle consists of 3 weeks. Pembrolizumab will be administered intraveinously on day 1 every 3 weeks (200 mg).~Cabozantinib will be administered per os, once daily (40 mg), and given on a continuous basis."
45849749|NCT05167110|Dietary Supplement|Placebo|Children assigned to the groups (ASD/ADHD) will be randomly prescribed placebo supplementation for 12 weeks (placebo subgroup).
45849750|NCT05167110|Dietary Supplement|Probiotic|Children assigned to the groups (ASD/ADHD) will be randomly prescribed supplementation with two GABA- and dopamine-producing strains at a total of 1 x 10 (9) CFU/capsule for 12 weeks (probiotic subgroup).
45849751|NCT05141370|Device|cataract surgery with CATSYS|patient diagnosed with cataract requiring surgery will have an anterior capsulorhexis with CATSYS
45505891|NCT03550586|Other|Questionaires|Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS)translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire . Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire .
45697516|NCT01895777|Drug|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
45697517|NCT01895777|Drug|standard of care|Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
45697518|NCT05005936|Procedure|Ultrasonography|Undergo ABUS
45697519|NCT05005936|Procedure|Ultrasonography|Undergo WBUS
45697520|NCT03299205|Behavioral|Exercise|The exercise intervention consists of moderate intensity aerobic exercise intervention that will include the wearing of an accelerometer (i.e. Fitbit Zip) to monitor daily activity and steps. Aerobic exercise will be conducted over 10-weeks in PLWHA +/- AUD. The programs will consist of aerobic exercise 3 days per week of moderate intensity for 30-45 minutes each session with the goal of achieving 135 minutes per week. The program will begin at low-moderate intensity and progress to higher intensity exercise after week 4 of the program. All exercise will be completed on a treadmill and supervised by study staff. Each participant will be provided with a Fitbit Zip to monitor daily activity and steps with a goal of 7000 steps per day.
45505892|NCT03626025|Other|Spaced learning|Instead of learning over a single session, teaching is carried out over a few weekly sessions but maintaining the overall total number of hours spent on teaching
45505893|NCT02127320|Drug|Rosuvastatin 20mg|
45505894|NCT02127320|Drug|Ezetimibe 10mg|
45505895|NCT02127320|Drug|Rosuvastatin 20mg + Ezetimibe 10mg|
45505896|NCT03604380|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
45505897|NCT03604380|Other|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
45397917|NCT05626426|Device|Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina
45397918|NCT01103050|Drug|QAV680 + Cetirizine Placebo|
45397919|NCT01103050|Drug|QAV680 + Cetirizine|
45397920|NCT01103050|Drug|Cetirizine + QAV680 Placebo|
45397921|NCT01103050|Drug|QAV680 Placebo + Cetirizine Placebo|
45397922|NCT01102816|Other|Individualized acupuncture treatment|"Individualized acupuncture treatment which focuses on each patient's symptoms and conditions will be provided twice a week for 6 weeks on a non-dialysis access day or before hemodialysis at dialysis-access day. 10-20 acupuncture needles will be inserted on the body except the arteriovenous fistula-located arm(s). Electrical stimulation of acupuncture will be conducted on 4 needles and the remained needles will be manipulated manually to elicit de-qi sensation. Needle retention time will be 20 minutes.~Routine care provided by dialysis staffs, primary physicians and other healthcare providers will be maintained.~Patients who received acupuncture treatment will be interviewed to explore patient's perceptions and experiences of acupuncture for their pain management. (Nested-qualitative study)"
45397923|NCT01102816|Other|Routine care|Patients in this group will maintain routine care provided by their dialysis staffs, primary physicians or other healthcare providers for symptomatic care and disease management of end-stage renal disease through 6 weeks. After post-treatment evaluation, acupuncture treatment will be provided to patients who want to receive acupuncture treatment.
45397924|NCT00075478|Procedure|Total-Body Irradiation|Undergo TBI
45397925|NCT00075478|Drug|Fludarabine Phosphate|Given IV
45397926|NCT00075478|Drug|Mycophenolate Mofetil|Given PO
45397927|NCT00075478|Drug|Cyclosporine|Given PO
45397928|NCT00075478|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
45397929|NCT00175916|Drug|Brivaracetam (ucb 34714)|10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.
45397930|NCT01089088|Drug|cisplatin|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 & 8) Sunitinib 37.5mg (po days 2 to 15)"
46057053|NCT02778321|Device|Uses of SpiderFlash monitor|"Investigators will use the SpiderFlash®, Holter monitor (technology Secure Data) to have a storage capacity enabling a registration up to 30 days with sufficient autonomy.~The data collected :~Demographic data: age, sex, vascular risk factors, antithrombotic therapy at the entrance, history of Transient Ischemic Accident (TIA) or Cerebral infarct (CI)~Data on the CI:~Monitoring Results scope ICU Neurovascular.~Presence palpitations~Treatment influencing the rate (beta-blockers or antiarrhythmic)~Data on cardiac monitoring:~A questionnaire evaluating the safety of SpiderFlash® will be given to the patient and the results of Holter will be communicated at the end of the recording to the blinded rhythm specialist"
46057054|NCT05069649|Drug|Ergoferon|Tablet for oral use.
45397931|NCT01089088|Drug|gemcitabine hydrochloride|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 & 8) Sunitinib 37.5mg (po days 2 to 15)"
45505898|NCT02125916|Other|oxygen therapy|
45505899|NCT03522415|Drug|HLX01|HLX01,Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection is recombinant human-mouse chimeric anti-cd20 CD20 monoclonal antibody.
45849752|NCT05132400|Behavioral|Psychological-informed Physical Therapy (PiPT) Training|An approach designed to incorporate the concepts of cognitive behavioral therapy (CBT) for pain management into routine clinical PT practice in order to modify maladaptive responses associated with chronicity. The goal of PiPT is to promote a fast and optimal recovery by removing psychological obstacles, obviating the need for referral to a psychologist and facilitating triage to other health professionals in a timely manner when needed. PiPT training includes education about the neuropsychology of pain, patient communication skills, and identification of psychosocial risk factors for chronicity and treatment approaches that include reassurance, relaxation, and psycho-behavioral reactivation.
46057055|NCT05069649|Drug|Placebo|Tablet for oral use.
45397932|NCT01089088|Drug|sunitinib malate|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 & 8) Sunitinib 37.5mg (po days 2 to 15)"
45397933|NCT03968432|Behavioral|MIAS&Q|There were two interventions compared in this study: 1) Be Sweet to Babies Videos and Pamphlet; and 2) Be Sweet to Babies Videos, pamphlet, and MIAS&Q. The Be Sweet to Babies vaccination pain management videos and pamphlet were provided to all participants as this information is publicly available, and demonstrates the effectiveness of the evidence-based recommended vaccination pain management strategies for infants. In addition, a pamphlet was used which was developed in partnership with CHEO and Ottawa Public Health as a knowledge translation tool. Those in the intervention arm were also given MIAS&Q included five questions and statements based on the MI approach consisted of four scaled questions and two open-ended questions, aimed to present brief informative and affirmative questions and statements to help the parents reflect on their own thoughts and support them to advocate for the use of the recommended pain management strategies during their infant's vaccination.
45397934|NCT03968432|Behavioral|Be Sweet to Babies Videos and Pamphlet|The Be Sweet to Babies vaccination pain management videos and pamphlet will be provided to all participants. Be Sweet to Babies vaccination pain management videos showing parents how to use breastfeeding, upright secure holding, and a small volume of sweet solution during vaccination, will be used. This pamphlet is a knowledge translation tool previously developed in partnership with the Children Hospital of Eastern Ontario (CHEO) and Ottawa Public Health and has been publicly available on the Ottawa Public Health Website since June 2013. The content presented about pain management for infants during vaccination is the same information as the video.
45397935|NCT00075400|Drug|imatinib mesylate|Given PO
45397936|NCT00075400|Other|laboratory biomarker analysis|Correlative studies
45397937|NCT03972722|Drug|GLS-010|Patients will be given 240mg GLS-010 every treatment.
45505900|NCT03522415|Drug|Methotrexate（MTX）|Methotrexate is a slow-acting antirheumatic drug.
45505901|NCT02125994|Procedure|Interscalene nerve block|
45505902|NCT04226833|Drug|entrectinib|1x100 milligram (mg) capsule given with approximately 240 milliliter (mL) of water within 30 minutes of consumption of a standardized meal
45397938|NCT03972644|Procedure|Aortic valve replacement|Open heart surgery or transcatheter surgery
45505903|NCT02131298|Drug|Palbociclib Alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection
45505904|NCT02131298|Drug|Palbociclib plus itraconazole|Itraconazole 200 mg once daily with food for a total of 11 days; on Day 5, a single oral 125 mg dose of palbociclib will be given with itraconazole after a meal, followed by 168 hours of PK sample collection.
45505905|NCT01375387|Drug|Lacosamide|100 mg oral tablet, single dose
45505906|NCT01375387|Drug|Lacosamide|Lacosamide 2 X 100 mg tablet
45505907|NCT01375387|Drug|Lacosamide|Lacosamide 4 X 100mg tablet
45505908|NCT01375387|Other|Placebo 3|Placebo - 3 tablets
45505909|NCT01375387|Other|Placebo 4|Placebo - 4 tablets
45505910|NCT01375387|Other|Placebo 2|Placebo - 2 tablets
45505911|NCT03936699|Device|Transcutaneous Nerve Stimulator (TENS)|"The Elira wearable patch system is a Radio Frequency (RF) coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.~Behavioral: Diet & Exercise Subjects to be instructed on a healthy 1200 calorie diet."
45505912|NCT03936699|Behavioral|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
45505913|NCT02126072|Dietary Supplement|Alcohol|They consume 1gram of alcohol per kilogram of bodyweight in wine (12%)
45505914|NCT02126072|Dietary Supplement|Water|Volunteers consume the same volume of water as the would in wine according toe the protocol.
45505915|NCT05194813|Other|Aqua alvim CM, neodent implant (Test)|Acqua, Hydrophilic sandblasted, and acid-etched dental implants
45505916|NCT05194813|Other|Neoporous alvim CM, neodent implant (Control)|Neoporous, Hydrophilic sandblasted, and acid-etched dental implants
45505917|NCT02853318|Biological|Bevacizumab|Given IV
45505918|NCT02853318|Drug|Cyclophosphamide|Given PO
45505919|NCT02853318|Other|Laboratory Biomarker Analysis|Correlative studies
45697521|NCT03291951|Behavioral|Resistance training|The intervention goal is for study participants to exercise with progressively higher weights for resistance training to achieve a 1-kg increase in lean body mass by the end of the intervention. During an in-person visit on the same day as a chemotherapy infusion session, exercise professionals will teach participants a series of exercises to be completed at home twice weekly throughout the intervention. Participants will also receive protein powder, which they will be instructed to consume with meals twice a day. During subsequent infusion sessions, the exercise professional will meet in-person with participants to evaluate their ability to increase weights, and adjust exercises appropriately. In between visits, the exercise professional will check-in with participants by phone.
45697522|NCT00992602|Drug|methotrexate|Given IV
45697523|NCT00992602|Drug|liposomal cytarabine|Given IT or via LP
45697524|NCT00992602|Other|quality-of-life assessment|Ancillary studies
45397939|NCT01103206|Drug|cinacalcet|Intake of a single tablet of cinacalcet
45505920|NCT02853318|Biological|Pembrolizumab|Given IV
45505921|NCT02127476|Drug|KHK6640|Single ascending dose and multiple ascending doses administration
45505922|NCT02127476|Drug|Matching Placebo|Single ascending dose and multiple ascending doses administration
45505923|NCT03918213|Diagnostic Test|High-Resolution anorectal manometry with the use of solid-state catheter|High resolution anorectal manometry with the use of solid-state catheter will be performed to eligible subjects willing to participate in the study
45505924|NCT03431545|Behavioral|PALS and|"Play and Learning Strategies (PALS) include web-based parent training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Parents will begin their 11 week (infant) or 14 week (toddler) parenting program in October and complete it by April. There will be monthly Parent Meetings related to the content they are learning online. Post-assessments will occur in late April and May. Each weekly online parent session will take approximately 30 minutes to complete with a 40 - 60 minute weekly remote coach call."
45397940|NCT01103206|Drug|cinacalcet dose 1|PTH suppression test in primary hyperparathyroidism using cinacalcet (dose 1).
45397941|NCT01103206|Drug|cinacalcet dose 2|Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
45397942|NCT00228566|Drug|Armodafinil|
45397943|NCT01105468|Device|Breath Collecting Unit|Collect two breath gas samples per patient on one day before surgery
45397944|NCT01105468|Device|Breath Collecting Unit|Collect two or more breath gas samples on different days during adjuvant or neo-adjuvant therapy.
45505925|NCT03431545|Behavioral|BEECH|"Beginning Education: Early Childcare at Home (BEECH) includes web-based teacher training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Teachers will complete the 20 online sessions weekly, except for planned center closings due to holidays or agency-related events. The three in-person trainings will occur before Session 1 and after Sessions 8 and 14. Each weekly online teacher session will take approximately one-hour for a teacher to complete with a 30 minute weekly remote coach call. Each in-person teacher training will be 6-hours in duration."
45505926|NCT03431545|Behavioral|Control condition|Parents and teachers conduct business as usual in regards to care-giving in the school and at home.
45505927|NCT05194657|Device|enhanced depth of focus IOL|Acrysof IQ Vivity, enhanced depth of focus IOL
45697525|NCT00992602|Other|laboratory biomarker analysis|Correlative studies
45697526|NCT04976686|Other|Diet modification|Participants will reduce their carbohydrate consumption to 80g daily
45697527|NCT05592652|Other|Survey|Survey including demographic, clinical and psychopathological questions
45505928|NCT05194657|Device|monofocal IOL|Acrysof IQ, monofocal IOL
45505929|NCT02131376|Procedure|Non-renorrhaphy|The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
45397945|NCT03949114|Behavioral|Evaluation|Evaluate a weak debilitating phenotype screening on the patients before surgery;
45505930|NCT02131376|Procedure|Renorrhaphy|After tumor resection the patient will have both a deep and cortical layer reconstruction
45505931|NCT05375370|Other|circulating tumor DNA dosage|blood sample for circulating tumor DNA dosage will be done to patient with hepatocellular carcinoma
45505932|NCT05194501|Other|Nine Hole Peg Test, Jamar dynamometer, pinchmeter|"Hand grip and pinch strengths: Hand grip strengths and tip pinch strengths were measured using a Jamar type hand dynamometer and pinchmeter available in our clinic.~The Nine Hole Peg Test (NHPT): Hand dexerities were evaluated with the NHPT available in our clinic."
45505933|NCT03626727|Drug|Sodium Oxybate Oral Solution [Xyrem]|Xyrem will be given to participants to determine if it is effective in treating post-traumatic narcolepsy and post-traumatic hypersomnia
45505934|NCT02237742|Drug|PF-06427878|Intravenous, 100 micrograms, single dose, 30 minute infusion
45505935|NCT02131454|Other|Inhalation technique training|Training in inhalation technique in asthmatics and COPD patients
45505936|NCT03604224|Drug|Canagliflozin 300 mg|Participants who are initiated on canagliflozin 300 mg will be observed. No study treatment will be administered as a part of this study.
45505937|NCT01373905|Procedure|Recruitment maneuver|group I: Recruitment by CPAP 30 cm/H2o for 30 seconds group II: Using pressure controlled ventilation with end-inspiratory minus end-expiratory pressure of 15 cmH2O, respiratory rate of 10-15 C / min. PEEP was increased by 5 cm/ H2O every 2 minutes till Maximum of 40 cmH2O, patient was considered recruited if PaO2 of 250 mmHg was achieved. Then progressive decreases of PEEP in steps of 2 cmH2O every 2 minutes till PaO2 dropped by a 10% or more (alveolar collapsing pressure)
45505938|NCT01373905|Procedure|recruitment maneuver|recruitment as done by CPAP 30 cm/ H2o for 30 seconds or by stepwise elevation of PEEP by 5 cm/ H20 till 40 Cm/ H2o
45505939|NCT04159753|Device|Spinal Cord Stimulator|We will record patient's experience on the 30-Day FDA approved Burst Spinal Cord Stimulator Trial (BurstDR™, Abbott Saint Jude Medical).
45505940|NCT02126384|Drug|pneumovax vaccination|vaccination
45505941|NCT02035410|Procedure|Hydrogen peroxide pretreatment group|Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
45505942|NCT02404155|Drug|Clozapine|
45697528|NCT00993226|Drug|SABER-Bupivacaine Treatment 1a|5.0 ml
45697529|NCT00993226|Drug|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
45397946|NCT03949114|Behavioral|nursing care|Traditional post-operative nursing care
45397947|NCT03949114|Behavioral|rehabilitation|"Postoperative vital signs were stabilized for 2 hours and then assisted to turn over; 2 to 3 hours to change position, awake without swallowing dysfunction, to fluid diet; 6 hours later, raise the bed 15 to 30 °, eat a half-flow diet.~On the first day after surgery, raise the bed 45 °, row and position training; catheter clamping training; assessment of pain, preventive analgesia. Early rehabilitation training was performed for 60 minutes each time for 5 consecutive days."
45505943|NCT05760235|Procedure|Endoscopic sleeve gastroplasty (ESG)|ESG will be performed under general anaesthesia with orotracheal intubation. The Endomina® suturing system (EndoTools Therapeutics S.A., Gosselies, Belgium) mounted on a single channel endoscope will be used. This system allows to obtain full thickness gastric sutures through the gastric wall of the gastric body, leaving the antrum and the gastric fundus free15. The procedure will be performed with the patient in supine position. Carbon dioxide will be blown to stretch the gastric lumen. An initial endoscopic evaluation will be performed immediately to confirm the absence of any contraindication to ESG before suturing. The ESG starts with the reduction of the gastric body, suturing from distal to proximal and starting from the notch of the angulus and ending at the level of the fundus. 4-8 full thickness stitches will be placed, with 2 passes per stitch.
45505944|NCT02127788|Drug|Micafungin|intravenous
45505945|NCT03601650|Behavioral|Mindful eating|Attending to the sensory properties of food as it is eaten
45505946|NCT03601650|Behavioral|Eating without distractions|Eating without intentionally attending to something else such as a television, smartphone, computer, book etc
45505947|NCT05194423|Device|Tricuspid Valve Replacement System via jugular vein|To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system via jugular vein.
45505948|NCT03626649|Device|DiamondTemp Cardiac Ablation System|"The DiamondTemp Ablation System is the test device in this investigational study. The DiamondTemp Ablation System consists of:~DiamondTemp Ablation Catheter~o Unidirectional and Bidirectional models~DiamondTemp Catheter-to RFG Cable~DiamondTemp GenConnect Cable~DiamondTemp FASTR Generator with Footswitch~DiamondTemp Irrigation Pump~DiamondTemp Irrigation Tubing Set"
45505949|NCT02131688|Drug|Mitoxantrone Hydrochloride Liposome|
45505950|NCT03604146|Behavioral|Medical quality control intervention strategy|Training and education for diagnosis, treatment and management of COPD for doctors and nurses; Regular inspection and supervision of medical quality
45697530|NCT00993226|Drug|Bupivacaine HCl Treatment 1c|40 ml
45697531|NCT00993226|Drug|SABER-Bupivacaine Treatment 2a|7.5 ml
45697532|NCT00993226|Drug|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
45697533|NCT00993226|Drug|Bupivacaine HCl Treatment 2c|40 ml
45397948|NCT01105546|Drug|recombinant activated factor VII|90 µg/kg/day i.v.
45505951|NCT01375465|Device|DIOR drug-eluting PTCA balloon|Treatment for 45 seconds with the DIOR balloon (3 µg/mm2 Paclitaxel concentration on balloon surface)
45505952|NCT03604068|Device|RecoveryRx|A pulsed shortwave therapy medical device
45505953|NCT03604068|Device|Sham RecoveryRx|A sham pulsed shortwave therapy medical device
45505954|NCT02126462|Biological|Na-APR-1 (M74)/Alhydrogel®|
45505955|NCT02126462|Biological|Na-GST-1/Alhydrogel®|
45505956|NCT02126462|Biological|Hepatitis B vaccine|Hepatitis B vaccine co-administered with saline
45849753|NCT05127330|Behavioral|LifePlans|LifePlans is a video-based intervention, in which patients watch episodes starting during a psychiatric hospitalization and continuing through 1 month post-discharge. Other mental health treatment is unrestricted.
45397949|NCT01105546|Drug|recombinant activated factor VII|treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
45397950|NCT00074152|Drug|chemotherapy|Given within 10 weeks after surgery.
45397951|NCT00074152|Radiation|radiation therapy|Given within 6 months after surgery
45397952|NCT00261846|Drug|Bosutinib|"Part 1, starting dose 400 mg oral, daily dosing in the dose-escalation component.~Part 2, 500 mg oral, continuous, daily dosing."
45397953|NCT00169442|Biological|Tritanrix™-HepB/Hiberix™ Kft.|GlaxoSmithKline (GSK) Biologicals Korlatolt Felelossegu Tarsasag [Kft] (Limited Company) combined diphtheria (D), tetanus (T), whole cell Bordetella pertussis (Pw), hepatitis B vaccine with new sources of D, T and Pw antigens mixed with Haemophilus influenzae type b (Hib2.5) vaccine.
45397954|NCT00169442|Biological|Tritanrix™-HepB/Hiberix™|GSK Biologicals' combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus Influenzae type b vaccine
45397955|NCT00169442|Biological|Hiberix™|GSK Biologicals' Haemophilus influenzae type b vaccine
45397956|NCT00169442|Biological|Polyribosil-Ribitol-Phosphate (PRP) vaccine|plain PRP polysaccharide vaccine
45397957|NCT00169442|Biological|Tritanrix™-HepB Kft|GSK Biologicals Korlatolt Felelossegu Tarsasag [Kft] (Limited Company) combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B vaccine with new sources of D, T and Pw antigens produced at GSK Biologicals Kft., Gödöllö, Hungary.
45397958|NCT05625724|Drug|Aspirin|Experimental drug administrated orally
45397959|NCT05625724|Drug|Placebo|Treatment for the control group
45397960|NCT02530762|Other|Novel Fiber|novel fiber supplemented beverage provided in one serving
45397961|NCT02530762|Other|Positive Fiber control|positive control fiber supplemented beverage provided in one serving
45397962|NCT02530762|Other|Negative Control|No added fiber beverage
45397963|NCT00261716|Behavioral|IPS|Individual Placement and Support Evidence based supported employment
45397964|NCT00261716|Behavioral|IE|Four sessions of manualized illness education about schizophrenia/schizoaffective disorder (tailored to the participant diagnosis) prior to each course of a job search
45697534|NCT04889248|Other|Inspiratory Muscle Training with Powerbreath IMT device.|"Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks.~Each day, each subject perform 15 repetitions in the morning and evening, from Monday to Friday, resting on weekends.~The endurance of the device increases along the study, initiating with the 30% of their own maximum inspiratory pressure (PImax) during the first week and increasing a 10% every other week, till reach the goal of 60% PImax."
45697535|NCT01885559|Drug|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
45397965|NCT00261716|Behavioral|VOMI|Four sessions of manualized motivational interviewing oriented to employment goals and concerns prior to each course of a job search
45397966|NCT01089166|Drug|Metformin|
45397967|NCT03809104|Other|Virtual reality-based rehabilitation programs|A virtual reality (VR)-based rehabilitation program that lasts for 12 weeks, twice per week, 30 minutes per time. The program was combined with progressive resistant training and functional movement of dominant upper (UE) limb. The device of the VR including one computer, one oculus headset, and one hand-hold sensor. The rehabilitation secession contains 4 different VR games in total, including (1) Leap Motion Blocks (2) Slum Ball VR Tournament (3) VR Super Sports 10th Edition- Basketball (4) VR Super Sports 10th Edition- Soccer.
45397968|NCT00203502|Drug|Bevacizumab|IV 15mg/kg 21 days
45397969|NCT00203502|Drug|Cyclophosphamide|500mg per meter squared, IV every 21 days
45397970|NCT00203502|Drug|Docetaxel|60 mg per meter squared, IV every 21 days
45397971|NCT03799198|Other|Weight Management Program (WMP)|As part of usual care, participants will: 1) Discuss and choose one of three diet options: protein-sparing modified fast, Mediterranean, or meal replacement. 2) Be referred to a nutritionist appointment. 3) Initiate a series of twelve monthly study visits in the context of shared medical appointments (SMAs) covering nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress. 4) Be referred to an exercise physiologist for a personalized physical activity program. 5) If assessed relevant by the study clinician, be referred to a mental health specialist and/or sleep clinic.
45397972|NCT03799198|Drug|Medication for chronic weight management (Rx)|"Following listed 5 drugs will be administered as prescribed by the study doctor:~1) Orlistat (Xenical® pills, per os [p.o.; by mouth]). 2) Lorcaserin or lorcaserin extended-release (Belviq®/Belviq XR® pills, p.o.). 3) Phentermine/topiramate extended-release (Qsymia® pills, p.o.). 4) Naltrexone/bupropion extended-release (Contrave® pills, p.o.). 5) Liraglutide 3.0 mg (Saxenda® injections, subcutaneously [under the skin])."
45397973|NCT01105780|Drug|Placebo|Matching placebo
45397974|NCT01105780|Drug|JNJ-41443532|250mg tablet once daily for 1 day
45505957|NCT03113071|Drug|Decitabine|Decitabine will be administered in combination with Digoxin
45505958|NCT03113071|Drug|Digoxin|Decitabine will be administered in combination with Digoxin
45505959|NCT03601572|Other|No intervention|No intervention
45697536|NCT01885559|Drug|Telmisartan|Telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
45697537|NCT01885559|Drug|Placebo|Placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
45697538|NCT01884545|Behavioral|Health coaching|Telephonic health coaching sessions with a trained certified health coach for a period of 6 months (total of 10 biweekly calls).
45505960|NCT02131844|Other|Facilitated early mobilization|Participants randomized to this group, in addition the preoperative education (usual care), will have early mobilization facilitated by a trained health professional. This health professional will: (1) visit the participant on the day of surgery to reinforce mobilization goals and assist with transfer to a chair and (2) visit the participant three times per day starting from POD 1 to reinforce mobilization goals and walk with the participant (at least the length of the hallway). Targeted walking distances will increase according to the participant's tolerance. This intervention will be undertaken until POD 3 or hospital discharge, whichever comes first.
45505961|NCT02131844|Other|Usual care|Participants randomized to this group will receive instructions about postoperative mobilization in a preoperative education session and will receive a booklet describing mobilization goals for each POD (sit in a chair for 2 hours on the day of surgery, stay out of bed for at least 6 hours/day from POD 1 until hospital discharge)
45505962|NCT03050307|Drug|TAK-438|TAK-438 tablets
45397975|NCT01103518|Drug|Ethinyl Estradiol + Cyproterone acetate|Ethinyl Estradiol (0.035mg) + Cyproterone acetate (2mg), coated tablets. Each treatment cycle consists of one tablet, once per day for 21 days followed by a 7-day rest period. A total of 4 treatment cycles will be completed during the study treatment period.
45397976|NCT03947086|Device|Transcranial Direct Current Stimulation (TDCS)- Active|A constant current stimulator (TCT Research Limited) will be used using electrodes of 5 × 5 cm2 embedded in saline (0.9 % NaCl) and application of 1.5 mA current for 20 minutes for 5 consecutive days. The cathode will be positioned in the right supra-orbital region, and while the anode will have the following provision in the left dorsolateral prefrontal cortex (F3).
45397977|NCT03947086|Device|Transcranial Direct Current Stimulation (TDCS)- Sham|The protocol for participants receiving simulated current is identical, but the device ceases to emit current after 30 seconds of initiation of pacing.
45505963|NCT03050307|Drug|Lansoprazole|Lansoprazole capsules
45505964|NCT03050307|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets
45505965|NCT03050307|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
45505966|NCT03050307|Drug|Bismuth-Containing Quadruple Therapy|1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
45505967|NCT03601494|Other|perineural injection of platelet-rich plasma|Sonographic guided injection was done under complete sterile conditions including skin sterilization, ultrasound probe covered with sterile pad, and a sterile gel. The needle was introduced from the lateral side toward midline using the in-plane approach to target the desired nerve, each nerve was injected by a single dose of 1.5 cc of PRP. Free hand one-man technique was used by the physician who simultaneously managed the ultrasound device by holding the syringe with one hand while scanning the nerve by moving the probe with the other hand. With continuous imaging of the tip of the needle, the syringe was put around the nerve and platelet-rich plasma was injected in the peri-neural tissue.
45505968|NCT03601494|Drug|medical|vitamin B complex, α lipoic acid, selective serotonin reuptake inhibitor (SSRI)
45505969|NCT05760157|Other|Possible risk factors of heart failure|Demographic data, previous medical history data, physical examination, ECG examination, blood routine, blood biochemistry, the peak value of myocardial injury markers, serum markers of heart failure, high-sensitivity C-reactive protein Coronary angiography, interventional treatment, microcirculation resistance index caIMR calculation based on coronary angiography Doppler echocardiography, medication during hospitalization, NYHA cardiac function grading before discharge, and 6-minute walk test before discharge.
45505970|NCT02126540|Device|Pantheris Atherectomy System|Treatment device in primary cohort arm; OCT image guided directional atherectomy
45505971|NCT03603990|Procedure|Vitrectomy|"During the first 6 month :Only Panretinal photocoagulation(if high-risk PDR or rubeosis iridis) may be given.~After First Six Months : All therapies for DME may be given at the discretion of the investigator"
45505972|NCT03603990|Procedure|Usual care|"Patients with usual care according to the investigator choice :~During the first 6 month : All therapies for DME may be given at the discretion of the investigator during the study, except a vitrectomy.~After First Six Months : All therapies for DME may be given at the discretion of the investigator, including a vitrectomy."
45505973|NCT02127866|Drug|CHF 5259 plus Foster 100/6 µg|Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)
45505974|NCT02127866|Drug|Foster 100/6 µg|"Active comparator~Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)"
45505975|NCT03601416|Drug|Transplantation of mesenchymal stem cell|"Human umbilical cord-derived mesenchymal stem cell will be given to participants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg"
45697539|NCT01884545|Genetic|Genetic risk counseling|In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
45697540|NCT01884545|Behavioral|Standard risk assessment|Standard risk assessment for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
45697541|NCT01895543|Drug|Elobixibat 10 mg|10 mg Elobixibat daily, with possibility for dose adjustment to 5 mg daily.
45697542|NCT00994318|Drug|FCM (Ferric carboxymaltose) high ferritin target|
45697543|NCT00994318|Drug|FCM (Ferric carboxymaltose) low ferritin target|
45397978|NCT03947086|Behavioral|Cognitive Training|"Considering that the effects of TDCS are potentiated when applied during the execution of a task (online) (Miniussi, & Ruzzoli, 2013), in the present study all participants received cognitive training, performed concomitantly with neurostimulation.~Cognitive training consists of two parts: standardized tasks directed to social cognition and activities that stimulate executive functions. The first part consists of tasks contained in a battery of social games (Gao & Maurer, 2009; Dillon, Kannan, Dean, Spelke, & Duflo, 2017). While the tasks directed to the executive domain are, namely: running mazes, assembling figures, completing parts of figures and the Super Lynx Memory Game. All participants, regardless of whether they underwent active or simulated stimulation, received cognitive training, respecting the ethical principles of ensuring therapeutic assistance to those involved."
45397979|NCT04928482|Behavioral|Backward Walking Training|Participants will receive 27 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground.
45505976|NCT03601416|Drug|No Transplantation of Mesenchymal Stem Cell|Human umbilical cord-derived mesenchymal stem cell will be not given to participants through intravenous infusion.
45505977|NCT03288025|Behavioral|Nutrition and Exercise|5 times a week exercise training and biweekly diet counseling for 12 weeks.
45505978|NCT04071379|Biological|Recombinant Hepatitis B + DTP-HB-Hib|1 dose of 0.5 ml Recombinant Hepatitis B + 3 dose of 0.5 ml of DTP-HB-Hib
45505979|NCT04071379|Biological|Hep B + Pentabio (registered)|1 dose of 0.5 ml Recombinant Hepatitis B (registered) + 3 dose of 0.5 ml of Pentabio (registered)
45505980|NCT03869697|Drug|SCB-313|5 mg or 20 mg lyophilized powder in a single-use glass vial
45397980|NCT04928482|Behavioral|Backward Walking Training|Participants will receive 18 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground.
45397981|NCT03948724|Behavioral|Therapeutic education program|Patient follow sessions the therapeutic patient education with manual therapy, therapeutic education, therapeutic exercize
45397982|NCT03948724|Behavioral|Usual Information|Patient receive usual informations
45397983|NCT04924504|Other|No interventions|No interventions
45505981|NCT03550508|Biological|Anti-RANKL Monoclonal Antibody|JMT103 is recombinant fully human anti-RANKL monoclonal antibody. JMT103 is provided as the injection,120 mg/vial. JMT103 was administered subcutaneously in the upper arm, upper thigh, or abdomen.
45505982|NCT03607578|Behavioral|Other: Control Group - Minimal Intervention|Basic Campaign Folder
45505983|NCT03607578|Behavioral|Experimental: Protection Routine 1|New folder, sun advice of Danish Sun Safety Campaign, rationale, prioritization, overview of sun prevention. Activity planner with outdoor activities like bathing, sports and excursions before and after noon (UVI maximum) and indoor activities; shopping, lunch, relaxation and transportation in middle of day and possibility to plan vacation to minimize risk. Instructions for download of UV-App includes use of alert, and information about the features of the app; how to be informed of current UV risk before and during vacation. Link for download of the app is sent by text-message and e-mail. Skintype guide is included in the app and as an individual entity. It includes scoring questions about tan and burn reaction in the sun, a color scale, eye and hair color and freckles. Participants get a description of their skin type and examples of time their particular skin type will resist the sun before erythema occurs at particular UV-levels and functions as an eye-opener.
45505984|NCT03607578|Behavioral|Experimental: Protection Routine 2|The sunscreen application instruction is based on a recently developed thorough application instructions for use of sunscreen to counter the problems and deficits of current sunscreen use. It describes every part of the body, the needed volume for that part and application patterns. The package will also include a hat specifically designed for protection and comfort and the availability of a hat will function to increase the use of hat. The hat is simple bucket hat version with a brim, cheap, in light fabric and foldable for easy packing.
45505985|NCT05760079|Dietary Supplement|Lactoferrin|750mg of Jarrow formulas taken three times daily for 30 days
45505986|NCT03603834|Drug|mFOLFOXIRI|"mFOLFOXIRI consists of the following combination of drugs:~Oxaliplatin, 85 mg/m2, IV over 2 hours~Leucovorin, 400 mg/m2, IV over 2 hours~Irinotecan, 150 mg/m2, IV over 90 minutes~5 FU, 400 mg/m2, IV bolus~5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection~each 14 day cycle, for 6 cycles"
45505987|NCT03551132|Other|Exercise test|Fat mass, Functional autonomy, muscular strength, quality of life questionnaire
45505988|NCT02400723|Behavioral|Progressive Muscle Relaxation|Progressive Muscle Relaxation is a treatment in which individuals tense and release their muscle groups in a sequential order. This helps reduce anxiety and tension. It also teaches individuals to differentiate between muscle tension and relaxation.
45505989|NCT02400723|Behavioral|Diaphragmatic Breathing|Diaphragmatic breathing is a way in which people breathe using their diaphragm. This type of breathing has been found to promote relaxation and reduce stress.
45505990|NCT02400723|Other|Psychoeducation (Placebo)|DVD-delivered psychoeducation. Participants will view videos that contain information about what anxiety is and information about one's well-being. This condition is an attention placebo control.
45505991|NCT03601338|Drug|Bemiparin|second generation low molecular weight Heparin
45505992|NCT03601338|Other|multivitamins and routine antenatal follow up|multivitamins and routine antenatal follow up
45505993|NCT02128022|Drug|GLP-1 (7-36) amide|Infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min
45505994|NCT02128022|Drug|Glibenclamide|Oral Glibenclamide 5mg
45505995|NCT03256045|Drug|Carfilzomib|Given IV
45505996|NCT03256045|Other|Chemosensitivity Assay|Undergo in vitro chemosensitivity testing
45505997|NCT03256045|Drug|Dexamethasone|Given PO
45505998|NCT03256045|Other|Laboratory Biomarker Analysis|Correlative studies
45505999|NCT03256045|Drug|Panobinostat|Given PO
45506000|NCT03551054|Behavioral|Healthy for Two, Healthy for You|Remotely delivered health coaching in pregnancy and postpartum to promote healthy weight gain.
45506001|NCT03551054|Behavioral|Health Education|
45506002|NCT03603756|Drug|SHR-1210|a novel anti-PD-1 antibody
45506003|NCT03603756|Drug|Apatinib|a VEGFR-2 tyrosine kinase inhibitor
45506004|NCT03603756|Drug|Irinotecan Injection|cytotoxic agent that binds to topoisomerase I
45506005|NCT03603756|Drug|Paclitaxel liposome|cytotoxic agent that prevent depolymerization of cellular microtubules
45506006|NCT03603756|Drug|Nedaplatin|cytotoxic agent that cross-links and denatures strands of DNA
45506007|NCT02372409|Device|MRI-guided laser ablation|
45506008|NCT02372409|Drug|Doxorubicin|
45506009|NCT02372409|Drug|Etoposide|
45506010|NCT02372409|Device|Dynamic contrast-enhanced (DCE) MRI|
45506011|NCT02372409|Device|Dynamic susceptibility contrast (DSC) MRI|
45506012|NCT03603678|Drug|BAY2253651|100 µg (500 µg/ml * 200 µl) BAY2253651 intranasally
45506013|NCT03603678|Drug|Placebo|Matching Placebo dosing
45506014|NCT03626259|Drug|Losartan and Amlodipine|Losartan and amlodipine in fixed combination capsules, 100mg/5mg. One time daily with the first bite of eat meal per 8 weeks
45697544|NCT00994318|Drug|Oral Iron (Ferrous sulphate)|
45697545|NCT04695808|Behavioral|yoga|Yoga practice will be done two days a week for 10 weeks.
45697546|NCT04525456|Dietary Supplement|Reduxium|Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days.
45697547|NCT00995722|Drug|Prednisone|Prednisone will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain 10mg of prednisone.
45697548|NCT00995722|Drug|Placebo|Placebo dosages will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain matching placebo.
45506015|NCT03626259|Drug|Losartan|Losartan capsules, 100mg. One time daily with the first bite of eat meal per 8 weeks
45506016|NCT03551366|Behavioral|Linear|The linear pedagogy arms consists of three, five-week phases of lesson delivery, commencing around two weeks after baseline assessments. The first phase focuses on dance, the second on gymnastics and the final phase on ball sports. Each phase has its own schemes of work which includes five lessons objectives, each taught over a two lesson period. The lesson objectives aligned to the aims of English national curriculum. Lessons are delivered twice a week by trained coaches, with each lesson lasting 60 minutes in total, with 45 minutes of on task teaching time. Linear curriculum lessons will be focused on the functioning of the body and children learning movement patterns. These lessons will be far more prescriptive and have clearly stated outcomes/goals for each lesson, with a typical lesson structure following the structure of warm up, isolated practice of technique or skill, simulated game and warm down.
45506017|NCT03551366|Behavioral|Nonlinear|The non-linear pedagogy arm consists of three, five-week phases of lesson delivery, commencing around two weeks after baseline assessments. The first phase focuses on dance, the second on gymnastics and the final phase on ball sports. Each phase has its own schemes of work which includes five lessons objectives, each taught over a two lesson period. The lesson objectives align to the aims of English national curriculum. Lessons are delivered twice a week by trained coaches, with each lesson lasting 60 minutes in total, with 45 minutes of on task teaching time. The nonlinear curriculum lessons will look to make sure that children are both engaged and empowered throughout the learning process. In adherence to representative learning design, we will look to contextualise lessons and guide learning through the use of books/stories, lived experiences and the sharing of ideas.
45506018|NCT03601260|Drug|Allopurinol|Treatment of gout patients by oral dosage of 100 mg-300mg/ day of Allopurinol
45506019|NCT03168373|Procedure|language rehabilitation therapy|language therapy is language rehabilitation by language therapist during subacute phase in stroke patients
45506020|NCT03717597|Behavioral|Intervention|"Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).~Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity."
45506021|NCT03603522|Dietary Supplement|BioGaia-DSM17938|2mL per day (1x10^9 CFU) per day taken orally for 28 days
45506022|NCT03603522|Other|Placebo Comparator: Placebo Control|2mL per day of placebo formulation taken orally for 28 days
45506023|NCT05193253|Procedure|Radiofrequency ablation|Treatment-naive patients with solitary HCC <= 3 cm who received ablation as the first-line treatment
45506024|NCT05193253|Procedure|Liver resection|Treatment-naive patients with solitary HCC <= 3 cm who underwent liver resection as the first-line treatment
45506025|NCT05193253|Procedure|Liver transplantation|Treatment-naive patients with solitary HCC <= 3 cm who were listed for liver transplantation as the first-line treatment
45697549|NCT05535088|Device|Virtual reality|Virtual reality consists for about a minute and a half 6 times per session. During the first and the second session, subjects will experiment virtual reality while sited. Moreover, during the third and the fourth session subjects will be standing with a side by side stand. During the last two experimental sessions subjetcts will be standing with a semi tandem stand.
45697550|NCT00996346|Drug|Irinotecan&Temsirolimus:Arm1, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
45506026|NCT05265182|Procedure|virtual reality|Create an immersive technology system for managing the behavioral and psychological symptoms of dementia and determine its acceptability, usability, and safety in the healthy adult population initially, using semi-Cave or head-mounted display.
45506027|NCT03676257|Other|Endocrine therapies|No intervention
45506028|NCT03601104|Other|High intensity eccentric training|High intensity eccentric training group with 80% of isometric peak torque.
45506029|NCT03601104|Other|High intensity eccentric training with BFR|Eccentric high intensity training group with 80% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).
45506030|NCT03601104|Other|Low intensity eccentric training with BFR|Low intensity eccentric training group with 40% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).
45506031|NCT03601104|Other|Low intensity eccentric training|Low intensity eccentric training group with 40% of isometric peak torque
45506032|NCT02131922|Procedure|Intensive Treatment|Intensive Surgical Treatment of Periodontitis
45506033|NCT02131922|Procedure|Dental Hygienization Treatment|
45506034|NCT02131922|Drug|Chlorhexidine (Intensive Treatment)|Chlorhexidine (PerioKIN) (0.2%) implantation in dental pockets
45506035|NCT03600948|Device|Orsiro Sirolimus Eluting Coronary Stent System|Percutaneous coronary intervention
45697551|NCT00996346|Drug|Irinotecan&Temsirolimus:Arm 1, Level 2|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
45697552|NCT00996346|Drug|Irinotecan&Temsirolimus:Arm 2, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
45849754|NCT05127330|Behavioral|Treatment as Usual|Individuals will receive unrestricted routine mental health care in the community as appropriate for their condition.
45849755|NCT05118360|Drug|ASC41 2 mg|2mg of ASC41 orally once daily for 52 weeks
45397984|NCT03947008|Other|Intuitive Eating Program|"A 5-week Intuitive Eating Curriculum created by a Registered Dietitian, Kaylee Frazier, will be used. The creator of this curriculum was contacted for permission and the curriculum was modified for use with college women.~The goal of the program is to challenge and eventually shift participant's mindset from the traditional diet culture towards a way of eating that is driven by their unique bodily needs. Content will focus on training participant to listen to their internal body cues for hunger opposed to restricting or eliminating foods. A list of intuitive eating principles and ways to incorporate them into daily routines will be provided to the participants throughout the sessions, coupled with homework assignments, journaling, and exercises to be completed before subsequent sessions."
45397985|NCT03946852|Device|Abdominal Regional Perfusion|Abdominal Regional Perfusion
45397986|NCT03948802|Diagnostic Test|Interleukine 33 test in blood plasma|ELISA test for Interleukin 33
45397987|NCT01103674|Device|Numeris®-AF Guided Coagulation System with VisiTrax®|Combined epicardial / endocardial procedure using the Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the Biosense Webster ThermoCool Catheter in conjunction with the Carto Navigation System endocardially.
45397988|NCT01089322|Drug|inhaled corticosteroid plus LABA plus oral corticosteroid|formoterol plus budesonide 12/400mcg 2times/day and 6/200 mcg as needed and prednisone 40 mcg
45397989|NCT01327534|Drug|Prasugrel|treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
45397990|NCT01327534|Drug|Clopidogrel|treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
45506036|NCT03551288|Drug|SUVN-911|Tablet
45506037|NCT03607344|Procedure|Cohort|Patients undergoing ambulatory laparoscopic sacrocolpopexy
45506038|NCT02132000|Drug|toremifene or tamoxifen|
45506039|NCT03118765|Drug|GSP304 (tiotropium bromide) Inhalation Solution|Once daily (QD) oral inhalation using a nebulizer
45506040|NCT03118765|Drug|GSP304 Placebo Inhalation Solution|Once daily (QD) oral inhalation using a nebulizer
45506041|NCT03118765|Drug|Spiriva® Respimat® inhalation spray|Once daily (QD) oral inhalation
45506042|NCT02252198|Other|Epistem Genedrive® and MolBio Truenat™|S1 will undergo direct smear and Epistem Genedrive® (optional for phase 2*) testing, before being homogenized with glass beads and split into three portions for testing with Epistem Genedrive®, MolBio Truenat™ and GeneXpert MTB/Rif® respectively. S2 and S3 will be randomized as to the order of testing using Epistem Genedrive® and MolBio Truenat™.
45506043|NCT03603444|Other|No intervention are provided|
45397991|NCT05625568|Drug|VYNT-0126|Liquid for oral administration once daily
45397992|NCT05625568|Drug|Placebo|Liquid for oral administration once daily
45397993|NCT03741166|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
45397994|NCT05625490|Drug|Ga-68 Galmydar|Two intravenous injection of the PET radiotracer 68Ga-Galmydar.
45506044|NCT02128100|Drug|Folfirinox|"Oxaliplatin 85 mg/m² for over 2 hours,~Leucovorin 400n mg/m² for over 2 hours,~Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion~Fluorouracil 400 mg/m² as a fast infusion over 15 minutes~Fluorouracil 2400 mg/m² as a slow infusion over 46 hours"
45506045|NCT02128100|Radiation|Stereotactic Body Radiation Therapy|5 treatments of stereotactic ablative radiotherapy (SABR) over the course of two weeks with a minimum of 36 hours in between each treatment.
45506046|NCT03603366|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|This study does not involve prescription of the drugs. This study is a cross-sectional survey of patients taking low-dose aspirin or patients who are eligible but not taking low-dose aspirin.
45849756|NCT05118360|Drug|ASC41 4 mg|4mg of ASC41 orally once daily for 52 weeks
45849757|NCT05118360|Drug|Placebo|Matching placebo orally once daily for 52 weeks.
45849758|NCT05102760|Procedure|Nerve Block using FIC Proceedure|Ultrasound Guided Nerve Block for Hip Fracture Patients using the FIC Proceedure
45849759|NCT05102760|Procedure|Nerve Block using PENG Proceedure|Ultrasound Guided Nerve Block for Hip Fractures Patients using the PENG Procedure
45506047|NCT03607032|Device|Respin Pad|RespinPad slid into the back of the patient sitting at 45° in the armchair or bed.
45397995|NCT05625490|Drug|13N-ammonia|Two intravenous Injection of PET radiotracer 13N-Ammonia.
45506048|NCT03607032|Other|usual treatment|medical aerosol session followed by aspiration or not, as required
45506049|NCT02128178|Drug|Enoxaparin 40 mg 2 hours before arm|Enoxaparin 40 mg 2 hours before surgery
45506050|NCT02128178|Drug|Enoxaparin 40 mg 12 hours before arm|Enoxaparin 40 mg 12 hours before surgery
45506051|NCT03606954|Combination Product|Combination topical corticosteroid|Comparison of a vasoconstriction index between the 2 study arms
45506052|NCT03600870|Drug|Midodrine|Midodrine is an oral alpha-1 agonist that increases vascular tone. It is administered orally. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
45697553|NCT03016468|Drug|Parenteral Remodulin (treprostinil) injection|Remodulin will be provided in vial strengths of 1, 2.5, 5, and 10 mg/mL. Subjects will be admitted to the hospital and IV Remodulin will be initiated within 12 hours after the last dose of selexipag. Subjects will remain under observation in the inpatient setting for at least the first 72 hours of Remodulin administration. Subjects will be transitioned to an equivalent dose of SC Remodulin at discharge.
45697554|NCT03016468|Drug|Oral Treprostinil|Oral treprostinil will be provided as 0.125-, 0.25-, 1-, or 2.5-mg extended-release tablets. Oral treprostinil will be dosed three times daily with food.
45697555|NCT00997204|Drug|Icatibant|Single subcutaneous injection of icatibant, 30 mg
45849760|NCT05096364|Biological|AK111/Placebo|After loading dose, investigational drug was administered subcutaneously up to 60 weeks.
45397996|NCT05614882|Behavioral|Written Stroke Education|The written education will be provided in the stroke folder currently in use by the Yale New Haven Health system. This written information is presented in a stroke folder and includes how to respond to the signs of stroke, dialing 9-1-1, following up with a health care provider after hospitalization due to a stroke and the importance of medication management as well as stroke risk factors, healthy eating habits, exercise habits, common changes following a stroke, stroke recurrence and stroke types. After being given two days to review the materials, patients will be asked to complete the stroke knowledge test (SKT). All participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.
45397997|NCT05614882|Behavioral|Verbal Stroke Education|Participants in the verbal education group will be provided with education over two days from therapists including occupational therapy, physical therapy, speech therapy as well as a physician or nurse. The disciplines will present general stroke information including causes, risk factors, prevention, nutrition and exercise recommendations, importance of managing chronic conditions and the significance of medication compliance. After the verbal education topics are presented, the participants will be tested with the stroke knowledge test (SKT) to measure learning. All the participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.
45397998|NCT03960736|Other|ESP block (Group A)|US probe will be placed longitudinally 2-3 cm lateral to the T5 transvers process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position 20G catheter will be inserted 5 cm in caudal direction. 20 ml %0.25 bupivacaine will be administered for block.
45397999|NCT03960736|Other|TEA group (Group B)|Local infiltration with 2% of lidocaine under the skin, in T4/T5 intervertebral space will be administered. An 18 G Tuohy needle will be inserted at T4/T5 intervertebral space to identify epidural space using the loss of resistance technique. 20G catheter will be inserted 3-4 cm in caudal direction in the epidural space. Bolus dose of 0.125% bupivacaine 10 ml will be administered through the catheter after the negative aspiration for blood or cerebrospinal fluid
45506053|NCT02128256|Device|Cerament G|
45506054|NCT03600792|Genetic|whole exome sequencing (WES)|"WES analysis will be performed in the UF de Génomique du Développement (APHP, Pitié-Salpêtrière hospital), using DNA extracted from amniotic fluid for the foetus (also used for chromosomal studies) and DNA extracted from peripheral blood for both parents. There will be no supplemental invasive sampling for this study. The result of WES will be returned during a consultation with the geneticist and the associated prognosis will be explained in case of molecular diagnosis"
45506055|NCT02128334|Drug|Eligard 45 mg Exposure|Subcutaneous injections
45697556|NCT00997516|Procedure|SILS appendectomy|Use of SILSPort to perform laparoscopic appendectomy
45697557|NCT00997516|Procedure|conventional laparoscopic appendectomy|conventional laparoscopic removal of the appendix
45849761|NCT05095038|Dietary Supplement|Appethyl®|Spinach extract, capsules, 5g/day, 26 weeks.
45849762|NCT05095038|Dietary Supplement|Placebo|Pea protein, capsules, 5g/day, 26 weeks.
45849763|NCT05048940|Biological|Janssen vaccine|0.5 ml millilitre(s) Intramuscular use
45849764|NCT05048940|Biological|Spikevax (Moderna) vaccine|0.5 ml millilitre(s) Intramuscular use
45849765|NCT05046990|Diagnostic Test|Regular Arrangement of Collecting Venules|This is a prospective, multicentre, international study without a control group.
45849766|NCT04987164|Dietary Supplement|Feminabiane CBU|EXTRACTS OF CRANBERRY, CINNAMON AND MICROBIOTIC STRAINS
45849767|NCT04985682|Biological|ADVATE|Antihemophilic factor (AHF) activity expressed in international units (IU) per vial.
45398000|NCT02530840|Behavioral|medical team|Lowering HbA1c by behavioral changes in meetings with the medical team.
45398001|NCT02530840|Behavioral|peers group|Lowering HbA1c by behavioral changes in meetings with the peers group.
45398002|NCT02530840|Behavioral|SMS notification|Lowering HbA1c by behavioral changes in meetings with the SMS notification
45398003|NCT01106170|Drug|Provex CV|dietary supplement, 2 capsules per day by mouth
45398004|NCT01106170|Other|placebo|corn starch, 2 capsules per day by mouth
45398005|NCT01103752|Other|no intervention, descriptive study|no intervention, descriptive study
45398006|NCT00232596|Drug|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 7, patients will enter a 12 week maintenance phase
45398007|NCT00232596|Drug|Placebo|Oral tablet.
45398008|NCT04771936|Other|Physiotherapy Exercises|All patients shall be randomly assigned to 3 groups: the control group who shall be awaiting surgery and not receiving a regular physiotherapy, the exercise group who shall be subject to a set of conventional exercises and a core exercise group who shall be performing the conventional exercises plus exercises aimed at the activation of core muscles. These exercises shall be carried out 3 times weekly for a period of 3 months. During the first 4 weeks, all sessions shall be supervised by a physiotherapist. From the 5th to the 8th week, patients shall attend 2 supervised sessions and complete the 3rd one at home. Between the 9th and the 12th week, patients shall then attend 1 supervised intervention and complete 2 sessions at home.Patients assigned to the control group shall be given a chance to enrol into the program upon completion of the study if they wish to do so.
45398009|NCT00073918|Drug|cyclophosphamide|Given IV
45398010|NCT00073918|Drug|etoposide|Given IV
45398011|NCT00073918|Radiation|iodine I 131 tositumomab|Given IV
45398012|NCT00073918|Procedure|quality-of-life assessment|Ancillary study
45398013|NCT00073918|Procedure|peripheral blood stem cell transplantation|Undergo ASCT given via central catheter
45398014|NCT01071642|Drug|stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure|ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure
45398015|NCT01071642|Drug|ACE/ARB stopped 24 hours before procedure and start immediately after|ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure
45398016|NCT00231894|Drug|Pioglitazone|pioglitazone 30-45 mg/day
45398017|NCT00231894|Behavioral|Life style diet group|life style diet education group 1x/week
45398018|NCT00231894|Other|Placebo|placebo comparator capsules
45398019|NCT00203424|Drug|Erlotinib + Bevacizumab|Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
45398020|NCT00203268|Drug|dihydroergotamine mesylate|1.0 mg. intramuscularly
45398021|NCT00168818|Drug|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
45398022|NCT00168818|Drug|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
45398023|NCT00168818|Drug|enoxaparin|40 mg once daily
45398024|NCT00260832|Drug|Cytarabine or Supportive Care|Patient's choice with physician's advice of either supportive care (IV fluids, nutrition, and antibiotics as needed) or cytarabine 20 mg/m^2 subcutaneously once daily for the first 10 consecutive days of each 28 day cycle, until progression or unacceptable toxicity develops. (These represent one intervention.)
45398025|NCT00260832|Drug|Dacogen (decitabine) only|20mg/m^2, 1 hour intravenous (IV) for 5 consecutive days of each 28 day cycle. Cycles continue until disease progression or unacceptable toxicity develops.
45398026|NCT00168038|Biological|Immunoglobulin Intravenous (Human)|A dose of 1 g IgG per kg body weight (bw) administered on two consecutive days resulting in the total treatment dosage of 2 g IgG per kg bw.
45398027|NCT00167414|Procedure|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy
45398028|NCT00167414|Radiation|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.
45398029|NCT00166712|Drug|Tacrolimus (TAC)|Tacrolimus (TAC) will be given standard of care by prescription twice a day (2.0 mg), orally. Doses will be adjusted by serum levels. The dose will be modified to achieve 12 hour trough concentrations of 5-8 ng/mL.
45398030|NCT00166712|Drug|Sirolimus|Sirolimus will be given standard of care by prescription, dosed at 5mg daily. The dosage will be adjusted by serum level to achieve 24 hour trough concentrations of 8-12 ng/mL by HPLC assay.
45398031|NCT00166712|Drug|Alemtuzumab|Patients receiving alemtuzumab will be premedicated with 50mg of diphenhydramine hydrochloride, and 650mg of acetaminophen 30-60 minutes to the first Alemtuzumab infusion. The of 30mg will be diluted in 100cc sterile 0.9% normal saline and infused over 2 hours. The infusion line must contain an in-line 0.22-micron filter. Alemtuzumab will be administered on the day of transplant (intraoperatively), and on post-operative day 2. Both doses will be administered while the patient is in the hospital. Alemtuzumab is supplied in single-use clear glass ampoules containing 30mg of alemtuzumab in 3mL of solution.
45506056|NCT03603210|Device|Drug coated balloon angioplasty|Drug coated balloons are semi compliant percutaneous coronary angioplasty balloons coated with a chemotherapeutic drug such as Paclitaxel used with an excipient which allows rapid absorption to vessel wall upon balloon expansion for 30-60s. This allows coronary angioplasty without any permanent or semi- permanent stent or scaffold provided there are no vessel threatening dissections or significant acute recoil.
45506057|NCT01375699|Drug|Doxorubicin|As prescribed by treating provider.
45506058|NCT01375699|Drug|Sildenafil|Given PO, by mouth
45506059|NCT02252276|Procedure|Experimental (proprioception exercises, muscle strengthening, joint mobilization)|The experimental group performed a combined protocol of proprioception (the patient doing exercises standing on an unstable plane)exercises and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle), and joint mobilization techniques of the ankle joint two session per week, during four weeks
45506060|NCT02252276|Procedure|Control (proprioception exercises, muscle strengthening)|The control group performed only proprioception exercises (the patient doing exercises standing on an unstable plane) and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle). Two sessión per week during four weeks
45506061|NCT03606720|Other|low level laser therapy|low level laser therapy (LLLT) is a modality that has been used by the medical profession for decades to treat acute and chronic pain conditions ranging from tendonitis and bursitis, to back pain and pelvic girdle pain.
45506062|NCT03606720|Other|pelvic stabilization exercises|special program of pelvic stabilization exercises depending on exercising of transverse abdominal in addition to co activation of lumbar multifidus muscles at the lumbosacral area , exercising of oblique abdominal, gluteus maximus, latissimus dorsi muscles , quadratus lumborum, erector spinae, also, hip abductors and adductors. will done by all patients
45506063|NCT01373983|Drug|Ziconotide|1.25 or 2.5 mcg or 3.75 mcg i.t. according to an algorithm
45506064|NCT03550430|Behavioral|alpha/delta neurofeedback|neurofeedback training protocol seeking to decrease the alpha/delta ratio, by simultaneous rewarding alpha and inhibiting delta activity.
45506065|NCT03550430|Behavioral|beta/theta neurofeedback|neurofeedback training protocol seeking to decrease the beta/theta ratio, by simultaneous rewarding beta and inhibiting theta activity.
45506066|NCT03550430|Other|Diary completion|completion of diary relating to participants' experience of tinnitus intensity, interference, coping, harm and disability. Rated three times daily on numerical scale (0 - 10) for two weeks.
45506067|NCT03603132|Drug|Hetrombopag Olamine|7.5mg in each cycle
46057056|NCT02778087|Behavioral|Mirror Box Therapy|The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on the mirror reflection of the unaffected arm throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: active range of motion (AROM), functional tasks with objects, and object manipulation.
45398032|NCT00166712|Drug|Mycophenolate mofetil (MMF)|MMF will be given at 1.0-1.5gm, twice daily, orally. The first dose will be given pre-transplant, open label fashion.
45398033|NCT03972566|Drug|INOMAX|INOMAX + PBM
45506068|NCT05173597|Drug|Follitropin delta|REKOVELLE® (follitropin delta), solution for injection - delivered with an injection pen, ATC code G03GA10, is a recombinant human FSH approved for the controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies such as an in vitro fertilisation or intracytoplasmic sperm injection cycle.
45506069|NCT03600636|Procedure|Diffusion tensor imaging MRI|"axial diffusion weighted sequence with 32 gradient encoding directions and two values b, 0 s / mm 2 and 1000 s / mm 2.~Fluid-attenuated inversion recovery~three-dimensional axial image weighted in T1~axial echo-planar image sequence~three-dimensional pulse sequence axial flight time"
45506070|NCT05812651|Other|Inspiratory muscle fatigue|"Muscle training according to the protocol that tends to induce inspiratory muscle fatigue. (60-80% MIP). Inspiratory resistive loading by starting at 60-80% (MIP) increasing every 10 minutes by 10% then measure MIP, until MIP measurement decrease of more than 10% from baseline will be performed.~When report a lower score of MIP and participants could no longer worked out, performed the functional mobility tests and see if there any variation."
45398034|NCT03973034|Diagnostic Test|Low depth whole genome sequencing|Low depth whole genome sequencing of the peripheral blood samples from different groups.
45398035|NCT02531750|Other|Immobilization due to an Achilles tendon rupture|
45398036|NCT01073306|Biological|Investigational Vaccine for Dengue Virus Subtype 2|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
45398037|NCT01073306|Other|Placebo|Subcutaneous injection of placebo
45398038|NCT03974438|Procedure|Superficial dry needling / Acupunture|Se arm-description.
45398039|NCT03972410|Behavioral|EMDR|2-4 sessions individual 60-min-long treatment sessions of EMDR Recent birth trauma protocol
45398040|NCT03972410|Behavioral|SEDP|2-4 sessions individual 60-min-long treatment sessions of SEDP
45398041|NCT01074710|Drug|[2-13C] uracil|po, in the form of semi-solid meal, granules, once a period
45398042|NCT01074710|Drug|[2-13C] uracil, placebo|po, in the form of semi-solid meal, granules, once a period
45398043|NCT01074788|Behavioral|mind body therapy|mind-body therapy includes guided imagery, relaxation techniques, mediation and touch therapy.
45398044|NCT00073528|Drug|Lapatinib|1500 mg orally once a day
45398045|NCT00073528|Drug|Letrozole|2.5 mg orally once a day
45506071|NCT05812638|Other|Mental imagery technique|Warm up Period Mental Imagery (Sit-stand task Static stance (30 seconds) Indoor walk on a leveled surface Walk indoor towards target Forward / Side Stepping) Walk outdoors
45849768|NCT04978350|Behavioral|Educational Workbook|"Let's Talk is an educational workbook on Lynch Syndrome and the benefits of cascade screening containing a series of lessons and activities on the following topics:~What is Lynch Syndrome? Why should a patient tell a patient's family members about Lynch Syndrome? Create a list of the patient's first-degree relatives at risk for inheriting Lynch Syndrome What should a patient tell family members about Lynch Syndrome? Create a script for the patient to use in discussing Lynch Syndrome with family What are common concerns the patient might hear from family members? How should the patient tell family members about Lynch Syndrome? Create a plan and goals for the patient to reach out to family members What the patient should do if conversation with family is difficult What are common terms and questions about Lynch Syndrome? How can the patient manage having Lynch Syndrome? Where can the patient find additional information about living with Lynch Syndrome?"
45506072|NCT05812638|Other|Virtual Reality technique|Virtual reality training (River rush, 20000 water leaks, reflex ridge.)
45506073|NCT05812625|Other|Myokinetic stretching technique|Myokinetic stretching technique (MST) is a form of myofascial release, which involves active or passive stretching and movement as well as muscle energy techniques until a desirable release from the taut band is achieved.
45506074|NCT05812625|Other|Post Isometric Relaxation|Post Isometric Relaxation (PIR) is the effect of the decrease in muscle tone in a single or group of muscles, after a brief period of submaximal isometric contraction of the same muscle.
45506075|NCT05812612|Drug|ursodeoxycholic acid|To study the incidence of COVID-19 infection and COVID-19 pneumonia in patients with autoimmune liver disease treated by UDCA, and to explore the impact of UDCA on COVID-19 infection, disease occurrence and clinical outcome.
46057057|NCT02778087|Behavioral|Sham Mirror Box Therapy|The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on an opaque mirror throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: AROM, functional tasks with objects, and object manipulation.
45506076|NCT05812599|Other|Educational Module|The COVID Test Learning Module will present four multi-part character scenarios that someone might experience when considering testing for COVID-19. Participants will answer questions about the character's behavior. Accurate guidelines will be provided in response to each scenario to educate participants about what to do in nuanced COVID testing decision-making situations.
45506077|NCT05812586|Biological|SCB-2019/Clover|SCB-2019/Clover Vaccine
45506078|NCT05812586|Biological|AstraZeneca/Fiocruz|AstraZeneca/Fiocruz Vaccine
45697558|NCT04263610|Drug|Dimethyl fumarate (DMF) standard scheme|Participants will receive DMF gastro-resistant tablet orally from baseline to Week 16, at a dose of 30 milligrams (mg) once daily, twice daily, thrice daily in Week 1, Week 2, Week 3 respectively, 120 mg only once in Week 4. Participants will increase DMF dose by 120 mg tablet per week for the subsequent 5 weeks. Participants achieving Psoriasis area and severity Index (PASI) 50-75 (partial responder) or 75 (responder) will continue the DMF treatment until Week 40. The maximum daily dose taken by a participant will be 720 mg.
45697559|NCT04263610|Drug|Dimethyl fumarate (DMF) simplified scheme|Participants will receive DMF gastro-resistant tablet orally at a dose of 60, 120, 180, 240, 360 mg daily in Week 1, Week 2, Week 3, Week 4, Week 5 respectively, and 480 mg daily from Week 6 to Week 8. If a PASI is greater than or equal to (>=) 30% at Week 8, no dose increase will be done and if PASI is less than (<) 30% at Week 8, participants will receive 600 mg daily in Week 9 and 720 mg from the Week 10 onwards.
46057058|NCT02778243|Biological|steroids concentrations determination|
45398046|NCT00073528|Drug|Placebo|Placebo (which matched with lapatinib tablet)
45398047|NCT01585012|Device|Cervical cap (Focus Touch™ Conception System)|Cervical cap
45506079|NCT05812586|Biological|Pfizer/Wyeth|Pfizer/Wyeth Vaccine
45398048|NCT01585090|Other|doing strengthening exercises of pelvic floor muscles|
45398049|NCT03801148|Drug|30 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release capsules.
45398050|NCT03801148|Drug|30 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release capsules.
45398051|NCT03801148|Drug|60 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release capsules.
45398052|NCT03801148|Drug|60 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release capsules.
45506080|NCT05812573|Other|no intervention|No intervention, only observation
45506081|NCT05812547|Device|Lumen|subjects will use the Lumen device and mobile phone application, which will guide them once a day after the night fast regarding their daily diet, sleep, and routines according to their Lumen measurements. Subjects will need Google Fit (Android) or Apple Health Kit (iOS) and will be encouraged to communicate with a study investigator via the app during the entirety of the study to resolve technical questions about the device and data collection.
45506082|NCT05812547|Other|Glucose monitoring mobile app|The control group will use a designated glucose monitoring mobile app to record their glucose levels
45506083|NCT05812521|Procedure|Paravertebral block with methylene blue|The paravertebral space is identified under ultrasound guidance and after negative aspiration a 3 ml test dose of anesthetic is injected. After observing widening of the paravertebral space and anterior pleural displacement to confirm the correct needle positioning, a bolus dose of 20 mL 0.5% ropivacaine with a solution of 1 ml 1% methylene blue and 4 ml of saline will be injected in the paravertebral space. At the start of the surgery, the spread of the solution of anesthetic and methylene blue will be assessed through visualization in thoracoscopy and if necessary the block will be repeated. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
45506084|NCT05812521|Procedure|Thoracic Epidural Anesthesia|The epidural catheter will be placed using the loss of resistance technique, and after ruling out intravenous or intrathecal catheter placement with a negative aspiration test dose, an initial dose of 10 mL 0.25% bupivacaine will be injected. Continuous infusion will be started with with 0.125 % bupivacaine + fentanyl 0.5 mcg/ ml at 6-10 ml/hour will be started based on the patient weight for 48 hours postoperatively. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
45506085|NCT05812508|Device|corneal topography|corneal topography before and after pterygium surgery by two techniques bare scleral and conjunctival autograft
45506086|NCT05812495|Procedure|Esophagogastric Side to Side Anastomosis|Esophagogastric Side to Side Anastomosis
45398053|NCT03960814|Drug|Insulin detemir|No treatment will be given to the patients in relation to this study. Patients have been included in this study because they have been treated with insulin glargine or detemir prior to study initiation (2004 - 2018) and according to routine clinical practice at that time. The decision to initiate treatment with commercially available insulin detemir and glargine has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
45506087|NCT05812495|Procedure|Esophagogastric End to Side Anastomosis|Esophagogastric End to Side Anastomosis
45506088|NCT05812482|Procedure|Drug balloon dilatation|The Drug balloon is covered with paclitaxel coating that diffuses the drug into the urethral wall when dilated
45506089|NCT05812482|Procedure|Direct vision internal urethrotomy (DVIU)|A control subject will choose DVIU surgery until the desired effect is achieved
45506090|NCT05812469|Behavioral|Brain Awareness Intervention|effect of brain awareness intervention on metacognition, self-efficacy and treatment motivation in patients with alcohol and substance use disorders
45398054|NCT04692532|Other|8-hour Time restricted eating|Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
45506091|NCT05812469|Behavioral|Being Healthy Education|This training included trainings on Healthy Nutrition, Sexually Transmitted Diseases, Importance of Physical Activity and Personal Hygiene prepared by the researcher in the form of presentations for the patients in the control group.
45398055|NCT04692532|Other|Calorie restriction|25% energy restriction every day
45506092|NCT05812456|Other|Estimation of Shear Bond Strength|"Measuring shear bond strength between the different bracket brands and the enamel will be estimated by aiming the edge of the blade of the universal testing machine at bracket-enamel interface. The force required to debond each bracket will be registered in Newtons (N), and converted to Megapascals by dividing the force registered in newtons on each bracket base area (mm2).~After bond failure, the brackets and the enamel surfaces will be examined and assessed for the amount of adhesive remaining on the bracket bases by using digital microscope at 35x magnification. this will identify the site of bond failure."
45506093|NCT05812430|Drug|anlotinib+TQB2450+nab-paclitaxel+cisplatin|"Anlotinib: 10mg, po, d1~14, q3w, until disease progression or unacceptable toxicity.~TQB2450: 1200mg, ivgtt, d1, q3w, until disease progression or unacceptable toxicity.~nab-paclitaxel: 200mg/㎡, ivgtt, d1, q3w, 6 cycles. cisplatin: 60mg/㎡, ivgtt, d1, q3w, 6 cycles."
45506094|NCT05812404|Drug|DWP14012|Potassium-competitive acid blocker
45506095|NCT05812404|Drug|DWC202201|Atorvastatin Calcium Trihydrate
45697560|NCT04263610|Drug|Tildrakizumab|Participants who achieve PASI less than (<) 50 (non-responders) at Week 16 will receive Tildrakizumab subcutaneous injection at a dose of either 100 or 200 mg [(as per the Summary of Product Characteristics (SmPC)] at Weeks 16, 20 and 32 up to Week 40.
45398056|NCT01103830|Drug|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3
45398057|NCT01103830|Drug|Riamet®|4 tablets of Riamet® (20mg artemether/120mg lumefantrine) on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.
45398058|NCT01103830|Other|Placebo and finally Moxifloxacin|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin) on Day 4 morning."
45398059|NCT01103830|Drug|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
45398060|NCT01103830|Drug|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
45398061|NCT01103830|Other|Placebo and finally Moxifloxacin|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin)on Day 4 morning."
45398062|NCT01106482|Other|Serology blood draw|Blood draw only, no vaccine
45398063|NCT01103908|Device|HCE101 Cardiopulmonary Support Monitor|Measurement of cardiac output using ultrasound dilution technology. The ultrasound dilution technology is in the HCE101 Cardiopulmonary Support Monitor.
45398064|NCT01106560|Procedure|Minimally Invasive Anterior Approach|Anterior minimally invasive surgery (AMIS)
45398065|NCT01106560|Procedure|Standard postero-lateral approach|
45398066|NCT01106638|Behavioral|Positively Smoke Free|An eight session, group therapy intervention targeting smokers living with HIV/AIDS
45398067|NCT01106638|Behavioral|Standard care|Advice to quit, smoking cessation brochure, and offer of nicotine patches
45398068|NCT05532670|Device|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
45398069|NCT02530684|Other|insole|Insoles available on the market without prescription
45398070|NCT04633408|Behavioral|STAR-C Virtual Training and Follow-up (STAR-VTF)|STAR-C Virtual Training and Follow-up (STAR-VTF) is adapted from an evidence-based, in-person program that trains family caregivers to manage BPSD (behavioral and psychological symptoms of dementia)
45398071|NCT04631770|Procedure|Systemic mediastinal lymph node dissection|Dissection of at least 3 groups of mediastinal lymph nodes, group 7 must be included.
45398072|NCT04631770|Procedure|No mediastinal lymph node dissection|Mediastinal lymph node is not dissection in this group.
45398073|NCT00072280|Biological|dactinomycin|Given Slow intravenous (IV) push over 1-5 minutes, dose < 1yr 0.025 mg/kg > or = 1 yr 0.045 mg/kg (max dose 2.5 mg) on days 1,22,43 and 64
45398074|NCT00072280|Drug|cyclophosphamide|Given IV over 60 minutes, dose 25 mg/kg on days 1,22,43 and 64.
45398075|NCT00072280|Drug|etoposide|Given IV over 1 hour, dose 3.3 mg/kg in normal saline (NS) 10 cc/kg (or to equal 0.4 mg/mL concentration) on days 1-5 of IE cycle.
45398076|NCT00072280|Drug|ifosfamide|Given IV over 1 hour, dose 60mg/kg in D5 1/4 NS 10 cc/kg IV on days 1-5 of IE Cycle
45849769|NCT04963920|Device|Cytosorb® 300 ml|patients wiil receive CytoSorb therapy in addition to standard of care therapy according to applicable guidelines
45849770|NCT04956666|Drug|Lyophilized S95014|"Each patient will be administrated, over 1 to 2 hours, every 2 weeks Lyophilized S95014 intravenously at the dose of 1000, 2000 or 2500U/m2, as per investigator's judgement.~In total, 9 infusions of lyophilized S95014 will be administrated (at week 7, 9, 11, 15, 17, 19, 23, 25 and 27).Patients will receive other backbone chemotherapy agents as per ALL-MB 2015."
45849771|NCT04945590|Behavioral|Virtual Intervention Program|Four separate virtual individual and group interviews (via telephone or online), which will be scheduled with the help of champions and leaders of the Latino community who will collaborate as companions to improve the commitment and experience of families.
45849772|NCT04935684|Drug|Fecal Microbiota Transplantation|"Patients randomized in the FMT group will received FMT within 4 weeks following neutrophils recovery after the allo-HSCT procedure. The stool transplant will be done by enema. The day before FMT, patient will undergo bowel cleansing by ingestion of two liters of polyethylene glycol solution. The day of FMT, a colon cleanse enema will be performed in the morning and FMT will be delivered around two hours after the cleanse enema. This colic preparation is essential to optimize the results of FMT.~The enema (50g of stools diluted in 250mL of NaCl 0.9%) will be performed by a qualified member of the study team (nurse) by using a rectal cannula (within 6 hours of thawing). The enema will have to be kept by the patient for as long as possible and at least 30 minutes."
45398077|NCT00072280|Drug|vincristine sulfate|Given IV Push over 1 minute, dose 0.05 mg/kg (max dose 2 mg) on days 1,8,15,22,29,36,43,50,57 and 64
45398078|NCT00072280|Procedure|Conventional Surgery|"Applied only when lesion is resectable. Surgery is the primary means of local control in this study and reasonable attempts at achieving clear margins with an envelope of normal tissue should be undertaken at the initial and/or subsequent resections."
45398079|NCT00072280|Biological|MESNA (mercaptoethane sulfonate)|Given orally. Oral daily MESNA dose is equal to at least 60% of the daily cyclophosphamide dose.
45398080|NCT00072280|Biological|Filgrastim|Given IV - Only use filgrastim if chemotherapy has been delayed or modified for hematologic toxicity, or if patient experiences a significant life-threatening toxicity due to bone marrow suppression
45398081|NCT05527834|Drug|VNRX-7145|Single oral dose
45398082|NCT05527834|Drug|Ceftibuten|Single oral dose
45398083|NCT03948412|Device|Closed Incision Negative Pressure Wound Therapy (Prevena)|Closed Incision Negative Pressure Wound Device (Prevena) applied to closed wound at completion of operation.
45506096|NCT05812339|Device|Gastric Alimetry System|Gastric Alimetry is a medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders. The device is indicated for use during the diagnostic work-up of patients reporting gastric symptoms, who are suspected of having an underlying gastric motility problem.
45506097|NCT05812326|Drug|AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells|AJMUC1 is a genetically modified T cell therapeutic product targeting the aberrantly glycosylated MUC1 protein. CAR targeting MUC1 is introduced into autologous T cells by lentiviral vector, so that T cells expressing the receptor can recognize and kill MUC1 positive tumor cells. Preclinical studies have shown that binding of scFv targeting MUC1 to the MUC1 epitope on the surface of the target cell can induce the costimulatory CD28 and CD3ζ costimulatory domains to activate downstream signaling pathways and promote T cell activation and expansion. Activated CAR-T cells secrete a series of inflammatory cytokines and chemokines, leading to apoptosis and necrosis of target tumor cells. Following introduction of a CAR structure, the PD-1 gene of CAR-T cells is knocked out using CRISPR/Cas9, so that the CAR-T cell does not express PD-1, resulting in improved tumor killing efficiency of AJMUC due to the release of inhibition in the signaling pathway PD-1/PD-L1 in the tumor microenvironment.
45506098|NCT03607110|Drug|Ketamine|sedation drugs
45506099|NCT03607110|Drug|fentanyl|sedation drugs
45506100|NCT03607110|Device|patient control analgesia|patient control analgesia
45506101|NCT05812300|Drug|Freshly manufactured 35 kDa hyaluronan fragment|The study was an open-label clinical trial. A pre- and posttreatment controlled study approach was used, whereby the investigator injected 35 kDa hyaluronan fragment HA35 into the periodontal pocket in a single dose of 100 mg. The distribution of the injection amount was determined by the location of gingival inflammation.
45506102|NCT05812274|Other|Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation|"The Apricity CARE program for Cancer Adverse events Rapid Evaluation is a cloud-based 24/7 on-demand clinical coverage service, delivered exclusively via the ApricityRx digital care platform by certified and licensed healthcare professionals who are trained to monitor patient's symptoms and conduct standardized triage following guideline-based or protocol-specified pathways with 3 parts:~ApricityCare™ Mobile Application - to collect health data (PGHD) on biometrics and self-reported symptoms (PRO) of symptoms and potential side effects at home, in between doctors' visits, and offers educational content in video.~ApricityOncology™ Web-based Application - to provide authorized healthcare providers an organized, longitudinal and summarized view of a patient's pertinent cancer history and real world PGHD for purpose of symptom monitoring.~ApricityManage™ Dashboard - a dashboard intended for administrators, sponsors or funders to track program status."
45506103|NCT05812222|Behavioral|Skin-to-Skin contact.|Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
45506104|NCT05812209|Procedure|Stellate Ganglion Block|Ultrasound guided block of the Stellate Ganglion with local anesthetics.
45506105|NCT05812144|Other|Remote monitoring program|Remote program is composed of some questionnaires and physical exercises performed at home and at hospital (depending on the concerned visit)
45506106|NCT05812092|Device|CONDUIT Interbody Cervical System with DePuy Synthes Cervical Plating System|CONDUIT Interbody Cervical System will be inserted between C2 through T1 and fixated using a DePuy Synthes Cervical Plating System at 1 or 2 levels.
45697561|NCT00997594|Procedure|Radiofrequency ablation|Radiofrequency (RF) ablation was done after RF electrodes were placed in the adrenal tumor in the adrenal RF ablation group. RF ablation was done after RF electrodes were placed in the targeted abdominal tumors other than adrenal gland in the abdominal RF ablation other than adrenal gland group.
45697562|NCT04225390|Drug|Dacarbazine (DTIC)|Dacarbazine powder for IV solution
45849773|NCT04927806|Device|Silver Knight|"Silver Knight breathing systems are all validated for up to seven days use, and remain active, in unopened packaging, for up to five years. Silver Knight is proven to help reduce the incidence of MRSA infection and other organisms including:~Staphyloccus epidermis~Pseudomonas aeruginosa~Klebsiella pneumoniae~Acinetobacter calcoaceticus~Escherichia coli"
45849774|NCT04911894|Drug|IBI321|Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
45398084|NCT03948412|Other|Control - Standard Dressings|Standard wound dressings applied to closed wound at completion of operation.
45398085|NCT05514964|Behavioral|Feasibility study|"Individuals wishing to participate in this study will be informed about the intervention via the project website and Facebook page of the project. Prior to the start of the study, participants will be instructed to read the Informed Consent and express their agreement to participate. Only then the participants will be able to complete the screening questionnaires online.~The ACT therapeutic program (based on Acceptance and Commitment Therapy protocol) consists of six treatment modules adapted to the online environment. Each module is structured like a therapy session and contains at least two or three homework assignments. Each participant will be assigned to an online psychotherapist. At the end of the six modules, participants will complete the post-test measurements."
45506107|NCT05812066|Procedure|all ceramic single-retainer resin bonded fixed partial denture|The intervention will be all ceramic single-retainer RBFPD using the upper canine as abutment with minimum preparation on the lingual surface within the enamel providing maximum area for the retainer bonding, to replace the upper lateral incisor and will be compared with the control/comparator group which is the all ceramic single-retainer RBFPD using the upper central incisor.
45506108|NCT05812053|Procedure|pulpotomy|Teeth will be anesthetized then Rubber dam and high suction will be used in pulpotomy procedure. Cavity outline was performed by sterile #330 high speed bur using water spray. Caries was removed by large spoon excavator. When pulpal exposure occurred, the roof of pulp chamber removed by low speed round bur. Haemostasis was obtained by applying pressure with moist cotton pellet with saline. Then the test materials was applied. after that, pulp stumps of all molars in each group will be dressed using Intermediate restorative material then the tooth will be restored with a preformed stainless steel crown
45506109|NCT05812053|Radiation|cone beam computed tomography (CBCT) assessment|a post-operative CBCT image will be taken immediately after completing the procedure with fixed exposure parameters (120 Kv, 5mA, and 0.125mm voxel size) using the smallest field of view (8D, 8Hcm) also, after 6 and 12 months follow-up periods.
45398086|NCT03946696|Other|Interactions with therapy-animals|How people interact with humans and non-humans animals during and outside visits from therapy-animal teams.
45398087|NCT01103986|Behavioral|Motivational/health literacy education (Test group)|"Attend a 1-hour class to learn how to use the book What to Do When Your Child Gets Sick."
45506110|NCT05812040|Diagnostic Test|Magnetic Resonance Ductography (MRD); and High-Resolution Magnetic Resonance Ductography (HR-MRD)|all participants will receive Magnetic Resonance Ductography (MRD) and High-Resolution Magnetic Resonance Ductography (HR-MRD) examination, using breast dedicated coil and microscopic coil, respectively
45506111|NCT05811975|Drug|KSX01-TCRT injection|individualization TCR-T cell injection
45506112|NCT05811962|Other|No intervention|No intervention, only comparison
45506113|NCT05811936|Behavioral|Survivorship Needs Assessment Planning (SNAP) tool|"SNAP includes 2 educational survivorship modules for caregivers and survivors. There are 3 main elements: needs assessment, a tailored care plan and a mobile support app. SNAP uses pre-specified categories of needs, resources, and messaging behind the scenes to automate the identification, rating and management of high priority needs. Generated tailored care plans include referrals, messages and educational materials mapped to prioritized dyad-reported concerns addressing survivorship domains (diagnosis, treatment, follow-up care). Care plans and referrals are reviewed with an Advanced Practice Provider. Barriers to uptake are addressed, goal-oriented action planning is refined with brief mobile app training. Dyads receive a personalized binder with care plan, referrals, and an action plan. Dyads receive e-monitoring for 6 weeks to check in and identify barriers with algorithm-driven messaging to reinforce progress, provide further resources and encouragement."
45506114|NCT05811923|Other|Venous Blood Collection|Within each supplementation condition, study participants will have their venous blood collected on six different occasions: 0, 30, 60, 90, 120, and 180 minutes after ingestion of their assigned study agent. Blood will be collected via a forearm vein using standard phlebotomy techniques using either an indwelling catheter or single venipunctures. All blood samples will be collected into ethylenediaminetetraacetic acid EDTA-coated Vacutainer™ tubes and gently inverted ten times before being centrifuged at 3000 revolutions per minute (rpm) (MegaFuge XFR, Thermo Fisher Scientific, Waltham, MA, USA) at 4oC for 20 minutes. After centrifugation, 400 μl aliquots of plasma will be removed and frozen at -80oC within four hours of collection.
45398088|NCT04597606|Other|Exercise with spontaneous ventilation.|"Patients will perform 10 minutes, constant load, exercise in a cycloergometer. To set the load, a baseline incremental effort test will be performed previously (VISIT 1).~Then, in a separate day (VISIT 2), the subject will perform 10 minutes cycling at the 75% load of that determined as maximum in VISIT 1, at a constant rate of 30 to 35 pedal revolutions per minute, in spontaneous breathing, with low flow oxygen through conventional nasal cannula adjusted to achieve SpO2 between 92to 94%"
45506115|NCT05811923|Other|Resting Metabolic Rate Determination|During all study visits and on six occasions during each of the seven experimental conditions (0, 30, 60, 90, 120, and 180 minutes after supplement ingestion), resting metabolic rates will be determined in a thermoneutral laboratory environment.
45506116|NCT05811923|Other|Mood State|Participants will complete electronic versions of the Profile of Mood States (POMS) questionnaire to evaluate perceptual responses. The Profile of Mood States (POMS) is a 65-item validated scale that uses a 5-point Likert scale with each individual area being scored and summed into profiles for tension, anger, vigor, fatigue, depression, and confusion. Finally, a total mood disturbance score will be calculated by summing all categories and subtracting the vigor score.
45849775|NCT04896372|Other|ACT comprehensive of standard care|"The proposed intervention was designed by the authors of the study. It was developed following the main ACT-based manuals, with adjustments according to the users and the context of the study implementation.~Specifically, we developed a practical and interactive intervention, which comprises practical activities such as roleplay and writing activities and imaginative activities supported by metaphors. The sessions are based on the use of age-appropriate language to convey the most complex therapeutic processes easily. According to Strosahl and colleagues' model, sessions will respectively target the components of openness, awareness, and engagement."
45398089|NCT04597606|Device|Exercise with NIV|VISIT 2 Non invasive mask ventilation: parameters will be titrated during a free cycling period at the end of the spontaneous breathing exercise. Then, in a separate day (VISIT 3), with the same constant load, cycling cadence and under NIV, the patient will perform 10 min of cycling.
45398090|NCT04597606|Device|Exercise with HFNC|With constant flows of 50 lpm and with FiO2 adjusted according to SPO2, to obtain a constant saturation between 92 and 94%. The same pedaling load and frequency will be maintained, with similar variables collected.
45398091|NCT01104064|Device|real rTMS combined with constraint induced therapy|10 minutes of priming followed by 10 minutes of low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
45398092|NCT01104064|Device|sham rTMS combined with constraint induced therapy|10 minutes of sham priming followed by 10 minutes of sham low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
45506117|NCT05811923|Other|Visual Analog Scales|"Participants will complete electronic versions of the visual analog (VAS) scale to evaluate perceptual responses. Each VAS scale will be completed using a 100-mm line anchored by Lowest Possible and Highest Possible to assess subjective ratings of focus, anxiety, concentration, energy, restfulness, wakefulness, swagger, confidence, hunger, and appetite. The validity and reliability of VAS to assess fatigue and energy have been previously established (Lee, Hicks, et al. 1991) and our methods have been published elsewhere (Ziegenfuss, Habowski, et al. 2017, Ziegenfuss, Lopez, et al. 2017, Ziegenfuss, Kedia, et al. 2018, Zabriskie, Blumkaitis, et al. 2020)."
45506118|NCT05811897|Behavioral|Self-Managed Online Treatment|"Self-help online cognitive-behavioural therapy focusing on post-traumatic stress, sleep and mood. The content is divided into three modules :~Coping with my trauma: psychoeducation about PTSD, cognitive restructuring prolonged exposure to avoided situations and memories (14 sessions)~Sleeping better: psychoeducation about, sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education), Imagery Rehearsal Therapy (10 sessions)~Improving my mood: psychoeducation about depression, behavioural activation; relaxation and mindfulness exercises; problem-solving strategies (6 sessions)~A small portion of material is unlocked each week, and access to one module will be accessible after the completion of a previous one. Access to the online material will be unlimited in time. Participants complete self-report questionnaires after each module, the platform then provides feedback and suggests corresponding modules."
45506119|NCT05811897|Behavioral|Therapist-Assisted Online Treatment|Same online intervention. Supervised graduate psychology students will provide brief regular weekly contacts for up to 30 weeks by video chat or phone, according to the participant's preference.
45506120|NCT05811884|Device|Rehabilitation|"The subjects will be provided of the powered exoskeleton for home use. No specific indications will be provided, but using the technology as much as possible.~The subjects will be asked to attend to periodic rehabilitation sessions by the clinical facility. The rehabilitation session will consist in an intense 1-week activities session every three months.~Every six months, the subjects will be asked to attend a single-day session by the clinical facility (follow-up session) consisting on the assessement of a series of qualitative and quantitative measurements."
45506121|NCT05811832|Other|Evaluation|Modified Medical research Council , Saint George Respiratory Two Minute Walk Test,Frail fragility scale ,Prisma-7 Vulnerability scale,Pase,Berg balance scale,manual muscle test,quadriceps muscle strength, hand dynamometer,Fatigue Severity Scale
45506122|NCT05811819|Device|Treatment using the MyHand System|Participants will undergo three weeks of 1-hour hand therapy with the MyHand System. The MyHand System provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy.
45849776|NCT04896372|Other|TAU only|adolescents will be assessed by a staff dietician and placed on an individualized hy-pocaloric balanced Mediterranean diet. They will also follow a nutritional counselling aimed at promoting the adoption of a healthy lifestyle. Moreover, they will attend a physical activity program consisting of five training sessions per week lasting one hour each with trainers; In addition, they will be involved in psychological counselling pro-vided once a week by a clinical psychologist, aimed to address psychological factors related to dysfunctional lifestyle habits.
45398093|NCT04593394|Diagnostic Test|Continous laryngoscopy exercise test|Participants walks on a tredmill with a a flexible naso-laryngoscope in the larynx allowing visulasion of the larynx and obstructions in the larynx at the epiglottic og glottic levels are scored
45398094|NCT04593394|Diagnostic Test|Overnight respiratory polygraphy|Overnight respiratory polygraphy is a continuous recording of nasal airflow, thoracic and abdominal movements, heart rate and oxygen saturation during the night used to detected sleep apnoea
45398095|NCT01106716|Drug|Placebo|Placebo IV Infusion
45398096|NCT01106716|Drug|KAI-1678|KAI-1678 IV Infusion
45398097|NCT01106716|Drug|Lidocaine|Lidocaine
45398098|NCT00071812|Drug|Placebo|Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
45398099|NCT00071812|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
45398100|NCT00071812|Drug|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
45398101|NCT00071812|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on the same dose of belimumab (10 mg/kg) for an additional 24 weeks.
45398102|NCT00071110|Procedure|Electroacupuncture|For subjects randomized to EA, needles were placed at points GV-20-on the crown of the head and yin tang-on the midline of the forehead roughly at the glabella and treated with electrical stimulation. 30 mm x 0.22 mm sterile stainless steel needles were placed obliquely to a depth of approximately 10 mm and were connected to face-microelectrodes which were connected to the Pantheon Research PENS-Electrostimulator. Electricity was provided at a frequency of 2 Hz and set to a voltage which resulted in the perception of a mild intensity stimulation.
45398103|NCT00071110|Procedure|Sham|For subjects randomized to SA, two needles were placed laterally on the scalp, 3 cuns superior to the temporal attachment of the helix of the ear. This point was selected as it does not correspond to any specific meridian acupuncture point. A disabled electrical cable was connected to the needles and the electrostimulator, with light blinking at 2 Hz but no electrical stimulation provided.
45506123|NCT05811806|Device|Treatment using the MyHand System|Participants will undergo three weeks of 1-hour hand therapy with the MyHand System. The MyHand System provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy.
45506124|NCT05811793|Drug|Tislelizumab and Bevacizumab|Tislelizumab is a drug material authorized for marketing in China. Tislelizumab will be administered off-label in this study. Subjects with recurrent GBM will receive intrathecal tislelizumab every 3 weeks for six times. Intrathecal administration of Bevacizumab will be performed via Ommaya reservoir or intraventricular catheter.
45506125|NCT05811767|Other|Health Examination|The study is a cross-sectional study and therefore there is no intervention. The study consist only of tests, questionnaires and a blood test. See the elements under outcomes measures.
45506126|NCT05811754|Other|Data collection|"This study will be conducted using data provided by U.S. Data Partners in the FDA's Sentinel System.~Three Data Partners will participate in this study: CVS Health Clinical Trial Services (CTS), HealthCore, Inc., and Optum."
45506127|NCT05811728|Radiation|Low level laser therapy|The low-level laser applied will be a Diode laser* emitting infrared radiation at a wavelength of 980 nm, in a continuous mode. On the experimental side, subjects will receive LLLT on days 0, 3, 7, 14, and every 2 weeks thereafter, till the termination of the study period (3 months).
45506128|NCT05811728|Other|without beam emission|The laser tip will be held passively on the control side without beam emission, providing a placebo effect.
45506129|NCT05811715|Other|whole body stretching excercise|For the WBS group, each 30 minutes exercise class was run by a one trained physiotherapist to serve a maximum of 10 participants (10 x 3 = 30 participants) working in the hospital. Participants invited to attend the exercise class 3 times a week for 6 weeks in their hospital during lunch-break. During each session, participants asked to perform WBS exercise (Franco et al., 2008).
45506130|NCT05811715|Other|educational program|Participants received an education program which includes ergonomic principles, WRMSDs and their risk factors, as well as manual handling techniques(Bolbol et al., 2017).
45506131|NCT05811689|Diagnostic Test|sm tbs group|"After collecting anthropometric data, information on environmental factors and lifestyle (smoking, alcohol intake, physical activity, sun exposure, vitamin D supplementation, fish consumption) will be acquired through a questionnaire.~The genetic and environmental aspects related to multiple sclerosis will also be studied. Disability status will be assessed through the Kurtzke Extended Disability Status Scale (EDSS). [10] All recruited patients will be administered the questionnaire (Multiple Sclerosis Quality of Life-54 (MSQOL-54) composed of 14 scales and 54 items. The scales investigate physical functions, limitations with respect to physical and emotional role, pain, emotional well-being, degree of energy, perceptions of one's health, social, cognitive and sexual functioning, distress, changes in health, satisfaction with sexual functioning and quality of life in general."
45697563|NCT05507164|Drug|Temporomasseteric Nerve Block|The TMNB injection is a local anesthetic injection technique that targets the anterior deep temporal and masseteric branches of the mandibular division of the Trigeminal Nerve. The surface landmark for the twin block injection site is located by palpating for the depression created by the greater wing of the sphenoid bone at the superior border of the zygomatic process and approximately 1 cm posterior to the posterior border of the frontal process of the zygomatic bone. This site is first disinfected with alcohol wipes prior to inserting a 27- or 25-gauge long dental needle (32 mm). Angled 35-45° away from the calvarium (skull) and perpendicular to the zygomatic arch (along the coronal plane), the needle is advanced to its length before injecting 1.8 mL of 2% lidocaine with 1:100,000 epinephrine.
45697564|NCT00997672|Drug|Lithium Carbonate|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
45849777|NCT04889898|Device|Digital recording of speech and swallow sounds using the Beiwe Digital Health App on a personal smartphone|[Patients only] Weekly completion of audio recordings of speech and swallowing performed at home by the subject using the study smartphone application on their personal device.
45849778|NCT04889898|Radiation|Modified Barium Swallow Study (MBSS)|[Patients only] MBSS is an instrumented evaluation of oropharyngeal swallowing function that is performed using videofluoroscopy.
45398104|NCT03960346|Procedure|Ablation with cryoenergy|Esophageal temperature-guided ablation using cryoengery and an esophageal temperature probe.
45398105|NCT01104142|Device|CGM|Continuous Glucose Monitoring System
45398106|NCT01327924|Drug|Norditropin NordiFlex®|Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.
45398107|NCT03946384|Other|data collection|data collection on the history of the disease, hemophilia
45398108|NCT01104298|Drug|Doxorubicin|A maximum of 6 cycles every 3 weeks of doxorubicin monotherapy 75 mg/square meter will be given in the absence of progression or not acceptable toxicity.
45398109|NCT01104298|Drug|Trabectedin|A maximum of 6 cycles every 3 weeks of the combination (Trabectedin 1,1 mg/square meter + doxorubicin 60 mg/square meter) will be given in the absence of progression or not acceptable toxicity.
45398110|NCT04013152|Other|Clinical database|Constitution of a prospective, multicenter clinical database of surgery with robotic assistance in colorectal pathologies
45398111|NCT01106872|Drug|Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid|
45398112|NCT00071032|Biological|Liberal (10 g/dL) Transfusion Strategy|This transfusion strategy will maintains postoperative Hgb levels above 10 g/dL. This threshold strategy will use enough red blood cell units to maintain Hgb levels at or above 10 g/dL through hospital discharge or up to 30 days after randomization.
45506132|NCT05811650|Behavioral|Oral Health Counseling and promotion|The intervention was cluster randomized control trial in design. We select six schools for the intervention group and six schools for the control group. Follow-up of the intervention was done after six months of baseline. Impact of the intervention was assessed among the same participants who enrolled in the baseline. The interventions were done in every three months.
45506133|NCT05811637|Other|Pilates Exercise|The program will be applied with the Pilates exercises every week. All patients were evaluated before and after the treatment (6 weeks).
45398113|NCT00071032|Biological|Restrictive (Symptomatic) Transfusion Strategy|Transfusion is withheld until the patient develops symptoms from anemia (i.e., chest pain or ECG changes thought to be ischemic, congestive heart failure, unexplained tachycardia or hypotension unresponsive to fluids) or until the hemoglobin level falls below 8 g/dL. Transfusion is permitted, but is not mandatory, if the hemoglobin level falls below 8 g/dL.
45398114|NCT03960268|Drug|Brodalumab|interleukin 17 receptor A antagonist
45398115|NCT05485480|Drug|conventional opioid-based group|In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the conventional opioid-based group will receive the following drugs: Remifentanil and Fentanyl
45398116|NCT05485480|Drug|opioid-sparing group|In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the opioid-sparing group will receive Ketamine, Fentanyl, Lidocaine, Magnesium, Clonidine, Remifentanil
45506134|NCT05811637|Other|Supervised Rehabilitation|The program will be applied with the progression of the supervised rehabilitation in the 4th week
45697565|NCT00997672|Drug|Placebo|
45697566|NCT04160650|Behavioral|Educational nursing intervention on nutrition intake related chemotherapy induced side-effects' self-care among the patients with colorectal cancer|"This is an educational intervention which aims to answer the questions:~In patients with CRC what is the effect of empowering education versus standard education on knowledge level in 4 months follow-up?~In patients with CRC what is the effect of empowering education versus standard education on activation level related to nutrition impact side effects' self-care in 4 months follow-up?~In patients with CRC what is the effect of empowering education versus standard education on malnutrition risk in 4 months follow-up?~In patients with CRC what is the effect of empowering education versus standard education on QoL in 4 months follow-up?"
45398117|NCT03960502|Drug|AG-881|Single oral dose of approximately 50 mg AG-881 (free form) containing approximately 100 microcuries (μCi) of [14C]AG-881.
45398118|NCT03960502|Drug|[13C315N3]AG-881|Single IV microdose of approximately 100 μg.
45398119|NCT01107028|Other|Standard pulmonary rehabilitation program|At the assigned time, subjects will complete a six-week, outpatient pulmonary rehabilitation program at any local center that has such a program.
45506135|NCT05811611|Behavioral|WeChat Mini Program plus tailored online health promotion videos|Participants have access to a WeChat Mini Program. Participants will also watch online health promotion videos tailored to their current sexual behaviors.
45506136|NCT05811611|Behavioral|WeChat Mini Program Only|Participants only have access to a WeChat Mini Program.
45506137|NCT05811585|Device|ADEPT|Adhesion Reduction Solution (4% icodextrin solution)
45506138|NCT05811572|Device|measurement of pelvic floor muscle with perinometer|Questions the person's perceptions about low back pain and related disability VAS questions the person's perceptions about low back pain severity
45506139|NCT05811559|Other|No intervention|No intervention
45697567|NCT04828161|Drug|ensovibep|IV on day 1 only.
45697568|NCT04828161|Drug|Placebo|IV on day 1 only.
45697569|NCT01000324|Procedure|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
45697570|NCT01000324|Biological|Engerix-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B
45697571|NCT01000324|Biological|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies
45697572|NCT04399629|Behavioral|PCIT-ED|12 sessions of PCIT-ED therapy
45697573|NCT04399629|Behavioral|Parenting Wisely|Teaches parents how to set more effective limits
45849779|NCT04889898|Behavioral|Speech Intelligibility Test (SIT)|[Patients only] The SIT is a standardized test for measuring speech intelligibility.
45398120|NCT05470270|Drug|Hydroxycarbamide|Single administration of the new dispersible form of hydroxycarbamide at the usual dose in children with sickle cell disease who are already treated with the current form of hydroxycarbamide.
45398121|NCT05372926|Device|high flow nasal canulae|high flow nasal canulae is a oxygen therapy technic which allows the administration of warmed and humidified oxygen with a flow up to 50L/Min and a monitored FiO2. Physiological previous studies reported various effects of this technic especially on work of breathing. In our study the investigators aim to test this physiological property during exercise.
45398122|NCT05372926|Device|Ventury mask|Ventury mask is a oxygen therapy technic which allows the administration with a mask of oxygen with a flow up to 15L/Min and a monitored FiO2.
45398123|NCT04468906|Procedure|Biceps Tenodesis|Biceps tenodesis describes the surgical procedure that will be performed to treat LHBT lesions.
45398124|NCT04468906|Procedure|"Self-locking T Tenotomy"|"Self-locking T Tenotomy describes the surgical procedure that will be performed to treat LHBT lesions."
45398125|NCT03945994|Other|Connecting People Intervention|Improve the resourcefulness of social networks of people with mental health problems
45398126|NCT01107106|Drug|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
45398127|NCT01107106|Drug|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
45697574|NCT03260361|Other|Hypnosis, kinesitherapy, MEOPA|classical intervention
45506140|NCT05811546|Diagnostic Test|Immunohistochemical staining for DNMT1 and EZH2|Immunohistochemical staining for DNMT1 and EZH2 using rabbit monoclonal/polycolonal antibodies with immunoperoxidase staining will be used as a visualization method. Antibodies dilutions, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions.
46057059|NCT02713971|Device|Gamepad system|Patients executed a set of tailored exercises including the control of weight-shift and body posture during static (e.g. upright sitting and standing), quasi-dynamic (e.g. sit-to-stand and gait initiation) and dynamic tasks (e.g. getting on a step, straight-line walking, walking with turns and over obstacles). Participants executed the tasks using Gamepad system which provided patients with visual and auditory feedback about their performances and assigned a score at the end of each exercise. The physiotherapist progressively adjusted training complexity by changing the reference values, including more difficult taks, changing the perceptive context, and/or including a dual-task.
46057060|NCT02713971|Other|Conventional physiotherapy|A set of tailored exercises was defined by the clinical staff following current guidelines for physiotherapy in Parkinson's disease. In particular, stretching, joint mobilization, and balance and gait exercises were provided to participants, without any instrumentation producing biofeedback or external cues.
46057061|NCT02778009|Radiation|iDEXA Scan|Subjects will receive pre study and post study scans to assess body mass composition
46057062|NCT02778009|Other|Wellness Lectures|Subjects in the Fit Physician Arm will be required to attend monthly wellness lectures
45506145|NCT05811507|Diagnostic Test|serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfate|Venous blood samples will be collected into sterile EDTA tubes around 10 am. Blood taken from controls will be collected at the same time. All samples will be delivered into the laboratory immediately after collection and centrifuged at 3000 × g, 4 °C for 10 min. Plasma samples were stored at -80 °C until the analysis using ELIZA
45506146|NCT05811507|Diagnostic Test|The Childhood Autism Rating Scale (CARS)|It is done by rating the child's behaviors from 1 to 4. 1 being normal for your child's age, 2 for mildly abnormal, 3 for moderately abnormal, and 4 as severely abnormal. Scores range from 15 to 60 with 30 being the cutoff rate for a diagnosis of mild autism. Scores 30-37 indicate mild to moderate autism, while scores between 38 and 60 are characterized as severe autism
45506147|NCT05811507|Diagnostic Test|DSM-5 Diagnostic Criteria for ASD|Persistent deficits in social communication and social interaction across multiple contexts. Restricted, repetitive patterns of behavior, interests, or activities. Symptoms must be present in the early developmental period, Symptoms cause clinically significant impairment in social, occupational, or other important areas of current functioning.These disturbances are not better explained by intellectual disability or global developmental delay.
45506148|NCT05811507|Diagnostic Test|Assesment of IQ: The Stanford-Binet V (Stanford-Binet Intelligence Scales):|"IQ Score ranges for the Stanford-Binet:~Low average: 80-89 Average: 90-109 High average: 110-119 High achiever: 120-129 Moderately gifted: 130-144 Highly gifted: 145-160+"
45506149|NCT05811494|Device|Lexo|Lexo is a Robot-Assited Gait device based on an end-effector system that supports the weight of the patient and help him to recover the walking function.
45506150|NCT05811494|Device|Lokomat|Lokomat is a Robot-Assited Gait device based on a fixed exoskeleton that supports the weight of the patient and help him to recover the walking function guiding the hips, knees and feet of the patient while walking.
45697575|NCT03260361|Other|Usual practice|Usual practice with treatments and physio
45398128|NCT01107184|Procedure|Remote ischemic conditioning|Patients will have a automated inflator cuff placed on the upper arm during surgery. The cuff will be used to induce fore arm ischemia by inflation to 200 mmHg for 3 x 5 minutes, interspersed with 5 minutes of no-inflation and thus reperfusion.
45398129|NCT01107184|Procedure|Sham|Patients will have a automated inflator cuff placed on the upper arm during surgery which will not be inflated.
45697576|NCT04606797|Drug|Nicotine patch|Nicotine transdermal patches as per product monograph
45849780|NCT04889898|Behavioral|SIT Scoring|[Listeners only] Listeners will judge the intelligibility of speech recordings made by patients in the study.
45849781|NCT04878276|Device|Dimet 5|The application is carried out according to the enclosed instructions for use.
45849782|NCT04867278|Procedure|External Beam Radiation (XRT)|Patients that undergo surgical fixation of an acetabular fracture will receive debridement and a single fraction of external beam radiotherapy to the surgical site within 72 hours of surgery.
45849783|NCT04867278|Procedure|Debridement|Gluteus minimus debridement in the OR
45849784|NCT04848402|Device|On-Body Delivery System (OBDS)/Multiple Bolus Injector|Used to administer placebo SC.
46057063|NCT02778009|Other|Exercise intervention|Subjects in the Fit Physician Arm will be required to attend weekly exercise interventions
45398130|NCT00259610|Drug|methotrexate|varies
45398131|NCT00259610|Drug|sulfasalazine|varies
45398132|NCT00259610|Drug|hydroxychloroquine|varies
45398133|NCT00259610|Drug|etanercept|varies
46057064|NCT02778009|Other|Activity monitor|Subjects in the Fit physician arm and the activity monitor arm will receive activity monitors to assess their activity level throughout the academic year
46057065|NCT00248703|Drug|Docetaxel|Docetaxel 100 mg/m2 3 qw x 6
45506151|NCT05811494|Device|C-Mill|C- Mill is a body weight support treadmill which includes virtual reality. I can provide feedback to the patient, assisting or hindering the gait task.
45506152|NCT05811494|Device|Body-weight support treadmill|Body-weight support treadmill group will receive the same time and intensity of training like the robotic groups but using the treadmill
45506153|NCT05811481|Procedure|TACE|Transcatheter Arterial Chemoembolization
45506154|NCT05811481|Drug|Regorafenib|Regorafenib alone
45506155|NCT05811455|Other|Aerobic exercises|To compare the effects of aerobic exercise and progressive muscle relaxation exercises on pain and quality of life in premenstrual syndrome
45506156|NCT05811455|Other|Progressive muscle relaxation|progressive muscle relaxation exercises.
45398134|NCT01090258|Device|Hamilton ventilator (G5 modify to S1) Automated settings|Automated settings (respiratory rate [RR], FiO2, Insp and exp pressures) Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)
45398135|NCT01090258|Other|Hamilton ventilator (G5) protocolized settings|Mechanical ventilation settings performed by the respiratory therapists according to the local protocols
45398136|NCT05371132|Procedure|Positron Emission Tomography|Undergo PET
45398137|NCT05371132|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45398138|NCT05371132|Drug|Zirconium Zr 89-Df-Crefmirlimab|Given IV
45506157|NCT05811442|Drug|50561 high dose|study drug
45398139|NCT05371132|Radiation|Intensity Modulated Radiation Therapy|IMRT for Lymphoma patients only
45398140|NCT01074866|Device|Neurally Adjusted Ventilatory Assist|Non invasive ventilation under Neurally adjusted Ventilatory Assist
45398141|NCT04460482|Device|Near-infrared spectroscopy (NIRS)|NIRS-guided PCI
45398142|NCT04460482|Device|Angiography|Angiography guided PCI
45398143|NCT00165776|Drug|BOTULINUM TOXIN TYPE B|
45398144|NCT04459468|Drug|Lipiodol|Lipiodol TACE procedure
45398145|NCT04389112|Other|biopsy|Skin biopsies will be performed according to standard practices in the usual aseptic conditions, the operator wearing sterile gloves. A circular knife 3 mm will be used. Procedure interventions do not involve a drug or a device.
45398146|NCT03945838|Other|Complete Decongestion Therapy|"It is given in two phases. First phase includes intensive therapy which aims to reduce the volume of the extremity. Second phase aims to preserve these reductions of volume.~All patients were prescribed lymphedema specific exercises and were advised to walk (for 30 minutes everyday) daywhile taking complete decongestive therapy. They were specifically informed that exercise does not aggravate the severity of their lymphedema.~Short stretch bandages were applied to the patients with self manual lymphatic drainage. Intensive phase was given 5 days a week, and short stretch bandages applied for 23 hours a day with 1 hour interval. To increase the local pressure on the areas required, foams were added. Patients were screened with arm circumferential measurements once a week. After gaining a plateau in the volumes, patients were prescribed compression garments."
45398147|NCT05337748|Device|Lexie Self Test and Fit Group|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with a slimtube and dome. The hearing aids will be accompanied and operated using the Lexie smartphone application. Participants will self-perform an in-situ hearing check (pure tones presented via the hearing aids). The prescriptive gain of the hearing aids will be programmed and applied automatically using the obtained in-situ hearing thresholds. Participants will be fitted according to the customized, Lexie optimal fit prescribed gain setting. The optimal settings include the original gain and compression requirements that NAL-NL2 suggests for various audiograms. No additional band equalizer or compression adjustments are added. After a specified period of time, participants will be able to self-adjust the hearing aids using the smartphone application.
45398148|NCT05337748|Device|Lexie Professional Test and Fit Group|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with slimtube and dome. Hearing aids will be fitted by a certified audiologist according to a gold-standard prescriptive formula (NAL-NL2) using a clinically obtained diagnostic pure tone audiogram. Participants will have access to the smartphone application, but the settings will be limited with only options to change the volume of the hearing aids.
45398149|NCT00165698|Drug|menatetranone|15 mg three times a day orally for 12 months
45506158|NCT05811442|Drug|50561 low dose|study drug
45506159|NCT05811442|Drug|Placebo|Non-active study drug
45849785|NCT04848402|Device|Single Auto Injector|Used to administer placebo SC.
45849786|NCT04848402|Drug|Placebo|Administered SC.
45506160|NCT05811429|Other|Aerobic exercises|16 sessions for 8 weeks ,per week 2 sessions will be given.
45506161|NCT05811429|Other|Pilates exercises|16 sessions for 8 weeks ,per week 2 sessions will be given.
45506162|NCT05811390|Device|erythritol jet|Use of an erythritol jet in the non-surgical treatment of periimplantitis together with systemic metronidazole
45506163|NCT05811390|Device|Manual instrumentation|Use of manual instrumentation in the non-surgical treatment of periimplantitis together with systemic metronidazole
45506164|NCT05811377|Drug|Ferumoxytol|After fully emptying the bladder with a catheter,1.5mg of Ferumoxytol combined with Gadobutrol 302 mg will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to an MRI scan of the bladder. After the MRI is completed, the Ferumoxytol will be drained through the catheter and the catheter will be removed.
45506165|NCT05811377|Drug|Gadobutrol|After fully emptying the bladder with a catheter, 302 mg of Gadobutrol (combined with Ferumoxytol) will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to a MRI scan of the bladder. After the MRI is completed, the Gadobutrol will be drained through the catheter and the catheter will be removed.
45849787|NCT04843410|Other|Hand-foot exercise|The experimental group will be taught a regular exercise program for 15 minutes twice a day. The sensory exercise ball required for exercise will be given to the patients by the researcher. In addition, visual training material will be provided for the exercise program so that the patient can repeat the training at any time to ensure the permanence of the patient education. The standard care protocol of the clinic will be applied to the control group.
45398150|NCT00165698|Drug|alfacalcidol|0.25 μg twice a day orally for 12 months
45398151|NCT05331196|Diagnostic Test|Preoperative cardiopulmonary exercise tetsing|Patients underwent a cardiopulmonary exercise test prior to surgery.
45506166|NCT05811338|Behavioral|Project 1, Phase 2: VR Program for Social, Activity, and Cognitive Engagement|The investigators will apply a systematic approach to the design and evaluation of an immersive Cognitive Activity Social Technology (CAST) VR intervention (using the Oculus Quest 2), that provides aging adults a suite of virtual cognitive, social, and activity engagement applications. The program will allow for virtual interactions (one-on one or groups), cultural, creativity, and educational opportunities, and gaming.
45506167|NCT05811338|Behavioral|Project 2, Phase 2: Intelligent Adaptive System|An innovative intelligent adaptive software package aimed at providing social and cognitive support to older adults with MCI. The system will be designed to adapt to the needs and abilities of the user.
45506168|NCT05811338|Behavioral|Project 3, Phase 3: Intelligent Decision Support Tool|An innovative intelligent decision tool for health decisions aims at providing health management support for older adults with and without MCI.
45506169|NCT05811325|Other|kinesiotaping without craniosacral therapy|The first treatment group will receive kinesio taping for 6 weeks atleast 4 times per week
45506170|NCT05811325|Other|kinesiotaping with craniosacral therapy|The second treatment group will receive kinesio taping with craniosacral therapy for 6 weeks atleast 4 times per week with each session lasting for 60 minutes
45506171|NCT05811286|Procedure|Hysteroscopic morcellation 19 Fr. intrauterine BIGATTI Shaver for uterine intracavitary lesions|"With the shaver, the lesion is removed in the OR. We will include endometrial polyps, FIGO 0-1 myomas and retained products of conception.~We will assess the completeness of hysteroscopic resection, operation time, need for cervical dilation, adverse events, pain, operator satisfaction; quality of tissue for histological examination, postoperative complications and pain."
45506172|NCT05811273|Other|physical readiness training|Bend and Reach:5 repetitions, Rear Lunge:5 repetitions per leg, High Jumper:5 repetitions, Rower:5 repetitions, Squat Bender:5 repetitions, Windmill:5 repetitions, Forward Lunge:5 repetitions per leg, Prone Row:5 repetitions, Bent-Leg Body Twist:5 repetitions per side, Push-Up:5 repetitions.
45506173|NCT05811273|Other|Control group|general exercises
45506174|NCT05811260|Other|Myofascial Release technique|on low back 3 repetitions (30 second rest between reps), lasting for 30 s for each myofascial track for 1 set to targeted muscles (plantar fascia, gastrocnemius, hamstrings, and erector spinae). The position will be held for 10-15 seconds when a pain point is found lacrosse ball excellent for this type of massage because their surface area is much less than that of foam rollers.
45398152|NCT01107340|Device|AMIStem Hip System|
45398153|NCT01075022|Drug|Colecalciferol (Vitamin D3) 300.000 UI|Colecalciferol (Vitamin D3) 300.000 UI Capsule, Single Dose
45398154|NCT01075022|Drug|Placebo|Placebo Capsule, Single Dose
45398155|NCT03946150|Diagnostic Test|P/FP Ratio|PaO2/Fio2 X PEEP
45398156|NCT03944824|Other|Exercise Plan using resistance bands|Exercise under the guidance of an exercise physiologist using elastic resistance bands and weekly meeting with an exercise physiologist for 12 weeks
45398157|NCT03944824|Diagnostic Test|Modified Fried Frailty Scale|Patients will be screened for frailty pre and post with sit-to-stand test, timed up and go test, handgrip strength test and administered the low physical activity questionnaire. These components together consist of the Modified Fried Frailty Index.
45506175|NCT05811260|Other|Post facilitation stretch .|static stretching exercises for the low back (plantar fascia, gastrocnemius, hamstrings, and erector spinae). Static stretching involved 3 sets of 3 repetitions for each muscle with a 30-second hold and 30-second rest interval for each repetition.
45506176|NCT05811234|Drug|CAL/BDP PAD Cream|As provided in real-world clinical practice.
45506177|NCT05811221|Drug|Esketamine of single injection|Single group: give esketamine 0.75 mg/kg at the time of induction
45506178|NCT05811221|Drug|Esketamine of Intermittent injection|Intermittent group: give esketamine 0.5mg/kg during anesthesia induction, and during the measuring ring esketamine 0.25mg/kg was given again
45506179|NCT05811208|Device|automated pupillometry|Automated pupillometry every 6 hours
45849788|NCT04836780|Drug|Dexamethasone|Dexamethasone base 6 mg once daily for seven days
46057066|NCT02713893|Drug|Econazole nitrate 1% plus Benzydamine HCl 0.12% intravaginal cream|
46057067|NCT02713893|Drug|Placebo plus Econazole nitrate 1% intravaginal cream|
45398158|NCT00225758|Drug|Lapatinib|1500 mg po daily for 26 weeks or longer
45398159|NCT03945214|Behavioral|Meditation|10 minute per day, 8 week digital meditation
45398160|NCT03945214|Behavioral|Healthy Eating|A single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
45398161|NCT03945214|Behavioral|Meditation + healthy eating|10 minute per day, 8 week digital meditation and a single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
45398162|NCT03944746|Other|Education Curriculum|Different educational curriculums were applied to each cohort
46057068|NCT02713893|Drug|Placebo plus Benzydamine HCl 0.12% intravaginal cream|
46057069|NCT02713893|Drug|Placebo intravaginal cream|
45506180|NCT05811208|Diagnostic Test|questionnaire|"CAM ICU questionnaire will be used for delirium screening the incidence of pain will be assessed using 3 valid scales. The Visual Analogue Scale (VAS), the Behavioral Pain Scale (BPS) and the Critical Care Observational Tool (CPOT) will be used.~questionnaires will be done the same time as pupillometry"
45506181|NCT05811195|Device|Diode Semiconductor, Duo|Intraoral photobiomodulation therapy (660nm, 3s/point, 10J/cm²) for the management for the oral mucositis in pediatric patients. Mainly in the decrease of oral mucositis rates severity, healing of the ulcers of OM. The results obtained will be compared with the other group.
45506182|NCT05811195|Device|Gemini laser|Extraoral photobiomodulation therapy (810 + 980 nm, 20s/point, 4.07J/cm²) for the management for the oral mucositis in pediatric patients. Mainly in the decrease of oral mucositis rates severity, healing of the ulcers of OM. The results obtained will be compared with the other group.
45506183|NCT05811169|Genetic|Next generation sequencing|Next generation sequencing
45506184|NCT05811156|Behavioral|Hybrid Multimodal digital intervention|Multimodal digital intervention, including an internet-delivered CBT treatment based on a biopsychosocial exposure treatment, tailored explicitly for Exhaustion due to persistent non-traumatic stress.
45506185|NCT05811104|Device|Sequential bilateral theta burst stimulation|Three sessions of active or sham bilateral TBS will be delivered daily for 10 days in 2 weeks (no session on weekend) with a total of 30 sessions for each patient. Daily low intensity (90% resting motor threshold) bilateral sequential continousTBS ( cTBI) will be applied first on the right DLPFC (1800 pulses) and then intermittent TBS (iTBS)on the left DLPFC (1800 pulses) with an intersession interval of 60 minutes. We will adopt 1800 pulse per session based on the previous studies. Patients will receive a stimulation of 3600 pulses a session, 10,800 pulses a day and 108,000 pulses in total. After the study, sham group will receive active stimulation following the same protocol
45506186|NCT05811078|Behavioral|training sessions with peer interactive group|"Data were collected with data collection forms consisting of  Diabetes Adolescent Diagnosis Form, Diabetes Information Evaluation Form, Diabetes Management Self-Efficacy Scale in Adolescents with Type 1 Diabetes and Child's Attitude towards Own Disease Scale ."
45506187|NCT05811065|Device|OPTIVF dosage|Opt-IVF dosage
45506188|NCT05811065|Device|traditional drug treament|Traditional drug treatment
45506189|NCT05811052|Other|Suboccipital Release Technique|The suboccipital release technique was applied to the participants in the experimental group by an experienced practitioner who had received osteopathy training. The individual lay in the supine position, and the practitioner applied the relaxation technique by placing his hands on the patient's nape-atlantooccipital joint. The application was continued until the relaxation of the muscles under the hand of the practitioner.
45506190|NCT05811052|Other|Sham Suboccipital Release|The participants in the control group were given a sham application by touching the hands of the therapist on the nape of the neck and waiting for a while.
45506191|NCT05811026|Device|Periorbital rejuvenation with a 1927 nm diode laser treatment (2-week interval)|"Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment~Visit 2 (W2): Clear + Brilliant™ Permea device periorbital treatment~Visit 3 (W4): Clear + Brilliant™ Permea device periorbital treatment~Visit 4 (W8): Four weeks after the third treatment, a follow-up assessment will be performed"
45506192|NCT05811026|Device|Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval)|"Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment~Visit 2 (W4): Clear + Brilliant™ Permea device periorbital treatment~Visit 3 (W8): Clear + Brilliant™ Permea device periorbital treatment~Visit 4 (W12): Four weeks after the third treatment, a follow-up assessment will be performed"
45506193|NCT05811000|Drug|PM012|PM012 650 mg tablet drug
45506194|NCT05811000|Drug|PM012 Placebo|PM012 tablet placebo
45506195|NCT05811000|Drug|Donepezil|Aricept 5 mg (donepezil hydrochloride) drug
45506196|NCT05811000|Drug|Donepezil placebo|Aricept 5 mg (donepezil hydrochloride) placebo
45506197|NCT05810922|Other|arbutus berry|consumption of 50 g arbutus berry/day or 200 g arbutus berry/day for 14 days
45398163|NCT03972332|Diagnostic Test|Quantitative Sensory Testing|"PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT)."
45506198|NCT05810909|Dietary Supplement|amorphous calcium carbonate/ Placebo|The dosage was 1000 mg calcium carbonate (400mg calcium element) per day, and placebo (calcium carbonate change to excipient)
45506199|NCT05810753|Behavioral|SPOONful|Participants will be asked to consume two ONS daily, in addition to their regular diet, for three weeks. Participants will be asked to consume one ONS with their breakfast, and one with lunch.
45506200|NCT05810350|Drug|Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed|Patients receive Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed (30 mg was administered on days 1 and 8) once every 3 weeks.
45506201|NCT05810064|Other|Falls-Risk Clinical Decision Support (CDS) Tool|CDS in the Electronic Health Record (EHR) to screen patients at high-risk for future falls enabling referrals to the UW Health Mobility and Falls clinic.
45398164|NCT05330260|Diagnostic Test|neurocognitive test battery|Assessment of the incidence of late postoperative cognitive decline (LPOCD)
45398165|NCT03968354|Biological|"Collection of additional blood tubes; Biobanking (plasma, liver tissue)."|"Preservation of liver tissue obtain by liver biopsy, constitution of a collection~Sampling of additional blood tubes for a biological collection (serum): Serum biomarker research and genetic research"
45506202|NCT05809947|Other|Neuromuscular electrical stimulation|One bout of neuromuscular electrical stimulation in conjunction with forced lengthening contractions on one leg
45398166|NCT03947944|Procedure|SMILE using manifest refraction planning|The treatments of astigmatism were planned using either the manifest refraction (manifest refraction group) or the vector planning method (vector planning group). The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a microspatula with a blunt circular tip and extracted with microforceps. The integrity of the lenticule was assessed subsequently. The treatment plan for the vector planning group involved a combination of refractive astigmatism with 60 % emphasis and corneal astigmatism with 40 % emphasis.
45506203|NCT05809752|Biological|Dendritic Cell Vaccine|"Intrathecal (IT) dendritic cell vaccine (DCV) will be administered once every week. As per standard procedures of IT chemotherapy or antibody administration it is administered over 5 -10 minutes or at 1 ml/minute while monitoring the patient under sterile conditions. In general, to assure delivery of the DCVs into the ventricular space and compensate for dead space in the Ommaya, the delivery of IT DCV cells is followed by the administration of 2.5 mls of saline. In general there is a maximum volume of 10 mls of DCVs."
45506204|NCT05808699|Device|handheld fundus camera|Fundus camera
45506205|NCT05808062|Procedure|Root canal obturation|Root canal dryness
45506206|NCT05807919|Other|Diet low in all FODMAP groups|Randomized participants will eat this diet for 4 weeks (all meals and snacks will be provided). Participants will only eat the study food for this intervention. Participants will be asked to complete surveys, food diaries, and have blood and stools samples pre and post treatment.
45506207|NCT05807919|Other|Diet - Mediterranean|Randomized participants will eat this diet for 4 weeks (all meals and snacks will be provided). Participants will only eat the study food for this intervention. Participants will be asked to complete surveys, food diaries, and have blood and stools samples pre and post treatment.
45506208|NCT05807360|Device|Hyaluronic acid eye drops|Hyaluronic acid (HA)-based eyedrops
45506209|NCT05804123|Drug|0.9% NaCl physiological saline Nasal-spraying|0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
45506210|NCT05804123|Combination Product|LiveSpo Navax®|In Vietnam, LiveSpo Navax® is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016
45506211|NCT05804123|Drug|Augmentin 500Mg Tablet|Augmentin (GlaxoSmithKline Pte, product declaration No. VN-20169-16) is an oral antibiotic available in the form of 625 mg tablets, which are prescribed as routine treatment for children and adults, respectively.
45506212|NCT05804123|Drug|Acetylcysteine|Acetylcysteine 200 mg (STADA Vietnam, product declaration No. VD-22667-15) is an oral expectorant, which is prescribed as routine treatment for children and adults, respectively.
45506213|NCT05804123|Drug|Xylometazoline Nasal|Otrivin (Xylometazoline 0.05%) (Novartis VietNam, product declaration No. VN-15558-12) is a nasal-spraying decongestant, which is prescribed as routine treatment for children and adults, respectively.
45506214|NCT05804123|Drug|Cefotaxime|Imetoxim 1g (Cefotaxime 1g) (Imexpharm Pharmaceutical, product declaration No. VD-26846-17) is an injection or infusion-administrative antibiotic, which is prescribed as routine treatment for children.
45506215|NCT05804123|Drug|Ciprofloxacin|Ciprofloxacin 0.3% (Vidipha Central Pharmaceutical, product declaration No. VD-15205-11) is an antibiotic ear drop, which is prescribed as routine treatment for children.
45506216|NCT05804084|Drug|Acetazolamide|Acetazolamide tablet (encapsulated)
45506217|NCT05804084|Drug|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide
45506218|NCT05803655|Other|36-hour duration between ovulation triggering and oocyte pick-up procedure|36-hour duration between ovulation triggering and oocyte pick-up procedure
45506219|NCT05803655|Other|38-hour duration between ovulation triggering and oocyte pick-up procedure|38-hour duration between ovulation triggering and oocyte pick-up procedure
45506220|NCT05801224|Drug|Nitric Oxide|20ppm for 15 minutes
45506221|NCT05801211|Procedure|primary tumor resection|"primary surgical tumor resection with a primary colorectal anastomosis (associated or not with a diverting loop ileostomy) or without a primary anastomosis (Hartmann's procedure)"
45506222|NCT05800743|Device|GORE® Ascending Stent Graft (ASG device)|Endovascular aortic repair of the ascending aorta
45506223|NCT05800743|Device|GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device)|Endovascular aortic repair of the ascending aorta/aortic arch
45506224|NCT05800743|Procedure|Surgery|Open surgical repair of the ascending aorta and/or the aortic arch
45506225|NCT05799391|Drug|SJC|Soothing cream jel
45506226|NCT05799391|Other|Placebo|Placebo cream jel
45506227|NCT05793489|Other|Silibinin|"WBRT will be concomitant to Silibinin. Silibinin at dose of 500 mg must be administrated twice a day for the first month, after once a day continuously.~Total dose and fractionation of WBRT: 30 Gy in 10 fractions."
45506228|NCT05792696|Behavioral|PPI guided strategies|For targeted MAP or lower, if PPI<1, more fluid therapy. if PPI>3, vasoconstriction therapy. For MAP<65mmHg and 1<=PPI<3, test bolus of 250 ml crystalloid fluid.
45506229|NCT05792696|Behavioral|Empirical strategies|Fluid therapy or vasoconstriction depended on experiences of anesthetic staffs.
45506230|NCT05791110|Diagnostic Test|Fecal pancreatic elastase 1 test|Fecal pancreatic elastase 1 test are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
45506231|NCT05787249|Behavioral|Patient nudge|Nudge directed to the patient with the aim of increasing the uptake of MRI in patients with extremely dense breasts
45506232|NCT05787249|Behavioral|Provider nudge|Nudge directed to the provider with the aim of increasing ordering of MRI in patients with extremely dense breasts
45506233|NCT05786209|Other|Whole-body Balm|Balm will be applied to cover newborn's entire body (while avoiding the mouth, eyes, diaper area, and scalp), and gently massaged onto the skin until the balm is fully absorbed.
45506234|NCT05786209|Other|Wash and Shampoo|"Wash and shampoo will be used to cleanse newborn baby using an in tub bathing method."
45506235|NCT05780060|Behavioral|Standard of care, RPM and digital feedback|Standard stroke follow up, RPM and a patient facing smartphone application containing real time BP feedback, educational models, treatment adherence push notification reminders, digital education and digital incentives (n=30). Outcomes will include recruitment, retention and follow up metrics, self-reported adherence to medication regimens and life-style recommendations, patient engagement with RPM data and patient-facing application, cost-effectiveness of the interventions and changes in blood pressure as well as biomarkers like LDL and Hemoglobin A1C.
45506236|NCT05780060|Behavioral|Standard of care and RPM only|Standard stroke clinic follow up and remote blood pressure monitoring (n=30). Outcomes will include qualitative patient and provider experiences with the TBIs including barriers and facilitators to the use of RPM and patient-facing application in the study population
45506237|NCT05778864|Drug|LY3473329|Administered orally.
45506238|NCT05778136|Other|Resistance training|Supervised resistance training. 2 sessions/week for 12 weeks. The exercises are one-legged leg-press and one-leg knee extension. Resistance training start-up phase comprises 3 sets of 10 repetitions in each of the two exercises with 50% of 1RM. Resistance training progressive phase comprises 3 sets (leg-press) of 5-8 repetitions (70-90% 1 RM) and 6 sets (knee extension) of 8 repetition (75% 1RM). Rest between sets: 3 minutes
45506239|NCT05773391|Drug|Take probiotics|Take medication for 21 days (Yihuo 0.2g bid+ Jin Bifid2g tid)
45697577|NCT02164240|Drug|Sunitinib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
46057070|NCT02713737|Device|heated humidified high-flow nasal cannula|HFNC device (Airvo™, Fisher＆Paykel, Auckland, New Zealand) with a heated circuit (Fisher＆Paykel,900PT501) and nasal cannula(optiflow TM,Fisher＆Paykel). It has adjustable FiO2: 21%-100%, gas flow up to 60 L/min, to maintain arterial blood hemoglobin oxygen saturation ( SPO2) > 92%.
45398167|NCT03947944|Procedure|SMILE using vector planning|The treatments of astigmatism were planned using either the manifest refraction (manifest refraction group) or the vector planning method (vector planning group). The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a microspatula with a blunt circular tip and extracted with microforceps. The integrity of the lenticule was assessed subsequently. The treatment plan for the vector planning group involved a combination of refractive astigmatism with 60 % emphasis and corneal astigmatism with 40 % emphasis.
45398168|NCT05326750|Device|Gamma tACS (40 Hz) over the superior parietal cortex|Single session of gamma tACS (40 Hz) over the superior parietal cortex
45398169|NCT01104532|Drug|ASP1941|oral tablet
45398170|NCT01104532|Drug|sitagliptin|oral tablet
45398171|NCT03945916|Dietary Supplement|Dark chocolate|180 g/d dark chocolate for 15 days followed by exercise testing
45398172|NCT03945916|Dietary Supplement|Placebo|Placebo: 180 g/d imitation dark chocolate for 15 days followed by exercise testing
45398173|NCT03945682|Other|Therapist|Intervention therapist at 2 centres providing 8 week intervention programme 50% embedded qualitative study
46057071|NCT02713737|Device|noninvasive ventilation|TBird VELA ventilator, CareFusion, USA. Pressure adjustments were to optimize patient comfort. Inspiratory pressure was raised every 5 mins until comfort was optimized. FiO2 was adjusted to maintain SPO2 > 92%.
45506241|NCT05766982|Other|Platelet Rich Plasma|Platelet rich plasma will be applied to assess rate of wound healing.
45506242|NCT05766254|Device|Active 10-Hz TMS to the DLPFC|The active group will receive 10hz TMS stimulation. Participants in the active stimulation group will receive10-Hz TMS to left DLPFC. The LDLPFC will be based on 4 targeting neuroimaging methods (cortical thickness, fMRI, diffusion imaging, functional connectivity). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the L-DLPFC using a active/placebo figure-8 coil and a magventure TMS device.
45506243|NCT05766254|Device|Sham TMS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
45506244|NCT05754853|Drug|MRG002|Administrated intravenously
45506245|NCT05754853|Drug|Docetaxel Injection|Administrated intravenously
45506246|NCT05754853|Drug|Paclitaxel Injection|Administrated intravenously
45506247|NCT05754853|Drug|Gemcitabine Hydrochloride for Injection|Administrated intravenously
45506248|NCT05754853|Drug|Pemetrexed Disodium Injection|Administrated intravenously
45506249|NCT05750420|Other|There was no intervention, the study was a cross-sectional observational study|Questionnaires for measuring self-care, anxiety, depression, emotinal distress and quality of live were administered to patients with chronic cardiovascular disease
45506250|NCT05747625|Biological|Panitumumab|Given IV
45506251|NCT05747625|Drug|Zirconium Zr 89 Panitumumab|Given IV
45398174|NCT01107574|Drug|Gabapentin|Gabapentin 900 mg po HS for 6 weeks treatment per patients enrolled in the Gabapentin Arm
45398175|NCT01107574|Procedure|Osteopathic Manipulative Medicine|Based on Osteopathic Structural Examination and Tender point Examination a 30 minute treatment of Osteopathic Manipulative Medicine was applied to each patient every week for 6 weeks.
45398176|NCT01107574|Other|Gabapentin and Osteopathic Manipulative Medicine|Combination therapy of gabapentin 900 mg po HS for 6 weeks and Osteopathic Manipulative Medicine 30 minute treatment weekly for each patient based on Osteopathic Structural Examination and Tender point Examination
45398177|NCT01104610|Device|Breas Vivo 40|The Vivo 40 will be used either in CPAP mode, PSV mode without Target Volume or PSV mode with Target Volume
45398178|NCT03971500|Drug|AntiPlatelet therapy|AntiPlatelet therapy with ticagrelor + aspirin or ticagrelor alone.
45398179|NCT03971500|Procedure|Percutaneous coronary intervention|PCI with DES implantation
45398180|NCT00259298|Drug|teriparatide|Subcutaneous, 20 microgram (mcg)/day, 18 months
45398181|NCT01108744|Drug|hypertonic saline|3% hypertonic saline, dosed by ideal patient weight
45398182|NCT01108744|Drug|Mannitol|Mannitol 20% intravenous solution, dosed by patient's ideal body weight
45506252|NCT05747625|Procedure|Positron Emission Tomography|Undergo PET/CT
45506253|NCT05747625|Procedure|Computed Tomography|Undergo PET/CT
45506254|NCT05747625|Other|Electronic Health Record Review|Ancillary studies
45506255|NCT05744349|Procedure|K-wires Fixation of Pediatric Shaft Both Bone Forearm Fractures|After administration of anesthesia, surgery will be performed with the patient supine on the operating table and fracture will be analyzed with an image intensifier. In radius, the wire will be inserted by surgical drilling through Lister's tubercle or the radial styloid while in ulna, the wire will be inserted through the tip of the olecranon.
45506256|NCT05742347|Device|DriGo Skin Protectant Textile|All participants in this study will have the DriGo skin protectant textile applied to their skin fold condition. Erythema, denudation, maceration, odor, and moisture will be assessed following application of the SPT.
45398183|NCT01581866|Drug|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
45398184|NCT01075334|Dietary Supplement|Porimore - A Carnitine based food supplement|A daily dose of 2 grams L-carnitine, 1 gr acetyl L-carnitine, 500mg Vitamin C, 400 IU vitamin E, 60 mg Q10, 30mg Zinc Picolinate, 500mcg Folic Acid, 200 Mcg Selenium, 100 MCG Vitamin B12.
45398185|NCT01075334|Dietary Supplement|Zinc and Folate Supplementation|500 Mcg Folic acid, 30-60 mg Zinc tablets/ day
45398186|NCT03892642|Drug|Avelumab|"Induction phase:~once weekly for weeks 1-6,~once every 2 weeks at week 8, 10, and 12~Maintenance phase:~Once every week for weeks 1-3~Once every 2 weeks starting at week 5, until the next BCG treatment"
45398187|NCT03892642|Biological|BCG|"Induction phase (cycle 1):~• Once weekly for weeks 1-6~Maintenance phase (Month 3, 6, and 12):~• Once weekly for 3 weeks"
45398188|NCT01107808|Drug|Calcium and Vit D|ergocalciferol (vitamin D2) treatment 50,000 IU orally, weekly for 8 weeks calcium carbonate orally 1200mg daily
45398189|NCT01107808|Drug|Metformin, Vit D and Calcium|ergocalciferol (vitamin D2)50,000 IU orally weekly for 8 weeks calcium carbonate orally 1200mg daily Metformin ER 1000mg daily with dinner for 7 days and then increased to a final dose of 2000mg orally, daily for the remainder of the study (7 weeks)
45398190|NCT03947554|Dietary Supplement|HRG80 Panax ginseng|Panax ginseng containing 63.4 mg ginsenosides
45398191|NCT03947554|Dietary Supplement|Panax ginseng|Panax ginseng containing 19.6 mg ginsenosides
45506257|NCT05732207|Procedure|cerebellar transcranial direct current stimulation|TDCS is a safe and non-invasive technique for modulating cortical excitability and behavior. TDCS, delivered via surface electrodes, induces an intracerebral current flow sufficient to achieve changes in cortical excitability. Anodal stimulation up-regulates cortical excitability, while cathodal stimulation decreases excitability.
45506258|NCT05729932|Drug|Inhaled vaporized cannabis|Double-blind cannabis and placebo doses, administered through vaporizer
45506259|NCT05729932|Drug|Intransal opioid|Double-blind opioid and placebo doses, administered intranasal route
45506260|NCT05727735|Device|Medtronic Signia Stapler|The Signia Stapler is a powered stapler that can be used for tissue dissection and vessel sealing during surgery.
45506261|NCT05727735|Drug|Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling|The Vessel Sealer Extend Energy Device is integrated with the da Vinci system and uses bipolar energy technology to facilitate tissue dissection and vessel sealing.
45506262|NCT05719441|Biological|VRC07-523LS|10 mg/kg intravenous infusion over approximately 15 to 30 minutes once at entry
45506263|NCT05719441|Biological|PGT121.414.LS|5 mg/kg intravenous infusion over approximately 30 to 60 minutes once at entry
45506264|NCT05719441|Other|Placebo|Sodium Chloride for Injection USP, 0.9%
45506265|NCT05719441|Drug|ART|Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet orally once daily with or without food
46057072|NCT00805480|Drug|AIN457|AIN457 was administered intravenously.
45398192|NCT03947554|Dietary Supplement|Placebo|800 mg excipient
45398193|NCT01104844|Drug|Full Dose Strength|Acetaminophen + ibuprofen, 2 tablets every 6 hours, with food for 24 hours (i.e a total of 4 x 1000/300 mg doses of study drug comprising of 8 tablets)
45398194|NCT01104844|Drug|Quarter dose strength|Investigational drug quarter dose strength (acetaminophen 125mg + ibuprofen 37.5mg) i.e. 2 tablets equating to 1/4 the dose in the standard investigational drug.
45398195|NCT01104844|Drug|Half dose strength|Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg) i.e. 2 tablets equating to 1/2 the dose in the standard investigational drug
46057073|NCT00805480|Drug|Placebo|Matching placebo to AIN457 was administered intravenously.
46057074|NCT02713815|Radiation|repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 4 weeks by Theta-burst stimulation (TBS), once a day
46057075|NCT02713815|Radiation|sham repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 4 weeks by sham Theta-burst stimulation (TBS), once a day
46057076|NCT02777853|Dietary Supplement|Green tea|The intervention product is regular green tea brewed with hot water in a large quantity. The tea obtained is dried and the powder, with added sugar, is distributed over sealed aluminium sachets (1 gram of powder per sachet). The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
46057077|NCT02777853|Dietary Supplement|Placebo tea|A product of similar colour and taste, but not the presumed actives of tea (polyphenols), is used as placebo. The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
45398196|NCT01104844|Drug|Acetaminophen standard dose|Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
45398197|NCT01104844|Drug|Ibuprofen low dose|Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
45398198|NCT01104844|Drug|Ibuprofen high dose|Ibuprofen high dose 300mg i.e. 2 tablet equating to twice the ibuprofen dose as in the standard investigational drug
46057078|NCT02713581|Biological|Blood sampling|Venous blood will be sampled for laboratory analyses (see outcomes).
45398199|NCT01104844|Drug|Placebo|2 placebo tablets
45398200|NCT03844672|Behavioral|Low Power|Participants will receive a low power e-cigarette to use for 3 weeks
45398201|NCT03844672|Behavioral|High Power|Participants will receive a high power e-cigarette to use for 3 weeks
45398202|NCT03844672|Behavioral|Low Concentration|Participants will receive a low concentration e-liquid to use for 3 weeks
45398203|NCT03844672|Behavioral|High Concentration|Participants will receive a high concentration e-liquid to use for 3 weeks
45506270|NCT05714267|Device|Active noise cancelling|During the operation, active noise canceling device (Sony wh100xm3) will be applied to the patients in Group-1 after spinal anesthesia is applied and will not be removed until the operation is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
45506271|NCT05714267|Device|Passive noice cancelling|During the operation, passive noise canceling device (3M Peltor X5a) will be applied to the patients in Group-2 after spinal anesthesia is applied and will not be removed until the operation is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
45506272|NCT05714267|Device|Active noise cancelling with music therapy|The patients in Group-3 will be given music therapy with an active noise canceling tool (Sony wh100xm3) during the surgery. The music that the patient will listen to will be left to the patient's preference. Music therapy with an active noise canceling device will be applied after spinal anesthesia is applied and will not be removed until the surgery is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
45506273|NCT05709132|Behavioral|iPeer2Peer Program|Behavioral: iPeer2Peer Support Mentorship Program iPeer2Peer is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
45506274|NCT05708989|Procedure|Caudal Block|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine into caudal spinal space. First attempt will be landmark-guided into the caudal spine region. Subsequent attempt(s) may be done using ultrasound.
45506275|NCT05708989|Procedure|Ultrasound-guided Pudendal Block|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine. Ultrasound-guided injection into each pudendal nerve region through skin of buttocks.
45506276|NCT05708989|Drug|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine into caudal spinal space. First attempt will be landmark-guided into the caudal spine region. Subsequent attempt(s) may be done using ultrasound.
45506277|NCT05708989|Drug|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine.|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine. Ultrasound-guided injection into each pudendal nerve region through skin of buttocks.
45506278|NCT05705427|Drug|Tenofovir Disoproxil Fumarate 300 MG|Pregnant women in the experimental arm will receive TDF daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum.
45506279|NCT05705427|Biological|Hepatitis B monovalent vaccine|All infants born to women in the study will receive a birth-dose hepatitis B vaccine.
45506280|NCT05705427|Drug|Placebo|Pregnant women in the placebo arm will receive a placebo pill daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum.
45506281|NCT05703100|Other|Incremental exercise test|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W)
45506282|NCT05703100|Other|Incremental exercise test under hyperthermia|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W) performed at a room temperature of 35-38ºC (degrees Celsius).
45506283|NCT05703100|Other|Incremental exercise test under glycogen depletion|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W) under glycogen depletion by performing an exercise protocol to deplete glycogen stores plus a low-carbohydrate diet 24 h before incremental testing
45506284|NCT05695300|Dietary Supplement|BLM ORGANIC GOLD+|Participants in this arm need to be fed the assigned infant formula daily for three months, no other formula or breast milk
45849789|NCT04793724|Device|Simeox|"A respiratory physiotherapy session with the Simeox device will be performed in accordance with the official PhysioAssist recommendations, which are;~clearance of the upper airways before the physiotherapy session~correct position of the mouthpiece in patient's mouth, with the lips placed on the thinnest part of the mouthpiece and the tongue positioned underneath the mouthpiece~slow nasal inhalation without too much recruitment of the inspiratory residual volume (IRV) and an exhalation with real deflation of the thorax~step-by-step shifting of the patient's tidal volume towards the expiratory residual volume (ERV), in order to target the most distal regions of the lungs~comfortable, relaxed sitting position with straightened spine~controlled cough, which will be encouraged only when it is productive"
45398204|NCT03945526|Drug|Astaxanthine|
45398205|NCT03945526|Drug|Placebo Oral Tablet|
45398206|NCT01105078|Procedure|Flow rate|Different flow rate during cardiopulmonary bypass
45398207|NCT01105156|Behavioral|VEW Questionnaire|Patient Self reported questionnaire filled in.
45398208|NCT03750136|Drug|Hypertonic saline|high dose furosemide with hypertonic saline 3x daily
45398209|NCT03750136|Drug|Furosemide Injection|high dose furosemide
45398210|NCT03947476|Device|thoracic band|Thoracic band fixation
45398211|NCT03945058|Device|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks
45398212|NCT03945058|Device|SHAM|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the earl lobule. Stimulator will be applied continuously for 1 hour daily for 4 weeks.
45506285|NCT05695300|Dietary Supplement|BLM ORGANIC|Participants in this arm need to be fed the assigned infant formula daily for three months,no other formula or breast milk
45506286|NCT05695300|Dietary Supplement|Breast milk|Participants in this arm need to be fed with breast milk daily for three months, no infant formula
45506287|NCT05692869|Drug|Propranolol|Administered orally.
45506288|NCT05692869|Drug|Pseudoephedrine|Administered orally.
45506289|NCT05692869|Device|ABPM and Wearable Novel Devices|ABPM and wearable novel devices including chest patch device, wrist device and smartwatch device worn throughout the trial.
45506290|NCT05692869|Other|No Intervention|No intervention during this period (Control Period)
45506291|NCT05691439|Behavioral|Sleep extension and advance|"Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses (blue blockers) beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives."
45506292|NCT05691439|Behavioral|Regular sleep duration and timing|Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
45506293|NCT05679284|Radiation|Low-dose X-ray of subcutaneous tissues|To identify needle fragment retentions, the radiologic imaging of all volunteers will be performed with X-ray using radiation doses as low as reasonably achievable (ALARA) and one projection per anatomic site.
45506294|NCT05676944|Device|Labyrinth Devices MVI™ Multichannel Vestibular Implant System|Unilateral implantation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System receiver/stimulator including insertion of electrode arrays in the semicircular canal ampullae of the inner ear, followed by motion-modulated prosthetic electrical stimulation.
45506295|NCT05663476|Other|Non Surgical Periodontal Therapy|Scaling and root planing using scalers and periodontal curettes will be done
45697578|NCT02164240|Drug|Regorafenib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
45697579|NCT03238755|Other|Cardiac MRI/MRS|whole blood, plasma, and serum
45697580|NCT02164396|Device|Spectacle Lens|Spectacle Lens Only
45697581|NCT02164396|Device|Habitual Soft Contact Lens|subject's own contact lens
45697582|NCT02164396|Device|Test Lens|senofilcon A or narafilcon A
45398213|NCT01108042|Drug|Taxotere, Cisplatin, 5-Fluorouracil (5-FU)|Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out. Phase 2: Optimal dose of phase 1 will be given.
45398214|NCT01108120|Drug|continuous intra-femoral thrombolysis group|Firstly, 20 0000 u urokinase is injected to the diseased foot via catheter. Then, continuous injection of urokinase via femoral artery by a artery mini-pump (100 ml 0.9% sodium chloride + 100 0000 unit urokinase at a rate of 4 ml per hour) is taken for 7 - 9 days.
45697583|NCT02169466|Drug|BIA 9-1067|OPC, Opicapone
45697584|NCT02169466|Drug|Placebo|PLC, Placebo
45697585|NCT02169466|Drug|Madopar® HBS|controlled-release levodopa 100 mg/benserazide 25 mg
45697586|NCT05440396|Diagnostic Test|Photographs collection phase|"Three medical experts have been selected to review the photo collected. Each expert medical assesses the presence of local signs of infection on the photographs by annotating them directly via a dedicated software. They will annotate local signs: redness, perfusion extravasation, necrosis, hematoma, edema, non-purulent discharge, and purulent discharge.~A convolutional neural network model will determine the probability of local sign presence. Each picture will be annotated to determine the main characteristics of the catheter. A dataset preparation with photo cropping will be performed for modelling."
45697587|NCT01001806|Drug|Ketorolac Tromethamine 0.45%|One drop BID the day before surgery and then 3 doses the day of surgery prior to surgery
45506296|NCT05660226|Other|Home blood pressure monitoring (telemonitoring)|Using a digital mobile phone based telemonitoring platform to A: monitor patients and adjust their treatment accordingly based on the remote monitoring outcomes and B: provide E-Coaching/self learning modules (lifestyle)
45506297|NCT05660226|Other|Standard care|Standard outpatient blood pressure management
45506298|NCT05657938|Device|Wearable Device|The wearable device used in this study is an FDA 510(k) cleared Class II medical device designed to collect medical grade, clinical quality biometric, physiological and other electronic clinician outcome assessments data in a clinical trial setting. The system processes raw data into recognizable clinical metrics including vital signs, activity and posture classifications, surface electromyography (sEMG), and sleep metrics. The sensors are multi-modal, multilocation, rechargeable and reusable.
45506299|NCT05657938|Other|Duchenne Video Assessment (DVA)|The DVA is a standardized tool that documents and assesses compensatory movement strategies as a marker of quality of movement.
45506300|NCT05655468|Drug|Dronedarone|oral administration fed conditions
45398215|NCT01108120|Drug|Conventional therapy group|All patients receive an intravenous injection of prostaglandin E1 20 ug per day during hospitalization period.
45398216|NCT05268250|Behavioral|R2D2 mHealth intervention|R2D2 mHealth treatment will use cognitive behavioral therapy, mindfulness, and behavioral activation strategies
45398217|NCT01105234|Drug|Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues.|
45398218|NCT01108198|Drug|Mometasone furoate cream|Study cream was applicated once per day for 4-8 weeks.
45398219|NCT01108198|Drug|moisturizing cream|study cream was applicated once per day for 4 to 8 weeks
45398220|NCT05237674|Behavioral|The TEACHOUT intervention|"The core component of the Intervention is a two-day training course on EOtC given to elementary school teachers followed by the teachers committing to apply EOtC for at least five hours a week, delivered in 1-2 weekly sessions for one school year (in this study, August 2022 to June 2023).~In the training course knowledge and understanding of the practice and theory of EOtC is facilitated in presentations and talks supplemented by illustrative examples in workshops and plenum discussions on local implementation. The 1-2 weekly EOtC sessions during the school year 2022-2023 may be delivered by one or more teachers simultaneously in various school subjects, at various places outside the school buildings."
45398221|NCT03947710|Other|High-protein meals|Patients on maintenance hemodialysis will consume high protein meals during dialysis for one week (3 dialysis sessions)
45398222|NCT03947710|Other|Low- protein meals|Patients on maintenance hemodialysis will consume low protein meals during dialysis for one week (3 dialysis sessions)
45506301|NCT05655468|Drug|Placebo|strictly identical in appearance with dronedarone,oral administration fed conditions
45506302|NCT05654454|Drug|Bevacizumab|Bevacizumab 15 mg/kg
45506303|NCT05654454|Drug|Paclitaxel|Paclitaxel 175 mg/m2
45506304|NCT05654454|Drug|Carboplatin|Carboplatin AUC 6
45506305|NCT05650242|Drug|BA1106|"In part A, after the observation period of DLT (28 days), intravenous (IV) once every 3 weeks (Q3W).~In Part B, intravenous (IV) once every 3 weeks (Q3W) or once every 2 weeks (Q2W)."
45398223|NCT03947710|Other|No meals|Patients on maintenance hemodialysis will not consume meals during dialysis for one week (3 dialysis sessions)
45398224|NCT03945370|Dietary Supplement|β-hydroxybuturate esters|Oral dietary supplement product containing β-hydroxybuturate esters
45398225|NCT03945370|Dietary Supplement|Placebo drink|Oral placebo drink
45398226|NCT01108276|Device|Convatec engenex negative pressure wound therapy|ConvaTec Engenex® is a negative pressure wound therapy that stimulates wound healing and promotes granulation tissue formation, removal of wound exudate and infectious materials by the application of negative pressure to wounds. It utilizes Bio-Dome™ Dressing technology to effectively control infection, drainage and odor while promoting granulation and wound healing at 75mmHg pressure.
45398227|NCT01108900|Drug|sildenafil|tables, 25,50,100 mg, on demand, 1 month
45398228|NCT01105390|Biological|rilotumumab|Given IV
45398229|NCT01105390|Drug|cisplatin|Given IV
45697588|NCT01001806|Drug|bromfenac 0.09%|One day pre operative 1 drop BID then 3 doses pre op day of surgery
45697589|NCT01001806|Drug|nepafenac 0.1%|One drop BID, 1 day pre operative and then 3 doses the day of surgery
45697590|NCT05417620|Behavioral|Social Media Campaign|PrEP social influence campaign, which will use online approaches to promote PrEP within communities in addition to the standard of care activities. Messaging crafted with community input will be geographically targeted to women, parents/mentors, and male partners on Facebook, Instagram, and Whatsapp, all with the intention to promote PrEP for women at high risk of HIV infection and change community norms and influence around PrEP. A combination of static imagery and brief videos will be used to engage these groups via social media platforms. A Facebook page will be created and maintained that can be accessed by anyone anywhere, but will only be advertised/promoted in the intervention districts.
45506306|NCT05649488|Device|Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus|"Introduction: After the preparation, release the intracoronary lithotripsy balloon catheter to the area to be treated and release the shock wave pulse for treatment. After the balloon reaches the predetermined position, use angiography to lock the position and fill the balloon to 6 atm. After the shock wave pulse therapy, the balloon was expanded to 8 atm according to the balloon compliance table and lasted for 10s. After the treatment, unload the balloon pressure, wait for the blood flow to recover, and repeat the second treatment after an interval of one minute, two cycles, releasing a total of 20 shock wave pulses as a treatment cycle.~Therapeutic apparatus specification: IVL-HVG-C01； Specifications of balloon catheter: C20012, C20015, C22512, C22515, C25012, C25015, C27512, C27515, C30012, C30015, C32512, C32515, C35012, C35015, C37512, C37515, C40012, C40015"
45506307|NCT05649488|Device|Dragonfly Opstar Imaging Catheter|OCT (optical coherence tomography) measurement using Dragonfly Opstar Imaging Catheter was performed in the OCT subgroup before or after the treatment of intracoronary lithotripsy balloon catheter and intracoronary lithotripsy therapeutic instrument, or after stent placement.
45398230|NCT01105390|Drug|pemetrexed disodium|Given IV
45697591|NCT05417620|Behavioral|PrEP Champions|Within venues served by the FSW and AGYW programs, the team will identify and train 1 venue-based PrEP champion per venue who will receive supplies (e.g. a hat, pin and posters, flyers, IEC material) to wear to promote PrEP, facilitate linkage between women interested in PrEP and the TB HIV Care PrEP programme. PrEP champions will be either peers with experience taking PrEP, venue managers or local influencers (e.g. women running shops next to the mobile serving AGYW) that have repeated contact with the women the programme is intended to serve. The final selection of PrEP champions will be made in consultation with the Community Advisory Groups, venues and by the programme who works closely with each of the sites.
45506308|NCT05645627|Drug|IBI112|IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
45506309|NCT05645627|Drug|placebo /IBI112|placebo by subcutaneous injection cross over IBI112 by subcutaneous injection at week 16 through week 48
45506310|NCT05645627|Drug|IBI112|IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
45506311|NCT05644353|Drug|Mirikizumab|Administered SC.
45506312|NCT05630053|Device|Cementless Persona Knee System|The Persona Keel Knee system is a total knee system used in the replacement of the knee joint.
45506313|NCT05630053|Device|Cemented Persona Knee System|The Persona Keel Knee system is a total knee system used in the replacement of the knee joint.
45506314|NCT05628155|Other|Oral diet including n-3 PUFA intake|menus to cover the recommended intake of n-3 PUFAs (ALA =1% of total energy intake, i.e. 2.1 g/d, and EPA+DHA = 500 mg/d) (n-3 PUFA MENU), based on mass-market products that guarantee the n-3 PUFA RDAs and are available from the catering sector
45506315|NCT05622682|Other|Observational only|Blood samples will be tested to measure antibodies to vaccine-preventable diseases and immune recovery
45398231|NCT01105390|Other|laboratory biomarker analysis|Correlative studies
45398232|NCT04250662|Device|Active tDCS with guided imagery|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have 20 minutes of stimulation with 25 minutes of guided imagery.
45506316|NCT05620966|Device|CGX Systems Quick-20m|The Quick-20m is an FDA-approved wireless, battery-operated 10-20 montage EEG headset, which utilizes dry sensor technology. This device provides an integrated approach to the wireless acquisition of electrical potentials arising from activity in the cortex. The Quick-20m includes advanced amplification and shielding to reject ambient electrical noise. The Quick-20m is placed on the participant's scalp and requires minimal scalp preparation. No conductive gel is used. Patients may or may not have hair. The sensor pads must have direct contact with the scalp and hair will be maneuvered to obtain direct contact. All three arms of participants will receive this intervention.
45506317|NCT05619809|Dietary Supplement|Thermogenic dietary supplement|Daily ingestion of OxyShred thermogenic dietary supplement.
45506318|NCT05619809|Dietary Supplement|Protein supplement|Daily ingestion of protein supplement.
45506319|NCT05619809|Dietary Supplement|Placebo supplement|Daily ingestion of a placebo dietary supplement.
45506320|NCT05619510|Behavioral|PRIME Intervention|Participants who are randomized to the intervention will participate in five virtual or in person visits with a nurse where the nurse uses self regulation theory as a guide to help them set their own goals surrounding pain and depression and use tailored strategies to address these goals. The second component will include six virtual Acceptance Commitment Therapy (ACT) sessions, led by a clinical psychologist. There will be 3-5 other research participants in the sessions.
45506321|NCT05617287|Dietary Supplement|Semaine Menopause Supplement|Synergistic Dietary Supplement
45506322|NCT05615480|Other|Controlled hypotension guided by cerebral oxygen saturation monitoring|In this group, intraoperative monitoring of cerebral oxygen saturation will be used. When the cerebral oxygen saturation decreased by 20% ~ 25% compared with the baseline for 300 seconds without improvement, or the cerebral oxygen saturation decreased by 25% ~ 30% compared with the baseline for 180 seconds without improvement, intervention would be carried out. When the cerebral oxygen saturation decreased by 30% compared with the baseline, immediate intervention would be carried out. The intervention measures were intravenous administration of deoxyepinephrine 50 ~ 100 μg or ephedrine 5 ~ 10mg, which can be administered multiple times until the cerebral oxygen saturation reaches more than 80% of the baseline.
45506323|NCT05613010|Behavioral|mHealth Messaging Intervention Group|Participants will receive an electronic pill box; the research team will instruct participants on how to use this device. Participants will be asked to use the electronic pill box for their prescribed medicines for the duration of the study (up to 16 months). During the 12-week micro-randomized trial, participants will be randomized within person to receive (1) adherence support text messages or (2) no text message after each missed dose, and (1) praise text message or (2) no text message after each on time dose. Dose timing will be determined based on participant report of when they typically take their tacrolimus or sirolimus medicine.
45506324|NCT05607719|Drug|Bevespi|Two puffs twice a day
45398233|NCT04250662|Device|Active tDCS alone (no guided imagery)|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. Active tDCS arm alone without guided imagery, will have 20 minutes of tDCS stimulation without guided imagery.
45398234|NCT04250662|Device|Sham tDCS with guided imagery|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus sham tDCS arm will have 30 seconds of tDCS stimulation with 25 minutes of guided imagery.
45506325|NCT05607719|Drug|Bretzri|Two puffs twice a day
45506326|NCT05604924|Other|virtual reality training for cesarean section|Participants who received virtual reality training for cesarean section can learn the surgical procedures as if they were in a real field.
45506327|NCT05600400|Radiation|Stereotactic Ablative Body Radiation|2 Fraction
45506328|NCT05581953|Other|Omnivorous|Pork-added plant-forward diet
45506329|NCT05581953|Other|Vegetarian|Plant-forward lacto-ovo-vegetarian diet
45398235|NCT04250662|Device|Sham tDCS alone (no guided imagery)|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. Sham tDCS alone arm will have 30 seconds of tDCS stimulation without guided imagery.
45398236|NCT05164120|Drug|Belnacasan|Oral administration
45506330|NCT05580458|Biological|Shingrix|Shingrix is a recombinant, adjuvanted vaccine for prevention of herpes zoster. It is supplied as lyophilized recombinant VZV surface gE antigen for reconstitution with AS01B adjuvant suspension. Each Shingrix dose will be 0.5mL and administered by IM injection in the deltoid region of the upper arm.
45506331|NCT05579639|Other|Xylitol|Xylitol wipes
45506332|NCT05579639|Other|Placebo|Placebo wipes
45398237|NCT05164120|Drug|Placebo|Tablet containing 0mg of API
45398238|NCT03945136|Behavioral|Dynamic Interpersonal Therapy|Dynamic Interpersonal Therapy is a time-limited, manualized, interpersonal and affect-focused psychodynamic treatment that is frequently used to target depression and anxiety.
45398239|NCT04162366|Drug|Aprocitentan 25 mg|Tablet, oral use once daily
45398240|NCT04162366|Drug|Placebo|Matching placebo tablet, oral use once daily
45506333|NCT05576051|Other|patterns of use of combination therapy and monotherapy|
45506334|NCT05575687|Other|Water (reference)|Ingestion of 500 ml mineral water
45506335|NCT05575687|Other|Sucrose|Ingestion of 500 ml of a flavored mineral water sweetened with sucrose
45506336|NCT05575687|Other|Sucralose|Ingestion of 500 ml of a flavored mineral water sweetened with sucralose
45506337|NCT05575687|Other|Stevia|Ingestion of 500 ml of a flavored mineral water sweetened with stevia extract
45506338|NCT05575687|Other|Monk fruit|Ingestion of 500 ml of a flavored mineral water sweetened with monk fruit extract
45506339|NCT05575687|Other|Allulose + stevia|Ingestion of 500 ml of a flavored mineral water sweetened with allulose and stevia extract
45506340|NCT05568277|Behavioral|Education on preventive health behaviors based on Pender's Health Promotion Model|Pregnant women included in the study will be given education on preventive health behaviors based on Pender's Health Promotion Model on the prevention of gestational diabetes over the web (ZOOM/Teams etc.) every two weeks. Pregnant women's questions will be answered. At the end of each training, data will be collected from pregnant women and follow-up charts will be filled. The education booklet prepared by the researcher will be given to the pregnant women after the first education and will be sent to their e-mail addresses.
45506341|NCT05563389|Drug|Atorvastatin 20mg|active arm
45506342|NCT05563389|Drug|Placebo|placebo arm
45697592|NCT05417620|Behavioral|Community Mobilization|A PrEP community mobilization team (2 peers, including one woman and one man) will be recruited within each ward to promote PrEP. The team will present information about PrEP and the PrEP programme at the ward councilors meeting, at Learning Support Agent meetings with parents/guardians, at local events/fairs, community meetings and through engaging men, women and parents across the community through informal conversations. Teams will be wearing branded material and will focus on presenting factual information and decreasing PrEP stigma. Each team will focus on promoting PrEP within their own ward over the 6-month period.
45697593|NCT05322993|Device|GI Genius|The use of artificial intelligence during colonoscopy to improve polyp detection.
45398241|NCT03947242|Drug|Pyrotinib and Trastuzumab plus Vinorelbine|Pyrotinib:400mg orally daily Trastuzumab:8mg/kg ivgtt load followed by 6mg/kg ivgtt 3-weekly for a total of 4 cycles Vinorelbine :25mg/m2 ivgtt 3-weekly for a total of 4 cycles,d1 d8
45398242|NCT03604432|Device|propylactic maze|Prophylactic limited left sided maze procedure for subjects in the treatment arm
45398243|NCT03944980|Drug|Docetaxel|Docetaxel injection
45398244|NCT03944980|Biological|PD1-T cells|PD1-T cells injection
45398245|NCT05094700|Other|Non-marketed Cosmetic Facial Cleanser|Participants will apply non-marketed cosmetic facial cleanser on cleanse facial skin, twice daily for 4 weeks.
45398246|NCT01108432|Other|Electronic Referral|Dental practices in this arm will be able to have option of making electronic patient referrals to the Decide2Quit website.
45398247|NCT03576664|Drug|Carvedilol 25mg|Cross-over, randomized, placebo-controlled study.
45398248|NCT03576664|Drug|Placebo oral capsule|Cross-over, randomized, placebo-controlled study.
45398249|NCT03502408|Procedure|Endovascular Thrombectomy|Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
45398250|NCT03502408|Procedure|Endovascular Thrombectomy|Procedure:Endovascular Thrombectomy Device: Solitaire™ FR Revascularization Device
45398251|NCT02529826|Procedure|Testicular Biopsy|An open testicular biopsy will be performed by an attending urologist under general anesthesia.
45398252|NCT01108978|Drug|Placebo|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
45506343|NCT05559736|Device|Artemis Proximal Femoral Nail (PFN) implant|Artemis Proximal Femoral Nail (PFN) implant
45506344|NCT05557214|Behavioral|Audit and Feedback Letter|Physicians in the Audit and Feedback Letter Arm will receive an initial letter indicating their high prescriber status with guidance on reducing unnecessary antimicrobial use. They will also receive a follow-up letter at the 6 month mark indicating any change in prescribing habits. There will be a study closure letter mailed at the 12 month mark.
45506345|NCT05553041|Drug|18F-Fluciclovine PET-MRI|18F-Fluciclovine will be injected via IV prior to Positron emission tomography (PET)-Magnetic resonance imaging (MRI)
45697594|NCT05322993|Device|Standard white light colonoscope|Standard colonoscopy.
45697595|NCT04021264|Drug|Ropivacaine-Sufentanil|Local anesthetic injection
45697596|NCT04021264|Drug|Dextrose 5|Sham injection
45697597|NCT03233139|Drug|Cemiplimab|Patients will be administered cemiplimab as per protocol. For Cohort A Only, patients with confirmed progressive disease may opt to receive up to 4 cycles of platinum doublet chemotherapy in addition to cemiplimab per investigator's judgement.
45697598|NCT03233139|Drug|Ipilimumab|To be administered per protocol
45697599|NCT03233139|Drug|Platinum-doublet chemotherapy|To be administered per protocol
45697600|NCT03233139|Drug|Gemcitabine|To be administered per protocol
45697601|NCT03233139|Drug|Pemetrexed|To be administered per protocol
45697602|NCT03233139|Drug|Paclitaxel|To be administered per protocol
45398253|NCT01108978|Drug|Dehypotin|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
45398254|NCT01109134|Drug|tirofiban intracoronary bolus-only|administer tirofiban bolus intracoronary during primary percutaneous coronary intervention with no additional maintenance infusion
45398255|NCT01109134|Drug|tirofiban intravenous bolus plus infusion|administer tirofiban bolus intravenously and maintain infusion for up to 18 hours
45398256|NCT04111588|Other|Diagnostic Amino acid PET/MRI examination|Diagnostic Amino acid PET/MRI examination
45398257|NCT01108588|Drug|Placebo (to match Aspirin)|Placebo grossly matched Aspirin 300 mg daily
45398258|NCT01108588|Drug|Aspirin|Aspirin 300 mg daily
45398259|NCT01108588|Drug|Clopidogrel|Clopidogrel 75 mg daily
45398260|NCT01108588|Drug|Comparator: Placebo (to match Clopidogrel)|Placebo (grossly matched Clopidogrel 75 mg) daily
45398261|NCT01208740|Drug|Metformin|500 mg three times daily
45398262|NCT01208740|Drug|Placebo|1 pill three times daily
45398263|NCT01208818|Drug|Cyclophosphamide + Bortezomib + Dexamethasone regimen|"Dosing regimen (21 day-cycle):~Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12.~Cyclophosphamide 900 mg/m2 on day 1, through a short I.V. infusion The regimen is given for 3 cycles in the absence of serious side-effect."
45398264|NCT01208818|Drug|Bortezomib +Dexamethasone regimen|"Dosing regimen (21 day-cycle):~Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12. The regimen is given for 3 cycles in the absence of serious side-effect."
45506346|NCT05552924|Other|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
45398265|NCT01208818|Device|HCO group|TheraliteTM dialyzer of 2.1 m2 in surface
45398266|NCT01208818|Device|conventional high-flux dialyzer|conventional high-flux dialyzer; polyacrylonitrile, polysulfone, or PMMA dialysers, with an ultrafiltration coefficient > 14 ml/min and ≥ 1.8 m2 in surface, are recommended.
45398267|NCT05067712|Procedure|Open Surgical Exposure Technique|"A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed~Follicular tissue is removed from the exposed crown area~The flap is repositioned back and sutured~The area over the exposed canine crown is excised leaving a window with the crown uncovered.~If the tooth is deeply embedded in the bone, a dressing is placed over the uncovered crown and kept in place with sutures.~The extraction of the primary canine (if present) is made before or in connection with the surgical exposure.~Ten to fifteen days later the dressing and sutures are removed and the tooth is left to erupt autonomously.~When the canine has spontaneously erupted above the palatal mucosa an attachment is bonded to the crown and the canine is moved into alignment in the dental arch above the mucosa with orthodontic appliances."
45506347|NCT05548660|Other|Pharmacogenetic testing|Genetic testing of CYP2B6, CYP2C19, CYP2C9, CYP2C cluster CYP2D6, CYP3A5, CYP4F2, DPYD, HLA-A, HLA-B, IFNL4, NUDT15, SLCO1B1, TPMT, UGT1A1, and VKORC1.
45506348|NCT05548660|Other|Pharmacist note with genotype-guided analgesic recommendations|"CYP2C9 normal metabolizers will be recommended to receive ibuprofen and intermediate and poor metabolizers will be recommended to receive naproxen.~CYP2D6 normal metabolizers will be recommended to receive tramadol and ultrarapid, intermediate and poor metabolizers will be recommended to receive oxycodone."
45506349|NCT05548660|Other|Pharmacist detailed note with genotype-guided recommendations per CPIC guidelines|Genotype-guided recommendations for all actionable phenotypes resulted from the 16-gene PGx panel per CPIC guidelines and FDA labeling
45506350|NCT05547347|Procedure|Magnetic Resonance Imaging|Undergo MRI
45506351|NCT05547347|Procedure|Mammogram|Undergo a mammogram
45506352|NCT05547347|Procedure|Ultrasound|Undergo a breast ultrasound
45506353|NCT05547347|Procedure|Ultrasound-Guided Biopsy|Undergo a percutaneous ultrasound-guided breast clip placement
45506354|NCT05539963|Drug|Stimulan-VG|Participants will receive Stimulan-VG via implantation during debridement surgery on Day 1.
45506355|NCT05539963|Drug|Systemic Antibiotics|Participants will receive Antibiotics per site-specific requirements via oral or intravenous route during Pre and post operatively.
45506356|NCT05532917|Other|Gupta score|The Gupta score is presented as an interactive risk calculation program in the 2014 guideline of the ACC/AHA. The Gupta score developed with this MICA model identified five predictors of perioperative myocardial infarction and cardiac arrest: type of surgery, functional status, creatinine increase (>130 mmol/L or >1.5 mg/dL), age, and American Association of Anesthesiologists (ASA) class. The frequency of cardiology consultation requests will be investigated according to the use of the Gupta score.
45506357|NCT05530434|Other|transpulmonary pressure guided positive end expiratory pressure|Positive end expiratory pressure will be titrated to achieve a transpulmonary pressure of 0-2 cm H2O
45506358|NCT05530434|Other|standard positive end expiratory pressure|Positive end expiratory pressure will be set to a standard 5-8 cm H2O by the clinician for spontaneous breathing trials
45506359|NCT05530265|Device|the smart watch and Samsung Health app|Use the smart watch (Galaxy Watch 4, Samsung Electronics Co., Ltd., Korea) and the Samsung Health app (Samsung Electronics Co., Ltd., Korea) for 90 days of positive airway pressure treatment
45506360|NCT05525273|Drug|Oral dabrafenib and trametinib|Neoadjuvant or postoperative treatment of patients with verified BRAF mutated papillary craniopharyngioma
45506361|NCT05521321|Behavioral|Stanford Cannabis Awareness and Prevention curriculum|Stanford Cannabis Awareness and Prevention curriculum delivered as a 5-session course administered in a school classroom setting.
45506362|NCT05516849|Drug|Oxandrolone|Oxandrolone is a synthetic anabolic androgenic steroid that induces its responses by binding to androgen receptors which modulates gene expression to increase protein synthesis and efficient utilisation of amino acids. Oxandrolone was first synthesized in 1962 through 17alpha-alkylation of testosterone resulting in a formal composition of (4bS,7S,9aS,9bR,11aS)-tetradecahydro-7-hydroxy-4aS,6aS,7-trimethyl- cyclopentanaphthopyran-2(1H)-one and molecular formula of C19H30O3.
45398268|NCT05067712|Procedure|Closed Surgical Exposure Technique|"A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed.~Follicular tissue is removed from the exposed crown area.~An attachment with a chain is bonded to the exposed canine crown.~The flap is repositioned back and sutured to cover the exposed crown leaving the chain through the palatal mucosa free in the oral cavity~The extraction of the primary canine (if present) made before or in connection with the surgical exposure~Ten to fifteen days later the sutures are removed.~Within days, traction is applied to the canine with orthodontic appliances by means of the chain, and the canine is pulled through the palatal mucosa out to the oral cavity and into alignment in the dental arch."
45398269|NCT05047120|Behavioral|Hypnosis Enhanced Cognitive Therapy|in-person hypnosis enhanced cognitive therapy for pain management following SCI
45398270|NCT03947320|Drug|Recombinant Human Coagulation FVIII|Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
45506363|NCT05516849|Other|Placebo|As there is currently no approved medication to aid in soft-tissue regeneration, we will be using a placebo control.
45506364|NCT05511766|Drug|Allopurinol 300 MG|a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation
45506365|NCT05511766|Drug|Atorvastatin 20mg|is lipid-lowering agent with anti-oxidative stress and anti-inflammation properties
45506366|NCT05511766|Drug|Placebo|not containing drugs
45506367|NCT05505422|Device|Routine ECMO|Routine ECMO during lung tansplant
45506368|NCT05505422|Device|On demand ECMO|"Selective, indication-based intraoperative cardiopulmonary support. In this group, the transplant will be planned without cardiopulmonary support. intraoperative ECMO will be used selectively based on hemodynamic and/or gas exchange abnormalities :~Inability to maintain adequate hemodynamics and stable perfusion or oxygenation during surgery~Prolonged high dose pressor required to maintain adequate perfusion~A sustained drop in cerebral saturation > 25% of baseline despite initial attempts at optimization~Inability to tolerate pulmonary artery clamping~Inadequate gas exchange despite attempts at the optimization of ventilator parameters and treatments related to respiratory mechanics and ventilation/perfusion matching~Inadequate exposure to the surgical field"
45506369|NCT05501444|Other|Topical antiperspirant|The participants will be instructed to use topical antiperspirant (aluminum chloride, 15 percent every evening for four weeks. The PI will contact the participants every week. If the participant experiences that antiperspirant have an effect, the use of antiperspirant will be reduced from daily use to 3 times a week.
45506370|NCT05495711|Biological|human umbilical cord mesenchymal stem cell complex collagen|1 * 10^7 cells (2ml)
45506371|NCT05495711|Procedure|intrauterine injection|intrauterine injection with human umbilical cord mesenchymal stem cell (19#iSCLife®-UT); total 1 time
45506372|NCT05495581|Drug|pudexacianinium chloride|Intravenous
45506373|NCT05493982|Behavioral|Stanford Vaping Prevention curriculum|Stanford vaping prevention curriculum delivered as a 5-session course administered in a school classroom setting.
45506375|NCT05479916|Dietary Supplement|Low glycated milk protein|40 grams of protein dissolved in 600 mL of water
45506376|NCT05479916|Dietary Supplement|High glycated milk protein|40 grams of protein dissolved in 600 mL of water
45398271|NCT01111630|Drug|recomon (Epoetin Beta)|administer once weekly
45506377|NCT05479604|Device|SinuSonic|Handheld device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion. The device is held over the nose and creates vibrations similar to humming.
45506378|NCT05479604|Device|Sham Device|Device looks exactly like study device but does not emit the same pressure or make the same noise as the study device
45398272|NCT01111630|Drug|recomon (Epoetin Beta)|administer three times weekly
45398273|NCT01208896|Drug|Reduced_intensity conditioning|The conditioning regimen is composed of Fludarabine (30 mg/m2) and Cyclophosphamide (750 mg/m2), both administered intravenously at Days -5, -4, -3 with Day 0 being the day of transplantation. Rituximab will be administered intravenously at 375 mg/m2 at Day -13 and 1000 mg/m2 at Days -6, +1, +8. Tacrolimus and low-doses of methotrexate will be used for prophylaxis of GVHD.
45398274|NCT03944278|Device|Thulium Laser|Thulium laser for skin resurfacing procedures
45506379|NCT05476796|Drug|Trifluridine/Tipiracil|Trifluridine/Tipiracil will be administered with a 14-day schedule (35 mg/m² BID for 5 days followed by 9 days of recovery) until disease progression or intolerable toxicity.
45506380|NCT05476796|Drug|Oxaliplatin|Oxaliplatin will be administered intravenously on day 1 of each treatment cycle (infusion duration: 2 hours), every 2 weeks. The first cycle will be administered at level -1 (70 mg/m²) and then increased to 85 mg/m² (if feasible) from the cycle 2 to 8 or until disease progression, whatever occurs first. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and Trifluridine/Tipiracil will be continued alone until disease progression or intolerable toxicity.
45506381|NCT05476796|Drug|FOLFOX regimen|Folinic Acid 400 mg/m² (or 200 mg/m² if L-folinic acid) + oxaliplatin 85 mg/m² (infusion duration: 2 hours) followed by 5-FU bolus 400 mg/m² and then 5-FU 2400 mg/m² as a 46-hour continuous infusion. Treatment repeated every 14 days. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and 5-FU (simplified LV5FU2 regimen) or capecitabine (1000 mg/m² BID during 2 weeks every 3 weeks) will be continued alone until disease progression or intolerable toxicity.
45506382|NCT05468346|Drug|[14C]-HEC585|Single Dose = Solution containing 200 mg/100 µCi [14C]-HEC585
45506383|NCT05466734|Drug|Cilostazol Tablet 100 mg|Two oral doses (total daily dose of 200 mg)
45506384|NCT05466734|Drug|PMR Tablet 135 mg|Single oral dose (total daily dose of 270 mg)
45506385|NCT05452317|Other|Chronic active AMR group|Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
45398275|NCT01327768|Procedure|Olfactory ensheathing cells|Recruited patients should be received the endoscopic surgery for picking the olfactory mucosa 1 to 2 months before transplantation. The OECs will be cultured and expanded under the rule of GTP. Finally, we will transplant the OECs (about 2 to 8 X 10´6 cells in saline) into the peri-infarcted area of the brain for old stroke ischemic patients.
45398276|NCT03942796|Drug|lyrica, vronogabic (pregabalin)|Patients would receive oral pregabalin is initiated at a dose of 75 mg twice daily and titrated up to 600 mg as tolerated by the patient at 1,2,3 weeks
45506386|NCT05452317|Other|Non-Chronic active AMR group|Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
45506387|NCT05450029|Drug|Sintilimab|6 cycles of mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) followed by long course chemoradiotherapy (50 Gy in 25 fractions) followed by surgery. Patients will receive sintilimab 3mg/kg every 2 weeks during chemoradiotherapy (2nd-6th cycle).
45398277|NCT03942796|Procedure|pulsed radiofrequency ablation of the dorsal root ganglion under fluroscopic guidance/ radiofrequency neurolysis/ radiofrequency denervation device name: Neuro Therm TM 1100|Patients would receive pulsed radiofrequency ablation of dorsal root ganglion using the following settings: 2-Hz frequency, 20-ms pulses in a 1 second cycle, 120 second duration and 42°C temperature. Impedance ranges between 150 and 400 Ohms at all levels under fluroscopic guidance. For each pulsed RF application, the procedure will be repeated 4 times, for a total duration of 8 minutes
45398278|NCT01114282|Drug|velcade|
45398279|NCT01114282|Drug|Pralatrexate|
45506388|NCT05439395|Device|Sternum Closure after Cardiac Surgery|Sternal closure using Steelex® Sternum Set after CABG or cardiac valve replacement / reconstruction.
45506389|NCT05432921|Behavioral|Lifestyle modification|50min of endurance combined with 50min of strength training; 1-2 sessions/week for 6 month, follow up after 3-6month
45697603|NCT01002118|Drug|Omega-3 Acid Ethyl Esters|1 gram capsules Omega-3 Acid Ethyl Esters for a total of 4 grams (4 capsules) per day for 16 weeks
45697604|NCT01002118|Drug|Placebo|4 capsules each day for 16 weeks
45849790|NCT04793724|Device|PARI O PEP|"ACT with PARI O-PEP will be performed in an upright sitting position, using four positions of the device for the most effective clearance of mucus from the lungs. These positions will be:~horizontal;~low;~transition of the device from the low position to the horizontal position;~upside down.~The mouthpiece will be placed between the patient's teeth as per standard procedure, and enclosed properly within the lips. Patients will perform slow and deep inhalation via the nose, then hold their breath for about 1 to 2 seconds at the end of inhalation. Exhalation will be performed slowly and completely into the PARI O-PEP through the patient's mouth. At the end of the session, the patient will perform huffing with the PARI O-PEP device in the upside down position in order to maintain open airways, and, if possible, expectoration sputum."
45398280|NCT01111708|Procedure|Close Rectal Dissection - IPAA|Comparison between conventional IPAA and Close Rectal IPAA and INRA after (sub)total proctocolectomy for Ulcerative colitis
45697605|NCT05322369|Other|periodontal charting only|Periodontal charting only
45849791|NCT04782492|Procedure|graft configuration in coronary artery bypass grafting|Saphenous vein could be used as Y-composite graft or aortocoronary conduit during coronary artery bypass grafting
45849792|NCT04779138|Behavioral|Increasing Willingness and Uptake of COVID-19 Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 vaccine hesitancy and increase willingness and uptake in COVID-19 vaccination.
45398281|NCT03944122|Device|ultrasound|therapeutical ultrasound were applied to the patients
45697606|NCT05311839|Other|Exercise|Hot packs, active range of motion exercises, pendular exercises, wall climb exercises, mobilization exercises, and shoulder capsular stretching
45697607|NCT05311839|Other|Thera band|graded Thera band exercises for shoulder flexion, abduction, internal, and external rotation
45849793|NCT04772898|Behavioral|Hippotherapy|The hippotherapy involves occupational therapy while being on a horse.
45849794|NCT04740294|Drug|Magnesium Sulfate|Randomized to receive either magnesium sulfate or normal saline placebo.
45849795|NCT04727736|Drug|18F-DCFPyL|18F-DCFPyL (single dose injection) - a radiolabeled prostate-specific membrane antigen (PSMA) ligand
45849796|NCT04723680|Other|Qualitative interview|Qualitative semi structured interview
45849797|NCT04721418|Radiation|11C-UCB-J|11C-UCB-J PET scan
45398282|NCT01109212|Drug|Bindarit|dosage form:tablet dosage:2x300 mg frequency:b.i.d duration:12 weeks
46059086|NCT02802553|Device|Smart Goggle|Smart Goggle is a novel stereoscopic wearable multimodal intraoperative imaging and display systems entitled Integrated Imaging Goggles for assessment of SLNs. The prototype system offers real time stereoscopic fluorescence imaging along with in vivo handheld microscopy. The investigators have found that the system can detect fluorescent targets with as low as 1.2 picomoles ICG (60 nM concentration). The hand-held microscopy module has a resolution of 25 micron. The prototype system has 2 complementary metal-oxide-semiconductor (CMOS) imaging sensors housed on a printed circuit board (PCB) with imaging lenses and emission filters optimized for ICG dye. The light source provides concurrent excitation centered at 780 nm and white light illumination with OD6 level cut-off. The Smart Goggles is a non-invasive imaging system that does not require contact with patients.
45506390|NCT05421988|Behavioral|Emotional Freedom Techniques (EFT)|EFT is an efficacious method demonstrated in over 100 clinical trials. It combines cognitive and exposure techniques with acupressure, in the form of fingertip percussion on acupuncture meridian points.
45398283|NCT01109212|Drug|Placebo|dosage form: tablet dosage: n.a. frequency: 2xplacebo b.i.d duration:12 weeks
45398284|NCT01111864|Dietary Supplement|fortification with iron and micronutrients|Iron 0 or 2.5 mg; Copper 0.34 mg; 30 µg Iodine; 7 µg Selenium; 2.5 mg Zinc; 100 µg Vitamin A; Vitamin D 5 µg; 5 mg Tocopherol Equivalent; 30 µg Vitamin K1; 10.5 mg Thiamine; 0.5 mg Riboflavin; 0.5 mg Pyridoxine; 90 µg Folic Acid Anhydrous; 6 mg Niacinamide; 60 mg Vitamin C; 0.9 µg Vitamin B12
45398285|NCT01111864|Dietary Supplement|Sprinkles|Daily 12.5mg Ferrous fumarate iron with microntrient is compared to no iron with micronutrients. Duration of intervention is 4 months, 80 infants will be inclulded.
45506391|NCT05420402|Drug|Propofol bolus|A bolus dose of propofol 1 mg/kg was administered intravenously at 3 minutes before the end of the surgery.
45506392|NCT05420402|Drug|Propofol continuous infusion|1 mg/kg propofol was started by continuous infusion 3 minutes before the end of surgery, and the infusion time was 3 minutes.
45398286|NCT01211782|Drug|caprylic triglyceride|oral, 20 gm, daily x 6 months
45506393|NCT05420402|Drug|Propofol bolus|A bolus dose of propofol 1 mg/kg was administered intravenously at the end of the surgery.
45506394|NCT05417646|Other|Hyperglycaemic clamp|Three-hour, three-step glucose clamp with plasma glucose targets 10, 14 and 18 mmol/l (each one hour)
45697608|NCT01003288|Biological|Adjuvanted influenza H1N1split virion vaccine|"Vaccination Pandemrix suspension and emulsion for emulsion for injection. 1 dose (0.5 ml) contains Split influenza virus, inactivated, containing antigen 3.75 micrograms of A/California/7/2009 (H1N1)v-like strain (X-179A)~* Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)"
45506395|NCT05417646|Drug|Placebo|Placebo comparator to empagliflozin
45697609|NCT04763343|Drug|Ketamine Hydrochloride|Ketamine hydrochloride will be given as an intravenous infusion using a standard regimen given in most studies conducted: 0.5 mg/kg over 40 minutes. Ketamine infusions will be given every other day until either the subject reports clinician rated Scale for Suicidal Ideation (SSI) score of<4, and >50% decrease from baseline, and clinical assessment of patient not being suicidal for three consecutive pre-infusion ratings, or a maximum of six infusions have been given over the course of 2 weeks, or they have been discharged from the inpatient unit.
45398287|NCT01211782|Drug|long-chain triglyceride|oral, 14 gm, daily x 6 months
45849798|NCT04705818|Drug|Durvalumab|Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)
45849799|NCT04705818|Drug|Tazemetostat|Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).
45398288|NCT01111942|Other|radiation combined with weekly carboplatin|"recommended premedications: Aloxi 0.25 mg IV; Dexamethasone 20 mg IV; Fosaprepitant 115 mg IV; Aprepitant 80 mg PO; Ativan 1.0 mg IV;~Mucositis treatment should involve local measures to maintain oral hygiene, oral nystatin or fluconazole, or valacyclovir for viral infection.~Induction Triple Therapy Treatment with TPF:~Docetaxel (Taxotere) 75 mg/m2 IV; Cisplatin (Platinol) 100 mg/m2 IV; 1500 cc Normal Saline w/20meq KCL, 1 gram MgSo4 IV; 5-Fluorouracil (Adrucil) 1000 mg/m2 day IV-continuous infusion over 4 days; Neulasta* 6 mg SC Day 5 (*Neupogen may be substituted at the investigator's discretion)"
45506396|NCT05417646|Drug|Empagliflozin|Single-dose, 25 mg, two hours before clamp
45506397|NCT05417087|Drug|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg equivalent to 20 mg of Vortioxetine
45506398|NCT05417087|Drug|Vortioxetine Hydrobromide Tablets|Vortioxetine Hydrobromide Tablets 20mg
45849800|NCT04703712|Procedure|Lens extraction combined with goniosynechialysis|The patients enrolled underwent phacoemulsification combined with goniosynechialysis surgery.
45849801|NCT04703712|Procedure|Trabeculectomy surgery|The patients enrolled underwent trabeculectomy surgery
45506399|NCT05416957|Drug|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg administration under fasting condition
45506400|NCT05416762|Drug|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg
45506401|NCT05416762|Drug|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg
45506402|NCT05416762|Drug|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg
45506403|NCT05408949|Behavioral|Single exercise into pain (SEP) program|"Baseline assessment & commencement of treatment: Resisted isometric shoulder abduction into pain (or lateral rotation or flexion into pain) against a wall, or Resisted shoulder abduction from 0 to 30° using moderate resistance from Theraband ( Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~Initial follow-up & progression: Resisted shoulder abduction into pain from 80 to 120° using light weight (Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~Second follow-up & progression: eccentric shoulder abduction into pain from 80 to 120° with progressively increasing repetition and weight, e.g. heavy Theraband or dumbbell.~Final assessment to identify any non-resolved functional limitations and progress eccentric exercises into pain as required~Functional rehabilitation program"
45506404|NCT05408949|Behavioral|Shoulder Symptom Modification Procedure (SSMP)|[1] Finger on the sternum,[2A] Scapula modification [3] 'Humeral head' modification [4] Isometric (most painful movement) Heavy slow resistance (HSR): start from the mid-range and pain-free
45506405|NCT05408949|Behavioral|Functional Rehabilitation Program|Mostly targetted into exercise such as multi-stage pushing, pulling, lifting and carrying, throwing, kinetic chain exercises and aerobics. FR involved (i). Weight-shifting activities to enhance dynamic joint stability[18] .(ii). Proprioceptive neuromuscular facilitation exercises to stimulating stretch receptors located on the muscle or tendon units [18]. Using resistive tubing exercises in a functional position using PNF patterns; diagonal pattern 1: flexion, abduction, external rotation (10-15 repetition 2-3 sets). (iii) Plyometric exercise: (A) throwing motions; (B) push-up (10-15 repetition 2-3 sets) . (iv). Table slide (10-15 repetition 2-3 sets).
45506406|NCT05408949|Behavioral|EPTL|In EPTL it involves eccentric training in Full range (with dumbbells 15-10 RM) of Internal and external rotation at scapular plane elevation (0-45) degree and Flexion, Abduction, in full range (5 repetitions with a 45 second hold at slow speed) to target the series elastic component of the muscle .
45506407|NCT05408949|Behavioral|HSR|In HSR it involves eccentric training in mid-range of motion (with dumbbells 15-10 RM) targeting the contractile component of the muscles and improving mechanical strength. Additionally, when there is 90% pain reduction on NPRS functional rehabilitation program start and they follow the same program as Group A.
45506408|NCT05404113|Other|sustained natural apophyseal glide|Mulligan's C1-C2 self-SNAG+ strengthening exercises for anterior and posterior neck muscles (extension, flexion, rotation, lateral flexion) Frequency: 2-3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 minutes/session Type: Mobilization with movement SNAG Conventional PT including strengthening exercises neck muscles 10 repetitions, 1 set Resisted neck flexion, extension, lateral flexion, rotation Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 minutes/session Type: Strengthening Exercise
45506409|NCT05404113|Other|deep friction massage|Cyriax deep friction massage+ strengthening exercises for anterior and posterior neck muscles (extension, flexion, rotation, lateral flexion) Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 20 minutes/session Type: Deep soft tissue massage Conventional PT including strengthening exercises neck muscles 10 repetitions, 1 set Resisted neck flexion, extension, lateral flexion, rotation Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 minutes/session Type: Strengthening Exercise
45697610|NCT04763343|Drug|Saline|Subjects randomized to placebo will be administered a saline (0.9% sodium chloride) drip for 40 minutes. Saline placebo infusions will be given every other day until either the subject reports clinician rated Scale for Suicidal Ideation (SSI) score of<4, and >50% decrease from baseline, and clinical assessment of patient not being suicidal for three consecutive pre-infusion ratings, or a maximum of six infusions have been given over the course of 2 weeks, or they have been discharged from the inpatient unit.
46059087|NCT02802553|Other|Cardio-Green|Indocyanine Green for Injection USP is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. Indocyanine Green for Injection USP is dissolved using Sterile Water for Injection, and is to be administered intravenously.
45398289|NCT01111942|Procedure|conservation surgery|Following induction triple chemotherapy, subjects will be restaged by physical examination and radiological imaging. If there is an absence of unequivocal evidence for residual disease (i.e. an apparent complete response), the subject will undergo conservation surgery under general anesthesia, using a transoral approach. Minimal tissue removal through direct access. The surgical specimen will be evaluated by a pathologist in the manner standard for the institution. The presence of residual tumor will be classified as a partial response to induction triple chemotherapy and the subject will undergo concomitant chemoradiotherapy. If there is no evidence of residual disease in the surgical specimen, the subject will be followed for recurrence.
45398290|NCT01112020|Device|CHG Catheter Dressing Patch|2% CHG dressing applied to 7 sites
45398291|NCT01112020|Device|Biopatch|Biopatch applied to 7 sites
45398292|NCT01112020|Device|Tegaderm CHG|Tegaderm CHG IV Securement Dressing applied to 7 sites
45506410|NCT05402566|Diagnostic Test|Deuterium metabolic imaging|MRI after oral administration of 75g of [6,6'-2H2]glucose.
45506411|NCT05402540|Other|STRAIN COUNTER STRAIN GROUP|"Strain Counterstrain Technique in combination with conventional physiotherapy (Hot pack, Codmans exercises, active assisted exercises, Pendulum exercises, Finger Ladder Exercise, Maitland mobilization of shoulder joint.~Therapist palpate surrounding and opposing tissues to locate trigger point by using one or two finger pads to monitor fasciculation and MTrP.~Hold the POC (position of comfort) until fasciculation decreases significantly or ceases. Average positions hold time while pressure is 90 s to 3 min.~Release tissue or joint slowly and reassess. Each patient will receive total 6 sessions (3sessions/week) over a period of 2 weeks.~Assessment would be done on baseline and after every three sessions."
45398293|NCT03944200|Drug|DA-1229_01(A), Sugamet SR Tab 5/1000mg®|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
45398294|NCT03944200|Drug|Sugamet SR Tab 5/1000mg®, DA-1229_01(A)|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar."
45506412|NCT05402540|Other|ACTIVE RELESAE TECHNIQUE GROUP|"Active Release Technique in combination with conventional physiotherapy (Hot pack, Codmans exercises, active assisted exercises, Pendulum exercises, Finger Ladder Exercise, Maitland mobilization of shoulder joint.~The targeted muscle will be palpated while the therapist will looks for localized tenderness or trigger points with referred pain elicitation.~With the thumb therapist will relieve the trigger point. In ART the particular muscle is taken from shortened to lengthened position or from lengthened to shortened position.~Duration of treatment will be 8-15 minutes. Each patient will receive total 6 sessions (3sessions/week) over a period of 2 weeks.~Assessment would be done on baseline and after every three sessions."
45506413|NCT05398588|Other|Cyriax Deep Friction Massage|Hotpack : 10 min TENS : 20 min, High frequency(100 Hz pulse ), 3 days/week Kaltenborn mobilization: End range - Anterior, posterior and caudal glides :10 repetitions with 10 sec hold x 3 sets, 3 days/week Cyriax DFM on targeted muscles (Supraspinatus, Infraspinatus, subscapularis, Deltoid and Pectoralis) 3 minutes each muscle (15 mins in total ) x 1 set , 3 days / week
45506414|NCT05398588|Other|Spencer Muscle energy technique|"Hotpack : 10 min TENS : 20 min, High frequency(100 Hz pulse ), 3 days/week Kaltenborn mobilization: End range - Anterior, posterior and caudal glides :10 repetitions with 10 sec hold x 3 sets, 3 days/week The Spencer technique will be applied in Abduction, External rotation and Internal rotation for targeting muscles Supraspinatus, Infraspinatus, subscapularis, Deltoid and Pectoralis.~10 repetitions x 3set , 3 days/week."
45506415|NCT05396612|Other|Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.|Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
45697611|NCT04763343|Behavioral|CAMS Therapy|CAMS weekly sessions will also be started immediately as an inpatient at the start of the study while receiving ketamine or saline. CAMS will be continued weekly after the patient is discharged and followed up as an outpatient. Weekly CAMS sessions will be terminated after the subject, as an outpatient, has a clinician rated Scale for Suicidal Ideation (SSI) score of<4, and >50% decrease from baseline, and clinical assessment of patient not being suicidal, for at least 3 consecutive sessions of CAMS.
45697612|NCT04759365|Drug|ASN51|ASN51 formulation for oral capsule
45697613|NCT04759365|Drug|Placebo|Placebo formulation for oral capsule
45398295|NCT03940534|Device|TAD|TAD is a device used to aid medication adherence.
45398296|NCT03942640|Other|subctaneous perineural injection|"Buffered glucose preparation :~2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%. Patients received 8 weekly injection"
45398297|NCT03942640|Other|deep prolotherapy|The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine
45506416|NCT05395481|Drug|LY3849891|Administered SC.
45506417|NCT05395481|Drug|Placebo|Administered SC.
45506418|NCT05394662|Device|Juveena Hydrogel System|Application of a novel hydrogel immediately following the transcervical procedure
45506419|NCT05391607|Drug|Hyperoncotic Albumin 20%|Intravenous administration during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
45398298|NCT01112098|Behavioral|Patient Pamphlet|letter informs patient of opportunity to self-schedule a DXA scan; pamphlet includes information about receiving a DXA scan
45398299|NCT01211860|Drug|Diazoxide Choline Controlled-Release Tablet|DCCR 290 mg once a day for 10 days
45398300|NCT01112176|Procedure|Increase in paced heart rate|The pacing rate will be increased by 10 bps at every stage
45506420|NCT05391607|Drug|Isooncotic Albumin 5%|Intravenous administration of Albumin 5% 12ml/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
45398301|NCT01589536|Other|interval-rehabilitation|The Patients in the intervention group receive a Stationary psychocardiological interval-rehabilitation.The Interval rehabilitation is divided into individual psychological therapy with focus of Behavior therapy and relaxation therapy.
45506421|NCT05391607|Drug|Ringer's Lactate Crystalloid Solutions (control group)|Intravenous administration of Ringer-lactate ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
45506422|NCT05388097|Other|Managed Services|coordination of care and assistance with community resources (food, transportation)
45506423|NCT05386563|Procedure|Transcutaneous Auricular Vagal Nerve Stimulation (taVNS)|"taVNS will be delivered by Digitimer DS7 Constant Current Stimulator (an FDA cleared medical device intended for human nerve and muscle stimulation).~Stimulation is delivered via sticky pad electrodes all placed on the left side of the body (cymba concha, earlobe, and ulnar side of the wrist). Stimulation is delivered by a 3000ms pulse train (100us pulse width and 25Hz stimulation frequency). The current applied will be between 0.01uA to 9uA. The intervention will be delivered over the course of four sessions approximately one week apart."
45506424|NCT05386563|Procedure|Sham Stimulation|"Sham stimulation will be delivered by Digitimer DS7 Constant Current Stimulator (an FDA cleared medical device intended for human nerve and muscle stimulation).~Stimulation is delivered via sticky pad electrodes all placed on the left side of the body (either earlobe or forearm)."
45697614|NCT05364112|Device|Compreflex|The Compreflex standard calf and foot (with basic liner) from Sigvaris (St. Gallen, Switzerland) is an easy-to-use interlacing Velcro wrap device with adjustable compression levels.
45506425|NCT05383742|Drug|Rifampicin (RIF)|Rifampicin 35 mg/kg
45506426|NCT05383742|Drug|Isoniazid (INH)|Isoniazid 10 or15 mg/kg
45398302|NCT01211938|Radiation|single-fraction radiotherapy with concomitant 5FU and Hydrea|single-fraction radiotherapy with concomitant 5FU and Hydrea
45398303|NCT01211938|Radiation|hyperfractionated radiotherapy with concomitant Cetuximab|hyperfractionated radiotherapy with concomitant Cetuximab
45506427|NCT05383742|Drug|Linezolid (LZD)|1200 mg
45506428|NCT05383742|Drug|Pyrazinamide (PZA)|25 mg/kg
45506429|NCT05383742|Drug|ethambutol (EMB)|20 mg/kg
45506430|NCT05383742|Drug|Rifampicin|10 mg/kg
45506431|NCT05383742|Drug|Isoniazid|5 mg/kg
45506432|NCT05377190|Other|Continuum HFC-IN|Combination of a mobile application (with remote monitoring) and digital therapeutics
45506433|NCT05377190|Other|Standard of care for the follow-up|No mobile application or digital therapeutics are used
45506434|NCT05377190|Other|Continuum HFC-OUT|Combination of a mobile application (without remote monitoring) and digital therapeutics
45506435|NCT05365802|Drug|68Ga-FAPi-46|Radiopharmaceutical will be administered via IV
45506436|NCT05365802|Procedure|Computed Tomography|As part of PET/CT scan
45506437|NCT05365802|Procedure|Positron Emission Tomography|As part of PET/CT scan
45697615|NCT04757571|Drug|Paroxetine|Paroxetine 20 mg tablet plus standard therapy
45506438|NCT05365802|Procedure|High Resolution Computed Tomography|Will be conducted immediately after FAPI PET/CT
45506439|NCT05363826|Combination Product|photochemotherapy using 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester(Photobac®)|"Intravenous injection of Photobac® 24 hours before surgical removal of recurrent GBMF.~Immediately after resection, the cavity will be treated with 50 joules/ square cm of 787nm light. This treatment will add a maximum of 50 minutes to the surgery"
45506440|NCT05358639|Drug|Olaparib tablet|Olaparib tablet will be administered alone for 14 days at a starting dose of 200 mg twice daily. Subsequently olaparib will be administered continuously over 28 days at a fixed dose and the dose of navitoclax will be escalated.
45398304|NCT02947438|Drug|EPREX®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
45506441|NCT05358639|Drug|Navitoclax|For navitoclax, a lead-in of 7 days at 150 mg PO will be used prior to dose escalation. The DLT period for dose levels above DL 3 will include the 14-day olaparib alone lead-in, the 7 days combination with navitoclax at 150 mg and the first 28 day cycle of the combination of olaparib and navitoclax cycle at the full dose level dosing (49 days).
45398305|NCT02947438|Drug|EPIAO®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
45398306|NCT03940768|Dietary Supplement|Lactobacillus plantarum 299v|Administration of Lactobacillus plantarum 299v in cancer patients who receive home enteral nutrition.
45398307|NCT03940768|Dietary Supplement|Placebo|Administration of placebo in cancer patients who receive home enteral nutrition.
45506442|NCT05355090|Dietary Supplement|PP|Protein Pacing three times per day
45506443|NCT05352698|Diagnostic Test|NT ProBNP (Roche)|This NT ProBNP assay is a point-of-care (POC) test that will be conducted on a 2 mL sample of whole blood collected in a non-heparinized tube. NT ProBNP results are used in this setting to predict perioperative cardiovascular risk.
45506444|NCT05351255|Device|Transcranial Magnetic Stimulation (TMS)|Aim 2 of the study includes an intervention where participants receive a repetitive TMS protocol called theta burst stimulation (TBS) to study its effect on motor learning behavior.
45506445|NCT05347225|Drug|Nemtabrutinib|Nemtabrutinib tablets will be administered orally QD.
45506446|NCT05330871|Biological|1 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
45506447|NCT05330871|Biological|2 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
45506448|NCT05330871|Biological|3 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
46059088|NCT02802553|Device|SPY Elite Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
45398308|NCT02804542|Other|Observational|
45398309|NCT02804542|Other|Retrospective review|
45398310|NCT01209052|Drug|GSK1325756|Drug will be orally administered in varying amounts over varying time periods as detailed in the 'arms' section.
45398311|NCT01209052|Other|Placebo|Placebo will be orally administered to at least 4 subjects in each treatment period of each cohort. In each sequence in each cohort, all subjects will receive one dose of placebo.
45398312|NCT01209130|Drug|DCDT2980S|Intravenous repeating dose
45398313|NCT01209130|Drug|rituximab|Intravenous repeating dose
45398314|NCT01209208|Drug|Budesonide|9 mg per day
45398315|NCT01209208|Drug|Mesalamine|3 g per day
45398316|NCT01209208|Other|Placebo|0 g per day
45506449|NCT05330871|Biological|4 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
45506450|NCT05330871|Biological|5 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
45506451|NCT05330871|Biological|6 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
45506452|NCT05330871|Biological|7 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
45506453|NCT05330871|Biological|8 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
45506454|NCT05330871|Biological|9 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
45506455|NCT05330871|Biological|10 Intramuscular injection for booster groups|1 dose 0.5ml
45506456|NCT05330871|Biological|11 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
45506457|NCT05330871|Biological|12 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
45506458|NCT05330871|Biological|13 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
45506459|NCT05330871|Biological|14 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
45506460|NCT05330871|Biological|15 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
45697616|NCT04757571|Drug|Placebo|Placebo tablet plus standard therapy
45697617|NCT03232593|Drug|Atezolizumab|Participants will receive atezolizumab as per the local label and standard of care at physician's discretion.
45697618|NCT02162446|Drug|satoreotide trizoxetan|
45697619|NCT04746183|Drug|CST-2: EIDD-2801|"CST-2 Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST.~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose."
45697620|NCT04746183|Drug|CST-2: Placebo|CST-2 Phase II: Placebo will be administered orally, twice daily (BID) for 10 doses (5 or 6 days).
45398317|NCT03940612|Dietary Supplement|STP4 (product with probiotics)|STP4 contains Lactobacillus plantarum LP115, Lactobacillus helveticus LA25, Lactobacillus rhamnosus LRH10, Lactobacillus paracasei LPC12, Lactobacillus fermentum LF26, Lactobacillus delbrueckii subsp. lactis, LDL114. Administration at 10 log CFU/day for 8-weeks.
45506461|NCT05330871|Biological|16 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
45506462|NCT05330871|Biological|17 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
45506463|NCT05330871|Biological|18 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
45506464|NCT05330871|Biological|19 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
45506465|NCT05330871|Biological|20 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
45398318|NCT03940612|Dietary Supplement|Placebo (product without probiotics)|Capsules are similar to STP4 except the presence of probiotics. Administration daily for 8-weeks.
45506466|NCT05330871|Biological|21 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
45506467|NCT05330871|Biological|22 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
45506468|NCT05330871|Biological|23 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
45506469|NCT05330871|Biological|24 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
45506470|NCT05327595|Drug|LY3549492|Administered orally.
45506471|NCT05327595|Drug|Placebo|Administered orally.
45506472|NCT05327595|Drug|Atorvastatin|Administered orally.
45506473|NCT05327595|Drug|Midazolam|Administered orally.
45506474|NCT05320796|Diagnostic Test|upper endoscopy|A wireless BRAVO™ - pH monitoring device is placed and the participant is discharged with ongoing pH monitoring. The next day, the participant is randomized to either receive Esomeprazol MUT Sandoz® tablet 40mg or Esomeprazol MUT Sandoz® 40mg in solution. Serum concentration of Esomeprazol is measured at 0, 60 and 120 minutes and the patient is discharged after. After 48 hours of pH monitoring, the patient returns the BRAVO™ - recorder, adverse events are assessed and the study is terminated.
45506475|NCT05314153|Drug|Brexanolone|Brexanolone injection is an Federal Drug Administration (FDA)-approved drug to treat postpartum depression. It is administered via continuous intravenous infusion over a 60-hour time period.
45506476|NCT05313035|Biological|SARS-CoV-2 protein subunit recombinant vaccine|candidate vaccine manufactured by PT. Bio Farma
45398319|NCT01112254|Procedure|MRI±biopsy|A MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm for from the initial lesion), which is not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI +/- ± biopsy results.
45506477|NCT05313035|Biological|placebo|the placebo is NaCl injection manufactured by PT. Bio Farma
45506478|NCT05308940|Drug|TB001|once-daily subcutaneous injection, on Day 1 in SAD stage
45506479|NCT05308940|Drug|TB001|once-daily subcutaneous injection, on Days 1-7 in MAD stage
45506480|NCT05308940|Drug|Placebo|once-daily subcutaneous injection, on Day 1 in SAD stage
45506481|NCT05308940|Drug|Placebo|once-daily subcutaneous injection, on Days 1-7 in MAD stage
45506482|NCT05306626|Behavioral|Building Emotion Awareness and Mental Health (BEAM)|The BEAM Program is based on best-practices in telehealth and science-based program design principles aimed at promoting maternal mental health and supportive parenting. The BEAM Program mobile application is designed and managed by Tactica Interactive and hosted on the University of Manitoba secure servers. The weekly group telehealth sessions will be led by clinical coaches (a mental health professional or trainee) and will use the secure videoconferencing platform Zoom (Healthcare license). Parent coaches will be mothers who have recently participated in another research group-based mental health intervention. Parent coaches will engage with participants on the community peer support forum and attend weekly telehealth sessions. The therapeutic aims of the BEAM program are to improve anxiety and depression symptoms and parenting skills using content that draws from the Unified Protocol, and emphasizes self-compassion, effective communication practices, and social support networks.
45506483|NCT05302830|Behavioral|Snackability app|This app allows user to search for a snack (scan barcode or type snack name), add a portion size consumed based on a portion size guide, and then provide a snack score and breakdown scores with a specific feedback message about the score.25 A score ranging from 0-10 points was designed taking into account the first ingredient, the nutrient standard by portion size, and the processing of foods (score ranging from -1 to 1 was subtracted or added depend on processed food classification). The final score ranged from -1 to 11 points. The higher the score, the more compliant it is to the guideline; therefore, the healthier the snack is. The app also provides gamification features as self-motivation (level up and achievement gained) and reporting features as goal-setting and self-monitoring (average daily score and consumed snack history).
45506484|NCT05302830|Behavioral|Control group|The control group received a 1-page with information on what is a healthy snack from the USDA: https://www.fns.usda.gov/cn/tools-schools-focusing-smart-snacks. They were given access to the app after the 12-week study period.
45506485|NCT05293756|Behavioral|OPTIMA-BP Intervention|"Participants will continue their regular medical care, supplemented by the OPTIMA-BP intervention:~Six weekly web-based education sessions on hypertension management.~Access to Medisafe, a medication management application (app) with a personalized medication adherence support (SMS reminder messages, adherence feedback, etc.) for 6 months.~Home Blood Pressure Monitoring (Omron series 10 home BP monitor). Participants will be asked to monitor and record their BP, 2x daily (AM and PM), twice a week, in a tracking log for 6 months.~Nurse Counseling Session with a research nurse for informal counseling, social support, and follow-up sessions regarding progress.~Optimizing HTN Treatment with 208 AA participants, in conjunction with their physician to maintain treatment goal BP: < 130/80 mmHg. based on current HTN guidelines and study recommendations including chlorthalidone 12.5-25 mg/day or amlodipine 5-10 mg/day or as chosen by their doctor."
45506486|NCT05290233|Behavioral|TRE + Exercise|"We will compare the effects of TRE combined with resistance exercise versus TRE combined with aerobic training.~Other Names:~resistance training endurance exercise"
45398320|NCT03940846|Diagnostic Test|Virtual biopsy|Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.
45398321|NCT01112332|Device|SmartStep insole|Smart StepTM is an innovative biofeedback and monitoring system designed to help clinicians effectively guide patients with compromised lower limb function due to orthopedic or neurological trauma towards optimal gait performance. It records and analyzes key gait parameters and provides instantaneous and accurate audio and visual feedback.
45398322|NCT01112410|Other|Hypertonic saline|"Hypertonic saline (6%) nebulised twice a day for 4 weeks.~(Randomised crossover trial)"
45398323|NCT01112410|Other|Isotonic saline|Isotonic Saline (0.9%) nebulised twice a day for 4 weeks.
45398324|NCT01114750|Drug|Insulin in dextran matrix capsule (and placebo)|Single dose capsule (and placebo)
46059089|NCT02802553|Device|Quest near-infrared (NIR) Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
45398326|NCT01328470|Drug|Clopidogrel, cilostazol|Patients with CKD received clopidogrel (75 mg/day)for 14 days Patients with CKD received clopidogrel (150 mg/day)for 14 days Patients with CKD received clopidogrel (75 mg/day)and cilostazol (100 mg twice daily)for 14 days 75mg clopidogrel in patients with normal kidney function for 14 days
45398327|NCT03942250|Biological|REGE pro dressing|REGE pro is a dressing of dried human amniotic membrane sterilized by gamma radiation
45398328|NCT01109446|Biological|Platelet Rich Plasma|27ml of autologous whole blood added to 3ml of ACD-A (Citrate Anticoagulant). After separation of the platelets, a high concentration of platelets (3-4ml Platelet Rich Plasma) is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.
45398329|NCT01109446|Procedure|Isotonic Saline Solutions|3ml of Isotonic Saline Solution is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.
45398330|NCT01109446|Drug|Triamcinolonacetonid|Triamcinolonacetonid 40mg/ml. 40mg of Triamcinolonacetonid is mixed with 2ml of Lidocaine 10mg/ml. It is injected deep into the tendon, guided by ultrasound.
45398331|NCT03940378|Drug|Levamisole Hydrochloride|Levamisole Hydrochloride Levamisole Hydrochloride 25mg/tablet; 150mg/d; po;
45398332|NCT03940378|Drug|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;
45506487|NCT05289310|Other|Normobaric hypoxia (NH)|Low oxygen exposure to mimic ~8500 feet elevation (experimental).
45697621|NCT04746183|Drug|Nitazoxanide|"CST3A & CST3B Phase I: Nitazoxanide will be administered orally, initially twice daily (BID) for 14 doses (7 days). The starting dose will be 1500mg BID based on existing dose information, but dose adaptations may occur.~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose."
45398333|NCT01112488|Other|Patient Engagement Programme|Patient's Diary, Ad Hoc medical support and Ad Hoc Clinical admission, Early post discharge Home visit
45398334|NCT03940222|Device|Interactive Binocular Treatment|The specified system which stimulate the fovea of the amblyopic eye directly by detailed and movable objects, while the fixation of the non- amblyopic eye will be focused on fixed targets.
45398335|NCT03940222|Procedure|Patching Therapy|Patching of the dominant eye with better best corrected visual acuity
45398336|NCT01783288|Other|Autonomic Function Testing|"heart rate and blood pressure will be continuously monitored while participants undergo a variety of breathing techniques (deep breathing, rapid breathing, blowing against resistance) and during sustained handgrip and cold pressor (hand in ice water). All tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the autonomic nervous system is functioning.~Also during autonomic function testing, cardiac output will be measured to analyze the shift of fluids in the body (body impedance) and / or by analyzing the air that is breathed."
45398337|NCT01783288|Other|Posture Study|Blood pressure, heart rate and blood samples (for catecholamines and hormones) will be measured & collected in the supine (lying) and upright position for each participant.
45398338|NCT01783288|Procedure|Measurement of Total Blood Volume|Total blood volume is measured by using iodinated I-131 tagged human serum albumin.
45398339|NCT01783288|Other|Exercise Capacity Test|Participants will ride on a stationary recumbent bicycle and the resistance will be gradually increased while expired air is measured.
45398340|NCT01115062|Drug|Synera Patch|Synera Patch (lidocaine 70 mg/ tetracaine 70 mg) will be applied for 30 minutes to the venipuncture site
45398341|NCT01115062|Drug|LMX 4 Cream|LMX 4 (4% liposomal lidocaine) cream (2g) will be applied under Tegaderm for 30 minutes to the venipuncture site.
45506488|NCT05289310|Other|Normobaric normoxia (NN)|Normal oxygen exposure to mimic sea level conditions (sham comparator).
45506489|NCT05287594|Behavioral|Integrated Exercise Program|"Neuromuscular warm-up: Each participant will perform a series of dynamic stretches, core stability, balance, and medicine ball exercises. The dynamic stretches include 8 repetitions of 6 stretches targeting the hip and thigh musculature, followed by 3 core stability isometric exercises (curl-up, side bridge, and bird dog). Participants will then perform 2 sets (per leg) of hop-to-stabilization (with a reach) balance exercises, followed by 3 separate medicine ball exercises emphasizing explosive full-body movements.~High Intensity Interval Training (HIIT): HIIT will include a series of high intensity exercise bouts on a stationary bike that includes a 1:1 work-to-rest ratio. Training intensity will be determined from the peak power output obtained during the baseline VO2 peak assessment and progressively increased by the number of bouts and intensity. The number of work bouts will increase from 5 to 8 bouts and the intensity will increase from 90 to 110% of peak power output."
45506490|NCT05283408|Drug|Dexmedetomidine infusion|Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
45398342|NCT01115062|Drug|Placebo Patch|A placebo patch with the same properties as the Synera patch but without lidocaine/tetracaine will be administered for 30 minutes to the venipuncture site.
45398343|NCT01115140|Drug|metformin plus placebo|metformin 850 mg cp, 2 cps daily
45398344|NCT01115140|Drug|Metformin plus folic acid|metformin 850 mg cp, 2 cps daily plus folic acid 0.4 mg daily
45506491|NCT05283408|Drug|Co-administration dexmedetomidine and low-dose esketamine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
45506492|NCT05283408|Drug|Co-administration dexmedetomidine and high-dose esketamine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
45506493|NCT05278000|Other|Presence of scarcity mindset|"This observational study will examine whether~Individuals exhibiting a scarcity mindset have lower adherence to asthma controller medication~Individuals with higher rates of future discounting have lower adherence to controller medication~Individuals with unmet social needs are more likely to experience scarcity and have higher rates of future discounting, and whether these relationships mediate adherence to asthma controller medication"
45506494|NCT05275400|Drug|Insulin Efsitora Alfa|Administered SC
45506495|NCT05275400|Drug|Insulin Degludec|Administered SC
45506496|NCT05264103|Device|Exoskeleton for gait rehabilitation (Atalante)|Subjects will walk with different levels of assistance given by the robot.
45506497|NCT05259410|Behavioral|TRE|All food eaten within the same self-selected 8 hour eating window daily, water fasting the remaining hours of the day.
45506498|NCT05259410|Behavioral|MedTRE|A mediterranean style diet will be eaten within the same self-selected 8 hour eating window daily, water fasting the remaining hours of the day.
45506499|NCT05257265|Drug|Centanafadine Hydrochloride|Capsule
45506500|NCT05257265|Other|Placebo|Capsule
45506501|NCT05255172|Other|Supervised Exercise|12 weeks of supervised aerobic exercise individually adapted to exercise capacity according to a VO2 peak test
45506502|NCT05254535|Other|I-SITE|I-SITE includes coaching facilitation, technical assistance, and an online toolkit to allow primary care clinics to tailor the integration of teleophthalmology into their daily workflows based on each clinic's unique needs and resources. The program includes a series of coaching sessions between a skilled practice facilitator and clinical personnel at each health system.
45506503|NCT05246618|Drug|TUM012|Ex-vivo infusion
45506504|NCT05246618|Drug|Placebo|Ex-vivo infusion
46059090|NCT02802553|Device|PDE Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
45398345|NCT01115140|Drug|placebo plus folic acid|Placebo 1 cp daily plus folic acid 0.4 mg daily
45398346|NCT01115140|Drug|placebo alone|placebo cp, 2 cps daily
45398347|NCT01112644|Drug|Oxycodone naloxone prolonged release tablets (OXN PR)|Different daily doses; intake every 12 hours
45398348|NCT01112644|Other|Placebo (PLA)|Different daily doses; intake every 12 hours
45398349|NCT01112722|Biological|Apitox, purified honeybee toxin, lyophilized in saline|intradermal injections of 0.1mg apitox in 0.1ml WFI over 12 weeks treatment period, injections twice weekly range from 1 to 20 injections
45398350|NCT01112722|Biological|histamine|imitates pain and erythema of honeybee venom
45398351|NCT01209676|Drug|IMCgp100 injection|a monoclonal T cell receptor anti-CD3scFv fusion protein
45506505|NCT05243303|Device|Active taVNS|A bipolar clip electrode is placed at the cymba conchae of the ear. Through this bipolar clip electrode, afferent nerve fibers within the auricular branch of the vagus nerve will be stimulated. Subjects self-administer the stimulation on a daily basis for 3 months.
45506506|NCT05243303|Device|Sham taVNS|A bipolar clip electrode is placed at the cymba conchae of the ear. However, active stimulation of the afferent nerve fibers within the auricular branch of the vagus nerve will not occur, because the electrode wire is electrically interrupted. Subjects self-administer the sham taVNS on a daily basis for 3 months.
45398352|NCT03941938|Procedure|Cyanoacrylate reinforcement|Anastomosis Reinforcement with with nebulization of 1cc of glue on the anastomosis line
45506507|NCT05240755|Drug|Cannabidiol Oil|Subjects will self-administer CBD sublingually.
45506508|NCT05229315|Drug|Toripalimab|PD-1 Immune Checkpoint Inhibitor Combined With IMRT,used at 2 weeks before radiotherapy, once every 2 weeks, 10 cycles in total
45506509|NCT05229315|Procedure|Intensity modulated radiotherapy|Intensity modulated radiotherapy
45398353|NCT03941938|Procedure|No reinforcement|Nothing applied on the anastomosis line
45398354|NCT01015222|Drug|Dasatinib|Starting dose of 50 mg daily PO for 28 day cycle
45398355|NCT01015222|Drug|Bevacizumab|Starting dose 5 mg/kg IV Day 1 and 15
45398356|NCT01015222|Drug|Paclitaxel|Starting dose 40 mg/m2 IV Day 1, 8 and 15
45398357|NCT00962728|Device|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
45398358|NCT00962728|Device|Sham Inspiratory Threshold Device|Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
45398359|NCT01115218|Procedure|Trabeculectomy|Trabeculectomy with mitomycin C
45398360|NCT01207336|Device|combined transcranial direct current stimulation and electrical peripheral nerve stimulation|tDCS: 1,2 mA 13 minutes rEPNS (radial nerve): 5 Hz, 0,7 x MT
45398361|NCT01115296|Dietary Supplement|L. reuteri DSM 17938 and ATCC PTA 6475|L. reuteri dose of 1x108 CFU.
45398362|NCT01115296|Other|Placebo|Placebo
45398363|NCT03940456|Other|Questionnaire|Questionnaire mainly focusing on low back pain, pain related disorders, psychosocial factors and the use of alternative treatments for pain
45398364|NCT01115374|Procedure|Manual lymphatic drainage|Application of manual lymphatic drainage (one session every work day during two weeks, total 10 sessions)
45398365|NCT01115374|Device|low frequency sound waves|Application of low frequency sound waves (one session every work day during two weeks, total 10 sessions)
45506510|NCT05222880|Device|JJVC Investigational Multifocal Contact Lenses manufactured in senofilcon A C3|TEST Lens
45697622|NCT04746183|Drug|VIR-7832|"CST-5: Phase I, Single doses of VIR-7832 will be administered by intravenous (IV) infusion over 1 hour. The starting dose will be 50 mg, and dose escalations of 150 and 500 mg are anticipated, with escalation guided by emerging safety data and decision by the SRC.~Phase II: As per Phase I, with the dose determined by the recommended phase II dose."
45697623|NCT04746183|Drug|VIR-7831|CST-5 Phase II: A 500 mg dose of VIR-7831 will also be given by IV infusion over 1 hour.
45697624|NCT04746183|Drug|CST-5: Placebo|CST-5 Phase 1, Phase II: Placebo given by intravenous infusion over 1 hour
45398366|NCT01209910|Other|Water|Subjects in this arm will be able to drink water with some conditions.
45398367|NCT01212250|Drug|carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol with a maximum of 6.25 BD.
45398368|NCT01212250|Drug|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 2 BD.
45398369|NCT01209988|Drug|tamsulosin 0.4mg|perioperative tamsulosin 0.4mg daily for three weeks
45398370|NCT01209988|Other|No medication|No medication
45398371|NCT02529748|Other|Participants for Surface Skin Sampling|Skin wipe samples will be collected to quantify the amount of the test substances transferred to and from the surface of the participants' skin.
45398372|NCT02529748|Other|Elemental metallic lead|Consumer product fishing tackle made of elemental lead will be handled by the participants.
45398373|NCT02529748|Other|Tinopal|Tinopal, a fluorescent tracer, will be handled by the participants.
45398374|NCT03943186|Device|Ectoin Lozenges Honey Lemon|application of Ectoin Lozenges (EHT02) in accordance with the instructions for use
45398375|NCT03943186|Device|Hyaluronic Acid/Icelandic moss Lozenges|application of the lozenges in accordance with the instructions for use
45398376|NCT01210066|Drug|Fentanyl|IV fentanyl 1mcg/kg
45398377|NCT01210066|Other|Cold pressor test|Non-dominant arm submerged in ice water (0 degrees Celsius) until it is no longer tolerable but less than 5 minutes
45398378|NCT01210066|Other|Fentanyl plus cold pressor test|fentanyl IV 1mcg/kg fifteen minutes prior to cold pressor test (arm submerged in ice water until no longer tolerable but no longer than 5 minutes)
45398379|NCT01115530|Other|Resistance exercise|Lower extremity resistance exercise (leg press/knee extension) twice per week for 12 weeks
45506511|NCT05220722|Drug|SD-101|SD-101 doses will be delivered via HAI using the PEDD method of administration.
45506512|NCT05220722|Biological|Pembrolizumab|During Phase 1b, Cohort B, pembrolizumab will be administered together with SD-101.
45506513|NCT05220722|Biological|Nivolumab|During Phase 1b, Cohort C, nivolumab will be administered together with ipilimumab and SD-101.
45506514|NCT05220722|Biological|Ipilimumab|During Phase 1b, Cohort C, ipilimumab will be administered together with nivolumab and SD-101.
45506515|NCT05216016|Other|RETAIN Program|Facilitates early intervention strategies to support workers in staying-at or returning-to-work (SAW/RTW) after injury or illness and preventing unnecessary disability. This is done by incorporating a Return-to-Work Case Manager as a member of the healthcare clinical team who acts as a liaison for the patient and assists in coordination of referrals between healthcare and Workforce Development services. Return-to-Work Case Managers will interact with treating providers of Minnesota RETAIN intervention group participants to ensure functionally based work restrictions are documented and shared with the patient's employer.
45506516|NCT05213143|Drug|Lurasidone|Lurasidone was oral administrated with a meal or within 30 min after eating in the evening. The maintenance dose of olanzapine from Day 0 to Day 6, than tapered until discontinuation from Day 7 to Day 27. Lurasidone initiated with 40mg/d on Day 0, maintained until Day 13, with a flexible dose (40-80mg/d, qd) from Day 28 to Day 111.
45506517|NCT05208931|Procedure|Anti-vascular endothelial growth factor therapy|0.05 ml anti-VEGF, intravitreal, monthly
45506518|NCT05208593|Behavioral|Negative Event + Counterfactual Task|Participants will complete a counterfactual based intervention where they come up with three if only..then statements about how a past drinking behavior could have been altered to be better and to think about protective behavioral strategies that they could use in a future similar situation to make the outcome better.
45506519|NCT05208593|Behavioral|Personalized Normative Feedback|Participants will be asked to rate the frequency and quantity of students who use protective behavioral strategies while drinking. They will be given feedback on how close their estimate is from the national averages.
45506520|NCT05208593|Behavioral|Negative Event + Factual Thinking Task|Active Control condition where participants write about a negative event and list three facts about it
45506521|NCT05208593|Behavioral|Negative Event Only|Participants are asked to write about a negative event related to alcohol and write about it
45506522|NCT05207813|Device|Intracept Procedure|Intraosseous Basivertebral Nerve (BVN) Ablation
45506523|NCT05205772|Device|transcranial magnetic stimulation|"Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. This device is FDA approved for treatment of depression and other neuropsychiatric disorders, and is regularly used in neurologic and psychiatric research.~iTBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz very quickly). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatments lasts approximately 3 minutes."
45506524|NCT05191862|Drug|Cilostazol 100 mg|One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)
45506525|NCT05191862|Drug|PMR 135 mg|Two PMR 135 mg at 08:00, single oral dose (total daily dose of 270 mg)
45506526|NCT05189704|Drug|NSAID|NSAID based patient-controlled analgesia will connected to intravenous line for pain control.
45506527|NCT05189704|Drug|Opioid|Opioid based patient-controlled analgesia will connected to intravenous line for pain control.
45506528|NCT05182255|Device|Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered|To aid in maintaining patency of the esophagus in cases of obstruction of the esophagus caused by an esophageal disease and to seal tracheoesophageal fistula.
45506529|NCT05181722|Other|Patient navigator support|Support of a patient navigator for patients who have experienced an abnormal screening mammogram
45506530|NCT05179421|Drug|saline (placebo) then oxytocin 1.3 micrograms|10 minute IV infusion of saline followed by a 10 minute infusion of oxytocin 1.3 micrograms
45506531|NCT05179421|Drug|Experimental: oxytocin 0.3 micrograms then oxytocin 7 micrograms|10 minute IV infusion of oxytocin 0.3 micrograms followed by a 10 minute infusion of oxytocin 7 micrograms
46059091|NCT02802553|Device|Gamma probe|Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
46059092|NCT02802553|Other|Blue Dyes|Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
46059093|NCT00583219|Drug|Botulinum-A toxin|A simple bladder catheterization in the office with a standard urinary catheter and instill the Botulinum-A toxin/DMSO solution.
45398380|NCT01115530|Dietary Supplement|Protein and HMB (see below) supplement|Ingested twice daily for 12 weeks Active components include: Protein and B-hydroxy-B -methylbutyrate
45398381|NCT03942172|Device|SpotOn balance glasses|SpotOn Balance Glasses comprising of personalized visual stimuli placed on the glasses's lenses
45398382|NCT01212328|Other|Care Coordinator + Decision Support Software|Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
45398383|NCT01212328|Other|Usual care|Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
45506532|NCT05143996|Drug|CLN-049|[FLT3] x [CD3] bispecific T cell engager
45506533|NCT05140876|Behavioral|START mHealth Intervention|The START mHealth intervention is a mobile application that will be downloaded by participants through their mobile phones. The application targets information, motivation, and behavioral skills relevant to ART adherence. Participants will have access to this application for 6 months.
45506534|NCT05137366|Diagnostic Test|Transthoracic ultrasound scan|"An ultrasound scan of the thoracic aorta will be performed using an ultrasound machine with 2 MHz phased array transducer. The patient will lay supine on an ultrasound scan couch.The measurements will be taken in B-mode but colour Doppler imaging may be used to identify the thoracic aorta if it is obscured by artefacts. The measurement will be taken inner wall to inner wall and several images will be taken to check reliability.~Three different acoustic windows will be used to image the thoracic aorta:~Suprasternal window~Parasternal long axis window~Apical two chamber views~Ultrasound assessment will be considered satisfactory when at least two of the three regions of the descending thoracic aorta were visualised, partially satisfactory when a single view was obtained and inconclusive when none of the three windows could be obtained."
45398384|NCT03939988|Radiation|Photobiomodulation|Immediately after the installation of the separators, the subjects will be submitted to photobiomodulation. The laser will be infrared, in continuous mode with wavelength of 808 nm. The tip will be positioned perpendicularly in the mucosa, without exerting pressure. At each point 2J of energy will be irradiated for 20 seconds, totaling 12J per tooth, 6J on the buccal side and 6J of the lingual side of the teeth.
45506535|NCT05136703|Behavioral|Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)|CBT-AD is a behavioral intervention administered either in person or via Zoom. Each session lasts approximately 50 minutes. Participants will receive up to 12 individually delivered sessions over 4 months.
45398385|NCT03939988|Radiation|Placebo photobiomodulation|In the placebo group, the same procedures will be made, but the laser will be turned off.
45398386|NCT01112878|Drug|Sugar pill|"Dosage form: capsule, by mouth~Dosage: not applicable~Frequency and Dosage:~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
45398387|NCT01112878|Drug|Gabapentin|"Dosage form: capsule, by mouth~Dosage: 600 mg~Frequency and duration:~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
45398388|NCT01112878|Drug|Clonidine|"Dosage form: capsule, by mouth~Dosage: 0.2 mg~Frequency and duration:~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
45398389|NCT01109680|Drug|Neramexane|Multiple dose Neramexane followed by single dose 14C Neramexane
45398390|NCT01115608|Other|Pharmacist follow-up|Drug review, drug conversation and written drug information. Follow-up concerning therapeutic goals and cooperation with the patient and the patient's GP to achieve these.
45506536|NCT05136703|Behavioral|Antiretroviral Therapy (ART) Adherence Counseling|"This treatment involves a single session integrating CBT for depression with CBT for adherence following our Life-Steps approach."
45398391|NCT01212406|Drug|Vitamin D|Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years
45697625|NCT04746183|Drug|Favipiravir|CST-6: Multiple doses of IV Favipiravir will be administered by intravenous (IV) infusion over 1 hour. Dosing regimen will be every 12 hours for 7 days duration. The starting dose will be 600mg (BID), and dose escalations to 1200mg (BID), 1800mg (BID) and 2400mg (BID) are anticipated as well as a de-escalation dose of 300mg (BID) if necessary, with de-escalation and escalation guided by emerging safety data and decision by the Safety Review Committee (SRC).
45697626|NCT04746183|Drug|Molnupiravir|Molnupiravir 800mg Twice a day (BD) for 5 days as starting dose, with a de-escalation protocol reducing in increments of molnupiravir to 600mg BD, then 400mg BD if required.
45697627|NCT04746183|Drug|Paxlovid|Paxlovid® (300mg nirmatrelvir + ritonavir 100mg) twice a day (BD) for 5 days. The dose of Paxlovid® will be fixed for all cohorts.
45697628|NCT01895309|Drug|Enbrel (etanercept)|
45697629|NCT01895309|Drug|SB4 (proposed biosimilar to etanercept)|
45398392|NCT03939910|Device|Pudendal Nerve Block needle in pre-packaged kits that include both the trumpet and the needle. The needle will limits its depth of penetration to 5 mm beyond the trumpet.|Patients will receive a pudendal nerve block injection on each side as previously described 5-10 minutes before the beginning of surgery. A tubular director that allows 1.0-1.5 cm of a 15-cm-long, 22-gauge needle to protrude beyond its tip will be used to guide the needle into the pudendal trunk at lesser sciatic foramen about 1 cm inferior-medial to attachment of the sacrospinous ligament to the ischial spine. The end of the director will be placed against the vaginal epithelium just beneath the tip of the ischial spine. The needle pushed beyond the tip of the director, and 5 ml of the anaesthetic solution will be injected. The needle advanced 1 cm posterior and lateral, and another 5 mL of the anaesthetic solution will be injected into this region.
45697630|NCT04745325|Behavioral|SMAART Canada smartphone app|a smartphone app designed to promote reductions in alcohol consumption among people who drink in a hazardous fashion
45697631|NCT03231657|Diagnostic Test|Placental biomarkers|sFlt1 and P1GF levels and sFlt1/PlGF ratio
45506537|NCT05132816|Diagnostic Test|high-resolution manometry|"High-resolution manometry is an outpatient examination and part of our routine diagnostic or pre-operative evaluation in GERD.~A thin catheter is placed through the nose into the esophagus, local anaesthesia can be used if the patient experiences a discomfort. Once the tip of the manometry catheter is placed below the esophagogastric junction, the patient is asked to take in water and bread. In rest and during deglutition, pressure measurements are registered with the manometry catheter, allowing the investigator to detect IEM. The examination takes about 1.5 hours. The manometry is a standard and routine intervention being performed for over 30 years with minimal risks.~The GSRS questionnaire pre- and postoperatively is part of our standard workup, no additional assessment for this study is needed."
45506538|NCT05130606|Behavioral|"Culturally Targeted Narrative Video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor."|Participants randomized to the video arm will receive a link with a password by email or text message to watch the video, depending on participants' preference. Participants without internet access will receive a DVD. Participants will be instructed to watch the video alone with no interruptions. We will ask them not to share the link with others.
45506539|NCT05130606|Behavioral|FORCE Fact Sheet|Participants will receive a PDF of the fact sheet by email, text message, or a printed fact sheet by mail depending on participants' preferences. The FORCE fact sheet includes information about genes, breast cancer, risk factors for HBOC, genetic counseling and testing, and resources.
45506540|NCT05123690|Device|Neurofeedback|A device that assists in training patients in relaxing.
45506541|NCT05110014|Other|Primary Care Office Visits|mPATH iPad program that contains self-administered screening items for depression, fall risk, and intimate partner violence
45506542|NCT05100160|Drug|Gabapentin|Given by PO
45506543|NCT05100160|Other|Placebo|Given by PO
45506544|NCT05098093|Dietary Supplement|SBE|Hard-shell capsule
45506545|NCT05098093|Dietary Supplement|DBE|Hard-shell capsule
45506546|NCT05098093|Dietary Supplement|BP|Hard-shell capsule
45506547|NCT05097521|Other|Practitioner-delivered CIH therapies (acupuncture, therapeutic massage, chiropractic care) as received in VHA and community practice settings|Practitioner-delivered CIH therapies (acupuncture, therapeutic massage, chiropractic care) as received in VHA and community practice settings
45697632|NCT04740255|Device|Straberi Epistamp|The patient's entire face will be treated. The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm
45697633|NCT04738071|Device|PFO closure|PFO closure after stroke or transient ischemic attack
45697634|NCT01884311|Biological|Subgam|Subgam-VF dose will be given as 1.37 of the established IGIV dose (expressed in mg/kg/week) for 26 weeks (26 infusions) beginning one week after the last IGIV infusion. Dose of Subgam-VF will then be adjusted based on the ratio of the Immunoglobulin G (IgG) average concentration achieved with Subgam-VF compared to IGIV.
45398393|NCT01109758|Drug|Fenofibrate|145 mg
45398394|NCT01115686|Drug|Branched-chain aminoacids|"Branched-chain aminoacids will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day. Every capsule containing 375 milligrams of branched-chain aminoacids.~The treatment will last 3 weeks."
45398395|NCT01115686|Drug|Placebo|"Placebo will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day.~The treatment will last 3 weeks."
45398396|NCT03939754|Behavioral|Dedalo project|Physical activity, healthy food, socialization and mental activity promotion
45398397|NCT01328236|Drug|Bortezomib|"INDUCTION THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
45398398|NCT01328236|Drug|Liposome doxorubicin|INDUCTION THERAPY: 30 mg/m2, IV (in the vein) on day 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
45398399|NCT01328236|Drug|Dexamethasone|"INDUCTION THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
45398400|NCT03939832|Other|Fraction of inspired oxygen level|A fraction of inspired oxygen level during cardiac surgery using cardiopulmonary bypass will be set differently: 0.5 versus 1.0.
45398401|NCT01328392|Drug|Dexlansoprazole|30mg a day, 3 months
45398402|NCT01113034|Drug|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
45398403|NCT01113034|Drug|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
45398404|NCT01212562|Procedure|Immunocryosurgery|Assessing the efficacy of cryosurgery during continued imiquimod application (immunocrysurgery) in the treatment of basal cell carcinoma of the skin
45506548|NCT05097521|Other|Self-care CIH therapies (yoga, Tai Chi/Qigong , meditation) as received in VHA and community practice settings|Self-care CIH therapies (yoga, Tai Chi/Qigong , meditation) as received in VHA and community practice settings
45506549|NCT05097521|Other|Combination of practitioner-delivered and self-care CIH therapies (described above) as received in VHA and community practice settings|Combination of practitioner-delivered and self-care CIH therapies (described above) as received in VHA and community practice settings
45506550|NCT05090332|Other|Facial Gun|Vibration massage applied for five Minutes directly on the trigger point
45506551|NCT05090332|Other|Dry Needling|For dry needling the outer skin should be clean with alcohol and the taut band should be placed between thumb and index finger. Without damaging any nerve or artery the needle is passed though the muscle into the trigger point and breaking it to relief pain
45398405|NCT01115842|Drug|Vitamin D|Vitamin D 4000IU per day for 5 days
45398406|NCT01115920|Drug|MTP-131 (Bendavia™)|Single 4 hour intravenous infusion
45506552|NCT05088525|Procedure|MRI|MRI for standard of care meniscus root repair surgery - noting with an added stabilization suture if it is able to successfully slow down the progression of osteoarthritis versus a standard root repair surgery.
45398407|NCT01116076|Behavioral|Decision+ program (to improve optimal drug prescription for ARI)|DECISION+ is a multifaceted intervention program that includes: On site course and Internet-based courses (2x120 min), reminders of expected behaviours and feedback.
45398408|NCT01210378|Drug|Nitroglycerin patch|Nitroglycerin patch
45398409|NCT01109836|Behavioral|Motivation and lifestyle intervention|Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
45398410|NCT01116154|Drug|lenalidomide|Given orally
45398411|NCT01116154|Drug|vorinostat|Given orally
45506553|NCT05082857|Behavioral|"traditional Parents as Teachers (PAT)"|A twice-a-month home visits from trained family educators. Home visits will continue for the remainder of the study period as will the other components of the Parents as Teachers model: regular Group Connections for peer interactions and support, age-appropriate health and developmental screenings, and referrals that reflect mother and infant needs to community agencies that include the Child Development Services Agency (which provides screening for Individuals with Disabilities in Education Act (IDEA) Part C services), family services, intensive mental health services, among others.
45506554|NCT05082857|Behavioral|"hybrid PAT model"|A six-week virtual evidence-based parenting class entitled What You Do Matters, which will be delivered in partnership with the Pediatric Advocacy Program at WFBMC which combines short parent-educator discussions followed by interactive activities and peer to peer networking.
45506555|NCT05079464|Other|tDCS|All participants randomized to tDCS will receive active tDCS
45506556|NCT05079464|Other|Exercise|Participants will exercise at Toronto Rehab.
45398412|NCT01116154|Other|laboratory biomarker analysis|Correlative studies
45398413|NCT01113190|Behavioral|Computer-delivered Brief Intervention (CBI)|"The multimedia, interactive Computer BI (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The proposed CBI condition will use actors with 'green screen' to deliver scripted therapist content that will be highly tailored to individual responses. 'Green screens' are standard recording formats that allow for inserting engaging background and other overlays onto recorded material. This program will be viewed on a touch screen tablet computer with audio delivered via headphones. The CBI will be designed in a therapist video-delivered interactive style, that provides tailoring options for reviewing patient goals, providing feedback regarding substance use patterns and consequences, completing a decisional balance exercise, and formulating a change plan. It requires active participation and is not a passive video that is merely viewed."
45506557|NCT05079464|Other|Sham stimulation|The same procedure for tDCS will be used for the sham condition, except without active current.
45506558|NCT05079464|Other|Treatment as usual|Exercise education/ treatment as usual will include routine advice about physical activity.
45506559|NCT05073276|Other|Physical Therapy|Patient is randomized to the weightbearing group the day after surgery.
45506560|NCT05073263|Other|Physical Therapy|Patient is randomized to the weightbearing group the day after surgery.
45506561|NCT05061004|Device|Cephea Mitral Valve System|Transcatheter mitral valve replacement
45506562|NCT05060822|Drug|HEC585|HEC585 Tablets，once daily
45506563|NCT05060822|Drug|Pirfenidone|Pirfenidone，three times a day
45506564|NCT05060822|Drug|Placebo|Placebo，once daily
45506565|NCT05052931|Drug|Nab-paclitaxel combined with oxaliplatin and S-1|Nab-paclitaxel 100mg/m^2, D1, Q3W; oxaliplatin 85 mg/m^2, D1, Q3W; S-1 60 mg/m^2, D1-14, Q3W; Neoadjuvant chemotherapy 2 cycles, followed by surgery, continue to receive 6 cycles of adjuvant chemotherapy.
45506566|NCT05052229|Drug|Nitric Oxide|Nitric oxide gas for inhalation
45506567|NCT05052229|Drug|Medical air|Medical grade air for inhalation (placebo)
45506568|NCT05048212|Drug|Nivolumab|Given by IV
45506569|NCT05048212|Drug|Ipilimumab|Given by IV
45506570|NCT05048212|Drug|Cabozantinib|Given by IV
45506571|NCT05040802|Other|Not applicable / dataset analysis|Not applicable / dataset analysis
45506572|NCT05037500|Drug|Decitabine and Cedazuridine|Given PO
45506573|NCT05037500|Drug|Enzalutamide|Given PO
45506574|NCT05025176|Device|Non invasive arterial pressure monitoring|Non invasive arterial pressure monitoring
45506575|NCT05020769|Drug|SI-B001|SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended).
45697635|NCT01004770|Drug|GE-145 (AN113111) Injection|40 healthy volunteers (10 per treatment group) will receive AH113111 320 mg I/mL at 1 of 4 possible doses (300, 450, 600, or 900 mg I/kg) as a single intravenous (IV) administration.
45697636|NCT01004770|Drug|Visipaque (iodixanol) Injection|An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
45506576|NCT05020769|Drug|Osimertinib|Osimertinib is administered at the recommended dose of 80mg daily.
45398414|NCT01113190|Behavioral|Intervener-delivered Brief Intervention (IBI)|"IBI is a 30-minute intervention session with a master's-level clinician. The interventions will include FRAMES (Miller & Rollnick, 2002): personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-Efficacy regarding making changes. The interventions are designed to address the primary target behavior of drug use, and will include a tailored review of participants' goals/values, feedback regarding their present substance use patterns and consequences, developing a discrepancy between their substance use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant. IBI will be highly individualized to participants' goals, values and substance use, and will will follow similar session outlines and length of delivery as the CBI sessions."
45398415|NCT01113190|Behavioral|Adapted Motivational Enhancement Therapy (AMET)|This session will have a similar general outline to the sessions conducted in the ED, including a review of participants' goals and values, and a review of their substance use and consequences, use of decisional balance exercises as indicated, and review and modification of their change plan. For the AMET intervention, the intervener (at least master's level) will conduct a single session (~30-45 minutes) in the community (HMC ED or our community research office). The therapist will be able to tailor their approach to each individual's needs and motivational state.
45398416|NCT01113190|Behavioral|Enhanced Usual Care (EUC)|The EUC group will receive brief advice to change their drug use, as well as a booklet including information on community support groups, location of substance use treatment centers, mental health services, suicide prevention hotlines, risk of injecting drugs including HIV and hepatitis and HIV prevention and testing information.
45506577|NCT05008614|Procedure|Erector spinae plane block group|"Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under ultrasound guidance in the procedure room.~Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 18G 85 mm perineural catheter (Silverstim, Vygon, Ecouen, France) (basal infusion: 10ml/hr, bolus 5ml, lockout time: 20min)"
45506578|NCT05008614|Procedure|Thoracic epidural analgesia group|"Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under fluoroscopy guidance in the procedure room.~Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 17-gauge catheter (FlexTip Plus®, Teleflex Medical, USA) (Silverstim, Vygon, Ecouen, France) (basal infusion: 3ml/hr, bolus 1ml, lockout time: 20min)"
45506579|NCT05002738|Drug|Desogestrel and Ethinyl Estradiol Tablets|Combined oral contraceptive pill
45506580|NCT04993443|Drug|LQ036|"For Each part of the study, a staggered dosing schedule may be used for the first dose level, in each cohort including 2 sentinel subjects (1 active and 1 placebo) initiating dosing first and the remaining 6 subjects for Part A-C and 8 subjects for Part D initiating dosing no sooner than the next day. Each study part (A, B, C, and D) will be completed sequentially, but with partial overlapping. Part B and C may only be initiated after review of the safety, tolerability, and PK data following dosing of the SAD Cohort 3 or 4.~Part D may be initiated when safety tolerability and PK data are known and deemed acceptable by the SRC for multiple doses in Part B, at least at the same concentration to be administered in Part D."
45506581|NCT04993443|Other|Matching Placebo|Matching Placebo for LQ036: Matching Placebo
45506582|NCT04990284|Drug|Opicapone|50 mg hard capsules. Oral administration, once-daily at bedtime, at least 1 hour before or after L-DOPA/carbidopa or benserazide (L-DOPA/DDCI).
45506583|NCT04990284|Drug|L-DOPA/DDCI|L-DOPA/carbidopa or benserazide (L-DOPA/DDCI), 100/25 mg, oral administration
45506584|NCT04986904|Behavioral|SHUTi (Sleep Healthy Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
45506585|NCT04986657|Device|ChromoSeq|Novel, streamlined whole genome sequencing approach
45697637|NCT04399317|Device|Flow controlled ventilation (Evone-ventilator)|The new ventilation technique will be applied
45697638|NCT03230877|Device|Toffee full face mask with 'Improved Seal'|Participants will be randomized to this arm for a total of 7 ± 4 days from visit 1. Participants will be using the Improved Seal in this treatment arm.
45697639|NCT03230877|Device|Toffee full face mask with 'Normal Seal'|Participants will be randomized to this arm for a total of 7 ± 4 days from visit 1. Participants will be using the Normal Seal in this treatment arm.
45398417|NCT01210456|Drug|Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate|"All patients receive N-Acetylcysteine(NAC) and sodium chloride. NAC is given orally at a dose of 700mg twice daily, on the day before and on the day of administration of the contrast media, for a total of two days.~154mEq/L of sodium chloride is given intravenously. The initial intravenous bolus is 3ml/kg per hour for 1 hour immediately before contrast injection. And then, patients receive the same fluid at 1ml/kg per hour during the contrast exposure and for 6 hours after the procedure.~In addition, intervention arms receive sodium bicarbonate.1000mEq/L of sodium bicarbonate is given intravenously twice at a dose of 40ml immediately before the contrast exposure and immediately after the procedure."
45398418|NCT01210612|Device|five-toed socks|five-toed socks usage
45398419|NCT01207804|Device|ValenTx Endo Bypass System|Patient is implanted with device and followed for 12 weeks
45398420|NCT01116310|Drug|Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L)|Bottles containing 60 capsules, 53.5 mg/capsule of isoflavones
45398421|NCT01116310|Drug|Placebo|Bottles containing 60 capsules.
45398422|NCT01210846|Drug|tivozanib|1 x 1.5 mg capsule of tivozanib orally once daily for 21 days
45398423|NCT01116388|Other|GFCF product with GFCF diet|"Group I: will receive the test product (product free of gluten and casein) with GFCF Diet for the 1st 6-weeks.~Group II: will receive the test product (product free of gluten and casein) with GFCF diet for the 2nd 6-weeks."
45398424|NCT01116388|Other|product containing gluten and casein (milk protein) with GFCF diet|"Group I: will receive the control product (product containing gluten and casein) with the GFCF diet for the 2nd 6-weeks.~Group II: will receive the control product (product containing gluten and casein) with the GFCF diet for the 1st 6-weeks"
45398425|NCT01109914|Biological|Dukoral|"Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:~Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria*~Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria*~Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria*~Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria*~Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)"
45398426|NCT01116622|Drug|Bexarotene (Targretin®)|Level -I 200 mg/m2 Level I 300 mg/m2 Level II 300 mg/m2 Level III 400 mg/m2
45398427|NCT01116622|Drug|Erlotinib (Tarceva™)|Level -1 100mg Level I 100mg Level II 150mg Level III 150mg
45398428|NCT01110070|Device|ChonDux|Comparison of ChonDux plus microfracture to microfracture only
45398429|NCT01110070|Device|ChonDux|single use device
45398430|NCT03941626|Biological|CAR-T/TCR-T cells immunotherapy|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
45398431|NCT01211002|Radiation|radiotherapy combined with EP|Tumor vo lume is 60-66 Gy / 30-33f and the combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.
45398432|NCT01211002|Drug|radiotherapy / EP combined with recombinant human endostatin|Anti-vascular targeting therapy The number of courses is 3 ~ 4 and each course last for 28 days. Recombinant human endostatin（Endostar）：15mg，d1-14, intravenous injection.
45398433|NCT01211080|Drug|Propranolol|Propranolol 2mg/kg/day divided to three oral doses with or without concomitant physical therapy (cryotherapy, laser)
45398434|NCT01116700|Drug|Dexmedetomidine|Dexmedetomidine will be administered to 2 groups: (1) Seizure disordered patients on anticonvulsants and (2) Healthy volunteers (Control group)
45398435|NCT01113346|Drug|Filtrum-STI (lignin hydrolytic)|"For children aged less than 1 y.o.: Filtrum-STI, 400mg per day (1/2 tablet 2 times a day) for 7 days.~For children aged 1-4 y.o.: Filtrum-STI, 800mg per day (1 tablet 2 times a day) for 7 days."
45398436|NCT01113346|Drug|Placebo|"For children aged less than 1 y.o.: Placebo, 1/2 tablet 2 times a day for 7 days.~For children aged 1-4 y.o.: Placebo, 1 tablet 2 times a day for 7 days."
45398437|NCT01113424|Drug|Nicotine|Single-dose of a new Nicotine Replacement Therapy (NRT) product 2 mg and 4 mg
45398438|NCT01113424|Drug|Nicorette® (Nicotine Gum)|Single-dose of marketed nicotine gum 2 mg or 4 mg
45398439|NCT01211158|Drug|Ketofol|Syringes containing ketofol (mixed propofol-ketamine) will contain propofol 5mg/ml and ketamine 5 mg/ml. Patients will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication. Patients in the propofol-ketamine group will receive 0.375 mg/kg each of ketamine and propofol as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
45398440|NCT01211158|Drug|Propofol alone|Propofol-only syringes will contain propofol 10 mg/ml. Patients in each group will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication (0.75 mg/kg). One minute after the initial dose of sedative, and every minute thereafter, the attending physician will assess the patient's level of sedation using the Ramsay Sedation Scale (RSS). If the attending physician determines the level of sedation to be inadequate (RSS<5), additional study drug will be administered at a dose of 0.0375 millilitres per kilogram (0.375 mg/kg) every minute until deep sedation is achieved (RSS=5 or greater).
45506586|NCT04979247|Drug|Oliceridine|Near the end of surgery, patients will be given ≤1.5 mg of oliceridine as a bolus. Postoperatively, patient-controlled analgesia (PCA) will be started with no background infusion, demand doses of 0.35 mg, with a 6 minute lock-out. Additional boluses (≤1 mg) of oliceridine will be given as deemed necessary (based on NRS score and clinical assessment of the patient) as soon as 15 minutes after the initial 1.5 mg loading dose. In addition to supplemental 1 mg bolus doses, the PCA demand dose can be increased to a maximum of 0.5 mg oliceridine.
45506587|NCT04973631|Genetic|Sex, Age|Evaluate the effect of sex and age on the incidence and survival of GC.
45506588|NCT04969835|Drug|AVA6000|AVA6000 is a FAP-activated prodrug of doxorubicin. AVA6000 will be administered via IV infusion every 3 weeks. Dosing will occur based on the calculated patient's BSA on the day of dosing.
45398441|NCT03943108|Diagnostic Test|Gait analysis|Gait recorded using a sensor on the 4th vertebrae of the lumbar spine, once a week across 6 weeks during the routine PAIDOS clinic. Critical changes in walking control, stride frequency and length will be observed as individuals change speed; effectively stressing their mobility.
45506589|NCT04965350|Biological|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)|sterile solution for intramuscular injection
45506590|NCT04955158|Drug|Dexmedetomidine|75 µg dexmedetomidine soaked pharyngeal pack (Group D) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
45506591|NCT04955158|Drug|Ketamine|50 mg ketamine soaked pharyngeal pack (Group K) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
45506592|NCT04955158|Other|saline 0.9%|20 ml 0.9% saline soaked pharyngeal pack (Group C) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
45506593|NCT04952077|Device|MRI|Magnetic Resonance Imaging (MRI)
45506594|NCT04938973|Procedure|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE)|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE) will be performed using the Da Vinci Robotic Surgical Platform.
45398442|NCT01116778|Biological|eN-Lac®|One capsule with 2x10^9 colony forming unit (cfu) LP GMNL-32, once daily, po
45398443|NCT01116778|Other|Placebo|One placebo capsule, once daily, po
45506595|NCT04938973|Procedure|Open Transthoracic Esophagectomy (OTE)|Open Transthoracic Esophagectomy (OTE) is the current standard of care.
45506596|NCT04938973|Device|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE)|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE) will be performed using the Da Vinci Robotic Surgical Platform.
45506597|NCT04936958|Other|patients having had an osteomyelitis since 2017|description of osteomyelitis and their management
45506598|NCT04935554|Other|Person centred care|physical activity, nutrition, motivation, health competence, psychosocial.
45398444|NCT01110148|Other|video-based informed consent for skin biopsies|video-based informed consent for punch and shave biopsies
45398445|NCT01110148|Other|traditional informed consent|traditional informed consent (standard of care) from physicians for shave and punch biopsies
45506599|NCT04931160|Other|Blood, fluid, sells and urine samples|Blood, fluid, sells and urine samples will be collected.
45697640|NCT04469374|Other|Jumping exercise|Participants will be required to perform 10 maximal vertical jumps, with a 10-s rest interval between each jump, using an arm swing in countermovement style on three days per week. The jumps will be performed without shoes on a hard surface. The jumps will be preceded by a warm-up lasting approximately 3 min and consisting of mobilisation exercises for the legs and lower back. Jumping will be progressed over time and in accordance with individual needs.
45398446|NCT01116856|Other|Exercise|Different groups will carry out different exercise protocols during 16 weeks under the same nutritional intervention.
45398447|NCT01110226|Drug|KML-001|"KML001 will begin given to patients first. It should be taken by mouth immediately prior to cisplatin infusion. Patients will be treated in cohorts of three beginning at 15mg. The Dose will be increased until Maximum Tolerated Dose is established.~KML001 will be administered daily for 14 days of a 21 day cycle. Patients will have one week off."
45398448|NCT01110226|Drug|Cisplatin|Cisplatin will be given to all patients at a dose of 75 mg/m2 on day 1 of every 21 day cycle over 30 to 90 minutes through an intravenous infusion immediately after the first dose of KML-001
45398449|NCT01211236|Other|application of wound dressing made of bio-bags (vitapads) containing maggots|
45398450|NCT01211236|Other|application of classical hydrogel/alginate wound dressing|
45506600|NCT04930289|Device|LungGuard|The LUNGguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of lungs during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the lungs. The intended organ storage time for the LUNGguard is up to 8 hours.
45506601|NCT04928391|Drug|Dexmedetomidine|A single dose of 0.5 µ/kg IV dexmedetomidine at the end of surgery
45506602|NCT04928391|Drug|Nalbuphine|A single dose of 0.1 mg/kg IV nalbuphine at the end of surgery
45506603|NCT04928391|Other|0.9% saline|Same volume of saline placebo IV at the end of surgery
45506604|NCT04928352|Drug|Bupivacaine Hydrochloride|Preoperative Nebulized Bupivacaine 0.50% 0.25 mg.kg-1
45506605|NCT04928352|Drug|Bupivacaine Hydrochloride|Preoperative Nebulized Bupivacaine 0.50% 0.50 mg.kg-1
45506606|NCT04928352|Other|0.9% saline|Preoperative nebulized same volume of saline placebo
45398451|NCT03789292|Biological|CT-P17 SC|Subcutaneous injection of Adalimumab 40mg every two weeks
45506607|NCT04928300|Drug|Dexmedetomidine|low dose dexmedetomidine infusion 0.2 µ/kg/hour IV for 5 days.
45506608|NCT04928300|Drug|Ketamine|low dose ketamine infusion 2.5 µ/kg/min for 5 days.
45506609|NCT04928300|Other|0.9% saline|the same dose and duration of normal saline will be given for 5 days.
45506610|NCT04924140|Drug|Aducanumab|Administered as specified in the treatment arm
45506611|NCT04920864|Device|rTMS|Repetitive transcranial magnetic stimulation
45506612|NCT04920695|Drug|Nitric Oxide|Pulmonary vasodilator (gas).
45506613|NCT04920695|Drug|Placebo|medical grade normoxic gas (FiO2 = 0.21)
45506614|NCT04915755|Drug|Niraparib|Niraparib will be administered.
45506615|NCT04915755|Drug|Placebo|Matching placebo will be administered
45506616|NCT04913948|Other|No intervention|No intervention
45506617|NCT04910464|Drug|Tranexamic acid|administer 1 gram of TXA in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of TXA IV over 8 hours in 0.9% normal saline for first 3 days.
45506618|NCT04910464|Other|0.9% saline|administer the same volume (100ml normal saline) and same duration (first three days).
45506619|NCT04905901|Drug|Tranexamic acid|Tranexamic acid nebulization 15 minutes before sinus surgery
45506620|NCT04905901|Other|Saline placebo|Normal saline placebo nebulization 15 minutes before sinus surgery
45506621|NCT04901988|Drug|Nivolumab 10 MG/ML|Eligible patients randomised to Arm B will receive 480 mg nivolumab monotherapy 4 weekly via IV infusion for up to 2 years.
45506622|NCT04901546|Other|Patient's own saliva|Infants with esophageal atresia will be given their own saliva
45398452|NCT03789292|Biological|Humira SC|Subcutaneous injection of Adalimumab 40mg every two weeks
45506623|NCT04900974|Drug|Doravirine|100mg
45506624|NCT04899687|Drug|Fluoxetine|Fluoxetine 20mg (or previously prescribed dose) will be taken once daily by mouth for 8 weeks
45506625|NCT04899687|Drug|Dextromethorphan|Dextromethorphan, an over-the-counter cough suppressant, will be taken by mouth twice daily for four weeks of the study, starting at 15mg per dose, and increasing weekly as tolerated to a maximum of 60mg per dose.
45506626|NCT04897893|Other|Eicosapentaenoic acid monoglycerid (MAG-EPA)|MAG-EPA is an omega-3 fatty acid classified in canada as a Natural Health Product (NHP). The NHP is approuved under the Natural Health Product number (NPN # 80050187).
45398453|NCT01212718|Drug|FUFA|2600/500 mg/m2 i.v. 24 h via port, 1 time weekly for six weeks, than have a break for 2 weeks (=8 weeks for 1 cycle)
45506627|NCT04897633|Device|transcranial electric stimulation|Simon's task assessment when under tDCS
45506628|NCT04866823|Behavioral|Medically Tailored Meals|Participants will receive weekly meals (20 per week) prepared by a local community kitchen and catering group. Each week, 10 dinners and 10 lunches will be delivered to the participant's home with instructions for storage, re-heating, recipes, and nutritional information.
45398454|NCT01212718|Drug|systemic chemotherapy|CPT-11, 80 mg/m2 for 90 minutes and 5 FU/FA 2000/500 mg/m2 iv. 24h via port; 1 time weekly for six weeks, than have a break for 2 weeks
45398455|NCT01211314|Drug|Lercanidipine/enalapril fixed combination|Lercanidipine 10 mg + enalapril 20 mg, once a day, used as a fixed combination drug. Unique dose during the study
45398456|NCT01113814|Device|FibroScan|
45398457|NCT01113814|Device|Acoustic Radiation Force Impulse (ARFI)- Imaging|
45398458|NCT01211392|Other|magnetic resonance imaging|magnetic resonance imaging is compared to dual-energy computed tomography for the detection of bone marrow changes
45398459|NCT01110304|Other|Conservative treatment - brace|Patients selected for this treatment will wear a light brace for pain release and analgesics will be prescribed. They can move the elbow, the wrist and the fingers immediately. After two weeks, they will begin a training program to restore shoulder motion and strength, and they will be asked to take off the brace progressively. They are allowed to start working and sporting activities when they feel comfortable.
45506629|NCT04854785|Other|[18F]FEPPA PET scan|One [18F]FEPPA PET for TSPO VT, and one MRI scan
45506630|NCT04854785|Other|[11C]SL25.1188 PET scan|One [11C]SL25.1188 PET scan for MAO-B VT, and one MRI scan
45506631|NCT04852809|Other|No intervention|This is an observational study
45506632|NCT04843124|Device|Remote HA adjustment|The intervention group is offered remote hearing aid adjustment whilst the control group is offered traditional hearing aid adjustment the requires physical appointments at the clinic. Remote hearing aid adjustment is applicable through mobile applications that hearing aid users download to their mobile phones.
45506633|NCT04843124|Other|Traditional hearing aid|Traditional hearing aid
45506634|NCT04838574|Other|15 years Follow-up group|Phone recruitment, screening interview and eligibility questionnaire. Patient inclusion during rheumatologic evaluation : questionnaire, examination and data collection in one of the 4 study hospital centers.
45506635|NCT04829877|Behavioral|Web-based mind-body intervention with HRVB|The web-based mind-body intervention with HRVB contains the following components: 1) Breathing training with HRV biofeedback; 2) 5 different topics will be included ; 3) Home exercise of slow breathing and mindfulness exercise.
45506636|NCT04829877|Behavioral|Web-based mind-body intervention|The web-based mind-body intervention will receive 5 different topics courses.
45506637|NCT04823845|Drug|Topical Adapalene Gel 0.1%|applying Adapalene Gel 0.1% to plantar warts topically
46059094|NCT00583219|Drug|Dimethyl sulfoxide (DMSO)|Subjects received 50 cc of DMSO in an aqueous solution for intravesical instillation with botulinum-A toxin. Each cc contained 0.54 gm DMSO.
45506638|NCT04810962|Drug|APP13007, 0.05%|APP13007 eye drop, 0.05%
45506639|NCT04810962|Drug|Matching Vehicle Placebo for APP13007, 0.05%|Matching vehicle placebo eye drop
45506640|NCT04806776|Other|24hrs dressings change|The first dressing change and sampling were completed 24 hours after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..Then the second dressing change and sampling were completed 7days later(if there is no clinical indication occur,such leaking,blood).
45697641|NCT04469374|Other|Balance exercise (sham control)|Participants will be required to perform balance exercises. Participants will be required to balance on one leg for up to 60 seconds (2 x 60 s is equivalent in duration to the 10 jumps). This exercise will be progressed.
46059095|NCT04501939|Drug|Cirmtuzumab|Cycle 1, Day 1 & 15 - 600mg Cycle 2, Day 1 to Cycle 6, Day 1 - 600mg
45398460|NCT01110304|Device|Hook plate by Synthes|The patient is in a beach-chair position with injured arm slightly out of the table, on a bracket. The incision is longitudinal, from the distal third of the clavicle to the lateral border of the acromion. The deltoid is detached anteriorly to present the clavicle and the AC joint. The width of the hook depends on the depth of the acromion. The plate will always be 5 holes 3.5mm hook plate (Synthes®), left or right. The hook is inserted after visual reduction of the AC joint at the posterior border of the distal end of the clavicle, under the acromion. Reduction is then maintained by a davier and fixation with three 3,5mm cortical screws is achieved. After washing, deltoid is reinserted. CC ligaments are not directly repaired. Wound closure and bracing for two weeks.
45398461|NCT01207960|Behavioral|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention consists of three 90-minute sessions of individual psychotherapy. Sessions take place weekly according to a treatment manual.
45398462|NCT03942874|Behavioral|Group Reward Retraining|Adapted behavioral activation group treatment for binge eating with values and cognitive skills integrated
45506641|NCT04806776|Other|7days dressings change|The first dressing change and sampling were completed 7 days after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..(if there is no clinical indication occur,such leaking,blood).
45398463|NCT02529514|Drug|Baclofen|25 mg for 7 days at 10 pm every day
45506642|NCT04806451|Drug|Crinecerfont|CRF1-receptor antagonist
45506643|NCT04806451|Drug|Placebo|Non-active dosage form
45506644|NCT04806269|Device|Fitbit and Glandy|Data collection from wearable devices (Fitbit Inspire 2 TM) and a mobile app (Glandy TM) Fitbit collects user's heart rate, activity, and sleep data. Glandy collects user's subjective symptom scores.
45506645|NCT04805983|Drug|BMS-984923|Day 1: Admission, administration of study drug, and 2 night in-patient stay; Day 3: Discharge following the completion of all scheduled procedures.
45506646|NCT04798378|Device|Neurosleeve|Myoelectric devices for restoration of independent arm function
45506647|NCT04792749|Drug|Metformin|Patients are given 750, 1500, and 2000 mgs of metformin per os daily (dose increases weekly, then maintain at 2000 mgs) in addition to 500 mgs of medroxyprogesterone acetate per os daily and levonorgestrel-releasing intrauterine device for the treatment of early stage endometrial cancer.
45506648|NCT04792190|Drug|dapagliflozin|Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily, for 12 months.
45506649|NCT04792190|Drug|Placebo|Subjects will take 1 blinded capsule of placebo drug dosed once daily
45506650|NCT04789070|Drug|Sirolimus|Sirolimus is a currently licensed drug primarily used for immunosuppression post-kidney transplantation to prevent organ rejection. Sirolimus was initially considered as a treatment in IBM for its immunosuppressive action and beneficial effects in an experimental myositis mouse model.(11) Transfer of effector T cells from affected to healthy animals resulted in myositis, but the presence of Treg cells were protective against development of myositis. As Sirolimus, which acts to deplete effector T cells but preserving the Treg cells, was effective in this mouse model of myositis, it was therefore postulated that it may also be effective in IBM, not only for its effects on effector T cells and Treg cells, but also for its additional effects on protein degradation.
45506651|NCT04789070|Drug|Placebo|Placebo
45506652|NCT04756427|Drug|Sodium Citrate 4% Inj Syringe 3Ml|3 ml of sodium citrate 4% locking solution instilled into the central catheter daily during the period that parenteral nutrition is not infusing, and will be withdrawn and disposed of prior to resuming infusion of parenteral nutrition
46059096|NCT04501939|Drug|Venetoclax|Venetoclax 400mg PO daily from cycle 1 day 1 for 6 cycles of 28 days.
45398464|NCT02529514|Drug|Placebo|Placebo for 7 days at 10 pm every day
45398465|NCT01208116|Other|Cardiovascular events|"Coronary intervention~Infarction~Congestive heart failure~Stroke~Cardiac death"
45398466|NCT03941002|Diagnostic Test|Assesment of diaphragm function|Diaphragm function will be assessed by standard mechanical parameters as assessed by esophageal and gastric pressure measurement, as well as by an ultrasonographic examination performed by an expert operator and by the continuous ultrasonographic assessment provided by the device under investigation
45398467|NCT03939130|Dietary Supplement|Fructose|Consumption of 1.0g / kg of body mass / day of fructose.
45398468|NCT03939130|Dietary Supplement|Glucose|Consumption of 1.0g / kg of body mass / day of glucose.
45398469|NCT03939130|Other|Fructose and exercise|Consumption of 1.0g / kg of body mass / day of fructose + 3 weekly sessions of 60 minutes of aerobic exercise.
45398470|NCT01113970|Drug|Indibulin|Indibulin given orally once a day for 5 days followed by a 9 day rest
45398471|NCT01211470|Drug|Daptomycin|Active Comparator: Daptomycin.
45398472|NCT01211470|Drug|PMX-30063-investigational drug|Experimental: PMX-30063
45506653|NCT04753359|Other|Med|Mediterranean diet
45506654|NCT04753359|Other|WL|Measuring change in weight
45506655|NCT04737265|Other|Biomarker Guided Intervention|NTproBNP above the upper limit of normal will trigger the initiation of heart failure therapy with counseling from a study investigator based on protocol specified algorithm.
45506656|NCT04733417|Drug|SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
45506657|NCT04733417|Drug|famitinib|Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3.
45697642|NCT01884077|Device|Reverse Shoulder Arthroplasty|REVERSE In a Reverse Total shoulder the ball is located on the shoulder blade (glenoid) and the socket is located on the arm bone (humerus), exactly the opposite of the situation in a conventional total shoulder. The ball (glenosphere) is screwed to the bone of the shoulder blade. The cup (humeral sock¬et) is fixed to a stem that is cemented down the inside of the arm bone (humerus).
45697643|NCT01884077|Device|Total Shoulder Arthroplasty|TOTAL In a conventional Total shoulder, the arthritic surface of the ball is replaced with a metal ball with a stem that is press fit in the inside of the arm bone (humerus) and the socket is resurfaced with a component.
45697644|NCT05221294|Drug|Modified Del Nido Versus Custodiol Cardioplegia|Modified Del Nido Versus Custodiol Cardioplegia For Myocardial Protection In Cardiac Surgery
46059097|NCT04490785|Procedure|MRI|1 MRI 5 days after surgery (-1; +4 days), with intravenous administration of gadolinium
45506658|NCT04731441|Behavioral|Home-based Exercise Program Prior to CRS-HIPEC|Exercise Program Subjects randomized to the intervention arm should have 6 weeks of home exercise prior to surgery, with a minimum of 5 weeks and not more than 7 weeks. The program will begin with an exercise consultation appointment with a certified fitness professional. During this consultation participants will receive an exercise manual for individualized home-based exercise and a practical introduction by an exercise and cancer specialist. PowerBlock adjustable dumbbells will be used for resistance training exercises and walking or jogging will be the primary type of aerobic training. The current program design was developed and successfully used with women with breast cancer. Thus, some components may need modification for this group of patients with advanced GI cancer.
45506659|NCT04731441|Behavioral|Exercise Education|Control arm: Subjects randomized to the control arm will receive education and a handbook on the benefits of exercise and will be encouraged to have adequate protein in their diet and provided with the list of high protein foods and nutritional information. These subjects will undergo the same assessments as the intervention arm at all time points. Control subjects will be offered a 6-week home exercise program 3 months after CRS/HIPEC, as described in sections 7.2.1-7.2.3. Results and outcomes will not be recorded.
45506660|NCT04724603|Other|patients having had avderse event after phagotherapy for bone or joint or implant infection|to determine the accountability of adverse effects in having had avderse event after phagotherapy for bone or joint or implant infection
45506661|NCT04723420|Other|Steamroller technique|Following intravitreal gas injection, patient positioned face down for 4-6 hours and subsequently patient changes the position of the head so that the bubble is then placed directly over the retina break.
45506662|NCT04723420|Other|Direct technique|Following intravitreal gas injection, patient is immediately positioned so that the bubble is placed directly over the retina break.
45506663|NCT04722601|Drug|Venetoclax|A drug used with other drugs to treat acute myeloid leukemia that is newly diagnosed. It is used in adults who are 75 years and older or in adults who cannot be treated with other anticancer drugs. Venetoclax is also used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma in adults. It is also being studied in the treatment of other types of cancer.
45506664|NCT04722601|Drug|Obinutuzumab|Obinutuzumab is a prescription medicine that can be used in combination with other cancer medicines to treat follicular lymphoma (a type of non-Hodgkin lymphoma), or to help delay the progression of this disease.
45506665|NCT04722601|Drug|CC-486|An oral form of azacitidine (a standard chemotherapy drug).
45506666|NCT04710550|Drug|F18-3F4AP|PET Scan
45506667|NCT04702243|Diagnostic Test|Genetic Testing for PCD or PID|Patients with high likelihood of a PID disorder or a high likelihood of PCD will initially undergo research genetic testing on a commercial approved panel for PID disorders or a panel of at least 37 PCD genes.
45506668|NCT04702243|Other|Unaffected Family Member Genetic Testing|Unaffected family members will undergo genetic testing if genetic findings are identified in their affected family member.
45506669|NCT04701762|Device|GlideScope videolaryngoscope (Verathon, Bothell, WA 98011)|After confirming adequate muscle relaxation, initial laryngoscopy will be performed using GlideScope videolaryngoscope with an appropriately sized blade (usually size 3 or 4). The GlideScope (Verathon, Bothell, WA 98011) is an FDA-cleared commercially available portable videolaryngoscope.
45506670|NCT04701762|Device|Direct laryngoscopy|After confirming adequate muscle relaxation, initial laryngoscopy will be performed using direct laryngoscopy with an appropriately sized Macintosh or Miller blade (usually size 3 or 4);
45506671|NCT04692844|Drug|Propranolol|Patients will receive Propranolol in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
45506672|NCT04692844|Drug|Primidone|Patients will receive Primidone in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
45506673|NCT04692077|Drug|Cabotegravir (CAB) tablet|30 mg tablets
45506674|NCT04692077|Drug|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter.
45697645|NCT04720209|Other|CARE|CARE is a 16-week, supervised, periodized AE and RE program performed in a circuit fashion 3 days/week on-site
45697646|NCT04720209|Other|TARE|TARE is a 16- week, supervised AE and RE program consisting of three sessions per week on-site
45697647|NCT04720209|Other|Home-Based Stretching|This group will perform a home-based program of the same stretches utilized in the CARE and TARE groups.
45697648|NCT04614311|Drug|Triamcinolone Hexacetonide 20 MG/ML|JIA patients (age 1-18 years) starting TNFi treatment randomised to intervention will receive treatment with intra articular glucocorticoids (triamcinolone hexacetonide) injections in inflamed joints
45697649|NCT03681639|Diagnostic Test|Serum Metal ion levels determined to monitor changes in chromium and cobalt levels|Analyses will be performed pre-operatively, 6 months, 1 year, 2 years and 5 years postoperatively for all study subjects enrolled in this study, as well as, all revision study subjects receiving the Metasul® LDH™ total hip system. To prevent intra-observer variation the metal ion concentrations will be analysed by an approved Central Laboratory. The Central Laboratory will provide specimen collection kits for the transfer of blood specimens to the Laboratory for analysis. The Laboratory will provide the results to the Investigators. The cobalt and chromium will be measured by induced coupled plasma mass spectrometry (ICP-MS). BUN, creatinine and GFR will be determined locally.
45697650|NCT03922204|Drug|MCLA-145|full-length IgG1 bispecific antibody specifically targeting PD-L1 and CD137
46059098|NCT04490785|Biological|Postoperative dosage of released troponin|Dosage of troponin I Hs H4, H8, H12, H24, H48, and H72 after the aortic cross-unclamping.
46059099|NCT05674669|Drug|Lysergic Acid Diethylamide (LSD) 50µg|
45506675|NCT04692077|Drug|Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet|300 mg/200 mg fixed-dose combination tablets
45506676|NCT04680611|Other|no study intervention. Patients receive standard clinical care|no intervention. observational study
45506677|NCT04657003|Drug|Tirzepatide|Administered SC
45506678|NCT04657003|Other|Placebo|Administered SC
45506679|NCT04650607|Other|Adverse event after injection of phages|rate and description of adverse event after injection of phages
45506680|NCT04648852|Other|Heart failure risk estimation|Evaluation by heart failure risk score
45506681|NCT04645420|Procedure|Global gene expression profiles obtained from synovial biopsies.|Global gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug in each patient.
45506682|NCT04643067|Drug|KPG-818 low dose|The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
45506683|NCT04643067|Drug|KPG-818 mid dose|The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
45506684|NCT04643067|Drug|KPG-818 high dose|The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
45506685|NCT04643067|Drug|Placebo|This is the comparative arm.
45506686|NCT04632810|Other|Ketogenic diet until reaching 10% weight loss|Participants will follow a low energy diet, with 1200 kcal per day. Carbohydrates 50g (17E%), protein 60 g (20E%), fat 84 g (63E%), until reaching 10% weight loss (approximately 10weeks).
45506687|NCT04632810|Other|non-ketogenic diet until reaching 10% weight loss|Participants will follow a low energy diet, with 1200 kcal per day. Carbohydrates 150g (50E%), protein 60 g (20E%), fat 40 g (30E%), until reaching 10% weight loss (approximately 10weeks).
45506688|NCT04632810|Other|Ketogenic eucaloric diet for weight stability|Participants will follow a low-calory-high-fat diet for 10 weeks. Carbohydrates10E%, protein 20E% and fat:70E%. Dietary plans will be based on individual measurement of energy needs by resting metabolic rate and physical activity level.
45506689|NCT04625361|Drug|HEC122505MsOH|Part2：Mulltiple doses once daily, up to 8 days
45506690|NCT04624906|Drug|Acalabrutinib|100 mg oral capsules twice daily for 1 year
45506691|NCT04624906|Drug|Bendamustine|90 mg/m2 on days 1 and 2 of each cycle.
45506692|NCT04624906|Drug|Rituximab|day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures).
45506693|NCT04610320|Drug|Daratumumab-SC|>Daratumumab-SC 1800 mg subcutaneous weekly for 8 doses and then every other week for 2 doses.
45506694|NCT04606134|Device|Hybrid fractional laser|two treatments given one month apart
45506695|NCT04606134|Other|Alastin Regenerating Skin Nectar with TriHex Technology|applied twice daily
45697651|NCT04717791|Device|Vivaer® ARC Stylus|The Vivaer procedure will be performed in the study clinic using the VivAer Stylus and Aerin Console. The VivAer Stylus is a disposable handheld device capable of delivering low-temperature bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have both nasal valves treated in a single study procedure session. Each nostril will be treated at up to 3 positions
45398473|NCT01114048|Drug|Thalidomide, cyclophosphamide, dexamethasone, bortezomib|"Induction therapy with CTD regimen for 4 cycles Thalidomide 50-100 mg P.O. HS D 1~28 Cyclophosphamide 150 mg/m² P.O. D 1~4 Dexamethasone 20 mg/ m² IV or P.O. D 1~4, 15-18 Repeated every 28 days~Intensification with Vel-CD regimen for 4 cycles (patients who fail to achieve more than PR after 2 cycles of CTD) Velcade 1.3 mg/m2 IV D1, 4, 8, 11 Cyclophosphamide 150 mg/m² P.O. D 1~4 Dexamethasone 20 mg/ m² IV or P.O. D1, 4, 8, 11 Repeated every 21 days~Bactrim prophylaxis during dexamethasone administration Acyclovir prophylaxis during velcade administration Aspirin medication during thalidomide administration"
45506696|NCT04606134|Other|Cetaphil face cream|applied twice daily
45506697|NCT04586426|Drug|Talquetamab|Talquetamab will be administered by subcutaneous (SC) injection.
45506698|NCT04586426|Drug|Teclistamab|Teclistamab will be administered by SC injection.
45506699|NCT04586426|Drug|Daratumumab|Daratumumab will be administered by SC injection.
45506700|NCT04568759|Other|Global postural re-education|GPR consists of active treatment posture and sensorimotor control exercises to regain back muscle symmetry and correct posture in daily activities
45506701|NCT04556188|Procedure|Cardiac surgery|
45506702|NCT04550598|Device|HD-tCES|The high definition transcranial electrical stimulation was applied using a 1*4 ring electrode configuration. The electrode will be applied at the left M1 or contralateral to pain side. The anodal electrode was placed on the C3/C4, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 5 times a week, lasting for 2 weeks.
45697652|NCT04713579|Other|No intervention - observational study|There is no intervention in this study as it is purely observational.
45697653|NCT04579029|Procedure|Lymphaticovenous anastomosis surgery combined with near infrared spectroscopy imaging|Lymphoedema is well recognized as a chronic debilitating disease resulting from an abnormal collection of protein-rich fluid within the subcutaneous tissues of the body. Given the need to identify more effective treatments, more recent advances in super microsurgical techniques have seen the introduction of new procedures, perhaps the most successful of which have involved re-routing the lymphatic fluid by using microsurgery to divert small lymphatic channels into venules in the sub-dermal plane (LVA surgery). This procedure is performed under regional or general anaesthetic as a day-case operation, leaving only a few very short scars in the skin of the arm or leg.
45398474|NCT01211548|Other|contrast CTA of the CAP|CT coronary angiography results will be reported for all patients by adjudicators blinded to their inclusion in the study.
45398475|NCT01208194|Drug|MGN1703|solution, 60 mg, twice a week, until progression
45398476|NCT01208194|Drug|Placebo|solution, 60 mg, twice a week, until progression
45398477|NCT01208272|Behavioral|Cognitive Behavioral Therapy (CBT)|
45398478|NCT01208272|Behavioral|Interpersonal Therapy (IPT)|
45398479|NCT01114126|Drug|Neu-P11|comparison of different dosages of drug
45398480|NCT01114126|Drug|Neu-P11 placebo|comparison of different dosages
45398481|NCT03939052|Dietary Supplement|Free amino acids intake|Oral consumption of eight hourly experimental meals- -4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil -4 isotopically labeled experimental meals. The same protocol will be repeated with glycomacropeptide (GMP).
45398482|NCT01208350|Behavioral|No intervention|Monthly weigh-ins for 6 months without financial incentives associated with weight loss, and follow-up weigh-in at 9 months
45398483|NCT01208350|Behavioral|Group-based payout|Monthly weigh-ins for 6 months where five sequential participants, randomized to this condition, will be joined into virtual groups where individual rewards for weight loss are dependent on the weight loss of others in the group, with follow-up weigh in at 9 months
45398484|NCT01208350|Behavioral|Individual payout|Monthly weigh-ins for 6 months and if monthly goals are met, participants receive payout at the end of the month, with follow-up weigh-in at 9 months
45398485|NCT03939208|Behavioral|BRISC|
45398486|NCT03939208|Behavioral|SAU|
45697654|NCT03285321|Drug|Nivolumab|480mg
45398487|NCT01213030|Drug|[F-18] FMISO|10 mCi [F18] HX4 and 10 mCi [F-18] FMISO within 7 days of each other regardless of sequence
45398488|NCT01213030|Drug|[F-18] HX4|10 mCi [F18] HX4 and 10 mCi [F-18] FMISO within 7 days of each other regardless of sequence
45697655|NCT03285321|Drug|Nivolumab|240mg
45697656|NCT03285321|Drug|Ipilimumab|1mg/kg
45398489|NCT01208428|Behavioral|Conventional cognitive behavioral therapy|Conventional cognitive behavioral therapy is a standard treatment for depression. There will be ten 50-minute sessions delivered.
45398490|NCT01208428|Behavioral|Religious cognitive behavioral therapy|Religious cognitive behavioral therapy is conventional cognitive behavioral therapy that includes consideration of the patient's religious beliefs in therapy. Subjects will receive ten 50-min sessions of therapy
45398491|NCT01211626|Drug|ANA773|ANA773 Tosylate Capsule
45398492|NCT01211626|Drug|Placebo|Matching Placebo Capsule
45398493|NCT01211704|Drug|Paliperidone Palmitate|NVEGA® SUSTENNA™ or placebo in equivalent ml doses according to the following schedule: Day 1: INVEGA® SUSTENNA™ 234mg vs. placebo injection (equivalent ml); Day 8 (week 1) INVEGA® SUSTENNA™ 156mg vs. placebo injection (equivalent ml); Day 36 (week 5): INVEGA® SUSTENNA™ 117 mg vs. placebo injection (equivalent ml) ( this latter dose could range from 39mg to 156mg according to tolerability and clinical symptoms of bipolar disorder). Treatment with INVEGA® SUSTENNA™ /Placebo will last 5 weeks.
45398494|NCT01211704|Drug|Placebo|Placebo in equivalent ml doses to experimental intervention (Paliperidone Palmitate)
45398495|NCT02529670|Procedure|Laser|Low level laser therapy will be delivered through Laser Photon III ® (DMC) in the second lumbar dorsal root ganglion.
45398496|NCT02529670|Procedure|Drug: Lidocaine|1 mL of Lidocaine will be delivered in the second lumbar dorsal root ganglion through fluoroscopy.
45398497|NCT02529670|Procedure|Radiofrequency|Radiofrequency will be delivered during 300 seconds, 42oC in the second lumbar dorsal root ganglion.
45398498|NCT03939286|Other|Clinical-neurological and neuropsychological tests|The tests include established standardized questionnaires and detailed clinical neuropsychological examinations (e.g., tests on cognition and perception). In order to avoid exercise effects in multiple examinations, so-called parallel procedures should be used.
45398499|NCT03939286|Diagnostic Test|Blood sampling|Venous blood sampling (40 ml) is performed according to the usual criteria of sterile working at baseline and after intervention.
45398500|NCT03939286|Other|Assessment of physical activity via fitness tracker/diary|All study participants, regardless of group classification, are randomly selected for a period of one week using Fitbit Charge 2® fitness trackers. The study participants are asked in this context to pursue their regular activity and to wear the bracelets for a week throughout. All study participants are asked to document their activities in a hand-written diary.
45697657|NCT04705545|Device|transpalatal arch group|transpalatal arch is a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a U loop pointing posteriorly, soldered to the palatal side of the molar bands.
46059100|NCT05674669|Drug|Lysergic Acid Diethylamide (LSD) 75µg|
45398501|NCT03939286|Other|MRI-examinations|Standard MRI-methods, Sodium MRI, Phosphor MRS, Wholebody-Fat-MRI
45398502|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects.
45398503|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 administered s.c. (under the skin) in healthy subjects.
45398504|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
45398505|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
45398506|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA.
45398507|NCT01208506|Drug|placebo|A single dose of NNC0114-0000-0005 placebo.
45398508|NCT03938896|Other|platelet rich plasma|Patients were put in supine position. Betadine was used to disinfect the skin of the heel. 1 ml of local anesthesitic (lidocaine) was injected;then, by the same syringe, 2.5 ml of PRP was injected in the tenderestarea.After extraction of the needle, a bandage was puton the injected area. The patient was kept in the supine position for twentyminutes and then discharged
45398509|NCT03938896|Other|corticosteroid|Patients were put in the supine position. Injection was done usingthe medial technique. Identification of the tenderest point of the heel was done by palpation. Antiseptic solution was used to disinfect the skin overlying theheel. Then1ml of 40 mg methylprednisolone acetate and 1 ml of local anaesthetic as lidocaine 2% were injected into the plantar fascia by a 22gauge needle. After injection, participants were advised to stay sitting without foot movement for 15 minutes
45398510|NCT01208584|Other|fMRI, DTI|functional magnetic resonance imaging (fMRI), MR diffusion tensor imaging (DTI)
45398511|NCT01213108|Behavioral|Örebro prevention program|6 presentations on alcohol-specific parenting practices to parents of 13-16 year olds youth
45398512|NCT01213108|Behavioral|Business as usual|Regular alcohol prevention activities and curricula in Swedish schools
45398513|NCT03938818|Behavioral|Tu'Washindi intervention|"The intervention includes the following components:~PrEP sensitization for men (community level). These activities will aim to provide men with basic information about PrEP and will be used to prepare men for more effective engagement in Buddy Days, described below.~Buddy Days (partner level). Buddy days will target male partner engagement by inviting couples to attend a community-wide event with health screenings, and PrEP sensitization, which aim to facilitate further communications about PrEP and increase men's support for AGYW's PrEP use.~Adherence support clubs (individual and peer levels). Support clubs will provide a forum for AGYW to discuss challenges and successes around PrEP use in relationships, including in the context of partner violence. Participation in these groups is hypothesized to increase self-efficacy for PrEP use by reducing social isolation and providing additional positive role-modeling from peer leaders."
45398514|NCT03938818|Other|Control|Standard of care will include PrEP delivery according to the usual DREAMS procedures, including attendance at routine Safe Space meetings and routine PrEP provision at the Safe Space, if applicable.
45398515|NCT03938506|Other|cuff pressure of the endotracheal tube|The endotracheal intubation will be performed after the anesthetic induction. The cuff will be inflated using the air by the palpation method. The cuff pressure of the endotracheal tube will be measured using the manometer.
45398516|NCT01117636|Drug|Acetylsalicylic acid (Fast release Aspirin, BAY1019036)|Single oral dose of fast release aspirin tablets 1000 mg (2 x 500 mg) with a full glass of water (240 milliliter [mL]) between 14 hours post dental surgery.
45398517|NCT01117636|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of regular aspirin tablet 1000 mg (2 x 500 mg) with a full glass of water (240 mL) between 14 hours post dental surgery.
45398518|NCT01117636|Drug|Placebo|Single oral dose of 2 placebo tablets with a full glass of water (240 mL) between 14 hours post dental surgery.
45398519|NCT03938740|Drug|HDV-Insulin Lispro and Insulin Degludec (-40%)|HDV-Insulin Lispro and Insulin Degludec (-40%)
45398520|NCT03938740|Drug|HDV-Insulin Lispro and Insulin Degludec (-10%)|HDV-Insulin Lispro and Insulin Degludec (-10%)
45398521|NCT01213186|Drug|high dose of MSC|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 1.5*10E6/kg for 48 weeks.
45398522|NCT01213186|Drug|low dose of MSC treatment|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 0.5*10E6/kg for 48 weeks.
45398523|NCT01117714|Procedure|Integrated Staging for Early Detection of Metastases in Lung Cancer|To determine the accuracy of EBUS/EUS-guided FNA when compared with surgical mediastinoscopy/thoracoscopy
45398524|NCT01110616|Drug|MK3134|MK3134, 25 mg tablets (5 x 5 mg capsule), orally
45398525|NCT01110616|Drug|Comparator: Lorazepam|Lorazepam, 2 mg (2 x 1 mg tablet), orally
45398526|NCT01110616|Drug|Comparator: Placebo|Placebo, to match MK3134, and placebo to match Lorazepam
45398527|NCT01117246|Device|High Intensity Focused Ultrasound|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
45697658|NCT04705545|Device|Nance button|Nance button is a 1.0mm stainless steel wire connecting the upper permanent first molar, with a Nance button incorporated in the middle of the wire, soldered to the palatal side of the molar bands
45697659|NCT05066698|Biological|ST266|Topical ocular application: one drop four times a day for eight weeks
45697660|NCT05066698|Other|0.67% Sodium Chloride Ophthalmic Solution|Topical ocular application: one drop four times a day for eight weeks
45697661|NCT05066698|Biological|Open-label ST266|Open label extension for non-healers after completion of double-blind treatment phase: topical ocular application of one drop four times a day for eight weeks
46059101|NCT05674669|Drug|Lysergic Acid Diethylamide (LSD) 100µg|
45506703|NCT04550598|Device|Sham HD-tCES|The high definition transcranial electrical stimulation was applied using a 1*4 ring electrode configuration. The electrode will be applied at the left M1 or contralateral to pain side. The anodal electrode was placed on the C3/C4, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
45506704|NCT04546399|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
45506705|NCT04546399|Biological|Blinatumomab|Given IV
45506706|NCT04546399|Drug|Cyclophosphamide|Given IV
45506707|NCT04546399|Drug|Cytarabine|Given IT
45506708|NCT04546399|Drug|Dexamethasone|Given PO or IV
45506709|NCT04546399|Drug|Etoposide|Given IV
45506710|NCT04546399|Drug|Hydrocortisone Sodium Succinate|Given IT
45506711|NCT04546399|Drug|Leucovorin Calcium|Given PO and IV
45506712|NCT04546399|Drug|Mercaptopurine|Given PO
45506713|NCT04546399|Drug|Methotrexate|Given IT, PO, and IV
45506714|NCT04546399|Biological|Nivolumab|Given IV
45506715|NCT04546399|Drug|Pegaspargase|Given IM or IV
45506716|NCT04546399|Drug|Thioguanine|Given PO
45506717|NCT04546399|Drug|Vincristine Sulfate|Given IV push or via infusion
45506718|NCT04540120|Drug|dapansutrile capsules|Hard opaque capsules containing 250 mg of API.
45506719|NCT04540120|Drug|placebo capsules|Hard opaque capsules containing 0 mg of API.
46059102|NCT05674669|Drug|Placebo/Lysergic Acid Diethylamide (LSD) 75µg|
45398528|NCT03938662|Dietary Supplement|formulation containing S-Adenosyl methionine and choline|Patients will be administered with formulation containing S-Adenosyl methionine and choline once daily for the period of 24 weeks.
46059103|NCT05674669|Drug|Lysergic Acid Diethylamide (LSD) 50µg/75µg|
45506722|NCT04529967|Other|no interventions|it is a observational study, do not have interventions.
45697662|NCT04277793|Behavioral|Monitored self-guided problem solving|Problem Solving is a behavioral modification intervention focusing on the training of adaptive problem-solving skills in order to cope more effectively with everyday stressful events.
45697663|NCT05058742|Device|AuriStim|Auricular vagal nerve Stimulator, which Targets the auricular branches of the vagal nerve
45697664|NCT03832101|Behavioral|MATB|MATB has two multitasking tasks and two attention tasks. The two multitasking tasks evaluates performance on multiple cognitively demanding assignments in both the auditory and visual domains. The two attention tasks measures performance in sustained and selective attention
45398529|NCT03938662|Dietary Supplement|Placebo|Placebo of same appearance, colour and taste,
45398530|NCT01110772|Device|2-octyl cyanoacrylate [InteguSEAL®]|At operating room arrival prior to surgery, povidone-iodine is applied on the skin surface on concentric circles as recommended; after drying, the cyanoacrylate device is opened and a layer of the sealant is applied on the incision and skin site(IS100 for patients undergoing mastectomy, and IS200 for patients undergoing gynecologic or digestive tract surgeries).
45398531|NCT01110772|Device|Iodine povacrylex in isopropyl alcohol [Duraprep®, 3M]|At the operating room arrival a few minutes before the incision, cleansing and skin antisepsis is done with the prefilled device with iodine povacrylex in isopropyl alcohol as recommended by 3M.
45506723|NCT04522791|Behavioral|RFB|The RFB protocol entails a combination of 8 weekly, in-lab training sessions using HRV biofeedback software (Physiocom, Seattle, WA) and daily paced breathing homework using a mobile-based HRV biofeedback app (Inner Balance, HeartMath, LLC, CA).
45506724|NCT04522791|Behavioral|VSOP|The investigators will use the INSIGHT online program (Posit Science). The platform will be built for our study, including 5 tasks (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice different cognitive processes with PS/A as the shared domain.
45697665|NCT03685318|Device|Use of conventional mouthguard|Use of a conventional custom-made mouthguard while playing water polo
45697666|NCT03685318|Device|Use of shortened mouthguard|Use of a shortened custom-made mouthguard while playing water polo
45697667|NCT03617302|Drug|Experimental: Nitrate-containing|Experimental
45697668|NCT03617302|Drug|Placebo: Nitrate-depleted|Placebo
45398532|NCT01213420|Other|Nivea Cream for scar hydration|3 applications per day during 6 months
45398533|NCT01213420|Other|Aloë Vera FORMULA F-BC-096 for scar hydration|3 applications per day during 6 months.
45506725|NCT04522791|Behavioral|IR|Guided imagery relaxation, equal in dose and frequency to RF practice, will be used to control for relaxation effects that may occur via RFB (which could provide an alternative explanation for outcomes). IR activities will be facilitated using the Insight Timer mobile-based app, which emphasizes the use of visualization and imagery strategies to help the body relax.
45506726|NCT04518059|Procedure|punch skin biopsy|An anesthetic medication is injected to numb the areas of skin and two samples of skin are obtained from punch biopsy.
45506727|NCT04517383|Procedure|post-operative sedation|Patients with ischemic stroke will undergo endovascular thrombectomy (ET) under general anesthesia. After the ET surgery is done, patients in POS group will be sedated for 6hrs before extubation.
45506728|NCT04517383|Procedure|routine recovery|Patients with ischemic stroke will undergo endovascular thrombectomy (ET) under general anesthesia. Patients in Con group will be routinely recovered and extubated after the ET surgery is done.
45506729|NCT04513665|Drug|ZW25|ZW25 at 20mg/kg intravenously (IV) every two weeks.
45506730|NCT04505930|Behavioral|Interventional HPV vaccination video modules|The study team provide participants in the intervention group with interventional education, using interactive video watch and dynamic discussion. The educational videos were aiming to reinforcement and improvement the awareness, knowledge, attitude, intention and actual uptake of HPV vaccination shots among Chinese parents.
45506731|NCT04505930|Behavioral|General Vaccination Education|Education session conducted using only handouts of vaccinations including HPV
45506732|NCT04489524|Behavioral|individualized counselor-led MI sessions|Intervention consisted of four 60-min in-person sessions of AMI counseling and a packet of self help smoking cessation materials.
46059104|NCT02583373|Drug|CAL02 Low-dose|Two doses of CAL02 (low-dose) administered 2 times (24 hours apart) as i.v. infusion
45506733|NCT04489524|Behavioral|general health education session|four in-person 60-min health education sessions and packets of general health self-help information, nutrition, exercise, and the harmful effects of tobacco.
45506734|NCT04489524|Behavioral|NRT|nicotine replacement therapy
45398534|NCT01213420|Other|Eucerin Calming cream for scar hydration|3 applications per day during 6 months
45398535|NCT01213420|Other|Aloë Vera with modified preservative for scar hydration|3 applications per day during 6 months
45398536|NCT01117402|Radiation|Radiotherapy|"Patients will receive external radiation therapy using IMRT to pelvis. Treatment volume (CTV, vault and uninvolved pelvic nodes) will receive a dose of 50-56Gy over 25-28# and gross pelvic nodes will receive 55-62Gy over 25-28 fractions over 5 weeks. Pre RT daily MV CT imaging would be done on Tomotherapy to look and correct for any set up error or anatomic variations.~Chemotherapy will be given weekly - cisplatin 40mg/m2 with prechemo medication. After completion of IMRT all patients will be evaluated for boost to vaginal vault with interstitial template brachytherapy to a dose of 16-20 Gy with HDR in 4-5 fractions. Patients not eligible for brachytherapy will get additional boost to vault and parametrium by EBRT to a dose of 15-20Gy in 6-8 fractions."
45398537|NCT01118104|Other|Vocational pulmonary rehabilitation|Multidisciplinary pulmonary rehabilitation with emphasis on vocational issues
45398538|NCT03938428|Other|Survey|Patients who are eligible for this study will have been previously identified as part of the PREFACES project. The pharmacist who has conducted the clinical medication review will obtain verbal permission from the patient to be contacted by the research study team. This will be documented on the referral outcome document that is returned to the YAS clinical team. A member of YAS clinical staff from the PREFACES project will forward the name and residential address of patients who have agreed to be contacted to the research paramedic for this study. A covering letter, participant information sheet, questionnaire and consent form, will be posted to potential participants. A stamped addressed envelope will be included to enable return of the completed booklet at no costs to participants.
46059105|NCT02583373|Drug|CAL02 High-dose|Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion
45506735|NCT04480086|Drug|Mivebresib|Tablet: Oral
45506736|NCT04480086|Drug|Navitoclax|Tablet; Oral
45506737|NCT04480086|Drug|Ruxolitinib|Tablet; Oral
45506738|NCT04476212|Other|Topical antibiotic prophylaxis|The surgical wound will be irrigated with an antibiotic solution, and then we will apply the same solution using gauze for two minutes on the wound
45506739|NCT04441138|Drug|Durvalumab|Adjuvant Durvalumab in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer who have completed concurrent, split course chemoradiation without progression of disease
45506740|NCT04433585|Drug|LY3471851|Administered SC
45506741|NCT04433585|Drug|Placebo|Administered SC
45506742|NCT04432688|Drug|Lurasidone HCl|This is a non-interventional, observational study
45506743|NCT04426825|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg intravenously on Day 1 of each 21-day cycle.
45506744|NCT04426825|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
45506745|NCT04424030|Diagnostic Test|Echocardiography|Standard echocardiography exam performed as part of clinical management.
45697669|NCT04334980|Biological|bacTRL-Spike|Each oral dose of bacTRL-Spike contains bacterial medium with either 1 billion (Group 1), 3 billion (Group 2) or 10 billion (Group 3) colony-forming-units of live Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.
45697670|NCT05003908|Biological|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
45697671|NCT04323748|Drug|rituxan|"The dose dense administration of rituximab will consist of 5 doses total~Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2"
45398539|NCT01110928|Drug|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, at study initiation and every 6 months until last visit.
45398540|NCT01213498|Drug|Atorvastatin|Zarator, 80 mg pr. day for 5 days
45398541|NCT01213498|Drug|Unikalk|1 tablet Unikalk pr day for 5. days
45506746|NCT04424030|Diagnostic Test|Magnetic resonance imaging (MRI)|Standard comprehensive cardiac MRI exam of the heart performed as part of clinical management.
45506747|NCT04424030|Diagnostic Test|Computed tomography (CT)|ECG-triggered, contrast-enhanced CT scan of the heart performed for research purposes in eligible study participants.
45506748|NCT04419233|Drug|Nusinersen Sodium Injection|Administered as specified in the treatment arm.
45697672|NCT03015298|Device|PET/MRI|The recruited patients will receive a PET/MRI examination to evaluation the stage and resectability of the cancer.
45697673|NCT03015298|Device|PET/CT|At the next day of PET/MRI examination,A PET/CT examination will be performed.
46059106|NCT02583373|Drug|Placebo|Placebo administered administered 2 times (24 hours apart) as i.v. infusion
45398542|NCT01213342|Dietary Supplement|Omega-3 Fatty Acid|"Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal). They will continue this regimen for 8 weeks. The total daily amount included in 4 soft gels includes:~EPA (Eicosapentaenoic Acid) 1300mg~DHA (Docosahexaenoic Acid) 900 mg~Other Omega-3's 360mg~Total Omega 3's 2560 mg"
45506749|NCT04418479|Drug|Aspirin|"Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients being treated with dual antiplatelet therapy (DAPT) at high risk for recurrent ischemic events who have been over 12 months after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken aspirin 100 mg once daily during the study period."
45506750|NCT04418479|Drug|Clopidogrel|"Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients being treated with dual antiplatelet therapy (DAPT) at high risk for recurrent ischemic events who have been over 12 months after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken clopidogrel 75 mg once daily during the study period."
45506751|NCT04417998|Drug|18F-FDG|A cohort of participants in Aim 2 will undergo a 18F-FDG PET/CT scan. This scan is done with a radiotracer called 18F-fluorodeoxyglucose (FDG). FDG looks at cellular activity.
45506752|NCT04417998|Drug|18F-AV1451|A cohort of participants in Aim 2 will undergo a 18F-AV1451 PET/CT scan. This scan is done with a radiotracer called 18F-AV1451 (TAU) that will find small areas of tau (abnormal protein) in the brain.
45398543|NCT01213342|Dietary Supplement|Soybean Soft Gels|Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal. The main ingredient in the placebos is soybean oil (95.6%).
45398544|NCT01111006|Device|Bidet (electronic cleansing toilet system)|The volunteers underwent rectal examinations and baseline manometry at lateral decubitus position. Subjects were then placed on a toilet with Bidet attached and manometry catheter was inserted and fixed placing the channels of the catheter at the high pressure zone (HPZ) of the anal canal. Anorectal pressures were measured before and after using the Bidet under different water pressures (4, 8, 16, 20 gram force, gf), types of water stream (narrow vs. wide), and different temperatures (24oC vs. 38oC).
45506753|NCT04417998|Device|Siemens E7 Reconstruction Tool|Software to correct for motion
45398545|NCT01121614|Device|LOTUS|Device used to seal blood vessel
45398546|NCT01121614|Device|Ethicon Harmonic Scalpel|
45398547|NCT01121614|Device|LigaSure bipolar vessel sealing device|
45506754|NCT04414384|Other|Abdominal Binder|Abdominal Binder placement
45506755|NCT04414384|Other|Step Counter|step counter to track steps
45506756|NCT04408508|Drug|Amoxicillin 250 MG|Low dose oral amoxicillin will be administered to patients enrolled in the study meeting the inclusion and exclusion criteria.
45506757|NCT04399538|Drug|PF-06865571|Tablet
45398548|NCT01111084|Drug|Follitropin alpha (r-FSH)|The dosage and administration of follitropin alpha was according to each centre's protocol and within technical specification recommendations.
45398549|NCT01121692|Behavioral|Couples Intervention|The Couples intervention is a merged intervention of three interventions (Women CoOp, men as partners's and couples). Couples attend together for two half day workshops and work on exercises on communication and problem solving, including a commitment pledge of fidelity.
45398550|NCT01121692|Behavioral|Women's CoOp|The Women's CoOp is a gender-focused intervention discussing women's risk in relationship to HIV and also discusses issues of HIV with South African women including skills for violence prevention. During this intervention, participants will also demonstrate the proper use of male and female condoms on penile and vaginal models. They attend two half day workshops.
45398551|NCT01121692|Behavioral|Women's CoOp and Men's Intervention|The Men's CoOp is adapted from Men as Partners, the Women's CoOp and the Couples intervention and contain similar material with a concentration on gender roles and violence prevention. Men attend two half day workshops.
45506758|NCT04399538|Drug|PF-05221304|Tablet
45506759|NCT04399538|Drug|Placebo|Tablet
45506760|NCT04359433|Behavioral|Exercise programme|"Exercise programme includes 8 anaerobic movements choosen from Tabata. This exercise programme workout is aimed at body fat reduction, and the structure is as follows:~8 anerobic movements in 20 seconds is a set~Rest for 10 seconds before another set~Finish 4 sets every time, it shall take you 4 minutes~Do 4 sets 2 to 3 times a week"
45506761|NCT04356261|Behavioral|Gamified Personalized Normative Feedback|Each week, all players will answer 3 questions of interest about first-year students' attitudes and behaviors (e.g., drinking, partying, exercising, studying, dorm life, etc.) generated by the student players. They will also guess how the typical same-sex student at their University answered the same questions and wager points on how close to the correct answer (group norm) each of their guesses is. Further, they will rate (e.g., thumbs up/thumbs down) the reported behaviors of other players and, then, submit and vote on questions for subsequent rounds. At the end of each week, players will receive enhanced personalized normative feedback feedback on two of the three questions, and receive feedback on how other students rated the answer they reported (preferred-sex injunctive norms).
45398552|NCT01213810|Biological|Zostavax|Biological/Vaccine
45398553|NCT01215760|Other|Training with a mirror|Early sensory reeducation group, started at the first week postoperatively, using specific guidelines using the mirror training and stimulation of the contralateral side. Initially, the stimulation will be unilateral and later bilateral, after the removal of the splint in 4 weeks.
45398554|NCT01215760|Other|No mirror therapy|The classical group iniciates after 16 weeks postoperatively and follow a standard home protocol for sensory reeducation without the mirror. It begins with recognition of textures and objects, and specific rehabilitation, if any associated injuries.
45506762|NCT04342091|Device|SOL Nova Device|A SOL Nova Device (brand) is tattoo machine will be used to stimulate hair regrowth.
45506763|NCT04334083|Behavioral|Comparison of biomarkers of stress|Emergency will be followed during a night shift and the rest day et during a day shift and the rest day. They will be observed by a medical externship student. We will assess the role of expertise and habituation to stressful emergency situations.
45506764|NCT04333342|Device|heart rate monitoring using wearable devices|Using Fitbit (TM) wearable devices, heart rate, activity data are collected. Based on these data, resting heart rate is monitored daily basis. If resting heart rate increase beyond set range, users are notified to visit the hospital.
45506765|NCT04332731|Device|Symplicity Spyral™ multi electrode renal denervation system|Symplicity Spyral™ multi-electrode renal denervation catheter (Symplicity Spyral catheter, Medtronic) and associated Symplicity G3™ renal denervation radiofrequency generator (Symplicity G3 generator, Medtronic) will be used in this study. The Symplicity Spyral™ multi-electrode renal denervation catheter is intended to deliver low-level radio frequency (RF) energy through the wall of the renal artery to denervate the human kidney.
45506766|NCT04332731|Diagnostic Test|Renal angiogram|Renal angiogram will be used in both treatment and sham groups. Renal angiography is an imaging test used to study the blood vessels in the kidneys. The test will examine the kidney artery anatomy using x-rays following the injection of an x-ray dye (contrast medium). Only patients with eligible renal artery anatomy (between 3 mm and 8 mm) will be randomized ( to treatment or sham groups).
45506767|NCT04327141|Behavioral|P-IF|Protein pacing and intermittent fasting
45506768|NCT04327141|Behavioral|HH|Heart Healthy
45506769|NCT04316026|Device|shock wave therapy|Shockwave therapy is a non-invasive treatment creating a series of low energy acoustic wave pulsations that are directly applied through the skin via a gel medium
45506770|NCT04314375|Drug|Low Dose Budesonide|3 milligrams once daily for ages 5 to 11 years 11 months. 6 milligrams once daily for ages 12 to 17 years.
45506771|NCT04314375|Drug|High Dose Budesonide|6 milligrams once daily for ages 5 to 11 years 11 months. 9 milligrams once daily for ages 12 to 17 years.
45398555|NCT03937492|Other|GMI protocol|"This group follow GMI program split in 3 step:~left/right descrimination~visual motor imagery~mirror therapy~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week."
45506772|NCT04314375|Drug|Placebo|Matching placebo once daily.
45506773|NCT04309864|Device|Use of CMAP app for education (in-hospital)|Clinicians will use the updated CMAP system during patient education for prevention of pressure injuries with Veterans with SCI who are completing their initial rehabilitation.
45506774|NCT04309864|Device|Use of CMAP app (in-home)|The Veteran will use the CMAP system at home for two weeks during their daily routines.
45506775|NCT04290611|Drug|Enzalutamide|Enzalutamide for the treatment of prostate cancer or other solid tumors
45506776|NCT04283188|Behavioral|Dialectical behavioral therapy|Participants will be provided with the option to continue treatment with their study therapist. For those who elect to continue with DBT sessions, they will discuss frequency of sessions with their therapist, in addition to selecting type of sessions (individual and/or family skills). Participants who elect not to continue with DBT sessions at the time of enrollment will retain the option of being able to request additional sessions at any point during the 12-month study. Irrespective of participation in additional DBT sessions, all participants will be asked to complete follow-up interviews and questionnaires.
45398556|NCT03937492|Other|Standard Rehabilitation Protocol|"This group follow standard rehabilitation protocol, with active and passive motion of upper limb structure, including hand, wrist, elbow, shoulder.~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week."
45506777|NCT04865419|Drug|AZD0466|AZD0466 powder for concentrate for solution for infusion will be administered by IV infusion.
45697674|NCT04296838|Drug|intravitreal injection of Conbercept|patients will receive intravitreal injection of Conbercept, and at the same time, aqueous humor sample will be obtained from the anterior chamber to measure the concentrations of cytokines.
45506778|NCT04865419|Drug|Voriconazole|Voriconazole film-coated tablet will be administered orally.
45697675|NCT03228459|Diagnostic Test|Dried blood spot test|Dried capillary blood testing creatinine, uric acid and total cholesterol (reflotron® Plus system, Roche). Determination of the complete lipid profile in cases in which total cholesterol is greater than 200 mg/dl: HDL cholesterol (mg/dl), LDL cholesterol (mg/dl) and triglycerides (mg/dl) (Cobas B 101® system, Roche). Calculation of non-HDL cholesterol levels. Glycated haemoglobin will be analysed with the Cobas B 101 system,Roche. The CKD-EPI glomerular filtration rate will be determined.
46059107|NCT04332211|Procedure|Hyperbaric Oxygen Therapy|Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen delivery at a pressure greater than 1 atmosphere for the treatment of various emergent medical conditions.
45398557|NCT02529592|Biological|Endotoxin|
45398558|NCT02529592|Biological|Placebo|
45398559|NCT01118260|Procedure|total intravenous anaesthesia|propofol and remifentanil
45398560|NCT01118260|Procedure|spinal anaesthesia|bupivacaine and fentanyl
45398561|NCT01121770|Drug|fondaparinux sodium injection|1.5mg subcutaneously every day
45506779|NCT04279470|Drug|CAR T-cell and Cellular Therapies|Chimeric Antigen Receptor T-cell and Cellular Therapies for the treatment of a cancer either solid or hematologic malignancy
45506780|NCT04262206|Drug|Atorvastatin 40 Mg Oral Tablet|To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,
45506781|NCT04262206|Drug|Placebo oral tablet|To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,
45506782|NCT04261010|Procedure|Global/single cell gene expression profiles obtained from Synovial biopsies|Global/single cell gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug.
45506783|NCT04252235|Device|Air purifier|The intervention is the placement of active HEPA air purifiers in the bedroom and living room of the true air purifier arm. These air purifiers have been shown to reduce levels of particles in the home.
45506784|NCT04252235|Device|Sham air purifier|The intervention is the placement of sham HEPA air purifiers in the bedroom and living room. These purifiers look identical to real HEPA air purifiers, but do not filter the air.
45506785|NCT04225117|Drug|enfortumab vedotin|intravenous (IV) infusion
45506786|NCT04217473|Biological|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
45506787|NCT04216589|Drug|Semaglutide|Administered subcutaneously
45506788|NCT04204668|Procedure|TMR|Surgical procedure to connect injured proximal nerve stumps to motor nerve branches directly innervating a muscle
45506789|NCT04204668|Procedure|RPNI|Surgical procedure to wrap the ends of injured nerves in small muscle grafts
45506790|NCT04204668|Procedure|VDMT|Surgical procedure that creates a small muscle graft that is both denervated and vascularized, which will then receive the damaged nerve ending
45506791|NCT04201782|Drug|There are no disallowed treatments|Genetic: SB-728-T or SB-728mR-T No study drug is administered in this study. Subjects who received SB-728-T or SB-728mR-T in a previous trial will be evaluated in this trial for long-term safety and efficacy.
45506792|NCT04435340|Diagnostic Test|Selective Sonography of the ventral abdominal hernia level|The primary outcome of the study is measured by an radiologist experienced in abdominal ultrasound with a linear ultrasound transducer (ML 6-15 Hz). In case of aggravated examination circumstances a different ultrasound transducer is used (linear 9 L or convex C 1-6 Hz)
45398562|NCT01118416|Behavioral|HIV prevention intervention randomized control trial|Substance using HIV-negative young MSM who engage in sexual risk are randomized to either a motivational interviewing or an education condition to reduce sexual risk and drug use.
45506793|NCT04181515|Drug|Placebo oral tablet|placebo stressor
45506794|NCT04181515|Drug|Yohimbine + Hydrocortisone|Yohimbine 54mg + Hydrocortisone 20mg
45506795|NCT04181515|Device|sham rTMS|sham rTMS (inactive coil)
45506796|NCT04181515|Device|active rTMS|active rTMS (10 Hz dlPFC stimulation in group 1; 1 Hz mPFC stimulation in group 2)
45506797|NCT04180969|Drug|yohimbine + hydrocortisone|yohimbine 54mg + hydrocortisone 20mg oral
45506798|NCT04180969|Device|medial prefrontal cortex rTMS|1 Hz mPFC rTMS
45697676|NCT03228459|Diagnostic Test|Urine test|A urine sample from spontaneous micturition will be collected and analyzed using Clinitek Microalbumin 2 Reagent Strips and a Siemens Clinitek Status® analyzer. It will be determined albuminuria (mg/l) and albumin/creatinine ratio (mg/g).
45697677|NCT03228459|Diagnostic Test|Artery ultrasound|Carotid and femoral artery ultrasound for atheroma plaque diagnosis. Abdominal aorta ultrasound for early diagnosis of aortic aneurism. Transcranial ultrasound for cerebral arterial blood flow alterations.
45398563|NCT01585480|Behavioral|Weight Gain Prevention Intervention|"Behavioral Approaches~Distribution of pedometers~Traffic light labeling in worksite cafeteria and vending machines~Informational & Persuasive Messages~Stair use prompts~Posters, pamphlets, table toppers~Website~Social Approaches~a. Identification and training of influential employees (Peer Helpers) to shape healthy norms~Environmental Changes~Traffic light labeling~1/2 portions at 1/2 price~Walking routes~Introduction of healthier foods~Rearrangement of foods in the cafeteria~Adjusting serving spoon size"
45398564|NCT01121848|Drug|Leucovorin|"Pharmaceutical form:vials of 50 mg/5 mL or 500 mg/50mL Route of administration: IV~Dose regimen:"
45398565|NCT01121848|Drug|OXALIPLATIN|"Pharmaceutical form: Lyophilized powder for injection (50 mg/vial or 100 mg/vial) or aqueous solution (50 mg/10 mL and 100 mg/20 mL) Route of administration: IV~Dose regimen:"
45398566|NCT01121848|Drug|5-Fluorouracil|"Pharmaceutical form: vials of 5 g/100mL Route of administration: IV~Dose regimen:"
45398567|NCT01122004|Drug|Pregabalin|
45398568|NCT01122004|Drug|Pregabalin|
45506799|NCT04180969|Drug|Placebo oral tablet|placebo stressor
45398569|NCT03933982|Drug|Pyrotinib Plus Vinorelbine|Pyrotinib: 320mg/d, q.d., p.o. A course of treatment need 21 days. Vinorelbine: 60mg/m2 q.d. d1,8,15, p.o. A course of treatment need 21 day.
45398570|NCT01118572|Drug|YM177|oral
45506800|NCT04180969|Device|sham rTMS|sham mPFC rTMS
45506801|NCT04172649|Other|Acupuncture|On the day before surgery, patients randomized to the intervention groups will receive routine postoperative analgesic care with application of 6 bilateral press tack needles (diameter of 0.15mm and length of 0.6mm for P-6 and Shenmen, diameter of 0.20mm and length of 1.2mm for SP-6, Seirin New Pyonex, Seirin Corp., Shizuoka City, Japan).
45506802|NCT04172649|Other|Acupressure|On the day before surgery, patients randomized to the intervention groups will receive routine postoperative analgesic care with application of 6 bilateral press tack placebos (knob without needle, diameter of 0.15mm and length of 0.6mm for P-6 and Shenmen, diameter of 0.20mm and length of 1.2mm for SP-6, Seirin New Pyonex, Seirin Corp., Shizuoka City, Japan).
45506803|NCT04141605|Device|SherpaPak Cardiac Transport System|"The Paragonix SherpaPak Cardiac Transport System (SherpaPak CTS) is an ultraportable hypothermic preservation and transport system intended for use with donor hearts. The device is a legally marketed, FDA cleared medical device in the United States and CE Marked medical device in the European Union.~The SherpaPak CTS consists of multiple components: 1) outer transport shipper which contains within various non-ice based temperature controlled packaging elements, 2) an inner and outer hard shell assembly which provides a rigid barrier enclosure in which the heart is immersed and suspended in a cold storage solution cleared for use in storing and transporting donor hearts, 3) a data logger that monitors and displays the temperature of the cold storage solution in which the heart is stored during transport, and 4) four size heart connectors designed to accommodate various size aortic stem diameters by which donor hearts are attached."
45506804|NCT04131725|Device|Cardiac Performance System (NSR)|Device: Cardiac Performance System Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function. The device will be worn at the time when Pulmonary Artery Catheter procedures are conducted.
45506805|NCT04128969|Dietary Supplement|CS+|Oral carnitine supplementation
45398571|NCT01118572|Drug|etodolac|oral
45506806|NCT04128969|Dietary Supplement|CS-|Placebo
45398572|NCT01118572|Drug|Placebo|oral
45398573|NCT03937648|Drug|COL-144 50mg|COL-144 50mg
45398574|NCT03937648|Drug|COL-144 100mg|COL-144 100mg
45506807|NCT04123470|Genetic|delolimogene mupadenorepvec|LOAd703 is an oncolytic adenovirus encoding TMZ-CD40L and 4-1BBL
45506808|NCT04123470|Biological|atezolizumab|Atezolizumab is an anti-PD-L1 antibody
45506809|NCT04099810|Diagnostic Test|three-dimensional echocardiography|"A focused echocardiographic exam will be performed. In details will be acquired:~high frame rate imaging clips acquired in a static position with attention to endocardial border optimization, minimum of 3 beats recorded with 'Acquire 2', of: a. Left ventricle 2c/3c/4c; b. left ventricle SAB, SAX-M, SAX-A; c. right ventricular focused apical view.~Full volumes: a. 3d left ventricular apical acquisition; b. right ventricular apical acquisition; c. subcostal right ventricular acquisition."
45506810|NCT04097314|Drug|Zibotentan|10mg OD Zibotentan
45506811|NCT04097314|Drug|Placebo oral tablet|Placebo
45398575|NCT03937648|Drug|COL-144 200mg|COL-144 200mg
45398576|NCT03937648|Drug|COL-144 400mg|COL-144 400mg
45398577|NCT03937648|Drug|Placebo|Placebo
45398578|NCT01219036|Drug|Budesonide (directly observed)|Budesonide 1600 micrograms daily directly observed for 7 days
45398579|NCT03936010|Drug|Canagliflozin|Canagliflozin dispensing claim is exposure
45398580|NCT03936010|Drug|DPP-4 inhibitor|DPP4 inhibitor dispensing claim is reference
45398581|NCT01124500|Drug|methylphenidate via transdermal patch compared to placebo|The participants will start with a 10mg MPH patch on day -4, the 1st day of the titration period. This will be increased up to 20mg over 4-day titration period as needed and tolerated, and continued on the optimal dose. Subjects will be seen on day 1 of the double-blind part of the study at a patient education room or the Dr.'s office and receive 10 identical patches including 5 MPH and 5 placebo patches that will be randomly assigned over the 10-day course. The patch will be placed at 9am and removed at 4pm daily for 10 days. During the 10 days, each subject will be monitored for continuous 240 hours by actigraphy based activity monitors to follow activity levels and energy expenditure.
45506812|NCT04083495|Biological|ATLCAR.CD30 T cells|Autologous T Lymphocyte Chimeric Antigen Receptor cells targeted against the CD30 antigen at dose of 2 × 10^8 CAR-T/m^2 with a maximum dose of 5 × 10^8 CAR-T cells
45506813|NCT04083495|Drug|Bendamustine|70 mg/m^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first cell infusion
45506814|NCT04083495|Drug|Fludarabine|30 mg/m^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first and second cell infusion
45506815|NCT04083495|Drug|Cyclophosphamide|300 mg/m^2 administered IV for 3 days for lymphodepletion 2-14 days prior to second cell infusion and 2-14 days prior to the first cell infusion for subjects who have previously had hypersensitivity to bendamustine
45506816|NCT04082442|Drug|Evolocumab|420 mg evolocumab.
45506817|NCT04082442|Drug|Placebos|Matching placebo.
45506818|NCT04080518|Drug|Dapagliflozin 10 MG [Forxiga]|24 Hour Urine Collection, Sodium (23Na) MRI and Magnetic Resonance (MR) spectroscopy scan, Blood collection for metabolomic and osmolyte analysis
46059108|NCT04332211|Drug|Pseudoephedrine 60 MG|administer either pseudoephedrine or placebo orally to patients requiring hyperbaric oxygen therapy
46059109|NCT04332211|Drug|Placebo oral tablet|administer either pseudoephedrine or placebo orally to patients requiring hyperbaric oxygen therapy
45506819|NCT04074811|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|The investigators will use the Figure of 8 coil, which affects ~10cm2 of cortical surface. The active condition will deliver stimulation at 110% of resting motor threshold (RMT). To determine RMT, the protocol will be: 10 trials of single-pulse TMS on the scalp position of the abductor pollicis brevis muscle (which controls thumb flexion); RMT is the lowest TMS power setting yielding visible motor contraction on >50% of trials.
45506820|NCT04069052|Drug|Nitric Oxide|Gaseous pulmonary vasodilator, SoKinox (nitric oxide) flowed into a mask and breathed in.
45506821|NCT04069052|Drug|Placebo|Room air (placebo) flowed into a mask and breathed in.
45506822|NCT04060108|Drug|MDMA|80mg, 120mg, Placebo
45506823|NCT04058639|Procedure|"custom felt relief"|Felt is adjusted to the wound by cutting it in different ways and layers once every week
45398582|NCT01216306|Behavioral|Television reduction curriculum|Students are taught the television reduction curriculum during the school day (15-30 minutes/day) 3-5 days/week over 7 weeks. Parents are invited to attend brief after-school meetings every other week to discuss reducing their children's television viewing.
45398583|NCT03937414|Device|The OSNA assay|SLN was defatted after SLNB. If the node weighed less than 100mg, the node was only assessed by histology postoperatively. If the node weighed more than 100mg, the node was sliced to equal blocks according to the length of short axis: If the length was less than 4mm, the node was sliced into two blocks along the long axis (a, b). Intraoperatively, the block a and b were tested by TIC, and the block a was prepared for OSNA. Postoperatively, the block b was assessed by histology. If the length was more than 4mm, the node was sliced into four blocks (a, b, c, d). Intraoperatively, all blocks (a, b, c, d) were tested by TIC, and the block a and c were prepared for OSNA.
45398584|NCT01118884|Drug|Promethazine|Syrup ,1 mg/kg, oral , 30 minutes before dental procedure , its duration is 4-6 hours
45398585|NCT01216384|Drug|BI 671800|In the SRD part subjects will receive a single dose and in the MRD part subjects will receive a total of 14 doses.
45506824|NCT04058639|Procedure|standard relief treatment|Felt in the shape of a letter U is put around the wound once every week.
45506825|NCT04043936|Behavioral|Cognitive Bias Modification Intervention for Help-Seeking Stigma|Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.
45506826|NCT04043936|Behavioral|Placebo Cognitive Bias Modification (CBM-Placebo)|Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.
45506827|NCT04043936|Behavioral|Self-Directed Psychoeducation|Material presented with information on mental health literacy, mental health stigma, & treatment options. This is based on the idea that increasing knowledge about psychiatric symptoms and treatment options encourages help-seeking behavior and engagement.
45506828|NCT04042766|Procedure|laser vaginal treatment|Er:YAG laser
45506829|NCT04038515|Drug|Nicotine 0 mg/mL|E-liquid containing no nicotine (0 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
45506830|NCT04038515|Drug|Nicotine 6 mg/mL|E-liquid containing low nicotine (6 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
45506831|NCT04038515|Drug|Nicotine 12 mg/mL|E-liquid containing medium nicotine ( 12 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
45506832|NCT04038515|Drug|Nicotine 24 mg/mL|E-liquid containing high nicotine ( 24 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
45506833|NCT04038515|Other|'Menthol' flavor|E-liquid containing 'menthol' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
45506834|NCT04038515|Other|'Menthol/Mint' flavor|E-liquid containing 'menthol/mint' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
45506835|NCT04038515|Other|'Green Apple' flavor|E-liquid containing 'green apple' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
45506836|NCT04038515|Other|'Watermelon' flavor|E-liquid containing 'watermelon' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
45506837|NCT04038515|Other|'Unflavored'|E-liquid containing no additional flavor (i.e., 'unflavored') will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
45506838|NCT04036123|Other|Urodynamic investigation|Simultaneous UDI (same session repeat filling cystometry and pressure flow study) with an air-charged and water-perfused measurement system.
45506839|NCT04028843|Behavioral|Healthy Beginnings|The program includes a 24 week intensive behavior modification program that targets healthy gestational weight gain through self-monitoring of weight and activity data, automated prescriptive feedback from the smartphone application, personalized feedback from counselors and, evidence-based behavioral intervention delivered throughout pregnancy.
45398586|NCT01216384|Drug|placebo|Subjects will receive according to the dose group matching number of placebo tablets
45506840|NCT04023773|Device|Liver Machine Perfusion (MP) device|Donor livers will have ex vivo continuous perfusion on the institutional-developed Liver MP device. The temperature of liver grafts will be controlled during perfusion.
45398587|NCT01122082|Behavioral|food preloads|Subjects will eat in the morning during breakfast 300g cottage cheese (627kJ - 147kcal; 13.2g carbohydrate, 0.3g fat, 23g protein) plus, according to the situations, either: 90g sucrose, HCB); 6g aspartame; 40g vegetable oil; 40g paraffin oil. Therefore two breakfast will have the same energy content (2072kJ - 495kcal), as did the other two(565 kJ - 135kcal).
45506841|NCT04017598|Dietary Supplement|Ferrous sulfate|60 mg elemental iron as ferrous sulfate
45506842|NCT04017598|Dietary Supplement|Ferrous Bisglycinate|18 mg elemental iron as ferrous bisglycinate
45506843|NCT04017598|Dietary Supplement|Placebo of microcrystalline cellulose|placebo
45506844|NCT04014803|Drug|Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin|"Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin will be given according to the allocated arms in patients undergoing elective percutaneous coronary intervention for complex coronary lesion~Prasugrel plus Aspirin arm~Clopidogrel plus Aspirin arm"
45506845|NCT04011371|Procedure|Cyanoacrylate closure|Cyanoacrylate glue embolization targeting venous insufficiency
45506846|NCT04007471|Other|Anonymous survey|Anonymous questionnaire to determine the prevalence of dysmenorrhea of adolescent girls, to assess the severity of dysmenorrhea, how girls experience their menses, the consequences on daily living activities or at school, and how they manage their pain.
46059110|NCT05439655|Device|Brain Interchange System|The CorTec Brain Interchange (BIC) is an implantable system with sensing and stimulation capability dedicated to promoting brain computer interface and closed-loop neuromodulation research. It is an externally powered implant which can provide neural data to a nearby computing station (communication unit connected to a personal computer) continuously. In return, computing station controls the implant e.g. for generating therapeutic electrical stimulation to the brain. It is expected that BIC will catalyze translational applications of electroceuticals in human subject by making the neural data immediately available as well as permit the investigation of novel closed-loop neuromodulation applications.
45506848|NCT03994302|Drug|Drug inducing antiphospholipid syndrome|Drugs susceptible to induce immune toxicities such as antiphospholipid syndrome
45697678|NCT03228459|Diagnostic Test|Ankle-brachial index|Systolic blood pressure measurement in the brachial artery, posterior tibial artery and dorsalis pedis artery in both limbs. The ratios between tibial and pedal systolic blood pressure in each leg and the higher brachial blood pressure will be calculated.
45506849|NCT03985189|Drug|ME-401|"[Phase 1 study (DLT evaluation)] ME-401 will be administered at 2 dosages as 45 mg (Cohort 1) or 60 mg (Cohort 2), daily oral administration, QD, and the trial will be initiated at Cohort 1, and medical specialists and the Efficacy and Safety Assessment Committee as needed will decide whether the Cohort will be shifted to the next stage based on their assessment of the safety and tolerability.~[Roll over study] 60 mg ME-401 will be administrated on intermittent schedule (1 week on and 3 week off in every 4-week cycle)and will continue until the prescribed mediation in ME-401-004 study is completed or discontinuation criteria are met."
45506850|NCT03980184|Drug|Guanfacine|Guanfacine 3mg/day Versus Placebo
45506851|NCT03980184|Other|Behavioral Counseling|placebo
45506852|NCT03978481|Combination Product|Helicobacter pylori eradication (combination therapy)|Antibiotic eradication therapy (triple or quadriple regimen)
45506853|NCT03976349|Drug|BIIB094|Administered as specified in the treatment arm.
45506854|NCT03976349|Drug|Placebo|Administered as specified in the treatment arm.
45506855|NCT03975387|Drug|ASTX295|ASTX295 orally for 28-day cycle continuous or on an intermittent dosing schedule.
45506856|NCT03959410|Diagnostic Test|Cervical biopsy|in office Cervical biopsy
45506857|NCT03950453|Behavioral|Parenting Mindfully for Health Nutrition (PMH)|"PMH will include included the following components:~mindfulness strategies as outlined in the MBSR manual,~mindful parenting concepts,~mindful eating and awareness of family choices;~self and child monitoring of food intake, PA and emotional reactivity;~utilizing mindfulness for emotion regulation and distress tolerance,~behavioral strategies of goal setting and implementing increasing frequency of healthy food intake and physical activity (PA)"
45506858|NCT03950453|Behavioral|Contact Control Nutrition (C+N)|Contact Control Group where parents engage in a quiet, relaxing, but stimulating activity with stress reduction benefits.
45398588|NCT03933592|Procedure|Serratus anterior block|after induction of anesthesia and Patients will be placed in the lateral position with the diseased side up. A linear ultrasound transducer (10-12 MHz) will be placed over the mid-axillary region of the thoracic cage in a sagittal plane. The rib will be counted inferiorly and laterally, until the fifth rib is identified in the mid-axillary line. The following muscles will be identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22- G, 50 - mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance a bolus of 30 ml of 0.25% levobupivacaine 30 mint before skin incision. At the end of surgery, surgeon will put the catheter deep to serratus muscle and get it out with chest tube and fix it followed by an infusion of 5 ml/hour of 0.125% Levobupivacaine.
45398589|NCT03933592|Procedure|thoracic epidural|In group I: thoracic epidural inserted at low thoracic level in sitting position then test dose will be administered to detect any complications then a bolus of 10 ml of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery.
45506859|NCT03945903|Drug|Golimumab|Participants will receive subcutaneous (SC) golimumab, where doses will be based on weight and/or body surface area.
45506860|NCT03944876|Drug|Botulinum toxin type A|Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
45506861|NCT03944876|Drug|placebo|0.5 ml Sodium Chloride (NaCl) 0.9% Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
45398590|NCT01219192|Drug|M2ES|M2ES IV D1,8,15,21 every 28 days a cycle
45398591|NCT01219192|Drug|M2ES|M2ES IV D1,8,15,21, every 28days a cyce.
45398592|NCT01219192|Drug|M2ES|M2ES 45mg IV D1,8,15,22 28days a cycle
45398593|NCT01219192|Drug|M2ES 60mg|M2ES 60mg IV D1,8,15,22 every 28days a cycle
45398594|NCT01119196|Other|Icodextrin dialysate|use of alternate SOC dialysate
45506862|NCT03943589|Drug|Imlifidase|All subjects will receive imlifidase (Day 1) prior to standard care IVIg
45506863|NCT03942211|Drug|Selexipag|Oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 (200 µg) to 8 (1600 µg) tablets at each administration
45506864|NCT03942211|Drug|Placebo|Oral tablets without active compound. Participants can receive 1 to 8 tablets at each administration.
45506865|NCT03937219|Drug|Cabozantinib|Specified dose on specified days.
45506866|NCT03937219|Biological|Nivolumab|Specified dose on specified days.
45506867|NCT03937219|Biological|Ipilimumab|Specified dose on specified days.
45506868|NCT03937219|Drug|Cabozantinib-matched placebo|Specified dose on specified days.
45506869|NCT03934684|Drug|Drug: Carfilzomib + Dexamethasone|"Drug: Carfilzomib + Dexamethasone~Carfilzomib will be administered as a 30-minute infusion.~Dexamethasone will be taken by mouth or intravenously."
45506870|NCT03934684|Drug|Drug: Carfilzomib + Lenalidomide + Dexamethasone|"Drug: Carfilzomib + Lenalidomide + Dexamethasone~Carfilzomib will be administered as a 10 minute infusion.~Lenalidomide will be taken orally.~Dexamethasone will be taken by mouth or intravenously."
45506871|NCT03918460|Device|ANEUFIX|ANEUFIX is administered through translumbar injection into the AAA using imaging techniques to guide the place of injection.
45506872|NCT03905148|Drug|Lifirafenib|RAF Dimer Inhibitor
45506873|NCT03905148|Drug|mirdametinib|MEK Inhibitor
45398595|NCT01119274|Other|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
45398596|NCT01119274|Other|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
45398597|NCT01119352|Drug|AZD7687|Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.
45398598|NCT01119352|Drug|Placebo|Oral suspension, once daily. Totally 8 doses
45398599|NCT03935776|Behavioral|Risk Factors Modification Programme|12- week supervised risk factor modification programme derived from the Euroaction study standards
45398600|NCT03935776|Behavioral|Standard Healthcare|Patients are advised to adjust lifestyle without the support of the structured supervised programme
45398601|NCT01213888|Drug|Trientine Hydrochloride|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10-day course of oral Trientine at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
45398602|NCT01213888|Drug|Oral placebo capsules|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions
45398603|NCT01119430|Drug|DU125530|20mg/twice a day
45398604|NCT01119430|Drug|Placebo|Similar pill as active comparator twice a day
45398605|NCT03781336|Behavioral|Mindfulness-based self care|Experimental: an abridged mindfulness-based program that is incorporated into the work day, which consists of five weekly 1.5 hour sessions.
45398606|NCT02529124|Dietary Supplement|CONTROL|Maltodextrin (generic) in powder form, flavoured and instantised to be dissolved in water.
45398607|NCT02529124|Dietary Supplement|PROTEIN|The milk protein matrix (PROTEIN) comprised a 9:2:1 ratio of milk protein concentrate (MPC, 80% (w/w protein) Glanbia Nutritionals, Kilkenny, Ireland), whey protein concentrate hydrolysate, degree of hydrolysis 32% (WPC DH 32, 78% (w/w protein) Carbery Ingredients, Ballineen, Ireland), whey protein isolate hydrolysate, degree of hydrolysis 45% (WPI DH 45, 75% (w/w protein) Glanbia Nutritionals). The total protein content was 72.7g/100g powder. The protein matrix was supplemented with 2187mg/100g powder of milk-based calcium (Trucal™, Glanbia) and 57.3mg/100g powder vitamin D3 (cholecalciferol), flavoured and instantised to be dissolved in water.
45398608|NCT02529124|Behavioral|PHYSICAL ACTIVITY|A structured, progressive programme of exercises using resistance exercise bands supervised by clinical therapists undertaken three times per week for 24 weeks of the intervention.
45398609|NCT03780400|Behavioral|Osteoarthritis Physical Activity Care Pathway|The intervention includes brief physical activity (PA) counseling delivered via phone by a PA Counselor trained in relevant aspects of PA and motivational interviewing. During the initial call, the PA counselor will assess readiness for change in PA and will utilize appropriate PA counseling components to assess participant's PA preferences/needs, as well as referral to PA resources and goal setting. Approximately two weeks after the initial call, the PA counselor will contact participants to check in on whether they have successfully connected with PA programs or resources discussed, review progress toward PA goals and set new goals. Participants will be provided with linkage to PA programs and resources to include: self-directed, group classes/community, physical therapy and other clinical/supervised programs. Three months after the initial call, the PA counselor will call participants to assess PA and stage of change using appropriate PA counseling components and goal setting.
45398610|NCT03780244|Device|Sculptra Aesthetic 8ml|Treatment of nasolabial folds
45398611|NCT03780244|Device|Sculptra Aesthetic 5ml|Treatment of nasolabial folds
45398612|NCT03937336|Behavioral|Bike Intervention Group|A 1-month biking-based program. The biking program consists of 4 sessions/month of 120 min at physical education lessons in school, and will focus on promote biking through theory and practice lessons about cycle training skills including on-road training
45506874|NCT03875235|Drug|Durvalumab|IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
45506875|NCT03875235|Drug|Placebo|IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
45506876|NCT03873805|Biological|Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Given IV
45506877|NCT03873805|Drug|Cyclophosphamide|Given IV
45506878|NCT03873805|Drug|Fludarabine|Given IV
45506879|NCT03873805|Drug|Fludarabine Phosphate|Given IV
45506880|NCT03869268|Drug|Aspirin|Aspirin will be allocated in different doses and will be used in conjunction with ticagrelor depending on the arm of the trial the participant is randomised to. The different doses are as follows: 20 mg, 75 mg and 300 mg.
45506881|NCT03869268|Drug|Ticagrelor|Ticagrelor will be allocated as a single loading dose of 180 mg (2 x 90 mg orodispersible tablets) and will be used in conjunction with aspirin depending on the arm of the trial the participant is randomised to.
45398613|NCT01119586|Genetic|DNA analysis|
45398614|NCT01119586|Genetic|genetic linkage analysis|
45398615|NCT01119586|Genetic|microarray analysis|
45398616|NCT01119586|Genetic|nucleic acid sequencing|
45398617|NCT01119586|Genetic|polymerase chain reaction|
45398618|NCT01119586|Genetic|polymorphism analysis|
45398619|NCT01119586|Other|laboratory biomarker analysis|
45398620|NCT01119664|Drug|SCH 721015|
45398621|NCT01216618|Device|InsuPatch|the InsuPatchTM device includes a heating pad and electronics. The heating pad is attached to an existing insulin infusion set by a simple procedure.
45398622|NCT01119742|Drug|Butenafine Hydrochloride 1%|Twice daily application for 7 days
45398623|NCT01119742|Drug|Butenafine Hydrochloride 1% B|Twice daily application for 7 days
45506882|NCT03868397|Diagnostic Test|Liver MRI|"Liver MRI including 4D flow sequence is performed twice in liver transplantation recipients, before and 1 month-after transplantation.~In donor candidates, liver MRI including 4D flow sequence is performed twice in 1-3 weeks to assess repeatability of the technique."
45506883|NCT03845465|Behavioral|Positive Affect + Education|Adolescents will complete a health behavior contract and receive an educational packet at baseline. Adolescents will complete a positive affect interview at baseline. They will receive automated text messages 5 days/week for 8 weeks. Messages will be tailored to include adolescents' responses to the baseline interview, including reminders to engage in gratitude and self-affirmation. Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths.
45398624|NCT01119742|Drug|Butenafine Hydrochloride 1%|Twice daily application for 7 days
45506884|NCT03845465|Behavioral|Education|Adolescents will complete a health behavior contract and receive an educational packet with information about diabetes management.
45506885|NCT03843463|Drug|Escitalopram 10mg|Escitalopram tablet
45506886|NCT03843463|Drug|Placebo|Sugar pill manufactured to mimic escitalopram 10 mg tablet
45506887|NCT03843463|Behavioral|Computer-delivered naming treatment|15 45-minute sessions of computer-delivered naming treatment beginning two months following stroke
45506888|NCT03828942|Drug|drug inducing hematological toxicity|Drugs susceptible to induce hematological toxicities
45506889|NCT03826433|Biological|Peripheral iv|6*10^7 cells
45506890|NCT03816852|Biological|hucMSCs|Human umbilical cord mesenchymal stem cells were transplanted by intravenous infusion
45506891|NCT03808467|Behavioral|Cognitive Remediation Therapy|Nine individual transdiagnostic CRT sessions will be delivered once per week, each session lasting approximately 45 minutes. Building on previously published CRT manuals for anorexia nervosa and obesity, a transdiagnostic CRT manual developed for this project will be used during the course of CRT treatment. The manual comprises an introduction to CRT for eating disorders, and a detailed nine-session structure incorporating cognitive and behavioral tasks in the following domains; (1) planning-impulsivity, (2) flexibility-rigidity and (3) central coherence-attention to details. A certain set of guiding questions will accompany each task with the aim of stimulating metacognition (i.e. thinking about thinking).
45506892|NCT03808467|Other|Treatment as usual|According to Norwegian guidelines established by the Norwegian Directorate of Health, the patients are likely to receive treatment focusing directly on the ED symptomatology, i.e normalization of weight in the case of underweight, reduction of binging and purging and normalization of other ED related thoughts and behaviors. Since both in-patients, patients in day treatment and out-patients will be included in the study, the number of hours with therapeutic interventions will vary. Records of the participants' received number of therapeutic hours will be logged weekly during the intervention for participants in both arms of the study.
45506893|NCT03805932|Drug|Moxetumomab Pasudotox-tdfk|Moxetumomab pasudotox-tdfk is administered at 30-40 ug/Kg iv over 30 min given on days 1, 3, 5 of each cycle.
45506894|NCT03805932|Biological|Rituximab|Rituximab will be administered at 375mg/m^2 iv, 50-400 mg/hr. On cycle 1, Rituximab is given on day -2, on subsequent cycles, Rituximab is given on day 1.
45506895|NCT03805932|Biological|Ruxience|Ruxience will be administered at 375mg/m^2 iv, 50-400 mg/hr. On cycle 1, Ruxience is given on day -2, on subsequent cycles, Ruxience is given on day 1 (Delta)
45398625|NCT01119742|Drug|Vehicle A|Twice daily application for 7 days
45398626|NCT01119742|Drug|Vehicle B|Twice daily application for 7 days
45506896|NCT03796104|Other|Delta-haemolysin|comparison of groups having infection with S. aureus with and without delta-haemolysin Production
45398627|NCT01119820|Other|Tissue Donation|Females over 18 who are scheduled to undergo elective surgery will have discarded tissue collected.
45398628|NCT01219348|Biological|IDO peptide vaccination|Vaccination every second week
45398629|NCT01216696|Drug|ipilimumab|Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first.
45506897|NCT03775486|Drug|Durvalumab|Initial therapy phase: IV infusion q3w for 4 cycles. Maintenance phase: IV infusion q4w.
45398630|NCT01119976|Behavioral|Reduced calorie diet and exercise plan|Participants will receive written diet and exercise instructions to follow for the duration of the study.
45398631|NCT01119976|Behavioral|Different reduced calorie diet and exercise plan|Participants will receive written diet and exercise instructions to follow for the duration of the study.
45398632|NCT01216774|Other|Strength training|"Leg extension exercise:~Experimental: 60 repetitions at 20-25% of 1RM, 10-12 repetitions at 40% of 1RM Active Comparator: 10-12 repetitions at 80% of 1RM Placebo Comparator: 10-12 repetitions at 40% of 1RM"
45398633|NCT03935386|Procedure|Standard Multi-layered Compression dressing|Compression therapy with a multi-layered compression dressing for the treatment of venous leg ulceration
45506898|NCT03775486|Drug|Placebo for Olaparib|Matching tablet
45398634|NCT03935386|Procedure|Standard Multi-layered Compression dressing with a cryopreserved skin allograft (TheraSkin)|Application of a cryopreserved skin allograft (TheraSkin) beneath compression therapy with a multi-layered compression dressing.
45398635|NCT03937258|Drug|PF-04965842|Participants will be administered a single oral 200 mg dose of PF-04965842 in the morning on Period 1 Day 1 and Period 3 Day 2 under fasted conditions. In Period 2, participants will receive oral 200 mg dose of PF-04965842 once daily (QD) in the morning of Day 1 to Day 4 under fasted conditions
45398636|NCT03937258|Drug|Probenecid|In Period 3, participants will receive probenecid 1000 mg twice daily (BID) in the mornings and evenings of Day 1 to Day 3. On the morning of Period 3 Day 2, after an overnight fast of approximately 8 hours, participants will be administered probenecid 1000 mg. A single 200 mg oral dose of PF 04965842 will be administered approximately 2 hours after the probenecid dose.
45398637|NCT01124656|Drug|Pioglitazone-Azilsartan|Pioglitazone-Azilsartan (30 mg + 20 mg) or (45 mg + 20 mg), tablets, orally, once daily for up to 52 weeks.
45398638|NCT01122472|Drug|Lenalidomide|Daily for 3 weeks every 4 weeks for 24 months
45398639|NCT01122472|Drug|Placebo|Daily for 3 weeks every 4 weeks for 24 months
45398640|NCT01214122|Drug|AZD9668|60 mg orally twice daily for 11 days
45398641|NCT01214122|Drug|Warfarin|10 x 2.5 (25) mg orally once daily on day 1 and on day 14
45398642|NCT03935152|Drug|Dydrogesterone|dydrogesterone capsule
45398643|NCT03935152|Drug|placebo|placebo capsule
45398644|NCT01216852|Drug|Losartan Potassium|100 mg tablet
45398645|NCT03936868|Procedure|Tendon transfer|flexor carpi radialis transfer in most of patients and boye-transfer in very few
45398646|NCT03936946|Behavioral|Audio Content 1|~30 minute daily audio recordings of content 1 for 28 days
45398647|NCT03936946|Behavioral|Audio Content 2|~30 minute daily audio recordings of content 2 for 28 days
45398648|NCT01124812|Other|131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy|"Lung tumor irradiation with a total dosage of between 60-66 Gy, fractionated in combination with the following concurrent chemotherapy options:~Cohorts 1, 2 & 3a is composed of cisplatin i.v. 80 mg/m2 on day 1, and vinorelbine i.v. 25 mg/m2 on day 1, 8, 15 for cycle 1 & 4. For patients with significant comorbidities, the dose of vinorelbine is reduced to 12.5 mg/m2 during cycles 2 & 3. Treatment cycles will be repeated every 28 days.~Protocol A (suggested for patients with comorbidities: Carboplatin 70 mg/m2, over 30 min iv, (Day 1-5 ) + Vinorelbine 12.5 mg/m2 as a 5-min bolus iv or short iv-infusion (Day 1, 8, 22), repeated on Day 28.~Protocol B (suggested for patients in good clinical condition): Paclitaxel 50 mg/m2 1 hour iv (Day 1, 15, 22, 29, 36, 43, 50) + Carboplatin AUC 2, 30 min iv on (Day 1, 15, 22, 29, 36, 43, 50).~Total treatment duration is 8-16 weeks"
45398649|NCT01328860|Biological|bone marrow progenitor cells (BMPC) autologous transplantation|Not more than 5ml/kg bone marrow will be collected under anesthesia; after the bone marrow has been processed, about 6-8 hours after bone marrow aspiration, subjects will receive the cells via intra-venous (in the vein) infusion and will be monitored for 24 hours for any adverse events.
45398650|NCT01216930|Other|Observation|Observation
45398651|NCT01124968|Other|eConsulta|It is a web specifically designed for the project where elected patients can consult virtually with their primary care physician and within 48 hours have an answer.
45398652|NCT03933748|Drug|Teicoplanin-PMMA|Therapeutic drug monitoring of teicoplanin
45398653|NCT01120132|Drug|CsA high dose|Solution of Cyclosporine (high dose) administered during 28 days
45398654|NCT01120132|Drug|CsA low dose|Solution of Cyclosporine (low dose) administered during 28 days
45506899|NCT03775486|Drug|Olaparib|150-mg tablets (2 × 150-mg tablets for 300-mg dose) 100-mg tablet available if dose reductions are required
45506900|NCT03775486|Drug|Nab-paclitaxel+carboplatin|Standard of Care chemotherapy (squamous and non-squamous patients)
45506901|NCT03775486|Drug|Gemcitabine+carboplatin|Standard of Care chemotherapy (squamous patients only)
45398655|NCT01120132|Drug|PA|Suspension of Prednisolone Acetate administered during 28 days
45398656|NCT01120132|Drug|Placebo|Placebo solution administered during 28 days
45398657|NCT01120288|Drug|EZN-2968|
45398658|NCT01214278|Drug|rTG|EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil; uncoated capsules (4 per day); 2016 mg n3 fatty acids daily (1008 mg EPA and 672 mg DHA)
45506902|NCT03775486|Drug|Pemetrexed+carboplatin|Standard of Care chemotherapy (non-squamous patients only)
45506903|NCT03775486|Drug|Gemcitabine+cisplatin|Standard of Care chemotherapy (squamous patients only)
45506904|NCT03775486|Drug|Pemetrexed+cisplatin|Standard of Care chemotherapy (non-squamous patients only)
45398659|NCT01214278|Drug|GArTG|EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG); 4 capsules per day; 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
45398660|NCT01214278|Drug|EE|EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules (4 per day); 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
45506905|NCT03772717|Device|VitalStim 400|The nVNS study intervention will be delivered using a handheld electrical neuromuscular stimulator device (VitalStim 400). Participants will deliver nVNS twice per day for 60 minutes each time for 2 years. The two electrodes for the device are placed on the left cervical (neck) region or on the left ear. Parents will be trained on where to place electrodes, how to ensure that the electrodes make a good contact with the skin, and how to set the stimulation parameters. The stimulation frequency (number of pulses) and amplitude (amount of current) will be set during the initial baseline session in the clinic at a level that prevents discomfort and does not impact cardiorespiratory parameters.
45506906|NCT03772717|Device|VitalStim400|Patients will be asked to continue their standard medication regimens which include in most cases will involve 3 weekly infusions of intravenous immunoglobulin (IVIG) (1 gm/kg) and rarely plasma exchange (PLEX).
45506907|NCT03755791|Drug|Cabozantinib|Supplied as 20-mg tablets; administered orally daily at 40 mg
45506908|NCT03755791|Drug|Cabozantinib|Supplied as 60-mg tablets; administered orally once daily at 60 mg
45506909|NCT03755791|Drug|Sorafenib|Supplied as 200-mg tablets; administered orally twice daily at 400 mg
45398661|NCT01214278|Drug|KPL|DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL); 7 capsules per day; 2100 mg n-3 fatty acids (1050 mg EPA and 630 mg DHA)
45398662|NCT01217008|Biological|GRNOPC1|One injection of 2 million GRNOPC1 cells.
45398663|NCT01120366|Drug|Tocilizumab plus methotrexate|Tocilizumab 8mg/kg 4weeks (i.v.) plus methotrexate up to 52weeks.The dosage of MTX will be fixed at least 24 weeks from the start of the study.
45398664|NCT01120366|Drug|Tocilizumab|tocilizumab 8mg/kg/4weeks (i.v.) up to 52weeks.
45398665|NCT01219426|Other|Filling of three questionnaires|The only intervention of the study was the completion of the three questionnaires, and of a mini-questionnaire assessing gender, age, and gambling activities.
45398666|NCT01217086|Drug|Infliximab|Infliximab 3mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
45398667|NCT01217164|Dietary Supplement|no intervention|received enteral diet with 4.5 g / kg / day of protein and 160cal/Kg/dia
45398668|NCT03933436|Other|Iodine swabs.|Children will then have their periurethral region gently cleansed for ten seconds with iodine swabs.
45506910|NCT03755791|Drug|Atezolizumab|Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
45697679|NCT03228459|Diagnostic Test|Spirometry|Spirometry will be used to assess lung capacity. It will be performed by the same nurse who will measure forced vital capacity (FVC); forced expiratory volume in one second (FEV1); the ratio between FEV1 and FVC and the lower limit of normality, as a percentage.
45398669|NCT03933436|Other|Saline flush.|Children will then have their periurethral region gently cleansed for ten seconds with saline flush.
45398670|NCT01120444|Device|BD Research Catheter with 34G x 1.5 mm needle|bolus injection of insulin given intradermal prior to standardized meal
45398671|NCT01120444|Device|Subcutaneous delivery of insulin using Disetronic Accu-Chek Rapid D infusion set|bolus delivery of insulin given subcutaneously prior to standardized meal
45398672|NCT03934996|Other|Runners with educational training|"Intervention will consist of an educational talk to know the anatomy and function of the Pelvic Floor Muscles and 20 minutes of both strength and endurance exercises with biofeedback. An exercise protocol will be carried out. The participants will be instruct to contract and maintain maximum force for a mean period of 6 seconds (endurance training) and rest for twice the length of the endurance training time, followed by three fast contractions in a row as strength training. It will be done twice a week, during 12 weeks.~Pelvic floor assesment: Perineometry, manual palpation, electromyography Trunk and lower limbs electromyography and kinematics"
45506911|NCT03726086|Diagnostic Test|laryngoscopy|A flexible camera (fiberoptic endoscope) is placed in the patient's nose to view the nose, throat, and airway.
45398673|NCT01214512|Other|blood-sample based diagnostic assay|A blood sample will be used in a Western blot and ELISA assay to determine CD24 levels
45398674|NCT01217320|Dietary Supplement|creatine|5g/d throughout 12 weeks
45506912|NCT03705156|Drug|ZL-2306(nirapairb)|The starting dose is 300 mg or 200 mg based on patient's body weight.
45697680|NCT03228459|Diagnostic Test|Determination of advanced glycation-end products|These will be measured using skin autofluorescence (SAF) in the forearm with the AGE Reader® system (Diagnostics, the Netherlands). SAF is measured using spectrophotometry which is calculated as the relationship of the intensity of reflected light compared to refracted light.
45398675|NCT01217320|Dietary Supplement|placebo (dextrose)|5g/d throughout 12 weeks
45506913|NCT03705156|Drug|Placebos|The starting dose is the matched dose of placebo (3 capsules or 2 capsules).
45506914|NCT03686371|Procedure|posterior surgery for spinal arthrodesis|posterior surgery for spinal arthrodesis
45506915|NCT03673709|Behavioral|Antenatal Care|Women in group care bypass the waiting room and have a 2-hour visit with the same provider with a group of 8-12 women at a similar stage of pregnancy. Women assess their own blood pressure and weight, briefly consult the midwife in a corner of the room, and meet for 80-90 minutes of interactive health promotion, enlivened by games and role-plays.
45506916|NCT03671694|Procedure|Erbium-YAG laser vaginal treatment|Erbium-YAG laser vaginal treatment
45506917|NCT03667339|Procedure|Direct Anterior Total Hip Arthroplasty|Direct Anterior Total Hip Arthroplasty
45398676|NCT03936712|Dietary Supplement|Energy Drink|Each participant visited the laboratory for two formal test sessions, drinking a caffeine-containing ED (RB) and a caffeine and taurine free beverage drink (PL). All sessions were arranged in the early evening hours to avoid any time of day effects. The two definitive test sessions were separated by an interval of seven days to allow sufficient recovery between tests and to ensure caffeine washout. To avoid identification, two opaque and unmarked cans of RB or PL were ingested by each participant (i.e., 500 mL) in the presence of a researcher. The two drinks were similar in volume, texture, and appearance. One can of RB drink (i.e., 250ml) contained 80 mg of caffeine, 1 g of taurine, 27 g of carbohydrates, 0.6 g of protein, 5 mg vitamin B6 and 487 kJ of energy.
45398677|NCT03936712|Dietary Supplement|Placebo Drink|The PL drink was prepared by an agri-food engineer; it did not contain any caffeine or taurine, but comprised carbonated water, carbohydrates, citric acid lemon juice reconstituted from concentrate (1 %), supplemented by flavorings, of sodium citrate, acesulfame K, sucralose, potassium sorbate and RB (a flavoring that contains propylene glycol E1520 (0.23 mL).
45398678|NCT01214590|Device|VascuActive device|self treatment by the patient, for 4 weeks, 3 sessions per day, approximately 30 minutes per session
45398679|NCT02529046|Dietary Supplement|CLA|CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%). Aerobic exercise associated with CLA
45398680|NCT02529046|Behavioral|Placebo|Placebo group received 4 g/day of olive oil. Aerobic exercise
45398681|NCT01217398|Biological|bevacizumab|
45398682|NCT01217398|Drug|temozolomide|
45398683|NCT01217398|Genetic|polymorphism analysis|
45398684|NCT01217398|Other|pharmacogenomic studies|
45398685|NCT01125124|Drug|Silver Nitrate|Instilation of silver nitrate solution through the pleural catheter. The catheter remains closed for 1h after the procedure and is then reopened. There will be 3 different dosages, corresponding to the 3 different arms.
45398686|NCT01214746|Drug|Placebo|1 tablet Unikalk 1 time pr day for 5 days
45398687|NCT01214746|Drug|Atorvastatin|Zarator, 80 mg pr day for 5 days
45398688|NCT03935074|Drug|intra-arterial administration of melphalan|
45398689|NCT01120522|Device|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
45398690|NCT01125280|Procedure|Conservative treatment versus surgical treatment|Conservative treatment: starving, nasogastric tube Surgical treatment: open laparotomy, adhesiolysis, with or without small bowel resection
45398691|NCT01217632|Drug|FG-3019|FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
45398692|NCT01217632|Drug|Placebo|Placebo will be administered every 3 weeks by intravenous (IV) infusion in a total volume of at least 250 mL in normal saline.
45398693|NCT01217632|Drug|Entecavir|
45398694|NCT01122628|Device|ORIF with DVR-A locking plate|Size, length of plate and number os screws decided by operating surgeon
45398695|NCT01217710|Behavioral|Activity monitor/smartphone health coaching|Initial health coaching at enrollment will involve the collaborative creation of an action plan with personally relevant, specific actions for increasing physical activity. The short term goals will be rated for self-efficacy and modified to maximize likelihood of success. Health coaches will discuss important mediators of physical activity (e.g., self-efficacy, enjoyment, social support, problem-solving). Weekly coaching calls will involve discussion of progress toward goals and problem-solving of barriers utilizing a motivational interviewing approach. Motivational messages will also be developed and sent daily to participants via the smartphone. These messages will indicate the percentage of steps related to their daily goal.
45398696|NCT03933280|Drug|Nalbuphine|i.v. nalbuphine bolus of 50 μg/kg.
45398697|NCT03933280|Drug|Propofol|A bolus i.v. dose of propofol 0.5 mg/kg followed by an infusion of 0.025 mg/kg/min
45398698|NCT03933280|Drug|Dexmedetomidine|i.v. loading dose of dexmedetomidine 1 μg/kg over 10 min followed by a maintenance infusion of 0.5 μg/kg/h.
45398699|NCT03933280|Drug|Benoxinate Hydrochloride 0.4% Eye Drops|Benoxinate hydrochloride 0.4% eye drops instilled twice, 5 minutes apart.
45398700|NCT01217788|Drug|PH94B intranasal spray|Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray
45398701|NCT03933514|Other|Plaque control|Children were instructed about the hygiene procedures
45506918|NCT03660930|Drug|Sirolimus Albumin-bound Nanoparticles|Given IV
45506919|NCT03660930|Drug|Pazopanib hydrochloride|Given PO
45506920|NCT03648372|Drug|TAK-981|Intravenous infusion.
45697681|NCT03228459|Diagnostic Test|Atrial fibrillation screening|The presence of atrial fibrillation is assessed with a device (SRA, EVINA Health Solutions) during one hour in the mobile unit.
45398702|NCT03936556|Drug|Marketed toothpaste|Marketed stannous fluoride (0.454%) toothpaste
45398703|NCT03936556|Drug|Marketed Cavity Protection Toothpaste|Marketed sodium monofluorophosphate (0.76 %) toothpaste
45398704|NCT01120912|Drug|Oshadi Oral Insulin|Oral insulin single administration
45398705|NCT01217866|Procedure|Laparoscopic assisted vaginal hysterectomy|Surgical removal of uterus vaginally
45506921|NCT03643796|Drug|Remifentanil|Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.
45506922|NCT03643796|Drug|Ketamine|Ketamine infusion of 2 mcg/kg/minute will be started at induction. It will be stopped at the beginning of the emergence from anesthesia, roughly 45 minutes from extubation.
45398706|NCT01122706|Other|Taiji training|Taiji training during 12 weeks (twice a week for 1 hour) (Sept. 6th till Nov. 25th 2010). The first 18 sequences of a series of 37 movements of the short form Yang style Taiji will be taught. The focus will be on memorizing the series of movements, developing a regular training routine and working on body alignment and flow of the movements.
45398707|NCT03785548|Other|Usage of a mirror|using a mirror during the pelvic examination
45398708|NCT01219582|Drug|Glucobay M (Acarbose/Metformin, BAY81-9783)|Oral Glucobay-M 25 every 8 hours (Q8H) titrated to Glucobay-M 50 Q8H or as per investigators discretion.
45398709|NCT03934918|Other|Treatment|Patients for IOL are sent home after placement of intracervical balloon
45398710|NCT03933358|Other|Thyroid hormone levels|This is an observational study. Exposure: Different thyroid hormone levels.
45398711|NCT01121068|Other|Blood samplings|About 3.5ml of blood will be drawn from the participants monthly.
45398712|NCT01122940|Drug|Epamin: Reference Drug|Single dose of 75 mg (10 ml in suspension) of Epamin
45398713|NCT01122940|Drug|Phenytoin: Study Drug|Single dose of 75 mg (10 ml in suspension) of Phenytoin
45398714|NCT01214902|Device|Constraint induced movement therapy (CIMT)|soft mitten worn on the non hemiplegic hand
45398715|NCT01214902|Behavioral|play|play which encourages the use of the hemiplegic hand
45398716|NCT03934762|Biological|Placebo|A placebo solution that will not include aloe vera will be applied on the quadriceps of one of the lower limbs.
45398717|NCT03934762|Biological|Natural Aloe Vera|Natural aloe vera solution including peel and leaf from aloe will be applied on the the quadriceps of one of the lower limbs.
45398718|NCT03934762|Biological|Aloe vera soup|Aloe vera solution including aloe vera soup will be applied on the the quadriceps of one of the lower limbs.
45398719|NCT01219816|Drug|Epratuzumab|Combination of chemotherapy + Epratuzumab
45398720|NCT01219816|Drug|Epratuzumab|Vincristine + Dexamethasone + Epratuzumab
45398721|NCT01121302|Drug|AZD5213|0.1 mg, 0.3 mg, 1 mg, 2 mg, 4 mg, 8 mg, 16 mg, 32 mg oral solution, single ascending doses
45398722|NCT01121302|Drug|Placebo|
45506923|NCT03643796|Drug|Dexmedetomidine|dexmedetomidine bolus of 0.5 mcg/kg over 10 minutes starting 5 minutes prior to induction followed by an infusion of 0.2-0.7 mcg/kg/hour that will be stopped with the start of closing the surgical wound.
45506924|NCT03623854|Biological|Nivolumab|Given IV
45506925|NCT03623854|Biological|Relatlimab|Given via infusion
45506926|NCT03592264|Drug|OBI-3424|liquid formulation for Intravenous infusion
45506927|NCT03584334|Radiation|18FDG PET|Diagnostic performance of 18FDG PET for identification of early tumor escape to immunotherapy in patients with unresectable melanoma or Broncho-Pulmonary Carcinoma No to Advanced or Metastatic Small Cells
45506928|NCT03575884|Behavioral|Screen Time Reduction Curriculum|"Fit5Kids classroom curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices offered over 7-8 weeks in the Fall semester. The classroom component will be taught by bilingual (English/Spanish) research staff interventionists. Parent newsletters, goal setting, and text messages will be offered in English and Spanish per parent preference. There will also be two booster weeks of classroom activities, daily parent newsletters, goal setting, and daily text messages on screen time parenting practices offered during the booster weeks in the Spring semester. The lending library of resources for parents/children will be available throughout the entire school year."
45506929|NCT03560167|Device|AccuCinch® Ventricular Restoration System|AccuCinch® Ventricular Restoration System in Patients with Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation
45506930|NCT03531892|Drug|AJM300|AJM300 film-coated tablets.
45398723|NCT01121380|Drug|BL-1021|"BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.~Dosage:~Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 & 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results."
45506931|NCT03531892|Drug|Placebo|Placebo matched to AJM300 tablets.
45506932|NCT03531502|Procedure|Ventricular Tachycardia Ablation|Ventricular Tachycardia Ablation
45849802|NCT04637724|Device|transcranial direct current stimulation (tDCS)|10 sessions of Anodal tDCS of the dorsolateral prefrontal cortex over a period of 5 consecutive days (two session a day). Each session includes the placement of two tDCS electrodes (anodal at left prefrontal area and cathodal above the vertex) and 20 mins of anodal prefrontal stimulation. The tDCS session is received two time a day with a 3-5 hours interveal betwen sessions.
45398724|NCT01121380|Drug|1021|1021
45398725|NCT01123096|Procedure|Cough Stress Test|A cough stress test is performed by using a catheter to introduce 300ml of sterile water into the bladder. The patient is then asked to stand and cough forcefully and the clinician will observe for urine loss.
45398726|NCT01123096|Other|24 Hour Pad Test|The patient will be provided with a standard number of pads in a sealed bag that have been pre-weighed. The patient will wear the pads for 24 consecutive hours then return the all the pads within the bag for weighing post usage.
45398727|NCT01215136|Drug|Everolimus|10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
45398728|NCT01215136|Drug|Everolimus|10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
45398729|NCT01215136|Drug|Paclitaxel|Paclitaxel 80 mg/m2 IV as a 1 hour infusion on days 1, 8, and 15, of a 28-day cycle.
45398730|NCT01125592|Device|IonCLeanse Footbath|Application of an ionic footbath for 30 minutes per week for 4 weeks
45398731|NCT01218022|Drug|Losartan Potassium Tablets|
45398732|NCT01123174|Behavioral|ALGOS algorithm of case management|"If the subject survives one 1st SA (first attempter): he leaves the center where he was included with a chart resource (crisis card) which contains addresses of the Web sites of associations of prevention of the suicide, as well as an accessible phone number 24/24h.~If the subject is not a first attempter : he will be recontacted on the telephone between the 10th and the 21st day following the SA. If the subject is not contacted or little observing in the plan of care, it will receive a series of postcards then regularly, with 4 recoveries: to 2, 3, 4 and 5 months after the attempt."
45506933|NCT03531502|Other|Standard Medical Therapy|For the antiarrhythmic naïve patients, the attending physician may initiate therapy with sotalol or amiodarone. For patients already on therapy with sotalol or amiodarone, the attending physician may choose to either increase the dosage/ frequency of these medications and/or add mexiletine to the regimen. Other alterations to medical therapy, such as adjusting the dose of beta-blockers, calcium-channel blockers, anti-hypertensive, diuretic or anti-anginal medications may be performed at the discretion of the attending physician.
45506934|NCT03531502|Procedure|Non-Invasive Programmed Stimulation (NIPS)|All patients will receive this procedure in attempt to induce ventricular tachycardia. The outcome of this procedure determines if a patient will be randomized.
45506935|NCT03530215|Drug|Antineoplastic and Immunomodulating Agents|Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
45506936|NCT03520075|Drug|ASTX029|Described above
45506937|NCT03505424|Other|Group 1: Standard of Care|"Those who are in Group 1 will receive the usual care which includes:~a welcome packet from the nursing staff~access to their infant's medical team including doctors and nurse~opportunities to ask any questions and understand the care their baby is receiving through participation in daily work rounds or through setting up family meetings with the medical team."
45506938|NCT03505424|Other|Group 2: NICU2HOME app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 2 parents will be asked to download the NICU2HOME app.
45506939|NCT03505424|Other|Group 3: SMART NICU2HOME app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 3 parents will be asked to download the SMART NICU2HOME app.
45506940|NCT03487926|Radiation|[18F]FEPPA|up to 3 PET Scans ([18F]FEPPA PET scans done 3 to 6 months apart, and one [11C]SL2511.88 PET scan) and 1 MRI
45506941|NCT03475277|Drug|Ketamine|Acute administration
45506942|NCT03472274|Drug|Durvalumab|Durvalumab 1500 mg every 4 weeks x 3 cycles
45398733|NCT01121458|Drug|Clevidipine|The clevidipine infusion is to be administered via IV infusion at a starting dose of 0.5 mg/hour. The dose may be doubled every three (3) minutes to a maximum dose of 32 mg/hr as tolerated, until a 20% reduction in PVR is achieved or until the patient experiences hypotension (SBP< 80 mmHg), hypertension (SBP>150 mmHg), tachycardia (120 beats per minute), bradycardia (<50 beats per minute), or symptoms of hypotension or ischemia (chest pain, anxiety, nausea, vomiting), allergic reaction (hives, urticaria) or other adverse event. Clevidipine infusion may be terminated at any time for a safety reason or at the investigator's discretion.
45506943|NCT03472274|Drug|Tremelimumab|Tremelimumab 75 mg every 4 weeks x 3 cycles
45506944|NCT03472274|Drug|Cisplatin-based neoadjuvant chemotherapy|"Regimen 1: 21-day treatment cycle x 3 cycles.~Gemcitabine 1,000-1,200 mg/m2 intravenously on days 1 and 8 every 21 days.~Cisplatin 70 mg/m2 intravenously on day 1 every 21 days. Regimen 2: ddMVAC 14-day treatment cycle x 4 doses.~Methotrexate 30mg/m2 intravenously on day 1~Vinblastine 3mg/m2 intravenously on day 2~Doxorubicin 30mg/m2 intravenously on day 2~Cisplatin 70mg/m2 intravenously on day 2 Granulocyte colony-stimulating factor (G-CSF) for 7 consecutive days (days 4 through 10).~Regimen 3: 21-day treatment cycle x 3 cycle~Gemcitabine 1,000 mg/m2 intravenously on day 1 and 8~Paclitaxel 80 mg/m2 intravenously on day 1 and 8~Cisplatin 70mg/m2 intravenously on day 1"
45506945|NCT03456284|Device|Normothermic Liver perfusion|The liver grafts will be preserved and evaluated at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase
45506946|NCT03437928|Device|Directional Deep Brain Stimulation|Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
45506947|NCT03436433|Drug|Lacosamide|LCM 100mg twice a day.
45506948|NCT03436433|Drug|Levetiracetam|LEV 1000mg twice a day.
45506949|NCT04227275|Biological|CART-PSMA-TGFβRDN|Intravenous administration of genetically modified autologous T cells engineered to express a protein capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA), as well as a dominant negative TGFβ receptor
45506950|NCT04227275|Drug|Cyclophosphamide|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
45506951|NCT04227275|Drug|Fludarabine|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
45506952|NCT04227275|Drug|Anakinra|In applicable cohorts, patients will receive anakinra prophylactically starting on the day of administration of investigational product, CART-PSMA-TGFβRDN genetically modified T cells
45506953|NCT03432832|Behavioral|EASE|Weekly behavioral sessions with therapist to work on emotional control through measures such as mindfulness.
45506954|NCT03432832|Behavioral|Supportive Therapy|Weekly behavioral sessions with a therapist to work on emotional control
45506955|NCT03425318|Device|CNAP|Application of CNAP in patients with ARDS
45506956|NCT03415854|Drug|Paricalcitol (Zemplar)|combination therapy
45506957|NCT03405090|Drug|Fentanyl Citrate|100 mcg fentanyl citrate will be inhaled via nebulizer
45849803|NCT04626804|Other|Remember Stuff: A Dyadic-focused Technology to Support Persons with Alzheimer's Disease in the Community|testing the usability, perceptions, and acceptability of R/S among dyads of older adults with early Alzheimer's disease and other related dementias
45849804|NCT04610736|Drug|Temozolomide Oral Suspension|One prescribed oral dose (range 75 to 200 mg/m2) once daily for 5 days
45849805|NCT04610190|Device|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with device.
45506958|NCT03405090|Drug|Combivent|0.5 mg ipratropium bromide + 2.5 mg salbutamol will be inhaled via nebulizer
45506959|NCT03383081|Biological|Low dose mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 * 10^7 cells (5ml);
45506960|NCT03383081|Biological|High dose mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (SCLnow 19#): group B, 2 * 10^7 cells (5ml)
45506961|NCT03383081|Procedure|Intraarticular injection|Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group
45506962|NCT03378414|Procedure|Intravenous infusion|Intravenous infusion of mesenchymal stem cells: 2 * 10^7 cells (30ml)
45398734|NCT03936322|Device|Minimally invasive fetoscopic repair of MMC|Uses a technique to open your belly (skin, muscles and abdomen) without opening the uterus, except for a small puncture, to repair the fetal spina bifida defect during the second trimester of pregnancy.
45398735|NCT01215214|Drug|midazolam|midazolam: 3mg iv
45398736|NCT03936166|Drug|CRN01941 Oral Solution|Investigational drug
45398737|NCT03936166|Drug|CRN01941 Oral Capsule|Investigational drug
45398738|NCT03936166|Drug|Placebo Oral Solution|Placebo
45398739|NCT03936166|Drug|Placebo Oral Capsule|Placebo
45398740|NCT01215370|Other|High-fat shake with Pea protein|Shake containing 95 gram of fat, additive 30 gram pea protein
45398741|NCT01215370|Other|High-fat shake with Pea protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten protein hydrolysate
45398742|NCT01215370|Other|High-fat shake - Control|Shake containing 95 gram of fat, no protein additive
45398743|NCT01215370|Other|High-fat shake with Gluten protein|Shake containing 95 gram of fat, additive 30 gram gluten protein.
45398744|NCT01215370|Other|High-fat shake with Gluten protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten gluten hydrolysate
45398745|NCT01123252|Dietary Supplement|Lactobacillus casei Shirota (LcS)|Subjects will receive one bottle of Yakult containing the probiotic bacterium Lactobacillus casei Shirota (active drink) once daily for 4 months (16 weeks).
45398746|NCT01123252|Dietary Supplement|Placebo|Subjects will receive one bottle of a placebo milk drink, once daily for 4 months (16 weeks).
45398747|NCT01218178|Drug|Sodium bicarbonate plus NAC|154 mEq/L sodium bicarbonate (infusion rate of 3 ml/Kg for 1 hour followed by 1 ml/Kg for 6 hours) plus NAC (1200 mg bid for 48 hours)
45398748|NCT01218178|Drug|Saline hydration plus NAC|0.9% saline (1 ml/Kg for 12 hours) plus NAC (1200 mg bid for 48 hours)
45398749|NCT01215448|Dietary Supplement|Wheatgrass juice|110 CC daily od frozen wheatgrass juice in the intervention arm
45398750|NCT03936400|Behavioral|Couple-based intervention and and evaluation of effectiveness in increasing adjustment of sexuality and intimacy|Three face-to-face therapeutic conversations and an optional web-based evidence based information (about sexual consequences of cancer treatment)
45398751|NCT03740854|Other|Pressure Controlled Ventilation|Patients will be ventilated with a pressure level which supplies a tidal volume corresponding 8ml/kg, 12 breaths per minute, 1/2 inspiration/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
45398752|NCT03740854|Other|Volume Controlled Ventilation|Patients will be ventilated with a tidal volume which corresponds 8ml/kg, 12 breaths per minute, 1/2 inspirastion/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
45398753|NCT01125670|Drug|YM150|oral
45849806|NCT04591236|Device|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to Parkinson patients.
45849807|NCT04591236|Device|Treadmill gait training|Treadmill gait training was applied to Parkinson patients.
45398754|NCT03934528|Device|Virtual environment activity|Patients undertake an activity using simulated arm movement within a virtual reality environment every day for two months
45398755|NCT01218256|Other|Physical exercise training|aerobic endurance training (cycle ergometer, 60-70% heart rate reserve) hypertrophy resistance training (2sets, 10-12 repetitions, 70% of the one-repetition maximum) endurance resistance training (2 sets, 25-30 repetitions, 40% of the one-repetition maximum)
45398756|NCT03934450|Drug|RPQ|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
45398757|NCT03934450|Drug|SPQ|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
45398758|NCT03934450|Drug|Primaquine Phosphate|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
45398759|NCT03934450|Drug|Placebo|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
45398760|NCT01215682|Dietary Supplement|vitamin D|2000 IU/day of vitamin D3 as a once-daily dose
45398761|NCT01215682|Dietary Supplement|placebo|sweetened water
45398762|NCT01222156|Procedure|Remote magnetic navigation|Remote magnetic navigation of electrophysiology catheters to target intracardiac anatomical sites at mapping-ablation procedures in patients with cardiac arrhythmias
45398763|NCT01222156|Device|Magnetecs Catheter Guidance Control and Imaging system|Magnetecs Catheter Guidance Control and Imaging (CGCI) system
45398764|NCT03932188|Behavioral|Mental Health Assessments and Computerized Cognitive Test|Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.
45398765|NCT03932188|Device|MRI scan|Up to two MRI scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.
45398766|NCT03932344|Drug|Anakinra|Anakinra according to prescription
45398767|NCT01220050|Drug|Paricalcitol|Paricalcitol capsules 1- 2 mcg/day/pts for 26 weeks
45398768|NCT01220050|Drug|Standard therapy|Standard therapy for hyperparathyroidism for 26 weeks
45506963|NCT03378414|Procedure|Intrathecal injection|Intrathecal injection of mesenchymal stem cells: 2 * 10^7 cells (1ml)
45506964|NCT03378414|Biological|umbilical cord mesenchymal stem cell|Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure
45398769|NCT01123330|Behavioral|Motivational Interviewing|
45398770|NCT01123408|Drug|Clozapine|500 mg/day
45506965|NCT03368742|Genetic|SGT-001|AAV9 vector containing muscle-specific promoter and microdystrophin construct
45506966|NCT03350243|Other|CCENT Intervention|"Acceptance and Commitment Therapy approach: engaging families through structured individual or group sessions within the NICU and continue this support once discharged.~Care coordination: supporting providers in clear communication when liaising across various levels of care as well as supporting families in system and resource navigation.~Anticipatory guidance: proactive education targeting normal challenges in caring for a child who required intensive care support."
46057079|NCT05752786|Behavioral|"Eat Less Meat Challenge"|Participants will be able to choose their goal for the challenge for one month: (i) no meat, (ii) meat 3 times a week, (iii) meat 6 times a week (which will need to be lower than current consumption). The first day of the challenge, the participants will receive by email a cookbook and a starter kit with advices and motivational tips, then they will receive an email each week with more advices and motivational tips. Participants will be also asked to follow the Instagram account of the challenge during one month where (i) one post will be posted each day, (ii) engaging stories requiring interactions will be posted regularly, (iii) participants can ask their questions to the research team, (iv) participants can interact with each other's. The Instagram posts will cover three main topics: (i) knowledge about meat and its impact on health and environment, (ii) tips for meat-free cooking, (iii) social/contextual pressure to eat meat and how to avoid it.
46057080|NCT05030103|Device|Reading glasses, +2.0 diopters|The participants in the glasses-group are asked to wear the reading glasses during near-work.
46057081|NCT02777775|Procedure|Skin Biopsy|"The procedure to sample the cutaneous neurofibroma involves a skin incision and will take approximately 10 to 15 minutes. The tissue will be taken in the following way:~The skin area will be cleaned~The skin area will be numbed (by either a numbing cream or a tiny numbing shot)~Cutaneous (skin) Neurofibroma: will be taken via a small incision and removal of the neurofibroma whenever possible.~A small piece of normal (skin) tissue will be numbed as above and taken using a special skin biopsy device.~Afterward, the area will be cleaned and the skin put back together with medical super glue or 1 to 2 dissolvable stitches that will dissolve as the incision heals, they do not require removal. The purpose of taking this piece of skin is to compare normal skin with the skin of a cutaneous neurofibroma."
45398771|NCT01123408|Drug|Olanzapine|20 mg/day
46057082|NCT00729937|Drug|Cephalexin|500 mg, four times per day.
45506979|NCT03324360|Drug|Hyperpolarized 13C-Pyruvate|MRI with Hyperpolarized 13C-Pyruvate Injection
45506980|NCT03284307|Drug|Dexmedetomidine|20 participants will be administered Dexmedetomidine.
45506981|NCT03284307|Drug|Ketamine|20 participants will be administered Ketamine.
45398772|NCT01123408|Drug|Haloperidol|20 mg/day
45398773|NCT00141297|Drug|PD-0332991|Dose ranging study - evaluating two oral schedule: (1) 3/1 Schedule - PD-0332991 administered days 1-21 of a 28-day schedule, doses ranging from 25 to 150 mg once daily; (2) 2/1 Schedule - PD-0332991 administered days 1-14 of a 21-days schedule, doses ranging from 100 to 225 mg once daily
45398774|NCT01123486|Drug|hydromorphone|hydromorphone 0.02 mg/kg
45398775|NCT01123564|Drug|ranibizumab|applied monthly in the first 3 months period, and after this only if visual acuity (VA) decreases with more than 5 letters at any monthly visits
45398776|NCT01123564|Radiation|Argon laser treatment|Conventional grid pattern argon laser treatment and panretinal argon laser photocoagulation in an as needed basis.
45398777|NCT01220206|Drug|Placebo|2 placebo capsules daily
45398778|NCT01220206|Drug|One POMx capsule daily|One POMx capsule, one placebo capsule daily
45398779|NCT01220206|Drug|2 POMx Capsules|2 POMx Capsules daily
45506982|NCT03284307|Drug|Propofol|20 participants will be administered Propofol.
45506983|NCT03284307|Drug|Midazolam|20 participants will be administered Midazolam.
45506984|NCT03279289|Drug|Aflibercept|4 mg/kg administered intravenous infusion on day 1
45506985|NCT03279289|Drug|Irinotecan|180 mg/m2 intravenous infusion
45506986|NCT03279289|Drug|folinic acid (dl racemic)|400 mg/m2 intravenous infusion
45506987|NCT03279289|Drug|5Fluorouracil|400 mg/m2 intravenous bolus
45506988|NCT03279289|Drug|5-FU|2400 mg/m2 continuous intravenous infusion over 46 hours
45506989|NCT03272373|Device|NexGen TM Monoblock Tibia|Primary cementless tibia total knee arthroplasty
45506990|NCT03272373|Device|NexGen TM Modular Tibia|Primary cementless tibia total knee arthroplasty
45506991|NCT03265535|Diagnostic Test|Single-Scan Two-Injection Protocol|Single-Scan Two-Injection Protocol
45506992|NCT03265431|Drug|18F-TPP|Imaging with 18-F-TPP (18F-BFPET)
45506993|NCT03242174|Other|Health Behavior Questionnaire Packet|Any pregnant woman offered the questionnaire at her prenatal appointment in the third trimester can complete
45506994|NCT03236441|Device|RIPC|Remote ischemic preconditioning
45506995|NCT03236441|Device|Sham-RIPC|Control
45506996|NCT03225989|Drug|LOAd703|Oncolytic adenovirus serotype 5/35 encoding TMZ-CD40L and 4-1BBL
45398780|NCT01222312|Drug|Cisplatin|75 mg/m2, d1 every 3 weeks
45398781|NCT01222312|Drug|Oxaliplatin|85 mg/m², d1 every 2 weeks
45398782|NCT01222312|Drug|Docetaxel|75 mg/m2, d1 every 3 weeks
45398783|NCT01222312|Drug|Docetaxel|50mg/m2, d1 every 2 weeks
45398784|NCT01218334|Device|12 Lead Glove|Comparison of EKG's derived from the 12 Lead Glove vs. the Gold Standard EKG machine
45398785|NCT03932266|Drug|Endostar|Endostar, 15 mg/m2, continous intravenous infusion, 3 cycles during induction chemotherapy, 4 cycles during concurrent chemoradiotherapy.
45398786|NCT03932266|Drug|Cisplatin|Cisplatin, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy; Cisplatin, 80 mg/m2, intravenous infusion, 2 cycles during concurrent chemoradiotherapy.
45398787|NCT03932266|Drug|Docetaxel|Docetaxel, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy.
45398788|NCT03932266|Radiation|Intensity Modulated Radiation Therapy (IMRT)|IMRT: 66 Gy, 2-2.2 Gy per fraction, a total of 33 fractions
45398789|NCT03933046|Diagnostic Test|PSG|polysomnography and urine analaysis for protein levels
45398790|NCT03932110|Diagnostic Test|omentin, visfatin|diagnostic blood test
45398791|NCT00141219|Drug|pregabalin|150-600mg/day, BID
45398792|NCT00141219|Drug|Placebo|Placebo
45398793|NCT01123798|Device|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
45398794|NCT01222468|Drug|nabilone 0.5 mg|nabilone 0.5 mg tablets od titrated to a maximum daily dose of 3mg po over an 11-week phase
45398795|NCT01222468|Drug|placebo|placebo 0.5 mg po daily, dose titrated to a maximum daily dose of 3.0mg po over an 11-week phase
45398796|NCT03931798|Diagnostic Test|Visual Scanning Test|The Visual Scanning Test (VST) involved a visual search for a target between similar visual distractors, projected in the far space, so as to simulate the search within a visual field. It is overall composed by four trials, each trial contained 20 cases and made up by 20 stimuli. On about the 80% of cases, the test provided the presence of target in the left, center or in right hemispace. In the remaining 20% of cases, the test provided the presence of a catch trial (absence of the target), to assess the presence of frontal disturbances or malingering. The test is constructed according to an increasing attentional load for the target on the left-hemispace. Participants, sitting in front a blank wall, were required to actively and free explore the projected visual field to search for the visual target, naming its identification (saying YES or NO). During the task, the examiner annotated the reaction times and the errors.
45398797|NCT01222546|Drug|CH5132799|
45398798|NCT01222624|Drug|PankoMab-GEX™|
45398799|NCT03931720|Biological|BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
45398800|NCT01218412|Behavioral|Web-based Motivational Interviewing|Participants will engage in 4 sessions of web-based motivational interviewing over the course of 4 weeks.
45398801|NCT03934060|Other|Exercise|specific strength training
45398802|NCT01220284|Drug|Satraplatin in combo with vinorelbine|"Satraplatin (gelatin capsules) p.o. on days 1 to 5 (from 60 mg/m2 up to 80 mg/m2)~Vinorelbine (soft capsules) p.o. on days 1, 8 and 15 (from 60 mg/m2 up to 80 mg/m2) The treatment is repeated every 4 weeks."
45398803|NCT01127464|Drug|DCVax-001|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
45398804|NCT01127464|Drug|Poly-ICLC|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
45398805|NCT01127464|Drug|Placebo|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
45398806|NCT01222780|Drug|Marqibo|Marqibo® intravenously (IV) over 60 minutes (+ 10 minutes) every 7 days (+ 3 days) for 4 consecutive weeks (day 1, 8, 15, 22) for a 28-day treatment cycle
45398807|NCT03931876|Drug|Placebos|Single ascending dose administration
45398808|NCT03931876|Drug|AV-006|Single ascending dose administration
45398809|NCT01222858|Behavioral|Diet and Activity Education|Education about behavioral modification of eating and activity habits for weight loss.
45398810|NCT01222858|Behavioral|Self-monitoring with Feedback|Participants self-monitor diet and activity behaviors, which are submitted via a website. Automated feedback on the self-monitoring record is provided to participants.
45398811|NCT01222936|Drug|LBH581|25 mg/5 ml solution packaged in 6 ml type I glass vials and given as a 30 minutes infusion at the dose of 20 mg/m2 i.v., on day 1 and 8, every 21 days.
45398812|NCT01223014|Drug|AZD2423|AZD2423
45398813|NCT01125904|Drug|crizotinib|Oral liquid. Taste assessment of new formulation. Subjects will not ingest the drug.
45398814|NCT01125982|Drug|Propofol|Continuous intravenous infusion at 3-6 µg/mL (Ce - Target Controlled Infusion) during anaesthesia to provide sleep.
45398815|NCT01125982|Drug|Desflurane|Continuous inhalation at 0.7-0.8 MAC (endtidal) during anaesthesia to provide sleep
45398816|NCT01220362|Drug|Bupivacain 0.125%|Bupivacain 0.125%
45398817|NCT01220362|Drug|Bupivacain 0.125%/Fentanyl 2mcg/ml|Bupivacain 0.125%/Fentanyl 2mcg/ml
45398818|NCT01220440|Drug|Methylphenidate|Methylphenidate:10mg x 3 for one week
45398819|NCT01220440|Drug|Placebo|Placebo: 1 pill x 2 for one week, 2 pills x 2 for one week.
45398820|NCT01220440|Drug|Dextroamphetamine|Dextroamphetamine: 5mg x 2 for one week, 10mg x 2 for one week
45398821|NCT01123876|Drug|Veliparib|Subjects will be given Veliparib twice daily on Days 1-5 and 15-19 every 28 days orally
45697682|NCT03228459|Other|Biological sample collection|Blood samples from a peripheral vein of the hand or forearm to obtain serum, plasma, DNA and RNA will be collected. Moreover, a saliva sample will be collected.These samples will be prepared in aliquots following a standardized protocol, and sent frozen (dry ice) to a centralized biobank (IRBLleida Biobank, Spain) for processing and storage for subsequent studies of CV, inflammatory and mineral-metabolism biomarkers and genetic polymorphisms. Urine samples will be frozen and stored in a biobank for subsequent study of biomarkers.
45697683|NCT03228459|Other|Result and recommendation report|A report with exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
45697684|NCT03228459|Diagnostic Test|Pulse wave velocity|Pulse wave velocity (PWV) will be used as an indicator of arterial stiffness. It will be measured non-invasively with the carotid to femoral PWV (cfPWV) according to standard protocols.
45697685|NCT03258177|Other|Virtual Visit|Participants will be given information about how to enroll in virtual care. Participants will use their own camera-enabled device with internet connection to see and speak to the medical professional in real-time and complete the virtual follow-up visit.
45697686|NCT03015064|Other|Myocardial Infarction|Observational study of myocardial Infarction patients
45849808|NCT04575324|Behavioral|Telemedicine Linkage Intervention|Participants will be immediately linked to telemedicine care provided by an FQHC provider waivered to prescribe buprenorphine and naltrexone or able to refer patients to methadone treatment. Participants will have their vitals checked and be virtually connected to the provider. The research assistant will share the vitals with the provider, and the provider will provide personalized care during which they discuss treatment options with the participant. If a medication for opioid use disorder is prescribed or if a methadone referral is made, transportation assistance will be provided to the participant as part of the intervention. Transportation to pick up the prescription or complete the first appointment will be provided via a HIPAA compliant ride-share company, and a bus pass will be provided to the participant for the return trip.
45849809|NCT04529538|Biological|Novel Oral Polio Vaccine Type 1 (nOPV1)|Each 0.1 mL (2 drops) dose of vaccine contains approximately 10^6.5 CCID50.
45849810|NCT04529538|Biological|Novel Oral Polio Vaccine Type 3 (nOPV3)|Each 0.1 mL (2 drops) dose of vaccine contains approximately 10^6.5 CCID50.
45398822|NCT01123954|Biological|Seasonal flu vaccine|This phase II is performed as a monocenter study site in a population of healthy subjects aged 1 to 45 years. Enrolled subjects received one single IM dose of trivalent subunit inactivated influenza vaccine during the vaccination visit, according to the study protocol (follow-up period: 30 days)
45398823|NCT01124032|Drug|methylphenidate|a capsule containing 20 mg
45506997|NCT03207867|Drug|NIR178|NIR178, a new, non-xanthine based compound, is a potent oral adenosine A2a receptor against antagonist being developed by Novartis.
45849811|NCT04529538|Biological|Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1)|The Sabin mOPV1 control vaccine contains ≥ 10^6.0 CCID50 per 0.1 mL (2 drops) dose.
45506998|NCT03207867|Drug|PDR001|PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
45506999|NCT03207529|Drug|Alpelisib|Given PO
45849812|NCT04529538|Biological|Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3)|the Sabin mOPV3 control vaccine contains ≥ 10^5.8 CCID50 per 0.1 mL (2 drops) dose.
45849813|NCT04522596|Drug|Umeclidinium/vilanterol|Umeclidinium/vilanterol 55/22 μg inhaled once a day
46057083|NCT00729937|Drug|Clindamycin|300 mg, four times per day.
46057084|NCT00729937|Other|Placebo|Placebo tablet administered orally.
46057085|NCT00729937|Drug|Trimethoprim-sulfamethoxazole|4 single strength Trimethoprim/Sulfamethoxazole (TMP/SMX), 80 mg/400 mg each, twice per day.
45507000|NCT03207529|Drug|Enzalutamide|Given PO
45398824|NCT03934294|Other|Specific acupuncture group|"In addition to routine ICU treatments, patients in the specific acupuncture group will also receive daily bilateral traditional Chinese medicine style acupuncture on the following acupuncture points: ST36 (Zu San Li), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Nei Guan) and LI4 (He Gu). The acupoints indications in this group are specific to treat indigestion related conditions. The treatment will take place once a day, over three days, for a total of three treatments. A total of 10 Needles will be used in each session Acupuncture treatment will be performed with sterile needles manufactured by Yu Kuang acupuncture needles 40mm with 30G."
45398825|NCT03934294|Drug|Metoclopramide 10mg|Patients in all groups will receive Metoclopramide 10mg/ per 8 hours in the case of poor digestion, alongside the individualized drug treatment prescribed by the ICU medical doctor as per individual patient needs.
45398826|NCT03934294|Other|Non-specific acupuncture group|Patients' in the non-specific acupuncture group (Con-Acu) will receive routine ICU treatment as well as a total of 3 daily non digestion related Traditional Chinese medicine style acupuncture treatments at the following acupoints: LI 15 (Jianyu), SJ 14 (JianLiao) LU3 (Tianfu), GB35 (Yangjiao), BL 59 (Fuyang). The selected control points are not indicated for the treatment of digestion related conditions, and are not reported to improve digestive function.
45398827|NCT01218490|Procedure|ovarian cancer surgery|
45398828|NCT01124110|Behavioral|Tobacco Tactics Web-Based Intervention|The Tobacco Tactics Web-Based Intervention contains website, medications, and nurse counseling.
45398829|NCT01124110|Other|1-800-QUIT-NOW Telephone Hotline|The control group receives efficacious smoking cessation treatment via the 1-800-QUIT-NOW telephone hotline. The 1-800-QUIT-NOW hotline is a national program. The first time smokers call the hotline, they receive a personal coach who assists them in setting a quit date and making an individualized quit plan. The personal coach also provides on-going support with up to five telephone coaching sessions around the caller's quit date.
45398830|NCT01223170|Behavioral|Tailored content|Participants will have access to content tailored for Stage of Change, Regulatory Focus and Self-Efficacy.
45398831|NCT01223170|Behavioral|Generic Internet-based information|Access to a website with general information about Cardiovascular Disease and self-management, including diet, physical activity, smoking and medications.
45398832|NCT01223170|Behavioral|Discussion forum|Access to a discussion forum for Cardiovascular Disease Rehabilitation.
45398833|NCT01223170|Behavioral|Behavioral monitoring|Participants will be offered behavioral monitoring, based on data collected from online self-reports and from activity sensors built into mobile phones.
45398834|NCT01218568|Drug|Rifaximin plus lactulose|Rifaximin 400 mg three times a day Lactulose 30-60 ml in two or three divided doses.
45398835|NCT01218568|Drug|Lactulose|Lactulose 30-60 ml in two or three divided doses.
45507001|NCT03186456|Biological|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells will transfusion into by forearm intravenous transplantation, 0.5 - 1 *10^6/kg. once a month, total 3 times.
45507002|NCT03186456|Drug|Aspirin Tablet|Drug: Aspirin Tablet, 100 mg/d
45507003|NCT03184935|Biological|Allogeneic umbilical cord mesenchymal stem cells|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
45507004|NCT03184935|Drug|Decitabine|Decitabine，20mg/m^2/d
45507005|NCT03180463|Drug|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) will be injected through surgery tunnel, 2*10^7 cells,
45697687|NCT03187054|Procedure|anterior or posterior colporrhaphy|will be performed in a traditional manner with midline plication of the fibromuscular layer using 2-0 delayed absorbable sutures.
45507006|NCT03180463|Procedure|core decompression|The surgery will drill into the femoral neck (hip bone) and through the necrotic area of the bone that died from the lack of blood flow, take out partial osseous tissue.
45697688|NCT04197310|Drug|Nivolumab|240mg, intravenously, Day 1 and 15 of a 28 day cycle
45697689|NCT04197310|Drug|Cabozantinib|40mg, orally, Daily for a 28 day cycle
45697690|NCT04760457|Procedure|Implant placement with flapped surgery|Four mini implants will be placed reflecting a flap.
45697691|NCT04760457|Procedure|Implant placement with flapless surgery|Four mini implants will be placed without reflecting a flap.
45697692|NCT04760457|Procedure|Implant immediate loading|Four mini implants will be immediately loaded.
45697693|NCT04760457|Procedure|Implant delayed loading|Four mini implants will be loaded after a 6-week healing period.
45697694|NCT02991586|Behavioral|Dialectical Behaviour Therapy|Group of families
45697695|NCT05330247|Other|Carbohydrate-reduced high-protein (CRHP) Diet|Macronutrient intake of 30 percentage of energy from carbohydrate, 30 percentage of energy from protein and 40 percentage of energy from fat.
45697696|NCT05330247|Other|Conventional diabetes (CD) Diet|Macronutrient intake of 50 percentage of energy from carbohydrate, 17 percentage of energy from protein and 33 percentage of energy from fat.
45507007|NCT03180450|Biological|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells will transfusion by intravenous transplantation.
45507008|NCT03180450|Drug|conventional treatment|The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.
45507009|NCT03176498|Biological|Allogeneic umbilical cord mesenchymal stem cell|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
45507010|NCT03176498|Drug|Aspirin Enteric-coated Tablets & Atorvastatin Calcium|Aspirin Enteric-coated Tablets, 0.1g/d by mouth; Atorvastatin Calcium, 20mg/d by mouth.
45507011|NCT03170960|Drug|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at dose levels of 20 mg, 40 mg, or 60 mg.
45507012|NCT03170960|Drug|atezolizumab|Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
45507013|NCT03170960|Drug|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage
45398836|NCT02529280|Behavioral|Intervention|Intervention includes 1) a 30-minute computer-based video (in English/Spanish), featuring instructional screens, graphics and animation to help participants understand the concepts presented. It will feature breast cancer patients who have participated in CTs, patients talking to their doctor or nurse and a bilingual narrator to guide participants. Video content will address common barriers and concerns regarding clinical trials, as well as the informed consent process, and how clinical trials are monitored and reviewed; 2) a bilingual easy to understand booklet with tailored information on clinical trials. The booklet will include many of the elements and messages featured in the video program; and 3) assistance from a trained, bilingual, bicultural, nurse navigator.
45398837|NCT01127542|Drug|Lenalidomide|Daily oral lenalidomide. Starting dose of 2.5mg daily, escalating to target dose of 10mg daily.
45507014|NCT03170960|Drug|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at 60 mg qd
45507015|NCT03126591|Drug|Olaratumab|Administered IV
45507016|NCT03126591|Drug|Pembrolizumab|Administered IV
45398838|NCT01127620|Drug|Bilastine|20 mg encapsulated tablets
45507017|NCT03122197|Drug|Letrozole Oral Tablet|Administration: Letrozole will be given orally once daily.
45507018|NCT03107000|Procedure|Trabeculectomy|Incisional surgery for glaucoma
45507019|NCT03107000|Procedure|Phako-trabeculectomy|Incisional surgery for glaucoma plus cataract
45507020|NCT03099109|Drug|LY3321367|Administered IV
45507021|NCT03099109|Drug|LY3300054|Administered IV
45507022|NCT03094832|Drug|Miransertib|Miransertib capsules administered orally at an initial dose of 15 mg/m^2 or 25 mg/m^2 QD and then titrated up to 25 mg/m^2 or 35 mg/m^2 QD at the investigator's discretion.
45507023|NCT03091192|Drug|Savolitinib|600 mg (400 mg if <50 kg) by mouth (PO) with a meal once daily (QD), continuously
45507024|NCT03091192|Drug|Sunitinib|50 mg by mouth (PO) once daily (QD), with or w/o food, 4 weeks on/2weeks off
45398839|NCT01127620|Drug|Cetirizine|10 mg encapsulated tablets
45398840|NCT01127620|Drug|Placebo|encapsulated tablets
45398841|NCT01220518|Drug|Infliximab|Infliximab 5mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
45507025|NCT03085004|Drug|Ethanol|The cyst will be lavaged for 3 to 5 minutes using >/=99% ethanol as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
45507026|NCT03085004|Drug|Normal saline|The cyst will be lavaged for 3 to 5 minutes using normal saline as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
45507027|NCT03085004|Drug|Paclitaxel + Gemcitabine admixture|Following lavage, cysts will be infused with an admixture of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
45697697|NCT04898296|Other|Questionnaire, Interview|During the stay, a study visit is arranged with the patient after the 6-minute walk test has been performed. This consists of filling out the questionnaire and an interview, which lasts about 45-60 minutes. This is carried out by the investigator on at least 5 subjects. After each interview, a list of influencing factors is kept. If new aspects continue to appear in the 5th interview, the interviews are continued (up to a maximum of the 10th subject). If no new aspects appear in the interviews from number 6 onwards, the interviews are discontinued and no further patients are recruited. The conversations are recorded with an audio recording.
45507028|NCT03082716|Drug|Custodiol Solution|After cross clamping patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
45507029|NCT03082716|Drug|Blood cardioplegia|After cross clamping patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
45507030|NCT03069287|Behavioral|Benjamin Rose Institute (BRI) Care Consultation™ Program|The BRI Care Consultation™ can be delivered via face-to-face contact, telephone, mail, and/or email by a Care Consultant and caregiver who assists with daily activities, tasks, and health-related issues. BRI CareConsultation™ uses a secure, web-based Care Consultation Information System (CCIS) to guide the delivery of the intervention.
45849814|NCT04522596|Other|Placebo|Placebo inhaled once a day
45507031|NCT03059862|Dietary Supplement|L-tryptophan|3 g/day of L-tryptophan added to the standardized low-tryptophan diet. Duration: 3 weeks.
45507032|NCT03059862|Dietary Supplement|Placebo|A placebo will be added to the standardized low-tryptophan diet. Duration: 3 weeks.
45507033|NCT03037723|Other|CT simulation|
45507034|NCT03036579|Device|Celtra Duo|Full ceramic crowns will be made from the high strength ceramic, Celtra Duo.
45507035|NCT03034811|Device|Persona Partial Knee system|Fixed bearing partial knee
45507036|NCT03015844|Drug|131-I-meta-iodobenzylguanidine|
45507037|NCT03014414|Behavioral|Fun First|Learn key enjoyable maintenance skills before losing weight
45507038|NCT03014414|Behavioral|Weight Watchers|Focus on losing weight first via convenient meetings and personalized online tools
45507039|NCT02976701|Drug|DLBS1033|
45507040|NCT02976701|Drug|Placebo|
45507041|NCT02976701|Drug|Standard therapy|Standard therapy which consists of: aspirin enteric-coated tablet 1 x 80 mg and clopidogrel film-coated tablet 1 x 75 mg daily for four weeks will be given to both arms.
45507042|NCT02949284|Drug|Abiraterone Acetate|Given PO
45507043|NCT02949284|Drug|Androgen Receptor Antagonist ARN-509|Given PO
45507044|NCT02949284|Biological|Gonadotropin-releasing Hormone Analog|Given SC
45507045|NCT02949284|Drug|Prednisone|Given PO
45697698|NCT04898296|Other|Focus Group|The focus group is carried out first in order to identify influencing variables that may be relevant for the interview (duration 60-90 minutes).
45697699|NCT04550013|Other|Heavy-Slow Resistance training|Resistance training for knee extensors. The exercise will be performed at 80% of 1 RM and slowly (6 s/repetition).
45697700|NCT04550013|Other|Low-Load Blood Flow Restriction training|Resistance training for knee extensors. The exercise will be performed at 30% of 1 RM and with a relative Artery Occlusion Pressure of 80%
45507046|NCT02949284|Other|Quality-of-Life Assessment|Ancillary studies
45507047|NCT02949284|Other|Questionnaire Administration|Ancillary studies
45507048|NCT02949284|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
45507049|NCT02916862|Dietary Supplement|Soluble Corn Fiber (SCF) without Calcium|Participants will consume a supplement with 12 g/day of SCF for 12 months
45398842|NCT01328938|Biological|GCPGC 3.6mg|Stage I:Single blinded
45398843|NCT01328938|Biological|GCPGC 6mg|Stage I: Single blinded;
45507050|NCT02916862|Combination Product|Soluble Corn Fiber (SCF) + Calcium|Participants will consume a supplement with 12 g/day of SCF + calcium carbonate (600 mg/day) for 12 months
45507051|NCT02916862|Dietary Supplement|Placebo|Participants will consume a supplement without SCF or calcium carbonate for 12 months
45507052|NCT02916862|Combination Product|Placebo + calcium|Participants will consume a supplement without SCF + calcium carbonate (600 mg/day) for 12 months
45507053|NCT02891447|Drug|Cisplatin|Given intraperitoneally
45507054|NCT02891447|Drug|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
45507055|NCT02891447|Drug|Mitomycin|Given intraperitoneally
45507056|NCT02885974|Drug|Celecoxib|Celecoxib (100 mg daily)
45507057|NCT02885974|Drug|Gemcitabine|1,000 mg/m2 (IV), on Days 1 and 8 of each 21-day cycle. Up to 4 cycles.
45507058|NCT02885974|Drug|Cisplatin|70 mg/m2 (IV), on Day 1 of each 21-day cycle. Up to 4 cycles.
45507059|NCT02867761|Drug|Indacaterol/Glycopyrrolate|27.5/15.6 mcg active indacaterol/glycopyrrolate
45507060|NCT02867761|Drug|Placebo|27.5/15.6 mcg placebo
45697701|NCT04894162|Other|Questionnaire|Consecutive, eligible inpatients in a participating specialist palliative care unit will be invited to participate in the research: those who wish to participate will complete a research questionnaire about research preferences.
45697702|NCT04134520|Device|ProLung System|Non-invasive bioconductance measurements
45398844|NCT01328938|Biological|Neulasta (pegfilgrastim) 6mg|Stage II: Active comparator, double blinded
45398845|NCT01328938|Biological|GCPGC 6mg|Experimental: Stage II
45398846|NCT01220596|Drug|Entecavir and Pegylated interferon α-2a Sequential Treatment Group|Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
45398847|NCT01220596|Drug|Pegylated interferon α-2a Monotreatment Group|Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
45507061|NCT02858050|Device|Portal-724 MEMs Cap|
45507062|NCT02766543|Device|MRI-guided Transurethral Ultrasound Ablation|Magnetic resonance imaging-guided transurethral ultrasound ablation is a novel minimally-invasive procedure where the therapeutic endpoint is prostate ablation through thermal coagulation.
45697703|NCT05320731|Procedure|Nebulization with lidocaine|A face mask nebulizer with oxygen flow rate of 8 L/min will be used to deliver 10 mL of 2% lidocaine. Patients will be encouraged to inhale deeply to facilitate entrainment of nebulized LA into their airway. Adequate topical anesthesia will be confirmed by heaviness or numbness of the tongue.
45507063|NCT02764476|Other|Embodied Virtual Reality Therapy|Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways and involves body tracking and controlled sensory feedback reinforcing movement in real and virtual time by immersive head mounted displays. This game will have subjects fully embody and inhabit an avatar from an egocentric perspective. In addition, over consecutive sessions subjects will be asked to use a mobile smart phone based virtual reality program designed to deliver various and customized emotionally provocative stimuli.
45507064|NCT02764476|Other|Virtual reality|Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways.
45507065|NCT02754726|Drug|Nivolumab|Nivolumab 240mg 240 mg as a 60 minute infusion on days 1, 15, 29 per 42 day cycle
45398848|NCT01218724|Drug|Losartan Potassium and Hydrochlorothiazide Tablets|
45398849|NCT01126216|Drug|Paclitaxel/Cisplatin|Experimental: Paclitaxel (20mg/m^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m^2/d) on days 1-4 and 29-32,
45507066|NCT02754726|Drug|Albumin-bound paclitaxel|125 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
45507067|NCT02754726|Drug|Paricalcitol|25 micrograms IV on days 1,4,8,12,15,18,22,26,29,32,36,39 (+/-1 day allowed for dosing per 42 day cycle
45507068|NCT02754726|Drug|Cisplatin|25 mg/m2 over 60 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
45507069|NCT02754726|Drug|Gemcitabine|1000 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
45507070|NCT02740790|Biological|HPV vaccine|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
45507071|NCT02740790|Biological|Placebo|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
45697704|NCT05320731|Procedure|Atomization with lidocaine|A simple atomization device as a modification of the McKenzie technique will be used. One end of oxygen bubble tubing will be cut to fit into the barrel of 1 mL syringe and attached to one connector of a 3-way tap. A 10-mL syringe filled with 2% lidocaine will be attached to the other connector of the 3-way tap. A 6 Fr suction catheter, with its colored end cut and its distal blind end cut open, will be attached to oxygen bubble tubing via the male Luer connector of the 3-way tap. The other end of bubble tubing will be then attached to an oxygen source turned on to deliver a flow of 6 L/min. As LA is slowly atomized as a jet-like spray, the catheter will be directed towards the soft palate and posterior pharynx in a controlled fashion during patients' inspiration to topicalize the airway. Patients will be asked to take full vital capacity breaths of atomized LA contained oxygen. Adequate topical anesthesia will be confirmed by tongue heaviness or numbness
45697705|NCT04823650|Device|COHORT A: Actigraph|The ActiGraph CentrePoint Insight Watch is a small worn activity monitor designed for documenting physical movement associated with applications in physiological monitoring.
45849815|NCT04521114|Drug|Placebo|Placebo will be administered subcutaneously every week for 13 weeks.
45849816|NCT04521114|Drug|leronlimab 700 mg|700 mg leronlimab will be administered subcutaneously every week for 13 weeks.
45849817|NCT04521114|Drug|leronlimab 350 mg|350 mg leronlimab will be administered subcutaneously every week for 13 weeks.
45849818|NCT04519164|Drug|Eplerenone|mineralocorticoid receptor antagonist and potassium-sparing diuretic
46057086|NCT05251207|Dietary Supplement|L-carnitine|L-carnitine-L-tartrate
45398850|NCT01126216|Radiation|Reduced RT|Experimental: 63,6 Gy accelerated hyperfractionated radiotherapy
45398851|NCT01126216|Drug|5-FU/Cisplatin|Active Comparator: 5-Fluorouracil(600mg/m^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m^2/d) on days 1-5 and 29-33
45398852|NCT01126216|Radiation|Standard RT|Active Comparator: 70,6 Gy accelerated hyperfractionated radiotherapy
45398853|NCT01329016|Drug|Glyburide|Women with GDM who require treatment will be given glyburide 2.5 mg. Medication will be given at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
45398854|NCT01329016|Drug|Metformin|Women with GDM requiring treatment will be given metformin 500 mg. Medication will be administered at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
45398855|NCT01329016|Drug|Glyburide-Metformin combination|Women with GDM requiring treatment will be given glyburide 2.5 mg with metformin 500 mg. Medications will be administered at least twice daily and equal doses will be given for each dosing time 3 days prior to the pharmacokinetic study day.
45398856|NCT01220674|Other|cognitive testing|computer-based cognitive assessment
45507072|NCT02740777|Biological|HPV-16/18 vaccine|HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.
45507073|NCT02719990|Drug|somavaratan|Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly
45507074|NCT02680626|Drug|Magnesium Sulfate|Given via transversus abdominis plane block
45507075|NCT02680626|Drug|Ropivacaine|Given via transversus abdominis plane block
45507076|NCT02576483|Behavioral|Questionnaire (QoV questionnaire)|Quality of vision and quality of life questionnaire
45398857|NCT01223326|Drug|Acetylcysteine (NAC)|NAC 150 mg/Kg; and infusion of 50 mg/kg, from 30 minutes before the ischemia up to 60 minutes later to the reperfusion
45398858|NCT01223326|Drug|Saline|Na Cl 0.9% infusion
45507077|NCT02573415|Procedure|Uterus Transplant|transplant of a deceased donor uterus.
45507078|NCT02494583|Biological|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
45398859|NCT03934138|Other|Educational movie on placebo mechanisms|"Educational movie on placebo mechanisms : animated video, duration : 12 minutes.~It will be followed by the CPTs : experimentally induced pain by keeping the non dominant hand in cold water (1° Celsius) for a limited time. The duration of immersion is personal and calibrated to be around to ensure that the intensity of pain will be homogeneous (around 7/10 on the visual analogue scale with no treatment)"
45398860|NCT03934138|Other|Informative movie on hand washing|Animated video, duration : 11 minutes. It will be followed by the CPTs : experimentally induced pain by keeping the non dominant hand in cold water (1° Celsius) for a limited time. The duration of immersion is personal and calibrated to be around to ensure that the intensity of pain will be homogeneous (around 7/10 on the visual analogue scale with no treatment).
45398861|NCT01124266|Procedure|standard of care colonoscopy|Single inspection by endoscopist during colonoscopy
45398862|NCT01124266|Procedure|standard of care colonoscopy|Dual inspection by both endoscopist and nurse during colonoscopy
45398863|NCT01223560|Drug|Insulin Aspart|Insulin bolus with and without carbohydrate intake.
45398864|NCT01223560|Other|Exercise|Exercise on tread mill
45398865|NCT01223560|Dietary Supplement|Carbohydrate|Carbohydrate intake
45398866|NCT01223638|Other|Audiometry|Audiometry
45398867|NCT01127776|Device|APOS SYSTEM|The trial group will receive APOS walking system The control group will receive the same walking protocol as the trial group without biomechanics units
45398868|NCT01127776|Other|APOS SYSTEM without biomechanics units.|The control group will receive the same walking protocol as the trial group without biomechanics units
45849819|NCT04519164|Drug|Chlorthalidone with potassium chloride|potassium-wasting diuretic with potassium chloride
45398869|NCT03932890|Device|Patient controlled fluid device administering high volume thirst guided fluid bolus|The administration of a 200ml fluid bolus in response to subjective thirst. Participant activates trigger in response to thirst which activates fluid pump to deliver 50ml IV fluid bolus of 4% dextrose & 0.18% sodium chloride
45398870|NCT03932890|Device|Patient controlled fluid device administering low volume thirst guided fluid bolus|The administration of a 50ml fluid bolus in response to subjective thirst. Participant activates trigger in response to thirst which activates fluid pump to deliver 50ml IV fluid bolus of 4% dextrose & 0.18% sodium chloride
45507079|NCT02494583|Drug|Cisplatin|Cisplatin 80 mg/m^2 IV on Day 1 of each week in 3-week cycles (6 cycle maximum per local country guidelines).
45507080|NCT02494583|Drug|5-FU|5-FU 800 mg/m^2/day IV continuous from Day 1-5 of each 3-week cycle.
45849820|NCT04510272|Other|Aloud Real-time Reading of ICU Diaries|Standard ICU diaries will be read aloud in real time daily to patients by ICU nurses/therapists/family members
45849821|NCT04504500|Behavioral|HSOG guidelines application|In their practice, as regards the mode of delivery, obstetricians are encouraged to conform to the three guidelines and two consent forms published by the Hellenic Society of Obstetrics and Gynecology (HSOG). The members of the appointed Steering Committee and/or local opinion leaders will discuss and disseminate these guidelines among the professional staff in the respective maternity units, providing them with the opportunity to identify specific barriers, overcome them, and develop an implementation timetable.
46057087|NCT05251207|Dietary Supplement|L-leucine|L-leucine
45507081|NCT02494583|Drug|Capecitabine|Capecitabine 1000 mg/m^2 twice daily by oral tablet on Day 1-14 of each 3-week cycle.
46057088|NCT05251207|Behavioral|Change of the circadian cycle|Reducing sleep at night for four consecutive days (enabling sleep between 8:00 and 17:00)
45398871|NCT03933124|Device|Virtual Reality|The Virtual Reality intervention is used for 10 minutes minimal 3 times a day on postoperative day 2-4.
45398872|NCT01126294|Dietary Supplement|5 mg melatonin|Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
45398873|NCT01126294|Dietary Supplement|10 mg melatonin|Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
45398874|NCT01126294|Dietary Supplement|Placebo|Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
45398875|NCT01124344|Drug|Placebo|Oral Solution, Oral, 0 mg, Once Daily, 14 days
45398876|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 3 mg, Once Daily, 14 days
45398877|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 10 mg, Once Daily, 14 days
45398878|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 30 mg, Once Daily, 14 days
45398879|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 45 mg, Once Daily, 14 days
45398880|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 60 mg, Once Daily, 14 days
45398881|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 90 mg, Once Daily, 14 days
45507082|NCT02494583|Drug|Placebo|Normal saline IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
45507083|NCT02473042|Procedure|Electrical Stimulation|Electrical stimulation to the wrist initiated at 1mHz, 1 pulse/second using two leads on a nerve stimulator. Stimulation continued throughout the breast surgery.
45849822|NCT04504500|Behavioral|Interactive workshops and courses|The workshops and courses will give instruction in indications for cesarean section and clinical scenarios, physiology-based cardiotocography (CTG) interpretation, obstetric emergencies (with topics including breech delivery, trial of labor after cesarean, delivery of twins, induction and augmentation of labor), organization of the labor ward, as well as launching of regular cesarean section and CTG meetings with review of the patient notes. The workshops will last four days and will be conducted by experienced trainers. The expectation is that the obstetricians will gain very considerable knowledge and skills, which will enable them to subsequently follow these practices safely and competently.
45849823|NCT04504500|Behavioral|Feedback through follow-up meetings|Regular follow-up meetings with members of the steering committee and local opinion leaders throughout the intervention period will enhance compliance with the guidelines. Feedback with positive phrasing will be incorporated to meet local needs.
45849824|NCT04504500|Behavioral|Robson criteria usage|Obstetricians are set to a routine to enable them to use the Robson 10-group classification criteria for cesarean sections and obtain feedback on the unit's cesarean section rates monthly. They thus know which category is higher and can be reduced further.
45849825|NCT04504500|Behavioral|Access to live real-time statistics|Live real-time statistics provided by an online platform, on a regular basis, is expected to improve adherence, through regular feedback. Each unit will see other units' statistics by means of an anonymous reporting system. This repetition will create silent signals that will remind the participating obstetricians to remain on task.
45507084|NCT02473042|Drug|Zofran|4 mg by vein for 1 dose.
45507085|NCT02473042|Drug|Dexamethasone|10 mg by vein for 1 dose.
45507086|NCT02473042|Drug|Phenergan|6.25 mg by vein for 1 dose.
45507087|NCT02473042|Drug|Pepcid|10 mg by vein for 1 dose.
45507088|NCT02473042|Behavioral|Questionnaire|Questionnaire completed about 15 minutes after participant wakes up after surgery, then every 30 minutes until they leave the clinic. It should take about 2 - 3 minutes to complete the questionnaire.
46059111|NCT04122313|Other|Evaluation of Dupuytren's Disease Treatment|There are no study interventions. The study interaction will be asking the patients to complete an additional outcome questionnaire and allow a medical record review.
45398882|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 3-60 mg, Once Daily, 14 days
45697706|NCT04823650|Device|Panoramic Bracelet and GENEActiv|"Panoramic Bracelet:~The Panoramic Digital Health Bracelet is a wearable inertial measurement unit intended for use by researchers and healthcare professionals for high frequency or continuous collection of physical data in home and professional healthcare settings during research studies. It includes a 3 axis accelerometer and gyroscope, as well as magnetometer, pressure, and temperature sensors. The bracelet has no interface or screen for participants to interact with.~GENEActiv:~The GENEActiv device is a wearable inertial measurement unit designed for public health research and clinical trials. The device is a circular unit with attachable wrist-bands, and has no interface or screen for participants to interact with. The GENEActiv device is FDA 510(k) exempt. The device records acceleration data and can collect data remotely for up to 1 month."
45697707|NCT04685655|Other|Therapeutic plasma exchange|Treatment with therapeutic plasma exchange. Plasma from healthy donors is used.
45697708|NCT02808364|Biological|Personalized cellular vaccine|Patients with recurrent glioblastoma will undergo tumor resection and receive tumor antigen pulsed cellular vaccines.
45697709|NCT04545177|Device|NICO Myriad and Tissue Preservation System (TPS)|Tumor tissue will be obtained by the NICO Myriad and Tissue Preservation System (TPS) via an automated, standardized methodology
45697710|NCT02709616|Biological|Personalized cellular vaccine|Biological: DC-based cellular vaccine. Subjects will undergo surgical resection and standard 6-week chemo/radiotherapy and cycles of TMZ treatment. They will receive biweekly cellular vaccines.
45398883|NCT01218880|Drug|M2ES 7.5mg|M2ES Dosage：7.5mg/m2
45398884|NCT01218880|Drug|M2ES 15mg|M2ES Dosage：15mg/m2
45398885|NCT01218880|Drug|M2ES 30mg|M2ES Dosage：30mg/m2
45398886|NCT01218880|Drug|M2ES 45mg|M2ES Dosage：45mg/m2
45398887|NCT00162266|Drug|Abatacept (BMS-188667)|IV, 10 mg/Kg, monthly, for the duration of the trial
45398888|NCT00162266|Drug|Abatacept (BMS-188667)|Intravenous (IV) infusion, 2 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
45398889|NCT00162266|Drug|Abatacept (BMS-188667)|Intravenous (IV) infusion, 10 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
45507089|NCT02466841|Procedure|Cubital tunnel release|Patients undergoing cubital tunnel release for ulnar nerve compression at elbow
45507090|NCT02371447|Drug|VPM1002BC|"Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)"
45507091|NCT02359799|Device|IntelliStretch|The impaired ankle of the participants are trained 3 times a week for 6 weeks in the lab or at home. The participants use the portable robotic device to stretch the ankle and increase range of motion (ROM). Then subjects use their gained ROM immediately in the active movement training to play video games and improve motor control.
45697711|NCT04534881|Drug|Progesterone 200 MG|Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.
45398890|NCT00162266|Drug|Placebo|Intravenous (IV) infusion, 0 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
45398891|NCT01223716|Behavioral|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
45398892|NCT01223716|Behavioral|Video Game|"Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week)."
45398893|NCT01223716|Behavioral|Crossover (Occlusion therapy + Video Game)|"Phase 1. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).~Phase 2. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks)."
45398894|NCT03931018|Other|Alcohol|Administration of one dose of alcohol among two possible different doses (in males) or only one possible dose (in females) simulating a binge drinking episode under experimental conditions.
45398895|NCT03928444|Procedure|intradermal injection of adipose derived stem cells to one side of the face|"Lipoaspiration for preparation of ADSC will be done according to the following technique:~Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of (50 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe.~Autologous adipose tissue derived stem cells (At-ADSCs) will be separated from the lipo-aspirate using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine.~Viability of collected cells will be checked using trypan blue stain. Characterization of the isolated ADSCs population will be performed by flow cytometry."
45398896|NCT03928444|Procedure|intradermal injection of saline to one side of the face|intradermal injection of saline to one side of the face
45398897|NCT01126450|Drug|lenalidomide|Given orally
45398898|NCT01126450|Biological|cetuximab|Given IV
45398899|NCT01126450|Other|mutation analysis|Correlative studies
45398900|NCT01126450|Other|polymerase chain reaction|Correlative studies
45398901|NCT01126450|Genetic|polymorphism analysis|Correlative studies
45398902|NCT03930940|Device|remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuffs placed on arm and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 4 to 5 times.
45398903|NCT03930940|Other|Regular treatment|Regular treatment is based on associated guidelines for ICH.
45398904|NCT03931096|Other|Quality of life questionnaire|Self and proxy PedsQL 4.0 questionnaires.
45398905|NCT01225978|Device|GeneInsight Clinic (GIC)|"GeneInsight Clinic (GIC) is a clinical interface tool that provides genetics IT support infrastructure designed to address key genetic data and knowledge management issues.~The GIC enables the delivery of patient specific alerts when new information is learned about a variant after it has been reported to a treating clinician. The prototype for this study shows multiple tests, Hypertrophic Cardiomyopathy test updates, hearing loss test updates and broad spectrum genotyping test updates. Our intention is to build this functionality in a scalable manner that will ultimately accommodate whole genome sequencing."
45398906|NCT01223872|Other|interview|"Standard Interview (2-15 years from last treatment)~Demographic data interview (pre-initial study interview)"
45398907|NCT01223872|Other|clinic visit and interview|"REACH Clinic Visit(initial or regular)~Post-REACH Clinic Interview (3mos from initial or regular clinic visit)~Demographic data interview(pre-initial study interview)"
45398908|NCT01223872|Other|interviews and clinic visit|"Pre-REACH Clinic Interview(2-15 yrs from last treatment)~REACH Clinic Visit(initial or regular)~Post-REACH Clinic Interview(1mo from initial clinic visit)~Post-REACH Clinic Interview(3mos from initial or regular clinic visit)~Demographic data interview(pre-initial study interview)"
45398909|NCT01220830|Device|Cytotron|Exposure to RFQMR with Cytotron for 28 consecutive days for one hour daily.
45398910|NCT01073384|Drug|SGX201 (delayed release beclomethasone 17,21-dipropionate)|Delayed release beclomethasone 17,21-dipropionate before the first administration of radiation therapy continuing for 7 days after the end of radiation therapy.
45398911|NCT01126528|Dietary Supplement|Vitamin D3|35,000 IU per week, started at 26-29 weeks gestation, until delivery.
45398912|NCT01126528|Dietary Supplement|Placebo control|Miglyol 812, administered weekly from 26-29 weeks gestation until delivery.
45398913|NCT01329172|Other|polyunsaturated fatty acids n-3|polyunsaturated fatty acids n-3 1 gram per day during two months
45398914|NCT01329172|Other|placebo|sun flower oil with Poly Unsaturated Fatty Acid 1g/day
45697712|NCT04534881|Drug|Placebo|Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.
45398915|NCT00225212|Drug|Rituximab 375 mg/m2|
45398916|NCT03853330|Device|Ultrasound|Ultrasound-guided Thoracic Epidural Analgesia and Erector spinae plane block.
45398917|NCT03853330|Drug|Bupivacaine HCl Inj 0.25%|Bupivacaine HCl Inj 0.25% will be used in both blocks by the same dose of 7.5-12 ml
45697713|NCT02468752|Drug|Oxygen|
45697714|NCT02468752|Other|Air|
45697715|NCT04817956|Drug|Atezolizumab|drugs used outside indication, based on biomarker
45398918|NCT03853330|Drug|Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution|infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h will be used in both blocks and also for breakthrough pain after both blocks as a bolus of 5-10 ml.
45398919|NCT01581944|Drug|2 Doses Goserelin|3.6mg administered monthly for 2 months prior to myomectomy
45398920|NCT01581944|Drug|3 Doses Goserelin|3.6mg administered monthly for 3 months prior to myomectomy
45398921|NCT01226056|Drug|RAD001 in combination with sorafenib|"Phase I / Dose escalation: during the first cycle RAD001 (2.5-10 mg/day) will be administered alone, once a day, on days 1-14 to allow PK-profiling of the drug. From day 15 sorafenib administration (400-800 mg/day) twice a day will be added.~The cycle 1 will last 6 weeks, subsequent cycles will last 4 weeks (the 2 drugs administered in combination from day 1 to day 28).~Phase II: The drugs will be administered at the Recommended Dose and each treatment cycle will last 4 weeks."
45398922|NCT01127932|Behavioral|Psychoeducation for substance abuse|This active control provides detailed information about substance use, suicide risk, and depression to those enrolled.
45398923|NCT01127932|Behavioral|CBT for suicide in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
45398924|NCT00162032|Drug|Sestamibi|Sestamibi
45398925|NCT01226134|Drug|Itopride,|Itopride,50 mg capsules,thrice a day,for Four weeks
45398926|NCT01226134|Drug|Placebo|placebo capsules,thrice a day for four weeks
45398927|NCT01126606|Drug|Dermacid Silver (Lactic acid)|Liquid soap, daily use
45398928|NCT01126606|Drug|Glycerine Vegetal Soap Granado Traditional|Vegetal soap, daily use
45398929|NCT03968120|Other|Change of ventilatory settings|Change of Positive End-Exspiratory Pressure during one-lung ventilation
45398930|NCT01329406|Drug|Milnacipran|1 tablet (100mg) by mouth twice daily for 28 days
45398931|NCT01329406|Drug|Placebo|1 tablet by mouth twice daily for 28 days
45398932|NCT00258674|Other|Medicare Claims Feedback|Physician practices received periodic feedback on their performance on selected diabetes quality of care measures as reflected by the Medicare claims data for their patients.
45398933|NCT00258674|Other|Medical Record Review|Physician practices received period feedback on their performance on selected diabetes quality of care measures, as reflected by data collected from their patients' medical records. These data were compiled by trained nurse abstractors using a standardized data collection tool developed for this study.
45398934|NCT00258674|Other|Diabetes Resource Nurse|Diabetes Resource Nurses (DRNs) were registered nurses with 3-5 years of experience as certified diabetes educations who performed initial patient assessments, developed plans of care, administered screening tools, and monitored clinical outcomes. Physicians at the practices randomised to this intervention had could access the DRN's services for their diabetes patients, but neither physicians nor patients had to take advantage of this resource.
45398935|NCT01126684|Drug|Atorvastatin|10 mg of atorvastatin once daily for six months
45398936|NCT01126684|Drug|Placebo|placebo once daily for six months
45398937|NCT01224028|Drug|Tacrolimus|oral
45398938|NCT01224028|Drug|Placebo|oral
45697716|NCT04672239|Behavioral|"Smartphone app Smiling instead of Smoking (SiS) Version 3"|Participants will be onboarded to the smartphone app SiS and will be asked to use it for 7 weeks to support them in quitting smoking.
45697717|NCT04672239|Behavioral|"Smartphone app QuitGuide (QG)"|Participants will be onboarded to the NCI smartphone app QG and will be asked to use it for 7 weeks to support them in quitting smoking.
45697718|NCT04672239|Behavioral|"Brochure Clearing the Air (CTA)"|"Participants will be onboarded to the brochure Clearing the Air and will be asked to use it for 7 weeks to support them in quitting smoking."
45697719|NCT01894919|Biological|Bexsero® vaccine (1 dose at study month zero)|
45398939|NCT01226212|Dietary Supplement|Synbiotic (Synergy 1/B. longum)|Combination of a prebiotic Synergy 1 and a probiotic Bifidobacterium longum
45398940|NCT01226212|Dietary Supplement|Placebo|maltodextrose
45507092|NCT02359331|Procedure|H. pylori culture and antimicrobial susceptibility testing|"This intervention will be performed in 7 days tailored therapy group.~All the patients who enrolled in this arm, they will be received endoscopy guided biopsy procedure. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin, clarithromycin, metronidazo, tetracycline and moxifloxacin for the H. pylori isolates were examined by use of the serial two fold agar dilution method"
45398941|NCT01075490|Drug|clonidine|addition of 1 µg/kg of clonidine to bupivacaine 1 mg/kg as spinal anesthesia
45398942|NCT01075490|Drug|clonidine|equivalent volume of saline added to bupivacaine, 1 mg/kg as spinal anesthesia
45697720|NCT01894919|Biological|Bexsero® vaccine (2 doses 1 month apart)|
45697721|NCT04418206|Other|patients COVID 19|Exposure to SARS-Cov2 but no symptoms (patient's family, medical staff) and General population (volunteers not exposed to SARS-Cov2)
45697722|NCT04130698|Behavioral|Distress Tolerance|The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with distress tolerance intervention to quit smoking and lose weight.
45507093|NCT02359331|Drug|14 days empirical bismuth quadruple therapy (Proton pump inhibitor)|"Giving the 14 days PBMT regimen as 2nd rescue therapy~Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d."
45507094|NCT02359331|Drug|Metronidazole|
45398943|NCT01126138|Drug|Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine|Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) Vinorelbine: 25 mg/m2 IV over 3 hours on day 1 and 8, every 3 weeks 21 days as one cycle and 6 cycles are required
45398944|NCT01126138|Drug|Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine|"Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14), Docetaxel: 75 mg/m2 IV over 3 hours on day 1, every 3 weeks, 21 days as one cycle and 6 cycles are required.~Followed by Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) 21 days as one cycle until progression or unacceptable toxicity"
45398945|NCT03930706|Other|Longer administration of estradiol (Progynova®)|All women included will take exogenous hormone with daily administration of Estradiol Valerate (Progynova®), the standard dose used will be 6 mg/day (Cobo et al., n.d.). On day 7 of endometrial preparation patients will be examined with vaginal ultrasound and blood test, to evaluate the endometrial thickness and the hormones levels. In both arms the FET will take place after 6 days of Progesterone supplementation (600 mg per day, vaginal administration of Utrogestan®) According to embryo quality after warming, embryo transfer to the uterine cavity will be performed on day 5 of development under ultrasound guidance whenever possible. Following embryo transfer, luteal support will be continued with vaginally administered P (Utrogestan®). All patients 12 days after the FET will undergo the pregnancy test (blood test to evaluate hCG).
45398946|NCT03930862|Device|Locator Attachment (positioner)|intra oral attachment
45398947|NCT01224184|Behavioral|Young Women's CoOp|Participants in this group will participate in three individual sessions and one group session of the young woman-focused intervention about HIV/STIs, pregnancy, alcohol and other drug use, violence, gangs and other issues. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
45398948|NCT01224184|Behavioral|Staying Healthy and Eating Well|Participants in this group will participate in three individual sessions and one group session of the nutrition intervention about healthy eating, physical activity and general wellness.
45398949|NCT03932578|Drug|Atropine sulfate|Patients will receive intrathecal 100 μg of a 1 mg/ml preservative-free atropine sulfate solution
45507095|NCT02359331|Drug|Tetracycline|
45507096|NCT02359331|Drug|tripotassium dicitrate bismuthate|
45507097|NCT02359331|Drug|7 days tailored therapy Proton Pump Inhibitor|
45507098|NCT02359331|Drug|Moxifloxacin|
45507099|NCT02359331|Drug|Amoxicillin|
45507100|NCT02322814|Drug|Cobimetinib|Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.
45507101|NCT02322814|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m^2) by intravenous (IV) infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.
45507102|NCT02322814|Drug|Placebo|Placebo matching to cobimetinib will be administered orally, once a day, on Day 3 through Day 23 of each 28 day treatment cycle.
45398950|NCT03932578|Drug|Metoclopramide|Patients will receive IV metoclopramide 10 mg in 2 ml
45398951|NCT01126762|Behavioral|Dietary advice|Dietary advice regarding consumption of low mercury, high DHA fish
45398952|NCT01126762|Behavioral|Control|Advice regarding healthful diet during pregnancy, not focused on fish intake
45507103|NCT02322814|Drug|Atezolizumab|Atezolizumab will be administered to Cohorts II and III at a dose of 840 mg IV every 2 weeks on Days 1 and 15 of each 28-day treatment cycle.
45507104|NCT02322814|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered to Cohort III according to the local prescribing information at a starting dose of 100 mg/m^2 by IV infusion on Days 1, 8, and 15 of each 28 day cycle.
45507105|NCT02234947|Procedure|MRI, US, and blood samples|All groups will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and blood samples. These test will be compared to the testing from the other groups.
45507106|NCT02170168|Other|integrated palliative care program|a standardised care pathway, an educational programme and information to general public, patients and their carers
45507107|NCT02161263|Other|Patient Quality of Life andVision after LASIK Surgery|Patient questionnaire
45507108|NCT02136134|Drug|Daratumumab|Daratumumab will be administered as an IV infusion or 16 mg/kg weekly for the first 3 cycles, on Day 1 of Cycles 4-9, and then every 4 weeks thereafter. As per protocol amendment-6 participants receiving treatment with daratumumab IV will have the option to switch to daratumumab SC 1800 mg on Day 1 of any cycle, at the discretion of the investigator.
45507109|NCT02136134|Drug|VELCADE (Bortezomib)|VELCADE will be administered at a dose of 1.3 mg/m2 subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle. Eight VELCADE treatment cycles are to be administered.
45507110|NCT02136134|Drug|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 VELCADE treatment cycles.
45507111|NCT02133521|Drug|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
45507112|NCT02133521|Drug|Placebo|Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
45507113|NCT02108964|Drug|EGF816|EGF816 will be dosed once daily. On the first day of each treatment cycle, the patient receives an adequate drug supply for self-administration at home. The investigator will instruct the patient to take EGF816 exactly as prescribed.
45507114|NCT02057133|Drug|LY2835219|Administered orally.
45398953|NCT00258440|Drug|Weekly procrit dosing|The dose is standard of care, the investigational piece is the dosing schedule itself. Either weekly or Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week.
45398954|NCT00258440|Drug|Interval Dosing|The dosing of Procrit is standard of care, it is the schedule that is the investigational piece.
45398955|NCT01075568|Dietary Supplement|Nutrigal Okara - 100|
45398956|NCT01226368|Other|Biological Sample collection|Cervix cells
45398957|NCT01220986|Procedure|Liver biopsy|0, 30, 60, 90 min post inflow-division
45849826|NCT04504500|Behavioral|Attendance of local cesarean section meetings|Local cesarean section meetings will be held weekly, in each unit. The members of the steering committee or local opinion leaders may actively participate in these meetings. Local obstetricians learn to judiciously adapt standard medical practices, thereby avoiding unnecessary medical interventions. This is a way to further enhance compliance, as during the discussions the behavior expected of the obstetricians is clearly stated by the participating opinion leaders.
45849827|NCT04504500|Behavioral|Attendance of local CTG interpretation meetings|"Local CTG interpretation meetings will be held weekly, in each unit, during which all abnormal CTG cases that led to cesarean section will be reviewed and discussed. Members of the Steering Committee or local opinion leaders may actively participate in these meetings. Obstetricians are encouraged to reflect on their medical practice through judicious physiology-based CTG interpretation."
45849828|NCT04504500|Behavioral|Reminders of proper clinical practice|Effective and reliable reminders concerning optimal obstetric practice will be placed in labor wards, staff rooms, patient notes, vaginal birth packages and above theater hand washers. There will be short messages with positive phrasing regarding the benefits of vaginal birth, thus reminding birth attendants to reduce unnecessary cesarean sections. Relevant SMS (short message service) will be sent to the participating obstetricians' mobiles on a regular basis, so as to motivate them via non-verbal signals.
46059112|NCT02583295|Behavioral|Music sound|The recorded preferred songs or music (commercially available) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
45398958|NCT01329250|Drug|Moxifloxacin|Patients will start on a standard dose of MFX 400 mg once daily. After 8 days the dose will be increased to 600 mg once daily and on the 15th day of treatment, the dose of MFX will be escalated to 800 mg. In patients who have been treated with rifampicin (RIF) in the past three weeks prior to start of MFX treatment an additional washout period of 3 weeks to reduce the rifampicin induced enzymatic activity will precede the dose escalation.
45398959|NCT00224120|Drug|Silodosin|8 mg daily for 12 weeks
45398960|NCT00224120|Other|Placebo|One capsule daily for 12 weeks
45398961|NCT01224340|Behavioral|lollipop|The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
45398962|NCT01224340|Behavioral|serious games|The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path.
45398963|NCT01224340|Other|control|The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
45398964|NCT01226446|Drug|vitamin D|Vitamin D on top of the standard treatment
45398965|NCT01224418|Drug|Tacrolimus|oral
45398966|NCT00257660|Biological|Botulinum toxin type A|500 units
45398967|NCT00257660|Drug|Placebo|500 units
45398968|NCT01221064|Procedure|Early drainage removal|Drainage will be removed in postoperative day 1
45398969|NCT01221064|Procedure|Late drainage removal|Drains will be kept until daily drainage is 30ml and then removed
45507115|NCT02057133|Drug|Letrozole|Administered orally.
45507116|NCT02057133|Drug|Anastrozole|Administered orally.
45398970|NCT01129180|Drug|azacitidine|Given SC
45398971|NCT01129180|Drug|bortezomib|Given IV
45398972|NCT01129180|Procedure|Correlative studies|Correlative studies will be collected pre-treatment, day 4 , day 15, day 29(pre-cycle 2)
45398973|NCT03972020|Behavioral|Mindfulness Based Intervention|"The MBI used in this study is called body-affective mindfulness (BAM); BAM is based on:~(1) awareness practices such as body scan, breath meditation, walking meditation and yoga exercises; (2) mindfulness in relationship practices such as loving kindness, enriching listening to nature and persons and self-compassion; (3) sensorimotor psychotherapy Sensorimotor psychotherapy emphasizes the use of somatic resources to attain and sustain a mindful disposition and integrates the concept of a stress response with the concept of a window of tolerance in order to maximize the clinical utility of the intervention and tailor it to breast cancer patients."
45398974|NCT03972020|Behavioral|Cognitive Behavioral Therapy|Cognitive behavior therapies will include cognitive restructuring, relaxation, skills training, and visual imagery, among other modalities.
45507117|NCT02057133|Drug|Tamoxifen|Administered orally.
45398975|NCT01221142|Device|"Cincinnati Sub-Zero, Blanketrol III"|
45398976|NCT01128166|Device|COGNIS CRT-D|"Patients with existing or newly implanted COGNIS® CRT-D pulse generators (PG)are enrolled in the study. PG is modified by the download of investigational software called Sensor Research Device-1™ (SRD-1). The goal of the SRD-1 system is to collect sensor data without affecting the delivered CRT-D therapy. This is accomplished through the conversion of an implanted COGNIS PG into a SRD-1 PG by downloading investigational software. Only a market approved COGNIS model N119/N120/P107/P108 device may be converted to a SRD-1 investigational device. There will be no PG hardware changes resulting from the conversion."
45398977|NCT00224042|Drug|Sodium Ferric Gluconate complex in sucrose|Sodium ferric gluconate complex in sucrose, 250 mg IV weekly for 4 doses
45398978|NCT00224042|Drug|Ferrous sulfate tablets|ferrous sulfate 325 mg three times daily for 6 weeks
45398979|NCT01129258|Drug|PF-04991532|Subjects will be dosed wtih PF-04991532 for 14 days. The tentative dosing schedule is 30, 100, 300, 1000, and 1500 mg QD, and 150 and 500 mg BID). Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as tablets (10, 50, and 150 mg strengths). In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
45398980|NCT01129258|Drug|Placebo|Placebo to match PF-04991532 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
45398981|NCT01224496|Drug|Chinese herbal concoction twice a day for 6 months|Definition of each TCM syndrome is based on TCM theory. Formulation composition is based on each defined TCM syndrome with addition or removal of herbs as indicated by the patient's manifestation
45398982|NCT01221220|Behavioral|Standard Packard Pediatric Weight Control Program|Six-month, family-based, group, behavioral weight control program
45398983|NCT01221220|Behavioral|Standard Packard Pediatric Weight Control Program plus Home-based advising on environmental changes|Six-month, family-based, group, behavioral weight control program plus Home-based Environmental strategies intervention
45398984|NCT01226524|Drug|Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan|A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulation
45398985|NCT01221376|Drug|Imatinib Mesylate|Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maximum allowed 400 mg, for 24 months.
45398986|NCT03928132|Behavioral|CPD Workshop on Depression and Diabetes|2 parallel face-to-face onsite workshops on diabetes and depression in primary care given by experts in French (control and experimental) using Powerpoint presentations.
45398987|NCT01224652|Drug|Paclitaxel|Paclitaxel, 70 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1, 8 and 15 of a 28-day cycle
45398988|NCT01224652|Drug|Irinotecan|irinotecan 150 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1 and 15 of a 28-day cycle
45398989|NCT00160706|Biological|Certolizumab Pegol (CDP870)|"Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Weeks 0, 2, 4 and thereafter every 4 weeks until Week 360.~Up to 84 months of therapy in this study."
45398990|NCT03928210|Drug|Digoxin|Patients will receive a daily maintenance dose of digoxin. The daily dose of digoxin will be calculated according to the renal function and the target serum digoxin concentration and applied in an adjusted regimen based on the availability of 0.125 mg and 0.25 mg pills in the morning (before 10 am). Blood samples for analyses of mean CTC cluster size will be drawn at screening, on day 0 (2 hrs after first oral intake), on day 3 and on day 7. Depending on the digoxin serum level maintenance therapy with digoxin will be continued up to 3 weeks if the digoxin serum level on day 7 or day 14 is below 0.70 ng/ml. For the third week of maintenance therapy individual dose adjustments will be carried out as needed.
45398991|NCT01226602|Drug|AZD6140|P2Y12 receptor antagonist
45507118|NCT02057133|Drug|Exemestane|Administered orally.
45507119|NCT02057133|Drug|Everolimus|Administered orally.
46059113|NCT02583295|Behavioral|Maternal sound|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
45398992|NCT01226602|Drug|Placebo|
45398993|NCT01221454|Procedure|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
45398994|NCT01221454|Drug|Conserved therapy|Oral or intravenous administration
45398995|NCT01224730|Drug|perifosine|100 mg daily
45398996|NCT03930316|Device|NOX T3|portable sleep study device
45398997|NCT03930784|Other|Nil intervention|
45507120|NCT02057133|Drug|Trastuzumab|Administered IV infusion.
45507121|NCT02057133|Drug|LY3023414|Administered orally.
45507122|NCT02057133|Drug|Fulvestrant|Administered IM.
45507123|NCT02057133|Drug|Pertuzumab|Administered IV infusion.
45507124|NCT02057133|Drug|Loperamide|Administered orally.
45507125|NCT02057133|Drug|Endocrine therapy|Endocrine therapy administered orally.
45398998|NCT01224808|Biological|Biostate|Single bolus doses, administered intravenously. Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
45507126|NCT02026908|Device|Prostate Artery Embolization|Procedure completed in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Embosphere microspheres to slow/block blood flow to the prostate.
45507127|NCT01922791|Dietary Supplement|Comparison of probiotics, fish oil and their combination to placebo|Double-blind randomized placebo controlled intervention
45398999|NCT03927976|Behavioral|Path2Quit - culturally specific text message intervention|SMS text delivers over 6 weeks with links to 20-120 second video clips from PTF. The message library contains 155 videos and assessment questions. First message is tailored to wake-up times, and the topic of the video (e.g., Never Quit Quitting) accompanies the text. Messages are pushed to participants 1-2 times/day, with 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP). Participants also receive inquiry texts, designed to push videos of interest/relevance to the individual. The cultural adaptations are infused throughout the video segments. Topics include deep structure: race and smoking in general, African American smoking statistics; norms for smoking; concerns about nicotine replacement/medication; family/collectivism; unique stressors; racism/discrimination, depression; co-morbid addiction; neighborhood/environmental influences; menthol cigarettes; race-specific weight issues and concerns; and working as a community against the tobacco industry.
45507128|NCT01904188|Device|Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z regularly)|The Gene Z device or other rapid diagnostic techniques that we have developed in our lab will be used to analyze previously processed specimens for microbial organisms and compared to prior culture and sensitivity results. It is not a separate arm - all samples will be cultured in lab per standard protocol and then the Gene Z device or other rapid diagnostic techniques developed in our lab will be used to re-analyze at a later date specimens that were previously frozen and stored and compared to culture results
45507129|NCT01896479|Drug|Cabozantinib (XL184) 140 mg|
45507130|NCT01896479|Drug|Cabozantinib (XL184) 60 mg|
45507131|NCT01896479|Drug|Placebo tablet|
45507132|NCT01896479|Drug|Placebo capsule|
45507133|NCT01894308|Drug|Testosterone|10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.
45507134|NCT01894308|Device|Pump Sprayer|A dose of product solution is delivered by means of a metered pump spray.
45507135|NCT01837862|Drug|Mebendazole|Mebendazole will be given orally twice daily for over the course of treatment (70 weeks for low-grade glioma patients, 48 weeks for high-grade glioma/pontine glioma patients). Mebendazole will be prescribed according to the particular dose cohort for each patient (50 mg/kg/day, 100 mg/kg/day, or 200 mg/kg/day).
45507136|NCT01837862|Drug|Vincristine|Low-grade glioma patients only. Vincristine will be dosed as per the following: For patients < 12kg: 0.05 mg/kg; for patient > 12kg: 1.5mg/m2 (maximal dose 2.0 mg). Vincristine will be administered intravenously on Day 1 of weeks 0,1,2,3,4,5 during the 10-week induction cycle and on Day 1 of Weeks 0,1,2 of the six 10-week maintenance cycles.
45507137|NCT01837862|Drug|Carboplatin|Low-grade glioma patients only. Carboplatin will be dosed at 175 mg/m2. Carboplatin will be administered intravenously on Day 1 of Weeks 0,1,2,3 of the 10-week Induction cycle, and on Day 1 of Weeks 0,1,2,3 during the six 10-week maintenance cycles.
45507138|NCT01837862|Drug|Temozolomide|Low-grade glioma patients only. Temozolomide will be dosed at 200 mg/m2/day. Temozolomide will be given orally for 5 days during Week 6 of the 10-week induction cycle and for 5 days during Week 6 of the six 10-week maintenance cycles.
45507139|NCT01837862|Drug|Bevacizumab|High-grade glioma/pontine glioma patients only. Bevacizumab will be dosed at 10mg/kg/dose. Bevacizumab will be administered intravenously on Days 1 and 15 of each maintenance cycle.
45507140|NCT01837862|Drug|Irinotecan|High-grade glioma/pontine glioma patients only. Irinotecan will be administered at doses 125 mg/m2, 150 mg/m2, 250 mg/m2, or 300 mg/m2, depending on patient tolerance and concomitant enzyme-inducing anti-epileptic medication use. Irinotecan will be administered intravenously on Days 1 and 15 of each maintenance cycle.
45507141|NCT01675219|Procedure|white light TUR-BT|traditional transurethral bladder tumor resection
45507142|NCT01675219|Procedure|blue light TUR-BT|photodynamic transurethral bladder tumor resection
45507143|NCT01675219|Drug|optimized MMC|six weekly optimized mitomycin-C instillations
45507144|NCT01675219|Drug|single immediate chemotherapy instillation|single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation
45507145|NCT01590069|Biological|Aerosolized Aldesleukin|Breathe aerosolized aldesleukin
46059114|NCT04307407|Behavioral|Aerobic Exercise|Participants will be randomized to supervised aerobic exercise or standard care. Women with no current or past malignant disease will comprise the reference group and will be matched for age to participants in the Aerobic Exercise arm
46059115|NCT04449211|Device|Implantation|Reconstructing the long bone defect with 3D-printed customised Titanium alloy implant
45507146|NCT01590069|Other|Laboratory Biomarker Analysis|Optional correlative studies
45507147|NCT01529593|Drug|Temsirolimus|"Starting dose: 25 mg by vein weekly.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled."
45507148|NCT01529593|Drug|Metformin|"Starting dose: 500 mg titrated over first 3 weeks.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled"
45399000|NCT01221532|Behavioral|SHHE Peridischarge Intervention|"Support from Hospital to Home (SHHE) Peridischarge Intervention patients will receive Usual care plus~a visit with in-hospital registered nurse, who provides additional patient education, assesses patient's needs post-hospitalization, communicates with the medical team, and develops a personalized discharge plan;~two phone calls from a nurse practitioner(NP)/physician assistant (PA) after discharge, in which adherence to medications, treatment plan, and access to outpatient care, and other issues identified during the hospitalization will be explored;~the provision of a phone support line, on which an NP/PA will call patients back within 24 hours to answer questions and assist transition to outpatient care."
45399001|NCT01226680|Drug|Tasocitinib|0.005% QD for 12 weeks
45399002|NCT01226680|Drug|Tasocitinib|0.003% QD for 12 weeks
45399003|NCT01226680|Drug|vehicle for Tasocitinib|vehicle QD for 12 weeks
45399004|NCT03930394|Diagnostic Test|Contrast ultrasound perfusion imaging|Contrast ultrasound perfusion imaging for microvascular perfusion, and carotid ultrasound data on intima-media thickness (or plaque size) will be serially assessed in subjects started on ponatinib.
45399005|NCT00257192|Drug|placebo|Placebo matching the oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing <45 kg, the doses will range from 20 mg BID to 40 mg BID.
45399006|NCT00257192|Drug|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg BID to a maximum dose range of 80 mg BID. For subjects weighing <45 kg, the doses will range from 20 mg BID to 40 mg BID.
45399007|NCT01226758|Biological|Influenza vaccine (FLU-v)|FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences) and adjuvant. Administered by single subcutaneous injection.
45399008|NCT01226758|Biological|Placebo (adjuvant only)|Single subcutaneous injection of adjuvant
45399009|NCT03927898|Drug|Toripalimab|Participants receive Toripalimab (240mg)/q3w till progression of disease after SBRT
45399010|NCT03927898|Radiation|Stereotactic Body Radiotherapy|Participants receive SBRT (BED>80Gy) to oligometastatic lesions followed by Toripalimab (240mg)/q3w
45399011|NCT01224964|Drug|Montelukast|Montelukast, 10 mg
45399012|NCT01224964|Drug|long acting beta2 mimetic|ICS+long acting beta2 agonist: twice daily
45507149|NCT01446133|Drug|Rituximab|375 mg/m2 by vein on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2.
45507150|NCT01446133|Drug|Lenalidomide|10 mg/day by mouth daily beginning on Day 9 of cycle 1.
45507151|NCT01436227|Other|Laboratory Biomarker Analysis|Correlative studies
45507152|NCT01436227|Drug|Pazopanib Hydrochloride|Given PO
45507153|NCT01424982|Drug|Cyclophosphamide|Given IV
45507154|NCT01424982|Drug|Cytarabine|Given IV
45507155|NCT01424982|Drug|Dexamethasone|Given IV or PO
45507156|NCT01424982|Drug|Doxorubicin|Given IV
45507157|NCT01424982|Drug|Doxorubicin Hydrochloride|Given IV
45399013|NCT03932734|Other|survey|Face-Q conversion table
45399014|NCT01126918|Behavioral|Body Project|Participants in this intervention attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
45399015|NCT00256724|Device|Impedance Threshold Device|Active impedance threshold device
45399016|NCT00256724|Device|sham ITD|sham impedance threshold device
45507158|NCT01424982|Other|Laboratory Biomarker Analysis|Correlative studies
45507159|NCT01424982|Drug|Methotrexate|Given IV
45507160|NCT01424982|Drug|Ponatinib|Given PO
45507161|NCT01424982|Drug|Ponatinib Hydrochloride|Given PO
45507162|NCT01424982|Drug|Prednisone|Given PO
45507163|NCT01424982|Biological|Rituximab|Given IV
45507164|NCT01424982|Drug|Vincristine|Given IV
45507165|NCT01424982|Drug|Vincristine Sulfate|Given IV
45507166|NCT01333033|Drug|Oxaliplatin|Given IV
45507167|NCT01333033|Drug|Leucovorin Calcium|Given IV
45399017|NCT03928054|Other|Kinesio Taping and therapeutic alliance|bandage used in the treatment of orthopedic diseases and the technique of therapeutic approach in the known patient with therapeutic alliance
45399018|NCT03930550|Procedure|Tracheal intubation by endoscopy with flexible bronchoscope|A blinking infrared light source is placed on the anterior neck at the level of the cricothyroid membrane to serve as a guide to facilitate finding the way to the trachea
45697723|NCT04130698|Drug|transdermal nicotine patch|Participants will use the patch for 8 weeks as outlined by the recommended usage for steps 1-3 going from 21mg for 4 weeks, 14mg for 1 week, and 7mg for 1 week.
45399019|NCT03967964|Drug|Dehydroepiandrosterone 2.2 g|Vaginal ring with 2.2 grams DHEA.
45697724|NCT04130698|Behavioral|Active Health Control|The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with psychoeducation intervention to quit smoking and lose weight.
45399020|NCT03967964|Drug|Dehydroepiandrosterone 1.5 g/Testosterone 25 mg|Vaginal ring with DHEA 1.5 grams/Testosterone 25 mg.
45399021|NCT03967964|Drug|Testosterone|Vaginal ring with 35 mg testosterone.
45399022|NCT03967964|Drug|Testosterone Topical Gel|Gel containing 1% testosterone.
45399023|NCT03967964|Drug|Dehydroepiandrosterone Oral Capsule|Capsule containing 25 mg DHEA
45399024|NCT01129414|Drug|Clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
45399025|NCT01129414|Drug|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
45399026|NCT01129414|Drug|Omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration: oral"
45507168|NCT01333033|Drug|Fluorouracil|Given IV
45507169|NCT01333033|Drug|Carboplatin|Given IV
45507170|NCT01333033|Drug|Paclitaxel|Given IV
45507171|NCT01333033|Procedure|Positron Emission Tomography|Undergo PET/CT scan
45507172|NCT01333033|Procedure|Computed Tomography|Undergo PET/CT scan
45507173|NCT01333033|Radiation|Radiation Therapy|Undergo RT
45507174|NCT01327690|Behavioral|CBT (Cognitive Behavior Therapy)|CBT group therapy sessions
45507175|NCT01327690|Behavioral|EFT (Emotional Freedom Techniques)|Group therapy sessions using EFT
45507176|NCT01192776|Procedure|Whole-body Cooling|Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.
45507177|NCT01187199|Drug|Temsirolimus|Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle.
45507178|NCT01187199|Drug|Bevacizumab|Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
45507179|NCT01187199|Drug|Paclitaxel|Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle.
45697725|NCT04667949|Drug|Fingolimod 0.5mg|Subjects will receive fingolimod 0.5mg capsule QD up to month 24
45697726|NCT05306223|Drug|Bedaquiline|Bedaquiline uncoated tablets will be administered orally.
45399027|NCT03967730|Combination Product|Sonodynamic therapy(SDT)|Sonodynamic Therapy (SDT) Sinoporphyrin Sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection(0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15 min of each lesion. Ultrasound parameters included intensity of 2.1W/cm2 for each lesion, resonance frequency: 1.0 MHz and duty factor: 30%.
45399028|NCT03930238|Behavioral|VA MapTrek|The objective is to report activity levels in our virtual environment to Veterans, thereby encouraging them to walk more.
45399029|NCT03930238|Behavioral|Fitbit Only|Fitbit Only
45399030|NCT03967886|Drug|YYD601 20mg|Patients should take drugs an hour before breakfast.
45399031|NCT03967886|Drug|Nexium 20mg|Patients should take drugs an hour before breakfast.
45399032|NCT03967886|Drug|Placebos|The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
45399033|NCT01129492|Device|Low-level Laser therapy|A continuous wave (CW) diode laser device (830nm, infrared) with a beam area of 0.2827cm2 and using the punctual method, continuous emission mode, output power of de 50mW and fluence of 70J/cm2 (40 seconds at the point of application).
45399034|NCT03968042|Drug|Nerve Growth Factor|Intramuscular injection for 2 weeks
45399035|NCT03968042|Drug|Edaravone|Intravenous injection for 2 weeks
45507180|NCT01187199|Drug|Sorafenib|Starting dose 200 mg by mouth daily for a 21 day cycle.
45507181|NCT01187199|Drug|Carboplatin|Starting dose AUC 2 by vein on day 1 of a 21 day cycle.
45507182|NCT01169831|Other|Exercise Training|2 weeks of daily aerobic exercise training
45507183|NCT01169831|Other|Exercise Cessation|Stopping all exercise for 2 weeks
45507184|NCT01048853|Procedure|Lymph Node Mapping|Undergo lymphatic mapping with sentinel lymph node biopsy
45507185|NCT01048853|Other|Quality-of-Life Assessment|Ancillary studies
45507186|NCT01048853|Procedure|Salpingo-Oophorectomy|Undergo hysterectomy with or without salpingo-oophorectomy
45697727|NCT05306223|Drug|Levofloxacin|Levofloxacin filmcoated will be administered orally
45697728|NCT05306223|Drug|Linezolid|Linezolid tablets will be administered orally
45697729|NCT05306223|Drug|Cycloserine|Cycloserine capsules will be administered orally.
45697730|NCT05306223|Drug|Clofazimine|Clofazimine capsules will be administered orally.
45849829|NCT04504500|Other|HSOG guidelines implementation|There will be application in daily practice of three guidelines and two consent forms pertaining to the mode of delivery published by HSOG. Obstetricians are informed on evidence-based medicine in obstetrics and provided with a structured and safe approach to labor management. The members of the appointed Steering Committee and/or local opinion leaders discuss and disseminate the guidelines among the professional staff at the respective maternity units, answer questions, and make available their knowledge and experience. Adoption of guidelines by the participating unit helps to establish clear, consistent rules that are direct and simple, and obstetricians are asked to embrace fully justified medical practice.
45399036|NCT03968042|Drug|Combination of vitamin B1, B6, C, E and mecobalamine|Medications of combination of vitamin B1, B6, C, E and mecobalamine for 6 months
45507187|NCT01048853|Procedure|Sentinel Lymph Node Biopsy|Undergo lymphatic mapping with sentinel lymph node biopsy
45507188|NCT01048853|Procedure|Therapeutic Conventional Surgery|Undergo hysterectomy with or without salpingo-oophorectomy
45507189|NCT00904241|Other|Cytology Specimen Collection Procedure|Correlative studies
45507190|NCT00904241|Other|Laboratory Biomarker Analysis|Correlative studies
46057089|NCT02713347|Behavioral|ADAPT Intervention|"The intervention includes 3 components:~nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, and pain.~social worker provides structured counseling targeting adjustment to illness and depression and advance care planning.~collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. The team has as-needed consultation with a cardiologist or pulmonologist. The nurse and social worker visits are in-person or by phone."
46057090|NCT04981366|Dietary Supplement|Protein supplement|40g of whey protein in the breakfast;
45507191|NCT00778063|Drug|dexmedetomidine|2 mcg/kg intranasally 30 minutes prior to surgery
45507192|NCT00778063|Drug|saline|a volume of intranasal saline, calculated based on body weight, will be given 30 minutes prior to surgery
45697731|NCT05306223|Drug|Pyrazinamide|Pyrazinamide tablets will be administered orally.
45399037|NCT01225042|Dietary Supplement|probiotics|Freeze-dried powder, dose 10E9 CFU twice daily for 4 weeks
45399038|NCT01225042|Dietary Supplement|placebo|placebo consisting of carrier material powder of identical appearance
45399039|NCT01128322|Drug|S-Amlodipine, Telmisartan|
45399040|NCT01128322|Drug|S-Amlodipine|
45399041|NCT01128322|Drug|Telmisartan|
45507193|NCT00737399|Behavioral|Lifestyle Counseling with Emotional Freedom Techniques (EFT)|Two series of four sessions of phone support group coaching instruction in the use of EFT
45399042|NCT01128322|Drug|Placebo|
45697732|NCT05306223|Drug|Protionamide|Protionamide enteric-coated tablets will be administered orally.
45399043|NCT00157820|Device|Single Chamber Implantable Cardioverter Defibrillator|Single chamber ICD implantation: Medtronic GEM, Medtronic Marquis family of SC ICD
45399044|NCT00157820|Device|Dual Chamber implantable cardioverter defibrilator|Dual chamber ICD implantation: Jewel AF & GemIII AT as DC ICDs (DC true and SC sim arms)
45399045|NCT01126996|Procedure|Venepuncture|"Venepuncture and blood sample collection in 2010 in a sample of children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.~A booster dose of a MenC conjugate vaccine (optional)."
45507194|NCT00547196|Biological|filgrastim|
45507195|NCT00547196|Drug|Busulfan|
45507196|NCT00547196|Drug|Cyclophosphamide|
45507197|NCT00547196|Drug|Cyclosporine|
45507198|NCT00547196|Drug|Fludarabine phosphate|
45507199|NCT00547196|Drug|Melphalan|
45507200|NCT00547196|Drug|Mycophenolate Mofetil|
45507201|NCT00547196|Procedure|allogeneic hematopoietic stem cell transplantation|
45507202|NCT00547196|Procedure|umbilical cord blood transplantation|
45507203|NCT00547196|Radiation|total-body irradiation|
45507204|NCT00547196|Radiation|Fractionated total body irradiation|
45507205|NCT00330941|Drug|lidocaine|
45697733|NCT03016000|Drug|Thalidomide|Thalidomide 50mg daily by mouth( increase 25mg after 2 weeks if tolerated Until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/ day, thalidomide discontinuation was allowed.
45697734|NCT03016000|Other|Observation|Just observation
45697735|NCT04130152|Drug|Palbociclib|Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle
45697736|NCT04130152|Drug|Letrozole|Letrozole: oral, 2.5 mg per day continuously. during the 28-day cycle.
45697737|NCT05304819|Device|AchilloCordPLUS™ System Implant|AchilloCordPLUS System Implant Set for Acute Achilles Tendon Repair
45849830|NCT04504500|Other|Interactive workshops and courses training|The workshops and courses will provide instruction in indications for cesarean section and case scenarios, physiology-based CTG interpretation, obstetric emergencies (with topics including breech delivery, trial of labor after cesarean, delivery of twins, induction and augmentation of labor), organization of labor ward and launching of cesarean section and CTG meetings. This type of formal training provides problem-solving strategies, using mnemonics, that are critical in emergencies and that also aid in learning and retaining the skills being taught. Functional and social skills that directly affect decision-making and effectiveness are addressed. Thus, units adopt a continuous educational procedure for their staff, enhancing their confidence when dealing with labor emergencies and redesigning labor management plans, so as to ensure high-level obstetric services.
45849831|NCT04504500|Other|Implementation of Robson criteria classification|Use will be implemented of an online application embedded in the REDCap electronic database questionnaire with Robson 10-group classification criteria and feedback on the unit's cesarean section rates monthly, so as to know which category is higher and can be reduced further. This change in the unit's practice will introduce a new medical reporting and audit system that can detect unjustified medical procedures much more easily.
45849832|NCT04504500|Other|Live real-time statistics online platform|Live real-time statistics provided on a regular basis by an online platform will provide feedback and essential information. Each unit will see other units' statistics using an anonymous reporting system. This information can trigger self-generative learning strategies and help obstetricians to become more effective learners.
45849833|NCT04504500|Other|Local cesarean section meetings|Local cesarean section meetings will be held weekly in each unit. The members of the Steering Committee or local opinion leaders may actively participate in these meetings. The unit's staff can hear about both justified and unnecessary surgical procedures and draw informed conclusions as to the optimal procedure in similar cases. They will also have the opportunity to actively participate in an elaborative problem-solving discussion. These meetings when routinely conducted, provide feedback and audit resources to help improve performance and further enhance compliance.
46057091|NCT04981366|Dietary Supplement|isocaloric supplement|42g of isocaloric supplement in the breakfast;
45697738|NCT03224481|Other|Electronic reminder|The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
45697739|NCT01894841|Behavioral|Coping Long Term with Active Suicide (CLASP)|6 month behavioral telephone-based intervention. Calls assess risk, problem solve any immediate issues, and case management
45697740|NCT01894841|Other|Safety Assessment and Follow Up Evaluation|enhanced risk monitoring with full assessment protocol at 3, 6, 9, and 12 month follow up. Results sent as a note to the patient's VA mental health provider
45697741|NCT04106674|Procedure|Open reduction internal stabilisation (ORIF)|Treatment allocated to surgical or non-surgical group. Implant choice pragmatic, surgeons choice.
45399046|NCT01129570|Drug|Silybin|4 dose levels of siliphos: 2, 4, 8, and 12 grams daily in three divided doses. This study will follow a standard sequential Phase I dose escalation design.
45399047|NCT00223808|Other|Robot-Low|1 hour/day of robot-assisted upper limb exercise therapy in addition to usual physical and occupational therapy
45399048|NCT00223808|Other|Robot-High|2 hours/day of robot-assisted therapy in addition to usual physical and occupational therapy
45399049|NCT00223808|Other|Control|1 hour/day of additional upper limb therapy that includes exposure to, but no manipulation by the robot
45399050|NCT03740620|Procedure|Bevel facing the cephalad direction of the patient|The bevel of the nasotracheal tube facing cephalad direction of the patient
45399051|NCT03740620|Procedure|Bevel facing leftward of the patient|The bevel of the nasotracheal tube facing the left side of the patient
45507206|NCT02135978|Other|Shoulder home exercise program|Patients receive instruction and practice on the shoulder home exercise program, receive a notebook with handouts including pictures and written instructions on how to perform the program, and receive a kit containing the exercise equipment. Patients are asked to perform the exercises at home 3 days a week over the next 3 years.
45507207|NCT03603054|Other|Active neck mobilization|The subjects, receive an active neck mobilization intervention.
46057092|NCT02609620|Device|Peristaltic Feeding Tube|
45507208|NCT03603054|Other|Active Mobilization of the sciatic nerve|The subjects, receive an active sciatic nerve mobilization intervention.
45399052|NCT03971942|Behavioral|Neutral ABMT|In the neutral attention bias, there are 108 pairs of neutral-negative words, 54 pairs of which are used in the training group and 54 pairs of which are used in the placebo group. The word pairs in each group are repeated 4 times, with a total of 216 trial. Participants received 8 sessions over 2 weeks (1 session every other day).In booster ABMT, participants received 4 sessions over 2 weeks (1 session every three days).90% of the targets in the training group appear in the neutral word position and 10% of the targets appear in the negative word position, while 50% of the targets in the placebo group appear in the neutral word position and 50% of the targets appear in the negative word position.
45399053|NCT03971942|Behavioral|Positive ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 8 sessions over 2 weeks (1 session every other day). In booster ABMT, participants received 4 sessions over 2 weeks (1 session every three days).90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position, while 90% of the targets in the placebo group appear in the neutral word position and 10% of the targets appear in the positive word position.
45399054|NCT01221610|Device|Passeo-18 Lux DRB|
45399055|NCT01221610|Device|Standard PTA (POBA)|
45399056|NCT01073540|Drug|Cephalexin suspension (Optocef, BAYO5448)|Single dose of 500 mg / 10 mL
45507209|NCT05759923|Drug|OATD-02|Boin Design Scheme will be applied for dose escalation. Dose will start with 2.5mg o.d., the desicion about dose escalations will be made based on the occurence of DLT
45507210|NCT02136056|Behavioral|Self-management program (SMP)|A self-management course
45507211|NCT03149107|Drug|N-Acetylcysteine|N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention (IPPI or PSM).
45507212|NCT03149107|Drug|Placebo|Will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM).
45507213|NCT03149107|Behavioral|IPPI (Integrated Preventive Psychological Intervention)|IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician & rater)
45507214|NCT03149107|Behavioral|PSM (Psychological stress management)|PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician & rater).
45507215|NCT03606564|Other|study of fasting time among pediatric patients undergoing day care surgery|parents of children undergoing day care surgery were given a questionnaire to be filled containing questions regarding time of fasting that was instructed and
45715249|NCT05273788|Device|2400 ThorS-MagNT Stimulations at 1Hz|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. 1 Hz ThorS-MagNT, one of 4 total trains is delivered over 5 minutes with 3-min rest intervals on both right and left sides (total 1200 pulses/side).
45849834|NCT04504500|Other|Local CTG interpretation meetings|"Local CTG interpretation meetings will be held weekly, in each unit during which all abnormal CTG cases that led to cesarean section will be reviewed and discussed. Members of the Steering Committee or local opinion leaders may actively participate in these meetings offering coaching and counseling services in decision-making. Through elaborative discussion the staff will improve their knowledge and skills in correct CTG interpretation, thus preventing unnecessary interventions, such as cesarean sections."
45399057|NCT01073540|Drug|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
45399058|NCT03930472|Behavioral|Market vouchers|Receiving $80 in vouchers good for fruits and vegetables or for SNAP-eligible foods at 4 out of 5 markets in late July and in August, 2019.
45507216|NCT03550976|Behavioral|The low-GI diet and muscle training|During the 12-28 weeks of pregnancy, the pregnant women received low-GI diet and exercise intervention.Every two weeks, the pregnant women were followed up to assess the dietary situation and analyze the body composition results.Collect birth outcomes
45507217|NCT03135301|Drug|letrozole plus metformin|letrozole 5 milligram tablets plus metformin 850 milligram tablets
45507218|NCT03135301|Drug|letrozole|letrozole 5 milligram tablets
45507219|NCT03550274|Device|App-based exercise rehabilitation|"App-based exercise rehabilitation available on any mobile device and/or tablet using Android or iOS operating systems. The app Injurymap© is hosting the exercise program. The app requires user-registrations and a monthly paid subscription fee to access the exercise program. The participants in this study will not be charged for using the app.~The exercise program consists of three phases with increasing difficulty. Each phase consists of several categories of exercise types. The categories are 1) mobility, 2) stability/balance, 3) strength and 4) stretching. Within each phase, there can be more than one exercise for each category. This makes it possible to adjust the difficulty of the exercises depending on user-feedback."
45507220|NCT03602898|Biological|Anti-Thymocyte Globulin|Given IV
45507221|NCT03602898|Drug|Busulfan|Given IV or PO
45507222|NCT03602898|Drug|Cyclophosphamide|Given IV
45507223|NCT03602898|Drug|Cyclosporine|Given IV or PO
45399059|NCT03741608|Behavioral|High blood pressure management education|The 7-part education series includes 5 sessions focused on mindfulness and breathing techniques for stress reduction. One session will focus on choosing healthy, low salt foods and will provide resources for smoking cessation. The final session will include a grocery store tour to teach participants how to read food labels and to purchase healthy food.
45399060|NCT03741608|Behavioral|Home blood pressure measurement|Participants will be taught to use an automated blood pressure cuff and will be asked to provide monthly blood pressure readings to study staff.
45399061|NCT03930160|Other|Logistic Organ Dysfunction System Score|Variables of logistic organ dysfunction system score, including: GCS; heart rate; systolic BP; blood urea; serum creatinine; urine output; leucocyte count; platelet count; PaO2/FiO2; serum bilirubin; prothrombin time.
45399062|NCT01075724|Device|Patient Warming with Forced Air|Forced Air warming via BairHugger
45399063|NCT01075724|Device|Resistive Warming|Resistive Warming via HotDog device
45399064|NCT01225120|Other|Gait Training|12 sessions, 30 minutes of walking on treadmill with real time therapist directed feedback on gait kinematics.
45399065|NCT03740386|Drug|Phentolamine Mesylate 0.235 MG/ML [OraVerse]|compare effect of phentolamine mesylate in three arms
45399066|NCT01226836|Other|LWWCOPD for Pulmonary Rehabilitation|As part of clinical care participants will attend a 6 week pulmonary rehabilitation programme consisting of supervised exercise and education sessions. The exercise component will be consistent with the usual pulmonary rehabilitation programme delivered at that site (BTS 2001, NICE 2004). The education sessions will be delivered using the revised LWWCOPD programme (1/week, approx. 30-45min). All health professionals will be provided with the health professionals' manual and supplementary posters for their respective education session. All participants will be provided with the revised LWWCOPD information booklet and an action plan for recognising and managing exacerbations.
45399067|NCT03927352|Biological|SCT630|Administered by subcutaneous injection
45399068|NCT03927352|Biological|Adalimumab|Administered by subcutaneous injection
45399069|NCT03929770|Procedure|with pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner pause the advancement for 10 sec. Next, the practitioner re-advance it to the pulmonary artery.
45399070|NCT03929770|Procedure|without pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner advance it continuously without pause to the pulmonary artery.
45399071|NCT01225198|Dietary Supplement|Multi-Vitamin/Mineral Supplement|A broad-spectrum vitamin/mineral supplement designed for children and adults with autism
45399072|NCT01225198|Other|Liquid Placebo|The placebo was formulated to look and taste like the intervention supplement. A small amount of beta-carotene was used for coloring. Natural cherry, citric acid, and a proprietary blend of natural flavors were used for flavoring to create a vitamin-like after-taste. Sucralose was used as a sweetener and the same preservatives were included (potassium sorbate, sodium benzoate).
45399073|NCT03929848|Procedure|Cuff pressure|observe and record the required cuff pressure to prevent gas leakage during mechanical ventilation for laryngomicrosurgery
45399074|NCT01226992|Drug|Vancomycin|"Oral Vancomycin:~Dose: 125 mg po qid x 2 weeks then 125 mg po bid x 1 week then 125 mg po od x 1 week then 125 mg po q every other day x 1 week then 125 mg po q every third day x 1 week then discontinue Route: oral"
45399075|NCT01226992|Biological|Fecal Transplant|Fecal slurry 50 grams stool in 500ml normal saline
45399076|NCT01127074|Biological|KS24.22 cells|"The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).~Immediately before administration, KS24.22 cells were thawed and lethally irradiated (200 gray). KS24.22 cells were adjusted to 107/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites."
45399077|NCT01127152|Procedure|Measure of arterial pressure|Measure of arterial pressure will occur every five minutes during the thirty minutes before the relay and during the fifteen minutes after the relay.
45399078|NCT03927586|Other|cognitive training|We will be using commercialized cognitive-based training programs in order to facilitate several cognitive functions. We will be targeting attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance different types of cognitive functions. Cognitive program difficulty will be adjusted automatically and continuously based on each participant's level of performance.
45507224|NCT03602898|Drug|Fludarabine Phosphate|Given IV
45507225|NCT03602898|Drug|Methotrexate|Given IV
45507226|NCT03602898|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplantation
45507227|NCT03602898|Other|Quality-of-Life Assessment|Ancillary studies
45507228|NCT03602898|Other|Questionnaire Administration|Ancillary studies
45507229|NCT03602898|Drug|Tacrolimus|Given IV or PO
45507230|NCT03602898|Radiation|Total-Body Irradiation|Undergo TBI
46057093|NCT02609620|Device|ConvaTec Levin Duodenal Tube|
45697742|NCT05304507|Behavioral|I-PROTECT model|The I-PROTECT model is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes exercises based on physical and psychological principles of effective injury prevention training, specifically tailored for youth handball players, and support for developing a continuous implementation strategy. The intervention is delivered through a mobile application specifically developed for the I-PROTECT project (the I-PROTECT GO), including coach, player, club administrator, and caregiver modules. Coaches are introduced to the intervention in a workshop, and they will conduct the exercises with their teams during handball practice. Players will have support for conducting exercises on their own, and club administrators for developing an implementation strategy. Caregivers will have tailored information about injury prevention training.
45399079|NCT03927586|Other|physical exercise training|The physical exercise programs will involve balance or strength training or aerobic exercises. These may include (but not limited to) stepping, walking, dancing, ball kicking and throwing, and etc. The exercise session will be break up into 2 to 3 parts, and the participants can rest as needed during the exercise period. The exercise intensity will be progressed as the participants improve their performance throughout practice. To prevent exercise-induced injuries, vital signs and the Borg Perceived Exertion Scale will be monitored and recorded in each training session. If the training therapist observed that the exercise may be too intense for the participants, he/she will immediately reduce the training intensity.
45849835|NCT04504500|Other|Follow-up meetings|Regular follow-up meetings of the participating obstetricians with members of the steering committee and local opinion leaders throughout the intervention period will enhance compliance with the guidelines. Establishment of commonly accepted practice augments the homogeneity of clinical action plans and team work in the unit.
45849836|NCT04494360|Other|No intervention|No investigational medicinal product will be administered as a part of this study.
45399080|NCT01128478|Procedure|Enteral tube feeding|Nasogastric tube feeding started within 24 h of hospital admission
45399081|NCT01128556|Drug|Bepreve|Bepreve (bepotastine besilate ophthalmic solution 1.5%) one drop in each eye twice daily
45399082|NCT01128556|Drug|Refresh Tears|Refresh Tears one drop to each eye twice daily for 7 days after the conclusion of Bepreve treatment
45399083|NCT03927664|Other|Radiological assessment|Radiological assessment of findings in the peritoneum, omentum, mesentery, ascites and other abdominal findings
45399084|NCT01129726|Device|Transillumination-guided Fiberoptic Intubation|Light guided, Non-invasive
45399085|NCT01225432|Other|Gait Training|12 sessions, 30 minutes of walking on a treadmill with real time therapist directed feedback on gait kinematics.
45399086|NCT03929692|Behavioral|Multi-layer health promotion program|
45399087|NCT03929692|Other|Standard health education|
45399088|NCT03740464|Drug|long-acting granulocyte colony stimulating factor|A 6 mg of polyethylene glycol granulocyte colony stimulating factor will be given to patients of study group
45399089|NCT03740464|Drug|Short-term granulocyte colony stimulating factor|Short-term granulocyte colony stimulating factor will be given to all patients according to the severity of myelosuppression
45399090|NCT03928990|Device|ActiGraph accelerometer|ActiGraph accelerometer + calibration with Cortex MetaMax3B ergospirometer
45399091|NCT03927118|Procedure|intravitreal dexamethasone implant application|Peripapillary RNFL thickness measurements and colored fundus photographs were compared before and 6 months after intravitreal DEX implant injection. The cup-to-disc ratios of fundus photographs were calculated using the Image-J program.
45399092|NCT03929380|Other|Squat protocol|60% of 1RM weight for 100 squat reps
45399093|NCT01128634|Drug|GSK573719|13 days dosing with GSK573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
45399094|NCT01128634|Drug|GW573719/GW573719|13 days dosing with GSK573719/GW573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
45399095|NCT03932422|Diagnostic Test|Evaluate if the individuals are resistant hypertensive patients|Evaluation of the individuals has the objective determine if they are resistant hypertensive patients. This is important because the resistant people have worse prognosis than the controlled people and need more attention from the health professionals. Analysis must be done using the ambulatory blood pressure monitoring.
45399096|NCT01227148|Other|Tightly glucose control|A continuous insulin infusion (50 IU of Actrapid HM) in 49.5 ml of 0.9 percent sodium chloride with the use of a pump was started when blood glucose level exceeded 140 mg/dl to maintain a blood glucose level of between 120 and 140 mg per deciliter. The dose of insulin was adjusted according to whole-blood glucose levels, measured at one-four-hour interval in arterial blood or arterial catheter was not available. The insulin dose was adjusted by a neuro-fuzzy method
45399097|NCT01227148|Other|Conventional glucose control|a continuous insulin infusion was delivered when the blood glucose level exceeded 200 mg/dl and insulin level was then adjusted to maintain a blood glucose level of between 180 and 200 mg per deciliter.
45399098|NCT01227226|Drug|Artificial tears|Instill one drop of artificial tears
45399099|NCT01127308|Drug|Ertugliflozin|Ertugliflozin 25 mg will be administered as a single oral suspension containing approximately 100 uCi of [14C]ertugliflozin
45399100|NCT01128712|Drug|Pregabalin|150 mg /day
45399101|NCT01128712|Drug|Pregabalin|450 mg/day
45507231|NCT02983747|Other|PRP Treatment(P)|Ultrasound(Philips® iU22 ultrasound system) guided intra-disk injection using 2 ml of platelet rich plasma, containing 0.2 ml of calcium chloride(SINE®, SHANGHAI XINYI PHARMACEUTIAL Co . Ltd .) per treatment
45849837|NCT04471974|Drug|BET Bromodomain Inhibitor ZEN-3694|Given PO
45849838|NCT04471974|Drug|Enzalutamide|Given PO
45399102|NCT01225510|Biological|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
45399103|NCT01225510|Biological|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
45399104|NCT01227304|Device|PiCCO-parameter-guided volume challenge|Infusion of 7ml/kg crystalloid over 30 minutes, Performing transpulmonary thermodilutions after 0min, 15min and 30min. Recording of pulse contour cardiac index, heart rate and mean arterial pressure after 5, 10, 15, 20, 25 and 30min. Catecholamines are kept stable over the 30min period.
45399105|NCT01127386|Drug|Lenalidomide|25mg od, dose reduction according to toxicity
45399106|NCT01127386|Drug|Lenalidomide|start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)
45399107|NCT01127386|Other|basic cachexia management (prokinetics, physical activity counselling, nutritional counselling)|twice during study
45507232|NCT02983747|Drug|Medication Treatment(Loxoprofen Sodium tablets,M)|Loxoprofen Sodium tablets(LOXONNIN®, DAICHI SANKYO PHARMACEUTIAL (SHANGHAI) Co . Ltd .)，P.O., 60mg, three times a day
45507233|NCT02128412|Device|Oversized stent deployed at low pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
45507234|NCT02128412|Device|Stent deployed at high pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
45849839|NCT04471974|Biological|Pembrolizumab|Given IV
45507235|NCT05759845|Drug|Topiramate 25Mg Tab|topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks
45507236|NCT05759845|Drug|Amitriptyline 25 Mg Oral Tablet|Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
45507237|NCT05759845|Drug|topiramate 25mg plus amitriptyline 25mg|topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks with Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
45399108|NCT03927196|Behavioral|extended counseling|Patients are handed out information leaflets on the correction of risk factors, SMS reminders, extended statins counseling.
45507238|NCT03550196|Other|Provisional stenting with rePOT technique|"All revascularizations have to be performed with complete rePOT technique: initial POT + side branch inflation + final POT. Compliant or semi compliant balloon have to be preferred to inflations. The POT balloon positioning have to be precise as obtain the loose of the parallelism just at the carina cut plan. The rest of the medication or procedure characteristics stay at the discretion of the operator.~The follow-up will be clinic every years."
45507239|NCT03931291|Drug|APR-246|APR-246 will be administered on Days 1-4, with azacitidine on Days 1-5, of every 28 day cycle. Patients may receive a maximum of 12 cycles.
45507240|NCT02136212|Behavioral|Approach-positive AAT|
45507241|NCT02136212|Behavioral|Control AAT|
45399109|NCT01221844|Dietary Supplement|Lattoglobina (Grunenthal) containing bLf|One capsule of Lattoglobina contains 100 mg of bLf. Dosage: one capsule twice a day before meals. In twin pregnancy or in severe anemia the dosage is increased to 2 capsules twice a day before meals
45399110|NCT01221844|Drug|FerroGrad by Abbott|Dosage: one tablet/day containing 540 mg of ferrous sulfate during meals
45507242|NCT02136290|Behavioral|Prepackaged meals|Portion-controlled prepackaged meals
45399111|NCT01128790|Other|Remote ischemic preconditioning|4 cycles x 5 mins upper limb blood pressure cuff inflation 20mmHg above systolic blood pressure
45399112|NCT01128790|Other|Sham Control|4 cycles x 5mins blood pressure cuff inflation to 10mmHg
45507243|NCT02136290|Behavioral|Usual Care|Usual care dietary counseling
45507244|NCT01375855|Procedure|Percutaneous transluminal Coronary Angioplasty|Coronary artery stent implantation
45507245|NCT00799110|Drug|GM-CSF|Injections given subcutaneously at the sight of vaccination on the day of the vaccination and for three days afterwards
45507246|NCT00799110|Biological|Dendritic Cell/Tumor Fusion Vaccine|Given subcutaneously once every three weeks for a total of three vaccines
45507247|NCT00799110|Drug|imiquimod|Cream applied to the skin at the injection sight 2 hours before injection and for 3 days following the injection
45507248|NCT05199727|Device|LI-ESWT|Low intenisty shockwave therapy newly used for treatment of erectile dysfunction by applying 6 sessions on 3 weeks (2 sessions /week)
45507249|NCT05199727|Drug|Tadalafil 20Mg Oral Tablet|Patients on this arm will allocate on on-demand tadalafil 20 mg for treatment of ED
45507250|NCT03600402|Other|Experimental|6 sessions of ankle manual therapy
45507251|NCT03600402|Other|Control|6 sessions of placebo intervention
45507252|NCT02132234|Drug|Etanercept|biological treatment according to rheumatologic indication
45507253|NCT02132234|Drug|Adalimumab|biological treatment according to rheumatologic indication
45507254|NCT02132234|Drug|Certolizumab|biological treatment according to rheumatologic indication
45507255|NCT02132234|Drug|Infliximab|biological treatment according to rheumatologic indication
45697743|NCT05304507|Behavioral|Control group|"Youth coaches in the control group club will be asked to use injury prevention training available in the coach education material (Ready for handball), i.e., current practice in Sweden."
45697744|NCT02236390|Behavioral|Exposure, Relaxation, and Rescripting Therapy|5 sessions that last approximately one hour addressing nightmares and sleep problems. Participants will log sleep events and associated symptoms
45849840|NCT04470648|Diagnostic Test|blood test for SARS-COV2 serology|each person who will accept to participate will have a bood test for a SARS-COV2 serology
46057094|NCT02713503|Other|Driving Observation|Driving observation using the DriveSafety CDS-250 Driving Simulator.
46057095|NCT02713503|Other|VisionCoach|Visual field evaluation using VisionCoach
45399113|NCT01128868|Device|Proximal femur locking plate|Proximal femur locking plate (PF-LCP, PF-LCP Hook Plate, Periloc)
45399114|NCT01128868|Device|Intertrochanteric nail|Intertrochanteric nail (PFNA, TFN, GN)
45399115|NCT01130194|Other|Combination of treatment modalities|"Intravenous cyclophosphamide, rituximab, and vincristine day 1 and 8 of 28 day cycles for 6 cycles total.~Oral prednisone and procarbazine day 1-14 of every 28 day cycle. Yttrium ibritumomab tiuxetan intravenous injection. Autologous stem cell transplant with intravenous BEAM (BCNU or carmustine, etoposide, ara-C or cytarabine, melphalan) chemotherapy conditioning."
45507256|NCT05415241|Drug|FB2001|"Stage 1 (Exploring the dose): Twenty participants will be enrolled for aerosol inhalation of FB2001 once daily for 5 consecutive days. If the drug is well tolerated but efficacy is inadequate, another twenty participants will be enrolled for aerosol inhalation of FB2001 BID for 5 consecutive days.~Stage 2 (Sample size expansion): Another twenty participants will be enrolled for aerosol inhalation of FB2001 once daily or twice daily for 5 consecutive days depending on the result of stage 1."
45507257|NCT03602742|Device|EZYPRO®|Wear two devices including 24-hour Holter and 14-day continuous EZYPRO® to evaluate the performance
46057096|NCT00611091|Other|Electronic delivery of enhanced discharge information to the ambulatory physician|Follow-up appointment needs/plans
45399116|NCT03928834|Behavioral|Adapted Nzira Itsva|Adolescents will be provided an enhanced adherence package consisting of VL testing using DBS, including the NI intervention and low-cost genotyping and drug resistance monitoring. Participants receiving the intervention will have their first session after recruitment and enrollment, and will schedule up to 4 additional booster sessions at a time convenient for them spaced approximately 1 month apart. This may be modified after the formative assessment.
45399117|NCT01221922|Device|RevLite Q-Switched Nd:YAG Laser|Laser treatment once every 2 weeks for a total of 10 treatments.
45399118|NCT01222000|Drug|apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side|After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
45399119|NCT01222000|Drug|apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side|After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
45399120|NCT01227538|Other|Mixed meal stimulated urinary C peptide for the assessment of residual beta cell function|Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
45399121|NCT03925090|Drug|Cisplatin+Toripalimab|chemotherapy and monoclonal antibody
45849841|NCT04461678|Diagnostic Test|HPV Genotyping Nucleic Acid Assay Kit|The total sample size of screening population is approximately 12,000 cases (all females ≥ 21 years of age). Two cervical cytology samples will be collected from each subject with a tube of SurePath sample followed by a tube of PreservCyt sample. The 1st tube of SurePath liquid-based cytology sample is used for cytology test and BD Onclarity Assay HPV detection. Subjects with cytology test results ≥ ASCUS or positive HPV test results will be suggested to return for baseline colposcopy within approximately 12 weeks.
45399122|NCT03925090|Drug|Cisplatin+placebo|chemotherapy
45399123|NCT03927040|Device|MemorEM 1000|The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. The device provides global treatment to forebrain. For each of the 120 days of in-home treatment, a single 1-hour treatment will be administered by the subject's caregiver, who will position the device on the patient's head and monitor treatment.
45399124|NCT03925012|Behavioral|Intervention|
45399125|NCT03928756|Behavioral|Push Notifications with Tailored Intervention Content|Participants will receive a push notification with a therapeutic message (e.g., about stress, mood, substance use motives, tools to reduce risky substance use) tailored to their recent daily or weekly survey responses. Messages include visual (memes, images, videos) and written content.
45399126|NCT03928756|Behavioral|Push Notifications with Engaging, Non-therapeutic Content|Participants will receive a push notification with an engaging, non-therapeutic message (e.g., fun facts).
45399127|NCT03928756|Behavioral|No Push Notifications|Participants will not receive a push notification.
45399128|NCT01225744|Drug|Cetuximab|"Cetuximab will be prepared under Good Manufacturing practice (GMP) and supplied by Merck KGaA (Darmstadt, Germany) as a solution for intravenous infusion. It will be made up into 250ml with N/Saline.~Dose administered is 400mg/m2 and will be given on day 1 and day 15 of a 28 day cycle.Cetuximab will always be administered first, i.e. the cetuximab infusion should be completed one hour before any chemotherapy begins. The cetuximab dose must always be based on the body surface area(BSA). There is no restriction for cetuximab in patients with a BSA > 2 m2 ."
45399129|NCT01225744|Drug|Irinotecan|Dose is 180mg/m2 made up into 250ml with 5% dextrose or 0.9% saline. It will be administered as a short infusion over 60-90 minutes after a 60 minute gap left after cetuximab administration. Irinotecan is administered on day 1 of the 28 day cycle.
45399130|NCT01225744|Drug|Oxaliplatin|Dose is 100mg/m2 and will be made up into 250ml with 5% dextrose. It will be administered as a short infusion over 120 minutes after the 60 minute gap left after cetuximab administration. Oxaliplatin is administered on day 15 of the 28 day cycle.
45399131|NCT01225744|Drug|UFT|UFT dose is 250mg/m2 and is given in three divided doses with calcium folate 30mg p.o. tds on days 1-21 of the 28 day cycle. The highest dose of UFT should be given in the morning if the dose cannot be divided equally.
45399132|NCT01585636|Drug|SQ109|Single oral dose
45399133|NCT03926806|Other|Plain yoghurt|cups of 200 g yoghurt
45849842|NCT04452084|Radiation|HA-WBRT|The accepted standard HA-WBRT doses in the control arm are 30Gy in 10 fractions.
45849843|NCT04452084|Radiation|HA-SIB-WBRT|The doses selected for experimental HA-SIB-WBRT arm are 30Gy in 10 fractions to the whole brain with 40 to 45Gy in 10 fraction SIB doses to tumours.
46057097|NCT00611091|Other|Electronic delivery of enhanced discharge information to the ambulatory physician|Laboratory follow-up needs
46057098|NCT00611091|Other|Electronic delivery of enhanced discharge information to the ambulatory physician|New medications
45697745|NCT02236390|Behavioral|Cognitive Processing Therapy - Cognitive|12 sessions cognitive behavioral treatment targeting posttraumatic stress symptoms.
45399134|NCT03926806|Other|Vitamin B yoghurt|cups of 200 g yoghurt
45399135|NCT03926962|Drug|WCK 4873|100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)
45399136|NCT03926962|Drug|Placebo Oral Tablet|Visually matching placebo
45399137|NCT01131208|Genetic|gene expression analysis|
45399138|NCT01131208|Other|laboratory biomarker analysis|
45399139|NCT03926884|Dietary Supplement|Three-seeds mixture|mixture of white mustard seeds, radish seeds and beefsteak plant (Korean perilla, a species of Perilla in the mint family, widely cultivated and edible for humans; a daily food for Korean people; many Japanese people drink as tea) seeds
45399140|NCT03926884|Dietary Supplement|Control|warm water with negligible amount of the three-seeds mixture
45399141|NCT01228240|Drug|Metformin|
45399142|NCT01227694|Other|Autologous MSC knee implantation|"Isolation and Ex-Vivo expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
45399143|NCT03740308|Device|Locally Made Zirconia Crowns|Occlusal reduction by decreasing the occlusal surface to less than the natural occlusal profile by about 1-1.5 mm roughly. Proximal reduction by unfastening the interproximal contacts. The tooth should be trimmed down circumferentially by around 0.5-1.25 mm as needed. Subgingival reduction, leaving no undercuts or subgingival ridges, about 1-2 mm subgingivally on every area should be prepared. Completion of the preparation by eliminating sharp lines and pointed angles to allow all prepared areas to be marginally rounded and smoothed. Locally Made Zirconia Crowns are fixed using Glass Ionomer cement (Fuji- Jaban).
45399144|NCT03740308|Device|ZR Zirconia Crwons NuSmile ® Crowns|Occlusal reduction by decreasing the occlusal surface to less than the natural occlusal profile by about 1-1.5 mm roughly. Proximal reduction by unfastening the interproximal contacts. The tooth should be trimmed down circumferentially by around 0.5-1.25 mm as needed. Subgingival reduction, leaving no undercuts or subgingival ridges, about 1-2 mm subgingivally on every area should be prepared. Completion of the preparation by eliminating sharp lines and pointed angles to allow all prepared areas to be marginally rounded and smoothed. ZR Zirconia Crwons NuSmile ® Crowns are fixed using Glass Ionomer cement (Fuji- Jaban).
45399145|NCT01227772|Biological|OTSGC-A24|OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.
45399146|NCT02528578|Device|thermal stimulation delivered by a thermode.|Empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
45399147|NCT02528578|Other|functional MRI|MRI realised with thermal stimulations and empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
45399148|NCT03926650|Device|Masimo Sedline Monitor Patient State Index|Masimo Sedline Monitor shows frontal electromyography and patient state index, Train of four monitor shows muscle strength on adductor pollicis muscle
45399149|NCT03919786|Procedure|topical local anesthesia of pulmonary vein combined with vagus nerve block|"Injecting 1% lidocaine 1.5ml+0.375% ropivacaine 1.5ml into vascular sheaths of all pulmonary vein of the surgery side at the beginning of surgery operation.~Wrapping all pulmonary vein of the surgery side with cotton sheet infiltrated with 1% lidocaine+0.375% ropivacaine at the end of surgery operation.~Blocking vagus nerve above the aortic vein on the right side of the trachea with 1% lidocaine 1ml+0.375% ropivacaine 1ml after exposing the pleural apex."
45399150|NCT03926572|Other|A biobank will be created from blood samples taken at admission, days 3 and days 7|A biobank will be created from the blood samples taken on admission, days 3 and 7 of admission. The prognostic value of the preselected biomarkers will be analyzed and a proteomic analysis will be performed to identify new biomarkers. The prognostic value of these new biological parameters will be compared to the usual surveillance parameters that will be collected during the follow-up (clinical, echocardiographic and hemodynamic parameters)
45399151|NCT03920020|Other|the concentric isokinetic exercise group|concentric isokinetic exercises
45697746|NCT03254589|Drug|Methotrexate|See arm descriptions
45697747|NCT03254589|Drug|Sulfasalazine|See arm description
45399152|NCT03920020|Other|the eccentric isokinetic exercise group|eccentric isokinetic exercises
45399153|NCT03920020|Other|the control group|conventional physiotherapy and standard therapeutic exercises predetermined by us
45399154|NCT01132066|Other|tDCS|tDCS will lead to an increase in cortical excitability
45399155|NCT01132066|Other|Sham|Sham will provide identical subjective sensation as tDCS
45399156|NCT03924544|Drug|Decorin|Antifibrotic agent
45399157|NCT03924544|Drug|Mitomycin c|Antifibrotic agent
45697748|NCT03254589|Drug|Other DMARDs|See arm
45697749|NCT01894607|Procedure|Contrast Enhanced Intraoperative Ultrasound|During standard of care surgery, radiologist will take images and videos with an ultrasound machine before and after patient given the contrast agent.
45697750|NCT01894607|Drug|DEFINITY|"During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.~Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier."
45697751|NCT01894607|Behavioral|Phone Call|Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having.
45697752|NCT03982888|Procedure|Deep Brain Stimulation|Stimulation of the nucleus accumbens via 2 electrodes implanted in the brain per patient to reduce self-injurious behaviours.
45507258|NCT02136368|Behavioral|Multi-modal exercise|Community-based group exercise classes following Canadian Centre for Activity and Aging exercise guidelines. Exercise classes consist of 5 min warm-up, 20 min aerobic exercise, 5 min aerobic cool-down, 10 min full-body resistance exercise, 5 min stretching (total 45 min)
45507259|NCT02136368|Behavioral|Mind-Motor Exercise|Square Step Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids (15 min).
45399158|NCT01131364|Drug|F16IL2 in combination with doxorubicin|"Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 up to 25 MioIU) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 30-minute i.v. infusion of doxorubicin (Dose escalation: from 20 up to 25 mg/m2) on Days 1, 8, 15 29, 36 and 43.~Patients with objective tumor responses or stable disease will receive repeated cycles of treatment starting on Day 56. Patients will receive additional cycles of combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent."
45399159|NCT02529202|Drug|Dexmedetomidine|Dexmedetomidine infusion
45399160|NCT00154310|Drug|Everolimus|Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL.
45849844|NCT04450914|Behavioral|CV Prevention Choice Tool|The CV Prevention Choice SDM tool is a shared decision making intervention. It is embedded in the electronic health record and uses EHR data to estimate and display cardiovascular risk for individual patients and then foster conversations between clinicians and patients about available options for preventive care based on individual risk and preferences.
45399161|NCT00154310|Drug|Cyclosporine|Tablets orally twice a day to maintain protocol specific target blood levels
45399162|NCT00154310|Drug|Enteric-coated mycophenolate sodium|Enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day.
45399163|NCT00154310|Drug|Corticosteroids|Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.
45399164|NCT03771664|Drug|SAGE-217|Administered as capsules.
45399165|NCT03771664|Drug|Placebo|Administered as capsules.
45399166|NCT03771352|Device|RxSight RxLAL|The patients will be assessed for 6 months
45399167|NCT03770728|Drug|Efpeglenatide SAR439977|Pharmaceutical form: solution for injection Route of administration: subcutaneous
45399168|NCT03770728|Drug|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
45399169|NCT03770728|Drug|Background therapy: Metformin alone or in combination with SU|Pharmaceutical form: tablet Route of administration: oral, administered as per investigator and in accordance with local labeling.
45507260|NCT02136368|Behavioral|Balance and range of motion exercises|Community-based group exercise designed to improve balance and range of motion of the joints (15 min)
45507261|NCT05199649|Drug|SintilimabCombined With Chemotherapy|Sintilimab and chemotherapy are carried out at the same time for every 3 weeks
45507262|NCT05373576|Behavioral|TACHIDINO|"TACHIDINO is based on two principles a) selective stimulation of a cerebral hemisphere and specific reading strategies, and b) the training of selective visuospatial attention, as well as the perception of rapid movement and the visual characteristics of words even in the presence of so-called visual crowding or crowding, an automatic effect of our perceptual system that leads to obfuscation of the visual areas surrounding the object to be analyzed, to make its vision clearer (as suggested by the Magnocellular theory of dyslexia; Stein et al., 2019)."
45507263|NCT02128568|Behavioral|Youth Readiness Intervention|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 12 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
45849845|NCT04450914|Behavioral|Implementation Facilitation Strategies|During the active implementation stage, health systems will deploy tailored implementation facilitation and other tailored implementation strategies aimed at increasing adoption and use of shared decision making using CV Prevention Choice.
45849846|NCT04389216|Device|Cool-tip electrode for Radiofrequency Ablation|Radiofrequency ablation of the tumour in the surgery group, associated whith axillary surgery when applicable
45849847|NCT04360824|Drug|Intermediate dose thromboprophylaxis|2) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI<30kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).
45849848|NCT04360824|Drug|Standard of Care thromboprophylaxis|Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI <30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30 kg/m2).
45399170|NCT01130428|Device|Juvent 1000 Vibration Platform|"As a mechanical intervention, mechanical stimulation in the form of vibration will be administered to the forearm using a Juvent 1000 Vibration Platform (Juvent Medical, Inc., Lakeland, FL, USA), which is a non-medicinal product. The device produces gentle, low-magnitude mechanical signals in the form of low-amplitude vertical displacements at a high frequency.~The intervention in the present study will be given at a fixed dosage that is defined by the intensity of vibration: frequency: 90 Hz, amplitude: 10 µm (~3.0 g). The mechanical stimulation will be administered in an intermittent fashion, as it has been shown that inserting short rest periods between loading cycles enhances the efficacy of mechanical loading [38]. Thus, the mechanical stimulation will be administered for three times 10 minutes (i.e. the vibration platform turned on), with 10-minute rest periods in between (i.e. the vibration platform turned off); the intervention will have a total duration of 50 minutes."
45399171|NCT01228396|Drug|Hyperimmune caprine serum against HIV lysate|1.0ml solution for subcutaneous injection (4.5mg total protein / ml) twice weekly for 4 weeks
45399172|NCT02529358|Behavioral|standardized text messages|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies
45399173|NCT02529358|Behavioral|Personalized text messages|Patients write their own messages
45399174|NCT02529358|Behavioral|Standardized text messages after 10 weeks|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies which are send to the patients 10 weeks after completing inpatient therapy
45399175|NCT01228474|Other|Select the Number of embryos to transfer|Select the Number of embryos to transfer
45399176|NCT01132222|Drug|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
45399177|NCT03926182|Drug|AST2818 Tablets|AST2818 Tablets: Period 1 Fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once) and 4 hours after dosing on day 1. Period 2 Allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1.
45399178|NCT03926182|Drug|AST2818 Tablets|AST2818 Tablets: Period 1 allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1. Period 2 fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once)and 4 hours after dosing on day 1.
45399179|NCT01132300|Device|Image Guided TENS (Auto-Targeted Neurostimulation, NeMa-st)|Patients will undergo 2 treatments per week during 4 weeks using the device. During the study Patients are allowed to maintain/continue taking medications/ analgesics for pain relief prescribed to them before the study. Medication use will be recorded.
45399180|NCT03926416|Biological|CodaVax-H1N1|Live-attenuated vaccine against influenza A H1N1, A/California/07/2009
45399181|NCT03926416|Biological|Fluzone quadrivalent|Fluzone® (QuadriFlu - TIV), inactivated, quadrivalent influenza vaccine
45399182|NCT01130506|Drug|Cytarabine|Given IV
45507264|NCT03600246|Device|WATCH-PAT|WatchPAT is an FDA-approved portable diagnostic device that uniquely uses finger based physiology and innovative technology to enable simple and accurate Obstructive Sleep Apnea (OSA) testing while avoiding the complexity and discomfort associated with traditional air-flow based systems.
45507265|NCT05199181|Procedure|Full pulpotomy|After applying the rubber dam. Caries, and weak tissues were removed, and the endodontic access was prepared with a carbide bur. Most of the pulp was removed with a sterile high-speed diamond bur under sterile saline solution irrigation and amputated to the canal orifices level. Hemostasis was achieved by irrigation of the cavity with the same solution and an application of small cotton pellets for max.10 min. White Mineral Trioxide Aggregate was mixed according to the manufacturer´s instructions and was placed against the wound after successful hemostasis using an amalgam carrier and packed using an amalgam standard condenser. The material was adapted and a moistened cotton pellet was placed directly over the Mineral Trioxide Aggregate. After 15 minutes, the cotton was removed and the tooth was restored with amalgam. A postoperative radiograph was taken after restoration, general care instructions were given to the patients, and the recommendation of three analgesic intakes.
45507266|NCT02132390|Drug|Goserelin|
45399183|NCT01130506|Drug|Decitabine|Given IV
45399184|NCT01130506|Other|Laboratory Biomarker Analysis|Correlative studies
45399185|NCT01130506|Other|Pharmacological Study|Correlative studies
45399186|NCT01130506|Drug|Vorinostat|Given PO
45399187|NCT01130584|Other|Pyruvate kinase isoform M2|
45399188|NCT01130662|Drug|combination therapy using decitabine and midostaurin|"Cohort 1:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 25mg bid days 8-21 of each cycle.~Cohort 2:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid days 8-21 of each cycle.~Cohort 3:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid x 28 days of each cycle."
45507267|NCT02132390|Drug|Toremifene|
46057099|NCT05755516|Device|Self-expanding Intracranial Stent (Tonbridge)|Stent assisted coiling with Self-expanding Intracranial Stent (Tonbridge).
45399189|NCT01228006|Dietary Supplement|NatusGerin|1 capsule, 2 times a day.
45399190|NCT01228006|Other|Placebo capsules|1 capsule, 2 times a day
45399191|NCT01132456|Device|Drug eluting stent treatment|Endeavor RESOLUTE Zotarolimus-Eluting Coronary Stent Implantation
45399192|NCT03924388|Device|Epidural spinal cord stimulation|The measurements will be obtained in 2 positions of supine and ~ 70° upright adjusted by the tilt-up table.
45399193|NCT03924388|Device|Trnascutaneous electrical spinal cord stimulation.|The measurements will be obtained in 2 positions of supine and ~ 70° upright adjusted by the tilt-up table.
45507268|NCT03875443|Other|Instructional video|Video (produced by AO Trauma and Prof. Daniel Rikli) includes a stepwise and structured explanation of the different fluoroscopic views necessary to evaluate intraoperatively with the fluoroscope different aspects of the proximal femur. The video is publically available under: (https://www.aointeract.org/#/watch/video/L3YxL3ZpZGVvcy8xOTc=/intraoperative-imaging-of-femur).
45399194|NCT03925948|Behavioral|PLAN 4 Success-Diabetes|The study intervention-PLAN 4 Success-Diabetes-consisted of four 1 to 1 ½-hour weekly health literacy training and disease knowledge education sessions for four weeks (4 in-person sessions), followed by two home visits and monthly phone counseling for over 6 months (5 phone sessions). The intervention is theory-driven and builds on von Wagner's model to incorporate key elements such as health literacy, disease knowledge, and self-efficacy for better glucose outcomes.
45399195|NCT03919630|Other|Thrust Mobilization|Once therapist has assessed subject and has found the patients most comparable sign they will be performing a high velocity thrust at the end of the patients available range, as described by Maitland's Approach. The thrust will be performed only once. The therapist will perform either a localized cervical rotation thrust which primary movement is rotation or a longitudinal cephalad C1 and C2 thrust, both targeting the upper cervical spine
45399196|NCT03919630|Other|Non-Thrust Mobilizations|Therapists will perform unilateral posterior to anterior mobilization (UPA) or central posterior to anterior (CPA) mobilizations grades I-IV as described above by Maitland concepts at levels C0-C3 which reproduce the patient's most comparable sign. Therapists will be instructed to perform 3x 30 second bouts of mobilizations at that level.
45399197|NCT03925792|Behavioral|Lifestyle Medicine|diet, sleep, exercise and mindfulness
45399198|NCT03925714|Other|life style|life sryle control only
45399199|NCT03925714|Drug|Metformin|metformin twice daily
45399200|NCT03925714|Drug|Nigetella salivata|NS twice daily
45399201|NCT03919240|Biological|CAR T-cell therapy|Patients enrolled will receive infusion of CD19-targeting CAR T-cells with a target dose of 5~10×10E6/kg of recipient weight, after the preparative regimen consisted of fludarabin (30mg/m2, day -5 to -3) and cyclophosphamide (300mg/m2, day -5 to -3).
45399202|NCT01228552|Drug|Topical, intra-oral ketoprofen gel|Ketoprofen gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
45507269|NCT03875443|Other|Reduction algorithm|Intraoperative reduction algorithm (developed by PD Henrik Eckardt); each step in the algorithm will be checked and documented with the fluoroscope and archived using the store function of the fluoroscope.
45507270|NCT02128646|Drug|EXPAREL|
45507271|NCT02128646|Drug|Ketorolac|
45849849|NCT04331652|Procedure|Polypectomy without anesthesia or analgo-sedation|"Premedication: paracetamol 1g oral. Patient will undergo polypectomy without anesthesia. During the procedure, pain will be monitored using a pain assessment scale from 0 to 10 (0 meaning no pain and 10 meaning maximum pain imaginable). At any time, if the patient express a pain strictly superior to 4 an analgo-sedation will be proposed and/or general anesthesia.~Pulse and blood pressure will be monitored. Assessment of patient satisfaction after the intervention."
45399203|NCT01228552|Other|Placebo gel|Placebo gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
45399204|NCT03924076|Dietary Supplement|UHT Milk + Lactobacillus plantarum IS-10506|125 ml UHT milk (+Lactobacillus plantarum IS-10506) given to treatment group
45399205|NCT03924076|Dietary Supplement|UHT Milk|125 ml UHT milk given to placebo group
45399206|NCT03925558|Dietary Supplement|Probiotics|
45399207|NCT03925558|Dietary Supplement|Placebo|
45399208|NCT01228162|Procedure|effect of muscle relaxation on muscle trauma, control group without relaxation|effect of muscle relaxation on muscle trauma, control group without relaxation
45507272|NCT02128646|Procedure|laparoscopic abdominal hernia repair|
45507273|NCT02128646|Procedure|an open surgery for abdominal hernia repair|
45507274|NCT05604547|Diagnostic Test|Non-Invasive Infrared Spectroscopy|NIRS is a non-Invasive optical technique for characterizing microvascular hemodynamics.
45507275|NCT02136446|Device|EchoGlo Nerve Block Catheter|Catheter used for a paravertebral anesthesia block
45507276|NCT02136446|Device|Pajunk® Nerve Block Catheter|Nerve Block Catheter
45507277|NCT03785665|Device|MDI|Capsule MD1 (Motility dummy 1)
45507278|NCT02136524|Drug|cobimetinib|Single, oral dose given as a tablet on Day 1 after a minimum 8 h fast
45507279|NCT02136524|Drug|cobimetinib|Single, oral dose given as 4 capsules on Day 1 after a minimum 8 h fast
45849850|NCT04288128|Procedure|Lumbar puncture|Each participant will undergo lumbar puncture at first visit (M0) and last visit (M12)
45697753|NCT03982888|Device|DBS|"Use of the Medtronic DBS device. DBS device consists of 2 parts:~DBS lead, a thin wire with 2 electrical contacts implanted into pre-determined brain regions, and~Implantable pulse generator, a small device containing the batter and computer source placed under the skin of the chest to generate electrical pulses"
45399209|NCT03919084|Other|THRIVE screening and referral|The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
45399210|NCT03919084|Other|Pharmacy Care Program services|Pharmacy services provided by a pharmacy liaison include assessing gaps in obtaining refills, identifying barriers to medication adherence, reviewing the patient's engagement in medical care, and developing an action plan with the patient. Action plans focus on strategies to increase medication adherence and engagement in care. The pharmacy liaison will also link the patient to a clinical pharmacist, when appropriate, and will assist the patient with prescription management. After the initial intake is completed, the pharmacy liaison will call patients monthly (or meet with them prior to or following scheduled appointments) over a twelve-month period to confirm medication adherence and address any new barriers to medication adherence and engagement in medical care. The pharmacy liaison in the control arm does not systematically initiate screening for health-related social needs.
45399211|NCT03919084|Other|Patient Navigation Services|In traditional patient navigation programs, a lay person from the community guides individuals through the healthcare system to receive appropriate services. For the present study, the research team will train pharmacy liaisons (pharmacy technicians or pharmacy interns with at least a high school degree and four years of pharmacy experience) to provide patient navigation services, in addition to providing medication adherence support and assistance resolving barriers to accessing medication. In an effort to avoid duplication of services the patient navigation intervention will be delivered via a pharmacy liaison trained in patient navigation, thereby decreasing multiple intervention providers and increasing the potential for sustainability should the intervention prove effective.
45507280|NCT05199103|Drug|rabbit anti-thymocyte globulin|0.8 - 1.0 mg/kg of rATG (cumulative dose of 150-200 mg given intravenously in two or three divided doses, 24 hours apart) after premedication with methylprednisolone i.v. (in total dose of 375 mg), 1 mg of antihistaminic agent clemastine and 1000 mg paracetamol i.v.
45697754|NCT04399395|Drug|Naltrexone/bupropion|Approved drug for obesity treatment
45697755|NCT04399395|Other|Lifestyle|Lifestyle
45399212|NCT03919084|Other|Motivational Interviewing|Motivational interviewing is a counseling method that encourages patient-centered discussions. Motivational interviewing will be delivered by the intervention arm pharmacy liaison-patient navigators to identify the patient's unmet needs and encourage the patient to adopt behavior change that will promote engagement with resources and services to mitigate or alleviate HRSN.
45399213|NCT03919084|Other|Linkage to Community Partner Organization|The pharmacy liaison-patient navigator will partner with a community organization, Action for Boston Community Development (ABCD). ABCD will help connect patients receiving THRIVE+ to community resources including childcare, food, heating, and housing. The pharmacy liaison-patient navigator will interface directly with ABCD to coordinate receipt of resources for their patients.
45399214|NCT03919318|Other|Root Canal Filling Sealers|Root Canal Obturation
45399215|NCT01329484|Behavioral|Reminiscence therapy|Personalized reminiscence therapy using a computerized system
45399216|NCT01329484|Behavioral|Cognitive training|Cognitive training using a computerized system
45399217|NCT01329484|Other|No treatment|Participants in the control group will receive neither of the 2 experimental interventions or any other similar interventions.
45399218|NCT03823690|Device|EUS-guided gastrojejunstomy|As listed in the arms description
45697756|NCT01883453|Device|Glucose oxidase+5%glucose|A hydrogen peroxide producing enzyme
45697757|NCT01883453|Device|Saline+5%glucose|Isotonic saline + 5% glucose in a bag-on-valve nasal spray device
45697758|NCT04613453|Drug|Ketamine Infusion|Participants will receive four Ketamine infusions over two weeks, each 0.5mg/kg over 40 minutes.
45849851|NCT04288128|Other|Magnetic Resonance Imaging (MRI)|Each participant will undergo scanning at 3 visits (M0, M6 and M12)
45697759|NCT04613453|Drug|Midazolam Infusion|Participants will receive four Midazolam infusions over two weeks, each 0.045mg/kg over 40 minutes.
45697760|NCT02000596|Drug|Trastuzumab plus Pertuzumab|
45399219|NCT03823690|Device|The pyloro-duodenal stent|As listed in the arms description
45399220|NCT03923842|Drug|Denosumab Inj 120 MG/1.7ML|Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
45399221|NCT03923842|Drug|Chemotherapy as clinical standard of care|platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Gemcitabine will continue for 12 months if the patient will not shown disease progression
45399222|NCT01130818|Drug|GLPG0492|single ascending doses, oral solution (25 to max. 120 mg/intake, 10 to 200 mg/mL)
45399223|NCT01130818|Drug|placebo|single dose, oral solution
45399224|NCT01130818|Drug|GLPG0492|single dose, solid formulation, 50 mg (2*25 mg/capsule), fasting
45399225|NCT01130818|Drug|GLPG0492|single dose, solid formulation, 50 mg (2*25 mg/capsule), after high fat breakfast
45399226|NCT03924154|Drug|RVT-1201|RVT-1201 600 mg immediate-release tablet
45399227|NCT03924154|Drug|Placebo|Inactive pill manufactured to mimic RVT-1201 600 mg immediate-release tablet
45399228|NCT03923998|Drug|Neoadjuvant chemotherapy|Three weekly concurrent chemotherapy with cisplatin 100 mg /m2
45399229|NCT03923998|Radiation|Neoadjuvant radiotherapy|Preoperative radiotherapy over 5 weeks- Dose 180-200cgys per day/ total 4500 cgys
45399230|NCT03923998|Procedure|Resection and reconstruction|Resection and reconstruction of mandibular/maxillary segment with prefabricated fibular graft
45399231|NCT03923764|Dietary Supplement|High protein and energy diet|Intervention group receives nutritional counseling to increase protein and energy in their diet to reach their estimated protein need (1.3 g/kg). Kontrol group continues their usual diet.
45399232|NCT03923764|Other|Habitual Diet|Patients continue their usual diet
45507281|NCT02132546|Drug|Chlorhexidine|
45399233|NCT01229956|Genetic|DNA methylation analysis|
45399234|NCT01229956|Genetic|gene expression analysis|
45399235|NCT01229956|Genetic|microarray analysis|
45399236|NCT01229956|Genetic|reverse transcriptase-polymerase chain reaction|
45399237|NCT01229956|Other|laboratory biomarker analysis|
45399238|NCT03919006|Other|non surgical periodontal treatment|SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
45399239|NCT03919006|Other|Gingival crevicular fluid, saliva and serum collection|GCF with filter paper using the intracrevicular method, saliva and serum collection
45399240|NCT01132768|Drug|Atenolol|Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily
45399241|NCT01132768|Drug|olmesartan medoxomil|Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily
45399242|NCT01230034|Drug|Ramipril|pill, 5 and 10 mg/day, od, 24 weeks
45399243|NCT01230034|Drug|Imidapril|pill, 10 and 20 mg/day, od, 24 weeks
45399244|NCT03918616|Drug|Memantine, Dopamine receptor-agonists|The study do not provide any experimental drugs. Patientes will receive treatment routinary used by Neurologist for these diseases.
45507282|NCT05198947|Drug|Permethrin Lotion 5%|Topical permethrin 5% lotion to apply on day 1 and repeat after 1 week.
45507283|NCT05198947|Drug|Permethrin Lotion 5% and Oral Ivermectin 200 mcg/kg|Topical permethrin 5% lotion and oral ivermectin 200 mcg/kg to be taken on day 1 only.
45399245|NCT03925168|Behavioral|Music therapy|Music therapy will be administered according to the Eyre (2008) decision tree model. According to this model, the patient chooses his or her preferred musical intervention at the beginning of each session. Choices include: sing songs, compose a song, listen to songs, play instruments, have an imagery experience, listen to music, improvise, and use music for relaxation.
45399246|NCT03918694|Dietary Supplement|Vitamin C|Daily use of Vit C tablets
45399247|NCT03918694|Dietary Supplement|Placebo|Daily use of placebo tablets
45399248|NCT03923608|Diagnostic Test|Maximal muscle strength Test|1RM test performed in 5 different tools (Elastic Band, Pulley, halter, digital dynamometer and isokinetic dynamometer)
45399249|NCT03923608|Diagnostic Test|Exhaustion test|Test performed until individual exhaustion in 5 different tools (Elastic Band, Pulley, halter and isokinetic dynamometer)
45507284|NCT05256212|Other|exposure to environmental contaminants|to measure levels of contaminants in different matrixes
45507285|NCT05239520|Other|3D movement analysis with surface electromyography and ultrasound|Single measurement session of 3D movement analysis with surface electromyography for upper limb movements and ultrasound measurements of upper muscles
45697761|NCT02000596|Drug|Hormonal Therapy with Anastrozole and Fulvestrant|Anastrozole 1mg by mouth daily FULVESTRANT 500mg i.m. D1, D15, D28 then every 28-30 days
45697762|NCT02000596|Drug|Chemotherapy with Eribulin|
45697763|NCT03223779|Drug|TAS-102|Trifluridine stops DNA replication which may prevent the cancer cells from growing
45697764|NCT03223779|Radiation|Photon SBRT|SBRT stands for Stereotactic Body Radiation Therapy. Radiation may help to kill the cancer cells while protecting your normal tissue cells
45697765|NCT04613297|Other|Baseline and during hospitalization blood samples|"Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed :~at day 3~day 5 and~In case of aggravation~At the discharge from hospital"
45399250|NCT01228630|Drug|Cloratadd-D|The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
45399251|NCT01228630|Drug|Allegra-D|The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
45507286|NCT05198869|Device|Spectral scan|Consenting participants will have a SpotLight-19 scan
45507287|NCT01367834|Drug|somatotropin|Subjects will receive 5 mg somatotropin (growth hormone) pens with cartridges. Subcutaneous injections are to be given every evening around bedtime. Dosing regimen: 50 mcg/kg/day to be adjusted at 4 month intervals to the closest 0.1 mg. Subjects will be given 12 months of treatment (from 12 to 24 months of life). Subjects will visit their pediatrician or pediatric endocrinologist at 4 and 8 months of life.
45507288|NCT03106753|Drug|Bupivacaine|intrathecal bupivacaine 7.5 mg
45507289|NCT03106753|Drug|Terbutaline|0.25 mg Terbutaline subcutaneously
45507290|NCT02132624|Biological|Autologous 3rd generation CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
45507291|NCT02128880|Behavioral|CARRII|CARRII is an interactive, personalized and tailored Internet intervention designed to reduce the risk of AEP among drinking women of childbearing age.
45399252|NCT05402644|Procedure|hepatectomy|Liver resection
45399253|NCT03918538|Behavioral|Home rehabilitation exercise program|After pre-test, the intervention participants received a 60 minutes of teaching regarding the home rehabilitation exercise program, with a printed exercise manual. The intervention participants also received a weekly phone call from the interventionist to enhance their exercise adherence and helping to overcome exercise barriers.
45399254|NCT01230190|Dietary Supplement|Ecologic ® Panda II|"Probiotic strains: 3 Bifidobacteria, 3 Lactococci, 1*10^9 Colony Forming Units/g.~Composition: rice starch, maltodextrins, bacterial strains and mix of minerals."
45399255|NCT01230190|Dietary Supplement|placebo|rice starch, maltodextrins, and mix of minerals. The placebo mixture is similar in aspect, consistency and taste as Ecologic ® Panda II (intervention).
45507292|NCT02128880|Behavioral|CARRII Education|CARRII Education provides information on women's health related to drinking and contraception in a static website format.
45507293|NCT02136758|Behavioral|CRC lifestyle modification program|Intervention group enrolled in lifestyle program in which they developed individualized therapeutic lifestyle plans to reduce cardiovascular risk.
45697766|NCT04613297|Other|Baseline blood sample|Blood sample will be performed at the inclusion visit only
45507294|NCT05385679|Procedure|Surgical Extraction of lower third molar|The surgical removal of mandibular third molar is one of the most common procedures done in oral and maxillofacial surgery. Patients often experience pain, swelling, trismus, dehiscence, alveolar osteitis, infection, nerve injury and periodontal tissue damage after third molar surgery. Flap design is an important step in third molar surgery. Envelope flap and modifications of triangular flap are the two most commonly used flaps in surgical removal of lower third molar.
45507295|NCT02132702|Device|Ekso|
45507296|NCT05198401|Other|covid-19|viral infection
45507297|NCT05711173|Biological|Additional blood sampling|The procedure will consist of an additional blood sample for ETDA tube collection (NGS analysis) and citrate tube collection (NETose analysis)
45507298|NCT05198323|Drug|LT3001 Drug Product|Administered by intravenous infusion
45507299|NCT05198323|Drug|Placebo|Administered by intravenous infusion
45507300|NCT03550898|Diagnostic Test|Dynamic Ultrasonography|Dynamic Ultrasonography was performed with patients in supine position, with a suprapubic sagittal position transductor, during filling phase of urodynamics.
45507301|NCT05704621|Procedure|secondary cytoreductive surgery|Maximum effort cytoreductive surgery
45507302|NCT05704621|Drug|chemotherapy|six cycles of bevacizumab [10 mg/kg, days 1 and 15] plus carboplatin [AUC 5, day 1] plus pegylated liposomal doxorubicin [30 mg/m2, day 1] every 4 weeks, followed by maintenance bevacizumab [15 mg/kg every 3 weeks]
45697767|NCT05168865|Drug|Letrozole 2.5mg|Letrozole 5 mg starting on day 3 of spontaneous menstrual period or after progesterone withdrawal bleeding for five consecutive days.
45697768|NCT02165722|Behavioral|4 Pillars Toolkit|"Behavioral: Pillar 1: Convenient Vaccination Services (e.g. use every visit [chronic and acute] as an opportunity to vaccinate; use express vaccination clinics and dedicated vaccination stations; use influenza vaccination as an opportunity to vaccinate for other vaccines).~Behavioral: Pillar 2: Patient Notification (e.g. use electronic reminders and social media for vaccination reminders; use physician recommendations).~Behavioral: Pillar 3: Enhanced Office Systems (e.g. implement Standing Order Programs; use EMR prompts; add vaccination status as a vital sign when rooming).~Behavioral: Pillar 4: Motivation (e.g. establish an office Immunization Champion to track goal progress, aided by research team feedback)."
45507303|NCT02133014|Procedure|laparoscopic-assisted percutaneous catheter drainage|Removing necrotic pancreatic organizations and putting the catheter around the region of pancreas.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline
45507304|NCT02133014|Drug|0.5% 5-fluorouracil normal saline|On the one hand,0.5% 5-fluorouracil normal saline directly inhibit DNA synthesis of pancreatic acinar cells which result in the synthesis of amylopsin of and trypsase is restrained.On the other hand,it can induce pancreatic cells apoptosis and alleviate pancreatic necrosis.
45507305|NCT05759455|Dietary Supplement|vitamin d|Assessment of Vitamin D level in Children with Autism in assiut university children hospital
45697769|NCT04654143|Drug|BVL-GSK098 capsule, placebo|Oral QD
45697770|NCT01882985|Drug|Docetaxel|Given IV
45697771|NCT01882985|Dietary Supplement|Lycopene|Given PO
46057100|NCT05755516|Device|LVIS and LVIS Jr. (MicroVention)|Stent assisted coiling with LVIS and LVIS Jr. (MicroVention).
45399256|NCT01228708|Other|Active implementation of a guideline for chronic disease|"Smoking cessation courses Remuneration to GPs for the planned follow-up and joint home visits Action card and sputum colour advice Webpage on How to live with COPD and the support the health system can provide Database with patients with COPD Feed-back from health centre to GPs, when patients have finished courses Fax from hospital to GPs, when patients with COPD is discharged Routines to recall patients for follow-ups Team audit, evaluate and adjust the strategies every 3rd month Joint home visit with GP and community nurse when a patient with COPD is discharged to plan future care Practice staff do part of follow-ups and monitoring Practice supervision with consultant in lung diseases Podcast with advice from specialists Guideline for COPD"
45399257|NCT05402488|Behavioral|Auditory stimulation|Auditory stimulation during sleep
45507306|NCT05759377|Device|V-A ECMO AUTO Mode algorithm|"The clinical effects of utilizing the V-A ECMO AUTO Mode in parallel with VA ECMO treatment shall be assessed in different clinical settings. For this, a set of relevant clinical situations and findings (events) has been defined as trigger points where technical (via AIC) and clinical data shall be collected, linked, and analyzed. This assessment of raw data is important to further develop and adapt the software."
45697772|NCT04648761|Biological|OPTIMAL algorithm|The OPTIMAL algorithm titrates anti IL 5 treatment by addjusting the intervals between injections by FEV1, blood eosinophils and exacerbations.
45507307|NCT02129114|Device|ReDura Onlay|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of ReDura Onlay.
45507308|NCT02129114|Device|DuraGen|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of DuraGen.
45507309|NCT03653143|Behavioral|JASPER|JASPER is a therapist and parent-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes parents as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
45507310|NCT02136992|Drug|Pirfenidone|Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
45697773|NCT04277481|Other|10 minute cold pack|10 min package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
45507311|NCT02136992|Drug|placebo|placebo will be taken two tablets 3 times a day during the whole study process
45507312|NCT03629119|Dietary Supplement|Dietary Fiber Supplement|Participants will be instructed to consume 1 tea spoon of psyllium per day for 3 months and otherwise maintain their habitual diet. Participants will be asked to keep a diary assessing bowel movement and intestinal symptoms such as bloating and flatulence beginning two weeks prior to the intervention.
45507313|NCT02133092|Other|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
45697774|NCT04277481|Other|12 minute cold pack|12 min package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
45697775|NCT04277481|Other|15 minute cold pack|15, min package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
45697776|NCT04277481|Other|20 minute cold pack|20 min package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
45507314|NCT03045081|Behavioral|PainTracker Self-Manager|Interactive web-based educational and assessment program supported by a nurse care manager
45399258|NCT03923062|Device|chemicalpeeling|"Cleansing and degreasing the face with alcohol .~The patients must be sitting at an angle of 45.~A 2 × 2 cm cotton gauze will be used to apply TCA 20%.~We will apply the acid from the midline to the right side of the forehead and under the right eye, covering the right cheek and perioral area.~We then will wait for a few minutes and will observe the frost developing.~The patient will be then allowed to wash her face."
45399259|NCT03923062|Device|cryopeeling|Cryopeeling will be performed by spraying the freezing substance(Liquid Nitrogen) on the face at 1-2cm distance and moving along the affected area until freezing appear.
45399260|NCT03923062|Combination Product|microneedling|"Tranexamic acid will be used in aconcentration of 4mg/ml ,1ml will be used fo half of the face.~After gentle cleansing, topical analgesic cream will be applied over the area to be treated.~The microneedles will be used, the skin will be stretched and microneedling will be carried out in vertical, horizontal, and both diagonal directions for about four to five times. Tranexamic acid, 0.5 to 1 ml (4 mg/mL), will be applied over this area, and the procedure will be repeated four to five times in the above-said directions"
45507315|NCT03621397|Device|brainHQ by Posit Science|This is an online cognitive training program. It consists of 29 online exercises that work out attention, brain speed, memory, people skills, navigation, and intelligence. The current study will focus on the following exercises: attention, brain speed (e.g., processing speed), executive function, and memory.
45507316|NCT02137148|Device|Use of Ultrasound to assist in needle placement|Use of the Sonic Window handheld Ultrasound device to assist in needle placement by providing a coronal image of the patient anatomy.
45507317|NCT02252978|Drug|ciprofloxacin|Given PO
45507318|NCT02252978|Other|placebo|Given PO
45507319|NCT02252978|Other|quality-of-life assessment|Ancillary studies
45507320|NCT02252978|Other|laboratory biomarker analysis|Correlative studies
46057101|NCT00913900|Biological|autologous CD133+ cells|Intramuscular injection
45399261|NCT03918226|Procedure|exploratory laparotomy|Patients presenting with acute abdomen were operated. Exploratory Laparotomy of patients was done. Further procedure was done according to peroperative findings. Ileostomy for perforation of gut, stricturoplasty for strictutre, biopsy for mesentric lymphadenopathy
45399262|NCT01230268|Other|Mulberry fruit extract|1000 mg oral daily dose for 2 weeks
45399263|NCT01134406|Device|Hydros Joint Therapy|Single intra-articular injection.
45399264|NCT01134406|Device|Hydros-TA Joint Therapy|Single intra-articular injection
45399265|NCT01134406|Device|Synvisc-One|Single intra-articular injection.
45399266|NCT01231828|Drug|L-carnitine|L-carnitine 4g per day (4 bottles of 10ml).
45399267|NCT01231828|Drug|Lactulose|Lactulose (30-60 ml per day)
45507321|NCT05507385|Behavioral|IMAGINE-POSITIVE|The intervention will combine aspects of Memory Specificity Training (MeST), which includes information about the links between memories and emotions, with Positive Prospective Mental Imagery (PPMI), to increase vividness and savouring of positive future images, in order to harness positive affect. IMAGINE-PA will follow a treatment manual and delivery will be accompanied by a therapy workbook.
45507322|NCT05507385|Behavioral|Control|Non-directive supportive therapy (NDST) consists of individual sessions, with an empathetic, emotionally supportive practitioner and provides non-directive problem solving and monitoring. Using NDST will control for factors that may contribute to change, which are not active components e.g. speaking to an empathetic therapist. NDST will follow treatment guidelines.
45507323|NCT02133170|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|The MBCT program is conducted in HULP (BRV and CBP), which also train therapists from Vitoria, in order to homogenize the intervention. Random sessions are video or audio recorded to be discussed and analyzed by the treatment team. The manualized MBCT therapy consists of 8 weekly sessions of 90 minutes and is applied in groups of approximately 10-15 patients. At least two programs in H. La Paz and two in the hospital de Santiago (Vitoria) will be provided.
45507324|NCT02133170|Behavioral|Psychoeducation|Psychoeducation program will be held in groups of 10 to 15 patients in 90-minute weekly sessions led by two therapists also outside the research team. The specific program of 8 sessions is focused addressing disease awareness, adherence to treatment and early detection of prodromal symptoms. Homework will also be included. The program is based on the Psychoeducation Manual for Bipolar Disorder . F.Colom , E.Vieta . Ars Medica, 2004. Attendance at least 80 % of the sessions of both interventions will be required to be considered complete.
45697777|NCT02166346|Drug|Dalfampridine|Dalfampridine 10 mg twice daily for 8 weeks
45399268|NCT03923218|Other|LL-37 levels in Gingival crevicular fluid|Collected gingival crevicular fluid
45399269|NCT03923218|Other|Serum Vitamin D3 levels|Collected serum
45399270|NCT03923218|Other|Clinical parameters|Recorded plague index, gingival index, probing depth, clinical attachment level
46057102|NCT00729859|Drug|Acyline|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + placebo Testosterone gel daily for 28 days + placebo oral anastrozole pill daily for 28 days
46057103|NCT00729859|Drug|Acyline + Testosterone gel|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + placebo oral pill 1 mg daily for 28 days
45507325|NCT02133170|Behavioral|Standard treatment|Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
45399271|NCT03923140|Drug|Tranilast|5mg/kg.d for juvenile patients with a maximum dose of 0.3g per day; 0.1g each time, three times a day for adults patients
45399272|NCT05402410|Diagnostic Test|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
45399273|NCT05402176|Other|Whole Lung Lavage|Whole Lung Lavage (WLL) is performed as standard of care. Outcome following WLL is observed.
45399274|NCT03922984|Procedure|MRI with Arterial Spin Labeling (ASL)|Week 0 (Before initiation of chemoradiation): MRI with ASL will be performed along with patient's standard of care imaging session Week 3: contrast-enhanced research MRI with ASL Week 6: contrast-enhanced research MRI with ASL Week 10: MRI with ASL will be performed along with patient's standard of care imaging session Week 18: MRI with ASL will be performed along with patient's standard of care imaging session Week 26: MRI with ASL will be performed along with patient's standard of care imaging session Week 34: MRI with ASL will be performed along with patient's standard of care imaging session
45399275|NCT01133080|Drug|Minocycline|minocycline 200 mg/day orally in two divided doses for the second week. From weeks 3 to weeks 5, minocycline 400 mg/day orally in two divided doses.
45399276|NCT01133080|Drug|placebo|"placebo 200 mg/day orally in two divided doses for the first week. placebo 200 mg/day orally in two divided doses for the second week.~From weeks 3 to weeks 5, placebo 400 mg/day orally in two divided doses."
45399277|NCT05402098|Procedure|Endodontic treatment using traditional access|Endodontic treatment will be carried out following complete removal of pulp chamber roof and achieving straight line access
45399278|NCT05402098|Procedure|Endodontic treatment using conservative access|Endodontic treatment will be carried out following partial removal of pulp chamber roof, extended only to the extent which helps to locate all the orifices with no efforts will be made to achieve straight line access
45399279|NCT01133236|Dietary Supplement|Salt and fluid restriction|"I: Intervention Prescription of low-sodium diet with additional 2 g of sodium and water restriction to 800 mL/day.~II: Control Prescription without sodium and fluid restriction."
45399280|NCT01230580|Drug|Protease Inhibitor|Switch to a regimen comprising a single ritonavir-boosted Protease Inhibitor
45507326|NCT03107377|Drug|EVO100|5 g dose applied up to 1 hour prior to coitus
45399281|NCT01230580|Drug|Standard-of-care Antiretroviral therapy|Regimen should consist of 3 drugs: 2 nucleoside reverse transcriptase inhibitors with either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor
45399282|NCT05401942|Other|Tele-monitoring through mobile application|Tele-monitoring of Patient reported outcomes
45399283|NCT01585792|Drug|TAK-875|
45399284|NCT01585792|Drug|TAK-875|
45507327|NCT03107377|Drug|Placebo|5 g dose applied up to 1 hour prior to coitus
45507328|NCT03529695|Behavioral|Standard HVP Curriculum|Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on strengthening children's cognitive skills, early literacy skills, social/emotional and physical development.
45399285|NCT01585792|Drug|Glimepiride|
45399286|NCT01585792|Drug|Placebo|
45399287|NCT03922672|Behavioral|Group piano training|The group piano training is scheduled over 4 months of a two-hour weekly group piano lesson. There is also a 3-hour weekly practice at home.
45399288|NCT01134484|Drug|Velcade|"INDUCTION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 4, 8 and 11 (3 courses, 21 days each)~REMISSION CONSOLIDATION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 8, 15 and 22 (2 courses, 35 days each)"
45507329|NCT03529695|Behavioral|Obesity Prevention|Obesity prevention curriculum program targets 4 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, and decreasing fried foods) aimed at reducing obesity risk in mothers and children. The module will also include weekly activity opportunities to develop social networks that foster healthy eating and physical activity.
45399289|NCT01134484|Drug|Thalidomide|"INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-63 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~AFTER PBSC COLLECTION: 100 mg/d from day after last PBSC collection until the day before first course of MEL-200~AFTER FIRST TRANSPLANTATION: 100 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200~REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation): 100 mg/d days 1-70"
45399290|NCT01134484|Drug|Dexamethasone|"INDUCTION THERAPY~VTD ARM: 40 mg/d days 1-2, 4-5, 8-9 and 11-12 (3 cycles, 21 days each)~TD ARM: 40 mg/d days 1-4 and 9-12 (3 cycles, 21 days each)~AFTER PBSC COLLECTION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide)~AFTER FIRST TRANSPLANTATION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide) and repeated every 28 days, for 3 months~REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation)~VTD ARM: 40 mg/d days 1-2, 8-9, 15-16 and 22-23 (2 cycles, 35 days each)~TD ARM: 40 mg/d days 14 and 20-23 (2 cycles, 35 days each)"
45399291|NCT01134484|Procedure|Peripheral Blood Stem Cell (PBSC) collection|"Cyclophosphamide (CTX): 4 g/sqm given in a single day (day 0)~G-CSF: 10 µcg/kg/d, starting on day +2 from CTX and continuing until completion of PBSC collection"
45507330|NCT02253056|Other|Fasting / Caloric Restriction|
45507331|NCT02253056|Other|Healthy Diet|
45507332|NCT02129270|Drug|Lidocaine HCl 2% .|comparison of different dosages of drug
46057104|NCT00729859|Drug|Acyline + testosterone gel + anastrozole|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
45507333|NCT02129270|Drug|Lidocaine HCl 1%|comparison of different dosages of drug
45507334|NCT03550742|Other|Fuco-N-Tetraose|Daily bolus of Fuco-N-Tetraose
45507335|NCT05505513|Device|percutaneous Utah Slanted Electrode Arrays (pUSEAs)|Microelectrode slanted arrays with a large number of electrodes will be surgically implanted into peripheral nerves of patients with limb amputations.
45507336|NCT03549884|Procedure|Delayed cord clamping|Cord clamping will be performed after 60 seconds of life in infants delivered by cesarean section
45507337|NCT03549884|Procedure|Early cord clamping|Cord clamping will be performed within 10 seconds of life in infants delivered by cesarean section
45507338|NCT05370547|Drug|Chidamide|"Chidamide monotherapy mode: Chidamide was administered for at least 6 times after leukapheresis, 10mg oral D1-4, 20mg oral D7 every 3 days to the beginning day of FC conditioning.~Chidamide combination mode: The combination of one or more of the following drugs in addition to chidamide is permitted: glucocorticoids, BTK inhibitors, chemotherapy, other previously used resistance drugs, etc."
45507339|NCT05370547|Drug|Fludarabine and cyclophosphamide|Patients should be received FC regimen conditioning 3 to 5 days prior to CAR-T cell infusion. The recommended regimen is intravenous fludarabine (25-30 mg/m^2) and cyclophosphamide (250-500 mg/m^2) daily for 3 consecutive days. The clinician may also adjust the cleansing regimen according to the patient's actual situation.
45507340|NCT05370547|Biological|Anti-CD19 CAR-T cells|A single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 100 × 10^6 for Relma-cel or 2 × 10^6/kg for Axi-cel. Other commercial CAR-T doses are determined by specific drug infusion instructions. The dose of experimental CAR-T was determined by the investigator. Infusion volume was calculated based on CAR-T cell density and recommended dose.
45507341|NCT02133326|Drug|Caldolor|Subject will be given Caldolor by IV prior to surgery.
45507342|NCT02133326|Drug|Ofirmev|Subject will be given Ofirmev prior to surgery.
45507343|NCT03551509|Biological|ArthroFLEX ECM scaffold graft|In patients receiving a graft, thru mini open technique the lateral portal incision will be extended vertically approximately 5-6 cm. A standard, deltoid-splitting, mini-open approach will then be performed, leaving the deltoid attachment to the acromion intact. For arthroscopic technique same method of fixation will be used below. The dermis graft will be sized and cut so as to cover the entire repair site in both medial-lateral and anterior-posterior dimensions.
45507344|NCT03551509|Procedure|Control|This group will undergo rotator cuff repair surgery, but will not receive the ECM scaffold graft.
45507345|NCT03551509|Biological|Crossover|Patients randomized to the control arm who cannot be repaired without an augmented graft will be followed for safety and remain in the study and put into a group for the intention to treat.
45507346|NCT02137304|Device|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA) mechanical insufflation to increase peak cough flow
45507347|NCT02133482|Drug|Placebo|placebo solution
45507348|NCT02133482|Drug|BI 639667|oral solution BI 639667, single rising doses
45507349|NCT05341141|Device|Frozen glove and sock|Preparation of frozen glove and sock: 4℃ for 3 hours.
45507350|NCT05341141|Drug|ddEC-ddT|Epirubicin (E) 90~100mg/m^2, i.v., d1 + cyclophosphamide (C) 600 mg/m^2, i.v., d1, q2w, for 4 cycles followed by albumin-paclitaxel (T) 260 mg/m^2, i.v., d1, q2w, for 4 cycles.
46057105|NCT05754892|Other|Blood sample|For patients with ACC : blood (30ml) sampling before surgery and every 3 months during 3 years after surgery for biobanking For patients with MPP : blood (30ml) sampling before surgery and every 6 to 12 months for MPP during 3 years after surgery for biobanking
45507351|NCT02137616|Drug|risperidone|Risperdal tablets
45507352|NCT02137616|Drug|olanzapine|olanzapine tablets
45399292|NCT01134484|Procedure|First Autologous Transplantation|"HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10^9/L for 3 consecutive days"
46057106|NCT05754892|Other|Urine sample|For patients with ACC : urine sampling before surgery and every 3 months during 3 years after surgery for biobanking For patients with MPP : urine sampling before surgery and every 6 to 12 months for MPP during 3 years after surgery for biobanking
46057107|NCT05754892|Other|Tumor sample|For patients with ACC and patients with MPP : tumor sample during surgery
46057108|NCT00918151|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study
46057109|NCT00810394|Drug|Sorafenib|Patients will be registered and started on the standard recommended dose-schedule for sorafenib (400 mg tablet by mouth twice a day continuously). Dose reductions will be instituted in the event of grade 3 or higher hematologic or non-hematologic toxicity or for any toxicity that is considered by the patient or physician as intolerable.
46057110|NCT00736333|Drug|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) 50 mg/m^2, given for up to 6 cycles
46057111|NCT02608840|Other|Auditory stimulation during sleep|The intervention is a brain computer interface program which measures brain electroencephalogram to identify slow waves and time the sounds. Barely audible sounds are delivered through headphones and played during sleep (specifically, during slow wave sleep).
45507353|NCT02137616|Drug|Quetiapine|quetiapine tablets
45507354|NCT02137616|Drug|Aripiprazole|Aripiprazole tablets
45399293|NCT01134484|Procedure|Second Autologous Transplantation|"HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10^9/L for 3 consecutive days"
45399294|NCT03922906|Device|Pure-Vu System|Pure-Vu System is intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating and/or cleaning the colon and evacuating the irrigation fluid (saline water), feces and other bodily fluids and matter, e.g. blood.
45507355|NCT02129504|Device|root coverage comparing two techniques|The aim of this study was to compare and show the benefits of the extended flap technique (new technique) compared to coronal advanced technique (gold standard technique) both techniques using the porcine collagen matrix for root coverage.
45507356|NCT02133560|Behavioral|Video recording|Subjects will be asked to monitor their daily iron chelator administration by taking a video recording of preparing it and ingesting at least one sip. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
45507357|NCT02133560|Behavioral|Medication Administration Log|Subjects will be asked to monitor their daily iron chelator administration by completing the medication administration log on a daily basis. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
45507358|NCT02133560|Behavioral|Education|"During this first six months period a study staff member will see subjects at each scheduled clinic visit they attend for regular blood transfusion.~Subjects will receive educational material and short quizzes related to sickle cell disease, thalassemia, iron overload, or iron chelation."
45507359|NCT05198011|Procedure|3D customized Titanium Mesh (Study)|approach for planning and augmenting atrophic posterior mandibular ridge using a pre-customized TiMe on a 3D model. The 3D surgical model will be virtually created from a cone-beam computed tomography (CBCT) and printed using Fused deposition modeling (FDM) machine. The 3D model will be then used to contour the TiMe in accordance with the needed amount of augmentation then will be used to help pack and contour the graft material.
45507360|NCT05198011|Procedure|Conventional ridge augmentation (Control)|the conventional technique of ridge augmentation using Titanium Mesh
45507361|NCT02133638|Drug|Sevoflurane|Induction of anesthesia: fentanyl 2 µg kg-1 and a bolus inhalation of 8% sevoflurane in an 8 L.min-1 fresh gas flow. Anesthesia maintenance: 1 minimal alveolar concentration (MAC) sevoflurane at a low fresh gas flow of 0.6-0.8 L min-1 in a 60% air-oxygen mixture supplemented with boluses of fentanyl.
45507362|NCT02133638|Drug|Propofol|Induction of anesthesia: propofol 2 mg kg-1 and fentanyl 4 µg kg-1. Maintenance of anesthesia: infusion of propofol 8 mg kg-1 h-1 and boluses of fentanyl 3 µg kg-1.
45507363|NCT05197933|Procedure|Laparoscopic resection|Laparoscopic resection for GIST at unfavorable anatomic site of stomach will be conducted
45507364|NCT02545283|Drug|Cytarabine|Participants will receive cytarabine 1 gram per square meter (g/m^2) intravenous (IV) infusion for 5 days of every treatment cycle.
45507365|NCT02545283|Drug|Idasanutlin|Participants will receive idasanutlin 300 mg per oral (PO) twice daily (BID) (in Cycle 1) or once daily (QD) (in Cycles 2 and 3) for 5 days of every treatment cycle.
45507366|NCT02545283|Other|Placebo|Participants will receive idasanutlin matching placebo PO BID or QD for 5 days of every treatment cycle.
45507367|NCT02137694|Other|vaginal auto-takings and urinary test|vaginal auto-takings and urinary test
45507368|NCT05304481|Biological|ATL administration|Subjects have ATL administration using intravenous infusion
45507369|NCT02260700|Drug|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment A (oral suspension formulation) under fasted conditions in one of the treatment periods.
45507370|NCT02260700|Drug|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment B (solid formulation) under fasted conditions in one of the treatment periods.
45507371|NCT02260700|Drug|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment C (solid formulation) under fed conditions in one of the treatment periods.
45697778|NCT02166346|Drug|Placebo|Placebo pill 1 tablet twice daily for 8 weeks
46057112|NCT02608840|Other|Sham Intervention|The brain electroencephalogram is measured and headphones are worn, but sounds are not played during sleep.
46057113|NCT03929302|Device|MyTAP oral appliance plus mouth shield|The midline traction oral appliance (MyTAP, AMI Inc., Dallas, Texas) is currently marketed as a medical device to treat snoring and obstructive sleep apnea and is FDA cleared will be used only in Phase-2 of the study. Phase-1 doesn't include any intervention.
45399295|NCT03918148|Drug|SGLT-2i|Dapagliflozin or canagliflozin or empagliflozin add on to metformin ± basal insulin
45399296|NCT03918148|Drug|DPP-4i|Sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin add on to metformin ± basal insulin
45399297|NCT03917680|Diagnostic Test|Factor XII dosage|Factor XII (FXII, Hageman factor) will be measured in plasma. It is converted to FXIIa by an activator. The FXIIa protease cleaves a chromogenic substrate and releases p-nitroaniline (pNA), which can be measured photometrically.
45399298|NCT03917680|Genetic|p.Thr328Lys mutation detection|Sequencing of exon 9 of franking introns of FXII, for identification of the p.Thr328Lys mutation.
45399299|NCT03917680|Diagnostic Test|Videocapillaroscopy|It is an optical method to visualize the most superficial part of the cutaneous microcirculatory network. It provides morphological information.
45399300|NCT03740074|Behavioral|PAI|"Consenting subjects will be given a Mio Slice, along with instructions on how to utilize the device.~They will register on line with PAI Health, and will be asked to sync their device at least once every 7 days. They will be encouraged to look at the device app on their smart phone at least once daily.~After 1 week of obtaining baseline data, subjects will be encouraged to try to obtain a PAI score of at least 30 initially. Once they obtain a score of 30 consistently, they will be encouraged to increase the score toward 50. If they consistently obtain 50, they can increase their goal sequentially toward a maximum goal of 100. The duration of the study will be 12 weeks."
45399301|NCT01133470|Drug|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's KLaboratories Limited
45399302|NCT01134718|Drug|TMC435 (G006)|one morning dose of 150 mg
45399303|NCT01134718|Drug|TMC435 (F021)|one morning dose of 150 mg
45399304|NCT01134718|Drug|TMC435 (G007)|one morning dose of 150 mg
45399305|NCT03922360|Behavioral|Smartphone-based Financial Incentives|"Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.~Best Practices + Financial Incentive- Women assigned to this condition will receive the best practices treatment described above plus the remote incentives intervention.~Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples < 6 ppm will be considered negative and those > 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced and incentives will be contingent on submitting a negative saliva cotinine test."
45399306|NCT03922360|Behavioral|Best Practices|Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.
45399307|NCT01228864|Procedure|quality of life|survey
45399308|NCT01228864|Procedure|Quality of life|
46057114|NCT00736255|Drug|Transdermal Nicotine Patch|All subjects will lreceive transdermal nicotine patch during beginning at Visit 0 (quit smoke date). The dose will be tapered down from 21 mg to 14mg after week 1,vthen to 7 mg after week 2. Subjects will remain at 7mg until the 4th week.
45399309|NCT03917758|Drug|SGLT2 inhibitor|Start of the treatment with SGLT2i.
45399310|NCT05206474|Device|IRADYN|"One course of IRADYN® at baseline, consisting of a mono-dose intra-articular administration (2 ml).~From week 1 to week 6, injection will be performed, if necessary, during the visit, following the dosage reported in the instruction for use / summary of product characteristic."
45399311|NCT01134874|Behavioral|Standard weight loss intervention|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week.
45399312|NCT01134874|Behavioral|Standard weight loss intervention plus technology|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
45399313|NCT01134874|Behavioral|Technology only|One intervention telephone call per month, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
45399314|NCT01230736|Drug|Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®)|One drop in study eye(s) once daily for 8 weeks
45399315|NCT05401552|Other|Meal|Comparison of two breakfast meals containing the same amount of phosphorus but one in the form of inorganic additives
45399316|NCT01133548|Drug|Testosterone Gel 1.62%|5 grams administered using an application Site Rotation
45399317|NCT01133548|Drug|Testosterone Gel 1.62%|5 grams administered using an a combination of Application sites
45507372|NCT05682391|Other|Bed rest|Strict bed rest ordered after surgery that does not allow the participant to elevate the head of bed over 30 degrees
45697779|NCT01893905|Drug|CS+SG|Chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
45507373|NCT02133716|Other|expressed breast milk|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of expressed breast milk given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
45697780|NCT01893905|Drug|Placebo|Placebo of chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
45849852|NCT04261296|Other|dry needling|In this treatment, depending on the thickness of the adipose tissue under the skin, 13 mm, 25 mm or 30 mm long; 0.20 mm thick acupuncture needle is used
45399318|NCT03917368|Other|Ultrasound scan of the internal jugular veins|Participants, lying at their hospital bed, will maintain their head in a fixed position on the longitudinal axis, while an operator gently places a linear probe L12-RS (7.5-11 MHz), smeared with gel, on one side of the neck, at the middle level. A 15-sec video clip of the ultrasound images will be recorded. This procedure will be repeated on the other side of the neck. In addition, three electrodes will be placed on participants' chests and connected to the ultrasound system for simultaneously measuring the ECG signal.
45399319|NCT03922438|Procedure|usage of cleft margin flap with anterior palatal closure during primary cleft lip repair.|Under general anesthesia, preparation of lip and palatal flaps will be done and then cleft margin flap which is designed to be inferiorly based will be used with anterior palatal closure in an attempt to decrease the incidence rate of naso-alveolar fistula (defect) that is usually occur and remain in those patients post-operatively.
45399320|NCT03922516|Diagnostic Test|ULDCT|Ultra-Low-Dose-CT (ULDCT) of the chest using tin filters with third-generation dual-energy CT devices. The projected dose used will be approximately 0.2 mSv per ULDCT of the chest.
45399321|NCT01135030|Procedure|Total knee|Primary Total knee
45399322|NCT05401474|Device|High Flow Nasal Cannula at 30L/min|Flow will be set at 30L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
45399323|NCT05401474|Device|High Flow Nasal Cannula at 45L/min|Flow will be set at 45L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
45399324|NCT05401474|Device|High Flow Nasal Cannula at 60L/min|Flow will be set at 60L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
45399325|NCT03917602|Procedure|human amniotic membrane plug with vitrectomy|using human amniotic membrane plug with vitrectomy to try to close large macular hole
45697781|NCT04460235|Drug|Prevenar13 Pneumo-23|Vaccination according national guidelines
45697782|NCT04643769|Drug|ORIN1001|Oral tablet - ORIN1001
45697783|NCT04643769|Drug|Placebo|Oral tablet - placebo
45849853|NCT04261296|Other|balneotherapy|"This treatment method; An alert-fit performed in a certain time interval and in a cure style by using the methods and doses of hot mineral waters, gases and peloids (sludge) from natural underground, determined in detail, repeatedly in series as bath, drinking and inhalation treatments. treatment can be defined as. There are studies showing that the effect of balneotherapy is mechanical, thermal, chemical, anti-inflammatory and immunological."
45849854|NCT04261296|Other|dry needling +balneotherapy|Both of these methods will be applied to patients in the third group.
45849855|NCT04252794|Procedure|Splenic artery ligation|Splenic artery will be ligated just after takeoff from coeliac trunk at the level of body of pancreas
45849856|NCT04252794|Other|No intervention|Splenic artery is not ligated despite the presence of portal hyperperfusion
45849857|NCT04243590|Behavioral|Hand-Use-at-Home Questionnaire (HUH)|The HUH assesses the amount of spontaneous use of the affected hand in children with unilateral upper limb paresis aged 3-10 years, performing 18 typical bimanual play and self-care activities. Parents rate items using a 5-point rating scale (never-sometimes-regularly-often-always). After completion, the ratings are converted into a 3-point score (i.e. never/sometimes = score 0, regularly/ often = score 1, always = score 2). A sum score can be calculated (range 0-36).
45507374|NCT02133716|Behavioral|sucrose 24% oral|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of oral sucrose 24% given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
45849858|NCT04243590|Behavioral|Pediatric Outcome Data Collection Instrument (PODCI)|The PODCI is designed to assess different aspects of daily living in children with musculoskeletal disorders. It has excellent psychometric properties, and it is a widely accepted instrument to provide parent/patient-reported information about upper extremity functioning. A Dutch version is available and it is validated for children with neonatal brachial plexus palsy. It consists of 85 questions and five scale scores and one total score can be calculated (range for all scales and total score 0-100, higher scores indicating better functioning/quality of life). Only the Upper Extremity and Physical Function Scale (8 items) were used in this study since this scale provides information about difficulties performing activities using the arms/hands (score 0-100; lower score, more difficulties).
45507375|NCT05257681|Procedure|Interlobar fissure completion and pleural adhesiolysis|A video-assisted thoracic surgery or robotic approach will be used to perform pleural adhesiolysis and the lobar fissure adjacent to the previously targeted lobe during bronchoscopic lung volume reduction will be completed using a surgical stapler.
45507376|NCT02137928|Drug|carboplatin periocular injection|20mg/2ml carboplatin periocular injection together with chemotherapy
46057115|NCT00736255|Drug|Lis-dexamphetamine (Vyvanse)|Subjects on this arm will receive Lis-dexamphetamine day after the identified quit date. All subject will start with 30mg once a day and will be titrated up to 50mg then to 70mg over a 3 week period to reach an optimized dose. They will then be maintained on this optimized dose until the 4th week.
45507377|NCT02137928|Drug|chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
45507378|NCT05678101|Device|transcutaneous electrical nerve stimulation (TENS)|Chattanooga Physio TENS (DJO Global, Vista, CA)
45507379|NCT05678101|Device|Sham transcutaneous electrical nerve stimulation (TENS)|Sham treatment with Chattanooga Physio TENS (DJO Global, Vista, CA)
45507380|NCT02138084|Drug|BMS-663068|BMS-663068
45507381|NCT02138084|Drug|Rifabutin|Rifabutin
46057116|NCT00736255|Drug|Placebo|Subjects on this arm will receive matching placebo, along with Nicotine Replacement Therapy.
46057117|NCT03920254|Drug|TD-1473 Dose A|See Arm description
45399326|NCT03922282|Procedure|Gasless BABA|BABA robotic-thyroidectomy that is using elevation of flap instead of using carbon dioxide.
45399327|NCT03922282|Procedure|Classic BABA|BABA robotic-thyroidectomy that is using carbon dioxide.
45399328|NCT01135108|Drug|Placebo|Placebo IV Infusion
45399329|NCT01135108|Drug|KAI-1678|KAI-1678 IV Infusion
45399330|NCT01135264|Behavioral|CBT|The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur & Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.
45399331|NCT01135264|Behavioral|CMBT|We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
45399332|NCT03917212|Other|No intervention|No intervention, observational study with metabolic characterisation
45399333|NCT05201092|Drug|[14C]-Lu AG06466|[14C]-Lu AG06466 will be administered per schedule specified in the arm description.
45507382|NCT02138084|Drug|Ritonavir|Ritonavir
45507383|NCT05677087|Behavioral|PREPARE Nutrition Education Module|The Perinatal Remote Education for Pandemic Resilience (PREARE) program is a 6-week intensive program aimed at increasing maternal and infant dietary diversity as well as maternal health literacy. Modules that will be completed in the program include education on early initiation of breastfeeding, food groups and the benefits of a balanced diet, appropriate meal frequency for mother and infant, and appropriate sources of health information. Information on personal hygiene and COVID-19 hygiene protocols as well as danger signs during pregnancy are included in the module to improve maternal knowledge on safety protocols and pregnancy complications.
45507384|NCT02129582|Radiation|total marrow irradiation|Undergo TMI
45507385|NCT02129582|Drug|fludarabine phosphate|Given IV
45507386|NCT02129582|Drug|busulfan|Given IV or PO
45507387|NCT02129582|Procedure|myeloid progenitor cell transplantation|Undergo allogeneic hematopoietic progenitor cell transplant
45507388|NCT02129582|Biological|anti-thymocyte globulin|Given IV
45507389|NCT02129582|Drug|tacrolimus|Given IV or PO
46057118|NCT03920254|Drug|TD-1473 Dose B|See Arm description
46057119|NCT03920254|Drug|TD-1473 Dose C|See Arm description
45507390|NCT02129582|Drug|methotrexate|Given IV
45507391|NCT02129582|Other|laboratory biomarker analysis|Correlative studies
45507392|NCT03282565|Other|Functional Resistance Training with Brace|A brace will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
45507393|NCT03282565|Other|Control|A brace will be strapped to the leg and will not apply resistance across the knee while subjects walk on a treadmill.
45507394|NCT03282565|Other|Functional Resistance Training with Elastic Band|An elastic band will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
45507395|NCT01355549|Biological|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
45507396|NCT02129738|Device|LoFric catheters|LoFric single use catheters to be used 4-6 times daily for 4 weeks.
45507397|NCT01362023|Behavioral|lifestyle counseling|"In 3 academic years, the intervention program consisted of three components:~Classroom practice by HPA to highlight healthy lifestyle habits~Teaching practice by HPA using books designed to include the nutritional objectives~Parental activities included with their children~In each of 12 activities (1 h/activity), the classroom practice consisted of three components:~Experimental development of activities regarding each healthy lifestyle habit~Assessment of activity performed in classroom~An activity developed for use at home"
45507398|NCT02133794|Device|Tomosynthesis|
45507399|NCT05759221|Procedure|Bronchoscopy with airway biopsy|Forceps biopsy of peripheral airways under direct endoscopic visualisation.
45507400|NCT05188625|Other|Telesupport - Telehealth|Online self-paced dietary education videos; Dietary counselling via video consultation; Blood glucose monitoring via a specially-designed health app
45507401|NCT02129816|Drug|Bryophyllum|
45507402|NCT05106205|Drug|DA-5213 10mg|single dose administration (one tablet once a day)
45507403|NCT05106205|Drug|DA-5213-R 10mg|single dose administration (one tablet once a day)
45507404|NCT05759143|Behavioral|Nest Platform|Patient- and clinician-facing portal via secure link
46057120|NCT04087993|Drug|Polyglucoferron|intravenous administration
46057121|NCT04087993|Drug|Ferric carboxymaltose|intravenous administration
45697784|NCT01050946|Biological|Haploidentical/cord transplant|"Myeloablative preparative regimen of chemotherapy and radiation followed by mismatch related(haploidentical)donor and one unit umbilical cord blood transplantation.~Conditioning Regimens Choice of regimen at the discretion of the treating physician~Fludarabine 30mg/m2(Days-7,-6,-5,-4,-3)-,Melphalan 70mg/m2(Day -3,-2), ATG 1.5mg/m2(Day-7,-5,-3,-1)~Fludarabine 50mg/m2(Day -6,-5,-4,-3,-2),Busulfan 3.2mg/kg(Day -5,-4,-3,-2),400cGY Total Body Irradiation(TBI)Day-1,ATG 1.5mg/kg(Day-7,-5,-3,-1)~Day 0 -Haploidentical donor and one umbilical cord blood unit infusion"
46057122|NCT04087993|Drug|Ferrous Sulfate|oral administration
46057123|NCT02593357|Device|COPD patients|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (EndoPAT®)
46057124|NCT05754814|Other|Malignant lymph nodes|Patients with a condition; either lymphoma on the neck or head and neck cancer with lymph node metastases on the neck.
46057125|NCT00729469|Drug|Ospemifene 60 mg|60 mg/day oral dose of ospemifene for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
46057126|NCT00729469|Drug|Placebo|oral dose of placebo,1 tablet/day, for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
46057127|NCT00742183|Device|Mepilex|Mepilex Ag - dressing changes every 5-7 days, more frequently if needed
46057128|NCT00742183|Device|Silvadene|Silvadene - dressing changes every day, more frequently if needed
45507405|NCT01362101|Behavioral|Mindfulness behavioral intervention (MT),cognitive behavioral intervention (CBT)|"60 smokers will enter a separate 4 wk group sessions trial that evaluates efficacy of MT in comparison to CBT for smoking cessation. During the parent study, participants will receive bi-weekly sessions of either MT or CBT, for 4 weeks and to set a quit date at the end of the 2nd week. In this context, we will examine participants at two points:~Week 0-1 of MT/CBT: development of smoking scripts based participant's descriptions of situations that trigger tobacco craving.~Then participants will undergo pre-treatment (week 0-1) and post treatment (week 4) psychophysiological activation to smoking-related cues using the script driven imagery technique, in vivo cues, salivary cortisol testing and to complete a computerized SST protocol."
45507406|NCT02129894|Device|abdominal Binder|placement of abdominal binder
45399334|NCT03917290|Behavioral|Neuromuscular training|Training will be conducted with a research assistant under the supervision of Dr. Howell (PI), a certified athletic trainer, who will meet with participants either at the individual or small group level (3-4 participants maximum). Training will be done within the Children's Hospital Colorado network-of-care locations, dependent on the location of participants. Due to in-person restrictions that have resulted from COVID-19, participants may also complete the intervention via remote (virtual) training sessions.
45507407|NCT04756739|Device|Clearblue Connected Ovulation Test System|Clearblue Connected Ovulation Test System which is a CE marked device used for tracking the menstrual cycle
45507408|NCT02129972|Device|Colon videocapsule endoscopy (PillCam colon 2)|"This is a simple blind (blind for the lecture of the CVC record) study to evaluate the diagnostic value of the colon capsule endoscopy for the detection and the control of colon lesions, the feasibility, tolerance and safety of the CVC compared to the conventional colonoscopy under general sedation in children presented with Inflammatory Bowel Disease.~Over one week, the patient will undergo two exams (CVC and colonoscopy under general sedation). The exams will be done by two different physicians.~In order to assess the tolerance, after the completion of both exams, the patients will be asked to answer a comfort score questionnaire.~In order to assess the safety of the CVC, the patients will have a follow-up for adverse events over a 3 weeks period after completion of the CVC and only if the colon video capsule was not recovered during the conventional colonoscopy."
45507409|NCT04715243|Device|High flow nasal cannula (HFNC)|High flow nasal cannula as a form of non-invasive oxygen delivery
45507410|NCT04715243|Device|Helmet NIV|NIV interface
45507411|NCT04715243|Device|Face-mask NIV|NIV interface
45507412|NCT02138162|Drug|enzalutamide|oral
45507413|NCT05167279|Biological|JS026/placebo|Five dose groups (30 mg, 100 mg, 300 mg, 600 mg, and 1000 mg) will be set to receive an intravenous infusion of JS026/placebo on Day1, and two dose groups (300 mg JS026 + 1200 mg JS016, and 600 mg JS026+ 1200 mg JS016) will be set to receive an intravenous infusion of JS026/placebo + JS016/placebo on Day1. The investigational product and placebo will be distributed in each dose group in a ratio of 3:1.
45507414|NCT05167279|Biological|JS016/placebo|Two dose groups (300 mg + 1200 mg, and 600 mg + 1200 mg) will be set to receive an intravenous infusion of JS026/placebo + JS016/placebo on Day1. The investigational product and placebo will be distributed in each dose group in a ratio of 3:1.
45507415|NCT02138318|Other|High definition (HD) endoscopy|
45507416|NCT02138318|Other|chromoendoscopy|
45507417|NCT03549572|Behavioral|Coma Recovery Scale-Revised|Patients will be assessed using the CRS-R and the CRSR-FAST. The CRS-R is a standardized neurobehavioral rating scale that consists of 23 items organized into six subscales that address arousal, auditory, visual, motor, oromotor/verbal, and communication systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors. Reliability and validity have been demonstrated in multiple studies. The CRSR-FAST consists of 10 items organized into 4 subscales that address arousal, visual, motor and verbal/oromotor systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors.
45697785|NCT03677661|Other|Conventional approach|The intervention will consist of light cognitive and physical activity with no symptoms exacerbation followed by graded exertion. Participant will be evaluated by a neuropsychologist. The neuropsychological intervention will consist of advice relative to cognitive rest in line with the clinical evaluation results followed by an individualized step-by-step graded exposition to cognitive stimulus according to symptoms evolution. A kinesiologist will also evaluate the symptoms response to cardio-vascular exertion. According to the result of this clinical evaluation, a graded physical exercise program will be given to the participants. 8 in-clinic cardio-vascular exercise sessions in a 6-week period supervised by the kinesiologist (30 to 45 minutes each session) will be provided.
46057129|NCT00808444|Biological|Pneumococcal conjugate vaccine GSK1024850A (different lots)|Intramuscular injection, 3 doses
46057130|NCT00808444|Biological|Infanrix hexa|Intramuscular injection, 3 doses in Malaysia and 2 doses in Singapore
45399335|NCT01230970|Drug|BN83495|40mg tablet oral daily administration from Day 1 to Day 14.
45399336|NCT01135576|Dietary Supplement|non-fortified fruit juices consumed as part of the usual diet|
46057131|NCT00808444|Biological|Infanrix-IPV/Hib|Intramuscular injection, only for Visit 2 in Singapore
46057132|NCT00808444|Biological|Rotarix|Oral, 2 doses
45507418|NCT02133950|Procedure|elective cryopreservation of available embryos after PGD|no elective fresh embryo transfer; freeze all
45507419|NCT02133950|Procedure|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD
45507420|NCT04566029|Biological|Blood test|The patients' blood will be collected in four 5mL heparinized tubes
45507421|NCT04566029|Biological|Stool sample|The patients' stools will be collected at home
45507422|NCT04566029|Other|Questionnaires|At each visit, the following questionnaires will be collected: QLQ-C30 and EQ5D-5L Appendix 16.2 and PRO CTCAE
45507423|NCT05758987|Behavioral|Blended Trauma focused Cognitive Behavioral Therapy (B-Tf-CBT)|A trauma-focused CBT where internet-based treatment is blended with face-to-face sessions with a therapist.
45507424|NCT05758987|Behavioral|Prolonged exposure|A gold standard trauma-focused CBT delivered with face-to-face sessions with a therapist.
45507425|NCT02138396|Drug|Fentanyl Sublingual Spray (FSS)|A single dose of fentanyl, 400 mcg per sublingual spray
46057133|NCT05752396|Other|Conditioned Pain Modulation|Conditioned pain modulation (CPM) procedure evaluates the change in mechanical and heat pain sensitivity by a contralateral conditioning stimulus (cold immersion). This psychophysical paradigm investigates inhibitory pain modulation processes.
46057134|NCT05752396|Other|Offset Analgesia|Offset analgesia (OFA) procedure evaluates the disproportionate change in heat pain sensitivity after a slight decrease in stimulus intensity. This psychophysical paradigm investigates inhibitory pain modulation processes.
45399337|NCT01135576|Dietary Supplement|Iron fortified fruit juice|Consumption of micronized iron pyrophosphate supplemented fruit juices as part of the usual diet
45399338|NCT01133782|Procedure|Access to diagnostic test|Randomization to receive a result of diagostic procedure the following day.
45399339|NCT02528890|Other|vaginal/anal swab for GBS from all participants|All eligible pregnant women, who meet the inclusion criteria and gave their informed consent to participate in the study has to complete a questionnaire and have a vaginal / anal swab taken to identify positive GBS carriers by PCR (polymerase chain reaction) test.
45399340|NCT01228942|Device|COXEN analysis for chemotherapy prediction|Using the affymetrix genechip along with the COXEN algorithm the subject's treatment will be determined
45399341|NCT05401396|Other|Swimming immediately after eating|After having the last bite of lunch, the participants will swim in the pool with a specific distance.
45399342|NCT03917134|Drug|cephalosporin + Metronidazole Vaginal|administration of cephalosporin in doses of 2 grams administered intravenously before surgery and metronidazole vaginal ovules 500mg twice a day for 5 days after performing laparoscopic hysterectomy
45507426|NCT02138396|Drug|Fentanyl Citrate Injection (FCI)|A single dose of fentanyl citrate, 100 mcg per intramuscular injection
45507427|NCT02138396|Drug|Naltrexone|Naltrexone is provided as a 50 mg tablet before and after product dosing to minimize unacceptable adverse effects of fentanyl.
45507428|NCT05551585|Device|Transcranial pulse stimulation|TPS will be performed in three treatment sessions per week, applying 1000 pulses per session (single ultrashort (3 μs) ultrasound pulses, 0.2-0.25 mJ mm-2, ~5 Hz pulse frequency,
45507429|NCT02138474|Other|Lacticum acidum homaccord|Homeopathic remedy, made using sucrose pillules
45507430|NCT02138474|Other|Placebo|Unmedicated sucrose pillules
45507431|NCT04560881|Biological|Inactivated SARS-CoV-2 vaccine (Vero cell)|Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.
45507432|NCT04560881|Biological|Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine|Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.
45507433|NCT02911675|Device|EVD/IVC and the IPM/Camino|This is an interventional device study utilizing the EVD/IVC and the IPM/Camino to provide and evaluate data for optimized treatment for the control of elevated ICP and CCP in patients with severe TBI.
45507434|NCT02252510|Other|HALOSPERM|
45507435|NCT02828761|Device|Coronary Calcium Scoring|Scan with 64-detector row or better CT scanners with quantification by the Agatston method.
45507436|NCT02828761|Procedure|Standard Care|Routine clinical monitoring of chest pain patients. Any of a number of non-invasive cardiac tests such as coronary CT angiography, stress echocardiography and stress radionuclide myocardial perfusion imaging may be performed.
45507437|NCT05223842|Behavioral|Family Promoting Positive Emotions (F-PPE)|F-PPE is an 8-session dyadic intervention designed to enhance positive emotionality and buffer against the effects of stress on anhedonia in children. The intervention will be administered online through videoconferencing sessions with a clinician to mothers and their children.
45507438|NCT05223842|Behavioral|Written Information|Mothers assigned to the Written Information condition will receive email newsletters providing resources relevant to depression.
45507439|NCT02875613|Drug|Avelumab|Avelumab 10mg/kg IV on days 1 and 15 of each 28-day cycle. Treatment will be given until disease progression, unacceptable toxicity, investigator decision or patient withdrawal.
45507440|NCT02823457|Behavioral|VBMI|12 week values based motivational interviewing intervention with a licensed psychologist
45507441|NCT02130128|Device|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
45507442|NCT02130206|Other|Caries Free|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
45507443|NCT02130206|Other|Caries Active|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
45507444|NCT02130206|Other|Caries Free - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
45507445|NCT02130206|Other|Caries Active - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
45507446|NCT02815267|Drug|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
45399343|NCT03917134|Drug|cephalosporin + Placebos|administration of cephalosporin in doses of 2 grams administered intravenously before surgery and vaginal ovules of placebo twice a day for 5 days after performing laparoscopic hysterectomy
45399344|NCT03916900|Procedure|Pulpotomy|Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health .This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, Complete caries removal and then access to the pulp chamber using drills
45399345|NCT03916900|Procedure|Root canal treatment|Root canal treatment is an often straightforward procedure to relieve dental pain and save teeth. Patients typically need a root canal when there is inflammation or infection in the roots of a tooth. During root canal treatment, an endodontist who specializes in such treatment carefully removes the pulp inside the tooth, cleans, disinfects and shapes the root canals, and places a filling to seal the space.
45399346|NCT03917056|Procedure|Cap-assisted endoscopic sclerotherapy using long needle|Participants were treated with CAES using long needle.
45399347|NCT03917056|Procedure|Cap-assisted endoscopic sclerotherapy using short needle|Participants were treated with CAES using short needle.
45399348|NCT03916822|Diagnostic Test|Alloantigen-specific B-cells|Alloantigen-specific B-cells which express CD154 and their subsets which also co-express cytokines, memory and naive markers, and additional derivatives of these markers will be measured with flow cytometry
45399349|NCT02528656|Device|Vacuum Bell|Patients will be submitted to a negative pressure treatment with the Vacuum Bell device.
45399350|NCT02528656|Device|Dynamic Compression System|Patients will be submitted to a dynamic compression system.
45399351|NCT03921892|Behavioral|Parenting Education|Parenting education such as positive parenting interactions with their child, knowledge of developmental milestones and interactions with the child to support that development, as well as co-parenting skills will be provided either in-person or on-line to adolescent fathers
45399352|NCT01229020|Other|Observational study - no intervention|Observational study - no intervention. Patients underwent VRI recordings and routine V/Q scan.
45399353|NCT01232140|Other|CRP-guided antibiotic treatment|If CRP> 50 mg/l patients with AECOPD receive antibiotic treatment, whereas in those patients with CRP =< 50 mg/l antibiotic treatment are withheld. This will be compared to the regular antibiotic treatment that has been advised by the GOLD strategy
45507447|NCT02815267|Drug|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
45507448|NCT02130440|Drug|Resveratrol nasal spray|
45507449|NCT02138552|Drug|Octenidine dihydrochloride|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
45507450|NCT02138552|Drug|Placebo|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
45507451|NCT02930837|Drug|alteplase|
45697786|NCT03677661|Other|Personalized rehabilitation program|The same advice and exercise program than the active comparator group will be provided. However, 2 physiotherapists will provide 8 treatment session ( 30 to 45 minutes). One physiotherapist will initially evaluate the physical dysfunctions associated to mTBI with a standardized evaluation to build the treatment plan. He will provide cervical manual therapy and therapeutic exercises based on the best current clinical approach and according to the impairment specifically found initially. A vestibular physiotherapist will provide treatment of canalith repositioning manoeuvre, vestibular adaptation, ocular motor exercises, balance and/or habituation exercises. This treatment will be adapted to the individual patient. No more than 8 sessions will be delivered.
45507452|NCT02138708|Other|Pharmacological test of pulmonary endothelial|
45507453|NCT03633175|Drug|Vaginal progesterone|400 mg vaginal progesterone [Prontogest® vaginal pessaries 400, Marcyrl, Cairo, Egypt] will be given, once at bed time starting from 26-28 weeks of gestation till 36 weeks of gestation or delivery (which is closer).
45507454|NCT02138864|Radiation|18F-FP-(+)-DTBZ|no available
45507455|NCT01362647|Procedure|neuromuscular transmission monitoring|The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of TOF-Watch®, Organon Ireland Ltd., a division of MSD, Swords, Co., Dublin, Ireland.
45507456|NCT01362647|Procedure|Pulse oximetry measurement|Pulse oximetry will be measured continuously throughout the PACU admission, and SpO2 values will be recorded at 1-min intervals for the first 30 min.
45399354|NCT05401162|Other|Autologous blood transfusion with haematopoietic stem cells|Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
45507457|NCT02539693|Drug|Clonidine 75 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 75 µg/mL clonidine in the anesthetic mixture
45507458|NCT02539693|Drug|Clonidine 150 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 150 µg/mL clonidine in the anesthetic mixture
45507459|NCT02539693|Drug|Lidocaine|3 ml lidocaine 1% is injected at each block site
45507460|NCT02539693|Procedure|Pilonidal sinus|Removal of pilonidal sinus
45507461|NCT02138942|Device|Learning Intravenous Resuscitator (LIR) system|The usual patient pathways and recommendations concerning vascular filling remain strictly unchanged in this study. The only thing that differs from usual care is the use of the LIR system to automatically optimize fluid resuscitation during general anesthesia, with continuous supervision by the anesthesiologist present during the entire period of use of the device.
45507462|NCT01362725|Device|Spinal cord stimulation system|An implantable pulse generator (IPG) will deliver low-intensity electrical pulses which travel from the IPG through the leads to the electrodes positioned at the selected nerve fibers to provide the therapeutic stimulation.
45507463|NCT05062135|Drug|Progesterone 400 Mg Vaginal Suppository on PCOS|The same drug will be used in control group
45697787|NCT03015922|Drug|Lenalidomide or Pomalidomide|Patients will received either lenalidomide or pomalidomide, depending on which drug they were receiving prior to the trial (they will receive the same as before).
45697788|NCT03015922|Biological|REOLYSIN|Patients will receive Reolysin alongside either lenalidomide or pomalidomide
45399355|NCT01135654|Other|Training & Tech Support for Delivery of Alcohol Screening, Brief Intervention, and Referral To Treatment|"We provide training and technical support for providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment. The training is based on the NIAAA clinician's guide to Helping Patients Who Drink Too Much."
45507464|NCT02130518|Drug|Auriclosene Irrigation Solution, 0.2%|
45507465|NCT02130518|Drug|Auriclosene Vehicle Solution|
45507466|NCT01355783|Drug|E7777|Treatment in both arms is for 6 cycles at 21 days/cycle.
45507467|NCT05061667|Procedure|Thoracic Paravertebral Block|Paravertebral block for postoperative analgesia in thoracic surgery
45507468|NCT05061667|Procedure|Rhomboid Block|Rhomboid block for postoperative analgesia in thoracic surgery
45507469|NCT02134106|Drug|Polymyxin B|Intravenous polymyxin B will be started on a standard dose of 25,000U/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
45507470|NCT02134106|Drug|Polymyxin B + Doripenem|Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
45507471|NCT01354301|Drug|Thymoglobulin|intravenously, beginning within the first 24 hours after graft revascularization. Pre-treatment includes hydrocortisone and dipyrone before antithymocyte globulin infusion, which will be reconstituted according to the package insert.
45507472|NCT01354301|Drug|Everolimus|initial 0.75 mg BID dose of everolimus on day 2. Doses will be adjusted from day 5 on to maintain everolimus whole blood trough concentrations between 4-8 ng/ml.
45697789|NCT01893827|Drug|XR-NTX (Extended-Release Naltrexone)|380mg (4cc) XR-NTX administered by IM injection 1x/month for 6 months.
45697790|NCT01893827|Drug|Oral Naltrexone (O-NTX)|50mg pill form of naltrexone taken 1x/day for 6 months.
45697791|NCT03015766|Other|auricular acupressure therapy|Auricular acupressure, is a therapeutic method in which specific acupoints on the ear are stimulated to treat various disorders of the body. This practice is based on the theory that there are specific points on the auricle which correspond to major organs or systems of the body; and therapeutic effect on the corresponding target organ or system can be exerted by manipulating auricular acupoints. Auricular acupressure applies stimulation through pressure on specific acupoints by the imbedded beads, usually Semen Vaccaria (Wang Bu Liu Xing) or stainless steel beads. This therapeutic method is non-invasive and can be self-manipulated by the recipients at times required.
45507473|NCT01354301|Drug|Basiliximabe|days 0 and 4, according to the package insert instructions.
45507474|NCT01354301|Drug|mycophenolate sodium|720 mg BID. This dose will be reduced according to adverse events.
45507475|NCT01354301|Drug|Tacrolimus|0.05 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-5 ng/ml.
45507476|NCT01354301|Drug|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml and 3-5 ng/ml after 3 months.
45507477|NCT01354301|Drug|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml.
45507478|NCT04867603|Drug|[Ga-68]PSMA|The injectable activity will be a maximum of 210 MBq (6.0 mCi) [Ga-68]PSMA at the time of injection and is administered to subjects by intravenous injection.
45507479|NCT04867603|Device|PET/CT imaging|PET/CT imaging procedure
45399356|NCT01231126|Drug|Misoprostol|Procedures were taken for induced labor delivery with misoprostol 25mcg, by vaginal rout. The pills were administered each 6 hours in a maximum number of six.
45399357|NCT01232218|Other|Standard education/exercises for hemiplegic shoulder pain|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with standard stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour.
45399358|NCT01232218|Other|Three dimensional Scapular-Humeral Mobilizations|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour. Participants in this group will receive an additional scapular humeral mobilization while simultaneously performing the standard stretching/strengthening exercise protocol.
45399359|NCT01135732|Procedure|brush cytology|brush cytology during ERCP
45399360|NCT01135810|Behavioral|Hypnosis|
45399361|NCT01135810|Behavioral|Meditation|
45399362|NCT03769090|Combination Product|Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol
45507480|NCT02134262|Drug|Cyclophosphamide or Bendamustine|Cyclophosphamide [1.5 g/m^2 x 1 day Intravenous (IV)] or Bendamustine [120 mg/m^2 x 2 days Intravenous (IV)] is administered as Pre-treatment medication of CD19-CAR-T.
45697792|NCT03015766|Other|sham auricular acupressure therapy|The intervention is the same as that in the experimental group only when the points are five Helix points (HX 5-9). These points are clearly remote from the inner ear area and have no evidence for insomnia treatment.
45697793|NCT03222843|Drug|Hetrombopag Olamine|once daily
45697794|NCT03222843|Drug|matching placebo|once daily
45399363|NCT03769090|Combination Product|Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol
45399364|NCT03769090|Drug|Albuterol sulfate metered-dose inhaler 180 μg|Albuterol sulfate inhalation aerosol
45399365|NCT01135888|Device|Skin cooling devices|Cooling vest and cooling bandana
45399366|NCT03921736|Drug|Perindopril|4 mg/day p.o. for 12 months
45399367|NCT03921736|Drug|Hydrochlorothiazide|hydrochlorothiazide 25 mg/day p.o. for 12 months
45399368|NCT03921736|Drug|Estracomb TTS|Transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 12 months
45399369|NCT01231204|Procedure|Placebo (normal saline) Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with normal saline. The normal saline infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
45507481|NCT02134262|Genetic|Dose Level -1|CD19-CAR-T [1 x 10^5 cells/kg x 1 day and 2 x 10^5 cells/kg x 1 day Intravenous (IV)] are administered.
45507482|NCT02134262|Genetic|Dose Level 1|CD19-CAR-T [1/3 x 10^6 cells/kg x 1 day and 2/3 x 10^6 cells/kg x 1 day Intravenous (IV)] are administered.
45507483|NCT02134262|Genetic|Dose Level 2|CD19-CAR-T [1 x 10^6 cells/kg x 1 day and 2 x 10^6 cells/kg x 1 day Intravenous (IV)] are administered.
45507484|NCT02134262|Genetic|Dose Level 3|CD19-CAR-T [1/3 x 10^7 cells/kg x 1 day and 2/3 x 10^7 cells/kg x 1 day Intravenous (IV)] are administered.
45507485|NCT01355861|Behavioral|Negative work exercise|Submaximal negative work exercise using an isokinetic dynamometer will be performed twice per week for 12 weeks. Exercise volume will be 3 sets of 10 repetitions for the knee and shoulder extensors.
45697795|NCT03015688|Radiation|x-ray images|
45697796|NCT01882907|Drug|vildagliptin|vildagliptin 50mg bid for 16 weeks
45697797|NCT01882907|Drug|Pioglitazone|Pioglitazone 15mg bid for 16 weeks
45697798|NCT04073823|Device|Flexitouch Plus|Flexitouch Plus full arm and core treatment
45697799|NCT04073823|Device|Flexitouch Plus FT with software modification|Flexitouch Plus full arm and trunk/chest treatment
45849859|NCT04243590|Behavioral|Children's Hand-Use Experience Questionnaire (CHEQ)|"The CHEQ is a questionnaire for children (aged 6-18) with unilateral functional limitations of hand use and is well validated for children with unilateral cerebral palsy. It was only partially validated for use in children with neonatal brachial plexus palsy and has not yet been used in studies. Therefore, it was not used in this group. The questionnaire consists of 29 bimanual activities, typically requiring the use of both hands. It assesses the child's experience using their affected hand when performing the activities and counts how many of the activities are executed independently (with and without using the affected hand).~In the mini-version of the CHEQ some items were deleted or replaced (with more age-appropriate activities for children aged three to eight years) and this version was used for all unilateral cerebral palsy children <six years in this study."
45399370|NCT01231204|Procedure|Ropivicaine 0.4% Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with 0.4%Ropivicaine. The 0.4%Ropivicaine infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
45399371|NCT05401006|Drug|Acitretin 25Mg Cap|Acitretin is an oral retinoid (a derivative of vitamin A) given in a dose 0.25-1 mg /kg/day for 3months in psoriatic patients
45399372|NCT05401006|Radiation|Narrowband ultraviolet B|Narrowband UVB is the most common form of phototherapy used to treat psoriasis, given 2-3 sessions per week for 3 successive months
45399373|NCT01134094|Procedure|Open reduction internal fixation of the ankle|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
45507486|NCT04858789|Behavioral|Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|CA-CBI is an intervention based on Culturally Adapted Cognitive Behavioral Therapy (CA-CBT) which was developed by Devon Hinton. This transdiagnostic intervention has a structured manual which can be culturally adapted and it will be used to decrease psychological distress and increase well-being by targeting cognitive and behavioral changes.
45507487|NCT01343277|Drug|Trabectedin|Type=exactly number, unit=mg/m2, number=1.5, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
45507488|NCT01343277|Drug|Dacarbazine|Type=exactly number, unit=g/m2, number=1, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
45507489|NCT02130596|Behavioral|Acceptance-Based Behavioral Intervention|
45507490|NCT02130596|Other|Nutritional Counselling|
45849860|NCT04234386|Radiation|GammaPod Radiation|The basic design is a dose-escalation phase Ib study with 4 predefined dose levels. With this study treatment, participants will receive the dose level assigned treatment of radiation therapy before the lumpectomy surgery.
45849861|NCT04198350|Procedure|Islet implantation|Transplantation of allogeneic pancreatic human islets will be performed into the anterior chamber of a single eye with the poorest visual acuity (see inclusion/exclusion criteria below). Up to 40 000 IEQ of islets in a maximum volume of 350µl will be transplanted.
45849862|NCT04188990|Dietary Supplement|Nutritional dietary intervention|The intervention will be carried out by the Endocrinology and Nutrition Service of hospital 1, where the type of therapeutic action to be developed will be established (Dietary advice, Oral Nutritional Supplementation (SNO), Enteral Feeding or Parenteral Nutrition). The Total Calorie Balance, calories from feeding or with Oral Nutritional Supplementation (ONS), enteral, parenteral, and protein intake will be recorded. The steps to be taken are the following: A.-In patients with preserved oral intake capacity apply the most appropriate dietary measures in each case. B.-If the oral route is contraindicated, it will be assessed if it is possible to use the gastrointestinal tract and enteral nutrition will begin until the patient recovers the oral intake capacity. C.-If the use of the gastrointestinal tract is not indicated, parenteral nutrition will be assessed until digestive function is restored.
45507491|NCT02130674|Drug|Dipeptiven|two groups: group 1: continuous infusion for 24 hours group 2: continuous infusion for 5 days
45507492|NCT04856293|Drug|Crizotinib|A single 250 mg crizotinib dose of the FC formulation
45507493|NCT04856293|Drug|Crizotinib|A single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial
45507494|NCT04856293|Drug|Crizotinib|A single 250 mg crizotinib dose of the single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules) . The intact capsules will be swallowed whole.
45507495|NCT02139020|Other|Plasma samples|Plasma samples at baseline (and one whole blood sample) and at every radiological evaluations
45507496|NCT03135899|Drug|BI 443651|Three doses, each 12 hours apart
45507497|NCT03135899|Drug|Placebo|Three doses, each 12 hours apart
45507498|NCT02253212|Device|SonoCloud|SonoCloud : dose escalation
45507499|NCT02253212|Drug|Carboplatin|Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC
45507500|NCT01355939|Procedure|Clinically-Indicated Abdominal Re-Exploration Surgery|This is a prospective observational study. Abdominal re-exploration surgery is clinically-indicated and planned as the standard of care for the patients regardless of their decision to participate in the study.
45507501|NCT01356017|Drug|Telmisartan 80mg, S-amlodipine 5mg|Telmisartan 80mg and S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out (19 days)
45507502|NCT01356017|Drug|Telmisartan 80mg|Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
45399374|NCT01134094|Procedure|Non Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
45507503|NCT05220332|Behavioral|Heart to Heart|The Heart to Heart intervention will be delivered at the churches over 6 months. The intervention consists of 12 bible study sessions (45 minutes) led by the Senior Pastor and 24 behavior change small group sessions (90 minutes) led by a trained Rush staff interventionist. These sessions are open to the entire church membership and focus on improving diet and physical well being. A community health worker will provide individualized support to participants with uncontrolled blood pressure who do not reduce their blood pressure by participating in small groups.
45507504|NCT05220332|Behavioral|Money Smart|The Money Smart program for adults was developed by the Federal Deposit Insurance Corporation (FDIC). It consists of training modules that cover basic financial topics including deposit and credit services offered by financial institutions, how to obtain and use credit effectively, and the basics of building or repairing credit. This group-based program will be delivered in 14 sessions over 6 months and will be led by a trained instructor.
45507505|NCT02281097|Other|Stimulation|Application of current to skin above auricular branch of vagal nerve to modulate heart rate and symptoms
45697800|NCT04049955|Procedure|endoscopy|In the case of a well-organized abscessed collection responsible for sepsis instability, or poorly organized collection, an external drainage is carried out, by a radiological or a surgical way. The endoscopy is performed 7 days later. If there is no hemodynamic instability and in presence of a well-organized abscessed collection, a first-line endoscopy is carried out. After laying 2 double pig tail stents, the external drainage is removed 2 to 7 days later.
45697801|NCT01051570|Drug|carboplatin|AUC = 5 by Calvert's formula, day 1 of each 21 day cycle
45697802|NCT01051570|Drug|RAD 001|5 mg orally starting on Day 2 then continuous
45697803|NCT01051570|Drug|prednisone|5 mg orally twice a day starting on Day 1 then continuous
45399375|NCT01135966|Behavioral|Conventional resistance training program|Conventional resistance training program is followed.
45399376|NCT01135966|Behavioral|Whole body vibration resistance training program|WBV training on FITVIBE
45399377|NCT01136044|Other|septocutaneous perforator flap|Perforator flaps can be based on septocutaneous or musculocutaneous perforators. If septocutaneous perforators are present, the harvest of these flaps is more straight forward and the dissection of the pedicle is easy.
45507506|NCT02281097|Other|Placebo|Application of low intensive current or frequency to skin above auricular branch of vagal nerve as sham intervention
46057135|NCT05752396|Other|Spatial Summation|Spatial summation (SS) procedure evaluates the change in heat pain sensitivity when applying two painful stimuli simultaneously compared to one stimulus alone. This psychophysical paradigm investigates facilitatory pain modulation processes.
46057136|NCT05752396|Other|Temporal Summation|Temporal summation (TS) procedure evaluates the change in mechanical pain sensitivity after exposure to a series of noxious stimuli of the same intensity. This psychophysical paradigm investigates facilitatory pain modulation processes.
45399378|NCT05400928|Device|Pulsed Field Ablation|pulmonary vein isolation will be performed with ring-shaped pulsed field ablation catheter directed by integrated three-dimensional mapping system
45399379|NCT01231282|Other|diffusion-weighted MRI|MRI scan without contrast administration and without radiation exposure
45507507|NCT02134340|Drug|[I-124]-CPD-1028 Injection|A single intravenous dose of [I-124]-CPD-1028 Injection will be given at Visit 2 (within 21 days of screening Visit 1), and may be followed by whole body PET/CT imaging approximately 3 hours post-injection. PET/CT imaging will occur at Visit 3 (2-3 days after Visit 2) and Visit 4 (5-7 days after Visit 2). PET/CT imaging may also occur at Visit 5 (16-18 days after Visit 2). Visit 6 (28 +/- 2 days after Visit 2) is a follow-up telephone call for a post-treatment safety assessment. At Visits 2-5, whole body biodistribution and tumour uptake will be assessed. At all visits, safety will be assessed.
45507508|NCT02134340|Biological|CPD-1061|[Optional] An intravenous dose of 0.4, 1.4 or 6 mg/kg of body weight of CPD-1061 may be given 1-2 hours prior to injection of [I-124]-CPD-1028 at Visit 2. The decision to use CPD-1061 and the dose amount is based on an adaptive design and is dependent on interim reviews of imaging data.
45697804|NCT01051570|Other|laboratory biomarker analysis|Samples will be collected from archival tissue.
45697805|NCT01051570|Other|pharmacological study|Samples will be collected Cycle 1, day 1, 2 & 8 and Cycle 2, Day 1 & 2
45399380|NCT01231360|Other|Exercise Training|Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
45399381|NCT01231360|Other|Normal routine|Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
45399382|NCT01229098|Drug|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) Topical suspension applied once daily for up to 8 weeks
45399383|NCT01136122|Device|CPAP Treatment|Effective CPAP treatment for one month
45507509|NCT04723615|Other|Orebro Musculoskeletal Screening Questionnaire-12|It is a 12-item self-report questionnaire that aims to estimate the severity of the problem, functional impairment, reporting status, cost and recovery time in musculoskeletal problems.
45507510|NCT04723615|Other|Visual Analog Scale|A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured.
45507511|NCT04723615|Other|The Tampa Scale of Kinesiophobia|The Tampa Scale of Kinesiophobia that was developed in 1990 is a 17 item scale originally developed to measure the fear of movement related to chronic lower back pain.
45507512|NCT04723615|Other|Short Form-12 (SF-12)|The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
45399384|NCT01232374|Drug|Nimotuzumab|200mg (4 bottles), once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
45507513|NCT01356095|Other|Knowledge translation intervention|Two part intervention includes an educational outreach intervention for health care workers and a point of care patient education/counselling tool, delivered to providers within health centers randomized to the intervention arm, using a train the trainer on-site training model.
45507514|NCT01356095|Other|Palm-Plus|Clinical guideline and training approach, designed for mid-level healthworkers.
45507515|NCT02134418|Behavioral|CBT of irony comprehension|Over the course of intervention participants will analyze and discuss short film scenario's that end with an ironic statement, and will experience completing short scenario's that contain irony. Intervention will include 5 sessions, each session will take 40 minutes, 3-5 subjects will participate in each group.
45507516|NCT04712305|Other|No intervention required|No intervention required
45507517|NCT02139098|Drug|Amitriptyline|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
45507518|NCT02139098|Drug|Zolpidem|5 mg capsule zolpidem before going to bed on 8 out of 17 nights
45507519|NCT02139098|Drug|Amitriptyline|50 mg capsule amitriptyline before going to bed on 13 out of 17 nights
45399385|NCT01232374|Drug|Placebo|4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
45849863|NCT04188990|Dietary Supplement|By demand|"In the By demand arm, it is by clinical judgement of the doctor responsible of each patient that can be demanded a nutritional intervention to the nutrition unit of the center's endocrinology service that will judge the type of intervention. This is their usual care right now"
45399386|NCT01232374|Drug|cisplatin|cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
45507520|NCT02139098|Drug|Placebo|Placebo
45507521|NCT04498715|Procedure|OSTEOSYNTHESIS|Routine procedure for anesthesia and infection prophylaxis according to the clinics routines will be followed. The patient is supine with the fractured leg positioned in traction table. The biplanar x-ray device is moved and adjusted for proper simultaneous AP and lateral view. Hip region is washed and dressed in sterile draping's. Using standard proximal femur osteosynthesis technique 2.0 mm diameter Kirschner wire is placed in the middle zone of the femoral neck in AP and lateral view. The canal is opened using 6 mm drill bit and measured length of dynamic hip screw is placed in the femoral head and neck.
45507522|NCT04498715|Drug|Zoledronic Acid|Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 4 mg (as per clinical protocol) will be injected intravenously 1-2 weeks after surgery. For local delivery, 1 or 2 mg Zoledronic Acid will be added to 5 or 10 mg CERAMENT BVF during mixing and the mixture will be injected.
45507523|NCT04498715|Device|CERAMENT BONE VOID FILLER (BVF)|"CERAMENT™|BONE VOID FILLER is a synthetic, injectable, osteoconductive bone void filler. CERAMENT™I is biphasic, consisting of 60% calcium sulfate and 40% hydroxyapatite mixed with the radio-opacity enhancing component CERAMENT™|C-TRU (iohexol 300 mg iodine/ml), which allows bone in-growth after curing. The high injectability of CERAMENT™ allows transcortical administration and ensures good intraosseous spread. In this trial, CERAMENT BVF paste will be injected by a sterilized metal needle (2-3 mm diameter and 15 cm length) through the hollow dynamic hip screw."
45507524|NCT02130752|Device|Monopolar electrocautery|During the procedures of the abdominal approach D2 distal gastrectomy, use the monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes .
45849864|NCT04188990|Dietary Supplement|Usual current care|"In th Usual care arm, there is no explicit nutritional intervention performed at this time for those patients and, therefore, their usual regular nutritional care will be provide"
45849865|NCT04174716|Drug|IDX-1197|Until progression or unacceptable toxicity develops
45507525|NCT02130752|Device|Ultrasonic scalpel|During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes
45507526|NCT01362257|Drug|Treatment Period 1 - IV dose of GSK573719|single dose of 65µg
45507527|NCT01362257|Drug|Treatment Period 2 - Oral dose of GSK573719|single dose of 1000µg
45507528|NCT02487979|Drug|Glembatumumab Vedotin|Given IV
45507529|NCT02487979|Other|Laboratory Biomarker Analysis|Correlative studies
45507530|NCT02487979|Other|Pharmacological Study|Correlative studies
45507531|NCT02134496|Procedure|assessment of motorfunction in PACU|assessment of motorfunction in PACU after spinal anesthesia
45507532|NCT01356173|Drug|GDC-0349|Oral escalating dose
45507533|NCT02130830|Drug|Topical 2,5% lidocaine + 2,5% prilocaine gel|The topical gel is administered in the anal canal at the moment of the anoscopy
45507534|NCT02130830|Drug|Placebo|Placebo gel to mimic topical anesthesia administered in the anal canal at the moment of the anoscopy
45507535|NCT02279771|Procedure|transanal anastomotic reinforcement|"a circular anal dilator (CAD) of 34mm in diameter will be introduced into the anus to facilitate the transanal introduction of the 29-31 circular stapler. The stapler shaft will be introduced trying to avoid the stapler line and connected with the anvil of the prepared proximal colon and then fired.~Patients selected on the TAR-LAR arm will have the stapled suture reinforced by 6 supplemental full thickness stitches in vycril 3/0 placed transanally with the aid of a semicircular valve introduced into the CAD (Epo Flier, SapiMed SPA, Alessandria, Italy), at hours 2-4-6-8-10-12."
45507536|NCT02279771|Procedure|protective ileostomy group|S-LAR patients will had a standard lateral protective ileostomy in the right iliac region or a colostomy in the left region.
45507537|NCT02279771|Device|a circular anal dilator (CAD)|Epo Flier, SapiMed SPA, Alessandria, Italy
45507538|NCT04471727|Drug|HPN328|HPN328 is a tri-specific recombinant protein construct (Tri-specific T Cell Activating Construct [TriTAC®]) containing 3 humanized antibody derived binding domains
45507539|NCT04471727|Drug|Atezolizumab|Atezolizumab is a humanized immunoglobulin (Ig) G1 monoclonal antibody which potently and selectively inhibits binding of programmed death receptor 1 ligand (PD-L1) on tumor cells and tumor infiltrating immune cells in the tumor microenvironment
45507540|NCT02139332|Behavioral|PFR Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session begins with a brief discussion and education on the target topic for that week . Then 20 minutes is spent on video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior (alternating weeks). Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
45507541|NCT02139332|Behavioral|Resource & Referral Group|The Resource & Referral program consists of 1) an initial needs assessment to determine if the enrolled family has any unmet needs (housing, financial, health, mental health, etc…), 2) a tailored resource and referral packet will be mailed to the participant with the most important referrals marked, 3) a follow-up call will be made two weeks after mailing the packet to verify that the participant has received it, and 4) a second follow-up call will be made three months after the initial session, to assess types of services actually received, barriers to receiving services, and reassessing resources needed and providing additional referrals if needed.
45849866|NCT04168710|Drug|ESP block with bupivacaine|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of 0.25% bupivacaine in the plane between the transverse process of the spine and the erector spinae muscle.
45849867|NCT04168710|Other|Saline control/sham injection|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of normal saline in the plane between the transverse process of the spine and the erector spinae muscle.
45849868|NCT04159740|Other|Tissue and blood collection|Tissue and swab (cells) collection for microbiome analysis. Blood collection for immune markers.
45399387|NCT01232374|Radiation|Radiotherapy|"A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.~Placebo: 4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)"
45399388|NCT01231438|Drug|Renvela|800mg t.i.d. over 2 weeks
45399389|NCT01231438|Drug|Etalpha|0.25ug o.d. for 2 weeks
45399390|NCT05609890|Dietary Supplement|Supplement|"Supplement: a mixture of saffron, tea extract, lemon balm and valerian.~Dose: The participant will take one sachet every day, one hour before going to bed, for six weeks."
45399391|NCT05609890|Other|Placebo|"Placebo sachet~Dose: The participant will take one sachet everyday, one hour before going to bed, for six weeks."
45399392|NCT01131754|Other|heparin 100U/L flushes|peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
45507542|NCT01360151|Drug|ranibizumab(Lucentis), verteporfin(Visudyne)|ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection
45507543|NCT02466685|Drug|JNJ-18038683|JNJ-18038683 10-20 mg/day for 8 weeks
45507544|NCT02134652|Other|diagnostic bedside ultrasound|"Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck."
45507545|NCT03633097|Other|Acupuncture and Usual care|patients after surgery receive usual care(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet) as well as acupuncture treatment as an adjunctive therapy
45507546|NCT03633097|Drug|Usual care|patients after surgery receive usual care alone(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet)
45507547|NCT02139410|Procedure|IGF-1 serum value|Evaluation of IGF-1 serum value at baseline, 24 and 48 months
45507548|NCT02139488|Other|Fiducial markers|
45507549|NCT02139488|Other|Fiducial markers, Pet and MRI|Insertion of Fiducial markers in esophageal wall.
45507550|NCT05647759|Behavioral|HEART Camp Connect|Once eligible and enrolled, participants will aim to complete 150 minutes of moderate-intensity exercise a week with the help of a virtual exercise coach
45507551|NCT03765320|Procedure|Peritoneal closure|Peritoneal closure after pelvic lymph node dissection for early gynecologic cancer
45507552|NCT03765320|Procedure|Retroperitoneal drainage|Retroperitoneal drainage after pelvic lymph node dissection for early gynecologic cancer
45507553|NCT01363037|Drug|Dapivirine Vaginal Ring|dosage form: dapivirine vaginal ring dosage:25 mg frequency:continuous use duration:28 days
45507554|NCT01363037|Drug|Maraviroc Vaginal Ring|dosage form: maraviroc vaginal ring dosage:100 mg frequency:continuous use duration:28 days
45507555|NCT01363037|Other|Placebo Vaginal Ring|dosage form: placebo vaginal ring dosage:N/A frequency:continuous use duration:28 days
45507556|NCT01363037|Drug|Dapivirine-Maraviroc Vaginal Ring|dosage form: combination vaginal ring dosage:25 mg dapivirine + 100 mg maraviroc frequency:continuous use duration:28 days
45507557|NCT02130908|Other|Lean fish|Participants consumed 150g of lean fish, five times per week for 4 weeks
45507558|NCT02130908|Other|Fatty fish|Participants consumed 150g of fatty fish, five times per week for 4 weeks
45507559|NCT02130908|Other|Lean meat|Participants consumed 150g of lean meat, five times per week for 4 weeks
45399393|NCT05608330|Other|PETRUSHKA tool|In the experimental arm, the PETRUSHKA tool will automatically select the antidepressants that have the best profile in terms of efficacy and acceptability for each individual participant (based on their baseline demographic and clinical characteristics) and then ask the participant to provide their preferences about common (and non-serious) adverse events. Based on patient's preferences and their individual characteristics, the PETRUSHKA tool will then identify the three best antidepressants for the participant. The clinician and the participant will be presented with an overall recommendation (in the format of a pictogram) showing how strongly each antidepressant is recommended for that individual patient. Via a shared decision-making process, the participant and the clinician will then agree on which antidepressant to choose from the shortlist.
45507560|NCT04936321|Behavioral|Internet-delivered CBT for Insomnia|The program delivers the core components of CBT for insomnia including sleep hygiene, stimulus control, and sleep restriction. Treatment duration is 6 weeks.
45507561|NCT04936321|Behavioral|Internet-delivered CBT for Pain Management|The program delivers the core components of CBT for pain management including: pain education, training in behavioral and cognitive pain coping skills, instruction in increasing activity participation, and training in parental operant and communication strategies. Treatment duration is 6 weeks.
45507562|NCT04936321|Behavioral|Internet-delivered Sleep Education|The program delivers publicly available information about sleep.
45507563|NCT01363115|Dietary Supplement|Orange Juice fortified with Calcium and Vitamin D|Three 240 mL glasses of orange juice fortified with 350 mg Ca and 100 IU of D per serving
45399394|NCT05608330|Other|Usual Care|Any antidepressant prescribed by clinician based upon their clinical judgement.
45507564|NCT01363115|Dietary Supplement|Orange juice without Ca or VitD|Three 240 mL glasses of orange juice without Ca or VitD
45507565|NCT01363115|Behavioral|Nutritional Counseling|Individual and group nutritional counseling by a registered dietitian
45507566|NCT02134730|Behavioral|FRIENDS for life|Friends for life (FFL). The FFL is a prevention program created by professor Paula Barrett, Brisbane, Australia. It is based on cognitive behavioral treatment strategies, for example the link between thoughts and feelings, negative and positive thoughts, breathing and relaxing exercises, support from others, breaking challenging situation in smaller steps, and problem-solving techniques. The children's workbook comprises practice-sheets for use during class, and homework assignments. The group leader manual comprises detailed instructions to all exercises.
45399395|NCT01136200|Other|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
45399396|NCT02528968|Behavioral|Educational Package|Patients will be invited to attend a PK educational session as part of the study protocol. This will form a discussion regarding clinical history and activity in the 6 months prior to study start, viewing of a short animated film giving additional detail on pharmacokinetics and prophylaxis in haemophilia A, followed by modelling of the patient's own PK and dose guidance based on 2 study blood samples.
45697806|NCT04046601|Device|impedance|After endoscopic resection of early esophageal cancer, the tissue will be measured by an impedance probe between 10Hz-1000000Hz, 20mV. 8 gold electrodes have been integrated to the probe. The impedance will be measured in different ways between the elctrodes. There will be 10 measurements in total for each specimen.
45399397|NCT05402800|Other|FSFI questionnaire|The FSFI is a reliable test for the assessment of sexual function in women. The Arabic version of this test, was used. The FSFI is comprised of six domains (desire, arousal, lubrication, orgasm, satisfaction, and pain) with score ranges of 0 (or 1) to 5. The total FSFI score ranges from 2.0 to 36. The translated version of the FSFI test was used in this study. All questions in the FSFI questionnaire were explained by the physician one by one, and they were filled in a suitable and silent environment where patients could comfortably share such intimate information
46057137|NCT00914134|Drug|Levodopa infusion|Naso-duodenal infusion line is inserted in fluoroscopy control. Levodopa infusion is then tested approximately 5 days. If patient responds favorably to the treatment, PEG-infusion line is inserted in gastroscopy control and patient is followed in hospital for 2 to 4 days to ensure stability of the infusion line. The dosage is individually adjusted, starting dose is estimated from earlier oral levodopa dose.
46057138|NCT04952896|Diagnostic Test|Synovitis diagnosis|
45399398|NCT01231594|Drug|GSK2118436|Study Drug
45399399|NCT01231594|Drug|GSK1120212|Study Drug
45399400|NCT01231594|Drug|Other approved anti-cancer agent|Study Drug
45399401|NCT01231672|Biological|Routine biological analyses|Bilirubinemia (total and conjugated), hematology, hemogram, SOFA score
45399402|NCT01136278|Drug|3,4-Methylenedioxymethamphetamine|125 mg, single dose
45399403|NCT01136278|Drug|Clonidine|150 μg per os
45399404|NCT01136278|Drug|placebo|capsules identical to MDMA or clonidine
45399405|NCT05402722|Drug|Eribulin|Eribulin Mesylate，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle
45399406|NCT05402722|Drug|anti-PD-1 antibody|Sintilimab Injection，Intravenous infusion，200mg，3-week cycle
45399407|NCT03921268|Drug|AZD1402|AZD1402 (PRS-060) is presented as a solution and dry powder for oral inhalation and belongs to a new class of therapeutics, Anticalin® proteins, which are modified lipocalins. AZD1402 is an inhaled IL-4Rα antagonist, which is being developed as controller therapy for asthma.
45399408|NCT01232608|Behavioral|Exercise|12 months of exercise training
45399409|NCT05597332|Other|Care bundle for AKI|To maintain mean arterial pressure (MAP) ≥ 65 mmHg; to keep the patient euvolemic; to avoid nephrotoxic drugs; to adjust dose of medication for kidney function; to exclude urinary obstruction; to monitor urine output and serum creatinine levels.
45507569|NCT01356329|Drug|Enoxaparin, Heparin|"Patients who meet the Inclusion Criteria and signed an informed consent will be randomly assigned to 1 of the 2 treatment groups (the Enoxaparin (Group A) and Unfractionated Heparin (Group B)~). Subjects will be assigned consecutive study numbers according to a predetermined random code generated by the Biostatistician."
45507570|NCT05579522|Procedure|Fat graft injection|Fat graft injection in the interdental papilla.
46057139|NCT04951336|Dietary Supplement|FoTv|Fomitopsis Officinalis and Trametes Versicolor
45399410|NCT03921346|Device|Mobile device app (PedAMINES™) 1st drug|To prepare 0.01 mg/kg epinephrine (0.1 mL/kg of 0.1 mg/mL concentration)
45507571|NCT05579522|Procedure|Hyaluronic acid injection|Hyaluronic acid injection in the interdental papilla
45399411|NCT03921346|Device|Mobile device app (PedAMINES™) 2nd drug|To prepare 0.1 mg/kg midazolam (of 5 mg/mL concentration ad 10 mL sodium chloride 0.9%)
45507572|NCT04579939|Diagnostic Test|Candy Glucose Tolerance Test|Participants will use a popular dextrose candy alternative to help assess glycemic response.
45507573|NCT02139566|Behavioral|Video consent (high-tech)|Consent provided by an animated video with captions
46057140|NCT05754736|Drug|Ametinib combined with bevacizumab|Ametinib 110mg po qd bevacizumab 15mg/kg ivdrip q3w
45399412|NCT03921346|Device|Mobile device app (PedAMINES™) 3rd drug|To prepare 4 mL/kg dextrose 10%
45399413|NCT03921346|Device|Mobile device app (PedAMINES™) 4th drug|To prepare 1 mmol/kg sodium bicarbonate (of 4.2% = 0.5 mmol/L concentration)
45399414|NCT03921346|Device|Conventional method 1st drug|To prepare 0.01 mg/kg epinephrine (0.1 mL/kg of 0.1 mg/mL concentration)
45399415|NCT03921346|Device|Conventional method 2nd drug|To prepare 0.1 mg/kg midazolam (of 5 mg/mL concentration ad 10 mL sodium chloride 0.9%)
45399416|NCT03921346|Device|Conventional method 3rd drug|To prepare 4 mL/kg dextrose 10%
45399417|NCT03921346|Device|Conventional method 4th drug|To prepare 1 mmol/kg sodium bicarbonate (of 4.2% = 0.5 mmol/L concentration)
45697807|NCT01893281|Drug|Topical Testosterone Solution|Administered topically to axillae.
45697808|NCT04024917|Other|Cardiac coherence|"An initiation session to cardiac coherence will take place D-11 before the operation (during the surgical consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 11 days preceding the operation.~- The program cardiac coherence will be performed during 90 days after the surgery"
45697809|NCT04024917|Other|Standard care|Standard care
45697810|NCT02981446|Drug|DE-117|DE-117 ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
45399418|NCT01137448|Behavioral|Weight Loss|Subjects will enroll in a weight loss program and participate in weight loss counseling 6 times over the course of 6 months.
45399419|NCT05480488|Drug|Midazolam|Subjects will receive a single oral dose of 2 mg midazolam (Treatment A, B, and C).
45399420|NCT05480488|Drug|Warfarin|Subjects will receive a single oral dose of 25 mg warfarin (Treatment A and B).
45399421|NCT05480488|Drug|Daridorexant|Subjects will receive an o.d. oral dose of 50 mg daridorexant from Day 1 to Day 7 of Treatment B and a single oral dose of 50 mg daridorexant on Day 1 of Treatment C.
45399422|NCT03921112|Device|lung ultrasound|bedside lung ultrasound will be done for patients
45399423|NCT03921112|Other|routine tools|chest X-ray , ABG, RSBI, Ventilator parameters will be done for all patients
45507574|NCT02139566|Behavioral|Video consent (low-tech)|This consent is a video production of the informed consent information, taped using a staff member with basic video equipment.
45399424|NCT01229332|Drug|Saline|Continuous 24 h administration
45399425|NCT01229332|Drug|Carbidopa|Continuous 24 h administration
45399426|NCT03921034|Drug|Ropivacaine|All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
45399427|NCT03921034|Drug|Saline|All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
45399428|NCT01136590|Drug|Tranexamic Acid|A 10-mg/kg dose of tranexamic acid will be administered as a bolus or as a fast, 20-minute intravenous infusion before performing the incision at the start of surgery, followed by perfusion of 2 mg/kg/hour up to the time the surgical wound is closed at completion of surgery.
45399429|NCT01136590|Drug|fisiologic serum|The placebo will be administered according to the same regimen and infusion time as the medication in the study arm (bolus or 20-minute fast infusion before the incision at the beginning of surgery followed by perfusion of 2 mg/kg/hour until closure of the surgical wound at completion of surgery)
45399430|NCT03920956|Other|ABPM service by Pharmacists|Patients will receive ABPM services provided by a pharmacist and complete a patient satisfaction survey
45399431|NCT01229488|Device|Intervention|Project was withdrawn before starting. There were no interventions
45399432|NCT01137760|Dietary Supplement|Sucrose|5 g of sucrose daily for 8 weeks
45507575|NCT02139566|Behavioral|FAQ format consent|"This consent modality will present the basic information from the informed consent in an interactive, frequently asked questions format. Upon clicking each question, the participant will be shown a short text response to that question."
45507576|NCT02139566|Behavioral|Standard consent|The standard consent form will present the full informed consent document in a scrolling text window within the browser window. Participants will be asked to review the document online.
46057141|NCT04029376|Drug|Iberogast®|The medication was applied 3 times 20 drops per day before or at meals with some liquid, ideally to one week insofar.
46057142|NCT04946812|Other|Split-belt treadmill training|18 sessions of SB-TM training, where the velocity of the belt will be adjusted to the over-ground speed of the subject, and will be reduced on the least affected side by 25%.
45399433|NCT01137760|Dietary Supplement|Galactooligosaccharide|2.5 g galactooligosaccharide plus 2.5 g sucrose daily for 8 weeks
45399434|NCT01137760|Dietary Supplement|Galactooligosaccharide|5.0 g galactooligosaccharide daily for 8 weeks
45399435|NCT01233388|Other|Text message surveillance|Text message surveillance for vaccine adverse events
45399436|NCT03920878|Drug|Aflibercept injected Pre- and Post-operatively|Three injections of aflibercept before cataract surgery, and aflibercept injections after surgery within 14-21 days of the day of surgery (number of injections depends on clinical exam findings, visual acuity and retinal thickness).
45507577|NCT02139566|Behavioral|PDF informed consent document|A PDF of the full consent document will be available for download, through hyperlink on the consent page. This is provided for video (low-tech), video (high-tech), FAQ format, and standard informed consent.
45507578|NCT05188079|Dietary Supplement|Beetroot juice|high nitrate supplement
45507579|NCT05188079|Dietary Supplement|Placebo drink|placebo
45507580|NCT04579549|Device|Saliva Assay|saliva assay test for high concentrations of SARS-CoV-2
45507581|NCT05188001|Other|Not an Interventional Study|Not an interventional Study
45697811|NCT02981446|Drug|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
45399437|NCT03920878|Drug|Aflibercept injected intraoperatively|Three injections of aflibercept before surgery and one injection of aflibercept during the course of the surgery by cataract surgeon.
45507582|NCT03549806|Diagnostic Test|No Intervention. Test is computer algorithm.|Diagnostic algorithms (test) will be run on already acquired clinical data. No study intervention in operator-prescribed clinical ablation. Predictive accuracy of test for study outcome will then be determined in follow-up
45507583|NCT01356485|Drug|MP4CO|43 mg/mL pegylated carboxyhemoglobin [≥ 90% CO hemoglobin saturation] in physiological acetate electrolyte solution
45849869|NCT04122924|Other|Abdominal muscle training|The intervention starts 6-12 months postpartum and will last for three months with weekly follow-up through an exercise app. Before commencing the home-based program, women in the intervention group will have an individual session in how to perform the program with a physiotherapist. The intervention consists of a 10 min 5 days a week exercise program, including the following exercises; headlift, crunch and twisted crunch. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum. The participants will be provided with a smartphone app (Athlete Monitoring) to be reminded to exercise and to register adherence.
45399438|NCT01136824|Other|Questionnaires|"Subjects will be given a series of questionnaires to assess the effect of AI chemotherapy, and the possible role of tumor load, on the amount of symptoms. The extent of nausea, vomiting, fatigue, anxiety, sleep disturbance, and cognitive changes will be measured. In adjuvant chemotherapy patients, we will also assess the relationship between tumor size and amount of chemotherapy-induced symptoms. These questionnaires will involve the following assessments:~Demographic & health Trait anxiety Quality of life Nausea Expectations Anxiety & total mood disturbance Nausea & vomiting Multiple symptoms"
45399439|NCT03920644|Drug|Scopolamine Transdermal Patch [Transderm Scop]|Current Motion Sickness treatment, 1 patch behind the ear.
45399440|NCT03920644|Drug|Scopolamine|IND, up to 6 administration of intranasal gel.
45507584|NCT01356485|Drug|Sodium chloride solution|Normal saline (0.9% sodium chloride solution)
45507585|NCT01363193|Drug|Lean Body Weight-based heparin dose|"For patients who meet the inclusion criteria including body mass index of 30 and greater (and do not have any exclusion criteria), will have intravenous weight-based heparin (unfractionated heparin) dose based on their Lean body weight.~Lean Body Weight is based on the formula by Janmahasatian et al. 2005. Calculated by a computer program; Male = [9270 x weight (kg)] / [6680+216 x BMI] Female = [9270 x weight (kg)] / [8780+244 x BMI]"
45507586|NCT03764930|Other|Unsuspected Retinoblastoma|To study the clinical characteristics and treatment outcomes of patients who experienced inadvertent trauma before diagnosis of retinoblastoma.
45507587|NCT02134808|Drug|Creatine|Creatine is a nutritional supplement.
45507588|NCT02134808|Drug|Placebo|The placebo is an inactive ingredient similar in appearance, weight and density to the active treatment.
45507589|NCT01319279|Drug|Hydrocodone bitartrate extended-release tablet|15 mg (single dose)
45507590|NCT02139722|Behavioral|Video Doctor, PA + PPN|The intervention consists of a Video Doctor and Provider Alert. For the Video Doctor, we will develop a series of 30-60 seconds video clips, a branching algorithm, and a mobile application linking the baseline survey to the clips. The Provider Alert is a point-of-care reminder printout generated by the mobile application to facilitate patient-provider communication. The intervention integrates guidelines, literature, guidance from the Systems Model, our prior work, and input from patients and providers.
45507591|NCT01363271|Drug|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
45507592|NCT01363271|Drug|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
45697812|NCT01893203|Drug|BF-200 ALA cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then sun protection factor (SPF) 20 cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Ameluz cream on the area. After appropriate absorption time of 30 minutes, the patients will be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
45849870|NCT04079166|Biological|SCIB1 DNA vaccine|"The plan for this research study is for SCIB1 to be given for up to 85 weeks, in combination with either nivolumab with ipilimumab or pembrolizumab according to the current label.~After receiving the first dose of SCIB1, the patient will receive SCIB1 at 4, 7, 13 and 25 weeks, then every 12 weeks up to Week 85. Nivolumab with ipilimumab or pembrolizumab treatment will be started 1 week after the first dose of SCIB1 and given as per standard treatment."
45849871|NCT04055298|Device|SMASS-Triage|SMASS-Triage is a web-based symptom checker developed by In4medicine Ltd. SMASS-Triage is based on a computerized transparent neural network, which was trained with the evidence of more than 1200 studies and the expertise of various panels of specialists in the field of preclinical medical triage. SMASS-Triage provides digitalized questionnaires of 87 frequent reasons of encounters (e.g. fever, cough, abdominal pain) and their associated red flags. The triage-result of SMASS-Triage encompasses the appropriate time-to-treat (T2T) and the adequate point-of-care (PoC).
45849872|NCT04049214|Other|Meditation|Two guided meditations will be provided to participants. They will be asked to meditate twice daily, once in the morning once before bed, for a total time of 12 minutes per day. Surgical treatment and postoperative care will be provided by surgeon preference and usual practice, including post-operative pain medications. For 12 weeks patients will maintain a daily meditation log, medication log and complete daily pain assessment questionnaire.
45507593|NCT01363271|Drug|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
45507594|NCT01363271|Drug|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
45507595|NCT02134886|Drug|Erlotinib Hydrochloride|Given PO
45507596|NCT02134886|Other|Laboratory Biomarker Analysis|Correlative studies
45507597|NCT02134886|Other|Pharmacological Study|Correlative studies
45507598|NCT02134886|Other|Quality-of-Life Assessment|Ancillary studies
45507599|NCT01360463|Behavioral|Behavioral Drug and Risk Counseling (BDRC)|"The BDRC counseling is rooted in cognitive behavioral theory. During one hour sessions, the counselors help participant identify short term behavioral goals and work with the participant to develop strategies to achieve their goals. These plans are referred to as contracts and these contracts are reviewed and revised at each subsequent session."
45507600|NCT01360463|Behavioral|methadone maintenance treatment|daily individualized doses of methadone will be provided by the program staff.
45507601|NCT02139956|Device|ultrasonography|open
45507602|NCT01360541|Procedure|Endoscopic radiofrequency ablation|HALO device Use of HALO 360° device for the fist procedure and possible use of HALo 90° device for further treatment sessions Treatment zone of 12cm high maximum. Energy delivered 10 J/cm², power 300W
45507603|NCT01360541|Other|Endoscopic surveillance|Upper gastro-intestinal endoscopy every 6 to 12 month under propofol sedation with acetic acid magnification of mucosa and multiple biopsy samples.
45507604|NCT02253368|Other|sleep|
45507605|NCT03548870|Other|CWRT with low frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes will be positioned by pair on quadriceps. Patients will have a low frequency TENS for 20 min at rest. During this period, intensity will be increased every 5 minutes to the maximum tolerated by the patient (below pain threshold, sensation strong but comfortable). Thereafter, intensity is not increased anymore during the test.~Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional"
45507606|NCT03548870|Other|CWRT with sham-low frequency transcutaneous electrical nerve stimulation|4 self adhesive surface electrodes are positioned by pair on quadriceps. Patients will have a sham-low frequency TENS for 20 min at rest. During this period, intensity will be increased for 1 minute to the maximum tolerated by the patient. After this procedure, intensity will be progressively setted back to 1mA. Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional
45507607|NCT01356563|Behavioral|pharmaceutical care|Hemodialysis patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including personal interview, medication review, medication reconciliation, patient education and recommended actions
45697813|NCT01893203|Drug|MAL cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then SPF20 sun protection cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Metvix cream on the area. After appropriate absorption time of 30 minutes, the patientswill be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
45849873|NCT04042038|Behavioral|Cognitive-behavior therapy (psychological treatment)|Participants will receive up to 20 hours of manualized and structured CBT based on exposure and response prevention by experienced clinicians
45849874|NCT04016142|Drug|Carboplatin-Paclitaxel adjuvant chemotherapy|"Patients will receive a first part of treatment corresponding to a standard of care (standard concomitant radio-chemotherapy, Part 1 of the study).~Then, they will be included in the second part of the study for the second part of treatment (experimental adjuvant chemotherapy, Part 2 of the study), providing they fulfill eligibility criteria at this stage.~The second part consists in 4 cycles of Carboplatin-Paclitaxel adjuvant chemotherapy (one cycle = 3 weeks of treatment and 1 free-week)"
46057143|NCT03850600|Other|Diet-CD|CD patients will self-select into the intervention arm to follow the diet for 8-10 weeks during their third trimester of pregnancy.
45697814|NCT04023435|Other|PNE edcuation|The PNE session will last 30 minutes and will be delivered in a one-on-one educational format with a clinician using prepared images, drawings and metaphors. The 30-minute PNE session was chosen to reflect a clinically meaningful intervention in a typical allocated time frame in clinical practice. The content of the PNE is described in detail elsewhere, using a metaphors to explain various aspects of pain including sensitization of the peripheral and central nervous system (sensitive alarm system metaphor); spreading pain (nosy neighbors metaphor); increases problems with focus and concentration (brain meeting metaphor) and difficulty with fatigue and sleep (lion metaphor).
46057144|NCT00742027|Drug|Panobinostat|Panobinostat hard gelatin capsules.
46057145|NCT03996369|Drug|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 12-Week Induction Treatment Period
46057146|NCT03996369|Drug|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 12-Week Induction Treatment Period
45399441|NCT03920644|Drug|Placebo Patch|Placebo Patch, 1 patch behind the ear.
45399442|NCT03920644|Drug|Placebo Gel|Placebo Gel,up to 6 administration of intranasal gel.
45399443|NCT01131832|Dietary Supplement|Plant sterol|
45399444|NCT01131832|Dietary Supplement|Placebo|
45399445|NCT01137916|Drug|Imatinib|800 mg
45399446|NCT01233544|Procedure|SBRT or RFA|Patients are allocated to one of the two arms in a 1:1 randomization
45399447|NCT01137994|Drug|Lapatinib|oral, reversible small molecule tyrosine kinase inhibitor of HER2 receptor
45399448|NCT01137994|Biological|Trastuzumab|monoclonal antibody directed to HER2 receptor
45399449|NCT01137994|Drug|Docetaxel|Taxane chemotherapy
45399450|NCT01137994|Drug|Paclitaxel|Taxane chemotherapy
45399451|NCT01137994|Drug|Vinorelbine|Vinka alkaloid
45399452|NCT05434390|Behavioral|Estoy PrEParado/ I am PrEPared intervention|Participants will receive an Information, Motivation, and Behavioral skills model PrEP intervention tailored for mixed immigrant status Latino men who have sex with men
45399453|NCT05434390|Behavioral|Usual Care|Participants will be offered PrEP navigation services as part of usual care at the study site.
45399454|NCT01138072|Drug|GSK2248761|200mg once daily
45399455|NCT01138072|Drug|Simvastatin|20 mg Simvastatin single dose
45399456|NCT01138072|Drug|Atorvastatin|20 mg atorvastatin single dose
45399457|NCT01138072|Drug|Rosuvastatin|10 mg rosuvastatin single dose
45399458|NCT01136902|Dietary Supplement|Oral Glucose Tolerance Test (OGTT)|75 g of glucose dissolved in 250 mL water.
45507608|NCT01356641|Drug|Antibiotic treatment alone|Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7 mg/kg once daily At least 48 hours intravenous administration, in total seven days of antibiotics Oral amoxicillin/clavulanic acid 50/12.5mg/kg
45507609|NCT01356641|Procedure|Appendectomy|Appendectomy either open or laparoscopic depending on the surgeon's preference
45507610|NCT03103087|Drug|Relugolix|Relugolix (40 mg) tablet administered orally once daily.
45507611|NCT03103087|Drug|Estradiol/norethindrone acetate|E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
45697815|NCT05263947|Drug|Bevacizumab and Icotinib|Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle; Icotinib orally twice daily at 250mg/day
45697816|NCT04415567|Drug|Lenvatinib|The patients in lenvatinib group received oral lenvatinib (Eisai, Japan) 12 mg/day (for bodyweight (BW) ≥60 kg) or 8 mg/day (for BW <60 kg) in 28-day cycles until HCC recurrence or serious adverse events (SAEs) or voluntary withdrawal. Dose interruptions followed by reductions for lenvatinib-related toxicities (to 8 mg and 4 mg/day, or 4 mg every other day) were permitted. All 14 patients took lenvatinib for more than 3 cycles.
45399459|NCT05410288|Device|Acu-TENS|A TENS stimulator will be used (NeuroTrac TENS; Verity Medical Ltd., Wexford, Ireland). Electrodes will be placed over selected acupoints (i.e., bilateral SP6, PC6 and HT7) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
45399460|NCT05410288|Other|acupressure+SHP|Participants in the acupressure group will receive acupressure coupled with SHP. The acupressure protocol was developed based on a protocol recommended by a review and will comprise the following: (1) applying consistent finger-tip pressure of 3-5 kg, with rotational movements; (2) counterclockwise and then clockwise circular motions for 2.5-min each; (3) confirming the precision of the acupressure based on participants feeling pain, numbness, distension, or warmth at the point of application; and (4) an acupoint sequence from the leg to the head, first on the left side of the body and then on the right side of the body; and (5) a 5-min treatment on each acupoint (i.e., bilateral SP6, PC6, and HT7) in each 30-min session. The SHP is the same with Acu-TENS+SHP group.
45399461|NCT05410288|Other|placebo stimulation+SHP|Participants in the placebo stimulation + SHP group will receive 30-minute placebo stimulation from identical-looking TENS devices with the electrical circuit disconnected inside.
45399462|NCT05410288|Other|sleep hygiene program(SHP)|SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. The sleep guide contains information on how much sleep is needed by every individual daily, factors that could affect sleep, and risk factors for sleep disorders. It also contains information on the types of sleep disorders, delayed sleep syndrome, insomnia-producing behavior that could affect sleep quality, and suggestions for inducing sleep. The participants will be instructed to read the guide after the baseline assessment (T0). Those instructions will be reinforced by the research practitioner after each treatment session, in order to maintain the healthy sleeping habits.
45507612|NCT03103087|Drug|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
45507613|NCT03103087|Drug|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
45507614|NCT05579288|Drug|Nitrous oxide (N2O/O2)|Nitrous oxide (N2O/O2) for pain alleviation
45507615|NCT05579288|Drug|Oxygen (O2)|Oxygen (O2) as placebo for control group
45507616|NCT02081105|Other|PEEP of 5 or 15 cm H2O|PEEP of 5 or 15 cm H2O set at the respirator and applied to the patient for 10 minutes. Then, measurements are made at each PEEP in the following order: arterial blood gas, CXR, pressure-volume curve.
45507617|NCT05579210|Behavioral|Online relapse prevention therapy|Participants in the e-RPT group will receive 10 weekly predesigned online modules. The content of this program will involve interactive therapy modules based on the principles of. On average each module consists of 30 slides and should take approximately 45 minutes to complete. At the end of each module, participants will be assigned homework to be completed and submitted to their respective therapists up to 48 hours before their next weekly session. The therapists will develop personalized feedback by using session-specific therapy feedback templates. These templates ensure that feedback is also more standardized and structured between different patients and therapists. In previous studies, therapists have been able to effectively use these templates to prepare feedback in approximately 15-20 minutes. The contents of each session are outlined on the detailed description section.
45715250|NCT05273788|Device|2400 ThorS-MagNT Stimulations at 10Hz|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. 10Hz ThorS-MagNT involves delivering one train of 100 pulses per minute with 50-second rest intervals over twelve minutes on both right and left sides (total 1200 pulses/side).
45399463|NCT01229566|Drug|AKR-963|3600mg/day in capsules of AKR-963, Placebo, or Active Comparator
45399464|NCT01232686|Other|Online disease surveillance data access|In the intervention areas we will give the study participants online access to the Snow disease surveillance system. The system will provide data about the incidents of respiratory and gastrointestinal communicable diseases in the patient population.
45399465|NCT01138306|Genetic|gene expression analysis|
45399466|NCT01138306|Genetic|mutation analysis|
45399467|NCT01138306|Other|flow cytometry|
45399468|NCT01138306|Other|laboratory biomarker analysis|
45507618|NCT05579210|Behavioral|Face to face relapse prevention therapy|Participants in the face-to-face intervention will meet with their therapist weekly through Microsoft Teams (video conference). During these 1-hour sessions, therapists will follow the same 10-week structure and content as e-RPT. Though compared to e-RPT, in face-to-face sessions, the homework will be reviewed with the participant, during the session, providing the appropriate feedback. Then the therapists will prepare a weekly patient report of each session for the principal investigator. At the end of each session, participants will receive the same homework as the e-RPT condition which they will receive feedback on during the following face-to-face session. Following the 10-week face-to-face intervention, participants will have the opportunity to join the e-RPT program.
45507619|NCT03132467|Biological|Durvalumab|Given IV
45399469|NCT01131910|Biological|TBE-vaccine|Solution of 0.5 ml for intramuscular use. Given in 2 doses separated by 1 month to healthy individuals less than 60 years old. (3 doses 0+1+3 months to those are 60 and above in Sweden)
45399470|NCT01131910|Biological|TBE-vaccine|Solution for injection 0.5 ml im. 2 or 3 doses first years, 1 dose next year
45849875|NCT03990792|Behavioral|e-predictD intervention|The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps patients to develop their own personalized plans to prevent (PPP) depression; 3) eight intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the patient. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improving sleep, expanding relationships, problem solving, improving communication skills, assertiveness training, making decisions and managing thoughts. Patients will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 3, 6 and 9 months. The intervention also includes an initial and single 15-minute face-to-face GP-patient interview.
45399471|NCT01131910|Biological|Vaccination against TBE|0.5 ml im at 0 and 1 month ( less than 60 years old) or 0 and 1 and 3 months (at least 60 years old)
45399472|NCT03739606|Biological|Anti-CD123/CD3 Monoclonal Antibody MGD006|Given IV
45399473|NCT01232764|Other|Exposure to multi-disciplinary wound care team|"Phase 1: In Person Support (3 mths)~Advance Practice Nurses (APNs) affiliated with Enhanced Multi-Disciplinary visit LTC facilities on a weekly basis. The APN may communicate with other members of an EMDT via telephone or online.EMDTs will collectively teach and mentor LTC facility wound care teams throughout the study.~Phase 2: Remote Support (2-11 mths) In the second phase, EMDTs will support LTC facility staff remotely via telephone and online communication, visiting the facilities on an as needed basis only.~All PU treatment will be based on RNAO evidence-based guidelines (updated in 2007)contextualized to the LTC setting."
45399474|NCT01136980|Device|TIF Transoral Fundoplication|A novel surgical technique that creates a gastric fundoplication and restores competency of the gastroesophageal valve now exists for patients who have limited anatomic defects (small hiatal hernia). This technique is performed transorally using the EsophyX device (EndoGastric Solutions, Inc. Redmond, WA, USA) recreates a gastric fundoplication at the gastroesophageal junction by creating a flap valve at the intersection of the stomach and the esophagus by deploying polypropylene SerosaFuse fasteners (EndoGastric Solutions)
45399475|NCT01136980|Other|Sham placebo procedure|The Sham Procedure (control) will consist of an upper GI endoscopy that will be conducted under general anesthesia in an operating room. The surgical team will follow the same steps before, during, and after the sham procedure similar to the TIF procedure, except they will never insert the EsophyX device into the patient. The endoscope will be manipulated for 30-45 min as if the device were around it to simulate the effect of many rotations and manipulations on the esophagus.
45399476|NCT01138384|Drug|Foretinib|Daily oral dosing at assigned dose beginning day 3 of cycle 1
45399477|NCT01138384|Drug|Lapatinib|Daily oral dosing at assigned dose beginning day 1 cycle 1.
45399478|NCT05533372|Drug|IA-14069|IA-14069 for oral administration.
45399479|NCT05533372|Drug|Placebo|Placebo for oral administration.
45399480|NCT05533372|Drug|Methotrexate|Methotrexate for oral administration.
45507620|NCT03132467|Biological|Tremelimumab|Given IV
45399481|NCT01137058|Device|U-healthcare service|Public switched telephone network (PSTN)-connected glucometer with U-healthcare system.
45507621|NCT01363505|Device|BARD® Intra-abdominal Pressure monitor|monitor linked to foley catheter that is able to measure pressure inside bladder
45849876|NCT03990792|Other|Brief psychoeducational intervention|The intervention consists of an App that weekly send brief psychoeducational messages about physical and mental health (depression, anxiety, sleep hygiene, physical activity, etc.)
45399482|NCT01137058|Device|SMBG group|Glucose control with self monitoring of blood glucose.
45399483|NCT01233622|Drug|Vildagliptin|
45849877|NCT03984396|Other|Educational Materials - Patient & Clinician|deprescribing information for patient & clinician
45507622|NCT02134964|Drug|OLT1177 Capsules|OLT1177 Capsules are an experimental drug.
45507623|NCT02134964|Drug|Placebo Capsules|Placebo Capsules are identical in all ways to the study drug, but contain no active pharmaceutical ingredient.
45507624|NCT01363583|Drug|epoprostenol versus normal saline|0.5 ng/kilogram/minute during 4 days
45507625|NCT01363583|Drug|normal saline|0.5-1.5 ml/hour during 4 days
45507626|NCT02135120|Drug|Combined spinal epidural anesthesia technique with intrathecal morphine|
45507627|NCT02135120|Drug|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block|
45507628|NCT02135120|Drug|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block|
45849878|NCT03952338|Other|Food coupons|Participants will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets.
45507629|NCT02135198|Drug|2 mg AZD7325|A single 2 mg oral dose of AZD7325
45507630|NCT02135198|Drug|10 mg AZD7325|A single 10 mg oral dose of AZD7325
45507631|NCT02135198|Drug|Placebo|A single oral dose
45507632|NCT03131999|Drug|Imatinib Mesylate 400Mg Capsule|Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
45507633|NCT03131999|Drug|Placebo - Capsule|Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
45507634|NCT01319357|Drug|Saxagliptin|orally 5 mg/d for 6 weeks
45507635|NCT01319357|Drug|Placebo|orally for 6 weeks
45507636|NCT02135354|Drug|Azithromycin|"From day 1 up to and including day 3: 500 mg azithromycin PO once a day~From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days"
45507637|NCT02135354|Drug|Placebo|"From day 1 up to and including day 3: 500 mg placebo PO once a day~From day 4 up to and including day 90: 250 mg placebo PO once every 2 days"
45507638|NCT01319435|Procedure|Collection of biological samples|"Sparse blood samples (n=2 or 3 depending on weight) will be drawn on day 1 and day 5- 7 (or last day of treatment if the course is completed before day 7).~Monitoring of adverse events DNA for pharmacogenetics (scavenged clinical samples or buccal) CSF (if required clinically) Faeces"
45507639|NCT05416489|Device|C-MAC videolayngoscopy technique|Endotracheal tube will be removed before percutaneous tracheostomy using a C-MAC videolaryngoscopy.
45507640|NCT05416489|Device|Laryngoscopy technique|Endotracheal tube will be removed before percutaneous tracheostomy using a laryngoscopy
45507641|NCT05416099|Procedure|laser|grid vs micropulse laser
45507642|NCT02140034|Procedure|Extensive Peritoneal Lavage|
45507643|NCT02055053|Drug|0.5% Bupivicaine|Local anesthetic
45849879|NCT03952338|Other|Nutrition skill-building|Participants will be invited to participate in nutrition skill-building activities throughout the intervention period. To be consistent with the real-world program, the frequency and types of skill-building activities offered will vary by community partner, and participation is not required.
45507644|NCT02303431|Drug|Edoxaban low dose|Edoxaban low dose
45399484|NCT01233622|Drug|Placebo|
45507645|NCT02303431|Drug|Edoxaban high dose|Edoxaban high dose
45507646|NCT01360697|Other|JADE|"The nurse will complete the CA using standardized protocol including blood & urine tests, eye & feet examination.~Whenever feasible, the nurse will arrange 2-4 hours of diabetes education in groups or on an individual basis as appropriate.~Between each follow-up (FU) visit, the nurse or HCA will contact the patient by phone or email to remind them to attend visits, adhere to medications & healthy lifestyles, perform self blood glucose monitoring as appropriate.~At each FU visit, the patients will first see the nurse or HCA for record of blood pressure, body weight & blood glucose (or A1c) measurement as appropriate. Compliance will also be checked using the 4-item questionnaire.~After the FU visit, the patients will see the nurse or HCA again to clarify any issues & concerns, reinforce compliance & record any changes in medications.~After each FU visit, the HCA will generate summary reports to be given to patients & doctors to promote sharing of information."
45507647|NCT01360697|Other|Non-JADE|Patients will receive a comprehensive assessments at baseline and again after 12 months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
45507648|NCT02135510|Drug|metoclopramide|
45507649|NCT02135510|Drug|dexamethason|
45507650|NCT02135510|Drug|palonosetron|
45507651|NCT02140112|Biological|Trichuris suis ova|
45507652|NCT02140112|Other|Placebo|
45507653|NCT02263885|Device|ExAblate Transcranial System|Transcranial MRgFUS
45507654|NCT05578742|Procedure|PEEP increase|Positive End Expiratory Pressure (PEEP) will be increased from 5 to 15 cmH2O.
45507655|NCT05578742|Procedure|PEEP decrease|Positive End Expiratory Pressure (PEEP) will be decreased from 15 to 5 cmH2O.
45507656|NCT02004275|Drug|pomalidomide|given PO
45507657|NCT02004275|Drug|ixazomib|given PO
45507658|NCT02004275|Drug|dexamethasone|given PO
45507659|NCT03548792|Radiation|RSA radiostereometric analysis|Tantalum beads will be inserted in polyethylene Component and in bone to assess micromotion of Components in radiographs
45507660|NCT03548792|Behavioral|Clinical comparison|ActivePAL, walking speed
45507661|NCT02192671|Procedure|Hepatic Resection|Indications for HR are the presence of appropriate residual liver volume determined by volumetric computed tomography.
45507662|NCT02192671|Procedure|Radiofrequency Ablation|
45507663|NCT03548714|Drug|PT150|Intervention 1 includes PT150 with alcohol consumption
45507664|NCT03548714|Other|Beverage|Alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in grape Kool-Aid (Kraft Foods, Northfield, IL). Placebo will be prepared in the same manner but contain 1% alcohol to mask taste.
45507665|NCT02160691|Device|Anxiety Meter|This is a new device developed to measure changes in heart rate and translate these into a visual display of arousal level in children with autism spectrum disorder.
45399485|NCT01137214|Device|Non-invasive positive pressure ventilator|All patients will initially be treated with CPAP for 12 weeks as part of usual clinical treatment for sleep apnea. A sleep study will be conducted after this and prior to randomization into the study. If this repeat sleep study demonstrates persistent central sleep apnea, patients will be randomized into 2 study groups. Group 1 - CPAP for 24 weeks. Group 2 - first 12 weeks CPAP (Continuous Positive Airway Pressure. Next 12 weeks - (ASV) Adaptive Servo ventilation. If the treatment is not working well at 12 weeks the participant/patients have the option of switching to the alternate treatment. Patients will be notified if they are to be switched to ASV. Participants will be asked to fill in the Epworth Sleepiness Score Questionnaire and Sleep Apnea Quality of Life Index form at 12 and 24 weeks.
45399486|NCT01232842|Genetic|cytogenetic analysis|
45399487|NCT01232842|Other|HUMARA assay|
45507666|NCT02135588|Drug|Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)|
45507667|NCT03633019|Drug|rhTPO|high dose rhTPO ih
45507668|NCT05578664|Drug|Pembrolizumab injection plus metastasis directed treatment (surgery or RT)|Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RT) from day 21 of cycle 1 to day 42 of cycle 1
45399488|NCT01232842|Other|fluorescence activated cell sorting|
45399489|NCT01232842|Other|laboratory biomarker analysis|
45399490|NCT01138462|Other|intervention|"5 days topical decolonisation including nasal mupirocin tid, chlorhexidine mouth wash tid, chlorhexidine body wash once daily.~Daily direct resident's environmental disinfection during decolonisation."
45399491|NCT05513014|Drug|Secukinumab|Patients with Psoriasis who initiated Secukinumab
45399492|NCT01138540|Other|lateral-Trendelenburg position|lateral-Trendelenburg position of patients laying in the bed of the ICU, keeping trachea and tracheal tube horizontal, compared to the standard treatment (semirecumbent position) for the prevention of VAP
45507669|NCT05578664|Other|Tumor resection or RT|Tumor resection or RT will be applied within 42 days from randomization.
45507670|NCT05755243|Device|glucose sensor|skin biopsy (punch)
45507671|NCT05578508|Drug|Mesenchymal Stem Cells (MSCs)|Endoscopic injection of allogeneic bone marrow derived mesenchymal stem cells (MSCs) to the ileal pouch.
45507672|NCT05380440|Behavioral|Families Actively Improving Relationships (FAIR)|FAIR is a behavioral intervention for the treatment of parental substance abuse and child neglect for families involved in the child welfare system. This project will adapt the existing FAIR intervention for prevention. FAIR involves four major treatment components, supported by ongoing purposeful engagement : (1) Substance use treatment including contingency management and positive reinforcement, frequent urinalysis, relationship building, day planning, healthy environments and peer choices, and refusal skills; (2) Mental health treatment including cognitive behavioral therapy, developing healthy coping skills, emotion regulation skills, exposure therapy, and referral for medication management; (3) Parent management training including parenting skills, nurturing and attachment, reinforcement, emotion regulation, supervision, structure, non-harsh discipline, and nutrition; and (4) Resource building and provision of ancillary supports including assistance with housing and employment.
45507673|NCT05380440|Behavioral|Standard Case Management and Referral|Parents will be referred for a substance abuse and mental health assessment with possible resulting treatment. Child Welfare treatment plans typically include a series of recommendations, including parenting classes, securing safe housing, psychosocial treatment (e.g., domestic violence), accessing self-sufficiency services (e.g., food stamps, WIC), securing employment or education, and meeting court dates and requirements.
45849880|NCT03941106|Device|Accelerated repetitive transcranial magnetic stimulation|Subjects will be given accelerated left sided rTMS and randomized to more of the same accelerated rTMS if not meeting remission criteria for depression or a different type of rTMS on the right side
46059116|NCT04116073|Drug|INCMGA00012 (PD-1 antibody)|"Treatment of INCMGA00012 will be administered every 4 weeks (28 days) while patient is on study. Intravenous administration of INCMGA00012 (500 mg) will occur on Day 1 of each 28 day cycle.~Drug: 500 mg is to be administered as a 30 minute IV infusion (-5/+15 min)"
45399493|NCT01138618|Device|Venous blod sample|Regular venous blood sample withdrawn from the laboratory
45399494|NCT01138618|Device|CHEMPAQ|Capillary blood sample analyzed by CHEMPAQ
45399495|NCT01138774|Dietary Supplement|Double blind dietary intervention with EPA and lipoic acid|Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA).
45399496|NCT01131988|Drug|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
45507674|NCT01491763|Drug|Imatinib|600 mg p.o. from day 1 until consolidation
45507675|NCT03597750|Device|Repose®|"Repose® Mattress~Repose® Cushion~Repose® Wedge or Foot Protectors"
45507676|NCT03549260|Biological|LIB003|LIB003 or placebo
45507677|NCT01563302|Drug|IONIS-STAT3Rx|Three-hour IV infusions on Cycle 0 Days 1, 3, 5, and weekly three-hour IV infusions in Cycles 1 and beyond, on Days 1, 8, and 15 of each cycle.
45507678|NCT04254341|Other|patients with OSA|Sleep study
45399497|NCT01229800|Drug|Polyethylene glycol|Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes. Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure.
45399498|NCT01229800|Drug|Sodium phosphate(NaP) solution|Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
45399499|NCT05497258|Device|Artificial intelligence assistant system|The AI-assisted diagnosis system can provide the direction of disease diagnosis in real time and assist the doctor to give the final diagnosis
45399500|NCT01234558|Drug|GLYX-13|single IV dose
45399501|NCT04797364|Diagnostic Test|Pharmacogenetic Testing|Participants will donate a 2ml (teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) developed by our group and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the child's current and future care
45399502|NCT01138852|Drug|Ampicillin-sulbactam|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
45507679|NCT02237586|Biological|PfSPZ Challenge|live, aseptic, cryopreserved P. falciparum sporozoites
45399503|NCT01138852|Drug|Cefuroxime|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
45399504|NCT01138930|Drug|Berberine|1.5g daily for 3 month
45399505|NCT01138930|Drug|Placebo|placebo daily
45399506|NCT05487196|Drug|Clonidine|Clonidine belongs to the drug classification of antihypertensives
45399507|NCT05487196|Drug|Dexmedetomidine|Dexmedetomidine belongs to the drug classification of sedatives
45399508|NCT05487196|Drug|Fentanyl|Fentanyl belongs to the drug classification of analgesic opioid agonists and is used as the standard of care
45399509|NCT05487196|Drug|Ropivacaine|Ropivacaine belongs to the drug classification of local or regional anesthesia for surgery and is used as standard of care
45399510|NCT01233154|Dietary Supplement|probiotic|
45507680|NCT02252822|Behavioral|Overcoming Bulimia Online Programme|
45507681|NCT01363817|Drug|BMS-906024|
45507682|NCT01363817|Drug|Dexamethasone|
45507683|NCT03597048|Behavioral|Curriculum|The curriculum intervention is a three- module, three-hour curriculum delivered by teachers in sixth grade classrooms over a three- to six-day period. The curriculum is designed to increase knowledge and improve attitudes about mental illnesses so as to improve the school climate with respect to mental illness stigma and encourage help seeking for youth in need.
45507684|NCT03597048|Behavioral|Contact|The contact intervention involves two college students-a 27-year-old male with a history of bipolar I disorder and a 24-year-old female with a history of bipolar II disorder-who each make a ten-minute in-class presentation (20 minutes total) describing onset and course of their symptoms, hospitalizations and treatments, their feelings about the illness, coping strategies, and impact of the illness on social relationships and functioning at school and work.
46059117|NCT04296877|Device|Daily Disposable Contact Lens|Soft, daily disposable spherical contact lens used to correct distance vision.
45399511|NCT01233154|Dietary Supplement|probiotic|
45399512|NCT01233778|Dietary Supplement|Canola Oil|60g Canola oil daily per 3000kcal diet provided in a supplemental shake
45399513|NCT01233778|Dietary Supplement|High Oleic Acid + DHA Canola Oil|60g high oleic acid canola oil + DHA daily per 3000kcal provided in a supplemental shake
45507685|NCT03597048|Behavioral|Materials|"The materials intervention is implemented by teachers who prominently display posters in the classroom for two weeks and provide students with bookmarks. The materials focus on individuals' with mental illnesses emphasizing their personal traits and abilities as opposed to language that labels a person as mentally ill."
45399514|NCT01233778|Dietary Supplement|High Oleic Acid Canola Oil|60g high oleic acid canola oil daily per 3000kcal provided in a supplemental shake
45507686|NCT02140268|Drug|Midazolam|Volunteers will receive a single dose of Midazolam 7.5 mg on Day 1
45507687|NCT02140268|Drug|AZD1722|Volunteers will receive twice daily, oral doses of AZD1722 15 mg on Days 2-14
45507688|NCT02140268|Drug|AZD1722 and Midazolam|On Day 15 volunteers will receive AZD1722 15 mg and Midazolam 7.5 mg at the same time in the morning. In the evening on Day 15 AZD1722 15 mg will be administered alone.
45507689|NCT05187689|Behavioral|VR + MHL intervention|The intervention will include: 1) a Virtual Reality (VR) interactive and immersive 30-minute session viewed using a low cost VR headset; and 2) an 8-week program of weekly WelTel SMS check-ins managed by Peer Navigators (PNs), weekly WelTel SMS blasts informed by Psychological First Aid (PFA) with mental health literacy (MHL) messages developed with PN, and weekly WelTel web-based secure platform social group discussions on MHL, stress coping, and stigma moderated by PN alongside a trained Coordinator. Weekly MHL WelTel platform moderated discussion foci will address MHL, stigma and stress coping strategies, including self-compassion and other strategies that emerge from the urban refugee youth interviews and focus groups, through diverse methods, including: 'scenarios' mimicking real life situations; a 'question box'; sharing photos demonstrating stress coping strategies; memes; songs; and ways participants interrupted stigma in their daily lives.
45507690|NCT05187689|Behavioral|Group PM+|"Participants will attend small groups (5-6 participants with a PN and a coordinator supporting) outdoors with physically distancing, for Group PM+ sessions following the adapted WHO Group-PM+ manual (adaptations made in Phase 1 explain above) 5 weekly 3-hour sessions delivered by PN who will co-facilitate sessions with the Coordinator. Each session has a mechanism of action:~Managing stress: mechanism of action-identify goals, learn deep breathing and techniques for stress management~Managing problems: mechanism of action-identify 1 solvable practical problem, brainstorm possible solutions together~Get going, keep doing: mechanism of action-learn about depression and inactivity, identify and plan small enjoyable activities~Strengthen social support: mechanism of action-discuss a range of social support resources, make plan to increase social support~Staying well: mechanism of action- this session reviews all of the mechanisms of action in the prior 4 sessions"
45507691|NCT01194817|Device|High-Flexion Knee Replacement System using Cemented Fixation|
45507692|NCT01194817|Device|High-Flexion Knee Replacement System using Cementless Fixation|
45507693|NCT03548636|Behavioral|Single-Arm Feasibility Study|Groups of 8 to 12 participants, consisting of >50% breast cancer survivors, were invited to apply for up to $2000 to enable access to equipment, resources, facilities, instruction and/or transportation to implement a physical activity intervention. Applicants were assessed by a Grant Review Panel. Successful applicants were informed that they would receive an additional $500 incentive if they increased their group's mean physical activity at six month follow-up (assessed via accelerometry).
45507694|NCT01360775|Behavioral|nutritional counseling|Nutritional counseling to caregivers of dependant patients at nutritional risk, Who were participants in the Home Care program conducted by nurses
45697817|NCT04723576|Behavioral|Stress First Aid|"Stress First Aid (SFA) is an evidence-based intervention to mitigate the psychosocial impact of COVID-19 on Health Care Workers (HCWs). SFA was initially developed for the United States Navy and Marine Corps as a framework of actions for peer support delivered by individuals without mental health training. SFA is designed to teach simple, supportive actions that can be seamlessly integrated into work environments. SFA training focuses on five essential principles: cover (restore and support a sense of safety), calm (encourage simple strategies such as breathing), connect (engage in and promote social support), competence (improve ability to address crucial needs and concerns), and confidence (increase hope and limit self-doubt and guilt). In this study, we are adapting the SFA model to include HCW-specific examples of SFA actions and case scenarios specific to the COVID-19 pandemic and will implement SFA using a train-the trainer model."
45697818|NCT03280251|Drug|Methylphenidate|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks
45399515|NCT01233778|Dietary Supplement|Flax Oil|36g flax oil + 24g safflower oil daily per 3000kcal provided in a supplemental shake
45399516|NCT01233778|Dietary Supplement|Safflower Oil|45g safflower oil + 15g corn oil daily per 3000kcal provided in a supplemental shake
45399517|NCT01139242|Behavioral|Body & Soul nutritional intervention|Pastoral and peer counseling, and church activities/menus to promote increased fruit and vegetable consumption among church members.
45507695|NCT03600168|Device|PuraStat®|Synthetic haemostatic material
45507696|NCT02252900|Other|Magnetic resonance imaging|All patients will undergo the diagnostic test specific to the study
45697819|NCT03280251|Drug|Placebo|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks
45697820|NCT03280251|Other|CogniPlus software|Structured cognitive training with CogniPlus software, twice per week during 6 weeks
45507697|NCT01363895|Procedure|Percutaneous closure of LAA|Percutaneous closure of LAA
45507698|NCT01363895|Procedure|Catheter ablation of AF|Catheter ablation of AF
45507699|NCT02237664|Procedure|Continuous paravertebral analgesia (C-PVB)|Patients will receive continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1
45697821|NCT03280251|Other|Pseudo cognitive training|Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
45697822|NCT01882829|Drug|dextromethorphan/quinidine|up to 45/10 mg every 12 hours in patients with TRD with a short 7 day tapering period in which subjects are tapered off 45/10 mg dose from twice a day to once daily for an additional 7 days at post 8-week treatment period to minimize the potential for discontinuation effects
45399518|NCT01139242|Behavioral|Experimental: newsletters and peer counseling|Four tailored newsletters and peer counseling calls to promote CRC screening in church members who are out-of-date with screening. Four tailored newsletters and peer counseling calls to others to increase physical activity.
45399519|NCT04764994|Device|Armeo®Spring ((Task-oriented upper extremity rehabilitation system)|Armeo®Spring is a functional upper extremity rehabilitation device to provide specific therapy with augmented feedback. The Armeo Spring instrument facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury or other neurological diseases and injuries. It combines an adjustable arm support, with augmented feedback and a large 3D workspace that allows functional therapy exercises in a virtual reality environment.
45399520|NCT04764994|Other|Conventional Physical Therapy Program|This intervention t will include: muscle facilitation exercises, proprioceptive neuromuscular facilitation exercises, strengthening activities, stretching exercises and postural reactions exercises.
45507700|NCT02237664|Procedure|Patient-controlled paravertebral analgesia (PC-PVB)|Patients will receive background continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1 with patient demand bolus dose of 3 mL and lockout time of 15 min with a 20 mL h-1 maximum dose, irrespective of their age
45507701|NCT05750095|Behavioral|Incredible Years Autism Spectrum and Language Delay Programme|Incredible Years Autism Spectrum and Language Delay Programme is a manualised group based intervention in 13 weekly 2-hour sessions. The programme targets parents of children aged 2-6 years, with autism spectrum disorder or language delay.
45507702|NCT05750095|Behavioral|First Aid for Parents|"First Aid for Parents is a program consisting of three full day work-shops targeting communication, interaction and daily living skills for parents of children with autism spectrum disorders"
45507703|NCT05578352|Other|Add oral hyppoglycemia drug|Oral hypoglycemic drugs with insulin sensitization effect are added, reduce insulin dose according to blood glucose
45507704|NCT05578352|Other|Add GLP-1 receptor agonist|Add GLP-1 receptor agonist and reduce insulin dose according to blood glucose
45507705|NCT05578352|Other|Change insulin|Change premix insulin to long-acting insulin
45507706|NCT04090229|Drug|ASLAN004|Subcutaneous injections of ASLAN004 100 mg/mL will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
45507707|NCT04090229|Drug|ASLAN004 Placebo|Subcutaneous injections of ASLAN004 Placebo will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
45507708|NCT03602508|Drug|mirabegron|oral
45507709|NCT03602508|Drug|solifenacin|oral
45507710|NCT03602508|Drug|darifenacin|oral
45697823|NCT04399005|Other|after-each-case room disinfection|After-each-case room disinfection was defined as after completing each case.
45507711|NCT03602508|Drug|imidafenacin|oral
45507712|NCT03602508|Drug|tolterodine|oral
45697824|NCT04399005|Other|daily room disinfection|Daily room disinfection was defined as disinfection after completing 8 non-general anesthesia gastroscopy or 4 general anesthesia gastroscopy.
45697825|NCT04760301|Drug|local tranexamic acid injection|local tranexamic acid injection to cervix- 1 g tranexamic acid diluted in 10 ml saline
45697826|NCT04760301|Other|local normal saline injection to cervix|local normal saline injection to the cervix- 20 ml saline
45697827|NCT04760301|Drug|IV 1 g tranexamic acid|IV 1 g tranexamic acid diluted in 100 ml saline
45697828|NCT04760301|Other|IV 1 g normal saline|IV 100 ml normal saline
45507713|NCT03602508|Drug|oxybutynin|oral
45507714|NCT03602508|Drug|trospium|oral
45507715|NCT03602508|Drug|fesoterodine|oral
45507716|NCT03602508|Drug|propiverine|oral
45507717|NCT05546671|Diagnostic Test|Hand grip strength measurement|"Preoperative hand grip strength will be measured in kilograms using a digital hand dynamometer (Baseline Smedley Digital Hand Dynamometer, Model 12-0286, Baseline Evaluation Instruments, China). Participants will be instructed to grip the hand dynamometer for 5 seconds with their dominant hand 3 times. They will be allowed to rest for 20 second between each grip. The highest measurement of 3 attempts will be recorded. Participants will be categorized as strong grippers or weak grippers according to Fried criteria as previously defined by Linda P. Fried and colleagues. A weak grip will be defined as follows:~For men:~BMI ≤24: hand grip strength ≤29 kg; BMI =24.1 to 28: hand grip strength ≤30 kg; BMI >28: hand grip strength ≤32 kg~For women:~BMI ≤23: hand grip strength ≤17 kg; BMI =23.1 to 26: hand grip strength ≤17.3 kg; BMI =26.1 to 29: hand grip strength ≤18 kg; BMI >29: hand grip strength ≤21 kg"
45697829|NCT02170870|Drug|Exendin 9-39|Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
45697830|NCT02170870|Drug|Microlipid|Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
45697831|NCT02170870|Drug|Placebo|Normal saline infusion will be prepared to match the appearance of Exendin 9-39
45399521|NCT01585870|Drug|Sorafenib (Nexavar, BAY43-9006)|"Sorafenib (starting dose of 200 mg bid, level 1) administration will begin on Day 11 of Cycle 1, and will be administered twice daily continuously. If the combination is well tolerated, the dose will be escalated in new cohorts to 200 mg AM and 400 mg PM (level 2), then subsequently to 400 mg bid (level 3).~If sorafenib starting dose (level 1) is not well tolerated with eribulin, the sorafenib dose will be de-escalated to 200 mg qd (Dose Level -1) in a new cohort."
45507718|NCT03549728|Drug|Granulocyte Colony-Stimulating Factor|In group A, at the day of oocyte retrieval, after oocytes collection, 30 mU (300 mcg/0.5 ml) of G-CSF (NeupogenTM, Filgastrim, Amgen Inc., Thousand Oaks, CA, USA) was administered by slow transcervical intrauterine infusion with IUI catheter (AINSEGREY, RIMOS, Italy). In controls, normal saline was used for intrauterine infusion instead of G-CSF.
45399522|NCT01585870|Drug|Eribulin|Eribulin: 1.4 mg/m2 as an intravenous infusion on Days 1 and 8 of each 21-day cycle.
45399523|NCT03754660|Drug|BAY1237592|Oral inhalation with dry powder inhaler, single dose.
45399524|NCT01234636|Dietary Supplement|Placebo oil|Placebo oil of 4g/day
45399525|NCT04746820|Other|single-center prospective pilot study|"fNIRS will be compared to evoked potentials in an experimental group consisting of unconscious neuro-intensive care patients and in a control group consisting of healthy, conscious subjects.~To compare fNIRS with evoked potentials there are two test phases:~The cerebral response to a somatosensory stimulus (peripheral nerve stimulation) is measured by fNIRS and SSEP~The cerebral response to an auditory stimulus is measured by fNIRS and AEP"
45399526|NCT05222464|Other|Standard of care treatments|Interventions will consist of 4 classes of standard of care treatments, namely, lifestyle modifications, complementary and alternative medicine (CAM) therapies, prescription medications, or adjustment of anti-cancer therapy.
45399527|NCT03738436|Other|Physical therapy traditional neuromuscular training, NMT|The NMT program includes re-position exercise using Swiss ball roll squat, strengthening and stretching exercises in various positions or combined using Swiss ball, Thera-Band or suspension system (Redcord), balance exercise on wobble board, proper landing strategy practices, and etc.
45399528|NCT03738436|Other|Physical therapy modified visual feedback, MVF|traditional neuromuscular training (as in NMT group), but with modified visual feedback by eyes closed, reduced lighting or wearing strobe goggles
45399529|NCT01139320|Genetic|DNA analysis|
45399530|NCT01139320|Genetic|polymerase chain reaction|
45399531|NCT01139320|Other|laboratory biomarker analysis|
45507719|NCT03549728|Procedure|Intrauterine infusion of normal saline|In group B (controls), normal saline will be used for intrauterine infusion instead of granulocyte colony-stimulating factor on the day of oocyte retrieval.
45399532|NCT01139320|Other|pharmacological study|
45399533|NCT05210140|Drug|Escitalopram|"Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is commercially known as ELORYQA®, Elicea®, Escital®,PRAMES® or Lata® in Serbia. The recommended dose for Major depressive disorder is 10mg/day. Based on the individual response, dose can be adjusted and the maximum dose is 20 mg/day; 5 mg/day dose is also available. Escitalopram is also indicated for treatment of Obsessive-compulsive disorder, Generalized anxiety disorder, Social anxiety disorder (Social phobia) and Panic disorder (with or without agoraphobia) by Medicines and Medical Devices Agency of Serbia.~In known CYP2C19 poor metabolizers, initial dose should be 5mg/day during first 2 weeks, and based on the individual response it can be increased up to maximum of 10 mg of escitalopram per day, according to the guidelines of Medicines and Medical Devices Agency of Serbia."
45399534|NCT01142986|Behavioral|Low intensity care|During the first 3-months (13 weeks), subjects will be scheduled to attend one individual counseling session per month. Subjects will not be required to attend any group counseling sessions during this time. After the first 3-months of care, subjects will start usual counseling care, at which time they will be required to attend one individual counseling session per week, and may be required to attend additional individual and group counseling sessions each week for missed sessions or continued use of drugs or alcohol.
45399535|NCT01142986|Behavioral|Voucher reinforcement|Subjects will receive usual counseling care during the 26 weeks of study participation.They will be required to attend one individual counseling session per week, and will be required to attend additional individual and group sessions each week for missed session or continued use of drugs or alcohol.In addition, subjects in this condition will have the opportunity to earn voucher incentives each week during the first 13 weeks of care.These incentives can be earned by taking daily methadone doses and attending all scheduled counseling sessions (individual and group).The first voucher is worth $12.00, and each voucher after that is worth an additional $13.50. Bonuses of $30.00 will be awarded for each 3 consecutive weeks of compliance.The total amount possible to earn in the study is $1329.00. Each week that the subject is not compliant,they will not earn a voucher and the value of the next voucher will be reset to $12.00.The vouchers can be used for goods and services in the community.
45399536|NCT01329718|Other|Blood Sample|Blood sample collection
45507720|NCT01356797|Drug|hypobaric levobupivacaine with fentanyl|SSSA with 4 mg hypobaric levobupivacaine 0,13% with 10 mcg fentanyl
45507721|NCT01356797|Drug|hyperbaric bupivacaine 0,5%|SUSA with 4 mg hyperbaric bupivacaine 0.5%
45507722|NCT05200585|Behavioral|Healthy Liver/Hígado Sano program|The program will last 4-6 months and include 16 sessions, each 30-60 minutes long, that focus on self-management strategies for dietary changes and physical activity and is meant to be delivered in 4-6 months. The 16 sessions are as follows: 1) Introduction to the program, 2) Get Active, 3) Track Your Activity, 4) Eat Well, 5) Track Your Food, 6) Get More Active, 7) Burn More Calories Than You Take In, 8) Shop and Cook, 9) Manage Stress, 10) Find Time for Fitness, 11) Cope with Triggers, 12) Keep Your Heart Healthy, 13) Take Charge of Your Thoughts, 14) Get Support, 15) Eat Well Away from Home, and 16) Staying Motivated
45507723|NCT05200585|Behavioral|Usual standard of care|Participants will receive ongoing monitoring of condition at the clinic per standard of care and a short informational pamphlet
45507724|NCT03600012|Other|Cycling Functional Electrical Stimulation|
45507725|NCT03600012|Other|Physiotherapy|
45507726|NCT05747443|Other|Stepped Reminders|Stepped Reminders, which directly reminds providers to order the next LDCT scan and then reminds patients they are due and prompts them to schedule LDCT with Radiology.
45507727|NCT05747443|Other|Patient Education|The Patient Voices Video is an educational video about lung cancer screening.
45507728|NCT02140346|Drug|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
45507729|NCT02140346|Drug|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
45507730|NCT02238132|Drug|ATROVENT® inhalets|
45507731|NCT05200507|Device|High Frequency Percussive Ventilation|High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz, superimposed to the ventilatory assistance
45507732|NCT03595722|Device|High Intensity Focused Ultrasound|High intensity focused ultrasound to rectal/pelvic cancer
45507733|NCT05200429|Drug|Trikafta|Highly Effective CFTR Modulator Therapy
45507734|NCT02000219|Biological|Oxalobacter formigenes|The dose will be (not less than) NLT ≥1E+09 colony forming units (CFU) twice daily. The dose (an enteric-coated capsule) will be administered orally with breakfast and dinner.
45507735|NCT02135666|Procedure|Blood sampling|At Years 16 - 20 after first dose of the primary vaccination in HAB-084 (208127/084) study.
45399537|NCT01139398|Dietary Supplement|Limicol (plant extract)|Artichoke extract, anti-caking agents: dicalcium phosphate, calcium citrate, vegetable magnesium stearate, red yeast rice, microcrystalline cellulose, natural vitamin E, garlic extract, sugar cane policosanols, inositol hexanicotinate, vitamin B3, vitamin B2.
45399538|NCT03711214|Procedure|Periodontal scaling|Periodontal scaling and root planing
45507736|NCT03595488|Drug|Dupilumab|dupilumab 300 mg subcutaneous injection every 2 weeks
45507737|NCT02135744|Behavioral|Bundle tool|Tool consists of 1. screening measures to identify the presence of various risk factors for COPD exacerbations and 2. Educational components for the disease of COPD.
45697832|NCT04400097|Procedure|suture|suture methods of autograft conjunctival transplantation
45507738|NCT01356875|Drug|BSC|The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
45507739|NCT01356875|Drug|HIDRA/VPA|In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycle.
45507740|NCT03594708|Dietary Supplement|Nutrition supplement|Fermentable fiber, omega-3 fatty acid, vitamin D3, vitamin E, zinc
45507741|NCT03594708|Dietary Supplement|Placebo supplement|rice starch, light olive oil, vegetable oil
45507742|NCT05578196|Drug|fecal bacteria solution|The gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° C, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. The other treatment measures were the same as those of the control group.
45697833|NCT04678648|Drug|RSC-1255 Dose Escalation|Phase 1a will enroll 24-34 participants to identify the dose limiting toxicity (DLT), recommended Phase 1b dose, and the safety and tolerability of RSC-1255. RSC-1255 is administered orally twice daily, without food. Each cycle is 21 days.
45697834|NCT04678648|Drug|RSC-1255 Dose Expansion|Phase 1b will enroll 48-104 participants to further characterize the safety, pharmacology, and clinical efficacy of RSC-1255. RSC-1255 is administered orally twice daily, without food. Each cycle is 21 days.
45399539|NCT01233934|Drug|Dexchlorpheniramine 1% Gel|Small amount applied over the lesion twice a day for 7 days.
45399540|NCT01233934|Drug|Dexchlorpheniramine 1% Cream|Small amount applied over the lesion twice a day for 7 days.
45399541|NCT01236508|Radiation|PET/CT imaging with F-18 fluorodeoxyglucose|Dose of 5 MBq/kg F-18-FDG given to fasting participant. Nuclear whole body imaging starting at 3 hours post-injection. The relation of the PET/CT image results and both the number of covert brain infarcts and the extent of white matter MRI hyperintensity will be investigated.
45399542|NCT05195944|Drug|Semaglutide Treatment|"The participants will be provided with Semaglutide, titrated up to 14 mg. The starting dose of Semaglutide is 3 mg once daily. At week 4, the dose will be increased to 7 mg once daily. At week 8, the dose will be increased to 14 mg once daily and will be maintained at 14mg until End of Treatment (week 26). Throughout the 26 week treatment period, participants in this arm will also take one sitagliptin placebo tablet per day."
45399543|NCT05195944|Drug|Sitagliptin 100mg|"participants will take 100mg tablet of Sitagliptin once daily, along with a semaglutide placebo pill for the duration of the 26 week treatment period"
45507743|NCT05578196|Drug|physiological saline solution|physiological saline solution 20ml
45507744|NCT05200273|Drug|AK114|AK114 administered by subcutaneous injection
45507745|NCT01363973|Device|VITALSTIM transcutaneous electrical stimulation|
45507746|NCT02135822|Drug|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
45507747|NCT02135822|Drug|gemcitabine|Gemcitabine is given intravenously at 1000 mg/m2 on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
45849881|NCT03915678|Drug|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
45507748|NCT05534893|Dietary Supplement|Blueberry powder group|Participants in the blueberry powder group will receive freeze dried blueberries in form of a powder
45697835|NCT04018053|Drug|18F-fluciclovine|18F-fluciclovine is a new radiotracer. This radiotracer targets amino-acid transporters, which are overexpressed in multiple cancers.
45697836|NCT04018053|Device|PET/CT|Positron emission tomography/computed tomography (PET/CT) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions.
45697837|NCT04392375|Drug|Nifedipine 30 MG|Nifedipine XL is a long-acting medication used to lower blood pressure. The investigators want to learn whether women who receive the study drug will experience fewer severe-range blood pressure readings, and therefore need fewer intravenous (IV) medications to safely lower blood pressure.
45399544|NCT05185882|Other|Single leg squat|Single leg squat exercise in different circumstances
45399545|NCT04713124|Behavioral|R2C-M|R2C-M comprises 12 modules addressing core practice elements and skills from evidence-based cognitive and behavioural interventions. Modules include: (i) self-monitoring, goal setting and behaviour change skills; (ii) identification of strengths and motivational enhancement; (iii) relapse prevention; (iv) psychoeducation and harm reduction; (v) emotion regulation skills; (vi) anger management skills; (vii) urges and cravings management skills; (viii) sleep hygiene skills; (ix) mindfulness skills; (x) interpersonal skills; (xi) anxiety management skills; (xii) depressed mood management skills. The R2C-M workbooks contain psychoeducation and intervention exercises, to facilitate counsellor-delivered exercises within sessions, and between-session practice.
45399546|NCT04713124|Other|Self-help booklet|A booklet of information and self-help strategies for methamphetamine use problems.
45399547|NCT04709692|Drug|(+)-SJ000557733 (SJ733)|Anti-Malarial
45507749|NCT05534893|Dietary Supplement|Placebo powder group|Participants in the placebo powder group will receive an isocaloric placebo powder
45507750|NCT02238210|Drug|Atrovent®|
45507751|NCT05739955|Other|Sani24|24-hour continuously acting quaternary ammonium salt disinfectant
45507752|NCT05739955|Other|Standard EPA-registered disinfectant|Standard EPA-registered disinfectant
45507753|NCT05739955|Other|Routine Disinfection|Routine disinfection at the study hospital
45507754|NCT02978456|Device|quantitative coronary angiography guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent|In the quantitative coronary angiography-guided group, sirolimus-eluting Orsiro/Orsiro mission stent size and length is chosen to cover the entire length of the culprit lesions according to quantitative coronary angiography measurements. Selection of the sirolimus-eluting Orsiro/Orsiro mission stent size should be guided by both quantitative coronary angiography measurement and visual estimate, and is recommended to be based on distal reference vessel diameter by quantitative coronary angiography (distal reference vessel diameter by quantitative coronary angiography plus ~10% of distal reference vessel diameter).
45697838|NCT04392375|Drug|Placebos|At the time of enrollment, patients will be randomized to either the study drug (oral Nifedipine XL 30mg) or identical placebo.
45399548|NCT04678726|Diagnostic Test|Lung ultrasound assessment for ruling out pneumothorax|Patients who have undergone heart surgery and have decided to enroll in our study, will have the standard chest x-ray and an additional lung ultrasound. Within a maximum of two hours of the chest tube removal, the standard chest x-ray will be performed, and then a different nurse will perform the lung ultrasound to check for pneumothorax.
45399549|NCT01236586|Drug|RO4929097|
45399550|NCT01236586|Drug|Dexamethasone|
45507755|NCT02978456|Device|intravascular ultrasound guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent|In the intravascular ultrasound -guided group, sirolimus-eluting Orsiro/Orsiro mission stent size and length is selected by intravascular ultrasound measurements.
45507756|NCT03598686|Diagnostic Test|OraQuick|Most trials assessing oral HIVST make use of OraQuick® (OraQuick ADVANCE HIV I/II test kits, packaged for self-use), an oral-fluid rapid self-test. OraQuick® is a 2nd generation serology assay with a sensitivity of 99.3% (95%CI; 98.4%, 99.7%) and a specificity of 99.8% (95%CI; 99.6%, 99.9%). In a pilot study with 59 participants conducted in Lesotho in 2015 more than 90% of the participants found utilization of OraQuick® easy, and trusted the results of the self-test kit. The WHO recently has announced that OraQuick becomes the first prequalified HIV self-test, in order to improve diagnosis in low-resourced health systems and in countries where stigma prevents people from getting tested. Therefore, OraQuick® is now available in Lesotho for as little as 2 USD per test kit.
45507757|NCT05736913|Biological|ID BNT162b2 vaccine|intradermal BNT162b2 vaccine
45507758|NCT05736913|Biological|IM BNT162b2 vaccine|intramuscular BNT162b2 vaccine
45507759|NCT03598452|Drug|Ganciclovir|Intravitreal Injection of Ganciclovir (IVG) was conducted in a week interval. The initial dose was 6mg/0.1ml at the first injection and it was reduced to 4.5mg/0.1ml at the second time; 3mg/0.1ml of IVG was maintained until the CMV could not be detected in aqueous humor.
45399551|NCT03559270|Drug|Baricitinib|Administered orally
45507760|NCT03549182|Drug|ATD treatment|oral administration of ATD (100g)(Acute Tryptophan Depletion)
45507761|NCT03549182|Drug|placebo treatment|oral administration of placebo (102.3g)
45697839|NCT03015454|Other|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
45697840|NCT03015454|Other|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the UCSF electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
45697841|NCT04760379|Other|Conventional therapy|Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
45697842|NCT04760379|Other|vibration therapy|Focal muscle vibrator (120 Hz) for 10 minutes on paraspinal muscles. Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
45399552|NCT05136586|Other|Biofeedback|"6 minutes of relaxing breathing exercise coupled with hert rate variability biofeedback guided on eMWave Pro software on a computer just before entering the examination circuit.~After the circuit, 6 minutes of free activity where the participants will not be given any instruction."
45399553|NCT05136586|Other|Meditation|"6 minutes of listening an audio tape made for the study that inspire mindfulness like meditation associated with psychological stimulation (positive encouragement) just before entering the examination circuit.~After the circuit, 6 minutes of free activity where the participants will not be given any instructions."
45399554|NCT05136586|Other|Control and biofeedback post OSCE|"6 minutes of standardised neutral video on general topics that generates no modification of affects just before entering the examination circuit.~After the circuit, 6 minutes of relaxing breathing exercise coupled with hert rate variability biofeedback guided on eMWave Pro software on a computer"
45399555|NCT05136586|Other|Control and control post OSCE|"6 minutes of standardised neutral video on general topics that generates no modification of affects just before entering the examination circuit.~After the circuit, 6 minutes of of free activity where the participants will not be given any instruction."
45399556|NCT01234792|Drug|6 mg Experimental nicotine gum|A single 6 mg dose of an experimental nicotine gum, with a 36-hour washout between visits
45507762|NCT05736055|Diagnostic Test|Cambodia Version Five Minutes Hearing Test|The FMHT was developed by American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). The FMHT is composed of 15 questions. Each answer is scored as 0, 1, 2 or 3 according to the frequency of experience. If they answered 'never', the score was 0. The answer 'occasionally' scored 1, the answer 'half the time' scored 2, and the answer 'almost always' scored 3. Furthermore, it has shown more aspects, more reliability, and more assessments of the hearing impairment of the patients. is a standard hearing questionnaire. So, we plan to translate the FMHT into Cambodian language and validate by comparing its result with those of audiometry.
45399557|NCT01234792|Drug|4 mg Nicotine Gum/|A single 4 mg dose of Nicorette® gum, with a 36-hour washout between visits
45399558|NCT01234792|Drug|2 mg Nicotine Gum|A single 2 mg dose of Nicorette® gum, with a 36-hour washout between visits
45399559|NCT03513328|Drug|Thiotepa--single daily dose|Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.
45399560|NCT03513328|Drug|Thiotepa--escalated dose|Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.
45399561|NCT01143220|Other|No specific interventions|Observational investigation, only procedures according to local hospital standard.
45399562|NCT03467932|Drug|Cohort A: ORMD-0801|"Part 1 In the first two weeks of active treatment (Part 1) subjects will receive double-blind therapy according to their randomized regimen (placebo or ORMD-0801) to be taken QHS, BID or TID. Subjects will undergo a step-wise dose escalation from a starting dose of 16 mg (Visit 3), to 24 mg (Visit 4), to a top dose of 32 mg (Visit 5 onward). Subjects will then enter Part 2.~Part 2:~During Part 2, subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia."
45399563|NCT03467932|Drug|Placebo oral capsule|Placebo provided QHS, BID, TID
45399564|NCT03467932|Drug|Cohort B: ORMD-0801|"Part 1 In the first two weeks of active treatment, subjects will receive double-blind therapy according to their randomized regimen (ORMD 0801 8 mg or 16 mg, or matched placebo) to be taken QHS or BID. Subjects will then enter Part 2 at the same dose and regimen administered in Part 1.~Part 2 Subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia."
45507763|NCT03598296|Other|Large size tube|Patients in Group A are inserted the large size tube (28F).
45507764|NCT03598296|Other|Drainage ball|Patients in Group B are inserted the small-bore tube connects with a negative pressure ball(drainage ball).
45399565|NCT05109052|Drug|PXS-5505 and Atezolizumab and Bevacizumab|Open label safety and tolerability assessment of PXS-5505 incorporating first-line combination therapy Atezolizumab and Bevacizumab
45399566|NCT05098444|Behavioral|Cognitive behavioral psychotherapy|Internet-based Cognitive Behavioural Therapy aims to reduce the impairment due to endometriosis by using cognitive behavioural intervention techniques. Furthermore, therapy should enable the patients in coping with symptoms in the future.
45507765|NCT05501834|Other|Supracondylar Pin Removal Before Imaging|Patients in the treatment group will: 1. Go to cast room for cast removal, 2. Have pins immediately pulled after cast removal, 3. Go to radiology for X-ray, 4. Will be seen in clinic room by provider. The order of these steps differs from our current standard of care, during which patients' pins are removed following cast removal and x-ray imaging.
45507766|NCT03549026|Drug|Duloxetine|The investigator will give the patients duloxetine capsule 60 mg orally before operation (skin incision) and anesthetize them with general anesthesia, then the investigator will test the postoperative analgesic efficacy in the form of 24 h analgesic consumption
45507767|NCT03549026|Drug|placebo|Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg
45507768|NCT03101371|Drug|Catheter insertion with Povidone Iodine|The catheter will be treated with Povidone Iodine prior to insertion.
45507769|NCT03101371|Procedure|Standard of care catheter insertion|Catheter inserted right out of package.
45507770|NCT03588078|Drug|APR-246|Azacitidine at maximum tolerated dose. APR246 at the Dose limited Toxicity (DLT) dose
45507771|NCT03588078|Drug|Azacitidine|azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m2
45697843|NCT03014908|Other|Blood sampling|Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
45849882|NCT03915678|Drug|Association atezolizumab + BDB001+ RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
45697844|NCT01054768|Drug|alpha-lipoic acid and acetyl-L-carnitine|none to report
45399567|NCT05098444|Other|Waiting list|Participants of the waiting list receive no treatment for 5 months. Afterwards they receive the same treatment as the experimental group.
45399568|NCT01234012|Biological|IMF-001|subcutaneous injection of fixed dose IMF-001 (100 or 200 mcg) every 2 weeks.
45697845|NCT01054768|Drug|Control|none to report
45697846|NCT04387617|Drug|Cannabidiol|The product is a liquid formulation that will be prescribed at a dosage of 20 mg per day for a total of 3 days.
45697847|NCT04387617|Drug|Placebo|The product is a liquid formulation placebo that will be prescribed at an equivalent volume as active drug for 3 days
45697848|NCT03014830|Drug|Alirocumab|150 mg SQ every 2 weeks
45697849|NCT03014830|Drug|Placebos|Placebo injections SQ every 2 weeks
45507772|NCT02238366|Drug|triptorelin|This is an observational study. Thus, the treatment selection with triptorelin (Diphereline® or Diphereline PR®) is at investigator's discretion based on the current practice principles and guidelines/protocols, in accordance with the Summary of Product Characteristics (SmPC) approved in Romania by the National Medicines Agency.
45507773|NCT05494190|Drug|Docetaxel|60 mg/m2 i.v. day 1
45507774|NCT05494190|Drug|Cisplatin|60 mg/m2 i.v. day 1-3
45507775|NCT05494190|Drug|Capecitabine|750 mg/m2 po bid day 1-14
45507776|NCT05494190|Radiation|Concomitant chemoradiotherapy|"Radiotherapy: using intensity-modulated radiation therapy (IMRT)~Gross tumor volume (GTV) for primary tumor: 66-70 Gy in total, 2.0~2.2 Gy per day, 5 days per week~Clinical target volume (CTV) for lesions closely related to the primary lesion and metastatic lymph nodes: 65~70 Gy in total, 1.7~2.0 Gy per day, 5 days per week~Prophylactic irradiation for sites of suspected subclinical spread: 50~60 Gy in total, 1.7~2.0 Gy per day, 5 days per week~Concurrent chemotherapy: cisplatin 80 mg/m2 on days 1-3 every 3 weeks."
45697850|NCT05237193|Diagnostic Test|The level of CIN|The extracted DNA from bile will be analyzed by UCAD to determine the level of CIN. And the patient will be followed for up to 2 years.
45697851|NCT04527406|Procedure|posterior hemivertebra resection|The subjects in early surgical group are arranged to be admitted to for surgical treatment very soon. The operation choice is posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
45399569|NCT01236664|Behavioral|Memory training|The Memory at Work program is a 4-hour classroom-based workshop that is led by a professional trainer. The format of the program is experiential, with a heavy focus on discussion, self-discovery, and hands-on use of trained skills. Specific memory compensation techniques are trained. Training consists of an explanation of each technique (i.e., how and when to use it, the science behind the technique) and ample opportunities for hands-on use of the strategies.
45399570|NCT01236664|Behavioral|Control Workshop|The control workshop consists of a 4-hour program that will train techniques for successfully completing Sudoku, word, and logic puzzles. Like the experimental intervention, the control workshop will be engaging and challenging, and will involve a combination of individual and group activities.
45399571|NCT01143298|Drug|LEO 27847 oral solution|
45399572|NCT01143376|Behavioral|High intensity training|high-intensity intermittent sprinting (HIIS) (8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
45399573|NCT01143376|Behavioral|short springs|short duration sprints (SDS)(8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
45697852|NCT04527406|Procedure|conservative treatment+ delayed posterior hemivertebra resection|In traditional surgical group, subjects received conservative treatment firstly with custom-made braces to delay the progression of scoliosis. It is planned to use the classic posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction to complete the correction around the age of 5. The operation choice is identical with early surgical group. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
45697853|NCT03984669|Diagnostic Test|The Juvenile Disease Activity Score (JADAS)|The JADAS includes the following four measures: physician's global assessment of disease activity, measured on a 0-10 visual analog scale (VAS) where 0 = no activity and 10 = maximum activity; parent global assessment of well-being, measured on a 0-10 VAS where 0 = very well and 10 = very poor; the erythrocyte sedimentation rate (ESR), normalized to a 0 to 10 scale; and a count of joints with active disease.
45399574|NCT01143376|Behavioral|Moderate intensity exercise|
45399575|NCT03318172|Device|Spinal Cord Stimulator|Implantation of spinal cord stimulator in patients included in the study and divided in conventional and high density stimulation groups
45399576|NCT04618822|Behavioral|Teaching involving whole-body movements|The intervention consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in small groups of six children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities involve whole-body movements and have been developed with the embodied learning theory in mind, linking movement closely to the learning content.
45507777|NCT05494190|Procedure|Surgery|Neck dissection and primary tumor resection
45507778|NCT03582540|Procedure|Double-guidewire cannulation technique|With the DGT, a guidewire is first inserted deep into the PD. The cannulation device is then withdrawn, reloaded with a second guidewire, and reinserted through the working channel of the endoscope to cannulate the common bile duct.
45507779|NCT05360095|Behavioral|Meaning of Screening|The Meaning of Screening game is a decision making tool that is accessible through the most common web platforms. Users have the ability to explore learn about prenatal screening through multiple approaches, including presentation of facts, personal stories, and values clarification. Users will access the game from their personal phone or computer prior to completing prenatal screening.
45507780|NCT05360095|Behavioral|Genetic Counseling|This intervention consists of a 45-minute prenatal screening genetic counseling session (in person or online) completed after confirmation of pregnancy and before actual screening.
45507781|NCT05360095|Behavioral|Usual Care|Participants in the Usual Care group will receive the brochure-based education about prenatal screening that is currently recommended by American College of Obstetrics and Gynecology (ACOG), delivered in an electronic format so they can read it before they complete prenatal screening.
45507782|NCT03548480|Dietary Supplement|Placebo|Intervention with a daily dose of placebo
45507783|NCT03548480|Dietary Supplement|Probiotic|Intervention with a daily dose of probiotic
45507784|NCT03587766|Drug|Fexinidazole|Drug: fexinidazole (FEXI)
45507785|NCT03587766|Drug|Placebo Oral Tablet|Drug: fexinidazole
45507786|NCT03734185|Other|Learning and Coping|'Experienced patients' plan, teach and evaluate, in cooperation with health professionals.
45507787|NCT03548402|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT is based on the theory that rigid attempts to control internal states, thoughts and feelings, and other forms of experiential avoidance contribute to symptom development and maintenance of anxiety and self-injury.
45507788|NCT05485610|Dietary Supplement|NMN intervention|NMN capsules (total of 600mg/day) for 3 months
45507789|NCT05485610|Other|Placebo|NMN-free placebo capsules for 3 months
45507790|NCT02850276|Drug|Pyridostigmine|
45507791|NCT05578040|Procedure|Auricular acupressure|To conduct this intervention, we used adhesive patches without Vaccaria seed to sham auricular acupressure at the cervical vertebra acupoint in the first trial phase and auricular acupressure at the cervical vertebra acupoint in the other two trial phases in 2 groups of auricular acupressure acupoints of the left and right cervical vertebra.
45507792|NCT03882372|Device|Nasal high flow|See arm description.
45507793|NCT05418517|Procedure|Tracheostomy|temporary tracheostomy insertion
45507794|NCT05418517|Procedure|Overnight intubation|Patient who had overnight intubation
45507795|NCT03592134|Other|esophageal pressure measurement|Measurement of esophageal pressure to determine the optimal non invasive respiratory support
45507796|NCT05577962|Drug|T group|OFA scheme (group T) was given dexamethasone 8mg for anti-inflammatory and antiemetic before operation, flurbiprofen axetil 50mg for preemptive analgesia, and dexmedetomidine was infused under ECG monitoring at an initial rate of 0.5 μ G/kg (more than 10min), then changed to 0.2ug/kg/h, and stopped infusion 20 minutes before operation closure. Before induction, lidocaine (1mg/kg), esketamine (0.5mg/kg), propofol (1-2mg/kg) and rocuronium (0.6mg/kg) were infused slowly, and endotracheal intubation was carried out when the anesthetic was fully effective and the BIS value was about 40. After successful intubation, an experienced anesthesiologist guided by ultrasound performed bilateral superficial cervical plexus block with 0.5% ropivacaine and injected 3-4ml at two points respectively; During the operation, sevoflurane (MAC1.0 - 1.4) was used to maintain the depth of anesthesia
45507797|NCT04961593|Drug|Caspofungin|For children 3 months of age, the recommended dose is 70 mg/m2 for load and then 50 mg/m2 for maintenance, intravenous injection, once daily up to 5 days.
45507798|NCT05577884|Diagnostic Test|noncontrast-enhanced whole-body CT|"noncontrast-enhanced low-dose whole-body CT using dual-source CT scanner using A-tube (75% radiation) and B-tube (25% radiation).~conventional low-dose CT data (A +B tubes, 100% dose) are reconstructed with iterative reconstruction~ultra-low dose CT data (B-tube only, 25% dose) are reconstructed with deep learning commercially available software."
45507799|NCT03862170|Drug|Ciprofloxacin|Ciprofloxacin 400 mg IV 120mn before HDR brachytherapy
45507800|NCT03862170|Drug|Cefazolin|
45697854|NCT03984669|Biological|(1-3)-ß-D-Glucan (BDG) assay (Fungitell)|Evaluation of the (1,3)-Beta-D-Glucans level in patients with JIA and correlation of the higher serum BDG levels with JIA activity of disease, comparatively with usual markers
45399577|NCT04618822|Behavioral|Teaching involving hand movements|The intervention consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in small groups of six children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities involve movements using hands and arms and have been developed with the embodied learning theory in mind, linking movement closely to the learning content.
45507801|NCT02140580|Device|Minimally invasive surfactant therapy|Active Comparator
45507802|NCT02140580|Other|Continuation on CPAP|Sham Comparator
45697855|NCT04277403|Radiation|Hippocampal Avoiding Whole Brain Radiation Therapy with Simultaneous Integrated Boost|Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a prescribed dose of 30Gy in 12 fractions, 2.5Gy per fraction and a simultaneously integrated boost (SIB) to each brain metastasis of 51Gy to 95% of PTV in 12 Fractions, 4.25Gy per fraction.
45697856|NCT04277403|Radiation|Single session or hypofractionated stereotactic radiosurgery|Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases. Single session SRS will be delivered in 18 to 22Gy to the tumour encompassing 80% Isodose. Hypofractionated stereotactic radiosurgery (HfSRS) will be delivered in 5 sessions of 6Gy each to the tumour encompassing 80% isodose.
45399578|NCT04618822|Behavioral|Teaching involving minimal motor movements (control)|The control condition consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in groups of app. twelve children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities are completed seated on a chair using paper and pencil.
45399579|NCT04595968|Device|Vestal DM Active device|Battery powered non-invasive neurostimulation device
45399580|NCT04595968|Behavioral|Lifestyle modification|Subjects are prescribed a low calorie (500kcal deficit) diet if their BMI is ≥25. If a subject has a BMI of ≤24.9, they will be provided with guidance on ensuring their recommended daily dietary intake is achieved throughout the course of the trial (i.e 2,500kcal/day for men and 2,000kcal/day for women)
45507803|NCT04955431|Behavioral|Sleep Restriction|Participants will be allowed ~4 hour sleep opportunity during the restricted night of sleep prior to reporting to lab for a simulated firefighting session.
45507804|NCT04955431|Behavioral|Normal Sleep|Participants will be allowed ~8 hour sleep opportunity the night of sleep prior to reporting to lab for a simulated firefighting session.
45399581|NCT04595968|Device|Vestal DM Sham device|Placebo comparator sham device (no active stimulation)
45849883|NCT03915678|Drug|Association atezolizumab + BDB001+ RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
45507805|NCT05577806|Drug|Dydrogesterone|progestin primed ovarian stimulation
45399582|NCT01139788|Drug|LY2624587|"6-900 mg, administered intravenously, weekly for a minimum of one (1) 28 day cycle.~If patients are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
45399583|NCT03250390|Device|Collection of volatile organic compounds during exhalation|"The volatile organic compounds (VOCs) are collected in sorbents at rest and at the end of exhalation according to the concentration of carbon dioxide using ReCIVA breath sampler.~The identification of the VOCs will be done by chromatography (Gas Chromatography Mass Spectrometry GC-MS)"
45399584|NCT01139944|Genetic|DNA methylation analysis|
45399585|NCT01139944|Genetic|polymerase chain reaction|
45399586|NCT01139944|Other|laboratory biomarker analysis|
45399587|NCT05632666|Other|Inspiratory and expiratory muscle training at a therapeutic intensity|"The active treatment group will receive inspiratory muscle training starting at a therapeutic intensity of 30% of maximum inspiratory mouth pressure (PImax) and expiratory muscle training starting at a therapeutic intensity of 30% of maximum expiratory mouth pressure (PEmax) for 4 months.~In the active treatment group, the inspiratory and expiratory threshold (intensity) will be adjusted to the perceived exertion (measured with a Borg scale)."
45399588|NCT05632666|Other|Inspiratory and expiratory muscle training at a non-therapeutic intensity|The sham-control group will receive the same training protocol as the active treatment group but with a low (10% of PImax and PEmax) and stable non-therapeutic intensity.
45399589|NCT03199612|Drug|Sildenafil|To conduct a randomized placebo controlled study to test the hypothesis that platelet activation and aggregation during ongoing low level hemolysis in outpatients on chronic CF pump support can be reduced by sildenafil.
45399590|NCT03199612|Drug|Placebo Oral Tablet|Negative control to understand the potential changes in platelet activation adn aggregation in comparison to sildenafil.
45399591|NCT05043454|Other|High Intensity Interval Training (HIIT) Exercise|Participants will exercise 4 days/week for 10 weeks using the High Intensity Interval Training (HIIT) protocol. Sessions can be conducted at home or at a gym with access to a cycle ergometer. Participants will undergo 2 supervised training sessions to learn the HIIT protocol. To record heart rate, session duration, and time at each exercise intensity, participants will be provided with an H10 Polar TM heart rate chest strap monitor and a Polar Beat/Polar Flow account. Participants will download the Polar Beat/Flow smart phone application to record exercise sessions and allow the researcher to conduct remote data monitoring. Research staff will contact participants twice per week to provide feedback.
45399592|NCT01140022|Other|CT Screening|Patients will use a kiosk module that will provide information about CT screening and assess their risk for CT. Patients choosing to get a CT screening will receive a printout instructing the provider or nurse to collect a urine sample for CT screening.
45399593|NCT01140100|Drug|propofol|
45399594|NCT01140100|Drug|thiopental,propofol|
45399595|NCT01141036|Drug|propofol|Propofol will be initiated with a 30-50 mg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
45399596|NCT01141036|Drug|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
45399597|NCT01235026|Dietary Supplement|Synbiotic|"5g of the prebiotic Oligofructose + 1 g of the probiotic Bifidobacterium animalis subsp. lactis Bb12 (4x10^10 CFU/g), twice a day, for 6 weeks."
45399598|NCT01235026|Dietary Supplement|Placebo|6g of maltodextrin, twice a day for 6 weeks.
45399599|NCT01141114|Other|Patient navigation|Letter and Colorectal Cancer Screening Brochure mailed to patients. Telephone outreach by Patient Navigators.
45399600|NCT01141114|Other|Usual care|Usual care
45507806|NCT03591432|Device|Transnasal humidified rapid insufflation ventilatory exchange (THRIVE)|Transnasal humidified rapid insufflation ventilatory exchange (THRIVE) is a new technique that is available for use in critically ill patients and in patients with difficult airways. The technique combines the benefits of apneic oxygenation and CPAP with a reduction in CO2 levels through gaseous mixing and flushing of the dead space. THRIVE is administered through a standard, commercially available, nasal, high-flow oxygen delivery system. Insufflation of O2 up to 70 L/min via a purpose-made nasal cannula is used initially to provide preoxygenation, which can be continued during intravenous induction until a definitive airway is secured. The THRIVE technique has been demonstrated to appreciably prolong the safe duration of apnea while avoiding increase in CO2.
45697857|NCT03014596|Other|Assert|The Assert-method is a counselling method used to assess and systematically follow up the individual adolescents' perceived needs.
45399601|NCT04978090|Device|3D printed EAF management device|Participants will receive a customized 3D printed device based on the EAF's output, size, shape, location, depth, and the participant's wound bed.
45399602|NCT04977856|Behavioral|Behavioral activation (BA)|The main goal of the BA is to increase engagement in values-based activities and decrease avoidant behaviors that serve to maintain depression. The adolescent will learn about depression, how behavioral activations works, monitor their own activities, plan and do more values-based activities and deal with obstacles to getting in touch with positive reinforcement, such as avoidance behaviors.
45399603|NCT04977856|Other|Regular care within primary or secondary mental health care for children|Regular care (supportive therapy, waitlist, psychological treatments, drugs, or a combination of different interventions)
45399604|NCT04971850|Other|Sleep study|"Procedures added by research during PSG :~SDB screening questionnaires~Electromyography (EMG) of accessory and abdominal muscles~Cerebral oxygenation~Mandibular movements~Sleep headband (pre-teens and teens) or other connected device~Automatic PSG analyzes~Psychological and neuropsychological assessment The recordings of the study will be repeated at one year if the patient needs a treatment (surgery or noninvasive ventilation) following the results of the PSG."
45399605|NCT04948060|Other|Enhanced lung cancer screening services|A theoretically sound and evidence-based, multi-component implementation strategy will be applied which includes care quality benchmarking and regular performance feedback, academic detailing provided by specially trained primary care clinicians, practice facilitation provided by trained and certified Practice Facilitators (PFs), health information technology (HIT) support, and facilitated professional networking to promote the cross-pollination and rapid dissemination of solutions and best practices in primary care settings
45399606|NCT04936594|Device|iTBS|1800 pulses of iTBS
45399607|NCT04936594|Device|Sham TMS|Sham TMS
45399608|NCT04917406|Drug|Application of lidocaine together with dexamethasone|Lidocaine 2% is applied on the positive pole while dexamethasone 4 mg/ml is applied on the negative pole. Through the use of current the drugs penetrate the fascia.
45399609|NCT04917406|Device|Application of ultrasound as physical therapy|The application dose will be 0.65 Watt for 7 minutes in the area of most painful affectation by means of a circular movement and a 1MZ head.
45399610|NCT01140178|Drug|HPPH|Given IV
45399611|NCT01235104|Procedure|Total nephrectomy|Total nephrectomy
45399612|NCT01236898|Drug|NPC-09|NPC-09 tablet NPC-09 contains 50mg or 100mg N-acetylneuraminic acid (anhydride)
45399613|NCT02685826|Drug|Durvalumab|single use vials administered via intravenous infusion
45399614|NCT02685826|Drug|Lenalidomide|capsules for oral administration
45399615|NCT02685826|Drug|Dexamethasone|tablets for oral administration
45399616|NCT04906720|Drug|Colchicine|colchicine 0.6mg oral twice daily for 7 days
45399617|NCT01140334|Behavioral|Voucher Reinforcement|Patients in this condition will be able to earn a voucher for each week that they have attended all scheduled psychiatric sessions. These sessions may include individual therapy appointments, group therapy appointments, or psychiatrist appointments. Each voucher will be worth $25, and can be exchanged for goods and services that will be purchased by a research assistant. The maximum amount of voucher earnings over the study is $300.
45399618|NCT01140334|Behavioral|Standard Control|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week. No voucher incentive will be offered in this condition.
45399619|NCT01141192|Dietary Supplement|vitamin D3, cholecalciferol|1 gelcap of 50,000 IU vitamin D3 plus 2 gelcaps of 5,000 IU vitamin D3 each; a total of 60,000 IU vitamin D3 dosed four weeks apart at weeks 0, 4, 8, and 12 of the 16 week study.
45507807|NCT03591432|Device|Facemask ventilation|Nowadays pre-oxygenation is usually achieved using oxygen delivered via a facemask before induction of anaesthesia; this potentially extends the time available for securing the airway before hypoxaemia to 6 min. In patients undergoing elective surgery, the lungs are normally ventilated with a bag/facemask technique after induction, and this can be repeated if attempts at intubating the trachea are prolonged.
45849884|NCT03915678|Drug|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
45399620|NCT01141192|Dietary Supplement|Inactive comparator|The inactive comparator dose provided was identical in appearance to the active comparator but contained no vitamin D3
45399621|NCT01144000|Drug|Daptomycin|10mg/kg/24h i.v.(intravenous) for 2-3 weeks with/or without rifampin (depending if the prosthesis is removed or not)
45399622|NCT01144078|Behavioral|Traditional Intensity Exercise|The exercise intensity will be set at a workload corresponding to 40% of the workload obtained at VO2peak during the baseline progressive maximal exercise tests. Based on the anticipated fitness of the participants this should to an intensity of about 3.5 METs, which is similar to walking at a moderate pace.
45399623|NCT01144078|Behavioral|High Intensity Interval Exercise|The High Intensity Interval Exercise intervention will replicate all aspects of the Traditional Intensity Exercise with the exception of exercise intensity. The High Intensity Interval Exercise protocol will involve alternating between 1-minute intervals at 100% workload obtained at VO2peak followed by 3-minute recovery intervals at 20% of workload obtained at VO2peak (average = 40% ). As many complete intervals as possible will be completed during a training session (e.g., 7 intervals can be completed in a 30 min period (7 x 4 min = 28 min), with the remaining time spent at 40% peak workload to ensure a similar work output as the Traditional Intensity Exercise.
45507808|NCT03547388|Device|Moderate whole body hyperthermia using water-filtered IR-A-radiation|four to six applications of whole Body hyperthermia concomitant to radiochemotherapy. Additional measurement of Perfusion and hypoxia by 18F-FMISO hypoxia PET and magnetic resonance Imaging
45399624|NCT01140412|Drug|Maraviroc|maraviroc 300 mg BID x 5 days
45399625|NCT01140412|Drug|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg BID x 10 days
45399626|NCT01140412|Drug|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
45399627|NCT01140412|Drug|Maraviroc|maraviroc 300 mg QD x 5 days
45507809|NCT03591276|Drug|Chemotherapy Drugs, Cancer|IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 (chemotherapy drugs) every 3 weeks in eligible breast cancer patients.
45507810|NCT03582384|Drug|Tocofersolan|After baseline labs are obtained, therapy with tocofersolan will be initiated at an initial dose of 17 mg/kg of d-alpha-tocopherol in the form of tocofersolan (0.34 ml/kg/day) and titrated based on blood levels.
45399628|NCT01140412|Drug|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 1400/100 mg QD x 10 days
45399629|NCT01140412|Drug|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
45399630|NCT02615860|Other|Topical 85% trichloroacetic acid (TCA)|In the experimental intervention arm, all visible lesions are treated with 85% TCA by dipping the wooden stick end of a cotton swab into a cup containing TCA. The stick end is saturated with TCA and is inserted through the anoscope and directed to the lesion under HRA guidance. TCA is applied to the lesion repeatedly until the lesion changes to a dense white colour. Each TCA application session is followed by another appointment four weeks later, where the clinician re-evaluates the lesions of the patient and determines whether a next TCA application is necessary up to a maximum of four times
45399631|NCT02615860|Procedure|Surgical electrocautery (ECA)|In the control arm, HRA-guided ECA, is performed every 4 weeks up to a maximum of four times. All visible lesions are ablated at every visit. Bleeding from small vessels can be stopped by ECA. Patients undergo local anaesthesia if necessary
45507811|NCT03783468|Other|decrease of sedation doses and switch of ventilator settings|tapering sedation doses (propofol) switch from assisted ventilation to pressure support ventilation
45507812|NCT05465876|Biological|EVUSHELD|EVUSHELD is a combination of 2 monoclonal antibodies (mAbs), Tixagevimab and Cilgavimab. The single dose, is to be administered intramuscular, each mAb sequentially into the deltoid
45507813|NCT03854526|Other|Evaluation of the quality of direct and indirect partial dental coronal restorations in adults|"The medical and dental anamnesis are registered. In addition to the medical history questionnaire, the patient completes the self-assessment questionnaire on oral health. Then, a complete and intra-oral clinical examination is performed. The collection of clinical data is done on the dentist's chair. All data are included in the e-CRF.~All radiographic procedures will be performed according to national guidelines. If the investigator deems it clinically necessary, a panoramic X-ray will be taken and stored in the patient's HER system. Periapical radiographs (using a parallelogram technique with a radiographic film holder) will be taken for teeth with periapical radiolucency on panoramic X-ray, or with defective coronal restoration, or when the clinician needs more information for diagnosis or planning."
45507814|NCT05577728|Drug|New use of semaglutide injection|New use of semaglutide injection dispensing claim is used as the exposure.
45507815|NCT05577728|Drug|"New initiation of standard of care (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)"|"New initiation of standard of care (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral) dispensing claim is used as the reference."
45399632|NCT01234324|Drug|Epirubicin, Cisplatin, Capecitabine, Panitumumab|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle; Panitumumab: 9 mg/kg bodyweight, administered IV by an infusion pump through a peripheral line or catheter over 60 min +-15 min on day 1 of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
45507816|NCT04928287|Biological|HB-adMSCs|HB-adMSCs will be administered intravenously to study participants who qualify.
45507817|NCT04928287|Other|Placebo|Placebo will be administered intravenously to study participants who qualify.
45507818|NCT03590964|Procedure|Open sinus lift using chin bone graft|Patients with atrophied posterior maxilla will undergo open sinus lift with chin bone graft according to standardized surgical approach.
45507819|NCT03590964|Procedure|Sinus lift using bone ring containing the implant.|Patients with atrophied posterior maxilla will undergo sinus lift with chin bone ring containing the implant.
45849885|NCT03915678|Drug|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
45399633|NCT01234324|Drug|Epirubicin, Cisplatin, Capecitabine|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
45399634|NCT04885192|Other|Stepped-Care Model|"Step 0: Screening via Manage My Pain (MMP) App. Patients using MMP will be prompted to complete questionnaires on pain catastrophizing, depressive symptoms, anxiety, suicide risk and opioid risk. Those scoring above clinical risk cut-offs will be referred to Step 1.~Step 1: Acceptance and Commitment Therapy (ACT) Workshop. Patients will be offered a virtual ACT workshop focusing on practical coping skills for dealing with pain, emotional dysregulation, and disability, while maximizing functioning and quality of life with chronic pain. Thirty days later, patients will be prompted to complete all questionnaires through MMP again; those who score above clinical risk cut-offs will be referred to Step 2.~Step 2: Dialectic Behavior Therapy (DBT) group. A 6-week DBT-based skills group will cover topics such as self-compassion, radical acceptance, distress tolerance, and mindfulness, among others. Thirty days later, patients will be prompted to complete questionnaires through MMP."
45399635|NCT01236976|Device|Therastride Treadmill System|This device supports spinal cord injured patients to stand (suspended in a harness by an overhead pulley) on the specially designed treadmill for locomotor training. It is registered with the FDA (Regulation Number 890.5380).
45399636|NCT01236976|Device|FES-assisted cycling|This intervention will be provided using a RT300 cycle (Restorative Therapies, Baltimore MD).
45399637|NCT01236976|Other|Trunk and upper and lower limb exercises|This intervention will comprise assisted and/or resisted movements aimed at facilitating and strengthening voluntary muscle activity and improving movement quality.
45399638|NCT01236976|Other|Upper body strength and fitness program|This intervention is a circuit-based exercise program incorporating resistance and cardiovascular training.
45399639|NCT02334124|Other|Home|The main intervention is for children with uncomplicated cellulitis to remain at home throughout the period of intravenous treatment but as it is not feasible to administer flucloxacillin four times a day by the Hospital-In-The-Home team, once daily ceftriaxone is the most ideal antibiotic to be given to this group
45697858|NCT04365465|Device|NSS-2 Bridge|The NSS-2 BRIDGE (Appendix 1) is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs.
45399640|NCT02334124|Other|Ward|Admission to a hospital based ward
45399641|NCT02334124|Drug|ceftriaxone|50mg/kg once daily
45399642|NCT02334124|Drug|flucloxacillin|50mg/kg 6 hourly
45399643|NCT04884334|Device|VAC-Stent®|treatment with the VAC-Stent®
45697859|NCT04365465|Device|Inactive NSS-2 Bridge|This is a sham device which is identical to the active NSS-2 Bridge, but will not provide percutaneous auricular nerve field stimulation when applied.
45399644|NCT01140490|Procedure|Sub-total Parathyroidectomy|Sub-total Parathyroidectomy
45399645|NCT02528812|Device|TheraBand Roller Massager|The roller massager was moved proximal to distal at a slow pace (2 seconds up and 2 second downs) over the muscle belly. Participants in the Sham group received very light pain-free cutaneous strokes of rolling massage with the same pace of rolling as performed for the Ipsi-R and Contra-R groups. The Control group did not receive any treatment.
45507820|NCT03548948|Other|High heme iron diet|"A Typical American diet with high heme/non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
45697860|NCT04365465|Other|Active control|Active control will include standard of care pain management during the postoperative period. Participants in this intervention arm will not receive or wear a device.
45697861|NCT04398615|Device|Wearable watch device|Every study participant will be given a wearable watch device at the beginning of the study and will be instructed on how to use the device and to wear it continuously throughout the duration of the study (6 months total follow-up). The device will register biometric data and automatically archived. During the follow-up period both healthcare personnel and investigators will not be aware of data (including fall events) registered by the experimental device.
45697862|NCT01055704|Drug|Methylnaltrexone only|0.30 mg/kg subcutaneous injection daily
45399646|NCT02528812|Other|Manual Massage|A massage therapist massaged the participant
45399647|NCT01141270|Drug|AFOLIA|single sc injection, 225 IU
45399648|NCT01141270|Drug|Gonal-f|single sc injection, 225IU
45399649|NCT01141348|Behavioral|Special Intervention|16 week behavioral weight loss intervention included 2 hour weekly group sessions
45399650|NCT01141348|Behavioral|Delayed Intervention|During the randomized controlled trial, the Delayed Intervention (DI) group received two newsletters with study updates and general health information. Following the trial, the DI group received a 10-week weight loss program.
45399651|NCT01144156|Drug|Treatment with Adalimumab|All patients will receive SC adalimumab 160 mg at week 0, 80 mg at week 2 and 40 mg from week 4 every 2 weeks up to 12 weeks
45399652|NCT04860934|Behavioral|Dual Task Training Program Group|Fifteen patients will receive Dual Task Training Program. Total Period: 8 Weeks.
45697863|NCT01055704|Drug|Codeine only|30 mg taken orally four times daily for 5 days
45507821|NCT03548948|Other|Low iron diet|"A Typical American diet with low heme/non-heme iron (8 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
45507822|NCT03548948|Other|Plant-based high non-heme iron diet|"A plant-based diet with high non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
45507823|NCT04926337|Device|Tight Fitting Facemask|Preoxygenation with tight facemask, 10 L/min, 100% oxygen.
45399653|NCT04860934|Behavioral|Control Group|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks.
45399654|NCT01141504|Dietary Supplement|PeakATP 250|The nutritional intervention provides for oral ingestion of 250 mg PeakATP per day
45399655|NCT01141504|Dietary Supplement|Placebo|Placebo capsules that are comparable in size and color to the active comparator for blinding purposes
45399656|NCT01141504|Dietary Supplement|PeakATP 400|The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day
45399657|NCT01141504|Dietary Supplement|PeakATP 400 plus proprietary blend|The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day plus a proprietary blend of additional nutrients
45399658|NCT05632432|Procedure|Epicardial AAMs-patch transplantation|Perioperative assembly of an AAMs patch with epicardial transplantation at the end of CABG surgery
45399659|NCT05632432|Diagnostic Test|RNA-stabilized whole blood sampling|Collection (preoperative and at 6-month-follow-up) of TEMPUS(TM) stabilizing whole blood for epitranscriptomics-oriented measurements
45399660|NCT05632432|Diagnostic Test|Plasma sampling|Collection (preoperative and at 6-month follow-up) of blood-derived both RNA-stabilized and non-stabilized plasma aliquots for epitranscriptomic-oriented and other CVD biomarker oriented measurements, respectively
45399661|NCT05632432|Diagnostic Test|Transthoracic echocardiography|To assess cardiac structure and function both pre- and postoperatively (at both 3- and 6-month of follow-up)
45507824|NCT04926337|Device|High Flow Nasal Oxygen (HFNO)|Preoxygenation with high flow nasal oxygen, 40-70 L/min, 100% oxygen.
45507825|NCT02238444|Drug|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
45507826|NCT02238444|Drug|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
45507827|NCT02238444|Drug|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
45507828|NCT02238444|Drug|Low Molecular Weight Heparin|From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
45507829|NCT03638479|Other|Data Capture|This is no intervention. Participants of all groups will receive data Capture with smartphones, smartwatches and tablets.
45507830|NCT02783768|Device|E-cigarette|The study e-cigarette exposure will be 10 puffs with 30-second inter-puff intervals, as directly observed by a trained research assistant, using a standardized e-cigarette. Cartomizers, batteries, and e-liquids will be obtained from commercial suppliers. The e-cigarette device will be loaded with 1 mL of flavorless e-liquid with a ratio of PG to vegetable glycerin of 70:30 and 1.8 mg/dL of nicotine.
45697864|NCT01055704|Drug|Methylnaltrexone + codeine|Methylnaltrexone 0.30 mg/kg by subcutaneous injection once daily and codeine 30 mg taken orally four times daily for 5 days
45697865|NCT01055704|Drug|Placebo + placebo|Placebo subcutaneous injection once daily and placebo taken orally four times daily for 5 days
45697866|NCT03280017|Drug|Ketamine|intravenous ketamine 0.2 mg/kg/hr (concentration 1 mg/ml)
45697867|NCT03280017|Drug|Normal saline|normal saline infusion
45697868|NCT01882439|Drug|Tofacitinib|tablets, 5 mg BID x 6 months
45697869|NCT01882439|Drug|Tofacitinib|tablets, 10 mg BID x 6 months
45697870|NCT01882439|Other|Placebo|tablets, to match tofacitinib 5 mg BID x 3 months
45697871|NCT01882439|Drug|Tofacitinib|tablets, 5 mg BID x 3 months
45697872|NCT01882439|Other|Placebo|tablets, to match tofacitinib 10 mg BID x 3 months
45697873|NCT01882439|Drug|Tofacitinib|tablets, 10 mg BID x 3 months
45697874|NCT05236491|Biological|COVID-19 vaccine|Participants are to receive a booster dose of a COVID-19 vaccine.
45399662|NCT05632432|Diagnostic Test|Late-gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMRI)|To assess detailed cardiac structure (i.e. interstitial fibrosis) and function both preoperatively and at 6-month follow-up postoperatively.
45399663|NCT05632432|Other|Symptom-scaling|Standardised evaluation of IHD and HF-related angina pectoris (CCS) and dyspnea (NYHA) and life quality (RAND36) pre- and postoperatively (at both 3- and 6-month follow-up).
45399664|NCT05632432|Other|6-minute walking test (6MWT)|Standardised assessment of physcial capacity pre- and postoperatively (at 6-month follow-up)
45399665|NCT05632432|Diagnostic Test|Blood sampling (NT-proBNP)|Collection of a blood sample measurement of NT-proBNP by an accredited hospital laboratory pre- and postoperatively (at both 3- and 6-month follow-up).
45399666|NCT05632432|Diagnostic Test|Transesophageal echocardiography|Performed by the perfusion-anesthesiologist at the beginning of the CABG surgery to evaluate both LAA and RAA for blood flow velocities, anatomy, possible sludge and thrombus.
45399667|NCT01235260|Other|Becaplermin nonusers|A cohort of becaplermin nonusers (ie, patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)
45399668|NCT01235260|Drug|Becaplermin users|A cohort of becaplermin users (ie, patients with diabetes treated with becaplermin)
45399669|NCT05396950|Device|CPAP|CPAP in conjunction with radiotherapy
45399670|NCT01144858|Other|a complete transesophageal echocardiography|All patients were evaluated by a complete transesophageal echocardiography with multiplane probes with a 7-MHz transducer before catheter ablation .LA appendage flow was obtained by placing the pulsed Doppler sample volume at the orifice of the LA appendage, after which peak flow velocities were measured and averaged within each RR interval of 10 consecutive cardiac cycles
45399671|NCT01144234|Behavioral|Invitation letter for male spouse|In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit
45399672|NCT01144234|Behavioral|Information letter|In this arm the pregnant women got an information letter
45399673|NCT01144312|Drug|Fentanyl|an initial intravenous bolus of fentanyl 100 μg and infusion of fentanyl at variable rates ranging from 250 to 400 μg/hr
45399674|NCT05395780|Drug|MAX-40279|MAX-40279 capsule will be administered orally
45399675|NCT01237288|Drug|Z-521|
45399676|NCT05394064|Genetic|SBT101|SBT101 Treatment
45399677|NCT05394064|Procedure|Imitation Procedure|Procedure that mimics SBT101 infusion, but contains no drug administered
45399678|NCT01238068|Device|gamma nail stryker|for acute unstable pertrochantric fractures the subjects will be treated randomaly with either Gamma nail device Vs Dynamic hip screw
45399679|NCT01237366|Behavioral|Resilient Affective Processing Therapy (RAPT)|Participants will be asked to complete 7 intervention sessions which include: 1) expressive writing exercises that focus on exploring thoughts and feelings surrounding a difficult life experience; and 2) stress management skills training to assist participants with managing any acute increases in distress that arise following the writing experience.
45399680|NCT01144390|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy, one session per week and psycho-education lecture in group once per month
45399681|NCT01144390|Drug|methadone maintenance treatment|methadone maintenance treatment
45399682|NCT01144936|Drug|VX-985 or matching placebo|low dose
45399683|NCT01144936|Drug|VX-985 or matching placebo|high dose
45399684|NCT01144936|Drug|VX-985 or matching placebo|dose TBD
45399685|NCT01144546|Procedure|passive leg raising (45 degree leg elevation for 1-2 min)|the patient's trunk was elevated 45 degrees for the first set of measurements. Then, the lower limbs were raised to a 45° angle while the patient's trunk was lowered to a supine position to measure peak CO (usually within 1-2 min)
45399686|NCT05350540|Other|ICG dye|Patients assigned to the intervention group will undergo surgery guided by tissue perfusion as directed by the ICG imaging
45399687|NCT01145014|Drug|BI 660848|2 mg oral drinking solution
45399688|NCT01145014|Drug|BI 660848|10 mg oral drinking solution
45399689|NCT01145014|Drug|BI 660848|20 mg oral drinking solution
45399690|NCT01145014|Drug|BI 660848|50 mg oral drinking solution
45399691|NCT01145014|Drug|BI 660848|100 mg oral drinking solution
45399692|NCT01145014|Drug|BI 660848|150 mg oral drinking solution
45399693|NCT01145014|Drug|BI 660848|200 mg oral drinking solution
45399694|NCT01145014|Drug|BI 660848|400 mg oral drinking solution
45399695|NCT01145014|Drug|BI 660848|600 mg oral drinking solution
45399696|NCT01145014|Drug|BI 660848|10,0 mg immediate release tablet
45399697|NCT01145014|Drug|BI 660848|50,0 mg immediate release tablet
45399698|NCT01145014|Drug|Placebo|matching placebo (oral drinking solution and IR tablets)
45399699|NCT01329640|Device|Drug: Paclitaxel; trastuzumab; doxorrubicin; cyclophosphamide|"Paclitaxel 100mg/m2 once a week for 8 weeks concomitant to trastuzumab 4mg/kg dose attack after 2mg/kg once a week for 8 weeks followed by;~Doxorrubicin 24mg/m2 once a week concomitantly with oral cyclophosphamide 100mg/day (flat dose) concomitantly with trastuzumab 2mg/kg for 9 weeks"
45507831|NCT02783768|Other|Sham|"The unexposed condition will be breathing from the study e-cigarette (10 puffs with 30-second inter-puff intervals) with the battery off."
45507832|NCT02783768|Drug|Hyperpolarized 3-Helium|Hyperpolarized 3-Helium will be used as an experimental contrast agent for the Ventilation MRIs performed twice per participant in both experimental arms. Approximately 250-600 mL of hyperpolarized 3He mixed with 300-750 mL nitrogen will be inhaled through a one-way valve in one inhalation starting approximately at residual volume.
45507833|NCT02783768|Drug|Gadolinium|Gadolinium contrast will be injected into the antecubital vein through an 18-20 gauge IV. The type of gadolinium will be 0.03 mmol/kg bodyweight of dotarem (gadoterate meglumine).
45849886|NCT03915678|Drug|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
45399700|NCT05335018|Drug|Glofitamab, Poseltinib, Lenalidomide|"Glofitamab: Increase from 2.5mg for 8days in 1 cycle to 10mg for 15days. 2cycles 1day 30mg, 30 mg on the 1st day of every week thereafter. Poseltinib: 40mg/day bid orally, administered daily from the 1st to the 21st of every week.~Lenalidomide: 20mg/day bid orally, administered daily from the 1st to the 14st of every week."
45399701|NCT00114777|Drug|Cyclosporin A|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months, 100-250 ng/mL, daily, 84 months
45399702|NCT00114777|Drug|Belatacept Less Intensive Regimen (LI)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
45399703|NCT00114777|Drug|Belatacept More Intensive Regimen (MI)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
45399704|NCT00139737|Drug|Ziprasidone|20mg capsules BID, 40mg capsules BID, 60mg BID or 80mg BID until drug commercialisation in Italy.
45399705|NCT03965559|Procedure|plasmapheresis|"Plasmapheresis is the removal, treatment, and return or exchange of blood plasma or components thereof from and to the blood circulation. It is thus an extracorporeal therapy (a medical procedure performed outside the body).[Wikipedia]~DFPP is a selectively removal of the immunoglobulin fraction from the serum and, as a result, to minimize the volume of substitution fluid required. [Tanabe K. Double-filtration plasmapheresis. Transplantation. 2007 Dec 27;84(12 Suppl):S30-2.]"
45399706|NCT03965793|Device|Automated management of hypotension|Fluid and vasopressor will be administered based on a novel automated clinical decision support system.
45399707|NCT00122187|Device|Electronic Consult System|Consult system is an event notification system programmed to function within the VA electronic medical record system.
45399708|NCT00139659|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
45399709|NCT00139659|Drug|Subcutaneous Insulin|Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
45507834|NCT02238522|Drug|ZEN003365|
45507835|NCT03131687|Drug|tirzepatide|Administered SC
45507836|NCT03131687|Drug|Dulaglutide|Administered SC
45507837|NCT03131687|Drug|Placebo|Administered SC
45507838|NCT03579888|Biological|Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells|Given IV
45507839|NCT03579888|Drug|Cyclophosphamide|Given IV
45507840|NCT03579888|Drug|Fludarabine|Given IV
45507841|NCT05344027|Drug|Mitotane|Individuals within the intervention group were on mitotane therapy as part of their ACC treatment.
45399710|NCT00137631|Behavioral|Many Men, Many Voices (3MV)|Small-group, 6-session HIV prevention intervention for Black MSM.
45399711|NCT01582815|Drug|JNJ-40411813|Type= range, unit= mg, number= 25 to 150, form= capsules, route= oral administration. JNJ-40411813 will be administered twice daily during 8 weeks, following fixed and flexible schedules in which the dose can range from 25 mg to 150 mg.
45399712|NCT01582815|Drug|Placebo|Form= capsule, route= oral administration. Matching placebo will be administered twice daily during 8 weeks.
45399713|NCT01076439|Drug|Fluticasone Furoate Nasal Spray|Fluticasone Furoate Nasal Spray: 110mcg QD
45507842|NCT05450354|Other|Questionnaires|"Questionnaires will be completed only once :~Neurodevelopment in children: Kiddie Schedule for Affective Disorders and Schizophrenia, Present and Lifetime version (K-SADS-PL-5), the Social Responsiveness Scale (SRS), The Children's Communication Checklist-2 (CCC-2), The Autism-Tics, ADHD and Other Comorbidities Inventory (A-TAC), CONNERS-3, Sensory Profile 2 (DUNN)~Psychopathological profile of the child by evaluating the presence of psychotic symptoms: K-SADS-PL-5, Prodromal Questionnaire (F PQ16)~Presence of mood and anxiety disorders: Child Depression Inventory (CDI), Revised Children's Manifest Anxiety Scale (RCMAS)~Presence of sleep disorders: Children's Sleep Habits Questionnaire (CSHQ). The K-SADS-PL-5 will only be completed by subjects who have attempted suicide after the start of the study; it requires a semi-structured interview of the child by a child psychiatrist and cannot be done remotely. The other scales will be completed by all included subjects."
45507843|NCT05435144|Dietary Supplement|Elderberry|European black elderberry extract
45507844|NCT05435144|Other|Placebo|Inactive placebo
45399714|NCT01076439|Drug|Olopatadine Nasal Spray|Olopatadine Nasal Spray: 2660mcg BID
45399715|NCT01076439|Drug|Saline Nasal Spray|Placebo
45507845|NCT05343247|Diagnostic Test|Willems method|Willems method measures the developmental stages of the seven left permanent mandibular teeth and is frequently used for dental age estimation. The score of each stage is allocated, and the sum of the scores provides an evaluation of the subject's dental maturity.
45507846|NCT05343247|Diagnostic Test|Cameriere method|Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
45507847|NCT05343247|Diagnostic Test|London Atlas method|The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
45507848|NCT03586986|Diagnostic Test|Brain MRI|Perform brain MRI; draw blood; fill out bioscreen questionnaire; perform SDMT
45507849|NCT05430698|Drug|PD-1antibody plus GEMOX|"PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1，intravenous infusion.~Three weeks is a course of treatment,a total of 6-8 courses."
45507850|NCT03585972|Behavioral|Frailty Prevention Program|4 face-to-face sessions, with a occupational therapist over 4 months to address function, safety, social participation, diet, exercise, sleep, and medication management. Sessions are expected to last between 60-120 minutes. The first session is a comprehensive occupational therapy evaluation and treatment plan. Sessions 2 and 3 involved physical activity and dietary education, counseling and goal setting. Session 4 involves reviewing program progress, and setting maintenance goals.
45507851|NCT05577416|Procedure|Biopsy|Patients will undergo stereotactic biopsy by craniotomy or burr hole.
45507852|NCT05577416|Drug|Part A: AB-218|Part A: AB-218 orally 250 mg BID for 28 days.
45507853|NCT05577416|Procedure|Surgery (maximal resection)|Surgery: Maximal safe resection, within 24 hours of last dose of AB-218.
45507854|NCT05577416|Drug|Part B: AB-218|Part B: AB-218 orally 250 mg BID for 28 days for up to 12 cycles.
45507855|NCT03585894|Other|Sumatriptan|Receive intravenous infusion of sumatriptan
45507856|NCT03585894|Other|Ketorolac|Receive intravenous infusion of ketorolac
45849887|NCT03915366|Drug|Valganciclovir Oral Solution [Valcyte]|Treatment for CMV
45849888|NCT03915366|Drug|Tuberculostatic Agents|Treatment for tuberculosis
45849889|NCT03903666|Other|Nocturnal gaz exchanges measurement|Nocturnal gaz exchanges at patient's home BRIEF neuropsychological questionnaire VINELAND-II neuropsychological questionnaire Clinical OSA assessment Dysautonomia assessment
45399716|NCT01078701|Biological|GHB11L1|GHB11L1 administration by liquid nasal spray at doses of 6.0 log10, 6.5 log10 and 7.0 log10 TCID50/volunteer
45399717|NCT01078701|Biological|Placebo|SPGN buffer
45399718|NCT01582893|Device|HCO1100|Dialysis
45399719|NCT01582893|Device|P210H|Dialysis
45399720|NCT03965715|Device|3D printing AFO, anterior AFO, off-the-shelf AFO|Subjects wear different AFOs and performed gait analysis.
45399721|NCT03965637|Drug|vitamin C|water-soluble vitamin C injection contain of 1000 mg vitamin C that given via intravenous injection
45399722|NCT01078779|Drug|Chloroquine|Chloroquine phosphate 250mg capsule, two capsules daily for 7 days then 2 capsules once a week for a total treatment duration of 12 weeks
45399723|NCT01078779|Drug|Placebo|Placebo capsules, 2 capsules daily for 7 days then 2 capsules weekly for a total treatment duration of 12 weeks
45399724|NCT00114231|Drug|capecitabine|
45399725|NCT00114231|Drug|oxaliplatin|Given IV
45399726|NCT00114231|Procedure|neoadjuvant therapy|Undergo surgery
45507857|NCT04912921|Dietary Supplement|palmitoylethanolamide|4 tablets taken daily (2 in the am and 2 in the pm)
45507858|NCT04912921|Dietary Supplement|Placebo|4 tablets taken daily (2 in am and 2 in pm)
45507859|NCT04912921|Dietary Supplement|Curcumin|500 mg HydroCurc® twice a day
45399727|NCT00114231|Radiation|radiation therapy|Undergo radiotherapy
45399728|NCT00113919|Drug|Busulfan|Dexamethasone 40 mg PO 1-4 Thalidomide 200 mg PO 1-6 Cisplatin* 10 mg/m, Continuous infusion 1-4 Adriamycin** 10 mg/m2, Continuous infusion 1-4 Cyclophosphamide 400 mg/2, Continuous infusion 1-4 Etoposide 40 mg/m2, Continuous infusion 1-4 All doses will be based on calculated body weight (actual weight + ideal body weight ÷ 2) and height, and not to exceed a BSA of 2.0 m2 The daily dose of cyclophosphamide, etoposide, and cisplatin will be mixed in a 1L bag of NS to be UAMS infused over 24 hours. Adriamycin will be mixed in at least 50cc D5W to be infused over 24 hours
45399729|NCT00113841|Drug|Curcumin|2 grams (Capsules) orally in 2 divided doses (a.m., p.m.)
45507860|NCT04912921|Dietary Supplement|Control (microcrystalline cellulose)|2 tablets taken daily
45507861|NCT03590808|Biological|Influenza vaccination|Purified inactivated influenza virus antigen (Green Cross Corp) 0.5 mL once IM
45507862|NCT05420324|Drug|YH003|YH003 will be administered intravenously over 30 minutes every 21-day cycle.
45507863|NCT05420324|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
45507864|NCT05420324|Drug|albumin paclitaxel|Albumin paclitaxel will be administered intravenously over 30 minutes every 21-day cycle.
45507865|NCT02238288|Drug|Aminocaproic acid|Crushed tablet in the dental socket
45507866|NCT02238288|Other|Routine dental care|Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
45507867|NCT02238288|Drug|lidocaine and epinephrine|2%
45507868|NCT02238288|Drug|Paracetamol|750 mg
45507869|NCT04901455|Biological|LAIV|Standard dose of LAIV administered by a licensed health care providers.
45507870|NCT01364129|Procedure|Ophthalmic Telemedicine|Participants receiving the intervention have digital images of their retina captured with a non-mydriatic camera. The images are then sent to Devers Eye Institute for review and report generation.
45507871|NCT01561040|Dietary Supplement|Omega 3, Vitamins A, D3 and E|omega 3 1480 mg vitamin A 1,000 IU vitamin D3 2,000 IU vitamin E 60 IU
45849890|NCT03892746|Device|Active tDCS + task oriented practice|Participants in this arm will receive active tDCS(2mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks.
45399730|NCT00113841|Drug|Bioperine|5 mg (Tablets) orally twice daily
45399731|NCT00113607|Drug|Trabectedin|Type=exact number, unit=mg/m2, number=1.1, form=solution, route=IV. Trabectedin will be administered over 3 hours every 3 weeks.
45399732|NCT00113607|Drug|DOXIL|Type=exact number, unit=mg/m2, number=30, 50, form=solution, route=IV. DOXIL will be administered over 90 minutes every 4 weeks when administered alone (monotherapy) and every 3 weeks when administered with trabectedin.
45399733|NCT00113607|Drug|Dexamethasone|Type=exact number, unit=mg, number=20, form=solution, route=IV. Dexamethasone or its equivalent will be administered over 30 minutes prior to the DOXIL infusion.
45507872|NCT03590496|Dietary Supplement|Calcium-Propionate 500mg|Calcium-Propionate capsules
45507873|NCT03590496|Other|Placebo|Placebo capsules without any active ingredient
45507874|NCT03914651|Drug|300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation|On menstrual cycle day 2 or day 3, 300IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of ovarian hyperstimulation syndrome（OHSS）.
45507875|NCT03914651|Drug|150IU rFSH Gonal-F® starting dose during controlled ovarian stimulation|On menstrual cycle day 2 or day 3, 150IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of OHSS or insufficient follicular growth.
45507876|NCT03101293|Drug|TAK-831|TAK-831 film-coated tablet.
45507877|NCT01356953|Other|Aerobic exercise|Intensity of aerobic exercise
45507878|NCT05577260|Drug|magnesuim sulphate|magnesuim sulphate
45507879|NCT05577260|Drug|Dexmedetomidine|Dexmedetomidine
45507880|NCT05577260|Drug|isobaric bupivacaine|20ml isobaric bupivacaine 0.25%
45507881|NCT01361087|Other|Blood draw|This study includes one blood draw to measure circulating blood levels of TGF-B.
45507882|NCT03590340|Biological|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
45507883|NCT03590340|Other|Normal saline|Normal saline is 0.9% sodium chloride
45507884|NCT03590340|Biological|PfSPZ Challenge (for CHMI)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
45507885|NCT03760562|Drug|Glucocorticoids|Oral Glucocorticoids.
45507886|NCT01357031|Drug|Amitriptyline|It will be administered Amitriptyline (25mg) once a day at bed time. Patients may keep their abortive treatment that they usually used. The drug will be encapsulated in a bottle of 30 capsules will be given to patients at every visit.
45507887|NCT01357031|Drug|Melatonin|It will be administered Melatonin (3mg) at bed time, half an hour before the usual time of sleep of the patient.
45507888|NCT01357031|Drug|Placebo|It will be administered placebo capsules, identical to Melatonin (3mg) and Amitriptyline (25 mg) patients will take the study medication at bed time
45507889|NCT05577104|Procedure|Negative pressure wound therapy (NPWT)|For patients in the NPWT group, the wound bed preparation was facilitated by vacuum-assisted closure (VAC).
45399734|NCT01080105|Behavioral|AIM Web based intervention + surveillance|The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach. Surveillance will consist of monthly screening of depression symptoms and outreach from the coach should there be an increase in symptoms.
45399735|NCT01080105|Behavioral|AIM web based intervention|The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach.
45399736|NCT01080105|Behavioral|Educational website|Participants will receive access to a static educational website for 12 weeks.
45399737|NCT01076517|Device|Therasphere|Beta-emitting 90yttrium encapsulated in glass microspheres for intraarterial administration to the liver.
45399738|NCT00113529|Drug|Gefitinib + Sunitinib|Until disease progression or unacceptable toxicity.
45399739|NCT01078857|Other|Skin biopsy|A 3-mm-diameter skin biopsy punch was taken at the lateral side of the distal leg and fixed in 4% paraformaldehyde overnight. Sections of 50 m perpendicular to the dermis were cut on a sliding microtome, quenched with 1% H2O2 in methanol, and blocked with 5% normal goat serum. Sections were incubated with rabbit antiserum to protein gene product 9.5 (PGP 9.5, UltraClone, Isle of Wight, UK, 1:1000) overnight. PGP 9.5 is a ubiquitin carboxyl hydrolase, which labels myelinated and unmyelinated nerve fibers in the peripheral nervous system. Sections were then incubated with biotinylated goat anti-rabbit immunoglobulin G (Vector, Burlingame, CA) for 1 h and the avidin-biotin complex (Vector) for another hour. The reaction product was demonstrated using chromogen SG (Vector).
45399740|NCT01078935|Dietary Supplement|probiotics|Each patient and volunteer will get the study medication for 6 weeks and will be evaluated twice - before enrollment and after 6 weeks of treatment. Routine clinical management will continue - with regular treatment as needed.
45399741|NCT01078935|Dietary Supplement|placebo|Each patient and volunteer will get the study medication for 6 weeks and will be evaluated twice - before enrollment and after 6 weeks of treatment. Routine clinical management will continue - with regular treatment as needed.
45507890|NCT05577104|Procedure|conventional moist dressings|For patients in the control group, the wound bed preparation was facilitated by conventional dressing change method (with alginates ).
45697875|NCT02246686|Drug|STW5-II (Iberogast N, BAY98-7410)|Application over 12 weeks 20 drops three time daily
45849891|NCT03892746|Device|Sham tDCS + task oriented practice|Participants in this arm will receive sham tDCS(0mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks
45849892|NCT03874338|Drug|Colchicine Pill|Participants in the main CLEAR SYNERGY trial are randomized to colchicine/spironolactone versus placebo in a 2x2 factorial design. The substudy is interested in the evaluation of biospecimens obtained from patients in the colchicine vs placebo group.
45507891|NCT01357109|Drug|Bosentan|62.5 mg bid for two weeks and 125 mg bid for two weeks
45507892|NCT01357109|Drug|Placebo|Matched placebo bid
45849893|NCT03853356|Device|Orthoss|Orthoss® granules. Orthoss® granules mixed with local bone and pedicle bone marrow aspirate.
45697876|NCT02246686|Drug|Placebo|Application over 12 weeks 20 drops three time daily
45399742|NCT01079013|Drug|treosulfan|12 g/m2 x 3 days
45399743|NCT00134901|Drug|Memantine|Memantine
45399744|NCT00134901|Drug|placebo|placebo
45399745|NCT01076595|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Betaferon 250 microgram
45399746|NCT00122109|Behavioral|12 sessions Anger Management Therapy.|Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills.
45399747|NCT03965325|Other|Use of a standardized set to collect clinical and patient-centered data, to assess the trend of the Global Health Status overtime in colorectal cancer patients|Patients' data (baseline characteristics, clinical and PROMs outcomes) will be collected according to patient-centered standardized set regarding ICHOM recommendations. Data collection and the follow-up schedule are carried out at : baseline (before any treatment or surgery), 1- and 6-month follow-up and then once a year.
45399748|NCT01326663|Drug|Medication Trial|
45399749|NCT00113373|Drug|lapatinib ditosylate|Given orally
45697877|NCT04400019|Drug|Hydroxychloroquine Only Product in Oral Dose Form|The dose to be used as chemoprophylaxis will be 800mg of HCQ on the first day and 400mg for the following four days.
45697878|NCT01055782|Device|Endoguide|Use of endoguide to facilitate completion of endoscopy
45697879|NCT05225805|Drug|Lefamulin|Antibiotic
45697880|NCT01056016|Other|ADHD Collaborative|This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a DSM-IV based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales.
45507893|NCT04808492|Device|CureWave High Intensity Laser|"The participant will lie prone and the HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. The dose will include:~Power (44 Watts)~Mode (continues wave)~Time on (60000 ms)~Time off (1 ms)~Repeats (9)~Distance of electrode from skin will begin 10 from skin surface. The participant may or may not feel mild warmth. Should the subject report excessive warmth or discomfort the probe distance will be increased in 2 intervals until it is comfortable. The entire process will take approximately 10 minutes.~The participant will lie prone and the Placebo treatment will consist of positioning the HILT probe over the 9 symmetrical positions for 1 minutes each however the no laser will be admitted."
45507894|NCT04808492|Other|Placebo|"The participant will lie prone and the NON ACTIVE HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. THE LASER WILL NOT BE ACTIVE.~o Distance of electrode from skin will begin 10 from skin surface. The entire process will take approximately 10 minutes."
45507895|NCT04792580|Drug|Lifitegrast 5% Ophthalmic Solution|Used twice a day in both eyes for 4 weeks after a 2 week washout.
45507896|NCT04792580|Drug|Placebo|Used twice a day in both eyes for 4 weeks after a 2 week washout with the same drops.
45507897|NCT03896399|Procedure|Laparoscopic ischemic conditioning followed by esophagectomy|All included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days.
45507898|NCT05398250|Behavioral|Safety Planning Intervention tailored for Autistic Individuals|To develop the SPI-A, clinicians work collaboratively with patients, and when indicated, their family members, to create a list of concrete coping mechanisms to be enacted leading up to or during a crisis. This list can be depicted in writing or pictorially, depending on patient preference. As part of the intervention, patients (and family members, when appropriate) also identify warning signs that signal the need to use the safety plan, as well as a detailed plan for reducing access to lethal means. SPI-A is a stand-alone intervention without a follow-up component.
45507899|NCT05398250|Behavioral|Safety Planning Intervention Tailored for Autistic Individuals Plus Structured Follow-Up Contacts|"SPI-A+ includes SPI-A plus a structured follow-up component. The structured follow-up component of SPI-A+ includes three elements:~A brief risk assessment and mood check~Review and, if needed, revision of SPI-A~Support related to outpatient mental health treatment initiation"
45697881|NCT03915405|Drug|KHK2455|orally, once daily.
45697882|NCT03915405|Drug|Avelumab|IV Administration
45399750|NCT00113373|Other|laboratory biomarker analysis|Correlative studies
45399751|NCT01079091|Device|ADVOS (Hepa Wash)|"Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)"
45399752|NCT01079091|Procedure|Standard Medical Therapy|Standard of care treatment
45399753|NCT01326351|Procedure|Regenerative injection therapy|Injection of 10cc of a 15% dextrose and 0.6% lidocaine solution free of epinephrine in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade (injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
45697883|NCT01056328|Device|SJM Irrigated Cardiac Ablation System|Irrigated ablation catheter
45697884|NCT01056328|Device|FDA approved Open Irrigated RF Ablation System|Irrigated ablation catheter
45697885|NCT04358913|Device|MR scan with the Alberta linac-MR P3 system|Single MR imaging session to develop and optimize the necessary MR sequences on the Alberta linac-MR P3 system to allow for MR-guided radiotherapy.
45697886|NCT01892657|Drug|Facial Moisturizer with SPF 50+|All subjects received applications of occlusive patches dosed with Cetaphil Daily Facial Moisturizer with SPF 50+
45697887|NCT04351581|Other|Discontinuation of ACEi/ARB|Discontinuation of ACEi/ARB
45507900|NCT02850978|Drug|Spiolto|
45507901|NCT03775343|Diagnostic Test|Neurocognitive Test Battery|neurocognitive testing: preoperative(baseline), 6 and 24 hours postoperative.
45507902|NCT03775343|Diagnostic Test|Blood sampling|Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery, investigating plasma levels of S 100-B, CRP, vitamines, homocysteine and folic acid
45507903|NCT02253446|Drug|Piroxicam|20 mg of piroxicam (Feldene ampoule-Pfizer-France) intramuscularly (IM) was given 200 patients,
45507904|NCT02253446|Drug|Diclofenac Sodium|Second Group: Diclofenac sodium 75mg (Miyadren ampoule-bulb-Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
45507905|NCT03589170|Diagnostic Test|Opportunistic atrial fibrillation screening|Opportunistic pulse palpation and/or ECG at least once a year when they visit doctors or nurse for other reasons.
45399754|NCT01326351|Procedure|Dry needle injection|Injection of dry needle in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade(injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
45507906|NCT05417893|Device|MeRes 100 Sirolimus-eluting Bioresorbable Vascular Scaffold System (BRS)|The MeRes100™ BRS (Meril Life Sciences Pvt. Ltd., India) is a novel thin-strut second-generation sirolimus-eluting poly-L-lactic acid (PLLA)-based bioresorbable coronary scaffold. The first-in-human MeRes-1 trial demonstrated the safety and effectiveness of MeRes100 BRS in the treatment of de novo coronary lesions with lower major adverse cardiac events (MACE) rate (0.93%) and notably, the absence of scaffold thrombosis at one-year follow-up. MeRes100 sirolimus-eluting bioresorbable vascular scaffold system is expected to bioresorb in the artery, approximately over a period of three years and thus, preventing chance of late clinical events like late scaffold thrombosis rates. The imaging analysis has shown that in-segment late lumen loss and in-scaffold late lumen loss (LLL) did not change significantly at two years follow-up as compared to six months data.
45507907|NCT03135431|Procedure|Bilateral Salpingectomy|Surgical removal of entire fallopian tubes
45507908|NCT03135431|Procedure|Bilateral Tubal Ligation|Surgical tying, cutting, or removal of a portion of the fallopian tubes
45507909|NCT03546452|Diagnostic Test|in vitro NGS-panel|cell free DNA ,which was purified from hydrothorax, is used to be tested by NGS-panel
45507910|NCT03585348|Other|Neuromuscular blocking agents|Neuromuscular blocking agent ED95 equivalent dose by provider
45507911|NCT03579810|Other|Investigational|"The educational intervention helped to increase the knowledge of attitudes, and habits of healthy lifestyle in children, parents and teachers and it was based on health promotion models and social cognitive theory, to be articulated with the Institutional Educational Project through the pedagogical component that integrates three areas, physical activity, healthy eating, and the knowledge of the body and the heart with the dynamics of the educative community.~The program covered self-care of the body and heart, healthy diet, and physical activity"
45507912|NCT03579810|Other|Control|The control group did not receive an educational intervention in areas of physical activity, healthy eating, and the knowledge of the body and the heart. Instead, children received the standard curriculum in health and physical activity of the national Ministry of Education.
45507913|NCT05384678|Drug|N,N-Dimethyltryptamine (54 mg)|A dose rate of 0.6 mg/min will be administered
45507914|NCT05384678|Drug|N,N-Dimethyltryptamine (108 mg)|A dose rate of 1.2 mg/min will be administered
45507915|NCT05384678|Drug|N,N-Dimethyltryptamine (162 mg)|A dose rate of 1.8 mg/min will be administered
45507916|NCT05384678|Drug|N,N-Dimethyltryptamine (216 mg)|A dose rate of 2.4 mg/min will be administered
45507917|NCT05384678|Drug|Placebo|A Placebo (saline infusion) will be administered.
45697888|NCT04351581|Other|Continuation of ACEi/ARB|Continuation of ACEi/ARB
45697889|NCT01057888|Other|Autodialer|Autodialer telephone calls
45697890|NCT01057888|Other|Letters|Mailed reminder letters
45697891|NCT01881737|Drug|Pregnenolone|"With Baseline serving as approximately day 1, twice daily intake of orally administered pregnenolone will occur on a schedule consisting of an up-titration followed by a down-titration as described below.~Week 1 and 2: 100 mg~Week 3 and 4: 200 mg~Week 5 and 6: 300 mg~Week 7 and 8: 400 mg~Week 9 -12: 500 mg~At the end of Week 12, pregnenolone was decreased by 50 mg twice a day every 3 days until it was discontinued.~If the participant is unable to tolerate a specific dose then he/she will be maintained at the highest tolerated dose until down titration occurs."
45507918|NCT05384678|Drug|N,N-Dimethyltryptamine (108 mg) + dose titration|A dose rate of 1.2 mg/min will be administered with subsequent patient-guided dose titration
45697892|NCT01109056|Drug|cyclosporine ophthalmic emulsion 0.05%|One drop in the study eye (or eyes) administered four times daily (QID)
45399755|NCT01326351|Behavioral|Exercise|At-home exercise program that patients must perform 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
45507919|NCT03556085|Device|Venous sinus stenting (Serenity River)|Patient is placed under general anesthesia. From femoral vein access, a standard guide-catheter is advanced in the internal jugular vein (on the side considered for stenting). The sigmoid then transverse sinus is catheterized with a microcatheter and guide-wire and an exchange guide-wire is placed in the superior sagittal sinus. The River stent delivery catheter is advanced over the exchange guide-wire in the sigmoid then transverse sinus up to the torcula. The River stent is deployed to cover the entire transverse sinus and the proximal half of the sigmoid sinus. The catheters are removed and hemostasis obtained by using a closure device or manual compression. The patient is kept overnight in the hospital for observation.
45697893|NCT01109056|Drug|Vehicle|One drop in the study eye (or eyes) administered four times daily (QID)
45697894|NCT04760145|Other|Multicomponent Exercise with Blood Flow Restriction|"10 minutes of initial warm-up.~20 minutes of strength exercises.~10 minutes of resistance exercises.~10 minutes of coordination and balance exercises.~5 minutes of flexibility.~5 minutes of return to calm and relaxation.~All of this multicomponent training will be performed with blood flow restriction."
45399756|NCT01079169|Dietary Supplement|Cranberry capsules|Cranberry capsules, 550mg, or placebo capsules, two capsules three times daily during in-patient rehabilitation
45399757|NCT01079247|Other|Restrictive transfusion threshold|maintain hemoglobin at 7-8 g/dL
45399758|NCT01079247|Other|Liberal transfusion threshold|Maintain hemoglobin at 10-11 g/dL
45507920|NCT03767634|Other|Parenteral nutrition|Parenteral nutrition is the administration of an intravenous solution containing amino acids (with or without lipids) to provide nutritional support.
45399759|NCT00113295|Drug|Continued Paroxetine CR|
45399760|NCT00113295|Drug|Quetiapine|
45399761|NCT00113295|Drug|Placebo|
45399762|NCT00112905|Drug|sorafenib tosylate|Given PO
45399763|NCT00112905|Other|laboratory biomarker analysis|Optional correlative studies
45399764|NCT03964857|Other|Refined olive oil (ROO)|Consumption of chicken dishes made with ROO for a period of 8 weeks
45399765|NCT03964857|Other|Blended Oil 1 (BO1)|Consumption of chicken dishes made with BO1 for a period of 8 weeks
45399766|NCT03964857|Other|Blended Oil 2 (BO2)|Consumption of chicken dishes made with BO2 for a period of 8 weeks
45399767|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
45399768|NCT00427895|Biological|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|0.5 mL dose administered on day 1
45507921|NCT01563224|Drug|Baclofen 10mg|Baclofen 10mg single dose po
45507922|NCT01563224|Drug|Baclofen 60mg|Baclofen 60mg single dose po
45507923|NCT01563224|Drug|placebo|placebo
45507924|NCT01361243|Behavioral|NOURISH+|6 week face-to-face parent intervention.
45507925|NCT01361243|Behavioral|Wellness Group|1 week face-to-face family group followed by 6 informational mailings on childhood overweight and obesity.
45697895|NCT04760145|Other|Multicomponent Exercise without Blood Flow Restriction|"10 minutes of initial warm-up.~20 minutes of strength exercises.~10 minutes of resistance exercises.~10 minutes of coordination and balance exercises.~5 minutes of flexibility.~5 minutes of return to calm and relaxation.~All of this multicomponent training will be performed without blood flow restriction."
45697896|NCT03870399|Drug|Tamoxifen|The treatment to be used will be tamoxifen 20mg orally once daily.
45849894|NCT03846570|Drug|Formoterol-beclomethasone|formoterol (fumarate dihydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler
45849895|NCT03846570|Drug|Placebo|Matching placebo (identically package) administered BID
45849896|NCT03838848|Drug|KN046|3mg/kg, Q2W, intravenous injection (IV)
45399769|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
45399770|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
45399771|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered 3-4 years after dose 1
45507926|NCT03632629|Other|interactive cognitive training|Using interactive brain club system training to children with attention deficit hyperactivity disorder with developmental delay
45507927|NCT05576870|Other|Plant based toddler nutrition|Plant based toddler nutrition fed daily ad libitum
45849897|NCT03838848|Drug|KN046|5mg/kg, Q2W, intravenous injection (IV)
45399772|NCT00427895|Biological|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|0.5 mL dose administered 3-4 years after dose 1
45399773|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered 3-4 years after dose 1
45399774|NCT00427349|Drug|AMG 706|AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the AM. AMG 706 was taken daily without breaks in treatment
45399775|NCT00427349|Drug|octreotide|One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles.
45399776|NCT02459327|Behavioral|Video Interaction Project|VIP utilizes pediatric well-child visits to build a relationship with an interventionist who facilitates self-reflection regarding interactions with the child through review of videotapes of the parent and child made that day and further facilitates interactions through provision of learning materials (toys and books).
45399777|NCT02459327|Behavioral|Family Check Up|FCU utilizes home visitation to build a relationship with an interventionist who assesses family strengths and challenges and uses motivational interviewing and evidence-based family management strategies to support parent and child behavioral change.
45399778|NCT01034189|Drug|Cetuximab|Cetuximab: loading dose 400 mg/m2, 2h- IVF, 3~ 5 days prior to starting CCRT (on week-1); followed by 250 mg/m2/ week, 1h- IVF, for 4 weeks (i.e., week 1 to week 4. during CCRT).
45399779|NCT01034189|Drug|Paclitaxel|T: Paclitaxel 35 mg/m2, 1h IVF, on day 1 and day 4 of each week, week1 to week4 during CCRT.
45399780|NCT01034189|Drug|Cisplatin|P: Cisplatin 15 mg/m2, 1 h IVF, on day 2 and day 5 of each week, week1 to week4 during CCRT.
45399781|NCT01034189|Radiation|Radiotherapy|Radiotherapy: (three-dimensional conformal radiotherapy or intensity modulated radiotherapy) 200 cGy/fraction, once daily, 5 days a week, to a total dose of 4000 cGy.
45399782|NCT00425945|Drug|Pine Bark Extract (Flavangenol®)|"Flavangenol 200 mg per day. Flavangenol is a brand of pine bark extract manufactured by Toyo Shinyaku of Saga, Japan.~Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day orally for 12 weeks."
45399783|NCT00416195|Drug|E2007|
45399784|NCT00416195|Drug|Placebo|
45399785|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (24 weeks short term [ST], 42 months long term [LT])
45399786|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 5 mg, Once daily (24 weeks ST, 42 months LT)
45399787|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT)
45507928|NCT05576870|Dietary Supplement|Dairy based toddler nutrition|Commercially available toddler nutrition fed daily ad libitum
45507929|NCT01369979|Procedure|Liver vein catheter|Liver vein catheter is placed in the heptic vein via the femoral vein, using fluoroscpoy as guidance.
45507930|NCT05417581|Procedure|adipose surgery|A quantity of adipose tissue equivalent to 10-20 cubic centimeter will be removed subcutaneously and from the omentum during surgical procedures (oncological, bariatric)
45399788|NCT00121641|Drug|Placebo matching Saxagliptin|Tablets, Oral, 0mg, Once daily (24 weeks ST, 42 months LT)
45507931|NCT03577860|Drug|Bupivacaine 4 mL|The interscalene brachial plexus block is performed with 4ml of bupivacaine-epinephrine 0,5%- 1:200,000
45507932|NCT03577860|Drug|Bupivacaine 15 mL|The interscalene brachial plexus block is performed with 15ml of bupivacaine-epinephrine 0,5%- 1:200,000
45507933|NCT03547661|Other|P-Dragees rosa Lichtenstein|Placebo dragées
45507934|NCT05336240|Behavioral|Physician Communication 2 Virtual (PCOM2-virtual)|The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. While this provider communication technique previously showed success in increasing HPV vaccination uptake, it is neither easy to disseminate nor sustainable due to it's nature of direct, intensive in-person training. Therefore, the intervention is to compare the standard-PCOM intervention to a new, PCOM2 intervention, that will be adapted virtually.
45507935|NCT05336240|Behavioral|Physician Communication Standard (PCOM-standard)|The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. PCOM-standard will be conducted in-person with providers.
45507936|NCT03577782|Biological|Entyvio (Vedolizumab)|"Antiretroviral treatment consisting in Dolutegravir (Tivicay) (50mg) + Tenofovir alafenamide (TAF) (25mg) / Emtricitabina (FTC) (200mg) (Descovy), once daily during 24 weeks.~Entyvio (Vedolizumab) (300mg), 7 intravenous infusions at week 0 (baseline) (concomitant with ART onset), 4, 8, 12, 16, 20 and 24.~At week 24 ART and Vedolizumab administration will be interrupted. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).~Patients will be followed up until week 48."
45507937|NCT03523793|Behavioral|Clinical Practice Guideline Implementation|The Study team will use several methods from the implementation strategy taxonomy of the Effective Practice and Organization of Care (EPOC) classification system to improve our likelihood for successful neck and low back pain implementation consisting of: 1) educational materials, workshops and outreach visits from trainers; 2) external consultant testimonials; 3) iterative quality improvement processes (including ongoing analysis of clinician feedback to improve process); 4) routine collection of patient reported outcomes to engage discussion among clinician groups and outpatient division leaders) and 5) local organization consensus process (including feedback from key outpatient division stakeholders).
45507938|NCT03523793|Other|Standard Care|Considering the stepped wedge design with a 12-week washout phase, clinics will be providing standard physical therapy prior to receiving clinical practice guideline training.
45507939|NCT03548090|Other|Skateboard exercise at an incline angle of 0 degrees and 50% body weight|Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
45507940|NCT03548090|Other|Skateboard exercise at an incline angle of 5 degrees and 50% body weight|Participants will stand on a specified incline angle (5 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
45697897|NCT01109602|Other|Yoga focused on strength, flexibility, and balance|Participants completed 8 weeks of yoga therapy. The yoga was focused on strength, flexibility, and balance therapy after stroke to impact fear of falling, balance, mobility, QoL, and blood pressure after stroke. The in-person yoga intervention included seated, standing, and floor poses. All study participants were able to complete transfers to the floor or mat table and complete all postures and breathing exercises.
45697898|NCT03867201|Biological|Erenumab|Administered by pre-filled syringe
45697899|NCT03867201|Other|Placebo|Administered by pre-filled syringe
45697900|NCT02175472|Device|Spectramax light therapy device|Spectramax light therapy device emits a specific combination of bandwidths and intensities of light.
45697901|NCT02175472|Device|Control light device|The control light device is identical in appearance to the Spectramax light therapy device, except that when turned on, emits a different combination of bandwidths and intensity, not believed to produce a therapeutic response.
45697902|NCT03014752|Other|Classical ketogenic diet|The classical ketogenic diet with a ratio of 4 to 1 (4:1), each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
45697903|NCT03014752|Other|Modified Atkins diet|The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
45697904|NCT01892501|Procedure|Guided punction of mediastinal lymphadenopathy by echoendoscopy|"EUS (by oesophageal) is performed within a maximum period of six weeks after the PET scan, under general anesthesia and endoscopic control, with a disposable 19-gauge needle (EchoTip, Cook Endoscopy) and 3 passes of the needle ganglion.~Pathological samples are taken :~3 tubes collected by node (one tube per needle pass), in most cases, only one node will be taken."
45697905|NCT01892501|Device|PET scan|The benefits of combined PET and punction EUS for the diagnosis and subsequent therapeutic management should be evaluated in these different contexts
45399789|NCT00121641|Drug|Metformin|Tablets, Oral, 500 mg, daily (42 months LT)
45399790|NCT00121641|Drug|Placebo matching Metformin|Tablets, Oral, 0 mg, daily (42 months LT)
45399791|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT) Open Label
45399792|NCT00121641|Drug|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue)
45399793|NCT00425555|Drug|Panobinostat|
45399794|NCT00424775|Drug|MK0683, vorinostat|vorinostat 300 mg or 400 mg once daily consecutive days (14 days) followed by 11 days of rest in the first cycle or 7 days of rest in the second or later cycle.
45399795|NCT01034267|Drug|F2695 SR|Drug F2695 SR (flexible dose) to be given orally in capsule form once daily
45399796|NCT01323881|Device|Intermittent theta burst stimulation|Intermittent theta burst stimulation with 1200 pulses or sham stimulation over the ipsilesional M1 hand region for 10 daily sessions in 2 weeks.
45399797|NCT00121485|Device|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
45399798|NCT01034345|Drug|Sirolimus|Switch from calcineurin inhibitor maintenance immunosuppression to sirolimus treatment at the doses needed to reach trough blood levels 8-15 ng/mL.
45507941|NCT03548090|Other|Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 75% body weight|Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (75%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
45507942|NCT03548090|Other|Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 90% body weight|Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (90%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
45399799|NCT01034345|Drug|Calcineurin inhibitor|Patients will maintain the same immunosuppressive regimen based on calcineurin inhibitors. No modifications in the treatment will be conducted.
45399800|NCT01763866|Biological|Evolocumab|Administered by subcutaneous injection
45399801|NCT01763866|Drug|Ezetimibe|Administered orally once a day
45507943|NCT03548090|Other|Control 4-week exercise intervention|This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The control group will perform three sets of ten repetitions of the following 4 exercises, for a total of 120 repetitions: 1) standing hip abduction against green theraband resistance with upper extremity support, 2) sit to stands from chair with no upper extremity support, 3) bilateral calf raises with upper extremity support, and 4) right and left weight shifting exercises using a wobble board with upper extremity support available if needed.
45399802|NCT01763866|Drug|Placebo to Evolocumab|Administered by subcutaneous injection
45399803|NCT01763866|Drug|Placebo to Ezetimibe|Administered orally once a day
45399804|NCT01763866|Drug|Atorvastatin|Administered orally once a day
45399805|NCT01763866|Drug|Rosuvastatin|Administered orally once a day
45507944|NCT03548090|Other|Experimental 4-week exercise intervention|This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The experimental group will perform the skateboard exercise with the optimal parameters established during studies 1 and 2 (that is, an incline angle of either 0 or 5 degrees and a body weight percentage of 50%, 75%, or 90%)--the forward and backward speed of the skateboard will be cued with a metronome that will set at a beats per minute that matches the foot strike cadence of someone walking at 0.7 m/s, and the magnitude of forward excursion of the skateboard will be individualized to the participant based on GAITRite® data (that is, step length of the non-paretic LE).
45697906|NCT04333407|Drug|Aspirin 75mg|• If patient not on aspirin, add aspirin 75mg once daily unless contraindicated.
45507945|NCT03548090|Other|Over-ground multi-directional gait training|In the over-ground multi-directional gait protocol, the participant will walk 750 steps forward, 50 steps backward, and 200 side steps over level surfaces. The over ground gait training will focus on equalizing step length while performing multi-directional gait training.
45507946|NCT03548090|Other|Home exercise|Home exercise consists of three sets of ten repetitions of the following three exercises to be performed on non-therapy days over the four weeks of phase 3: 1) sit to stands from chair with no upper extremity support, 2) bilateral calf raises with hand support, and 3) resisted side stepping to the non-paretic side using a green theraband with upper extremity support.
45507947|NCT01364441|Drug|ONO-2952|3 mg to 800 mg at a single dose; 10 mg and 200 mg for food effect study
45507948|NCT01364441|Drug|Placebo|Placebo dosed in the same manner as ONO-2952
45507949|NCT02238756|Biological|CV8102|Subjects will receive 2 intramuscular doses of CV8102 given 21 days apart
45507950|NCT02238756|Biological|Rabipur|Subjects will receive 2 intramuscular doses of Rabipur given 21 days apart
45507951|NCT02238756|Biological|CV8102 + Rabipur|Subjects will receive 2 intramuscular doses of CV8102+Rabipur given 21 days apart
45697907|NCT04333407|Drug|Clopidogrel 75mg|• If patient not on clopidogrel or equivalent, add clopidogrel 75mg once daily unless contraindicated
45697908|NCT04333407|Drug|Rivaroxaban 2.5 MG|"If patient not on an anticoagulation, add rivaroxaban 2.5mg bd unless contraindicated~If patient on DOAC then change to rivaroxaban 2.5mg unless contraindicated"
45697909|NCT04333407|Drug|Atorvastatin 40mg|• If patient not on a statin, add atorvastatin 40mg once daily unless contraindicated
45697910|NCT04333407|Drug|Omeprazole 20mg|• If patient not on a proton pump inhibitor, add omeprazole 20mg once daily.
45697911|NCT04398225|Drug|Centanafadine|Extended release capsule
45399806|NCT01763866|Drug|Simvastatin|Administered orally once a day
45697912|NCT04398147|Biological|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
45697913|NCT04398147|Biological|Placebo|Intramuscular administration
45697914|NCT04398927|Drug|Folfirinox|Systemic Chemotherapy (Oxaliplatin，5-fluorouracil and Irinotecan)
45697915|NCT04398927|Drug|Sintilimab|Sintilimab
45697916|NCT03204123|Drug|Ga-HBED-iPSMA PET|Patients will be injected with 100-300 MBq of 68Ga-HBED-iPSMA and after a waiting of 60-90 minutes patients will be scanned from mid-skull to mid-thigh.
45849898|NCT03838848|Drug|KN046|5mg/kg, Q3W, intravenous injection (IV)
45849899|NCT03838848|Drug|Carboplatin|AUC 5 IV Q3W; total dose calculated according to the Calvert formula, with the highest dose not exceeding 750 mg; 4 cycles.
45849900|NCT03838848|Drug|Pemetrexed|500 mg/m2, Q3W, intravenous injection (IV)
45399807|NCT01324037|Other|diagnostic algorithm|diagnostic algorithm consisting of a clinical decision rule, D-dimer and (serial) ultrasonography
45849901|NCT03838848|Drug|Ningetinib|Oral, QD
45849902|NCT03787602|Drug|KRT-232|KRT-232 is an experimental MDM2 anticancer drug taken by mouth.
45849903|NCT03787602|Drug|Avelumab|Avelumab is a PD-L1 blocking antibody anticancer drug administered by intravenous infusion.
45399808|NCT01034423|Dietary Supplement|Omega-3|Capsules with omega-3 fatty acids.
45399809|NCT01034423|Dietary Supplement|sun flower oil|Capsules with sun flower oil.
45399810|NCT00132873|Drug|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution
45399811|NCT01034501|Device|sham procedure|non activated laser tip
45399812|NCT01034501|Device|photodynamic therapy|photodynamic therapy 660 nm,40 mW,60 Hz
45399813|NCT01037543|Drug|HM10460A or placebo or Neulasta|Single SC injection of the appropriate dose of drug ranging from 1.1 mcg/kg to 270 mcg/kg.
45399814|NCT00120627|Behavioral|Mantram Repetition Program (MRP) plus Usual Care|"The MRP teaches 3 strategies to train attention and manage symptoms: Mantram Repetition, Slowing Down and One-Pointed Attention. A mantram is a self-selected, sacred word or phrase that is meaningful to the participant. Slowing down refers to setting priorities and doing things carefully so one is not rushed or does not make mistakes. One-pointed attention refers to concentrating on one thing at a time (similar to mindfulness). These three tools are presented to work together synergistically and cumulatively to interrupt negative thoughts and emotional states such as anger, rage, irritability and hyper-arousal. The unique focus on spiritual words is linked to what one might call inner spiritual resources. MRP was delivered in a 6-week (90 minutes/week) group setting."
45399815|NCT00120627|Other|Usual care consisting of medication and case management|Usual care consisted of case management or meeting with Veterans at least once per month and monitoring medications, if prescribed.
45399816|NCT01588925|Device|Cochlear Implantation|Cochlear implantation using Hybrid L24 Implant
45399817|NCT01588925|Drug|Cochlear Implantation+dexamethasone|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window
45399818|NCT01588925|Drug|Cochlear Implantation+dexamethasone+hyaluronic acid|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window and hyaluronic acid (10mg/ml) in the electrode array
45399819|NCT01589003|Other|Low Glycaemic index growing up milk|Low Glycaemic index growing up milk
45399820|NCT01589003|Other|High GI growing up milk|High glycaemic index growing up milk
45399821|NCT05332756|Other|Conservative management|Patients and their first-degree relatives will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
45399822|NCT01238146|Drug|bendamustine hydrochloride|Given IV
45399823|NCT01238146|Drug|obatoclax mesylate|Given IV
45399824|NCT01238146|Biological|rituximab|Given IV
45507952|NCT03432065|Drug|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial. During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
45507953|NCT03577626|Drug|Hemay005|Hemay005 tablets will be taken orally in dose of 52.5mg at fasted dosing on period one followed by fed dosing on period two.
45507954|NCT03577626|Drug|Hemay005|Hemay005 tablets will be taken orally in dose of 52.5mg at fed dosing on period one followed by fasted dosing on period two
45507955|NCT03412799|Drug|SBP-101|Administered as subcutaneous (SC) injection, escalating dose cohorts
45507956|NCT03412799|Drug|nab-paclitaxel|Administered as intravenous (IV) infusion
45507957|NCT03412799|Drug|Gemcitabine Injection|Administered as intravenous (IV) infusion
45507958|NCT03375359|Diagnostic Test|cfDNA screening|cfDNA screening test for aneuploidy risk assessment
45399825|NCT05292196|Drug|TQC3721 suspension for inhalation|TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
45399826|NCT05292196|Drug|TQC3721 suspension placebo for inhalation|TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
45399827|NCT01141894|Other|Goal directed haemodynamic treatment|Treatment by fluids and Dobutamine to attain fixed haemodynamic goal
45399828|NCT01141894|Other|Routine fluid treatment|Protocol guided fluid treatment used in the clinical routine
45399829|NCT02528422|Drug|Acyl-Ghrelin|
45399830|NCT01238224|Drug|Tadalafil|This is an acute study. Tadalafil 20 mg administered prior to a meal
45399831|NCT01237444|Drug|lopinavir/ritonavir plus one nucleoside|"ARM 1:~Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid"
45507959|NCT03579732|Drug|Aspirin (Acetylsalicylic Acid, BAYE4465)|Low dose of aspirin, i.e. < 150 mg daily
45507960|NCT03579732|Other|No drug|Non-consumers
45507961|NCT01365533|Drug|Roflumilast|Roflumilast 500 μg, one tablet once daily, orally
45507962|NCT01365533|Drug|Placebo|Placebo, one tablet once daily, orally
45507963|NCT03583788|Behavioral|Hypnotherapy|The intervention consisted of hypnotherapy given as five one-hour sessions over 5 weeks as individual therapy instead of motivational interviewing.
45507964|NCT03583788|Other|Motivational Interviewing|The intervention consisted of Motivational Interviewing given as five one-hour sessions over 5 weeks as individual therapy instead of hypnotherapy.
45399832|NCT01237444|Drug|lopinavir /ritonavir plus two nucleosides|"ARM 2:~3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype."
45399833|NCT01145092|Behavioral|exercise training, endurance training|The endurance training group exercised on a cycle ergometer (90% of power output determined at the respiratory compensation point = RCP). The duration of each training unit was increased with time. The resistance group trained on 8 weight machines where the workload gradually increased every 2-3 weeks. At week 13 an additional physical examination, OGTT and spiro-ergometry for adjusting the training were performed.
45399834|NCT01145170|Radiation|Radiotherapy|Radiotherapy will be given at the standard dose between 54 and 60 Gy for irradiation of tumors of the central nervous system.
45399835|NCT01145170|Biological|Nimotuzumab|The patients will receive the induction therapy for 12 weeks. If the patient reaches a complete, partial response (CR, PR) to the treatment or is at least evaluated as stable disease (SD) on week 12, the consolidation therapy should be initiated. The consolidation therapy will consist of the nimotuzumab administration, every 2 weeks.
45399836|NCT01145248|Device|double-balloon enteroscopy forceps biopsy|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . Then, the cannulation of the bile duct is performed by a pusher using a guidewire/guiding catheter. Subsequently, 2 histology samples are taken via a double-balloon enteroscopy (DBE) forceps (BF1725DF, Fujinon GmbH, Willich, Germany), which is placed under the guidance of the pusher.
45399837|NCT01145248|Device|Transpapillary brush cytology|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . The region of interest is then brushed five times in both directions to obtain cytology specimen.
45507965|NCT03548012|Behavioral|The Carer Support Needs Assessment Tool (CSNAT) intervention|The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
45507966|NCT05272345|Procedure|sexual therapy|In sexual therapy; A total of 4 sessions of therapy were initiated with the patients, one session per week for 1 month.
45507967|NCT05191589|Other|Haptic|Trainees are randomized in this group to use the haptic device.
45507968|NCT05477095|Biological|UB-313|A synthetic peptide-based immunotherapy
45507969|NCT05477095|Biological|Placebo|Normal saline
45399838|NCT03762616|Diagnostic Test|Micro-ultrasound targeted biopsy|Micro-ultrasound targeted biopsy using the ExactVu micro-ultrasound system
45507970|NCT03547934|Device|High Intensity Focused ElectroMagnetic system.|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
45507971|NCT02259816|Drug|Telmisartan|
45507972|NCT02259816|Drug|Amlodipine|
45507973|NCT04639505|Diagnostic Test|ELISA|ELISA kit detecting the serum AMH level
45399839|NCT03762616|Diagnostic Test|mpMRI targeted biopsy|Multiparametric MRI targeted biopsy using software assisted MRI/US fusion
45399840|NCT01141972|Dietary Supplement|Vitamin D|We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml [≥75 nmol/L]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency.
45399841|NCT01141972|Other|Placebo|Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
45507974|NCT04639505|Diagnostic Test|Chemiluminescence|CLIA method detecting the serum AMH level
45399842|NCT01142050|Biological|mesenchymal stem cells|1.1st transplantation: after finishing all required examines according to protocol in Day 0, ABM-MSCs are transplanted through pancreas artery percutaneously; 2. 2nd transplantation: after finishing all required examines in Day 7±1, BM-MSCs are transplanted intravenously; 3. 3rd transplantation: after finishing all required examines in Day 14±2, BM-MSCs are transplanted intravenously.
45399843|NCT04316806|Dietary Supplement|Probiotic|Probiotic (dietary supplement) administrated once daily (u.i.d) for 8 weeks (3 billion cfus per day)
45399844|NCT04316806|Drug|Rifaximin|Antibiotic rifaximin consisting 400 mg capsules administrated twice daily (b.i.d) for 1week.
45399845|NCT01145326|Drug|4% lidocaine gel application with sham microneedle device|Topical 4% lidocaine gel (LG4) applied to subject, after application of sham microneedle device (FMA).
45399846|NCT01145326|Drug|Microneedle-facilitated lidocaine application|Application of 4% lidocaine gel (LG4), after application of microneedle (FMA) device
45399847|NCT01144702|Drug|artesunate & mefloquine combination|A therapeutic trial of a single arm for prospective evaluation of responses of individuals with uncomplicated malaria by P. falciparum treated with combination artesunate + mefloquine for three days and monitored clinically and biochemically for 42 days.
45399848|NCT01145404|Drug|Lapatinib|Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.
45399849|NCT01145404|Drug|Lapatinib plus capecitabine|Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
45399850|NCT01237522|Drug|Metformin|A single dose study with one tablet of metformin 500 mg, time frame 24 hours
45399851|NCT02528344|Behavioral|HIIT|All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
45507975|NCT03547310|Behavioral|MyoBeatz|Training of the patient's muscle coordination, strength and ability to separately contract muscles, while holding up patient motivation. The patient is expected to follow a protocol of 4 weeks of training.
45507976|NCT03577548|Other|Auto- questionnaires|10 auto-questionnaires are submitted to the patient during his/her consultation (which is part of the standard care).
45507977|NCT01567735|Drug|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TMC435 capsule is taken once daily for 12 weeks.
45507978|NCT04631471|Drug|Ibudilast|Increasing dose of ibudilast from 60mg/6 capsules per day to 100mg/10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
45507979|NCT04631471|Procedure|Cervical decompressive surgery|Surgical decompression of degenerate cervical myelopathy
45507980|NCT04631471|Drug|Matching placebo|Increasing dose of matching placebo from 6 capsules per day to 10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
45399852|NCT01238302|Procedure|Conventional arthroscopic rotator cuff repair|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~The surgical area was prepared and draped with Betadine.~Small stab incisions were made in the creation of 4-5 portals as needed.~A scope was explored via the arthroscopic portal into the GH joint & subacromial space.~Repair of full thickness rotator cuff tear was done with suture anchors.~The skin was closed with Nylon or medical staples.~Sterile dressing was applied on surgical wound."
45399853|NCT01238302|Procedure|Arthroscopic rotator cuff repair with PRP|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~The surgical area was prepared and draped with Betadine.~Small stab incisions were made in the creation of 4-5 portals as needed.~A scope was explored via the arthroscopic portal into the GH joint & subacromial space.~Repair of full thickness rotator cuff tear was done with suture anchors.~After tying sutures of the medial row, PRP gels were applied on the repair site.~The lateral row was secured using suture anchors.~The skin was closed with Nylon or medical staples.~Sterile dressing was applied on surgical wound."
45399854|NCT01235416|Drug|AMG 706|In each of these 3 planned treatment cohorts, approximately 6 evaluable subjects will be treated with gemcitabine (1000-mg/m2 intravenously over 30 minutes, once weekly starting on day 1, week 1 of cycle 1) and erlotinib (100 mg orally once daily starting on day 1, week 1 of cycle 1)
45507981|NCT03577470|Drug|D/C/F/TAF Fixed-Dose Combination (FDC)|Participants in treatment with D/C/F/TAF FDC, coming from different treatment histories will be observed in this study. No interventions will be administered as a part of this study.
45507982|NCT05269771|Drug|Ruxolitinib|Patients may self-administer daily ruxolitinib tablets qd or bid orally, without regard to food, in accordance with specified dosing schedule provided by the investigator.
45507983|NCT03577392|Drug|oxaliplatin + capecitabine (XELOX chemotherapy)|Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
45507984|NCT03577392|Drug|rebombniant human endostatin|Endostar is a recombinat human endostatin with antiangiogenic properties that has been useful in treating a wide range of cancers and shows promise for use in combination treatment for advanced colorectal cancer. The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
45507985|NCT05575778|Diagnostic Test|computed tomographic perfusion|The recruited patients would complete both pre- and post-operative computed tomographic perfusion
45507986|NCT03577314|Other|miscarriage|(ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).
45507987|NCT04534517|Device|JJV Investigational Multifocal Contact Lens|TEST Lens
45507988|NCT04534517|Device|ACUVUE OASYS® with HYDRACLEAR® PLUS|The spherical test lens was used in the troubleshooting steps only for low ADD subjects who have reported a distance vision complaint.
45507989|NCT03577236|Device|Zenflow Spring System|The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
45507990|NCT03579654|Biological|Proscavax|Proscavax is a prostate cancer vaccine which combines the prostate antigen PSA with immune stimulatory cytokines (IL-2 and GM-CSF).
45507991|NCT04508075|Biological|SARS-CoV-2 vaccine (inactivated)|SARS-CoV-2 vaccine (inactivated) manufactured by Sinovac
45507992|NCT04508075|Biological|Placebo|Placebo manufactured by PT. Bio Farma
45507993|NCT05259397|Drug|PF-07225570|PF-07225570 given IVe in a 28-day cycle (as induction and maintenance regimen). Multiple dose levels will be evaluated.
45507994|NCT05259397|Drug|sasanlimab|Sasanlimab will be administered SQ on day 1 of each 28 day cycle.
45507995|NCT03579576|Drug|sofosbuvir 400 mg/velpatasvir 100 mg (SOF/VEL) orally once daily for 12 weeks with or without weight-based ribavirin.|Direct Acting anti-HCV drugs given to all HCV infected participants at baseline.Those with Co-infections like HIV and or HBV will be given treatment as per national guidelines.
45507996|NCT01364519|Drug|Fluticasone Propionate|Dry powder for inhalation, Single Dose, 500mcg
45849904|NCT03782376|Drug|Ustekinumab approximately 6 mg/kg (IV)|Participants will receive ustekinumab approximately 6mg/kg intravenously at Week 0.
45849905|NCT03782376|Drug|Placebo (SC)|Participants will receive SC injection of placebo at Week 0.
45849906|NCT03782376|Drug|Placebo (IV)|Participants will receive IV infusion of placebo at Week 0.
45849907|NCT03782376|Drug|Ustekinumab 90 mg (SC) Group 1|Participants will receive SC injection of ustekinumab 90 mg at Weeks 8 and 16.
45507997|NCT01364519|Drug|Placebo for Fluticasone Propionate|Dry powder for inhalation, Single Dose, placebo
45507998|NCT03579420|Behavioral|Brief lifestyle program|3-session program for modification of lifestyle habits (exercise and diet)
45507999|NCT03579420|Behavioral|Conventional lifestyle program|6-session program for modification of lifestyle habits (exercise and diet)
45508000|NCT01370057|Device|Thoraco-lumbo-sacral Orthosis|Treatment with Thoraco-lumbo-sacral Orthosis for Adolescent Idiopathic Scoliosis
45508001|NCT02239146|Drug|catridecacog|Single doses of rFXIII administered intravenously (i.v.) to eight subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
45508002|NCT02239146|Drug|placebo|Single doses of placebo administered intravenously (i.v.) to two subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
45508003|NCT03225365|Biological|Blood and biopsy sampling|"Blood samples (52mL) will be taken at week 1, week 3, week 7, week 13, week 53 or at the progression.~Skin biopsies will be taken at week 1, week 7, week 53 or at the progression."
45508004|NCT02831257|Drug|AZD2014|
45508005|NCT03577158|Device|Closed-loop controller with exercise mitigation module|"Each subject will undergo three exercise tests, each one at 1-2 week intervals, thus completing the 3 experiments in about 6 weeks. The day of the experiment, the participant will do 3 sets of 15 minutes of cycloergometer at 70% of VO2max with 5 minutes of rest between them. On the first arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration with a mitigation mode, based on subcutaneous continuous glucose monitoring (First arm, Closed-loop study with mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
45508006|NCT03577158|Device|Closed-loop controller without exercise mitigation module|"On the second arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration without a mitigation mode, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study without mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
45508007|NCT03577158|Device|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin sensibility. Commercial insulin infusion systems and continuous subcutaneous glucose monitoring devices will be used.
45508008|NCT03092609|Behavioral|Attention Bias Modification|Attention bias modification (ABM) sessions will consist of a modified dot-probe task that only contains incongruent trials (i.e., target-dot - neutral stimulus 100% pairing).
45508009|NCT03092609|Behavioral|Attention Control|Attention control (AC) sessions, will consist of a standard dot-probe task (i.e., target-dot - neutral/threat stimulus 50% pairing). Thus, for AC participants, bias should remain the same, while ABM participants should show a reduced bias to threat.
45508010|NCT02253914|Drug|BILR 355 BS, solution|
45508011|NCT02253914|Drug|BILR 355 BS, tablet|
45508012|NCT02253914|Drug|Ritonavir|
45697917|NCT03204123|Diagnostic Test|PET/CT|PET/CT will be acquired using a GE 710 or 690 time-of-flight PET/CT scanner. Following a waiting period of 60-90 minutes post 68Ga-HBED-iPSMA administration, patients will be scanned from top of the skull to mid-thigh. Images will be acquired with patients in a supine position with their arms raised above their head. If patients cannot raise their arms above the head, the arms will be comfortably positioned and secured by the side of the patient. The PET may be combined with a CT scan as a PET/CT or a MRI scan as PET/MR.
45697918|NCT03204123|Diagnostic Test|MRI|Patients may undergo a diagnostic MRI of the prostate, other body parts or a whole-body MRI at the same imaging session as clinically indicated.
45399855|NCT04246996|Drug|gentamicin sulfate|Subjects in the gentamicin arm will receive an bladder instillation of 80mg of gentamicin sulfate in 50 mL of normal saline through a standard-of-care Foley catheter.
45399856|NCT04246996|Other|Catheter clamping only|Subjects in the control arm will have their standard-of-care transurethral catheter clamped for 1 hour post-placement to maintain subject masking to study arm.
45399857|NCT01238380|Other|patient care pathway|"Stage 1: Urinary c-peptide creatinine ratio (UCPCR); if positive progress to Stage 2.~Stage 2: Pancreatic auto-antibodies measurement (GAD65 & IA2); if negative progress to genetic testing.~Genetic testing for HNF1A, HNF4A, GCK. If positive, progress to Stage 3.~Stage 3: review and potential change of diabetes treatment. Monitor success via use of three standardised health and quality of life questionnaires and Hba1c pre-treatment change and at 1, 3, 6 and 12 months post-treatment change."
45508013|NCT02253914|Drug|Placebo|
45508014|NCT01364675|Drug|Metformin+Enalapril+Simvastatin|Poly-pill - composed of Metformin (500 mg), Enalapril (10 mg) and Simvastatin (10 mg) in single tablet given once daily after dinner for 4 years
45508015|NCT01364675|Drug|Placebo tablet|Identical Placebo Tablet
45697919|NCT03203889|Behavioral|CRAFT-AI|Community Reinforcement Approach and Family Training (CRAFT) uses principles of operant conditioning to help a concerned significant other improve their own psychological functioning and influence the identified person with addiction to seek help
45849908|NCT03782376|Drug|Ustekinumab 90 mg (SC) Group 2|Participants will receive SC injection of ustekinumab 90 mg at Weeks 0, 8 and 16.
45508016|NCT03577080|Other|ET+RT+ NMES|Endurance training, resistance training and neuromuscular electrical stimuation were prformed. Intensity was gradually increased.
45508017|NCT02253758|Drug|Propofol|Propofol will be injected as a continuous infusion by TCI intravenously
45508018|NCT05191511|Radiation|Far- infrared|safety of far- infrared
45508019|NCT03100825|Drug|QVM149|QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate)
45508020|NCT03757832|Device|Liver Imaging|The device will acquire thermoacoustic data while the ultrasound probe acquires ultrasound images, and an MR of the liver is acquired as a comparative modality.
45508021|NCT03547232|Drug|Indomethacin SR|Indomethacin SR 50mg given q12h from admission day 1 to day 7
45399858|NCT00424463|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days ) - observation (14 days) cycle is repeated eight times.
45399859|NCT00424463|Drug|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated eight times.
45399860|NCT01324115|Drug|NG-nitro-L-arginine|
45399861|NCT01324115|Other|laboratory biomarker analysis|
45399862|NCT01324115|Other|pharmacological study|
45508022|NCT03547232|Drug|Placebos|Similar shape and size suppositories (Placebos) without indomethacin given q12h from admission day 1 to day 7
45508023|NCT02250534|Other|Very low nicotine content cigarettes|
45508024|NCT01370135|Drug|0.5mg intraocular Ranibizumab (Lucentis)|short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rubeosis and neovascular glaucoma
45508025|NCT05252221|Other|ATC Intervention|The ATC intervention offers convenient access to specialty consultation for PCPs and offers patients direct access to addiction treatment in a non-stigmatized primary care setting
45508026|NCT03634787|Diagnostic Test|CT Scan Day 5-7|Computed Tomography on Day 5-7 according to a clinical protocol.
45508027|NCT05266586|Drug|Obicetrapib|tablets
45508028|NCT05266586|Drug|Ezetimibe 10mg|capsules; 10 mg ezetimibe tablets filled into capsule shells, 1 tablet per capsule.
45508029|NCT05266586|Other|Obicetrapib placebo|tablets; no active ingredient
45508030|NCT05266586|Other|Ezetimibe placebo|capsules; no active ingredient
45849909|NCT03778164|Other|Fast Track Partner Services-Sexual Health Intervention|The Partner Services-Sexual Health Intervention enhances the current standard of care by introducing four service innovations to the DOHMH Partner Services program: (1) enhanced field-based combination HIV and STI testing; (2) immediate field-based ARV/PrEP start; (3) navigation to a sexual health clinic for test results and treatment; and (4) enhanced linkage support to facilitate ongoing PrEP or HIV care.
45399863|NCT01324115|Procedure|computed tomography|
45697920|NCT03203889|Behavioral|TSF-CSO|In individual sessions, the counselor facilitates the CSO's affiliation and involvement in Nar-Anon or Al-Anon groups to work the steps.
45697921|NCT03203187|Other|Mango|330 grams (2 cups) of daily mango intake for two weeks, one cup in the morning, the other in the evening
45399864|NCT01324115|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
45399865|NCT01034735|Biological|r-hGH liquid (Saizen)|Treatment Arm A: r-hGH liquid multidose formulation 5.83 mg/mL, needle injection (0.686 mL)
45399866|NCT01034735|Biological|r-hGH liquid (Saizen)|Treatment Arm B: r-hGH liquid multidose formulation 8.0 mg/mL, needle injection (0.5 mL)
45399867|NCT01034735|Biological|r-hGH freeze-dried|Treatment Arm C: r-hGH 8 mg (8.8 mg/1.51 ml) freeze-dried formulation ( reconstituted in metacresol 0.3% w/v) needle injection (0.686 mL)
45399868|NCT01037621|Drug|Valacyclovir|Valacyclovir 500 mg, 2 caplets twice daily for eight weeks
45399869|NCT00424385|Drug|Gleevec + Sorafenib|400 mg Sorafenib every day (QD) 300mg Gleevec QD
45399870|NCT03994055|Other|Omega-3 fatty acids|Diet will include foods rich in omega-3 fatty acids.
45508031|NCT01370291|Other|active Risperidone and active rTMS|active Risperidone:------- active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC) negative symptoms:high-frequency（10Hz）applied over the left temporoparietal cortex(LTPC)
45508032|NCT01370291|Other|active rTMS and sham Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
45508033|NCT01370291|Other|sham rTMS and active Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
45508034|NCT05575544|Procedure|Acupuncture plus morphine|The acupuncture was combined with intravenous use of morphine to achieve anesthesia during the ablation procedure
45508035|NCT01364831|Behavioral|Sleep extension|Athletic performance evaluated at baseline and following about 1.5 hours of sleep extension
45508036|NCT01364909|Other|Exercise|"The subjects will be given 2 x 30 minute sessions of exercise per day consisting of either passive, active, active assisted depending on level of sedation and stability of condition.~According to level of sedation and stability they may also perform sitting exercises"
45508037|NCT01364909|Other|Usual practice|These patients will not receive exercise early in their intensive care admission
45508038|NCT05179772|Drug|Olanzapine|Olanzapine (2.5 mg to 20 mg)
45508039|NCT05191199|Diagnostic Test|Penile Duplex Study|A penile duplex study will be done to assess PSV, EDV, RI, angle and degree of curvature and Erection quality using the erection hardness grading scale
45697922|NCT03203187|Other|No intervention|No mango intake for two weeks.
45697923|NCT05195073|Biological|Laparoscopy|3 D laparoscopy
45697924|NCT05194059|Behavioral|Home-based physical activity|Participants will follow a personalized activity pacing program
45697925|NCT01059682|Drug|Dalcetrapib|Dalcetrapib 600 mg orally once daily
45697926|NCT01059682|Drug|Placebo|Placebo orally once daily
45508040|NCT05417503|Other|Non-invasive ventilation bi-level|For the NIV intervention, two levels of positive airway pressure (bi-level) were used: the positive inspiratory airway pressure (IPAP) was fixed at 6 cmH2O (centimeters of water), which could be gradually increased up to 14 cmH2O (2 cmH2O every minute), depending on the patient's comfort. and gradually increased to 14 cmH2O (2 cmH2O every minute), While the expiratory airway pressure (EPAP) was set at 3 cmH2O, it could be gradually increased up to 7 cmH2O (1 cmH2O every minute), depending on the patient's comfort.while expiratory airway pressure (EPAP) was fixed at 3 cmH2O and gradually increased to 7 cmH2O (1 cmH2O every minute).
45399871|NCT03994055|Other|Antioxidants|Diet will include foods rich in antioxidant vitamins, trace elements, and polyphenols.
45399872|NCT03994055|Other|Soluble fiber|Diet will include foods rich in soluble fiber.
45399873|NCT03994055|Other|Probiotics|Diet will include foods rich in probiotics.
45508041|NCT05417503|Other|Non-invasive ventilation placebo|The same pressure chosen by the subject during adaptation was used in the placebo intervention; however, a T tube was connected between the equipment and the circuit, creating a leak and leaving the circuit open. The tube characteristics were: 22 x 18 x 22 mm nebulizer T-connector.
45508042|NCT05575232|Behavioral|Application Group (GA)|The main focus of the application is to assist in the treatment of patients with SAH. The application will address the components of adherence to medication use, blood pressure monitoring and promotion/monitoring of physical activity. In addition, health education tips will be provided, including guidelines for reducing sodium consumption, adopting an adequate and healthy diet, controlling body weight, moderate alcohol consumption and stress management, in accordance with the recommendations of the main guidelines related to the theme¹ ³. The intervention will last eight weeks.
45508043|NCT01370681|Drug|Period I : HKB0701 and SLM0807, Period II : CJ30001|
45508044|NCT01370681|Drug|Period I : CJ30001, Period II : HKB0701 and SLM0807|
45508045|NCT02848326|Drug|Atogepant|Atogepant capsule.
45508046|NCT02848326|Drug|Placebo-matching Atogepant|Placebo-matching atogepant capsule.
45508047|NCT05190965|Device|OCTAngiography .FFangiography|octa.ffa findings in pts with diapetic retinopathy
45508048|NCT02477657|Procedure|Paracentesis|Paracentesis
45508049|NCT02477657|Device|Tunneled Intraperitoneal Drain (IPD)|Tunneled Intraperitoneal Drain (IPD)
45508050|NCT02477657|Device|Peritoneal-Venous shunts (PVS)|Peritoneal-Venous shunts (PVS)
45508051|NCT04450043|Behavioral|Run-In Sessions 1-5|Session 1 explores patient goals and wishes for life after cancer treatment with a study interventionist. Sessions 2-5 focuses on learning and practicing skills to enhance post-treatment quality of life.
45508052|NCT04450043|Behavioral|RCT Transitions Program Sessions 1-5|Sessions 1-5 focuses on learning and practicing skills to enhance post-treatment quality of life.
45399874|NCT03994055|Other|Lactose restriction|Diet will be restricted to 5g lactose/day
45508053|NCT04450043|Behavioral|RCT Control Session|Participants will receive a 1-session intervention, focused on reviewing goal progress for post-treatment quality of life, providing encouragement and support, identifying any current concerns, and providing tailored recommendations and resources.
45508054|NCT01567514|Procedure|Glass ionomer cement lining|Resin-modified glass ionomer lining
45508055|NCT01364987|Drug|ASP015K|oral
45508056|NCT01364987|Drug|Mycophenolate Mofetil|oral
45508057|NCT01365923|Drug|remifentanil|remifentanil effect site-TCI 2-4ng/ml
45508058|NCT01365923|Drug|dexmedetomidine with remifentanil|remifentanil effect site-TCI 2-4ng/ml with dexmedetomidine 0.5mcg/kg
45508059|NCT05264168|Drug|Rivaroxaban|Any rivaroxaban dispensing claim is used as the reference group
45849910|NCT03778164|Other|Partner Services Standard of Care|Participants in neighborhoods that have not yet been assigned to the intervention condition in the stepped wedge trial will receive standard Partner Services components, including field-based HIV testing and referral to clinical sites for HIV prevention or treatment.
45399875|NCT03994055|Other|Fiber restriction|Diet will be restricted to 20g fiber/day
45399876|NCT03994055|Other|Fat restriction|Diet will be restricted to 20% total energy intake
45399877|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone|
45399878|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone|
45399879|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
45399880|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
45399881|NCT00423917|Biological|bevacizumab|
45399882|NCT00423917|Drug|fulvestrant|
45399883|NCT00845026|Drug|LY2140023|80 milligram (mg), oral tablets, twice daily: 40 mg in the morning, 40 mg in the evening, for 24 weeks. The dose may be adjusted to a minimum of 40 mg or a maximum of 160 mg.
45508060|NCT05264168|Drug|Apixaban|Any apixaban dispensing claim is used as the exposure group
45849911|NCT03759678|Drug|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
45849912|NCT03745170|Drug|Sintilimab|Weight<60Kg: 3mg/kg Q3W Weignt>=60Kg:200 mg Q3W on Day 1 by IV infusion
45849913|NCT03745170|Drug|Oxaliplatin|130 mg/m^2 Q3W on Day 1 by IV infusion
45849914|NCT03745170|Drug|Capecitabine|1000 mg/m^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
45508061|NCT03579342|Behavioral|App-technology and active coaching to improve lifestyles behaviors|Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
45508062|NCT03579342|Behavioral|App-technology to improve lifestyle behaviors|Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
45508063|NCT03128723|Device|Acne Mask|The light therapy acne mask contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes.
45508064|NCT05575154|Device|optical coherence tomography (OCT)|measuring retinal nerve fiber layer and neuroretinal rim thickness
45508065|NCT03579264|Behavioral|My Viva Plan|Use of the online platform, My Viva Plan, to support health and wellness.
45508066|NCT05261906|Behavioral|LIBERATE|"Five bi-weekly, followed by three monthly, one-hour videoconferencing group education classes via Microsoft Teams video platform will be offered. Participants will be given the choice to communicate with the LIBERATE clinical team (exercise specialist, MD, and/or RN) weekly between the group classes using their preferred method of communication i.e., email.~Classes will offer FreeStyle® Libre-assisted behavioural coaching (i.e., nutrition and exercise). FreeStyle® Libres will be used during the first three months of the program and optionally in the last three months of the intervention. The FitBit Inspire 2™ monitors will be worn for six months. Participants are provided the option to receive individualized aerobic and resistance training prescriptions."
45508067|NCT03579108|Other|Retrospective Chart Review|Chart review
45508068|NCT01370759|Other|Cleaning capsule|Capsules containing the tested materials aimed to improve colon cleansing
45508069|NCT05154110|Other|stretching on whole body vibration|"SSubjects will be refrained from maximum-effort or new routines for exercise the day before each treatment.Static stretching of hamstring on whole body vibration will include Pre- and post-test active and passive ROM for the both legs, with subjects first undergoing a 5-minute warm-up on a stationary bicycle. The traditional static stretch consisted of a supine active knee extension on whole body vibration (WBV) at 30 Hz at the high amplitude setting will be performed. The stretch will be held at the point of the onset of discomfort 3 times each for 30 seconds, with a 20-second rest period between each stretch. Participants will stretch for 4 days per week for 4 weeks. Active hamstring ROM will be measured via active knee extension using a goniometer with the leg in 90° of hip flexion, with the opposite leg extended. Passive ROM will be measured via clinician-assist ted knee extension with the leg in 90° of hip flexion."
45508070|NCT05154110|Other|strength training|In second group, strength training will be done for 4 days per week for 4 days. Subjects will have 5 minutes warm up. In 1st week, the protocol will be Nordic hamstring curl (NHC) with bend (3 sets of 8 reps), Prone hamstrings curl (4 sets of 12 reps/leg), Physio-ball leg curl (3 sets of 8 reps), Glute bridge (2 sets of 50 s/leg). In 2nd to 4th week, the protocol will be NHC with bend (3 sets of 12 reps) Prone hamstrings curl (3 sets of 14 reps/leg) Physio-ball leg curl (3 sets of 10 reps) Glute bridge (2 sets of 50 s/leg). There will be 30 seconds rest between each set and 1 minute rest between each exercise . Pre and post AROM and PROM will be measured. Active hamstring ROM will be measured via active knee extension using a goniometer with the leg in 90° of hip flexion, with the opposite leg extended. Passive ROM will be measured via clinician-assisted knee extension with the leg in 90° of hip flexion.
45508071|NCT01370915|Drug|Pregabalin (Lyrica)|Patients receive oral Pregabalin 150 mg 1 hour before septal surgery, and 12 hours later
45508072|NCT01370915|Drug|Vitamin complex (placebo)|Patients receive oral Placebo(Vitamin complex) 150 mg 1 hour before septal surgery, and 12 hours later
45697927|NCT04398693|Dietary Supplement|Prebiotic|It shall be a double-blinded, randomized, placebo-controlled crossover study and treatment with prebiotic for 4 weeks. After a washout period of 4 weeks, the study protocol will be repeated in the other arm. Participants will receive supplementary diet based on high-amylose cornstarch, which releases large amounts of SCFA (acetate and butyrate) in a sachet with a powder that must be dissolved in a glass of liquid to your choice, during 4 weeks (20 g 2x/day). Participants will undergo anthropometric, biochemistry and GUT microbiota assessment, before and after the end of the first phase of the crossover study. Later, when the inversion of the treatment groups occur all participants will also be subjected to the same procedures before and after the end of the second phase of the study.
45849915|NCT03745170|Drug|placebo|Weight<60Kg: 3mg/kg Q3W Weignt>=60Kg:200 mg Q3W on Day 1 by IV infusion
45849916|NCT03737370|Drug|Docetaxel|Docetaxel will be administered every 2 weeks (on Day 1 and Day 15 of a 28 day cycle). Fractionated dosing dependent on cohort.
45399884|NCT00845026|Drug|aripiprazole|10 mg, oral tablets, once a day in the evening for three days. Followed by a dose increase to 20 mg, 2-10 mg oral tablets, once a day in the evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 30 mg (3-10 mg oral tablets).
45399885|NCT00845026|Drug|olanzapine|10 mg dose (2-5 mg oral tablets) once every evening, for 3 days. Followed by an increase to 15 mg (3-5 mg oral tablets) once every evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 20 mg (4-5 mg oral tablets).
45508073|NCT03577002|Other|Serious Illness Care Program (SICP)|SICP includes the Serious Illness Conversation Guide, which provides patient-tested language for initial and follow-up conversations; training materials, including didactic materials and case studies for structured role playing; and implementation guidance including recommended approaches to identifying appropriate patients and templates for documentation of conversations
45849917|NCT03737370|Radiation|Radium 223|Radium 223 will be delivered every 28 days (on day 1) for 6 cycles.
45399886|NCT00845026|Drug|risperidone|2 mg dose, 2-1 mg oral tablets, given once or twice a day for 3 days. Followed by an increase to 4 mg (4-1 mg tablets), given once or twice a day, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 2 mg/day or a maximum of 6 mg/day (6-1 mg tablets).
45399887|NCT01145716|Procedure|Arthroscopy, surgery|Ulno-volar wrist approach to the TFCC
45508074|NCT05574998|Drug|Recombinant human endostatin (Endostar)|"The specific treatment regimen is as follows: Non-squamous NSCLC: Endostar (210 mg, CIV for 120 h) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) +pemetrexed 500 mg/m2 (d4) Q3W is administered in this regimen for 4 cycles followed by Endostar plus pemetrexed until disease progression or intolerable toxicity.~Squamous NSCLC: Endostar (210 mg, CIV for 120 hours) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) + paclitaxel 175 mg/m2 (d4) Q3W.Endostar is administered after 4 cycles of this treatment regimen until disease progression or intolerable toxicity developed."
45508075|NCT03579030|Drug|Placebo oral capsule|Placebo capsule matched to an RTA 1701 capsule
45508076|NCT03579030|Drug|RTA 1701 capsules|Capsule containing RTA 1701, multiple dosages
45508077|NCT05574842|Behavioral|Double duty interventions using nutrition behavior change communication approach|The packages of the double-duty interventions were modified and adapted from the 2017 WHO policy brief report and Hawkes et al., 2020. These interventions are optimized strong education and nutrition behavior change communication focused on promotion of healthy diets (adequate adolescent nutrition, dietary diversity), physical activity (doing moderate intensity physical exercise, avoiding sitting for log time), prevent undue harm from energy-dense foods (avoiding Junk processed foods, avoiding fizzy sweetened drinks, street fast foods, chips, salt, sugar, fats etc.), and regulations on marketing foods from the customer side (e.g., buying of packed foods frequently).
45697928|NCT04399083|Dietary Supplement|Caffeine|"Caffeine will be administered to each participant following an individualized optimal dosing schedule created by the 2B-Alert app. Individualized caffeine dosing schedules will be created by the 2BAlert app on the smartphone the participant uses to do Smart-PVT tests. Study staff will run the optimization at 1900 on Day 15. The algorithm will recommend caffeine dosing to optimize performance during the Peak Alertness window (e.g. from 0300-0900 on Day 16, 44-50 hours of continuous sleep loss). Doses could be recommended at any hour from 2000 on Day 15 to 0800 on Day 16. HOWEVER, the algorithm will not exceed 800 mg of caffeine across the entire study AND it will not dose more than 300 mg of caffeine at a time. Gum will be chewed for a total of 10 minutes by each participant and then discarded.~As there will be no placebo in this protocol, randomization and blinding procedures are not necessary. IT IS IMPORTANT TO NOTE THAT SOME PARTICIPANTS MAY NOT RECEIVE CAFFEINE AT ALL."
45697929|NCT01892345|Drug|Eculizumab|Induction Phase: 900 mg IV weekly for 4 weeks, followed by 1200 mg for the fifth dose; Maintenance Phase: 1200 mg IV every 2 weeks
45399888|NCT01238458|Drug|[18F]AV-45 PET amyloid binding imaging|"This study will recruit a total of 150 evaluable subjects (30 cognitively normal volunteers, and 60 MCI, and 60 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
45399889|NCT01145794|Behavioral|smoking hygiene intervention|The intervention, SHI, will address SHS and quitting. It will include behavioral counseling to address health hazards of SHS for children, brief advice to quit and to adopt a no smoking policy around children and self-help materials (related to second hand smoking).
45399890|NCT02445131|Drug|Bendamustine|Debulking: Cycles 1 - 2, d1 & 2: 70 mg/m2 i.v.
45399891|NCT02445131|Drug|GA101|"Induction: Cycle 1: d1: 100mg, d1(or2): 900mg, d8 & 15: 1000mg; Cycle 2-6: d1: 1000mg~Maintenance: Cycle 1-8 (Duration 12 weeks): d1 1000 mg."
45399892|NCT02445131|Drug|CAL-101|"Induction: Cycle 2-6: d1-28: 150 mg p.o.~Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84 150 mg p.o."
45399893|NCT01235572|Procedure|standard follow-up care|Undergo early discharge and standard outpatient care
45399894|NCT01235572|Other|medical chart review|Undergo early discharge and standard outpatient care
45399895|NCT01235572|Procedure|quality-of-life assessment|Ancillary studies
45399896|NCT00691678|Drug|Chondroitin|400mg chondroitin three times a day (TID) for twenty-four weeks
45399897|NCT00691678|Drug|Glucosamine|500mg glucosamine TID for twenty-four weeks
45399898|NCT00423605|Drug|Xyrem®|flexible dosing
45399899|NCT01237600|Procedure|Cultivated limbal transplantation|Cultivated corneal epithelial stem cell transplantation. Autograft, Living related allograft, and Cadaveric allograft
45399900|NCT01237756|Device|measurement of left and right lung ventilation|Patients are ventilated after endotracheal tube placement and left and right lung ventilation if determined using electrical impedance tomography
45399901|NCT01142206|Behavioral|Dietary|All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
45399902|NCT01142206|Behavioral|Physical Activity|All participants will receive a physical activity goal of 200 minutes/week of moderate-intense physical activity.
45697930|NCT01892345|Drug|Placebo|Induction Phase: matching placebo (900 mg) IV weekly for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose; Maintenance Phase: matching placebo (1200 mg) IV every 2 weeks
45697931|NCT01059760|Behavioral|Fasting First|28±4 hours of water-only fasting followed by 28±4 hours fed
45697932|NCT01059760|Behavioral|Fed First|28± 4 hours fed followed by 28± 4 hours of fasting
45697933|NCT05179551|Procedure|Proximal Medial Gastrocnemius Recession|. A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied
45697934|NCT04399785|Other|Camrelizumab and SBRT|Camrelizumab: 200mg every 3 weeks; SBRT
45849918|NCT03711786|Other|Basic implementation package|The basic implementation package will involve identifying an internal coordinator who is one of the full-time on-site providers at the clinic. The internal coordinator provides mentoring to peers and support to leadership in implementing the treatment program and aligning it with clinic priorities.
45849919|NCT03711786|Other|Enhanced implementation package|The enhanced implementation package will combine the internal coordinator with an external quality assurance committee. This committee will complete quarterly audits at the facility to evaluate compliance with the depression treatment protocol as well as providing high-level support in implementing the treatment program through clinical expertise and limited on-site presence.
45849920|NCT03701490|Drug|Progesterone subcutaneous|25 mg/twice a day.
45849921|NCT03701490|Drug|Progesterone Vaginal Product|200 mg three times a day.
45849922|NCT03723720|Device|Colonoscopy|Endoscopic examination of large bowel
45849923|NCT03694392|Biological|Flublok Quadrivalent|Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs.
45849924|NCT03694392|Biological|Standard Dose Inactivated Influenza Vaccine (SD-IIV)|For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent.
45849925|NCT03691974|Drug|Fasinumab|Subcutaneous (SC) every four weeks (Q4W)
45849926|NCT03691974|Other|Placebo|Subcutaneous (SC) every four weeks (Q4W)
45849927|NCT03675360|Behavioral|Low-Carbohydrate Diet|"Behavioral modification to reduce carbohydrate consumption. Target <40 g net carbohydrates per day for first 3 months; <60 g net carbohydrates per day for months 4 onwards. The intervention will consist of 4 weekly individual counseling sessions, followed by 4 group sessions held every other week, with phone follow-ups in between group sessions. For the last 3 months of the study, there will be 3 monthly group sessions and 3 telephone follow-ups.~At baseline, participants will receive written information with standard physical activity recommendations."
45849928|NCT03662022|Drug|Rifampicin|Rifampicin will be given in the same way to arms 2, 3 and 4 (weight dependent). Only the strategy of whom to offer PEP differs between the arms.
45849929|NCT03652428|Drug|Gemcitabine|see arm description
45849930|NCT03652428|Radiation|Hypofractionated Ablative Proton Therapy|see arm description
45849931|NCT03592290|Diagnostic Test|Lower body negative pressure|We will be monitoring the changes in central and peripheral monitors/waveforms during gradual hypovolemia induced by lower body negative pressure in healthy volunteers.
46057147|NCT03844282|Diagnostic Test|Clinical assessment (SCAT5)|The SCAT5 is a standardized tool for evaluating sports-related concussions designed for use by physicians and licensed healthcare professionals in patients aged 13 years and above. It is a ten minute paper-based assessment which includes immediate and office/off-field assessments. SCAT5 incorporates the Maddocks' questions, Glasgow Coma Scale (GCS), cervical spine assessment and symptom evaluation, in addition to cognitive and neurological screening.
45399903|NCT01142206|Behavioral|TV Watching + Physical Activity|The TV Watching + physical activity arm will receive a TV watching goal of watching less than 10 hours of TV/week.
45399904|NCT03994289|Behavioral|Motor-assisted cycling|Participants will perform the motor-assisted cycling exercise using a physical therapy bike (RECK; Betzenweiler, Germany). Participants will perform 3×10-min bouts of motor-assisted cycling at the highest tolerable cadence. Before each bout, participants will perform 1-2 minutes of motor-assisted cycling at 5-10 rpm as a warm-up.
45399905|NCT03994289|Behavioral|FES cycling|"The testing procedures will be identical to that in the motor-assisted cycling visit except for the exercise type. Participants will wear FES cuffs on the upper and lower legs, bilaterally.~. The FES cycling will be performed on the motor-assisted bike using the wearable FES equipment. The purpose of motor-assisted cycling is to provide constant cadence. The Bioness L300 Plus system (Bioness, Valencia, CA) will be worn on the upper and lower legs to stimulates the quadriceps and dorsiflexors muscles during the motor-driven cycling exercise. An embedded gyroscope of the cuff can detect the motion of the lower leg so that the electrical stimulations will be generated at appropriate timing to activate leg muscles during the cycling exercise."
45399906|NCT01238614|Other|CHICA PSF plus JIT|
45399907|NCT01238614|Other|CHICA maternal depression PSF|
45399908|NCT01238614|Other|Control|
45399909|NCT00003838|Procedure|T-cell replete PBPC allograft|Subjects will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m2 intravenously (IV) over 30 minutes daily x 5 days with or without ATG followed by a PBPC graft targeted to deliver >5x10^6 CD34+ cells/kg.
45508078|NCT03576846|Other|Stretching and Spinal manipulative therapy|Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles. In addition, subjects will be treated with Spinal manipulative therapy
45697935|NCT03828513|Device|High flow nasal cannula oxygen is applied|Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after High flow nasal cannula oxygen. Pulmonary function tests and blood gas parameters are compared.During the procedure, the patient's blood pressure, heart rate, oxygen saturation, any complications that may develop will be recorded.Induction of anesthesia; difficult airway management, difficult mask and / or difficult intubation incidence, Mallampati scores, the use of one of the difficult intubation techniques during intubation, perioperative mechanical ventilation parameters (ventilation mode, tidal volume, respiratory frequency, end of tidal CO2 (carbon dioxide) pressure, PEEP usage, SpO2 (saturation oxygen), airway peak pressure, urine volume, arterial blood gas parameters are recorded.
45697936|NCT03828513|Device|High flow nasal cannula oxygen is not applied|Apply preoxygenation with facemask. Prior to induction of general anesthesia, preoxygenation will be applied with an oxygen supplement of 5 l / min to an endtidal O2> 90%.Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after preoxygenation.
45697937|NCT01059994|Drug|Placebo sildenafil|Oral, daily, 1 week.
45399910|NCT00003838|Drug|Methotrexate|IV MTX on days +1, +3, and +6 will be given
45399911|NCT00003838|Drug|Cyclosporine|CSA will be given beginning on day -4 for graft versus host disease prophylaxis. Participants with mixed T-cell chimerism on day 30 will begin a CSA taper. Participants with 100% donor T-cell chimerism by day 30 will be tapered off CSA from days 60 through 100 (25% reduction in dose every 10 days-off by day 100). CSA will not be tapered in any subjects with grade > II acute GVHD regardless of chimerism results. In addition, participants with evidence of disease progression without grade > II GVHD will have CSA discontinued regardless of chimerism results.
45697938|NCT01059994|Drug|Sildenafil|oral, 25mg, daily for 1 week
45697939|NCT01061476|Device|Treatment sleep study (Provent™ device used)|The patient's sleep apnea severity is determined on this night while using the Provent™ device. The patient only uses the Provent™ device on this night (single night use only).
45697940|NCT01061476|Other|Baseline sleep study (No device)|The patient sleeps for 1 night in the sleep lab to determine their baseline sleep apnea severity without sleeping with the Provent device.
45697941|NCT01061476|Other|Physiology sleep study (Provent™ on/off)|During this sleep study night, the patient is sleeping with a modified Provent™ device that can be turned on and off to assess changes in airflow during the night (single night use only).Provent™ on/off is bracketed in 10 minute intervals during stable stage 2 sleep.
45697942|NCT01111162|Biological|H1N1 vaccination|Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
45697943|NCT04398303|Biological|ACT-20-MSC|1 million cells / kg body weight in 100 ml in conditioned media
45399912|NCT00003838|Drug|G-CSF|G-CSF will be administered based on body weight for at least 5, and up to 7 days, subcutaneously.
45399913|NCT05258188|Other|Instrument-assisted Soft Tissue Mobilization|Instrument-assisted soft tissue mobilization is used for a mechanical benefit for the therapist providing deeper approach and braces remodeling of connective tissues through dissolution of extravagant fibrosis, while provoking repair and reconstructing forwarded by the recruitment of fibroblast.
45399914|NCT05258188|Other|Compressive Myofascial Release Technique|Compressive Myofascial Release Technique is a technique of soft tissue stretching that uses compression and sustained myofascial stretches to create a releasing force in the targeted area
45399915|NCT01145872|Behavioral|Mindfulness Based Cognitive Therapy|
45399916|NCT01145872|Behavioral|Health Enhancement Program|
45399917|NCT05400772|Other|electromyographic device|An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.
45508079|NCT03576846|Other|Stretching|Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles.
45508080|NCT03547778|Drug|Misoprostol 50 mcg pesssary|Participants in the study arm will receive vaginal misoprostol (50 mcg) to be inserted the night before the procedure. Whereas the control group will get a placebo.
45399918|NCT05214586|Procedure|Follow up of the clinical stage|Pain, Swelling, Infection, Patient satisfaction and recurrence of the disease will be measured
45508081|NCT03547778|Drug|Placebos|The control group will receive placebo pessaries to be inserted vaginally the night before the procedure.
45508082|NCT02238912|Drug|kandhaga rasayanam|KANDHAGA RASAYANAM is a siddha herbo mineral drug with sulphur as a sole mineral ingredient. It is chosen from the classic Siddha text Siddha Vaidhya Thirattu.
45508083|NCT03547700|Drug|Romidepsin|Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression.
45508084|NCT03547700|Drug|Ixazomib|Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.
45508085|NCT02239458|Drug|Saxagliptin|
45508086|NCT03546218|Device|Smartphone Application (SPSRS)|"Participants use application on iPhone and watch videos showing positive-word stimuli. This application repeats positive-word stimuli every 5 seconds.~The participants watch 3-minute motion picture displaying positive-word stimuli."
45508087|NCT03546218|Device|Smartphone Application (YouTube)|Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
45399919|NCT01142362|Biological|VGX-3400X|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
45399920|NCT01235806|Radiation|MRI|MRI of the scaphoid bone fracture suspicion
45508088|NCT03574740|Other|Tobacco Smoking|Influence of Tobacco Smoking on the development of OSA
45508089|NCT04606550|Device|Microablative Fractional CO2 Laser Therapy|Microablative Fractional CO2 Vaginal Laser Therapy
45508090|NCT03574662|Other|Frailty assessment|This assessment consists of a combination of gait speed measurement via infrared sensors as well as a grip strength assessment. Patients will then attend cardiac rehabilitation for an abbreviated six week program.
45508091|NCT03574662|Other|Quality of life assessment|This assessment consists of two questionnaires, Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure questionnaire. Patients will then attend cardiac rehabilitation for an abbreviated six week program.
45508092|NCT05144048|Other|Inpatient setting|These women stay at the maternity unit
45399921|NCT02528266|Device|Nerve Capping Device|
45399922|NCT01238770|Drug|Pazopanib|"Phase I Cyclophosphamid Pazopanib Dose level I 50 mg/day 400 mg/day Dose level II 50 mg/day 600 mg/day Dose level III 50 mg/day 800 mg/day~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally~Phase II:~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally The dose for the phase II part of the trial will be based on the MTD of phase I."
45399923|NCT01145950|Drug|LBEC0101|Etanercept 25mg, single dose
45399924|NCT01145950|Drug|Enbrel|Etanercept 25mg, single dose
45399925|NCT01243606|Behavioral|Single Diagnosis Treatment Protocol|SDPs include: Managing Social Anxiety: A CBT Approach; Mastery of Anxiety and Panic-IV; Mastery of Anxiety and Worry-II; and Obsessive-Compulsive Disorder: A CBT Approach
45399926|NCT01243606|Behavioral|Unified Protocol (UP)|The UP is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. Treatment and session length of the UP will be matched to the SDPs for each principal diagnosis (see description above).
45508093|NCT05144048|Other|Outpatient setting|These women leave the maternity unit
45508094|NCT03578952|Device|TAVR with Evolut R valve|TAVR with Evolut R valve
45508095|NCT05137652|Device|Radiofrequency ablation of medial nerve using single needle approach|The primary outcome is to study the efficacy of the described technique which creates a lesion that we estimate to be 11.0-mm wide and 11.6-mm long along the course of the medial branch adjacent to the SAP ensuring adequate coverage and treatment using VAS score. Responder status was defined as a 30% or greater improvement in VAS pain score from the pre-procedural VAS pain score. Outcomes were summarized by means and standard deviations for continuous outcomes, and frequencies (%) for categorical outcomes.
45508096|NCT05137652|Device|Radiofrequency ablation of medial nerve using three needle approach|The primary outcome is to study the efficacy of the described technique by maximizing the lesion size (compared to control group) along the course of the medial branch adjacent to the SAP ensuring adequate coverage and treatment using VAS score.
45508097|NCT03128411|Drug|Bosutinib|All patients will receive bosutinib at a starting dose of 400 mg QD.
45508098|NCT03578874|Drug|Sorafenib|PO
45508099|NCT03578874|Drug|Capecitabine|PO
45508100|NCT03578874|Drug|Oxaliplatin|IV
45508101|NCT05130632|Behavioral|The community working group|"The intervention consists of educational working group (WG) sessions over a 12-week period. Eight core modules-the essential ingredients-and 4 periphery modules to help identify community-driven interventions to reduce plastic burning in household fires, consume less plastic, recycle, and repurpose plastic, will be held.~Participants will prioritize 1 task that can be attained in the next 9 months, with the guidance of village champions, such as: -starting an organic compost pile free of plastic waste -training on community recycling, focusing on plastics recycling -making organic soaps, to use for personal grooming or washing clothes, eliminate plastic packaging -creating materials out of plastic, like bottle planters, crocheted plastic bags, purses."
45508102|NCT04586504|Drug|Intranasal midazolam|5 mg/mL concentration of midazolam. Maximum dose = 10 mg. Administered using a mucosal atomization device.
45508103|NCT02847858|Behavioral|Health-E You: a computer-based intervention to improve the use of effective contraception among Hispanic adolescents|School-based health centers which were randomized into the intervention arm will use the Health-E You App (n=7 clinics).
45508104|NCT05168306|Device|FreeStyle Libre 2 Flash Glucose Monitoring System|The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older.
45399927|NCT05138380|Device|Foot orthoses|"Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: inbuilt.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist > 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Orthoses are fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)"
45508105|NCT01366001|Drug|ALKS 33-BUP|Sublingual administration, ALKS 33 + buprenorphine, administered once daily for 10 consecutive days.
45508106|NCT01366001|Drug|ALKS 33|Sublingual administration, ALKS 33 administered once daily for 10 consecutive days.
45508107|NCT01366001|Drug|Placebo|Sublingual administration, Placebo administered once daily for 10 consecutive days.
45508108|NCT03574584|Drug|NNC0165-1562|Participants will receive NNC0165-1562 subcutaneous (s.c., under the skin) injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
45508109|NCT03574584|Drug|Semaglutide|Participants will receive semaglutide s.c. injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
45508110|NCT03574584|Drug|Placebo (NNC0165-1562)|Participants will receive placebo (NNC0165-1562) s.c. injection(s) once-weekly for 20 weeks.
45508111|NCT03546998|Diagnostic Test|Clinical instrumental examinations|Achalasia patients were periodically submitted to clinical assessment, barium swallow (esophageal diameter and residual barium column were measured), endoscopy. Mucosal esophageal biopsies were taken in order to diagnose dysplasia or epidermoid carcinoma.
45508112|NCT01365065|Drug|Vorinostat|Vorinostat 400mg (4 x 100mg) orally daily for 14 days
45508113|NCT03576456|Drug|Alprazolam 0.5 mg|receive alprazolam prior to angio
45508114|NCT03576456|Drug|Placebo Oral Tablet|receive placebo prior to angio
45508115|NCT01320215|Procedure|Robot-assisted promontofixation|Sacrohysteropexy with robotic assistance (da Vinci robot)
45508116|NCT01320215|Procedure|Non-robot assisted promontofixation|Laparoscopic sacrohysteropexy, without robot assistance
45508117|NCT04537988|Other|Behavioral: eCHANGE|eCHANGE is an eHealth intervention aiming to support long-term weight maintenance after initial weight loss
45508118|NCT03576378|Drug|BrentuximabVedotin (BV)|All patients will be treated with 6 cycles of BV-EPEM
45508119|NCT04380701|Biological|BNT162a1|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
45508120|NCT04380701|Biological|BNT162b1|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
45508121|NCT04380701|Biological|BNT162b2|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
45508122|NCT04380701|Biological|BNT162c2|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
45508123|NCT05572190|Drug|ETR028, ETR029, [ETR028 + ETR029] or HCBT|Hydrocodone prodrugs
45508124|NCT01365143|Procedure|Robotic Radical Prostatectomy|Robotic assisted radical prostatectomy
45508125|NCT01365143|Procedure|Open Radical Prostatectomy|Open radical prostatectomy
45508126|NCT02035722|Behavioral|Printed materials|AMD-related information is presented to patients in the form of a brochure (i.e. printed materials)
45508127|NCT02035722|Behavioral|Video|AMD-related information is presented as in the form of a video
45508128|NCT01365221|Drug|Prasugrel|Patients who have received 600 mg loading dose of clopidogrel will receive a reloading dose of 60 mg prasugrel
45508129|NCT01365221|Drug|Prasugrel|Patients who have not received a loading dose of clopidogrel will receive a 60 mg loading dose of prasugrel.
45508130|NCT03576222|Device|PICO DRESSING|USE PICO DRESSING ON SURGICAL INCISION AFTER ABDOMINAL WALL REPAIR IN THE SURGICAL ROOM
45508131|NCT03576222|Device|MEPORE dressing|MEPORE dressing
45508132|NCT01366079|Procedure|Position change|Patients change position (cecum to hepatic flexure, left lateral; transverse colon, supine; splenic flexure and descending colon , right lateral) during colonoscopy withdrawal.
45508133|NCT01366079|Procedure|Left lateral|In left lateral position group patients are positioned left lateral decubitus during colonoscopy withdrawal.
45508134|NCT05567588|Combination Product|Drug: Pembrolizumab|200mg(body weight >75kg) or 100mg(body weight≤75kg) given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria.
45399928|NCT05138380|Device|Flat shoe insert|"Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: no.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist > 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)"
45399929|NCT01238926|Dietary Supplement|PD vitamin supplementation|25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid
45399930|NCT01238926|Other|PD exercise intervention|Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum [RM]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
45399931|NCT01238926|Other|PD vitamin + exercise|25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum [RM]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
45399932|NCT05137990|Behavioral|HIIT Exercise Intervention|Exercise trainers will provide encouragement and supervision for exercise prescription adherence and youth will select an age-appropriate music playlist from Spotify to enhance enjoyment throughout each session. Each exercise session consists of a 5-minute warm-up (10% HRmax), followed by a 20-minute HIIT protocol. The 20-minute HIIT protocol consists of seven bouts of 1-min high intensity exercise (90% HRmax) followed by 2-min of active recovery (10% HRmax). Participants will be encouraged to complete each exercise session with at least 24 hours of rest between each session.
45399933|NCT05137990|Behavioral|Stretching Intervention|This group will perform a home-based program of the same stretches utilized in the exercise group. The stretching protocol consists of one set of 4 static stretching exercises held for 30 seconds and performed 3 days/week. As flexibility exercises are low-intensity, low-impact and low-volume, minimal caloric expenditure is expected to be incurred. To increase compliance and aid in the standardization of the home-based stretching, participants will be provided a booklet of the flexibility exercises. Participants will be shown how to use the booklet and instructed in the stretching exercises by an exercise trainer prior to the intervention.
45399934|NCT01239004|Drug|Placebo|6 tablets daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
45399935|NCT01239004|Drug|Colesevelam|6 tablets (3750 mg total) daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
45399936|NCT05171998|Procedure|venous blood sample|Phlebotomy procedure for a venous blood draw.
45399937|NCT05134402|Diagnostic Test|Sleepiz One Connect|Sleepiz One Connect measurements over 10 nights
45399938|NCT01235884|Dietary Supplement|Lactobacillus reuteri|1000000000 CFU per day (5 drops) for 28 days
45399939|NCT01235884|Dietary Supplement|Placebo|5 drops daily for 28 days
45399940|NCT01142440|Behavioral|behavioral intervention|"Dietary instructions~Oral hygiene instructions: GC plaque indicator kit~Antibacterial therapy: medident sol. one week a month, for 6 months~Fluorides: VOCO Profluorid varnish, once every 3 month~Restoration~Follow ups"
45399941|NCT01245322|Drug|lactobacilli|women were given a seven days course of daily 2% vaginal clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral clindamycin 300 mg BID for 7 days (Dalacin 300 mg, Pfizer Norway Ltd). Oral clindamycin treatment was also given to the patient's sexual partner.
45399942|NCT03789994|Behavioral|Affective touch|The affective touch comprises of two elements, namely the signal of care, love and acceptance, and stimulation of CT afferent of the skin. Caregivers will be trained to perform light stroking on stroke survivor's forearm while reviewing happy events with the use of photos.
45399943|NCT03789994|Other|Fine motor exercise|Fine motor exercises that are commonly used for rehabilitation.
45399944|NCT01142518|Drug|Interferon beta 1a|Interferon beta 1a was administered at a dose of 44 μg x 3 as a subcutaneous self-injection.
45399945|NCT03711994|Other|Alkantis|cold therapy pack placed on the wound post operatively
45399946|NCT00423449|Drug|vorinostat|Dose escalation study: vorinostat 300-500 mg capsules once daily for 7-14 days in continuous cycles of 21 days
45399947|NCT00423449|Drug|Gemcitabine|Dose escalation study: Gemcitabine 1000-1250 mg/m2 will be given for 2 days in each 21 day cycle
45399948|NCT00423449|Drug|Platinum-based agent|Cisplatin IV 75 mg/m2 will be given for 1 day in each 21 day cycle or carboplatin dosed according to renal function.
45399949|NCT00423293|Drug|fluorouracil|1000 mg/m^2/day 96-hour continous infusion (M-F) starting on day 1 and again on day 29 of radiation therapy.
45399950|NCT00423293|Drug|mitomycin C|10 mg/m^2 intravenous therapy on day 1 and day 29 of radiation therapy.
45399951|NCT00423293|Radiation|Intensity-modulated radiation therapy|"Prescription dose depends on tumor staging.~T2N0: The primary tumor PTV (planning target volume) (PTVA) receives 50.4 Gy in 28 fractions (fx) at 1.8 Gy/fx. The nodal PTVs receive 42 Gy in 28 fx at 1.5 Gy/fx. PTVA receive 50.4 Gy in 28 fractions at 1.8 Gy/fx. PTV42 receive 42 Gy in 28 fx at 1.5 Gy/fx and will include all nodal regions.~T3N0 or T4N0: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. The nodal PTVs will receive 45 Gy in 30 fx at 1.5 Gy/fx. PTVA will receive 54 Gy in 30 fx at 1.80 Gy/fx. PTV45 will receive 45 Gy in 30 fx electively at 1.5 Gy/fx and will include all nodal regions.~For N+ disease: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. For involved nodes ≤ 3 cm in maximum dimension, the involved nodal PTV will receive 50.4 Gy in 30 fx at 1.68 Gy/fx. For involved nodes > 3 cm in maximum dimension, the involved nodal PTV will receive 54 Gy in 30 fx at 1.80 Gy/fx."
45399952|NCT00423137|Drug|BIBW 2948 BS|Capsule
45399953|NCT00423137|Drug|Placebo|Capsule
45399954|NCT00422903|Drug|lapatinib|1500 mg administered orally daily
45399955|NCT00422903|Drug|letrozole|2.5 mg administered orally daily
45399956|NCT00422903|Other|placebo|1500 mg administered orally daily
45399957|NCT00422669|Device|Medtronic Dual-Chamber Pacemaker|A Medtronic market-approved dual-chamber implantable pulse generator (IPG)
45399958|NCT00422669|Device|Medtronic SelectSecure 3830 Lead|Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
45399959|NCT00422591|Drug|Cytarabine|1.5 g/m2 IV over 24 hours daily on day 1-4 (age <60 years) or days 1-3 (age > 60 years).
45399960|NCT00422591|Drug|Idarubicin|12 mg/m2 IV over 1 hour daily x 3 (days 1-3)
45399961|NCT00422513|Drug|methoxy polyethylene glycol-epoetin beta|120-360 micrograms intravenous (iv) monthly, starting dose
45399962|NCT00422513|Drug|Epoetin alfa|As prescribed, iv, 3 times weekly
45399963|NCT00202878|Drug|ezetimibe/simvastatin|Ezetimibe/simvastatin 10/40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
45399964|NCT00202878|Drug|simvastatin|Simvastatin 40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
45399965|NCT00202878|Drug|Placebo for simvastatin 40 mg|one or two tablets orally daily
45399966|NCT00202878|Drug|Placebo for ezetimibe 10 mg/simvastatin 40 mg combination|one tablet orally daily.
45399967|NCT00414011|Drug|Moxifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
45399968|NCT00414011|Drug|Gatifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
45399969|NCT03994133|Other|Measurement of the hydration state by bio-impedance spectroscopy|"The measurements will be performed in each center by a reference physician or nurse, using a portable whole body bioimpedance spectroscopy device, BCM (Fresenius Medical Care).~The electrodes will be attached to one hand and one foot on the ipsilateral side, after the patient has been in the supine position for at least 5 minutes.~The measurement will be done in pre-dialytic"
45399970|NCT00231816|Biological|ZOSTAVAX™ (concomitant)|a single administration of 0.65 mL subcutaneous injection of zoster vaccine live on Day 1 and placebo at Week 4
45399971|NCT00231816|Biological|Comparator: Influenza Vaccine|a single administration of 0.5 mL intramuscular injection of influenza vaccine (inactivated) at Day 1
45399972|NCT00231816|Biological|ZOSTAVAX™ (Nonconcomitant)|Placebo injection on Day 1 and a single administration of 0.65 mL subcutaneous injection of zoster vaccine live at Week 4
45399973|NCT00260208|Drug|Cyclosporine A|Initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v.) within the first 24 hours post-transplantation.
45399974|NCT00260208|Drug|Tacrolimus|Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses either orally or via a nasogastric (NG) tube or intravenously (i.v).
45399975|NCT00202644|Drug|Anagrelide|Anagrelide hydrochloride 0.5mg capsules;initial dose administered will be 1.0mg/day administered as 0.5mg bid. The dose will be titrated such that the total daily dose is incremented by no more than 0.5mg per week as required depending on platelet reduction versus adverse event profile.
45399976|NCT00202644|Drug|Hydroxyurea|Hydroxyurea is 500mg hydroxycarbamide capsules; initial dose is 1000mg/day, administered in two divided doses (500mg/dose). Dose titrated to effect to achieve a response.
45399977|NCT01235962|Drug|pazopanib|Pazopanib monohydrochloride salt was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.
45399978|NCT01235962|Drug|placebo|Placebo matching pazopanib was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.
45399979|NCT01235962|Drug|pazopanib|Pazopanib 600 mg daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
45399980|NCT01235962|Drug|placebo|placebo matching pazopanib daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
45399981|NCT00259740|Drug|DENOSUMAB|120 mg administered subcutaneously on study days 1, 8, 15, and 29 and every 28 days thereafter. Each dose will be administered in two separate injections of 60 mg (1.0 mL) each.
45399982|NCT00201006|Behavioral|Face-to-face counseling|Biweekly group behavioral counseling sessions conducted in a face-to-face format
45399983|NCT00201006|Behavioral|Telephone counseling|Biweekly telephone counseling sessions conducted in a one-on-one format
45399984|NCT00201006|Other|Mail contact|Biweekly written newsletters with weight management advice delivered via U.S. mail
45399985|NCT00200850|Biological|House Dust Mite SLIT|low dose SLIT 143 Allergen Units(AU)/ml daily
45399986|NCT00200850|Biological|High dose SLIT|House Dust Mite SLIT- 10,000 Allergen units(AU)/ml daily
45399987|NCT00200850|Biological|Placebo SLIT|Placebo SLIT daily
45399988|NCT01073202|Drug|ursodeoxycholic acid|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
45399989|NCT01073202|Drug|identical-appearing placebo|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
45399990|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2590066A|Intramuscular injection, two doses
45399991|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2592984A|Intramuscular injection, two doses
45508135|NCT03124199|Drug|Rifaximin|Rifaximin 400 mg/8 h added to the standard triple therapy
45508136|NCT03546920|Behavioral|ALIGN Intervention Phase|"Communication: The PCSW will follow this structured process to improve and facilitate communication for intervention patients. 1. Attend routine weekly facility-led rounds/meetings reviewing patients, their needs and attend discharge planning conference; 2. Visit with patient and caregiver after the discharge planning conference to ensure understanding of the plan of care; 3. Ensure all appropriate community programs (home health, community palliative care) have made contact and established care, assess the transition, and revisit domains from the initial assessment; 4. Suggest questions that need to be asked of community providers. Throughout the intervention, the PCSW will communicate updates from the visits to all involved providers.~Visits will also focus on increasing goal alignment with the objective that all participants have a ROLT score that is most aligned. Visits will also explore goals of care; this includes completion or review of advance directives."
45508137|NCT03574428|Drug|GNbAC1|Monoclonal Antibody infused i.v.
45508138|NCT03574428|Other|GNbAC1 Placebo|Equivalent to GNbAC1 Buffer
45697944|NCT04398303|Biological|ACT-20-CM|100 ml of conditioned media only
45697945|NCT04398303|Biological|Placebo|100 ml of MEM-α
45697946|NCT03784287|Drug|AX 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
45399992|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2340274A|Intramuscular injection, two doses
45399993|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2340273A|Intramuscular injection, two doses
45399994|NCT01236040|Other|Placebo|Intramuscular injection, two doses
45399995|NCT03812224|Drug|Erenumab|Administered by subcutaneous injection once a month
45399996|NCT03812224|Drug|Placebo|Administered by subcutaneous injection once a month
45399997|NCT01146730|Behavioral|Workcoping and IPS|Maximum 15 sessions of CBT-based counseling with workcoping as primary focus in addition to work support according to the IPS-model (individual placement and support)
45399998|NCT01146730|Behavioral|Ordinary care by GP or NAV|Ordinary care by the participants physician or the local Labour and Welfare Administration
45508139|NCT05565950|Biological|AI-09|Botulinum toxin, Type A, intramuscular injection, administered once at baseline
45508140|NCT05565950|Biological|Vehicle|Vehicle Formulation
45508141|NCT01366157|Genetic|microarray analysis|
45508142|NCT01366157|Genetic|protein expression analysis|
45508143|NCT01366157|Other|immunohistochemistry staining method|
45508144|NCT01366157|Other|laboratory biomarker analysis|
45508145|NCT03574350|Behavioral|KS in Kangaroo Position|KSKP was applied daily at regular interval corresponding to the presence of parents. Our protocol is based on the Tiffany Field's protocol with some adjustments corresponding to the constraints of the hospital : the KS was applied 3 times a day and during 15 consecutive days in the hospital or at home and parents were responsible of delivering the intervention. Sunflower oil was used. During the first 5 days, parents performed KSKP with the support of the psychologist. After day 5, parents were expected to perform KSKP by themselves but could ask for help at any moment while in hospital or in the ambulatory follow-up. The KS always began approximately 60 minutes after the feed.
45697947|NCT03772743|Other|Culprit-only revascularization|Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI. Each patient should receive revascularization with Supraflex stent or its newer versions
45697948|NCT03772743|Other|Complete functionally-guided revascularization|Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI and in all non culprit lesions with positive functional assessment. Each patient should receive revascularization with Supraflex stent or its newer versions
45697949|NCT01111318|Drug|BI 10773|2 tablets BI 10773 25 mg single dose
45697950|NCT05165433|Biological|NG-350A plus Pembrolizumab|Patients receive three doses of NG-350A by intravenous infusion and a single dose of Pembrolizumab by intravenous infusion.
45697951|NCT04760067|Other|Sports Injury Anxiety Scale|Sports Injury Anxiety Scale
45508146|NCT03574350|Behavioral|KS in incubator|The infant is in the incubator, unclothed with diaper. Parents delivered KSI with the infant in supine position, stroking with the flats of the fingers with moderate pressure. Five 1-minute intervals, consisting of six 10-s periods of stroking, were applied to the following body regions: head, back, both legs and arms. The same process was repeated in prone position. The last part of the intervention was composed of 6 flexions of each extremity.
45508147|NCT01365377|Other|booklet deliverance and use in the process of daily information|The brochure shows with text and pictures the day-living of the ICU ; Medical and para-medical staff and organization, the devices, complications and treatment
45508148|NCT03578640|Drug|Elbasvir, Grazoprevir 50-100Mg Oral Tablet|Daily, fixed-dose combination of Elbasvir 50 mg and Grazoprevir 100 mg given in a single oral tablet for 8 weeks.
45508149|NCT02035644|Drug|Jinlida granules|
45508150|NCT02035644|Drug|placebo granules|
45508151|NCT03578562|Other|Targeted training intervention|An 8-week progressive homebased training intervention with supervised booster-sessions
45508152|NCT04465916|Drug|EYP001a|Oral tablets
45508153|NCT04465916|Drug|Placebo|Oral tablets
45508154|NCT04465916|Drug|Nucleotide analogue (Entecavir or Tenofovir Disoproxil)|Oral tablets
45399999|NCT01146028|Drug|Tizanidine|Tizanidine HCl Tablets 4 mg
45400000|NCT00231114|Device|Alair System|Treatment of airways with the Alair System
45400001|NCT00231114|Device|Alair System|Sham treatment of airways with the Alair System
45508155|NCT03575988|Other|Diabetes|The patients have diabetes without diabetic retinopathy from the diabetic outpatient
45508156|NCT01366235|Drug|chloroquine phosphate 1000 mg|1000 mg, 1day
45508157|NCT03578484|Diagnostic Test|Aesthetic assessment 3D breast scanning|Vectra TM - Canfield Inc breast scan. 3D digital photography scan.
45508158|NCT04871165|Diagnostic Test|S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests|S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests.
45508159|NCT04871165|Diagnostic Test|Assessment of proinflammatory cytokine production and immunophenotypic analysis after stimulation with overlapping S-peptides in peripheral blood mononuclear cells (PBMC)|Quantitative evaluation of proinflammatory cytokine (IFN-gamma, IL-2 and IL-4) production after stimulation with overlapping S-peptides in peripheral blood mononuclear cells and immunophenotypic analysis (CD45, CD3, CD4, CD8, CD16, CD56, CD14, CD19)
45508160|NCT04871165|Diagnostic Test|Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens|Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens
45508161|NCT05090852|Device|Hi-VNI|Hi-VNI used instead of or along with endotracheal intubation or jet ventilation to provide oxygen to patients during upper airway surgery
45508162|NCT03578406|Drug|HPV E6-specific TCR-T cells|Patients were infused with HPV E6-specific TCR-T cells
45508163|NCT04465760|Drug|Xisomab 3G3|Given IV or via catheter
45508164|NCT03575676|Drug|SOM3355 100mg BID|Oral
45508165|NCT03575676|Drug|SOM3355 200mg BID|Oral
45508166|NCT03575676|Drug|Placebo BID|Oral
45508167|NCT04249739|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Keytruda ™ (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
45400002|NCT03613480|Other|Motivational Interviewing|Regular sessions of Motivational Interviewing at 2 weeks and then at monthly intervals for a period of 6 months
45697952|NCT03571048|Behavioral|Reduced Calorie Diet (RCD)|Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD.
45400003|NCT03543046|Device|Tortle Midliner|The Tortle Midliner will be applied in the treatment group within the first 3 hours of life and maintained until 72 hours of life.
45400004|NCT03530800|Drug|Dronabinol|Dronabinol for 10 weeks (5mg per day first 2 weeks, 10mg per day second two weeks, 15mg per day last six weeks)
45400005|NCT03530800|Drug|Placebo|Placebo for 10 weeks
45508168|NCT04429958|Other|GDM|different degrees of hyperglycaemia during pregnancy
45508169|NCT03574272|Other|Patient Transfer Monitoring System|The subjects will be provided with portable oximeter and smart-phone which application for monitoring is installed, and the transmitted data will be monitored in real time via monitoring equipment in the (Patient-hospitalized) ward.
45508170|NCT01366313|Drug|Paracetamol|initial doses was 1.5g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
45508171|NCT01366313|Drug|Morphine|Initial of morphine was 5mg, with dose adjustment intervals 1 mg .
45508172|NCT01366313|Drug|Paracetamol- Morphine|The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
46057148|NCT03844282|Diagnostic Test|ImPACT|ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing) is a neurocognitive assessment administered online or using desktop software in a controlled environment. ImPACT has two components: baseline testing and post-injury testing, both of which are used to determine if a patient can safely return to sporting activity post-concussion.
45508173|NCT05561738|Dietary Supplement|Nicotinamide Riboside Chloride|The intervention consists of 6 months to 1 year of daily oral therapy with Nicotinamide Riboside Chloride (Niagen) in addition to standard therapy.
45508174|NCT05561738|Dietary Supplement|Placebo|The intervention consists of 6 months to 1 year of daily oral therapy with placebo (Maltodextran capsules of similar size, shape and color as Niagen) in addition to standard therapy.
45508175|NCT05561738|Other|Standard of Care|Standard of Care
45508176|NCT05190809|Procedure|Goldilocks mastectomy and fat transfer|Skin sparing mastectomy (Goldilocks mastectomy), then autologous fat grafting in the medial and lateral breast pillars as well as the inferior dermal flap
45508177|NCT01371149|Other|Surface parasternal electromyography (EMG) set up|Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
45508178|NCT02253524|Drug|Dimenhydrinate|50 mg Dramamine with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
45508179|NCT02253524|Drug|Metoclopramide|10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
45508180|NCT01371227|Drug|JNS002|30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
45508181|NCT03575598|Drug|Sitravatinib|Sitravatinib (MGCD516) is an orally-available, potent small molecule inhibitor of a closely related spectrum of tyrosine kinases, which has shown antitumor activity in a variety of in vitro and in vivo model systems.
45508182|NCT03575598|Biological|Nivolumab|Nivolumab (OPDIVO®) is a human IgG4 kappa immunoglobulin that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
45508183|NCT02253602|Drug|Ferumoxytol|maximum rate of administration 1 ml/sec
45508184|NCT05190497|Device|Exercise group|Maximal respiratory pressure and reflecting muscles strength were measured by a mouth pressure meter
45400006|NCT03479008|Diagnostic Test|Therapeutic Vibration Device|The Therapeutic Vibration Device is capable of applying force through the axial skeletal spine, through bidirectional compression loading (or prestressing) between the shoulder and the plantar surfaces of the feet. It is placed around the body like a mobile frame so that the applied vibration can affect the whole body. The vibration actuators (drivers) are mobile and can vary in size, frequency response, and force. The design minimizes the possibility of mechanical interference for ventilated/intubated patients.
45508185|NCT03575520|Drug|Pegfilgrastim|A fixed dose of 6.0 mg pegteograstim was administered subcutaneously on day 2 of each chemotherapy cycle (between 22 and 26 hours after the completion of chemotherapy).
45508186|NCT03575520|Drug|Doxorubicin/Cyclophosphamide(AC) treatment|"doxorubicin 60mg/m2 IV every 2 weeks cyclophosphamide 600mg/m2 IV every 2 weeks~Four cycles of dose dense AC treatment will be given every 2 weeks."
45508187|NCT01366391|Drug|Metformin|Metformin 500 mg tablet (1000 or 1500 mg/day)
45508188|NCT04589195|Behavioral|Mindfulness Training|The intervention includes four weeks of MT application use, accessed via phone or computer, consisting of 15-minute daily mindfulness practices 5 days a week.
45508189|NCT03546764|Device|Percutaneous catheter|tube inserted to drain hemothorax
45508190|NCT04408586|Drug|Phentermine-Topiramate Extended Release|Dosing of 3.75/23 mg daily for 15 days, increased to 7.5/46 mg daily
45508191|NCT04408586|Drug|Placebo|Placebo looks exactly like the study drug, but it contains no active ingredient
45508192|NCT04408586|Other|Online support system|VitalCare (VitalTech Affiliates LLC) is a digital health platform that allows remote collection of date from the wearable tracker and digital wellness devices used as part of this study. It also will allow subjects to document study medication compliance and will allow the remote visits to be conducted through a video conference between subjects and appropriate study team members.
45508193|NCT00075816|Biological|Allogeneic bone marrow transplantation|Bone marrow transplant from HLA compatible unrelated donors.
45400007|NCT04982146|Drug|Bromelin|0.5mg per mL of total tumor volume calculated, administered percutaneously
45400008|NCT04982146|Drug|N-Acetylcysteine|20mg per mL of total tumor volume calculated, administered percutaneously
45400009|NCT04958746|Drug|Ciprofol|intravenous bolus
45400010|NCT04958746|Drug|Propofol|intravenous bolus
45400011|NCT01146106|Drug|Pravastatin Sodium|Pravastatin Sodium Tablets 80 mg
45508194|NCT00075816|Biological|Peripheral blood stem cell transplantation|Peripheral blood transplant from HLA compatible unrelated donors.
45508195|NCT04479917|Drug|TPN171H|Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
45508196|NCT04479917|Drug|placebo|Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
45508197|NCT05159726|Other|Video Education|12-minute educational video covering postpartum topics of hemorrhage, infection, hypertension, and depression. Created by Cicatelli Associates Inc.
45508198|NCT03578328|Procedure|targeted temperature management|Temperature control to targeted temperature (32-36C) after return of spontaneous circulation after cardiac arrest and resuscitation
45508199|NCT05542862|Biological|SpikoGen vaccine|Recombinant spike protein based Covid-19 vaccine
45400012|NCT05631340|Other|Discharge education|Researcher's newly prepared discharge education supported by a booklet and mobile app
45400013|NCT03431584|Drug|infiltration of corticosteroids|infiltration of corticosteroids
45508200|NCT03575442|Behavioral|"3 session program of art therapy"|With this program, we expect to offer socio-emotional well-being in the psychiatric context, and creative self-expression through painting. In addition, we hope to provide contributions towards the creation of quality standards of the professional practice of nurses, within the context of implementing psychosocial programs in mental health.
45508201|NCT03578250|Other|Robotic Training|Upper extremity training on a robotic device with or without error augmentation force field.
45508202|NCT03575286|Diagnostic Test|Pregnancy test|Detects hormone (hCG, Human Chorionic Gonadotropin) produced by the body during pregnancy
45508203|NCT03578016|Other|Circle of Security-Parenting|COS-P is a brief, behavioral and insight oriented therapeutic group approach for parents with the aim to promote parental sensitivity and attachment and autonomy in the parent-child relationship. The parents will participate in ten weekly 1,5-hour sessions at the clinic conducted by two COS-certified therapists. Groups will include 4-5 families at a time.
45508204|NCT03578016|Other|Treatment as Usual|TAU consists of clinical assessment and treatment.
45508205|NCT02239614|Biological|TDENV-LAV|0.5 mL of the post-transfection LAV F17 vaccine
45508206|NCT02239614|Biological|TDENV-PIV 4 µg + alum adjuvant|0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant
45508207|NCT05031572|Other|dietary intervention|Chronic caloric restriction diet vs intermittent fasting on energy sensing metabolites and metabolic homeostasis
45508208|NCT02253680|Procedure|Actico, short-stretch, inelastic dressing|Worn 24hr post-operatively
45508209|NCT03572400|Drug|Gemcitabine|Neoadjuvant: Weekly Gemcitabine 200 mg/m2 iv Adjuvant: Gemcitabine 1000mg/m2, D1, 8, 15 Q 4 weeks total 6cycles
45508210|NCT03572400|Drug|Durvalumab|Neoadjuvant: Durvalumab 1.5g iv Q 4weeks Adjuvant: Durvalumab 1.5g iv Q 4weeks for 1 year
45508211|NCT02253836|Drug|Tipranavir|TPV
45508212|NCT02253836|Drug|Ritonavir|RTV
45508213|NCT02253836|Drug|Atazanavir|TAZ
45400014|NCT03431584|Drug|infiltration of corticosteroids and hyaluronic acid|infiltration of corticosteroids and hyaluronic acid
45508214|NCT03575130|Drug|Ripasudil eye drops|Rho-kinase-Inhibitor (IMP)
45508215|NCT03575130|Drug|Optive eye drops|Artificial tears (placebo)
45400015|NCT00259272|Drug|olanzapine|5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks.
45400016|NCT01239706|Drug|NTx 265|10,000IU of hCG, every other day for three doses followed by 4000IU once daily for three days of erythropoietin
45400017|NCT01239784|Behavioral|Home-based neurodevelopmental rehabilitation programme|Participation in the study will require the parent and child to attend two assessment visits in addition to completing a series of parent and infant activities on a daily basis throughout the 10-week intervention period. The parent-led activities will include activities such as walking with the child, stacking blocks, rolling a ball to the child, hiding a toy under a blanket for the child to find, encouraging the child to kick a rattle while the child is lying on his/her back, or crawling or rolling in different directions.
45400018|NCT03425422|Device|VITARIA System|Chronic stimulation of the right cervical vagus nerve
45508216|NCT03575130|Procedure|Descemetorhexis|Corneal endothelial cells are removed prior to IMP administration by Descemetorhexis.
45508217|NCT02241018|Drug|CD25 monoclonal antibody|
45400019|NCT01246570|Behavioral|Exercise training|The patients will meet for organized exercise training once monthly and also exercise testing every third month.
45400020|NCT01246570|Other|Control|The patients will receive the usual care provided by the hospitals and the community health services
45400021|NCT04899856|Device|TransAeris|TransAeris is used to provide neuromuscular electrical stimulation to the diaphragm while the patient is on mechanical ventilation to prevent, slow, or reverse diaphragm disuse atrophy and, more generally, to prevent and treat VIDD.
45400022|NCT01239862|Other|Autologous cell transplantation|Intrabronchial Instillation Of Bone Marrow Derived Mononuclear Cells
45400023|NCT03106324|Drug|Revlimid (lenalidomide)|Treatment with first line Revlimid containing regimen as prescribed in routine clinical practice
45400024|NCT01147276|Drug|Vildagliptin|Vildagliptin (50 mg BID) in four weeks
45508218|NCT02241018|Drug|calcineurin inhibitors|
45508219|NCT02241018|Biological|MSCs|
45508220|NCT04039022|Drug|AXS-05 (dextromethorphan and bupropion) oral tablets|Oral tablets, taken twice daily for up to 12 months.
45508221|NCT03570684|Device|Cable Tie|During the operation, after mobilization the rectum, the disinfected Cable Tie was introduced into the pelvic cavity.then the rectum was bundled by the tie which was easy as the tie is auto-locked. pulling the tie and the rectum would be explored clearly, and then the endoscopic linear cutter was introduced to transect the rectum. the tie made the rectum folded not applanate, that the cutter was able to transect the rectum easily and with less reloader. when the rectum was resected completely, the tie was get out with the specimen, and do not live in the abdomen.
45508222|NCT02244450|Biological|SCID screening|
45508223|NCT04000178|Device|polyurethane stent|patients were prospectively enrolled in the study and stratified (non-randomly) into either group A - polyurethane - control group or group B - silicone - experimental group
45508224|NCT04000178|Device|silicone stent|silicone stent
45508225|NCT03570450|Drug|Adipose derived Stem Cell|3 doses
45508226|NCT03570450|Drug|placebo|placebo
45508227|NCT03573726|Other|Closed diurnal indwelling catheter (CDIC)|Each participant underwent an evaluation during standard of care CIC use vs evaluations during use of the study intervention (CDIC).
45508228|NCT03573570|Other|Fortified rice kernels|The proposed project will leverage the existing state-run public distribution system (PDS) to provide fortified rice through Fair Price Shops (FPS) using a domestically manufactured rice grain (Fortified Rice Kernels: FRK). FRKs are grains made from rice flour, enriched with iron, zinc, Vitamin A, Vitamins B1, B3, B6, B9 and B12, and shaped like a conventional grain of rice. It is mixed into conventional rice in specified ratio of 1:100. The proposed study will be conducted as a cluster-randomized controlled trial, with baseline and follow-up surveys conducted 12-15 months apart. In the interim, 110 Treatment FPS, and all households receiving rice from them, will be randomly assigned to receive fortified rice, and another 110 randomly assigned Control FPS, and the households receiving rice from them, will continue receiving conventional rice and represents the status quo. This study will be conducted in one sub-district of Tamil Nadu with a population of about 1/2 million people.
45400025|NCT01250782|Drug|Glutamine|0.5 g/kg/day of dipeptide N (2)-L-Alanyl-L-Glutamine
45400026|NCT01250782|Drug|Physiological serum|100 mL of physiological serum indistinguishable from active comparator
45400027|NCT03913624|Other|Neuromuscular electrical stimulation|
45400028|NCT05153122|Device|SenseGuard|"SG is a wireless, wearable medical device, which includes nano-based sensors. It can seamlessly measure patient's tidal breathing during daily activities. SG extracts series of critical respiratory parameters, including; Respiration Rate (RR), Inhalation and Exhalation duration and ratio (I/E), as well as novel biomarkers. SG parameters are applicable to evaluate COPD patients' condition, or for monitoring patients with other respiratory conditions.~SG components are:~RSM (Respiratory Sensing Module): non-invasive module with sensors that can detect the exhaled humidity and condensation. The RSM is a non-sterile, disposable, single patient use.~ECU (Electronic Control Unit): a re-usable, wireless data acquisition and transmission unit. The ECU is connected to the RSM during the measurement and transmits the data via Bluetooth to the SG software.~SenseGuard™ Software: for data management, acquisition, processing, logging and presentation of the digital respiratory signals."
45400029|NCT01239940|Device|Coronary angioplasty using the paclitaxel-eluting balloon|Balloon angioplasty
45400030|NCT01239940|Device|Coronary angioplasty using the Everolimus-eluting stent|Stent implantation
45400031|NCT03090412|Drug|HPPH|Given IV
45400032|NCT03090412|Other|Laboratory Biomarker Analysis|Correlative studies
45508229|NCT00109772|Drug|lenalidomide|Two 5 mg capsules taken one time per day
45508230|NCT00109772|Drug|Placebo|Two placebo capsules taken one time per day
45508231|NCT03573492|Other|Education|Type of teaching being assigned to student arms
45508232|NCT03572010|Dietary Supplement|FeFum fortified maize test meal|Maize porridge extrinsically labeled with 2 mg ferrous fumarate (58FeFum); only for iron deficient children (defined by plasma ferritin <40 mikrogramm/L and/or sTfR >8.3 mg/L); cereal staple foods, like maize, depending on milling, may be high in phytic acid, a potent iron absorption inhibitor
45508233|NCT03572010|Dietary Supplement|FeSO4 fortified LNS|self-made Lipid-based nutritional supplement (LNS) extrinsically fortified and labeled with 6 mg ferrous sulfate (57FeSO4); only for iron deficient children (defined by plasma ferritin <40 mikrogramm/L and/or sTfR >8.3 mg/L); LNS may be a better food matrix for iron supplementation compared to maize-based porridge; contains canola oil, peanut paste, milk powder, sugar, maltodextrin and palm stearin
45508234|NCT03572010|Dietary Supplement|FeSO4 supplement|170 mg iron tablets as FeSO4 (containing 55 mg of elemental iron) with 6 mg extrinsically labeled 57Fe; will be given together with a glass of water; only for iron deficient children (defined by plasma ferritin <40 mikrogramm/L and/or sTfR >8.3 mg/L);
45400033|NCT03090412|Drug|Photodynamic Therapy|Undergo PDT
45400034|NCT03090412|Other|Quality-of-Life Assessment|Ancillary studies
45400035|NCT03090412|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
45400036|NCT01146886|Drug|Placebo to BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on on placebo) on Day 1
45400037|NCT01146886|Drug|BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on placebo) on Day 1; Part 2 - oral doses given to 12 subjects on Day 1
45400038|NCT01250860|Other|Derotational manual therapy techniques in selected segments in spine|Derotational manual therapy techniques in selected segments of spine in preparation for the exercises according to the DoboMed method.
45400039|NCT01250860|Behavioral|Sham therapy|
45400040|NCT02782390|Other|Dental Restoration with Stainless Crown|Lesions allocated to this group will be treated with stainless dental crowns according to the Hall Technique protocol (Evans & Innes, 2010).
45400041|NCT02782390|Other|Dental Restoration with Composite Resin|"Surfaces allocated to this group will be treated with composite resin (Z250, 3M ESPE, USA) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 15 seconds, followed by spray of water/air for at least 15 seconds. Then, the adhesive system (Single Bond, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions. Finally, composite resin (Z250, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions."
45508235|NCT03572010|Dietary Supplement|FeSO4 fortified fruit juice|Fruit juice labeled with 12 mg 57Fe as FeSO4; in the group for iron sufficient children
45508236|NCT03571932|Behavioral|Family planning and immunization service integration|The approach involved integration of immunization and family planning services at health facilities. Vaccinators provided brief FP messages one-on-one to mothers and offered a referral for same-day, co-located FP services at the end of each routine immunization visit. For women coming directly for FP, if women had an infant with them, FP providers asked to see the child's health card, checked the return date for the next vaccination and reminded the mother of the date to return. For women without their child or the child health card with them, FP providers reinforced the importance of vaccination, and encouraged the mothers to bring their child for all their vaccines and complete the immunization schedule in a timely manner. A job aid, referral cards, and IEC materials were introduced to support the integration process.
45508237|NCT02245152|Dietary Supplement|LNS|A monthly dose of LNS (31 sachets of 20g) will be distributed to mothers attending well-baby visits and participating in small group counseling
45400042|NCT04877314|Other|Intermittent fasting|30 overweight male volunteers who will have 3 weeks intermittent fasting which has 16 hours fasting and 8 hours eating in a day period.
45400043|NCT01146184|Device|Flexible endoscope and Ethicon Manually Articulating Device|Using the Flexible Endoscope and the Ethicon Manually Articulating Device, removal of the gallbladder through a single incision is improved.
45400044|NCT01247896|Drug|PF-05190457|Single Dose 2 mg
45400045|NCT01247896|Drug|PF-05190457|Single Dose 10 mg
45400046|NCT01247896|Drug|PF-05190457|Single Dose 30 mg
45400047|NCT01247896|Drug|PF-05190457|Single Dose 100 mg
45400048|NCT01247896|Drug|PF-05190457|Single Dose 300 mg
45400049|NCT01247896|Drug|PF-05190457|Single Dose 600 mg
45400050|NCT01247896|Drug|PF-05190457|Single Dose - to be determined with food
45400051|NCT01247896|Drug|PF-05190457|Single Dose - to be determined
45400052|NCT01247896|Drug|Placebo|Single Dose Placebo
45400053|NCT02693080|Device|CAPP-Seq|Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) is an assay which allows quantitative assessment of the levels of circulating-tumor DNA in the blood sample.
45508238|NCT02245152|Behavioral|Child's health and nutrition topics|"After the well-baby visit. Caregivers will be invited to participate in a small group counseling or BCC (2-3 caregivers at a time).~Every month a set of topics related to child's health and nutrition will be treated. These BCC sessions will be organized in an interactive way centering around the condition of the participating children."
45508239|NCT02245152|Behavioral|National policy well-baby visits|
45508240|NCT03908450|Device|PTCA of coronary de novo lesion PCB|PTCA of coronary de novo lesion with drug coated balloon
45508241|NCT03908450|Device|PTCA of coronary de novo lesion SCB|PTCA of coronary de novo lesion with drug coated balloon
45508242|NCT03571854|Device|Group PCV-VG|Pressure controlled ventilation-volume guaranteed
45508243|NCT03571854|Device|Group VCV|Volume controlled ventilation
45400054|NCT02693080|Drug|Isovue-200|Contrast agent
45400055|NCT02693080|Radiation|Computed Tomography Perfusion Imaging|
45400056|NCT02526004|Drug|Ceftazidime|
45400057|NCT02526004|Drug|Tobramycin|
45400058|NCT01146262|Other|cell therapy product|Patients receive for up to 5 doses of apoptotic corpse pulsed dendritic cells after CR1 ou CR2 documentation (9/10 subcutaneously and 1/10 intradermally) every week, except the last injection performed at 2 weeks from the 4th injection.
45400059|NCT01146262|Procedure|injection of the cell therapy product|Cytapheresis D0: 1st injection of the cell therapy product, J7 2nd injection of the cell therapy product, J14 third injection of the cell therapy product,J17 cutaneous biopsies, J21 fourth injection of the cell therapy product, J35 fifth injection of the cell therapy product
45400060|NCT00421889|Drug|belinostat|
45400061|NCT00421889|Drug|Paclitaxel|
45400062|NCT00421889|Drug|Carboplatin|
45400063|NCT01146964|Procedure|MSSICS|Manual super small incision cataract surgery
45400064|NCT01146964|Procedure|Phacoemulsification|cataract surgery with Phacoemulsification
45400065|NCT01440010|Radiation|IORT with 50 kV x-rays, 20 Gy|Intraoperative radiotherapy with the INTRABEAM System with 20 Gy
45400066|NCT01146340|Radiation|Hypofractionated radiotherapy|40 Gy / 5 fractions / 29 days
45400067|NCT03913468|Drug|Intravenous Ascorbic Acid|1.5 grams IV ascorbic acid q6h, 50 mg IV hydrocortisone q 6 hours, and 200mg IV thiamine BID administered (as documented in medical record)
45508244|NCT01560104|Drug|Veliparib|
45508245|NCT01560104|Drug|Carboplatin|
45508246|NCT01560104|Drug|paclitaxel|
45400068|NCT03913312|Biological|Unrelated cord blood|Unrelated cord blood comes from Shandong cord blood bank. TNC>1.5*107/kg;HLA 4-5/6
45400069|NCT03913546|Procedure|Spinal manipulative therapy|Participants in the actual spinal manipulative therapy group will be assessed through the activator basic method protocol. SMT will be performed with an Activator IV (Activator Methods International, Phoenix, AZ) setting the force at level 3 for the low thoracic spine (T7-T12), and level 4 for the lumbar spine and pelvis.
45508247|NCT01560104|Drug|placebo|
45508248|NCT03573258|Dietary Supplement|Fiber or Placebo (depending on the randomization)|ingestion of dietary fibers prior to meal intake
45508249|NCT04338152|Behavioral|Family Focused Therapy for Clinical High Risk Youth (FFT-CHR)|Family-Focused Therapy (FFT) has been tested in randomized trials involving persons with bipolar disorder, depression, and clinical high-risk syndromes. FFT-CHR provides families with psychoeducation (sessions 1-6) about prodromal symptoms and the role of the family in helping maintain stability. Clients are supported in building coping skills and monitoring thoughts, perceptions, and mood. The family formulates a prevention action plan to prevent prodromal symptoms from escalating into full episodes. Communication training (sessions 7-13) teaches families to express positive and negative feelings, listen actively, make positive requests for change, and communicate clearly through role-playing and between-session practice. In problem solving (sessions 14-18) participants learn to break down problems into smaller ones, evaluate pros/cons, and choose solutions to implement.
45508250|NCT04338152|Behavioral|Enhanced Care (EC)|Enhanced care (EC) has been tested as a family educational treatment in CHR and bipolar youth. The first 3 sessions of EC involve the CHR person and family (parents, siblings) and cover the same content as the psychoeducational module of FFT in abridged form. The objective of these sessions is to develop a prevention action plan. Then, the CHR person is offered monthly individual sessions with the same clinician over the next 5 months, for a total of 8 sessions over 6 months. The individual sessions focus on applying the prevention action plan when symptoms emerge, and supportive, nondirective problem-solving regarding areas of conflict with family, with peers or in the educational or occupational arena. The clinician also serves as case manager.
45508251|NCT00101972|Biological|monoclonal antibody RAV12|Escalating doses of RAV12 (weekly 0.3, 1.0, 1.5, 3.0, 4.0, 5.0, 6.0 mg/kg or 0.5 mg/kg BIW or TIW; 0.75 mg/kg BIW) for 4 weeks
45508252|NCT02245854|Device|Exacto™|Cold snare polypectomy
45508253|NCT00100256|Drug|Rhenium (Re 188 P2045, BAY86-5284)|Infusion once only
45508254|NCT03571698|Device|Neuromuscular Electrical Stimulator|The treatment group received exercise programme with simultaneously active contraction with NMES with large or standart electrodes.
45508255|NCT02245932|Dietary Supplement|Resveratrol|4 weeks of 150 mg resveratrol (2 times 75mg/day)
45508256|NCT02245932|Dietary Supplement|Placebo|4 weeks of placebo supplementation (two doses per day)
45400070|NCT03913546|Other|Sham spinal manipulative therapy|Participants in the sham SMT group will undergo a protocol identical to the actual one, with the exception that a sham mechanical thrust (force set at level 0) will be delivered to the targeted areas. In the force level 0 no excursion of the stylus occurs, but the instrument produces the same clicking sound as in the actual SMT condition
45400071|NCT01147354|Dietary Supplement|selenium yeast|The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.
45400072|NCT01147354|Other|placebo capsules|The patients in this arm took one placebo capsule daily for 12 weeks.
45400073|NCT01435408|Other|Conventional primary PCI|Conventional primary PCI in STEMI with implantation of DES.
45400074|NCT01435408|Other|Ischemic postconditioning.|Primary PCI in STEMI with implantation of DES. Following re-opening of the culprit artery mechanical postconditioning with 4 cycles of 30/30 sec. reperfusion/re-occlusion i performed.
45400075|NCT01435408|Other|Deferred stenting in primary PCI.|In STEMI re-opening of the artery with guidewire/thrombectomy/small size balloon inflation DES stenting is postponed for 48 hours.
45508257|NCT03573102|Drug|SGLT2 inhibitor|SGLT2 inhibitor 10 mg/day
45508258|NCT03573102|Drug|ACE inhibitor|ACE inhibitor once daily
45508259|NCT03865706|Drug|Inulin Oral Suspension|Inulin powder, derived from chicory root and re-suspended in 250cc water Dosage will be either 8g twice a day or 16g twice a day - dissolved in 250cc sterile water, given oral or via enteric tube
45508260|NCT03865706|Drug|Placebo Oral Suspension|250cc sterile water alone, given twice daily a sweetener is added to the water to create identical flavor
45508261|NCT03865706|Drug|Broad-spectrum antibiotics|Standard of care treatment for infections
45508262|NCT02246088|Procedure|MT + NE|"Manual therapy will be applied using mobilization with movement (MWM) techniques. MWM will consist of a sustained manual glide of the tibia (either medial, lateral, anterior, posterior, or rotation) during active knee flexion and extension, depending on which are the limited/painful movements for each patient.~The content and pictures of the neuroscience education (NE) will be based on the text Explicando el dolor (Spanish version of Explain Pain)."
45508263|NCT02246088|Procedure|MT + E|Program of education based on the traditional biomedical model (i.e. through visualization of several videos related to anatomy, biomechanics and surgical procedure of the knee), plus the same manual treatment as per the MT+NE group
45508264|NCT02254070|Drug|BIBT 986 BS|
45508265|NCT04980248|Biological|ALXN1850|ALXN1850 will be administered as an IV infusion and via the SC route.
45508266|NCT04960046|Procedure|Placement of an infraclavicular perineural catheter using a costoclavicular approach|"The high-frequency linear probe will be used to image the axillary artery in the long axis and nearby nerve structures of interest, namely the posterior, lateral and medial bundles. The plane chosen will be located inferior to the clavicle, also in its distal third. The needle will be inserted with a latero-medial orientation in the plane. The initial injection will be a single injection laterally to the axillary artery, where the three nerve bundles are still joined together.~The catheter will then be positioned and its location verified by injecting an additional 5 mL of bupivacaine into the catheter under direct ultrasound visualization. Catheter fixation will be standardized to minimize the risk of accidental displacement and the point of entry of the catheter to the skin will be covered with an opaque dressing."
45508267|NCT04960046|Procedure|Placement of an infraclavicular perineural catheter by paracoracoid approach|"The high-frequency linear probe will be used to image the axillary artery in the short axis and nearby nerve structures of interest, namely the posterior, lateral and medial bundles. The plane chosen will be located inferior to the clavicle, in its distal third. The needle will be inserted with a cranio-caudal orientation in the plane. The initial injection will be a single injection posterior to the axillary artery, the expected distribution being a U distribution around the artery.~The catheter will then be positioned and its location verified by injecting an additional 5 mL of bupivacaine into the catheter under direct ultrasound visualization. Catheter fixation will be standardized to minimize the risk of accidental displacement and the point of entry of the catheter to the skin will be covered with an opaque dressing."
45508268|NCT04944368|Biological|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
45508269|NCT04944368|Biological|Saline placebo|0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
45508270|NCT03720704|Device|GORE VIABAHN VBX Balloon Expandable Endoprosthesis|GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted in peripheral vessels in patients who require interventional treatment.
45508271|NCT03545672|Diagnostic Test|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
45508272|NCT04268498|Drug|Bortezomib|1.3 mg/m2 administered Subcutaneous (SC) or intravenous (IV) on days 1, 4, 8 and 11 of a 21 day treatment cycle for participants randomized to Arm A.
45508273|NCT04268498|Drug|Dexamethasone|"20 mg or 40 mg per dose administered by mouth (PO) or IV.~Participants randomized in Arm A:~20 mg/dose on days 1, 4, 8 and 11 on a 21 day treatment cycle;~Participants randomized in Arm B:~Cycles 1 through 8 - 40mg/dose on days 1, 8 and 15 on a 28-day cycle~Participants randomized in Arm C:~Cycle 1-2 - 40 mg/dose on days 1, 8, 15 and 22 on a 28-day cycle; Cycles 3-8 - 40mg/dose on Days 1, 8, 15 on a 28-day cycle;"
45508274|NCT04268498|Drug|Lenalidomide|"10 or 25 mg/day capsules administered PO.~Participants randomized in Arm A:~25 mg/day capsules on Days 1 through 14 of a 21 day cycle.;~Participants randomized in Arm B:~Cycles 1 through 8 - 25 mg/day capsules on Days 1 through 21 of a 28 day cycle;~Participants randomized in Arm C:~Cycles 1 - 25 mg/day capsules on Days 2 through 21 of a 28 day cycle; Cycles 2 through 8 - 25 mg/day capsules on Days 1 through 21 of a 28 day cycle;~Maintenance Therapy:~10 mg capsules on Days 1 through 21 on a 28 days cycle."
45849932|NCT03580044|Combination Product|ATM-AVI|ATM-AVI doses (loading, extended loading and maintenance) and the dosing frequency of the maintenance dose are dependent on renal function. Subjects will be given a loading dose of 500 mg ATM plus 167 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 30 minutes. This treatment will immediately be followed by an extended loading dose of 1500 mg ATM plus 500 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 3 hours. Then there will be a 3 hour or 5 hour gap. Subjects will receive a maintenance dose of 1500 mg ATM plus 500 mg AVI every 6 hours or 750 mg ATM plus 250 mg AVI every 6 hours, or 675 mg ATM plus 225 mg AVI every 8 hours. Subjects with cIAI will also receive Metronidazole (MTZ) 500 mg IV q8h over 60 minutes. The first dose of MTZ will be started immediately after the extended loading dose of ATM-AVI has completed and treatment will be continued until the end of the treatment period.
45400076|NCT03916666|Procedure|Epiduroscopy|Endoscopic intervention
45400077|NCT01248286|Other|Whole grain rice|Whole grain rice arm (treatment arm): Subjects will be provided a supply of whole grain rice and will be asked to prepare rice items in their meal with the provided whole grain rice while participating in the study
45400078|NCT01248286|Other|Refined grain rice|Refined grain rice arm (control arm): Subjects will be provided a supply of refined grain rice and will be asked to prepare rice items in their meal with the provided refined grain rice while participating in the study
45508275|NCT04268498|Drug|Acetaminophen|"650 mg administered PO.~Participants randomized to Arm C:~Cycles 1 through 8 - 650 mg administered on Days 1, 8 and 15."
45508276|NCT04268498|Drug|Diphenhydramine|"25 mg administered via IV~Participants randomized to Arm C:~Cycles 1 through 8 - 25 mg administered on Days 1, 8 and 15."
45508277|NCT04268498|Drug|Montelukast|10 mg administered PO to participants randomized to Arm C prior to the first 4 doses of Daratumumab.
45508278|NCT04268498|Drug|Carfilzomib|"20 mg or 56 mg/m2 per dose administered via IV.~Participants randomized to Arm B:~Cycle 1 - 20 mg/m2 per dose on Day 1 and 56 mg/m2 per dose on days 8 and 15 of a 28 day cycle; Cycles 2 through 8 - 56 mg/m2 per dose on days 1, 8 and 15 of a 28 day cycle;~Participants randomized to Arm C:~Cycle 1 - 20 mg/m2 per dose on Day 2 and 56 mg/m2 per dose on days 8 and 15 of a 28 day cycle; Cycles 2 through 8 - 56 mg/m2 per dose on days 1, 8 and 15 of a 28 day cycle"
45508279|NCT04268498|Drug|Daratumumab|"16 mg/kg administered via IV or 1800 mg SC, per treating physician discretion.~Participants randomized to Arm C:~Cycles 1 though 2 - 16 mg/kg IV or 1800 mg SC on days 1, 8, 15, and 22 of a 28 day cycle; Cycles 3 through 6- 16 mg/kg IV or 1800 mg SC on days 1 and 15 of a 28 day cycle; Cycles 7 through 8 - 16 mg/kg IV or 1800 mg SC on day 1 of a 28 day cycle"
45400079|NCT04744480|Procedure|The combined topical anesthesia induction group|The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia，3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.
45400080|NCT03916588|Behavioral|Individualized Care Plan|Medical, neuropsychological, and social assessment of patient's cognitive, behavioral, medical, and environmental needs with a focus on improving quality of life, reducing health care utilization, and improving staff/family caregiving burden along with a specific plan to address and monitor identified patient and staff/facility needs
45400081|NCT03913780|Other|Aerobic exercise more force|The work force for aerobic exercise is 50 to 70% of your maximum heart rate (HRM) achieved in the stress test according to the Naughton protocol. For strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale.
45400082|NCT01147432|Drug|PF-04427429|Single dose IV infusion up to 300mg
45400083|NCT01147432|Other|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
45400084|NCT01147432|Drug|Placebo|Placebo IV infusion (saline) to be administered during two of the three treatment periods
45400085|NCT01147432|Other|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
45400086|NCT01147432|Other|EMLA positive control|2g EMLA cream to be applied ONCE during study period 1
45400087|NCT01147510|Drug|Combination of low ICS and montelukast|Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m and take orally a tablet of Singulair® 10mg one time per day.
45400088|NCT01147510|Drug|Monotherapy of medium dose ICS|Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m. and between 7 p.m. and 10 p.m. two times per day
45400089|NCT03916432|Device|HELIOS biodegradable polymer sirolimus-eluting stents|HELIOS biodegradable polymer sirolimus-eluting stents
45400090|NCT00421733|Drug|Zemplar (paricalcitol ) capsules|Group 2 - paricalcitol 1 mcg capsules once daily (one paricalcitol 1 mcg capsule once daily and one matching placebo capsule once daily)
45400091|NCT00421733|Drug|Zemplar (paricalcitol) capsules|Group 3 - paricalcitol 2 mcg capsules once daily (two paricalcitol 1 mcg capsules once daily)
45400092|NCT00421733|Drug|Placebo|Group 1 - Placebo once daily (two placebo capsules once daily)
45508280|NCT04268498|Biological|Autologous Stem Cell Transplant (ASCT)|Participants who are MRD positive at the conclusion of 8 cycles of study treatment, and were able to have their stem cells that were extracted, will receive ASCT from participants' bone marrow samples.
45400093|NCT01249378|Other|All subjects receive three sequences of a standard breakfast|"All subjects receive three sequences of a standard breakfast containing :~10 g non emulsified~or 40 g non emulsified~or 40 g finely emulsified of milk fat with stable isotope (13C triglyceride). The administration order is determined by randomized allocation. The wash-out period is three weeks. There are not diet or exercise interventions. Only, one week before and three days after, the subjects consume neither naturally enriched in 13C foods or pre/probiotics. In addition, three days before and three days after each test, the subjects receive dietary instructions"
45400094|NCT00421343|Drug|alendronate with cholecalciferol|alendronate 70mg /cholecalciferol 2800IU orally once weekly
45400095|NCT00421343|Drug|calcium carbonate with cholecalciferol|calcium carbonate 500mg /cholecalciferol 200IU orally twice daily
45400096|NCT00421343|Behavioral|Falls prevention measures|personalized exercises, home safety evaluation, referral to an eye doctor if needed, review of medications
45400097|NCT03915808|Dietary Supplement|Conjugated linoleic acid group|supplementation of 3.2 g/day conjugated linoleic acid in 8 capsules, and receive education sessions every four weeks (Dietary and lifestyle counselling, featured with low fat and low added sugar, moderate physical activity)
45400098|NCT03915808|Dietary Supplement|Sunflower oil group|supplementation of equivalent sunflower oil in 8 capsules, and receive education sessions every four weeks (Dietary and lifestyle counselling, featured with low fat and low added sugar, moderate physical activity)
45508281|NCT04260464|Drug|PF-06700841|A single dose of 30 mg PF-06700841 will be administered on Day 1
45508282|NCT02783066|Device|Offloading boot: PulseFlow|A new offloading boot, which may enhance balance, gait, and lower extremity blood flow
45400099|NCT03915730|Other|Initial periodontal therapy|Scaling and root planing and polishing with specific curettes were performed to patients with CP and oral hygiene education was provided to each patient.
45400100|NCT01147588|Drug|lansoprazole|60 mg (2x30-mg capsule), once daily
45400101|NCT01147588|Drug|omeprazole|80 mg (2x40-mg capsule), once daily
45508283|NCT03754868|Diagnostic Test|Detailed coagulation monitoring|Monitoring of coagulation using activity of coagulation factors, rotational thrombelastometry and multiple electrode aggregometry
45508284|NCT03687710|Behavioral|Multidomain precision medicine intervention|Participants will receive individualized evidence-based multidomain interventions (education, pharmacologic, non-pharmacologic) in the setting of routine outpatient clinical care.
45508285|NCT03651518|Drug|Kineret|100 mg, once/day sc 6 months
45508286|NCT03651518|Drug|Humira|40 mg/15 days sc 6 months
45508287|NCT03651518|Drug|Stelara|45 mg/12 weeks sc, 6 months
45400102|NCT01147588|Drug|esomeprazole|40 mg (1x40-mg capsule), once daily
45400103|NCT01147588|Drug|clopidogrel|300 mg loading dose on Day 1 then 75 mg daily for 28 days
45400104|NCT03908710|Other|Treatment of hypertension using blood pressure self-measurement at home|The primary aim of the present study is to investigate whether home blood pressure recording via Bluetooth and continuous communication between doctor and patient will give improved blood pressure values when comparing the initial values with the blood pressure values recorded after 3 months. Secondary examinations include treatment of hypotension and adverse events, the patient's experience, the user's potential problems with the blood pressure cuff, app downloading, problems with history issues or problems with technical
45400105|NCT03915886|Drug|JNJ-0440|JNJ-0440 tablets will be administered orally.
45400106|NCT03915886|Drug|Placebo|Matching placebo tablets will be administered orally.
45400107|NCT01253434|Drug|E2022|E2022 Type A patch
45400108|NCT01253434|Drug|E2022|E2022 Type B patch
45400109|NCT01253434|Drug|E2022|E2022 Type C patch
45400110|NCT01253434|Drug|E2022|E2022 Type D patch
45400111|NCT01253434|Drug|E2022|E2022 Type E patch
45508288|NCT03651518|Drug|Cosentyx|300mg sc every week for 1 month, then 300 mg/month sc for 5 months
45508289|NCT03651518|Drug|Roactemra|480 mg/perf/4 weeks 6 months
45508290|NCT03651518|Drug|Rituximab|2 sessions of 1000 mg at inclusion and 15 days after inclusion
45508291|NCT03640208|Behavioral|Education presented by trained caregiver|After participants complete the Pre-test, an educational session will be presented by a trained caregiver, delivered in a lecture-style manner with Power Point projection of educational material. The slides in this presentation will be scripted to mitigate variability among different presenters. Topics addressed in the presentation include: CRC basics (including brief anatomy), data on disparity, risk factors, screening modalities, preventative measures, population disparities of CRC, colonoscopy exam and other screening tests. The emphasis will be on CRC risks factors and prevention. All required information that is needed to correctly answer post-test questions is embedded within the presentation.
45508292|NCT03546530|Drug|Interferon|Interferon
45508293|NCT03546530|Drug|Interferon+resveratrol|Interferon+resveratrol
45508294|NCT04912466|Drug|Biological: IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
45508295|NCT04897568|Other|Patient decision aid|Each subject will receive an informational flyer describing lung cancer screening options and smoking cessation from a trained person on the medical staff at each clinic. Staff will lead a shared decision-making discussion with the patient.
45508296|NCT03568994|Drug|Atovaquone|"Patients will receive standard of care MRC based Induction chemotherapy (such as ADE 10+3+5 with daily atovaquone dosing starting on day 6. In order to accommodate potential drug shortages modifications to ADE 10+3+5 that retain the MRC based induction backbone regimen of DA are allowed (see second Arm). These include but are not limited to substitution of etopophos for etoposide, exclusion of etoposide, use of CPX-351 (VYXEOS (daunorubicin and cytarabine) liposome) only, and daunorubicin and cytarabine (DA) + gemtuzumab ozogamicin (GO).~Patients will be monitored for adherence to and tolerance of daily dosing of atovaquone. Peripheral blood (PB) and bone marrow plasma samples will be obtained to measure atovaquone concentrations."
45508297|NCT03568994|Drug|Cytarabine|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
45508298|NCT03568994|Drug|Daunorubicin|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
45508299|NCT03568994|Drug|Etoposide|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
45508300|NCT03568994|Drug|Gemtuzumab Ozogamicin|As part of routine Induction 1 chemotherapy(DA 3+10 + GO)
45508301|NCT03568526|Other|Educational Intervention|Attend a therapy session
45400112|NCT03916120|Genetic|Genetic analysis|Collect 2ml intravenous blood from patients after anaesthesia.
45400113|NCT03908164|Biological|Pertussis containing vaccine|Participants will receive a pertussis containing vaccine licensed for use in pregnancy at one of three time periods.
45400114|NCT01147120|Behavioral|Progressive Muscle Relaxation (PMR)|Progressive Muscle Relaxation (PMR) will be recorded on PDAs integrated with EMA software and offered to patients who will be instructed in the techniques and PDA use by study coordinators. They will be instructed to practice 25 minutes/day the first two weeks, 35 minutes/day weeks 3 and 4, and 45 minutes/day weeks 5 through 12. These time periods (25/35/45 minute) were selected to allow a more gradual acclimation to PMR.
45508302|NCT03568526|Behavioral|Exercise Intervention|Complete exercise
45508303|NCT03568526|Other|Quality-of-Life Assessment|Ancillary studies
45508304|NCT03568526|Other|Questionnaire Administration|Ancillary studies
45508305|NCT03568526|Other|Survey Administration|Ancillary studies
45508306|NCT04211480|Biological|γ-globin reactivated autologous hematopoietic stem cells|gene edited autologous hematopoietic stem cells with γ-globin expression
45508307|NCT03545828|Diagnostic Test|Multi-channel aEEG monitoring|18 channel aEEG monitoring in comatose TTM-treated patients
45508308|NCT04203056|Drug|Aripiprazole Lauroxil|12 month longitudinal aripirprazole lauroxil treatment and assessment follow-through
45508309|NCT04203056|Drug|ARI-ORAL|oral aripiprazole
45508310|NCT04203056|Drug|AL-NCD|Aripiprazole Lauroxil 675 MG/2.4 ML Intramuscular Suspension, Extended Release
45508311|NCT04894994|Drug|FLX475|Tablet
45508312|NCT04894994|Drug|Ipilimumab|IV infusion
45508313|NCT03480386|Behavioral|Home Based Pulmonary Rehabilitation|The intervention consists of doing 12 weeks of exercises at home, with a weekly call from a health coach.
45400115|NCT01147120|Procedure|Clinical Massage Therapy (CMT)|PCPs will have the opportunity to refer patients with CLBP to local Licensed Massage Therapists (LMTs) to receive up to 10 clinical massage sessions over a 12-week period. CMT will be provided at no cost to the patients. At their first two sessions, the LMT will evaluate the patient and, with the patient, estimate the number of sessions and determine treatment goals. Based on previous literature, 10 sessions are anticipated over an average 12-week period. However, treatment will vary depending on assessment and progress. At the end of the treatment period, the patients will receive a list of all participating LMTs to facilitate patients' continued or future participation in massage therapy.
45508314|NCT04178252|Other|mask|investigators will add eye mask to standard treatment
45508315|NCT04178252|Other|headset|investigators will add headset to standard treatment
45508316|NCT04178252|Other|standard drug|investigators will use 10 mg metoclopramide in 150 ml saline given IV over 10 minutes
45508317|NCT04872140|Dietary Supplement|Low phytate pea powder|Exercise performance with low phytate pea powder
45508318|NCT04872140|Dietary Supplement|Regular pea powder|Exercise performance with regular pea powder
45508319|NCT04872140|Dietary Supplement|Placebo (maltodextrin)|Exercise performance with placebo (maltodextrin)
45508320|NCT01371305|Drug|BG00011|BG00011 will be administered at varying doses via subcutaneous (SC) injection
45508321|NCT01371305|Drug|Placebo|Sterile normal saline (0.9% Sodium Chloride for Injection) via Subcutaneous (SC) injections.
45400116|NCT03908242|Drug|salvianolic acid A|salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
45400117|NCT03908242|Drug|Placebo|salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
45508322|NCT03397550|Other|salt restriction education|Salt intake target：<5g/d Method：the standard salt restriction education will be lasting for 10-15 minutes by oral explanation at baseline.
45508323|NCT03545204|Other|Kangaroo Mother Care Package|"The KMC package will include creation of KMC Champions from within the community, social mobilization to create awareness and its acceptance with families using powerful IEC tools such as docudrama, flip charts, pictorials in local languages; engagement of community and community leaders, capacity building of health care providers on Kangaroo mother care, essential newborn care ENC, policy dialogues with stake holders in the public and private sectors and delivery of a KMC kit  to the pregnant female by the Implementation team"
45508324|NCT03545204|Other|Routine Standard Care|Routine Standard Care ( essential Newborn care )ENC
45508325|NCT01366547|Drug|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
45697953|NCT03571048|Behavioral|Time Restricted Feeding (TRF)|Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD. Participants in this group will also instructed to eat only during a window of 10 hours, starting within 3 hours of waking. They will also be instructed in specific strategies to support TRF including: strategies to deal with hunger outside eating windows, distraction techniques, and choosing a balanced diet/appropriate portions during feeding windows.
45400118|NCT00230178|Drug|Rasburicase (SR29142)|30-min IV infusion
45400119|NCT00230178|Drug|Allopurinol|Oral administration
45400120|NCT03908008|Drug|Botox (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
45508326|NCT01366547|Drug|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
45508327|NCT01366547|Drug|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
45508328|NCT01319669|Drug|recombinant human thrombopoietin|Recombinant human thrombopoietin injection in 15000U/ml/amp.
45697954|NCT01892189|Drug|Ketamine|Ketamine intravenous administration.
45697955|NCT01892189|Drug|TAK-063|TAK-063 tablets
45697956|NCT01892189|Drug|TAK-063 Placebo|TAK-063 placebo-matching tablets
45697957|NCT04746729|Other|No intervention|No intervention
45508329|NCT04032041|Device|Structure Sensor|A 3D representation of each participant's lower limb geometry will be obtained using a Structure Core scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
45508330|NCT05190341|Drug|Ibuprofen 800 mg oral|1 hour before HSG
45508331|NCT05190341|Drug|Ketorolac 30mg oral|1 hour before HSG
45508332|NCT04347239|Drug|Placebos|Placebos
45508333|NCT04347239|Drug|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
45508334|NCT00109928|Drug|cisplatin|
45508335|NCT00109928|Drug|etoposide|
45508336|NCT00109928|Drug|gemcitabine|
45508337|NCT00109928|Drug|methylprednisolone|
45508338|NCT02104310|Drug|Fluorine-18-L-dihydroxyphenylalanine|5 millicuries ± 10%; Intravenous injection; 1 time
45508339|NCT04114682|Other|Multi parametric MRI scan|There will be no intervention to the standard of care these patients receive. However, consented participants will be asked to make two study visits where a multiparametric MRI scan will be performed - these visits will be defined as visit 2 and visit 3. An optional echocardiogram may be included at Visit 2.
45400121|NCT03908008|Drug|MT10107 (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
45400122|NCT01253512|Drug|THR-18|A single 0.25 or 0.5 mg/kg of THR-18 in combination with tPA treatment.
45400123|NCT01253512|Drug|Placebo|Intravenous
45400124|NCT01253590|Behavioral|questionnaire about the use of ECG device|Patients will be fitted with a continuous ECG monitor and blood pressure device. Data on every heart beat, including episodes of atrial fibrillation, for 4-6 weeks of continuous monitoring will be collected and transmitted wirelessly. Based on this information and blood pressure readings performed by patients in their home setting, clinicians can adjust oral coagulant dosage. Participants will attend 2 follow-up outpatient visits at the MSKCC outpatient cardiology practice upon the cardiologist's recommendation. Upon completion of the study, 4-6 weeks, a questionnaire will be sent via mail, including a pre-paid envelope, to participants to assess feasibility, acceptance, and overall experience with remote cardiac monitoring.
45400125|NCT01251172|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
45400126|NCT01251172|Drug|Gamma-Secretase Inhibitor RO4929097|Given orally
45508340|NCT00109850|Biological|cetuximab|400mg/m^2 loading dose, intravenous (IV) over 120 min, day 1 of cycle 1 only. 250mg/m^2 maintenance dose, IV over 60 min, Days 8 & 15 of Cycle 1 and Days 1, 8, and 15 of subsequent cycles.
45508341|NCT00109850|Drug|cisplatin|30mg/m^2, bolus intravenous (IV), on Days 1 & 8 of each cycle.
45508342|NCT00109850|Drug|irinotecan hydrochloride|65mg/m^2, intravenous (IV) over 30 min, on Days 1 & 8 of each cycle.
45508343|NCT00109850|Radiation|radiation therapy|The total dose to the prescription point will be 5,040 cGy given in 28 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter. The dose variation in the planning target volume (PTV) will be +7% and -5% of the prescription point dose.
45508344|NCT02143232|Device|remote patient monitoring (Telus RPM)|All joint replacement patients in the study will use the same type of remote patient monitor for 4 days post operation at home.
45400127|NCT01251172|Procedure|Hematopoietic Stem Cell Mobilization|Undergo standard mobilization
45400128|NCT01251172|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
45400129|NCT01251172|Other|Laboratory Biomarker Analysis|Correlative studies
45508345|NCT03318770|Drug|Dasatinib and blinatumomab|Patients treated frontline with the sequential administration of dasatinib and the bispecific monoclonal antibody blinatumomab according to the protocol LAL2116
45596673|NCT03527563|Behavioral|Internet Medical Model|Subjects in the Internet group should upload blood pressure monitoring data at least once per day. It is highly recommended to upload two pressure monitoring results to capture more blood pressure information. The warning value of blood pressure set in the cloud database is systolic blood pressure ≥ 180mmHg or ≤ 100mmHg and diastolic blood pressure ≥ 110mmHg or ≤ 60mmHg. After enrollment, subjects and physicians communicate via telephone or Internet every two weeks until blood pressure is well controlled judged by physician. Then the frequency of communication will be changed to once a month. Once there are lacks of blood pressure data in 3 days of each week, or. blood pressure values of the subject exceed the warning value in 2 days of consecutive 3 days, the physician will take the initiative to contact the patient for disease inquiry.
45400130|NCT01251172|Drug|Melphalan|Given IV
45508346|NCT05499273|Procedure|scalpel-bougie tracheostomy|"The assistant places themselves with two preparation clamps at the head end of the table and assists with each hand placed lateral to the neck, so that the operating field is freely accessible. After the trachea or cricoid is palpated, a long median longitudinal skin incision of 2-3 cm is made from the cricoid caudally~The assistant uses straight clamps to pull the two edges of the skin incision apart dorso-laterally. In the event of major bleeding this maneuver should allow the blood to drain off dorsally and the view of the anatomical structures should be less impaired.~Layer by layer of the anatomical structures are cut through with the scalpel and tightened with the clamps accordingly.~Using a longitudinal incision, two to three tracheal rings are cut through distally to the cricoid~An 8 FR Frova catheter is inserted through the orifice into trachea.~A tracheal tube (ID 3.0 mm) is inserted over the Frova catheter to secure the airway permanently."
45508347|NCT05499273|Procedure|rapid sequence tracheotomy|"Orientational palpation and vertical midline skin incision followed by separation of the strap muscles~Exposure of the trachea and cricoid followed by anterior luxation of the trachea with a Backhaus towel clamp~Perform a vertical puncture with a tip scissors between the cricoid and 1st tracheal ring followed by a vertical incision of no more than 2 rings in length.~A tracheal tube (inner diameter 3.0 mm, cuffed) is inserted to secure the airway permanently."
45400131|NCT00413777|Drug|Tolvaptan|Participants were titrated to either the tolvaptan 45/15 or 60/30 mg split-dose over a 2-month Titration Period. They received the titrated dose for 34 months during the Fixed-dose Period. Following a planned off-treatment period, participants had the option to enter an Extension Period for an additional 12 months. Tolvaptan was supplied as tablets.
45400132|NCT03912922|Other|Activity regime|Activity regime of 4 days followed by a test day.
45400133|NCT01250080|Dietary Supplement|Total Parenteral Nutrition with Glutamine|daily glutamine supplement of 0.35 g/kg weight as N2-L-Alanyl-L-Glutamine (0.5 g/kg/d - Dipeptiven Fresenius Kabi España) during five days.
45400134|NCT01250080|Other|Total Parenteral Nutrition without glutamine|The control group received a supplemental volume of the basic TPN solution to achieve an isocaloric an isonitrogenated formula with the study group.
45400135|NCT03908320|Other|Menstrual Cycle Timing|Quit date is set to menstrual phase.
45400136|NCT03908320|Other|Menstrual Cycle Timing|Menstrual cycle timing of quit date is monitored
45400137|NCT03908320|Drug|NRT Patch|NRT patch is provided
45400138|NCT03908320|Behavioral|Cessation Counseling|Cessation counseling is provided
45400139|NCT03908086|Other|Risk factors in RA cohort|
45400140|NCT03908086|Other|Risk factors in general population|
45400141|NCT01148290|Procedure|Tension free vaginal tape|Small incision sites in the vagina and suprapubically. Bilateral retropubic insertion of the sling by means of needles
45400142|NCT01148290|Procedure|Bulking agent injection|Three Periurethral injections of Bulkamid ® (Ethicon,Somerville, NJ, USA)
45400143|NCT00197028|Biological|RTS,S/AS02D|3-dose intramuscular injection in the thigh
45400144|NCT00197028|Biological|TETRActHib™|3-dose intramuscular injection in the thigh.
45400145|NCT00197028|Biological|Engerix-B®|3-dose intramuscular injection in the thigh.
45400146|NCT01250158|Device|Liver-PILP kit|"Device: Liver-PILP kit The Liver-PILP kit (three devices) is composed of percutaneous, disposable (single-use), catheter-based devices for targeted, isolated, organ specific (liver), drug delivery and perfusion with high dose drugs.~The Portal Vein Device (PVD): balloon catheter to occlude the portal vein and allow aspiration through a central lumen for portal veno-venous bypass.~The Hepatic Artery Device (HAD): balloon catheter to occlude arterial flow to the liver.~The Vena Cava Device (VCD): catheter based device to isolate and access hepatic outflow to vena cava by creating a closed chamber in vena cava at ostia of the hepatic veins while maintaining central vena cava blood flow from lower extremities to right atrium through reduced central lumen."
45400147|NCT01251250|Other|laboratory biomarker analysis|Correlative studies
45400148|NCT01251250|Genetic|western blotting|Correlative studies
45596674|NCT02364063|Other|urotherapy with or without pharmacotherapy|Individualized
45596675|NCT05300893|Other|No night splint|Instead of the usual treatment with a night splint for three months after percutaneous needle fasciotomy patients do not receive treatment with a night splint.
45400149|NCT01251250|Genetic|gene expression analysis|Correlative studies
45400150|NCT01251250|Other|pharmacological study|Correlative studies
45400151|NCT01251250|Other|flow cytometry|Correlative studies
45400152|NCT01251250|Genetic|fluorescence in situ hybridization|Correlative studies
45400153|NCT01251250|Biological|azadirachta indica|Given orally
45400154|NCT01251250|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
45400155|NCT01073982|Dietary Supplement|tart cultivar Montmorency cherry juice|21 ounces of experimental or placebo juice, consumed daily for 21 days.
45400156|NCT01250236|Drug|brimonidine 0.1%|brimonidine 0.1% eye drops twice daily
45400157|NCT01250236|Drug|placebo|sodium hyaluronate 1.8mg/ml eye drops twice daily
45400158|NCT01074060|Drug|plerixafor|Given IV
45400159|NCT01074060|Biological|filgrastim|Given SC
45400160|NCT01074060|Drug|cyclophosphamide|Given IV
45400161|NCT01074060|Procedure|autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cell transplantation
45400162|NCT01074060|Other|laboratory biomarker analysis|Correlative studies
45400163|NCT03907930|Procedure|percutaneous nephrolithotripsy|removal of kidney and upper ureteric stones through small incision in the loin using nephroscope after disintegration by lithoclast
45400164|NCT03915340|Drug|Propafenone|Propafenone is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 300 mg of propafenone hydrochloride.
45400165|NCT03915340|Drug|Rytmonorm|Rytmonorm is manufactured by Famar Lyon, France (MAH: Mylan Healthcare GmbH, Germany). Each tablet contains 300 mg of propafenone hydrochloride.
45400166|NCT03907618|Diagnostic Test|ovarian reserve|To assess ovarian reserve in patients with Type 1 Diabetes Mellitus aged 18-40 years; ultrasonographic and laboratory parameters will be looked at.
45400167|NCT01250314|Other|Radiology|Spine radiography, densitometry, evaluation of bone architecture and micro-architecture (computed tomography of lumbar spine and hip and peripheral micro-scanner (XREME SCANCO) at tibia and wrist).
45508348|NCT03625947|Other|Argon Plasma Coagulation|Patients will be treated with Argon Plasma Coagulation. Argon plasma coagulation (APC) is a form of non contact electrocoagulation. APC utilizes electrically conductive argon plasma as a medium to deliver high-frequency current via a flexible probe. The argon plasma flow transfers electricity between the probe and the target tissue. Tracheobronchial access is obtained by passing the probe through the working channel of the bronchoscope. On arrival to the tissue, the application of energy causes uniform zones of desiccation, coagulation and devitalization in the areas receiving treatment, thus inducing hemostasis.
45508349|NCT01065519|Device|Xience V everolimus eluting stent|Xience V everolimus eluting stent
45400168|NCT01250314|Other|Biological, biochemical and genetic samples|"*Serum calcium and phosphore evaluation, bone remodeling markers, 25-hydroxyvitamin D level assessment: Blood samples plasma (5 ml):Creatin, calcemia, phosphoremia, alkaline phosphatase, bone alkaline phosphatase, osteocalcin, CTX, 25 hydroxyvitamin D and parathormone~Urinary samples :~Deoxy-pyridinoline, creatinuria Fasting morning urine on a sample Calciuria, creatinuria, cortisoluria Day urine on a sample~*Assessment of possible determinants of fractures in man~Blood samples plasma (5 ml):~Sexual Hormones: Estradiol, Testosterone, SHBG, LH, FSH~Homocysteine~IGF1~Extraction of DNA for a genetic polymorphism study:~Sample of 10 ml of blood on EDTA for DNA extraction.~Tested polymorphisms will be: LRP5, CYP19 (Aromatase), COL1A1 (Collagen I),MHTFR, IGF-1,VDR vitamin D receptor~Globally 20 ml of blood will be taken for each subject. Every biological sample for biochemical dosages and for genetic analysis will be preserved in an anonymous way."
45400169|NCT03907696|Other|Anti-stigma interventions curriculum|educational curriculum aimed at reducing stigma
45400170|NCT03973710|Dietary Supplement|Lactobacillus paracasei dietary supplement|a commercial probiotic dietary supplement
45400171|NCT03973710|Dietary Supplement|Placebo controls|placebo with a similar appearance to probiotics supplement
45508350|NCT01065519|Device|Biolimus A9-eluting Biomatrix stent|Biolimus A9-eluting Biomatrix stent
45508351|NCT05539989|Biological|VPM1002 Vaccine|0.1 mL (2-8x10^5 CFU)
45508352|NCT05539989|Biological|BCG Vaccine|0.1mL (0.075 Mycobacterium bovis)
45508353|NCT05539989|Drug|Placebo|0.1 mL (sodium chloride for injection 0.9%)
45508354|NCT01342926|Drug|GSK933776|GSK933776
45508355|NCT01342926|Drug|Placebo|Placebo
45508356|NCT05493111|Drug|AR-15512 Ophthalmic Solution|Topical ocular administration of one drop in both eyes BID for 365 days.
45508357|NCT05493111|Drug|Vehicle|Topical ocular administration of one drop in both eyes BID for 365 days.
45508358|NCT03626181|Device|Theta Burst Stimulation ( Transcranial Magnetic Stimulation)|"Participants will receive bilateral TBS, 5 times daily (15 minutes between), over 5 consecutive days (25 sessions total). In each session they will receive intermittent TBS (iTBS) over left dorsolateral prefrontal cortex (DLPFC), followed by continuous TBS (cTBS) over right DLPFC. Stimulation sites will be targeted with the Localite neuronavigation system and Visor2 software, and according to Talairach coordinates in relation to individual MRIs. Intensity will be standardized at 120% of RMT.~The MagPro stimulator will deliver iTBS over left DLPFC with 1620 pulses in 54 triplet bursts (5Hz) with train duration of 2 seconds, and intertrain interval of 8 seconds. cTBS over right DLPFC will consist of 1620 pulses in 54 triplet bursts, train duration of 2 seconds, with no intertrain interval."
45508359|NCT02524002|Dietary Supplement|Accel Gel|Accel Gel by PacificHealth Labs in Matawan, NJ.
45508360|NCT02524002|Dietary Supplement|Usual clear diet|Usual clear liquids
45508361|NCT01810016|Biological|Ipilimumab|Ipilimumab was administered IV over 90 minutes at a dose of 3 mg/kg directly preceding the NY-ESO-1 injection every 3 weeks for 4 doses.
45508362|NCT01810016|Biological|NY-ESO-1 Protein Vaccine|NY-ESO-1 recombinant protein (250 µg) was mixed with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
45508363|NCT01810016|Biological|NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide|NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
45508364|NCT01810016|Biological|NY-ESO-1 OLP4 Vaccine with Poly-ICLC|NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
45508365|NCT02843178|Behavioral|Vouchers|A voucher is given that can be used at the cashier of participating grocery stores, corner stores, and farmer's markets, enabling a participant to have the voucher's value subtracted from their grocery bill.
45697958|NCT03750201|Device|Direct Selective Trabeculoplasty|Laser surgery by automated direct automated SLT device to lower intraocular pressure
45697959|NCT03750201|Device|Selective Trabeculoplasty|Laser surgery by standard SLT device to lower intraocular pressure
45508366|NCT03571620|Drug|Q301 Cream|1.0% or 1.4% Q301 Cream
45508367|NCT03571620|Drug|Vehicle|Vehicle Control
45508368|NCT01722266|Drug|Liraglutide|"Patients randomized to 1.2 mg of liraglutide : They will start liraglutide 0.6 mg sc once daily for one week and will increase the dose to 1.2 mg sc once daily thereafter.~Patients randomized to 1.8 mg of liraglutide: They will start liraglutide 0.6 mg sc once daily for one week; will increase to 1.2 mg sc once daily for second week and will stay on 1.8 mg of liraglutide from third week onwards."
45508369|NCT01722266|Drug|Placebo|"Patients randomized to 1.2 mg of placebo: They will start placebo 0.6 mg sc once daily for one week and then increase to 1.2 mg once daily thereafter.~Patients randomized to 1.8 mg of placebo: They will start placebo 0.6 mg sc once daily for one week; increase to 1.2 mg sc once daily for second week and then to 1.8 mg sc once daily from third week onwards."
45508370|NCT03571542|Other|pulmonary function|The aim of this study is to assess the respiratory function thanks to pulmonary function tests in renal transplanted children in France.
45508371|NCT03571464|Device|GGRO Mobile App|"GGRO was designed to challenge maladaptive beliefs that underlie common OCD symptoms (e.g., contamination, repugnant thoughts) as well as relationships obsessions. Users are presented with 'blocks' featuring statements such as I take things as they come or Everything can end in a catastrophe. Users then have to respond to these statements by either pulling 'blocks' towards themselves (i.e., downwards) or throwing the blocks away from themselves (i.e., rejecting them upwards)."
45508372|NCT03123185|Drug|Placebo|Tablet and solution formulation
45508373|NCT03123185|Drug|BI 705564 (Test)|Fed state
45508374|NCT03123185|Drug|BI 705564 (Reference)|Fasting state
45508375|NCT03123068|Drug|CocoaVia®|CocoaVia® is manufactured by Mars, Inc. It is a dietary supplement of cocoa bean extract, containing 125 mg cocoa flavanols per capsule.
45508376|NCT03123068|Other|Placebo|The placebo capsules will contain an inert ingredient packaged to be indistinguishable from the active treatment.
45508377|NCT01372631|Device|miniature spectral imaging system|Use of miniature spectral imaging system
45508378|NCT01372631|Device|Bench-top optical spectrometer|Use of bench-top optical spectrometer
45508379|NCT01372631|Device|High resolution microendoscope|Use of high resolution microendoscope
45508380|NCT02254148|Drug|midazolam|single dose of midazolam given as oral solution (day 1 of visits 2 and 3)
45508381|NCT02254148|Drug|caffeine|single dose of caffeine given as tablets (day 1 of visits 2 and 3)
45508382|NCT02254148|Drug|digoxin|single dose of digoxin given as tablets (day 3 of visits 2 and 3)
45508383|NCT02254148|Drug|warfarin|single dose of warfarin given as tablets (day 1 of visits 2 and 3)
45508384|NCT02254148|Drug|omeprazole|single dose of omeprazole given as tablet (day 1 of visits 2 and 3)
45508385|NCT02254148|Drug|BI 187004|multiple doses of BI 187004 given as tablets (day 7-12 of visit 2 and day 1-6 of visit 3)
45508386|NCT02254148|Drug|metoprolol|single dose of metoprolol given as tablets (day 1 of visits 2 and 3)
45508387|NCT01366625|Device|Renal denervation with a catheter-based procedure (Symplicity® Catheter System)|Disruption of the renal nerves with a catheter-based procedure.
45508388|NCT02842866|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM), single dose on Day 0.
45508389|NCT02842866|Biological|Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined|0.5 mL, Subcutaneous (SC), single dose on Day 0.
45508390|NCT03078296|Other|survey respondents|all survey participants will be asked to complete a questionnaire
45508391|NCT01316913|Drug|GSK573719/GW642444 125/25|125/25 mcg once-daily
45400172|NCT03915028|Other|Spa therapy|"The standardized treatment will consist of 4 spa treatments per day for 3 consecutive weeks.~Each day, the patient receives at least four treatments, among which:~Cure of Drink (in addition to 4 daily cares)~Bath in running water: Bath~Bath in running water: Pool at 32 ° C~Bath with aerobain~Immersion shower bath~Shower of high pressure under immersion in swimming pool~General penetrating shower~General jet shower~Local jet shower~Local mud bath at the feet~Single poultice~Multiple poultice~Compress~Mobilization pool~Massages under water"
45400173|NCT03972618|Behavioral|Installation of water filtration system for filtering existing water source|Installation of water filtration system and education on hand washing.
45508392|NCT01316913|Drug|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
45508393|NCT01316913|Drug|GSK573719|125 mcg once-daily
45508394|NCT01316913|Drug|tiotropium bromide|18 mcg once-daily
45508395|NCT02875067|Biological|Pembrolizumab|
45508396|NCT02875067|Drug|Lenalidomide|
45508397|NCT03544580|Procedure|immediate implant with dentine chips|Using dentin chips
45508398|NCT03544580|Procedure|conventional immediate implant|using xenograft
45508399|NCT02254538|Drug|BILR 355 BS|
45508400|NCT02254538|Drug|PEG 400|
45508401|NCT03572946|Procedure|Targeted prostate biopsy|MRI-guided targeted prostate biopsy
45508402|NCT03572946|Procedure|Standard biopsy|Transperineal ultrasound guided prostate biopsy(SB).
45508403|NCT01366703|Device|implantable loop recorder Medtronic reveal XT Full view|Medtronic Reveal implantable loop recorder with home-monitoring using carelink will be implanted in every patient and used to continuously monitor the patients during follow-up to detect symptomatic and asymptomatic arrythmias during follow-up
45508404|NCT02143544|Device|Intra-aortic balloon pump.|Preoperative placement of the intra-aortic balloon pump.
45508405|NCT03570294|Drug|Atosiban|The initial dose of Atosiban (Tractocile, Ferring Pharmaceuticals A/S, Copenhagen, Denmark) will be give as a single intravenous bolus dose (6.75 mg in 0.9 ml isotonic sodium chloride solution). This will be follow immediately by intravenous infusion of 300 μg/min of Atosiban in 5% glucose for 3 hours, and then 100 μg/min for up to 48 hours. Venous blood samples from a forearm vein will take before and after 48 hours of continuous administration tocolytic therapy with Atosiban.
45508406|NCT02143622|Biological|LJM716|antibody
45508407|NCT02143622|Biological|cetuximab|antibody
45508408|NCT03142659|Other|registry-no intervention|registry-no intervention After filling the informed consent the patients will be evaluated for clinical history and physical examination by the nurse and a cardiologist. Then, the patients may perform the following test: ECG, Chest X-RAY, Blood test including: complete blood count, renal and liver function, electrolytes, thyroid function, cholesterol, glucose, Troponin and Brain Natriuretic Peptide
45400174|NCT01581918|Drug|Carbamazepine|Patients will receive Carbamazepine in first chemotherapy cycle as planned: - One tablet (200mg) at night on third day before chemotherapy; - One tablet (200mg) every 12 hours on second day before chemotherapy; - One tablet (200mg) every 8 hours from the day before until fifth day after chemotherapy.
45400175|NCT03907306|Procedure|Wound healing|The measurement of a wound area is committed on the 2nd, 8th, 14th, 21nd and 30th day after operation. By means of the mathematical formulas the wound healing speed will be defined. The wound process will be researched with the help of cytological method. The wound prints will be taken on the 2nd, 8th, 14th, 21nd and 30th day after operation. Microbiological research of a wound will be held on the 2nd, 8th, 14th, 21nd and 30th day after operation (in study groups before and after the usage of CAP, in control groups once). The pain assessment will be measured by a visual analogue scale on the 2nd, 3rd,4th, 5th, 6th, 7th, 8th, 14th, 21nd and 30th day after operation. The life quality will be researched by means of Health Status Survey on the 8th and 30th day before operation.
45400176|NCT01582542|Drug|Desmopressin|"Patients after radical cystectomy with orthotopic bladder reconstruction that suffer from night time urinary incontinence will be enrolled in the study. They will be given for a period of one month after informed consent, Desmopressin At a dosage of 0.1 MG per day. The rate of improvement of night time urinary incontinence will be measured."
45400177|NCT03907384|Behavioral|Mat Pilates training|This group completed 12-weeks of training
45400178|NCT01582620|Procedure|Telestroke|remote videoconference consultations
45400179|NCT03913000|Drug|ID-085|Hard capsules for oral administration formulated at a strength of 200 mg
45508409|NCT02781506|Drug|Nivolumab|Nivolumab IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist
45508410|NCT02781506|Radiation|SAbR|SAbR (1-3 lesions)
45400180|NCT03913156|Other|B2970 Metabolic Texture Modified Protein Substitute|The study product is a powdered phe-free protein substitute supplemented with long chain polyunsaturated fatty acids (LCP's), containing essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and trace elements and has been designed for use in the management of proven PKU in children aged 6 months to 5 years.
45400181|NCT03912766|Diagnostic Test|serum copeptin|routine surgical method using resectoscope inserted into the urinary bladder
45400182|NCT01251328|Procedure|General anaesthesia|general anaesthesia is performed according to the hospitals standard
45400183|NCT01251328|Procedure|Sedation|Sedation is performed according to the hospitals standard
45400184|NCT01250392|Behavioral|The Effect of Active Choice on Nurse Visit Participation|"The goal of this project is to see if active choice will increase an individual's likelihood of participating in a nurse visit.~The employees in our sample will schedule their nurse visit time slot via e-mail and a health service provider website. The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment. The treatment group, the active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening. The treatment group will also receive email reminders one week before their appointment."
45400185|NCT00420641|Drug|GSK372475|GSK372475 1.0-1.5 mg/day
45508411|NCT03780179|Biological|MMRvaxpro|MMRvaxpro vaccine
45508412|NCT03780179|Biological|Placebo|Placebo
45400186|NCT00420641|Drug|Paroxetine|Paroxetine 20-30 mg/day
45400187|NCT00420641|Other|Placebo|Placebo to Match
45508413|NCT03570216|Other|Cardiopulmonary exercise test|Participants will perform a graded cardiopulmonary exercise test to asses their cardiorespiratory fitness. It will also provide a peak exercise stimulus to examine acute changes in arterial stiffness, and to prescribe both moderate intensity continuous exercise and high intensity interval exercise.
45508414|NCT03570216|Other|Moderate-intensity continuous exercise|Participants will perform a 30-minute session of moderate-intensity continuous exercise.
45508415|NCT03570216|Other|High-intensity interval exercise|1 week later, participants will perform a 19-minute session of high-intensity interval exercise.
45508416|NCT03755297|Other|Blood sample analysis of patients treated as standard care|Blood sample to analyse percentage of blood cells (regulatory B cells et T cells)
45508417|NCT03132753|Behavioral|SUPPORT|SUPPORT clients will be offered 12 months of support service with a recovery coach. The recovery coach will guide the client through their recovery, offering guidance and support, while coordinating their treatment services, including support services. The program will provide clients with up to $700 worth of vouchers to cover the cost of additional flexible support services over the 12 months of program enrollment, which will be personalized to fit the needs of the client. These cost vouchers will cover support services, such as housing, employment services, substance use treatment, transportation, childcare, educational or vocational services, or aftercare planning. The costs of each service is determined by the service provider. Further, the recovery coach will assist the client in choosing appropriate services and coordinating/monitoring service completion.
45849933|NCT03580044|Drug|BAT|The comparator treatment in this study is best available therapy (BAT) based upon site practice and local epidemiology. The choice of BAT (monotherapy or combination) for each subject must be recorded prior to randomization. If the chosen BAT does not provide adequate anaerobic coverage for cIAI subjects MTZ is to be administered as a co therapy. BAT dose, frequency, dose adjustments with renal impairment will be based on per local package inserts.
45508418|NCT03572868|Other|Evaluation of the long term neurodevelopmental outcome|Evaluation of the long-term neurodevelopmental outcome of newborns who have an isolated transverse cerebellar diameter < 5th centile during the second or the third trimester of pregnancy.
45508419|NCT05190185|Biological|TAA06 injection|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be treated with 1×106~1×108 CAR-T/kg. And the subjects will be administered once.
45508420|NCT03571230|Drug|two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)|Patients will receive a 10-day triple therapy for the H.pylori eradication. The regimen contains one PPI and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
45508421|NCT03571230|Drug|two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone)|Patients will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.
45508422|NCT03571230|Drug|one proton pump inhibitor(PPI)|All the patients need this drug.
45508423|NCT03571230|Drug|Colloidal Bismuth Pectin|All the patients treated with 14-day bismuth-based quadruple therapy need this drug.
45508424|NCT03571230|Drug|two antibiotics for failed eradication(tetracyclin,furazolidone)|If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains one PPI, Colloidal Bismuth Pectin, tetracycline and furazolidone.
45508425|NCT03644615|Other|Mindfluness and usual care|Intervention based on a mindfulness training program as a therapeutic alternative in osteoarthritis of the knee or hip. Mindfulness is a technique of attention training, which is to focus one's attention on the present moment and to examine the sensations that come to mind, how they appear, how they last time, and how they disappear.
45508426|NCT03644615|Other|Usual care|No intervention on the patients
45508427|NCT01468454|Drug|18 F-DOPA|1 time injection of 0.08 - 0.16 mCi/kg of 18F-DOPA
45400188|NCT01251406|Drug|Placebo|Daily subcutaneous administration for 8 hours a day for 10 days
45400189|NCT01251406|Drug|rhNRG-1 Dose 1|Daily subcutaneous administration for 8 hours a day for 10 days
45849934|NCT03571776|Procedure|Surgery|Laparoscopic ovarian cystectomy
45849935|NCT03571776|Procedure|Sclerotherapy|US-aspiration and alcohol sclerosis
45849936|NCT03525678|Drug|Belantamab mafodotin frozen liquid|Belantamab mafodotin will be available as frozen liquid. Frozen liquid will be available as 30 milligram (mg)/vial solution in a single use vial with unit dose strength of 2.5 or 3.4 mg/kg. Belantamab mafodotin will be administered as IV solution over at least 30 minutes. Frozen belantamab mafodotin will be diluted in 0.9 percent saline and administered via infusion pump.
45400190|NCT01251406|Drug|rhNRG-1 Dose 2|Daily subcutaneous administration for 8 hours a day for 10 days
45400191|NCT00257556|Drug|Menotrophin|150 IU Menotrophin daily subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
45400192|NCT00257556|Drug|Follitropin alfa|150 IU follitropin alfa daily by subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
45400193|NCT03907228|Dietary Supplement|RHT-3201|PROBIOTIC
45400194|NCT03906916|Diagnostic Test|1,3-β-D-glucan quantification|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be evaluated by 1,3-β-D-glucan test and by means of blood culture to confirm the diagnosis
45400195|NCT03906916|Drug|Micafungin|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be treated with an echinocandin (micafungin) as timely as possible, and they will continue the antifungal treatment according to international guidelines when diagnosis is confirmed by positive 1,3-β-D-glucan test.
45400196|NCT03907150|Diagnostic Test|Strain ultrasound|Post-interpretation of recorded ultrasound loops
45400197|NCT03972540|Behavioral|Mindful eating intervention|A Mindful Eating Workshop™ workbook was used for standardization and reproducibility of these sessions. The group sessions were focused on teaching applied strategies to consume food with intention and attention and aimed at improving emotional relationships with food. Intervention sessions were held once a week in the evening for 2 hours per session over 8 weeks. The intervention was delivered in a large conference room on the University of Georgia campus. Participants were required to attend seven out of eight sessions. If participants missed a session, they met with the instructor 30 minutes before the beginning of the following week's session to receive individual instruction on content of the missed session.
45400198|NCT01250470|Other|Laboratory Biomarker Analysis|Correlative studies
45400199|NCT01250470|Drug|Montanide ISA-51/Survivin Peptide Vaccine|Given SC
45400200|NCT01250470|Biological|Sargramostim|Given SC
45400201|NCT01148368|Drug|fimasartan|single administration of fimasartan 120mg
45508428|NCT01366781|Other|Meal ingestion|Meal 511 kcal, meal 743 kcal or meal 1034 kcal
45508429|NCT02143700|Other|Cognitive assessment|Patients are going to be assessed regarding the outcome measures
45400202|NCT03912688|Device|acupoint stimulation|
45400203|NCT03912688|Device|single acupoint|
45508430|NCT04151225|Drug|GSK2330811|GSK2330811 will be available as SC injection with a unit dose strength of 150 mg/mL. GSK2330811 will be available in single-use pre-filled syringe.
45508431|NCT04151225|Drug|Placebo|Placebo will be available as SC injection of 0.9 percent saline solution. It will be available as single-use pre-filled syringe.
45508432|NCT03067077|Procedure|SMILE|SMILE surgery
45508433|NCT03067077|Procedure|LASIK|LASIK surgery
45508434|NCT02143856|Drug|100 mg GLPG1205|A single dose of 100 mg GLPG1205 administered as two capsules of 50 mg
45400204|NCT03912688|Device|dual acupoints|
45400205|NCT01250548|Biological|apremilast|30 mg BID apremilast taken orally for the first 12 weeks followed by responders randomized to either 30 mg BID apremilast (oral) or 30 mg BID placebo (oral) for 8 weeks
45400206|NCT01250548|Other|Placebo|
45400207|NCT03906838|Drug|Ropivacaine injection|Regional Anesthesia Nerve Block: Incremental injections up to total of 20 mL of 0.5% ropivacaine is administered.
45400208|NCT01251484|Drug|BIBF1120|Tablet 200 mg twice daily until progression
45400209|NCT03912610|Diagnostic Test|Functional magnetic resonance examination|Functional magnetic resonance examination by a Ultra high field magnetic resonance instrument named MAGNATOM 7T.
45400210|NCT03914638|Drug|Salbutamol 4Mg Tablet|Salbutamol 4 mg, three times daily
45400211|NCT03914638|Drug|Placebo oral capsule|Placebo, three times daily
45400212|NCT01148446|Drug|Cyclophosphamide|750 mg/mq IV, day 1
45400213|NCT01148446|Drug|Cyclophosphamide|50 mg/mq IV, day 1
45400214|NCT01148446|Drug|Doxorubicin|50 mg/mq IV, day1
45400215|NCT01148446|Drug|Vincristine|1,4 mg/mq (max 2 mg)IV, day 1
45400216|NCT01148446|Drug|Prednisone|75 mg/mq IV, days 1-5
45400217|NCT01148446|Drug|Prednisone|60 mg/mq IV/PO, days 1-5
45400218|NCT01148446|Drug|Epirubicin|50 mg/mq IV, day 1
45400219|NCT01148446|Drug|Vinblastine|5 mg/mq IV, day 1
45400220|NCT01148446|Drug|Rituximab|375 mg/mq IV, day 1
45400221|NCT01148446|Drug|G-CSF|300 µg tot., SC; days 7-11
45400222|NCT00228384|Device|GORE VIABAHN Endoprosthesis|Implantation
45400223|NCT00228384|Device|Bare Nitinol Stent|Implantation
45508435|NCT03368963|Drug|Nanoliposomal Irinotecan|Given IV
45508436|NCT03368963|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
45508437|NCT03545438|Biological|LIB003|LIB003 or placebo
45508438|NCT05489211|Drug|Datopotamab deruxtecan (Dato-DXd)|Intravenous (IV) Antibody drug conjugate
45508439|NCT05489211|Drug|AZD5305|Oral poly ADP ribose polymerase (PARP) inhibitor
45508440|NCT05489211|Drug|Durvalumab|Administered as an IV
45508441|NCT05489211|Drug|Capecitabine|Administered orally
45508442|NCT05489211|Drug|5-Fluorouracil|Administered as an IV
45508443|NCT05489211|Drug|Nivolumab|Administered as an IV
45508444|NCT05489211|Drug|Carboplatin|Administered as an IV
45508445|NCT05489211|Drug|Leucovorin LV|Administered as an IV
45508446|NCT05489211|Drug|Bevacizumab|Administered as an IV
45508447|NCT01372709|Device|Ovation™ or Ovation Prime™ Abdominal Stent Graft System|Single occurrence permanent implant of AAA device.
45508448|NCT02939612|Behavioral|App for stress management|An app consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
45508449|NCT05365841|Drug|Mepolizumab 100 MG|Patients with SEA eligible to receive anti-IL5 treatment, which is a biologic treatment for SEA
45508450|NCT02254226|Drug|Salmeterol Diskus low|
45508451|NCT02254226|Drug|Salmeterol Diskus high|
45508452|NCT02254226|Drug|Salmeterol MDI low|
45508453|NCT02254226|Drug|Salmeterol MDI high|
45508454|NCT02143934|Drug|Primaquine|
45508455|NCT02143934|Drug|Placebo|Sugar pills, appearance identical to Primaquine tablets
45508456|NCT02143934|Drug|Chloroquine|
45508457|NCT02143934|Drug|Artemether Lumefantrine|
45508458|NCT04214873|Device|PiQo4 Laser System|PiQo4 Laser System for treatment of POH
45508459|NCT01366859|Dietary Supplement|Whey Protein|The experimental study group will consist of thirty children that will be treated with Immunocal® 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months to determine the supplement's effect in core areas of behavior in children with autism.
45508460|NCT01366859|Dietary Supplement|Rice Protein (Placebo)|The control or placebo study group will consist of thirty children that will be treated with rice protein (placebo) 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months.
45508461|NCT03096847|Drug|ribociclib|All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.
45508462|NCT03096847|Drug|letrozole|All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.
45508463|NCT03096847|Drug|goserelin|Premenopausal patients additionally received goserelin 3.6mg as monthly implant
45508464|NCT01365182|Behavioral|BF+SUPPORT|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 group sessions of the Problem-Solving Therapy (teaching self-management skills).
45508465|NCT01365182|Behavioral|BF+PHONE|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 telephone sessions of the Problem-Solving Therapy (teaching self-management skills).
45508466|NCT05190107|Diagnostic Test|DASS-21 scale|"Each construct consists of 7 questions. The participants must select the answer that better represents their feelings over the last week in each scenario. Each question has a Likert scale of 4 options where 0 represents did not apply to me to 3 applied to me very much."
45508467|NCT02144090|Device|Fractional flow reserve measurement|Fractional flow reserve measurement
45508468|NCT03019575|Drug|Corifollitropin alfa|CFA administered 100 μg (if body weight ≤60 kg) or 150 μg (if body weight >60 kg) by SC injection, once every 2 weeks for 64 weeks (Day 1, Week 0 through Week 64).
45508469|NCT03019575|Drug|hCG|hCG 500-5000 IU reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64).
45508470|NCT03634709|Behavioral|Memory Flexibility training (MemFlex)|MemFlex is a primarily self-guided, paper workbook-based program which aims to reduce overgeneral memory bias and improve recall of positive, specific event memories. Prior to completing one month of self-guided, workbook-based intervention, the participant will attend one 45 minute face-to-face session in which the facilitator outlines the importance of autobiographical memory in everyday life, discusses the impact of trauma on autobiographical memory, and provides information on the different types of autobiographical memories (e.g., specific, general) and their potential everyday functions. The session also introduces the cued-recall tasks which were used to train the memory skills throughout the workbook, and provides facilitator-assisted practice with the tasks. Once participants are comfortable with the training exercises, they set a schedule for completion of the eight-session workbook over the following four weeks.
45508471|NCT02144168|Dietary Supplement|Prebiotics-free enteral formula|Patient will be given Osmolite 1 cal for 2 weeks after baseline stool sample obtained
45508472|NCT02144168|Dietary Supplement|Prebiotics containing enteral formula|Patient will be given Ensure Fos for 2 weeks after baseline stool sample obtained
45508473|NCT03128099|Behavioral|Virtual reality social skills training|Participants play a virtual reality video game involving social interactions with various characters ( avatars) at a bus stop, a cafeteria and a grocery store. The games become progressively more complex as the participant improves task performance. Eye tracking patterns are recorded throughout the game to observe the patterns of social attention
45400224|NCT03914404|Drug|γ-linoleic acid and placebo(Thioctic Acid)|"γ-linoleic acid (Evoprim soft capsule) twice a day and 4 capsules at a time.~Thioctic Acid(LipoA HR Tab. 600mg) placebo once a day and 1 tablet at a time."
45400225|NCT03914404|Drug|Thioctic Acid and placebo(γ-linoleic acid)|"Thioctic Acid(LipoA HR Tab. 600mg) once a day and 1 tablet at a time.~γ-linoleic acid (Evoprim soft capsule) placebo twice a day and 4 capsules at a time."
45508474|NCT03545516|Drug|Bupivacaine|Injection of bupivacaine into the surgical incision prior to its closure.
45508475|NCT03545516|Drug|Dexmedetomidine|Injection of dexmedetomidine ( an adjuvant) into the surgical incision prior to its closure.
45508476|NCT03545516|Drug|Placebo|Injection of a placebo into the surgical wound
45508477|NCT04756453|Device|clip-traction|A endoscopic clip with a loop of tied dental floss will be attached to the lesion. The loop will then be caught by another endoscopic clip and attached to adjacent bowel wall, thus creating tension in the tissue, making dissection easier.
45508478|NCT02947035|Procedure|Thyroid lobectomy|Thyroid lobectomy is removal of only part of the thyroid
45508479|NCT02947035|Procedure|Total thyroidectomy with CCND|Total thyroidectomy with central compartment lymph node dissection is removal of the entire thyroid with the surrounding lymph nodes
45400226|NCT01147198|Dietary Supplement|Ready to Use Supplementary Food|Children received two Supplementary-plumpy® packages per day (184g) providing 1000 Kcal, 26g (10.4%) protein, 68g (61.2%) fat, and 100% of micronutrient requirements based on the Daily Recommended Nutrient Intake.
45400227|NCT01147198|Dietary Supplement|Premix CSB-oil treatment|Children received 2 kg of premix per week (226g CSB, 37g oil, and 23g sugar / day) providing 1277 Kcal, 40.7g protein (12.7%), 50.6g (35.7%) fat, and 100% of micronutrient according to the DRNI guidelines
45400228|NCT01073280|Procedure|cerebral flexible endoscopy|The investigators will make a burrhole in the precoronal suture introducing the flexible endoscope taking a cerebral and a basal meningeal biopsy
45400229|NCT03905980|Procedure|vaginal delivery|pregnancy ended by vaginal delivery
45508480|NCT04753879|Drug|Nab-paclitaxel|"Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~Nab-paclitaxel (80 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~Other Name: Abraxane"
45400230|NCT03905980|Procedure|Cesarean section|pregnancy ended by cesarean delivery
45400231|NCT01251562|Drug|Sterile Compound C31510 for Injection|During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.
45508481|NCT04753879|Drug|Gemcitabine|"Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~Gemcitabine (500mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~Other Name: Gemzar"
45508482|NCT04753879|Drug|Cisplatin|"Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~Cisplatin (20mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~Other Name: N/A"
45508483|NCT04753879|Drug|Irinotecan|"Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~Irinotecan (20 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~Other Name: N/A"
45508484|NCT04753879|Drug|Capecitabine|"Patients will receive treatment Day 1-7 and Day 15-21 of each cycle (28 days).~Capecitabine (500 mg) will be administered orally twice a day on days 1-7 and 15-21 of each cycle (28 days).~Other Name: Xeloda"
45508485|NCT04753879|Drug|Pembrolizumab|"Patients will receive treatment Day 1 every other cycle (every 6 weeks) (28 days) during maintenance phase.~Pembrolizumab (400 mg) will be administered IV on day 1 every other cycle (every 6 weeks).~Other Name: MK-3475; Keytruda"
45508486|NCT04753879|Drug|Olaparib|"Patients will receive treatment on Days 1-21 during the maintenance phase.~Olaparib (300 mg) will be administered orally twice a day on Days 1- 21 of each cycle (28 days).~Other Name: Lynparza"
45508487|NCT04545333|Diagnostic Test|clonoSEQ Assay|minimal residual disease (MRD) assay using blood, bone marrow, or other tissue containing tumor cells
45508488|NCT01372787|Procedure|Assessment of Therapy Complications|Ancillary studies
45508489|NCT01372787|Other|Medical Chart Review|Ancillary studies
45508490|NCT01372787|Other|Quality-of-Life Assessment|Ancillary studies
45508491|NCT01372787|Other|Questionnaire Administration|Ancillary studies
45508492|NCT02886494|Drug|BAC treatment|BAC, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
45508493|NCT02886494|Drug|Matched vehicle|BAC matched vehicle, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
45508494|NCT04660903|Procedure|Autologous fat cell transplantation|Up to 75 ml of fatty tissue mixture fluid
45508495|NCT04519749|Biological|4D-310|4D-310 is a novel adeno-associated virus (AAV) gene therapy comprised of two active components: the capsid (4D-C102) and the transgene cassette, which encodes a codon-optimized full length human GLA transgene driven by the CAG promoter. 4D-310 has been engineered so that it cannot replicate (replication incompetent).
45508496|NCT00204477|Dietary Supplement|soy milk|Each drink contained soy protein, fat, and carbohydrates calcium and phosphorous to give a total energy of 177.8 kcal. Subjects took two drinks per day.
45400232|NCT01251640|Drug|BAY86-9766+Gemcitabine|Phase I: 40 mg/day (20 mg twice daily), 60 mg/day (30 mg twice daily, 100 mg/day (50 mg bid) dependent on safety/tolerability Phase II: Recommended Phase II dose (RP2D) dependent on the results of the Phase I part of this study Route of administration: Oral, twice daily (bid) in combination with gemcitabine 1000 mg/m2 Intravenous infusion over 30 minutes weekly for seven out of eight weeks (Cycle 1); followed by 1000 mg/m2 Intravenous infusion over 30 minutes weekly for three out of four weeks (Cycle 2 and subsequent)
45400233|NCT00257166|Drug|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
45400234|NCT00257166|Drug|placebo oral capsules|Oral placebo capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
45400235|NCT03912142|Diagnostic Test|three dimensional Transperineal Ultrasound Scan|Diagnostic test: three dimensional transperineal ultrasound scan
45400236|NCT03914092|Drug|triamcinolone acetonide injection|,1 mm percutaneous intralesional injection
45400237|NCT03914092|Behavioral|Smith Accent method of voice therapy|regular sessions of smith accent voice therapy (about 24 sessions, twice session / week) for 3 months
45400238|NCT03905824|Biological|Allogenic stromal mesenchymal cells derived from the umbilical cord|Platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord added to the traditional treatment for osteochondral lesions of the talus
45400239|NCT03905824|Procedure|Debridement and microfracture|Debridement and microfracture in LOC is the traditional treatment for osteochondral lesions of the talus
45508497|NCT00204477|Dietary Supplement|cow's milk|Each drink contained casein, fat, carbohydrates, calcium and phosphorous to give a total energy of 178.6 kcal. Subjects took two drinks per day.
45508498|NCT02835326|Behavioral|Exercise and Dietary Weight Loss|The EX+DWL intervention consists of group and individual exercise sessions, as well as, nutritional and dietary counseling. Bimonthly phone calls are made in the final year of the study to aid in maintenance of the program.
45508499|NCT02835326|Behavioral|Walk with Ease|The WWE 6 week program consists of health education lectures on arthritis self-management, a walking exercise portion, and at- home strength exercises. Participants will complete two consecutive WWE programs. Monthly and bimonthly phone calls are made to participants in months 4-12 and 12-24, respectively, to aid in maintenance of the program.
45508500|NCT04514367|Drug|ANX005|Intravenous Infusion
45508501|NCT03545048|Other|Internet based exercises|Exercises for knee OA (online- digital health)
45508502|NCT02846532|Drug|Rivaroxaban|Participants will receive oral suspension containing rivaroxaban 1 milligram per milliliter (mg/ml) twice daily in Part A and Part B. Following total daily doses of Rivaroxaban will be administered based on the weight of the participants: 7 to <8 kilogram (kg) will receive 2.2 milligram (mg); 8 to <10 kg will receive 3.2 mg; 10 to<12 kg will receive 3.4 mg; 12 to <20 will receive 4.0 mg and 20 to <30 will receive 5.0 mg.
45508503|NCT02846532|Drug|Acetylsalicylic Acid|Participants will receive 5 milligram per kilogram (mg/kg) of acetylsalicylic acid once daily up to 12 months in Part B.
45508504|NCT05417347|Other|Low-fat dairy products|Milk: low fat (less than 2% M.F.) Yogurt: less than 2% M.F. Cheese: less than 20% M.F.
45508505|NCT05417347|Other|Full-fat dairy products|Milk: full-fat milk Yogurt: 2% and more M.F. Cheese: Regular cheese products
45508506|NCT02809521|Other|Activity Liking|
45400240|NCT01251718|Drug|donepezil hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
45400241|NCT03913936|Other|YES portal|The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician
45508507|NCT01371383|Dietary Supplement|Omega-3 fatty acids|1.6~2.8 gram/day (5 capsules)
45508508|NCT01371383|Dietary Supplement|placebo|5 gram/day (5 capsules)
45508509|NCT02744001|Other|Low Added Sugar Diet|1-week intake of Low Added Sugar Diet 3 day rotating menu
45508510|NCT03634631|Other|Focused Ultrasound|Test ultrasound in 7T MRI scanner
45508511|NCT01371461|Drug|Paroxetine|
45508512|NCT02731521|Device|3 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
45508513|NCT02731521|Device|7 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
45508514|NCT02728557|Behavioral|Supportive-Expressive Therapy|Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
45508515|NCT02728557|Behavioral|Supportive Therapy|Supportive psychotherapy for depressive disorder for 16 weeks.
45400242|NCT03913858|Procedure|Obesity Surgery with Low-Flow Anesthesia|Group 1 had 1 liter/minute (50% O2, 50% air) flow administered.
45400243|NCT03913858|Procedure|Obesity Surgery with High-Flow Anesthesia|Group 2 had 4 liter/minute (50% O2, 50% air) flow administered.
45400244|NCT01148602|Other|LED stopwatch-clock timers|"We will attach a large, in-your-face red LED stopwatch-clock timers to the patient's stretcher at the moment of ED arrival to act as a constant visual reminder to all team members (physicians, RN's, CT technologists) of the urgency of the situation."
45400245|NCT01254682|Device|Ostenil|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment). Add-on treatment with Ostenil after standard arthroscopic procedure. Application twice: first injection directly after arthroscopic procedure and second injection 3 weeks post arthroscopic.
45400246|NCT01254682|Procedure|Standard arthroscopic procedure|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment) without add-on treatment.
45508516|NCT03571152|Other|Educational videos|The level of practice and knowledge of the caregiver will be evaluated according to the video(s) corresponding to the session. Patient participation is expected for the evaluation of the caregiver's level of practice. After thirty minutes of use of the video, the level of practice and knowledge of the caregiver will be evaluated again for the same video. In each session this methodology will continue until the eighth video. At the end of all the videos, the level of satisfaction of the caregivers in relation to the videos will be evaluated.
45508517|NCT05337527|Dietary Supplement|beetroot juice|Acute effects of beetroot juice or placebo juice ingestion
45508518|NCT05324423|Drug|Colchicine|Colchicine0.5 mg Oral Tablet Day-7~Day25 qd；Febuxostat 40 mg Oral Tablet Day1 and Day14 qd；XNW3009 0.5 mg Oral Tablet Day8 and Day21 qd
45508519|NCT03570138|Device|FREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring System|Specific therapeutic education for diabetes self management
45508520|NCT03570138|Device|Usual self monitoring Blood Glucose device|Standard therapeutic education for diabetes self management
45508521|NCT02659605|Procedure|Delayed cord clamping above the perineum|After delivery, the infant will be placed on the mother's abdomen and the cord will be clamped 30-45 seconds after delivery of the infant.
45508522|NCT02659605|Procedure|Delayed cord clamping below the perineum|The infant will be held below the perineum, and the cord clamped and cut 60-75 seconds after delivery of the infant.
45508523|NCT03570060|Biological|Blood sample|2 ml of blood for testing for serum biomarkers (IL-6, GDF-15, soluble ST-2 soluble, osteoprotegerin, galectin 3)
45508524|NCT03570060|Procedure|Long term ECG monitor|Fitting and removal of a long term ECG monitor (SpiderFlash, LivaNova)
45508525|NCT03570060|Procedure|Monitoring ECG|Recording of automatic ECG monitor results (CSM Philips IntelliVue MP50 system)
45508526|NCT05232539|Device|Intraoperative Optical Coherence Tomography (iOCT)|The use of iOCT during surgery offers the advantage of a new view of the operating field, theoretically allows more precise performance and can also change decision-making mechanisms during surgery with more precise visual control of some surgical steps.
45400247|NCT05570188|Biological|anti-CD19 UCAR-NK cells|"Enrolled participants are chosen to receive one of three different dose levels of U-CAR-NK cells:~Dose level one: 5-10×10^6/kg; Dose level two:1-2×10^7/kg; Dose level three:2-5×10^7/kg."
45508527|NCT02242188|Drug|Iron|"Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age."
45508528|NCT02242188|Dietary Supplement|Placebo|Maltodextrin (packed in identical sachets as active products)
45508529|NCT04704843|Drug|Guselkumab|Guselkumab will be administered as IV infusion (induction dose) and SC injection.
45508530|NCT04704843|Drug|Placebo|Matching placebo to guselkumab will be administered as IV infusion (induction dose) and SC injection.
45508531|NCT03572712|Other|No Interventional study|every patient will be monitored with a blood gase, a nocturnal oximetry and a transcutaneous capnography
45508532|NCT05189873|Drug|Long GnRH agonist + HRT|Intervention group:(Long GnRH agonist + HRT) From day 18-21 of the previous cycle, 0.5 cc of Superfect is injected daily and vaginal ultrasound is performed 10-14 days later If the endometrial thickness is less than 5 mm and there are no ovarian cysts, estradiol is started like HRT treatment and the agonist dose of GnRH starts with estradiol. It is halved (0.25 cc superfect) and superfect is prescribed until progesterone is started. At the time of progesterone administration, the administration of superfect is discontinued. Injections of estradiol and progesterone is the same as for the HRT group
45508533|NCT05189873|Drug|HRT|In the HRT group, from the second day of the cycle, the participant receives 2 mg of estradiol daily and this drug is increased to 6 mg per day in three days.Ten days later, they undergo vaginal ultrasound to check the thickness of the endometrium. If the thickness of the endometrium is greater than 8 mm, inject able progesterone is prescribed and the patient is a candidate for FET transfer. If the thickness is less than 7 mm, it is necessary to increase the dose of estradiol and continue treatment with it. The patient undergoes vaginal ultrasound every three days and if the desired thickness does not reach 21 days after the start of the cycle, the cycle is canceled
45508534|NCT02524080|Procedure|Triage to optimal healthcare level|Triage to optimal healthcare level
45508535|NCT04704219|Biological|Pembrolizumab|Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation.
45508536|NCT04704219|Drug|Lenvatinib|Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.
45508537|NCT01367015|Other|Early Feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
45508538|NCT01367015|Other|Late Feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
45508539|NCT01371617|Drug|IPI-926|Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive disease or intolerability to study treatments or withdrawal of ICF
45508540|NCT04051671|Device|Transcranial direct current stimulation|Dual Active/sham tDCS will be applied over the leg motor area (M1) during the first 20 mins of conventional physical therapy. Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 2 weeks. The two experiments will be performed in random order for each subject.
45508541|NCT02243982|Other|[F18]-FDDNP|radiopharmaceutical tracer, intravenous, single dose, of 360+/- 20 megabecquerel
45508542|NCT02552277|Biological|PDA-002|PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.
45508543|NCT02552277|Drug|Placebo|Subjects will receive placebo administered on study days 1, 29, and 57.
45508544|NCT05185817|Biological|Pasocovac vaccine|All enrolled post-Allo-SCT participants who meet the inclusion criteria are recruited to study from 3 to 12 months after Allo-HSCT and vaccinated with 2 doses of Pastucovac, with a 4-week (±7 days) interval and a booster dose at an 8-week (±7 days) interval from the second dose.
45400248|NCT03905278|Behavioral|Parental guidance|A psychological intervention including 4 sessions to assess how participants communicate with their children about the disease and take stock of their questions and difficulties. To identify children's reactions and needs. Practical situation are analyzed and worked through role play centered on communicational difficulties to enhance communicational self-efficacy and mutual support among participants. Emotional regulation strategies are learned through relaxation exercises. A relaxation booklet is given to the participants to practice at home too. Moreover, all participants receive an informational booklet containing age-appropriate recommendations on communication with children about cancer.
45508545|NCT03571074|Other|Oxygenation|Oxygenation measured as oxygen supply and saturation before cardiac arrest, and oxygenation measured as PaO2 after cardiac arrest.
45508546|NCT00842348|Drug|lanreotide (Autogel formulation)|Autogel 120 mg
45508547|NCT03095599|Biological|IVACFLU-S|"IVACFLU-S is seasonal inactivated, split virion, trivalent influenza vaccine (A/H3N2, A/H1N1, and B), produced in GCP facility by IVAC uses embryonated chicken eggs. This vaccine is purified by sucrose gradient ultracentrifugation (Alfa Wassermann, West Caldwell, NJ), and inactivated with formaldehyde. Each 0.5 mL dose of vaccine contains~NYMC X-179A (A/California/7/2009) (H1N1) - 15μg hemagglutinin (HA)~NYMC X-263B (A/HongKong/4801/2014) (H3N2) - 15μg HA~NYMC BX-35 (B/Brisbane/60/2008) (B) - 15μg HA"
45508548|NCT03095599|Other|Placebo|Phosphate buffered saline with pH 7.2; 0.5 ml/per dose
45508549|NCT03569826|Other|Observational; no intervention|Observational; no intervention
45508550|NCT02144246|Other|Non-hormonal period|
45508551|NCT02144246|Drug|Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg|
45508552|NCT03569670|Device|Posterior stabilized all-polyethylene tibial component|Patients randomized to this arm will have a Triathlon implant with a posterior stabilized, all-polyethylene tibial component used during surgery.
45508553|NCT03569670|Device|Cruciate retaining all-polyethylene tibial component|Patients randomized to this arm will have a Triathlon implant with a cruciate retaining, all-polyethylene tibial component used during surgery.
45508554|NCT03544502|Device|CD player|CD player opened during anesthesia induction and continued until postoperative 15 minute
45400249|NCT03905590|Procedure|Periapical surgery with amniotic membrane|periapical surgery will be done followed by amniotic membrane placement over the defect
45400250|NCT03905590|Procedure|periapical surgery without amniotic membrane|periapical surgery will be done without placement of membrane over the defect.
45400251|NCT03905512|Drug|SEL-212|SEL-212
45400252|NCT03905512|Drug|SEL-037|SEL-037, PEGylated uric acid specific enzyme (uricase)
45508555|NCT03544502|Device|CEL-480 Sound Level Meter Sonometre|Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.
45508556|NCT03544502|Device|Earplug|the independent anesthesiologist placed earplug into the patients' ears during anesthesia induction and the ear plug were removed immediately before tracheal tube extubation.
45508557|NCT03544502|Procedure|Ambient operating room noise|patients were exposed to the ambient operating room noise.
45508558|NCT03572556|Biological|Blood samples|"5 mL dry tube to separate serum~Two 6 mL EDTA tubes for plasma separation~Eight 6 mL heparinized tubes for flow cytometry (quantification of TANG such as CD3+CD31+CXCR4+ and CEC) and quantification of angiogenesis markers."
45508559|NCT03572556|Other|Epistaxis charts|Three monthly epistaxis charts to be completed
45400253|NCT03905512|Drug|SEL-110|ImmTOR (SEL-110)
45400254|NCT03905512|Drug|KRYSTEXXA®|KRYSTEXXA®, PEGylated uric acid specific enzyme (uricase)
45508560|NCT03095521|Drug|Angal, lozenges [menthol],|Angal, administered per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution.
45508561|NCT03095521|Drug|ANTI-ANGIN® FORMULA|"0,2 mg + 2 mg + 50 mg (LLC Valeant, Russia). Administered per 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution."
45508562|NCT01372865|Drug|Mometasone furoate|
45508563|NCT01372865|Drug|Mometasone furoate|
45596676|NCT04439487|Diagnostic Test|Anthropometric measurements during routine preoperative visit|During routine preoperative anaesthetic visit and physical examination the following predictive test measurements are obtained by a research team member not involved in the further assessment of laryngoscopy: score in modified Mallampati test, Thyromental height, Sternomental distance, Thyromental distance, Neck circumference, Mouth opening distance
45596677|NCT04439487|Other|Assesment of intubation parameters during induction of general anaesthesia|During induction of general anaesthesia and intubation research team member not involved in obtaining anthropometric measurements notes Number of intubation attempts, Intubation time, Subjective intubation difficulty, Use of bougie and Need of technique modification.
45400255|NCT00227370|Drug|valganciclovir|valgan 900mg QD x 9 months post lung transplant
45400256|NCT00227370|Other|Placebo|
45400257|NCT03905122|Device|bioreactans tool|It is a completely non-invasive method by bioreactance method and it can be done to measure the intra-body fluid status with the help of the probes.
45508564|NCT05368116|Other|Video Assisted Self Management Program|"The main aim of this intervention is to educate the cancer patients receiving chemotherapy regarding the management of chemotherapy related side effects.~It will be one to one teaching session of 10-20 minutes conducted by the principal researcher with the help of a video on self management of chemotherapy related side effects and the video will focus on the self management of selected side effects of chemotherapy including nausea vomiting , Diarrhea , Fever , Mucositis , Skin changes , and Alopecia related distress.~The participants were given video when they comes to the Oncology day care and researcher instructs the participants to watch the video and at the same time the doubts asked by the participants were cleared by the researcher."
45508565|NCT05368116|Other|Standard of care|Standard of care
45508566|NCT05708898|Device|Pharyngeal exerciser|
45508567|NCT05708898|Device|sham pharyngeal exerciser|
45508568|NCT02144324|Device|Tandem Appliance|We are going to use a modified version of the Tandem Appliance
45508569|NCT01372943|Biological|"synthetic stool or pure cultures of probiotic intestinal bacteria"|"synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI"
45508570|NCT02254382|Device|Adaptive servo ventilation (ASV)|Non-invasive Ventilation used to control central and obstructive sleep apnea.
45508571|NCT03569592|Behavioral|Overdose Prevention Intervention|Evaluate an overdose prevention education with incarcerated people living with HIV/AIDS.
45508572|NCT01371773|Procedure|repositioning method for left-sided double lumen tubes|When a left-sided double lumen tube were placed in right mainstem bronchus, after withdrawing the tube into mid-trachea, it was re-advanced with patient's head turned right and counterclockwise rotation of the tube.
45508573|NCT00475280|Procedure|Geriatric assessment adapted therapy|Geriatric assessment is performed before the induction phase starts.
45508574|NCT00475280|Procedure|Stem cells autotransplantation|Stem cells autotransplantation is performed after consolidation treatment
45508575|NCT05242315|Drug|Envarsus Oral Product|as described in arm/group description
45508576|NCT05242315|Drug|Prograf (SOC)|Prograf (SOC)
45508577|NCT03569358|Device|Immersive Virtual Reality|The immersive virtual reality headgear used is the commercially available FOVE VR headset. It incorporates a 2560x1440 pixel display, position tracking-and eye-tracking. The headset weight 520g with adjustable velcro straps. Softwares are run via a computer connected by HDMI or USB cables.
45508578|NCT03569358|Device|EEG headband|The EEG headband is commercially available MUSE band. It incorporates 4-channel dry electrode EEG system where data can be recorded with bluetooth connection.
45508579|NCT03033875|Behavioral|Tele-Savvy|The Tele-Savvy program engages groups of six dementia family caregivers in a program that extends over 43 days. The program begins with a scheduled 75-minute group videoconference led by facilitators; similar group videoconferences then take place weekly for six weeks. In between the video-conferences, caregivers will receive daily emails with links to 5-15 minute on-line video lessons that can be watched on their own schedule as often as they wish. The videoconferences allow caregivers to report enactment of learned and self-developed management strategy behaviors into their own caregiving and allow them to raise questions. Each daily video presents a teaching point linked to the overall curriculum. The lesson is carried forward by brief, scripted talks by experts or is enacted in vignettes in which a fictional family caring for a father living with Alzheimer's demonstrates effective caregiving techniques linked to the day's teaching points.
45697960|NCT01062568|Drug|Adrenocorticotropin|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
45400258|NCT03969030|Other|PEBRA model|"The participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the PE, as much as feasible according to the participants' preferences. Thus, the preferences of each participant are captured at enrolment and after a strict schedule thereafter. The PE conducts the preference assessment using a tablet-based application, called PEBRApp, accoring to a specific schedule. First, the participant will be asked his/her preference regarding different domains of DSD (see below) and this will be entered into the PEBRApp. Secondly, the chosen preferences are assessed regarding feasibility with specific questions, as not all preference options are available to everyone all the time. The preference assessment entails the following three domains of DSD:~ART Refill~SMS notifications~Support"
45400259|NCT03905200|Diagnostic Test|3D-speckle tracking imaging|The strain peak value and strain peaking time of each segment (including 16 segments) of the left ventricular myocardium can be obtained by 3d-sti technology.
45400260|NCT01251796|Drug|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ197 and orally once daily administration of erlotinib hydrochloride
45400261|NCT01251874|Drug|Carboplatin|Given IV
45400262|NCT01251874|Other|Fluorothymidine F-18|Correlative studies
45400263|NCT01251874|Other|Laboratory Biomarker Analysis|Correlative studies
45400264|NCT01251874|Other|Pharmacological Study|Correlative studies
45400265|NCT01251874|Procedure|Positron Emission Tomography|Correlative studies
45400266|NCT01251874|Drug|Veliparib|Given PO
45400267|NCT03911674|Other|Oral manual stimulation of feeding in preterm infants|Manual stimulation of the cheeks (internal and external), lips, gums, tongue and palate by finger-strokin.
45697961|NCT01062568|Drug|Dexamethasone|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, 0.25 mg adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
45400268|NCT03903250|Dietary Supplement|A-GPC|Taken orally in liquid form
45400269|NCT03903250|Dietary Supplement|Sugar|Taken orally in liquid form
45400270|NCT01147978|Behavioral|End of ICU stay conference|Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
45400271|NCT01252030|Device|physical activity monitors|physical activity monitors
45400272|NCT01252030|Other|No physical activity monitors|No physical activity monitors
45400273|NCT01252108|Drug|SQ109|300 mg SQ109 daily for 14 days
45400274|NCT01148680|Biological|Islet Graft|Iterative injection of pancreatic islets (minimum: 250,000 IEQ / injection or 3500 IEQ / kg / injection) with a threshold required total of 11,000 IEQ / kg in 2 or 3 injections per patient)
45400275|NCT05560048|Dietary Supplement|rice protein RP-80N|rice protein RP-80NY were dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight
45400276|NCT05560048|Dietary Supplement|placebo|placebo were dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight
45400277|NCT03903328|Other|Sarcopenia assessment|Sarcopenia assessment by measurement of Skeletal Muscle mass index, hand grip strength and usual gait speed for 5 meter distance, as per the guidelines of Asia Working group for Sarcopenia study, was carried out.
45400278|NCT03904810|Behavioral|Exercise intervention|HIIT groups performed 30-meter shuttle runs on a rooftop covered field whereas MICT group ran on a footpath with an overall flat and non-slippery road surface. All training sessions were preceded by a 5-minute self-pace warm-up jogging and ended with a 5-minute self-pace jogging or walking cool-down. Each session of MICT consisted of 30 minutes of continuous exercise at an intensity of 60% of heart rate reserve (HRR); [i.e., (maximal HR - resting HR) × intensity + resting HR]. For each HIIT session, the intensity was set at 90% HRR for high-intensity bouts, interspersed with active recovery at 70% HRR. All exercise sessions were supervised by qualified athletic coach or strength and conditioning coach.
45400279|NCT03904966|Device|Kinesio tape|Kinesio tape will be applied on the plantar heel (the most painful area) of the patients for the treatment of plantar fasciitis, in addition to the extracorporeal shock wave therapy
45400280|NCT03904966|Device|Extracorporeal shock wave therapy|Extracorporeal shock wave therapy will be used for all patients with plantar fasciitis. (5 sessions for 5-week)
45400281|NCT03905044|Other|eyes with congenital cataracts|observation
45697962|NCT03739281|Diagnostic Test|PET/MR|The included patients are imaged with PET/MR as part of the research protocol.
45400282|NCT03911440|Drug|Doxycycline|Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
45400283|NCT03911440|Drug|Azithromycin|Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
45400284|NCT01254838|Biological|HLA-A02 restricted HIG2|
45400285|NCT00191100|Drug|Gemcitabine|
45400286|NCT00191100|Drug|Cisplatin|
45400287|NCT00191100|Radiation|Brachytherapy|Brachytherapy, 30-35 Gy over 1 week
45400288|NCT00191100|Radiation|Pelvic radiation|Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
45400289|NCT03911518|Procedure|Loop drainage|Loop drainage will occur via 2 small incisions, approximately 2 cm, with the cuff from the base of a sterile glove pulled through and then tied off.
45400290|NCT03911518|Procedure|Incision and drainage|The wound will be incised with a #11 blade scalpel along the point of maximal fluctuance, approximately 2-3 cm, and then all loculations bluntly dissected with a set of Kelly clamps. After drainage of pus, the wound will be loosely packed with gauze.
45596678|NCT03528967|Drug|Enoxaparin 40 mg / 0.4 mL Prefilled Syringe|
45596679|NCT03528967|Drug|Aspirin 100 mg Oral Tablet, Enteric Coated|
45697963|NCT03739281|Diagnostic Test|PET/CT|The included patients are imaged with PET/CT as part of normal clinical routine.
45400291|NCT03911362|Behavioral|Lumbopelvic Stabilisation Exercises Group|Lumbopelvic stabilisation exercises will be taught the basic movement, starting with co-contraction of the transversus abdominis (TA) muscle and other muscles together with diaphragm breathing, and continuing the exercises with upper and lower extremity movements together with TA and multifidus contraction.
45400292|NCT03911362|Behavioral|Pelvic Floor Exercises Group|The pelvic flor exercise will be in the form of contraction-release for rapidly contracting muscle fibres, and for slowly contracting muscle fibres, slow contraction by counting to ten, hold for a count of ten, then gradually relax by counting to ten
45508580|NCT03033875|Behavioral|Healthy Living Education Program|The Healthy Living Education Program contains video and text materials on exercise, diet, and healthy living. Participants will be asked to log into the Canvas site daily over the course of six weeks to view the videos. Each participant will also receive 7 weekly brief scripted phone or video calls from a project facilitator to inquire about participants' use of the materials. Additionally, all participants will convene weekly for a video conference centered on the application of healthy living strategies. Facilitators will greet and check in with each of the caregivers, coach and debrief caregivers on the homework, answer questions and/or respond to feedback about the week's material, review key points and concepts from the week's video sessions and introduce new material, report on any activities that caregivers may have implemented based on the materials, and provide homework assignments.
45508581|NCT05241457|Device|Ekso gait training|Ekso sessions will be 60 minutes each. Patients will be measured to optimize Ekso fit during their initial training session. Ekso settings will be progressed as deemed appropriate by the trained clinician. The progression of Ekso settings allows the patient to use their maximum effort while the Ekso assists only as much as the patient requires to complete stepping. Patients may also spend time working on pre-gait activities and balance activities including weight shifting, stepping in place, side-stepping and backwards ambulation based on the patient's needs as determined by the clinician.
45400293|NCT01148758|Drug|RO5323441|cohorts receiving multiple doses iv
45400294|NCT01254448|Drug|TC-5619|Group 1: 25 mg TC-5619 administered once daily for 28 days. Group 2: 50-150 mg TC-5619 administered once daily for 10 days.
45508582|NCT05241457|Procedure|Standard physical therapy|Standard physical therapy sessions will be 60 to 90 minutes a day. Clinicians typically focus on gait, balance, and strengthening activities that address goals related to functional mobility. Other devices that would normally be used during PT sessions, including the Lite Gait and Rifton tram body weight support devices and electrical stimulation devices including the XCITE and RT300 (from Restorative Therapies).
45400295|NCT01254448|Drug|Placebo|Group 1: matching placebo administered once daily for 28 days. Group 2: matching placebo administered once daily for 10 days.
45400296|NCT03902548|Drug|[18F]P16-129|Injection of < 10 mCi [18F]P16-129 followed by PET/CT scanning
45400297|NCT03904576|Drug|BI 1358894|Film-coated tablet
45400298|NCT03904576|Drug|Placebo|Film-coated tablet
45400299|NCT03902626|Other|Physiotherapy students|
45400300|NCT03902626|Other|Medical students|
45508583|NCT02144402|Other|infant formula with DHASCO|
45508584|NCT02144402|Other|infant formula with DHASCO-B|
45508585|NCT03569046|Drug|local anaesthetic injection|ear block by 0.25% bupivacaine
45697964|NCT03014518|Other|Clinical assessments and blood samples; follow-up for 12 mos|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge and other time points throughout 12 months follow-up. Blood samples taken at baseline (admission to unit) and day of discharge.
45849937|NCT03525678|Drug|Belantamab mafodotin lyophilized powder|Belantamab mafodotin will be available as lyophilized powder. Lyophilized powder will be available as 100 mg/vial in single-use vial for reconstitution with unit dose strength of 3.4 mg/kg. Lyophilized belantamab mafodotin will be reconstituted using water for injection and diluted with saline before use.
45400301|NCT01149226|Drug|chloral hydrate|30 min before the induction of anesthesia, chloral hydrate (40 mg/kg) or placebo was administered to the children orally.
45400302|NCT01252342|Drug|Oxytocin|10 U intramyometrial oxytocin bolus immediately after cesarian delivery, and an infusion of 20 U/L of oxytocin at 500ml/hr.
45400303|NCT01252342|Drug|Saline|10U intramyometrial normal saline bolus immediately after cesarian delivery, and an infusion of 20U/L of oxytocin at 500ml/hr.
45400304|NCT03902470|Procedure|Thoracic epidural anaesthesia video assisted thoracoscopic surgery|Patients in (TEA) group will pre-medicated using midazolam 3-4 mg (IV)and fentanyl 50 mcg (IV). Then An epidural catheter will be inserted between T3-T4 and T4-T5 . A test dose (5 ml) of 2% lidocaine will be given, followed by 15-20 ml of bupivacain 0.5%.
45400305|NCT03911050|Dietary Supplement|Apple consumption|Apple blends (600 g) One single dose
45400306|NCT03911050|Dietary Supplement|Control group|Breakfast without any apple-related products
45400307|NCT00189540|Genetic|HGF plasmid|Intramuscular injections into the index leg on days 0, 14, and 28
45400308|NCT00189540|Genetic|Placebo|Intramuscular injections into the index leg on days 0, 14, and 28
45400309|NCT03904654|Behavioral|Mindfulness-based cognitive therapy (MBCT)|MBCT is an evidence-based psychotherapy which combines mindfulness skills with cognitive therapy strategies.
45400310|NCT01254994|Drug|entecavir|Patients in the ETV Group were prescribed 0.5 mg entecavir following oral fasting one time per day.
45508586|NCT03569046|Drug|Normal Saline Flush, 0.9% Injectable Solution|ear block by Normal Saline Flush, 0.9% Injectable Solution
45508587|NCT03569046|Drug|general anesthetic|general anesthetic by midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 μg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air.
45508588|NCT03569046|Drug|Hypotensives|hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
45508589|NCT02935595|Drug|Ketamine|Ketamine Hydrochloride Injection
45508590|NCT02649673|Drug|LCL161|
45508591|NCT02649673|Drug|Topotecan|Topotecan will also be administered orally. Patients in DL 1 will receive topotecan at 1.8 mg/m2 per day for the first 5 days of each 21-day cycle. Patients in DL 2 will receive topotecan at 2.3 mg/m2 per day for the first 5 days of each 21-day cycle. The maximum dose for topotecan will not exceed 2.3 mg/m2 per day in this study.
45508592|NCT02649673|Drug|Pegylated GCSF (PEG-GCSF)|Pegylated GCSF (PEG-GCSF) (e.g. pegfilgrastim) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.
45508593|NCT02140658|Behavioral|multiple health education interventions|
45508594|NCT02140658|Behavioral|conventional health education|
45508595|NCT03568968|Dietary Supplement|Nicotinamide Riboside|1000mg one time daily. Given as tablets. Duration of the trial, 52 weeks.
45508596|NCT03568968|Drug|Placebo|Placebo drug, given 1 time daily for the duration of the trial; 52 weeks.
45508597|NCT02817347|Drug|piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%|
45508598|NCT02817347|Drug|piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%|
45508599|NCT02817347|Drug|piperacillin 2% + tazobactam 0.25%|
45508600|NCT02817347|Drug|piperacillin 4% + tazobactam 0.5%|
45508601|NCT02817347|Drug|piperacillin 8% + tazobactam 1.0%|
45508602|NCT02503111|Device|The Hyfrecator ® 2000 Electrosurgical System|Lesion is ablated by the The Hyfrecator ® 2000 Electrosurgical System. During electrocautery (EC) with The Hyfrecator, a gentle brushing technique occurs and the tissue is removed with forceps.
45508603|NCT02503111|Other|Observation Alone|No treatment to AIN-2 or AIN-3, only active surveillance.
45508604|NCT01367327|Behavioral|Loaded sit-to-stand exercise|Loaded sit-to-stand exercise at home, 3 times a week for 6 weeks
45508605|NCT01367327|Behavioral|Synchronized music|Synchronized music for loaded sit-to-stand exercise to guide movement
45508606|NCT05708820|Behavioral|Online education programme|Online group will follow the education programme through videos that they can view at any time and a live session to answer questions.
45508607|NCT05708820|Behavioral|Standard education programme|Face-to-face educacion programme in a group session
45508608|NCT05417191|Behavioral|Conventional fish|Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
45508609|NCT05417191|Behavioral|Enriched fish|Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using a diet enriched with olive pomace. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
45849938|NCT03459222|Biological|Relatlimab|Specified dose on specified days
45508610|NCT02742311|Procedure|Endoscopic disectomy|Endoscopic discectomy is an established method for treatment of lumbar disc herniation. Edoscopic discectomy provides a safe and minimal access corridor for lumbar discectomy. The technique also allows early postoperative mobilization and faster return to work.
45508611|NCT01811394|Radiation|protons|Treatment is performed using 16 x 4 GyE protons
45508612|NCT01811394|Radiation|carbon ions|Treatment is performed using 16 x 4 GyE carbon ions
45508613|NCT05018507|Other|Data collection only|No intervention, just data collection from system machines
45508614|NCT04617769|Behavioral|Psychoeducation|psychoeducational materials on trauma and safety behaviors
45508615|NCT04617769|Behavioral|Exposure|six 3-minute video exposure trials with an inter-trial interval of 2 minutes
45508616|NCT03570762|Procedure|hybrid percutaneous intervention|
45596680|NCT05723965|Other|As training material for deep learning model.|Using labeled images as training materials for artificial intelligence to develop object detecting model.
45849939|NCT03459222|Biological|Nivolumab|Specified dose on specified days
45849940|NCT03459222|Drug|BMS-986205|Specified dose on specified days
45849941|NCT03459222|Biological|Ipilimumab|Specified dose on specified days
45508617|NCT02464553|Other|periradicular therapy (PRT)|RTG controlled periradicular therapy (PRT) is a microinvasive interventional pain release procedure. Advantage of targeted pain therapy is exact administration of effective drugs to the nerve root in the area of the thoracic, lumbar or sacral spines.
45508618|NCT05708508|Drug|ROVALCYTE|"Immuno-guided strategy arm"
45508619|NCT04700449|Drug|CBP-307|CBP-307 capsules oral administration
45508620|NCT04700449|Drug|Placebo|Placebo capsules oral administration
45508621|NCT01373021|Drug|Fentanyl|Fentanyl 2500mcg+NS50ml
45508622|NCT01373021|Drug|Dexmedetomidine|Fentanyl 2500mcg+Dexmedetomidine 500mcg + NS 45ml
45400311|NCT01254994|Drug|Traditional comprehensive medical treatment|bed rest, sufficient energy and vitamins, reduced glutathione, prostaglandin E1, hepatocyte growth factor (HGF), plasma and albumin, maintenance of water and electrolyte balance, and prevention and treatment of complications, such as infections, hepatic encephalopathy, hemorrhage, hepatorenal syndrome and ascites.
45697965|NCT03014518|Other|Clinical assessments and blood samples; no 12mo follow-up|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge time point (5-7 days after baseline). Blood samples taken at baseline and discharge time points (5-7 days after baseline).
45697966|NCT05155137|Drug|Drug Capsule (Valsartan + Amlodipine + Rosuvastatin)|Polypill with 3 medications (Valsartan 80 mg + Amlodipine 5 mg + Rosuvastatin 10 mg)
45400312|NCT01148914|Other|Inflammatory biomarkers|tTst blood samples for cardiac biomarkers at baseline, 24-hours and 3 month post-ablation
45508623|NCT03568812|Drug|Rillus®|Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
45508624|NCT03568812|Other|Placebo|Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
45508625|NCT02690558|Drug|pembrolizumab, gemcitabine and cisplatin|neoadjuvant administration of pembrolizumab with gemcitabine and cisplatin prior to cystectomy
45508626|NCT01367405|Procedure|Surgical decompression|Surgical decompression within 24 hour postinjury
45508627|NCT01367405|Procedure|Conservative treatment|Usual conservative treatment without surgery
45508628|NCT03568734|Other|Fecal transplant|At delivery, i.e. 39-40 weeks of gestation, the newborn infant is given 0.1 g maternal fecal sample (in 0.5 ml of the isotonic saline+10 % glycerol) dissolved in 10 ml of bank milk orally. The sample is given within 2 h of birth. Milk containing fecal sample (2 ml) is given as a part of a total feeding of 5-10 ml.
45697967|NCT05155137|Behavioral|Stroke Riskometer|the primary care units will be randomized to use Stroke Riskometer App together with health community workers to help in the lifestyle modifications
45697968|NCT04179981|Device|Positive airway pressure|Positive airway pressure therapy. OVS patients randomized to PAP therapy arm will be titrated to optimal PAP therapy per standard protocol and assigned to use PAP therapy.
45697969|NCT04179981|Other|Conservative care (control arm)|Eligible OVS patients will receive conservative care/usual care with education about sleep apnea and sleep hygiene via handouts and video instructions. This is the control arm.
45697970|NCT05154201|Drug|ORIN1001|Dose escalation of ORIN1001 as a single agent or in combination with standard of care. Dose expansion of ORIN1001 as a single agent or in combination with standard of care.
45697971|NCT05153343|Drug|flonoltinib 25mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
45400313|NCT03902236|Other|Reaction Time and Postural Control|Reaction Time and Postural Control: With ''Fitlight TrainerTM'', 6 light emitting diode (LED) lights placed at certain points on the wall are randomly lit and expected to deactivate them as fast as possible. In the protocol, the leds will be placed according to the physical structure of the person, and the scores of 29 LED's will be kept in seconds. The scores will be compared cystic fibrosis, bronchiectasis and healthy groups.
45400314|NCT03902236|Other|Muscle oxygenation|Muscle oxygenation will be assessed with wearable lactate threshold predicting device in cystic fibrosis, bronchiectasis and healthy groups.
45508629|NCT02144480|Behavioral|Intensive training|The IT group will receive physiotherapy twice daily with longer duration and higher intensity
45508630|NCT02144480|Behavioral|traditional training|usual care: conventional rehabilitation
45508631|NCT03568578|Drug|Entecavir 0.5 mg|Patients in this group will be given Entecavir 0.5 mg a day for 2 years.
45508632|NCT03568578|Drug|Anluohuaxian Pill 12g|Patients in this group will be given Entecavir 0.5 mg and Anluohuaxian Pill 12g a day for 2 years
45697972|NCT05153343|Drug|flonoltinib 50mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
45697973|NCT05153343|Drug|flonoltinib 100mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
45697974|NCT05153343|Drug|flonoltinib 150mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
45697975|NCT05153343|Drug|flonoltinib 225mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
45508633|NCT04700371|Device|Interwoven stent|Interwoven nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
45400315|NCT03902236|Other|Exercise capacity|Exercise capacity will be assessed with incremental shuttle walk test in cystic fibrosis, bronchiectasis and healthy groups.The patient is required to walk around two cones set 9 metres apart (so the final track is 10 metres) in time to a set of auditory beeps played on a CD. Initially, the walking speed is very slow, but each minute the required walking speed progressively increases.The patient walks for as long as they can until they are either too breathless or can no longer keep up with the beeps, at which time the test ends The number of shuttles is recorded. Each shuttle represents a distance of ten metres
45400316|NCT03902236|Other|Balance|Balance will be assessed with functional reach test in cystic fibrosis, bronchiectasis and healthy groups Functional Reach measures the maximum distance a person can reach forward, the distance of the person standing at the edge of the wall with a 90-degree shoulder flexion and the maximum distance to the front of the thumb will be noted.
45508634|NCT04700371|Device|Laser-cut stent|Laser-cut nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
45508635|NCT01367483|Drug|IV methylnaltrexone (MNTX)|
45508636|NCT02140736|Drug|Epoetin biosimilar|
45508637|NCT05417035|Drug|Nebido|To evaluate if traditional treatment induces puberty similary to newer treatment
45508638|NCT05708742|Device|Ultrasound|A linear US transducer (Phillips-Saronno Italy) was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between.
45508639|NCT05708742|Drug|Bupivacaine Hydrochloride|The ESP block group underwent US-guided ESP block at L4 vertebrae level with 20 ml of bupivacaine 0.25%.
45508640|NCT05708742|Drug|saline solution|The control group underwent the same procedure but had a sham injection (20 ml of saline).
45508641|NCT05708742|Device|Needle|A 22-gauge short bevel needle (Spinocan, B. Braun Melsungen AG, Germany) was inserted in the cranial-caudal direction towards the TP in-plane with the US transducer until the needle touched the TP crossing all three muscles.
45508642|NCT01968785|Radiation|Radiation Dose 25 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 25 Gy to the renal artery.
45508643|NCT01968785|Radiation|Radiation Dose 50 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 50 Gy to the renal artery.
45508644|NCT01373099|Procedure|Implantation of a static, non-articulating cement spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made with a rod of antibiotic-impregnated cement and cement beads of sufficient quantity to fill the acetabulum.
45508645|NCT01373099|Procedure|Implantation of an articulating spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic-impregnated cement using the Stage One system (Biomet, Warsaw, IN) sized to fit the endosteal and acetabular bone defect.
45508646|NCT05354388|Procedure|Resection surgery of gastrointestinal stromal tumor|oral administration of Ripretinib 150 mg QD. Resection of gastrointestinal stromal tumors was performed in patients who achieved PR or SD
45508647|NCT03095287|Biological|Alphanate|Bolus IV injection.
45400317|NCT03904732|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Low-dose acetylsalicylic acid, Aspirin (75-150 mg)
45400318|NCT01252420|Drug|Enoxaparin|1.5mg/kg daily for 2 weeks
45400319|NCT03911206|Behavioral|Inspiratory muscle training (IMT)|IMT exercises at home will gradually ramp up
45400320|NCT03911206|Behavioral|Exercise alone|Subjects will be asked to exercise 2x/week for 6 weeks in person at the Duke research facility and again 2x/week at home for 30 minutes.
45400321|NCT03911206|Behavioral|IMT and Exercise|Combining IMT training and exercise
45400322|NCT03902158|Device|Glasses|The patient will wear virtual reality glasses during anesthesia
45400323|NCT03902158|Behavioral|Distraction techniques|The patient will undergo distraction techniques
45400324|NCT01149304|Drug|Pentoxifylline|Pentoxifylline is given for 8 weeks since the evening of the day of intervention with a dose of 400mg applied three times daily (morning, noon, evening).
45400325|NCT01149304|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid is administered for 8 weeks since the evening of the day of intervention. Dosage is 250mg given three times daily (morning, noon, evening).
45508648|NCT01335581|Device|Q-Switched Nd:YAG Laser (RevLite)|Laser treatment added to a microdermabrasion and topical lightening agent regimen
45400326|NCT01149304|Drug|Enoxaparin|Enoxaparin with a dose of 40mg is injected subcutaneously once a day for 8 weeks since the evening of the day of intervention after the HDR-brachytherapy.
45508649|NCT01335581|Drug|Retin-A and microdermabrasion|Microdermabrasion and topical lightening agent regimen
45508650|NCT05354310|Combination Product|VOILA|Participants will be given dietary supplement powder containing protein, galactooligosaccharide (GOS), vitamin D, and calcium throughout the twelve weeks of intervention. This will be accompanied with a resistance training regime whereby participants will train three times a week for the three months. A variety of measurements will be carried out at baseline and at endline.
45508651|NCT05204563|Drug|Combination of Imipenem/Cilastatin and XNW4107|Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for Injection
45508652|NCT05204563|Drug|Imipenem/Cilastatin/Relebactam|Imipenem/Cilastatin/Relebactam 1.25 g for Injection
45508653|NCT02144558|Other|penile vibratory stimulation (PVS) or masturbation|penile vibratory stimulation (PVS) or masturbation
45508654|NCT03566940|Biological|sIPV|Participants will receive 0.5 milliliter (mL) of sIPV as a solution for IM injection.
45508655|NCT03566940|Biological|cIPV|Participants will receive 0.5 mL of cIPV as a suspension for IM injection.
45508656|NCT02144636|Dietary Supplement|herbalife protein shake|
45508657|NCT03566862|Diagnostic Test|Leicester Cough Monitor (LCM)|The Leicester Monitoring Cough (LCM) kit includes a digital flash voice recorder (Sony ICD-PX333), aA clip-on lapel microphone (Philips LFH9173) and a small carry/travel waist bag.
45508658|NCT03545360|Device|BTL-703 (Treatment group)|Treatment with BTL-703 device
45508659|NCT03566784|Procedure|Inguinal hernia repair|Standard procedure for inguinal hernia repair
45508660|NCT01209923|Device|BC1|Body composition measures taken twice at the same visit for BIA, DEXA, and hydrostatic weighing.
45508661|NCT02424955|Drug|perflutren lipid microspheres|
45508662|NCT02424955|Diagnostic Test|3D ultrasound|
45508663|NCT02140814|Dietary Supplement|Niacinamide|
45508664|NCT03015090|Drug|Theophylline|After oral theophylline 200mg per day for one week, blood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2
45508665|NCT02140892|Procedure|respiratory physical therapy manual technique- Autogenic Drainage|
45508666|NCT02140892|Device|respiratory physical therapy technique- IPV|
45508667|NCT00139139|Biological|Hepatitis A vaccine|
45508668|NCT05189353|Other|Ghrelin|Ghrelin infusion
45697976|NCT05153343|Drug|flonoltinib 325mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
45400327|NCT03902002|Drug|Omaveloxolone 50 mg capsules|Capsules containing 50 mg of omaveloxolone
45400328|NCT01254526|Drug|GDC-0980|Oral repeating dose
45400329|NCT01254526|Drug|bevacizumab|Intravenous repeating dose
45400330|NCT01254526|Drug|paclitaxel|Intravenous repeating dose
45400331|NCT01148992|Drug|Lofexidine|0.8mg alone and concurrent with IV cocaine infusions of 20 mg and 40 mg
45400332|NCT01148992|Drug|Placebo|0mg
45508669|NCT05189353|Other|Placebo|Saline infusion
45508670|NCT02141048|Behavioral|Positive Parenting Skills Training|This parenting programme is delivered by facilitators from the Parent Centre. It is intended for any caregivers of children between the ages of 6-12 years. It consists of seven weekly 3-hour sessions, and is group-based. Once the group size reaches 20 or more people sessions are co-facilitated. The first session provides an overview of the programme. The remaining sessions consider topics including: factors that affect child behaviour, understanding children's feelings, building children's self-esteem, assertive parenting, gaining child-co-operation, effective discipline, and problem solving. The programme is knowledge-based and encourages the development of various parenting skills through the inclusion of experiential activities (e.g., role-plays and homework practice).
45508671|NCT02355301|Procedure|orthopedic|Compare the type of treatment chosen by the orthopedist with a functional assessment (ICF-WHO model)
45697977|NCT01881425|Procedure|Glaucoma Surgery|"An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a fornix-based conjunctival incision at the corneoscleral junction. A partial thickness scleral flap with its base at the corneoscleral junction after cauterization of the flap area, and a window opening is created under the flap with a Kelly-punch to remove a portion of the sclera, Schlemm's canal and the trabecular meshwork to enter the anterior chamber. An iridectomy is done in many cases to prevent future blockage of the sclerostomy. The scleral flap is then sutured loosely back in place with several sutures. The conjunctiva is closed in a watertight fashion at the end of the procedure."
45508672|NCT01367639|Behavioral|Inquiry Based Stress Reduction (IBSR) program|"The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life"
45508673|NCT01373177|Diagnostic Test|Bayley Scales of Infant Development-II|Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-II was published in 1993. BSID-II provides normative data from two scales - Mental Development Index (MDI), and Psychomotor Development Index (PDI).
45508674|NCT01373177|Diagnostic Test|Bayley Scales of Infant Development-III|Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-III was released in 2006. BSID-III provides normative data from five scales - Cognitive, Language, Motor, Social-Emotional, and Adaptive.
45400333|NCT03910582|Procedure|personalized frozen-thawed embryo transfer|The blastocysts were delayed or advanced transferred after ovulation depending on the endometrium dating in RIF group
45400334|NCT03910582|Procedure|routine frozen-thawed embryo transfer|The blastocysts were transferred 5 days after ovulation regardless of endometrium dating in control group.
45400335|NCT03901846|Device|ColdZyme|ColdZyme is a Class I medical device (CE-marked) with the following composition: glycerol, water, Tris buffer, CaCl2, menthol and trypsin
45400336|NCT03904186|Behavioral|QUIT|QUIT is a transdiagnostic Cognitive Behavioral Therapy-based smoking cessation protocol designed to address distress intolerance, anxiety sensitivity, and anhedonia in people living with HIV who smoke. QUIT is delivered in 9 60-minute individual weekly sessions over a 10-week period. Sessions are active, with treatment components practiced within and outside of the session. Participants will also receive the transdermal nicotine patch for 8 weeks, starting when they attempt to quit smoking during week 7 of the study.
45400337|NCT03904186|Behavioral|Time-Matched Control (TM)|Participants will receive a standard smoking cessation treatment, based on the clinical practice guidelines from the U.S. Department of Health and Human Services, Treating Tobacco Use and Dependence. Treatment will be delivered in nine, 60-minute sessions over a ten-week period. The treatment is based on a treatment protocol developed and used previously by Dr. Zvolensky. Because clinical guidelines recommend that all smokers attempting to quit smoking receive pharmacotherapy, participants will also receive the transdermal nicotine patch for 8 weeks.
45400338|NCT01255072|Procedure|Transcranial Magnetic Stimulation|20 Sham daily sessions:25 trains, 10seconds at 5Hz, train interval of 25 seconds (time off). Target: left dorsolateral prefrontal cortex.
45400339|NCT01255072|Procedure|Repetitive Transcranial Magnetic Stimulation|20 daily sessions: each one with 25 trains of 10seconds at 5Hz, train interval of 25 seconds (time off), pulse intensity corrected based on atrophy degree by a specific correction formule. Target: left dorsolateral prefrontal cortex.
45400340|NCT03901612|Drug|Ropivacaine 0.2%|Continuous post operative regional analgesia
45400341|NCT03901612|Drug|saline 09%|Continuous post operative regional analgesia
45508675|NCT02620748|Drug|Tranexamic Acid|
45508676|NCT02620748|Other|Saline Solution|
45400342|NCT03904342|Behavioral|Sophie CBT System|The Sophie CBT system is a tablet-based system that delivers self-paced cognitive behavioral therapy educational curriculum in the format of 6 discrete modules.
45400343|NCT03904342|Behavioral|iHope CBT|Licensed therapists will use the iHope HIPAA-compliant telemedicine platform to deliver cognitive behavioral therapy to patients via telephone, videoconferencing, and/or text chat.
45400344|NCT03903952|Dietary Supplement|Vitamin B12 and folate|Vitamin B12 and folate levels in blood
45400345|NCT03910348|Device|Whole-body vibration exercise|The WBV training consisted of a high frequency (30-40 Hz) vibration stimulus at a low setting on a Power Plate pro5 vibration platform (Performance Health Systems, LLC, Northbrook, IL, USA).
45400346|NCT03910348|Other|High-impact exercise|In the high-impact exercise program, the patients were asked to jump using a jump-rope at the beginning of each session
45508677|NCT01373255|Procedure|internal iliac catheterization|Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
45508678|NCT03566706|Behavioral|Discussion Tool: Unhealthy Eating|Parents will randomly be assigned to one of three discussion tools that will provide parents with tools on how to communicate with their children about unhealthy eating, marijuana use, or sedentary behavior.
45508679|NCT03566706|Behavioral|Discussion Tool: Marijuana Use|Parent Discussion Tools
45508680|NCT03566706|Behavioral|Discussion Tool: Sedentary Behavior|Parent Discussion Tools
45508681|NCT03566628|Other|Warmed Isotonic Saline|Isotonic saline warmed to 39ºC.
45508682|NCT03566628|Other|Room-Temperature Isotonic Saline|Isotonic saline at room temperature
45508683|NCT02141126|Other|Resistance training|Usual physiotherapy care and twice weekly tailored and progressive resistance lower limb exercises Circuit-type format, sessions will last 35 minutes and will include a warm-up and cool-down period. Exercises tailored to each patient and will use ankle weights as the resistance, using 65-75% of their 1-Repetition Maximum. Intervention will last for 6 weeks.
45508684|NCT02141126|Other|Usual care|Standard inpatient 'usual care' physiotherapy
45849942|NCT03398304|Other|Graded Exercise|Study arm 1 (Graded Exercise) participants will complete either 20 minutes of mild or moderate intensity at 2 different study visits. The third study visit will consist of 20 minutes of sitting.
45400347|NCT00257010|Drug|Almotriptan Malate|Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain
45508685|NCT03566472|Diagnostic Test|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System for 72 hours
45508686|NCT02144792|Drug|[11C] -verapamil PET|While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
45508687|NCT03564990|Other|interactive, multifaceted approach|A health education module consisting of a lecture and workshop was incorporated into a health-care course.
45508688|NCT03564990|Other|conventional approach|conventional follow-up
45508689|NCT02144870|Behavioral|Habit Reversal Training|awareness training, competing response training
45508690|NCT02144870|Behavioral|Resources activation|
45508691|NCT03566394|Drug|Gabapentin 300mg|Gabapentin 300mg orally three times a day, from 2 days before to 5 days after taxane infusion
45508692|NCT03544424|Other|No intervention|No intervention
45508693|NCT00033293|Other|Clinical Observation|Undergo observation
45508694|NCT00033293|Drug|Cyclophosphamide|Given IV
45508695|NCT00033293|Other|Laboratory Biomarker Analysis|Correlative studies
45508696|NCT00033293|Procedure|Magnetic Resonance Imaging|Correlative studies
45508697|NCT00033293|Drug|Prednisone|Given orally
45508698|NCT00033293|Biological|Therapeutic Immune Globulin|Given IV
45508699|NCT03566316|Drug|Telmisartan/Amlodipine|
45508700|NCT03566316|Drug|Rosuvastatin|
46059118|NCT02581501|Drug|GAX - Gemcitabine, Abraxane and Xeloda|GAX represents a novel approach to the development of cancer chemotherapy agents in pancreatic cancer and is based upon extensive laboratory investigations for the induction of apoptosis in pancreatic carcinoma cells. It is our expectation that this combination will induce apoptotic pathways downstream of biochemical mechanisms of resistance and synergistically induce pathways for apoptosis that are non-p53 dependent, which have not been previously explored in chemotherapy trials for this cancer.
45400348|NCT03901768|Drug|Dexamethasone|a syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection.
45400349|NCT03901768|Drug|Triamcinolone|1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
45400350|NCT03901768|Drug|Placebos|A syringe having 4ml of saline is used for intravenous injection. 1ml of saline is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
45400351|NCT03903718|Drug|Oseltamivir|75 mg capsules orally twice a day from Day 2 to Day 7
45400352|NCT03903718|Biological|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody administered as a single IV infusion at either dose 1 or dose 2 on Day 2.
45400353|NCT03903718|Drug|Placebo|Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 2.
45508701|NCT03566316|Drug|Telmisartan|
45508702|NCT02144948|Drug|e.-coli-nissle|1 ml qd for 24 weeks
45508703|NCT03566004|Diagnostic Test|Stool specimen collection|The stool specimen collection was performed at the hospital or at home using a disposable device to be placed on the toilet seat and an E-nat Tube sent by postal to the lab.
45508704|NCT03565926|Other|Manual Therapy|"Articulation technique L4-S1~Lumbar neuromuscular technique~Fascial technique of crossed hands~Posteroanterior mobilizations of the lumbar vertebrae"
45508705|NCT03565926|Other|Hypopressive exercises|Protocol 5 Hypopressive exercises
45508706|NCT02145104|Drug|valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg|
45508707|NCT03565848|Procedure|Mesenteric vascular and nerve sparing surgery in laparoscopic segmental colorectal resection|Laparoscopic segmental colorectal resection performed by dissecting adherent to the intestinal wall with mesenteric vascularization and innervation entirely preserved.
45508708|NCT02145338|Drug|Nitrofurantoin or Trimethoprim or Cefalexin|Antibiotic prophylaxis
45508709|NCT02145338|Other|No prophylaxis|Discrete treatment courses of antibiotics as indicated by symptoms or signs of UTI.
45508710|NCT03565770|Other|individual coaching|coaching on the phone or with messages on line twice a month in order to help patients to adjust their insulin doses and fill in their self-assessment test.
45508711|NCT03565770|Other|Standard care|completion of the self-assessment test at inclusion, at M6 and M12 for all study participants
45508712|NCT03565692|Biological|the lung mycobiota and microbiota profile|"All sputum samples will follow regarding mycological and metagenomic analyses as summarized :~Pre-analytical treatment combining pre-treatment with mucolytic agent and sonication action~Separation of the pellet and supernatant, stored at -20 ° C until testing~Galactomannan (GM) Assay on each sputum supernatant to correlate with Aspergillus colonization history~Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification)~Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts.~Pseudomonas aeruginosa load measured by qPCR"
45508713|NCT03565692|Biological|the gut mycobiota and microbiota profile|All stool samples will follow regarding mycological and metagenomic analyses as summarized : - Separation of the pellet and supernatant, stored at -20 ° C until testing - Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification) - Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts. - Measurement of inflammation.
45508714|NCT02254616|Behavioral|Mirror Therapy with tDCS|The MTtDCS group will receive a 20-minute tDCS at 1.5 mA current intensity per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
45508715|NCT02254616|Behavioral|Mirror Therapy with sham-tDCS|The MTtDCS(m) group will receive a 20-minute sham-tDCS per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
45508716|NCT02254616|Behavioral|Mirror Therapy|The MT group will receive a 60-minute MT per session followed by a 30-minute functional training.
45508717|NCT02254616|Behavioral|Control Intervention|The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training.
45508718|NCT02254694|Other|high heeled shoes|see detailed study description
45508719|NCT03565614|Behavioral|Reablement|Intensive home-based rehabilitation is delivered up to 3 months by an interprofessional team (nurse, enrolled nurse, physiotherapist, occupational therapist, social worker). The entire team completed a 5-week college course. The team negotiates goal-directed contents of the rehabilitation initiatives with the user. Each user is handled deliberately based on decisions in the team in cooperation with the care managers overarching goals in admitted services. All participants have personal contact persons, and these contact persons have twice the time per participant as compared to traditional home care. The interprofessional team also has regular meetings to discuss every participant, and all rehabilitation goals activities related to those are documented.
45508720|NCT03565614|Behavioral|Traditional home care|Traditional home care and required rehabilitation efforts as by the municipality's current practice. Includes the same professions as is included in the reablement intervention, but the team has had no joint college course, does not use the systematic goal-directed and negotiated approach as the reablement intervention, and has about half the time per participant as compared to the reablement intervention.
45400354|NCT03910504|Drug|Rocuronium 0.3 mg*kg|Patients randomized to the control group will receive rocuronium at 0.3 mg*kg ev bolus at the induction of anesthesia.
45508721|NCT03565536|Drug|Nexavar|for Unresectable tumors ,After the patient had diagnosed as anaplastic thyroid cancer, Nexavar 400mg Bid was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed.
45508722|NCT03565536|Procedure|operation|If computed tomography (CT) evaluates for possible surgical treatment, complete thyroidectomy and cervical lymph node dissection are performed to completely resect thyroid tissue and metastatic lymphatic tissue.
45508723|NCT03565536|Radiation|External radiation therapy|As the successful surgery, then continue on the basis of taking on Nexavar plus external beam radiation therapy
45400355|NCT03910504|Drug|No Rocuronium|Patients randomized to the interventional group will not receive neuromuscular blockade at the induction of anesthesia.
45400356|NCT03901690|Drug|Betaglucin soluble gel 0.2%|With the prior informed consent of the 51 study participants, 5 grams of 0.2% soluble betaglucin gel will be self-applied every 12 hours for 5 days. Both groups will receive an unlabeled tube so that none of the study participants will know what topical treatments they are receiving.
45400357|NCT03901690|Drug|Imiquimod 5% cream|With the prior informed consent of the 51 study participants, 1 gram of 5% imiquimod will be self-applied once a day for 5 days. Both groups will receive an unlabeled tube so that neither study participant knows what topical treatments they are receiving.
45400358|NCT03901378|Drug|Pembrolizumab|Intravenous administration of pembrolizumab in combination with cisplatin or carboplatin and etoposide in first line metastatic or unresectable high grade neuroendocrine carcinoma:
45400359|NCT03909958|Other|Electroacupuncture+Routine rehabilitation training Group|"Electroacupuncture： Major acupoints: Jiaji points. With urinary and stool dysfunction:+Shenshu (BL23) ,Huiyang(BL35).~Localization:Jiaji points of the upper 1 and the lower 1 segment of the Spinal cord injury plane, a total of 4 points.~Operation: Insert Jiaji points By using Hwato-brand disposable acupuncture needles(0.30mm*50mm), with 0.5 inch from the median line and a depth of 50 to 60mm with perpendicular insertion.Then, participants will receive electroacupuncture treatment by connecting Han's pain irritant instrument (HANS100A) for 30min with the stimulation frequency of 2 /100 Hz and intensity of 1-2mA. Once a day, 5 days a week and rest 2 days, a week is one course and the duration need 12 courses.~Routine rehabilitation training:~Same as Routine rehabilitation training Group."
45508724|NCT05128253|Other|High fat meal in a subset of patients with NAFL or NASH|In a subset of NAFL (n=11) and NASH (n=11) patients venous blood samples will also be taken 2 (T0+2h), 4 (T0+4h) and 6 (T0+6h) hours after consumption of a high fat meal.
45508725|NCT05360862|Procedure|Prone positioning session|To perform respiratory measurements before, during and after a prone positioning session.
45508726|NCT05193383|Behavioral|Imaginal exposure|Session 1 (Day 1): Participants receive repeated exposure to mental imagery of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.
45508727|NCT05193383|Behavioral|Exposure|Session 2 (Ca one week): Participants receive both imaginal and in vivo exposure to fear-provoking stimuli and neutral stimuli (both arms are exposed to both video clips (in vivo exposure) and mental imagery (imaginal exposure). Session 2 is conducted in the laboratory, i.e., no brain imaging.
45508728|NCT05193383|Behavioral|Approach-avoidance conflict|Session 2 (Ca one week): Spider fear is probed by an approach-avoidance conflict task. Participants can receive varying small rewards for watching pictures of spiders, or avoid the spider pictures at the cost of not receiving a reward (neutral pictures are shown instead).
45400360|NCT03909958|Behavioral|Routine rehabilitation training Group|"Routine rehabilitation training:~Participants with good spinal stability will receive sitting training as early as possible, and will carry out standing training if participants had no adverse reactions (postural hypotension, etc.) after sitting training. Muscle strength training will be performed in recovery phase, and functional movement training will be selected according to participants' conditions. Functional movement training and transfer training will be performed for 20min each time and once a day;Standing and walking training, 2 times a day, 30min each time."
45400361|NCT02527876|Behavioral|High Intensity Interval Training|High Intensity Interval Training
45400362|NCT02527876|Behavioral|Moderate Intensity|Moderate Intensity Training
45508729|NCT05193383|Behavioral|In vivo exposure|Session 1 (Day 1): in vivo exposure. Participants receive repeated exposure to film clips of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.
45508730|NCT03565458|Drug|Gemigliptin|zemiglo 50mg,LG Chem
45508731|NCT03565458|Drug|Dapagliflozin|forxiga, dapagliflozin 10mg
45400363|NCT02527876|Behavioral|Delayed Control|Delayed Control
45400364|NCT02527876|Device|FitBit Flex|Use to measure increase in Physical Activity
45400365|NCT05619016|Diagnostic Test|[68Ga]Ga-ABY-025 PET|[68Ga]Ga-ABY-025 PET: Each patient in Cohort 1 will be imaged with a PET/CT twice using the radiolabeled investigational product ABY-025 as a tracer. At the time of injection, a 45-minutes long dynamic scan will take place over a pre specified region of interest. Three hours after injection a full body PET scan followed by a CT scan will be performed.
45400366|NCT05619016|Diagnostic Test|Biopsy and analysis of HER2 expression|Biopsy: Within 3 days after the first ABY-025-PET a tissue sample from at least one metastasis >10 mm available for biopsy, preferably shallow lymph nodes, will be analyzed for HER2 expression through immunohistochemistry- (IHC) and in situ hybridization- (ISH) analysis in patients with GEAC and HER2low mBC.
45400367|NCT03901222|Device|tDCS|20 minutes of anodal tDCS (C3 & C4/FPZ) 2mA or sham
45400368|NCT03900676|Drug|VB-1953 - 2%|Topical Gel
45400369|NCT03900676|Drug|VB-1953 - 0% (Vehicle)|Topical Gel
45400370|NCT00256854|Drug|Ropinirole IR 1 mg|Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 1.0mg of active drug substance.
45400371|NCT00256854|Drug|Ropinirole IR 2 mg|Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2.0mg of active drug substance.
45400372|NCT00256854|Drug|Ropinirole IR 1 mg Placebo|Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 1 mg.
45400373|NCT00256854|Drug|Ropinirole IR 2 mg Placebo|Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.
45400374|NCT00256854|Drug|Ropinirole CR 2 mg|Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2mg of the active drug substance.
45508732|NCT03565458|Drug|Empagliflozin|jardiance 25mg, empagliflozin
45400375|NCT00256854|Drug|Ropinirole CR 3 mg|Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 3mg of the active drug substance.
45400376|NCT00256854|Drug|Ropinirole CR 2 mg Placebo|Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.
45400377|NCT00256854|Drug|Ropinirole CR 3 mg Placebo|Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 3 mg.
45400378|NCT01256242|Device|Augment Rotator Cuff|rhPDGF-BB and bovine collagen matrix
45400379|NCT01256242|Procedure|Standard Suture Repair|standard suture repair
45400380|NCT01256320|Other|Classic Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial classic eggs
45400381|NCT01256320|Other|Omega 3 Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial Omega-3 eggs
45400382|NCT03898492|Other|Physical training|Training two times/week for an hour each time in 8 weeks. The training included strength training, aerobic training, balance training and flexibility training. The training was modified to the participants and initiated by the staff at the center.
45508733|NCT01367717|Dietary Supplement|Creatine Monohydrate|Each subject ingested 10 grams of commercially available creatine monohydrate orally. This was equivalent to two teaspoons according to the manufacturer's recommendations. The creatine was then solubilized in 8 oz. of water and 2 tablespoons of Tang brand orange flavored drink mix.
45596681|NCT05723965|Other|As materials for external validation for the buildup model.|Using the external validation set to evaluate prediction rate and survival outcome.
46059119|NCT05292079|Device|CAPTURER|Patients in whom treatment with (CAPTURER) has been attempted
45400383|NCT00189462|Drug|Montelukast|
45400384|NCT00189462|Drug|Placebo|
45400385|NCT03898258|Other|Qualiveen full version|Qualiveen full version questionnaire with 40 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
45400386|NCT03898258|Other|Qualiveen short-form|Qualiveen short-form questionnaire with 8 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
45400387|NCT01150318|Drug|Administration of 131 iodine|100 mCi 131 iodine irradiation
45400388|NCT03910114|Drug|Magnevist|GBCA enhancement
45400389|NCT03910114|Drug|Dotarem|GBCA enhancement
45400390|NCT03910114|Drug|Gadovist|GBCA enhancement
45400391|NCT01255228|Other|Low glycemic index diet|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
45400392|NCT03900364|Procedure|partial nephrectomy|Partial nephrectomy is the standard technique for organ-sparing resection of renal tumors. The EAU Guidelines recommend partial nephrectomy to all patients with T1 tumours and can be performed either with an open, pure laparoscopic or robot-assisted approach, based on surgeon's expertise and skills.
45400393|NCT03910192|Behavioral|Mindfulness-based coaching|16 week mindfulness-based protocol focused on home-based and weekly group practice of mindfulness meditation and mindful movement.
45400394|NCT03910192|Behavioral|Dietary cardiovascular risk reduction coaching|Regular in-person meetings, phone calls, or email from study coordinator instructing them on how to integrate exercise and dietary changes in their lifestyle to reduce their risk of future cardiovascular events.
45400395|NCT02528110|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.
45400396|NCT02528110|Procedure|D2 radical gastrectomy|radical gastrectomy with D2 lymphadenectomy
45400397|NCT02528110|Other|SOX postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.
45400398|NCT02528110|Other|XELOX postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
45400399|NCT03910036|Biological|platelet rich plasma|Thirty ml of venous blood was taken from every patient and collected in sodium citrated sterile tubes. Platelet concentrates obtained by adjusting centrifuge at 1800 rpm for 15 min to separate erythrocytes, then at 3500 rpm for 10 min to concentrate the platelets. The preparation was done by a single laboratory technician. Thus 5 ml of PRP were obtained, 0.2 mL of 10% calcium chloride was added to the final product to activate the platelets and injected immediately without storage.
45400400|NCT05667298|Drug|Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)|"Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~Standard of Care Arm (CROSS):~Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible."
45400401|NCT05667298|Drug|Adjuvant chemoradiotherapy|"Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~Standard of Care Arm (CROSS):~Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible."
45400402|NCT01256554|Procedure|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation.
45400403|NCT01256554|Behavioral|Questionnaires|Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
45400404|NCT01256632|Drug|Ranibizumab|All study eyes will receive 0.5mg, of intravitreous monthly injections of ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
45400405|NCT00256698|Drug|Fulvestrant|intramuscular injection 250 mg loading dose (LD) regimen
45400406|NCT00256698|Drug|Anastrozole|1 mg oral tablet
45400407|NCT01150630|Drug|capecitabine|1250 mg/mq/day per os for 14 days every 14 days for 6 months
45400408|NCT01150630|Drug|cisplatin|30 mg/mq every 14 days for 6 months
45400409|NCT01150630|Drug|epirubicin|30 mg/mq every 14 days for 6 months
45400410|NCT01150630|Drug|gemcitabine|ARM A: 1000 mg/mq for 3 weekly infusions every 4 weeks for 6 months ARM B and C: 800 mg/mq every 14 days for 6 months
45400411|NCT03909880|Device|kinesio tape|Kinesio taping(kinesio taping;kinesio holding corporation,USA) is given between the pretest and the posttest. The taping is operated by a physical therapist who is the co-host of this experiment in 614 room, Research Building, National Yang-Ming University. Posttest will be started immediately after taping. After posttest, kinesio tape will be removed. There are 3 types of taping conditions. Kinesio tape is pulled from 5 cm distal wrist joint line to medial epicondyle and 5 cm at both ends of the head and tail without tension .All participants will receive all conditions of taping. They will be randomly assigned to any taping conditions. In order to wash out the effect of taping, the interval of any condition is at least 7 days.
45400412|NCT03909568|Procedure|Third molar surgery|Comparing complete removal of third molar with removal of crown only on contralateral side
45400413|NCT03969342|Device|Point of care ultrasound training|Five-day in-person training on point of care ultrasound using portable ultrasound devices followed by remote monitoring of practice scanning
45596682|NCT02374905|Device|Drinksmeter|Web-based application delivering Identification and Brief Advice of Alcohol Use
45400414|NCT03900052|Device|Haptic cane|• A haptic biofeedback cane was designed and manufactured to measure the user applied axial cane load, compare the load to the targeted 20% BW threshold, and then deliver a vibrotactile feedback in the cane handle when the loading was greater than threshold. The cane data acquisition was temporally synchronized to the motion analysis system and recorded axial cane loads at 100 Hz for later analysis. The haptic biofeedback cane consisted of a conventional bariatric walking cane (Patterson Medical Ltd) with a loadcell (Digi-Key100 LBS. Load Cell) placed inside a 3D printed modular cane foot. A microcontroller (Sparkfun™ Pro Micro), SD disk storage (Sparkfun™ OpenLog), eccentric rotating mass vibration motor (model 306-109, Precision Microdrives Limited), USB communications port, and battery completed the system.
45400415|NCT03900052|Device|typical cane|Typical training cane loading training
45400416|NCT03909802|Behavioral|Self-and family management of diabetic foot ulcers programs|The intervention combines self-management and family management focusing on behavioral changes in patients with diabetic foot ulcers. Self-management focuses on intensive health education of physical activities, diet, medication, foot care, and blood glucose control. Family management focuses on problem-solving, establishing roles, and effective involvement in providing care amid individuals suffering DFU.
45400417|NCT03909802|Other|Usual care|Usual care
45400418|NCT00189306|Drug|Imiquimod 5% cream|Aldara (imiquimod) 5% cream - 250 mg / packet - once daily 7 days per week for 6 weeks
45400419|NCT03898102|Drug|Regorafenib|regorafenib plus zinc gluconate
45400420|NCT03898102|Dietary Supplement|Zinc gluconate supplement|Zinc gluconate supplement
45400421|NCT03898336|Other|broad-spectrum micronutrient|daily intake of capsules containing a blend of Vitamin B3 (NADH), Vitamin B6 (pyridoxal-5-phosphate), folic acid (5-MTHF), Vitamin B12 (methylcobalamin), Vitamin D3 (25-hydroxyvitamin D3), Magnesium (magnesium oxide), Zinc (zinc methionine), Iron (ferric phosphate), Selenium (selenomethionine), Phospholipids, L-carnitine (L-carnitine-L-tartrate)
45400422|NCT03898336|Other|placebo|daily intake of capsules
45400423|NCT03972462|Drug|NPC-12G Gel 0.2%|Period 1
45400424|NCT03972462|Drug|Rapamune® 2 mg tablet|Period 2
45400425|NCT01150786|Dietary Supplement|Selenium Supplement|The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
45400426|NCT01150786|Other|placebo|The patients in this arm took one placebo capsule daily for 12 weeks.
45400427|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|187.5 mg/60 g
45400428|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|375 mg/60 g
45697978|NCT01881425|Device|InnFocus MicroShunt|"An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a fornix-based conjunctival incision at the corneoscleral junction. After cauterization of the flap area, a knife is used to create a shallow pocket at the scleral surface and an opening into the AC. The device is then threaded through the track until the proximal end is in the anterior chamber and the fin of the device is pushed into the shallow scleral pocket. The device is checked to observe aqueous flow and the distal end placed under the Tenons/conjunctiva. The conjunctiva is closed in a watertight fashion at the end of the procedure."
45715251|NCT05273788|Device|Sham Stimulations|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. Sham stimulations, one of 4 total trains is delivered over 5 minutes with 3-min rest intervals on both right and left sides (total 1200 pulses/side).
45400429|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|750 mg/60 g
45400430|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|1500 mg/60 g
46059120|NCT01072175|Drug|GSK2118436|GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.
45400431|NCT01256710|Device|Implantation of the Trifecta Valve|Implantation of the bioprothesis valve, Trifecta Valve
45400432|NCT03897790|Other|Transcranial Doppler (DTC)|Evaluation of Vasoconstrictor Vasoreactivity with Transcranial Doppler
45400433|NCT01586182|Radiation|Stereotactic Body Radiotherapy|Starting dose is 5.5 Gy x 2 boosts in addition to 57.24 Gy to the primary disease
45400434|NCT03900130|Dietary Supplement|Preload|"In the 2 x 2 factorial design we vary two factors:~caloric load of the preload such that it is either high calorie or low.~protein to carbohydrate ratio of the preload such that it is either high or low"
45400435|NCT01150864|Device|Airway Conditioning|Each Passive device will be changed daily. When using Active and Passive devices as well as Active-Passive devices the ventilatory circuit will be changed every 7 days.
45596683|NCT02374905|Behavioral|Brief Advice of Alcohol Use|Lifestyle counseling regarding alcohol intake and completion of Audit-10 questionnaire done chair-side with clinician
45596684|NCT05723887|Behavioral|Attachment-Based Intervention Program|Attachment-Based Intervention Program
45596685|NCT03443973|Drug|Gantenerumab|Gantenerumab will be administered as per the schedule specified in the respective arm.
45596686|NCT03443973|Drug|Placebo|Placebo matching to gantenerumab will be administered as per the schedule specified in the respective arm.
45596687|NCT05723809|Device|Percussive Therapy Device|Same as group description
45400436|NCT03909724|Drug|Sunitinib Malate|After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
45508734|NCT01367717|Dietary Supplement|Creatine Ethyl Ester|Each subject ingested 10 grams of creatine ethyl ester orally. This was equivalent to 14.25 pills according to the manufacturer's ingredient description. The pill capsules were ground into a powder, which was added to 8 oz of water along with 2 tablespoons of Tang brand orange drink.
45508735|NCT03565302|Drug|Formoterol|Subjects are treated with daily inhalation of formoterol
45508736|NCT03565302|Drug|Terbutaline|Subjects are treated with daily inhalation of terbutaline
45508737|NCT03565302|Other|Placebo|Subjects are treated with placebo
45508738|NCT05193227|Drug|ST-01|Administration of up to 8 mL ST-01 (70 mg/mL lidocaine)
45508739|NCT05193227|Drug|Control (Lidocaine HCl Injection USP Xylocaine® or Bupivacaine HCl Injection USP Marcaine®)|Administration of up to 3 mg/kg bupivacaine hydrochloride injection (0.25%) or up to 4.5mg/kg lidocaine hydrochloride injection (0.5-1%)
45508740|NCT03568032|Diagnostic Test|Measurement of intima media thickness of carotid artery|IMT measurements were performed using ultrasound machine in the pre-radiation and the post-radiation group. IMT was assessed at the common carotid artery (CCA) and the internal carotid artery (ICA) of both the left and right side.
45508741|NCT03568032|Diagnostic Test|Detection and measurement of carotid plaques|Detection and measurement of plaques within internal carotid artery and common carotid artery by ultrasound
45508742|NCT03568032|Diagnostic Test|Carotid Color Flow Duplex Testing|Velocity measurement of carotid artery to determine carotid stenosis
45508743|NCT03568032|Diagnostic Test|Montreal Cognitive Assessment|Cognitive assessment
45508744|NCT03568032|Other|Medical history of cardiovascular risk factors and cardiovascular diseases|Cardiovascular risk factors include smoking, alcohol consumption, hypertension, diabetes mellitus, hypercholesterolemia, obesity. Cardiovascular diseases include ischemic stroke, ischemic coronary heart disease, TIA, etc.
45508745|NCT03567798|Dietary Supplement|UPLAT|Carica papaya leaf Extract + Tinospora cardifolia Extract
45508746|NCT03567798|Other|Placebo|Placebo
45508747|NCT01372007|Drug|Lanreotide Autogel 120mg|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are <10%, study medication (0.246mg lanreotide base/mg solution) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
45508748|NCT01372007|Drug|Placebo|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are <10%, placebo (Sodiumchloride 0,9% 1 ampoule) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
45508749|NCT03037164|Device|INTERCEPT Blood System for Red Blood Cells|The pathogen reduction process begins with a unit of RBCs derived from whole blood that is separated according to local regulations and standard operating procedures at the Blood Centers. RBCs are suspended in AS-5 or SAG-M for non-US sites. Leukocyte-reduction of whole blood or RBCs will be performed per manufacturer's instructions. The INTERCEPT Blood System process is performed on a single unit of leukocyte-depleted RBC in AS-5.
45715252|NCT05257018|Drug|R-CDOP+intrathecal MTX|"R-CDOP+intrathecal MTX：~Rituximab 375 mg / m^2，D1~Cyclophosphamide 750 mg / m^2，D2~Doxorubicin Hydrochloride Liposome Injection 35mg / m^2，D2~Vincristine 1.4mg/m^2 (dose capped at 2 mg)，D2~Prednisone 50 mg， bid D2-6~Cycle1-5：Intrathecal MTX 12 mg + DXM 5 mg after chemotherapy （PK patients will be given 24 h after chemotherapy）"
45508750|NCT03037164|Device|Conventional (Control)|Conventional RBC components ordered and administered to study patients by their treating physicians according to the local standards of care
45508751|NCT01373411|Drug|ticagrelor|ticagrelor 90 mg BID for 90 days
46059121|NCT01072175|Drug|GSK1120212|GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.
45400437|NCT03909724|Drug|TAS 102|After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
45508752|NCT01373411|Drug|Placebo|Placebo 1 pill BID for 90 days
45508753|NCT03567564|Diagnostic Test|Abdominal muscles ultrasound|Abdominal muscles ultrasound during a spontaneous breathing trial using the M-mode to calculate the thickening fraction of the anterior and lateral abdominal muscles under multiple circumstances (tasks performed by the patients)
45508754|NCT03567408|Procedure|Selective PCI|Selective PCI for treatment of elderly patients (age≥65) presenting with diabetes mellitus.
45508755|NCT03567408|Drug|Bivalirudin|Before, during and after surgery, bivalirudin was used according to the dosage regimen to assess it's impact on elderly patients with diabetes mellitus undergoing selective PCI.
45508756|NCT05354154|Procedure|endotracheal intubation|Consenting healthy patients of either sex will be endotracheally intubated under controlled environment
45508757|NCT05354076|Drug|doxorubicin hydrochloride liposome injection|According to the clinical diagnosis and treatment norms, it is suitable for patients with advanced malignant tumors diagnosed by histopathology with doxorubicin hydrochloride liposome injection chemotherapy.(For breast cancer patients: liposomal doxorubicin 35mg/m2 q3w)
45508758|NCT05192993|Other|visual motor integration group|Oculomotor exercises as follow:(1) Eye follow with a stationary head 2)Saccadic eye movements 3) Gaze stability 4)Eye/head co-ordination 5)Balancing exercises
46059122|NCT04078711|Drug|Losartan 100Mg Tab|100Mg Tab, qd, po, 6 months
46059123|NCT04078711|Drug|Qianyangyuyin 20g Granule|20g, Granule, bid, po, 6 months
46059124|NCT04078711|Drug|placebo|Similar granule manufactured to mimic qianyangyuyin granule, 20g, Granule, bid, po, 6 months
45400438|NCT03899974|Other|Test meal|"Participants received in random order the three test meal (700Kcal, 80g available carbohydrates) containing breads prepared with amylose-rich wheat flours (70% or 85%) or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.~After 4 hours, all participants consumed a standard lunch (700 kcal, 100 g available carbohydrates) identical on all the three experimental days to evaluate the second meal effect from breakfast to lunch."
45400439|NCT01253122|Drug|TRx0037|
45400440|NCT03909646|Drug|Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram|A layer of methylaminolevulinc acid 160 mg/g cream (about 1 mm thick) is applied to the lesion, with a clinical margin of 5-10 mm surrounding of normal skin and then covered by an occlusive dressing. After 3 hours the occlusive dressing will be removed and the area is illuminated with Omnilux or Actilite (Galderma). After PDT the treatment site is covered again with the above mentioned occlusive dressings during 48 hours. Treatment is performed by an authorized nurse in the hospital. Two sessions should be administered with an interval of one week between sessions.
45400441|NCT03909646|Drug|5Fluorouracil|5-FU is applied on the treatment area by the patient in a thin layer twice daily during 4 weeks.
45400442|NCT03909646|Other|Surgical excision|Local anesthesia with lidocain 1% (1-2ml) will be used before performing standard surgical excision with 5 mm safety margin followed by routine histological examination. The skin will be closed using cutaneous sutures, which will be removed after 1-2 weeks. The surgical excision will take place in the hospital by the treating physician
45400443|NCT01256866|Drug|Dexmedetomidine|
45400444|NCT01256866|Drug|Midazolam|
45400445|NCT03897946|Biological|Birth dose hepatitis B vaccine|Groups A and C will receive a birth dose of hepatitis B vaccine within 24 hours of life.
45400446|NCT01257022|Behavioral|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV.
45400447|NCT03902782|Procedure|ESP block|"ESP with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham intercostal block with 20 ml Normal Saline"
45400448|NCT03902782|Procedure|Intercostal block|"Intercostal block with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham ESP with 20 ml Normal Saline"
45400449|NCT03902782|Procedure|Sham ESP block|As described earlier
45400450|NCT03902782|Procedure|Sham Intercostal block|As described earlier
45400451|NCT03902782|Drug|Bupivacaine-epinephrine|As described earlier
45400452|NCT03902782|Drug|Dexamethasone injection|As described earlier
45400453|NCT03902782|Drug|Normal saline|As described earlier
45400454|NCT01150942|Biological|JE vaccine|3 times, IM
45400455|NCT03899740|Other|Brainstorming 1|Expert recommendation statements will be collected for peer evaluation.
45400456|NCT03899740|Other|Ranking - Round 1|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
45400457|NCT03899740|Other|Ranking - Round 2|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
45400458|NCT03899740|Other|Ranking - Round 3|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
45400459|NCT03897478|Diagnostic Test|ISCDX blood test|"The ISCDX test is based on gene expression changes that occur as a result of the ischemic stroke. When the stroke occurs, the immune system in the body reacts and causes changes in gene expression in several types of cells, including white blood cells, related to activation of innate and adaptive immune systems.~The ISCDX test distinguishes between cardioembolic and large artery atherosclerotic origin of stroke using a gene signature. The pattern or signature of up or down regulation for all genes for a patient determines whether the patient's pattern of gene expression is more like the pattern seen in other cardioembolic patients or more like the pattern seen in patients with large artery atherosclerotic cause of stroke."
45400460|NCT03897400|Other|AMH levels in young women with crohn's disease will be considered.|Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease;Blood will be taken from both the study and control groups and the AMH level will be evaluated.
45508759|NCT05192993|Other|Handwriting intervention programs|(1)Eye motor coordination (2)position in space(3)coping-figure ground(4)spatial relationship(5)visual closure(6)constancy of shapes(7)far and near coping
45508760|NCT05192993|Other|visual motor integration program and Handwriting intervention programs|"Oculomotor exercises as follow:(1) Eye follow with a stationary head 2)Saccadic eye movements 3) Gaze stability 4)Eye/head co-ordination 5)Balancing exercises 6)Eye motor coordination (7)position in space(8)coping-figure ground(9)spatial relationship(10)visual closure(11)constancy of shapes(12)far and near coping~Hand writing intervention as follow (1)Eye motor coordination (2)position in space(3)coping-figure ground(4)spatial relationship(5)visual closure(6)constancy of shapes(7)far and near coping"
45508761|NCT01367873|Drug|Placebo|Oral, matching number of placebo capsule(s) with active arm
45508762|NCT01367873|Drug|VIA-3196|Oral, capsule(s)
45400461|NCT03909256|Other|NUTRI-HAB|"The rehabilitation program is a coordinated multidisciplinary effort involving several specialists e.g. clinical dietitians, nurses, physiotherapists, occupational therapists (responsible for dysphagia management in Denmark), psychologists and social workers.~The program includes group sessions with patient education on how to handle the different aspects of living with eating problems and other late effects. Practical kitchen exercises, physical activity sessions and instruction in swallowing training are included. Individual counseling sessions with clinical dietitians and other health professionals (e.g. physicians) are offered depending on participants' needs.~Participants stay at the premises and all meals throughout the day are served in the dining room or in the café. Foods of different textures and flavors are served to inspire participants and to allow them to experiment.~Between the initial stay and follow-up participants are contacted twice by a clinical dietitian."
45400462|NCT01253278|Drug|LY2393910|as capsules, administered orally once daily for two weeks
45400463|NCT01253278|Drug|Placebo|as capsules, administered orally once daily for two weeks
45400464|NCT03899818|Device|drug-eluting balloon|Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES)
45400465|NCT03899818|Device|drug-eluting stent|Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES).
45400466|NCT03899662|Other|Cognitive Training|Cognitive training included memory, attention, velocity, intelligence
45400467|NCT03899662|Other|Physical Training|Physical training included aerobic, strength, flexibility and balance.
45400468|NCT01150006|Other|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
45400469|NCT01253356|Device|IABP|Insertion of intra-aortic balloon < or = 3 hours before noncardiac surgery and maintained > or = 12-24 hours after surgery
45400470|NCT03908944|Drug|Methadone|Individuals in this group will receive an identical anesthetic without the addition of remifentanil. They will be given methadone 0.2 mg/kg IV at the beginning of the anesthetic. A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.
45400471|NCT03908944|Drug|Standard of Care|Standard of Care patients will be given an infusion of remifentanil 0.15-0.25 mcg/kg/min as part of their intraoperative anesthetic regimen. The infusion will be maintained until the end of surgery and will be discontinued upon emergence. Prior to emergence, 100-200 mcg of fentanyl will be titrated for additional analgesia after emergence.
45400472|NCT03897010|Device|Socket Graft|5 patients had bilateral decayed upper premolar or anterior teeth, in one side SCPC graft was inserted in socket and in the contralateral site was a control, 5 months months postoperative core biopsies were taken from both grafted sockets and control ungrafted sockets during implant insertion. The biopsy samples from SCPC-grafted and control ungrafted sockets were fixed, decalcified and embedded into paraffin wax. All samples were serially sectioned in serial 5μm-thin sections were stained separately with Hematoxylin and Eosin staining, Sirius red and Mason trichrome and immunostaining with osteopontin.
45400473|NCT01257178|Drug|LY2624803|Administered orally
45400474|NCT03899506|Drug|Olanzapine|Patients receiving Olanzapine per the ED protocol
45400475|NCT03899506|Drug|Midazolam|Patients receiving Midazolam per the ED protocol
45400476|NCT03897166|Device|Trimodality|Positron Emission Tomography coupled with Computed tomography and immediately followed by Magnetic Resonance Imaging
45400477|NCT03896932|Other|minipooled- Intravenous immunoglobulin(MP-IVIG)|The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
45400478|NCT03908866|Other|PICC(Peripherally inserted central catheter)|The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.
45400479|NCT03908866|Other|CVC(Central venous catheter )|The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, using the Seldinger technique. A suitable sterile field will be established.
45849943|NCT03398304|Other|Marathon participation|Study arm 2 (Marathon participation) participants will take part in a marathon. On the day of the marathon prior to start, the participant will be seated for 10 minutes prior to measuring their baseline heart rate. A 4.5 mL blood sample will be collected prior to initiation of exercise. Immediately after completion of the marathon, a 4.5 mL blood draw will be completed. Additional 4.5 mL blood draws will be taken at 1 and 2 days post-marathon to measure to length of time required to return to baseline coagulation, fibrinolysis, and inflammation following the prolonged, intense exercise.
45400480|NCT03908554|Other|WORKPLACE HEALTH PROMOTION PROGRAM|WHPP was PMR training, posture and breath exercises, and ergonomic suggestions.
45400481|NCT01257334|Drug|BI 10773|patients with type 2 diabetes mellitus with insufficient glycaemic control despite treatment with metformin alone or metformin in combination with a sulfonylurea
45508763|NCT05106335|Drug|camrelizumab + famitinib|camrelizumab for intravenous injection; famitinib malate capsules for oral administration
45508764|NCT05106335|Drug|famitinib|famitinib malate capsules for oral administration
45508765|NCT05106335|Drug|docetaxel|docetaxel for intravenous injection
45400482|NCT01150084|Other|16-week lunchtime walking intervention|10 week group led lunchtime walks (each 30 minutes) followed by 6 weeks independent walking
45400483|NCT01150084|Other|delayed treatment|to start at week 10
45400484|NCT01151176|Drug|Regular Insulin|1,8U Regular insulin/h from 180mg/dL of blood glucose increasing each hour according to capillary blood glucose. Between 100-150mg/dL keep infusion and bellow 100mg/dL stop infusion
45508766|NCT02836236|Drug|TAF|TAF 25 mg tablet administered orally once daily
45508767|NCT02836236|Drug|TDF|TDF 300 mg tablet administered orally once daily
45508768|NCT02836236|Drug|TAF Placebo|TAF placebo tablet administered orally once daily
45508769|NCT02836236|Drug|TDF Placebo|TDF placebo tablet administered orally once daily
45596688|NCT05723809|Behavioral|Physical Therapy|Same as group description
45400485|NCT01151176|Drug|Regular Insulin|"Regular Insulin SC according to Blood Glucose(mg/dL) and Insulin Sensitive with usual dose describe and less 2U for sensitive and plus 2U for insulin resistant:~Blood Glucose >141-180=4U ;181-220=6U; 221-260=8U; 261-300=10U;301-350=12U; 351-400=14U; > 400=16U"
45400486|NCT01257412|Drug|Dapagliflozin|5mg Oral dose od
45400487|NCT01257412|Drug|Dapagliflozin|10 mg Oral dose od
45400488|NCT01257412|Drug|placebo|5/10 mg Oral dose od
45400489|NCT01257490|Behavioral|counseling vs. advice|1 session of brief physician advice to quit smoking plus bupropion (12 weeks) compared to 4 sessions of intensive counseling plus bupropion (12 weeks)
45400490|NCT03896542|Device|Commercial video game.|Stroke patient had played with commercial video game, along 12 sessions.
45400491|NCT03896542|Device|rehabilitation video game|Stroke patient had played with an specific video game for rehabilitation, along 12 sessions
45400492|NCT03896698|Device|Transcranial Ultrasound Stimulation|TUS activate the brain cells
45400493|NCT03894280|Drug|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals|2 inhalations in one study period
45400494|NCT03894280|Drug|SERETIDE DISKUS® 250/50 inhalation powder/GSK|2 inhalations in one study period
45400495|NCT03894280|Other|Activated Charcoal suspension|oral suspension before and after inhalation of study Investigational Products
45400496|NCT03893968|Behavioral|Information by an assistant nurse|Information received by patients after ambulatory hand surgery under local anaesthetic about postoperative self care given by an assistent nurse.
45400497|NCT03893968|Behavioral|Information by a doctor|Information received by patients after ambulatory hand surgery under local anaesthetic about postoperative self care given by a doctor.
45400498|NCT01255462|Biological|LFG316|
45400499|NCT01255462|Biological|LFG316|
45400500|NCT01255462|Biological|LFG316|
45596689|NCT05271565|Dietary Supplement|Oligomeric enteral feeding|Oligomeric enteral formula
45596690|NCT05271565|Dietary Supplement|Polymeric enteral feeding|Polymeric enteral feeding will be administered to the PICU patients
45400501|NCT01255462|Biological|LFG316|
45400502|NCT03899584|Drug|4-Aminopyridine|Each patient will take 10 mg per kilogram of weight (example: a person weighing 60 kg, will take two capsules three times a day after meals, for a total of 6 capsules / day). Each capsule will contain 10 milligrams of 4-Aminopyridine that will allow to be administered sequentially at progressively higher doses / day. The dose of 4-aminopyridine will increase 10 mg / 2 to 4 weeks.
45400503|NCT03899584|Drug|Placebo oral capsule|The placebo arm will include a placebo of microcrystalline cellulose.
45400504|NCT03893890|Biological|Previously Treated with EN3835|No treatment to be administered - Observational only
45400505|NCT01258270|Procedure|Postop Dressing|The AQUACEL® Ag Surgical Dressing is a silver impregnated, waterproof, adhesive dressing that sticks to the skin around the wound and blocks bacteria from the outside.
45400506|NCT01258270|Procedure|Postop Dressing|A standard island dressing consists of adhesive tape and gauze.
45400507|NCT01150162|Drug|Rebamipide and Omeprazole|open label, oral route, Rebamipide, 100mg tablet t.i.d and Omeprazole 20 mg tablet B.I.D. for 8 weeks
45400508|NCT01150162|Drug|Omeprazole|open label,oral route, Omeprazole 20mg tablet, B. I.D.; alone, for 8 weeks
45400509|NCT03893734|Drug|methadone|Patients in the methadone group will receive a syringe of methadone at induction of anesthesia and a syringe of saline at the end of anesthesia
45400510|NCT03893734|Drug|Hydromorphone|Patients in the hydromorphone group will receive a syringe of saline at induction of anesthesia and a syringe of hydromorphone at the end of anesthesia
45400511|NCT03899194|Dietary Supplement|fish oil capsules|fish oil capsules(1000mg，EPA 180mg；DHA 120mg)
45400512|NCT03899194|Drug|escitalopram|escitalopram 10-20 mg/d
45400513|NCT01151800|Other|Using IVR to maintain ACS patients on best practice guidelines|
45400514|NCT03893578|Device|Mitral valve-in-valve|The Synecor Conveyor System shall be used to position the Edwards SAPIEN 3 valve at the mitral location.
45400515|NCT01257646|Other|Gait analysis|A Gaitrite system, a goniometer, and EMG are used to record data while the patient walks 10 meters.
45400516|NCT03896074|Drug|Atezolizumab|Atezolizumab administered intravenously at 1200 mg every 3 weeks
45400517|NCT03896074|Drug|Bevacizumab|Bevacizumab intravenously at 15 mg/kg every 3 weeks
45400518|NCT03899116|Other|deflation of pneumatic tourniquet|gradual deflation with variable degrees
45400519|NCT03899038|Procedure|spinal anesthesia|Patients will receive real-time ultrasound guided spinal anesthesia using Taylor's approach. Various doses of bupivacaine 0.5% (Bupivacaine hydrochloride injection, Harvest Pharmaceutical CO., LTD., Shanghai, China) will be administered.
45400520|NCT01151878|Dietary Supplement|Glucomannan|1.26 g per sachet; 2 sachets per day for 4 weeks.
45400521|NCT01151878|Dietary Supplement|maltodextrin|prepared in sachets (1.3g); 2 sachets per day for 4 weeks
45400522|NCT03893422|Other|WB-010|Medical food formulation
45400523|NCT03893422|Other|WB-011|WB-011 medical food product
45400524|NCT03893422|Other|Placebo|Placebo Capsules identical to those containing WB-010 and WB-011.
45508770|NCT05065697|Other|Brain MRI|Brain MRI will be scheduled within three days before the procedure and within seven days after the procedure, as well as at 1-year follow-up. MRI will be preferably performed using a 3.0-Tesla system unless patients are pacemaker-dependent after the procedure. In such case, a 1.5-Tesla system will be used. The MRI protocol consists of standardized conventional diffusion-weighted MRI (DW-MRI), T2-FLAIR (fluid-attenuated recovery inversion) and SWI (susceptibility-weighted imaging) parameters.
45508771|NCT01367951|Procedure|Surgical fixation|"The fractures will be reduced and stabilized by use of plates and screws~Attempt will be made to stabilize ribs 3-7, as these are surgically accessible and most important in maintaining integrity of the chest cavity.~Goal is not to fix all the fractures, but to fix sufficient fractures to create an internal splint and allow chest wall motion to occur as a unit. In case of fibs fractured at numerous locations, as many fragments will be reduced and stabilized as necessary to ensure movement as a unit.~Chest tube(s) will be placed at the discretion of the treating surgeon in patients with pre-operative or intra-operative violation of the pleural cavity (ie pre-op pneumothorax/haemothorax, iatrogenic pleural injury). No post-operative drains will be inserted."
45508772|NCT05708664|Procedure|precision breast conserving surgery guided by wire guided localization combined with MDCT guided 3D reconstruction|Local anesthesia was induced by using 1% lidocaine before wire location. The wire (localization set, PAJUNK) was placed in the superior, inferior, lateral and interior edge of the tumor through a 20-gauge needle using US guidance one day before BCS, respectively. Then, the patient underwent an immediate supine contrast enhanced CT (Philips Brilliance iCT) scan of the breast. The radiologist performed 3D reconstruction of CT images prior to surgery. Finally, the surgical procedures were performed by experienced breast surgeons combing 3D reconstruction of CT images and wire localizations one day after the localization.
45400525|NCT03898882|Drug|oxytocin|PK measurements of oxytocin
45508773|NCT05192759|Device|Transcranial Magnetic Stimulation|The stimulations were performed by MagStim Rapid2.
45508774|NCT05192681|Drug|Tislelizumab|Tislelizumab in combination with docetaxel until the development of PD, unacceptable toxicities, withdrawal of informed consent, end of study, lost to follow-up, or death, whichever occurs first.
45508775|NCT05192447|Behavioral|Exercise treatment|Patients selected to EG will carry out complementary cognitive and physical training under supervision of rehabilitation staff. For neuropsychological exercises, the investigators will use the RehaCom system - high quality scientific neurocognitive disorder therapy programs and software. (Time: 30 min./5 times/week per patient during RT). In this time, EG patients will do physical training (such as cycling, running on properly calibrated equipment for the circulatory system parameter measurement (1hour/ 5 days/ week), and neuromuscular and cognitive reeducation exercises using a technically advanced tool - Neuroforma computer software - 30 min/ 5 times/ week). After the end of RT, patients in EG will do a special exercise training at home under supervision of staff from the Department of Rehabilitation, and cognitive training using special tasks (3 times an hour/per week) at home, and two times/week using RehaCom and Neuroforma (60 min/sesion) in our cancer ceter.
45508776|NCT01368029|Biological|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
45508777|NCT01368029|Biological|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
45849944|NCT03351348|Drug|Bupivacaine|The intervention in this study is the insertion of 20cc of 0.5% bupivacaine via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
45400526|NCT03898882|Device|Shore durometer|The investigators will take serial readings from a digital durometer at the uterine fundus at 3, 6, 9 and 12 minutes following OXT administration to provide data that will inform an estimate of the timing of peak effect. Shore durometers measure the hardness of materials on a scale of 0-100 Shore Units (SU). Preliminary (unpublished) data provided a range of 10-56 SU after oxytocin administration at cesarean delivery. Durometer readings were also shown to correlate positively with the obstetrician's manual assessment of uterine contractility, which is traditionally used to determine the success or failure of uterotonic therapy.
45400527|NCT03893344|Diagnostic Test|detection of STAT4 gene|Individuals within both groups will be subjected to STAT4 gene polymorphism typing using both PCR and flow cytometry from a peripheral blood sample
45400528|NCT01589692|Procedure|Open Reduction and Internal Fixation|Internal fixation with a volar locking plating system
45400529|NCT01589692|Procedure|External Fixation|External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.
45400530|NCT01589692|Procedure|Percutaneous Pinning|Pinning with any number of Kirschner wires
45400531|NCT01589692|Procedure|Closed Reduction and casting|Closed reduction and immobilization with a cast and/or splint
45400532|NCT01151254|Drug|Isoflurane/sevoflurane|Volatile for sedation in the CVICU while intubated
45400533|NCT01151254|Other|Propofol|Propofol for sedation in the CVICU
45400534|NCT01255618|Device|INVOS 5100|Near-infrared range and has been used in newborn infants since 1985. Fibre-optic bundles or optodes are placed either on opposite sides of the tissue being interrogated (usually a limb or the head of a young baby) to measure transmitted light, or close together to measure reflected light. Light enters through one optode and a fraction of the photons is captured by a second optode and conveyed to the measuring device. NIRS uses a frequency band between 650 nm and 1000 nm and relies on three important phenomena: (1) human tissue is relatively transparent to light in the near-infrared region of the spectrum; (2) pigmented compounds known as chromophores absorb light as it passes through biological tissue; and (3) human tissues contain substances whose absorption spectra at near-infrared wavelengths are well defined and depend on their oxygenation status.
45400535|NCT01257724|Other|SHARE (Synthesized HIV/AIDS Research Evidence)|"SHARE (Synthesized HIV/AIDS Research Evidence) consists of several components:~an online searchable database of HIV-relevant systematic reviews;~monthly email updates highlighting new reviews;~access to user-friendly summaries produced by us or by others (when available);~links to scientific abstracts;~peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;~an interface for participants to leave comments in the records of systematic reviews in the database;~links to full-text articles (when publicly available); and~access to worksheets that help CBOs find and use research evidence"
45400536|NCT01255774|Drug|ranibizumab|An open-label, study of intravitreally administered ranibizumab
45400537|NCT03895918|Other|Educational Activity|Undergo parenting skills intervention
45400538|NCT03895918|Procedure|Patient Monitoring|Undergo medication adherence monitoring
45400539|NCT03895918|Other|Questionnaire Administration|Ancillary studies
45400540|NCT01255852|Drug|atorvastatin|Patients in atorvastatin group will received 80 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
45400541|NCT02527720|Behavioral|Mindfulness Therapy|BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention. A key component in BBMT is to be mindful of breathing whenever possible, and breathe at near resonance frequency (RF), known as heart rate variability biofeedback. The human cardiovascular system is known to have resonance characteristics, with the first RF at ~0.1 Hz. RF varies between 4.5 and 7 cycles per minute. Breathing at RF stimulates the cardiovascular system to oscillate at that frequency at a very high amplitude and greatly stimulates the baroreflex system. RFB is known to reduce depression and stress symptoms as well as various diseases related to malfunction of the autonomic nervous system, such as asthma and hypertension.
45400542|NCT01153360|Drug|liothyronine sodium|liothyronine sodium 20ug, every 12hour (before anesthetic induction, total 4 times)
45400543|NCT01153360|Drug|placebo|vitamin B12
45400544|NCT03895606|Other|Data collection|This study is an observational study collecting perioperative data. There is no intervention regarding this study.
45400545|NCT03895528|Drug|Lonafarnib|Farnesyl transferase inhibitor
45400546|NCT03895138|Other|Standard Glucommander Protocol (SGP)|Subjects receive standard Glucommander-based insulin therapy from the clinical staff of U.Va.'s cardiothoracic ICU and follow manufacturer's guidelines for starting with an initial multiplier value of .05.
45400547|NCT03895138|Other|Optimized Glucommander (OGM)|The experimental arm of the study involves treating subjects with a lower initial multiplier (.02 versus .05), a higher set of BG thresholds (140-180 mg/dl vs 120-160) in the first eight (8) hours of care for avoidance of hypoglycemia in that time period, and a requirement for consistent hourly-or-faster sampling of BG (as opposed to the Glucommander recommendation which is dependent on the trajectory of BG and can sometimes allow intervals of two hours between samples). After the eight (8) hours, the Glucommander is set back to the standard protocol for the entire duration of the subject's post-operative hospital stay.
45400548|NCT01257958|Drug|19 nor vitamin d|
45400549|NCT05521672|Drug|Adipose derived allogenic mesenchymal stem cells (adAMSC)|adAMSC will be administered in the perilesional adipose tissue, through a laparoscopic procedure
45400550|NCT03893032|Drug|Modafinil 200mg|single 200 mg dose
45400551|NCT03893032|Drug|mixed amphetamine salts|single 10 mg dose
45400552|NCT03893032|Drug|Placebo|single oral-administration placebo tablet
45715253|NCT05237128|Behavioral|Very low-carbohydrate diet|"Participants in this arm will be taught to manage their type 2 diabetes using a very low-carbohydrate diet, also called a ketogenic or keto diet. This diet involves eating non-starchy vegetables, leafy greens, cheese, meats, berries, nuts, and seeds and avoiding starchy foods like pasta, bread, rice, beans, many fruits, etc.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
45400553|NCT03893110|Procedure|surgical stabilization of the spine due to primary and secondary spinal tumors|Posterior instrumentation with pedicle screw system
45400554|NCT01258036|Radiation|HRpQCT|High Resolution peripheral Quantitative Computerized tomography
45400555|NCT01258036|Biological|Sampling|Urine and blood samples
45400556|NCT01258036|Radiation|Bone absorptiometry|DXA at the lumbar spine, hip, radius and whole body
45400557|NCT01259986|Procedure|Laser treatment|Laser treatment of using 635 nm laser with a dose of 3.0 J/cm^2 to small area (2cm x 2cm) of vitiligo once to twice a week for a total of 12 weeks.
45400558|NCT01258114|Other|SPA treatment (ST)|"Drug: spa treatment soon after randomization :~Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts (mineral water drinking, bath with automatic air (bubble bathing), mud body wrapping, manual massages, water exercises ;~nutritional counseling (french nutritional recommendations booklet) ;~caloric restriction and physical training on demand (non mandatory)."
45400559|NCT01258114|Other|Non SPA treatment (NST)|"Drug: General practitioner (GP) counselling After randomisation Verbal and/or written advice based on the French national guidelines for a healthy life style brochure (given to the patient by the GP at baseline)"
45400560|NCT03889366|Drug|Aprepitant 125 mg|Single dose in the fasted state during treatment period 1,2 or 3
45400561|NCT01151488|Other|Resistance Training|RT 3x/wk for 4 months
45400562|NCT03895294|Other|Health care under the strategic purchase-Clinical pathway|1) purchase of DAA by the MoHSP; 2) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in internal medicine, hepatology or Infectious disease; 3) daily supervised drug administration by a nurse or weekly treatment dispensing by pharmacist; 4) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, week of the end of treatment (8, 12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support. In case of identifying any Drug-related Problem, the respective pharmaceutical intervention was made.
45400563|NCT03895294|Other|Usual care process prior strategic purchase-clinical pathway|1) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in hepatology; 3) weekly treatment dispensing by pharmacist; 4) patient use; 5) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, 8, week of the end of treatment (12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support). In case of identifying any Drug-related problem, the respective pharmaceutical intervention was made.
45400564|NCT01260064|Procedure|Open appendectomy|The subjects will have traditional open appendectomy procedure.
45400565|NCT01260064|Procedure|Laparoscopic appendectomy with metal endoclips|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
45400566|NCT01260064|Procedure|Laparoscopic appendectomy with suture ligation|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
45400567|NCT03895060|Device|autogenous ring blockls with GBR covered by collagen membrane|"A crestal incision is made using No. 15 blade extending over the anterior maxilla, an anterior vertical releasing incision is made and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge and the lateral aspect of the maxilla~Autogenous onlay ring blocks is taken by a trephine bur from the chin area and then fixed by screws to the deficient maxillary alveolar height.~Equally autogenous and xenograft bone particles is packed around the screw to fill the defect area completely.~The collagen membrane is fixed to the alveolar ridge by bone tacks and the mixture of autogenous and xenograft bone is then packed.~The flap will then be closed using interrupted 4/0 resorbable sutures."
45400568|NCT03894982|Other|Group Classes|Family Learning on Asthma Topics classes will aim to emphasize, encourage, and support teaching methods that include standardized instructions. There will be three topics lasting approximately 45 minutes: General Asthma Knowledge; Asthma Triggers, Medications, and Self-Management. These topics were chosen based on the EPR-3 guideline recommendations to ensure the continuity of messaging. Each class size will be approximately 8 persons and will be taught by a Certified Asthma Educator (AE-C) and will be held in the Family Learning Center at the Children's Hospital Colorado. Classes will be taught in both English and Spanish.
45400569|NCT03889054|Behavioral|Education program|"The education sessions will be given in 3 opportunities (15-30, 45 and at 90 days from diagnosis of the exacerbation) and it will be individualized. The program will include measures of self-care and self-management recommended in patients with COPD:~Plan of action in an exacerbation.~Education related to COPD.~Information on pharmacological medication.~Management of the exacerbation.~Management of stress and / or anxiety.~Nutritional recommendations.~Physical exercise recommendations.~Healthy lifestyle recommendations. The first session will last 90 minutes and will be explain according to the contents of the manual Controlling COPD. A presentation designed for this purpose will be displayed and this manual will be provided to patients to carry out their reading at home. The second and third sessions will last 15 minutes and the purpose will be to resolve doubts."
45715254|NCT05237128|Behavioral|Moderate-carbohydrate plate-method diet|"Participants in this arm will be taught to manage their type 2 diabetes using a plate-method approach. This diet involves eating different categories of foods based on the proportions of a plate, balancing proteins, vegetables, fruits, starches, and fats.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
45715255|NCT05229094|Device|Eva Nexus|Eva Nexus vitrectomy device
45508778|NCT05192213|Drug|Vitamin C|Patients will be allocated in a 1: 1 ratio to the treatment group, receiving intravenous Vitamin C (1.5 g every 6 hours), Thiamine (200 mg every 12 hours) and Hydrocortisone (50 mg every 6 hours) for 7 days
45400570|NCT03894826|Drug|Vorinostat 100 MG|Vorinostat administered by mouth, once daily at a dose of 230 mg/m2/day for a total of 6 weeks
45400571|NCT03889210|Other|HVMN Ketone|Water-based, flavoured sport beverage
45400572|NCT03889210|Other|Placebo|Water, stevia, malic acid, and thickening agent
45400573|NCT02527642|Other|embryo culture in buffered media|compare media that supports human embryo development in the laboratory (in vitro) using Time-Lapse system.
45400574|NCT01258816|Drug|Elacytarabine for infusion|Elacytarabine 2000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w schedule.
45400575|NCT03888820|Drug|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
45400576|NCT03888820|Drug|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
45400577|NCT01153594|Behavioral|Recovery Management Checkups (RMC)|After interviewers completed the quarterly research interview and determined participants' eligibility and need for early re-intervention, they transferred RMC participants who were eligible and in need to a Linkage Manager. Using motivational interviewing, the Linkage Manager: a) provided feedback to participants regarding their current substance use and related problems, b) discussed implications of managing addiction as a chronic condition, c) discussed treatment barriers and solutions, d) assessed and discussed level of motivation for treatment, e) scheduled treatment appointments, f) accompanied participants to treatment intake and stayed through the process, and g) implemented Engagement and Retention Protocol during the 14 days of treatment
45400578|NCT03894748|Drug|Botulinum Toxin Type A|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
45508779|NCT05192213|Other|Placebo|Patients will receive 2 placebos (every 6 hours and every 12 hours) + Hydrocortisone (50 mg every 6 hours) for 7 days.
45508780|NCT03634553|Other|Training with e-health product|The training program follows the recommendations for training from ACSMS and SoS who states the importance that exercise programs should include muscle strengthening, cardiovascular as wells as balance exercises. Therefore, the training program includes: Strengthening exercises for the upper and lower extremities (number: 5-8 pc. with progression in three levels), daily (5-7 times / week), 30 minutes walks and balance training.
45508781|NCT03634553|Other|Usual care|usual care, i.e. participates in regular training regime at the physiotherapy department
45508782|NCT01368107|Drug|placebo|Placebo before the 1st (D0, D7, D14)and during the 3rd CT cycle (D57, D64, D71)
45508783|NCT01368107|Drug|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and the placebo during the 3rd CT cycle (D57, D64, D71)
45508784|NCT01368107|Drug|interleukin 7|patients will receive the placebo before the 1st CT cycle (D0, D7, D14) and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
45508785|NCT01368107|Drug|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
45508786|NCT02039674|Biological|Pembrolizumab|IV on Day 1 of each 3-week cycle prior to chemo/immunotherapy
45400579|NCT03894670|Other|Standard mixed breakfast meal|"The standard mixed breakfast meal consists of:~150 g yoghurt, 20 g muesli; 50 g wheat bun; 22 g rye bread; 25 g cheese; 25 g marmalade; 8 g butter; Total energy content: 500 kcal Macronutrient composition: 34 E% fat, 17 E% protein, 49 E% carbohydrate"
45508787|NCT02039674|Drug|Paclitaxel|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
45508788|NCT02039674|Drug|Carboplatin|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
45508789|NCT02039674|Biological|Bevacizumab|IV on Day 1 of each 3-week cycle
45508790|NCT02039674|Drug|Pemetrexed|IV on Day 1 of each 3-week cycle
45849945|NCT03351348|Behavioral|patient-reported pain scores|Will be recorded by the nurse in the PACU as per usual practice. Patients will be given a follow-up Brief Pain Inventory (short form) 6 months and 1 year after surgery to assess their level of chronic pain. Patients may be discharged when table either on the day of surgery or post-operative day 1 (on pill diary for same-day discharge patients).
45508791|NCT02039674|Biological|Ipilimumab|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
45508792|NCT02039674|Drug|Erlotinib|Orally tablet once daily
45508793|NCT02039674|Drug|Gefitinib|Oral tablet once daily
45508794|NCT03126227|Biological|AR101|AR101 powder provided in capsules
45508795|NCT03126227|Biological|Placebo|Placebo powder provided in capsules
45508796|NCT01373567|Drug|TINEFCON|Two 700 mg tablets of Tinefcon in the morning and evening to be taken orally.
45508797|NCT01373645|Device|Yinyi stent|subjects with Yinyi stent implantation
45508798|NCT03099187|Drug|Pirfenidone|Pirfenidone 267 mg capsules three times in a day.
45508799|NCT03099187|Drug|Placebo|Matching placebo capsules three times in a day.
45508800|NCT04192474|Device|Flexible cystoscopy|Treatment with the investigational device: Ambu® aScope™ 4 Cysto
45508801|NCT03634475|Drug|PP-001|Drug - no placebo
45508802|NCT04162756|Biological|Brexucabtagene Autoleucel (KTE-X19)|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
45508803|NCT04162756|Drug|Fludarabine|Administered per package insert
45400580|NCT03894670|Other|SmartBar™|SmarBar™ (Medtronic, North Haven, MA, USA). Weight: 72 g; Total energy content: 260 kcal Macronutrient composition: 7 E% fat, 19 E% protein, 74 E% carbohydrate.
45400581|NCT01151644|Biological|Anti-pandemic H1N1 influenza vaccine|inactivated, NON-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
45400582|NCT01153750|Drug|Glivec|
45508804|NCT04162756|Drug|Cyclophosphamide|Administered per package insert
45508805|NCT04544267|Biological|Quadrivalent influenza vaccine, high-dose|Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
45508806|NCT04544267|Biological|Quadrivalent influenza vaccine, standard dose|Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
45400583|NCT03894592|Other|Virtual reality|Trauma patients enrolled in the study will be offered Virtual Reality experieince per the protocol
45400584|NCT03894436|Combination Product|Ultrasound assessment of diaphragm thickness in B-mode|assess the thickness of diaphragm needed as a tool for prediction of extubation and proper timing of weaning from mechanical ventilation in the ICU which is measured by B mode ultrasound in ventilated cancer patients
45400585|NCT00187278|Device|Biventricular Pacing|Biventricular Pacemaker implant
45400586|NCT00187278|Device|RV Pacing|Standard Pacemaker implant
45400587|NCT03888664|Drug|gamma interferon|1st two weeks: gIFN 100 ugr/three times a week from the 3rd week: gIFN 200 ugr/ three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks
45508807|NCT05036746|Other|No intervention|No intervention
45400588|NCT03894124|Drug|Doravirine|Non-nucleoside reverse transcriptase inhibitor. Administered as film coated tablet.
45400589|NCT01258972|Device|Tryton Side Branch Stent with main branch DES|Tryton Side Branch Stent
45400590|NCT01258972|Device|POBA|Balloon angioplasty
45508808|NCT04535453|Biological|Ad26.COV2.S|All participants, both adults and adolescents, will receive intramuscular (IM) injections of Ad26.COV2.S.
45508809|NCT04535453|Other|Placebo|Adult participants in Groups 4, 5, 6, 8, and 10, and adolescent participants in Group C will receive at least one injection of placebo.
45508810|NCT04926220|Device|Trans-esophageal Doppler monitoring|Trans-esophageal Doppler monitoring (CARDIOQ-ODM; Deltex Medical, Chichester, UK) for monitoring of cardiac output
45508811|NCT04926220|Device|MostCareUP Haemodynamic Monitor|MostCareUp (Vytech, Padova, Italy) waveform analysis cardiac output monitor
45508812|NCT04926220|Device|Argos Cardiac Output (CO) Monitor|Argos monitor (Retia Medical, Valhalla, NY, USA) for cardiac output monitoring
45508813|NCT04895488|Drug|Vortioxetine|"First treatment phase: vortioxetine will be initiated at 10 mg / day for 2 weeks, followed by 20 mg /day for 22 weeks. The dose of vortioxetine can be lowered to 5 mg or 10 mg for tolerability reasons at clinician criteria.~Wash-out period 2 weeks"
45508814|NCT04895488|Drug|Usual Antipsychotic Treatment|Second treatment phase. Usual antipsychotic treatment for 26 weeks: Allows for whatever medication, routine support, or referral to other services was felt appropriate by the clinician.
45508815|NCT04463069|Other|Adapted physical activity|This PA program was modified from an adapted physical activity (APA) program that designed for obesity management among adolescents with intellectual disability (ID). The aim of the APA program was to promote PA and health for people in special needs. In this study, the APA program was carefully designed based on a comprehensive pre-intervention assessment of each adolescent with ID, so that can be able to address their individual needs in learning and adaption. The APA program comprised three stages of APA training at school and each stage consisted of simple and fun endurance and strength-building exercise, at a frequency of two sessions per week, and lasting for about three months.
45508816|NCT04397029|Device|SureTouch|"The first group will consist of 70 women who are believed to be free of masses, recruited during a screening mammography appointment.~The second group will include 125 women presenting for diagnostic mammography and/or biopsy appointment with known masses identified on mammogram, ultrasound or both.~Both groups will receive breast cancer screening with mammography and SureTouch."
45508817|NCT04893460|Behavioral|CoQuit App|The CoQuit App is a cognitive dissonance based app for smoking cessation.
45508818|NCT04835272|Procedure|the Decannulation Protocol With Suctioning|In the intervention group, the decision to decannulate was based on suctioning frequency. Patients underwent decannulation when they had had no more than two aspirations every 8 hours during during a 24-hour period. Patients in this group did not undergo capping trials.
45508819|NCT04342715|Drug|Sodium stibogluconate / paramomycin|Treatment with Sodium stibogluconate / paramomycin
45508820|NCT04811248|Other|telephone call for parents of patients|telephone call for parents of patients aged 6 years old
45508821|NCT01373333|Drug|3,4 DAP|Recommended maximum dosage: 20mg four times daily and if needed an additional 20 mg per day for a total of 100 mg per day. Drug must be kept refrigerated at all times.
45508822|NCT01368341|Drug|Doxycycline|1 tablet, 100 mg, b.i.d. 14 days
45508823|NCT01368341|Drug|Phenoxymethylpenicillin|Tablet 650 mg, 2 tablets, t.i.d., 14 days
45508824|NCT01368341|Drug|Amoxicillin|Capsula, 500 mg, t.i.d., 14 days
45508825|NCT01368419|Drug|Endostar|75mg Endostar in 235mL normal saline, 24h continuous infusion, 6 weeks
45400591|NCT03888508|Other|SIT|"sensory integration therapy along with standard therapy.~Primary care giver will be trained to perform sensory integration therapy at home.~. Sensory interventions will include maneuvers for both hypo and hyper-reactive behaviors in five senses as tactile, vestibular, proprioception, vision and auditory using a sensory integration kit and other items available at home~Daily sessions of approx 60 minutes/ day with each sensory stimulus given for 10-30 minutes 6 days in a week will be done."
45508826|NCT01368419|Radiation|Radiotherapy|6～15MV X-ray, 2Gy/time，5times/week，6 weeks
45508827|NCT03139864|Procedure|controlled physical activity|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
45508828|NCT05171933|Behavioral|Survey|This study is based on a survey made on COVID-19
45400592|NCT00256308|Drug|Oxaliplatin|70mg/m2 IV over 120 min once a week during radiation
45508829|NCT04639219|Drug|Trastuzumab deruxtecan|Trastuzumab deruxtecan (T-DXd) by intravenous infusion
45400593|NCT00256308|Procedure|Radiation|200 cGy/day - Megavoltage equipment with energy of Cobalt 60 or higher - Daily from Monday to Friday
45400594|NCT01153828|Drug|Retapamulin|Prescription for retapamulin
45400595|NCT01153828|Drug|Co-prescription of retapamulin and topical mupirocin|Same day prescriptions for retapamulin and topical mupirocin
45400596|NCT01153828|Drug|Co-prescription of retapamulin and topical fusidic acid|Same day prescription for retapamulin and fusidic acid.
45508830|NCT01373723|Other|Different alternatives to improve the coverage of the populational screening programmes of cervical cancer|Cost-effectiveness analysis of 3 strategies to increase the recruitment of population screening for cervical cancer. These interventions will be compared to the current opportunistic screening strategy
45400597|NCT03968952|Other|SMARThealth Pregnancy|Education and Training package on high-risk pregnancies and the associated long-term cardiometabolic risks; An mHealth platform providing mobile decision support to Community Health Workers.
45400598|NCT01151722|Procedure|bevacizumab injection|bevacizumab injection before vitrectomy
45400599|NCT01151722|Procedure|bevacizumab injection|bevacizumab injection after vitrectomy
45400600|NCT01073358|Procedure|Routine hilar lymphadenectomy|Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases
45400601|NCT01260220|Procedure|Circumferential Antral Ablation|The goal is to complete ablation in all segments around the pulmonary veins until a circle of ablation lesions is created in the antrum with at least 30 seconds of ablation, 25W on the posterior surface, 30W on the anterior surface at each site, and change in the local electrogram. Entry and Exit block will be confirmed in each vein. The left superior pulmonary vein and left inferior pulmonary vein will be isolated with one circle, and the right superior and right inferior pulmonary veins will be isolated with one circle.
45400602|NCT01260220|Procedure|Segmental Antral ablation|If the patient is in atrial fibrillation, ablation will begin in the segment with the highest frequency signals in the pulmonary vein antrum. If the patient is in sinus rhythm, mapping and ablation will occur during coronary sinus pacing. Segments with the earliest signals in the Lasso catheter will be targeted, and reassessed after each ablation lesion. This will continue in a segmental fashion on the antrum until pulmonary vein isolation is achieved. Lasso should be moved between veins between lesions to assess the earliest electrogram. Entry and exit block will be confirmed at each vein.
45400603|NCT01071720|Drug|CKD-501 1mg|This study is randomized, balanced, single-dose, two treatment (fed versus fasting), two-period, two sequence crossover design to assess the effects of food on pharmacokinetics profile.
45400604|NCT01258192|Drug|albumin-bound paclitaxel plus cisplatin|neo-chemotherapy program:Albumin-bound paclitaxel:100 mg/m2, IV (in the vein) on days 1,8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle.Number of Cycles: 2 cycles before operation.If it is effective ,2 cycles will be given in 6 weeks after radical resection.
45508831|NCT05415319|Behavioral|Laboratory tasks in middle childhood/pre-adolescence|Children will watch a 2-minute clip from a live-action movie and complete Storytelling and Mask tasks from the Laboratory Temperament Assessment Battery.
45508832|NCT04516564|Drug|AK119|Single dose of AK119 is administered via intravenous infusion to healthy subjects
45508833|NCT04516564|Drug|Placebo|Single dose of placebo is administered via intravenous infusion to healthy subjects
45508834|NCT05166317|Other|This is an observational study|This is an observational study
45508835|NCT04455100|Drug|SHR1459/Itraconazole|SHR1459 will be administered on Day 1 and Day 7. Itraconazole will be administered on Day 4 to Day 8
45508836|NCT04332523|Drug|JNJ-53718678|Participants will receive a single oral dose of JNJ-53718678 suspension on Day 1.
45508837|NCT04439578|Drug|SHR6390 tablet single oral dose of SHR6390 or co-administered with rifampicin|600 mg rifampicin was administered in the morning.
45400605|NCT01073436|Other|Discontinuation of therapy|Patients with chronic-phase chronic myeloid leukemia (CP-CML) previously treated with interferon-alpha (IFN) and presently on a tyrosine kinase inhibitor (TKI) (imatinib mesylate, dasatinib, or nilotinib) with achievement of a complete cytogenetic and at least a major molecular remission.
45400606|NCT01260298|Device|MC1 Ultrasonic Device|Ultrasonic and zonal massage device.
45400607|NCT01326078|Drug|propofol|3 - 4 mg/kg IV, adjustment dose if necessary
45400608|NCT03894358|Dietary Supplement|FeFum and 7.5 g prebiotic mixture|"The 3 weeks intervention will consist of 24 g of wheat-based instant cereal and 90 ml of water per portion and will contain 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 7.5 g prebiotics mixture~The absorption study test meals will consist of 24 g wheat-based instant cereal and 90 ml of water per portion and additionally:~Test meal 1 will be composed of: 3.6 mg of Fe as 57FeFum and 0 g prebiotic mixture added extrinsically.~Test meal 2 will be composed of: 3.6 mg of Fe as 1.5 mg iron as 58FeFum, 2.09 mg iron as 56FeFum and 7.5 g prebiotic mixture added extrinsically."
45400609|NCT03894358|Dietary Supplement|FeFum and 3 g prebiotic mixture|Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 3 g prebiotics mixture per portion
45400610|NCT03894358|Dietary Supplement|Fefum and no prebiotic mixture|Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) per portion.
45400611|NCT01155310|Drug|Helium/Oxygen 78%/22%|"The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices."
45400612|NCT01155310|Drug|Air/Oxygen|"The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices."
45400613|NCT03892876|Diagnostic Test|Auditory High Frequency Tetanizing Stimulation|50 ms tone pips presented at high frequency for 120 seconds
45400614|NCT03892876|Diagnostic Test|Sham Comparator|auditory tone pips with interstimulus interval (ISI) 1 sec
45508838|NCT04082585|Behavioral|Total Health Improvement Program|The Total Health Improvement program is a 13 week community based nutrition program designed to assist participants in improving their physical and emotional well being. The program focuses on a plant based diet and increased physical activity.
45508839|NCT03110848|Drug|Atorvastatin|Atorvastatin 20 mg daily
45508840|NCT03110848|Drug|Methylprednisolone|500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
45508841|NCT03992417|Drug|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
45400615|NCT01153906|Other|Data collection|New onset of cases for endpoints of interest in the targeted population will be identified from ambulatory and inpatient electronic administrative data and will be confirmed by blinded review of the medical record by an Endpoint Adjudication Committee (EAC) that will confirm the AID case and will assess whether the onset of disease falls within the observation period. Fibromyalgia and psoriasis, for which a high number of cases are expected, will be identified from the electronic administrative data only.
45400616|NCT03892798|Other|No interventions are planned|No interventions are planned
45400617|NCT01260376|Drug|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
45508842|NCT03139474|Drug|Gonadotropin-Releasing Hormone Analogue|Triptorelin at a dose 1 mg per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.
45508843|NCT03139474|Drug|Gonadotropin releasing hormone antagonist|antagonist group :Multiple dose gonadotrophin-releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .We will give them gonadotrophin for 5 days , Triggering by Human Chorionic Gonadotrophin will be administered for each group when size of follicle reach > 17 millimeter .Oocytes will retrieved by transvaginal ultrasound , 34-36 hours after Human Chorionic Gonadotrophin administration .
45508844|NCT05166148|Other|Session (a)|Eccentric cycling
45508845|NCT05166148|Other|Session (b)|High intensity concentric cycling realized at the same mechanical power output than eccentric cycling
45508846|NCT05166148|Other|Session (c)|Low intensity concentric cycling realized at the same metabolic demand than eccentric cycling
45508847|NCT01368575|Procedure|CABG|CABG
45508848|NCT01368575|Procedure|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
45508849|NCT01368575|Procedure|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
45508850|NCT01368575|Procedure|CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus|CABG combined with MV repair with remodeling annuloplasty
45508851|NCT01368575|Procedure|CABG and MV replacement|coronary artery bypass grafting and mitral valve replacement
45508852|NCT04029142|Diagnostic Test|Review of routine lab data|Review of routine lab data from pregnant women (first trimester)
45508853|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
45508854|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
45508855|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
45508856|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
45508857|NCT01372163|Drug|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
45508858|NCT01372163|Drug|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
45508859|NCT01372163|Drug|PF-05190457 or Placebo|Once (or twice) daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast (and dinner if twice) in Type 2 Diabetic patients.
45508860|NCT03991000|Drug|Ferric carboxymaltose|Intravenous iron
45508861|NCT03991000|Drug|Saline|Saline application according to dosing rules of iron.
45508862|NCT04170478|Device|Echolaser X4 system|Transperineal laser ablation
45508863|NCT05137210|Other|Male Counseling and Facility Navigation|At enrollment, study staff distribute pamphlet with male-specific messaging and contact information for nearest facility. Low-level cadre traces participants and provides one-on-one, in person male-specific counseling. Meeting at location of participants choice. Follow-up male-specific counseling is offered every 14 days thereafter until 90 days is reached OR 4-week follow-up ART refill visit is completed. Participants who choose to initiate ART are escorted to nearest health facility and provided facility navigation assistance.
45508864|NCT05137210|Other|Home-Based ART Initiation and Facility Navigation|"At enrollment, study staff distribute two pamphlets on: 1) male-specific messaging and 2) details about home-based ART initiation. Low-level cadre traces participants and provides one-on-one, in person male-specific counseling, and a detailed description of home-based ART initiation with a nurse. Meeting at the location of participants choice. Follow-up male-specific counseling and information about home-based initiation is offered every 14 days thereafter until 90 days OR 4-week ART follow-up refill visit is complete. Participants who choose to initiate ART at home or in the community will meet with a nurse at a place of the participants choosing. Those who choose to initiate at the facility will receive facility navigation and initiation. All clients will receive a warm handover for their 4-week ART follow-up visit."
45508865|NCT05137210|Other|Stepped Intervention|"Day 0-14 Arm 1 (Male-specific counseling and facility navigation arm) implemented. Day 14-30, if not yet initiated, a psychosocial counsellor will trace the participant to provide advanced counselling and motivational interviewing. Psychosocial counsellors will act as 'Male Mentors' and meet with men as frequently as needed. Day 30-89 if not yet initiated, nurse-led home-based ART initiation will be offered, following the same steps as listed in the Home-Based ART Initiation Arm."
45508866|NCT05142553|Biological|COVID-19 Vaccine HIPRA|Subjects will receive one injection of COVID-19 Vaccine HIPRA
45508867|NCT05142553|Biological|Cominarty (Pfizer-BioNtech)|Subjects will receive one injection of Cominarty Vaccine
45400618|NCT03888586|Device|Trigger Point Dry Needling Technique|The type of needle and the depth of the entrance varied depending on the estimated muscle thickness (0.25 - 25 mm, 0.25 - 30 mm and 0.25-40 mm). The disposable stainless-steel sterile needles were inserted through the skin over the trigger point in the taut band of muscle using the fast-in/out technique. Forward and backward needling was repeated until the local twitch responses were obtained. The depth of the needle was changed depending on the muscle thickness. After the first local twitch response, the needle was moved up and down 3 to 5 mm in only vertical directions until no more local twitch responses were elicited. After removing the needle, the insertion area was compressed with a piece of cotton
45400619|NCT03888586|Other|Deep Friction Massage Technique|For supporting the normal healing conditions, the deep and transverse friction causes hyperaemia in the involved soft tissue, which results in increased blood ﬂow to the area.
46059125|NCT04078009|Diagnostic Test|Aquagen|To compare the clinical allergic response after direct installation of an aqueous solution of Aquagen Timothy Grass pollen extract via nasal allergen challenge with the clinical allergic response after direct installation of an aqueous solution of Grazax Timothy Grass lyophilisate tablets via nasal allergen challenge in grass pollen allergic individuals.
45400620|NCT01262014|Drug|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until disease progression, the development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient, or investigator decision.
45508869|NCT03943966|Diagnostic Test|18F-GP1 PET CT|PET CT scan using platelet radiotracer 18F-GP1
45508870|NCT01373801|Device|The HemCon GuardaCare|The HemCon GuardaCare (HemCon Medical Technologies Inc., Portland, OR) is a hemostatic dressing made of chitosan, a complex carbohydrate derived from chitin from shellfish and is designed as a hemostatic dressing, and a topical antimicrobial dressing. GuardaCare contains no pro-clotting agents, providing a safe and localized hemostatic solution and is latex free and sterile.
45508871|NCT01373801|Device|Control|Standard packing gauze roll bandage.
45400621|NCT03886012|Device|Otoband|The Otoband will be used by participants during migraine associated vertigo (MAV). We expect the research subjects to use the device for at least 20 minutes, with the hardware limiting any one session to a duration of 30 minutes, up to 4 times per calendar day. The Otoband will be set to the effective power level during the course of a given calendar day.
45400622|NCT03886012|Device|Otoband sham|The Otoband will be used by participants during migraine associated vertigo (MAV) for a maximum of 30 minutes, up to 4 times per calendar day. The Otoband will be set to an ineffective power level (considered a sham device) during the course of a given calendar day.
45400623|NCT01152034|Behavioral|psychoeducation group therapy|This program consists of 15 sessions of closed group, with each session lasting 120 minutes, each aims at improving four main issues: illness awareness, early detection of prodromal symptoms and recurrences, treatment adherence, and lifestyle regularity. The program will be in groups of 6-12, conducted by two experienced therapists. The structure of each session consists of 30-40 minutes talk on the topic of the day, followed by an exercise related to the issue and a discussion.
45400624|NCT01259050|Drug|Zinc and Copper|Optizinc 90 mg/d Copper 1 mg
45400625|NCT03886090|Behavioral|aerobic exercise|Single-bout of moderate intensity aerobic exercise on a cycle ergometer following motor skill practice
45400626|NCT03886090|Behavioral|rest|Seated rest following motor skill practice
45400627|NCT03886090|Behavioral|motor learning|Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in a horizontal position.
45400628|NCT03888430|Procedure|PtcCO2 measure during intubation|Transcutaneous measure during intubation. Non invasive measure without any risk according to the literature
45400629|NCT03888196|Dietary Supplement|Panax Ginseng Supplementation|500 mg/day of Panax Ginseng
45400630|NCT03888196|Dietary Supplement|Placebo Supplementation|500 mg/day of Cellulose
45400631|NCT03892486|Other|The high PUFA diet group|Assumptions of nutritional intervention: in a randomized manner volunteers will be assigned to one of two groups: a control group which will receive general nutritional recommendations, based on the Polish nutrition pyramid, and the intervention group which will receive nutritional recommendations, based on the Polish nutrition pyramid and will consume at least 4 tablespoons of olive oil or 30 grams of nuts every day for 12 weeks.
45400632|NCT00255840|Behavioral|Monitoring by an HIV-trained medical doctor|Participants will receive care from an HIV-trained medical doctor
45508872|NCT01372241|Behavioral|Lay health advisor visits and newsletter|The focus of the intervention was on reducing participants' self-identified barriers to obtaining Pap tests.
45596691|NCT02374749|Behavioral|self-assessment/self-management|Nurse led-program of self-assessment/ self-management of spondyloarthritis
45849946|NCT03351348|Other|saline|The intervention in this study is the insertion of 20cc of saline via a drain into the mastectomy wound for 2 ± 30 minutes hours postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
45400633|NCT00255840|Behavioral|Monitoring by an HIV-trained primary care nurse|Participants will receive care from an HIV-trained primary care nurse
45400634|NCT00255840|Drug|Efavirenz|600 mg tablet taken orally daily
45400635|NCT00255840|Drug|Lamivudine|150 mg tablet taken orally daily
45400636|NCT00255840|Drug|Lopinavir/Ritonavir|400 mg lopinavir/100mg ritonavir tablet taken orally twice daily
45400637|NCT00255840|Drug|Nevirapine|200 mg tablet taken orally for 14 days before taking a 200 mg tablet orally twice daily
45400638|NCT00255840|Drug|Stavudine|Tablet taken orally daily. Dosage depends on weight.
45400639|NCT01154062|Drug|Pazopanib|Pazopanib tablet
45400640|NCT01155544|Behavioral|Behavioral Intervention|Preventing recurrence of substance use.
45400641|NCT03972228|Combination Product|Microdevice loaded with 19 chemotherapeutic agents|The microdevice containing 19 FDA-approved chemotherapeutic agents will be placed in the suspected tumor tissue at the time of surgical resection. Multiple chemotherapeutic agents will passively diffuse into local, confined regions (several microns) of the surrounding microenvironment. The agents are released at approximately one millionth of a systemic dose. The device(s) will be removed for analysis at the time of resection, which will be performed for clinical indications independent of enrollment in this study.
45400642|NCT01586416|Behavioral|Behavioral Intervention|Two or three one-hour sessions of an individual behavioral intervention led by a doctoral-level licensed psychologist during the first 12 weeks of chemotherapy. Intervention addresses modifiable behaviors for managing chemotherapy challenges.
45400643|NCT03885856|Other|single row repair technique|single row repair technique
45400644|NCT03885856|Other|double row repair technique|double row repair technique
45400645|NCT03885778|Drug|Besifovir dipivoxil|150mg Besifovir dipivoxil, single dose, oral
45508873|NCT03442504|Diagnostic Test|FES PET/CT|"There will be no premedication or other treatment before and after PET FES. PET / CT will be performed at the center level on a hybrid PET camera.~The first TEP FES acquisition begins at the time of injection and continues for 30 minutes,~The second acquisition of 20 minutes takes place 60 minutes after the injection is a total of 50 minutes of imaging and 1:30 in the service."
45508874|NCT03140566|Diagnostic Test|Ultrasound evaluation of the inferior vena cava diameter|Treatment will be guided by clinical assessment and ultrasound evaluation of the inferior vena cava (IVC) diameter. Decongestion should lead to maximal IVC diameter ≤2.1 cm and IVC collapsibility index >50% in addition to relief of symptoms and signs of congestion before discharge.
45508875|NCT03140566|Diagnostic Test|Sham ultrasound evaluation of the inferior vena cava diameter|Teatment guided by clinical assessment alone. Decongestion should lead to relief of symptoms and signs of congestion before discharge. IVC ultrasound evaluation is performed, but results are not reported to treating physicians.
45508876|NCT01319747|Procedure|PVI|For catheter ablation, we used irrigated 4mm RF-ablation catheters, at a maximum power of 30-35Watt, an irrigation rate of 20 mL/min. PV isolation was performed by wide circumferential ablation, encircling all ipsilateral PVs.
45508877|NCT01319747|Procedure|VATS-PVI|A bilateral video-assisted thoracoscopic (VATS) pulmonary vein isolation and left atrial appendage (LAA) excision is performed under general anaesthesia and double-lumen endotracheal ventilation.
45508878|NCT02038972|Genetic|Autologous Stem Cells|The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.
45508879|NCT03895684|Drug|SP-2577 Seclidemstat|Dose escalation and dose expansion of SP-2577.
45508880|NCT01368887|Drug|DPS-102|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
45508881|NCT01368887|Other|Vehicle / Placebo|The patient will apply the vehicle twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
45508882|NCT01368887|Drug|Calcipotriol Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
45508883|NCT01368887|Drug|Nicotinamide Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
45508884|NCT03859258|Device|Transvaginal sonography|Niche is assessed using TVS, SIS (cases only) and office hysteroscopy
45508885|NCT05049083|Drug|New Process SHR2554 tablet、Former Process SHR2554 tablet|New Process, 350 mg SHR2554 tablets on study day 1 - Former Process, 350 mg SHR2554 tablets on study day 8
45508886|NCT05049083|Drug|Former Process SHR2554 tablet、New Process SHR2554 tablet|Former Process, 350 mg SHR2554 tablets on study day 1 - New Process, 350 mg SHR2554 tablets on study day 8
45508887|NCT05088616|Behavioral|Virtual Diabetes Wellness Classes and Medically Tailored Meals|Four weeks of virtual diabetes wellness classes and 12 weeks of medically tailored meals.
45508888|NCT01369043|Dietary Supplement|Vitamin E and Vitamin C|Vitamin E 400 iu/dose daily times 56 days Vitamin C 500 mg/dose twice daily times 56 days
45508889|NCT04477096|Drug|HS-10234|HS-10234
45697979|NCT04165473|Behavioral|Training Program for Developing Social- and Personal Resources|"The training-method shows how one's own resonance can be exposed in order to live the balance between one's own needs and those of others.~Living one's own resonance means: more quality of life, work-life balance, holistic health through living feelings and talents, live equal, respectful and loving relationships, more personal responsibility, authentic decision making find new role models in private and professional areas.~The teaching and learning methods of the trainings and seminars are implemented according to the latest state of brain research and enable new perspectives with regard to new learning strategies, goals, enthusiasm and motivation.~With the Kutschera-Resonanz® method we teach and learn to consciously use this unconscious reservoir so that completely new dimensions in thinking and acting open up.~In this training program the basic tools of communication and interaction according to the Kutschera-Resonanz® method are taught and experienced by the participants."
45697980|NCT01064284|Drug|PLASMA DERIVED Factor VIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
45697981|NCT01064284|Drug|Recombinant FVIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
45508890|NCT04477096|Drug|Emtricitabine|Emtricitabine
45508891|NCT01369121|Drug|XERECEPT|BID dosing, subcutaneous for 1 year
45508892|NCT03868150|Drug|Amiodarone Injection|Patients stratified into the amiodarone study group were administered amiodarone until day of discharge. Amiodarone administration began intraoperatively with the administration of a 150 mg IV amiodarone loading bolus prior to separation from coronary pulmonary bypass, followed by 1 mg/min IV amiodarone for six hours (360 mg), then 0.5 mg/min IV amiodarone for 18 hours (540 mg), then transitioned to 400 mg oral amiodarone twice a day until discharge. In total, patients in the amiodarone treatment group received 1,050mg of IV amiodarone plus 800mg/day of oral amiodarone thereafter until discharge.
45508893|NCT03868150|Device|Intraoperative Rapid Atrial Pacing|Intraoperative rapid atrial pacing for 30 seconds after cannulation and prior to initiation of cardiopulmonary bypass by having the surgeon attach insulated forceps to the superior right atrial free wall and connected to a temporary pacemaker to burst pace at a rate of 800 bpm for 30 seconds (pulse width 1.0 ms, output: 20 mA) Patients are monitored for successful atrial fibrillation induction defined as 30 seconds of sustained atrial fibrillation on ECG.
45596692|NCT02374749|Behavioral|Comorbidities (detection/prevention)|Standardized assessment of comorbidities by nurses
45596693|NCT02363985|Dietary Supplement|Mega-dose of vitamin A supplement|vitamin A supplementation normally given every six months for under five children in Ethiopia. In addition, there is also dietary intervention like orange flash sweet potato and promotion of other vitamin A rich foods to tackle vitamin A deficiency in Ethiopia.
45400646|NCT03885700|Behavioral|Educational program for 2 months|"The intervention was suggested based on the recommendations for adolescents' healthy diet and physical activity, it was derived from the 2008 Physical Activity Guidelines for Americans and Dietary Guidelines for Americans, 2010 by the U.S. HHS, Physical activity guidelines for children and adolescents by CPS 2012. The Food Guide Pyramid by the USDA, Nutrition &Healthy Eating by Mayo clinic & CDC website. The program was modified according to the age of the child. This plan was typically pursued in a School-based Intervention to Promote Healthy Lifestyles in Sousse, Tunisia, by Harrabi et al. The 1st month covered the healthy diet & the 2nd month covered the physical activity as follow:~1st & 5th week: A 60-minutesession in health education.~2nd & 6th week: Group counselling.~3rd & 7th week: Students were divided into 8 groups & each group was asked to make presentation about a task related to the topic.~4th & 8th week: Discussing the presentation."
45508894|NCT03606239|Radiation|isotoxic hypofractionated group|the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible，and the same time use the Platinum-containing drugs: docetaxel + lobaplatin Docetaxel 60 mg/m2, d1; Lobaplatin 30 mg/m2, d1, repeated every 28 days. The first cycle of chemotherapy started on the first day of radiotherapy.Consolidate chemotherapy up to 4 cycles after radiotherapy, as above.
45508895|NCT03551795|Biological|Infusion of iNKT cells|The eligible patients receive twice infusions of iNKT cells(1E8~1E10) in one course of treatment.
45508896|NCT03141892|Device|FreeStyle Libre Flash Glucose Monitoring System|Blood Glucose Monitoring
45400647|NCT01262170|Dietary Supplement|CigRx Lozenge|lozenge made of dietary supplements
45400648|NCT01262170|Other|Tobacco Lozenge|lozenge made of compressed cured tobacco extract
45400649|NCT00224874|Drug|Etanercept|Etanercept [25 mg subcutaneously twice weekly for up to 4 weeks; discontinue if in complete response by 4 weeks].
45697982|NCT04611815|Procedure|Total knee arthroplasty|Participant will undergo robotic-assisted or conventional total knee arthroplasty
45400650|NCT00224874|Drug|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) [20 mg/kg (maximum 1 gm) orally or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks].
45400651|NCT00224874|Drug|Denileukin Diftitox|Denileukin Diftitox (ONTAK®) [9 mcg/kg intravenously Days 1, 3, 5, 15, 17, 19].
45508897|NCT05084794|Procedure|Internal fixation|Fixation of posterior malleolus with either plate or screws.
45508898|NCT03521687|Drug|Apremilast|30 mg BID
45508899|NCT03141658|Drug|TS-134|Multiple dose titrations from 10 mg to 20 mg once daily for 6 days
45508900|NCT03141658|Drug|TS-134|Multiple dose titrations from 10 mg to 60 mg once daily for 6 days
45508901|NCT03141658|Drug|Placebo|Multiple doses of placebo once daily for 6 days
45697983|NCT04611815|Diagnostic Test|Computer tomography scan|CT scans of the affected knee joint before and after the surgical procedure
45697984|NCT04611815|Diagnostic Test|biomechanical assesment|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
45400652|NCT00224874|Drug|Pentostatin|Pentostatin [1.5 mg/m2 daily for 3 days; Days 1-3 and repeat Days 15-17
45400653|NCT03892330|Drug|Vincristine|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
45400654|NCT03892330|Drug|Oxytetracycline/ Cyclophosphamide|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
45400655|NCT03892330|Drug|Liposomal doxorubicin|The dosage of Liposomal doxorubicin is half of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
45400656|NCT03892330|Drug|Doxorubicin|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
45400657|NCT03892330|Drug|Pharmorubicin|The dosage of pharmorubicin is 2 times of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
45400658|NCT03892330|Drug|Pirarubicin|The dosage of pirarubicin is equal to doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
45400659|NCT03888118|Device|Luna EMG|The duration of the overall therapeutic intervention in both groups will be the same.
45400660|NCT00186186|Drug|Depakote ER|Depakote ER
45400661|NCT03892408|Device|Optiflow ™|supply of 100 % of oxygen at 70 L / min through Optiflow ™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand) plus standard oxygen supply through rigid bronchoscope during apnea period.
45508902|NCT03141658|Other|Ketamine|0.23 mg/kg bolus over one minute on Screening (baseline) and Day 6
45508903|NCT03139396|Procedure|tub shaped inlay bridge design|inlay retained bridge with tub shaped retainer on both abutments
45508904|NCT03498911|Procedure|Mucogingival surgery|The gingiva around the mucosal recession at implant site will be coronally positioned by releasing the underlying mucosa
45508905|NCT03142048|Other|Schools of Health for the Elderly|"The intervention School of Health for the Elderly  consists of 22 weekly group sessions of 1.5 hours each. In addition to helping participants learn about different health issues, the intervention encourages interaction among participants and works on personal skills. Furthermore, most sessions are led by professionals who are experts on the topic covered and work in the neighborhood (professionals from the health services, social services, markets or neighborhood associations), making it easier to inform participants of the neighborhood's available resources. The aim of the intervention is to decrease social isolation and loneliness and, therefore, to improve mental health, self-perceived health and wellbeing"
45508906|NCT05411419|Procedure|Spinal cord stimulation|Two leads for spinal cord stimulation would be implanted.
45508907|NCT03498131|Drug|3 mg Melatonin|3 mg melatonin once each day
45508908|NCT03498131|Drug|5 mg Melatonin|5 mg Melatonin once each day
45715256|NCT05227534|Device|OverC multi-cancer detection blood test|Blood collection for the OverC multi-cancer detection blood test and standard-of-care screening with return of results
45715257|NCT05227222|Device|PEP-device|PEP-device
45715258|NCT05218798|Diagnostic Test|Cardio Respiratory Fitness testing|"In a randomized cross over designed study, we will measure Vo2max by using different tests:~Continous Treadmill Running Test~Continous 2-mile run test~30-15 Intermittent Fitness Test - first trial and second trial"
45400662|NCT03969108|Drug|Indocyanine Green|ICG is a fluorescent dye which binds tightly to plasma proteins and becomes confined to the vascular system.
45400663|NCT03973944|Device|Cardiac resynchronization therapy|Atrio-biventricular pacing to shorten the prolonged PR interval
45400664|NCT03885544|Other|Controlled Lacto-ovo vegetarian diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian (LOV) diet for 3 weeks. All foods will be provided to subjects during the intervention. Each subject's energy requirement will be estimated using sex-specific equations published by the Institute of Medicine for weight maintenance during the intervention.
45400665|NCT03885544|Other|Controlled Unprocessed red meat diet|The unprocessed red meat diet will be the same as the LOV diet except that one 3-ounce portion of unprocessed red meat per day, 7 days per week (21 oz/wk) will be included. The unprocessed red meat will include beef tenderloin and pork loin. All foods will be provided to subjects during the intervention.
45400666|NCT03885544|Other|Controlled processed red meat diet|The processed red meat diet will be the same as the LOV diet except that one 3-ounce portion of processed red meat per day, 7 days per week (21 oz/wk) will be included. The processed red meat will include a variety of beef and pork luncheon meats with different methods of preservation. All foods will be provided to subjects during the intervention.
45400667|NCT03888040|Other|Exercise|The participant will attend 3 training sessions per week for 8 weeks. Resistance training will be performed by each leg with a load of 30% of maximal strength: one leg with and the other without blood flow restriction.
45400668|NCT00185640|Drug|Cyclosporine|Starting day -3 at a dose of 5 mg/kg orally twice daily with a target trough level of 350 to 450 ng/mL
45400669|NCT00185640|Drug|Anti-thymocyte globulin (ATG)|1.5 mg/kg for total dose of 7.5mg/kg, IV starting on day -11 to day -7 before HCT
45400670|NCT00185640|Drug|Mycophenolate mofetil (MMF)|Begins on day 0 after HCT at a dose of 15 mg/kg. Transplant recipients who received related donor grafts received MMF twice daily and those who received unrelated donor grafts received MMF 3 times daily.
45400671|NCT00185640|Drug|Filgrastim|"Donors mobilized with 16 µg/kg/day filgrastim.~As needed, myelosuppression in transplant recipients will be managed with subcutaneous filgrastim 5 µg/kg/day"
45400672|NCT00185640|Radiation|Total Lymphoid Irradiation (TLI)|0.8 Gy/day from day -11 to day -7 (inclusive) from day -4 to day -2 (inclusive) with 2 additional fractions of 0.8 Gy delivered on day -1 for total dose of 8 Gy.
45400673|NCT03885388|Drug|MTX|multicourse methotrexate chemotherapy
45400674|NCT03885388|Drug|MTX+ACTD|combination use of methotrexate and actinomycin
45400675|NCT03973788|Procedure|repetitive transcranial magnetic stimulation (rTMS)|A single section of rTMS (2,000 pulses)
45400676|NCT03884686|Other|Web-based education resource|Intervention includes fact sheets, question and answers, short videos featuring patients and/or clinicians.
45400677|NCT03968640|Dietary Supplement|CoQ10|The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
45400678|NCT03968640|Dietary Supplement|Placebo|The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
45400679|NCT01152346|Drug|Azacitidine for Injection|75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
45400680|NCT01152346|Drug|Vidaza®|75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
45400681|NCT01260610|Drug|Tenofovir|300 mg of Tenofovir daily
45400682|NCT01260610|Drug|Telbivudine|600 mg of Telbivudine daily
45715259|NCT05218252|Procedure|Posterior interosseous artery flap|The use of distally based posterior interosseous artery flap from the forearm in reconstructing mild to moderate hand soft tissue defects
45715260|NCT00368602|Drug|Timoptic|Timoptic to be applied to the target wound daily for up to 12 weeks.
45715261|NCT00368602|Other|Placebo|Saline solution with no active ingredients to be applied to the target wound daily for up to 12 weeks.
45715262|NCT01683071|Drug|Placebo|Normal saline 20 mL as single-injection femoral nerve block prior to total knee arthroplasty
45715263|NCT01683071|Drug|EXPAREL 67 mg|5 mL EXPAREL expanded with 15 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty
45849947|NCT03351270|Other|Standardized strength, respiratory and motor function assessments|Standardized assessments will be adjusted by the age, the ambulant status and the respiratory status of the patient. The visit frequency will also be adjusted according to the age and to the time spent in the study varying between quarterly to yearly.
45508909|NCT03141580|Diagnostic Test|Near-infrared spectroscopy and intravascular ultrasound (NIRS-IVUS)|Examination of the extracranial portion of the internal and common carotid artery with pre-existing stent with NIRS-IVUS.
45508910|NCT03632551|Other|Specific binaural hearing evaluations|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
45508911|NCT05013827|Behavioral|Filling in an online survey|Company representatives are questioned about three aspects: 1) goals in treating patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.
45508912|NCT03287752|Device|BASKA MASK|Patients will be anesthetized using BASKA mask after lubrication with water soluble lubricant
45508913|NCT03287752|Device|Endotracheal tube|Patients will be anesthetized using appropriate sized cuffed oral endotracheal tube.
45508914|NCT04566289|Device|PiCSO|Percutaneous coronary intervention
45508915|NCT01319825|Drug|milnacipran|100 mg and 200 mg orally daily for a total of 4 months including a one month titration period.
45508916|NCT01369277|Drug|PF-04991532|Single dose administration of PF-04991532 (100 mg, 300 mg and 750 mg) in tablet formulation under fasted condition.
45508917|NCT01369277|Drug|Placebo|Single dose administration of matching placebo in tablet formulation at the fasted state
45508918|NCT01369277|Drug|PF-04991532|Single dose administration of PF-04991532 (300 mg and 750 mg) in tablet formulation under fasted condition.
45508919|NCT02983006|Biological|DS-8273a|"Starting Dose: 4 mg/ kg IVQ 3 weeks (Cohort 1)~Dose Escalation: 8 mg/kg IV Q 3 weeks (Cohort 2), 16 mg/kg IV Q 3 weeks (Cohort 3), 24 mg/kg IV Q 3 weeks (Cohort 4), 2 mg/kg IV Q 3 weeks (Cohort -1), 4 mg/kg IV Q 3 weeks (Cohort -2)"
45715264|NCT01683071|Drug|EXPAREL 133 mg|10 mL EXPAREL expanded with 10 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty
45400683|NCT01260610|Drug|Tenofovir plus Telbivudine|Tenofovir (300 mg daily) plus Telbivudine (600 mg daily)
45400684|NCT01155622|Procedure|Endovascular Cooling|Infusion of <8°C cold saline followed by the implantation of the Icy 9.3F 38-cm catheter (ZOLL Medical Corporation, Chelmsford, MA) placed in the inferior vena cava through a femoral vein connected to the Thermogard XP Temperature Management System (ZOLL Medical Corporation). Cooling was set at a maximum rate with a target temperature of 32°C or 34°C according to randomization.
45400685|NCT03885076|Procedure|Blood collection and bone marrow aspirate|Blood and bone marrow samples will be collected for the trial alongside routine tests.
45400686|NCT05477836|Device|MiWEndo-assisted colonoscopy|"All colonoscopies will be performed with high-definition technology. The MiWEndo System (MiWEndo Solutions, Barcelona) will be fitted to the tip of the endoscope before colonoscopy is started and connected to the microwave processor unit. Endoscopies will be performed by experienced endoscopists who will be previously trained on the use of the MiWEndo System.~At the beginning of the extubation, the MiWEndo System will be turned on. During extubation, each segment will be carefully examined with both white light and MiWEndo. In case one of them identifies a polyp, the exploration will be stopped and check if it has been detected by the alternative method as well. All the polyps will be resected and sent to the Pathological Department for histological analysis following the usual clinical practice. A stopwatch will be used to measure both total procedure time and withdrawal time."
45400687|NCT03884764|Procedure|pulsed radiofrequency|patients with chronic pelvic pain due to chronic prostatitis will receive pulsed radiofrequency on sacral root number 3 and ganglion impar denervation and the patients will be followed for 6 months to assess pain severity radiofrequency procedure: patients will positioned prone on the operating table and under x-ray guidence sacral foramen number 3 will be identified and through it radiofrequency needle will be advanced to target the sacral root ganglion impar procedure: under x-ray guidance the sacrococcygeal junction is identified and spinal needle will be introduced through it to target ganglion impar and 4 ml of alcohol 50% will be injected
45400688|NCT03884764|Procedure|ganglion impar denervation|patients with chronic pelvic pain due to chronic prostatitis will receive ganglion impar denervationand and the patients will be followed for 6 months to assess pain severity ganglion impar procedure: under x-ray guidance the sacrococcygeal junction is identified and spinal needle will be introduced through it to target ganglion impar and 4 ml of alcohol 50% will be injected
45400689|NCT03884842|Biological|Dupilumab/Dupixent|a monoclonal antibody designed for the treatment asthma and atopic dermatitis.
45400690|NCT03884842|Biological|Placebo|Matched placebo
45400691|NCT01155700|Drug|omalizumab|
45400692|NCT03892252|Other|No intervention|No intervention
45400693|NCT03887884|Drug|CVT-301|Levodopa Inhalation Powder
45400694|NCT03887884|Drug|Sinemet|Single oral dose of Carbidopa/Levodopa 25 mg/100 mg
45400695|NCT03887650|Drug|Liposomal Bupivicaine 1.3%|10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
45400696|NCT03887650|Drug|Bupivacaine 0.5%|20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
45508920|NCT02983006|Biological|Nivolumab|5 mg/kg IV Q 3 weeks
45508921|NCT05409859|Other|Manual therapies|Manual therapies were determined based on the clinician evaluation and could include spinal mobilization delivered by hands or mechanically assisted and soft tissue therapies.
45508922|NCT04983953|Device|cHS|Clinical decision support system for diagnosing intracranial haemorrhage
45715265|NCT01683071|Drug|EXPAREL 266 mg|20 mL EXPAREL as single-injection femoral nerve block prior to total knee arthroplasty
45715266|NCT00368680|Device|Early Bubble CPAP|
45715267|NCT04707508|Drug|Valsartan 80 mg and metformin|Valsartan 80 mg once daily in addition to metformin monotherapy
45715268|NCT04707508|Drug|Metformin|Metformin monotherapy
45715269|NCT05193526|Other|No intervention|No intervention
45849948|NCT03315390|Other|"Narrative Exposure Therapy-oriented intervention"|Narrative Exposure Therapy (NET) in an Primary-care adapted Version in 3 sessions (S) 6 weeks (S1), 8 weeks (S2) and 12 weeks (S3) after baseline data collection at T0.
45849949|NCT03315390|Other|improved treatment as usual (iTAU)|improved standard primary care for PTSD according to Guidelines, customized to patients' needs and symptoms during 3 consultations between T0 and T1
45508923|NCT03811756|Dietary Supplement|Test syrup containing CoQ10 and collagen|Test group will receive investigational product - test syrup (daily dose 10 mL: fish collagen: 4000 mg, water soluble CoQ10 (Q10Vital®): 50 mg, vitamin C: 80 mg, vitamin A: 920 μg, biotin: 150 μg); continuous administration of investigational product for 12 weeks.
45508924|NCT03811756|Dietary Supplement|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, water soluble CoQ10 (Q10Vital®): 0 mg, vitamin C: 0 mg, vitamin A: 0 μg, biotin: 0 μg); continous administration of placebo product for 12 weeks.
45508925|NCT03125915|Behavioral|Communication skills training video|This video includes 4 scenes of gay couples discussing issues related to HIV prevention, testing, sexual agreements, and drug use. Each scene is viewed twice. The first viewing includes common communication errors. The second viewing portrays more skillful interpersonal communication and a more adaptive resolution to the conversation.
45508926|NCT03125915|Behavioral|substance use module|This activity involves completion of a calendar detailing partners' substance use in the past month and a structured debriefing activity designed to facilitate the formation of couples' goals and limits around substance use.
45508927|NCT03125915|Behavioral|Couples HIV Testing and Counseling|CHTC delivered as per the CDC protocol.
45508928|NCT05397067|Behavioral|Peer specialist (PS) and vouchers|this participants will receive vouchers from PS
45400697|NCT03887962|Device|Virtual Environment Biofeedback|Treadmill walking. Modified available technology for gait capture. Tailored software for virtual environment rendering and immersive qualities
45400698|NCT03887962|Device|Treadmill walking with no Virtual Environment Biofeedback|Treadmill walking. Flat screen / no virtual environment to act as attentional control.
45400699|NCT03892096|Diagnostic Test|Blood-based cell-free cfDNA qPCR assay|Up to 30mL of blood via venipuncture
45400700|NCT03892174|Other|Treatment protocol with adsorption|Adsorption while patients are in the OR on the extracorporeal circuit
45400701|NCT01262326|Other|Calorie and Carbohydrate Restriction|Carbohydrate Restriction = <20 g/d of dietary carbohydrate intake Calorie Restriction = 1200 kcal/d for women and 1500 kcal/d for men
45400702|NCT01154530|Other|Chlorhexidine|Mouthwash with a 0,2 % chlorhexidine solution for 30 seconds
45400703|NCT03887572|Other|MOVIN|MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.
45400704|NCT05077852|Diagnostic Test|Urethrocystoscopy|Patients diagnosed with a primary bladder cancer at the base, trigone or neck of the bladder with USG in the urology clinic will be evaluated with urethrocystoscopy. With urethrocystoscopy, patients definitive diagnosed with bladder cancer and IPP.
45508929|NCT04476940|Behavioral|COVID-19 Breastfeeding Support|Intervention will be implemented by trained prenatal care providers to provide comprehensive exclusive breastfeeding and COVID-19 breastfeeding guideline education and support to study participants.
45508930|NCT03141268|Diagnostic Test|Lactulose breath test|Lactulose 0.67 mg/mL, dose 15 mL (10 grams). No contaminants of lactose. Pharmacy quality.
46059126|NCT04078009|Diagnostic Test|Grazax|To compare the clinical allergic response after direct installation of an aqueous solution of Aquagen Timothy Grass pollen extract via nasal allergen challenge with the clinical allergic response after direct installation of an aqueous solution of Grazax Timothy Grass lyophilisate tablets via nasal allergen challenge in grass pollen allergic individuals.
45508931|NCT03139006|Device|Dual-layer spectral detector CT|A dual energy CT approach
45400705|NCT03887416|Drug|Dapagliflozin 10 MG Oral Tablet [Farxiga]|"The investigational medicinal product (IMP) is dapagliflozin10 mg given once daily (film coated tablets, oral use).~Dapagliflozin will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: 10 mg, Green, plain, diamond shaped, film coated tablet (orally)"
45400706|NCT03887416|Drug|Placebo Oral Tablet|"The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient"
45508932|NCT03122171|Other|Occupational Therapy Treatment|Each occupational therapy treatment will be a one-hour standardized session that will include the following: stretching/strengthening (approximately 20 minutes), bi-manual training (approximately 20 minutes), and activities of daily living (approximately 20 minutes).
45508933|NCT03138850|Device|Olympus standard bite block|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and nasal cannula with oxygen 5L/min
45508934|NCT03138850|Device|YX mandibular advancement bite block|Intravenous sedative upper gastrointestinal endoscopy performed under mandibular advancement bite block for endoscopy (Yong Xu breathing mouth piece, Yong Xu) and oxygen connected to mouth piece 5L/min
45715270|NCT05189080|Other|Text message reminders|Text messages will be sent to parents/guardians of children ages 0 to 17 years who no-showed for their well child visits.
46059127|NCT04291573|Device|HD-tDCS|Real stimulation (2mA, 20min) with anode on C3/C4 of the lesioned hemisphere and 4 return electrodes ~4cm away
46059128|NCT04291573|Device|Sham HD-tDCS|Sham stimulation (2mA, ramp up and down phases of 30s) with anode on C3/C4 of the lesioned hemisphere and 4 return electrodes ~4cm away
45400707|NCT01260766|Device|Oplon Active Patch|Patches are placed over acne lesion overnight. Treatment is a single treatment.
45400708|NCT01260766|Device|Placebo Patch|same as active patch
45400709|NCT01155856|Other|Telemedical admission and treatment in the patients´ own homes instead of conventional admission and treatment at the hospital|For this study a telemedical platform has been developed on which it is possible to treat patients in their own homes. The platform consists of a videoconference part that allows the patients to make contact to qualified medical staff and a technology part that can transfer vital indicators of the patients health condition (lung function, oxygen saturation, pulse etc.)175 patients will be included with an expected drop-out of 20 % or 35 patients. The patients will be equally recruited from two hospitals (Frederiksberg and Herlev Hospital). All patients must have an exacerbation in their COPD that requires hospitalization to be included in this study. Each patient participate in the study for 6 months after discharge with follow-up at 1, 3 and 6 months.
45400710|NCT03891940|Procedure|patients recieving anterior cervical spine surgery|Anterior cervical discectomy with fusion, or ACDF, is a surgery designed to relieve spinal cord or nerve root pressure in the neck by removing all or part of a damaged disc
45508935|NCT03138850|Device|Optiflow High flow nasal cannula|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and high flow nasal cannula
45508936|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
45508937|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
45508938|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 1 x 10^8 pfu IM 8 weeks later
45508939|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
45508940|NCT01373879|Biological|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
45508941|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 1 x 10^8 pfu IM 8 weeks later
45508942|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
45508943|NCT01373879|Biological|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
45508944|NCT03663088|Other|GPR-A|Standard Global postural re-education physiotherapy scoliosis specific exercises
45508945|NCT03663088|Other|GPR-B|Experimental Global postural re-education physiotherapy scoliosis specific exercises combining individual and class exercises
45508946|NCT03138928|Device|XEN45 gel stent implantation in glaucoma surgery|The XEN gel stent (Allergan, Dublin, Ireland) is a recently developed, permanent, ab interno collagen implant that reduces IOP by draining aqueous fluid from the anterior chamber into the subconjunctival space
45508947|NCT03634696|Other|mPCL|Smart phone application to support palliative care among late-stage cancer patients
46059129|NCT05290129|Drug|Oxytocin|Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
45400711|NCT01260844|Drug|briakinumab|single dose briakinumab and 2 doses of CYP substrates
45400712|NCT03891472|Drug|Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy.|mFOLFIRINOX > SBRT > mFOLFIRINOX > Surgical Intervention
45400713|NCT03887494|Device|Implantation|Implantation of Y-Strut + cementoplasty in the femoral neck
45400714|NCT01154608|Drug|Creon|
45400715|NCT01154608|Other|No enzyme therapy|Current enzyme therapy of the patient is stopped during 7 days
45400716|NCT01262482|Drug|Oxaliplatin|130 mg/m2, IV during 2 hours on day 1 of each 21 day cycle. Number of cycles: until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
45400717|NCT01262482|Drug|Sorafenib|400mg, orally, 2 times per day. Until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
45400718|NCT01261078|Drug|Placebo|intrathecal 8 mg of bupivacaine only
45400719|NCT01261078|Drug|epinephrine 25|intrathecal 8 mg of bupivacaine mixed with 25 mcg of epinephrine
45400720|NCT01261078|Drug|Epinephrine 50|intrathecal 8 mg of bupivacaine mixed with 50 mcg of epinephrine
45400721|NCT01261078|Drug|epinephrine 100|intrathecal 8 mg of bupivacaine mixed with 0.1 mg of epinephrine
45400722|NCT01261078|Drug|Epi 200|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
45508948|NCT03634696|Other|Usual Care|Usual care through OCRI palliative care clinic
45508949|NCT03634163|Behavioral|Neighbourhood exchange|Facilitated coaching support to identify needs and priorities and link with resources - personal, community, friend and family, or from professional service providers; plan and implement a personalized care pathway through community exchange
45508950|NCT03634163|Behavioral|Quality of Life Assessment|Completion of baseline measures
45508951|NCT05084170|Procedure|Bilateral anterior cingulotomy|Stereotactic bilateral anterior cingulotomy is a brain operation with demonstrated efficacy in the treatment of intractable pain from a variety of causes, including a few cases of spinal cord injury related neuropathic pain.
45508952|NCT03316781|Drug|HLX03|80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
45508953|NCT03316781|Drug|adalimumab|80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
45508954|NCT03138772|Other|This is an observational study, no intervention used.|No intervention is being used in this study.
46059130|NCT04283851|Diagnostic Test|testing functional haemodynamic parameters for preload assessment|dynamic testing of preload responsivity plus echocardiography
45508955|NCT01427725|Drug|Lipacreon|This study was an observational study and no intervention was specified
45508956|NCT01319903|Biological|CaCP29, a humanized monoclonal antibody|CaCP29 or placebo single i.v. infusion in ascending doses in healthy human males
45508957|NCT05084014|Other|Deep Stripping|The deep longitudinal stripping can be applied on adhesions and knots in muscles. The lengthening stokes are parallel to muscle fiber and applied in an oblique direction with the help of the thumbs of hands/ elbow/ knuckles
45508958|NCT05084014|Other|Kneading|kneading lifts the muscle in circular movements with the help of the hands. It lifted, rolled, and squeezed muscle
45400723|NCT03884218|Other|Infra red thermal imaging|thermal image using a non-touch, non-ionising, thermal camera system
45508959|NCT03138694|Other|BHCG monitoring|Participants in the study will be invited to our outpatient clinic for BHCG monitoring including blood count and BHCG levels test and serial Transvaginal Ultrasound examination
45508960|NCT02839200|Drug|ACT-541468 5 mg|Capsule for oral administration containing ACT-541468 at a strength of 5 mg
45508961|NCT02839200|Drug|ACT-541468 10 mg|Capsule for oral administration containing ACT-541468 at a strength of 10 mg
45508962|NCT02839200|Drug|ACT-541468 25 mg|Capsule for oral administration containing ACT-541468 at a strength of 25 mg
45508963|NCT02839200|Drug|Zolpidem|Over-encapsulated zolpidem tablet at a strength of 10 mg
45508964|NCT02839200|Drug|Placebo 1|Placebo capsules matching ACT-541468 capsules
45508965|NCT02839200|Drug|Placebo 2|Placebo capsules matching over-encapsulated zolpidem
45697985|NCT01891721|Behavioral|Brain Fitness Program (BFP)|"This computerized bottom-up cognitive intervention is designed to improve the speed and accuracy of auditory information processing through increasingly more difficult stimulus recognition, discrimination, sequencing, and memory tasks under conditions of close attentional control, high reward, and novelty. BFP consists of 6 exercises. Stimuli across the exercises are chosen such that they span the acoustic and organizational structure of speech, from very simple acoustic stimuli and tasks to complex manipulations of continuous speech. The exercises adaptively progress based on the subject's individual performance during a training session and become more challenging as the subject's abilities improve. Participants will work with 4 of the 6 exercises (15 min per exercise) in each session."
45697986|NCT01891721|Behavioral|Cognitive Package (Cogpack)|"This computerized top-down cognitive intervention is designed to provide training across a broad range of cognitive functions. Cogpack consists of domain-specific exercises aimed at training specific cognitive areas (attention, working memory, verbal and visual memory, executive functioning, reasoning, language) and non-domain-specific exercises that require the use of several functions at a time. Cogpack includes low-level cognitive exercises (i.e., scanning, hand-eye coordination, and psychomotor speed) that will not be included in this protocol to better separate bottom-up from top-down training interventions. There will be a total of 34 exercises and variants of the same exercises with different levels of difficulty. In each session, participants will work on a different subset of 4 to 6 exercises."
45697987|NCT01891721|Behavioral|Commercial Computer Games (Sporcle)|"Sporcle computer games will be used as a placebo treatment to control for the effects of computer exposure, contact with research personnel, time spent being cognitively active, and financial compensation for participation. The games cover trivia-type questions about geography, entertainment, science, history, literature, sports, movies, etc. Subjects will receive the same amount of attention from staff members and the same monetary reinforcements as participants in the experimental treatment groups. They will also complete 3 hours of training per week over 12 weeks, for a total of 36 hours."
45697988|NCT01064362|Drug|Fondaparinux sodium|Fondaparinux sodium for thromboprophylaxis (ATC: B01AX05)
45697989|NCT01064362|Drug|Low molecular weight heparin (LMWH)|LMWH including: dalteparin, nadroparin, enoxaparin or tinzaparin (ATC:B01AB (excluding B01AB01))
45697990|NCT03646461|Drug|Ibrutinib 560mg PO daily (Imbruvica)|BTK inhibitor combined with PD-1 inhibitor
45697991|NCT03646461|Drug|Cetuximab|Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle
45697992|NCT03646461|Drug|Nivolumab|Nivolumab 3mg/kg biweekly 28 day cycle
45697993|NCT03013738|Behavioral|Growing Pro-Social Program|GPS is a structured cognitive-behavioral group program aimed to reduce the prominence of early maladaptive schemas
45697994|NCT03013738|Other|Treatment As Usual|TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
45697995|NCT01880957|Drug|Lithium|
45697996|NCT01880957|Drug|Lamotrigine|
45697997|NCT04152837|Drug|Lixivaptan|Oral vasopressin V2 receptor antagonist
45697998|NCT01064830|Drug|topical cyclosporine ophthalmic suspension 0.05%|apply 2 drops to 2 target fingernails under occlusion daily
45697999|NCT01064830|Drug|vehicle|apply 2 drops to 2 target fingernails under occlusion daily for 20 weeks
45400724|NCT01155934|Drug|Risperidone Orally Disintegrating Tablets|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
45400725|NCT03891628|Behavioral|Modified Attachment and Biobehavioral Catch-up|Intervention targets include enhancing nurturance and following the child's lead, as well as supporting use of kangaroo care, swaddling, and breastfeeding.
45400726|NCT03891628|Behavioral|Modified Developmental Education for Families|Intervention targets include supporting developmental monitoring and parental engagement in activities that promote cognitive and motor development.
45508966|NCT04846907|Other|Web-based survey|Eligible participants received emails or text messages with links to a REDCap-created and managed web-based questionnaire
45508967|NCT04908280|Drug|Ruxolitinib|1.5% cream; Ruxolitinib cream will be applied topically twice daily to areas with active lesions.
45508968|NCT05083936|Drug|[18F]FET|Imaging evaluation using LAT1/4F2hc substrate overexpressed in brain tumor
45508969|NCT01375907|Drug|Rotavin|Rotavin-M1, 10e6.3FFU/dose, 2 doses, 1-month between doses
45596694|NCT05723731|Device|taVNS|"Patients will receive taVNS (device produced by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; amplitude of 0-2 mA at the maximum level that the patient could tolerate; pulse width: 0.5ms)"
45596695|NCT05723731|Drug|Laxative Agent|Bisacodyl or glycerin enemas can be used in patients who do not have a bowel movement for more than 3 days.
45596696|NCT05653791|Diagnostic Test|Intestinal ultrasound|Ulcerative colitis patients treated with filgotinib will undergo intestinal transabdominal ultrasound at baseline, week 4 and at the time of the follow-up endoscopy (week 10-16)
45596697|NCT05723653|Behavioral|Project nGage|"Project nGage (nGage) is an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among young Black sexual minority men. The nGage intervention consists of (1) selection and invitation of a Support Confidant (SC), (2) a face-to-face intervention between the Intervention Case Manager and the Index and SC, and (3) quarterly interactive mini-booster sessions delivered to the Index and SC via text or telephone, based on participant preference."
45596698|NCT02367495|Device|PCB|PCB with Citrate-based excipient
45508970|NCT05083858|Other|Classical Physiotherapy Program + Cervical Stabilization Exercises|First of all, patients will be taught correct craniocervical flexion movement without activation of superficial muscles in different positions (supine, prone, crawling, sitting, standing). The program will be continued by asking to maintain the cranio-cervical flexion position during all movements. In order to gain dynamic stabilization, unilateral, bilateral, contralateral, ipsilateral and reciprocal extremity movements will be added to the program together with craniocervical flexion movement. Resistance will be added to the exercises as control of the movement is achieved. The exercises will progress from static to dynamic, from stationary floors to moving floors, from simple movements to complex movements.
45508971|NCT05083858|Other|Classical Physiotherapy Program + Oculomotor Exercises|Oculomotor Exercises is a program consisting of exercises that support proprioception in the cervical region. It consists of 4 main contents; Sacadic Eye movements, Gaze stability, Head/eye coordination, Head repositioning exercise.
45508972|NCT05083858|Other|Classical Physiotherapy Program|"Conventional TENS will be applied to apply analgesic current. TENS application will be made to the cervical paravertebral region, using four 5 x 5 cm adhesive surface electrodes, at 80 Hz frequency for 20 minutes, 100 msec.~All participants will be asked to lie in a prone position. The neck will be in a neutral position. The hot pack will be applied to the cervical region for 20 minutes.~Classical massage will be applied for 20 minutes using the Swedish technique. The technique will be performed on the upper and neck region of the back with 3 strokes, 3 kneading and 3 strokes. The patient will be massaged while lying in the prone position.~Stretching/Posture Exercises Exercises will be applied as a 5-10 minute warm-up-cool-down program at the beginning and end of the study. Cervical flexor, lateral flexor, rotator muscles, pectorals, inferior shoulder joint capsule will be stretched. In addition to this, posture exercises will also be done."
45508973|NCT01369667|Dietary Supplement|Vitamin D3|
45508974|NCT01369667|Other|Placebo|
45508975|NCT05083702|Procedure|Fluoroscopy-guided superior hypogastric plexus block transdiscal approach|Patient lies prone, L5-S1 interspace identified under fluoroscopy, the skin is prepared and sterile drapes are placed after local anesthetic infiltration of the skin the subcutaneous tissue with 2% lidocaine a 20 guage, 15 cm needle with short bevel is inserted at the center of L5- S1 interlaminar space under anteroposterior fluoroscopic vision. The needle is then advanced toward the intervertebral disc. After confirmation, the needle is advanced through the intervertebral disc until it exists at its anterior surface confirmed by administration of 4 ml of soluble contrast media in both lateral and anteroposterior fluoroscopic view. Neurolysis is performed with 8 ml 8 % phenol solution. After neurolysis, 0.5 ml of saline is given to avoid the deposition of phenol within the intervertebral disc material. While withdrawing, the needle cephazoline 50 mg in 1 ml is injected into the disc.
45508976|NCT05083702|Procedure|ultrasound-guided superior hypogastric plexus block|Patients are placed in the supine position and after sterilization, the low-frequency curved probe is used in the longitudinal axis to visualize the aortic bifurcation and is identified using a longitudinal Ultra-Sound (Phillips Healthcare, Andover, Massachusetts, US). Next, the probe is placed deeply transverse till aorta end and bifurcation seen of iliac vessels once seen we enter out of plane and inject.as it lies in front the vertebral body of the L5 vertebra. Local infiltration with 1% lidocaine is obtained at port of entry 1-1.5 inches below the umbilicus. A 15-cm, 22-G Chiba needle is inserted (out-of-plane) and advanced by avoiding vascular structures until contact with the L5-body. The needle will be withdrawan the 1-2 mm and inject 8 ml 8% phenol in saline. Finally, 0.5 ml of lidocaine is injected during Chiba needle removal
45508977|NCT03564912|Drug|Capecitabine Oral Tablet [Xeloda]|2 week group: capecitabine 1000mg/m2 d1-10; oxaliplatin 85mg/m2; q2w 3 week group: capecitabine 1000mg/m2 d1-14; oxaliplatin 130mg/m2; q3w
45508978|NCT05078593|Drug|HLX26|Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
45508979|NCT05083624|Behavioral|rehabilation therapy|After comprehensive assessment by doctors, nurses and rehabilitation therapists, patients gradually begin rehabilitation treatment.IMS 0: no mobilisation or passively exercised by staff. IMS 1: sitting in bed and actively exercising .IMS 2: passively moved to chair without standing.IMS 3: sitting over edge of bed.IMS 4: standing in front of bed.IMS 5: transferring bed to chair.IMS 6: marching on spot.IMS 7: walking with assistance of more than one person.IMS 8: walking with assistance of one person.IMS 9: walking independently with a gait aid.IMS 10: walking independently without a gait aid.
45508980|NCT01369901|Behavioral|A functional exercise program|
45508981|NCT01369901|Behavioral|A stretching exercise program|
45596699|NCT02363829|Drug|Nelfinavir|
45596700|NCT02363829|Biological|Cisplatin|
45596701|NCT03528889|Procedure|Femoral Extension and Derotation Osteotomy (ExtFDO)|Correction of malrotation of the femoral bone and flexed knee gait by osteotomy, derotation and osteosynthesis
45596702|NCT03113019|Biological|Immunotherapy based on dendritic cells|Intravenous injection of cells
45596703|NCT03528811|Diagnostic Test|Five points test of Tongji university|"In each group, we will evaluate the microcirculation of diabetic foot using the newly-established Five points test of Tongji university before or after the operation, and then compare the temperature of the five points with the other data."
46059131|NCT04304573|Diagnostic Test|Total serum calcium blood test|Total serum calcium measurements will be done on the first postoperative day. Also ionized calcium, corrected total serum calcium for serum albumin with Payne's formula and PTH will be monitored.
45698002|NCT01879553|Biological|TIV|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, egg-derived)
45698003|NCT01115452|Drug|5% Potassium nitrate|5% potassium nitrate solution
45698004|NCT01115452|Drug|2.5% Potassium nitrate|2.5% potassium nitrate solution
45400727|NCT03891550|Drug|Epclusa|sofosbuvir (SOF) 400 mg/Velpatasvir(VEL) 100 mg fixed-dosage combination once-daily for 12 weeks for all HCV genotype patients with and without hepatic decompensation
45400728|NCT01152658|Biological|PRGF|enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control in the ssp gap
45400729|NCT01152658|Other|NACL|Nack 0.9 5 will be then injected to the control group group in sterile conditions under ultrasound control
45400730|NCT01261156|Drug|E5555 100 mg and diltiazem|E5555 single 100 mg oral dose in Treatment Period 1 Day 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
45508982|NCT01567969|Behavioral|Intensive In-home Child and Adolescent Psychiatric Service|A six to seven month intensive intervention provided by a clinical team consisting of a master's-level clinician and a bachelor's-level mental health counselor delivering comprehensive psychiatric and case management services in the child's home. One or both members of the team works with the child and the family three times a week in the home. Delivery of direct and indirect services average 5.5 hours of service per week.
45508983|NCT01567969|Behavioral|Home-based Child Treatment Coordination|A six to seven month home-based case management service delivered by a master's level clinician. The coordinator meets with the child's parent/legal guardian in the child's home once a month and conducts weekly phone conversations to facilitate referral and access to appropriate mental health services for the child.
45508984|NCT03551626|Drug|Dabrafenib|Supplied as dabrafenib 50 mg, 75 mg Capsules for oral use
45508985|NCT03551626|Drug|Trametinib|supplied as trametinib 0.5mg, 2.0mg tablets for oral use
45508986|NCT03565146|Device|PiQo4 Laser System|PiQo4 Laser System for treatment of pigmented lesions
45508987|NCT05353686|Drug|Placebo|Subjects in the placebo arm will receive an oral tablet containing no active drug twice daily
45508988|NCT05353686|Drug|XEN-D0501|Subjects in the XEN-D0501 arm will receive an oral tablet containing 4 mg/tablet of IMP twice daily
45508989|NCT05760053|Drug|EP/EC+PD-1|Toripalimab 240 mg, administered on the first day of each cycle, and a cycle of administration every 3 weeks. Etoposide 100mg/m2, d1-3, cisplatin 25mg/m2, d1-3 or carboplatin AUC=5 d1, administered on the first day of each cycle, a cycle of administration every 3 weeks. Toripalimab combined with etoposide and cisplatin/carboplatin was used for 4 to 6 courses of treatment.
45508990|NCT03509116|Other|Observations|Consultation observations
45508991|NCT03509116|Other|Interviews, key stakeholders, documents|Qualitative interviews, key stakeholders, documentary analysis
45508992|NCT03121157|Behavioral|Multi-Component Technology Based Intervention|The intervention group receives two sessions of computer-delivered MI via software programmed to target adherence to medications and text messaged adherence reminders between sessions. Sessions are provided by an avatar. The intervention engages the youth with the avatar's communication of empathy, optimism, and autonomy support. The intervention focuses the youth on adherence and relevant health behaviors with feedback on adherence, asthma symptoms, and tailored education. Participants are guided in the planning process through goal setting activities. The length of the intervention sessions are about 30 minutes each, with the total duration of the visit (assessment and intervention) lasting about 1.5 hours.
45508993|NCT03505060|Biological|DNA CON-S env|Administered by intramuscular injection in the deltoid.
45508994|NCT03505060|Biological|IHV01|Administered by intramuscular injection in the deltoid.
45698005|NCT01115452|Other|Sterile water|Sterile water
45698006|NCT04126551|Other|Methylation status|Participants will be recruited, and muscle biopsies will be obtained for methylation analyses and measuring mitochondrial function
45698007|NCT01890785|Drug|Lisdexamfetamine Dimesylate|Single dose of a 70 mg capsule on Day 1
45698008|NCT03582891|Device|Summit RC+S for Motor|Using the RC+S pulse generator, investigators will measure cortical biomarkers of hyper and hypokinesia in Parkinson's and dystonia patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
45698009|NCT03582891|Diagnostic Test|8-week pilot trial of Closed-loop vs. Open-loop Stimulation|These patients will participate in an 8 week clinical trial of open loop versus adaptive mode (4 weeks for each mode (interleaved), with the order counterbalanced across subjects ).
45698010|NCT03582891|Device|Summit RC+S for Sleep|Using the RC+S pulse generator, investigators will measure cortical biomarkers of sleep stages in Parkinson's patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
45400731|NCT01261156|Drug|E5555 300 mg and diltiazem|E5555 single 300 mg oral dose in Treatment Period 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
45400732|NCT03884530|Drug|Ticagrelor (Brilique) 90|Drug name Brilique 90 ml Drug form tablet
45400733|NCT03884530|Drug|Aspirin 75mg|Drug name Aspirin 75 ml Drug form tablet
45400734|NCT05477680|Device|Navigation-guided surgery|Surgeon removes brain lesions and assesses brain shift with neuronavigation
45400735|NCT03887338|Other|Transnasal Fiberoptic Laryngoscopy|Use of Transnasal Fiberoptic Laryngoscopy during NIV titration to optimalize the NIV settings to laryngeal responses during the NIV treatment.
45400736|NCT03884062|Drug|DAAs|lab, U/S, Fibroscan & CT if needed
45400737|NCT03891316|Diagnostic Test|HFIP and Sevoflurane are measured after 3 consecutive days of work.|Concentration of hexafluoroisopropanol and Sevoflurane are measured in urine by gas chromatography
45400738|NCT03887260|Drug|Morphine PCA pump|Morphine given postoperatively.
45400739|NCT03887260|Procedure|ESP block|Regional anaesthesia technique performed under ultrasound guidance before surgery
45400740|NCT03887260|Drug|Fentanyl|Fentanyl administration during procedure, calculated per patient's weight and duration of surgery (minutes).
45400741|NCT03891004|Procedure|Subcuticular Skin Closure|We will only close the subcuticular layer with suture
45400742|NCT03891004|Device|Tissue Adhesives|No subcuticular closure will be done. Only tissue adhesives applied to the approximated skin
45508995|NCT03505060|Biological|Placebo|Sodium Chloride for Injection, USP 0.9%; administered by intramuscular injection in the deltoid.
45508996|NCT03500614|Behavioral|Air cleaner use method 1|All interventions in the first cohort will start at noon on Tuesday or Thursday and continue to the next morning of Tuesday or Thursday.
45508997|NCT03500614|Behavioral|Air cleaner use method 2|All interventions in the second cohort will start from the beginning to the end of smog episodes.
45508998|NCT03495700|Procedure|L-PRF block|The use of the L-PRF block as graft material for sinus augmentation procedure will be analysed
45508999|NCT03495700|Procedure|DBBM|The use of bovine xenograft will be analysed
45509000|NCT04811170|Other|Counselling|Participants with mild to moderate mood symptoms will receive a maximum of 6 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W8), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention. Participants with severe mood symptoms will receive a maximum of 10 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W12), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention.
45400743|NCT03891082|Procedure|B-Lynch|A 70 mm round bodied hand needle on which a No. 2 absorbable suture is mounted is used to puncture the uterus 3 cm from the right lower edge of the uterine incision and 3 cm from the right lateral border. The mounted No. 2 absorbable suture is threaded through the uterine cavity to emerge at the upper incision margin 3 cm above and approximately 4 cm from the lateral border
45509001|NCT03118739|Drug|Verinurad 9 mg+Febuxostat 80 mg|Capsule administered orally, once daily for 24 weeks
45509002|NCT03118739|Drug|Placebo|Capsule administered orally, once daily for 24 weeks
45509003|NCT03181126|Drug|Navitoclax|tablet
45509004|NCT03181126|Drug|Chemotherapy|peg-asparaginase (or other form of asparaginase, per local standard of care (intravenous) + vincristine (intravenous) + dexamethasone (oral) + tyrosine kinase inhibitor (TKI) (if applicable, oral)
45509005|NCT03181126|Drug|Venetoclax|tablet
45698011|NCT03571971|Other|Load modification education|Load modification education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities, but will also include education on common daily postures and movement patterns that may increase load and stress on the muscles and tendons around the hip.
45698012|NCT03571971|Other|Standard exercise education|Standard exercise education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities.
45400744|NCT03891082|Procedure|BALLOON INSERTION|Insert the balloon portion of the catheter in the uterus; making certain that the entire balloon is inserted past the cervical canal and internal ostium. NOTE: Avoid excessive force when inserting the balloon into the uterus. Place a Foley catheter in patient bladder to collect and monitor urine output. To ensure maintenance of correct placement and maximize tamponade effect, the vaginal canal may be packed with iodine or antibiotic soaked vaginal gauze at this time.
45509006|NCT03157492|Behavioral|Aural Rehabilitation Group|Participants will complete sessions in their home or office via the internet. Sessions will include listening activities, informational counseling and communication strategies training. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with a cochlear implant.
45509007|NCT03157492|Behavioral|Cognitive Training Group|The Cognitive Training Group will receive six 90-minute sessions including training exercises (Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Difference) to improve speed and accuracy. Three assessment sessions are also required.
45509008|NCT03146338|Other|Magnesium-rich mineral water (Rozana)|intakes of 1.5 L by day
45509009|NCT02995889|Device|FLT-PET|
45698013|NCT03306862|Dietary Supplement|Whole yellow pea soup|Soup containing whole yellow peas
45698014|NCT03306862|Dietary Supplement|Split yellow pea soup|Soup containing split yellow peas
45698015|NCT03306862|Dietary Supplement|Potato soup|Soup containing potatoes
45698016|NCT03564015|Other|Smartphone app|Apple or Android app to provide education to guide functional recovery and allow recording of pain, management, and functional outcome using the Activities Scale for Kids performance version (ASKp) at home
45698017|NCT03564015|Other|Paper handout|Paper handout to guide functional recovery. Also includes a version of the smartphone app described above that only allows recording of pain, functional outcome, and management at home.
45698018|NCT04616651|Behavioral|Online Survey|Participants respond to online survey questions either before or after using the Chatbot O2O intervention.
45715271|NCT05189080|Other|Interviews|Interviews will be conducted with a subset of participants to identify the top one or two performing text messages.
45715272|NCT05189080|Other|Survey|Alongside notification text messages regarding no-showed visits, participants will be invited to participate in a survey about their experience with the health system. This survey will assess reasons for missing the WCV and primary caregiver's perspective on the experience at the prior visit.
45400745|NCT01154686|Behavioral|Cogmed|The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. Training is implemented with a software program (RoboMemo©). It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
45400746|NCT03883984|Drug|Cysteamine Bitartrate|Cysteamine bitartrate administered four times per day (QID) for 8 weeks. 125mg tablet QID.
45400747|NCT03883984|Drug|Placebo Oral Tablet|Placebo administered for 8 weeks. 125mg tablet QID.
45509010|NCT03141502|Device|Skin stretching device (SSD)|By making use of skin viscoelasticity, the special metal crochet of SSD would be embedded in both sides skin of the wound. Multiple cycles of stretching and relaxing wound lead to extended skin, changing the high tension incision into a low tension incision and facilitating the direct suture.
45509011|NCT03141502|Procedure|Skin grafting|the standard technique of skin grafting after wound preparation.
45509012|NCT04477252|Device|App-core|"Farmalarm App of the Inmovens group - Vall d´Hebrón Hospital will be used, adapted and updated by the main researcher. The App will have the rehabilitation option where the user can consult the description of the exercise and view a demonstration video so that it can be carried out correctly at home, independently or with help. The administrator therapist of the App has the permission to create users, contact them directly through chat or video-call and personalize the exercise program.~The exercises that will be carried out in this study phase, are described in previous studies by the author Rosa Cabanas et al. All possible exercises will be included in the administration platform, and according to of each user, the prescription of some exercises or others will be made."
45509013|NCT04477252|Other|Conventional physiotherapy|Conventional physiotherapy is considered neuromotor development therapy as the most frequently used therapy in the management of stroke patients and in the center where the study is performed.
45509014|NCT05139875|Drug|Betamethasone Dipropionate / Betamethasone Sodium Phosphate|Single intra-articular Betamethasone Dipropionate / Betamethasone Sodium Phosphate (Diprospan) injections to affected knee
45509015|NCT05139875|Drug|Triamcinolone Acetonide 40mg/mL|Single intra-articular Triamcinolone Acetonide injections to affected knee
45509016|NCT03094195|Drug|EMA401|EMA401
45849950|NCT03306576|Device|ELS Extra composite|One of the teeth will be restored using ELS composite. Procedures will be done under local anesthesia if necessary. The preparation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
46059132|NCT02581735|Other|Patients with haemophilia|"Using the platform Upatient, patients with hemophilia will register for one year, the prophylactic treatment who receive at home. Likewise, they indicate a replacement therapy as a result of joint bleeds.~At baseline, a month, 6 months and at the end of the study, patients shall complete two questionnaires. The same way in the initial evaluation and end of the study, the clinical joint status will be evaluated with HJHS scale ."
45509017|NCT03094195|Drug|Placebo|Placebo
45509018|NCT03140410|Other|Antibiotic resistance|"Test for susceptibility to linezolid using phenotypic tests, according to guidance from EUCAST group.~Screening for the presence of crf gene, and mutations associated"
45509019|NCT05759975|Device|Photobiomodulation therapy (intraoral)|Intraoral photobiomodulation therapy (660nm, 100mW, 10 J/cm 2 , 3 s/point) for the management of oral side effects related during hematopoietic stem cell transplantation (HSCT). Mainly in the decrease of oral OM rates and OM severity, healing of OM ulcers and pain relief. Second, evaluate quality of life,hyposalivation/xerostomia, functional evaluation and dysfagia, in the arm. All results obtained in the group will be compared with the other arm.
45509020|NCT05759975|Device|Photobiomodulation therapy (extraoral)|Extraoral photobiomodulation therapy (810 + 980 nm, 1 W, 6.11 J/cm2 , 30 s/point) for the management of oral side effects related during hematopoietic stem cell transplantation (HSCT). Mainly in the decrease of oral OM rates and OM severity, healing of OM ulcers and pain relief. Second, evaluate quality of life,hyposalivation/xerostomia, functional evaluation and dysfagia, in the arm. All results obtained in the group will be compared with the other arm.
45509021|NCT04799548|Drug|Transcatheter Arterial Chemoembolization|"Patients will sequentially receive one cycle TACE (3 weeks), one cycle SOX regimen (3 weeks), one cycle TACE (3 weeks) and one cycle SOX (3 weeks) regimen, a total of 12-week neoadjuvant therapy.~TACE cycle: Day 1: trans-femorally performed with infusion of oxaliplatin (85 mg/m2) into tumor blood vessels. Then, Embosphere® Microspheres (300-500 μm) will be injected for embolism. Day 1-14: Oral Tegafur Gimeracil Oteracil Potassium Capsule 40-60 mg bid.~SOX cycle: Day 1: Oxaliplatin 130mg/m2 intravenous. Day 1-14: Oral Tegafur gimeracil oteracil potassium capsule 40-60 mg bid."
45509022|NCT04799548|Drug|Tislelizumab|PD-1 antibody Tislelizumab will be administrated by 200mg, ivgtt, q3w throughout 12-week neoadjuvant treatment.
45509023|NCT05083234|Other|Moisturizing with SSO|Vital signs of newborns in the sunflower seed oil group were measured. The skin of newborns in the sunflower seed oil group was wiped without rubbing. The skin of newborns in the sunflower seed oil group was evaluated with the NSCS scale.
45849951|NCT03306576|Device|ELS composite|the other teeth will be restored with a ELS resin composite with ordinary restorative techniques.
46059133|NCT04667117|Biological|Quadrivalent influenza vaccine|2020-2021 inactivated quadrivalent influenza vaccine
45509024|NCT05083234|Other|Moisturizing with LV|Vital signs of newborns in the liquid vaseline group were measured. The skin of newborns in the liquid vaseline group was wiped without rubbing. The skin of newborns in the liquid vaseline group was evaluated with the NSCS scale.
45509025|NCT05083234|Other|The control group was not moisturized.|Vital signs of newborns in the control group were measured. The skin of newborns in the control group was wiped without rubbing. The skin of newborns in the control group was evaluated with the NSCS scale.
45509026|NCT01375985|Drug|AVI-7100|Single intravenous administration
45400748|NCT03886870|Behavioral|Lifestyle and work intervention|"The intervention period lasted for a year with three institution-based stays, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan. At all three stages: The intervention contains activity training with a focus on the joy of movement, strength- and cardio-training. There were lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. Exercise programs was designed to use at home. The Cognitive Information Processing model of career guidance was the mainframe for the work dimension. All participants had talks with the work consultant at baseline, 6 and 12 months. Two work lectures, Duties and rights as employees and Work as medicine. When needed the work consultant contacted the employer in order to facilitate changes."
45509027|NCT01375985|Drug|Placebo|Single intravenous administration
45509028|NCT05391295|Other|Short daily questionnaire|This study includes 1 survey that needs to be filled out by the patient on his/her phone daily during the course of corticosteroid treatment. The investigators will start the survey few days before the corticosteroid treatment and it will continue till the end of the treatment regime. The treatment regime is regular care and patient specific, but will approximately have a duration of 40 days. In case of prolonged treatment with steroids it is decided to have a limit for our study: either until 7 days after the end of corticosteroid treatment or a maximum of 60 days.
45509029|NCT05384821|Drug|Vincristine|IV, D1-D22-D43 and D64
45400749|NCT03886870|Behavioral|Lifestyle intervention|"The intervention period lasted for a year with three institution-based stay, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan.~At all three stages: The intervention contains activity training with focus on joy of movement, strength- and cardio-training. There was lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. They developed exercise programs designed to use at home."
45509030|NCT05384821|Drug|Irinotecan|Oral, 5 days/week during W1,W2,W7 and W8 (D1 to D5, D8 to D12, D43 to D47, D50 to D54)
45509031|NCT05384821|Drug|Temozolomide|Oral,3 weeks in a row, twice per cycle (D1 to D21, D43 to D63)
45509032|NCT05384821|Drug|Etoposide|Oral, 3 weeks in a row, twice per cycle (D22 to D42, D64 to D84)
45509033|NCT05384821|Drug|Cis-Retinoic acid|Oral, 2 weeks in a row, thrice per cycle (D15 to D28, D43 to D56, D71 to D84)
45509034|NCT01376063|Drug|FG-4592|"FG-4592 on days 3,5,7,9~Rosiglitazone maleate on days 1 and 9"
45509035|NCT02893150|Behavioral|TAU|"TAU (Treatment as Usual), individuals presenting with overweight (BMI of 25 kg/m ² to 29.9 kg/m ²), but without comorbidities, teams of primary care (PC) organized care plans to return to the track of normal BMI (BMI of 18.5 kg/m ² to 24.9 kg/m ²).~For those who have comorbidities such as hypertension and diabetes, in addition to including individuals in group activities, evaluates the need for individual dietary prescription by the nutritionist. This decision is discussed among the team of PC and Matrix support team"
45400750|NCT03890926|Radiation|radioactive Iodine-125 seed implantation under the guidance of 3D template|3D-PNCT assisted with CT-guidance for radioactive Iodine-125 seed brachytherapy is a conventional treatment for patients with local recurrent rectal carcinoma. Retrospective data on the effectiveness and adverse effects of the past radioactive Iodine-125 seed implantation is collected.
45400751|NCT03883672|Behavioral|Personality and transactional factors|"Pre-admission transplant questionnaire: given and collected by the transplant physician during the pre-graft consultation before entering hospitalization (approximatively 15 days before). To be completed by the patient on site (approximately 45 minutes to complete the questionnaire)~Transplant admission questionnaire: given during the first days of hospitalization. To be completed within 6 days and returned to the transplant physician (approximately 30 minutes to complete the questionnaire)~Post-transplant follow-up questionnaire: given in consultation at 6 months by the transplant physician (between 30 and 45 minutes to complete the questionnaire in consultation)"
45509036|NCT02893150|Behavioral|TAU+MBHP|"TAU (Treatment as Usual) + MBHP. We used a general (general vulnerability, not specific) mindfulness-based intervention (MBI) developed by our research group, an 8-week-group-based MBI called Mindfulness-Based Health Promotion (MBHP) program . It is based on the original model developed by Jon Kabat-Zinn and colleagues (MBSR), and subsequently adapted by our research group in order to fit it better into the context and needs of Primary Care (PC) and national and local Health Systems, which has been applied by the Center Mente Aberta in Brazil (www.mindfulnessbrasil.com), and by the University of Zaragoza, in Spain (www.webmindfulness.com). One of the sessions (the sixth one) is developed in silence, with the goal of deepening the mindfulness practice; more feasible to be implement in health services and facilities"
45509037|NCT02893150|Behavioral|TAU+MB-EAT|TAU (Treatment as Usual) + MB-EAT (mindfulness-based eating awareness training). Adapted from the MBSR, Mindfulness-based Eating Awareness Training (MB-EAT) or awareness training. This program was specially developed for the compulsive eating disorders and related problems[47]. In addition the four main techniques of meditation mentioned in the MBHP program includes modifications to these basic techniques, and include experimentation with different flavors, sweet and savory foods, etc. Has 10 weekly sessions of 2,5h
45509038|NCT05759897|Drug|HRS-7535|HRS-7535
45509039|NCT05759897|Drug|Placebo|Placebo
45698019|NCT04616651|Behavioral|Chatbot prototype|An online, automated, menu-based agent in which all responses are pre-programmed to be consistent with the existing O2O program. The chat-like responses help guide the participant through a process with the goal of developing a list of questions for their upcoming appointment with a cancer clinician. The session is meant to be completed in one sitting and estimated to take about 45 minutes to complete (including the pre- or post-intervention survey); however, if a participant stops in the middle, they may go back and complete the Chatbot session (or survey).
45400752|NCT01586494|Drug|ULTRAM ER|One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
45400753|NCT01586494|Drug|ULTRAM ER|The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
45400754|NCT03886948|Drug|LY3074828|Administered subcutaneously (SC)
45400755|NCT03886948|Device|PFS|PFS used to administer LY3074828
45400756|NCT03886948|Device|AI|AI used to administer LY3074828
45400757|NCT02527330|Other|MR T2* imaging|Cardiac magnetic resonance imaging with T2* imaging
45400758|NCT01259362|Procedure|Transcranial Magnetic Stimulation|5 Hz, 120 % motor threshold, intertrain interval 20s, number of pulses in train 50.
45400759|NCT01259362|Procedure|Transcranial Magnetic Stimulation|Cocaine addicted will receive 20 sham TMSr
45400760|NCT03886792|Behavioral|Triggered reinforcement|This group will participate in a home-based experimental intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray secured anterior to the trunk. This intervention will involve reinforcement of biceps muscle activation in the affected arm if the infant generates a muscle contraction above a pre-set threshold (V). The threshold needed to trigger a toy to move and make sounds (reinforcement) will be set at baseline as determined by surface electromyography (SEMG). During the training time-points, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
45509040|NCT03981497|Procedure|Microwave ablation (MWA)|Thermal ablation
45509041|NCT04097743|Behavioral|Coping Statement|Daily practice of coping statement
45509042|NCT04754074|Behavioral|Education|Weekly education related to behavior change
45400761|NCT03886792|Behavioral|Social interaction|This group will participate in a home-based dose-equivalent control intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray. This control program will combine social interaction between infant/parent with the opportunity for self-initiated play with toys repeatedly placed on the tray. A toy will be placed in front of the infant seat and tray but it will not be connected to the SEMG unit nor will the infant have an SEMG electrode attached over the biceps. During the intervention, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
45400762|NCT03684070|Behavioral|Self-Monitoring, peer support and motivational prompts|The intervention compares the effect of technologically delivered motivational messages, and peer support upon daily step counts.
45400763|NCT03684070|Behavioral|Self-monitoring|Self-monitoring of data from wearable step count tracker
46059134|NCT04667117|Drug|Ofatumumab|"Auto-injector containing 20 mg sc ofatumumab (20 mg/0.4ml) for subcutaneous administration.~Novartis will supply participants in Cohort 1 with ofatumumab treatment in the Investigational Period and the optional 6-month Extension Period.~Participants in Cohort 2 will continue on their commercially prescribed ofatumumab treatment during the Investigational Period. Novartis will supply participants in Cohort 2 with ofatumumab treatment in the optional 6-month Extension Period."
45400764|NCT03891238|Drug|Avelumab|Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).
45400765|NCT01261234|Drug|Cilostazol or Non-Cilostazol|Cilostazol group administrate 100-200mg/day per oral, unrestricted use of other antiplatelet agents and concomitant drugs.
45400766|NCT01152736|Drug|Nicotine|2 mg Single-dose
45400767|NCT01154764|Drug|CG100649|I period: CG 100649 single dose 6 mg II period: Ketoconalzole + CG100649 at the same time washout period: 42 days
45400768|NCT01154764|Drug|CG100649 and ketoconazole|I period: ketoconazole 400 mg + CG100649 6 mg II period: CG 100649 single dose 6 mg washout period: 42 days
45400769|NCT05092750|Device|FerroTraceTM|A magnetic
45400770|NCT05092750|Drug|indocyanine green (ICG)|Given by SC injection
45400771|NCT01262794|Biological|CDP6038|100 mg/mL solution for injection, single dose
45400772|NCT01262794|Biological|Placebo|0.9% sodium chloride for injection Single-dose
45400773|NCT03883438|Procedure|Modified coronally advanced flap and acellular dermal matrix graft|Evaluation of the effectiveness of vertical incisions in the management of multiple gingival recessions (Miller Class I&II ≥3 mm) treated with coronally advanced flap and acellular dermal matrix graft
45400774|NCT01261468|Device|Active SCS|SCS IPG activated
45509043|NCT04754074|Behavioral|Personalized coaching|Weekly calls with personalized coaches in behavior modification, nutrition, and physical activity/exercise.
45509044|NCT04754074|Behavioral|Weekly behavior modification challenges|Weekly challenges to address behavior change
45509045|NCT02851121|Other|Sensorial stimulations|
45509046|NCT02851121|Other|Experimental protocols|
45509047|NCT02851121|Behavioral|Emotional protocols|
45509048|NCT02851121|Other|Protocol with a spatial dimension|
45509049|NCT05039047|Other|Standard stroke acute care and rehabilitation|According to Swiss national guidelines and local protocols
45596704|NCT02363673|Other|Individualised homoeopathic remedy in aqua distilla|Each participant is to receive an individualised homoeopathic remedy according to their symptoms and characteristic manifestations of their disorder.
45596705|NCT03527329|Device|WarmTouch Model 5900, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied following routine clinical practice. The pre-warming time will depend on the time the patient has to wait before entering in the operating room. Prewarming time will be recorded for each patient.
45596706|NCT02367261|Device|SPI implant|SPI implant - the original spiral implant
45400775|NCT01261468|Device|Deactivated|SCS IPG deactivated
45509050|NCT04741594|Device|Densah|Alveolar bone remodeling after tooth extraction may result in significant ridge resorption and inadequate bone volume for implant placement. Several methods have been designed for ridge augmentation, among which is the new technique of osseodensification, using the Densah® burs by Versah® (Versah®, LLC, Jackson, MI, USA). This method compresses the trabecular bone to periphery of the osteotomy site and has shown up to 80% ridge expansion in animal histological studies , , , , , . Apart from being an animal model with a short follow-up, another limitation of these studies is the lack of three-dimensional evaluation of the change in morphology of the ridge. Human clinical studies , , , , have reported similar results, but they do not evaluate if this bone volume is retained during osseointegration and loading periods. No standardization method or long-term evaluation of peri-implant health was reported.
45509051|NCT05029687|Behavioral|Youth-Led Hypertension Education Digital Intervention|The intervention is a youth-led HTN education digital intervention, which will be comprised of a 6-week playlist of one module per week comprising the playlist. Youth will learn from the module and will teach the adult in their dyad about hypertension education in each week's themed module.
45509052|NCT05029687|Behavioral|Job Readiness/Non-Hypertension Digital Modules|"For ED dyads that are randomized into the control arm, the youth will complete job readiness digital modules. These will include Career & Job Readiness digital badge playlists, with such playlists as, Interview Preparation, Resume Ready, and Professionalism. While this group may complete multiple digital badges, the total time needed to complete the badges will be approximately equivalent to that of the intervention group (eg. one hour per week for each arm). This arm will not be available in the school cohort, as all participants will be given the intervention."
45509053|NCT02654080|Biological|HIV-1 nef/tat/vif, env pDNA vaccine|1500 mcg to be administered as 0.5 mL intramuscular (IM) in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device
45509054|NCT02654080|Biological|rVSV HIV envC vaccine|1 × 10^7 PFU to be administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)
45509055|NCT02654080|Biological|Placebo|"Sodium Chloride for Injection, USP 0.9%;~At Months 0, 1, and 3: administered as 0.5 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device.~At Months 6 and 9: administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)."
45509056|NCT05375305|Drug|SHR8554 Injection|SHR8554 Injection; high dose
45509057|NCT05375305|Drug|SHR8554 Injection|SHR8554 Injection; low dose
45509058|NCT05375305|Drug|Saline Solution|Saline Solution
45509059|NCT05375305|Drug|Morphine|Morphine
45698020|NCT04616651|Behavioral|Open to Options (O2O) Program|Evidence-based program developed by Cancer Support Community that helps patients actively engage in their treatment decision process by preparing them for their upcoming appointments.
45698021|NCT01066624|Drug|0.9% Sodium Chloride irrigation solution|Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study
45400776|NCT01262950|Other|portable motion detector|
45400777|NCT03890848|Behavioral|Wechat application reminder intervention|precautions and rehabilitation progress reminders and other news by optimized WeChat applet regularly
45400778|NCT03890848|Behavioral|routine guidance during discharge|rehabilitation exercise guidance during routine discharge
45400779|NCT03890692|Procedure|flexible nasoendoscopy|"nasopharyngeal endoscopy : After washing nasal cavities with a sterile physiologic solution to remove secretions or scabs, and decongesting them with an oxymetazoline solution in the subjects with turbinate hypertrophy,~Endoscopy will be performed by passing the endoscope along either the floor of the nose or just under the middle turbinate. the condition of the nasal mucosa\ septum\ turbinates and the presence of discharge The postnasal space will be assessed . All abnormalities will be recorded .the images will be recorded and assessed separately by two independent otolaryngologists"
45400780|NCT01259518|Drug|TRIN2755|In treatment schedule A (Group A), the planned starting dose to be investigated is 25 mg TriN 2755 given once followed by a recovery period of 4 weeks. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after infusion (end of Cycle 1) does not indicate relevant toxicity.
45400781|NCT01259518|Drug|TRIN2755|In treatment schedule B (Group B), the starting dose to be investigated is 800mg, given once every 7 days in a 4 week cycle. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after the start of the first infusion (end of Cycle 1) does not indicate relevant toxicity.
45400782|NCT01156168|Genetic|DNA analysis|
45400783|NCT01156168|Genetic|gene expression analysis|
45400784|NCT01156168|Genetic|polymorphism analysis|
45400785|NCT01156168|Genetic|protein expression analysis|
45400786|NCT01156168|Other|immunohistochemistry staining method|
45400787|NCT01156168|Other|laboratory biomarker analysis|
45400788|NCT01261546|Drug|Dexamethasone|"Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.~Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present~Ranitidine 5 mg/kg IV, q.d. for 2 days~Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days."
45400789|NCT01261546|Drug|Placebo|"Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~Ranitidine 5 mg/kg IV, q.d. for 2 days.~Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days."
45400790|NCT03883360|Drug|Cannabidiol (CBD)|Participants receive a single dose of CBD (600 mg p.o.) per day for 12 weeks.
45509060|NCT05372809|Biological|SkinTE|SkinTE is an Autologous Heterogeneous Skin Construct (AHSC), which is manufactured from a small piece of healthy full-thickness skin harvested from the patient at the time of randomization to the SkinTE arm. SkinTE is manufactured aseptically by PolarityTE following current Good Manufacturing Practice (cGMP). SkinTE is not cultured ex vivo; rather, it is returned to the provider expeditiously to maintain cellular viability. SkinTE includes various multicellular segments as a result of the manufacturing process. The different multicellular segments contain different types of skin cells, such as keratinocytes, dermal fibroblasts, dermal endothelial cells, and follicular cells, as well as extracellular matrix. The multicellular segments have a surface area-to-volume ratio for improved sustenance by imbibition prior to engraftment.
45509061|NCT05372809|Other|Control|"Standard care is defined in this protocol to include the following:~Debridement~Collagen-alginate primary wound dressing~Local offloading with felt pad for wounds on weight bearing surfaces~Foam~Multi-layer compression dressing~Off-loading device such as a full-length boot or total contact cast (if full-length boot cannot accommodate the patient) or surgical shoe for ulcers in non-weight bearing locations"
45509062|NCT03140332|Other|Scannographic evaluation of the tumor response performed with mRECIST criteria after 3 months of treatment with sorafenib|To evaluate the association between tumor perfusion criteria (blood flow, blood volume, mean transit time, capillary permeability) at the initial perfusion scan and tumor control according to the mRECIST criteria after 3 months of treatment with sorafenib.
45509063|NCT05082532|Other|Interwoven supera stent (IW; Supera Veritas®; Abbott Vascular, Santa Clara, CA, USA) .|we here conduct a prospective study to evaluate the efficacy and safety of self- expandable nitinol stent especially interwoven supera stent (IW; Supera Veritas®; Abbott Vascular, Santa Clara, CA, USA) in femoropoliteal complex occlusive lesions.
45509064|NCT05079724|Procedure|Cardiac Surgery|About 3.5-31.0% of Patients undergoing cardiac surgery Complains from Postoperative Acute renal injury (AKI) that is a severe complication increasing the risk factor for mortality about 8-folds, The occurrence of AKI in patients undergoing cardiac surgery raises the mortality rate from 0.4-4.4% to 1.3-22.3%; when those same patients require dialysis.
45509065|NCT02835690|Biological|Pembrolizumab|IV infusion
45509066|NCT04629820|Device|Spectacles|Intervention group workers receive free glasses within one week of undergoing vision assessment (September 2021). The assessment period will be three months
45509067|NCT02486224|Dietary Supplement|Kona Deep|Subjects will receive Kona Deep post exercise
45509068|NCT02486224|Dietary Supplement|Spring Water|Subjects will receive Spring Water post exercise
45509069|NCT02486224|Dietary Supplement|Sports Drink|Subjects will receive Sports Drink post exercise
45509070|NCT03564834|Procedure|Laparoscopic gastrectomy|Patients will receive laparoscopic gastrectomy within one week after randomization.
45509071|NCT03564834|Procedure|Open gastrectomy|Patients will receive open gastrectomy within one week after randomization.
45698022|NCT01066624|Other|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion.
45698023|NCT01066624|Device|Calcium phosphate (Caphosol) Ca2+/PO43- mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
45698024|NCT01878383|Device|Genexpert assay|
45698025|NCT04123197|Other|Stress Challenge|The stress challenge will assess how different parts of the body react to stress. Participants will be given no specific details about the contents of the test before administration.
45400791|NCT03883360|Drug|Placebo|Participants receive a single daily dose of the oil vehicle used to dissolve CBD but without any active ingredient, in the same amount as the CBD group, for 12 weeks.
45509072|NCT03564288|Drug|SKI-G-801|SKI-G-801 is administered as an IV infusion over 10 minutes
45509073|NCT02033980|Device|NBI|All detected colorectal lesions will be examined by high-definition NBI. For type 2 and type 3 lesions, subsequent magnifying NBI examination will be performed.
45509074|NCT05352906|Diagnostic Test|Intraocular pressure|Measurements of intraocular pressure in millimeter mercury (mmHg).
45509075|NCT05054920|Other|concentric exercises|concentric exercises for rotator cuff. internal rotators, external rotators and abductors Patient will do 3 sets of 10 repetitions resistance will be personalized to each patients
45509076|NCT05054920|Other|eccentric exercises|Eccentric exercises exercises for rotator cuff internal rotators, external rotators and abductors Patient will do 3 sets of 10 repetitions resistance will be personalized to each patients
45698026|NCT05132907|Biological|HDT-301|HDT-301 Investigational Vaccine (a Nanoparticle Carrier-Formulated Replicon RNA (repRNA-CoV2S))
45698027|NCT04398771|Drug|Rosuvastatin/Valsartan|Rovatitan QD for 12 weeks
45698028|NCT05117151|Diagnostic Test|hypotension prediction index|monitor intraoperative hypotension prediction index as well as hemodynamic variables to exam the ability in predicting hypotension events of each variable
45698029|NCT01067716|Device|STAR S4IR LASIK with VSS-R ablation profile|LASIK treatment targeted for emmetropia
45698030|NCT01863953|Drug|Fixed-Combination Bimatoprost/Brimonidine|One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
45400792|NCT01261702|Drug|Placebo|Normal saline IV
45400793|NCT01261702|Drug|magnesium sulphate|The magnesium group (Group M, n=16) received 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
45698031|NCT01863953|Drug|Bimatoprost Ophthalmic Solution 0.01%|One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.
45509077|NCT05054920|Other|Stretching|stretching exercise for posterior capsule and pectoralis minor each stretch will be done for 30 seconds and repeated 3 times
45509078|NCT03564210|Behavioral|Screen time permitted|Cohort will not be directed to abstain from screen time
45509079|NCT03564210|Behavioral|Screen Time Abstain|Cohort will be directed to abstain from screen time
45400794|NCT01156246|Drug|Dapagliflozin/Metformin|oral fixed dose combination tablet 5 mg Dapagliflozin / 1000 mg Metformin given on day 1 at visit 2 and 3.
45400795|NCT03890770|Drug|BMS-986165|Oral administration
45400796|NCT03890302|Drug|FB704A|Administered by IV infusion
45509080|NCT04496986|Diagnostic Test|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
45509081|NCT04496986|Diagnostic Test|Simultaneous FEES and Videofluoroscopy instrumental swallowing exam|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism. The participant will be asked to perform some voicing tasks, once completed, a videofluoroscopic swallowing exam will occur at the same time. This is like moving x-ray of the participant swallowing foods and liquids (barium).
45509082|NCT04496986|Other|Voluntary Cough Peak Expiratory Flow (PEF) Testing|Cough PEF will be performed to index a participant's physiologic airway defense capacity and strength. Testing will occur with the participant seated upright at 90 degrees using an analog peak flow meter with a one-way expiratory valve that prevents a participant from breathing air in from the device to reduce contamination.
45509083|NCT04496986|Other|Reflex Cough Screen|Participants will be seated upright and administered reflex cough testing via a disposable adult aerosol mask with an attached nebulizer that contains a solution to elicit a cough response.
45509084|NCT04496986|Other|Lingual Pressure Testing|Lingual strength will be evaluated using the Iowa Oral Pressure Instrument (IOPI). Participants will be seated upright, and the SLP will place the IOPI air-filled sensing bulb in the midline anterior position on the participant's tongue, posterior to the alveolar ridge.
45509085|NCT04496986|Diagnostic Test|Speech Testing|"Speech assessment will occur with the participant comfortably seated headset microphone with a lapel windscreen connected to a TASCAM DR40 to allow for high-quality audio recordings. Individuals will be asked to perform two maximal performance speech tasks that include vowel prolongation of /a/, and a Diadochokinetic (DDK) rate task to examine SMR for production of the word buttercup."
45509086|NCT02837952|Drug|FDC IBU/APAP 250 mg/500 mg|FDC IBU/APAP 250 mg/500 mg
45509087|NCT02837952|Drug|Placebo|Placebo
45509088|NCT02832167|Biological|Nivolumab|Specified dose on specified days
45509089|NCT04941040|Drug|Opioid free anesthetics|"Patients will receive over the 10 minutes prior to induction:~Acetaminophen 1 gm i.v. infusion in 100ml over 10 minutes.~Ketorolac 30 mg i.v. infusion in100 ml over 10 minutes.~Mg SO4 loading dose 30 mg/kg i.v. infusion in 100 ml over 10 minutes.~Dexmedetomidine loading dose 1 μg/kg i.v. infusion.~Lidocaine loading dose 1.5 mg/kg i.v. infusion.~Ketamine loading dose 0.25 mg/kg i.v. infusion.~The weight based doses of dexmedetomidine, lidocaine, ketamine will be prepared on 20 ml syringe and infused over 10 minutes prior to induction. In a dose of 0.1 ml/kg~Then after induction maintenance analgesic infusion will start in a rate that ranges from 0.025 to 0.05 ml/kg/h which is equivalent to:~Dexmedetomidine 0.25-0.5 μg/kg/h~Lidocaine 0.375-0.75 mg/kg/h~Ketamine 0.0625- 0.125 mg/kg/h"
45509090|NCT04941040|Drug|Opioid Anesthetics|Placebo equivalent to acetaminophen, ketorolac, magnesium sulphate will be infused as 100 ml normal saline each over 10 minutes ,patients will receive fentanyl 2 μg/kg loading dose which will be prepared over 20 ml syringe and infused over 10 minutes prior to induction, Then after induction maintenance of analgesic infusion by fentanyl 0.5-1 μg/kg/h.
45509091|NCT03632395|Diagnostic Test|computed tomography|computed tomography
45698032|NCT01863953|Drug|Vehicle Ophthalmic Solution|One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
45400797|NCT03890302|Drug|Placebo|Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion
45400798|NCT03886480|Device|SaeboVR|Use of the SaeboVR rehabilitation system for approximately 1 hour, 3 times per week for 4 weeks. Each intervention session will consist of the participant engaging in a series of virtual occupations involving their affected upper extremity and will include a 5 minute warm up activity followed by 3, 15 minute sessions of virtual occupation practice separated by 2, 5 minute breaks. The virtual occupations will include: grocery shopping, grocery storage, breakfast preparation, pet shopping, pet feeding, pet bathing, garden planting, garden harvesting, dinner preparation, closet organizing, and soup kitchen volunteering.
45400799|NCT01261858|Device|Kryptonite|osteoconductive biologic bone cement to be applied upon sternal closure
45509092|NCT04937374|Other|Rehmannia glutinosa leaf extract|One capsule to be taken after breakfast.
45509093|NCT04937374|Other|Microcrystalline Cellulose (MCC)|One capsule to be taken after breakfast.
45509094|NCT05708430|Drug|SVF injection into wrist|Intra-articular injection of autologous cells from the stromal vascular fraction derived from adipose tissue
45509095|NCT04936516|Device|Endotracheal intubation|Endotracheal intubation using either McGrath or C-MAC video laryngoscopy
45509096|NCT00913705|Drug|Neoadjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21-day intervals. Prior to surgery.
45509097|NCT00913705|Drug|Adjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21 days interval. Post-surgery
45509098|NCT00913705|Procedure|Surgery|Surgery
45509099|NCT04934410|Drug|Etomidate|Use of etomidate during induction as decided by attending anesthesiologist
45509100|NCT04934410|Drug|Midazolam|Use of midazolam during induction as decided by attending anesthesiologist
45509101|NCT04934410|Drug|Sevoflurane|Use of sevoflurane during induction as decided by attending anesthesiologist
45698033|NCT01863953|Drug|Brimonidine Tartrate Ophthalmic Solution 0.2%|One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
45698034|NCT03287453|Other|Educational Intervention|View an inflatable colon interactive exhibit, PowerPoint presentation, flip books, and flipcharts
45698035|NCT03287453|Other|Survey Administration|Ancillary studies
45400800|NCT03886636|Other|neuroscience pain education|A total of 4 NPE (Neuroscience paine education) sessions were held, once each week, before an MT session. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, one-on-one sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
45509102|NCT02787239|Drug|HLX01|
45509103|NCT02787239|Drug|Rituximab|
45509104|NCT02787239|Drug|CHOP|
45509105|NCT03140956|Drug|Levodopa, carbidopa, ODM-104|Crossover design. Study treatments will be administered in randomized order 4 times a day.
45509106|NCT02681237|Drug|Cediranib|Small-molecule inhibitor of several tyrosine kinases including VEGFR-1, VEGFR-2, VEGFR-3 and c-kit.
45509107|NCT02681237|Drug|Olaparib|Poly (ADP-ribose) polymerase (PARP) inhibitor.
45509108|NCT00089245|Drug|Iodine I 131 MOAB 8H9|Patients will be injected, intrathecally, with 2 mCi 131I-Omburtamab during week 1 of a 5 week cycle.
45509109|NCT00089245|Drug|Iodine I 131 MOAB 8H9|The dose used in this study is 50 mCi 131IOmburtamab, (averaging 5 mCi/mg Omburtamab at 50 mCi dose) which will be administered to each patient during week 2 of a 5 week cycle.
45509110|NCT03141112|Procedure|renal replacement therapy|
45509111|NCT04362007|Drug|ASTX660|Treatment of ASTX660 for r/r PTCL and r/r CTCL
45509112|NCT04362007|Drug|ASTX660|Treatment of ASTX660 for r/r ATLL
45509113|NCT04362007|Drug|ASTX660|Treatment of ASTX660 for r/r PTCL
45509114|NCT02674529|Drug|Escitalopram|Selective Serotonin Reuptake Inhibitor (SSRI)
45509115|NCT02674529|Drug|Placebo|Placebo
45509116|NCT02674529|Behavioral|Real-time Neurofeedback fMRI task pre- and post-RCT|Placebo experiment during an fMRI scanning session
45509117|NCT05082064|Diagnostic Test|arterial blood gases and serum electrolytes|arterial bloog gases parameters serum potassium serum sodium serum calcium
45509118|NCT05000437|Other|HIIT|3x/week high intensity interval training for 12 weeks
45509119|NCT05081986|Device|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
45509120|NCT05081986|Drug|Cycloserine|Cycloserine 100mg
45509121|NCT05081986|Drug|Placebo Oral Tablet|Placebo capsule matched to cycloserine capsule
45509122|NCT05250427|Other|No treatment given|No treatment given
45509123|NCT05081908|Procedure|Radiosurgery|Multisession radiosurgery (hypofractionated radiotherapy) with Cyberknife
45509124|NCT01374035|Other|Quality improvement intervention|A complex intervention will be implemented within the group of GPs in the intervention group. It includes participation in defining criteria for good referral letters, information about the correlation between information in the referral letters and outcome, introduction to the guideline, and consecutive feedback on own preformance regarding content of referral letter and outcome for the patient.
45596707|NCT03528733|Device|Multi-Energy Digital Radiography Detector System|A Multi-energy digital flat panel detector for Single Exposure Dual-Energy Subtraction radiography is developed to capture x-ray images with improved tissue differentiation. Tissue-selective images can be produced at various tissue levels such as bone and soft tissue to visualize obscured anomalies that are not apparent to General Radiography.
45596708|NCT02363751|Drug|Bevacizumab|"Patients will be treated for a maximum of 6 (21days) chemotherapy cycles (Gemcitabine+platinum salt+bevacizumab).~In case of disease control (complete, partial or stable disease) treatment with bevacizumab 15 mg/Kg monotherapy every 21 days will be continued until disease progression or until the end of the 24 months of follow-up."
45596709|NCT03530839|Procedure|Arthrodesis|see study group description
45596710|NCT03530839|Procedure|Resection arthroplasty|see study group description
45509125|NCT02626949|Behavioral|MBSR Course|Formal mindfulness meditation methods taught in the MBSR course include: Body Scan Meditation (a supine meditation), Gentle Hatha Yoga (practiced with mindful awareness of the body), Sitting Meditation (mindfulness of breath, body, feelings, thoughts, and emotions), and Walking Meditation. Informal Mindfulness Meditation Practices (mindfulness in everyday life) include: 1) awareness of pleasant and unpleasant events, and, 2) deliberate awareness of routine activities and events such as eating, weather, walking, and interpersonal communication. Daily home assignments include a minimum of 30 minutes daily formal mindfulness practices and 5-15 minutes informal practice, 6 days per week for the entire duration of the course. Course sessions will consist of discussions oriented around weekly homework assignments, including an exploration of obstacles, and development of self-regulatory skills and capacities.
45509126|NCT02626949|Behavioral|HEP Course|HEP is an active control that matches MBSR in non-specific factors, such as the amount of time participants interact, but does not include mindfulness practice as an active component. HEP instructors will be selected from experts in the areas covered: music, nutrition education, and, functional movement. The study's RC will coordinate HEP sessions and monitor attendance. Following the 8-week HEP protocol, subjects will meet monthly in 1.5-hour educational sessions to match the booster sessions of MBSR participants.
45509127|NCT05418907|Radiation|68Ga-NODAGA-exendin-4 PET/CT|PET/CT imaging 1 hour after injection of 100 MB 68Ga-NODAGA-exendin-4
45509128|NCT03140878|Dietary Supplement|LGG|LGG is dissolved in water and consumed at one occasion (either at visit 2 or 3)
45509129|NCT03140878|Dietary Supplement|Placebo|Placebo is dissolved in water and consumed at one occasion (either at visit 2 or 3)
45509130|NCT01374113|Drug|50mg safinamide|50 mg safinamide on Day 1
45509131|NCT02666599|Radiation|18F-FDG PET/CT|"A 18F-FDG PET/CT will be done. A dose of 19 µSv/MBq will be received by the patient. Surgery will be conducted within 3 hours after the I.V. injection of 18F-FDG according to the standard procedure applied in the visceral surgery department. During the surgery, emission of β+ from the lesion (s) seen durint the PET/CT will be detected with the probe.~Resected pieces will be analysed histologically."
45509132|NCT04459936|Other|URICORI|Treatment for cardiovascular risk factors according to national guideline administered at the department of Rheumatology
45509133|NCT04459936|Other|CONTROL|Treatment for cardiovascular risk factors according to national guideline administered at the General Practitioner
45509134|NCT02616887|Radiation|Single dose SBRT and VMAT technique|One fraction of 18 Gy delivered in one day with VMAT and Flattening filter-free (FFF) beams.
45509135|NCT03632317|Drug|Panobinostat|30 mg/m^2
45509136|NCT03632317|Drug|Everolimus|3.0 mg/m^2
45509137|NCT04394494|Other|Motor Imagery. Imaging doing Extension exercises without actually doing them.|This study will compare imagining doing specific extension based exercises for LBP vs. actually performing the exercises. This intervention will be just imaging doing the exercises.
45509138|NCT04394494|Other|Control: Physically performing extension based exercises.|This study will compare imagining doing specific extension based exercises for LBP vs. actually doing them. This intervention will be actually, physically performing the exercises.
45509139|NCT02591784|Drug|Nimotuzumab|the nimotuzumab treatment; 200mg/w,weekly,5-6 weeks.
45698036|NCT01068964|Drug|0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
46059135|NCT04426669|Drug|Cyclophosphamide|Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
45400801|NCT03886636|Other|manual therapy|In our study, Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
45400802|NCT03886636|Other|home exercises|All participants in all groups were assigned the home exercise program. The program aims to increase strength and flexibility of the abdominal, erector spinae, gluteal, quadriceps, and hamstring muscles. The participants were then asked to perform all of the exercises with 10 repetitions of each exercise 3 times a day for 4 weeks.
45509140|NCT02591784|Radiation|Radiotherapy|the Radiotherapy treatment;95%PTV A dose of 50-60Gy will be administered in 25-30 fractions ( 2 Gy /fraction)
45509141|NCT05203003|Other|Assessment of MRD|"Bone marrow aspirate for assessment of MRD will be performed at 2 years (+/- 3 month) after randomization in patients still under treatment and in complete response.~Thereafter, bone marrow aspirate for assessment of MRD will be repeated at 3 and 4 years in patients that maintain complete response, irrespective of the randomization arm and therefore of treatment administration."
45509142|NCT03116399|Behavioral|PRISM 2.0 Condition|Access to the PRISM 2.0 program
45509143|NCT03116399|Behavioral|Tablet Condition|Access to the tablet
45509144|NCT04316962|Other|Complex cancer rehabilitation|"The program is conducted as group rehabilitation, organized by four hour weekly over 12 weeks (approximately 50 hours) with 8-10 participants in each group over three years. The program is located in Askøy Municipality's 'Health Central' and conducted by a multidisciplinary team.~The content of the program is based on prior research and clinical experience, consisting of five elements:~Individual goal-setting~Physical activity (2 hours/week) focusing on balance/coordination, cardio and strength.~Psychoeducation: Five teaching sessions and discussions focusing on physical activity, fatigue and late-effects, nutrition, coping, social support and work/studies. In addition, two sessions (first and last) will also include next of kin.~Individual follow-up: Mandatory session at the start and end of the program, otherwise based on individual request and need.~Peer support."
45509145|NCT02653963|Drug|Adjunctival Triamcinolone|Intraoperative Periplate 10 mg Triamcinolone Injection during AGV Implantation
45596711|NCT02367339|Other|ESBL|Evaluation of the prevalence of ESBL-Enterobacteriaceae colonization among ICU staff
45400803|NCT03886402|Device|GID SVF-2|Treatment of erectile dysfunction with the subjects own cells
45400804|NCT03883204|Drug|Aripiprazole|Initial dose: 10 mg.
45509146|NCT02623933|Radiation|MRI assisted focal boost with HDR monotherapy|Prior to brachytherapy treatment, a multiparametric MRI will be obtained for identification of the dominant intraprostatic lesion (DIL) and fused with the preplanning transrectal ultrasound. A total of 19 Gy will be prescribed to the prostate, organ at risk limits will be observed and up to 22.5 Gy can be delivered to the DIL
45509147|NCT05092997|Diagnostic Test|POC viral load testing|POC viral load testing- women randomized to have POC VL at enrollment, delivery and 6 months post-partum, will have a finger prick to obtain whole blood for the Cepheid Xpert HIV-1 RNA cartridge on the Xpert IV machine with results in 90 minutes. Women who are randomized to POC VL who have VL >200 c/ml will receive additional adherence counseling, following the STREAM protocol, [26] to address the challenges that they are having with ART use. At the delivery visit, infants of women in the POC VL arm will also have viral load testing done.
45509148|NCT05092997|Other|Wellness visit services for male partners|Wellness visits for men- additional prevention services for men randomized to the intervention arm, including dual syphilis and HIV testing, blood pressure, visual acuity screening, and COVID-19 screening as part of wellness
45400805|NCT03883204|Drug|Risperidone|Initial dose: 2 mg.
45400806|NCT03890380|Device|Magneto Wire|Patients will be treated with Magneto Wire
45509149|NCT03939364|Drug|SBS-101|Isotretinoin Oral-Adhesive Film
45509150|NCT03939364|Drug|Placebo|Placebo
45400807|NCT03890458|Drug|DEVIT-3|The physicians gave the women in the experimental group vitamin D oral drops in an ampoule of 300,000 IU and a vial of 50,000 IU to take during the IVF treatment. Written and verbal information about how to take vitamin D was provided to the participants by the nurses. The women took 300,000 IU vitamin D orally for the first week. In the second week of the treatment, 50,000 IU vitamin D (15 drops/day) was used as maintenance dose until the pregnancy test day.
45400808|NCT01156324|Behavioral|Online Stress Management Group (Upliv)|Personalized online stress management program
45400809|NCT01156324|Behavioral|Control|Control group receiving routine care along with $50 gift certificate at end of cycle
45400810|NCT01155076|Dietary Supplement|Vitality Product|Proprietary blend of ginseng, cordyceps, and pomegranate taken twice a day for 8 weeks
45400811|NCT01155076|Dietary Supplement|Placebo|Placebo taken twice a day for 8 weeks
45400812|NCT01263418|Drug|Ofatumumab|Intravenous; Dosage: 1000mg; Frequency: one time per week; Duration: 8 weeks
45509151|NCT05418829|Drug|AT-007|AT-007 20 mg/kg once daily
45509152|NCT04288960|Device|Gwalk accelerometer walking trials|No intervention. Participants will wear a belt mounted accelerometer and complete walking trials to assess validity of the device
45509153|NCT03097861|Drug|Lubiprostone|24 mcg administered orally BID
45400813|NCT03882814|Drug|pethidine|Pethidine 50 mg intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. Opioid analgesia (pethidine HCl - 50 mg I.M.) was given following amniotomy.
45509154|NCT03097861|Drug|Placebo|24 mcg administered orally BID
45698037|NCT01068964|Drug|0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
46059136|NCT04426669|Drug|Fludarabine|Day -7 to Day -3 : Fludarabine 25 mg/m^2/dose as a 1 hour intravenous infusion per institutional guidelines once a day for 5 doses beginning on Day -7. Fludarabine will be started approximately 1 to 2 hours after the cyclophosphamide on Day -6 and Day -5.
45400814|NCT03882814|Drug|Placebo - Concentrate|Intramuscular saline was administered to the control group as placebo. Salin intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. salon was given following amniotomy.
45400815|NCT03886558|Other|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months.|The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
45400816|NCT01156402|Behavioral|Healthy Families-Childhood Obesity Prevention and Oral Health|The active intervention was adapted from the We Can! parent intervention to be culturally-appropriate for Hispanic families of children ages 5-7. The tailored intervention is based on Social Cognitive Theory and Behavioral Choice Theory to provide parents and children with cognitive and behavioral skills to enable change in the target behaviors, and to encourage them to practice using these skills to strengthen their perceived competence in using these behaviors effectively.
45509155|NCT05393830|Behavioral|Sleep Restriction|Three nights of sleep restricted to 4 hours per night.
45509156|NCT04215562|Combination Product|rehabilitation|electro-therapy, heat therapy, massage and exercise therapy
45509157|NCT03910673|Drug|Fosfomycin disodium|Fosfomycin (a phosphonic acid derivative) formulated as a disodium salt.
45509158|NCT03137914|Biological|Autologous chondrocyte transplantation|intraarticular injection into the TMJ (arthrocentesis) of autologous chondrocytes diluted in hyaluronic acid
45698038|NCT03217162|Drug|surfactant combined with mechanical ventilation (MV)|surfactant combined with mechanical ventilation (MV) is given to the infant with ARDS
45698039|NCT03217162|Drug|mechanical ventilation (MV)|mechanical ventilation (MV) is given to the infant with ARDS
45698040|NCT00768274|Drug|RVX000222|RVX000222 twice daily (b.i.d.) for 28 days
45400817|NCT03890224|Device|home ventilators|The 3 test treatments are home non-targeted NIV, home targeted NIV and rescue home NIV. COPD patients will be equipped with home ventilators and fitted with either nasal, oronasal or facial masks. All the ventilators used will be CE marked.
45400818|NCT03889990|Device|IQOS|"Smoke IQOS"
45509159|NCT03137914|Procedure|orthognathic surgery|Orthognathic surgery for correction of dentofacial deformity, performed before the cellular transplantation
45509160|NCT03137758|Drug|PCUR - 101|PCUR-101 Capsules 25 mg are solid dosage forms for oral administration
45509161|NCT05087927|Behavioral|Gain framing plus demographically targeted photos|"Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races."
45509162|NCT05087927|Behavioral|Loss framing plus demographically targeted photos|"Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races."
45509163|NCT05087927|Behavioral|Gain framing plus not demographically targeted photos|"Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of an African American woman."
45698041|NCT00768274|Drug|Placebo|Placebo twice daily (b.i.d.) for 28 days
46059137|NCT04426669|Biological|Tumor-Infiltrating Lymphocytes (TIL)|Day 0 : Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes at assigned dose level.
45400819|NCT01153048|Other|Intensification of education|The main objective is to assess impact of the establishment of involved patients (peer educators) network in Mali. Peer educators and persons targeted by the project will be recruited through Post-Test Club on diabetes (PTC). PTC will be a social support club that provides on going prevention counseling, education and support services to people who have diabetes. PTC represents an important link between patients, educators and general medical services. PTC will be defined as clubs, which are facilitated by well-trained peer educators, and will have 3 objectives: to provide social and emotional support to diabetic patients, to provide assistance in daily management and living with diabetes and to provide linkage to clinical care. To lead the sessions, in clubs, we will use a very innovative methodology for peer education: the learning nests method. To evaluate, we propose a classical randomized controlled experimental (RCT) design, with randomization at the person-level.
45400820|NCT03647566|Diagnostic Test|18F Sodium Fluoride Positron Emission Tomography / Computed Tomography|PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan
45400821|NCT03647566|Diagnostic Test|CT Aortic Angiogram|CT scan to assess aortic morphology and contextualise PET scan
45400822|NCT03647566|Diagnostic Test|Aortic MRI|Aortic MRI to assess aortic morphology and contextualise PET scan
45400823|NCT03591952|Procedure|Suction-Driven Thoracentesis|Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
45400824|NCT03591952|Procedure|Gravity-Driven Thoracentesis|Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
45509164|NCT05087927|Behavioral|Loss framing plus not demographically targeted photos|"Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of an African American woman."
45509165|NCT01376141|Drug|Sumatriptan|
45509166|NCT04180852|Other|Functional tests without clinical consequence for the patients therapy|Battery of tests, which measure the patients functional outcomes regarding their muscle mass, their muscle strength, fat mass, physical function, neuropsychological function and quality of life.
45509167|NCT03642067|Drug|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
45509168|NCT03642067|Drug|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
45509169|NCT03642067|Drug|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
45509170|NCT03642067|Drug|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
45509171|NCT03861689|Diagnostic Test|MRI pelvis|MRI pelvis monitoring every 6 months; FiLAC to treat fistula tract within 24 months if the anatomy of the fistula is favourable
45509172|NCT03137680|Behavioral|Hand Exercise|Exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of six weeks.
45698042|NCT01116466|Device|ActiGait|ActiGait - implantable drop foot stimulator
45698043|NCT05111145|Drug|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration.
45698044|NCT05111145|Drug|IVA|Tablet for oral administration.
45509173|NCT03215914|Device|MiniMed 670G system|Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels < 70 mg/dl.
45509174|NCT03691402|Behavioral|MCT-Silver|Metacognitive training for depression in later life (MCT-Silver) is a cognitive-behaviorally based group therapy, which focuses on helping participants gain (metacognitive) distance from their thought patterns that contribute to depression. Over 8 modules, MCT-Silver addresses issues specific to depression in later life, such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and re-defining values in later life and how one may move toward acceptance of situations that cannot be prevented or changed. MCT-Silver addresses cognitive and metacognitive biases that contribute to the onset and maintenance of depression through fun and engaging exercises, as well as using examples from daily life.
45509175|NCT03691402|Behavioral|Cognitive Remediation|mybraintraining© is a computer-based cognitive remediation program, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The program is administered individually on personal computers and each session lasts approximately 45-60 min. To match the MCT-Silver group, participants will complete up to eight sessions of cognitive remediation.
45509176|NCT03636100|Device|Cryoballoon ablation|Cryoballoon ablation using standard equipment and techniques
45509177|NCT01816139|Drug|Vehicle|Vehicle Cream applied to the vagina daily for 2 weeks followed by dosing 2 times a week for 10 weeks
45509178|NCT01816139|Drug|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream applied daily for 2 weeks followed by dosing 2 times a week for 10 weeks
45400825|NCT03882502|Other|anodal transcranial direct current stimulation (tDCS)- accompanied naming therapy or sham stimulation|anodal tDCS or sham stimulation will be combined with an intensive naming training and the number of items that could be named will be assessed immediately after the intervention.
45509179|NCT03443674|Drug|SCB-313|Lyophilized powder in a single-use vial
45509180|NCT04052776|Drug|Buspirone|40mg
45509181|NCT04052776|Drug|Levodopa-Carbidopa|400mg/100mg
45509182|NCT04052776|Drug|Buspirone + Levodopa-Carbidopa|40mg + 400mg/100mg
45509183|NCT04052776|Drug|Placebo oral tablet|Non-active metabolite
45509184|NCT01100879|Drug|Ferric carboxymaltose|"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 3 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."
45509185|NCT05070689|Procedure|ACCSS|A. Chohan Continuous Squeezing Suture (ACCSS)
45509186|NCT00904553|Radiation|Novalis Shaped Beam Surgery|Treatment using Novalis SRS
45849952|NCT03207984|Procedure|Root coverage surgery|Periodontal plastic surgery aiming the treatment of multiple gingival recessions in aesthetics areas with SCTG and CM
46059138|NCT04426669|Drug|Aldesleukin|Days 1-4 : Aldesleukin at 720,000 U/kg as an intravenous infusion, every 8 -12 hours but, no more than 24 hours apart as tolerated for up to 6 doses.
46059139|NCT00627107|Device|ReWalk - a motorized exoskeleton suit|The subject will wear the ReWalk suit and have training sessions for walking with the device.
46059140|NCT02874989|Drug|Dasatinib + Quercetin|
45400826|NCT01156636|Drug|Sildenafil|50 mg 3 times/day for 1 year
45400827|NCT01156636|Drug|Placebo|
45400828|NCT01259674|Device|AboMeg-B-09|Syrup: AboMeg-B-09 5ml to be taken 4 times a day during the entire study period
45400829|NCT01259674|Other|Placebo|Placebo syrup: 5ml to be taken 4 times a day during the entire study period
45400830|NCT03881722|Dietary Supplement|Mg alginate|Mg alginate after feedings
45400831|NCT03889678|Diagnostic Test|Color flow doppler|Color flow doppler proximal to vein insertion site to document flow
45400832|NCT01153126|Behavioral|Comprehensive Health Enhancement Support System (CHESS.)|Half of the participating women will be randomly assigned to usual care and half will be offered a fully CHESS.
45400833|NCT03889288|Device|Medical device - electronic-pain killer|Treatment sessions with the medical device (no-marked EC): 2 sessions before surgery and 4 or 5 sessions until 48 hours after surgery. Each treatment sessions takes 45 minutes. Each session is spaced by 12 +/-3 hours.
45400834|NCT01153204|Behavioral|Group Psychotherapy|
45400835|NCT01153204|Other|Group Psychotherapy plus Sildenafil citrate|
45400836|NCT01153204|Drug|Sildenafil citrate|
45509187|NCT05392660|Other|assumed upright position during first stage of labor|The study group assumed one of upright positions during first stage of labor, defined as walking , sitting, standing, kneeling & squatting positions )
45509188|NCT01374191|Drug|onabotulinum toxin type-A|1 injection of Btx-A
45509189|NCT01374191|Other|placebo|1 injection of saline solution
45509190|NCT01374191|Drug|2nd phase - onabotulinum toxin type-A|2 - 3 injections of Btx-A, specific to patient pain recurrence
45509191|NCT04021810|Device|Continuous Positive Airway Pressure (CPAP) and patient education|Mask connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airways. Plus patient education.
45849953|NCT03206736|Other|Loop DS surgery|these patients will receive a loop DS bariatric procedure
46059141|NCT02874989|Drug|Placebo|
46059142|NCT01071317|Drug|Naproxen|Naproxen 500mg PO bid prn headache
46059143|NCT01071317|Drug|Sumatriptan|100mg po q day prn headache
45400837|NCT03760666|Drug|Brequinar/Brequinar + Ribavirin|The first 14 participants had brequinar monotherapy; the final 3 subjects were also exposed to a combination of brequinar + ribavirin.
45400838|NCT03760510|Device|Tube Fastener|Endotrachel tube secured with tube fastener
45400839|NCT03760510|Device|Adhesive Tape|Endotracheal tube secured with adhesive tape.
45509192|NCT04021810|Device|Mandibular Advancement Device|Adjustable oral prosthesis which retains the lower mandible in an anterior position, thus limiting sleep apneas
45509193|NCT03140098|Device|cardiac surgery requiring a collagen membrane COVA™+|At the end of the cardiac surgery, the collagen membrane is implanted on the dissection area in order to prevent the formation of postoperative adhesions.
45400840|NCT03882112|Drug|HIP1601 40mg|Single dosing of HIP1601 40mg, orally
45509194|NCT03140020|Procedure|Clipping|During the microsurgical operation a titan clip will be placed round the aneurysm neck to exclude the aneurysm from the bloodflow and prevent fatal subarachnoidal hemorrhage.
45509195|NCT03140020|Procedure|Coiling|Using a catheter technique the aneurysm dome will be filled up with coils to prevent subarachnoidal hemorrhage.
45509196|NCT03764735|Drug|Low Dose - SkQ1|SkQ1 Low dose ophthalmic solution
45509197|NCT03764735|Drug|High dose - SkQ1|SkQ1 High Dose ophthalmic solution
45509198|NCT03764735|Drug|SkQ1 (Vehicle)|Vehicle for SkQ1 ophthalmic solution
45509199|NCT03957694|Drug|Romiplostim|Romiplostim SC. Initial dose is 10 ug/kg/. Maximum dose is 20 ug/kg. Original duration is 6 months from first administration but if investigator decide that the patient is needed more treatment, they move to extention period and take treatment up to 1 year.
45400841|NCT01263574|Drug|70% ethanol|Administration of the lock solution will occur between cycles of parenteral nutrition. Lock solutions will be administered three days per week. The pre-measured volume of lock solution will then be injected into the catheter for 4 hours. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. Volume of lock solution administered will be determined by catheter size.
45400842|NCT03882190|Drug|GnRHa|patients in the experimental group are supposed to receive GnRHa preoperatively and postoperatively according to their individual situation
45400843|NCT03882346|Combination Product|LifeLiver|LifeLiver is an extracorporeal bioartificial liver (BAL) system. The system has shown remarkable detoxification capacity and sustained hepatic functions and also provides a bridge to transplant for patients who are unable to receive timely liver transplantation.
45400844|NCT03464734|Drug|Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel|At study entry, patients will receive 2 cycles of pembrolizumab at the dose of 200 mg, intravenously in 30 min, on day 1 and nab-paclitaxel 125 mg/m2 intravenously in 30-40 min, on day 1 and 8.
45400845|NCT01156870|Drug|SAR566658|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
45400846|NCT01156948|Drug|misoprostol|400ug vaginally the day before surgery
45400847|NCT01156948|Drug|oral misoprostol|400ug misoprostol orally the day before the surgery
45400848|NCT03881956|Behavioral|Health-promoting lifestyle education program|The intervention group were included in the health-promoting lifestyle education program. The education program consisted of three 45-min sessions, which included a face-to-face lecture with the dissemination and presentation of written and visual materials. Each participant in the intervention group was given the Health-Promoting Lifestyle Booklet and the Diary of a Woman with GDM card. The booklet features all of the health-promoting practices (self-monitoring of blood glucose, nutrition, physical activity, stress, sleeping, smoking, self-care and breastfeeding). The Diary of a Woman with GDM card features the daily program that women should follow (the hours for main meals and snacks, insulin hours, etc.). The education and counseling were maintained through follow-up via phone for intervention group.
45400849|NCT01157104|Drug|IDX320|IDX320 400 mg in tablets (8x50 mg) administered orally once daily
45400850|NCT01157104|Drug|IDX184|IDX184 100 mg in capsules (2x50 mg) administered orally once daily
45400851|NCT01157104|Drug|IDX184 placebo|IDX184 matching placebo in capsules administered orally once daily
45509200|NCT05759507|Procedure|abdominal surgery|
45509201|NCT05041673|Drug|Metformin|Antidiabetic drugs
45509202|NCT03907540|Drug|Belumosudil 200 mg tablet|Belumosudil 200 mg tablet, development candidate
45509203|NCT03907540|Drug|[14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose|test investigational medicinal product
45509204|NCT03907540|Drug|[14C]-KD025 200 mg capsule|test investigational medicinal product
45509205|NCT05759429|Other|BWRP|Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP, which includes a low-calorie diet, physical activity, psychological support, and nutritional education
45509206|NCT05759429|Other|BWRP + melatonin|Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP and melatonin (4 mg/die), administered 2-3 hours before bedtime
45509207|NCT04005209|Drug|Ketamine|The experimental group will receive a ketamine intravenous infusion, initiated at 0.2 mg/kg/hr within the first 12 to 24 hours on an inpatient admission for sickle cell pain crisis, and titrated per hospital policy by the inpatient pain service.
45509208|NCT04005209|Other|Pain management|Pain management
45509209|NCT05088304|Other|no intervention|
45596712|NCT05238493|Drug|VEL-101|Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1
45596713|NCT05238493|Drug|Placebo|Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1
45849954|NCT03030066|Drug|DS-1001b|Generic not assigned
45509210|NCT05088226|Drug|Ruxolitinib combined with Chidamide.|"Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide .~Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI , Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;"
45509211|NCT01376219|Other|asthma control test|results of asthma control testing collected
45509212|NCT03751553|Drug|obsteric gel(k-Y jelly)|A sterile obstetric gel( K-Y Jelly 82GM; manufactured by Johnson&amp; Johnson) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that have purely physical activity. Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child manually or using the sterile obstetric gel applicator without any manipulation or massage.
45509213|NCT03904108|Drug|Ramucirumab|platinum doublets chemotherapy plus ramucirumab, intravenously(IV)
45509214|NCT03636581|Behavioral|Lifestyle counseling|This group will receive online education modules to educate them on exercise prescription, nutrition and behavioral changes.
45509215|NCT04976309|Drug|Lu AG09222|Single dose
45509216|NCT04976309|Drug|Placebo|Single dose
45509217|NCT05392348|Dietary Supplement|stachyose|Stachyose is a tetrasaccharide consisting of sucrose having an alpha-D-galactosyl-(1->6)-alpha-D-galactosyl moiety attached at the 6-position of the glucose.
45509218|NCT05392348|Dietary Supplement|Maltodextrin|Maltodextrin is a polysaccharide that is used primarily in foods and beverages as a thickener, sweetener, and/or stabilizer. It is a relatively short-chain polymer (some would call it an oligomer); commercial products contain an average of ≈3 to ≈17 glucose units per chain. It is manufactured by partially hydrolyzing grain starches, usually corn or wheat.
45509219|NCT05392270|Behavioral|Ageless Grace|This unique program attempts to combine multiple aspects that easily fit together including music and a group setting for socialization. The use of music to improve cognition as has been shown in other research studies to improve participation in exercise program. By linking cognitive retraining, low intensity exercise, group activities and music, the researchers of this project can determine if a movement program with these attributes can benefit individuals as a program of wellness once their rehabilitation plans have been completed. The researchers are specifically interested in the effect on balance, activity and incidence of falls in people with chronic stroke. Additionally, the researchers will investigate the differences that this structured program will make on older adults who will act as a comparison group. This will bring insight into some of the additional challenges that people with stroke encounter on a daily basis.
45509220|NCT03843034|Genetic|Measure endometrial markers|Endometrial biopsies will be taken from participants in both groups
45509221|NCT03137524|Device|Hand Held Fan Therapy|Hand-Held fan therapy used to generate airflow directed to face during specific exercise test
45509222|NCT02833350|Drug|GDC-0853|Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.
45509223|NCT02833350|Drug|Adalimumab|Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.
45509224|NCT02833350|Drug|Folic Acid|Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
45509225|NCT02833350|Drug|MTX|Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
45509226|NCT02833350|Drug|Placebo|Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
45509227|NCT03137602|Device|ATOMIC mobile app|(a) PA Coach, One-on-one Chats. Coaches will conduct three one-on-one phone or video conferencing sessions and will also conduct a text messaging session once per week to reinforce and follow-up on the one-on-one phone sessions during the course of the intervention. (b) PA-Self Monitoring. An activity tracker (Fitbit Charge 2) will be used to allow participants to monitor their activity behaviors (e.g. step counts). (c) PA Information. In addition the coach will send weekly tailored PA informational posts/messages aligned with Social Cognitive Theory (SCT) to all participants. (d) Educational Modules. MS specific web-based interactive PA modules will be provided to patients.
45509228|NCT03137212|Combination Product|thrombolysis and PCI of A type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 3-6 hours after thrombolysis.
45509229|NCT03137212|Combination Product|thrombolysis and PCI of B type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 6-24 hours after thrombolysis.
45509230|NCT03137134|Drug|Crizotinib|Crizotinib in a coated microsphere formulation
45509231|NCT03137134|Drug|Esomeprazole|Proton pump inhibitor, esomeprazole
45509232|NCT03137368|Drug|Exemestane Tablets|drug therapy
45849955|NCT02972034|Drug|MK-8353|PO capsule
45849956|NCT02972034|Biological|Pembrolizumab|IV infusion
45400852|NCT01157104|Drug|IDX320 placebo|IDX320 matching placebo in tablets administered orally once daily
45400853|NCT01157260|Drug|Kremezin|AST-120 2g three times a day
45400854|NCT01157026|Dietary Supplement|Tocotrienol Rich Fraction (TRF)|Tocotrienol Rich Fraction (200mg), daily for five years
45400855|NCT01157026|Other|placebo plus tamoxifen|20mg tamoxifen daily
45400856|NCT01263652|Drug|Diclofenac hydroxyethylpyrrolidine|IM/PO
45400857|NCT01263652|Drug|orphenadrine|IM/PO orphenadrine
45400858|NCT01263652|Drug|Tramadol|IM/PO tramadol
45400859|NCT01263652|Drug|Dipyrone|PO/IM Dipyrone
46059144|NCT01071317|Behavioral|Migraine education|Educational program available through NIH/ national library of medicine/ X-plain
45509233|NCT03137368|Other|ovarian function suppression/ablation|Gonadotropin-releasing hormone analogue Goserelin Injection 3.6mg or Leuprorelin Injection 3.75 mg, a subcutaneous injection should be done every 28±2 days; or Bilateral ovariectomy.
45509234|NCT03137368|Genetic|CYP2D6*10 gene test|CYP2D6*10 gene test
45509235|NCT03137368|Drug|Tamoxifen|drug therapy
45509236|NCT05391958|Behavioral|base on Lean Body Mass Pattern|PTC(post-tetanic count) was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on lean body weight mass pattern once when PTC > 2.
45509237|NCT05391958|Behavioral|base on Actual Body Weight|PTC was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on actual body weight once when PTC > 2.
45509238|NCT05391958|Genetic|obese patients|obese patients with elective laparoscopic colorectal surgery were selected，and the inclusion criteria were as follows: age 18-65, body mass index (BMI) 30-35, waist circumference (WC) : female ≥80cm, male ≥90cm, and American Society of Anesthesiologists (ASA) grade Ⅰ ~ Ⅲ.
45509239|NCT05391958|Genetic|normal patients|normal patients with elective laparoscopic colorectal surgery whose body mass index (BMI) 18-24 were selected,and American Society of Anesthesiologists (ASA) grade Ⅰ ~ Ⅲ.
45400860|NCT01259752|Device|compression stockings|compression stockings
45400861|NCT01259752|Other|standard non compressive stockings|standard non compressive stockings
45400862|NCT03881644|Drug|Imigran|All patients will undergo this intervention on one of two study days
45400863|NCT03881644|Other|Isotonic Saline|All patients will undergo this intervention on one of two study days
45400864|NCT03881644|Other|Pituitary adenylate cyclase-activating peptide-38|All patients will undergo this intervention on both study days
45400865|NCT01263730|Behavioral|Tai Chi|Tai Chi training consists of a sequence of slow, soft, and graceful movements derived from the martial arts. It is considered as a moving form of yoga and meditation combined. Tai Chi has been considered as one form of oriental healing arts, like acupuncture, which fosters the circulation of this 'chi' or energy within the body.
45400866|NCT01265368|Biological|MGN1601|Genetically modified allogeneic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)
45400867|NCT01259830|Drug|Arcoxia®120 mg|Arcoxia® over encapsulated 120 mg; Perioperatively 6 days 1 tablet (Arcoxia® 120 mg) for oral use
45400868|NCT01259830|Drug|P Tablet White Lichtenstein|P Tablet White Lichtenstein over encapsulated; Perioperatively 6 days 1 tablet for oral use
45509240|NCT05391802|Device|Transcatheter mitral valve repair|Transcatheter mitral valve repair (TMVr) is a minimally invasive procedure. Doctors place a thin tube (calleda catheter) into a large vein to reach your heart. A clip is then placed onto the center of your mitral valve. The valve continues to open and close, allowing blood to flow through while reducing MR.
45509241|NCT03138616|Drug|vitamin D|take 1600 units of vitamin D daily for nine months
45400869|NCT01157338|Procedure|diagnostic cardiac catheterization|coronary intervention: angiography
45400870|NCT01157338|Procedure|therapeutic cardiac catheterization|cardiac catheterization: angioplasty
45400871|NCT03881878|Drug|TAHP and AHP|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~Docetaxel (75mg/m2, IV)~Atezolizumab (1200mg, IV)~Tastuzumab (600mg, SC)~Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with pCR:D1 X 11-12 cycles, q3weeks~Atezolizumab (1200mg, IV)~Trastuzumab (600mg, SC)~Pertuzumab (420mg, IV)"
45400872|NCT03881878|Drug|TAHP plus AC and AHP|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~Docetaxel (75mg/m2, IV)~Atezolizumab (1200mg, IV)~Tastuzumab (600mg, SC)~Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with non-pCR~Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) D1 X 4cycles q3weeks followed by~Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks"
45509242|NCT03137290|Drug|Neostigmine|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF Watch Sx was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it was between 2-3. Then a reversal dose for TOF count of 2 to 3 was 0.05 mg/kg of Neostigmine with 0.02 mg/kg of Atropine. Therefore the volume would be 0.2 mls per kg is to be administered.
46059145|NCT01071317|Behavioral|Reenforcement of diagnosis|Patient advised has migraine headache and how the headache meets migraine criteria
45400873|NCT01159522|Drug|SCB01A|This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
45400874|NCT00224484|Biological|GSK208141|3 intramuscular doses
45400875|NCT00224484|Biological|Havrix (investigational formulation)|3 intramuscular doses
45509243|NCT03137290|Drug|Sugammadex Sodium|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it between 2-3. Then the dose for reversal of sugammadex with a TOF count of 2 or 3 would be 2 mg/kg. This will also be equivalent to a volume of 0.2 mls per kg and given at the end of surgery.
45509244|NCT03782818|Drug|Olaparib|Olaparib up to 300 mg BID for 24 weeks
45509245|NCT05391724|Drug|CMX001|single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg
45509246|NCT03137446|Other|Intravenous Fluid Cap|Normal Saline or Ringers Lactate limited to 60ml/kg for first 72 hours
45509247|NCT03641248|Drug|Enteric coated Devil's Claw|Enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
45509248|NCT03641248|Drug|Non-enteric coated Devil's Claw|Non-enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
45509249|NCT03138460|Other|standard medications crossed over to cannabis|
45509250|NCT05391490|Genetic|KCAT19 T cells|Allogeneic, cord unit derived KCAT19 T cells
45509251|NCT03355534|Drug|Intravenous dexmedetomidine|drug is intravenously infused to patients
45509252|NCT03355534|Drug|nasal dexmedetomidine|drug is nasally given to patients
45509253|NCT03355534|Drug|intravenous saline|saline is given to patients intravenously
45509254|NCT03355534|Drug|nasal saline|normal saline is given to patients nasally
45509255|NCT05341284|Other|Questionnaire Survey and Cervical Cancer Screening|"A brief questionnaire will be administered to all participants at enrollment and at the pre-scheduled follow-up visit at Month 36.~For the subject who are eligible for the screening (i.e. (1)≥ 18 years old; (2) had sexual debut prior to enrollment, (3) no contradiction to the screening, (4) voluntary to the screening) will be referred to the study site hospitals by offering the subjects a cervical cancer screening voucher, and the type-specific HPV test will be performed as primary screening approach at Month 0 and 36."
45509256|NCT05385640|Other|NO intervention|NO intervention
45698045|NCT04352842|Other|Echocardiography|An expert with 17-year professional experience performed all the echocardiography examinations using a GE LOGIQTM e portable color ultrasound diagnostic machine (GE Healthcare, WI, USA) that was specially used in the contaminated area. Two-dimensional and Doppler echocardiographic measurements were conducted following the recommendations of the American Society of Echocardiography
45400876|NCT00224484|Biological|Placebo|3 intramuscular doses
45400877|NCT01265602|Drug|LAS41007|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
45400878|NCT01265602|Drug|LASW1510|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
45400879|NCT01265602|Drug|vehicle of LAS41007|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
45400880|NCT01265680|Drug|Erythropoietin|80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital.
45400881|NCT01157494|Other|classification of hand manipulation function|To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
45400882|NCT03879148|Other|Erector spinae plane block|Erector spinae plane block was performed to the patients under aseptic conditions
45400883|NCT01265758|Device|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
45400884|NCT01263808|Drug|Indacaterol 150 µg|Once daily (QD) via single-dose dry powder inhaler (SDDPI)
45400885|NCT01263808|Drug|Indacaterol 300 µg|QD via SDDPI
45400886|NCT01263808|Drug|Indacaterol 600 µg|QD via SDDPI
45400887|NCT01263808|Drug|Placebo|QD via SDDPI
45400888|NCT01263808|Drug|Placebo/moxifloxacin|Placebo QD via SDDPI for 14 days, followed by a single dose of moxifloxacin 400 mg
45698046|NCT03550911|Other|Biological Collection From Samples From The Gut Microbiota|The aim of this study is just to constitute a biological collection from samples from the Gut microbiota in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No analysis will be done for instance.
45509257|NCT05385562|Drug|Triamcinolone Acetonide and sodium hyaluronate and chondroitin sulfate|formulated with sodium hyaluronate and chondroitin sulfate
45509258|NCT05385562|Drug|Triamcinolone Acetonide alone|Triamcinolone Acetonide alone
45509259|NCT01343043|Drug|NY-ESO-1(c259)T Cells|Lymphodepleting chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 0.
45509260|NCT01343043|Drug|Fludarabine|Fludarabine will be used as lymphodepleting chemotherapy.
45509261|NCT01343043|Drug|Cyclophosphamide|Cyclophosphamide will be used as lymphodepleting chemotherapy.
45509262|NCT05384470|Drug|Marihuana|Two doses of marijuana given.
45698047|NCT02984475|Drug|Metformin|
45698048|NCT01069354|Device|Radiesse® Injectable Dermal Filler with Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier with 3% lidocaine hydrochloride (HCl)
45509263|NCT05384470|Device|BID2 Instrument - breathalyzer|The commercial device that we will be testing is designed to detect breath cannabinoid concentrations utilizing Differential Mobility Spectrometry technology, and was developed by Draper, to detect a wide range of chemicals and organisms in breath. Differential Mobility Spectrometry (DMS) is a robust, data-rich, ultra-trace, chemical detection technology. Unlike gas chromatography mass spectroscopy (GCMS) systems that are large and expensive, DMS is small, portable (approximately the size of a shoe box) and is able to measure the presence of volatile organic compounds (VOC) at parts per trillion (ppt) detection levels. The participant will exhale into the device via a plastic tube and the breath sample will be analyzed in situ. The participant does not come in contact with the device itself-they will simply exhale into a tube via a disposable mouthpiece.
45509264|NCT03139708|Drug|Alphagan|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one."
45509265|NCT03139708|Drug|Phenylephrine|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one."
45509266|NCT03139708|Drug|Tropicamide|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one."
45509267|NCT03548987|Drug|Semaglutide|Subcutaneous (under the skin) injection of semaglutide once-weekly.
45509268|NCT03548987|Drug|Placebo|Subcutaneous (under the skin) injection of semaglutide placebo once-weekly.
45509269|NCT01358760|Drug|Placebo|Placebo vaginal suppository
45509270|NCT01358760|Drug|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA
45509271|NCT01358760|Drug|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA
45509272|NCT03139942|Device|Optical spectral reflectance and autofluorescence imaging|When a suitable area of tissue is identified by the clinician during a patient's colonoscopy (e.g., a polyp), the imaging probe is inserted into the colonoscope so that it can view the tissue. Optical spectral reflectance and autofluorescence imaging is then performed to collect white light reflected by, and fluorescent light emitted from, the tissue. This is then analysed by hardware and software components in the external analysis unit.
45698049|NCT01069354|Device|Radiesse® Injectable Dermal Filler without Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier without 3% lidocaine hydrochloride (HCl)
45698050|NCT03517917|Other|Tumour tissue collection|Collection of tumour tissue and blood
45698051|NCT03490929|Drug|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|injection of Lumason (ultrasound contrast agent)
45698052|NCT03490929|Device|contrast-enhanced ultrasound|ultrasound of the abdomen after injection of ultrasound contrast agent (Lumason)
45698053|NCT03080974|Drug|Nivolumab|Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.
45698054|NCT03080974|Procedure|Irreversible Electroporation|Non-thermal ablation of tumor
45698055|NCT01069510|Drug|Spironolactone 25mg|Spironolactone 25 mg daily for 12 months
45400889|NCT01159678|Behavioral|online psychoeducation|"The online psychoeducation contains 12 modules which will be administered once per week over the course of three months. The content of each module is as follows:~Important of sexuality to quality of life. & Definitions of sexual desire and arousal.~Consideration of the predisposing, precipitating, and perpetuating factors in his/her sexual difficulties.~Sexual beliefs.~Mindfulness.~Genital anatomy and physiology.~Body Image.~Relationship satisfaction and communication.~Body-oriented mindfulness exercises (focusing and self-observation).~Using Thought records.~Mindfulness and the thought stream.~Sexual aids to boost arousal.~Moving on.~In addition to these weekly modules, all participants will have access to a moderated and password-protected bulletin board to which participants can post questions and the PI will respond."
45400890|NCT01159756|Drug|Travacom|Travacom ophthalmic solution (1 drop per day)
45400891|NCT01071876|Drug|BF2.649|1 capsule in the morning before breakfast
45400892|NCT01071876|Drug|Placebo|1 capsule in the morning before breakfast
45400893|NCT01161706|Other|Vegetable Juice|Participants consumed vegetable juice daily in the amount of 0, 8 or 16 fluid ounces.
45400894|NCT01581996|Drug|lanthanum carbonate|All patients will receive the following doses of lanthanum carbonate in random order for 10 -12 days each. O mg, 500 mg tid, 1000 mg tid, 1500 mg tid.
45400895|NCT01157572|Drug|Metoprolol|Patients with moderate to severe aortic valve insufficiency will be randomized to Metoprolol
45596714|NCT02374437|Drug|Aramchol|PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
45596715|NCT02374437|Drug|Placebo|PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
45596716|NCT05576623|Biological|AdCLD-CoV19-1 OMI (Part A)|20 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular injection in the deltoid muscle
45698056|NCT01069510|Other|Placebo|Placebo daily for 12 months
45509273|NCT05692557|Device|Virtual reality|"The Oculus Rift's (Lenovo, Beijing, China) Fujii - Mystical Journey was the game played by the VRD group on a tablet. The game is a peaceful, ethereal voyage that passes through several surreal, natural locations.~The game combines elements of adventure, agriculture and revitalizing music. It alternates between outdoor exploration and inventive gardening. Players explore three different magical biomes. The life force in each biome is restored by interacting with the plants and animals there."
45509274|NCT05692557|Procedure|Progressive muscle relaxation|The patients of the control group performed Progressive muscle relaxation technique, a relaxation technique used to control pain. It is believed that anxiety-inducing thoughts result in muscle tension and hence muscle relaxation can reduce anxiety. The relaxation technique consisted of tensing and relaxing different muscles, starting from the toes and finally involving muscles of the head and neck. It was recommended that this be done in a peaceful, distraction-free environment. The muscle groups were tensed for a period of 5 seconds and then relaxed for 30 seconds.
45509275|NCT03137056|Device|Hemodialysis with Theranova|"Theranova is a polyarylethersulfone-based hemodialysis membrane manufactured by Baxter International Corp All the dialysis sessions in this arm will be performed with the theranova membrane. This membrane will exclusively be used in hemodialysis.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
45509276|NCT03137056|Device|Hemodialysis with FX1000|"FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodialysis.~Modalities of hemodialysis: Blood flow: 300-400 mL/min ; Dialysate flow: 500-800 mL/min"
45509277|NCT03137056|Device|Hemodiafiltration with FX1000|FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodiafiltration Modalities of hemodialysis: Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min ; post reinjection convection volume of at least 25L.
45509278|NCT04432701|Behavioral|proactive extubation|when children is breathing spontaneously and adequately in PACU,endotracheal tube was removed directly
45509279|NCT05330364|Drug|Chidamide|Chidamide 30mg/d p.o. begin at day 1, twice per week, during a 28-days cycle.
45509280|NCT05330364|Drug|Cladribine|Cladribine 5mg/m2/d i.v. d1-5, once per day, during a 28-days cycle.
45509281|NCT05087602|Drug|Toripalimab and Anlotinib|Toripalimab 240 mg IV on Day 1 of each 14-day cycle plus Anlotinib capsules given 10mg orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
45509282|NCT05087368|Biological|ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
45509283|NCT05087368|Biological|CoronaVac (Sinovac Biotech)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
45698057|NCT04398069|Procedure|hemodynamic optimisation aiming to achieve normal cerebral perfusion|hemodynamic optimisation aiming to achieve normal cerebral perfusion: titration of catecholamin infusion.
45698058|NCT03013660|Other|Limited Financial Support|Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment.
46059146|NCT01071317|Other|Typical care|Care to be determined by attending physician
46059147|NCT04283149|Device|EVO/EVO+ Visian ICL|The investigational lenses are intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
46059148|NCT00783094|Drug|Tadalafil 2.5 mg|oral, daily
46059149|NCT00783094|Drug|Tadalafil 5 mg|oral, daily
45400896|NCT01157572|Drug|Placebo|Patients with moderate to severe aortic valve insufficiency will be randomized to Placebo
45400897|NCT01074372|Drug|REGN727|4 cohorts (dose 1, 2, 3, 4)
45400898|NCT01074372|Drug|Placebo|4 cohorts (dose 1, 2, 3, 4)
45400899|NCT01161784|Dietary Supplement|Probiotics fermented milk|80ml fermented milk containing min. 30 billion live L. casei Shirota strain, administered orally once a day for 4 weeks
45400900|NCT01161784|Dietary Supplement|Nutrient drink|80ml fermented milk without L. casei Shirota strain, administered orally once a day for 4 weeks
45400901|NCT03881254|Other|Human Autologous Homologous Skin Construct|Application of a autologous human derived skin polar units
45400902|NCT03881254|Other|Additional Outer Dressing Applicaiton|Application of Moisture retentive dressing, and a multi-layer compression dressing
45400903|NCT03881254|Other|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
45509284|NCT05087368|Biological|Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
45509285|NCT01341990|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, reconditioning, disinfecting, and storage solution for silicone hydrogel and soft contact lenses
45509286|NCT01341990|Device|ReNu Fresh Lens Comfort Multi-Purpose Solution (MPS)|Commercially marketed prodouct indicated for cleaning, removing protein deposits, rinsing, disinfecting, and storing soft contact lenses
45400904|NCT03881254|Other|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
45400905|NCT01265914|Biological|FP-01.1|Ascending doses of FP-01.1 will be administered
45400906|NCT01265914|Biological|placebo|
45400907|NCT01263964|Procedure|coronary angiogram|coronary angiogram
45400908|NCT01267942|Drug|Enhancin|"Intravenous Enhancin at induction at a dose of 25 mg/kg amoxycillin equivalent.~Oral dose of the same at the same dosage for the active comparator arm."
45400909|NCT02527252|Other|Craniosacral therapy|
45509287|NCT01341990|Device|Silicone Hydrogel Contact Lenses|Commercially marketed silicone hydrogel contact lenses per habitual prescription for daily wear use, at least 8 hours/day. New pair dispensed at Day 0 (Baseline Visit) and at the conclusion of Day 1 (Visit 2).
45509288|NCT05087134|Drug|11C-Choline|11C-Choline were injected into the patients before the PET/CT scans
45509289|NCT05086900|Other|Non-interventional Cross-sectional Patient Reported Outcome Measure Development|Development of Patient Reported Outcome Measure
45509290|NCT03048747|Drug|Tolvaptan Oral Tablet|Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
46059150|NCT00783094|Drug|Placebo|oral, daily
45400910|NCT02527252|Other|Classic Massage|
45400911|NCT00254982|Biological|Infliximab|Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.
45400912|NCT01264042|Dietary Supplement|Ferrous Sulfate|60 mg with 200 mL water, single administration
45400913|NCT01074528|Behavioral|mindfulness based stress reduction program|8-week mindfulness training program
45400914|NCT01268020|Drug|[18F]-FMH3|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not >10% of 5 mCi limit) or 2 ug of [18F]-FMH3, whichever is greatest.
45400915|NCT03968796|Other|Transcutaneous Electrical Nerve Stimulation (TENS)|
45400916|NCT03968796|Other|Sham Transcutaneous Electrical Nerve Stimulation (TENS)|
45400917|NCT03968796|Other|Kinesio Taping|
45400918|NCT03968796|Other|Sham Kinesio Taping|
45400919|NCT03879226|Device|PBMT|PBMT will be applied bilaterally using the direct contact method with light pressure on the skin at different sites, namely 9 sites on the knee extensor muscles, 6 sites on the knee flexor muscles, and 2 sites on the plantar flexor muscles. A 12-diode cluster, with 4 905-nm laser diodes (12.5W peak power for each diode), 4 875-nm LED diodes (17.5 mW mean power for each diode), and 4 640-nm LED diodes (15 mW mean power for each diode), manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used to apply the PBMT. The dose used for the applications during the training and/or detraining periods will be 30 Joules (J) per site (510 J per lower limb). PBMT will be applied before and after each training session and during the detraining period, depending on the group to which the volunteers are allocated.
45509291|NCT05086822|Drug|Irinotecan liposome|Irinotecan liposome
45509292|NCT05354128|Drug|Thrombolytic|Standard intravenous thrombolysis.
45509293|NCT05354128|Procedure|percutaneous coronary stenting|Percutaneous coronary stenting
45509294|NCT03670277|Device|etafilcon A|Test Soft Contact Lens
45509295|NCT03670277|Device|Habitual Orthokeratology Lenses|CONTROL
45509296|NCT05533671|Procedure|medial patellofemoral reconstruction|Surgery to correct dislocated (knocked out of place) knee cap. This surgery anchors the kneecap back into the correct position and supports the kneecap.
45509297|NCT05533671|Procedure|Non-operative group|Physical therapy by following a specific regimen.
46059151|NCT02874599|Procedure|Dental restoration|
46059152|NCT02581579|Dietary Supplement|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis, 1 capsule per day during 14
45400920|NCT03879226|Device|Placebo|Placebo will be applied bilaterally using the direct contact method with light pressure on the skin at different sites, namely 9 sites on the knee extensor muscles, 6 sites on the knee flexor muscles, and 2 sites on the plantar flexor muscles. The placebo PBMT will per performed using the dose of 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). Placebo will be applied before and after each training session and during the detraining period, depending on the group to which the volunteers are allocated.
45400921|NCT03968718|Behavioral|Systematic ePROMs Assessment|"Depending on the care setting, eligible patients will be asked to fill in one of the following e-PROMs assessment:~Edmonton symptom assessment scale (ESAS-r) (outpatients)~Distress Thermometer (inpatients)~An ad hoc questionnaire adapted from the Bench-Can and EURACAN projects plus the institutional customer satisfaction survey (patients followed by multidisciplinary teams)"
45400922|NCT01264120|Behavioral|Health Psychology Intervention|The health psychology intervention will involve a bariatric rehabilitation service (BRS) which will involve those allocated to the intervention receiving usual care plus three 50 minute sessions with a health psychologist pre-operatively (1 week before surgery), perioperatively (before they are discharged from hospital) and at 3 month follow up.
45400923|NCT01582698|Biological|FSME-IMMUN 0.5 ml|Solution/suspension for injection (intramuscular injection into the deltoid muscle of the right or left upper arm). Dosage frequency of booster vaccination: dependent on serum TBE antibodies.
45400924|NCT01586572|Drug|mOPV1|Monovalent type 1 oral poliovirus vaccine (mOPV1) containing at least106 TCID50 of Sabin- strain poliovirus type 1.
45400925|NCT01586572|Drug|bOPV 1,3|The bivalent vaccine containing at least 106 CCID50 of Sabin poliovirus type 1 and 105•8 CCID50 of Sabin poliovirus type 3.
46059153|NCT02581579|Other|Placebo|Placebo, 1 capsule per day during 14
45400926|NCT03971916|Drug|HBM9161(HL161BKN)|Subcutaneous injection; Single dose on Day 1
45400927|NCT03971916|Drug|Placebo|Subcutaneous injection; Single dose on Day 1
45400928|NCT03759340|Drug|ATI 502 0.46% Topical Solution|apply ATI-502 Topical Solution, 0.46% Twice a day (BID) to the entire scalp and if applicable, the eyebrow(s)
45400929|NCT03881176|Device|PoNS Treatment|"The study site will deploy either PoNS Treatment Schedule A or PoNS Treatment Schedule B. Both PoNS Treatment Schedules will consist of three stages: an in-clinic training program, a home training program, and an extended home training program.~During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week. Daily evening sessions and training sessions on weekends will always be performed independently, at-home by the subject"
45400930|NCT03877042|Device|Cruciate-retaining (CR) prostheses|One leg is conducted TKA with Cruciate-retaining (CR) prostheses.
45400931|NCT03877042|Device|Posterior-stabilized (PS) prostheses|One leg is conducted TKA with Posterior-stabilized (PS) prostheses.
45400932|NCT00224016|Drug|Oxybutynin|1.3, 2.6, 3.9 mg/day transdermal
45400933|NCT00224016|Drug|Oxybutynin|5 to 15 mg/day immediate release or extended release tablets, or syrup
45400934|NCT03878680|Other|Study questionnaires|"Completion of the International study of Asthma and Allergies in Children(ISAAC)core questionnaires:~Core questionnaire on wheezing.~Core questionnaire on rhinitis.~Core questionnaire on atopic dermatitis."
45400935|NCT01266226|Device|Autologous conditioned plasma|4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
45400936|NCT01266226|Device|Control group|4mL saline application under the footprint following an arthroscopic repair of the rotator cuff.
45400937|NCT03881410|Procedure|different types of ultrasound technique|Shear-wave elastography-guided or Convention ultrasound-guided
45400938|NCT02527174|Drug|Volasertib|Addition of single dose of volasertib intravenously (IV) on Day 4 of treatment protocol.
45400939|NCT02527174|Drug|Idarubicin|Given IV daily on Days 1-3 of treatment protocol.
45400940|NCT02527174|Drug|Cytarabine|Given IV daily as 24-hour continuous infusion on Day 1-7 of treatment protocol.
45509298|NCT05230186|Procedure|Tumor Biopsy|Research biopsy of solid tumor or sharing of excess tumor tissue during a planned surgical or biopsy procedure and a companion blood sample.
45400941|NCT01264198|Behavioral|Resistance Training|Supervised Resistance Training
45400942|NCT03880942|Other|Informative story book|Patients will be given a colorful story book that tells the hospital and operation procedure named 'Elif Ameliyat Oluyor'(Elif is undergoing surgery) and will be asked to read the book with children at least once before the operation.
45400943|NCT03880942|Other|Non Informative Story Book|Patients will be given a non-medical colorful story book called 'Çiftlik Öyküleri-Kamp' (Farm Stories-Camp) and will be asked to read the book with children at least once before the operation.
45400944|NCT02526940|Procedure|rectal biopsies|6 rectal biopsies
45400945|NCT02526940|Other|Blood samples|Blood samples
45400946|NCT01161940|Drug|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
45400947|NCT01161940|Drug|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
45509299|NCT04954469|Biological|CoVAC-1|Peptide vaccination should be started as soon as possible after the screening visit.
45509300|NCT04051827|Drug|Midazolam|Midazolam Oral Solution and Midazolam Intravenous Infusion.
45509301|NCT04051827|Drug|TAK-788|TAK-788 Oral Capsules.
45509302|NCT05346874|Drug|Oxaliplatin|"The first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1.~The second and fourth cycles: intra-venous oxaliplatin 135mg/m2, day 1."
45400948|NCT01157650|Other|Autologous mesenchymal stem cells|"The trial is divided in three phases:~I. - Selection: Patients evaluation for study eligibility will take place within two weeks after Informed Consent signature.~II.- Treatment phase includes:~Liposuction procedure to obtain adipose tissue.~Processing and production of Autologous Mesenchymal Stem Cells from adipose tissue (ASCs)~ASCs implant~III.- Follow up: Study visits post-implant will take place at the 1st week (+/- 3 days), 4th week (+/- 3 days), 8th week (+/- 7 days), 12nd week (+/- 7 days), 24th week (+/- 7 days), and 1 year (+/- 7 days) after implant."
45509303|NCT05346874|Drug|Teysuno|Oral S-1, 40mg-60mg, day 1-14 for four 21-day cycles.
45509304|NCT05346874|Procedure|Transarterial chemoembolization (TACE)|In the first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1; transcatheter arterial embolism of tumor feeding arteries, day 1.
45509305|NCT05532189|Procedure|ACL reconstruction with BTB autograft with internal brace augmentation (suture tape)|The ACL will be reconstructed using a participant's own patella tendon (BTB autograft), and the graft will be fortified by suture tape during the surgery in order to strengthen it.
45509306|NCT05532189|Procedure|ACL reconstruction with BTB autograft without internal brace augmentation (suture tape)|The ACL will be reconstructed using a participant's own patella tendon (BTB autograft). The graft will not be fortified by suture tape in this group. It will be used as is without any modification.
45509307|NCT05532189|Other|Standardized Rehabilitation Protocol|Participants will undergo a standardized rehabilitation protocol with twice weekly physical therapy
45509308|NCT05325502|Dietary Supplement|caffeine|two doses per day: 200 mg caffeine in the morning; 100 mg caffeine in the afternoon
45509309|NCT05325502|Dietary Supplement|mannitol|two doses per day: 200 mg in the morning & 100 mg in the afternoon
45509310|NCT03730636|Procedure|PCT dosage|Measurement of PCT concentration will be performed every two days and the ATB therapy will be stopped when PCT level reaches a value equal or below 0.5ng/mL.
45509311|NCT03136588|Device|Feedback using ICT based monitoring system|In case of a missed immunosuppressant dose, the first violation does not generate a feedback while the second one does within one hour at the break of the ±3 hour range from the fixed dosing time. Up to two additional alarms/texts are sent at an interval of 30 minutes if the dose is still not taken after the feedback. For any discrepancy between the dosage taken and the dosage prescribed, a feedback is sent within 1 hour from the moment of recognition. Again, the first violation goes without response, while any violation after that generates feedbacks. Similarly, if a dose is taken outside of the allowed ±3 hour dosing time range, a feedback is sent within 1 hour of recognition, starting with the second violation.
45400949|NCT01266382|Device|AposTherapy|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
45400950|NCT03880864|Radiation|Ultrasound|Lung ultrasound
45509312|NCT02123823|Drug|Everolimus|10mg dose
45509313|NCT02123823|Drug|Everolimus|at recommended dose as per Phase I data
45509314|NCT02123823|Drug|Everolimus|Dose escalation (24-48 patients) in Phase I. 3 dose levels depending on the dose cohort explored: 5mg, 7,5mg and 10mg
45509315|NCT02123823|Drug|Exemestane|Fixed dose at 25mg
45509316|NCT02123823|Drug|BI 836845|Human monoclonal antibody at recommended dose as per Phase I data
45509317|NCT02123823|Drug|BI 836845|Human monoclonal antibody. Dose escalation (24-48 patients) in Phase I. 2 dose levels (high or low) depending on the dose cohort explored
45509318|NCT02123823|Drug|Exemestane|Fixed dose at 25mg
45509319|NCT02123823|Drug|Exemestane|Fixed dose at 25mg
45509320|NCT03380273|Behavioral|Implementation of the AO Trauma SSI Prevention Bundle|"AOT SSI Prevention Bundle~Preventive measure~Antibiotic prophylaxis~Perioperative antibiotics~Oxygen administration~Patient temperature~Surgeon protective wear~Patient operative skin preparation~Suction drains~Blood glucose level~Red cell transfusion~Dressing changes"
45509321|NCT05086666|Drug|AZD4547|"In Phase 1b study, subjects will receive continuous twice daily dosing in 21-day cycles (no matter if missed doses or delays exist), with pre-set dose cohorts of 80 mg BID and 120 mg BID.~In Phase 2, subjects will receive continuous twice daily dosing in 21-day cycles with the RP2D or other doses as determined by the investigator and sponsor."
45509322|NCT03328091|Other|Traditional pre-test genetic counseling|Participant meets with a genetic counselor at the Center for Cancer Genetics and Prevention and traditional pre-test cancer genetic counseling is provided
45509323|NCT03328091|Other|Pre-test video education|The video is designed to mirror the educational components of a traditional genetic counseling visit
45509324|NCT05086042|Diagnostic Test|Ultrasonography, Magnetic resonance imaging|The cross-sectional area of the median nerve was measured with US and MRI.
45849957|NCT02882802|Behavioral|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format. MBSR groups will be delivered virtually.
45596717|NCT05576623|Biological|AdCLD-CoV19-1 OMI (Part B)|250 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular injection in the deltoid muscle
45596718|NCT05576623|Other|Placebo (Part B)|50 participants will receive placebo via intramuscular injection in the deltoid muscle
45596719|NCT02374515|Device|EndoCuff-assisted colonoscopy|Adenoma detection rate
45596720|NCT02374515|Device|Standard Colonoscopy|
45596721|NCT03528655|Other|Decision aid|Decision aid is a tool that helps pregnant women become involved in decision making on choosing rooming-in or separation care. Decision aid provides information about the options and outcomes, and by clarifying personal values.
45596722|NCT02374281|Drug|Glucose sucking|
45596723|NCT02374281|Drug|Water sucking|
45596724|NCT02374281|Other|No sucking|
45509325|NCT03138304|Behavioral|Video game|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center.
45509326|NCT03138304|Behavioral|Educational program|Two commercially available applications designed to teach physicians the trauma triage guidelines disseminated by the American College of Surgeons.
45509327|NCT03287687|Drug|Carbon dioxide (CO2) gas insufflation|CO2 gas use for insufflation during endoscopy instead of air insufflation
45509328|NCT03287687|Drug|Air insufflation|Air insufflation is the standard of practice (used in the control arm)
45509329|NCT01991067|Biological|TBE virus vaccine|TBE virus vaccine FSME Immun is used in both arms for the study population and the control group
45509330|NCT03138148|Other|Routine mechanical ventilation|Routine mechanical ventilation in PICU amid children with acute respiratory failure
46057149|NCT03844282|Behavioral|CANTAB|"Originally developed at the University of Cambridge, the Cambridge Neuropsychological Test Automated Battery (CANTAB) platform includes highly sensitive, precise and objective measures of cognitive function, correlated to neural networks. These tests have demonstrated sensitivity to detecting changes in neuropsychological performance and include tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control.~The CANTAB touchscreen battery (www.camcog.com) will be utilised to perform neuropsychological assessments within RESCUE-RACER, whose study-specific protocol may include assessments of: Spatial Working Memory (working memory and strategy), Reaction Time (processing and psychomotor speed), Paired Associated Learning and the Multi-Tasking Test."
46057150|NCT03844282|Diagnostic Test|I-PAS/Dx100|I-PAS™ (now re-named Dx 100) is a portable, head-mounted, neural functional assessment tool. With its integrated clinical eye tracking and digital display, the FDA has cleared (K171884) fourteen tests and an unmatched list of variables for clinical use for a variety of conditions. This utility of this device will be investigated for motorsport-related concussion.
45400951|NCT01162018|Procedure|acupuncture|The eligible women would be randomized and stratified by sleep problems to two arms: (Acupuncture Arm vs. Sham Acupuncture) with a goal of having 48 patients complete the study (we anticipate about 20% attrition rate). The study interventions will begin after patients completed their treatment. The placebo control for acupuncture will be a validated sham acupuncture control Assessments will be made with daily diaries and with weekly questionnaires. There are ten sessions each lasting approximately 20 minutes. All participants will have PSG data collected.
45400952|NCT01162018|Other|placebo|
45400953|NCT01162174|Dietary Supplement|Oligonol|
45509331|NCT03285269|Diagnostic Test|Ultrasound Protocol|Ultrasound of the inferior vena cava, heart and lungs.
45509332|NCT03285269|Device|Bioreactance|Bioreactance assessment using Cheetah Bioreactance Device (FDA Approved). Bioreactance is a non-invasive measure of cardiac output.
45509333|NCT03285269|Procedure|Passive Leg Raise|A passive leg raise involves placing the patient supine and raising the legs to simulate an intravenous fluid bolus.
45509334|NCT05085652|Procedure|spinal anesthesia induced hypotension in SARS-CoV-2 patients.|SARS-CoV-2 infection prognosis remains unclear during pregnancy. according to ESA, ASRA and WHO regional anesthesia was recommended to use for caesarian section procedures. But at the beginning of the pandemic Chen et al shared their retrospective analyses about regional anesthesia for caesarian section and they showed high spinal anesthesia induced hypotension in 14 patients of the 17 and also again Chen and Zahng et al made another study and this time they found 57,4% hypotension incidence. In our study we aimed to find if the spinal anesthesia safe procedure in the 249 patients and one center hospital.
45509335|NCT01940835|Procedure|Upper endoscopy with small bowel biopsies and brushings.|
45509336|NCT01940835|Other|Blood draw|Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC).
45509337|NCT01940835|Other|Stool sample|Stool samples will be collected at baseline for future microbiome and virome studies.
45509338|NCT03089398|Procedure|Hybrid Coronary Revascularization (isolated LIMA-LAD)|sternal-sparing, off-pump, isolated LIMA-LAD revascularization
45509339|NCT03089398|Device|Hybrid Coronary Revascularization (PCI)|percutaneous revascularization of at least one non-LAD target
45509340|NCT03089398|Device|Percutaneous Coronary Intervention|Multi-vessel PCI with metallic drug-eluting stents (DES) including the LAD and or LM. Only FDA approved commercially available metallic drug-eluting stents may be used in this protocol.
45509341|NCT01872273|Other|Moderate Physical Exercise|This intervention is comprised of two separate visits at least one week apart. The purpose of visit 1 is to determine the cycle ergometer workload that produces a moderate exercise intensity of 60% heart rate reserve to be used on visit 2. The purpose of visit 2 is to determine changes in platelet reactivity in response to moderate exercise.
45509342|NCT02886845|Genetic|rs183489969,rs185670819|compare the frequency of two germline mutations in breast cancers and controls
45509343|NCT01787643|Other|Height-Adjustable Desk Intallation in Office|
45509344|NCT01374503|Biological|ALX-0651|single or multiple (once daily for maximum 3 consecutive days) i.v. administration, 0.003-12 mg/kg
45509345|NCT01374503|Biological|Placebo|single or multiple i.v. administration
45509346|NCT05085418|Biological|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
45509347|NCT05759195|Diagnostic Test|Biomolecular tumor analysis|NGS analysis, other molecular analyses on FFPE tumor tissue
45509348|NCT03466996|Behavioral|Intervention group|More frequent follow up with face to face interaction.
45509349|NCT03466996|Behavioral|Standard of care group|Transition goal setting during annual follow up.
45509350|NCT01709331|Drug|Corifollitropin alfa|Corifollitropin alfa 150 μg by SC injection, once every 2 weeks for 52 weeks
45509351|NCT01709331|Drug|hCG|hCG 1500 or 3000 IU by SC injection twice a week; administered alone for 16 weeks (pre-treatment phase) and then in combination with corifollitropin alfa for 52 weeks (combined treatment phase)
45509352|NCT04883099|Device|APIOC for Presbyopia and APIOC for Presbyopia for Astigmatism|Contact Lenses for Presbyopia
45400954|NCT01159990|Biological|rAd5 Gag-Pol Env A/B/C|1×10^10 particle units (PU) rAd5 Gag-Pol, Env A/B/C (3:1:1:1 mixture) delivered via intramuscular injection
45400955|NCT01159990|Biological|rAd5 Gag-Pol|5×10^9 PU rAd5 Gag-Pol delivered via intramuscular injection
45400956|NCT03880630|Other|Inspiratory muscle training|Patients will perform 3 inspiratory loading tests (15%, 30%, and 50% of maximum inspiratory pressures) on 3 separate days with the sequence will be randomized. Patient will then be trained with individualized IMT program based on the results of 3 inspiratory loading tests.
45400957|NCT01160068|Drug|Metformin|Metformin Tablets 1000 mg
45400958|NCT01160068|Drug|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
45400959|NCT01266616|Biological|Profectus HIV MAG pDNA vaccine|3,000 mcg admixture of two vaccine plasmids: ProfectusVax DNA Plasmid (HIV-1 gag/pol) and ProfectusVax DNA Plasmid (HIV-1 nef/tat/vif, env) at Weeks 0, 4, and 12
45400960|NCT01266616|Biological|IL-12|Administered at Weeks 0, 4, and 12
45400961|NCT01266616|Other|Placebo|Saline injections at Weeks 0, 4, and 12
45400962|NCT01162252|Behavioral|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
45400963|NCT01162252|Behavioral|Living Well|The Living Well (LW) program involves a series of informational presentations and group discussions on a variety of topics related to the promotion of health and well-being. The 8-week program is designed to provide participants with knowledge about ways to improve their physical and emotional health as a complement to traditional medical treatments.
45400964|NCT01162330|Other|Screening urine and saliva tests for congenital Cytomegalovirus|With consent for the study babies who are referred for further hearing tests will have a urine and saliva sample sent to be analysed for CMV infection
45400965|NCT01157806|Radiation|short course of palliative radiotherapy|5x5 Gy + XELOX 7 days after radiotherapy
45400966|NCT01266694|Drug|Colchicines|oral form, 1 mg, once a day during 14 days
45400967|NCT01266694|Drug|Placebo|oral form, placebo
45400968|NCT03878836|Other|Routine assessments|Routine assessments, no specific intervention
45400969|NCT03876886|Drug|Epirubicin|Epirubicin 90mg/m2 iv d1 or divide into two days
45400970|NCT03876886|Drug|Cyclophosphamide|cyclophosphamide600mg/m2 iv d1,q14d*4cycles;with G-CSF support: 3ug/kg ih
45400971|NCT03876886|Drug|Paclitaxel|paclitaxel 175mg/m2 iv d1, q14d*4cycles
45400972|NCT03876886|Drug|Carboplatin|carboplatin AUC=3 iv d2, q14d*8cycles;with G-CSF support: 3ug/kg ih
45400973|NCT03876886|Drug|Paclitaxel|paclitaxel 175mg/m2 iv d1, q14d*8cycles
45698059|NCT04746261|Behavioral|ASSIP + treatment as usual|"ASSIP:~First session: Videotaped narrative interview focusing on the background to the suicidal crisis.~Second session: Video playback. The patient and the therapist watch the recorded interview together, stopping the film regularly to add information. The patient is given a psychoeducational text to read and comment on as homework.~Third session: Compilation of a written case formulation of the individual's vulnerability and triggering events that preceded the suicidal crisis. Individual preventive measures are developed by the patient and the therapist together and written down in a document that the patient keeps and which is attached to the patient's medical record.~Fourth session (optional): Mini-exposure.~Standardized letters: The therapist contacts the patient by letter during two years, every three months the first year and every six months the second year.~Treatment as usual: As described bellow"
45400974|NCT03878992|Drug|Genotropin miniquick 0.5 mg, injection|GH will be given as an injection. Muscle biopsy will be obtained from m. vests laterals of the dominant leg. Fat biopsies will be obtained from subcutaneous abdominal fat. Tracers will be given as a bolus followed by continuous infusion for 6 hours. For palmitate tracer the infusion will be for only 1,5 hours followed by a one hour break and then another 1 hour infusion. Blood tests will be drawn from a venous catheter placed on the dorsal side of the hand.
45400975|NCT01266772|Drug|Montelukast sodium.|Children with asthma treated with montelukast and budesonide.
45400976|NCT01266772|Drug|Placebo tablet and budesonide|Children with asthma treated with placebo tablet and budesonide.
45400977|NCT01264354|Drug|Clevudine 30mg|Clevudine 30mg
45400978|NCT01264354|Drug|Clevudine 20mg+Adefovir dipivoxil 10mg|Clevudine 20mg+ Adefovir 10mg
45400979|NCT01264354|Drug|Clevudine 20mg|Clevudine 20mg
45400980|NCT01264432|Other|Laboratory Biomarker Analysis|Correlative studies
45400981|NCT01264432|Other|Quality-of-Life Assessment|Ancillary studies
45400982|NCT01264432|Radiation|Radiation Therapy|Undergo LDFWAR
45400983|NCT01264432|Drug|Veliparib|Given PO
45400984|NCT03880318|Procedure|Joint Preserving Surgery in spasmodic flat foot|extensor digitorum longus, peroneus brevis and tertius lengthening together with calcaneal osteotomies
45400985|NCT02527096|Drug|dolutegravir (Tivicay®) - Phase 1|• Phase 1 (8 weeks) : switch of the third agent with dolutegravir(Tivicay®) 50 mg once a day.
45400986|NCT02527096|Drug|lamivudine (Epivir®) - Phase 2|• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
45596725|NCT05227573|Procedure|Orthopedic surgery|Knee-, hip-, shoulder- and elbow surgery
45509353|NCT03136510|Drug|Apixaban 5 mg|"Bood collection for biological analyses at:~inclusion visit~follow-up visit at 1 month~end of research at 3 month"
45509354|NCT05693259|Device|Electrolyzed Alkaline Reduced Water (EARW) generated from electrolyzed ionizer|Patient will be allocated randomly to two groups: EARW and PW groups. For 6 weeks, patients drink water (10mL/kg body weight/day ) generated from the device installed in the house before starting intervention. Patients will be instructed to drink in empty stomach, and to drink immediately after generation of water. The total amount that the patient drank the day before will be monitored by a researcher using survey form of mobile phone everyday.
45509355|NCT03451474|Procedure|Upper extremity nerve transfer surgery|Upper extremity nerve transfer surgery is a surgical procedure where axons from an intact, functioning upper extremity peripheral nerve are moved to a target muscle that demonstrates significant weakness or paralysis as a result of spinal cord injury. After allowing time for recovery from surgery and for nerve growth to occur, the patient undergoes hand/occupational therapy in order to retrain motor skills.
45509356|NCT05693181|Biological|Multiple systemic (i.v.) administration of allogenic non-related group- and rhesus-compatible mononuclear cord blood cells|Each HUCBCs sample contain 500 +/- 50 x 10*6 allogenic non-related group- and rhesus-compatible mononuclear cord blood cells
45509357|NCT05693181|Other|Control vehicle (sterile saline)|Sterile saline infusion in control patients
45509358|NCT03136354|Procedure|Endoscopic Submucosal Dissection|
45509359|NCT03136354|Procedure|Laparoscopic assisted Gastrectomy|
45509360|NCT05692245|Drug|Ondansetron|Administered Medication
45509361|NCT05692245|Drug|Dexamethasone|Administered Medication
45509362|NCT03136276|Other|IPS Empress CAD|standard etchable glass ceramics
45715273|NCT05164822|Other|Necrotizing Vasculitis|"Pain scale Diagnosis of necrotizing vasculitis and peripheral neuropathy, Clinical characteristics of the disease, Biological analysis, Treatment and evolution of the disease,~Questionnaires :~Neuropathy Impairment Score (NIS) sensitive sub-questionnaire that measures extremity sensitivity.~MRC (Medical Research Council), which evaluates three motor functions on each member.~RODS questionnaire on the relationship between your daily activities and your health.~BVAS (Birmingham Vasculitis Activity Score) disease activity questionnaire. VDI (Vasculitis Damage Index) questionnaire evaluates the sequelae of the disease.~Rankin Score modified to measure the degree of disability~Two tests will be performed:~EMG (electromyogram) to evaluate the electrical activity of the muscles, Walking Test of 10 meters which aims to measure the time taken to travel 10 meters."
45849958|NCT02882802|Behavioral|Trauma Recovery Education Class|Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions. TREC groups will be delivered virtually.
45849959|NCT02881554|Procedure|Computed Tomography|Undergo SC SPECT/CT
45400987|NCT02527096|Drug|dolutegravir (Tivicay®) - Phase 2|• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
45400988|NCT01160224|Drug|GW766944|Drug: GW766944 (Active Drug Treatment)
45400989|NCT01160224|Other|Placebo|This is placebo to match.
45400990|NCT03876730|Other|ICF CP Core Set|Core set
45400991|NCT01162564|Device|NG-TSM|Flexible Composite Next Generation Tissue Separating Mesh
45400992|NCT01162642|Dietary Supplement|Green Tea|Green Tea 4 cups daily
45400993|NCT01162642|Other|Placebo|4 cups placebo tea for 6 weeks
45400994|NCT01266928|Drug|vitamine C and E|Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
45400995|NCT01157962|Procedure|Lymphadenectomy in cervical cancer|Sentinel lymphadenectomy vs systematic pelvic lymphadenectomy
45400996|NCT03879928|Drug|Single ascending doses of FM101|The study drug (FM101 and placebo comparator) will be administered orally as SAD doses
45400997|NCT03879928|Drug|Multiple ascending doses of FM101|The study drug (FM101 and placebo comparator) will be administered orally as MAD doses
45400998|NCT03879928|Drug|Food effects of FM101|The study drug (FM101) will be administered orally under fasted condition and fed condition.
45400999|NCT01160302|Drug|Microgranular Curcumin C3 Complex®|4 grams twice daily for 21-28 days
45509363|NCT03136276|Other|polished Celtra Duo|new glass ceramic material
45509364|NCT05693103|Device|High-Intensity Focused Electromagnetic therapy|"The HPM-6000UF is a non-invasive therapeutic device. The device produces electromagnetic field that interacts with the tissues of the human body.~The electromagnetic field delivered in the muscular or neuronal tissue area is triggering the stimulation and tonisation."
45509365|NCT05085106|Drug|Felbinac trometamol eye drop|Felbinac trometamol eye drop: 0.025%、0.05%、0.1%、0.2%、0.3%, 1 drop will be instilled as instructed over one day in single-dose study; 0.1%, 0.2%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
45509366|NCT05085106|Drug|Placebo eye drop|Placebo eye drop: 0.0%, 1 drop will be instilled as instructed over one day in single-dose study; 0.0%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
45509367|NCT03079336|Behavioral|Implementation - SOTA|The implementation of an evidence-based treatment is largely principle-based - allowing considerable therapeutic flexibility in determining and timing of different treatment aspects. In this condition progress, subtle changes and sudden gains may be an explicit topic and there is no restraint to avoid such topics. However, the therapists are not obligated to take a systematized focus on potential subtle changes and they may use the timing of the sessions to involve the patients into the other tasks of therapy.
45849960|NCT02881554|Procedure|Single Photon Emission Computed Tomography|Undergo SC SPECT/CT
45401000|NCT01162720|Procedure|Long duration tourniquet|Patients randomised to this arm will have the tourniquet applied at the commencement of surgery and removed prior to wound closure.
45401001|NCT01162720|Procedure|Short duration tourniquet|Patients assigned to this arm will have the tourniquet applied during cement fixation of the prosthesis only (ie removed just prior to wound closure).
45401002|NCT01268176|Dietary Supplement|cholecalciferol|50,000 IU once per month for 3 months
45401003|NCT03878290|Behavioral|Resilience, Stress, and Ethnicity (RiSE)|Group based stress reduction program focused on helping minorities develop coping and empowerment skills
45401004|NCT01264588|Other|Topical calcium glycerophosphate lotion|2g once daily for 6 weeks (post-op day 3 thru 42)
45401005|NCT01267006|Drug|GSK1325756|GSK1325756 will be available as white, film coated immediate release tablets with dose strengths of 50 mg, 100 mg and 200 mg. The tablets will be administered twice daily by oral route with 240 milliliters of water.
45401006|NCT01267006|Drug|Placebo tablet|Placebo will be available as white film coated GSK1325756 matching tablet which will be administered twice daily by oral route with 240 milliliters of water.
45401007|NCT01268332|Drug|Non-medicated Intravaginal Ring|Cured silicone elastomer composed of an elastomer base, normal propylorthosilicate, and titanium dioxide. The ring will not contain an active pharmaceutical ingredient.
45401008|NCT01162798|Other|infant formula|test infant formula fed to infants until 6 months corrected gestational age
45401009|NCT01162798|Other|control infant formula|commercially available infant formula
45401010|NCT01158196|Device|infra-red diode laser|"laser treatment of scar after keloid excision~laser treatment of surgery scar"
45401011|NCT01162876|Drug|saxaglipitin|oral administration of 5 mg tablet before breakfast for 14 consecutive days
45401012|NCT03877588|Dietary Supplement|Oral Nutritional Support|Preoperative oral nutritional support is provided according to malnutrition grade
45401013|NCT05666908|Device|HFNO|After the patient's mask-assisted ventilation makes the end-expiratory oxygen concentration (EtO2) > 90%, wear the HFNO device according to the pre-adjusted mode (temperature 34°C, oxygen concentration 100%, flow rate 50 litres per minute). The nasal cannula will remain in place until intubation is complete (including DLT intubation, direct FOB guidance, and DLT alignment with FOB). After securing the HFNO device, the glottis was exposed using a laryngoscope, and the DLT main tracheal cuff was passed through the glottis and paused under direct vision. Insert the DLT into the bronchial tube lumen of the DLT using the FOB, and then advance the DLT into the corresponding main bronchus under the guidance of the FOB. After confirming the appropriate depth of the catheter using the FOB, insert the DLT into the anesthesia machine to complete the intubation process. After the DLT was connected to the anesthesia machine and mechanical ventilation was started, the HFNO device was removed.
45401014|NCT05075200|Drug|Tranexamic acid|Participants in both groups will be given single intravenous bolus of TXA 20 mg/kg over 15 min after induction of spinal (or other regional technique) or general anesthesia as per standard of care.
45401015|NCT03876418|Diagnostic Test|Intra-abdominal Pressure|Aggressive screening, prevention and treatment of intra-abdominal hypertension
45401016|NCT01158274|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
45401017|NCT01158274|Drug|capecitabine|Given orally
45401018|NCT01158274|Other|laboratory biomarker analysis|Correlative studies
45401019|NCT05666830|Device|Lando® artificial dermal regeneration matrix|Participants will be treated with artificial dermis that perfomed with STSG simultaneously.
45401020|NCT03876496|Device|SensableCare System|"The Sensable®Care Mattress has sensors embedded in it. Sensable®Care System is able to identify if the subject is stirring in bed, sitting up from the bed, attempting to leave the bed, or being out of the bed. If the subject is found to be in any of these four scenarios, four different types of alerts/notifications will warn clinicians: Stirring Notification, Sitting Up Notification, Bed Leaving Alert, Out of Bed Alert, will be generated by Sensable®Care System respectively.~Once these four alerts/notifications are generated, designated attending nurses or caregivers equipped with a mobile app will receive audible, vibratory, and/or visual alerts from the Dashboard with subject's room number and type of alert displayed mobile app. Thus, interventions/assistance can be carried out presumably early. Harm to patient safety may be prevented."
45401021|NCT01267084|Drug|Trabectedin|Patients will receive trabectedin 1.3 mg/m2 when given alone and 0.2mg/m2 when given with ketoconazole, intravenously (into a vein) for 3-hour.
45401022|NCT01267084|Drug|Ketoconazole|Patients will receive ketoconazole 1 X 200 mg tablet, two times a day, orally (by mouth)
45401023|NCT01267084|Drug|Dexamethasone or equivalent steroid|Patients will receive dexamethasone 20 mg or equivalent steroid intravenously, 30 minutes before trabectedin in each cycle.
45401024|NCT01158352|Dietary Supplement|Nutritional supplementation formula|Nutritional supplementation formula
45401025|NCT01158352|Dietary Supplement|Placebo Comparator|Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
45401026|NCT01162954|Drug|DA-6034|
45401027|NCT01162954|Drug|Placebo|
45401028|NCT01264666|Dietary Supplement|Chinese tea flavor liquor|60 mL of Chinese tea flavor liquor (45% alcohol content) is consumed with high-fat meal.
45401029|NCT01264666|Dietary Supplement|Chinese Meijiao liquor|
45401030|NCT01264666|Dietary Supplement|Water control|
45401031|NCT01160692|Dietary Supplement|Multivitamin/Multimineral/Ginkgo (BAY 81-2775)|Multivitamin/Multimineral/Ginkgo (BAY 81-2775), daily oral intake of film coated tablets for 3 months
45401032|NCT01160692|Other|Placebo|Daily oral intake of matching placebo tablets for 3 months
45401033|NCT01158430|Behavioral|ACT group therapy|Group therapy (ACT) in groups of 9 patients in 9 weekly 3.5-hours sessions & 1 booster session 1 month after 9th session, a total of 35.5 hours
45401034|NCT01264822|Drug|Rabeprazole Sodium|"The following 3 drugs are taken orally at the same time twice daily for 7 days: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and clarithromycin 200 mg.~The dose of clarithromycin may be properly increased as needed, although the upper limit is 400 mg twice daily.~If Helicobacter pylori eradication with proton pump inhibitor, amoxicillin, and clarithromycin fails, the following 3 drugs will be taken at the same time twice daily for 7 days as an alternative treatment for adults: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and metronidazole 250 mg."
45596726|NCT03240861|Other|18F-FHBG|Given IV
45596727|NCT03240861|Biological|Aldesleukin|Given SC
45509368|NCT03079336|Behavioral|Implementation - Prolonged focus on changes|Systematized sequence of exploration of subtle changes at a prolonged check-in phase: (1) the precise change situation, (2) related emotional states, (3) related helpful thoughts and self-verbalizations, (4) reinforcement of generalized self-efficacy and treatment motivation, (5) benefit for the upcoming session goals (Flückiger, Grosse Holtforth, et al. 2013, 2014).
45401035|NCT05025280|Other|Adolescent/Adult Sensory Profile Questionnaire|"The Adolescent/Adult Sensory Profile Questionnaire (AASP), was developed based on Dunn's model of sensory processing. It is a 60-item self-assessment questionnaire that evaluates behavioral patterns related to sensory processing. The questionnaire consists of six different subsections such as taste/smell processing, movement processing, visual processing, touch processing, auditory processing, and activity level. According to the answers given, individuals are evaluated in 4 quartiles as low registration, sensory sensitivity, sensation avoiding, and sensation seeking."
45509369|NCT03079336|Behavioral|Mastery your Anxiety and Worry (MAW)|"In the present study, the MAW-packet will be applied within a usual 16-session individual therapy format and up to 3 further booster sessions.~The session format of 50-60 minute usually consists of (a) a check-in phase of 5 to 15 minutes that includes a patients welcoming, reviewing self-help and agenda setting, (b) a working phase around 35-45 minutes that focuses on the previously agreed session goals, (c) a feedback phase of 5 to 10 minutes that summarizes the session and previews the upcoming self-help assignment."
45509370|NCT05692167|Drug|Topical dexmedetomidine|Patients will receive mixture of one milliliter of dexmedetomidine-HCl and local anesthetic
45509371|NCT05692167|Drug|Reginal dexmedetomidine|Patients will receive mixture of bupivacaine 0.5% (4.5 ml) + lidocaine 2% (4.5 ml) + dexmedetomidine 50 μg (1 ml) in peribulbar block
45509372|NCT05084872|Drug|Hydroxychloroquine|Patients will be treated by hydroxychloroquine at a dose of 6 to 6.5mg/kg/day during 12 month
45509373|NCT00159796|Drug|Asenapine|Asenapine, 3 weeks
45509374|NCT00159796|Drug|Olanzapine|Olanzapine, 3 weeks
45509375|NCT00159796|Drug|Placebo|placebo, 3 weeks
45509376|NCT03626571|Other|18F-FDG|Hybrid 18F-FDG PET/MR or PET/CT imaging for observational diagnostic purposes.
45509377|NCT05084560|Drug|AWZ1066S|Candidate drug to treat lymphatic filariasis by targeting Wolbachia endosymbiont
45509378|NCT05084560|Drug|Placebo|Placebo
45509379|NCT03368014|Behavioral|Lyrics-writing and singing show|"Participants will participate in a Lyrics-Writing and Singing Competition. They will first attend a lyrics-writing workshop and a short talk on SME (Sharing, Mind, Enjoyment) focusing on praising family members and knowledge of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; submit SME (Sharing, Mind, Enjoyment) worksheet, such as Express Your Love to Family Member after the workshops; participate in the SME (Sharing, Mind, Enjoyment) Lyrics-writing and Singing Show and Award Ceremony (sharing) with a live performance by awarded entries and prize presentation ceremony."
45509380|NCT03361462|Behavioral|Joyful Adventure Day|"Participants will participate in two joyful adventure days with adventure games and a short talk on SME (Sharing, Mind, Enjoyment) focusing on positive thinking and understanding of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; provide physical activity diary, such as Zero-time Exercise after 1st session of adventure day, and invite family members / peers to join the competition at the 2nd session."
45509381|NCT03327844|Drug|RET using antibiotics (Ciprofloxacin and Metronidazole)|RET using antibiotics Ciprofloxacin and Metronidazole. First Treatment Visit: Local analgesic, tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal drying using paper points. Delivery of mixture of Bi antibiotic paste (Ciprofloxacin and Metronidazole with sterile water). Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstriction, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
45596728|NCT03240861|Drug|Busulfan|Given IV
45849961|NCT02881554|Drug|Technetium Tc-99m Sulfur Colloid|Given IV
45849962|NCT02829918|Drug|Nivolumab|Participants will receive nivolumab at a dose of 240 mg intravenously (IV) every 2 weeks (Q 2W) for 16 weeks (16W) and then 480 every 4 weeks (Q4W) from 17 weeks to end of study.
45849963|NCT02795988|Biological|IMU-131|IMU-131 vaccine is a P467-CRM197 peptide antigen in PBS buffer and Montanide ISA 51 Sterile adjuvant
45401036|NCT03880006|Behavioral|Case management|Case management intervention is a multi-step process to coordinate care and provide a family-like support system for people living with HIV. Individuals are assigned to a specific case manager who will provide support throughout the study. The case management approach has five key components: 1) initial meeting between person living with HIV and case manager; 2) follow up meeting between case manager and participant; 3) biweekly automatic text messages sent to participant; 4) monthly phone calls from case manager; and 5) face-to-face meetings between case manager and participant every 6 months.
45401037|NCT01161004|Drug|Sugammadex - Nacl 9/00|"Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~Nacl 9/00: same volume as Sugammadex"
45401038|NCT01161004|Drug|Nacl 9/00 - sugammadex|"Nacl 9/00: same volume as Sugammadex~Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses."
45401039|NCT03876340|Other|Treatment algorithm|Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures. The thermograms will be used to dictate the initial treatment.
45596729|NCT03240861|Biological|Cellular Therapy|Given LV-NYESO TCR/sr39TK PBSC IV and RV-NYESO TCR PBMC IV
45596730|NCT03240861|Procedure|Computed Tomography|Undergo PET/CT
45596731|NCT03240861|Biological|Filgrastim|Given SC
45596732|NCT03240861|Drug|Fludarabine|Given IV
45596733|NCT03240861|Procedure|Leukapheresis|Undergo leukapheresis
45596734|NCT03240861|Drug|Plerixafor|Given SC
45596735|NCT03240861|Procedure|Positron Emission Tomography|Undergo PET/CT
46059154|NCT04303637|Behavioral|Phone use|Objective and subjective reports of smartphone use (e.g., number of hours, number of pick-ups, how phones are used)
45509382|NCT03327844|Drug|RET using non-setting Calcium Hydroxide|First Treatment Visit: Local analgesic, Tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the non-setting Calcium Hydroxide. Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstrictor, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
45509383|NCT05692947|Device|Core body temperature device|This study is to verify the claims of CORE™ body temperature system to estimate core body temperature from skin temperature and heart rate during exercise under varying environmental conditions. Subjects will ingest a temperature sensing pill and be outfitted with skin temperature sensors, a chest strap heart rate monitor, and the CORE and CaleraResearch devices. Athletes will run or cycle in hot/dry and hot/humid conditions for 45 minutes at an absolute workload of 60% VO2 Max/Peak.
45509384|NCT03288766|Procedure|PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software|The SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) is an FDA-cleared fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology, indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients without any alterations of cardiac rhythms that change the normal presentation of the P-wave. A software package, MODUS II, has been developed to accurately analyze the entire ECG complex and identify the correct placement of the PICC tip based on a patient's individual ECG, in the absence of an easily identifiable P-wave. This software system is designed to provide visual and/or audio cues to notify the PICC placer of the location of the PICC tip relative to the cavoatrial junction (CAJ) of the patient.
45509385|NCT03230032|Device|pacifier-activated device|The utilization of the pacifier-activated-music player combines the sound of the mother's voice with a pacifier routinely used with each patient during their inpatient NICU stay
45509386|NCT05691855|Drug|89Zr-NY009|Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY009
45509387|NCT03123640|Other|Medication reconciliation and medication review|Pharmacist performed medication reconciliation and medication review
45509388|NCT03068416|Biological|CAR T cells|Autologous CD19-targeting, 3rd generation CAR T cells
45509389|NCT03109912|Behavioral|Personalized-Coaching Interventions|At the baseline fitness assessment, participants receive exercise prescriptions based upon their individual assessment. One of the ultimate exercise prescription goals is to achieve 30-minutes of an endurance-style exercise 5 times/week which may vary depending upon baseline fitness assessment. Aside from team sports, endurance-style exercise prescriptions may include simply walking, jump roping or stair climbing to more complex Tabata-style workouts. Two additional physical therapy (PT) 30-minute appointments are scheduled about 4-6 weeks and 8-10 weeks from enrollment. These 30-minute PT follow-up appointments will vary based on initial assessment and previous exercise prescription success but will include strength training for major muscles groups and/or flexibility exercises with yoga as well as reinforcement of previously learned techniques. PT will add additional individualized recommendations.
45509390|NCT03109912|Behavioral|Motivational Messages|Intervention participants are enrolled to receive motivational messages starting 14 days after enrollment via preferred contact method (SMS, telephone call and/or email) every 3-4 days over the 6-month study period.
45509391|NCT03109912|Behavioral|Online Exercise Tutorials|Participants are given access to Do More, B'More, Live Fit webpage which includes spotlighted exercises, instructional exercise photos and videos.
45509392|NCT03109912|Behavioral|Social Support and Peer Challenges|Participants are invited to join the Do More, B'More, Live Fit Activity Group via the FitBit Dashboard and are invited to friend the study team members and other exercise-intervention participants in order to take part in FitBit step-goal challenges.
45509393|NCT05691621|Drug|Standard Reagents, Whole Blood|All patients receive standard treatment, only their blood and urine samples are needed
45509394|NCT05058820|Other|Post Facilitation stretch|Hot pack 10 mins/ 1set/ (3 days/ week), TENS 10 mins/ 1 set/ (3 days/ week), Post facilitation stretch 15 secs isometric hold/ 15 secs stretch/ 30 secs relax/ 5 reps/ 1 set/ (3 days/ week), Deep friction massage 5 minutes/ (3 days/ week). A total of 6 weeks (18 sessions, 3 days/ week) were given each consisting of 30 mins.
45596736|NCT04605211|Behavioral|Online Mindfulness Meditation|Complete online audio-based mindfulness meditation exercises
46057151|NCT03844282|Biological|Saliva sample|Micro RNA's (miRNA's) are easily measured in saliva and have proven to have both diagnostic and prognostic use in sports-related concussion across the adolescent and adult populations, with levels persisting for some weeks after the concussive event. RESCUE-RACER will collect saliva samples for analysis of biomarkers of concussion, which may include miRNA and other markers of injury.
45401040|NCT03876340|Other|Current treatment|Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures, but the results will be kept sealed until the study is finished. The patients will receive the usual standard of care as dictated by the surgical team.
45401041|NCT01163110|Dietary Supplement|Realbuild|Patient with chemotherapy induced thrombocytopenia takes RNA fragments orally to accelerate time to platelet recovery
45401042|NCT01264900|Behavioral|Psychotherapy|Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment or supportive psychotherapy
45401043|NCT01264978|Device|Repetitive magnetic stimulation of the quadriceps muscle|"During 8 weeks, 7-10 days after hospital release, patients will receive repetitive magnetic stimulation sessions, 15 minutes on each thigh, alternatively two and three days /week.~Coil location: centered on the union between upper and lower two thirds of the vastus lateralis.~Stimulation bursts at 10-7 HZ lasting 2 seconds, followed by 4 seconds rest. Intensity will be from 40 to 70% of maximal output, adjusting frequency so that the coil does not overheat, (more than 41ºC).~Coils are cooled down to 5ºC before sessions."
45401044|NCT03876574|Procedure|DSA-guided implantation of hepatic artery infusion pump|Implant the infusion catheter and injection port (Celsite, B. Braun, Chasseneuil, France) under DSA-guiding. The proximal end of the infusion catheter was connected to the injection port and the device was implanted in a subcutaneous pocket in the right inner thigh; the distal end of the infusion catheter guarantee uni-direction infusion to liver.
45401045|NCT03876574|Drug|Gemcitabine|Given intra-arterially for 30 minutes
45401046|NCT03876574|Drug|Floxuridine|Given intra-arterially continuously for 14 days
45401047|NCT03876574|Drug|dexamethasone|Given intra-arterially continuously with 5-FUDR
45401048|NCT01158508|Procedure|Remote ischemic preconditioning|Transient lower limb ischemia will be induced by inflation of a blood pressure cuff on the thigh. Four five minute cycles of ischemia will be performed, each followed by five minutes of reperfusion with the cuff down. This procedure will be performed in four rounds, typically on post-hemorrhage days 2, 3, 6 and 9.
45401049|NCT01268722|Device|Balloon angioplasty|This arm will include patients randomized to undergo the treatment of a chronic total occlusion of the femoropopliteal artery with the use of balloon angioplasty
45401050|NCT01268722|Device|Primary stenting|This arm will include patients randomized to undergo primary stenting of the femoropopliteal chronic total occlusion
45401051|NCT01161082|Drug|REGN727(SAR236553)|subcutaneous
45401052|NCT01158586|Drug|Levobupivacaine|patient control epidural analgesia using 0.2% levobupivacaine with 2ug/ml fentanyl
45401053|NCT01158742|Other|Glomerular Filtration Rate with Iothalamate|used to determine kidney function
45401054|NCT01158742|Other|Glomerular Filtration Rate with Iohexol|used to determine kidney function
45401055|NCT01267396|Drug|Sertraline|Sertraline Hydrochloride Tablets 100 mg
45401056|NCT05018884|Procedure|Observation of surgical site infections|No intervention is done, only observation of routine clinical practice
45401057|NCT01158898|Drug|TPI ASM8|ASM8 4mg/mL (low dose) daily for 14 days by inhalation
45401058|NCT01158898|Drug|TPI ASM8|ASM8 4mg/mL (high dose) daily for 14 days by inhalation
45401059|NCT01158898|Drug|TPI ASM8|Placebo PBS solution daily for 14 days by inhalation
45715274|NCT05145400|Drug|Isatuximab|Pharmaceutical form: Solution for infusion Route of administration: Intravenous Isatuximab :10 mg/kg intravenous will be administered in cycle 1-24.
45401060|NCT02527018|Device|Sphygmomanometer|Non-invasive reliable method of continuous measuring arterial blood pressure in pregnant women. Nextfin provides continuous blood pressure, heart rate, cardiac output, stroke volume, systemic vascular resistance and left ventricular contractility indices.
45401061|NCT01161238|Other|Monitored for limb volume|Subjects are monitored for limb volume change using bioimpedance analysis
45401062|NCT01267474|Other|Nutritional education|"A nutritional education program was carried out during seven months of one school year aiming to reduce added sugar in school meals by the school lunch cooks and in their own consumption.~All women in the intervention group participated in three sections about sugar consumption and one section on food labeling, as well as recipes competition of with reducing sugar.~Printed material and gifts, such as mugs, refrigerator magnets and small purses with the logo of the campaign were given to the participants.~All sections of education were delivered in the schools. The activities required 20 to 30 minutes and were facilitated by trained research assistants. Printed instructions and orientations on the facilitation process supported the assistants' efforts."
45401063|NCT01267474|Other|Control|The control group received only three one-hour general sessions on health issues.
45401064|NCT01267552|Procedure|Non drains will be placed during operation|Non drains will be placed during operation
45401065|NCT01267552|Procedure|Closed suction drainage|Closed suction drainage will be placed during operation
45401066|NCT01159132|Drug|raltegravir|12 hour PK will be done on day 1 while subjects is on stable regimen with RAL 400 mg BID. After performing intensive PK, subjects will be randomized to either group A (RAL 400 mg OD) or B (RAL 800 mg OD) for 14 days and on day 15, a second 24 hour full PK will be carried out. After the intensive PK, subjects in both the groups will switched to the other dosing regimen, group A (RAL 800 mg OD) and B (RAL 400 mg OD) for another 14 days and on day 29, the third 24 hour full PK will be carried out.
45401067|NCT01161316|Drug|mFOLFOX-6 + cetuximab until disease progression or early withdrawal.|"Treatment regimen:~mFOLFOX-6, day 1, every two weeks; OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations."
45596737|NCT04605211|Other|Internet-Based Webinars|Attend webinars
45715275|NCT05145400|Drug|Lenalidomide|"Pharmaceutical form: Capsule for oral use, Route of administration: Oral Lenalidomide capsule will be given oral, the dose will be adjusted according to glomerular filtration rate (GFR): 15 mg daily if GFR > 60 mL/min, 5 mg daily if GFR 30-60 mL/min, 2.5 mg daily if GFR < 30 mL/min. Note that dialysis-dependence comprises an exclusion criterion for this study.~Lenalidomide will be continued until disease progression, excessive toxicity or death."
45509395|NCT05058820|Other|Active Isolated Stretching|Hot pack 10 mins/ 1set/ (3 days/ week), TENS 10 mins/ 1 set/ (3 days/ week), Active Isolated Stretching 2 secs hold/ 10 reps/ 1 set/ (3 days/ week), Deep friction massage 5 minutes/ (3 days/ week). A total of 6 weeks (18 sessions, 3 days/ week) were given each consisting of 30 mins.
45509396|NCT05691543|Procedure|sacrospinous fixation Using Posterior Vaginal wall flap|"Identification of the sacro spinous ligament.~Insertion of the sacrospinous stitch. Using a long - handled needle holder, a J - shaped Ethibond suture is placed 2 - 3 cm medial to the right ischial spine. Using posterior vaginal wall flap (rectangular flap )will be incised and retracted Superior to the right , the stitch of sacro spinous ligament will be attached to the flap not the vault after adjusting its size , then the sit . The stitch should be placed through and not around the ligament. The application of firm traction to the suture length will test the correctness of its placement. A second suture is inserted for additional support. We may do it directly or by using an alternative surgical instruments for placement of the suture include the knee scorpion. Per rectum examination should be undertaken to check for misplaced sutures.~Attachment of the sutures to the vaginal flap . The two sutures are then secured to the upper posterior aspect of the vaginal flap ,"
46057152|NCT03844282|Other|fMRI|RESCUE-RACER participants will be invited to complete a functional MRI scan, whose 90-minute protocol may include: multi-parametric mapping (MPM), susceptibility weighted imaging (SWI), diffusion weighted imaging (DWI), proton spectroscopy and functional MRI (fMRI) with blood oxygenation-level dependent contrast (BOLD), completed at 7T (Tesla), or 3T if this is not possible.
45401068|NCT01161316|Drug|8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.|"Treatment regimen.~mFOLFOX-6. day 1 every two weeks. OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations."
45401069|NCT01161550|Drug|Granulocyte colony-stimulating factor (G-CSF)|
46057153|NCT03967951|Other|CT radiomic feature evaluation|"Radiomic features will be calculated and extracted from all contrast and non-contrast CT-scans. First order features will be evaluated and high order features will be grouped in parent matrices. Parent matrices of second and third order will be chosen and evaluated.~In the second part, based on the results of inter-correlation of the operator analysis, the most significant radiomic features will be chosen. Morphological and histopathological features will be evaluated will be.~Histopathology will be performed on a biopsy specimen; percentage of Ki67 and grading will be evaluated."
45509397|NCT05042206|Biological|Cellgram-CKD|Allogeneic bone marrow-derived mesenchymal stem cell therapy for the treatment of chronic kidney disease
45509398|NCT05008510|Drug|Sabizabulin|Sabizabulin (Veru-111)
45509399|NCT05008510|Drug|Sacituzumab Govitecan-hziy|Sacituzumab govitecan-hziy
45509400|NCT05008510|Drug|Sabizabulin/Sacituzumab govitecan-hziy Combo|Sabizabulin/Sacituzumab govitecan-hziy Combo therpy
45509401|NCT05001256|Other|questionnaire study|Participants will be surveyed through face-to-face interviews.
45509402|NCT03019510|Behavioral|No exercise|No exercise will be done on the day of the study night to be tested
45509403|NCT03019510|Behavioral|Morning exercise|Early morning exercise will be done on the day of the study night to be tested
45509404|NCT03019510|Behavioral|Evening exercise|Evening exercise will be done on the day of the study night to be tested
45509405|NCT04402996|Other|Saliva|"individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
45509406|NCT04402996|Other|gingival crevicular fluid|"GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
45509407|NCT05194995|Drug|JAB-21822|JAB-21822 administered orally as a tablet.
45401070|NCT01161550|Drug|Cladribine|
45401071|NCT01161550|Drug|Cytarabine|
45401072|NCT01161550|Drug|All-Trans Retinoic Acid (ATRA)|
45401073|NCT01161550|Drug|Midostaurin|
45401074|NCT01159210|Biological|Prothrombin complex concentrate (coagulation factors IX, II, VII and X in combination)|Intravenous infusion; regimen is guided by the pre-treatment international normalised ratio (INR); dosage and duration of replacement therapy depend on the severity of the disorder, on the location and extent of bleeding and on the patient´s clinical condition.
45401075|NCT03877198|Device|Automated oxygen control by the CLiO2 algorithm|Automated oxygen control for 24 hours by the CLiO2 algorithm, preceded by a 1 hour wash-out period
45401076|NCT03877198|Device|Automated oxygen control by the Oxygenie algorithm|Automated oxygen control for 24 hours by the Oxygenie algorithm, in case of switch in ventilator preceded by a 1-hour wash-out period.
45509408|NCT05194995|Drug|Cetuximab|Cetuximab administered as an intravenous (IV) infusion.
45509409|NCT02972944|Procedure|Laparoscopic cholecystectomy|
46057154|NCT03790852|Drug|KSI-301|Intravitreal injection
46057155|NCT02609698|Device|Coroflex ISAR|This stent platform has a thin-strut cobalt-chromiun alloy backbone, no polymer, microporous surface.
46057156|NCT02609698|Drug|3 months DAPT|
46057157|NCT02609698|Drug|6 months DAPT|
46057158|NCT02609464|Device|Interrupted Knotted Sutures|
46057159|NCT02609464|Device|STRATAFIX Symmetric PDS PLUS Knotless Tissue Control Devices|
46059155|NCT02874833|Other|Exercise|After performance diagnostics, participants will complete an 8-week supervised, individualized exercise program. Training will include up to 3 aerobic training sessions and up to two resistance training units per week.
45509410|NCT02972944|Procedure|Non-operative treatment|
45509411|NCT03136978|Diagnostic Test|Evaluation of M1 and M2 macrophages by flow cytometry.|To assess surface expression of macrophage markers, tissue samples will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.
45509412|NCT05187039|Other|Electrical impedance tomography during anesthesia|Thoracic electrical impedance tomography measurements ( min each) will be performed at the following time points: before induction of the anaesthesia; before the surgical procedure when the induction is terminated and recruitment manoeuvers have been performed; after the termination of the surgical procedure; before transport to the Post anaesthesia Care Unit (PACU); before the discharge from the PACU after 2 hours of monitoring. An additional thoracic EIT-measurement will be performed before discharge at home. For this, resulting potential differences are measured, and impedance distribution sampled at 30 Hz will be calculated. Relative change in poorly ventilated lung regions (silent spaces) and end-expiratory lung impedance (EELI) and measures of ventilation inhomogeneity will be calculated using customised code (Matlab R2021a, The MathWorks, Nattick, Massachusetts, USA).
45509413|NCT04401280|Drug|BiominF|in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached
45509414|NCT04401280|Drug|Novamin|in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached
45509415|NCT04401280|Drug|CPP-ACP|applied in accordance with the manufacturer's specifications
45509416|NCT02963272|Other|Conventional strategy|Conventional strategy to manage the patients with HF, following the international guidelines.
45509417|NCT02963272|Other|ST2-guided strategy|patients wit ST2 over the median are targeted with higher doses of drugs with putative effects on fibrosis and anti HF pathophysiology
45509418|NCT03137836|Behavioral|Intervention|"Multi-level intervention focused on school environment (furniture) will be conducted.~Device: Sit-to-stand desks (Ergotron LearnFit®); Device: (Actigraph, Pensacola, FL, USA); Device: ActivPALTM ."
45401077|NCT01159288|Biological|Dex2|"Metronomic dosage of Cyclophosphamide during 3 weeks (50mg/day orally) as reported 15, before specific treatment.~Induction immunotherapyIntradermal injections of Dex once a week during 4 consecutive weeks.(Peptides pulsed onto DC, sources of Dex: PRS pan-DR, MAGE-3 DP04, MAGE-1 A2, MAGE-3 A2, NY-ESO-1 A2 et MART-1 A2)~Continuation Immunotherapy: Intradermal injections of Dex every two weeks during 6 weeks."
45401078|NCT03879460|Drug|Naltrexone Hydrochloride|50 mg per os naltrexone hydrochloride
45509419|NCT05181891|Behavioral|Contingency Management|Incentives for submitting negative-alcohol urine samples
45509420|NCT05181891|Behavioral|Non-contingent control|Incentives for submitting urine samples
45401079|NCT03877120|Drug|Dexmedetomidine 0.004 MG/ML|Experimental studies and single case reports suggest the α2-agonist dexmedetomidine is effective in managing the autonomic symptoms seen with alcohol withdrawal.
45401080|NCT03877120|Drug|Diazepam Injectable Solution|diazepam start with 5-20 mg IV as a dose response, steps until a maximum dose of 120 mg diazepam.
45509421|NCT05180487|Behavioral|Family Check-Up|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers. A minimum of 5 coaching sessions will be provided.
45401081|NCT01159366|Procedure|percutaneous coronary intervention|early timing
45401082|NCT01267786|Procedure|Liver surgery|hepatectomy
45401083|NCT03879382|Biological|anti-CD19/BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
45401084|NCT03879382|Drug|Fludarabine|30mg/m2/d
45401085|NCT03879382|Drug|Cyclophosphamide|300mg/m2/d
45509422|NCT04896970|Other|Concert|A musical show in a closed hall, lasting for about 2 hours, in respects of safety measure (masks, hydroalcoholic gel, etc…) with approximately 200 participants.
45509423|NCT03136666|Drug|Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil|Candesartan and nifedipine were administered together as loose combination with 240 mL non-sparkling water in the morning after a fasting period of at least 10 hours.
46059156|NCT04303247|Biological|CD19 and CD22 targeted CAR-T cells|The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
45509424|NCT05355363|Diagnostic Test|Standard Colonoscopy|Standard colonoscopy: All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards.
45509425|NCT03255083|Drug|DS-1205c|DS-1205c 200 mg capsule
45401086|NCT03874780|Device|Vibe Delivery system|delivery of Botox (TM) to the bladder wall using an ultrasound technology with the Vibe delivery system
45401087|NCT03874390|Other|ozone|gaseous ozone was applied on periodontal pocket two times in one week.
45401088|NCT01265290|Device|repeated 24 hours ECG Holter monitoring|repeated 24 hours ECG Holter monitoring
45401089|NCT01265290|Device|Telemetric ECG monitoring|Telemetric ECG full disclosure monitoring with GSM technology
45401090|NCT01166932|Drug|Amoxycillin/clavulanic acid|100mg/Kg/day/10 days.
45401091|NCT01166932|Drug|ceftriaxone/oxacillin|75 mg/Kg/day/10 days.
45401092|NCT01167010|Drug|Formoterol/Budesonide|formoterol and budesonide will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
45401093|NCT01167010|Drug|Foraseq|foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
45509426|NCT03255083|Drug|Osimertinib|Osimertinib 80 mg tablet
45509427|NCT02514148|Behavioral|Therapeutic patient education|Therapeutic patient education based on pain physiology from a biobehavioral perspective adding a training in coping strategies.
45509428|NCT02514148|Other|Therapeutic exercise|Therapeutic exercise consist on stretch of cervical-scapular muscles ( Trapezius and angular of the scapula), Cranium-cervical flexor stabilization exercise, auto cervical tractions, shoulders rotation, low intensity exercise ( walking), craniocervical extension, cervical flexion and extension.
45509429|NCT02514148|Other|No intervention|No intervention consist on measure the whole variables in chronic migraine patients to compare it with experimental interventions
45509430|NCT02514148|Other|Manual Therapy|Manual therapy consist on ; oscillatory traction , maintained craniocervical traction, upper cervical flexion mobilization, side glide roll, anterior-posterior upper cervical mobilization with wedge, lateral glide at the C1-C2 and C2-C3 levels, retraction technique, trigeminocervical neural mobilization , and upper cervical traction, followed by posterior-anterior glide at C4.
45509431|NCT05244915|Other|Experimental (Delphi Surveys)|The Delphi method, a process used to arrive at a group opinion or decision by surveying a panel of experts, will be used with experts in geriatric oncology to develop a supportive care management intervention for older caregivers of older adults with cancer.
45509432|NCT05244915|Other|Experimental (Focus Groups)|Focus group qualitative interviews will be conducted with key stakeholders consisting of older adults with cancer and their caregivers.
45509433|NCT05244915|Other|Qualitative interviews|Qualitative interviews will be conducted with older caregivers of older adults with cancer to inquire about their experience with caregiving and unmet supportive care needs.
45509434|NCT05234853|Drug|PUR001|Monoclonal antibody
46057160|NCT05750134|Other|OBPLUS Clinical Database : data analysis|The data processed relates to patients cared for in the Hepato-gastroenterology and nutrition department of the Antoine Béclère Hospital at the Assistance Publique - Hôpitaux de Paris (AP-HP. All of the clinical and paraclinical data are collected during the visits and entered into the OBPLUS database (database registered in the AP-HP register). These data will be analyzed in order to identify the predictive factors of the effectiveness of the fundo-plication.
45401094|NCT01167010|Drug|Alenia|Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
45401095|NCT01280188|Drug|Desmopressin Oral Melt|Oral melt formulation starts on Day 2. The target initial dose of the orally disintegrating tablet is 180µg/day (60µg taken 3 times a day) and adjusted to optimally stabilise the participant's condition.
45401096|NCT01280188|Drug|Desmopressin intranasal|Self-administered intranasal desmopressin throughout the pre-study observation period (Days -30 to Day 0) and on study Day 1
45401097|NCT01269502|Device|"Temp Touch Diabetica Solutions inc."|Daily measurement of skin temperature on feet for one year
45401098|NCT01269502|Other|Inspection|Inspection of feet daily for one year
45509435|NCT05759039|Procedure|Medial patellofemoral ligament reconstruction|Medial patellofemoral ligament reconstruction
45509436|NCT04861558|Drug|5Fluorouracil|Injection of 250-850 mg/m2.
45509437|NCT04861558|Drug|Irinotecan|Injection of 360 mg/m2
45509438|NCT04861558|Drug|Oxaliplatin|Injection of 460 mg/m2
45509439|NCT03240419|Dietary Supplement|Probiotics|Bifidobacterium BB12 and Lactobacillus Rhamosus LGG (50%:50%) capsules.
45509440|NCT03240419|Dietary Supplement|Placebo|capsule manufactured to mimic probiotic capsules.
45509441|NCT03745053|Device|Xlimus DES Implantation during coronary angioplasty|Xlimus DES Implantation during coronary angioplasty
45509442|NCT03745053|Device|Synergy DES Implantation during coronary angioplasty|Synergy DES Implantation during coronary angioplasty
45509443|NCT01665118|Device|Trusculpt (Radio Frequency) Device|
45509444|NCT03735537|Drug|Teriparatide Pen Injector|
45509445|NCT03735537|Drug|Zoledronic Acid|Any brand or preparation may be used to deliver the required dose of 5mg
46057161|NCT05750134|Other|"Biological collection Liver, bile ducts and pancreas: sample analysis"|"The samples (plasma, serum, saliva, stool) collected during the samples taken as part of the patient's care were the subject of a biological collection Liver, bile ducts and pancreas. These samples will be analyzed in order to identify the predictive factors of the effectiveness of the fundo-plication."
45401099|NCT03872050|Diagnostic Test|No intervention apart from tests, including interview|No interventions
45401100|NCT01167088|Drug|Mitoquinone mesylate|2 tablets to be taken daily upon wakening, with a glass of water and at least one hour before food.
45401101|NCT01167088|Drug|Placebo|Placebo
45401102|NCT03871972|Drug|Umbilical Cord Blood Unit|3 infusions of umbilical cord blood (UCB) unit (TNC > 2.0ⅹ107cells/kg) each 4 months apart and take oral Sirolimus (1 mg/m2/day) for 7 days (from 3 days before UCB infusion until 3 days after UCB infusion)
45401103|NCT01164982|Device|Mepitel One|Each subject will be followed once a week for 3 weeks or until healing if that occurs earlier
45401104|NCT01165060|Drug|Bezafibrate|Week 0 to 12: 400 mg once daily 1 tablet. Week 13 to 24: 400 mg once daily 2 tablets.
45401105|NCT01280578|Device|Transcatheter PFO Closure|Transcatheter PFO Closure
45401106|NCT01165294|Drug|Placebo|An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
45401107|NCT01165294|Drug|ketamine|An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
45401108|NCT05406310|Device|Ablation Index-guided ablation|Radiofrequency catheter ablation guided by Ablation Index software.
45401109|NCT05406310|Device|High-power, short-duration ablation using QDOT Micro catheter|Radiofrequency catheter ablation guided by high-power, short-duration ablation using QDOT Micro catheter
45401110|NCT03871738|Other|Proprioceptive training|"The intervention to the experimental group will consist of the application of the protocol of proprioception exercises. Before the exercises of the protocol, a warm-up will be carried out that will last 3 minutes and consists of exercises of joint mobility and jumping rope.~The protocol consists in carrying out two exercises per session, of 10 minutes each. A minute of rest will be implemented between the warm-up and the completion of the protocol, in addition to one minute between the two proprioception exercises in each session. The exercises will vary from week to week, and all the protocol exercises should be done barefoot. The exercise protocol proposed in this study consists of a total of 7 exercises: of unipodal and bipodal support, with unstable surfaces and postural changes."
45401111|NCT01165372|Drug|Artesunate or dihydroartemisinin-piperaquine|artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily
45401112|NCT03871660|Device|FreeStyle Libre Pro|Flash glucose monitoring device. Measures patients interstitial glucose levels continuously.
45401113|NCT03871582|Other|No intervention|Cross-sectional
45401114|NCT01167322|Drug|NPC-07 for oral administration|NPC-07, containing 1.5g of 5-aminolevulinic acid hydrochloride per vial, is dissolved in 50 mL of water and will be administered orally 3 hours (range 2-4 hours) prior to induction of anesthesia at a dose of 20mg/kg body weight.
45401115|NCT01269814|Procedure|Gastroscopy|Gastroscopy
45401116|NCT01280734|Drug|Circadin (R) 2 mg|One 2 mg tablet at 23:00
45401117|NCT01280734|Drug|Stilnox (R) 10 mg|One 10 mg encapsulated tablet at 23:00
45401118|NCT01280734|Drug|Placebo|One tablet or encapsulated tablet at 23:00
45401119|NCT03871504|Other|Submaximal isometric exercise|The exercise is a submaximal isometric contraction
45401120|NCT01269892|Dietary Supplement|lactose-free milk|a milk without lactose
45401121|NCT01269892|Dietary Supplement|conventional milk|a milk with lactose
45401122|NCT01280890|Behavioral|Staff training using VIPS|Staff training using the VIPS framework
45401123|NCT01280890|Behavioral|Staff training using DCM|The staff will be supervised using Dementia Care Mapping
45401124|NCT01280890|Behavioral|Control group|Filmed traditional Lectures will be given to care staff
45401125|NCT01269970|Other|18-FDG-PET-CT|
45401126|NCT01587430|Drug|high dose ARA-C|high dose ARA-C consolidation together with high cumulative dose of anthracyclines daunorubicin, idarubicin, mitoxantrone(720-660 mg/m2)
45401127|NCT01587430|Drug|standard dose ARA-C|
45401128|NCT03874000|Biological|Sintilimab|Given IV
45401129|NCT03874000|Drug|Metformin Hydrochloride|Given PO
45401130|NCT01165528|Procedure|type of mechanical ventilation|patients are randomized to receive one of the two types of mechanical ventilation for ARDS
45401131|NCT01167400|Behavioral|Cybercycling|exercising on a videogame-enhanced interactive 3D stationary bicycle for 3 months, 3-5x/wk
45401132|NCT01167400|Behavioral|Traditional exercise|exercising on a traditional stationary bike for 3 months, 3-5x/wk
45401133|NCT03757234|Drug|Omadacycline|po tablets
45401134|NCT03757234|Drug|Levofloxacin|iv solution/po tablets
45401135|NCT03757234|Drug|Omadacycline|iv solution
45401136|NCT03756766|Diagnostic Test|RSV point of care testing|Patients will have 2 nasopharyngeal swabs, a nasal swab, a stool and urine taken at baseline/ enrolment and the RSV positive ARTI group will have samples repeated at 6-8weeks.
45401137|NCT03874156|Drug|Atorvastatin 40mg|Oral tablet fabricated and labelled at Krageroe Tablettproduksjon AS
45401138|NCT03874156|Drug|Placebo Oral Tablet|Oral tablet fabricated and labelled at KrageroeTablettproduksjon AS
45401139|NCT01165606|Procedure|Chest physiotherapy|
46057162|NCT02713113|Drug|sugammadex reversal of neuromuscular blockade|
45509446|NCT04552587|Behavioral|Heart APP|The HEART intervention includes a care planning visit for patients and caregivers and an App for caregivers focused on nutrition, self-care and support.
45509447|NCT04809922|Device|cardiac wearable devices|"five cardiac wearable devices~Apple Watch, Apple Inc., Model Number: A1977 / A1978~Kardia Mobile, AliveCor Inc., AC-009/Kardia Mobile 6L, AliveCor Inc., AC-019~Fitbit Sense, Fitbit, Inc, Model Number: FB512~Samsung Galaxy Watch 3 Samsung Inc., Model Number: SM-R855F~Withings Scanwatch, Withings SA, Model Number: HWA09 Used for recording of one single-lead ECG. The results will be 274 compared to a simultaneous 12-lead ECG, which is considered the gold standard for detecting AF. There is no comparator in this trial."
45509448|NCT04531059|Drug|Esomeprazole|Proton pump inhibitor
45509449|NCT04531059|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
45509450|NCT04531059|Drug|Tetracycline,Metronidazole|Antibiotics for H. pylori eradication
45509451|NCT04531059|Drug|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
45509452|NCT03136744|Behavioral|Sit Less with MS|The Sit Less with MS intervention has a total duration of 16 weeks and consists of two stages: sit less and move more stages. During the first stage (sit less), we will conduct coaching sessions with participants every week and the focus will be on interrupting their sitting time every 30 minutes. Facebook and Twitter will be also used to provide information and supplement coaching sessions. During the second stage, the focus will be on encouraging the participants to move more by replacing sitting with light intensity activities frequently throughout waking hours.
45401140|NCT01586650|Other|aerobic training|The intervention comprises fifty minutes of walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
45509453|NCT05171127|Procedure|Diffuse Reflectance Spectroscopy|Measurements of DRS patterns in extirpated tumor and cerebral tissue
45509454|NCT05090176|Other|povidone-soaked suture|suture soak with povidone solution for 3 mins
45509455|NCT05090176|Other|ordinary suture|suture no need to soak with povidone solution
45509456|NCT05090020|Procedure|Treatment|Surgery and PAIR
45509457|NCT04530981|Drug|Ripretinib|Oral KIT/PDGFRA kinase inhibitor
45509458|NCT04530981|Drug|Repaglinide|Oral antihyperglycemic agent
45509459|NCT05158335|Drug|MBX 2109 (Part A)|Single ascending SC dose of MBX 2109: 50 µg, 150 µg, 300 µg, 460 µg, 600 µg
45401141|NCT01586650|Other|Stretching exercises|Global stretching exercises will be performed for about 20 minutes 3 times a week for 12 weeks with supervision of specialized physiotherapists.
45509460|NCT05158335|Drug|MBX 2109 (Part B)|Repeated ascending SC doses of MBX 2109: 200 µg, 300 µg, 460 µg, 600 µg, 900 µg
45509461|NCT05158335|Drug|Placebo|Single SC dose or repeated SC doses of placebo.
45509462|NCT04543786|Device|Transcutaneous spinal cord stimulation|Neuromodulation with transcutaneous spinal cord stimulation applied on lower back adjacent to spine for 30-60 minutes for 5 consecutive days.
45509463|NCT04716166|Other|Volume-oriented incentive spirometry|3 sets of 5 repeated deep breaths using volume oriented incentive spirometry 3 times a day for 2 days
45509464|NCT04716166|Other|Flow-oriented incentive spirometry|3 sets of 5 repeated deep breaths using flow oriented incentive spirometry 3 times a day for 2 days
45401142|NCT01586728|Other|Air - oxygen|"his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period)~nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 > 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.~During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 <= 90%."
45401143|NCT01586728|Other|Oxygen - Air|"nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 > 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.~his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period) During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 <= 90%."
45509465|NCT04701502|Dietary Supplement|Viusid|"Patients received daily doses of 30 ml of Viusid every 8 hours plus standard care for COVID-19. Viusid is administered orally.~Treatment duration: 21 days"
45509466|NCT04701502|Dietary Supplement|Asbrip|"Patients received daily doses of 10 ml of Asbrip every 8 hours plus standard care for COVID-19. Asbrip is administered orally.~Treatment duration: 21 days"
45509467|NCT04701502|Drug|Standard Care|Standard care for COVID-19
46057163|NCT05749822|Drug|Fenofibrate 200mg|Fenofibrate 200mg/day
46057164|NCT05749822|Drug|Placebo|1 tablet/ day
46057165|NCT05749822|Drug|UDCA|UDCA 13-15mg/kg/day
45509468|NCT01316055|Drug|Dalfampridine-ER|2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up
45509469|NCT04700878|Behavioral|Internet-based compassion course for stress managemant|A five week long, structured self-help program with weekly reports to, and feedback from a compassion-focused (CFT) therapist over the Internet. Includes traditional CFT-methods for stress-related problems.
45509470|NCT04700878|Behavioral|General Internet-based cognitive behavioural course for stress management|A five week long, structured self-help program with weekly reports to, and feedback from a cognitive-behavioral (CBT) therapist over the Internet. Includes traditional CBT-methods for stress-related problems.
45596738|NCT03527251|Drug|Ipilimumab|Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
45596739|NCT03527251|Drug|SHR-1210|Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
45401144|NCT01167478|Dietary Supplement|Caffeine|After ingestion of 6 mg.kg-1 of body mass of caffeine, subjects will perform the one exercise trial.
45401145|NCT01167478|Dietary Supplement|Caffeine|6 mg/kg of body mass of caffeine will be ingested by subjects before exercise.
45401146|NCT01281358|Other|HOP-ON|A programme of activities which promote motor development
45401147|NCT01281358|Other|SMILES|Details are provided on ways for parents to interact with their premature infants
45401148|NCT01281436|Other|HeartSmartKids & Web-based Provider Training|The providers assigned to Group 2 will receive the web-based training described in the web-based training arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
45401149|NCT01281436|Other|Web-based Provider Training|The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
45715276|NCT05145400|Drug|Dexamethasone|Pharmaceutical form: Tablet for oral use, Route of administration: Oral Dexamethasone tablet will be given oral: 20 mg given on days 1, 8, 15 and 22 of cycles 1-8. Administration may continue beyond cycle 8, if needed, for the prevention of infusion reactions.
45849964|NCT02795988|Drug|Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.|Chemotherapy will consist of: cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle), or (in Phase 2 only) oxaliplatin, by intravenous administration at 130 mg/m2 on Day 1 of each cycle and capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle).
45401150|NCT01587196|Drug|Vivitrol|There are monthly injections of depot naltrexone for 3 months.
45401151|NCT01281514|Drug|everolimus|Given PO
45401152|NCT01281514|Drug|carboplatin|Given IV
45401153|NCT01281514|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
45401154|NCT01281514|Other|laboratory biomarker analysis|Correlative studies
45401155|NCT00223080|Biological|ALVAC-HIV vCP1521 + AIDSVAX|Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL
45401156|NCT00223080|Other|ALVAC Placebo + AIDSVAX Placebo|ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection
45401157|NCT03871192|Diagnostic Test|FACET JOINT UNDER CT GUIDANCE|injection of triamcinolone in the facet joint under CT guidance
45401158|NCT03871192|Diagnostic Test|NERVE BLOCK UNDER CT GUIDANCE|injection of triamcinolone around the dorsal ramus under CT guidance
45401159|NCT03871192|Diagnostic Test|FACET JOINT UNDER FLUOROSCOPY GUIDANCE|injection of triamcinolone in the facet joint under fluoroscopy guidance
45401160|NCT03871192|Diagnostic Test|NERVE BLOCK UNDER FLUOROSCOPY GUIDANCE|injection of triamcinolone around the dorsal ramus under fluoroscopy guidance
45401161|NCT03871192|Diagnostic Test|FACET JOINT UNDER ULTRASOUND GUIDANCE|injection of triamcinolone in the facet joint under ultrasound guidance
45401162|NCT03871192|Diagnostic Test|NERVE BLOCK UNDER ULTRASOUND GUIDANCE|injection of triamcinolone around the dorsal ramus under ultrasound guidance
45401163|NCT02526784|Drug|degarelix|
45401164|NCT03971682|Behavioral|PSYCHOPATHY.COMP program.|"The PSYCHOPATHY.COMP program is a structured individualized program for detained youth based on Compassion Focused Therapy, aimed to develop a compassionate motivation in these youth.~Treatment As Usual Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation."
45401165|NCT03971682|Other|Treatment As Usual - TAU|Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation.
45401166|NCT02526706|Other|VisionBlue|VisionBlue is a staining solution designed to assist in making complete capsulorhexis during cataract surgery. The dye is injected into the anterior chamber via a paracentesis port and stains the anterior lens capsule, assisting in adequate visualization of the anterior lens capsule. This study proposes to explore the use of VisionBlue during cataract surgery as a means to assess functioning of an existing filtering bleb placed during prior trabeculectomy in patients with glaucoma.
45596740|NCT02363517|Drug|Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP)|SOF + LDV tablets contain 400mg of SOF and 90mg of LDV.
45715277|NCT05140642|Other|Automated annotation of the left ventricle through deep learning|A semantic segmentation deep learning model will identify the left ventricle and label the left ventricle. The AI model will produce an assessment of LVEF using video based features.
45715278|NCT05140642|Other|Sonographer Measurement of LVEF|Standard practice sonographer measurement of left ventricle and assessment of LVEF
45509471|NCT04685668|Behavioral|The PartoMa guidelines and training|"All health care providers (physicians and nurse-midwives) working at the Department of Obstetrics in five study sites during the study period will be invited to participate in knowledge tests of obstetric care and qualitative participant observations as well as in-depth interviews regarding quality of care. This is a part of evaluating the use and effectiveness of the PartoMa intervention.~The intervention includes the following two components:~Implementation of a pocket booklet with simple and locally achievable clinical guidance for safe and respectful care at birth developed by the research team and birth attendants at the five hospital study sites;~Quarterly, the birth attendants will be offered training in the use of the booklet in 3-hour case-based seminars."
45509472|NCT05349357|Other|Sliding Neural mobilization|Sliding neural mobilization to femoral, sciatic and tibial nerve
45509473|NCT05349357|Other|Tensioner Neural mobilization|Tensioner neural mobilization to femoral, sciatic and tibial nerve
45509474|NCT05349357|Other|Stretching exercises|Stretching exercises
45509475|NCT05349357|Device|TENS|TENS
45509476|NCT04674124|Behavioral|Brief Online Mindfulness Intervention|A nine-week mindfulness course compromising of 9x weekly 15 minute group sessions which will be on an online platform and daily micro meditations for participants to undertake.
45509477|NCT01340976|Drug|LY2787106|Administered IV.
45509478|NCT01340976|Dietary Supplement|Iron Supplementation|Administered orally.
45698060|NCT04746261|Other|Treatment as usual and patient safety|"All patients follow their usual care, regardless of whether they are treated with ASSIP or not. Usual care is multidisciplinary and combines psychotherapy, pharmacotherapy and other treatments, including referral to specialist psychiatric units or primary care. This depends on the assessments made by the patient's usual care provider. Treatment as usual is monitored by the research team through a standardised medical record review.~In order to increase patient safety, some standardisation of usual care takes place. The research nurse communicates with the referring healthcare provider to ensure that the patient receives a follow-up appointment within the usual care setting after the initial visit and the research team informs the usual care provider and acts when acute suicide risk is detected. In most sites, some information from SIS, CSSR-S and MINI assessments is noted in the patient's medical records."
45698061|NCT04278495|Drug|Cozaar (Losartan Potassium 25mg)|Cozaar (Losartan Potassium 25mg)
45698062|NCT04278495|Drug|Placebo|Placebo
45401167|NCT01281592|Drug|LOR-253 HCl|LOR-253 HCl will be given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate target dose is reached. Patient will be treated on LOR-253 HCl for 2 cycles for the evaluation.
45401168|NCT03971604|Drug|Vitamin A|treated with Vitamin A
46057166|NCT04226781|Diagnostic Test|Hyperspectral-Imaging|Photos were taken with the hyperspectral camera of the gastrointestinal anastomosis.
46057167|NCT04226781|Diagnostic Test|Indocyaningreen-Fluorescence imaging|Photos were taken with the Fluorescence camera after injection of the indocyaningreen-dye of the gastrointestinal anastomosis
45401169|NCT03971604|Drug|Vitamin E|treated with Vitamin E
45401170|NCT02531490|Drug|Labetalol|
45401171|NCT02531490|Drug|Nifedipine|
45401172|NCT02531490|Drug|Methyldopa|
45401173|NCT02526472|Procedure|ET under transabdominal US guidance (UGET)|When UGET was used, a second physician performed trans-abdominal US, and the embryos were discharged when the tip of the catheter was visualized approximately at 1,5 cm from the fundal endometrial surface
45401174|NCT02526472|Procedure|ET after transvaginal US uterine measurement (mTVET)|When mTVET was scheduled, the physician performed a transvaginal US scan just before ET, measured the length of the cervix and of the uterine cavity, and calculated the distance between the internal uterine os and the fundal endometrial surface. Then, ET was performed inserting the inner cannula in order to discharge embryos at a point obtained subtracting 1.5 cm from the total length of the cavity.
45401175|NCT03871114|Drug|Triamcinolone Acetonide in orabase|treatment of OLP with topical steroid
45401176|NCT01272622|Radiation|Radiation|Immediate irradiation after incomplete resection (fractionated, percutaneous irradiation, 54 gy)
45401177|NCT01272622|Other|wait and watch|wait ans watch, MRI controls, irradiation at the time of progression of residual tumor
45401178|NCT01281670|Other|vibration|8 week vibration
45509479|NCT05675007|Dietary Supplement|Colon-delivered multivitamin supplement|Colon-delivered multivitamin supplement containing the following dose of the indicated vitamin: vitamin B2 (10 mg), vitamin B3 (4.0 mg), vitamin B6 (1.4 mg), vitamin B9 (400 μg), vitamin C (200 mg) and vitamin D3 (15ug). Vitamin capsules are filled with microcrystalline cellulose and magnesium stearate up to 200 mg. Control of release in the colon is achieved by the Eudragit S 100 coating layer technology that surrounds the vitamins contained in the core capsules.
45509480|NCT05675007|Dietary Supplement|Placebo capsule|Placebo capsule containing microcrystalline cellulose and magnesium stearate up to 200 mg. Placebo capsules are coated with the Eudragit S 100 coating layer.
45509481|NCT05089240|Device|Ophthalmic lens with extra power|
45509482|NCT05089006|Procedure|Partial nephrectomy with robot-assisted and open surgery|Robot-assisted partial nephrectomy (RAPN) is considered as a feasible minimally invasive alternative to open partial nephrectomy (OPN) for the surgical treatment of renal tumors. The main advantages of this technique include a three-dimensional magnified view of the surgical field, enhanced dexterity, and greater precision in both dissection and reconstruction.
45401179|NCT01281748|Drug|intravenous methylprednisolone|methylprednisolone 0,5 mg/kg every 6 hours for 72 hours, 0,5 mg/kg every 12 hours on days 4 through 6, 0,5 mg/kg daily for day 7 through day 10
45401180|NCT01281748|Other|intravenous normal saline solution|50 ml of intravenous normal saline solution every 6 hours for 72 hours, 50 ml every 12 hours on days through 6, 50 ml daily for day 7 through day 10.
45401181|NCT03873610|Behavioral|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
45401182|NCT03873610|Behavioral|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
45401183|NCT00220740|Drug|Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified|2 g/kg body weight ideally over 2-4 days . Thereafter, study drug infusion (IGIV-C) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
45401184|NCT00220740|Drug|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin 25%, USP diluted with dextrose 5% to a final concentration of 0.1% as an intravenous infusion. Alternatively, it may be a bottled placebo of 0.1% Albumin (Human) in 0.2 M Glycine, 1.1 mm sodium caprylate, 0.25% sodium chloride. 2 g/kg body weight ideally over 2-4 days . Thereafter, infusion (placebo) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
45401185|NCT03870958|Procedure|GIC sealant (GC Fuji TRIAGE®)|Children allocated to this group will receive the same dietary advices and brushing instructions. Additionally, all MIH molars from will receive a GIC sealant (GC Fuji TRIAGE®, GC Europe, Leuven, Belgium).
45401186|NCT03870958|Procedure|Control|Children allocated to this group will receive the same dietary advices and brushing instructions.
45401187|NCT01167556|Behavioral|Family Motivational Intervention|A intervention with provided parents 6 sessions of Interaction Skills training and 6 sessions Motivational Interviewing training.
45401188|NCT01074606|Device|AcrySof Toric Intraocular Lens|Implantation of the AcrySof Toric Intraocular Lens (IOL)
45401189|NCT01273402|Drug|TF2/IMP288|TF2 is administered 4 days prior to radiolabeled IMP288. Each are given weekly for 2 weeks.
45401190|NCT01273714|Procedure|thyroid resection|bilateral subtotal versus total thyroidectomy
45401191|NCT03873688|Other|expiratory muscle training|The intensity of training will been determined after assessment of maximal expiratory pressure (MEP). The first training session will perform under the supervision of a physiotherapist, patients will perform training at home. MEP measurement will reevaluate every two weeks and the intensity of training will set according to MEP levels.
45401192|NCT01167790|Procedure|buccal cavity examination|autofluorescence examination
45401193|NCT03873454|Device|Sennheiser non-occlusive headphones|Patients listened to music of their choice using non-occlusive headphones
45401194|NCT03873454|Device|Sennheiser non-occlusive headphones without music|Patients wore non-occlusive headphones but had no music playing
45509483|NCT05088915|Behavioral|Primary Care Intervention for PTSD (PCIP)|"This program is adapted from the B.R.E.A.T.H.E. - Brief Relaxation, Education and Trauma Healing: A Brief Intervention for Persons with PTSD and Co- Occurring Serious Mental Health Conditions. Treatment Program Manual and Patient Handouts (Version 3) by Kim T. Mueser, Rachael Fite, Stanley D. Rosenberg, and Jennifer D. Gottlieb."
45509484|NCT05088915|Behavioral|Treatment As Usual|Receive standard care treatment and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
45509485|NCT05088850|Other|no intervention|no intervention
45509486|NCT05665959|Other|Reiki|Reiki is based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distant Reiki, Reiki practitioners followed the traditional Usui Reiki protocol for distant healing.
45401195|NCT03873454|Other|No Sennheiser non-occlusive headphones|Patients did not wear non-occlusive headphones and did not listen to music
45401196|NCT01274728|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention with at least use of drug-eluting balloon and if necessary cross-over to bail-out stenting with BMS.
45401197|NCT03873298|Drug|Inhaled nitric oxide|Inhaled nitric oxide delivered through a pulsatile nitric oxide drug delivery system
45401198|NCT00184002|Drug|Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone|"Cycle 1 Doxil 40 mg/m2 iv day 1 over a minimum of 60 min.~Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min.~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum).~Prednisone 100 mg po days 1-5.~Cycle 2 until study completion~Doxil 40 mg/m2 iv day 1~Rituxan 375 mg/m2 iv day 1~Cyclophosphamide 750 mg/m2 iv day 1~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum)~Prednisone 100 mg po days 1-5~1 cycle = 21 days.~Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles."
45401199|NCT01167868|Drug|FosD|oral tablet
45401200|NCT01167868|Drug|Placebo|oral tablet
45401201|NCT01167946|Drug|methylprednisolone sodium succinate|Group A will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
45401202|NCT01167946|Drug|methylprednisolone sodium succinate|Group B will receive 2 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
45509487|NCT05086497|Diagnostic Test|Whole Brain Spectroscopy Imaging Array Mapping Layout|All study participants will receive whole brain spectroscopy imaging as a part of MRI study time points. Participants assigned to the advanced MR imaging array mapping layout study arm will receive tumor treating fields mapping from Optune that is created from the spectroscopy sequences or advanced MR imaging. Participants assigned to the conventional array mapping layout will still receive advanced imaging sequences or spectroscopy imaging at all time points.
45509488|NCT05659563|Drug|Giredestrant|Giredestrant is a highly potent, non-steroidal, oral selective ER antagonist and degrader (SERD)
45401203|NCT01167946|Drug|methylprednisolone sodium succinate|Group C will receive 3 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
45401204|NCT01326234|Behavioral|Personalized Feedback|The interactive program will provide assessment and personalized feedback on the participants' level of nicotine dependence, daily cigarette consumption, money spent on cigarettes, behavioral consequences of smoking, individual medical consequences of smoking, and family members' medical consequences of secondhand smoke.
45401205|NCT01326234|Behavioral|Treatment as Usual|Practitioners are able to provide normal care with regard to smoking; participants will complete the Treatment Fidelity Questionnaire to assess whether any smoking cessation interventions occurred
45401206|NCT01072110|Procedure|Colonoscopy|Patients will undergo colonoscopy for evaluation of their symptoms.
45401207|NCT01072110|Procedure|Confocal Laser Endomicroscopy|Patients will undergo CLE during their endoscopy. Findings will be compared to group 1.
45401208|NCT01166074|Biological|Subcutaneous IgG (SCIG)|Administered according to normal clinical practice
45401209|NCT03971292|Genetic|RNA sequencing|Testing interest of messenger RNA sequencing for the etiological diagnosis of unresolved patients after sequencing coding regions.
45401210|NCT01275508|Drug|FITC-Adalimumab|The study product FITC-Adalimumab will be topically applied via a spray catheter to the intestinal mucosa of Crohn's disease patients during endomicroscopy of the gut. One mL of the diluted study product will be applied each time to overall four selected intestinal areas at a concentration of 20 μg/mL respectively (equivalent to 20 μg of FITC-Adalimumab per area). Total amount applied will be 80 μg FITC-Adalimumab per patient.
45401211|NCT01073670|Drug|Indomethacin|Indomethacin was given via suppository at time of induction for anesthesia (2 x 50 mg) followed by one 50 mg suppository at 6, 12, 18 and 24 hours following cardiac bypass surgery.
45401212|NCT01073670|Drug|Acetaminophen & Indomethacin|Subjects were given a loading dose of acetaminophen (1300 mg) and indomethacin (50 mg)by suppository at the time of induction for anesthesia and then given 650mg acetaminophen + 25 mg indomethacin at 6, 12, 18 and 24 hours following cardiac bypass surgery.
45401213|NCT01073670|Drug|Acetaminophen|Subjects were given a loading dose of 2600 mg of acetaminophen (via suppository) at time of induction for anesthesia then given 1300mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
45401214|NCT01166152|Behavioral|social skills training|meeting once a week or biweekly to play together using toys, games, and physical exercises.
45401215|NCT01582464|Behavioral|Social Marketing for protective headgear|"Social marketing was done using a CQI manner after each focus group with experts and with seniors using a structured interview approach with an iterative process to develop a progressive method of presenting information about head injuries and their input on a new prevention.~To measure changes in attitudes, the participants were given an attitudes questionnaire (PHAQ), & a demographic & functional status questionnaire. Input into the social marketing content was sought in a structured interview manner, and by using an audience response system with questions projected by power point. At the conclusion of the social marketing, the PHAQ was repeated and sent to participants 2 weeks after the focus group to gage stability of changes in attitudes."
45401216|NCT01168180|Other|Traditional Thai massage|The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks
45401217|NCT01168180|Other|Ultrasound therapy and hot pack|
45401218|NCT03971370|Biological|Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)|Essen post-exposure immunization schedule at day 0,3,7,14,28.
45401219|NCT03971370|Biological|Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)|Zagreb post-exposure immunization schedule at day 0,7,21.
45401220|NCT03971370|Biological|Human diploid cell rabies vaccine (Chengdu Kanghua Biological Products Co., Ltd.)|Essen post-exposure immunization schedule at day 0,3,7,14,28.
45401221|NCT03873142|Behavioral|Mindful Parenting|The mindful parenting intervention is an adaption for parents of the Mindfulness-Based Cognitive Therapy (MBCT) for depression (Kabat-Zinn, 1990), and the Mindful-Based Stress Reduction program (MBSR; Kabat-Zinn, 1990). The mindful parenting intervention will follow the manual developed by Bögels and Restifo (2014). The intervention consists of 9x3hour sessions. Eight of these sessions are run on consecutive weeks and the final session is run eight weeks after the eighth session. These groups involve group discussions around parenting, meditation exercises, and yoga, amongst other things.
45509489|NCT05659563|Drug|Tamoxifen|Tamoxifen is a selective estrogen receptor (ER) modulator
45855740|NCT04158219|Behavioral|Behavioral activation for health and depression (BA-HD)|Consistent with successful BA manuals, we plan to conduct up to 10 sessions of treatment over 12 weeks (the recommendation will be at least 8 sessions; scheduling of sessions will be flexible and conform to patient preference). The initial two sessions will be about 50 minutes long and later sessions will be 20-30 minutes long. Sessions can be done on site or over the phone; home visits will be offered for sessions 1-2 if a participant cannot travel. Treatment sessions will use behavioral activation techniques to assess participant values and link these values to behavior change. Goal-setting will focus on sequential, idiographic behavior change (tobacco use, medication adherence, physical activity, and diet) and be accompanied by educational materials and commercially available tools (e.g. activity trackers, pillboxes).
45401222|NCT01168336|Drug|Betahistine standard formulation|betahistine 24 mg tablets
45401223|NCT01168336|Drug|Betahistine Extended Release formulation|betahistine 32 mg tablets
45401224|NCT01168336|Drug|Placebo|matching placebo
45401225|NCT00165672|Drug|RABEPRAZOLE SODIUM|rabeprazole sodium 5 mg: once daily orally for 4 weeks
45401226|NCT00165672|Drug|RABEPRAZOLE SODIUM|rabeprazole sodium 10 mg: once daily orally for 4 weeks
45401227|NCT01166308|Radiation|Carbon Ion Radiotherapy|Carbon Ion Radiotherapy in the RD determined within the Phase I part of the Study (10 x 3Gy E to 16 x 3 Gy E)
45401228|NCT01166308|Radiation|Fractionated Stereotactic Radiotherapy (FSRT)|Standard Treatment as Re-Irradiation performed as Fractionated Stereotactic Radiotherapy (FSRT)up to 36 Gy in single doses of 2 Gy
45401229|NCT01168414|Drug|Ganfort|Fixed combination of Bimatoprost and Timolol (BTFC; Ganfort (300 microgram + 5 mg/ml eyedrops solution)
45509490|NCT04592692|Drug|PEGylated Liposome (PEGLip)|Intravenous co-administration of PEGLip with Simoctocog alfa
45509491|NCT04558294|Drug|Lysergic Acid Diethylamide|A moderate dose of 100 μg LSD will be administered.
45509492|NCT04558294|Drug|Ketanserin Placebo|Mannitol capsules instead of capsules containing Ketanserin.
45509493|NCT04558294|Drug|Ketanserin|A dose of 40 mg Ketanserin will be administered.
45401230|NCT01168414|Drug|Duotrav|Fixed combination of Travoprost and Timolol (TTFC; Duotrav (40 micrograms + 5 mg/ml eyedrops solution)
45401231|NCT00180414|Device|CRT devices with ventricular rate regulation [VRR] (CE labeled)|
45401232|NCT01277224|Behavioral|Movi2 Program|In the Movi2 program we will perform a recreational physical activity intervention during one year that include standardized recreative and non competitive activities conducted by sports instructors. It consisted of two 90-min after school sessions per week on school days and one 150-minute session on Saturday morning.
45401233|NCT03870646|Combination Product|Hypertonic saline of NaCl (7%) in combination with hyaluronic acid|Critical adult tracheostomized patients will receive, in the intervention arm, nebulized Hypertonic saline of NaCl (7%) in combination with hyaluronic acid 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with hypersaline in order to avoid bronchospasm.
45401234|NCT03870646|Combination Product|Isotonic saline of NaCl (0,9%)|Critical adult tracheostomized patients will receive, in the control arm, nebulized isotonic saline of NaCl (0,9%) 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with isotonic saline in order to avoid bronchospasm.
45401235|NCT03968484|Biological|platelet transfusion|Transfusion of platelets
45401236|NCT03873220|Device|Wrist Actigraphy Devices|A watch-like wearable sensor
45401237|NCT03873220|Device|Sleep Monitor|Remote Sensor
45401238|NCT03873220|Device|Polysomnography|Sleep Monitor
45401239|NCT03873220|Device|Videography|Thermal Camera
45401240|NCT01166464|Behavioral|text messaging for smoking cessation|A 7-week program of daily text messages
45401241|NCT01166464|Behavioral|Generic text messages|non-smoking related text messages will be given on the same daily schedule as matches the active intervention to establish a control for contact time.
45401242|NCT01281904|Behavioral|Relaxation Acupressure|Apply pressure on 9 relaxatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
45401243|NCT01281904|Behavioral|Stimulating Acupressure|Apply pressure on 10 excitatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
45401244|NCT01168492|Drug|ketamine|0.5mg/kg ketamine iv
45401245|NCT03870490|Drug|VNRX-5133 + cefepime|IV infusion (3 doses)
45401246|NCT00174252|Drug|Genotonorm (Somatropin)|0.40 mg/kg/week dived in 7 daily subcutaneous injections during 2 years
45509494|NCT05057247|Drug|Duvelisib|"Duvelisib capsules should be swallowed whole with a glass of water (approximately 8 ounces).~Advise patients not to open, break, or chew the capsules. Duvelisib may be administered without regard to meals; however, subjects should avoid grapefruit and grapefruit juice while on duvelisib.~continue for up to 24 months."
45509495|NCT05057247|Drug|Docetaxel|Docetaxel chemotherapy once every 21 days (by intravenous infusion) over about 30- 60 minutes at each visit. This will continue for up to 24 months
45509496|NCT05088538|Other|Patient Education|After completing the necessary forms, it is planned to give the QR-coded education booklet prepared by the researcher to the patients and to inform the patients and their relatives about the use of QR codes. At that time, it is planned that the teaching will be carried out using various training methods such as lecture, question-answer, demonstration and practice. It is thought that the teaching will be divided into 3 parts: pre-operative, post-operative and discharge. According to the physical conditions of the clinic, it is planned to provide patient education in an suitable area for teaching as much as possible. Patients will be reminded that they can access the information whenever they want and as many times as they want by scanning the QR code from their phone.
45401247|NCT01278082|Drug|Budesonide|Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
45401248|NCT01278082|Drug|Placebo|Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
45401249|NCT03870256|Drug|misoprostol|Patient receive 600mic gm sublingual misoprostol
45401250|NCT03870256|Drug|Carbetocin|Patient receive 100 mic gm carbetocin IV
45401251|NCT03870256|Drug|TA|The patient receives 1gm oral tranexamic acid
45401252|NCT01166542|Biological|REOLYSIN|3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
45401253|NCT01166542|Drug|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
45401254|NCT01166542|Drug|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
45401255|NCT01166542|Drug|Placebo|Placebo
45401256|NCT00169104|Drug|G-CSF|5 mcgm/kg daily Monday through Friday weeks 3-14
45401257|NCT00169104|Drug|trastuzumab|4 mcgm/kg intravenously (IV) over 90 minutes week 1, then 2 mg/kg IV over 30 minutes weeks 2-14
45401258|NCT00169104|Drug|vinorelbine|25 mg/m2 over 6 minutes IV weekly, weeks 3, 4, 6, 7, 9, 10, 12, 13
45401259|NCT00169104|Drug|G-CSF|5 mcgm/kg SQ daily for ten days, Monday through Friday of the first two weeks of the study
45401260|NCT00169104|Drug|saline placebo|Saline will be given SQ daily for ten days, Monday through Friday of the first two weeks of the study
45401261|NCT03870412|Drug|PEG-rhG-CSF|The test drug PEG-rhG-CSF was administered prophylactically to elderly lymphoma patients who met the inclusion/exclusion criteria 24-72 hours after chemotherapy.
45401262|NCT03872674|Biological|high-flow humidified oxygen-delivery system (OptiFlow THRIVE)|stand oxygenation arm will receive oxygen at 5 L/min via nasal cannula, while Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE during the procedure.
45401263|NCT01168648|Behavioral|Yoga as stress management|Yoga specially designed to reduce stress is practiced for approximately 30 minutes at least three times a week for three months, once in a group session led by a trained yoga instructor and twice or more at home. The yoga techniques used are physical postures or movements, meditation and breathing exercises. Every time they do the techniques, participants fill in a form detailing how they feel before and after and providing information on the experience of doing the exercises.
45401264|NCT01168648|Other|Rest without using any relaxation technique|The participants rest at home at least 30 minutes, at least three times a week for three months and without using any relaxation technique
45401265|NCT03872986|Device|SDF|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI)
45401266|NCT03872986|Device|Giomer|Beautifil II dental restorative material
45401267|NCT03872986|Device|GIC|Equia forte dental restorative material
45401268|NCT03872830|Drug|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours."
45401269|NCT03872830|Drug|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours."
45401270|NCT02526316|Biological|P16_37-63 peptide combined with Montanide® ISA-51 VG|Patients will receive P16_37-63 peptide (100 µg) combined with Montanide® ISA-51 VG vaccination subcutaneously once a week for four weeks, followed by a 4 week rest period
45401271|NCT02526316|Biological|P16_37-63 peptide without Montanide® ISA-51 VG|Patients will receive 30 mcg P16_37-63 peptide injected intradermally for test on delayed-type hypersensitivity (DTH) reactions.
45401272|NCT03872596|Drug|Seroquel IR 300mg|Administered during Part A, administered orally BID with water, over 5 days.
45401273|NCT03872596|Drug|Seroquel IR 25mg|Administered during Part B, as a single, 25mg dose taken with water.
45401274|NCT03872596|Drug|Quetiapine Formulation A 300mg|Administered during Part A, administered orally BID with water, over 5 days.
45401275|NCT03872596|Drug|Quetiapine Formulation B 300mg|Administered during Part A, administered orally BID with water, over 5 days.
45401276|NCT03872596|Drug|Quetiapine Formulation 25mg|Administered during Part B, as a single, 25mg dose taken with water.
45401277|NCT00163020|Drug|17-alpha-hydroxyprogesterone caproate injectable|250mg of 17-alpha-hydroxyprogesterone caproate (+ preservatives) injectable weekly starting as early as 19wks gestation until 34.0wks gestation of delivery which ever comes first.
45401278|NCT00163020|Drug|Placebo|Weekly doses of placebo (NS + preservatives) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
45401279|NCT03870100|Drug|SHR-1222|Pharmaceutical form: water injection Route of administration: subcutaneous
45401280|NCT03870100|Drug|Placebo|Pharmaceutical form: water injection Route of administration: subcutaneous
45401281|NCT03870178|Device|Transcranial direct current stimulation (tDCS)|The noninvasive and nonpharmacological weak electrical current applied to the scalp to modulate cortical excitability.
45509497|NCT04409301|Other|My Special Aflac Duck (MSAD)|The hospital Child Life Specialist or research team member will introduce the child and parent to My Special Aflac Duck MSAD), with instructions on how to use the duck. MSAD is a robotic toy with an associated app. Children can use MSAD for play, exploring feelings, and describing medical procedures. Intervention hospitals are permitted to provide their standard of care from Child Life with the exception of providing stuffed animal-like objects. Data will be recorded by Child Life or research team member on what tools are used outside of the MSAD.
45401282|NCT01166698|Drug|AZD9819|Inhaled single doses of suspension via SPIRA nebuliser
45401283|NCT01166698|Drug|AZD9819|Inhaled multiple doses of suspension via SPIRA nebuliser, once daily for 10 (maximum 14) days
45401284|NCT01166698|Drug|Placebo|Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B)
45401285|NCT01168804|Drug|bendamustine plus bortezomib plus dexamethasone|Bendamustine 70 mg/m2 on days 1+4 Velcade 1.3 mg/m2 on days 1,4,8,11 Dexamethasone 20 mg on days 1,4,8 and 11 Repeated every 4 weeks
45401286|NCT01168882|Drug|RGB-286638|The starting dose is a flat-fixed dose of 40 mg given i.v. over 60 min, weekly x3, of a 28-days cycle (q4 weeks)
45509498|NCT04409301|Behavioral|Standard of care control|Sites will follow their individual standard of care from Child Life. Data will be recorded by Child Life on what tools are used. After completion of the 3-month survey, patients at hospitals assigned to not initially receive MSAD will each receive a MSAD.
45509499|NCT05626257|Other|Xolair|There is no treatment allocation. Patients administered Xolair by prescription that have started before inclusion of the patient into the study will be enrolled.
45509500|NCT04396821|Drug|TST001|TST001 is a humanized IgG1 monoclonal antibody.
45698063|NCT04276545|Drug|IV administration of DEX to investigate the effects for functional nasal endoscopic surgery|IV administration of a single loading dose DEX (0.5μg/kg) after induction within 10 minutes.
45698064|NCT04276545|Drug|IV administration of Midazolam to investigate the effects for functional nasal endoscopic surgery|IV administration of midazolam (0.05mg/kg) after induction.
45698065|NCT01117948|Drug|Lornoxicam|Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
45698066|NCT01117948|Drug|Placebo|Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
45855741|NCT04156217|Biological|EBV-TCR-T cells|EBV-TCR-T cells are prepared via lentiviral infection. patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).
45401287|NCT03872362|Diagnostic Test|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
45401288|NCT01168960|Behavioral|Cognitive behavioral therapy for alcohol dependence|12-session behavioral treatment that incorporates behavioral skills training targeting high-risk drinking behavior.
45509501|NCT04396821|Drug|Nivolumab Injection [Opdivo]|Nivolumab is one of the PD-1 checkpoint inhibitors, and has proved clinical benefit for multiple late-stage malignancies
45509502|NCT04396821|Drug|mFOLFOX6|mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
45509503|NCT04396821|Drug|Gemcitabine|Chemotherapy medication
45509504|NCT04396821|Drug|Albumin-Bound Paclitaxel|Chemotherapy medication
45509505|NCT01680016|Biological|Zagreb|Subjects received Zagreb schedule (2-1-1) i.e. 4 vaccinations of Rabipur at days 1 , 8 and 22
45509506|NCT01680016|Biological|Essen|Subjects received Essen schedule (1-1-1-1-1) i.e. 5 vaccinations of Rabipur at days 1, 4, 8, 15 and 29
45509507|NCT05020587|Behavioral|Open pilot trial of a group therapy manual.|Open pilot trial of a group therapy manual.
45509508|NCT04530994|Drug|maralixibat|Maralixibat is an Apical Sodium-dependent Bile acid Transporter (ASBT) inhibitor
45698067|NCT02445027|Device|MGH OCT Imaging Capsule|Imaging of the esophagus using the OCT Capsule and system.
45698068|NCT01118338|Device|Redesigned Purevision Contact Lens|Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.
45698069|NCT01118338|Device|PureVision Contact Lens|Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.
45698070|NCT03602157|Biological|ATLCAR.CD30.CCR4 cells|Three dose levels are being evaluated: 2x10^7, 5x10^7, 1x10^8
45698071|NCT03602157|Biological|ALTCAR.CD30 cells|Fixed dose level of 1x10^8
45509509|NCT03378466|Drug|Unfractionated heparin|UFH initiated at 18 IU/kg/hr, dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin (aPTT) of 1.5 to 2.5 times that of the reference aPTT value or anti-Xa values targeted to local practice levels. Duration of study intervention will be a maximum of 5 days (120 hours) or until vasopressors have been discontinued for 24 continuous hours. All participants will then receive venous thromboprophylaxis according to local practice.
45509510|NCT03378466|Other|Venous thromboprophylaxis (VTE)|May include subcutaneous heparin or dalteparin, sequential compression device or graduated compression stockings
45509511|NCT04339413|Drug|Gantenerumab|Gantenerumab will be administered as SC injection Q4W
45509512|NCT05080270|Biological|Tolerogenic Fibroblasts|administrating single dose of 100 million tolerogenic fibroblasts via intravenous infusion
45509513|NCT05077540|Drug|oxytocin|20 unit of oxytocin infusion in 500 ml lactated ringer's solution 125 ml/h (Syntocinon, Novartis, Switzerland)
45509514|NCT05077540|Drug|misoprostol|800 µg sublingual misoprostol (Cytotec Pfizer, New York, USA)
45509515|NCT03619473|Behavioral|Standard motorcycle child safety helmet|"Educational session followed by demonstration on~proper helmet wearing~how to differentiate non-standard and standard helmets~how to keep motorcycle safe using ABCD concept~importance of wearing bright clothes~police summon for not wearing helmets~live demo on poor performance of non-standard helmet~giving away standard motorcycle child safety helmets~oath taking by parents and children~distribution and placement of VEM on parents' motorcycles"
45509516|NCT04977375|Drug|Pembrolizumab|Pembrolizumab 400mg administered intravenously on Day 1, and then beginning 6 weeks post-surgery, subjects will receive 400 mg pembrolizumab every 6 weeks
45509517|NCT04977375|Radiation|Stereotactic Radiation Therapy|Standard of care stereotactic radiation of 24 grays over 3 days, administered beginning on Day 7
45509518|NCT04977375|Procedure|Surgical Resection|Standard of care surgical resection of tumor on Day 10-28
45509519|NCT05412225|Diagnostic Test|Pre-neoadjuvant radiotherapy (NART) biopsy|Participants will undergo pre-NART core biopsy guided by post-NAC MRI to the area of residual enhancement or to the previously biopsied cancer if no residual enhancement remains
45509520|NCT05412225|Radiation|Neoadjuvant radiotherapy|After biopsy, participants will undergo neoadjuvant radiotherapy/NART
45401289|NCT01169116|Radiation|hypofractionated stereotactic radiotherapy|hypofractionated stereotactic radiotherapy with 4 fractions of 7 Gy at the periphery of the brain metastasis with 3 mm margin.
45401290|NCT01278940|Biological|Dendritic Cells (DC) malignant melanoma|The patients were assigned to intradermal or intranodal DC vaccination
45401291|NCT01278940|Procedure|IL-2|IL-2 were administrated by intranodal injection
45401292|NCT01282450|Radiation|Radiotherapy|Radiotherapy
45401293|NCT03873532|Drug|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 21-day treatment cycle).
45401294|NCT03873532|Drug|Capecitabine|Capecitabine is given at 1250 mg/m2 by oral administration twice a day (BID, one dose each in the morning and evening, with a total dose of 2500 mg/m2 per day) for 2 weeks followed by 1 week of drug interruption. Each course of treatment will last 3 weeks. Capecitabine tablets should be swallowed with water within 30 minutes after a meal.
45401295|NCT01282528|Biological|infliximab|3mg/kg, at week 0, 2, 6, 14, 22
45401296|NCT01166854|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy
45401297|NCT01169272|Device|CRT-SonR 9770|Active implantable defibrillator with capacity of cardiac resynchronization therapy
45509521|NCT05412225|Procedure|Unilateral total mastectomy with axillary lymph node dissection|At 2-6 weeks after completion of NART, participants will undergo unilateral MRM (total mastectomy with axillary lymph node dissection), with resection of all involved breast skin. Skin-sparing mastectomy will not be permitted. All patients will also undergo simultaneous unilateral autologous-based breast reconstruction with DIEP, ms-TRAM, or latissimus dorsi flap.
45509522|NCT04945239|Behavioral|Amplification of Positivity Training (6 Sessions)|6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
45509523|NCT04945239|Behavioral|Stress Management Training (6 Sessions)|6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for activity exercises designed to decrease stress.
45509524|NCT03625791|Biological|blood sample|1 tube with 4 ml of blood per patient
45509525|NCT05407545|Device|Current prosthesis|A unilateral transfemoral amputee will conduct experiments with the current prosthesis
45509526|NCT05407545|Device|Active Prosthesis (PowerKnee)|A unilateral transfemoral amputee will conduct experiments with the Power Knee. The PowerKnee is an active prosthesis developed by Össur.
45509527|NCT01340898|Biological|Meningococcal vaccine GSK 134612|Intramuscular injection
45509528|NCT01340898|Biological|SynflorixTM|Intramuscular injection
45509529|NCT01340898|Biological|Infanrix-IPV/HiberixTM|Intramuscular injection
45509530|NCT02470585|Drug|Veliparib|Capsules for oral administration
45509531|NCT02470585|Drug|Paclitaxel|Administered by intravenous infusion, either 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle (weekly dosing), or 175 mg/m² of BSA on Day 1 of each 21-day cycle (3-week dosing).
45509532|NCT02470585|Drug|Carboplatin|Administered by intravenous infusion at an area under the curve (AUC) of 6 mg/mL/min every 3 weeks.
45509533|NCT02470585|Other|Placebo to Veliparib|Capsules for oral administration
45509534|NCT02426749|Device|Active repetitive Transcranial Magnetic Stimulation (rTMS)|The treatments will be administered daily (five days/week) for two weeks, followed by three days on the third week (total of 13 treatments). Patients of both real and sham treatment groups will undergo rTMS treatment of 1.5-second duration trains of pulses at 20 Hz for a total of 25 trains with intertrain interval of 10 seconds applied to DLPFC bilaterally at 100% of the resting motor threshold. Thus, there will be a total of 1500 pulses per two sides of the brain per day, which is well within the safety limit of the rTMS application. During the intertrain intervals, the patients will be presented a series of objects and actions and asking to name them. The images will be projected on the wall in front of patient with duration of three seconds for each image. The aim is to keep the brain active while we stimulate it with rTMS.
45509535|NCT02426749|Device|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS is similar to Active rTMS but instead of a real coil, it uses a coil that attenuates the pulses such that no current will be induced in the brain.
45509536|NCT02744898|Drug|Carboplatin AUC|
45401298|NCT01169428|Behavioral|Mindfulness Based Weight Loss Maintenance (MBWLM)|This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss. Mindfulness meditation is a technique for training awareness. The program will train subjects to increase awareness of the somatic, cognitive, affective, interpersonal and environmental factors that mediate eating and physical activity by incorporating empirically-supported and theoretically-synergized components, including: general mindfulness meditation skills, mindful and intuitive eating, appetite-satiety awareness, mindful movement and yoga, a mindful approach to exercise engagement, and training in enhancing emotion regulation and stress management skills. In addition, the MBWLM group will be supported by Maintenance Partners who are trained as Integrative Health Coaches.
45401299|NCT01169428|Behavioral|Behavioral: Standard Behavioral Weight-Loss Maintenence|Attention/Education/Support Control group, designed to control for educational content as well as nonspecific treatment factors [e.g., natural history (time), amount of time and energy spent in the intervention, attention by group leaders, social support, as well as information & education]. Like the experimental group(MBWLM), this group meet once a week for 2 hours during the 12-week intervention, and then at 4 weeks, 8 weeks, and 12 weeks post the 12 week intervention. Participants also receive the same amount of telephonic support through Maintenance Partners as the experimental group, but their Maintenance Partners employed empathic listening only rather than myriad coaching techniques.
45401300|NCT01169506|Device|sublingual silicon capillary|Stable patients with COPD and healthy individuals were asked to open their mouth and a small butterfly silicon capillary was placed sublingually. After 15 minutes, while the mouth was closed completely and nose breathing was performed, the capillary system was connected to a capnometer and sublingual tonometric PCO2 was measured. At the same time, PETCO2 was also measured and arterial blood was drawn for pH, PO2 and PCO2 analysis
45401301|NCT01169740|Procedure|Measurement of bilirubin in blood and skin color|Blood sampling and analysis, measurement of skin color by transcutaneous bilirubinometry
45401302|NCT01169584|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intratumoral Injection Dosage from 1 x 10^6 pfu/kg to 3 x 10^7 pfu/kg is administered once to 1-3 injectable tumors in pediatric patients.
45401303|NCT01282684|Drug|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in dosage strengths of 25 mg and 100 mg with matching placebo
45401304|NCT01282684|Drug|Placebo|Matching placebo for PLX5622.
45401305|NCT01169818|Drug|Insulin Glargine|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous~Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target"
45401306|NCT01282762|Biological|HEPLISAV|"0.5 mL administered intramuscularly (IM) at Week 0, Week 4 and Week 24.~HEPLISAV booster injection = one dose of 0.5 mL volume when needed."
45509537|NCT02744898|Drug|Abraxane|100mg/m2
45509538|NCT03563820|Behavioral|Resilience and Well-Being Program|"The Resilience and Well-Being Program is offered through VA Puget Sound Rehabilitation Care Services as part of standard clinical care offerings. The program includes five (5) positive psychology group sessions once a week for five weeks. Participants will use strengths-based strategies, narrative strategies, and prospective strategies to learn ways to deal with stressful life challenges and improve their mental health and well-being.~Each participant will be given a brief rating sheet at the end of each session to fill out. The rating sheet will ask participants to rate different aspects of the session (e.g., how helpful or interesting the session was to the participant), if home practice activities were assigned, whether the participant completed the home practice assignment, as well as feedback to improve that session."
45509539|NCT03587311|Biological|Anetumab Ravtansine|Given IV
45509540|NCT03587311|Biological|Bevacizumab|Given IV
45509541|NCT03587311|Drug|Paclitaxel|Given IV
45509542|NCT04040088|Procedure|Computed Tomography|Undergo PET/CT
45509543|NCT04040088|Drug|Gallium Ga 68-DOTATATE|Given IV
45509544|NCT04040088|Procedure|Positron Emission Tomography|Undergo PET/CT
45509545|NCT03036813|Drug|voxelotor|
45509546|NCT03036813|Other|Placebo|
45401307|NCT01282762|Biological|Engerix-B|"2.0 mL administered intramuscularly (IM) at Week 0, Week 4, Week 8 and Week 24.~Engerix-B booster injection = one dose of 2.0 mL volume when needed"
45401308|NCT01169662|Dietary Supplement|Vegetable/fruit juice|450ml active juice, 45ml no added sugar fruit squash (for flavour)
45401309|NCT01169662|Dietary Supplement|Placebo juice|50 ml No Added Sugar fruit squash, 45 ml Pressed Apple Juice, 405ml with water.
45401310|NCT01282840|Drug|Tolterodine SR|Tolterodine SR 4 mg qd
45401311|NCT05328622|Behavioral|Aqueduct Contingency Management Platform|"All individuals who consent to participate will engage with the Aqueduct contingency management system. Once participants are enrolled, they accumulate points in Aqueduct for each prenatal/postpartum appointment they attend. They also earn points for attending pregnancy and birth related classes, monitoring their health (e.g., blood sugar, blood pressure), and taking prescribed medications. Participants then redeem their points for money on a Visa gift card.~Enrolled participants also receive daily text messages that contain motivational and mini-educational content regarding pregnancy from trusted sources such as the American College of Obstetricians and Gynecologists, Evidence Based Birth, and Postpartum Support International. These texts serve as reminders to participants to remain engaged in their pregnancy care."
45401312|NCT01282918|Device|ICD implantation w/o DF test|ICD implantation without Defibrillation Test
45401313|NCT01282918|Device|ICD implantation with DF test|ICD implantation with DF test according to standardized procedure
45401314|NCT01282996|Other|Abdominal surgery|to compare the influence of a lung protective ventilation with conventional ventilation on postoperative complications following major abdominal surgery
45401315|NCT01172548|Drug|imatinib mesylate|
45401316|NCT03869476|Diagnostic Test|Non-invasive diagnosis score|"spleen fibrosis by elastography~plasma cytokines levels~mutationnal landscape by NGS~CD34 circulating cells"
45401317|NCT05323474|Other|Usual rehabilitation|"Usual rehabilitation according to the practice of the Haute Autorité de Santé (HAS)"
45401318|NCT05323474|Other|Rehabilitation optimized|Rehabilitation optimized according to the study protocol
45401319|NCT01283230|Device|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
45401320|NCT01172626|Drug|valproate sodium|oral administration,15-30mg/kg,daily
45509547|NCT05328492|Device|iVAPS-AE|Patients randomised to this intervention will commence home NIV in iVAPS-AE mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.
45401321|NCT01172626|Genetic|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the deactivation and elimination of Valproate sodium
45401322|NCT01172626|Other|Pharmacokinetic analysis|laboratory analysis of concentration of Valproate sodium and 4-ene-Valproate in plasma
45401323|NCT01169974|Other|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest before and following tourniquet ischemias of 1 , 2 & 3 minutes
45401324|NCT02526082|Other|Intervention|Multifactorial intervention with lifestyle changes and drugs as needed
45401325|NCT03869242|Device|NovoTTF-200A|newly diagnosed GBM patients treated with NovoTTF-200A concomitant to RT and TMZ.
45401326|NCT01283308|Behavioral|Lifestyle Intervention|Intervention arm participants will attend 6 months of weekly classes where they will be taught the skills necessary to reach these goals. The curriculum for the classes is based on the DPP lesson plans. Social support will be provided by trained lay health educators and peer support groups. Participants who remain at highest risk of T2DM after four or more months in the program will be prescribed metformin in addition to continuing the lifestyle program. Metformin dosages will start at 500 mg per day, and, when appropriate, will increase to 1000 mg per day (given as 500 mg twice per day). This group will be comprised of individuals who have (1) Fasting plasma glucose values of 100 mg/dl or more and (2) elevated fasting HbA1c measures of 5.7% or more.
45698072|NCT03602157|Drug|Bendamustine|70 mg/m^2/day Bendamustine for 3 days for lymphodepletion prior to cell infusion
45698073|NCT03602157|Drug|Fludarabine|30 mg/m^2/day Fludarabine for 3 days for lymphodepletion prior to cell infusion
45401327|NCT01283308|Behavioral|Standard of Care|Participants randomized to the standard of care group will meet with a physician and a dietician, attend one class/awareness lecture on diabetes prevention through weight loss and diet change and one class on exercise, and receive handouts reinforcing what they learn in class and with the dietician, fitness consultant, and physician.
45509548|NCT05328492|Device|ST-mode|Patients randomised to this intervention will commence home NIV in ST-mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.
45509549|NCT03097315|Drug|4 mg CLS-TA Suprachoriodal Injection|CLS-TA, 40 mg/mL (4 mg in 100 microliters), will be administered as a single injection at 2 timepoints
45509550|NCT04884165|Device|Remote monitoring of home mechanical ventilation (NIV) using SRETT|Patients will use the SRETT device attached to their home ventilator.
45509551|NCT04884165|Other|Home mechanical ventilation (NIV) without remote monitoring|Usual care
45509552|NCT05048953|Diagnostic Test|Muscle ultrasound measurements (the index test)|"The following parameters will be measured by muscle ultrasound~Muscle thickness~Muscle echogenicity~Muscle fasciculations"
45509553|NCT05530707|Other|Moisturizer containing saccharide isomerate and niacinamide|Moisturizer containing saccharide isomerate and niacinamide
45509554|NCT05379907|Other|SIGNATERA™ ctDNA testing|Information collection about how SIGNATERA™ ctDNA testing changes how doctors make treatment recommendations to patients with early-stage pancreatic cancer.
45509555|NCT05376475|Device|Infrared video-audio camera|Wyze Cam V2 by Wyze Labs, Inc., Seattle, USA
45509556|NCT05376475|Device|Level III home sleep apnea test|NightOwl® by Ectosense, Leuven, Belgium
45509557|NCT05376475|Device|Maternal-fetal transabdominal electrocardiographic heart rate monitor|The Monica AN24 Antenatal Fetal Holter by Monica Healthcare, Nottingham, UK
45509558|NCT05376475|Device|Pressure sensing mat|Tactilus® V Series Mattress Pressure Monitoring System by Sensor Products Inc., Madison, USA
45509559|NCT05372731|Other|Recruitment Maneuver|RM after BAL
45509560|NCT03518671|Behavioral|cognitive behavioral therapy, face to face|self-limited cognitive behavioral therapy delivered weekly for 6 weeks via face-face delivery method
45509561|NCT03518671|Behavioral|cognitive behavioral therapy, telemedicine|self-limited cognitive behavioral therapy delivered weekly for 6 weeks via tablet-based telemedicine platform
45401328|NCT01172704|Behavioral|Skills Building - Motivational Interviewing|"SB-MI incorporates Motivational Interviewing strategies into a psycho-educational HIV risk reduction protocol to help participants identify high-risk behaviors, reduce ambivalence about these behaviors, increase motivation to change behaviors, and develop a specific plan of action for risk reduction. Consistent with MI, information gathered at baseline regarding HIV risk behaviors is systematically reviewed in a personalized way with each participant at the outset of the intervention. This is designed to engage participants in becoming active agents in the change process and to assist participants in recognizing discrepancies between their current risk behaviors and goals and values, which typically do not include HIV infection or transmitting HIV to others. Also consistent with the principles of MI, participants are empowered to choose those educational and skills-based modules which fit their personal risk profile and values."
45401329|NCT01172782|Drug|Hydromorphone|2.5, 5, 10 ug of hydromorphone, intrathecal injection, single injection. duration of intrathecal injection are not fully studied.
45509562|NCT03039699|Drug|Ergoferon|
45509563|NCT03039699|Drug|Placebo|
45509564|NCT02003443|Behavioral|Self-Administered Acupressure|The intervention involves teaching and supporting subjects to administer acupressure on themselves.
45509565|NCT02833974|Drug|GSK2245035 Nasal Spray Solution|GSK2245035 Nasal Spray Solution 0.2 microgram (mcg)/mL delivering 10 ng GSK2245035 per actuation. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate.
45509566|NCT02833974|Drug|Placebo Nasal Spray Solution|Nasal Spray Solution as for GSK2245035 without active ingredient.
45509567|NCT03632005|Device|Vacuum Assisted Closure|Patients will be randomized to receive either standard dressing changes or the Prevena™ System on the day of their operation.
45509568|NCT03632005|Other|Sterile dressing|Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
45509569|NCT05303493|Biological|Camu Camu Capsules (Camu Camu powder encapsulated (500mg each) + ICI|Evaluate the safety and tolerability of CC prebiotic in addition to ICI in patients with NSCLC and melanoma
45698074|NCT03014440|Drug|Cannabidiol|
45509570|NCT03093415|Drug|elbasvir-grazoprevir (50 mg/100 mg)|12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)
45509571|NCT04145817|Genetic|BRIDGES gene panel testing|"The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-BOADICEAV5/PLUS predicts lifetime and age-specific breast cancer (BC) risks on the basis of family history, all known BC genes test-results, common single nucleotide polymorphisms (SNPs) combined in a PRS, and other non-genetic risk factors. This model is developed within the BRIDGES consortium."
45509572|NCT04145817|Genetic|Breast cancer risk polygenic risk score (PRS)|"The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-BOADICEAV5/PLUS predicts lifetime and age-specific breast cancer (BC) risks on the basis of family history, all known BC genes test-results, common single nucleotide polymorphisms (SNPs) combined in a PRS, and other non-genetic risk factors. This model is developed within the BRIDGES consortium."
45509573|NCT04145817|Behavioral|Questionnaires|Self-administered questionnaires for counselees to evaluate Psychosocial Aspects of Hereditary Cancer (PAHC), Breast Cancer risk perception adequacy, risk communication within the family and cancer risk management choice,
45509574|NCT05470257|Other|Cast|Application of fiberglass long arm cast.
45509575|NCT01358526|Drug|Oxycodone/Naloxone Controlled-release|Oxycodone/Naloxone Controlled-release tablets (10/5 mg, 20/10 mg, 30/15 mg, 40/20 mg) taken orally every 12 hours
45509576|NCT01358526|Drug|Placebo|Placebo tablets to match OXN taken orally every 12 hours
45509577|NCT04095039|Procedure|Hemodialysis|Patients in both arms will undergo hemodialysis to remove phosphate from the blood; however, patients in the Hi Arm will only be titrated down to no lower than 6.5mg/dl
45509578|NCT03564054|Procedure|Photodynamic Therapy|Participants on this arm will be treated with photodynamic therapy. PDT is a two-stage process. The first stage of PDT is the intravenous injection of porfimer sodium (Photofrin) administered as a single slow intravenous injection over 3 to 5 minutes. The second stage involves the application of laser light to the tumor by bronchoscopy.
45509579|NCT03564054|Procedure|Argon Plasma Coagulation|"Participants on this arm will be treated with argon plasma coagulation. A flexible probe housing a wire delivers high-frequency, high-voltage electric current to a monopolar tungsten electrode present at the tip of the probe. Argon gas flows through the probe, and is charged or ionized to produce plasma as it flows around the tungsten electrode. Electric current flows through the plasma to the nearest tissue, and heat is produced as it passes through the tissue. Increased resistance created by coagulated tissue impairs the flow of electric current, and keeps the ablation depth to 1 to 2 mm."
45509580|NCT05434689|Drug|Iberdomide|Iberdomide (Iber, CC-220) is a novel cereblon E3 ligase modulator (CELMoD) in development for treatment of multiple myeloma and other conditions.
45509581|NCT05434689|Drug|Daratumumab|Anti-CD 38 monoclonal antibody established in the treatment of multiple myeloma
45509582|NCT05434689|Drug|Dexamethasone|Corticosteroid active against multiple myeloma in combination with other agents
45509583|NCT05434689|Drug|Carfilzomib|Second generation proteasome inhibitor with activity in multiple myeloma
45509584|NCT02156232|Procedure|TIPS|TIPS is performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.
45509585|NCT02156232|Procedure|SPSS embolization|Embolization of SPSS will be conducted via the same jugular vein before TIPS implantation. The major procedures included (a) angiography of SPSS after successful intrahepatic puncture of a branch of the portal vein and (b) embolization of SPSS with coils of varying diameters or Amplatzer Vascular Plug, which resulted in the SPSS disappearing at postembolization angiography.
45509586|NCT03563898|Other|Sweating with Portable Sauna Bath|Patients will be subjected daily for 30 minutes to the Portable Sauna Care steam bath (45 degree C temperature). The patient will decide if the time and / or temperature of the Sauna Bath is reduced to Tolerance. Before being subjected to the sauna bath, blood pressure will be taken 10 minutes prior. Weigh the patient with a Scale. You will be informed of the symptoms that may occur during the bath, and if present, you will let the health staff know that you will be present at all times during the bathing period, which will have a SURVEILLANCE TABLE which It will be filled during the intervention where they are monitored and comply with the stipulated norms as well as notes for adverse effects. After the completion of the bath, there will be a space of 15 minutes for the patient to dry the skin and the bathing suit with a towel. After 15 minutes, the patient will be weighed and the blood pressure will be taken again.
45401330|NCT01172860|Device|EndoVe endoscopic electroporation|The EndoVe device enables the endoscopic treatment of gastrointestinal tumor tissues. The device is placed on the tumor tissue and an electrical pulse of less than 1msec is delivered. The tumor tissue becomes permeabilised and absorbs much greater concentrations of the drug than the surrounding healthy tissue
45509587|NCT01310010|Drug|dasatinib|Treatment with 100 mg QD of dasatinib (Sprycel®) administered orally as continuous daily dosing (CDD).
45509588|NCT02830776|Drug|bimatoprost 0.03% ophthalmic solution|Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)
45509589|NCT03039621|Drug|Ergoferon|For oral use.
45509590|NCT03039621|Drug|Placebo|For oral use.
45509591|NCT01235130|Drug|OMEGA-3|600mg, 2 caps, twice a day
45509592|NCT01235130|Drug|Placebo soybean oil|600mg, 2caps twice a day
45509593|NCT05708118|Diagnostic Test|Echocardiographic assessment.|Patients will be contacted to carry out an echocardiography at least 90 days after surgery. Measurements will be taken for aortic annulus, sinuses of Valsalva, sino-tubular junction, tubular ascending aorta. Aortic valve will be assessed as well.
45698075|NCT03013036|Device|Ultrasonography|
45698076|NCT03013036|Drug|Sevoflurane|
45509594|NCT05708118|Diagnostic Test|Computed-tomography assessment|All enrolled patients will undergo a multislice CT scan (retrospectively ECG-gated, whenever possible) with standard contrast medium injection protocol of nonionic contrast agent. All post-surgery controls will be performed at least 90 days after surgery. All CT datasets will be analysed on a dedicated workstation for the qualitative and quantitative assessment of the aortic root including measurements for aortic annulus, sinuses of Valsalva, sino-tubular junction, tubular ascending aorta.
45401331|NCT03866746|Drug|Aflibercept Injection|Group A;Under complete aseptic conditions; intravitreal aflibercept injections with dose of 2 mg/0.05 mL per injection was given for the patients. Patients were scheduled to receive 3 loading injections at monthly interval. At the 3rd month; further treatment was planned pro re nata (PRN) according to the response. Injections were discontinued when the CMT reached 250 µm or less. If there was no change in the CMT after two consecutive injections; patients shifted to other line of treatment. Reinjection was continued for the other eyes with re-evaluation of the response every month.In group B Patients received the initial 3 monthly loading doses of IVI of aflibercept followed by MPL therapy (within one week after the 3rd injection). Patients were scheduled for follow-up monthly. Injection followed by MPL was then repeated according to the response as in group A.
45401332|NCT03866746|Other|micropulsed yellow laser|Micropulse yellow IQ 577nm laser (Iridex Corporation, Mountain View, CA, USA) was employed. The Area Centralis lens (laser spot size magnification 0.94) was utilized with 400 mw power, 200μm spot size and 200 ms pulse duration with 5% duty cycle after micropulse mode activation. Laser was applied on clinically visible thickened macula with different number of confluent non- spacing shots in 7x7 grids. Care was taken to begin treatment outside the foveal avascular zone and not to treat the fovea when there was no visible reaction. If there was any visible reaction; treatment was stopped and the power was reduced until there was no visible reaction.
45509595|NCT05708196|Other|Alloplast bone grafting material (EthOss, Ethoss Regeneration Ltd, Silsden, UK).|After tooth extraction, the tooth socket will begrafted with Alloplast grafting material
45509596|NCT05708196|Other|Allograft bone grafting material.|After tooth extraction, the tooth socket will be grafted with allograft grafting material
45509597|NCT03563664|Procedure|Pre-treatment endometrial biopsy|Timed suction endometrial biopsy was obtained from participants via Wallach Endocell® 908014A endometrial cell sampler timed during the implantation window of the pretreatment cycle; followed by immunohistochemical staining using immunoperoxidase staining incorporating avidin-biotin complex (ABC) method.
45509598|NCT03563664|Drug|Danazol|Participants were treated with danazol (Danol® 200mg capsules, Sanofi, Guildford, UK) in daily dosage of 400 mg for 12 weeks.
45509599|NCT03563664|Procedure|Post-treatment endometrial biopsy|Post-treatment suction endometrial biopsy was obtained during the implantation window following the first ovulation after danazol treatment, timed, processed and stained as described previously.
45509600|NCT01904136|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
45509601|NCT01904136|Procedure|Bone Marrow Transplantation|Undergo allogeneic PBSC or bone marrow transplant
46057168|NCT05749744|Other|cardiac telerehabilitation program by videoconference|"A video conference interview with an Adapted Physical Activity (APA) teacher before starting physical training~Exercise training for 3 weeks via distance coaching~Therapeutic patient education (TPE) workshops conducted remotely with 1 workshop per week.~Medical follow-up via teleconsultation~Psychological and/or dietetic follow-up if necessary.~Final assessment at 1 month with evaluation of aerobic metabolism, functional evaluation and final shared educational assessment (BEP).~Appointment with an association Cœur et Santé and Sport-Santé 42 or setting up of an individual physical activity"
45509602|NCT01904136|Drug|Cyclophosphamide|Given IV
45509603|NCT01904136|Drug|Fludarabine|Given IV
46057169|NCT02713191|Drug|Dexmedetomidine|Dexmedetomidine 1µg/Kg in 100 mL saline intravenously over 10-15 minutes immediately prior to procedure, followed by Dexmedetomidine infusion at 0.6 µg/kg/hour as maintenance dose during entire procedure
45509604|NCT01904136|Other|Laboratory Biomarker Analysis|Correlative studies
45509605|NCT01904136|Drug|Melphalan|Given IV
45509606|NCT01904136|Drug|Mycophenolate Mofetil|Given PO
45509607|NCT01904136|Biological|Natural Killer Cell Therapy|Given IV
45509608|NCT01904136|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
45509609|NCT01904136|Drug|Tacrolimus|Given IV and PO
45509610|NCT01904136|Radiation|Total-Body Irradiation|Undergo TBI
45509611|NCT03041181|Drug|Docetaxel|Docetaxel 75 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
45509612|NCT03041181|Drug|Nivolumab|Nivolumab 360 mg IV Day 1 of each cycle (21 days = 1 cycle)
45509613|NCT03041181|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV Day 1 and Day 8 of each cycle (21 days = 1 cycle)
46057170|NCT02713191|Drug|Midazolam bolus|Midazolam 2 mg as slow intravenous bolus immediately prior to procedure
45509614|NCT03041181|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
45509615|NCT02828436|Device|Precision Spectra System|Spinal Cord Stimulation
45509616|NCT02828436|Behavioral|Exercise Intervention|Standard Exercise
45509617|NCT05278221|Device|Software EstimLT|Healthy volunteers will receive a single per os dose of Lacosamide (200 mg), Brivaracetam (50 mg) or placebo and then the software will be tested
45509618|NCT05369247|Other|High intensity Interval Training|HIIT protocol consisted of 10 one-minute intervals of high-intensity work (i.e., > 90% HRmax) interspersed with nine one-minute intervals of self-paced active recovery (19-minutes total).
45509619|NCT05369247|Other|Moderate Intensity Continuous Training|The MICT protocol consisted of 30-minutes of moderate intensity cycling (i.e., 64 - 76% HRmax).
45698077|NCT03013036|Drug|intravenous midazolam|
45698078|NCT03013036|Drug|Propofol|
45698079|NCT03013036|Drug|fentanyl and rocuronium|
45509620|NCT05271435|Device|PAMSys Activity Monitoring System|This system is composed of a Study Tablet running custom fall detection and reporting software and PAMSys sensors. PAMSys provides clinical-grade physical activity monitoring, storing the raw accelerometer data that can be used for analyzing activity parameters such as those listed in Table 3. Sensor data will be downloaded manually upon receipt of the study device by Biosensics, the study sponsor. Sensors can be worn during all activities including while showering and sleeping. The rated battery life is 3-6 months for the fall sensor, and 4 weeks for the activity sensors. This system is not classified as a medical device. Reports of sensor use, step number, battery level, and memory availability are sent hourly to a secured and HIPAA compliant back-end server provided by BioSensics. The Study Tablet also contains modules for performing speech, handwriting, and pattern tracing tasks.
45509621|NCT05271435|Behavioral|Motor, Speech, and Handwriting Assessment|"These assessments occur at each study visit. After equipping the subject with 3 activity sensors (1 on pendant around neck and 2 on wrists).~10-meter walk task (5 minutes) - The subject starts from a standing position and walks a length of 10 meters. The best time of three trials is used.~Timed Up and Go (TUG) test (5 minutes) - Subjects stand, walk to a marker on the floor 3 meters ahead, turn around the marker, walk back to the chair, and sit. The best time of three trials is used.~Handwriting Assessment Battery (HAB) (15 minutes) [Faddy2008] - The subject is seated at a table with a pencil and paper and performs a series of writing tasks.~Speech Assessment Battery (SAB)(10 minutes) - The participant will perform a set of audio recordings using the study tablet while sitting in a quiet room."
45509622|NCT04059159|Device|Connected Catheter|Patients will use the Connected Catheter to empty the bladder during the course of treatment.
45401333|NCT03869320|Drug|ACT-1004-1239|ACT-1004-1239 will be available for clinical study use as hard gelatin capsules for oral administration formulated in strengths of 1, 10, and 100 mg. For the ADME subpart, a single oral dose of 1 μCi of 14C radiolabeled ACT-1004-1239 will be given simultaneously with the ACT-1004-1239 capsule. For the absolute bioavailability subpart, a single intravenous dose of a maximum of 1 μCi of 14C radiolabeled ACT-1004-1239 will be given at the expected tmax after the administration of the ACT-1004-1239 capsule.
45509623|NCT05351229|Drug|Morphine Sulfate|5 mcg/kg intrathecal preservative free morphine sulfate
45509624|NCT05351229|Other|Placebo|Sterile saline
45509625|NCT05342103|Procedure|high flow oxygenation|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
45509626|NCT05121909|Other|Colgate (R) Cavity Protection Toothpaste|Participants will use Colgate (R) Cavity Protection Toothpaste for brushing teeth twice daily.
45509627|NCT05121909|Device|Colgate (R) Cello Toothbrush|Participants will use Colgate (R) Cello Toothbrush for brushing teeth twice daily.
45509628|NCT05121909|Other|Prototype 1 Mouthwash|Participants will use 20 mL of Prototype 1 Mouthwash for 30 seconds after brushing twice daily.
45509629|NCT05121909|Other|Prototype 2 Mouthwash|Participants will use 20 mL of Prototype 2 Mouthwash for 30 seconds after brushing twice daily.
45509630|NCT05121909|Other|Prototype 3 Mouthwash|Participants will use 20 mL of Prototype 3 Mouthwash for 30 seconds after brushing twice daily.
45509631|NCT05121909|Other|Listerine (R) Cool Mint (R) Antiseptic Mouthwash|Participants will use 20 mL of Listerine (R) Cool Mint (R) Antiseptic Mouthwash for 30 seconds after brushing twice daily.
45509632|NCT05121909|Other|5% Hydroalcohol Mouthwash|Participants will use 20 mL of 5% Hydroalcohol Mouthwash for 30 seconds after brushing twice daily.
45698080|NCT03364803|Other|Cushing's QoL (Quality of Life Questionnaire)|Cushing's QoL is a validated disease specific questionnaire consisting of 12 questions on a five-point Likert scale ranging from always to never. The total score ranges from 12 to 60, with a lower score indicating a greater negative impact on health related QoL. This is converted to a 0-100 scale, 0 indicating the worst and 100 indicating the best QoL
45698081|NCT03364803|Other|Nottingham Health Profile (NHP)|NHP is used in patients to assess general health and quality of life. This assessment consists of 38 yes/no questions that are subdivided into six scales assessing impairments: pain (eight items), energy level (three items), sleep (five items), emotional reactions (nine items), social isolation (five items) and physical mobility (eight items). A higher score indicates more impairment
45698082|NCT03364803|Other|Hospital Anxiety and Depression Scale (HADS)|HADS consists of 14 items pertaining to anxiety and depression, with each item measured on a four-point scale. Total scores for the anxiety and depression subscales range from 0 to 21. A higher score indicates greater symptomatology
45698083|NCT03364803|Other|Perceived Stress Scale (PSS)|The PSS predicts both objective biological markers of stress and increased risk of disease in patients with higher stress levels.
45698084|NCT03364803|Other|Barratt's Impulsivity Scale (BIS)|BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
45698085|NCT03364803|Other|Beck Depression Inventory (BDI)|BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
45698086|NCT03364803|Other|State-Trait Anxiety Inventory (STAI)|The STAI provides data to help distinguish between anxiety and depression.
46057171|NCT02713191|Other|Saline placebo|100 mL saline infusion over 10-15 minutes immediately prior to procedure
46057172|NCT02713191|Drug|Rescue midazolam|Rescue boluses of 0.5 mg midazolam, if needed during procedure
45401334|NCT03869320|Other|Placebo|Matching placebo is available as matching capsules for oral administration, formulated with the same excipients but without ACT-1004-1239.
45401335|NCT03869320|Drug|ACT-1004-1239 (Food-effect subpart)|ACT-1004-1239 will be available for clinical study use as hard gelatin capsules for oral administration formulated in strengths of 1, 10, and 100 mg.
45509633|NCT05323071|Other|Sucrose 24%|"According to the age of the newborn:~24-26 weeks : 0.1 mL, 27-31weeks : 0.25 mL, 32-36 weeks : 0.5 mL, >37 weeks : 1 mL"
45698087|NCT03364803|Other|State Food Craving Questionnaire-State (FCQ-S)|The FCQ-S consists of 15 items assessing: desire to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement (reduction of negative affect) from eating, lack of control over eating, and (physiological) hunger; higher scores reflect stronger food craving. Participants respond, using a Likert-type scale, how much each item is true of them right now.
45715279|NCT05099068|Biological|Blood and tumor samples|Longitudinal molecular profiling of tumor and liquid biopsies.
46057173|NCT02713191|Drug|Fentanyl|1 µg/kg fentanyl as slow intravenous bolus immediately prior to procedure
45401336|NCT03869320|Other|Placebo (Food-effect subpart)|Matching placebo is available as matching capsules for oral administration, formulated with the same excipients but without ACT-1004-1239.
45509634|NCT05263713|Other|Suture Closure of Linear Wounds|Half of the wound is repaired with running subcuticular sutures and the other half is repaired with running horizontal mattress sutures.
45509635|NCT02828124|Biological|BMS-986183|specified dose on specified days
45509636|NCT02828124|Biological|Nivolumab|specified dose on specified days
45509637|NCT04761393|Procedure|Hyperpolarized 129Xe (Xenon) diffusion-weighted MRI|Participants will inhale a one litre gas mixture containing hyperpolarized 129Xe mixed with nitrogen (N2) or helium (4He) from a one litre dose bag. Breath-hold will be up to 16 seconds
45509638|NCT03619629|Other|Kinesio-tape|"Kinesiotape will be applied both ankles as Correction technique."
45509639|NCT03619629|Other|Mulligan's mobilization with movement|'Posterolateral glide mobilization with movement' will be applied 10 times to both ankles.
45509640|NCT03619629|Other|Sham Kinesio-taping|Sham Kinesio-taping technique will be applied both ankles.
45509641|NCT03619629|Other|Sham Mulligan's mobilization with movement|Sham Mulligan's mobilization with movement technique will be applied both ankles.
45509642|NCT05397171|Drug|AZD8853|Monotherapy given until progressive disease or upon meeting other discontinuation criteria.
45509643|NCT05397171|Drug|Zirconium-89 crefmirlimab berdoxam|CD8+ T cell tracer for positron emission tomography (PET) at two time points in addition to monotherapy AZD8853
45509644|NCT02259894|Drug|BIRT 2584 XX|
45509645|NCT02259894|Drug|Placebo|
45509646|NCT02829996|Drug|trabodenoson 6.0% / latanoprost 0.005% QD|Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
45509647|NCT02829996|Drug|trabodenoson 3.0% / latanoprost 0.005% QD|Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
45509648|NCT02829996|Drug|trabodenoson 6.0% / latanoprost 0.0025% QD|Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
45509649|NCT02829996|Drug|latanoprost 0.005% QD|Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
45509650|NCT02829996|Drug|latanoprost 0.0025% QD|Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
45401337|NCT03869398|Dietary Supplement|Tums|start their calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
45509651|NCT05306457|Biological|CNS10-NPC-GDNF|Unilateral injections of CNS10-NPC-GDNF into the motor cortex
45509652|NCT02827500|Drug|ivabradine|Active Comparator: ivabradine
45715280|NCT01567865|Biological|Vaccine produced in existing facility|Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China
46057174|NCT00611169|Drug|tirofiban|tirofiban (25 μg/kg bolus and 0.15 μg/kg/min maintenance infusion for 24 hours)
45401338|NCT03869398|Dietary Supplement|Calcitriol|start their calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
45401339|NCT01170052|Drug|Temsirolimus|Temsirolimus 75mg i.v. day 1, 8, 15, 21 for a 28 day cycle with a maximum of 6 Cycles.
45401340|NCT01170052|Drug|Bendamustine|Bendamustin 90mg/m2 i.v. day 2 and 3 for a 28 day cycle with a maximum of 6 Cycles.
45401341|NCT01170052|Drug|Temsirolimus|Consolidation Therapy for Patients reached CR or PR with Temsirolimus 75mg weekly until progression.
45509653|NCT02827500|Other|Usual Care|Placebo Comparator: usual care
45509654|NCT05248659|Drug|Sibeprenlimab 400 mg s.c. Q4weeks|Sibeprenlimab 400 mg s.c. q 4 weeks
45509655|NCT05385549|Drug|Imatinib Mesylate|Imatinib Mesylate, 400 mg once daily, oral. 5 years of adjuvant imatinib treatment (standard treatment 3years + IP treatment : 2yesrs)
45509656|NCT05708040|Device|InPen Medtronic|Patients with DM1 ≥ 18 years of age who initiate Inpen system.
45509657|NCT05708040|Device|Minimed 780G system|Patients with DM1 ≥ 18 years of age who initiate Minimed 780G system.
45509658|NCT05238285|Behavioral|Production of vocal sounds|"Participants will be asked to produce vocal sounds of different nature according to the non-verbal parameters of interest for the given study.~For example, they can read a script containing vowels ('a', 'e', 'i', 'o', 'u'), short sentences ('hello, how are you'), longer passages of standardised reading texts, and can also be asked to speak freely about any topic ('freedom of speech'). They can be asked to play a role or to imitate a particular emotional state. For example, imagine that you have just been told that you have won a million euros in the lottery. Produce a vocalisation to express your excitement or talk to your dog your dog by imagining that he has done a negative action and then do the same thing by imagining that this time imagining that the action was positive."
45509659|NCT03563586|Other|Bowel Preparation plus antibiotics|Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
45509660|NCT03563586|Other|Bowel Preparation|Mechanical Bowel Preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm) alone Both groups will receive iv antibiotics (cefoxitin 2 gr plus metronidazole 500gr) perioperatively and discontinuation within 24 hours
45509661|NCT03929679|Drug|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
45509662|NCT02826798|Drug|VBI-1501A 0.5 μg|VBI-1501A: 0.5 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
45509663|NCT02826798|Drug|VBI-1501A 1.0 μg|VBI-1501A: 1.0 μg with alum with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
45509664|NCT02826798|Drug|VBI-1501A 2.0 μg|VBI-1501A: 2.0 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
45509665|NCT02826798|Drug|VBI-1501 1.0 μg|VBI-1501: 1.0 μg without alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
45401342|NCT01283620|Behavioral|modified constraint induced movement therapy (mCIMT)|The intervention group will receive usual care plus mCIMT. mCIMT consists of two components delivered in parallel: three 30 min therapy sessions/week focusing on progressively more difficult tasks performed with the arm/hand, and five hours/weekday of restraint of the unaffected upper limb. Each 30 min therapy session consists of using the affected upper limb in practicing 4-5 functionally relevant tasks.
45509666|NCT02826798|Drug|Placebo|buffer/sucrose used for VBI-1501 suspension- administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168.
45509667|NCT05263362|Other|no intervention|At one timepoint patients will get physical examination of the breasts, medical photographs will be taken, and they will fill in five questionnaires about satisfaction of the breasts, quality of life and general health.
45509668|NCT02829138|Genetic|Genetic information and Omega-3 fat intake|Only the Genetic group will receive their personal genetic information prior to beginning the 3-month study.
45509669|NCT02829138|Behavioral|General Nutrition related to Omega-3 fats|Both the Genetic and Non-Genetic groups will receive general nutrition information about omega-3 fats.
45509670|NCT05267184|Procedure|Endovascular treatment of the middle meningeal artery|The middle meningeal artery on the same side(s) as the chronic subdural hematoma is embolized with liquid embolic agents.
45509671|NCT05267184|Procedure|Standard neurosurgical hematoma evacuation|Standard neurosurgical evacuation of chronic subdural hematoma through burr-hole or mini craniotomy and postoperative subdural or subgaleal drainage.
45509672|NCT03832842|Diagnostic Test|Blood sample|Blood sample
45401343|NCT01283620|Other|Usual and Customary Care|Patients in this arm will receive usual care dose-matched to the experimental care group. Usual care will consist of occupational and physiotherapy intervention focused on affected upper limb range of motion (i.e., active range of motion incorporated into functional tasks such as reaching), strengthening (i.e., upper limb resisted exercise), manual dexterity exercises (i.e., grasp and release, stacking cones), and general aerobic conditioning (i.e., recumbent stepper, treadmill).
45401344|NCT01284478|Drug|Dexamethasone Implant|Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally
45509673|NCT03563430|Other|Active Recovery Group|Participants in this group will exercise for 15 minutes, for a range of 65 to 70% of the maximum heart rate as a recovery method following a single bout high-intensity interval exercise program
45509674|NCT03563430|Other|Self-Massage with Foam Roller Group|This group will perform 15 minutes self-massage with foam roller following the exercise session as a recovery method following a single bout high-intensity interval exercise program.
45401345|NCT00252720|Drug|candesartan|32 mg oral tablet
45509675|NCT03563430|Other|Neuromuscular Electrical Stimulation|Participants of this group will be applied electrical stimulation on quadriceps femoris and hamstring muscles for 15 minutes while they are comfortable lying position as a recovery method following a single bout high-intensity interval exercise program.
45509676|NCT05218590|Device|Video rigid stylet|Nasal intubation was performed using the video rigid stylet.
45509677|NCT02825550|Device|Taiwan ACE Beads|Similar with conventional TACE, radiologist inject lipiodol with doxorubicin first, then use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
45509678|NCT03563352|Other|Interview|Attend an interview
45509679|NCT03563352|Other|Survey Administration|Ancillary studies
45509680|NCT05197062|Drug|14C-aticaprant|14C-aticaprant will be administered orally as capsule on Day 1.
45509681|NCT03563196|Radiation|Chest Radiograph|Chest radiogram will be obtained on day 1
45401346|NCT01283698|Drug|Experimental: LAS 41004 dosage 1|dosage 1, once daily
45401347|NCT01283698|Drug|Experimental: LAS 41004 dosage 2|LAS 41004 dosage 2, once daily
45401348|NCT01283698|Drug|Experimental: LAS 41004 dosage 3|dosage 3, once daily
45401349|NCT01283698|Drug|Placebo Comparator: placebo|once daily
45401350|NCT01283698|Drug|Reference|Active Comparator,once daily
45401351|NCT03869164|Device|ValveClamp|ValveClamp is an easy-to-operate transcatheter edge-to-edge mitral valve repair system with larger coaptation width
45401352|NCT00167778|Device|Transverse plane rotation adaptor pylon|Potential future practice
45401353|NCT00167778|Device|Rigid pylon|Current clinical practice
45401354|NCT01284556|Drug|Phenobarbital|tablet
45509682|NCT03563196|Diagnostic Test|Lung Ultrasound|Lung ultrasound will be done on day 1
45698088|NCT03364803|Other|Trait Food Craving Questionnaire-Trait (FCQ-T)|Trait food craving will be assessed with the Food Craving Questionnaire-Trait (FCQ-T). The FCQ-T consists of 39 items assessing: intentions/plans to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement from eating, lack of control over eating, preoccupation with food, (physiological) hunger, emotions preceding or following food cravings or eating, environmental cues that may elicit food cravings, negative emotions including guilt experienced as a consequence of food cravings, and/or indulging such cravings; higher scores again indicate higher trait craving. Individuals are asked to respond, using a Likert-type scale, how much each item is true of them in general.
46057175|NCT02608138|Other|Iodine status among portuguese school children|
45401355|NCT01284556|Drug|Placebo tablet|tablet
45401356|NCT03869086|Other|Freeze dried blueberry powder|36 g of freeze-dried blueberry powder to be mixed with milk and served together with an energy-dense meal.
45401357|NCT03869086|Other|Anthocyanin free, sugar-matched placebo|36 g of isocaloric placebo, matched for sugars to be mixed with milk and served together with an energy-dense meal.
45509683|NCT05004870|Device|Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)|The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
45509684|NCT05122260|Drug|Q-Griffithsin|intranasal spray administered as a single dose
45509685|NCT05122260|Other|Placebo|intranasal spray administered as a single dose
45509686|NCT05000736|Drug|palbociclib + aromatase inhibitor|palbociclib + aromatase inhibitor therapy
45509687|NCT05000736|Drug|fulvestrant|fulvestrant monotherapy
45509688|NCT02744040|Drug|ART initiation at time of HIV diagnosis|Immediate ART initiation
45509689|NCT02744040|Drug|ART at 24 weeks|ART initiation 24 weeks after enrollment
45509690|NCT03833856|Procedure|colonoscopy perforation|The development of perforation after colonoscopy
45401358|NCT01170130|Drug|Lidocaine 1% (sterile)|during the phacoemulsification surgery patients will be given intracamerally lidocaine 1% (0.2 ml) and the pupil size will be recorded after 90 seconds
45401359|NCT02526238|Device|TMS and trunk rotation|TMS and trunk rotation
45401360|NCT02526238|Device|Sham TMS and trunk rotation|Sham TMS and trunk rotation
45509691|NCT02743962|Device|Therapeutic Wand|The therapeutic wand will be used to apply a gentle caudad pressure on the pelvic floor, encouraging a release and gentle stretch of the muscles. The participants will follow a protocol of sweeping gently along one side then the other to find tender or tight areas, and then to apply the wand to relax and stretch the muscles for up to 5 minutes in total, twice weekly for the duration of the study.
45509692|NCT02743962|Other|Routine physiotherapy control|This group will receive standard specialist physiotherapy intervention for bladder pain syndrome as stated in the arm descriptor, and will not use the therapeutic wand.
45509693|NCT05314920|Behavioral|Transdiagnostic cognitive-behavioral therapy (TD-CBT)|Transdiagnostic cognitive-behavioral therapy (TD-CBT)
45509694|NCT05314920|Behavioral|Bernstein and Borkovec progressive muscle relaxation (PMR)|Bernstein and Borkovec progressive muscle relaxation (PMR)
45401361|NCT00167310|Drug|Eicosapentaenoic acid (omega-3 fatty acid)|2 g of Eicosapentaenoic acid in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
45401362|NCT00167310|Drug|Placebo|2 g of Placebo (soy bean oil) in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
45401363|NCT02525770|Device|radiostereometric analysis (RSA)|
45401364|NCT03973476|Other|Phone care support by midwife|Mothers can call the midwife's telephone every working day from 8 a.m. to 8 p.m.
45401365|NCT03754582|Drug|Perampanel|Oral tablets.
45401366|NCT03754582|Drug|Perampanel|Intravenous infusion.
45401367|NCT03866824|Drug|injection of Platelet Enhanced Plasma(PRP)|intra-articular injection
45401368|NCT03866824|Drug|injection of corticosteroids|intra-articular injection
45401369|NCT03866824|Device|RMI|A CONTROL RMI at 1 year follow-up.
45401370|NCT03869008|Device|gammaCore Sapphire|"gammaCore SapphireTM (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck. gammaCore provides a mild electrical stimulation to the vagus nerve, which runs through the neck and carries information to the central nervous system.~Subjects will be instructed to use the gammaCore Sapphire to stimulate 2 minutes on each side of the neck, twice a day, every day. The subject controls the intensity level of the electrical stimulation."
45401371|NCT03869008|Device|Sham Device|The Sham device delivers no electrical stimulations but subjects randomized to the Sham device will received the same instructions to use the Sham device to stimulate 2 minutes on each side of the neck, twice a day, every day for the first 4 weeks after randomization.
45401372|NCT00161616|Drug|InductOs|InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage
45509695|NCT03834792|Other|No intervention but exposure|Different sleep disorders will be considered as an exposure. The data elements included in the database: demographics, date of the sleep study, study type, all available polysomnography indices, symptoms, sleep schedule, comorbidities, medications, social history, electrocardiography, positive airway pressure treatment related variables.
45509696|NCT03563274|Device|Selective Internal Radiation Therapy with QuiremSpheres®|The main purpose of this study is to further assess treatment efficacy and safety after using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases suitable for SIRT and allocated to this treatment by a multidisciplinary tumor board.
45509697|NCT03828162|Drug|Anticoagulants|
45509698|NCT04985214|Other|Questionnaire|Questionnaire on the quality of life
45401373|NCT03868852|Drug|Apatinib mesylate tablets|Apatinib mesylate tablets were orally administered 250 mg QD from 1 week before radiotherapy to the whole radiotherapy period. (Appatinib is no longer used after radiotherapy)
45401374|NCT03868852|Radiation|Three-dimensional conformal intensity modulation|Three-dimensional conformal intensity modulation (IMRT) technique was used for post-operative radiotherapy. The radiation dose was 45-54 Gy.
45401375|NCT01283776|Drug|Cyclophosphamide|100 mg/kg total dose, infused on day +3 and +3 after allogeneic stem cell transplantation
45509699|NCT04898010|Device|Selective Cytopheretic Device|The Selective Cytopheretic Device (SCD) treatment will be delivered using a two-cartridge system using a type of dialysis equipment commonly used for conventional hemodialysis therapy. The SCD cartridge will be added immediately post-hemofilter to the circuit of a standard hemodialysis system, and treatment will be delivered for 24 hours. Blood exchange will occur using a dialysis catheter.
45509700|NCT03563040|Drug|Methoxsalen|"Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.~During each photopheresis treatment with methoxsalen, the dosage of methoxsalen is calculated according to the treatment volume (which is displayed on the display panel of the instrument) using the formula:~Treatment volume x 0.017 ml of methoxsalen (20 µg/mL) for each treatment For example: Treatment volume = 240 mL x 0.017 = 4.1 mL of methoxsalen (20 µg/mL)"
45401376|NCT01163422|Device|Implantation of 3-chamber pacemaker|Implantation of pacemaker with leads in right atrium, right ventricle, and coronary sinus (left ventricle) with the aim of providing right ventricular resynchronization therapy (RVRT); this is accomplished by pacing the right ventricle ahead of the left ventricle, e.g., by setting (shortening) the A-V delay between right atrium and right ventricle to an optimal level.
45401377|NCT01170286|Biological|Whole peanut extract|Four different doses of whole peanut extract expressed as micrograms (mcg) of peanut proteins (20, 100, 250, 500 mcg) and two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested for determination of the maximum tolerated dose during a 2-week treatment period.
45401378|NCT01170286|Biological|Placebo formulation|Matching placebo at two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested in parallel to the peanut proteins doses for determination of the maximum tolerated dose during a 2-week treatment period.
45401379|NCT01284712|Biological|blood sample|blood sample coming from therapeutic bleeding in hospital
45401380|NCT01163500|Dietary Supplement|Coenzyme Q10|coenzyme Q10 supplements 60 mg/day and 150 mg/day
45401381|NCT01163500|Other|Placebo|Placebo controlled (dextrin)
46057176|NCT02777697|Other|chronic pain|
45401382|NCT01173094|Device|Percutaneous Transluminal Angioplasty|Before operation, take aspirin 100mg every day. During the operation, balloon is delivered by a catheter and positioned through the narrowing in the artery. Then expand the balloon against the wall of the blood vessel to provide a wider channel for blood.
45401383|NCT01173094|Device|below-knee arterial bypass|Before operation, take aspirin 100mg every day. Perform bypass to below-knee(posterior tibial，anterior tibial or peroneal)arteries, saphenous vein graft with end to side anastomoses
45509701|NCT03563040|Device|THERAKOS CELLEX Photopheresis System|Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.
45509702|NCT03828552|Other|Questionnaire|"Parents will be recruited in a Pediatric Resuscitation Department of the Mother and Child Hospital for 3 months. The doctor taking care of a child and his parents meeting the eligibility criteria will distribute, during the stay, a questionnaire accompanied by a pre-stamped envelope to the two parents not opposing the study.~A phone call and / or an email reminder by the intern in the month of the exit will invite each parent to return the questionnaire.~The completed questionnaire will be mailed back by the parents using the pre-stamped envelope."
45509703|NCT04777734|Biological|efgartigimod|an intravenous infusion of efgartigimod
45509704|NCT05306886|Other|ICB Medical Insoles|After the foot analysis of the participants in the intervention group, special insoles will be designed in a computer program. In these insoles, 3-6 mm medial wedge support, 1-3 mm heel wedge support, 2-4 mm medial longitudinal arch support will be provided. These values will be determined according to the needs of each participant. A single physiotherapist will design all insoles. All drawings will be made by a single physiotherapist. After the design of the insoles is completed, insoles will be produced by transferring them to a Computer Numerical Control (CNC) machine. Ethyl vinyl acetate (EVA), the use of which has been found useful before, will be used as the material in the insoles molds. After processing, 1mm thick fabric will be used for the top coating. All insoles will be produced by the same physiotherapist.
45509705|NCT05306886|Other|ICM Insoles|As in the intervention group, insoles will be designed for the participants in the control group, processed by CNC machine and the production will be completed. Only 2mm medial longitudinal arch support will be given to the insoles of the people in this group.
45509706|NCT03094416|Drug|levothyroxine sodium capsule|after the run-in period, patients will be switched to levothyroxine sodium capsule at the same dose used during run-in
45698089|NCT03364803|Other|Visual Analogue Scale (VAS)|"A validated visual analogue scale (VAS) questionnaire will be completed in the fasting state. The VAS consists of 100-mm lines with words anchored at each end describing extreme sensations of hunger, prospective consumption (How much do you think you can eat?), fullness, and satisfaction, as well as craving (sweet, salty, fatty or savory). Patients will be asked to make a vertical mark across the line corresponding to their feelings. Quantification will performed by measuring the distance from the left end of the line to the mark."
45698090|NCT03364803|Other|Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant|A validated questionnaire that assesses perceived subjective value attributed to expected/hypothetical foods and other primary reinforcers will be administered. This variant of this questionnaire was initially developed by Dr. Goldstein to assess 'liking' and 'wanting' of expected drug rewards for patients with cocaine addiction. The current assessment uses a modified version to assess 'liking' and 'wanting' for food.
45401384|NCT01284790|Device|Cochlear implants|
45401385|NCT01283854|Behavioral|Supervised home-based exercise|"Each participant randomised to the exercise group will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist. The exercise program will be implemented in accordance with the American College of Sports Medicine and the American College of Obstetrics and Gynecology guidelines. All sessions will be conducted on a stationary cycle ergometer.~Heart rate will be measured continuously during exercise to ensure that the exercise intensity is maintained as prescribed. In addition, blood pressure and rate of perceived exertion will be monitored at 10-min intervals. Perceived exertion will not be allowed to exceed a rating of 14 (i.e. somewhat hard)."
45401386|NCT01173250|Procedure|adding diverting ileostomy|
45698091|NCT01071538|Drug|Buprenorphine|Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.
45698092|NCT03346395|Behavioral|Problem solving based intervention|Problem solving based intervention
45698093|NCT03346395|Behavioral|Care as usual|Medical treatment, or behavioral therapy or a coordination of behavioral therapy and medical treatment. Meeting with a rehabilitation coordinator.
45698094|NCT04352686|Drug|Buspirone|Administration of buspirone to assess esophageal sensitivity
45849965|NCT02782104|Drug|Esketamine Nasal Spray|Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram [mg] or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585) or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
45698095|NCT04352686|Drug|Placebo|Administration of placebo to assess differences in esophageal sensitivity
45849966|NCT02454972|Drug|lurbinectedin (PM01183)|
45849967|NCT02025270|Biological|Stem Cells|60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.
45849968|NCT01821690|Drug|Buspirone|Buspirone/placebo will be given in increasing increments of 15 mg as needed. Subjects will start with 15 mg on day one and end with 60 mg on day 91 or placebo equivalent. Dose is titrated based on treatment response.
45401387|NCT01173250|Procedure|omitting diverting ileostomy|
45401388|NCT01163734|Drug|Ranolazine|Intravenous treatment followed oral treatment for 13 days.
45401389|NCT01163734|Other|Saline 0.9% and placebo tablet|Intravenous treatment followed by oral treatment for 13 days
45698096|NCT03146091|Other|Nonantibiotic treatment of uncomplicated diverticulitis|Patients randomized to this arm will be treated without antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
45698097|NCT03146091|Other|Antibiotic treatment of uncomplicated diverticulitis|Patients randomized to this arm will be treated with antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
45715281|NCT01567865|Biological|Vaccine produced in new facility|Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China
45715282|NCT05049226|Biological|AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) full dose|"Astrazeneca COVID-19 (ChAdOx1 AZD1222) vaccine:~One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S* recombinant) 5 × 10^10 viral particles (vp)~*Recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike glycoprotein. Produced in genetically modified human embryonic kidney (HEK) 293 cells.~Administer: Intramuscular (IM) injection in the deltoid muscle"
45849969|NCT01821690|Drug|Placebo|The placebo tablets taste and look identical to buspirone.
45849970|NCT01649388|Biological|FCR001|Enriched hematopoietic stem cell infusion
45849971|NCT01394016|Drug|LY2835219|Administered orally, daily for 28-day cycles for two planned cycles. For Part G only in addition to LY2835219 as above, fulvestrant is administered as specified in the label. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
45849972|NCT01394016|Drug|Fulvestrant|Fulvestrant is administered intramuscularly into the buttocks as specified in the label in Part G only.
45849973|NCT01096368|Radiation|3-Dimensional Conformal Radiation Therapy|Patients undergo conformal radiotherapy
45849974|NCT01096368|Drug|Carboplatin|Given IV
45849975|NCT01096368|Drug|Cisplatin|Given IV
45849976|NCT01096368|Other|Clinical Observation|Patients undergo observation
45849977|NCT01096368|Drug|Cyclophosphamide|Given IV
45849978|NCT01096368|Drug|Etoposide|Given IV
45698098|NCT01119040|Procedure|Natural Orifice Translumenal Endoscopic Surgery|"Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures involve transmural passage of flexible endoscopes introduced via a natural orifice whereby permitting access to the peritoneal cavity while avoiding skin incisions. No clear indication due to a number of physiologic, microbiologic, immunologic, and technical limitations. The concept of NOTES PEG Rescue in the setting of a dislodged naïve PEG tube may spare individual patients the physiologic stress of traditional surgery while concomitantly providing a natural segue to further study the NOTES platform in the human setting. PEG Rescue may represent a unique, practical, and empowering application of the burgeoning experience of natural orifice translumenal endoscopic surgery."
45698099|NCT04275687|Radiation|thoracic irradiation|"For peripherally located recurrent tumors, stereotactic body radiation therapy is used at 5000-6000 cGy in 10 fractions.~For centrally located recurrent tumors, adaptive hypofractionated radiation is used: Patients are irradiated at 3000-4000cGy in 6-10 daily fractions in the first course. After a four-week interval, patients who have non-progressive disease and an adequate pulmonary function undergo adaptive re-planning, and are irradiated at 2400-3500cGy in 4~7 daily fractions as a boost."
45698100|NCT04275687|Drug|Concurrent chemotherapy|For centrally located recurrent tumors, concurrent chemotherapy consists of weekly docetaxel and nedaplatin.
45698101|NCT02287311|Biological|MABEL CTLs|"Dose escalation:~DL1:2x10^7 cells/m2+2x10^7 cells/m2~DL2:2x10^7cells/m2+5x10^7 cells/m2~DL3:5x10^7 cells/m2+1x10^8 cells/m2~*Doses are based on total CD3+cells/m2~Patients with active disease that have apparent clinical benefit at the 8 wk post 1st infusion (6 wks after 2nd infusion) or subsequent evaluations may receive up to 6 additional doses of CTLs at intervals at least 6 wks apart, each of which will consist of the same cell number as their second injection or below the original dose if there is not enough product available for the original dose. Patients may receive lymphodepleting chemotherapy (Cy/Flu) before additional infusions. Patients cannot receive additional doses until the initial safety profile is completed at 6 wks following the second infusion."
45849979|NCT01096368|Biological|Filgrastim|Given SC or IV
45849980|NCT01096368|Other|Laboratory Biomarker Analysis|Optional correlative studies
45849981|NCT01096368|Drug|Mesna|Given IV
45849982|NCT01096368|Drug|Vincristine|Given IV
45849983|NCT00978822|Drug|Clevidipine butyrate injectable emulsion|Clevidipine butyrate injectable emulsion infusion starting at 2 mg/hour and titrating up for effect till 32 mg/h for up to 24 hours starting in the emergency department and continued in the critical care units.
45849984|NCT00577200|Drug|Midazolam|Midazolam
45849985|NCT00577200|Drug|Sufentanil|Sufentanil
45509707|NCT03094416|Drug|Proton pump inhibitor (PPI)|for the whole study duration all subjects will keep taking their proton pump inhibitor medication, as per prescription and as before inclusion
45509708|NCT03094416|Drug|Levothyroxine Sodium (LT4) Tablets|during the run-in period, subjects will continue taking their levothyroxine sodium tablet medication as per prescription and as before inclusion
45509709|NCT03106038|Drug|Nerindocianine for Injection|Procedure: routine minimally invasive pelvic surgery.
45698102|NCT02287311|Drug|Cyclophosphamide|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
45849986|NCT00577200|Drug|Propofol|Propofol bolus of 300 µg/kg + infusion at 75 µg/kg/min.
45849987|NCT00063882|Radiation|Brachytherapy (100/110)|100 Gy Palladium-103 (P-102) or 110 Gy Iodine-125 (I-125) seeds within 2-4 weeks of completion of external beam radiotherapy.
45849988|NCT00063882|Radiation|Brachytherapy (125/145)|125 Gy Palladium-103 (P-103) or 145 Gy Iodine-125 (I-125) seeds within 4 weeks of study entry.
45849989|NCT00063882|Radiation|External Beam Radiation Therapy|Total dose of 45 Gy to the prostate and seminal vesicles as a daily dose of 1.8 Gy given 5 times per week. The prescribed dose is defined at the International Commission of Radiation Units and Measurements (ICRU) reference point. Both 3D-conformal radiation therapy (3DCRT) and intensity modulated radiation therapy (IMRT) are permitted.
45849990|NCT00002796|Drug|fluorouracil|Given IV
45849991|NCT00002796|Drug|sodium phenylbutyrate|Given IV
45849992|NCT00002796|Drug|indomethacin|Given orally
45849993|NCT00002796|Biological|recombinant interferon gamma|Given subcutaneously
45849994|NCT00002802|Drug|carboplatin|
45849995|NCT00002802|Drug|cisplatin|
45849996|NCT00002802|Drug|cyclophosphamide|
45849997|NCT00002802|Drug|dacarbazine|
45849998|NCT00002802|Drug|doxorubicin hydrochloride|
45849999|NCT00002802|Drug|etoposide|
45850000|NCT00002802|Drug|ifosfamide|
45850001|NCT00002802|Drug|melphalan|
45850002|NCT00002802|Drug|mesna|
45850003|NCT00002802|Drug|vincristine sulfate|
45850004|NCT00002802|Drug|vindesine|
45850005|NCT00002802|Procedure|autologous bone marrow transplantation|
45850006|NCT00002802|Procedure|conventional surgery|
45401390|NCT01284868|Drug|mirabegron|oral
45401391|NCT01284868|Drug|Bisoprolol|oral
45401392|NCT01284868|Drug|propranolol|oral
45401393|NCT01284868|Drug|placebo|oral
45850007|NCT00002802|Radiation|low-LET cobalt-60 gamma ray therapy|
45850008|NCT00002802|Radiation|low-LET electron therapy|
45850009|NCT00002802|Radiation|low-LET photon therapy|
45850010|NCT00002802|Radiation|radioisotope therapy|
45850011|NCT00002814|Biological|filgrastim|
45850012|NCT00002814|Drug|paclitaxel|
45850013|NCT00002814|Drug|topotecan hydrochloride|
45401394|NCT01163812|Procedure|Laparoscopic D2 distal gastrectomy|"Under general endotracheal anesthesia, Five or six ports are used. Lymph node dissection and ligation of vessels are carried out in the laparoscopic field. A partial omentectomy encompassing perigastric nodes is performed laparoscopically. D2 lymphadenectomy is carried out according to the guidelines of the The Japanese Research Society for Gastric Cancer for the corresponding location of the primary tumor. A 5- to 6-cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, the stomach is removed from the abdominal cavity and resected. A Billroth-I gastroduodenostomy using an EEA stapler and GIA or a Billroth-II gastrojejunostomy with a hand-sewing technique is performed. The abdomen is then closed after hemostasis is achieved."
45401395|NCT01170442|Drug|vitamin D3 2000 IU|vitamin D3 2000 IU orally, daily for 6 months
45401396|NCT01170442|Drug|vitamin D3 5000 IU|vitamin D3 5000 IU orally, daily for 6 months
45401397|NCT01170442|Drug|Placebo|placebo orally, daily for six months
45401398|NCT03866356|Behavioral|intervention group|The women in the intervention group were provided care according to SICP
45401399|NCT01173328|Behavioral|Pursed-lip breathing|Pursed-lip breathing involves a nasal inspiration followed by expiratory blowing against partially closed lips, avoiding forceful exhalation.
45401400|NCT01173328|Behavioral|Normal Breathing|
45401401|NCT01170520|Device|repetitive transcranial Stimulation|rTMS using the figure of 8 magstim for 4 weeks or 20 work days, using 100% threshold to the LDPFC 42 trains per day 4 sec pretrain inter train interval of 30 sec.
45401402|NCT03868696|Procedure|MUA with sham ultrasound|Standard MUA with sham ultrasound
45401403|NCT03868696|Procedure|MUA with active ultrasound|Standard MUA guided by ultrasound
45401404|NCT01170676|Behavioral|Puff City GA|Puff City GA focuses on three areas of health behavior: 1) adherence to controller medications; 2) immediate availability of rescue medication; 3)smoking cessation/reduction.
45401405|NCT01170676|Behavioral|General Asthma Education|Students will be directed to generic public websites on asthma and smoking that contain helpful information on general asthma management.
45698103|NCT02287311|Drug|Fludarabine|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide and fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
45401406|NCT03876184|Other|Aesthetic archwires|During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.Questionnaires will be answered by participants.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
45401407|NCT03876184|Other|Control group|During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.This group will not answer the questionnaire.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
45401408|NCT01173406|Behavioral|CPAP education|Standard CPAP education plus an session and one telephone follow up
45401409|NCT01163890|Behavioral|Work and Health Initiative|Telephone-based multi-modal intervention, consisting of: vocational coaching, cognitive-behavioral therapy strategies and care coordination strategies provided by specially-trained EAP counselors
45401410|NCT01163890|Behavioral|Usual Medical or Behavioral Intervention|Referral to treatment as usual through personal physician, mental health professional, behavioral health program, and/or Employee Assistance Program
45401411|NCT00252564|Drug|Bevacizumab|5 mg/kg over 30 minutes on Days 1 and 15
45401412|NCT00252564|Drug|Oxaliplatin|85 mg/m2 on Days 1 and 15
45401413|NCT00252564|Drug|Leucovorin|400 mg/m2 on Days 1 and 15
45401414|NCT00252564|Drug|Fluorouracil|400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)
45698104|NCT02172742|Drug|BIA 2-093|BIA 2-093 1200 mg once-daily
45698105|NCT02172742|Drug|Placebo|matching placebo
45401415|NCT00252564|Drug|Cetuximab|400 mg/m2 over 2 hours (Cycle 1 Day 1 only) All subsequent doses (Day 8, 15, 22 of Cycle 1 and Days 1, 8, 15, 22 other cycles)250 mg/m2 over 1 hour
45698106|NCT02172742|Drug|Digoxin|Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).
45698107|NCT03831633|Drug|Akynzeo|"1 single oral dose of NEPA (capsule) on Day 1 to be administered approximately 1 hour prior chemotherapy (containing 300 mg netupitant and 0.5 mg palonosetron).~- Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4"
45698108|NCT03831633|Drug|Standard of Care|"oral aprepitant 125mg (Day 1) and 80mg daily (on Day 2 and Day 3)~IV ondansetron 8 mg on Day 1~Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4"
45698109|NCT04396509|Behavioral|Maternal Attachment Inventory Score|three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken.
45698110|NCT02216175|Other|SLIT to cow's milk|Sublingual immunotherapy
45509710|NCT03041025|Drug|GSK2330811|GSK2330811 will be provided in vials and packed in 1 vial per carton. Each vial will contain 1.2 mL fill with 1 mL extractable volume at 100 mg/mL.
45509711|NCT03041025|Drug|Placebo|Normal saline (0.9 percent weight per volume sodium chloride).
45509712|NCT04765566|Device|Endovascular revascularization of peripheral arteries|Endovascular revascularization of peripheral arteries involves placement of a self-expanding Nitinol Stent encapsulated with ePTFE in diseased vessel segments
45698111|NCT02216175|Other|Low dose OIT|Oral Immunotherapy (low dose)
45698112|NCT02216175|Other|Conventional OIT to cow's milk|Oral Immunotherapy
45698113|NCT03145857|Drug|[68]Ga-HA-DOTATATE|All participants will be injected with [68]Ga-HA-DOTATATE approximately 60 minutes before PET/CT or PET/MRI scan.
46057177|NCT05749120|Procedure|Recipient vessel selected for microanastomosis|Free tissue flaps harvesting and microanastomosis were performed by the same surgeon and in a similar way in both group. Postoperative course, and complications were recorded and analyzed.
45401416|NCT03868462|Device|Optos P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
45698114|NCT02172820|Behavioral|Financial incentives|Patients in the experimental group will receive financial incentives for completing exercise sessions.
45401417|NCT03868462|Device|Predicate Device|The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
45401418|NCT01284946|Drug|Exjade|Orodispersible Tablet, 10 mg/Kg/day ± 5 mg/Kg/day during 24 weeks Deferasirox should be taken daily 30 minutes before breakfast
45698115|NCT03086889|Other|immersion virtual reality (VR)-based rehabilitation|Intervention group received VR-based rehabilitation,including Virtual kitchen and so on.The patients took part in the exercise program for 30 minutes each day, five times per week, for 3 weeks. All subjects received physiotherapy, which accounts for an average of 30 minutes of physiotherapy per day on tolerance.
45698116|NCT03086889|Other|traditional rehabilitation training|The traditional rehabilitation training included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 60 minutes each day, five times per week, for 3 weeks.
45698117|NCT02393079|Device|Transcranial LED Therapy (TCLT)|Whereas the geometry of the skull and to uniformly distribute the light radiation, the TLTC is applied using as light source a set of LEDs installed in a helmet, emitting radiation in the range between 600nm and 650nm with a peak at 630nm, so in the red region.
45698118|NCT02393079|Device|Sham|A SHAM identical helmet will be used in the control group.
45401419|NCT01173562|Drug|Mebendazole|Type= exact number, unit= mg, number= 500, form= chewable tablet, route= oral use. One mebendazole 500-mg chewable tablet taken on Day 1.
45698119|NCT01074034|Device|AV Therapy Assessment-B301 investigational device|Atrial and ventricular tachyarrhythmia therapy delivered by the B301 investigational device
45850014|NCT00002832|Biological|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to first PBSC collection then daily starting 1 day after PBSC infusion until blood counts recover.
45850015|NCT00002832|Drug|Cyclosporine|IV daily on day -2, then orally once dose is tolerable, dose may be escalated.
45850016|NCT00002832|Drug|Decitabine|IV for 6 hours every 12 hr for 5 days.
45401420|NCT01170910|Procedure|Static incubation|"Kidneys in this group are conserved in University of Wisconsin (eg, UW, Belzer® or Viaspan®), IGL-1, or SCOT solution before being transplanted.~."
45509713|NCT05109429|Behavioral|Neutral Cue-induced Craving|For the neutral cue condition, the participant will be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of water bottles via E-Prime software (Psychology Software Tools Inc., PA), presented for five seconds each in randomized order. The images will include pictures of a water bottle alone, water being poured from a bottle to a glass, and an individual drinking from a bottle of water. Next, participants will watch as research staff open a bottle of water, pour it into a glass, and place it on a table in front of the participant. Participants will also be asked to look at a water bottle, hold it, sniff it, and take a drink of water.
45850017|NCT00002832|Procedure|Allogeneic Bone Marrow Transplantation|Stem cell infusion on Day 0.
45401421|NCT01170910|Procedure|Pulsatile perfusion|Kidneys in this group are placed in the pulsatile perfusion machine(RM 3) within two hours and should be kept there at least 6 hours and 8 hours if possible, before being transplanted
45401422|NCT00166296|Drug|Escitalopram|15 mg/day starting 2 weeks before and 12 weeks during interferon therapy
45401423|NCT00166296|Drug|Placebo|Placebo, 15 mg/day, starting 2 weeks before and for 12 weeks during interferon therapy.
45401424|NCT01173640|Drug|Midazolam|2 mg oral dose
45401425|NCT01173640|Dietary Supplement|resveratrol (single dose)|1 g oral dose
45401426|NCT01173640|Dietary Supplement|resveratrol (multiple dose)|1 g oral dose for 8 days
45401427|NCT03868774|Procedure|repetitive transcranial magnetic stimulation|rTMS is a new non-invasive antidepressant method, which implies non-convulsive focal stimulation of the prefrontal cortex of the brain through a time varying magnetic field.
45401428|NCT00252174|Drug|Stage 1 Active Methylenedioxymethamphetamine|"Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg."
45401429|NCT00252174|Drug|Stage 1 Low dose Methylenedioxymethamphetamine|"Drug:~Dosage form: capsule~Dosage frequency and duration for the control arm (4 subjects):~Session 1: 25 mg followed 2.5 hours later with optional 12.5 mg for total of 37.5 g Session 2 (two to three weeks later): 25 mg followed 2.5 hours later with optional 12.5mg for total of 37.5mg."
45401430|NCT00252174|Behavioral|Psychotherapy|Psychotherapy conducted with low or active dose MDMA
45401431|NCT00252174|Drug|Stage 2 Active Methylenedioxymethamphetamine|"Administered open label Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg."
45401432|NCT01170988|Procedure|T-Graft|T-Graft
45509714|NCT05109429|Behavioral|Visual Opioid Cue-induced Craving|For the visual opioid cue-induced craving condition, the participant will again be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of opioid-related imagery, presented for five seconds each in a randomized order. The opioid-related imagery will be customized for heroin or prescription opioids based upon the participant's primary opioid of choice. The images will include pills and white powder, stages of drug taking preparation (e.g., holding spoon over flame, pills being crushed).
45509715|NCT05109429|Behavioral|Visual and Tactile Opioid Cue-induced Craving|For the visual and tactile opioid cue condition, procedures will differ depending on the participants' most preferred route of administration. . Intranasal users will be instructed to watch as research staff opens a wallet, removes a $1 bill, removes a packet of powder mimicking heroin/crushed pills, open the packet, and roll the dollar bill. The participant will then be given the packet and the dollar bill to hold for approximately 30 seconds. Intravenous users will be instructed to watch the research nurse open the packet of fake heroin, pour its contents into a spoon, added a few drops of water to the spoon, hold an open flame from a lighter under the spoon, add cotton to the spoon, and draw the fluid into a syringe.
45509716|NCT01338870|Drug|Placebo|Tablets (n=4), 0 mg twice daily for 84 days
45509717|NCT01338870|Drug|25 mg PF-04991532|Tablets (n=1), 25 mg strength + tablets (n=3) 0 mg twice daily for 84 days
45509718|NCT01338870|Drug|75 mg PF-04991532|Tablets (n=3), 25 mg strength + tablets (n=1) 0 mg twice daily for 84 days
45509719|NCT01338870|Drug|150 mg PF-04991532|Tablets (n=1), 150 mg strength + tablets (n=3) 0 mg twice daily for 84 days
45509720|NCT01338870|Drug|300 mg PF-04991532|Tablets (n=2), 150 mg strength + tablets (n=2) 0 mg twice daily for 84 days
45509721|NCT01338870|Drug|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=3) 0 mg once daily in the morning for 84 days; and tablets (n=4) 0 mg once daily in the evening for 84 days.
45509722|NCT02824224|Drug|Tamoxifen|10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course
45509723|NCT02824224|Drug|Placebo (for Tamoxifen)|Sugar pill manufactured to mimic the tamoxifen 10mg tablet
45509724|NCT04837638|Behavioral|Diet|No intervention. Cross-section assessment of the relationship between diet, medication, lifestyle and coronary artery calcification.
45850018|NCT00002832|Procedure|Peripheral Blood Stem Cell Transplantation|Peripheral blood stem cells (PBSC) are administered 5 days after last dose of decitabine.
45850019|NCT00002838|Biological|Filgrastim (G-CSF)|
45850020|NCT00002838|Drug|Cyclophosphamide|
45850021|NCT00002838|Drug|Fludarabine Phosphate|
45850022|NCT00002838|Procedure|Peripheral Blood Stem Cell Transplantation|
45850023|NCT00002844|Drug|Cyclophosphamide|Daily intravenous infusions of cyclophosphamide for two days,
45850024|NCT00002844|Procedure|Allogeneic Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
45850025|NCT00002844|Procedure|Autologous Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
45850026|NCT00002844|Radiation|Total Body Irradiation (TBI)|Following 2 days of cyclophosphamide, TBI in four daily exposures then bone marrow transplant.
45850027|NCT00002862|Drug|perillyl alcohol|
45698120|NCT02173522|Device|Prostate artery embolization (PAE)|Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.
45698121|NCT02817958|Drug|Chemotherapy TIP|Paclitaxel, ifosfamide, and cisplatin
45850028|NCT00002880|Drug|Etoposide phosphate|50 mg PO q day for 21 days; repeat every 28 days escalate dose to 100 mg PO q day if ANC remains greater than 1500/microliter during cycle 1: no specified maximum of cycles if PR or CR
45850029|NCT00002892|Biological|recombinant interferon alfa|
45850030|NCT00002898|Biological|dactinomycin|
45850031|NCT00002898|Drug|carboplatin|
45698122|NCT01075204|Drug|clarithromycin modified release 500 mg|clarithromycin modified release 500 mg for 7 days
45698123|NCT01120834|Drug|azacytidine|"Dose level 1: azacitidine 55 mg/m2 on days 1-5~Dose level 2: azacitidine 75 mg/m2 on days 1-5~Dose level 3: azacitidine 55 mg/m2 on days 1-5~Dose level 4: azacitidine 75 mg/m2 on days 1-5~Each cycle = 28 days. Subjects may receive up to 6 cycles."
45698124|NCT01120834|Drug|vorinostat|"Dose level 1: oral vorinostat at 300 mg BID on Days 1-7.~Dose level 2: oral vorinostat at 200 mg BID on Days 1-7.~Dose level 3: oral vorinostat at 300 mg BID on Days 1-14.~Dose level 4: oral vorinostat at 200 mg BID on Days 1-14.~Each cycle = 28 days. Subjects receive up to 6 cycles."
45850032|NCT00002898|Drug|cyclophosphamide|
45850033|NCT00002898|Drug|epirubicin hydrochloride|
45850034|NCT00002898|Drug|etoposide|
45850035|NCT00002898|Drug|ifosfamide|
45850036|NCT00002898|Drug|vincristine sulfate|
45850037|NCT00002898|Procedure|adjuvant therapy|
45850038|NCT00002898|Procedure|conventional surgery|
45850039|NCT00002898|Procedure|neoadjuvant therapy|
45850040|NCT00002898|Radiation|brachytherapy|
45509726|NCT03824964|Biological|Anti-CD19/CD22 CAR NK Cells|Total dose of 50-600 thousand /kg Anti-CD19/CD22 CAR NK cells will be administered at day0
45509727|NCT01338792|Drug|oxaliplatin|Given IV
45509728|NCT01338792|Drug|pemetrexed disodium|Given IV
45509729|NCT01338792|Other|questionnaire administration|Ancillary studies
45509730|NCT01338792|Other|laboratory biomarker analysis|Correlative studies
45850041|NCT00002898|Radiation|radiation therapy|
45850042|NCT00002904|Drug|trabectedin|
45850043|NCT00002916|Biological|human papillomavirus 16 E7 peptide|
45850044|NCT00002916|Biological|synthetic human papillomavirus 16 E6 peptide|
45850045|NCT00002916|Procedure|adjuvant therapy|
45850046|NCT00002916|Procedure|surgical procedure|
45850047|NCT00002916|Radiation|radiation therapy|
45850048|NCT00002928|Drug|paclitaxel|
45850049|NCT00002940|Drug|hydroxyurea|
45850050|NCT00002946|Drug|penclomedine|
45850051|NCT00002952|Biological|MART-1 antigen|Melan-A peptide loaded PBMCs (sc, q3wk x 3)
45850052|NCT00002952|Biological|recombinant MAGE-3.1 antigen|
45850053|NCT00002952|Biological|recombinant interleukin-12|rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
45509731|NCT01338792|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
45509732|NCT01338792|Genetic|polymorphism analysis|Correlative studies
45596741|NCT04467463|Procedure|peripheral nerve block by 0.25% levobupivacaine|SUBMANDIBULAR nerve block will be performed using a 25G 90 mm beveled needle . the entry point of the needle will be situated at the angle formed by the superior edge of the zygomatic arch below and the posterior orbital rim forward .The needle will be inserted perpendicular to the skin and advanced approximately 20 mm depth to reach the greater wing of the sphenoid deep to the pterygopalatine fossa. Injection of 1ml of 0.25% levobupivacaine will be done over 20 seconds afterensuring negative blood aspiration .greater Palatine Nerve will be blocked bilaterally as it leaves on palatal side through the foramen on the opposite direction of the anterior part of the 3rd molar orthe posterior part of the 2nd molar tooth.
45715283|NCT05049226|Biological|Pfizer/BioNTech BNT162b2 vaccine (PF) full dose|"Pfizer-BioNTech COVID-19 (BNT162b2) vaccine:~Diluent: 0.9% sodium chloride (normal saline, preservative-free)~Administer: Intramuscular (IM) injection in the deltoid muscle"
45850054|NCT00002964|Drug|porfimer sodium|
45850055|NCT00002964|Other|fluorophotometry|
45850056|NCT00002970|Drug|nelarabine|Given IV
45850057|NCT00002970|Drug|methotrexate|Given IT
45850058|NCT00002970|Drug|cytarabine|Given IT
45850059|NCT00002970|Drug|therapeutic hydrocortisone|Given IT
45850060|NCT00002976|Drug|conjugated estrogens|
45850061|NCT00002982|Biological|filgrastim|
45850062|NCT00002982|Drug|carboplatin|
45850063|NCT00002982|Drug|carmustine|
45850064|NCT00002982|Drug|cytarabine|
45850065|NCT00002982|Drug|etoposide|
45850066|NCT00002982|Drug|ifosfamide|
45850067|NCT00002982|Drug|melphalan|
45850068|NCT00002982|Procedure|autologous bone marrow transplantation|
45850069|NCT00002982|Procedure|peripheral blood stem cell transplantation|
45850070|NCT00002982|Radiation|radiation therapy|
45850071|NCT00002988|Drug|carmustine|
45850072|NCT00002988|Drug|irinotecan hydrochloride|
45850073|NCT00002994|Biological|interleukin 2|low dose: 1 million IU/square meter subq injection q day days 1-7 and 11-20 cycle 1; days 4-14 subsequent cycles Intermediate dose: 12 million IU/square meter subq injection on days 8-10 of cycle 1; days 1-3 of subsequent cycles
45850074|NCT00002994|Biological|rhuMAb|90 min IV infusion day 7 of each cycle
45850075|NCT00003000|Drug|fentanyl citrate|
45850076|NCT00003000|Drug|morphine sulfate|
45850077|NCT00003006|Genetic|reverse transcriptase-polymerase chain reaction|
45850078|NCT00003006|Other|immunohistochemistry staining method|
45850079|NCT00003012|Drug|CMF regimen|
45850080|NCT00003012|Drug|cyclophosphamide|
45850081|NCT00003012|Drug|epirubicin hydrochloride|
45850082|NCT00003012|Drug|fluorouracil|
45850083|NCT00003012|Drug|methotrexate|
45850084|NCT00003048|Drug|Amifostine Trihydrate|Escalating dose IV for two weeks, followed by 2 weeks of rest. Each treatment cycle is 4 weeks.
45698125|NCT01120990|Other|Blood Pressure Measurement|All patients have their blood pressure measured simultaneously by two observers using parallel connected mercury sphygmomanometers and by a supervisor using the tested device, NISSEI DM 3000. Six sets of measurements are performed.
45698126|NCT04346836|Behavioral|Low-intensity, general-fitness exercises|"24 session of low-intensity, general-fitness exercises (12 weeks, twice a week)~A single session of exercise lasted 40 minutes and consisted of 42 low-intensity, general-fitness exercises. Perception of effort was monitored using the Borg 6-20 rating the perceived exertion (RPE).~Thirty-three exercises were done sitting down, seven standing, and two in the hand-and-knees position. The exercises were classified as either aerobic, musculo-articular, or stabilising. The aerobic portion served as a general warm-up for the subsequent exercises, and the musculo-articular section focused on strengthening muscles and enhancing the mobility of joints in the upper limbs, the lower limbs and the torso. Stabilising exercises were designed to improve the stability of the body and to augment spatio-visual coordination."
45698127|NCT04346836|Behavioral|Psychoeducation|A psychoeducation provided by psychotherapist. Twenty minutes of psychoeducation, which contained mini lectures about mental well-being, psychohygiene and healthy dietary habits.
45698128|NCT02798224|Behavioral|e-assist: Colon Health|Online e-assist program uses educational messages and workflow tools. The intent is to reduce mental workload in terms of how to proceed by filtering and presenting information in a usable manner at a time of peaked situational awareness. The program will prompt patients to indicate their decision stage based on the Precaution Adoption Process Model. e-assist users are then prompted to view additional information and logistical assistance personalized for their decision stage.
45698129|NCT02798224|Behavioral|Healthwise Educational Program|Online access to fact sheets that provide basic information about colorectal cancer and screening.
45698130|NCT01122160|Drug|omeprazole|omeprazole 20.6 mg tablet with berries (blackberries + strawberries)
45698131|NCT01122160|Drug|placebo|Placebo with berries (blackberries + strawberries)
45698132|NCT02623816|Drug|Optimal Dosing of Omeprazole|Omeprazole 20 mg
45698133|NCT02180230|Device|Shorty implants|Dental implant insertion to maxilla or mandible
45698134|NCT03012958|Other|Lung clearance index (LCI)|LCI is determined by the number of lung volume turnovers necessary to clear the lungs of an inert tracer gas such as nitrogen that is inhaled at the beginning of the test. The LCI is calculated by determining the cumulative expired volume (CEV) and then dividing the CEV by the functional residual capacity. Values of less than7.0 indicate normal values while an LCI greater than 7.0 is associated with heterogeneity in ventilation and distal airway abnormalities. The ability to detect peripheral airway disease may make LCI a better modality for detecting distal airways abnormalities seen on lung histopathology but often missed on traditional pulmonary function testing.
45698135|NCT01122238|Drug|Nicotine Patch|"If randomized to only the Nicotine Patch condition (and not the Nicotine Gum):~Participants randomized to this condition will receive a 6-week supply of 14 mg patches at the initial visit. Participant will be instructed to use one patch daily for 6 weeks."
45698136|NCT01122238|Drug|Nicotine Gum|"If randomized to only the Nicotine Gum condition (and not the Nicotine Patch):~Participants randomized to this condition will receive a 6-week supply of 2 mg gum at the initial visit. Participants will be instructed to use 10 pieces of gum daily for 6 weeks."
45698137|NCT01122238|Behavioral|Motivational Interviewing|"Participants randomized to this condition will receive an initial MI counseling session during the in-person clinic visit followed by three counseling phone calls over the 6-week intervention period (a total of four intervention contacts). The phone counseling sessions will occur during weeks 2, 4, and 6. Case managers will engage the participant in a series of motivation building exercises such as reviewing feelings and thoughts about the pros and cons of quitting and smoking, reinforcing the positives of quitting, helping to dispel myths and concerns about the negatives of quitting, and posing questions about the good aspects of smoking."
45850085|NCT00003054|Drug|paclitaxel|
45850086|NCT00003060|Biological|filgrastim|
45850087|NCT00003060|Drug|busulfan|
45850088|NCT00003060|Drug|cyclophosphamide|
45596742|NCT02363361|Drug|Imatinib|Day 1. 800 mg, Day 2-14: 2 * 400 mg per day
45850089|NCT00003060|Drug|cyclosporine|
45850090|NCT00003060|Drug|methotrexate|
45850091|NCT00003060|Procedure|allogeneic bone marrow transplantation|
45850092|NCT00003066|Drug|docetaxel|
45850093|NCT00003066|Drug|estramustine phosphate sodium|
45850094|NCT00003072|Drug|amifostine trihydrate|
45850095|NCT00003072|Drug|carboplatin|
45850096|NCT00003072|Drug|paclitaxel|
45850097|NCT00003078|Drug|cisplatin|
45850098|NCT00003078|Drug|fluorouracil|
45596743|NCT04594915|Drug|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics [SmPC]).
45596744|NCT02363205|Behavioral|Tailored Internet-administrated CBT-Treatment|Guided internet-delivered CBT with chat sessions
45596745|NCT05556811|Device|Dynamic Light Therapy Device, LSA-1|Dynamic Light Therapy
45596746|NCT05556811|Device|Dynamic Light Therapy Device, LSA-2|Dynamic Light Therapy
45596747|NCT05556811|Device|Dynamic Light Therapy Device, LSA, 3|Dynamic Light Therapy
45596748|NCT03227757|Device|Tricuspid Valve Repair System|Subjects who received TVRS will be included in this arm. The TVRS is intended for reconstruction of the insufficient tricuspid valve through tissue approximation.
45850099|NCT00003078|Radiation|brachytherapy|
45850100|NCT00003078|Radiation|radiation therapy|
45850101|NCT00003084|Drug|Doxorubicin Hydrochloride|Doxorubicin IV on days 1, 15, and 29.
45850102|NCT00003084|Drug|Estramustine phosphate sodium|"Arm I: Oral estramustine three times a day for 21 day cycle.~Arm II: Oral estramustine three times a day on days 8-14, 22-28, and 36-42 in 8 week cycle."
45850103|NCT00003084|Drug|Etoposide|Oral etoposide twice daily on days 1-14.
45850104|NCT00003084|Drug|Ketoconazole|Oral ketoconazole three times a day on days 1-7, 15-21, and 29-35.
45850105|NCT00003084|Drug|Paclitaxel|IV over 1 hour on day 2.
45850106|NCT00003084|Drug|Vinblastine|IV on days 8, 22, and 36.
45850107|NCT00003090|Biological|aldesleukin|
45850108|NCT00003096|Genetic|DNA ploidy analysis|
45850109|NCT00003096|Genetic|comparative genomic hybridization|
45850110|NCT00003096|Genetic|cytogenetic analysis|
45850111|NCT00003096|Genetic|fluorescence in situ hybridization|
45850112|NCT00003108|Drug|bryostatin 1|
45850113|NCT00003108|Drug|cisplatin|
45850114|NCT00003114|Biological|filgrastim|Filgrastim (granulocyte colony-stimulating factor) is given subcutaneously on days 5-21 and 33-42.The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
45850115|NCT00003114|Drug|cyclophosphamide|Oral cyclophosphamide on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
45850116|NCT00003114|Drug|etoposide|Oral etoposide on days 1-3. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
45401433|NCT03868306|Other|CBC , Iron study and Haemoglobin electrophoresis .|The study will conducting on 100 patients of microcytic hypochromic anaemia who recruited from the hematology outpatient clinic , Assiut University Children Hospital . Beside history and clinical examination , the studied cases will be subjected to the following investigations Complete blood count ( CBC ) with comparison of MCV , RBCs count , RDW and RDWI . Determination of serum ferritin , serum iron and total iron bending capacity ( TIBC ) . HB electrophoresis . Patient with HBA2 more than 3.2 % are identified as beta thalassemia trait and patients with serum ferritin less than 12 ng / ml are identified as IDA cases. Validity of both discrimination indices are evaluated by calculating there sensitivity , specificity , positive predictive value , negative predictive value and Youden index ( YI ) Based on statistical criteria in ideal test should have high sensitivity and specificity and Youden index.
45850117|NCT00003114|Drug|lomustine|Patients receive oral lomustine on day 1.
45850118|NCT00003114|Drug|procarbazine hydrochloride|Oral and procarbazine on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
45850119|NCT00003114|Radiation|radiation therapy|Patients with partial response or stable disease receive radiation therapy and/or continued chemotherapy.
45850120|NCT00003120|Drug|paclitaxel|135 mg/m2 IV every 28 days
45401434|NCT01077180|Device|Implantation of the Rheos System|Open label
45850121|NCT00003126|Drug|Interleukin-2|High-dose bolus interleukin-2 is a systemic therapy used to treat metastatic RCC
45401435|NCT01077180|Other|Standard of care medical management|Patients will continue with medical therapy for standard of care of their hypertension.
45401436|NCT01171066|Device|Tasman CPAP system|Participants will trial the Tasman CPAP system for a duration of 1 week in place of their current CPAP system.
45401437|NCT01164046|Drug|low molecular weight heparin|weight adjusted dose of low molecular weight heparin, any type allowed if approved, 65-75% of full therapeutic dose
45509733|NCT04752072|Behavioral|Enhanced Skills Training in Affective and Interpersonal Regulation|"The first (formulation) session enables linking present difficulties and traumatic events, identifying current issues/concerns, and collaboratively agreeing on the order of modules based on symptom severity and client readiness.~The PTSD module provides narrative exposure to the traumatic memories and targets re-experiencing, avoidance and hyperarousal symptoms. The AD module focuses on identifying and labelling feelings, emotion management, distress tolerance, acceptance of feelings and experiencing positive emotions. The NSC module focuses on staying in the present moment and combating dissociation; self-compassion and mindfulness skills; challenging thinking patterns and developing a balanced view of self. The DR module focuses on exploring and revising maladaptive schemas; effective assertiveness; awareness of social context; and flexibility in interpersonal expectations and behaviours displayed in social interactions."
45509734|NCT04752072|Behavioral|Treatment as usual|The first session will involve a mental health assessment by either a psychiatrist or psychologist. A treatment package will be developed based on the information collected during the assessment. Details of the interventions delivered to each participant receiving TAU, which will include elements of psychoeducation, symptom-management and trauma-focused cognitive behaviour therapy, will be recorded.
45850122|NCT00003132|Drug|bryostatin 1|
45850123|NCT00003132|Drug|cisplatin|
45850124|NCT00003144|Drug|amifostine trihydrate|
45850125|NCT00003144|Drug|cisplatin|
45850126|NCT00003144|Drug|gemcitabine hydrochloride|
45850127|NCT00003150|Biological|rituximab|
45850128|NCT00003150|Drug|CHOP regimen|
45850129|NCT00003150|Drug|cyclophosphamide|
45401438|NCT01164046|Drug|vitamin K antagonists|Target INR between 2-3. Any type allowed, if approved for use in that country.
45850130|NCT00003150|Drug|doxorubicin hydrochloride|
45850131|NCT00003150|Drug|prednisone|
45850132|NCT00003150|Drug|vincristine sulfate|
45850133|NCT00003156|Drug|topotecan hydrochloride|
45850134|NCT00003162|Procedure|pain therapy|
45850135|NCT00003162|Radiation|radiation therapy|
45850136|NCT00003174|Drug|bryostatin 1|
45850137|NCT00003174|Drug|cladribine|
45850138|NCT00003186|Drug|isosulfan blue|
45850139|NCT00003186|Procedure|lymphangiography|
45850140|NCT00003186|Procedure|sentinel lymph node biopsy|
45850141|NCT00003192|Drug|aminocamptothecin|
45698138|NCT01122238|Behavioral|Smoking Reduction|Participants randomized to Smoking Reduction will receive an initial counseling session during the in-person visit followed by 6 weekly phone counseling sessions over the 6-week intervention period. During the initial session, participants will be told that the goal is to reduce cigarette consumption by 50% over the course of the intervention (approximately 10% reduction per week). During the initial meeting and subsequent counseling calls, case managers will work with participants to problem-solve strategies for reduction (e.g., increasing time between cigarettes, delaying smoking, or eliminating smoking in specific situations). Participants will be asked to record information in a provided smoking log to help keep track of daily smoking patterns and as a feedback mechanism for identifying successes and challenges.
45698139|NCT01122238|Other|No Intervention|No Intervention
45698140|NCT01122238|Drug|Nicotine Patch + Nicotine Gum|"If randomized to both the Nicotine Patch and the Nicotine Gum conditions:~Participants randomized to this condition will receive a 6-week supply of 14 mg patches and a 6-week supply of 2 mg gum at the initial visit. Participant will be instructed to use one patch daily and to use 10 pieces of gum daily for 6 weeks."
45698141|NCT01122316|Drug|Metformin|3. Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
45698142|NCT01076452|Device|Bilateral Deep Brain Stimulation|The DBS site (STN or GPi) was assigned on a random basis at the time the patient enters the surgical phase of the trial.
45698143|NCT01076686|Drug|Questionnaire and Physical Exam|A 10-question survey and a six-item physical exam were completed.
45698144|NCT03049449|Biological|Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells|Dose-escalation trial starting dose: 0.3x10^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) (up to a maximum dose of 18x10^6 CAR+ T cells/kg) infuse on day 0
45850142|NCT00003018|Drug|dipyridamole|75mg/dose, PO, Days 1-28 of 5 week cycle
46059157|NCT02875925|Other|MTM|Medication management is a process that ensures each patient's medications are assessed to determine the appropriateness, effectiveness, safety, and convenience of each medication for the patient. Medication management is fully integrated with the care team. Pharmacists provide this service to identify, prevent, and resolve drug therapy problems improve outcomes.
45401439|NCT01074762|Behavioral|Structured personal care|General practitioners (GPs) were recommended to perform regular follow up every three months and an annual screening for diabetic complications. The GP was requested to define, together with the patient, the best possible goals for blood glucose concentration, glycated haemoglobin (HbA1c), diastolic blood pressure, and lipids within three predefined categories. At each quarterly consultation, the GP was asked to compare the achievements with the goal and consider changing either goal or treatment accordingly. The doctors received annual descriptive feedback reports on individual patients. The GPs were introduced to possible solutions to therapeutic problems through clinical guidelines supported by an annual half day seminar. Patient leaflets were produced for the doctor to hand out.
45401440|NCT01075464|Drug|MEGF0444A|Intravenous escalating dose
45401441|NCT01075464|Drug|bevacizumab|Intravenous repeating dose
45401442|NCT01075464|Drug|paclitaxel|Intravenous repeating dose
45401443|NCT01285180|Drug|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
45401444|NCT01075542|Device|AcrySof Toric intraocular lens, model SN60TT|The lens is made of foldable acrylic material and is implanted in the capsular bag
45401445|NCT01075542|Device|AcrySof Monofocal IOL, model SN60AT|The lens is made of foldable acrylic material and is implanted in the capsular bag
45401446|NCT01075620|Device|PFC-Sigma RP|Posterior stabilizing rotating platform total knee components
45401447|NCT01075620|Device|LPS RP|non-posterior stabilized rotating platform design
45509735|NCT01314105|Drug|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
45509736|NCT01314105|Drug|BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
45698145|NCT03049449|Drug|Cyclophosphamide|300 or 500 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
45698146|NCT03049449|Drug|Fludarabine|30 mg/m^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
45698147|NCT04396431|Behavioral|education|"The intervention group was offered a six-hour training program based on the transtheoretical model in order to promote sun protection behavior and to reinforce self-efficacy. The program was prepared by the researchers in consideration of the SunSmart Program implemented in Australia, the SunWise School Program developed by the United States Environmental Protection Agency. The program included various educational tools such as a sun protection story, activity book, PowerPoint presentations, cartoons, and puzzles.~Refresher training was conducted 15 days, 1 month, and 2 months after the initial training. Sun protection behavior and self-efficacy of the children were evaluated at the beginning of the study and six months after the program. As gifts to support their sun protection behavior, the children were given an FDA-approved sunscreen with 50+ SPF, a white cotton short-sleeved T-shirt as protective clothing, sunglasses with 100% UV protection, and a wide-brimmed hat."
45698148|NCT03186729|Drug|Antithrombotic Agent|Anticoagulant or antiplatelet drugs
45698149|NCT03019029|Other|18-F Florbetapir PET/MR scan|18-F Florbetapir PET/MR scan, PET/MR on a GE SIGNA PET/MR scanner
45698150|NCT02399943|Drug|Trametinib|
45850143|NCT00003018|Drug|fluorouracil|200 mg/m^2/day, continuous IV, Days 1-28 of 5 week cycle
45698151|NCT02399943|Drug|Panitumumab|
45698152|NCT03186027|Dietary Supplement|Coenzyme Q10 plus NADH|"Active arm: Coenzyme Q10 plus NADH CFS/ME patients who will be randomized to measure the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH 20 mg/day; 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: Reconnect"
45698153|NCT03186027|Dietary Supplement|phosphoserine plus vitamin C|"Placebo arm: phosphoserine plus vitamin C CFS/ME patients who will be randomized to measure the effect of oral Placebo supplementation (phosphoserine and vit C, 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: placebo"
45401448|NCT03968250|Behavioral|Cognitive Behavioral Therapy for Treating Fatigue|"The internet-based CBT postcancer fatigue intervention includes two face-to-face sessions with their therapist and eight web-based treatment modules, each approximately 45 minutes in length, delivered over 6 months.~The intervention will be specifically tailored to the individual needs of each patient: The CBT model of cancer-related fatigue distinguishes six perpetuating factors: 1) insufficient processing of being diagnosed with HL and being treated for it; 2) excessive fear of disease recurrence; 3) inactivity or a dysregulated (physical) activity pattern; 4) dysfunctional fatigue-related beliefs; 5) dysregulated sleep-wake pattern and 6) lack of social support. For each of these six cognitive-behavioural factors that can perpetuate fatigue a treatment module has been developed."
45401449|NCT01074840|Other|Peanut flour|Peanut-allergic subjects will be given peanut flour in increasing amounts.
45698154|NCT02595892|Drug|Berzosertib|Given IV
45698155|NCT02595892|Drug|Gemcitabine|Given IV
45698156|NCT02595892|Drug|Gemcitabine Hydrochloride|Given IV
45698157|NCT04397913|Drug|Paracetamol|15 mg/kg, q6h
45698158|NCT04397913|Drug|Ibuprofen|10 mg/kg qd for the 1st day, 5 mg/kg qd for the 2nd and 3rd day
45698159|NCT04397523|Biological|anti-SARS-CoV-2 convalescent plasma|Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection
45698160|NCT02176408|Behavioral|Behavioral Activation|Behavioral Activation Therapy (BA). All participants will receive a standard behavioral activation treatment based on the manualized treatment described by Lejuez et al., 2011. Treatment will be delivered in 60-minute weekly sessions over a 6-week period followed by 3 biweekly booster sessions. Behavioral activation includes scheduling activities the patient will enjoy and find important with the purpose of improving mood.
45698161|NCT02176408|Behavioral|Exercise Intervention|Exercise Intervention (EX). The exercise intervention will immediately follow each of the first six weekly BA sessions. Each EX session will comprise 30 minutes of either providing rationale for the program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 40 minutes of aerobic exercise at 60-75% of maximum heart rate on three days each week, with 5 minute stretching warm up and cool down. We will help all participants initiate and plan their at-home program of exercise.
45698162|NCT02176408|Behavioral|Stretching Intervention|Stretching Intervention (STR). The stretching intervention will also follow each of the first six weekly BA sessions. These sessions will comprise 30 minutes of providing rationale for the stretching program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 50 minutes of stretching on three days each week. Participants in this condition will be provided with a 50-minute DVD of stretching exercises and will work with the therapist to plan their at-home stretching exercises.
45698163|NCT02176486|Drug|Ixazomib|Ixazomib capsules.
45850144|NCT00003018|Drug|leucovorin calcium|30 mg/m^2/day, IV, Days 1,8,15,22 of 5 week cycle
45401450|NCT01077492|Other|Virtual Bronchoscopy Navigation|Use of dedicated virtual bronchoscopy navigation software using 4D CT-PET scan spacial data.
45401451|NCT01074918|Drug|Potassium, Magnesium, Citrate|Potassium MAgnesium Citrate - 30 mEq potassium, 15 mEq Magnesium, 45 mEq Citrate in a powder mixture twice a day, mixed with a glass of water.
45850145|NCT00003018|Drug|mitomycin C|10 mg/m^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
45401452|NCT01074918|Drug|Potassium Chloride|Potassium Chloride
45401453|NCT01074996|Drug|S-1|40-60mg bid , days 1-14, every 3 weeks
45401454|NCT01074996|Drug|S-1 plus Leucovorin|S-1 40-60mg bid, days 1-14 , every 3 weeks Leucovorin 25mg bid , days 1-14 , every 3 weeks
45401455|NCT00160680|Drug|Levocetirizine|"Pharmaceutical form: Tablet~Concentration: 5 mg~Route of administration: Oral use"
45401456|NCT00160524|Biological|Certolizumab Pegol (CDP870)|Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Week 2, and every 4 weeks thereafter until Week 362. Up to 84 months of therapy in this study.
45401457|NCT01077570|Drug|repaglinide|Repaglinide prescribed at the discretion of the investigator, according to local labelling, and evaluated at week 0, 8 and 16 of the study
45698164|NCT02176486|Drug|Placebo|Ixazomib placebo-matching capsules.
45698165|NCT01124188|Drug|Higher-dose venlafaxine|Dosing of venlafaxine will range from 187.5-300 mg/day.
45850146|NCT00003198|Drug|ifosfamide|
45850147|NCT00003198|Drug|topotecan hydrochloride|
45401458|NCT01075698|Drug|Non-ARB (standard therapy)|Blood pressure lowering therapy except ARB
45850148|NCT00003204|Drug|cyclophosphamide|Given IV
45850149|NCT00003204|Drug|fludarabine phosphate|Given IV
45850150|NCT00003204|Drug|vincristine sulfate|Given IV
45850151|NCT00003204|Drug|prednisone|Given PO
45850152|NCT00003204|Biological|rituximab|Given IV
45698166|NCT01124188|Behavioral|Supportive management|Supportive management encourages participants to take the medication and manages any treatment-emergent side effects. Ten sessions will be delivered over the course of 14 weeks.
45698167|NCT01124188|Behavioral|Problem Solving Therapy for Depression and Pain|PST-DP will be delivered over the course of 10 sessions over 14 weeks. Along with teaching the participant 7 steps of problem solving, PST-DP also includes a medication support and management component.
45698168|NCT02220478|Device|Posterior Lateral Approach Total Hip Arthroplasty|All patients enrolled in the study are indicated for a total hip replacement, and will receive this replacement from the surgeon via a Posterior Lateral surgical approach.
45401459|NCT01075698|Drug|ARB (Telmisartan)|Telmisartan 20-80 mg/day
45401460|NCT03966300|Other|Multi-faceted knowledge translation intervention|The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
45698169|NCT01125202|Behavioral|SCT-based behavioral intervention|Intervention group continues to receive routine dialysis care. The intervention duration is 16 weeks. Intervention contacts are 2x/week for weeks 0-8, weekly for weeks 9-12, and every other week for weeks 13-16. Personal digital assistant dietary records are use to provide targeted counseling and engaged the participant in problem solving around dietary issues.
45698170|NCT01125202|Behavioral|Attention Control|Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
45698171|NCT03013114|Drug|Bortezomib|Bortezomib was given by intravenous bolus injection at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, repeated every 21 days. It will be given four cycles.
45698172|NCT01077310|Drug|Vivitrol- Intramuscular naltrexone (depot-formulation)|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
45698173|NCT01077310|Drug|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.
45698174|NCT02989857|Drug|AG-120|Tablet administered orally
45401461|NCT00159822|Drug|Voriconazole|"Voriconazole oral : loading dose on day 1 : 400mg/12 hours; maintenance dose 200 mg /12 hours for 6 to 12 months depending on clinical response.~Alternatively, patients may start on Voriconazole, IV, for 7 days loading dose, 6mg/Kg/12 hours on day one and maintenance dose 4 mg/Kg/12 hours"
45401462|NCT01164124|Dietary Supplement|Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)|The probiotic regimen consisted of 500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter & Gamble.Inc)
45401463|NCT01164124|Other|Placebo|routine feedings
45698175|NCT02989857|Drug|Placebo|Tablet administered orally
45698176|NCT02393937|Drug|Reference: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
45698177|NCT02393937|Drug|Test: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
45850153|NCT00003204|Other|laboratory biomarker analysis|Correlative studies
45401464|NCT01171144|Other|Epidemiologic Surveillance System of the Ministry of Health of Panama|Reviewing the Epidemiologic Surveillance System of the Ministry of Health of Panama
45401465|NCT01171144|Other|Mortality database of the Contraloria General de la Republica|Reviewing the Mortality database of the Contraloria General de la Republica
45401466|NCT01171144|Other|Hospital discharge records|Reviewing the hospital discharge records
45401467|NCT01285258|Procedure|hysterectomy|excluding the uterus with saving ovaries
45401468|NCT00158262|Drug|Propranolol|Propranolol short-acting or long-acting capsule
45401469|NCT00158262|Drug|Placebo|Placebo-matching propranolol short-acting or long-acting capsule
45698178|NCT02393937|Drug|Placebo Gel|Participants are assigned to one of three groups in parallel for the duration of the study
45850154|NCT00003210|Biological|recombinant interleukin-12|Given subcutaneously
45850155|NCT00003210|Other|laboratory biomarker analysis|Correlative studies
45850156|NCT00003216|Drug|fluorouracil|
45850157|NCT00003216|Drug|gemcitabine hydrochloride|
45850158|NCT00003216|Radiation|radiation therapy|
45850159|NCT00003234|Drug|vinorelbine tartrate|
45850160|NCT00003240|Drug|cisplatin|
45401470|NCT03868072|Drug|XELJANZ 5Mg Tablet|XELJANZ 5Mg Tablet 1T single oral administration under fasting
45401471|NCT03868072|Drug|Chong Kun Dang Tofacitinib Tablet|Chong Kun Dang Tofacitinib Tablet 1T single oral administration under fasting
45401472|NCT02526394|Biological|Meningococcal vaccine|Meningococcal vaccination
45850161|NCT00003240|Drug|ifosfamide|
45850162|NCT00003240|Drug|mitomycin C|
45850163|NCT00003240|Drug|vinblastine sulfate|
45850164|NCT00003240|Drug|vindesine|
45850165|NCT00003240|Drug|vinorelbine tartrate|
45850166|NCT00003240|Procedure|conventional surgery|
45401473|NCT02526394|Drug|Pertussis containing vaccine|Pertussis containing vaccination
45401474|NCT00157950|Biological|Gardasil™|Gardasil™ 3 dose regimen (Day 1, Month 2 and Month 6)
45401475|NCT00157950|Biological|Placebo|Gardasil™ matching placebo 3 dose regimen (Day 1, Month 2 and Month 6)
45401476|NCT01283932|Drug|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg
45401477|NCT01075308|Drug|HDAC inhibitor SB939|SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
45401478|NCT05666752|Dietary Supplement|Allium Cepa L. Peel Heated Water Extract|4 capsules/day after meal(1,200 mg/day) for 8 weeks
45401479|NCT05666752|Dietary Supplement|Placebo|4 capsules/day after meal(1,200 mg/day) for 8 weeks
45401480|NCT03966144|Device|RoboHear Device|Delivery of haptic sensations followed by testing to assess the ability to interpret stimuli as sounds and words
45401481|NCT01171300|Other|18F- FDG PET scans|We aim to investigate the value of FGD-PET for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
45401482|NCT01171300|Other|DW-MRI scans|We aim to investigate the value of DW-MRI for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
45401483|NCT03964896|Other|Survey|Complete survey
45401484|NCT03964896|Other|Survey Administration|Ancillary studies
45698179|NCT01877915|Drug|Rivaroxaban|Each participant, randomly allocated to the rivaroxaban arm, will receive one 2.5 mg tablet of rivaroxaban orally (by mouth) twice daily (once in the morning and once in the evening at approximately the same time each day) until the global treatment end date (GTED) (defined as the date when 1200 primary efficacy outcome events have occurred). Rivaroxaban will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
45698180|NCT01877915|Drug|Placebo|Each participant, randomly allocated to the placebo arm, will receive one matching placebo tablet orally twice daily (once in the morning and once in the evening at approximately the same time each day) until the GTED. Placebo will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
45698181|NCT01877915|Other|Standard of care for heart failure and coronary artery disease|Each participant's standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician) should be continued throughout the study.
45401485|NCT03964896|Behavioral|Telephone-Based Intervention|Receive telephone calls
45401486|NCT01171378|Drug|Ofatumumab|"1000mg vials (50ml @ 20mg/ml), or 100mg vials (5ml @20mg/ml), to be given as an Intravenous (IV) infusion.~Ofatumumab will be infused intravenously on day 1 (300 mg), day 8 (1000 mg) and day 15 (1000mg) in the first cycle, followed by infusions every 3 weeks of 1000 mg on the first day of each cycle for a total of 6 cycles. Maintenance treatment will start 4 weeks after day 1 of cycle 6 in week 20 and consists of six infusions of ofatumumab every 8 weeks"
45401487|NCT01164280|Other|Pulse Rate Change|Different pulse rate settings of the implantable neurostimulator
45401488|NCT03875560|Biological|IC14|recombinant chimeric anti-human CD14 monoclonal antibody
45401489|NCT03875560|Drug|Placebo|Inactive
45401490|NCT02526862|Device|Allevyn Thin®|Protection of the dermis with autoadhesive polyurethane dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
45401491|NCT02526862|Device|Askina Transorbent Border®|Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
45401492|NCT02526862|Device|Linovera®|Protection of the dermis with hyper hydrogenated fatty acids. It will be applied with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
45401493|NCT01171456|Drug|Metformin|Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
45401494|NCT01171456|Drug|Placebo|Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
45401495|NCT03865888|Drug|Cyclosporins|Cyclosporins eye drops to be administered in dry eyes
45401496|NCT03865888|Drug|Tacrolimus|Tacrolimus eye drops to be administered in dry eyes
45401497|NCT01173796|Procedure|catheter ablation|perimitral flutter ablation by blocking the mitral isthmus
45401498|NCT01173796|Procedure|catheter ablation|cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers
45401499|NCT03865966|Other||No intervention
45698182|NCT01876979|Device|IMF Screws|stainless steel screws placed in bone
45698183|NCT01876979|Device|Erich Arch Bars|Surgical braces wired around teeth
45698184|NCT04397601|Drug|Folfiri/Bevacizumab|Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with bevacizumab (5 mg/kg) on day 1 of each 14-day cycle.
45401500|NCT03866122|Device|NTM Monitoring|NTM and a patient monitor will continuously collect temperature for up to 72 hours. Additionally, Bempu and Thermospot may monitor temperature for up to 72 hours.
45698185|NCT04397601|Drug|Folfiri/Aflibercept|Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with aflibercept (4 mg/kg) on day 1 of each 14-day cycle.
45698186|NCT01860989|Drug|KAE609|KAE609 75mg single dose
45698187|NCT01860989|Drug|KAE609|KAE609 150mg single dose
45401501|NCT03875404|Diagnostic Test|Functional MRI|A special type of MRI measuring the metabolic changes that occur within the brain. It may be used to examine the brain's anatomy and determine which parts of the brain are handling critical functions. It helps identify important language and movement control areas in the brain.
45698188|NCT01860989|Drug|KAE609|KAE609 225mg single dose
45401502|NCT01284010|Genetic|DNA analysis|
45401503|NCT01284010|Genetic|fluorescence in situ hybridization|
45401504|NCT01284010|Genetic|gene expression analysis|
45509737|NCT01314105|Drug|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
45509738|NCT03562884|Drug|BLI800|Two bottles of BLI800 are needed for appropriate cleansing of the bowel. Prior to administration, the content of each bottle must be diluted in water, using the cup provided, to a total volume of approximately 0.5 L, and must be followed by the ingestion of 1 additional litre of water.
45509739|NCT03562884|Drug|Fortrans®|Fortrans® (Powder for Oral Solution) will be given according to Chinese approved Summary of Product Characteristics (SmPC). Fortrans® is provided as a powder for Polyethylene Glycol (PEG) based solution available in sachets containing a white powder readily miscible with water. The dosing for Fortrans® administration will be adapted to subjects' body weight as following: 1 L of solution for 15 to 20 kg, an average of 3 to 4 L (maximum 4 L).
45509740|NCT05339724|Other|platelet count and mean platelet volume are obtained from whole blood count|The records of cystic fibrosis patients will be retrospectively evaluated for acute pulmonary exacerbation, chronic airway colonization for bacteria, clinical stable status. PC and MPV will be obtained and matched in 6 groups (described above). Then, PC and MPV will be compared among the groups.
45509741|NCT05297799|Device|Ameda Pearl breast pump|The Ameda Pearl breast pump is a powered, multi-user breast pump with stimulation and expression modes and independently user-selectable speed and suction control in each mode.
45698189|NCT01860989|Drug|KAE609|KAE609 300mg single dose
45401505|NCT01284010|Genetic|microarray analysis|
45509742|NCT05265156|Other|Plant based formula for children aged between 12 and 36 months|Daily intake of plant based formula for 3 weeks (400ml-600ml per day).
45401506|NCT01284010|Genetic|mutation analysis|
45698190|NCT02906241|Behavioral|Patients: Questions to Ask Your Doctor: A Workbook for Patient-Doctor Teams|This booklet encourages patients to view themselves as members of the patient-doctor team and to participate actively during clinical interactions by asking questions and stating concerns.
45401507|NCT01284010|Genetic|polymerase chain reaction|
45401508|NCT01284010|Other|laboratory biomarker analysis|
45401509|NCT01285336|Genetic||
45401510|NCT03359434|Device|Clearsight device (Edwards) around the finger|Continuous measurement of blood pressure with the Clearsight device (Edwards) around the finger, within 24 hours after reperfusion:
45698191|NCT02906241|Behavioral|Physicians: Educational Module|Physicians will participate in an educational module and receive email prompts to encourage them to discuss trials with all patients who are eligible for a clinical trial, using patient-centered communication
45698192|NCT01860677|Device|Fisher Wallace Cranial Stimulator|The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies.
45698193|NCT02870829|Drug|menaquinone-7|Oral supplement given post dialysis 3x/week
45698194|NCT02861391|Device|CO2 AcuPulse Laser|Each subject will receive 3 laser treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
45698195|NCT02861391|Device|Sham Laser|Each subject will receive 3 sham treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
45698196|NCT02843529|Other|Altoida: neuropsychological, MRI, EEG and CSF biomarkers|"Data collection at baseline: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects. In both Prodromal and Preclinical AD subjects, APOE genotyping. The local clinical Unit should document the positivity at the baseline session of at least one of the biomarkers of AD mentioned above.~Data collection at 6, 12, 24 and 36 months of follow up: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects."
45850167|NCT00003240|Radiation|radiation therapy|
45850168|NCT00003252|Drug|amifostine trihydrate|
45850169|NCT00003264|Drug|cisplatin|
45850170|NCT00003264|Drug|gemcitabine hydrochloride|
45850171|NCT00003276|Drug|irinotecan hydrochloride|
45850172|NCT00003282|Drug|EF5|Given IV
45850173|NCT00003282|Procedure|therapeutic conventional surgery|Undergo resection
45850174|NCT00003282|Procedure|biopsy|Undergo biopsy
45401511|NCT03359434|Device|Intermittent blood pressure measurements with cuff.|Standard method: 35 blood pressure measurements with cuff within 24 hours after reperfusion
45401512|NCT01171846|Other|Pelvic Floor Muscle training|"Women allocated to the intervention group will have five appointments with a specialist women's health physiotherapist (intervention physiotherapist) over 16 weeks who will prescribe a daily exercise programme and provide a Lifestyle Advice Sheet (focusing on weight loss, constipation, avoidance of heavy lifting, coughing and high-impact exercise) and relevant tailored advice (phase 1).~Thereafter women in the intervention group will be offered Pilates-based classes, including PFMT, as maintenance (phase 2). Classes will be led by a physiotherapist who has undertaken Pilates training and will take place in six week blocks; each woman will be offered two six week blocks over a year. An exercise DVD will be provided for home use. Each woman will be offered a one-to-one review physiotherapy appointment at one and two years after randomisation."
45401513|NCT01284088|Device|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
45401514|NCT01284088|Procedure|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
45509743|NCT03562962|Behavioral|Functional Analytic Psychotherapy|FAP is a therapeutic procedure based on behavior analytic principles. This approach seeks to implement procedures to manipulate the contingencies of reinforcement involved in clients' problem and alternative behaviors within the context of a meaningful therapeutic relationship that is functionally equivalent to other interpersonal contexts outside (Follette, Naugle & Linnerooth, 2000; Kohlenberg & Tsai, 1991). FAP therapists modify CRBs by implementing contingent responding (TCRB) within the therapeutic setting. That is, FAP aims to administer differential reinforcement (TCRB1) to reduce CRB1s and to provide positive reinforcement to enhance CRB2s. Based on the changes within the therapeutic setting, clients are prompted to discriminate contexts where those repertoires are likely reinforced and to generalize those responses to such environments (Kohlenberg & Tsai, 1991).
45401515|NCT01284166|Drug|dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution|1 drop of Triple Combination Therapy (dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution) administered to each eye, twice daily for 12 weeks.
45401516|NCT01164514|Biological|CPG 7909|CPG 7909 is a synthetic oligodeoxynucleotide used as an adjuvant and administered at 2 different dosages: 250 mcg and 500 mcg.
45698197|NCT01876901|Procedure|2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA)|"2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) Whatever the mode of continuity restoration used, resection is the same in the two groups. It consists of total excision of the rectum and its mesorectum, that intervention should be performed by laparotomy or laparoscopy.~After surgical resection, the colon is exteriorized through the anus and attached to the buttock.~By day 6, exteriorized colon is resected and coloanal anastomosis is performed without preventive stoma derivation"
45850175|NCT00003282|Other|pharmacological study|Correlative studies
45850176|NCT00003288|Biological|filgrastim|
45850177|NCT00003288|Drug|cyclophosphamide|
45401517|NCT01164514|Biological|J5-OMP Vaccine|J5-OMP vaccine 10 mcg to be administered with and without CpG 7909 adjuvant 250 or 500 mcg, intramuscularly on Days 0, 29 and 59.
45401518|NCT01164514|Drug|Placebo|Normal saline.
45401519|NCT01164592|Device|adaptive servoventilation (ASV)|Patients randomised to therapygroup should use the adaptive servoventilation (ASV) device each night at least 3 hours
45401520|NCT01285414|Drug|Verubulin|Verubulin, dose determined in Part A, i.v. once weekly, Temozolomide & Radiation Therapy
45401521|NCT01285414|Drug|Temozolomide & Radiation Therapy|Temozolomide & Radiation Therapy
45401522|NCT03875248|Device|Blood pressure measurement|Measure optically the blood pressure through the use of a smartphone
45401523|NCT03875014|Device|surgery with implant for hip fracture|hip replacement with bipolar hemiarthroplasty or total hip arthroplasty dual mobility done and patients was followed
45509744|NCT03040713|Drug|Flortaucipir F18|370 megabecquerel (MBq)(10 millicurie [mCi]) injection, single dose
45509745|NCT03040713|Procedure|Brain PET scan|positron emission tomography (PET) scan of the brain
45509746|NCT04726176|Biological|Exposure to COVID-19|To study the exposure of COVID-19 on the brain and executive functioning
45850178|NCT00003288|Drug|tirapazamine|
45850179|NCT00003294|Biological|filgrastim|
45850180|NCT00003294|Drug|amifostine trihydrate|
45850181|NCT00003294|Drug|carboplatin|
45850182|NCT00003294|Drug|paclitaxel|
45850183|NCT00003312|Radiation|iodine I 125|
45850184|NCT00003324|Procedure|conventional surgery|
45850185|NCT00003324|Radiation|radiation therapy|
45850186|NCT00003330|Biological|recombinant interleukin-12|
45850187|NCT00003336|Biological|anti-thymocyte globulin|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
45401524|NCT03875170|Other|Experimental|The technique will be carried out with the subjects in the positions of supine, prone and lateral position, for the flexor muscles of the hip, hamstrings and quadriceps, where the musculature and the joint to be treated will be taken to a range of functional mobility. The subject will be asked to perform an isometric contraction, with a series of 3 seconds for sustained contraction and a rest between contraction of 2 to 3 seconds after activating the Golgi apparatus, making an inhibition of the stimulus and bringing the joint and muscle to the highest possible range of motion without pain.
45401525|NCT03875170|Other|Control|The active stretching technique will be performed for the hip, quadriceps and hamstring flexors with a voluntary antagonist activation to relax the agonist muscle, holding the movement to be performed for 30 seconds to stimulate the neuromuscular spindle and produce a relaxation of the muscle fibers.
45401526|NCT01172002|Drug|Leflunomide|"Leflunomide, 20 mg/d, ORAL ,each day. Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks."
45850188|NCT00003336|Drug|busulfan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
45850189|NCT00003336|Drug|cyclophosphamide|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
45850190|NCT00003336|Drug|melphalan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
45401527|NCT01172002|Drug|Azathioprine|"Azathioprine,50-100 mg/d, ORAL ,each day . Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks."
45401528|NCT03867994|Drug|Atorvastatin|
45401529|NCT03867994|Drug|Carvedilol|
45401530|NCT03867994|Drug|saline|
45401531|NCT01172080|Other|protocol of reminders regarding due colonoscopy|Participants receive two standardized letters followed by a phone call if they have not scheduled or completed their upcoming due colonoscopy
45401532|NCT03867604|Procedure|Sham injection|Injection to the subcutaneous layer at upper trapezium level
45401533|NCT03867604|Procedure|Fascia injection|Injection to the fascia below upper trapezium muscle
45401534|NCT01285570|Drug|Ulimorelin Intravenously (IV)|480 microg/kg daily (QD)
45401535|NCT01285570|Drug|Ulimorelin Intravenously (IV)|160 microg/kg daily (QD)
45401536|NCT01285570|Drug|5% dextrose in water|Placebo
45850191|NCT00003336|Drug|methylprednisolone|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
45401537|NCT01164748|Radiation|Lymphoscintigraphy|in all women a lymphoscintigraphy was done to investigate drainage patterns of a previous operated breast and axilla
45850192|NCT00003336|Procedure|bone marrow ablation with stem cell support|
45850193|NCT00003336|Procedure|umbilical cord blood transplantation|One day after the conditioning regimen is completed, patients receive the UCBT.
45850194|NCT00003336|Radiation|radiation therapy|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
45401538|NCT01172236|Drug|Lactoferrin|"Experimental group: newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.~Control group: newborns (group B) will receive only standard therapy and they will be used as controls."
45401539|NCT01172236|Drug|Lactoferrin|Experimental group: 650 newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.Control group: 650 newborns (group B) will receive only standard therapy and they will be used as controls.
45401540|NCT02525926|Procedure|denervation|The examination proceeds under rigorous aseptic technique. Femoral, jugular or brachial venous access will be performed. A flexible catheter is first introduced across a 7-Fr venous introducer, and passed through the right heart chambers toward the origin of the pulmonary arteries. The pressures in the right heart chambers and the pulmonary artery will be measured. At the end of the examination, the catheter is removed, a dressing is applied and the venous puncture is compressed by hand.
45509747|NCT05221125|Behavioral|Psychologically-Informed Physical Therapy (PIPT)|The PIPT group will receive evaluation and treatment based on the PT's assessment of the individual patient's clinical presentation and condition.
45850195|NCT00003342|Biological|filgrastim|
45850196|NCT00003342|Drug|carboplatin|
45850197|NCT00003342|Drug|doxorubicin hydrochloride|
45850198|NCT00003342|Drug|gemcitabine hydrochloride|
45850199|NCT00003342|Drug|paclitaxel|
45850200|NCT00003348|Drug|O6-benzylguanine|
45401541|NCT02525926|Procedure|sham procedure|"Right heart catheterism is mandatory in PAH patients care (for diagnosis and during follow-up) and will serve as a  sham  procedure. A usually performed and after a venous punction, cardiac outpout and pulmonary artery pressures will be recorded.~Acoustically isolated headphones will be given to patients during the procedure in order to assure simple-blind during the study."
45401542|NCT02525848|Drug|dexamethasone|dexamethasone 8 mg iv 2 minutes before induction of anesthesia
45401543|NCT02525848|Drug|Gabapentin|oral gabapentin 600 mg 1 hour before induction of anesthesia
45401544|NCT02525848|Drug|Aprepitant|oral aprepitan 80mg 1 hour before induction of anesthesia.
45401545|NCT03865576|Diagnostic Test|Non-invasive ICP measurement|Intracranial pressure will be measured non-invasively using transorbital Doppler ultrasound. Values will be compared to ICP measured by lumbar puncture or implanted ICP sensors
45509748|NCT01966471|Drug|Trastuzumab Emtansine|Trastuzumab emtansine IV infusion (duration 90 minutes) will be administered at 3.6 mg/kg q3w for up to 18 cycles (1 cycle = 21 days).
45509749|NCT01966471|Drug|Trastuzumab|Trastuzumab IV infusion (duration 90 minutes) will be administered at 8 mg/kg loading dose followed by 6 mg/kg IV q3w for up to 18 cycles (1 cycle = 21 days).
45509750|NCT01966471|Drug|Pertuzumab|Pertuzumab infusion (duration 60 minutes) will be administered at 840 mg loading dose followed by 420 mg IV q3w for up to 18 cycles (1 cycle = 21 days).
45509751|NCT01966471|Drug|Paclitaxel|IV infusion of paclitaxel 80 mg/m^2 once weekly may be administered concurrently with trastuzumab in combination with pertuzumab for 12 weeks.
45509752|NCT01966471|Drug|Epirubicin|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using epirubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
45509753|NCT01966471|Drug|Doxorubicin|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using doxorubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
45698198|NCT01876901|Procedure|Colo-anal anastomosis (CAA)|"After the surgical resection, coloanal anastomosis is performed usually after completion of a reservoir J when it is possible. Preventive ostomy is performed most often.~In the absence of fistula, the patient will reoperation for stoma closure of its branch"
45401546|NCT01172314|Dietary Supplement|EAA+LEU vs total AA|15 g as a bolus
45401547|NCT01172314|Dietary Supplement|Total AA vs EAA+LEU|15 g as a bolus
45401548|NCT01269112|Device|citrate regional anticoagulation|"Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation"
45401549|NCT01269112|Device|citrate regional anticoagulation|"Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation"
45401550|NCT01174420|Device|Use of ologen Collagen Matrix in trabeculectomy|After trabeculectomy, place ologen Collagen Matrix on the top of the scleral flap under the conjunctiva before suturing
45509754|NCT01966471|Drug|Docetaxel|IV infusion either docetaxel every 3 weeks (q3w) (at 100 milligram per square meter [mg/m^2] for 3 cycles (1 cycle = 21 days); at 75 mg/m2 for 4 cycles; or start at 75 mg/m^2 in the first cycle and escalate to 100 mg/m^2 if no dose limiting toxicity occurs, for a total of 3 cycles at minimum) may be administered concurrently with trastuzumab in combination with pertuzumab.
45509755|NCT01966471|Drug|Cyclophosphamide|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using cyclophosphamide (FEC) may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
45509756|NCT01966471|Drug|5-Fluorouracil|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using 5-fluorouracil, may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
45698199|NCT03136887|Device|JOURNEY II XR Total Knee System|JOURNEY II XR Total Knee System
45401551|NCT01174420|Drug|Use of Mitomycin-C in trabeculectomy|After creating a scleral flap, a sponge with Mitomycin-C (0.02%) is applied on the scleral surface for 3 minutes. Afterwards, Mitomycin-C was rinsed out with balanced salt solution.
45401552|NCT01164826|Drug|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
45401553|NCT01164826|Drug|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
45401554|NCT03867370|Drug|Toripalimab (JS001 )|Given IV
45401555|NCT03867370|Drug|Toripalimab (JS001 ) Lenvatinib|Given IV 4 mg capsules
45698200|NCT01876823|Drug|es-citalopram|es-citalopram 10mg/day will be given for the first week, and 20mg/day starting at week 2.
45698201|NCT01876823|Drug|Memantine|After two weeks on Lexapro, Memantine 5mg will be added. The dose will increase to 10mg for the second week and will be increased at a rate of 5mg per week. Memantine dosage will not exceed 20mg.
45698202|NCT01876511|Drug|MK-3475|MK-3475 10 mg/kg every 14 days
45698203|NCT01993719|Drug|Aldesleukin|720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
45698204|NCT01993719|Drug|Fludarabine|25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days
45698205|NCT01993719|Drug|Fludarabine|30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days.
45850201|NCT00003348|Drug|carmustine|
45850202|NCT00003354|Procedure|conventional surgery|
45850203|NCT00003354|Procedure|laparoscopic surgery|
45850204|NCT00003360|Radiation|iodine I 131 monoclonal antibody A33|
45850205|NCT00003372|Drug|topotecan hydrochloride|
45850206|NCT00003378|Drug|carboplatin|
45401556|NCT03867370|Drug|Toripalimab (JS001 ) Lenvatinib|Given IV 4 mg capsules
45401557|NCT03867292|Other|Myofascial|"The aim of the application of the crossed hands technique is to produce a deep fascial release, placing the subject in prone position, while the standing physiotherapist will contact with one hand on the spine at the level of the thoracolumbar hinge and with the other hand on the sacrum, so that the hands are crisscrossed. The crossed hands technique will be performed between 90 seconds and 5 minutes.~The application of the TENS, will be performed for 10 minutes by means of a device, model Compex in the lumbar area, subjects will receive a TENS application of low frequency (less than 40Hz). The electrode - (black) in proximal position or on the most painful zone. The electrode + (red) will be placed distally."
45698206|NCT01993719|Drug|Cyclophosphamide|60 mg/kg/day X 2 days intravenous (IV)
45698207|NCT01993719|Drug|Cyclophosphamide|Days -5 to -3 (low-dose arm):30 mg/kg IV over 60 minutes for 2 days
45698208|NCT01993719|Drug|Cyclophosphamide|Days -5 to -3 (low-dose arm): 300 mg/m^2 IV over 60 minutes.
45698209|NCT01993719|Biological|Young TIL|Day 0: Cells will be infused intravenously (IV)
45698210|NCT01993719|Drug|Pembrolizumab|2 mg/kg intravenous (IV) on Days -2, 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days).
45698211|NCT00638235|Device|AMS Apogee™ with IntePro|Mesh implant for posterior wall pelvic organ prolapse
45698212|NCT00638235|Device|AMS Apogee™ with Intexen LP|Graft implant for posterior wall pelvic organ prolapse
45698213|NCT00638235|Device|AMS Perigee™ with IntePro|Mesh implant for anterior wall pelvic organ prolapse
45698214|NCT00638235|Device|AMS Perigee™ with IntePro Lite|Mesh implant for anterior wall pelvic organ prolapse
45850207|NCT00003378|Drug|gemcitabine hydrochloride|
45850208|NCT00003378|Drug|paclitaxel|
45850209|NCT00003384|Other|Cervical Papanicolaou Test|Undergo Pap smear
45850210|NCT00003384|Procedure|Conization|Undergo cone biopsy
45850211|NCT00003384|Other|Laboratory Biomarker Analysis|Correlative studies
45850212|NCT00003390|Drug|irofulven|
45850213|NCT00003396|Biological|anti-thymocyte globulin|
45850214|NCT00003396|Biological|graft-versus-tumor induction therapy|
45698215|NCT00638235|Device|AMS Apogee™ with IntePro Lite|Mesh implant for posterior wall pelvic organ prolapse
45698216|NCT00638235|Device|AMS Elevate™ Apical & Posteiror with IntePro Lite|Mesh implant for apical and posterior wall pelvic organ prolapse
45698217|NCT00638235|Device|AMS Elevate™ Apical & Posteiror with IntXen LP|Graft implant for apical and posterior wall pelvic organ prolapse
45698218|NCT00638235|Device|AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 1, For Study Use Only)|Mesh implant for anteiror and apical wall pelvic organ prolapse
45698219|NCT00638235|Device|AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 2)|Mesh implant for anteiror and apical wall pelvic organ prolapse
45698220|NCT01848171|Drug|L-thyroxine|
45698221|NCT02758665|Drug|ibrutinib|
45698222|NCT02758665|Drug|obinutuzumab|
45698223|NCT02758665|Drug|venetoclax|
45850215|NCT00003396|Drug|cyclophosphamide|
45850216|NCT00003396|Drug|melphalan|
45850217|NCT00003396|Procedure|peripheral blood stem cell transplantation|
45850218|NCT00003396|Radiation|radiation therapy|
45850219|NCT00003402|Drug|carmustine|
45850220|NCT00003402|Drug|cisplatin|
45850221|NCT00003402|Drug|cyclophosphamide|
45850222|NCT00003402|Drug|dexamethasone|
45850223|NCT00003402|Drug|etoposide|
45850224|NCT00003402|Drug|melphalan|
45850225|NCT00003402|Drug|paclitaxel|
45850226|NCT00003402|Procedure|bone marrow ablation with stem cell support|
45850227|NCT00003402|Procedure|peripheral blood stem cell transplantation|
45850228|NCT00003408|Biological|aldesleukin|
45850229|NCT00003408|Biological|recombinant interferon alfa|
45850230|NCT00003408|Biological|sargramostim|
45850231|NCT00003414|Biological|aldesleukin|
45850232|NCT00003414|Biological|recombinant interferon gamma|
45850233|NCT00003414|Drug|busulfan|
45850234|NCT00003414|Drug|cyclophosphamide|
45850235|NCT00003414|Drug|cyclosporine|
45850236|NCT00003414|Procedure|peripheral blood stem cell transplantation|
45850237|NCT00003414|Radiation|radiation therapy|
45401558|NCT03867292|Other|Electrotherapy|The application of the TENS, will be performed for 10 minutes by means of a device, model Compex in the lumbar area, subjects will receive a TENS application of low frequency (less than 40Hz). The electrode - (black) in proximal position or on the most painful zone. The electrode + (red) will be placed distally.
45401559|NCT01174498|Device|Cerbomed t-VNS® transcutaneous stimulation|Subjects experience a transcutaneous, electrical, vagal stimulation with the t-VNS device.
45401560|NCT01174498|Device|t-VNS Sham stimulation|t-VNS Sham stimulation
45401561|NCT01284322|Drug|Fresolimumab|intravenous fresolimumab 1mg/kg, first 8 patients; 5 mg/kg following 8 patients
45401562|NCT01284400|Other|Home-based disease management|Symptom monitoring, comprehensive advice, and counseling at home by nurses, as well as telephone follow-up by nurses
45401563|NCT01285648|Procedure|Cpap|This study did not involved drugs. The Oxygenation index, Borg Scale, pain scale and the presence and duration of thoracic drainage was determined in the immediate postoperative (POi) period and in the first and second postoperative (PO1, PO2) days in 40 patients who underwent elective lung resection,in two groups of intervention: chest physiotherapy, and associate this with cpap
45401564|NCT01172392|Drug|Pegylated interferon-alpha-2a|180 mcg / wk / SC from D0 to W48
45401565|NCT01172392|Drug|Nucleotidic or Nucleosidic Treatment|Analog treatment according to investigators practice
45401566|NCT01172470|Drug|Gemcitabine|4 doses of induction chemotherapy every 2weeks, IV (in the vein)
45401567|NCT01172470|Drug|Pemetrexed|"Induction Chemotherapy:~4 doses of induction chemotherapy every 2weeks(Days 1, 15, 28, and 42), through an infusion for approximately 10 minutes.~Chemoradiotherapy:~Day 1,22, and 43through IV infusion over a period of 10 minutes"
45401568|NCT01172470|Drug|Carboplatin|"Chemoradiotherapy:~Day 1, 22 and 4 through IV infusion over a period of 1 hour."
45401569|NCT01164904|Drug|Amg 181|Ten escalating dose levels of AMG 181 administered as single dose SC or IV, in healthy volunteers and SC subjects with mild-to-moderate ulcerative colitis.
45401570|NCT03865186|Behavioral|Psychoeducation Program|"The program titled, Psychoeducation Program for Emotion Identification and Expression in Those Diagnosed with Schizophrenia was conducted with the patients in the intervention groups once a week for ten weeks."
45401571|NCT03865186|Behavioral|no intervention|
45401572|NCT03863938|Drug|Tegoprazan 50mg|K-CAB
45401573|NCT01175044|Procedure|Betadine Lavage|Following revision knee surgery, a dilute betadine lavage prior to surgical closure for 3 minutes followed by 2000 ml of sterile saline irrigation
45401574|NCT01175044|Procedure|Saline Lavage|Following revision knee surgery, 2000ml sterile saline lavage prior to closure
45401575|NCT03864016|Drug|Induction and maintenance of anesthesia|The hypnotic agent used is Propofol and the morphine agent used is Sufentanil.
45401576|NCT03864016|Drug|Adaptation of sufentanil doses according to the usual protocol|At induction the target concentration of sufentanil is 0.5 ng/ml. The sufentanil dose is decided by the anaesthetist, taking into account the operating times (induction, TIO, incision, opening and sternal spacing, CEC, closure), the usual data provided by the monitoring: heart rate, blood pressure, BIS, EtCO2, modification of insufflation pressures.
45401577|NCT03864016|Drug|Adjustment of sufentanil doses according to pupillometry|At induction, the target concentration of sufentanil is 0.5 ng/ml. The dose of sufentanil is then adjusted according to the dilation reflex obtained with the PPI (Pain Pupillary Index) at predefined times.
45850238|NCT00003420|Procedure|computed tomography|
45401578|NCT03860662|Diagnostic Test|Nociceptor flexor reflex|The nociceptive flexion reflex (NFR) is a physiological, polysynaptic reflex allowing for painful stimuli to activate an appropriate withdrawal response
45401579|NCT03860662|Drug|Botox|botox
45401580|NCT03860662|Drug|Baclofen|baclofen
45401581|NCT01177696|Behavioral|Psychotherapeutic intervention|A psychotherapeutic intervention will be 8 sessions of 90 minutes in a pilot study groups. This intervention has been initially developed for family caregivers of patients with dementia.
45401582|NCT01177852|Drug|diphenhydramine + dropropizine + pseudoephedrine|"Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).~Posology: The medicine treat will be as follows:~- Notuss® syrup Age: 2-5 years / Dosage: 5,0 mL Age: 6-12 years / Dosage: 10,0 ml"
45401583|NCT01177852|Drug|Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).|"Dropropizine:~Age: 2 - 3 years / Dosage: 5,0 ml Age: 4 - 12 years / Dosage: 10,0 ml~Pseudoephedrine hydrochloride + brompheniramine maleate:~Age: 2 - 3 years / Dosage: 2,5 ml Age: 4 - 6 years / Dosage: 5,0 ml Age: 7 - 9 years / Dosage: 7,5 ml Age: 10 - 12 years / Dosage: 10,0 ml"
45401584|NCT01285726|Other|Non-interventional study|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists.
45850239|NCT00003426|Drug|gemcitabine hydrochloride|
45850240|NCT00003426|Radiation|radiation therapy|
45850241|NCT00003432|Biological|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses.
45850242|NCT00003450|Biological|Ad5CMV-p53 gene|
45850243|NCT00003462|Drug|busulfan|
45401585|NCT01288144|Other|Quality improvement initiative|In intervention clinics, the LMR will use the existing reminder function to alert providers that a patient has a probable history of gestational diabetes. The provider will then have the opportunity to clarify the subject's history and order appropriate screening testing. Providers will also have access to online reference material regarding GDM follow-up screening and lifestyle interventions.
45401586|NCT01285804|Other|Cuffed ETT|Kimberly Clark
45401587|NCT01285804|Other|Uncuffed ETT|Kimberly Clark
45401588|NCT01178008|Procedure|Active acupuncture|Active acupuncture regimen consists of electroacupuncture stimulation on cranial and body acupoints which are empirical for treating depression in term of traditional Chinese medicine theory. It is done by a registered Chinese medicine practitioner with at least 3 years experience of providing acupuncture treatment. An electric-stimulator is connected to these needles to give an electric-stimulation in a continuous wave The needles will be left for 30 min and then removed. Acupuncture treatment will consist of two sessions per week for 4 consecutive weeks.
45401589|NCT01178008|Procedure|Placebo acupuncture|Streitberger's non-invasive acupuncture needles will be applied to serve as placebo control at the same acupoints and the same stimulation modality, except that the needles only affixed on the skin with adhesive tapes instead of insertion. Since all the points used are beyond patients' vision as they lay on bed, they could not visualize the acupuncture procedure. The acupuncturist, setting, treatment frequency, and duration of the treatment course are the same as the active acupuncture group.
45401590|NCT01288222|Other|KIR genotype|KIR genotype data from unrelated donor are collected
45401591|NCT01175122|Biological|H2N3 MO 2003/AA ca Vaccine|0.2 mL of H2N3 MO 2003/AA ca vaccine delivered by an Accuspray nasal spray device on Day 0 and Day 28
45401592|NCT03863392|Drug|Misoprostol|induction of labor
45401593|NCT01175200|Drug|Clopidogrel|antiplatelet agent
45401594|NCT01175200|Drug|Prasugrel|antiplatelet agent
45401595|NCT01175200|Drug|Lansoprazole|proton pum inhibitor
45850244|NCT00003486|Drug|antineoplaston A10|
45850245|NCT00003486|Drug|antineoplaston AS2-1|
45850246|NCT00003486|Procedure|alternative product therapy|
45850247|NCT00003486|Procedure|biological therapy|
45401596|NCT01175200|Drug|Placebo|placebo comparator similar to lansoprazole
45401597|NCT01288300|Behavioral|Picture good health/Imaginate una buena salud|Diabetes education, self-empowerment training, exercise, patient navigator
45509757|NCT03439735|Drug|Endocrine Therapy and a CDK 4/6 inhibitor|Participants with untreated metastatic disease receiving ET and a CDK 4/6 i as first line therapy.
45509758|NCT03439735|Drug|Endocrine Therapy and a CDK 4/6 inhibitor|Participants initiating a CDK 4/6 i after progression on ET.
45850248|NCT00003486|Procedure|biologically based therapies|
45850249|NCT00003486|Procedure|cancer prevention intervention|
45850250|NCT00003486|Procedure|complementary and alternative therapy|
45401598|NCT01288300|Behavioral|Diabetes lecture|Diabetes self-management lecture
45401599|NCT03865108|Procedure|Ultrasound imaging|This standard of care procedure is being done for research purposes and used to collect information and measure the maternal and fetal anatomy.
45850251|NCT00003486|Procedure|differentiation therapy|
45850252|NCT00003516|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
45509759|NCT01568437|Procedure|TAP-Block|Block needle will be inserted out-of-plane to the ultrasound beam, perpendicular to the skin surface, until the tip lies deep between the fascia of the transversus abdominis muscle and the internal oblique muscle. 30 ml of the study solution in each side will be injected at this location and should be observed to spread in an anterior-posterior direction between two muscles. Each patient will receive a total dose of 60 ml of 0.25% bupivacaine (150 mg) + 1:200,000 epinephrine.
45509760|NCT01568437|Other|Conventional Managment|For these group.no TAP block administration. just conventional management for post operative pain.
45509761|NCT05287399|Drug|ASC61 200 mg 1|200mg of ASC61 orally once daily for cycles of 28 days
45509762|NCT05287399|Drug|ASC61 200 mg 2|200 mg of ASC61 orally twice daily for cycles of 28 days
45509763|NCT05287399|Drug|ASC61 300 mg|300 mg of ASC61 orally twice daily for cycles of 28 days
45698224|NCT03182673|Drug|SHR7390|SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg,0.5 mg and 2mg. Multiple tablets of SHR7390 will be administered orally to achieve targeted doses of SHR7390: 0.125 mg-4 mg. Tablets will be administered once daily or for 21 days and discontinued for 7 days with 240 ml water after 2 hours of the meal.
45698225|NCT03182673|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 immunoglobulin G4 (IgG4) monoclonal antibody. SHR-1210 is provided as the lyophilized powder,200 mg/vial.SHR-1210 was given with 200mg fixed dose intravenously per 2 weeks at the D1 and D15.Intravenous infusion over 30 min
45509764|NCT05287399|Drug|ASC61 400 mg|400 mg of ASC61 orally twice daily for cycles of 28 days
45509765|NCT05287399|Drug|ASC61 600 mg|600 mg of ASC61 orally twice daily for cycles of 28 days
45509766|NCT04791865|Behavioral|Disclosure intervention|Participants who are assigned to the Sankofa intervention will take part in the process of disclosure (pre-disclosure, disclosure, and post-disclosure phases) with the adherence and disclosure specialist (ADDS).
45698226|NCT03182673|Drug|SHR3162|SHR3162 is provided as capsules containing SHR3162 at dosage strengths of 10mg,40mg and 100mg. The capsule of SHR3162 will be orally administered with 240ml water twice a day to achieve targeted doses of SHR3162 and the interval of SHR3162 capsules taken twice a day is about 12 hours.
45850253|NCT00003522|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Cancer of the Small Intestine will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45698227|NCT00638157|Drug|daptomycin|Intravenous (i.v.) 6 mg/kg q24h
45401600|NCT03865108|Procedure|Cervical speculum examination|This standard of care procedure is being done for research purposes and used to collect tissue and measure the strength and stiffness of cervix.
45698228|NCT00638157|Drug|daptomycin and gentamicin|i.v. daptomycin 6 mg/kg q24h plus initial i.v. gentamicin
45698229|NCT02530437|Drug|Carboplatin|Given IV
45698230|NCT02530437|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
45698231|NCT02530437|Other|Laboratory Biomarker Analysis|Correlative studies
45850254|NCT00003528|Drug|raltitrexed|Given IV
45401601|NCT01178164|Genetic|Blood sampling for biological and genetic analysis|"Clinical examination~Blood sampling for biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females."
45401602|NCT03860350|Dietary Supplement|Aged Garlic Extract|
45401603|NCT03860350|Dietary Supplement|Placebo|
45401604|NCT01174654|Behavioral|Contingency management|A 12-week contingency management intervention
45401605|NCT01175278|Procedure|Vertebral Augmentation with Balloon Kyphoplasty|Two small metal tubes will be inserted through the skin into the collapsed bone. Inflatable bone tamps (balloon catheters) will be inserted through each of these two tubes into the bone. The balloons will be inflated with a liquid that can be seen on xrays (contrast) to return the bone toward its natural shape and create a cavity. The balloons will then be deflated and removed. The cavity in the bone will be filled with bone cement to stabilize the broken backbone.
45401606|NCT01175278|Other|Non-surgical Treatment|Non-surgical treatment means the institution of therapies other than cancer chemotherapy and surgical treatment aimed at alleviation of back pain and restoration of decreased function associated with the patient's VCF(s).
45509767|NCT04791865|Behavioral|Usual Care|During the control period, patients and caregivers recruited at the clinics will receive the current practice in the clinic, where the health care provider is expected to assess the caregiver and child readiness for disclosure during clinic appointments and give some information as they think indicated.
45698232|NCT02530437|Drug|Paclitaxel|Given IV
45698233|NCT02530437|Drug|Taladegib|Given PO
45698234|NCT00637377|Drug|Ranibizumab|Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
45698235|NCT00637377|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
45698236|NCT00637377|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
45698237|NCT00637377|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
45698238|NCT01787409|Dietary Supplement|Cholecalciferol|Given PO
45698239|NCT01787409|Other|Laboratory Biomarker Analysis|Correlative studies
45698240|NCT01721343|Behavioral|telephone-based intervention|Undergo telephonic monitoring
45698241|NCT01721343|Other|case management|Participate in an individualized conditioning program with an RCM
45698242|NCT01721343|Procedure|management of therapy complications|Undergo enhanced usual care with an RCM and PCM
45698243|NCT01721343|Procedure|physical therapy|Participate in an individualized conditioning program with an RCM
45698244|NCT01721343|Other|questionnaire administration|Ancillary studies
45698245|NCT01721343|Procedure|quality-of-life assessment|Ancillary studies
45698246|NCT01721343|Procedure|management of therapy complications|Undergo enhanced usual care
45698247|NCT01721343|Procedure|assessment of therapy complications|Undergo enhanced usual care
45698248|NCT01721343|Other|educational intervention|Participate in an individualized conditioning program with an RCM
45698249|NCT01721343|Procedure|management of therapy complications|Undergo enhanced usual care with an RCM
45698250|NCT01721343|Procedure|assessment of therapy complications|Undergo enhanced usual care with an RCM
45698251|NCT01721343|Procedure|assessment of therapy complications|Undergo enhanced usual care with an RCM and PCM
45698252|NCT00636987|Device|Biocor and Biocor Supra valves|Replacement for a diseased, damaged, malformed aortic or mitral heart valve
45698253|NCT01475110|Drug|Imatinib|Observation of Imatinib resistant patients treated with Nilotinib.
45698254|NCT01080118|Device|Airtraq|Subjects were taught with the Airtraq video laryngoscope
45401607|NCT01286350|Behavioral|FL3X: Flexible Lifestyle Empowering Change|The FL3X Adaptive Intervention is designed to increase adherence to T1D self-management including medical management (blood sugar testing and insulin dosing), diet, and physical activity. FL3X relies on MI, and problem-solving skills training (PSST) as the basis for the counseling strategy, and creates a coherent integration across three key components of 1) behavior family systems therapy focused on family communications and teamwork; 2) individualized diabetes education in response to knowledge gaps relevant to behavioral goal attainment; and 3) use of currently available communications technology to support behavioral goal attainment through participant-defined reminders and motivational boosters, and/or peer support.
45401608|NCT01285882|Other|Representations|"A pre-test with 5 medical persons and 5 persons without mucoviscidosis will be realized to adjust the tools and place of the interview.~To collect analyzable data for 30 patients, 40 patients will be included in the study. A conceptual card will be associated to a semi-structured interviews to gather information.Two subgroups will be considered in th a analysis :~1st sub-group : After the announcement of the transplant indication by the doctor and before the consultation in the transplant centre.~2nd subgroup : After the consultation in the transplant centre but before the inscription on the waiting list. The analysis of conceptual cards in these two subgroups will permit to study the differences between the representations of patients before and after the consultation in the transplant centre.~Realize a 2nd interview on the same principle with all patients, 1 year after their lung transplantation."
45698255|NCT01080118|Other|Control group, taught with a standard Macintosh laryngoscope|Subjects were taught how to use the Mackintosh blade first
45698256|NCT03013582|Biological|Amnion Tendon Wrapping|Tendon is wrapped with the allograft
45401609|NCT03863626|Other|Frusemide IV shots|"giving frusemide by IV shots~And if developed diuretic resistance (diminishing diuretic effect despite incremental dose of IV loop diuretic), adjuvant oral Metolazone will be given for sequential nephron blockade comparing its administration timed 60 minutes prior to the morning Frusemide shot versus given after. (This will be in a second level of randomization)"
45698257|NCT03013582|Procedure|Surgical Tenolysis|Surgical release of peritendinous scarred tissue
45698258|NCT05307796|Behavioral|Strategy training|The strategy training of focus in this study is metacognitive strategy training intended to build awareness of naming and methods to overcome instances of difficult naming. Strategy training involves (a) teaching the participant to identify instances in which they are unable to name objects, (b) learn a 6-feature framework (e.g. group, use, action) that has been identified to support semantic feature activation in aphasia, (c) learn and practice strategies to utilize the framework in instances of word finding difficulty
45698259|NCT05307718|Drug|Oral Anticoagulant, Direct-Acting|Newly indicated indication for use: DOAC; platelet aggregation inhibitors from the P2Y12 receptor antagonist group; and HMG-CoA reductase inhibitors (statins); as monotherapy or without restriction with respect to any other concomitant pharmacotherapy. Subjects will be followed up during regular visits.
45698260|NCT05307562|Other|Interval training + analytical strength|Patients will receive a training program
45698261|NCT05307562|Other|Interval training + analytical strength and IMT|Patients will receive a training program + IMT
45698262|NCT05307484|Other|Serious game|This is a serious game in the form of a mobile application, designed to educate adults on dengue prevention.
45698263|NCT05307484|Other|Dengue prevention website|This is a website containing information regarding dengue prevention.
45698264|NCT01376596|Behavioral|Cognitive-Behavioral Therapy based intervention immediately|This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring: Identify negative thoughts that occur before, during, or after anxiety-provoking situations; Evaluate the accuracy of their thoughts in the light of data derived from Socratic questioning or as a result of so-called behavioral experiments; and derive rational alternative thoughts based on the acquired information; iii) Exposure component, which focuses on the collection of information that will allow patients to revise their judgments about the degree of risk to which they are exposed in feared situations, challenge their dysfunctional beliefs about the self relative to the illness and their self-efficacy (social status related), and iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia.
45698265|NCT01376596|Behavioral|Wait list|The group receiving treatment as usual (TAU) will be put on a wait list to receive the CBT intervention at the end of the experimental group, the one receiving the intervention immediately
45698266|NCT01033864|Drug|MMF|1 g per day b.i.d. p.o. for at least 1 month
45698267|NCT01033864|Drug|EC-MPS|720 mg b.i.d. p.o. for at least 1 month
45698268|NCT01033864|Drug|Prednisone|5 mg per day p.o.
45698269|NCT03012568|Device|SJM Implantable cardiac devices|SJM implantable devices undergoing MRI scan
45401610|NCT03863626|Other|Frusemide IV infusion|"giving frusemide by continuous IV infusion~And if developed diuretic resistance (diminishing diuretic effect despite incremental dose of IV loop diuretic), adjuvant oral Metolazone will be given for sequential nephron blockade"
45401611|NCT01178242|Procedure|Salivary Gland and Labial Mucous Membrane Transplantation|"Minor salivary glands (SG) will be obtain en block from the same donor site, at the inferior or superior labial mucous membrane, above the orbicularis oris muscle to correct lubrication. The thin split thickness graft of mucous membrane will be suture to the sclera with absorbable sutures"
45401612|NCT01288378|Drug|caspofungin acetate|intravenous route, at a 70 mg loading dose on day 1 of antifungal therapy, followed by 50 mg once a day thereafter.
45401613|NCT03860116|Behavioral|APP-based case management service|The intervention consists of 4 parts, educational articles, online communication with case managers, supportive service information and visit reminder. Educational articles are both delivered automatically and retrieved by participants. Online communication can also be initiated by participants and case managers. Case managers are request to respond to questions from participants as well as care about medication taking behaviors of each patients during the first month. Supportive service information, which include time, location and charges of service providers will be retrieved by participants, with reminders of available service information scheduled at the beginning of every month. Visit reminders are scheduled at one week before due date.
45401614|NCT03860116|Behavioral|Standard-of-care followup service|When participants initiate HIV antiretroviral treatment (ART), they receive 20-minute ART-related education from the case managers, and have physical examination including blood test, CD4 count, hepatic and renal function tests. Subsequent visits are scheduled at month 1, 2, 3, 6 and 12. During each visit, pills enough to cover days until the next visit will be distributed. And patients will be asked about their medication adherence, high risk behavior and side effects experienced. Any relevant questions from patients will be answered. Physical tests are also included in the routine of each visits.
45401615|NCT03864874|Diagnostic Test|Intraoperative intracavitary lung ultrasonography|Ultrasonography on the deflated lung for detection of lung nodules
45401616|NCT03860194|Dietary Supplement|Protison with High Protein 51(Original Flavor)|Contents of each supplement sachet has a calorie of 88 kcal, 12.8 g protein( including 8.5 g whey protein concentrate), 1.2 g leucine, 7.3 g carbohydrates, 0.8 g fat and 120 IU vitamin D per serving. This supplement was added 200 ml water and stirred well, then drank before meal.
45401617|NCT01178320|Drug|Simvastatin, simvastatin plus extended-release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
45401618|NCT03864718|Procedure|photodynamic therapy|Intralesional 5-aminolevulinic acid gel 2% was directly injected into the fistula. The internal and external orifices were closed. After an incubation period of 2 h, the fistula was irradiated using an optical fibre connected to a red laser (MULTIDIODE 630 PDT, INTERmedic, Spain) operating at 1 W/ cm for 3 min (180 Joules).
45401619|NCT01175512|Drug|Naltrexone|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
45401620|NCT01175512|Drug|Placebo|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
45401621|NCT01178476|Device|Hyposafe Hypoglycaemia alarm device|An EEG based hypoglycemia alarm is tested against standard glucose measurement on the risk of severe hypoglycemia
45401622|NCT03864484|Device|iPad Application + Usual Rehabilitation|The experimental group receives usual rehabilitation. In addition, the experimental group will watch movies using the iPad application for 3 minutes, once daily for 5 weeks.
45698270|NCT05307016|Diagnostic Test|Two dimensional ultrasonography power and color doppler|"transabdominal and transvaginal two-dimensional power Doppler ultrasound volumes of the placental bed were obtained according to a predefined protocol with the participant in a semi-recumbent position and a full bladder using a RAB4-8-D 3D/4D curved array abdominal transducer (4-8.5 MHz) on a Voluson E8. Predetermined machine settings were used. To allow for differences in attenuation of the power Doppler signal resulting from variation in placental site and maternal adiposity.~Intraoperative staging of degree of placental invasion will be done according to clinical grading system by Collins et al., 2015.~Specimens obtained from patients who underwent hysterectomy or resection of segment of anterior uterine wall in cases with anterior placenta previa will be immersed in formalin 10% concentration and will be sent for histopathological evaluation that will be done by the same pathologist."
45401623|NCT03864484|Behavioral|Usual rehabilitation|The control group receives usual rehabilitation.
45850255|NCT00003534|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Refractory Stage IV Prostate Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
45401624|NCT03859570|Drug|Pentoxifylline|Pentoxifylline (PTX) is a methylxanthine derivative that is a nonselective inhibitor of cyclic nucleotide phosphodiesterase (PDE). This enzyme, which has at least 5 subtypes, is responsible for inactivation of the important second messengers, Cyclic adenosine monophosphate (AMP) and cyclic guanosine monophosphate (GMP)
45401625|NCT03859570|Drug|Placebos|Placebo
45401626|NCT01178554|Behavioral|psychotherapy|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
45401627|NCT01178554|Behavioral|evidence-based treatment|Evidence-based treatment manuals were used for anxiety (Coping Cat Manual; Kendall, 1994; Kendall et al., 1994 ), depression (Primary and Secondary Control Enhancement Training; Weisz et al., 1997, 1998), and conduct problems (Defiant Children Manual; Barkley, 1997).
45401628|NCT01178554|Behavioral|modular evidence-based treatment|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, or Conduct Problems (MATCH-ADC; Chorpita & Weisz, 2004)
45850256|NCT00003540|Drug|gemcitabine hydrochloride|
45850257|NCT00003546|Drug|gemcitabine hydrochloride|given IV
45850258|NCT00003546|Radiation|radiation therapy|1.8 Gy to tumor bed
45401629|NCT03859882|Other|Sleep deprivation|40 hours of continuous awaking in the sleep laboratory in order to compare before and after sleep deprivation for each treatment (Caffeine vs. placebo).
45509768|NCT05257525|Other|Esophageal manometry catheter at various PEEP levels and tidal volumes|Participants will undergo placement of an esophageal manometry catheter before planned sternal closure. This catheter will be used to measure esophageal pressure which is a surrogate for pleural (intrathoracic) pressure. Esophageal pressure will then be used to estimate changes in respiratory system mechanics and hemodynamics following sternal closure and across different levels of positive end-expiratory pressure (PEEP) and tidal volumes.
45401630|NCT03859726|Diagnostic Test|NIRS|Near-infrared spectroscopy (NIRS) offers non-invasive, in-vivo, real-time monitoring of tissue oxygenation. Changes in regional tissue oxygenation as detected by NIRS may reflect the delicate balance between oxygen delivery and consumption.
45401631|NCT03859726|Diagnostic Test|Sublingual microcirculation|The sidestream dark field (SDF) imaging devices provide high contrast images of the microvasculature.
45401632|NCT03745768|Device|Intermittent Theta Burst Stimulation|Intermittent theta burst stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain for 6 weeks.
45401633|NCT03745768|Device|sham stimulation|Sham stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain for 6 weeks.
45401634|NCT03745222|Drug|Tislelizumab|PD-1 inhibitor (monoclonal antibody against PD-1)
45509769|NCT04188847|Drug|Chemotherapy plus apatinib|"A combination of cisplatin, paclitaxel and apatinib would be given for all patients:~Cisplatin: 50 mg/m2 body surface area, on the first day, every 3 weeks. If the creatinine clearance rate was less than 40 ml/min, the cisplatin would be replace by carboplatin (area under ther curve = 5)~Paclitaxel: 50 mg/m2 body surface area, on the first day, every 3 weeks~Apatinib: 250 mg every day The total courses of cisplatin and paclitaxel would be no more than 6."
45401635|NCT03745222|Drug|Concurrent chemoradiotherapy (cCRT)|Chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide per standard of care. Radiotherapy will also be given concurrently with chemotherapy.
45401636|NCT03745222|Other|Placebo|Placebo
45401637|NCT01286584|Drug|varenicline|one 0.5mg varenicline capsule on first 3 days one 0.5mg varenicline capsule, twice daily for 4 days one 1.0mg varenicline capsule, twice daily until end of treatment (12weeks of medication
45401638|NCT01286584|Drug|placebo|lactose filler in capsules identical to the varenicline capsules one 0.5mg capsule for 3 days one 0.5mg capsule twice daily for 4 days one 1.0mg capsule twice daily until end of treatment (12weeks of medication)
45401639|NCT03863314|Device|Virtual Simulation|Virtual simulation of workplace-related scenarios of pre-recorded videos using the same actors
45401640|NCT03863314|Other|In-person Simulation|In-person simulation of workplace-related scenarios with live actors
45401641|NCT03743038|Drug|FMX101 vehicle|FMX101 vehicle - hydrophobic oil based vehicle (Test Article A)
45401642|NCT03743038|Other|Hydro-alcohol solution|Hydro-alcohol solution based vehicle (Test Article B)
45401643|NCT03864250|Drug|Tacrolimus|The initial dose of TAC is 0.05-0.1 mg/kg/d, taking 2 hours before and after meals. The interval is strictly 12 hours. The blood concentration is measured after taking the drug. According to the concentration of blood drug valley, the dose of tacrolimus (blood concentration of ≤10ng/ml) is adjusted. If the blood drug concentration is low, the drug dose (≤0.1mg/kg/d) is increased accordingly. After 6 months of treatment, the drug is discontinued. The TAC dose is maintained at the original dose after 6 months of treatment with complete or partial remission of urinary protein until the end of the 48-week trial.
45401644|NCT03864250|Drug|Prednisone|The initial dose of prednisone is 0.5 mg/kg/d orally (maximum dose 40 mg/d), and after 8-12 weeks, the dose was gradually reduced until discontinuation. TAC treatment is given at the same time (the treatment plan is the same as the experimental group).
45401645|NCT01175746|Drug|Nicardipine|
45698271|NCT01082380|Drug|PF-02341066|oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of [14C]PF 02341066
45698272|NCT01083628|Behavioral|Group CBT for Depression with MoodText|Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.
45401646|NCT01175746|Drug|remifentanil|0.1-0.5 ugkg/min during hypotensive anesthesia
45698273|NCT01083628|Behavioral|Group CBT for Depression|Standard group CBT for depression using BRIGHT manual
45698274|NCT01083706|Drug|azacitidine|Given SC or IV
45698275|NCT01083706|Other|laboratory biomarker analysis|Correlative studies
45698276|NCT03014128|Other|Clinical examination and data processing of questionnaires|xy
45698277|NCT01035346|Drug|Ibuprofen|Single dose of a novel ibuprofen formulation (equal to 400mg ibuprofen)
45698278|NCT01035346|Drug|Placebo|Single dose of a placebo
45698279|NCT03012802|Procedure|Colorectal Surgery|Postoperative Audit
45698280|NCT05306392|Device|Moderate Hypothermia|moderate hypothermia will be induced using the heat controller of the VV-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 48 hours followed by a progressive reheating (0.2±0.1°C/h) to reach 36 °C. Temperature at 36°C will be maintained during 48 hours after having reached 36 °C.
45401647|NCT01174810|Drug|Exenatide|Exenatide, 5 micrograms twice a day for 1 month and 10 micrograms twice a day for 11 months. Total duration of treatment 12 months
45401648|NCT01288690|Behavioral|Narrative Exposure Therapy|3, 1-1/2 hour sessions, individual, meeting weekly.
45401649|NCT01178632|Drug|Passiflora|01 tablet Passiflora p.o., b.i.d.
45401650|NCT01178632|Drug|Valeriana officinalis|Active Comparator group will receive 01 tablet of Valeriana officinalis, p.o., b.i.d.
45401651|NCT03859492|Device|Contrast Enhanced Digital Mammography|High-resolution, low-energy, full-field digital mammography (FFDM) image and contrast-enhanced image
45401652|NCT01178710|Drug|Simvastatin|20 mg per day, start at 5 days before surgery and continue for one year. For some congenital heart diseases which other drugs such as digoxin, antistone, furosemide were prescribed less than half year, simvastatin will be prescribed less than half year.
45401653|NCT03864328|Drug|RVT-1601|Inhaled RVT-1601 administered TID via eFlow nebulizer
45698281|NCT05306392|Device|Normothermia|Temperature at 36°C will be maintained during 48 hours after having reached 36 °C
45698282|NCT05306314|Dietary Supplement|TREATAPROST|oral administration before meals 30 minutes
45401654|NCT03864328|Drug|Placebo|Inhaled Placebo administered TID via eFlow nebulizer
45401655|NCT01174888|Drug|midostaurin|Drug midostaurin, Given orally given twice daily days 1-14
45401656|NCT01174888|Drug|Bortezomib|Bortezomib given IV on days 1, 4, 8, and 11
45401657|NCT01174888|Drug|mitoxantrone hydrochloride|Patients receive mitoxantrone hydrochloride IV over 10 minutes
45401658|NCT01174888|Drug|etoposide|Patients receive etoposide IV over 1 hour
45596749|NCT05546749|Device|RelieVRx|The virtual reality device that will be piloted is called RelieVRx, which incorporates evidence-based principles of cognitive behavioral therapy, mindfulness, and pain neuroscience education into an immersive and enhanced biofeedback experience. RelieVRx includes breathing training and relaxation response exercises that activate the parasympathetic nervous system. RelieVRx was designed for at-home use and comes with a sequence of daily immersive experiences.
45401659|NCT01174888|Drug|cytarabine|Patients receive cytarabine IV over 6 hours on days 1-6
45401660|NCT01178788|Drug|17 alpha-hydroxy progesterone caproate|weekly injection of 17 P
45401661|NCT01178788|Drug|micronized Progesterone|daily administration of vaginal progesterone
45401662|NCT01178788|Procedure|Control|
45596750|NCT05546749|Device|Sham VR|The sham VR control is a non-immersive set of 56 daily virtual experiences, tuned to the length of the RelieVRx.
45596751|NCT04546633|Drug|KAF156|Provided as 50 mg or 100 mg tablets, to be taken QD 2 Days in combination with LUM-SDF, dose is based on body weight
45698283|NCT01085344|Biological|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose prophylaxis
45698284|NCT01085344|Biological|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose
45850259|NCT00003552|Drug|allogeneic lymphocytes|
45401663|NCT00153816|Drug|Calcium Carbonate|3 gm/daily; 1200 mg elemental calcium/daily; two tablets per day; 600 mg elemental calcium/tablet
45401664|NCT00153816|Drug|Vitamin D3|1000 IU/daily; two tablets per day; 500 IU per tablet
45401665|NCT00153816|Drug|placebo|placebo; two tablets per day
45401666|NCT02525146|Other|Modified ARTAS (Antiretroviral Treatment and Access to Services) intervention|
45401667|NCT02525224|Dietary Supplement|Nutritional Supplement|2 Hard-shell liquid capsules taken twice daily with breakfast and dinner.
45401668|NCT03966222|Device|Endoscopic vein harvest|An endoscope is introduced adjacent to the vein, allowing its dissection under direct vision via a small incision.
45401669|NCT03966222|Other|Open vein harvest|Open vein harvest
45401670|NCT03862846|Drug|REN001|Once daily
45596752|NCT04546633|Drug|LUM-SDF|Provided as 60 mg, 120 mg or 240 mg powder in sachet, to be taken QD 2 Days in combination with KAF156, dose is based on body weight
45596753|NCT03525535|Other|data collection|data from patient included will be collected during the study
45596754|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg oral suspension (dry powder) in fasted conditions.
45596755|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 20 mg oral suspension (dry powder) in fed conditions.
45596756|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg oral suspension in fasted conditions.
45698285|NCT01085500|Behavioral|Mastery Learning TEP Curriculum|A simulation-based educational curriculum
45401671|NCT01077648|Drug|Trastuzumab or Lapatinib|Anti-erbB2 therapy for breast cancer treatment will be analyzed as a class level variable; individual drugs including trastuzumab and lapatinib will also be explored as exposures if sufficient numbers of patients exist.
45401672|NCT03863002|Biological|Mesenchymal Stem Cell|Mesenchymal stem cell transplantation via peripheral vein: 1.0-10x10^5 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2, 3 weeks
45401673|NCT00151476|Drug|Celecoxib|800 mg total daily dosing
45401674|NCT00151476|Other|Routine Medical Care|
45509770|NCT05255107|Combination Product|Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution|Standard Of Care: Moxifloxacin 0.5% eyedrop therapy every 1 hour (q1h) while awake; to be tapered at treating physician's discretion. Following SOC, for subjects randomized to the experimental arm, riboflavin will be administered (1 drop every 2 min for 40 min with PESCHKE-L solution [0.23%], or longer as needed to assure adequate corneal penetration). Then the eye will be aligned under the PXL Platinum 330 light (the treatment plane will be at the correct working distance from the PXL Platinum 330 beam aperture when the border of the projected beam is in sharp focus). The correct aperture setting (3 to 12 mm) will be selected for the size of the eye and area needing to be treated (2 mm larger than the maximal ulcer diameter), and the eye will be irradiated at 18 mW/cm2, with pulsed mode (5 seconds on, 5 seconds off) for 10 min, during which time instillation of riboflavin will continue (1 drop every 2 min).
45509771|NCT05255107|Other|Standard of Care Therapy + Sham CXL + Artificial Tears|Standard Of Care: Moxifloxacin 0.5% eyedrop therapy every 1 hour (q1h) while awake; to be tapered at treating physician's discretion. Following SOC, for subjects randomized to the Sham comparator group, artificial tears (1 drop every 2 min for 40 min) will be administered. After instillation of artificial tears, the eye will be aligned under the PXL Platinum 330 light. The instrument will be kept off and the subject will be kept under the device for 10 min, during which time instillation of artificial tears will be performed (1 drop every 2 min) to maintain corneal hydration. The operator will keep track of sham exposure time independently to confirm the actual duration.
45509772|NCT04788589|Other|Sedation and ventilator weaning protocol|Subjects randomized to this group will underwent sedation and ventilator weaning protocol as mentioned before.
45401675|NCT03859804|Procedure|Standard transrectal 12 core biopsy|TRUS-guided SPB was performed by obtaining 12 core samples in each patient. 6 cores from left and right. the cores labeled as, apex, mid, base, apex far lateral, mid far lateral and base far lateral
45401676|NCT03859804|Procedure|MRI- US fusion prostate biopsy (FPB)|FPB was performed by obtaining 10-12 core samples in each patient, followed by the acquisition of 2-4 core samples for each suspected lesion detected on MpMRI (combined biopsy)
45596757|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg tablet in fasted conditions.
45596758|NCT03527095|Drug|FDL169|CFTR corrector
45596759|NCT02374359|Other|follow-up|
45596760|NCT04512781|Device|Control Cannula|The purpose of this intervention is to evaluate the efficacy of a conventional legacy cannula design to provide targeted relief of dyspnea.
45698286|NCT01085500|Procedure|Current Practice|The current practice of learning how to perform the TEP repair in the operating room is under direct supervision of the staff surgeon without any simulation pre-training.
45596761|NCT04512781|Device|Test Cannula #1|The purpose of this intervention is to evaluate the efficacy of a next generation cannula to provide relief of dyspnea.
45596762|NCT04512781|Device|Test Cannula #2|The purpose of this intervention is to evaluate the efficacy of a conventional legacy cannula design in providing targeted relief of dyspnea in hypercapnic adults.
45401677|NCT01077726|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle
45401678|NCT01286116|Device|Parachute Implant|Mechanical ventricular partitioning
45401679|NCT01179100|Drug|Lidocaine|Lidocaine (10mg/ml) Loading: 1.5 mg/kg + Infusion: 0.035 mg/kg/min
45698287|NCT01035658|Drug|Pazopanib|All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.
45401680|NCT03864172|Dietary Supplement|Usual intake + placebo fruit juice|Participants will consume 200 mls of placebo fruit flavoured juice
45401681|NCT03864172|Dietary Supplement|Usual intake+SCF fruit juice|Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF)
45596763|NCT05187793|Drug|Olokizumab|Olokizumab, 128 mg, solution for subcutaneous administration 160 mg/mL
45596764|NCT05187793|Drug|Standard therapy|"Standard treatment including:~Baricitinib, 4 mg, film coated tablets~Favipiravir, 200 mg, film coated tablets~Dexamethasone IV or IM OR Methylprednisolone IV"
45596765|NCT05100979|Other|The Art of Medicine Series|The Art of Medicine Series is a smartphone-based educational tool focused on teaching communication strategies to clinicians and patients.
45698288|NCT01035658|Drug|Doxil|Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle
45401682|NCT03864172|Dietary Supplement|Adequate calcium + placebo fruit juice|Participants will consume 200 mls of placebo fruit flavoured juice added with 600 mg calcium to meet RNI
45401683|NCT03864172|Dietary Supplement|Adequate calcium+ SCF fruit juice|Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF) added with 600 mg calcium to meet RNI
45698289|NCT05306236|Other|LLL therapy , postural correction ex|"study group: will receive low level laser therapy 2 sessions per week for 6 weeks in addition to posture correction exercises.~control group: will be treated by posture correction ex only."
45401684|NCT02525302|Drug|HT-100|HT-100 is Akashi Therapeutics' proprietary delayed-release formulation of halofuginone hydrobromide, a small molecule therapeutic with anti-fibrotic properties. May be administered in either fed or fasted state. Not mutation specific.
45509773|NCT04298047|Other|participatory art-based activity|The intervention is a 3-month cycle of weekly guided tours carried out at the MMFA. Each visit will be performed with a group of 8 participants and a trained guide. They will meet at the museum once per week for a 45 min museum guided tour during a 3-month period. Each visit will be different and supervised by a museum guide. Regardless the topic of the visits, each visit will be standardized and separated in two consecutive phases: (1) Presentation of the objectives of the activity and (2) tour with a guide. Guided tours will target visual art (i.e., painting). They will be tailor-made and based on emotions and interactions in front of painting. The levels of information given to participants will regularly (i.e., each month) increase during the 3-month cycle of museum guided tours. The participants will be separated in 8 groups of 8 individuals per week. The same guide will manage each group of 8 participants during the 12 planned visits.
45509774|NCT04774081|Device|24h Continuous glucose monitoring and urinary C-peptide collection|Participants will be admitted to the research clinic for a 24-hour stay in a metabolic chamber. During the chamber stay, all urine excreted will be collected to assess C-peptide urinary excretion rate and interstitial glucose will be measured by a continuous glucose monitor (CGM). Participants will consume a eucaloric diet (50% carbohydrates, 30% fat and 20% protein).
45509775|NCT05224843|Behavioral|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
45509776|NCT04692493|Drug|targeted synthetic DMARD class|Switching to a targeted synthetic DMARD (choice from targeted synthetic DMARDs; currently available are tofacitinib, baricitinib, upadacitinib) in people with active RA despite current treatment
45698290|NCT01037452|Drug|Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg|Tablet
45509777|NCT04692493|Drug|non-TNFi-biologic class|Switching to a non-TNFi-biologic (choice from non-TNFi-biologics; currently available are rituximab, abatacept, tocilizumab, or sarilumab) in people with active RA despite current treatment,
45509778|NCT05200741|Biological|DelNS1-2019-nCoV-RBD-OPT1|Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray
45698291|NCT01037452|Drug|Lansoprazole|Tablet
45698292|NCT01037452|Drug|Calcium carbonate/magnesium hydroxide|Tablet
45401685|NCT01286194|Drug|Rabeprazole sodium|Rabeprazole sodium 10 mg orally every day for 14 days
45698293|NCT01037452|Drug|Placebo|Tablet
45698294|NCT03012646|Drug|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
45698295|NCT05289856|Drug|combination of Avelumab and Cabozantinib|Cabozantinib 40 mg daily PO in combination with Avelumab at a dose of 800 mg as a 1h intravenous (i.v.) infusion every two weeks (q2w) until disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawalis met, for a maximum of 12 months
45850260|NCT00003552|Drug|anti-thymocyte globulin|
45401686|NCT01179256|Dietary Supplement|CURCUMIN|oral supplementation of curcumin 2000mg
45401687|NCT01179256|Other|no intervention other than stopping study|no intervention other than stopping study
45401688|NCT03858088|Procedure|Liver transplantation|Liver transplantation from deceased donors
45850261|NCT00003552|Drug|cyclophosphamide|
45850262|NCT00003552|Drug|fludarabine|
45401689|NCT03859180|Behavioral|Focused breathing|Focused breathing is a series of focused, controlled breaths that aid in relaxation. Each participation in this group will be taught how to do focused breathing by the study investigator. Once determined to be able to perform focused breathing, participants will be asked to practice it for 4 minutes, twice a day, for 6 weeks. If they choose to do so, they may practice focused breathing if they become anxious at other times. They will be asked to keep a diary of each time they practice and/or use focused breathing.
45401690|NCT01179412|Drug|2% povidone-iodine|apply 4 times a day for one week
45401691|NCT01179412|Drug|2% povidone-iodine|apply 2% povidone-iodine 4 times per day for one week
45401692|NCT03862690|Drug|BIAsp 30|Participants will receive commercially available BIAsp 30 once daily (QD), twice daily (BID) or thrice daily (TID) for 24 weeks according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose. The decision to switch the patient to NovoMix® 30 is at the treating physician's discretion and independent from the decision to include the patient in the study.
45401693|NCT03863548|Other|complication|collection of post-operative bleeding complications
45401694|NCT03862768|Procedure|surgery|Surgery requires at least removal of all drug-resistant lesions.
45401695|NCT03862768|Drug|Imatinib 400 MG|Imatinib 400 MG/d should be taken once the patients resume oral diet
45509779|NCT05200741|Biological|Matching placebo|Solution for Intranasal Spray
45509780|NCT03227471|Drug|IVA|IVA tablet for oral administration
45509781|NCT03227471|Drug|TEZ/IVA|TEZ/IVA fixed-dose combination for oral administration.
45509782|NCT03227471|Drug|VX-445|VX-445 tablet for oral administration.
45509783|NCT03227471|Drug|Matched Placebo|Matched placebo.
45509784|NCT03227471|Drug|TEZ|Tablet for oral administration.
45509785|NCT03227471|Drug|VX-561|Tablet for oral administration.
45509786|NCT03227471|Drug|VX-445|VX-445 IV injection
45850263|NCT00003558|Drug|carboplatin|
45850264|NCT00003558|Drug|etoposide|
45850265|NCT00003558|Drug|fluorouracil|
45850266|NCT00003558|Drug|leucovorin calcium|
45850267|NCT00003558|Drug|paclitaxel|
45850268|NCT00003564|Drug|Isotretinoin|Oral isotretinoin is administered every 12 hours on days 15-28 every 28 days.
45850269|NCT00003564|Drug|Procarbazine Hydrochloride|"Arm I: Oral procarbazine once daily on days 1-14 every 28 days for 6 courses of combined therapy.~Arm II: Oral procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses."
45850270|NCT00003576|Drug|cisplatin|
45850271|NCT00003576|Drug|fluorouracil|
45850272|NCT00003576|Procedure|surgical procedure|
45509787|NCT01354314|Drug|Fluconazole|One 100 MG capsule taken twice daily, 12 hour dosing
45401696|NCT03862768|Drug|Imatinib escalation|Imatinib 600 MG/d
45401697|NCT03862768|Drug|Sunitinib|Sunitinib 37.5 MG/d
45401698|NCT03862456|Other|Azithromycin|azithromycin (500 mg/24h/3 days)
45401699|NCT03862456|Other|Metronidazole|metronidazole (500 mg/8h/7 days)
45509788|NCT01354314|Drug|Paroxetine|Two 10 MG capsules paroxetine once daily in the evening
45509789|NCT01354314|Drug|Paroxetine and Fluconazole|One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening
45509790|NCT01354314|Drug|Placebo|One capsule in the morning, three capsules in the evening
45401700|NCT03859102|Dietary Supplement|Pre-operative Carbohydrate PreLoad drink|Pre-operative Carbohydrate PreLoad drink, 1 sachet given the night before surgery. One sachet given 2-4hours before surgery.
45509791|NCT04567836|Other|Investigation of the prevalence of test positivity|"The study consists of an investigation by means of a prospective observational study with the aim of assess the prevalence of test positivity (swab or serological examination) ti covid-19 in relation to the duties and related occupational risk.~It is used CLIA method test designed to recognize IgG antibodies directed against the S1 and S2 domains of the SARS-CoV-2 virus spike protein, selected for their ability to provide specificity for SARS-CoV-2 compared to other Coronaviruses ."
45698296|NCT01085968|Behavioral|PC based training|Subjects sit at a computer and type a string of numbers that appears on the screen. As performance improves (# correct), the strings of numbers get longer. They are then instructed to repeat the string from memory. Performing these key entries from memory is a test of internally generated movement initiation.
45698297|NCT01087918|Device|RAGT|16 sessions / 4 times/week / 45 minutes Lokomat training
45509792|NCT04561908|Device|Transseptal puncture with Brockenbrough-needle|Conventional transseptal puncture with Brockenbrough-needle
45509793|NCT04561908|Device|Microguidewire-assisted transseptal puncture|Microguidewire-assisted transseptal puncture (0.014-inch microguidewire)
45401701|NCT03859102|Drug|Oral Gabapentin pre-op|One dose of Gabapentin pre-operatively, 300mg orally.
45401702|NCT03859102|Drug|Oral Lansoprazole pre-op|One dose of Lansoprazole pre-operatively, 30mg orally.
45401703|NCT03859102|Drug|Intravenous Paracetamol intra-operatively|One dose of Paracetamol intra-operatively, 1gram intravenous infusion.
45401704|NCT03859102|Drug|Intravenous Dexamethasone intra-operatively|One dose of Dexamethasone intra-operatively as an anti-emetic, 8mg intravenous.
45401705|NCT03859102|Drug|Intravenous Ondansetron intra-operatively|One dose of Ondansetron intra-operatively as an anti-emetic, 4mg intravenous
45401706|NCT03859102|Drug|Infiltration of surgical wounds with local anaesthetic|Infiltration of surgical wounds with local anaesthetic at the end of surgery, Bupivacaine 1-2mg/kg.
45401707|NCT03859102|Drug|Intravenous Magnesium intra-operatively|One infusion of intravenous Magnesium Sulphate intra-operatively as an analgesic, 50mg/kg given over 30minutes.
45401708|NCT03859102|Drug|Post-operative Gabapentin analgesia|Post-operative oral Gabapentin 300mg, three times daily as an analgesic.
45401709|NCT03859102|Drug|Post-operative oral Paracetamol analgesia|Post-operative Paracetamol as an analgesic. Initially intravenously, then orally. One gram four times daily.
45401710|NCT03859102|Drug|Post-operative Ondansetron anti-emesis|Intravenous Ondansetron administered post-operatively as prophylactic anti-emesis. 4mg three times daily, for 24 hours. Then as required.
45401711|NCT03859102|Procedure|Early extubation|Removal of the endotracheal tube in the Intensive Care Unit as soon as is safe.
45509794|NCT04509336|Drug|Orphenadrine|100 mg twice daily
45509795|NCT04509336|Drug|Baclofen|initial dose of 10 mg tablet once daily, dose will be gradually increased according to the patients responses
45509796|NCT03194321|Drug|Tacrolimus Extended-Release Oral Capsule|Maintenance immunosuppression will consist of tacrolimus extended-release, mycophenolate mofetil 500mg twice daily or mycophenolate sodium 360mg twice daily, and prednisone.
45509797|NCT05231460|Drug|Active Comparator: narcotic regimen with TAP block|"Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Narcotic Pain Regimen post-operatively:~PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~IV Dilaudid 1mg q3h for breakthrough pain"
45509798|NCT05231460|Drug|Active Comparator: narcotic regimen with no TAP block|"Patient will not receive TAP block and will be administered the following Narcotic Pain Regimen post-operatively:~PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~IV Dilaudid 1mg q3h for breakthrough pain"
45509799|NCT05231460|Drug|non-narcotic regimen with TAP block|"Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Non-narcotic Pain Regimen post-operatively:~Toradol 15mg q6h~Tylenol 1000mg q8h~Gabapentin 100mg three times a day"
45509800|NCT05231460|Drug|non-narcotic regimen with no TAP block|"Patient will not receive TAP block and will be administered the following Non-narcotic Pain Regimen post-operatively:~Toradol 15mg q6h~Tylenol 1000mg q8h~Gabapentin 100mg three times a day"
45698298|NCT01087918|Other|Strength Training|16 sessions / 4 times/week / 45 minutes lower extremity strength training
45698299|NCT00636441|Drug|Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)|Doxorubicin 60 mg/m² and Cyclophosphamide 600 mg/m² (AC) or Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² (TC) every 3 weeks for 4 cycles as neoadjuvant therapy
45698300|NCT01087996|Biological|Auto-hMSCs|Biological: Autologous human mesenchymal stem cells (Auto-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10^8 (20 million) Auto-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10^8 (100 million) Auto-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10^8 (200 million) Auto-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
45698301|NCT01087996|Biological|Allo-hMSCs|Biological: Allogeneic human mesenchymal stem cells (Allo-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10^8 (20 million) Allo-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10^8 (100 million) Allo-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10^8 (200 million) Allo-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
45698302|NCT00636363|Device|Bausch & Lomb Multipurpose Solution - Rub Care|Daily care for contact lenses - rub care regimen
45698303|NCT00636363|Device|Bausch & Lomb Multipurpose Solution - No Rub Care|Daily care for contact lenses - no rub care regimen
45698304|NCT00636363|Device|Ciba Vision Aquify Multipurpose Solution|daily care for contact lenses
45698305|NCT02984397|Drug|Ketotifen Fumarate|Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.
45698306|NCT02984397|Drug|Placebo|
45401712|NCT03859102|Procedure|Early mobilisation/physiotherapy|Mobilisation (active and passive limb movements, deep breathing) with the assistance of nurse/physiotherapist to occur as soon as possible post-operatively.
45401713|NCT03859102|Other|Encourage early oral food intake|Patients will be encouraged to start eating as soon as possible post-operatively
45698307|NCT02984397|Other|Standard of Care|
45698308|NCT01922427|Drug|RNS60|
45698309|NCT01600131|Behavioral|Caregiver problem-solving|This is a problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.ciddr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
45698310|NCT01600131|Other|Standard Care|No intervention or treatment will be provided. The investigators will closely monitor the usual care that is provided to caregivers.
45698311|NCT01088464|Biological|IMC-11F8|600 milligrams (mg) intravenously, Days 1 and 8 every 3 weeks
45698312|NCT01088464|Biological|IMC-11F8|800 mg intravenously, every 2 weeks
45698313|NCT01088464|Biological|IMC-11F8|800 mg intravenously, Days 1 and 8 every 3 weeks
45850273|NCT00003576|Radiation|radiation therapy|
45401714|NCT02525068|Drug|AZD5363|Until confirmed disease progression.
45401715|NCT02525068|Drug|Enzalutamide|Until confirmed disease progression.
45401716|NCT02524678|Drug|Placebo|
45401717|NCT02524678|Drug|URC102|
45401718|NCT01181206|Procedure|Intervention Arm 1: Covering with approved abdominal 3M™ Steri-Drape™ Wound Edge Protector Intervention Arm 2: Covering with standard woven swabs|
45698314|NCT01090180|Drug|Dexamethasone|anti-inflammatory adrenocortical steroid The following dose schedule will be given: 0.15mg/kg (based on body weight) every 7 days for 4 consecutive weeks
45698315|NCT01090180|Drug|Placebo (sugar pill)|inactive
45698316|NCT00636207|Drug|Montelukast|Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg
45698317|NCT00636207|Drug|Placebo|Placebo dry powder inhaler
45698318|NCT01922505|Drug|PPI triple therapy|
45401719|NCT05274880|Drug|CKD-393|PO, QD
45401720|NCT00149994|Drug|Cyclosporine A|
45401721|NCT00149994|Drug|Tacrolimus|
45401722|NCT00149994|Drug|Basiliximab|Each patient was given two 20mg doses of Basiliximab as intravenous bolus injection at Day 0 and Day 4 post-transplant surgery.
45401723|NCT00149994|Drug|Methylprednisolone|Methylprednisolone was given as an intravenous bolus of 500mg during transplant surgery
45698319|NCT04395885|Other|Electronic questionnaire|Assess the current sexuality according to the gender using sexual questionnaires for men and women were adapted from the Arabic validated version of the five-item International Index of Erectile Function which is a validated, multidimensional, self-administered questionnaire used for the clinical assessment of erectile dysfunction.and for female Arabic validated version of the Female Sexual Function Index
45698320|NCT01091116|Drug|MEN16132 - 0.125 mg|Intra-articular administration of two low doses of MEN16132 at 2-week interval.
45698321|NCT01091116|Drug|MEN16132 - 0.25 mg|Intra-articular injection of two intermediate doses of MEN16132 at 2-week interval
45698322|NCT01091116|Drug|MEN16132 - 0.5 mg|Intra-articular injection of two high doses of MEN16132 at 2-week interval
45698323|NCT01091116|Drug|MEN16132 - 0.5 mg|Single intra-articular injection of one high dose of MEN16132, followed by one dose of placebo at 2-week interval
45698324|NCT01091116|Drug|Placebo|Intra-articular injection of 2 doses of Placebo control at 2-week interval
45850274|NCT00003582|Drug|amifostine trihydrate|
45850275|NCT00003582|Drug|cisplatin|
45401724|NCT00149994|Drug|Prednisone|Post-operatively prednisone was tapered from an initial dose of 20mg/day to zero at 3 months or continued at 5-10mg if the indication for Orthotopic Liver Transplantation (OLTx) was of auto-immune nature.
45401725|NCT01179646|Drug|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
45401726|NCT01075776|Drug|C-type natriuretic peptide (CNP)|360 pmol/min for 15 minutes intra-arterially
45401727|NCT01075776|Drug|Saline|Sodium Chloride 0.9% intra-arterially 0.5ml/min
45401728|NCT01075776|Drug|Acetylcholine|2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb
45401729|NCT01288768|Procedure|Knee arthroscopy|Knee arthroscopy within 4 weeks.
45850276|NCT00003582|Drug|fluorouracil|
45850277|NCT00003582|Drug|paclitaxel|
45850278|NCT00003582|Procedure|quality-of-life assessment|
45850279|NCT00003582|Radiation|radiation therapy|
45850280|NCT00003588|Biological|Ad5CMV-p53 gene|
45850281|NCT00003588|Procedure|laparoscopic surgery|
45850282|NCT00003594|Drug|irinotecan|
45850283|NCT00003594|Drug|fluorouracil|
45850284|NCT00003594|Drug|leucovorin calcium|
45850285|NCT00003594|Drug|oxaliplatin|
45850286|NCT00003600|Biological|epoetin alfa|
45698325|NCT03169881|Drug|Darbepoetin|Darbepoetin 10 micrograms/kg/once every week (IV or SC). Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.
45850287|NCT00003600|Other|placebo|
45401730|NCT01079910|Drug|isopropylmethylphenol and Fluoride|0.1% isopropylmethylphenol and 1150ppm fluoride
45401731|NCT01079910|Drug|Fluoride and Silica|NaF/Silica toothpaste containing 1150ppm fluoride
45401732|NCT01286896|Drug|Sunitinib|"Patients will start treatment with a continuous once-daily dose of 37.5 mg sunitinib. After 22 days the first dose modification will be performed based on the total trough levels (TTL) combined for sunitinib plus SU12662 as measured by dried blood spot (DBS) analyses taken at day 15 ± 1day. A second dose modification will be performed after 36 days (7 days after the first dose adjustment) based on the TTL taken at day 29 ± 1day. One treatment cycle is defined as 28 days.~After 8 weeks a third analyses for TTL will be performed without further consequences for sunitinib dosing. Patients will be evaluated by CT- or MRI-scans for the response to therapy at week 8, and thereafter every 12 weeks. One blood sample will be harvested for pharmacogenetic analyses."
45401733|NCT03965988|Drug|DHA|Docosahexaenoic acid
45850288|NCT00003606|Drug|cisplatin|
45850289|NCT00003606|Drug|cyclophosphamide|
45401734|NCT03965988|Drug|Placebo|Placebo
45401735|NCT01286974|Drug|[14C]linifanib|[14C]linifanib, single administration, oral liquid
45401736|NCT01286974|Drug|ABT-869, linifanib|linifanib once a day (QD), oral tablet
45850290|NCT00003606|Drug|epirubicin hydrochloride|
45850291|NCT00003606|Drug|etoposide|
45509801|NCT04684602|Biological|PrimePro™/ PrimeMSK™|Injection via condition specific route of administration.
45509802|NCT04367142|Diagnostic Test|COVID-19 RT-PCR|Nasopharyngeal swabs for COVID-19 RT-PCR
45509803|NCT04367142|Diagnostic Test|Biosensor|Portable and Connected Biosensor viral
45401737|NCT03857854|Drug|Pirfenidone|treatment group
45401738|NCT03857854|Drug|Placebos|placebo group
45401739|NCT03858946|Procedure|Simple trapeziectomy|A curvilinear incision is made over the base of the 1. metacarpal towards the tendon of the extensor pollicis brevis in the distal part of the anatomical snuffbox. The joint is opened as widely as possible and the trapezium is dissected free in a proximal direction until the articulation with the scaphoid is reached. Then trapezium is removed taking care not to damage tendon of the flexor carpi radialis. The joint capsule is closed and skin sutured in the usual manner. At the completion of the procedure two small shame incision are made (1 cm each) involving only epidermis on the volar aspect of the palm and forearm. Each of them will be closed with one stitch
45401740|NCT03858946|Procedure|Weilby|The first part of the surgical procedure is identical to simple trapeziectomy. In addition, the tendon sheath of the first extensor compartment is divided. After this, a strip consisting of approximately one-third of flexor carpi radialis tendon is dissected using two small incisions on the volar aspect of the wrist and distal forearm. The distally based tendon strip is tunneled to its insertion on the second metacarpal bone. Then the strip of tendon is winded around the abductor pollicis longus tendon and the rest of the tendon at least twice, pulling those tendons together into the space created after excision of the trapezium. The tendons are sutured together with non-absorbable sutures while the skin is sutured in the usual manner
45509804|NCT02259972|Drug|BI 113823 solution|
45509805|NCT02259972|Drug|BI 113823 tablet|
45509806|NCT02259972|Drug|Placebo|
45509807|NCT02259972|Other|High fat, high calorie breakfast|only for dose group 5
45509808|NCT01374581|Drug|Artemether/Lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~Weight in kg Number of tablet per dose Age 5 to < 15 kg 1 tablet per dose 15 to < 25 kg 2 tablets per dose 25 to < 35 kg 3 tablets per dose"
45698326|NCT03169881|Drug|Placebo|normal saline for IV administration, or sham dosing. Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.
45698327|NCT03013426|Drug|NVX-508|Administration of NVX-508 emulsion intravenously
45698328|NCT01092364|Behavioral|Behavioral weight loss intervention|Behavioral lifestyle intervention for weight loss, compared to advice-only control.
45698329|NCT01092442|Procedure|Echocardiogram|Patients will have a yearly echocardiogram after enrollment in the study.
45698330|NCT01092676|Drug|Ibuprofen Regular Dosing|Regular dosing
45698331|NCT01092676|Drug|PRN dosing Ibuprofen|PRN dosing Ibupofen
45698332|NCT01092910|Device|Esteem Totally Implantable Hearing System|The Esteem System is a totally implantable hearing system designed to improve hearing in adult subjects suffering from mild to severe hearing loss that is sensorineural in origin.
45850292|NCT00003606|Radiation|radiation therapy|
45850293|NCT00003612|Biological|trastuzumab|
45850294|NCT00003612|Drug|carboplatin|
45850295|NCT00003612|Drug|paclitaxel|
45850296|NCT00003624|Drug|amifostine trihydrate|
45850297|NCT00003624|Drug|cisplatin|
45850298|NCT00003624|Drug|paclitaxel|
45850299|NCT00003630|Drug|arsenic trioxide|
45850300|NCT00003636|Drug|carboplatin|
45850301|NCT00003636|Drug|cisplatin|
45850302|NCT00003636|Procedure|conventional surgery|
45850303|NCT00003636|Procedure|neoadjuvant therapy|
45850304|NCT00003642|Drug|cisplatin|
45850305|NCT00003642|Drug|fluorouracil|
45850306|NCT00003642|Radiation|radiation therapy|
45509809|NCT01374581|Drug|Artesunate/Amodiaquine|"Age (Weight in Kg) Dose Treatment duration 2 to 11 months (= 4,5 to < 9kg):1 tablet (25 mg/675mg) for 3 days~1 to 5 years (= 9 kg to < 18 kg)1 tablet(25mg/67,5mg)for 3 days"
45698333|NCT05289622|Device|Polyurethane expandable valve stent implant|The baseline assessment of patients will include the admission of patients and the performance of preoperative exams (cardiological imaging for the correct selection). An estimated surgery time of 5 hours. During the entire procedure, patients will be under general anesthesia and controlled mechanical ventilation. The material collected in the laboratory will be processed, the result released and discarded. After the patient enters the operating room, hemodynamic monitoring, ECG, arterial saturation, with peripheral sensor, central venous access with double lumen catheter will be carried out; blood pressure monitoring by radial artery puncture, bladder catheter and thermometer in the nasopharynx and rectum. After preoperative preparation, patients will undergo a surgical approach by median thoracotomy and installation of the Cardiopulmonary bypass (ECC) circuit, by placing a cannula in the ascending aorta, Superior Vena Cava (SVC) and Inferior Vena Cava (IVC).
45698334|NCT05273320|Drug|Nabilone|Nabilone capsules at a maximum dose of 1 mg twice a day
45698335|NCT05271994|Procedure|endoscopic biliary drainage|endoscopic biliary drainage
45698336|NCT05190640|Dietary Supplement|De-Stress Gummies|one gummy a day for De-Stress Gummies and one gummy a day for Sleep Gummies
45698337|NCT05106244|Other|Real-Time Guidance of Home Care for Patients with PICC or PORT|the experimental group adopted the family self-nursing mode, mainly by the patients' family members to observe the catheter and do regular nursing, and the specialist nurses provided remote real-time online guidance to monitor the family nursing of central venous catheter. The procedures are as follows: (1) make nursing videos recorded by central venous catheter specialist nurses; (2) evaluate the nursing operation ability of the patients' family members and carry out relevant training and health education, repeat until they are qualified; (3) distribute nursing guidance prescriptions and maintenance manuals for central venous catheters; (4) provide online simulated realistic nursing video materials; (5) provide real-time telephone audio and video connection to complete remote nursing guidance. (6) set up a home nursing volunteer service group, establish a doctor-patient exchange group by using Wechat and other media.
45698338|NCT05088148|Other|. Pesticide and Pharmaceutical analysis|Pesticide and Pharmaceutical analysis will be done with LC-MS/MS device.
45698339|NCT01039792|Drug|Methyl B12|75 µg/Kg subcutaneously injected once every 3 days
45698340|NCT01039792|Dietary Supplement|Placebo|placebo
45698341|NCT03013816|Behavioral|Organ Donation Education: Testimonial Messaging|The testimonial messaging video intervention will be shown
45698342|NCT03013816|Behavioral|Organ Donation Education: Informational Messaging|The informational messaging video intervention will be shown
45698343|NCT03013816|Behavioral|Organ Donation Education: Blended Messaging|The blended messaging video intervention will be shown
45698344|NCT03012724|Device|H7-Coil|Deep transcranial magnetic stimulation for the treatment of major dispersion disorder with the H7-Coil
45698345|NCT03012724|Device|H1-Coil|Deep transcranial magnetic stimulation for the treatment of major depression disorder with the FDA cleared H1-Coil
45698346|NCT05023720|Other|nonintervention|
45698347|NCT01041274|Drug|Citalopram|40 mg by mouth daily for 12 months. Dosing will start at 20mg daily and may be increased after a minimum of one week to the target dose of 40 mg daily. Dose decreases will be made in the presence of side effects. Allowed dose range will be 10 mg daily to 40 mg daily.
45850307|NCT00003648|Genetic|DNA stability analysis|
45509810|NCT01374581|Drug|Quinine + Clindamycin|"this arm consist to 7 days treatment of 60 patients with quinine tablet 125mg + clindamycin syrup as follow;~Quinine:~9 to < 11 kg: ½ tablets 12 to < 19 kg: 1 tablets per dose 20 to < 27 kg: 1½ tablets per dose 28 to < 35 kg: 2 tablets per dose~Clindamycin syrup:~10 mg/kg twice daily"
45698348|NCT01041274|Drug|Placebo|Placebo by mouth daily for 12 months.
45850308|NCT00003648|Genetic|gene rearrangement analysis|
45850309|NCT00003654|Drug|patent blue V dye|
45850310|NCT00003654|Procedure|lymphangiography|
45850311|NCT00003654|Procedure|radionuclide imaging|
45850312|NCT00003654|Procedure|sentinel lymph node biopsy|
45596766|NCT04462471|Diagnostic Test|I-124 PET/CT lesion dosimetry|I-124 PET/CT scans will be performed during this process to quantify baseline RAI avidity in index metastatic lesion(s)
45596767|NCT04462471|Drug|Vemurafenib|Dose level 1 & 2: 960 mg PO bid Dose level -1: 720 mg PO bid Dose level -2: 480 mg PO bid
45596768|NCT04462471|Drug|Copanlisib|Dose level 2: 60 mg IV weekly Dose level 1, -1, -2: 45 mg IV weekly
45596769|NCT03525457|Procedure|Non Surgical Periodontal Therapy|Non Surgical Periodontal Therapy in 2 to 3 sessions
45596770|NCT03525301|Radiation|standard treatment|3000 cGy in 10 daily fractions
45850313|NCT00003654|Radiation|technetium Tc 99m sulfur colloid|
45850314|NCT00003666|Drug|6-hydroxymethylacylfulvene|11mg/sq m IV infusion over 5 min q day for 5 days each 28 day cycle
45850315|NCT00003678|Drug|tamoxifen citrate|
45850316|NCT00003678|Procedure|adjuvant therapy|
45850317|NCT00003684|Drug|theophylline|
45850318|NCT00003684|Procedure|quality-of-life assessment|
45596771|NCT03525301|Radiation|short course treatment|1800 cGy in 4 fractions administered twice a day
45596772|NCT03528499|Other|Scapular Movement Training|Orientation about the proper scapular position and movement and training to modify the scapular movement pattern.
45596773|NCT03528499|Other|General Exercises|Strengthening and stretching exercises.
45850319|NCT00003690|Drug|alvocidib|
45850320|NCT00003690|Drug|carboplatin|
45401741|NCT01287052|Drug|Nitrous Oxide|Once consent is obtained, the research assistant will notify the charge RN and MD of the patient's study participation. The patient will then be placed in a treatment room and nitrous oxide will be administered per the existing protocol. Each participant will be given nitrous oxide until he/she reports a pain score of zero or up to fifteen minutes. Study subjects will be asked to rate their pain on a scale of 0-10 before the treatment and after the treatment, the time duration of administering nitrous oxide will be recorded. In addition, the pain scores at 30, 60, 90, and 120 minutes post baseline measurement will be collected in order to evaluate the sustained effect of nitrous oxide in treating acute migraine pain. Someone from the study will also make a follow-up phone call 24 - 48 hours to see if pain relief persisted.
45698349|NCT01041274|Behavioral|Psychoeducation|16 sessions of weekly, individual psychoeducation and relapse prevention planning followed by 8 monthly sessions
45850321|NCT00003690|Drug|cisplatin|
45401742|NCT01288924|Drug|Parecoxib|Parecoxib 40 mg intravenous before surgery and every 12 hours for two days.
45401743|NCT01288924|Other|Control|NSS 2 ml intravenous before surgery and every 12 hours for two days.
45401744|NCT03857932|Procedure|Participants receive SLNB as well as non SLNs resection|Participants only receive SLNB preoperative CT lymphography SLNB with stained non-SLN resection SLNB with ARM dissection
45401745|NCT01181362|Procedure|Endoscopy|All patients will meet the physician at the Head and Neck centre at PMH, where they will have a topical anesthetic (lidocaine endotracheal aerosol, 10 mg/dose) sprayed into both nostrils. After allowing 5-10 minutes to let the anesthetic take effect, they will have an endoscopy procedure using a flexible scope inserted through the nostrils. The procedure will first be performed while patients are sitting up. During the procedure, patients will be asked to rate their discomfort on a 10-point scale. The endoscope will then be removed. After a short rest (15 minutes), the endoscopy procedure will be repeated with patients lying down. They will again be asked to rate their level of discomfort. After another short rest for recovery, they will meet with the physician to discuss both endoscopic procedures and to complete a questionnaire on discomfort, tolerance and acceptability
45401746|NCT01179724|Drug|high dose proton pump inhibitor|IV loading PPI before 2hr to conduct ESD, and IV 8mg/h continuous infusion within 48hr, and then 40mg oral pantoprazole for one month
45401747|NCT01179724|Drug|H2RB|IV 50mg loading H2 receptor antagonist before 2hr to conduct ESD, and IV 13mg/h continuous infusion within 48hr, and then 300mg oral H2 receptor antagonist for one month
45401748|NCT01176136|Behavioral|Homework, Organization, and Planning Skills (HOPS) Intervention|HOPS is a 16 session school-based intervention. School counselors and psychologists deliver the intervention during the school day. Each session lasts 20 minutes. Initially, sessions are 2 times per week and the entire HOPS intervention is completed in 11 weeks. The study uses a waitlist control design. HOPS intervention participants (Arm 1) receive the intervention in the fall quarter of the school year and Treatment As Usual participants (Arm 2) receive the intervention in the spring quarter.
45401749|NCT03862612|Procedure|regional anaesthesia with Levobupivicaine 0.25% 30mls with two methods either erector spinae plane block or serratus anterior plane block|Erector Spinae Plane Block will be compared to the Serratus Anterior Plane Block in patients undergoing Video assissted thoracic surgery
45401750|NCT03862534|Procedure|CAF|After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised, coronally advanced and sutured to cover the recession
45509811|NCT05224362|Device|A repeated measures acute study using using elastic resistance bands in older adults to challenge stability.|A repeated measures acute study using using elastic resistance bands in older adults to challenge stability. Exercises with an elastic resistance band anchored from the ground and placed at the hip and chest region will be trialled. Bertec force plate analysis will be performed to assess the acute effects on balance and stability. A semi- structured interview will identify the impact and practicalities of the intervention. The information will be used in the development of an evaluation process with key consideration of the planning phase of the intervention. Questions with verbal cues to provide perceptions of the exercise selection such as likes/ dislikes, safety, confidence, difficulty, enjoyment and band placement will be asked to determine the acceptability, accessibility, appropriateness and usability of the protocol and build insights into the participant preferences.
45509812|NCT02585921|Behavioral|Video Interventions|Participants will watch 2 5-minute videos and then discuss them as a group.
45509813|NCT02585921|Behavioral|Donation Discussion Education|Participants will learn techniques for introducing and discussing organ donation with parents and guardians.
45596774|NCT04233853|Behavioral|CoLiPri intervention|General practitioners and their screened patients have access to the consultation-liaison services for a total duration of 12 months, including standard screening, expert consultations, on demand patient referral for structured mental health diagnostics, psychoeducation and treatment planning, as well as brief psychotherapeutic intervention and triage.
45596775|NCT04233853|Other|Usual primary care enhanced|Usual primary care practice as offered in routine care. Enhanced means that practitioners receive a basic training which consists of guideline-based structured screening procedures for depression and anxiety mental disorders in primary care.
45596776|NCT02751827|Other|Blood sample|"One blood sample before treatment initiation (Cycle 1 Day predose) for pharmacogenomics~One blood sample at the end of the firth month of treatment (postdose) for pharmacokinetic"
45596777|NCT02374203|Dietary Supplement|high protein enteral nutrition|supply protein over 1.5 gm/kg body weight
45596778|NCT02363049|Procedure|Colectomy|
45596779|NCT02363049|Drug|Chemotherapy|
45596780|NCT05521009|Other|Control grup, sticky tube holder|In patients using adhesive tube holders and non-adhesive tube holders, it will be investigated whether there is bacterial growth on the tube.
45850322|NCT00003696|Drug|carboplatin|
45850323|NCT00003696|Drug|cyclophosphamide|
45850324|NCT00003696|Drug|doxorubicin hydrochloride|
45850325|NCT00003696|Drug|etoposide|
45850326|NCT00003696|Drug|paclitaxel|
45401751|NCT03862534|Procedure|CAF + CTG|After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised. Then a connective tissue graft was harvested from the palate and sutured over the exposed root. Finally the flap was coronally advanced and sutured to cover the recession
45401752|NCT03857698|Other|Conservative Physical Therapy|"Patients who were discharged from the hospital and received the sutures will be supervised 2 days a week for 8 weeks. Exercise programs will be promoted individually.~Ice application for pain, edema control~Patellar mobilization~Three-way straight leg lifting exercises~Isometric exercises around the hips and knees~Active assisted, active, resistant knee range of motion exercises~Heel shift exercises in supine and sitting~Hip abduction on the side lying~Stretching exercises for patients with gastrosoleus, hamstring, hip flexor muscles~Neuromuscular Electrical Stimulation (NMES) for quadriceps muscle of patients will be applied. The isometric quadriceps contraction observed during the procedure will be required to actively participate in the patients."
45401753|NCT03857698|Other|Body Stabilization Exercise|"In the first session, breathing control and alet abdominal hallawing of movement will be taught to the patients with the help of the pressure biofeedback device. The degree of difficulty of the exercises will be improved by using different positions, by adding rotations to the motion, making the pelvic control more difficult and increasing the number of repetitions. In case of exacerbation of symptoms, the level will not be advanced. Exercises will be advanced according to the patient's initial level and response to exercise.~Consecutive shoulder flexion and extension in supine~Building a bridge~Lower body and hip flip~Single leg extension with bilateral arm elevation~Resilient leg stretch with bilateral arm elevation~Hip external rotation in lateral hospitalization~Side-lying arm opening~Shoulder girdle retraction on ball, horizantal abduction and extension"
45401754|NCT01287130|Drug|Cetuximab|Day 1 administer cetuximab 400 mg/m2 IV loading dose over 120 minutes. On days 8, 15 and 22 administer cetuximab 250 mg/m2 IV loading dose over 60 minutes
45401755|NCT01287130|Drug|AZD6244|Given orally once or twice a day depending on dose level.On days 1, 8, 15 and 22. Repeat every 28 days
45698350|NCT01041274|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants who exhibit symptoms of moderate suicidality at any point during the trial will be treated with 12 sessions of CBT, either once or twice weekly based on clinical judgment. Participants who continue to exceed suicidality criteria after 4 weeks of CBT will be dropped from double-blind treatment and may be prescribed openly an SSRI
45698351|NCT01041274|Radiation|Functional Magnetic Resonance Imaging (fMRI)|3 1-hour sessions of fMRI brain scanning, assessed at baseline, and weeks 24 and 52
45401756|NCT00149214|Drug|pemetrexed|500 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4)
45401757|NCT00149214|Drug|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days, 4 cycles (1-4)
45401758|NCT00149214|Drug|doxorubicin|60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4)
45401759|NCT00149214|Drug|docetaxel|100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)
45401760|NCT03034018|Drug|suvorexant|10-20 mg taken at bedtime for four weeks
45401761|NCT03034018|Drug|placebo|placebo taken at bedtime for four weeks
45401762|NCT02524990|Behavioral|Home-based follow-up with SQPT|Participants will be followed-up at home. They will receive an SQPT to perform at home two weeks after enrollment, and a scheduled follow-up phone call by study providers to determine the outcome of the procedure.
45509814|NCT04501536|Behavioral|Word Learning Intervention|The word learning intervention uses the 10 commercially available children's books and 6 target vocabulary words from each book that meet common criteria for appropriate vocabulary targets. Children will receive 1-on-1 treatment sessions with a trained, speech-language research assistant. Each week, 2 of 10 storybooks chosen for the study will be read with 3 of 6 targeted vocabulary words targeted from each book. The book and words targeted will be consistent between random assignment conditions. For each book reading, speech-language interns will implement word learning strategies during pre reading, during reading, and post reading. Strategies include providing a definition, a synonym, and a contextual sentence. The number of strategies used will vary on which word is being targeted; all words will be randomly assigned to a particular dose, ranging from 0 (no strategies) to 20 (all of the strategies at each reading).
45509815|NCT03562650|Behavioral|Safety Behavior Fading|Participants are asked to fade their three most common safety behaviors associated with their social anxiety
45509816|NCT03562650|Behavioral|Present Centered|Participants are asked to try to increase their focus on the present.
45509817|NCT01354938|Drug|Clarithromycin modified release 500 mg|Clarithromycin modified release 500 mg was prescribed. The dosage given was either 1 tablet or 2 tablets once a day, depending on the severity of the treatment.
45509818|NCT02516969|Radiation|Stereotactic Body Radiotherapy|Radiation
45509819|NCT04364256|Device|RS-4i Plus Sequential Stimulator (RS Medical, Vancouver, WA)|Active or Sham Neuromuscular electrical stimulation. US Food and Drug Administration-approved 2012
45509820|NCT03092791|Biological|Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)|sIPV intramuscular injection
45509821|NCT03092791|Biological|Reference IPV|Reference IPV intramuscular injection
45509822|NCT03092791|Biological|sIPV Placebo|sIPV placebo-matching intramuscular injection
45509823|NCT03065556|Drug|188-0551 Solution|Topical solution containing active drug
45698352|NCT00635427|Biological|VPRIV®|Intravenous infusion, every other week (EOW)
45698353|NCT04988386|Drug|Acoramidis (AG10)|Acoramidis (AG10) twice daily
45401763|NCT03965910|Other|Demonstration the Importance of Early Rehabilitation in Stroke Patients Based on Diffusion Tensor Imaging Data|"Twenty-eight stroke patients aged 36-72 years admitted to the our Physical Medicine and Rehabilitation Outpatient Clinics were included in this prospective study. After the approval of the ethics committee, written informed consent was obtained from the patients after they were informed about the content and purpose of the study, the schedule of rehabilitation to be administered, and the features of cranial magnetic resonance imaging (MRI) to be performed. Patients with confirmed diagnosis of stroke by computed tomography and/or MRI techniques were randomized into two groups according to the onset of post-stroke rehabilitation. The patients were randomized according to the duration of their admission to our clinic for rehabilitation. Group 1 consisted of patients admitted to our clinic within 1-4 weeks after stroke; Group 2 consisted of patients admitted within 5-8 weeks after stroke.~Late initiation of rehabilitation in Group 2 patients is not a condition related to our clinic."
45401764|NCT02525458|Device|QAMS-containing PMMA|Wear retainer with QMAS-containing PMMA on one side of retainer
45401765|NCT02525458|Device|QAMS-free PMMA|Wear retainer with QMAS-free PMMA on other side of retainer
45401766|NCT03967782|Behavioral|CON|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
45401767|NCT03967782|Behavioral|EX-MEAL|Condition with an acute exercise set right before lunch The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) right before ad ad libitum lunch meal. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
45401768|NCT03967782|Behavioral|MEAL-EX|. condition with an acute exercise set right after lunch. The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) right after an ad libitul buffet meal. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
45509824|NCT03065556|Drug|Vehicle Solution|Topical solution containing no active drug
45509825|NCT01374737|Drug|Dexmedetomidine|dexmedetomidine, 0.1ug/kg up or down
45401769|NCT03858556|Procedure|Chuna manipulation|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
45401770|NCT03858556|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
45401771|NCT03858556|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
45509826|NCT01374815|Other|The Online Advocate|The Online Advocate is a Web-based social problems screening and referral tool developed at Children's Hospital.
45509827|NCT01374815|Other|The Online Advocate|The Online Advocate is a Web-based screening and referral tool for health-related social problems
45509828|NCT02350595|Other|Lean fish|
45509829|NCT02350595|Other|Fatty fish|
45509830|NCT02203409|Procedure|Laparoscopic ALPPS|Laparoscopic Associating Liver Partition and Portal Vein Ligation for Two-stage Hepatectomy
45509831|NCT04283461|Biological|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.
45698354|NCT00635349|Drug|Meloxicam|Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.
45401772|NCT03858556|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
45401773|NCT03858556|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
45401774|NCT03858556|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
45401775|NCT03858556|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
45401776|NCT03858556|Other|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
45401777|NCT03857776|Other|Open dialogue about complementary alternative medicine|1-hour dialogue about CAM with a nurse specialist as an Integrated part of conventional oncology care
45401778|NCT03857776|Other|Standard care|Standard care including referral to a homepage about CAM
45401779|NCT02555254|Procedure|Low Speed of Rewarming|Speed of rewarming will be at 0.25°C/h with specific temperature controlled external device
45401780|NCT02555254|Procedure|High Speed of Rewarming|Speed of rewarming will be at 0.50°C/h with specific temperature controlled external device
45401781|NCT01179802|Other|Strenuous Endurance exercise|"Jungfraumarathon: Mountain-Marathon with a length of 42km and a altitude-difference of approximately 1830meters."
45401782|NCT01179880|Drug|E6005|Four Steps of Ointment Application: Step 1: 0.01% of E6005; Step 2: 0.03% of E6005; Step 3: 0.1% of E6005; Step 4: 0.2% of E6005.
45401783|NCT01179880|Drug|Placebo|Matching placebo for each step
45401784|NCT03862222|Other|Retinal Imaging|Retinal imaging will be conducted on the Heidelberg SPECTRALIS (FDA 510k cleared) device, routinely used in clinical care in ophthalmology. Optical Coherence Tomography (OCT) and Angiography (OCT-A) sequences will be conducted, as well as a sequence examining macular pigment (MPOD).
45401785|NCT03862222|Other|Pupillometry|Participants will complete a task studying pupillary response to light
45401786|NCT03862222|Other|Contrast Sensitivity|Participants will complete a task evaluating contrast sensitivity
45401787|NCT03862222|Diagnostic Test|Neuropsychological Evaluation|Neuropsychological evaluation will be completed, including testing in domains of memory, executive function, visuospatial ability, language, processing speed. Results will be used for research purposes only.
45401788|NCT03862222|Genetic|APOE genotyping|APOE genotyping will be completed during screening to assign participants to the correct group. Results will not be shared with participants as part of the study.
45509832|NCT05172505|Device|prefrontal tDCS|2 mA prefrontal tDCS (anode over F3, cathode over F4 10/20 EEG System) for 6 weeks, 5x/week in a home treatment Setting (self application) for 30 mins.
45509833|NCT01374893|Behavioral|Exercise|The intervention group will perform the multi-session per day training program
45509834|NCT01374893|Behavioral|Control|Usual care
45509835|NCT04638127|Behavioral|PREEMIE PROGRESS|PREEMIE PROGRESS is a video-based training program for parents of preterm infants hospitalized in the neonatal intensive care unit (NICU).
45509836|NCT04638127|Behavioral|Attention Control|usual care and welcome videos
45509837|NCT05197283|Other|Glucose as reference food|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested two times, in different visits, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
45401789|NCT03862222|Other|blood draw|Blood will be drawn and banked for proteomic, biomarker, and GWAS analysis
45401790|NCT03862222|Other|Gait Assessment|Gait assessment will be conducted by trained researcher
45401791|NCT03862222|Other|Actigraphy|Actigraphy monitors will be worn by all participants for 2 weeks after each visit to examine physical activity, movement, and sleep patterns.
45401792|NCT01181440|Device|Dermagraft(R)|Weekly application of Dermagraft(R) with conventional care
45401793|NCT01181440|Other|Conventional care|Weekly application of conventional care
45401794|NCT01289626|Drug|lanthanum carbonate|FOSRENOL® will be administered orally in a dose of 1500- 3750 mg daily in divided doses with meals. Dose escalation will be utilized to a target dose of 3750 mg daily or as designated by clinician over a 4-week period from start of study. The drug will be administered for 12 weeks.
45401795|NCT01289626|Drug|Lanthanum for calciphylaxis|Lanthanum use in calciphylaxis
45401796|NCT01176214|Procedure|Early tracheostomy|"Patients with supratentorial ICH who require mechanical ventilation, fulfill the inclusion criteria, and have been randomized to the treatment arm will receive an early tracheostomy within 72h after symptom onset."
45401797|NCT01176214|Procedure|Late tracheostomy|"Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails"
45401798|NCT01179958|Behavioral|aerobic training|24 weeks of aerobic training, 4X/week
45401799|NCT01179958|Behavioral|stretching/toning|stretches and toning exercises designed to promote flexibility and improved core strength
45401800|NCT00114972|Device|Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent|Drug Eluting Stent
45401801|NCT00114972|Procedure|Coronary Artery Bypass Surgery|Coronary Artery Bypass Surgery
45698355|NCT00635349|Drug|Aceclofenac|Aceclofenac 100 mg twice a day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and aceclofenac 100 mg twice a day from Day 29 to Day 85.
45401802|NCT02444728|Drug|Hydroxychloroquine|Hydroxychloroquine 200 mg BID for 12 months
45401803|NCT02444728|Drug|Cyclophosphamide|Cyclophosphamide 1000mg intravenous infusion every month for 6 months
45401804|NCT02444728|Drug|Azathioprine|After Cyclophosphamide treatment, Azathioprine 100mg once daily for 6 months
45401805|NCT02444728|Drug|Methylprednisolone|Methylprednisolone 40-50 mg once daily for 1 months and then taped for 12 months
45401806|NCT03858790|Device|PINS Spinal Cord Stimulator|Subjects will be implanted with PINS spinal cord stimulator
45698356|NCT00635349|Drug|Tramadol Hydrochloride Plus Acetaminophen|Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam [7.5 mg or 15 mg once daily] or aceclofenac [100 mg twice daily]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
45401807|NCT01180114|Behavioral|Suubi-Maka ('Hope for Families')|Each child in the SUUBI-MAKA condition receive the usual care plus asset focused services, specifically: a matched Child Development Account (CDA); twelve 1-2 hour training sessions on career planning, setting short-term and long-term career goals, and how to save money; and monthly mentorship program with young adult peers (undergraduate students) on life options and how to avoid risk behaviors. In addition, participants receive a 2:1 match for their deposits into the account. Further, participants and their adult caregivers receive specific training on microenterprise development and specifically on how to start an income-generating project using up to 50% of the matched savings. The intervention is delivered over a period of 24 months.
45401808|NCT01180114|Other|Usual Care|Each child in the control condition receives the usual services for orphaned children (counseling, school lunches, and textbooks).
45401809|NCT01289704|Other|TreSPE|"treadmill: 5'warm up, 20'aerobic exercise (gradually incremented to 30', from session to session, if possible), 5'warm down, controlling hearth rate, blood pressure and SaO2.~Respiratory Physiotherapy: positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training, for the other 10'.~Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors digitorum longus and brevis, both at the bed and in a static position.~Proprioceptive and postural kinesitherapy according to the Perfetti method.~Balance Exercising consists of exercises carried on by basculating bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handbar preventing falls."
45401810|NCT01289704|Other|SPE|"Respiratory Physiotherapy for 20', consisting of Positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training according to the Mèzières technique, for the other 10'.~Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors longus and brevis, both at the bed and in a static position.~Proprioceptive and postural kinesitherapy according to the neurocognitive method.~Balance Exercising consists of exercises carried on by moving bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handlebar preventing falls."
45401811|NCT00129402|Drug|ezetimibe with simvastatin|Ezetimibe 10 mg plus simvastatin 10 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 20 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 40 mg once a day for six weeks
45401812|NCT00129402|Drug|simvastatin|Ezetimibe matching placebo plus simvastatin 10 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 20 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 40 mg once a day for six weeks
45401813|NCT01180192|Drug|oxygen|either 8 L/minute O2 via face mask for 2 hours
45401814|NCT01181830|Drug|magnesium pidolate|administration of 8.1 mmol bid of magnesium pidolate
45401815|NCT01181830|Drug|placebo|administration of 8.1 mmol bid of placebo
45698357|NCT00634803|Behavioral|CBT|Cognitive behavioral therapy
45698358|NCT00634803|Drug|Buprenorphine|buprenorphine/naloxone
45698359|NCT00634803|Other|Educational Counseling|Didactic, lecture-discussion format to supplement information and advice provided by physicians
45698360|NCT00634803|Other|Physician Management|Brief physician counseling
45698361|NCT01401699|Device|Optical Frequency Domain Imaging (OFDI)|Optical Frequency Domain (OFDI) imaging of esophagus
45698362|NCT01042288|Drug|Carboplatin|Carboplatin AUC=6IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
45509838|NCT05197283|Other|White bread|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from white bread, along with 300ml water, tested two times, in different visits, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
45698363|NCT01042288|Drug|Pemetrexed|Pemetrexed 500mg/m² IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
45401816|NCT03739528|Drug|Levofloxacin + dexamethasone followed by dexamethasone|Levofloxacin + dexamethasone ophthalmic solution for 7 days, 1 drop - 4 times a day, followed by dexamethasone ophthalmic suspension (Maxidex®) for an additional 7 days, 1 drop - 4 times a day.
45698364|NCT01042288|Drug|Panitumumab|Panitumumab 9mg/kg IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
45698365|NCT01217385|Procedure|DOSI|Bedside DOSI images of the tissue concentrations of deoxy-hemoglobin (ctHHb), oxy-hemoglobin (ctHbO2), water (ctH2O), lipid, tissue oxygen saturation (StO2), and TOI (ctHHb x tH2O/lipid) were acquired on both breasts up to four times during neoadjuvant chemotherapy (NAC) treatment.
45698366|NCT01042366|Biological|Vaccination|Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
45698367|NCT01043146|Drug|COR-1|single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
45401817|NCT03739528|Drug|Tobramycin + Dexamethasone|Tobramycin + dexamethasone ophthalmic suspension (Tobradex®) for 14 days, 1 drop - 4 times a day.
45401818|NCT01176370|Device|C-Pulse™ (Implantable Counterpulsation Therapy)|Implantation of a heart assist device that provide counterpulsation without blood contact for an extended period.
45401819|NCT01176370|Device|C-Pulse™ (Implantable Counterpulsation Therapy)|Implantation and activation of counterpulsation therapy for the full duration of the study period. The device may be turned off briefly for personal hygiene, etc.
45401820|NCT03857386|Procedure|PECS group|Pecs block performed using ultrasound guidance
45401821|NCT03857386|Procedure|Control group|Local infiltration anesthesia performed during the operation
45401822|NCT01587586|Biological|PEGASYS 180 µg Q1W|48 doses, solution, 48 weeks
45401823|NCT01587586|Biological|P1101 180 µg Q1W, 48 doses|48 doses, solution, 48 weeks
45401824|NCT01587586|Biological|P1101 270µg Q1W, 48 doses|48 doses, solution, 48 weeks
45401825|NCT01587586|Biological|P1101 450µg Q2W, 24 doses|24 doses, solution, 48 weeks
45401826|NCT01181908|Drug|single dose|Subjects will receive a single dose of GSK1144814 or placebo.
45401827|NCT01289236|Drug|milnacipran|1 tablet (50mg) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period
45401828|NCT01289236|Drug|Milnacipran|1 tablet (100mg) BID (twice daily, approximately 12 hours apart)for 12 weeks after appropriate titration period.
45401829|NCT01289236|Drug|Placebo|1 tablet (placebo) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period.
45509839|NCT05197283|Other|Regular spaghetti|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from regular spaghetti No 7, along with 300ml water, tested once, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
45698368|NCT01043146|Drug|placebo|intravenous 0.9 % NaCl
45698369|NCT04906018|Device|Ultrasound scans|Each subject will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
45401830|NCT01287286|Dietary Supplement|AC-Can|Antrodia cinnamomea compounds of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
45401831|NCT01287286|Dietary Supplement|placebo|Placebo of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
45401832|NCT01289860|Dietary Supplement|Flavonoids|475g of anthocyanidins in 300ml of blueberry drink.
45509840|NCT05197283|Other|Whole wheat spaghetti|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from whole wheat spaghetti No 7, along with 300ml water, tested once, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
45698370|NCT04880668|Device|Aerosol Box (Splashguard)|The aerosol box is a transparent, plastic cube covering the patient's head and shoulders, with circular access ports on the front of the box allowing for access to manage the airway. An additional four access holes (i.e. two on either side of the box) allow for airway assistants to access the patient airway.
45698371|NCT01043926|Drug|Suvorexant|single 20 mg dose of suvorexant will be administered as 2 x 10 mg film coated tablets on Day 1 after an overnight fast with water.
45698372|NCT04801810|Other|Normobaric hypoxia|Low oxygen exposure to mimic ~8500 feet elevation (experimental).
45698373|NCT04801810|Other|Normobaric normoxia|Normal oxygen exposure to mimic sea level conditions (sham comparator).
45698374|NCT01044706|Drug|Bicalutamide|50 mg Oral Tablet
45401833|NCT01289860|Dietary Supplement|Control|29g powder: sugars (glucose, sucrose, fructose), vitamin C and citric acid.
45401834|NCT03858478|Drug|Biktarvy arm|BIKTARVY : one tablet QD, every day between D0 and M12 includind - TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg)
45401835|NCT01289938|Drug|Diphenhydramine|Diphenhydramine 50 mg oral once
45698375|NCT04447534|Drug|Chloroquine or hydroxychloroquine|Chloroquine or hydroxychloroquine
45698376|NCT04447534|Drug|zinc|Zinc tablets
45850327|NCT00003708|Drug|temozolomide|Patients receive oral temozolomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at escalating doses of temozolomide. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity (DLT) during courses 1 or 2, with at least 2 patients experiencing DLT at the next higher dose level.
45850328|NCT00003714|Drug|Pyrazoloacridine|IV (by vein) over 3 hours every 3 weeks
45850329|NCT00003720|Drug|semaxanib|
45509841|NCT05197283|Other|High fibre - low carbohydrates spaghetti|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from high fibre - low carbohydrate spaghetti No 7, along with 300ml water, tested once, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
45596781|NCT04199533|Behavioral|RUBI|Parent-mediated behavioral program targeting disruptive behavior utilizing principle of applied behavior analysis
45596782|NCT04199533|Behavioral|RUBIES|School-staff mediated behavioral program targeting disruptive behavior utilizing principle of applied behavior analysis
45698377|NCT03014050|Device|e-Tapper TT-R1|"The e-Tapper is a non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hands at specified points representing various body parts, such as the head, leg, or foot. This is one form of Bio-Electro Stimulation Therapy known as the 11-point Hand Treatment System. The current delivered is less than one milliampere."
45698378|NCT01044862|Drug|Letrozole (aromatase inhibitor)|A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
45698379|NCT01044862|Drug|Clomiphene Citrate|CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
45698380|NCT01044862|Drug|Follicle Stimulating Hormone (gonadotropin)|A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
45698381|NCT01045174|Device|Nebulizer (breath-actuated versus conventional continuous-output)|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer. Standard unit doses of albuterol/ipratropium bromide or albuterol are used in both devices.
45698382|NCT04365478|Procedure|Radial Extracorporeal Shock Wave Therapy|rSWT group: One radial shock wave therapy session a week for 8 weeks (parameters: 1.5 bar, 10 Hz, 2000 shots for each muscle group treated) administered daily during the morning for 40 minutes of conventional rehabilitation treatment.
45698383|NCT04365478|Procedure|Conventional physiotherapy|Control group: 40-minutes of conventional rehabilitation treatment 5 days per week in the morning (strength exercise, trunk control exercise, stretching exercise, occupational therapy, and neurodevelopmental facilitation techniques) for 8 weeks
45850330|NCT00003732|Drug|carboplatin|
45401836|NCT01289938|Drug|Metoclopramide|10 mg i.v. metoclopramide once
45401837|NCT00114738|Drug|Rituximab (R)|Rituximab is given with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and bortezomib every 3 weeks for 6 cycles.
45401838|NCT00114738|Biological|EPOCH|EPOCH is given with Rituximab and bortezomib every 3 weeks for 6 cycles.
45401839|NCT00114738|Drug|Bortezomib (B)|Bortezomib is given alone for one cycle.
45401840|NCT00114738|Drug|Bortezomib|Bortezomib is given with EPOCH and rituximab every 6 weeks for 12 cycles.
45401841|NCT00114738|Drug|Bortezomib or observation|At the beginning of Part C, patients are randomized to receive bortezomib maintenance or be observed w/o bortezomib.
45401842|NCT01180348|Drug|Botulift|Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
45698384|NCT04361656|Drug|PEG-ELS current standard of care|Standard of care for inpatient colonoscopy
45850331|NCT00003732|Drug|paclitaxel|
45850332|NCT00003732|Drug|topotecan hydrochloride|
45850333|NCT00003744|Drug|gemcitabine|
45850334|NCT00003750|Biological|hu14.18-IL2 fusion protein|
45850335|NCT00003762|Drug|docetaxel|
45850336|NCT00003762|Drug|gemcitabine hydrochloride|
45850337|NCT00003768|Drug|fosbretabulin disodium|
45850338|NCT00003780|Biological|tumor infiltrating lymphocyte therapy|
45850339|NCT00003780|Drug|gemcitabine hydrochloride|
45850340|NCT00003786|Drug|irofulven|
45850341|NCT00003792|Biological|MART-1 antigen|
45850342|NCT00003792|Biological|filgrastim|
45401843|NCT01180348|Drug|Botox|Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
45698385|NCT04361656|Drug|PEG-ELS current standard of care plus Lubiprostone 24 microgram Oral Cap (x2)|The dose of Lubiprostone will be 24 mcg capsule orally (roughly every 12 hours) for total of 2 doses, with the last dose being at least 4 hours prior to the scheduled colonoscopy if it is BEFORE 11 a.m., and Lubiprostone 24 mcg capsule orally 2 hours before each dose of the PEG-ELS if colonoscopy is scheduled AT or AFTER 11 a.m..
45509842|NCT03631615|Drug|Neoadjuvant chemoradiation plus PD-1 antibody(SHR-1210)|"Patients will be given the perioperative treatment as below once recruited:~induction Neochemotherapy (3w): one cycle of XELOX regimen before surgery;~within one week after the induction, concurrent neochemoradiation will be started (5w): intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas.~consolidation neochemotherapy will be started in 2-3w after concurrent chemoradiation: one cycle of XELOX regimen; From the beginning of induction chemo to 3w before surgery, PD-1 antibody SHR-1210 will be given q3W.~Re-evaluation will be conducted in 1-3w after consolidation chemo, resectable patients will receive D2 resection.~Adjuvant chemo: We advise starting 4 cycles of XELOX regimen in 4-6w after surgery."
45698386|NCT04242394|Procedure|ERCP|Routine ERCP procedures with gallbladder in situ patient
45698387|NCT04238338|Other|monocyte / lymphocyte ratio|The lymphocyte / monocyte ratio should be tested every 3-6months after the start of the study, and the final value is the average
45698388|NCT01047358|Drug|Aromasin|25 mg table QD
45698389|NCT01047358|Drug|Aromasin|25 mg table QD
45698390|NCT01048606|Behavioral|Placebo + exercise|"Placebo: Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day)~Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist."
45698391|NCT01048606|Dietary Supplement|Phytoestrogens without exercise|"Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.~Without exercise: participants will be asked to do only their usual activities without being involved in any kind of structured exercise sessions."
45698392|NCT01048606|Other|Phytoestrogens + exercise|"Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.~Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist."
45698393|NCT04224766|Procedure|Suprascapular Nerve Block with 5ml bupivicaine 0.5%|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of bupivicaine 0.5%.
45401844|NCT01180426|Drug|CHR-2797|120mg once daily oral for 48 weeks
45509843|NCT05197205|Procedure|nasopharyngeal swabbing|A nasopharyngeal swab is collected during the consultation, with bacteriological analysis. No follow-up visit is required for this study
45509844|NCT03631537|Other|NST group|Nutrition-support-team based intervention on nutrition, including dietary supplement, parenteral nutrient solutions and patient education
45698394|NCT04224766|Procedure|costoclavicular Block 10ml bupivicaine 0.5%|transverse ultrasound imaging of the medial infraclavicular fossa to identify the cords of the brachial plexus at the costoclavicular space (CCS) then inject 10ml bupivicaine 0.5%
45850343|NCT00003792|Biological|flu matrix peptide p58-66|
45850344|NCT00003792|Biological|gp100 antigen|
45850345|NCT00003792|Biological|recombinant MAGE-3.1 antigen|
45850346|NCT00003792|Biological|tyrosinase peptide|
45850347|NCT00003792|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45850348|NCT00003798|Drug|motexafin gadolinium|
45850349|NCT00003798|Radiation|radiation therapy|
45850350|NCT00003804|Biological|dactinomycin|
45850351|NCT00003804|Drug|vincristine sulfate|
45401845|NCT01289314|Procedure|TLH|Total laparoscopic hysterectomy (TLH)
45401846|NCT01289314|Procedure|Laparoscopic supracervical hysterectomy|Laparoscopic supracervical hysterectomy (LSH)
45401847|NCT02524756|Procedure|laparoscopic nerve-sparing radical hysterectomy-type III/C1|
45401848|NCT02524756|Procedure|laparoscopic radical hysterectomy (type III/C2).|
45401849|NCT01180504|Radiation|intensity-modulated whole-abdominal radiotherapy|Consolidation intensity-modulated whole-abdominal radiotherapy using helical tomotherapy to a total dose of 30 Gy in 1.5 Gy fractions
45401850|NCT01290016|Behavioral|2 servings dairy + exercise|Subjects in this group will receive family based counseling to maintain the intake of 2 servings of dairy per day and also receive instruction on how to improve their physical activity.
45401851|NCT01290016|Behavioral|4 servings dairy + exercise|Subjects in this group will receive family based counseling to increase intake of dairy to 4 servings per day and also receive instruction on how to improve their physical activity.
45401852|NCT01290016|Behavioral|Control|The group will receive information during the study about diet and exercise but will not receive the intervention until 6 months into the study protocol.
45401853|NCT01287442|Procedure|Trabeculectomy|A scleral flap is created. The aqueous humor is so guided under the conjunctiva to lower IOP.
45850352|NCT00003804|Procedure|conventional surgery|
45850353|NCT00003822|Drug|apomine|
45850354|NCT00003828|Drug|vinorelbine|
45850355|NCT00003834|Drug|fluorouracil|
45850356|NCT00003834|Drug|leucovorin calcium|
45850357|NCT00003834|Drug|oxaliplatin|
45401854|NCT00148122|Drug|Docetaxel|Each four-week cycle consists of three infusions through a vein of docetaxel, on days 1, 8, and 15. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
45401855|NCT00148122|Drug|Capecitabine|Each four-week cycle consists of fourteen days of a medication that the subject will take two times a day orally, on days 5-18. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
45401856|NCT03857308|Behavioral|Mindfulness Training|"This stress reduction training will last 14 days and teach participants skills in concentration, monitoring of present-moment bodily experience, and acceptance of experience. Participants are encouraged to mentally welcome all physical and emotional experience. Each day will consist of approximately 25 to 30 minutes of training.~A full explanation of the mindfulness training compared to the reappraisal training could interfere with study blinding procedures. A complete description can be provided after data collection is complete."
45401857|NCT03857308|Behavioral|Reappraisal Training|"This stress reduction training will last 14-days. Each day consists of 25 to 30 minutes of daily practice in Coping control. Participants are encouraged to reframe and reappraise life events, both past and present, and encouraged to solve personal problems through active change.~A full explanation of the reappraisal stress reduction program compared to the mindfulness program could interfere with study blinding procedures. A complete description can be provided after data collection is complete."
45698395|NCT04224766|Procedure|Interscalene Brachial Plexus Block 15ml bupivicaine 0.5%|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of bupivacaine 0.5%.
45401858|NCT01182142|Drug|Capecitabine|1,250 mg/m2 orally twice a day, days 1-14
45401859|NCT01180582|Device|Triathlon Periapatite (PA)-coated Tibial Component|Triathlon Periapatite (PA)-coated Total Knee Arthroplasty Tibial Component for uncemented fixation
45401860|NCT03858166|Drug|PEG-rhG-CSF|6mg PEG-rhG-CSF was administrated subcutaneously at different time after chemotherapy.
45401861|NCT01180738|Behavioral|Body weight supported treadmill training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking on a treadmill using a body weight support system.
45401862|NCT01180738|Behavioral|Overground walking training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking overground.
45401863|NCT01587742|Drug|CCB use|Prescription of CCB during the study period between January 1, 1996 to December 31, 2009. The CCBs administered to the patients include isradipine and lacidipine.
45401864|NCT01180816|Drug|Super-Selective Intraarterial Intracranial Infusion of Temozolomide|A single dose of Intraarterial Mannitol to open the blood brain barrier followed by Intra-arterial Temozolomide single dose (starting at 75mg/m2 and up to 250mg/m2)
45401865|NCT01587664|Device|NewBreez ILP|NewBreez ILP implantation
45401866|NCT01287598|Drug|Regorafenib (Stivarga, BAY73-4506)|BAY73-4506 administered once a daily (od) in a 21-day on / 7-day off schedule
45401867|NCT01287598|Drug|Warfarin|CYP 2C9 (warfarin) at Cycle 1
45401868|NCT01287598|Drug|Omeprazole|CYP 2C19 (omeprazole) at Cycle 1
45401869|NCT01287598|Drug|Midazolam|CYP 3A4 (midazolam) at Cycle 1
45698396|NCT04210882|Behavioral|Moderate-Intensity Exercise|See description of study arm.
45401870|NCT01287598|Drug|Rosiglitazone|CYP2C8 (rosiglitazone) at Cycle 1
45401871|NCT03861910|Dietary Supplement|hypoallergenic formulas|hypoallergenic formulas used for cow milk allergy treatment
45401872|NCT03855514|Other|NuShield|NuShield® is a dehydrated placental allograft.
45401873|NCT01182532|Other|Western therapy|"Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.~Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;"
45401874|NCT01182532|Drug|TCM Syndrome Differentiation and Treatment|"Lung-Spleen Damp-Heat Syndrome Symptoms: Fever, maculopapule and herpes on hand, foot and buttock; herpes on oral mucous membrane; redness in throat, salivation, tiredness, faint red tongue or reddish tongue, greasy fur, speedy pulse, red and purple fingerprint.~Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Lonicera japonica Thunb (Jin Yin Hua), Scutellaria baicalensis Georgi (Huang Qin), etc.~Dosage: Adjusting by age and weight of patients. Decoction.~Dampness-Heat Retention Syndrome Symptoms: High fever, dirty color of tetter, tiredness, oral ulcer, reddish tongue or deep red tongue, little saliva, yellow and greasy fur, fine and rapid pulse, deep purple fingerprint.~Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Gardenia jasminoides Ellis (rough Zhi Zi), Scutellaria baicalensis Georgi (Huang Qin), etc.~Dosage: Adjusting by age and weight of patients. Decoction."
45850358|NCT00003840|Biological|DTGM fusion protein|
45401875|NCT01182532|Other|Western therapy plus TCM treatment|"Symptomatic treatment using the same treatment methods in western therapy group;~Syndrome differentiation and treatment adopting the same methods in TCM treatment group."
45401876|NCT03862144|Drug|Netupitant/Palonosetron|
45698397|NCT03012256|Other|Cardio-respiratory management model|Includes scheduled nurse-led self-management support (based on a training program, and tool-kit), advanced care and goal planning, clinical pharmacist education reconciliation, team case rounds, Situation, Background, Assessment and Recommendation (SBAR) communication protocol with primary care, and a standardized transition package
45698398|NCT04184362|Device|Empower Neuromodulation System Transcutaneous Electrical Nerve Stimulation|Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.
45850359|NCT00003846|Biological|filgrastim|
45850360|NCT00003846|Drug|carboplatin|
45401877|NCT03857152|Diagnostic Test|Contrast enhanced spectral mammography (CESM)|"Contrast enhanced spectral mammography (CESM) will be undertaken in addition to routine practice.~CESM is a specialist mammography test that aims to 'highlight' areas of concern within the breast in more detail than a standard mammogram.~The difference between CESM and a standard mammogram (x-ray of the breast) is the use of a special dye (called contrast medium) that is injected into the veins before the mammogram images are taken. The contrast enhanced images give more detailed information to the breast radiologists (expert doctors trained to analyse breast imaging)."
45850361|NCT00003846|Drug|cyclophosphamide|
45698399|NCT04128514|Device|Panoptix Toric|Cataract surgery and IOL implantation
45698400|NCT01049776|Drug|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months
45698401|NCT01772004|Drug|Avelumab|Participants received intravenous infusion of Avelumab in dose escalation and expansion cohorts until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
45698402|NCT02930044|Other|Early administration of subcutaneous insulin glargine dose|DKA patients in the prospective intervention arm will receive subcutaneous glargine within two hours of starting their intravenous insulin infusion. The dose of glargine is 0.3 units/kg with a maximum dose of 30 units.
45698403|NCT02930044|Other|IV insulin infusion|All patients will receive the standard of care which is a protocol based continuous insulin infusion
45698404|NCT02930044|Drug|IV fluid repletion|0.9% NaCl or Plasmalyte A will be initiated as a continuous infusion for volume repletion. Fluids will be switched to contain potassium if serum potassium is less than 3.3 mEq/L. Fluids will be switched to contain dextrose if the serum glucose is less than 250 mg/dL.
45698405|NCT02181400|Device|Ellex Integre NIR laser|"Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period."
45698406|NCT04352218|Device|"PTA + Stenting using Petalo stent"|PTA and Petalo's Stenting are a minimally invasive endovascular procedures, performed by a percutaneous access to the common femoral vein under local anesthesia and Duplex Ultrasound Guidance.
45698407|NCT04352218|Procedure|Percutaneous Transluminal Angioplasty (PTA)|PTA is a minimally invasive endovascular procedure, performed by a percutaneous access to the common femoral vein under local anesthesia and Duplex Ultrasound Guidance.
45698408|NCT03012178|Procedure|Mitral valve surgery|ACC/AHA guideline directed mitral valve repair or replacement
45698409|NCT02849158|Other|Biopsy|Rectoscopy with biopsy
45698410|NCT03012412|Behavioral|Mindfulness Based Program for Infertility|The Mindfulness Based Program for Infertility is a manualized group psychological intervention derived from contextual or 3rd wave cognitive-behavioral therapies intended to develop mindfulness and acceptance skills, as well as to promote perceptions of self-efficacy to deal with the demands of an infertility diagnosis and medical treatment. It comprises 10 weekly sessions of approximately 2hr each, run in small groups (ranging from 10 to 13 participants).
45698411|NCT02666638|Other|Control Volunteers|MRI on up to a 7T scanner without contrast.
45698412|NCT02666638|Other|Clinical Volunteers|One-hour MRI on up to a 7T scanner without contrast + 10 minutes of research development imaging using radio frequency (RF) coils
45850362|NCT00003846|Drug|thiotepa|
45698413|NCT03683524|Drug|Dolutegravir (DTG) plus Darunavir/cobicistat (DRV/cobi).|bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)
45698414|NCT03683524|Drug|Current ART|To continue with their current ART
45698415|NCT02246842|Biological|D-Gam® (human anti-D immunoglobulin)|
45698416|NCT02246842|Biological|Rhophylac® (human anti-D immunoglobulin)|
45698417|NCT02623426|Drug|Dexamethasone intravitreal implant 0.7 mg|Standard preparation as described for intravitreal injections.
45850363|NCT00003846|Drug|vincristine sulfate|
45850364|NCT00003846|Procedure|bone marrow ablation with stem cell support|
45850365|NCT00003846|Procedure|peripheral blood stem cell transplantation|
45850366|NCT00003846|Radiation|radiation therapy|
45698418|NCT02623426|Drug|Intravitreal Methotrexate 400 µg|Intravitreal Methotrexate 400 µg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
45698419|NCT02623426|Drug|Intravitreal Ranibizumab 0.5 mg|Intravitreal Ranibizumab 0.5 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
45698420|NCT02617342|Behavioral|Robot-mediated Intervention|The intervention follows the curriculum developed by RoboKind to target and improve upon social interactions through core vocabulary and modeling.
45698421|NCT02550886|Other|Survey|Patients and their caregivers will be asked to complete surveys about their expected and actual time taken off from work. They will also answer questions about the patient's recovery, as well as the patient/caregiver relationship.
45698422|NCT02515474|Procedure|Laparoscopy|After removing the gallbladder, Laparoscopic common bile duct exploration (LCBDE) was performed by one fulltime attending in laparoscopy in a routine fashion. Access from the opening of the anterior wall of common bile duct or from the dilated cystic duct was acceptable, removed stone(s) and irrigated the duct followed by choledochoscope detection simultaneously. Cholangiograms were also can be a alternative method to obtain stone clearance. If needed, all fluoroscopy was performed by the principal author in the presence of and concurrence with the ERCP endoscopist. Once the LCBDE was completed, the incision of the bile duct was sewed intermittently by absorbed threads, or ligated cystic duct. T-tube was acceptable if needed.
45850367|NCT00003852|Biological|filgrastim|
45850368|NCT00003852|Drug|carboplatin|
45850369|NCT00003852|Drug|cyclophosphamide|
45401878|NCT01290172|Drug|Administration of Somatostatin|"6 mg will be diluted in saline in a 60 cc syringe to be infused over 24 h (250 mcg/h). The treatment will be started during the hepatectomy phase, after 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) >= 10 mmHg.~5 cc will be injected in 2 minutes as a single bolus of 500 mcg. Somatostatin will be given a second time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h(infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) >= 90 ml/min * 100 g LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued for 5 days."
45509845|NCT05197127|Device|exoskeleton-based gait training|Gait training included dynamic over-ground walking (both self-selected and fast-paced), variable conditions of multi-directional walking, and training on ramps, stairs, and obstacle negotiation.
45509846|NCT04275817|Other|Data collection|Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
45509847|NCT01376375|Procedure|Acupuncture|
45509848|NCT04632667|Behavioral|Comparison School Group|All control schools will receive training and materials for the CATCH sun safety curriculum. Ray and the Sunbeatables®: A Sun Safety Curriculum is an evidence-based curriculum educates children, parents and teachers about sun protection and promotes sun safety behaviors in an effort to reduce children's lifetime risk of developing skin cancer. Training will be conducted with booster trainings yearly.
45509849|NCT04632667|Behavioral|Intervention School Group|"This intervention includes toothbrushing which will be implemented as a daily activity to develop skills and technique,classroom curriculum, which includes theory-based interactive lessons on oral health care,the physical education component consisting of an activity box containing different structured physical activities that will integrate the nutrition and oral health education messages, all cafeteria-based intervention materials including the tooth friendly Eat Smart guide, signage, nutrition labeling, menu planning and labeling using the tooth-friendly Go-Slow-Whoa CATCH terminology will be provided to the food service staff that is displayed across the cafeteria and sent home to parents and parents will be provided with tools and tips for maintaining oral health with website resources,parent-child homework activities, send-home infographics on dental care, parent-monitored tracking of child oral health,family fun nights in schools, and social media."
45509850|NCT01376453|Drug|Sorafenib|In addition to radiation and 5-FU, sorafenib will be taken by mouth daily every day until the last day of radiation. The dose of sorafenib will be one of the following: 200 mg every other day, 200 mg daily, 400 mg daily, or 800 mg daily
45509851|NCT01376453|Drug|5-Fluorouracil (5-FU)|5-FU will be delivered at a dose of 225 mg/m^2 daily through a catheter in a large vein continuously until the last day of radiation.
45509852|NCT01376453|Radiation|Radiation|Radiation sessions will be daily, Monday through Friday, except for holidays.
45509853|NCT05196893|Behavioral|Link Intervention|Eligible students met with staff trained in specialize intervention skills. Staff met with students multiple times per month, for approximately 10-30 minutes. During these sessions, staff had conversations with students, using intervention communication skills, assessed student stress, and implemented strategies for behavior change. Details of the sessions were recorded in a case management tool. Students were referred to additional resources, as necessary, and these referrals were also recorded. Rates of student office referrals were assessed over time.
45850370|NCT00003852|Drug|epirubicin hydrochloride|
45850371|NCT00003852|Drug|etoposide|
45850372|NCT00003852|Drug|ifosfamide|
45850373|NCT00003852|Drug|paclitaxel|
45401879|NCT01290172|Drug|Administration of placebo|"The placebo treatment will be started during the hepatectomy phase, after the 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) >= 10 mmHg.~5 cc of the 60 cc solution will be injected in 2 minutes as a single bolus of 500 mcg. The placebo will be given a 2nd time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h (infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) >= 90 ml/min * 100 gram LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued everyday to complete 5 days of therapy."
45401880|NCT03861598|Drug|Carvedilol|Carvedilol orally starting at 6.25 mg and increasing to 12.5 mg if tolerated after 1-2 weeks for a total of 4 cycles of treatment.
45401881|NCT01184482|Drug|cetuximab and lapatinib|"Cetuximab: 400 mg/m2 on Day 1 then 250 mg/m2 weekly~Lapatinib: Start once daily on Day 1. Dose escalating cohorts:~750 mg (3 tabs)~1000 mg (4 tabs)~1250 mg (5 tabs)"
45401882|NCT03855124|Device|Posture shirt|Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle actitity, reduce musculoskeletal pain and discomfort.
45698423|NCT02515474|Procedure|Endoscopy|Initially endoscopic retrograde cholangiopancreatography (ERCP) was performed by a fulltime attending and concurrence of the principal author in endoscopy. Patients randomized to ERCP+ LC group were scheduled to undergo the endoscopic procedure using fluoroscopy in the endoscopy center under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Gastric intestinal atony during ERCP was routinely achieved using scopolamine butylbromide injection. Sphincterotomy (EST) and Endoscopic papillary balloon dilatation (EPBD) can be choose accordingly. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible following the ERCP in one month.
45850374|NCT00003852|Drug|thiotepa|
45850375|NCT00003852|Procedure|bone marrow ablation with stem cell support|
45850376|NCT00003852|Procedure|peripheral blood stem cell transplantation|
45850377|NCT00003858|Drug|mitoxantrone hydrochloride|
45509854|NCT05110183|Device|electrical stimulation|A cochlear implant electrode will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software on a laptop computer will be used to control the delivery of a sequence of charge balanced current pules.
45509855|NCT05110183|Other|optical stimulation|Optical fibers will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software will be used to control the delivery of a sequence of charge balanced current pules.
45698424|NCT02249650|Drug|TSB-9-W1|Product name: TSB-9-W1 Unit dose: 100 mg per capsule Dosage form: Capsule Treatment cycle: A treatment cycle consists of 2-day on-dose oral administering and followed by a 3-day off-dose.
45698425|NCT02182492|Drug|Clarithromycin|Clarithromycin 250 mg tablet once daily for 3 months
45850378|NCT00003870|Drug|cyclophosphamide|
45698426|NCT02182492|Drug|Glucocorticoid|Fluticasone propionate nasal spray 200 μg/d for 3 months
45698427|NCT02182804|Device|Olympus|narrow band imaging with magnification
45698428|NCT02182804|Device|Cellvizio|probe-based confocal laser endomicroscopy
45850379|NCT00003870|Drug|methotrexate|
45850380|NCT00003870|Procedure|allogeneic bone marrow transplantation|
45850381|NCT00003870|Radiation|iodine I 131 monoclonal antibody BC8|
45850382|NCT00003870|Radiation|radiation therapy|
45850383|NCT00003876|Drug|polifeprosan 20 with carmustine implant|
45850384|NCT00003876|Procedure|surgical procedure|
45850385|NCT00003876|Radiation|iodine I 125|
45850386|NCT00003882|Drug|anhydrovinblastine|
45850387|NCT00003888|Drug|cisplatin|
45850388|NCT00003888|Drug|docetaxel|
45850389|NCT00003888|Drug|fluorouracil|
45850390|NCT00003888|Radiation|radiation therapy|
45850391|NCT00003894|Drug|thalidomide|
45850392|NCT00003900|Drug|docetaxel|
45850393|NCT00003900|Drug|irinotecan hydrochloride|
45850394|NCT00003906|Drug|Raloxifene|60 mg/day plus placebo for 5 years
45850395|NCT00003906|Drug|Tamoxifen|20 mg/day plus placebo for 5 years
45850396|NCT00003912|Drug|carboplatin|
45850397|NCT00003912|Drug|cisplatin|
45850398|NCT00003912|Drug|doxorubicin hydrochloride|
45850399|NCT00003912|Procedure|conventional surgery|
45850400|NCT00003924|Biological|recombinant interferon alfa|
45698429|NCT01668082|Procedure|surgical resection of a brain tumor|The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.
45509856|NCT05110183|Other|combined optical and electrical stimulation|A short hybrid array consisting of optical sources and electrical contacts will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Biphasic electrical current pulse and optical pulse delivery will be controlled in amplitude and timing by a computer.
45509857|NCT05196581|Drug|BREATHOX 5 sessions|5 sessions
45401883|NCT01184560|Drug|Sibutramine|"○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily"
45401884|NCT01184560|Drug|Orlistat|"○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily"
45401885|NCT03861832|Dietary Supplement|KB220Z|Acts to enhance dopamine
45509858|NCT05196581|Drug|BREATHOX 10 sessions|10 sessions
45509859|NCT05107219|Procedure|Biopsy|Undergo biopsy
45509860|NCT05107219|Procedure|Biospecimen Collection|Undergo collection of luminal fluid
45401886|NCT03861832|Dietary Supplement|Placebo|A placebo that looks the same, but does not contain amino acid precursors or any active ingredients in the nutraceutical
45401887|NCT01290250|Other|Orange juice based beverage enriched in polyphenols|2 daily doses (250 ml each) during 3 months
45401888|NCT03861520|Device|Midtrimester anomaly scan|A detailed anomaly scan to detect soft markers at 16 to 24 weeks pregnancy
45401889|NCT03861520|Genetic|Fetal Karyotyping|Fetal karyotyping after birth to confirm chromosomal anomaly diagnosed clinically
45401890|NCT01184638|Drug|Sevoflurane|1-8% sevoflurane for maintaining the whole period of general anesthesia
45401891|NCT01184638|Drug|Propofol|1-4 mg/kg/h of propofol during the whole period of general anesthesia
45401892|NCT01290328|Drug|Epoetin Alfa|150 units/kg/weekly
45509861|NCT05107219|Procedure|Esophagogastroduodenoscopy|Undergo EGD
45509862|NCT05107219|Drug|Linaclotide|Given PO
45698430|NCT03010306|Other|CASITA|
45850401|NCT00003930|Drug|cisplatin|
45850402|NCT00003930|Drug|gemcitabine hydrochloride|
45850403|NCT00003930|Drug|paclitaxel|
45850404|NCT00003930|Procedure|conventional surgery|
45401893|NCT01184716|Other|Vitamin D fortification|Bread and milk fortified with vitamin D3
45401894|NCT01184794|Drug|levobupivacaine|40 ml over 48 hours
45401895|NCT01587508|Drug|meloxicam/cyclobenzaprine hydrochloride|two oral capsules a day during approximately 07 days
45401896|NCT01587508|Drug|meloxicam - Movatec®|two oral tablet a day during approximately 07 days
45401897|NCT01587508|Drug|cyclobenzaprine - Miosan®|two oral tablet a day during approximately 07 days
45401898|NCT00147498|Drug|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 6 weeks
45401899|NCT00147498|Drug|CP-690,550|Oral tablets administered at a dose of 15 mg BID for 6 weeks
45401900|NCT00147498|Drug|CP-690,550|30 mg BID for 6 weeks
45509863|NCT05107219|Drug|Plecanatide|Given PO
45509864|NCT04569253|Device|TempSure|Non-invasive radiofrequency treatments
45509865|NCT05420779|Drug|TSL-1502 capsules(low dose)|350 mg each time, orally administered QD, every 3 weeks as a treatment cycle.
45509866|NCT05420779|Drug|TSL-1502 capsules(high dose)|500 mg each time, orally administered QD, every 3 weeks as a treatment cycle.
45509867|NCT05420779|Drug|Investigator's choice of chemotherapy|Capecitabine tablets, 1250 mg/m2 each time, BID oral administration; Vinorelbine tartrate injection, 25 ~ 30 mg/m2 each time, intravenous drip (15 ~ 20 min); Eribulin mesylate injection, 1.4 mg/m2 each time, intravenous injection (2 ~ 5 min)
45509868|NCT02547311|Behavioral|Team Clinic|
45509869|NCT01376531|Procedure|continuous veno-venous hemodialysis|continuous veno-venous hemodialysis
45509870|NCT01568125|Drug|Incretin-related drugs|DPP-IV inhibitors are administered via per os. GLP-L receptor agonists are administered via subcutaneous injections.
45509871|NCT05598931|Device|Transcranial Magnetic Stimulation|Subjects will participate in an on-line neuro-navigation session in which 6 TMS coil positions will be recorded.
45509872|NCT02505425|Behavioral|Behavioral Support|"ENABLE CHF-PC includes:~In-person comprehensive Palliative Care Team (PCT) Consultation- as soon as feasible after enrollment.~Palliative Care Nurse Coach (PNC) embedded within HF teams, instituting a phone-based 6-session patient and a 4-session caregiver curriculum followed by monthly phone-based supportive care for 48 weeks or patient death.~The PNC uses the manualized curriculum: Charting Your Course (CYC): An Intervention for Patients with Heart Failure and their Families.~Usual Care: Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines."
45509873|NCT02505425|Behavioral|Usual HF Care|Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
45698431|NCT03010384|Other|Rehabilitation program|
45698432|NCT01163656|Device|Miller Laryngoscope|Device is used to facilitate tracheal intubation.
45698433|NCT01163656|Device|Glidescope Cobalt Video Laryngoscopes|The laryngoscope design with the integration of video technology into the laryngoscope blade.
45698434|NCT01129804|Behavioral|Coping Skills Training|Patients in both treatments will be taught skills to help them keep from drinking.
45698435|NCT01165840|Drug|Dapsone|100 mg PO x 1 dose
45850405|NCT00003930|Radiation|radiation therapy|
45850406|NCT00003936|Drug|bryostatin 1|
45850407|NCT00003942|Biological|RevM10 gene|
45850408|NCT00003942|Biological|RevM10/polAS gene|
45850409|NCT00003942|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45401901|NCT00147498|Other|Placebo|Placebo tablets
45401902|NCT05267704|Device|Samsung Gear Virtual Reality Headset|VR headset displaying preselected game during renal biopsy
45401903|NCT02974036|Other|Patient education for osteoarthritis|Group sessions and optional supervised exercise.
45401904|NCT03856762|Dietary Supplement|traditional Jiangnan diet|traditional Jiangnan diet supplement from Monday to Friday for six months
45401905|NCT03856762|Dietary Supplement|Mediterranean diet|Mediterranean diet supplement from Monday to Friday for six months
45401906|NCT03856762|Dietary Supplement|Current Shanghai diet|current Shanghai diet supplement from Monday to Friday for six months
45401907|NCT01176760|Drug|Dipeptidyl peptidase 4 (DPP 4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
45401908|NCT01176760|Other|oral glucose|50 g glucose dissolved in 300 ml water with 1,5 g paracetamol is to be ingested orally within the first 15 minutes.
45401909|NCT01080066|Other|No Intervention|Subjects administered with Cetuximab, once weekly by intravenous infusion at a first dose of 400 milligram per square meter (mg/m^2) body surface area for 120 minutes infusion period and subsequently at a dose of 250 mg/m^2 for 60 minutes infusion period, will be observed. The maximum infusion rate must not exceed 10 milligram per minute (mg/min).
45401910|NCT01185184|Drug|CP-690,550|Single doses separated by a minimum of 72 hour washout between treatments
45401911|NCT01077882|Behavioral|education on skin disease conditions|information about several skin diseases skin function recommendation on care of skin
45401912|NCT01077882|Behavioral|Stress-reduction techniques|Physical Training yoga mindfulness-based stress reduction
45401913|NCT01077882|Behavioral|Lifestyle factors and psycho-education|by dietician and psychiatrist
45401914|NCT01077882|Other|no educational program|standard care without educational program
45401915|NCT03856606|Behavioral|Prolonged sitting without exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
45401916|NCT03856606|Behavioral|Prolonged sitting with interval exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo a prolonged sit which with will be broken up every hour on the hour by a small bout of interval exercise. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
45850410|NCT00003942|Procedure|peripheral blood stem cell transplantation|
45850411|NCT00003954|Drug|melphalan|Given IV
45401917|NCT04988464|Behavioral|Sleep Scholar|A single-session, internet-based insomnia intervention for college students
45401918|NCT04988464|Behavioral|Building Healthy Habits|A single-session, self-guided, internet-based intervention focused on healthy eating and exercise
45401919|NCT03861754|Behavioral|Lifestyle modification|
45401920|NCT00113568|Drug|Tranexamic acid tablets (XP12B)|Two 650 mg tranexamic acid tablets (XP12B) taken 3 times daily (3900 mg/Day) for a maximum of 5 days during monthly menstruation
45509874|NCT03360721|Drug|Abiraterone Acetate|Given PO
45509875|NCT03360721|Drug|Apalutamide|Given PO
45509876|NCT03360721|Drug|Prednisone|Given PO
45850412|NCT00003954|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous bone marrow or PBSCT
45850413|NCT00003954|Procedure|autologous bone marrow transplantation|Undergo autologous bone marrow or PBSCT
45850414|NCT00003954|Procedure|peripheral blood stem cell transplantation|Undergo autologous bone marrow or PBSCT
45850415|NCT00003954|Radiation|total-body irradiation|Undergo TBI
45401921|NCT05266768|Drug|IBI346|IBI346 Antibody and IBI346 CAR-T cell injection
45401922|NCT03856372|Radiation|Hypofractionated|daily fractions, five fractions per week.
45401923|NCT03856372|Radiation|Conventional|daily fractions, five fractions per week.
45509877|NCT05196425|Genetic|Blood sampling|Blood sample for detection of PARP-1 gene and correlate to changes of the optic disc, RNFL and GCC layers of the retina of MS patients
45509878|NCT03089047|Biological|Transfusion of rejuvenated and washed autolgous RBCs|Rejuvenation refers to the process of adding a mix of solutes (Rejuvesol®, Citra Labs, Braintree, MA; consists of sodium pyruvate, inosine, adenine, mono- and dibasic sodium phosphate) to older, stored (i.e., 2-3 DPG-depleted) blood to immediately restore 2,3-DPG and ATP levels in the stored red blood cells15. Rejuvenation was originally developed to prolong the storage life of rare-phenotype RBC units. It is FDA-approved for use in RBC units stored in CPD, CPDA-1, and AS-1. The major contraindication for the use of Rejuvesol® is in RBC units stored for fewer than 6 days due to high baseline 2,3-DPG and ATP levels. Rejuvenated units must be washed prior to administration to remove residual Rejuvesol that is not approved for iv administration in such concentrations.
45850416|NCT00003954|Procedure|peripheral blood stem cell transplantation|Undergo donor PBSCT
45850417|NCT00003954|Drug|cyclosporine|Given IV and PO
45850418|NCT00003954|Drug|mycophenolate mofetil|Given PO
45850419|NCT00003954|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
45850420|NCT00003960|Drug|busulfan|
45850421|NCT00003960|Drug|cyclophosphamide|
45850422|NCT00003960|Drug|methylprednisolone|
45850423|NCT00003960|Procedure|allogeneic bone marrow transplantation|
45850424|NCT00003960|Procedure|in vitro-treated bone marrow transplantation|
45850425|NCT00003966|Drug|defibrotide|
45401924|NCT01185262|Drug|Lenalidomida and Rituximab|"Lenalidomide: Oral use. It will be administered from day 1 to 21 of 28 days cycles in a total of 6 cycles.~Rituximab, intravenous use. The dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).~In the first cycle Rituximab will be administered in two divided doses:100mg/m2 total on day 1 and the rest up to 375mg/m2 on day 2.~If lenalidomide treatment starts on day 1, Rituximab will be administered, in this first cycle, on days -2 (100 mg/m2) and -1 (275 mg/m2).~In the second and subsequent cycles, 500 mg/m2 of Rituximab will be administered on day -1."
45401925|NCT03855358|Drug|TQB2450 Injection and Anlotinib Hydrochioride Capsules|TQB2450 1200mg intravenously (IV) every-3-weeks (Q3W) and Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
45401926|NCT01291030|Dietary Supplement|magnesium supplementation|The supplementation starts with 450 mg of magnesium oxide daily, up to a maximum of 3 times 450 mg daily, while aiming at a serum magnesium level of > 1,9 mg/dl.
45401927|NCT00113490|Biological|motavizumab (MEDI-524)|Patients will receive 15 mg/kg MEDI-524 administered IM every 30 days for a total of 4-5 injections.
45401928|NCT00113490|Biological|palivizumab 15 mg/kg|Patients will receive 15 mg/kg palivizumab administered IM every 30 days for a total of 4-5 injections.
45401929|NCT01182922|Behavioral|Invitation letter|Invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
45698436|NCT04351854|Other|Retrospective data collection|Retrospective data collection to identify predicting factors in the clinical picture of COVID-19 patients presenting to the ED.
45698437|NCT00952692|Biological|dHER2 + AS15 ASCI|"Patients will receive dHER2 ASCI injections IM every 2 weeks for 2 cycles . In between cycles there is 4 weeks without vaccine.~For each dose of 500µg of dHER2 + AS15 ASCI, two sterile glass vials will be supplied:~One vial with the lyophilized preparation containing 500 ug of recombinant dHER2 antigen combined with the immunostimulant.~One vial with liquid adjuvant diluent. The final dHER2 + AS15 ASCI for administration is obtained by reconstitution of the lyophilized preparation with the adjuvant diluents. A dHER2 + AS15 ASCI dose consists of 0.5 ml."
45698438|NCT00952692|Drug|Lapatinib|The daily dose of lapatinib is 5 tablets (1250 mg of lapatinib) taken orally at approximately the same time each day for 43 weeks while on study.
45698439|NCT01168024|Device|CINCOR™ System and contrast conservation unit (CCS-1)|Catheter based system to reduce and remove contrast media and contrast modulator to reduce contrast media
45698440|NCT01168024|Other|Standard of Care plus peri-procedural hydration|The control group will receive a peri and post-procedural hydration rate.
45698441|NCT05389566|Diagnostic Test|Quantative Sensory Testing|Evaluation of small fiber neuropathy
45850426|NCT00003972|Biological|filgrastim|
45401930|NCT02524522|Device|INTELLiVENT-ASV mode|Discontinuation with INTELLiVENT-ASV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided by quick-wean option of INTELLiVENT-ASV mode
45401931|NCT02524522|Device|SIMV mode|Discontinuation with SIMV mode: discontinuation with SIMV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided in SIMV mode using physician driven algorithm
45401932|NCT01326624|Device|wearable defibrillator (LifeVest)|LifeVest wearable defibrillator for unattended treatment of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation
45509879|NCT03089047|Biological|Transfusion of washed autolgous RBCs|Autologous RBCs will be washed prior to transfusion to maintain blinding and equalize volume and Hct with the rejuvenated and washed intervention arm
45698442|NCT05389566|Diagnostic Test|NCStat-DPN-Check|Evaluation of large fiber neuropathy
45698443|NCT05389566|Diagnostic Test|Composite Autonomic Symptom Score 31|Evaluation of autonomic neuropathy
45850427|NCT00003972|Biological|sargramostim|
45850428|NCT00003972|Drug|busulfan|
45401933|NCT01176994|Device|Formulations for in-vivo fixation|Formulations are comprised of non-toxic ingredients used in dermatology.
45401934|NCT00146640|Drug|MR Prednisone|Participants will receive tablets containing MR prednisone (to achieve the appropriate dose of 3-10 milligrams [mg] prednisone per day) at bed time.
45401935|NCT00146640|Drug|IR Prednisone|Participants will receive tablets containing IR prednisone (to achieve the appropriate dose of 3-10 mg prednisone per day) in the morning.
45401936|NCT00146640|Drug|Placebo - MR Prednisone|Participants will receive placebo matching to MR prednisone tablet at bed time.
45401937|NCT00146640|Drug|Placebo - IR Prednisone|Participants will receive placebo matching to IR prednisone tablet in the morning.
45698444|NCT05389566|Diagnostic Test|Computerized dynamic posturography|Evaluation of dynamic postural control
45698445|NCT05389566|Diagnostic Test|Video Head Impulse Test|Evaluation of vertigo and the vestibular organ
45698446|NCT05389566|Diagnostic Test|Accelerometer|Evaluation of gait pattern
45698447|NCT05389566|Diagnostic Test|Handgrip strength|Evaluation of muscle strength
45850429|NCT00003972|Drug|carboplatin|
45850430|NCT00003972|Drug|cyclophosphamide|
45850431|NCT00003972|Drug|melphalan|
45850432|NCT00003972|Drug|paclitaxel|
45850433|NCT00003972|Drug|tamoxifen citrate|
45850434|NCT00003972|Drug|thiotepa|
45850435|NCT00003972|Procedure|peripheral blood stem cell transplantation|
45850436|NCT00003972|Radiation|radiation therapy|
45850437|NCT00003984|Biological|lintuzumab|
45850438|NCT00003996|Drug|carmustine|
45850439|NCT00003996|Drug|chemotherapy|
45850440|NCT00003996|Drug|cisplatin|
45850441|NCT00003996|Drug|etoposide|
45850442|NCT00003996|Radiation|radiation therapy|
45850443|NCT00004002|Drug|bortezomib|
45850444|NCT00004008|Drug|bryostatin 1|
45850445|NCT00004014|Drug|pegylated liposomal doxorubicin hydrochloride|Doxorubicin HCl liposome IV over 45 minutes every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then every 9 weeks thereafter.
45850446|NCT00004026|Drug|CT-2584|
45850447|NCT00004026|Drug|chemotherapy|
45850448|NCT00004032|Biological|ALVAC-hB7.1|Given IP
45850449|NCT00004032|Biological|recombinant interferon gamma|Given IP
45850450|NCT00004032|Other|laboratory biomarker analysis|Correlative studies
45401938|NCT01183000|Procedure|Closure of the peritoneum at cs|Injection of 5 mg Marcaine (anesthetic solution) to the leg
45401939|NCT01185418|Drug|risperidone|
45401940|NCT01185418|Drug|aripiprazole|
45401941|NCT01185418|Drug|haloperidol|
45401942|NCT01185418|Drug|amisulpride|
45401943|NCT01185418|Drug|lactose|
45401944|NCT03856450|Device|DTS|Subjects undergo wrist imaging using DTS.
45401945|NCT03856450|Device|X-ray|Subjects undergo wrist imaging using standard X-ray imaging.
45401946|NCT03856450|Device|MRI or CT|Subjects may undergo wrist imaging using MRI or CT.
45401947|NCT01183156|Behavioral|Re-invitation letter|Re-invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
45401948|NCT01183156|Behavioral|Invitation to educational meeting|Invitation will be sent 6 weeks prior to educational meeting date and followed by a reminding letter 3 weeks later. Educational meetings will be held in a local culture developement centers and conducted by a medical team responsible for the Polish Colorectal Cancer Screening Program. The aim of the meeting is to overcome barriers to screening colonoscopy. The program of the meeting is tailored to individual needs, doubts, and concerns of the participating group as assessed using brief survey at the beginning of the meeting. The major points to be discussed are: risk and benefit of screening, colorectal cancer risk, pain and sedation, preparation to colonoscopy, consecutive stages of the procedure, comfort and embarrassment.
45401949|NCT01185574|Dietary Supplement|Vitamin D supplementation|Vitamin D2 50,000 IU will be administered once a week for six months.
45401950|NCT03861364|Drug|Propofol|2,4 mg/kg
45401951|NCT03861364|Drug|Propofol|1,4 mg/kg
45698448|NCT05389566|Diagnostic Test|Dual Energy X-ray Absorbtimetry scan|Evaluation of body composition
45850451|NCT00004038|Biological|Ad5CMV-p53 gene|
45401952|NCT01177072|Other|Cognitive Processing Therapy|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
45401953|NCT01177072|Other|Components-Based Intervention|This is a 'components-based' intervention include psychoeducation, relaxation, life-enhancing skills (problems solving and safety planning), exposure, and cognitive processing of life problems and traumatic events. The duration of sessions are approximately one hour), the expected frequency of treatment is weekly, and recommended number of sessions are 12.
45401954|NCT01177150|Drug|JNJ-28431754/ Placebo|Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses, the evening dose will be administered at 10 hours after the morning dose.
45401955|NCT01177150|Drug|JNJ-28431754|Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
45401956|NCT05250466|Procedure|Radiofrequency technology|The vulva and vagina were routinely disinfected with iodophor, the negative plate was placed on the patient's waist and abdomen, and the vulva module was selected for treatment for 10 minutes per side, for a total of 20 minutes. Parameters: power 10-20W, temperature 38-42C°, once every 10 days, 5 times in total
45850452|NCT00004038|Drug|chemotherapy|
45401957|NCT05250466|Procedure|Electrical stimulation|Routine vulvovaginal disinfection with iodophor, vaginal probes are placed in channel A, electrode pads are placed in channels B\C\D respectively, the frequency of electrical stimulation (the most comfortable amount) is adjusted, 10 times is a course of treatment, and mild lesions are treated for 1-2 courses of treatment , 2 to 3 courses of treatment for moderate to severe lesions.
45401958|NCT01185730|Procedure|Right Heart Catheterization|all patients of the all centers will have Right Heart Catheterization at the diagnosis
45401959|NCT03855202|Biological|CBMNC|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
45698449|NCT05389566|Diagnostic Test|Force Plate Platform|Evaluation of balance while standing still
45850453|NCT00004050|Biological|Leuvectin|Leuvectin injected intratumorally followed by prostatectomy
45401960|NCT03855202|Biological|PS+CBMNC|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
45698450|NCT01168726|Behavioral|Protective Behavioral Strategies|Personalized feedback on use of protective behavioral strategies.
45698451|NCT01168726|Behavioral|Personalized Normative Feedback|Personalized feedback on how one's own drinking compares to relevant norms.
45698452|NCT01168726|Behavioral|Alcohol Education|Educational information about harms associated with heavy drinking.
45698453|NCT03535506|Drug|Palbociclib|Palbociclib capsules for oral administration contain 125 mg, 100 mg, or 75 mg of palbociclib, a kinase inhibitor.
45698454|NCT01170754|Drug|PEG-3350 and Gatorade|255 grams of miralax mixed with 64 ounces gatorade for colonoscopy preparation.
45698455|NCT01170754|Drug|Golytely 4 liters|Golytely 4 liters
45698456|NCT02522832|Other|Titre 1|Virus infection
45698457|NCT02522832|Other|Titre 2|Virus infection
45698458|NCT02522832|Other|Titre 3|Virus infection
45698459|NCT05166330|Drug|Ketofol equal ratio|5mg/ml10 mL propofol (100 mg) will be mixed with 2 mL ketamine (100 mg) and then diluted to a total volume of 20 mL to have a final concentration of 5 mg/mL propofol and 5 mg/mL ketamine
45401961|NCT03855202|Biological|PS|PS,dose is 70mg/kg
45401962|NCT03855202|Other|Placeo|0.9% sodium chloride installation after 24 hours
45401963|NCT01185808|Biological|Vitamin D|Vitamin D 5000IU/day for 6 weeks
45401964|NCT01183624|Other|Herbal Patch|1 herbal patch applied for approximately 8 hours per day for 14 days
45401965|NCT01183624|Other|Placebo Patch|Control patch with no herbal ingredients
45401966|NCT01291186|Drug|BPV6NO|intrathecal bupivacaine 6 mg for BMI less than 27.5 kg/m2
45401967|NCT01291186|Drug|BPV7NO|intrathecal bupivacaine 7 mg for BMI less than 27.5 kg/m2
45401968|NCT01291186|Drug|BPV8NO|intrathecal bupivacaine 8 mg for BMI less than 27.5 kg/m2
45401969|NCT01291186|Drug|BPV9NO|intrathecal bupivacaine 9 mg for BMI less than 27.5 kg/m2
45401970|NCT01291186|Drug|BPV10NO|intrathecal bupivacaine 10 mg for BMI less than 27.5 kg/m2
45401971|NCT01291186|Drug|BPV11NO|intrathecal bupivacaine 11 mg for BMI less than 27.5 kg/m2
45401972|NCT01291186|Drug|BPV6O|intrathecal bupivacaine 6 mg for BMI over 27.5 kg/m2
45850454|NCT00004056|Biological|filgrastim|
45850455|NCT00004056|Drug|asparaginase|
45401973|NCT01291186|Drug|BPV7O|intrathecal bupivacaine 7 mg for BMI over 27.5 kg/m2
45401974|NCT01291186|Drug|BPV8O|intrathecal bupivacaine 8 mg for BMI over 27.5 kg/m2
45401975|NCT01291186|Drug|BPV9O|intrathecal bupivacaine 9 mg for BMI over 27.5 kg/m2
45401976|NCT01291186|Drug|BPV10O|intrathecal bupivacaine 10 mg for BMI over 27.5 kg/m2
45401977|NCT01291186|Drug|BPV11O|intrathecal bupivacaine 11 mg for BMI over 27.5 kg/m2
45401978|NCT04979338|Other|Ultrasound guided Continuous Infraclavicular Brachial Plexus Block|20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op [administered by anesthesiologist]
45401979|NCT04979338|Other|Ultrasound guided Continuous Femoral Nerve Block|20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op [administered by anesthesiologist]
45401980|NCT04979338|Other|Ultrasound guided Pudendal Nerve Block|20-40cc of 0.25% bupivacaine + 1:200K epinephrine [administered by anesthesiologist, pre-incision]
45401981|NCT04979338|Drug|Bupivacaine|0.25% or 0.5% with or without 1:200K epinephrine
45401982|NCT04979338|Other|Bilateral ultrasound guided Transversus Abdominis Plane Block|40-60cc of 0.25% bupivacaine + 1:200K epinephrine [administered by anesthesiologist post-op or at end of surgery]
45401983|NCT04979338|Other|Bilateral spermatic cord block|10cc per spermatic cord of 0.5% bupivacaine [administered by surgeon @ intraop]
45401984|NCT04979338|Other|Pecs I & II Block|0.25% bupivacaine: 15-30mL per side for Pecs I-III
45401985|NCT04979338|Other|Local anesthetic|0.25% or 0.5% bupivacaine into the appropriate surgical site
45401986|NCT01177306|Drug|extended release guanfacine|1-4 mg daily. Dose determined by response of ADHD symptoms to drug and by body mass limitations
45401987|NCT03856294|Drug|Rikkunshito|Rikkunshito, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
45401988|NCT03856294|Drug|Placebos|Placebo, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
45401989|NCT01183702|Procedure|LASIK surgery|Participants have received LASIK surgery and their eyes are healthy.
45401990|NCT01183702|Other|No Intervention|Participant has healthy eyes not altered by LASIK surgery.
45850456|NCT00004056|Drug|cytarabine|
45401991|NCT03854968|Other|Quality control|The performance of the home mechanical ventilator of all patients in the study will be evaluated with a portable device
45401992|NCT01185886|Genetic|gene expression analysis|
45401993|NCT01185886|Genetic|mutation analysis|
45401994|NCT01185886|Genetic|polymorphism analysis|
45401995|NCT01185886|Other|biologic sample preservation procedure|
45401996|NCT01185886|Other|laboratory biomarker analysis|
45401997|NCT01185886|Other|pharmacogenomic studies|
45401998|NCT01290406|Drug|BEZ235|
45401999|NCT03854890|Drug|Indocyanine Green|Indocyanine Green will be injected to the submucosal layer around the lesion one day before surgery.
45850457|NCT00004056|Drug|daunorubicin hydrochloride|
45850458|NCT00004056|Drug|melphalan|
45850459|NCT00004056|Drug|thioguanine|
45850460|NCT00004056|Procedure|peripheral blood stem cell transplantation|
45850461|NCT00004062|Drug|azacitidine|
45850462|NCT00004062|Drug|liothyronine sodium|
45850463|NCT00004062|Radiation|iodine I 131|
45850464|NCT00004068|Drug|irinotecan hydrochloride|
45850465|NCT00004068|Drug|temozolomide|
45850466|NCT00004068|Procedure|conventional surgery|
45850467|NCT00004068|Radiation|radiation therapy|
45850468|NCT00004074|Biological|recombinant interleukin-12|Given IV
45850469|NCT00004074|Biological|ABI-007/carboplatin/trastuzumab|Given IV
45850470|NCT00004080|Biological|recombinant adenovirus-p53 SCH-58500|
45698460|NCT05166330|Drug|Ketofol 1:3 ratio|15 mL propofol (150 mg) will be mixed with 1 mL ketamine (50 mg) and then diluted to a total volume of 20 mL to have a final concentration of 7.5 mg/mL propofol and 2.5 mg/mL ketamine).
45698461|NCT01378104|Drug|peginterferon alfa 2a (pegasys)|dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable
45850471|NCT00004080|Procedure|conventional surgery|
45850472|NCT00004086|Biological|filgrastim|
45850473|NCT00004086|Drug|cisplatin|
45850474|NCT00004086|Drug|cytarabine|
45402000|NCT03854812|Drug|Magnesium Sulphate|a loading of 50 mg/kg in 15 minutes of Magnesium sulphate, and will be followed by continuous infusion at 1 ml/kg/h of 15 mg/ml solution
45402001|NCT03854812|Drug|Fentanyl|loading of 1 mcg/kg in over 15 minutes of fentanyl then will receive continuous infusion starting at 1 ml /kg/h. of 0.5 mcg/ml solution
45402002|NCT03854812|Drug|Propofol|0.5-1.5 mg/kg bolus of propofol over 10 minutes to achieve target Ramsay sedation scale (RSS) of 3 (respond to command), if RSS afterwards does not reach 3 a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, and will be followed by 1-2.5 mg/kg/hr infusion to maintain Intraoperative BIS readings between 60 - 80
45402003|NCT01186042|Other|Observational|No intervention
45402004|NCT03861208|Other|diet|foods with high satiation (high protein and high fiber foods) are offered to modify children's hunger and fullness ratings postprandial
45402005|NCT03861208|Other|usual diet|foods representing the usually provided foods at childcare are offered
45402006|NCT03860896|Drug|GB004|GB0004 high dose
45402007|NCT03860896|Drug|Placebo|Placebo
45402008|NCT03860896|Drug|GB004|GB004 low dose
45402009|NCT01183936|Procedure|2-cm margin|Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
45402010|NCT01183936|Procedure|4-cm margin|Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
45402011|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
45402012|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
45698462|NCT01378104|Drug|peginterferon alfa-2a (pegasys)|These patients would be treated with standard dose 180ug /week for 48 weeks. In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.
45698463|NCT03344250|Drug|EGFR BATs with TMZ following SOC RT/TMZ|Standard of care: 6 weeks of RT and TMZ and 6 cycles of TMZ (150-200 mg/m2) on days 1-5 of each 28 day cycle Experimental: EGFR BATs 2 and 3 weeks after completing RT, and then on day 21 of each cycle of TMZ.
45698464|NCT03344250|Drug|Weekly EGFR BATs following SOC RT/TMZ|Standard of care: 6 weeks of RT and TMZ Experimental: 8 weekly doses of EGFR BATs following SOC RT and TMZ
45698465|NCT01130740|Behavioral|Osteoarthritis Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations two times (0 and 6 months); patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
45850475|NCT00004086|Drug|etoposide|
45850476|NCT00004086|Drug|ifosfamide|
45850477|NCT00004086|Procedure|autologous bone marrow transplantation|
45850478|NCT00004086|Procedure|peripheral blood stem cell transplantation|
45850479|NCT00004086|Radiation|indium In 111 LL2 IgG|
45850480|NCT00004086|Radiation|yttrium Y 90 epratuzumab|
45850481|NCT00004104|Biological|liposomal interleukin-2|
45850482|NCT00004104|Biological|polyvalent melanoma vaccine|
45850483|NCT00004104|Biological|recombinant interferon alfa|
45850484|NCT00004110|Biological|monoclonal antibody 3F8|
45850485|NCT00004110|Drug|etoposide|
45850486|NCT00004110|Drug|isotretinoin|
45850487|NCT00004122|Biological|BCG vaccine|
45850488|NCT00004122|Biological|recombinant interferon alfa|
45850489|NCT00004128|Biological|aldesleukin|
45850490|NCT00004128|Biological|filgrastim|
45850491|NCT00004128|Drug|busulfan|
45850492|NCT00004128|Drug|cyclophosphamide|
45850493|NCT00004128|Drug|cytarabine|
45850494|NCT00004128|Drug|daunorubicin hydrochloride|
45850495|NCT00004128|Drug|etoposide|
45850496|NCT00004128|Procedure|autologous bone marrow transplantation|
45850497|NCT00004128|Procedure|peripheral blood stem cell transplantation|
45850498|NCT00004128|Radiation|radiation therapy|
45850499|NCT00004152|Drug|iodinated contrast dye|
45850500|NCT00004152|Procedure|computed tomography|
45850501|NCT00004152|Procedure|positron emission tomography|
45850502|NCT00004152|Radiation|fludeoxyglucose F 18|
45850503|NCT00004158|Drug|melphalan|
45850504|NCT00004158|Procedure|peripheral blood stem cell transplantation|
45850505|NCT00004158|Radiation|holmium Ho 166 DOTMP|
45850506|NCT00004164|Biological|filgrastim|
45850507|NCT00004164|Drug|cisplatin|
45850508|NCT00004164|Drug|docetaxel|
45850509|NCT00004164|Drug|fluorouracil|
45850510|NCT00004164|Drug|leucovorin calcium|
45850511|NCT00004164|Radiation|radiation therapy|
45402013|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
45402014|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
45402015|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
45402016|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
45402017|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
45402018|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
45402019|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
45509880|NCT05009719|Biological|Prophylactic Donor lymphocytes infusions|"Donor lymphocytes is taken by apheresis or dose of blood from allogeneic donor. After apheresis lymphocytes arel freezed for next using. DLI is transfused to patients IV using central venous access.~Donor lymphocytes infusion start from D+60 - D+100 and continue with escalating doses every 1.5-3 months during first year after HSCT up to appearance of GVHD or signs of disease. First dose is 1*10*6 CD3+/kg. Subsequent doses increases by 0.5 log for haploidentical and unrelated donor and 1 log for sibling donor up to 1*10*8 CD3+/kg."
45509881|NCT05009719|Biological|Preventive Donor lymphocytes infusions|"Donor lymphocytes is taken by apheresis or dose of blood from allogeneic donor. After apheresis lymphocytes freeze for next using. DLI are transfused to patients IV using central venous access.~Donor lymphocytes infusion continue with escalating doses every 1.5-3 months up to achieving MRD negative status or appearance of GVHD or signs of active disease.~First dose is 1*10*6 CD3+/kg for patients without previous GVHD and 1*10*5 CD3+/kg for patients with previous GVHD. Subsequent doses increases by 0.5 log for haploidentical and unrelated donor and 1 log for sibling donor up to 1*10*8 CD3+/kg."
45509882|NCT04776265|Other|Evaluation of therapeutical approach after ASCT|Evaluation of therapeutical approach after ASCT
45509883|NCT05196113|Behavioral|sipIT|Intervention has two components: (a) education about fluid intake guidelines and encouragement them to adhere to those guidelines (i.e., drink enough to produce >2.5 L of urine daily), and (b) just-in-time adaptive intervention using a semi-automated tracking system to detect drinking and, following lapses, trigger reminder messages
45509884|NCT01371006|Drug|low dose|efavirenz single dosing once daily
45509885|NCT01371006|Drug|normal dose|efavirenz once daily
45509886|NCT01371006|Drug|low dose|Efavirenz single dosing once daily
45509887|NCT05195957|Procedure|Robotic tranversus abdominis release operation|Mini-invasive robotic-assisted TAR using either DaVinci Xi or Si systems and 6 laparoscopic ports.
45715284|NCT05049226|Biological|AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) half dose|"Astrazeneca COVID-19 (ChAdOx1 AZD1222) vaccine:~One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S* recombinant) 5 × 10^10 viral particles (vp)~*Recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike glycoprotein. Produced in genetically modified human embryonic kidney (HEK) 293 cells.~Administer: Intramuscular (IM) injection in the deltoid muscle"
45715285|NCT05049226|Biological|Pfizer/BioNTech BNT162b2 vaccine (PF) half dose|"Pfizer-BioNTech COVID-19 (BNT162b2) vaccine:~Diluent: 0.9% sodium chloride (normal saline, preservative-free)~Administer: Intramuscular (IM) injection in the deltoid muscle"
45715286|NCT05006872|Device|DIABE-TEXT|Participants will receive 170 text messages in their mobile phones during twelve months.
45715287|NCT05005546|Behavioral|Yoga|Yoga will be applied to mothers in the yoga group
45715288|NCT05005546|Behavioral|Laughter Yoga|Laughter Yoga will be applied to mothers in the yoga group
45850512|NCT00004176|Drug|amifostine trihydrate|
45850513|NCT00004176|Drug|cisplatin|
45402020|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
45402021|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
45850514|NCT00004176|Drug|etoposide|
45850515|NCT00004176|Radiation|radiation therapy|
45850516|NCT00004188|Biological|filgrastim|Given IV
45850517|NCT00004188|Drug|carboplatin|Given IV
45850518|NCT00004188|Drug|cisplatin|Given IV
45402022|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
45402023|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
45402024|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
45402025|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
45402026|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
45698466|NCT05397288|Behavioral|Resistance exercise (R)|"A 6-month program led by trained young-old exercise coaches consisting of structured training with 5 progressive levels of intensity, with protocols for implementation in a home surrounding and community center settings. During the 6-month program, group practice and home visit (individual) sessions (45 mins each) are delivered in a tapering schedule:~1st month: group practice (1 time/week), home visits (2 times/week)~2nd month: group practice (1 time/week), home visit (1 time/week), phone call (1 time/week)~3rd month: group practice (1 time/week), phone calls (2 times/week)~4th month: phone calls (2 times/week)~5th month: phone calls (1 time/week)~6th month: weaning period"
45698467|NCT05397288|Behavioral|Aerobic exercise (A)|"A 6-month programs led by trained young-old exercise coaches consisting of structured training with 5 progressive levels of intensity, with protocols for implementation in a home surrounding and community center settings. During the 6-month program, group practice and home visit (individual) (45 mins each) are delivered in a tapering schedule:~1st month: group practice (1 time/week), home visits (2 times/week)~2nd month: group practice (1 time/week), home visit (1 time/week), phone call (1 time/week)~3rd month: group practice (1 time/week), phone calls (2 times/week)~4th month: phone calls (2 times/week)~5th month: phone calls (1 time/week)~6th month: weaning period"
45698468|NCT05397288|Behavioral|Healthy lifestyle education (E)|"A 6-month program led by retired nurses covering topics including nutrition, sleep, medication, cognition, and exercising. During the 6-month program, group talks and individual consultation (45 mins each) are delivered in a tapering schedule:~1st month: group talk (1 time/week), individual consultation (2 times/week)~2nd month: group talk (1 time/week), individual consultation (1 time/week), phone call (1 time/week)~3rd month: group talk (1 time/week), phone calls (2 times/week)~4th month: phone calls (2 times/week)~5th month: phone calls (1 time/week)~6th month: weaning period"
45698469|NCT04453644|Other|Muscle static stretching|On day-I: Static Stretching done for 2 minutes (SS2), on day-II: Static Stretching done for 4 minutes (SS4), and on day-III: Static Stretching done for 8 minutes (SS8).
45698470|NCT05166174|Procedure|Transvaginal ultrasound in the third trimester pregnancy|Ultrasonographic transvaginal exam in patients at third trimester pregnancy (34-38 weeks of gestation)
45698471|NCT05396976|Behavioral|Yoga and Muscle Relaxation Exercise Practices|Yoga and Muscle Relaxation Exercise Practices will be done two days a week for 10 weeks.
45698472|NCT01131052|Drug|Insulin Glargine|glargine once a day
45698473|NCT01131052|Drug|Insulin|sliding scale regular insulin (SSRI) given before meals and at bedtime as needed
45698474|NCT01131052|Drug|Insulin glulisine|glulisine given as needed before meals
45698475|NCT03687138|Other|24h urin sample|The samples will analyzed by proteomic techniques
45698476|NCT01132144|Procedure|Endometrial injury|"Evaluate the position and size of the uterus by transabdominal ultrasonography, with the bladder comfortably full.~Identify the cervix with a disposable speculum. Open one sealed opaque envelope for allocation.~Endometrial injury:~Slide the Pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France) gently through the cervix up to the uterine fundus. Transbadominal ultrasound might be used to confirm position.~Draw back the piston to the end of the biopsy cannula until it locks creating a negative pressure.~Sweep the uterine fundus slowly several times up to the internal orifice of the cervix, using regular to-and-fro movements while rotating the sampler to include the whole uterine cavity in the specimen, for 30 seconds or until participant ask for stopping."
45698477|NCT01132144|Procedure|Control group|The investigator will dry the cervix with gauze and forceps for for 30 seconds or until participant ask for stopping.
45698478|NCT01379274|Drug|Lenalidomide and azacitidine combination|"lenalidomide 10 mg will be administered orally on Days 1-28 of each 28-day cycle. Patients who fail to achieve an erythroid response per 2006 IWG criteria after 3 cycles of monotherapy will receive lenalidomide at the same dose administered in cycle 3 and low-dose azacitidine25 mg/m2 subcutaneously (SC) or intravenously (IV) for 5 days (on Days 1-5) of every 28-day cycle.~Patients who fail to respond (2006 IWG criteria) after receiving two cycles of combination therapy will receive lenalidomide at the same dose administered in Cycle 3 and azacitidine 50 mg/m2 SC or IV given daily on Days 1-5 of each 28-day cycle, if no grade 4 toxicity developed or no delay greater than 2 weeks in starting a new cycle was experienced during the first 2 cycles of combination therapy."
45698479|NCT05389410|Device|PICO 7|Participant will receive 7 days of NPWT following revision hip or revision knee surgery.
45850519|NCT00004188|Drug|cyclophosphamide|Given IV
45402027|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
45402028|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
45402029|NCT01186120|Device|Biolimus A9-eluting stent|drug-eluting stent
45402030|NCT01186120|Device|Everolimus-eluting stent|drug-eluting stent
45509888|NCT05195957|Procedure|Open transversus abdominis release operation|Original open TAR using midline incision.
45850520|NCT00004188|Drug|doxorubicin hydrochloride|Given IV
45850521|NCT00004188|Drug|etoposide|Given IV
45698480|NCT05389410|Device|PICO 14|Participant will receive 14 days of NPWT following revision hip or revision knee surgery.
45402031|NCT01184170|Behavioral|overfeeding|Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits.
45698481|NCT01171690|Drug|Teriparatide|The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
45402032|NCT01186198|Device|MINI TREK RX 1.20 mm Coronary Dilatation Catheter|Enlarging coronary luminal diameter during percutaneous coronary intervention (PCI) procedures in subjects with ischemic heart disease due to stenotic lesions
45698482|NCT03153384|Procedure|Blood Culture|For each patient, one single high volume blood culture (3 aerobic and 3 anaerobic of 8 to 10 mL each, numbered), and then 2 samples of 16 to 20 mL (one aerobic bottle and one anaerobic for each sample).
45698483|NCT02522988|Behavioral|Open-label placebo intervention|An open-label placebo intervention is an administered placebo that is fully disclosed to participants. It is delivered with a script that tells participants they are receiving placebos; placebos have been found to have effects that are comparable to some clinical treatments; placebos work because of conditioning, expectancies, interactions with care team and biochemical factors (i.e., dopamine, endorphins). Participants are given placebos to take for a 3-week period and will not receive placebos for a 4-week period (including a one-week washout period).
45698484|NCT05396742|Drug|Ravulizumab|Solution for infusion or injection, as applicable
45509889|NCT05009173|Procedure|Lumbar puncture using the stylet-in technique|This method consists of inserting the needle with the stylet-in, then only remove the stylet once the desired depth is achieved and CSF flow is expected. If no CSF comes back, the stylet is replaced before continuing to advance the needle until the subarachnoid space is entered. This is the technique generally used in our emergency department and will serve as the control treatment group.
45698485|NCT05396742|Drug|rHuPH20|Solution for infusion
45698486|NCT01171924|Drug|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively for 5 days on each 14 day cycle.
45698487|NCT01171924|Drug|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 on Monday, Wednesday, Friday for three consecutive weeks of each 28 day cycle.
45402033|NCT01287910|Other|Cardiac MRI|Cardiac MRI within 30 days prior to TMR procedure and 6 months after TMR procedure.
45402034|NCT05666674|Other|TSA algorithms|Our study will be composed of an experimental and an active comparator (i.e., control) arm. Both arms will perform a postural tremor test (PTT) to elicit parkinsonian tremors. The PTT is where subjects stabilize their backs against a wall and position their hands in the air against gravity for two minutes. The experimental arm will receive VR plus activated Tremor Stabilization Algorithms (TSA-ON) while the active comparator arm will receive VR only (TSA-OFF). Thus, subjects in the experimental arm will not see their digital arms tremor while those in the active comparator arm will. Our primary outcome is the severity of PTT elicited tremors. Tremors will be recorded by VR motion-capture controllers.
45698488|NCT05396664|Behavioral|ATWA|The Adolescent Transition in West Africa (ATWA) program is an in-school (Niger, Mali, Burkina Faso) and out-of-school (Niger and Mali) educational intervention implemented by local staff members at Save the Children, local community members, and teachers. ATWA provides internationally-recognized life skills education (LSE) to adolescents ages 10-19 years, and seeks to improve adolescents' knowledge and behaviors regarding sexual and reproductive health and rights. Outcome indicators to assess knowledge, behavior and attitudes of adolescents will vary by adolescent demographics as well as by country context, as based on the final set of curriculum deemed appropriate by the respective Ministries of Education (MOE).
45698489|NCT05389254|Device|continuous glucose monitoring system|use real-time CGM system to check and adjust blood glucose
45698490|NCT05389254|Device|capillary blood glucose monitoring|monitor blood glucose with finger blood; real-time CGM is blind to both participants and researchers
45402035|NCT03860506|Drug|PSI-697|
45402036|NCT03860506|Drug|Placebo|
45402037|NCT01186354|Behavioral|Receiving results via genetic counselor|participants will receive genetic risk information for Type 2 diabetes from a board certified genetic counselor
45509890|NCT05009173|Procedure|Lumbar puncture using the stylet-out technique|This method consists of inserting the needle through the epidermis and the dermis, which is estimated as a 0.5 to 1 cm length in children, then remove the stylet before progressing through the other structures until the subarachnoid space is entered. This approach will be used in the experimental technique group.
45509891|NCT04864925|Drug|Colgate Total Clean Mint|2 minutes of whole mouth toothbrushing
45698491|NCT01132378|Procedure|Total knee arthroplasty|staged bilateral total knee arthroplasty (not more than 7 days between surgeries)
45698492|NCT05389176|Drug|Esmolol|a continuous esmolol infusion titrated to maintain heart rate between 70/min and 100/min
45698493|NCT05396508|Procedure|interfacial injection|10 ml of bupivacaine and steroid injection was applied between the leaves of the thoracolumbar fascia under the guidance of ultrasonography.
45402038|NCT01290562|Radiation|Stereotactic Body Radiotherapy (SBRT)|One or more high dose(s) of radiation to treat the tumour.
45402039|NCT01186432|Drug|PDS 1.0|
45402040|NCT03855826|Drug|Nifekalant hydrochloride|Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.
45698494|NCT05396508|Procedure|physical therapy|protocol including hot pack for 20 min/session, therapeutic continuous Ultrasound (frequency, 1 MHz; intensity 1.5 W/cm2) for 6 min/session, therapeutic exercises for low back muscles. Therapeutic exercises included stretching ,posterior pelvic tilt ,hyperextension ,bridge and cat-camel exercises
45698495|NCT01132690|Drug|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 12 months
45698496|NCT05396352|Device|Transcranial direct current stimulation|TDCS involves applying small (1-2 mA) electric currents to the scalp in order to transiently modify local neuronal electrical potentials in the brain.
45850522|NCT00004188|Drug|isotretinoin|Given IV
45850523|NCT00004188|Drug|melphalan|Given IV
45850524|NCT00004188|Drug|topotecan hydrochloride|Given IV
45850525|NCT00004188|Drug|vincristine sulfate|Given IV
45850526|NCT00004188|Procedure|autologous bone marrow transplantation|
45850527|NCT00004188|Procedure|bone marrow ablation with stem cell support|
45850528|NCT00004188|Procedure|conventional surgery|All patients undergo delayed surgical resection of the residual tumor after course 5 of induction chemotherapy
45850529|NCT00004188|Procedure|peripheral blood stem cell transplantation|
45850530|NCT00004188|Radiation|radiation therapy|After completion of consolidation (at least 28 days from stem cell infusion), all patients receive local radiotherapy daily over 7 days
45850531|NCT00004194|Drug|fludarabine phosphate|
45850532|NCT00004200|Drug|prinomastat|
45850533|NCT00004200|Drug|temozolomide|
45850534|NCT00004206|Drug|FOLFOX regimen|
45850535|NCT00004206|Drug|fluorouracil|
45402041|NCT03855826|Drug|Amiodarone|Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.
45402042|NCT01184248|Behavioral|Sound stimulation|Listening to sound stimuli at the lowest audible level.
45402043|NCT01588288|Procedure|Galectin 3 dosage|Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy.
45402044|NCT02355418|Procedure|Mitral valve repair|Standard mitral valve repair surgery
45402045|NCT01186510|Procedure|lung perfusion|see literature of proceeding
45509892|NCT04864925|Drug|Tom's Botanically Bright Peppermint|2 minutes of whole mouth toothbrushing
45850536|NCT00004206|Drug|leucovorin calcium|
45850537|NCT00004206|Drug|oxaliplatin|
45850538|NCT00004212|Biological|filgrastim|
45850539|NCT00004212|Drug|exatecan mesylate|
45850540|NCT00004218|Drug|chlorambucil|
45850541|NCT00004218|Drug|cyclophosphamide|
45850542|NCT00004218|Drug|doxorubicin hydrochloride|
45850543|NCT00004218|Drug|fludarabine phosphate|
45850544|NCT00004218|Drug|prednisolone|
45850545|NCT00004218|Drug|vincristine sulfate|
45402046|NCT01186510|Procedure|no lung perfusion|see literature of proceeding
45402047|NCT01287988|Drug|ocriplasmin|Subjects were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study TG-MV-006 or TG-MV-007
45402048|NCT01287988|Drug|placebo|Subjects were exposed to a single intravitreal injection of placebo in a previous phase III study TG-MV-006 or TG-MV-007
45698497|NCT05380830|Other|Tied deep-Water Running|4 efforts of tied deep-water running for 5 minutes at 100-110%Vo2max under normoxia with 5 minutes of passive rest under hypoxia (FiO2=13%) or normoxia (FiO2= 20%). Frequency: 3x/week for 8 weeks.
45698498|NCT05396274|Device|High Flow Nasal Cannula|high flow nasale cannula
45698499|NCT04454034|Procedure|arthroscopic synovectomy|arthroscopic synovectomy
45698500|NCT01132846|Other|Placebo|Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.
45850546|NCT00004224|Drug|cyclophosphamide|
45850547|NCT00004224|Drug|etoposide|
45850548|NCT00004224|Drug|vincristine sulfate|
45850549|NCT00004224|Procedure|adjuvant therapy|
45850550|NCT00004224|Procedure|conventional surgery|
45850551|NCT00004224|Radiation|radiation therapy|
45850552|NCT00004236|Drug|pegylated liposomal doxorubicin hydrochloride|
45850553|NCT00004242|Drug|fluorouracil|
45850554|NCT00004242|Drug|gemcitabine hydrochloride|
45850555|NCT00004242|Drug|oxaliplatin|
45850556|NCT00004248|Biological|aldesleukin|
45850557|NCT00004248|Drug|doxorubicin hydrochloride|
45850558|NCT00004254|Drug|raltitrexed|
45850559|NCT00004260|Biological|recombinant interleukin-12|
45850560|NCT00004260|Biological|rituximab|
45850561|NCT00004266|Drug|Lisinopril|
45850562|NCT00004266|Drug|Nifedipine|
45850563|NCT00004266|Drug|Simvastatin|
45850564|NCT00004278|Drug|ganciclovir|
45850565|NCT00004284|Drug|potassium citrate|
45850566|NCT00004284|Drug|potassium phosphate|
45850567|NCT00004314|Drug|aminomidazole carboxamide riboside|
45850568|NCT00004338|Drug|zinc acetate|
45850569|NCT00004344|Drug|leuprolide|
45850570|NCT00004344|Drug|testosterone|
45850571|NCT00004368|Drug|colchicine|
45850572|NCT00004380|Drug|relaxin|
45850573|NCT00004386|Genetic|recombinant adenovirus containing the ornithine transcarbamylase gene|
45850574|NCT00004398|Drug|heme arginate|
45850575|NCT00004398|Drug|tin mesoporphyrin|
45850576|NCT00004404|Drug|clotrimazole|
45850577|NCT00004404|Drug|hydroxyurea|
45850578|NCT00004410|Drug|tauroursodeoxycholic acid|
45850579|NCT00004416|Drug|botulinum toxin type A|
45850580|NCT00004422|Drug|immune globulin|
45850581|NCT00004428|Drug|CPX|
45850582|NCT00004440|Drug|ibuprofen|
45850583|NCT00004446|Drug|fluoxetine|
45850584|NCT00004464|Drug|cyclophosphamide|
45850585|NCT00004464|Drug|filgrastim|
45509893|NCT04111068|Device|anodal tDCS Active Stimulation|a weak electric current is applied to the head through electrodes to affect the cortical excitability of the targeted cells in the brain.
45509894|NCT04111068|Device|anodal tDCS Sham/Placebo Stimulation|The tDCS machine will be used as in active stimulation, except the electrical current will not be applied.
45509895|NCT05195333|Other|The exercise program|The exercise program prepared for the 1st group gestational diabetes will be explained to the pregnant women by the physiotherapist and the exercises will be taught to the patient.
45509896|NCT05195333|Other|The exercise program|The same exercise program will be given to the participants only as a brochure and they will be asked to do 10 repetitions at home, 3 days a week, until the 34th week of pregnancy.
45509897|NCT03820050|Device|Freestyle LIbre Flash Glucose Monitoring System|System Performance will be characterized with respect to YSI reference venous plasma measurements
45509898|NCT04180098|Behavioral|C-mill intervention|A five week personalised rehabilitation program. Participants train gait adaptability via obstacle negotiation, precision stepping and unexpected accelerations and decelerations. The strategies are trained in a safe environment on the C-mill, a treadmill providing augmented reality via visual and acoustic cues. The treatment is implemented in a five week period via 10 biweekly sessions. Each treatment session lasts 60 minutes. In total, participants will receive C-mill training for a total of ten hours. The training will be carried out by a skilled physiotherapist.
45509899|NCT04180098|Other|No intervention|Participants in the control group are placed on a waiting list.
45402049|NCT03860818|Other|Health services delivery|Technology-enabled pharmacist intervention
45509900|NCT02288897|Drug|PV-10 (10% rose bengal disodium)|
45509901|NCT02288897|Drug|Dacarbazine, temozolomide or talimogene laherparepvec|
45402050|NCT01184404|Drug|Bosentan|The treatment group receives a starting dose of 62.5 mg tablet bosentan twice daily for four weeks followed by 125 mg tablet of bosentan twice daily two weeks prior to and 12 weeks after surgery.
45402051|NCT02525380|Procedure|Device(DC Bead)|Doxorubicin-Eluting-Bead Embolization (DEBDOX), DC Bead are a novel drug delivery embolization system
45402052|NCT02524366|Device|Artificial Urinary Sphincter|
45402053|NCT02524600|Device|myocardial IQ-SPECT imaging applied to scintigraphic imaging|
45509902|NCT01371552|Device|delefilcon A contact lens|Investigational, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1 and one week in Part 2.
45509903|NCT01371552|Device|filcon II 3 contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
45509904|NCT01371552|Device|narafilcon A contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
45509905|NCT02207075|Drug|[C11]PK-1195 PET scan|PET scan with tracer [C11]PK-1195
45509906|NCT05707572|Drug|methylprednisolone|a single injection of 1 mL methylprednisolone [40 mg] and 1 mL 2% lignocaine
45509907|NCT05707572|Procedure|manual manipulation|The lesser MTPJs of the affected foot will be manually manipulated using a high velocity, low amplitude thrust technique.
45509908|NCT04854629|Other|Spinomed active|Wearing of the orthosis 2-3 h/twice a day for 16 weeks Supplementation of a maximum of 1000 mg/d calcium and 800 IE/d vitamin D
45509909|NCT04068636|Procedure|Radioactive tracer injection via flexible endoscopy and SPECT scan for visualization of lymph nodes.|Flexible endoscopy will be performed by one of two experienced head and neck surgeons. Inspection of larynx and pharynx will be performed to determine the extensions of the tumor in all directions. After local anesthesia, 2-4 peritumoral injections of Tc-99m-nanocolloïd will be given. Ten minutes after injection of Tc-99m-nanocolloïd a SPECT scan will be performed.
45509910|NCT03633071|Other|Web-knee brace|Web -Knee Brace
45509911|NCT02035800|Drug|Adalimumab|Patient will received medication as standard of care
45509912|NCT04977349|Other|Manual Therapy|This group will be treated by manual therapy: suboccipital inhibition, myofascial extracavitary treatment in (superior trapezius fibers, ECOM, masseter and temporalis) and intracavitary muscles (medialis and lateral pterygoid muscles).
45402054|NCT02524600|Device|scintigraphic imaging|
45509913|NCT04977349|Other|Exercise program|Isometric exercises for: cranial protrusion, mouth opening, laterality cervical movement and cervical coordination by laser assessment. And the manual therapy from the Active Comparator group.
45698501|NCT01132846|Drug|Nesiritide|"Active Comparator: Low Dose Nesiritide~Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial."
45402055|NCT01186588|Drug|Canagliflozin|One 300-mg dose of canagliflozin on Day 1
45402056|NCT03854266|Drug|Low dose alteplase|Low dose alteplase is 4 milligram per pulmonary artery (maximum dose 8 milligram) infused in the pulmonary arteries over 2 hours
45402057|NCT03854266|Drug|Unfractionated heparin|Unfractioned heparin is administered in a peripheral vein with an initial dose of 80 international units per kilo (IU/kg) bolus followed by 18 IU/kg as continuous infusion with dose adjustment every 6 hours and once daily when activated partial thromboplastin time (APPT) is 1.5-2.3 times control value.
45402058|NCT03854266|Device|Infusion catheter|A sidehole catheter (Unifuse, AngioDynamics, US) catheter will be advanced to the pulmonary arteries to facilitate the catheter directed thrombolysis
45402059|NCT01187992|Drug|Atorvastatin|80 mg/day
45402060|NCT03854422|Device|left position|colonoscopy will be performed in 3 different locations. Left position, the patient will be in the left-side position during the entire colonoscopy
45402061|NCT03854422|Device|left supine position|Colonoscopy in the Left supine position
45402062|NCT03854422|Device|dynamic position|Colonoscopy in the Dynamic position
45509914|NCT04807361|Behavioral|Auditory biofeedback traing|Subjects who wear MFCLs for myopia control will receive one episode of auditory biofeedback training, and their accommodative responses to various demands (0, 2.5, 3, and 4 D) before and after the training were measured using a power refractor.
45509915|NCT05195021|Device|EDDY|EDDY (VDW) sonic irrigation activation system
45402063|NCT01186666|Device|Coronary intervention using IVUS-VH & FDG PET-MDCT|All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
45509916|NCT05195021|Device|Diode Laser device|980-nm diode laser device
45509917|NCT05195021|Device|Conventional irrigation|Conventional root canal irrigation with 31-guage side port needle
45509918|NCT05707650|Procedure|reverse breech extraction technique or push technique|using reverse breech extraction technique or push technique for disimpaction of fetal head during cs of a fully dilated cervix
45509919|NCT04946071|Behavioral|Arts-based HIV stigma intervention|The intervention will consist of 2-hour weekly sessions offered to students in participating schools. HIV-related stigma will be addressed by providing key information related to HIV and stigma, facilitating the acquisition of coping skills, and utilizing local cultural practices facilitated by Elders using creative methods to shift existing social and cultural norms that produce and perpetuate stigmatization. Specific intervention activities will include three interrelated activities. The core 2-hour weekly session will cover (1) transformative educational activities; (2) arts-based activities; (3) a summative activity consisting of (3) participatory theatre activites.
45509920|NCT03993912|Drug|Daratumumab SC in combination with Lenalidomide|"Daratumumab SC 1800 mg~once every week for 8 weeks~then once every other week for 16 weeks~thereafter once every 4 weeks, until progression"
45509921|NCT03993912|Drug|Lenalidomide PO (25mg)|Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression
45509922|NCT03993912|Drug|Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression|Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
45509923|NCT05194943|Procedure|revisional bariatric surgical procedures|Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
45509924|NCT05598697|Behavioral|Life Skills Building (LSB) curriculum for males|"The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All male study participants attending LSB curriculum classes are married to BISP-CT clients.~For men, the MEWE intervention provides access to the LSB curriculum only."
45509925|NCT05598697|Behavioral|Life Skills Building (LSB) curriculum for females|"The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All female study participants attending LSB curriculum classes are BISP-CT clients.~For females, the MEWE intervention comprises access to LSB curriculum + BISP CTs."
45509926|NCT05598697|Other|Cash transfer to adult females|The BISP intervention offers access to quarterly unconditional cash transfers to adult females.
45509927|NCT01568749|Drug|Paracetamol|Paracetamol
45850586|NCT00004482|Drug|Cyclosporine|
45509928|NCT01568749|Drug|Paracetamol formulation 1|Paracetamol
45509929|NCT01568749|Drug|Paracetamol Formulation 2|Paracetamol
45509930|NCT01568749|Drug|Paracetamol formulation 3|Paracetamol
45509931|NCT01568749|Drug|Paracetamol formulation 4|paracetamol
45850587|NCT00004482|Drug|methylprednisolone|
45850588|NCT00004482|Drug|Muromonab-CD3|
45509932|NCT03920358|Device|FRED, FRED Jr and FRED X|Subjects aged ≥ 18 requiring treatment for an unruptured or recanalized intracranial aneurysm
45509933|NCT03633851|Device|Toric intraocular MX60T lens|one eye will receive toric MX60T lens
45509934|NCT03633851|Other|Standard MX60 plus corneal incisions|the other eye will receive standard MX60 lens with corneal incisions
45850589|NCT00004482|Drug|prednisone|
45850590|NCT00004488|Drug|alendronate sodium|
45850591|NCT00004488|Drug|calcium carbonate|
45850592|NCT00004488|Drug|cholecalciferol|
45850593|NCT00004554|Drug|naltrexone (Revia)|100mg/day
45850594|NCT00004554|Drug|sertraline (Zoloft)|200mg/day
45850595|NCT00004554|Drug|Placebo|Placebo
45850596|NCT00004560|Device|defibrillator|
45850597|NCT00004572|Procedure|Sustacal challenge|
45402064|NCT01186666|Device|Coronary intervention using IVUS-VH & FDG PET-MDCT|All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
45509935|NCT04443829|Biological|CD19CAR T-cells|Infusion with: CD19CAR T-cells
45509936|NCT02819310|Drug|BLI400 Laxative|oral laxative
45509937|NCT03633773|Biological|MUC-1 CART cell immunotherapy|After fludarabine and cyclophosphamide pre-chemotherapy，MUC-1 CART immunotherapy is given. A decent interval later, levels of specific antibodies, CART cells and serum cytokines will be assessed.
45509938|NCT01375361|Drug|Albuterol|2.5mg Albuterol inhaled on enrollment and at 4 hours in the emergency department.
45509939|NCT01375361|Drug|Normal Saline|2.5mg Normal Saline inhaled on enrollment and at 4 hours in emergency department.
45402065|NCT01293604|Other|Daily ingestion of whole grain barley and oats|Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats. After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast. During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.
45402066|NCT03849976|Behavioral|Therapeutic communication|Patients will be accompanied to the operating room by a stretcher bearer trained in therapeutic communication
45402067|NCT01191034|Drug|Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.|"The vaccine will be either the MAGE-3.A1 peptide, or the NA17.A2 peptide, or both,matching the patient's HLA type and the gene expression of his tumor. If both antigens are expressed, then the patient will receive both peptides.~This treatment will combine subcutaneous peritumoral injections of IL-2, IFN-α and GMCSF,as well as topical applications of imiquimod."
45402068|NCT03852940|Other|Parenteral nutrition|
45402069|NCT03852940|Other|Enteral Nutrition|
45402070|NCT01191112|Other|Peptide based enteral formula|Sole source nutrition as per HCP
45402071|NCT01186822|Device|Lung Flute|Used twice daily
45509940|NCT03087643|Other|Passive mobilization - PM|
45509941|NCT05194865|Device|cardiac MRI|assessment of the viability using CMR
45509942|NCT05194865|Procedure|Percutaneous coronary intervention|direct revascularization using PCI
45509943|NCT02821962|Behavioral|Sedentary prompts from a VTAP device|
45509944|NCT05194787|Diagnostic Test|Cognitive test scores, clinical diagnosis and blood biomarkers|"Clinical diagnosis of Alzheimer's disease, mild cognitive impairment or normal ageing.~Cognitive test score on CANTAB Blood biomarker (p-tau 181) level"
45509945|NCT05598541|Procedure|Surgical or non-surgical treatment|Surgical treatment (depending on diagnosis) Non-surgical treatment (such as exercise therapy, pain medication, watch and wait)
45509946|NCT01376765|Drug|Aluminum hydroxide adjuvant (Alhydrogel®)|Aluminum hydroxide adjuvant (Alhydrogel®);given with SARS vaccine; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine with adjuvant at 45 micrograms per dose
45509947|NCT01376765|Other|Phosphate buffered saline Placebo|Phosphate buffered saline Placebo; 2 intramuscular doses, 28 days apart. Cohort 1: 4 subjects given placebo at 5 micrograms per dose; Cohort 2: 4 subjects given placebo at 15 micrograms per dose; Cohort 3: 4 subjects given placebo at 45 micrograms per dose
45509948|NCT01376765|Biological|Recombinant S protein SARS vaccine|Recombinant S protein severe acute respiratory syndrome (SARS) vaccine given with adjuvant or without adjuvant; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine only or vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine only or vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine only or vaccine with adjuvant at 45 micrograms per dose
45509949|NCT04404205|Diagnostic Test|Postural stability measurements by Biodex Balance System|Postural stability measurements will be done by Biodex Balance System. Three preprogrammed main tests will be applied. Postural stability, fall index, sensory integration will be calculated. All tests will be done in four conditions; implant off(1), implant on(2), implant on music on(3), and implant off again(4).
45402072|NCT01186900|Procedure|ultrasound-guided needle aspiration|one time drainage at time of randomization
45509950|NCT03278509|Drug|Metoprolol Succinate|Eligible patients randomized to active treatment will receive long-term oral beta-blockade (metoprolol succinate or bisoprolol).
45509951|NCT03278509|Drug|Bisoprolol|Please see the section above.
45402073|NCT03853018|Device|CWAT intervention|Participant in the intervention group will wear an activity tracker for 12 weeks.
45402074|NCT03853018|Device|CWAT + motivation intervention group|Participant in the intervention group will wear an activity tracker for 12 weeks and are also motivated by the researcher via a lifestyle data platform.
45509952|NCT05754593|Biological|Anti-Mullerian hormone (AMH) level|Measure of Anti-Mullerian hormone (AMH) level by blood sample
45509953|NCT05754593|Other|Antral follicle count (AFC)|Measure of Antral follicle count (AFC) by ultrasound imaging
45509954|NCT05754593|Other|Clinical assessment|MS history and MS treatments and Expanded Disability Status Scale (EDSS) score will be recorded
45402075|NCT01187056|Behavioral|Training programme|2 x 2 hours of training (workshops)
45402076|NCT01188070|Behavioral|Usual Care|Educational materials
45402077|NCT01188070|Behavioral|Psycho-education|Educational group sessions
45402078|NCT01188070|Behavioral|Psycho-education plus physical exercise|Psychoeducation intervention plus an individualized exercise program
45402079|NCT01293760|Other|Immediate insertion|Insertion of Copper T 380A immediately after c-section delivery of baby and placenta
45402080|NCT01293760|Other|6 weeks interval insertion|Insertion of Copper T 380A 6 weeks after c-section delivery of baby and placenta
45402081|NCT01188148|Drug|Memantine|5 mg per day of memantine
45402082|NCT01188148|Drug|Placebo|
45402083|NCT01187134|Behavioral|Change Management|Hospitals have to create local change teams which are supported and trained by the study center. Local awareness of the staff is increased by PowerPoint presentations, posters, and brochures. The change teams receive monthly information about their quality indicator (duration until antimicrobial therapy). Anonymous comparison to other hospitals is possible (Benchmarking). Hospitals are visited three times a year to discuss progress of quality. In case of failure to improve, the change team is supported with specific tools for change management such as SWOT-analysis or resistance radar.
45850598|NCT00004578|Drug|Lopinavir/Ritonavir|Lopinavir, range from 200 mg to 400 mg, every 12 hrs and Ritonavir, range from 100 mg to 200 mg, every 12 hrs
45402084|NCT01187212|Drug|Capecitabine/Cisplatin + Sorafenib|Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
45402085|NCT01187212|Drug|Capecitabine/Cisplatin|Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day 1
45402086|NCT01588600|Other|Dietary Fiber|Fiber added to breakfast
45402087|NCT03849508|Drug|Norepinephrine|"Drug: Norepinephrine Norepinephrine tartrate variable infusion with a starting rate of 0,1μg/kg/min (equivalent to norepinephrine base of 0.05 μg /Kg/min).~Other name: Noradrenaline~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg"
45402088|NCT03849508|Drug|Phenylephrine|"Drug: Phenylephrine variable infusion with a starting rate of 0,5μg/kg/min~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg"
45402089|NCT03849664|Drug|Cytoflavin® solution|Single drip infusion of 20 ml of Cytoflavin® solution in 200 ml of 0.9%NaCl intravenously once a day
45402090|NCT03849664|Drug|Cytoflavin® enteric-coated tablet|2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
45402091|NCT03849664|Drug|Placebo solution|Single drip infusion of 20 ml of placebo solution in 200 ml of 0.9%NaCl intravenously once a day
45850599|NCT00004578|Drug|Lamivudine|150 mg, every 12 hours
45850600|NCT00004578|Drug|Stavudine|40 mg every 12 hours
45850601|NCT00004638|Procedure|pathogenesis study|
45402092|NCT03849664|Drug|Placebo enteric-coated tablet|2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
45402093|NCT01291732|Drug|Matching placebo|single dose of matching placebo
45402094|NCT01291732|Drug|BI 135585 XX|single dose of low, medium or high dose of BI 135585 XX
45402095|NCT03849742|Other|Quality-of-Life Assessment|Ancillary studies
45402096|NCT03849742|Other|Questionnaire Administration|Ancillary studies
45402097|NCT03849742|Procedure|Supportive Care|Receive Uber rides
45402098|NCT05671432|Biological|CM326|CM326 injection
45402099|NCT05671432|Other|Placebo|Placebo
45402100|NCT01291810|Biological|TNF Kinoid|TNF Kinoid
45402101|NCT01291810|Biological|WFI|WFI
45402102|NCT03854188|Procedure|Acupuncture|Use acupuncture therapy in the treatment of chronic pelvic pain.
45509955|NCT04788563|Other|Heat-sensitive moxibustion plus original antihypertensive treatment (compulsively randomized arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
45509956|NCT04788563|Drug|Original antihypertensive treatment (compulsively randomized arm)|In this group, patients will maintain their original antihypertensive treatment.
45509957|NCT04788563|Other|Heat-sensitive moxibustion plus antihypertensive treatment (voluntarily randomized arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
45509958|NCT04788563|Drug|Original antihypertensive treatment (voluntarily randomized arm)|In this group, patients will maintain their original antihypertensive treatment.
45402103|NCT03853720|Procedure|balloon-occluded retrograde transvenous and endoscopic obliteration of high-risk gastric varices|"Catheterization of the left renal vein and the inferior diaphragmatic vein and occlusion with a balloon placed in the distal portion of this vein.~Endoscopic access to the gastric cavity, gastric varices identification and flow measurement, including velocity, by endoscopic Doppler ultrasound (US). The balloon in the draining vein will be inflated and the velocity will be reassessed. Endoscopic puncture of the varices will be done and the embolization will be conducted under balloon-occlusive conditions (Injection of Cyanoacrylate: Lipiodol mixture 1:1 slowly and gradually). Balloon will be kept inflated and a microcatheter will be used through its lumen inside the variceal bed to inject occlusive agent (cyanoacrylate) mixed with Lipiodol.~At the end of the procedure an occlusion device (plug amplatzer 2) will be placed."
45402104|NCT01187290|Radiation|neoadjuvant chemoradiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
45402105|NCT01293838|Drug|Cipralex®|"Based on a starting rate of 5 mg/day, increased by 5 mg every 2 weeks to a maximum of 20 mg/day for weeks 7-16, each participant will receive up to:~10 mg tablets: 28~20 mg tablets: 84~Total for 30 participants:~10 mg tablets: 840~20 mg tablets: 2520~Continuation study for participants who respond to Cipralex - Across 12 weeks, each participant will receive up to:~*20 mg tablets: 84~Total for continuation study for all participants (assuming a 60% response rate, N=18):~*20 mg tablets: 1512"
45509959|NCT04788563|Other|Heat-sensitive moxibustion plus original antihypertensive treatment (preference selection arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
45402106|NCT01188304|Drug|aleglitazar|repeated daily doses
45402107|NCT01188304|Drug|aspirin|repeated daily doses
45509960|NCT04788563|Drug|Original antihypertensive treatment (preference selection arm)|In this group, patients will maintain their original antihypertensive treatment.
45402108|NCT01188304|Drug|placebo|repeated daily doses
45509961|NCT05196347|Drug|Dapagliflozin|In dapagliflozin arm, subjects will be received dapagliflozin 5 mg for 4 weeks. Uptitration to 10 mg will be done between 5 to 12th weeks, if eGFR dip <20%.
45509962|NCT03092479|Behavioral|Behavioral Intervention|Eight bi-weekly small group sessions of approximately 10 participants with session content focused on addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
45509963|NCT01358201|Drug|vINCRISTINE|
45402109|NCT01188382|Procedure|CSF dynamic investigation|
45402110|NCT02524444|Drug|Mefloquine|Tabs Mefloquine 250mg
45402111|NCT02524444|Drug|Sulphadoxine-Pyrimethamine|Sulphadoxine 500mg , Pyrimethamine 25mg
45509964|NCT01358201|Drug|Dexamethasone|
45509965|NCT01358201|Drug|Methotrexate|
45509966|NCT01358201|Drug|Cytosine arabinoside|
45509967|NCT02969083|Procedure|RNU|Radical surgical removal by open or laparoscopic access
45509968|NCT02969083|Drug|Gemcitabine/Cisplatin|Gemcitabine (1000 mg/m²) day 1 and 8 and Cisplatin (70 mg/m²) day 1
45698502|NCT01132846|Drug|Dopamine|Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.
45509969|NCT02969083|Drug|M-VAC Protocol|Methotrexate (30 mg /m²) and Vinblastine 3 (mg /m²) day 1; Adriamycin 30 mg /m² and Cisplatin 70 mg /m² in day2
45509970|NCT00732797|Behavioral|Self-treatment booklet|A booklet outlining vestibular rehabilitation exercises
45509971|NCT00732797|Behavioral|Remote telephone support|Up to an hour's remote support from an expert vestibular therapist
45402112|NCT01293916|Other|Spica casting|single versus double leg spica casting
45509972|NCT03086551|Device|Active continuous theta burst stimulation (cTBS)|Active cTBS over dorsolateral prefrontal cortex that has an effect upon dorsolateral prefrontal cortex brain activity.
45509973|NCT03086551|Device|Placebo (Sham) continuous theta burst stimulation|Sham stimulation over dorsolateral prefrontal cortex that looks and sounds like active cTBS but does not have any effect upon dorsolateral prefrontal cortex brain activity.
45509974|NCT03086551|Behavioral|Motor Practice|Upper limb reaching task to be practiced. Practice will be paired with Active/Sham stimulation. Twenty trials will occur before Active/Sham stimulation. 40 trials will be practiced after Active/Sham stimulation.
45698503|NCT03130608|Other|Inspiratory Muscle Training|Subjects will breath through a hand held valve that has adjustable resistance to strengthen the muscles used for breathing. Subjects will perform the exercise approximately 20-30 minutes, twice a day for 8 weeks.
45850602|NCT00004644|Drug|acyclovir|
45850603|NCT00004650|Drug|conjugated estrogens|
45402113|NCT01291966|Behavioral|Motivational interview|
45698504|NCT05378802|Other|different modes of mechanical ventilation|Four different ventilation modes were performed one by one and respiratory parameters were recorded.
45698505|NCT05396196|Device|Kinesio® Tape|Manual Fascial Glide Application
45698506|NCT01173016|Drug|Laronidase|Laronidase 0.58 mg/kg intravenously (IV) once a week for a maximum of 2 years
45698507|NCT05165784|Procedure|femoral vein identification|Femoral vein identification using V technique
45698508|NCT05165784|Procedure|femoral vein identification|Femoral vein identification using palpation technique
45850604|NCT00004650|Drug|Medroxyprogesterone|
45850605|NCT00004656|Procedure|Metabolic assessment with body composition evaluation|
45850606|NCT00004662|Drug|dehydroepiandrosterone|
45850607|NCT00004686|Drug|methotrexate|
45850608|NCT00004686|Drug|prednisone|
45402114|NCT03852238|Other|Blood test and self-administrated questionnaires|
45402115|NCT03853408|Procedure|Cholecystectomy|Cholecystectomy (removal of the gallbladder) for acute cholecystitis
45509975|NCT01375439|Other|Active search of lower genital tract infections|Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome.
45509976|NCT05193773|Other|multifactorial interventions|The experimental group underwent multifactorial interventions to reduce physical restraint, including developing routines for physical restraint, promoting institutional policies to reduce the use of physical restraint, developing alternative methods, education, and consultations.
45509977|NCT05193617|Drug|GP+Peramprizumab+Anlotinib|GP combine with peramprizumab and anlotinib neoadjuvant therapy+CCRT+peramprizumab adjuvant therapy
45509978|NCT05193617|Drug|GP+Peramprizumab|GP combine with peramprizumab neoadjuvant therapy+CCRT+peramprizumab adjuvant therapy
45509979|NCT03265249|Device|BRIDGE device|an externally placed, FDA-cleared device that delivers percutaneous electrical stimulation with alternating frequencies to branches of cranial nerves (V, VII, IX, and X) through the external ear via a field effect
45509980|NCT04778111|Other|Measurement of the actual and perceived maximum reachable distance|A device (a table) will present luminous targets (green circles) to the subjects. Subjects will be asked to determine whether or not they are able to reach this target with their upper limb.
45509981|NCT04772261|Diagnostic Test|13C-Spirulina GEBT|Various lots of 13C-Spirulina GEBT test meals
45402116|NCT03853564|Behavioral|Video-Feedback Intervention|Mothers and infants of the VFG arm will participate to a 6-session video-feedback intervention structured as follows: 4 sessions of video-review discussions with a trained clinician + 2 sessions of integrative intervention aimed at translating into practical caregiving the insights developed during the video-review discussions.
45402117|NCT03853564|Other|Phone-Call Intervention|Mothers of the PCG arm will participate in 6-session of telephone call during which a trained collaborator will ask details on different domains of infants behavioral development.
45715289|NCT01567163|Biological|Ramucirumab|ramucirumab 10 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1 of 3-week cycle
45715290|NCT01567163|Drug|Docetaxel|docetaxel 75 milligrams/square meter (mg/m^2) intravenous infusion administered on Day 1 of each 3-week cycle
45402118|NCT01188616|Behavioral|Telephone Linked Care-HEAT (TLC-HEAT)|A primary care intervention linked with Telephone Linked Care-HEAT (TLC-HEAT), and delivered through an electronic health record (EHR). The HEAT system will guide children in the early stages of overweight toward healthy weight management and assist the child's parent(s) and primary care provider (PCP) to support the child's efforts.
45715291|NCT05002114|Drug|Cannabidiol|Topical CBD cream - special formulation
45402119|NCT01291576|Procedure|Rectal/colorectal segmental resection|Resection of the rectum +/- sigmoid colon involved by the deep infiltrating endometriosis
45402120|NCT01291576|Procedure|Rectal nodule excision|Either full thickness excision or rectal shaving
45402121|NCT03853642|Other|Blood sampling|Blood sampling, Spirometry, Fraction exhaled Nitric Oxide
45402122|NCT01292044|Other|Elastography|A conventional thyroid echography performed before a the time of fine needle aspiration will include elastographic measurements for each node under study.
45715292|NCT05002114|Other|Placebo|Not the drug
45850609|NCT00004728|Drug|Warfarin|
45402123|NCT02296918|Drug|acalabrutinib|100 mg twice daily continuous
45402124|NCT02296918|Drug|Obinutuzumab|Cycle 2 Day 1, 100 mg IV will be administered. Then on Cycle 2 Day 2, 900 mg administered. On Cycle 2 Days 8 and 15, 1000 mg IV will be administered. On Cycles 3-7, 1000 mg on Day 1 of each cycle will be administered.
45402125|NCT02296918|Drug|Venetoclax|20 mg daily for 1 week, 50 mg daily for 1 week, 100 mg daily for 1 week, 200 mg daily for 1 week, then 400 mg daily for duration of treatment.
45402126|NCT02296918|Drug|Rituximab|Rituximab will be given at a starting dose of 375 mg/m2 on Day 1 of Cycle 2, followed by 375 mg/m2 every week for 3 doses and then every 4 weeks for 5 doses for a total of 9 infusions
45402127|NCT01294072|Dietary Supplement|curcumin|tablets-3.6 gram (gm) taken daily for 7 days - 15 subjects
45402128|NCT01294072|Dietary Supplement|Curcumin conjugated with plant exosomes|tablets-taken daily for 7 days - 15 subjects
45402129|NCT01294072|Other|No intervention|no treatment
45402130|NCT01191346|Other|3T MRI|3T MRI in addition to standard 1.5T MRI for treatment planning
45402131|NCT01191424|Drug|CHF1535 NEXT DPI|FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100µg PLUS FORMOTEROL FUMARATE 6 µg DRY POWDER INHALER
45402132|NCT01191424|Drug|BDP DPI and formoterol DPI|FREE COMBINATION OF LICENSED BECLOMETHASONE DPI AND FORMOTEROL DPI
45715293|NCT04973566|Drug|Nipocalimab|Nipocalimab will be administered as an IV infusion.
45715294|NCT04973566|Drug|Etanercept|Etanercept will be administered subcutaneously.
45850610|NCT00004728|Drug|Aspirin|
45850611|NCT00004734|Drug|pyridoxine|
45850612|NCT00004734|Drug|cyanocobalamin|
45402133|NCT04956718|Other|Cold Pressor Test (CPT)|Cold Pressor Test (CPT): apparatus for the task is a tank of water of temperature of 4 °C (+-0.5 °C), with instruction to immerse the hand until too uncomfortable to continue. A maximum time limit per immersion of 3-5 min is applied. Quantitative measurement can then be made of pain threshold (point first perceived as painful) and tolerance time.
45402134|NCT04956718|Other|Placebo NaCl Nasal spray|placebo nasal spray containing NaCl solution
45402135|NCT01187680|Device|Spraygel|
45402136|NCT01187680|Device|Control|Good surgical technique, no adhesion barrier
45402137|NCT01291654|Drug|Paracetamol|po Paracetamol 15 mg/kg every 6 hours x 3 days
45402138|NCT01291654|Drug|NSAID|IV indomethacin 2 mg/kg/dose for three doses at 12 hour intervals; or IV Ibuprofen 10 mg/kg infused over 15 minutes, followed by two doses of 5mg/kg each at 24 hour intervals (total of 3 doses).
45509982|NCT05193461|Procedure|Pulsed mood radiofrequency on dorsal root ganglion|3) Pulsed radio frequency (PRF): PRF of the dorsal root ganglion (DRG) will be performed to all participants in this study. The procedures will be performed in the operating room under fluoroscopic guidance following radiation safety standards. The dorsal root ganglion of lumbosacral roots will be targeted. The patients will be positioned prone .Lidocaine 1% will be infiltrated at the skin entry site. A 10 cm, 22-gauge radiofrequency needle with a 5 mm curved active tip will be used. A radiculogram will be done to confirm appropriate placement and DRG will be stimulated for confirmation of the appropriate nerve root involved. Proximity of the needle to the DRG will be determined by appropriate sensory stimulation with 50 Hz (0.4-0.6 V), and motor stimulation at 2 Hz will be used to determine a threshold 1.5-2.0 times greater than the sensory threshold to avoid placement near the anterior nerve root. A pulsed lesion will be generated by applying 45 V to the DRG for 6 minutes at 42°C.
45402139|NCT01291654|Drug|D5W|Since the paracetamol is given q 6 hours, in order to maintain blinding of the clinical staff, a placebo (D5W) must be given intermittently between the doses of NSAID such that each infant will receive drug every 6 hours.
45509983|NCT04726475|Behavioral|Interoceptive Aversive Memory Reactivation|In order to reactivate interoceptive aversive memory, participants will be asked to breathe a medical grade 35% CO2/65% O2 gas mixture which produces somatic perturbations. The 35% CO2 challenge is a widely used and safe symptom induction technique that has been utilized in our laboratory in several experiments. Participants will be informed that breathing the gas is safe, but that it will likely cause changes in their physical sensations. Participants will specifically be asked to breathe the gas mixture normally with their mouth open through an oxygen mask for 10 seconds.
45715295|NCT04973566|Drug|Hydroxychloroquine|HCQ will be administered orally.
45402140|NCT03853174|Other|Endurance Training ET|Endurance training were prformed. Intensity was gradually increased.
45402141|NCT03853174|Other|Resistance Training RT|Resistance training were prformed. Intensity was gradually increased.
45402142|NCT01187758|Behavioral|Workshops and focus group meetings|Multifacet intervention that includes: Guideline preparation and implementation, preparing clinic campaign, improving knowledge about Ab resistance and diagnosis of respiratory infections
45402143|NCT03853096|Drug|Cefazolin|Cefazolin 100mg/mL, 3mL in three locations will be administered around a surgical incision on the anterior shoulder in a standard deltopectoral approach interval. This will be a one time administration. Administration and route will be subcutaneous.
45850613|NCT00004734|Drug|folic acid multivitamin|
45850614|NCT00004740|Drug|isoniazid|
45402144|NCT05671276|Drug|aspirin and clopidogrel|DAPT (until 6 months) + ASA
45402145|NCT05671276|Drug|Rivaroxaban|half-dose NOAC
45402146|NCT03848026|Other|Middle ear fluid viscosity|The patients were subdivided into two groups according to median viscosity level
45402147|NCT03848026|Other|Tympanostomy tube extrusion time|Tympanostomy tube extrusion time of the all patients recorded prospectively.
45402148|NCT03852160|Drug|Esketamine 28 mg|Participants will receive 28 mg esketamine as nasal spray (Initial dose for elderly participants with 65-74 years of age on Day 1 and then uptitrated to 56 mg on Day 4).
45850615|NCT00004758|Drug|carbamazepine|
45402149|NCT03852160|Drug|Esketamine 56 mg|Participants will receive 56 mg esketamine as nasal spray (Initial dose for participants with 18-64 years of age) on Day 1. The dose may be increased/may remain same based on the efficacy and tolerability. Participants with 65 to 74 years of age will receive esketamine 56 mg from Day 4 onwards.
45402150|NCT03852160|Drug|Esketamine 84 mg|Participants may receive 84 mg (maximum uptitrated esketamine dose). The dose may be decreased/may remain same based on the efficacy and tolerability.
45850616|NCT00004758|Drug|corticotropin|
45850617|NCT00004758|Drug|nitrazepam|
45850618|NCT00004758|Drug|pyridoxine|
45850619|NCT00004758|Drug|valproic acid|
45850620|NCT00004758|Procedure|Surgery|
45850621|NCT00004770|Drug|thioctic acid|
45850622|NCT00004776|Drug|topiramate|
45850623|NCT00004794|Drug|cidofovir|
45850624|NCT00004800|Biological|diphtheria-tetanus-pertussis vaccine containing whole-cell pertussis|
45850625|NCT00004800|Biological|diphtheria-tetanus vaccine|
45402151|NCT03852160|Drug|Placebo|Participants will receive matching placebo as nasal spray.
45509984|NCT04726475|Dietary Supplement|Cannabidiol (CBD)-Rich Broad Spectrum Hemp Extract Oil|300mg CBD-rich hemp-derived formulation in MCT coconut oil.
45509985|NCT04726475|Dietary Supplement|Placebo Oil|3ml oral dose of MCT coconut oil.
45509986|NCT05747495|Other|Online training in CPR-AED|"The online training has been designed according to the Catalan Resuscitation Council (CCR) and the European Resuscitation Council (ERC) guidelines. The aim of this training is to provide theoretical and practical knowledge to respond to aid situations (from unconscious people to drowning, both adults and children), as well as the use of the AED.~The contents are available at the link [https://register.magnore.com/registre-curs-de-reanimacio-cardiopulmonar-dea/]."
45509987|NCT05183945|Device|Localization needle|A localization needle which is used for preoperative localization of lung nodules.
45509988|NCT05183945|Device|Coil|A coil which is used for preoperative localization of lung nodules.
45509989|NCT02951767|Drug|Atezolizumab|Atezolizumab 1200 mg will be given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.
45509990|NCT05182541|Other|Guided self help|Introduce the knowledge about twins pregnancy, and reduce the pregnant stress, and relief the anxiety and depressor.
45402152|NCT03852160|Drug|Escitalopram|Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for escitalopram is 5 mg once daily (for elderly participants) and 10 mg once daily (for adults). The dose may be increased to 10 mg (for elderly participants) and 20 mg (for adults) once daily at the discretion of treating physician/investigator.
45402153|NCT03852160|Drug|Sertraline|Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for sertraline is 50 mg once daily and may be increased up to 200 mg once daily.
45402154|NCT03852160|Drug|Duloxetine|Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for duloxetine is 60 mg once daily and may be increased to 120 mg once daily.
45402155|NCT03852160|Drug|Mirtazapine|Mirtazapine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for mirtazapine is 15 to 30 mg once daily and may be increased to 45 mg once daily.
45402156|NCT03852160|Drug|Agomelatine|Agomelatine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for agomelatine is 25 mg once daily and may be increased to 50 mg once daily after 2 weeks.
45402157|NCT03852160|Drug|Bupropion|Bupropion can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for bupropion is 150 mg once daily and may be increased to 300 mg once daily after 4 weeks.
45402158|NCT03852160|Drug|Trazodone Prolonged Release|Trazodone prolonged release can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for trazodone prolonged release is 75 to 150 mg once or twice daily and may be increased up to 450 mg (adults) and 300 mg (elderly).
45402159|NCT01193998|Other|Treatment as per model probability|Patients randomized to the arm where the clinician is exposed to the model results should be treated as per the model probability (i.e. if the model probability suggests AHF the clinician should treat for AHF).
45402160|NCT01193998|Other|Treatment as per usual care|Patients randomized to the arm where the clinician is blinded to the model results will undergo diagnostic tests and receive treatment as per the clinician's judgment and usual care standards.
45402161|NCT03849352|Behavioral|Lifestyle changes with the support of health technology|Written instructions will be provided to participants, to include how to download supportive apps on smartphones. Participants will be asked to complete a 3 day food diary using an online platform (MyFood24) prior to attending a face to face consultation which will reinforce the participant's responsibilities. Participants will be assisted to set specific diet and lifestyle goals. 3 fortnightly follow ups will be arranged via 15 minute telephone consultations, three 24 hour dietary diaries will be completed via MyFood24 prior to each fortnightly digital consultation. Participants will be asked to measure their daily activity via a pedometer on their smart phones. Participants will be asked to complete the Godin leisure time questionnaire to assess changes in leisure time exercise.
45402162|NCT01294540|Drug|Drug: E2609|E2609 orally at varying ascending doses
45402163|NCT01294540|Drug|Placebo|Matching Placebo
45402164|NCT01292122|Device|VCT-01|Application of bi-layered living cell-based product (VCT-01) to STSG donor site wound at Day 0
45509991|NCT05182541|Other|Problem solving therapy|Based on the steps of problem-solving therapy, nurses guide mothers with mild psychological problems to solve the existing problems through wechat and telephone, 10-15 min each time for 4 weeks
45850626|NCT00004806|Genetic|Cystic fibrosis transmembrane conductance regulator|
45850627|NCT00004812|Behavioral|Exercise|
45850628|NCT00004842|Drug|budesonide|Oral budesonide, 9 mg daily was administered for 1 year
45402165|NCT01194076|Behavioral|5-day intensive treatment|Exposure Based Cognitive Behavioral Therapy administered in 10 appointments over 5 days with an added focus on training parents to be exposure coaches
45402166|NCT02524210|Drug|Dabigatran|dabigatran etexilate 150 mg/day (1 day)
45402167|NCT02524210|Drug|Rabeprazole and Dabigatran|rabeprazole 20 mg / day for 5 days, then the 6th day concomitant rabeprazole 20 mg of dabigatran etexilate 150 mg;
45850629|NCT00004854|Drug|Carvedilol|
45850630|NCT00004866|Drug|exatecan mesylate|
45402168|NCT02524210|Drug|Omeprazole and Dabigatran|omeprazole 20 mg / day for 5 days, then the sixth day concomitant omeprazole 20 mg and 150 mg dabigatran etexilate
45402169|NCT01292200|Behavioral|watch DVD and small group discussion|Women in the small-group discussion mode will be called by their community educators to determine possible dates, times, and places for group meetings. The small group sessions will be conducted near the participants' homes. Each small-group will consist of 5-10 participants who will first view a 20-minute video together and then discuss the content of the video as well as their barriers to screening for about 30 minutes. A community educator and an RA at the study site will facilitate the discussion in Chinese languages according to a structured guide.
45509992|NCT05182541|Other|Face to face PST course|Face to face interviews with nurses with psychological counselors, combined with auxiliary tools, identify patients' problems, set goals for patients, provide different solutions, and let patients choose appropriate ways according to their preferences. Once a week, 1 hour for the first time and 45 min for the rest for 5 weeks.
45509993|NCT05182541|Other|Professional psychological intervention|The mental health physicians and (or) psychological counselors strengthened the intervention and carried out specialized nursing
45402170|NCT01292200|Behavioral|watch DVD|Women in the single video mode will receive a cultural video along with an information sheet on local free and low-cost screening programs by mail.
45402171|NCT03847792|Drug|Group DB/Dexamethasone-Bupivacaine|The patient were received an intra-articular injection of 18ml bupivacaine 0.25% added to 8mg dexamethasone.
45402172|NCT03847792|Drug|Group FB /Fentanyl-Bupivacaine|The patient were received an intra-articular injection of 1 ug/kg fentanyl added to 18ml of 0.25% bupivacaine.
45402173|NCT03847792|Drug|Group PB/Placebo-Bupivacaine|Patients were received an intra-articular injection of 2ml isotonic saline added to 18ml of 0.25% bupivacaine.
45402174|NCT01294618|Drug|Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.|Combination of both treatments active by different means on the leukemic cells, in order to enhance the response rates of CP CML patients since diagnosis.
45402175|NCT01188850|Biological|VGX-3100|DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
45509994|NCT05181839|Drug|Burosumab|To describe the lived experience of XLH for adolescents who are being treated with burosumab at the end of skeletal growth with a focus on adolescent-reported symptoms, activity duration and intensity, and wider burden, describing change over time for those who continue and discontinue burosumab after the end of skeletal growth.
45402176|NCT01194232|Drug|Sildenafil|8 week course of Sildenafil administered at a dose of 1 mg / Kg three times a day with a maximum dose of 20 mg per dose.
45402177|NCT01296334|Drug|morphine LO|intravenous infusion, 10 mg, once, 4 hours
45402178|NCT01296334|Drug|Morphine Hi|intravenous infusion, 20 mg, once, 4 hours
45402179|NCT01296334|Drug|Buprenorphine LO|intravenous infusion, 0.3 mg, once, 4 hours
45402180|NCT01296334|Drug|Buprenorphine Hi|intravenous infusion, 0.6 mg, once, 4 hours
45509995|NCT05760833|Procedure|Ablation|Ablation of either the pulmonary veins or the atrioventricular node
45509996|NCT05170763|Drug|PA9159 nasal spray solution, 10 μg one day treatment|Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, one spray each in the left and right nostril.
45509997|NCT05170763|Drug|PA9159 nasal spray solution, 20 μg one day treatment|Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
45509998|NCT05170763|Drug|PA9159 nasal spray solution, 40 μg one day treatment|Single dose of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
45850631|NCT00004872|Biological|recombinant human endostatin|
45402181|NCT01296334|Other|saline|intravenous infusion, 0.9% saline, once, 4 hours
45402182|NCT03851770|Other|Characterization of Vagus nerve stimulation|Characterization of Vagus nerve stimulation induced larynx evoked motor potential. Patients participating in the study will be asked to come to perform the experiment (duration maximum 1 hour) at the Neurophysiology Department of Saint Luc .
45402183|NCT03847558|Diagnostic Test|FSH((Follicle Stimulating Hormone) and LH (Luteinizing Hormone) hormone for females and Testosterone hormone for males|assess of sexual maturation by clinical examination and hormonal studies (FSH.LH,Testosterone)
45402184|NCT01194310|Procedure|phaco|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) alone
45402185|NCT01194310|Procedure|phaco-ELT|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) plus excimer laser trabeculotomy (ELT)
45402186|NCT01194310|Procedure|phaco-Trabectome|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) plus Trabectome
45509999|NCT05170763|Drug|PA9159 nasal spray solution, 80 μg one day treatment|Single dose of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, four sprays each in the left and right nostril.
45510000|NCT05170763|Drug|PA9159 nasal spray solution, 20 μg 7-day treatment|Repeated doses of PA9159 (5 μg/nasal spray) or Placebo is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
45850632|NCT00004878|Biological|therapeutic allogeneic lymphocytes|
45850633|NCT00004878|Drug|cytarabine|
45850634|NCT00004878|Drug|fludarabine phosphate|
45850635|NCT00004878|Drug|idarubicin|
45850636|NCT00004878|Drug|methotrexate|
45850637|NCT00004878|Drug|tacrolimus|
45510001|NCT05170763|Drug|PA9159 nasal spray solution, 40 μg 7-day treatment|Repeated doses of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
45510002|NCT05170763|Drug|Placebo, the same intranasal spray solution without PA9159 active ingredient|Placebo is delivered intranasally through a metered-dose mechanical spray pump with the same volume as the corresponding PA9159 dose group
45510003|NCT05734391|Diagnostic Test|Routine Infection control|routine part of hospital IPC activities
45402187|NCT01189006|Drug|Dextromethorphan|Add-On double-blind study treatment commenced at randomization for 11 weeks while patients were continuing open-label risperidone. Randomization was immediately preceded by a one week open-label Risperidone-Only Treatment period. Patients who were receiving antipsychotics medication(s) at screen other than risperidone alone was withdrawn from previous non-risperidone medication(s) and at the same time commenced risperidone in titrating doses over a week. This Antipsychotic Switch-Over Period occurred between Screen and Risperidone-Only Treatment period. Patients remained hospitalized for at least during the Risperidone-Only treatment Period and first week of Add-On treatment Period.
45510004|NCT03093181|Other|Washout / Standard Cleanser|Participants will apply standard cleanser (Simple Kind to Skin Moisturising Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the standard cleanser in a 5-7 day washout period and during the test phase of the study
45510005|NCT03093181|Other|Test product|Participants will apply 0.6 gram (g) of Test product (Moisturising Cream with Niacinamide) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the test product during the test phase of the study.
45510006|NCT03093181|Other|Positive control cleanser|Participants will apply positive control cleanser (Neutrogena Visibly Clear Spot Clearing Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control cleanser during the test phase of the study.
45510007|NCT03093181|Other|Positive control moisturiser|Participants will apply 0.6 g of positive control moisturiser (Vivatinell Acnecinamide Gel Cream) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control moisturiser during the test phase of the study.
45510008|NCT05200091|Other|Combined explosive strength and specific balance training group|"Training will consist to perform one hour of combined ankle explosive strength training and specific balance training using randomized perturbations.~Explosive strength training: Participants will perform only 2 sets of 3 min (12 contractions for each set) for both lower limbs and both ankle plantar- and dorsiflexion movements.~Balance specific training: Participants will be standing, secured by an adjusted harness, which do not support the weight but is strictly there to prevent a fall. They will have online visual feedback of their CoP via an avatar on the screen in front of them. Each training session will consist of 10 sequences of 3 min, including the 5 different conditions:~Forward tilt of base of support;~Backward tilt of base of support;~Translation forward;~Translation backward;~Without moving their feet, participants will have to move their avatar to reach different targets placed around them on the screen, at different distance from the center."
45510009|NCT04666181|Behavioral|Dual-task training|See descriptions under arm description. The dual-task training will occur across a total of 5 consecutive workday visits.
45850638|NCT00004878|Procedure|in vitro-treated peripheral blood stem cell transplantation|
45402188|NCT01294774|Drug|KRP203 - 1.2mg|
45402189|NCT01294774|Drug|Placebo to KRP203 - 1.2 mg|
45402190|NCT01292356|Drug|cetuximab|
45510010|NCT02922439|Behavioral|Tailored Intervention|The intervention will focus on improving the health literacy of low literacy individuals by providing chronic disease self-management information tailored to cultural and linguistic characteristics of participants.
45510011|NCT02922439|Behavioral|Control Intervention|This intervention will provide information similar to that provided in the control condition, but will not utilize tailoring.
45402191|NCT01194388|Device|MicroFx™ PGLA COILS|. This observational evaluation will evaluate early experience using the Axium™ MicroFx™ Detachable Coils as compared to published literature of coils with electrolytic, thermal or hydraulic detachment process or the Axium™ bare Detachable Coils arm obtained from previous evaluation conducted following the same protocol.
45510012|NCT05199623|Drug|tailored Guizhi decoction|Tailored guizhi decoction powder is a compound Chinese herbal medicine which contains 7.0g of guizhi, 1.5g of chuanxiong, 1.5g of zhimu, 1.5g of xinyi, 0.3g of mahuang, 1.0g of baizh, 2.0g of jili, 1.5g of fuling, and 1.0g of danshen.
45510013|NCT05199623|Behavioral|Olfactory training (OT)|Four odorant bottles of PEA, lemon, eucalyptus, and clove oils were given. Patients were instructed to sniff the liquid in each bottle for 10 seconds, twice a day.
45510014|NCT05413031|Device|relative motion splint|splint with ability to move the fingers
45510015|NCT05413031|Device|static splint|splint with immobility of wrist, and fingers
45510016|NCT03091777|Drug|GDC-229|GDC-229 is a vaginal gel.
45510017|NCT03091777|Drug|Metronidazole Vaginal Gel 0.75%|Metronidazole Vaginal Gel 0.75% is an FDA-approved drug
45510018|NCT03091777|Drug|Placebo|Inactive arm of the study
45510019|NCT04648085|Device|Trigeminal Nerve Stimulation|Applied to to the forehead using a self-adhesive electrode positioned bilaterally over the upper branches of the trigeminal nerve.The device generates electrical impulses allowing to stimulate the trigeminal nerve.
45850639|NCT00004878|Procedure|peripheral blood stem cell transplantation|
45850640|NCT00004884|Drug|cisplatin|
45850641|NCT00004884|Drug|docetaxel|
45850642|NCT00004884|Drug|gemcitabine hydrochloride|
45850643|NCT00004890|Biological|aldesleukin|
45850644|NCT00004890|Drug|Biomed 101|
45850645|NCT00004920|Drug|cisplatin|
45510020|NCT03632837|Device|Hemoadsorption|see arm description
45510021|NCT04624997|Other|biological sample|biological sample
45510022|NCT05603741|Drug|0.9% Sodium Chloride Injection|All participants will be injected subcutaneously with a single 0.5ml dose
45402192|NCT01294852|Other|surfactant prophylaxis|Premature infants born before 28 weeks' gestation and infants born at 29 to 30 weeks' gestation who did not receive antenatal steroid were randomized before delivery to receive either immediate bolus or post-resuscitation surfactant prophylaxis at 15 minutes after birth. Those infants who were randomized to immediate bolus surfactant were intubated as rapidly as possible after birth, were administered 100 mg/kg surfactant (Curosurf[Chiesi, Farmaceutici, Parma, Italy]), and received standard resuscitation measures as indicated. Those infants who were randomized to post-resuscitation surfactant received standard resuscitation measures first, were intubated electively at 15 minutes after birth and received 100 mg/kg surfactant (Curosurf[Chiesi, Farmaceutici, Parma, Italy]).
45402193|NCT03851848|Other|Joint mobilization (JM)|Joint mobilization (JM) is a manual therapy to move the joint in a desired direction. It is commonly used for improving the joints' ROM and pain intensity, and to overcome joint restriction.
45510023|NCT05603741|Drug|Lidocaine Injection 2%|All participants will be injected subcutaneously with a single 0.5ml dose
45510024|NCT05601947|Other|Structured Proprioception and Closed Kinetic Chain Exercises Group|In this group, an exercise program consisting of 3 stages, ranging from simple to difficult and including closed kinetic chain exercises and proprioceptive exercises, will be applied.
45510025|NCT05601947|Other|Wii Based Balance Training Program Group|"In addition to electrotherapy and conventional exercise program, wii-based balance training program will be applied 5 days a week for 3 weeks. Balance Surf, which includes lateral weight transfer, Balance Adventure, which includes versatile balance exercises, and balance bowling for static and dynamic postural control will be implemented in the Fizyosoft Balance System. Each game will be practiced under the supervision of a physiotherapist for a total of 3 minutes, respectively, Balance surf, Balance adventure, Balance surf, Balance bowling and Balance surf, for a total of 15 minutes."
45510026|NCT04592861|Radiation|carbon ion RT|daily carbon ion radiotherapy
45715296|NCT03900533|Behavioral|Adjunctive group emotion regulation skills training|The adjunctive emotion regulation skills training is delivered in a group format once a week during 7 weeks to adolescents and parents jointly together with treatment as usual
45510027|NCT04592861|Drug|Chemotherapy drug|Subjects who receive carbon ion radiotherapy may receive additional chemotherapy afterwards, at the discretion of the treating physicians. Subjects on the control arm are also expected to receive chemotherapy, using a regimen selected by the treating physicians.
45510028|NCT05403359|Drug|Steroids|"Description of the intervention in each of the work packages:~WP1A admission: Steroid dose >6mg/day dexamethasone equivalent will be compared to control (steroid = 6mg/day dexamethasone or equivalent steroid).~WP1B late: After 10 days of dexamethasone therapy patients are stratified in high-dose steroids (> 6 mg dexamethasone or equivalent steroid) or no steroids up to day 28.~WP2 ICU admission: High-dose steroids (dexamethasone >6 mg daily or equivalent corticosteroids) compared to dexamethasone 6 mg up to 72 hours after admission~WP3 ICU late: After dexamethasone 6 mg for 10 days patients are stratified in high-dose steroids (dexamethasone >6 mg daily or equivalent corticosteroids) or no steroids up to day 28."
45510029|NCT05392361|Drug|gabapentin (neurontin® capsule 300mg) treatment|Taking gabapentin (neurontin® capsule 300mg, Pfizer) medication at night as a conservative treatment
45715297|NCT03900533|Behavioral|Treatment as usual|Treatment as usual at the child- and adolescent psychiatric clinic is delivered during 7 weeks
45715298|NCT02986061|Device|Urinary catheter|
45850646|NCT00004920|Drug|raltitrexed|
45850647|NCT00004926|Dietary Supplement|vitamin D3 analogue ILX23-7553|
45850648|NCT00004932|Drug|imatinib mesylate|
45850649|NCT00004938|Drug|fluconazole|
45850650|NCT00004986|Drug|Nitazoxanide|
45850651|NCT00004992|Behavioral|Intensive lifestyle|
45850652|NCT00004992|Drug|Metformin|
45850653|NCT00004992|Drug|Placebo|
45850654|NCT00004998|Drug|Lamivudine/Zidovudine|
45850655|NCT00004998|Drug|Capravirine|
45850656|NCT00004998|Drug|Nelfinavir mesylate|
45850657|NCT00005010|Drug|Irbesartan|
45850658|NCT00005010|Drug|Pravastatin|
45850659|NCT00005022|Drug|cisplatin|
45510030|NCT05392361|Drug|baclofen (baclofen Tab. 10mg) treatment|Taking baclofen (baclofen Tab. 10mg, Handok co, Seoul, Korea) medication at night.
45510031|NCT05338541|Drug|Tucidinostat and etoposide|Tucidinostat: 3+3 design，14 mg/m2，17.5 mg/m2，23 mg/m2 etoposide: 50mg/m2,
45510032|NCT05760755|Behavioral|Stick Together|The intervention consists of 12 online modules, completed flexibly during and immediately after primary cancer treatment. The intervention contains interviews with other couples, psychoeducational information, and interactive exercises on themes such as dyadic coping and communication, being diagnosed at a young age, fertility and children, and life after treatment.
45510033|NCT05335655|Drug|Dexmedetomidine injection|IV initial bolus and trans operative dexmedetomidine infusion.
46057178|NCT04226703|Diagnostic Test|Ultrasonographic upper airway measurements|"Ultrasonographic upper airway measurements: Epiglottis-skin distance, Hyoid bone-skin distance, Anterior commissure-skin distance and Thickness of tounge root.~Indirect Laryngoscopy: Grading of laryngoscopic view (I=Visible anterior commissure and vocal cords, II= visible posterior part of vocal cords and posterior commissure, III= Visible posterior commissure and epiglottis, IV= Visible only epiglottis tip and posterior pharyngeal wall)"
45510034|NCT05335655|Drug|Sodium Chloride 0.9% infusion|IV initial bolus and trans operative infusion of 0.9% saline solution.
45850660|NCT00005022|Drug|etoposide|
45850661|NCT00005022|Radiation|radiation therapy|
45850662|NCT00005028|Drug|bryostatin 1|
45850663|NCT00005028|Drug|paclitaxel|
45850664|NCT00005040|Drug|arsenic trioxide|
45850665|NCT00005046|Drug|chemotherapy|
45850666|NCT00005046|Drug|paclitaxel|
45402194|NCT03851848|Other|Myofascial release (MFR)|Myofascial release (MFR) is a technique in which a slow, sustained pressure is applied to the restricted soft tissue in order to restore optimal length, reduce pain and improve function.
45402195|NCT01292434|Behavioral|Lunch is in the Bag behavioral intervention|Multi-component behavior-based activities, includes: parent handouts, teacher training, age-appropriate child classroom activities, parent/child activity stations
45510035|NCT04589351|Drug|Ezetimibe 10mg|Ezetimibe is a cholesterol absorption inhibitor with marketing approval. The recommended dose as per label is 10mg once a day.
45510036|NCT04589351|Drug|Placebo|Matching placebo
45510037|NCT05280821|Dietary Supplement|daily ferrous sulfate|Daily intake of 100 mg ferrous sulfate capsules for 3 months
45510038|NCT05280821|Dietary Supplement|alternate day ferrous sulfate|Alternate day intake of 100 mg ferrous sulfate capsules for 6 months
45510039|NCT05202743|Other|Observational for ALS patients|Open to ALS patients interested in mindfulness training.
45850667|NCT00005052|Biological|GM2-KLH vaccine|
45850668|NCT00005052|Biological|QS21|
45850669|NCT00005052|Procedure|adjuvant therapy|
45850670|NCT00005058|Procedure|ultrasound imaging|
45850671|NCT00005064|Drug|bortezomib|Given IV
45850672|NCT00005070|Drug|irofulven|
45402196|NCT03847246|Drug|Baraclude® tablets,1.0 mg|oral,once,under fasting condition
45402197|NCT03847246|Drug|Entecavir tablets,1.0 mg|oral,once,under fasting condition
45402198|NCT01292512|Other|Prognostic screening for complicated grief|Patients in the intervention group are prognostically screened for development of complicated grief to identify those in need of help.
45402199|NCT05282914|Drug|administration of UI058|Test
45402200|NCT05282914|Drug|administration of UIC202004|Reference
45402201|NCT01296490|Other|Stress test|Stress test while running on a treadmill until exhaustion for 8-12 minutes. Blood will be drawn before, 5 minutes after and an hour after the test.
45402202|NCT01294930|Other|Urine density|measurement of urine color, density and plethysmographic variability index before and during surgery.
45402203|NCT01292590|Other|High fat meal|40 grams saturated fat
45402204|NCT03849196|Drug|2L PEG-Asc|PEG-Asc powder
45850673|NCT00005076|Biological|cetuximab|
45850674|NCT00005076|Drug|irinotecan hydrochloride|
45850675|NCT00005082|Procedure|biopsy|
45850676|NCT00005082|Procedure|magnetic resonance imaging|
45850677|NCT00005088|Drug|cisplatin|
45850678|NCT00005088|Radiation|radiation therapy|
45850679|NCT00005094|Drug|celecoxib|Given orally
45850680|NCT00005094|Other|placebo|Given orally
45850681|NCT00005106|Drug|Lamivudine/Zidovudine|
45850682|NCT00005106|Drug|Abacavir sulfate|
45850683|NCT00005106|Drug|Nelfinavir mesylate|
45850684|NCT00005106|Drug|Lamivudine|
45850685|NCT00005106|Drug|Stavudine|
45850686|NCT00005118|Drug|Indinavir sulfate|
45850687|NCT00005118|Drug|Ritonavir|
45850688|NCT00005520|Drug|Hydrochlorothiazide|
45850689|NCT00005520|Drug|Candesartan|
45850690|NCT00005574|Drug|Gentamicin|
45850691|NCT00005580|Drug|bryostatin 1|
45850692|NCT00005580|Drug|fludarabine phosphate|
45850693|NCT00005586|Drug|L-leucovorin|
45850694|NCT00005586|Drug|fluorouracil|
45850695|NCT00005586|Procedure|adjuvant therapy|
45850696|NCT00005592|Biological|90-Y-ibritumomab tiuxetan|IDEC-Y2B8 is a mouse monoclonal antibody with small particles of radioactivity that join to the CD20 antigens on lymphoma cells. It is used to deliver radiation therapy to kill lymphoma cells. This is a one time intravenous infusion for eligible patients and is given over a ten-minute time period.
46057179|NCT04897048|Procedure|Incremental exercise test (IET)|Incremental cardio pulmonary exercise test until exhaustion
46057180|NCT04897048|Procedure|Constant work rate exercise test (CWRET)|constant (on 75% Wmax) cardio pulmonary exercise test until exhaustion
45510040|NCT04580615|Device|CardiacSense1 and capnograph Respiratory rate measurement|Inpatients Subjects with respiratory disease/impairment and Inpatients Subjects with no known respiratory disease/impairment will be measured simultaneously with both CardiacSense1 and capnograph for at least 30 minutes up to 24 hours. During this time capnograph data will be recorded in parallel to CardiacSense1.
45402205|NCT03849196|Drug|Bisacodyl 10Mg Suppository|bisacodyl 10 mg suppository
45510041|NCT02818998|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|
45402206|NCT03849196|Drug|1L PEG-Asc|PEG-Asc powder
45510042|NCT05760677|Drug|control group: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone|the control group： classic treatment: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone
45510043|NCT05760677|Drug|the experimental group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar|the experimental group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar (32mg QD)
45402207|NCT05282836|Device|Hydrogen Oxygen Generator with Nebulizer|Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) during a 7-day stay in the intensive care unit.
45402208|NCT01292668|Drug|methyl-5-aminolevulinate hydrochloride cream|Applied topically
45402209|NCT01292668|Drug|photodynamic therapy|Undergo light-emitting diode photodynamic therapy
45402210|NCT01292668|Procedure|laser therapy|Undergo laser light photodynamic therapy
45402211|NCT01189084|Biological|Observational|Measure anti-Amyloid-beta antibody in serum during 24-26 weeks extension period to 48 weeks (after first vaccine treatment).
45510044|NCT05118113|Procedure|Collection of mobilized hematopoietic stem cells (apheresis products) from healthy volunteers|Mobilisation of hematopoietic stem cells by injection of filgrastim (authorized auxiliary medicinal product) for 4 consecutive days and leukapheresis on Day 5
45510045|NCT05042219|Diagnostic Test|Cardiac MRI|Cardiac MRI and Echocardiography before treatment initiation of pulmonary disease and 3 months thereafter
45510046|NCT05579015|Device|Theta-burst stimulation (TBS)|TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz), as described previously. iTBS consists of 2-second trains with an inter-train interval of 8 seconds. The investigators will repeat the trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20). cTBS will comprise uninterrupted bursts to reach a total of 600 pulses. Concurrent TBS/fNIRS stimulation will be applied over the left (iTBS) and right (cTBS) DLPFC at an intensity of 90% resting motor threshold (RMT). This corresponds to ~110% of the active motor threshold. Stimulation at 90% RMT will also ensure compliance, reduce sensory discomfort and minimize dropout rates. Still, scalp discomfort will be recorded directly after the stimulation. The stimulation site over the DLPFC will be determined using the international 10-20 system and correspond to the F3 label.
45510047|NCT05579015|Other|telephone interviews|Telephone interviews will be conducted at the follow-up stage. RMDD group will receive follow-up telephone interviews every 3 months for 2 years to monitor major depressive episode recurrence
45510048|NCT05575583|Device|repetitive transcranial magnetic stimulation|The neural navigation system was used to accurately locate the stimulus target.Continuous theta short rapid pulse mode was used. CTBS mode consisted of a slave stimulus delivered every 0.2 seconds (5Hz), and each slave stimulus consisted of three bursts of 50Hz. A single stimulus lasts about 40 seconds and totals 600 pulses.
45510049|NCT05575583|Device|pseudo repetitive transcranial magnetic stimulation|Participant in control group receive pseudo repetitive transcranial magnetic stimulation
45510050|NCT02821416|Biological|Benralizumab|Benralizumab subcutaneously on study day 0 until study week 16 day 1 inclusive
45510051|NCT02821416|Other|Placebo|Placebo subcutaneously on study week 0 until study week 16 day 1 inclusive
45402212|NCT03851692|Other|Intravenous Cannulation (iv placement)|The aim of our study is to determine whether one should make intravenous attempts placement during the early induction period (at 60seconds) or lately (90 or 120 s) and waiting until the child receives additional sevoflurane inhalation anesthesia.
45402213|NCT01296724|Other|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various Intravesical pressure measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
45510052|NCT03108521|Drug|Sitagliptin|100mg.QD for 3 months
45510053|NCT03992274|Other|Enhanced implementation of PrEP|During Enhanced Implementation study sites will receive Implementation Support to plan and introduce PrEP by following the eight stages of the PrEP-adapted SIC. Implementation Support specifically will involve a centralized technical assistance system developed using US-based PrEP experience focused on addressing implementation issues identified through real-time analysis of client, clinic, and implementation data.
45850697|NCT00005592|Biological|rituximab|Rituxan is a mouse/human monoclonal antibody and reacts with the CD20 antigens found on lymphoma cells and causes the body's immune system to destroy the lymphoma cells. It is infused at a dose of 250 mg/m2 followed by a second infusion approximately one week later of the same dose.
45850698|NCT00005592|Radiation|indium In 111 ibritumomab tiuxetan|IDEC-In2B8 is a mouse monoclonal antibody that contains Indium, routinely used in nuclear medicine. It is given as a one-time intravenous injection over a ten-minute time period immediately following a Rituxan infusion. The physician will then be able to see and evaluate the location and concentration of the antibody in the body.
45402214|NCT01296724|Other|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various IVP measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
45402215|NCT01296802|Drug|dexfenfluramine|oral, 40 mg to 60 mg, single application as a challenge
45402216|NCT01189162|Device|NIMV with SLE ventilator vs HFNC via Vapotherm|Nasal respiratory support for RDS
45402217|NCT03851536|Procedure|Transvaginal Ultrasound Guided ET|Use of TVUS to guide ET
45850699|NCT00005598|Drug|amifostine trihydrate|
45402218|NCT03851536|Procedure|Transabdominal Ultrasound Guided ET|Use of TAUS to guide ET
45402219|NCT01296958|Drug|Niclosamide|Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)
45402220|NCT01296958|Behavioral|Community education campaign|Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.
45510054|NCT04500509|Drug|diclofenac potassium + dinoprostone|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal dinoprostone (6 mg) 6 hours prior to the procedure by the patient
45402221|NCT01191580|Behavioral|Interpersonal Psychotherapy|Interpersonal Psychotherapy will consist of twelve 50-minute sessions delivered within a period of 16 weeks. IPT is divided into three phases.
45510055|NCT04500509|Drug|diclofenac potassium + placebo|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal placebo 6 hours prior to the procedure by the patient
45510056|NCT03854838|Drug|Tolipalimab|Radiation begun the day after the first dose of Toripalimab. Toripalimab (240mg dose every 3 weeks for 7 cycles, one cycle is three weeks) will be administered as an intravenous infusion over 60 minutes.
45510057|NCT03854838|Radiation|Reirradiation|intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks
45510058|NCT05001191|Other|Gentle Human Touch|Gentle human touch, which has a pain and stress-reducing effect, is a sensitive tactile stimulus applied to the skin, without caress or massage, which provides a kind of relaxation.
45510059|NCT05760599|Drug|Candonilimab|10mg/kg, iv.drip, every 3 week
45510060|NCT05760599|Drug|Bevacizumab|15mg/kg, iv.drip, every 3 week
45510061|NCT04454255|Behavioral|FunSpeech|Weekly sessions of regular speech therapy as regularly performed for the individual participant (one hour, once or twice a week) and parent-supervised home use of a serious game. It will be recommended to use FunSpeech every day, 15 minutes per day.
45510062|NCT04454255|Behavioral|Control|Weekly sessions of regular speech therapy as regularly performed for the individual participant (one hour, once or twice a week).
45510063|NCT04442945|Drug|ANAVEX3-71|Active oral dose of ANAVEX3-71
45510064|NCT04442945|Drug|Placebo|Oral placebo
45510065|NCT04441073|Drug|Lignocaine|preoperative nebulization of lignocaine
45510066|NCT04441073|Drug|Placebo|preoperative nebulization of normal saline (Nacl 0.9%) as a placebo
45510067|NCT03633539|Procedure|Single-incision Laparoscopic Surgery|Patients undergo single-incision laparoscopic surgery. In this group，the surgery is performed through a transumbilical port. The surgeon will adjust surgical position to expose the operative field with the help of gravity. Besides，hand over hand cross and parallel techniques are needed to achieve the SILS. All the other operative procedures are the same as conventional laparoscopic surgery.
45510068|NCT03633539|Procedure|Conventional Laparoscopic Surgery|Patients undergo conventional laparoscopic surgery. In this group，the surgery is performed through 3-5 ports according to the surgeons habits and specific conditions.
45510069|NCT02036034|Device|forced air warmer (Bair Hugger)|forced air warmer placed under the chin before draping, forced air warmer inflated after draping is completed.
45510070|NCT02036034|Device|warming blanket|warming blanket placed on torso of patient under the drape.
45510071|NCT04343989|Drug|Clazakizumab 25 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.
45510072|NCT04343989|Drug|Clazakizumab 12.5 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 12.5 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 12.5 mg clazakizumab will be given no later than day 3.
45850700|NCT00005598|Drug|azacitidine|
45850701|NCT00005604|Biological|recombinant interleukin-12|Given IV
45402222|NCT01191580|Behavioral|Problem-Solving Therapy|Problem-Solving Therapy will also consist of 12 50-minute sessions. The goals of the PST are: 1) to assist patients to identify and link life situations related to the depression; 2) to increase the effectiveness of the patient's problem-solving attempts at coping with current problems based on an intervention carried out in a concrete, structured and, unambiguous manner.
45510073|NCT04343989|Other|Placebo|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
45850702|NCT00005604|Biological|aldesleukin|Given SC
45850703|NCT00005604|Other|laboratory biomarker analysis|Correlative studies
45850704|NCT00005610|Biological|sargramostim|
45850705|NCT00005616|Procedure|conventional surgery|
45850706|NCT00005616|Procedure|neoadjuvant therapy|
45850707|NCT00005616|Procedure|radionuclide imaging|
45402223|NCT01191580|Behavioral|Brief Supportive Psychotherapy|"The treatment approach will follow the standard supportive therapy approaches used in depression and medical illness, as noted below.~Brief Supportive Psychotherapy has a biopsychosocial perspective, recognizing contributions of genetic predisposition and neuroendocrine factors (Novalis et al., 1993, p. 257-277). Its goals are to maximize patient function during crisis, to support the patient's judgment with the therapist's reasoning skills, and to engender hope for recovery. Primary techniques and practices include reality testing; being relatively accepting of existing defenses but attempting to restructure them when appropriate; and, using self-esteem enhancing measures."
45510074|NCT04354259|Drug|Peginterferon Lambda-1A|Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain. Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose.
45510075|NCT04354259|Other|placebo|injection of 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
45510076|NCT05598073|Behavioral|Vinyasa yoga session|One hour of vinyasa yoga will be completed.
45510077|NCT04089787|Other|Intervention|Shortened antibiotic treatment of 5 days
45510078|NCT04089787|Other|Control|Antibiotic treatment of 7 days or longer at the discretion of the treating physician
45510079|NCT02817828|Drug|15 mg E4/3 mg DRSP|15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
45510080|NCT03632681|Drug|Intranasal Insulin|Intranasal insulin
45402224|NCT01295086|Drug|Docetaxel|42, 51 or 60 mg/m² day 1 every 3. week
45402225|NCT01295086|Drug|Oxaliplatin|100 mg/m² day 1 every 3. week
45402226|NCT01295086|Drug|Capecitabine|1250 mg/² continuously
45402227|NCT01295086|Drug|Trastuzumab|Trastuzumab 8 mg/kg day 1, cycle 1. Following cycles 6 mg/kg every 3. week
45402228|NCT03847012|Other|exercise|The test order will be random. After at least 12 times of cardiopulmonary rehabilitation training, the test will be performed again.
45402229|NCT03851224|Procedure|control group|immediate implant with immediate loading using no graft
45402230|NCT03851224|Procedure|study group|immediate implant with immediate loading using autogenous bone graft
45402231|NCT03851224|Procedure|study group 2|immediate implant with immediate loading using (Geistlich Bio-Oss®) xenograft
45402232|NCT01194700|Drug|Seretide 250(8puffs) via Evohaler actuator|8 puffs of Seretide250/Placebo via Evohaler actuator
45510081|NCT03632681|Drug|Intranasal Placebo|Intranasal placebo manufactured to mimic smell of insulin
45510082|NCT05483387|Device|Treatment with HBS 2 Resorb Mg|Treatment of fractures, arthrodesis or pseudarthroses of small bones and bone fragments
45510083|NCT05597995|Drug|Sodium Tetradecyl Sulfate|subjects epidermoid cysts will be treated with 1.5% sodium tetradecyl sulfate foam
45510084|NCT05760365|Other|3D printed educational model|3D printed cardiac catheterization model
45510085|NCT05760365|Other|Slide-based presention|Slide-based presention
45510086|NCT05597917|Drug|Trabectedin|Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.
45510087|NCT05597917|Biological|tTF-NGR|Patients will receive standard trabectedin 1.5 mg/m2 plus 3 mg/m2 (or safe dose according to phase II part) tTF-NGR (1-hour rate-controlled infusion, port central venous access, 0.9 % NaCl ad 100 mL) per day for 4 consecutive days following each trabectedin cycle (within 1 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 9 am and on the following days (last tTF-NGR on friday), q d 22 x until disease progression or contraindications against further application.
45510088|NCT04880057|Other|Resistance+Aerobic training|"The RT focuses on lower extremity workout, including leg press, hamstring curls, and calf raises. The participants start with intensity at 12 RM and finished with intensity at 8 RM after 3 weeks. There are 8 repetitions, 2 sets for each action. It will take 15 minutes to complete RT.~The AeT is composed by cycling on stationary bikes in the first week, stepping on steppers in 2nd week, and running on treadmills in the last week. Participants are asked to wear a portable heart rate monitor throughout the experiments. They have to maintain their heart rates in 60%-75% of predicted maximal heart rate (moderate intensity exercise), which has been shown to be benefit on cognition[3]. It took the participants 25 minutes to complete AeT."
45402233|NCT01194700|Drug|Seretide 250 (8 puffs)/placebo via Volumatic spacer|8 puffs of Seretide 250/placebo via volumatic spacer
45402234|NCT01194700|Drug|Seretide 250/placebo 8 puffs via Aerochamber Plus spacer|Seretide 250/placebo 8 puffs via Aerochamber Plus
45402235|NCT01194700|Drug|Seretide 250/placebo via Synchro-Breathe|Seretide 250/placebo 8puffs via breath actuated Synchro-Breathe device
45402236|NCT01189318|Drug|Quetiapine Fumarate Extended Release|Day 1 50mg, Day 2 50mg, Day 3 150mg, Day 4~28 50~150mg (increments and deduction of 50mg are allowed)
45402237|NCT01194778|Dietary Supplement|placebo|1 placebo sachet per day containing only sucrose during 12 weeks
45510089|NCT04880057|Other|Agility training|AT program consists of three parts: technical drills, pattern running and reactive agility training. There will be nine sessions over 3 weeks and progress the intensity, complexity or velocity every week.
45510090|NCT02817906|Drug|ITI-007|
45510091|NCT02817906|Drug|Placebo|
45510092|NCT05597605|Device|The SHINE SYSTEM|The FUSHO sensor, which is part of the SHINE SYSTEM, is a continuous multi-metabolite monitoring (CMM) sensor which is a miniaturized near-infrared spectrometer that measures the absorption of light in the interstitial fluid to quantify the concentration of multiple metabolites
45510093|NCT04338971|Device|IpsiHand Therapy|The IpsiHand system utilizes a Brain-Computer Interface (BCI) to enable operation of a robotic hand exoskeleton worn on the hand and wrist as participants are guided through a rehabilitation program on a tablet. Participants will complete 12 weeks of hometherapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 12 weeks completion of IpsiHand use.
45510094|NCT03796650|Other|Fecal microbiota transplantation|50 g donor feces suspended in saline with added glycerol, administered by a enema kit.
45510095|NCT03796650|Drug|Vancomycin|Peroral vancomycin 125 mg q.i.d. for ten days.
45510096|NCT05597527|Drug|Fluzopari and apatinib|Fluzopari was used as 100mg capsules orally twice a day (one time in the morning and one time in the evening), every four weeks as a cycle, a total of 3-4 cycles. Apatinib was used as 250 mg orally once a day, every 4 weeks as a cycle, 2-3 cycles in total, and stop 4 weeks before operation.
45510097|NCT04234295|Procedure|Fat Tissue Biopsy|If subjects are scheduled for a surgical procedure a fat sample will be collected during the beginning of the surgery. If subjects are not scheduled for a surgical procedure, a small sample of subcutaneous (superficial) fat tissue from subjects abdomen area will be collected.
45510098|NCT02912143|Other|documentation only|
45510099|NCT05198999|Other|Aquatic-based Plyometric Exercises|The Aqua-PLYO group received the aquatic plyometric exercise training for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association
45510100|NCT05198999|Other|Standard Physical Therapy|The control group received the standard physical rehabilitation program conducted for 45 minutes, thrice a week for 12 consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
45510101|NCT05707494|Device|Efferon LPS NEO|Efferon LPS NEO, a medical device, which is a cylindrical body filled with a polymeric hemosorbent that selectively absorbs LPS and excess cytokines. The device is used for extracorporeal therapy to relieve septic shock in the treatment of sepsis.
45402238|NCT01194778|Dietary Supplement|vitamin K1|15 µg vitamin K1 per day during 12 weeks
45402239|NCT01194778|Dietary Supplement|vitamin K2|15 µg vitamin K2 per day during 12 weeks
45402240|NCT01194778|Dietary Supplement|vitamin K2|30 µg vitamin K2 per day during 12 weeks
45402241|NCT01194778|Dietary Supplement|vitamin K2|45 µg vitamin K2 per day during 12 weeks
45402242|NCT01194934|Drug|NOX-A12|4 mg/kg daily IV for 5 days
45402243|NCT01194934|Drug|NOX-A12|2 mg/kg daily IV for 5 days
45510102|NCT02896699|Behavioral|PrEP Intervention Group|
45510103|NCT02896699|Other|Control Group|
45402244|NCT01194934|Drug|Filgrastim|5 µg/kg SC daily for 5 days
45402245|NCT01194934|Drug|NOX-A12 in combination with Filgrastim|Safe and efficacious dose regimen according to results of groups A and B
45510104|NCT04230941|Behavioral|MAAT-G|Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies. MAAT-G has been adapted to optimize usability. We are now testing the feasibility of MAAT-G in older cancer survivors with Mild Cognitive Impairment.
45510105|NCT02036112|Procedure|conventional ELAPE|device
45402246|NCT01353118|Biological|gastric bypass|Optimise glucose control within 3 months before operation
45510106|NCT02036112|Procedure|Individual ELAPE|device
45510107|NCT05707416|Device|gallium aluminum arsenide (Ga-Al-As) semiconductor diode laser (SMARTTM PRO, LASOTRONIX, Poland)|The laser will be applied to 4 points of application for each tooth two labial and two palatal started immediately after first intrusive wire then at days 3,7,14 and then every 15 day until achievement of the study objectives
45510108|NCT05707416|Other|group B|Will includes 9 patients who will receive intrusive arches after leveling and alignment without laser application
45510109|NCT02036268|Behavioral|Standard|Standard ostomy education
45510110|NCT02036268|Behavioral|Pre-operative Education|In addition to standard ostomy education, an additional pre-operative ostomy education session will be conducted with the subject.
45850708|NCT00005616|Radiation|iodine I 131 monoclonal antibody F19|
45850709|NCT00005622|Drug|cyclophosphamide|Cyclophosphamide is administered at a dose of 60 mg/kg on each of two successive days (Days -6 and -5)
45510111|NCT02036268|Behavioral|Two-week Post Operative Education|In addition to standard ostomy education and an additional pre-operative ostomy education session, another ostomy education session will be conducted with the subject two weeks post-op.
45510112|NCT04749251|Procedure|Individualized blood pressure management|During the EVT procedure, mean arterial blood pressure (MABP) is targeted to remain within +/- 10 % of a reference value using vasoactive drugs and/or fluids
45510113|NCT04749251|Procedure|Standard blood pressure management|During the EVT procedure, mean arterial blood pressure (MABP) is targeted to remain within a fixed range of 70-90 mmHg
45510114|NCT04215185|Device|Arterial LIne|Continuous non-invasive recording of CS6BP will be taken parallel to the recording of an invasive arterial line. ECG data recorded in the ICU will also be collected.
45510115|NCT05198609|Procedure|FOLFOX-HAIC|Hepatic arterial infusion of oxaliplatin (85mg/m2,IA,day 1, hour 0-2), fluorouracil (400mg/m2,IA,day 1, hour 3), leucovorin (400mg/m2, IV,day 1, hour 2-3) and fluorouracil (2400mg/m2, IA, hour 3-23) repeated every 4 weeks for a total of six times
45850710|NCT00005622|Radiation|TBI|FTBI is performed on day -3 through day 0 The total dose of radiation is 1,320 cGy.
45850711|NCT00005628|Biological|vitespen|
45850712|NCT00005634|Drug|vorinostat|
45850713|NCT00005640|Procedure|Preoperative Endoscopy|
45402247|NCT03849040|Procedure|Endobronchial Ultrasound|All patients will undergo EBUS-TBNA as per routine care, except for the one difference where the procedures will be video-recorded so that they can be used for computer analysis at a later time. Static images will be obtained from EBUS videos in order to perform segmentation. Segmentation will be conducted by both an experienced endoscopist and NeuralSeg.
45402248|NCT01189474|Device|Blephasteam|Eye lid warming goggles
45402249|NCT01297036|Drug|Donepezil, ODT 10 mg|Test- Donepezil Hydrochloride 10 mg Tablet single dose
45402250|NCT01297036|Drug|Donepezil, 10 mg tablet|Reference: Donepezil Hydrochloride 10 mg Tablet
45402251|NCT01189552|Behavioral|LETS ACT Behavioral Activation Treatment|LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001). Treatment includes eight sessions over a four-week period and is provided in small group format, with each group consisting of 3-5 patients.
45850714|NCT00005640|Radiation|Technetium Tc 99m Sulfur Colloid|
45850715|NCT00005640|Procedure|Gamma Probe|
45850716|NCT00005640|Procedure|Biopsy of Sentinel Lymph Nodes|
45850717|NCT00005646|Drug|paclitaxel|150 mg/sq m IV over 3 hours weekly for 6 weeks per cycle
45850718|NCT00005652|Drug|rituximab|
45850719|NCT00005658|Drug|Glycine|
45850720|NCT00005724|Behavioral|Computer Program Intervention Group|A user-friendly, interactive computer program providing dietary counseling tailored to the needs of the participant.
45510116|NCT05198609|Drug|Camrelizumab|Camrelizumab was administered 200mg intravenously for 30-60 minutes every 2 weeks, and the maximum cumulative duration of Camrelizumab is 2 years. The shortest time interval between two administrations should not be less than 12 days.
45510117|NCT05198609|Drug|Apatinib|Apatinib was administered orally 250mg once per day
45402252|NCT01189552|Behavioral|Nondirective Therapy (NDT)|The purpose of Nondirective Therapy (NDT) is to provide group therapy interaction, allowing for the development of a close therapeutic relationship and a safe and accepting environment to facilitate change. NDT will be conducted as outlined by Crits-Cristoph (1997). That is, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. Patients will received NDT in a small group format (3-5 participants) and will meet over the course of 4 weeks.
45402253|NCT01297114|Drug|Florbetaben|This is a purely observational study. Results of the Florbetaben PET scan will be correlated with other observations.
45510118|NCT04187495|Drug|MAX-40279-01|"Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1.~For each dose level, a single dose of MAX-40279-01 will be first administered orally followed by 1 day observation, then continuous treatment will start 4 weeks treatment (per cycle)."
45510119|NCT03633383|Device|Transcatheter aortic valve|Self-expandable aortic valve prothesis
45510120|NCT05198141|Drug|Letrozole tablets|GI: Patients who were undergoing laparoscopic salpingectomy GII: patients who medically treated with 5 mg d-1 of letrozole using two tablets (2.5 mg of Femara) every day for 10 d GIII patients who medically treated with 10 mg d-1 of letrozole using four tablets (2.5 mg of Femara) every day for 10 d (group III)
45510121|NCT05198141|Procedure|laparoscopic salpingectomy|laparoscopic salpingectomy
45510122|NCT02813694|Drug|lefamulin|antibacterial agent
45510123|NCT02813694|Drug|Moxifloxacin|antibacterial agent
45402254|NCT01292824|Drug|ITX 5061|ITX 5061 (150mg) pre-transplant, immediately post-transplant and daily thereafter for 1 week.
45510124|NCT03632161|Drug|Dexmedetomidine|isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg)
45510125|NCT03632161|Drug|Bupivacaine|isobaric bupivacaine 0.5% (0.3ml/kg)
45510126|NCT03631459|Drug|Kanglaite Injection/Capsules|Kanglaite injection 200 mL, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles
45510127|NCT03631849|Procedure|peri implantitis sanitation surgery|"an intrasulcular vestibular and lingual / palatal incision with respect to the implant-supported restoration involved is performed, it extends to at least one tooth on either side in order to give laxity to the flap. The use of an incision of discharge will be necessary if the muco-periosteal detachment of the flap (that is to say of full thickness) is considered insufficient to access and unclamp the peri-implant lesion.~Then, the debridement will be carried out using manual curettes in titanium: the products (waste) removed with this curette will constitute the peri-implant pocket specimens. This sample will be deposited in a Roswell Park Memorial Institute Medium (RPMI) supplemented with serum.The surface of the titanium implant will then be disinfected with betadine, or with hydrogen peroxide for patients with an allergy to polyvidone iodine.~The flap will then be repositioned and sutured with simple stitches made with a resorbable suture of Vicryl type 5.0."
45850721|NCT00005724|Other|Minimal Intervention Group|Dietary Information pamphlets.
45510128|NCT03631849|Other|Care|descaling and maintenance of implants
45510129|NCT03103919|Device|Kinesia-ONE™|Kinesia-ONE™ wearable sensor uses a subject-worn finger sensor and iPad mini application (APP) to objectively measure specific motor tasks related to Parkinson's disease symptoms such as tremor, bradykinesia (slowed movements), and dyskinesia (involuntary movements) in the Investigator's office. Subjects should wear the Kinesia-ONE™ device on the most affected side.
45510130|NCT03103919|Device|Kinesia-360™|Kinesia-360™ wearable sensor includes a wrist and ankle device, along with a cell phone, which is also APP-based, and is designed for continuous day time monitoring of Parkinson's disease symptoms. Subjects will wear Kinesia-360™ while they go about their daily lives, and symptom severity is continually captured to enable objective assessment of Parkinson's disease symptoms. Subjects should wear the Kinesia-360™ device bands on the most affected side.
45510131|NCT03103919|Drug|Rotigotine|All subjects will start Neupro treatment at a dose of either rotigotine 2 mg/24 h or 4 mg/24 h (according to the disease stage of the subject) which will then be adjusted based on symptom assessment either via standard care alone or via a combination of standard care and evaluation of the recordings made available by the Kinesia wearable technologies.
45510132|NCT01568203|Drug|AMG 579|3 dose levels of single oral dose administration of AMG 579 in healthy subjects (Part A), and 5 dose levels of single oral dose administration of AMG 579 in patients with schizophrenia or schizoaffective disorder (Part B)
45850722|NCT00005724|Behavioral|Health Counselor Intervention Group|Food for Heart Program - a structured diet treatment program for low income patients with high cholesterol, given by a health counselor at 4 treatment visits.
45850723|NCT00005766|Drug|Creatinine|
45850724|NCT00005772|Device|Induced hypothermia|Whole-body cooling using the Blanketrol II or III Units in the Automatic Control Mode with a YSI 400 series temperature probe placed in the distal esophagus over a 96-hour period
45850725|NCT00005772|Device|Control|Control group: standard care
45850726|NCT00005778|Drug|High-dose immunoablative therapy|"High dose cyclophosphamide for 4 days.~NIH monthly IV cytoxan for 6 months followed by quarterly for 2 years."
45850727|NCT00005790|Other|laboratory biomarker analysis|
45402255|NCT01292902|Other|inspiratory muscle exercise|To conduct the exercise to the inspiratory muscles was used for IMT Threshold ® device (Threshold Inspiratory Muscle Trainer, HealthScan Products Inc., Cedar Grove, New Jersey) is one of the most used for training of inspiratory muscles in patients with several pathologies such as ICC.Threshold ® has been engaged in the patient's mouth by a mouthpiece, with the nose occluded by a nose clip. The exercise time was 3 minutes. During this period, participants were encouraged to only breathe through the mouth and maintain a respiratory rate between 12 and 16ipm. The exercise would be stopped if HR increased more than 20% and / or SpO2 < 88%.
45402256|NCT01292902|Other|inspiratory muscle exercise|Equal to the group with chronic heart failure.
45402257|NCT01195012|Behavioral|Helping HAND (Healthy Nutrition and Activity Directions)|6-month behavioral intervention targeting 5-8 year old children and their parents to improve the child's lifestyle behaviors to improve their weight status. The families met monthly with trained Health Advisors for individual sessions in the pediatric clinic with phone calls in between visits to check on progress.
45402258|NCT03846700|Device|aquablation|"minimally invasive, robot-assisted and ultrasound-guided ablation of the prostate in targeted way and in heat-free way working by high pression water jet"
45402259|NCT03846700|Device|holep|holmium laser enucleation of prostate
45510133|NCT01568203|Drug|Placebo|Matching placebo control for AMG 579 at each dose level
45510134|NCT02036892|Behavioral|Lifestyle counseling with smartphone|Lifestyle counseling with health promoting smartphone software
45698509|NCT04215900|Behavioral|High-speed yoga multi-directional yoga|The yoga training will be performed over a 4-month period where classes will be held two times per week. Each session will include a warm-up, speed and balance training section, and cooldown phase. The yoga program will include four separate progressions with the first four weeks serving as a familiarization phase, where the participants will be introduced to the poses and proper technique will be demonstrated. The second four-week phase will emphasize a speed component used to target improvements in aerobic capacity. The same poses previously learned will be used. The final two phases will increase in intensity maintaining the speed element and include skill-based training, where the participants will be asked to complete each pose moving as quickly as possible in response to visual and auditory cues.
45850728|NCT00005790|Procedure|biopsy|
45510135|NCT02036892|Behavioral|Lifestyle counseling|Lifestyle counseling
45510136|NCT04173325|Drug|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|PD-1 inhibitor approved by the US FDA for treatment of patients with lung cancer.
45698510|NCT01133158|Drug|Rituximab, Bendamustine, Mitoxantrone, Dexamethasone|Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv Dexamethasone 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv
45698511|NCT03109626|Dietary Supplement|DHA|
45850729|NCT00005790|Procedure|magnetic resonance imaging|
45850730|NCT00005790|Radiation|gadopentetate dimeglumine|
45850731|NCT00005796|Procedure|filgrastim|GCSF is given after chemo administration
45402260|NCT03846700|Device|pvp|photoselectivevaporization of prostate
45698512|NCT05396118|Drug|18F-FDG|Injection of 4 MBq/kg of 18F-FDG followed by dynamic positron emission tomography (PET) imaging
45850732|NCT00005796|Biological|gene therapy|stem cells are collected and given back to the patients after chemotherapy adminstration
45850733|NCT00005796|Drug|lomustine|chemotherapy is administered every 21 days
45510137|NCT04173325|Drug|Irinotecan Injection [Camptosar]|Chemotherapy drug currently FDA approved for treatment of multiple tumors, including small cell lung cancer.
45698513|NCT05396118|Drug|Injection of hyperpolarized [1-13C]Pyruvate|Injection of one bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized [1-13C]Pyruvate followed by magnetic resonance spectroscopy (MRS) / magnetic resonance spectroscopy imaging (MRSI). After a 5-30 min pause, injection of a second bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized [1-13C]Pyruvate followed by MRS / MRSI.
45698514|NCT05396118|Procedure|PET/MR/MRS/MRSI scanning|Regional dynamic PET acquisition for up to 90 minutes following 18F-FDG injection is performed focused on a region-of-interest (ROI). Anatomical magnetic resonance imaging (MRI) is performed in the ROI, including diffusion weighted imaging (DWI) and contrast enhanced imaging (DCE). MRS/MRSI is performed following the injections of hyperpolarized [1-13C]Pyruvate.
45698515|NCT01133860|Drug|eltrombopag|Eltrombopag, administered orally, 50 mg/daily for 21 days. Patients with platelet counts between 100 and 150x10e9/L at day 21 will continue eltrombopag 50 mg/daily for 21 additional days. Patients with platelet count lower than 100x10e9/L at day 21 will receive eltrombopag 75 mg/daily for additional 21 days. Patients with more than 150x10e9 platelets/L at day 21 will stop therapy.
45850734|NCT00005796|Drug|procarbazine hydrochloride|chemotherapy is administered every 21 days.
45850735|NCT00005796|Drug|vincristine sulfate|chemotherapy is administered every 21 days
45850736|NCT00005796|Procedure|in vitro-treated peripheral blood stem cell transplantation|stem cells are reinfused after chemotherapy administration
45850737|NCT00005802|Biological|aldesleukin|
45510138|NCT05597449|Behavioral|YouTube videos on care after urologic surgery|Supplemental educational videos regarding care following pediatric urologic surgery
45510139|NCT05597371|Other|the use of the platform|the use of the platform
45510140|NCT04550741|Other|telerehabilitation|After obtaining consent, the volunteers will be included in the study at the start of the 4th week and randomized into two arms: Experimental and Control group
45510141|NCT02810964|Drug|Sulforaphane Nutraceutical|Sulforaphane Nutraceutical 6 tablets by mouth daily
45510142|NCT02810964|Drug|Identical-appearing Placebo|Identical-appearing Placebo 6 tablets by mouth daily
45510143|NCT05596123|Behavioral|Therapeutic Chinese foot massage|Participants in the TCFM group will receive six weekly 25-minute TCFM sessions by a therapist. Each session will start with an assessment of the legs and toes of the affected extremity for broken skin and lesions, which the therapist will try to avoid. The participant will be positioned with support to their foot and legs, with the sole directed downward and the therapist directly in alignment with the soles of the foot. The therapist will sequentially perform the following four steps for each TCFM session.
45510144|NCT05596123|Behavioral|Placebo massage|The same therapist will give six weekly 25-minute placebo massage sessions to participants in the placebo massage group. These sessions will include assessing the affected extremity's legs and toes for lesions and broken skin in order to avoid them during the massage, as well as gentle foot and toe rubbing without any point stimulation or other TCFM techniques.
45510145|NCT04392947|Device|Transcranial Magnetic Stimulation|MagVenture Coil Cool B70 A/P
45510146|NCT04392947|Device|Sham Transcranial Magnetic Stimulation|MagVenture Coil Cool B70 A/P without TMS being actively delivered
45402261|NCT01295164|Device|classic aberrometer and aberrometer AOVIS-1|"Measurement of aberrations in early stages (1 and 2) of keratoconus as compared aberrometer AOVIS-1 with a classic aberrometer."
45510147|NCT05591131|Other|genetic testing|Undergo genetic testing
45510148|NCT05591131|Other|Survey Administration|Complete survey
45510149|NCT02036346|Dietary Supplement|Oral Ηydration Solution|Oral rehydration solution containing: sodium chloride, sodium citrate, glucose, magnesium citrate, food additives and water.
45510150|NCT02036346|Other|Advise on calculated oral fluid requirements|
45510151|NCT02036346|Other|No nutritional advice will be given|
45510152|NCT04344899|Other|Observational|Enhanced Recovery After Surgery protocol at five tertiary-care pediatric hospitals in pediatric patients undergoing abdominal or retroperitoneal surgical resections for cancer.
45510153|NCT02810652|Other|Usual Care|Usual Care participants will not meet with a geriatric clinician perioperatively, though they may receive a geriatric consult at their request or at the discretion of their treating cancer team.
45510154|NCT02810652|Other|Perioperative Geriatrics Intervention|Patients randomized to the perioperative geriatrics intervention will undergo evaluation with a board-certified Massachusetts General Hospital (MGH) geriatric clinician, both pre- and post-operatively. The geriatric clinician visits will focus on the following issues: comorbidity, polypharmacy, nutrition, physical and mental function, and social support.
45510155|NCT05197985|Behavioral|IECD Intervention|The Nurturing Care curriculum contains: 1) responsive caregiving, 2) the important role everyone plays in raising a child, 3) maternal health and nutrition, 4) responsive feeding and good nutrition, 5) how children grow and develop, 6) hygiene, 7) language development, 8) the importance of play, 9) managing the stress of parenting, 10) protecting your child from harm. Modules will be delivered through group sessions for caregivers, individualized home visits and Social Behavior Change Communication. IECD will build families' capacity to grow and raise healthy food to consume themselves, and connect them to agricultural markets. Specifically, IECD will provide agriculture technical training to Village Model Farms and households, and will facilitate linkages to markets by identifying buyers and connecting them to the farmers. IECD will train and support volunteers to conduct disability screening, and train disability interventionists to provide appropriate therapies and support services.
45510156|NCT02742883|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Patients with diffuse intrinsic pontine glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
45510157|NCT05760131|Other|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
45510158|NCT04167943|Drug|Dual cured resin modified tricalcium silicate cement|A resin based, dual cured tricalcium silicate based cement
45510159|NCT05571319|Drug|Metformin Extended Release Oral Tablet|Glucophage XR 500 mg
45510160|NCT04073147|Drug|Venetoclax|Venetoclax per os
45850738|NCT00005802|Biological|filgrastim|
45402262|NCT01295164|Device|Aberrometer AOVIS-I|Measurement of aberrations in high stages (3 and 4) of keratoconus. Objective characterization of the optical quality of the patient eye by application of wave-front sensing technology in late stage keratoconus The complete procedure in one patient takes less than 5 minutes in only one consultation and is completely non invasive. The optical measurements only involve the use of low power infrared laser
45850739|NCT00005802|Biological|therapeutic allogeneic lymphocytes|
45850740|NCT00005802|Drug|cytarabine|
45402263|NCT03848806|Drug|HAT1|During the treatment phase, patients will be ask to apply the product twice daily on all lesional areas. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
45402264|NCT03848806|Drug|Calcipotriol|During the treatment phase, patients will be ask to apply the product twice daily on all lesional areas. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
45402265|NCT03737110|Drug|Rilonacept|Rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥12 and <18 years old) SC , followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and <18 years old) injections once weekly
45510161|NCT04073147|Drug|Obinutuzumab|ObintuzumabIV
45510162|NCT02707159|Drug|Nab paclitaxel / gemcitabine|Patients will receive gemcitabine/nab-paclitaxel combination chemotherapy
45510163|NCT05197907|Procedure|Fascial release of diaphragm muscle.|The intervention consists of deep tissue massage techniques and manual mobilization of the fascia performed within the diaphragm attachments in the area of the costal arches.
45402266|NCT03737110|Drug|Placebo|Placebo SC injections once weekly
45402267|NCT03848884|Behavioral|Adherence monitoring and education|Standardized medication counseling and education combined with individual patient customized guidance and counseling - administered monthly.
45402268|NCT01189708|Device|Ultrapro® Mesh implantation|After the aortic procedure (aortic aneurysm repair) an Ultrapro absorbable mesh will be used for the wound closure of the abdominal wall using an onlay technique.
45402269|NCT01189708|Other|Standard wound closure|Abdominal closure will be performed with standard sutures without a mesh.
45510164|NCT05197907|Procedure|Classic massage of the abdomen.|The intervention consists of selected classic massage techniques - mainly stroking (effleurage) - performed on the superficial layers of the abdominal region
45402270|NCT03850990|Behavioral|Placebo pill and no placebo pill|The placebo pills will be green and white gelatin capsules containing microcrystalline cellulose and other inert ingredients.
45510165|NCT04113187|Drug|Propranolol treatment|40 mg twice a day (morning and evening), per os, during three months
45510166|NCT04113187|Drug|Placebo|per os, twice a day (morning and evening) during three months
45850741|NCT00005802|Drug|etoposide|
45402271|NCT00867802|Behavioral|Mindfulness-Based Stress Reduction program|Mindfulness- Based Stress Reduction comprising of 8 classes and a one-day retreat, taught over a period of 6 weeks. Intervention also includes practice at home for 20-30 minutes.
45510167|NCT05559697|Device|Sponsor incisional negative pressure wound therapy device and dressing|A sponsor incisional dressing placed on the knee and connected to a sponsor disposable negative pressure therapy device
45510168|NCT05559697|Device|Standard of Care incisional negative pressure wound therapy system|The control incisional negative pressure wound therapy system represents the standard of care system and market leader. It consists of a disposable negative pressure therapy device and incisional dressing.
45402272|NCT01189864|Drug|Ciprofloxicin or Vigamox or other.|Ciprofloxicin or Vigamox or other to be used qid till epithelialized.
45402273|NCT01189864|Drug|Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) qid up to 5-10 days post-op
45402274|NCT01189864|Drug|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid to qd for 1-8 weeks.
45402275|NCT05598814|Biological|Mepolizumab Injection|All patients in both the intervention group and the control group will be treated with Mepolizumab injections every month.
45402276|NCT05598814|Procedure|Functional Endoscopic Sinus Surgery (FESS).|The Functional Endoscopic Sinus Surgery will be performed 2 weeks after the first injection of Mepolizumab in the intervention group.
45402277|NCT01195246|Biological|HEPLISAV|Intramuscular (IM) injection on Day1
45402278|NCT01195246|Biological|Engerix-B|Intramuscular (IM) injection on Day 1
45402279|NCT01195246|Biological|Fendrix|Intramuscular (IM) injection on Day 1
45402280|NCT01292980|Device|AFT bed|All identified patients will receive a AFT bed for a maximum of 21 days or until discharge
45510169|NCT03103763|Drug|Warfarin|Patients on warfarin for atrial fibrillation
45510170|NCT04092127|Other|Video Record|Video Record of the premature infant face before and during the RetCam screening of retinopathy of prematurity
45510171|NCT04604275|Drug|Sucrase|1 mL (8,500 I.U.) (one full measuring scoop or 28 drops) per meal or snack for patients up to 15 kg in body weight. 2 mL (17,000 I.U.) for patients over 15kg in body weight. Dosage is 1 or 2 mL (8,500 to 17,000 I.U.) taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
45510172|NCT04604275|Other|Placebo|1 mL of placebo per meal or snack for patients up to 15 kg in body weight. 2 mL of placebo per meal of snack for patients above 15kg in body weight. Dosage is 1 or 2 mL of placebo taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
45510173|NCT05197829|Device|Continuous Glucose Monitoring|Participants in the experimental arm will receive an unblinded flash continuous glucose monitor.
45510174|NCT05197829|Other|Care Coordination|All participants will receive diabetes education, written handouts, and help setting up ambulatory appointments.
45510175|NCT05197517|Drug|Rosuvastatin 10 mg|Film Coated Tablets products containing 10 mg Rosuvastatin
45850742|NCT00005802|Drug|fludarabine phosphate|
45850743|NCT00005802|Drug|methotrexate|
45850744|NCT00005802|Drug|mitoxantrone hydrochloride|
45850745|NCT00005802|Drug|therapeutic hydrocortisone|
45510176|NCT05503927|Other|No Intervention|This is a non-interventional study, therefore no intervention is used.
45510177|NCT05499559|Behavioral|Joint Academy digital treatment|The Joint Academy® (www.jointacademy.com) program for people with hand OA consists of video instructed and progressively adaptable daily exercises, patient education through text lessons, possibility for a social chat group with other patients and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period. The program also contains three telephone consultations with a physiotherapist that were compulsory, one at the start, one after six weeks and one after three months.
45402281|NCT03846856|Other|Biopsy|Biopsy taken during surgical procedure
45402282|NCT03846934|Device|Ultrasonography thoracic|Thoracic ultrasonography will be performed as soon as possible after admission to the ED, without delaying the start of treatment and in addition to routine thoracic radiography.
45402283|NCT05671120|Procedure|Transcutaneous levator recession|recession of the upper and lower eyelid retractors can improve the upper eyelid contour if the patient has lateral flare (common in TED). The choice of procedure depends on severity of lid retraction and associated features like proptosis, status of extraocular muscles, and corneal condition
45510178|NCT04011475|Drug|Tiotropium + Olodaterol|Spiolto®
45510179|NCT04011475|Drug|Other LABA/LAMA|tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium
45402284|NCT01191814|Procedure|Metal stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.
45510180|NCT04011475|Drug|LAMA|aclidinium bromide, glycopyrronium, tiotropium, umeclidinium
45510181|NCT05110781|Biological|Atezolizumab|Given IV
45510182|NCT05110781|Radiation|Radiation Therapy|Undergo radiation therapy
45698516|NCT04455516|Procedure|Meniscus repair; partial meniscectomy|69 cases of meniscus repair (repair group) and 96 cases of partial meniscectomy (partial meniscectomy group), were retrospectively analyzed. The 69 patients of the repair group were divided into the nonfailure group (62 cases) and the failure group (7 cases) depending on the repair effect.
45698518|NCT05372406|Other|• no intervention|• no intervention
45698519|NCT01134016|Drug|Antroquinonol|"Antroquinonol was taken orally, daily, within 15 minutes after a breakfast at the assigned dose level: 50, 100, 200, 300, 450, 600 mg/day for 4 weeks.~Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.~The accelerated phase ended when either 1 DLT or MT was observed to start standard phase. Study ended when reach the highest dose level or DLT founded."
45698520|NCT04819074|Procedure|Microsurgery|Microsurgery for unruptured intracranial aneurysm
45850746|NCT00005802|Radiation|radiation therapy|
45402285|NCT01191814|Procedure|Plastic stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a 10Fr plastic stent.
45402286|NCT03850834|Drug|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
45510183|NCT05110781|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45510184|NCT05063903|Other|Demographic and clinical characteristics, incremental shuttle walk test, six minute walk test, hand grip strength, M. Quadriceps isometric muscle strength, body composition|"Demographic and clinical characteristics Age and complaints, post-operative follow-up, other problems, medications, ECHO and ECG findings, laboratory tests (complete blood count, liver and kidney function tests, brain natriuretic peptide (BNP) level)~Hand grip strength Right and left hand grip strength the highest of the three measurements~Lower extremity muscle strength Maximum isometric muscle strength of the quadriceps femoris~Body composition Body fat ratio, lean body weight and fat weight by bioelectrical impedance analysis~6 minute walk test The six minute walk test distance recorded in meters~Incremental shuttle walk test The lap number, the number of laps of the last level they can reach, and the walking/running distances recorded in meters"
45850747|NCT00005808|Drug|motexafin lutetium|Given IV
45850748|NCT00005808|Drug|photodynamic therapy|Undergo laser therapy
45850749|NCT00005808|Procedure|loop electrosurgical excision procedure|Undergo LEEP
45850750|NCT00005808|Other|laboratory biomarker analysis|Correlative studies
45510185|NCT04212221|Drug|MGD013 monotherapy|MGD013 monotherapy will start from Phase I dose escalation first, starting dose will be 120mg Q2W, the dose level may escalate sequentially following traditional 3+3 dose escalation scheme (120mg, 240mg, 400mg, 600mg) to determine the RP2D(recommended phase II dose) of MGD013 monotherapy. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 monotherapy with RP2D determined in Phase I study.
45510186|NCT04212221|Drug|MGD013 in combination with Brivanib Alaninate|After determining the RP2D of MGD013 monotherapy, MGD013 at the fixed dose will be combined with Brivanib Alaninate. Dose escalation study of the combination therapy in Phase I will adopt traditional 3+3 dose escalation scheme; the dosage of Brivanib will start from 200 mg QD, and may escalate to 400 mg QD, 600 mg QD and a maximum of 800 mg QD to to determine the RP2D of MGD013 in combination with Brivanib Alaninate. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 and Brivanib Alaninate combination therapy with RP2D determined in Phase I study.
45510187|NCT04138277|Drug|AT2221|Participants received ATB200 co-administered with AT2221 (Miglustat)
45510188|NCT04138277|Biological|ATB200|Enzyme Replacement Therapy via intravenous infusion
45510189|NCT03663335|Biological|CFZ533 - MMF - CS|Comparison with standard of care immunosuppression
45510190|NCT03663335|Drug|Tacrolimus - MMF - +/- corticosteroids|Standard of care immunosupprevive regimen
45510191|NCT03632915|Drug|Levetiracetam|Standard of care
45510192|NCT03632915|Drug|Lacosamide|Standard of care
45510193|NCT03632915|Drug|Phenytoin|Standard of care
45510194|NCT03632915|Drug|Phenobarbital|Standard of care
45510195|NCT03632915|Drug|Ketamine|Standard of care
45510196|NCT03632915|Drug|Valproic Acid|Standard of care
45402287|NCT03850834|Drug|placebo enteric-coated tablets|There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
45402288|NCT01191892|Drug|carboplatin|
45402289|NCT01191892|Drug|gemcitabine hydrochloride|
45698521|NCT01173874|Drug|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
45698522|NCT04815798|Combination Product|Bacteriophage-loaded Microcapsule Spray|Study intervention consists of a dosage-metered airless spray containing a cocktail of 14 bacteriophages encapsulated in a biodegradable polymer. This bacteriophage product will be delivered topically every 3 days for 56 days or until wound has healed.
45402290|NCT01191892|Drug|vandetanib|
45402291|NCT01191892|Drug|Placebo|Placebo of vandetanib tablet
45402292|NCT05596474|Dietary Supplement|Beet-root juice|Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a 400mg nitrate once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third 400mg dose of nitrates at least 150 minutes before forearm endurance testing.
45402293|NCT05596474|Radiation|red-light therapy|Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to 660nm wave length light for 10-minutes.
45510197|NCT05346575|Behavioral|Teaching Obesity Treatments to Adult Learners (TOTAL)|TOTAL includes both video component and motivational telemedicine calls delivered via VA Video Connect (VVC) by a study interventionist. We will invite study participants to watch the 18-minute video at least once. The motivational component of TOTAL will consist of three telemedicine-based (VVC), one-on-one, 30-minute calls at 1 week, 6 months, and 12 months after randomization. This timing was selected so Veterans would have regular interactions with the interventionist within one year of initiating the intervention. Each motivational session will be tailored to where Veterans are in the treatment initiation process. Electronic outcome assessment surveys will be sent to the participants at baseline, at each motivational telemedicine visit, and for the 18 month assessment.
45510198|NCT05346575|Behavioral|Usual care|The usual care group will be electronically sent the 1-week, 6-month, 12-month, 18-month assessments. All usual care participants will be offered the opportunity to watch the educational video component of TOTAL after the final outcome assessment is performed (18 months post-randomization). Veterans in the usual care arm will also have access to the MOVE! program via referrals from the PCP or self-referral to MOVE!. If they initiate treatment in MOVE!, they may progress through MOVE! and receive obesity medications or be referred for bariatric surgery if they choose to do so.
45510199|NCT04836845|Device|Focus extracorporeal shock wave therapy|Focus extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
45510200|NCT04836845|Device|Radial extracorporeal shock wave therapy|Radial extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
45510201|NCT04836845|Device|Sham extracorporeal shock wave therapy|Sham extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
45510202|NCT03538535|Behavioral|Go/No-Go Active Learning (GOAL)|Behavioral Activation psychotherapy adapted to engage go/no-go learning
45510203|NCT04769375|Other|Evaluation of pain|The presence of pain localization pelvic girdle pain will be questioned in the body chart. Inaddition to this, the level of the pelvic girdle pain will be evaluated by visual analog scale.
45850751|NCT00005814|Biological|cetuximab|
45850752|NCT00005814|Drug|cisplatin|
45850753|NCT00005814|Radiation|radiation therapy|
45850754|NCT00354666|Drug|GSK159797|
45402294|NCT05596474|Dietary Supplement|Placebo|Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a nitrate depleted placebo once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third dose of the nitrate depleted placebo at least 150 minutes before forearm endurance testing.
45402295|NCT05596474|Radiation|sham light|Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to sham light for 10-minutes.
45402296|NCT01189942|Drug|OMP-21M18|The first 6 participants will receive OMP21M18 2.5 mg/kg once every other week, the next 6 participants will receive 5 mg/kg once every other week, and the final 6 participants will receive 10 mg/kg once every other week. A Data Safety Monitoring Board (DSMB) will review the data for the 6 participants in each dose level after the last participant in that group has been treated for 56 days and decide whether it is safe to move up to the next highest dose level. After confirming the optimum dose, 14 additional participants will be treated at the highest dose level that the DSMB considers safe.
45402297|NCT01293058|Drug|Intranasal naloxone|spray naloxone, 0.4 mg/ each 4 minutes till increasing patient level of consciousness
45402298|NCT01293058|Drug|Intravenous|Amp naloxone, 0.4 mg / each 4 minutes till increasing patient level of consciousness
45402299|NCT05671042|Other|Patients with Upper excretory tract tumors|Standard of care for patients with Sezary Syndrome
45402300|NCT01195324|Drug|Canagliflozin/Warfarin|Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6 followed 14 days later by Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1
45510204|NCT04769375|Other|Application of pelvic girdle pain tests|The tests will be applied sequentially to investigate the presence and severity of the pain (Tests: Posterior Pelvic Pain Provocation, Patriarch FABER, Long Dorsal Sacroiliac Ligament Pain Provocation, Simpsis Palpation, Modified Trendelenburg and Active Straight Leg Raise)
45510205|NCT04769375|Other|Application of pelvic girdle questionnaire|Pelvic girdle questionnaire will be filled by pregnant women with pelvic girdle pain.
45510206|NCT04740515|Other|pharmacists involved PPMTM|This was an open labelled randomised study. Preterm Infants With iron supplementation were recruited and arbitrarily divided into the intervention group (usual care plus PPMTM) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.
45510207|NCT03524729|Device|Rocker bottom shoe|Walking shoe with a anterior posterior rocker sole.
45510208|NCT03524729|Device|Ankle foot orthosis|Dynamic carbon fiber ankle brace.
45510209|NCT03524729|Device|Standard walking shoe|Standard walking shoe (control shoe) with no rocker sole.
45402301|NCT01195324|Drug|Canagliflozin/Warfarin|Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1 followed 14 days later by Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6
45402302|NCT05565898|Device|positron emission tomography for exclusion of bone marrow infiltration in lymphoma|compare the diagnostic accuracy of PET/CT scan against Bone Marrow Biopsy in detection of bone marrow involvement for staging of lymphoma
45402303|NCT05555056|Device|MxN-9 HD-tES Stimulator (Soterix Inc.)|Patients will be stimulated with high definition transcranial direct current stimulation (HD-tDCS) for 5 weeks (every weekdays; one session per day). In each session, a constant current at 2mA will be passed on the target brain areas for 20 minutes.
45510210|NCT04717505|Other|Gait Assessments|"10 Meter Walking Test: It is applied by walking at a normal walking speed (like walking in a shopping mall) without any assistance at a marked distance of 10 meters.~1- Evaluation of walking under single task conditions is done with the 10 Meter Walk Test and without any cognitive or motor second task. Evaluation of walking under dual task conditions is applied in two different ways: 2-adding a cognitive task to the walking motor task (motor + cognitive dual task) 3-adding one more motor task to the walking motor task (motor + motor dual task). While performing dual tasks, the time-distance (walking speed, cadence, stride length) characteristics of the gait are recorded using with wearable gait device."
45510211|NCT04717505|Other|Arthritis Impact Measurement Scales 2|It is a multidimensional, disease-specific, self-administered questionnaire designed to measure health status outcomes in patients with arthritis.
45510212|NCT04717505|Other|Visual Analogue Scale|The Visual Analogue Scale is a reliable and easily applicable scale used to measure the pain intensity of patients, accepted in the world literature.
45510213|NCT04717505|Other|Standardized Mini Mental Test|Although the test has limited specificity in terms of differentiating clinical syndromes, it is a short, useful and standardized method that can be used to determine the cognitive level globally.
45850755|NCT00354822|Drug|Zevalin|Yttrium-90 (90Y) ibritumomab tiuxetan 0.4 mCi/kg is delivered to patient achieving at least a partial remission (PR) after chemotherapy as a single dose for patients with baseline platelet counts>150x10^9/L or 0.3 mCi/kg for patients with baseline platelet counts of 100 to 149x10^9/L. Rituximab 250mg/sqm is given prior to therapeutic radiolabeled antibodies.
45510214|NCT05649605|Drug|Testosterone treatment|Cross-sex hormone therapy consisting of intramuscular injection of testosterone undecanoate 250mg/ml. 4ml (total dosage of 1000mg) administered by trained nurse in the gluteal region at visit 1.
45510215|NCT05649605|Other|Placebo treatment|Saline solution. Intramuscular injection of physiological saline solution. 4ml administered by trained nurse in the gluteal region at visit 1.
45510216|NCT05321927|Device|Trancutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation produces an electrical current to stimulate the nerves for therapeutic purposes. continuous high frequency (≥ 50 Hz) stimulation for 5 minutes followed by high frequency (≥ 50 Hz) bursts with 9 pulses per burst for the last 5 minutes, with a stimulation/rest ratio of 1:2.
45510217|NCT05321927|Other|Strength training|Three training sessions for 10 minutes per muscle, per week, for four weeks in total.
45850756|NCT00354900|Drug|Aprotinin|
45850757|NCT00355212|Procedure|percutaneous ablation of hepatocellular carcinoma|
45850758|NCT00355290|Behavioral|Changes on Oral Vitamin K Intake|
45850759|NCT00355446|Drug|Bimatoprost 0.03%|
45850760|NCT00355524|Drug|TMC114|TMC114 will be administered as oral tablets (75 milligram [mg] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.
45510218|NCT05321927|Device|Sham stimulation|Continuous stimulation at 1 Hz for 2 seconds, then no stimulation for 10 seconds. This will alternate for 10 minutes. The intensity equals the intensity that is just felt by the individual.
45510219|NCT04712123|Other|relapse due to S. aureus|to find out if it is the same S. aureus in both infections
45510220|NCT04946279|Other|Best Practice|Receive usual/standard of care
45510221|NCT04946279|Other|Informational Intervention|Receive conversation tool
45402304|NCT05555056|Device|Sham Stimulation|The same stimulation protocol will be used as in Active stimulation except that a sham mode will be selected in the stimulator machine.
45402305|NCT01195402|Procedure|pulmonary outpatient rehabilitation|Subjects take part in once weekly training sessions of 60 min duration. Sessions take place in local physiotherapist practice and involve simple training devices (chairs, elastic bands, balls). In addition, subjects take part in a structured and validated educational program concerning COPD (COBRA) of 8 h duration. They are offered counselling regarding nutrition (2 h), psycho-social (2 h) and social (2 h) aspects.
45402306|NCT01192360|Procedure|Phase contrast flow velocity mapping (PC)|An MRI is done using the phase contrast flow velocity mapping (PC)technique. Using PC, an imaging slice is prescribed perpendicular to the vessel's course. Within the pulmonary circulation, PC can quantify total pulmonary blood flow and the right / left distribution of the lung blood flow volume.
45510222|NCT04946279|Other|Questionnaire Administration|Ancillary studies - Baseline and follow-up questionnaires
45510223|NCT05312021|Drug|IMR-687|150 mg and 200 mg tablets
45510224|NCT05312021|Other|IMR-687 Placebo|Matching placebo to IMR-687
45510225|NCT05640479|Drug|Pregabalin|patients will receive pregabalin capsules (75 mg) will be given 2 h prior to induction of anesthesia and every 12 hours
45510226|NCT05640479|Drug|Dexmedetomidine|patients will receive dexmedetomidine after induction of GA a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/kg/h
45510227|NCT05309525|Drug|Collagenase Clostridium Histolyticum-Aaes|subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple).
45510228|NCT05309525|Drug|Lysteda 650 MG Oral Tablet|Subjects will be given the therapeutic dose of tranexamic acid for menorrhagia, which is 1300 mg PO TID for up to 5 days during menstruation
45510229|NCT03101267|Drug|ASP4070|Intradermal vaccination at 2-week intervals
45510230|NCT03101267|Drug|Placebo|Intradermal vaccination at 2-week intervals
45510231|NCT04922801|Diagnostic Test|Nuclear Medicine whole-body|Gamma-Camera Whole-body scan at 24-48 hour post-Molecular Radiotherapy (MRT).
45510232|NCT04922801|Diagnostic Test|SPECT/CT imaging.|SPECT/CT scan at 24-48 hr post MRT
45510233|NCT04922801|Diagnostic Test|PET/CT imaging.|3-6 months Pre and post-therapy PET/CT imaging
45510234|NCT04922801|Device|Patient-led radiation monitor (SELFIE)|"Following MRT administration, a standard whole body dosimetry measurement will be taken by medical physicist at 1 and 2 meters distance. The patient will begin to take SELFIE readings at the same time under supervision so that their records can be compared with the physicists' results.~After 28 days, patients will be asked to return the diary sheet and SELFIE monitor by post to GSTTFT in a pre-paid, pre-addressed envelope.~On completion of the 28 day exercise, patients will be asked to complete and return a feedback questionnaire."
45510235|NCT04922801|Diagnostic Test|LAB TEST|Biochemistry, haematology and tumour markers blood tests pre, post and during MRT.
45510236|NCT04911101|Device|Excision with 7G needle|Vacuum-assisted excision using a biopsy needle with two alternative dimensions
45510237|NCT04911101|Device|Excision with 10G needle|Vacuum-assisted excision using a biopsy needle with two alternative dimensions
45510238|NCT05296187|Device|TEAS|Transcutaneous electrical acupuncture stimulation
45510239|NCT04905563|Drug|Acetaminophen-Hydrocodone|Narcotic
45510240|NCT04905563|Drug|Acetaminophen and Ibuprofen|Non-narcotic
45510241|NCT05418257|Other|(exposure) telemedicine|medical counseling or treatment only using phone
45510242|NCT05253131|Drug|Selumetinib|"Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low grade gliomas, and NF1-associated plexiform neurofibromas.~BI is a potent and selective inhibitor of BRD4/BET bromodomain currently in development for adult malignancies.~Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that is currently indicated for patients with advanced urothelial carcinoma and unresectable non-small cell lung cancer."
45510243|NCT04886219|Other|Eye examination|"Multimodal fundus imaging (color fundus photography, optical coherence tomography (OCT))~orthoptic assessment (Visual acuity, Refraction, Cover test, Stereopsis evaluation~ocular biometry~corneal topography~monocular photographs in photopic and scotopic condition"
45510244|NCT02810418|Drug|LMB-100|Arms A1 and A2 (short infusion): Administered intravenously (IV) on days 1, 3 and 5 of a 21 day cycle for a maximum of 2 cycles Arm B1 (continuous infusion): Administered IV for 24, 48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 21 day cycle for a maximum of 2 cycles. Arm B2 (continuous infusion): Administered IV for 24,48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 14 day cycle for a maximum of 3 cycles.
45402307|NCT01192360|Procedure|Dynamic contrast-enhanced magnetic resonance imaging|Dynamic contrast-enhanced magnetic resonance (DCE MR) perfusion imaging imaging is a non-invasive method to quantify regional pulmonary blood flow. A bolus of gadolinium-containing contrast medium is injected and its passage through the pulmonary circulation traced using a repetitive rapid three-dimensional (3D) T1 weighted angiography sequence.
45402308|NCT05671588|Procedure|Controlled combined exercise group|Patients will undergo protocol-defined combined aerobic-resistant therapy on a cycling ergometer and multifunctional fitness device
45402309|NCT05671588|Procedure|Conventional rehabilitation|Patients will undergo conventional rehabilitation.
45402310|NCT01190332|Procedure|endoscopic sphincterotomy by conventional method|
45402311|NCT01190332|Procedure|endoscopic sphincterotomy by rendezvous method|
45402312|NCT01190488|Behavioral|End-of-Life / Advanced Care Decision Aid|Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.
45402313|NCT01190488|Behavioral|Active Comparator|TAU
45402314|NCT05668390|Drug|STALORAL® Birch 300 IR|2 treatment periods will consist of 2 steps: an escalation phase, where the treatment dose will gradually increase, followed by a maintenance phase.
45402315|NCT01192438|Procedure|Laser-based thermotherapy|MRI-guided transperineal placement of a laser probe into the prostate
45402316|NCT03846466|Drug|KHK4323 IV/S|IV / Single administration
45402317|NCT03846466|Drug|KHK4323 SC/S|SC / Single administration
45402318|NCT03846466|Drug|KHK4323 IV/M|IV / Multiple administration
45402319|NCT03846466|Drug|Placebo IV/S|IV / Single administration
45402320|NCT03846466|Drug|Placebo IV/M|IV / Multiple administration
45510245|NCT02810418|Drug|Nab-Paclitaxel|Administered intravenously (IV) on days 1 and for Arms A1, A2 and B1 on day 8 of each 14-21 day cycle for a maximum of 2 (Arms A1, A2 and B1) or 3 (Arm B2) cycles
45402321|NCT03846466|Drug|Placebo SC/S|SC / Single administration
45402322|NCT01293136|Procedure|Femoral nerve block|Ropivacaine
45402323|NCT01293136|Drug|Intravenous opioids|Whatever opioids prescribed
45402324|NCT01195480|Genetic|donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta|All patients will be treated at the same total dose level of 2 x 10^8/m2
45402325|NCT01195480|Biological|Irradiated donor-derived Lymphoblastoid Cell Line|"The initial cohort of 5 patients (regardless of arm of study) will be treated as described. If transduced CTL infusion is safe in this initial cohort and real-time DNA PCR studies demonstrate that transduced CTL are undetectable in > 50% of patients by 2 months post-infusion, the remaining 25 patients (in either arm of the study) will be treated as above but with an additional vaccination of CD19-zeta-transduced EBV-LCL infusion.~Vaccination will consist of 3 doses of 5 x 10^6 irradiated (70Gy) donor-derived EBV-lymphoblastoid cell line used to generate CTL and will be administered subcutaneously into the thigh (volume 0.3 ml) at day -2, week 4 and 8 post-transduced CTL infusion."
45510246|NCT02810418|Device|Mesothelin Expression|Research blood test for Arm B1 eligibility
45510247|NCT02810418|Drug|LMB-100|A 40 mcg/kg loading dose of LMB-100 is administered over 30 minutes immediately prior to the start of each long infusion.
45510248|NCT04875221|Combination Product|Connectivity-based neurofeedback|Real-time fMRI neurofeedback will be used to non-invasively regulate neural network connectivity patterns associated with symptoms and emotional arousal among patients with PTSD and healthy individuals, with the aim to induce lasting neuronal effects and reduce symptoms.
45510249|NCT02963363|Other|Home-based Adapted Physical Activity|"Home-based adapted physical activity to attend progressively 150 minutes of physical activity per week at the end of neoadjuvant chemotherapy.~5 times 30 minutes of walking + 3 times 30 minutes of muscle strengthening exercises per week during 18 weeks"
45698523|NCT04815798|Combination Product|Placebo|Placebo intervention consists of a dosage-metered airless spray containing a buffer solution analogous to the study intervention. This placebo will be delivered topically every 3 days for 56 days or until wound has healed.
45402326|NCT01295398|Device|nebulisations|
45402327|NCT01293292|Drug|Teriparatide|Teriparatide (Forsteo) 20 mcg subcutaneous injection once daily. Duration 104 weeks.
45402328|NCT01295476|Genetic|gene expression analysis|
45402329|NCT01295476|Genetic|microarray analysis|
45402330|NCT01295476|Other|laboratory biomarker analysis|
45402331|NCT03846388|Diagnostic Test|follicular stimulating hormone|in the serum of our patients
45402332|NCT03846388|Diagnostic Test|Anti-mullerian hormone|in the serum of our patients
45402333|NCT03846388|Radiation|Basal antral follicle count|by ultrasound
45402334|NCT01195558|Other|Data collection on blindness and sleep problems|Data related to degree of vision impairment and sleep problems is collected through a phone or web survey
45402335|NCT01195714|Drug|Ofatumumab|solution for perfusion, 1000mg per cycle, 1 cycle every 3 weeks, total 6 cycles
45402336|NCT01195792|Drug|GSK1521498|GSK1521498 2mg or 5mg will be given for up to 35 days and subjects will be assessed weekly
45402337|NCT01195792|Drug|Placebo|Placebo will be given for up to 35 days and subjects will be assessed weekly
45402338|NCT01295554|Other|NCE MRA and CE MRA|"Each patient will receive on the same day:~NCE MRA~CE MRA usually performed in the clinical routine~After each MRA examination, the CE images will be interpreted by a radiologist and the report transmitted to the prescriber within the usual delay. The radiologists in charge of this interpretation will not be involved in the evaluation of NCE images nor in the comparison between CE and NCE images."
45402339|NCT05668468|Dietary Supplement|Bifidobacterium adolescentis IVS-1 capsule|Daily Bifidobacterium adolescentis IVS-1 capsule containing up to 6x10 ninth cfu per capsule or daily cellulose capsule
45402340|NCT05668468|Other|Placebo cellulose capsule|Daily cellulose capsule
45402341|NCT01192594|Behavioral|Training in all modules including MAPP Recovery Model|50% of the case managers will complete all five modules: Disease state,psychopharmacology,symptom management, motivational interviewing and adherence, and the Milestones of Adjustment Post-Psychosis Recovery Model including the MAPP treatment guide.
45402342|NCT01192594|Behavioral|Training in all modules except MAPP Recovery Model|50% of the case managers in the study will complete only four training modules: Disease state, psychopharmacology, symptom management, and motivational interviewing and adherence. They will not complete the Milestones of Adjustment Post-Psychosis Recovery Model module.
45402343|NCT03848494|Procedure|Surgery|Laparoscopic floppy Nissen, laparoscopic-left thoracoscopic Collis-Nissen, laparoscopic gastric fundus wrapped around the stomach
45510250|NCT05417945|Device|JensClip transcatheter valve repair system|"Transcatheter mitral valve repair system is derived from the Edge-to-Edge technique in traditional surgery. The principle is roughly to clamp the midpoint of the anterior leaflet and the midpoint of the posterior leaflet of the mitral valve to form a double-hole inflow channel and then improve the regurgitation."
45510251|NCT02959541|Drug|Leucovorin|
45510252|NCT02736305|Drug|Regorafenib|Once a day for 21 days in a 28 days cycle
45510253|NCT05417633|Procedure|intraocular lens - RayOne EMV (Rayner Surgical GmbH,Berlin, Deutschland)|Inducing different values of monovision
45510254|NCT04849871|Radiation|External Beam Accelerated Partial Breast Irradiation|APBI simulation must take place no more than 8 weeks from final definitive breast surgery.
45510255|NCT02810340|Biological|Adjuvanted MCV-5|Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM), and 125 μg Al3+adjuvant.
45510256|NCT02810340|Biological|Non-Adjuvanted MCV-5|Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, and 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM).
45510257|NCT02810340|Biological|Menactra®|Menactra® vaccine was a clear to slightly turbid solution supplied in a 0.5 mL single dose vial. Each 0.5 mL dose of vaccine was formulated in sodium phosphate buffered isotonic sodium chloride solution to contain four mcg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 μg of diphtheria toxoid protein carrier and residual amounts of formaldehyde of less than 2.66 μg (0.000532%), by calculation.
45510258|NCT05695014|Other|Teach Back Metod|teach-back method is a way of checking understanding by asking patients to state in their own words what they need to know or do about their health. It is a way to confirm that you have explained things in a manner your patients understand.
45510259|NCT02675465|Drug|ATB200|
45510260|NCT02675465|Drug|AT2221|
46057181|NCT02713035|Behavioral|Self help intervention|For participants randomized to receive the treatment, the self-help intervention will be briefly described by a member of the clinical staff, and a brief pamphlet will be distributed to the parent or guardian at the end of the visit. The pamphlet describes behavioral strategies for coping with and reducing scratching behaviors. Participants randomly selected to not receive the treatment will not receive the pamphlet at the end of the visit.
46057182|NCT05754502|Drug|Trastuzumab emtansine|observational study. After the signature of the Informed Consent Form, all their data reported in the medical charts up to then (as detailed in section 12 of the protocol) will be extracted retrospectively and inserted in the study database. From the end of the washout period following the last treatment with T-DM1, each subject will enter in an observation phase for a maximum of 3 years, or until death whichever happens first. This phase will be prospective after the signature of the Informed Consent Form.
46057183|NCT02712957|Drug|NEO6860|TRPV1 antagonist
46057184|NCT02712957|Drug|NEO6860 placebo|Inactive substance
46057185|NCT02712957|Drug|Naproxen|NSAID
45510261|NCT02036658|Behavioral|Cognitive Behavioral Group Therapy|Cognitive Behavioral Group Therapy for social anxiety disorder is a 12-week treatment that involves psychoeducation, cognitive restructuring and exposure to social situations.
45698524|NCT04815798|Procedure|Standard of Care|Standard of care consists of but is not limited to offloading, positioning, cleansing, debridement, and wound dressing. A topical antimicrobial hydrogel will applied to wounds with signs of localized infection.
45402344|NCT03850132|Behavioral|FAM-SOTC-PL|"The adapted FAM-SOTC-PL intervention was delivered at the home of the participants and focuses on supporting the effective, cognitive, and behavioural domains of the bereaved family caregivers experience by targeting concerns/issues in these categories. The FAM-SOTC-PL comprises of the following five components:~Drawing forward narratives about the pre- and post-loss experience.~Asking therapeutic/interventive questions, emphasising on the most pressing concerns also assessing health issues.~Validating/acknowledging emotional responses.~Assessing the need for specific information and recommendations regarding bereavement.~The use of commendation/commending strengths, by focusing on and affirming the strengths of the family caregiver."
45402345|NCT01190722|Drug|etoricoxib|120 mg once daily for the 1st 6 postoperative days
45698525|NCT05391282|Other|ultrasound assessment|Transfontanel ultrasound assessment before and after prone positioning
45402346|NCT01190722|Drug|Diclofenac|50 mg oral 3 times daily the 1st 6 postoperative days
45402347|NCT01192672|Behavioral|Expressive Writing|Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.
45510262|NCT02036658|Behavioral|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction will be completed in 12 weeks in the study and includes enhancing one's awareness non-judgmentally by focusing on the present moment through the use of mindfulness meditation.
45510263|NCT04824521|Behavioral|Mindfulness-Oriented Recovery Enhancement|MORE is a mindfulness-based intervention.
45510264|NCT05705700|Drug|Dutasteride|High dose Dutasteride (3.5 mg daily) as add-on therapy at time of PSA progression
45698526|NCT05337384|Diagnostic Test|Sonography|Sonographic Venous Doppler Imaging
45698527|NCT05388240|Other|Education via a Mobile App|"This group will have access to Education and Resources tab that includes customary information given at a pre-op appointment plus some additional related education and resources."
45850761|NCT00355524|Drug|Ritonavir|Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.
45850762|NCT00355602|Drug|Cefuroxime|
45850763|NCT00355602|Drug|Ciprofloxacin|
46057186|NCT02712957|Drug|Naproxen placebo|inactive substance
46057187|NCT04883476|Other|Observation study only|
45510265|NCT05705700|Drug|Abiraterone|1000 mg PO daily
45510266|NCT04109365|Diagnostic Test|Electrical Epidural Stimulation Test (EST)|EST measures sensory/motor responses
45510267|NCT05227547|Other|Thoracic resection surgery|Patients undergoing thoracic resection surgery (pneumonectomy, lobectomy, segmentectomy) for cancer or suspected cancer, including smokers (active or ex-smokers) and non-smokers, with COPD and without COPD, and non-smoking patients.
45402348|NCT01192672|Behavioral|Control Writing|Subjects were asked to write about the actions they performed during the last 24 hours. They were asked not to write about their feelings or thoughts related to these actions.
45850764|NCT00355602|Drug|Clarithromycin|
45510268|NCT04796909|Behavioral|Occupational Performance coaching|The OPC intervention comprises three components: (1) connect - building parents' trust in the coach by using verbal and nonverbal strategies; (2) structure - building parents' competence by adopting a problem-solving framework of setting goals, exploring options, planning action, carrying out plans, checking performance, and generalizing; and (3) share - building parents' autonomy by reciprocally exchanging information between the coach and parents with an emphasis on eliciting parents existing knowledge. During the exploration of the options for a particular goal, collaborative performance analysis is used. The coach follows the four steps to (a) identify parents' perception of what currently happens, (b) identify what they would like to happen, (c) explore barriers and bridges to the desired performance, and (d) identify their needs for taking actions to achieve goals. Parents are guided to find strategies to facilitate their child's performance to support goal achievement.
45850765|NCT00355602|Drug|Cotrimoxazole|
45402349|NCT01192750|Other|immunohistochemistry staining method|
45850766|NCT00355602|Drug|Coamoxiclav|
45402350|NCT01192750|Other|laboratory biomarker analysis|
45402351|NCT01192750|Other|medical chart review|
45402352|NCT01196260|Drug|Capecitabine and Oxaliplatin|Capecitabine and Oxaliplatin will be under the NSCLC guideline
45402353|NCT01196338|Behavioral|Early weight-bearing and range of motion exercises|"0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;~At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed placed in orthosis, with instructions to be weightbearing as tolerated. Instructions for limited range of motion to be given;~At 2 weeks to 6 weeks: Weightbearing as tolerated in orthosis, follow range of motion instructions;~After 6 weeks: Instructions to continue weightbearing as tolerated, wean from orthosis."
45402354|NCT01196338|Behavioral|non-weight bearing, no range of motion|"0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;~At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed, BK fibreglass cast or other orthosis applied, with instructions to continue non-weightbearing;~At 2 weeks to 6 weeks: Ankle remains immobile and non-weightbearing;~After 6 weeks: Begin weightbearing as tolerated. Instructions for limited range of motion to be given, and wean from orthosis."
45402355|NCT05103436|Other|TENS|Electrical nerve stimulation
45402356|NCT03850210|Device|Short Splint|Short Splint that permits maximal wrist flexion and up to 45° of wrist extension with a block to 30° of MCP joint extension.
45698528|NCT05388240|Other|Education and Exercise via a Mobile App|"This group will have access to Education and Resources tab that includes customary information given at a pre-op appointment plus some additional related education and resources. The app will also be used to help guide participants through an eight-week shoulder exercise program, together with physical therapy remote support."
45698529|NCT01174030|Drug|CD07805/47 Gel|CD07805/47 Gel 0.5% QD
45698530|NCT01174030|Drug|Vehicle Gel|Vehicle Gel QD
45850767|NCT00355602|Drug|metronidazole|
45850768|NCT00355602|Drug|neomycin|
45850769|NCT00355602|Drug|rifaximin|
45850770|NCT00355602|Drug|Vancomycin|
45698531|NCT01174030|Drug|CD07805/47 Gel|CD07805/47 Gel 0.18% QD
45698532|NCT01174030|Drug|CD07805/47 Gel|CD07805/47 Gel 0.18% BID
45698533|NCT01174030|Drug|Vehicle Gel|Vehicle Gel BID
45698534|NCT04092894|Drug|Suvorexant 20 mg|Administration of oral Suvorexant 20 mg
45698535|NCT04092894|Drug|Placebo oral tablet|Administration of oral placebo (same non-identifiable form as active comparator)
45850771|NCT00355602|Drug|Doxycycline|
45850772|NCT00355680|Device|Green Laser (Aurolas, Aurolab)|Green laser developed by Aurolab
45850773|NCT00355680|Device|Green Laser (Iridex)|Already available green laser
45850774|NCT00356070|Drug|Strattera|
45850775|NCT00356226|Drug|clonidine|
45850776|NCT00356382|Drug|Lactobacillus (L.) casei|
45850777|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.1 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.1 mg/kg IV (one dose every 14 days)
45850778|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.3 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.3 mg/kg IV (one dose every 14 days)
45850779|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 1.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 1.0 mg/kg IV (one dose every 14 days)
45850780|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 3.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 3.0 mg/kg IV (one dose every 14 days)
45510269|NCT04796909|Behavioral|Parent consultation|The parent consultation consists of the use of the toolbox to provide parents with available environmental resources and strategies to enhance community participation of their child with developmental disability, followed by the understanding of current situation and the identification of problems encountered by parents. Direct informing approach will be used to instruct parents about the availability of environmental resources close to their living areas and what they can plan to do by using possible supportive strategies. In addition, information about child disability and/or developmental milestone may be provided if needed.
45510270|NCT05416619|Device|REMO®|The patients receive daily 1 hour of conventional therapy and 1 hour of treatment of REMO®, that is a wearable composed by 8 bipolar electrodes able to detect the surface electromyography of the forearm muscles. REMO® allows the control of a computer interface using the surface electromyography to execute sEMG-biofeedback exercises for hand rehabilitation. The movements required for hand rehabilitation are the following: thumb abduction, pinch, finger flexion, finger extension, wrist flexion, wrist extension, forearm pronation, forearm supination, radial wrist deviation and ulnar wrist deviation. The treatment consists in 15 sessions, 1hour/day, for 5 days/week, for 3 weeks. The patients are clinically evaluated before and after the REMO® treatment.
45850781|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 10.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 10.0 mg/kg IV (one dose every 14 days)
45850782|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
45850783|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
45850784|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 or 10.0 mg/kg IV (based on safety profile of part 2, cohort 1) followed by a 28 day observation period and then 3 additional doses of 15.0 or 10.0 mg/kg IV (one dose every 14 days)
45850785|NCT00356616|Drug|Trizivir (AZT+3HT+Abacavir) twice daily|Trizivir (AZT+3HT+Abacavir) twice daily
45850786|NCT00356616|Drug|Viread (300 mg Tenofovir disoproxil fumarate) once daily|Viread (300 mg Tenofovir disoproxil fumarate) once daily
45850787|NCT00356772|Drug|Azithromycin|
45402357|NCT03850210|Device|Traditional Long Splint|Traditional splint is a forearm-based dorsal thermoplastic splint that immobilizes the wrist in neutral position with a block to 30° of metacarpophalangeal (MCP) joint extension
45402358|NCT01293526|Device|Control|Patients who respond will have leads will be placed using standard procedures.
45698536|NCT01174576|Other|caffeinated and decaffeinated coffee|3 treatments on separate days, i.e. a standard breakfast with oral ingestion of 200 ml of either caffeinated coffee (3mg caffeine/kg body weight), decaffeinated coffee or water
45850788|NCT00356850|Drug|Azithromycin|
45850789|NCT00356928|Drug|Cyclophosphamide|50 mg/kg/day intravenously (IV) on Days -2 and -1.
45850790|NCT00356928|Biological|Donor T cells|"CD8-depleted T cells given IV on Day 0. Dose levels are as follows (all doses in cells/kg):~Dose level 1: 1E5 CD4+ cells and less than 3.2E3 CD8+ cells Dose level 2: 1E6 CD4+ cells and less than 3.2E4 CD8+ cells Dose level 3: 1E7 CD4+ cells and less than 3.2E5 CD8+ cells Dose level 4: 5E7 CD4+ cells and less than 1.6E6 CD8+ cells"
45850791|NCT00357084|Drug|methotrexate|
45850792|NCT00357084|Drug|methylprednisolone|
45850793|NCT00357084|Drug|prednisone|
45510271|NCT02817516|Drug|TAK-828|TAK-828 solution.
45510272|NCT02817516|Drug|Placebo|TAK-828 placebo-matching solution.
45698537|NCT04641936|Other|No intervention required|No intervention required
45850794|NCT00357240|Drug|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
45850795|NCT00357240|Drug|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
45850796|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 300/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
45850797|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
45850798|NCT00357240|Drug|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
45402359|NCT01293526|Device|Experimental|Patients who respond will have their leads placed based on study measurements.
45402360|NCT01293526|Device|Experimental 2|Patients who respond will have their leads placed based on standard lead placement.
45402361|NCT01192984|Biological|KW-0761|Intravenously 8 times at 1-week intervals
45402362|NCT01196728|Drug|CM3.1-AC100|SAD study with single ascending subcutaneous doses
45698538|NCT01134328|Drug|AC-150 Combo|1 drop in each eye for up to 14 days
45698539|NCT01134328|Drug|AC-150A 0.1%|1 drop in each eye once per day for up to 14 days
45698540|NCT01134328|Drug|AC-150B 0.005%|1 drop in each eye once per day for up to 14 days
45698541|NCT01134328|Drug|Vehicle|1 drop in each eye once per day for up to 14 days
45698542|NCT04636554|Other|Phage Therapy|Personalized intravenous phage therapy in Covid-19 patients along with anti-microbial treatment for pneumonia, bacteremia or septicemia due to A. baumannii, P. aeruginosa or S. aureus.
45850799|NCT00357240|Drug|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
45850800|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in AM, 7 days.
45850801|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in PM, 7 days.
45850802|NCT00357318|Drug|sunitinib malate|Given PO
45850803|NCT00357318|Biological|bevacizumab|Given IV
45850804|NCT00357318|Other|pharmacological study|Correlative studies
45850805|NCT00357318|Other|laboratory biomarker analysis|Correlative studies
45850806|NCT00357474|Procedure|Transarterial chemoembolization|lipiodol, adriamycin and/or mitomycin
45850807|NCT00357474|Procedure|Percutaneous ethanol injection therapy|99% ethanol 2-4cc per one session, two to three sessions per single procedure for one week
45850808|NCT00357630|Drug|gemcitabine hydrochloride|
45850809|NCT00357630|Procedure|quality-of-life assessment|
45850810|NCT00357708|Drug|decitabine|Given IV
45510273|NCT05416463|Procedure|Intra-Operative Device for THA|The intervention group will receive primary elective THA with the use of Intellijoint HIP 3D mini-optical navigation tool.
45510274|NCT05416385|Other|Carotid Contrast Enhanced Ultrasound|Carotid Contrast-Enhanced Ultrasound (CEUS), a diagnostic ultrasound enhancing agent that opacifies the blood to delineate the vessel walls.
45402363|NCT01193062|Drug|PF-04995274|Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo
45402364|NCT01193062|Drug|PF-04995274|Doses for cohort 2 will be decided based on an Interim analysis of data from cohort 1. The highest dose to be used in Cohort 2 not to exceed 15mg
45402365|NCT01196494|Procedure|intraoperative colon lavage with primary anastomosis|Patients with obstructive left-sided colonic cancer in wich treatment in one stage procedure is intraoperative colon lavage with primary anastomosis to avoid Hartamnn´s Procedure
45510275|NCT02498951|Procedure|Cognitive Assessment|Ancillary studies
45510276|NCT02498951|Biological|Obinutuzumab|Given IV
45510277|NCT02498951|Other|Quality-of-Life Assessment|Ancillary studies
45510278|NCT05687214|Other|Osteopathic manipulative treatment|"Each participant in the experimental group will receive eight osteopathic manipulative treatments. Each treatment will include the following manipulations:~Pompage Cv4;~Occipital-sternal technique;~Relaxining manipulation of the diaphragmatic domes;~Pelvic and abdominal diaphragm synchronization;~Dynamogenic technique;~Mesenteric traction;~Release of colic angles;~Manipulation and mobilization of the sacrum."
45510279|NCT05416151|Other|Freeze-dried biotic|2 sticks of 3g consumed daily for 28 days
45510280|NCT05416151|Other|Maltodextrin|2 sticks of 3g consumed daily for 28 days
45510281|NCT02260050|Drug|WAL 801 CL dry syrup new formulation|
45510282|NCT02260050|Drug|WAL 801 CL dry syrup conventional formulation|
45510283|NCT05415995|Device|Drug eluting Balloon|Drug eluting Balloon is a kind of the product that has been used for many years. By filling the micropores on the surface of the balloon with anti-proliferative drugs like immunosuppressive agents, the balloon is expanded and contacted with the lesion to rapidly release the drug to the local arterial wall.
45510284|NCT02047656|Drug|LFF269|LFF269 capsules twice daily (b.i.d)
45510285|NCT02047656|Drug|Placebo to LFF269|Placebo LFF269 b.i.d for 10 days in healthy volunteers
45510286|NCT04761965|Diagnostic Test|Bone marrow cellularity by mDixon-quant|if trepanobiopsy was performed during the diagnosis, then comparison with MRI Bone marrow cellularity by mDixon-quant
45850811|NCT00357708|Drug|vorinostat|Given orally
45850812|NCT00357708|Other|laboratory biomarker analysis|Correlative studies
45850813|NCT00357708|Other|pharmacological study|Correlative studies
45402366|NCT04890574|Device|CellMist™ System|Open Label, Safety and Feasibility
45402367|NCT05412082|Radiation|Intensity-modulated radiation therapy|MRI-guided pelvic IMRT to the Planning Tumor Volume (PTV) at a dose of 50 Grays (gy) delivered in 25 fractions (fx) over 5 weeks.
45402368|NCT05412082|Drug|5-fluorouracil|"5-FU dose of 400 mg/m2 will be administered intravenously (IV) over 5-15 minutes beginning on Day 1; then a dose of 2400 mg/m2 via continual infusion (CI) over 4446-478 hours total dose during Days 1 and 2 of every 14-day cycle, for 4 to 6 cycles.~During SMART TNT Plan I, 5-FU dose of 225 mg/m2 per day will be administered via CI on Day 1 radiation therapy, delivered either 5 or 7 days per week."
45510287|NCT02047890|Drug|BAY1000394 (2.5mg)|BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)
45510288|NCT02047890|Drug|BAY1000394 (5mg)|BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)
45510289|NCT02047968|Behavioral|wake therapy|
45510290|NCT02048124|Device|25g standard needle|
45510291|NCT02048124|Device|25d ProCor needle|
45510292|NCT03729102|Biological|Blood drawn after rabies vaccine booster vaccination|All participants would be given one dose of rabies vaccine and monitor the immunological cells i.e., regulatory T cell, regulatory B cell, T follicular helper cells, cytokines i.e., IL-10, TGF-Beta, and Rabies neutralizing antibody titers, before and after the booster injection
45510293|NCT02036736|Drug|Intraoperative anesthetic strategy by Propofol|"1- Arm Propofol: Propofol TCI induction target between 2 and 6 mg / mL~Sufentanil (0.15 mg / kg intravenously (IV))~Atracurium (0.5 mg / kg IV) Maintenance mode by Propofol TCI target between 2 and 4 micrograms / mL tune to 40 <BIS <60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
45510294|NCT02036736|Drug|Intraoperative anesthetic strategy by Desflurane|"2- Arm Desflurane Desflurane induction (2-3 mg / kg)~Sufentanil (0.15 mg / kg IV)~Atracurium (0.5 mg / kg IV)) Desflurane closed by maintenance target with minimal alveolar concentration (MAC) to adapt the circuit to obtain a figure 40 <BIS <60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
45510295|NCT05415839|Device|Laser|Laser
45510296|NCT05693688|Drug|Atosiban|atosiban i.v. administred for 48 hours. The medication will be administered by a bolus injection of 6.75 mg/0.9 mL in 1 min followed by a continuous infusion of 18 mg/hour for 3 hours followed by a continuous infusion of 6 mg/hour for the remaining 45 hours.
45510297|NCT05415683|Diagnostic Test|DV-SSP Imaging|DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.
45850814|NCT00357786|Drug|Replagal agalsidase alfa|
45850815|NCT00357786|Drug|Replagal|
45850816|NCT00357864|Drug|carbachol|
45850817|NCT00357942|Drug|morphine solution for injection|morphine solution for injection 2 mg/ml, 50 microg/kg bodyweight, every 3 hour for 24 hours and placebo mouthwash
45850818|NCT00357942|Drug|Placebo|Placebo mouthwash
45850819|NCT00357942|Drug|morphine mouthwash|morphine mouthwash 2 mg/ml, 50 microg/kg bodyweight every 3 hour for 24 hours and placebo solution for injection
45850820|NCT00357942|Drug|Placebo|Placebo solution for injection every 3 hour for 24 hours
45850821|NCT00358020|Drug|THALIDOMIDE|
45850822|NCT00358020|Drug|BORTEZOMIB|
45850823|NCT00358176|Drug|Risedronate (HMR4003)|
45402369|NCT05412082|Drug|Leucovorin|Leucovorin dose of 400 mg/m2 bolus will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.
45510298|NCT03813966|Diagnostic Test|Sofia Influenza A+B FIA|The Nasal Swab Home Collection Kit (NSHC Kit) provides the materials and training needed for you to safely collect a nasal swab at home. The sample can then be delivered to a designated test site for influenza testing.
45510299|NCT03814044|Device|PEEK Suture Anchors|Subjects who have undergone hip joint repair using PEEK Suture Anchors: Bioraptor Knotless Suture Anchor and SpeedLock Hip
45510300|NCT03671850|Biological|VT-EBV-N|Epstein-barr virus human cytotoxic T lymphocytes (EBV-CTL)
45698543|NCT05165004|Behavioral|Kangaroo Mother Care|the preterm neonate was carefully put naked except for the head and diaper area on the mothers' bare chest with flexed arms and legs as in froglike position, and the head was turned sideways. The researchers wrapped and secured the mother's gown and put a blanket on the neonates' back to ensure neonatal thermal insulation
45402370|NCT05412082|Drug|Oxaliplatin|Oxaliplatin dose of 85 mg/m2 will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 - 6 cycles.
45402371|NCT05412082|Drug|Capecitabine|Capecitabine will be administered orally at a dose of 825 mg/m2 via tablet twice per day (BID) on Day 1, 5 days per week.
45402372|NCT05412082|Radiation|Accelerated Radiation Therapy|"MRI-guided Pelvic accelerated radiation therapy (ART) given over one week at one of the following dose levels :~Dose level -1: 10 Gy delivered in 4 fractions~Dose level 0: 12 Gy delivered in 4 fractions~Dose level 1: 14 Gy delivered in 4 fractions~Dose level 2: 16 Gy in delivered 4 fractions"
45402373|NCT01196572|Procedure|Internal Urethrotomy|surgical incision of urethral stricture using endoscopic cold knife vs. endoscopic laser
45402374|NCT01196650|Drug|IN 10 003 formulation A|
45402375|NCT01196650|Drug|IN 10 003 formulation B|
45402376|NCT01196650|Drug|Placebo capsules|
45402377|NCT03846154|Behavioral|Comprehensive family intervention including individual sessions of FORNET|"A group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug abuse, anger management, roles within families, developing plans for the future, communication skills, sex education.~Access to schools and school material~Family visits~Their parents received training regarding agriculture and microcredit projects, and financial assistance~FORNET if affected by trauma-related symptoms, and/or acting aggressive~If needed medical assistance /.) If needed, legal assistance"
45510301|NCT03671850|Other|Placebo|Peripheral blood mononuclear cell, PBMC
45510302|NCT05415293|Dietary Supplement|Expecta 200mg DHA|
45510303|NCT05415293|Dietary Supplement|Promise 275mg DHA|
45510304|NCT02036814|Behavioral|Program Health Education|
45510305|NCT02048280|Procedure|NAVA level|Peak inspiratory pressure will be measured at each NAVA level
45850824|NCT00358410|Drug|GW679769 oral tablets|2x GW679769 60mg tablets
45850825|NCT00358410|Drug|Placebo|Placebo oral tablets to match experimental intervention
45402378|NCT01193296|Drug|Vildagliptin|
45402379|NCT01193296|Drug|Sitagliptin|
45402380|NCT03845998|Procedure|use the three-finger method|The size of the laryngeal mask airway was determined by choosing the laryngeal mask that best matched the combined widths of the patient's index, middle and ring fingers.
45402381|NCT03845998|Procedure|use the weight-related method|The size of the laryngeal mask airway was determined by the patient's weight.
45402382|NCT01193374|Behavioral|Clinician enhanced screening and counseling prompts|PDA based health risk screening for well child issues and obesity risks
45402383|NCT01193374|Behavioral|Tailored education and motivational materials|Specific tailoring for those interested in change vs not . Two newsletters over 3 mpn.
45402384|NCT01193374|Behavioral|basic educational brochure|Booklet by ADA sent x 1.
45402385|NCT04888156|Other|Unchanged treatment|Treatment is the same pre- and post self-tonometry
45402386|NCT04888156|Other|Changed treatment|Treatment is changed post self-tonometry
45402387|NCT01196962|Device|Central venous catheter|Central venous catheter insertion to subclavian vein
45402388|NCT01197040|Drug|Prednisone|1 mg/kg/day for 4 weeks. Then, the dose will be progressively tapered if the remission will be achieved. For patients who exhibit incomplete remission at this time, high dose steroid will be continued for 4 weeks again before the tapering.
45850826|NCT00358488|Drug|GSK159797 (10, 15, and 20mcg)|GSK159797 (10, 15, and 20mcg)
45402389|NCT01197040|Drug|acid mycophenolic (Myfortic)|patients will receive prednisone 0.5 mg/kg/day combined with mycophenolic acid (MyforticR) 1440 mg/day. The management of steroid therapy will be identical in both groups, while MyforticR will be continued for six months
45402390|NCT05387824|Device|Magnetic stimulation -Armchair type MS • NovaMag NT-60|MS was applied two days a week, 20 minutes a day, a total of 12 sessions for 6 weeks.
45402391|NCT05387824|Device|Electrical Stimulation- TTNS|TTNS were performed 2 days a week, for 30 min a day, for a total of 12 sessions for 6 weeks.
45510306|NCT02048280|Other|NAVA level|Increase NAVA level every 3 minutes
45510307|NCT03562260|Procedure|bipolar release|the bipolar release is the surgery that cut the origin and insertion of the sternocleidomastoid muscle that cause the torticollis from its contracture
45510308|NCT02047422|Drug|Furosemide|furosemide (doubling previous furosemide dose)
45510309|NCT02047422|Drug|metolazone|metolazone (add 2.5mg qod)
45510310|NCT02047422|Drug|furosemid/spironolactone|spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user)
45510311|NCT02047422|Drug|metolazone/spironolactone|no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user)
45510312|NCT02048358|Drug|2B3-201|
45510313|NCT02048358|Drug|Placebo|
45510314|NCT02048358|Drug|Methylprednisolone hemisuccinate|
45510315|NCT03562338|Other|Manual Therapy and Exercise (Physiotherapy Intervention)|Participants in this group will receive a 6-weeks program of mobilization and progressive exercise for the neck flexors, 2 times a week.
45698544|NCT05165004|Behavioral|Hammock Positioning|After one hour of feeding, the preterm neonate was placed in a supine fetal position in the hammock where the head was supported in a neutral midline position by using rolled towel without neck hyperflexion or hyperextension. Moreover, the spine of the preterm neonate was supported while arms and knees were flexed
45850827|NCT00358488|Drug|salbutamol|salbutamol
45510316|NCT03562338|Other|Usual Care (Physiotherapy Intervention)|Participants in this group will receive usual care in physiotherapy during the 6-weeks period.
45510317|NCT02051478|Other|Thoracic mobilization|Patients will receive 20 seconds bouts of grade III-IV of central posterior-anterior (PA) non-thrust mobilization from T3 to T6 spinous process as described by Maitland et al for an overall intervention time of approximately 2 minutes
45510318|NCT02051478|Other|Thoracic manipulation|A high-velocity, end range, anterior-posterior thrust applied through the elbows to the mid-thoracic spine will be applied
45510319|NCT02048514|Device|The Nellix® EndoVascular Aneurysm Sealing System|
45510320|NCT02928029|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Sequential dose escalation in Intravenous (IV) injection
45510321|NCT02928029|Drug|Placebo|Matching placebo
45510322|NCT02928029|Drug|Bortezomib|Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose
45510323|NCT02928029|Drug|Dexamethasone|Dexamethasone is administered orally at 40 mg
45510324|NCT03562182|Other|blood draw|Blood draw (2.5mL) to assess mRNA LPCAT1 levels
45510325|NCT02048592|Dietary Supplement|Impact-Nutridrink|"IMPACT (immunonutrition) will be given in the first 8 weeks. Afterwards the patients will be returned to their previous nutrition support |(Nutridrink) for another 8 weeks."
45510326|NCT02048592|Dietary Supplement|Nutridrink-Impact|In this group of patients - the study starts with period of 8 weeks with no change of previous nutrition support (Nutridrink). After 8 weeks the laboratory results will be examined ant the patients will switch to immunonutrition (Impact) for another 8 weeks. After the laboratory examination including oxidative stress parameters will be evaluated.
45510327|NCT02050074|Drug|Colesevelam|
45510328|NCT02050074|Drug|Metformin|
45510329|NCT02050074|Other|Placebo|
45510330|NCT02050152|Behavioral|Explicit and Implicit memory|Explicit and implicit memory will be tested visually (showing an animal) and auditory (telling a joke, stating a food type that starts with the letter B) and smell recall (bad smell of anesthesia)
45510331|NCT02050152|Drug|0% nitrous oxide, 30% nitrous oxide and 60% nitrous oxide|
45698545|NCT05165004|Behavioral|Routine Care of NICU|; encircling the neonate in a fetal position using rolled towel inside the incubator.
45698546|NCT04622124|Drug|Placebo|
45402392|NCT05387824|Behavioral|Bladder Training|"Control group All women were informed about BT for 30 minutes. Then it was given as a written brochure to be implemented as a home program.~BT, consisting of four stages, did not contain any PFMT programs in two groups."
45402393|NCT05436340|Device|The Effect Of Heel Protector In Intensive Care Units|In the experimental group, foot joint opening and heel pressure sore formation will be observed by using heel protector pad.
45402394|NCT05436340|Device|Control group|Heel pads will not be used in the control group. Routine maintenance will be applied
45402395|NCT03848338|Procedure|Electrocochleography|Electrocochleography measurement Intra-operatively and Post-operatively at follow-up appointments along with correlative measurements (Impedance, eCAP, PTA, Speech)
45402396|NCT01193452|Drug|S-1, Leucovorin|"S-1 :~The initial dosage of S-1 is determined by the body surface area:~Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day~Leucovorin:~25mg twice per day po.~The treatment is given for one week,and no chemotherapy is given for the following one week."
45510332|NCT02050230|Biological|Blood transfusion|One unit of red blood cells will be transfused over the course of 20 minutes
45510333|NCT02806986|Biological|IGSC 20%|Weekly administration of IGSC 20% via intravenous infusion
45510334|NCT02050386|Other|Cold pressor stimulation|Immersion of the foot in 0-2 degrees C water for 50 seconds
45510335|NCT02050386|Other|Sham Stimulation|Immersion of the foot in room temperature water for 50 seconds
45510336|NCT03562104|Other|videofluoroscopy|Swallowing description in Minimally consciousness Patient
45510337|NCT03562104|Other|Wessex Head Injury Matrix scale|Wessex Head Injury Matrix scale in Minimally consciousness Patient
45510338|NCT02037360|Behavioral|Active Comparator App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
45510339|NCT02037360|Behavioral|Experimental App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
45510340|NCT02037750|Behavioral|LINKS|"In the LINKS, foster/kin parents will participate in weekly group meetings led by well-trained and supervised paraprofessional facilitators (school behavioral aids and foster parents) where the curriculum is based on parent management training (PMT). In previous studies, attendance at such groups has been high, averaging about 75-80%. Missed sessions will be made up with an in-person visit to the foster/kin home during the week of the original session. In addition, youth in the intervention condition will receive individual skill building sessions from a Life Skills Coach to increase their competency at goal setting, refusal skills, and peer relations."
45698547|NCT04622124|Dietary Supplement|fasted vs. high-fat meal|
45698548|NCT04622124|Drug|Placebo|
45510341|NCT02050542|Procedure|systematic biopsies|90 patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate
45510342|NCT02050542|Procedure|Targeted biopsies guided by a fusion of MRI and ultrasound- images|Immediately after the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system
45510343|NCT02048748|Device|Weight and blood pressure device|Weight and blood pressure device integrated in a home telemonitoring kit. The weight scale is Withings The Smart Bodyscale. The blood pressure device is MEDISANA iHealth BP3.
45510344|NCT02048748|Device|Home telemonitoring device|An iPad 2 WiFi 16GB (Model A1395) tablet integrating the telemonitoring kit.
45510345|NCT02048982|Behavioral|Guideline|Physicians will receive information on the Choosing Wisely Guideline
45510346|NCT02048982|Behavioral|Cost|Physicians will receive cost information.
45510347|NCT02048982|Behavioral|Victim|Physicians will receive information on an identifiable victim.
45510348|NCT02051556|Behavioral|Physical Therapy WSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the most affected side (WSI).
45510349|NCT02051556|Behavioral|Physical Therapy BSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the least affected side (BSI).
45510350|NCT02051556|Behavioral|Physical Therapy ST|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down and an active part that includes exercises with a number of repetitions according to the aim of potentiating both sides equally (ST). In this case the number of repetitions was the same for both sides.
45510351|NCT02049060|Drug|Tivantinib|"•- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks"
45510352|NCT02049216|Other|Flexible tape|Flexible, elasticised, adhesive athletic tape
45510353|NCT02049216|Other|Fixomull|
45510354|NCT02049216|Other|Exercise|Participants in both groups will be prescribed a home exercise program to complete.
45510355|NCT03095651|Biological|MK-5160 16 nmol/kg|MK-5160 16 nmol/kg, subcutaneous injection administered daily for 12 days
45510356|NCT03095651|Biological|MK-5160 32 nmol/kg|MK-5160 32 nmol/kg, subcutaneous injection administered daily for 12 days
45510357|NCT03095651|Biological|MK-5160 64 nmol/kg|MK-5160 64 nmol/kg, subcutaneous injection administered daily for 12 days
45510358|NCT03095651|Biological|Glargine 0.4 U/kg|Glargine 0.4 U/kg, subcutaneous injection administered daily for 12 days
45402397|NCT01193452|Drug|leucovorin, 5-fluorouracil|"leucovorin: 400mg/m2 intravenous infusion d1;~5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours~repeat every 2 weeks"
45402398|NCT05670886|Procedure|uterine artery ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally Lower uterine incision was done followed by fetal extraction and placental delivery . bilateral uterine artery ligation were done 2cm below the uterine incision.
45402399|NCT03845608|Combination Product|Pulmonary Recruitment Maneuver|Pulmonary recruitment maneuver will be performed manually using positive-pressure ventilation to inflate the lungs and lower the diaphragm, which can increase intraperitoneal pressure mechanically and remove residual carbon dioxide from the peritoneal cavity.recieve100 mg hydrocortisone in 250 ml normal saline at end of surgery and carbon dioxide will be removed by applying gentle abdominal pressure and removing carbon dioxide by passive exsufflation
45402400|NCT01197118|Radiation|sequence chemoradiotherapy|"Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 15MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative chemotherapy regimen: see arm 2"
45698549|NCT01134952|Drug|Mycophenolate to sirolimus switch|Sirolimus given for 3 months instead of mycophenolate at a starting dose equivalent of 1 mg sirolimus equal to 1000 mg of mycophenolate.
45510359|NCT03095651|Biological|Placebo to Glargine|Placebo to glargine, subcutaneous injection administered daily for 12 days
45510360|NCT03095651|Biological|Placebo to MK-5160|Placebo to MK-5160, subcutaneous injection administered daily for 12 days
45510361|NCT03095651|Drug|Dextrose|20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.
45510362|NCT03095651|Biological|Glargine 0.6 U/kg|Glargine 0.6 U/kg, subcutaneous injection administered daily for 12 days
45510363|NCT04740905|Drug|Faricimab|Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.
45510364|NCT04740905|Drug|Aflibercept|Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).
45698550|NCT03130686|Device|OMRON blood pressure monitor HEM-9210T|To measure systolic blood pressure, diastolic blood pressure and pulse rate in patients.
45850828|NCT00358488|Drug|salmeterol 50mcg|salmeterol 50mcg
45850829|NCT00358488|Drug|placebo|placebo
45510365|NCT04740905|Procedure|Sham Procedure|The sham is a procedure that mimics an intravitreal (IVT) injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
45698551|NCT04590222|Other|blood sample|One blood sample of 60 mL (EDTA)
45698552|NCT01175434|Other|School-Based Medication Delivery|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
45850830|NCT00358566|Biological|GV1001|0.56mg GV1001 day 1, 3, 5, 8, 15, 22, week 6 and every 4 weeks thereafter. When gemcitabine is add it is given in cycles of once a week for 3 weeks and 1 week. Gemcitabine is dosed as per the SmPC.
45402401|NCT01197118|Drug|chemotherapy alone following radical resection|Postoperative chemotherapy regimen: The OLF regimen was administrated: Oxaliplatin, 130 mg/m2/day on day1, i.v. 2 h; fluorouracil, 425 mg/m2/day on day1~5, i.v.; leucovorin, 200 mg/m2/day on day 1~5, i.v.; every 21 days repeated, for 6 cycles.
45402402|NCT03845764|Diagnostic Test|Rapid on-site evaluation|Specimens obtained with endoscopic sampling procedures are stained with a rapid method (i.e., Diff Qui) and submitted to on-site cytologic review
45402403|NCT01197196|Behavioral|Behavioral Weight Loss Intervention|Participants assigned to this condition will receive an intensive group-based lifestyle program modeled after the DPP and Look AHEAD trials. Participants will attend 16 weekly sessions involving provision of behavioral goals and strategies to modify diet and exercise behaviors in order to achieve a weight loss of at least 7% of initial body weight.
45402404|NCT01197196|Other|Migraine Education|Participants assigned to this condition (Healthy Living for Migraine Relief [HLMR]) will receive basic education and didactic instruction in migraine headaches and treatments that are the standard of care. Participants will attend 4 months of weekly group lectures focused on 3 different major topic areas: 1) migraine symptomatology and pathophysiology, 2) standard abortive and preventive pharmacological treatment options, and 3) standard and alternative non-pharmacological treatment options.
45402405|NCT03848572|Diagnostic Test|Repetitive assessment of PRECISE-DAPT score|The PRECISE-DAPT score, which takes into consideration age, creatinine clearance, haemoglobin, white blood-cell count and previous spontaneous bleeding, will be reassessed every 3 months during the 12-month follow-up period
45402406|NCT01295632|Drug|ridaforolimus|10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.
45402407|NCT01295632|Drug|MK-0752|300 mg capsule, orally, 6 capsules per dose, once each week.
45402408|NCT01295632|Drug|MK-2206|Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.
45402409|NCT05416450|Device|intravaginal electrical stimulation added to bladder training|BT was given as a home program. After information session, squeezing the PFM was shown in practice at least once to use in the urgency suppression strategies via digital palpation technique. The second stage strategies was aimed to delay urination, inhibit detrusor contraction, and prevent urgency by squeezing the PFM several times on a row, breathing deeply and self-motivating. In the third stage, a timed voiding program was started; a timed voiding and increasing the time between urination considering the voiding diary. IVES was applied in addition to BT in both groups. It was performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with a vaginal probe; three days a week, a total of 24 sessions for 8 weeks. Every session lasted 20 minutes. The stimulation parameters were a 10 Hz of frequency, a 5-10 s of work-rest cycle duration and, a 100 ms of pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100 mA.
45402410|NCT03845530|Diagnostic Test|Blood Test|Blood test taken and sent for laboratory analysis
45402411|NCT03844594|Drug|Eptifibatide Injection|Recommendation: first, intravenously or intraductal injection of 135ug / kg (completed in 5 minutes), followed by continuous intravenous infusion of 0.75ug / kg / min for 24 hours.
45402412|NCT03848650|Device|OpSens Medical OptoWire|"The OptoWire is FDA approved to measure pressure in coronary vessels during diagnostic angiography and coronary interventions.~The OptoWire Deux pressure wire (OpSens Medical, Quebec, Canada) is a novel technology utilizing optical coherence technology to enhance FFR assessment of the coronaries."
45402413|NCT03848650|Procedure|FFR|A guide wire-based procedure that can accurately measure blood pressure and flow through a specific part of the coronary artery. FFR is done through a standard diagnostic catheter at the time of a coronary angiogram (a.k.a. cardiac catheterization).
45402414|NCT03848182|Drug|Gemcitabine|Gemcitabine will be administered on days 1, 8, 15 every 28 days
45698553|NCT01175902|Drug|dorzolamide/timolol|dorzolamide/timolol fixed combination eyedrop, 2 times a day
45698554|NCT01175902|Drug|latanoprost|compare with dorzolamide/timolol fixed combination eyedrop one time a day
45510366|NCT02808312|Drug|Cilofexor|Tablet(s) administered orally in a fed state on Day 1
45510367|NCT05176223|Procedure|Computed Tomography|Undergo 68Ga PSMA PET/CT
45510368|NCT05176223|Drug|Gallium Ga 68 Gozetotide|Undergo 68Ga PSMA PET/CT
45510369|NCT05176223|Procedure|Positron Emission Tomography|Undergo 68Ga PSMA PET/CT
45402415|NCT03848182|Biological|TT vaccine booster|One human TT childhood vaccine booster will be administered on day 8
45402416|NCT03845920|Combination Product|tdcs (sham/anodal) + drug (placebo/tyrosine)|"tDCS= A DC Stimulator Plus (neuroConn, Germany) with one 5 cm x 7 cm rubber electrode (anode) and a 10 cm x 10 cm (cathode; reference electrode), encased in saline soaked sponges will be used. The anode will be positioned over the left dlPFC, centered on F3 in the 10e20 electroencephalography (EEG) system, while the cathode on the contralateral supraorbital ridge (Fp2).Current will be delivered at 1.5mA for 20 min plus 30 s fade in/fade out periods.For sham stimulation, the current will be faded in over 30 s, at 1.5mA and then will be switched off.~Drugs= 2.0 g of L-Tyrosine and 2.0 g of the placebo microcrystalline cellulose will be dissolved in 400ml of orange juice as per previously published protocols."
45402417|NCT01197274|Device|Simple blood lancet|Skin prick testing with blood lancet and DuoTip is performed on the back of mite-sensitized person. Allergen(Der p)is placed in 1st and 2nd row whereas histamine is placed in 3rd row. Allergen and normal saline are placed alternately in 4th row. Block randomization were allocated subjects into 2 groups; Group1:blood lancet is performed in 1st row and DuoTip in 2nd row. Group2:DuoTip is performed in 1st row and blood lancet in 2nd row. Blood lancet is applied in 3rd and 4th row in all subjects. A technician performed device applications and another technician who is blinded to device performed all readings. Pain was assessed on a scale from 0 to 10 with 0 being no pain and 10 being the worst imaginable pain
45402418|NCT00146328|Drug|Tipranavir|
45510370|NCT03561948|Procedure|Experimental group|After performing the surgical intervention, the patient will undergo intraoperative intra-abdominal chemotherapy with mitomycin C. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.
45402419|NCT01197352|Behavioral|Motivational and Normative Feedback|Weekly feedback based on their frequency and degree of at-risk drinking behavior using normative, educational and motivational feedback
45402420|NCT01197352|Behavioral|Self-Awareness|Weekly queries to raise awareness and allow self-reflection about drinking habits
45510371|NCT03561948|Procedure|Control group|In the control group (40 patients), after laparotomy and revision, peritoneal lavage will also be performed with subsequent immunological examination. Patients of this group will not receive intraperitoneal chemotherapy. After performing the surgical intervention, the patient will be irrigation of the abdominal cavity with physiological saline. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.
45510372|NCT04717193|Drug|Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine|Bilateral rectus sheath block plus infiltration local anesthetic at incision sites.
45698555|NCT04691232|Biological|Regulatory T cells|Autologous, ex vivo expanded, regulatory T cells
45698556|NCT05384730|Other|Group nutrition and exercise support|Weekly group nutrition and exercise support delivered online through trained volunteers
45698557|NCT01135186|Drug|sapropterin dihydrochloride|sapropterin dihydrochloride: 10mg/kg/day
45510373|NCT04717193|Procedure|Local Anesthetic Infiltration with 0.25% bupivicaine with 1:200 000 epinephrine|Infiltration of local anesthetic at incision sites.
45698558|NCT03892980|Device|Nipple-Sparing Mastectomy|Nipple-sparing mastectomy using da Vinci Xi Surgical System.
45510374|NCT02050698|Procedure|Protected weightbearing in a hard-soled shoe|Patients allocated to experiment group are allowed tolerable weightbearing in a hard-soled shoe after one week of immobilization in a posterior splint
45510375|NCT02050698|Procedure|Protected weightbearing in a short leg walking cast|Patients allocated to control group are allowed tolerable weightbearing in a short leg walking cast after one week of immobilization in a posterior splint
45510376|NCT02050776|Biological|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally and intramuscularly in limb girdle muscular dystrophy patients
45698563|NCT05379114|Other|INVESTIGATIONAL DEVICE|new medical device for the treatment of head lice infestation: Paranix ®
45698564|NCT05379114|Other|Comparator device|well established medical device for the treatment of head lice infestation (dimethicone based) - Pouxit ®
45698565|NCT05376228|Drug|Oral Vancomycin|As part of standard of care
45698566|NCT05164848|Drug|JMT101|JMT101 will be administered intravenously at 6 mg/kg every 2 weeks (q2w) in each 28-week cycle.
45698567|NCT05164848|Drug|Afatinib|Afatinib will be administered orally at 30 mg or 40 mg per day (qd) in each 28-week cycle.
45698568|NCT04663074|Diagnostic Test|IVUS control|Intravascular Control of the bridging stentgrafts during branched EVAR
45715299|NCT04738786|Procedure|1.5 cm surgical safety margin for cT1-2N0 oral tongue cancers|"Surgical resection including 1.5 cm normal tissue around the gross tumors~Definition of safety margin: A surgical safety margin is defined as the margin of apparently non-tumorous tissue around a tumor that has been surgically removed (Resected normal-looking tissues from the gross tumor border). The surgical safety margin is applied to all directions of 3-dimensional tumors (mucosal and deep side)."
45715300|NCT04738786|Procedure|1.0 cm surgical safety margin for cT1-2N0 oral tongue cancers|Surgical resection including 1.0 cm normal tissue around the gross tumors
45510377|NCT02051634|Drug|Fermented Papaya Preparation (FPP)|A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, slowly empty contents into their mouth, and let it dissolve before swallowing.
45402421|NCT04918030|Procedure|In-hospital staged PCI|After revascularization of the culprit lesion, all significant non-culprit vessel will be complete revascularzed during index the index procedure (7±3 day).
45510378|NCT02051634|Drug|Sugar Pill|A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once with breakfast, once with lunch, and once with dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
45510379|NCT02051712|Behavioral|exercise training|individualized exercise training
45715301|NCT00368758|Drug|Probiotic bacteria (Trevis R)|
45402422|NCT04918030|Procedure|Out-hospital staged PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 30±15 days to undergo PCI of the other significant coronary lesions.
45402423|NCT04916938|Behavioral|Interaction Guidance Therapy|Mother child psychotherapy based on video-feedback interaction after a free play session. The therapy usually enhances parent sensibility to the child.
45402424|NCT04916938|Behavioral|Mother's child psychotherapeutic session|Mother's representation of the event, mother's representation of the relation to her child, maternal emotions.
45402425|NCT04916938|Behavioral|Interview|History and perception of the mother's issues.
45402426|NCT04916938|Behavioral|Self-rated questionnaires|Parental Self-Questionnaire to assess the perception of the evolution of the father, mother and child
45402427|NCT01295788|Device|Simultaneous RT-CGM and Pump Initiation|Subjects in this group will start using RT-CGM at the same time as they initiate insulin pump therapy.
45402428|NCT01295788|Device|Delayed Initiation of RT-CGM|Subjects in this group will start using RT-CGM 6 months after initiation of insulin pump therapy.
45402429|NCT01197430|Other|exercise training|
45402430|NCT01295866|Device|nasal nitric oxide|
45402431|NCT03848104|Other|bone and joint infection treated with cefoxitin|the patients had cefoxitin in combination in continuous parenteral administration to treat their bone / joint infection
45510380|NCT02051712|Behavioral|Adherence measures|Measures to increase adherence to exercise training
45510381|NCT05212025|Drug|Adavosertib|Taken Orally
45510382|NCT05212025|Drug|Gemcitabine|Intravenous Infusion
45510383|NCT02051868|Drug|Cisplatin|Cisplatin 60 mg/m2 as a 1 hour i.v. infusion once every 3 weeks.
45510384|NCT02051868|Drug|5-Fluorouracil (5-FU)|5-FU 1000 mg/m2/24h as a 96-hour continuous infusion over days 1 to 4 every 3 weeks.
45510385|NCT02051868|Drug|Carboplatin|Carboplatin 1-hour i.v. infusion to an area under the curve (AUC) of 5 once every 4 weeks.
45510386|NCT02051868|Drug|Paclitaxel|Paclitaxel 80 mg/m2 as a 1-hour i.v. infusion on day 1,8 and 15 of each (4-weekly) cycle.
45715302|NCT04635826|Drug|Adderall 10Mg Tablet|Participants will be administered Adderall
45402432|NCT03844516|Other|Peak oxygen uptake test with pacing|Peak oxygen uptake test with paced heart rate
45715303|NCT04635826|Drug|Placebo|Participants will be administered placebo
45402433|NCT03844516|Other|Peak oxygen uptake test without pacing|Peak oxygen uptake test without paced heart rate
45402434|NCT03844126|Other|Transition classes|90 minutes spent with patients and their families (separately) to review the changes and challenges associated with healthcare transition and help alleviate some of the barriers traditionally associated with this process.
45510387|NCT04696757|Drug|Capecitabine|Capecitabine without surgery
45510388|NCT02049294|Biological|Omalizumab (Xolair)|
45510389|NCT02049294|Drug|Placebo|
45510390|NCT05155943|Device|KALPA X™|Before and after a transseptal puncture, the right atrium (RA), left atrial appendage (LAA), and left upper superior pulmonary vein (LUSPV) will be mapped using the KALPA™ system (WS Software ver. 1.0.229-0 Source control ID: 65f1dbf7) in combination with a commercially available catheter. Subjects will then undergo LAAC as per routine clinical care. The entire LAAC procedure will be conducted as customary practice using standard and approved off-the-shelf equipment (body surface electrodes, catheters, etc.) the operator will be blinded to the KALPA™ and KALPA X™ system information.
45510391|NCT02051946|Device|Retroject Device|
45510392|NCT02051946|Drug|ethacrynic acid injection|
45510393|NCT02051946|Drug|balanced salt solution|
45850831|NCT00358566|Drug|Gemcitabine (Chemotherapy)|Gemcitabine is given as per the Burris regime and the SmPC, i.e. 7 weeks, followed by cycles of 1 weeks rest and 3 weeks chemotherapy.
45850832|NCT00358800|Device|REMStar Auto with C-Flex|
45850833|NCT00359112|Drug|metformin|
45402435|NCT03844204|Device|Thermal servo-controlled system|All patients will be positioned under the infant warmer. In the treatment group, a probe positioned on the skin of the neonate will guide the thermal exposure in a servo-controlled modality. In the control group, thermal exposure will be determined manually by setting the power of the heater at the maximum output.
45402436|NCT05670808|Drug|Epinephrine injection|Different doses on epinephrine will be administered to study arms to observe its impact on blood loss
45510394|NCT02049528|Drug|CC-122|CC-122
45510395|NCT02049528|Drug|CC-122|CC-122
45510396|NCT02049528|Drug|CC-122|CC-122
45510397|NCT02049606|Drug|LAYLA tablet|1 Tablet twice a day
45510398|NCT02049606|Drug|CENATONE tablet|2 Tablets once a day
45510399|NCT02049684|Procedure|Patch|
45510400|NCT05071703|Drug|Trilaciclib|"Carboplatin combined with Etoposide (ES-SCLC patients)~plus Topotecan (second/third line ES-SCLC patients)"
45510401|NCT02037516|Device|Accelomyography|quantitative measurement of the train-of-four with the TOF Watch to determine timing of administration of neostigmine and extubation To assure patient flow the time to reversal administration will be limited to approximately 30 minutes after achieving 4 twitches in qualitative monitoring
45510402|NCT02037516|Drug|Neostigmine|Neostigmine is used to reverse the effects of neuromuscular blocking agents
45510403|NCT02037516|Device|Qualitative Monitor|Qualitative (tactile or visual) assessment of residual neuromuscular paralysis
45510404|NCT01568099|Biological|AFFITOPE® PD01A|s.c. injection
45510405|NCT01568099|Other|Control|Untreated control
45510406|NCT02050932|Dietary Supplement|60 mg Fe as FeSO4 with stable isotopic labels|Subjects will receive FeSo4 supplements labeled with stable isotopic labels (54Fe, 57Fe, 58Fe) and iron absorption will be measured for each administration
45510407|NCT03561792|Other|Diaphragm ultrasound|In the semi-sitting position ultrasonography for diaphragmatic displacement was performed by the same intensivist. Diaphragmatic movement was evaluated by using 2 to 5 MHz US probe (Sonosite M-Turbo machine). The right hemidiaphragm was examined by two-dimensional (2D) and M-mode to record diaphragm displacement.in M-mode, the diaphragmatic displacement (cm) was measured and then DRSBI was calculated by respiratory rate (RR)/ diaphragmatic displacement (DD) (in mm)
45510408|NCT04981223|Device|ExactVu|clinical micro-ultrasound, imaging Device, Manufacturer; Exact Imaging
45715304|NCT04597840|Procedure|Incisional hernia repair with reinforcement of biosynthetic mesh|The biosynthetic mesh (Phasix or Bio-A meshes) will be placed as a sublay in the retromuscular position to reinforce midline fascial closure. All the surgical procedure (including placement and fixation of the mesh) will be performed according to a standardized protocol.
45715305|NCT04597840|Procedure|Incisional hernia repair with simple suture or synthetic mesh reinforcement.|Based on the discretion of the surgeon, the incisional hernia repair will be done by simple suture or by synthetic mesh reinforcement. All the surgical procedure (including placement and fixation of the mesh if applicable) will be performed according to a standardized protocol.
45402437|NCT01197664|Drug|paricalcitol|Given PO
45402438|NCT01197664|Radiation|radiation therapy|Undergo radiotherapy
45402439|NCT01197664|Other|laboratory biomarker analysis|Correlative studies
45510409|NCT02052024|Drug|Botox|Treatment group will receive 100 units of BOTOX and subjects will receive 1-3 injections per muscle at each visit.
45402440|NCT01197664|Drug|fluorouracil|Given PO
45402441|NCT01199458|Drug|alfentanil|20 mikrogr/kg
45510410|NCT02052024|Drug|MYOBLOC|Treatment group will receive 5,000 units of MYOBLOC and subjects will receive 1-3 injections per muscle at each visit.
45510411|NCT02037672|Drug|metformin|
45510412|NCT02037672|Drug|metformin and roflumilast|
45510413|NCT02049762|Drug|Aspirin|Aspirin 100 mg vs. placebo in ACS patients on P2Y12 inhibitors a month following PCI.
45510414|NCT02049840|Device|Altis Single Incision Sling System|Altis Single Incision Sling (SIS) System is a permanently implantable synthetic sling for the surgical treatment of Stress Urinary Incontinence
45510415|NCT02037594|Behavioral|Sexual Health Counseling|This brief intervention presents PrEP within the context of a patient's comprehensive sexual health plan and is designed to enhance decision-making around PrEP use and decrease sexual risk taking.
45510416|NCT02037594|Behavioral|Enhanced Adherence Intervention|This brief intervention is provides standard of care PrEP adherence information plus specific counseling, troubleshooting, and support.
45510417|NCT02037594|Behavioral|PrEP Information (Active Control)|Standard of Care Information about PrEP
45510418|NCT02037594|Behavioral|Standard of Care Adherence Support (Active Control)|Standard of care information and instruction about PrEP adherence.
45510419|NCT02052102|Radiation|Radiation therapy|
45715306|NCT04567810|Drug|anti-SARS-CoV-2 IgY|anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
45402442|NCT01199458|Drug|saline|The amount of saline will be equal the amount (in ml) of the study-drug (alfentanil)in order to keep it blinded.
45402443|NCT03733444|Drug|GLPG1690|GLPG1690, film-coated tablets for oral use.
45402444|NCT03733444|Drug|Placebo|Matching placebo, film-coated tablets for oral use.
45402445|NCT01199614|Drug|open-label PTH(1-84)|open label PTH(1-84) at either 25mcg every other day, 25mcg every day, 50mcg daily, 75mcg daily, or 100mcg daily
45402446|NCT01296100|Behavioral|Lifestyle intervention (nutrition)|The 200 study participants of this arm will first receive 6 months of Nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
45402447|NCT01296100|Behavioral|Lifestyle intervention (physical activity)|The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
45402448|NCT01197820|Device|MRI|"Patients will have a regular hepatic or kidney MRI investigation; we will add our sequences on their initial protocol. At first, one thermometry sequence is performed before angular correction is achieved with the following parameters: FOV=300 mm, matrix=96*96, TE/TR=18/72 ms, 67 lines/TR, Sense factor=1.4, 5 slices (4 coronal et 1 sagittal), 30° Flip angle.~In order to determine the main direction of motion, a set of 200 images are acquired during motion with two interleaved orthogonal slices (one coronal and one sagittal) centered on the region of interest, with the read out direction aligned with the head-feet direction. True-fisp images are acquired during 40 seconds with the following parameters: FOV=400 mm, matrix=128*109, TE/TR=1.2/2.43 ms, 60° flip angle, and 6 mm slice thickness.~Then the tested software proposes an angular correction to minimize out of plane motion. For each set of orientations, MR thermometry is performed"
45698569|NCT05164770|Drug|Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX|"Zanubrutinib+R-CHOP Regimen: Zanubrutinib 160mg bid; R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg /m2 d1, Doxorubicin 50mg /m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg /m2 or Vindesine 3mg /m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~Zanubrutinib+R-DA-EPOCH Regimen: Zanubrutinib 160mg bid; R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/ m2, Epirubicin 15mg/ m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~Zanubrutinib+R-HD MTX Regimen: Zanubrutinib 160mg bid; R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy."
45715307|NCT04567810|Drug|Placebo|Placebo matching anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
45402449|NCT01586104|Radiation|intensity-modulated radiation therapy|Undergo cardiac-sparing whole lung IMRT
45510420|NCT03561558|Drug|Ibuprofen D|Ibuprofen D, oral suspension, 200 mg / 5ml, manufactured by LLC Pharmtechnology, Belarus
45715308|NCT04556344|Behavioral|Emotional skills|3 sessions of 1,5 hour each. The first session can be face to face or over the phone, the two last ones will be held over the phone.
45715309|NCT04556344|Behavioral|Short free talk and relaxation|3 sessions of 1,5 hour each. The first session can be face to face or over the phone, the two last ones will be held over the phone.
45850834|NCT00359112|Drug|sulphonylurea|
45402450|NCT04871854|Drug|Tocilizumab|patients treated with Tocilizumab for Covid-19 infection
45402451|NCT04871854|Drug|traditional Covid -19 therapy|patients treated with traditional therapy for Covid-19 infection
45402452|NCT04839406|Behavioral|Structured support of caregivers at the ICU|Structured support of caregivers at the ICU provided by a trained group of 10-15 ICU nurses
45402453|NCT05282758|Other|Free Movement Dance|Free Movement Dance as a physiotherapy intervention
45402454|NCT05282758|Other|Modified person-centred progressive resistance exercise|Modified person-centered progressive resistance exercise as a physiotherapy intervention
45402455|NCT01588522|Drug|compound 31543 Calcitriol|topical compound 31543 will be applied to the scalp twice daily 7 +/- 2 days prior to the dose of chemotherapy and continue the application twice daily for 3 months or until termination of chemotherapy treatment.
45402456|NCT04834336|Device|inspiratory muscle training device|Inspiratory muscle training will be performed with an inspiratory muscle training device.
45510421|NCT03561558|Drug|Nurofen® for Children|Nurofen® for Children, Oral Suspension, 100 mg / 5 ml, marketed by Reckitt Benckiser Healthcare International Ltd, UK
45850835|NCT00359112|Drug|Avandamet|
45850836|NCT00359190|Drug|lapatinib|GW572016 ditosylate salt (lapatinib) will be given as 250 mg tablets via oral route
45850837|NCT00359658|Drug|prednisolon|prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal
45510422|NCT02037906|Radiation|Escalating Energy SWL|Dose escalation, 1500 SW at 18 kv, followed by 1500 SW at 20 kv and the following 1500 SW at 22 kv.
45510423|NCT02037906|Radiation|Constant Energy SWL|Constant dose at 20 kv
45510424|NCT02037906|Radiation|Reduction Energy SWL|Dose reduction, 1500 SW at 22 kv, followed by 1500 SW at 20 kv and the following at 18 kv.
45510425|NCT03099161|Drug|preladenant|Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle
45402457|NCT04834336|Other|Physical training|Physical training will be performed with exercise including balance, mobility, functional strength, and endurance.
45402458|NCT01296178|Drug|IDARUBICINE|"Administration of chemotherapy induction~Idarubicin IV Dose of 12 mg/m2/day days 1 to 3"
45402459|NCT01296178|Drug|ARA-C|ARA-C 200 mg/m2/day dose continuous infusion of IV days 1 to 7
45402460|NCT03845686|Diagnostic Test|Perfusion functional Magnetic Resonance Imaging (perfusion fMRI)|The goal of this test is to measure brain activity during subacute and chronic post-stroke period using a widely available non-invasive neuroimaging tool - functional Magnetic Resonance Imaging (fMRI). Because fMRI relies in part on cerebral blood flow, which is altered in stroke, measuring longitudinal changes in neural activity with fMRI requires that we control for concomitant changes in blood circulation. To do this, we will employ a novel dual-echo perfusion fMRI sequence, which will allow us to separately estimate neural and vascular contributions to fMRI.
45510426|NCT03099161|Biological|pembrolizumab|Administered as IV infusion on Day 1 of each 21-day cycle
45510427|NCT05142371|Other|Best Practice|Continue current activities of daily living
45510428|NCT05142371|Other|Exercise Intervention|Participate in exercise intervention
45510429|NCT05142371|Other|Quality-of-Life Assessment|Ancillary studies
45510430|NCT05142371|Other|Questionnaire Administration|Complete questionnaires
45510431|NCT04931849|Drug|Avatrombopag|Avatrombopag is a small molecule thrombopoeitic receptor agonist (TPO-RA) that mimics the biological effects of thrombopoeitin (TPO)
45510432|NCT04309565|Behavioral|Transitions Clinic Network Primary Care|Transitions Clinic Network (TCN)- participants in this arm will be referred to a TCN program for primary care and community Opioid Treatment Program (OTP). All TCN programs have the ability to prescribe buprenorphine and Extended-release naltrexone (XR-NTX) and assist with referrals to methadone. The primary features of the TCN include (1) primary care and onsite MOUD or referral to community treatment when indicated, (2) addressing social determinants of OUD and care coordination through a Community Health Worker (CHW), and (3) addressing the discrimination and stigma that exist based on incarceration.
45510433|NCT04309565|Behavioral|Standard Primary Care|Those randomized to the standard primary care arm will be referred to primary care and community Opioid Treatment Program (OTP). Participants may receive buprenorphine or Extended-release naltrexone (XR-NTX) through primary care or with a community addiction treatment provider.
45510434|NCT04855487|Behavioral|Nurse-patient dyadic storytelling intervention|During the 5-week online intervention, adolescents/young adults with cancer will create their stories following the guiding questions and online meetings with nursing research staff. The target audience of their stories will be their primary nurses. This online dyadic storytelling intervention is designed to promote in-depth self-reflection and meaningful and therapeutic relationships within bedside nurses. The intervention is designed following the Story Theory and Pennebaker's Expressive Writing paradigm.
45698570|NCT05164770|Drug|R-CHOP; R-DA-EPOCH; R-HD MTX|"R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg/m2 d1, Doxorubicin 50mg/m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg/m2 or Vindesine 3mg/m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/m2, Epirubicin 15mg/m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy."
45402461|NCT05670652|Other|clinical examination|Clinical examination with optimal (Lighting, using a disposable mouth mirror and a millimeter-ruler) will be performed, in addition to an upper and lower arch impression will be made and a study cast will be prepared.
45402462|NCT01193764|Dietary Supplement|100% cocoa powder|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
45510435|NCT04304339|Other|Hypercapnic respiratory failure|Patients with hypercapnic respiratory failure will be followed without any additional intervention
45510436|NCT03095027|Device|FID122819 contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
45402463|NCT01193764|Dietary Supplement|gelatin (Gelita)|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
45402464|NCT04793620|Other|TQL1055|Semisynthetic saponin adjuvant
45402465|NCT04793620|Biological|Acellular pertussis vaccine|Acellular pertussis vaccine
45510437|NCT03095027|Device|Stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
45510438|NCT05123729|Behavioral|Crowdsourced campaign package|COVID-19 prevention intervention developed using a crowdsourcing process.
45510439|NCT05123729|Behavioral|Standard information|Standard informational videos promoting the adoption of health-protective behaviors and COVID-19 testing
45402466|NCT01296256|Drug|Bendamustine-EAM|Bendamustine 200 mg/m2 starting dose on day -7 and -6 Etoposide 200 mg/m2 from day -5 to day -2 Ara-C 400 mg/m2 from day -5 to day -2 Melphalan 140 mg/m2 on day -1
45402467|NCT01197976|Device|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
45402468|NCT01197976|Device|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
45698571|NCT05374668|Behavioral|Video-based Yoga Exercises|They were trained face-to-face with social distancing and a maximum of three participants. They were observed while practicing and necessary alerts and corrections were made. Documents related to the videos for yoga exercises and posture exercises specially prepared for this study by the qualified physiotherapist (MD) were provided to the participants
45850838|NCT00359658|Drug|Mycophenolatmofetile|Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily
45402469|NCT04781062|Diagnostic Test|Blood and urine molecular analysis (Timing 0)|peripheral blood and urine sample collection
45510440|NCT04639115|Drug|Ozanimod|Ozanimod
45510441|NCT04271735|Dietary Supplement|Niagen|Subjects will take two capsules of nicotinamide riboside by mouth (250mg NR or placebo) twice daily for a total of 4 weeks.
45510442|NCT04271735|Other|Placebo|placebo capsule to match the active supplement
45698572|NCT05164692|Combination Product|LiveSpo Navax|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
45698573|NCT05164692|Drug|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
45698574|NCT01922583|Drug|AUY922|AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
45698575|NCT01922661|Drug|REGN1908-1909|
45698576|NCT01922661|Other|placebo|
45698577|NCT05090982|Other|Audio recordings during the consultations|50 patients with audio recordings of the consultation
45698578|NCT05090982|Other|Audio recordings during the consultations and test of the shared medical decision-making tool for modification|50 patients with audio recording of the consultation and Test of the shared medical decision-making tool for modification
45698579|NCT05090982|Other|Audio recordings during the consultations and test of the shared medical decision-making tool for validation|50 patients with audio recording of the consultation and test of the shared medical decision-making tool for validation.
45715310|NCT04338802|Drug|Nintedanib 150 MG|Nintedanib cloth sulfonate 150 mg, twice a day, about 12 hours apart. Continuous medication for 8 weeks.
45715311|NCT04338802|Other|Placebo|Empty capsules with the same appearance and ingredients as Nidanib soft capsules: one capsule at a time, twice a day, with an interval of about 12 hours each time. Continuous medication for 8 weeks.
45850839|NCT00359658|Drug|Cyclosporin A|Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 ng/ml
45596783|NCT02366949|Drug|BAY1217389|"BAY1217389 will be given orally, with a starting dose of 0.25 mg twice daily, on D1, D2, D8, D9, D15 and D16 of a 28 day cycle. BAY1217389 will be dosed in combination with paclitaxel in Arm 1 (Experimental Treatment) and from Cycle 2 onwards in Arm 2 (Standard Treatment).~After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.~In a higher dose level Cohort 4 > (or equal to) a relative bioavailability assessment of BAY1217389 liquid capsule formulation compared to BAY1217389 oral solution will be performed."
45510445|NCT04260659|Drug|Dexmedetomidine Hydrochloride [Dexdor]|Initial dosis of dexmedetomidine 1 mcg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 1 mcg/kg IBW / h will be initiated and continued until the end of operation.
45402470|NCT04781062|Diagnostic Test|Blood and urine molecular analysis (Timing 1)|peripheral blood and urine sample collection
45402471|NCT05344378|Behavioral|ATTAIN NAV Technology-Enhanced Family Navigation Model|The purpose of ATTAIN NAV is to test the impact of family navigation in multiple primary care clinics in Southern California for children with autism who have additional mental health needs. Family navigation includes: screening and behavioral health referral, supporting access to behavioral health services, engaging in evidence-based treatment, monitoring to achieve family goals, family strengthening, and connecting to concrete resources.
45510446|NCT04260659|Drug|Remifentanil [Ultiva]|Remifentanil TCI Minto Model will be used during induction in dosis 6 ng/ml and intraoperatively appropriately to maintain hemodynamical stability.
45510447|NCT04260659|Drug|Ketamine [Ketalar]|Ketamine 0,5mg/kg IBW iv will be administered during induction of general anesthesia.
45510448|NCT04260659|Drug|Lidocaine [Xylocaine 2%]|Initial dosis of lidocaine 1,5 mg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 3 mg/kg IBW / h will be initiated and continued until the end of operation.
45510449|NCT04260659|Drug|Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma]|Magnesium Sulphate will be administered in dosis 50 mg/kg IBW iv intraoperatively.
45510450|NCT04260659|Drug|Fentanyl [Fentanyl WZF]|Rescue dosis of 100 mcg iv will be administered if hypertension > 140/90 mmHg or tachycardia > 120min occurs. If necessary rescue dosis may be repeated.
45510451|NCT05068661|Drug|Ropivacaine 0.1% Injectable Solution|DPE
45510452|NCT05068661|Drug|Bupivacaine 0.25% Injectable Solution|CSE
45698580|NCT05370222|Behavioral|Dietary weight loss intervention|Based on an energy assessment from the data collected at T0 (energy intake, physical activity level, and resting metabolism), individualized nutritional advice will be given during an interview in order to propose a dietary rebalancing and a light caloric restriction. Caloric restriction will be generated to decrease body weight by ≈ 0.5 to 1 kg per week, as advised in several publications. As for the dietary rebalancing, it will concern in particular the distribution of macronutrients and their nature (glycemic index, nature of lipids), the fibers intake, or the reduction of consumption of refined and/or energy-dense foods based on the ANSES Recommended Dietary Allowances and on the food consumption guidelines of the National Nutrition and Health Program.
45698581|NCT00634569|Biological|Flebogamma 5% DIF|Intravenous Immune Globulin (Human)
45698582|NCT04247100|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Active Transcutaneous Auricular Microstimulation delivered by TENS device
45698583|NCT04247100|Device|Sham Transcutaneous Electrical Nerve Stimulation|Sham therapy will be delivered by applying the TENS device with non-conductive electrodes so that no microstimulation is delivered
45850840|NCT00359814|Drug|Mycophenolatmofetile|Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily
45850841|NCT00359814|Drug|Cyclosporin A|Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
45402472|NCT03731182|Biological|V114|V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
45402473|NCT03731182|Biological|Prevnar 13™|Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
45402474|NCT05668312|Other|Tele-prehabilitation|Preoperative tele-rehabilitation using a virtual reality system.
45850842|NCT00359892|Drug|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
45850843|NCT00359970|Drug|Azithromycin 500 mg|A single 500 mg dose at the start of treatment
45850844|NCT00359970|Drug|Azithromycin 1000 mg|A single 1000 mg dose at the start of treatment
45850845|NCT00359970|Drug|Loperamide|A single 4 mg loading dose at the start of treatment and then 2 mg after each loose stool
45850846|NCT00359970|Other|Placebo|A single loading dose at the start of treatment and then a dose after each loose stool
45850847|NCT00360048|Drug|oxytocin|
45850848|NCT00360204|Behavioral|Home Nurse Visit|Home nurse visit by maternal child health nurse within first 24-48 after post-partum hospital discharge.
45850849|NCT00360438|Drug|Rasburicase|0.15mg/kg intravenously over 30 minutes once per day for 5 consecutive days.
45850850|NCT00360516|Behavioral|metabolic (nutrient controlled) diet|metabolic (nutrient controlled) diet
45850851|NCT00360594|Drug|Acamprosate|3 pills (666 mg) for 1998mg/day
45850852|NCT00360594|Drug|Placebo|3 pills (666mg) for 1998mg/day
45850853|NCT00360750|Drug|carboplatin|
45850854|NCT00360750|Drug|cytarabine|
45850855|NCT00360750|Drug|etoposide|
45850856|NCT00360750|Drug|vincristine sulfate|
45850857|NCT00360750|Other|clinical observation|
45850858|NCT00360750|Procedure|adjuvant therapy|
45850859|NCT00360750|Radiation|radiation therapy|
45850860|NCT00360906|Drug|Triomar™ (omega-3 fatty acids)|
45850861|NCT00360984|Drug|insulin glargine|
45850862|NCT00360984|Device|continuous subcutaneous insulin infusion|
45510453|NCT04455815|Drug|Camostat|Patient to receive treatment with camostat tablets, 200mg four times daily (qds) for 14 days.
45510454|NCT04197713|Drug|Adavosertib|Given PO
45402475|NCT05668312|Other|Standard prehabilitation|Preoperative home-based rehabilitation delivered with a printed booklet for the Con-O subjects and no intervention for the Con-Y subjects.
45402476|NCT05339308|Other|Magnesium oil (BetterYou) dermal application|10 sprays (200 mg) of magnesium oil (BetterYou) will be applied to skin covering knee extensor muscles. The magnesium oil will be applied only once
45402477|NCT05339308|Other|Placebo Control|Natural mineral-free oil (10 sprays) will be applied as the control condition. This will be done only once
45402478|NCT03730012|Drug|gilteritinib|Oral tablet
45402479|NCT03730012|Drug|atezolizumab|Intravenous infusion
45402480|NCT03728140|Procedure|Self-spent Culture Medium|Replace embryo transfer solution with Self-spent culture medium in IVF-ET.
45402481|NCT03842332|Behavioral|Life Skills and Resilience Program|The 12 week life skills course includes resiliency modules that complement the strengths of participants as they progress toward the development and achievement of personal goals. The first module of the intervention engages youth through a caring/supportive relationship that sets these expectations. Activities are designed to support youth in identifying their existing strengths/skills. The second module explores, with youth, how they can apply and build upon their strengths/skills in the pursuit of self-generated goals. The third module is dedicated to building upon key problem solving skills that are especially important for young adults with autism, including conflict resolution and the management of stressors. The fourth module builds leadership capacity and self-advocacy skills.
45402482|NCT05288842|Biological|Lumbar puncture|5 mL of CSF
45402483|NCT05288842|Biological|blood sample|6x5 mL of blood sample collected :1 dry tube, 2 EDTA tubes, 1 fluoride tube, and 2 polypropylene tubes
45402484|NCT03844360|Drug|Bortezomib|bortezomib was administered follow the doctor's advice.
45402485|NCT03844360|Drug|Eltrombopag|eltrombopag was administered follow the doctor's advice.
45510455|NCT04197713|Drug|Olaparib|Given PO
45510456|NCT04193189|Biological|HEPLISAV-B|Administered by IM injection
45850863|NCT00361062|Behavioral|comparative computer simulation|comparative computer simulation assessing the level of aggressiveness before and after the beginning of SSRI treatment.
45850864|NCT00361452|Drug|nebulized epinephrine and nebulized albuterol|
45850865|NCT00361530|Drug|Statin|
45402486|NCT03844360|Drug|Imatinib|imatinib was administered follow the doctor's advice.
45402487|NCT03844360|Drug|dasatinib|dasatinib was administered follow the doctor's advice.
45402488|NCT03844360|Drug|Pegaspargase|pegaspargase was administered follow the doctor's advice.
45510457|NCT04193189|Biological|ENGERIX-B|Administered by IM injection
45510458|NCT04396145|Diagnostic Test|Subjective Visual Vertical|All subjects will have Virtual SVV before and after the operation
45510459|NCT04170335|Procedure|Bariatric surgery|Patients selected and consented for elective bariatric surgery will undergo standard of care preoperative mammogram, as well as inflammatory markers measurements and breast cancer risk score calculation. Post bariatric surgery the patients will have follow up mammogram, inflammatory markers, and breast cancer risk score calculation
45510460|NCT04340609|Biological|Mesenchymal Stem Cells|The UC-MSCs from a donor will be cultured in a clinical grade laboratory with xeno-free medium. Maximum passage of expanded-UC MSCs was VI and doubling population is less than 30. To assure the quality of our expanded-UC MSCs at ProSTEM the following tests are done: cell adherence, cell surface marker, in vitro differentiation, cell viability, sterility, Mycoplasma, endotoxin, and karyotyping.
45510461|NCT04303403|Drug|Trametinib|Taken orally once daily
45510462|NCT04303403|Drug|Ruxolitinib|Taken orally twice daily
45510463|NCT04148495|Drug|placebo of acetaminophen IV|"Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes (taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Placebo of acetaminophen IV: Sodium chloride 0.9%"
45510464|NCT04148495|Drug|acetaminophen IV|"Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes ((taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Acetaminophen IV: 1 g"
45510465|NCT05060003|Drug|Atezolizumab|Atezolizumab is provided by Genentech.
45850866|NCT00361608|Device|EarlySense ES 16|
45850867|NCT00361686|Drug|tramadol|
45402489|NCT03844360|Drug|Anti-Infective Drugs|anti-infective drugs was administered follow the doctor's advice.
45402490|NCT03844360|Drug|PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor|pegaspargase was administered follow the doctor's advice.
45510466|NCT05060003|Drug|Tiragolumab|Tiragolumab is provided by Genentech.
45510467|NCT05060003|Device|Signatera Assay|"To detect residual disease or to determine cancer recurrence with ctDNA~Step 2 screening (4-12 weeks after date of surgery), cycle 3 day 1, cycle 6 day 1, cycle 9 day 1, cycle 12 day 1, and end of treatment (optional)"
45510468|NCT05378789|Procedure|Nap|"ICU nurses can take a 20-mn nap between 2 and 5 am according to a rotation of personal.~Naps will be carried out with the help of a Nap and Up ® cocoon deckchair."
45510469|NCT04227197|Other|Down Syndrome Clinic to You (DSC2U)|DSC2U is a web-based tool for families to get up-to-date, personalized health and wellness information, based on national guidelines and expert consensus, for a person with Down syndrome.
45510470|NCT04203641|Biological|L-DOS47|A treatment cycle will be 28 days, with patients receiving L-DOS47 on Days 1, 8, 15, and 22.
45402491|NCT01198054|Drug|Lenalidomide|"Initial dose of oral lenalidomide is 10 mg/day for 28 days every 28 days, during 6 months.~In case of response on day 169, patient will follow a treatment extension phase. The dose of lenalidomide should be the same as the last dose for initial phase, until 24 months or progression disease"
45402492|NCT01199770|Other|Control, small|control pasta, small portion
45402493|NCT01199770|Other|Experimental B, small|experimental pasta, small portion
45402494|NCT01199770|Other|Experimental pasta C, small|experimental pasta C, small portion
45402495|NCT01199770|Other|control, medium|control pasta, medium portion
45402496|NCT01199770|Other|experimental pasta B, medium|experimental pasta B, medium portion
45510471|NCT04203641|Drug|Doxorubicin|A treatment cycle will be 28 days, with patients receiving doxorubicin on Days 2, 9, 16 and 23
45510472|NCT03632447|Device|Leva|Subjects randomized to Leva will use a vaginal probe containing motion-based sensors to direct the performance of pelvic muscle exercises.
45510473|NCT03632447|Device|PFDx|All subjects (in both study arms) will be evaluated using a vaginally placed device that will evaluate pelvic floor motion to document change in pelvic floor muscle function resulting from pelvic floor muscle exercises.
45698584|NCT04396353|Other|Electronic questionnaire|Clinical, anthropometric, and sociodemographic variables to characterize the sample will be collected using the Google Form. The same tool will be used to collect clinical variables (outcomes), as well as to obtain data on the level of physical activity and sedentary behavior time (predictor variables) prior to SARS-CoV-2 contamination. For this, we will use the International Physical Activity Questionnaire (IPAQ).
45698585|NCT01175980|Other|Laboratory Biomarker Analysis|Correlative studies
45698586|NCT01175980|Drug|Vorinostat|Given PO
45698587|NCT04246554|Drug|Ketorolac|Oral ketorolac for pain control following ACL reconstruction surgery
45698588|NCT04246554|Drug|Oxycodone-Acetaminophen|Oral oxycodone-acetaminophen for post-operative pain control
45850868|NCT00361686|Drug|remifentanyl|
45402497|NCT01199770|Other|experimental pasta C, medium|experimental pasta C, medium portion
45402498|NCT01199770|Other|NL|no pasta, water only
45402499|NCT01202032|Drug|Association of Bevacizumab (BVC)+ Pazopanib (PZP)|"Treatment is administered in 28-day cycles, during which patients received BVC intravenously every 2 weeks and oral PZP once daily from days 1 to 28. For the first cycle, PZP is administered alone from days 1 to 14.~The starting dose for dose escalation is BVC at 7.5 mg/kg in combination with PZP 400 mg (level 1).~The therapy regimens for each dose level are respectively:~BVC 7.5 mg/kg + PZP 600 mg (level 2) BVC 10 mg/kg + PZP 600 mg (level 3) BVC 10 mg/kg + PZP 800 mg (level 4). Patients who experience grades 3 to 4 adverse events have dose adjustments to one or both drugs. Dose reductions affect in priority the administration of PZP. Doses reductions to PZP are made in 200-mg decrements and to BVC to 2.5-mg/kg decrements.~Patients with toxicities that warrant reductions at either PZP 400 mg or BVC 7.5 mg/kg are withdrawn from the study."
45402500|NCT05266300|Genetic|DPYD genotype|"The SNPs included in this study are the following (dbSNP Reference SNP)~rs3918290(c.1905+1G>A) rs67376798(c.2846A>T) rs55886062(c.1679T>G) rs56038477(75017182)/(c.1236G>A)"
45402501|NCT03844984|Drug|ketamine full dose|This group will receive induction of anesthesia using Ketamine 1 mg/Kg.
45402502|NCT03844984|Drug|Midazolam|This group will receive midazolam 0.05 mg/Kg
45402503|NCT03844984|Drug|Normal saline|This group will receive normal saline 10 mL
45402504|NCT03844984|Drug|ketamine half dose|This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg.
45402505|NCT03844984|Drug|Lidocaine|This group will receive lidocaince 1 mg/Kg diluted in 10 mL normal saline.
45402506|NCT03842176|Procedure|Neoadjuvant chemotherapy before surgery|The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.
45402507|NCT03842176|Procedure|Surgery followed by adjuvant chemotherapy|The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
45402508|NCT03842020|Other|Blood pharmacokinetic samples|1 or 3 sample(s) will be taken in the following time windows: [H0-H3]; [H5-H9] and just before the next set [H24], depending if the child is or is not admitted to hospital
45510474|NCT05051189|Drug|Fentanyl Citrate|Ventilatory response to fentanyl in patients with OSA Specifically: respiratory changes, CO2, RR, TV
45510475|NCT04540289|Drug|Optimal Medical Therapy (OMT)|"Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2016 ESC guidelines for the management of acute and chronic heart failure"
45510476|NCT04540289|Device|Implantable cardioverter-defibrillator (ICD)|"An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed."
45402509|NCT03843658|Other|There is no intervention, but a diagnosis.|Cohorts will be determined by the primary rheumatology diagnosis.
45402510|NCT03843814|Procedure|APT MRI|
45510477|NCT05027165|Other|Non-interventional|No intervention
45402511|NCT04704544|Other|Tele-rheumatology|Participants will receive virtual visits via video conferencing and/or phone.
45402512|NCT01200004|Drug|Azacitidine|75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle.
45402513|NCT01200004|Drug|Lenalidomide|Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
45402514|NCT01200004|Drug|Grifola Frondosa|3 mg/kg by mouth twice a day on days 1 - 21 of a 28 day cycle.
45402515|NCT01198210|Drug|saline|local peritonsillar infiltration of 2 ml saline,
45510478|NCT04521647|Drug|Nicotine|Participants will receive two nicotine concentrations via e-cigarettes. Each exposure will be 10 3-sec puffs and ad libitum use
45510479|NCT04172597|Drug|Poziotinib Hydrochloride|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
45510480|NCT04172597|Drug|Loperamide|Loperamide as prescribed by the physician.
45510481|NCT04097873|Other|Diaphragm ultrasonography reeducation plus inspiratory training|Diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
45510482|NCT04097873|Other|Isolated inspiratory training|Isolated high-intensity inspiratory muscle training during 8 weeks
45698589|NCT01922817|Drug|Saxagliptin|5mg saxagliptin
45698590|NCT04275765|Behavioral|Arm 2:Behavioral Intervention with nudges & Facebook interaction|Participants will receive nudges and be enrolled to Facebook group for self-learning.
45698591|NCT04275765|Other|Arm 3: Community Intervention with individualised teleconferencing sessions and phone calls.|Participants will receive individualised teleconferencing sessions and phone calls by skilled midwives.
45402516|NCT01198210|Drug|Ketamine|local peritonsillar infiltration of ketamine (0.5 mg/kg)
45402517|NCT01198210|Drug|Dexamethasone|local peritonsillar infiltration dexamethasone (0.2 mg/kg))
45402518|NCT01198210|Drug|ketamine-dexamethasone|local peritonsillar infiltration combination of ketamine0.5mg/kg-dexamethason 0.2mg/kg
45402519|NCT03843736|Behavioral|Lifestyle intervention|"Balance the diet;~Limit high-calorie and high-fat food intake, reduce eating out, and establish regular eating habits;~Monitor body weight, avoid sedentary, get more sun and regular activities;~Mental health regulation."
45402520|NCT03843736|Drug|Probiotic Agent|Patients have to take a probiotic powder (product name: Tangwen Tai, lactobacillus plantarum LP45 + Lactobacillus acidophilus La28 + Bifidobacterium lactobacillus BAL531) twice a day for three months.
45402521|NCT03843736|Drug|Oral contraceptive|The patient needs to take drospirenone ethinyl estradiol tablets (trade name: Yousi Yue) 1 tablet daily for 3 months.
45402522|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
45402523|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
45402524|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
45510483|NCT04087655|Behavioral|Exercise|Eight weeks of interval exercise training
45698592|NCT05697432|Diagnostic Test|Oral Examination|A complete examination of oral and dental hygiene any health problems will be registered
45698593|NCT05697432|Diagnostic Test|PUFA index|An assessment of the presence of oral conditions resulting from untreated caries. P=Pulpal involvement, U=ulceration, F=fistula, A=abscess index
45698594|NCT05697432|Diagnostic Test|Plaque index|An assessment of the amount of dental plaque visible on the vestibular and lingual surfaces of all teeth. The index varies between 0-4.
45698595|NCT05697432|Diagnostic Test|Streptococcus mutans screening|A strip test for specific bacteria named streptococcus mutans, which plays an important role in caries formation, from patients' collected saliva
45510484|NCT04015427|Device|implant crown|After the second 16 week period the screw-retained crowns will be (re-) inserted in all patients, single tooth x-rays taken and clinical baseline values obtained. Additionally, a soft tissue biopsy will be harvested at the time of insertion of the final screw-retained crown. Patients will be followed up for another 16-week period.
45510485|NCT00446225|Drug|Erlotinib|"150 mg/day Patients will receive treatment until disease progression or unacceptable toxicity.~For all practical effects a treatment cycle will be defined as three weeks of continuous treatment with erlotinib"
45510486|NCT00446225|Drug|Carboplatin|"Gemcitabine 1000 mg/m2 days 1 and 8 and Carboplatin AUC = 5 day 1, every 21 days.~Docetaxel (75 mg/m2) /carboplatin (AUC=6); Gemcitabine (1000 mg/m2; day 1 and 8) / Carboplatin (AUC=5)~Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given."
45510487|NCT00446225|Drug|Gemcitabin|Cisplatin (75 mg/m2) / Gemcitabine (1250 mg/m2; day 1 and 8) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
45510488|NCT00446225|Drug|Docetaxel|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
45510489|NCT00446225|Drug|Cisplatin|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
45510490|NCT03080935|Drug|Evolocumab|Subjects will receive Evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
45510491|NCT04031105|Device|Theta-burst stimulation (TBS)|"intermittent (iTBS) and continuous (cTBS) will be applied at an intensity of 70% or 100%* resting motor threshold (RMT) on the dorsolateral prefrontal cortex, position F3 (EEG 10-20 international system)~*The optimal %RMT will be evaluated in a pilot study before commencement of the main study"
45510492|NCT03976115|Drug|DDO-3055|Oral
45510493|NCT03976115|Drug|Placebos|Oral
45510494|NCT03973255|Behavioral|Rehabilitation|Posturography, Whole body vibration
45510495|NCT04479449|Drug|SP-8203|SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
45510496|NCT04479449|Drug|Placebo|Placebo will be intravenously administered twice daily (intervals of 12 hours)
45510497|NCT05303207|Dietary Supplement|YOUR SUPER Detox Bundle|During days 1-5, participants will complete the 5-day Your Super Detox, consuming 2 smoothies daily (breakfast and dinner) containing Your Super Detox superfood powders.
45510498|NCT05419531|Other|prospective observational study - screening and follow up colonoscopy|Involves two visits and a colonoscopy. The first visit will be prior to the colonoscopy. 4-35 days after the colonoscopy, there will be a one time appointment to go over the results of the colonoscopy.
45698596|NCT05697432|Behavioral|Education|Education on correct toothbrushing technique, oral hygiene, dietary education on foods detrimental for dental hygiene.
45698597|NCT01176448|Device|Fractionated laser|Fractionated laser in the form of the Re:Pair CO2 laser manufactured by Solta Medical.
45698598|NCT01176448|Device|Dermabrasion|Diamond Fraise Dermabrasion will be performed in standard fashion down to papillary dermis.
45698599|NCT04275609|Other|AI generated report|After the endoscopic procedure, the physicians click the structured reporting button of computer to automatically complete the report through the structured diagnostic report generation system. The physicians only make minor corrections to the report.
45698600|NCT04275609|Other|physicians writing report|After the endoscopic procedure, the physicians writing the report in computer according the procedure.
45698601|NCT05351268|Radiation|Radioactive seed brachytherapy|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. 3D-printing coplanar template includes information on the path of the implantation needle, the needle path can be controlled accurately which can make the operation more accurate.
45698602|NCT03011710|Device|ProVari v2.5 (E-cigarette)|An electronic cigarette or e-cigarette is a handheld electronic device that vaporizes a flavored liquid. The user inhales the vapor. The fluid in the e-cigarette, called e-liquid, is usually made of nicotine, propylene glycol, glycerine, and flavorings.
45698603|NCT03011710|Device|Marlboro Gold (Conventional cigarette)|Conventional cigarette
45698604|NCT03011710|Device|Cigarette tip|Placebo device
45698605|NCT04275921|Diagnostic Test|MRI scan|MRI analysis using TWIST and HASTE
45402525|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
45402526|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner or once daily for 14 days immediately after breakfast
45402527|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
45402528|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
45698606|NCT04275921|Diagnostic Test|4D MRI|4D MRI alongside 4D CT in lung cancer
45402529|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
45402530|NCT03841630|Drug|LY3437943|Administered subcutaneously (SC)
45402531|NCT03841630|Drug|Placebo|Administered SC
45402532|NCT05668234|Other|interview|semi-directive interview
45402533|NCT04088578|Other|Training|Controlling movement of an object on computer screen by adjusting muscle activity.
45402534|NCT04088578|Other|Vagus Nerve Stimulation|Recruits the auricular branch of the vagus nerve which activates brain structures that release chemicals mediating cortical plasticity.
45402535|NCT04088578|Other|Sham Stimulation|Sub-threshold stimulation that does not activate neural structures.
45402536|NCT01198288|Other|domiciliary rehabilitation|a respiratory rehabilitation programme at the patient home
45402537|NCT01198288|Other|Standard Care|As describe in the standard care arm
45402538|NCT03841942|Other|clinically-based spacing strategy|All patients (as there are free from symptoms) will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission is maintained (CDAI < 150 for CD, Partial Mayo score < 3 for UC), patients will have a second step of a 2 weeks infliximab infusion spacing which will be maintained until the end of the study.
45402539|NCT03841942|Other|Trough level-based strategy|"patients will have at inclusion a determination of the infliximab trough level. According to this dosage, only patients with a trough level ≥ 7 µg/ml will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission (CDAI < 150 for CD, Partial Mayo score < 3 for UC) is maintained and if infliximab trough level is still ≥ 7 ug/ml, patients will have a second step of 2 weeks infliximab spacing until the end of the study.~Patients with a baseline infliximab trough level < 7 ug/ml will keep their baseline infliximab infusion interval until the end of the study."
45402540|NCT01200316|Procedure|Standard of Care|Post surgical patient to sit in a non-rocking chair for at least sixty minutes per day, and ambulating at least three times per day.
45698607|NCT05350644|Other|Primary exposure variable|"Specific activated CD8+ T-cell transcriptome signature in biopsies is associated with better treatment outcome~Specific activated CD8+ T-cell transcriptome signature in blood is associated with better treatment outcome"
45402541|NCT01200316|Procedure|Rocking Chair Motion|Post surgical patient to rock in a rocking chair in 10-20 minute increments for at least sixty minutes per day, and ambulating at least three times per day.
45402542|NCT01200316|Behavioral|Questionnaire|Beginning on day of surgery till discharge (3-5 days)
45402543|NCT05670574|Procedure|Surgery with extended (D3) mesenterectomy for small bowel tumors|
45402544|NCT01200472|Drug|Apremilast|Apremilast is supplied as 10 mg capsules for oral administration. After a 7-day titration phase patients will receive 20 mg PO BID apremilast.
45402545|NCT01200472|Drug|Placebo|Placebo capsules identical to apremilast
45402546|NCT04087486|Diagnostic Test|Implementation of a behavioural test for patients with TBI|"The following data will be collected: (1) sociodemographic variables (2); clinical and psychological data; (3) functional tests (neuropsychological testing, TEM version CRR and TEM-PRO).~On day one, patients will undergo standard neuropsychological tests and questionnaires listed hereafter, which are commonly used in the clinical practice at the CRR.~The Patient Competency Rating Scale (PCRS)~TEM (Multiple errands test)~GREFEX~5 POINTS TEST~TAP 2.3~Behavioral Assessment of the Dysexecutives Syndrome (BADS)~On day two, the patients will perform the TEM-PRO test ambulatory in our vocation rehabilitation unit.~Predictors variables will be collected before testing: Sociodemographic: age, sex, education, marital status, mother language, time since TBI, severity of the TBI (moderate or severe), type of lesion (contusion, diffuse axonal injury grade 1-3, ischemic or other complications), history of TBI, stroke or meningitis."
45402547|NCT01200628|Behavioral|DEPITAC|heteroevaluation scale by a nurse during hospitalization
45402548|NCT04638790|Drug|Doxorubicin|25 mg/m2 i.v. day 1,15 for ABVD/AVD
45402549|NCT04638790|Drug|Bleomycin|10,000 units/m2 i.v. days 1,15 for ABVD
45402550|NCT04638790|Drug|Vinblastine|6 mg/m2 i.v. days 1,15 for ABVD/AVD
45402551|NCT04638790|Drug|Dacarbazine|375 mg/m2 i.v. days 1,15 for ABVD/AVD
45402552|NCT04638790|Drug|Etoposide|100 mg/m2 i.v. days 1-3
45698608|NCT05350644|Other|Other (exploratory) exposure variables|Specific transcriptomic signatures in intestinal biopsies and peripheral blood mononuclear cells (PBMCs) of IBD patients can work as a predictive biomarker for the tumor necrosis factor inhibitors (TNFi) treatment response
45402553|NCT04638790|Drug|Doxorubicin|50 mg/m2 i.v. day 1 for EACODD-14
45402554|NCT04638790|Drug|Cyclophosphamide|650 mg/m2 i.v. day 1
45402555|NCT04638790|Drug|Vincristine|1,4 mg/m2 i.v. day 8
45402556|NCT04638790|Drug|Dexamethasone|20 mg i.v. days 1-3
45698609|NCT04397289|Drug|Heparin and Rivaroxaban|Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation
45850869|NCT00361686|Device|patient contolled analgesia|
45402557|NCT04638790|Drug|Dacarbazine|375 mg/m2 i.v. day 1 for EACODD-14
45402558|NCT05225428|Behavioral|Video Education|Investigator-developed, professionally animated and produced 8-minute video (Video Education) summarizing the core educational components of a genetic counseling visit
45402559|NCT05225428|Behavioral|Genetic Counseling|Standard genetic counseling
45402560|NCT05212402|Dietary Supplement|Cannabinol|Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.
45850870|NCT00361920|Drug|prednisone|
45402561|NCT05212402|Other|Placebo|Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.
45510499|NCT04434131|Drug|Convalescent Plasma|Study subjects will receive 1 unit (200mL) of SARS-CoV-2 convalescent plasma collected from a single donor who recovered from COVID-19.
45510500|NCT01383811|Other|Moderate Intensity Aerobic Exercise|Individuals in this group will receive moderate intensity exercise in addition to their usual care (Medications+/-Psychotherapy). The moderate intensity exercise program will involve gradual progression in exercise intensity and duration. During the first 4 weeks, participants will attend 3 supervised sessions/week and will be asked to complete at least 2 unsupervised aerobic exercise sessions/week. From weeks 5-8 the number of supervised sessions will be 2/week with at least 3 unsupervised aerobic exercise sessions/week. From weeks 9-12, the participants will have only 1 supervised session/week and will be asked to complete at least 4 unsupervised aerobic exercise sessions/week. In total, the participants will be required to complete 150 minutes of moderate physical activity/week.
45510501|NCT01383811|Other|Wait-list|The wait list/usual care group will continue with their usual standard treatment (Medications +/- Psychotherapy) as before.
45402562|NCT04606498|Other|Observational|Observational study only - no intervention
45402563|NCT04075864|Behavioral|Behavioral Counseling and Exercise|exercise program combined with behavioral counseling for patients who are hospitalized with a cystic fibrosis exacerbation
45402564|NCT04072978|Device|Intraocular lens implantation|Implantation of an intraocular lens using either an anterior chamber IOL or a scleral fixated IOL using the modified Yamane technique.
45510502|NCT05418959|Diagnostic Test|DermTech PLA noninvasive adhesive biopsy|The clinician will firmly press the DermTech noninvasive adhesive on the lesion and use their thumb to make five circular motions on the lesion. The adhesive patch will then be pulled off of the area. This will be repeated for an additional three patches.
45510503|NCT03787901|Other|Morula Vitrification|Evaluating the ongoing pregnancy rate following Morula vitrification compared with Blastocyst Vitrification.
45850871|NCT00361998|Drug|NITROFURANTOIN MACROCRYSTALS|
45698610|NCT01135420|Behavioral|Telephone Monitoring (TM) with Motivational Interviewing|Patients in the TM condition will receive an in-person session while in the inpatient psychiatry program, followed by monitoring delivered over the telephone for three months after discharge. The TM intervention will have a motivational interviewing component to address patients' motivation to obtain help for and reduce their substance abuse. The purpose of the intervention condition is to monitor patients' substance use, facilitate patients' entry into outpatient substance use disorder (SUD) treatment, and encourage ongoing 12-step selfhelp group participation to support sobriety.
45698611|NCT01135420|Other|Usual care|All patients in the trial will receive usual care (i.e., the care they would have received in the absence of a study).
45698612|NCT05349552|Radiation|stereotactic body radiation therapy|The patients were treated with high-dose and low fractionated radiotherapy, using modern precision radiotherapy technology.
45698613|NCT04396275|Other|Food-1|Cooked whole navy beans (300 kcal)
45698614|NCT04396275|Other|Food-2|Cooked whole yellow split peas (300 kcal)
45698615|NCT04396275|Other|Food-3|Cooked rice considered as control (300 kcal)
45850872|NCT00362310|Drug|indinavir|
45402565|NCT05282602|Other|baseline physical therapy treatment along with Wii Fit based exercises|Group A performed Wii Fit based exercises for 6 weeks. Group A will be treated with Wii Fit based exercises (40 mins session, 3 days/week, Penguin slide, soccer heading, tilt table, tightrope walking)
45402566|NCT05282602|Other|Proprioceptive exercises|Group B will be treated with Proprioceptive training (40 min session, 3 days/week, toe walking, heel walking, cross-body leg swings right and left sides, partial squat, ). In both groups pre and post-test measurements of Balance and Fall of risk will be assessed through Berg Balance scale, STAR excursion, Modified Fall Efficacy scale, and Timed Up and Go (TUG). Evaluation will be done before session start and at the end of 6th Week.
45402567|NCT04549246|Radiation|Spatially Fractionated Radiation (GRID) Therapy|Grid therapy allows for high doses of radiation to be delivered over several spatially distinct, small regions. This permits regions of very high dose to a large tumor away from critical structures, which could be beneficial in both palliative and definitive treatments. Additionally, allowing for high doses to be delivered could pose a benefit for radioresistant histologies.
45402568|NCT03249142|Drug|ARM A Durvalumab/chemotherapy association|"NEO-ADJUVANT Cycle 1 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1), every 3 weeks Cycle 2 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1) Cycle 3 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1)~ADJUVANT :~If complete surgical resection at interval debulking surgery : 3 cycles of durvalumab 1125 mg IV + carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV at day1, every 3 weeks.~If residual tumor at interval debulking surgery : the tremelimumab 75 mg IV will be added to the durvalumab-chemotherapy combination at day 1 of cycle 2 before a salvage surgery. Durvalumab 1125 mg IV (with one cycle of tremelimumab 75 mg IV post S3) will be pursued in maintenance treatment, up to 1 year or until disease progression, unacceptable toxicity or patient withdrawn."
45510504|NCT04992299|Behavioral|Mindfulness-Based Intervention|6-week mindfulness-based intervention of 6 weekly 1 hour group sessions
45510505|NCT04992299|Behavioral|Cognitive-Behavioral Therapy|6-week cognitive-behavioral therapy intervention of 6 weekly 1 hour group sessions
45510506|NCT04992299|Behavioral|Health Education|6-week health education didactic program of 6 weekly 1 hour group sessions
45698616|NCT05697354|Procedure|Cognitive rehabilitation using interactive tablet|the cognitive rehabilitation exercises will be administered using the Khymeia VRRS Home Tablet. Patients will be asked to actively carry out exercises focused on the following cognitive functions: language, attention, executive functions, verbal memory, visuo-spatial memory.
45850873|NCT00362388|Procedure|Intramyocardial injection of autologous bone marrow cells|
45850874|NCT00362544|Drug|Ambisome|
45850875|NCT00362700|Drug|Clevudine|
45850876|NCT00362778|Drug|Insulin|intravenous continuous insulin infusion for 48 hours
45850877|NCT00362856|Drug|larazotide acetate|capsule
45850878|NCT00362856|Drug|Placebo|capsule
45850879|NCT00362934|Drug|fenofibrate / simvastatin|Combination of fenofibrate and simvastatin 20 mg and 40 mg
45850880|NCT00362934|Drug|Atorvastatin|Atorvastatin 10 mg and 20mg
45850881|NCT00355836|Behavioral|Mental Imagery|
45850882|NCT00363090|Biological|alemtuzumab|
45698617|NCT05697354|Procedure|Cognitive rehabilitation using smartphone App Medico Amico|the cognitive rehabilitation exercises will be administered through patients' smartphone using the Medico Amico App. Patients will be asked to observe and concentrate on exercises focused on the following cognitive functions: language, attention, executive functions, verbal memory, visuo-spatial memory.
45698618|NCT00634179|Drug|Bortezomib|Bortezomib 1.6 mg/m² given on days 1 and 8
45698619|NCT00634179|Biological|Rituximab|Rituximab 375 mg/m²
45698620|NCT00634179|Drug|Doxorubicin|Doxorubicin 50 mg/m²
45698621|NCT00634179|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m²
45698622|NCT00634179|Drug|Vincristine|Vincristine 1.4 mg/m² (capped at 1.5 mg maximum) given on day 1
45402569|NCT03249142|Drug|ARM B Durvalumab/Tremelimumab/chemotherapy association|"NEO-ADJUVANT Cycle 1 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1), every 3 weeks Cycle 2 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV + tremelimumab 75 mg IV (day1) Cycle 3 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1)~ADJUVANT :~If complete surgical resection at interval debulking surgery : 3 cycles of durvalumab 1125 mg IV + carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV at day1, every 3 weeks.~If residual tumor at interval debulking surgery : patients will be treated according to investigator choice."
45402570|NCT01200706|Drug|Amoxicillin|amoxicillin 50mg/kg/day given in two different administration schemes
45402571|NCT01200784|Drug|Nicotinamide|dosage
45402572|NCT01200862|Drug|Investigational new drug company code: BGS649|
45402573|NCT01200862|Drug|Placebo|
45402574|NCT03843502|Drug|Kava Dietary Supplement|Participants will be given three 75mg kava capsules.
45402575|NCT01200940|Other|Sucralose|sucralose will be given at doses of 68 mg (equivalent to one 12 oz soda) 170 mg (equivalent to two and one-half 12 oz sodas, and 250 mg (equal to 100% of the FDA s acceptable daily intake for a 50kg individual).
45698623|NCT00634179|Drug|Prednisone|Prednisone 100 mg/day given orally on days 1-5
45698624|NCT01178944|Other|Laboratory Biomarker Analysis|Correlative studies
45402576|NCT01200940|Other|Aspartame|To determine the impact of sucralose and acesulfame- potassium ( aspartame) together on GLP-1 secretion, satiety, and the rate of intestinal glucose absorption. The doses of sucralose and acesulfame- potassium reflect the sweetener concentrations in the previously used Diet Rite Cola .
45402577|NCT01200940|Other|Acesulfame-Potassium|To determine the impact of sucralose and acesulfame- potassium ( aspartame) together on GLP-1 secretion, satiety, and the rate of intestinal glucose absorption. The doses of sucralose and acesulfame- potassium reflect the sweetener concentrations in the previously used Diet Rite Cola .
45402578|NCT01200940|Other|Control|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
45402579|NCT01201018|Drug|Oshadi D, Oshadi R|Oral administration
45698625|NCT01178944|Drug|Oxaliplatin|Given IV
45698626|NCT01178944|Drug|Pralatrexate|Given IV
45698627|NCT03011788|Drug|Golytely Oral Solution|Bowel purge prior to,colonoscopy
45698628|NCT01179490|Drug|SyB L-0501|SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible).
45698629|NCT01179490|Drug|prednisolone|Prednisolone will be administered (60 mg/m2/day) orally for 4 consecutive days and the course will be observed for the next 24 days.
45698630|NCT01179568|Drug|Citalopram|16 weeks of medication provided flexibly up to 40 mg/day. Medication will be administered in a double-blind fashion.
45698631|NCT01179568|Behavioral|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided within 20 weeks.
45698632|NCT01179568|Other|Placebo|16 weeks of daily inactive medication. It will be administered in a double-blind fashion.
45698633|NCT01180036|Drug|Rituximab|1000 mg, I.V. on Days 1 and 15 and will be retreated at month 6 independent of cluster of differentiation (CD) 19+ B cell count
45715312|NCT04455022|Other|Bedside blood culture bottles weighing combined with educational interventions.|Educational actions will be taken to raise the awareness of importance of collecting adequate volume of blood for culture (posters, leaflets and educational activities). The minimum volume will be defined as at least 1 ml. The paramount role of blood culture in process of ruling out newborn sepsis will be emphasized. The sample volume control by using bedside precision scale will be introduced.
45715313|NCT04453150|Other|Standard hypocaloric die|Standard hypocaloric diet
45715314|NCT04453150|Other|Intermittent fasting 16/8 (early fasting)|Intermittent fasting 16/8 (early fasting)
46057188|NCT05023083|Other|Functional Status Questionnaire Urdu version|The FSQ instrument translated into Urdu consists of only 34 items, main sections addressed physical function in the activities of daily living, psychological function, role function, social function and variety of performance measures.(8) Scores range from a 0 - 4, 1 - 4, and 1 - 6 scale per question depending on section. It increases reliability and patients ease and comfort. Total score range from 0 to 100 higher score represents the more severe condition.
45402580|NCT03841552|Device|Augmented Feedback|An inertial measurement unit (IMU) system is the basis of the augmented feedback (AF) system, where the IMU-system communicates with a laptop using a bluetooth dongle. The corresponding software includes therapeutic games. Movements of the lower back and pelvis by the patient are used to control an avatars movement or the graphical interface in computer exercises. The AF-system provides real-time feedback regarding the patient's performance and helps to rectify incorrect execution of the exercises. The intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
45510510|NCT03674567|Drug|FLX475|tablet
45510511|NCT03674567|Drug|Pembrolizumab|IV infusion
45510512|NCT03503435|Behavioral|Group art therapy|Participants will undergo 6 weeks of group art therapy in which they will learn tools to cope with a variety of cognitive, emotional and social aspects of life after TL.
46057189|NCT05023083|Other|Original Functional Status Questionnaire|FSQ was developed to allow the comprehensive and efficient assessment of physical, psychosocial, social, and role functioning in ambulatory patients. It is a self-administered survey that takes approximately 15 min to complete. The results can be scored to produce a one-page report for clinicians to use in their practices. The responses to items within a scale are averaged and transformed to a scale with a potential range of 0 to 100.Higher score represents the more severe condition.
46057190|NCT05748652|Device|digital CBT|An app-based intervention based on principles from cognitive behavioral therapy for anxiety.
45510513|NCT04407767|Behavioral|Case Formulation plus Cognitive Processing Therapy|The CF approach alters the CPT protocol in two ways: expanding the protocol to intentionally and systematically address impairment in functioning, and enhancing the providers' latitude to navigate challenges to optimal therapy outcomes (COTOS). CF-CPT begins with a formal CF assessment session; elements of CF are then integrated throughout CPT. CF modifications to the original CPT protocol occur in each session by intentionally attending to cognitions that are impeding the patient's functional recovery. The second modification includes enhancing the provider's latitude to diverge from the protocol when clinically wise. CF-CPT provides guidance around the identification, monitoring and management of COTOs, and, importantly, the expedient return to the CPT protocol with continued attention to COTOs.
45402581|NCT03841552|Other|Control Group|Conventional impairment-specific physiotherapy exercises for low back pain patients.The control intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
45510514|NCT04407767|Behavioral|Cognitive Processing Therapy|CPT is a brief therapy for PTSD predominantly based on cognitive theory. Traditionally delivered over 12 one-hour sessions weekly or twice weekly, CPT is now variable length depending on patient's recovery from PTSD. CPT is delivered in three phases: education, processing, and challenging and focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Changing dysfunctional beliefs alters negative emotions emanating from those beliefs.
45402582|NCT05667844|Behavioral|interoceptive mind-body exercise|A interoceptive mind-body exercise program in a patient with Generalized Anxiety Disorder and Major Depressive Disorder based on a Multidimensional Assessment of Interoceptive Awareness. Each session of the body-mind intervention lasts 80 minutes and is supervised by physical education professionals. The intervention is divided in 4 parts, that are: Preparatory phase (reception) the subjects will be welcomed through subjective analyzes of the researcher; Initial phase (preliminares) Mindfulness, grounding, sensory stimulation and joint warm-up exercises are performed; main phase (exercises) stretching, mobility, posture and balance exercises are performed with full attention and listening after each exercise; Final phase (relaxation) breathing exercises, stretching exercises, body scanning and relaxation are performed.
45402583|NCT03841396|Drug|Sodium chloride|All participants received a single dose of sodium chloride as placebo
45715315|NCT04453150|Other|Intermittent fasting 16/8 (late fasting)|Intermittent fasting 16/8 (late fasting)
45402584|NCT03844438|Drug|LPM3480226|The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg, 200 mg, 400 mg, 600mg.
45715316|NCT04453150|Other|Alternate-day fasting|Alternate-day fasting
45715317|NCT04453150|Other|Ketogenic diet|Ketogenic diet
45715318|NCT04439656|Diagnostic Test|Eye movement analysis|Eye movements will be analyzed to identify if seizures are present and compared to the EEG read
45850883|NCT00363090|Drug|cyclophosphamide|
45850884|NCT00363090|Drug|doxorubicin hydrochloride|
45850885|NCT00363090|Drug|prednisone|
45850886|NCT00363090|Drug|vincristine sulfate|
45850887|NCT00363090|Other|flow cytometry|
45850888|NCT00363090|Other|pharmacological study|
45850889|NCT00363324|Procedure|intracoronary injection of bone marrow cells|
45850890|NCT00363402|Procedure|PET-CT|
45850891|NCT00363714|Drug|AGN211745|100microgram single intravitreal injection
45850892|NCT00363714|Drug|AGN211745|200microgram single intravitreal injection
45850893|NCT00363714|Drug|AGN211745|400microgram single intravitreal injection
45850894|NCT00363714|Drug|AGN211745|800microgram single intravitreal injection
45850895|NCT00363714|Drug|AGN211745|1200microgram single intravitreal injection
45850896|NCT00363714|Drug|AGN211745|1600microgram single intravitreal injection
45850897|NCT00363792|Drug|Glyceryl trinitrate, azetazolamide|
45850898|NCT00363870|Biological|Fluarix vaccine|
45850899|NCT00363948|Drug|Placebo|Double-blind period (12 wk); Placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
45850900|NCT00363948|Drug|Sitagliptin phosphate|Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
45850901|NCT00364026|Drug|darusentan|
45510515|NCT05291273|Diagnostic Test|Closed Kinetic Chain Upper Extremity Stability Test|Each patient receive the same intervention, the Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST). The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
45510516|NCT05291273|Diagnostic Test|Prone Bridge Test|"The prone bridge test also known as the plank or hover measures the muscular endurance of the abdominal muscles. Subjects will start in the down push up position with their feet together and their hands shoulder width apart. When the test starts the subject will push up to the prone bridge position so they are resting on their hands and toes making sure they maintain a straight line from the shoulders through the hips to the knees. The outcome measure will be the time where the subject stay in this position."
45510517|NCT05291273|Diagnostic Test|Measurement of the muscle strength of the shoulder complex|Maximum isometric force of the external and internal rotators and abductors/adductors measured by a dynamometer.
45510518|NCT05418881|Device|Mobile Tracking Device (one spot)|Patients will be fitted with 4 different tracking devices (Garmin Fenix 6 Pro®, Apple Watch 7®, FitBit Sense®, Withings ScanWatch®).
45510519|NCT05418881|Device|Mobile Tracking Device + Activity Sensor (longitudinal)|Patients will be fitted with 1 of 3 different tracking devices (Garmin Fenix 6 Pro®, Apple Watch 7®, Withings ScanWatch®). The type of tracking device will be randomized. Additionally an Activity Tracker and one-channel ECG (Movesense®) will be worn by the patients.
45510520|NCT03845335|Device|dental implant-supported restoration|During the oral surgery session for dental implant insertion, after implant site preparation, the opaque sealed envelope containing the patient allocation will be opened. Following the group allocation, the patient will receive either an HA-coated Hybrid or moderately rough dental implant
45510521|NCT04986605|Device|Extracorporeal Photopheresis (ECP)|Drug Intervention using a medical device. The ECP device is already licensed in Canada. License No.7703. ECP treatment, using the drug UVADEX, will be given on 2 consecutive days every 4 weeks for a total of 26 treatment days (48 weeks).
45510522|NCT04986605|Drug|UVADEX|The phase II aspect of the study refers to the drug, methoxsalen. Methoxsalen is being used off label from the currently approved indications in the monograph. The study is proposing to use methoxsalen in combination with with extracorporeal photopheresis for the treatment of diffuse cutaneous systemic sclerosis. Treatment will be given in addition to standard of care medications for SSc.
45402585|NCT03841474|Drug|Psychiatric treatment with sertraline|Psychiatric treatment with sertraline (range from 50 mg/day to 200mg/day according to clinical appearance) of newly recognized depression in patients after PCI
45402586|NCT03841474|Drug|Psychiatric treatment with escitalopram|Psychiatric treatment with escitalopram (range from 10 mg/day to 20 mg/day according to clinical appearance) of newly recognized depression in patients after PCI
45402587|NCT04507594|Procedure|Lung lobectomy OR esophagus cancer resection|Lunge lobectomy (total) Resection of esophagus cancer
45402588|NCT03843112|Drug|Vivag Plus|Contains two lactobacilli strains; l. gasseri and l. rhamnosus
45402589|NCT03843112|Drug|Placebo - Cap|Vaginal supplements
45510523|NCT02868541|Other|Naso pharyngeal swab|Naso pharyngeal swab
45510524|NCT05418725|Device|PVI and Linear lesion using PEF|PVI and Linear lesion using PEF
45850902|NCT00364104|Drug|Quadruple sequential Helicobacter pylori eradication + iron sulfate|A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
45402590|NCT01198444|Drug|EE/DRSP (Yasmin Product Family)|One tablet per day, orally, 21 tablets followed by 7 days, during three consecutive cycles.
45402591|NCT05670184|Drug|LSD|Single dose of LSD (50 µg) will be administered in a small amount of alcohol (ethanol, 2ml/95% Vol.) orally.
45402592|NCT05670184|Drug|Ethanol|Identical ampules containing pure ethanol without the investigational product will be used (1mL ethanol, 95% Vol.).
45402593|NCT05084248|Drug|Ergocalciferol Capsules|Capsules of ergocalciferol at 400 IU and 4000 IU
45402594|NCT04469452|Device|Apollo Device|Comparisons will be made between the Apollo EE Device (Sable Systems International, Las Vegas, NV) and the TrueOne 2400 metabolic cart (Parvo Medics, Salt Lake City, UT)
45402595|NCT04467814|Behavioral|Better Together|"Patient and caregiver dyads from both groups will receive usual care during hospitalization and following discharge. This will include a handout on strategies for safely remaining active.~Caregiver participants in the intervention group will receive up to six telephone or video calls with the research assistant or Clinical Resource Therapist. Sessions will review the knowledge translation (KT) product with family members (~15 minutes), art goals, brainstorm strategies, and discuss setbacks. The calls with the caregiver may occur 1 to 2 times in the hospital, within one week of going home, and then in Months 2 and 3."
45510525|NCT05418725|Device|PVI and Linear lesion using CFRF|PVI and Linear lesion using CFRF
45510526|NCT01568983|Dietary Supplement|Placebo|500 ml/day Per 100g 6.25 g sucrose 6.25 g maltodextrin 1.3 g citric acid E330 (pH 3.0) 2.5 g Carmine solution E120 (4% carmine colouring agent) 0.025 g blueberry aroma Potassium sorbate E202 water
45850903|NCT00364104|Drug|Quadruple sequential Helicobacter pylori eradication therapy|A 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
45850904|NCT00364104|Drug|Ferrous sulfate|6-weeks of iron supplementation only plus 10-days matching placebo of Hp infection eradication therapy
45402596|NCT04467814|Behavioral|Usual Care|Patient and caregiver dyads from both groups will receive usual care during hospitalization and following discharge. This will include a handout on strategies for safely remaining active.
45402597|NCT01198678|Dietary Supplement|Boost Nutritional Supplement|Boost- Nutritional Supplement
45510527|NCT01568983|Dietary Supplement|Mana-juice|500 ml/day of a grape,cherry, bilberry,aronia juice 13g carbohydrates/100g 150mg K/100g
45850905|NCT00364104|Drug|Placebo|Placebo only (10-days of matching placebo of Hp eradication therapy and 6-weeks of matching iron supplementation).
45402598|NCT01201096|Radiation|177Lutetium|two cycles of 177Lutetium radioreceptor therapy within two month
45402599|NCT01201096|Procedure|Liver transplantation|about 9 month after finishing the receptor therapy liver transplantation takes place
45402600|NCT03842800|Other|MRI|Patients and volunteers will receive an MRI.
45510528|NCT01568983|Dietary Supplement|Optijuice|500 ml/day of a Grape,cherry, bilberry,aronia, black current juice 13g carbohydrates/100g 150mg K/100g
45402601|NCT03842800|Drug|Ketamine|Ketamine will be administered to a subset of healthy controls that agree to receive the drug as part of receiving an MRI.
45402602|NCT01201174|Other|fermented papaya preparation (FPP)|Hemolysis will be assayed by suspending 3 ml of packed RBC in PBS or in the autologous plasma and overnight incubation in the presence of various concentrations of antioxidants such as fermented papaya preparation (FPP) at 37oC in humidified atmosphere of 5% CO2 in air (10). Following 5 min centrifugation at 800 rpm, the supernatants will collected for Hb determination by measuring the absorbance at 540 nm.
45402603|NCT04415788|Device|Test of Incremental Respiratory Endurance - IMT|The TIRE training regimen will involve the use of a tablet provided to assigned subjects with the training software installed and a PrO2® device through which they will train. The software allows subjects to track their inspiratory muscle performance via real-time graphic representations of their efforts as training progresses.
45402604|NCT04415788|Device|Threshold - IMT|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
45402605|NCT04415788|Device|Sham IMT (Low resistence)|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
45402606|NCT01201252|Procedure|Stool sampling|Stool samples will be collected, tested and genotyped for the presence of rotavirus
45402607|NCT03841006|Device|MRI|dynamic MRI pelvis
45402608|NCT01202422|Drug|Pregabalin controlled release, 165 mg|Two tablets of 165 mg controlled release (administered concurrently) once daily for four days.
45402609|NCT01202422|Drug|Pregabalin controlled release, 330 mg|330 mg controlled release tablet administered once daily for four days.
45402610|NCT01202422|Drug|Pregabalin immediate release, 150 mg|150 mg immediate release capsules administered every 12 hours for four days
45402611|NCT03840694|Other|Smoking Abstinence|Participants will abstain from smoking for 24 hours.
45402612|NCT03840694|Other|Ad Lib Smoking|Participants will continue smoking as usual (i.e. ad lib) and smoke one cigarette of their own brand immediately prior to scanning.
45402613|NCT03892018|Drug|Oraxol|Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
45402614|NCT03842644|Device|Tension reduction device|Continue using this device for 3 months post surgery.
45402615|NCT01201564|Procedure|intraperitoneal onlay mesh repair|The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
45402616|NCT01201564|Procedure|sublay mesh repair|The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
45402617|NCT05018104|Other|This is not an interventional study|This study utilizes data from the St. Paul's Hospital Peripheral Nerve Block Database.
45402618|NCT03725722|Drug|Delgocitinib cream|Cream for topical application
45402619|NCT03725722|Drug|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
45402620|NCT01198912|Drug|placebo|during 56 days
45402621|NCT01198912|Drug|doxycycline 100 mg|during 56 days
45402622|NCT04316572|Behavioral|mental health specialist video consultation|"The consultations will be based on a psychodynamic understanding with a solution-oriented stance and will follow a manual:~Session 1: Getting familiar with the telemental health setting, building a working alliance and deepening diagnostics.~Session 2: Clarification of the task/objective, focus building, motivational interviewing if necessary.~Session 3-4: Focused brief interventions e.g. psychoeducation, promotion of social resources, activation of health-promoting lifestyles (sleep hygiene, eating diary, relaxation etc.), work on personal problems and, if necessary, initiation of further specialised treatment.~Session 5: Ending the intervention, stabilisation, subsequent treatment plan and communicating a case summary to the general practitioner"
45402623|NCT04300894|Device|Mamma Mia|"Users of the Mamma Mia program progress through the intervention in a sequence of modules.~Every day that a module should be completed, you will receive a notification with a reminder to access the program. By clicking on the reminder, you can access that particular day's session content. Modules involve a variety of information and activities; for example, there are guided mindfulness practices, information on breastfeeding, instructional videos on how to interpret your baby's cries, and discussions on how to have effective discussions with your partner or healthcare provider about your needs."
45402624|NCT04300894|Other|Mamma Mia Plus|Participants will use the Mamma Mia program, plus receive contact (phone calls or emails or texts) from study staff every few months.
45402625|NCT03842488|Drug|Experimental: RAL QD|Prescription of 2x RAL 600mg (1200MG) once daily
45510529|NCT04390399|Biological|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
45510530|NCT04390399|Drug|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
45510531|NCT04390399|Biological|PD-L1 t-haNK|PD-L1 t-haNK suspension for infusion
45850906|NCT00364260|Drug|epoetin alfa|
45850907|NCT00364338|Behavioral|gourment cooking workshop|
45850908|NCT00364416|Other|Any treatment used to treat CHF|Clinical Outcomes of Chronic Decompensated Heart Failure patients
45850909|NCT00364494|Procedure|Different timing of red blood cells transfusion (substudy 1); Acute hemodilution versus no hemodilution (substudy 2)|Subgroup 1,with Ht<21% receive an hemotransfusion before or after CEC;subgroup 2,with Ht>25% bleed or not
45402626|NCT03842488|Drug|Active comparator: DRV/cb|Prescription of DARUNAVIR/COBICISTAT 800 Mg-150 Mg once daily
45402627|NCT04256824|Drug|coated vicryl plus|Coated Polyglactin 910 with Triclosan (coated vicryl plus)
45402628|NCT04256824|Drug|Vicryl|Coated Polyglactin 910 without Triclosan (vicryl)
45402629|NCT03842254|Drug|Erythropoietin|Subcutaneous injection of erythropoietin 10,000 units
45402630|NCT01202500|Procedure|reducing treatment to 3 months|The treatment will be stopped after 3 months
45402631|NCT01202500|Procedure|registered length of treatment|The treatment procedure will follow the actual recommandation
45402632|NCT04223050|Drug|Oxygen gas|Administering oxygen to achieve the desired peripheral oxygen saturation
45402633|NCT01198990|Behavioral|Group 1|Subjects will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.
45402634|NCT01198990|Behavioral|Group 2|Subjects will be randomized to the small change eating strategy and a physical activity goal.
45402635|NCT01201642|Drug|Prednisolone|Prednisolone as 5 mg tablets will be given as a single dose of 40 mg daily for 10 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
45402636|NCT01201642|Device|acupuncture|The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. For acute stages acupuncture, shallow puncturing is used at facial acupoints and routine puncturing is used at other acupoints. For resting stage acupuncture, penetrative needling is used from Dicang (ST4) to Jiache (ST6) and from Taiyang (EX-HN5) to Quanliao (SI18) 2-3 cun, and routine puncturing is used at other acupoints. Filiform needles (33 - 49.5 mm, 0.32 mm) will be used with moderate stimulation to get an acupuncture sensation, and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
45402637|NCT01201642|Other|other treatment|common medicine or other physical treatment which are different from those 5 Arms Previously.
45402638|NCT05004064|Drug|Acalabrutinib|Patients will receive acalabrutinib 100mg twice daily for up to six 28 day cycles. Patients can receive 100mg once daily for cycle 1, day 1 to day 7, according to the investigator's discretion.
45402639|NCT05004064|Drug|Rituximab|Patient will receive rituximab 375 mg/m2 IV on day 1 (+/- 3 days) of each cycle, for a maximum of 6 cycles
45402640|NCT03842410|Device|Single-Incision Sling|Solyx Single-Incision Sling for correction of stress urinary incontinence done in the office.
45402641|NCT03798418|Behavioral|elastic band strengthening exercise|2-3days per week(150min per week)
45402642|NCT03798418|Dietary Supplement|diet counseling|each patients in this group will receive4-5times diet counseling
45402643|NCT04982692|Drug|intravaginal prasterone|6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
45510532|NCT04390399|Drug|Nab-paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
45510533|NCT04390399|Drug|Gemcitabine|2', 2'-difluoro 2'deoxycytidine, dFdC
45510534|NCT04390399|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
45402644|NCT04982692|Drug|Placebo ovules|Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
45402645|NCT01202734|Drug|Methylphenidate HCl|Period 1: One tablet, oral, 36 mg, once daily, single-dose on Day 1
45402646|NCT01201720|Procedure|Plasma exchange with albumin|Realization of 6 plasma exchange with albumin in 11 days
45402647|NCT01201954|Drug|sucrose|oral sucrose solution, 24%, 0,5 ml/kg, 2 minutes before start the suctioning sterile water, 0,5 ml/kg, 2 minutes before start the suctioning
45402648|NCT04971148|Other|HFNC flow set at patient peak tidal inspiratory flow|HFNC flow will be set at the level equal to patient peak tidal inspiratory flow
45402649|NCT04971148|Other|HFNC flow set at 1.33 times of patient peak tidal inspiratory flow|HFNC flow will be set at 1.33 times of patient peak tidal inspiratory flow
45402650|NCT04971148|Other|HFNC flow set at 1.67 times of patient peak tidal inspiratory flow|HFNC flow will be set at 1.67 times of patient peak tidal inspiratory flow
45510535|NCT04390399|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
45510536|NCT04390399|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
45510537|NCT04390399|Procedure|SBRT|Stereotactic Body Radiation Therapy
45510538|NCT04390399|Drug|Irinotecan liposome|Irinotecan hydrochloride trihydrate is (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano[3',4':6,7]-indolizino[1,2-b]quinolin-9-yl-[1,4'bipiperidine]-1'-carboxylate, monohydrochloride, trihydrate
45510539|NCT01383733|Drug|RO5458640|Multiple ascending doses intravenously, weekly or every 2 weeks or every 3 weeks
45510540|NCT01383655|Drug|Magnesium Sulfate|i.v. magnesium 40mg/kg in 20 min
45510541|NCT01383655|Drug|Placebo|NaCl
45510542|NCT03541525|Other|Biological sampling|Biological samples including blood, surgical remainder, urine,...
45850910|NCT00364572|Drug|epidural injection of etanercept|2 injections of etanercept 2 weeks apart with doses ranging from 2 mg to 6 mg
45850911|NCT00364572|Drug|placebo (control procedure)|Two injections of epidural saline 2 weeks apart
45850912|NCT00364650|Drug|Probiotic Supplement|2 capsules twice daily
45850913|NCT00364650|Other|Placebo|placebo
45850914|NCT00364806|Drug|Prochlorperazine|
45850915|NCT00364806|Drug|Metoclopramide|
45850916|NCT00364884|Drug|ketoaminoacid|
45850917|NCT00365040|Procedure|Prk with mitomycin vs Lasik|
45698634|NCT01180036|Drug|Cyclosporine|Patients randomized to the Cyclosporine arm will be started at a dose of (CsA = 3.5 mg/kg/day p.o. divided into 2 doses for 12 months). Target trough CsA blood levels, as determined in whole blood by High Performance Liquid Chromatography (HPLC), are 125 to 175 ng/ml. A persistent and otherwise unexplained increase in serum creatinine >30% would prompt an approximate 25% dose reduction of CSA, aiming for a corresponding 25% reduction in CSA trough level. If with this dose reduction the creatinine does not return to within 30% of baseline levels within 3 weeks, then a second dose reduction of approximately 25% with similar reduction in CSA trough level will be used. If the creatinine does not fall to baseline values with this second dose reduction, the drug will be discontinued. At the end of 12 months, Cyclosporine will be tapered by 1/3 of the maintenance dose monthly and hence discontinued after 3 months.
45698635|NCT01180894|Drug|Iron sucrose|100 mg IV TIW
45850918|NCT00365118|Device|Pulsed dye laser (Candela), Intense pulsed light (Palomar)|
45402651|NCT04971148|Other|HFNC flow set at 2 times of patient peak tidal inspiratory flow|HFNC flow will be set 2 times of patient peak tidal inspiratory flow
45402652|NCT03173092|Drug|Ixazomib|Ixazomib capsules.
45402653|NCT03173092|Drug|Lenalidomide|Lenalidomide capsules.
45402654|NCT03173092|Drug|Dexamethasone|Dexamethasone.
45402655|NCT03037684|Diagnostic Test|neurophysiology|electrophysiologic measurements of peripheral nerves
45402656|NCT01202812|Dietary Supplement|Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)|Eicosapentaenoic Acid (EPA)/Docosahexaenoic Acid (DHA) 30mg/kg (LOVAZA capsules) given by mouth daily for 6 months.
45402657|NCT01202812|Other|Placebo Capsules|Placebo capsules given by mouth daily for 6 months.
45510543|NCT01623193|Other|All-blood cardioplegia|The treatment group will receive all-blood cardioplegia for myocardial protection during surgery
45510544|NCT01623193|Procedure|Standard cardioplegia|This arm will receive standard 4:1 cardioplegia for myocardial protection during surgery
45510545|NCT01615159|Behavioral|Behavior and lifestyle counseling|20 week intervention period where one group gets behavior and lifestyle counseling and the other group gets no active intervention
45510546|NCT02136355|Radiation|Stereotactic Body Radiation Therapy plus Surgery|Stereotactic body radiation therapy followed by surgical resection
45850919|NCT00365196|Behavioral|CBT Hostility Reduction Program|
45510547|NCT01568281|Drug|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF with water.
45510548|NCT01568281|Drug|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
45510549|NCT01568281|Drug|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF without water.
45850920|NCT00365430|Behavioral|safety program|Education, patient involvement, tailored implementation and a computerized registration system
45402658|NCT04948918|Procedure|Anatomically optimized distal renal denervation|Bilateral radiofrequency renal denervation will be performed using Symplicity Spyral renal denervation system. Generally, at least two separate applications of radiofrequency energy will be performed in each segmental branch of renal artery. Each application will be done through 4 electrodes deployed in helical manner according to the design of the catheter
45402659|NCT03840850|Other|Personalized Risk Communication for People with Type 2 Diabetes|The risk communication intervention consists of communicating the impact of being poorly controlled on two types of outcome: (1) absolute 10-year risk of experiencing a cardiovascular event, i.e. heart attack or stroke (10-year CV risk); (2) life expectancy. These personalized risk estimates are calculated based on the UKPDS outcomes model (version 2), which is a prognostic model of reference in the area of Type 2 diabetes.
45402660|NCT01203748|Procedure|PVI + Lines ablation|Pulmonary vein antrum isolation with additional linear ablation (mitral line and roof line)
45402661|NCT01203748|Procedure|PVI|Pulmonary vein antrum isolation
45402662|NCT01203748|Procedure|PVI + CFE ablation|Pulmonary vein antrum isolation with additional complex fractionated electrogram ablation
45402663|NCT02966314|Drug|Omalizumab|Omalizumab 300mg subcutaneous injection once monthly for 6 months. Total dose will be divided into two 150mg/1.2mL injections.
45510550|NCT01568281|Drug|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
45698636|NCT01180894|Drug|Placebo|
45698637|NCT01181050|Drug|NNC0142-0002|A single dose of 4 mg NNC 0142-0000-0002/kg bodyweight. Administered subcutaneously (s.c., under the skin).
45850921|NCT00365586|Drug|Ketoprofen Topical Patch , 20%|
45402664|NCT02966314|Drug|Placebos|Placebo Group (Sodium Chloride 0.9%) two 1.2mL subcutaneous injections once monthly for 6 months.
45402665|NCT01203982|Drug|Rosuvastatin|Rosuvastatin 5mg/day for one year
45850922|NCT00365742|Drug|simvastatin|
45850923|NCT00365742|Drug|red yeast rice|
45850924|NCT00365742|Drug|pharmaceutical grade fish oil|
45850925|NCT00365742|Behavioral|therapeutic lifestyle changes|
45402666|NCT01203982|Drug|Rosuvastatin|Rosuvastatin 40mg/day for one year
45402667|NCT04938154|Device|DBS ON|The DBS system will be turned on and the patient will be left on their best setting for 3 months.
45402668|NCT04938154|Device|DBS OFF|The DBS system will be turned off, and will be left off for 3 months.
45850926|NCT00365820|Drug|Tegaserod|
45850927|NCT00365898|Drug|Hydromorphone Hydrochloride Extended-Release|
45850928|NCT00366210|Behavioral|Constraint-Induced Movement (CI) Therapy|
45510551|NCT01013935|Other|CARE+ Spanish computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 12 months total.
45510552|NCT01013935|Other|CARE+ Spanish brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 12 months total.
45510553|NCT03965143|Device|3D talar augmentation|Patients with an avascular necrosis of the body if the talar bone will undergo a 3D custom talar augmentation with or without concomitant ankle arthroplasty
45510554|NCT01383577|Procedure|Single hemorrhoidal ligation|Effective ligation of one hemorrhoidal group and sham ligation of the two other major hemorrhoidal groups is performed in each of three sessions of treatment. Final revision is performed 90 days after first session of hemorrhoidal ligation.
45510555|NCT01383577|Procedure|Triple hemorrhoidal ligation|The three major hemorrhoidal groups are ligated in the first session of ligation. Sham triple hemorrhoidal ligations are performed 30 and 60 days after the first session. Final revision is done 90 days after first ligation session.
45510556|NCT04178551|Other|Implementation Facilitation|The foundation of CONDUIT's implementation activities are the structured interactions between external facilitation teams and internal facilitation teams. A core set of internal facilitation activities will be used across all facilitation teams, and external facilitation teams will use additional activities based on the needs of their sites or clinical settings.
45510557|NCT05420233|Diagnostic Test|MRE|Magnetic Resonance Enterography at year 1 (in some patients)
45510558|NCT02921789|Drug|Bleselumab|Intravenous infusion
45510559|NCT02921789|Drug|Basiliximab|Bolus injection
45510560|NCT02921789|Drug|Mycophenolate Mofetil (MMF)|Oral Intravenous
45510561|NCT02921789|Drug|Tacrolimus Capsules|Oral Capsule
45510562|NCT02921789|Drug|Methylprednisone|Oral or Intravenous
45510563|NCT02921789|Drug|Prednisone|Oral Tablet
45510564|NCT03948061|Other|Cherry juice|FruitSmart® Cherry Concentrate: Dark Sweet Cherry Juice Concentrate produced from dark sweet cherries to retain the characteristic color and flavor of the whole fruit.
45850929|NCT00366210|Behavioral|Stretching, Relaxation, & Biofeedback|Passive stretching of both arms, EMG biofeedback for more-impaired arm
45850930|NCT00366288|Drug|PAZ-417|2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.
45850931|NCT00366366|Biological|Infanrix-Hexa|
45510565|NCT03948061|Other|Placebo beverage|Cherry flavored placebo beverage prepared from commercially available cherry syrup with food coloring and thickener to match the color and viscosity of the cherry concentrate.
45510566|NCT05420155|Procedure|Surgical resection|Surgical treatment of hepatic hydatidic cyst
45698638|NCT01181050|Drug|placebo|A single dose of 4 mg NNC 0142-0000-0002 placebo/kg bodyweight. Administered subcutaneously (s.c., under the skin).
45698639|NCT03011944|Other|Quality Improvement Program|Nutrition screening, Nutrition consult, Oral Nutritional Supplement will be implemented in the Home Health branches as standard of care.
45850932|NCT00366522|Drug|LXR-623|
46057191|NCT05748652|Other|Psychoeducation|Participants will be provided with psychoeducation which will be delivered digitally upon allocation to the psychoeducation arm.
45402669|NCT01204060|Other|Nasal allergen challenge|Subjects will receive a nasal spray containing an allergen to which they are allergic
45402670|NCT01204060|Other|Nasal placebo challenge|Subjects will receive a nasal spray with allergen diluent
45402671|NCT01202890|Drug|Lenalidomide, Liposomal Doxorubicin, Bevacizumab|"At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course.~Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease."
45510567|NCT02564900|Drug|DS-8201a (DP1)|DS-8201a to be administered via intravenous (IV) dose. DS-8201a (DP1) was used for the Dose Escalation phase and for Dose expansion Parts 2a, 2b, 2c, and 2d.
45510568|NCT02564900|Drug|DS-8201a (DP2)|DS-8201a is to be administered via intravenous (IV) dose. DS-8201a (DP2) was used only used for Dose Expansion Part 2e.
45510569|NCT02564900|Drug|DS-8201a (DP)|DS-8201a (DP) is to be administered via intravenous (IV) dose.
45698640|NCT03877926|Biological|AV7909|AV7909 consists of Anthrax Vaccine Adsorbed (AVA) drug substance and CPG 7909 adjuvant. AVA drug substance in AV7909 is similar in composition and manufactured using the same process as commercial BioThrax® vaccine. BioThrax is licensed for post-exposure prophylaxis of anthrax disease. CPG 7909 is an immunostimulatory synthetic oligodeoxynucleotide that functions as an adjuvant. It is designed to induce an enhanced immune response.
45698641|NCT03877926|Biological|BioThrax|BioThrax vaccine (Anthrax Vaccine Adsorbed; AVA) is licensed for post-exposure prophylaxis of anthrax disease.
45850933|NCT00366600|Drug|neratinib|HKI-272
45850934|NCT00366834|Drug|Casopitant (GW679769) oral tablets|
45510570|NCT05419843|Other|HSCT Arm group|"Conditioning regimen Stem cell source Only Bone Marrow With a minimal target dose of 4x108 nucleated cells/kg recipient ideal body weight. If the graft is less rich than the minimum target dose, it can be administered at the discretion to the physician.~GVHD Prophylaxis Prevention of EBV reactivation : Rituximab 150mg/m2 IV at Day+5 post HSCT."
45510571|NCT01568333|Drug|Decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.
45510572|NCT03437005|Drug|Desonide 0.05%|Desonide 0.05% ointment topically twice daily for two weeks
45850935|NCT00366834|Drug|Casopitant (GW679769) intravenous|
45850936|NCT00366834|Drug|Dexamethasone intravenous|
45850937|NCT00366834|Drug|Ondansetron oral tablets|
45850938|NCT00366834|Drug|placebo|casopitant placebo
45850939|NCT00366912|Device|non-invasive ventilation|
45402672|NCT01202890|Drug|Revlimid, Doxil, Avastin|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
45510573|NCT03437005|Drug|Ketoconazole 2%|Ketoconazole 2% cream topically twice daily for two weeks
45402675|NCT03118804|Diagnostic Test|Assessment of Lung Tidal Distribution With EIT|Changes of lung tidal distribution during SBT with mechanical ventilation were recorded by EIT can be used to predict weaning success or failure
45402676|NCT01199224|Drug|veliparib|veliparib formulation A
45402677|NCT01199224|Drug|veliparib|veliparib formulation B
45402678|NCT01199224|Drug|veliparib|veliparib formulation C
45402679|NCT01199224|Drug|veliparib|veliparib formulation C
45402680|NCT03840304|Other|Yoga@work|Each session included warm-up practices(for the large joints, spine, and extremities), Physical postures (Asana), breathing exercises (pranayama) and supine meditation/relaxation (savasana).
45402681|NCT03839056|Device|IC+PIEB+PCEA high flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~This intervention is included in the clinical practice routine"
45402682|NCT03839056|Device|PIEB+PCEA high flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~In the group of pure boluses 10ml / h of perfusion will be administered through the high flow and standard flow infusion system, and the maximum sensory level achieved will be compared.~This intervention is included in the clinical practice routine"
45402683|NCT03839056|Device|PIEB+PCEA standar flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~In the group of pure boluses 10ml / h of perfusion will be administered through the high flow and standard flow infusion system, and the maximum sensory level achieved will be compared.~This intervention is included in the clinical practice routine"
45402684|NCT01204138|Drug|Apremilast|Apremilast 30mg BID
45402685|NCT01204138|Drug|Placebo|Placebo BID
45402686|NCT05668156|Other|Consensus Decision Making|Consensus-based decision-making process, where experts are asked to comment definitions of terms used for fasting interventions
45402687|NCT02962570|Device|On Demand Oxygen Delivery|Supplemental oxygen flow is controlled such that it is on only during inhalation.
45402688|NCT02962570|Device|Traditional, Always-On, Oxygen Delivery|Supplemental oxygen flow is constantly on, irrespective of whether the patient is inhaling or exhaling.
45402689|NCT02962570|Device|Oxygen Flow Stopped|Supplemental oxygen flow is stopped completely for a brief period to allow undisturbed end-tidal oxygen and CO2 measurements
45402690|NCT02927392|Drug|Leuprolide acetate|A subset of premenopausal women will receive GnRHAG (leuprolide acetate) 3.75 mg/mo by intramuscular injection every 4 weeks for 24 weeks (6 doses).
45510574|NCT03943823|Drug|Estrogen vaginal cream|Either Premarin or Estrace cream will be used (dependent on patient's insurance). Premarin 1 gram every night for the first 7 days, then 0.5 grams twice weekly. Estrace cream 2 grams daily for first 7 days, then 1 gram twice-weekly.
45510575|NCT03943823|Drug|Trimo-San vaginal gel|Half applicator for three times a week for 1st week, then half applicator for 2 times a week.
45510576|NCT03413189|Other|Review of medical records|Medical records of patients will be reviewed to establish the median and highest level of functional achieved in Intensive Care (intensity) and the percentage of exercise sessions performed (frequency)
45510577|NCT03413189|Other|Assessment of physical and cognitive function|This will be performed in person through the Function Independence Measure (FIM), grip strength, functional reach, 6-minute walk test (6MWT) and Montreal Cognitive Assessment (MoCA-Blind).
45402691|NCT03840538|Drug|Probiotic Product - Cap|probiotic capsule complex composed of L.acidophilus, L. bulgaricus, Streptococcus thermophilus, and Bifidobacterium bifidus
45698642|NCT01181674|Drug|insulin glargine|sc injection
45402692|NCT05668078|Diagnostic Test|Rapid Antigen Testing (RAT) for COVID-19|COVID-19 RAT intervention done among the school students to see if RAT test can play a role in reducing absenteeism. School type-1-only for symptomatic participants, School type-2-Serial testing at three days interval for all participants and School type-3 got no testing.
45402693|NCT01206088|Drug|nilotinib|administration of nilotinib as 2nd line
45402694|NCT01202968|Procedure|Transcutaneous neuro-muscular electrical stimulation|Neuro-muscular electrical stimulation with two pairs of surface electrodes was applied to submental area. One paired electrodes to be placed horizontally was attached on the anterior half of area between mandible and hyoid bone. The other was affixed to posterior half of the same area far laterally. Bipolar electrical stimulation with pulse rate of 80-Hz, duration of 700 µs and intensity to evoke visible muscle contraction was performed for 60 minutes a day until one day before extubation.
45402695|NCT05281900|Diagnostic Test|Clinical Tests|Shoulder impingement and instability tests and shoulder normal range of motion measurement.
45402696|NCT05281900|Other|MVIC measurements|For the normalization of muscle activation during exercises, muscle activation levels during maximum voluntary isometric contraction (MVIC) of the dominant side Upper Trapezius, Middle Trapezius, Lower Trapezius, Serratus Anterior, Biceps Brachii, Triceps Brachii and Infraspinatus muscles will be recorded. Participants will be asked to stop for 10 seconds at the point where they show resistance. A total of three measurements will be taken and the highest value recorded. The areas where the electrodes will be placed will be prepared by shaving and cleaning with alcohol. The electrode placement will be made parallel to the muscle fibers. A rest period of at least 2 minutes will be allowed between measurements.
45510578|NCT03413189|Other|Interview of patients, carers and/or family members|Questions will be asked to participants regarding their recovery from Intensive Care to establish themes
45510579|NCT03364673|Other|Fitness Tracker|Fitness trackers (e.g. Fitbit) are accelerometers that are worn on the wrist and tracks users' heart rate continuously in addition to steps, distance, calories, and active minutes
45510580|NCT03364673|Other|Social Incentive (Way to Health)|The Way to Health platform is an automated information technology platform that integrates wireless devices, clinical trial randomization and enrollment processes, messaging (text, e-mail or voice), self-administered surveys, automatic transfers of financial incentives, and secure data capture for research purposes.
45510581|NCT03097289|Device|Trima Accel system|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 5 day storage. The entire procedure is painless and should take 90 to 120 minutes.
45510582|NCT02535338|Drug|Erlotinib Hydrochloride|Given PO
45510583|NCT02535338|Other|Laboratory Biomarker Analysis|Correlative studies
45510584|NCT02535338|Drug|Onalespib Lactate|Given IV
45510585|NCT02535338|Other|Pharmacological Study|Correlative studies
45510586|NCT02484248|Drug|Ketotifen|Ketotifen is an anti-histamine approved by the U.S. FDA to prevent and treat itching of the eyes caused by allergies.
45510587|NCT02484248|Drug|Placebo|The placebo tablet looks identical to the ketotifen tablet, but does not contain ketotifen.
45850940|NCT00366990|Behavioral|Low Sodium Diet|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral & weight loss topics with a focus on lowering sodium intake.
45510588|NCT02419742|Drug|Carboplatin|TCH regimen: Carboplatin dose = Target Area Under Curve (AUC) (6 milligrams*milliliter/minute [mg*mL/min]) multiplied by (Glomerular Filtration Rate [GFR] + 25). Carboplatin will be administered as IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
45510589|NCT02419742|Drug|Cyclophosphamide|AC-TH regimen: Cyclophosphamide 600 mg/m^2 IV bolus every 3 weeks for 4 cycles (Cycles 1 to 4).
45510590|NCT02419742|Drug|Docetaxel|AC-TH regimen: Docetaxel 100 mg/m^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8). TCH regimen: Docetaxel 75 mg/m^2 IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
45510591|NCT02419742|Drug|Doxorubicin|Participants will receive Doxorubicin 60 mg/m^2 administered as I.V. bolus injection over 5 to 15 minute every 3 weeks for 4 cycles for AC-TH regimen.
45510592|NCT02419742|Drug|Paclitaxel|AC-TH regimen: Paclitaxel 175 mg/m^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8).
45698643|NCT01181674|Drug|metformin|oral administration
45698644|NCT01181674|Drug|acarbose|oral administration
45698645|NCT01181674|Behavioral|lifestyle therapy|diet and exercise
45698646|NCT01181674|Drug|insulin glargine|sc injection
45698647|NCT01181674|Drug|metformin|oral administration
45698648|NCT01181674|Drug|acarbose|oral administration
45698649|NCT01181674|Behavioral|lifestyle therapy|diet and exercise
45698650|NCT01181674|Other|Standard glycemic care|as informed by the current clinical practice guidelines
45402697|NCT05281900|Other|Exercises|"Activation of the scapula and shoulder girdle muscles will be measured during variations of the plank exercise.~In the tests, participants will be asked to stay in this position for 10 seconds after providing the standardized stance in the plank position. During the test, a video will be taken and incorrect attempts will be repeated.~Determined plank variations will be done in mixed order. Each exercise will be repeated 3 times and the average of the repetitions will be recorded as the result. A 2 minute rest period will be given between exercises.~After each exercise, the perceived effort level will be questioned with the BORG scale.~4 assisted exercises:~Low plank~Low plank w/ isometric shoulder external rotation~High plank~High plank plus~Bear plank~3 assisted exercises:~Low plank w/ front reach~High plank w/ shoulder taps~High plank w/ toe touch~2 assisted exercises:~Low plank bird dog~High side plank"
45402698|NCT02878174|Procedure|internal jugular vein catheterization|internal jugular vein catheterization using ultrasound (US) or US-based prelocation techniques
45510593|NCT02419742|Drug|Trastuzumab|AC-TH regimen: For weekly administration, 4 milligrams per kilograms (mg/kg) loading dose on Day 1 of Cycle 5, followed by 2 mg/kg on Day 8 of Cycle 5 and 2 mg/kg every week for 4 cycles (up to Cycle 8). For 3 weekly administration, 8 mg/kg loading dose on Day 1 of Cycle 5, followed by 6 mg/kg every 3 for 4 cycles (up to Cycle 8). From Day 1 of Cycle 9, 6 mg/kg will be administered every 3 weeks up to Cycle 22. TCH regimen: For weekly administration, 4 mg/kg loading dose followed by 2 mg/kg weekly from Cycles 1 to Cycle 6. For 3 weekly administration, 8 mg/kg loading dose followed 6 mg/kg every 3 weeks from Cycles 1 to 6. From Cycle 7, 6 mg/kg every 3 weeks up to Cycle 18. All administrations will be intravenous (IV) infusion.
45510594|NCT02409290|Drug|Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)|Drug: Locally-used WHO-approved MDR-TB regimen
45510595|NCT02409290|Drug|Moxifloxacin|Moxifloxacin is an 8-methoxy quinolone, and an anti-bacterial fluoroquinolone
45850941|NCT00366990|Behavioral|Regular Sodium Intake|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral & weight loss topics.
45850942|NCT00367068|Drug|baclofen, intrathecal|
45402699|NCT01204372|Drug|Gemcitabine - Trastuzumab - Erlotinib|"Treatment will be administered until disease progression, patient's refusal, unacceptable toxicity or investigator's decision.~Gemcitabine: IV 1000 mg/m2 on D1, D8, D15, D22, D29, D36 and D43 followed by one week of rest. Subsequently on D1, D8 and D15 followed by one week of rest.~Trastuzumab: IV once a week; 4 mg/kg over 90 min. at D1, and 2 mg/kg over 30 min. for the subsequent infusions.~Erlotinib: oral route 100 mg/day from C1D1."
45402700|NCT01567228|Other|CHICA GIS (enhanced electronic medical record)|An electronic medical record enhanced with geographic information systems will assist physicians in directing patients to community resources for increasing physical activity, preventing dental caries or addressing school problems
45510596|NCT02409290|Drug|Clofazimine|Clofazimine, is an antileprosy and anti-bacterial agent. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-sopropyliminophenazine.
45402701|NCT01204450|Drug|Temsirolimus|60-230mg/m2 weekly during each 28 day course, for up to 12 courses
45402702|NCT01204450|Drug|Valproic Acid|All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses
45402703|NCT03835780|Other|No intervention|A observation of outcomes in usual practice
45402704|NCT02605486|Drug|Palbociclib|
45402705|NCT02605486|Drug|Bicalutamide|
45402706|NCT03834454|Drug|Bupivacaine|5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
45510597|NCT02409290|Drug|Ethambutol|Ethambutol is a bacteriostatic that acts against virtually all strains of Mycobacterium tuberculosis and M. bovis and is also active against other mycobacteria such as M. Kansasii.
45850943|NCT00367068|Device|infusion pump for intrathecal baclofen, Synchromed, Medtronic|
45850944|NCT00367146|Drug|MMF|
45402707|NCT03834454|Drug|Bupivacaine|7.5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
45402708|NCT02428270|Drug|GSK2256098|Small molecule inhibitor of focal adhesion kinase (FAK)
45402709|NCT02428270|Drug|Trametinib|Allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK)1 and MEK2 activation and kinase activity.
45402710|NCT01204528|Drug|Zemplar|Vitamin D receptor activator (VDRA)
45402711|NCT02299492|Other|Person Centered Care Planning|PCCP is a manualized provider-based intervention that maximizes consumer choice for adults receiving mental health services. PCCP focuses on engagement and individualized care, thereby enhancing the impact of existing evidence based practices.
45402712|NCT02178046|Device|optical measurements|Laser Speckle Imaging, Optical Coherence Tomography and Multiphoton Microscopy
45402713|NCT01566916|Procedure|Total Hip Arthroplasty|
45698651|NCT01182376|Drug|dronedarone|Dronedarone will be prescribed by the patient's team according to established guidelines.
45698652|NCT01182376|Drug|Placebo|Placebo will be administered by the patient's team according to established guidelines.
45698653|NCT01183312|Drug|Flumazenil|Sublingual flumazenil
45698654|NCT05219136|Other|Modified Fasting Group|a new fasting protocol is applied to subjects.
45698655|NCT05219136|Other|Conventional Fasting Group|a conventional fasting protocol is applied to subjects.
45698656|NCT03188172|Drug|Cyclophosphamide|Chemotherapy
45698657|NCT03188172|Drug|Bortezomib|Chemotherapy
45698658|NCT03188172|Drug|Lenalidomide|Chemotherapy
45698659|NCT03188172|Drug|Daratumumab|Chemotherapy
45850945|NCT00367224|Procedure|6 to 9 ultraviolet B treatments|Treatments with ultraviolet B with gradually progressive doses
45850946|NCT00367224|Procedure|Skin biopsies|4 mm punch biopsies of the skin
45850947|NCT00367302|Drug|buprenorphine|maintenance
45850948|NCT00367302|Drug|methadone|maintenance
45850949|NCT00367536|Drug|bazedoxifene/conjugated estrogens combination tablet|
45850950|NCT00367614|Drug|pantoprazole|
45850951|NCT00367692|Drug|PSI-697|
45850952|NCT00367926|Drug|American ginseng root / polysaccharides|
45850953|NCT00368160|Drug|Eszopiclone|eszopiclone 3 mg
45850954|NCT00368160|Drug|Placebo|Placebo tablet
45698660|NCT03188172|Drug|Dexamethasone|Chemotherapy
45698661|NCT03188172|Drug|Melphalan|Chemotherapy
45698662|NCT03188172|Drug|Filgrastim|Haematopoietic agent for the stem cell harvest
45850955|NCT00368238|Drug|Recombinant human erythropoietin alfa (drug)|
45510598|NCT02409290|Drug|Pyrazinamide|Pyrazinamide is bactericidal against intracellular mycobacterium tuberculosis. It is a prodrug that is converted into its active form, pyrazinoic acid, by a mycobacterial enzyme, pyrazinamidase, as well as through hepatic metabolism.
45510599|NCT02409290|Drug|Isoniazid|Isoniazid is a bactericidal in vitro and in vivo against actively dividing tubercle bacilli. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique constituents of mycobacterial cell wall.
45510600|NCT02409290|Drug|Prothionamide|Prothionamide has a bacteriostatic action.
45510601|NCT02409290|Drug|Kanamycin|Kanamycin is a bactericidal antibiotic from the group of aminoglycosides.
45510602|NCT02409290|Drug|Levofloxacin|Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
45850956|NCT00368238|Drug|Aspirin (drug)|
45850957|NCT00368238|Drug|Clopidogrel (drug)|
45402714|NCT01566994|Behavioral|TTM Tailored|This treatment is tailored on three occasions (baseline, 6, and 24 weeks) on each of the 14 TTM variables. This treatment provides both normative and ipsative feedback on each of the variables found to predict progress across specific stages
45402715|NCT01566994|Behavioral|Motivational Enhancement Therapy|This intervention will be driven by the manual developed by Carpenter et al. (2004) based on the USPHS recommendations for smokers not motivated to quit and for those who become ready to set a quit date.
45510603|NCT02409290|Drug|Bedaquiline|Bedaquiline is a novel diarylquinoline antibiotic with bactericidal activity
45698663|NCT05340036|Procedure|Bimaxillary orthognathic surgery using conventional plates|"le fort I osteotomy will carried out in the classic way guided by the classic landmarks (maxillary roots apices) as described by Wassmund.~Complete separation of the maxillary segment using chisels and mallets in regular fashion.~Reposition maxilla using the interocclusal wafer while mandible is gently positioned to centric relation position.~Mandible is maintained in place until fixation of the maxilla with plates and screws takes place.~Complete separation of the mandibular segment using chisels and mallets in regular fashion.~Repositioning of mandible using the final interocclusal wafer while condylar segment is gently positioned to centric relation position.~Fixation of mandibular segments with plates and/or screws in regular fashion.~Incision was closed with 4-0 resorbable sutures in a continuous running fashion."
45850958|NCT00368394|Drug|Insulin glulisine|
45850959|NCT00368628|Procedure|continuous positive airway pressure|Continuous Positive Airway Pressure initiated within 48 hours of stroke onset and continued for 90 days.
45850960|NCT00368706|Drug|solifenacin succinate|Oral
45402716|NCT01566994|Behavioral|Integrated Treatment|This enhanced condition would combine MET, Reduction Counseling and NRT and TTM Tailoring.
45850961|NCT00368706|Drug|tolterodine|oral
45850962|NCT00368862|Drug|Ebixa (memantine hydrochloride)|
45850963|NCT00368862|Drug|Cipralex (escitalopram)|
45402717|NCT01203124|Drug|AZD8848|The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo.
45402718|NCT01203124|Drug|Placebo|Placebo
45402719|NCT03422848|Dietary Supplement|Water|Increased daily water intake with 1.5 L of water on top of habitual water intake.
45510604|NCT02351414|Device|Total Knee Arthroplasty (EVOLUTION®)|
45510605|NCT02323880|Other|Pharmacological Study|Correlative studies
45510606|NCT02323880|Drug|Selinexor|Given PO
45510607|NCT02145494|Radiation|Radiotherapy|Stereotactic body radiotherapy (SBRT) to the whole prostate (36.25 Gy in 5 fractions) with a focal boost (47.5 Gy in 5 fractions) to the MRI-defined dominant tumour nodule.
45510608|NCT02147756|Device|CO2RE|"Subjects will be randomly assigned to three different time-points of laser treatment: immediately, 1 week or 4 weeks prior the scheduled abdominoplasty. Subjects will be required to attend between 2 to 3 visits depending on the interval between the treatment and the abdominoplasty procedure. One side of the abdomen will be treated using the CO2RE device and the other side with the RePair device. The investigator will also leave an untreated area (control).~Punch biopsies will be obtained before or during the abdominoplasty procedure from the two treated areas (CO2RE and RePair) and one control (un-treated) areas (on the abdominoplasty area) for histological evaluation."
45510609|NCT02147756|Device|Repair|
45850964|NCT00369018|Drug|methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)|MAL 1.2M, HAL 10mM and HAL 40mM solutions for 3 and 12 hours application
45850965|NCT00369096|Drug|bemiparin 3500 IU/day|
45850966|NCT00369174|Drug|rosiglitazone maleate|Given orally
45402720|NCT03422848|Behavioral|general life style advice|oral and written advice on diet and physical activity
45402721|NCT05281822|Other|The stress management training|The women in the experimental group were provided with stress management training to help cope with stress conditions how to use positive coping in conditions in case of stress and tension.
45510610|NCT05435755|Biological|hAESCs treatment|Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.
45850967|NCT00369174|Other|laboratory biomarker analysis|Correlative studies
45510611|NCT05435755|Biological|placebo (saline)|2 times placebo (normal saline) injections as control group
45850968|NCT00369252|Drug|Nimotuzumab (TheraCIM h-R3)|
45850969|NCT00369330|Device|external electrical cardioversion|
45850970|NCT00369408|Drug|Naltrexone|naltrexone (50 mg orally) for 12-week treatment period; 3 and 6 months post-treatment follow-up
45850971|NCT00369408|Drug|placebo|placebo for 12-week treatment period; 3 and 6 months post-treatment follow-up
45850972|NCT00369642|Behavioral|Cognitive-behavioral therapy|
45850973|NCT00369720|Procedure|Titration of oxygen in delivery room|
45850974|NCT00369798|Procedure|PET scan|
45850975|NCT00369798|Drug|Rolipram|
45850976|NCT00369954|Drug|carboplatin|
45850977|NCT00369954|Drug|gemcitabine hydrochloride|
45850978|NCT00370110|Drug|Itopride 100 mg|100 mg three times daily
45850979|NCT00370110|Other|Placebo|
45850980|NCT00370110|Drug|Itopride 200 mg|200 mg three times daily
45850981|NCT00370188|Drug|Topiramate|
45850982|NCT00370266|Drug|Triamcinolone|
45850983|NCT00370344|Procedure|Laparoscopic cholecystectomy|Operation by experts in laparoscopy. The operation may be performed as laparoscopic or converted to an open operation.
45402722|NCT03829930|Drug|Entinostat|"Entinostat is formulated for oral administration. A food effect is evident for entinostat; exposure is significantly reduced when entinostat is administered with a high fat meal. Accordingly, entinostat is to be administered on an empty stomach, at least 1 hour before and 2 hours after a meal. Entinostat tablets should not be split, crushed, or chewed. Consult the individual clinical protocols for specific dosing instructions.~Dose level 1: 3mg PO weekly. Dose level 2: 5mg PO weekly."
45402723|NCT03829930|Drug|Enzalutamide|Dose level 1: 160 mg PO daily. Dose level 2: 160 mg PO daily.
45402724|NCT01203202|Drug|Clomipramine|15mg and 30mg on demand
45402725|NCT03829384|Biological|mRNA-1944|mRNA encoding Chikungunya antibody
45402726|NCT03829384|Other|Placebo|Saline
45402727|NCT01203280|Other|icing massage|The intervention, ice massage, was conducted by replacing a bag of crushed ice (100 cc) inside a moistened towel and lightly rubbed over lumbosacral region for 10 minutes. The moisture towel increased the intensity of the cooling sensation more than the dry wrappings
45510612|NCT02147912|Other|Aerobic Exercise|Aerobic exercise intervention consists of lower (treadmill and cyclette) and upper arts (arm ergometer Davenbike®) training, as well as calisthenic exercises with increasing intensity from a minimum of 80% to a maximum workload for lower arts in a minimum time.
45402728|NCT02047474|Drug|oxaliplatin|Given IV
45402729|NCT02047474|Drug|leucovorin calcium|Given IV
45402730|NCT02047474|Drug|irinotecan hydrochloride|Given IV
45402731|NCT02047474|Drug|fluorouracil|Given IV
45402732|NCT02047474|Procedure|therapeutic conventional surgery|Undergo surgical resection
45402733|NCT02047474|Other|laboratory biomarker analysis|Correlative studies
45402734|NCT01204606|Procedure|Arthroscopic rotator cuff repair with intraoperative periarticular injection|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~The surgical area was prepared and draped with Betadine.~Small stab incisions were made in the creation of 4 or 5 portals as needed.~A scope was explored via the arthroscopic portal into the GH joint & subacromial space.~Repaired of rotator cuff tear was done with suture anchors.~Mixed MMA drugs(ropivacaine 300mg;40ml, morphine 10mg;1ml, cefotetan 1g; dilution to ropivacaine, epinephrine 0.3mg;0.3ml, total volume:41.3ml) and sodium hyaluronate 20mg;2ml were injected divisionally periarticular area; intra-articular(sodium hyaluronate 20ml;2ml + 10.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~The skin was closed with Nylon or medical staples.~Sterile dressing was applied on surgical wound.~Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
45402735|NCT01204606|Procedure|Arthroscopic rotator cuff repair with non-injection of MMA drugs|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~The surgical area was prepared and draped with Betadine.~Small stab incisions were made in the creation of 4 or 5 portals as needed.~A scope was explored via the arthroscopic portal into the GH joint & subacromial space.~Repaired of rotator cuff tear was done with suture anchors.~43.3ml of saline was injected divisionally periarticular area; intra-articular(12.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~The skin was closed with Nylon or medical staples.~Sterile dressing was applied on surgical wound.~Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
45402736|NCT03833518|Other|Rehabilitation using motorized glove for stroke and spinal cord injury|Individuals with hand impairment due to stroke or spinal cord injury will wear a motorized glove (Gloreha Sinfonia), or exoskeleton, as part of a rehabilitation protocol to improve dexterity. For each exercise, participants will attempt to do the action, receiving assistance as necessary via powered motors that can move each finger through its passive range of motion based on the current and target position.
45402737|NCT03833518|Other|Functional MRI for stroke and spinal cord injury|All participants will undergo 3 functional MRI's (fMRI's), two at the beginning of the experiment to document brain activity related to movement intention and ability to sense movement. A third MRI will be performed after the rehabilitation is completed to document the change in brain activity related to movement intention and ability to sense movement.
45510613|NCT02898077|Drug|Ramucirumab|Administered IV
46057192|NCT02777463|Other|diffusion-weighted MRI|Diffusion MRI Patients undergo MRI within 3 weeks before start of neoadjuvant therapy/ 5 weeks after the last dose. The setting of MRI scans for b-values is 0, 50, 1000 s/mm2. The same MRI (the MRI system/scanner Intera Achieva 3.0T from Philips Medical Systems) in the independent institution is used for all patients analyzed on this study. The region of interest is determined by consensus between two experienced MR radiologists in a largest diameter based on images of abdominal CT scans avoiding the vascular area on the image of ADC map. The mean ADC values for each tumor are automatically calculated on the image of ADC map using a tomographic software program.
46057193|NCT04226625|Drug|Propofol|Intravenous administration
46057194|NCT04226625|Drug|Desflurane|Volatile administration
46057195|NCT05748184|Device|ULDCT PACS prototype|The ULDCT viewer prototype is a non-medical unreleased device that will be used by study participants on de-identified image cases in a research setting. The Prototype integrates new tools to speed up the diagnostic interpretation process of radiological images.
45698664|NCT05340036|Procedure|Bimaxillary orthognathic surgery using patient specific plates|"The cutting guide of the maxilla will be placed onto the exposed bony surface and manipulated to the best fit.~Then, the guide will be fixed using four 2.0-mm screws to avoid any mobilization during drilling of the reference holes. Sixteen reference holes will be established using the cutting guide; eight on each side.~Then, a reciprocating saw will be used to perform the planned Le Fort I osteotomy. After adequate maxillary mobilization and removal of bony interferences, the maxilla will be repositioned using the patient-specific osteosynthesis material guided by the previously established reference holes and fixed using 2.0-mm screws.~Then, the mandibular cutting guide will be fixed in the same manner and bilateral sagittal split osteotomy will be carried out.~After adequate mobilization, the mandible will be repositioned by the patient-specific osteosynthesis material using the reference holes made by cutting guide and fixed using 2.0-mm screws."
46057196|NCT05748184|Device|PACS viewer prototype|A PACS system mimicking the clinical PACS system used in LUMC.
45510614|NCT02898077|Drug|Paclitaxel|Administered IV
45510615|NCT02898077|Drug|Placebo|Administered IV
45510616|NCT03544346|Other|Exploratory brain and general health assessment|Exploratory brain and general health assessment
45510617|NCT03544892|Other|Low carbohydrate diet|60-80 g total carbohydrate per day
45510618|NCT03544892|Other|Standard of care diet|> 150 g total carbohydrate per day
45510619|NCT03692975|Other|Clinical assessment|Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
45402738|NCT03833518|Other|Transcranial magnetic stimulation (TMS) for stroke and spinal cord injury|Stimulation of the nervous system may be performed using a magnetic stimulator. TMS of the central nervous system is optional. Whether or not a participant undergoes TMS will depend upon their consent, their eligibility for TMS (i.e. no seizure history), and their neurological response to TMS.
45402739|NCT01774552|Device|Photo Acoustic Microscopy and Optical Coherence tomography|Photo Acoustic Microscopy and Optical Coherence tomography
45402740|NCT01298284|Drug|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
45402741|NCT01204840|Drug|Growth Hormone|Subjects in this trial will use a 3.33mg vial (1 vial =10 IU) by daily subcutaneous injection. This will start on day 1 of the menstrual cycle preceding the stimulation phase of an IVF cycle, and will continue until the day of the human chorionic gonadotropin (hCG) trigger (approximately 5-6 weeks)
45510620|NCT03692975|Other|Neuropsychological evaluation|cognitive tests exploring episodic memories, information processing speed, attention/concentration and working memory.
45510621|NCT03692975|Other|Psychological evaluation|included questionnaires for depression, anxiety, fatigue, cognitive complaint and reserve
45510622|NCT03692975|Device|MRI Evaluation|Diffusion including NODDI, 3DT1 with and without gadolinium, 3D-FLAIR before and after gadolinium infusion, 3D White Matter nulled-MPRAGE, 3D Double-Inversion recovery sequences-weighted imaging and Resting state functional MRI
45510623|NCT02145650|Other|No Intervention|There is no intervention administered in this study.
45510624|NCT02145728|Behavioral|Individual Cognitive Functional Therapy|Cognitive functional therapy (CFT) is a novel, patient centred behavioural intervention which addresses multiple dimensions in non-specific chronic low back pain (NSCLBP). It combines a functional behavioural approach of normalising provocative postures and movements while discouraging pain behaviours, with cognitive restructuring of the NSCLBP problem.
45510625|NCT02145728|Behavioral|Group Exercise Classes|Each class involves a combination of education, exercise and relaxation/mindfulness. The education topics include pain and the nervous system, posture and ergonomics, exercise and relaxation and sleep. The exercise component includes 10 stations of a combination of aerobic, strength and flexibility exercises. These will be walking/jogging on the spot, mini-squats, sit to stands, wall push ups, bridging, step-ups and a combination of leg and low back stretches. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
45510626|NCT03544034|Behavioral|HomeTeam Toolkit|"A multi-component intervention (8S's)~Safety at home through partnership.~Safety risk assessment at the admission~Safety agenda setting for coordinating efforts among professionals to prepare patient/ family for self-management~Safety tools. Cognitive tools to support patient/family after discharge~Safety education. Enhanced Patient/ family medication safety education~Safety briefings with patient/family A mechanism to proactively address common and patient/family specific risks.~Safety through learning routines across the care continuum~Safety assessment after discharge"
45698665|NCT01184014|Drug|NPH insulin plus Complete Insulin Orders|NPH dosed per study-specific algorithm which incorporates total daily dosage of steroid to determine NPH dose. Complete insulin orders include background, meal-time and correction factor.
45698666|NCT01184014|Drug|Complete Insulin Orders|3-part insulin which includes background, meal-time and correction factor
45698667|NCT03130140|Procedure|Macroscopic on-site evaluation|Macroscopic on-site evaluation: any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). Length of MVC will be measured to determine the adequacy of that puncture.
45698668|NCT03130140|Other|Control|Conventional EUS-FNA
45698669|NCT05672550|Drug|Bayesian based dose adjustment of enoxaparin|"A first recommended dose of enoxaparin 50 IU/kg subcutaneously is administered during transplantation or within the first 24 hours.~Then a Bayesian estimate of individual pharmacokinetics is performed to adapt the next twice daily (Hour 12;Hour 24) enoxaparin dose until achievement of the target on two consecutive measurements. Then anti-Xa activity will be evaluated once a day until day 7."
45850984|NCT00370344|Procedure|Small-incision open cholecystectomy|Operation by experts in small-incision open cholecystectomy.
45402742|NCT01204840|Drug|Patch protocol|"Group A (n=10; control group) will receive patch protocol: 100ug estrogen patch (Estradot), Gonadotropin releasing hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), gonadotropin stimulation 412 IU recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris). With 3 or more follicles at mean diameter equal to or greater than 17mm, urinary human chorionic gonadotropin (u-hCG) 10,000 IU self-injected to complete final maturation of oocytes. Egg retrieval will occur 36 hours after hCG injection. Eggs fertilized by standard IVF or intra-cytoplasmic sperm injection (ICSI) depending on semen parameters. Embryos cultured to day 2 and the best 2-4 will be transferred back under ultrasound guidance. Surplus embryos will be frozen as per clinic protocol. Luteal support: Endometrin 100mg vaginally three times daily, starting on the day of egg retrieval and continuing until menses or positive serum beta-hCG, then stopped."
45402743|NCT01203358|Drug|Exosurf|Infants received up to four intratracheal doses of the surfactant.
45402744|NCT01203358|Drug|Survanta|Infants received up to four intratracheal doses of the surfactant.
45510627|NCT03543956|Behavioral|Questionnaire|Questionnaire
45510628|NCT02145884|Drug|timolol maleate 0.5% gel|Apply timolol gel 1-2 drops twice a day to lesion
45698670|NCT05672550|Drug|Usual dose adjustment of enoxaparin|A first recommended dose of enoxaparin 50 IU/kg is administered during transplantation or within the first 24 hours. Then anti-Xa activity is measured and twice-daily (hour 12 ; hour 24) enoxaparin empirical dose-adjustment is performed according to the usual practices in the investigating centers to target.
45698671|NCT01185028|Drug|Nitazoxanide With Pegylated Interferon And Ribavirin|Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
45698672|NCT03011866|Drug|Wound topically irrigated with 500mg TXA|
45698673|NCT03011866|Drug|1mg/kg/hr TXA intravenous infusion till the last suture|
45850985|NCT00370422|Drug|Triamcinolone, Bevacizumab|
45402745|NCT01203436|Procedure|Supplemental Oxygen Management|Supplemental arm with pulse oximetry targeted at 96% to 99% saturation, for at least 2 weeks, and until both eyes were at study endpoints.
45402746|NCT01203436|Procedure|Conventional Oxygen Management|Conventional oxygen arm with pulse oximetry targeted at 89% to 94% saturation.
45402747|NCT05669560|Combination Product|PerioProtect ™= plastic tray +1.7% hydrogen peroxide|Subjects will receive PerioProtect ™ in adjunct to mechanical therapy. 15minutes, twice a day, for 3 months.
45402748|NCT01485484|Device|Optic imaging use near-infrared trans-illumination methods|Optic imaging use near-infrared trans-illumination methods
45402749|NCT03832426|Drug|Narlaprevir|100 mg film-coated tablets
45402750|NCT03832426|Drug|Ritonavir|100 mg film-coated tablets
45402751|NCT03840070|Device|Potenfill|Maximum: 22ml
45402752|NCT03312010|Device|Spinal Cord Stimulator HF|A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
45402753|NCT03312010|Device|Spinal Cord Stimulator Sham|A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
45402754|NCT03272698|Drug|Ketamine|IV Ketamine 0.50 mg/kg
45402755|NCT03272698|Procedure|ECT|ECT with unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method
45402756|NCT01203514|Drug|Erythropoietin|Infants received 400 U/kg Erythropoietin (Epo) 3 times weekly and a weekly intravenous infusion of 5 mg/kg iron dextran until they had an enteral intake of 60 mL/kg/d.
45402757|NCT01203514|Other|Sham Comparator|Infants in the placebo/control group received sham subcutaneous injections when intravenous access was not available.
45402758|NCT03723070|Device|The Cryterion Cardiac Cryoablation System|Cryoablation System that includes a Balloon Catheter, Circular Mapping Catheter, Steerable Sheath and Cryoablation Console. In combination, components of the System will be inserted into the left atrium and a thermal injury at the PV ostium will be created to electrically isolate the veins
45402759|NCT01473784|Procedure|transoral robotic surgery|Undergo TORS using the Da Vinci Robotic Surgical System
45402760|NCT01473784|Procedure|quality of life assessment|After surgery regular clinical assessments will be scheduled to see how the patient is doing. Patients will be asked to answer a quality of life assessment as part of the study. If patients are unable to come to the Ohio State University Medical Center for a physician appointment they will be contacted via phone or mailed a questionnaire to complete.
45402761|NCT00842764|Procedure|Holmium: YAG laser|Minimally Invasive Holmium:YAG laser Blepharoplasty
45402762|NCT05668000|Other|Mobile application with device|"AIDA/KT-app with devices:~The mobile application provide self-management interventions with devices including sphygomanometer and body water meter."
45402763|NCT05668000|Other|Mobile application|The mobile application provide self-management interventions.
45402764|NCT01204996|Drug|CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection|10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
45402765|NCT01204996|Drug|CNTO888 + gemcitabine|15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
45402766|NCT01204996|Drug|CNTO888 + Paclitaxel and carboplatin|15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
45402767|NCT01204996|Drug|CNTO888 + docetaxel|15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
45402768|NCT03831022|Other|Capillary refill time and skin mottling score measurement at the admission to the emergency department|Patients who meet the inclusion criteria and none of the non-inclusion criteria will benefit from capillary refill time and skin mottling score measurement at the admission to the emergency department (ED) and followed during their hospital stay to precise the destination after ED (home, ICU, ward) and 30- and 90-days mortality after hospital admission.
45510629|NCT02145962|Device|Forearm tissue exposure with ELF-MF|The treatment was delivered 2 hours/day, 2 times/week and consisted of sinusoidal oscillating magnetic fields of 120 Hz using a solenoid, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the forearm device is approximately 30 ml/min or 3.6 lt/session.
45510630|NCT02145962|Device|Thorax tissue exposure with ELF-MF|The treatment was delivered 25 minutes/day, 2 times/week and consisted of 120 Hz using a quasi-Helmholtz coil configuration, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the thorax device should be approximately 6,500 ml/min or 162.5 lt/session, which is approximately 45 times more blood volume stimulation per unit of time compared with the Forearm exposure system.
45402769|NCT01297192|Drug|solifenacin succinate|Oral
45510631|NCT02148068|Procedure|Bariatric Surgery|Patients enrolled will undergo either a laparoscopic Roux-en-y Gastric Bypass or laparoscopic Sleeve Gastrectomy. The determination of which operation performed will be made independent of patients' enrollment in the study.
45402770|NCT01297192|Drug|mirabegron|Oral
45402771|NCT01205074|Device|13C Methacetin Breath Test|
45402772|NCT01205074|Dietary Supplement|Grape fruit juice|
45402773|NCT01205074|Drug|Non selective beta blocker - Propranolol|
45510632|NCT02148146|Drug|Omegaven|Fish oil emulsion given 1g/kg/day as infusion
45402774|NCT01205074|Dietary Supplement|Ethanol|
45402775|NCT05667376|Other|Local drug delivery|Local application of curcumin gel into the periodontal pocket
45402776|NCT05667376|Drug|curcumin gel|curcumin gel
45402777|NCT03722524|Drug|amlodipine / indapamide / perindopril arginine FDC|CCB / diuretic / ACE inhibitor
45510633|NCT03544814|Drug|icotinib combined with pemetrexed plus cisplatin|Continued using the icotinib (125 mg/time, 3 times/day every day) combined with Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with icotinib every four weeks.
45850986|NCT00370500|Drug|Quetiapine fumarate|Dosage and frequency are judged by the study physician. The dosage must not excess 800mg/d.
45402778|NCT03722446|Device|Arrow Catheter Kit.|The group will be randomized to receive this labor analgesia kit.
45402779|NCT03722446|Device|B.Braun Catheter Kit|The group will be randomized to receive this labor analgesia kit.
45402780|NCT05667220|Drug|Sitagliptin|Sitagliptin monotherapy group (Group A): 20 eligible patients were planned to be included and given Sitagliptin 100 mg Qd orally; the treatment period was 1 week.
45402781|NCT05667220|Drug|Sitagliptin combined with Beidougen capsule|Sitagliptin combined with Beidougen capsule treatment group (Group B): 20 eligible patients were planned to be included and given sitagliptin 100mg Qd orally combined with Beidougen capsule 60mg Tid orally. The treatment period was 1 week.
45402782|NCT01205308|Dietary Supplement|Vegetable oil based margarine with plant stanol ester enrichment|3 g plant stanols/ day
45402783|NCT01298830|Drug|GLP-1 CellBeads|GLP-1 CellBeads are alginate microcapsules containing allogenic mesenchymal cells, transfected to secrete Glucagon like peptide-1. By implantation into brain tissue cavity after surgical evacuation of the hematoma, a volume of 500μl GLP-1 CellBeads which equals approximately 2330 GLP-1 CellBeads resulting in a total number of approximately 7.8 million cells is administered to the patient. The cells are removed by second surgery after a 14 days treatment period.
45850987|NCT00370578|Device|repeated thrombus aspiration during primary PCI|
45850988|NCT00370656|Drug|Pregabalin|capsule, 150mg bd, 300mg bd
45510634|NCT03544814|Drug|first icotinib and then pemetrexed plus cisplatin|Continued using the icotinib (125 mg/time, 3 times/day every day)) alone until the investigator judged that continuation was adiaphorous, and switched to Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) alone, repeat every four weeks for up to six cycles and then continue to receive pemetrexed every four weeks.
45510635|NCT03097133|Drug|Esketamine|Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
45698674|NCT05263596|Diagnostic Test|dual x-ray absorptiometry, body impedance analysis, muscle strength measurements, ultrasound|"Results from the routine geriatric assessment:~Mini Mental State Exam (MMSE)~Clock-drawing test (CDT)~Geriatric depression scale (GDS)~Functional independence measure (FIM) at admission~Timed up and go Test (TUG)~Gait speed~Hand grip strength (HGS)~Nutritional risk screening (NRS)~Additional measurements:~Chair-stand-test~Clinical frailty scale (CFS)~Calf circumference and mid-arm circumference~Body impedance analysis (BIA)~US~DXA"
45698675|NCT05199168|Procedure|intraoperative nerve monitoring|Intraoperative bilateral recurrent laryngeal nerve monitoring was utilized during dissection of right and left recurrent laryngeal nerve lymph nodes.
45698676|NCT01143142|Behavioral|Computer-based tailoring system|Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will produce messages for a two-page educational brochure based on participants' responses to survey questions. Only the intervention group will receive this brochure.
45698677|NCT02186938|Device|FloTrac|
45698678|NCT05190822|Other|College student|Our research will be conducted by face-to-face interviews within the scope of questionnaires prepared by us for students studying in departments other than Physiotherapy and Rehabilitation at Acibadem Mehmet Ali Aydinlar University.
45698679|NCT02187016|Device|AirFloss + BreathRx|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
45402784|NCT01203592|Drug|Albuterol|4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
45402785|NCT05281276|Drug|chidamide|During the run-in period, the patients will take a single dose of chidamide on Day 3. In a 28-day treatment cycle, the dosing schedule is four/six table (20/30mg) BIW .
45510636|NCT03097133|Drug|Placebo|Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
45850989|NCT00370656|Drug|Duloxetine|Capsule, 60mg on, 60mg bd
45850990|NCT00370656|Drug|Amitriptyline|Capsule. 25 mg bd, 25 mg om and 50 mg on
45850991|NCT00370734|Drug|Botulinum toxin A injection|
45850992|NCT00370812|Procedure|amniotic membrane transplantation|AMT with conventional medical therapy (group A) or medical treatment only (group B). AMT will be performed within 24h of presentation. Amniotic membrane will remain in place for 7-14 days.
45850993|NCT00370968|Drug|Zinc sulphate|
45850994|NCT00371046|Procedure|Transvaginal ultrasound cervical length|
45850995|NCT00371046|Procedure|Cervicovaginal fetal fibronectin|
45402786|NCT05281276|Drug|celecoxib|During the run-in period, the patients will take a single dose of celecoxib on Day 1. In a treatment cycle, the dosing schedule is one capsule(200 mg) daily.
45402787|NCT05669326|Other|NODDI TRACT|"Compared to their usual management, the participation of the patient in this study implies an additional visit during which an MRI examination without contrast injection will be performed, lasting approximately 40 minutes (including installation and deinstallation).~The operative time, surgical procedures and postoperative follow-up are not modified in this study."
45402788|NCT01297582|Drug|ONO-6950|1mg, 3mg, 10mg, 30mg,100mg,300mg,1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
45850996|NCT00371124|Drug|Atropine Eye drops|
45850997|NCT00371202|Procedure|keratoplasty|
45402789|NCT01297582|Drug|ONO-6950|1mg, 3mg, 10mg, 30mg, 100mg, 300mg, 1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
45402790|NCT01203670|Dietary Supplement|Phytalgic|Volunteers have to take three soft capsules per day, one in the morning and two in the evening.
45402791|NCT03829150|Drug|Dexlan|Dexlansoprazole MR 60 mg qd for 7 days
45402792|NCT03829150|Drug|Amoxicillin|Amoxicillin (Amolin) 1 g bid. for 7 days
45850998|NCT00371280|Procedure|orbital implant|Implantation of pegged versus unpegged hydroxyapatite orbital implants
45850999|NCT00371592|Drug|Acyclovir|800 mg tablet taken orally twice daily
45851000|NCT00371592|Drug|Acyclovir placebo|800 mg placebo tablet taken orally twice daily
45851001|NCT00371670|Drug|balicatib (AAE581)|
45851002|NCT00371748|Device|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent, 2.25 mm
45851003|NCT00371748|Device|TAXUS™ Express2|Paclitaxel-Eluting Coronary Stent System
45851004|NCT00371748|Device|Express2|Coronary Stent System
45851005|NCT00371904|Drug|Rituximab|Single dose (375 mg/m2) of rituximab to be given intravenously (IV) 14 days prior to transplantation
45402793|NCT03829150|Drug|Clarithromycin 500mg|clarithromycin (Klaricid) 500 mg bid for 7 days
45402794|NCT03829150|Drug|Metronidazole|Metronidazole (Flagyl) 500 mg bid daily for 7 days
45402795|NCT03820804|Other|Diet|A specific dietary treatment for patients with Phenylketonuria.
45402796|NCT03820804|Drug|Sapropterin|A pharmacological treatment for patients with Phenylketonuria, used alone or in combination with dietary treatment.
45402797|NCT01205386|Device|1. CROSSER System|The Crosser system will be used to recanalize the chronic total occlusion in the SFA (superficial femoral artery). The IVUS (Intravascular Ultrasound Imaging) System will be used in the treated occlusion after the Crosser to generate real-time images of the artery.
45402798|NCT01205464|Drug|Doxycycline|Doxycycline, 100 mg, 2 capsules once daily, 24 hour time interval, 21 days.
45510637|NCT03097133|Other|Standard of Care|The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
45402799|NCT01205464|Drug|Placebo|Placebo, 100 mg, 2 capsules once daily, 24 hour dosage interval, 21 days.
45402800|NCT01205542|Behavioral|Training|Training of scapular function with strengthening exercises using bodyweight and elastic resistance
45510638|NCT02148380|Drug|pemetrexed plus carboplatin|
45402801|NCT01205542|Behavioral|Reference|Health check and advice to continue ordinary physical activity
45402802|NCT01205620|Device|ITPR|• Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).
45510639|NCT02148380|Drug|gefitinib|
45510640|NCT02146118|Drug|Erlotinib|Erlotinib 150 mg/day q 4 weeks
45510641|NCT02146118|Dietary Supplement|Silybin-phytosome|Silybin-phytosome 1g bid/day q 4 weeks
45402803|NCT01205620|Other|No intervention|No intervention will be performed in the control group
45402804|NCT03828838|Drug|Lu-177 PSMA-617|Two cycles of Lu-177 PSMA (3GBq and 3-6 GBq)
45402805|NCT01205698|Other|Nutritional drink|
45402806|NCT03828526|Other|High Fidelity Simulation|Teaching strategy based on high fidelity simulation, which simulates the reality of health care to promote meaningful learning.
45402807|NCT03828526|Other|Traditional teaching strategy|Classroom-based strategy
45402808|NCT01297660|Other|Video-urodynamic examination|
45402809|NCT01297738|Other|Meal size increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® with their meals, which results in an increase in meal size.
45510642|NCT02146196|Device|4 weeks robotic assisted training with the Lokomat®|During a prespecified time period (4weeks) a three times weekly robotic assisted gait training during 30-45 minutes. Strength training, interval training and endurance training are possible.
45510643|NCT02146196|Device|One week robotic assisted gait training with the Lokomat®|During a prespecified time period (1week) a three times weekly robotic assisted gait training during 10-40 minutes. Strength training, interval training and endurance training are possible
45402810|NCT01297738|Other|Meal size increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages with their meals, which results in an increase in meal size.
45402811|NCT01297738|Other|Meal frequency increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® 3 times a day in between meals, which results in an increase in meal frequency.
45402812|NCT01297738|Other|Meal frequency increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
45402813|NCT03819010|Drug|Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib|Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 18-25
45510644|NCT05418569|Device|Intervention arm - A new smartphone application for pediatric type 1 DM|An evidence-based locally tailored Chinese smartphone application for pediatric type 1 DM
45510645|NCT05418569|Other|Standard diabetic eduction|Received standard diabetic care (diabetic nurse education and regular follow-ups) with optional use of an existing smartphone application for general diabetic
45510646|NCT02142140|Behavioral|Academic and Organization skills|This program aims at teaching children organization, time management and stress management skills. They are also taught academic strategies in reading, writing, and math. The program consists of six, 90 minute sessions.
45510647|NCT02142140|Behavioral|Parent Training|The Parent Training Program: The parent training program is designed to increase parental understanding of ADHD; establish attentive, positive interactions, and solve problems collaboratively. Eight weekly group sessions lasting about 2 hours each will be conducted by trained psychologists, social workers, or clinical nurses. Homework assignments and detailed summary sheets will be used to promote technique acquisition and generalization.
45698680|NCT02187016|Device|AirFloss + Listerine|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
45402814|NCT03819010|Drug|Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib|Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 26-100
45402815|NCT05099536|Drug|3D011-08|participants will receive 15mg (starting dose)intravenous drop of 3D011-08,All subjects in each cohort will receive a single dose of 3D011-08 first, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive doses on 1,3,5day of each week (28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first.Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RPTD).
45402816|NCT03818932|Drug|Celecoxib|Post-Operative Non Opioid Pain Protocol
45402817|NCT03818932|Drug|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
45402818|NCT03818932|Drug|Ketorolac|Post-Operative Non Opioid Pain Protocol
45402819|NCT03818932|Drug|Gabapentin|Post-Operative Non Opioid Pain Protocol
45402820|NCT03818932|Drug|Acetaminophen|Post-Operative Non Opioid Pain Protocol
45402821|NCT03818932|Drug|Diazepam|Post-Operative Non Opioid Pain Protocol
45402822|NCT03830554|Other|Organic Atlas cedar wood essential oil (Cedrus Atantica)|At first day of admission, Intervention group received an intervention kit consist of 5 small glass essential oil bottles. Each essential oil bottle contains a small cotton ball saturated with two drops of Organic Atlas cedar wood essential oil (Cedrus Atantica). Participants were asked to open the bottle, inhale the smell directly and put it opened at 20 cm beside bed during night.
45402823|NCT01205854|Device|Ultrasonography|Standardized ultrasonographic assessment of 32 joints, assessed for both grey scale synovitis and power doppler signal, at each visit. Dose escalations based on DAS response in combination with change in US score. All joints with US Power Doppler signal are targets for intra articular injections.
45402824|NCT01205932|Drug|Rivaroxaban (BAY59-7939)|Daily dose: 5mg/day (5mg, once daily) for 34 to 35 days (±4 days)
45402825|NCT01205932|Drug|Rivaroxaban (BAY59-7939)|Daily dose: 7.5mg/day (7.5mg, once daily) for 34 to 35 days (±4 days)
45402826|NCT01205932|Drug|Rivaroxaban (BAY59-7939)|Daily dose: 10mg/day (10mg, once daily) for 34 to 35 days (±4 days)
45698681|NCT02187016|Device|Dental Floss|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning used once daily.
45402827|NCT01205932|Drug|Enoxaparin|daily dose: 40mg/day (20mg each, twice daily) for 6 to 7 days (±2 days)
45402828|NCT01300780|Drug|Etoricoxib|Group 2 - experimental Etoricoxib will receive two doses of selective anti-inflammatory to enzyme cyclooxygenase 2 (COX-2) (Etoricoxib 60 mg) given once every 24 hours;
45402829|NCT01300780|Other|Placebo|Group 1 - Control Group will receive two doses of placebo tablet administered a every 8 hours,
45402830|NCT01297816|Drug|placebo|100mg,BD, fo three month
45402831|NCT01297816|Drug|Minocycline|100mg
45698682|NCT02187016|Device|Manual Toothbrush|Manual Toothbrush used twice daily, 1 minute.
45402832|NCT01206634|Procedure|Regenerative injection therapy|Injections of 1cc of a 15% dextrose and 0.6% lidocaine solution free of adrenaline in each of eight administration sites in the collateral ligaments and a 5 cc injection of a 20% dextrose and 0.5% lidocaine without adrenaline solution inside the knee joint.
45402833|NCT01206634|Behavioral|Exercise|the exercise program consists of 4 strengthening exercises for which participants are asked to perform 3 sets of 10 repetitions daily
45402834|NCT01297894|Drug|colistin|Colistimethate sodium 2.5-5mg/kg of colistin base
45402835|NCT01297894|Drug|colistin plus fosfomycin|colitimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
45402836|NCT03830008|Behavioral|Problem Management Plus|PM+ is a new, brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
45402837|NCT01298908|Procedure|Operative treatment|In operative treatment the great saphenous vein will be removed after flush ligation by femoral vein and stripping of the trunk.
45402838|NCT01298908|Procedure|Laser ablation|In intravenous laser treatment a thin laser fiber is inserted through a tiny distal entry point. The probe is guided into place using ultrasound and the procedure is performed under local tumescence anesthesia. Laser energy is delivered to seal the faulty vein.
45402839|NCT01298908|Procedure|Foam sclerotherapy|Ultrasound guided foam sclerotherapy involves an injection of foam (sodium tetradecyl sulfate mixed with air according to the Thessari method) directly into the venous trunk under ultrasound control.
45402840|NCT05666362|Drug|benoxinate hydrochloride 0.4% group|They will receive benoxinate hydrochloride 0.4% immediately before fundus
45402841|NCT05666362|Drug|saline 0.9% .|They will receive saline 0.9% before fundus examination in each eye .
45510648|NCT02142140|Behavioral|Social Skills Training|Social Skills and Anger Management Training: The social skills training program is based on understanding yourself and others, and being able to understand things from the other's perspective. The program uses direct instruction, modelling, behavioural rehearsal, feedback, and social reinforcement. The following are covered: joining in, understanding emotions, dealing with anger, using self-control, responding to teasing / bullying, and staying out of fights.
45698683|NCT05439798|Drug|Ondansetron+Dexamethasone|"The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg) The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).~The patients In Group D (Group Dexamethasone) will be given iv only dexamethasone (0.5 mg.kg-1)"
45698684|NCT05439798|Drug|Palonosetron+Dexamethasone|"The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg) The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).~The patients In Group D (Group Dexamethasone) will be given iv only dexamethasone (0.5 mg.kg-1)"
45698685|NCT05439798|Drug|Dexamethasone|Dexamethasone
45698686|NCT02188576|Drug|high dose TXA|
45698687|NCT02188576|Drug|Low dose TXA|
45402842|NCT01206010|Drug|Varenicline|Participants will increase varenicline dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard dose of 1.0 mg twice daily.
45402843|NCT01206010|Drug|Placebo|Participants will increase placebo dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard varenicline dose of 1.0 mg twice daily.
45402844|NCT01206010|Drug|Varenicline|All participants will receive the standard dose of Varenicline (14 weeks): 0.5 mg once daily for days 1-3, 0.5 mg twice daily for days 4-7, and then a continuation dose of 1.0 mg twice daily. In addition to this participants will use an tailored varenicline/placebo dose up to maximum of 2.5 mg twice daily for 3 weeks.
45851006|NCT00371904|Drug|Standard Care|Standard care
45510649|NCT02142140|Drug|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed at regular once per three month visits for medication monitoring. In this group the child can be referred for a medication reevaluation and adjustment as many times as is needed.
45402845|NCT01297972|Biological|Intravenous bone marrow mesenchymal stem cells infusion|After standard immunosuppressive therapy with rabbit antithymocyte globulin 3,5 mg/Kg/day during 5 days, allogeneic unrelated bone marrow derived mesenchymal stem cells will be infused intravenously. Oral cyclosporine 5 mg/Kg/day (with dose correction weekly to keep serum cyclosporine level between 150-250 mg/dl) up to 6 months will be added.
45402846|NCT01298050|Procedure|ECMO|Insertion of peripheral Veno-Arterious ECMO, subsequent therapeutic hypothermia
45402847|NCT05621824|Device|Endoscopic ultrasound|Use endoscopic ultrasound to examine the pancreatic lesions.
45402848|NCT05621824|Procedure|EUS-Fine needle aspiration|If solid mass of pancreas was found during EUS, EUS-FNA shall be conducted for diagnosis.
45402849|NCT05665582|Other|Family program|A 4-day psychoeducational family program.
45510650|NCT02142140|Drug|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed by their pediatrician, with a frequency at his/her discretion.
45510651|NCT02148458|Other|Mediterranean diet|Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week)
45510652|NCT02148458|Other|Control group|control group eating their usual Western diet for 8 weeks, followed by 8 weeks of usual diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week).
45510653|NCT02148536|Procedure|Transjugular intrahepatic portosystemic shunt|
45698688|NCT05439720|Dietary Supplement|Ketone ester|A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime. The total dose is 75g of ketone ester.
45698689|NCT05439720|Dietary Supplement|Placebo|Collagen peptan (3g) mixed with 1 mM bitter sucrose octaacetate and 20ml of pure water. A dose of 25g of placebo drink is provided after each training session and 30 minutes before sleeptime. The total dose is 75g of placebo drink.
45698690|NCT05439720|Behavioral|Exercise|A 120 minutes cycling endurance training session (ET) two hours after breakfast and an evening high-intensity-interval training (HIIT) ending one hour before bedtime
45510654|NCT02142218|Drug|Nivolumab|
45510655|NCT03543800|Device|Cytorich PRP kit|Subjects randomized to the PRP treatment arm will receive PRP only without the anti-inflammatory component of ABP added
45851007|NCT00371982|Drug|Fish oil (Maxepa)|
45851008|NCT00372138|Procedure|PRP + autologous thrombin|simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
45851009|NCT00372216|Drug|Clopidogrel (Iscover/Plavix)|Pre-hospital loading-dose of 600 mg Clopidogrel as early as possible
45851010|NCT00372294|Drug|pyrimethamine-sulfadiazine + prednisolone|Administration of pyrimethamine-sulfadiazine + prednisolone
45851011|NCT00372294|Drug|Clindamycin+Dexamethasone|Intravitreal injection of Clindamycin+Dexamethasone
45851012|NCT00372372|Drug|risedronate|
45851013|NCT00372450|Procedure|management of therapy complications|
45402850|NCT01298986|Procedure|Pulmonary vein isolation ablation procedure for atrial fibrillation|The catheters will be introduced to the right atrium using the femoral vein as an access. Following a trans-septal puncture, ablation catheters will be placed in the left atrium under appropriate imaging and anticoagulation conditions (Standard of care). Following the positioning of the ablation catheters in the left heart cavity ablation to achieve PVI and left atrial isthmus line are going to be performed. Following the appropriate protocol of mapping and AF induction the right sided isthmus is going to be ablated to achieve a flutter line ablation as well. Following the procedure and following the appropriate standard of care protocols, the catheter are going to be retrieved and the procedure will be concluded. The left atrial appendage will be managed surgically. All ablation lines will be placed according to their current standard of practice using radiofrequency ablation technology and based on CARTO mapping.
45402851|NCT01298986|Procedure|Hybrid procedure for ablation of atrial fibrillation|The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
45402852|NCT01298986|Procedure|The Cox Maze Procedure for Ablation of Atrial Fibrillation|A 7-cm incision is placed and the chest is entered through the 4th or 5th intercostal space. The femoral artery and femoral vein are cannulated. The pericardium is opened. Cardiopulmonary bypass is instituted. The right sided lesions are applied using 3 purse-strings that are placed over the right atrial free wall. The right and left atrial lesions are done using cryoablation using either nitrous oxide or Argon. Next the left atrium is entered through a standard atriotomy placed in the interatrial groove. The base of the left atrial appendage is cryoablated and connected to the left upper pulmonary vein. All four pulmonary veins are then encircled using multiple application of cryo. An endocardial cryolesion is then placed posteriorly down to the level of the mid-mitral valve annulus and an epicardial cryolesion is placed on the coronary sinus directly across the atrial wall from the endocardial lesion. The left atrial appendage is then surgically managed.
45402853|NCT01298986|Procedure|Hybrid Procedure for Left Atrium >5 cm but < 6.1 cm|The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
45402854|NCT05665114|Drug|QN-030a|NK cell therapy
45402855|NCT05665114|Drug|Cyclophosphamid|Lympho-conditioning Agent
45402856|NCT05665114|Drug|Fludarabine|Lympho-conditioning Agent
45402857|NCT05665114|Drug|Cytarabine|Lympho-conditioning Agent
45402858|NCT05665114|Drug|VP-16|Lympho-conditioning Agent
45510656|NCT03543800|Device|PRP kit|PRP kit legally marketed in Canada for PRP
45510657|NCT02142296|Drug|Eylea|monthly injections for 3 months and then every other month to 1 year. volume administered is 0.05ml
45510658|NCT02148614|Drug|Placebo|Phase 1. Two tablets in a single preprandial dose Phase 2. Two tablets daily for 60 days
45510659|NCT02148614|Drug|Libramed|Phase 1. Two tablets in a single postprandial dose Phase 2. Two tablets daily for 60 days
45510660|NCT03889639|Drug|SAR442168|Pharmaceutical form: Film coated tablet; Route of administration: Oral
45510661|NCT03889639|Drug|Placebo|Pharmaceutical form: Film coated tablet; Route of administration: Oral
45510662|NCT03889639|Drug|Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
45510663|NCT02148692|Procedure|Higher PEEP|
45510664|NCT02148692|Procedure|Lower PEEP|
45510665|NCT02142452|Behavioral|behavioral intervention|Behavioral intervention will include a group class for women in their 3rd trimester followed by a mobile texting program to support behavior change postpartum.
45510666|NCT02142452|Other|Usual Prenatal Care|
45510667|NCT05418985|Behavioral|Monthly reminder message about breast self-exam.|Monthly reminder message about breast self-exam.
45510668|NCT02142530|Drug|Carfilzomib|
45510669|NCT02142530|Drug|Belinostat|
45510670|NCT05418439|Dietary Supplement|Drink Poppi Soda|Drink Poppi Vinager Soda
45698691|NCT05439642|Other|Evaluation of health related quality of life|Evaluation of health related quality of life of boys with hemophilia with the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool and the Pediatric Inventory of Quality of Life
45698692|NCT02189122|Drug|Bradykinin|Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
45402859|NCT01206790|Behavioral|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
45402860|NCT03814486|Other|descriptive|evaluate in number and efficacy platelet transfusion at the end of life, demographic characteristic are also noted
45402861|NCT05619874|Behavioral|HIFCT-S|"A functional circuit training of 30 sessions will be carried out as follows:~Sessions 1 to 6: General circuit (two series) composed of four blocks of three exercises.~Sessions 7 to 14: Concentrated circuit (two sets) composed of four blocks of three exercises of greater complexity than the exercises of the general circuit.~Sessions 15 to 22: Circuit by blocks (two sets) composed of four blocks of two exercises of greater complexity than the exercises from sessions 7 to 14.~Sessions 23 to 30: Circuit by blocks (two sets) composed of four blocks of two exercises of greater complexity than the exercises from sessions 15 to 22."
45510671|NCT02146508|Procedure|Endoscopic Mucosal Resection (EMR)|Endoscopic removal of regions of ESD.
45698693|NCT02189122|Drug|Aspirin 81 mg|Subjects will take Aspirin 81 mg per day for five days.
45402862|NCT05619874|Behavioral|HIFCT-P|"A functional circuit training of 30 sessions will be carried out as follows:~Sessions 1 to 6: General circuit (two series) composed of two blocks of 6 exercises.~Sessions 7 to 14: Concentrated circuit (two sets) composed of two blocks of 6 exercises of greater complexity than the exercises of the general circuit.~Sessions 15 to 22: Circuit by blocks (single set) composed of five blocks of two exercises of greater complexity than the exercises from sessions 7 to 14.~Sessions 23 to 30: Circuit by blocks (single set) composed of five blocks of two exercises of greater complexity than the exercises from sessions 15 to 22."
45402863|NCT03814798|Biological|IGSC 20% daily push versus every 2 weeks pump|IGSC 20% syringe daily push dosing for 16 weeks followed by every 2 weeks pump dosing for 16 weeks or the reverse sequence
45402864|NCT03814798|Biological|IGSC 20% daily push versus once a week pump|IGSC 20% syringe daily push dosing for 16 weeks followed by once weekly ambulatory pump administration dosing for 16 weeks or the reverse sequence
45402865|NCT03814798|Biological|IGSC 20% daily push versus 2 times per week pump|IGSC 20% syringe daily push dosing for 16 weeks followed by 2 times/week ambulatory pump administration on preselected days (eg, Monday and Thursday) not less than 3 days apart for 16 weeks or the reverse sequence
45402866|NCT03814798|Biological|IGSC 20% 150 mg/kg|loading dose of IGSC 20% consisting of 5 consecutive daily doses of 150 mg/kg/day (Week 0, Days 1-5) followed by weekly infusions of IGSC 20% 150 mg/kg starting Week 1 (Day 8) through Week 32 using an infusion SC pump
45402867|NCT03814408|Biological|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene, PGK-FANCA-WPRE
45402868|NCT05345002|Drug|Retifanlimab|Administered 500mg IV on day 1 of every 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.
45510672|NCT02146508|Device|Radiofrequency ablation|Endoscopic radiofrequency ablation of regions of ESD
45510673|NCT01383343|Biological|Bevacizumab|Given IV
45510674|NCT01383343|Drug|Fluorouracil|Given IV
45510675|NCT01383343|Drug|Irinotecan Hydrochloride|Given IV
45510676|NCT01383343|Drug|Leucovorin Calcium|Given IV
45510677|NCT01383343|Drug|Sorafenib Tosylate|Given PO
45698694|NCT02189122|Drug|Aspirin 162 mg|Subjects will take aspirin 162 mg per day for 5 days.
45402869|NCT05345002|Drug|All-trans retinoic acid|All-trans retinoic acid (ATRA) 45mg/m2 orally in two equally divided doses on days 1-14 of each 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.
45402870|NCT05618704|Dietary Supplement|Hydrolyzed protein infant formula|The subjects will take the formula for 16 weeks
45402871|NCT01299142|Drug|FGI-101-1A6|anti-TSG101 human monoclonal antibody, single dose
45402872|NCT05618314|Drug|AT-527|single dose AT-527
45402873|NCT05618314|Drug|AT-527|Single dose of AT-527 pre- and post-dialysis
45402874|NCT05618314|Drug|AT-527 and Probenecid|Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19
45402875|NCT05281120|Device|Low-level mechanical vibrations WITH vertical sinusoidal acceleration|Small platform designed to induce vertical, sinusoidal acceleration.
45510678|NCT02254850|Procedure|Flow Mediated Dilation|"Patients performed FMD by an high-resolution ultrasound linear probe in a supine decubitus and conditioned room.The probe was placed on humeral artery and connected to a mechanically arm. Then were performed several measurement s of the internal diameter of the vessel (edge to edge distance), on the R wave of the ECG, and software calculated the average value.The post-ischemic vasodilation was induced using a sphygmomanometer placed on the forearm, distal to the elbow crease, kept inflated to 250 mmHg for 5 minutes. The flow rate was recorded immediately after the desufflation; the diameter of the brachial artery was measured several times after desufflation (for 60-90 seconds). Nextly, the FMD was calculated as the percentage difference between the maximum diameter of the post-ischemic reached and the mean diameter of the vessel."
45510679|NCT02254850|Drug|Mesoglycan|The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml.
45510680|NCT02254850|Drug|Mesoglycan|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg.
45698695|NCT02189122|Drug|NHP544-C 81 mg|Subjects will take NHP544C 81 mg per day for five days.
45698696|NCT02189122|Drug|NHP544C 162 mg|Subjects will take NHP544C 162 mg once a day for five days.
45402876|NCT05281120|Device|Low-level mechanical vibrations WITHOUT vertical sinusoidal acceleration|Small platform designed to NOT induce vertical, sinusoidal acceleration
45851014|NCT00372450|Procedure|quality-of-life assessment|
45851015|NCT00372606|Behavioral|Online MiDieta Diet and Weight Management Program for Hispanics|
45851016|NCT00372684|Genetic|with severe malaria hospitalized in ICU|with severe malaria hospitalized in ICU
45402877|NCT00146172|Drug|neratinib|HKI-272
45851017|NCT00372684|Genetic|with uncomplicated malaria|with uncomplicated malaria
45851018|NCT00372762|Drug|Furosemide|Current dose of furosemide will be maintained and equivalent dose bumetanide will be used following crossover
45851019|NCT00372762|Drug|Bumetanide|Equivalent dose to pre-existing furosemide will be used
45851020|NCT00372762|Drug|furosemide|20mg to 80mg orally once or twice daily
45851021|NCT00372762|Drug|bumetanide|0.5mg to 2mg orally once or twice daily
45851022|NCT00372840|Other|educational intervention|
45402878|NCT01206868|Procedure|Fenestration|Fenestration of the peritoneum according to the length of the transplanted kidney
45402879|NCT01206868|Procedure|Control|Standard kidney transplantation
45851023|NCT00372840|Procedure|psychosocial assessment and care|
45851024|NCT00372840|Procedure|quality-of-life assessment|
45851025|NCT00372918|Procedure|Transnasal Esophagoscopy|fiberoptic exam of esophagus thru nares
45851026|NCT00373074|Other|Epidural Blood Patch|Use 15 cc of blood
45851027|NCT00373074|Other|Epidural Blood Patch|Inject 20 cc of blood into epidural space
45851028|NCT00373074|Other|Epidural Blood Patch|Inject 30 cc of autologous blood
45851029|NCT00373152|Procedure|Lumpectomy|Standard lumpectomy or mastectomy will be performed 1 to 21 days after the post-RFA MRI.
45851030|NCT00373152|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Dynamic-contrast enhanced breast images will be visualized with parametric image maps to assist in identifying regions with residual cancer.
45402880|NCT03814642|Drug|Clopidogrel 75 mg|Clopidogrel 75 mg tablet
45402881|NCT03814642|Drug|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
45402882|NCT03814642|Drug|Esomeprazole 20 mg|Esomeprazole 20 mg tablet
45402883|NCT01299220|Drug|Acitretin|Acitretin 10 mg by mouth daily
45402884|NCT03814330|Diagnostic Test|State-Trait Anxiety Inventory|State-Trait Anxiety Inventory measures state anxiety levels and is an easy-to-implement inventory that the individual can answer on his/her own. State-Trait Anxiety Inventory determines how the individual feels himself / herself at a given moment and under certain conditions. It is widely used in preoperative anxiety measurement
45402885|NCT03814330|Diagnostic Test|Quality of Recovery Score|Recovery Quality Score-40 (Quality of Recovery Score) and is used to measure the quality of postoperative recovery. This form consists 40 items and is divided into 5 subgroups according to various aspects of the improvement. There are a total of 40 items, 9 related to emotional state, 12 related to physical comfort, 7 related to psychological support, 5 related to physical independence and 7 items related to pain. The questionnaire is scored as a minimum of 40 to a maximum of 200.
45402886|NCT03814330|Other|Sedation/Analgesia|Patients will be performed the procedure with sedation/analgesia under the condition of spontaneous breathing.
45851031|NCT00373152|Procedure|radiofrequency ablation|RFA is accomplished by placing a multi-array needle within a tumor. The tines of the needle are advanced and opened like an inverted umbrella. High frequency, alternating current moves from the tip of an electrode into the surrounding tissue. Oscillating ions generate frictional heat within the tumor. Cell death occurs at sustained temperatures above 45-50 degrees C. The multi-array configuration creates an egg-shaped ablation zone up to 5 cm in diameter.
45851032|NCT00373152|Radiation|gadopentetate dimeglumine|Injected at baseline MRI and post radiofrequency ablation MRI.
45851033|NCT00373230|Behavioral|telemedicine|One year behavioral modification weight control program comparing in-person consultations (monthly) to a computer based telemedicine system (available 24/7).
45851034|NCT00366132|Device|Extracorporeal Shockwaves|
45851035|NCT00373464|Drug|etoricoxib|
45851036|NCT00373620|Drug|paclitaxel|
45851037|NCT00373776|Drug|miltefosine 2.5 mg/kg/day for 28 days|
45851038|NCT00373932|Behavioral|Coached exercise persistence intervention|Collaborative symptom and exercise monitoring and weekly reinforcement for exercise persistence from nurse coach via a mobile device and telephone.
45851039|NCT00373932|Behavioral|Self-Monitored exercise persistence intervention|Self-monitoring of symptoms and exercise using a mobile device
45698697|NCT02189122|Drug|Placebo|Subjects will take matching placebo for five days.
45698698|NCT05309460|Drug|Labetalol Oral Tablet|See Labetalol arm.
45698699|NCT05309460|Drug|NIFEdipine ER|See Nifedipine arm.
45698700|NCT03261804|Behavioral|relation between vaginal douching and vaginal infection|personal hygiene including performing external or Internal vaginal douching, how she is performing this douching (by hand, water, jet, pump), how frequent and why they perform this internal vaginal douche.
45698701|NCT01093690|Drug|metoclopramide|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg oral four times a day on day 2-5
45698702|NCT01093690|Drug|placebo|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
45698703|NCT05301426|Other|Stretching of the hamstring muscles.|Passive stretching of the hamstring muscles.
45402887|NCT03814330|Device|Laryngeal Mask Airway|Patients will be performed the procedure with Laryngeal Mask Airway during the procedure. Laryngeal Mask Airway is a supraglottic airway device to ventilate the patients during anesthetic procedure.
45402888|NCT03813784|Drug|SHR-1210|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
45402889|NCT03813784|Drug|Capecitabine|1000 mg/m^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
45402890|NCT03813784|Drug|Oxaliplatin|130 mg/m^2 administered IV Q3W on Day 1 of each 3-week cycle.
45402891|NCT03813784|Drug|Apatinib|250 mg administered as continuous oral once daily (QD) of each 3-week cycle.
45402892|NCT03818542|Drug|ABBV-181|intravenous infusion
45402893|NCT03818542|Drug|ABBV-368|intravenous infusion
45402894|NCT03818542|Drug|ABBV-927|intravenous infusion
45402895|NCT03818542|Drug|ABBV-927|intratumoral injection
45402896|NCT03818152|Other|Functional strength assessment|Functional strength exercises to assess strength in lower limbs.
45402897|NCT03818308|Drug|Sofosbuvir and Velpatasvir|All subjects will receive one film-coated tablet of sofosbuvir/velpatasvir (400/100 mg) orally once daily for 8 weeks.
45402898|NCT03827044|Drug|Avelumab|Avelumab is a fully human monoclonal antibody (MoAb) of the immunoglobulin G (IgG) 1 subtype which specifically binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.
45402899|NCT03814096|Diagnostic Test|Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)|Syphilis Health Check (SHC) POC-test is a treponemal POC-test based on 3d generation enzyme immunoassay (EIA) method detecting both Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies.
45402900|NCT05316532|Device|Prismalung + treatment|Low-flow extracorporeal CO2 removal with or without concurrent continuous renal replacement therapy
45402901|NCT05283928|Device|OsseoDensification (OD) protocol|Osseodensification is a drilling process by which bone is being compacted and auto-grafted in an outwardly expanding direction from the osteotomy. When the osseodensification drills are being rotated in a reversed, non-cutting direction a strong and dense layer of bone is formed along the walls and base of the osteotomy.
45402902|NCT05283928|Device|standard drilling (SD) protocol (NobelReplace® Conical)|osteotomy preparation through bone excavation is necessary in implant site development for the placement of dental implants. The process involves a forward cutting process with removal of bone tissue creating appropriate size osteotomy for the dental implant.
45402903|NCT05659030|Other|Education|In order to develop the training material, first of all, a literature review will be made and a training booklet will be prepared. The training booklet will be submitted to expert opinion and a pilot application will be made by giving its final form. The training content is based on Pender's Health Promotion Model, which consists of 3 components.
45402904|NCT00145626|Drug|Chemotherapy and antibodies|Study participants will receive a non-TBI based preparative regimen consisting of Cyclophosphamide, fludarabine, thiotepa, melphalan, and muromonab-CD3 (OKT3) followed by an infusion of a T-lymphocyte depleted haploidentical hematopoietic stem cell graft. Seven days posttransplant, participants will receive an infusion of additional donor derived cells called NK cells.
45402905|NCT00145626|Device|Miltenyi Biotec CliniMACS|Stem cell selection device
45510681|NCT02254850|Drug|Placebo|The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.
45698704|NCT05301426|Other|Neural slippage of the sciatic nerve.|Neurodynamic technique on the sciatic nerve.
45698705|NCT05301426|Other|Passive upper limb mobilisations.|Passive mobilisations performed on the upper limbs used as a placebo.
45698706|NCT04455360|Other|Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol|EMDR is a form of psychotherapy treatment whereby the client verbally relates a narrative of a traumatic episode or emotionally disturbing material in brief sequential doses while simultaneously focusing on an external stimulus. The EMDR Recent-Traumatic Events protocol (R-TEP) aims to enable an individual to process memories of the event in order to reduce psychological morbidity. EMDR R-TEP should be delivered within 3-months of the onset of a traumatic event.
45402906|NCT00145626|Procedure|Allogeneic stem cell transplantation|Allogeneic natural killer (NK)cell infusion
45402907|NCT01206946|Drug|Betamethasone|A single course of betamethasone (two doses of 12 mg/dose given at 24 hourly intervals)
45402908|NCT01206946|Other|Normal Saline|Two doses of 2ml of normal saline given at 24 hourly intervals
45402909|NCT01207024|Other|knee MRI|knee MRI before surgery (inclusion) and one year after
45402910|NCT03813940|Biological|HPV Vaccine,135μg/0.5ml|HPV vaccine (135μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
45402911|NCT03813940|Biological|HPV Vaccine,270μg/1.0ml|HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
45402912|NCT03967938|Drug|Olaparib Oral Capsule|Olaparib tablets 300mg twice daily
45402913|NCT03817918|Procedure|Lung ultrasonography|Patients undergoing thoracic surgery under general anesthesia using one-lung ventilation will have lung ultrasonography at 2 predetermined sites at four different time points
45402914|NCT03817996|Other|Fluid challenge|250ml of saline in Responders (those who increased >10% their cardiac output after a passive leg raising maneuver).
45402915|NCT05617066|Behavioral|Cognitive behavioral therapy|With the cognitive behavioral therapy will work on different aspects for coping and tools psychological stress.
45402916|NCT01299298|Drug|mipomersen|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) subcutaneous (SC) single dose of study drug
45402917|NCT01299298|Drug|placebo|50 mg (cohort A), 100mg (cohort B), or 200mg (cohort C) subcutaneous (SC) single dose of study drug
45402918|NCT00153062|Drug|Aggrenox|25mg aspirin, 200 mg dipyridamole
45402919|NCT00153062|Drug|Aggrenox|25mg aspirin, 200 mg dipyridamole
45402920|NCT00153062|Drug|Clopidogrel placebo|placebo
45402921|NCT00153062|Drug|Clopidogrel placebo|placebo
45402922|NCT00153062|Drug|Micardis|80 mg micardis
45402923|NCT00153062|Drug|Micardis|80 mg micardis
45402924|NCT00153062|Drug|Aggrenox placebo|placebo
45402925|NCT00153062|Drug|Aggrenox placebo|placebo
45402926|NCT00153062|Drug|Clopidogrel|75 mg clopidogrel
45402927|NCT00153062|Drug|Clopidogrel|75 mg clopidogrel
45402928|NCT00153062|Drug|Micardis placebo|placebo
45402929|NCT00153062|Drug|Micardis placebo|placebo
45402930|NCT05616208|Biological|Bioengineered Internal Anal Sphincter|Autologous Bioengineered Internal Anal Sphincter
45402931|NCT05264974|Biological|Autologous total tumor mRNA loaded DOTAP liposome vaccine|"All participants will receive three doses of RNA-NP vaccine (1 dose every 2 weeks) intravenously.~The vaccine dose given will be determined by a 3 + 3 design. The first cohort of 3 participants will be enrolled on a low vaccine dose (0.02 mg/kg mRNA encapsulated in 0.3 mg/kg NPs). If no dose limiting toxicity (DLT) is observed, then a new cohort will be enrolled at the next dose of vaccine (0.04 mg/kg mRNA encapsulated in 0.6 mg/kg NPs). However, if > 1 in 3 subjects experience a DLT, an additional 3 subjects will be enrolled at initial dose cohort. If no more than 2 subjects in 6 experience a DLT, then the criteria for MTD has not been met and dose escalation will continue with an additional cohort enrolled at a high dose vaccine level (0.08 mg mRNA encapsulated in 1.2 mg/kg NPs). However, should 3 or more of the initial 6 subjects experience a DLT, then the initial starting dose will be reduced (dose de-escalation) to 0.01 mg/kg mRNA encapsulated in 0.15mg/kg NPs."
45402932|NCT05255380|Behavioral|Mindfulness and compassion-based practices; approximately 5-10 minutes two times/day|The app-based (audio-guided) interventions consist of mindfulness and compassion-based practices that are selected to maximize their effect on stress targets. Interventions include, for example, practices that focus on the breath/body (e.g., 3-minute breathing space; compassionate body scan; five senses mediation), on increasing participants' inner resources (e.g., imaging a safe person or safe place), on reducing negative affect (e.g., self-compassion and acceptance-based practices), or on increasing positive emotions (e.g., gratitude practice; metta practices).
45402933|NCT05255380|Behavioral|Mindful awareness and reporting of current thoughts and feelings, 2 times/day|Participants are instructed to be mindful (pay attention) to their current thoughts and feelings and complete ecological momentary assessments of their current psychological stress states (e.g., stress appraisals, affect, perseverative cognitions, self-criticism, social connection)
45402934|NCT01207180|Other|Phone call follow-up|A nurse will call the patient to counsel patients on their medications and following up with their primary care provider.
45402935|NCT01207180|Other|Satisfaction survey|Patients will be given a satisfaction survey.
45510682|NCT02254850|Drug|Placebo|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.
45698707|NCT01143610|Procedure|Newly forming bone technique for root coverage|A granulation tissue will be obtained 21-25 days after the creation of an alveolar socket and grafted to receptor site.
45698708|NCT01143610|Other|Subepithelial connective tissue graft for root coverage.|A subepithelial connective tissue graft will be used for the treatment of Miller class I or II deep recessions.
45698709|NCT05439486|Device|hyperbaric oxygen therapy within hyperbaric oxygen therapy chamber.|ED patients in this group exposed to hyperbaric oxygen 100 % concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.
45698710|NCT01143688|Drug|albuterol|
45698711|NCT01143688|Drug|placebo inhaler|
45698712|NCT01143688|Procedure|placebo acupuncture|
45402936|NCT01207180|Other|Control group --- no intervention|Control group
45402937|NCT03813550|Diagnostic Test|Fecal and blood samples|Fecal samples for intestinal microbiota analysis; Blood and fecal samples for assessment of various forms of vitamin K
45402938|NCT00145470|Drug|Asenapine|Asenapine fast dissolving SL tablets 5 and 10 mg; starting dose 5 mg BID on Day 1; 5-10 mg BID after Day 1.
45402939|NCT00145470|Drug|Placebo|Placebo fast dissolving SL tablets, BID
45402940|NCT03813706|Procedure|lymph node dissection|The right cervical central compartment VI is subdivided into right cervical central VI-1 subzone and VI-2 subzone. Right central VI-1 subzone lies anterior to the RLN bounded by the hyoid bone superiorly, the suprasternal notch inferiorly, the inner edge of the common carotid artery laterally, and the midline of the trachea medially. Right central VI-2 subzone lies posterior to the right RLN. The superior, inferior, lateral, and medial borders are the laryngeal entry points of RLN, the intersection of the RLN with the innominate artery (near the right apical pleura), the inner edge of the common carotid artery, and esophagus, respectively. The floor of right central VI-2 is the prevertebral fascia.
45402941|NCT03813628|Other|polished celtra press full coverage crown|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by just polishing
45698713|NCT04455594|Drug|Almonertinib|Oral, 110mg QD
45698714|NCT04455594|Drug|Erlotinib|Oral, 150mg QD
45698715|NCT04455594|Drug|Cisplatin|Cisplatin(75mg/m2) be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
45698716|NCT04455594|Drug|Carboplatin|Carboplatin (AUC=5) to be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
45402942|NCT03813628|Other|glazed celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by glazing
45402943|NCT03813628|Other|contralateral natural teeth|the polished and glazed all ceramic crowns will be compared by the contralateral natural teeth
45402944|NCT03813394|Drug|pembrolizumab|-Pembrolizumab in Solution for Injection
45510683|NCT02142686|Device|Filling pressure 80|After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm Hg.
45402945|NCT03813394|Drug|bevacizumab|"Bevacizumab in Concentrate for Solution~Bevacizumab in Concentrate for Solution"
45510684|NCT02142686|Device|Filling pressure 50|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg.
45510685|NCT02142686|Device|Filling pressure 30|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm
45510686|NCT05416645|Procedure|patients with GERD after LSG|patients with GERD after LSG
45510687|NCT02148770|Device|Neurofeedback|Networks involved in eating behaviour can be modified by neurofeedback training. We will perform a neurofeedback task using the technology of fMRI-based Brain Computer Interface (BCI). BCI approaches based on real-time fMRI (rtfMRI) allow voluntary regulation of brain regions. For the rtfMRI, a well-established setup will be used which translates the blood oxygen level dependent (BOLD) signal of a specific brain region of interest into a visual signal (e.g. moving bar) in real time using brain voyager® and matlab. The study will include 1 training-sessions In the up-regulation condition subjects will learn to up regulate their dlPFC. In the sham-condition subjects are get the same instructions, however they will receive sham feedback.
45510688|NCT03631147|Drug|Rifaximin|400mg bid for 8 weeks
45402946|NCT03813316|Drug|DPP-4 inhibitor|Adding sitagliptin (DPP-4i) add-on using a fixed-dose combination with metformin (Janumet® 50/1000 mg BID).
45402947|NCT03813316|Drug|SGLT2 inhibitor|Adding ertugliflozin (SGLT2i) add-on using a fixed-dose combination with metformin(Segluromet® 2.5/1000 mg BID)
45402948|NCT03813316|Drug|SGLT2 inhibitor and DPP-4 inhibitor|Adding both a DPP-4i as Fixed dose combination (Janumet) plus SGLT2i ertugliflozin (steglatro) as add-on to metformin.
45402949|NCT03813004|Diagnostic Test|Reaction for gait perturbation|"Participants were subjected to four different perturbation types while walking on the treadmill:~left treadmill belt deceleration for right leg toe off~right treadmill belt deceleration for left leg toe off~left treadmill belt acceleration for right leg heel strike~right treadmill belt acceleration for left leg heel strike~Motion analysis was conducted to analyze effect of the intervention on gait."
45402950|NCT03817840|Procedure|Treatment of Cushing's|Surgical resection of ACTH-secreting tumor to achieve cure of hypercortisolism
45402951|NCT01301170|Procedure|dry needling|The needling will take place bilaterally at both the suboccipital region and the paravertebral muscles between C4 and T4. The needling will take place with the patient in the prone position. Following all needle placement, they will rotated clockwise till the point that tension on the needle is felt by the therapist. This will create more tension between the needle and tissue fibers, after which the needles were removed.
45402952|NCT01207258|Behavioral|Motivational Enhancement Therapy|20 minute manual-driven, optionally audio-recorded Motivational Enhancement Training intervention by a MI-trained therapist during their ED visit and a 10-15 minute phone booster at 7 to 10 days.
45402953|NCT05624086|Behavioral|exercise|Hepatitis-C Men With Sexual Dysfunction (erectile dysfunction) Complaint will receive exercise-training sessions (one hour walking on treadmill, for 3 months, three walking sessions per the week)
45402954|NCT03817450|Behavioral|Daily Mouth Care|Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention nursing homes.
45510689|NCT02148848|Drug|Risedronate|Take risedronate 35 mg orally every week
45510690|NCT03265145|Drug|Stiolto Respimat|Duration - 12 months
45510691|NCT03265145|Drug|ICS (Inhaled Corticosteroid) (Triple therapy)|Duration - 12 months
45510692|NCT03265145|Drug|LABA (Long-Acting Beta Agonist) (Triple therapy)|Duration - 12 months
45510693|NCT03265145|Drug|LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)|Duration - 12 months
45510694|NCT03786679|Device|Ultrasling ER III orthosis|Application of orthosis and start of rehabilitation after four weeks.
45510695|NCT05404867|Other|fMRI|fMRI scan for 1 hour
45510696|NCT02146664|Drug|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
45402955|NCT01301248|Other|Chemoradiation plus Cetuximab|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
45402956|NCT01301248|Other|Chemoradiation|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2
45402957|NCT03817684|Drug|BPN14770|Drug BPN14770
45402958|NCT03817684|Drug|Placebo|Placebo
45402959|NCT03817372|Device|Anterior-posterior electrode position|Escalating energy shocks (100 J, 150 J, 200 J, 360 J) using anterior-posterior electrode position
45402960|NCT03817372|Device|Anterior-lateral electrode position|Escalating energy shocks (100 J, 150 J, 200 J, 360 J) using anterior-lateral electrode position
45402961|NCT01301326|Device|subthreshold and threshold laser treatment|subthreshold laser treatment
45402962|NCT01301326|Device|Threshold laser treatment|threshold laser treatment
45402963|NCT01302028|Drug|ASP1941|Oral
45402964|NCT01302106|Drug|Clofarabine plus low dose Ara-C|Clofarabine 10 mg/m2 by a 1-hr i.v infusion, once daily, from day 1 to 5. Ara-C 10 mg/m2, subcutaneously, twice a day (q12 hrs), from day 1 to 15. Clofarabine will be given 4 hours before the 2nd dose of Ara-C.
45402965|NCT00152516|Drug|levetiracetam (LEV)|Per protocol oral tablets or oral solution at 10 to 30mg/kg/day bid for 48 weeks, or approximately 52 weeks should a subject choose to discontinue levetiracetam (LEV) at the end of the maintenance period.
45510697|NCT02146664|Drug|Placebo|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
45510698|NCT05402059|Drug|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Any kind of treatment or observation (no treatment) initiated or planned in accordance with current clinical practice
45510699|NCT02142764|Biological|Blood samples|The blood will be sampled in order to be tested in Immunology, twice, the day they sign their agreement and six months after in case of positive myelin pentamer test (at inclusion and 6 months after the inclusion).
45510700|NCT02142764|Biological|Blood samples|The blood will be sampled in order to be tested in Immunology, once, the day they sign their agreement (at the inclusion)
45510701|NCT02146742|Drug|ASP1707|oral
45402966|NCT00145158|Biological|8 HLA-A2-restricted peptides and Montanide ISA51|
45402967|NCT00145158|Biological|8 HLA-A2-restricted peptides and CpG 7909|
45402968|NCT03813082|Behavioral|Prolonged wakefulness|40 hours of prolonged wakefulness
45402969|NCT03812926|Device|Compuflo assited procedure|number of needle entry required to identify the ligamentum flavum
45510702|NCT02146742|Drug|Placebo|oral
45510703|NCT03240965|Diagnostic Test|FEES (flexible endoscopic evaluation of swallowing)|Endoscopical swallowing study in stroke patients only
45510704|NCT03240965|Other|Sensitivity threshold|Determining sensitivity threshold using a pudendal electrode
45510705|NCT03240965|Diagnostic Test|Taste-/smell-test|Taste-/smell-test
45510706|NCT03240965|Diagnostic Test|Neuropsychological testing|Neuropsychological testing for neglect, agnosia
45510707|NCT05344495|Drug|hyalase group|bupivacaine 15 mg 0.5% plus 2 mL normal saline containing 300 international units (IU) hyaluronidase.
45510708|NCT05344495|Drug|midazolam group|2 mg midazolam dissolved in 2 ml sterile saline plus 15 mg bupivacaine 0.5%
45510709|NCT05079386|Device|New Voice Prosthesis|Replacement of the current prosthesis with the experimental device and use the New Voice Prosthesis for the duration of two weeks with the option of leaving the device in situ until replaced for device failure or other reason, with a maximum of 12 months.
45510710|NCT01593241|Drug|Carboplatin|Stage IIA: 1 infusion Carboplatin AUC7 followed by 15 x 2 Gy involved node radiotherapy Stage IIB: 1 infusion Carboplatin AUC7 followed by 18 x 2 Gy involved node radiotherapy
45510711|NCT01593241|Radiation|Involved node RT|Involved node RT
45510712|NCT01590355|Radiation|Radiotherapy|Gross Tumour and Nodes: 70 Gy in 35 fractions over 7 weeks. High-risk nodal areas: 63 Gy in 35 fractions over 7 weeks. Low-risk nodal areas: 56 Gy in 35 fractions over 7 weeks
45510713|NCT01590355|Procedure|Transoral Robotic Surgery + Neck Dissection|Transoral robotic excision will be carried out using the da Vinci surgical robot.
45510714|NCT03064763|Drug|Talimogene laherparepvec|Talimogene laherparepvec will be administered as an intralesional injection.
45510715|NCT02782676|Device|Investigational Healon5 OVD|ophthalmic viscosurgical device
45698717|NCT04455594|Drug|Pemetrexed|Pemetrexed (500mg/m2) to be administered with Cisplatin(75mg/m2) or Carboplatin (AUC=5) on Day 1 of every 3-week cycle for 3 cycles
45698718|NCT01143766|Drug|Gabapentin|gabapentin 900mg PO x 1 dose, 1 hour prior to the procedure
45402970|NCT05161390|Drug|LM-302 Injection|LM-302 Injection with dose escalation stage of different dose levels, as well as dose expansion stage with recommended dose level from dose escalation stage.
45402971|NCT01302184|Device|Lokomat®|"Patients of the experimental group were trained at 50% of BWS for 15 minutes and 30% of BWS for 15 minutes on the Lokomat®. Treadmill speed was initiated at 1.5km/h and increased to 3.0km/h by increments of 0.5km/h as tolerated.~A physical therapist supervised the treatment, adjusting treadmill speed and BWS.~Treatment was performed for 3 days/week, for 4 weeks"
45402972|NCT01302184|Device|Treadmill|"Patients of the control group had 30 minutes of treadmill gait training. After having calculated the speed during 6MWT, the patient was trained on a treadmill (RHC770CE - RAM Medical srl). They were trained using 80% of the maximum speed that the patient reached during the test for the first week, 90% for the second week, 100% for the third and fourth week.~A Physical Therapist provided auditory cueing and direct, continuous feed-back to the patient.~Treatment was performed for 3 days/week, for 4 weeks."
45402973|NCT03812458|Behavioral|website and brochure|website and brochure
45402974|NCT05624008|Other|Bioceramic glass ionomer restoration|bioactive glass ionomer with unique biocompatibility and biological regenerative properties
45510716|NCT02782676|Device|Healon5 OVD|ophthalmic viscosurgical device
45698719|NCT01143766|Other|Standard sedation regimen|Combination opiate and benzodiazepine will be administered to achieve moderate sedation. This is the standard of care.
45510717|NCT03033095|Drug|Etanercept ® 50 mg|The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.
45851040|NCT00374010|Behavioral|Patient-Centered Advance Care Planning|"The PC-ACP is a scheduled interview with the dyad, delivered by a trained nurse facilitator. It consists of 5 stages and lasts about an hour:~Representational assessment (10 - 15 minutes);~Exploring concerns related to planning for future medical decision-making (10 - 15 minutes);~Creating conditions for conceptual change (5 minutes);~Introducing replacement information using a disease-specific Statement of Treatment Preferences document (15 minutes); and~Summary (3 - 5 minutes)"
45510718|NCT02471339|Behavioral|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT), a newer generation of cognitive-behavioral therapy, focuses on encouraging individuals to engage in more adaptive ways of coping with pain.
45402975|NCT05624008|Other|Resin modified glass ionomer restoration|A hybrid of glass ionomer and composite resin with acid-base and polymerizable components
45402976|NCT03817216|Device|Prostatic Urethral Lift (PUL)|PUL/ UroLift® is an FDA-approved device for the treatment of obstructive symptoms due to benign prostatic hyperplasia (BPH). This study evaluates UroLift's efficacy participants with obstructive symptoms who are candidates for radiotherapy or those who developed obstructive symptoms after radiotherapy.
45402977|NCT05623930|Device|laser acupuncture|In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
45402978|NCT05623930|Other|wet cupping|in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.
45402979|NCT05623852|Dietary Supplement|fucoidan|It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
45402980|NCT05154058|Procedure|Medial Subperiosteal Release with Sharp Dissection|Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This is commonly performed both via scalpel (aka sharp medial peel) or electrocautery
45402981|NCT05154058|Procedure|Medial Subperiosteal Release with Electrocautery|Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This group will receive this procedure using electrocautery.
45402982|NCT03812692|Device|MATRx plus|The MATRx plus device is a feedback-controlled mandibular positioner that uses data collected during sleep to control movement of the mandible in real-time using a mandibular positioner. The test provides a prediction of the individual's response to oral appliance therapy; i.e., if the individual can treat his or her obstructive sleep apnea using a mandibular advancing oral appliance. For individuals predicted to respond to the therapy, the test also provides a mandibular position at which the appliance will be effective.
45402983|NCT03812536|Other|No Void|Currently the protocol at The Ohio State University Hospital requires voiding spontaneously prior to discharge from the PACU. Our intervention group will be discharged home without having to void spontaneously as a discharge criteria.
45402984|NCT03817294|Other|Comparison of exercise training modalities|As above
45402985|NCT03817060|Procedure|cryopreservation of embryos at cleavage stage|cryopreservation of embryos at cleavage stage (day 3) of embryo development
45402986|NCT03817060|Procedure|cryopreservation of embryos at blastocyst stage|cryopreservation of embryos at blastocyst stage (day 5 or 6) of embryo development
45402987|NCT03817138|Other|Exposures: Markers of disease progression|From early phases of the study, it is expected that six main domains will be assessed which will include over N=100 potential markers reflecting different markers of dementia disease progression identifiable from patients' primary care EHR.
45510719|NCT02142842|Biological|Autologous adipose tissue stromal vascular fraction and platelet rich plasma|
45510720|NCT03632057|Device|Fixed Tilt (65%)|This is the standard group, so device programming for shock energy is the default setting
45510721|NCT03632057|Device|Fixed Pulse Width|The device has to be programmed with fixed pulse width for each phase of the biphasic waveform
45510722|NCT05075720|Dietary Supplement|Meat with added nitrate|"The intervention comprises 50 g salami and 35 g ham on white bread sandwich at breakfast and lunch.~This intervention will allow us to determine both endogenous formation of N-nitrosamines as well as N-nitrosamines present in the commercially prepared meat."
45510723|NCT05075720|Dietary Supplement|Meat without added nitrate|"The intervention comprises 65 g Pork mince on white bread sandwich at breakfast and lunch. Nitrate is not an allowed additive in pork mince.~This intervention will allow us to determine if there is endogenous formation of N-nitrosamines as well as N-nitrosamines present in the prepared meat due to the natural content of nitrate in meat."
45510724|NCT05075720|Dietary Supplement|Control|The control comprises low nitrate vegetable protein burger on white bread. Protein content matched to interventions 1 and 2.
45851041|NCT00374478|Drug|Scopolamine|
45851042|NCT00374634|Drug|rFSH drug dose|"Individual rFSH dose (50, 75 or 100 IU rFSH/day)"
45851043|NCT00374634|Drug|"Standard rFSH dose"|"Standard rFSH dose was 75 IU/day"
45851044|NCT00374790|Drug|Ferrous sulfate|
45851045|NCT00374946|Device|THA|
45698720|NCT05439408|Drug|Dasatinib ASD 100 mg|XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 100 mg Test Formulation
45698721|NCT05439408|Drug|Dasatinib 140 MG [Sprycel]|SPRYCEL® (dasatinib) 140 mg Film-Coated Tablets
45851046|NCT00375024|Procedure|Patient Navigation|Inclusion of Patient Navigator in treatment plan.
45851047|NCT00375024|Procedure|Clinic Staff|Specific Patient Navigator will not be included in treatment plan. Existing clinical staff will work with the patients.
45851048|NCT00375102|Procedure|Acupuncture|
45402988|NCT05623696|Device|Sham or actual non-invasive (Magnetic) brain stimulation|5 Hz rTMS applied using an actual or sham coil over the left or right DLPFC
45402989|NCT01302340|Drug|Delta-THC|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
45402990|NCT01302340|Drug|placebo|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
45402991|NCT01302340|Drug|Delta-THC|In case either 2 times daily 1 tablet 0,75mg or 2 times daily 1 tablet 1.5mg Delta-THC appeared to be efficacious for a particular patient, this patient can continue the effective dose of delta-THC in an open label extension phase during 6 months.
45402992|NCT00150800|Drug|Brivaracetam|"Active Substance: Brivaracetam~Pharmaceutical Form: Tablet~Concentration: 10 mg and 25 mg~Route of Administration: Oral"
45402993|NCT03812770|Drug|Sorafenib|Oral Sorafenib, 400mg, Bid
45402994|NCT03812770|Drug|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
45402995|NCT03812770|Drug|HAIC of OXA|administration of Oxaliplatin via the tumor feeding arteries
45402996|NCT00144300|Drug|Mirapex|Standard marketed product dispensed according to manufacturer's guidelines
45402997|NCT00144300|Drug|Requip|Standard marketed product dispensed according to manufacturer's guidelines
45402998|NCT03812068|Behavioral|Long-distance developmental behavioral intervention|Long-distance learning program combined parent-mediated developmental behavioral intervention
45402999|NCT03812068|Behavioral|Developmental behavioral intervention|Parent-mediated developmental behavioral intervention
45403000|NCT01582724|Procedure|Self-care acupressure at three predefined points|Self-care acupressure, one minute for each point, starting 5 days before menstruation, once up to twice daily; when pain is present: twice daily up to five times
45510725|NCT02931851|Other|ICU Families Website|Professionally developed website for relatives of ICU patients
45698722|NCT05261880|Other|Neural mobilization|Neural mobilization and bone are two common physical therapy interventions used for Carpal Tunnel Syndrome. Neural mobilization reinstates the plasticity of the nervous system and restoring the capacity of stretching.
45698723|NCT05261880|Other|Scaphoid , hamate mobilization|Bone mobilization in Carpal Tunnel Syndrome involves gliding at scaphoid and hamate.
45698724|NCT04453800|Drug|sofadil【Neu2000KW】|500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
45698725|NCT04453800|Drug|Sofadil|750mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
45403001|NCT00149630|Drug|Disulfiram|Disulfiram 250 mg/day by mouth daily during study weeks 2-13. Disulfiram discontinued during study weeks 14-15.
45510726|NCT02931851|Other|Placebo|Standard Information provided online
45851049|NCT00375102|Behavioral|Relaxation Response|
45851050|NCT00373542|Drug|ropinirole CR-RLS|
45851051|NCT00375258|Drug|Tranexamic acid|Loading dose of 1 gram then 1 gram by infusion over 8 hours
45851052|NCT00375258|Drug|Sodium Chloride 0.9%|Visual matched placebo
45851053|NCT00375414|Procedure|PEG-Gastropexy|
45851054|NCT00375570|Drug|ME-609|Topical treatment 5 times daily for 5 days
45851055|NCT00375648|Drug|Zoledronic acid|
45851056|NCT00375726|Biological|rDEN3/4delta30(ME)|Live attenuated rDEN3/4delta30(ME) vaccine (one of three doses)
45851057|NCT00375726|Biological|Placebo|Placebo for rDEN3/4delta30(ME)
45403002|NCT00149630|Drug|Methadone|Initial dose 25 mg; increased by 5 mg at each subsequent daily dosing until 60 mg maintenace dose reached.
45403003|NCT00149630|Behavioral|CBT|1-hour weekly, individual, manual-guided Cognitive Behaviorial Therapy.
45403004|NCT00149630|Other|Lactose|Lactose was added to both the active disulfiram and placebo doses so they tasted identical.
45403005|NCT01302496|Biological|TriMix-DC and ipilimumab|Patients will receive 5 administrations of autologous TriMix-DC, administrations 2, 3, 4 and 5 will be preceded by ipilimumab (a CTLA-4 blocking monoclonal antibody, at a dose of 10 mg/kg). Patients who are free from progression according to the irRC will be offered ipilimumab maintenance administrations of ipilimumab (10mg/kg q12wks).
45403006|NCT00127842|Drug|Etanercept|Administered according to the product monograph by subcutaneous (SC) injection
45403007|NCT03720652|Behavioral|8-Week Mindful Self-Compassion (MSC)|"The 8-week MSC is a course of eight 2.5 hour weekly sessions that is based off self-compassion, a construct closely related to mindfulness. Self-compassion (SC) has three main interrelated components: self-kindness, common humanity, and mindfulness. MSC is an 8-session program that integrates SC and mindfulness.~It includes the following components:~Discovering Mindful Self-Compassion~Practicing Mindfulness~Practicing Lovingkindness~Discovering your Compassionate Voice~Living Deeply~Meeting Difficult Emotions~Exploring Challenging Relationships~Embracing Your Life"
45403008|NCT03720652|Behavioral|6-Week Mindful Self-Compassion (MSC)|"The 6-week MSC is a course of six 1 hour weekly sessions that is based off self-compassion, a construct closely related to mindfulness. Self-compassion (SC) has three main interrelated components: self-kindness, common humanity, and mindfulness. MSC is an 6-session program that integrates SC and mindfulness.~It includes the following components:~What is Self-Compassion~Practicing Self-Compassion~Discovering your Compassionate Voice~Self-Compassion and Resilience~Self-Compassion and Burnout~Going Forward This program is a shortened version of the 8-week program, specifically created for the needs of health care staff."
45403009|NCT03968016|Device|SYSMEX HLSCL|Diagnostic device
45403010|NCT03964740|Other|Mobile App intervention|The intervention is based on the interventional group subjects use of a mobile device with an ad-hoc designed application (called ASMATIC). This app permit them (in a daily basis) to record asthma control variables (peak-flow and presence of core symptoms), have daily reminders on their medication for asthma control and decision support for patient disease self-management; and contains advice on healthy lifestyle habits, including personalized diet recommendations based on clinical criteria and associated recipes. The device also permits the study subject to communicate with the hospital and for the study team to review potential issues of interest on the patient's asthma control parameters which might need an intervention such us additional in-person consultations
45403011|NCT00112866|Drug|cilengitide|Given IV
45403012|NCT00112866|Procedure|therapeutic conventional surgery|Undergo tumor resection
45403013|NCT00112866|Other|pharmacological study|Correlative studies
45403014|NCT00112866|Other|laboratory biomarker analysis|Correlative studies
45403015|NCT03824626|Diagnostic Test|TEVAR patients|Computed Tomography Angiography (CTA) will be performed using a 16-slice unit before and after intravenous administration of 100 mL of iodinated contrast material. Phase contrast-Magnetic Resonance (pc-MRI) will be performed using a 1.5-T unit with 40-mT/m gradient power and a four-channel cardio-thoracic coil. ECG-triggered, free-breathing through plane, and in-plane pc-MRI sequences will be performed for phase-velocity mapping of aortic and branches flow. Ad hoc processing of preoperative CTAs, based on 3D multiplanar reconstruction, will be performed with 3Mensio Vascular software 8.0® (3Mensio Medical Imaging B.V.), which provides specific functions for automatic measurements.
45403016|NCT00127608|Procedure|Collection of clinical samples|"The following samples were obtained from each subject:~Vesicle fluid (VF) and vesicle swabs (VS) from four vesicles (for a total of eight samples)~Papule swabs (PS) from four papules~Crusts from two lesions~One throat swab (TS) Up to 15 samples were to be obtained for each subject, when possible. VFs, VSs, PSs, and crusts were either stored dry or in liquid medium. TS samples were stored in liquid medium.~After extraction of DNA, samples were tested for the presence of varicella virus using a Quantitative Polymerase Chain Reaction (Q-PCR) technique."
45403017|NCT00149396|Drug|NV1020|NV1020 dose levels: 3x10^6, 1x10^7, 3x10^7, and 1x10^8 plaque forming units, administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks
45403018|NCT03816904|Other|Blood samples|Blood samples before the introduction of chemotherapy
45403019|NCT03741348|Procedure|Erector Spinae Plane Block|In (ES) group After skin sterilization, ESPB was performed in sitting position at the level of T9 linear ultrasound (US) transducer (Phillips-Saronno Italy) was placed vertically 3cm lateral to midline to visualize the muscles of the back, transverse process and simmering pleura in between the two transverse processes. After local infiltration of needle insertion site with 2-3ml of 2% lidocaine, a 22-gauge Short bevel needle (Spinocan, B.Braun Melsungen AG, Germany) was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles. Then, up to 20 ml of bupivacaine 0.5% was injected. The procedure was repeated following the same steps on the other side of back.
45403020|NCT03741348|Procedure|control|in control group, Erector Spinae Plane Block will not be done
45403021|NCT05080504|Device|Eko DUO|"Each subject will take an Eko DUO device home and take DUO recordings immediately before or after their prescribed CardioMEMS measurements.~The DUO recordings will be taken at 3 predefined chest locations: the right upper sternal border, left upper sternal border, and right anterolateral. Each DUO recording lasts about 15 seconds. The total time per recording session is expected to be 2-4 minutes, which allows for time between recordings and any potential repeat recordings. Study participation will last for 90 days."
45403022|NCT01075802|Drug|Tamoxifen|Dose escalation
45851058|NCT00375882|Procedure|hypothermia|
45851059|NCT00375882|Procedure|cochlear implantation with mild hypothermia|
45851060|NCT00375960|Drug|V3381|
45851061|NCT00375960|Drug|Placebo|
45851062|NCT00376038|Drug|GSK189075 oral tablets|
45510727|NCT02146820|Device|GentleMax system|Picosecond Laser System for the Treatment of Pigmented Lesions
45698726|NCT04453800|Drug|Sofadil|1500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
45698727|NCT04453800|Other|placebo|Saline was administered intravenously
45698728|NCT01188460|Behavioral|Self-help manual for insomnia|Implementation of chapters of self-help manual at home, and completion of sleep diary in terms of time in bed, hours of sleep, time to fall asleep, number of awakenings, and sleep quality
45698729|NCT01188460|Behavioral|Sleep diary|
45698730|NCT03011476|Drug|Donepezil|"Start with 5 mg/day for 4 weeks~Increased to 10 mg/day for 8 weeks"
45403023|NCT03967314|Other|TLIP block group (group T)|In group T, the block was performed bilaterally under aseptic conditions using the US device with a high-frequency 12-MHz linear US probe. The probe was covered with a sterile sheath and placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe was moved forward in a lateral direction to visualize the longissimus and iliocostal muscles. Using the in-plane technique, a 22-G, 50-mm block needle was inserted between the muscles in a medial-to-lateral direction in the interfascial plane. Once the needle tip was placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 ml of saline was injected to confirm the accuracy of the injection site. A dose of 0.25% bupivacaine (20 ml) was then injected in each side (total 40 ml).
45403024|NCT03967314|Other|Wound infiltration group (group W)|In group W, a dose of 0.5% bupivacaine (20 ml) was injected for wound infiltration into the surgery site.
45403025|NCT03816592|Procedure|Opioid free anaesthesia|patient anesthtesized with lidocaine, ketamine and dexamethasone
45403026|NCT03816592|Procedure|Opioid anaesthesia|patients anesthetized with sufentanil ketamine and dexamethasone
45403027|NCT01078038|Device|Cypher|Sirolimus-eluting stent implantation
45403028|NCT01078038|Device|Xience V|Everolimus-eluting Stent implantation
45403029|NCT00223496|Drug|Aripiprazole|Aripiprazole5mg - 30mg, every day (QD), for 12 weeks.
45403030|NCT05623618|Behavioral|PACE labelling|PACE labelling implemented near at least one discretionary food item in secondary school canteens for up to 6 weeks.
45403031|NCT02531412|Drug|Spironolactone|After a major surgery event a time 0, 24h and 48h
45403032|NCT02531412|Drug|Placebo|After a major surgery event a time 0, 24h and 48h
45403033|NCT00255944|Behavioral|Youthnet Internet-based program|Messages from the Youthnet program will be interactive and tailored specifically to HIV/STD risk reduction. Participants will be exposed to five flash computer vignettes of 30 seconds each, concerning condom attitudes, norms self-efficacy, and risk awareness.
45403034|NCT00255944|Behavioral|Control Internet based program|The control program will deliver standard STD/HIV prevention messages.
45403035|NCT03811990|Behavioral|Cleveland Clinic Stress Free Now Meditations For Healers|Phone-based meditation application
45403036|NCT01071824|Procedure|Transverse coloplasty pouch (Long limb)|Transverse coloplasty pouch with long limb
45403037|NCT01071824|Procedure|Transverse coloplasty pouch (Short limb)|Transverse coloplasty pouch with short limb
45403038|NCT03823456|Other|Self-acupressure|We teach participants how to using self-acupressure to manage insomnia, depression, and anxiety. Six acupoints are included in our acupressure protocol which are Baihui, Yintang, Fengchi, Neiguan, Shenmen, and Taichong. Participants are requested to stimulate each acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from Anxiety and Depression Association of American.
45403039|NCT03823456|Other|Sham Self-acupressure|We using a sham acupressure protocol to teach participants in this group. Six sham acupoints are included in the protocol. The sham acupoints are located 2-5cm away from the true acupoints. Participants are requested to stimulate each sham acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from the Anxiety and Depression Association of American.
45403040|NCT00143598|Device|Knee-length, graduated elastic compression stocking|Worn daily for 2 years, 30-40 mm Hg
45403041|NCT00143598|Device|Knee-length, placebo stocking|Worn daily for two years
45403042|NCT03971240|Procedure|evacuation of traumatic acute subdural hematoma|craniotomy will be done with evacuation of the hematoma
45403043|NCT03816826|Other|physical therapy|both are physical therapy intervention technique used to treat the soft tissue acute injuries
45510728|NCT02142920|Drug|PF-05212384|Single 89 mg Dose via 30 minute IV infusion
45698731|NCT03011476|Drug|Placebos|"Start with 5 mg/day for 4 weeks~Increased to 10 mg/day for 8 weeks"
45698732|NCT05438784|Procedure|orbital bone reconstruction with patient specific titanium implant|orbital defects reconstruction will be virtually planned by software and a patient specific titanium implant will be manufactured using milling technique depending on CAD-CAM technology
45698733|NCT05438784|Procedure|orbital bone reconstruction with preformed titanium plate preoperatively bended on stereolithographic model|orbital defects reconstruction will be virtually planned by software and a reconstructed stereolithographic model will be 3D printed and used for preoperatively bending of preformed titanium implant.
45698734|NCT02522754|Biological|Placebo Protesomal Vaccine|Intranasal vaccine Protesomal Vaccine
45698735|NCT02522754|Biological|Experimental: Protesomal Vaccine 1 x 30 µg|Experimental: Protesomal Vaccine 1 x 30 µg
45698736|NCT02522754|Biological|Experimental: Protesomal Vaccine 2 x 30 µg|Experimental: Protesomal Vaccine 2 x 30 µg
45851063|NCT00376038|Drug|metformin tablets|
45851064|NCT00376116|Device|Cardiac resynchronisation therapy|
45851065|NCT00376116|Device|Implantable cardioverter-defibrillator|
45851066|NCT00376194|Drug|DMSA|
45851067|NCT00376272|Drug|Valsartan|
45851068|NCT00376272|Drug|Placebo|
45510729|NCT03544112|Behavioral|Employ a multifaceted approach to facilitate clinical protocol implementation|Implementation will include developing clinical protocols containing core components of the intervention to which fidelity is expected, along with aspects that may be adapted by local sites to aid implementation. In partnership with multidisciplinary teams at each site, we will adapt clinical practices from other contexts and available information about SL-BUP and XR-BUP to site-specific clinical protocols and implementation strategies. The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
45510730|NCT03544112|Drug|Initiate BUP (SL-BUP or XR-BUP) in the ED|The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
45510731|NCT05346809|Drug|Isatuximab|Isatuximab in IV form 10 mg/kg doses
45510732|NCT05346809|Other|Standard Procedures|Standard procedures (standard of care) for transplant
45510733|NCT02142998|Other|24 pH monitoring|The study is performed with the patient fasting for a minimum of 6 hours. A single channel or dual channel (15 cm spacing) pH probe is inserted trans nasally. The pH sensor, or distal pH sensor in the case of 2 channel testing, is positioned 5 cm above the proximal margin of the LES, as determined by esophageal manometric testing. pH-Z ambulatory monitor (Given Imaging Digitrapper) is used for data acquisition and the data analyzed with pH Analysis Program (Given Imaging AccuView). The number of reflux events, defined as a drop in esophageal pH readings below 4.0, is recorded and the percentage of time with esophageal acid exposure is analyzed using defined protocols and accepted normal values.
45510734|NCT02142998|Other|Esophageal Manometry:|A high resolution esophageal manometry catheter is used for testing and inserted Trans nasally. The patient is given 10 liquid swallows (5mL of water), at intervals of approximately 30 seconds. The catheter (Sierra Scientific/Given Imaging) has 36 sensors, each one averaging pressures from 12 circumferential positions. This gives a total of 432 data points. The sensors are placed 1 cm apart, spanning a length of 35 cm. The catheter simultaneously records pressure readings from the esophagus, sphincter regions (UES and LES), pharynx and stomach without the need for a station pull-through technique. Results are reported according to defined protocols and accepted normal values.
45510735|NCT01383785|Other|Intracoronary direct injection|"Abciximab bolus dosage: 0,125 mg/kg.~Group A: Intracoronary full bolus dose of abciximab proximal to thrombus occlusion. The investigators inject the bolus of abciximab by catheter guide before cross the occlusion. This in the normal way in study' laboratory."
45510736|NCT01383785|Other|Intracoronary and distal injection by aspiration device|"Abciximab bolus dosage: 0,125 mg/kg.~Group B: Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter. The investigators inject half of the dose like group A and the other half like group C."
45510737|NCT01383785|Other|Intracoronary distal injection by aspiration catheter device|"Abciximab bolus dosage: 0,125 mg/kg.~Group C: Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter. The investigators inject the bolus after cross the occlusion using an aspiration catheter."
45510738|NCT02146898|Other|Position|
45510739|NCT02923739|Biological|Bevacizumab|Given IV
45510740|NCT02923739|Biological|Emactuzumab|Given IV
45510741|NCT02923739|Other|Laboratory Biomarker Analysis|Correlative studies
45510742|NCT02923739|Drug|Paclitaxel|Given IV
45510743|NCT02923739|Other|Pharmacological Study|Correlative studies
45510744|NCT02146976|Drug|propofol|introvenious infusion of propofol
45510745|NCT02146976|Drug|sevoflurane|sevoflurane (1.0-1.3 Minimum Alveolar Concentration)
45510746|NCT02365883|Device|Photoacoustic Imaging System|manufactured by Endra
45510747|NCT02147054|Drug|Rocuronium|
45698737|NCT02522754|Biological|Experimental: Protesomal Vaccine 2 x 15 µg|Experimental: Protesomal Vaccine 2 x 15 µg
45851069|NCT00376350|Procedure|Spinal Manipulation|5 minutes high velocity, low amplitude lumbar thrust
45510748|NCT02147054|Drug|Sugammadex|Effect of Rocuronium will be reversed at the appropriate time using Sugammadex 16mg/kg as a single dose which may be repeated once.
45510749|NCT02149082|Device|Infrascanner Model 2000|The Infrascanner Model 2000 device is a small, portable handheld device that uses near infrared (NIR) technology to screen patients for intracranial bleeding.
45510750|NCT02149160|Drug|FRM-0334|
45510751|NCT02149160|Drug|Placebo|
45510752|NCT02149238|Dietary Supplement|flavanol|
45510753|NCT02149238|Dietary Supplement|methylxanthine|
45510754|NCT02149238|Dietary Supplement|flavanol + methylxanthine|
45510755|NCT02149316|Procedure|RIPC+RIPostC|Four 5 min cycles of upper limb ischemia and reperfusion by a cuff inflated to 200 mmHg, twice (after anesthesia induction and before surgery started, at 20min after aortic declamping)
45510756|NCT02149316|Procedure|control|a deflated cuff placed on the right upper arm
45698738|NCT01188694|Drug|Psychotherapy plus Methylene Blue, USP|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, 260 mg of methylene blue, USP will be given.
45698739|NCT01188694|Behavioral|Psychotherapy plus Placebo|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, capsules containing the placebo will be given.
45698740|NCT01188694|Behavioral|Delayed Psychotherapy|Individuals must wait approximately five to six weeks to start treatment. They will come in for two check-in appointments before starting treatment. Treatment will consist of ten twice-weekly psychotherapy sessions (90-120 min each session).
45698741|NCT04453566|Other|Online Survey|Online Survey
45851070|NCT00376350|Procedure|Light Massage|light pressure massage of the low back.
45851071|NCT00376350|Procedure|Pulsed Ultrasound|5 minutes pulsed ultrasound
45851072|NCT00376428|Drug|Gentamicin|
45851073|NCT00376584|Drug|MK-0524A|
45510757|NCT02149394|Other|Ice popsicle|"Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The experimental group received an ice popsicle made of 10 mL mineral water.~The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice were supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort."
45510758|NCT02149394|Other|Water at room temperature|Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
45510759|NCT02143076|Behavioral|Demographic Questionnaire|At study enrollment, participants will complete a questionnaire to collect demographic information about the participant's family background, education and living situation.
45510760|NCT02143076|Behavioral|Medical Adherence Measure Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire describing all medications prescribed for them, when they take their medications, how much medication they take each time, how many times during the week they missed taking or were late taking each medication, reasons why they missed or were late, and how they manage their medications.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
45510761|NCT02143076|Behavioral|Acceptability Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire about their perceptions of using the Wise electronic medication container.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
45510762|NCT02147210|Other|biological analysis|
45510763|NCT00107978|Drug|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
45510764|NCT00107978|Drug|Vancomycin|Vancomycin 1 Gm IV administered every 12 hrs for up to 14 days.
45510765|NCT03543644|Other|Sugar-sweetened beverage (SSB)|SSBs will be provided to each participant. Participants will be able to choose their SSB of choice from the list in the protocol. They will be instructed to drink their usual SSB intake, study drinks provided, while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
45510766|NCT03543644|Other|Non-nutritive sweetened beverages (NSB)|NSBs will be provided to each participant. Participants will be be given the NSB equivalent to the usual SSB chosen from the list in the protocol. They will be instructed to replace their usual SSBs with the NSBs while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
45403044|NCT01080144|Other|Critical flicker frequency procedure|After TIPS, patients will be followed during one year and the psychometric test and Critical flicker frequency procedure will be performed every 3 months
45403045|NCT01299844|Behavioral|Diabetes Peer Counseling|16 Home visits from a bilingual/bicultural diabetes peer counselor.
45510767|NCT03543644|Other|Water|Water will be provided to each participant. They will be instructed to replace their usual SSBs with the water while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
45510768|NCT02781818|Drug|Triamcinolone Acetonide 10mg/mL|Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
45510769|NCT02781818|Drug|Triamcinolone Acetonide 40mg/mL|Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
45403046|NCT01301404|Dietary Supplement|10% carbohydrate drink|In the study group, 10% carbohydrate drink 400 ml will be given between 18-24 hr the night before surgery and another 400 ml will be drunk at 6-7 hr in the morning of surgery.
45403047|NCT03816670|Drug|Corifollitropin Alfa|late start (day 4) vs. corifollitropin-alfa standard start (day 2)
45510770|NCT02781818|Drug|Normal Saline|Normal saline 0.1 mL will be administered intralesionally at the selected site.
45510771|NCT02149550|Other|NF135 n=5|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
45510772|NCT02149550|Other|NF135 n=2|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
45510773|NCT02149550|Other|NF135 n=1|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
45510774|NCT02149550|Other|NF166 n=5|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
45698742|NCT04454112|Device|24-hour esophageal pH monitoring using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands).|24-hour esophageal pH monitoring application
45698743|NCT04454268|Procedure|cyst extirpation|complete removal of the cyst without rupture
45698744|NCT01188928|Drug|Calcipotriol plus betamethasone|Topical suspension once daily for up to 8 weeks.
45698745|NCT01188928|Drug|Betamethasone-17,21-dipropionate|Topical suspension once daily for up to 8 weeks.
45698746|NCT01188928|Drug|Calcipotriene|Topical suspension once daily for up to 8 weeks.
45698747|NCT01188928|Drug|Topical suspension vehicle|Topical suspension once daily for up to 8 weeks.
45851074|NCT00376584|Drug|ER Niacin|
45851075|NCT00376584|Drug|Placebo|
45851076|NCT00376662|Drug|Hormone Replacement Therapy and Etidronate|
45851077|NCT00376740|Drug|zoledronic acid|Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
45403048|NCT03816514|Procedure|SpHb monitoring|Noninvasive, continuous pulse oximetry-based hemoglobin (SpHb) monitoring
45403049|NCT03816514|Procedure|Conventional management|Conventional management without SpHb monitoring
45510775|NCT02149550|Other|NF166 n=2|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
45510776|NCT02149550|Other|NF166 n=1|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
45510777|NCT02149628|Drug|propofol|
45510778|NCT02149628|Drug|Desflurane|
45510779|NCT02147366|Behavioral|Music & lifestyle changes|Music intervention involved listening to raga bhimpalas played on bansuri/flute (an Indian instrument) for 15 minutes daily for 3 months.
45510780|NCT02147366|Behavioral|Lifestyle|Lifestyle intervention was based on Joint national committee VII guidelines for hypertension
45510781|NCT02927873|Biological|RSV (GSK3389245A) low dose formulation vaccine|2 doses of 0.5 ml each of RSV (GSK3389245A) low dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
45510782|NCT02927873|Biological|RSV (GSK3389245A) middle dose formulation vaccine|2 doses of 0.15 ml each of RSV (GSK3389245A) middle dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
45510783|NCT02927873|Biological|RSV (GSK3389245A) high dose formulation vaccine|2 doses of 0.5 ml each of RSV (GSK3389245A) high dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
45510784|NCT02927873|Drug|Placebo|2 doses (0.5 mL each for Placebo LD and Placebo HD groups and 0.15 mL each for Placebo MD group) of Placebo administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
45510785|NCT05230667|Other|PRP injection (PRP group)|Patients in the PRP group will receive both shoulder joint (GHJ) and SASD bursa injection for one time. PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. About 2ml PRP and 3ml platelet poor plasma (PPP) will be extracted, then 4ml 1% xylocaine will be added to make 9ml injectate. 6ml injectate will be injected into the posterior GHJ with a 7 cm 23-gauge needle under ultrasound (US) guidance. Another 3ml injectate will be injected into the SASD bursa of the affected shoulder with a 3.8 cm 22-gauge needle under US guidance.
45698748|NCT05171244|Behavioral|virtual reality training|training of multisensory processing capacities in virtual reality in addition to usual program of interventions in usual care
45698749|NCT05171244|Behavioral|usual care|usual program of interventions in usual care
45698750|NCT05438706|Drug|chidamide|Chidamide, an HDAC inhibitor
45698751|NCT05438706|Drug|camrelizumab|Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer.
45510786|NCT05230667|Other|Corticosteroid injection (CS group)|Three ml triamcinolone (1ml= 10mg), 4ml 1% xylocain, and 2ml normal saline to make a 9ml injectate is injected into the affected shoulder (6ml to posterior GHJ and 3 ml to SASD bursa). The techniques of injection are the same as those used in the PRP injection.
45698752|NCT05438706|Drug|carboplatin|Carboplatin [diammine(1,1-cyclobutanedicarboxylato)platinum(II)] is one of the most promising second generation platinum compounds. Its greater chemical stability in comparison with cisplatin accounts for its lower reactivity with nucleophilic sites of DNA.
45510787|NCT05230667|Other|Normal saline injection (NS group)|Four 4ml 1% xylocaine mixed with 5ml normal saline will be injected into the affected GHJ (6ml) and SASD bursa (3ml). The techniques of injection are the same as those used in the PRP injection.
45510788|NCT01383629|Behavioral|Counselling|Preoperative counselling
45510789|NCT04722731|Behavioral|Confident Parents - Brave Children (CPBT)|"Session 1: Psychoeducation.~Session 2: How to decrease criticism and rejection. Skills that provide a warm parenting style and acceptance of the child: validation and child directed play/activities.~Session 3: Strategies to increase the autonomy of the child. The parents will learn how to use a stepladder approach to decrease overprotective behaviours.~Session 4: How to decrease modelling of anxious behaviours and how to be a brave role model.~Session 5: How to recognise and respond when your child is anxious. How to help your child approach new or scary things by using a stepladder approach.~Session 6: Review of the principles and skills learned during the program. The group members will make a plan for how to continue the work on their own."
45510790|NCT04722731|Behavioral|"Self-help book What all parents ought to know"|Participants in the control group will receive a self-help parenting book containing general research-based parenting strategies. They will be instructed to read the book within the 10 weeks from baseline to post.
45510791|NCT02460419|Drug|capecitabine|capecitabine 1250mg/m2 bid, oral, for 14 days, every 3 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
45510792|NCT02460419|Other|Best supportive care (BSC)|Best supportive care and following-up every 6-8 weeks
45510793|NCT01220999|Drug|CS-1008|CS-1008 was administered once weekly as an intravenous infusion over 30 ± 10 minutes at a dose range of 0.2 to 6 mg/kg. On Days 1 and 36, CS-1008 infusions were radiolabeled with 111^In (5-7 mCi).
45510794|NCT03513731|Device|Adipose-derived stem cell injection|ADRC injection into the facet joint
45510795|NCT03513731|Drug|Corticosteroid injection|Corticosteroid injection into the facet joint
45510796|NCT01568411|Drug|TD-1211|Period 1
45510797|NCT01568411|Drug|TD-1211+ itraconazole|Period 2
45510798|NCT05215379|Drug|xintilimab injection|neoadjuvant chemoradiation therapy +xintilimab injection 200mg/3week 4cycle
45510799|NCT05215379|Other|Control|neoadjuvant chemoradiation therapy
45510800|NCT00142415|Drug|111-In-DOTA-cG250|On Day 1, each subject received a single intravenous (IV) infusion of 10 mg of cG250 coupled to DOTA and labeled with 5 mCi of 111-In.
45403050|NCT05054530|Drug|GMA106 Injection|GMA106 solution for injection. Subjects in each cohort will receive a single injection of GMA106 or matching placebo under fasting conditions and at the following target dose levels.
45510801|NCT00142415|Drug|177-Lu-DOTA-cG250|On Day 8, 9, or 10, each subject received a single IV infusion of 10 mg of cG250 coupled to DOTA and labeled with a dose of 177-Lu at a starting dose of 30 mCi/m^2 in the initial cohort.
45510802|NCT01383551|Behavioral|"Becoming Parents intervention"|"A Becoming Parents programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education."
45510803|NCT03631745|Behavioral|NAMI Mental Health 101 and NAMI FaithNet|"Congregants of Intervention Churches will receive:~NAMI Mental Health 101, a 60-90 minute, contact-based educational intervention~NAMI FaithNet which consists of congregational support and training to cultivate supportive environments within faith communities for those with mental health conditions and their families."
45698753|NCT05438706|Drug|capecitabine|Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of various malignancies. Hereditary genetic variants may affect a drug's pharmacokinetics or pharmacodynamics and account for differences in treatment response and adverse events among patients.
45715319|NCT04395508|Drug|Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)|PH FDC SC is given as a fixed dose (i.e. non-weight based) subcutaneous injection. Two dosage configurations of PH FDC SC may be administered in the study: a 15-millilitre (mL) loading dose consisting of 1200 milligrams (mg) pertuzumab and 600 mg trastuzumab and a 10-mL maintenance dose consisting of 600 mg pertuzumab and 600 mg trastuzumab. Participants who have had ≥6 weeks since their last P+H IV, PH FDC SC, or are receiving trastuzumab SC treatment must receive a loading dose before continuing with maintenance doses for subsequent administrations. Note that participants receiving trastuzumab SC only (i.e. without pertuzumab) must receive a loading dose regardless of time since last treatment.
45403051|NCT05054530|Drug|GMA106 Matching Placebo|Matching Placebo for GMA106
45510804|NCT05420363|Other|different walking surfaces|different surfaces materials and textures as sand ,grass, air mattress , foam mattress ,gravels and Rollator
45510805|NCT05420363|Other|traditional gait training over hard surface only|The children will receive gait training over hard surface and even ground only and bare feet without wearing any foot ware or orthosis
45510806|NCT03631901|Drug|oral melatonin|Both melatonin and diazepam were given only during the febrile illness.
45510807|NCT03631901|Drug|oral diazepam|Both melatonin and diazepam were given only during the febrile illness.
45403052|NCT00126672|Drug|Rapamycin|
45403053|NCT01302574|Dietary Supplement|lactisole|Lactisole-liquid meal: Lactisole (450 ppm) will be mixed with a liquid meal. Liquid meal only: The comparator will be the liquid meal alone.
45403054|NCT01080378|Procedure|Dietary and Exercise Intervention|Participants will be enrolled into a 16 weeks weight loss programme that consists of (a) dietary interventions and (b) structured exercise sessions and (c) physical activity to achieve 7 - 10% decrease (more than 8 kg) in initial body weight in 16 weeks. They will be subjected to a caloric deficit of 40% of the subject's energy expenditure or 1000kcal, which ever it is higher. (allowance given for dietary control and physical activity).
45403055|NCT03811678|Drug|Kangdaprevir Sodium Tablet|Tablet，administered orally once daily
45403056|NCT03811678|Drug|placebo|Tablet，administered orally once daily
45403057|NCT00145574|Drug|colesevelam HCl|Tablets
45510808|NCT03631589|Biological|MSCs|mesenchymal stem cells therapy
45510809|NCT01383395|Drug|simvastatin/cilostazol|
45510810|NCT05419661|Other|Operational Pre-Planning|Using a 3D printer, printing of the patient's aneurysm from the segmented 3D images obtained during the initial assessment and thus allowing a simulation of the embolization procedure. This pre-operative planning (PPO) carried out in real conditions aims to anticipate the possible complications that could be encountered on the same day of treatment.
45510811|NCT05084651|Drug|Ganaplacide|Treatment A/Period 1: 400 mg (4 x 100 mg tablets) at Hour 0 on Day 1 Treatment B/Period 2: 400 mg (4 x 100 mg tablets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.
45510812|NCT05084651|Combination Product|Lumefantrine|Treatment A/Period 1: 480 mg (2 x 240 mg sachets) at Hour 0 on Day 1 Treatment B/Period 2: 480 mg (2 x 240 mg sachets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.
45510813|NCT05084651|Drug|Itraconazole|200 mg (20 mL of 10 mg/mL oral solution) q.d. on Days 1 to 18
45510814|NCT05419271|Procedure|home hemodialysis session with 9L internal convection|home hemodialysis session with 9L internal convection
45403058|NCT00145574|Drug|placebo|Matching Tablets
45403059|NCT05660668|Other|Transbond LR|cleaning the lingual surface using oil free pumice then apply acid etch 35% phosphoric acid for 20 second then rinse then Transbond LR will be applied directly on the fixed retainer and lingual surface of the teeth then light cured.
45403060|NCT05660668|Other|Transbond XT|cleaning the lingual surface using oil free pumice then apply acid etch 35% phosphoric acid for 20 second then rinse then Transbond XT will be applied directly on the fixed retainer and lingual surface of the teeth then light cured.
45403061|NCT04984486|Device|dental implant|"The procedure used to accomplish its intended use is as follows :~The recipient implant site is prepared using a drilling sequence, then the implant is placed at the crestal level~After a period of osseointegration of the implant, a transgingival healing screw is placed to allow the healing of soft tissues. After this healing phase, the final prosthesis will be loaded on the implant."
45403062|NCT05599750|Procedure|Incisional hernia repair|Participants will undergo incisional hernia repair
45403063|NCT05034562|Procedure|Computed Tomography|Undergo PET/CT
45403064|NCT05034562|Drug|Gallium Ga 68-labeled PSMA-11|Given IV
45403065|NCT05034562|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
45403066|NCT05034562|Procedure|Positron Emission Tomography|Undergo PET/CT or PET/MRI
45403067|NCT00145496|Drug|Asenapine|5-10 mg sublingually twice daily for up to 26 weeks
45403068|NCT00145496|Drug|Olanzapine|5-20 mg by mouth once daily for up to 26 weeks
45403069|NCT01299922|Drug|cyclosporine +mycophenolic acid+prednison|Cyclosporine for 26 weeks Prednisone+mycophenolic acid 106 weeks
45403070|NCT01299922|Drug|Mycophenolic Acid + prednison|Mycophenolic Acid + prednison for 106 weeks
45403071|NCT03967574|Device|Transcranial direct current stimulation|"The tDCS anode was applied on the primary motor cortex area responsible for the control of the rotator cuff, as determined using transcranial magnetic stimulation and surface electromyography. The cathode was applied on the contralateral forehead, just above the eyebrow. The electrodes were soaked in saline solution to improve conductivity and the montage was secured with rubber bands and adhesive tape.~The tDCS device (Soterix Medical 1x1 tDCS device) was then gradually turned to an intensity of 2mA. This stimulation was continued for a total of 20 minutes, after which it was gradually stopped."
45403072|NCT05030818|Drug|Polypill of acetylsalicylic acid, ramipril and atorvastatin|Administration of acetylsalicylic acid, ramipril and atorvastatin in a polypill during 3 months more
45698754|NCT05438472|Other|data collection in healthcare professionals with COVID-19 mRNA vaccine booster|Day 3 (48 - 96h) post COVID-19 mRNA booster: data collection on symptoms (chest pain, dyspnea, myalgia, fever, chills); blood sample for cardiomyocyte injury (hs-cTnT, hs-cTnI). If elevated hs-cTnT concentration, participant has to avoid strenuous exercise. Work-up on Day 4: clinical evaluation, ECG, 2. blood sampling for hs-cTnT. If hs-cTnT > 100 ng/l, cardiac magnetic resonance imaging is done for signs of cardiac inflammation. If hs-cTnT rises above upper limit but doesn't exceed 100 ng/l, clinical exam might be evaluated. In confirmed myocarditis, a clinical assessment (treatment, need for hospitalization, length of rhythm monitoring, rest) is evaluated by a cardiologist. Day 4: EDTA blood from all subjects with elevated troponin at day 3 post-vaccination is collected for pathomechanism of mRNA vaccine associated myocarditis. 1-month follow-up: questionnaire on predefined cardiac endpoints.
45698755|NCT05167344|Behavioral|Healthy Relationships Program-Enhanced|The Healthy Relationships Program-Enhanced (HRP-E) is a small group mental health promotion and healthy relationship program designed for vulnerable, at-risk youth. It is a trauma-informed, 16-session manualized program.
45698756|NCT01189240|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
45698757|NCT01189240|Biological|bevacizumab|Given IV
45403073|NCT05030818|Drug|Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin|Patients will be receiving during 3 months more the same components acetylsalicylic acid, ramipril and atorvastatin than with the polypill
45403074|NCT01582022|Drug|Bupivacaine|local application for 5 minutes
45403075|NCT01582022|Drug|normal saline|local application for 5 minutes
45403076|NCT03967418|Behavioral|Cognitive and clinical assessment|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (neurocognition, social cognition, metacognition, emotional reactivity) and a clinical assessment (impulsivity, personality, psychiatric and addictive comorbidities)
45510815|NCT01825187|Device|ULTRAPRO Mesh|Patients who are randomized to this group will received ULTRAPRO Mesh for their hernia repair
45510816|NCT01825187|Device|3DMAX|Patients who are randomized to this group will receive 3DMAX mesh for their hernia repair
45510817|NCT01825187|Other|Evaluation|To evaluate the ease of use and time it takes residents to place and perform the surgery using these two different meshes.
45510818|NCT02781584|Drug|SEL|Administered orally once daily
45510819|NCT02781584|Drug|FIR|Administered orally once daily
45510820|NCT02781584|Drug|CILO|Administered orally once daily
45403077|NCT01301482|Device|Ear Acupuncture|Ear acupuncture utilizes up to 10 needles (see figure 6). If at any point the subject decides not to continue with the placing of the needles, the acupuncture will cease and the number of points will be documented. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero (see figures 1-5).
45403078|NCT01582412|Drug|Isavuconazole|oral
45403079|NCT01582412|Drug|digoxin|oral
45403080|NCT01300000|Other|Human Milk|ad lib
45403081|NCT01300000|Other|Investigational infant formula|ad lib
45403082|NCT01300000|Other|Milk based standard infant formula|ad lib
45403083|NCT03816436|Other|Follow- up (FU) assessment|Follow- up (FU) assessment (clinical examination and patient questionnaires) at least 24 months after surgery (clavicular midshaft and lateral non- union treated by plate and iliac crest bone grafting)
45403084|NCT00255164|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
45403085|NCT00255164|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
45403086|NCT00255164|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
45403087|NCT03811444|Device|Haemolance Plus safety lancet|Haemolance Plus safety lancet type 420 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients
45403088|NCT03811444|Device|Prolance safety lancet|Prolance safety lancet type 430 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
45403089|NCT03811444|Device|MediSafe Solo safety lancet|MediSafe Solo safety lancet type 520 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
45698758|NCT01189240|Other|laboratory biomarker analysis|Correlative studies
45403090|NCT02915614|Procedure|Pulmonary rehabilitation|3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)
45403091|NCT03967652|Diagnostic Test|Nanomaterial-based sensors|Chemical sensors based on Monolayer-Capped Metallic Nanoparticles (MCMNPs) can recognize and classify exhaled breath by special recognition algorithm, which achieves the purpose of disease diagnosis.
45403092|NCT01300078|Drug|MF101|MF101 10 g/day MF101 15 g/day
45403093|NCT03816280|Procedure|Elective cardiopulmonary bypass (CPB)|All groups undergo elective cardiopulmonary bypass (CPB)
45403094|NCT03816280|Procedure|Alpha-stat acid-base management|Acid-base status during CPB will be maintained using the alpha-stat regime
45403095|NCT03816280|Procedure|pH-stat acid-base management|Acid-base status during CPB will be maintained using the pH-stat regime
45403096|NCT05578690|Behavioral|Diet|An initial 8 weeks of low-calorie diet including meal replacements (total of 800 kcal/day) will be initiated with the objective to lose at least 10% of initial body weight. From week 8 until week 12, an individual food-reintroduction plan will take place with partial meal product substitution. At week 12 and until pregnancy dieticians will ensure sustained compliance with diet aligned with the general recommendations for women seeking pregnancy (low-fat diet, rich in protein and carbohydrates and in some individuals slightly carbohydrate-reduced diet (prediabetes or family disposition to diabetes) with focus on carbohydrate quality (more fiber and whole grain). Consultations with a dietician for mapping diet and eating patterns and regular follow-up with a dietitian to maintain diet changes and modify diets if needed.
45403097|NCT05578690|Behavioral|Exercise|After an initial 8-week ramp-up phase (during the initial low-calorie diet), the women will be encouraged to attend supervised exercise sessions on the study location (combination of vigorous-intensity, interval-based indoor cycling, and circuit training) twice weekly and to perform additional moderate-to vigorous-intensity exercise to obtain at least 150 min per week of moderate-intensity or 75 min per week of vigorous-intensity physical activity or a combination. The plan will include individual exercise and/or group exercise. Exercise watches with heart-rate monitors will be worn at each exercise session to determine whether the requirement regarding weekly time spent at moderate or vigorous intensity will be met. Regular follow-up with the women to maintain exercise changes and modify the exercise plan if needed.
45403098|NCT05578690|Behavioral|Mentorship|"Women are offered an individualized plan to successfully fulfil the multifactorial lifestyle intervention and the women will be offered both individual and/or group sessions with a mentor. After 8 weeks of the intervention, the women will be invited to another meeting where the choice of mentor will be evaluated, and the women will be offered to join a pre-parents-group. Group sessions will include conversational sessions, cooking classes and exercise classes with focus on changing lifestyle and maintaining a healthy lifestyle change. At the time of pregnancy groups will be reconsidered and the women will be offered participation in pregnancy-groups."
45403099|NCT01300156|Drug|Oxaliplatin-based chemotherapy (ESHAOx)|"Etoposide 40 mg/m2, D1-4~Methylprednisolone 500mg, D1-5~Cytarabine 2 g/m2, D5~Oxaliplatin 130 mg/m2, D1"
45403100|NCT03811522|Other|carbon dioxide insufflation|Receives CO2 insufflation
45403101|NCT03811522|Other|Air insufflation|Receives air insufflation
45510821|NCT02781584|Drug|FENO|Administered orally once daily
45510822|NCT02781584|Drug|VAS|Administered orally two times daily
45698759|NCT01189240|Other|pharmacological study|Correlative studies
45403102|NCT03811288|Other|No treatment given|No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
45510823|NCT02149706|Biological|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA
45510824|NCT02149706|Biological|IFA Incomplete Freund's Adjuvant|IFA Placebo Incomplete Freund's Adjuvant
45403103|NCT00126594|Drug|Sorafenib Tosylate|Given orally 400 mg orally (PO) every 12 hours
45403104|NCT00126594|Biological|Recombinant Interferon Alfa-2b|Given subcutaneously (SC) 0.5 million with +/- 5 % variance (0.475 MU - 0.525 MU); Dose level 0: 0.5 X 10^6 international units twice daily
45403105|NCT00126594|Other|Laboratory Biomarker Analysis|Correlative studies
45403106|NCT01080456|Drug|Tacrolimus 1 mg capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
45510825|NCT03544658|Procedure|Dental prophylaxis|Professional dental prophylaxis including dental scaling and dental polishing with prophylactic paste
45510826|NCT03544658|Procedure|Tooth color assessment by the participant|Tooth color assessment using the VITA Classical shade guide. Assessment will be done with normal light conditions and with a light correcting device
45403107|NCT03822052|Other|Lactated ringers|IV fluid
45510827|NCT03544658|Procedure|Tooth color assessment by the investigator|Tooth color assessment using the VITA Classical shade guide and the VITA Toothguide 3D Master. Assessment will be done with normal light conditions and with a light correcting device
45510828|NCT03544658|Procedure|Tooth color assessment with SpectroShade|Tooth color assessment using SpectroShade (dental spectrophotometer). Color will be registered in VITA Classical and VITA Toothguide 3D Master and CIELab parameters
45698760|NCT03467490|Behavioral|DED self-management|This an educational intervention. The interventional will include watching a series of short videos and a DED handbook. The short videos will address the following topics: anatomy of the eye, pathophysiology of DED, treatment options for DED, management of DED with allergies/glaucoma/ computer use, and new developments in treatment and research of dry eye disease. The handbook will include tools and resources for self management of DED.
45403108|NCT03822052|Other|5% dextrose lactated ringers|IV fluid
45403109|NCT03811054|Drug|Apatinib（250mg/d） combined with EGFR-TKI|Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
45698761|NCT03462264|Device|Scoliogold App|The mobile application will include a list of the specific exercises that the patient has to complete on a daily basis. It will have a start/stop button which the patient presses at the beginning and the end of each time that they complete their home exercise programme. This will get logged on to their application which can be accessed by the researcher to monitor home exercise compliance.
45698762|NCT03462264|Other|Pre-Formatted Diary|The pre-formatted diary will prompt the date, start time, end time and a list exercises that the patient has completed that day that the patient will be requested to fill out.
45698763|NCT03013348|Device|Brain Sentinel's sEMG Post-processing algorithm|Brain Sentinel has developed a post processing method that identifies sEMG signals (recorded from the biceps brachii or as muscle artifact in electroencephalography [EEG] recordings) that are pathognomonic for PNES activity.
45698764|NCT03467334|Dietary Supplement|B. breve|Bifidobacterium probiotic strain at 1E+08 cfu/day
45698765|NCT03467334|Dietary Supplement|B. breve plus L. fermentum|Probiotic combination at 2E+08 cfu/day
45698766|NCT03467334|Drug|Simethicone 20 MG|Standard treatment for infant colic
45403110|NCT00126438|Drug|123I-mIBG (meta-iodobenzylguanidine)|Single Dose
45403111|NCT03821818|Behavioral|Food Allergy Elimination + Willis Exercise|Food Allergy Elimination + Willis Exercise (performing a 2-minute Aerobic-surge exercise > 75% max heart rate, 5/day)
45403112|NCT01075854|Drug|Gonal-F (Follitropin alfa)|Follitropin alfa FbM solution for injection in a prefilled pen is available in three strengths: 300 IU/0.5 ml (22 µg/0.5 ml), 450 IU/0.75 ml (33 µg/0.75 ml) and 900 IU/1.5 ml (66 µg/1.5 ml). The starting dose is usually recommended to be between 150 and 300 IU. The dose is then adjusted according to the ovarian response.
45403113|NCT03967392|Drug|Xylocaine|TREATMENT
45403114|NCT04898764|Drug|Mometasone Furoate|Mometasone furoate nasal spray suspension, 50µg/actuation
45403115|NCT03821116|Other|Milk|Swedish milk from cow.
45510829|NCT02147678|Drug|Etomidate|
45510830|NCT02147678|Drug|Propofol|
45510831|NCT02147678|Drug|Remifentanil|During anesthesia maintenance, all patients will be given remifentanil at the speed of 0.2~0.4 μg/kg/min.
45510832|NCT02147678|Drug|Anesthesia induction|For all patients, the induction protocol is midazolam 0.1 mg/kg, sufentanil 0.3 μg/kg, cisatracurium 0.15 mg/kg.
45510833|NCT02151344|Biological|H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10^7.0 fluorescent focus units (FFU) of the vaccine; the vaccine will be administered with a nose spray device.
45510834|NCT02151344|Biological|Inactivated subvirion H7N9 vaccine|Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.
46057197|NCT05748184|Device|Optimized ULDCT viewer prototype version(s)|The ULDCT viewer prototype is a non-medical unreleased device that will be used by study participants on de-identified image cases in a research setting. The Prototype integrates new tools to speed up the diagnostic interpretation process of radiological images. Optimized version(s) of previous version.
46057198|NCT02777541|Dietary Supplement|Resumption of feeding 3 hours after PEG placement|The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
45403116|NCT03821116|Other|Soured milk (filmjölk)|Swedish soured milk (from cow milk).
45403117|NCT04896736|Other|Multisite tissue oxygenation-guided care|"The following intervention algorithm is intended to be used as a guidance only. We emphasize the different aspects that can cause changes in SctO2/SstO2 in a systematic approach. We avoid recommending a concrete drug and method of dosing for a specific condition.~Manage tissue perfusion Preload: overall picture including direct observation of the heart, findings of echocardiography, urine output, blood loss, labs results, HR, BP, PPV, SVV, fluid responsiveness (SV increase >/= 10% following 250 ml fluid bolus) Contractility: direct observation of the heart, findings of echocardiography Stroke volume and heart rate: important determinants of CO Systemic vascular resistance: important determinant of BP Regional vascular resistance: important determinant of tissue perfusion along with perfusion pressure Maintain autoregulation: normalize CO2, avoid potent vasodilators~Manage arterial blood oxygen content~Manage tissue metabolic activity"
45403118|NCT04896736|Other|Usual care|Usual care in this study means the standard perioperative care. Patients who are meant to receive usual care will receive both cerebral and muscular tissue oxygen saturation monitoring; however, the monitor screen will be covered and the monitoring data will not be used to guide clinical care.
45510835|NCT02151422|Behavioral|Breathing exercise|Patients will be thought 3 different exercises included yoga pranayama, diaphragmatic breathing and pursed lip breathing. Patients will be asked to repeat these exercises at least twice daily for a one month period. Also patients will be thought 4 different exercises which they could use in the event of an asthma exacerbation. Teaching will be supplemented by a breathing exercise brochure and patients will be asked to demonstrate proper technique at initial visit and at the return visit.
45510836|NCT02151500|Behavioral|Stress and Health Interview|A stress and health interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms; b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations.
45510837|NCT03543488|Diagnostic Test|Neuromuscular and functional capacity tests|"The Timed Up and Go test; Maximal knee-extensor muscle strength (isometric and concentric tests) was measured with a Biodex System 3 dynamometer; A B-mode ultrasonography system with a linear-array probe (60 mm, 7.5 MHz) was used to determine VL and RF muscle thickness, pennation angle, fascicle length and tendon CSA. Measurements were obtained with the volunteer seated in the dynamometer, during isometric contraction at 90° of knee flexion.~An 8-channel EMG system was synchronized with the dynamometer through a Windaq data acquisition system and used to evaluate the vastus lateralis and rectus femoris electrical activity during isometric knee-extensor tests."
45510838|NCT02149784|Procedure|Surgical resection of primary tumor|Surgical resection of primary tumor of mCRC patients who were respond to first line chemotherapy'
45851078|NCT00376818|Behavioral|exercise intervention|All participants will convene once per week for 8 weeks for a 90-minute session that will be based on yoga principles for a stress reduction.
45851079|NCT00376818|Other|educational intervention|A 15-minute educational session on a particular topic (mind-body connection; fight or flight response; relaxation response; the science and philosophy of yoga; the science of meditation; sleeping well; mindfulness; the healer within - how to harness your innate healing potential).
45851080|NCT00376818|Other|physiologic testing|Both patients and family caregivers will complete Perceived Stress Scale (PSS) and Beck Anxiety Inventory (BAI) questionnaires.
45851081|NCT00376818|Other|management of therapy complications|Brain Cancer module-20 questionnaire to assesses problems specific to brain tumor.
45403119|NCT00142584|Drug|Nebivolol (NEB)|Patients randomized to nebivolol will initiate therapy with nebivolol 5 mg once daily for 4 weeks.
45403120|NCT00142584|Drug|Metoprolol (MET)|Patients randomized to metoprolol will initiate therapy with 100 mg once daily for 4 weeks.
45510839|NCT02155634|Drug|Lenalidomide|Treatment with lenalidomide capsules 10 mg, 5mg daily or 5mg every other day given on days 1-21 of each 28 day cycle.
45510840|NCT02151578|Other|home/community case management|
45510841|NCT02151656|Drug|F17464|
45510842|NCT02151656|Drug|Placebo|
45510843|NCT03543020|Radiation|radiation therapy to brain|OSL placed over the scalp for initial 5 fractions for patients undergoing partial/ whole brain radiation therapy
45510844|NCT02155790|Device|The Peregrine System Infusion Catheter|The ASI catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
45510845|NCT02151734|Drug|KALOMIN™ Tab.|
45510846|NCT02151734|Drug|Umckamin syrup|
45510847|NCT02151812|Device|Agent Paclitaxel-coated balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
45510848|NCT02151812|Device|SeQuent® Please Paclitaxel-coated Balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
45510849|NCT02155868|Other|Correction rSO2 desaturation.|"Predefined protocol of interventions for correcting rSO2 desaturation (< 60%) during cardiac surgery and the first six hours after it.~In case of rSO2 decrease less than 60% correct:~head position; position of aortic,venous cannulae and central venous catheters; partial pressure of carbon dioxide in arterial blood < 35 mmHg; mean arterial pressure < 60 mmHg; central venous pressure > 10 mmHg; cardiac index < 2.0 l/min/m2; mixed venous oxygen saturation < 60%; hemoglobin < 65 g/L during cardiopulmonary bypass or hemoglobin < 90 g/L after cardiopulmonary bypass; decrease cerebral O2 consumption."
45403121|NCT04848064|Drug|Cyclophosphamide|Given IV
45510850|NCT02155868|Other|Standard treatment|Standard treatment
45510851|NCT02151890|Biological|Stem Cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
45510852|NCT02151968|Procedure|Local Anaesthetic Injection|Local anaesthetic is injected into the eye.
45403122|NCT04848064|Drug|Fludarabine|Given IV
45403123|NCT04848064|Biological|Mogamulizumab|Given IV
45403124|NCT04848064|Biological|Natural Killer Cell Therapy|Given via infusion
45510853|NCT02151968|Procedure|Ultrasound-Guidance|"Device: Ultrasound Machine~Peribulbar block local anaesthetic is injected into the eye with ultrasound guidance."
45510854|NCT02776670|Other|Propylene glycol, 0.6% eye drops|
45510855|NCT02776670|Other|Lubricant eye drops|
45510856|NCT02149862|Other|Urine infrared analysis|Collected urine sample will be stored at -80°C for further infrared analysis. Spectra will be analyzed by visual inspection, and statistical method such as Principal Components Analysis and logistic regressions methods.
45510857|NCT02149940|Other|heart-failure related pharmaceutical intervention|
45510858|NCT03744260|Diagnostic Test|Patients undergo ultrasound and lumbar MRI|Patients undergo ultrasound, physical therapy exam and MRI before and after the radiofrequency ablation procedure that they are getting as part of their regular care.
45510859|NCT02150018|Other|non invasive ventilation|
45510860|NCT02150096|Other|continuous ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
45698767|NCT02880384|Other|FilmArray LRTI v.2.0 IUO Panel|Patients will provide sputum or sputum equivalent to be probed with FilmArray LRTI v.2.0 IUO Panelpanel.
45698768|NCT03462186|Other|Healthfinder invitation|Invitation to use healthfinder (healthfinder.gov/myhealthfinder
45403125|NCT04848064|Other|Quality-of-Life Assessment|Ancillary studies
45403126|NCT04848064|Other|Questionnaire Administration|Ancillary studies
45403127|NCT00126126|Other|EBAR Program|Evidence Based Amputee Rehabilitation Program
45403128|NCT04817644|Drug|Oral semaglutide|Oral semaglutide once daily for a total of 10 days
45403129|NCT03816046|Drug|botulinum toxin A|injection in hair bearing area of armpits
45403130|NCT00125268|Device|MIRE|Monochromatic near infrared photo energy (MIRE). A 30-minute application of MIRE results in a radiant exposure of 43.2 joules per square centimeter (J/cm^2). The design of the flexible pads allows the infrared energy to be delivered perpendicular to and in contact with the involved site. MIRE applied to the skin facilitates the release of a small molecule of the free radical nitric oxide from hemoglobin and other proteins in surrounding tissue. Increased levels of nitric oxide improve the circulation of blood enhancing wound healing and reducing pain.
45403131|NCT00125268|Device|Sham Device|The sham device is non-active but otherwise identical to the study device.
45403132|NCT03816124|Procedure|radiofrequency ablation|radiofrequency ablation of the genicular nerves
45510861|NCT02150096|Other|pulsed ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
45510862|NCT02150096|Other|low level laser therapy group|the group will be treated with 3 J 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
45510863|NCT04906226|Behavioral|Self-foot massage|The individuals in the foot massage group will be given foot massage training by the researcher. Later, people with diabetes will be enabled to continue self-massage at home. To encourage the continuation of the intervention, the researcher will be called once a week by phone and her questions will be answered. At the end of the four weeks, the patient will be interviewed again and data collection forms will be filled.
45403133|NCT03815968|Other|low sodium diet|included in the diet mostly low sodium food. avoid tinned or smoked, food. avoid adding salt to the food.
45403134|NCT03964662|Device|WeReha|Rehabilitation of stroke patients with the device WeReha
45403135|NCT01080534|Drug|Tacrolimus 5 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
45403136|NCT01301560|Radiation|Radiosurgery|Gamma knife surgery for asymptomatic oligo-metastasis to brain from NSCLC
45403137|NCT01301560|Radiation|Observation|No local treatment
45403138|NCT03819946|Device|esophageal cooling device (Attune Medical, Chicago, IL)|The esophageal cooling device is a silicone soft tubing that is designed to be inserted into the esophagus. It is currently used clinically to provide whole body cooling or temperature control for intensive care patients (in medically induced coma or general anesthesia). The tubing is established but not been used in the clinical setting of catheter ablation for AF (which is performed under general anesthesia). During application of ablation energy to the posterior left atrial wall, the tubing is cooled to medium-low levels (25 degrees) and this is controlled by the operator.
45403139|NCT03819946|Other|Standard esophageal temperature probe|If the participant is randomized to the control group, then a standard esophageal protection method will be used during their catheter ablation procedure. This comprises of an esophageal temperature probe, inserted whilst the patient is under general anesthesia. If during application of ablation treatment to the posterior left atrial wall causes the esophageal temperature to rise above 38 degrees the ablation treatment is halted in this region. If ablation treatment is incomplete, re-application can be applied again cautiously if temperatures fall back to 37 degrees. Further temperature rise of over 38 degrees at the same region is a contra-indication to further ablation work here.
45403140|NCT05623384|Procedure|Stellate ganglion block|A cross-sectional scan with a high-frequency line array probe reveals the pre-C6 transverse nodule or C7 transverse process, and the structures of the thyroid, carotid sheath, vertebral artery, inferior thyroid artery, trachea, and esophagus are identified by observation. The carotid sheath is pushed out as far as possible laterally, the needle is inserted in the paratracheal sulcus, and the tip of the needle is passed through the lateral border of the thyroid into the deep anterior fascial surface of the long cervical muscle.After backdrawing no blood, cerebrospinal fluid or gas, 5 ml of lidocaine was injected.（lidocaine 80mg；Physiological saline 1ml）
45403141|NCT05623384|Procedure|Facial and glossopharyngeal nerve blocks|The operator touches the position of the mastoid process and needles vertically at the front of the mastoid process directly below the external auditory canal. When the surface of the mastoid is touched, the needle is adjusted to pass through the front of the mastoid and then slowly needled for about 1 cm, and when the patient develops swelling and pain, 3 ml of the drug is injected. then the needle is slowly needled backward for about 1 cm, and when the patient develops swelling and pain, 2 ml of the drug is injected. （mecobalamin injection 1mg；lidocaine 20mg； dexamethasone 10mg ；Physiological saline 2ml）
45403142|NCT05623384|Drug|Mecobalamin Tablets|oral Mecobalamin Tablets tid-8
45698769|NCT02874144|Drug|AZ compound|40 mg three times daily po for 12 weeks
45698770|NCT02874144|Other|Collection of Biological Specimens|collection of biomarkers for analysis of nasal disease
45698771|NCT02874144|Drug|Intranasal corticosteroid|QD Nasal Spray
45403143|NCT00125190|Drug|rhIGF-1 (mecasermin) for a period of 86 weeks|Once a day rhIGF-1 injections
45403144|NCT03810820|Device|mobile Cardiac Arrhythmia Diagnostics Service (m-CARDS)|A wearable cardiac monitoring device is provided to patients pre- and post-TAVI. The monitor transmits cardiac data in real time to the m-CARDs team. Cardiac abnormalities are reported to the clinical team who then assess the abnormality and intervene as clinically necessary.
45510864|NCT02150174|Behavioral|Retrieval practice effect using word pairs and cued recall tests with feedback|"In the first phase (encoding), people study a list of 48 word pairs non semantically associated.~Then (initial test), they recall half of word pairs or restudy the other half.~In the second phase (final test) which takes place 2 days later, they recall all the 48 the word pairs."
45510865|NCT02156024|Drug|Gastrodia and Uncaria Drink|Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
45510866|NCT02150252|Drug|Bu-Yang-Huan-Wu Tang|control group,Recruited patients should be received the placebo-BYHWT 3.0 g TID every day for continuously 6 weeks except ordinary medical care; 2) treatment group, the method is identical control group
45698772|NCT02874144|Drug|Placebo|looks like AZ compound, made by same company, double blind. 40 mg three times daily po for 12 weeks
45698773|NCT03467178|Drug|Decitabine|Nucleic Acid Synthesis Inhibitor
45510867|NCT04883918|Biological|ASC930|4 intravenous doses of ASC930
45698774|NCT03467178|Drug|Carboplatin|Chemotherapy medication
45698775|NCT03467178|Drug|Pegylated Liposomal Doxorubicin|Chemotherapy medication
45698776|NCT03467178|Drug|Gemcitabine|Chemotherapy medication
45403145|NCT04786600|Device|Signatera ctDNA assay|Subjects will be tested with the Signatera ctDNA assay every 2 weeks.
45403146|NCT04786600|Drug|pre-specified sequence of FDA-approved drugs and drug combinations|Subjects will receive treatment with a pre-specified sequence of FDA-approved drugs and drug combinations
45403147|NCT03810664|Drug|Somatrogon|A single dose of 12 mg of somatrogon will be injected as one sc injection to the arm on each dosing day (Day 0 and Day 14).
45698777|NCT03467178|Drug|Paclitaxel|Chemotherapy medication
45698778|NCT03462108|Biological|Rotavirus (Bio Farma) Vaccine|Rotavirus (Bio Farma) Vaccine
45510868|NCT02152202|Other|Semi-upright position|In this group patients' bed will be set into 45 degree angle during sleep in the night time.
45510869|NCT02152202|Other|Supine position|Control: Supine position during nocturnal sleep for at least two postoperative nights.
45510870|NCT02152280|Drug|Danhong Injection|Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
45510871|NCT02152280|Drug|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
45510872|NCT02255084|Behavioral|Group 1 remove self sample kit at gp consulting room or perform pap smear|"Selected general practitioners are briefly informed about the study and they receive a package of kits for vaginal self-sampling.~Selected women receive a mail inviting them either to remove a kit for vaginal self-sampling at their general practitioner's consulting room or to perform a pap smear. When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
45510873|NCT02255084|Behavioral|Group 2 perform self sample at home or pap smear|"Selected general practitioners are briefly informed about the study. Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
45510874|NCT02150330|Drug|Dehydroepiandrosterone (DHEAS)|
45698779|NCT03462108|Other|Placebo|Placebo contains 30% sucrose in DMEM
45698780|NCT03467100|Drug|XEN901|Capsule filled with XEN901
45510875|NCT02255162|Drug|Lenalidomide|Patients will receive lenalidomide starting on day 6 of each post-remission cycle, following conclusion of cytarabine post-remission therapy on days 1-5. Following count recovery in the third post-remission cycle, patients will then receive lenalidomide daily as a maintenance therapy.
45510876|NCT02255162|Genetic|HLA-mismatched stem-cell Microtransplantation|Patient will receive HLA-mismatched stem cell microtransplant infusion on day 6 of each post-remission cycle, following conclusion of course of cytarabine in each cycle.
45698781|NCT03467100|Drug|Inert Ingredients Oral Product|Placebo capsule
45698782|NCT04722822|Behavioral|(Intervention) Recommending HPV vaccine for patients 9-10 years of age|Providers within intervention practices will receive training which includes both standardized communication strategies and strategies for switching from 11-12 years to 9-10 years including: challenges with 11-12 strategy, long-term immunity, success of other practices and tips to help standardize to age 9-10. Trainings will be a combination of online and in-person or virtual. Annual trainings will be offered and providers will receive Maintenance of Certification credits (MOC) for participating. Providers will routinely recommend HPV starting at age 9 for all patients -- which is already approved for this vaccine but is not routinely recommended at age 9 years.
45510877|NCT02255162|Drug|Cytarabine|Patients will receive cytarabine post-remission therapy for 3 cycles, on days 1-5 of each cycle.
45698783|NCT04722822|Behavioral|(Control) Recommending HPV vaccine for patients 11-12 years of age|Providers within control practices will receive a training on standardized communication for HPV vaccine including: using strong recommendations, using presumptive recommendation, providing specific phrases to use with parents, answering common questions and, HPV vaccine as a cancer prevention. Annual trainings will be offered and providers will receive professional development credit (MOC).
45698784|NCT05434182|Procedure|Intradermal Suture|Skin closure with an intradermal suture using Monosyn® (Braun®) 4/0 absorbable monofilament.
45403148|NCT03810586|Device|Non-invasive measurement of blood pressure|Comparing non-invasive measurement of blood pressure using the PPG-based BB-613 device to a blood pressure manomtry holter device (HUGECARE NIBP Monitor)
45403149|NCT00141726|Drug|Etanercept|Etanercept will be given on an open label, single arm basis to patients with non-infectious, sub-acute lung injury. 0.4 mg/kg/dose to a maximum of 25 mg, subcutaneously, twice weekly, for a total of 24 dosages.
45403150|NCT03967548|Drug|Germinal peptide eye drops|Germinal peptide eye drops of 0.004%
45698785|NCT05434182|Procedure|Metallic Staples|Skin closure with metallic stapling using Visistat® (Weck®) 35W skin stapler.
45715320|NCT04387474|Device|Brain-computer interface|brain-computer interface rehabilitation training.
45715321|NCT04387474|Other|Traditional rehabilitation|traditional rehabilitation training.
45510878|NCT02152436|Other|Simulation - based curriculum|Operating room medical and non-medical members will be asked to carry out a simulation session preceded by an educational maze with videos. Outcomes will be compared and correlated after and before this curriculum
45510879|NCT02152514|Drug|Intrathecal Morphine/Sufentanil|
45510880|NCT02152514|Device|PCA|
45510881|NCT02261090|Drug|Formulation B: Pramipexole Slow release (SR) tablet|
45510882|NCT02261090|Drug|Formulation C: Pramipexole Slow release tablet|
45510883|NCT02261090|Drug|Formulation D: Pramipexole Slow release tablet|
45510884|NCT02261090|Drug|Formulation E: Pramipexole Slow release tablet|
45510885|NCT02261090|Drug|Formulation F: Pramipexole Slow release tablet|
45510886|NCT02261090|Drug|Formulation G: Pramipexole Slow release tablet|
45510887|NCT02261090|Drug|Formulation H: Pramipexole Slow release tablet|
45510888|NCT02261090|Drug|Pramipexole immediate release (IR) tablets|
45698786|NCT02847078|Device|smart phone app|App for this study is provided with real time updating educational materials, reminder, and consultation for improving secondary prevention, and the related information is pushed to a patient in chronological order after his or her PCI operation.
45698787|NCT02847078|Device|A guideline booklet|A guideline booklet with general advice on secondary prevention of coronary artery disease.
45403151|NCT03819868|Procedure|High cost|Surfaces allocated to this group will be treated with a high-cost sealant (Fluroshield®, Dentsply, São Paulo, Brazil), according to the manufacturer's instructions.
45403152|NCT03819868|Procedure|Low Cost|Surfaces allocated to this group will be treated with a low-cost sealant (Prevent®, FGM Produtos Odontológicos, Santa Catarina, Brazil), according to the manufacturer's instructions.
45698788|NCT02835534|Drug|rhTNK-tPA|Dose:16mg; Mode of admin: Single bolus Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
45698789|NCT02835534|Drug|alteplase|Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
45698790|NCT02722200|Drug|hydrocortisone|Hydrocortisone will be used as the steroid of choice because it is bio-identical to cortisol and is subject to the same metabolism as cortisol.
45403153|NCT03815812|Drug|IBI306|Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
45698791|NCT02722200|Other|saline|Saline will be used as the placebo comparator. It will be administered in the same manner as the active drug.
45403154|NCT03815812|Drug|placebo|Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
45403155|NCT01301716|Drug|GDC-0980|Oral escalating dose
45510889|NCT03542396|Behavioral|ImPuls|Participants receive an supervised exercise intervention and behaviour change techniques for 4 weeks and, after that, they are encouraged to engage in physical activity for 8 weeks independently. During this 8-week individual phase, patients have weekly phone contacts with a psychotherapist
45510890|NCT02152592|Drug|PCM/Oxy1|Controlled Release oxycodone 10 mg orally twice a day for 24 hours
45510891|NCT02152592|Drug|PCM/Oxy2|CR oxycodone 10 mg orally twice a day for 48 hours
45510892|NCT02152748|Genetic|analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance|
45510893|NCT03543332|Diagnostic Test|Measures of physical activity and kinesiophobia|Groups will be compared regarding kinesiophobia with TSK heart.
45510894|NCT01307423|Drug|Apremilast 20mg|Apremilast 20mg twice daily, orally
45403156|NCT01301716|Drug|bevacizumab|Intravenous repeating dose
45403157|NCT01301716|Drug|carboplatin|Intravenous repeating dose
45403158|NCT01301716|Drug|cisplatin|intravenous repeating dose
45403159|NCT01301716|Drug|paclitaxel|Intravenous repeating dose
45403160|NCT01301716|Drug|pemetrexed|intravenous repeating dose
45510895|NCT01307423|Drug|Apremilast 30mg|Apremilast 30mg twice daily, orally
45510896|NCT01307423|Drug|Placebo|Placebo
45510897|NCT04849052|Behavioral|MASTERY|In MASTERY, participants will have interactive, two-way text message 'sessions' (5-10 minutes of two-way text communication with an automated text-message program) once weekly for 12 weeks. Furthermore, study trainers will conduct 4 brief calls with participants (Weeks 1, 4, 7, and 12) to introduce the program, assess progress, answer questions, and provide support.
45510898|NCT04849052|Behavioral|Attentional Control|Participants in the control condition will also receive text messages once per week. To ensure time matching, the program will have 4 phone check-ins (on physical activity) as in MASTERY.
45715322|NCT00368914|Drug|sirolimus|
45715323|NCT00368914|Other|laboratory biomarker analysis|
45851082|NCT00376818|Behavioral|mind-body intervention procedure|"Meditation practice in this study will consist of 15 minutes of body scan to completely relax the body from head to toe and will be followed by 15 minute silence during which the study participants will maintain awareness of their breath, bodily sensations and thoughts as they spontaneously arise. The remainder of the class will be devoted to a group discussion of personal reflections and challenges."
45851083|NCT00376818|Procedure|Measurement of stress-related hormones|Measurements of stress-related hormones: Stress hormones cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin will be measured in saliva because their levels in saliva accurately reflect blood levels (Carlson et al, 2004). The non-invasive saliva collection method by cotton swabs (Salivette® by Sardstedt Inc.) will be used in this study.
45851084|NCT00376896|Drug|GW876008 200mcg|GW876008
45715324|NCT00368914|Other|pharmacological study|
45510899|NCT03542318|Other|Pulmonary Rehabilitation|A multidisciplinary PR programme was delivered twice weekly for 12 weeks. Each class was of 2 hours in duration. The first hour had an exercise component. Inspiratory muscle training was carried out using the Respironics IMT Threshold trainer® during the class. Educational sessions covered various aspects of pulmonary fibrosis care and self-management delivered. Patients also received an individualized home exercise programme consisting of exercise similar to what was being carried out during the classes. Each participant was encouraged to perform at least 20 minutes of these exercises per day.
45510900|NCT03543254|Drug|BoNT-A|"90U BoNT-A, given in one treatment as 18 injections of 5u (0.2 ml) each, on specific preselected sites along the sutures of the skull.~First 100 U of Botox® is solved in 4 ml (cc) of isotone saline water (9 mg/ml), distributed in 4 syringes. This is half the usual concentration, allowing for better diffusion in order to reach the target structures."
45403161|NCT01075932|Dietary Supplement|DHA-rich fish oil|Either 1 g or 2 g DHA-rich fish oil taken daily for 12 weeks. Participants in the 1 g group will also consume 1 g olive oil placebo capsules per day to maintain double blind.
45510901|NCT02156336|Drug|Ranolazine|Oral administration, BID; for a maximum of 51 days.
45510902|NCT02156336|Drug|Placebo|Oral administration, BID; for a maximum of 51 days.
45510903|NCT03542240|Dietary Supplement|Curcumin|500 milligram daily supplement
45510904|NCT02778074|Behavioral|Internet cognitive behavioural therapy|A nine-week tailored I-CBT program for patients with CVD. The CBT program consists of the components of psychoeducation, relaxation, problem-solving and behavioural activation.
45510905|NCT02778074|Behavioral|Moderated Discussion Forum|Participants will be allocated to an internet moderated discussion forum during 9 weeks. Patients will discuss issues related to cardiovascular disease. A new topic will be discussed every week. After 9 weeks, those in the moderated discussion forum will be offered to perform the I-CBT program.
45851085|NCT00376896|Drug|GW876008 20mcg|GW876008 20mcg
45851086|NCT00376896|Other|Placebo|placebo
45510906|NCT00911183|Biological|filgrastim|Given subcutaneously
45403162|NCT01075932|Dietary Supplement|Placebo|2 g placebo (olive oil) taken daily for 12 weeks
45403163|NCT01303042|Drug|Insulin lispro mix 50/50|Insulin lispro mix 50/50 t.i.d : six months
45403164|NCT03810430|Behavioral|health promotion|health promotion on water, sanitation and hygiene and child feeding along with hygiene kits were delivered to the mothers in the intervention arm
45403165|NCT03810118|Diagnostic Test|fluid challenge|4 ml/kg fluid challenge infused over in either 10 or 20 minutes
45510907|NCT00911183|Biological|pegfilgrastim|Given subcutaneously
45510908|NCT00911183|Biological|rituximab|Given IV
45510909|NCT00911183|Drug|cyclophosphamide|Given IV
45510910|NCT00911183|Drug|liposome-encapsulated doxorubicin citrate|Given IV
45510911|NCT00911183|Drug|prednisone|Given orally
45698792|NCT04712994|Other|PrEP Optimization Interventions|There will be four strategies or bundles of strategies tested, one bundle in each of the four interrupted-time series evaluations. Three of the bundles of strategies will be determined based on the qualitative information gathered in Aim 1 by stakeholders and are unknown at this time. One bundle of strategies is pre-developed and includes 3 components: video-based PrEP counselling, HIV Self-Testing [HIVST] for women undergoing repeat HIV testing, and optimized PrEP delivery and prescription processes
45698793|NCT04066218|Other|Interviews|"Participation will serve as verbal consent.~Qualitative PRA will call participant to schedule either phone or in person interview. If via phone, the study PRA performing the interview, will remind them to find a private space to speak.~REDCap link will be sent for PROMIS SexFS Brief.~PRA will perform semistructured interview and guide Think-Aloud to complete the PROMIS SexFS Brief.~Participants will not submit responses to PROMIS SexFS Brief responses after completing the tool."
45715325|NCT00368914|Procedure|biopsy|
45510912|NCT00911183|Drug|vincristine sulfate|Given IV
45510913|NCT05414435|Behavioral|Reading of informed consent form|Patients that adequately read informed consent forms
45510914|NCT05056805|Other|Aerobic Exercise|Receive aerobic exercise encouragement
45510915|NCT05056805|Other|Dietary Intervention|Consume high protein snack/meal/shake
45510916|NCT05056805|Other|Nutritional Intervention|Receive nutritional consultation and guidelines
45510917|NCT05056805|Other|Quality-of-Life Assessment|Ancillary studies
45510918|NCT05056805|Other|Questionnaire Administration|Ancillary studies
45510919|NCT05056805|Other|Resistance Training|Complete strengthening exercise
45510920|NCT03631121|Drug|Basalin to Lantus|continuous glucose monitoring system will used twice when patients are using Basalin and Lantus respectively to assess glycemic variation.
45510921|NCT01568489|Drug|HL-009 Liposomal Gel|a semi-transparent red-color gel and is supplied as a laminated tube
45510922|NCT03392519|Other|Chronic stroke|MRI data acquisition and behavioral test
45851087|NCT00376974|Behavioral|American Academy of Ophthalmology Glaucoma Educational Tape|
45851088|NCT00377052|Drug|bortezomib|1.0 mg/m2 IV; injection bolus (3-5 sec) Twice weekly x 2 weeks every three weeks
45851089|NCT00377052|Drug|gemcitabine hydrochloride|1000 mg/m2 IV; injection 30 minute infusion Once weekly x 2 weeks every three weeks
45403166|NCT01300312|Drug|Eperisone hydrochloride and Diclofenac sodium|Fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given 3 times a day after meals for 7 to 10 days
45403167|NCT01300312|Drug|Eperisone hydrochloride|eperisone hydrochloride 50 mg as tablet formulation to be given 3 times daily after meals for 7 to 10 days
45403168|NCT01567384|Drug|OSI-906 and Pemetrexed|"Pemetrexed will be administered intravenously on day 1 of cycle 1 at a dose of 500 mg/m2 as a 10-minute infusion. Subsequent doses will be defined by tolerability.~OSI-906 will be administered orally twice daily (12 hours apart) at approximately the same times each day on a continuous schedule, beginning on Day 0 of cycle 1."
45403169|NCT00111228|Device|Guardian RT|
45403170|NCT00111228|Device|SMBG only|SMBG only
45403171|NCT04742842|Biological|COVIGEN C19 0.8 mg ID or Placebo ID|2 doses of COVIGEN C19 0.8 mg ID or Placebo ID will be given at Day 1 and Day 29.
45403172|NCT04742842|Biological|COVIGEN C19 2.0 mg IM or Placebo IM|2 doses of COVIGEN C19 2.0 mg IM or Placebo IM will be given at Day 1 and Day 29.
45403173|NCT04742842|Biological|COVIGEN C19 4.0 mg IM or Placebo IM|2 doses of COVIGEN C19 4.0 mg IM or Placebo IM will be given at Day 1 and Day 29.
45403174|NCT04742842|Biological|COVIGEN C20 1.0mg vaccine ID|COVIGEN C20 1.0mg ID vaccine will be given at Day 1
45403175|NCT01080612|Drug|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 400 to 500 calorie meal
45403176|NCT01080612|Drug|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 600 to 750 calorie meal
45403177|NCT01080612|Drug|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following an 800 to 1000 calorie meal
45403178|NCT01080612|Drug|300 mg pregabalin immediate release|A single dose of 300 mg immediate release capsule will be administered in the fasted state
45403179|NCT03810274|Device|3DV+TPS；VARIAN TPS；FonicsPlan|
45403180|NCT03810040|Device|140 microns denuding pipette|the degranulated needle size was 140 microns
45403181|NCT03810040|Device|150 microns denuding pipette|the degranulated needle size was 150 microns
45403182|NCT01301794|Dietary Supplement|Omega 3 fatty acid (Lovaza)|Lovaza is an FDA approved omega 3 fatty acid taken as 4 grams a day (two one gram formulations twice a day).
45403183|NCT03815344|Drug|Standard|20 units diluted in 100mL of Normal Saline injected laparoscopic needle
45403184|NCT03815344|Drug|Standard-vaginal misoprostol|20 units diluted in 100mL of Normal Saline injected laparoscopic needle and misoprostol 400 mcg
45403185|NCT03819790|Drug|Basal insulin glargine and lixisenatide|Soliqua (insulin glargine and lixisenatide): a titratable combination of long-acting basal insulin glargine and lixisenatide (Glucagon-like peptide-1 receptor agonist)
45403186|NCT03819790|Drug|Basal insulin Basaglar/Lantus + gliclazide MR|basal long-acting insulin Basaglar/Lantus with gliclazide MR 60 mg OD
45403187|NCT03819790|Drug|Metformin|Patients can be administered with most tolerant dose of metformin
45510923|NCT02768792|Drug|pembrolizumab,|Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2 years of maintenance therapy (i.e., beginning on day 1 of maintenance).
45698794|NCT04703322|Drug|Pexidartinib|400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)
45403188|NCT01301872|Other|check biomarker :RAGE|We will check RAGE for all patients who have ARDS included in our study
45403189|NCT01560364|Other|renal replacement therapy|Prospective observational clinical multicentric study in ICU with acute renal failure requiring renal replacement therapy.
45403190|NCT01560442|Drug|Buprenorphine and Methadone Hydrochloride|To study the relation between pupillary diameter measured under scotopic conditions, and the pain thresholds measured at the time of peak and residual effect of methadone / buprenorphine in opiate-dependent patients following a substitution program.
45403191|NCT03819712|Procedure|Collection of blood samples|23 mL of blood will be collected during the inclusion visit
45403192|NCT03819712|Other|Collection of fecal samples|Fecal sample self-collected after the inclusion visit
45403193|NCT03819712|Other|Collection of urine samples|10 mL of urine will be collected during the inclusion visit
45403194|NCT03819712|Other|Collection of vaginal swaps|Sample of vaginal microbiota collected during the inclusion visit
45403195|NCT05623150|Diagnostic Test|Liver biopsy|Liver biopsy planned as part of routine care. Clinical-biological characterisation with bio collections.
45403196|NCT03807934|Other|Stimulation via Soterix Medical or Neuroelectrics noninvasive brain stimulation systems|Active (at or below 2mA) versus sham (at or below 0.5mA) stimulation targeting brain regions engaged during verbal and/or spatial perceptual and cognitive processing. Brain stimulation devices are not currently regulated by the United States Food and Drug Administration. Local IRB has determined the devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
45403197|NCT01300468|Drug|PHA-848125AC|
45403198|NCT01303120|Drug|Femoral Nerve Block|Preoperative Bupivacaine 0.5%, perineurally as single shot
45403199|NCT01303120|Drug|Combined nerve blocks|Preoperative Bupivacaine 0.5%, perineurally as single shot
45403200|NCT01303120|Drug|Patient-controlled analgesia|Patient controlled analgesia with morphine
45403201|NCT00110994|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg, 2 tablets (200 mg each) po (per os) bid (twice daily) Study days 1-21
45403202|NCT00110994|Drug|Placebo|Placebo, 2 tablets, po (per os) bid (twice daily) Study days 1-21
45403203|NCT00110994|Drug|Dacarbazine|Dacarbazine, 1000 mg/m^2 intravenous on Study Day 1
45403204|NCT01078194|Device|Secondary Bypass Banding (adjustable A.M.I. Soft Gastric Band)|Secondary Placement of the A.M.I. Soft Gastric Band for laparoscopic bypass banding
45403205|NCT04435990|Biological|10,000 MM09|Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 10,000 UT / mL
45698795|NCT04453176|Other|Patient Satisfaction|Patient satisfaction evaluated with EVAN G questionnaire
45851090|NCT00377130|Other|Self Administered Stress Management|"The SSMT kit includes a DVD and booklet will discuss the sources and manifestations of stress during chemotherapy and the potential benefits of stress management training. The videotape/DVD and booklet will also include brief instruction in paced breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements as well as recommendations for practicing the techniques before the start of chemotherapy and using them after the start of treatment. The exercise combines abbreviated progressive muscle relaxation training with use of relaxing mental imagery. The positive thinking exercise provides participants with brief instruction in the use of coping self-statements using techniques borrowed from stress inoculation training."
45403206|NCT04435990|Biological|30,000 MM09|Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae). The concentration is 30,000 UT / mL
45403207|NCT04435990|Biological|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients.
45403208|NCT01560052|Drug|methylprednisolone|"Original Cohort:~Oral methylprednisolone or placebo 0.8mg/kg/day with a maximum of 48mg/day x 2months, taper by 8mg/day every month, patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines~Low Dose Cohort:~Oral methylprednisolone or placebo 0.4mg/kg/day with a maximum 32mg/day and minimum of 24mg/day then reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy."
45403209|NCT01560052|Drug|Placebo|"Intervention: Drug: Placebo~Original Cohort:~Matching placebo tablets, all the patients will receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Low Dose cohort:~Matching placebo will be given reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy"
45403210|NCT01560130|Behavioral|Shape Up Rhode Island + Online weight loss program|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention and an Internet-based behavioral weight loss program.
45698796|NCT01094548|Biological|Tecemotide (L-BLP25)|After receiving single low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
45698797|NCT01094548|Biological|Tecemotide (L-BLP25)|After receiving multiple low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 mcg of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
45851091|NCT00377208|Behavioral|Web-Based Intervention|"My Expert Doctor is a web-based program that helps patients to ask the right questions regarding specific tests and treatments during their doctor visits. Upon entering medication and treatment information into the web site, patients are provided with individualized feedback and recommended questions to ask their doctor."
45851092|NCT00377286|Dietary Supplement|Glucosamine (a dietary supplement)|1500 mg in 16 oz lite lemonade, once per day for 6 months
45851093|NCT00377286|Other|16 oz lite lemonade|16 oz lite lemonade 1 time daily for 6 months
45851094|NCT00377442|Drug|GK Activator (2)|100mg po
45851095|NCT00377442|Drug|Simvastatin|80mg po
45851096|NCT00377598|Drug|TAK-583|TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks
45851097|NCT00377598|Drug|TAK-583|TAK-583 25 mg, tablets, orally, once daily for up to 8 weeks
45851098|NCT00377598|Drug|TAK-583|TAK-583 50 mg, tablets, orally, once daily for up to 8 weeks
45851099|NCT00377598|Drug|TAK-583|TAK-583 100 mg, tablets, orally, once daily for up to 8 weeks
45851100|NCT00377598|Drug|Placebo|TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks
45851101|NCT00377910|Drug|Aethoxysclerol|2 ml Aethoxysclerol 10 mg/ml 2 ml. lidocaine 10mg/ml
45510924|NCT05023226|Procedure|RM|RM refers to that under FiO2=100% oxygen concentration and fixed inspiratory pressure (15cmH2O), the PEEP starts from 10 cmH2O and increases at a pressure of 5 cmH2O every minute until the Peak inspiratory Pressure(PIP) reaches 55cmH2O, and the level was fixed to 40 seconds in each increment. Then, the ventilator was transferred to PEEP-titration phase, the PEEP was adjusted to 25 cm H2O, and it was reduced by increments of 5 cm H2O each time. The each increment was fixed to 5 minutes till the end-maneuver PEEP.
45510925|NCT05023226|Procedure|LPVS|LPVS was used by the pressure-controlled mode and the PEEP was titrated by the level of FiO2 to keep the saturation of oxygen (SaO2) more than 90%. The level of pressure control was adjusted to maintain low tidal volume (6-8 mL/kg predicted body weight [PBW]) strategy. The respiratory rate and tidal volume were setting to avoid unstable hemodynamic data and adjusted by blood gas data and lung mechanics.
45510926|NCT01568567|Dietary Supplement|Lactobacillus Reuteri DSM 17938|One stick pack in the morning and one stick pack afternoon/evening for 28 days.
46057199|NCT02777541|Dietary Supplement|Resumption of feeding 8 hours after PEG placement|The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
45510927|NCT05420753|Procedure|Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation|During a TIPS procedure, the interventional radiologist, with the help of x-ray and ultrasound guidance, makes a channel through the liver to connect the portal vein (the vein that carries blood from the digestive organs to the liver) to one of the hepatic vein (three veins that carry blood away from the liver back to the heart) using a special type of needle. The interventional radiologist then replaces the needle with a wire and catheter, and a small tubular device called a stent graft is placed in this channel to keep the pathway open between the two blood vessels.
45510928|NCT03542162|Biological|Healaflow|For the RRD patients, after 27G PPV, air-liquid exchange and endolaser photocoagulation around the tear(s), Healaflow is going to be fully covered on the surface of all retinal tears using 27G needle, the amount of Healaflow injection was determined according to the size of tears.
45510929|NCT05420597|Drug|Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w. Then a total dose of 70Gy in 35 fractions was administered, with concurrently weekly cisplatin (30mg/m2 qw).~At 3-6 weeks post-radiotherapy, maintenance Toripalimab was administered for 8 cycles (240mg d1 q3w, in total 8 cycles)."
46057200|NCT02777619|Drug|0.0ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.0ng/ml
45403211|NCT01560130|Behavioral|Shape Up Rhode Island + Online weight loss program + Groups|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and the option to attend group sessions.
45403212|NCT01560130|Behavioral|Shape Up Rhode Island + Online weight loss + Incentives|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and monetary incentives for submitting self-monitoring information and for achieving clinically significant weight loss.
45510930|NCT02775344|Device|Three dimension laparoscopy|Surgery will be performed either with three dimension laparoscopy or two dimension laparoscopy.
45510931|NCT05420441|Device|Phonophoresis with chitosan|Patients in this group will receive chitosan through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program
45510932|NCT05420441|Device|Phonophoresis with glucoasmine|Patients in this group will receive glucosamine through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program.
45510933|NCT05420441|Procedure|Conventional Physical Therapy|Patients in the control group will receive the conventional treatment for knee osteoarthritis only, which will include the application of TENS, pulsed ultrasound, infrared light and exercise.
45510934|NCT05598593|Drug|cytarabine+thiotepa+ fludarabine + busulfan|cytarabine+thiotepa+ fludarabine + busulfan intravenous injection
45403213|NCT05515588|Drug|BI 690517 (C-14)|BI 690517 (C-14)
45510935|NCT01569269|Behavioral|Yoga Intervention|"The yoga intervention will take place for one hour per week for six weeks. All sessions will be guided by a Registered Yoga Teacher (RYT) who is also a Licensed Clinical Social Worker (LCSW).~Each yoga session will follow a similar protocol. The introductory period (10 minutes) will focus participants on increasing interoceptive and proprioceptive capacity. The main segment is comprised of a series of yoga postures that progress from lying or seated postures that provide gentle muscle stretching to standing stretches that increase balance and flexibility. The postures will be introduced, practiced, and combined with breathing exercises for forty minutes.~The conclusion of the session will be comprised of 10 minutes of relaxation."
45698798|NCT01094548|Drug|Single low dose cyclophosphamide|An intravenous (IV) infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
45698799|NCT01094548|Drug|Multiple low dose cyclophosphamide|An IV infusion of 300 mg/m^2 (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment plus an intravenous dose of cyclophosphamide (300 mg/m^2, to a maximum of 600 mg) 3 days prior to the tecemotide (LBLP25) administration at week 5 of the weekly treatment phase and 3 days prior to every tecemotide (L-BLP25) administration during the treatment phase with 6-Weekly administration of tecemotide (L-BLP25), commencing at Week 14 up to a maximum treatment period of 2 years.
46057201|NCT02777619|Drug|0.4ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.4ng/ml
45403214|NCT05515588|Drug|BI 690517|BI 690517
45403215|NCT05098132|Drug|STK-012|pegylated alpha/beta-biased engineered interleukin-2
45403216|NCT05098132|Drug|Pembrolizumab|anti-PD-1 humanized monoclonal antibody
45510936|NCT01569269|Behavioral|Meditation Intervention|The meditation intervention will be conducted weekly for weeks. Each class will follow a similar protocol: During the one-hour meeting, participants will focus on developing attention to the breath. In a supine or seated position and with eyes closed, participants will be guided to attend solely to their breathing. As physical sensations, thoughts, and emotions begin to arise, participants will be taught to recognize, acknowledge, and accept the presence of the sensations or emotions and then to step back, release the thought or sensation, and refocus attention toward the breath At the conclusion of each meeting, the meditation instructor will encourage participants to voluntarily engage in daily meditation practices.
45510937|NCT01569269|Behavioral|Reiki|The Reiki intervention will be conducted for one hour per week for 6 weeks. Protocol for each session: Briefly meet with the Reiki practitioner to review experiences with symptoms of CIPN. Then, the participant will be directed to lie supine and fully clothed on a massage table. Beginning at the top of the head, the practitioner will move inferiorly and pause while holding their hands above, but facing the participant at each energy point until reaching the feet. Upon reaching the participant's feet, the participant will roll from the supine position to a prone position and the process repeated. After being guided to a seated position on the massage table, the practitioner will spend a few moments in conversation with the participation before ending the session.
45510938|NCT01569269|Other|Holistic Education|The psychoeducational intervention will be presented in a traditional classroom format with weekly one hour meetings taking place during the six week study period. Each class meeting will address specific aspects of CIPN. Participants will be presented with content related to basic neuroanatomy, physiology, the effects of chemotherapy on peripheral nervous system, how available allopathic treatments (pharmacological/psychopharmacological) can be helpful, and psychosocial issues related to CIPN. The final week of the psychoeducational group will include the identification of complementary interventions that may be of help to people living with CIPN.
45510939|NCT02777918|Behavioral|Recipe provision|6 recipes will be provided every 2 weeks by post for 12 weeks
45403217|NCT04356352|Drug|Lidocaine|1 mg/kg lidocaine to a max of 100 mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
45403218|NCT04356352|Drug|Esmolol|0.5 mg/kg esmolol to a max of 50mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
45403219|NCT04356352|Other|Placebo|saline water administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
45510940|NCT05337449|Other|silver diamine fluoride|silver diamine fluoride is a colorless with high PH topical fluoride solution of 38% weight/volume use for arresting early childhood caries
45510941|NCT05337449|Other|conventional composite resin restoration|Dental composite resins are dental cement made of synthetic resins which were insoluble, of good tooth-like appearance, insensitive to dehydration, and easy to manipulate.
45510942|NCT02156414|Procedure|Radical Prostatectomy|Radical Prostatectomy
45510943|NCT02156414|Procedure|Extended Lymphadenectomy|Extended Lymphadenectomy
45510944|NCT05292443|Other|Observation|observe the association of ctDNA with efficacy of treatment
45510945|NCT02150720|Drug|Tranexamic Acid|1g intra-articular before closing the wound surgery
45698800|NCT01094704|Drug|sodium chloride (7%)|4mL nebulized 7% sodium chloride
45698801|NCT02611830|Drug|Vedolizumab 300 mg IV|Vedolizumab intravenous infusion
45698802|NCT02611830|Drug|Placebo IV|Vedolizumab intravenous infusion placebo
45698803|NCT02611830|Drug|Vedolizumab 108 mg SC|Vedolizumab subcutaneous injection
45698804|NCT02611830|Drug|Placebo SC|Vedolizumab subcutaneous injection placebo
45715326|NCT04357990|Device|Viruxal Oral and Nasal Spray|Viruxal Oral and Nasal Spray is a Class I CE marked medical device manufactured by Kerecis hf. The Device contains Omega3 Viruxide. The main components in Omega3 Viruxide are Neem oil and St. John's Wort oil. The Device is administered from a pressurized canister into the oral and nasal cavity, where it creates a physical barrier for temporary protection of the mucosal tissue.
45403220|NCT01303198|Device|APAP - Therapy|automatic positive pressure therapy
45403221|NCT01303354|Procedure|Lumbar Transforaminal Epidural Steroid Injection|
45403222|NCT03804970|Behavioral|cash rewards for the fellow up|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
45403223|NCT03804970|Behavioral|Showing retinal photos to participants|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
45403224|NCT03804970|Behavioral|SMS reminders for participants and their family|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
45403225|NCT03804970|Behavioral|Watching brief video and basic explanation for disease|This basic explanation will be offered by professional doctors or nurses.
45403226|NCT03804970|Behavioral|Having the Diabetic Club|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
45715327|NCT04357990|Other|Placebo|The placebo will be a similar spray containing saline only.
45715328|NCT01567085|Drug|Eculizumab|
45715329|NCT04344184|Drug|L-ascorbic acid|50 mg/kg intravenous vitamin C infusion every 6 hours for up to 96 hours
45403227|NCT05622994|Drug|Rimonabant|Rimonabant 5mg per day is administered for 90 days. The comparator is placebo for the same duration.
45510946|NCT02150720|Drug|Fibrin glue|5mL intra-articular before closing the wound surgery
45510947|NCT02150720|Procedure|Electrocauterization|Coagulation blood from vessels by means of a electrocautery.
45715330|NCT04344184|Other|Placebo|Dextrose 5% Water
45851102|NCT00377988|Drug|Transdermal Contraceptive System|In each 4-week period, exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
45403228|NCT01303432|Dietary Supplement|Yogurt supplemented with Mobilee|One yogurt (125mL) per day including 80mg of Mobilee
45403229|NCT01303432|Dietary Supplement|Yogurt|One yogurt (125mL) per day
45403230|NCT05622916|Drug|Topical Ethanol Extract (Piper crocatum)|Topical ethanol extract of red betel leaves (Piper crocatum) 30% with the details of formulation on detailed description section
45403231|NCT05622916|Drug|Trichloroacetic Acid Topical|Trichloroacetic acid topical 90%
45403232|NCT05467150|Dietary Supplement|Probiotic Supplement|The probiotic that will be used is Culturelle® Digestive Daily Probiotic Capsules. Each capsule contains 10 billion CFU of Lactobacillus rhamnosus GG (LGG).
45403233|NCT03815032|Device|Drift assessment of OptoWire Deux FFR wire (1)|Simultaneous data of two different OptoWire DeuxTM guidewires (group 1) to assess a single coronary stenosis and detect any difference if any.
45403234|NCT03815032|Device|Drift assessment of OptoWire Deux FFR wire (2)|Simultaneous data of one Optowire Deux TM guide wires and one VERRATA-TM FFR wire (group 2) to assess a single coronary stenosis and detect any difference if any.
45403235|NCT04285606|Behavioral|Patient-led rehab with short immobilization|Short immobilization followed by patient-led shoulder rehab
45403236|NCT03819556|Other|Milk protein in fresh milk|Milk protein in increasing doses.
45403237|NCT03804034|Device|Block of resin|
45403238|NCT03804034|Device|Buccal tube, Bracket and 0.0017 × 0.025 in titanium molybdenum alloy wire|
45403239|NCT03819244|Device|940 nm Gallium Aluminum Arsenide Diode Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with diode laser for placing the healing abutment.
45403240|NCT03819244|Device|2780 nm Er,Cr:YSGG Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
45403241|NCT01303588|Behavioral|Yoga|24 group training sessions Yoga, 2 training sessions per week, 45 min duration , over 3 months
45403242|NCT01303588|Behavioral|Qigong|12 group training sessions Qigong, 1 training per week, 90 min duration , over 3 months
45403243|NCT04965142|Behavioral|Exercise Training|The intervention group will be asked to complete aerobic exercises 3 to 5 times per week (≥ 150 minutes of at least moderate aerobic intensity) and resistance training at least twice a week over a 12-week period.
45403244|NCT02855554|Other|Cardiac Magnetic Resonance (CMR) imaging techniques|Evaluation of clinical potential of fast quantitative myocardial tissue characterization using recently emerged CMRI techniques to aid the diagnosis, treatment, and follow up of patients with myocardial diseases.
45403245|NCT05417932|Biological|SCG101|Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.
45403246|NCT01303666|Procedure|Intra-articular CSI|After full aseptic preparation, 40 mg triamcinolone acetonide and 2 ml 1% lignocaine were injected into the joint cavity using the medial patello-femoral approach via a 21-gauge needle.
45403247|NCT01303666|Procedure|TI of the knee|"This was done as a day case procedure under local anaesthetic. The medial patello-femoral approach was used. After full aseptic preparation, the skin and soft tissues were infiltrated with 5e10 ml of 1% lignocaine. The joint was then instilled with a further 10 ml of 1% lignocaine.~After an initial puncture using a scalpel, a 3.2 mm diameter wrist arthroscope was advanced into the joint cavity. Up to 1 l of 0.9% normal saline was then irrigated through the joint: saline was run into the joint until fully distended and then allowed to flow out of the joint in a cyclical method until the aspirated fluid runs clear for at least three successive cycles."
45403248|NCT03819166|Device|with deep touch pressure application|The deep touch pressure is applied by the weight loading devices, including but not limited to, weight blanket and weight vest.
45403249|NCT03819166|Device|without deep touch pressure application|The deep touch pressure will not be applied.
45403250|NCT01304446|Dietary Supplement|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
45403251|NCT03801460|Other|Remotely administered physiological reconditioning program|Patients assigned to intervention arm will be provided a personalized, tailored and graduated exercise program to improve physical strength and conditioning.
45403252|NCT04246762|Drug|Olokizumab|Sterile solution for subcutaneous (SC) injection, 128 mg (0.8 mL injection)
45403253|NCT04246762|Drug|Omeprazole|Tablets, 20 mg, oral
45403254|NCT04246762|Drug|Caffeine|Tablets, 100 mg, oral
45403255|NCT04246762|Drug|Warfarin+ Vitamin K|Warfarin -Tablets 10 mg, oral. Vitamin K - solution for intravenous injection, 10 mg/mL ampoule
45403256|NCT04246762|Drug|Midazolam|Syrup, 2 mg/mL, oral
45715331|NCT04337944|Procedure|Boston keratoprosthesis type 1 and anterior hyaloid membrane peeling assisted by endoscopy|Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.
45851103|NCT00377988|Drug|Norgestimate-containing oral contraceptives with EE|NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days, then no pill or a drug-free pill 7 days.
45403257|NCT03796624|Device|Micropure 1.2.3.|"Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per patient will be implanted"
45403258|NCT03796624|Device|PODEYE|"Implantation of intraocular lens (IOL). Name: PODEYE It is a monofocal intraocular lens consisting of hydrophobic acrylic material. The IOL will be implanted in the contralateral eye of the same patient already implanted with Micropure 1.2.3."
45403259|NCT03799978|Drug|ACT-541468|ACT-541468 50 mg film-coated tablets
45403260|NCT03799510|Biological|Sm14|Three 0.5 mL intra-muscular injections of the vaccine solution (50μg Sm14) will be administered on D0, W4, W8 (D = day, W = week).
45851104|NCT00378066|Drug|Bevacizumab|Bevacizumab, Capecitabine, Oxaliplatin
45403261|NCT03799510|Drug|GLA-SE solution|The lot concentration 10μg/mL for injection of 2.5μg GLA-SE/injection.
45403262|NCT03799120|Drug|Tamsulosin BID|comparison of once daily versus twice daily tamsulosin
45403263|NCT03799120|Other|Placebo|Placebo
45403264|NCT03796312|Behavioral|Tub Bathing|The infant's face was washed and dried while still wrapped before being immersed. The water level in the tub was set at approximately 9-12 cm or deep enough to cover the baby's shoulders. A folded cloth towel was placed into the tub before bathing. The temperature of the bath water was controlled using a special water thermometer and adjusted to 37-38°C. The infant was held securely; the head and neck were supported on the researcher's forearm, and the shoulder was grasped using the researcher's thumb and finger. Cleaning was performed using a soft cloth and baby skin cleaner. The front and back areas were cleaned without turning the infant. The newborn was safely removed from the water and wrapped in a clean towel.
45403265|NCT03796312|Behavioral|Sponge Bathing|Sponge bathing is routine care of the clinic
45403266|NCT03792724|Drug|Urelumab + Nivolumab|Treatment with intratumoral urelumab after which Nivolumab will be given.
45403267|NCT03792646|Dietary Supplement|Whey protein|Exercise training + 20g whey protein
45403268|NCT03792646|Other|Exercise training|Strength exercise
45403269|NCT00499330|Procedure|lobectomy|
45403270|NCT00499330|Procedure|segmentectomy or wedge resection|
45403271|NCT00144170|Drug|Tipranavir (with low dose ritonavir)|
45403272|NCT00144170|Drug|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
45403273|NCT03799042|Device|Virtual Reality|Subjects will wear a 3D glass and watch 3D pictures (or video) of landscapes or tourist sites in Hong Kong.
45403274|NCT03799042|Behavioral|Inter-generation interaction|Secondary school student will play games and chats with secondary school students. Games involve identifying famous landscapes or tourist sites in Hong Kong
45403275|NCT03798886|Other|natural cycle|When follicle is ready for ovulation, we will use this injection by intra-dermal route
45403276|NCT03798886|Other|modified natural cycle|we will use that drug in the natural modified transfer group after embryo transfer
45403277|NCT03798886|Other|embryo transfer|we will do transfer when the endometrium is ready
45403278|NCT03798808|Other|Consumption of fruits, vegetables and dairy products|Family Nutriathlon was an eight-week, family-based nutrition program where children and their parents were encouraged to reach individual and team goals with respect to the quantity and variety of fruit, vegetable and dairy product consumption.
45403279|NCT03798730|Behavioral|Solid Model|"Cake and biscuit will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods of rating drying and discrimination tests which is the stronger in drying)"
45403280|NCT03798730|Behavioral|Liquid Model|"Intervention Description: To study the effect of protein denaturation on perception of whey protein beverages using sensory methods (rating drying as well as discrimination tests which is the stronger in drying). Measuring mucoadhesion via protein content remaining in saliva following swallowing of whey protein beverages."
45510948|NCT04835714|Drug|BI 1701963|BI 1701963
46057202|NCT02777619|Drug|0.6ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.6ng/ml
45403281|NCT03798652|Device|Research CMR scan|CMR scanning at a 3Tesla scanner at King's College London
45403282|NCT03798652|Device|Research 3D transthoracic echocardiogram|The scan is required to assess left ventricular systolic function
45403283|NCT03798652|Other|6-minute walk test|Sub maximal exercise that provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.
45510949|NCT04835714|Drug|BI 3011441|BI 3011441
45510950|NCT05234957|Procedure|Bilateral Lateral Rectus Recession|Symmetric bilateral lateral rectus muscle recession involves equal recession of both lateral rectus muscles. Asymmetric bilateral lateral rectus muscle recession involves recession of the lateral rectus muscle by 2mm more in the non-dominant eye.
45510951|NCT02150798|Other|High fat and low carbohydrate diet|high fat and low carbohydrate diet. At baseline and at 2 month of following, the variables that were evaluated,
45851105|NCT00378144|Drug|Pseudoephedrine/Paracetamol|Fixed oral tablet doses, 2 tablets 3 times a day for 5 days with at least 4 hours between each treatment (morning-noon-evening) and last dose not later than 2 hours before bedtime [Paracetamol (500 mg) and Pseudoephedrine (30 mg)]
46057203|NCT02777619|Drug|0.8ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.8ng/ml
45403284|NCT03796390|Biological|CD123 CAR-T cells|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CD123 CAR-T cells will be infused.
45403285|NCT03796234|Other|Dietary and physiotherapy|3 group talks were carried out, in a period of 3 months, in which different topics related to healthy eating were treated. In addition, a 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
45403286|NCT03796234|Other|Physiotherapy|A 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
45403287|NCT04186468|Other|ICU follow-up clinic|The intervention aims at improving health-related quality of life and will contain three components: information, consultation and networking. More information will be available for the participants from the intensive care stay onwards, e.g. an information brochure, and during the entire follow-up period, e.g. by contacting the outpatient clinic via telephone. Participants will be invited to visit the ICU follow-up clinic at least once during the first six months after discharge from ICU. During the visits, participants will be screened for symptoms of PICS and, if required, referred to specialists for further treatment. The aim of the networking part is to improve the exchange between the health sectors and disciplines, e.g. through a special referral letter from the ICU follow-up clinic, and thus to provide a network of outpatient care providers for the former ICU patients.
45403288|NCT03798496|Procedure|Open reduction and internal fixation|Open reduction of the Galeazzi fracture dislocation with a plate.
46057204|NCT02777619|Drug|Propofol|
45403289|NCT03798340|Other|Vibratory perturbed task-specific movement training|The perturbation-based pinch task training was conducted with the affected hand placed on the pinch device. The horizontal vibratory perturbation was generated for a total of 20 minutes by two recoil-type actuators with a frequency of 30 Hz and an amplitude of 2 mm, and intermittent exposure (10 s per 30 s). Each training session was divided into eight cycles with a training interval of 2 min per 2.5 min.
45510952|NCT02150798|Other|Control diet|Control diet. At baseline and at 2 month of following, the variables that were evaluated,
45510953|NCT02153060|Drug|Dexamethasone|Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days
45510954|NCT02153060|Drug|Dexamethasone|Dexamethasone was given at a dose of 20 mg,daily for 4 consecutive days
45510955|NCT02153138|Device|Endo-pat 2000|"The endo peripheral arterial tonometry (PAT) provides an index of endothelial function in two forms:~The reactive hyperemia index (RHI) is the post-to-preocclusion PAT signal ratio in the occluded side, normalized to the control side and further corrected for baseline vascular tone.~The logarithm RHI (LnRHI) is s similar index as RHI after natural log transformation with a matched cutoff. LnRHI provides better double-sided distribution than RHI and one that is closer to normal distribution"
45510956|NCT02153138|Device|carotid intima media thickness Ultrasound|cIMT is the distance between the intimal-luminal interface and the medial-adventitial interface. It will be studied by B-mode ultrasonography of the extracranial carotid arteries. A duplex system with a 7-10 megahertz (MHz) linear array multi-frequency transducer will be used.
45510957|NCT02153138|Device|Dexa- Bone densitometer & Bone ultrasonometer System|A means of measuring bone mineral density and body composition by a dual energy X-ray absorptiometry (DEXA) machine
45510958|NCT03542864|Dietary Supplement|Nasogastroduodenal Protocol|Complete nutrition (carbohydrates, lipids, proteins, vitamins, oligoelements)
45510959|NCT03542864|Other|Control|Progress registration of body composition values
45510960|NCT03542864|Other|Data analysis|Statistical analysis of all data
45510961|NCT01383239|Other|Immediate Postoperative Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The Immediate group will began physical therapy 3-7 days postoperatively.
45510962|NCT01383239|Other|Delayed Physical Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The delayed group will began physical therapy 6 weeks postoperatively
45403290|NCT03798340|Other|Traditional task-oriented facilitation|Reach-to-grasp training and hand release training
45510963|NCT02156570|Drug|Sofosbuvir and ribavirin|Sofosbuvir 400mg daily plus weight-based dosing ribavirin (1000mg <75kg, 1200mg >/= 75 kg) Treatment will be for 6 weeks in all participants.
45510964|NCT05208749|Device|Rotablation of shockwave|Patients will be randomized to treatment with rotablation or shockwave
45698805|NCT03461874|Behavioral|Education of patients|"During withdrawal treatment, patients are given recommendations on the approach to the use of drugs for acute treatment of migraine headache and on lifestyle issues. With regard to drugs, patients will be encouraged to restrict use of acute medications to headaches with severe pain; i.e., those rated as 8 or greater on a 0-10 (no pain - pain as bad as it could be). In these instances, patients will be instructed to take Eletriptan (40 mg) and/or Almotriptan (12.5 mg) as the first-line treatment, indomethacin (50 mg) as the second line, and will be specifically urged to avoid opioids. With regard to healthy lifestyle issues, patients will be encouraged to engage in moderate physical activity (i.e., 45 minutes twice per week of aerobic exercise), remain well hydrated, consume 3 meals per day, and maintain a regular sleep/wake pattern with at least 7-8 hours of sleep per night."
45698806|NCT03461874|Behavioral|ACT|"ACT consists in 6 weekly sessions, 90 minutes each, and 2 supplementary booster sessions, at two and four weeks after the conclusion of the weekly session. The main focus of the six ACT session will be the following: 1) Creative helplessness: the problem of control; 2) Indentifying values: introduction to Mindfulness; 3) Actions guided by values: working with thought; 4) Working with Acceptance and Willingness; 5) Committed Actions: self-as-context; 6) Integration: working with obstacles - wrap-up. The booster session starts with a mindfulness exercise, followed by a review of the contents covered across the ACT program.~Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions."
45715332|NCT04290754|Behavioral|CATCH-IT|Competent Adulthood Transition with Cognitive-behavioral & Interpersonal Training (CATCH-IT) is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious.
45403291|NCT03798340|Other|Sensorimotor training|Targeted to goals that are relevant to the sensorimotor facilitation of the patient
45510965|NCT02156648|Other|Feasibility study|All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.
45510966|NCT05188547|Device|Video education|Participants will be shown a video educating them on anesthesia and perioperative instructions.
45510967|NCT02153294|Procedure|low tidal volume|Patients are randomized and ventilated with a low tidal volume (4-6 ml/kg PBW)
45510968|NCT02153294|Procedure|high tidal volume|Patients are randomized and ventilated with a high tidal volume (8-10 ml/kg PBW)
45510969|NCT05598437|Device|Dry eye device|Dry eye analysis
45510970|NCT02153372|Other|BMC2012|
45510971|NCT02767856|Device|IO-therapy Glasses|
45403292|NCT00255086|Drug|Memantine|10mg Memantine
45403293|NCT00255086|Drug|Placebo pill|10mg placebo pill
45403294|NCT00110214|Drug|docetaxel|Given IV
45403295|NCT00110214|Other|placebo|Given IV
45403296|NCT00110214|Drug|prednisone|Given orally
45403297|NCT00110214|Biological|bevacizumab|Given IV
45403298|NCT00110214|Other|laboratory biomarker analysis|Correlative studies
45403299|NCT04176172|Drug|Varenicline|Participants will receive open-label varenicline for 12 weeks.
45510972|NCT03087851|Drug|Zoledronic Acid|Intravenous infusion of 5 mg zoledronic acid
45510973|NCT02156726|Drug|low-dose FCR|FCR with attenuated dose of fludarabine and cyclophosphamide
45510974|NCT02153450|Drug|metformin hydrochloride|Given PO
45510975|NCT02153450|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
45510976|NCT05598281|Drug|AMG 510|Oral tablet
45510977|NCT05598281|Drug|Digoxin|Oral tablet
45510978|NCT05598203|Behavioral|Operative group of nutrition education|The intervention will be carried out with operational nutritional education groups. Three meetings will be held, each meeting lasting one hour, weekly or fortnightly (according to the availability of the patient). The following foods foods proposed foods: Meeting 1 = education on classification labels and proposed foods proposed foods (education on classification labels and substitution of Brazilian foods), in this guide meeting the proposal is processed or ultra-processed by an in natura food or minimally processed; Meeting 2 = assembly of the healthy dish (food portions, food index and glycemic load, food clothes), the proposal in this meeting is the assembly of the complete dish in the meals eaten throughout the day; and Encounter 3 = hunger and satiety (aiming to increase the perception of hunger and satiety signals), encounter as a task to be accomplished.
45510979|NCT03979417|Other|Blood draw and liver resection|The samples are transferred to the research unit for immunological studies.
45510980|NCT03956407|Device|Repetitive peripheral nerve stimulation|Active repetitive peripheral nerve stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For active stimulation, intensities will be set at the highest intensity able to induce sensory paraesthesias without overt muscle contraction or pain, and adjusted if required.
45510981|NCT03956407|Device|Sham Repetitive peripheral nerve stimulation|Sham repetitive peripheral nerve stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For sham stimulation, intensities will be set at 10mv - 15mv lower than de lowest intensity able to induce sensory paraesthesias, and adjusted if required.
45851106|NCT00378222|Procedure|Autologous Stem Cell Transplantation|
45510982|NCT03092375|Drug|Glecaprevir/Pibrentasvir (G/P) 300mg/120mg|daily
45510983|NCT03092375|Drug|Ribavirin 200Mg Tablet|Weight-based 1000-1200 mg
45510984|NCT04983485|Other|Observational|Respiratory muscle electromyographic activations of individuals will be evaluated during the test while breathing rapidly and deeply from the beginning of the constant threshold load endurance test and the increasing threshold load endurance test until the end of the test, and at rest. Respiratory muscle endurance will be evaluated with constant threshold load endurance test and increasing threshold load endurance test, respiratory functions with pulmonary function test, respiratory muscle strength with intraoral pressure measurement device, health condition disorder with Chronic Obstructive Pulmonary Disease Assessment Scale, dyspnea with Modified Medical Research Council Dyspnea Scale and Modified Borg Scale. Participants' names, anthropometric measurements, demographic data, contact information and medical history will be collected and recorded with the patient anamnesis form.
45510985|NCT01995513|Drug|Enzalutamide|160 mg by mouth once daily
45510986|NCT01995513|Drug|Abiraterone|1000 mg by mouth once daily
45510987|NCT01995513|Drug|Placebo for Enzalutamide|Sugar pill manufactured to mimic Enzalutamide 40 mg capsule
45510988|NCT01995513|Drug|Prednisone|5 mg by mouth twice daily
46057205|NCT05754424|Drug|AT278|Concentrated rapid acting insulin aspart
46057206|NCT05754424|Drug|NovoRapid|Rapid-acting insulin aspart
46057207|NCT05754424|Drug|Humulin R 500 UNT/ML Injectable Solution|Regular human insulin
45698807|NCT03461874|Drug|Pharmacological prophylaxis|Pharmacological prophylaxis will be prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or Flunarizine. Doses will depend on patients' features, and the doses herein reported are to be intended as approximate ones: Topiramate at the dose of 50mg/day; Propanolol at the dose of 20mg/day; Amytriptiline at the dose of 10mg/day; Flunarizine at the dose of 5mg/day.
46057208|NCT05003271|Other|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions.
45698808|NCT03461718|Drug|Ketamine|Experimental arm for sedation.
45698809|NCT03461718|Drug|Midazolam injection|Part of standard sedation regimen and anxiolysis and for minimization of emergence reaction
45851107|NCT00378300|Drug|Oral Probiotics|
46057209|NCT05747560|Dietary Supplement|Buckwheat|Take buckwheat at a dose of 500 mg twice a day for 6 months.
46057210|NCT05747560|Dietary Supplement|Astragalus extract|Take astragalus extract at a dose of 450 mg twice a day for 6 months.
46057211|NCT05747560|Dietary Supplement|Wolfiporia extract|Take wolfiporia extract product at a dose of 15 g twice a day for 6 months.
46057212|NCT02777307|Other|Hemopatch Sealing Hemostat|Place of Hemopatch Sealing Hemostat after laparoscopic cholecistectomy
45510997|NCT04953377|Behavioral|PFMT educational intervention|an educational intervention to learn about the pelvic floor and how to train it
45510998|NCT05038761|Device|CGM System|"Following the manner of observational study, no intervention will be used for the study.~Participants will wear the CGM on abdomen or lower area for no longer than 14 days."
45510999|NCT05038761|Procedure|Standard Venous Blood Glucose Test|Necessary venous blood glucose testing will be performed during the study as clinically required as comparator.
45511000|NCT05598125|Device|electronic cigarette (e-cigarette)|
45511001|NCT05598125|Device|conventional tobacco cigarette|
45698810|NCT03461718|Drug|Fentanyl|Part of standard sedation regimen
45851108|NCT00378456|Drug|Antioxidants- (Vitamins A,C,E Selenium and Zinc)|
45851109|NCT00378456|Drug|Folinic acid|
45851110|NCT00378456|Drug|Vitamins A,C,E Selenium and Zinc and Folinic acid.|
45851111|NCT00378456|Drug|Placebo|
45851112|NCT00378612|Device|Cypher sirolimus eluting coronary stent|Cypher® sirolimus eluting coronary stent ranging in diameters 2.5 to 3.5 mm and available in length from 8 to 33 mm.
45851113|NCT00378690|Drug|leuprorelin acetate|LHRH antagonist
45511002|NCT03180359|Biological|Recommended vaccine scheme according to French Vaccine Schedule 2015|"BCG~Measles mumps rubella (MMR)~Varicella (chicken pox)~Rotavirus~Seasonal flu (live vaccine delivered nasally and inactivated vaccine injectable)~Yellow Fever~Diphteria tetanus poliomyelitis whopping cough (DTwP)~Haemophilus influenzae type b~Hepatitis B~Meningococcus conjugate~Pneumococcus~Human papillomavirus~Hepatitis A~Vaccine administration would be done according to French Vaccine Schedule 2015 for mainstream population and for grafted children or transplant candidate children"
45511003|NCT00948129|Other|Laboratory Biomarker Analysis|Correlative studies
45511004|NCT00948129|Behavioral|Smoking Cessation Intervention|Undergo standard of care smoking cessation intervention
45511005|NCT00948129|Behavioral|Telephone-Based Intervention|Undergo telephone based smoking cessation intervention
45511006|NCT00948129|Other|Tobacco Cessation Counseling|Undergo smoking cessation counseling
45511007|NCT01382771|Drug|Intra-articular corticosteroid injection|Intra-articular injection of 0.5 cc triamcinolone acetonide (40 mg/cc) within each joint
45511008|NCT01382771|Drug|Intra-articular saline injection|Intra-articular injection of 0.5 cc normal saline in each joint
45511009|NCT04819451|Other|Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF)|The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the patient wards in a special container. Finally, it will be used in the CSF replacement. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.
45511010|NCT02927171|Other|IntenSive Therapeutic Rehabilitation for Older Skilled Nursing Home Residents|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
45403300|NCT04176172|Drug|Nicotine patch|Participants will receive open-label nicotine patch for 12 weeks. (Participants in the NMR-tailored treatment arms will receive either varenicline OR patch; they will not receive both)
45403301|NCT04176172|Behavioral|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks.
45511011|NCT04933253|Procedure|Saline irrigation|Mediastinal irrigation with 2 L of 37 degree Celsius saline prior to chest closure
45698811|NCT05431920|Dietary Supplement|Vitamin D₃ (25-hydroxy vitamin D)|Vitamin D3 oral supplementation
45698812|NCT05431920|Dietary Supplement|Vitamin D₃ (25-hydroxy vitamin D)|Vitamin D3 oral supplementation
45511012|NCT04878419|Other|Virtual Educational Program|Multiple virtual interactive sessions to provide education/knowledge about Type 1 Diabetes Mellitus care
45511013|NCT05199285|Biological|Ipilimumab|Given IV
45511014|NCT05199285|Biological|Nivolumab|Given IV
45511015|NCT01382693|Behavioral|TimeSlips|TimeSlips is a group-based creative storytelling program for people with dementia. The intervention will be held twice a week for six weeks, in hour-long sessions.
45511016|NCT01382693|Behavioral|Standard care activity program|Standard-of-care activities for the study site's skilled-nursing dementia Special Care Units.
45511017|NCT05597891|Device|Viper Catheter System|Treatment with the Viper Catheter System for thromboembolectomy
45511018|NCT01304511|Drug|Orgalutran|
45511019|NCT03087617|Device|Imbio Smoking Cessation Report|Research coordinators at the University of Michigan and HealthPartners will be provided access to the research version of LDA via an Imbio website. Following consent and lung screen, research coordinators will manually upload the study participants' images and download a resulting Report. Radiologists have been designated at both sites to review and approve the Report prior to mailing to participants. The Report will include information including the percent of damaged lung volume.
45511020|NCT03087617|Behavioral|Smoking Cessation Counseling|45 minute counseling session with a tobacco treatment specialist.
45511021|NCT03087617|Other|Usual Care|Usual Care for Lung Cancer Screening patients.
45511022|NCT04808973|Drug|Dolutegravir plus lamivudine in a FDC|All participants will receive an ART regimen composed by Lamivudine plus Dolutegravir in a single pill (FDC)
45698813|NCT05430360|Biological|GT201|Autologous tumor infiltrating lymphocyte injection
45698814|NCT03467022|Drug|Vitamin C|Patients depleted or deficient in vitamin C by blood test were supplemented orally in vitamin C 1 gram per day for three months
45698815|NCT02522364|Device|BioMonitor device|Implantation of a BioMonitor device and continuously monitoring heart rhythm for study duration
45698816|NCT02522364|Other|Standard|Clinical and intermittent electrocardiographic follow-up of patients
45698817|NCT03129594|Diagnostic Test|plasma glucagon-like peptide-1 levels|The plasma GLP-1 levels was determined by enzymatic assays.
45851114|NCT00378768|Biological|anti-thymocyte globulin|
45851115|NCT00378846|Procedure|infrared thermography|
45851116|NCT00379158|Drug|Micronutrient supplements|
45403302|NCT04176172|Behavioral|Standard treatment + Managed Problem Solving (MAPS) adherence intervention|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Managed Problem Solving (MAPS) is a therapeutic process that involves the systematic delineation of a participant's medication adherence problems and construction of a series of individualized solutions that therapists and participants explore together. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks. The first session will directly address potential medication adherence barriers, and therapist and participant will collaboratively brainstorm ways to overcome these barriers.
45403303|NCT03798262|Other|Gluten|Tereos
45403304|NCT03798262|Other|Placebo|Whey protein from Nestlé Healthy Science
45403305|NCT01078272|Other|Remote ischemic preconditioning|Randomized subjects are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
45403306|NCT01078272|Other|Sham Remote Ischemic Preconditioning|Randomized subjects who are exposed immediately prior to stenting to sham remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff placements without inflation on their nondominant arms, with intervening 5 minute rest periods.
45403307|NCT03795844|Procedure|liver retraction Nathanson retractor|liver retractor will be used for the retraction of left lobe of liver
45403308|NCT03795844|Procedure|liver retraction snake retractor|liver retractor will be used for the retraction of left lobe of liver
45403309|NCT03795844|Procedure|liver retraction fan retractor|liver retractor will be used for the retraction of left lobe of liver
45511023|NCT00103610|Drug|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
45511024|NCT00103610|Drug|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
45511025|NCT04871321|Drug|nab-paclitaxel plus gemcitabine-cisplatin|- gemcitabine 800mg/m2 + cisplatin 25 mg/m2 + nab-paclitaxel 100mg/m2 on day 1 and day 8, every 21 days
45511026|NCT01568801|Behavioral|SingaPACE|Individuals in the intervention group will go through an integrated program of community based health and social care, based on intake and ongoing evaluation by the SingaPACE team.
45511027|NCT05597657|Other|Fluid administration (Fresenius Kabi Sodium Chloride 0.9%)|All participants in substudy 2 will be administered 2 liters of isotonic saline infusion (Fresenius Kabi Sodium Chloride 0.9%) intravenously. CMR and echocardiography will be performed before and after infusion.
45511028|NCT02151188|Dietary Supplement|Bread, Soy milk and cow milk|The study will examine the metabolic effects of two liquid proteins (soy milk and cow milk) with carbohydrate (bread) meals.
45511029|NCT02151188|Device|real-time ultrasonography (GE LOGIQ P5 ultrasound in CNRC)|
45511030|NCT05597579|Diagnostic Test|DAPAR Tests (IQ equivalent test)|This study will compare DAPAR scores before and after the onset of the psychotic illness.
45511031|NCT02156960|Drug|Denosumab treatment in osteoporotic patients|To examine the effectiveness of denosumab in osteoporotic patients
45511032|NCT02156960|Drug|Teriparatide treatment in osteoporotic patients|To examine the effectiveness of teriparatide in osteoporotic patients
45511033|NCT02156960|Drug|Denosumab and teriparatide treatment in osteoporotic patients|To examine the effectiveness of denosumab and teriparatide in osteoporotic patients
45715333|NCT04290754|Behavioral|TEAMS|Teens Achieving Mastery over Stress (TEAMS) is an 8-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
45715334|NCT01566773|Drug|PT001 MDI|Administered as two puffs BID for 14 days
45851117|NCT00379314|Procedure|TVT and TVT-O minimally invasive surgical procedures|
45403310|NCT03795844|Procedure|liver retraction laparoscopic grasper|laparoscopic grasper without any special tools
45403311|NCT03792802|Procedure|laparoscopic appendectomy port sites|one group will have classic port sites ;.Port sites located 1 infraumbilical , 1 right lower quadrant and 1 left lower quadrent . one group will have same dermatome port sites ; One of the port will put in infraumbilical site and the other ones will put 10 cm right and left side from infraumbilical port
45403312|NCT05669170|Behavioral|Psychosocial intervention|"The counseling session, in which a trained study clinician will counsel the primary caregiver, will take place at each study visit and after the randomization visit. It will last approximately 20-30 minutes. Each counseling session will consist of the following elements:~Review and adjustment of the patient and caregiver supportive care plans~Emotional support and the opportunity to ventilate feelings~Counseling regarding specific caregiving skills~Assistance with problem-solving of specific issues that the caregiver brings to the sessions~Answers to questions regarding the educational materials The educational materials will consist of a copy of the book The 36-Hour Day by Nancy L. Mace and Peter V. Rabins. The caregiver also will be provided with 24-hour phone access to the study nurse or physician for assistance with crises that may arise after hours."
45403313|NCT05669170|Drug|Methylphenidate|norepinephrine and dopamine reuptake inhibitor
45403314|NCT03792568|Other|ALK Inhibitor|Any ALK inhibitor like crizotinib, alectinib and so on.
45511034|NCT03630965|Other|CPR Video|"A 7.07 minutes' CPR video will be administered to the ICU patients' surrogates in Group B.~After viewing the video, the surrogate will complete the Hamilton Anxiety Rating Scale, a five-question survey about CPR, and a one-question form about comfort using the Likert Scale."
45511035|NCT02153606|Drug|Glycerin Suppository|The treatment intervention will be a 250 mg glycerin suppository placed in the rectum once daily starting 48-72 hours after birth.
45511036|NCT02153606|Other|Sham Suppository|Sham suppositories will be created by placing a 250 mg glycerin suppository in the diaper once daily starting 48-72 hours after birth. This intervention works as a non-invasive placebo to maintain blinding.
45403315|NCT01303822|Behavioral|Mindfulness-based day-care clinic group program|11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
45511037|NCT03631511|Procedure|direct pulp capping with RetroMTA|The study included seven caries-free third molars from three adults. These teeth were subjected to pulp exposure, direct capping with RetroMTA, and restoration with a composite resin. Seven months later, the teeth were clinically and radiographically evaluated. The teeth were then extracted and subjected to histological processing and evaluation.
45403316|NCT03798184|Procedure|Non-carious cervical lesion restoration|Restoration of non-carious cervical lesions with Prime&Bond Active in self-etch or selective-etch mode with or without bioglass
45511038|NCT02157038|Device|Pedometer|
45511039|NCT02157038|Device|MRI|
45511040|NCT02153762|Drug|Locoid Lipocream|Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
45511041|NCT02153762|Drug|Hylatopic Plus|Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
45511042|NCT04687631|Drug|mFOLFOXIRI plus Cetuximab|cetuximab 500mg/m2 + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks
45511043|NCT04687631|Drug|mFOLFOXIRI Plus Bevacizumab|bevacizumab 5mg/kg + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks
45511044|NCT02159300|Behavioral|experience brain activity recording|Intervention: experience brain activity recording
45403317|NCT03798028|Biological|UC-MSCs|The UC-MSCs will be administrated by intravenous injection at the dose of 1×10^6 cells/kg.
45403318|NCT03799822|Drug|Rivaroxaban 10 MG Oral Tablet|replacement of warfarin by rivaroxaban
45403319|NCT03799822|Dietary Supplement|MK-7 2000µg thrice weekly|dietary supplement of vitamin K2 MK-7 2000µg thrice weekly
45403320|NCT03799822|Drug|Vitamin K Antagonist - Drug|treatment with a vitamin K antagonist
45403321|NCT03795766|Procedure|Surgeries for gynecologic disease|All patients accept surgeries for gynecologic disease.
45511045|NCT05597501|Behavioral|manual-based group interventions|weekly group interventions (90min) following manuals of either CBT, integrative therapy or existential analysis&logotherapy
45511046|NCT04833023|Drug|Haldol 2mg/ml oral solution|"Starting dose: 1mg~Maximum Dose within 24 hours: 6mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Haloperidol has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN)."
45511047|NCT04833023|Drug|Olanzapine Actavis 5mg orodispersible tablet|"Starting dose: 2.5mg~Maximum Dose within 24 hours: 15mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Olanzapine has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN)."
45511048|NCT02159378|Other|Fructosamines|
45511049|NCT02159456|Other|Continuous enteral feeding via infusion pump|
45511050|NCT02159456|Other|Intermittent enteral feeding via gravity-based infusion|
45511051|NCT03091439|Drug|Dalbavancin|Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.
45511052|NCT03091439|Drug|Standard of Care|Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment was 4-6 weeks.
45851118|NCT00379314|Procedure|Surgery for female stress urinary incontinence|
46057213|NCT04867473|Behavioral|Teleyoga|12 weekly 75 minute therapist-led teleyoga sessions
45511053|NCT02153840|Drug|PSORI-CM01（YXBCM01） granule|
45511054|NCT02153840|Drug|placebo|
45511055|NCT03631823|Other|Chemotherapy with temozolomide or no chemotherapy|This study is just an observational study.
45511056|NCT02157272|Drug|Experimental: Rivaroxaban|The investigated drug is Rivaroxaban 20mg, a film coated tablet, which is a highly selective direct factor Xa inhibitor. It should be administered orally, every day at any time (always the same), with food. The treatment should be performed for all the treatment period.
45511057|NCT05597423|Other|Massage|The massage will be applied for 16 minutes on the quadriceps, calf, hamstrings and lower back bilaterally with 4 different pressures.
45511058|NCT05597423|Other|Placebo|The cream will be applied to the quadriceps, calf, hamstring and lower back bilaterally and the participant will wait 16 minutes lying down in the supine position.
45511059|NCT04729712|Procedure|Anaesthesiologist-administered ultrasound guided Erector Spinae block with catheter insertion|Erector Spinae block: A bolus of 20 ml 0.375% Levobupivacaine will be administered into the erector spinae plane prior to surgical incision. A further bolus of 10 ml 0.25% Levobupivacaine will be given at skin closure if it has been greater than 1 hour after the first bolus of local anaesthetic medication. A continuous infusion of 0.125% Levobupivacaine will be commenced via the sited nerve catheter for postoperative analgesia. This will be started at 10 ml/hr and titrated to effect to a maximum rate of 15 ml/hr.
45511060|NCT04729712|Procedure|Surgeon-administered video-assisted Paravertebral block with catheter insertion|Paravertebral block: A bolus of 20 ml 0.375% Levobupivacaine will be administered into the paravertebral space after the thoracoscopic ports have been sited. A further bolus of 10 ml 0.25% Levobupivacaine will be given at skin closure if it has been greater than 1 hour after the first bolus of local anaesthetic medication. A continuous infusion of 0.125% Levobupivacaine will be commenced via the sited nerve catheter for postoperative analgesia. This will be started at 10 ml/hr and titrated to effect to a maximum rate of 15 ml/hr.
45511061|NCT01382537|Device|InterX 5000|A computer driven electrical stimulation unit that contains a cutaneous impedance sensor.
45511062|NCT01382537|Device|InterX 5000|Placebo treatment
45511063|NCT02154074|Drug|general anesthesia induction|general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg
45511064|NCT02154074|Drug|Isoflurane|inhale Isoflurane 1.5MAC
45511065|NCT02154074|Drug|Dexmedetomidine|anesthesia induction period: intravenous pumping Dexmedetomidine 4ug/Kg/h; after 10 minutes,turn to 0.4ug/Kg/h.
45715335|NCT01566773|Drug|Tiotropium Bromide|Taken as 1 capsule containing 18 µg of tiotropium via the Handihaler DPI
45715336|NCT01566773|Drug|PT001 Placebo MDI|
45511066|NCT02154074|Drug|normal saline|the same volume of saline + Isoflurane during operation
45511067|NCT02154152|Drug|Homoeopathic Medicine causticum 200c|
45511068|NCT03086447|Device|Investigational Contact Lens|Senofilcon C Toric
45511069|NCT03086447|Device|Marketed Contact Lens|Air Optix for Astigmatism
45511070|NCT02159534|Other|Primebrain|Primebrain stimulation programme aims to facilitate the infant's self-organization of postural competences by proposing varied sensorimotor experiences in a context supporting parent-child interaction.
45511071|NCT02159612|Other|MRI|MRI scan of muscles in the back and legs. Including T1, DIXON and STIR images.
45511072|NCT05593055|Drug|Eplerenone|After the Pre-Treatment Assessment, participants in the eplerenone arm will be given 50 mg eplerenone. At 2 weeks, eplerenone will be increased to 100 mg.
45511073|NCT05593055|Drug|Chlorthalidone|After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
45511074|NCT05593055|Drug|Potassium|After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
45511075|NCT02933801|Drug|ODM-201|ODM-201 will be given at a dose of 600 mg BID orally on a continuous basis.
45511076|NCT02933801|Other|Placebo|Placebo will be given at a dose of 600 mg BID orally on a continuous basis.
45511077|NCT04794725|Procedure|Blood sampling|blood samples from venepuncture (10mL)
45403322|NCT03799900|Drug|Rapastinel|During the Treatment Phase in Part 2, participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
45511078|NCT05557955|Other|Breathing test|Dynamic breathing testing will be performed before, during, and after radiotherapy. Volatile organic compounds (VOCs) will be collected.
45511079|NCT04787393|Device|Heartfelt device|The Heartfelt device uses a system of scanner in a compact device to generate depth images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit, For the measurements to take place, the participant walks in the field of view of the device, measurments are only taken when the patients has bare feet and no slippers/shoes, so the location of the device in the home is choosen to match this requirement. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.
46057214|NCT00636831|Drug|Antibiotic: cefazolin Sodium|1g continuous IV at 30 minutes before starting operation
45403323|NCT03799900|Drug|Ketamine|"Part 1~Part 2, Qualification Phase:~Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner~Part 2, Treatment Phase:~Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner."
45403324|NCT03799900|Drug|Placebo|"Part 1~Part 2, Qualification Phase:~Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner~Part 2, Treatment Phase:~Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner."
45403325|NCT03795688|Other|Pregnancy|Peripartum transition from pregnant to postpartum state
45403326|NCT03795532|Procedure|SWL|Shock wave lithotripsy
45403327|NCT05625022|Drug|Lianhua Qingke tablets|Lianhua Qingke tablets: 4 tablets once, three times daily
45403328|NCT05624866|Drug|Dexmedetomidine|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydro-dissection
45403329|NCT05624866|Drug|Triamcinolone|injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection
45403330|NCT03792178|Other|Bulk fill composite|Composite resin dental material
45403331|NCT03792178|Other|Nano resin composite|Dental composite material
45403332|NCT01303978|Drug|APD421|Single dose
45403333|NCT03994900|Diagnostic Test|Blood sampling for HbNO assessment|Blood sampling
45403334|NCT01304056|Device|Ventilatory therapy|
45403335|NCT03799666|Other|Pulmonary Rehabilitation|Patients will be treated with daily medication prescribed by the physician. Additionally patients will participate in a 12-w.eek community-based pulmonary rehabilitation programme, with two exercise training sessions per week and six psycho-education sessions, managed by a multidisciplinary team, once every two weeks. Patient's families will be invited to participate in the psychoeducational component
45403336|NCT03799666|Other|Daily medication|Patients will be treated with daily medication prescribed by the physician and will continue to receive the standard care from the primary care centre team.
45403337|NCT01304602|Drug|Irinotecan|IV over 90 minutes on day 1 of each cycle (every 2 weeks) at the cohort assigned dose level
45403338|NCT01304602|Drug|BKM120|BKM120, oral, daily starting with cycle 1/day 2 at the cohort defined dose level
45403339|NCT01304134|Drug|Oxycodone|dosage:10mg/l dosage form:injection frequency:via PCA pump, background rate:0.5ml/h, 2ml/time duration:48 hours
45403340|NCT01304134|Drug|Morphine|dosage: 10mg/ml dosage form: injection frequency: via PCA pump, background rate: 0.5ml/h, 2ml/times duration: 48 hours
45403341|NCT00124020|Drug|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days
45403342|NCT00124020|Drug|Vancomycin|Vancomycin 1 Gm administered every 12 hrs IV for up to 21 days
45403343|NCT05630794|Procedure|Biopsy|Undergo biopsy
45403344|NCT05630794|Procedure|Biospecimen Collection|Undergo collection of blood
45715337|NCT04276714|Other|Socket without Revofit system|All the tests are evaluate during one week with the classical type of fittings
45715338|NCT04276714|Other|Socket with Revofit system|All the tests are evaluate during one week with the adjustable type of fittings (that is to say with Revofit system)
45851119|NCT00379392|Behavioral|Mental Imagery only|Listening to an audio tape to enhance mental imagery of functional activities of the affected upper extremity
45403345|NCT05630794|Procedure|Colonoscopy|Undergo colonoscopy
45403346|NCT05630794|Drug|Dordaviprone|Given PO
45403347|NCT05630794|Other|Questionnaire Administration|Complete questionnaire
45403348|NCT05630794|Procedure|Sigmoidoscopy|Undergo sigmoidoscopy
45403349|NCT01080690|Procedure|EGD|In this arm EGD will be performed before EUS.
45403350|NCT01080690|Procedure|EUS|In this arm EUS will be performed before EGD.
45403351|NCT05626270|Device|LunulaLaser OTC|The LunulaLaser™ OTC is a nonthermal and non-invasive procedure designed to restore the growth of clear, healthy nails in clients with onychomycosis.
46057215|NCT02712567|Drug|Th-302|300 mg/m2 IV on Days 1 and 8 of a 21-day cycle.
45403352|NCT01080846|Drug|Misoprostol|600 mcg of sublingual misoprostol
45403353|NCT03792412|Other|Usability Questionnaire|Patients receive the usability questionnaire and a structured nutrition and lifestyle program for post-bariatric follow-up visits. Twice in six months the patients visit their family doctor and hand over the usability questionnaire to evaluate the structured follow-up program for postbariatric patients. Family doctors fill out the questionnaire and returns it to the investigator.
45403354|NCT01076322|Drug|Meptin® Swinghaler|"Meptin® Swinghaler®~Ingredient: Procaterol HCL~Dosage form: 10g/puff~Dose(s): 10g~Dosing schedule: 20g (total 20g)"
45511080|NCT04787393|Device|Connected weighing scales|"The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional. The weighing scales display weight so that the participants can record the weight in their own heart failure records if they wish to do so.~The scales will communicate with the Personal Computer (PC) contained in the Heartfelt device and the data will be sent to the Heartfelt server through an encrypted link.~The data from the scales will be reviewed retrospectively, as the comparison in this study is with standard care, not with enhanced provision of care, which would be the case if we were using automatic reporting of weights."
45511081|NCT04666025|Procedure|Biospecimen Collection|Undergo collection of nasopharyngeal swabs, blood, and saliva samples
45403355|NCT01076322|Drug|Ventolin® MDI|"Ventolin® MDI~Ingredient: Salbutamol sulfate~Dosage form: 100g/puff~Dose(s): 100g~Dosing schedule: 200g (total 200g)"
45403356|NCT03795064|Procedure|Foam sclerotherapy|Foam sclerotherapy is used to all patients for endovenous ablation of insufficient veins in subulcer plexus area.
45403357|NCT03795064|Procedure|Endothermal ablation|Endothermal ablation is performed in early setting when truncal vein(s) anatomy is suitable.
45403358|NCT01078350|Procedure|tumor tissue aspiration|
45403359|NCT01078350|Procedure|phlebotomy|
45403360|NCT03966066|Drug|erythromycin|3-5mg/kg.d orally for 6 months
45403361|NCT03792100|Drug|SmofKabiven emulsion for infusion|Total Parenteral Nutrition
45403362|NCT03792100|Drug|"Hospital compounded All in one emulsion"|Total Parenteral Nutrition
45403363|NCT00215540|Drug|Lucinactant 175 mg/kg|Administered via slow intra-tracheal instillation at a dose of 175 mg/kg (5.8 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to day of life (DOL) 18).
45511082|NCT04666025|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
45511083|NCT04666025|Other|Electronic Health Record Review|Medical charts are reviewed
45698818|NCT03461640|Other|Community-based doula support for labour|CBDs will be recruited, trained and employed by non-profit organization MIRA. Women allocated to receive CBD support will be contacted by an either a Somali, Arabic-, Russian- or Tigrinya-speaking CBD as appropriate, and arrangements made for them to meet twice prior to the birth to get to know each other and discuss the woman's wishes regarding support in labour and what the CBD can offer. Each woman will then contact her CBD when she goes into labour and the CBD will attend hospital with her and stay with her throughout her labour and birth, in addition to any other support people she may have, such as her partner.
45403364|NCT00215540|Drug|Lucinactant 90 mg/kg|Administered via slow intra-tracheal instillation at a dose of 90 mg/kg (3.0 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
45403365|NCT00215540|Drug|Placebo|Sham air was administered via slow intratracheal instillation at a dose of 3.0 mL/kg volume of air. The initial treatment was given no later than 1 hour after randomization. Additional treatment were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
45403366|NCT03966846|Dietary Supplement|Kefir|
45403367|NCT03966846|Dietary Supplement|Milk|
45403368|NCT03791944|Device|3DV+TPS/VARIAN|Use imported 3DV+TPS to map targets and develop treatment plans
45403369|NCT03791944|Device|TPS / VARIAN|Use imported TPS to map targets and develop treatment plans
45403370|NCT03791944|Device|3DV + TPS / Domestic Accelerator|Use domestic 3DV+TPS to delineate target areas and develop treatment plans
45403371|NCT03791944|Device|TPS / Domestic Accelerator|Use domestic TPS to map targets and develop treatment plans
45403372|NCT03797950|Behavioral|Voice Reminder (Group A)|Woman with a recent delivery will be contacted via mobile phone by a central study staff member to encourage them to vaccinate their newborn with OPV0 and BCG, and information on where and when vaccines are available in this community will be provided. Community volunteers will receive small incentives for documenting births in the community.
45403373|NCT03797950|Behavioral|Cash Incentive (Group B)|Mobile phone based monetary incentives will be provided to community volunteers and to women with a recent delivery who vaccinate newborns with OPV0 and BCG on time. Community volunteers will receive small incentives for documenting births in the community.
45511084|NCT04666025|Other|Questionnaire Administration|Complete questionnaire
45511085|NCT05498831|Other|Pain assessment at 15 minutes, 30 minutes, 60 minutes, 120 minutes after initial assessment by the triage nurse|Pain will be assessed using a numerical scale
45511086|NCT05460455|Drug|Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo|HB0034 and Placebo
45511087|NCT03104413|Drug|placebo for risankizumab IV|placebo for risankizumab administered as intravenous (IV) infusion.
45511088|NCT03104413|Drug|risankizumab SC|risankizumab administered by subcutaneous (SC) injection
45511089|NCT03104413|Drug|risankizumab IV|risankizumab administered as intravenous (IV) infusion.
45403374|NCT03797716|Device|Little Journey app|"The Little Journey app allows children to explore 360-degree hospital environments familiarising and desensitising them to areas and staff they'll see on the day of surgery. Children can visit the day case ward, anaesthetic and recovery rooms where their operation will occur -all while feeling safe in their own home. As the child explores the three areas, they are introduced to animated characters of staff who explain what will happen, the equipment that will be used and how they might feel. Using head tracking technology, the child triggers the animated characters by looking at them; meaning they control the pace of learning and speed at which they progress. The preparatory tool follows a pre-set story-line reflecting what happens from admission to discharge on the day of surgery."
45403375|NCT01304212|Drug|several drugs: morphine chloride,ropivacaine,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
45403376|NCT01304212|Drug|ropivacaine,morphine chloride,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
45403377|NCT01304212|Drug|ropivacaine|The lock is held before starting the operation, viewing with ultrasound and confirmed the femoral nerve with nerve stimulation at an intensity of 0.5 mA and a frequency of 2 Hz Pajunk 50mm needle, patellar flexion. It be administered 30ml of ropivacaine 0.75% (225mg)
45511090|NCT05451875|Device|Non-invasive monitoring|Comparison of VitalTracer monitoring devices with invasive and/or non-invasive gold standard reference
45511091|NCT04536155|Other|questionnary SF36|"This is a validate questionnary:~Ware et al,1992, McHorney et al, 1993, McHorney et al, 1994 French version : Author : Alain Leplège; et coll. En 2001"
45511092|NCT04536155|Other|Hospital Anxiety and Depression Scale|this is a validate scale: author: Zigmond A.S., Snaith R.P. in 1983
45511093|NCT04536155|Other|Chronic Pain Acceptance Questionnaire|"This is a validate questionnaire:~Fish, R., McGuire, B.E., Hogan, M., Stewart, I. & Morrison, T. (2010)."
45511094|NCT04536155|Other|digital pain scale|this is a validate scale A.N.A.E.S. February 1999
45511095|NCT04534127|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
45511096|NCT01382147|Drug|Ara-C, Mitoxantrone, Daunorubicin, Thioguanin|Chemotherapy
45511097|NCT03630887|Device|WarmTouch Model 5900, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied in the preanesthetic room during different time periods.
45511098|NCT01382069|Drug|Dimethandrolone Undecanoate|Daily doses of 100, 200 and 400mg of dimethandrolone undecanoate
45511099|NCT01382069|Drug|Placebo|Placebo with capsules that look like the DMAU capsules but with no active ingredients
45511100|NCT01381991|Device|i-scan|For all the study procedures, Pentax EPKi processor and high-resolution adult video endoscopes (EG-2890i; Pentax, Japan) with push button switch from WL to i-scan were used. I-scan consist of three modes of image enhancement including SE, CE, ant TE. For SE and CE, switching among three enhancement levels (2+,3+,4+) is possible. Although SE and CE modes can allow detailed observation of subtle mucosal irregularities, noise increases as enhancement becomes more intense. In addition, TE is possible to switch p (pit pattern), v (vessel), b (Barrett), e (esophagus), g (stomach) and c (colo-rectum) mode.
45511101|NCT01381835|Drug|TMC435|150 mg capsule once daily for 7 days
45511102|NCT04429685|Drug|Ketamine|Low dose ketamine - Ketalar (Racemic Ketamine Hydrochloride) Saline - Isotonic/Normal Saline
45511103|NCT04429685|Drug|Saline (placebo)|Saline (placebo)
45511104|NCT04411277|Device|Application of the FreeStyle Libre Flash Glucose CGM.|Assessment of glycemic control and hypoglycemia, adherence to therapy and CGM use.
45511105|NCT04411277|Diagnostic Test|InBody 270 multifrequency bioimpedance|analysis of body composition to calculate appendicular skeletal muscle.
45698819|NCT03461640|Behavioral|Standard labour support|"Standard labour support by health care providers only. Women allocated to the comparison arm of the trial will receive standard intrapartum care as provided at their chosen hospital of birth. That is emotional, information and instrumental support from a helping nurse or a midwife or in some cases a doctor. The support includes caring actions, such as comforting, massage, information and presence.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation."
45511106|NCT01379417|Dietary Supplement|Probiotic supplementation|1 capsule per day, from inclusion to 4 or 6 weeks after inclusion
45511107|NCT03752827|Device|Adipose Derived Regenerative Cells|Adipose-derived regenerative cells isolated with the Transpose Ultra system
45511108|NCT03752827|Drug|Corticosteroid|Corticosteroid injection into subacrominal space
45511109|NCT01384279|Drug|metformin, topiramate|metformin 250 mg/d is gradually increased to 1000 mg/d over four weeks, and topiramate 50 mg/d is gradually increased to 200 mg/d over four weeks
45511110|NCT01568879|Other|Control|The control group will receive care from their primary care physician that reflects the actual current care received by KPNC patients, but will not receive any treatment recommendations from the study protocol. The control subject will have regular monitoring of serum uric acid levels and will be provided with educational material and dietary counseling.
45511111|NCT01568879|Other|Gout Disease Management Program|The experimental group will utilize standard guidelines for the initiation of uric acid lowering treatments, and approved medications. The study protocol treatments include medication management, dietary guidelines, and basic educational materials on gout and its management. No non-formulary medications or devices will be used. The experimental procedure to be tested is the use of a structured protocol to manage and monitor standard treatments.
45511112|NCT01383265|Procedure|Water method and chromoendoscopy|Study method will employ a 0.008% IC solution used with the water method for screening colonoscopy
45511113|NCT01383265|Procedure|Water method|Control method will use plain water with water method for screening colonoscopy
45511114|NCT01381601|Drug|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
45511115|NCT05216965|Drug|9MW2821|All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
45511116|NCT02823353|Drug|Fenofibrate|Fenofibrate 200mg/day
45511117|NCT02823353|Drug|UDCA|UDCA 13-15mg/kg/day
45511118|NCT04509193|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Participants receive rivaroxaban (per written prescription, medication administration or self-report of medication use)
45511119|NCT04509193|Drug|Warfarin|Participants receive warfarin (per written prescription, medication administration or self-report of medication use)
45511120|NCT01379339|Drug|Cabazitaxel 10mg/m2|"Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
45511121|NCT01379339|Drug|Cabazitaxel 12.5mg/m2|"Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
45511122|NCT01379339|Drug|Cabazitaxel 15mg/m2|"Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
45511123|NCT01379339|Drug|Cabazitaxel 17.5mg/m2|"Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
45511124|NCT01379339|Drug|Cabazitaxel 20mg/m2|"Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
45511125|NCT01383187|Procedure|DE graft and PRP concentrate|Application of DE graft together with PRP concentrate
45511126|NCT01383187|Procedure|DE graft|DE grafting presents a standard treatment method in patients with deep-burn trauma.
46057216|NCT04226859|Other|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2000 in European and North American centers, who have eGFR follow-up and data from protocol and for cause biopsies available for allograft survival assessment; Randomized controlled trials conducted over the past 20 years with available data on protocol biopsy within the first year and follow up clinical, biological and histological data.
45403378|NCT01304212|Drug|morphine ,ketorolac|ultrasound-assisted femoral nerve block is performed and leaks intraoperatively with a 100 ml solution containing: 5 mg of morphine to 0.1% (5ml) +30 mg of ketorolac (1 ml) +96 ml of 0.9% saline.
45403379|NCT03797638|Device|Finger Force Manipuladum (FFM)|Tasks performed with the device Finger Force Manipuladum (FFM), to assess abilities such as finger individuation but also fine finger force control, finger movement regularity and speed.
45403380|NCT03797794|Device|Pulsating Electrostatic Field|A pulsating electrostatic field is generated by the New Health 9000 (Akern). During the session the patients sits on a chair which contains the apparatus for 30 minutes.
45403381|NCT03797794|Device|SHAM Pulsating Electrostatic Field|The same apparatus which produces the pulsating electrostatic field contains a 'sham-inlet'. This inlet will be used as placebo.
45596784|NCT02366949|Drug|Paclitaxel|Paclitaxel will be given once per week IV at 90 mg/m^2 on D1, D8, and D15 of a 28 day cycle. Paclitaxel will be dosed as a single-agent in Cycle 1 of Arm 2 (Standard Treatment Arm), and in combination with BAY1217389 in Arm 1 (Experimental Treatment Arm) and from Cycle 2 onwards in Arm 2 (Standard Treatment Arm). After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.
45698820|NCT03466788|Other|Self questionnaires of quality of life and living conditions|Patients will complete self-questionnaires of living conditions and quality of life (QLQ-C30; EN24; CIPN20; IPAQ; HADS)
45511127|NCT02782247|Device|Transient elastography|"Transient elastography will be measured using a Fibroscan® machine which is manufactured by echosens®. It has a CE mark of 0459.~It is a non-invasive method to accurately measure stiffness of a patient's liver without the need for a liver biopsy. This is measured by an externally placed ultrasound probe which creates an elastic shear wave at 50Hz, and measures the velocity of the echo through the liver tissue. The liver stiffness is measured in kilopascals (kPa). It has been shown to be 99% effective in detecting cirrhosis in hepatitis C and has been shown to correlate with hepatoma production in both hepatitis C and hepatitis B. Values range from - normal < 9.6 kPa, significant fibrosis 9.6-11.4kPa, cirrhosis >11.5kPa. It cannot be used in patients with ascites."
45511128|NCT02782247|Device|Indocyanine Green excretion|The machine to monitor the elimination of Indocyanine green is manufactured by PULSION medical systems (Munich, Germany) and consists of the PulsioFlex monitor and LiMON module. The LiMON module is a finger probe which measure near-infrared wavelengths between 805nm and 905nm. The absorption maximum for Indocyanine green is 800nm and emission at 830nm. This is then used to produce two calculations. The first is plasma disappearance rate of indocyanine green (PDRICG). This is based on working out the constant and backward extrapolation and expressed as a percentage per minute. The other is the retention ratio after 15 minutes (ICG15).
45511129|NCT05096611|Behavioral|Attachment and Biobehavioral Catch up|ABC is delivered by a trained parent coach. The parent coach provides information about parenting and child development. The focus is on providing support for parents of young children and improving the parent-child relationship.
45511130|NCT05096611|Behavioral|Attachment and Biobehavioral Catch up Plus Depression Treatment|ABC+D offers the same 10-sessions of parenting support that is provided by ABC and additionally provides weekly short videos that help mothers develop skills for coping with stress and regulating mood.
45403382|NCT03849898|Procedure|Surgery|Surgical fracture treatment
45403383|NCT03849898|Other|Non-Surgical fracture treatment|Non-Surgical fracture treatment
45403384|NCT01560520|Behavioral|Physical activity|Observation only
45403385|NCT00143390|Drug|exemestane|take orally one tablet per day of exemestane 25 mg and one tablet per day of anastrozole placebo daily after meal
45403386|NCT00143390|Drug|anastrozole|take orally one tablet of anastrozole 1 mg and one tablet of exemestane placebo daily after meal
45403387|NCT01305616|Procedure|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light (380-500 nanometer)
45511131|NCT02697383|Drug|Ixazomib (MLN9708)|
45511132|NCT02697383|Drug|Dexamethasone|
45511133|NCT01383031|Procedure|CLC|CLC（4 ports or 3 ports）will be performed in a routine fashion by one full time faculty member with fellowship training in laparoscopy.
45511134|NCT01383031|Procedure|TU-LESSC|TU-LESSC will be performed in a routine fashion which is same to CLC by one full time faculty member with fellowship training in laparoscopy through the conventional laparoscopic instruments.
45511135|NCT01569061|Device|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT)
45511136|NCT01569061|Device|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT) sham treatment
45511137|NCT05422547|Diagnostic Test|Immunoscore Colon Test|Immunoscore® is a tissue-based immune test that measures the host's immune response at the site of the tumor. It is performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from resections of localized colon cancer. The test uses whole slide imaging and artificial intelligence algorithms for assessment of the type, density, and location of T cells in FFPE tumor sections to determine an individual Immunoscore® for each patient.
45511138|NCT03631303|Device|Cardiac stimulation through the device leads|During scheduled device replacement extra-systolic beats with various extrasystolic and post-extrasystolic coupling intervals will be evoked by electrical stimulation via the right atrial and ventricular device leads of the patient. Throughout the stimulation study blood pressure will be measured non-invasively using a finger arterial blood pressure photoplethysmographic device and a continuous electrocardiogram will be recorded.
45511139|NCT05422469|Device|Medtronic Percept RC neurostimulator|Medtronic SenSight directional DBS leads and implanted pulse generators (IPGs) will be implanted
45403388|NCT01305616|Procedure|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light.
45403389|NCT03238534|Device|Neobianacid®|Oral administrations of Neobianacid® (30' after meals and on demand)
45403390|NCT03238534|Drug|Omeprazole 20mg|Daily administration Omeprazole 20mg (per os, 30' before breakfast).
45403391|NCT03238534|Other|Neobianacid® placebo|Oral administrations of Neobianacid® placebo (30' after meals and on demand)
45403392|NCT03238534|Other|Omeprazole placebo|Daily administration Omeprazole placebo (per os, 30' before breakfast).
45511140|NCT04173949|Drug|Ramipril 2.5 MG|3 month of treatment with daily Ramipril 2.5 MG
45403393|NCT05624476|Diagnostic Test|mNGS of urine cell-free DNA|Metagenomic sequencing of urine cell-free DNA
45403394|NCT03792022|Behavioral|Adherence to timely vaccine uptake|Adherence to timely vaccine uptake
45403395|NCT05624242|Procedure|cardiac magnetic resonance imaging|all patients had magnetic resonance imaging at baseline and during follow-up.
45511141|NCT05422001|Drug|low dose ketamine|"Low dose ketamine 0.1 mg/kg Product: Esketamin Orifarm 5 mg/ml"
45511142|NCT05422001|Drug|Placebo (saline)|Isotonic Saline
45511143|NCT05080075|Biological|Platelet Rich Plasma Injection|Research participants own blood will be used to prepare the platelet rich plasma injectate, which will be injected into the affected knee using ultrasound guidance.
45511144|NCT04150133|Other|Low Residue Diet|Variable cohort will eat 3 low residue meals on the day prior to their planned colonoscopy
45511145|NCT01382017|Drug|Lacosamide|Lacosamide 200 or 400 mg
45511146|NCT01382017|Drug|Placebo|Placebo
45511147|NCT01382017|Drug|Carbamazepine|Carbamazepine 600 mg
45511148|NCT01381523|Drug|Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)|Patients with new pharmacy claims for SumaRT/Nap with separate analyses for patients with at least one triptan pharmacy claim in the 6-month, pre-index period and those who are triptan-naive based on 6 months of data
45511149|NCT01381523|Drug|Single-entity oral triptans|Patients are propensity score matched to patients in the SumaRT/Nap groups and analyzed separately if patient has a pharmacy claim for a different type of triptan in the previous 6 months or is triptan treatment naive. Triptans included almotriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, sumatriptan.
45511150|NCT01382953|Device|Standard Holter/Investigational patch|The standard Holter and Investigational patch will be worn simultaneously for 24 hours. A single follow-up visit will follow in 2 days to remove both systems which will be sent away for analysis with the results of the standard system used, if pertinent, for patient management.
45511151|NCT04233047|Drug|Fostemsavir|Fostemsavir 600 mg extended release tablets, administered 600 mg twice daily, will be supplied for compassionate use for the identified individual patient.
45851120|NCT00379392|Procedure|Mental Imagery and Constraint induced therapy|Listening to an audio tape to enhance mental imagery AND participation in constraint induced therapy
45851121|NCT00379470|Device|NovoTTF-100A|multiple four-week courses of continuous NovoTTF-100A treatment
46057217|NCT04193631|Drug|Cannabidiol (CBD)|A single dose of Cannabidiol (CBD) when patients experience musculoskeletal pain in the trial.
45511152|NCT01381445|Drug|GW870086 0.2%|White to slightly coloured opaque cream
45511153|NCT01381445|Drug|GW870086 2%|White to slightly coloured opaque cream
45511154|NCT01381445|Drug|Clobetasol Propionate|White cream
45511155|NCT01381445|Drug|Placebo|White to slightly coloured opaque cream
45511156|NCT05421845|Behavioral|mobile-based combining with hospital-based lifestyle interventions|The same as that stated in arm descriptions.
45511157|NCT01568957|Behavioral|Gait training|Twelve 30-minute sessions plus 10-minute stretching and warm up, provided 3 times per weeks for 4 weeks. Up to 6 weeks are allowed to complete the 12 sessions.
45511158|NCT01379261|Procedure|Cooling|1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI
45511159|NCT05421767|Procedure|nerve stimulation guided renal denervation procedure|RNS-in
45511160|NCT03083639|Drug|Esomeprazole Capsule|Esomeprazole Capsule
45511161|NCT03083639|Drug|Esomeprazole Tablet|Esomeprazole Tablet
45511162|NCT02927431|Drug|Danirixin 15 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion to provide a dose of 15 mg FBE.
45596785|NCT03532919|Diagnostic Test|Serum Tropinin|Blodsamples will be taken 4 times from preoperatively to 2 Days postoperatively
45596786|NCT05503225|Drug|Colchicine 0.5 MG|0.5mg Orally Taken Colchicine
45511163|NCT02927431|Drug|Danirixin 50 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion.
45511164|NCT02927431|Drug|Placebo|No vials of placebo to match IV DNX will be provided. A normal saline solution of matched volume will be prepared by unblinded personnel at the site to act as a placebo to DNX. Clear solution of placebo will be administered as IV infusion.
45511165|NCT02927431|Drug|Oseltamivir 75 mg|Oseltamivir (Tamiflu - manufactured by Roche) formulation is available as 75 mg Capsule and as powder for oral suspension. After constitution with 55 mL of water, each bottle delivers a usable volume of 60 mL of oral suspension equivalent to 360 mg oseltamivir base (6 mg/mL). No oseltamivir capsules or powder for oral suspension will be provided. Sites will source the OSV locally and it will be provided open-label.
45511166|NCT03083483|Device|transcranial direct current stimulation (tDCS)|tDCS will apply a low, direct current for the duration of the study session while the subject is training the specific laparoscopic tasks.
45511167|NCT05421221|Device|Sniffin' sticks Duftquartett|"4-odor training set over 12 weeks with Sniffin' sticks Duftquartett"
45511168|NCT05027893|Drug|Moxifloxacin 400 mg Oral Tablet|All used film-coated tablets (400 mg moxifloxacin) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
45511169|NCT05027893|Drug|Cefixime 400 mg Oral Tablet|All used film-coated tablets (400 mg cefixime) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
45403396|NCT01304290|Other|Hyperinsulinemic/normoglycemic clamp|"Dextrose/insulin therapy will start. Dextrose and insulin are given using the so-called normoglycemic, hyperinsulinemic clamp. Plasma insulin concentration will be increased by a 2ìU/kg/min continuous infusion of insulin. Dextrose will be infused at the rate required to maintain normoglycemia (4-6 mmol/l) until cross clamping of the aorta. The dextrose/insulin therapy will be maintained for a time period of minimum 6 hours."
45511170|NCT05027893|Other|Placebo|All used film-coated placebo-tablets were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
45511171|NCT04113083|Other|Blood sampling for cholestanol analysis|Blood sampling will be performed by Düzen Laboratories group for cholestanol
45511172|NCT01381783|Procedure|Phacoemulsification|Phacoemulsification under topical anesthesia
45511173|NCT01381367|Biological|PPSV23 pneumococcal vaccine (Pneumovax®)|The adult anti-pneumococcal vaccine was a 23-polyvalent pneumococcal vaccine (Pneumovax®, Aventis Pastuer MSD), 0.5 ml of which was given subcutaneously. Duration of the efficacy is about 4-5 years.
45511174|NCT01381367|Drug|Normal Saline|normal saline, 0.5ml given subcutaneously
45511175|NCT04989361|Procedure|Soluble Hyaluronic Acid Microneedle|The soluble hyaluronic acid microneedle eye mask is a nanometer-sized microneedle made of water-soluble hyaluronic acid, which can directly inject the active ingredients into the dermis, and after being absorbed and dissolved by the skin, it can achieve the purpose of improving the water content and elasticity of the skin.
45511176|NCT04989361|Procedure|Non-fractional laser|he non-ablative fractional laser use 1565nm fiber laser, which acts on the target base in the dermis-water. The beam penetrates the epidermis and acts on the dermis. Using the principle of focal light and heat, the tissue cells are heated to initiate the repair process, which promotes increased collagen synthesis, thereby Achieve the effect of firming the skin and improving wrinkles.
45511177|NCT01381289|Drug|VX-770|150 mg tablet, oral use, twice daily every 12 hours (q12h)
45511178|NCT01382875|Other|Multi-disciplinary management program|conventional healthcare program for fragility fracture patients plus vibration treatment, exercise class and educational talk
45511179|NCT05420987|Dietary Supplement|Jing Si herbal tea liquid packet|Jing Si herbal tea includes eight Taiwan native-grown herbs: such as mugwort leaves, fish needle grass, Ophiopogon japonicus, platycodon, perilla leaves, chrysanthemum, and licorice
45511180|NCT04899193|Drug|Pergoveris FD|Participants will be administered with 900 IU of recombinant human follicle-stimulating hormone (r-hFSH) and 450 IU of recombinant human luteinizing hormone (r-hLH) freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
45511181|NCT04899193|Drug|Pergoveris Liquid|Participants will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Pergoveris Liquid) as subcutaneous injection using disposable pen-injector on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
45851122|NCT00379548|Behavioral|2 groups of population responding to 2 types of diets|Intervention groups include: Asian intervention and Caucasian intervention- both these groups switch from an Asian diet to a Western diet halfway through the study.
45851123|NCT00379626|Drug|cognitive and hormone treatment|cognitive and hormone (Leuprorelin) treatment
46057218|NCT04856631|Drug|Toripalimab Injection|240mg once per 3 weeks
45403397|NCT03797248|Combination Product|Chinese herbal medicine|All Chinese herbal products prescribed from TCM physicians in our hospital during patients receiving adjuvant chemotherapy
45851124|NCT00379782|Other|Navigation|Navigation and escourt
45851125|NCT00379860|Drug|LXR-623|
45851126|NCT00380016|Procedure|Percutaneous Transluminal Angioplasty|
45511182|NCT04899193|Drug|Gonal-f|Participants will be administered with 900 IU of folitropin alfa (Gonal-f) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
45511183|NCT04899193|Drug|Luveris|Participants will be administered with 450 IU of lutropin alfa (Luveris) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
45511184|NCT01381705|Biological|rituximab|
45511185|NCT01381705|Genetic|DNA analysis|
45511186|NCT01381705|Genetic|gene expression analysis|
45511187|NCT01381705|Genetic|polymorphism analysis|
45511188|NCT01381705|Other|laboratory biomarker analysis|
45511189|NCT01381705|Other|medical chart review|
45511190|NCT03613675|Device|Video games|"The 4 videos games consists of:~Asthmonaut, a desktop game in which the child navigates through different scenarios and interacts with nine characters to learn about asthma symptoms and management (30 minutes)~Lung Launcher, a mobile game in which the character encounters different asthma triggers (customizable to the child) and the child has to find the correct preventive method to address each trigger (4 minutes)~Asthma Heroes, a desktop game where the player interacts with several characters to learn about their symptoms, treatment and context, and collects objects to help them manage their asthma (30 minutes)~Bloïd, a mobile game where the player uses a pressure sensor as an input device to guide a spacecraft and destroy meteorites in its path (4 minutes)."
45511191|NCT03085927|Behavioral|Active Music Engagement|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
45511192|NCT03085927|Behavioral|Audio Storybooks|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
45511193|NCT05418803|Drug|YHP1807 Tab. 2.5mg|Rivaroxaban 2.5mg
45511194|NCT05418803|Drug|YHR1901 Tab. 2.5mg|Rivaroxaban 2.5mg
45511195|NCT04401709|Drug|Gemcitabine/Capecitabine|gemcitabine 1,000 mg / m2 IV on day 1, 8, and 15 of each cycle Capecitabine 1,660mg / m2 PO twice daily 1 ~ 21 days for 4 weeks
45511196|NCT04401709|Drug|Capecitabine|total 8 cycles Capecitabine 1,250 mg / m2 PO twice daily 1 ~ 14 days for 3 weeks
45403398|NCT01304368|Procedure|Thermotherapy|Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
45403399|NCT00141102|Drug|Celecoxib|Participants are assigned to one of two groups in parallel for the duration of the study
45403400|NCT00141102|Drug|Diclofenac + Omeprazole|Participants are assigned to one of two groups in parallel for the duration of the study
45511197|NCT02472665|Drug|plasma-derived FVIII/VWF concentrate|1 single dose of 80 IU/kg VWF:RCo of Fanhdi will be administered
45511198|NCT04392583|Device|ENTACT Septal Staple system|The ENTACT Septal Stapler delivers implantable septal staples which are intended to connect internal tissues to aid healing and for approximation of soft tissue during nasal septal surgery.
45715339|NCT04134442|Drug|Bupivacaine Liposome Injection|"Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist)~Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33%"
45403401|NCT03663712|Biological|Talimogene Laherparepvec|TVEC is an oncolytic, genetically modified virus designed to reproduce in tumor tissue and stimulate your immune system to attack the tumor cells
45403402|NCT03797092|Biological|Allogeneic adipose-derived stromal cells (CSCC_ASC)|Active group
45403403|NCT03797092|Other|Control group|No treatment
45511199|NCT05417009|Device|trans-cutaneous auricular sensory stimulation|Transcutaneous auricular sensory stimulation
45511200|NCT04497987|Drug|Bamlanivimab|Administered IV.
45511201|NCT04497987|Drug|Placebo|Administered IV.
45511202|NCT04497987|Drug|Etesevimab|Administered IV.
45596787|NCT02362893|Other|Direct Observed Therapy|Patients allocated to the intervention group take their medication (from original blister packaged) in front of the invistigator who observe the patient swallowing the medication. To secure the principals of Direct Observed Therapy, the patient do not leave the clinic for two hours.
45596788|NCT05261555|Device|NoObesity app|The NoObesity system consists of two linked apps - the NoObesity Family app and the NoObesity Professional app.
45851127|NCT00380172|Device|Rheopheresis blood filtration|
45851128|NCT00380328|Drug|neratinib|HKI-272
46057219|NCT04856631|Drug|Cetuximab Solution for infusion|First infusion 400mg/m2，Subsequent infusions 250mg/m2。once per week
45403404|NCT03796936|Behavioral|Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) Therapy|a novel treatment for PTSD combining aspects of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR), within the Computer Assisted Rehabilitation Environment (CAREN)
45403405|NCT03796780|Dietary Supplement|Extra-Virgin Olive Oil|Daily consumption of 25 mL Extra-Virgin Olive Oil in adjunct to medical treatment for 6 weeks
46057220|NCT00611481|Behavioral|Tai Chi|a set of pre-designed Tai Chi Movements
45403406|NCT03796780|Dietary Supplement|Refined Olive Oil|Daily consumption of 25 mL Refined Olive Oil in adjunct to medical treatment for 6 weeks
45403407|NCT01080924|Device|Low frequency ultrasound spectroscopy after broncholysis|Low frequency ultrasound spectroscopy is a novel non-invasive approach to real-time diagnostics of the lungs. Low frequency ultrasound at 10 to 1000 kHz permits monitoring of the air and water contents of the human thorax.
45511203|NCT04757545|Other|HM-PRO|"The intervention group will have a predetermined consultation appointment planned to assess medical status and symptom control. Seven days prior to the scheduled visit, the patient will receive an electronic invitation via RedCap to complete and send PRO data (HM-PRO). Prior to each appointment PRO data will be evaluated by a nurse from an algorithm deciding one of three tracks for the patients:~Worsening in symptoms results in a nurse-led telephone consultation within two days guided by the symptom management manual.~Minor changes in patient's symptom assessment result in a nurse-led telephone consultation within seven days using the symptom management manual.~Patients that are completely stable in the symptom assessment will receive an electronic answer via min-SP (electronic patient journal) regarding the results and a new appointment, including PRO-data prior to this."
45403408|NCT03573856|Behavioral|Active Living|Participants will be provided with education and support for diet and lifestyle modification related to healthy eating and active living.
45403409|NCT03573856|Other|Health and Safety|Participants will be provided with education related to general health and safety topics.
45403410|NCT01078428|Other|Topical silicone gel|Topical silicone gel will be applied to the scar twice daily for a period of 8 weeks
45403411|NCT01078428|Other|Vaseline|Topical petrolatum gel will be applied to the scar twice daily for a period of 8 weeks
45511204|NCT01381627|Drug|Remifentanil|Remifentanil IV bolus 0.5 mcg/kg bolus in 10 minutes. Initial bolus followed by infusion 0.05-0.25 mcg/kg/min for OAA/S 2-3. Remifentanil IV bolus 0.3 mcg/kg PRN for time-limited painful stimuli.
45511205|NCT01381627|Drug|Dexmedetomidine|Dexmedetomidine 0.4 mcg/kg IV bolus in 10 minutes. Dexmedetomidine 0.5-1.0 mcgg/kg/h for OAA/S 2-3. Midazolam 0.015 mg/kg bolus IV PRN.
45403412|NCT01081002|Drug|Lidocaine 10%|3 min before the endoscopy under propofol sedation 4 puffs of lidocaine 10% will be sprayed on the pharynx as a pharyngeal anesthesia
45698821|NCT03466710|Procedure|Colposcopy|"Women will undergo colposcopy at 6 and 12 months after randomization. Those with CIN II will be managed according to standard of care. Those with CIN 1 6 months post randomization will have a second exam 6 months later and if still CIN I will have an exit colposcopy 6 months later.~All women in the Pap and HPV testing policies as well as all women in the colposcopy policy with CIN 1 after 2 exams will have an exit colposcopy 18 months after randomization. The exit colposcopy is a safeguard against the possibility of any false negatives in the follow up policies. The exit colposcopy will also establish the true numbers of CIN lesions in the 3 policies in order to determine their sensitivities and specificities. At the exit colposcopy,all will have an endocervical curettage,and either a minimum of 2 directed biopsies of any mucosal abnormality or in the event no abnormality is identified,2 random biopsies from the cervix."
45851129|NCT00380406|Drug|Leuprolide acetate|
45851130|NCT00380484|Drug|Budesonide|200µg daily
45851131|NCT00380484|Drug|Montelukast|5 mg daily
45851132|NCT00380562|Behavioral|Experience Corps|High intensity volunteering (15 hours a week or more) over a two year time period working with children in grades K-3 in Baltimore City Schools. Controls are assigned to usual activities for two years and then offered opportunity to volunteer with children at the end of two year.
45851133|NCT00380640|Drug|Trimethoprim|This group will receive the active intervention (trimethoprim) first, followed by the placebo.
45851134|NCT00380640|Drug|Trimethoprim|This group will start the study with placebo, followed by the active intervention (trimethoprim).
45403413|NCT01081002|Drug|Diluted gentian root solution|As a basis, an infusion of water (45%), ethanol (35%) and gentian root cut will be used. The gentian root infusion is approved as a natural flavor in the food industry.3 min before the endoscopy under propofol sedation 4 puffs of this gentian root infusion will be sprayed on the pharynx as a pharyngeal anesthesia
45403414|NCT03789136|Other|Not applicable, observational study|Not applicable, observational study
45511206|NCT04726813|Behavioral|MyADHD|The main goals of the intervention are to help participants with better functioning in daily life; offer strategies that will lead to stress reduction and reduce inattention and improve quality of life.The intervention includes: a short introductory chapter (open to everyone), followed by a start module (goal setting), followed by 6 different themed optional modules. Module content is based on GMT, DBT and CBT techniques and is tailored towards key concerns and difficulties experienced adults with ADHD as informed by previous research (focus-groups, lived experience groups) and experiences from group GMT and DBT.
45596789|NCT04528407|Other|Observation without intervention|This study is a follow-up study without intervention.
46057221|NCT00611481|Behavioral|Strength training|Lower-extremity strength training exercises
46057222|NCT00611481|Behavioral|Low-Impact Exercise Control|a set of chair-based low-impact exercises
45511207|NCT04726813|Behavioral|Psychoeducation|Participants in the control condition will be assigned to psychoeducation modules (see Table 2) and will receive restricted access to the platform. They can contact or be contacted if their symptoms levels increases.
45511208|NCT04487691|Biological|Nebulized Platelet Lysate|Approximately 520 cc of autologous venous blood (within AABB guideline limits) will be drawn and platelet lysate (PL), maximizing the patients baseline platelet levels (~2-4x baseline) will be produced in a clean room setting using the Regenexx, LLC proprietary lab protocols (PL-M) utilizing a double lysis technique. From that sample, a high growth factor lysate will be created using a double lysis technique, and a sample will be retained to quantify the protein profile of the PL via ELISA quantitative analysis. The PL will be aliquoted into 56 (n=28x2) 2-ml ampules using sterile technique which will then be frozen at -20°C. The patient will unfreeze each ampule and place it into a handheld ultrasonic nebulizer and inhale the platelet lysate following the nebulizer manufacture's protocol until the treatment is completed. The treatment will be applied once a day for 8-weeks.
45511209|NCT04487691|Other|Nebulized Sterile Saline|Approximately 520 cc of autologous venous blood (within AABB guideline limits) will be drawn and donated for research purposes to keep patient blinded to group allocation. Sterile normal saline to mimic the appearance of the platelet lysate will be aliquoted into 56 (n=28x2) 2-ml ampules using sterile technique which will then be frozen at -20°C. The patient will unfreeze each ampule and place it into a handheld ultrasonic nebulizer and inhale the sterile saline following the nebulizer manufacture's protocol until the treatment is completed. The treatment will be applied once a day for 8-weeks.
45511210|NCT01382641|Device|Hoya AF-1 IOL|The patients will be assessed for three months
45511211|NCT01382641|Device|Revital vision|The patients will be assessed for three months.
45511212|NCT04694833|Behavioral|Motor and cognitive virtual reality-based assessments|Motor and cognitive testing in virtual reality
45511213|NCT04694833|Behavioral|Motor and cognitive virtual reality-based serious games|Serious games implemented in virtual reality to rehabilitate motor and cognitive impairments.
45511214|NCT00974571|Drug|montelukast sodium|montelukast 10 mg tablet orally once daily at bedtime for 6 weeks
45511215|NCT00974571|Drug|Comparator: cetirizine|cetirizine 10 mg tablet orally once daily at bedtime for 6 weeks
45511216|NCT00974571|Drug|Comparator: placebo|placebo tablet orally once daily at bedtime for 6 weeks
45511217|NCT04636879|Other|Positive expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding message.
45511218|NCT04636879|Other|Neutral expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding
45511219|NCT04636879|Other|Negative expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding
45511220|NCT02766608|Drug|BFF MDI 320/9.6 μg|Blinded Treatment
45403415|NCT03789058|Drug|Ibuprofen 400 mg|Surgical removal of wisdom teethb with different regimen of Ibuprofen frequency ; three times versus two times .
45511221|NCT02766608|Drug|BFF MDI 160/9.6 μg|Blinded Treatment
45511222|NCT02766608|Drug|FF MDI 9.6 μg|Blinded Treatment
45511223|NCT02766608|Drug|BD MDI 320 μg|Blinded Treatment
45511224|NCT02766608|Drug|Symbicort® TBH 400/12 μg BID|Open Label
45511225|NCT01382485|Other|RIA harvesting group|Subjects allocated to the RIA group will have the graft harvested in a standardized fashion using the technique described by Quintero et al. Briefly, the RIA device is a single-pass reamer that is connected to an aspirator and irrigator, allowing simultaneous reaming, irrigation, and aspiration of the contents of the femoral canal. RIA head size and tube length will be chosen based on preoperative templating of anteroposterior and lateral radiographs of the donor femur (a head size of 2mm larger than the inner cortical diameter at the isthmus of the femur will be selected). Fluoroscopic imaging will be used to confirm guidewire positioning and avoid eccentric reaming. Bone graft will be harvested from the central femoral canal and from each femoral condyle in 3 separate passes.
45851135|NCT00380796|Drug|Collection of safety data for Cohort 1|Twice-yearly collection of information about cancer incidence and cause of death among patients who participated in clinical trials of infliximab in the treatment of COPD. The follow-up period is 5 years.
45403416|NCT03788902|Drug|Ritalin|Single dose of Ritalin IR 0.3-0.5 mg/kg OR placebo
45403417|NCT05068414|Diagnostic Test|Blood panel|"Thrombin generation test~Residual plasma concentration of dabigatran, rivaroxaban and/or apixaban (direct oral anticoagulants)~International Normalized Ratio (if anti-vitamin K therapy is prescribed)~Platelet aggregation test"
45403418|NCT05669092|Drug|Toripalimab|3mg/Kg iv d1q2w
45403419|NCT05669092|Radiation|CRT|IMRT 50Gy/25fx 625mg/m2 bid d1-5 qw Irinotecan:1、Full wild (GG+6/6): 80mg/m2/week for 5 times 2、Single site mutation (GG+6/7 or GA+6/6): 65mg/m2/week for 5 times 3、Double locus mutation (GG+7/7 or AA+6/6 or GA+6/7): 50mg/m2/week for the 1st, 2nd, 4th and 5th week for 4 times
45403420|NCT05669092|Radiation|SCRT|25Gy/5fx
45403421|NCT05669092|Drug|XELIRI|Capecitabine: 1000mg/m2 bid d1-14 Irinotecan: 200mg/m2 ivgtt d1 q3w
45596790|NCT02203175|Drug|saline|Before the anesthesia induction, 5 ml isotonic saline
45596791|NCT02203175|Drug|fentanyl|before the anesthesia induction 50 mcgr fentanyl
45596792|NCT02203175|Drug|propofol|during anesthesia 50 mg proposal with 50 mcgr fentanyl
45596793|NCT03527017|Other|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of Germany.
45511226|NCT01382485|Other|AICBG harvesting group|Iliac crest bone graft will be harvested from the anterior iliac crest through an incision beginning 2cm posterior to the anterior superior iliac spine and carried posteriorly. A window will be made in the iliac crest and a curette will subsequently be used to harvest the cancellous bone. The incision will be closed in 3 layers. The infiltration of local anaesthetic will be at the discretion of the surgeon.
45511227|NCT03630731|Drug|chidamide|For those who responded to induction chemotherapy, chidamide will be given OR orally 30mg biw for at least half a year
45511228|NCT01382407|Drug|Cetuximab|Once a week:Loading dose-400 mg/m2;subsequent-250 mg/m2 on days 8,15, 22,29,36 if administered as a single agent, or together with Irinotecan 125 mg/m2 on days 1,8,15,29 followed by administration every 42 days.
46057223|NCT00808210|Drug|Infliximab|Intravenous repeating dose
45403422|NCT05669092|Drug|FOLFRINOX|Irinotecan: 150mg/m2 ivgtt d1 (double locus mutation downregulated to 120mg/m2) Oxaliplatin: 85mg/m2 ivgtt d1 5-FU: 2400mg/m2 ivgtt 46h q2w
45403423|NCT00255008|Biological|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
45511229|NCT02235857|Device|LIPOSORBER® LA-15 System|LIPOSORBER® LA-15 System is an extracorporeal blood purification system. Approximately 3 to 4 L of plasma is treated in a single treatment session and it takes 2 to 3 hours. Recommended frequency of the treatment is twice weekly for 3 weeks followed by once weekly for 6 weeks, thus it takes 9 weeks for a total of 12 treatment sessions.
45511230|NCT01382329|Biological|H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)|Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm
45403424|NCT00255008|Drug|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 48 weeks
45511231|NCT05082285|Combination Product|MenABCWY-2Gen low dose vaccine|MenABCWY-2Gen low dose vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and study Part II.
45511232|NCT05082285|Combination Product|MenABCWY-2Gen high dose vaccine|MenABCWY-2Gen high dose vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 2 and study Part II.
45511233|NCT05082285|Combination Product|MenABCWY-1Gen vaccine|MenABCWY-1Gen vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part II.
45511234|NCT05082285|Combination Product|MenB vaccine|MenB vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and Step 2 and study Part II.
45511235|NCT05082285|Combination Product|MenACWY-TT vaccine|MenACWY-TT vaccine is administered intramuscularly in the lower thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and Step 2 and study Part II.
45511236|NCT03325231|Other|Reconstructive surgery following bladder removal.|Investigating patient experience of bladder reconstructions.
45511237|NCT03317119|Other|Laboratory Biomarker Analysis|Correlative studies
45511238|NCT03317119|Drug|Trametinib|Given PO
45511239|NCT03317119|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
45511240|NCT05347589|Other|Post isometric relaxation of quadratus lumborum and gluteus Gluteus maximus activation exercises|Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range.
45596794|NCT03527017|Other|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in adult IQOS users residing in Germany.
45596795|NCT05792085|Behavioral|EHR-based GDMT Optimization|Patients will be prescribed appropriate GDMT for HFrEF if they meet clinical criteria by the study team, appropriate lab work and follow up testing will be sent and followed up by the team. All recommendations and plans will be copied to primary care providers who can opt out if disagree, but also to improve telementoring to build clinical comfort.
45698822|NCT03466710|Other|Pap test|"Women will receive Pap tests at 6 and 12 months after randomization. The Pap test will be prepared using the Thinprep® system which is the standard at Calgary Laboratory Services. Women with a Pap test result of malignant, HSIL, AIS, AGC, ASC-H, or LSIL-H (>LSIL) at 6 or 12 months post randomization will be referred for colposcopic examination. Women with an ASC-US or LSIL result (</=LSIL) will have a second follow up Pap test 6 months later (12 months post randomization). Those with a persistent result of ASC-US or LSIL or >LSIL at 6 or 12 months will be referred for colposcopic examination. Outcome in the Pap policy is positive when the histopathology is >/=CIN II. Results of </=CIN I equal a negative outcome.~All other Pap test results will have an exit colposcopy 6 months later (18 months post randomization)."
45403425|NCT00255008|Biological|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
45596796|NCT05792072|Device|rTMS|High-frequency rTMS
45596797|NCT05792072|Device|Sham rTMS|sham rTMS
45851136|NCT00380952|Device|Dune Device|
45851137|NCT00381030|Drug|carvedilol plus nurse management|
45851138|NCT00381108|Drug|Placebo Tablet|Two tablets, twice daily.
45511241|NCT05347589|Other|post isometric relaxation of the Quadratus lumborum|Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range
45511242|NCT05347355|Other|Spencer technique along with conventional treatment|"Subjects in this group will receive conventional exercises and 7 stages of Spencer technique: (A) extension, (B) flexion, (C) circumduction with compression, (D) circumduction with traction, (E) abduction, (F) internal rotation, (G) lymphatic pump.~Spencer technique will be used to increase range of motion of the glenohumeral joint. The patient will be positioned lying on the side with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand will provide force into the restrictive barrier of shoulder in 7 different movements. These will be shoulder extension, circumduction with distraction, abduction, adduction with internal rotation and glenohumeral pump. During all the movements, patient will be asked to use muscle energy against the slight resistance offered by the therapist for 3-5 seconds. The exercise will be repeated 3-5 times with rest intervals over 3 sessions per week on alternate days for 4 weeks."
45511243|NCT05347355|Other|Gongs Mobilization along with conventional treatment|The Gong's mobilization can be done either in high sitting or in side-lying position with the affected shoulder upward. The subject's shoulder will be abducted at 90° so that the humerus will be maintained at vertical position. The elbow joint will be flexed and maintained at 90°; the therapist will maintain this position by placing his/her hand below the subject's elbow. The humeral head will be pressed from anterior to posterior direction with the other hand. The therapist will hold the vertical axis of the humerus by maintaining the shoulder in abduction and the elbow in 90°. The therapist will raise his own body by slightly pulling on the anterior capsule and this pull will be maintained for 10-15 seconds and then relax for five seconds and will be performed for about two to three minutes. At this moment the subject will be asked to perform shoulder abduction with no external rotation, while elbow flexion will be maintained throughout.
45511244|NCT03306355|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
45403426|NCT00255008|Drug|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 24 weeks
45511245|NCT03306355|Device|IOL implantation active comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
45511246|NCT04411199|Drug|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
45511247|NCT04411199|Other|Standard of Care (SoC)|prophylactic, pre-operation per institution guidelines
45851139|NCT00381108|Drug|Pomegranate Tablet|Two tablets, twice daily.
45851140|NCT00381186|Behavioral|diet- and exercise intervention|
45851141|NCT00381264|Drug|Cesamet™ (nabilone)|
45851142|NCT00381342|Drug|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day
45403427|NCT01306240|Procedure|Surfactant instillation|Intra-tracheal poractant alpha instillation after tracheal intubation
45403428|NCT01306240|Procedure|nCPAP|Nasal Continous Positive Airways Pressure (nCPAP). Positive End Expiratory Pressure (PEEP) is set between 4 to 6 cm H2O. FiO2 is adjusted for a target post-ductus arteriosus SpO2 between 92% and 96%.
45403429|NCT03714022|Drug|Abatacept|Participants will receive abatacept at a single dose 750 mg as IV infusion.
45403430|NCT05624164|Procedure|Lateralised microfracture|making microfracture(4 holes with 2mm diameter) at the lateral side of the footprint right after arthroscopy rotator repair.
45403431|NCT00143312|Drug|voriconazole|Voriconazole is given to patients at least 48 hours after chemotherapy
45403432|NCT03967028|Procedure|cesarean section|lower segment cesarean section either elective or emergency
45403433|NCT03791866|Other|Nutrition|Enteral nutrition
45403434|NCT03967262|Behavioral|Brief Motivational Intervention|The objective of motivational intervention is to make the patient aware of the relationship between the consumption of alcohol and other drugs and the accident, and induce them to carry out a change in habits.
45403435|NCT04833946|Other|Andrographis paniculata [150 mg]|One capsule to be taken orally, 30 minutes after breakfast & 30 minutes before bedtime
45403436|NCT04833946|Other|Microcrystalline Cellulose (MCC)|One capsule to be taken orally, 30 minutes after breakfast & 30 minutes before bedtime
45403437|NCT01077206|Drug|Simvastatin|80mg daily versus 40mg daily, for 21 days.
45403438|NCT03791710|Procedure|autologous fat grafting|regular liposuction procedure at which sufficient amount of fat is extracted from the patient and then the fat is processed then grafted underneath the burn wound
45403439|NCT03791710|Drug|Topical Cream|serial dressing with topical agents e.g Silver Sulphadiazine
45511248|NCT02157350|Procedure|Panretinal laser photocoagulation|Panretinal photocoagulation. Laser energy is given to the retina in two sittings, carefully avoiding the macular. The energy are placed 2 to 3 disc diameters away from the macula and the disc outside the arcades and extended peripherally upto the equator and beyond.
45403440|NCT03791710|Procedure|split thickness skin grafting|depridment and split thickness skin grafting
45403441|NCT05623540|Drug|Bisphosphonates, Combinations|
45511249|NCT03252535|Biological|Cellavita HD lower dose|The participants will receive a total of 9 intravenous administrations of 1x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
45511250|NCT03252535|Biological|Cellavita HD higher dose|The participants will receive a total of 9 intravenous administrations of 2x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
45511251|NCT03252535|Other|Placebo|The participants will receive a total of 9 intravenous administrations of placebo divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
45511252|NCT04356495|Dietary Supplement|Vitamins|2 tablets daily from the first day (day 0) to day 9
45511253|NCT04356495|Drug|Telmisartan|1 tablet daily from the first day (day 0) to day 9
45511254|NCT04356495|Drug|Ciclesonide|2 puffs twice a day in an inhalation chamber from the first day (day 0) to day 9
45511255|NCT04356495|Drug|interferon β-1b|A 10-minute nebulization, once a day, from the first day (day 0) to day 4, of 9.6 MIU / 300 µg of IFN-β-1b (EXTAVIA®) diluted in 2 mL of water
45511256|NCT05345249|Drug|Ropivacaine Hydrochloride Injection|Investigating the effectiveness of erector spinae plane block with ropivacaine for lumbar spinal fusion surgery versus placebo.
45511257|NCT05345249|Drug|Sodium chloride|Placebo comparator
45511258|NCT03542084|Other|Unsolicited endocrine e-consult|The PCP for intervention arm patients will receive an unsolicited e-consult from an endocrinologist with recommendations on how to improve glycemic control in the intervention patient
45511259|NCT03230695|Device|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
45511260|NCT03230695|Device|Active stimulation|Active transcranial direct current stimulation will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
45511261|NCT03230695|Device|Sham stimulation|In sham transcranial direct current stimulation, no current will be delivered through the transcranial direct current stimulation device after the first 30 seconds.
45511262|NCT05654961|Other|Use of telemedicine|Use of telemedicine (any type: telephone only, non-invasive, implantable-cardioverter-defibrillator-based, invasive) in heart failure management
45698823|NCT03466710|Diagnostic Test|HPV test|Women will have an HPV test performed on a cervical scrape sample 12 months after randomization. Women with a positive result will be referred for colposcopy. Outcome in the HPV testing policy is positive when histopathology obtained at the colposcopic exam shows CIN II. All other results equal a negative outcome. HPV negative women will have an exit colposcopy 18 months post randomization. HPV testing will be performed using Cervista™HPV HR(Third Wave Technologies Inc./Hologic Inc, Madison, WI, USA).This HPV DNA test identifies 14 high risk types (16,18,31,33,35,39,45,51,52,56,58,59,66,68). Testing will be performed on the residual cervical scrape sample which is fixed in the PreservCyt® solution of the Thinprep® liquid based system(Hologic Inc, Marlborough, Ma, USA). Cervical samples may be held for up to 24 wks at room temperature before DNA extraction.This allows time for transportation without refrigeration.The samples will be sent by overnight express delivery to the laboratory.
45511263|NCT02154230|Dietary Supplement|"Acqua Santa di Chianciano® (sulphate-bicarbonate-calcium water)"|"During the first 4 weeks the SW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Acqua Santa di Chianciano® at room temperature."
45511264|NCT02154230|Dietary Supplement|Tap water|During the first 4 weeks the TW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of tap water at room temperature.
45511265|NCT01384045|Other|Health promotion outreach|Calling patients who are due for diabetes related services, sending them an interventional letter and assisting them in getting over due serves.
45403442|NCT05622838|Diagnostic Test|Alpha1 -Antitrypsin level|measuring alpha1 -antitrypsin level in pregnant women
45403443|NCT01305694|Biological|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10^5 MSCs per kg,qw,for 4 weeks
45403444|NCT03791476|Drug|rhC1INH|C1 esterase inhibitor
45403445|NCT03791476|Other|Saline Solution|saline solution
45403446|NCT03791632|Other|classical lecture style presentation|classical lecture style presentation
45403447|NCT03791632|Other|an intervention in the form of fun workshops|an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)
45511266|NCT04721522|Diagnostic Test|blood sampling & ultrasound|"Blood sampling:~Serum P4 & estradiol will be performed on the day of triggering and on the day of embryo transfer. Progesterone/ Estradiol (P4/E2) ratio will be calculated Ultrasound: On triggering day, at time of ovum pick up and on ET day, we will measure~Endometrial thickness~Endometrial pattern~Endometrial compaction: the difference in measurement of endometrial thickness between the day of embryo transfer and the day of triggering.~Junctional zone thickness~Uterine contraction (peristalsis).~Blood flow of uterine vessels: PI of the uterine arteries will be calculated also Endometrial - sub endometrial blood flow"
45511267|NCT04724941|Other|No intervention|No intervention
45511268|NCT04200963|Drug|IK-175|Subjects will be administered IK-175 PO daily for every 21-day treatment cycle during the Single Agent Treatment dose escalation or for every 28-day treatment cycle during the Single Agent dose expansion.
45403448|NCT03791632|Other|digital media intervention|digital media intervention
45403449|NCT03791554|Procedure|Group A (Lateral closed tunnel subepithelial CT graft)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the adjacent teeth to treating gingival recession with edges of the recession sutured together after placing connective tissue graft
45403450|NCT03791554|Procedure|Group B (Tunnel procedure with subepithelial CT graft)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the prepared tunnel to treating gingival recession
45403451|NCT05620732|Biological|Claudin18.2 CAR-T cells|patients treated with Claudin18.2 CAR-T cells
45403452|NCT04796350|Device|AGN1 LOEP treatment|the implantation site is injected with the AGN1 implant material
45511269|NCT04200963|Drug|IK-175 and nivolumab|Subjects will be administered IK-175 PO daily and administered a single dose of nivolumab IV on Day 1 for every 28-day treatment cycle during the Combination Treatment dose escalation and expansion.
45511270|NCT02157428|Drug|Flumazenil|
45403453|NCT01306318|Drug|eperisone hydrochloride plus diclofenac sodium capsule|Single dose of fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given in healthy volunteers in fasting conditions
45511271|NCT02157428|Drug|saline|
45511272|NCT01383967|Drug|LY2979165|Administered orally
45698824|NCT03466632|Drug|Propofol|propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure.
45698825|NCT03466632|Drug|Dexmedetomidine|dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure
45698826|NCT04018092|Device|Active NIR-PBM|See Experimental arm for description.
45698827|NCT04018092|Device|Sham NIR-PBM|See Sham Comparator arm for description.
45698828|NCT03466554|Device|Hyperbaric oxygen-90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes|60 daily HBOT sessions will be administrated 5 days per week. comprise of 90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes.
45698829|NCT03461562|Other|Aerobic Exercise|Aerobic exercise wil be held for 40 minutes. Dynamic exercises will be accompanied by physiotherapist on the vibration platform for 15 minutes. Same excercises will be held stable platform (when the devices turned off) by control group for 15 minutes.
45698830|NCT05348928|Device|Continuous glucose monitoring device|Continuous glucose monitoring device
45403454|NCT01306318|Drug|eperisone hydrochloride tablet and diclofenac sodium tablet|Single dose of eperisone hydrochloride 50 mg as tablet formulation and diclofenac sodium 50 mg as tablet formulation to be given in healthy volunteers in fasting conditions
45403455|NCT03191656|Device|IASD Implant|Implantation of the IASD device using trans-septal puncture and the IASD system
45403456|NCT03788668|Procedure|Hyoid suspension|Hyoid suspension will be done with barbed reposition pharyngoplasty
45403457|NCT05385328|Device|EYEFUL: healthy people|"This kind of study implies that we do not require the use of any substance, medicine or therapeutic technique and neither imply any risk to the participants.~The data to be captured are exclusively video and audio recordings, and different signals from smart watches (mainly related to movement). Addittionaly, the clinical evaluation of the performance of these activities will be carried out according to the assessment scales to be defined in the project. The results of this evaluation will be exclusively used in the training of the automatic systems developed in the project and in order to establish a correlation between the captured observations (video, audio, smart watches signals) and the diagnostic assessment."
45403458|NCT05385328|Device|EYEFUL: people with pathology|"This kind of study implies that we do not require the use of any substance, medicine or therapeutic technique and neither imply any risk to the participants.~The data to be captured are exclusively video and audio recordings, and different signals from smart watches (mainly related to movement). Addittionaly, the clinical evaluation of the performance of these activities will be carried out according to the assessment scales to be defined in the project. The results of this evaluation will be exclusively used in the training of the automatic systems developed in the project and in order to establish a correlation between the captured observations (video, audio, smart watches signals) and the diagnostic assessment."
45403459|NCT00254540|Drug|SU011248 capsule|50mg, PO on day 28 of each 42 day cycle, until progression or unacceptable toxicity develops
45511273|NCT01383967|Drug|placebo|Administered orally
45511274|NCT02254928|Drug|Corifollitropin alfa|One dose of 150 μg of corifollitropin alfa will be administered at day 1 of stimulation. Stimulation will be continued with 250-300 IU/day of rFSH from day 8 forward.
45511275|NCT01383889|Other|Physical exercise|Two modalities of exercise will be compared: treading mill and stationary bicycle. Pregnant women enrolled in the study will perform exercise during 20 minutes and will be monitored 20 minutes before, during and 20 minutes after exercise.
45511276|NCT00960141|Drug|montelukast sodium|montelukast 10 mg tablet, taken orally once daily at bed time for 2 weeks
45511277|NCT00960141|Drug|Comparator: loratadine|loratadine 10 mg tablet, taken orally once daily at bed time for 2 weeks
45511278|NCT00960141|Drug|Comparator: placebo|placebo tablet, taken orally once daily at bed time for 2 weeks
45698831|NCT05348928|Other|Laboratory plasma glucose concentration determination|Laboratory plasma glucose concentration determination
45698832|NCT01144624|Drug|AZD9773|A single loading dose followed by 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
45511279|NCT02771522|Device|Calcivis System|Following de-bond, and identification of active post-orthodontic white spot lesions at baseline with the Calcivis System, each active tooth will be again be imaged at 2, 4, 8 and 12 weeks. Both black & white and luminescent images images of the teeth are taken. The images of each tooth are overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
45511280|NCT00759655|Biological|Moroctocog alfa|Patients will receive Moroctocog alfa according to their investigator's prescription.
45511281|NCT03918915|Drug|SYD-101 Dose 1|Sterile topical ophthalmic solution
45511282|NCT03918915|Drug|SYD-101 Dose 2|Sterile topical ophthalmic solution
45511283|NCT03918915|Drug|Vehicle|Sterile topical ophthalmic solution without active ingredient
45403460|NCT05380492|Biological|VOY-101|Intravitreal injection of VOY-101
45511284|NCT00518869|Drug|PG2|500 mg PG2 / 500 ml normal saline IV infusion for 3 hours once daily for 4 doses in the 1st week, 3 doses in the 2nd week and 3 doses in the 3rd week of each chemo-cycle for three cycles. Total 10 doses will be given in each cycle even with skip days.
45511285|NCT02255006|Device|Active acupuncture|Active acupuncture treatment group receive electroacupuncture (EA). For EA treatment, unilateral acupuncture meridian point Pericardium5 (PC5), Pericardium6 (PC6), Stomach36 (ST36), and Stomach37 (ST37) are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2 Hertz continuous wave current. After FMD measurement, a pneumatic cuff placed above the upper arms is inflated to 200 mmHg for 15 minutes. The cuff is then deflated, and 15 minutes of reperfusion is allowed before FMD measurement again. Acupuncture is performed from after ten minutes of ischemia till end time of reperfusion
45511286|NCT02255006|Device|Sham acupuncture|"For sham intervention, nonacupuncture points are used. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.~Volunteers undergo FMD measurement and acupuncture like above methods."
45511287|NCT02255006|Drug|Euglucon 5mg|8 healthy volunteers are administered 5 mg of glibenclamide (Euglucon, Roche Pharma) 3 hour before FMD measurement. This dosage has previously been shown to be able to completely inhibit forearm KATP channels. With the glibenclamide administration, a 10% dextrose infusion is started and titrated to maintain blood sugar levels between 80 and 120 mg/dL throughout the study period. 3 hours after glibenclamide administration, the subjects undergo FMD measurement before and after ischemia reperfusion injury. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method.
45511288|NCT02255006|Drug|Celebrex 200mg|8 healthy volunteers are administered celecoxib, a selective COX-2 inhibitor, 200 mg twice daily for 5 days. Last dose of celecoxib is administered at morning. Volunteers undergo FMD measurements before and after ischemia reperfusion injury in that morning of last dose of celecoxib. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method
45511289|NCT02771366|Drug|Fermented Papaya Preparation|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
45511290|NCT02771366|Other|Granulated Sugar|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
45511291|NCT03396471|Drug|Pembrolizumab|200mg IV at day -21, then day 1 of each 21-day cycle for a maximum of 24 continuous months of Pembrolizumab (35 cycles) from Cycle 1 Day 1 (C1D1) can be administered.
45511292|NCT03396471|Radiation|External Beam Radiation Therapy|20-30 Gy over five fractions for up to two cycles.
45511293|NCT00103142|Biological|falimarev|Given subcutaneously and intradermally
45511294|NCT00103142|Biological|inalimarev|Given subcutaneously and intradermally
45511295|NCT00103142|Biological|sargramostim|Given subcutaneously
45511296|NCT00103142|Biological|therapeutic autologous dendritic cells|Given subcutaneously and intradermally
45511297|NCT02157584|Drug|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fed conditions /high-fat / high caloric meal)
45698833|NCT01144624|Drug|Placebo|Intravenous infusion of a saline solution
45698834|NCT05339334|Drug|PF-07321332/ritonavir|PF-07321332/ritonavir will be given by mouth two times a day for 10 days
46057224|NCT00808210|Drug|Methotrexate|Oral or parenteral repeating dose
45403461|NCT03973658|Device|Hearing aids|Fitting of hearing aids (for the first time)
45403462|NCT01077440|Genetic|DNA analysis|DNA analysis will be performed on samples collected.
45403463|NCT01077440|Genetic|polymerase chain reaction|A polymerase chain reaction (PCR) assessment will be done on the samples collected.
45403464|NCT01077440|Other|flow cytometry|Flow cytometry will be done on the samples collected.
45403465|NCT01077440|Other|laboratory biomarker analysis|Laboratory biomarker analysis will be performed on the samples collected.
45403466|NCT03791320|Diagnostic Test|Vessel Fractional Flow Reserve|FFR measurement based on coronary angiography
45403467|NCT01326494|Drug|Arm 1 Oral Cortico Steroids|"Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs.~Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )"
45403468|NCT03794674|Other|No intervention.|No intervention, since this is a validation study
45511298|NCT02157584|Drug|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fasted conditions)
46057225|NCT00808210|Drug|Methylprednisolone|Intravenous repeating dose
45511299|NCT00943683|Drug|montelukast sodium|Montelukast 4-mg oral granules mixed with applesauce once daily at bedtime for 6 weeks
45511300|NCT00943683|Drug|Comparator: Placebo|Placebo oral granules mixed with applesauce once daily at bedtime for 6 weeks
45511301|NCT02154308|Biological|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
45511302|NCT03738644|Other|Monitoring with near-infrared spectroscopy|"No interventions are used. Stroke patients are examined with near-infrared spectroscopy (NIRS). NIRS examinations are done with Octamon system (Artinis Medical Systems, Elst, The Netherlands) consisting of 8 transmitters emitting infrared light of 760 and 850 nm and 2 receivers measuring oxygenated and deoxygenated hemoglobin in the frontal cortex.~Examination protocol can be found in detailed description."
45511303|NCT03542006|Drug|Brinzolamide Ophthalmic|Topical brinzolamide given bd for 3 months
45511304|NCT02157740|Device|Residents of nursing homes with telemedicine after implementation of telemedicine|
45511305|NCT02154464|Drug|Paracetamol|
45511306|NCT02154464|Drug|Placebo|
45511307|NCT00911547|Drug|montelukast sodium|10 mg tablet taken once daily at bedtime for 16 weeks
45511308|NCT00911547|Drug|beclomethasone|200 ug inhaled, taken twice daily for 16 weeks
45511309|NCT00911547|Drug|Placebo inhaler|placebo inhaler taken twice daily for 16 weeks
45511310|NCT00911547|Drug|placebo tablet|placebo tablet taken once daily at bedtime for 16 weeks
45511311|NCT02159690|Drug|Enzalutamide|160mg
45511312|NCT02159690|Drug|Abiraterone acetate|1000mg
45403469|NCT01306396|Behavioral|dietary intervention mainly focusing on fructose reduction|Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake by 50%. In the first study year, every three months and in the second study year, every six months, nutritional counseling is repeated in small groups in which parents and children are separately trained.
45511313|NCT02159690|Drug|Prednisone|5mg twice daily (to blunt mineralocorticoid side effects from abiraterone)
45511314|NCT02159690|Drug|Dutasteride|0.5mg
45511315|NCT02159690|Drug|Degarelix|240mg SC loading dose on day 1, then three 80mg SC injections every 4 weeks thereafter
45511316|NCT02154542|Device|Neurovent Monitor XIII|
45511317|NCT03696771|Drug|NJH395|Immune stimulator antibody conjugate (ISAC), consisting of a monoclonal antibody which targets HER2 conjugated to an immune-stimulatory agent
45511318|NCT02157818|Drug|midazolam|
45511319|NCT02157818|Drug|Dexmedetomidine|
45403470|NCT03794830|Other|manipulation group (MG)|Patients were treated with sacroiliac joint osteopathic semidirect manipulation twice a week every 3 to 4 days over a period of time of 3 weeks
45403471|NCT03794830|Other|electrotheraphy group (EG)|Patients were treated with micro-waves (circular antenna in lumbar area, pulsating-mode 120W for 12 minutes) and later conventional analgesic TENS (80Hz frequency, 30 minutes) 5 days per week over a period of time of 3 weeks (15 sessions)
45403472|NCT05316220|Drug|Mesalamine|Oral Capsules
45403473|NCT05316220|Drug|Placebo|Oral Capsule
45403474|NCT05297188|Device|ergonomic sleep mask|Ergonomic sleep mask; It is a material that covers the eye and ear completely and can be adjusted according to the patient, can be washed and reused at 30 degrees after use, 95% cotton, 5% polyester structure and 100% light proof properties.
45511320|NCT02154620|Procedure|Volar plate|An anatomically countoured volar plate is implanted through a Henry's incision.
45511321|NCT02154620|Device|Synthes TCP volar plate|
45511322|NCT03542786|Dietary Supplement|Probiotic|"The probiotic i3.1 is a commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A.~It contains:~Lactobacillus plantarum CECT7484~Lactobacillus plantarum CECT7485~Pediococcus acidilactici CECT7483"
45511323|NCT03542786|Dietary Supplement|Prebiotic|"ProSeed prebiotic is a non-commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A.~It contains:~Partially Hydrolyzed Guar Gum (PHGG)~Inulin HPD~Oat Beta-Glucans~Pectin~Inulin Low Protein Diet (LPD)~Polydextrose~Maltrodextrins"
45511324|NCT03542786|Dietary Supplement|Placebo|It is a non-commercialized product. It is composed of the same excipients as the probiotic and the prebiotic. It will be supplied by the promoter and manufactured in ALIFARM S.A.
45511325|NCT02154698|Other|22-gauge Standard Needle|Acquisition of lymph nodes samples using the 22-gauge Standard Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
45511326|NCT02154698|Other|22-gauge ProCore Needle|Acquisition of lymph nodes samples using the 22-gauge ProCore Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
45511327|NCT00899379|Drug|rizatriptan benzoate|Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache
45511328|NCT00899379|Drug|Comparator: Placebo|Placebo to Rizatriptan, Oral Tablet
45511329|NCT04984538|Other|Pharmacogenomic Testing|Cheek swab as a part of routine care
45511330|NCT02255318|Device|Taurolock|
45511331|NCT02255318|Drug|Placebo|
45511332|NCT04326439|Drug|Cytarabine|100 mg/m²/dose every 12 hours IV Days 1-10
45511333|NCT04326439|Drug|Daunorubicin|50 mg/m²/dose IV Days 1, 3, 5
45511334|NCT04326439|Drug|Erwinase|25,000 International Units/m²/dose IM Days 2, 9
45511335|NCT04326439|Drug|Etoposide|150 mg/m²/dose IV Days 1-5
45511336|NCT04326439|Drug|Gemtuzumab ozogamicin|Administered as a single 3 mg/m2 dose of GO to be given between days 6-10 during Induction I for patients with CC genotype, in addition to ADE therapy.
45511337|NCT04326439|Procedure|Stem cell transplantation (SCT)|Transplantation of multipotent hematopoietic stem cells from bone marrow
45511338|NCT04326439|Drug|Sorafenib|200 mg/m2/dose daily, rounded to accommodate tablet size. The maximum dose will be 400 mg. Days 7 through 34.
45511339|NCT02255240|Behavioral|Physical activity intervention|Participants will receive counseling on self-regulatory skill building that has been adapted to complement the video games used. We anticipate that the games used will consist of fitness, sports, and dance games and will be played on a Wii U console. The games played will be chosen by each participant from a pool of potential appropriate games.
45698835|NCT01096810|Drug|TBL 12|TBL 12 will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression.
46057226|NCT00808210|Drug|Ocrelizumab|Intravenous repeating dose
45403475|NCT01306552|Behavioral|Student-Intervention only group|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) during 7th grade.~The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php."
45403476|NCT01306552|Behavioral|Multi-component Intervention|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) + one parent night with information about smoking prevention and one informational letter by mail"
45403477|NCT01306552|Behavioral|Control Group|"One visit to the Nutrition and Physical Activity Parcours offered by KARUNA e.V. (Kinderleicht gesund zu leben).~(same set up as the smoking prevention parcours with topics around healthy nutrition and promotion of physical activity)"
45403478|NCT03791242|Device|Cpap and ketogenic diet|Patients with severe OSAS who are BS candidates will be treated with CPAP only at night (Group 1), or CPAP at night + KMED daily (Group 2), for 4 weeks
45511340|NCT03541928|Drug|HSV-Tk|"Injection of the HSV-tk gene therapy product in four quadrants of prostate to enhance the immune system via bystander effect in which cytotoxicity is conferred to non-transduced neighboring cells. In vivo bystander effects are likely due to a combination of host immunological responses and to gap junction-mediated transport of phosphorylated prodrug metabolites to surrounding cells."
45403479|NCT03791164|Behavioral|The Pain Toolkit|the Pain Toolkit is a leaflet that encourages self management techniques for patients with chronic pain
45511341|NCT03541928|Drug|Valacyclovir|The recommended dose for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45). This dose has been calculated to give a similar AUC as 10 mg/kg of intravenous acyclovir administered every 8 hours. This is the same dose regimen used in a previous phase I clinical trial of ADV/HSV-tk plus acyclovir and topotecan in patients with recurrent ovarian cancer.
45511342|NCT03541928|Drug|Bicalutamide|"The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that Bicalutamide be taken at the same time each day.~The use of an oral antiandrogen with medical castration for the treatment of prostate cancer is referred to as combined androgen blockade (CAB). Compared with LHRH-agonist monotherapy, CAB with bicalutamide did not reduce overall QoL but provided an early improvement in QoL related to lower urinary tract symptoms and pain."
45511343|NCT03541928|Drug|Leuprolide Acetate|Leuprolide acetate 7.5 mg depot injection will be injected monthly for a total of 2 months.
45511344|NCT03541928|Radiation|Brachytherapy, External beam radiotherapy|On day 60, patient will undergo high dose rate (HDR) Brachytherapy. The patient will have 8-14 needle catheters inserted under ultrasound guidance. CT simulation and radiation treatment planning will be performed. The needle catheters will be connected to an HDR afterloader containing an Iridium 192 source. A single dose of 1250cGy will be delivered.
45403480|NCT03791164|Behavioral|the Back Book|The Back Book is a patient information leaflet that offers information and advice about back pain
45403481|NCT03790930|Diagnostic Test|deep learning|manually labeled samples will be used to train, validate and test deep learning algorithm, and then realize automatic classification.
45403482|NCT01305850|Drug|placebo|Patients in the control group will administer antihypertensive agents, except angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone. Dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
45403483|NCT01305850|Drug|Aliskiren|Patients with hypertension will take fixed-dose 150 mg aliskiren per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blocker and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
45511345|NCT03541928|Procedure|Radical prostatectomy|approximately 2-3 weeks after radiotherapy completion, patient will undergo radical retropubic prostatectomy. Use of laparoscopy or robotic assistance will be at the urologist's discretion. Lymph node dissection will be performed.
45511346|NCT00145795|Drug|Kaletra + Current Dual NRTI Backbone|
45511347|NCT00145795|Drug|Current Regimen|
45511348|NCT01379365|Device|Cryo-Touch III|Percutaneous treatment with the device
45403484|NCT01305850|Drug|Aliskiren plus Losartan|Patients with hypertension will take fixed-dose 150 mg aliskiren + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
45403485|NCT01305850|Drug|Enalapril plus Losartan|Patients with hypertension will take fixed-dose 20 mg enalapril + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
45511349|NCT02771210|Biological|Secukinumab|Induction: Week 0,1,2,3 150 mg or 300 mg Secukinumab s.c. Maintenance: 150 mg or 300 mg Secukinumab s.c. every 4 weeks starting at Week 4
45511350|NCT02771210|Drug|Secukinumab Placebo|Induction: Week 0,1,2,3 Secukinumab Placebo s.c. Maintenance: Secukinumab Placebo s.c. every 4 weeks starting at Week 4 until Week 24 followed by 150 or 300 mg Secukinumab s.c. every 4 weeks
45511351|NCT01382095|Biological|Recombinant fimbrial adhesin dscCfaE|10 ug on study days 0, 21 and 42
45511352|NCT01382095|Biological|Recombinant fimbrial adhesin dscCfaE|50 ug on study days 0, 21 and 42
45851143|NCT00381342|Drug|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day, then exenatide subcutaneous injection, 10 mcg twice a day
45851144|NCT00381342|Drug|placebo|subcutaneous injection, volume equivalent to appropriate dose of exenatide, twice a day
45851145|NCT00381420|Device|drug-eluting stent|sirolimus-coated Bx VELOCITY Balloon-Expandable Stent
45851146|NCT00381420|Device|bare-metal stent|un-coated Bx VELOCITY Stent
45851147|NCT00381576|Behavioral|Resistance training|Intervention group: 12 weeks of resistance training for the lower extremity. Control group: No intervention - 12 weeks of normal daily living
45511353|NCT01382095|Biological|Recombinant fimbrial adhesin dscCfaE|250 ug on study days 0, 21 and 42
45511354|NCT01382095|Biological|Modified E. coli heat labile enterotoxin LTR192G|50 ug on study days 0, 21 and 42
45403486|NCT03790696|Device|Cognitive Training Program|"The cognitive training program has been designed by Dr. Sylvester. It is a simple computer game looking at some shapes and faces on a computer screen and pressing a button when a target shape appears.~This is the first study to use this exact computer training regimen for testing in its ability to reduce symptoms of anxiety in children with anxiety disorders. Each session of the computer game takes approximately 45-60 minutes and subjects complete 8 total sessions over one month. The computer game involves paying attention to parts of the screen while distracting square boxes appear at other locations. A target X appears at the location that participants are paying attention to and the subjects press a button when it appears."
45403487|NCT03790774|Behavioral|Neurofeedback|Participants receive intermittent visual and auditory cues to adjust their attentional engagement with a letter identification task.
45511355|NCT00898677|Drug|rizatriptan benzoate|single dose administration of 5mg rizatriptan (by Mouth) p.o.
45511356|NCT00898677|Drug|rizatriptan benzoate|single dose administration of 10 mg rizatriptan p.o.
45511357|NCT00898677|Drug|Comparator: sumatriptan|single dose administration of sumatriptan 100 p.o.
45403488|NCT01306630|Drug|tivozanib (AV-951) and capecitabine (Xeloda®)|Tivozanib 1.0 mg or 1.5 mg oral once daily for 2 weeks followed by 1 week off. Capecitabine 825 mg/m2, 1000 mg/m2, or 1250 mg/m2, oral twice daily for 2 weeks followed by 1 week off. 1 cycle= 3 weeks. Cycles will be repeated in the absence of disease progression or unacceptable toxicity.
45511358|NCT00898677|Drug|Comparator: Placebo|placebo to rizatriptan
45511359|NCT04315285|Behavioral|Treadmill gait training with verbal instruction|Each participant will receive 12 treatment with special verbal instruction which depends on participant's group. Each training session will last 60 minutes, including 5 minutes of warm-up stretching exercise, 40 minutes of treadmill training, and 15 minutes of over-ground gait and balance training. Throughout the 40 minutes of treadmill walking, the participants will walk on the level of 0% slope with a body-weight support system (LikorallTM 200, Liko, Sweden) used to protect the participants from falling; no actual weight support of the body will be provided. The frequency of intervention will be 2-3 days a week, spread across 4-6 weeks. The intervention protocols will be the same for all groups except the instruction provided to the participants in each group.
45511360|NCT01381393|Drug|Ibandronate|Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
45511361|NCT02154776|Drug|LEE011|3 weeks on and 1 week off
45511362|NCT02154776|Drug|Buparlisib|daily
45511363|NCT02154776|Drug|Letrozole|2.5 mg daily;
45511364|NCT04967157|Dietary Supplement|Placebo supplement|Cellulose
45511365|NCT04967157|Dietary Supplement|Citicoline supplement|Cognizin®
45511366|NCT03388749|Drug|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
45511367|NCT02770820|Biological|Aldesleukin|Given SC
45511368|NCT02770820|Biological|Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Given IV
45511369|NCT02770820|Other|Laboratory Biomarker Analysis|Correlative studies
45511370|NCT01377571|Biological|Rotarix|2 doses of Rotarix vaccine, 106.5CID/dose, 1-month interval between doses
45511371|NCT04051359|Other|Low carbohydrate (130 g) diet|Isocaloric moderately reduced carbohydrate diet (RCD, reduced carbohydrate diet) (~130 grams of carbohydrates)
45511372|NCT02154854|Drug|Tacrolimus targeted half-dose|
45511373|NCT02154854|Drug|Tacrolimus targeted plain dose|
45511374|NCT01377493|Dietary Supplement|chewing gum|chewing gum containing no active ingredients, or Ca-P bioavailable ions, or Ca-P and F bioavailable ions
45511375|NCT05422729|Behavioral|mHealth-supported coaching|The intervention includes two components. Three individual consultation sessions based on a health coaching protocol developed by a multidisciplinary team. A mobile application provides educational information about healthy lifestyles, knowledge quizzes, telemonitoring function and virtual platform for sharing.
45511376|NCT05422729|Behavioral|Conventional Health coaching|Three individual consultation sessions delivered by a nurse.
45511377|NCT02160080|Drug|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
45511378|NCT05422495|Behavioral|training with Cycléo device (COTTOS ®),|8 weeks of training
45511379|NCT05422495|Other|non intervention|non intervention
45511380|NCT03541538|Device|Global manipulation|The therapist positioned himself at the head of the stretcher and with one hand supported the side of the participant's face. With the other hand supported the opposite face of the same and then performed contralateral rotation of the cervical and a slight traction to the tissue barrier to perform the manipulation impulse of high speed and short amplitude in rotation. The procedure was carried out bilaterally.
45596798|NCT05792020|Device|Focused Ultrasound Stimulation|This aim will test whether motor tFUS parameters thought to be excitatory (50% duty cycle) vs. inhibitory (5% duty cycle) elicit their predicted effects on MEPs before and after each of three stimulation blocks, using 50 MEPs at each time point.
45403489|NCT01306708|Drug|amitriptyline|Nerve suprascapular blockade with local anaesthetic agent (novabupivacaine 0.25%, 10 ml, once per week) + oral tricyclic antidepressant (amitriptyline 25 mg, twice per day, for 14 days);
45403490|NCT03794518|Drug|Pioglitazone Plus dapaglifliozin|Pioglitazone Plus dapaglifliozin
45403491|NCT03794518|Drug|Placebo|(Beta blockers, ACEI, ARB, and aldosterone )
45403492|NCT05566288|Drug|Cytisinicline|compressed film-coated tablet containing 3 mg cytisinicline
45403493|NCT05566288|Drug|Placebo|Placebo tablets to match compressed film-coated tablet containing 3 mg cytisinicline
45403494|NCT05566288|Drug|Moxifloxacin|400 mg tablets
45403495|NCT05557864|Device|Deep Brain Stimulation|Pallidal Deep Brain Stimulation
45511381|NCT03541538|Device|Especific manipulation|The therapist positioned himself at the head of the stretcher and with one hand kept the middle phalange of the second finger laterally on the articular processes of the C6-7 vertebrae. With the contralateral hand he supported the opposing face of the participant by performing a tilt up to the C6-7 segment and contralateral rotation up to the tissue barrier to carry out the impulse quickly and short. The procedure was carried out bilaterally.
45511382|NCT05422183|Drug|Envafolimab|400mg，sc，d1，Q3W
45511383|NCT05422183|Drug|Lenvatinib|8 mg(BW<60 kg) OR 12 mg(BW≥60 kg)，po，qd，d1-21，Q3W
45511384|NCT05422183|Drug|VP-16|50 mg/d, po,d1-14，Q3W
45511385|NCT03318549|Diagnostic Test|Visual Performance tests|The overall goal of this proposal is to improve our understanding of functional disability in glaucoma by using virtual reality tests to investigate objective performance during simulated daily life activities.
45511386|NCT03318549|Device|Brain-computer interface for assessment of multifocal steady-state visual evoked potentials|The brain-computer interface (BCI) device consists of a modified virtual reality goggle integrated with wireless no-prep electroencephalogram (EEG). The portable BCI is able to objectively measure multifocal steadystate visual evoked potentials in response to brain stimulation through presentation of visual stimuli in the goggle.
45511387|NCT05421949|Other|Exercise group|Incremental Shuttle Walking Test
45511388|NCT00702585|Drug|Org 36286|Org 36286 single-dose subcutaneous injection
45511389|NCT00702585|Drug|Placebo|Placebo to Org 36286 as a single-dose subcutaneous injection
45511390|NCT02160158|Drug|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
45511391|NCT02160158|Drug|Fesoterodine SR3 (fasted)|Fesoterodine SR3 4 mg (single dose)
45511392|NCT02160158|Drug|Fesoterodine SR3 (fed)|Fesoterodine SR3 4 mg (single dose) with high-fat meal
45511393|NCT02160158|Drug|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
45511394|NCT02160158|Drug|Fesoterodine SR3 (sprinkle)|Fesoterodine SR3 4 mg (single dose) beads sprinkled on applesauce
45511395|NCT02160158|Drug|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
46057227|NCT00808210|Drug|Placebo|Intravenous repeating dose
45403496|NCT03788278|Device|BioBeat|The watch incorporates sensors, a battery, a software system, memory components, and a communications component. the watch will be worn 24 hours a day, 7 days a week.
45403497|NCT03790540|Device|DentalVibe|It is a vibrotactile device that aids in reducing pain during local anesthesia injection in pediatric patients
45403498|NCT03790540|Drug|Topical Benzocaine 20%|Topical benzocaine 20% gel on the mucosal injection site prior to injection
45403499|NCT03794596|Drug|Avelumab|Colourless odourless aqueous solution for infusion at dose of 10mg/kg
45403500|NCT03794596|Drug|Aspirin|300mg tablets
45403501|NCT03794596|Drug|Lansoprazole (Proton Pump Inhibitor)|300mg capsule
45511396|NCT02160158|Drug|Fesoterodine SR4 (fasted)|Fesoterodine SR4 4 mg (single dose)
45403502|NCT05604976|Device|Percutaneous coronary intervention|Primary PCI for ST elevation myocardial infarction initiating with a universal guiding catheter or an angiographic catheter
45403503|NCT01306786|Drug|Quadruple therapy|"First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d"
45511397|NCT02160158|Drug|Fesoterodine SR4 (fed)|Fesoterodine SR4 4 mg (single dose) with high-fat/high calorie meal
45511398|NCT02160158|Drug|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
45511399|NCT02160158|Drug|Fesoterodine SR4 (sprinkle)|Fesoterodine SR4 4 mg (single dose) beads sprinkled on applesauce
45511400|NCT05421871|Behavioral|Spinal Stabilization Exercises|Spinal Stabilization Exercises technique
45511401|NCT05421871|Behavioral|Maitland Mobilization Along With Laser Therapy|Maitland Mobilization Along With Laser Therapy technique
45511402|NCT02158208|Other|Blood sample drawn into a 5 mL dry tube at the diagnosis and after 3 months of treatment|
45511403|NCT02158208|Other|16 blood samples drawn into 6 mL heparinized tubes at the diagnosis and after 3 months of treatment|
45511404|NCT02158208|Other|Blood sample drawn into a 5 mL dry tube|
45511405|NCT02158208|Other|16 blood samples drawn into 6 mL heparinized tubes|
45596799|NCT05792007|Procedure|Biological sampling in patients|blood and bone marrow samples from patients with Acute Leulemia.
45596800|NCT05792007|Procedure|Biological sampling in control patients|blood and bone marrow samples from children undergoing orthopedic surgery exposing the bone marrow.(osteotomy of the pelvis).
45698836|NCT03461328|Drug|Magnesium Sulphate|intra-operative infusion of of 10% MgSO2 , stating by a laoding dose of 30be used, a loading dose of 30 mg/kg over 20 min followed by continuous infusion of 10 mg/kg/hr accomplish the total laryngectomy.
46057228|NCT02712411|Drug|HCP1303|
46057229|NCT02712411|Drug|HGP1201|
46057230|NCT02712411|Drug|HIP1402|
46057231|NCT02777229|Drug|Dolutegravir 50 mg|1 tablet once a day
45511406|NCT01381315|Procedure|Injection of isotope|On the day of surgery, if the radioactive SLN cannot be located using the gamma probe prior to incision, lymphazurin or methylene blue dye will be used in the breast in the subareolar plexus at the discretion of the surgeon for assistance in identifying the sentinel nodes. This contingency, expected to occur <3% of the time, will be used since locating the SLN for staging is of greater importance than the study. If radioactive isotope is sufficient to identify the sentinel node draining from the breast, then the blue dye will be injected dermally in the upper inner arm along the bicipital groove of the ipsilateral arm in order to locate the draining lymphatics from the arm. No more than 5cc of blue dye will be injected in any of the above mentioned scenarios.
45511407|NCT01381315|Procedure|Axillary lymph node dissection|The one-year lymphedema rate among subjects undergoing axillary lymph node dissection with or without sentinel lymph node biopsy is ≥ 0.13. With our sample size of 58 subjects undergoing ALND, we will reject that hypothesis in favor of the alternative-that the lymphedema rate is <0.13 for subjects undergoing ALND-if lymphedema is confirmed in three or fewer (ie, 0, 1, 2, or 3) subjects.
45511408|NCT02160236|Drug|dexketoprofen trometamol|before end of the surgery via intravenous administration 50 mg dexketoprofen trometamol in 0.9 % NaCl 100 cc
45511409|NCT02160236|Drug|tenoxicam|before the end of the surgery via administration intravenous 20 mg tenoxicam in 0.9% NaCl in 100 cc
45511410|NCT02160236|Drug|serum physiologic|before end of the surgery via administration intravenous 0.9 % NaCl 100 cc
45698837|NCT02455284|Device|MRI|In vivo MRI with B0 cartography, FLAIR, 3D T1 anatomic images, DWI, and Tractography from DWI images
45698838|NCT03466398|Behavioral|Vivify Health RPM Protocol|The Vivify RPM Protocol includes a wireless tablet and glucometer/Bluetooth device that can directly upload blood glucose readings to the tablet. Patients will daily Care Plan questionnaires on the tablet, as well as upload blood glucose readings twice a day. The tablets will also be used for weekly video conferences with study investigators.
45698839|NCT04453254|Other|Whole Food Meal|Isocaloric/ macronutrient whole food meal
45698840|NCT04453254|Other|Supplement Food Meal|Isocaloric/ macronutrient supplement food meal
46057232|NCT02777229|Drug|Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg|Fixed dose combination, 1 tablet once a day
46057233|NCT02777229|Drug|Efavirenz 400 mg|1 tablets once a day
45403504|NCT01306786|Drug|Triple therapy|First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
45403505|NCT03788590|Device|Jenscare TAVI|Jenscare TAVI and delivery system will implant a percutaneous bioprosthesis value, which is positioned in the native aortic valve, plays a role to control blood flow, and help your heart to work better. It may also shorten your recovery time to getting back to everyday activities.
45403506|NCT03788200|Procedure|Bracing|Treatment arm #1 (8 weeks of post-injury bracing with rigid cervical collar): Participants randomized to this treatment arm will be treated with 8 weeks in a rigid cervical collar.
45403507|NCT03788200|Procedure|posterior C1-C2 instrumented fusion|Treatment arm #2 (posterior C1-2 instrumented fusion): Participants randomized to this treatment arm will undergo posterior C1-2 instrumented fusion with either local bone grafting or autologous iliac crest bone grafting with or without allograft bone grafting. Bone grafting decision will be made by the treating surgeon. All remaining decisions surrounding medical and surgical care will be made by the attending spine surgeon involved in each case.
45403508|NCT01304758|Device|ExAblate Transcranial MRgFUS System|Treatment with the ExAblate Transcranial MRgFUS System.
45403509|NCT03788434|Drug|VE303|VE303 is a live biotherapeutic product containing 8 clonal human commensal bacterial strains manufactured under GMP conditions.
45403510|NCT03788434|Drug|Placebo|Placebo capsules contain micro-crystalline cellulose. They are visually identical to VE303 capsules. They will be taken by mouth for 14 days. Placebo capsules will not contain any VE303 Drug Product.
45403511|NCT05571748|Dietary Supplement|Alpha-lipoic acid|A trial of acute exercise before and after 4 weeks of alpha-lipoic acid supplementation.
45403512|NCT05571748|Other|Placebo|A trial of acute exercise before and after 4 weeks of placebo supplementation.
46057234|NCT02712489|Other|No intervention|
46057235|NCT02606812|Dietary Supplement|Traditional-food|Intake of ethnic local food
46057236|NCT02712177|Biological|4CMenb|
45511411|NCT03273855|Other|Fecal microbiota transplantation|The intervention treatment is fecal microbiota transplantation made of frozen donor feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
45511412|NCT03273855|Other|Placebo: fecal microbiota transplantation|The placebo group get fecal microbiota transplantation made of their own feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
45511413|NCT05421559|Procedure|thyroidectomy|removal of the diseased thyroid gland by conventional method vs transection method of sternothryroid muscle
45511414|NCT02154932|Drug|2 doses 400 microgram misoprostol|2 doses 400 microgram misoprostol, 3 and 1 hours
45511415|NCT02154932|Drug|single dose misoprostol|1 dose, 1 hours, prior surgery
45511416|NCT05421403|Procedure|adenotonsillectomy|all patients with adenoid or tonsillar or adenotonsillar hypertrophy of grade >2 will undergo adenoidectomy, tonsillectomy or adenotonsillectomy (AT) according to the indication. Overweight or obese patients with mild or moderate OSAS will undergo 6-m trial of lifestyle intervention (LSI) and CPAP if indicated, responders will undergo more follow-up otherwise surgical interference was indicated
45511417|NCT05421403|Behavioral|Lifestyle intervention|After baseline testing, all subjects began a structured 6-month LSI consisting of dietary modification and exercise. Intensive dietary counseling was provided weekly for the first 4 weeks of the intervention, monthly subsequently until 6 months. A target caloric deficit of ~250.500 cal/d was recommended throughout dietary counseling. Dietary regimen consisted of diets composed of nutrients contributing to total energy as 55% carbohydrate, 15% protein, and 30% fat. Other lifestyle changes included calorie restriction depending on reduction of the frequency of snack consumption, ingestion of low-calorie and low-fat snacks, limiting sugar-based carbonated drinks and the duration of television watching or mobile games. Exercise sessions consisted of both aerobic and strength training three times weekly.
45511418|NCT02158286|Other|Measuring emptying rate from the gastric tube|
45511419|NCT02961465|Device|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period.~If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF <3 a week), the lead is explanted. Patients are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
45511420|NCT03659773|Biological|immune biomarkers to evaluate vaccine response in HSCT recipients|a 38mL-blood sample will be collected before and at 3, 12 and 24 months after complete block vaccination and at 4 weeks after influenza vaccination for the ancillary study
45511421|NCT03541772|Dietary Supplement|Oncoxin-Viusid®|Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and Oncoxin-Viusid® (75 ml/day) before/during/after both treatments
45511422|NCT03541772|Dietary Supplement|Placebo|Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and placebo (75ml/day) before/during/after both treatments
45511423|NCT02918565|Behavioral|Drinking Cognition Feedback (DCF)|12 weeks of interactive text messaging focused on providing feedback related only to pre-weekend drinking cognitions (plans, desire to get drunk).
45511424|NCT02918565|Behavioral|Alcohol Risk Feedback (ARF)|12 weeks of interactive text messaging focused on providing feedback related only to post-weekend alcohol consumption (max drinks consumed on any occasion over the weekend).
45511425|NCT02918565|Behavioral|Adaptive Goal Support (AGS)|12 weeks of interactive text messaging focused on providing adaptive goal support (based on running average of max drinks consumed).
45511426|NCT02918565|Behavioral|COMBO|12 weeks of interactive text messaging incorporating features of DCF, ARF and AGS.
45511427|NCT01381237|Behavioral|game-based balance exercises|16 sessions, scheduled two per week, each lasting 45 minutes.
45511428|NCT03542630|Diagnostic Test|salivary MMP8 test|All female participants will make salivary MMP8 test and certain blood parameters to determine systemic inflammatory response
45511429|NCT03542630|Other|periodontal examination|Periodontal examination by a specialist of periodontology will be made to all female participants, using periodontal probe and dental mirror.
45511430|NCT03542630|Other|blood tests|All female participants who do not have recent blood tests will make new blood tests to determine certain blood parameters.
45511431|NCT01377415|Drug|bupivacaine|bupivacaine 5 mg/ml infusion 2 ml/h 48 h
45511432|NCT02678403|Device|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
45511433|NCT02678403|Device|SHAM Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
45511434|NCT02155088|Drug|BYL719|Dose escalation beginning at 250 mg/day
45511435|NCT02155088|Drug|Gemcitabine|Dose escalation beginning at 800 mg/m^2
45511436|NCT02155088|Drug|(nab)-paclitaxel|125 mg/m^2 dose
45511437|NCT05421325|Biological|QBKPN SSI|Site-Specific Immunomodulator
45511438|NCT05421325|Other|Normal Saline Placebo|Normal Saline
45698841|NCT01145638|Drug|iron isomaltoside 1000|intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose
46057237|NCT02712177|Biological|diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB|
46057238|NCT02712177|Biological|conjugated pneumococcal vaccine|
46057239|NCT02712177|Biological|MMRV|
45403513|NCT03788356|Device|Inspiratory muscle training|Inspiratory muscle training with a device
45403514|NCT03788356|Other|Diaphragmatic breathing|Diaphragmatic breathing exercise
45403515|NCT05695144|Device|tDCS active stimulation combined with rTMS sham stimulation|"Active tDCS positive stimulation: left dorsolateral prefrontal cortex (DLPFC) or BeamF3 method; negative stimulation: right frontal, 2mA, 20 mins stimulation, 1 time/day, 5 consecutive days, weekend suspension, lasting 4 weeks, total 20 times.~Sham stimulation rTMS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the coil facing outward."
45403516|NCT05695144|Device|rTMS active stimulation combined with tDCS sham stimulation|"Sham stimulation tDCS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the switch off.~Active rTMS: stimulation site: left dorsolateral prefrontal cortex (DLPFC); consisting of a total of 3000 pulses per session at 10Hz (4 seconds on and 16 seconds off) at 110% resting motion threshold (RMT), 40 pulses per string; total 75 strings; 1 time/day, 5 consecutive days, weekend suspension, total 20 times. Resting motor thresholds (RMT) were measured before the start of each day of treatment."
45511439|NCT03625635|Other|Individualized food-based intervention|Diet plans and recommendations will be based on the individual's nutritional status, symptoms and treatment side-effects, socioeconomic and cultural preferences; as well as the WCRF/AICR guidelines adapting 1.5g/kg/d of dietary protein and when required, a caloric restriction (500-1000 kcal/d). Garlic and cruciferous vegetables will be encouraged as well as 5-9 servings of fruits and vegetables a day. The program will be based on the macronutrient meal-equivalent menu method, and standard food servings will be based on the Mexican Food Equivalent System. Breast cancer patients follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed.
45511440|NCT02160392|Procedure|Endometrial biopsy|Endometrial biopsy (EMB) specimens were collected via a 3 mm diameter plastic pipelle that was inserted into the uterus following EML. A sample of tissue was obtained by retracting the pipelle's plunger leading to negative suction and rotating the cannula for approximately 15 seconds.
45511441|NCT02160470|Behavioral|Exposure Therapy with Retrieval|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a fear retrieval trial, which is a brief exposure to the feared stimulus (snake or spider). Based on recent basic science research, the fear retrieval trial is expected to enhance the efficacy of exposure therapy.
45511442|NCT02160470|Behavioral|Exposure Therapy with Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. As a component of therapy, participants will receive compound extinction, which consists of exposure to two feared stimuli simultaneously (two spiders or two snakes). Based on recent basic science research, compound extinction is expected to enhance the efficacy of exposure therapy.
45511443|NCT02160470|Behavioral|Exposure Therapy with Retrieval and Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a brief fear retrieval trial. As a component of therapy, participants will also receive compound extinction.
45511444|NCT02160470|Behavioral|Therapist-guided Exposure Therapy|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes.
45851148|NCT00381654|Drug|AV-412|Solid oral dosage; 4 dosage strengths; 25, 50, 100, or 200 mg per capsule Dosing Frequency: Once daily dosing for 4 weeks (4 weeks equals 1 cycle)
45851149|NCT00381732|Drug|tadalafil|2.5 mg or 5 mg tadalafil tablet taken by mouth once a day for 24 weeks. Followed by an open label extension where all patients receive 5 mg doses.
45851150|NCT00381732|Drug|placebo|Placebo tablet taken by mouth once a day for 24 weeks. Placebo patient will receive 5 mg tadalafil tablet during the open label extension.
45851151|NCT00382044|Drug|Eprex; Neorecormon; Aranesp|
45851152|NCT00382278|Procedure|Autologous bone marrow-derived mononuclear cells infusion|Under local anesthesia, 100 mL of bone marrow were aspirated from the posterior iliac crest. ABMMC were isolated by density gradient centrifugation in Ficoll-Hypaque gradient, 10% of the cells were labeled with SnCl2-99mTc, and a small fraction was used for cell counting and viability analysis. At least 100 millions of mononuclear-enriched BMC suspended in 20 mL of saline were delivered preferentially in the common hepatic artery by celiac trunk catheterism.
45851153|NCT00382356|Drug|Dutasteride|once daily dosing of 0.5mg Dutasteride for 12 months
45851154|NCT00382434|Procedure|presence of an emergency pharmacist in the ED|
45851155|NCT00382512|Drug|Raptiva (efalizumab)|
45851156|NCT00382668|Drug|Dasatinib|Tablets, Oral, 50 mg, once daily, for one day
45851157|NCT00382668|Drug|Dasatinib|Tablets, Oral, 20 mg, once daily for one day
45851158|NCT00382668|Drug|Dasatinib|Tablets, Oral, 70 mg, once daily for one day
45403517|NCT05695144|Device|tDCS active stimulation combined with rTMS active stimulation|"Active tDCS positive stimulation: left dorsolateral prefrontal cortex (DLPFC) or BeamF3 method; negative stimulation: right frontal, 2mA, 20 mins stimulation, 1 time/day, 5 consecutive days, weekend suspension, lasting 4 weeks, total 20 times.~Active rTMS: stimulation site: left dorsolateral prefrontal cortex (DLPFC); consisting of a total of 3000 pulses per session at 10Hz (4 seconds on and 16 seconds off) at 110% resting motion threshold (RMT), 40 pulses per string; total 75 strings; 1 time/day, 5 consecutive days, weekend suspension, total 20 times. Resting motor thresholds (RMT) were measured before the start of each day of treatment."
45403518|NCT05695144|Device|tDCS sham stimulation combined with rTMS sham stimulation|"Sham stimulation tDCS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the switch off.~Sham stimulation rTMS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the coil facing outward."
45403519|NCT03790618|Drug|3,4-Methylenedioxymethamphetamine|Participants will be given 0.75mg/kg of 1.5mg/kg MDMA
45403520|NCT03790618|Drug|methamphetamine|Please see above.
45403521|NCT03790228|Drug|Anlotinib Combined With Pemetrexed And Carboplatin|Anlotinib(12mg, QD, PO, d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2, IV, d15-21,21 days per cycle) and Carboplatin(AUC5,IV, d15-21,21 days per cycle,using 4 cycles)
45403522|NCT01304836|Drug|Advagraf|oral
45403523|NCT01304836|Drug|Mycophenolate Mofetil|oral
45403524|NCT01304836|Drug|Simulect|IV
45511445|NCT05005845|Drug|NFX-179 gel|NFX-179 topical gel is the active investigational product being studied
45511446|NCT05005845|Drug|Vehicle gel|NFX-179 vehicle gel is the placebo comparator for this study
45511447|NCT02160548|Drug|Standard care|Standard management for OP poisoning
45511448|NCT02160548|Drug|Standard care+ 2.5 mg Salbutamol|Ventolin respiratory solution 2.5 mg
45511449|NCT02160548|Drug|Standard care+ 5 mg Salbutamol|Ventolin respiratory solution 5 mg
45403525|NCT01304836|Drug|Corticosteroids|IV & oral
45403526|NCT01306864|Device|Hemospray Kit|Hemostasis of Arterial GI Bleeding
45403527|NCT03788122|Other|In-depth interview|The 'intervention' administered to this group of participants are two or three in-depth interviews (average 30-60 m minutes per interview) on their experiences, views, feelings and thoughts (perceptions) regarding acceptability of the fetal surgery.
45403528|NCT01307176|Behavioral|Home exercise program|The home exercise program uses standard physical therapy exercises that have never been rigorously tested for people with cerebellar ataxia. These include sitting balance exercises (e.g. sitting on a peanut-shaped exercise ball and moving arms or legs), standing balance exercises (e.g. weight shifting, moving arms and legs), and walking exercises (e.g. walking heel-to-toe). The exercises are in a progression, going from less to more challenging. Though the exercises are standard, they are the intervention that we are testing and we will consider them experimental.
45403529|NCT01307254|Procedure|blood analysis|A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)
45511450|NCT02158598|Drug|Vitamin D chewable tablet supplementation|
45511451|NCT02158598|Drug|Vitamin D pill supplementation|
45511452|NCT03082729|Drug|Apremilast|Apremilast (brand name Otezla) is a medication for the treatment of certain types of psoriasis and psoriatic arthritis.
45511453|NCT02513043|Drug|medical abortion|medical abortion
45511454|NCT02160704|Drug|Enclomiphene citrate|25 mg daily for 16 weeks
45511455|NCT02160704|Other|Placebo|placebo daily for 16 weeks
45511456|NCT03541382|Device|OraQuick® HIV Self-Test|"Community leaders, including GVHs, Village Health Committee members, Village Development Committee members, and members of key community groups will participate in a workshop to facilitate planning of a HIVST campaign. Identified community distributors, who are unpaid volunteers from the community, will also receive a training package in HIVST promotion.~Campaigns will be conducted over a short period (approximately seven days) and under a fixed budget. Community distributors will deliver HIVST kits free of charge to community members, and provide information on how to self-test and access the nearest clinic for linkage to confirmatory HTS, treatment and prevention. Distributors will also provide HIV prevention messages around serodiscordancy, treatment as prevention and VMMC."
45511457|NCT03542552|Drug|Magnesium Sulfate|Patients received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
45511458|NCT03542552|Drug|Nifedipine|received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
45511459|NCT05067777|Procedure|Massage Therapy|Receive SMT
45511460|NCT05067777|Other|Questionnaire Administration|Ancillary studies
45511461|NCT05067777|Procedure|Sham Intervention|Receive light touch control procedure
45851159|NCT00382746|Device|EarlySense monitoring device|
45403530|NCT01307332|Drug|MabCampath-1h|Drug:10 mg/mL alemtuzumab intravenous infusion. Form: Sterile, clear, colorless solution. Dosage: 2 cycles. Month 0 dosed over 5 consecutive days; month 12 dosed over 3 consecutive days.
45403531|NCT03790462|Other|Music intervention|"A raga out of 3 select Indian classical ragas Puriya/Hindol/Todi will be played for 10 minutes & data collected."
45511462|NCT02158676|Dietary Supplement|Prebiotic|Fructooligosaccharides
45511463|NCT02158676|Dietary Supplement|Synbiotic|Fructooligosaccharides + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019
45511464|NCT02158676|Other|Placebo|Maltodextrin
45511465|NCT02155166|Drug|Intracervical anesthesia with lidocaine 2%|5 min before LNG-IUS placemen
45851160|NCT00382902|Device|OptiFree Multi-Purpose Disinfecting Solution|
45511466|NCT02155166|Drug|ibuprofen 400 mg|1 hour prior to the LNG-IUS insertion
45511467|NCT02158754|Diagnostic Test|Corus CAD (ASGES)|
45511468|NCT00398931|Drug|MK0217, alendronate sodium / Duration of Treatment : 5 Years|
45511469|NCT00398931|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 5 Years|
45403532|NCT01305928|Other|Warm Hand-off|"Warm Hand-Off~Staff brief intervention and warm hand-off (5 min):~Assess withdrawal, need for medication change~Describe warm hand-off process~Provide 2-page flyer~Perform call, leave room~Notify patients' nurse patient is talking to quitline~Quitline session (20 min):~Collect minimum data set~Explore thoughts/feelings toward quitting~Provide medication education~Build plan to stay quit~Schedule next call~Staff check-back (5 min):~Ask patient how session went~Ask if patient requests cessation medication script on discharge"
45403533|NCT01305928|Other|Fax|"Fax~Staff standard in-patient session: (30 minutes):~Assess withdrawal, need for medication change~Conduct assessment of smoking history, interest in quitting~Explore relevance, risks, rewards, and roadblocks (4Rs) related to smoking and quitting~Provide 2-page flyer~Provide medication education~Build plan to stay quit~Describe fax-referral process~Ask if patient requests cessation medication script on discharge"
45403534|NCT03790384|Drug|Mitomycin|Patients receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG) with a 40 mg mitomycin instillation the day before .
45511470|NCT02160938|Other|3-year follow-up|"When the infants reach 24 months of age, the Study Follow-up Specialist will send all participants an age- appropriate Ages and Stages Questionnaire (ASQ) for completion.~At the age of 3, the following exams will be performed and are described below:~The Vineland-II Adaptive Behavior Scale (VABS)~Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV), or Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V, for siblings older than 7 years 7 months, when necessary)~Children will also be photographed (for review by the study dysmorphologist)"
45511471|NCT02155400|Device|Bair Hugger|Forced Air Warming Blanket placed over the body of the patient during surgery
45511472|NCT02155400|Device|Prototype / Experimental device|Contact heating device provides heat to the sole of the foot and popliteal fossa while providing intermittent compression to the lower leg.
45403535|NCT05694910|Other|Reiki|Reiki has based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distance Reiki, Reiki practitioners followed the traditional Usui Reiki protocol healing.
45511473|NCT01593111|Other|Environmental Intervention|Home-based environmental intervention
45511474|NCT03541694|Biological|Stamaril®|Routine vaccination with Stamaril yellow fever vaccine
45511475|NCT02158832|Device|Acupuncture + Electrical Stimulation|"2 acupuncture needles are inserted into the upper back. 10Hz, 0.5ms biphasic square wave electrical pulses are applied to needles x20 mins. Current >sensation threshold & maintained at a level that is comfortable/painless & does not elicit skeletal muscle contractions (~5mA, <10mA).~Needle locations are in the vicinity of nerves that supply the affected upper limb:~EX-B1': Affected hemisphere, 1.5cm lateral to C5 spinous process. Insertion angle: shallow, 'inferior-lateral', ~15⁰ perpendicular to the skin, ~15⁰ lateral to the midline. Depth: ~1.5 cm (secure anchorage).~EX-HN15': Affected hemisphere, 1.5cm lateral to the C7 spinous process. Insertion angle: shallow, 'inferior-medial' ~15⁰ perpendicular to the skin, ~15⁰ medial. Depth: ~1.5 cm (secure anchorage)."
45511476|NCT05225727|Behavioral|Me & You - Tech|The 13 MYT lessons will train youth to adopt a zero tolerance approach to dating violence (DV) and contain activities to enable youth to recognize healthy (non-abusive) and unhealthy (abusive) relationships, assess their own relationships, and adopt and practice a lifestyle paradigm of select-detect-protect informed by SCT self-regulatory frameworks. Within this lifestyle paradigm, youth select their personal rules to have only healthy (non-abusive) relationships, detect unhealthy (abusive) relationships that might threaten their rules, and learn to protect their rules using communication, management, and avoidance skills. MYT will tailor content by gender, relationship status, and the youth's DV profile of perpetration or victimization based on the Conflict in Adolescent Dating and Relationship Inventory (CADRI).
45511477|NCT02155478|Device|ISERT 250 (HOYA, Japan): a standard IOL|
45511478|NCT02155478|Device|AMO ZCB00 IOL (Abbott Medical Optics, United States): a standard IOL|
45511479|NCT04956003|Behavioral|45-minute daily physical activity|45-minute daily physical activity session as an integral part of learning (during regular school sessions)
45511480|NCT00920361|Drug|Follitropin beta|Normally, Follistim Injection 150 or 225 IU will be administered (s.c. or i.m.) once a day for 4 days as follitropin beta (genetical recombination). The dosage will be adapted to growth of follicles (75-375 IU for 6-12 days, in general). If more than 3 follicles of mean diameter 16-20 mm are confirmed by ultrasound tomography, ovulation will be stimulated by using Human Chorionic Gonadotropin (hCG) drugs.
45511481|NCT02161094|Behavioral|Give incentives to physicians based on their patient's HbA1c improvement|
45511482|NCT02161094|Behavioral|Give incentives to patients based on their own HbA1c improvement|
45511483|NCT00651807|Drug|etonogestrel|Lowest dose of Org 3236 per two days, lowest dose of Org 3236 per day, highest dose of Org 3236 per day for 8 weeks
45511484|NCT00651807|Drug|Placebo|Every day one tablet up to 8 weeks
45851161|NCT00382980|Biological|Aluminum hydroxide|Adjuvant administered with A/H5N1 vaccine dosages 7.5 mcg and 15 mcg.
45851162|NCT00382980|Biological|Inactivated Vero cell based whole virus influenza A/H5N1|Inactivated Vero cell-grown, whole virus, influenza A/H5N1 vaccine at dosages 7.5 mcg and 15 mcg of hemagglutinin (HA) per 0.5 mL, each dosage with and without aluminum hydroxide adjuvant; 45 mcg HA/0.5 mL without adjuvant.
45851163|NCT00382980|Drug|Placebo|Saline injected into the deltoid muscle. 2 identical dosages will be given approximately 28 days apart.
45851164|NCT00383058|Drug|the extract of green tea|
45403536|NCT04915924|Device|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Advanced heart failure patients will be implanted with the HM3 LVAS
45403537|NCT03787732|Drug|Fluid Bolus|500 milliliters of an intravenous crystalloid solution of the operator's choosing
45403538|NCT03787732|Other|No Fluid Bolus|No additional intravenous crystalloid administration initiated between randomization and two minutes after completion of endotracheal intubation
45403539|NCT01307488|Drug|Ritonavir boosted Atazanavir + Lamivudine|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
45403540|NCT01307488|Drug|Ritonavir boosted Atazanavir + 2 NRTIs|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
45511485|NCT01381081|Biological|platelet-rich plasma|a single intra-articular injection
45511486|NCT01381081|Drug|Corticosteroid|A single betamethasone and bupivacaine intra-articular injection
45403541|NCT03790072|Biological|OmnImmune®|infusion of OmnImmune® (expanded gamma delta T lymphocytes)
45511487|NCT05583513|Diagnostic Test|MLHFQ (Minnesota Living with Heart Failure Questionnaire)|The MLHFQ, a 21-item HF-specific questionnaire, was adopted to evaluate the quality of life of the study subjects with score ranging 0-105 and lower the scores the better QoL
45511488|NCT05583513|Diagnostic Test|KCCQ (the Kansas City Cardiomyopathy Questionnaire)|The KCCQ, is a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, with score ranging 1-100 and higher scores the better QoL
45511489|NCT02161250|Dietary Supplement|Resistant Starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing resistant starch. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
45511490|NCT02161250|Dietary Supplement|Control|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing maltodextrin. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
45511491|NCT03344887|Other|RBC Transfusion from male donor|Patients requiring an RBC transfusion for the treatment of anemia will receive products from a male donor at initial and any subsequent hospitalizations during the trial period.
45511492|NCT03344887|Other|RBC Transfusion from female donor|Patients requiring an RBC transfusion for the treatment of anemia will receive products from a female donor at initial and any subsequent hospitalizations during the trial period.
45698842|NCT01145638|Drug|iron sulphate|oral, 200 mg per day (100 mg bid),12 weeks
45698843|NCT03466320|Biological|NKR-2|This Phase I study will explore the hypothesis that the administration of modified T-cells targeting NKG2D-ligands expressed by AML/MDS cells, after a prior nonmyeloablative preconditioning treatment, in patients refractory to and/or relapsing after prior therapies, is safe and, considering the poor outcomes and lack of therapeutic strategies for this patient population, may have a strategic advantage over current approaches and provide potential clinical benefit.
45851165|NCT00383136|Drug|tirofiban high-bolus dose regimen|bolus of 25 mcg/kg of body weight, followed by 18 hours infusion of 0.15 mcg/kg/min.
45403542|NCT01306006|Biological|Providing measles vaccine for all children 9-35 months who have not yet received a routine measles vaccine|Normal measles vaccines licensed for distribution through the national EPI program
45403543|NCT01304992|Dietary Supplement|Protein drink - low dosage|The subjects will consume 500 mL of a protein drink containing 25 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
45403544|NCT01304992|Dietary Supplement|Protein drink - high dosage|The subjects will consume 500 mL of a protein drink containing 40 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
45698844|NCT03466242|Drug|Dexmedetomidine|Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine
45698845|NCT03466242|Drug|Ketamine|Evaluate sedative and analgesic effects of Intravenous Ketamine
45715340|NCT04134442|Other|Standard Therapy|"Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist)~Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 20ml 0.5% bupivacaine and epinephrine 1:200,000."
45851166|NCT00383136|Drug|Abciximab|bolus of 0.25 mg/kg of body weight, followed by 12 hours infusion of 0.125 mcg/kg per minute
45851167|NCT00383214|Drug|Epratuzumab|360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
45851168|NCT00383214|Other|Placebo|Intravenous
45851169|NCT00383370|Drug|VEGF Trap|VEGF Trap formulation 1, ITV-1
45403545|NCT03787342|Procedure|Double Flap Incision|A full-thickness crestal incision will be made over the edentulous ridge, and then one partial-thickness vertical incision will be made on the buccal side. A partial-thickness flap will be raised first to separate the mucosal layer from the overlying periosteum. Subsequently, the periosteal layer will be elevated to expose the underlying alveolar process. Xenograft and Ti-mesh will be used to augment the defective site then periosteal flap will be sutured first, with periosteal sutures securing the regenerative site. Then the mucosal flap will be closed.
45403546|NCT03787342|Procedure|Modified Periosteal Releasing Incision|"A full-thickness muco-periosteal flap is reflected on the buccal side (crestal incision and two vertical releasing incisions). Near the base of mucoperiosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The shallow incision helps in preventing damage to the submucosal layer. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade with sweeping motion to allow flap advancement."
45511493|NCT03319927|Behavioral|IPM educational workshop and consultation|The interventions include a baseline assessment conducted by a research assistant and objective measures of pesticide exposure (center dust samples, children's silicone wristbands), review of assessment by the nurse child care health consultant, goal setting with the director, educational workshop, 7 monthly consultation visits, and post-intervention review of goals and post-assessment findings (conducted by research assistant and objective measures of pesticide exposure).
45511494|NCT02161328|Other|EIT belt|
45511495|NCT03246529|Drug|BL-8040 1.25mg/kg + G-CSF|Up to 2 SC injections of BL-8040 are anticipated during the study. Injections of G-CSF per standard of care
45511496|NCT03246529|Drug|Placebo +G-CSF|Up to 2 SC injections of Placebo are anticipated during the study. Injections of G-CSF per standard of care
45511497|NCT03541148|Dietary Supplement|Oncoxin-Viusid|Oncoxin-Viusid supplement before/during/after standard surgical and adjuvant treatment or chemotherapy.
45698846|NCT03013270|Other|Aerobic-Resistance-Inspiratory|Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1 Repetition Maximum (1RM) for quads training and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets) for 10 min, combined also with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 20 min (Aerobic (30min) + Resistance (10min) + Inspiratory (20min) = 60 min)
45851170|NCT00383370|Biological|VEGF Trap|VEGF Trap formulation 2 at higher concentration in Open label cohort
45851171|NCT00383526|Biological|Inactivated, split-virion influenza vaccine|Vaccine
45403547|NCT03787342|Procedure|Coronally Advanced Lingual Flap|A full-thickness crestal incision will be performed in the keratinized tissue from the distal surface of the more distal tooth to the retromolar pad. The flap design will be continued intrasulcularly on both vestibular and lingual sides of the mesial portion of the flap, buccally, it will be finished with a vertical releasing incision. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. Then, using a blunt instrument it will be localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. The blunt instrument will be inserted below this connective band, and, with gentle traction in the coronal direction, this muscular insertion will be detached from the lingual flap.
45403548|NCT03787342|Procedure|Periosteal releasing incision|
45403549|NCT05694754|Device|Theta Burst Transcranial Magnetic Stimulation|Magventure MagPro R30 stimulation Device, MCF-B70 stimulation Coill
45403550|NCT03794128|Procedure|Blood collection for research (next-generation sequencing [NGS])|Participants will have whole blood collected for next-generation sequencing (NGS).
45403551|NCT03794128|Procedure|Blood collection for research (HLA typing)|Participants will have whole blood collected for HLA typing.
45403552|NCT03794440|Drug|Sintilimab|200mg IV d1， Q3W
45403553|NCT03794440|Drug|IBI305|15mg/kg IV d1， Q3W
45403554|NCT03794440|Drug|Sorafenib|400mg PO BID
45403555|NCT05534542|Other|exercıse|ıntradıalıtıc core stabılızatıon
45511498|NCT01377337|Drug|sodium bicarbonate|"1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR. Dose may be repeated every 5-10 minutes up to 3 doses.~Note: The Placebo Arm receives 1 ml/Kg of 0.9% NaCl (in a blinded fashion)."
45511499|NCT05655039|Other|Rehabilitation|Stroke Rehabilitation Program
45511500|NCT02158910|Drug|Aricept|5 mg Aricept increasing dose to 10 mg Aricept, or 10 mg Aricept increasing dose to 23 mg Aricept
45511501|NCT01381003|Genetic|pCCLchimGp91s lentiviral vector transduced CD34+ cells infusion|pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
45511502|NCT05058339|Other|Survey Administration|Complete survey
45511503|NCT04008199|Other|Super Abbu|The investigators have developed, piloted, and propose to expand and to experimentally evaluate a speech-based service that connects expectant fathers to doctors and to each other over a simple phone call. This service is dubbed Super Abbu (Super Dad in English).
45511504|NCT05225649|Behavioral|Behavior Change Intervention|Health coaching sessions; self-monitoring: Fitbit, home scale, and app; personalized health information by mobile health: growth charts and age-specific health behavior information via text message and email; behavior change support by mobile health: family-based health behavior goal setting via chatbot; and usual clinical care.
45511505|NCT02158988|Procedure|HIPEC|"HIPEC:~Mitomycin C: 15 mg/m2 (max. 30 mg/ m2, max. 5 L Perfusion). Cisplatin: 75 mg/m2/L (max. 150 mg/m2, max. 5 L Perfusion). 4-12 weeks after cytoreductive surgery 3 cycles postoperative chemotherapy will be applied."
45851172|NCT00383526|Biological|Inactivated, split-virion influenza vaccine|Vaccine
45851173|NCT00383682|Drug|morphine and mexiletine|
45851174|NCT00383838|Behavioral|brief, voluntary substance use intervention|
45851175|NCT00383916|Drug|pantoprazole|
45851176|NCT00383994|Drug|GM-CSF|250 micrograms subcutaneously 3 times a week for 4 weeks starting a day before the administration of Rituximab.
45851177|NCT00383994|Drug|Rituximab|375 mg/m^2 by vein followed by 1000 mg/m^2 weekly for 3 weeks for a total of 4 doses.
45511506|NCT05225493|Behavioral|Peer to peer feedback|HIV experts contact non-HIV specialised treating physicians on individual patient care to recommend HIV testing
45511507|NCT05225493|Diagnostic Test|HIV rapid test|Free HIV rapid tests are provided to non-HIV specialised treating physicians to use in individual patient care in patients at risk of HIV
45511508|NCT02159144|Other|cold stress|
45511509|NCT05053113|Device|Activity Monitor|Monitor physical activity with FitBit
45403556|NCT05089552|Other|1-WHOQOL-BREF(WHO-Quality of life-BREFF) Arabic version Scale|WHOQOL-BREF(WHO-Quality of life-BREFF) Arabic version Scale The WHOQOL-BREF is composed of 26 self-administered items. Using a 5-point Likert response scale ranging from 1 (very dissatisfied/very poor) to 5 (very satisfied/very good), family caregivers were asked to rank each item accordingly. Caregivers were asked to respond to the items indicating their assessment of QOL during the preceding 2 weeks, Ohaeri and Awadalla developed and tested the Arabic version of the WHOQOL-BREF among an Arab population in Kuwait. The translated Arabic WHOQOL-BREF has considerable reliability and validity indices . As reported in the Kuwaiti study, a satisfactory (≥0.7) Cronbach's alpha was reported for the full questionnaire and the domains
45403557|NCT05089552|Other|SCL-90-R(Symptoms Checklist-90-Revised) Arabic version scale|"developed by Derogatis et al. and El-Behairy. established the validity and reliability of the Arabic version.SCL-90-R is a 90-item self-report symptom inventory, and reflect the psychologic symptom pattern of psychiatric and medical patients. Each item of the 90 is rated on a five-point scale of distress (0-4), ranging from not at all to extremely.Under usual circumstances, SCL-90-R requires between 12 and 15 minutes to be completed.SCL-90-R is a measure of the current psychologic symptom status. It is not a measure of personality, except indirectly, in that certain personality disorders may manifest a characteristic profile on the primary symptom dimensions."
45851178|NCT00383994|Biological|NK Cell Infusion|NK cells will be infused one week after the fourth dose of Rituximab and GM-CSF.
45403558|NCT05089552|Other|addiction severity index|a semi-structured interview that takes approximately 45 minute. developed to evaluate treatment outcome in substance abusers. The instrument focuses on seven areas that are typically affected in the lives of substance abusers: medical status, employment, drug use, alcohol use, legal status, family/social status, and psychiatric status. Information regarding frequency, duration, and severity of problems in these seven areas is collected for both lifetime and recent (past 30 days) history. The ASI provides two types of scores: severity and subjective ratings of the client's need for treatment, and composite scores of problem severity during the prior 30 days. Specific alcohol-related questions include total lifetime years of use, money spent on alcohol, and number of days that alcohol problems are experienced.
45403559|NCT03789682|Drug|Adjuvant chemotherapy|adjuvant chemotherapy using Gemcitabine plus Cisplatin
45403560|NCT05527522|Combination Product|nutritional and educational intervention|individualized diet plus educational intervention with/without nutritional supplements
45403561|NCT05527522|Other|standard practice|The patients received the usual treatment and clinical practice
45403562|NCT05694598|Genetic|VGR-R01|CYP4v2-coding gene delivered by AAV vector
45403563|NCT01307566|Device|Continuous Positive Airway Pressure CPAP|CPAP treatment
45511510|NCT05053113|Device|Activity Monitor|Wear accelerometer
45511511|NCT05053113|Other|Educational Intervention|Receive educational newsletter
45511512|NCT05053113|Other|Survey Administration|Ancillary studies
45511513|NCT05053113|Behavioral|Telephone-Based Intervention|Receive phone call from health coach
45511514|NCT02764190|Behavioral|I-ACT with Check Yourself|
45511515|NCT02161796|Drug|FG-4592|Oral
45511516|NCT02161796|Drug|Placebo|Oral
45511517|NCT03541070|Device|Kinesiology tape|Kinesiology taping (KT) was developed by Kenzo Kase in the 1970s. KT has similar thickness and flexibility to the skin. These tapes are used in orthopedic and sports injuries as well as neurological and rheumatic diseases, pediatric patients, lymph edema and painful conditions. These tapes are used for correcting muscle function, increasing circulation, increasing proprioception, reducing pain, and repositioning the sublease joint according to the usage method
45511518|NCT03077659|Drug|NanoPac®|Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.
45511519|NCT05225181|Behavioral|perform physical exercise|one 60-min session of physical training
45511520|NCT05225181|Behavioral|cognitive training|one 60-min session of cognitive training
45511521|NCT05225181|Behavioral|control group|perform body stretching(15min) and health education courses(90min)
45511522|NCT05052723|Drug|Cabozantinib|Cabozantinib (XL184) is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) known to play important roles in tumor cell proliferation and/or tumor neovascularization.
45511523|NCT05052723|Drug|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
45511524|NCT05420545|Biological|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
45511525|NCT05420545|Biological|CD70 CAR-T cells|Administration method: intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
45851179|NCT00384072|Drug|bazedoxifene BZA-20|
45851180|NCT00384228|Drug|Nilotinib|
45596801|NCT05791994|Procedure|Visual cognitive stimulation exercises|Patients included in Intervention group will receive a 30-minute session of complex visual stimuli on a touch screen (3 10-minute exercises : saccade exercises, then pursuit exercises, then matching exercises) every other day for 30 days, with increasing difficulty of the exercises as the sessions progress.
45596802|NCT05791994|Procedure|Broadcast of a television program|Patients included in Comparator group will watch a 30-minute television program (Allô Docteurs) on a touch screen every other day for 30 days.
45715341|NCT04103476|Combination Product|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
45715342|NCT04103476|Other|Placebo|Placebo
45851181|NCT00384306|Drug|prednisolone|
45851182|NCT00384384|Drug|oral 18B Glycyrrhetinic acid versus placebo|
45403564|NCT00139776|Drug|Celecoxib|"24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind celecoxib 200 mg daily.~Placebo used as flare medication when directed."
45403565|NCT00139776|Drug|Celecoxib|"24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind placebo daily.~Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed."
45511526|NCT05578131|Procedure|high flow nasal oxygen|In the intervention group, pre-oxygenation was provided using HFNO via Optiflow THRIVE™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand) until SpO2 on pulse oximetry was > 95% and for at least 3 min. A flow of 0.5 l/kg/min-1 was used until induction agents had been administered, and then increased to 2 l/kg/min-1. Nasal oxygenation was continued without ventilation of the lungs while waiting for neuromuscular blockade, and during placing, replacing or repositioning the airway. Anaesthetists were free to carry out bag-mask ventilation of the lungs if they considered this necessary to maintain safe oxygen saturations. After securing the airway, the patient was connected to a circle circuit primed with 100% oxygen and the FIO2 was continued at 100% for a period of at least five more minutes. Relevant times were recorded, including start of pre-oxygenation and start of induction of anaesthesia.
45511527|NCT05578131|Procedure|face mask|In the control group, pre-oxygenation was provided using 100% oxygen via a sealed facemask and a circle-absorber anaesthetic circuit primed with 100% oxygen by installing a ventilation bag to the mouthpiece filter and ventilating the circuit with 100% oxygen. Anaesthetists were free to carry out bag-mask ventilation of the lungs once induction medications had been administered.
45511528|NCT05417737|Other|Ozone therapy|Systemic and/or local ozone administration. Dosage, frequency, and duration of ozone treatment will depend on the treated symptom and clinical evolution. Usually planned 40 sessions.
45511529|NCT05576571|Diagnostic Test|Met-score|methylation analysis
45511530|NCT05224947|Other|Infant Formula|Two infant formulas differing in composition
45511531|NCT02807883|Drug|Blinatumomab|Participants receive Blinatumomab as continuous intravenous infusion at a dose of 28 µg/24 hours over 4 weeks followed by a treatment-free period of 2 weeks, defined as one 6-week treatment cycle. In the first induction cycle, the initial dose of Blinatumomab is 9 µg/day for the first 7 days of treatment which then will be escalated (dose step) to 28 µg/day starting on day 8 (week 2) through day 29 (week 4). For all subsequent cycles, 28 µg/day is the dose for all 4 weeks of continuous treatment. Participants receive 4 cycles of blinatumomab at 3, 6, 9, and 12 months following hematopoietic cell transplantation (HCT).
45511532|NCT02807883|Procedure|Hematopoietic Cell Transplantation|Hematopoietic progenitor cell infusion
45403566|NCT03787186|Drug|GLPG1690 film-coated tablets|a single oral dose of GLPG1690
45403567|NCT03787186|Drug|[14C]-GLPG1690 solution for infusion|a 15-minute IV infusion [14C]-GLPG1690
45403568|NCT03787186|Drug|[14C]-GLPG1690 capsules|single oral dose of [14C]-GLPG1690
45403569|NCT03787420|Other|communication system|"We will use the questionnaire Amyotrophic Lateral Sclerosis Supportive Care Needs ,Amyotrophic Lateral Sclerosis Specific Quality of Life Instrument-Revised, Beck Depression Inventory and Caregiver Burden Scale."
45403570|NCT00413699|Drug|CP-690,550|5 mg PO BID open label; may increase to 10 mg PO BID to provide greater control of RA if no related AEs are present. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
45403571|NCT00413699|Drug|CP-690,550|10 mg PO BID open label; may decrease to 5 mg PO BID for mild to moderate AEs. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
45511533|NCT04051281|Behavioral|Letter|Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
45511534|NCT05563155|Drug|Dexamethasone 24 mg|Dexamethasone 24 mg on day 1 after surgery.
45511535|NCT05563155|Drug|Placebo|Placebo tablet given on day 1 after surgery.
46057240|NCT00635037|Drug|bupivacaine and acupuncture|"trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.~acupuncture twice a week"
46057241|NCT02777151|Drug|REGN3470-3471-3479|
45403572|NCT01037855|Other|Non-intervention observational study|Non-intervention observational study
45403573|NCT03713320|Drug|Cobomarsen|At least weekly doses of cobomarsen (282 mg) throughout study treatment period
45403574|NCT03713320|Drug|Vorinostat|Daily doses of vorinostat throughout study treatment period
45403575|NCT03712930|Drug|Pamiparib|60 mg orally twice daily (BID)
45403576|NCT00420407|Drug|normal saline control|no vasopressin added to bolus or 5 hour continuous infusion
45403577|NCT00420407|Drug|vasopressin|vasopressin bolus 4 units followed by continuous infusion 2.4units/hr for 5 hours
46057242|NCT02777151|Drug|Placebo|
45403578|NCT03793972|Other|Triage with referral to primary care|During intervention weekends(and holidays) a nurse will triage patients using a newly developped extended Manchester Triage System (eMTS). Patients appropriate for primary care will be referred to the general practitioner on call.We will inform patients about the nature of the intervention using leaflets and broadcasting in the waiting room of the Emergency Department.
45698847|NCT03013270|Other|Aerobic-Resistance|"Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1RM for quads training, pectoralis m, serratus anterior m, and latissimus dorsi m and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets).~(Aerobic (30min) + Resistance (30min) = 60 min)"
45698848|NCT03013270|Other|Aerobic-Inspiratory|Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 30min (Aerobic (30min) + Inspiratory (30min) = 60 min)
45698849|NCT03013270|Other|Aerobic Training|Patients will be submitted to a 12 week, 3 times/week continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with callisthenics progressing to treadmill or bike (at the same intensity) for 30 min (Aerobic training = 60 min)
45511536|NCT05545449|Behavioral|PrEP Peer Mentor Program|Five PrEP peer mentors will provide outreach, education, and referral for HIV pre-exposure prophylaxis. Peer mentors have received training on HIV, PrEP, family planning, adolescent development, peer support, and action planning. Interactions will include 1:1 informal interactions as well as planned group outreach interactions.
45511537|NCT03082261|Device|Prodigy, Prodigy MRI or Proclaim Elite IPG|Subjects will be permanently implanted with either a Prodigy, Prodigy MRI or Proclaim Elite IPG
45698850|NCT03461250|Diagnostic Test|HCV serology|Apply CRF to identify risk factors for HCV infection. In patients with positive HCV serology measure the level of viral load and HCV genotype by PCR Abbott-real time and determine the stage of liver fibrosis by elastography (Fibroscan)
45698851|NCT03461172|Procedure|Surgery of breast cancer|Surgery of breast cancer
45851183|NCT00384540|Procedure|Dobutamine stress echocardiography, coronarography, brachial arterial echography|DSE: cumulative doses of dobutamine (max = 40 µg/kg/min) and atropine (max = 1.5 mg), to reach a maximal heart rate under clinical, electrocardiographic and echocardiographic surveillancesCoronarography: invasive injection into coronary arteries of a radiological product showing a contrast visible on an x-ray. FMD: Flow-mediated dilatation of the brachial artery induced by 5-min forearm arterial occlusion
45851184|NCT00384618|Drug|pravastatin|
45851185|NCT00384618|Drug|vitamin E|
45851186|NCT00384696|Drug|Nicotine Replacement Therapy|4 Weeks of nicotine patch. Patch therapy for participants who smoke >10 cigarettes/day consists of 2 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches.
45851187|NCT00384696|Behavioral|Questionnaire|Survey taking 1 and 1/2 hours at each study visit.
45851188|NCT00385086|Drug|TNF blocker|Treatment with TNF-alpha blocker
45851189|NCT00385086|Drug|Placebo|Treatment with placebo
45851190|NCT00385164|Procedure|PET/CT scan for RT planning|
45851191|NCT00385242|Procedure|Positron emission tomography: FDG viability imaging|FDG PET viability imaging
45851192|NCT00385242|Other|PET imaging|PET viability imaging
45851193|NCT00385320|Biological|HRV vaccine|
45851194|NCT00385398|Drug|erlotinib hydrochloride|Erlotinib will be administered orally on at a dose of 200 mg/day on Days 1-23 of each 28 day cycle.
45851195|NCT00385398|Drug|temozolomide|Temozolomide will be administered orally at a dose of 150 mg/m2 on Days 1-5 for Cycle 1 then increased to 200 mg/m2 for Cycle 2 forward.
45851196|NCT00385398|Radiation|stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to chemotherapy.
45851197|NCT00385476|Behavioral|PMKT Questionnaire|Patient Medication Knowledge Tool - Questionnaire entailing the medications the patient is currently taking.
45851198|NCT00385554|Drug|UC-781 carbomer gel, 0.1% and 0.25%|
45851199|NCT00385632|Drug|Antiretroviral Regimens|Various antiretroviral therapy combinations already being administered to participants
45851200|NCT00385710|Drug|valproic acid|Depakine
45851201|NCT00385710|Drug|Placebo|Placebo
45851202|NCT00385866|Behavioral|cancer screening and health education|The control group will receive cancer screening and health education materials on a quarterly basis but will not have access to patient navigation services.
45511538|NCT04051047|Drug|Gemcitabine|Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
45715343|NCT01566149|Drug|Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI|Two oral inhalations per dose
45715344|NCT01566149|Drug|Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI|Two oral inhalations per dose
45851203|NCT00385866|Behavioral|facilitation of Services to improve cancer screening|The intervention group will receive cancer education and faciliation of services in the form of patient navigation
45851204|NCT00386178|Drug|Vitamin E supplement rich in gamma tocopherol|daily dose of Vitamin E supplement rich in gamma tocopherol
45851205|NCT00421590|Drug|SMC021|
45851206|NCT00421668|Drug|Zinc|zinc
45851207|NCT00421668|Drug|Multivitamins|Vitamins C, E, B1, B2, niacin, B6, folate and B12
45851208|NCT00421668|Drug|Placebo|Placebo
45851209|NCT00421746|Drug|Piboserod|
45851210|NCT00421824|Drug|Oxaliplatin, capecitabine|OXA 130 D1 + Capecitabine 2000 / day D1-D14 for 4 cycles. After 10 weeks of rest, XELOX-RT regimen x 5 weeks followed by surgery
45511539|NCT04051047|Procedure|Tumor biopsy and blood draw|As part of standard of care, all participants will undergo tumor biopsy and collection of peripheral blood.
45511540|NCT02759133|Device|Metal wire|Localization technique for breast surgery using metal wire
45511541|NCT02759133|Device|Radioactive Iodine Seed|Localization technique for breast surgery using Radioactive Iodine Seed
45511542|NCT00102440|Drug|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 52 weeks.
45511543|NCT00102440|Drug|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 52 weeks.
45511544|NCT00102440|Drug|Allopurinol|Allopurinol 300 mg, capsules, orally, once daily for up to 52 weeks.
45511545|NCT02742363|Other|Collecting data|Collecting data from patient records
45511546|NCT05224791|Procedure|Roux-en-Y Gastric Bypass|The RYGB connects a limb of the intestine to a much smaller stomach pouch, which prevents the bile from entering the upper part of the stomach and esophagus, thereby effectively bypassing the remaining stomach and first segment of the small intestine.
45511547|NCT05224791|Procedure|Sleeve Gastrectomy|"The SG is a restrictive procedure in which a partial left gastrectomy of the fundus and body of the stomach is performed in order to create a long tubular sleeve along the lesser curvature. The weight loss and resolution of comorbidities are attributed not only to the restrictive nature of the procedure but also to restriction by the pylorus, decreased ghrelin, increased satiety, increased gastric emptying, and faster small bowel transit times with a component of malabsorption"
45698852|NCT03461172|Other|Clinical data collection|The collection centralizes the main characteristics of the patients, the tumor and the treatments. Also included are the date of first recurrence, the localization (local, regional or distant) as well as the death or the date of the latest news.
45698853|NCT03466164|Behavioral|Mindfulness Based Stress Reduction Program|8 week, 10-session course of mindfulness training
45403579|NCT03793972|Other|Usual care|During a control weekend (and holidays), all data registration and collection will be the same as during intervention weekends but patents will not be informed about their allocation advice. The emergency physician will see all patients deciding to stay at the ED, without influence of the triage advice. As in standard clinical care, patients will have the right to change their mind and go spontaneously to the general practitioner. . During control weekends, we will only inform about triage in general but no about the general practioner or the intervention.
45511548|NCT01380847|Genetic|mRNAs encoding genes|investigate whether the levels of 21 mRNAs encoding genes involved in EMT/fibrogenesis and the alloimmune response are a sensitive and specific non-invasive diagnostic test for CAN in renal allografts
45511549|NCT05224167|Drug|Melatonin 5 MG Sublingual Tablet|Melatonin 5 mg 12 hours and 2 hours prior to surgery
45403580|NCT01037933|Other|Humor intervention|"A 45-minute humorous DVD (Bananas Bunch) using a portable DVD player."
45511550|NCT05224167|Drug|Hydroxyzine|Hydroxyzine 1mg/kg 12 hours and 2 hours prior to surgery
45511551|NCT01377259|Other|tissue oxygen saturation, spinal anesthesia|regional tissue oxygen saturation(rSO2)detected over upper and lower extremities before and after spinal anesthesia
45511552|NCT05223933|Behavioral|Proactive community case management|CHWs in the intervention arm conducted door-to-door fever screening for all inhabitants of all consenting households in their catchment area every fortnight. All individuals with temperature ≥ 37.5°C or history of self-reported fever in the previous two weeks were tested with an RDT; positive individuals who were not pregnant and did not have signs of severe disease were treated with artesunate-amodiaquine according to treatment guidelines. Individuals identified as requiring a referral during Pro-CCM visits were assisted with transfer to the healthcare center, with transportation handled by the project staff.
45403581|NCT01037933|Other|Non-humor intervention (distraction)|"A 45-minute non-humorous DVD (The A to Z of Steam Railways) using a portable DVD player"
45511553|NCT02884219|Drug|Ibuprofen|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
46057243|NCT02776995|Other|Thermography imaging|Thermography imaging of the treated - irradiated body area.
45403582|NCT01038011|Drug|drug treatment|
45403583|NCT03787108|Other|Magnetic resonance spectroscopy measurement|Magnetic resonance spectroscopy measurement will be performed to measure liver fat content.
45403584|NCT03789448|Other|Early Access to ART for All|All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines
45403585|NCT03789370|Drug|Propofol|Maintanance of general anaesthesia with propofol
45403586|NCT03789370|Drug|Sevoflurane|Maintainance of general anaesthesia with sevoflurane.
45403587|NCT00420095|Drug|Human insulin 30/70|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
45403588|NCT00420095|Drug|Insulin lispro low mix|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
45403589|NCT01307644|Behavioral|Experimental: Web-based only (WO) weight intervention|The WO intervention included evidence-based lifestyle modification for healthy eating and activity, with self-monitoring and goal setting, and messages based on constructs from the Health Promotion Model across 3 phases. The intent of the phases was to deliver more intensive intervention during Phase 1, transitioning to less intensive intervention during phase 2, to providing support for self managed weight maintenance during Phase 3.
45403590|NCT01307644|Behavioral|Experimental: WO plus peer-led discussion board (WD)|Includes WO intervention plus asynchronous discussion board managed by peer leader, whose identity is masked. The peer leader who posted theme-based messages, called primers, that were consistent with WO themes across phases.
45403591|NCT01307644|Behavioral|Experimental: WO & professional email counseling (WE)|Includes WO intervention plus professional email counseling provided by a registered dietitian whose identity is masked. The email counselor is responsible for reviewing eating, activity, weight logs, and goals on the web-site and send e-mail feedback, in addition to responding to email questions. The e-mail process will follow the 5A's Model for Behavioral Counseling (assess, advise, agree, assist, and arrange) that was adapted for this study.
45403592|NCT03789526|Procedure|ultrasound guidance|ultrasound guidance of tendon injection
45511554|NCT02884219|Other|Expectative Management|Expectative PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
45403593|NCT04904692|Procedure|Blood draw|8x9mL EDTA tubes. In subjects treated with hydroxychloroquine treatment an extra EDTA tube (4mL) will be collected for the REVIVE substudy.
45403594|NCT04904692|Procedure|Bronchoalveolar lavage|Only in case of diagnostic or therapeutic indication.
45403595|NCT04904692|Procedure|SARS CoV-2 swabs|Nasopharyngeal, oropharyngeal and nasal swabs
45403596|NCT01038089|Dietary Supplement|Resveratrol|Resveratrol
45698854|NCT02980120|Other|SCID-I|The structured clinical interview for DSM-IV Axis I Disorder (SCID-I, German translation, see Wittchen, Zaudig & Fydrich, 1997) is a semi-structured interview to diagnose AN and BM. It allows a detailed assessment of ED symptoms across different settings and time periods necessary to make an accurate diagnosis.
46057244|NCT02777073|Drug|Farxiga|Single dose of dapagliflozin
45403597|NCT01305070|Device|Admiral Xtreme|For balloon angioplasty of in-stent restenosis in the superficial femoral artery
45403598|NCT01305070|Device|In.Pact Admiral|For balloon angioplasty of in-stent restenosis in the superficial femoral artery
45403599|NCT05495464|Drug|Acalabrutinib|Given by PO
45403600|NCT05495464|Drug|Rituximab|Given by IV (vein)
45403601|NCT05495464|Other|Brexucabtagene Autoleucel|Given by IV (vein)
45403602|NCT05495464|Drug|Cyclophosphamide|Given by IV (vein)
45403603|NCT05495464|Drug|Fludarabine Phosphate|Given by IV (vein)
45403604|NCT00419393|Drug|Keppra XR (Levetiracetam XR)|500 mg tablets, 1000 - 3000 mg/day, flexible dosing for duration of the study (planned: approximately 6 months-3 years).
45403605|NCT04738708|Other|Patients referred to CGS at NCCS for HBOC or Lynch syndrome pre-test genetic counselling.|Patients are given a series of questions evaluating cognitive and psychosocial outcomes, either via hardcopy in-person or online internet-facing questionnaire.
45403606|NCT01038167|Drug|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-11 of Period 2
45403607|NCT01038167|Drug|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-13 of Period 2
45403608|NCT01038167|Drug|cyclosporine|Solution, Oral, 100mg, Day 1 of Period 1
45403609|NCT01038167|Drug|cyclosporine|Solution, Oral, 10mg, Day 1 and Day 8 of Period 2
45403610|NCT01038167|Drug|tacrolimus|Capsule, Oral, 2mg, Day 1 of Period 1
45403611|NCT01038167|Drug|tacrolimus|Capsule, Oral, 0.5mg, Day 8 of Period 2
45511555|NCT02884219|Drug|Indomethacin|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
45511556|NCT05223777|Device|KINCISE|The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument.
45403612|NCT04690738|Diagnostic Test|Fecal Elastase Concentration|Stool sample for fecal elastase-1 (FEC) analysis and microbiome for sequencing and analysis will be obtained pre- and post-transplant.
45403613|NCT01307722|Other|left atrial distensibility-guiding prescription of heart failure drugs|This study is a prospective, observational, and open label investigation. The guide group will be followed 1 time per 2 week at first 3 months, then 1 time per month later, and then 1 time per 3 months. Each time, the guide group should receive echocardiography, including the measurement of LA distensibility. LA distensibility-guided therapy is enabled in 2 ways. Prescriptions should be adjusted according to overall left ventricular filling pressure estimated by LA distensibility. The specified treatments after adjustment by the current LA distensibility are also allowed. Investigators individually adjust medications for each patient according to the ranges of LA distensibility. The specified therapy is based on 5 LA distensibility ranges (very low, low, optimal, high, and very high). Each range is associated with a prescription for medication dosing, sodium and fluid intake, or activity level.
45511557|NCT05223777|Device|Traditional Handheld Mallet|The handheld mallet traditionally used in total hip arthroplasty.
45511558|NCT05409547|Drug|PEG-rhG-CSF|PEG-rhG-CSF 6 mg/d (single dose) will be given on the second day after chemotherapy.
45511559|NCT04994535|Drug|OnabotulinumtoxinA|Injection
45511560|NCT04994535|Drug|Placebo|Injection
45511561|NCT03909607|Drug|Ketamine 0.75 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 0.75mg/kg
45511562|NCT03909607|Drug|Ketamine 1.0 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 1.0 mg/kg
45511563|NCT03909607|Drug|Ketamine 1.5 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 1.5 mg/kg
46057245|NCT02777073|Drug|Victoza|Single dose of Liraglutide
46057246|NCT02777073|Drug|Placebo|Single dose of generic placebo
45511564|NCT02498925|Behavioral|Behavioral Activation|Behavioral Activation is a psychosocial treatment for depression focused on gradually re-engaging patients with sources of reinforcement and reward in their environment (e.g., increasing activites and interpersonal interactions). In contrast to Cognitive Behavioral Therapy, and as the name implies, Behavioral Activation focuses on behavioral change strategies to improve mood and places little emphasis on cognitive restructuring techniques.
45511565|NCT02762084|Drug|Patidegib|
45403614|NCT03787030|Drug|Vitamin E Acetate ointment|Application of 1 ml of ointment to the distal anal canal, every 12 hours for an 8-week period.
45403615|NCT03787030|Drug|Glyceryl trinitrate ointment|Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
45511566|NCT02762084|Drug|Vehicle gel|
45511567|NCT03902509|Drug|Pirfenidone|pirfenidone capsule made in China
45511568|NCT03902509|Drug|basic treatment|glucocorticoid and expectant treatment etc.
45511569|NCT05223543|Diagnostic Test|Blood sample|extraction of blood samples from women undergoing ovarian cystectomy or oophorectomy due to suspected Dermoid cyst and analysing plasma for antibodies
45511570|NCT05503017|Behavioral|Psycho-social, computerized intervention targeting error sensitivity|The computer-based intervention is designed to directly reduce the sensitivity to errors through cognitive behavioral techniques. The intervention takes approximately 45 minutes and includes interactive quizzes, information, and behavioral tasks relevant to making mistakes, implications of making errors, and ways to deal with making mistakes, among other topics relevant to increased error sensitivity. The intervention uses developmentally appropriate language and stories that young children can relate to and understand.
45511571|NCT05503017|Behavioral|Psycho-social, computerized intervention on healthy lifestyle choices|The computer-based control condition will be in the same format and duration as the active intervention, but instead focuses on self-care topics and healthy lifestyle choices (e.g., eating healthy foods and getting a good night sleep), unrelated to error sensitivity.
45511572|NCT02159222|Procedure|Additional physical therapy|
45511573|NCT01380613|Behavioral|Workshop|10 session intervention
45511574|NCT01380613|Behavioral|Workshop control|1 session intervention on standard HIV/STD information
45511575|NCT02166632|Procedure|Intracapsular Injection|"The amount of bupivacaine liposome (ExparelTM) will be injected directly into the joint capsule (intracapsular injection), effectively bathing the joint in the medication."
45511576|NCT02166632|Procedure|Periarticular Injection|The amount of bupivacaine liposome (ExparelTM) will be injected periarticulary, via 9 standard periarticular tissue sites around the joint
45511577|NCT03625401|Drug|AD-35 60mg group|AD-35 60mg QD
45403616|NCT03993977|Diagnostic Test|Rotational thromboelastometry|ROTEM-guided protocol of hemostatic resuscitation
45511578|NCT03625401|Drug|Placebo group|Placebo: 3 placebo of AD-35 30mg tablets
45511579|NCT02161952|Drug|Pirfenidone|Pirfenidone was supplied orally in 400 mg gel capsules three times daily (every 8 hours) for a full dosage of 1200 mg daily during 24 months.
45511580|NCT02161952|Drug|Matched equivalent placebo|
45511581|NCT05223465|Other|Survey|Google form distributed for students and faculties
45511582|NCT03590145|Diagnostic Test|Clinical examination|Standardized clinical examination consisting of pain provocation test, including palpation, muscle resistance and stretch test.
45511583|NCT04993677|Drug|SEA-CD40|Given into the vein (IV; intravenously); schedule is cohort-specific
45511584|NCT04993677|Drug|pembrolizumab|Given by IV; schedule is cohort-specific.
45511585|NCT04993677|Drug|pemetrexed|Given by IV on Day 1 of each 21-day cycle.
45511586|NCT04993677|Drug|carboplatin|Given by IV on Day 1 of Cycles 1-4. Each cycle will be 21 days long.
45511587|NCT05202249|Procedure|muscle layer fixation of thoracic drainage tube|The thoracic drainage tube is fixed on the muscle layer of the uniport
45511588|NCT05111223|Device|Real transcranial magnetic stimulation (TMS) before conditioning|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the conditioning phase of the task.
45511589|NCT05111223|Device|Real transcranial magnetic stimulation (TMS) before devaluation test|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the devaluation test phase of the task.
45511590|NCT05111223|Device|Sham transcranial magnetic stimulation (TMS)|Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.
45511591|NCT04984161|Other|education|The aim of this project is to examine the effect of stoma care education on the knowledge and skill levels of pediatric surgery nurses about stoma care.
45511592|NCT04979403|Other|Physiotherapy|Participants from each group will receive 8 intervention sessions (45 min) over 11 weeks by a physiotherapist. For both groups, each intervention will be tailored to the patient's profile and the choice of interventions and parameters will be at the judgment of the physiotherapist.
45511593|NCT05100069|Drug|Brigatinib|Brigatinib Tablets
45511594|NCT05085795|Device|Impulse Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
45511595|NCT05195697|Other|Observational study of different treatments and time to treatment|Different treatment based on the clinical decision
45511596|NCT03705039|Other|Pulsed Ultrasound Treatment|Patients will receive treatment with 1 MHz probe with the intensity of 1w/cm2, pulsed at a ratio of 1:4 for 10 minutes and at an interval of 3 sessions per week during 8 weeks, a total of 24 sessions.
45511597|NCT03705039|Other|Control group|Sham US will be applied to control group for the same times and periods as treatment group. A home exercise program will be given to both of two groups which contains knee range of motion and isometric strengthening exercises.
45511598|NCT03704961|Behavioral|music and audiobook listening|
45511599|NCT05047731|Drug|Antihypertensive medication|Antihypertensive medication will be deprescribed to a blood pressure of 140 ±5 mmHg following the study algorithm.
45511600|NCT05349981|Device|Phonak Lyric self-replacement procedure|The self-replacement procedure is an experimental procedure in which the Lyric user replaces the Lyric devices independently at every other device replacement, using dedicated candidacy, training, and management procedures, conducted by and at the discretion of his/her hearing care provider (HCP).
45511601|NCT05322447|Drug|L Carnitine ( low dose)|will receive a maintenance dose of L- carnitine 6 gm/day to keep normal level (normal L-carnitine level is normal 25-50 mmol/L)
45511602|NCT05322447|Drug|L-Carnitine ( high dose)|will receive a high dose of L- Carnitine 18 gm/day as a continuous intravenous infusion to reach double the normal plasma level
45511603|NCT04795869|Drug|Brentuximab Vedotin|Given IV
45511604|NCT04795869|Biological|Pembrolizumab|Given IV
45511605|NCT05006781|Drug|DAOIB|The DAOIB dose in each group will be fixed during the 24 weeks duration
45511606|NCT03704727|Dietary Supplement|Probiotic|Probiotics (beneficial microorganisms) VSL#3 is a probiotic formula containing a mixture of 9x10^10 CFU/g Lactobacilli strains (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus), 8x10^10 CFU/g Bifidum strains (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis) and 20x10^10 CFU/g Streptococcus thermophilus
45511607|NCT03704649|Behavioral|Participatory video|Participatory video education is an intervention model that gives communities the film-making skills necessary to make videos that can be used in nutrition promotion. For the purposes of this study, we will be using a participatory video model as an approach to educate participants in a school-based girls club on nutrition education topics. Participants are taught how to use film equipment and accompanied to draft scripts, create characters, video-record the shots, and act (if they wish) in the video. These videos will be used in the group as a means of sharing nutrition information with students and in stimulating discussion around the nutrition topic.
45511608|NCT05292183|Other|Electrical Stimulation|We will use a computer randomized stimulation of specific areas in the amygdala while showing a computer randomized set of pictures.
45511609|NCT04050813|Behavioral|Exercises program for hamstring architecture and function|To assess the effectiveness of the inertial flywheel resistance program in the architecture and function of the hamstrings post structural hamstring injury
45511610|NCT05278377|Behavioral|"Apprenti en Action program"|"The Apprenti en Action program aims to teach students how to read and follow recipes, prepare and cook various foods using various culinary techniques, and apply food safety practices. Students are also taught the basics of healthy food, nutrition, and cooking."
45511611|NCT04907799|Behavioral|Daily caloric restriction|Weight loss based on daily caloric restriction and increased physical activity
45511612|NCT04907799|Other|Standard advice control|Initial nutrition consultation without subsequent counseling
45511613|NCT04050735|Other|Alcohol, ethyl, moderate dose|Moderate oral dose of ethyl alcohol
45511614|NCT04050735|Other|Placebo|Placebo beverage
45698855|NCT02980120|Other|EAT|The Eating Attitudes Test (EAT) is a standardized questionnaire of symptoms and concerns related to ED (Garner & Garfield, 1979, German translation by Steinhausen). The questionnaire consists of 40 items on a six-point Likert scale, providing information
45851211|NCT00421824|Drug|Oxaliplatin, capecitabine|XELOX-RT x 5 weeks followed by surgery and 4 cycles of adjuvant XELOX with the same scheme as arm A.
45851212|NCT00421902|Procedure|Acupuncture|Patients will be have acupuncture (with electro stimulation)
45403617|NCT03993977|Other|Conventional treatment|Clinical judgement and conventional coagulation tests
45851213|NCT00421980|Drug|Etanercept|
45851214|NCT00422214|Drug|Quetiapine fumarate (Seroquel) SR|
45851215|NCT00422370|Device|lipid based additives based on vegetable oil & lecithin|
45851216|NCT00422526|Drug|Micronised progesterone (Utrogestan)|
45851217|NCT00422604|Drug|salmeterol|
45851218|NCT00422604|Drug|tiotropium|
45851219|NCT00422604|Drug|GSK233705|
46057247|NCT02711865|Biological|IGF1R antibody MK0646|
46057248|NCT02711865|Other|Saline solution|
45403618|NCT03786874|Other|Identify work interruptions|estimate baseline characteristics of the collaborative working model (proportion expressed as a percentage)
45403619|NCT03786874|Other|Understand work interruptions|Team-review of the results of the task interruption and professional representations, identify activities to protect from task interruption
45403620|NCT03786874|Other|Act to limited work interruptions|Adaptation of organizations; Awareness raising and Coaching for change
45403621|NCT02174549|Drug|Tirapazamine|Intra-arterial injection into the tumor feeding artery
45403622|NCT02174549|Procedure|Transarterial embolization (TAE)|Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia
45403623|NCT03786562|Drug|Intrathecal Morphine|Group 1
45403624|NCT03786562|Drug|Intrathecal Morphine + Intravenous Nalbuphine|Group 2
45511615|NCT04784559|Drug|Plitidepsin|"Plitidepsin 2 mg powder is provided as a sterile, preservative-free, and white to off-white lyophilised powder/cake comprising 2 mg plitidepsin and mannitol in a single-dose, 10 mL clear type 1 glass vial.~Solvent for plitidepsin is provided as a sterile, preservative-free, clear, slightly viscous aqueous liquid (4 mL) containing macrogolglycerol ricinoleate and ethanol in a single-dose type 1 clear glass ampoule.~For administration, vial contents are reconstituted by addition of 4 mL of solvent for plitidepsin to obtain a slightly yellowish solution containing 0.5 mg/mL plitidepsin with mannitol, macrogolglycerol ricinoleate and ethanol excipients. The required amount of plitidepsin reconstituted solution is added to bag containing 0.9% sodium chloride or 5% glucose for IV injection and administered as an IV infusion over 60 minutes."
46057249|NCT02712021|Other|Lycra suit and physiotherapy treatment|Garments will be fitted by an occupational therapy with the treating therapist and child neurologist present. The garments will be constructed of Lycra with the possibility of adding reinforcing panels or derotation bands. All the children will be involved in regular physiotherapy treatment (2-3/week).
46057250|NCT02712021|Other|physiotherapy treatment|All the children will be involved in regular physiotherapy treatment (2-3/week).
46057251|NCT02711943|Drug|Levofloxacin 500|Oral levofloxacin (Levolet®) at a dose of 500 mg once a day for 28 days
45403625|NCT05694364|Drug|Fludarabine|Fludarabine is an antimetabolite given prior to lymphodepletion.
45403626|NCT05694364|Drug|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
45403627|NCT05694364|Biological|PRGN-3007|PRGN-3007 T cells are autologous T cells that are genetically modified ex vivo with the Sleeping Beauty (SB) system to express a ROR1-specific chimeric antigen receptor (ROR1 CAR), membrane bound interleukin-15 (mbIL15), a kill switch derived from truncated form of human epidermal growth factor receptor (HER1t) and include a built-in mechanism for intrinsic downregulation of programmed cell death receptor 1 (PD-1) expression on UltraCAR-T cells.The transgenes are delivered from a SB transposon which ensures co-expression all transgenes in all transfected cells. T cells are selected from the apheresis product and can be modified with the SB system to manufacture the T cells with the potential of infusing within 2 days from genetic modification.
45403628|NCT02173613|Other|procalcitonine|"The recommendations will be based on the level of PCT: 4 levels of advice will be given:~It is highly recommended to stop antibiotics if PCT <0.1ng/ml, and the recommended stop if 0.1ng/ml <PCT <0.25 ng / ml.~It is recommended to continue treatment if 0.25 ng / ml <PCT ng / ml.~Finally, if the initial PCT greater than 10 ng / ml, a stop will be advised in case of reduction to less than 10% of baseline level."
45403629|NCT02639728|Other|Regular Coffee|Regular coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
45511616|NCT04784559|Drug|Dexamethasone|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
45511617|NCT04784559|Drug|Remdesivir|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
45511618|NCT04784559|Drug|Favipiravir|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
45511619|NCT03704571|Drug|Polyethylene Glycol|"In the Tailored group, high-risk people are given intensified bowel preparation regimens, low-risk people are given routine regimens.~In the control group, all the patients are given routine regimens."
45511620|NCT03704493|Diagnostic Test|Video Group|A video of a group of five amateur runners running along woods and fields. The group was filmed from behind to give the patient the impression of running within the group.
45403630|NCT02639728|Other|Decaffeinated coffee|Decaffeinated coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
45511621|NCT04050657|Other|appointment interval|To change the appointment interval for one group and keep the standard interval for the other group by measuring alignment duration, measured as days needed to align the teeth using full-arch fixed appliances
45511622|NCT03704337|Dietary Supplement|Commercially Available Food Bar|Active
45511623|NCT03704337|Dietary Supplement|Placebo|Placebo
45511624|NCT04910763|Behavioral|Resistance Exercise|Increasing strength and fitness and thereby influencing hormones and perceptions involved in appetite regulation.
45511625|NCT03704259|Other|Ceramic coating|coating the laparoscope lens with commercial brand ceramic coating, bought from car service centers specialized in such applications
45511626|NCT03704181|Drug|Colchicine 0.5 MG twice day for one year|placebo twice day for one year
45511627|NCT03704181|Drug|Placebo Oral Tablet|placebo twice day for one year
45511628|NCT03625011|Drug|Gabapentin|This double blinded randomized control trial will enroll 50 children age 3-18 years, undergoing T/As. Patients will be receiving either one gabapentin dose (15mg/kg up to 600mg) or placebo preoperatively. Both control and test group will receive the standard narcotic regimen intraoperatively.
45511629|NCT04891965|Biological|ART24|Each ART24 capsule will contain lyophilized ART24 and inactive excipients. ART24 will be supplied in a dose strength of 5×10^9 CFU/capsule. Subjects will receive 1 capsule daily.
45851220|NCT00422682|Drug|bsi-201 + topotecan|21 day cycle
45851221|NCT00422682|Drug|bsi-201 + temozolomide|28 day cycle
45511630|NCT04891965|Drug|Placebo|Each placebo capsule is identical in appearance, weight, and packaging to ART24 capsules, but will contain only the inactive excipients. Subjects will receive 1 capsule daily.
45511631|NCT03701841|Drug|PEG-rhG-CSF|All patients need to receive PEG-rhG-CSF 6mg approximately 24h or 48h after chemotherapy administration once per cycle, at least 2 cycles
45511632|NCT03624933|Behavioral|Weekly Behavioral Coaching Session|The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days of abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.
45511633|NCT03624933|Behavioral|Contingency Management|If the participant's weekly abstinence is successful as determined by the urine results on day 28, the participant will receive an additional $300.00 cash bonus on top of their hourly $10 compensation for attending all visits. We predict that this cash bonus is enough incentive to allow for the behavioural change of abstinence in this patient population.
45511634|NCT03701685|Procedure|nerve flap|sensory reconstruction via a nerve graft included in the flap
45511635|NCT04760847|Other|Intermittent Fasting|These subjects will will then receive information regarding intermittent fasting, which would include fasting for a 16-hour period each day, followed by ingestion of an appropriate number of calories for the remaining part of the day. See attached IF Quick Facts for details provided to the patient.
45511636|NCT04760847|Other|No intermittent fasting|These subjects will undergo standard caloric dietary guidance. Patients in group B will also be given the above information, though not be asked to intermittently fast
45511637|NCT04775355|Procedure|Biospecimen Collection|Undergo collection of stool and urine
45511638|NCT04775355|Other|Electronic Health Record Review|Medical records are reviewed
45511639|NCT04775355|Other|Quality-of-Life Assessment|Complete quality of life questionnaires
45511640|NCT04775355|Other|Questionnaire Administration|Complete questionnaires
45511641|NCT02763644|Drug|LFG316 active drug|LFG316
45511642|NCT02763644|Other|Standard of care treatment|SoC (site specific)
45511643|NCT02162030|Behavioral|Acceptance and Commitment Therapy|Half of the participants will receive an eight-session ACT intervention whereby each component of the psychological flexibility model will be covered. Half of the participants will receive an eight-session act intervention whereby each component except self as context will be covered.
45511644|NCT03703713|Drug|Sodium chloride|Treatment with Sodium chloride
45511645|NCT04742907|Drug|TU-100|Treatment with investigational product
45403631|NCT02639728|Other|Warm water|Warm water will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
45403632|NCT01038401|Procedure|GI endoscopy and GALT biopsies|This project aims to characterize the residual replication of HIV-1 in subjects on HAART, particularly in the gut-associated lymphoid tissue (GALT)
45403633|NCT01038401|Biological|A sample of venous blood will also be collected|These samples of blood will be use to characterize the residual viral populations on effective HAART in three compartments, plasma, monocytes, and GALT
45403634|NCT05694286|Procedure|Juvederm Volbella XC hyaluronic acid dermal filler injection|Infraorbital filler injection
45511646|NCT04742907|Drug|Placebo|Treatment with placebo product
45511647|NCT04722627|Drug|AT-752|Parallel Assignment
45511648|NCT04722627|Drug|Placebo|Parallel Assignment
45698856|NCT02980120|Other|EDI-2|The Eating Disorder Inventory 2 (Paul & Thiel, 2004) is a self-report questionnaire on psychological features generally associated with AN and BN.The instrument consists of 91 items on a six-point Likert scale. The 11 scales are drive for thinness, bulimia, body dissatisfaction, ineffectiveness, perfectionism, interpersonal distrust, interoceptive awareness, maturity fears, asceticism (provisional), impulse regulation (provisional) and social insecurity (provisional). It was designed as a diagnostic aid; its psychometrics have been tested, with studies demonstrating satisfactory internal consistency reliability coefficients (between .44 and .93), test-retest reliability of .79 to .95 (after one week) and above .80 (after three weeks), and content, convergent and discriminant validity.
45851222|NCT00422682|Drug|bsi-201 + gemcitabine|28 day cycle
45851223|NCT00422682|Drug|bsi-201 + carboplatin/paclitaxel|21 day cycle
45403635|NCT03793894|Behavioral|Smoking Cessation Counseling|All participants will receive inpatient smoking cessation counseling by the tobacco-trained NP. Inpatient smoking cessation counseling is the standard of care at BMC.
45511649|NCT04728555|Procedure|Game about radiotherapy|A digital pedagogical game about radiotherapy
45511650|NCT03625167|Other|Treatment with petrolatum|Petrolatum is applied twice daily to the intervention arm.
45511651|NCT04893759|Drug|Pelcitoclax|Multiple dose cohorts, 30 minute IV infusion, once a week, 28 days as a cycle
45511652|NCT04576689|Drug|IBE-814 70ug|Up to 25 participants will receive IBE-814. Route of administration: intravitreal injection.
45511653|NCT04576689|Drug|IBE-814 140ug|Up to 25 participants will receive IBE-814. Route of administration: intravitreal injection.
45511654|NCT04575909|Behavioral|Aprosodia Intervention|Intervention will focus on improving participants' use and understanding of emotional prosody using implicit and explicit cues, biofeedback, modeling, and feedback.
45511655|NCT04575909|Behavioral|No-Intervention|Sessions will comprise conversation about current events, recovery progress (including speech therapy goals targeted in outside intervention [if relevant]), hobbies, and other similar topics.
45511656|NCT04573491|Genetic|Pharmacogenetic test|genotyping for genes that affect drug metabolism
45511657|NCT04573491|Other|Medication review|systematic and interdisciplinary method aiming to increase quality of medication treatment
45511658|NCT03701607|Other|PD-L1 group|PD-L1 expression is evaluated using immunohistochemical assay
45511659|NCT04718727|Drug|Placebo|oral Placebo tablets one-hour preoperatively
45511660|NCT04718727|Drug|5 mg Olanzapine Tablets|oral 5 mg Olanzapine tablets one-hour preoperatively
45511661|NCT04718727|Drug|10 mg Olanzapine Tablets|oral 10 mg Olanzapine tablets one-hour preoperatively
45511662|NCT03703557|Diagnostic Test|Sorbstar®|Thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry.
45511663|NCT03703557|Diagnostic Test|Odour sampling|Analyzed by the dogs of Curie Institute at the training centers
45851224|NCT00422838|Procedure|fine-needle aspiration biopsy|aspiration of intrahepatic cells
45511664|NCT03703479|Other|autologous blood clot made from the patient own clot without any additive|advanced Platelet-rich fibrin clot is made from venous blood withdrawn from the patient
45511665|NCT03701529|Drug|Sevoflurane|1.5-2.5 vol % sevoflurane is used for maintenance of anesthesia.
45851225|NCT00422916|Behavioral|behavioral intervention|
45403636|NCT03793894|Behavioral|Decision Aid|"The AHRQ Is Lung Cancer Screening Right for me? patient decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about tradeoffs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW)"
45403637|NCT03793894|Behavioral|Shared decision making (SDM)|"During the smoking cessation consultation, the nurse practitioner (NP) will conduct SDM, using the 4-page AHRQ Is Lung Cancer Screening Right for me? decision aid as a guide. The purpose of SDM is three-fold: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with Centers for Medicare & Medicaid Services (CMS) requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context."
45403638|NCT03793894|Behavioral|CHW Navigation|The CHW will meet with the participant after the SDM to initiate the coordination of outpatient tobacco treatment, referral to LCS, and resources to address the barriers to preventive services. The CHW will follow patients subjects in the intervention arm for 3 months to help navigate and address negative social determinants of health that are barriers to LCS and tobacco treatment. For patients who agree to screening, the CHW will schedule the appointment, arrange the transportation to appointment, and meet participant at the appointment to facilitate the screening.
45511666|NCT03701529|Drug|Propofol|2-5 mcg/ml of propofol is used for maintenance of anesthesia.
45511667|NCT04050891|Device|combined supraclavicular and interscalene block|"Supraclavicular block An in plane approach, a 22G needle 75mm was advanced from lateral to medial to the corner pocket where the lower trunk commonly lies at this area between the subclavian artery medially, first rib inferiorly and the plexus superiorly then 10ml of the mixture local anesthetic was injected, the remaining volume was injected just above and lateral to the subclavian artery.~Interscalene block After local anesthetic infiltration of the skin, a 22G needle 75mm was inserted in plane approach from lateral to medial toward the inter-scalene groove between the anterior and middle scalene muscles. The anesthetic mixture 15 ml was injected toward C5, C6 cervical nerve roots aiming to block nerves escaped from supraclavicular nerve block."
45851226|NCT00422994|Drug|ropinirole dosing for up to 28 days|
46057252|NCT02711787|Device|Experimental group|Robotic assisted passive mobilization (Gloreha, Idrogenet, Italy) and traditional rehabilitation.
46057253|NCT02711787|Device|Control group|Physiotherapy and occupational therapy.
45511668|NCT04535271|Drug|Trabectedin|This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
45511669|NCT04553133|Drug|PF-07104091 monotherapy dose escalation|PF-07104091 will be administered orally
45403639|NCT03786328|Behavioral|Standard Psychiatric Treatment|Standard psychiatric treatment is offered individuals identified with a clinical mental disorder. Treatment will follow golden standard treatment in the psychiatric clinic, meaning a combination of therapy and psychopharmacological treatment.
45403640|NCT03786328|Behavioral|Preventive Psychological Treatment|Preventive Psychological Treatment is offered individuals identified with a sub-clinical mental condition. Treatment consists of 8 sessions of cognitive-behavioural therapy.
45403641|NCT01305148|Device|Warfarin GenoSTAT Test|Use of genetic information from the GenoSTAT test to determine the warfarin dose
45511670|NCT04553133|Drug|PF-07104091 + palbociclib + fulvestrant|PF-07104091 will be administered orally in combination with palbociclib and fulvestrant
45403642|NCT01305226|Drug|THR-100|THR-100: 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)
45403643|NCT01305226|Drug|Streptokinase|Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
45403644|NCT03786250|Procedure|Geriatric Assessment|Systematic screening of delirium, prevention of delirium, early treatment, pain management with scales adapted to chronicity, conciliation of medication to emergency discharge, among others.
45511671|NCT04553133|Drug|PF-07104091 + palbociclib + letrozole|PF-07104091 will be administered orally in combination with palbociclib and letrozole
45511672|NCT04553133|Drug|PF-07104091 monotherapy dose expansion (ovarian)|PF-07104091 will be administered orally
45511673|NCT04553133|Drug|PF-07104091 monotherapy dose expansion (SCLC)|PF-07104091 will be administered orally
45698857|NCT02980120|Other|SCID-II|The SCID-II interview (German, see Wittchen, Zaudig & Fydrich, 1997) is a widely used and researched instrument to assess DSM-IV-TR personality disorders.The interview covers all ten DSM-IV personality disorders (antisocial, avoidant, borderline, dependent, histrionic, narcissistic, obsessive-compulsive, paranoid, schizoid and schizotypal), PD not otherwise specified, and appendix categories (depressive PD and passive-aggressive PD) and is used to make personality disorder diagnoses either dimensionally or categorically (present-absent). Furthermore, it allows the investigation of patterns of PD that co-occur with other mental disorders as well as the analysis of the underlying structure of personality pathology.
45698858|NCT02980120|Other|LoPF|In order to specifically focus on certain personality traits, we use the LoPF as an additional measure. It is a well-validated and reliable self-report questionnaire to measure healthy and pathological personality functioning in adolescents. It is based on the DSM-5 Section III Alternative Model for Personality disorders and covers core impairments in adolescents' personality functioning: identity, self-direction (self-related personality functioning), intimacy/ attachment and empathy/ social-related personality functioning (Sevecke & Krischer, 2011).
45698859|NCT02980120|Other|HAWIK-IV|The Wechsler Intelligence Scale for Children (HAWIK-IV, Petermann & Petermann, 2008) will be used assess intelligence. For adolescents older than 16.11 years, we will use the German version of the Wechsler Adult Intelligence Scale (HAWIE-IV).Results from test-retest reliability demonstrate that the mean retest scores for all subtests are higher than the mean test scores from first administration, with effect sizes ranging from .08 (comprehension) to .60 (picture completion). The test has demonstrated an acceptable relationship to other measures of achievement, memory, adaptive behavior, emotional intelligence and giftedness in children and adolescents (Canivez, 2014). For the non-clinical adolescent sample, we will use two subtests of the HAWIK.
45511674|NCT04553133|Drug|PF-07104091 + Fulvestrant (post CDK4/6)|PF-07104091 will be administered orally in combination with fulvestrant
45511675|NCT04553133|Drug|PF-0704091 + Fulvestrant (post CDK4/6)|PF-07104091 + fulvestrant (post 4/6) dose expansion
45511676|NCT03703245|Other|Sodium bicarbonate|Experimental dentifrice containing 67% w/w sodium bicarbonate in 3 studies and additionally 62% w/w sodium bicarbonate in 3 studies.
45511677|NCT03703245|Other|Control Dentifrice|Negative control dentifrice containing 0% w/w sodium bicarbonate
45511678|NCT03701451|Drug|Demethylated drug decitabine|Induced treatment by demethylating drug decitabine 7mg/m2 d1-5 and cisplatin 80mg/m2 d1 for 3 cycles to regionally advanced nasopharyngeal carcinoma followed by concurrent chemoradiotherapy with cisplatin 80mg/m2 d1 for 3 cycles.
45511679|NCT04505397|Drug|SKL24741|An inhibitor of voltage-gated sodium channels and a possible activator of Big Potassium channels. Administered as an oral dose in the form of a capsule or tablet.
45511680|NCT04505397|Drug|Placebo|Sugar pill manufactured to mimic SKL24741
45511681|NCT04703985|Dietary Supplement|Enteral Nutrition|Protocol of Enteral Nutrition adapted to the conditioning autograft (BEAM or Melphalan 200)
45403645|NCT05694208|Behavioral|Education Group|In the first pre-operative interview at the gynecological oncology outpatient clinic of the relevant hospital, the purpose of the research will be explained to the patients and an informed consent form will be filled. The patients in the experimental group will use the mobile-based care support application developed within the scope of the research.
45403646|NCT01308268|Drug|Ivermectin + Albendazole|Ivermectin: 200µg/kg, single dose, PO + Albendazole 200 (children between 12 and 23 months) or 400 mg (>= 2 years old) single dose, PO
45403647|NCT03785938|Dietary Supplement|Probiotic|Liquid probiotic supplied by the company Symprove
45403648|NCT03785938|Other|Placebo|Placebo made of maltdextrin. Will be similar in taste and consistency
45403649|NCT01305304|Other|repeated long term endurance exercise|competitive running at a national level during a period of at least 5 years (i.e. approximately 50km per week over more than 10 years)
45403650|NCT01305304|Other|Other|No history of endurance sports activity
45511682|NCT03703089|Drug|Gemcitabine|Administered by intravenous infusion over 30 minutes.
45511683|NCT03703089|Drug|nab-paclitaxel|Administered by intravenous infusion over 30-40 minutes.
45511684|NCT03703011|Device|Accelerometers positioned at the wrinkle, the hip, and the ankle|Accelerometers are positioned at the wrinkle, the hip, and the ankle. The subject stands and walks 10 meters, followed up by a physiotherapist in the physiotherapy area. The accelerometers are triggered by a smartphone. The protocol is filmed (without the face), and 2 physicians will watch the film and count the steps blind to the results of the accelerometers (and blind to each-other steps counts)
45511685|NCT03701373|Drug|S-1 maintenance|S-1 maintenance till disease progression or untolerable toxicities, in oral doses of 40 mg (BSA<1.25 m2), 50 mg (1.25≤BSA<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-14 for each 21-day cycle.
45511686|NCT03701373|Other|Observation|Observation without anti-tumor treatment
45511687|NCT03702933|Dietary Supplement|D-serine|dosage
45851227|NCT00423228|Drug|ZT-1|Patients in the ZT-1 treatment group will receive ZT 1-1 mg capsules administered p.o. daily during the first month of treatment, followed by ZT-1 implants (9 mg) administered s.c. during the second month of treatment, followed by ZT-1 implants (12 mg) administered s.c. every 4 weeks during months 3 to 6 of treatment. Patients in the ZT-1 treatment group will receive dummy donepezil capsules during months 2 to 6 of the treatment period.
45851228|NCT00423228|Drug|Donepezil|Patients in the donepezil treatment group will receive donepezil 5 mg capsules administered p.o. during the first month of treatment, followed by donepezil 10 mg/day during months 2 to 6 of the treatment period. Patients in the donepezil treatment group will also receive s.c. injections of dummy ZT 1 implants every 4 weeks during months 2 to 6 of the treatment period.
45403651|NCT05693818|Other|Clinical Limping Evalution|"Patients will be asked to perform a Clinical Limping Evaluation in the clinic during their post-operative follow-up visit. This will be performed in a controlled environment within the physician's clinic. Each patient will be asked to walk at their normal walking speed down a hallway for at least 7 consecutive steps and back toward the physician. Walking down the hallway and back is one walking trial. Each patient will be asked to perform 2 walking trials. The health care provider will assess the patient's limp using a 3-point Likert scale (0=No limp, 1=mild/moderate limp, 2=severe limp).~If required, patients may use an assistive device and the type of device should be documented. If a patient requires assistance, only the minimum amount of assistance required for a patient to complete the task should be provided."
45403652|NCT01308346|Device|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)|Bioabsorbable Everolimus Eluting Coronary Stent
45403653|NCT01308346|Device|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
45403654|NCT03785704|Drug|Xinmailong Injection|Xinmailong injection is extracted, separated, purified and refined from Periplaneta americana. It is the second class of new drugs and the only small molecular bioactive peptide preparation approved by the State Pharmaceutical Administration (P.R.China) for the prevention and treatment of heart failure. Its main constituents include complex nucleoside bases and binding amino acids.
45403655|NCT05694130|Drug|Prednisolone|Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks.
45403656|NCT05694130|Drug|Tacrolimus|Oral Tacrolimus 1-2mg twice daily for 12 weeks.
45403657|NCT01308112|Dietary Supplement|iron|Daily supplementation with iron (60 mg) as ferrous sulphate
45403658|NCT03786172|Behavioral|Smoking cessation Intervention|"A 10 to 15 minute standardised counseling session performed peri-operatively by an ENT resident, and based on the 5 As motivational interviewing model (Ask, Advise, Assess, Assist, Arrange)~A motivational gadget distributed to the patients~Nicotine replacement therapy (NRT), consisting of nicotine transdermal patches for 8 weeks, offered to the patients"
45403659|NCT03786172|Behavioral|Usual care|A 10-second brief advice to quit smoking, performed peri-operatively by an ENT resident
45511688|NCT02807844|Drug|MCS110|MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
45511689|NCT02807844|Drug|PDR001|MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
45511690|NCT02763566|Drug|Abemaciclib|Administered orally
45851229|NCT00423306|Drug|Darinaparsin|420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest, for up to 6 months
45511691|NCT02763566|Drug|Anastrozole|Administered orally
45511692|NCT02763566|Drug|Letrozole|Administered orally
45511693|NCT02763566|Drug|Placebo|Administered orally
45511694|NCT02763566|Drug|Fulvestrant|Administered intramuscularly
45511695|NCT03702855|Drug|Tetrabenazine Tablets 25 mg|
45511696|NCT04542681|Drug|Placebo - 1st Cycle|Subjects will receive a single SQ injection of placebo/normal saline
45511697|NCT04542681|Drug|MANP - 1st Cycle|Subjects will receive a single SQ injection of MANP at a concentration of 2.5 μg/kg
45511698|NCT04542681|Drug|MANP - 2nd Cycle|Subjects will receive a single SQ injection of MANP 5 μg/kg concentration.
45511699|NCT02052180|Drug|Exparel|EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
45511700|NCT02052180|Drug|Marcaine (Control)|15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
45511701|NCT03561402|Drug|Teriflunomide|Each patient will receive 1 tablet (14 mg) on a daily basis.
45511702|NCT04542135|Drug|Sulindac Pill|Randomized participants will receive either 150 mg oral sulindac twice daily.
45511703|NCT04542135|Drug|Placebo|placebo pills twice daily
45511704|NCT02053428|Procedure|percutaneous image-guided gastrostomy|
45511705|NCT02166710|Device|Adductor canal femoral nerve block|A 18 Gauge Tuohy needle will be inserted and its position will be confirmed using ultrasound guidance. Once the adequacy of the position is confirmed, the anesthesiologist will administer 15 mL of bupivacaine 0.25% with epinephrine in divided doses and examine the quality of its spread. A 20 Gauge polyamide catheter will be inserted at 2 cm in the space. The needle will then be withdrawn and the catheter will be fixed in place. Three mL of the same mixture of local anesthetics will be administered through the catheter and the anesthesiologist will observe the quality of its distribution. Bupivacaine 0.125% will be administered through the catheter using an infusion pump for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
45511706|NCT02166710|Device|Simulated nerve blockade|The insertion of the Tuohy needle and the injection of 15 mL of bupivacaine 0.25% with epinephrine will be simulated. The insertion of the polyamide catheter, the withdrawal of the needle and the injection of local anesthetics through the catheter will also be simulated. The infusion of bupivacaine 0.125% will also be simulated for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
45511707|NCT02053506|Dietary Supplement|Immune-enhancing nutritional beverage|Combination of arginine, glutamine, omega-3 fatty acids, vitamin C and zinc.
45511708|NCT02053506|Dietary Supplement|Probiotics (BB-12)|Probiotics (Bifidobacterium Animalis Lactis, BB-12®, Chr Hansen A/S, Hoersholm, Denmark) will be administered as a strawberry-flavored, powdered candy (1 g). The candy will be packaged in a small foil pouch, and each pouch will contain approximately 1 billion colony forming units (CFU) of BB-12® in powder form.
45511709|NCT02053506|Dietary Supplement|Placebo (for nutritional beverage and probiotic)|Dietary protein at RDA of 0.8 grams•kg-1 body weight•day-1 and a placebo beverage during and after the period of sleep restriction.
45511710|NCT02763254|Biological|baltaleucel-T|Autologous EBV-specific T cells
45511711|NCT02053662|Procedure|Sample Collection|A collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
45511712|NCT04694781|Drug|LVGN6051|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
45511713|NCT04694781|Drug|Pembrolizumab|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
45403660|NCT03793816|Device|BiZactTM Open Sealer/Divider|The BiZactTM Open Sealer/Divider creates a seal by application of radiofrequency (RF) electrosurgical energy to blood and lymphatic vessels or tissue bundles interposed between the jaws of the instrument. A cutting blade within the instrument is surgeon-activated to divide tissue. It is a single-use device and will not be reused in other patients.
45403661|NCT03793582|Diagnostic Test|ApneaLink Type III portable sleep study|Type III portable sleep study
45511714|NCT02166866|Other|Quality of Life Questionairre and Education|
45511715|NCT03624855|Other|Bone or joint infection due to Pseudomonas aeruginosa|Description of bone or joint infection on implant due to Pseudomonas aeruginosa
45511716|NCT02805972|Drug|Naloxone|4 mg / 0.1 ml
45403662|NCT05567302|Other|Manual therapy|"In lower cervical lateral flexion problems, manipulative correction technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.~In lower cervical lateral flexion problems, manipulative correction technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.~A rotational maneuver will be performed from the posterior side of the articular pillar part of the superior vertebra, on the opposite side of the side where the movement restriction is present."
45403663|NCT05567302|Other|myofascial release|The soft tissue is palpated by the physiotherapist and pressure is applied directly to the skin until the tissue barrier is felt in the direction of restriction. Once the tissue barrier is present, it is applied for 90-120 seconds, without slipping on the skin or forcing the tissue, until the fascia complex begins to loosen and a softening sensation is achieved.
45403664|NCT03786094|Drug|Eribulin|Eribulin alone
45403665|NCT03786094|Drug|Balixafortide|balixafortide + eribulin
45403666|NCT00419159|Drug|Everolimus (RAD001)|Everolimus was supplied in 5 mg tablets in blister packs.
45403667|NCT05693896|Behavioral|Centering Appetite|A digital treatment of Appetite Awareness Treatment (AAT) and behavioral weight loss treatment (BWL) over 6 months, delivered remotely using Zoom. The goal of AAT is to enable participants to be able to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. AAT has been successful in helping participants diagnosed with Binge Eating Disorder (BED) and bulimia nervosa reduce binge eating, overeating, urges to eat in response to non-appetite stimuli, and prevent weight gain.
45851230|NCT01799382|Other|Rapid on-site evaluation|Rapid on-site evaluation consists on the cytological evaluation of samples obtained during a diagnostic procedure by a pathologist present in the diagnostic suite. In the present study, cytological samples obtained with EBUS-TBNA during bronchoscopy will be evaluated.
45511717|NCT02805972|Drug|Placebo|0.1 ml
45511718|NCT03702699|Device|Auricular point detector|This device is only for auricular detection. No additional intervention will be delivered.
45511719|NCT03032523|Diagnostic Test|Standard of care glucose test|If the CGM in the remote monitoring group detects a blood sugar less than 46mg/dl, a confirmatory standard of care glucose test will be performed to confirm the low blood sugar.
45851231|NCT01799382|Device|EBUS-TBNA|EBUS-TBNA is a needle aspiration procedure guided by endobronchial ultrasounds performed during bronchoscopy
45851232|NCT01799616|Drug|Pamidronate|
45851233|NCT01799616|Other|Placebo|
46057254|NCT02711787|Device|traditional rehabilitation|Assisted stretching, shoulder and arm exercises, and functional reaching tasks
46057255|NCT02776761|Biological|Hantaan Vaccine:|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
46057256|NCT02776761|Biological|Puumala Vaccine|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
46057257|NCT02776761|Biological|Hantaan/Puumala Vaccine|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
45403668|NCT03785782|Device|Ultrasound|Breast ultrasound
45403669|NCT05693662|Behavioral|Mindfulness-Based Self-Compassion Education|An education booklet created within the scope of ASD diagnosis will be presented to the parents of children with ASD. The booklet will be prepared in line with the relevant literature, including the development of the child with ASD, activities of daily living, social communication skills, and the processes of awareness-based self-compassion education in an 8-session interview with parents. The booklet will be presented to the parents participating in the research at the first session of the Mindfulness-Based Self-Compassion Training. During the creation of the training booklet, the final form of the booklet will be given by taking the opinions of the experts and in line with the relevant suggestions.
45403670|NCT03717064|Drug|RO7049389|RO7049389 will be taken orally, in tablet form, BID on Days 1-6 of Period 2.
45851234|NCT01799772|Behavioral|Comprehensive Behavioral Intervention|"Evidence-based exercise program - Combination of high intensity lower extremity strengthening, endurance on the treadmill, functional task-oriented exercises, and balance techniques. During 12 sessions, subjects will be instructed to become independent in performing the exercises at home.~Physical activity promotion - Instructions to engage in moderate intensity exercise 5 days/week will be delivered along with the exercise program.~Healthy nutrition guidance - Instructions on healthy nutrition delivered by a dietitian.~Self-management - Basic self-management skills advocated by the Arthritis Foundation Self-Help Program and behavioral strategies (self-monitoring, problem solving, relapse prevention, and goal-setting) and feedback into approaches a, b and c."
45851235|NCT01799772|Other|Standard of Care Exercise Program|Typical rehabilitation after TKA surgery
45851236|NCT01799850|Drug|Pioglitazone|pioglitazone 30 mg daily, pill, eight weeks, placebo randomly assigned
45403671|NCT03717064|Drug|Pitavastatin|Pitavastatin will be taken orally, in tablet form, once on Day 1 of Period 1, and once on Day 4 of Period 2.
45403672|NCT03716050|Drug|Nitroglycerin|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 2,4,6, and 8 will include Nitroglycerin cream.
45403673|NCT03716050|Device|Negative Pressure Wound Therapy/ Wound VAC|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 3,4,7,and 8 will receive iVAC therapy.
45403674|NCT03716050|Other|Fluorescent Angiography with indocyanine-green (not to exceed 5mg/kg)|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 5,6,7,and 8 will receive angiography.
45403675|NCT03716050|Other|No treatment|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 1 will include no treatment.
45403676|NCT05693584|Other|distraction|diverting the patient's attention with virtual reality glasses
45403677|NCT03782038|Device|MCD|Micro coring skin removal with automated coring device
45403678|NCT02069860|Device|Bone Anchored Port System (BAP)|The port body will be implanted onto the petrous bone and a sealing cap, a twofold valve system and a catheter are connected to the port body. The catheter is tunneled under the skin, enters the internal jugular vein and ends in the right atrium of the heart. The novelty of the access lies in its location (retro auricular on petrous bone) and its bone fixation.
45403679|NCT01310920|Other|observation|genotyping
45403680|NCT03785860|Other|Dietary Fiber|Dietary fiber will be given in a powder form to mix with a beverage of one's choice.
45403681|NCT03785860|Other|Placebo|Placebo will be given in a powder form to mix with a beverage of one's choice.
45403682|NCT00413231|Device|Valiant Thoracic Stent Graft System|Surgical procedure in which a device is implanted inside the aorta, isolating the diseased area (aneurysm).
45403683|NCT01988584|Biological|umbilical cord blood (hUCB) cells|Autologous umbilical cord blood banked with the Cord Blood Registry.
45851237|NCT01799850|Drug|placebo|placebo assigned randomly, double blind
45403684|NCT01988584|Drug|Saline Infusion (Placebo)|A total of 10 children (5 from each cohort) will be randomized to a placebo infusion at the baseline visit and then have the opportunity to cross-over to stem cell treatment at the 1yr. visit.
45403685|NCT01988584|Biological|bone marrow derived mononuclear cells (BMMNCs)|Autologous stem cells from bone marrow harvest.
45403686|NCT02113163|Drug|Metformin Eicosapentaenoate|
45403687|NCT02113163|Drug|Metformin HCl and Vascepa|
45403688|NCT00413153|Drug|atazanavir/ritonavir|atazanavir 300mg + ritonavir 100mg once daily
45403689|NCT00413153|Drug|lopinavir/ritonavir|patient remains on their pre-study dose of lopinavir/ritonavir
45403690|NCT01308502|Device|Dx-pH probe|Dx-pH probe with 24 hour recording
45403691|NCT01310998|Behavioral|High intensity exercise|4x4 intervals
45403692|NCT02107937|Biological|DCVAC/OvCa with Standard of Care|DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel
45403693|NCT02107937|Biological|DCVAC/OvCa sequentially chemotherapy|DCVAC/OvCa added sequentially after Carboplatin and Paclitaxel
45403694|NCT02107937|Drug|Standard of Care|Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
45403695|NCT03781882|Procedure|Platelet rich plasma infiltration in the wound edges|platelet rich plasma will be injected in the wound edges
45403696|NCT03781882|Procedure|Closure of wound without platelet rich plasma infiltration|No infiltration of platelet rich plasma is done
45403697|NCT01038479|Dietary Supplement|Xylitol consumption|Mothers will eat 6 grams of xylitol per day
45511720|NCT05661084|Device|Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex.
45511721|NCT05661084|Device|Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham)|A sham transcranial electrical stimulation (tES) will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex. It will physically mimic active stimulation.
45511722|NCT05661084|Device|Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Active tACS to the left angular gyrus and sham tDCS to the prefrontal cortex.
45511723|NCT05661084|Device|Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Sham tACS to the left angular gyrus and active tDCS to the prefrontal cortex.
45511724|NCT03701217|Drug|Eltrombopag|Eltrombopag 25mg bid, starts from the day when platelet count decreases lower than 30×10'9/L, and the treatment lasts for at least 5 days, and stops until platelet count goes up to more than 30×10'9/L, after consolidation therapy in AML patents.
45511725|NCT02052258|Drug|Oxytocin|
45511726|NCT02051088|Procedure|Revascularization with drug-eluting technology|Endovascular intervention with the use of drug-eluting devices (drug-coated balloons and/or drug-eluting stents).
45511727|NCT02051088|Procedure|Revascularization without drug-eluting technology|Endovascular intervention without using drug-eluting balloons or stents
45511728|NCT02051088|Device|drug-coated balloons and/or drug-eluting stents|
45511729|NCT03701139|Procedure|posterior capsulotomy|After phacoemulsification with intraocular lens implantation, primary posterior capsulotomy will be performed to remove the primary posterior capsule opacification after posterior capsule polishing. A limited anterior vitrectomy will be performed if the anterior hyaloid surface is broken.
45511730|NCT03701139|Procedure|laser capsulotomy|A routine phacoemulsification with intraocular lens implantation is performed. Then the Nd:YAG laser capsulotomy will be performed 1 month postoperative to remove the primary posterior capsule opacification.
45511731|NCT04002063|Behavioral|CBT MobileWork-V plus CBT|a smartphone app to assist with CBT homework skills practice plus CBT
45511732|NCT04002063|Behavioral|CBT alone|CBT therapy individual
45511733|NCT02053740|Drug|Add R-S-Y-R-T (500 mg 3 times per day) for 6 months|
45511734|NCT02053740|Drug|Routine western medicine|
45511735|NCT03702543|Behavioral|SymTrend, Inc.|Use of SymTrend and Apple Health apps with feedback and strategies provided.
45511736|NCT02053818|Drug|Remifentanil|Randomization to receive Remifentanil (ultrashort acting opioid) as basic opioid in anaesthesia
45511737|NCT02053818|Drug|Sufentanil|Randomization to receive Sufentanil (medium/long acting opioid) as basic opioid in anaesthesia
45511738|NCT03702387|Procedure|standard intravenous regional anesthesia (IVRA) with reapplication of esmach|his intervention simply adds one additional step to the standard IVRA procedure: reapplication of the Esmarch bandage after lidocaine has been injected intravenously. Everything else about this experimental procedure is standard of care.
45511739|NCT03031899|Procedure|Biopsy|rose bengal stain and toluidine is applied over a premalignant lesion and positively stained lesions are subjected to biopsy.
45511740|NCT03031899|Diagnostic Test|Rose Bengal|the lesions stained positive were subjected to biopsy
45511741|NCT03031899|Diagnostic Test|toluidine blue|the lesions stained positive were subjected to biopsy
45511742|NCT03700983|Dietary Supplement|Nutri-PEITC jelly|an edible, easily to swallow nutritious gel containing a bioactive compound PEITC
45511743|NCT03700905|Procedure|Surgical resection of primary tumor|Surgical resection of primary tumor including neck dissection according to standard of care
45511744|NCT03700905|Radiation|Adjuvant radio(-chemo)therapy|Risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43, or Cisplatin once weekly (40mg/m2) for high risk patients only)
45511745|NCT03700905|Drug|Neoadjuvant Nivolumab|Neoadjuvant dose with Nivolumab 3mg/kg after randomization within 2 weeks before surgery
45511746|NCT03700905|Drug|Adjuvant Nivolumab|Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
45511747|NCT03700905|Drug|Adjuvant Nivolumab and Ipilimumab|Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks and Ipilimumab 1mg/kg i.v. d1 every 6 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
45511748|NCT03702153|Procedure|Abdominal wall reconstruction|The repair of abdominal wall defects with polypropylene mesh
45511749|NCT03700827|Other|Resistance Training|High-intensity Resistance Training Group
45511750|NCT03700827|Other|Aerobic Training|Aerobic Interval Training Group
45511751|NCT03700749|Drug|2% chlorhexidine + non-coated suture|"Interventions:~2% alcoholic chlorhexidine non-coated suture"
45511752|NCT03700749|Drug|2% chlorhexidine + coated suture|"Interventions:~2% alcoholic chlorhexidine triclosan coated suture"
45851238|NCT01792050|Drug|Docetaxel|Docetaxel chemotherapy regimen given by vein over 1 hour on day 8 of each cycle.
45851239|NCT01792050|Other|Placebo|Placebo taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six pills to be taken each time for a total of 12 pills per day.
46057258|NCT04848753|Combination Product|Toripalimab combined with cisplatin and paclitaxel|Specified doses on specified days.
45511753|NCT03700749|Drug|10%povidone-iodine + non-coated suture|"Interventions:~10% povidone-iodine non-coated suture non-coated suture"
45511754|NCT03700749|Drug|10%povidone-iodine + coated suture|"Interventions:~10% povidone-iodine triclosan coated suture"
45511755|NCT03086369|Drug|Olaratumab|Administered IV
45511756|NCT03086369|Drug|Nab-paclitaxel|Administered IV
45511757|NCT03086369|Drug|Gemcitabine|Administered IV
45511758|NCT03086369|Drug|Placebo|Administered IV
45511759|NCT03700593|Device|Single Port Robotic Colorectal Surgery|Single Port Robotic Colorectal Surgery
45511760|NCT03574545|Biological|ianalumab|Human monoclonal antibody (mAb) of type IgG1/κ binding to B-cell activating-receptor (BAFF-R)
45511761|NCT00101582|Drug|Placebo|
45511762|NCT00101582|Drug|palifermin|
45511763|NCT00101582|Drug|cisplatin chemotherapy|Commercially available cisplatin was administered as an intravenous infusion at a dose of 100 mg/m^2 on Days 1, 22, and 43.
45511764|NCT00101582|Radiation|Radiotherapy|Radiotherapy was delivered in 200 cGy daily fractions, 5 days a week.
45511765|NCT05326373|Drug|Stannous fluoride|brush twice daily with stannous fluoride toothpaste for 8 weeks
45511766|NCT03370107|Device|rTMS|Conventional magnetic stimulations will be applied with a MacPROX100 machine using neuronavigation system. H-coil rTMS will be delivered with the Brainsway H-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head corresponding to the primary motor cortex (H10 coil) and connected to a Masgtim Rapid2 stimulatior (Mastim, Whitland, UK), while sham stimulation will be delivered with a sham coil placed in the helmet encasing the active rTMS coil. Active rTMS sessions with H-coil will use exactly the same parameters of stimulation as conventional rTMS.
45511767|NCT01379105|Other|neural mobilization|In the neural mobilization group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and performed 30 oscillations of plantar-to-dorsal flexion for one minute
45511768|NCT01379105|Other|Static Stretching|In the static stretching group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and held for 30 seconds; this type of stretching corresponds to the maintenance of increased amplitude posture, without surpassing the maximum movement limit, three times with an interval of 10 seconds between the repetitions.
45851240|NCT01792050|Drug|Indoximod|Indoximod (1200 mg) taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six 200 mg pills to be taken twice a day for a total of 12 pills per day.
45403698|NCT01038479|Behavioral|Childsmile preventative programme|Mothers will receive the childsmile preventative programme
45403699|NCT03793192|Other|PACE2 Intervention|Written educational materials regarding physical activity, telephone-based coaching to integrate physical activity in daily life activities and address barriers to attending pulmonary rehabilitation.
45403700|NCT01035125|Behavioral|Self-management program|Participants will receive a one week inpatient self-management program
45511769|NCT02166944|Drug|tamoxifen 40 mg daily for one year|both arms with riluzole daily
45511770|NCT03238677|Behavioral|Speech Motor Chaining without Biofeedback|These procedures target sound sequences (consonant-vowel, consonant-consonant, or vowel-consonant). Sessions begin with Pre-practice to elicit the target sounds, with verbal cueing and shaping strategies. The Practice component then includes chaining that is response-contingent. Participants practice in blocks of 6 consecutive trials beginning at the syllable level. If 5/6 are correct, the participant advances to monosyllabic word practice, then multisyllabic word practice, phrase practice, and sentence practice (with the target syllable embedded within each level of complexity). If fewer than 5/6 trials are correct, a different syllable with the target sound pattern is practiced next. Verbal feedback is faded from 5 of 6 trials at the syllable level to only 3 of 6 trials at the sentence level. For more description, see http://speechproductionlab.syr.edu/Resources%20for%20Researchers.html
45698860|NCT02980120|Device|fMRI|To measure food-related brain activation, event-related fMRI will be used, with phases of high-caloric images alternating with phases of low-caloric images and images of fixation cross (not related to food images). A total of 18 blocks will be performed - see figure below. The duration of each phase will be 30 seconds. In a second run, the patients and control subjects will drink chocolate milk and water, alternating every 30 seconds, through a long silicon tube. This procedure was successfully tested in a previous fMRI study with adult AN patients (Gizewski et al. 2010, Vocks et al. 2011) and has now been adopted in preliminary measurements for young AN patients.
45851241|NCT01792050|Drug|Paclitaxel|Paclitaxel chemotherapy regimen given by vein over 1 hour weekly x 3 followed by a week of rest each cycle.
45403701|NCT03793270|Diagnostic Test|for patients and healthy donors|"Detection of (CD19, CD24, CD38 & CD27) markers in peripheral blood samples by Flow Cytometry~Determine the serum level of IL 10 using ELISA plate"
45403702|NCT03781648|Diagnostic Test|NBI withdrawal method|The newly available second generation of NBI using the 290 system (290-NBI) provides an at least twofold brighter image compared with the previous version
45698861|NCT03466008|Behavioral|Whole-Body Cryotherapy|10 sessions of WBC were performed (in addition to usual care) in a standard cryotherapy room over a duration of 8 days.
45698862|NCT05324280|Procedure|Acupuncture|Acupuncture treatment will be performed according to a defined protocol, and includes body and ear acupuncture.
45698863|NCT02522052|Other|Blue mussel diet|5 meals a week containing blue mussels
45698864|NCT02522052|Other|Meat/Control diet|5 meals a week containing meat
45698865|NCT01190878|Drug|ISV-303|0.075% of bromfenac in DuraSite dosed QD
45698866|NCT01190878|Drug|ISV-303|0.075% of bromfenac in DuraSite dosed BID
45698867|NCT01190878|Drug|DuraSite Vehicle|Vehicle dosed BID
45403703|NCT01312090|Biological|Whole body cryotherapy|Cryotherapy: The whole-cody cryotherapy device (Univers Cryo-Combi;Oy MJG Univers Ab, Helsinki, Finland) consists of 3 chambers set at different temperatures. The first 2 chambers are meant for precooling (-30°Cand-60°C), and the patient remains in these for a very short time. The third chamber temperature reaches -110°C, and the patient remains inside for 3-4 minutes wearing a bathing suit or trunks, acral parts covered.
45403704|NCT01312090|Behavioral|counseling and behavioral therapy for weight loss|Weight loss intervention with Very Low Calory Diet (VLCD, 500-1000 kcal / d + dietary supplements) and group and individual treatment (eating, physical activity counseling and behavioural therapy).
45403705|NCT01312402|Drug|topical brinzolamide 1% in 5mL ophthalmic medication|1 drop three times a day in both eyes on days 2,3 and 4
45403706|NCT01312402|Drug|Placebo in 5 mL dispenser|Placebo ophthalmic solution in 5 mL dispenser; 1 drop three times a day on days 2,3 and 4
45403707|NCT01312480|Other|5A's Model|"The smoking cessation intervention is based on the 5A's model, which includes the following elements:~Ask if the patient smokes.~Advise every patient to quit.~Assess readiness to quit.~Assist in quitting and finding services.~Arrange for cessation services and follow-up."
45851242|NCT01790256|Device|Cereve Sleep System at 30 degrees C|
45403708|NCT01312480|Other|Media Use Assessment|The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
45403709|NCT00412607|Device|NAVISTAR® THERMOCOOL® Catheter|The primary objective is to provide additional, corroborative safety data for the NAVISTAR THERMOCOOL catheter for the treatment of subjects with sustained, monomorphic VT or incessant VT associated with coronary artery disease
45403710|NCT03785392|Procedure|Group 1 In-plane|"Group 1: Study will involve total of 15 patients with the procedure done in-plane. Before the block placement and after the block placement lung function will be measured.~FEV1 (forced expiratory volume in 1 second ) and FVC ( forced vital Capacity ) values will be recorded. Block will be performed in plane and postprocedure lung function test will be repeated. New values of FEV1 and FVC will be obtained after the placement of the nerve block."
45403711|NCT03785392|Procedure|Group 2 out of plane|Group 2 study will adopt the out of plane technique and will involve a total of 15 patients in this group. We will do the procedure out of plane and will have lung function FEV1 and FVC measured bedside.FEV1 and FVC values will be recorded. Block will be performed out of plane and postprocedure lung function test will be measured. New values of FEV1 and FVC will be obtained
45403712|NCT01035203|Behavioral|Exercise|Endurance exercise 3 times weekly for 45 minutes, 4 weeks long
45403713|NCT01035203|Behavioral|Cognitive behavioural therapy|Teaching of techniques to reduce fatigue and to improve stamina
45403714|NCT05693428|Drug|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 5-6 mg/kg/h intravenously on a perfusor.
45403715|NCT05693428|Drug|Isoflurane|isoflurane was used as anaesthetice of - 1.1-1.2 MAC.
45403716|NCT05693428|Drug|Sevoflurane|sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC
45851243|NCT01790256|Device|Cereve Sleep System at 14-16 degrees C|
45403717|NCT01035281|Drug|Nabilone, flexible dosing|nabilone at 0.5 - 4 mg/day
45403718|NCT05693350|Diagnostic Test|DUS|Duplex ultrasound
45403719|NCT01035359|Procedure|External fixation|Bridging external fixation of a distal radius fracture with an optional addition of k-wire(s)
45403720|NCT01035359|Procedure|Volar plate|Operation of distal radius fracture with open reduction and fixation with a plate from the volar side of the wrist.
45511771|NCT03238677|Behavioral|Biofeedback|Real-time images of the tongue are made available using ultrasound placed beneath the chin. Participants practice speech movements and can be cued to modify their tongue shape or position to achieve clearer speech. Practice structure is similar to the Speech Motor Chaining procedures, but with the addition of a visual reference.
45511772|NCT03238677|Behavioral|Distributed Practice|2 sessions per week for 10 weeks
45851244|NCT01790100|Drug|VX-135|12 weeks of VX-135
45851245|NCT01790100|Drug|Ribavirin|12 weeks of ribavirin
45851246|NCT01791660|Device|Zeltiq Coolsculpting System|Non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
45851247|NCT01793220|Other|SMS reminder|A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
45851248|NCT01797588|Procedure|Adductor-canal block|The adductor-canal will be located via ultra sound and a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve.
45851249|NCT01797588|Procedure|Periarticular infiltration|Periarticular infiltration will be performed intra-operatively and involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. In each Knee: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (~60mL) is used to infiltrate the muscle, subcutaneous tissues.
45403721|NCT01561066|Procedure|Autologous platelet-rich fibrin glue (PRFG)|"Preparation of autologous platelet-rich fibrin glues (PRFG) The platelet-rich plasma (PRP) was separated by centrifugation from 300-400 ml whole blood for 6 min at 1000g, 22°C twice, keeping most of the platelets (50%-60%) in the plasma fraction. For 50g PRP from each patient, with citric acid (2.84mM) lowering and NaHCO3 (75mM) adjusting the PH value, thrombin solution was produced. On the other hand, cryoprecipitate was produced from the rest of the plasma. Frozen at -80°C for at least 6h and then thawed at 4°C, PRP went through centrifugation at 4000rpm/min for 5min.~PRFG application The application of the glues through the external opening of the fistula was controlled by the drainage tube through a double-syringe system with distal mixing device. The distance was based on fistulography to assure total occlusion of the internal hole. After the FG was instilled, any redundant glue was removed from the external openings."
45403722|NCT01561066|Drug|Octreotide|subcutaneous injection, 0.3mg/8h until enteral nutrition resolution
45403723|NCT03793036|Dietary Supplement|preoperative nutrition|The participants of experimental group received 400 mil of a clear carbohydrate drink (12,5 gr/100 mil carbohydrate, 50 kcal/100ml, pH 5.0) at 10:00 pm the evening before surgery and another 200 mil of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
45403724|NCT00419003|Drug|Lamotrigine|anticonvulsant medication
45511773|NCT03238677|Behavioral|Massed --> Distributed Practice|Week 1: 10 hours of treatment Week 2: 3 hours of treatment Week 3: 3 hours of treatment Week 4: 2 hours of treatment Week 5: 2 hours of treatment
45511774|NCT05292599|Other|Experimental|CCFE will be performed with the patient in a supine position with both knees flexed at 45°. This exercise involves a craniocervical movement. The IFE will be performed with the patient in a supine position while the IEE will be performed in a prone position. Both exercises will activate cervical muscles. RFE and RRE will be performed with the patient in a sitting or standing position at the same time he resists with his hands on his head. ME the function of these exercises is to depress and stabilize the scapula.
45511775|NCT05292599|Other|Control|CCFE will be performed with the patient in a supine position with both knees flexed at 45°. This exercise involves a craniocervical movement. The IFE will be performed with the patient in a supine position while the IEE will be performed in a prone position. Both exercises will activate cervical muscles. RFE and RRE will be performed with the patient in a sitting or standing position at the same time he resists with his hands on his head. ME the function of these exercises is to depress and stabilize the scapula.
45403725|NCT00419003|Drug|Ketamine|subanesthetic dose of NMDAR antagonist
45403726|NCT00419003|Drug|Riluzole|glutamate release inhibitor
45403727|NCT03793348|Device|MCD|Micro coring skin removal with automated coring device
45403728|NCT01035437|Drug|HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)|HPPH in D5W, 4.0 mg/m2 infused over 1 hour
45403729|NCT00418691|Drug|IR Methylphenidate|10 mg by mouth (PO) twice daily x 4 Weeks
45403730|NCT00418691|Drug|Modafinil|200 mg PO Once Daily x 4 Weeks
45403731|NCT00418691|Drug|SR Methylphenidate|18 mg PO Once Daily x 4 Weeks
45511776|NCT03540836|Drug|Relacorilant (3x100 mg softgel capsules)|A single relacorilant 300mg dose (3x100 mg softgel capsules) will be given once on Day 1 of one of three treatment periods.
45511777|NCT03540836|Drug|Relacorilant (3x100 mg hard-shell capsules)|A single relacorilant 300mg dose (3x100 mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
45511778|NCT03540836|Drug|Relacorilant (6x50mg hard-shell capsules)|A single relacorilant 300mg dose (6x50mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
45698868|NCT01190878|Drug|Xibrom™|0.09% bromfenac dosed BID
46057259|NCT04848753|Combination Product|Placebo combined with cisplatin and paclitaxel|Specified doses on specified days.
45511779|NCT05274737|Device|Novel sling|The novel sling was designed and created by the principal investigator to address these concerns of the traditional slings that are currently available for postsurgical protection and immobilization after shoulder surgery. It is anticipated that the novel sling will allow the patient to be more active and more comfortable while still providing a safe healing environment after a shoulder injury or shoulder surgery.
45511780|NCT05274737|Device|Traditional abduction sling|An abduction sling is the most common type of sling utilized to protect patients after rotator cuff surgery and total shoulder of arthroplasty and can be considered the current standard of care.
45511781|NCT02255630|Other|Cycling Exercise|
45511782|NCT02163122|Procedure|Nasal Allergen Challenge|Cat allergen (FelD1) applied directly to the nasal tissues
45511783|NCT02163122|Other|Environmental Exposure Chamber|The mobile EEC (mEEC) is a movable facility, designed with clean-room technology, used to expose subjects to aeroallergens (in this trial, the allergen FelD1 from cats) at controlled, consistent airborne levels, similar to that experienced in subjects' daily lives.
45403732|NCT03777592|Procedure|erector spinae plane block|local anesthetic or saline is administered in to the interfascial plane between the transverse process of the vertebra and the erector spinae muscles, spreading to multiple paravertebral spaces
45511784|NCT02163122|Biological|Cat allergen (FelD1)|
45511785|NCT04211675|Biological|Natural Killer Cells|NK cells dose 1x 108 cells/ kg on day 8 of each cycle
45511786|NCT04211675|Drug|Temozolomide|Temozolomide 100mg/m2/dose PO or IV daily on Days 1-5; if given orally, must be at least one hour prior to Irinotecan. For patients whose body surface area is <0.5m2, temozolomide dosing is based on body weight in (kg), at a dose of 3.3 mg/kg/dose.
45511787|NCT04211675|Drug|Irinotecan|Irinotecan 50mg/m2/dose IV daily on Days 1-5
45511788|NCT04211675|Drug|Dinutuximab|Dinutuximab 17.5mg/m2/dose IV daily on Days 2-5
45511789|NCT04211675|Drug|Sargramostim|Sargramostim 250mcg/m2/dose subcutaneous daily on Days 6-12
45511790|NCT04507269|Drug|VIR-2218|VIR-2218 given by subcutaneous injection
45511791|NCT04507269|Drug|Placebo|Saline given by subcutaneous injection
45511792|NCT02162264|Drug|Donepezil Hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
45403733|NCT03781258|Drug|Warfarin|Anti-thrombotic monotherapy (ASA)-Warfarin withdrawal.
45511793|NCT03700515|Drug|Erythropoietin|Subjects receive weekly infusions of EPO
45511794|NCT03700515|Drug|Placebo|Subjects receive weekly infusions of saline
45511795|NCT05113277|Behavioral|Tonic Immobility Psychoeducation (TIP)|TIP is a 45-minute computerized psychoeducation intervention aimed at addressing maladaptive cognitions and emotions associated with TI while using educational and behavioral techniques commonly used in the treatment of trauma-related disorders. Throughout the psychoeducation program vignettes will be presented to clarify concepts and promote participant engagement. In addition, practice exercises and rating scales will be integrated, where applicable, to increase the interactive nature of the program. The following modules will be addressed in the TI psychoeducation intervention: education, myth busting, and behavioral experiments.
45511796|NCT05113277|Behavioral|Health Education Training (HET)|The Healthy Education Training intervention was developed as a 45-minute online intervention that provides education about physical health habits that can impact mental health, such as diet, exercise, and sleep. This intervention has been used in prior clinical trials to control for effects of general education, general coping techniques, and use of technology. Participants in past clinical trials have reported that HET is engaging and beneficial. However, HET is not expected to have an effect on the main symptom outcomes of the current study (guilt, shame, PTSD symptoms).
45511797|NCT03702075|Other|self-administered program|One session was a session supervised by a physical therapist in the Faculty of Health Sciences. This session took place in groups of three or four people. All participants had to follow the physiotherapist instructions about the correct way to do the exercises with the foam roller or ball and nerve mobilizations of upper limbs.The other two weekly sessions were performed at home, following the instructions given by the physiotherapist in session.
45511798|NCT04740008|Drug|Low Nicotine Content Cigarettes|Low Nicotine Content Cigarettes 0.4 mg/g nicotine; 9 mg tar Other Name: Reduced Nicotine Content Cigarettes
45511799|NCT04740008|Other|Control message|Participants will read control message
45511800|NCT04740008|Other|Test message|Participants will read test message
45511801|NCT03700359|Drug|Anlotinib Hydrochloride|Anlotinib: Maintenance therapy 12mg/day P.O., day 1-15 every 21 days (2 weeks on, 1 week off) until progressive disease or treatment discontinuation
45511802|NCT03700359|Drug|Lobaplatin|Lobaplatin:30 mg/m2 IV every 21 days for up to 4 cycles of 21 days
45511803|NCT03700359|Drug|Etoposide|Etoposide: 60 mg/m2 IV every 21 days for up to 4 cycles of 21 days
45511804|NCT02047955|Procedure|Shoulder Arthroplasty|
45511805|NCT02167178|Other|Administration of 0.9% NaCl solution|Volunteers administered 0.9% NaCl solution in 250ml boluses
45511806|NCT02167178|Other|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor.
45403734|NCT03781102|Behavioral|16-Week Diabetes Prevention Program for Mothers and Children|The 16-week intervention is focused on ways to modify behaviors associated with the pathogenesis of Type 2 Diabetes in youth, while engaging participants in fun, active, and interactive food demonstrations, energy balance, and physical activities appropriate for all the family. Weekly sessions will consist of: (1) physical activity upon arrival; (2) small group discussions; (3) hands-on food preparation and tasting opportunities; (4) low- to no-cost fun family physical activities; (5) energy balance activities (e.g. label reading) to increase foundational knowledge; and, (6) opportunities to set new weekly goals.
45403735|NCT05397340|Device|Deep brain stimulation|active DBS with optimal stimulating parameters
45403736|NCT00412373|Drug|Placebo|for 6 weeks
45403737|NCT00412373|Drug|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
45511807|NCT02167178|Other|Measurement of microvascular blood flow|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan.
45511808|NCT02167178|Other|Administration of gelofusine|Volunteers administered gelofusine in 250ml boluses
45511809|NCT01379027|Behavioral|Pure self-help Internet CBT for depression|Internet, CBT, Depression
45511810|NCT01379027|Behavioral|Guided self-help Internet CBT|CBT, Depression, Website intervention, coaching
45511811|NCT01379027|Behavioral|Stepped-Care Internet CBT condition|Depression CBT, Internet intervention
45511812|NCT03625089|Drug|Atorvastatin|"Group 1 patients will be prescribed statin when FRS > 10%; while group patients will be prescribed statin upon presence of carotid plaque as reported from carotid ultrasound. The decision will solely be made base on the randomized group by either FRS>10% or presence of carotid plaque.~Atorvastatin 20 mg is recommended as the preferred initial high intensity statin to use because it is clinically and cost effective for the primary prevention of CVD according to the national institute for Health and Care Excellence (NICE) guideline from the United Kingdom."
45511813|NCT01378949|Drug|Bupivacaine|Bupivacaine 0.5% with adrenaline 5 mcg/cc
45511814|NCT01378949|Drug|Morphine|Morphine 1 mg/cc
45511815|NCT03701997|Device|EXCOR Pediatric|Mechanical circulatory support using ventricular assist device
45511816|NCT03540446|Device|First Relief Treatment|To prove the effectiveness of Percutaneous Electrical Neuro-stimulation therapy for the treatment of conditions associated with peripheral neuropathy, in a double-blind environment.
45511817|NCT01381133|Behavioral|Chestnut Bloomington Outpatient (CBOP)|CBOP is an evidence-informed intervention that has developed over 20 years and been shaped by treatment research. The underlying theory of change is that the combination of multiple evidence-based and best-practice treatment components will increase the adolescent's desire to change, provide the necessary skills, and create an environment supportive for this change. The intervention is based on a manual and is primarily delivered through skill and therapy groups, combined with a limited number of family and individual sessions for treatment planning and progress reviews.
45511818|NCT01381133|Behavioral|Motivational Enhancement Therapy/Cognitive Behavior Treatment (MET/CBT 7)|A manual-based 5-session MET/CBT model was supplemented with 2 family sessions. First was a family session to provide parents with an overview. Next was an individual adolescent MET session that focused on building rapport, explaining treatment, building motivation, and reviewing personalized feedback. In the third session, the therapist helped the adolescent complete a functional analysis of substance use and a personal goal worksheet. During sessions 4-6, the adolescent joined a closed group of 6 for 90-min CBT skills groups focusing on substance refusal skills, enhancing social support, planning for high-risk situations, and coping with relapse. The last session was a family session to review progress, relapse signs, and continuing care plans. Treatment lasted about 12 weeks.
45511819|NCT01381133|Behavioral|Assertive Continuing Care (ACC)|ACC is a home-based continuing care approach that takes place over a 12-14 week period and has shown promise in a randomized clinical trial of adolescents discharged from residential treatment. Following an operant reinforcement and skills training model, ACC combines the Adolescent Community Reinforcement Approach and case management services to help adolescents and their caregivers engage in prosocial activities, skills, and needed community services during weekly home visits.
45511820|NCT01381055|Drug|Pentoxifylline|Patients with cutaneous leishmaniasis treated with pentavalent antimony/Meglumine antimoniate 20mg/kg/day during 20 days and pentoxifylline pills 400mg three times a day during 20 days.
45403738|NCT00412373|Drug|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
46057260|NCT00736099|Drug|linagliptine 5 mg|safety and efficacy of linagliptine 5 mg open label
45403739|NCT05357170|Other|Human feces collection|Human feces collection and blood sampling
45403740|NCT05692726|Other|Patients|Patients will get study-specific measurements within first 5 days of standard of care treatment of hyponatremia or until discharge
45403741|NCT01308658|Drug|Darunavir (DRV)|2x400-mg DRV tablet or 800-mg tablet
45403742|NCT01308658|Drug|ritonavir|on Day 3
45403743|NCT03785314|Other|thoracic epidural catheterization|thoracic epidural catheterization with different posture
45403744|NCT05154214|Procedure|Adenotonsillectomy|Removal of tonsils and adenoids
45511821|NCT01381055|Drug|Placebo|Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.
45511822|NCT04720664|Drug|SM-88|"SM-88, Two 230 mg capsules taken orally twice daily (920 mg daily).~Methoxsalen, One 10 mg capsule taken orally once daily.~Phenytoin, One 50 mg tablet taken orally once daily.~Sirolimus, One 0.5 mg tablet taken orally once daily."
45511823|NCT01380977|Behavioral|Impact of Crime group intervention|A group intervention for 16 1.5 hr sessions held twice a week
45511824|NCT02163278|Drug|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
45511825|NCT02163278|Drug|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
45511826|NCT04649229|Drug|LCZ 696|Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).
45511827|NCT04649229|Drug|Placebo|Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4
45511828|NCT04649229|Drug|Para-aminohippurate|Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
45511829|NCT04649229|Drug|Iohexol|Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.
45511830|NCT04649229|Drug|Aprepitant|Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4
45511831|NCT02167334|Device|positive pressure ventilation|Positive Pressure Ventilation with a 4 cmH2O inhale pressure, a positive end-expiratory pressure of 4 cm H2O, a trigger 2, an inspiratory slope of 0, an inhaled oxygen fraction of 100% administered at a 10 L / min flow.
45511832|NCT02167334|Procedure|Oxygenation with simple breathing mask|Spontaneously breathing preoxygenation with adapted face mask, to restrict leakage, at 10L/min oxygen, with inhaled fraction of 100% and a 2 L balloon volume.
45511833|NCT03122613|Dietary Supplement|Curcumin|3g of Curcumin per day
45511834|NCT03122613|Drug|Placebo|3g of Curcumin Placebo per day
45851250|NCT01799460|Drug|The Comprehensive Treatment Regimen of Traditional Chinese Medicine|"①ShenQiMoShen Decoction: which plays vital therapeutic effect in the CTR,the dosage is 150ml per serving and two services per day.Dosage and administration:150ml per time,twice per day~②HuoXueTongMai Capsule : which plays a vital role of promoting blood circulation and removing blood stasis. Its main components are the leeches. Dosage and administration: 4 capsules 3 times daily.~③HeiLiaoDou Particle: which will be prescribed when hypoproteinemia (serum albumin concentration≤30g/L)occurred and should be stopped taking until the serum albumin is above 30g/L. Dosage and administration: 2 packages 3 times daily."
45403745|NCT05154214|Procedure|Drug-induced sleep endoscopy directed surgery|Surgeries selected based on direct visualization of airway collapse using endoscopy during drug-induced sleep
45511835|NCT04709978|Diagnostic Test|Videofluoroscopic Swallowing Study|Participants enrolled in supplemental study will swallow different barium containing liquid and food boluses types that are captured on fluoroscopic imaging in real time.
45511836|NCT04709978|Diagnostic Test|Nuclear medicine pulmonary aspiration study|Participants enrolled in supplemental study will be administered radiotracer (Tc-99m-Sulfur Colloid) orally and static images of the chest will then be obtained at specified intervals over the next 2 hours to determine location of the radiotracer.
45511837|NCT04709978|Diagnostic Test|TOR-BSST and 3 oz Water Swallow|"The research specialist will conduct ten 1 tsp water swallows, one cup sip of water and a 3 ounce water swallow test with the patient. After each swallow, the participant is asked to say ah so that their voice quality can be assessed."
45511838|NCT04709978|Diagnostic Test|Sputum Culture|Patients will have sputum collected during stay (ED participants only)
45511839|NCT04709978|Diagnostic Test|MeMed BV®|A blood test to help determine if the infection is viral or bacterial (ED participants only)
45511840|NCT04709978|Diagnostic Test|Lung Ultrasound|To image the lungs (ED participants only)
45698869|NCT03465930|Procedure|Supermicrosurgical lymphatico-venous anastomoses|Supermicrosurgical lymphatico-venous anastomoses (sLVA) require an accurate visualization of the lymphatic vessels that are still functional. Lymphatic vessels are visualized with lymphography using a fluorescent dye, indocyanine green. Adjacent superficial veins mapping is obtained with Accuvein device.
45698870|NCT01146496|Device|Ultraviolet light-resistant plastic in-ground pesticide storage container|In-ground pesticide storage container to be supplied to every household that uses pesticides in intervention villages
45403746|NCT03785002|Other|Strength training|24 strength training sessions, with approximately 1 hour duration, that will occur 2x/week
45403747|NCT03785002|Other|Protein intake|Guidance on the adequacy of protein intake (at least 20g of protein in breakfast, lunch and dinner)
45403748|NCT03781024|Combination Product|Footwash|footbath/footwash can help cleanse the wound, remove dead tissue, increase circulation and puts the wound in direct contact with medication to promote faster healing.
45403749|NCT03780946|Procedure|Magnetic anastomosis for pancreaticojejunostomy|Magnetic anastomosis for pancreaticojejunostomy
45851251|NCT01799460|Drug|The immunosuppressive agents|According to Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for glomerulonephritis
45403750|NCT03780946|Procedure|Traditional hand-sewn anastomosis|Traditional manual anastomosis for pancreaticojejunostomy
45511841|NCT04709978|Diagnostic Test|Respiratory Function Tests|To measure respiratory pressures.
45511842|NCT03931265|Diagnostic Test|ketohexokinase|Check the isoforms of ketohexokinase in the specimen of endometrial cancer
45511843|NCT03700281|Behavioral|Messaging|The participants will receive influenza promotion emails, text messages, and U.S. mail from Sendero Health Plans.
45511844|NCT03700281|Behavioral|Incentive|Participants will be eligible for a gift card to a local grocery store chain as an incentive for obtaining an influenza vaccine
45511845|NCT03630575|Procedure|Umbilical cord blood and hair collection|At the birth of the newborn, a first hair sample and a cord blood sample will be taken. A follow-up of the newborn will be performed between 4 and 6 months in order to obtain a second hair sample.
45511846|NCT03540368|Drug|Tranexamic acid injection|Administering tranexamic acid loading dose 1 gram in 100 cc sodium chloride 0,9%, followed by maintenance dose 3 grams in infusion for 24 hours.
45511847|NCT03540368|Other|Placebo|Administering placebo or sodium chloride 0,9% intravenously
45511848|NCT02162342|Other|Rehabilitative treatment|Surgical intervention, orthotics or injections of muscle/nerve medications as prescribed by the treating physician and unrelated to the study.
45511849|NCT03086135|Device|Osia System|An external Sound Processor captures and digitize the sound which is transferred to the internal implant where it is converted to an electrical signal. The electrical signal is further transferred as a vibration through an osseointegrated implant to the mastoid bone and eventually to the cochlea.
45511850|NCT02162498|Behavioral|Feeding buddies|"The Window of Opportunity program is implementing feeding buddies within their comprehensive programming. Their feeding buddies intervention targets all mothers at ANC for promoting health behaviors, especially exclusive breastfeeding.~The NIH study is an implementation science award to evaluate the feeding buddies intervention, specifically among HIV positive recipients and evaluating the outcome of adherence to PMTCT recommendations."
45403751|NCT03777514|Drug|Ferumoxytol|treatment of iron deficiency anemia with IV iron.
45511851|NCT03700125|Procedure|ECMO resuscitation|Extracorporeal Cardio-Pulmonary Resuscitation (ECPR) using ECMO within 30 minutes of cardiac arrest
45511852|NCT02163590|Other|2Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
45511853|NCT02163590|Other|0,5Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
45511854|NCT02163590|Other|Placebo|Intervention that mimics the experimental procedures
45698871|NCT03461094|Device|Preload assessment and volume expansion|Fluid therapy perform
45403752|NCT03777514|Drug|Ferrous sulfate|treatment of iron deficiency anemia with oral iron
45851252|NCT02994966|Device|Surrosense|
45851253|NCT02994966|Other|Standard care|
46057261|NCT00736099|Drug|linagliptine 5 mg and pioglitazone 30 mg|efficacy and safety of the combination linagliptine and pioglitazone
45403753|NCT03777514|Other|Oral vitamin C|Oral vitamin C to be used as a placebo for participants receiving IV iron
45403754|NCT03777514|Other|Intravenous normal saline|Intravenous normal saline will be used as placebo for participants receiving oral iron
45403755|NCT03777124|Drug|SHR-1210|Subjects receive SHR-1210 intravenous every 2 weeks
45403756|NCT03777124|Drug|Apatinib|Subjects receive Apatinib orally every day
45403757|NCT03777124|Drug|Pemetrexed|Subjects receive Pemetrexed intravenous every 3 weeks
45403758|NCT03777124|Drug|Carboplatin|subjects receive carboplatin intravenous every 3 weeks
45403759|NCT00418379|Drug|300 IR (4M)|300 IR grass pollen allergen extract tablet starting 4 months before the pollen season
45403760|NCT00418379|Drug|300 IR (2M)|300 IR grass pollen allergen extract tablet starting 2 months before the pollen season
45403761|NCT00418379|Drug|Placebo|Placebo tablet
45403762|NCT03780556|Drug|Lornoxicam and mepridine|compare the effect of each to control pain
45403763|NCT01038791|Device|heated humidification|temperature 35°
45403764|NCT01038791|Device|heat and moisture exchanger|single patient device
45403765|NCT01038791|Device|usual mechanical ventilation without humidification|mechanical ventilation with usual parameters
45511855|NCT02167568|Genetic|Genetic|
45511856|NCT02255396|Other|ESTRADIOL|
45511857|NCT02163668|Other|Yoga Group|8 months of Yoga training
45511858|NCT02167646|Procedure|Flap including bilateral nerve branches|Two nerve branches are attached with the flap for sensory coverage
45511859|NCT02163980|Drug|Caudal ropivacaine + normal saline|
45403766|NCT03780868|Procedure|external dacryocystorhinostomy|external DCR under general anesthesia with standard sterilization procedures.
45403767|NCT03780868|Procedure|canalicular silicone intubation with MMC|canalicular silicone intubation with MMC under general anesthesia with standard sterilization procedures.
45403768|NCT00418145|Drug|megadose oral methylprednisolone|1400 mg qd/5 days
45403769|NCT00418145|Drug|IV methylprednisolone|1000 mg/qd/5 days
45403770|NCT03780634|Procedure|HAIC|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
45511860|NCT02163980|Drug|Caudal ropivacaine + dexmedetomidine|
45511861|NCT02164058|Device|TandemHeart System|
45511862|NCT02164058|Procedure|Percutaneous coronary intervention|
45698872|NCT05301816|Device|Spinal Cord Stimulator (SCS)|Spinal cord stimulation system (SCS) is an approved system to manage chronic intractable pain of the limbs and/or leg by delivering electrical stimulation using implantable leads and rechargeable implantable pulse generator (IPG) with 16 output channels. The IPG is implanted in a subcutaneous pocket and is capable of stimulating the spinal cord nerves when used with one or two 8-contact percutaneous or paddle leads.
45698873|NCT01146808|Drug|Adefovir dipivoxil and hepatitis B vaccination|Adefovir 10mg po daily, or adjusted for renal function and option for Hepatitis B vaccination, double dose
45698874|NCT02522130|Drug|Lidocaine|intracervical injection
45698875|NCT02522130|Drug|oral misoprostol|oral treatment
45403771|NCT03780634|Drug|PD-1 antibody|200mg intravenously every 3 weeks
45511863|NCT02164136|Procedure|L-PANP-TME|
45511864|NCT02164136|Procedure|O-PANP-TME|
45511865|NCT01380821|Radiation|Myocardial SPECT|Myocardial SPECT according to clinical standards for patients with a clinical indication to undergo this imaging test.
45511866|NCT02162654|Procedure|Remote ischemic preconditioning|The blood pressure cuff is inflated to 200 mmHg for 3 x 5 minutes with 5 minutes of reperfusion by complete cuff deflation each.
45511867|NCT02162654|Procedure|Sham preconditioning|The blood pressure cuff is inflated to 10 mmHg for 3 x 5 minutes with 5 minutes of complete cuff deflation each.
45511868|NCT01700543|Procedure|Shoulder Arthroplasty|Implantation of the Sidus Stem-Free Shoulder follows standard shoulder replacement procedures.
45511869|NCT04733222|Other|Perturbation training|"The treadmill perturbation training will be performed on a computer-controlled treadmill. The perturbation will be induced by fast forward (slip) or backward (trip) accelerations of the treadmill at specific gait cycle timings. The perturbations will be delivered randomly to enhance the unpredictability. A ceiling-mounted body-harness ensures the safety of the participants.~Participants will be assigned to three initial sessions of treadmill slip- and trip-perturbation training on two days separated by a week and a booster-session after six months. On day 1, participants will first undergo a session 1 with 40 slip perturbations and then a session 2 with 40 trip perturbations. On day 2, participants will undergo a session 3 with 20 slip and 20 trip perturbations in random order. The booster-session after six months will be similar to session 3 (20 of each perturbation in random order)."
45511870|NCT04733222|Other|Treadmill walking|Participants allocated to the walking group will walk at a self-selected pace on a computer-controlled treadmill for the same amount of time as the treadmill perturbation training participants.
45511871|NCT01378793|Behavioral|Relaxation Acupressure|Apply pressure (stimulate) to the 9 acupoints for 3 minutes per point giving a total treatment time of 27 minutes done once daily for a period of 6 weeks.
45511872|NCT01378793|Behavioral|Stimulating Acupressure|Apply pressure (stimulate) to the 10 excitatory acupoints for 3 minutes per point giving a total treatment time of 30 minutes done once daily for a period of 6 weeks.
45511873|NCT02162888|Drug|Test Product (Bendamustine)|
45511874|NCT04494867|Device|Core Warming|Esophageal heat transfer device will be set to 42°C temperature after initial placement, and maintained at 42°C for the duration of treatment.
45511875|NCT04494867|Other|Standard of Care|Standard temperature management and treatment
45511876|NCT01569035|Drug|warfarin|3 mg warfarin oral tablet for 2 to 3 weeks
45511877|NCT03886181|Device|Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
45403772|NCT03780634|Drug|Sorafenib|400 mg Bid Po
45403773|NCT03780478|Drug|Nerve block|0.25% bupivacaine with epinephrine (1:100k), with total volume of 2mL
45511878|NCT04622085|Device|ANIMERS Chiara LA|20mg/SciVision Biotech Inc.
45511879|NCT04622085|Device|JUVÉDERM VOLUMA®|20mg/Allergan, Inc.
45511880|NCT02762708|Procedure|Roux-en-Y Gastric Bypass (RYGB)|Subjects will be studied prior to surgical intervention and 12 weeks post surgery. Subjects in surgical arm will start diet intervention after surgery. Follow up with dietary will be per standard of care following RYGB surgery.
45511881|NCT02762708|Behavioral|Caloric Restriction|Subjects participating in caloric arm of this study will be asked to consume an identical diet that is controlled for caloric content and macronutrient composition. This is identical to that consumed by patient undergoing RYGB. Subjects in the caloric restriction arm will start the diet after the screening visit. Compliance will be monitored by alternating weekly meetings with a clinical psychologist and dietician.
45511882|NCT02762708|Drug|Exendin-9,39|"A subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
45511883|NCT02762708|Drug|Normal Saline|"subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
45511884|NCT03699969|Radiation|Hypofractionated dose escalated VMAT|measure the local control, progression free survival and overall survival
45511885|NCT03841565|Biological|Daratumumab|Given IV
45511886|NCT03841565|Drug|Dexamethasone|Given PO
45511887|NCT03841565|Drug|Pomalidomide|Given PO
45403774|NCT03780478|Drug|Placebo Saline Injection|Saline injection, total volume 2ml
45403775|NCT03785080|Other|restart NOAC very early|withhold NOAC less than 24 hours Post OGD
45403776|NCT03785080|Other|restart NOAC early|withhold NOAC for 72 to 84 hours Post OGD
45403777|NCT03777358|Device|3D-TVS|The 3D-TVS will be done by an experienced gynecological sonographer. The uterine cavity will be assessed by obtaining a mid-coronal view. Then hysteroscopy will be performed
45511888|NCT02162966|Drug|High Dose Colistin|High Dose Colistin
45511889|NCT02162966|Drug|Standard Dose Colistin|Standard Dose Colistin
45511890|NCT02839317|Biological|Biological|comparison of microbiota, genetic profile between pediatric- and elderly-onset CD
45511891|NCT04697420|Procedure|Thoracic paravertebral block|Thoracic paravertebral block is a technique in which , the local anesthetic agent is injected in the paravertebral space to anesthetise the spinal nerves after emerging from the vertebral canal in order to provide analgesia in the thoracic and upper abdominal area .
45511892|NCT04697420|Procedure|Transversus abdominis plane block|Transversus abdominis plane block is a technique is mostly done under ultrasound guidance to identify the transversus plane between the internal oblique muscle and the transverses abdominis muscle , the space in which the neurovascular supply of the anterior abdominal wall is present , and hence the injection of local anesthetic agent in this space results in anesthesia of the anterolateral aspect of the abdominal wall.
45511893|NCT04919525|Device|TrainPain|Participants will use gamified sensory perceptual training technology once daily for 28 days. This will involve participants completing a 15 minute sensory training session using the provided technology and viewing a 5 minute web based pain management lesson; additionally, participants will receive daily text messages. The device used in this study has two components. The first is a video game that can be downloaded onto any smartphone device. The second component is two vibrational devices that can be attached to the arms, legs, upper back, and lower back.
45511894|NCT03540290|Procedure|Modification of the implant supported prostheses in order to facilitate oral hygiene|Peri-implant mucositis will be treated by individualized oral hygiene instructions and decontamination of the implant surface by ultrasonic device with a plastic tip and plastic curettes plus the modification of the implant prosthesis in order to facilitate oral hygiene access
45511895|NCT01595321|Drug|Cyclophosphamide|Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional Cy-vaccine boosts may be given every 6 months thereafter until disease recurrence.
45511896|NCT01595321|Biological|PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine|Vaccine will be administered one day after cyclophosphamide (day 1). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional Cy-vaccine boosts may be given every 6 months thereafter until disease recurrence.
45403778|NCT03777280|Device|peek framework RPD|it is a polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base made by injecting technique and have several advantages regarding strength and esthetics
45511897|NCT01595321|Radiation|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy) will be administered over 5 days starting between 13-17 days after the first vaccine dose (Arm 2) or within 6-10 weeks of surgery (Arm 1).
45511898|NCT01595321|Drug|FOLFIRINOX|FOLFIRINOX will be administered over 6 cycles starting at least 14 days after SBRT (Arms 1 and 2) and at least 28 days after the first vaccine (Arm 2).
45511899|NCT03699891|Device|Fortilink IBF System with TETRAfuse Technology|Cervical and lumbar fusion
45511900|NCT02167724|Other|Bucco-dental examination|
45511901|NCT02167724|Other|Blood sample|
45511902|NCT02167724|Other|Clinical and social questionnaire|
45511903|NCT03699813|Other|Comparison of two approaches to bleeding management|
45511904|NCT04869527|Device|BIOTRONIK ICDs with DX Technology|The BIOTRONIK DX system offers a single chamber ICD that enables sensing of atrial signals through floating atrial dipoles, using a single ventricular lead. This technology enables enhanced arrhythmia diagnosis based on atrial and ventricular electrograms and, in addition, early diagnosis and automatic transmission of AF and heart failure (HF) diagnostic data. The DX technology provides several features in a single chamber device that are usually only found in dual chamber devices, including atrial diagnostics and SVT discrimination - early detection of SAF, increased diagnostics accuracy, dual-chamber discrimination. Nevertheless, the benefits of a single chamber device are preserved: reduced lead complications, reduced procedure complexity, elimination of costs for atrial lead. The DX system also integrates with BIOTRONIK Home Monitoring, allowing physicians to remotely follow their patients' clinical and device statuses with daily updates.
45511905|NCT02164214|Drug|etanercept Treatment|
45511906|NCT03698565|Other|Nerve stimulation of the ulnar nerve|"The intervention is the nerve stimulation of the ulnar nerve for evaluation / realization of PPI by videopupillometry.~The realization of PPI and ANI measurements is carried out at the end of the surgical procedure, it implies a maintenance of the anesthesia for approximately 5 additional minutes."
45511907|NCT03768947|Other|Heat therapy via hot water immersion|Participants will be asked to participate in a 4-week heat therapy intervention, which consists of ~12-15 visits (45 min each) of immersion in to a hot tub.
45698876|NCT02522130|Drug|naproxen|oral treatment
45698877|NCT02522130|Other|placebo|oral treatment
46057262|NCT02711709|Other|Frailty Measurements|"A frailty index will be determined as a combination of factors.~An older adult is considered physically vulnerable when they experience:~muscle weakness~fatigue~low physical activity, and unintentional loss in body weight, which has been agreed upon by a consensus of experts.~This will be collected at baseline, 3, 6 and 12 months."
45403779|NCT03777280|Device|cobalt chromium framework RPD|standard framework device
45403780|NCT00417989|Device|MiniMed Paradigm REAL-Time System|Paradigm 722 insulin pump Paradigm REAL-Time Transmitter Sensor ComLink Paradigm Link glucose meter
45511908|NCT03699735|Device|Bolero B90-SP|Behind the ear Hearing device fitted with an individual ear mold to compensate a Hearing loss
45511909|NCT02164292|Procedure|ALPPS|Associating Liver Partition and Portal vein ligation for Staged hepatectomy
45511910|NCT03722849|Drug|Adenosine Triphosphate|Participants will inhale escalating concentrations of Adenosine Triphosphate (ATP) to induce cough and the urge-to-cough
45511911|NCT03722849|Drug|Capsaicin|Participants will inhale escalating concentrations of capsaicin to induce cough and the urge-to-cough
45511912|NCT03722849|Other|Functional Brain Imaging|Participants will have scans of their brain activity using 3 Tesla (3T) brainstem restricted functional brain imaging (fMRI)
45511913|NCT03699657|Device|DSM|Monopolar RFA using dual switching mode (DSM)
45511914|NCT03699657|Device|SSM|Monopolar RFA using single switching mode (SSM)
45511915|NCT03699657|Device|Separable clustered electrodes|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
45511916|NCT02170844|Drug|BIBR 1048 MS|
45511917|NCT02170844|Drug|Placebo of BIBR 1048 MS|
45403781|NCT03784768|Other|Plantar Vibration Group|Patients in plantar vibration group will be received 45-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities. In addition, three sessions a week will be applied to the soles of the feet for 15 minutes with a 15-100 Hz vibration device on both sides of the soles of the feet before conventional physical therapy.
45403782|NCT03784768|Other|Control Group|Patients in control group will be received 60-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.
45511918|NCT03624465|Device|Levita Magnetic Surgical System|Device for use as a surgical tool.
45511919|NCT03996239|Behavioral|exercise (walking)|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. This trial will evaluate one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
45698878|NCT03461016|Behavioral|Exposure Therapy|"Exposure therapy is a form of behavior therapy that is widely used to treat anxiety disorders, including specific phobia. It involves systematic and repeated confrontation with a feared stimulus. It works by (a) implosive therapy, habituation, in which repeated exposure reduces anxiety over time by a process of extinction; (b) disconfirming fearful predictions; and (c) increasing feelings of self-efficacy and mastery. In vivo exposure [is] a type of exposure therapy, generally used for treating individuals with phobias, obsessive compulsive disorder, and other anxiety disorders, in which the client directly experiences anxiety-provoking situations or stimuli in real-world conditions. (VandenBos, 2015)"
45698879|NCT01148524|Biological|No Vaccine|
46057263|NCT02711709|Other|Modified Minnesota Leisure Time Activities|A questionnaire used to assess physical activity will be administered at baseline, 3, 6 and 12 months.
46057264|NCT02711709|Other|Computed tomography morphometrics|A CT scan will occur as standard of care while the patient is hospitalized. Two additional CT scans will occur at 3 and 12 months to assess for sarcopenia.
45403783|NCT03780712|Other|Non applicable|No intervention as it is an observational study
45698880|NCT01148524|Biological|rMenB+OMV-NZ|Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).
45403784|NCT01038947|Biological|Uricase-PEG 20|Intramuscular injection of Uricase-PEG 20 without premedication
45403785|NCT03777046|Behavioral|Standard of Care (SOC)|Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.
45511920|NCT03996239|Other|plasma samples|Plasma samples will be obtained at baseline.
45511921|NCT03996239|Other|blood draw|fasting blood
45511922|NCT02170922|Drug|BIBR 1048 MS tablet|
45511923|NCT02170922|Drug|BIBR 1048 MS solution|
45511924|NCT03698253|Drug|Regorafenib|Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle
45511925|NCT03698253|Genetic|UGT1A1 genotyping (TA6/TA6)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2
45511926|NCT03698253|Genetic|UGT1A1 genotyping (TA6/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2
45511927|NCT03698253|Genetic|UGT1A1 genotyping (TA7/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2
45511928|NCT02047461|Drug|ORGN001 (formerly ALXN1101)|IV infusion
45511929|NCT02167958|Drug|Fludarabine|"Fludarabine 30 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2. Fludarabine will be dosed according to the recipient's Adjusted Ideal Body Weight (AIBW) unless AIBW is less than Ideal Body Weight (IBW).~For decreased creatinine clearance (< 61 mL/min) determined by the Cockcroft Formula:~Cockcroft-Gault CrCl = (140-age) * (Wt in kg) * (0.85 if female) / (72 * Cr)~Fludarabine dosage should be reduced per standard of care."
45511930|NCT02167958|Drug|Cyclophosphamide|"Pre-transplant~Cy 14.5 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -6 and -5. Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW~Post-transplant~Hydration prior to cyclophosphamide may be given according to Standard Practice Guidelines.~Cyclophosphamide [50mg/kg] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW. Cyclophosphamide will be given as an IV infusion over 1-2 hours.~."
45511931|NCT02167958|Drug|Mesna|"Pre-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide.~Post-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide."
45403786|NCT03777046|Behavioral|SOC with Psychology Therapy (CBT)|Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive the experimental intervention. Intervention includes SOC treatment as well as psychology therapy (CBT) in the hospital.
45511932|NCT02167958|Radiation|Total Body Irradiation|200 cGy will be administered in a single fraction on Day -1 via linear accelerator.
45511933|NCT02167958|Other|Hematopoietic stem cell infusion|Donors who consent to PBSC donation will receive 5 daily doses of G-CSF, 10 μg/kg/day by subcutaneous injection commencing on day -5. PBSC's will be collected in the afternoon of day -1, stored at 4C overnight, and infused as soon as possible on day 0. If the collection on day -1 contains less than 5.0 X 106 CD34+ cells per kg recipient weight, a second collection will be performed the following morning and infused on day 0. Quantitation of CD34 and CD3 cells will be performed by the Cellular Therapy Lab. For all patients, the target number of CD34 cells to be infused should be 5-6 X 106 cells per kg recipient weight. PBSC in excess of 6.0 x 106 CD34 cells/kg recipient weight may be cryopreserved.
45511934|NCT02167958|Drug|Tacrolimus|Tacrolimus will be given at a dose of .03 mg/kg IV over 24 hours. Tacrolimus will be changed to a PO dosing schedule once a therapeutic level is achieved and the patient is tolerating PO. Whole bloodblood levels of tacrolimus will be measured around Day 7 and then should be checked at least weekly thereafter and the dose adjusted accordingly to maintain a level of 5-10 ng/mL. Tacrolimus will be discontinued after the last dose around Day 180, or may be continued if active GVHD is present. Cyclosporine (target concentration 200-400 ng/ml) may be substituted for tacrolimus if the patient is intolerant of tacrolimus.
45511935|NCT02167958|Drug|Mycophenolate|Either the sodium salt of mycophenolate or mycophenolate mofetil (MMF) may be used as prophylaxis of GvHD and will be dosed by actual bodyweight. Only MMF is available as IV formulation. Sodium mycophenolate will be given at a dose of 10mg/kg PO TID rounded to the nearest number of 180mg tablets. MMF will be given at a dose of 15 mg/kg PO TID. The maximum total daily dose should not exceed 2160 mg (sodium salt) or 3 grams (mofetil). Mycophenolate prophylaxis will be discontinued after the last dose on Day 35, or may be continued if active GVHD is present.
45511936|NCT02167958|Drug|G-CSF|G-CSF will be given beginning on Day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is > 1,000/mm3 for three consecutive days.
45403787|NCT03780166|Drug|Parsaclisib|Parsaclisib administered orally once daily at the cohort-specified dose level.
45851254|NCT02991690|Other|Hypothermia|To deliver intravascular hypothermia, an Alsius Icy CoolGuard® catheter (US Food and Drug Administration approved, Premarket Notification [510(k), K030421]; Alsius Corporation, Irvine, California) will be inserted through the femoral vein using a sterile technique. Patients will be cooled at a maximum rate (2-2.5 ºC/hr.) until they reach the target temperature (T 33 ºC), which will be maintained for 48 hours, and then re-warmed at 0.1 ºC/hr. until normothermia (T 37ºC) is achieved.
45851255|NCT02992080|Other|miRNAs isolation from blood samples of patients and control|Blood sample collection in specific PAXGene tubes
45851256|NCT02992782|Behavioral|Standard Care|Home program of decongestive exercise and daily use of a compression sleeve
45851257|NCT02992782|Behavioral|Exercise and Compression Garment|Decongestive progressive resistance exercise using flat-knit garment and daily use of a compression sleeve
45403788|NCT02043587|Drug|DNR|Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A
45403789|NCT02043587|Drug|VCR|1.4 mg/m2 IV, days 1, 8, 15, 22 (cap at 2mg for ages >50) during Courses 1A, 2A; Maintenance: Day 1 during months 2-12
45403790|NCT02043587|Drug|PEG-asp|2,000 IU/m2 IV for ages </= 50, age > 50, 1000 IU/m2 IV Day 16, Courses 1A & 2A; Day 18, Course 1B; Day 17, Course 2B; Day 16, Maintenance, Month 1
45403791|NCT02043587|Drug|CTX|750 mg/m2 IV, days 1 &15 for subjects <40 year of age, substitute cyclophosphamide 500 mg/m2 IV over 60 minutes every 12 hours for 4 doses on days 15 & 16 for subjects < 40 years of age if day 14 bone marrow M2 or M3; Courses 1A & 2A
45403792|NCT02043587|Drug|Prednisone|60 mg/m2 orally once daily on days 1-28 during Courses 1A & 2A; Maintenance: Monthly, days 1-5
45403793|NCT02043587|Drug|Liposomal AraC|25 mg intrathecal (IT), on days 1 & 15 during Courses 1A & 2A; 50 mg intrathecal on day 1 during Maintenance Months 1 through 4
45511937|NCT03698175|Behavioral|Three good things exercise|Participants are asked to remember each evening three things that went well during their day and to write them down in a journal including a short explanation of why they think each of them has happened.
45511938|NCT03698175|Behavioral|Placebo exercise|Participants are asked to briefly recall a childhood memory (no further specification) and to write it down including a short explanation why they think it has happened.
45511939|NCT01384331|Drug|Marvelon|"7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules~21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days~21 days daily oral placebo capsules Treatment will be for one cycle of 21 days"
45511940|NCT03699423|Drug|0.01% atropine eye drops|0.01% atropine sulphate
45511941|NCT03699423|Drug|0.02% atropine eye drops|0.02% atropine sulphate
45511942|NCT03699423|Drug|0.03% atropine eye drops|0.03% atropine sulphate
45511943|NCT02164448|Drug|the dexmedetomidine group|the dexmedetomidine group: dexmedetomidine infusion from induction of anesthesia to end of surgery
45511944|NCT02164448|Drug|the control group|saline infusion from induction of anesthesia to end of surgery
45511945|NCT03624413|Behavioral|Social Media Intervention|The social media intervention is a behavioral intervention developed by the study investigators and is delivered via mobile phones. The intervention uses the Social-ecological Model of Adolescent and Young Adult Readiness to Transition (SMART) model, highlighting modifiable targets of intervention that can be addressed through a social media platform. The SMART model incorporates modifiable factors such as knowledge, skills/self-efficacy, relationships and social support that can be targets of interventions to improve transition care. The SMART model emphasizes eight modifiable factors, three key stakeholders (adolescents, caregivers, and clinicians) and their interconnected relationship in influencing successful transition to adult care. The intervention is designed to overcome barriers and enhance facilitators to transitioning care among adolescents living with HIV who are transitioning to adult care in South Africa.
45511946|NCT03624413|Other|Standard of Care|Standard of care transition from pediatric to adult care for HIV.
45511947|NCT03612713|Drug|Oxycodone Medication First|Participants will be given 15mg oxycodone one hour before fMRI scan. After at least 1 week wash out participants will be given placebo one hour before fMRI scan.
45511948|NCT03612713|Drug|Placebo First|Participants will be given placebo one hour before fMRI scan. After at least 1 week wash out participants will be given 15mg oxycodone one hour before fMRI scan.
45511949|NCT02164526|Other|Routine therapy|Routine therapy
45511950|NCT03697941|Procedure|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).
45403794|NCT02043587|Drug|MTX|220 mg/m2 IV bolus over 15 minutes then 60 mg/m2/hour for 36 hours once on days 2-3 and 16-17 during Courses 1B & 2B; 20 mg/m2 orally one day per week every 7 days during Maintenance Months
45511951|NCT03697941|Procedure|Surgical cut-down and arterial puncture under direct vision|Surgical cut-down and arterial puncture under direct vision.
45511952|NCT01380509|Drug|Metronidazole|Capsules, single-dose, fasting
45511953|NCT01380509|Drug|Flagyl|Capsules, single-dose, fasting
45511954|NCT03699267|Other|US-guided Bilateral TAP block|
45511955|NCT01378715|Drug|Rosuvastatin|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
45698881|NCT03460938|Procedure|Remote ischemic preconditioning|RIPC: 3 periods of 5 minutes of ischemia followed by 5 minutes of reperfusion are created by inflating a blood pressure cuff on the upper extremity after induction of anesthesia and prior to surgery.
45403795|NCT02043587|Drug|LCV|50 mg/m2 IV over 15-30 minutes every 6 hours for 3 doses to begin immediately after completion of methotrexate infusion, then 10 mg/m2 orally or IV over 15-30 minutes every 6 hours until methotrexate level less than 0.1 micromolar during Courses 1B & 2B
45403796|NCT02043587|Drug|AraC|2,000 mg/m2 IV, days 1-4 during Courses 1C & 2C
45403797|NCT02043587|Drug|Etoposide|500 mg/m2 IV over 3 hours once daily on days 1-4 during Courses 1C & 2C
45403798|NCT02043587|Drug|Dasatinib|140 mg orally daily if BCR/ABL positive and/or Ph+
45403799|NCT02043587|Drug|Rituximab|375 mg/m2 IV once daily on days 1 & 15 (precursor B-cell ALL only, administer per institutional protocol) during Courses 1A, 1B, 1C & 2A
45511956|NCT04818515|Drug|Atogepant|Oral; Tablet
45511957|NCT04818515|Drug|Ubrogepant|Oral; Tablet
45511958|NCT02760602|Drug|Solanezumab|Administered IV
45511959|NCT02760602|Drug|Placebo|Administered IV
45511960|NCT04855929|Drug|ANV419|ANV419 administered by intravenous (IV) infusion
45511961|NCT04129073|Other|Intensive care treatment|Intensive care treatment; Utilization of neuroprognostication tools
45511962|NCT04853043|Drug|Cetuximab|Cetuximab will be administered every 2 weeks (14 days). The initial dose of 500 mg/m2 is to be administered by IV infusion over 120 minutes on the first day of the treatment. In the absence of infusion reactions, subsequent doses are to be administered over 60 minutes biweekly. Each cycle will be defined as 14 days of treatment.
45511963|NCT04687241|Drug|Almonertinib|The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.
45511964|NCT04687241|Drug|Placebo Almonertinib|Placebo Almonertinib
45698882|NCT03460860|Dietary Supplement|Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)|The intervention is to be taken once daily, for 12 weeks.
45698883|NCT03460860|Dietary Supplement|Placebo|The intervention is to be taken once daily, for 12 weeks.
45403800|NCT02043587|Drug|Hydrocortisone|Randomize patients proceeding to Course 1B to hydrocortisone versus placebo prior to PEG-asparaginase treatments in Courses 1B, 2B, 3B, and Maintenance month 1
45403801|NCT01561222|Drug|Calcitriol|0.25 ug per day for one year
45511965|NCT00976131|Drug|CoQ10|"Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d CoQ10 (2 capsules) Dose Level 2: 600mg/d CoQ10 (4 capsules) Dose Level 3: 1200mg/d CoQ10 (8 capsules)"
45511966|NCT00976131|Other|CoQ10 Placebo|"Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d placebo (2 capsules) Dose Level 2: 600mg/d placebo (4 capsules) Dose Level 3: 1200mg/d placebo (8 capsules)"
45511967|NCT00976131|Drug|Doxorubicin|Standard of care chemotherapy medication used to treat cancer.
45511968|NCT00976131|Drug|Cyclophosphamide|Standard of care chemotherapy medication used to treat cancer.
45511969|NCT01384253|Other|²¹²Pb-TCMC-Trastuzumab|The starting dose level will be 200 μCi/m² of ²¹²Pb-TCMC-Trastuzumab. Three to six patients will be treated at each dose level, and dose escalation will proceed if no more than 1 out of 6 patients in a cohort experiences dose limiting toxicity. Six patients will be treated at the maximum tolerated dose.
45511970|NCT01384253|Biological|trastuzumab|4 mg/kg.
45511971|NCT03697863|Procedure|Noninvasive Respiratory Support|Noninvasive Respiratory Support delivered by conventional flow triggered ventilation or neurally triggered ventilatory assist
45511972|NCT03631277|Device|photo-activated oral disinfection|Application of PAD solution using disposable tip with agitation of the solution for 60 seconds using a brush; Placement of the light disposable tip in center of lesion and holding it just above the surface; Activation of the red light for 60 seconds; (h)Sealing the cavity with glass ionomer and then filling with composite resin as a final restoration
45403802|NCT01561222|Drug|placebo|one pill per day
45403803|NCT05289154|Other|self- applied acupressure plus Qigong course plus advice literature|daily self applied acupressure over 20min plus 2 times per week online live Qigong course of each 45min- both over 8 weeks.
45511973|NCT03631277|Drug|Calcium Hydroxide|calcium hydroxide( Dycal ® Dentsply Caulk )was applied using calcium hydroxide applicator followed by glass ionomer and then composite resin as a final restoration
45403804|NCT05289154|Behavioral|advice literature with naturopathy|advice literature with naturopathic remedies will be handed out and application will be supported with dairies and phone calls
45511974|NCT02171000|Drug|BIBR 1048 MS|150 mg capsules, b.i.d, 7 days
45511975|NCT01378637|Device|AMES- Leg treatment|30 minutes of treatment of the leg consisting of the AMES device passively moving the ankle between plantarflexion and dorsiflexion with vibration of the tendons being stretched, while the participant tries to assist in the movement as much as possible.
45511976|NCT03697785|Device|Beacon Care System|Beacon has been developed by Mermaid Care in Denmark. BEACON is a critical care ventilation assist system (http://beaconcaresystem.com/beacon-5/), which potentially enables better ventilation strategies and a more efficient patient care workflow. As an add-on to standard ventilation systems it provides ventilation recommendations 24/7 based on non-stop, personalised monitoring/diagnostics of patients. Based on unique mathematical algorithms and physiological models, it recommends changes in ventilation settings, supporting the critical decision-making processes.
45511977|NCT04841265|Dietary Supplement|Vitamin D3|The intervention arm will receive 400 IU vitamin D3 from routine antenatal multivitamin supplement tablet + 400 IU vitamin D3 daily until delivery.
45403805|NCT01035515|Drug|Placebo|Single dose oral capsule placebo comparator
45403806|NCT01035515|Drug|BIIB014 50mg|Single dose oral capsule 50mg BIIB014
45511978|NCT02261168|Other|Standardized living protocol|Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
45698884|NCT05215236|Other|Opiate Sparing|Subjects will receive non-opiate medications for pain control
45698885|NCT05215236|Other|Opiate Based|Subjects will receive opiate based medications for pain control
45698886|NCT01191736|Behavioral|No training, assessed within 60 mins|Subjects receive no training in resuscitation
45698887|NCT01191736|Behavioral|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
45698888|NCT01191736|Behavioral|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
45698889|NCT01191736|Behavioral|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
45403807|NCT01035515|Drug|BIIB014 100mg|Single dose oral capsule 100mg BIIB014
45403808|NCT01308892|Dietary Supplement|High flavanol chocolate|chocolate high in flavanols
45403809|NCT01308892|Dietary Supplement|Low flavanol chocolate|chocolate low in flavanols
45403810|NCT01308892|Dietary Supplement|High fat challenge|Milkshake with 95g fat
45403811|NCT01039025|Drug|Topotecan|After stem cells are collected, Topotecan 3.5 mg/m^2 intravenously given over 30 minutes on Days 1 - 5.
45403812|NCT01039025|Drug|Cyclophosphamide|After stem cells are collected, Cyclophosphamide 1 g/m^2/day intravenously given over 2 hours on Days 1 - 3.
45403813|NCT01039025|Drug|Melphalan|After stem cells are collected, Melphalan 70 mg/m^2/day intravenously given on Days 4 and 5.
45403814|NCT01039025|Other|Peripheral Blood Stem Cells|On Day 7, some or all of the stem cells will be reinfused.
45403815|NCT01308970|Behavioral|Stress Management Group 1|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
45511979|NCT03699189|Behavioral|Immediate ANAIS|"ANAIS is a structured therapeutic education programme aimed at providing the patients with the necessary skills to manage their diabetes independently and confidently. The programme particularly promotes dietary freedom, in an intensive insulin regime, by enabling effective carbohydrate counting and accurate prandial insulin dose adjustment and avoiding hypoglycaemia.~ANAIS was organised as a five day (Monday to Friday), seven-hour, outpatient programme using principles of adult education, with explicit learning objectives, in a group setting."
45511980|NCT02164604|Drug|intravitreal injection of 0.03ml ranibizumab|
45511981|NCT04380831|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
45511982|NCT04380831|Drug|Cyclophosphamide|Undergo HSCT
45511983|NCT04380831|Radiation|Intensity-Modulated Radiation Therapy|Undergo TBI using IMRT
45511984|NCT04380831|Procedure|Total-Body Irradiation|Undergo TBI using IMRT
45511985|NCT02168114|Other|Exercising|This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy. Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
45511986|NCT02168114|Procedure|Optical and Magnetic Resonance Imaging and Spectroscopy|This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
45511987|NCT04676048|Biological|ASC618|ASC618 will be given as a single IV infusion
45511988|NCT03852719|Biological|Bulevirtide|Administered via SC injections
45511989|NCT03697473|Other|Nordic hamstring exercise|The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
45511990|NCT03697473|Other|Hip extension exercise|The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
45511991|NCT04571645|Drug|Dociparastat sodium|Dociparstat is a glycosaminoglycan derived from porcine heparin.
45511992|NCT04571645|Other|Placebo|0.9% Normal Saline
45511993|NCT04050267|Drug|Nitrous Oxide|Breathing nitrous oxide, concentrations 5, 7, 10, 12, 15, 20 % in air with 21 % oxygen, in random order.
45511994|NCT04050267|Other|Placebo - air|Breathing air with 21 % oxygen, no nitrous oxide.
45511995|NCT03086057|Behavioral|PrEPare for Work: Strength Based Case Management (Stage 1)|Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
45511996|NCT03086057|Behavioral|PrEPare for Work: Adherence Training and Counseling (Stage 2)|Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
45511997|NCT03697317|Behavioral|Televideo Lifestyle Coaching|Six month total intervention: Three months of weekly 1-hour televideo healthy lifestyle coaching sessions involving 30 minutes of structured physical activity and 30 minutes of nutrition education and daily healthy lifestyle habit tracking. This is followed by 3 months of healthy lifestyle habit tracking only.
45511998|NCT03697317|Behavioral|Enhanced Usual Care|Six months of healthy lifestyle habit tracking with access to written diet and physical activity materials.
45511999|NCT02759120|Drug|Antimicrobial therapy: Co-trimoxazole or Doxycycline|160mg trimethoprim/800mg sulfamethoxazole (double strength co-trimoxazole) twice daily plus folic acid 5 mg daily OR doxycycline 100mg once daily if weight < 50 kilograms or 100mg twice daily if weight > 50 kilograms for up to 36 months
45512000|NCT02759120|Other|No Intervention: Standard of Care|Standard of care
45512001|NCT01569113|Drug|Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)|UPA: 30 mg, 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
45512002|NCT01569113|Drug|placebo + ethinylestradiol/levonorgestrel|placebo: 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
45512003|NCT04435821|Drug|[18F]FTC-146|Participants will be injected with 0.08 mCi/kg [18F]FTC-146. A whole-body PET/MRI scan will be performed after injection.
45512004|NCT03699033|Radiation|2.5 Gy/fraction|Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction to PET-avid Disease Combined with Carboplatin and Paclitaxel
45512005|NCT03699033|Drug|Carboplatin|"The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation."
45512006|NCT03699033|Drug|Paclitaxel|"The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation."
45512007|NCT04451135|Diagnostic Test|Electroencephalographic (EEG)|EEG on nights after ECT session will be recorded using the DREEM device. Sleep EEG data will also be acquired for a minimum of one night prior to the first ECT session, providing a true baseline measure. The DREEM device allows continuous recording of multichannel EEG
45698890|NCT01191736|Behavioral|Ultra-brief video; assessed at 2 months|Subjects see ultra-brief video (90-seconds), are assessed two months later
45698891|NCT01191736|Behavioral|Brief video; assessed 2 months later|Subjects see brief video (5 minutes), are then assessed two months later
45512008|NCT04451135|Diagnostic Test|Closed loop acoustic stimulation (CLAS)|Closed loop acoustic stimulation will be enabled on the DREEM headband on a subset of study participants. The device delivers stimulation in phase with the upstroke of the EEG slow wave (STIM) to boost slow oscillation activity. The timing of this stimulus augments the expression of subsequent slow waves.
45512009|NCT04451135|Diagnostic Test|Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16)|The Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16) is a measure of depression symptom severity that has been validated for clinical and research use53. It is a standard self-report measurement completed by patients prior to each ECT session
45512010|NCT04451135|Diagnostic Test|Ictal Electroencephalographic (EEG) Measurements|A high-density 65-electrode EEG scalp electrode net (EGI/Philips) with Elefix conductive gel injected within Ag/AgCl electrode sensors is utilized to monitor brain activity during the ictal period
45512011|NCT04451135|Diagnostic Test|Post-Ictal Electroencephalographic (EEG) Suppression Measurements|A board-certified epileptologist will review all seizures to assess seizure parameters, including duration of seizure and interval of PGES. Preprocessing of the PGES periods will be accomplished with band-pass filtering from 2 to 30 Hz with 1st order Butterworth filters.
45512012|NCT04451135|Diagnostic Test|Quantitative Measurements of Sleep Microstructure|Following EEG preprocessing of DREEM sleep recordings, SWA will be quantified using a custom-written MATLAB module as the average of total power spectral estimates within the 0.5-4 Hz frequency band in one minute intervals, during the first cycle of N3 sleep.
45512013|NCT03697239|Drug|Ascorbic Acid|25, 37.5, 56.25 or 75 grams/m2
45512014|NCT03697239|Drug|Paclitaxel protein-bound|125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
45851258|NCT02992782|Behavioral|Exercise and Adjustable Compression Wrap|Decongestive progressive resistance exercise using adjustable compression wrap and daily use of a compression sleeve
45403816|NCT01308970|Behavioral|Stress Management Group 2|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
45403817|NCT01308970|Behavioral|Stress Management Group 3|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
45403818|NCT03776968|Drug|HC1119|oral
45403819|NCT03779776|Other|Vitamin AD|In Vitamin AD group, the very preterm infants will receive the daily vitamin AD with vitamin A at 1500 IU/day and vitamin D at 500 IU/day in drop form added to their enteral feeds when minimal feeding is introduced, and continue to 28 days or discharge. In this group ,the patient also will receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
45512015|NCT03697239|Drug|Cisplatin|25mg/m2 in 500*mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
45512016|NCT03697239|Drug|Gemcitabine|1000mg/m2 in 500*mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
45512017|NCT03629015|Biological|Stemchymal®|ALF/ ACLF patients will receive Stemchymal® through intravenous infusion
45512018|NCT02164682|Procedure|IV PCA group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen
45512019|NCT02164682|Procedure|IV PCA+ caudal block group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen + caudal block was 0.15% ropivacaine 1.2 cc/kg; a total volume of 100 cc, basal 2 cc, bolus 0.5 cc, and lockout time 15 minutes.)
45403820|NCT03779776|Other|Control|In this group ,the patient will only receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
45512020|NCT01378559|Other|Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire|A questionnaire accessing satisfaction with a penis prosthesis
45512021|NCT03698955|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following the vegan diet.
45512022|NCT03698955|Other|Mediterranean Diet|Weekly instructions will be given to the participants in the intervention group about following the Mediterranean diet.
45512023|NCT02164760|Device|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
45512024|NCT01380431|Drug|Lisinopril|Tablets, 40 mg, single oral dose
45512025|NCT01380431|Drug|lisinopril|Tablets, 40 mg, single, oral dose
45512026|NCT01380431|Drug|Lisinopril|50% of subjects received the Par formulated product.
45512027|NCT03697161|Drug|OV101 (gaboxadol)|OV101 (gaboxadol)
45698892|NCT01191736|Behavioral|Brief video + hands-on; ass'd 2 ms later|Subjects see brief (5-minute) video, receive hands-on training, and are assessed two months later
45698893|NCT03460782|Biological|Ipilimumab|"Each patient receives Ipilimumab in regimen and dose according to the official manufacturer's instructions (IV 1 mg / kg every 6 weeks for maximum of 4 doses).~Participation of the patient in the program must necessarily be agreed with the current treatment and contain a written agreement with the attending physician.~This program is not covered by health insurance. For patients in the postoperative period to provide a mandatory conclusion of histology and molecular-genetic for the identified mutations and the type of tumor."
45403821|NCT05106478|Device|AuraGain|Ambu® AuraGain, a relatively novel supraglottic airway device, has been introduced recently. AuraGain has an inflatable cuff and a curved body.
45512028|NCT02168192|Behavioral|Simulation-Debrief|Subjects underwent a formal debrief, reviewing the BBN skills exhibited in their prior simulation of an obstetrical communication skills scenario.
45512029|NCT02168192|Behavioral|Traditional lecture|Control group underwent lecture for approximately 10 minutes reviewing BBN skills.
45512030|NCT03164993|Drug|Atezolizumab|Atezolizumab is a monoclonal antibody designed to target and bind to a protein called PD-L1 (programmed death ligand-1), which is expressed on tumour cells and tumour-infiltrating immune cells. PD-L1 interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, Atezolizumab may enable the activation of T cells, restoring their ability to effectively detect and attack tumour cells.
45512031|NCT03164993|Drug|Pegylated liposomal doxorubicin|Chemotherapy
45512032|NCT03164993|Drug|Cyclophosphamide|Chemotherapy
45512033|NCT03164993|Other|Placebo|Placebo
45403822|NCT00412217|Drug|Placebo|Participants will receive placebo tablets (matched to erlotinib) once daily.
45512034|NCT02171156|Drug|nintedanib|soft gelatin capsule
45512035|NCT01380353|Drug|Diclofenac epolamine patch|Patch (10cm X 14cm) is comprised of an adhesive material containing 1.3% diclofenac epolamine which is applied to a non-woven polyester felt backing and covered with a polypropylene film release liner [B].
45512036|NCT02168348|Other|biological examination at consultations at 3 and 6 months|
45512037|NCT01384175|Procedure|intravenous analgesia|Patients received postoperative analgesia with intravenous infusion of fentanyl 10 µg/ml 3-8 mL/h
45512038|NCT01384175|Procedure|epidural infusion|Postoperative analgesia was performed using continuous epidural infusion of ropivacaine 0.2% 3-8 mL/h and fentanyl 2 µg/mL
45512039|NCT01384175|Procedure|patient-controlled epidural analgesia|Postoperative analgesia was performed by continuous epidural infusion of ropivacaine/fentanyl mixture combined with patient-controlled epidural analgesia with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min.
45512040|NCT02171312|Device|iDETECT Assessment|The iDETECT device is an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury. The apparatus includes an enhanced heads-up display visor with integration motion detection technology, noise-reducing headphones optimized with pink noise, and a handheld display for test battery administration, subject response inputs, and user data output. iDETECT will be used to assess multimodal neurologic function in participants.
45512041|NCT02171312|Behavioral|Routine Balance and Vestibular Testing|A clinician will assess balance and vision by standard of care routine tests for neurologic function.
45512042|NCT02168426|Procedure|Guardix|Applying 6g of guardix during abdominal surgery
45851259|NCT02995434|Device|Virtual Reality Headset|"The following VR experiences will be used:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ Carpe Lucem: http://store.steampowered.com/app/433700/Carpe_Lucem__Seize_The_Light_VR/"
45851260|NCT02995434|Other|2D PC|"The control group will be exposed to 2D equivalent versions of the same multimedia experiences but on their PC screen (without the VR headset use). These will be functionally similar to the VR experiences. These will include:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ The Witness: http://store.steampowered.com/app/210970/"
45851261|NCT02999880|Procedure|Polychromatic layering|Only two composite resin material shades will be used (opaque dentine composite and enamel shade composite).
45851262|NCT02999724|Drug|Gabapentin|Gabapentin 300-600 mg 1 hour preop
45851263|NCT02999724|Other|placebo|placebo capsule(s) 1 hour preop
45403823|NCT00412217|Drug|Erlotinib|Erlotinib will be given as 150 mg PO once daily.
45403824|NCT00412217|Other|Standard of care|Additional clinical management including surgical resection and chemoradiotherapy or radiotherapy alone will be at the discretion of the Investigator according to local standard of care.
45403825|NCT04532242|Behavioral|Cognitive reappraisal|Participants will be trained to follow instructions to look/respond naturally or use cognitive reappraisal to reframe or reconsider a negative picture to decrease negative emotion.
45512043|NCT02168426|Procedure|Seprafilm|Applying 1 sheet of seprafilm during abdominal surgery
45698894|NCT01192282|Procedure|Medical / Surgical Treatment|All participants received treatment based on the morphology and distributions of lesions. For the treatment with Trichloroacetic Acid (TCA), patients were advised to attend the clinic weekly until no visible lesions seen. For electrosurgery or laser, patients were given a date for admission a day prior to surgery. Post-operatively, she remained in the ward for at least five days.
45698895|NCT04607382|Drug|LEP|LEP dosage up to the discretion of the treating gynecologists.
45698896|NCT04607382|Drug|NSAIDs and/or Chinese medicine (CM)|Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Chinese medicine (CM) dosage up to the discretion of the treating gynecologists.
45698897|NCT01192828|Drug|taurine|Take Taurine for 4 1/2 days, two doses per day
45403826|NCT05510440|Dietary Supplement|Alpha-amino acid derivatives|Alpha-amino acid derivatives mainly citrulline will be used as a supplement to reduce kidneys and other internal organs damage
45403827|NCT01312558|Behavioral|Prudent diet group|
45403828|NCT01312558|Behavioral|Mediterranean diet group|
45403829|NCT01035593|Procedure|plasmapheresis and IVIG|Plasmapheresis with either 5% human albumin or FFP replacement, plus IVIG 100mg/kg IV after each PP session, every other day x 5 treatments
45403830|NCT01035593|Drug|recombinant C1 inhibitor|100units/kg IV for seven consecutive days (once daily on PP/IVIG days, twice daily on non-PP/IVIG days).
45403831|NCT03784534|Other|Imaging|high= density (64 sensors) EEG and anatomical MRI (T1 and tensor imaging) scan
45512044|NCT04812717|Device|CytoSorb device|The CytoSorb device will be placed in the CPB circuit in half of the study population during their cardiac operation.
45851264|NCT02999490|Radiation|18F-FDG|18F-FDG is positron emission tomography imaging agent which is already widely used in PET/CT examination.
45403832|NCT03784534|Behavioral|Clinical and behavioral testing : Motor recovery progress|NIHSS with motor subitems and Rankin and Barthel score, measure of functional independence and Hemispatial neglect, test of Ashworth
45403833|NCT03784534|Behavioral|Clinical and behavioral testing : Motor skills|the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, Fugl Meyer
45512045|NCT01380275|Drug|Docetaxel (Taxotere)|This study : Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
45512046|NCT01380275|Drug|Irinotecan|This study : Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
45512047|NCT02171390|Drug|Testosterone 250mg injection|The testosterone 250mg ester intramuscular injections performed in three weeks
45512048|NCT02171390|Drug|Testosteron 50 mg transdermal gel|50mg testosterone gel implemented on every night
45512049|NCT03697005|Other|BioHPP PEEK single posterior crowns|BioHPP is a 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymeric material, used for fabrication of high strength fixed and removable prostheses. it has advantages of bio-compatibility, low density, light weight, shock absorption.
45403834|NCT03776734|Other|Cryotherapy application|Effects of 5-10- 20 minutes cold application on quadriceps muscle
45512050|NCT03697005|Other|zirconia-based single posterior crowns|ZrO2, a ceramic material used for medical devices, displays good esthetic appearance, high mechanical strength, and high biocompatibility and is used in a wide range of indications, such as frameworks, implants, and abutments. In addition, it's very good long-term stability and reliability was proven in a 10-year clinical study. These excellent material properties and the transformation behavior are explained by the yttrium oxide stabilization of ZrO2.
45512051|NCT01378481|Drug|Vorinostat|Given PO
45403835|NCT01317784|Device|Rapid tests for HIV, HCV, HBV, and syphilis|Choice of 16 different rapid tests. Only 12 manufacturer and names are shown because some are used with both blood and oral fluid. When they are used on both specimens, they are counted as two tests.
45512052|NCT01378481|Radiation|Stereotactic Radiosurgery|Undergo fractionated stereotactic radiation therapy
45512053|NCT01378481|Other|Laboratory Biomarker Analysis|Correlative studies
45512054|NCT01378481|Other|Pharmacological Study|Correlative studies
45403836|NCT01317784|Device|HIV/HCV|Choice of 10 different tests for HIV and hepatitis C.
45403837|NCT01317784|Device|HIV/syphilis|Choice of 7 different tests for HIV and syphilis
45512055|NCT01378481|Procedure|Therapeutic Conventional Surgery|Undergo neurosurgery
45512056|NCT02168582|Behavioral|physiotherapy as usual in primary care|
45512057|NCT02171468|Drug|Dabigatran high dose|
45512058|NCT02171468|Drug|Dabigatran low dose|
45512059|NCT03502031|Drug|Renin-Angiotensin (RAAS) alone|maximal RAAS blockade alone for 24months.
45512060|NCT03502031|Drug|Renin-Angiotensin (RAAS) blockers in combination with Spironolactone|maximal RAAS blockade alone or in combination with Spironolactone (25 mg) for 24 months.
45403838|NCT01317784|Device|HIV only|Choice of 4 different tests for HIV only.
45403839|NCT01318330|Drug|Homeo-GH|Bone Marraw derived Clonal Mesenchymal Stem Cell (cMSC)
45403840|NCT03780088|Behavioral|mTranS-C|mobile health
45403841|NCT03779698|Other|BiodentineTM|In the experimental group, BiodentineTM was used following the manufacturer's recommendations. The whole pulp chamber was entirely filled with BiodentineTM until the occlusal surface. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
45403842|NCT03779698|Drug|Formocresol|In control group, a sterile cotton pellet moistened with 1:5 concentration formocresol then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
45512061|NCT02168738|Drug|13-C labeled AceDoPC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
45698898|NCT01099618|Drug|metformin|The study subject will receive metformin (MET) 1000 mg tablet once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
45512062|NCT02168738|Drug|13-C labeled TG-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
45512063|NCT02168738|Drug|13-C labeled PC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
45512064|NCT04372953|Procedure|Positive End-Expiratory Pressure (PEEP)|"PEEP is the delivery of any level of positive pressure to the lungs during expiration, by any method of assisted respiratory support. As the intervention in the Delivery Room PEEP will be administered via any of:~Continuous Positive Applied Pressure (CPAP; non-invasive respiratory support) During CPAP, no other type of positive pressure is delivered as the infant supports tidal ventilation using her/his own spontaneous breathing effort.~Positive Pressure Ventilation (PPV) During PPV, PEEP is delivered between periods of an applied inflating pressure (PIP) delivered at a clinician-determined rate. PPV can be delivered via a mask or other non-invasive interface (also termed non-invasive positive pressure ventilation; NIPPV), or via an endotracheal tube (often termed continuous mechanical ventilation; CMV)."
45512065|NCT02171546|Drug|Dabigatran etexilate capsules|
45512066|NCT02171546|Drug|Quinidine sulfate tablets|
45512067|NCT02171546|Drug|Fexofenadine tablets|
45512068|NCT04385693|Procedure|Pulpotomy|Pulpotomy using bioactive bioceramic cement of 1.5 mm layer of a newly FDA approved calcium-based silicate cement (Nusmile NeoPutty) will be placed on the pulp chamber floor and canals' orifices for pulp and root therapy. Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health.This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, complete caries removal and then access to the pulp chamber using drills.
45512069|NCT04385693|Procedure|Extraction and placement of space maintainer|If during the pulpotomy procedure, hemostasis is not obtainable, or signs of advanced pulp degeneration such as dark and limited or no bleeding from canals, the pulp will be diagnosed as chronically inflamed or necrotic, and tooth will be extracted. As part of the standard of care after extractions of primary molars, space maintenance will be assessed, and a space maintainer fabricated if indicated. Extracted teeth will serve as controls, and information regarding the need or not of space maintenance.
45512070|NCT02171624|Drug|dabigatran etexilate|
45512071|NCT02171624|Drug|quinidine|
45512072|NCT03705351|Device|Tumor Treating Fields|Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Treatment will begin approximately 1 week prior to start of radiation and temozolomide treatment and continue concurrently throughout the duration of the study.
45512073|NCT03705351|Drug|Temozolomide|Patients will be given temozolomide according to routine treatment dosing and schedule.
45512074|NCT03705351|Radiation|Radiation Therapy|Patients will be given radiation therapy according to routine treatment dosing and schedule.
45512075|NCT02691767|Drug|pazopanib|
45512076|NCT03696849|Other|polished emax Press|lithium disilicate glass ceramic crowns subjected to polishing only
45512077|NCT04360083|Other|Collected data from Rhône RéPPOP database|BMI Z-scores at the start and the end of RéPPOP care programs.
45512078|NCT04360083|Other|telephonic questionnaire|Collected data though the telephonic questionnaire : current declared BMI Z-score.
45512079|NCT04398849|Biological|Licenced 4CMenB Vaccine|Two doses (0.5 mL each) of Bexsero ® vaccine at least 2 months apart to be given to consenting 14-19 year olds
45512080|NCT03696693|Device|acoustic vocal analysis|Computerized Speech Laboratory (model 4300; Kay Elemetrics Corporation)
45512081|NCT03698721|Procedure|Transurethral Resection of Prostate|Transurethral resection of the prostate is a urological operation used to treat benign prostatic hyperplasia (BPH). It is performed by visualising the prostate through the urethra and removing tissue by electrocautery or sharp dissection with a resectoscope. This is considered the most effective treatment for BPH. This procedure is done with spinal or general anaesthetic. A triple lumen catheter is inserted through the urethra to irrigate and drain the bladder after the surgical procedure is complete. Outcome is considered excellent for 80-90% of BPH patients.
45512082|NCT04263207|Other|No intervention|No intervention
45403843|NCT03779542|Procedure|cataract surgery|phacoemulsification and intraocular lens implantation
45403844|NCT03779464|Drug|S1 or Gemcitabine|Gemcitabine 1000 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area < 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area >1.5 m²; D1-14, q3w)
45403845|NCT05489380|Device|AccuMeasure|intracolonoscopy measurement of polyps using a laser-based device
45403846|NCT03776578|Procedure|swallow fuction and swallow training|nasogastric tube dependence rate
45403847|NCT01314820|Other|normal saline injection|20 cc normal saline injection into knee joint
45403848|NCT01314820|Other|sham injection|no saline injection
45512083|NCT03692793|Other|Pulmonary rehabilitation|Patients will perform continuous aerobic training (treadmill walking) during 30min (60% of the 6MWT mean speed) and progression according to dyspnea (4-6 of the modified Borg scale). Upper limbs resistance training will be performed using the modified diagonals from the proprioceptive neuromuscular facilitation method (2 sets of 2min). Lower limbs strength training will be performed for quadriceps and triceps sural (2 sets of 10 repetitions), with progression when the patients report that the exercise are ´easy´. All the muscle exercised and the breathing accessory muscles will be stretched for 30s. Eleven educational sessions will be delivered addressing topics related to COPD self-management.
45512084|NCT03692637|Biological|anti-Mesothelin Car NK Cells|anti-Mesothelin Car NK Cells injection
45512085|NCT03692559|Other|full aseptic dressing|Replacement of the central venous catheters in the dressing process
45512086|NCT03705195|Drug|Gliclazide|Low dose liquid gliclazide will be used with the second matched clamp (OGTT/IGII) in visits 4 & 5.
45512087|NCT03705117|Biological|V565|Capsules for oral administration
45512088|NCT00101192|Biological|cetuximab|
45512089|NCT00101192|Drug|cisplatin|
45512090|NCT03688269|Drug|Intravenous dexamethasone|Intravenous injection of 8mg/2ml dexamethasone
45512091|NCT03688269|Drug|Intravenous saline|Intravenous injection of 2ml Saline 0.9%
45512092|NCT03688269|Drug|Perineural ropivacaine|Perineural injection of 20ml ropivacaine with adjustment of the concentration determined by sequential up and down method
45512093|NCT03688191|Drug|Sirolimus|Patients will receive oral sirolimus at a starting dose of 2 mg per day for 3 days and a sequential dose of 1mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/mL.
45512094|NCT02255708|Other|Proprioceptive Neuromuscular Facilitation - PNF|
45512095|NCT03540602|Dietary Supplement|Tart Cherry|NordicCherry Tart Cherry Extract Powder 500 mg from Specnova, inc
45512096|NCT03540602|Other|Placebo Oral Capsule [CEBOCAP]|Rice flour
45403849|NCT03784690|Other|Individualized intraoperative BP management|"In the treatment group, the nurse will measure resting blood pressure three times in the ward one day before surgery (after a 5-min rest while lying supine). Average measurement will be used to calculate mean arterial pressure (MAP).~Before and after CPB patients will receive continuous infusion of norepinephrine to maintain MAP within ± 10% of patients resting MAP. If targeted MAP during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will used. After CPB, the choice of vasopressors/inotropes to maintain predefined MAP will be left on attending anesthesiologists based on patient status."
45512097|NCT02164838|Drug|Axitinib|
45851265|NCT02999568|Other|Physical exercise|Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years will be recruited. These women will will be asked to fulfill the International Physical Activity Questionnaire and additional questionnaire regarding relevant demographic and medical information. Blood samples to anti-mullerian hormone , leptin, and hormonal profile will be obtained in day 3 of menstruation. Ultrasound will be performed to measure Antral Follicular count and ovarian blood flow
45512098|NCT03688113|Behavioral|Tinnitus application|Use of tinnitus application
45403850|NCT03784690|Other|Standard intraoperative BP management|Standard treatment strategy will be used aiming to maintain pre-bypass and post-bypass MAP at 65-75 mm Hg. MAP during CPB will be maintained at 50-60 mm Hg. If MAP of 50-60 mm Hg during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will be started. No vasodilators will be used if MAP will exceed predefined range.
45512099|NCT02171702|Drug|BIBW 2992|
45698899|NCT01099618|Drug|placebo|The study subject will receive a placebo tablet once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
45698900|NCT01099618|Drug|Sitagliptin|The study subject will receive a sitagliptin 100mg once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
45851266|NCT02999256|Dietary Supplement|Montmorency Tart Cherry Juice|
45851267|NCT02999256|Other|Placebo|
45512100|NCT03031431|Device|Non-Electric Infant Warmer|Electric warmers are the standard of care in developed countries, but are extremely costly, complicated with risk of causing both hypo and hyperthermia with misuse, and often not feasible in settings without stable electricity. Through a multi-institutional collaboration, the investigators have developed an electricity-free infant warmer.
45512101|NCT03540056|Diagnostic Test|Ultrasound|We use ultrasound to measure the PRF and the testicular volumes.
45512102|NCT03696615|Other|Tabata Kettlebell Swing Workout|See description of experimental arm.
45512103|NCT03696615|Other|Control|see description of control arm
45512104|NCT02171780|Drug|BI 1744 CL|
45512105|NCT02171780|Drug|Placebo|
45512106|NCT03540524|Drug|GLPG2451 dose regimen A|GLPG2451 oral suspension, daily.
45512107|NCT03540524|Drug|GLPG2451 dose regimen B|GLPG2451 oral suspension, daily.
45512108|NCT03540524|Drug|GLPG2222|GLPG2222 tablet for oral use, daily.
45512109|NCT03540524|Drug|GLPG2737|GLPG2737 capsules for oral use, daily.
45512110|NCT03539978|Other|SM-THINk|Patients will receive the SM-THINk enhanced discharge method.
45512111|NCT02255864|Device|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
45596803|NCT05791981|Behavioral|Harmony & Health Intervention|"Participants will attend group in person sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation.~Participants will be instructed to practice the exercises at home 2 times each week during the entire 6-month period. You will be given instructions and a yoga mat, belt, and block. After your Week 9 assessment, you will attend in-person or Zoom sessions 1 time each month over the final 4 months of the study"
45698901|NCT01099774|Drug|Bimatoprost 0.03% Formulation B Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
45698902|NCT01099774|Drug|Bimatoprost 0.03% Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
45698903|NCT03013192|Other|Text message reminder|Patients will receive automated text message reminders regarding their physical therapy
45698904|NCT01328574|Drug|TRC105|15 mg/kg intravenously
45698905|NCT03460626|Drug|Lavender Oil|The oil used in this study will be lavender oil with a final concentration of 3% using almond oil (90%) as diluent. The oil after dilution and final preparation will be converted to proper clean vial in a fix amount (10 ml) and given to the students.
45512112|NCT02168894|Procedure|Acupuncture|"Group 1: Acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study.~Group 2: Acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study.~Group 3: Acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment."
45512113|NCT02168894|Procedure|Nerve Function Tests|Nerve function tests consisting of hand tasks and balance evaluation performed at visit before acupuncture, and at end of study visit.
45512114|NCT02168894|Behavioral|Questionnaires|Questionnaire completion at baseline, visit before acupuncture, after 6th and 12th acupuncture session, and at end of study visit.
45512115|NCT02171936|Other|Questionnaire EPICES (Evaluation of the Precariousness and the Disparities of Health for the Centers of Examination of Health).|
45512116|NCT05142488|Biological|Covid -19 (recombinante) vaccine|Third dose of the Covid-19 (recombinante) vaccine, 6 months after the second dose of a two dose Covid-19 (recombinante) homologous vaccine schedule.
45512117|NCT02172014|Drug|midazolam and fentanyl citrate infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
45512118|NCT02172014|Drug|midazolam and normal saline infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
45512119|NCT02168972|Device|Global mapping and ablation device|During the procedure the Globe catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the LA will be followed by pulmonary vein isolation (PVI) by RF ablation. Additional lesions will be created as deemed appropriate by the investigator.
45403851|NCT05091502|Diagnostic Test|Personalised musculoskeletal modeling|Magnetic resonance images, electromyography and dynamometry data will be used to develop personalised musculoskeletal models
45403852|NCT01309048|Device|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
45512120|NCT02165150|Other|Wheelchair-bound Senior Elastic Band exercise program|three times per week, 40 minutes per practice
45512121|NCT02165228|Behavioral|Mindfulness-based stress reduction|Stress reduction class and behavioral intervention
45403853|NCT01309126|Biological|Imprime PGG + cetuximab|Imprime PGG: 4 mg/kg and will be administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36) preceding the administration of cetuximab Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
45403854|NCT01309126|Drug|Cetuximab|Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
45512122|NCT02165228|Behavioral|Nutrition Enhancement|Nutrition education class and behavioral intervention
45512123|NCT02172092|Drug|SodiumChloride|Infusion of SodiumChloride, blood samples to calculate extracellular volume.
45512124|NCT02261246|Procedure|Spinal manipulation treatment|Up to 4 sessions of spinal manipulation treatment (once per week).
45512125|NCT02165306|Behavioral|Motivational Interviewing (MI)|"A multifaceted intervention program was used to improve adherence and clinical outcomes in epileptic patients. However, this study mainly focused on behavioral treatment in the patients.~Patient's intervention A three-week session will perform to improve medication adherence in patients in the intervention group. Face to face introductory motivational interviews (MI) will conduct to resolve patient ambivalence about change.~Besides providingthe intervention for the patients, the health care team and the patient's family member will receive a brief intervention.All GPs and nurses as well as patients' family members participate in a single session MI with the same procedure"
45512126|NCT02165306|Behavioral|Routine counseling|All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 5 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
45512127|NCT02169206|Radiation|Bilateral shoulder anteroposterior radiography|"Patient standing with the tube in front and 105 cm far from the shoulder radiating perpendicular to the cassette in the back, both arms hanging aside the trunk in 0 degrees of arm abduction, 0 degrees of rotation and 0 degrees of extension with the thumb facing forward to obtain true bilateral shoulder anteroposterior view. Voltage and exposure time differs regarding each person's body mass.~In the same position, the patient only elevates the arm up to 90 degrees of abduction."
45512128|NCT03539120|Other|Follow up for survival|No intervention, this is an observational study of survival outcomes.
45512129|NCT02169362|Device|Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)|Application of up to 18 mL of autologous PRP gel (Magellan® Bio-Bandage™) to the surface of an acute deep partial thickness burn wound no greater than 72 cm squared within 72 hours of the initial injury. Intervention is in addition to standard of care treatment. The PRP Bio-Bandage™ is prepared using the Magellan® System and is FDA cleared via BK030040 and BK040068.
45698906|NCT03460626|Other|Placebo|an odorless oil without any therapeutic effect
45698907|NCT04453410|Other|Questionnaire Quality-of-recovery 15 (QoR-15)|Children will use the questionnaire Quality-of-recovery 15 (QoR-15)
45698908|NCT04453488|Biological|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli.
45698909|NCT04453488|Biological|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo
46057265|NCT02711709|Other|Mobility Monitors|Mobility monitors will be placed on the patients during the duration of their hospital stay. They will then where them at 3, 6 and 12 months for up to 10 days.
45403855|NCT03784378|Drug|RXDX-105|RXDX-105 capsules will be administered orally on a continuous daily dosing regimen. Patients will be continue to be treated at the dose level they were previously treated on during participation on Study of RXDX-105.
46057266|NCT00611637|Biological|CMV pp65 Specific T Cells|Donor derived CMV pp65 specific T cells (1 x 105 CD3+ cells/kg (maximum 1 x 107 CD3+ cells) will be infused into recipient over 10 minutes.
46057267|NCT04188795|Procedure|Delirium Preventive Care Protocol|"Nursing care was applied to hip fracture patients in the experimental group in accordance with the care protocol developed to prevent delirium. Delirium preventive care protocol was consist of; psychosocial care, monitoring of oxygen saturation, prevention of dehydration, nutritional support, normal elimination, pain control, sleep regulation, avoidance of bladder catheterization and early mobilization.~Confusion Assessment Method, Barthel Index and Richards-Campbell Sleep Questionnaire were repeated to patients on the first postoperative day and on the third day."
46057268|NCT02711397|Other|Observational study|Comparison excretion levels of gluten immunogenic peptides
45512133|NCT02172170|Drug|BI 10773 single rising dose|
45512134|NCT02172170|Drug|Placebo|
45512135|NCT02255942|Other|Ferric Pyrophosphate and Zinc Oxide|Rice fortified with Ferric Pyrophosphate and Zinc Oxide (ZnO)
45512136|NCT02255942|Other|Ferrous sulfate|Rice fortified with Ferrous Sulfate (ZnSO4)
45512137|NCT02255942|Other|Ferric Pyrophosphate and Zinc Sulfate|Rice fortified with Ferric Pyrophosphate and Zinc Sulfate
45512138|NCT02255942|Other|Ferric Pyrophosphate|Rice fortified with Ferric Pyrophosphate
45512139|NCT03029247|Drug|Daprodustat|Daprodustat will be available as oral tablets at unit dose strength of 1, 2, 4, 6, 8 and 10 mg.
45512140|NCT03029247|Drug|Epoetin alfa|Epoetin alfa will be administered according to local labelling and clinical practice guidelines to keep Hgb in the target range (10.0-11.0 g/dL)
45512141|NCT03696459|Drug|JNJ-53718678, 2000 mg|Participants will be administered JNJ-53718678, 2000 mg as oral suspension in Part 1 (Panel 1).
45512142|NCT03696459|Drug|JNJ-53718678, 3000 mg|Participants will be administered JNJ- 53718678, 3000 mg as oral suspension in Part 1 (Panel 2).
45512143|NCT03696459|Drug|JNJ-53718678, 4500 mg or Dose to be decided|Participants will be administered JNJ-53718678, 4500 mg as oral suspension in Part 1 (Panel 3). If this dose is considered safe and tolerable and if pharmacokinetic data require further dose escalation, then participants will receive JNJ-53718678 (Dose to be decided) in Part 1 (Panel 4). This dose (either from Panel 3 or Panel 4 ) will be used in Part 2 (Dose may be lower/higher based on review of safety, tolerability, and PK data obtained in Part 1).
45512144|NCT03696459|Drug|JNJ-53718678 500 mg|Participants will be administered JNJ-53718678, 500 mg as oral suspension in Part 2.
45512145|NCT03696459|Drug|JNJ-53718678 Placebo|Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.
45512146|NCT03696459|Drug|Moxifloxacin 400 mg|Participants will be administered moxifloxacin 400 mg as capsule in Part 2.
45512147|NCT03696459|Drug|Moxifloxacin Placebo|Participants will be administered moxifloxacin matching placebo in Part 2.
45512148|NCT03696381|Other|Real tRNS|The treatment consists of a set of 1-h sessions, three sessions per week for 8 weeks. A series of cognitive exercises of attention, memory, and executive functions will be conducted in each session. During the first 20 minutes of each cognitive training session, patients will receive bi-frontal and bi-parietal tRNS. It has a start and end ramp of two seconds in each case to avoid the slight unpleasant sensation that occurs in the first moments of the introduction of direct current DC.
45403856|NCT03784456|Dietary Supplement|25% protein|Compared to usual group of 15% protein in meals, intervention group will receive 25% protein contents under same estimated calorie menus. Protein may come from either egg, meat, fish, soy, or milk product.
45403857|NCT03784456|Dietary Supplement|15% protein|Designed as comparator , compared to empirical arm of 25% protein in meals, intervention group will receive 15% protein contents under same estimated calorie menus. Protein may come from either egg, meat, fish, soy, or milk product.
45403858|NCT01314898|Drug|3 mg PF-03882845|3 mg PF-03882845, single oral dose
45403859|NCT01314898|Drug|10 mg PF-03882845|10 mg PF-03882845, single oral dose
45403860|NCT01314898|Drug|30 mg PF-03882845|30 mg PF-03882845, single oral dose
45512149|NCT03696381|Other|Sham tRNS|The treatment consists of a set of 1-h sessions, three sessions per week for 8 weeks. A series of cognitive exercises of attention, memory, and executive functions will be conducted in each session. We will apply a sham tRNS for the first 20 minutes of each cognitive training session. The subjects will receive sham tRNS and will perform the same type of cognitive training as the rest of patients and will receive the same type of adverse reaction questionnaire. Subjects receiving simulated stimulation will receive the same type of ramps at the beginning and end of the session to ensure triple-blind maintenance .
45512150|NCT03624153|Behavioral|Robotic-assisted intervention|Participants received the 12-session robot-assisted intervention 3 sessions a week for 4 consecutive weeks. Each session consisted of 20-minute continuous passive motion, 20-minute active motion practice, and 30-minute task-oriented practice.
45512151|NCT03624153|Behavioral|Conventional rehabilitation intervention|Participants received the 12-session conventional rehabilitation intervention 3 sessions a week for 4 consecutive weeks. The intervention consisted of warm up including range of motion exercise, and strengthening exercise followed by task-oriented training for activities of daily living.
45512152|NCT03624075|Other|application of kinesio taping|application of kinesio taping in the rectus femoris muscle and in the medial and lateral region of the knee
45512153|NCT03692247|Other|Smartphone-based Music Intervention|The smartphone-based music intervention (Unwind) is a music protocol that gathers basic information from the patient including a 0-10 pain scale and 0-10 anxiety scale as well as recorded heart rate. Using these variables, a machine learning protocol pieces together a music intervention between 5-20 minutes long. The duration of the intervention can be controlled by the patient or experimenter. No identifying data is kept on the smartphone.
45512154|NCT03692169|Procedure|Half-dose photodynamic therapy|Half-dose photodynamic therapy was achieved by administering 3mg/m² of Verteporfin (Visudyne; Novartis, Switzerland) intravenously over a period of 10 minutes. Fifteen minutes after commencing the verteporfin infusion the greatest linear dimension was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm². Optical coherence tomography angiography (OCTA) with the split-spectrum amplitude-decorrelation angiography algorithm (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
45512155|NCT03624309|Drug|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
45512156|NCT03624309|Drug|Docetaxel|Docetaxel (75mg/m2 IV d1)
45512157|NCT04327791|Drug|Baloxavir|administered PO once
45512158|NCT04327791|Drug|Placebos|administered PO once
45512159|NCT03624387|Other|Painting Sessions|During the GIA painting session, each participant will be given a white canvas, four brushes and four different colors of painting.Their only instruction will be to cover the white color of the canvas. At the end of each session, the performance of the participants will be evaluated based on their neuropsychological conditions before and after Geriatric Inclusive Art session.
45512160|NCT04050111|Biological|Stromal-vascular fraction|Concentrate of stromal-vascular fraction of cells derived from autologous adipose tissue
45512161|NCT03624231|Drug|Durvalumab|Durvalumab (1500 mg) starting on week 1 to complete a total of 12 months
45512162|NCT03624231|Drug|Tremelimumab|Tremelimumab (75 mg) for up to 4 doses/cycles
45512163|NCT03624231|Radiation|Radiotherapy|Radiotherapy with 35 fractions (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks)
45512164|NCT03687879|Other|Questionnaires|Reporting of medical gestures or acts, speech, embarrassing or hurtful attitudes during pregnancy follow-up or during hospitalization outside childbirth, or during childbirth or immediate after birth among women giving birth in one of the 26 maternity hospitals in the period of observation period.
45512165|NCT03696147|Device|Magnetic resonance imaging|Diffusion weighted sequence of MRI
45403861|NCT01314898|Drug|100 mg PF-03882845|100 mg PF-03882845, single oral dose
45512166|NCT03687801|Behavioral|Online hearing support|The intervention group will follow an online hearing support for five weeks
45403862|NCT01314898|Drug|Spironolactone|100 mg spironolactone, single oral dose
45403863|NCT03779386|Other|music|music during labor and delivery
45403864|NCT03779308|Device|whole body vibration therapy|The study participants will receive the WBVT when standing still on a vibration platform independently or with own hand support on the platform rail. The vibration protocol is modified from the study by Gusso et al (2016). The WBVT training is of 20 Hertz, a peak-to-peak amplitude of 2 mm and peak acceleration of 15.79m/s or 1.61g. The sessions will be 18 minutes in length, 4 days per week for 4 weeks. The vibration frequency, duration and amplitude will be progressively increased over 2 weeks to the desired parameters.
45512167|NCT03687801|Behavioral|Standard care|The control group will follow standard care during the time the intervention group receives online haring support
45512168|NCT03687645|Diagnostic Test|Hyperpolarised MRI|Hyperpolarized (HP) 13C MR is an advanced imaging technique that allows monitoring of dynamic metabolic processes non-invasively. Hyperpolarisation is a process that provides dramatic gains in sensitivity (>10,000) of MRI signal collected from 13C-labelled substrates that can be injected into living systems, allowing in-vivo metabolism for the first time to be observed in real-time using imaging.
45512169|NCT03692091|Procedure|Subacromial Injection|Injection in to subacromial space in the shoulder from anterior portal
45403865|NCT03776422|Behavioral|Mobile self-help intervention|Participants receive several apps on their phone including IntelliCare apps, which are based on principles of cognitive-behavioral therapy. Participants also receive the Pocket Helper app, which has been designed for this study. The tools within the Pocket Helper app include a crisis text line that is available 24/7, the Illinois Warm Line which is available Monday through Friday from 8am to 5pm, directions to call 911 in the case of an emergency, the Koko web app that provides crowdsourced emotional support, brief cognitive-behavioral interventions, daily tips, and daily surveys. Phones will also include the StreetLight Chicago app, which provides homeless individuals with up-to-date information on shelters, health clinics, emergency contacts, mental health services, and more.
45403866|NCT03778918|Other|inflammatory bowel disease|blood based biomarkers in IBD such as REG3 alpha, serum calprotectin and hs-CRP
45403867|NCT03778918|Other|IBS or Normal Control|blood based biomarker compared normal control with IBD
45403868|NCT03784144|Diagnostic Test|Biering-Sorensen Test and Prone Plank Test|All patients will be encouraged to achieve the maximum time to task failure, stopped only by muscular fatigue or pain precluding to maintain the position.
45403869|NCT05519644|Other|Sleep Deprivation|The sleeping protocol will be monitored by investigators and personnel with experience in sleep medicine. Participants will be required to reduce sleep by 50% of normal, for 4 consecutive nights, to observe potential deficits in physical and cognitive performance
45403870|NCT05519644|Other|Heart Rate|HR will be assessed by wrist-based acceleration with cloud technology (Polar Unite™, Polar USA). This monitor is less burdensome than other sleep monitoring technologies and less likely to interfere with normal sleep and activity demands of the cadets. Each participant will be fitted with the watch for acclimatization and then establish 3-day baseline patterns for 3 nights before the sleep loss protocol.
45403871|NCT05519644|Other|Sleep Monitoring|Sleep will be assessed by wrist-based acceleration with cloud technology (Polar Unite™, Polar USA). This monitor is less burdensome than other sleep monitoring technologies and less likely to interfere with normal sleep and activity demands of the cadets.Each participant will be fitted with the watch for acclimatization and then establish 3-day baseline patterns for 3 nights before the sleep loss protocol.
45403872|NCT05519644|Other|Diet|Diet will be included and the same meals will be available for all subjects while controlling for caffeine. Participants will be given food during each intervention week.
45403873|NCT05519644|Other|Exercise Performance|Since weight training is now a crucial part of any warfighter's physical preparation, we will have subjects perform weight training workouts emphasizing all major muscle groups on Days 2, 3 and 4
45403874|NCT05519644|Behavioral|Surveys, McGill Pain Questionnaire, Shortened Profile of Mood States, Pittsburg Sleep Index|These will be administered on Days 1 and 5 of each intervention trial to assess different behavioral outcomes.
45512170|NCT03695991|Procedure|percutaneous nephrostomy|The percutaneous nephrostomy will be done under sonographic or fluoroscopic guidance. Establishment of intravenous access and antibiotics will be performed half an hour prior to procedure particularly in patients presenting with urinary tract infection. The procedure will be done under local anesthesia but general anesthesia may be used for uncooperative patients. percutaneous nephrostomy will be performed in the prone position, however, in case of relative contraindication to prone position
45698910|NCT01100242|Drug|Velcade and Sorafenib|Velcade will be administered intravenously; sorafenib will be self-administered on an outpatient basis. At least 2 courses will be administered to each patient unless there is early progression of disease or unacceptable toxicity. Repeated courses may be given to patients who benefit from the treatment (complete or partial remission or stabilization of disease)
45698911|NCT05159388|Drug|PRS-344/S095012|PRS-344/S095012 Monotherapy
45403875|NCT05519644|Other|Cognitive performance|Automated Neuropsychological Assessment Metrics (ANAM), Cambridge Neuropsychological Test Automated Battery. (CANTAB),Gradual-onset Continuous Performance Task (GRAD-CPT),Face-Name Task will be used to assess cognitive function and performance.
45403876|NCT05519644|Other|Marksmanship Performance|The Virtual Training Simulator (VirTra V-100) system (VirTra Corporate HQ, Tempe, AZ) is used by both military and law enforcement agencies to provide training. The V-100 and associated compatible weapons are equipped with recoil kits for unsurpassed live-fire simulation, at distances up to 2,000-m, authoring capabilities for the creation of customized scenarios on 4 individual firing lanes. Multiple metrics of marksmanship (total number of shots fired/silhouette target presentation, percentage of targets successfully hit/min, the radial distance of a shot from the center on target, shot group tightness, and time from target presentation to trigger pull) will be collected during each visit.
45403877|NCT05519644|Other|Quick Board|Upper body and lower body reaction tests will be assess using Quick Board Analysis on days 1 and 5 of the sleep restriction intervention.
45403878|NCT05519644|Other|Advanced Medical Technologies Inc, Jump Test|Whole body power will be assessed with a repetitive jump test. Power (peak, average, curve functions) will be assessed using an AMTI force plate with Accupower 2.0 software (Advanced Mechanical Technology Inc, Watertown, MA).
45403879|NCT05519644|Other|CGM/CKM|Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at ~2- week intervals during the study. The sensor will be removed at the end of the final test day.
45403880|NCT05519644|Biological|Blood Draw|Blood samples will be collected according to the schedule in Figure 1.
45403881|NCT05519644|Dietary Supplement|Ketone Supplement|Participants will take a diester of hexanoic acid (a ketogenic medium chain fatty acid) and (R)-1,3 butanediol (C6 Di-ester) during one of the trial interventions
45403882|NCT01560676|Behavioral|HEALTH[e]TEEN|8 lessons over 6-8 weeks
45851268|NCT02999334|Behavioral|Group Antenatal Care|To examine the effect of type of care on completion of the recommended antenatal and postnatal visits as well as perinatal health outcomes, including knowledge, behaviors, psychosocial well-being, pregnancy-related empowerment, satisfaction with ANC care.
45403883|NCT01560676|Behavioral|HEALTH[e]TEEN + CST|12 lessons over 6-8 weeks
45403884|NCT01315366|Dietary Supplement|Euro D and Ci-CalD|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) daily, plus a supplement of vitamin D3 (20,000 IU/wk) for one year.
45403885|NCT01315366|Dietary Supplement|Euro D, Ci-CalD|Ci-Cal D(1000mg/day) and vitamin D (500IU/day) Ci-CalD daily, plus a weekly placebo Euro D supplement for one year.
45403886|NCT03778762|Procedure|Blind tracheal intubation through AirQ|underwent blind intubation with correction manoeuvres
45403887|NCT03778762|Procedure|Fiberscopic tracheal intubation through AirQ|: underwent fibreoptic guided intubation
45403888|NCT01315756|Device|Use of Few Touch Application (FTA)|"The users will receive a Smartphone with the diabetes diary application (the Few Touch application), a self-help tool that consists of five main elements accessible to the user. The five elements are the food habits registration, blood glucose data management system, physical activity registration, personal goals setting and general information. While blood glucose data is automatically transferred to the phone from the blood glucose meter when the user has performed a measurement, activity data and food habits have to be entered manually by the user."
45512171|NCT03692013|Drug|Losartan|Participants will be divided into 2 groups as daytime group and nighttime group The participants in daytime group will take 100-200mg Losartan in the morning between 6AM to 8AM. The participants in nighttime group will take 100-200mg Losartan at night between 9PM to 11PM .
45512172|NCT03687489|Device|Abdominal Aortic Aneurysm Stent Graft System|Abdominal aortic bifurcation stent and iliac artery extension stent were preloaded into abdominal aortic bifurcation stent transporter and iliac artery extension stent transporter, respectively. In the operation, the abdominal aorta bifurcation stent and the iliac artery extension stent will be delivered to the corresponding lesion position of the abdominal iliac artery and release. The abdominal aortic bifurcation stent and the iliac artery extension stent will form a whole through docking and thereby reducing the risk of rupture of an infrarenal abdominal aortic aneurysm due to the shock of blood flow.
45512173|NCT04313283|Behavioral|Parents Taking Action|A peer-led intervention, Parents Taking Action is the psychoeducational and child behavior management intervention led by trained Parent Leaders.
45698912|NCT01148836|Dietary Supplement|Coenzyme Q-10 in Pulmonary Hypertension subjects|Take 100mg Co-Q for three times daily
45698913|NCT01148836|Dietary Supplement|Coenzyme Q-10 in Normal Control subjects|Take 100mg Co-Q for three times daily
45698914|NCT03460548|Device|Remogen|instil 1 drop of the product in each eye, 4 times per day
45698915|NCT03460548|Device|Cationorm|instil 1 drop of the product in each eye, 4 times per day
45698916|NCT01149616|Drug|Dexamethasone 8mg iv x1|Dexamethasone 8mg iv x1
45698917|NCT01149616|Drug|placebo|2 ml normal saline IV x1
45698918|NCT03465462|Dietary Supplement|group/arm C (control group)|Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
46057269|NCT02711631|Behavioral|MedBIKE|MedBIKE is an exercise cardiac rehabilitation system that allows participants to perform clinical cardiac rehabilitation at home or at a local center, instead of having to travel to the hospital. It provides a high level of physiological monitoring to allow patient safety to be continually monitored while exercising.
46057270|NCT02711085|Other|No intervention|No intervention - observational study
46057271|NCT02711319|Device|rTMS|For real (active) rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes
46057272|NCT02711319|Device|sham rTMS|"Sham Comparator: sham rTMS (SHAM GROUP)~For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2)."
46057273|NCT04616547|Other|Questionnaire Administration|Ancillary studies
46057274|NCT04616547|Radiation|Tin Sn 117m Pentetate|Given IV
46057275|NCT00735943|Other|No intervention|No intervention
46057276|NCT02693613|Drug|ASP1517|Oral
45403889|NCT01315756|Device|Use of FTA and health counseling based on TTM and CBT|The users will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via SMS from the diabetes nurse which is based on the patient's initiative (via SMS). In addition, the diabetes nurse will call the patients three times during this period and discuss progress. Both the SMS-messages and the calls will be based on CBT according to the TTM-level. The intervention allows information to be given both in an individualized and tailored manner for each particular patient by the nurse, but also in a general way via SMS. The patients need to understand the relationship between areas such as glucose levels, diet, exercises and medicine, in the context of their own lifestyle needs.
45403890|NCT01319656|Behavioral|Support, management, educational, counselling, follow-up|The project offers a range of activities (educational, counselling, follow-up) by several professionals. The varied range of services is spread out over six months and may include individual or group meetings with professionals. Informational documents and follow-up tools are provided to patients based on their condition, to facilitate the acquisition and maintenance of knowledge, self-management, and changes in risk behaviour.
45403891|NCT03778684|Diagnostic Test|Visceral fat thickness|An initial longitudinal sweep will be done from the xiphoid process to the umbilicus to determine the area of maximum pre-peritoneal fat thickness.
45403892|NCT03778684|Diagnostic Test|Body mass index|Weight and height will be measured with subjects in a standing position wearing light clothes and no shoes.
45403893|NCT01315912|Drug|Letrozole|2.5 mg /day for 5 days
45403894|NCT03784222|Drug|Blonanserin|patients were prescribed blonanserin 4-24mg/d according to the patients' response and tolerability
45403895|NCT03784222|Other|MRI and serum BDNF|60 patients receive MRI and serum BDNF test, 60 controls receive MRI, 20 of the 60 controls receive serum BDNF test
45403896|NCT01319890|Procedure|Patients will be divided in two groups- those having right colectomy by standard laparoscopy and those having Single Incision Laparoscopic Surgery (SILS)|Patients will be divided into 2 arms- those with right colon tumors treated by conventional laparoscopic right colectomy and those having a Single Incision Laparoscopic Surgery (SILS)
45403897|NCT03783910|Drug|GRT9906|One prolonged-release tablet containing 40 mg of GRT9906
45403898|NCT03783910|Drug|Placebo|Placebo matching GRT9906 tablets
45403899|NCT03778450|Drug|Analgesics, Opioid|"Patients are included in the long-term opioid group if they started an opioid-therapy between 2013 and 2017 and received consecutive prescriptions for opioid medications over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The treatment will be assessed using the ATC codes of opioid~treatment N02AA01, N02AA05, N02AB03, N02AE01, N02AX02, N02AX01, N02AX06) reported in reimbursed medicines to patients."
45403900|NCT03778450|Drug|Non-Opioid Analgesic|Patients with non-opioid pain medication are included, if they received a medication therapy with anticonvulsants (gabapentin, pregabalin, carbamazepine), antidepressants or non-opioid analgesics (NSAIDs, Metamizole) over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The non-opioid treatment will be assessed using the ATC codes (N03AX12, N03AX16, N03AF01) of treatment reported in reimbursed medicines to patients.
45512174|NCT03695835|Drug|Immunotherapeutic Agents|Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
45403901|NCT03776500|Drug|PBTZ169|PBTZ169 crystalline supplied as powder for oral solution
45403902|NCT03776500|Drug|Placebo|matching placebo supplied as powder for oral solution
45403903|NCT01319968|Drug|Estriol 0.1% vaginal cream|Patients with both vulvovaginal atrophy (according to cytologic criteria) and dyspareunia will apply 0.5 ml of the cream (0.5 mg) to the vulvar vestibule once daily for one month and will return for check-up visit. In case both atrophy and dyspareunia will resolve, treatment with the cream will be continued 3 times a week.
45403904|NCT05000164|Device|Bausch + Lomb Ultra® Multifocal for Astigmatism|Study Lens
45512175|NCT03695835|Device|Ablation|Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
46057277|NCT02693613|Drug|Kremezin®|Oral
45403905|NCT03778528|Procedure|cataract surgery|tissue collection.
45403906|NCT03776110|Drug|GRT9906 PR tablet|40 mg GRT9906 PR tablet oral (minimal release of 80 percent after 480 minutes)
45403907|NCT03776110|Drug|Placebo|Placebo tablet matching 40 mg GRT9906 PR tablet
45403908|NCT03778216|Behavioral|Family Based Treatment|
45512176|NCT03691701|Other|strict blood pressure control|Home SBP target < 120 mmHg or 90th percentile for age and height (whichever is lower)
45512177|NCT03695757|Biological|Part A) Healthy subjects|Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
46057278|NCT04087837|Device|bougie|The endotracheal tube is used in the bougie mode under the direct view of the electronic imaging laryngoscope.
46057279|NCT04087837|Device|Nasogastric(NG) tube|The endotracheal tube is used in the NG tube mode under the direct view of the electronic imaging laryngoscope.
46057280|NCT02711241|Drug|Dipyrone|1 gram by slow IV infusion
46057281|NCT02711241|Drug|Papaverine|80 mg by slow intravenous infusion
45403909|NCT05616130|Other|Data Collection|Researcher will collect data from subject's medical records: information regarding your medical history, trauma injury, heart rate, blood pressure, temperature (vital signs), use of antibiotics (medications used to treat infection) and other medications, development of infection, and treatment results will be recorded and kept with your research records. Demographic information (such as name, address, phone number, gender, race, height and weight, age and birth date), medical record notes (including but not limited to history and physical exam notes, progress notes, consultation reports, laboratory test results, operative reports, information relating to acquired immunodeficiency virus (HIV) infection, radiologic (x-ray studies) results, and blood samples)
45512178|NCT03695757|Biological|Part B) Advanced solid tumor|Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
45512179|NCT03687255|Drug|cefepime/AAI101 combination|cefepime 2 g / AAI101 500 mg
45512180|NCT03687255|Drug|Piperacillin/tazobactam|piperacillin 4 GM / tazobactam 500 MG
45403910|NCT05616130|Procedure|Bone marrow collection and blood collection|At time of scheduled surgery, researcher will collect a 20ml (approximately 4 teaspoons) sample of bone marrow while you are in the operating room receiving surgery for your orthopedic (bone) injuries or elective hip repair. Blood collection will occur at time of surgery, day 14 on study or discharge from hospital and at 3 and 6 months. Up to 58 ml (about 4 tablespoons) sample of blood will be collected from an existing intravenous line or peripheral needle stick.
45403911|NCT05616130|Other|Serial interviews to complete surveys and questionnaires|Participants will be asked to complete questionnaires and surveys that assess your health, quality of life, daily living activities, and mobility. These activities occur at enrollment, day 14 in hospital or discharge, and at the 3, 6, and 12-month visits.
45512181|NCT03695523|Behavioral|PLAY (PhysicaL ActivitY) Policy Intervention|An evidence-based physical activity policy that was developed by researchers and childcare stakeholders and directed by the Canadian 24-Hour Movement Guidelines for the Early Years will be adopted by experimental group childcare centres for 8 weeks. The policy incorporates 8 items (i.e., encouraging children to engage in higher intensity energetic play often, aiming to accumulate 40 minutes each day, exposing children to a variety of indoor and outdoor physical activities, child-directed and teacher-facilitated active play daily, short bouts of outdoor time for a total of 120 minutes each day made up of primarily unstructured free play, encouraging physical literacy by practicing fundamental movement skills, not exposing children to screen-based technology during childcare, and purposefully breaking up sustained sedentary time using physical activities).
45512182|NCT03687177|Other|With visual cue and nurses informed|Using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
45512183|NCT03687177|Other|Without visual cue and nurses informed|Not using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
45512184|NCT03691545|Behavioral|interactive sessions|This arm will receive personalized health coaching (behaviour change counseling)
45512185|NCT03691467|Device|immediate dental implant|immediate dental implant placement in freshly extracted socket.
45512186|NCT03691467|Drug|Hyaluronic Acid|topical application of hyaluronic acid
45512187|NCT03968211|Biological|Salmonella typhi polysaccharide vaccine|Salmonella typhi polysaccharide vaccine
45512188|NCT03695289|Behavioral|iOTA SMI|Participants randomized to the iOTA SMI arm will undergo an assessment of individual behavior risks, will participate in collaborative goal-setting with a health coach, and will use an interactive text system that will provide ongoing support and self-monitoring of behavior change goals.
45512189|NCT03695289|Behavioral|Health Education Control|Participants randomized to the Health Education Control arm will receive monthly counseling on energy balance, physical activity and nutrition.
45512190|NCT02760368|Drug|Olokizumab|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
45698919|NCT03465462|Dietary Supplement|group/arm D (diet group)|Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
46057282|NCT02594059|Other|endothelial function|measure of reactive hyperemia-peripheral artery tone index
46057283|NCT02711163|Dietary Supplement|Extensively Hydrolyzed formula|
45512191|NCT02760368|Drug|Placebo|sodium chloride 0.9% solution supplied in polypropylene plastic ampoules of 10 mL cartons to contain 10 ampoules
45512192|NCT02165540|Other|Doula|A specially trained support person or doula will accompany the patient to offer physical and emotional support during the procedure.
45512193|NCT02165618|Other|Medication review, based on but not limited to the RASP list|"Systematic approach:~Medication reconciliation~Applying the RASP list~Expert review (not based on the RASP list)~Multidisciplinary discussion"
45512194|NCT02165696|Other|Multimodal treatment: compression bandaging and manual lymph drainage.|30 minutes and one hour maximum time of manual lymphatic drainage and compression bandaging with multilayer inelastic bandages with low extensibility. It is possible to apply bandages two or three times per week. Also, an elastic bandage is also held in hand fingers with slight compression and other protective bandage is used in skin. The treatment will be carried out for six weeks five days a week
45512195|NCT02165696|Other|Manual lymph drainage|30 minutes and one hour maximum time of manual lymphatic drainage. The treatment will be carried out for six weeks five days a week.
45512196|NCT03539588|Device|trigger point dry needling|placement of the dry needle into the muscle tissue to elicit a local twitch response. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
45512197|NCT03539588|Device|Electrical Stimulation|uses the dry needles as nodes to stimulate muscular contraction. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
45403912|NCT05616130|Other|Telephone follow up call|The study team will contact you at 12 months to complete a telephone interview to learn about your health and well being.
45403913|NCT03776266|Procedure|No intervention is required due to retrospective observational study|Red blood cell transfusion on or after percutaneous coronary intervention
45403914|NCT03776344|Device|Virtual Reality intervention - Oculus Rift HD|During the VR experience patients will have the opportunity to choose from different VR environments (VR application - Nature Treks VR) and explore them using Oculus Rift Device.
45512198|NCT03695211|Procedure|Conventional landmark technique|inject at the midpoint of the posterior border of the sternocleidomastoid muscle
45512199|NCT03695211|Procedure|Precise block technique|inject at the point where the great auricular nerve emerges the posterior border of the sternocleidomastoid muscle
45512200|NCT03687099|Other|no intervention|Histological samples from 10 GBM removed from patients with long-term survival and 10 GBM removed from patients with short-term survival
45512201|NCT02165774|Device|Turning OFF the neuromodulator|Turning OFF the neuromodulator in 50% of the patients in a randomized way by an investigator not involved in the assessment of the clinical outcome during the regular outpatient visit 2 months after neuromodulator implantation. It then follows a 2 months double-blind phase. Thereafter, i.e. during the regular outpatient visit 4 months after neuromodulator implantation, the unblinding takes place and in patients with sacral neuromodulation OFF, the neuromodulator is switched ON.
45512202|NCT02165774|Device|Turning ON the neuromodulator|
45512203|NCT02165852|Procedure|Papillectomy without injection|Conventional endoscopic mucosal resection of ampulla of Vater using a snare with electrocurrent.
45512204|NCT02165852|Procedure|Papillectomy with injection|Conventional endoscopic mucosal resection of ampulla of Vater without submucosal saline or diluted epinephrine injection.
45512205|NCT03695133|Behavioral|Group-based interventions|"Group-based interventions Elderly women will have a walk for physical activity for 12 weeks, three days a week. It is planned that each of the sightseeing, picnic, theater and cinema activities will be done twice. The topics that elderly women need most for group educations will be determined. Group educations will be held once every four weeks approximately three hours.~Individual interventions After the pre-tests are applied to the women in the intervention group, the home environment and the individual's health problems will be assessed, interventions will be implemented and the results will be evaluated during home visits at online. During the home visit to the elderly women and twelve-week intervention period, each woman will meet four times and initiatives will be implemented."
45512206|NCT02165930|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with water, under fasting conditions
45512207|NCT02165930|Drug|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before,and 12 hours after study drug administration).
45512208|NCT02165930|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with 40% ethanol, under fasting conditions
45512209|NCT02165930|Drug|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
46057284|NCT02711163|Dietary Supplement|Amino acid formula|
46057285|NCT02711007|Drug|apatinib|Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor, similar to vatalanib (PTK787), but with a binding affinity 10 times that of vatalanib or sorafenib.
46057286|NCT04226235|Behavioral|Yoga session|a 1-hour yoga session was completed by all participants following a DVD.
46057287|NCT02776839|Device|Mobile sensing|
45403915|NCT03783988|Combination Product|DHEA and TRIAC|The new topical gel contains dehydroepiandrosterone (DHEA) and triiodothyroacetic acid (TRIAC)
45403916|NCT03778138|Drug|Anlotinib plus Pemetrexed|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2 IV d1)
45403917|NCT03777670|Diagnostic Test|Blood test|Drop of blood for RNA and metabolic analysis
45403918|NCT03777748|Device|dental implants and stud attachments|
45403919|NCT03783754|Drug|telmisartan 20 mg + amlodipine 2.5mg + indapamide 1.25mg|low-dose combination therapy
45403920|NCT03783754|Drug|Placebo oral capsule|matched placebo
45403921|NCT03783832|Other|OCT ANGIOGRAPHY DATA|Follow-up of diabetic macular edema treated by Aflibercept (EYLEA®) with OCT angiography
45403922|NCT01309438|Drug|Rivaroxaban (normal renal function)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2
45512210|NCT03695055|Drug|Maintenance therapy post-HSCT|Rituximab vs DPP/DCEP-G vs observation
45512211|NCT03694977|Drug|MCS110/PDR001 combination|MCS110 7.5mg/kg iv since 1st cycle PDR001 300 mg iv since 2nd cycle Q 3weeks
45512212|NCT02172248|Drug|BI 10773|
45512213|NCT02172248|Drug|Metformin|
45512214|NCT03691233|Drug|Clinical audit on diagnosis and management of neonatal shock|intervenous
45596804|NCT05791981|Behavioral|Attention Control|Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and well-being topics. After your Week 9 assessment, you will have the ability to attend additional in-person or Zoom health education sessions 1 time each month over the final 4 months of the study.
45403923|NCT01309438|Drug|Rivaroxaban (mild and moderate renal impairment)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 5 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 3
45596805|NCT05791981|Device|Fitbit|Participants will be given a Fitbit and instructions on how to use it. The Fitbit will record your physical activity and report it to the study staff.
45403924|NCT01309438|Drug|Erythromycin (normal renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Period 2
45403925|NCT01309438|Drug|Erythromycin (mild and moderate renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Periods 2 and 3
45403926|NCT03776032|Drug|Darbepoetin alfa|Administered by subcutaneous injection once a week
45403927|NCT03776032|Drug|Placebo|Placebo matching to darbopoetin alfa administered by subcutaneous injection once a week.
46057288|NCT04193241|Procedure|Closure of chest tube wound|At the time of chest tube removal, the chest tube site or thoracostomy wound will be closed in such a way as to prevent an iatrogenic pneumothorax or contamination of the pleural space
45403928|NCT03775798|Drug|Direct antiviral agents for hepatitis C|Direct-acting antivirals for hepatitis C
45403929|NCT01309516|Behavioral|Complex Intervention|This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component and a parenting programme.
45403930|NCT03775876|Procedure|Shoulder Arthroscopy|patients in both groups are programmed for an elective shoulder arthroscopy surgery
45403931|NCT03775876|Procedure|Regional Block|patients in both groups received regional block for anesthesia: brachial plexus blockade was performed using the interscalene approach under ultrasound combined to nerve stimulation. 20 ml ropivacaine 0.375% were injected.
45403932|NCT03775876|Drug|Propofol|propofol 10mg/ml was used for sedation as described in the arms section
45403933|NCT03775876|Drug|Dexmedetomidine|Dexmedetomidine was diluted to 4mcg/ml and used for sedation as described in the arms section
45403934|NCT03775876|Diagnostic Test|BIS|sedation level was monitored using bispectral index to achieve values described in the arms group
45403935|NCT01320514|Drug|Fibrin Sealant (Artiss)|
45403936|NCT03773536|Drug|Artesunate-amodiaquine given with single low dose primaquine|Three day treatment with ASAQ with SLD primaquine given with the first dose of ASAQ.
45403937|NCT03773848|Procedure|Open Reduction Internal Fixation (ORIF)|Open Reduction Internal Fixation (ORIF) of fracture lateral third clavicle by hook plate & tightrope
45403938|NCT01320592|Drug|PD0332991|
45403939|NCT01320592|Drug|Paclitaxel|
45403940|NCT03773692|Behavioral|Passive feedback and JITAI|"Second Phase - PA Level Feedback~A PA recommendation handout based on PA guidelines for individuals with SCI will be provided. Participants continue to use the same sensing equipment as in phase one (baseline). The equipment consists of a smartwatch, a smartphone, and a wheel rotation monitor. Participants can view their feedback whenever they want, but will not be prompted with the information.~Third Phase - PA Level Feedback and Just-in-time Adaptive Intervention (JITAI)~The third phase of the study will be similar to the second phase of the study, but with an additional JITAI component. The JITAI component of the study will include providing proactively-prompted, real-time feedback through the smartphone and smartwatch when the participant performs a bout of moderate PA."
45403941|NCT03783676|Drug|Remifentanil|Receive remifentanil bolus and infusion guided by an algorithm.
45403942|NCT03783676|Drug|Normal saline|Receive normal saline bolus and infusion guided by the remifentanil algorithm.
45596806|NCT05791955|Behavioral|Reminder of preventive care measures|"The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures."
45403943|NCT03783598|Behavioral|Person centered, occupation based intervention support with problem solving therapy|This program that was developed from the occupational therapy perspective which is person centered and occupation based for T2D intervention was designed as 6 modules. The intervention group received person centered, occupation based intervention support with problem solving therapy as 6 modules. The control group had not any intervention, just had a education about effect of diabetes on life.
45403944|NCT01309594|Procedure|Hematopoietic stem cell transplantation|Harvest and apheresis of bone marrow cells from HIV infected patients with cirrhosis under general anesthesia, using bone marrow collection system and transplanting the patients' hematopoietic stem cells back to the patients
45403945|NCT01320748|Behavioral|Dual Processing|A 10-week, 20-session program, which meets two times per week for 2 hours each time. It is a psychosocial intervention that combines a visual processing (structured drawing activities to engage in sensory-based cue exposure) and a verbal processing component (structured cognitive-behavioral therapy). The treatment focuses on sensory-based emotional expression and cognitive reappraisal and containment strategies that facilitate emotional regulation around a patient's drug and alcohol use experiences.
45403946|NCT01320748|Behavioral|Relapse Prevention|The program's standard care outpatient program is a Relapse Prevention 10-week, 20-session, psychosocial intervention program, which meets two times per week for 2 hours each time. This RP program is based on Gorski's Relapse Prevention model and is a primarily didactic approach.
45403947|NCT03775642|Behavioral|Intervention video|The intervention video will employ the debiasing strategies. It will avoid directly articulating contraception-related myths, but instead will provide a limited number of alternative explanations related to IUD and implant safety.
45403948|NCT03775642|Behavioral|Control video|The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration
45403949|NCT04422886|Device|active transcranial direct current stimulation (tDCS)|20 minutes at 2.0 mA with electrodes positioned at Cz and Fpz (as per 10-20 electrode placement guidelines)
45403950|NCT04422886|Behavioral|Physiotherapy|motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
45403951|NCT04422886|Device|sham transcranial direct current stimulation (sham)|1 minutes at 1.0 mA with electrodes positioned at Cz and Fpz (as per 10-20 electrode placement guidelines) and 19 minutes with unit shut off and electrodes remaining on the scalp
45403952|NCT03783520|Device|Er,Cr:YSGG Laser|Er,Cr:YSGG Laser is used for disinfection of the root canals.
45403953|NCT03783520|Other|Sodium hypochlorite|Sodium hypochlorite is used for disinfection of the root canals
45403954|NCT05582200|Diagnostic Test|Positron Emission Tomography (PET) using two PET tracer under IND|Positron Emission Tomography
45403955|NCT03775720|Behavioral|Dietary advice|Based on their genetic risk, participants are given advice to either adhere to general dietary guidelines related to salt intake or to reduce their salt intake to no more than 4 grams per day.
45403956|NCT01320904|Procedure|NMES|"We used a electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings. Initially, a warm-up protocol that was five minutes long was used at a stimulation frequency of 40 Hz to activate the slow fibers. These fibers activated with a four-second-contraction time (on), a four-second-stimulus rise time, a four-second-stimulation decay time and a 12-second relaxation time (off).~We then increased the frequency to 70 Hz to activate the fast fibers for an additional 10 minutes using the parameters described above, and finally, the frequency was increase to 150 Hz for 10 minutes to achieve maximal muscle potentiation."
45403957|NCT01320904|Procedure|Closed Kinetic Chain|During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
45403958|NCT03775564|Other|REMEDRUGBY PROGRAM|"1st Session presentation of the programme, its objectives and a common reflection on the concepts of stigmatization/destigmatization.~2nd to 4th session devoted to a group reflection on social conventions and their meaning followed by a practice by means of role-playing.~5th to 7th session devoted to writing comments about tournaments on the blog by working on the intentions of others and the emotional impact of comments on their recipients.~8th, 9th 11th sessions devoted to media relations with group reflection on the image of themselves and their pathology that participants wish to refer to the media, followed by a practice in role-playing games Interviewer-interviewed~10th session devoted to planning and organizing the day of matches with writing a program of the day and spreading on the blog~12th General Debriefing session Including : - 3 tournaments~8 hours of Touch Rugby"
45403959|NCT03775564|Other|TOUCH RUGBY PROGRAM|Practical training Program at Touchrugby at the rate of 12 weekly sessions of 2 hours and 3 inter-institutional tournaments per day
45403960|NCT03775564|Other|TAU|Treatment as usual
45403961|NCT01320982|Drug|minocycline|minocycline 100 mg/bid
45403962|NCT01320982|Drug|pramipexole|pramipexole 0.125, 0.25, 0.5 and 0.75 mg/bid
45403963|NCT01320982|Drug|acetylsalicylic acid|acetylsalicylic acid 500mg/ bid
45403964|NCT01320982|Drug|placebo|placebo bid
45403965|NCT04431232|Device|Endoscopic Band Ligation|Band ligation of the gastric body for weight loss
45403966|NCT01321060|Procedure|Aspiration|
45403967|NCT01321060|Procedure|Catheter drainage|
45403968|NCT01321060|Drug|Conservative treatment|Including antibiotics,somatostatin, proton pump inhibitors and sufficient fluid resuscitation
45512215|NCT05142410|Diagnostic Test|Analysis of post-translational histone modifications via mass spectrometry|"During the GrossHist study (NCT04205383), only 3 post-translational histone modifications available in ELISA at the time were quantified thanks to a collaboration with the VOLITION™ company [Bouvier and Fortier et al. 2021]. The development of a new mass spectrometry approach based on nucleosome enrichment of plasma, developed by collaborators at VOLITION™, has made it possible to consider the description of all post-translational histone modifications (about 40 post-translational modifications involving histones H2A, H2B, H3 and H4)."
45403969|NCT03773224|Procedure|Irrigation|upon closure of the peritoneum gentamicin-saline solution (160 mg of gentamicin in 400 ml of normal saline 0.9%) will be used for irrigation of every layer of the wound before its closure
45403970|NCT03783208|Drug|G-CSF|Slow infusion of G-CSF into the endometrial cavity using a soft embryo transfer catheter.
45403971|NCT03783208|Other|Saline|Slow infusion of saline into the endometrial cavity using a soft embryo transfer catheter.
45403972|NCT03773068|Drug|BAY1817080 - Formulation A|Formulation A
45403973|NCT03773068|Drug|BAY1817080 - Formulation B|Formulation B
45403974|NCT03773068|Drug|[13C715N]-BAY 181708 stable isotope label (SIL)|0.1 mg [13C715N]-BAY181708, 15 minutes i.v. infusion at the estimated tmax after administration of Formulation B
45403975|NCT04893382|Procedure|PlasmaLyte for fluid resuscitation|Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to PlasmaLyte infusion (as clinically prescribed).
45403976|NCT04893382|Procedure|Ringer's Lactate for fluid resuscitation|Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to Ringer's Lactate infusion (as clinically prescribed).
45403977|NCT01321138|Procedure|Femoral nerve block|The femoral nerve block will be performed with ultrasound 30 minutes before the intervention
45403978|NCT01321138|Procedure|PCA morphine|Postoperative analgesia with self-administration iv morphine
45403979|NCT01320046|Other|Questionnaires, gynecological exam , vaginal smear, and measurement of urine leakage|"Patients will undergo the following evaluation:~Questionnaires- age, medical background, BMI, UI characteristics , usage of pads, other hygiene practices,hormonal therapy, presence of allergic tendency and history etc.~Medical history.~Gynecological exam including bladder/rectum/uterine prolapse, vaginal atrophy, discharge, findings of VCD (as part of the usual evaluation in the clinic).~Vaginal smear: this will be used for vaginal pH measurement and for wet mount, which will assess estrogen deficiency, yeast infection and other inflammatory conditions. Vaginal smears are done as part of the usual evaluation in the clinic.~Evaluation of the severity of urinary incontinence will be done by collection and weighting of pads during 24 hours."
45512216|NCT03691155|Other|The Crohn's Diet|All recruited participants will be educated on the Crohn's Diet and instructed to adhere to the study diet for 14 days.
45512217|NCT02172326|Drug|Tiotropium inhalation capsules for oral inhalation|Powder inhalation via HandiHaler®
45512218|NCT02169596|Drug|Ticagrelor|Blood tests taken for flow cytometry
45512219|NCT02169596|Other|EndoPAT - endothelial assessment|
45403980|NCT05540782|Behavioral|PROMIS-SF v2.0 -Cognitive Function 8a|Patient-Reported Outcomes (PROs)
45403981|NCT01309750|Radiation|Small Bowel Transit Study|Patients that are enrolled and consented in the study will be given 300ml of water containing 5 millicurie (mCi) of technetium-99m (Tc-99m) diethylenetriamine pentaacetate (DTPA). This nuclear tracer/water mix will either be drank orally or placed down a nasogastric tube to begin the study. The patient will have to have nothing else to eat or drink for the duration of the study. The patients will have a nuclear scan performed at 2, 4, and 6 hours after ingestion of the nuclear tracer.
45403982|NCT03772756|Procedure|Endoscopic ultrasound guided radiofrequency ablation|Endoscopic ultrasound guided radiofrequency ablation （EUS-RFA） will be done in 3 different sessions with 2 weeks interval between each session on Day 1, Day 15 and Day 30. Each session will involve multiple applications of EUS-RFA (up to 10) with RF setting of 25 Watts over 90 seconds for each application.
45512220|NCT02166008|Drug|Repamipide|
45512221|NCT02166008|Drug|Placebo|
45512222|NCT02166086|Procedure|Endoscopy|Endoscopy involving advanced imaging techniques
45512223|NCT02169752|Drug|Ambrisentan|"Subjects will be randomized 1:1 ratio according to computer generated random numbers to receive either placebo or ambrisentan 5mg daily for one month followed by 10 mg daily for the 5 months in a double-blinded manner."
45512224|NCT02172404|Device|Placebo capsule administered via the HandiHaler®|
45512225|NCT02172404|Device|Ipratropium metered dose inhaler (MDI)|
45512226|NCT03538964|Procedure|toric intraocular lens|cataract surgery with implantation of an toric intraocular lens
45512227|NCT03538964|Procedure|non toric intraocular lens|cataract surgery with implantation of a non toric intraocular lens
45512228|NCT02166164|Other|Brief thermal sensitization|A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
45512229|NCT02166164|Other|Long thermal stimulation|A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
45512230|NCT02166164|Other|Heat-pain-detection threshold|"The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered.~4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements."
45512231|NCT02169908|Device|Thermotest|
45512232|NCT02169908|Device|von Frey hairs|
45512233|NCT02166320|Device|Partially covered SEMS|
45512234|NCT02166320|Device|Fully covered SEMS|
45512235|NCT02166398|Drug|UI15AML055MT|tab, PO
45512236|NCT02166398|Drug|Amosartan 5/50|tab, PO
45512237|NCT00109538|Drug|Lonafarnib|200 mg twice daily (BID, ie, approximately 12 hours apart with food), oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
45512238|NCT00109538|Other|Placebo|BID, oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
45512239|NCT02172482|Drug|Tiotropium bromide|Tiotropium bromide18 micrograms (capsule with powder for inhalation)
45403983|NCT03772756|Radiation|chemoradiotherapy|Receive chemoradiotherapy
45403984|NCT03775252|Dietary Supplement|Ketogenic diet|Diet rich in fats and poor in carbohydrate, to induce metabolic ketosis
45403985|NCT04664998|Diagnostic Test|Diagnostic test for NG/CT|All participants will receive diagnostic testing for NG/CT at each quarterly visit.
45403986|NCT04664998|Diagnostic Test|HIV testing|All participants will receive diagnostic testing for NG/CT at each quarterly visit.
45403987|NCT03772678|Drug|LSALT peptide|novel 16 amino acid peptide
45403988|NCT03772678|Other|0.9% Saline|saline
45403989|NCT04628572|Drug|Ceftazidime-avibactam|Non-Interventional Study
45403990|NCT03772912|Device|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
45403991|NCT03772990|Drug|Calcium Chloride|Calcium Chloride
45403992|NCT03772990|Drug|0.9% Sodium Chloride|0.9% Sodium Chloride
45512240|NCT02169986|Behavioral|electronic reminders|
45512241|NCT02172560|Drug|Tiotropium|
45512242|NCT00106808|Drug|Muraglitazar|
45512243|NCT00106808|Drug|Pioglitazone|
45512244|NCT02166554|Other|Saline|On the day of initial surgery
45512245|NCT02166554|Device|Cross-linked Hyaluronan Hydrogel|On the day of the initial surgery
45512246|NCT02170142|Device|MRI|non-invasive MRI techniques (DTI) and (ASL) will be used to assess normal brain development. DTI is capable of invasively delineating macroscopic anatomic components with high contrast and revealing structures at the microscopic level. ASL is capable of measuring cerebral blood flow and cerebral metabolic rate of oxygen.
45512247|NCT02172638|Procedure|Fast-Track Protocol|
45512248|NCT02172638|Procedure|Usual management|
45512249|NCT03538886|Procedure|Coronary artery bypass grafting (CABG)|Revascularization of LAD lesion by CABG
45512250|NCT03538886|Procedure|Percutaneous coronary intervention (PCI)|Revascularization of LAD lesion by PCI
45512251|NCT03539510|Behavioral|HF-ACP Website|Each module is broken down into weekly topics and each module takes 3-6 weeks to complete. Participants can access and review the material as often as needed as well as revisiting the information from modules they have completed.
45512252|NCT03538730|Behavioral|Memory Reframing|The intervention will draw from existing narrative-based interventions, past pain memory reframing interventions and findings from our recent data. Specifically, parents will be taught to reminisce with their children about the in-hospital and post-surgery periods by encouraging children to provide more explanations, using less utterances about pain, avoiding repetitions, emphasizing positive aspects of the child's surgery memory (e.g., when children used coping methods such as deep breathing, when they got a treat), and enhancing children's self-efficacy regarding their ability to cope with pain.
45512253|NCT02172716|Procedure|Nonsurgical periodontal treatment|"All patients with GCP will receive full-mouth scaling and root planning under local analgesia in one session. Hopeless teeth will be treated similarly and extracted after de 30 days visit. Oral hygiene instructions will be given as needed.~Supragingival scaling Periodontally healthy subjects will receive supra-gingival scaling and polishing in one appointment as needed. Oral hygiene instructions will be given as needed."
45512254|NCT03694899|Behavioral|phone contact|patients will be called prior to their outpatient appointment
45512255|NCT02174666|Dietary Supplement|Red clover extract|Aglycone isoflavones 80mg/d
45512256|NCT02174666|Dietary Supplement|Supplementation (placebo)|
45512257|NCT03687021|Drug|Progesterone|Different routes of administration of progesterone; Whether there is endometriosis
45512258|NCT02170454|Procedure|magnetic stimulation|rTMS on pharyngeal cortical area in healthy subjects or sham rTMS on pharyngeal cortical area in healthy subjects
45512259|NCT03691077|Drug|Ocrelizumab|The first dose of ocrelizumab will be administered as two 300-mg IV infusions (600 mg total) in 250 mL 0.9% sodium chloride each separated by 14 days (i.e., Days 1 and 15), followed by one 600-mg IV infusion in 500 mL 0.9% sodium chloride every subsequent doses (i.e., every 24 weeks) for 72 weeks.
45512260|NCT02174744|Other|numeric pain rating scale|
45512261|NCT03694743|Device|2Shape rotary system|root canal preparation
45512262|NCT02172794|Drug|Tiotropium|
45512263|NCT02172794|Drug|Placebo to tiotropium|
45512264|NCT02172794|Drug|Salmeterol|
45403993|NCT03782974|Dietary Supplement|beta glucan|Following screening and enrollment, participants will be treated with 2 tablets (Proglucamune or placebo) per day for a total duration of 8 weeks. Each Proglucamune tablet contained ~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
45403994|NCT03782896|Other|acute postoperative pain|All patients assessed postoperative pain score in the recovery room and postoperative 2 month
45403995|NCT03775018|Procedure|Transversus abdominis plane blockade|Patients will undergo Transversus abdominis plane blockade with Bupivacaine 0.25% 30ml, applied in the plane between the internal oblique muscle and the trasnversus abdominis. The injection will be performed laterally to the port-sites, bilaterally at the same levels.
45403996|NCT03775018|Drug|Intravenous analgesia|Acetaminophen 1g/6h iv will be administered
45512265|NCT02172794|Drug|Placebo to salmeterol|
45512266|NCT04173819|Biological|3BNC117-LS-J|300mg
45698920|NCT03465462|Dietary Supplement|group/arm S (supplementation group)|Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
45698921|NCT03460470|Drug|Sildenafil|PDE5 Inhibitor
45403997|NCT03784612|Behavioral|App-technology for healthy eating habits|Access to smartphone-app, including a 12 week healthy eating program. A new theme on healthy dietary habits is presented each week.
45403998|NCT03773458|Device|An artificial system for the screening of scoliosis|An artificial intelligence to make evaluation of scoliosis using back images
45698922|NCT03460470|Drug|Placebo oral capsule|Placebo for Sildenafil
45512267|NCT04173819|Biological|10-1074-LS-J|300mg
45512268|NCT04173819|Biological|Combination 3BNC117-LS-J and 10-1074-LS-J|30mg/kg of each
45403999|NCT03782662|Drug|Itraconazole|Itraconazole capsules
45512269|NCT04173819|Biological|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1|Total ~300 mg (< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
45512270|NCT04173819|Biological|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2|Total ~300 mg (< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
45512271|NCT04173819|Biological|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3|Total ~300 mg (< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
45512272|NCT04173819|Biological|Placebo|0.9% Saline
45698923|NCT03465306|Behavioral|Cognitive Behavioral Therapy|Cognitive-behavioral therapy is a psycho-social intervention that is the most widely used evidence-based practice for improving mental health and requires active interactions between the participants and a therapist or coach.
45698924|NCT03465306|Device|Self-guided|Self-guided refers to any contact between the participants and a therapist or coach.
45698925|NCT01101100|Drug|AMG 827|210 mg SC or 140 mg SC
45698926|NCT05072574|Other|Specific dietary treatment and follow-up using coaching techniques|Intervention group will receive specific dietary treatment and follow-up using coaching techniques, supported by new technologies, and will attend a nutritional education program
45404000|NCT03782662|Drug|Verapamil|Verapamil tablets
45404001|NCT03782662|Drug|Rifampicin|Rifampicin capsules
45404002|NCT03782662|Drug|Midazolam|Midazolam oromucosal solution
45404003|NCT03782662|Drug|Placebo for RV521|Placebo for RV521 capsules
45404004|NCT03782662|Drug|RV521|RV521 capsules
45404005|NCT01309984|Drug|Lusedra|Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge [up to 24 hours], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
45512273|NCT04173819|Biological|Placebo|Buffer Solution
45512274|NCT03539354|Device|Temporary spinal cord stimulation|Percutaneous trial (temporary) electrodes are placed through a 14-gauge needle.The skin is entered at the medial aspect of the pedicle with the Tuohy needle usually angled 30-45° toward the midline for optimal entry into the epidural space at the interlaminar edge 1 or 2 levels of cephalad (usually, Th5-Th6 level). The 14-gauge needle is then passed with the bevel facing up at a 30-45° oblique angle to reach the depth of the midline laminar target.The Tuohy needle is then carefully removed and the operative site is cleaned with chlorhexidine and alcohol. Temporary stimulation is carried out till coronary artery bypass grafting surgery for 3 days, then stimulation turns off during surgery. At the end of coronary artery bypass grafting the temporary stimulation turns on in the intensive care unit and continues for 7 days. After that, the temporary leads will be removed.
45512275|NCT03539354|Procedure|Coronary artery bypass grafting|Standart coronary artery bypass grafting procedure.
45404006|NCT01309984|Drug|Propofol|Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge [up to 24 hours], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
45851269|NCT02998866|Procedure|Esophageal Temperature-Guided Ablation|Esophageal temperature-guided ablation (if esophageal temperatures drop too low during cryoablation, the physician will stop the ablation) in order to increase the safety profile of cryoballoon pulmonary vein (a vein carrying blood from the participants lungs to the left side of the participants heart known as the left atrium) isolation (PVI [means a balloon shaped catheter will be placed at the opening of each pulmonary vein and tissue will be cooled in order to create an ablation line (line of scar tissue) between the left side of the participants heart and each pulmonary vein. This is done to prevent the triggers that typically cause intermittent atrial fibrillation (known as Paroxsymal Atrial Fibrillation) by providing one center's experience.
45851270|NCT02998632|Procedure|Mineralized plasmatic matrix for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using MPM (Mineralized Plasmatic Matrix) bone graft.
45851271|NCT02998632|Procedure|Autogenous bone for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using autogenous bone graft (gold standard) covered by titanium membrane.
45404007|NCT03772132|Biological|mutation and signal pathway activation status analysis Drug: FORFIRINOX|Conventional chemotherapy:5FU plus irinote- can plus oxaliplatin combination therapy
45404008|NCT03772054|Drug|Sevoflurane|Inhalation anesthetic agent
45404009|NCT03772054|Drug|Propofol|Intravenous anesthetic agent
45404010|NCT03771820|Drug|NC-6004|NC-6004 should be administered to subjects once every 3 weeks. On Day 1 of each treatment cycle NC-6004 will be administered first followed by pembrolizumab.
45404011|NCT03771820|Drug|Pembrolizumab|The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.
45698927|NCT03460392|Drug|Antibiotic therapy|To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
45698928|NCT01149772|Behavioral|ACCESS|Participants received 6 treatment sessions (2 core and 4 electives). The two core modules are increasing awareness and controlling physical and emotional symptoms. After completion of the core modules the participant was able to choose elective modules from Managing Physical Health, The Power of Thoughts, Increasing Pleasant Activities, and Relaxation. Participants were required to complete the first session in person and subsequent sessions participants had the option to complete in-person or over the phone. Participants also had the option to receive 2 brief follow-up booster calls to aid in reinforcing the changes made.
45698929|NCT05201118|Drug|Selinexor|Selinexor, 20 mg/tablet, is a first-in-class, oral Selective-Inhibitor-of-Nuclear-Export (SINE) compound that impedes XPO-1which is a major nuclear export protein of macromolecular cargo frequently overexpressed in MM.
45698930|NCT05201118|Drug|CT103A|CT103A consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that containing a unique CAR structure with a fully human single-chain variable fragment (scFv).
45698931|NCT05012436|Drug|YHD1119 75mg|A single oral dose
45698932|NCT01101880|Biological|filgrastim|Given SC
45698933|NCT01101880|Drug|clofarabine|Given IV
45698934|NCT01101880|Drug|cytarabine|Given IV
45698935|NCT03460080|Diagnostic Test|AFP-L3 and PIVKA-II in HCC|"Serum samples are tested for tumor markers including PIVKA-II, AFP, AFP-L3% and biochemical tests.~Imaging: CT or MRI"
45698936|NCT04989972|Drug|PSIL428|1 mg of psilocybin
45698937|NCT04989972|Dietary Supplement|Oyster mushroom|1 mg of oyster mushroom
45698938|NCT04989972|Drug|PSIL428|1 mg psilocybin
45698939|NCT01101958|Device|Chartis System|The Chartis System provides a value that represents the quantification of the average resistance to airflow through collateral airways.
45698940|NCT01101958|Device|Endobronchial Valve (EBV) Treatment|The endobronchial valve is designed to induce target lobe volume reduction.
45698941|NCT04978038|Drug|mRNA- COVID-19|Pfizer-BioNtech mRNA- COVID-19 0.3ml dose administered intramuscularly
45851272|NCT02998242|Drug|Apatinib|
45851273|NCT02998242|Radiation|SBRT to symptomatic bony metastatic bony site(s)|
45851274|NCT02998398|Other|Switch from REMICADE® to INFLECTRA®|Treatment with an infliximab biosimilar (i.e. INFLECTRA® ) for all patients which have been treated by REMICADE® for at least 4 months
45851275|NCT02998320|Drug|Genvoya|Oral use (one tablet each day); 150/150/200/10 mg; 28 days
45851276|NCT02998086|Behavioral|Promoting Resilience in Stress Management|Skills-based intervention designed to promote resilience resources
45851277|NCT02997696|Drug|ONO-4474|
45851278|NCT02997696|Drug|Placebo matching ONO-4474|
45404012|NCT03771742|Procedure|transverse scan, in-plane, posterior-anterior TMQLB|The patients will receive the transmuscular quadratus lumborum block(TMQLB) before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivocaine is injected when the correct needle location is confirmed.
45512276|NCT03539354|Drug|B-blockers|Standart b-blocker therapy will be administered in each group for AF prophylactics
45404013|NCT03771742|Procedure|paramedian sagittal scan, in-plane, caudal-cranial TMQLB|The patients will receive the transmuscular quadratus lumborum block(TMQLB) before surgery using the paramedic sagittal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivocaine is injected when the correct needle location is confirmed.
45404014|NCT03774940|Diagnostic Test|peripheric blood count|preoperative peripheric blood count
45404015|NCT03771976|Procedure|Cesarean section|Risk of cesarean section between the cohorts
45404016|NCT03771976|Procedure|No cesarean section|Vaginal birth rate between the cohorts
45404017|NCT01320358|Drug|ECMPS-IEM|ECMPS-IEM
45404018|NCT05531890|Drug|GTX-102 medium dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 fast
45404019|NCT05531890|Drug|GTX-102 medium dose slow Period 1 and Period 2|GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 slow
45404020|NCT05531890|Drug|GTX-102 high dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered in Period 1 and Period 2 fast
45404021|NCT05531890|Drug|GTX-102 low dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.025 mg/kg) administered in Period 1 and Period 2 fast
45404022|NCT05531890|Drug|Betamethasone solution as intramuscular injection Period 1 and Period 2|reference product 0.1 mg/kg betamethasone solution as an intramuscular injection
45404023|NCT05531890|Drug|Betamethasone Oral Solution Period 1 and Period 2|Comparator product 0.1 mg/kg betamethasone oral drops solution
45404024|NCT03782584|Other|modified pilates exercise|modified exercises from original pilates exercises.
45404025|NCT03782584|Other|daily life advises|they will be given daily life advises to prevent neck pain
45404026|NCT03782428|Dietary Supplement|Probiotic|30 billions colony-forming unit (CFU) of a mixture of six viable strains including 107 mg of Lactobacillus acidophilus BCMC® 12130, Lactobacillus lactis BCMC® 12451, Lactobacillus casei subsp BCMC® 12313, Bifidobacterium longum BCMC® 02120, Bifidobacterium bifidum BCMC® 02290 and Bifidobacterium infantis BCMC® 02129
45404027|NCT03782428|Other|Placebo|Placebo samples produced were identical to the probiotics in term of taste and texture without live microorganisms.
45698942|NCT04978038|Drug|Prevnar13|Pfizer Prevnar-13 pneumococcal vaccine 0.5ml dose administered intramuscularly
45698943|NCT04958694|Behavioral|CEDARS|This intervention is intended to help adolescents cope with stress.
45698944|NCT01194466|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Four adhesive electrodes (1.375in x 1.375in) will be placed bilaterally on the: 1) temporomandibular joint (1/3rd of distance between ear and nose); and 2) upper neck area (2cm from spine, i.e., Cervical 1 and 2).
45404028|NCT00123474|Drug|dasatinib|Tablets, Oral, 50 mg BID, indefinitely, survival study
45404029|NCT00123474|Drug|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
45404030|NCT00123474|Drug|dasatinib|Tablets, Oral, 100 mg QD, indefinitely, survival study
45698945|NCT03011632|Drug|Mometasone Nasal|a group of children who will receive a nasal mometasone in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% Sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months
45512277|NCT03686943|Other|Family pharmacy|Observation of the family pharmacy in elderly group
45404031|NCT00123474|Drug|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
45404032|NCT00142298|Drug|Telbivudine (LdT)|Telbivudine was to be supplied as white to off-white, oval, bi-convex tablets for the 200 mg tablets and white to off-white ovaloid, slightly curved, beveled edges, film coated tablets for the 600 mg tablets. Study drug (600 mg) was to be self-administered by patients orally (p.o.) in a once daily regimen for 104 weeks; for study consistency, the daily dose had to be taken at the same time each day, with or without food.
45404033|NCT03774628|Biological|Chengdu Kanghua (one booster shot)|A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0
45404034|NCT03774628|Biological|Chengdu Kanghua (two booster shots)|A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0 and 3
45404035|NCT03774706|Drug|Misoprostol|two tablets misoprostol 400 μg sublingual
45404036|NCT03774706|Drug|Tranexamic Acid|two ampoules of tranexamic acid (1gm in 10 ml) in 100ml saline
45404037|NCT03774706|Drug|placebo to tranexamic acid|placebo to tranexamic acid (110 ml saline)
45404038|NCT03967496|Procedure|Types of Anesthesia|"General Anesthesia includes: Inhalational anesthesia and total intravenous anesthesia.~Regional blocks includes: Spinal Anesthesia, Epidural Anesthesia, Plexus Block, Peripheral Nerve Block,... etc Monitored Anesthesia Care: No anesthetic administered but care given for hemodynamic and blood sugar control intraoperatively."
45404039|NCT03967496|Procedure|Access of Surgery|Type of surgical access
45512278|NCT02174900|Drug|Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine|
45512279|NCT02174900|Drug|Artemether-Lumefantrine (AL) combination|
45512280|NCT02174900|Drug|Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine|
45512281|NCT02170610|Drug|BIBR 1048 MS|
45512282|NCT02170610|Drug|Pantoprazole|
45512283|NCT03686865|Device|dental implants|extraction sockets regenerated with xenograft
45698946|NCT03011632|Drug|placebo mometasone|a group of children without IgE-dependent hypersensitivity who will receive nasal mometasone placebo in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% NaCl solution in a nasal nebuliser once a day for 3 months,
45698947|NCT01102270|Drug|Eszopiclone|3mg tablet once prior to sleep
45698948|NCT01102270|Drug|Placebo|1 placebo capsule prior to sleep
45698949|NCT01102894|Device|SmartPill|SmartPill
45512284|NCT02173106|Drug|steroid & Cyclosporin|oral methylprednisolone 0.4mg/kg/d and Cyclosporin for 6 months
45512285|NCT03932721|Drug|Evolocumab 140 MG/ML|Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C.
45512286|NCT00106340|Drug|vildagliptin|
45512287|NCT00106340|Drug|glimepiride|
45512288|NCT00106340|Drug|Metformin|
45512289|NCT00106340|Drug|Vildagliptin matching placebo|
45512290|NCT00106340|Drug|Glimepiride matching placebo|
45512291|NCT04167969|Drug|(64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots|Patients will be injected with approximately 5 mCi (+/- 10%) of a copper-64 (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots, up to 48 hours before surgery.
45851279|NCT02997852|Behavioral|Therapy dog visitation|The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
45851280|NCT02997930|Behavioral|fMRI|fMRI for measuring function connectivity and DTI will be done between day 2 to day 5.
45512292|NCT04167969|Diagnostic Test|PET/MRI|Imaging will be performed using the GE Signa PET/MRI.
45512293|NCT04167969|Other|Blood and urine sampling|Staff will perform the IV blood draws and collect urine samples
45851281|NCT02997930|Behavioral|Montreal Cognitive Assessment (MoCA)|A measure of general cognition
45851282|NCT02997930|Behavioral|Digital Clock Drawing Test Command and Copy|A measure of current cognition using digital pen technology
45851283|NCT02997930|Behavioral|Wide Range Achievement Test reading subtest|A measure of premorbid intellectual estimate
45512294|NCT04167969|Procedure|laparoscopic radical prostatectomy and bilateral pelvic LN dissection or a salvage lymph node dissection|Surgery will be performed within 24 h of the third PET/MRI scan.
45512295|NCT02255786|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an intervention that fosters acceptance of uncomfortable thoughts and emotions as a coping strategy, and encourages engagement in valued behavior in the presence of these emotions. ACT has been successfully applied to parents of children with a variety of mental health presentations.
45512296|NCT04167891|Diagnostic Test|Calculation of early prognosis score|Early prognosis score will be calculated at intensive care unit admission for each patient based on clinical and biological values as required
45512297|NCT03538496|Drug|Bupivacaine Hcl 0.25% Inj|Single shot 20 ml 0.25 bupivacaine
45512298|NCT03694665|Other|Lung recruitment maneuver|A Lung recruitment maneuver is aimed to resolve atelectasis during mechanical ventilation. It consists in a brief and controlled increment in airways pressure using pressure control ventilation. Positive end-expiratory pressure (PEEP) is increases every 5 centimeters of water (cmH2O), from 0 to 20 cmH2O keeping a fixed driving pressure of 20 cmH2O. A final step of 40 cmH2O of plateau pressure was maintained for 10 breaths, returning then to standard ventilatory settings.
45851284|NCT02997930|Behavioral|Hopkins Verbal Learning Test (HVLT)|A measure of declarative memory
45404040|NCT03967496|Other|Comorbidities|A patient may have more than one comorbidity
45404041|NCT03967496|Drug|Preoperative Medication|Preoperative medications
45404042|NCT03967496|Diagnostic Test|Routine blood test|Preoperative and Intraoperative Investigations
45404043|NCT03709654|Biological|NB01|5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01
45404044|NCT03709654|Other|Vehicle Control|5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control
45512299|NCT03538418|Other|WAT|The WAT intervention consists of 12 weekly WAT-based exercise sessions and 7 sessions of support for BCTs and technical issues.
45512300|NCT03686787|Drug|Tranexamic Acid|A split face study of oral tranexamic acid in combination with laser treatment
45512301|NCT02174978|Biological|FMP012 with AS01B adjuvant system|Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)
45512302|NCT02174978|Other|P falciparum Controlled Human Malaria Infection (CHMI)|
45512303|NCT03694587|Drug|Ibuprofen 200 mg TEPI Medicated Plaster|Ibuprofen 200mg TEPI medicated plaster applied to the upper back daily for 24 hours for 5 days
45512304|NCT03694587|Drug|Aktren® 200 mg überzogene Tabletten (Ibuprofen)|one dose of Aktren® 200 mg überzogene Tabletten (Ibuprofen tablet)
45512305|NCT03539276|Behavioral|Knowledge exchange|OptimaMed
45512306|NCT03694509|Other|Breakfast tea with full fat milk|Assessment of gastric emptying using ultrasound. Black breakfast tea (200ml) with full fat milk (50ml) - The volume of milk added to the tea is at the discretion of the patient but the remaining milk must be consumed afterwards.
45512307|NCT03694509|Other|Water|Water 250ml.
45512308|NCT02175056|Biological|HL2351|Dose-escalation For 5 level dose groups A ~ E(each 1, 2, 4, 8, 12mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group, and the study drug or placebo is subcutaneously administered for the relevant dose group.
45512309|NCT02175056|Biological|Kineret(Anakinra)|Active comparator(group F) is implemented in parallel with dose groups A~E in an open-label manner and 8 subjects subcutaneously administer Kineret® 100 mg.
45512310|NCT02173184|Biological|Gynevac|1 IM injection of Gynevac per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
45512311|NCT02173184|Biological|Placebo|1 IM injection of Placebo per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
45512312|NCT03694431|Other|Tech-supported HBPC|Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
45512313|NCT03694431|Other|Standard HBPC|Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
45512314|NCT02170766|Drug|BIBR 1048 low1|
45512315|NCT02170766|Drug|BIBR 1048 low2|
45512316|NCT02170766|Drug|BIBR 1048 medium|
45512317|NCT02170766|Drug|BIBR 1048 high|
45698950|NCT01103440|Drug|Intravenous Glycoprotein inhibitor + ASA, Clopidogrel|IV Glycoprotein IIb/IIIa inhibitor bolus intra procedurally
45512318|NCT02170766|Drug|Pantoprazole|
45512319|NCT04156659|Biological|Tisagenlecleucel|A single intravenous (i.v.) infusion of CAR-positive viable T cells.
45512320|NCT03538340|Procedure|Thoracic Epidural|The control arm will receive standard of care pain management which includes a Thoracic Patient Controlled Epidural
45512321|NCT03538340|Procedure|Intercostal Cryoanalgesia|The study arm will receive standard of care pain management which includes a Thoracic Epidural plus Intraoperative Intercostal Cryoanalgesia
45512322|NCT03694119|Drug|Phenelzine|Phenelzine
45512323|NCT03694119|Drug|Tyramine|Tyramine
45512324|NCT03694119|Drug|Phenelzine placebo|Phenelzine placebo
45512325|NCT03694119|Drug|ozanimod placebo|ozanimod placebo
45512326|NCT03694119|Drug|ozanimod|ozanimod
45512327|NCT02178254|Drug|Fosfomycin tromethamine|A phosphonic acid derivative is the mono-acid salt of Fosfomycin with Tromethamine. Sequence 1-3 receive 3 grams oral sachet
45512328|NCT02178254|Drug|Fosfomycin disodium|ZTI-01 is a phosphonic acid derivative formulated as a disodium salt intravenous formulation. ZTI-01 acts by inhibiting peptidoglycan assembly, thereby disrupting cell wall synthesis. Sequence 1-3 receive 1 gram and 8 grams of Intravenous ZTI-01 for 1-hour infusion
45698951|NCT01103440|Drug|Antiplatelet Therapy (ASA, Clopidogrel)|Standard antiplatelet PCI treatment
45698952|NCT03011554|Device|Implantable Miniature Telescope (IMT)|Monocular implantation of the IMT.
45512329|NCT02173262|Drug|G-CSF|
45512330|NCT02173262|Drug|Ciprofloxacin|
45512331|NCT02175134|Other|Blood and Ascites ELISPOT|
45512332|NCT03537638|Behavioral|Multicomponent intervention|Intervention to rheumatologist and internist responsible for the care of patients with SLE. Implementation multicomponent intervention consisting of: educational component, a computerized clinical decision support system developed from the clinical practice guide - SLE and automated feedback integrated into the electronic medical record system.
45512333|NCT04150653|Device|Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)|Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)
45512334|NCT04147923|Dietary Supplement|Floradapt Mature Immune Defense + Multivitamin|The product consists of two L. plantarum strains, KABP XXXX and KABP XXXX with a combined strength of >1 x 10^9 CFU. Participants will also consume a multivitamin.
45512335|NCT04147923|Dietary Supplement|Placebo + Multivitamin|No active ingredients + a multivitamin supplement
45512336|NCT03690687|Procedure|Primary anastomosis|
45512337|NCT03690687|Procedure|Delayed anastomosis|
45404045|NCT00412061|Drug|Octreotide|Octreotide 30 mg intramuscularly (i.m.) every 28 days.
45512338|NCT03690687|Procedure|Enterostomy|
45512339|NCT02173418|Drug|Phrenic nerve block with Ropivacaine|
45512340|NCT02173418|Drug|Phrenic nerve block with saline|
45512341|NCT03686709|Diagnostic Test|Post therapy PET/CT Imaging|whole-body PET/CT following Y90 radioembolization
45512342|NCT02173496|Other|Colour Contrast Sensitivity|Reading of numbers or letters from a monitor
45512343|NCT02173574|Drug|DEB025|
45512344|NCT02173574|Drug|EDP239|
45512345|NCT03932331|Drug|Acalabrutinib|Acalabrutinib 100 mg orally twice daily
45512346|NCT02178488|Drug|Cholecalciferol|Cholecalciferol 4000 IU/day for 12 months
45512347|NCT02178488|Other|Placebo|Placebo (mimic of cholecalciferol) in the same amount and same time frame as Cholecalciferol for 12 months
45512348|NCT03686631|Behavioral|Smartphone Arm|"The smartphone arm will have an associated smartphone application, available in kiosk mode, that will remind and encourage patient to utilize the spirometer and provide a gamified application for that patient to do so."
45404046|NCT00412061|Drug|Placebo|A 10-mg oral daily dosing regimen (two 5-mg tablets) of matching placebo.
45404047|NCT00412061|Drug|Everolimus|A 10-mg oral daily dosing regimen (two 5-mg tablets) of everolimus.
45404048|NCT03964350|Drug|Ethanol|"The 0.8 g/kg body weight dose of gelatin alcohol will be divided into an average of 10 servings of 0.08 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol.~The 0.4 g/kg body weight dose of gelatin alcohol will be divided into an average of 5 servings of 0.08 g/kg each. The 0.4 g/kg dose is equivalent to 2 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol."
45404049|NCT03964350|Other|Placebo|The placebo comparator will be individual servings of back cheery sugar-free jello.
45404050|NCT01310452|Drug|insulin detemir|insulin detemir once daily with metformin
45512349|NCT02173652|Drug|BI 1356, high dose|
45512350|NCT02173652|Drug|BI 1356, low dose|
45512351|NCT03694041|Drug|SAD: APX-115|Drug: APX-115 SAD APX-115 SAD for 1day
45512352|NCT03694041|Drug|SAD: Placebo|Drug: Placebo Placebo for 1day
45512353|NCT03694041|Drug|MAD: APX-115|Drug: APX-115 MAD APX-115 MAD repeatedly administered.
45512354|NCT03694041|Drug|MAD: Placebo|Matching study drug will be repeatedly administered.
45512355|NCT03694041|Other|Food effect: fasted and fed|A single dose of APX-115, selected from the SAD study, will be administered under fasted and fed condition.
45512356|NCT03694041|Other|Metabolic probe with or without APX-115|A metabolic probe will be administered with and without APX-115.
45512357|NCT02173730|Drug|BIBR 1048 MS|BIBR 1048 MS capsule 150 mg
45404051|NCT01310452|Drug|neutral protamine insulin|neutral protamine insulin once daily with metformin
45404052|NCT01035671|Drug|alpha-tocopherolquinone (A0001)|28 days of low dose (1.0 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
45404053|NCT01035671|Drug|alpha-tocopherolquinone (A0001)|28 days of high dose (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
45404054|NCT01035671|Drug|placebo|28 days of placebo oral capsules. Treatment taken twice daily with meals.
45404055|NCT05510284|Other|Doula-coordinated, midwife-delivered postpartum care|A doula will coordinate all postpartum care and provide support to the participant. A midwife will be available on-site in the NICU to provide postpartum care.
45404056|NCT03966534|Other|Blood diversion|Diversion of initial blood obtained at venipuncture to biochemistry tube in order to try and reduce incidence of blood culture contamination
45404057|NCT03771196|Other|Bioactive Restorative Material|enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth
45404058|NCT03771196|Other|Resin-modified glass ionomer|Enhanced glass ionomer with acceptable mechanical properties and esthtic properties
45404059|NCT03770962|Behavioral|Two midwives|"Two midwives will be present during the active phase of the second stage and the birth of the baby. Midwife no 1 is the midwife who has been responsible for the care of the woman and midwife no 2 will assist her."
45404060|NCT04869982|Biological|RZV|2 doses of RZV in 0, 2 months schedule, administered intramuscularly in the deltoid region of the non-dominant arm
45404061|NCT04869982|Drug|Placebo|2 doses of placebo in 0, 2 months schedule, administered intramuscularly in the deltoid region of the non-dominant arm
45404062|NCT04560868|Device|Control mHealth program|The intervention includes a mHealth intervention that is grounded in best practice recommendations for treatment of nicotine dependence.
45404063|NCT04560868|Device|Experimental mHealth program|The intervention includes a mHealth intervention that is grounded in best practice recommendations for treatment of nicotine dependence. Experimental participants also receive additional content designed to motivate smoking reduction/quitting and provide skills training.
45404064|NCT04560868|Drug|Nicotine patch|Participants in both arms can earn the ability to request a 2-week supply of over-the-counter nicotine patches. Patches are earned through accumulated use of the assigned mHealth program.
45404065|NCT03769714|Drug|Saline Solution for Injection|Injection of 20mL of 0.9%Normal Saline
45404066|NCT03769714|Drug|Exparel|Exparel (bupivacaine liposome injectable suspension) is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated (bupivacaine liposome injectable suspension) for administration into the surgical site to produce postsurgical analgesia.
45404067|NCT03769636|Device|GaitUp Physilog 5|"The primary outcomes are measured by the Physilog 5 (physical activity) at four different periods (T1-T4). Physilog 5 is worn for 4 weeks in total.~The secondary outcomes are fatigue, measured by FSMC (fatigue scale for motor and cognitive functions questionnaire), self-rated health-related quality of life, measured by the EQ-5D (health-questionnaire) and self-rated walking capacity, measured by the MSWS-12 (Twelve Item MS Walking Scale)."
45404068|NCT05479084|Other|Kinesiotaping|Kinesio taping will be applied on the lower part of the trapezius.
45404069|NCT03769558|Other|Non-Interventional|Non-Interventional
45404070|NCT03769480|Other|Muscle strength evaluation and Respiratory function Tests|Muscle strength evaluation and Respiratory function Tests
45404071|NCT03769402|Drug|Citric acid|Citric acid ph1, 50% concentration solution
45404072|NCT03769402|Drug|Control Test|Control group, xenograft was used to fill infrabony defects without treating bone surface
45404073|NCT04466410|Biological|XT-150|Single bolus intrathecal injection
45404074|NCT04466410|Biological|Placebo|Placebo is a sterile phosphate-buffered saline
45404075|NCT04444180|Diagnostic Test|Virtual hand illusion (VHI)|Using VHI, the two basic self-representation of sense of ownership and sense of agency of the subjects will be observed.
45404076|NCT01321294|Procedure|laparoscopic anti-reflux surgery|
45404077|NCT00411671|Drug|Sorafenib|400 mg By Mouth Twice Daily for 28 Days.
45404078|NCT04419688|Drug|STT-5058|Monoclonal Antibody STT-5058
45512358|NCT02173730|Drug|Pantoprazole|Pantoprazole tablet 40 mg
45404079|NCT04419688|Drug|Placebo|Matching placebo to STT-5058
45404080|NCT01035983|Drug|Frovatriptan 2.5 mg|
45404081|NCT03770806|Procedure|Femoral Nerve Block|Standard Ultrasound-guided peri-neural femoral nerve block with Ropivacaine 0.5% and Dexamethasone 6-8mg.
45404082|NCT03770806|Procedure|Adductor Nerve Block|Standard Ultrasound-guided peri-neural adductor nerve block, mid-thigh, with Ropivacaine 0.5% and Dexamethasone 6-8mg
45404083|NCT03770806|Other|No Block|routine iv and oral pain medication alone-observation only
45512359|NCT03686553|Other|laboratory-based data collection|laboratory-based surveillance of SSI
45512360|NCT03686475|Other|Biodentine|pulpotomy for primary molars , clinical and radiographic evaluation at 1,3,6 and 12month
45512361|NCT03686475|Other|MTA pulpotomy|MTA pulpotomy
45404084|NCT01039103|Drug|PEG-liposomal prednisolone sodium phosphate|PEG-liposomal prednisolone sodium phosphate 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
45404085|NCT01039103|Drug|Methylprednisolone|Methylprednisolone 1 g, IV, infusion over 2 hours on days 1, 2 and 3
45512362|NCT02175446|Drug|Bevacizumab and eribulin|"In this study, Bevacizumab and Eribulin are considered to be the investigational study drugs. Bevacizumab is provided as 25 mg/ml concentrate for infusion. Vials contain 100 mg of Bevacizumab in 4 ml and/or 400 mg in 16 ml. Eribulin is provided as vials containing 1 mg/2 mL Eribulin as a 500 µg/mL solution in ethanol/water"
45512363|NCT03686319|Other|Reflexology|Reflexology: foot massage
45512364|NCT03686241|Procedure|Tibiotalocalcaneal (TTC) arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
45512365|NCT03686241|Device|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
45512366|NCT02178644|Drug|Chemo with concomitant Capecitabine and KD018|Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
45512367|NCT03686163|Drug|Nerve Growth Factors|the experimental group patients will receive NGF 20ug/d intranasally for 2 weeks
45512368|NCT03686163|Drug|normal saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks
45512369|NCT02256098|Device|ATTUNE™ Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with ATTUNE™ Knee Prosthesis by DePuy
45512370|NCT02256098|Device|PFC Sigma Knee Prosthesis by DePuy|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
45512371|NCT03690609|Dietary Supplement|CytoQuel|3 capsules daily.
45512372|NCT03690609|Dietary Supplement|CytoQuel|2 capsules twice daily.
45512373|NCT02173808|Biological|levonorgestrel butanoate|
45512374|NCT03690531|Device|Take-Pause virtual reality|Take-Pause virtual reality simulation lasting 3 minutes shown through a virtual reality goggle, headset and iPhone.
45512375|NCT03690531|Device|Passive Distraction|Standard or passive distraction technique, lasting 5 minutes.
45512376|NCT02256020|Other|Original lifestyle|Control group with 3 times of watching 50-minute television a week for 6 months.
45512377|NCT02256020|Other|Wheel-chair music aerobic exercise (WC-MAE)|Wheel-chair music aerobic exercise with 3 times of 50-minute session a week for 6 months.
45512378|NCT03690297|Device|Linked Color Imaging|Use of narrow band imaging with LCI for colon inspection during both insertion and withdrawal phase of colonoscopy
45512379|NCT04132401|Diagnostic Test|algorithm|The diagnostic capacity of the algorithm will be compared with that of the family medicine physicians and with retina specialists. The reference will be a blinded double reading conducted by the retina specialists
45512380|NCT02173886|Drug|Bupropion SR and XL|
45512381|NCT03690219|Other|no intervention|no intervention
45512382|NCT02173964|Drug|pinaverium bromide|pinverin 50 mg per oral single dose versus simple water ingestion
45512383|NCT02173964|Drug|water|same amount of water for pinverin administration
45512384|NCT03690141|Drug|tomivosertib (eFT508)|This Phase 2 study examines the efficacy, safety, tolerability, and PK of tomivosertib (eFT508) in advanced CRPC patients who have documented PSA progression on treatment with apalutamide and/or abiraterone and/or enzalutamide and for whom no suitable curative therapy exists.
45512385|NCT02175602|Drug|Escitalopram|10 milligrams administered each morning
45512386|NCT02175602|Drug|Sertraline|50 milligrams administered each morning
45512387|NCT02175602|Drug|DCV 3DAA FDC|Fixed dose combination (daclatasvir [DCV] 30 milligrams, asunaprevir [ASV] 200 milligrams, and BMS-791325 75 milligrams) one tablet administered twice daily
45512388|NCT02175602|Drug|BMS-791325|75 milligrams single-agent film coated oral tablet administered twice daily
45512389|NCT04290741|Procedure|Auricular (Battlefield) Acupuncture|Placement of needles based on battlefield acupuncture protocol which includes up to 5 sites on each ear to treat pain.
45404086|NCT01036061|Drug|GSK618334 Low Dose|GSK618334 low dose
45404087|NCT01036061|Drug|GSK618334 PET subjects|PET subjects
45404088|NCT01036061|Drug|GSK618334 Medium Dose|Medium Dose
45404089|NCT01036061|Drug|GSK618334 High Dose|GSK618334 High Dose
45512390|NCT04290741|Procedure|Peripheral Acupuncture|Placement of needles in up to 30 specific sites in the head, neck, arms from the shoulders to the hands, and legs from the knees to the feet
45512391|NCT03686085|Drug|Dinoprostone 3 mg|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
45512392|NCT03686085|Drug|placebo vaginal tablet|1 vaginal tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
45512393|NCT03693963|Device|Serranator|The Serranator® PTA Serration Balloon Catheter is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
45512394|NCT02754440|Device|Trima Accel System with Version 7.0 Software|Platelet Apheresis Procedure
45512395|NCT03690063|Other|Follow up|Follow up of treatment, behavior, co-morbidity
45512396|NCT03689829|Drug|MOR106|The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human interleukin-17C (IL-17C).
45512397|NCT03689829|Drug|Placebo|Corresponding placebo s.c. injections.
45512398|NCT02174042|Drug|Tangning Tongluo Capsule|Taken drugs 3 times a day, with each time 3 grains
45512399|NCT03693885|Other|Oxytocin challenge test (OCT)|Infusion of oxytocin 5 IU/500 ml Ringer® lactate at a rate of 12 ml/h and doubled every 10 min until three uterine contractions per 10-min interval are induced, at which point it will be stopped.
45512400|NCT02174120|Drug|propofol|
45512401|NCT02174120|Drug|etomidate|
45512402|NCT03922893|Other|Family History Information|The family history ascertainment focuses on self-reported family history of first-, second-, and third-degree family members, including types of malignancies/ pre-malignant lesions and age at diagnosis.
45512403|NCT03922893|Genetic|ORAGENE|Approximately 2-4mL of saliva may be collected in specialized Oragene DNA Self-Collection Kit tubes or buccal swab-based collection devices.
45512404|NCT03922893|Genetic|Blood|For select participants, 1-2 tubes of blood will be drawn for DNA and RNA analysis
45512405|NCT03922893|Other|Skin Biopsy|In certain circumstances, for Memorial Sloan Kettering participants and their family members, it may be necessary to obtain a skin biopsy.
45512406|NCT02175914|Drug|Erythromycin|Oral Treatment with Erythromycin 500mg, twice daily, for 12 weeks
45512407|NCT03693729|Device|HD-tDCS|Participants will complete a metamemory and memory task
45512408|NCT02753816|Drug|Tranexamic Acid|
45512409|NCT02753816|Drug|Placebo Comparator|
45512410|NCT03689751|Other|LSCS Video|LSCS video created depicting the patient journey for elective LSCS patients.
45512411|NCT03689751|Other|TVT/TOT Video|TVT/TOT video created depicting the patient journey for elective TVT/TOT patients.
45512412|NCT03689673|Other|Data collection|
45512413|NCT02178878|Genetic|Progress, Pain|Progress, Pain
45512414|NCT03689517|Other|placebo|participants took placebos (pills made by starch) that were told to be an effective analgesic.
45404090|NCT03770104|Procedure|ETT insertion depth using Spanish recommendations|Infants included in this assignment group will be intubated using the formula 5.5 plus weight, when requiring oral intubation in the delivery room.
45404091|NCT03770104|Procedure|ETT insertion depth using international recommendations|Infants included in this assignment group will be intubated using the formula 6 plus weight, when requiring oral intubation in the delivery room.
45512415|NCT03689517|Device|orthodontic elastic separators|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar.
45512416|NCT03685851|Procedure|DSAEK type corneal transplant|All surgeries were performed by the same surgeon and according to the same protocol
45512417|NCT02179034|Drug|Nicotine|Participants will receive no nicotine, low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
45512418|NCT02179034|Other|Low Dose Menthol|A low dose of menthol will be added to the tobacco flavor.
45512419|NCT02179034|Other|High Dose Menthol|A high dose of menthol will be added to the tobacco flavor.
45404092|NCT01039181|Drug|Calcitriol|12 mcg Calcitriol will be given orally three times per week for 6 months. In this portion of the study, all patients will get the same dose of calcitriol along with the standard chemotherapy (5-fluorouracil-mitomycin C-leucovorin).
45404093|NCT01036139|Drug|BF2.649 (pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
45512420|NCT03623997|Other|Iron stable isotope labeled iron(II) sulfate|Administration of oral stable isotope labels using different dosings and different regimens in women with iron deficiency anemia
45512421|NCT02174588|Drug|Midazolam + propofol|Midazolam and propofol are used for sedation drug. Balanced propofol sedation (BPS) refers to the administration of an opiate, a benzodiazepine, and propofol.
45512422|NCT02174588|Drug|propofol|propofol are used for sedation drug
45512423|NCT03693573|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
45512424|NCT03693573|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at 15 mg/kg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
45512425|NCT02176304|Drug|Depomedrol|Depomedrol 40 mg/ml, 1 ml injected to knee on day one of intervention.
45512426|NCT02176304|Drug|Lidocaine|Lidocaine 2% soln, 4 ml injected to knee on day 1 of intervention
45512427|NCT02176460|Drug|Colchicine|0.5mg twice daily for 16 weeks
45512428|NCT02176460|Drug|Placebo|1 tablet twice daily
45512429|NCT03689439|Diagnostic Test|bone scintigraphy|bone scintigraphy
45596807|NCT05791955|Behavioral|Acknowledgement of personal responsibility|"The message will contain a request for the participant to take personal responsibility for their health by either clicking on the link to make an appointment or replying noted to the text message."
45404094|NCT03770026|Drug|clomiphene citrate|Clomiphene citrate-only arm: Patients will receive Clomiphene citrate induction (in a dose of 100 mg/day starting from day 3 of the cycle for 5 days). Sonographic assessment of endometrial thickness together with Power Doppler evaluation endometrial and sub-endometrial blood flow a will be done in the Day of HCG injection.
45512430|NCT03623919|Other|FallSensing multiplayer games|"FallSensing multiplayer games is a technological solution based on an interactive (exer)game.~Players will wear a strap on the lower limbs contaning an inertial sensor. This device enables movement identification on the characterization in real time, triggering actions in the game.~The exercise games are based on a validated fall prevention exercise plan - the Otago Exercise Programme. The exercises were designed to promote mobility and improve muscle strength and balance."
45512431|NCT02179112|Procedure|Emergency Abdominal Surgery|Emergency intra-peritoneal surgery (only exclusion: Caesarian section).
45512432|NCT03693495|Diagnostic Test|ellume·lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic participants. The sample type used is a throat swab.
45512433|NCT03693495|Diagnostic Test|Bacterial Culture|Pharyngeal swab is collected from participant and this specimen is inoculated into 5% sheep blood agar plates. Beta-haemolytic colonies are isolated, followed by latex agglutination test.
45512434|NCT03693495|Diagnostic Test|Polymerase Chain Reaction (PCR)|Polymerase Chain Reaction (PCR) is a molecular diagnostic technique for the detection and identification of Group A Streptococcus, both for clinical samples and isolates. Polymerase Chain Reaction (PCR) allows template bacterial RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
45404095|NCT03770026|Drug|Saline cervical flushing|Cervical irrigation with 1 ml of 0.9% normal saline will be done at cycle day 8 and 10 to convince patient-blinded procedure.
45512435|NCT02176538|Drug|Product 0405|Product 0405 will be administered topically twice daily for 28 days
45512436|NCT02176538|Drug|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
45512437|NCT03623841|Other|Dual-task training|Participants in experimental group will do dual-task training via exer-game which combined with treadmill
45512438|NCT03623841|Other|Treadmill training|Participants in control group will do treadmill training only
45512439|NCT02256254|Drug|Simvastatin|2 Simvastatin capsules of 20 mg every evening for 14 days
45512440|NCT02256254|Drug|Placebo|2 placebo capsules every evening for 14 days
45512441|NCT02256332|Dietary Supplement|Low dose plant based ingredient|Reference food with low dose of plant based ingredient
45512442|NCT02256332|Dietary Supplement|High dose plant based ingredient|Reference food with high dose of plant based ingredient
45512443|NCT02256332|Dietary Supplement|Reference food format|Reference food without plant-based ingredient
45512444|NCT03689361|Combination Product|MRI|Routine MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 *, vascular sequences (AngioRM and TOF) and perfusion).
45512445|NCT03689361|Diagnostic Test|MRI control|MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 *, vascular sequences (AngioRM and TOF) and perfusion)
45512446|NCT03689361|Other|telephone consultation|telephone consultation
45512447|NCT02176616|Procedure|linear ablation|The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
45851285|NCT02997930|Behavioral|General Depression Scale (GDS)|A measure of the of presence of depression.
45404096|NCT03770026|Biological|Intrauterine Autologous platelet-rich plasma|Under complete aseptic cares and ultrasound supervision, Autologous platelet-rich plasma (0.5 - 1 ml) was immediately injected into the uterine cavity using an intrauterine insemination catheter in the cycle days 8 and 10. The Autologous platelet-rich plasma is prepared in collaboration with the Department of Clinical Pathology, Faculty of Medicine, Benha University.
45512448|NCT02176616|Procedure|pulmonary vein isolation|The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
45512449|NCT03689283|Other|Dry Needling|Individuals randomized to the Dry Needling Group will receive dry needling to latent trigger points of the gastrocnemius muscle
45512450|NCT03689283|Other|Sham Dry Needlling|Individuals randomized to the Control group will receive sham needling to the gastrocnemius muscle
45512451|NCT02182076|Drug|BIBF 1120|150 mg of BIBF 1120 ES soft gelatine capsules
45512452|NCT03693417|Device|Heated circuit on|Heated circuit will be turned on.
45512453|NCT03693417|Device|Heated circuit off|Heated circuit will be turned off.
45512454|NCT02179268|Drug|sertraline|50mg, 50-150mg/d,qd for one year
45851286|NCT02997774|Other|Cooler dialysis|Having dialysis at a slightly cooler temperature (35 vs 36.5 degrees Celsius)
45851287|NCT02997774|Other|Standard Dialysis|Having dialysis at a standard temperature (36.5 degrees Celsius)
45851288|NCT02997618|Behavioral|Community based exercise programme|20 week community (home or gym based) exercise programme
45851289|NCT02997618|Other|Control|Usual care consisting of advice.
45698953|NCT01152112|Device|Myomectomy|Removal of fibroids and / or polyps
45404097|NCT01561846|Dietary Supplement|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
45404098|NCT01561846|Dietary Supplement|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
45404099|NCT03769870|Drug|Teneligliptin 20mg/day|cross-over
45404100|NCT03769870|Drug|Atorvastatin 40mg/Day|cross-over
45404101|NCT03769870|Drug|Teneligliptin 20mg/day + Atorvastatin 40mg/day|cross-over
45404102|NCT03769792|Diagnostic Test|Blood and faeces tests|During V0 - Laboratory tests, particularly for calprotectin concentration assessment
45404103|NCT03769792|Device|Impedance spectroscopy test|During V1 - the electrical impedance of pelvic floor muscles will be measured
45512455|NCT02179268|Drug|citalopram|20mg, 20-40mg/d,qd,for one year
45512456|NCT02179268|Drug|venlafaxine|venlafaxine,25mg, 75-100mg/d, bid, for one year
45512457|NCT02179268|Drug|reboxetine|reboxetine,4mg, 4-8mg/d,qd for one year
45512458|NCT02179268|Behavioral|control|50min, every week for three months, every month, for nine months
45404104|NCT03769792|Diagnostic Test|Full gynecological and proctological examination|During V1 - Examination with a gynecological speculum, Two-handed examination, Rectal examination and Anoscopy
45404105|NCT03769792|Diagnostic Test|Transanal ultrasonography|During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
45404106|NCT03769792|Diagnostic Test|Anorectal manometry|During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
45404107|NCT01321918|Other|Case Controls|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised on a route of vascular development place in the context of medical practice.Clinical data will be indicated in the CRF and the computerized database. In the event an eligible patient has not been included during his support by an emergency ambulance service but, after successful resuscitation, he has been hospitalised in a cardiology department, its inclusion may be realised during the hospitalization by a physician investigator of the study. A blood sample of 10 ml of 2 EDTA tubes will be realised on a route of vascular development in the context of routine care.
45404108|NCT01321918|Other|Control subjects|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised and clinical data will be indicated in the CRF and the computerized database.
45404109|NCT03769324|Diagnostic Test|Osmolarity Test|Osmolarity Test
45404110|NCT03769246|Device|Upright Go Device|Participants will be asked to use the Upright device everyday for four (4) weeks. After four (4) weeks, the participants will be asked to complete a couple of questionnaires regarding their pain scale and back posture.
45404111|NCT03769246|Other|Ergonomic Handout|Participants will be asked to use the ergonomic handout everyday for four (4) weeks. After four (4) weeks, the participants will be asked to complete a couple of questionnaires regarding their pain scale and back posture.
45404112|NCT03769012|Dietary Supplement|Beta-Glucan|95% beta-glucan sourced from whole cell Euglena Gracilis
45404113|NCT03769012|Dietary Supplement|Placebo|microcrystalline cellulose
45404114|NCT03835481|Drug|BI 730357|Film-coated tablet
45404115|NCT03835481|Drug|Placebo to match BI 730357|Film-coated tablet
45404116|NCT03768934|Other|1X airtime incentive|An incentive given in the form of airtime.
45404117|NCT03768934|Other|2X airtime Incentive|An incentive given in the form of airtime.
45512459|NCT02182154|Drug|BIBF 1120 ES|
45512460|NCT03693339|Drug|Capmatinib|Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
45512461|NCT02176694|Behavioral|Text Messaging|Website that allows adolescents to create, schedule and send one-time or recurring text messages that will serve as a reminder to take asthma medication or follow up with another health-related matter.
45512462|NCT03689127|Device|Heated breathing circuit on|Heated breathing circuit will be turned on.
45512463|NCT03689127|Device|Heated breathing circuit off|Heated breathing circuit will be turned off.
45698954|NCT04352374|Other|Aerobic exercise|a Low-Intensity Aerobic Exercise with Borg scale RPE at 11.
45851290|NCT02997384|Other|Information|information of women about their risk of breast cancer and the screening methods recommended for them
45512464|NCT02176772|Other|Stable iron isotopes, non-drug intervention|
45512465|NCT03538184|Procedure|Piezosurgery|Preparation of implant beds entirely with piezo surgery implant tips
45512466|NCT03538184|Procedure|Drill|Preparation of implant beds entirely with conventional implant drills
45512467|NCT02182232|Drug|BIBF 1120|
45512468|NCT02182232|Drug|Paclitaxel|
45512469|NCT02182232|Drug|Carboplatin|
45512470|NCT04356560|Diagnostic Test|COVID-19 test, polymerase chain reaction for SARS-CoV-2|surveillance
45512471|NCT02179502|Drug|GLPG1690 single ascending doses|Single dose, oral suspension or solid formulation, starting dose of 20mg escalating up to 1500mg
45512472|NCT02179502|Drug|Placebo single ascending doses|Single dose, oral suspension or solid formulation matching placebo
45512473|NCT02179502|Drug|GLPG1690, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension, anticipated doses: 300mg to 1000mg
45512474|NCT02179502|Drug|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
45512475|NCT02182310|Drug|BI 201335 low dose|
45512476|NCT02182310|Drug|BI 201335 placebo|
45512477|NCT02182310|Drug|Moxifloxacin|
45512478|NCT02182310|Drug|BI 201335 high dose|
45512479|NCT02176850|Drug|Micardis®|
45512480|NCT02177006|Behavioral|Sun Protection Program|"The intervention includes two phases:~Phase 1: From June to August 2014, a voucher to obtain a swim shirt for sun protection provided by the Pediatric Sun Protection Foundation will be affixed to the anticipatory guidance sheet provided by the practice to caregivers of children 2-6 years of age.~Phase 2: Analysis of online redemption of vouchers in comparison with the self-reported surveys"
45512481|NCT02177084|Device|PTNS|
45512482|NCT02179580|Drug|Xiang-Sha-Liu-Jun-Zi-Tang|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient
45512483|NCT02179580|Drug|Placebo|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .
45698955|NCT04352374|Device|Device guided breathing|The device consists of a control box, headphones and a respiratory rate monitor attached as a sensor belt around the user's chest.
45698956|NCT01105312|Drug|letrozole|
45404118|NCT03768934|Other|Lottery airtime incentive|An incentive given in the form of airtime.
45512484|NCT02182388|Drug|Placebo|
45512485|NCT02182388|Drug|BI 207127 NA powder for solution|
45512486|NCT02182388|Drug|BI 207127 NA tablet|
45512487|NCT03537326|Drug|Budesonide|Patients will be given, on an empty stomach since a minimum of 10 hours, a single dose of 3 mg of Budesonide, in the form of Entocord® capsuls. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.
45512488|NCT02182466|Device|Colon capsule endoscopy|
45404119|NCT03768778|Procedure|Debridement and dural repair|
45404120|NCT01589081|Drug|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study session day. The nicotine solutions (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg; and 1.5 mg/70kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
45404121|NCT01589081|Drug|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
45512489|NCT02182544|Drug|WAL801CL dry syrup|
45512490|NCT02182544|Drug|Ketotifen fumarate dry syrup|
45512491|NCT02182544|Drug|Ketotifen fumarate dry syrup placebo|
45512492|NCT02182544|Drug|WAL 801 CL dry syrup placebo|
45512493|NCT03537248|Device|ASP-57|an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
45512494|NCT03537248|Device|ReNu® Multiplus|a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
45512495|NCT02177240|Device|GlideScope® intubation with Flex-it® stylet|GlideScope® intubation with Flex-it® stylet of a simulated difficult airway
45512496|NCT02177240|Device|GlideScope® intubation with GRS® stylet|GlideScope® intubation with GRS® stylet of a simulated difficult airway
45512497|NCT02179658|Drug|OPT-80|oral
45512498|NCT02179658|Drug|vancomycin|oral
45512499|NCT02177318|Drug|Spiriva (tiotropium bromide) inhalation capsules|Survey of patients with COPD using Spiriva (tiotropium bromide) inhalation capsules
45512500|NCT03693261|Procedure|Coronary artery bypass grafting (CABG)|CABG, as part of the standard medical care
45698957|NCT01105312|Drug|panobinostat|
45698958|NCT01105312|Genetic|RNA analysis|
45698959|NCT01105312|Genetic|microarray analysis|
45698960|NCT01105312|Genetic|reverse transcriptase-polymerase chain reaction|
45698961|NCT01105312|Other|enzyme-linked immunosorbent assay|
45698962|NCT01105312|Other|immunohistochemistry staining method|
45404122|NCT02680366|Device|collagen/ABMNC scaffold|The patients will receive a bone marrow puncture to collect bone marrow cells which are used to isolation of ABMNCs. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. Then, the collagen/ABMNCs scaffold was covered on a Foley catheter balloon and placed into the uterine cavity. The catheter balloon was kept for 24 hours and then removed. Oral antibiotics were given to prevent infection in the second and third days after operation. 72 hours after the surgery, a vaginal speculum examinations will be done in order to make patients unknown about their arms. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
45404123|NCT02680366|Device|Foley catheter balloon|The patients will receive a sham bone marrow puncture which just has a local anesthesia and collects no bone marrow cells to isolation. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. And then, a Foley catheter balloon will be placed into the uterine cavity and kept for 72 hours before it is removed. Oral antibiotics were given to prevent infection in the second and third days after operation. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
45404124|NCT00708695|Behavioral|Nurse Home Visiting|Visits from nurses from mid-pregnancy to child age 2 years.
45404125|NCT01567540|Drug|Sitagliptin|100 mg Sitagliptin daily for 15 weeks
45404126|NCT01039259|Device|piercings of four different materials|randomly assigned sterile piercings are inserted for two weeks
45404127|NCT01039337|Other|Hip School|The hip school consists of one initial personal interview, three group sessions, and one follow-up personal interview. The hip school is a patient education programme which involves anatomy/physiology, epidemiology, disease progression and pain, advice on self-help and exercises.
45404128|NCT01039337|Other|Hip School and Manual Treatment|Hip school as above. Patients receive manual treatment twice a week for 6 weeks. Manual treatment consists of joint manipulation and muscle energy techniques to the articular and soft-tissue structures of the hip.
45404129|NCT01039337|Other|Minimal control intervention|As control group, an information leaflet is used with instructions to live as usual during the 6 weeks intervention period. The exercise sheet of the hip school is given to the patients with no further instruction.
45404130|NCT01885637|Other|Transition program|Accelerated transition program from oncological treatment to continuous specialized palliative care and psychological intervention at home for incurable cancer patients
45404131|NCT01036841|Drug|desmopressin tablet|Administration of desmopressine tablet
45404132|NCT01036841|Drug|desmopressin MELT formulation|Administration of desmopressine MELT formulation
45512501|NCT03693261|Procedure|Valve replacement|cardiac surgery for aortic or mitral valve replacement as part of their standard medical care
45512502|NCT03685695|Other|Laboratory Biomarker Analysis|Correlative studies
45512503|NCT03685695|Device|Monitoring Device|Wear Fitbit Charge 2
45512504|NCT03685695|Other|Physical Activity|Complete aimed walking steps
45512505|NCT03685695|Other|Quality-of-Life Assessment|Ancillary studies
45512506|NCT03685695|Other|Questionnaire Administration|Ancillary studies
45512507|NCT02177396|Drug|Telmisartan|
45512508|NCT02177396|Drug|Valsartan|
45512509|NCT02177396|Drug|Placebo|
45512510|NCT02030054|Drug|Atorvastatin|Patients were randomly assigned to atorvastatin (40 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
45512511|NCT02030054|Drug|Rosuvastatin|Patients were randomly assigned to rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
45512512|NCT02182622|Drug|Docetaxel|
45404133|NCT03709576|Drug|Pevonedistat|To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
45512513|NCT02182622|Drug|Prednisone|
45512514|NCT02182622|Drug|LDE225|
45512515|NCT02182700|Drug|salbutamol sulfate + ipratropium bromide|120 mcg (salbutamol sulfate) + 20 mcg (ipratropium bromide), inhalation (metered aerosol plus spacer)
45512516|NCT02182778|Drug|Gemcitabine/Cisplatin|Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
45512517|NCT02182778|Drug|Gemcitabine/Cisplatin /S-1|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
45512518|NCT03688971|Drug|Omiganan|Omiganan Topical Gel
45512519|NCT03688971|Drug|Ketoconazole|Ketoconazole Cream
45512520|NCT03688971|Drug|Placebo|Vehicle
45698963|NCT01105312|Other|laboratory biomarker analysis|
45404134|NCT03709576|Procedure|transplant|Although hematopoietic stem cell transplantation (HSCT) is curative for many patients with AML, AML in relapse at the time of transplant is still a major challenge with low rates of leukemia-free survival even with an intensive myeloablative conditioning.
45404135|NCT03709576|Drug|Azacitidine|To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
45404136|NCT01039571|Procedure|double row repair|double row repair for torn rotator cuff were performed to compare with the conventional single row repair
45404137|NCT00122460|Drug|Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)|Subjects in will receive initial dose of 400 mg/m^2 cetuximab (over 2 hours) followed by weekly doses of 250 mg/m^2 (over 1 hour). All doses will be given by intravenous (IV) infusion. Subjects will receive either Cisplatin (100 mg/m^2 on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (Area under the curve (AUC) 5 IV on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks
45404138|NCT00122460|Drug|Platinum (Cisplatin or Carboplatin) + 5-FU|All doses will be given by IV infusion. Subjects will receive either Cisplatin (100 mg/m^2 on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (AUC 5 IV on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks
45404139|NCT03768466|Drug|Brand Name: Targin®|Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral
45404140|NCT03768388|Drug|levoketoconazole|food effect
45404141|NCT03763396|Drug|Ketoconazole (KCZ)|Oral Tablet
45404142|NCT03763396|Drug|Posaconazole (PCZ)|Delayed Release Oral Tablet
45404143|NCT01320436|Dietary Supplement|Curcumin|3 capsules (820 mg containig 500 mg curcumin each) twice daily.
45404144|NCT01320436|Drug|5-aminosalicylic acid|The dosage of 5ASA medication will be the maximum dosage given in this group of patients according to clinical guidelines (4gr' per os + topical 1gr mesalamine
45404145|NCT04794088|Drug|Imatinib Mesylate intravenous solution|A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 200mg imatinib (100mg/h).
45404146|NCT04794088|Drug|Placebo|A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 25ml placebo (12.5ml/h).
45404147|NCT03763084|Drug|Acetaminophen|For patients in the acetaminophen group, oral acetaminophen supplemented dexmedetomidine sedation will be provided after surgery.
45404148|NCT03763084|Drug|Sufentanil|For patients in the control group, sufentanil supplemented dexmedetomidine sedation will be provided after surgery.
45404149|NCT03763006|Procedure|Eyelid cleaning|This is a pure hypochlorous acid that kills many microbes, but remain very friendly and non-toxic for the ocular surface.
45404150|NCT01567618|Drug|Docetaxel|"Docetaxel 50mg/m2 iv drip, repeat every two weeks;~Efficacy will be evaluated every three cycles."
45404151|NCT01567618|Drug|Fluorouracil|Fluorouracil 400mg/m2 iv D1; Fluorouracil 2400mg/m2 civ 46 hours; repeat fortnightly and evaluate every two cycles
45404152|NCT03768154|Procedure|Supine + spontaneous effort|without muscle paralysis in supine position
45404153|NCT03768154|Procedure|Supine + paralysis|administer muscle paralysis in supine position
45512521|NCT03536624|Behavioral|6 days spa residential program|6 days spa residential program combining psychological intervention, physical activity, thermal spa treatment, health education and corrections of eating disorders.
45512522|NCT03693027|Dietary Supplement|PTx800 lozenges|PTX800 is a nutritional supplement containing generally recognized as safe designated active ingredients in a rapid melt oral lozenges.
45404154|NCT03768154|Procedure|Prone + paralysis|change the patient position from supine to prone with muscle paralysis
45404155|NCT03768154|Procedure|Prone + spontaneous breathing|cease the paralysis in supine position
45404156|NCT04771078|Biological|Nonconforming idecabtagene vicleucel|Nonconforming idecabtagene vicleucel is to be administered to participants after lymphodepleting chemotherapy
45404157|NCT03762928|Drug|PF-06651600|200 milligram (mg) PF-06651600 once daily (QD) orally for 11 days
45404158|NCT03762928|Drug|midazolam|single administration of midazolam 2 mg oral solution
45404159|NCT03762928|Drug|efavirenz|single administration of efavirenz 50 mg capsule
45404160|NCT01561456|Drug|AXL1717|AXL1717 administered as oral suspension at 400 mg twice daily for 21 days per cycle; i.e. daily for up to four cycles
45404161|NCT01561456|Drug|Docetaxel|Docetaxel administered as a standard treatment (75 mg/m2 IV infusion over 1 hour) once every three weeks throughout the 4-cycle study
45404162|NCT01321996|Procedure|68Ga-DOTA-NOC PET/CT|procedure: PET/CT scan with 68Ga-DOTA-NOC
45404163|NCT00137436|Drug|Docetaxel|Docetaxel Phase 1 - escalating doses (60 and 75 mg/m2), intravenous therapy (IV), administered every 3 weeks. Phase 2 - Phase 1 optimal combination dose (75 mg/m2, IV, every 3 weeks).
45404164|NCT00137436|Drug|Prednisone|Prednisone Phase1/2 - 5 mg twice a day (BID), oral.
45404165|NCT00137436|Drug|SU011248|SU011248 Phase 1 - escalating doses (12.5, 37.5, and 50 mg), oral, administered on a 2-weeks on, 1-week off daily regimen (Schedule 2/1). Phase 2 - Phase 1 optimal combination dose (37.5 mg/day, oral, Schedule 2/1).
45404166|NCT03762772|Drug|TAF/EVG Vaginal Insert|1 combination vaginal insert (20mg TAF/16mg EVG)
45404167|NCT03762538|Drug|Propofol|Patients will be induced to unconsciousness using propofol intravenously.
45512523|NCT03693027|Dietary Supplement|Placebo control|The placebo of PTX800 is a rapid melt oral lozenge without the active ingredients found in the PTX800 lozenges.
45404168|NCT03721822|Drug|[18F]NOS|[18F]NOS is an investigational radiotracer which each subject will have one [18F]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
45512524|NCT02179814|Drug|AMPT/ Demser|alpha-methyl-paratyrosine (AMPT, trade name: Demser) body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 medication intake time points over 24 hours
45512525|NCT02179814|Drug|Diphenhydramine|Diphenhydramine (25mg) at the first medication intake time point
45512526|NCT02179814|Drug|Placebo|Placebo at the second, third and fourth medication intake time point
45512527|NCT03688893|Device|Laser Application for Dental Bleaching|The Laser used was the Whitening Lase II (DCM EQUIPMENTS).
45512528|NCT04099797|Genetic|(C7R)-GD2.CART cells|"Dose level 0: 1 x 10^7 GD2.CART cells single transduced without C7R with lymphodepletion chemotherapy~Dose Level 1: 1 x 10^7 C7R-GD2.CART cells with lymphodepletion chemotherapy~Dose Level 2: 3 x 10^7 C7R-GD2.CART cells with lymphodepletion chemotherapy"
45512529|NCT05141942|Procedure|Endoscopic Retrograde Cholangiopancreatography (ERCP)|Endoscopic procedure employed to manage biliary and pancreatic diseases
45512530|NCT03688815|Diagnostic Test|myocardial perfusion scintigraphy|Myocardial perfusion scintigraphy as it is described in the international literature.
45512531|NCT02179970|Drug|Plerixafor|A continuous 7 day intravenous infusion, starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.
45512532|NCT03538028|Biological|INCAGN02385|INCAGN02385 administered as an intravenous infusion over 30 minutes.
45512533|NCT03537950|Drug|PLC|Single oral dose of PLC.
45512534|NCT03537950|Drug|CBD|Single oral dose of cannabidiol (CBD) - 600mg.
45512535|NCT03537950|Drug|CBDV|Single oral dose of cannabidivarin (CBDV) - 600mg.
45404169|NCT03762382|Drug|TFV/LNG IVR|TFV/LNG IVR is an intravaginal ring that releases approximately 8-10 mg/day of TFV and approximately 20ug/day of LNG to be used for 90 continuous days.
45404170|NCT03762382|Drug|TFV IVR|TFV IVR is an intravaginal ring that releases approximately 8-10mg/day of TFV to be used for 90 continuous days.
45404171|NCT03762382|Drug|Placebo IVR|Placebo IVR is an intravaginal ring containing no active experimental ingredients to be used for 90 continuous days.
45404172|NCT03767998|Other|Respiratory muscle training for IMST|2 sets of 30 breaths or 6 sets of 10 repetitions with one or two minute of rest between sets, once per day, 5 days per week, training with breathing trainer.
45512536|NCT03685617|Device|Dual Chamber Pacemaker|1. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.
45512537|NCT03685617|Device|His Bundle Pacemaker|1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
45512538|NCT02182856|Drug|Ipratropium bromide 500 µg/salbutamol sulphate 3 mg|
45512539|NCT02182856|Drug|Ipratropium 500 µg|
45404173|NCT03767998|Other|Regular Rehabilitation|Regular Rehabilitation: 2-3 times a week, 6 weeks.
45512540|NCT02182856|Drug|Salbutamol sulphate 3 mg|
45512541|NCT02182856|Drug|Salbutamol sulphate 6 mg|
45512542|NCT03685383|Device|Cytosorb removal column in eCPR|In addition to standard treatment in eCPR in the study group a CytoSorb removal column is added to the va-ECMO system for the prevention of post-cardiac arrest syndrome.
45512543|NCT03685383|Device|standard eCPR (va-ECMO)|Standard treatment in eCPR with a established va-ECMO system.
45512544|NCT02182934|Drug|Ginsana|
45512545|NCT02182934|Drug|Placebo|
45512546|NCT03692949|Drug|LY3451838|One dose administered (IV)
45512547|NCT03692949|Drug|Placebo|Administered IV
45512548|NCT03692949|Drug|Placebo|Administered SC
45512549|NCT03692949|Drug|LY3451838|One dose administered SC
45512550|NCT02183012|Drug|Ibuprofen extrudate|
45512551|NCT02183012|Drug|Ibuprofen lysinate|
45512552|NCT02183012|Drug|Ibuprofen|
45596808|NCT05791955|Behavioral|Planning prompt|The message will prompt people to either click on the link to make an appointment now or text back when they plan to close their health gap
45512553|NCT03688737|Other|low level laser|LLLT with wavelength (λ) of (600 nm to 700nm), The laser will be held 1 cm away from the surface of the target tissue, the irradiated area is 0,5 cm2.The area of impact is the surgical wound zone and the neighboring 0,5-1,0 cm of the adjacent oral mucosa for 1min and 22sec, at day of surgery, 1st day and 3rd day and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative
45512554|NCT03688737|Other|placebo|placebo like device as it like low level laser device shape but with no effect to blind the intervention
45512555|NCT02180048|Dietary Supplement|400 mg of caffeine/day (Two 200mg pills/day)|One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.
45512556|NCT02180048|Dietary Supplement|200 mg of caffeine/day (One 200mg pill and one placebo pill)|This arm will receive one 200 mg caffeine pill and one sugar pill (placebo pill)
45512557|NCT02180048|Dietary Supplement|Two placebo pills/day|This arm will have participants consume two placebo pills each day.
45512558|NCT03688659|Drug|Vancomycin and gentamycin|intravenous
45512559|NCT02180126|Other|Follow-up|Follow-up of of patients with borderline positive ANCA test results
45698964|NCT01328496|Drug|Preparative Regimen|"Fludarabine (75 mg/m2), fractionated total body irradiation (TBI) (12.0 Gy), and cyclophosphamide (120mg/kg) with mesna. Fludarabine will be given once a day at 25 mg/m2 for three days on day -10 to day -8, TBI will be given twice a day at 150 cGy for four days on day -7 to day -4, and cyclophosphamide will be given once a day for at 60mg/kg for two days on day -3 and day -2.~Post-transplantation immunosuppression with cyclosporine and MMF will begin on day -3. Cord Blood infusion will occur on day 0 and G-CSF will start on day +1."
45698965|NCT04488978|Drug|Irbesartan/Amlodipine|QID
45851291|NCT02997306|Procedure|Superior/Medial Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Superior/Medial half of the incision, and interrupted sutures being used on the Inferior/Lateral half of the incision.
45512560|NCT03683043|Drug|Long GnRH agonist protocol|"8. The patients follow long protocol, which includes down regulation starting on day 21 of the previous cycle. The patient is seen after 14 days to confirm down regulation. Serum E2 ≤ 50 pg/ mL and no ovarian cysts observed in transvaginal US.~9. Induction is started on day 3 of the current cycle by gonadotrophins (FSH and LH) daily IM or SC injections provided that the different preparations at the market can be used."
45512561|NCT03683043|Procedure|Embryo transfer|Cusco speculum was used to allow access to the cervix. The vagina was flushed by saline, and the cervical mucus is removed by Q-tips and/ or suction tubes. In few cases, where patients had long vaginae; two Sims' speculums were used to spread the vaginal anterior and posterior vaginal walls apart. In these cases, the attending nurse assisted the gynecologists during transfer The gynecologist asks the embryologist to load the embryos in the transfer catheter, and the gynecologist receives the loaded catheter from a window connecting the lab and operating room. In cases of trans-vaginal ultrasound guided embryo transfer the embryologist hands in the catheter to the gynecologists in the outer sheath and the gynecologist injects slowly the fluid containing the embryo/s. All patients are asked to rest for 30 minutes after the transfer
45512562|NCT02180204|Drug|Tenecteplase|Tenecteplase 0.25 mg/kg IV - Maximum 25 mg
45512563|NCT02180204|Drug|Alteplase|Alteplase 0.9 mg/kg IV - Maximum: 90 mg
45512564|NCT03685227|Other|Yoga Nidra|This is a mind/body technique. Specifically, it is a guided meditation, performed while lying down.
45512565|NCT02183090|Drug|Meloxicam ampoule|
45512566|NCT02183090|Drug|Meloxicam tablet|
45512567|NCT03682887|Procedure|Cryoballoon PV isolation group|"Pulmonary vein isolation will be performed using a cryoballoon catheter.~Esophageal temperature will be monitored to prevent esophageal injury.~A 28mm cryoballoon catheter will be used.~Cryoablation will be performed for 180 secs at -30 C or below on condition that the pulmonary vein is occluded with a cryoballoon.~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~The procedure and ablation times will be evaluated.~The procedure will be completed without checking any other trigger came from beyond pulmonary vein after the administration of isoproterenol~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
45512568|NCT03682887|Procedure|Cryoballoon PV isolation with Additional RA linear ablation group|It is a percutaneous catheter procedure to ablate the source of atrial fibrillation. By femoral vein access, the investigators conduct trans-septal puncture and introduce cryoballoon catheter into left atrium. Because the main foci of atrial fibrillation is pulmonary veins, the investigators isolate 4 pulmonary veins by freezing with cryoballoon catheters. However, in the discovery arm, the investigators conduct additional linear ablation on right atrial cavotricuspid isthmus and septum to reduce potential recurrence in patients with persistent atrial fibrillation.
45512569|NCT03685071|Other|role of CBC as prognostic tool in sepsis.|"Our study will be conducted on children who admitted to PICU in Assuit University Hospital .CBC parameters as TLC , platelet count , and Hb will be evaluated at time of admission , another CBC will be done at 5th day and another one at day of discharge or last one before death.~patients will be classified into three groups according to the outcome(discharge, mortality and has morbidity sequel.)~correlation between the outcome and CBC will be done."
45512570|NCT02752802|Device|Diagnostic Coronary Angiogram|Diagnostic angiographic procedure with the use of the DyeVert System.
45512571|NCT04059471|Biological|Yellow fever vaccine, Institut Pasteur|Full dose and 500IU/dose
45512572|NCT04077099|Drug|REGN5093|Intravenous (IV) infusion. There will be a series of dose escalation cohorts followed by an expansion phase.
45596809|NCT05791890|Drug|Gilteritinib|observational study to evaluate the incidence of infections during therapy with Gilteritinb
45512573|NCT02180282|Device|M22-IPL|"The M22 is an advanced computer-controlled light emission system that incorporates several different light modules.~The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filter that will be used for this evaluation is the Acne Filter that cuts off all light with the wavelength of 400-600 and 800-1200nm."
45512574|NCT02177474|Behavioral|Telephone based peer support|
45512575|NCT02180360|Other|Capoeira training group|"Capoeira training: The experimental Capoeira training protocol, based in the modern styles of Capoeira was applied by an instructor with 17 years of experience in teaching Capoeira, followed the directions of the Basic Programmed Lesson, created by Geraldo Pereira d'Santana (Master Santana) in a Capoeira group called IUNA from the city of São Paulo, Brazil.~In order to perform the Basic Programmed Lesson program, the activities were divided in four stages, being composed of the main movement that characterizes Capoeira (the ginga) and by other movements such as: dodging, unbalancing, traumatizing and acrobatic.~An important thing to highlight in the experimental protocol is that the training performed in the present study used only specific movements of Capoeira, without applying any other traditional stretching exercises. Therefore, it is possible to infer that the results obtained are due to the experimental protocol."
45512576|NCT02177552|Drug|Carboplatin|
45512577|NCT02177552|Drug|Docetaxel|
45512578|NCT02177552|Drug|Capecitabine|
45512579|NCT02177552|Drug|Epirubicin|
45512580|NCT02177552|Drug|Oxaliplatin|
45404174|NCT03767998|Other|Respiratory muscle training for EMST|5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
45404175|NCT03767920|Drug|bupivacaine|TAP block with 20 ml of 0.25% bupivacaine bilaterally
45404176|NCT03767920|Drug|dexamethasone|TAP block with 4 mg dexamethasone bilaterally
45512581|NCT03682653|Drug|Azithromycin|a single dose of Azithromycin will be administered to infants between their 8-27th days of life
45512582|NCT03682653|Drug|Placebo|a single dose of Placebo will be administered to infants between their 8-27th days of life
45512583|NCT04548128|Device|HeartMate 3 Left Ventricular Assist System (HM3 LVAS)|This clinical trial investigates implant of the HM3 LVAS by techniques other than full median sternotomy.
45512584|NCT03684993|Drug|Arabic, Gum|natural gum of acacia tree: Antimicrobial, anti-inflammatory medicinal plant used as a traditional oral hygiene substance (anticariogenic). It is used in treating sore throats, colds, bronchitis, toothache, gingival bleeding and mouth ulcers.
45698966|NCT04464486|Other|SCH Intervention|In addition to receiving usual care from their oncologist and staff, the SCH intervention group will report COVID-19 and cancer-related symptom presence and severity daily into the automated SCH system. Participants in the intervention receive automated self-management support messages for symptoms reported. In addition, COVID-19 symptoms and poorly controlled or worsening cancer symptoms will generate alerts. Based on preset thresholds, alerts automatically generate immediately from the patient's daily call data. The study nurse practitioners (NPs) monitor alerts. The NPs provide follow-up care using the guideline based SCH symptom clinical decision support system. The NPs log into the SCH Alert and Call Data website which displays all of the patients who have called that day and met an alert threshold. The NP calls the patient, delivers symptom management care by phone, and documents care in the patients' electronic health records.
45404177|NCT03767920|Drug|placebo to dexamethasone|TAP block with 4 mg placebo to dexamethasone bilaterally
45404178|NCT03834623|Drug|CC-122|Oral CC-122 at 2 mg daily, 5 days out of 7
45404179|NCT03834623|Drug|Nivolumab|240 mg Nivolumab intravenously days 1 and 15 in each 28 day cycle
45512585|NCT03684993|Drug|Licorice Root|natural licorice, herbal plant to relieve coughs, sore throats, and gastric inflammation. flavouring and sweetening agent. it's anti-caries, soothing anti-inflammatory and anticancer properties benefit against oral diseases and dental caries
45404180|NCT03767842|Device|Visor System|Subjects are monitored one time with the Visor System.
45512586|NCT03684993|Drug|Chlorhexidine|chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
45404181|NCT03767764|Diagnostic Test|Test Yliver|Test Yliver is used to detect autoantibodies against alpha fetoprotein in serum by an ELISA technique
45404182|NCT03993743|Biological|CD147-CART|Three infusions of CD147-CART cells over the course of three weeks into the hepatic artery.
45404183|NCT03773926|Device|Neuro-feedback therapy|The therapy consists of 10 Neuro-feedback training sessions, 2 times per week over 5 weeks.
45404184|NCT03762304|Other|Household blood pressure screening with care encouragement|"During the household survey visit, survey enumerators collected two measurements of the respondent's blood pressure. If either of the measurements exceeded 140 mmHg systolic or 90 mmHg diastolic, enumerators told participants: Your blood pressure readings are higher than normal. High blood pressure is dangerous because it makes the heart work too hard. High blood pressure increases the risk of heart disease and stroke. High blood pressure can also cause other problems, such as heart failure, kidney disease, and blindness. You can control high blood pressure by taking action. Then the enumerators recommend that an individual seek medical care within 2 months."
45404185|NCT01039727|Other|care as usual + 5 specific CDs|care as usual + 5 specific CDs (3 'General pain relief' + 2 'Short relaxations')
45404186|NCT01039727|Other|care as usual + email assistance + AurelisOnLine (AoL) + CDs|care as usual + email assistance (password protected) + AurelisOnLine (AoL) + 5 CDs at the start (same as in arm 2) + more CDs as needed after 1 month
45404187|NCT03762226|Drug|Anti-VEGF|Patients will undergo as part of the routine care 4 monthly anti-VEGF injections.
45404188|NCT03993899|Device|FineHearing strategy or HDCIS strategy|Cochlear implant with FineHearing strategy or HDCIS strategy
45404189|NCT03762148|Dietary Supplement|ferrous fumarate|nutritional iron (14 mg) supplement in form of ferrous fumarate
45404190|NCT03762148|Dietary Supplement|ferrous sulphate|nutritional iron (14 mg) supplement in form of ferrous sulphate
45404191|NCT03762148|Dietary Supplement|ferric pyrophosphate|nutritional iron (14 mg) supplement in form of ferric pyrophosphate
45698967|NCT03465228|Device|Training and LED group|The LED application will be performed before GTL training sessions and will be applied through the spot method with direct contact of the equipment over the irradiated site for 30 seconds. The application will be in four points in the lumbar region, above the gluteal region, with an angle of 90 ° in relation to the cutaneous surface. A wavelength of 660 to 850nm will be used with a frequency of 0 to 1500 Hz and energy irradiated of 0.9 J of each diode totaling 43.2J (48 diodes).
45698968|NCT03465228|Device|Training group|The training sessions will be monitored based on the subjective perception of exertion of the session (PSESession) (FOSTER, 1998), and heart rate. There will be two types of training: continuous and interval training. The sessions of the training group (GT) and group training + LED (GL) will be preceded by a warm-up of 15 minutes. Participants in the two training groups will undergo weekly training twice weekly on non-consecutive days during four weeks. Continuous training will be 30 minutes at 70% to 80% of maximum heart rate, and interval training will be performed 30 minutes at 100% maximum heart rate of laced racing with fixation of an elastic tube in the floating vest, 30 seconds of intense running and 30 seconds interval. The LED off will be performed before training sessions.
45404192|NCT03762148|Dietary Supplement|ferrous fumarate + 3.5 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (3.5 g GOS)
45404193|NCT03762148|Dietary Supplement|ferrous fumarate + 7 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS)
45404194|NCT03762148|Dietary Supplement|ferrous sulphate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferrous sulphate with addition of prebiotics (15 g GOS)
45404195|NCT03762148|Dietary Supplement|ferrous fumarate + Vitamin C|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of Vitamin C
45404196|NCT03762148|Dietary Supplement|ferric pyrophosphate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferric pyrophosphate with addition of prebiotics (15 g GOS)
45404197|NCT03762148|Dietary Supplement|ferrous fumarate + 7 g GOS + Vitamin C|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS) and Vitamin C
45404198|NCT01589159|Drug|Capecitabine|Drug:capecitabine 700mg/m2, twice daily on days 1-14.
45404199|NCT01589159|Drug|Etoposide|Etoposide 30mg/m2, once daily on days 1-7.
45404200|NCT03974711|Other|"In this evaluation, no interventions are performed. It is a data collection effort only. The procedure for this study is the data collection effort."|There is no intervention performed in this evaluation. Data is being collected in an on-label standard of care lateral lumbar interbody fusion procedure.
45404201|NCT03762070|Device|CL Detect™ Rapid Test|Observational study of a FDA cleared device, the CL Detect™ Rapid Test.
45404202|NCT03711292|Behavioral|Antibiotic Stewardship|For the 12-month intervention period, in a stepped-wedge fashion, sites will be exposed to a site-adapted multifaceted stewardship intervention consistent with CDC core elements for outpatient antimicrobial stewardship: commitment, action, monitoring, reporting and education, and also included a behavioral component that used individualized audit and feedback, peer comparison, and public commitment, in addition to standard patient and clinician education on antibiotic prescribing for antibiotic nonresponsive ARIs.
45404203|NCT03937895|Biological|'SMT-NK' Inj (allogeneic Natural Killer cell)|In 120 mL, 3x10^6 (± 20%) cells/kg. weekly administration via Intravenous for 2 weeks. After that, 1 week is a withdrawal period.
45404204|NCT03937895|Drug|Pembrolizumab Injection [Keytruda]|Administration via Intravenous of 200 mg every 3 weeks(one administration per cycle.).
45404205|NCT03761992|Dietary Supplement|Gingko Baloba|Tablets
45512587|NCT03684915|Device|Rotary files|using rotary files in cleaning root canals of infected primary molars
45512588|NCT02177630|Other|Endomyocardial Biopsy|
45698969|NCT03465228|Other|LED group|This group will be applied through the spot method with direct contact of the equipment over the irradiated site for 30 seconds. The application will be in four points in the lumbar region, above the gluteal region, with an angle of 90 ° in relation to the cutaneous surface. A wavelength of 660 to 850nm will be used with a frequency of 0 to 1500 Hz and energy irradiated of 0.9 J of each diode totaling 43.2J (48 diodes).
45404206|NCT03761992|Other|Placebo|Tablets
45404207|NCT03625648|Drug|Pentoxifylline|The non-specific phosphodiesterase inhibitor pentoxifylline (PTX) was approved by the FDA in 1984 for the treatment of peripheral vascular disease.
45404208|NCT03625648|Drug|Placebo|placebo
45512589|NCT04059315|Other|surgical treatment of facial bone fracture|oral and maxillofacial injury patients admitted in our hospital. patients are getting treatment of soft and bone frature as follow soft tissue repaire, IMF, ORIF, consrvative.
45512590|NCT04062279|Diagnostic Test|serum alpha synuclein autoantibodies, motor and non motor scales|measuring serum alpha synuclein autoantibodies by ELIZA at baseline assessment
45512591|NCT03623685|Diagnostic Test|measurement of uterocervical angle|We will measure between internal cervikal os and external cervical os. After we will draw a line between anterior uterine wall and internal cervical os. Then we will measure angle between two lines
45404209|NCT03761836|Device|ShangRing|The ShangRing™ is a device for male circumcision that was invented by Jian Zhong Shang and has been on the Chinese market since 2005. It consists of a sterile device with two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. It currently holds a European Conformity (CE) mark, an EN ISO certificate, and is FDA approved. Clinical data from ShangRing studies in Africa were reviewed by the WHO Technical Advisory Group (TAG) on Innovations in Male Circumcision in January 2013 and were found to meet its clinical requirements. The ShangRing manufacturer was accepted by the WHO Prequalification Programme for Male Circumcision Devices in 2015.
45404210|NCT03767452|Drug|Xiaflex® 0.58 mg|0.25 mL injections.
45512592|NCT02756078|Device|TEST Contact Lens|
45512593|NCT02756078|Device|CONTROL Contact Lens|
45512594|NCT02030132|Behavioral|Feedback compared to 75th percentile|
45512595|NCT02030132|Behavioral|Forgiveness|
45404211|NCT04731142|Device|Huma|V. Digital remote patient monitoring using blood pressure and blood sugar devices in combination with a smartphone application ('the Huma app'). Participants are provided with home monitoring devices and download the Huma app. Participants are shown how to use the devices, how to input measurements into a smart phone and how to set personal goals. Data recorded via the Huma app is self-reported and includes activity data, diet information, blood glucose measurements, blood pressure measurements, weight, and the Diabetes Distress Scale (a self-reported questionnaire used to measure distress related to living with diabetes).
45512596|NCT02030132|Behavioral|Financial Incentive|For the first three months of the study, a weekly lottery will be held. Teams whose average daily step count for that week is ≥ 7000 will be eligible to collect their lottery winnings. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
45512597|NCT02030132|Behavioral|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
45512598|NCT02183168|Drug|Meloxicam suppository|
45512599|NCT02183168|Drug|Meloxicam tablet|
45512600|NCT02183168|Drug|Indomethacin|
45404212|NCT04731142|Behavioral|Video group consultations|"Each patient is invited to attend a total of three VGCs during the 12-weeks lasting approximately one hour and 15 minutes each. Each session is facilitated by a Practice Nurse (PN) and consists of 6-10 people with T2DM. The self-reported Huma app (see below) and patient EPR data are used to populate a Discussion Dashboard which is used in each VGC to facilitate discussion. During the first VGC session, patient goals are discussed and adjusted in a group setting with topics relevant to their condition covered by the PN. Between each VGC session, patients spend time working on their goals and continuing to enter self-reported metrics into the Huma app. During the second and third VGC sessions, each patient is discussed, along with their performance against agreed goals. The PN also uses pre-prepared content to discuss topics relevant to managing diabetes (e.g., staying motivated, low carb diets)."
45404213|NCT04731142|Behavioral|KNOW Diabetes|Each patient is signed up to a series of educational email campaigns to complement the VGC sessions and provide broader education around diabetes management. Patients receive two emails per week during the 12-week service on a variety of topics.
45404214|NCT04731142|Other|Standard of care|Normal primary care service provided to matched control group.
45404215|NCT03767374|Procedure|Inguinal swab sample|Inguinal samples using swab at cross-sectional visit
45512601|NCT02183246|Drug|Porfiromycin|
45512602|NCT02183246|Drug|Placebo|
45512603|NCT02183246|Radiation|Radiotherapy|
45512604|NCT02183324|Drug|Low dose of BI 1356 BS|
45698970|NCT03460002|Biological|Measles vaccine|A measles vaccine prequalified from the World Health Organization will be administered in one dose by deep subcutaneous injection into the left subscapular region by a local nurse.
45512605|NCT02183324|Drug|Medium dose of BI 1356 BS|
45698971|NCT03460002|Biological|Oral polio vaccine|A bivalent oral polio vaccine prequalified by the World Health Organization will be administered in one or two doses directly into the mouth of the vaccinee with two drops per dose by a local nurse.
45698972|NCT01105702|Drug|Temozolomide|
45404216|NCT03767374|Procedure|Anal swab sample|Anal samples using swab at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
45404217|NCT03767374|Procedure|Fecal sample|Fecal sample at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
45404218|NCT03767374|Other|Risk factor assessment|Patients will be asked questions on risk factors associated with MDR/XDR colonization at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization
45512606|NCT02183324|Drug|High dose of BI 1356 BS|
45512607|NCT02183324|Drug|Placebo|
45698973|NCT01105702|Drug|Bevacizumab|
45698974|NCT01105702|Drug|Lithium Carbonate|
45512608|NCT02183402|Drug|Digoxin|
45512609|NCT02183402|Drug|BI 1356|
45512610|NCT02183480|Drug|Linagliptin, low dose|
45512611|NCT02183480|Drug|Linagliptin, medium dose|
45512612|NCT02183480|Drug|Linagliptin, high dose|
45512613|NCT05141864|Biological|Acmella oleracea gel|Study group will use Acmella oleracea gel during the digital rectal examination.
45512614|NCT05141864|Drug|Lidocaine 2 % Topical Cream|Control group will use lidocaine 2% gel during the digital rectal examination.
45512615|NCT05141864|Other|Ultrasound gel|Control group will use ultrasound gel during the digital rectal examination.
45512616|NCT02177864|Dietary Supplement|Fiber|
45512617|NCT02177864|Other|Placebo (low fiber bar)|
45512618|NCT02180516|Drug|Meloxicam|
45512619|NCT02180516|Drug|Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac|
45698975|NCT01105702|Radiation|Radiation|
45698976|NCT03465150|Other|acne|Patient with acne
45698977|NCT01197898|Biological|Collagenase Santyl Ointment|Topical daily application
45698978|NCT01197898|Other|Placebo Comparator|Topical daily application
45698979|NCT03129750|Device|Drug Coated Balloon|Peripheral PTA with a drug coated balloon
45698980|NCT03468582|Combination Product|123I radiolabeled 3BNC117|123I radiolabeled 3BNC117
45512620|NCT03537872|Behavioral|Miner-Friendly (MF) Service Venues TB/HIV Integration Strategies|"In addition to the control condition strategies (marked PS), the MF intervention includes additional strategies (marked MF):~STRUCTURAL LEVEL Co-location of TB and HIV services (PS); Co-location of clinical and non-clinical services (MF); Demand creation (MF); Weekend service hours (MF) CLINIC LEVEL Intensified TB case finding and IPT (PS); Test and START (PS); Training for healthcare workers (PS); Job aids and mentorship for healthcare workers (MF) INDIVIDUAL/FAMILY LEVEL Health literacy for patients (PS); Family counseling (PS - limited); One-way SMS text messaging and lay counselor support for adherence and retention (MF); A menu of options for medication refills for miners unable to visit the clinic on a monthly basis (MF)"
45512621|NCT03537872|Behavioral|Public Sector (PS) Health Facilities TB/HIV Integration Strategies|STRUCTURAL LEVEL Co-location of TB and HIV services CLINIC LEVEL Intensified TB case finding and IPT; Test and START; Training for healthcare workers INDIVIDUAL/FAMILY LEVEL Health literacy for patients; Family counseling (limited); Adherence support from nurses and village health workers
45512622|NCT02183636|Drug|Linagliptin/pioglitazone, FDC formulation C5|film coated tablet (5 mg/45 mg)
45512623|NCT02183636|Drug|Linagliptin/pioglitazone, FDC formulation C8|film coated tablet (5 mg/45 mg)
45512624|NCT02183636|Drug|Linagliptin tablet|5 mg
45512625|NCT02183636|Drug|pioglitazone tablet (Actos®)|45 mg
45512626|NCT05141786|Drug|MRG002|Administrated intravenously
45512627|NCT02180750|Other|Memory Work Therapy|
45512628|NCT02180750|Other|Standard care|Pediatric clinic, ART
45512629|NCT02183714|Drug|Songha Night ®|
45512630|NCT02183714|Drug|Placebo|
45404219|NCT03767296|Drug|Ephedrine Hydrochloride 3 MG/ML|"Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Ephedrine (E): 6 mg, 6mg, 9 mg, 9 mg, 12 mg, …..(max 24mg/bolus) A total amount of 140 mg Ephedrine will not be exceeded.~Titrated according to the desired effect (= MAP decrease < 20%)"
45404220|NCT03767296|Drug|Phenylephrine|"Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Phenylephrine (PE): 50μg, 50μg, 100μg, 100μg, 150μg, 150μg,…(max 500µg/bolus) A total amount of 1500 μg will not be exceeded. Titrated according to the desired effect (= MAP decrease < 20%)"
45404221|NCT03761758|Device|Spectacle lenses|Spectacle lenses with clear central apertures
45404222|NCT03761602|Other|Not applicable (for observational studies)|This study is an observational study. No intervention will be administered for research purposes.
45512631|NCT02256410|Device|Stimulation|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief electric stimulation, thus targeting the treatment to specific peak pain regions. Preliminary evidence supports the effectiveness of this device in reducing pain and disability over 6 sessions
45512632|NCT02256410|Other|Sham|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief mechanical pressure.
45512633|NCT02183948|Drug|Oxytocin|
45512634|NCT02183948|Drug|Placebo|
45698981|NCT04947150|Behavioral|Location-triggered notification|"If participants are randomized to have this component ON, the app will send the notification when the participant's smartphone is within a 50-meter geofence around designated grocery stores. No more than one notification will be sent per week. Mindfulness of program goals in the moment of decision making is expected to facilitate program-consistent food purchasing behaviors. Participants assigned to have location-triggered message delivery OFF will receive their weekly recommendations and reminders messages at standard times throughout the week. The content of the messages will not differ according to whether this component is ON vs. OFF."
45512635|NCT02184026|Behavioral|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing, child-friendly exposure to the trauma-nightmare, and rescription.
45512636|NCT03537716|Device|Treatment with High Intensity Focused ElectroMagnetic system|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
45512637|NCT05141630|Procedure|sentinel lymph node biopsy or targeted axillary dissection alone|sentinel lymph node biopsy or targeted axillary dissection alone
45512638|NCT05141084|Other|Education, lifestyle|The weight loss program itself is the intervention, which will involve lifestyle modifications and intervention.
45512639|NCT02178020|Device|knee arthroplasty, standard polyethylene|total knee replacement follow-up; clinical and radiographic; revision rate
45512640|NCT02178020|Device|knee arthroplasty, XLP polyethylene|total knee arthroplasty with highly crosslinked polyethylene tibial liner
45512641|NCT04530032|Other|ketogenic/modified Atkins diet|ketogenic/modified Atkins diet use
45512642|NCT04530032|Other|Standard diet|standard (normal) diet use
45512643|NCT02184104|Dietary Supplement|Caffeine|
45512644|NCT02184182|Procedure|VLS ablation/portal ligation/hepatectomy|"Step1:~exploratory laparoscopy to exclude extrahepatic disease~right portal vein ligation if surgically feasible~RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)~radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible~CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1~Step 2: only if FRL/body weight > 0.5~- laparoscopic/laparotomic right trisectionectomy"
45512645|NCT02184260|Drug|Metamizole|
45512646|NCT02184260|Drug|Placebo|
45512647|NCT02178176|Behavioral|Education, encouragement, card sort|"Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.~We will recognize patients' social and cultural context by addressing health-related priorities identified by the patient. The goal will be to identify those priorities which are likely to influence engagement in care and adherence to treatment. We will assess both biomedical (physical symptoms, diet and exercise) and nonbiomedical (financial, social and emotional) needs patients with Type 2 diabetes mellitus and depressive symptoms may wish to discuss in the context of their health. After the patients complete the card sort, interventionists will engage the patient in the 4-step problem solving process."
45512648|NCT02178176|Behavioral|Education, encouragement|Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.
45512649|NCT05140928|Other|Dadiah Pudding|Supplementation of Dadiah Pudding to pregnant women. One cup a day for 18-26 weeks of pregnancy
45512650|NCT05140928|Other|Pudding without Dadiah|Supplementation of Milk Pudding without dadiah to pregnant women. One cup a day for 18-26 weeks of pregnancy
45512651|NCT03813147|Drug|Azacitidine|Given IV
45512652|NCT03813147|Drug|Cytarabine|Given intrathecally and IV
45512653|NCT03813147|Drug|Fludarabine Phosphate|Given IV
45512654|NCT03813147|Drug|Methotrexate|Given intrathecally
45512655|NCT03813147|Drug|Pevonedistat|Given IV
45512656|NCT03813147|Drug|Therapeutic Hydrocortisone|Given intrathecally
45512657|NCT02180984|Device|TMS|Transcranial Magnetic Stimulation has developed into a powerful tool that utilizes magnetic fluxes to non-invasively stimulate the human cortex. The technique involves placement of a small coil over the scalp; passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex.
45512658|NCT02181062|Behavioral|Walking Intervention|"4-week series of twice-weekly 1-hour group-based case-manager-led interactive sessions.~The intervention will provide the knowledge necessary to improve stroke risk factors. Case manager group leaders will teach that seeing a healthcare provider regularly and monitoring blood pressure prevents strokes; all participants will be provided with the National Institute on Aging booklet, How to Talk to your Doctor and the contact information for their healthcare provider.~Participants will be given a pedometer and be trained to use it to measure steps, with the goal of reaching 10,000 steps each day.~The intervention will utilize attribution retraining to teach seniors that stroke risk factors including sedentary lifestyle should not be attributed to old age."
45512659|NCT03684837|Dietary Supplement|Vitamine D supplementation|a vitamine D dose for week
45512660|NCT03684837|Other|chronic exercise in whole body vibration (WBV)|exercise in WBV during 03 months, e times per week
45512661|NCT03810417|Drug|Digoxin Antibodies Fab Fragments|Digoxin antibodies
45698982|NCT04947150|Behavioral|Reflections on benefits of change|Participants will reflect on anticipated benefits of purchasing healthy foods, consistent with motivational interviewing and self-determination theory. Message content will be personalized as follows: During the initial workshop, all participants will complete an exercise identifying benefits of healthy eating that are important to them. Message content will then be programmed to be personalized according to anticipated rewards important to that participant. Participants assigned to have this intervention component OFF will not have content about anticipated benefits of change added to any messages.
45512662|NCT03810417|Other|Placebo|Saline
45512663|NCT03902691|Drug|Pegol-Sihematide|Participants received Pegol-Sihematide by subcutaneous injection once every 4 weeks ; the dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
45512664|NCT03902691|Drug|ESPO|Participants received ESPO by subcutaneous injection or subcutaneous injection weekly. The dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 g/dL.
45512665|NCT03808155|Drug|Tamsulosin|The drug ist taken once a day per os five days prior to the operation and two days after the operation.
45512666|NCT03808155|Drug|Placebo Oral Tablet|The placebo ist taken once a day per os five days prior to the operation and two days after the operation.
45512667|NCT03677583|Other|Duckweed|various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
45512668|NCT03677583|Other|Spinach|various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
45512669|NCT02752958|Drug|stannous fluoride|0.454% w/w (weight per weight) stannous fluoride
45512670|NCT02185664|Procedure|landmark technique|The apex of the imaginary triangle formed between the two heads of sternocleidomastoid and clavicle was used as the point of needle entry, just lateral to the pulsation of the internal carotid artery and directed towards the ipsilateral nipple at an angle of 45 degrees.
45512671|NCT02185664|Device|Static Ultrasound technique|Static ultrasound guided internal jugular vein cannulation was performed by using the transthoracic echocardiography probe supplied with the transesophageal echocardiography machine in the cardiothoracic surgery operation theatre. The internal jugular vein was located and marked using this method prior to puncture.
45512672|NCT02185742|Behavioral|Strength Based Case Management|
45512673|NCT02181218|Drug|Romidepsin|
45512674|NCT02181218|Drug|Gemcitabine|
45512675|NCT02181218|Drug|Oxaliplatin|
45512676|NCT02181218|Drug|Dexamethasone|
45512677|NCT02181218|Drug|Pegfilgrastim|
45512678|NCT02184650|Other|Premature infants with a GA < 32 weeks|At 3 years of age: ASQ (filled in by parents)
45512679|NCT03536234|Drug|Triptorelin acetate depot|3.75 mg triptorelin depot (monthly injections). 3 doses in total
45512680|NCT03682497|Drug|AZD9977|AZD9977 capsules taken orally for 28 days.
45512681|NCT03682497|Drug|Spironolactone|Spironolactone tablets taken orally for 28 days.
45404223|NCT03761524|Procedure|Customized V plate fixation|(CT) scan is taken for the patients and a customized V pattern plate will be designed .Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position guided by the CAD/CAM plate. MMF will be done.Fracture fragments will be fixed using CAD/CAM plate .
45404224|NCT03761524|Procedure|Conventional miniplates fixation|Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position. MMF will be done.Fracture fragments will be fixed using conventional miniplates fixation of angle fracture.
45512682|NCT02950922|Drug|RVT-501 0.2% ointment|
45512683|NCT02950922|Drug|RVT-501 0.5% ointment|
45512684|NCT02950922|Other|Vehicle ointment|Placebo comparator
45512685|NCT04059627|Device|Heart Track|"Description of the device: Wearable heart rate sensors are used in Heart-track, and a receiver on a smartphone app. Real-time wireless heart rate data is sent to paired mobile device with a wireless distance of up to 10m. The sensor is able to monitor a heart rate range of 30 to 240 beats per minute.~Another component of Heart-track is a Heart-track mobile app which captures and reflect real-time heart rate from the heart rate sensor. The mobile app also includes warm-up and cool down exercises that are gamified and supported on a smart-phone running on Android or iOS platforms.~The HR sensor will be purchased by our collaborator, Immersive Play Pte Ltd."
45512686|NCT02184728|Device|End-tidal CO2(portable capnometer)|End-tidal CO2(portable capnometer: EMMATM, Side stream capnometry module:Datex-Ohmeda S5 Anesthesia Monitor )levels were recorded at the time of arterial blood gas sampling.
45512687|NCT03469791|Procedure|Surgical treatment of Degenerative Spondylolisthesis|
45512688|NCT02184806|Procedure|orthotopic graft|(1) laparoscopy (2) ovarian fragments can be put back inside the pelvic cavity close to the natural location of the ovaries or
45851292|NCT02997306|Procedure|Inferior/Lateral Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Inferior/Lateral half of the incision, and interrupted sutures being used on the Superior/Medial half of the incision.
45404225|NCT00410813|Drug|dasatinib|given orally
45404226|NCT02366572|Other|Control|Non pulse extruded cereal
45404227|NCT02366572|Other|Pea protein|Pulse extruded cereal
45404228|NCT02366572|Other|Pea starch|Pulse extruded cereal
45404229|NCT02366572|Other|Pea fibre + pea starch|Pulse extruded cereal
45404230|NCT02366572|Other|Pea protein + pea starch|Pulse extruded cereal
45404231|NCT02366572|Other|Pea fibre + pea starch + pea protein|Pulse extruded cereal
45404232|NCT03767140|Procedure|acupuncture|The patients were randomized in two groups, one verum acupuncture, submitted to real acupuncture treatment, and the other sham acupuncture, treated with false acupuncture
45512689|NCT02184806|Procedure|heterotopic graft|"put under the skin~the ovarian fragments can be put under the skin of the abdomen"
45512690|NCT02185898|Other|Leading U.S. non-menthol cigarette|Tobacco-burning non-menthol cigarette
45512691|NCT02185898|Other|Leading U.S. menthol cigarette|Tobacco-burning menthol cigarette
45512692|NCT02185898|Other|Electronic cigarette #1|Electronic cigarette
45512693|NCT02185898|Other|Electronic cigarette #2|Electronic cigarette
45512694|NCT02185898|Other|Electronic cigarette #3|Electronic cigarette
45512695|NCT02185898|Other|U.S. Market-sample electronic cigarettes|Marketed electronic cigarettes
45512696|NCT02185976|Other|cartoon|5 different cartoons which will be recorded on a tablet PC.
45512697|NCT02186054|Device|MRI examinations|Consented patients will be required to stay in the MRI scanner to complete the 2 additional sequences once their standard exam is completed.
45512698|NCT02030444|Procedure|PET-MRI and EBUS-TBNA|
45851293|NCT02996916|Drug|Olmesartan|10-40mg daily
45404233|NCT03704194|Behavioral|Adapted LiFE|The standardized components include presenting the Adapted LiFE user manual to participants, and teach participants to embed the exercise activities in their daily routine with the LiFE activity calendar.
45404234|NCT03704194|Behavioral|Attention control|Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.
45404235|NCT03760978|Drug|Dexmedetomidine|
45404236|NCT03760900|Combination Product|Autologous Umbilical Cord Blood Stem Cells Therapy|Autologous Umbilical Cord Blood Stem Cells Therapy,the dose is 5×107cells/kg, within 24 hours after birth
45404237|NCT03766984|Drug|Diclofenac sodium 25 mg|Diclofenac sodium 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
45512699|NCT03684681|Behavioral|Peer Navigator Intervention|A peer navigator delivers an intervention to current drug users and uses their own training and real- life experiences to help people meet their goals.
45512700|NCT03684681|Behavioral|Social Work Intervention|A hospital social workers uses their own previous training to help people meet their goals.
45404238|NCT03766984|Drug|Tramadol hydrochloride 25 mg|Tramadol hydrochloride 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
45404239|NCT03766984|Drug|Diclofenac sodium 25 mg/Tramadol hydrochloride 25 mg|Fixed-dose combination tablet containing diclofenac sodium 25 mg and tramadol hydrochloride 25 mg (Laboratorios Tecnandina S.A., Ecuador)
45512701|NCT03677505|Device|KoMAC videolaryngoscope|Double lumen endotracheal intubation was performed with the KoMAC videolaryngoscope
45512702|NCT03677505|Device|Macintosh Laryngoscope|Double lumen endotracheal intubation was performed with the Macintosh Laryngoscope
45512703|NCT02805660|Drug|Mocetinostat - 50 mg|Participants received mocetinostat three times weekly as an oral capsule.
45512704|NCT02805660|Drug|Mocetinostat - 70 mg|Participants received mocetinostat three times weekly as an oral capsule.
45512705|NCT02805660|Drug|Mocetinostat - 90 mg|Participants received mocetinostat three times weekly as an oral capsule.
45512706|NCT02805660|Drug|Mocetinostat - Recommended Phase 2 Dose (70 mg)|Participants received mocetinostat three times weekly as an oral capsule, at the dose recommended after Phase 1 (70 mg).
45512707|NCT02805660|Drug|Durvalumab - 1500 mg|Participants received durvalumab as an intravenous infusion every 4 weeks.
45512708|NCT02186132|Drug|Atropine 0.6 mg|Atropine 0.6 mg intravenous
45512709|NCT02186132|Drug|Atropine 1.2 mg|Atropine 1.2 mg intravenous
45512710|NCT03682419|Procedure|VKA Patients|Venepuncture and capillary blood collection from Patients receiving Warfarin Therapy
45512711|NCT03682419|Procedure|Non-VKA Patients|Venepuncture and capillary blood collection from Patients not receiving Warfarin Therapy
45512712|NCT02030522|Behavioral|Accelerated Resolution Therapy (ART)|"The ART protocol will be delivered in 2-5 sessions. Imaginal Exposure (IE) will be used whereby service members and veterans will be asked to recall (verbally or non-verbally) details of the traumatic event(s) while focusing their attention on physiological sensations, thoughts, and emotions. This short period of exposure to the memory will be followed by identification and diminishment of the emergence of any uncomfortable emotional or somatic symptoms. Imagery Rescripting (IR) will be used to change (replace) negative traumatic images to positive images. The service member/veteran will imagine and play out an affectively-driven solution to change sensory components of the memory, as if they were the director of the movie of the memory they are working on."
45404240|NCT03758872|Diagnostic Test|cuff assisted colonoscopy(with cuff use of endocuff vision second generation)|this is a cohort prospective comparative, a group without cuff in 2017, 517 patient included in the retrospective phase, and in 2018, 517 patient will be included in the prospective phase with CUFF for detecting polyps
45404241|NCT00405821|Drug|Acyclovir|400mg twice daily for 24 months
45404242|NCT00405821|Drug|Placebo|Placebo tablet twice daily for 24 months
45404243|NCT03766828|Procedure|inside-out-access technique with inside-out access device (Surfacer (R))|inside-out-access technique with (Surfacer (R)) with a new CE certified device (Surfacer (R), Bluegrass Vascular)
45404244|NCT03766828|Procedure|access technique including Sharp recanalization|access technique with Sharp recanalization via interventional radiology
45404245|NCT03928600|Combination Product|Cervical Foley combined with Misoprostol|Placement of cervical Foley catheter along with application of vaginal misoprostol 25ug that will be repeated 4/4h until 150ug
45404246|NCT03928600|Drug|Dinoprostone 10mg insert OR|Application for 24h of Dinoprostone 10mg insert
45404247|NCT03928600|Drug|Misoprostol|Application of vaginal misoprostol 25ug 4/4h until 150ug
45404248|NCT03924856|Drug|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
45404249|NCT03924856|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2, IV infusion on Days 1 and 8 of each 21-day cycle
45404250|NCT03924856|Drug|Cisplatin|Cisplatin 70 mg/m^2, IV infusion on Day 1 of each 21-day cycle
45512713|NCT02181764|Drug|KRN23|Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg
45512714|NCT03536156|Other|Four intra-oral optical impression taken successively|"Four intra-oral optical impression images will be taken successively on a patient:~Optical impressions are designed to record adjacent implant site teeth and peri-implant soft tissue PEI using an Optical Camera. The optical camera works like a camera and does not come into contact with the patient's mucous membranes or teeth. The images obtained are saved in STL format on an anonymized file.~The 4 aligned surfaces thus obtained will be cut using a 3D image processing software. A fixed cylinder will extract the PEI from the 4 surfaces. The volume of these 4 PEIs at T0 min, T30 sec, T2 min and T5 min will be calculated using a software"
45512715|NCT02184884|Device|MACE after OPCAB|
45512716|NCT02184884|Device|without MACE after OPCAB|
45512717|NCT03536780|Drug|Avelumab and Gemcitabine|"Avelumab: 10 mg/kg by IV infusion over 1 hour, every 2 weeks~Gemcitabine: 1000 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle"
45512718|NCT02052336|Drug|CJ-12420 200mg + Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
45512719|NCT02052336|Drug|CJ-12420 200mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
45512720|NCT02052336|Drug|Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
45512721|NCT02181920|Drug|Metamizole|
45698983|NCT04947150|Behavioral|Coach monitoring|Coaches will monitor participant food purchases via a dashboard for viewing purchase data, and send messages designed to provide feedback and enhance supportive accountability for program goals. The messages will provide reinforcement for purchases consistent with program goals and express concern for areas in which adherence is low. Participants assigned to have this component OFF will not receive these extra messages or phone calls, and their food purchases will only be viewed by research staff for research outcome assessment purposes.
45698984|NCT04947150|Behavioral|Household support|If participants are assigned to have household support ON, one adult in the household will receive weekly text messages designed to elicit support for changing food purchases. In addition, the index participant and household member will be invited to participate in one extra workshop session and three brief coaching calls focused on household support. If participants are assigned to have this OFF, household members will have no program involvement.
45404251|NCT03924856|Procedure|Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])|Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
45404252|NCT03924856|Drug|Placebo|Placebo to pembrolizumab by IV infusion, given on Day 1 of each 21-day cycle
45512722|NCT02181920|Drug|Diclofenac|
45512723|NCT02181920|Drug|Diclofenac placebo|
45512724|NCT02181920|Drug|Metamizole placebo|
45698985|NCT04453332|Drug|Oral hormone therapy (estradiol and micronized natural progesterone)|Oral hormone therapy - estradiol 1mg every day and micronized natural progesterone 200mg only 14 days a month
45698986|NCT04453332|Drug|Non-oral hormone therapy (estradiol and micronized natural progesterone)|Percutaneous estradiol gel 1.5mg every day and micronized progesterone 200mg vaginal only 14 days a month
45404253|NCT05419960|Diagnostic Test|Vestibular Assessment|"During the usual hearing assessment (immittance testing and pure-tone and speech audiometry) carried out by patients, a vestibular assessment will be done for the study to detect vestibular disorders:~Videonystagmography (VNG) Is the study of eye movement with the help of infrared googles.~Subjective Visual Vertical (SVV) The patient is asked to orient a line on the vertical axis.~Video Head Impulse Test (vHIT)~Cervical and Ocular Vestibular Evoked Myogenic Potential (cVEMP and oVEMP)"
45512725|NCT02185118|Drug|oxygen|"Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
45512726|NCT02185118|Drug|Sevoflurane|"Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
45512727|NCT02185118|Drug|Isoflurane|"Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~Treatment of 100% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
45512728|NCT02186288|Other|High-flow nasal cannula oxygen|
45512729|NCT02807376|Device|Surgeon's 'standard of care' stapler|
45512730|NCT02807376|Device|Ethicon Powered Vascular Stapler|
45512731|NCT02256566|Behavioral|emotional memory training exercise|
45512732|NCT02256566|Behavioral|memory training exercise|
45512733|NCT02186366|Other|Abdominal Massage Therapy|Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
45512734|NCT02186366|Drug|Buspirone|Buspirone by mouth 5mg three times per day for 6week. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
45512735|NCT02053974|Drug|Spironolactone|Spironolactone
45512736|NCT02053974|Other|Placebo|Placebo
45512737|NCT02185196|Drug|Vitamin D3|20,000 IU vitamin D3 in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
45512738|NCT02185196|Drug|Placebo|20,000 IU Miglyol-oil in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
45512739|NCT02052492|Drug|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
45512740|NCT02181998|Drug|Full dose tenecteplase|
45512741|NCT02181998|Drug|Unfractioned heparin|
45512742|NCT02181998|Drug|Enoxaparin|
45512743|NCT02054052|Drug|Bevacizumab|Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE
45512744|NCT03810222|Other|N/A (Observational Study)|This is an observational study and does not include interventions. Exposure is TBI.
45512745|NCT02186444|Other|Personalized Health Information Navigator (PHIN)|"The application (or app) titled Personalized Health Information Navigator (PHIN) is an interactive psycho-educational intervention that will be delivered via mobile tablet technology. The PHIN provides patient-centered education. At the first meeting, the community navigator will provide a visual demonstration of PHIN on the Apple iPad. The community navigator will leave the iPad with the participant for 6-weeks and will stress the importance of using the PHIN app to address any educational or psychosocial needs."
45512746|NCT02186444|Other|NCI Information Booklets (IB)|"Participants will receive a packet of information booklets (What You Need to Know About Prostate Cancer; Taking Time: Support for People with Cancer; and Facing Forward, Life After Cancer Treatment) that address prostate cancer treatment options, the late and long term effects, follow-up care, and sources of support. At the first meeting, the community navigator will provide a review of the print materials and stress the importance of reading the booklets carefully to help prepare for the discussion with your healthcare provider. The community navigator will leave the print materials with the participant for 6-weeks."
45512747|NCT02051322|Device|Jet Nebulizer|
45512748|NCT02051322|Device|Trunk Mask Nebulizer|
45512749|NCT02051322|Device|Aerobika Nebulizer|
45512750|NCT02185352|Drug|BEEP regimen|Bevacizumab 15mg/kg IVF on D1, Etoposide 70 mg/m2 IVF QD, D2-4, Cisplatin 70 mg/m2 IVF on D2, repeat every 3 weeks, for 3 cycles
45404254|NCT05419960|Diagnostic Test|Petrous bone Computed Tomography (CT)|"For patients diagnosed with hearing loss, whether conductive, mixed, and/or a vestibular deficit, a CT scan (without injection) will be proposed for their care.~Petrous bone Computed Tomography (CT) is an imaging technique used as the standard method of evaluation of the boney structures in the ear."
45404255|NCT05419960|Diagnostic Test|Magnetic Resonance Imaging (MRI)|"Patients that have done a CT and for who CT results was abnormal, will additionally require an MRI for their standard care.~Magnetic Resonance Imaging (MRI) is an imaging technique used as the standard method of evaluation of the cochlear, retrocochlear and central and peripheral nervous system. An injection of Gadolinium contrast media will be used to enhance certain recordings."
45404256|NCT03760822|Drug|Ramucirumab|IV ramucirumab at 8 mg/kg on D1 and D15
45404257|NCT03760822|Drug|Paclitaxel|IV paclitaxel at 80 mg/m² on D1, D8 and D15
45404258|NCT01322152|Drug|irinotecan, capecitabine|Irinotecan: 90 mg/m2, d1, iv gtt; Capecitabine: 1200mg/m2 Bid, d1-5, po; The regimen is repeated every 7 days.
45851294|NCT02996916|Drug|Amlodipine|2.5-10mg daily
45512751|NCT02051400|Device|the McGrath® MAC video laryngoscope|
45698987|NCT03464994|Diagnostic Test|ophthalmological examination|"Refraction~Best corrected visual acuity~Intraocular pressure~Slit lamp examination with vital dye (Oxford grading)~Tear break-up time (TBUT)~Schirmer I testing~Specular (TMS-4 Tomey) and elevation (pentacam Oculus and Orbscan Bausch & Lomb) corneal videotopographies~Pachymetry~Questionnaires: Ocular surface disease index, quality of vision (visual analogic scale), and quality of life (NEI-VFQ25)~questionnaire about ichthyosis severity~questionnaire about life quality specifically for patient presenting ichthyosis"
45851295|NCT02997150|Drug|IL-2 Low dose|"Patients receive low doses of Interleukin 2: 0.5 million UI/m²/ injection subcutaneously.~The treatment is initiated with an induction phase of one injection per day for 5 consecutive days, followed by a maintenance phase in which patients will receive one injection every 14 days for 6 months.~At the same time, corticoid treatment will be tapered until its complete withdrawal no later than 3 months from the first injection"
45404259|NCT05414344|Behavioral|Standard Brief Intervention|Immediately following completion of the baseline assessment, participants will be texted a link to a secure website which contains the participant's personalized feedback. Personalized feedback is automatically presented via a programming algorithm that is based on the participants baseline survey responses. The personalized feedback component will include a personalized substance use profile, information on peer norms, prior substance-related consequences experienced by the participant, practical costs (e.g., money spent on substances, fees for a DUI), and standard protective behavioral strategies to limit substance-related risk.
45512752|NCT02051400|Device|the GlidesScope® Ranger video laryngoscope|
45512753|NCT02051400|Device|the Macintosh laryngoscope|
45512754|NCT02186600|Drug|Calcium Carbonate|Used as daily supplement to ensure subject obtains 1200 mg of calcium per day (diet + supplement)
45512755|NCT02186600|Drug|Vitamin D3|Subjects will receive Vitamin D3 supplements to ensure serum level of Vitamin D is at least 30 ng/ml.
45851296|NCT02996838|Drug|TQ-B3234|TQ-B3234 p.o. qd
45851297|NCT02996604|Other|acupuncture|Manual acupuncture treatment will be conducted. thirty minutes duration every time, five times per week for one course, a total four courses.
45512756|NCT02186600|Drug|Risedronate|Risedronate 35 mg orally will be ingested weekly by subjects in Risedronate group.
45851298|NCT02996370|Other|papilla fill index|The clinical photographs were taken baseline, 3 and 6 month. Two T shaped full-round hexagonal straight filaments, each 5 mm, were used in the taking of standardized images.
45851299|NCT02996370|Other|crestal bone loss|Crestal bone loss was measured on digital radiographs at baseline, 3 and 6 month with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
45851300|NCT02996370|Other|probing depth|The change of probing depth between baseline, 3 and 6month. Probing depth was measured with a plastic periodontal probe (mm)
45851301|NCT02996370|Other|Modified sulcus bleeding index|Modified bleeding index was measured baseline, 3 and 6 month. Presence of bleeding on probing were performed at four sites of implants.
45404260|NCT05414344|Behavioral|Trauma-Informed and Peer-Supported Brief Intervention|In addition to the components of the standard brief intervention, the TIPS-BI will include personalized feedback about participants use of substances to cope. Additionally, participants will be provided with psychoeducation about the link between substance use, trauma, and coping motives, and information highlighting the iatrogenic effects that substance use has on negative emotions. Participants will also be given a series of evidence-based alternative coping strategies for managing trauma-related distress such as anxiety, depression, and PTSD. Participants will be asked to set goals related to utilization of these alternative coping strategies. Participants will then be informed that a trained peer who is part of the research team will follow up with them via text message at the monthly time points to review adherence to their goals and offer support.
45404261|NCT05414344|Behavioral|Assessment only|Following the baseline survey, participants in the assessment only group will be texted again 3 and 6 months later to complete follow up assessments. Following the end of the 6-month follow-up, participants will be offered an opportunity to complete the TIPS-BI without peer coach follow-up.
45404262|NCT01446016|Drug|Paclitaxel|Chloroquine 250mg po daily together with Paclitaxel (Taxane) 175 mg/m2 three hours infusion every three weeks.
45404263|NCT01446016|Drug|Docetaxel|Chloroquine 250mg po daily together with docetaxel 75 mg/m2 administered intravenously over one hour every three weeks
45404264|NCT01446016|Drug|Abraxane|Chloroquine 250mg po daily together with Abraxane 260 mg/m2 administered intravenously over 30 minutes every three weeks.
45404265|NCT01446016|Drug|Ixabepilone|Chloroquine 250mg po daily together with Ixabepilone is 40 mg/m2 administered intravenously over three hours every three weeks.
45404266|NCT00137046|Drug|Subcutaneous Insulin|Subcutaneous insulin with dose adjusted according to premeal blood glucose
45404267|NCT00137046|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose
45404268|NCT03383458|Biological|Nivolumab|Specified dose on specified days
45404269|NCT03383458|Other|Placebo|specified dose on specified days
45404270|NCT03760354|Drug|Methylprednisolone|Dose: 500mg/day for the first two days then 2mg/kg per day for three days. Dilution in 0.9% NaCl, 100 ml as a single slow intravenous administration over 60 minutes Total processing time of 5 days
45404271|NCT03760354|Other|Placebo|NaCl 0.9%, 100ml per day as a single slow intravenous administration over 60 minutes for a total treatment duration of 5 days
45851302|NCT02996370|Other|Modified plaque index|Modified plaque index was measured baseline, 3 and 6 month. Presence of plaque index was performed at four sites of implants.
45851303|NCT02996214|Drug|Paclitaxel Liposome|Paclitaxel liposome injection 175 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
45404272|NCT01322230|Other|Control|Multimedia Control
45851304|NCT02996214|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2, given on days 1 and 8 of a 21-day cycle, for 4-6 cycles.
45404273|NCT01322230|Other|WISEMD Original|Current WISEMD
45404274|NCT01322230|Other|Social Networking|Social networking feature
45404275|NCT01322230|Other|Social Networking plus Emotional Design|social networking features plus user interface enhancements
45404276|NCT03760276|Drug|Voriconazole Oral Product (Vfend®)|To be determined mg of Voriconazole (Vfend®, anti-fungal agent)
45404277|NCT03766594|Drug|Sildenafil Citrate|Respatio(R) 25mg tablets four times daily for 24 days preconceptionally starting first day of previous period
45404278|NCT03766594|Drug|Folic Acid|Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally
45851305|NCT02996214|Drug|Cisplatin|Cisplatin 75 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
45404279|NCT03766594|Drug|Placebo Oral Tablet|Placebo tablet apparently identical to Respatio(R) 25mg tablets, taken four times daily for 24 days preconceptionally starting first day of previous period
45404280|NCT03923374|Drug|Subutex / Buprenorphine|Pregnant Mothers must be taking buprenorphine / subutex for opioid use disorder.
45404281|NCT03923374|Diagnostic Test|Fetal & Neonatal MRI|Mothers who consent will be given a fetal MRI and after the baby is born, a neonatal MRI.
45404282|NCT03923374|Diagnostic Test|DNA/Genetic/Pharmacokenetic Blood Draws|Throughout the pregnancy, Mothers will be participating in blood collection throughout the study. At enrollment, we will collect DNA, Genetic and PK blood specimens, then throughout the study, we will be collecting random PK samples.
45851306|NCT02996058|Drug|Dexmedetomidine 0.35µg/kg /h|the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
45512757|NCT02186600|Behavioral|Bone-loading exercises|Subjects will participate in bone loading exercises (weight-bearing and resistance) three times weekly at community YMCAs.
45512758|NCT02054208|Biological|human umbilical cord blood derived mesenchymal stem cells|"Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals~High dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals"
45512759|NCT02054208|Other|Normal saline 2mL|Intraventricular administrations of 2mL Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations
45512760|NCT02052726|Biological|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at Month 0, 1, and 3.
45512761|NCT02052726|Biological|Placebo|Placebo administered at Month 0, 1, and 3.
45512762|NCT02052726|Biological|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at day 1, 8, 30.
45512763|NCT02052726|Biological|placebo|Placebo administered at Day 1, 8, and 30.
45512764|NCT02185430|Drug|saline infusion|saline infusion, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
45512765|NCT02185430|Drug|dexmedetomidine infusion|dexmedetomidine, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
45512766|NCT03536390|Drug|Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)|Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)
45512767|NCT03536390|Drug|Placebo|Placebo
45512768|NCT03561480|Drug|Ferric carboxymaltose|Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50Kg .
45512769|NCT03561480|Drug|0.9% Normal Saline|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight <50 Kg.
45512770|NCT02190188|Device|Wedge Insole 5mm|
45512771|NCT02190188|Device|Knee Brace|
45512772|NCT03561870|Drug|Olaparib 150 MG|Olaparaib: 600 mg/day: 300 mg BID (2 x 150 mg tablets taken orally) each 28 days cycle, until disease progression or unacceptable toxicity
45512773|NCT02054286|Biological|THV01-1|Intramuscular injection of THV01-1 (week 0)
45404283|NCT03758794|Other|interactive lecture|an interactive lecture will be given to a group of dental interns students on child abuse recognition and reporting
45404284|NCT03758794|Other|online education|an online educational module will be sent to a group of dental interns students on child abuse recognition and reporting
45512774|NCT02054286|Biological|THV01-2|Intramuscular injection of THV01-2 (week 8)
45512775|NCT02054286|Biological|Placebo|Intramuscular injection of placebo matching THV01-1 and THV01-2
45512776|NCT02186756|Other|EMG-Biofeedback and Usual care|Please refer to arm description
45512777|NCT02184338|Drug|BIBR 1017 BS powder|
45512778|NCT02184338|Drug|Placebo|PEG 400
45512779|NCT02190344|Device|8-channel paddle coil|MRI Coil
45512780|NCT02054364|Behavioral|FBT and CRT|
45512781|NCT02054364|Behavioral|FBT and art therapy|
45404285|NCT03766360|Behavioral|Functional Analytical Psychotherapy (FAP)|The intervention itself is based on the procedures of Functional Analytic Psychotherapy, a behavioral intervention focusing on improving social functioning.
45512782|NCT03807648|Other|Data Inclusion|Patients in this group will be included in the project
45512783|NCT02186912|Device|Nobel Active, Nobel Procera IBO|
45512784|NCT02186990|Drug|propofol|2,5 mg/kg
45512785|NCT02186990|Drug|etomidate|0,3 mg/kg
45512786|NCT02186990|Drug|etomidate-propofol|0,15 mg/kg etomidate + 1,25 mg/kg propofol
45512787|NCT05657028|Drug|Dexmedetomidine|-In the Dexmedetomidine group, patients will be given IV bolus infusion of dexmedetomidine 0.5 μg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4 μg/kg/hour until 30 min before the end of surgery.
45512788|NCT05657028|Drug|Lidocaine IV|In the Lidocaine group, the patients will be given an IV bolus infusion of lidocaine (2%)1.5mg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg /hour until 30 min before the end of surgery.
45512789|NCT02187068|Drug|Dexmedetomidine|Dexmedetomidine administered intravenously
45512790|NCT02054442|Drug|Cetuximab|We will perform a randomized phase II study to investigate in first line if the addition of cetuximab to MTX is beneficial, i.e. improvement in the PFS, for the patient.
45512791|NCT02054442|Drug|Methotrexate|
45512792|NCT02185586|Procedure|laparoscopic cholecystectomy|
45512793|NCT02038296|Procedure|transarterial chemoembolization|
45404286|NCT00122382|Drug|Abatacept|abatacept 10 mg/kg IV monthly, methotrexate weekly, for 24 months
45404287|NCT00122382|Drug|placebo|placebo IV, monthly, methotrexate weekly for 12 months followed by abatacept 10 mg/kg IV monthly, methotrexate weekly for 12 months
45512794|NCT02053038|Device|iFR|Treatment guided by instantaneous wave-free ratio
45512795|NCT02053038|Device|FFR|Treatment guided by Fractional Flow Reserve
45512796|NCT02053194|Behavioral|Pharmacist-led educational intervention|1) Educational material to participants in the form of a written educational brochure on inappropriate prescriptions that was developed and tested during the EMPOWER study. 2) Evidence-based pharmaceutical opinions sent to the treating physicians.
45512797|NCT02190578|Device|Reveal G4|All subjects tested with the investigational device, Reveal G4, plus with an algorithm of approved assays for HIV.
45512798|NCT03536078|Other|home phototherapy|
45512799|NCT02804178|Drug|ATR-101|125-1000 mg twice per week
45512800|NCT02190734|Other|Sitting in wheel chair|Placebo/control intervention- No treatment, sitting in a wheelchair for 30 minutes
45512801|NCT02190734|Other|Gait training on treadmill|Walking on a treadmill with or without body weight support during 30 minute treatment
45512802|NCT02190734|Other|Gait training overground|Walking overground with or without body weight support during 30 minute treatment
45512803|NCT02054598|Behavioral|Decision aid and navigation|Patients in the intervention group will receive a combined intervention consisting of a CRC screening decision aid and assistance from a trained patient navigator.
45851307|NCT02996058|Drug|Dexmedetomidine 0.5µg/kg /h|the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
45851308|NCT02996136|Device|Flu Symptoms|Flu Symptoms
45851309|NCT02995512|Drug|Colchicine 0.6 mg tablets|1.2 mg PO followed by 0.6 mg PO 1 hour later
45404288|NCT00122382|Drug|methotrexate|Oral, titrated to at least 15 mg per week not to exceed 20 mg per week administered every 28 days from Month 12 to Month 24
45404289|NCT01028716|Drug|Cyclophosphamide|Given IV
45404290|NCT01028716|Biological|Filgrastim|Given SQ
45404291|NCT01028716|Drug|Fludarabine Phosphate|Given IV
45404292|NCT01028716|Drug|Mycophenolate Mofetil|Given PO
45404293|NCT01028716|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC
45404294|NCT01028716|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
45404295|NCT01028716|Drug|Tacrolimus|Given IV or PO
45512804|NCT02190812|Device|Forearm supporter|The forearm supporter be use in tennis elbow.
45512805|NCT02190812|Device|Grip ball|
45512806|NCT02667444|Drug|SB204 4%|Applied topically once daily
45512807|NCT02667444|Drug|Vehicle Gel|Applied topically one daily
45512808|NCT02054676|Radiation|Cone-Beam Computed Tomography preoperative evaluation.|"Procedure: Cone-beam computed tomography (CBCT) preoperative evaluation (e.g. i-CAT, Imaging Sciences International, Hatfield, Pennsylvania, USA). CBCT voxel size is about 0,2 - 0,25 mm . Manufacturer recommended software is used. CBCT evaluation of partially edentulous jaw segments are made during preoperative stage (see Appendix 1):~Non aesthetic and aesthetic zone edentulous jaw segment parameters (height, width, length, mandibular canal walls identification/jawbone quality type visual identification) evaluation;~Every edentulous jaw segment parameter should be graded following: Type I (low risk), Type II (moderate risk), Type III (high risk).~All graded measurements provide overall risk evaluation for implant treatment in non aesthetic and aesthetic zone without aesthetic parameters evaluation. Dental implant is selected if surgery is possible."
45512809|NCT02054676|Procedure|Intraoperative edentulous jaw segment parameters evaluation.|"Surgery is planned preliminary according to preoperative stage edentulous jaw segment evaluation results.~Intervention related study parameters are provided on Appendix 2. Aesthetic parameters related to implant treatment success are evaluated after mucoperiosteal flap elevation: alveolar ridge vertical position, mesial and distal interproximal bone peak height (in the aesthetic zone).~The additional parameters (non aesthetic) are evaluated after dental implant osteotomy preparation and implant placement:~implant drill slippage deeper than planned;~implant threads coverage;~etc."
45851310|NCT02995590|Drug|Hyperpolarized He3|Hyperpolarized Helium can be used as a Contrast Agent for Lung Images using MRI.
45851311|NCT02995278|Other|Does not include a drug needing FDA approval and therefore it is not by definition, a Clinical Drug Trial as defined by FDA.|
45851312|NCT02995200|Behavioral|Accelerometer Based Feedback|
45851313|NCT02995044|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z09-180)
45851314|NCT02995044|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
45851315|NCT02995122|Drug|BAY987516|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code: Z43-090)"
45404296|NCT01028716|Radiation|Total-Body Irradiation|Undergo total-body irradiation (TBI)
45404297|NCT02531724|Drug|Levosimendan|
45404298|NCT02531724|Drug|Placebo|Sodium chloride
45404299|NCT03758482|Other|Probe meal|The probe meal (total caloric content 750 Kcal) will be ingested at a standard rate in 10 min.
45404300|NCT03760198|Drug|Meditoxin|50U of MEDITOXIN is injected intradermally to each axilla
45404301|NCT03760198|Other|Placebo|normal saline is injected intradermally to each axilla
45404302|NCT03760042|Drug|Within-Subject Active vs Placebo Topical Applications|Crisaborole 2% ointment (right side) and Placebo vehicle ointment (left side)
45512810|NCT02054676|Device|Endosseous dental implant placement.|"Endosseous dental implant (e.g. Bone Level SLA implant, Straumann AG, Basel, Switzerland) is placed if possible during intraoperative stage according to study protocol in the aesthetic or non aesthetic zone edentulous jaw segment. Optimally positioned dental implant is surrounded by at least 1 mm of bone for successful treatment outcome in the non aesthetic zone.~Aesthetic zone implant is placed in the optimal three dimensional position. It is surrounded by bone at least 1 mm from lingual side and at least 2 mm from buccal side for successful treatment outcome.~Dental implant apex is at least 2 mm away from anatomically important jaw vital structures.~Dental implant parameters (length, width) are individual (depends on edentulous jaw segment parameters).~Bone and soft tissue augmentation are made if necessary after dental implant placement."
45512811|NCT02054676|Radiation|Dental implant position evaluation.|"Periapical radiograph (e.g. Kodak RVG 6100 Intraoral Digital Imaging System, Carestream Health, Rochester, NY) evaluation is necessary (Appendix 2) to examine implant apex distance to anatomically important vital structures (possible injury) (mandibular canal, nose base) during early postoperative stage.~Digital periapical radiographs are used to assess the edentulous jaw segment after implant placement. The long cone paralleling technique should be used for taking periapical X-ray (prevention of possible creation of foreshortening and elongation).~Postoperative patient's neurosensory evaluation is necessary to assess possible inferior alveolar nerve and lingual nerve injury. After finishing of local anaesthesia patient should be contacted and if there are some sensory deficit complains, patient should be examined."
45512812|NCT02054676|Drug|Medications.|"Patients will be given amoxicillin 500mg for every 8 hours or clindamycin 300mg for every 8 hours for 7 - 10 days after surgery.~Patients will be given Ibuprofen 600mg every 12 hours for pain relief following surgery at least for first three days as needed.~Patients will be given chlorhexidine 0,12% mouth rinse at least every 8 hours starting 24 hours after surgery for 14 days."
45512813|NCT02054676|Procedure|Late postoperative soft tissue evaluation.|"Mesial and distal papillae appearance, vertical soft tissue deficiency (Appendix 3) evaluation during late postoperative stage is necessary for classification accuracy assessment during final single-tooth implant crown placement in the region of aesthetic zone (both parameters are evaluated) and non aesthetic zone (soft tissue vertical deficiency) edentulous jaw segment.~The time after surgery is case depending before provisional and final crown placement.~Peri-implant soft tissue conditioning is recommended with screw retained provisional single-tooth implant crown for approximately 4 - 8 weeks.~Healing abutment placement after dental implant osseointegration is not recommended because of the treatment time saving."
45512814|NCT02256956|Drug|Amitriptyline|25 mg / day for 10 days
45512815|NCT02256956|Drug|Tolterodine|Placebo 1 mg / day for 10 days
45512816|NCT02187536|Drug|Telmisartan|
45512817|NCT02187536|Drug|Simvastatin|
45512818|NCT02187536|Drug|Telmisartan placebo|
45512819|NCT02256722|Drug|KUC 7483 CL|
45512820|NCT02256722|Drug|Bisoprolol|
45404303|NCT03760042|Drug|Within-Subject Active vs. Placebo Topical Applications|Crisaborole 2% ointment (left side) and Placebo vehicle ointment (right side)
45851316|NCT02995122|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
45512821|NCT02256722|Drug|Propranolol|
45851317|NCT02994888|Drug|Cetuximab|All patients will be offered cetuximab 500mg/m2 every 2 weeks, until the time of progression
45404304|NCT03759964|Drug|Ferric carboxymaltose|1g of Ferric carboxymaltose diluted in 100 mL of IV isotonic serum saline at day 1 following surgery
45404305|NCT03759964|Drug|Placebo|100 mL of IV isotonic serum saline at day 1 following surgery
45512822|NCT02256722|Drug|Acipimox|
45512823|NCT02256722|Drug|Salmeterol|
45404306|NCT00106704|Drug|Comparator: Sitagliptin|sitagliptin 10 mg tablet, once daily for 54 weeks
45512824|NCT05655624|Other|Pursed lip Breathing along Mat Pilates|Experimental Group: will be treated with Pursed lip Breathing along Mat Pilates Training.
45512825|NCT05655624|Other|pursed lip breathing without Mat Pilates Training|Control Group will be treated pursed lip breathing without Mat Pilates Training
45512826|NCT02190890|Procedure|Dry needling|
45851318|NCT02994810|Other|Breastfeeding guidance|Breastfeeding guidance
45851319|NCT02994342|Device|Vaginal gel, Medical Device Class 2A|Application twice a day of vaginal gel for 56 consecutive days
45512827|NCT02190890|Procedure|Control|
45851320|NCT02994186|Procedure|Bariatric Surgery|These are patients who will be having either Vertical Sleeve Gastrectomy or Roux-en-Y Gastric Bypass.
45851321|NCT02994186|Other|Medical Weight Loss Program|These are patients who will be starting a structured medical weight loss program.
45404307|NCT00106704|Drug|Comparator: Placebo|Placebo oral tablet once daily for 24 weeks
45404308|NCT00106704|Drug|Comparator: Pioglitazone|Pioglitazone 30 mg tablet once daily for 30 weeks
45404309|NCT03759886|Drug|Paromomycin Sulfate Powder|The patients receive Paromomycin and Metronidazole the day prior to colorectal surgery after mechanical bowel preparation
45404310|NCT03965364|Device|INCRAFT|Device: Endovascular abdominal aortic aneurysm repair Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
45404311|NCT03766282|Device|ECMO|Extracorporeal membrane oxygenation (ECMO) temporarily supports patients with severe cardio-respiratory failure
45404312|NCT01081158|Drug|Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)|"Drug: SCH 900518~Biologic: Peginterferon alfa-2b(PegIntron)~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days .~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly."
45512828|NCT02056314|Other|electronic tutorial|The electronic tutorial will provide information to the participants about the nature of gambling, and how to protect themselves against the risks of problem gambling including information on coping skills, and myths associated with gambling.
45512829|NCT02056314|Other|brochure|The brochure is the current means of informing people about the risks of problem gambling. It includes information about problem gambling and help resources.
45512830|NCT02193620|Drug|PHN131 soft capsule with Nalbuphine HCl 60 mg/cap|Multiple dose of oral PHN131 soft capsule with Nalbuphine HCl 60 mg/cap, initial dose : 120 mg ( 2 capsules), then 60 mg (1 capsule); t.i.d.
45512831|NCT02193620|Drug|Placebo soft capsules|Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.
45512832|NCT02193620|Drug|Dicofenac|All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
45512833|NCT02190968|Behavioral|Usual Depression Care|Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.
45512834|NCT02190968|Behavioral|Mindful Mood Balance|Mindful Mood Balance is an individually tailored, web-based version of Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2002) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participated in 8 internet sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
45512835|NCT02056470|Device|Freedom Total Knee|The Freedom Total Knee System is being implanted in subjects suitable for a total knee replacement
45512836|NCT02056470|Device|Total Knee Replacement|total Knee replacement implant
45512837|NCT02056470|Device|Freedom Total Knee System|Total Knee replacement implant
45512838|NCT02187614|Drug|Diclofenac|
45512839|NCT02187614|Drug|Morphine|
45512840|NCT02187614|Drug|Paracetamol|
45512841|NCT02187614|Drug|Placebos|
45512842|NCT02030678|Drug|irinotecan|Irinotecan monotherapy (trade name: Aili; batches 180103AG [40 mg] and 171231AG [100 mg]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.
45512843|NCT02054832|Dietary Supplement|Glycosade|
45512844|NCT03677349|Procedure|neurorrhaphy|"During the surgery, the flap is removed from its donor site, placed on the recipient site (instead of carcinological excision) and its survival is ensured by arterial and venous anastomosis (to the artery and facial vein or to the external carotid artery and thyro-linguofacial veinous trunk).~We then propose a reconstruction complement: nerve anastomosis (neurorrhaphy) to the lingual nerve for the antebrachioradial and anterolateral thigh flaps, and to the lower alveolar nerve for the fibular bone flaps. This supplement is performed during microsurgical time by a suture for the patient in group 1."
45512845|NCT02187692|Behavioral|MCT|The meta-cognitive training (the MCT) consists of eight structurized psychological therapy modules that provides basic knowledge about cognitive biases that are associated with schizophrenia and it provides the sklills how to overcome negative consequences of the biases. The MCT includes: Module 1 manages self-serving bias (i.e. external-personal attribution for failure, internal attribution for positive events); Module 2 and 7 target the jumping to conclusion; Module 3 and 7 concern beliefs flexibility and bias against disconfirmatory evidence; Module 4 and 6 target deficits in theory of mind; Module 5 is devote to ameliorate the cognitive over-confidence in false memories; Module 8 deals with depressive thinking style.
45512846|NCT02058732|Other|MRI|Subjects will have an MRI that lasts approximately 60 minutes at the same time points as during the stem cell study schedule; once before the stem cell surgery, and again at 1, 6, 12, 18, 24, 36, and 48 months after receiving stem cells. This magnetic resonance imaging(MRI)scan will be of the cervical spine and brain.
45512847|NCT03684603|Behavioral|melody during motor training and slow wave sleep|sequence of tones which are presented to the patient using earphones
45404313|NCT01081158|Drug|Drug: SCH 900518 Biologic: Peginterferon alfa-2b|"Drug: SCH 900518~Biologic: Peginterferon alfa-2b~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly."
45404314|NCT01081158|Drug|Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|"Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension + ritonavir (200 mg BID) (2-100 mg oral capsules) for 7 days.~Period 2: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension+ ritonavir (200 mg BID) (2-100 mg oral capsules) + PegIntron (1.5 µg/kg QW) for 14 days."
45404315|NCT01081158|Drug|Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|"Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1, Amorphous SCH 900518 (400 mg) or placebo BID administered as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) for 7 days.~Period 2, SCH 900518 (400 mg) or placebo BID as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) +PegIntron (1.5 µg/kg SC QW) for 14 days."
45851322|NCT02993952|Device|Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.
45404316|NCT00105066|Drug|Metformin|850mg tablet once a day for one month, then twice a day for 3 months
45404317|NCT00105066|Drug|Placebo|placebo tablet once a day for one month, then twice a day for 3 months
45404318|NCT05232838|Device|eShunt Implant|The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.
45404319|NCT01322308|Drug|pioglitazone|30 mg tablet QD (taken once daily)
45404320|NCT01322308|Drug|placebo|tablet taken once a day
45404321|NCT05208268|Drug|Pariet|Pariet Tablets.
45404322|NCT03766048|Procedure|Single-Anterior-Mesh, SAM|laparoscopic sacropexy is only performed with the anterior mes
45404323|NCT03766048|Procedure|Double-Mesh, DM|laparoscopic sacropexy is performed using two synthetic non-absorbable meshes, both sutured to the promontory (Double-Mesh, DM): one mesh is placed in the vesicovaginal space and sutured to the uterine cervix or vaginal apex, and one mesh is placed in the rectovaginal space
45404324|NCT05195710|Drug|Yttrium-90 (Y-90) resin microspheres|Given by scan
45404325|NCT00104520|Drug|AZLI 75 mg two times a day (BID)/three times a day (TID)|
45404326|NCT00104520|Drug|Placebo two times a day (BID)/three times a day (TID)|
45404327|NCT03759652|Behavioral|before-after study|The data analysed involve the time when the targeted, active surveillance of infections was establised, initially: 2003-2017, using tools (definitions, protocols) in accordance with the National Healthcare Safety Network (NHSN), then from 2012, HAI recognition methodology and HAI record-keeping has followed the Surveillance Network (HAI-Net), European Centre for Disease Prevention and Control (ECDC).
45404328|NCT03963882|Drug|Two cycles of neoadjuvant chemotherapy|Two cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).
45404329|NCT03963882|Diagnostic Test|First imaging evaluation|First imaging evaluation consists of pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET)
45404330|NCT03963882|Diagnostic Test|Second imaging evaluation|Second imaging evaluation consists of pelvic magnetic resonance imaging
45404331|NCT03963882|Drug|The third cycles of neoadjuvant chemotherapy|The third cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).
45404332|NCT03963882|Procedure|RH|Radical hysterectomy
45404333|NCT03963882|Radiation|Radiochemotherapy|Concurrent radiochemotherapy
45512848|NCT03684603|Behavioral|melody only during motor training|sequence of tones which are presented to the patient using earphones
45404334|NCT03963882|Diagnostic Test|Pathologic evaluation|Pathologic evaluation for RH patients
45404335|NCT05180188|Behavioral|Training|In the 8-week training period, participants will have three training sessions with a duration of 30 minutes at 70% of VO2peak per week.
45404336|NCT01081314|Behavioral|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy as described in the 2 DBT treatment manuals (Linehan, 1993a,b).
45404337|NCT01081314|Behavioral|PTSD Protocol|A modified version of Prolonged Exposure therapy for PTSD
45404338|NCT03165292|Radiation|mIBG|Day 1 131I-mIBG course 1: about 444MBq/kg with in vivo whole-body dosimetry Day 15 131I-mIBG course 2: the target is to deliver a combined whole-body radiation dose of 4 Gy
45404339|NCT03165292|Drug|Topotecan|Day 1-5 Topotecan 0.7 mg/m2 daily Day 15-19 Topotecan 0.7 mg/m2 daily
45404340|NCT03165292|Drug|Thiotepa|Day 1-3 Thiotepa
45404341|NCT03165292|Procedure|Autologous stem cell transplant|ASCT as soon as radiation level allows it in ARM A
45512849|NCT02187770|Device|IMED-4|Non invasive recording electrode used to assess lung fluid
45851323|NCT02993952|Device|Sham Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator was turned off after 30 seconds of stimulation. Therefore, patients in the sham group felt the initial itching sensation but received no current for the rest of the stimulation period.
45512850|NCT02054988|Other|caffeine|"After 5 day coffee wash-out period, patients were randomly assigned to caffeine for 10 days. At baseline: 2 cups of coffee consecutively after 5 hour by clopidogrel or prasugrel intake. Afterwards, 3 cups of coffee daily for 10 days.~Platelet reactivity (expressed as P2Y(12) reaction units (PRU) by the point-of-care VerifyNow assay [Accumetrics, San Diego, California]) was measured at baseline and after 10-days of coffee intake."
45404342|NCT03114046|Behavioral|Lower extremity Constraint-induced movement therapy(LE-CIMT)|"Both phases (A and B) will last 10 weekdays, and during baseline and treatment phases, the data will be collected on 5 different odd days. Considering the long period of data collection. During the baseline phase, no assessment will be administered on even days. The treatment will be delivered daily, along 10 weekdays, 3.5 hours per day. The motor training will be delivered during 3 hours and 30 minutes will be allocated to the administration of the TP.~Both caregivers and participants will be individually interviewed before and after treatment."
45404343|NCT05161078|Device|CARPEDIEM|CARPEDIEM treatment as per local standard of care
45512851|NCT02054988|Other|not caffeine|evaluate the platelet reactivity after 10 days of no caffeine intake
45698988|NCT03458286|Device|BRH-A2 wound healing device|Combined ultrasound and electric current stimulation (CUSECS) is a combination therapy provided by the BRH-A2 wound healing device. This study is testing the effectiveness of the treatment CUSECS. The electric current stimulation is provided by attaching small electrodes around the ulcers. A probe is used on the ulcers to provide the ultrasound waves. Both aiming to increase the blood flow to an area to increase wound healing.
45404344|NCT05145322|Device|Composite with 90 degree cavosurface angle|Lesion-specific cavity design with 90 degree cavosurface angle throughout the cavity margins will be prepared. The total etch method will be performed, i.e. with a 32% by weight phosphoric acid (3M Scotchbond™ Universal Etchant) on enamel and dentine for 15 seconds. The etchant will be rinsed away and an adhesive (3M Scotchbond™ Universal Adhesive) will be applied on dentine with a microbrush for 20 seconds. The adhesive will be light-cured for 10 sec with the Elipar S10 curing light (3M Oral Care). Subsequently the preparation will be restored with a bulkfill resin composite (3M Filtek™ One Bulk Fill Restorative) and cured for 20 seconds.
45512852|NCT03682341|Genetic|endometriosis|patients with or without ovarian endometriosis
45512853|NCT02055066|Drug|ARGX-111|
45512854|NCT03684525|Procedure|Extraction of primary canines|"At Baseline (T0): Clinical examinatiion + CBCT scan and then both primary canines will be extracted At 6 month follow-up (T1): Clinical examination only At 12 month follow-up: Clinical examination +/- CBCT scan~Treatment Plan :~If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department~If Canine is emerged to oral cavity: No further CBCT scan will be taken~If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
45851324|NCT02994264|Radiation|adjuvant concurrent chemoradiation|
45512855|NCT04615754|Dietary Supplement|Hyperketonemia - use of ketone (3-OHB) infusion|The effect of intravenous ketone supplement
45512856|NCT04615754|Dietary Supplement|Placebo - use of saline infusion|Saline is infused as an comparator
45512857|NCT02058810|Device|Nasal high flow|
45512858|NCT02058810|Device|Conventional nasal oxygen|
45512859|NCT03677271|Behavioral|Physical Activity|
45512860|NCT02191124|Drug|Paroxetine|Patients in both groups (MBC or ST) receive open-label paroxetine (20-60mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China.
45512861|NCT02191124|Drug|Mirtazapine|Patients in both groups (MBC or ST) receive open-label mirtazapine (15-45mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China
45512862|NCT03677193|Behavioral|Playing ICP game|Participants will play the ICP game from their home this is expected to be 30 min * 5 days / week for 4 weeks. Once per week, participants will play the ICP game with a researcher.
45512863|NCT02193698|Drug|Lenalidomide+Dexamethasone|Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
45512864|NCT03682185|Behavioral|Attention-Control Condition|This condition will contain no active elements beyond its nonspecific components, and no theoretical basis to support an effect on CRDs. The attention-control group will also involve 4 in-home visits and 4 brief telephone education sessions. The attention control group will receive printed educational and training materials from the Alzheimer's Association and the NIH on home modification, health promotion, talking to your doctor, and advanced care planning that coincide with session content.
45512865|NCT03682185|Behavioral|Timed Activity Intervention|The timed activity group will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed activity intervention provides activities delivered at specific times in the daily cycle. The in-home sessions are spaced weekly so that the participants can have the opportunity to practice the activity with the interventionist and then on their own. During each session, the interventionist will reinforce activity use, review problem-solving approaches, and provide education.
45512866|NCT02191202|Drug|Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)|
45512867|NCT03561168|Diagnostic Test|Change in plan of care based on MRI results|"Study subjects have received the intervention if the results of their MRI either 1. provide an etiology for said MRI's indication or 2. the patient received a change in plan of care based on MRI results."
45512868|NCT04992650|Procedure|Fat grafting|Fat grafting
45512869|NCT02055300|Drug|LY03005|
45512870|NCT02055300|Drug|Placebo|
45512871|NCT02055300|Other|Meal|
45512872|NCT02055300|Drug|Pristiq|
45512873|NCT04974710|Diagnostic Test|Outpatient MRI|All participants will undergo a standardised imaging protocol in a MRI scanner. This will take place during the same visit or following the transvaginal ultrasound (TVUS) and in advance of any surgical procedure (laparoscopy).
45512874|NCT02056860|Procedure|Group 1 will receive 15 Hz|Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.
45512875|NCT02056860|Procedure|Group 2 will receive 30 Hz|Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.
45512876|NCT02056860|Procedure|Group 3 will receive 60 Hz|Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.
45512877|NCT02056860|Procedure|Group 4 will receive 100 Hz|Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.
45512878|NCT02056860|Procedure|Phase II Optimal Frequency|Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.
45512879|NCT02191280|Drug|Antistax®, low dose|
45512880|NCT02191280|Drug|Antistax®, high dose|
45698989|NCT03468504|Device|Mirror Therapy|Participants view the reflective side of a simple mirror which is placed in their mid-sagittal plane to view a mirror reflection of their non-affected limb for 30 mins per day, 3 days per week, for four weeks.
45698990|NCT03468504|Device|Placebo Mirror Therapy|"Placebo Mirror Therapy: Participants view the reflective side of a simple mirror which is placed forward/ahead of them in their mid-sagittal plane, and thus cannot see a reflection of either lower limb as their leg does not pass in front of the mirror for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
45512881|NCT02191280|Drug|Placebo|
45512882|NCT03684369|Device|Transcutaneous electrical nerve stimulation|Commercially available device will be used to apply weak electrical currents to arm and leg muscles in each of 18 treatment sessions.
45512883|NCT03684291|Procedure|Mode of Mechanical Ventilation|Adjustment of mechanical ventilation mode
45512884|NCT02193854|Device|Mobile Phone|Investigators used Sana system, that is a mobile phone-based, open source software platform for telemedicine services. The Android-based system supports multimedia, location-based data, and text. In the village health clinic, a healthcare worker will interact with a patient and collects data through a step-by-step clinical questionnaire on a smart mobile phone. As patients' data is uploaded to an open source electronic medical record system (OpenMRS) with a diagnosis-specific information and images. The consultant can access the clinical information about the patient and make appropriate diagnoses and treatment recommendations from the secondary hospital.
45512885|NCT02055378|Drug|Atropine|topical 0.125% atropine eye drops
45512886|NCT02055378|Device|auricular acupoint stimulation|Five auricular acupoints (Shenmen, Xin, Yan, Mu 1 and Mu 2) Tapping stimulation was administered by using a 1-mm alloy ball (Magrain®; Sakamura, Kyoto, Japan) three times a day, each time for five minutes.
45512887|NCT04558190|Drug|Intralipid, 20% Intravenous Emulsion|Lipid infusion
45512888|NCT04558190|Dietary Supplement|MitoQ|Oral administration of MitoQ capsules
45512889|NCT04558190|Drug|Salbutamol|Beta2-agonist infusion
45512890|NCT03441321|Other|Lifestyle and Values Intervention|Participate in Facebook group focusing on avoiding tanning and promoting healthy body image
45698991|NCT03468504|Device|Treadmill|Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks.
45698992|NCT04920318|Combination Product|tDCS + language therapy|In this study fMRI-guided noninvasive neuromodulation will be applied, called Transcranial Direct Current Stimulation (tDCS) to the frontal and parietal brain regions that show reduced activation but still are structurally intact. TDCS will be paired with personalized speech-language therapy to enhance language functions.
45512891|NCT03441321|Other|Lifestyle Intervention|Participate in Facebook group focusing on other health topics
45512892|NCT03441321|Other|Survey Administration|Ancillary studies
45512893|NCT02055456|Drug|Nandrolone Decanoate|
45512894|NCT03676959|Drug|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
45512895|NCT03676959|Drug|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
45512896|NCT03676959|Drug|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
45512897|NCT02059044|Other|ISTOP-ADE|Interactive Voice Response System + Pharmacist
45512898|NCT04917146|Other|Self-administered questionnaires for relatives (caregivers=CG)|"Sociodemographic and medical information for the patient and the CG. SF36 questionnaire for the quality of life (physical, mental) of family CGs This assessment will be supplemented by specific questions relating to: physical health, emotional state, personal and leisure activities of the caregiver.~The CG's knowledge and representations of the disease : questions adapted from the Brief-IPQ disease representation questionnaire.~Questions will also focus on the caregiver's reactions to the patient's illness.~We have constructed a questionnaire to assess the main areas of aid in the context of SSc: emotional, domestic help, administrative, medical, for trave (16 items and an open question).~The CG Reaction Assessment-CRA questionnaire to assess the positive and negative dimensions of helping (24 items). It assesses five dimensions: self-esteem, financial impact, impact on health, impact on time and lack of family support.~The reason for the assistance provided."
45512899|NCT03755973|Drug|CFA|Long-acting exogenous ovarian stimulation
45512900|NCT03755973|Drug|rFSH|Daily rFSH
45512901|NCT03755973|Procedure|Fixed daily rFSH dosing protocol of 200-300 IU|The dose of daily rFSH is fixed at 200 or 300 IU
45512902|NCT03755973|Procedure|Step-down daily rFSH dose|The dose of daily rFSH is progressively reduced
45698993|NCT04920318|Combination Product|sham TDCS + language therapy|sham control will be applied with language therapy to the same regions as active TDCS.
45512903|NCT02055534|Other|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the oncologists
45404345|NCT05145322|Device|Composite with wide bevel|Lesion-specific cavity design with wide bevel throughout the cavity margins will be prepared. The total etch method will be performed, i.e. with a 32% by weight phosphoric acid (3M Scotchbond™ Universal Etchant) on enamel and dentine for 15 seconds. The etchant will be rinsed away and an adhesive (3M Scotchbond™ Universal Adhesive) will be applied on dentine with a microbrush for 20 seconds. The adhesive will be light-cured for 10 sec with the Elipar S10 curing light (3M Oral Care). Subsequently the cavity will be restored in with a pre-warmed (using Bioclear Heatsync Kit) bulkfill resin composite (3M Filtek™ One Bulk Fill Restorative) and cured for 20 seconds.
45512904|NCT02055534|Other|General dietary advices|General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the oncologists
45512905|NCT03681717|Device|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a ReTrack Utopia 360 VR Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
45512906|NCT03623451|Drug|Chinese Medicine Formula|Chinese Medicine Formula, composed of American ginseng 10g, Poria cocos 15g, bighead atractylodes rhizome 20g, Astragalus mongholicus 30g, Crataegus pinnatifida Bunge 20g, Salvia miltiorrhiza Bge. 20g, Pericarpium Citri Reticulatae 10g will be decocted and packaged into vacuum packs by the pharmaceutical department of First Affiliated Hospital, Heilongjiang University of Chinese Medicine (140 mL/pack). Subjects will take 2 packages per day for three months.
45512907|NCT02056938|Drug|Anti-Thymocyte Globulins treatment|
45512908|NCT02056938|Drug|Basiliximab treatment|
45512909|NCT02059200|Behavioral|Mindfulness Based Compassionate Living|The MBCL program consists of eight biweekly group sessions of 2.5 hours, in which the participants get formal meditation exercises, some theoretical information and participate in inquiry on the meditation exercises and homework assignments. Homework assignments are given after every session, consisting of formal and informal meditation exercises primarily and some diary instructions.
45512910|NCT03536000|Diagnostic Test|Fetal echocardiography using the aCMQ-Strain method|Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation
45698994|NCT04906434|Drug|60mg ABSK-011capsule|Three 20mg capsules,QD for oral administration
45698995|NCT04906434|Drug|120mg ABSK-011capsule|One 20mg capsule and one 100mg capsule,QD for oral administration
45698996|NCT04906434|Drug|180mg ABSK-011capsule|One 100mg capsule and four 20mg capsules,QD for oral administration
45698997|NCT04906434|Drug|240mg ABSK-011capsule|Two 100mg capsules and two 20mg capsules,QD for oral administration
45698998|NCT04906434|Drug|320 mg ABSK-011capsule|Three 100mg capsule and one 20mg capsule,QD for oral administration
45404346|NCT03759262|Drug|Cholecalciferol|A single dose of ultra-high-dose vitamin D (cholecalciferol) will be given prior to hematopoietic stem cell transplant. Research labs including inflammatory biomarker panels will be obtained prior to and after the dose is given.
45404347|NCT03765658|Drug|GRT0151Y dose escalation|Single doses of 150, 200, 250, 300, 350 and 400 mg (3, 4, 5, 6, 7 or 8 capsules of 50 mg)
45404348|NCT03765658|Drug|Matching placebo|Matching placebo capsules (3, 4, 5, 6, 7 or 8 capsules)
45404349|NCT00135330|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
45512911|NCT02191670|Drug|METALYSE®|weight-adjusted dosage as single bolus over 5 to 10 seconds
45512912|NCT02188082|Drug|IvabRadine hemisulfate Sustained-release Tablets|
45512913|NCT02188082|Drug|placebo|
45512914|NCT02057094|Dietary Supplement|Protein, High-Protein, and Control|
45512915|NCT02917941|Drug|Ixazomib|Ixazomib capsules
45512916|NCT02917941|Drug|Lenalidomide|Lenalidomide capsules
45512917|NCT02917941|Drug|Dexamethasone|Dexamethasone Tablets
45512918|NCT02055690|Drug|Pazopanib|Tyrosine Kinase Inhibitor
45512919|NCT02055690|Drug|Fosbretabulin|Vascular Disrupting Agent
45512920|NCT04301258|Other|Articular cartilage repair|Patient reported outcomes will be collected on patients who have had a cartilage repair procedure using ProChondrix CR in the knee, hip, foot or ankle.
45512921|NCT03684135|Other|Cosmetics|"Tendre Caresse au cold cream body cream from Cosmétosource Crème de douche face and body cleanser from Cosmétosource"
45512922|NCT02038608|Device|PET|
45404350|NCT00135330|Drug|rosiglitazone|oral tablet, 2mg or 4mg, twice a day
45404351|NCT05128318|Procedure|Nissen Fundoplication, cholecystectomy|Collection of adipose tissue pieces in the context of programmed abdominal surgery to treat to treat hiatal hernia, gastroesophageal reflux or vesicular lithiasis. During the surgery treatment, adipose tissue of 1-2 cm3 will be collected for the protocol by laparoscopy by the surgeon in charge of the procedures.
45404352|NCT03765580|Dietary Supplement|Fish|Lunch containing fish
45512923|NCT02193932|Other|EEG Triggered fMRI using Micro Maglink|
45512924|NCT03741699|Drug|Pre-treatment with rLH (Luveris 75 IU),|Treatment with 150 IU/day rLH (Luveris 75 IU), administered subcutaneously for 4 consecutive days prior to COS (Controlled ovarian stimulation)
45512925|NCT03535064|Other|Hand Hygiene Workshop|Workshops included video-clip and interactive lecture about common infections in schools, methods of transmission, and hand washing procedure and time. Puzzle games related to hand hygiene were distributed among schoolgirls. Posters with cartoon princess picture promote for hand hygiene were also distributed among the schools.
45512926|NCT02055846|Procedure|Realisation of blood sample, urinary sample and tumor biopsy|
45512927|NCT03733041|Device|rTMS|This group will receive rTMS treatment
45404353|NCT03765580|Other|Control|Lunch containing no fish
45404354|NCT03765424|Diagnostic Test|Ultrasound|Ultraosund of temporal, carotid and axillary arteries
45404355|NCT02914600|Drug|Filgotinib|Tablet(s) administered orally once daily
45404356|NCT02914600|Drug|Placebo|Tablet(s) administered orally once daily
45404357|NCT01076478|Drug|Cilostazol|100 mg, 200mg tablet Cilostazol
45404358|NCT01076556|Drug|Alvocidib Hydrochloride|Given IV
45404359|NCT01076556|Drug|Cyclophosphamide|Given IV
45404360|NCT01076556|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
45404361|NCT01076556|Other|Pharmacological Study|Correlative studies
45404362|NCT01076556|Biological|Rituximab|Given IV
45404363|NCT00134784|Drug|[123I]B-CIT SPECT imaging|To assess [123I]B-CIT SPECT imaging
45404364|NCT03965442|Drug|Control|Patients who underwent mastectomy under standard general anesthesia
45404365|NCT03965442|Drug|Esmolol|Patients who underwent mastectomy under general anesthesia with esmolol infusion
45512928|NCT03733041|Device|Sham|This group will receive sham treatment
45512929|NCT03733041|Other|No intervention|This group will receive no intervention
45512930|NCT02191748|Procedure|Needling|Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch.
45512931|NCT02191748|Drug|Triamcinolone|During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area
45698999|NCT04906434|Drug|400mg ABSK-011capsule|Four 100mg capsules,QD for oral administration
45699000|NCT04904250|Device|Emboshield|a distall occlusion Emboshield NAV6 will be used as the embolism protection device during CAS
45699001|NCT04904250|Device|Spider|a distal SpiderFX will be used as the embolism protection device during CAS
45699002|NCT04348422|Diagnostic Test|COVID-19 RT-PCR|Nasoropharyngeal swabs for COVID-19 RT-PCR - initial screening/retest +every 10 days in 100 days followup period
45404366|NCT00134082|Biological|KGEL vaccine|Vaccine was administered at weeks 0, 4, 8, 12, 16, and 24 at a dose of 1 x 10^8 cells per dose. The first dose was given on Day +1.
45512932|NCT03676881|Device|Computerized cognitive battery: Cognigram (CG)|is a validated, computerized battery of cognitive tasks based on card games, developed by Cogstate Ltd. This technology includes four tasks, with a total duration of 10-15 minutes. The subject is asked to answer each task by pressing either 'D' or 'K' keyboard buttons. The technology supports the measurement of attention/vigilance, processing speed, concentration, visual working memory and visual recognition memory. The software will run on a computer supplied by the Bruyère Research Institute, in a private test room. The RA will be present during the testing session, reading out loud the batteries standardized instructions and doing the practice trials with the participants. After the practice trials, the RA will not give any feedback or support.
45512933|NCT03676881|Device|The NeuroCatch™ Platform (NCP)|the NCP includes 6 stimulus sequences specifically designed to elicit desired brain responses. Each sequence contains both the oddball task and semantic word-pair task, and lasts 6 minutes. In our protocol, two sequences will be used. For the setup, EEG electrodes are placed on the participant's scalp, and the EEG signal quality is ensured by gently abrading the skin beneath each of the electrodes. A conductive gel is then placed between the skin and the electrode. Most electrodes are contained in an elastic cap, which is worn by the participants, but some electrodes are attached to the skin with adhesive. This part of the session takes around 10 minutes. EEG scan will commence once the setup is completed. Two auditory scans of 6 minutes each, separated by a one-minute break, will be administered. The total time of EEG testing for participants, including setup, will be of ≈25 minutes.
45512934|NCT02191826|Drug|SOM0226|Oral
45512935|NCT01333956|Drug|Pregabalin 50mg|Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
45512936|NCT01333956|Drug|Pregabalin 100mg|Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
45512937|NCT01333956|Drug|Pregabalin 150mg|Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
45512938|NCT01333956|Drug|Placebo|Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
45512939|NCT03623607|Other|Diabetes Survival Skills Education|Application of human factors and education principles to refine and optimize an DSSE program for delivery to inpatients with type 2 diabetes (D2Go - IN) using a table-based e-learning platform ; utilization of implementation science to inform design of implementation processes for delivery within nursing unit workflow; establishment of a D2Go program toolkit; and evaluation of the feasibility and preliminary impact of the program when delivered by nursing unit staff on medical-surgical units (MSUs) to adults with type 2 diabetes. Barriers and facilitators of the D2Go - Inpatient program's reach, effectiveness, adoption, implementation and maintenance (RE-AIM)(31) were explored
45512940|NCT02055924|Drug|Ibrutinib and immunochemotherapies|Combination of immunochemotherapies (R-DHAP or R-DHAOx) and ibrutinib
45512941|NCT02191904|Other|Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes|
45512942|NCT02188238|Other|Saliva Sample Collection|Saliva samples will be collected from healthy volunteers recruited locally. Stimulated whole mouth saliva is collected through stimulation by inert gum, and collecting the saliva by gently spitting into a sterile tube.
45699003|NCT04348422|Diagnostic Test|COVID-19 Serology|Blood samples for COVID-19 serology - initial screening/retest +every 10 days in 100 days followup period Each sample will be examined by 4-6 serology kits.
45699004|NCT04348422|Other|Symptoms questionnare|Symptoms questionnaire which will be filled by participant on initial screening/retest visit + every 10 days in 100 days followup period
45404367|NCT00134082|Biological|Filgrastim|5 mcg/kg/day starting on Day +6 until ANC is >= 1000/mcL.
45404368|NCT00134082|Biological|Rituximab|375 mg/m^2/day on Days -10, -7, and at weeks 4, 5, 6, and 7.
45404369|NCT00134082|Drug|Cyclophosphamide|50 mg/kg/day on Day -3, -2, -1, and 0.
45404370|NCT05108818|Biological|Seasonal influenza vaccine|The seasonal influenza vaccine is administered intramuscularly at a dose of 15 ug of HA per component, as approved by the FDA.
45404371|NCT01081392|Biological|LPS|LPS 20mcg sd inhaled via nebulizer, 3 periods
45404372|NCT03765346|Drug|Oxycodone IR ADF|Oxycodone IR ADF manipulated/crushed (mass of 540 mg, containing oxycodone hydrochloride 30 mg), in a standardized procedure.
45512943|NCT02057328|Drug|TELMISARTAN|Patients of the group of telmisartan will take 40 mg of telmisartan daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients still classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
45512944|NCT02057328|Drug|NEBIVOLOL|Patients will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. For patients classified in the stage I hypertensive range 12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project
45512945|NCT02188316|Device|Jumbo forceps|comparison of different polypectomy devices
45512946|NCT02188316|Device|Hot biopsy forceps|comparison of different polypectomy devices
45512947|NCT02057484|Drug|Tacrolimus|oral
45512948|NCT03880461|Behavioral|Lifestyle Intervention|Behavioral lifestyle intervention
45512949|NCT02191982|Behavioral|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
45512950|NCT02192060|Other|Test - Using of a suspension containing Triclosan|The participants should have used only the suspension containing Triclosan during 5 days and have stopped with their biofilm control homemade procedures.
45512951|NCT02192060|Other|Control - Using of a suspension without Triclosan|The participants should have used only the Placebo suspension during 5 days and have stopped with their biofilm control homemade procedures.
45512952|NCT02188394|Drug|Anesthetic blockades with bupivacaine|
45512953|NCT02188394|Drug|Isotonic saline injection|
45512954|NCT02192138|Procedure|Therapeutic thoracentesis|Therapeutic thoracentesis with pleural fluid withdrawal
45512955|NCT02192138|Device|Pleural catheter|
45512956|NCT02192138|Device|Pleural manometer|
45512957|NCT01333722|Drug|Hydrocodone/Acetaminophen Extended Release|
45512958|NCT01333722|Drug|Placebo|Placebo tablet
45512959|NCT02188472|Drug|Penicillin V|Penicillin V: 2 x 330mg tablets should be taken twice daily
45512960|NCT02188472|Drug|Trimethoprim|Trimopan: 2 x 100mg tablets should be taken twice daily
45512961|NCT02188472|Drug|Placebo|Placebo: 2 tablets should be taken twice daily
45512962|NCT02188550|Drug|everolimus and letrozole|"This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented~The duration of the study will be until disease progression~Everolimus and Letrozole will be administered as noted below;~6.1.1 Dosing regimen~Dosage : Everolimus Dose: 10 Unit: mg Frequency: daily Route of administration: Orally Dosage : Letrozole Dose: 2.5 Unit: mg Frequency: daily Route of administration: Orally"
45851325|NCT02993874|Dietary Supplement|Creatine|The experimental group will ingest for seven days (Loading - phase 1), 5g (4x/day) of creatine monohydrate associated with the clinical treatment (30-45 minutes of walking, 3 times a week). Subsequently, they will ingest for 49 days (Maintenance - phase 2), 3g (1x / day) creatine monohydrate associated with clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
45512963|NCT02038374|Procedure|biopsies|
45512964|NCT02059590|Drug|Pyridinylmethyl-14C-labeled isavuconazonium sulfate|Intravenous
45512965|NCT02192216|Behavioral|Exercise|
45512966|NCT02056002|Other|Usual Care|- Standard CPAP educational training
45699005|NCT04453098|Behavioral|3-week residential program based on a tryptic (diet,|"3-week residential program based on a tryptic (diet, exercise, education). The three weeks intervention was followed by a 1-year at-home follow-up.~In the original protocol, participants were involved in a 3-week residential program based on a tryptic (diet, exercise, education)."
45699006|NCT03456570|Drug|Dydrogesterone 10 mg|Dydrogesterone 10 mg twice daily
45699007|NCT03456570|Drug|Placebo Oral Tablet|oral tablets twice daily
45512967|NCT02056002|Other|Peer-Buddy System|"Two 30-minute in person sessions with Peer Buddy~Standard CPAP educational training~Eight phone conversations with Peer Buddy over 3 months~Subsequent 3 months use of phone system to contact Peer Buddy as needed~One Month Visit:~- Home visit to collect CPAP information~Three Month Visit:~Questionnaires~Psycho Motor Vigilance Test (PVT) Video Game~Collect CPAP information~Measure weight~Measure blood pressure~Six Month Visit:~Questionnaires~PVT (Video game)~Collect CPAP information~Measure Weight~Measure Blood Pressure~Evaluate the program and Peer Buddy"
45851326|NCT02993874|Dietary Supplement|Placebo|The placebo group will ingest for seven days (Loading - phase 1), 5g (4x / day) of dextrose associated to clinical treatment (30-45 minutes of walking, 3 times per week). Subsequently, they will ingest for 49 days (Maintenance phase 2), 3g (1x / day) of dextrose associated with the clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
45512968|NCT02056002|Other|Usual Care|- Educational Brochures
45699008|NCT04452864|Device|Computerized Cognitive Training|The study intervention consists of a tablet-based cognitive training, targeting the cognitive domains mostly affected by Alzheimer Disease.
45699009|NCT04452864|Device|Documentaries with delayed Computerized Cognitive Training|The active control group watches documentaries for three months before starting with the CCT.
45699010|NCT05203224|Drug|Dornase Alfa|Intravenous Dornase alfa
45404373|NCT03765346|Drug|Oxycodone API powder|Oxycodone API powder (mass of 30 mg), containing oxycodone hydrochloride 30 mg.
45404374|NCT03765346|Drug|Placebo to match oxycodone API powder|Placebo to match oxycodone API powder (mass of 30 mg).
45404375|NCT03765346|Drug|Placebo to match manipulated oxycodone IR ADF.|Placebo to match oxycodone IR ADF, manipulated (mass of 540 mg).
45512969|NCT02056002|Other|Usual Care|- Educational DVD videos mailed to participant
45512970|NCT02192294|Drug|Oral Bosutinib|a single dose of 500 mg oral bosutinib
45512971|NCT02192294|Drug|Intravenous infusion of bosutinib|a single dose of 120 mg of bosutinib intravenous infusion (1 hour)
45512972|NCT05620134|Drug|JK08|Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα.
45512973|NCT02188628|Device|H-Man|H-man is a portable end-effector planar upper limb robot.
45512974|NCT02188628|Other|Additional Conventional Therapy|Repetitive goals based arm therapy
45512975|NCT02057796|Device|Xpert MTB/RIF®, Determine TB LAM, Chest X-ray|"The following point-of-care TB tests will be systematically performed:~Xpert MTB/RIF® on sputum (in all patients able to provide sputum; no sputum induction will be requested in others), Urine LAM (all patients). Depending on clinical presentation, Xpert MTB/RIF® will also be performed on any relevant extra-pulmonary specimen.~TB treatment will depend on the result of the tests:~Criteria met for confirmed or probable TB : TB treatment will be initiated immediately (Visit 1) followed by ART initiation 2 weeks later (Visit 2); No evidence of confirmed or probable TB: ART will be started immediately (Visit 1)."
45404376|NCT01078818|Drug|IV trivalent saccharose hydroxide ferrous|"Preoperative Period 5-10 days 200 mg Iron iv (Venofer® )in 200cc physiologic solution /24-48h x 3 dosis +1 oral placebo /24h Postoperative Period 1-3weeks 200 mg Iron iv (Venofer® )in 200cc physiologic solution/24-48h x 3 dosis + 1 oral placebo /24h One month Follow-up~1 month 1 oral placebo /24h"
45404377|NCT01078818|Drug|Oral ferrous fumarate|"200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®)~Postoperative Period:~200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®) One month Follow-up: 1 oral iron tablet/24h Ferogradumet"
45404378|NCT01078818|Drug|Oral and intravenous Placebo|Preoperative Period:1oral placebo/24h Postoperative Period:200cc physiologic solution iv placebo /24-48h x 3 dosis + 1oral placebo/24h One month Follow-up:1 oral placebo/24h
45699011|NCT03464838|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that applies a very low electrical current to the scalp. tDCS will be applied with intensity of 1.8 milliamps in real stimulation condition and 0 milliamps in sham condition, during 20 minutes, using a high density (HD) tDCS montage over the Prefrontal Cortex (PFC). Electroencephalography (EEG) resting state activity will be measured before and after tDCS.
45851327|NCT02993718|Drug|Dexmedetomidine|As a loading dose, 0.5 μg/kg dexmedetomidine was administered over 10 min, which was then administered continuously at a dose of 0.2-0.8 μg/kg/h. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
45851328|NCT02993718|Drug|Propofol|Propofol was infused continuously via a target-controlled infusion device, and the effect-site concentration was maintained with a range of 0.5-2.0 μg/ml. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
45404379|NCT03964038|Drug|gilteritinib|oral
45404380|NCT03964038|Drug|gilteritinib mini tablet|oral
45512976|NCT02057796|Drug|ART (Atripla, Truvada, Efavirenz, Combivir)|"ART (TDF-3TC/FTC or AZT-3TC + efavirenz) will be started immediately after randomization in patients not put on TB treatment, and 2 weeks after initiation of TB treatment in others.~ART will be initiated 2 weeks after the onset of TB treatment (V2) for Arm 2"
45512977|NCT02057796|Drug|Rifampin, isoniazid, pyrazinamide, ethambutol|Arm 1: Only patients who meet standardized criteria for TB at inclusion or during follow-up will receive a standard TB treatment (2ERHZ/4RH); Arm 2: • All patients will start a 6-month standard TB treatment (2ERHZ/4RH) at randomization
45512978|NCT03681171|Other|Therapeutic Dance|Participants attended therapeutic ballet sessions three times per week for six weeks.
45512979|NCT03676569|Biological|ADRC transplantation in autoimmune refractory epilepsy|
45512980|NCT02059746|Other|Questionnaires sent by mail|The questionnaires necessary for the study are mailed to patients at 3 and 12 months post-partum.
45512981|NCT02192450|Drug|Insulin aspart/glargine|
45512982|NCT02192450|Drug|Insulin aspart/degludec|
45512983|NCT03680937|Other|Gavi , Merck® (automated vitrification instrument)|Gavi, Merck ® permits semi-automated vitrification with closed system.
45512984|NCT03680937|Other|Vitrification|Group 1: immature ovocytes vitrified before IVM; Group 2: immature oocytes vitrified after IVM; Group3: fresh immature oocytes treated by IVM (without vitrification, control group).
45512985|NCT03535454|Other|working hours|weekly working hours
45512986|NCT03284385|Drug|Adavosertib|Given PO
45512987|NCT03676491|Other|Music Intervention|Music intervention
45512988|NCT03680703|Behavioral|Guided Self-Help Behavioral Weight Loss|Participants will be provided with patient-focused materials and worksheets that contain all the necessary information, procedures, and techniques of the behavioral weight loss program. For 12 weeks, treatment will be provided over the internet. This therapy focuses on making gradual and modest lifestyle changes with goals of normalizing eating patterns, decreasing caloric intake, building coping skills, and increasing physical activity.
45512989|NCT02188940|Behavioral|Dietary|The dietary therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a dietitian. Patients will be advised to follow restricted-calorie diet based on the hypocaloric dietary guidance, multiplying the patient's weight by 20 to 25 calories. The Nutwin ® program will be used to structure the patient's diets, based on 24 hours food record and calories tables. Throughout the program, issues related to food control, the benefits of following a balanced diet and the changing food habits will be discussed.
45699012|NCT03464838|Behavioral|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is the current treatment available for disordered gamblers at the UK National Problem Gambling Clinic. During the therapy sessions patients acquire learning strategies, cognitive and motivational elements, and develop personal skills to help them improve the understanding of their problems.
45699013|NCT04870554|Behavioral|Enteric feeding|All subjects will be given nutrition enterally, corresponding to their calculated nutritional needs.
45699014|NCT03456180|Device|Haemoadsorption with Cytosorb cartridge|microcirculatory monitoring in septic shock patients requiring renal replacement therapy for acute renal failure and haemoadsorption with Cytosorb cartridge
46057289|NCT02710773|Other|Backward Walking Treadmill Training|The intervention will consist of 5 minutes of forward walking (warm-up phase), 10 minutes of backward walking (intervention phase) and 5 minutes of forward walking (cool-down phase). The session will be performed on a treadmill device. The backward training speed will be increase consecutively: during the week 1, the intervention will be performed at 0,8 km/h; during the week 2 the speed will be 1,0 km/h; finally, during the week 3 the speed will be increased till 1,2 km/h.
45699015|NCT03468348|Drug|Duloxetine|patients scheduled for mastectomy and axillary evacuation for cancer breast will receive orally, 2 hours before the operation either, placebo capsule, duloxetine 30 mg,duloxetine 60 mg or duloxetine 90 mg capsule.
45404381|NCT03964116|Other|Questionnaires set all 3 months|"This longitudinal study based upon repeated and multicentric measurement will recruit AYA with cancer in care Units dedicated to them or not. Measures will be quantitative, and repeated every 3 months by questionnaires, as well as qualitative (social network questionnaire, psychological research interview) for teenagers declaring a negative event or a death event during treatments.~Those patients presenting a high depression score will be contacted by a research psychologist for semi-directed interview."
45404382|NCT01326390|Device|dTA/dBA C-arm fluoroscopy system with Dyna CT|C-arm CT of the liver; state-of-the-art flat panel detector on a ceiling or floor mounted C-arm gantry
45404383|NCT01326390|Procedure|DSA arteriogram- hepatic arteries|Standard of care
45404384|NCT01326390|Procedure|CO2 aortogram|Standard of care
45404385|NCT01079052|Drug|Famotidine|Tablets
46057290|NCT02710773|Other|Treadmill Training|The intervention will consist of 20 minutes of forward walking on a treadmill device.
46057291|NCT04226469|Procedure|Tooth movement|The subject's canines will be retracted distally and crevicular fluid is collected
46057292|NCT02710695|Behavioral|Control|This group will receive a standardized 10 minute discussion.
46057293|NCT02710695|Behavioral|Intervention|This group will receive a standardized 10 minute discussion
45512990|NCT02188940|Behavioral|Education Program|The education program will consist of 4 classes lasting 6 hours at the beginning of the interventions, in which issues related to asthma and physical activity will be discussed. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peakflowmeter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
45404386|NCT01326468|Drug|Temsirolimus|All patients will receive temsirolimus. The dose of temsirolimus in this study will range from 15-25 mg depending on the dose level. Temsirolimus will be infused over a 30-60 minute period once a week for the duration of radiation therapy.
45512991|NCT02188940|Behavioral|Behavioral Therapy|The Behavioral therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a psychologist. Sessions of group dynamics will be performed to increase the patient adherence in a weight loss program using behavior modification techniques, such as self-management, motivational strategies, positive reinforcement and relapse prevention. Relaxation techniques, experiences and patient's report will also be used.
45512992|NCT02188940|Other|Exercise Training|The aerobic training will be performed on a treadmill and a bike (or an elliptical), twice a week, totaling 24 sessions of 60 minutes each. The initial intensity will be 50% to 60% of VO2 max reaching a maximal 75% of VO2 max and the progression will take place according to the level of effort (Borg) in the last two sessions. Patients will be advised to walk outside at least twice a week for 30 minutes and write down their activity in a diary. Furthermore, they will be given an accelerometer in week 6 to record their daily steps. The resistance training will consist of exercises for the upper and lower limbs. Initially, the patients will perform 2 sets of 10 repetitions with load of 50% to 70% of 1-RM and the progression will take place in the number of repetition, and then in the load.
45512993|NCT02188940|Other|Stretching and Breathing exercise|"Breathing exercise will consist of 3 exercises adapted from yoga's breathing technique (kapalabhati, uddhiyana and agnisara) twice a week, totaling 24 sessions of 30 minutes each. Every exercise will be performed in sets of 3 (2 minutes each) with 60 seconds of rest between them. The stretching will consist of stretching exercises for the major muscle groups in 3 sets of 10 seconds each. The program will be performed twice a week, totaling 24 sessions of 30 minutes each.~*Both breathing and stretching exercises will be performed as placebo to ensure the same duration of treatment between the two groups."
45512994|NCT03560856|Drug|Fulvestrant + palbociclib|Patients will be treated by Fulvestrant 500mg (day 1 and day 15) and then on Day 1 of each subsequent cycle and every 28 days with palbociclib 125 mg daily for 3 weeks on/1 week off (3/1 schedule).
45512995|NCT03676413|Drug|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals|new generic product of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder twice daily inhalation throughout the study
45512996|NCT03676413|Drug|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|twice daily inhalation throughout the study
45512997|NCT03676413|Drug|Placebo|twice daily inhalation throughout the study
45512998|NCT02257034|Other|Taichi|
45512999|NCT02257034|Other|Dance|
45513000|NCT03561324|Device|Imaging Beta Probe (IBP)|Using IBP for imaging of PET positive lymph nodes
45513001|NCT03676335|Drug|CsA eye gel|The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg
45513002|NCT03676335|Drug|CsA for eye emulsion|The CsA for eye emulsion of 0.4 ml: 0.2 mg
45513003|NCT03676335|Drug|Hypromellose Eye Drops|Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop
45513004|NCT04841486|Other|Data collection|evaluation of women's stress
45513005|NCT02260128|Other|Chewing gum|The intervention group will receive chewing gum four times daily following surgery.
45513006|NCT02192840|Procedure|Coronary angioplasty with stent implantation|Coronary angioplasty in bifurcation lesion with drug-eluting stent implantation: BiOSS or regular DES (rDES)
45513007|NCT03676179|Procedure|patella denervation|patella denervation
45513008|NCT03676179|Procedure|patella non-denervation|patella non-denervation
45513009|NCT02058030|Device|Insertion of ProSeal laryngeal mask airway|"The patient's head was placed on the 3 cm or 6 cm height of a pillow in supine and PLMA was inserted using a standard method in the sniffing position.~The success rate at first and second attempt, insertion time, Seal pressure, hemodynamic variables, complications(blood staining on cuff, sore throat and hoarseness) were assessed"
45699016|NCT03464682|Drug|HS-25 10mg|HS-25 10mg 1tablet add placebo of HS-25 1 tablet, placebo of Atorvastatin 1 tablet
45699017|NCT03464682|Drug|HS-25 10mg combination with Atorvastatin|HS-25 10mg 1 tablet , Atorvastatin 10mg 1 tablet, Placebo of HS-25 1 tablet
45699018|NCT03464682|Drug|HS-25 20mg combination with Atorvastatin|HS-25 10mg 2 tablets, Atorvastatin 10mg 1 tablet
45699019|NCT03464682|Drug|Atorvastatin 10mg|Atorvastatin 10mg 1 tablet, placebo of HS-25 2 tablets
45699020|NCT03464682|Drug|HS-25 20mg|HS-25 10mg 2 tablets, placebo of Atorvastatin 1 tablet
45699021|NCT03464682|Drug|Placebe of HS-25 and Atorvastatin|Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets
45699022|NCT03464526|Drug|Orvepitant|Tablet, once daily, oral
45404387|NCT01326468|Drug|Cetuximab|"All patients will receive cetuximab. An initial loading dose of cetuximab 400 mg/m2, intravenously over 120 minutes at least 4 days before radiation therapy but no more than 7 days before the start of radiation therapy.~Thereafter, cetuximab will be infused at 250 mg/m2 dose over 60 minutes weekly for the duration of radiation therapy."
45404388|NCT01326468|Drug|Cisplatin|All patients in Cohort A will receive cisplatin. The dose will be 20 mg/m2 or 30 mg/m2 depending upon the dose level.
45513010|NCT02189096|Other|NEWS and Sepsis Screening|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). The NEWS will be available to the paramedic crew.
45513011|NCT02189096|Other|Point of care lactate measurement|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, then a Lactate will be measured on the CG4+ i-STAT cartridge.
45404389|NCT01326468|Device|Radiation Therapy|Patients will be treated on a linear accelerator fitted with multi-leaf collimators with 1.6-2.3 Gy fractions delivered daily 5 days per week over 4-7 weeks to a cumulative dose of 66 Gy. A variance of +/- 10% in this nominal prescription dose is allowable and will depend on the extent of residual disease, at the discretion of the attending radiation oncologist.
45404390|NCT03703336|Biological|ROTAVIN (liquid formulation)|Live attenuated human rotavirus vaccine containing ≥ 2x10^6 plaque forming units (PFU) of strain G1P[8] per dose of 2 mL.
45513012|NCT03683979|Behavioral|Interpretation Bias Modification|A computer based interpretation bias modification program that aims to reinforce neutral interpretations of ambiguous social situations.
45513013|NCT03683979|Behavioral|Control Training Program|A sham training program that is similar in design and delivery to the experimental training condition.
45404391|NCT03703336|Biological|ROTAVIN-M1 (frozen formulation)|Live attenuated human rotavirus vaccine containing ≥ 2x10^6 PFU of strain G1P[8] per dose of 2 mL.
45404392|NCT01076634|Drug|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
45404393|NCT01076634|Drug|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
45513014|NCT02189174|Drug|CLR457|
45513015|NCT01370694|Drug|MK-8808|
45404394|NCT03702166|Behavioral|Cognitive Processing Therapy (CPT)|CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions. CPT is delivered in three phases: education, processing, and challenging.
45513016|NCT01370694|Drug|cyclophosphamide|
45513017|NCT01370694|Drug|vincristine|
45513018|NCT01370694|Drug|prednisolone|
45513019|NCT03680547|Other|patient with sickle cell disease|assess degree of renal affection in patientswith sickle cell disease attending Assuit university Children hospital by estimating some predictors of glomerular and tubular dysfunction.
45513020|NCT02256878|Drug|BIRT 2584 XX|
45513021|NCT02256878|Drug|Amitriptyline|
45513022|NCT03676101|Biological|9-valent HPV Recombinant Vaccine|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
45513023|NCT03676101|Biological|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
45851329|NCT02993640|Drug|vasopressin + nitro|vasopressin infusion 4,8 U/h for 20 minutes, thereafter nitroglycerine infusion to a MAP of 60 for 5 minutes.
45851330|NCT02993562|Drug|Levothyroxine|Normal treatment with levothyroxine.
45851331|NCT02993484|Drug|Dimethyl Malonate|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
45404395|NCT00132678|Drug|Risperdal Consta|12.5, 25, 37.5 or 50mg intramuscular (IM) injection every 2 weeks
45404396|NCT00132678|Drug|Placebo|Matching placebo intramuscular (IM) injection every 2 weeks
45404397|NCT01081548|Drug|atorvastatin|20 mg
45404398|NCT01081548|Drug|atorvastatin|20 mg
45404399|NCT00101868|Device|Discharge communication software|Computerized physician order entry software used by discharging physician
45404400|NCT00101868|Other|Usual care discharge process|Handwritten
45404401|NCT00101400|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg administered twice daily (b.i.d.)
45513024|NCT02058186|Drug|oral vitamin D|
45513025|NCT02058186|Drug|Placebo|
45513026|NCT02189330|Drug|Tafamidis|20 mg of current commercial formulation.
45513027|NCT02189330|Drug|Tafamidis|12.2 mgA free acid tablet.
45513028|NCT02189330|Drug|Tafamidis|20 mg new soft gelatin capsule.
45513029|NCT02189330|Drug|Tafamidis|4 capsules of 20 mg tafamidis of current commercial formulation.
45513030|NCT02189330|Drug|Tafamidis|4 capsules of 12.2 mg tafamidis of free acid tablet..
45513031|NCT03676023|Drug|Tranexamic Acid|Inhalation of Transexamic acid in age adjusted dosing
45513032|NCT02059824|Device|Aesthesiometer|"The eyelid sensation will be tested on every third by applying the tip of the aesthesiometer filament perpendicular to the eyelid skin and tarsal plate until the filament bent slightly. The filament length will be set at 6 cm (longest length) and applied to the test site 3 times. This process will be repeated 3 times and if the patient verbally responded to the 3rd touch, the number 6 will be recorder.~If the patient responded less than 3 of the 3 times, the filament will be shortened by 0.5 cm and the test will be repeated. This process will be continued by shortening the filament 0.5 cm each time, until the patient feels the filament touch 3 of 3 times. This filament length number will be recorded as the touch reading for that time period."
45699023|NCT03464526|Drug|Placebo|Tablet, once daily, oral
45851332|NCT02993484|Biological|Ischemic preconditioning|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
46057294|NCT02710539|Drug|perindopril, indapamide , amlodipine|Free combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
45851333|NCT02993484|Other|Ischemia reperfusion|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
45404402|NCT03821064|Other|Patient Navigation|NDURE is a theory-based, multi-level patient navigation (PN) intervention consisting of clinic-based sessions of manualized PN to reduce barriers to care, increase HNC care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (~3 months). The three in-person NDURE sessions, which are expected to take 30-60 minutes each, will coincide with the presurgical consult, hospital discharge, and 1st postoperative clinic visit. During the first session, the navigator will 1) elicit barriers and facilitators to timely PORT, 2) develop the personalized barrier reduction plan (BRP), review the BRP with the patient, caregiver, and provider, and 3) implement the BRP. At the two subsequent sessions, the navigator will review and update the BRP in an iterative, dynamic fashion, identifying new barriers and systematically tracking resolution of prior barriers until the start of PORT.
45513033|NCT03633279|Drug|Branched chain amino acid|Branched chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg).
45513034|NCT03633279|Drug|Placebo|an equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)
45513035|NCT05630118|Behavioral|SHUTi Intervention|"Sleep Healthy Using the Internet (SHUTi) is a well-validated version of e-CBT-I comprised of 6 weekly educational modules and daily sleep diaries. Participants will have 9 weeks to complete 6 once-weekly educational cores. Cores consist of: insomnia overview, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention, and last approximately 45 minutes each. Participants will receive weekly objectives, as well as review and feedback on the previous core's assignments and sleep diary data, new material, assignments, and a summary. These features are supplemented with interactive features (i.e., personalized goal-setting, video vignettes). Participants receive daily emails prompting them to complete the 11-item sleep and alcohol use diary daily during the intervention."
45513036|NCT05630118|Behavioral|Web-Based Insomnia Education Program|"Participants will be given access to a web-based program on sleep education to read at their own pace during the 9-week intervention period. The program content overlaps with SHUTi on the following topics: insomnia symptoms, impacts, and causes, basic sleep improvement strategies, and when to see a doctor. The information is akin to that found on WebMD or National Sleep Foundation website. Unlike the SHUTi program, the information is fixed, accessible immediately (no week-to-week information unlocking) and there are no customized bedtime or wake-time suggestions based on sleep diary data."
45513037|NCT02189408|Biological|Platelet rich plasma|
45513038|NCT02257190|Behavioral|Control|One hour of rest.
45513039|NCT02257190|Behavioral|IW3|A one hour exercise bout with repeated cycles of 3 min of fast and 3 min of slow walking
45513040|NCT02257190|Behavioral|IW1|A one hour exercise bout with repeated cycles of 1 min of fast and 1 min of slow walking
45513041|NCT02058342|Behavioral|Active Play at Home|The Active Play at Home (APAH) curriculum includes age-appropriate goal-oriented physical activities that combine playground and video games using the Nintendo Wii™ with exercises targeting: muscular strength and endurance, aerobic endurance, flexibility, balance, agility, and motor coordination. APAH was designed for children ages 8-11 without disability and ages 8-15 years with PWS. The playground games and interactive console-based games are to be performed twice weekly each. The activity is progressed from 25 to 45 minutes of moderate to vigorous physical activity throughout the 24 weeks period. Parents and children are trained to use the curriculum hands-on at baseline.
45513042|NCT03680391|Procedure|Cesarean section|"Both groups cesarean section will be held with the same technique:~spinal anethesia~pfennenstiel imcision~lower segment cesarean section~suturing uterus in two layers while exterionezed~gentle manibulation~no towels in gutters will be used"
45513043|NCT03680313|Procedure|Hypertension outpatient treatment|Patients who have been diagnosed with primary hypertension and meet the conditions of the study will receive outpatient treatment
45513044|NCT02260206|Drug|Colchicine|Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
45513045|NCT02192918|Behavioral|Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants in the airbrush condition will receive 4 airbrush tan sessions, once every two weeks, over the course of 2 months.
45699024|NCT04336878|Behavioral|Healthy Habits in Pregnancy and Beyond|Habit-based intervention to support the development of 10 healthy dietary and activity behaviours for pregnant women with overweight or obesity.
45699025|NCT03468192|Other|Non-precaution group|Patients in the NPG had no restrictions on mobility, i.e. they were encouraged to move freely during the recovery phase and assistive equipment were prescribed only if needed
45699026|NCT02522598|Drug|VVZ-149 injections|Colorless, transparent liquid in water for injection
45699027|NCT02522598|Drug|Placebo|water for injection
45851334|NCT02993484|Other|Sham|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
45851335|NCT02993328|Drug|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
45513046|NCT02192918|Behavioral|Airbrush Plus|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class.
45513047|NCT02192918|Behavioral|Delayed Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class
45513048|NCT03535610|Device|Uterine Embolization|Uterine Embolization with PVA Microspheres
45513049|NCT03535532|Procedure|unilateral laparoscopic adrenalectomy|unilateral laparoscopic adrenalectomy is a kind of minimally invasive surgery commonly operated in patients diagnosed with adrenal diseases with a high likelihood of malignance or surplus hormone secretion.
45513050|NCT03535532|Drug|standard medical treatment|standard medical treatment: detailed medicine strategy chosen for each patient will be associated with their own conditions based on current guidance recommendations.
45513051|NCT02058576|Drug|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fed condition.
45513052|NCT02058576|Drug|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fed condition
45513053|NCT03675867|Other|Correlation between resting respiratory parameters and cardio-respiratory parameters at exercise|Correlation between resting respiratory parameters and cardio-respiratory parameters at exercise
45513054|NCT02192996|Dietary Supplement|Probiotic|blood and fecal samples were collected from five VLBW preterms which were supplemented with a probiotic mixture of Bifidobacterium breve / Lactobacillus salivarius isolated from human milk
45513055|NCT02058654|Drug|Creatine|Creatine powder (5 g)
45513056|NCT02058654|Drug|Placebo|Bulking agent powder (5 g)
45513057|NCT03680235|Other|Informational Intervention|Receive standard information about breastfeeding and pregnancy
45513058|NCT03680235|Other|Informational Intervention|Receive information about breastfeeding and cancer
45513059|NCT03680235|Other|Interview|Participate in focus groups
45404403|NCT03963726|Radiation|stereotactic radiotherapy|The liver metastases were treated with Cyberknife stereotactic radiotherapy.Using multimodal image fusion to outline the target area.According to the volume, location, organ function and other factors, the dosage of radiotherapy was determined. The range of BED value of radiotherapy was 90-120 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 70-90 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).
45513060|NCT03680235|Other|Survey Administration|Ancillary studies
45513061|NCT03535220|Combination Product|Protease Inhibitors|Nucleic Acid Synthesis Inhibitors,Hydroxyurea,Antineoplastic Agents
45513062|NCT02660424|Drug|VX-150|
45513063|NCT02660424|Drug|Placebo|
45513064|NCT02189564|Behavioral|Feedback about good performance|
45513065|NCT02189564|Behavioral|Feedback about good performance + money|
45513066|NCT02189564|Behavioral|Feedback about average performance|
45513067|NCT03680079|Other|Group education sessions|Peer support and interaction both in-person during group education sessions and online via social media platforms
45513068|NCT02060448|Behavioral|Emotion awareness training|Four weekly individual treatment sessions focused on increasing awareness of one's emotions.
45513069|NCT02060448|Behavioral|Cognitive reappraisal|Four weekly individual treatment sessions focused on thinking about stimuli in a way that diminishes one's emotions.
45513070|NCT02189720|Drug|Amifampridine Phosphate|"Dosage form: tablets containing the equivalent of 10 mg amifampridine per tablet.~Amifampridine Phosphateis given based on Investigator assessment of optimal neuromuscular benefit. Doses range from 30 mg to 80 mg, divided into doses taken 3 to 4 times per day, with a maximum single dose of 20 mg."
45513071|NCT03675633|Diagnostic Test|FEUrea|FEUrea in decompansated liver cirrhosis
45513072|NCT03517254|Dietary Supplement|Glutamine|At the beginning and at the end of the training session, the experimental group will receive by mouth 15 grams of glutamine dissolved in 120 milliliters of water. The aminoacid will be inside gray envelopes.
45513073|NCT03517254|Other|Strength training program|One training session consists of 20 minutes of warm-up, 40 to 60 minutes of aerobic and anaerobic exercises and 15 minutes of cooling down. The exercises of the lower part of the body consist in 3 sets of 10 repetitions for healthy knee, and 12 repetitions for knee with anterior cruciate ligament reconstruction in a modular leg press, leg curl and leg extension machine.
45513074|NCT03517254|Other|Placebo|Maltodextrin powder to mimic glutamine,
46057295|NCT02710539|Drug|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
45404404|NCT03963726|Other|microwave alabation|The colorectal cancer patients with liver metastases will receive microwave ablation.3D printing template was used to assist microwave ablation.For those whose lesions are directly smaller than 5.0cm, the ablation time is about 10 min and 15 min, and the ablation time is more than 15min in patients larger than 5.0cm.
45404405|NCT03966456|Drug|Chemotherapy|compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.
45404406|NCT01076712|Other|Physiotherapy Interventions|Physiotherapy interventions including strengthening exercise, balance training, gait training with visual cus and gait training with treadmill
45404407|NCT01076712|Other|Education Classes|Education Classes
45404408|NCT01076790|Drug|Dexmedetomidine|Dexmedetomidine infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
45404409|NCT01076790|Drug|Saline|Saline infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
45404410|NCT01582932|Drug|Calcipotriene 0.005% Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face).
45404411|NCT03965520|Behavioral|exercise rehabilitation by near-infrared spectrometer|We adjust exercise intensity by the oxygen saturation change show in near-infrared spectrometer
45404412|NCT03965286|Drug|DAAs|Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) 12 weeks Daily simeprevir (150 mg) plus sofosbuvir (400 mg) 12 weeks Daily daclatasvir (60 mg) plus sofosbuvir (400 mg) 12 weeks Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) with dasabuvir (600 mg) 12weeks
45404413|NCT02531334|Dietary Supplement|TA-65|2 pills of TA-65 or placebo daily for 12 weeks. Subjects will be monitored weekly for side effects and every 4 weeks for compliance and safety monitoring. The whole intervention is a randomized double blind study for a duration of 27 weeks; 12 weeks for TA-65 or placebo allocated randomly and after a 3 week washout period, allocation to the alternate supplement TA-65 or placebo.
45404414|NCT02531178|Biological|ABBV-257|subcutaneous injection
45404415|NCT02531178|Biological|Placebo|Placebo for ABBV-257
45404416|NCT01079208|Other|test starter infant formula|infants are fed for 6 months with this starter formula
45404417|NCT01079208|Other|test starter infant formula with synbiotics|infant are fed for 6 months with this formula
45851336|NCT02993328|Drug|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
45404418|NCT01079208|Other|control standard formula|infant are fed 6 months with this formula
45404419|NCT01079286|Drug|Nelfinavir and temsirolimus|Nelfinavir tablets of 250mg given twice daily in an escalating dosis schedule, Temsirolimus i.v. given weekly in an escalating dosis schedule
45404420|NCT01081704|Drug|ustekinumab|Single dose of 45 mg subcutaneous injection
45404421|NCT01081704|Drug|ustekinumab|Single dose of 90 mg subcutaneous injection
45404422|NCT00141518|Drug|Levodopa-carbidopa intestinal gel (LCIG)|
45404423|NCT00141518|Device|CADD-Legacy® 1400 ambulatory infusion pump|
45404424|NCT00141518|Device|percutaneous endoscopic gastrostomy tube (PEG tube)|
45404425|NCT00141518|Device|jejunal extension tube (J-tube)|
45404426|NCT03973736|Other|application of a diagnostic and therapeutic protocol (multidisciplinary discussion and radiological CT review)|Since the introduction of the new protocol in 2012, a single central multidisciplinary team has been formalized, with weekly discussion of cases, including different specialists from all the provincial hospitals. CT scans of discussed cases are reviewed by one of two experienced radiologists based on pre-defined criteria.
45404427|NCT02531360|Drug|[18F]MNI-815 (MNI-815)|All enrolled subjects will undergo an [18F]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo [18F]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.
45404428|NCT00253448|Radiation|radiation therapy|No more than 2 weeks later, patients undergo conventional radiotherapy once daily, 5 days a week, for 6 weeks.
45851337|NCT02993094|Drug|Ixazomib|Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
45404429|NCT00253448|Radiation|stereotactic radiosurgery|stereotactic radiosurgery to high-risk areas of active tumor determined by MR-spectroscopy
45404430|NCT01075880|Drug|Rebif (Interferon beta-1a)|The treatment to be administered is interferon beta-1a on prescription, used as per SmPC, i.e. both doses 22 and 44 mcg s.c. tiw, and the titration pack 8.8 mcg and 22 mcg s.c. tiw when initiating the therapy.
45404431|NCT03967106|Other|Ischaemic Preconditioning|IPC to the upper arm using a manual blood pressure machine with cuff. Three cycles of 5 minute cuff inflation to 30mmHg above the systolic blood pressure (BP) followed by 5 minute cuff deflation.
45404432|NCT03967106|Other|Sham|Sham intervention to the upper arm using a manual blood pressure machine with cuff. Three cycles of 5 minute cuff inflation to 30mmHg below the diastolic blood pressure (BP) followed by 5 minute cuff deflation.
45404433|NCT00098748|Drug|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
45404434|NCT00098748|Drug|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily
45404435|NCT00098748|Drug|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
45404436|NCT00098748|Drug|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
45404437|NCT00098748|Drug|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
45404438|NCT00130520|Drug|bevacizumab|10mg/kg every two weeks IV-bevacizumab
45404439|NCT00130520|Drug|erlotinib|150mg daily by mouth-erlotinib
45404440|NCT00132132|Behavioral|Behavioral education program|Monthly 4 hr session which incorporates: exercise, empowerment, education, and incentives
45699028|NCT03464370|Other|Measure of emotional stressors|"For the Epileptic Group~Rapid interrogation, completing the clinical data~A scale of impact of the precipitating factors of crises~An emotional Stroop~A task of detecting emotional targets against threatening information~A measure of the perception of emotions using film clips~A scale of measurement of perceived stress~The transfer of psychiatric scales~For the healthy volunteers group :~A rapid interrogation, gathering the possible medical history, the level of studies, the manual laterality~An emotional Stroop~A task of detecting emotional targets against threatening information~A scale of measurement of perceived stress~A measure of the perception of emotions using film clips~A rapid neuropsychological assessment"
45699029|NCT03453996|Other|Intervention|"Computerized clinical decision support intervention. This intervention consists of 2 decision support components for CI-AKI prevention:~Estimation of safe contrast limit to reduce the relative risk of CI-AKI by 20% (ePRISM Acute Kidney Injury Model with Contrast Sensitivities and Dialysis Risk software from Health Outcomes Sciences)~Patient weight and left ventricular end diastolic pressure (LVEDP) based intravenous crystalloid fluid recommendation."
45699030|NCT03453996|Other|Control|Usual procedural care provided by cardiologist without introduction of the computerized clinical decision support information.
45699031|NCT04862052|Procedure|Intravascular management of prior implanted coronary drug eluting stent restenosis|Intravascular devices will be assessed for the management of prior implanted drug eluting stent restenosis management.
45851338|NCT02993094|Drug|Carboplatin|Cycles will be repeated every four weeks. Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
45851339|NCT02993016|Procedure|patient-specific instruments|
45851340|NCT02993016|Device|The Signature™ Vanguard|
45404441|NCT00130442|Drug|PI-88 and dacarbazine|190 mg daily by subcutaneous injection for PI-88 and 1000 mg/m2 on day 1 of each 21 day cycle by intravenous infusion
45404442|NCT00130442|Drug|dacarbazine or DTIC|intravenous infusion 1000 mg/m2 on day 1 of every 21 day cycle
45404443|NCT00130208|Drug|Sulodexide|100 mg sulodexide gelcaps
45404444|NCT00130208|Drug|Placebo|0 mg gelcap
45404445|NCT00253370|Drug|BAY 43-9006|Given orally
45851341|NCT02993016|Procedure|conventional instruments|
45404446|NCT00253370|Drug|docetaxel|Given IV
45404447|NCT00253370|Drug|cisplatin|Given IV
45404448|NCT01071980|Other|Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck|Participants will be randomized at the cluster level to a control group or 20 weeks of specific resistance training for 3 x 20 min a week
45404449|NCT03966482|Behavioral|Group before-after|The group was submitted to four weeks of speech therapy intervention with Semiocluded vocal tract exercise. The 12 participants were evaluated before and after the intervention with a multidimensional evaluation comprised of analysis of images generated by specialized videonasoendoscopy software, analysis of speech emissions by perceptual-auditory evaluation and acoustic analysis, and vocal self-assessment.
45404450|NCT03966170|Drug|Citicoline|Citicoline as neuroprotector
45513075|NCT03517254|Other|Dietary recommendations|All participants, irrespective of the supplement that they receive, will be closely monitored by a nutritionist, who will give dietary recommendations to standardize protein consumption (1.2 gr/kg weight). Status nutritional will be assessed according to BMI ( 19.9-24.9, 25-29.9).
45513076|NCT02189876|Behavioral|Standard of Care|All participants will be provided a STD/HIV pre-test counseling session. This session will be provided by either certified project staff or clinical staff at a Los Angeles clinic that conduct State of CA Fam Pact services for patients who are of child bearing age, including our current study partner St. John's Well Child and Family Center and our former study partner, JWCH (John Wesley Community Health) Institute-Wesley Health Center Clinics. Following the counseling session, the participant will be asked to provide a sample of urine to test for Chlamydia and Gonorrhea.
45513077|NCT02189876|Behavioral|FemAALES|Women will attend 9 small group sessions over 4 weeks. Three of these sessions will focus specifically on participants learning to use a computer, set up an email account, communicate with the team and the group using the Internet, and developing a prevention message for display on project website and social media accounts. The other 6 sessions will include discussions on the following topics: being a Black woman in American, Black history, assessing personal health, changing current behaviors, HIV/AIDS information, and education, self-empowerment, communication skills, reasons to change, and goal setting.
45404451|NCT03966170|Drug|Placebo oral tablet|placebo drug
45404452|NCT01076426|Drug|Pro-biotics|Pro-biotics and placebo one pack per day is given to the two group. And then evaluate the peritonitis rate and nutrition status.
45513078|NCT03675555|Drug|Mirtazapine|Each patient received 30 mg Mirta tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline [NS]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
45513079|NCT03675555|Drug|Dexamethasone phosphate|Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
45754187|NCT05581706|Other|Sample collection for immunofluorometric assay|Periapical exudate samples were collected at the beginning of the RET and at 14th day. MMP-8 levels were measured by immunofluorometric assay (IFMA). Briefly, two monoclonal MMP-8-specific antibodies, 8708 and 8706 (Oy Medix Biochemica Ab, Espoo, Finland) were used as catching antibody and tracer antibody, respectively. Samples were diluted in enzyme buffer (50 mM Tris-HCl, pH 7.5; 0.2 mM NaCl, 1 mM CaCl2). Twenty microlitres of samples and 80 μl of assay buffer (20 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 5 mM CaCl2, 0.5% BSA, 0.05% sodium azide and 20 mg/l diethylenetriaminepentaacetic acid with 2 μg/ml normal mouse serum) were pipetted into the wells. The tracer antibody was labelled using europium chelate. After adding the enhancement solution, fluorescence was measured using a 1234 Delfia Research Fluorometer (Wallac, Turku, Finland).
45404453|NCT01076426|Dietary Supplement|Oligosaccharide|oligosaccharide one pack per day
45404454|NCT00140426|Drug|Risperidone|risperidone titrated 0.5 to 4 mg over study enrollment. Mean Length of Phase 1 is currently 10 weeks.
45404455|NCT00140426|Drug|Placebo|Comparison of risperidone versus placebo for the treatment of symptoms related to anorexia nervosa.
45404456|NCT03966560|Drug|Brimonidine Tartrate|Brimonidine tartrate 0.15% 1 eye drop, every day for 6-months
45404457|NCT03966560|Drug|Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops|Dorzolamide and timolol fixed combination 2 eye drops, every day for 6 months
45851342|NCT02993016|Device|Vanguard PS(posterior stabilized)|
45404458|NCT03966560|Drug|Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension|Brinzolamide and timolol fixed combination 2 eye drops, every day for 6 months
45404459|NCT03966560|Drug|Travoprost and Timolol|Travoprost and Timolol fixed combination 1 eye drop, every day for 6 months
45404460|NCT03966560|Drug|Bimatoprost and Timolol|Bimatoprost and Timolol fixed combination 1 eye drop, every day for 6 months
45404461|NCT03966560|Drug|Latanoprost|Latanoprost 0.005% 1 eye drop, every day for 6 months
45404462|NCT01072058|Drug|TNF blockers (infliximab, adalimumab, etanercept)|Subjects enrolled, who were eligible to anti-TNF therapy, were evaluated by echocardiography (conventional and tissue doppler imaging)and biomarkers (NT-proBNP and troponin T)at baseline. Then, they were treated with adalimumab 40mg subcutaneously every 2 weeks or infliximab 3 or 5mg/Kg (0, 2 and 6 weeks and thereafter every 8 weeks)or etanercept 50mg subcutaneously every week. And they were re-evaluated with 6, 12, 18 and 24 months from first dose of the TNF blocker .
45404463|NCT01072214|Drug|pazopanib|gw786034
45404464|NCT01072214|Drug|pazopanib|gw786034
45513080|NCT03675555|Drug|Placebo|Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 h preoperatively.preoperatively.
45513081|NCT02190032|Device|Mallinckrodt endotracheal tube with a modified angle|At sniffing position, the distal tip of a double-lumen tube is located at the patient's cricoid cartilage level and then the tube is bent at the intersection point of oral axis and the pharyngolaryngeal axis with an angle between the two axes.
45513082|NCT02190032|Device|Mallinckrodt endobronchial tube with a conventional angle|Inserting a manufacturer-provided conventional-angled tube
45513083|NCT03679923|Dietary Supplement|NEM® brand eggshell membrane|Dietary supplement for the support of joint health.
45513084|NCT03679923|Dietary Supplement|Placebo|Placebo
45513085|NCT02060994|Other|No intervention|No intervention
45513086|NCT02194166|Drug|Trastuzumab|Trastuzumab IV or SC will be administered as described.
45513087|NCT02194166|Drug|Paclitaxel|Paclitaxel will be administered in accordance with local hospital practice.
45513088|NCT02194166|Drug|Docetaxel|Docetaxel will be administered in accordance with local hospital practice.
45513089|NCT03679845|Drug|Sarilumab|Sarilumab is an IL-6 monoclonal antibody that has shown to be potentially important in the creation of sclerosis in SSc.
45513090|NCT02061072|Other|Population pharmacokinetic estimation|Pre-existing individual PK data will be used to derive population PK models. Sparse concentration time data, acquired via a website, will be used to estimate individual pharmacokinetic parameters
45513091|NCT02194244|Drug|RG1662 granules|Single dose, oral administration of RG1662 immediate release granules
45513092|NCT02194244|Drug|RG1662 tablet|Single dose, oral administration of film-coated RG1662 immediate release tablet
45699032|NCT03453918|Dietary Supplement|polyphenols|"After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~Starter: duck gizzard salad.~Main course: black pudding and pasta.~French cheese.~Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic."
45513093|NCT03679533|Dietary Supplement|Freeze-Dried Cranberry Powder|Freeze-dried cranberry powder (or matched placebo), approximating 500mg active flavonoids per day, taken twice daily for 12 weeks.
45513094|NCT03679533|Dietary Supplement|Placebo|Placebo food powder matched for taste, colour, energy and macronutrient content to the active cranberry powder.
45754188|NCT00494975|Device|Narrow band UVB phototherapy , long wave UVA phototherapy|A UV irradiation cubicle (HOUVA II, National Biological Corporation, OH, U.S.A.) equipped with 24 UVA lamps (F72T12/BL9/HO UVA, National Biological Corporation, OH, U.S.A. ) and 24 UVB lamps (TL100W/01 311NB UVB, Philips Company, Eindhoven, The Netherlands).
46057296|NCT04846803|Biological|ABU bladder lavage|Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with the non-pathogenic bacterial strain (ABU)
45404465|NCT01072214|Drug|pazopanib|gw786034
45404466|NCT01072214|Drug|Placebo|placebo
45404467|NCT00121134|Drug|Bevacizumab|Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
45404468|NCT00121134|Drug|Cyclophosphamide|Once a day for 6 months
45404469|NCT00121134|Drug|Methotrexate|Twice daily for the first two days of every week for 6 months
45404470|NCT00121134|Drug|Capecitabine|"Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks)~Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)"
45404471|NCT03966690|Device|Isokinetic leg extension/-flexion on a legpress device|Maximum strength and rate of leg-flexion /-extension during legpress exercise
45404472|NCT03966690|Device|Isokinetic leg extension/-flexion on a legcurl device|Maximum strength and rate of leg-flexion /-extension during legcurl exercise
45513095|NCT02194322|Drug|BIBN 4096 BS - in single rising doses|
45513096|NCT02194322|Drug|Placebo|
45513097|NCT03675399|Other|Supra-threshold isometric exercise|The supra-threshold intensity will be stablished at 120% of participant's PFIS pre-session measurement (20% above the individual's pain threshold).
45513098|NCT03675399|Other|Infra-threshold isometric exercise|The infra-threshold intensity will be stablished at 80% of participant's PFIS pre-session measurement (20% bellow the individual's pain threshold).
45513099|NCT02195882|Procedure|Exercise program of the scapular muscle stabilizers|
45513100|NCT02193308|Drug|Telmisartan/Amlodipine FDC|
45513101|NCT02193308|Drug|Telmisartan|
45513102|NCT02193308|Drug|Amlodipine|
45404473|NCT03966378|Other|Grape seeds extract|Grape seeds extract powder
45404474|NCT03966378|Other|Casein-phosphopeptide/amorphous-calcium phosphate|CPP-ACP paste
45404475|NCT02657434|Drug|Atezolizumab|Participants received IV infusion of 1200 mg atezolizumab on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
45404476|NCT02657434|Drug|Carboplatin|Participants received IV infusion of carboplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period with doses calculated using Calvart formula.
45404477|NCT02657434|Drug|Cisplatin|Participants received IV infusion of 75 mg/m^2 cisplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period.
45404478|NCT02657434|Drug|Pemetrexed|Participants received IV infusion of 500 mg/m^2 pemetrexed on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
45404479|NCT03758248|Genetic|CYP2C19|The CYP2C19 enzyme plays a vital role in the two bioactivation steps of clopidogrel leading to lower (CYP2C19*17 carriers) or higher (CYP2C19*2 carriers) risk of major adverse cardiovascular events.
45404480|NCT02652052|Other|Standard of Care - Observation Only|Control Arm - Observation only
45404481|NCT02652052|Drug|Group 2: Quercetin|Quercetin - take four 250mg capsules daily (total 1000 mg daily) for 3 consecutive days.
45404482|NCT02652052|Drug|Group 2: Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days
45404483|NCT00119262|Drug|doxorubicin hydrochloride|Given IV
45404484|NCT00119262|Drug|cyclophosphamide|Given IV
45513103|NCT03683199|Procedure|Rhinoplasty|"The cleft lip rhinoplasty will be performed under general anesthesia.~1: 100,000 epinephrine will be infiltrated in the columellar incision and in the septum.~Open approach rhinoplasty will be used. A step ladder incision placed at the patient's columella, and continued with infra-cartilaginous incision.~The columellar skin flap along with the nasal tip skin will be dissected from the lower lateral cartilages.~Harvesting of the septal cartilage, to be used as spreader graft and columellar graft. Correction of the septal deviation.~Lengthening of the columella on the expense of the ala. Correction of the nasal tip by suturing techniques and by cartilage grafts."
45513104|NCT02195960|Dietary Supplement|Placebo|intake corn extract poor in anthocyanins: three daily stick packs containing water-soluble extract from corn cobs poor in anthocyanins
45851343|NCT02992860|Drug|JNJ-56022473|JNJ-56022473 will be supplied as a lyophilized product containing 100mg of active pharmaceutical ingredient (50 mg/mL after reconstitution with 2.0 mL sterile water for injection). The JNJ-56022473 dose administered will be dependent upon the subject's weight at baseline. The JNJ-56022473 dose should be adjusted in case the subject's weight changes by > 10%. JNJ- 56022473 will be administered in 250 mL IV infusion over approximately 180 minutes using an infusion pump.
45404485|NCT00119262|Biological|bevacizumab|Given IV
45404486|NCT00119262|Drug|paclitaxel|Given IV
45404487|NCT00119262|Biological|filgrastim|Given SC
45404488|NCT00119262|Biological|pegfilgrastim|Given SC
45404489|NCT00119262|Radiation|radiation therapy|Undergo radiation therapy
45404490|NCT00119262|Drug|tamoxifen citrate|Given orally
45404491|NCT00119262|Drug|aromatase inhibition therapy|Receive aromatase inhibition therapy
45404492|NCT01077102|Other|Eccentric exercise training|The eccentric exercise training will be performed using a specially built cycle ergo meter where the pedals are driven in backward direction by an electric motor, which has to overcome the adjustable resistance of the electromagnetic brake. During eccentric cycle ergometry patients have to resist the turning pedals.
45404493|NCT03703882|Drug|Edasalonexent|100 mg/kg/day
45404494|NCT03703882|Drug|Placebo|Placebo
45404495|NCT00131664|Drug|Avandamet|Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily compared to Avandia 4 mg and Amaryl 1 mg once daily over 6 months or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
45404496|NCT00131664|Drug|Avandia and Amaryl|Avandia 4 mg and Amaryl 1 mg once daily compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily, or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
45404497|NCT00131664|Drug|Metformin|Metformin 500 mg twice daily up to 1000 mg over 6 months compared to Avandia 4 mg and Amaryl 1 mg once daily or compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily
45404498|NCT03765268|Procedure|Neurectomy in inguinal hernia repair|Mesh hernioplasty of inguinal hernia with neurectomy of ilioinguinal and iliohypogastric nerve
45404499|NCT03765268|Procedure|nerve sparing in inguinal hernia repair|Mesh hernioplasty of inguinal hernia with sparing of ilioinguinal and iliohypogastric nerve
45404500|NCT03765190|Combination Product|Radiation: Proton Therapy+PD-1 Ab|combination of proton radiotherapy with PD-1 antibody
45404501|NCT03765112|Device|Optical coherence tomography angiography|Multiple scans of the retina will be recorded to evaluate microvascular changes.
45404502|NCT00131508|Drug|Glutamine|0.6 gm/kg of oral glutamine per day, in two doses for one year.
45404503|NCT00131508|Drug|Placebo|Placebo
45404504|NCT03765034|Behavioral|Constrain-induced Movement Therapy|8-week therapy program utilizing constraint of the unaffected arm
45404505|NCT03765034|Behavioral|Usual Occupational Therapy|8-week therapy program without constraint of the unaffected arm
45404506|NCT01321684|Other|lateral decubitus position with full spinal flexion|The patients maintained the lateral decubitus position with the hips and back fully flexed for 15 minutes.
45404507|NCT01321684|Other|lateral decubitus position without spinal flexion|the patients are allowed to straighten their flexed hips and back to obtain the normal lordotic curvature of spinal column
45513105|NCT02195960|Dietary Supplement|intake anthocyanin-rich corn extract|intake anthocyanin-rich corn extract: three daily stick packs containing water-soluble extract from high-anthocyanin rich corn cobs
45513106|NCT02060604|Drug|Ketorolac + Ranibizumab|3 monthly ranibizumab, then as needed Ketorolac TID
45513107|NCT02060604|Drug|Ranibizumab|3 monthly ranibizumab, then as needed
45513108|NCT03679455|Drug|Obinutuzumab 25 MG/ML|Study treatment, obinutuzumab is a Type II humanized anti-CD20 monoclonal antibody of the IgG1 subclass derived by humanization of the parental B-Ly1 mouse antibody and produced in the Chinese Hamster Ovary cell line by recombinant DNA technology. The Study Treatment, obinutuzumab is a liquid concentrate for infusion. Obinutuzumab vials are type 1 glass vials with a butyl rubber stopper. Obinutuzumab is provided as a single 1000 mg dose liquid concentrate with a strength of 25 mg/mL. It is supplied in 50 mL glass vials containing 40 mL of the 25 mg/mL liquid concentrate.
45513109|NCT02193386|Other|No intervention, no follow-up, only registration|Usual Care
45513110|NCT02193386|Other|Intervention period|Predefined intervention program
45513111|NCT03315143|Drug|Sotagliflozin|Sotagliflozin was administered as a tablet(s), orally once daily.
45404508|NCT05088772|Device|Hyperbaric Oxygen Therapy|"Hyperbaric Oxygen Therapy performed at 100% oxygen at 2.0-2.4 ATA, with 1-3 air breaks, typically at 5 sessions per week, with limited variation depending on the treatment indication and patient/clinician preference."
45404509|NCT05050318|Biological|Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation|Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)
45404510|NCT05050318|Biological|Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation|Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)
45513112|NCT03315143|Drug|Placebo|Placebo was administered as a tablet(s) (identical to the sotagliflozin tablet in appearance), orally once daily.
45699033|NCT03453918|Other|Placebo|"After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~Starter: duck gizzard salad.~Main course: black pudding and pasta.~French cheese.~Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic."
46057297|NCT04846803|Biological|Saline bladder lavage|Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with saline
45404511|NCT03764956|Other|Low glycemic Index Therapy (LGIT)|Specific dietary therapy called Low glycemic Index Therapy (LGIT) which provides diet including food items with glycemic index less than 50 only. For this purpose, various dietary menus will be provided to the parents.
45404512|NCT03764956|Other|Modified Atkins Diet (MAD)|Specific dietary therapy called Modified Atkins Diet (MAD) which provides diet with restricted carbohydrates upto 20 grams per day and increased fat and protein ratio. For this purpose, various dietary menus will be provided to the parents.
45513113|NCT02194400|Biological|RSLV-132|0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
45513114|NCT02062086|Dietary Supplement|deuterated creatine 30 mg|Study participants will take a single oral dose of deuterated creatine 30 mg in capsule form
45513115|NCT03675165|Behavioral|Best Possible Self|A writing exercise developed in 2001 by Laura King. The frequency of engagement with the exercise is down to the user's discretion though we recommend to them to write things down once every week for the duration of the study.
45513116|NCT02194478|Behavioral|Meditation|30 minute, 8 week meditation
45513117|NCT02061228|Device|Pipelle de Cornier®|Women in the intervention group will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France). This class I individually and sterile-packaged medical device, complies with Directive 93/42/European Economic Community (EEC) and is routinely used in our centre for endometrial sampling. It is comprised of a flexible disposable polypropylene suction cannula with an outer diameter of 3.1 mm and a 2.4 mm diameter opening on the distal end, on one side of the cannula. An inner plunger creates a vacuum essential for the blind endometrial biopsy. After the introduction of the Pipelle into the uterine cavity, it will be rotated 360 degrees and moved up and down four times after withdrawing the piston.
45513118|NCT04715204|Other|High Energy Oral Nutrition Supplement|Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density >0.9 kcal/mL. Formula with caloric density of >1.2 kcal/mL is categorized as high energy ONS. This intervention has caloric density of 1.5 kcal/mL.
45513119|NCT04715204|Other|Standard Energy Oral Nutrition Supplement|Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density >0.9 kcal/mL. This intervention has caloric density of 1 kcal/mL and it is categorized as standard energy ONS.
45513120|NCT04715204|Other|Formula-75/Formula-100|"Formula-75/Formula-100 is a special therapeutic foods to treat children with severe acute malnutrition. WHO designed F75 as a starter formula for stabilization phase with 75 kcal/100 mL, then it is continued with F100 for rehabilitation phase with 100 kcal/100 mL Formula-75 and Formula-100 are made according to recipe from WHO. The ingredients are skimmed milk powder, coconut oil, and sugar. Mineral mix is added, i.e. 2 ml every 100 ml of formula.~The composition of F-75:~Skimmed milk 25 g, coconut oil 100 g, sugar 30 g, mineral mix 20 ml, add water to 1000 ml~The composition of F-100:~Skimmed milk 80 g, coconut oil 50 g, sugar 60 g, mineral mix 20 ml, add water to 1000 ml"
45513121|NCT02060682|Device|Navvus Catheter FFR|Navvus Catheter provides Fractional Flow Reserve (FFR) measurement for each lesion identified according to standard of care of the center and the Instructions for Use (IFU).
45513122|NCT02194556|Drug|Sequential and maintenance icotinib|Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, sequential icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib until disease progression or intolerable toxicity.
45513123|NCT02194556|Drug|Maintenance icotinib|Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib (125 mg three times per day) until disease progression or intolerable toxicity.
45513124|NCT03679377|Device|Mandibular slotplate|Mandibular slotplates are placed during the osteosynthesis phase of the BSSO surgery. After testing of the plates they are removed and the osteotomy is fixated with three bicortical screws.
45513125|NCT02062242|Other|Transvaginal electrical stimulation|The current employed is biphasic and the stimulation parameters are: frequency of 50 Hz, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds and relaxation time (Toff) of 10 seconds. The current intensity is defined according to the tolerance of patient and the total stimulation time is 20 minutes.
45513126|NCT02062242|Other|Palpation|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
45513127|NCT02062242|Other|Palpation with posterior pelvic tilt|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM associated with posterior pelvic tilt and contraction of accessory muscles. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
45513128|NCT02062242|Other|Control|The patient receive verbal instructions related to the pelvic floor and its contraction.
45513129|NCT02194634|Drug|Conbercept|Intravitreal injection of 0.5 mg Conbercept at first month, then repeated as needed.
45699034|NCT03468114|Behavioral|Safe Start|Participant households will receive four visits over a 10 week period from health extension workers promoting safe food preparation, storage and feeding, and will be provided with products to support these practices (a bowl, spoon, cup, hand washing station, liquid soap dispenser).
45699035|NCT03468114|Behavioral|Active Control|Participant households will receive 4 visits by health extension workers delivering standard care
45699036|NCT03452982|Other|sentinel node technique|Injection of a tracer in the stump of the infundibulo-pelvic ligament and uterus-ovary for sentinel node detection.
45699037|NCT03468036|Other|none, does not apply|none: does not apply
45404513|NCT03778996|Drug|Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)|Daily oral combination therapy for cancer
45404514|NCT03764722|Drug|Levosimendan|"The patient will initially receive a standard dose of 0.1 mcg/kgmc/min. In case of good tolerance of the drug - the dose will be increased to 0.2 mcg/kgmc/min. If hypotension SBP <90 mmHg occurs, the dose will be reduced to 0.05 mcg / kgm / min. If the hypotension persists despite the reduction of the drug - the infusion will be terminated and the patient will be excluded from the study. The infusion will be terminated within 24 hours, the patient will be examined again 4 hours after the end of the infusion, by the attending physician and unless there are contraindications - discharged home.~Patients will be hospitalized every 4 weeks for the next 6 months."
45404515|NCT03756610|Device|Active tACS|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 active tACS sessions.The active tACS group will be stimulated with a 2 mA current for 20 minutes.
45513130|NCT02194634|Other|Sham injection|Sham intravitreal injection at first month, then repeated as needed.
45513131|NCT02194634|Procedure|Laser|Laser treatment at first month, then repeated as needed.
45513132|NCT02194634|Other|Sham laser|Sham laser at first month, then repeated as needed.
45513133|NCT03679143|Drug|ZSP1273 100 mg|ZSP1273 tablet administered orally once daily under fasted condition
45513134|NCT03679143|Drug|Placebo 100 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state.
45699038|NCT04854018|Drug|Indocyanine green|Intravenous or intraparenchymal injection
46057298|NCT02710461|Dietary Supplement|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test
45404516|NCT03756610|Device|Sham tACS|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 sham tACS sessions.The sham tACS group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
45404517|NCT03756610|Device|Active boosting|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of active tACS.The active boosting group will be stimulated with a 2 mA current for 20 minutes.
45513135|NCT03679143|Drug|ZSP1273 200 mg|ZSP1273 tablets administered orally once daily under fasted condition
45513136|NCT03679143|Drug|Placebo 200 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
45513137|NCT03679143|Drug|ZSP1273 400 mg|ZSP1273 tablets administered orally once daily in the fasting state
45513138|NCT03679143|Drug|Placebo 400 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
45513139|NCT03679143|Drug|ZSP1273 600 mg|ZSP1273 tablets administered orally once daily under fasted condition
45513140|NCT03679143|Drug|Placebo 600 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
45513141|NCT03679143|Drug|ZSP1273 900 mg|ZSP1273 tablets administered orally once daily in the fasting state
45513142|NCT03679143|Drug|Placebo 900 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
45513143|NCT03679143|Drug|ZSP1273 1200 mg|ZSP1273 tablets administered orally once daily in the fasting state
45513144|NCT03679143|Drug|Placebo 1200 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
45513145|NCT03679143|Drug|ZSP1273|ZSP1273 tablets administered orally once daily under fasted or fed condition
45513146|NCT03679143|Drug|Placebo|Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition
45513147|NCT03679143|Drug|ZSP1273 Low Dose|ZSP1273 tablets administered orally once daily under fasted or fed condition for 5 Days.
45513148|NCT03679143|Drug|Placebo|Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition for 5 Days.
45513149|NCT03679143|Drug|ZSP1273 Median Dose|ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
45513150|NCT03679143|Drug|Placebo|Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
45513151|NCT03679143|Drug|ZSP1273 High Dose|ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
45513152|NCT03679143|Drug|Placebo|Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
45513153|NCT02061462|Procedure|EVLP-DCD Group|Events: application of an open lung protective ventilatory strategy (recruitment manoeuvre, low volume-low frequency ventilation-high PEEP) to the DCD donors; procurement of lungs and cold storage on ice; reconditioning/evaluation by EVLP to assess suitability for transplantation; cold storage on ice; transplantation. Endpoints of suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy
45513154|NCT02030912|Drug|3 doses of amoxicillin daily for 7 days|
45513155|NCT02030912|Drug|2 doses of minocycline daily for five days|
45513156|NCT02030912|Other|2 doses of placebo daily for five days|
45513157|NCT03675009|Other|Educational Programming|Green Cleaning educational programming to day care staff.
45513158|NCT03560700|Dietary Supplement|lactobacillus probiotic strain|Approved Dietary supplement
45513159|NCT03560700|Other|placebo|placebo comparator
45513160|NCT02196116|Other|PET|PET Scan with [18F]-Flutemetamol
45513161|NCT02196116|Other|MRI|
45513162|NCT02196116|Other|neuropsychological tests|
45513163|NCT02060916|Drug|PAZ320|Single-center pilot study, open label dose escalation design
45404518|NCT03756610|Device|Sham boosting|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of sham tACS.The sham boosting group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
45404519|NCT05024734|Drug|Epirubicin|"In PDOs from patients that show highest response to Epirubicin, this drug will be instilled intravesically once weekly for 6 times.~Epirubicin is also the default drug, in case of failure of drug prediction in the in-vitro drug screen in PDO.~Epirubicin will be used as a concentrate for injection/instillation 2 mg/ml in total 50mg per vial. Prior to use, the concentrate for injection is diluted with 25ml of 0.9% saline solution to obtain the final Solution with 1mg/ml of Epirubicin."
45404520|NCT05024734|Drug|Mitomycin|"In PDOs from patients that show highest response to Mitomycin, this drug will be instilled intravesically once weekly for 6 times.~Mitomycin C will be used as 20mg dry powder. Prior to use, the powder will be dissolved in 50ml of 0.9% saline solution according to the manufacturer instructions"
45404521|NCT05024734|Drug|Gemcitabine|"In PDOs from patients that show highest response to Gemcitabine, this drug will be instilled intravesically once weekly for 6 times.~Gemcitabine will be used as 2000 mg/50ml. For intravesical application, 1000mg of gemcitabine (corresponding to 25ml) will be diluted in 25ml 0.9% saline solution, to obtain the gemcitabine concentration of 1000mg/50ml used for instillation."
45404522|NCT05024734|Drug|Docetaxel|"In PDOs from patients that show highest response to Docetaxel, this drug will be instilled intravesically once weekly for 6 times.~Docetaxel will be used as 140mg/7ml solution. For intravesical application, 48.825ml of saline will be added to 1.875ml Docetaxel solution (according 37.5mg of Docetaxel). The concentration of this solution is 0.74mg/ml by a total volume of the instillation solution of 50,7."
45404523|NCT03699124|Biological|FD MVA-BN|Vaccinations with a 0.5 mL dose of vaccine containing at least 0.5 x 10E8 Infectious Units (Inf.U)
45404524|NCT05461066|Behavioral|CESAR training|Intervention community pharmacists received the CESAR training to improve their smoking cessation services, consisting of an initial interview and follow-up visits to identify obstacles and reinforce behaviours.
45404525|NCT03764644|Behavioral|Combined ABMT and CBT|ABMT: A trial begins with a fixation cross (+) for 500 ms, immediately followed by a stimuli pair consisting of a neutral and threatening stimulus that is centred horizontally. Stimuli pairs consist of two faces, pictures or words. After presentation of the stimuli pair, a probe (: or ..) always appears on the location of the neutral stimulus. The probe remains on the screen until the participant presses the corresponding key (: or ..), after which the next trial begins. Each session, participants see 160 trials of which 128 trials include one neutral and one threatening stimulus. The remaining 32 trials include a neutral-neutral stimuli pair. CBT: FRIENDS program individual
45404526|NCT03764644|Behavioral|Combined Sham ABMT and CBT|ABMT: A trial begins with a fixation cross (+) for 500 ms, immediately followed by a stimuli pair consisting of a neutral and threatening stimulus that is centred horizontally. Stimuli pairs consist of two faces, pictures or words. After presentation of the stimuli pair, a probe (: or ..) always appears on the location of the neutral stimulus. The probe remains on the screen until the participant presses the corresponding key (: or ..), after which the next trial begins. Of the 160 trials, the probe appears with equal frequency on the location of the neutral and threatening stimulus (128 trials). The remaining 32 trials include a neutral-neutral stimuli pair. CBT: FRIENDS program individual
45404527|NCT03764566|Behavioral|Questionnaires|The intervention will include the implication of related questionnaires, followed by a lab experiment for social belonging with multiple modalities. Participants will be shown pictures of different faces and asked to judge their feelings towards them. Further, a VR task will include finding the way through a virtual maze with the help of two virtual characters.
45699039|NCT04815096|Drug|[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)|[18F]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
45699040|NCT04803786|Drug|Transition from Xyrem to Xywav|This is a single-group non-interventional study where participant's transitioning from Xyrem to Xywav will be observed. Investigational product (IP) or drug support or requested changes to their medication will not be provided to participants by Jazz Pharmaceuticals. The Xyrem and Xywav that the participants will take will be provided by the participant's health care provider.
45404528|NCT05460988|Procedure|Flap surgery|All the sites showing a residual pocket in a sextant allocated to surgery group will receive flap surgery. After the administration of oral local anaesthesia (Articaine 1:100000) an intrasulcular flap will be raised. In order to preserve interdental tissue the flaps will be designed accordingly the principles of papillary preservation flap. Toot root will be carefully debrided using both ultrasonic instruments and Grecey's curettes. Bone recontouring and ostectomy/osteoplasty will be avoided. Single simple sutures will be used to close the flap (Vicryl 5-0).
45404529|NCT05460988|Procedure|Non surgical re-instrumentation|The sites showing remaining pockets (PD>4mm), in the sextants allocated to re-instrumentation group, will be treated with subgingival debridement. The subgingival debridement will be performed after the administration of local oral anaesthesia (Articaine 1:100000) using a periodontal tip on ultrasonic instrument (EMS) and Gracey's curettes.
45404530|NCT05002972|Behavioral|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
45404531|NCT03756298|Drug|Atezolizumab|Atezolizumab is 1,200 mg iv. administered every 3 weeks for 8 cycles with capecitabine (2,000mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
45404532|NCT03756298|Drug|Capecitabine|capecitabine monotherapy (2,500mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
45404533|NCT05460910|Other|core stability exercises with treadmill|swiss ball use patient is lying in supine position with 15 repitations and 3 sets.
45404534|NCT05460910|Other|core stability exercise without treadmill|technique used to improve stability
45404535|NCT03756220|Drug|Combination therapy of vitamin C and thiamine|Vitamin C (50 mg/kg up to 3 g, every 12 hours) and thiamine (200 mg every 12 hours) intravenously administered mixed in 50 mL solution bags of normal saline for 2 days
45404536|NCT03756220|Drug|Normal saline solution|Normal saline solution in a volume to match the treatment components administered mixed in 50 mL solution bags of normal saline for 2 days
45404537|NCT04651114|Behavioral|Decision-making tool|"Women will be directed to a secure website to download a copy of the decision making tool and worksheets (they can download as many copies as they wish to). The women will use the tool and worksheets at their own pace for the pilot study period.~The decision making tool is a 23-page tool and set of 9 downloadable worksheets. The tool covers topics relevant to women with disabilities in considering or planning a pregnancy: 1) Overview of Pregnancy: 2) Knowing what is important; 3) Partners, family and important relationships; 4) Physical function and independence; 5) Health and wellbeing; 6) Caring for an infant; 7) Financial resources & insurance; 8) How to find reliable information and resources; 9) Connecting with other women with physical disabilities; 10) Dealing with reactions of others, stigma and bias, pressure; and 11) Reaching a decision."
45404538|NCT03764410|Procedure|Non-surgical periodontal treatment|all the individuals included in the study received periodontal treatment with scaling and root planing with the use of local anesthesia and removal of factors that could cause biofilm retention such as fixed prosthesis, restorations, cervical abrasions. Four weekly sessions lasting 30 minutes each.
45404539|NCT03764332|Device|Stabilometry|To evaluate the static balance of subjects when barefoot and when using three types of footwear with their eyes closed or open.
45404540|NCT04980040|Drug|Alogliptin Benzoate|Alogliptin benzoate tablets
45404541|NCT04647916|Biological|Sacituzumab Govitecan|Given IV
45404542|NCT00131352|Device|hylan G-F 20|Single injection of 6 mL of hylan G-F 20 (Synvisc).
45404543|NCT00131352|Other|Phosphate Buffered Saline|Single injection of 6 mL phosphate buffered saline.
45404544|NCT04646200|Behavioral|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
45513164|NCT02257268|Behavioral|VAMOS program - Active life improving health|All participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for 12 weeks. VAMOS is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by a weekly meeting, in group, lasting about 90 min. In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories. The participants of this group will receive an educational material and, in the middle of the program, they will earn a pedometer to aid in motivation and in the self-monitoring physical activity.
45699041|NCT03464214|Device|Neck Muscle Vibration|Local vibration device applied on neck muscles for 8 weeks
45699042|NCT03464214|Behavioral|Cervical Stabilization Exercises|Cervical stabilization exercises performed by healty individuals for 8 weeks
45699043|NCT03464058|Drug|BOS172767 tablets|Oral tablets
45699044|NCT03464058|Drug|BOS172767 liquid capsules|Oral capsules
45404545|NCT04646200|Behavioral|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
45513165|NCT02063256|Dietary Supplement|7 nuts a day|add 7 nuts a day (whole shelled weight 75 grams) to standard diet
45851344|NCT02992860|Procedure|Bone marrow analyses and CBC with differential|Bone marrow analyses and CBC with differential will be performed by a central laboratory. If the marrow cannot be aspirated, a biopsy should be performed.
45513166|NCT02063256|Other|Diet modification|modify the diet allowing more intake of PUFA rich food and cutting the consumption of saturated fatty acids
45513167|NCT02797080|Drug|interferon γ-1b|ACTIMMUNE® will be administered three times per week by subcutaneous injection. The initial dose will be individualized for each participant and will be determined by the investigator, provided that the initial dose does not exceed the maximum tolerated dose in HZNP-ACT-302 (NCT02593773). The investigator may subsequently adjust the dose for any participant if deemed clinically appropriate, provided that the dose does not exceed 100 μg/m².
45513168|NCT02196194|Drug|Tiotropium|
45513169|NCT03534830|Diagnostic Test|MRI|pre-operative MRI to be performed on all patients and then based on the imaging studies, the patient will be divided into the two comparative cohorts
45513170|NCT02915835|Drug|Riociguat|riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
45513171|NCT02915835|Drug|Placebo|Placebo 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID;
45513172|NCT02194712|Other|Urine CAA detection|In addition to routine diagnostics, serum and urine samples are stored for retrospective UCP-CAA antigen determination.
45513173|NCT01370616|Drug|Ertapenem sodium|Ertapenem sodium, 1.0 g IV daily over 30 minutes at Hour 0 for 5 to 28 days
45513174|NCT01370616|Drug|Piperacillin/tazobactam sodium|Piperacillin/tazobactam sodium, 4.5 g, IV every 8 hours, given over 30 minutes at Hours 0, 8, and 16 for 5 to 28 days
45513175|NCT01370616|Drug|Piperacillin/tazobactam-matching placebo|Placebo, IV over 30 minutes, 2 times per day at Hours 8 and 16 for 5 to 28 days
45699045|NCT03464058|Drug|BOS172767 micronized capsules|Oral capsules
45851345|NCT02992860|Other|Flow cytometry analyses|Characterization of LSCs and blasts (including CD123 and CD38 expression) will be performed as study-related analyses in the context of this protocol by central flow cytometry using bone marrow samples.
45513176|NCT01370616|Drug|Amoxicillin/clavulunate potassium|If clinically indicated, participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
45513177|NCT02196272|Behavioral|Nurse-led reminder program through email|"Both groups will receive an educational program and usual care. The educational program will consist of:~- 1-hour session, during which the NCM give advices and enphasize the importance of the correct procedure of glycemic control, report non-pharmacological strategies for a healty lifestyle and instruction on how to fill a self assessment form."
45404546|NCT03756142|Diagnostic Test|Motion Analysis|Analysis of orthostatic posture, initiation of walking and walking by a motion analysis system
45404547|NCT04633642|Procedure|Ultrasound group|Every week during a six-week treatment period
45404548|NCT04633642|Procedure|Surgical group|Every week during a six-week treatment period
45513178|NCT02688881|Drug|sirolimus|Rapamune
45513179|NCT02196350|Behavioral|Intervention A: Diet|subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice
45513180|NCT02196350|Behavioral|Intervention B: Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
45699046|NCT03464058|Drug|BOS172767 immediate release capsules|Oral capsules
45699047|NCT03464058|Drug|BOS172767 matching placebo capsules|Oral capsules
45513181|NCT02196350|Behavioral|Intervention C: Diet and Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
45513182|NCT02197208|Procedure|Daily monitoring of LH and E2|ultrasound scanning would be carried out from 18 days before the expected period to confirm follicular growth, followed by daily blood monitoring of serum E2 and LH levels when the dominant follicle reaches 13-14mm in diameter. Ultrasound scanning can be arranged accordingly if the leading follicle remains less than 10mm in diameter. 5 ml of blood would be taken daily. LH surge is defined as the LH level being double of the average of the previous three days and higher than 20 IU/L. Ultrasound examination will be performed on the next day after the LH surge to measure the endometrial thickness. The transfer will be scheduled three or four days after the LH surge (for cleavage stage embryos) or six days after LH surge (for blastocyst transfer).
45513183|NCT02197208|Procedure|hCG induced natural cycle|ultrasound monitoring would be started from 18 days before the expected period to monitor follicular growth, followed by USG every 2-3 days. hCG, 5,000-10,000 IU will be given when the leading follicle is >/= 17 mm and the endometrium measures >/=8 mm. Serum E2, LH and progesterone levels will be measured on the day of hCG. Embryo transfer would be scheduled on the fourth or fifth days after hCG injection (for cleavage stage embryos) or seventh days (for blastocyst transfer).
45513184|NCT02197208|Device|ultrasound|
45513185|NCT02062476|Dietary Supplement|Lactobacillus GG|
45513186|NCT04243889|Device|NEOX Cord 1K applied fetoscopically|Under general anesthesia and tocolysis, in-utero repair begins with a laparotomy that is followed by exteriorization of the uterus. The fetus is then positioned by external cephalic version. Uterine entry will be accessed using 3 cannulas, followed by heated-humidified carbon dioxide insufflation for visualization. Then, fetoscopically the placode will be examined and dissected. The lesion will be repaired using NEOX Cord 1K® (HUC) for closure of the first layer over the neural placode. Primary closure of the skin will then occur, or NEOX Cord 1K® (HUC) will be used for skin closure at the discretion of the neurosurgeon. Finally, the laparotomy site will be sutured in multiple layers.
45513187|NCT03560310|Drug|Ticagrelor 90mg twice daily and ASA 75-100 mg daily|Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
45513188|NCT03560310|Drug|ASA 75-160 mg daily|Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
45513189|NCT03630497|Drug|Comparison of BN201 treatment with Placebo|Single Dose or Multiple Dose of BN201 IV administration
45513190|NCT02197286|Drug|Cholecalciferol|One capsule containing 4,000 IU of Cholecalciferol, per day
45513191|NCT02197286|Drug|Placebo|Daily dose of a single gelatin placebo capsule.
45513192|NCT01378247|Behavioral|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as outpatient sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of six months.
45513193|NCT03674775|Other|DART QI Program Participation|Antibiotic prescribing data will be collected at multiple time points both before and after the initiation of the intervention.
45513194|NCT02197442|Drug|Valsartan|
45513195|NCT03672669|Genetic|Advanced Platelet Rich Fibrin (A-PRF)|blood samples collected in 10 ml of vacuumed plain glass tubes were centrifuged for 14 minutes at 1500 rpm without anticoagulant agents in order to obtain A-PRF
45513196|NCT03672669|Genetic|Leukocyte- and platelet-rich fibrin (L-PRF)|blood samples collected in 10 ml of glass coated plastic tubes were centrifuged without anticoagulant agents for 10 minutes in order to obtain L-PRF
45513197|NCT02194790|Behavioral|Community-based Integrated CKD Care|Patients received, in addition to the standard care, educational activities provided by nutritionist, pharmacist and physiotherapist, and quarterly home visits. Our home visits team consisted of nurse, health care officers and village health volunteers
45513198|NCT02062788|Dietary Supplement|Oral rehydration solution|Preoperative day #1: able to drink Oral rehydration solution (ORS) freely On day of Surgery: Allowed administration until 2hrs prior to surgery. 8AM patients(the first patients to undergo surgery of the day) are recommended to administer ORS at 5:30AM
45513199|NCT02196428|Other|Telemonitoring and Teleconsultation|The interventions of this study are supported by a so-called Ambient Assisted Living Wizard (AAL Wizard). This is an IHE-compliant documentation and communication platform with an integrated electronic health record, which enables the study participants (elderly) to manage and store their relevant health data. It includes personal master data and the documentation of telemonitoring data. Additionally, the AAL-Wizard provides the communication modules such as telephone -, video- and time- and online consultation. The tele doctor assess the data (eg, vital signs and content of the medical teleconsultation) and collaborates in this way with the older person, family physicians and other health care providers based on an innovative and flexible telemedical home care service.
45513200|NCT02061618|Behavioral|Bollywood Dance Exercise|
45699048|NCT03464058|Drug|BOS172767 matching placebo tablets|Oral tablets
45699049|NCT03464058|Drug|Rabeprazole|Oral tablets
45513201|NCT04102280|Device|Dialyser|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Xevonta Hi 15 (B. Braun) and comparator Elisio 150H (Nipro)
45513202|NCT03560622|Device|multi-modality neuroimaging|multi-modality neuroimaging consists of structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI).
45513203|NCT03534674|Dietary Supplement|vitamin D3|a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, then 2000 IU vitamin D3 daily.
45513204|NCT02063334|Dietary Supplement|Vitamin D3|In total 25 pills will be taken by the subjects, each containing 80 micrograms of vitamin D3 or placebo. Of the 25 pills, 13 will be taken in the morning with breakfast and 12 with lunch.
45513205|NCT02063334|Dietary Supplement|Placebo|
45513206|NCT02031068|Behavioral|Active Rehabilitation Program|"The active rehabilitation program will be implemented for a maximum of 6-8 weeks. Each participant will be followed by regular weekly telephone calls or personal follow-up relating to outcome from concussion and managing symptoms. The participant will receive TAU (above) in addition to the 4 components listed below:~Sub-maximal aerobic training for up to 15 minutes~Light coordination and sport-specific exercises for up to 10 minutes~Visualization and imagery techniques~Home program~A physiotherapist will supervise the rehabilitation."
45513207|NCT02031068|Behavioral|Treatment-as-usual (TAU)|"The TAU program will be implemented after the initial assessment. It will consist of 2 components:~An initial education session by an occupational therapist, relating to outcome from concussion and managing symptoms A school consultation to provide teacher education, recommend accommodations, and facilitate return to school"
45513208|NCT02194946|Drug|CM therapies|The choice of CM patterns will be at the treating physician's discretion. The dosing regimen of Chinese herbs and Chinese patent medicine will be as per the 2010 Chinese pharmacopoeia.The oral Chinese herbal formula will be composed of 18 herbs:Radix Astragali, Radix Codonopsis, Rhizoma Atractylodis Macrocephalae, Rhizoma diosscoreae, Poria, Semen Cuscutae, Radix Morindae Officinalis, Herba Epimedii, Herba Cistanches, Fructus Ligustri Lucidi, Rhizoma Polygonati, Fructus Amomi, Herba Agastaches, Rhizoma Coptidis, Radix et Rhizoma Rhei, Semen Coicis, Radix Salviae Miltiorrhizae, and stir-baked Semen Persicae. The Chinese herbal formula via Colonic administration will be composed of 3 herbs: Radix et Rhizoma Rhei, Calcined Concha Osterae, Herba Taraxaci.
45513209|NCT02194946|Drug|CKD-related management|Western medicine treatment for CKD are practised following KDIGO and KDOQI guidelines, to reach the recommended goals of nutrition, blood pressure, hemoglobulin, electrolytes, fluid control and acid-base balance.
45513210|NCT02063490|Behavioral|Adherence support|"One-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills)~+ One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions"
45699050|NCT03463902|Device|left IFG anodal|"Single session of transcranial direct current stimulation (tDCS) over left IFG anodal stimulation~2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop"
45699051|NCT03463902|Device|left IFG cathodal|"Single session of transcranial direct current stimulation (tDCS) over left IFG cathodal stimulation~2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop"
45404549|NCT00136916|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose
45404550|NCT00136916|Drug|Subcutaneous insulin|Subcutaneous insulin with dose adjusted according to premeal blood glucose
45851346|NCT02992860|Other|Central biobanking|Central biobanking of study samples (bone marrow, peripheral blood as well as a buccal swab) will be carried out in Dresden.
45404551|NCT04633564|Biological|Bevacizumab as MYL-1402O|Bevacizumab as MYL-1402O 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV
45404552|NCT04633564|Biological|Bevacizumab as Avastin|Bevacizumab as Avastin 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV
45404553|NCT04960228|Behavioral|Altruism Video|The video provides three vignettes about a diverse set of people who may be more vulnerable to serious health consequences from COVID-19. In each of the stories, high vaccine uptake of those around these vulnerable individuals serves to protect them. This communicates that getting the COVID-19 vaccine can be done for prosocial reasons and to foster a sense of community, as it provides protection not only to oneself, but also to others.
45404554|NCT04960228|Behavioral|COVID-19 Informational Text|The topics included in the text are how COVID-19 spreads, hygiene, physical distancing, and travel restrictions. Participants will complete three comprehension questions, one after each of the following sections: hygiene, physical distancing, and travel restrictions.
45513211|NCT03792438|Diagnostic Test|Transvaginal 3D Power Doppler Ultrasound|Samsung H60 ultrasound machine with 4-9 MHz volume transducer using VOCAL system and Histogram Facility
45513212|NCT02062866|Procedure|Purse-String|"The wound will be closed using one, long, continuous suture which will enter and exit run through the skin along the inner edge of the wound. The start and stopping point will be adjacent to one another. The suture will then be pulled on either side to essentially cinch down the wound, decreasing the size of the wound."
45851347|NCT02992860|Procedure|Histopathology analysis|A bone marrow biopsy is taken whenever it seems necessary to the investigator.
45404555|NCT03756064|Drug|Pyrotinib|Pyrotinib: 400mg orally daily
45404556|NCT03756064|Drug|Trastuzumab|Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;
45404557|NCT03756064|Drug|Docetaxel|Docetaxel: 75mg/m2 for a total of 6 cycles
45404558|NCT03756064|Drug|Carboplatin|Carboplatin: AUC=5 for a total of 6 cycles
45404559|NCT03756064|Drug|Placebo Oral Tablet|Placebo Oral Tablet: 400mg orally daily
45513213|NCT02062866|Procedure|Second Intent|The wound will not be sutured, and allowed to heal on its own.
45513214|NCT02195024|Procedure|cardiac MRI group|• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
45513215|NCT02195102|Device|Transcatheter aortic valve Replacement|
45513216|NCT03533972|Drug|Ashwagandha|ashwagandha capsules given to the subjects twice daily after meals for 1 month
45513217|NCT03533972|Other|Placebo|placebo capsules given twice daily after meals for 1 month
45513218|NCT02916927|Drug|Ketamine IV Infusion|Ketamine 0.3 mg/kg in 100mL normal saline minibag administered over 15 min and placebo 10 mL normal saline syringe administered over 1 minute.
45513219|NCT02916927|Drug|Ketamine IV push|Ketamine 0.3 mg/kg in 10 mL normal saline syringe administered over 1 minute and placebo 100mL normal saline minibag administered over 15 min.
45513220|NCT02197598|Drug|nalmefene|
45513221|NCT02196662|Drug|IBD98-M:|single adiministration
45513222|NCT02196662|Drug|IBD98-M without HA|single adiministration
45513223|NCT02196662|Drug|Delzicol|single adiministration
45513224|NCT02195180|Drug|ERY001|
45513225|NCT02195180|Drug|Gemcitabine|
45513226|NCT02195180|Drug|5-fluoro-uracil/oxaliplatin/leucovorin (folfox)|oxaliplatin 85 mg/m2 levo-leucovorin 200 mg/m2 5-FU 400 mg/m2
45513227|NCT03672591|Other|Renal clearance examination|Evaluation of renal hemodynamic parameters by constant-infusion input clearance technique with p-aminohippuric acid and Iohexol
45404560|NCT03755986|Device|ATOMO Diagnostic Test|The ATOMO diagnostic test device is the only intervention used in this study.
45404561|NCT04628416|Device|PICO dressing|Use of a portative miniature negative pressure dressing system named PICO® on the split-thickness skin graft of fibula free flap donor sites
45404562|NCT04628416|Device|Conventional dressing|use of a conventional dressing (parrafin gauze) on the split-thickness skin graft of fibula free flap donor sites
45404563|NCT04619992|Device|Currently marketed Hydrophillic Intermittent Catheter|Currently marketed Hollister standard with tip hydrophilic intermittent catheter
45404564|NCT04619992|Device|Test Hydrophilic Intermittent Catheter|Hollister standard with tip hydrophilic intermittent catheter with design enhancements
45513228|NCT03623529|Drug|LJPC-501 (angiotensin II)|Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption.
45513229|NCT03623529|Drug|Placebo|Placebo Arm
45513230|NCT03161379|Drug|Cyclophosphamide|Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
45513231|NCT03161379|Drug|Nivolumab|Nivolumab (240 mg) will be administered one day prior to vaccination. First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
45513232|NCT03161379|Drug|GVAX Pancreas Vaccine|Vaccine will be administered one day after cyclophosphamide and nivolumab. 3 weeks after the first dose of immunotherapy the second dose will be given.
45513233|NCT03161379|Radiation|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy over 5 days) will be started during the second dose of immunotherapy (3 weeks after the first dose of immunotherapy).
45699052|NCT03463902|Device|left IPL anodal|Single session of transcranial direct current stimulation (tDCS) over left IPL anodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop
45513234|NCT02197676|Drug|SGI-110 administration|"SGI-110 will be administered SC at 60 mg/m²/day x5 consecutive days for each cycle. Cycle duration is 28 days. Patients with Complete Remission (CR), Partial Remission (PR), marrow CR or Hematological Improvement (HI) after 6 Cycles of therapy (IWG 2006 criteria) may continue treatment until progression.~A dose reduction to 45 and even 30 mg/m²/day will be made in case of haematological toxicity. Patients with no response (NR) to treatment will be withdrawn from the protocol after the last treatment Cycle."
45404565|NCT04607980|Drug|ABP 654|Participants will receive SC injection of ABP 654.
45513235|NCT02916693|Drug|Mirabegron|FDA-approved, beta 3 agonist for over active bladder
45404566|NCT04607980|Drug|Ustekinumab|Participants will receive SC injection of ustekinumab.
45404567|NCT00136604|Biological|Tritanrix-HepB/Hib-MenAC|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine
45404568|NCT00136604|Biological|Mencevax ACWY|GSK Biologicals' Meningococcal serogroups A, C, W135 and Y polysaccharide vaccine
45404569|NCT00136604|Biological|Tritanrix-HepB/Hiberix|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine
45404570|NCT00136604|Biological|Meningitec|Wyeth's MenC CRM197 conjugated vaccine, Meningitec
45404571|NCT03764176|Procedure|Conventional impressions|"In the conventional group, a polyether impression (ImpregumTM, 3M ESPE, Seefeld, Germany) will be taken with a customized tray (Diatray Top, Dental Kontor, Stockelsdorf, Germany). The impression will be poured with Gypsum IV Class Scale 5° (T6, Techim, Techim Group s.r.l., Arese, Italy) and then, the models mounted in a fully adjustable articulator (Protar Evo 7, KaVo Dental, Biberach, Germany). Afterwards, a dental wax-up will be made accordingly to the functional and esthetic requirements. Finally, master model and wax-up will be digitalized by using a lab scanner.~A surgical template will be derived from the mounted casts (conventional group) and used to place the implants using guided surgery."
45513236|NCT02195336|Device|dMRT|Baseline, day 8, day 28, day 92, progression/relapse.
45513237|NCT02195336|Drug|Bevacizumab|7.5mg/kg every 3 weeks for 3 cycles. Thereafter every 3 weeks until progression/relapse or unacceptable toxicity.
45513238|NCT02195336|Drug|paclitaxel and carboplatin|Standard of care NSCLC first-line chemotherapy Every 3 weeks for 3 cycles. Doublets containing paclitaxel and carboplatin are preferred
45513239|NCT03679065|Drug|Paracetamol|Each patient received 1g paracetamol tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline [NS]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
45699053|NCT03463902|Device|left IPL cathodal|Single session of transcranial direct current stimulation (tDCS) over left IPL cathodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
45513240|NCT03679065|Drug|Dexamethasone|Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
45513241|NCT03679065|Drug|Placebo|Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
45513242|NCT02196740|Drug|Metronidazole-Ciprofloxacin gatifloxacin-Clindamycin paste|Pulp removal,Root canal irrigation and disinfection,
45513243|NCT02196740|Drug|creosote|Pulp removal,Root canal irrigation and disinfection
45513244|NCT02197754|Other|Controlled diet|"Volunteers will be provided a controlled diet during the entirety of the 10 week treatment period. Meals will be prepared using traditional American foods.~The controlled diet will include polyphenol-rich foods, including apples, berries, and green tea. A blend of multiple polyphenol-rich foods was chosen to investigate whole foods, multiple commodities, and multiple bioactives."
45513245|NCT02195492|Drug|Synvisc®|
45513246|NCT02195570|Other|Quit Smoking Now (QSN)|"The Quit Smoking Now (QSN) program, offered by the Florida Area Health Education Center, was developed based on principles of the Centers for Disease Control and Prevention's Best Practices for Comprehensive Tobacco Control, and the U.S. Department of Health and Human Services' Treating Tobacco Use and Dependence Clinical Guidelines with an emphasis on reaching medically-underserved populations. The QSN curriculum will be delivered in 6 one-hour sessions . Pregnancy-specific session goals and content cover the effects of smoking on the developing fetus, secondhand smoke exposure, the importance of social support, and postpartum relapse."
45513247|NCT02195570|Behavioral|Prize-based Contingency Management (CM)|Women will earn chances to win prizes for biochemically verified abstinence from tobacco.
45513248|NCT03678987|Diagnostic Test|P-MPA concentration|We will calculate AUC_0-12 of MPA based on 4 measurements of P-MPA
45513249|NCT03678987|Drug|mycophenolic acid|Patient will ingest mycophenolic acid as prescribed by their physician under the surveillance of an investigator.
45513250|NCT02197832|Procedure|Endometrial biopsy|The procedure was performed in a standard approach using a Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France). The pipelle catheter was introduced through the cervix up to the uterine fundus. The piston was drawn back to the end of the sheath to create a negative pressure. The sheath was rotated and moved back and forth between the fundus and internal os for at least 3-4 times before it was gently withdrawn.
45513251|NCT02197832|Procedure|control procedure|Using pipelle catheter without entering the uterine cavity.
45513252|NCT02197832|Device|Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France)|
45513253|NCT03672513|Dietary Supplement|Placebo Comparator|Oral administration of 1 daily capsule containing lactose
45513254|NCT03672513|Dietary Supplement|Zinc Supplement|Oral administration of 1 daily capsule containing 50 mg/day of Zn
45513255|NCT03672513|Dietary Supplement|Magnesium supplement|Oral administration of 1 daily capsule containing 500 mg/day of Magnesium
45513256|NCT02195648|Other|Suboccipital inhibition|"Experimental: Suboccipital inhibition~The intervention group will receive a session of 20 minutes (5 minutes for the patient's reception, 10 for treatment and the following 5 minutes for rest and hemodynamic stabilization), twice a week for 4 weeks. The intervention will consist of suboccipital muscle inhibition and interferential current on the occipital muscles."
45513257|NCT02919345|Drug|Dapagliflozin 10 mg|Dapagliflozin 10 mg in addition to Metformin 1500 mg/day
45699054|NCT03463902|Device|Placebo|Single session of placebo tDCS over left IFG 10 min duration, 30 sec ramp during start and end
45404572|NCT03764176|Procedure|Digital impressions|"Patients will be randomly assigned to undergo intraoral digital impression (digital group) or conventional impression (conventional group). In the digital group, a digital impression will be taken using CS 3600 intraoral scanner (Carestream Dental LLC, Atlanta, GA, USA). The digital data (STL, STereo Lithography interface format) will be imported in a 3D design software to realize a virtual wax-up according to the functional and esthetic requirements.~A surgical template will be derived from the virtual plane (digital group) and used to place the implants using guided surgery."
45404573|NCT04953910|Drug|ASTX727|Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
45404574|NCT03764020|Drug|Placebo oral capsule/placebo comparator|3 mg placebo capsule one hour before bedtime for three weeks along with life style modification according to ACC/AHA 2013 guideline
45404575|NCT03764020|Drug|Melatonin/experimental|Melatonin ,capsule, 3 mg, one dose one hour before bedtime, for three weeks along with life style modification according to ACC/AHA 2013 guideline.
45513258|NCT02919345|Drug|Glibenclamide 5 mg|Glibenclamide 5 mg in addition to Metformin 1500 mg/day
45699055|NCT05163444|Device|Gait analysis with rolling cane|6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
45699056|NCT05163444|Device|Gait analysis with quadripod cane|6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
45404576|NCT00135512|Drug|bupropion hydrochloride|Study drug
45404577|NCT04325386|Other|Education Sessions|Project ECHO (Extension for Community Healthcare Outcomes) based intervention sessions for improving the use of clozapine in people with treatment-resistant schizophrenia. The sessions will include: 1) active dissemination of knowledge and information by an expert followed by 2) clozapine case presentations and vignettes.
45513259|NCT02195726|Procedure|Remote ischemic preconditioning|four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg up per than baseline), followed by 5-minute intervals of reperfusion.
45513260|NCT02195726|Procedure|Sham remote ischemic preconditioning|In the control group sham preconditioning will be performed with inflation of 10 mmHg more than baseline.
45513261|NCT02919189|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.
45513262|NCT02195804|Drug|Ranitidine hydrochloride ODT|Ranitidine hydrochloride ODT#1 150 mg (Vanilla-Mint)
45513263|NCT02195804|Drug|Ranitidine hydrochloride ODT RM|Ranitidine hydrochloride ODT Reduced Mannitol (RM) 150 mg Vanilla-Mint (ODT#2)
45404578|NCT04325386|Other|No Education Session|No Education Session
45404579|NCT00130728|Drug|bevacizumab|intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
45404580|NCT00130728|Drug|erlotinib HCl|oral erlotinib HCl 150 mg/day orally
45513264|NCT02195804|Drug|Ranitidine hydrochloride|
45513265|NCT03672435|Drug|Topical Solution|proparacaine 0.5% eye drop
45513266|NCT03534128|Other|Evaluation of the effect of cues on virtual spatial navigation using a virtual district|Evaluation of the effect of cues on virtual spatial navigation using a virtual district
45513267|NCT03674463|Drug|LCAR-B4822M CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the LCAR-B4822M CAR-T Cell Immunotherapy by intravenous injection.
45513268|NCT03674385|Dietary Supplement|vitamin E|Vitamin E is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect
45513269|NCT03674385|Drug|Metformin|Metformin is in the biguanide class. It works by decreasing glucose production by the liver and increasing the insulin sensitivity of body tissues. It is also used in the treatment of polycystic ovary syndrome (PCOS)
45404581|NCT00130728|Drug|placebo|intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
45404582|NCT00129974|Drug|pemetrexed and gemcitabine|
45513270|NCT03674385|Drug|Clomiphene Citrate|is a medication used to treat infertility in women who do not ovulate
45513271|NCT02197910|Other|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence Low->High)|
45513272|NCT02197910|Other|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence High->Low)|
45513273|NCT02574455|Drug|Sacituzumab govitecan|10 mg/kg administered as a slow intravenous (IV) infusion either by gravity or with an infusion pump. Infusion rate for the first 15 minutes will start with 50 mg/hour or less with a subsequent infusion of 100 to 200 mg/hour up to a maximum recommended rate (advanced every 15 to 30 minutes) of 500 mg/hour with a subsequent infusion of 1000 mg/hour.
45699057|NCT03451734|Drug|antipsychotic medications|olanzapine, risperidone, aripiprazole, amisulpride, ziprasidone, and haloperidol groups
45404583|NCT04947436|Device|High Frequency Chest Wall Oscillation|The HFCWO aims to mobilize the secretions to the pharynx to allow the patient to expel the secretions. However, many ALS patients are unable to expel their secretions due to atrophied expiratory muscles. The HFCWO device uses a small air compressor with a vest that wraps around the chest to induce airflows that pull secretions from the walls of the airways, thin the secretions and move them up the airways towards the larger airways and pharynx.
45513274|NCT02574455|Drug|Eribulin|Administered IV over 2 to 5 minutes at a dose 1.4 mg/m^2 at North American sites and 1.23 mg/m^2 at European sites on Days 1 and 8 of a 21-day cycle for up to 15.3 months. Lower doses will be administered on the same schedule to participants with moderate hepatic impairment (ie, Child-Pugh B; 0.7 mg/m^2 and 0.67 mg/m^2 for North American and European sites, respectively).
45513275|NCT02574455|Drug|Capecitabine|1000 to 1250 mg/m^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest period for up to 10.6 months.
45513276|NCT02574455|Drug|Gemcitabine|800 to 1200 mg/m^2 will be administered IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle for up to 8.1 months.
45513277|NCT02574455|Drug|Vinorelbine|25 mg/m^2 will be administered as a weekly IV injection over 6-10 minutes for up to 11.5 months. Vinorelbine will not be allowed as TPC for any participant with Grade 2 neuropathy.
45513278|NCT02196896|Other|deprexis®|Online self-help program in addition to inpatient psychosomatic treatment for 90 days.
45513279|NCT02196896|Other|Information|The patients receive online information about depression once a week for 90 days.
45513280|NCT03533894|Device|colic capsule|colic polyp diagnosis
45513281|NCT02197988|Drug|Exparel 1.33% (20ml Volume)|Transversus Abdominis Plane Block
45513282|NCT02197988|Drug|0.125% bupivicaine with 2 mcg/ml Fentanyl.|Thoracic Epidural Anesthesia
45699058|NCT03451734|Drug|adjunctive group|antipsychotic plus placebo, antipsychotic plus sulforaphane(3 tables per day, consisting of 30 mg of SFN-glucosinolate per day), and antipsychotic plus minocycline(200mg per day) groups.
45699059|NCT03451734|Drug|metformin and lifestyle intervention|different dose metformin combines lifestyle intervention
45851348|NCT02992860|Genetic|Cytogenetic analysis|The cytogenetic analysis with banding analysis (optional FISH) have to be performed at local labs. Therefore 2 - 5 ml of bone marrow will be collected and analysed.
45404584|NCT04947436|Device|Mechanical insufflation/exsufflation|A noninvasive therapy, removes secretions in patients who have an ineffective cough because their peak cough flows are less than 270 L/min. This device applies a positive pressure to the airway and rapidly switches to a negative pressure applied to the airway. The rapid switch between the two types of pressure simulates a natural cough, thus assisting with expulsion of the secretions.
45404585|NCT03966326|Drug|sevoflurane and fentanil|Patients will receive standard general anesthesia
45404586|NCT03966326|Drug|sevoflurane and fentanil plus PECS II block|Pacients will receive standard general anesthesia with sevoflurane and fentanil associated to PECS II block
45404587|NCT02531256|Device|LMA Protector|Insertion of airway device for airway management during gynaecological procedure
45404588|NCT01321840|Procedure|Specific Autoregulation Therapy (SART)|Complex intervention involving acupuncture and hypnotherapeutic techniques after an extensive diagnosis using chinese medical concepts. Patients will receive a maximum of 10 treatments, which are delivered weekly.
45404589|NCT00119106|Drug|Tenofovir disoproxil|Antiretroviral
45513283|NCT03672357|Procedure|Laparoscopic liver resection|Laparoscopic hepatectomy
45513284|NCT03672357|Procedure|Open liver resection|Traditional open hepatectomy
45513285|NCT02795832|Drug|ZPL-5212372 1% w/w Ointment BID|
45513286|NCT02795832|Drug|Placebo Ointment BID|
45513287|NCT02196974|Procedure|cryobiopsy|
45513288|NCT03678909|Procedure|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure
45513289|NCT02201030|Biological|NBP606|A single intramuscular injection into the thigh
45513290|NCT02201030|Biological|Prevnar13|A single intramuscular injection into the thigh
45513291|NCT03674073|Biological|Neoantigen Vaccines|HCC (3cm≤D ≤5 cm, fewer than three tumors) patients were treated with Microwave Ablation and 7 courses of neoantigen-based DC vaccines.The first neoantigen-based DC vaccine injection will take place up to 30 days following the completion of Microwave Ablation. The day of the first vaccine injection will be referred to as Day 1.The schedule of vaccination is Day 1, Day 8, Day 15, Day 22, Day 50, Day78, Day106.
45513292|NCT03674073|Procedure|Microwave Ablation|ALL the HCC patients will be treated by Microwave Ablation.
45699060|NCT03129984|Device|Mandibular movement tracking|Patients wore the Brizzy device while sleeping. Mandibular movements (A mid-sagittal mandibular movement magnetic sensor measured the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and chin.) were tracked during sleep.
45699061|NCT03467880|Other|Clinical Observation|No treatment given but observation with IOS
45851349|NCT02992860|Procedure|Serum chemistry|For serum chemistry 15 ml (2 x 7,5 ml) of peripheral blood have to be collected.
45513293|NCT02198534|Device|Methodology of visual acuity assessment|
45404590|NCT00119106|Drug|Placebo|Placebo
45404591|NCT03755908|Device|Forced oscillation technique (FOT)|FOT will be measured using the TremoFlo C-100 Airwave Oscillometry System (Thorasys , Montreal, Quebec, Canada). R5, R20, R5-20 (resistances in the reported frequency), X5 (reactance in 5hz) and Ax5 (reactance area in 5hz) will be reported.
45513294|NCT03678597|Other|Medium Supplemented with Latrunculin B|A medium with in-house supplementation of Latrunculin B to decrease oocyte degeneration after ICSI and improve the survival rate
45513295|NCT02198066|Other|Dry Sterile Dressing|Described in Arm Description.
45513296|NCT02198066|Other|Metallic Silver Dressing|Described in Arm Description.
45513297|NCT02198066|Other|Ionic Silver Dressing|Described in Arm Description.
45513298|NCT03673995|Dietary Supplement|Myo-inositol+L-tyrosine|PCOS patients were treated every day, with one sachet containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid. All patients underwent, before starting the therapy, after 3 months and 6 months, hormonal, hirsutism and ovulation assesment.
45513299|NCT03673917|Other|Educational video|The educational video on skin cancer for cosmetologists
45513300|NCT03673917|Other|Control video|A publicly accessible healthy lifestyle video on YouTube, which does not contain any information on skin cancer
45513301|NCT02198612|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
45513302|NCT01378091|Drug|Lenalidomide|"Supplied as 5 mg and 25 mg capsules.~The lenalidomide dose levels to be studied include 10, 15, 20, 25, 30, 35 and 40 mg/day."
45513303|NCT01378091|Drug|Docetaxel|"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.~Doses of docetaxel to be studied include 60 and 75 mg/m2 once every three weeks."
45513304|NCT01378091|Drug|Prednisone|"Prednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug.~5 mg BID daily."
45513305|NCT02794974|Other|cervical plexus block|ultrasound-guided application of 20ml ropivacaine 0.75%
45513306|NCT02794974|Other|facial nerve block|ultrasound-guided application of 5ml prilocaine 1%
45513307|NCT02794974|Other|perivascular block|ultrasound-guided application of 5ml prilocaine 1%
45513308|NCT03673839|Other|Animal Proteins (crossover)|Animal proteins mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
45404592|NCT04944706|Drug|Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time|Take 3 times a day after meals,24 weeks
45404593|NCT04944706|Drug|Qishen Yiqi dripping pills 4 bags/time|Take 3 times a day after meals,24 weeks
45513309|NCT03673839|Other|Plant-based protein blends type 1 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
45513310|NCT03673839|Other|Plant-based protein blends type 2 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
45513311|NCT03673839|Other|Plant-based protein blends type 3 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
45513312|NCT02201186|Other|Manuka honey enema|Study patients diagnosed with acute pouchitis will perform manuka honey enemas twice a day for 30 days.
45513313|NCT02063568|Drug|Oxytocin|
45513314|NCT02257502|Drug|aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated with a TAE regimen until 20 weeks (3 mandatory injections at inclusion, week 8 and 20 with reinjection at week 4, 12 and 16 only in case of CNV activity). Then, a PRN regimen is considered until 52 weeks (reinjection in case of CNV activity). Therefore, each patient receives between 3 and 13 injections in the whole study.
45513315|NCT02907099|Drug|CXCR4 Antagonist BL-8040|Given SC
45513316|NCT02907099|Biological|Pembrolizumab|Given IV
45404594|NCT04944706|Drug|Qishen Yiqi dripping pills placebo 4 bags/time|Take 3 times a day after meals,24 weeks
45404595|NCT05460598|Other|beddings with cooling effects|beddings with cooling effects (mattress topper and bed linen)
45404596|NCT05460598|Other|commonly used bedding|commonly used bedding
45404597|NCT03758014|Drug|Chlorogenic acid for Injection|Chlorogenic acid (CHA) is a class 1 innovative small molecular natural drug, developed by Sichuan Jiuzhang Biological Science and Technology Co., Ltd. The mechanism of broad-spectrum antitumor activity is immunoregulation.
45513317|NCT02907099|Other|Pharmacological Study|Correlative studies
45513318|NCT01380119|Biological|V7|experimental arm
45513319|NCT01380119|Other|placebo|placebo pill
45513320|NCT02063646|Dietary Supplement|Polyphenol-rich extract|Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product.
45513321|NCT02063646|Dietary Supplement|Placebo|"The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.~Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product."
45513322|NCT02198144|Other|barbershop-based BP measurement|BP Measurements and blood pressure reducing medication
45513323|NCT03678519|Diagnostic Test|Pulmonary function test|Pulmonary Function tests using Spirometry. It will show following indices of ventilatory functions: Forced vital capacity (FVC), Forced expiratory volume in the 1st second (FEV1) and Forced expiratory volume in the 1st second as a percentage of the Forced vital capacity (FEV1/FVC %).
45513324|NCT01383941|Drug|Guidelines-based asthma and rhinitis/rhinosinusitis therapy|All participants receive standardized asthma and rhinitis treatment. Asthma and rhinitis medication regimens were based on 1.) the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report -3 (EPR-3) and 2.) the Rhinitis and its Impact on Asthma (ARIA) 2008 guidelines-derived treatment algorithms. References: 1.) J Allergy Clin Immunol 2007; Volume 120, Issue 5, Supplement s93-140. 2.) Allergy 2008; Volume 63, Issue Supplement s86, pages 7-160.
45513325|NCT02450123|Drug|sunitinib|
45513326|NCT02063802|Drug|metformin|total dose: 1 gr per day (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
45513327|NCT02063802|Dietary Supplement|Conjugated Linoleic Acid|total dose: 3gr/día(500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner for four months.
45513328|NCT02063802|Drug|Placebo|Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months
45513329|NCT02063802|Behavioral|Healthy habits program|
45513330|NCT03672045|Drug|Carbetocin|carbetocin administered IV, over 1 minute following delivery of the fetal head
45513331|NCT02198300|Procedure|Coronary angioplasty with stent implantation|
45513332|NCT02198300|Drug|Dual antipletlet therapy (DAPT)|DAPT given to each patient before stent implantation
45513333|NCT03673761|Other|MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing|3.Dixon, T2 mapping MRI microRNAs
45513334|NCT03560232|Drug|Ceftriaxone|See arm description
45513335|NCT03560232|Drug|Ampicillin/sulbactam|See arm description
45513336|NCT03560232|Drug|Piperacillin/tazobactam|See arm description
45513337|NCT03560232|Drug|Cefazolin + Gentamicin|See arm description
45513338|NCT03560232|Drug|Clindamycin + Gentamicin|See arm description
45513339|NCT02196935|Other|clinical course|Detailed presentation including labs, demographics, imaging of those who undergo ERCP/EUS with be prospectively recorded. Details of procedure including sedation strategy and success will be collected. Results of procedure including final pathology results with be recorded.
45513340|NCT03533192|Behavioral|It's Your Game...Keep it Real|It's Your Game...Keep it Real consists of 12 50-minute lessons delivered in 7th grade (8 in class and 4 via computer) and 12 50-minute lessons delivered in 8th grade (7 in class and 5 via computer). In each grade, the curriculum integrates group-based classroom activities with personalized journaling and individually tailored computer-based activities. A life-skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal rules regarding risk behaviors, detect signs or situations that might challenge these rules, and use refusal skills and other tactics to protect these rules. The curriculum is grounded in social cognitive theory, the theory of triadic influence, and social influence models.
45513341|NCT02201342|Drug|Udenafil|Drug
45513342|NCT02063958|Drug|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety not to exceed a dose of 100 mg/m2. Maintenance therapy of SNX-5422 at the MTD will be allowed for all patients not experiencing significant toxicity.
45513343|NCT03560544|Behavioral|Breaking up sitting|"A three-part behaviour change intervention, including:~Supportive organisational culture and knowledge of consequence of prolonged sitting~Environmental Modification~Behavioural Changes"
45513344|NCT03963830|Behavioral|MOVE UP|Each of the 12-group-sessions will focus on incremental behavioral strategies for maintaining recommended healthy eating, activity, and weight loss behaviors. Participants will monitor body weight and weight loss behaviors. Body weight will be measured at each in-person session and participants will also be encouraged to measure their body weight on their own. Beginning in Session 3, participants are given a home physical activity goal of 10 minutes/day, 50 minutes/week. The goal is raised by 5 minutes/day, 25 minutes/week every other session, the final goal being 30 minutes/day, 150 minutes/week. All subjects will be recommended to engage in an energy restricted dietary intervention that evidence demonstrates has effectively reduced body weight by 5-7% within the initial 4 months of the intervention. This will include reducing energy intake to 1200 to 1800 kcal/d based on initial body weight (<200 pounds = 1200 kcal/d; 200 to 250 pounds = 1500 kcal/d; >250 pounds = 1800 kcal/d).
45404598|NCT03758014|Drug|Lomustine|Lomustine (INN), abbreviated as CCNU (original brand name (formerly available) is CeeNU, now marketed as Gleostine), is an alkylating nitrosourea compound used in chemotherapy. It is closely related to semustine and is in the same family as streptozotocin. It is a highly lipid-soluble drug, thus it crosses the blood-brain barrier. This property makes it ideal for treating brain tumors, which is its primary use.
45404599|NCT04925908|Diagnostic Test|RT-PCR for SARS-Cov-2|Nasopharyngeal swab for detecting Novel Coronavirus-2 by reverse transcriptase polymerase chain reaction
45404600|NCT00135356|Drug|Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)|Capsules, Oral, ATV 300 mg + RTV 100 mg once daily up to 96 weeks
45404601|NCT00135356|Drug|continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)|Protease inhibitor [PI] combination + 2 NRTIs
45404602|NCT00118716|Drug|Fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol
45513345|NCT02201498|Procedure|Pulpotomies with Formocresol/OZE and Biodentine|
45513346|NCT02061852|Device|Simeox|
45513347|NCT02061852|Procedure|Physiotherapy|
45851350|NCT02992860|Procedure|Automated CBC|For CBC a minimum of 3 ml of peripheral blood have to be collected.
46057299|NCT02710461|Dietary Supplement|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test right after taking the mixture of grape and pomegranate polyphenols
45513348|NCT02201576|Drug|Bortezomib|"Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~two cycles of bortezomib (1.3 mg/m2 IV at day-1, day-4, day-8, day-11) + oral dexamethasone (20 mg po at day-1, day-4, day-8, day-11)~four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg, the first two courses are performed simultaneously with the two bortezomib cycles)"
45513349|NCT02201576|Drug|Plasma exchanges and intravenous immunoglobulins|"Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg)~oral dexamethasone (20 mg po at day-1, day-3, day-5, day-7 of the two first intravenous immunoglobulins courses)"
45513350|NCT02201654|Other|EBUS without stylet|the patient will receive both conventional ebus with the stylet and experimental ebus (without the stylet). The two techniques will then be compared to each other on a per lymph node basis.
45404603|NCT00118716|Drug|Fluticasone Propionate|Fluticasone Propionate
45404604|NCT04584346|Dietary Supplement|Liquigen MCT oil|MCT oil is a nutritional supplement. The Ketogenic diet restricted carbohydrates to reach 80/5-10/10-15 (lipid:carb:protein daily energy) values
45404605|NCT04584346|Other|Standard American Diet|Standard diet with macronutrient composition lipid 35%, protein 10-15%, carbohydrate 50-55%
45404606|NCT04907032|Drug|Mirabegron 50 MG|Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
45404607|NCT04907032|Device|Posterior Tibial Nerve Stimulation (PTNS)|Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
45404608|NCT01079858|Other|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
45404609|NCT03755830|Other|Skin biopsy|Two skin biopsies (lesional and non-lesional) will be taken from every patient. Also a skin biopsy will be taken from each control subject.
45404610|NCT05124782|Other|Rheumatoid Arthritis Impact of Disease questionnaire|Rheumatoid Arthritis Impact of Disease questionnaire
45404611|NCT05039788|Other|Measurement of systolic and diastolic blood pressure, impedancemetry, weight, creatinemia and Pro-BNP measurements|"Measurement of systolic and diastolic blood pressure, impedancemetry, weight, creatinemia and Pro-BNP measurements At D30 and D90~Measurement of systolic and diastolic blood pressure, impedancemetry, weight, 3 times a week between D30 and D90 post-transplant,"
45404612|NCT00118482|Drug|fludrocortisone acetate|Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily
45404613|NCT03966950|Dietary Supplement|melatonin|melatonin 10 mg per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights.
45513351|NCT02061930|Procedure|single crowns supported by implants|The implant placement procedures were planned based on clinical and radiographic evaluation. During the surgeries, the mid-crestal incision and intra-crevicular incision were made following local articaine infiltration anesthesia. No releasing incisions were made. After full-thickness flaps were elevated labially and lingually to expose the alveolar ridge, the implants were placed according to the standard surgical procedures defined by the manufacturer. After a healing time of 10-16 weeks, implant-level impressions were taken. The porcelain (Ivoclar-Vivadent AG, Schaan, Lichtenstein) fused to noble metal crowns were fabricated. Abutment screws were torqued to 15 Ncm. Crowns were cemented with HY-bond Glassionomer Cement
45513352|NCT03533738|Other|Food sequence 1|Vegetables first then meat & rice together
45513353|NCT03533738|Other|Food sequence 2|Meat first then vegetables & rice together
45513354|NCT03533738|Other|Food sequence 3|Vegetables first then meat followed by rice
45513355|NCT03533738|Other|Food sequence 4|Vegetables first followed by meat and rice together
45404614|NCT03966950|Drug|Placebo oral tablet|placebo taken per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights
45404615|NCT03755752|Procedure|Phacoemulsification with and without Trypan Blue capsule staining|Phacoemulsification for patients with diabetic retinopathy having cataract in both eyes. One eye underwent phacoemulsification with trypan blue capsule staining and the other eye underwent phacoemulsification without trypan blue.
45513356|NCT03533738|Other|Food sequence 5|Rice first followed by vegetables & meat together
45513357|NCT01377857|Behavioral|Monetary Incentive|$1, $5, or $10 incentive
45513358|NCT01377857|Behavioral|Questionnaire Timing|Timing of the questionnaire--either before or after testing is offered.
45513359|NCT01377857|Behavioral|HIV Test Offering|HIV Test will be offered as opt-in, opt-out, or active choice.
45404616|NCT03755674|Procedure|CHRONOTYPE-ADJUSTED DIET|Those patients followed a daily caloric distribution attending to their chronotype. In this regards, 'morning' subjects ate a higher quantity of calories at the first part of the day, while 'evening' subjects ate a higher amount of calories at the second half of the day.
45404617|NCT01076582|Drug|EE20/DRSP (YAZ, BAY86-5300)|4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DRSP 3 mg) daily for 24 days followed by 1 placebo tablet daily for 4 days
45404618|NCT01076582|Drug|Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)|4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DSG 0.15 mg) daily for 21 days followed by 1 placebo tablet daily for 7 days
45404619|NCT01081938|Drug|INSULIN GLARGINE|"Pharmaceutical form: Lantus® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device.~Dose regimen: Single daily dose of Insulin Glargine"
45404620|NCT01081938|Drug|INSULIN GLULISINE|"Pharmaceutical form: Apidra® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device~Dose regimen:~Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine"
45404621|NCT03763864|Other|Skin Biopsy|Skin Biopsy
45404622|NCT01082796|Drug|Glipizide|Each subject received 5 mg glipizide extended release tablet once daily for 7 days.
45404623|NCT03763786|Drug|Cetrorelix Acetate|Used a standard
45404624|NCT03965936|Procedure|lipofilling|Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. then with blunt cannula,subcutaneous injection of the required volume of microfat is placed into temporal region.
45513360|NCT02198378|Drug|MEOPA and paracetamol|The patient will be equipped with a facemask after he/she has been informed. The facemask is adapted to the patient. The patient breathes normally in the mask which is held in place by a member of the SMUR team who has received previous training in use of MEOPA. The gas flow received by the patient is adapted to his/her ventilation.
45513361|NCT02198378|Drug|Morphine|Bolus of 2 mg intravenously if EN = 4 or 5 and 3 mg bolus if EN> 6 followed by reinjection of 2mg every 5 minutes until effective analgesia.
45513362|NCT02063100|Drug|Shenyankangfu tablets|Shenyankangfu tablets 2.4g, po, 3/day and Losartan potassium placebo 2 tab, po, 1/day,all drugs and placebo are taken for 48 weeks.
45513363|NCT02063100|Drug|Losartan potassium 50mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab,po, 1/day, all drugs and placebo are taken for 48 weeks.
45513364|NCT02063100|Drug|Shenyankangfu tablets and Losartan potassium 50mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab, po, 1/day, all drugs and placebo are taken for 48 weeks.
45513365|NCT02063100|Drug|Shenyankangfu tablets and Losartan potassium 100mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
45513366|NCT02063100|Drug|Losartan potassium 100mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
45513367|NCT01377779|Drug|Oxiplex/AP gel|Intrauterine application of Intercoat following hysteroscopy
45513368|NCT01377779|Drug|Normal Saline|No intrauterine application of Intercoat following hysteroscopy
45513369|NCT02198846|Device|insulin pump|stop any antihyperglycemic medication and convert to insulin pump
45513370|NCT02198846|Drug|conventional treatment|intensification of conventional treatment by adding oral antihyperglycemic agents or subcutaneous insulin (once / twice/ multiple injection)
45513371|NCT01379885|Behavioral|Standard technique|Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
45513372|NCT01379885|Behavioral|Parent participation technique|The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
45513373|NCT02198924|Drug|Parecoxib and Celecoxib|Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.
45513374|NCT02198924|Drug|placebo|control patients are supplied with the corresponding placebo with the same instructions.
45513375|NCT02201732|Procedure|Hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis in accordance to center practices may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
45513376|NCT02201732|Procedure|Curettage|Performed under general or local anesthesia, the used material may be rigid or flexible vacurette. In the same way, the prophylactic antibiotic, the diameter of the used vacurette, the importance of cervical dilation necessary and a possible peroperative ultrasound guidance will be left at the discretion of the operator and habits of the center. A check of the uterine vacuity by foam curette will be conducted at the end of curettage.
45513377|NCT05462093|Device|Liver Multiscan sequences|Additional Liver Multiscan sequences will be performed after the MRI liver with MRCP is performed, taking approximately 15 minutes.
45513378|NCT05462093|Device|Liver Multiscan analysis|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
45699062|NCT03451344|Other|Integrated rehabilitation group|Participant in integrated rehabilitation group needs to visit their corresponding social worker and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary. The integrated rehabilitation group received the standardized community-based rehabilitation described above and simultaneously received a 6-month integrated rehabilitation based on CAREs (Community-based Addiction Rehabilitation Electronic System).CAREs was developed by the department of addiction research in Shanghai Mental Health Center(SMHC), with functions including education, support, psychological intervention and other functions.
46057300|NCT02710461|Dietary Supplement|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test ten hours after taking the mixture of grape and pomegranate polyphenols
45513379|NCT05462093|Device|MRCP+|Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
46057301|NCT02710617|Device|Blood glucose monitoring systems for point-of-care-testing|
45699063|NCT03451344|Other|Community-based rehabilitation group|Participant in community-based rehabilitation group needs to visit their corresponding social worker for six months and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary.
45513380|NCT02201888|Behavioral|Computer-assisted cognitive training|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
45513381|NCT02201888|Other|Computerized active condition|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
45513382|NCT02201888|Other|Treatment as usual (TAU)|TAU: Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities.
45513383|NCT02065440|Drug|Rhinoebastel|Rhinoebastel(ebastine 10mg/pseudoephedrine 120mg) 1 cap/day for 1 week unless progression or unacceptable toxicity develops.
45699064|NCT03467802|Biological|enamel matrix derivative|Enamel matrix derivative (EMD), sold under the brand name Emdogain®, is an amelogenin derivative of embryonal porcine enamel and is FDA approved for application to root surfaces to treat recession defects. Amelogenins comprise the majority of the proteins in EMD while others such as tuftelin, ameloblastin and amelin make up the remainder. EMD is thought to mimic the role of proteins crucial to cementogenesis and root development, which may promote new gingival attachment to exposed roots. The properties of EMD may favor early healing of the soft tissue and stimulate angiogenesis.
45699065|NCT03467802|Device|Porcine collagen matrix|Mucograft® is a bi-layered grafting material composed of Type I and III collagen. It is derived from veterinary certified pigs, sterilized by gamma irradiation and has a low antigenicity in conjunction with good biocompatibility. The material is approximately 2.5-5mm thick and is indicated for root coverage, increasing keratinized tissue, covering of implants placed immediately and alveolar ridge reconstruction. A compact outer layer contributes to protection, structure and allows for better control during suturing; while the inner layer is thick, porous and spongy in nature, providing a suitable environment for early vascularization and promotion of cellular in-growth.
45699066|NCT01198366|Biological|AERAS-402 1.5 x 10^10 vp|
45513384|NCT02065440|Drug|Placebo|Placebo 1 cap/day for 1 week unless progression or unacceptable toxicity develops
45513385|NCT02202122|Other|OSA Scoring|Comparison of the preoperative OSA scoring (STOP-BANG, DES-OSA, P-SAP and OSA50) with the postoperative mortality at one month.
45699067|NCT01198366|Biological|AERAS-402 3.0 x 10^10 vp|
45699068|NCT01198366|Biological|AERAS-402 1.0 x 10^11 vp|
46057302|NCT00735709|Drug|Vortioxetine|Encapsulated immediate-release vortioxetine tablets
45513386|NCT02064348|Drug|semaglutide|Solution for subcutaneous (s.c., under the skin) injection. Dose escalation to 1.5 mg.
45513387|NCT02064348|Drug|placebo|Solution for s.c. injection or tablets for oral administration
45513388|NCT02064348|Drug|moxifloxacin|Tablets for oral administration
45699069|NCT01198366|Biological|Placebo|
46057303|NCT00735709|Drug|Placebo|Vortioxetine placebo-matching capsules
46057304|NCT00635115|Device|a new generation of corrective lens for presbyopia (i.e., Varilux Panamic Orma Crizal)|
45513389|NCT02202200|Drug|PD- 0332991|"PD-0332991 Inhibitor of cyclin-dependant kinase (CDK) 8 schedules will be evaluated PD-0332991 PO QD either at 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg and 200 mg~All patients will receive vemurafenib as background therapy ,bid at 720mg bid for the first group (during the first 2 cycle then 960 mg bid if good tolerance) and 960mg bid for all other patients"
45513390|NCT05077956|Diagnostic Test|Cerebrospinal and Blood Serum Semaphorin 4A Levels|Cerebrospinal fluid and serum will be collected at baseline to measure the level of semaphorin 4A.
45513391|NCT02064504|Drug|GSK961081|Dry white to off white powder
45513392|NCT02064504|Drug|Fluticasone furoate|Dry white powder
45404625|NCT03965936|Procedure|lipofilling enriched with adipose tissue derived stem cells|"Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. 25 ml is used for preparation of autologous adipose tissue derived stem cells (At-ADSCs) using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine.~Subcutaneous injection of the required volume of microfat combined with stromal vascular fraction containing adipose tissue derived stem cells, is placed into temporal region."
45404626|NCT01079364|Drug|Insulin glulisine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
45404627|NCT01079364|Drug|Insulin glargine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
45404628|NCT01079364|Drug|Premixed insulin (Insulin Aspart 30/70 )|Pharmaceutical form:boxes of 5 FlexPens Route of administration: Injection Dose regimen: twice daily
45404629|NCT01077752|Drug|continuous ropivacaine preperitoneal infusion|Bolus of 20 mg after the surgery then 20 mg per hour during 48 hours
45404630|NCT01077752|Drug|intravenous lidocaine infusion|Bolus of 60 mg after the surgery then 60 mg per hour during 48 hours
45404631|NCT01077752|Drug|parenteral analgesia combining acetaminophen and morphine|parenteral analgesia combining acetaminophen and morphine
45404632|NCT01077752|Drug|NaCl|NaCl
45513393|NCT01696565|Drug|PG2|Injectable
45513394|NCT03790254|Other|systematic review|
45513395|NCT02202356|Drug|ALS-008176|
45699070|NCT03130218|Other|Peppermint oil aromatherapy|Aroma therapy with peppermint oil administered with presoaked diffuser and bag.
45404633|NCT03763630|Drug|House dust-mite SLIT|received 2000 standard treatment units of glycerinated HDM allergen extract (ALK-AbellÓ) per day. Normal saline was administered to the placebo group. 11 µg of HDM allergen (equal parts of Dermatophagoides pteronyssinus and Dermatophagoides farinae) administered twice daily as oral drops.
45404634|NCT03763630|Drug|Normal saline|Normal saline administered in same frequency and manner as intervention
45513396|NCT02202356|Drug|Placebo|
45513397|NCT02065674|Drug|Abroma Augusta Q (mother tincture)|30 drops in 1 cup of water three times a day for 3 months
45513398|NCT03560154|Other|Whole Body Vibration Training|whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.
45513399|NCT01569425|Other|Dietary intervention|High Calorie breakfast and high calorie dinner
45513400|NCT02199158|Procedure|Argon Laser Peripheral Iridoplasty|ALPI was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA) by the same ophthalmologist (JML). Twenty to 40 spots of 400 mW power with 500 microns of size and duration of 500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. It was considered an effective contraction as that which causes a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain.
45513401|NCT02067936|Drug|Group A propofol + remifentanil|Predicted TOL90% according to Bouillon model
45513402|NCT02067936|Drug|Group B propofol + remifentanil|TOL 90% according to the Bouillon interaction model
45513403|NCT02067936|Drug|Group C propofol + remifentanil|TOL 90% according to the Bouillon interaction model
45513404|NCT02067936|Drug|group D propofol + remifentanil|TOL 90% according to the Bouillon interaction model
45513405|NCT05461937|Behavioral|Getting things done after stroke|A two-session, online rehabilitation intervention focussing on cognitive executive functions supplemented with weekly homework tasks.
45513406|NCT05461937|Behavioral|Stroke psychoeducation|A two-session, online stroke psycho-education intervention supplemented with weekly homework tasks.
45513407|NCT02916446|Biological|Viaskin Peanut 250 mcg|
45513408|NCT02916446|Biological|Placebo|
45513409|NCT03788928|Diagnostic Test|serum mitochondrial DNA|serum mitochondrial DNA will be measured using RT-PCR within first 72 hours of symptoms of acute pancreatitis
45513410|NCT01377545|Procedure|Local Anesthetic given via perineural catheter for infraclavicular nerve block.|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
45699071|NCT03129906|Dietary Supplement|Gluten|
45699072|NCT03129906|Dietary Supplement|Rice protein|
45699073|NCT03011320|Drug|EC1456|intravenous (IV) bolus dose
45404635|NCT01082016|Other|Sleep Enhancement Program (SEP)|Sleep promotion in the ICU Multifaceted tool to promote sleep in ICU patients
45513411|NCT01377545|Procedure|Local Anesthetic given via needle for infraclavicular nerve block|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
45513412|NCT01379807|Drug|panitumumab + docetaxel + cisplatino|Panitumumab, docetaxel and cisplatin combination treatment will be administered for 6 months or until disease progression (PD) according to investigator's criteria unacceptable toxicity or consent withdrawal.
45513413|NCT02031380|Device|Open angle glaucoma - iDropper device|The iDropper system is an eye drop dispensing device and medication monitor designed to optimize adherence behaviors for glaucoma patients.
45513414|NCT02064660|Device|massager|The patients will be doing self-stimulation using acupressure device, The acupuncture treatment will be applied two times per day for six months. Acupressure divice will stimulate for 14 minutes. Examples of acupuncture points to be used might include GB1, GB14, TE23, ST1, ST2, BL01, BL02, the Extra-point Tae-yang, In-dang.
45513415|NCT05461859|Procedure|Cardioneuroablation (CNA) of the right anterior ganglionated plexus (RAGP)|CNA of RAGP
45513416|NCT02202512|Drug|Placebo|tablets
45513417|NCT02202512|Drug|Cimetidine|
45513418|NCT02202512|Drug|Placebo|tablets
45513419|NCT02202512|Drug|Placebo|tablets
45513420|NCT02202512|Drug|BI 1060469 high dose|tablets
45513421|NCT02202512|Drug|BI 1060469 low dose|tablets
45699074|NCT03011320|Drug|99mTc-Etarfolatide|Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
45699075|NCT03463746|Device|LYRA® gait trainer|The EG will get standard individual physical therapy (5x/week, 45min) whereby three sessions of electromechanical-assisted gait training on LYRA® gait trainer.
45404636|NCT03964844|Other|No intervention|No intervention
45513422|NCT02202512|Drug|Naproxen|
45513423|NCT02202512|Drug|BI 1021958|tablets
46057305|NCT00635115|Device|an old generation of corrective lens for presbyopia (i.e., Varilux Comfort Orma Crizal)|
45404637|NCT01079442|Other|Postoperative coffee|"schedule for coffee administration for the present trial was chosen as follows (starting 6 hours postoperatively):~08:00 100mL beverage~12:00 100mL beverage~16:00 100mL beverage"
45404638|NCT01079442|Other|water|"The control drink consists of 100 ml warm water which is administered according a same fixed schedule as Group A starting 6 hours postoperatively:~08:00 100mL beverage~12:00 100mL beverage~16:00 100mL beverage"
45404639|NCT03755596|Drug|Z. officinale extract|Oral dose of 160mg dry ginger root (Z. officinale) extract in tablet form.
45404640|NCT00129272|Drug|Bupropion-SR|150mg tablets taken orally twice daily for 9 weeks.
45404641|NCT00129272|Other|Placebo|Matching placebo (to Buproion-SR) twice daily for 9 weeks.
45513424|NCT02065752|Drug|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
45513425|NCT02065752|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
45513426|NCT02065752|Drug|CANA/MET XR FDC, Formulation 1, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
45513427|NCT02065752|Drug|CANA/MET XR FDC, Formulation 2, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
45513428|NCT01379729|Other|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
45513429|NCT01379729|Other|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
45513430|NCT02202668|Device|TRS|"TRS measurements of subcutaneous deep wound soft tissue and underlying bone will be collected at the same standard locations that are used to measure wound dimensions. The probe will never be in contact with the wound, but we will sterilize the probe head in advance in order to ease potential concerns regarding equipment sterility. A single point TRS measurement can be obtained in less than 60 seconds. At a minimum we will collect measurements at the geometric center of the wound as well as at the 6 and 12 and 3 and 9 ulcer coordinates. These coordinates are commonly used to estimate ulcer dimensions. It is anticipated that the PhAT probe will be used with a beam diameter of 7.5 mm. It is possible that the incident laser beam diameter will need to be adjusted (7.5 mm to 6.0 mm) to accommodate smaller wounds. If incident laser beam diameter adjustment is necessary we will also adjust the laser intensity to maintain the maximum permissible exposure of 0.3 W/cm2 per ANSI guidelines."
45513431|NCT02064738|Behavioral|Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams|
45513432|NCT02202824|Other|Survey questionnaire|Each of the scale versions elicits personal attitudes toward intimate partner violence and perceived norms about intimate partner violence, in a different fashion
45513433|NCT05461781|Procedure|distal radial artery|primary percutaneous coronary intervention via distal radial aretry
45513434|NCT05461781|Procedure|proximal radial aretry|primary percutaneous coronary intervention via proximal radial aretry
45513435|NCT05057442|Other|Proprioception assessment, functionality assessment|Proprioception assessment, functionality assessment
45513436|NCT05461625|Procedure|ACL reconstruction|Anterior cruciate ligament reconstruction
45513437|NCT05461625|Other|ALL anatomic|anatomic anterolateral ligament reconstruction
45513438|NCT05461625|Other|ALL tenodesis|anterolateral ligament teondesis
45513439|NCT02202902|Other|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before and 6 month after treatment
45513440|NCT02202902|Other|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before treatment
45513441|NCT03560076|Other|SBIRT Training and Implementation Strategies|A train-the-trainer approach will be used to train site coordinators on the SBIRT process and implementation strategies.
45513442|NCT02206490|Drug|naltrexone|Randomized controlled trial of naltrexone for Gulf War Illness.
45513443|NCT02206490|Drug|Dextromethorphan|Randomized controlled trial of dextromethorphan for Gulf War Illness
45513444|NCT02068170|Drug|Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib|
45404642|NCT03963804|Device|BrainScope Ahead 300iP|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
45404643|NCT01326338|Drug|Nitazoxanide|Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years twice daily for 3 days or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years twice daily for 3 days
45404644|NCT03963648|Diagnostic Test|Fractioned Exhaled Nitrogen Oxide measurements|Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
45404645|NCT01326416|Dietary Supplement|L-Leucine and L-arginine|Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g L-Leucine and 9 g of L-arginine), to be distributed during each of the 3 main meals.
45404646|NCT01326416|Other|Physical Reconditioning by a trainer|Physical reconditioning sessions begin with a warm-up for five minutes for the type of effort made, and then correspond to a sporting course composed of elements of strength training and / or aerobic exercises and will be completed by a return to simple stretching and general advice on managing their physical life. The duration of each session will be 45 minutes at the beginning of the protocol and then gradually increased over time to achieve 1:30 of total physical activity at the end of protocol.
45513445|NCT02203058|Other|Pursed-lips breathing|Expiration with pursed-lips during functional capacity tests.
45513446|NCT02203058|Other|No pursed-lips breathing|To avoid pursed-lips breathing, subjects use a a mouthpiece (2cm diameter X 2cm length) such as the one used in pulmonary functional tests.
45513447|NCT05545020|Drug|Trivalent chromium versus synthetic and/ or biological DMARDs|Supplement and immunesuppressants
45513448|NCT02206568|Drug|URAL|
45513449|NCT02068248|Dietary Supplement|Soluble Fibre|
45513450|NCT02203136|Procedure|Tissue Biopsy|During bladder cancer surgery, tissue specimen taken for molecular profiling.
45404647|NCT02531282|Behavioral|Patient education|Self-management patient education in groups once a week for 6 weeks. Each session include pain-related theory, group discussions and physical exercises focusing on posture and relaxation. Instructors with education in health promotion and behavioural change in addition to psychomotor physiotherapy.
45404648|NCT02531282|Behavioral|Physical activity|Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. Each session has a duration of one hour. The instructor has education in physical activity.
45404649|NCT04899232|Drug|Antithrombin III|Five total doses of daily 1,821 to 9,100 IUs Antithrombin III, depending on participant's weight, will be administered intravenously every other infusion day (Days 1, 3, 5, 7 and 9).
45404650|NCT03757936|Drug|HLX04|Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection
45513451|NCT02203136|Procedure|Magnetic Resonance Imaging (MRI)|3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
45513452|NCT02068326|Behavioral|Mentalization Based Treatment|
45513453|NCT02068326|Behavioral|Treatment As Usual|Treatment As Usual
45513454|NCT02206646|Drug|Metalyse|
45513455|NCT03788148|Device|Stent, red blood cell transfusion|BMS (Bare Metal Stent) and DES (drug-eluting stent) transplants with periprocedural red blood cell transfusion
45513456|NCT02419417|Drug|BMS-986158|Specified dose on specified days
45513457|NCT02419417|Biological|Nivolumab|Specified dose on specified days
45513458|NCT02206724|Radiation|STEREOTACTIC BODY RADIOTHERAPY to the prostate gland|
45513459|NCT02203214|Device|Ligamys|All patients are treated with Ligamys within 21 days after injury. The Ligamys implant has to be used in accordance with the instructions for use.
45513460|NCT02068404|Drug|Nifedipine|
45513461|NCT02257658|Drug|Doxycycyline|
45513462|NCT02257658|Behavioral|Incentive|
45513463|NCT02068482|Drug|Rifaximin|Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months
45404651|NCT03757936|Drug|HLX10|Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection
45513464|NCT02206802|Drug|5% minoxidil topical foam|5% minoxidil topical foam
45699076|NCT03463746|Device|Standard individual physical therapy|The CG will get standard individual physical therapy (5x/week, 45min) without any instrument-based locomotion therapy (i.e. treadmill training, electromechanical/robot-assisted gait training).
45699077|NCT03451266|Drug|Vitamin C|1,5g of IV vitamin C in 100 ml 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
46057306|NCT02776527|Drug|Apatinib Mesylate Tablets|taking Apatinib Mesylate Tablets 500mg/qd orally, 28 days as a cycle, till disease progresses
46057307|NCT04845945|Biological|PCV15|Blood draw after the vaccination
46057308|NCT02596165|Device|Pulse wave analysis measurement with Schiller BR-102 Plus PWA device|Measurement of central and peripheral blood pressure and central arterial stiffness simultaneously with the Schiller BR-102 Plus PWA device
45404652|NCT04574908|Device|ViSi device|Mobile patient monitoring system for vital signs.
46057309|NCT04088617|Dietary Supplement|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour high carbohydrate mixed meal tolerance test.
45404656|NCT04559698|Behavioral|LGBTQ-affirmative CBT training|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week.
45513465|NCT02065986|Drug|Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)|
45513466|NCT02068560|Drug|dDAVP infusion|
45513467|NCT01377103|Drug|testerone gel|5g daily for 4 weeks then 7.5 or 10g daily for 8 weeks; transdermal testosterone gel
45513468|NCT01377103|Drug|Placebo|
45513469|NCT02206958|Behavioral|Defeating Urinary Incontinence with Exercise Training|"12 week multi-component program. Continence program administered by a nurse practitioner during 4 home visits. Participants do pelvic floor muscle exercises 5 days/week using a 13-minute instructional audio CD. Based on participant symptoms and preferences the following strategies are taught: bladder training, urge and suppression techniques, caffeine reduction, eliminating bladder irritants, medication adjustment, adequate fluid intake, constipation management, and reducing nocturia.~2. Physical activity program including moderate intensity walking (30 minutes, 5 days weekly) and twice weekly group strength training sessions using Therabands led by a trained exercise instructor."
45699078|NCT03451266|Drug|placebo|100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
45699079|NCT05322486|Procedure|surgery of the primary tumour|Surgical resection of the colon tumour, R0. No surgical intervention on metastasis.
45513470|NCT02068638|Procedure|IHE first, CONT second|IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes. CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes
45513471|NCT02068638|Procedure|CONT first, IHE second|CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes
45513472|NCT02068638|Procedure|GLU first, GLU-FRU second|: ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes
45513473|NCT02068638|Procedure|GLU-FRU first, GLU second|GLU-FRU : ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): : ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes.
45513474|NCT01377025|Drug|Placebo|two tablets in the morning and two in the evening.
45513475|NCT01377025|Drug|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was PR or CR
45513476|NCT01377025|Drug|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was SD
45513477|NCT02207036|Behavioral|Facebook intervention|90 days of Facebook messaging, weekly Ask the Doctor sessions
45513478|NCT02207036|Behavioral|Smokefree.gov|referral to the NCI Smokefree.gov website
45513479|NCT03630757|Other|Treatment|In the study group, a total of 15 sessions of a manual therapy program including myofascial release and mobilization techniques were applied for 60-minute session for 3 weeks(5/wk).
45699080|NCT05322486|Drug|chemotherapy|Chemotherapy with or without biological drugs.
46057310|NCT04088617|Dietary Supplement|Placebo|Acute ingestion of a taste-matched placebo prior a 2-hour high carbohydrate mixed meal tolerance test.
45404657|NCT03963258|Device|whole-body vibration training|The subjects were exposed to alternating vertical sinusoidal vibration using a Galileo tilting table system.The frequency of WBV ranged from 5 to 20 Hz, and the amplitude ranged from 1 to 6 mm.The subjects were kneeled on the ground, both shoulders flexed at 90 degrees, elbows slightly flexed, their trunk bent in this position and contacted on the platform board with their palms equidistant from the midpoint of the board
45404658|NCT03963258|Other|conventional upper limb training|compensatory techniques for activities of daily living, UE strength, therapist-guided techniques for facilitating normal UE movement patterns,and range of motion and traditional positioning
45404659|NCT01079520|Procedure|Endobronchial ultrasound (EBUS)|Minimally invasive technique to stage lung cancers
45513480|NCT02203292|Behavioral|Liberal transfusion strategy|Patients will have red blood cells transfused only if Hb < 9.0 g/dL
45513481|NCT02203292|Behavioral|Restrictive transfusion strategy|Patients will have red blood cells transfused only if Hb < 7.0 g/dL
45513482|NCT02066064|Procedure|Standard Colonoscopy|Standard Colonoscopy
45513483|NCT02066064|Procedure|G-EYE(TM) Colonoscopy|G-EYE(TM) Colonoscopy
45699081|NCT03463668|Device|uncovered metal duodenal prosthesis|Implantation of an uncovered metal duodenal prosthesis for symptomatic tumor stenosis
45699082|NCT03467646|Procedure|Sleeve Gastrectomy|The patients undergo a Sleeve Gastrectomy as bariatric procedure
45699083|NCT03467646|Procedure|Roux-en-Y gastric bypass|The patients undergo a Roux-en-Y gastric bypass as bariatric procedure
45699084|NCT03467646|Procedure|One-Anastomosis Gastric Bypass|The patients undergo a One-Anastomosis Gastric Bypass as bariatric procedure
45699085|NCT01199146|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg by mouth per day
45699086|NCT01199848|Dietary Supplement|Placebo|whole milk shake without strawberry powder served with the high fat/carbohydrate test meal
45699087|NCT01199848|Dietary Supplement|10G|whole milk shake with 10g strawberry powder served with the high fat/carbohydrate test meal
45699088|NCT01199848|Dietary Supplement|20G|whole milk shake with 20 strawberry powder served with the high fat/carbohydrate test meal
45699089|NCT01199848|Dietary Supplement|40G|whole milk shake with 40g strawberry powder served with the high fat/carbohydrate test meal
45699090|NCT01199848|Dietary Supplement|Placebonofiber|Placebo without Fiber
45404660|NCT01079520|Procedure|Mediastinoscopy|Traditional surgical method to stage lung cancers
45513484|NCT05353075|Other|Sub Occipital Muscle Inhibition|The therapist sits at the head end of the table, palms beneath the subject's head, pads of his fingertips on the posterior arch of the atlas, which will be palpated by the therapist between the external occipital protuberance and the spinous process of the axis vertebra. The therapist locates the gap between the occipital condyles and the spinous phase of the C2 vertebra with the middle and ring fingers of both hands the therapist then rests the base of the skull on his or her hands, with toward the therapist. The pressure will be held at the same level for four minutes until tissue relaxation will be achieved. The subject will be asked to keep his eyes closed during the SMI technique to prevent eye movements disturbing the Sub occipital muscle tone.
45513485|NCT05353075|Other|Sub Occipital Inhibition with Hold Relax Agonist Contraction|Therapist will passively flex the lower extremity with knee extended to the end range of Hip Flexion. Once the end range of motion will attain the patient will apply a 10second isometric force against the therapist manual resistance. After the isometric contraction of hamstring the patient will ask to perform a concentric contraction of opposing muscle (hip flexors) for 10 seconds. As the patient performs the concentric contraction the therapist takes up the slack into any ROM that was gained keeping limb into new stretch position for 10-15 seconds and then rest for 5 seconds. Three repetitions of this technique will be performed on each subject.
45513486|NCT02207192|Other|Postural change in lung volumes: sitting to Supine|"Pulmonary function and arterial blood gases were assessed both prior to and after weight loss as part of pre-operative and 12-month follow-up evaluations.~Pulmonary function tests were performed both in the sitting and then in the supine position."
45513487|NCT03579121|Other|Pharmacogenomic (PGx)|Administer a pharmacogenomics test (buccal swab) during the pre-operative setting
45513488|NCT03579121|Other|Review results|Pharmacogenomic (PGx) results reviewed by the clinicians during their treatment and the results may guide clinical decisions.
45513489|NCT02203370|Device|NIRS - Near-infrared spectroscopy|
45404661|NCT03763474|Combination Product|Euglyca application|'Euglyca' is a mobile application developed by two of the authors (CC and DF). The application has a data base of 7000 foods and food products met in greek eating habits as well as the corresponding amount of carbohydrates and lipids for each of them. Subsequently, the amount of carbohydrates and lipids contained in a meal are calculated automatically by the application. By taking into consideration the amount of carbohydrates and lipids to be consumed, the preprandial and target post-prandial glycemia concentrations, the insulin correction factor for the patient, the carbohydrates and lipids factors and the active insulin (in case of CSII), 'Euglyca' calculates the required bolus dose of insulin.
45404662|NCT01082094|Biological|ACRX-100|Three cohorts (16 total subjects) will be studied. There will be no concurrent controls. The dose will be escalated by increasing the total amount of ACRX-100 delivered per subject from low dose (n=4 subjects) to middle dose (n=6 subjects) to high dose (n=6 subjects). ACRX-100 will be injected directly into the myocardium as a single dose at multiple sites through a percutaneous, left ventricular approach using a needle injection catheter.
45513490|NCT05037786|Behavioral|Infographic|Key themes related to pain and injury in elite players based on previous studies presented using an A3 infographic
45513491|NCT05037786|Behavioral|Powerpoint|Key themes related to pain and injury in elite players based on previous studies presented using a Powerpoint
45513492|NCT02203448|Device|Facet Wedge spinal system|
45513493|NCT02066142|Device|3D mammography (Tomosynthesis)|Tomosynthesis will be used as normally employed in clinical practice
45513494|NCT02066142|Device|Ultrasound|
45513495|NCT02068872|Procedure|Sleeve Gastrectomy|To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of > 40 or > 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.
45513496|NCT02342275|Drug|Propranolol|Initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2 to 24.
45513497|NCT02342275|Drug|Atenolol|Initiated at a dosage of 0.5 mg/kg per day in a single dose for 1 week, and then increased to 1 mg/kg per day in a single dose from weeks 2 to 24.
45513498|NCT04988568|Other|None. This is a qualitative interview study.|There is no intervention in this study. This is a qualitative research study where patients will be interviewed.
45513499|NCT02207270|Behavioral|Same day discharge|Patients randomized to SDD will be discharged home on the day of their PCI, at least 6 hours following its completion. They will receive a follow up phone call from a study coordinator the next day and at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
46057311|NCT02708589|Dietary Supplement|probiotic|
45513500|NCT02207270|Behavioral|Overnight Stay|Patients who experienced uncomplicated PCI, as well as an uncomplicated 6-hour observation period, will be randomly assigned to an overnight stay, generally considered standard or routine care. Patients randomized to overnight stay will be discharged the following morning to receive a follow up phone call at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
45404663|NCT03753568|Device|Electronic medicine reminder system|Electronic surveillance device is attached to the participants push through pill sheet and the smart phone application reminds the participants to take their medicine if they are about to take their daily dosage.
45513501|NCT02068950|Behavioral|Progressive resistance training|A 12-week, supervised, group based, progressive resistance training program involving the major muscle groups of the body will be tested. Details of the program: 12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
45404664|NCT01082172|Device|Implant Thoracic Stent Graft|Endovascular implant of Thoracic Aortic Aneurysm Stent Graft
45513502|NCT01827553|Drug|Induction chemotherapy with gemcitabine or FOLFIRINOX|According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m^2 2 h infusion, folinic acid 400 mg/ m^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m^2 for 90 minutes, bolus application 5-FU 400 mg/m^2 followed by 46h infusion of 5-FU 2400 mg/m^2)
45404665|NCT03757858|Device|Thermotron RF-8|Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week for a total of 10 times.
45404666|NCT03757858|Biological|Adoptive cellular Immunotherapy|Mononuclear cells were collected from 50ml peripheral blood , and cultured cytokine-induced killer cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of CIK Immunotherapy . If the evaluation of the treatment is complete response, partial response or stable disease, additional cycles were eligible.
45404667|NCT03757858|Drug|Anti-PD-1 antibody|Patients will receive pembrolizumab 100mg every three weeks and assess the clinical outcome every 2 dosage of anti-PD-1 antibody treatment.
45404668|NCT03757858|Drug|Chemotherapy|Patients will receive standard chemotherapy until disease progression, unacceptable toxicity or patient refusal.
45513503|NCT01827553|Radiation|Radiotherapy, 28 x 1.8 Gy|Radiotherapy combined with chemotherapy starts on day 1 of chemotherapy. Radiation volume is restricted to macroscopic visual tumor region. Radiation is performed in 28 fractions with 1.8 Gy resulting in a total dose of 50.4 Gy.
45513504|NCT01827553|Drug|Chemotherapy, gemcitabine|5 cycles of 300 mg/m^2/d gemcitabine infusions and than 3 administrations of 1000 mg/m^2/d
45513505|NCT01827553|Drug|Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy|Chemotherapeutic administration started with during induction chemotherapy is continued; Gemcitabine: 3 cycles a 3 administrations of 1000 mg/m^2/d gemcitabine infusions FOLFIRINOX: 6 cycles
45699091|NCT03467568|Dietary Supplement|Sodium Chloride|300mg sodium chloride will be provided in a capsule
45404669|NCT01079676|Drug|Filgrastim (Eurofarma)|Filgrastim will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
45404670|NCT01079676|Drug|Filgrastim (Granulokine, Amgen)|Granulokine will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
45404671|NCT03753256|Device|Transbond XT|"Application of~• Transbond XT (activator comparator) to labial surfaces of teeth of randomized quadrants."
45404672|NCT03753256|Device|Protecto®CaF2Nano|"Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
45513506|NCT02207348|Drug|liraglutide|Each subject will receive two single doses of 0.6 mg liraglutide (one with each of the two pen-injectors)
45513507|NCT02066454|Drug|Apixaban|2.5mg x 2 per day during 6 months
45513508|NCT03526484|Behavioral|Standard of Care|The provider will review the urinalysis results prior to conducting the in-office procedure and will make clinical decisions taking into account those results.
45513509|NCT03526484|Behavioral|Experimental|The provider will not review the urinalysis results prior to conducting the in-office procedure, and therefore will not make clinical decisions taking those results into account.
45404673|NCT03753256|Device|Pro Seal®|"Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
45404674|NCT03753256|Device|Opal®Seal|"Application of~• Opal®Seal (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
45404675|NCT01082250|Drug|Lurasidone HCl|120mg dose. 3-way cross-over for 21 days
45404676|NCT05460286|Other|Chiropractic Manipulation|20 participants with low back pain existing more than 3 months was included in the CSMT group. Lumbar region chiropractic HVLA (High Velocity, Low Amplitude) spinal manipulation and/or sacroiliac joint chiropractic HVLA manipulation were applied to participants. Participants were treated three times with an interval of three days. Before and after treatment were evaluated lower extremity (hamstring and quadriceps) muscle strength with an isokinetic dynamometer (CSMI Humac-Norm), balance performance with BBS (Biodex Balance System), lumbar range of motion and mobility with inclinometer and hand finger floor distance (HFFD), low back pain intensity with visual analog scale (VAS), functional status with Modified Oswestry low back pain disability questionnaire (OSW), quality of life with Short form-36 (SF-36).
45404677|NCT05460286|Other|Spinal Decompression Device Treatment|20 participants with low back pain existing more than 3 months was included in the SD group. Lumbar region spinal decompression (traction) device therapy was applied to participants, and as a standard of treatment was given a hot pack for 15 minutes before applying and a cold pack for 10 minutes after applying. Participants were treated three times with an interval of three days. Before and after treatment were evaluated lower extremity (hamstring and quadriceps) muscle strength with an isokinetic dynamometer (CSMI Humac-Norm), balance performance with BBS (Biodex Balance System), lumbar range of motion and mobility with inclinometer and hand finger floor distance (HFFD), low back pain intensity with visual analog scale (VAS), functional status with Modified Oswestry low back pain disability questionnaire (OSW), quality of life with Short form-36 (SF-36).
45404678|NCT01082406|Drug|catridecacog|Single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) administered iv.
45404679|NCT01082406|Drug|recombinant factor XIII|Single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) to be administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv.
45404680|NCT03755362|Procedure|Standard Treatment|Dental evaluation at baseline, 3, 6, and 9 months.
45513510|NCT00979693|Drug|psilocybin|25 mg psilocybin administered orally once during each of the two day-long psychotherapy sessions.
45513511|NCT00979693|Drug|psilocybin|4 mg psilocybin orally administered once during each of two day-long psychotherapy session
45513512|NCT02207426|Drug|Tobramycin|
45513513|NCT00777491|Drug|induction cisplatin|15 mg/m^2 administered as a 60-minute infusion on days 1,2,3,8,9,10,15,16,17.
45404681|NCT03755362|Procedure|Intensive Treatment|Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to <20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
45513514|NCT00777491|Drug|induction 5-fluorouracil|400mg/m^2 administered as a 24-hour infusion on days 1,2,3, and 15,16,17.
45513515|NCT00777491|Drug|induction gemcitabine|27 mg/m^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15, 18, 22, 25.
45513516|NCT00777491|Radiation|Induction BID radiation therapy|Twice daily (BID) on days 1-5,8-12,15-17. The first daily treatment consists of 1.6 Gy delivered to the pelvis. The second fraction consists of 1.5 Gy to the bladder for the first 5 treatment days. Then, 1.5 Gy is delivered to bladder tumor volume as the second treatment for the remaining 8 treatment days. The bladder tumor volume receives a total of 40.3 Gy.
45513517|NCT00777491|Radiation|Induction QD radiation therapy|Once daily (QD) on days (1-5,8-12,15-19,22-26). For the first 10 treatment days, 2 Gy is delivered to the pelvis. Then, 2 Gy is delivered to the bladder for the next 4 treatment days, followed by 2 Gy to the bladder tumor volume for the remaining 6 treatment days. The bladder tumor volume receives a total of 40 Gy.
45513518|NCT00777491|Radiation|Consolidation BID radiation therapy|Twice daily (BID) for 8 days on days 1,2,3,4,5,8,9,10 of consolidation. 1.5 Gy per fraction for a total of 24 Gy delivered to the pelvis.
45513519|NCT00777491|Radiation|Consolidation QD radiation therapy|Once daily (QD) pelvic radiation therapy for 12 days on days 1-5,8-12,15-16 of consolidation. 2 Gy per fraction for a total of 24 Gy delivered to the pelvis.
45513520|NCT00777491|Drug|consolidation gemcitabine|27 mg/m^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15 of consolidation.
45513521|NCT00777491|Drug|consolidation 5-fluorouracil|400 mg/m^2 administered as a 24-hour infusion on days 1, 2, 3 and 8, 9, 10 of consolidation.
45513522|NCT00777491|Drug|consolidation cisplatin|15 mg/m^2 administered as a sixty-minute infusion on days 1, 2, 8, 9 of consolidation.
45513523|NCT00777491|Procedure|radical cystectomy|Operable patients who have a pT1 or worse tumor response on re-evaluation following initial transurethral resection and induction chemoradiotherapy will have a radical cystectomy 3-8 weeks following the post-induction response evaluation.
45404682|NCT03755284|Other|Sacral Massage|● In addition to providing them with routine nursing/midwifery care, the women in the experimental group were administered a massage to the sacral region under the supervision of a doctor for 30 minutes using the effleurage (patting) ( 15 minutes) and vibration technique ( 15 minutes) in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour. To achieve this, the patients were placed in the left lateral position in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour.
45404683|NCT00133952|Drug|Ruboxistaurin|Administered orally
45404684|NCT00133952|Drug|Placebo|Administered orally
45513524|NCT00777491|Procedure|Post-Induction Chemoradiotherapy Endoscopic Response Evaluation|Urine cytology, cystoscopy, tumor site transurethral biopsy, and bimanual examination after biopsy.
45513525|NCT00777491|Drug|adjuvant gemcitabine|1000 mg/m^2 administered intravenously over 30-60 minutes (preferably 30 minutes) on days 1 and 8 of each 21-day cycle for four cycles.
45404685|NCT03755050|Other|general and specific data|General and specific data collected
45513526|NCT00777491|Drug|adjuvant cisplatin|70 mg/m^2 administered as a sixty-minute infusion on day 1 of each 21-day cycle for four cycles.
45513527|NCT02207582|Device|Verum Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
45404686|NCT00118092|Drug|tanespimycin|Given IV
45404687|NCT00118092|Other|laboratory biomarker analysis|Correlative studies
45404688|NCT01083108|Other|Roux-en-Y Gastric Bypass|The surgical group will be studied before and 6 days after bariatric surgery.
45404689|NCT01083108|Other|Caloric Restriction|The non-surgical group will be studied before and after receiving a hypocaloric diet for 6 days mimicking the typical postoperative diet.
45404690|NCT04555096|Drug|GC4419|180 Minute IV Infusion
45404691|NCT04555096|Drug|Placebo|180 Minute IV Infusion
45404692|NCT00097500|Drug|exenatide|subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets
45513528|NCT02207582|Device|Placebo Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
45404693|NCT00097500|Drug|Insulin glargine|subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets
45513529|NCT02069106|Dietary Supplement|Pro-Omega LDL|
45513530|NCT02069106|Other|Placebo|
45513531|NCT02199392|Drug|Lenvatinib|subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
45513532|NCT03630445|Other|Isomaltooligosaccharides (IMOs)|Isomaltooligosaccharides (IMOs) incorporated into yogurt were tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
45699092|NCT03467568|Other|Placebo capsule|A capsule of identical appearance to that providing salt, but not containing electrolytes, will be consumed
45699093|NCT03467568|Dietary Supplement|Water|Twice during the morning a drink of 150ml of water will be consumed
45699094|NCT03467568|Biological|No water consumed|No water will be consumed during the monring
45699095|NCT01199926|Dietary Supplement|Vitamin D|4000 IU of vitamin D per day for 12 weeks.
45699096|NCT01199926|Drug|Placebo|Placebo (microcrystalline cellulose) ingestion each day for 12 weeks.
46057312|NCT02708589|Other|Placebo|
46057313|NCT02708823|Other|CogCheck application|The application is administered once to all study participants.
45404694|NCT00097500|Drug|Metformin|Patients usual dosage
45404695|NCT01082484|Drug|treprostinil|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
45404696|NCT01082484|Drug|iloprost|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
46057314|NCT02611089|Procedure|Tissue biopsy|Sampling of tissue as described.
46057315|NCT00729157|Radiation|Fludeoxyglucose F-18|Correlative studies
46057316|NCT00729157|Other|Laboratory Biomarker Analysis|Correlative studies
46057317|NCT00729157|Other|Pharmacological Study|Correlative studies
46057318|NCT00729157|Procedure|Positron Emission Tomography|Correlative studies
46057319|NCT00729157|Biological|Ziv-Aflibercept|Given IV
45404697|NCT01082484|Drug|NaCl 0.9%|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
45404698|NCT04551898|Drug|BGB-DXP593|Intravenous (IV) infusion administered over 30 to 90 minutes at a dose as specified in the treatment arm
46057320|NCT02710305|Drug|oral hyoscine butyl bromide tablets plus lidocaine cream|patients will take oral hyoscine butyl bromide 30 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before the procedure
45404699|NCT04551898|Drug|Placebo|Placebo to match BGB-DXP593 administered as specified in the treatment arm
45513533|NCT03630445|Other|Xtend® sucromalt|Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
45513534|NCT03630445|Other|Combination of IMOs and Xtend® sucromalt|A combination of IMOs and Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
45513535|NCT03630445|Other|Raw corn starch|Raw corn starch incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
45513536|NCT03630445|Other|Maltodextrin|Maltodextrin incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
45513537|NCT02069262|Other|rebleeding|Those who developed rebleeding during the observation would be crossed over to the other investigation modality.
45404700|NCT03757780|Other|Questionaire|A questionaire will be made to pregnant ladies who take caffeine during pregnancy
45404701|NCT04849780|Device|ACUVUE Oasys 1-Day|TEST
45404702|NCT04849780|Device|Habitual Lens|Subjects' own Habitual Lenses
45513538|NCT01379495|Behavioral|educational program+telephone follow up|burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
45513539|NCT05320627|Drug|Edoxaban|Eligible patients will receive Edoxaban tablet once a day for 12 weeks
45513540|NCT03559920|Drug|Sedate using sevoflurane via anesthetic conserving device(ACD, Anaconda®) after surgery|The investigators sedate the patients in the ICU for several days after head & neck surgery using sevoflurane via anesthetic conserving device in sevoflurane group.
45513541|NCT03559920|Drug|Sedate using propofol.|Retrospectively, the investigators compare the sevoflurane group with intravenous sedation group using propofol.
45851351|NCT02992860|Procedure|Pregnancy Test|Serum or urine pregnancy testing β-HCG with a sensitivity of at least 25 mIU/mL is to be done not more than 3 days prior to initiation of JNJ-56022473 in female patients with childbearing potential. Furthermore, serum or urine pregnancy testing has to be done after end of treatment (EoT) visit.
45513542|NCT02203760|Drug|Pazopanib plus Gemcitabine|Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
45513543|NCT02203760|Drug|Pazopanib|Pazopanib 800 mg orally once daily
45513544|NCT03630107|Other|WO 5101 Shampoo for Scalp and Hair|Wash the hair at least three times a week for a period of four weeks
45513545|NCT02064972|Other|Patients undergoing allo-HSCT, who manifest GvHD.|Changes in CEC counts in relation to GvHD ONSET
45513546|NCT03703271|Drug|Methotrexate|single-agent 5-day methotrexate, two weeks a cycle
45513547|NCT03703271|Procedure|hysteroscopic repeat curettage|Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
45513548|NCT03532802|Drug|Metoprolol Succinate|"week: uptitration with 50 mg capsules per day, until maximum dosage of 150 mg´s/day.~week: steady state treatment with the maximum tolerated dose of the 1.week."
45513549|NCT03532802|Drug|Placebo oral capsule|"week: uptitration with 1 capsule per day, until maximum tolerated dosage of 3 capsules/day.~week: steady state treatment with the maximum tolerated dose of the 1. week"
45513550|NCT03430531|Drug|Lidocaine|Lidocaine 2% viscous (0.5ml) will be squirted on two cotton swab sticks and one will be gently inserted into each nostril, along the floor of the nose. Slight rotatory motion of the stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab sticks will be left undisturbed for 5 minutes. The swabs will be taken out and this will be repeated twice more, using fresh swabs and 0.5ml of 2% lidocaine. The block would take about 30 minutes.
45404703|NCT03757702|Other|Evaluation|Trunk position sense will be evaluated with a digital inclinometer. Trunk reposition test will be used in evaluation.The postural stability will be evaluated with a special balance device in eyes opened and closed position. Ellipse area (mm2) and perimeter (mm) parameters will be recorded.The angles of thoracal kyphosis and lumbar lordosis will be evaluated with a digital inclinometer.
45404704|NCT03757624|Procedure|shrinkage|shrinkage of gastric specimen in %10 formol solution after Laparoscopic Sleeve Gastrectomy
45404705|NCT03754894|Device|ready made plastic stent application|full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement covered by ready-made plastic stent.
45404706|NCT03754894|Procedure|simple interrupted sutures|full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement and securing the flap with simple interrupted sutures
45513551|NCT02066532|Drug|Ruxolitinib|25 mg bid, 20 mg bid, 15 mg bid, or 10 mg bid, (oral, twice a day) on days 1 through 21 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
45513552|NCT02066532|Drug|Trastuzumab|6 mg/kg every 3 weeks (cycle = 21 days). If no trastuzumab > 28 days, patients will be initially re-loaded at 8 mg/kg, then 6 mg/kg.
45513553|NCT05763329|Drug|Lemborexant 5 MG Oral Tablet [Dayvigo] Day 1|Patients will receive Lemborexant 5 mg per day on the first day of sleep test
45851352|NCT02992938|Drug|Acetazolamide|
45851353|NCT02992938|Drug|Placebo Oral Tablet|
45851354|NCT02992704|Drug|Peginterferon Alfa-2A|peginterferon alpha 2a 180mcg weekly for either 24 or 48 weeks
45851355|NCT02992470|Dietary Supplement|Hydrolyzed oyster extract|1 tablet of oyster extract t.i.d. for 8 weeks
45851356|NCT02992470|Dietary Supplement|Placebo|1 tablet of maltodextrin t.i.d. for 8 weeks
45851357|NCT02992548|Drug|Pravastatin|
45851358|NCT02992626|Other|Human-dog interaction|The tests are completed in the presence of a dog. Further, before starting the tests, the children have 15 minutes to interact with the present dog.
45851359|NCT02992626|Other|Stuffed toy dog|The tests are completed in the presence of a stuffed toy dog. Further, before starting the tests, the children have 15 minutes to play with the stuffed toy dog.
45851360|NCT02992392|Drug|Liposic|one eye of the participant recieved Lipoic
45513554|NCT05763329|Drug|Lemborexant 5 MG Oral Tablet [Dayvigo] Day 2|Patients will receive Lemborexant 5 mg per day on the second day of sleep test
45513555|NCT05763329|Drug|Placebo Day 1|Patients will receive placebo on the first day of sleep test
45513556|NCT05763329|Drug|Placebo Day 2|Patients will receive placebo on the second day of sleep test
45513557|NCT03532724|Device|Patient Self-Management of VKA therapy|Trained patients check weekly the INR using a portable coagulometer an decide by themselves the dosis of VKA
45513558|NCT02065050|Other|team-based care|Patients in the eDMS arm are called at least every month for their diabetes treatment.
45513559|NCT04088513|Drug|Aspirin|This group will receive a 100 mg/day aspirin plus clopidogrel placebo for 90 days.
45513560|NCT04088513|Drug|Clopidogrel|This group will receive a 75 mg/day clopidogrel plus aspirin placebo for 90 days.
45513561|NCT02207660|Drug|Cisplatin,P-HDFL|The P-HDFL regimen was given as follows: In each 21-day cycle, patients received 24-hour infusions of cisplatin at 45 or 50 mg/m2 and 5-FU 2,600mg/m2 plus leucovorin 300 mg/m2 intravenous 24-hour infusion on Day 1. Normal saline hydration (≧1000 mL), dexamethasone, and antiemetics (ondansetron or granisetron) were given prophylactically before each dose of cisplatin.
45513562|NCT05292469|Behavioral|Comprehensive approach to hypertension management|Trained health workers will review blood pressure (BP) logs and provide treatment. The patients will receive a BP lowering informational package, BP monitoring device and log book and pill-box and medication table. The participants will receive monthly home visits (6 visits) to discuss hypertension and ways to manage it. They will be encouraged to identify problems and developing an action plan to solve them. The participants will be encouraged to set behavioral goals. The follow up visits will review the progress made in implementing action plan and goals set and updating them. Review BP logs and facilitate tailored discussion on topics based on problems faced by participants on barriers to medication adherence, physical activity, weight management or diet. The family members will be involved and be accountable in supporting the patients in achieving the action plans.
45404707|NCT04823494|Device|Hearing aids|Earbud style hearing aids fit to both ears
45513563|NCT02069340|Drug|zoledronic acid|Given IV
45513564|NCT02069340|Other|pharmacological study|Correlative studies
45513565|NCT02199548|Other|Interview|This study involves teen participants taking part in one private interview with the study team. Interviews last less than one hour and are scheduled at the participant's convenience. Interviews will be audio/digital recorded. Participants may answer any or all of the questions.
45513566|NCT02069418|Radiation|18F-FLT-TEP|Patients are going to have two 18F-FLT-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
45513567|NCT02069418|Radiation|18F-FDG-TEP|Patients are going to have two 18F-FDG-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
45513568|NCT02207738|Device|microneedling radiofrequency device|Microneedling radiofrequency device is composed of 49 insulated microneedle which emit radiofrequency from the needle tip. This radiofreqeuncy generates dermal heat which evokes biological effect.
45513569|NCT02207738|Device|bipolar radiofrequency|bipolar radiofrequency instrument gives out bipolar radiofrequency from the hand piece tip. This bipolar radiofrequency generates dermal heat which has a lot of bilogical effect.
45513570|NCT04422847|Device|3D obturator|Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer
45513571|NCT03386357|Combination Product|A (pembrolizumab+RT)|Pembrolizumab (200mg absolute, q3w) combined with radiotherapy (12x3Gy) of one, two or three metastases. Only metastases that perspectively require radiotherapy will be treated. The irradiated tumor volume must be at least 10cm³. Radiotherapy of brain metastases is not allowed.
45513572|NCT03386357|Drug|B (pembrolizumab)|Pembrolizumab (200mg absolute, q3w)
45513573|NCT02208128|Drug|Sunitinib, Pazopanib, Bevacizumab, Everolimus...|Clinical standard
45513574|NCT04411771|Behavioral|Brief interventions|'Brief Interventions' (BI) is a generic term for a multitude of tools and interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. As such, there is no separation between assessment and intervention. The interventions within BI often have their foundation in CBT, ACT or MI. The common theme is that they are principle-based rather than manual-based and focus on behavioral change in relation to a problem that is perceived both possible to affect and relevant to the patient, rather than focusing on a specific diagnosis or condition. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. Usually a BI treatment consists of 1-4 appointments with several weeks apart and ends when the patient feels that they are moving in the right direction.
45699097|NCT03463590|Device|Bilateral surgical implantation of DBS system to habenula|The DBS device utilized in the present study may include the Medtronic, PINS and SceneRay DBS device depending on patients' choice.
45851361|NCT02992392|Drug|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
45851362|NCT02992314|Device|Metaqil™ Oral Rinse|Metaqil™ is a proprietary formulation of GRAS ingradients
46057321|NCT02710305|Drug|oral placebo tablets plus placebo cream|patients will take oral placebo 30 minutes before the procedure plus placebo cream placed into their cervix immediately before the procedure
46057322|NCT02708511|Diagnostic Test|Computed Tomography|Undergo PET/CT
46057323|NCT02708511|Drug|Copper Cu 64-DOTA B-Fab|Given IV
46057324|NCT02708511|Other|Laboratory Biomarker Analysis|Correlative studies
46057325|NCT02708511|Other|Pharmacological Study|Correlative studies
46057326|NCT02708511|Diagnostic Test|Positron Emission Tomography|Undergo PET/CT
45404708|NCT05384392|Other|Recorded interview|A recorded clinical interview, transcribed verbatim and blinded analyzed
45404709|NCT05384392|Other|Clinical scales|Answering to clinical scales : PANSS (Positive and Negative Syndrome Scale); BPRS (Brief Psychiatric Rating Scale); CDSS (Calgary Depression Scale for Schizophrenia); MADRS (Montgomery-Åsberg Depression Rating Scale); Altman; YMRS (Young Mania Rating Scale); GAF (Global Assessment of Functioning); SF-36 (36-Item Short Form Survey); CGI-S (Clinical Global Impression Scale) et CGI-I (CGI-Improvement)
45513575|NCT04411771|Behavioral|Guided self-help CBT|The patient receives a previously scientifically evaluated CBT-based self-help book for one of the following conditions: depression, generalized anxiety disorder, panic disorder, social anxiety, health anxiety, insomnia, or stress/burnout. The therapist support consists of 3-6 contacts throughout the 6-12 weeks long intervention period as decided by the clinician and patient together, as long as at least one and not more than three are physical visits at the center and the rest via phone, video conferencing, or secure internet messages. Clinicians delivering shCBT will need four days of reading and two days of training to be able to make initial assessments and problem profiling and use the self-help books.
45513576|NCT03119883|Other|5-Carbon C 13-labeled Glutamine|Given IV
45513577|NCT03119883|Procedure|Biospecimen Collection|Undergo collection of blood
45513578|NCT03119883|Procedure|Biospecimen Collection|Undergo collection of bone marrow aspirate samples
45513579|NCT03119883|Other|Uniformly-labeled [13C]glucose|Given IV
45513580|NCT02069496|Biological|Arepanrix®|Injected according to the prescribing information in the locally approved label by the authorities.
45513581|NCT02066610|Other|selenium and sodium selenate supplementation|Parenteral nutrition with selenium and sodium selenate supplementation of infant formula
45513582|NCT02066610|Other|selenium and sodium selenite supplementation|Parenteral nutrition with selenium and sodium selenite supplementation of infant formula
45513583|NCT02066610|Other|Without selenium and sodium selenate supplementation|Parenteral nutrition without selenium and sodium selenate supplementation of infant formula
45513584|NCT02066610|Other|Without selenium and sodium selenite supplementation|Parenteral nutrition without selenium and sodium selenite supplementation of infant formula
45513585|NCT03077711|Drug|Trimethoprim|suppressive antibiotic. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
45513586|NCT03077711|Drug|Methenamine hippurate|antiseptic used in the prevention of recurrent UTIs. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
45513587|NCT03673683|Behavioral|SANDWICH protocol|A protocol based intervention incorporating co-ordinated care with greater nursing involvement; patient-relevant sedation plans linked to regular assessment using the COMFORT scale; regular assessment of ventilation parameters with a higher than usual trigger for undertaking an extubation readiness test; a spontaneous breathing trial (SBT) on low levels of respiratory support to test extubation readiness
45513588|NCT03673683|Behavioral|Usual care|Usual sedation and weaning management that is not protocol based
45513589|NCT03533426|Procedure|Serratus anterior plane catheter block|Ultrasonographic guided placement of a catheter under the serratus anterior muscle in cases of open thoracotomies for chest malignancies in an attempt to reduce the emergence of postthoracotomy pain syndrome.
45513590|NCT03533426|Procedure|Patient controlled analgesia|The use of patient controlled analgesia through a pump aiming to reduce the development of postthoracotomy pain syndrome
45404710|NCT05384392|Biological|Blood sample|Blood collection of inflammatory markers (IL-1, sIL-2R, IL-4, IL-6, IL-8 and TNF levels) and 2 EDTA tubes and 2 dry tubes for biological collection (plasma bank and serum bank). This blood sample will be taken during routine sampling.
45404711|NCT05384392|Other|MRI scans of the brain|The MRI scans of the brain will be performed. This exam is performed in routine care in the context of this pathology
45513591|NCT02069574|Procedure|non-surgical periodontal therapy|
45513592|NCT04374019|Drug|Ivermectin|"Ivermectin:~Days 1-2: Weight < 75kg: 4 tabs (12 mg total daily dose) Days 1-2: Weight > 75kg: 5 tabs (15 mg total daily dose)"
45513593|NCT04374019|Drug|Camostat Mesilate|Days 1-14: 2 tab TID after a meal (600 mg total daily dose)
45513594|NCT04374019|Dietary Supplement|Artemesia annua|Days 1-14: tea or coffee pod TID (1350 mg total daily dose)
45513595|NCT04374019|Drug|Artesunate|Days 1-14:
45513596|NCT02199704|Other|Self Directed Positive Parenting Program|"Individuals with psychosis who are parents will receive a copy of the Every Parent's Self Help Workbook (Markie-Dadds, Sanders & Turner, 1999) and up to ten sessions of support. This is a case series study."
45513597|NCT03678363|Other|Tai chi chuan|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breating, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
45404712|NCT05459974|Drug|Colchicine 0.6 mg|Colchicine 0.6 mg once daily for 30 days after the atrial fibrillation ablation
45404713|NCT05459974|Drug|Placebo|Placebo pill once daily for 30 days after the atrial fibrillation ablation
45404714|NCT03754816|Procedure|PECS II and parasternal block|10 ml of Levobupivacaine 0.375% injected between minor and major pectoralis muscles. 20 ml of Levobupivacaine 0.375% injected between minor and serratus muscles. 10 ml of Levobupivacaine 0.375% injected between major and intercostal muscles at II and IV intercostal space.
45513598|NCT02069652|Behavioral|Lifestyle Counseling|Lifestyle Counseling
45513599|NCT02199782|Other|Welsh language Cognitive Assessment|This intervention may intervene by displaying a more realisitic reflection of the patient's cognitive ability by assessing the patient in their first language
45513600|NCT02069808|Drug|Follistim|Follicle stimulating hormone promotes recruitment of follicles for ovulation.
45513601|NCT02069808|Drug|Ganirelix|GnRH antagonist preventing a problematic risk of premature LH surge during ovulation induction therapy.
45513602|NCT02069808|Drug|Menotropins|Combination of follicle stimulating hormone and Luteinizing hormone activity promotes recruitment of follicles for ovulation. Absence or presence of this medication is the difference being tested between the two arms of the study.
45404715|NCT03754816|Drug|Levobupivacaine|Levobupivacaine
45404716|NCT04542694|Drug|Favipiravir|200 mg coated tablets
45513603|NCT02069808|Drug|Leuprolide|Promotes endogenous LH surge signaling oocyte maturation followed by ovulation. This controls timing for oocyte collection.
45513604|NCT02069808|Procedure|Transvaginal ultrasound guided needle aspiration of oocytes|
45513605|NCT03678207|Other|Anesthesiologist phone call|Patients receiving ambulatory surgery with no prior diagnosis of hypertension but have elevated blood pressure prior to surgery. Patients will receive a phone call from a participating anesthesiologist 1-3 days after surgery notifying them of their high blood pressure and obtaining oral consent to participate in the study. Patients will receive reminders via mail about following up with their PCP.
45513606|NCT02199860|Drug|SD I|
45513607|NCT02199860|Drug|SD II|
45513608|NCT02199860|Drug|Placebo|
45513609|NCT03673605|Drug|Rivaroxaban 15 mg|Rivaroxiban in stroke prevention in patients with Mitral Stenosis and AF.
45404717|NCT04542694|Drug|Standard of care|"Drug: Standard of Care Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.~Other Name: Hydroxychloroquine, chloroquine, lopinavir/ritonavir, etc."
45404718|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
45513610|NCT03673605|Drug|Warfarin|Warfarin in stroke prevention in patients with Mitral Stenosis and AF.
45404719|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
45404720|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
45513611|NCT02069886|Drug|deferasirox|125, 250, 500 mg dispersable tablets
45513612|NCT04311463|Drug|Paroxetine hydrochloride|Paroxetine hydrochloride will be administered.
45513613|NCT04311463|Drug|PAXIL (Paroxetine hydrochloride )|PAXIL will be administered.
45513614|NCT02203994|Device|"Duolith® SD 1 T-Top (Storz Medical AG, Switzerland)"|2000 pulses per muscle, energy level: 0.030 mJ/mm2, frequency: 4 Hz
45513615|NCT03070587|Behavioral|Positive Affect Training for SAD|The PAT-S protocol will teach the participants the basics of mindfulness and how to be aware of their physical sensation, thoughts, and emotion at present moment by a nonjudgmental way in breathing, standing, or eating. After two mindfulness sessions, lovingkindness meditation (LKM) will be introduced. The participants will be taught to identify and focus the positive feelings such as gratitude, love, kindness, peacefulness, or friendliness when they wish their benefactor and beloved ones who they feel grateful or respectful, and transfer these feelings first to themselves, then to a neutral individual, to people whom they dislike, and finally to all living beings.
45513616|NCT02065128|Other|Capsaicin cough challenge test|The capsaicin cough challenge testing will be conducted in the pulmonary function laboratory at SMH by a pulmonary function technologist. The test involves having the participant inhale increasing concentrations of capsaicin solutions and assessing their response. The tidal breathing method and solution preparation presented by Nejla, et al. 12 will be used to conduct this testing. The tidal breathing method is preferred to the alternative dosimeter method as it produces similar results with lower capsaicin concentrations thereby resulting in less throat irritation for the participant. The technique is detailed in the following sections.
45513617|NCT03678051|Behavioral|Treatment as Usual (TAU)|Standard of care residential treatment
46057327|NCT00728689|Drug|ST-246 Days 1 - 3|First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
45404721|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
45404722|NCT01589328|Other|Early Palliative care integrated with usual oncologic care|"Drug: The interventions consisted of the following:~(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education"
45404723|NCT03965208|Drug|Bivalirudin|titrated continuous infusion
45513618|NCT03678051|Behavioral|TAU+CBT4CBT|45-minute web-based modules covering core concepts to substance use treatment. The information is presented via graphics and voiceovers and key concepts are illustrated with brief videos depicting the material. Participants will be scheduled for a minimum of two sessions/week over the 3.5 weeks post-randomization (7 modules). These seven sessions will provide protected time to access the interventions, but the women will be able to access the modules and complete homework as much as they wish.
45513619|NCT01569503|Device|vagus nerve stimulation (VNS)|VNS therapy consists of an implanted pacemaker-like device that delivers mild, intermittently pulsed signals to the patient's left vagus nerve. Roughly the size of a small pocket-watch and weighing less than one ounce, the pulse generator is implanted in the patient's left chest area. A thin thread-like wire, attached to the generator, runs under the skin to the left vagus nerve in the neck
45513620|NCT04296565|Behavioral|Usual Care|Usual Care condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff
45513621|NCT04296565|Behavioral|WATER+CT|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
45513622|NCT03677895|Drug|Hyaluronic Acid|Hyaluronic Acid 2cc into subacromial bursa at weeks 0, 2 and 4
46057328|NCT00728689|Drug|ST-246 Days 11 - 13|Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
46057329|NCT02596243|Biological|GX-188E|1mg of GX-188E administered IM using EP device at day 0, week 4 and week 12.
46057330|NCT02596243|Biological|Placebo|0.5mL of Placebo administered IM using EP device at day 0, week 4 and week 12.
45404724|NCT03965208|Drug|Unfractionated heparin|titrated continuous infusion
45404725|NCT01083264|Drug|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: buttocks
45513623|NCT04295005|Drug|Empagliflozin|film coated tablet
45513624|NCT04295005|Drug|DPP-4i|film coated tablets
45513625|NCT04295005|Drug|Sitagliptin|film coated tablet
45513626|NCT04295005|Drug|GLP-1-RA|subcutaneous injection or tablet
45513627|NCT03174353|Drug|Lanreotide Prefilled Syringe|All patients enrolled in this study will receive SOMATULINE DEPOT 120 mg immediately prior to planned pancreatic resection. The pharmacist will dispense loaded syringes of the study drug. The single preoperative dose will be given in the pre-surgical center at the University of Washington by a trained health care professional. The study drug will be injected via the deep subcutaneous route in the superior external quadrant of the buttock.
45513628|NCT02260284|Other|Yaotong points acupuncture|Patients receive the treatments of Yaotong points penetration
45404726|NCT01083264|Drug|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: arm
45404727|NCT01083264|Drug|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: abdomen
45404728|NCT01083342|Drug|MTX, MVD, VIA|MTX: Methotrexate,Leucovorin MVD: Methotrexate,Vincristine,Dexamethasone VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)
45404729|NCT00129116|Biological|Hib-MenCY-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
45404730|NCT00129116|Biological|Hib-MenC-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
45404731|NCT00129116|Biological|Menjugate ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
45513629|NCT02260284|Other|the usual care|participants received no study-related care-just the care, if any, that they and their physicians chose: mostly massage and physical therapy visits and continued use of medications (mostly nonsteroidal anti-inflammatory drugs (NSAIDS))
45513630|NCT02260284|Other|standardized acupuncture|Patients were given to the standardized acupuncture groups. This prescription included six acupuncture points that are commonly applied for the treatment of CLBP (Bladder 23-bilateral, Bladder 40-bilateral, and Kidney 3-bilateral) on the low back and lower leg.
45513631|NCT03673449|Device|SilkBridge|SilkBridge is a biocompatible silk fibroin-based scaffold, which recruits the patients' own cells to remodel or regenerate the nerve, without pre-seeding of the scaffold nor biological/chemical treatments.
45513632|NCT05214235|Drug|Hypoglycemic Drugs|Patients were divided into metformin group and sitagliptin group according to the type of hypoglycemic drugs they took.
46057331|NCT02717793|Other|Strength testing|"isometric muscle strength~1RM measurement of muscle strength"
45404732|NCT00129116|Biological|Infanrix penta ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
46057332|NCT02710227|Other|(PSQI), (STQ).|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
45404733|NCT00129116|Biological|Infanrix hexa ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
45404734|NCT04276584|Device|Positive airway pressure|Three blocks of 10 deep inspiration followed by expiration against a positive airway pressure device of 10-15 cm of water pressure. Repeated three times. Estimated time of 3 minutes time.
45404735|NCT04276584|Other|Speaking loudly during about 3 minutes|A specified swedish text
45404736|NCT04276584|Other|Singing|Singing a Swedish song
45513633|NCT02204306|Genetic|TSER|TS gene will be genotyped for each patients prior to chemotherapy. Patients will be assigned to different arms according to specific TSER genotype.
45513634|NCT03439319|Device|MyndMove®|This FES therapy can be used as a short-term therapeutic intervention to help improve voluntary grasping function
45513635|NCT03439319|Other|Conventional Therapy|Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
45513636|NCT05208151|Other|Creative Drama Education|Effective Communication with Creative Drama in Health Course will be given to students for 2 hours a week for 14 weeks.
45513637|NCT03054363|Drug|Tucatinib in Combination with Palbociclib and Letrozole (Safety Cohort)|"Starting dose of combination therapy :~Tucatinib 300 mg PO BID Palbociclib 125 mg PO daily 21 day on, 7 days off Letrozole 2.5 mg PO daily"
45513638|NCT03054363|Drug|Tucatinib in Combination with Palbociclib and Letrozole|Subjects 11-20 Tucatinib 300 mg PO BID Palbociclib 75mg PO daily 21 days on followed by 7 days off Letrozole 2.5 mg PO daily.
45513639|NCT02199938|Other|Identification and characterization of molecular markers in musculoskeletal tumors|
46057333|NCT02594137|Procedure|Without watertight duraplasty|After standard craniectomy and dural opening, provided there is no brain contusions or hematomas requiring surgical evacuation, no watertight duraplasty is performed. The dura is left opened and the brain parenchyma is covered with Surgicel. Usual closure is then performed.
45404737|NCT00117156|Drug|Fludarabine|
45404738|NCT00117156|Drug|Rituximab|
45404739|NCT01083420|Drug|Minocycline|Minocycline 0.2% mouthwash
45404740|NCT01083420|Drug|Dexamethasone|Dexamethasone 0.01% mouthwash
45513640|NCT04080947|Drug|Control group|patients received matching-image placebo once daily at bedtime for 12 weeks.
45513641|NCT04080947|Drug|Montelukast group|patients received montelukast (10-mg chewable tablet) once daily at bedtime for 12 weeks.
45513642|NCT02208284|Drug|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
45513643|NCT02208284|Drug|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
45513644|NCT02208284|Drug|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
45513645|NCT02208284|Drug|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
45513646|NCT02208284|Drug|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
45513647|NCT02208284|Drug|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
45513648|NCT02066688|Drug|folic acid|Patients receive oral folic acid 1mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
45513649|NCT02066688|Drug|folic acid calcium vitamin D3|Patients receive oral folic acid 1mg + calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects .
45513650|NCT02066688|Drug|calcium|calcium 1200mg/d + vitamin D3 250 IU/d daily supplements
45513651|NCT05763251|Other|therapy duration|the standard-course arm will receive 14 days total of antifungal therapy and the short-course arm will only receive 7 days of therapy
45513652|NCT03671733|Drug|Liraglutide|The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards, 1.8mg per day, subcutaneous injection.
45513653|NCT03671733|Drug|Exenatide|10mcg once a day for 4 weeks increased to 10mcg twice a day for 8 weeks.
45513654|NCT03671733|Drug|Exenatide Microspheres for Injection|Exenatide 2 mg injection once weekly for 12 weeks.
45513655|NCT02200016|Procedure|Ultrasound guided short axis (SAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the short axis of the sciatic nerve behind the knee.
45513656|NCT02200016|Procedure|Ultrasound guided long axis (LAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the long axis of the sciatic nerve behind the knee.
45513657|NCT02200016|Device|B Braun Contiplex S catheter|
45513658|NCT03119363|Device|AYO light glasses (Experimental)|The AYO does not contain UV or infra-red light; the light spectrum begins at approximately 420nm. The circadian-effective AYO is programed at over 100 lux with 470nm frequency and irradiance of 250 qW/cm2, which is 100% intensity level. Irradiance over lux itself with AYO light glasses is believed to be more representative due to light frequency and proximity to the eye. Traditional Lightbox usual measure is Lux , AYO can be seen as comparable to 1,000 lux light box. The device is classified as a device that is safe for the eyes in accordance with the international standard IEC 62471 and is independently certified by TÜV Rheinland. AYO complies with the EU's CE marking (CE EMC EN 55014, EN 61000-4-3) as well as other national regulatory directives. AYO also complies with the United States of America's FCC marking (FCC Title 47, Chapter 1, Part 15, Class B FCC VOC: 47 CFR PART 15 OCT, 2016. CLASS B ANSI C 63.4: 2014) as well as other national marking regulatory directives.
45513659|NCT03119363|Device|AYO light glasses (Comparator)|The comparison group will wear the same AYO glasses, but with a circadian ineffective (sham) light. The circadian-ineffective (sham) is programed at 1% intensity, therefore according to our calculation and checks it is below circadian threshold of 2 lux as specified.
46057334|NCT02710149|Biological|Anti-CD20-CAR-transduced T cells|Patients receive autologous-derived CD20-targeted CAR-T cells on day 1, 2 after receiving lymphodepleting chemotherapy.
45404741|NCT01083498|Device|Ablative fractional laser therapy|10,600 nm ablative fractional laser Irradiance: 10 mJ/microbeam. Coverage: 35-45%. Number of treatment sessions: 3
45404742|NCT00096954|Drug|omalizumab (Xolair)|Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of > 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site.
45404743|NCT00096954|Drug|placebo|The dose of placebo consisting of sucrose, L-histidine, L-histidine hydrochloride monohydrate, and polysorbate 20 was administered by subcutaneous injection every 2 or 4 weeks.
45404744|NCT00096486|Drug|everolimus|
45513660|NCT02070042|Drug|Omega 3 Fatty Acid|Trunature® Triple Strength Omega-3, given twice a day. Each capsule contains 647 mg Eicosapentaenoic Acid (EPA) and 253 mg Docosahexaenoic Acid (DHA).
45513661|NCT02070042|Drug|Placebo|Placebo capsules (olive oil) twice a day
45513662|NCT04059081|Drug|Obinutuzumab|"Obinutuzumab is provided as single-use vials for intravenous administration only. Obinutuzumab 1000mg fixed dose will be administered Chlorambucil would be provided as oral tablet with dose of 0.5mg/kg~Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, until 6 cycles."
46057335|NCT02592811|Procedure|ERCP|Common bile duct cannulation with a cannulation catheter
46057336|NCT02592811|Procedure|Endoscopic Sphincterotomy|Endoscopic large sphincterotomy
46057337|NCT02592811|Device|Large Balloon Dilatation of Oddi Sphincter|Large Balloon Dilatation : with the HERCULES, Cook 12, 15, 18 or 20 mm of diameter (adapted to stone diameter)
45404745|NCT00096486|Drug|gefitinib|
45404746|NCT00116844|Drug|Valaciclovir|Valtrex 1g once daily
45404747|NCT00116844|Drug|Placebo|placebo
45513663|NCT03671655|Device|Drug-eluting stent|Drug eluting stent which are nitinol stent coated with Paclitaxel drug
45513664|NCT03671655|Device|Bare metal stent|Bare metal stent is Nitinol alloy self expandable stent. Other Names: Bare metal stent Nitinol stent SMART Stent Viabahn stent
45513665|NCT02204384|Other|HFD Meal: High fiber from food|High amount of fiber from diet food sources (HFD; total fiber 9.7g; soluble fiber 5.4g)
45404748|NCT03963336|Drug|LMWH|Subcutaneous LMWH 1mg/kg/day for 2 weeks
45404749|NCT03963336|Drug|acetazolamide|Carbonic anhydrase inhibitor 1-2g/day for 6 months
45513666|NCT02204384|Dietary Supplement|HFS Meal: High fiber from supplement|High amount of soluble fiber from guar gum supplement (HFS; total fiber 9.1g; soluble fiber 5.4g) - sachet 5 g Fiber Mais, Nestlé Brasil, São Paulo, BR
45513667|NCT02204384|Other|UF Meal: usual amount of fiber|Usual amount of fiber (UF; total fiber 2.4g; soluble fiber 0.8g)
45404750|NCT00128492|Drug|AZLI 75 mg two times a day (BID)/ three times a day (TID)|
45404751|NCT03966794|Device|Epidural Electrical Stimulation|Participants had finished the previous clinical trial with functional neural regeneration collagen scaffold transplantation, and will receive epidural electrical stimulation of the spinal cord in this group.
45513668|NCT01377311|Procedure|Transplant of cultured limbal stem cells on cornea|Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
45404752|NCT03966794|Combination Product|Functional scaffold & Epidural Electrical Stimulation|Participants with acute complete SCI or chronic complete SCI will receive functional neural regeneration scaffold transplantation and epidural electrical stimulation of the spinal cord.
45404753|NCT00132314|Drug|IM risperidone|long-acting injectable risperidone
45404754|NCT00132314|Drug|oral antipsychotic medication|doctor's choice (excluding other long-acting injectable medications but not specifying any particular oral agents or dosages)
45404755|NCT04539262|Drug|Remdesivir (RDV)|Administered as an aerosolized solution
45513669|NCT02208440|Procedure|Best Repair of torn Rotator Cuff|
45404756|NCT04539262|Drug|Placebo|Administered as an aerosolized solution
45404757|NCT03754738|Device|Balloon guide catheter|Use a balloon guide catheter in the mechanical thrombectomy
45404758|NCT03754738|Device|Non-balloon guide catheter|Use a non-balloon guide catheter in the mechanical thrombectomy
45404759|NCT05459818|Device|Viabahn implanted|An individual patient data analysis obtained from databases used in prospective studies that published results of patients treated with the latest generation heparin-bonded Viabahn in the femoropopliteal artery.
45404760|NCT03702010|Device|spinal cord stimulation conventional|If the patient has been assigned to the branch of the CME control group, after mapping the search for the pain zone, the neurostimulator is programmed to conventional stimulation.
45404761|NCT03702010|Device|spinal cord stimulation experimental|If the patient has been randomized to the branch of the EME experimental group, after a mapping of the search for the pain zone, a 90% subthreshold stimulation is programmed.
45404762|NCT04538170|Behavioral|pain after surgery|
45404763|NCT04537234|Biological|High-Dose Quadrivalent Influenza Vaccine|"Pharmaceutical form: Suspension for injection in pre-filled syringe,~Route of administration: IM"
45404764|NCT04537234|Biological|Standard-Dose Quadrivalent Influenza Vaccine|"Pharmaceutical form: Suspension for injection in pre-filled syringe,~Route of administration: IM"
45404765|NCT04537078|Drug|Duphaston|will be used for pituitary suppression in the first arm:20 mg/day will be started from the first day of the ovulation induction in the follicular phase and in the luteal phase will be started the next day after oocyte pickup at 20 mg/day.
45404766|NCT04537078|Drug|Gonadotropin|will be used for controlled ovarian hyperstimulation in both arms
45404767|NCT04537078|Drug|Cetrotide Injectable Product|will used in the second arm for pituitary suppression in the second group daily when the biggest oocyte reaches size 14 mm till ovulation triggering
45513670|NCT02208440|Device|InSpace™ system|
45513671|NCT03671577|Behavioral|Building Closer Friendships|Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships
45513672|NCT02200094|Drug|Low dose of Telmisartan, once daily|
45513673|NCT02200094|Drug|High dose of Telmisartan, once daily|
45513674|NCT01370538|Drug|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
45513675|NCT03623295|Other|Blood sample|Blood withdrawal.
45513676|NCT03623295|Other|Questionnaire|Online questionnaire about the bleeds that patients experienced in the past.
45513677|NCT03623295|Other|MRI-imaging|MRI imaging of joints.
46057338|NCT02592811|Procedure|Stone extraction|After dilatation, extraction of stones is done with dormia basket or extraction balloon and if not possible a mechanical lithotripsy is performed
45513678|NCT03623295|Other|Physical examination|Physical examination of joint status.
45513679|NCT03248297|Drug|Azithromycin|Azithromycin tablet
46057339|NCT02717091|Drug|FOLFIRINOX|
45513680|NCT03248297|Drug|Azithromycin and amoxicillin|azithromycin and amoxicillin
45513681|NCT03248297|Drug|Placebo|Placebo tablet
45851363|NCT02992314|Device|Placebo|Placebo formulation with out the active ingredients
45404768|NCT04537078|Drug|Decapeptyl|will be used for ovulation triggering.in the first arm:in a dose of 2 ampules of 0.2 mg will be administered when leading follicle >18 mm in diameter. in the second arm:in a dose of 2 ampules 0.2 mg will be administered when leading follicle >18 mm in diameter in the first cycle only.
45404769|NCT04537078|Drug|Chorionic Gonadotropin|will be used in the second cycle of the second arm for ovulation triggering in a dose of 10,000 IU when the leading follicle >18 mm in diameter.
45513682|NCT02208518|Procedure|endoscopy ultrasound elastography|During a endoscopy ultrasound (EUS) procedure, in patients with normal pancreas at EUS, elastography was performed using a software already included in Hitachi-Avius machine, pressing the button and obtaining colors and pressure curve given by the software
45513683|NCT02208518|Device|EUS-elastography|
45513684|NCT02199626|Device|Second generation of colon capsule endoscopy (GIVEN IMAGING)|
45513685|NCT02208596|Drug|pentazocine|Every patient enrolled in the study will be given 15 mg pentazocine before induction.
45513686|NCT02208596|Drug|propofol|
45513687|NCT02208596|Drug|Etomidate|
45513688|NCT02070120|Drug|Mitomycin C|Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.
45699098|NCT01106326|Behavioral|Intervention|"Teens participating in this study will have:~directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study~three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications)."
45699099|NCT03463434|Device|Air Fluidized Therapy|AFT bed used for pressure injury treatment
45404770|NCT04537078|Drug|Combined Oral Contraceptive|luteal phase priming from day 21 of the cycle before controlled ovarian stimulation for one week .
45404771|NCT04537078|Drug|Cyclo-Progynova|Starting from cycle Day 3 of the intented cycle for thawed embryo transfer, patients will receive the white tablets of Cyclo-Progynova daily. From Day 10 onwards, endometrium growth will be monitored by transvaginal ultrasound.
45404772|NCT04537078|Drug|progesterone|in the intended cycle of embryo transfer when endometrial thickness ≥ 7 mm. Progesterone administration (as 800 mg/day vaginal suppositories per day and 100 mg ampule IM every other day) will be continued until pregnancy testing 18 days after embryo transfer and in pregnant cases will continued till the 12 weeks of gestation.
45513689|NCT02070120|Procedure|Surgical Management|Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation.
45513690|NCT03673215|Drug|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class A
45513691|NCT03673215|Drug|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
45513692|NCT03673215|Drug|Placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
45513693|NCT03673215|Drug|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 150 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
45513694|NCT03673215|Drug|Placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
45513695|NCT03673215|Drug|recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
45513696|NCT03673215|Drug|placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
45699100|NCT03463434|Device|Continuous Low Pressure-LAL|Continuous Low Pressure/Low Air Loss Mattress for Pressure injury treatment
45699101|NCT05321862|Drug|[68Ga]Ga-PentixaFor|Tomography by Emission of Positons (PET) with the radiopharmaceutic [68Ga]Ga-PentixaFor
45699102|NCT03463356|Behavioral|Shame Intervention|In the Shame Intervention, participants will meet with a therapist and learn to: 1) Recognize the experience of shame, 2) Understand the connection between shame and social anxiety, 3) Identify shame triggers and vulnerabilities, 4) Identify the thoughts and behaviors that keep participants stuck in shame, and 5) Learn how to use new, healthier thoughts and behaviors that will help participants move through and decrease shame.
45513697|NCT03673215|Drug|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 450 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
45513698|NCT03673215|Drug|placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
45513699|NCT02200172|Other|Melatonin|Sublingual 3mg non-animal synthetic source melatonin daily at 21.00 hours (±1 hour).
45699103|NCT03463278|Diagnostic Test|Pregnancy Rate|The pregnancy and live birth rate according to number of blastocysts formed in our three groups
45699104|NCT03463200|Other|Functional elastic tape tensioned|Application of Kinesio Taping with tension in the erector spine muscles.
45513700|NCT02200172|Other|Placebo|
46057340|NCT02717091|Drug|gemcitabine + nab-paclitaxel|
45513701|NCT03673137|Device|Irreversible electroporation|During the IRE process, we employed a CT scanner and an ultrasound system to guide percutaneous insertion of the electrode probes (one main electrode and one to three standard electrodes were used per treatment). The electrode number, electrode-insertion mode and intraoperative parameters were decided upon during pretreatment planning. The IRE parameters were visually simulated in the pulse generator and set up as follows: energy was applied at 1500 V/cm for 90 ms/pulse for a total of 7-9 pulses. After an initial testing pulse train was discharged to establish the best voltage value, the remaining 80 pulses were completed in 1-2 minutes. After ablation, we confirmed completion of IRE by measuring real-time resistance or current changes, in addition to intraoperative ultrasound and CT.
45404773|NCT04532164|Drug|Butenafine HCl 1% (BAY1896425) - Induction Phase|To each of two test sites, approximately 20 μl/cm^2 of the Butenafine HCl 1% was applied directly to the skin and covered with a 25 mm Hilltop chamber with a Webril pad (2 cm in diameter, within an area of approximately 3 cm^2), and tape was applied over the chamber to secure the occlusive patch to the skin. On the next day, the chambers were removed and both test sites were lightly wiped. Approximately 2 μl/cm^2 of Butenafine HCl 1% was reapplied directly to the skin and lightly spread over the treated irradiated test site. The treated non-irradiated test site did not receive a similar reapplication. Between 5 and 15 minutes after application, the treated irradiated test site was irradiated with two times the subject's Minimal Erythema Dose (MED). Evaluation of the test sites occurred two days after the irradiation. This procedure was repeated two times per week for three consecutive weeks for a total of 6 induction exposures per test site.
45404774|NCT04532164|Drug|Butenafine HCl 1% (BAY1896425) - Challenge Phase|5 μl/cm^2 of the Butenafine HCl 1% was applied directly to each of the two virgin sites (treated sites) adjacent to the induction patch sites and covered with Hilltop chambers with Webril pad and tape was applied over the chambers to secure the occlusive patches to the skin. Two additional sites with no Butenafine HCl 1% (untreated sites) were also occluded. Sites were at least 2.5 cm apart. The patches were removed 24 hours later and the sites were lightly wiped. Test sites were evaluated. Butenafine HCl 1% (2 μl/cm^2) was applied to the treated irradiated site. After 15 minutes, the treated irradiated site and the untreated irradiated site were irradiated with 0.5 MED of UVA/UVB irradiation followed by 10 Joules/cm^2 of UVA from a xenon arc solar simulator equipped with a Schott WG345 to eliminate UVB radiation. The remaining sites served as the treated non-irradiated site and untreated non-irradiated site.
45513702|NCT03673137|Drug|Gemcitabine|Gemcitabine hydrochloride (Qilu pharmaceutical [Hainan] Co., Ltd. Haikou, China] was administered by intravenous infusion at a dose of 1000 mg/m2.
45513703|NCT02066766|Other|No treatment given|Patients will fill out a questionnaire by interview.
45513704|NCT02204540|Behavioral|Mock study intervention|Participants will swallow a pill and consume food in a mock research study, while their performance of the task is being monitored.
45513705|NCT02066844|Drug|Celestone|2cc
45513706|NCT02066844|Drug|Lidocaine|5cc
45513707|NCT03669783|Drug|treatment Vincristin|1 x Vincristin 1,5mg/m² iv bolus day 1 in week 1,2,3,4,5,6
45513708|NCT03669783|Drug|treatment Actinomycin-D|1 x Actinomycin D 45µg/kg iv bolus day 1 in week 1, 3, 5
45513709|NCT03669783|Drug|treatment Doxorubicin|1 x Doxorubicin 50mg/m² 6h Infusion day 1 in week 1,5
45513710|NCT03669783|Drug|treatment Carboplatin|1 x Carboplatin 200 mg/m² 1h infusion day 1,2,3 in week 1,4
45513711|NCT03669783|Drug|Etoposide|1 x Etoposide 100mg/m² 1h infusion day 1,2,3 in week 1,4
45513712|NCT02204618|Device|cochlear implantation|
45513713|NCT02204618|Other|6 months initial abstention|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
45513714|NCT02067078|Drug|Dexamethasone 4 mg + Clonidine 75 microgram + Marcaine 90 mg + Adrenaline 90 microgram|Dexamethasone 4 mg Clonidine 75 microgram Marcaine 90 mg Adrenaline 90 microgram
45513715|NCT02067078|Drug|Dexamethasone 2 mg + Clonidine 37,5 microgram + Marcaine 45 mg + Adrenaline 45 microgram|Dexamethasone 2 mg Clonidine 37,5 microgram Marcaine 45 mg Adrenaline 45 microgram
45513716|NCT02067078|Drug|Ropivacaine + Toradol + Adrenaline|Ropivacaine 300 mg + Toradol 45 mg + Adrenaline 0,75 mg
45513717|NCT03673059|Drug|OTC Eczema Moisturizer Regimen|Subjects were assigned to use an OTC, oatmeal-containing eczema therapy moisturizing cream twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group B) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
45513718|NCT03673059|Other|Cosmetic Moisturizer Regimen|Subjects were assigned to use a non-fragranced, dry skin daily moisturizer twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group A) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
45513719|NCT05461235|Drug|Pembrolizumab|2mg/kg or 200mg,iv,q3w
45513720|NCT05461235|Drug|Nivolumab|3mg/kg or 240mg,iv,q2w
45513721|NCT05461235|Drug|Sintilimab|200mg,iv,q3w
45513722|NCT05461235|Drug|Toripalimab|3mg/kg or 240mg,iv,q2w
45513723|NCT05461235|Drug|Camrelizumab|200mg,iv,q2w or q3w;3mg/kg,iv,q3w
45513724|NCT05461235|Drug|Tislelizumab|200mg,iv,q3w
45513725|NCT05461235|Biological|NK-Cell or DC-Cell|50ml of peripheral blood was collected 1 day before the dosing cycle for in vitro isolation and amplification of DC and NK cells; the first transfusion of DC and NK cells (not less than 1x10^6 cells/Kg) was completed on day 14.
45513726|NCT02204696|Procedure|Tonsillectomy|Study participants will be scheduled for tonsillectomy based on clinical indications, with the need for surgery determined prior to study enrollment and not based on study enrollment.
45699105|NCT03463200|Other|Functional elastic tape non-tensioned|Application of Kinesio Taping without tension in the erector spine muscles.
45699106|NCT03463200|Other|Rigid Tape|Application of Micropore tape in the erector spine muscles.
45513727|NCT02070198|Drug|Long acting FSH and GnRH antagonist|Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
45513728|NCT02070198|Drug|Daily FSH and GnRH antagonist|Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
45404775|NCT01561924|Drug|eptacog alfa (activated)|Subjects will be called to attend the clinic in a non-bleeding state. Blood samples will be drawn for thromboelastogram profiling and will be in-vitro spiked with different doses of activatated recombinant human factor VII.
45513729|NCT02070198|Drug|Triptorelin and recombinant FSH|Women in Triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of Triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day untill the day of HCG administration.
45513730|NCT03672981|Behavioral|Exercise Intervention|Undergo resistance training program and cardiovascular exercise
45513731|NCT03672981|Other|Quality-of-Life Assessment|Ancillary studies
45513732|NCT03672981|Other|Questionnaire Administration|Ancillary studies
45513733|NCT03672981|Behavioral|Telephone-Based Intervention|Participate in phone calls with exercise physiologist
45513734|NCT02918201|Drug|Tranexamic Acid|TXA 25 mg/ml applied topically to moisten the wound
45513735|NCT02918201|Drug|saline|Saline solution (0.9% NaCl) applied topically to moisten the wound
45513736|NCT02208674|Other|Protocolized, pharmacist-delivered CKD Action Plan|The CKD Action plan protocolizes the screening and treatment of primary risk factors for CKD progression and cardiovascular disease among individuals with stage G3A CKD
45513737|NCT03672903|Device|Weight Vest|A vest with added weights up to a maximum of 15 kg.
45513738|NCT02067156|Drug|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
45513739|NCT04058613|Drug|ALB Protein, Human|Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy
45513740|NCT04058613|Other|placebo|placebo
45513741|NCT02067234|Other|Routine Care/Education|Nursing staff will spend time educating the patient and family about therapy involved in medically treating atopic dermatitis. This might include different topical therapy to use as well as how often to apply and when to apply.
45513742|NCT02067234|Behavioral|Psychoeducation/Coping Prevention|In addition to routine care, the psychologist will meet with family to review psychoeducation about the mind-body connection as well as introduce and review different strategies regarding coping with stress, sleep strategies, and behavior strategies.
45513743|NCT02801747|Behavioral|Heart to Heart2 (HTH2)|The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.
45699107|NCT04212780|Device|Medtronic Summit Rechargable (RC)+S|Dual channel closed-loop pulse generator with connection to both new DBS leads for deep stimulation of VIM vs VO
45699108|NCT04212780|Procedure|ipsilateral thalamic (VIM+VO) DBS|Implantation of two new ipsilateral thalamic (VIM+VO) DBS
45699109|NCT04212780|Procedure|standard ET DBS|Single Lead VIM
45699110|NCT04212780|Procedure|ipsilateral VO|second lead in the ipsilateral VO
45699111|NCT01106950|Biological|Natural Killer Cells|Given by infusion on Day 0. The product is T cell-depleted (CD3-) and B cell-depleted (CD19). Target dose for infusion is < or = 8 x 10^7 nucleated cells/kilogram.
45699112|NCT01106950|Drug|Fludarabine|Administered as a 1 hour intravenous infusion once a day for 5 doses beginning on day -6.
45404776|NCT00116688|Biological|Romiplostim|Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
45404777|NCT04531540|Drug|Butenafine HCl 1% (BAY1896425)|Approximately 0.2 g of cream containing butenafine HCl 1% were applied to the upper back skin.
45699113|NCT01106950|Drug|Cyclophosphamide|Administered as a 2 hour intravenous infusion with high volume fluid flush and mesna per institutional guidelines on day -5 and -4 one hour after fludarabine infusion. (Day -4 administration may be omitted if patient has had a transplant in the previous 4 months.)
45699114|NCT01106950|Drug|Denileukin diftitox|12 ug/kg/day will be administered on day -1 and day -2 intravenously.
45699115|NCT01106950|Procedure|Donor lymphapheresis|Day -1 before planned NK cell infusion, the donor will undergo lymphapheresis (Removal of lymphocytes from donated blood, with the remainder of the blood retransfused into the donor).
45699116|NCT01106950|Drug|IL-2|Administered after NK cell infusion, 10 million units every other day for a total of 6 doses. (Patients weighing less than 45 kilograms will receive a dose of 5 million units/m^2 every other day for 6 doses).
45699118|NCT01107730|Drug|Vitamin C|VitC intravenously (2g/day [500mgX4] for 2 days prior to surgery, and postoperatively for 4 days
45404778|NCT04799782|Drug|Mirtazapine|15 mg dose before bed-time
45404779|NCT04799782|Drug|Placebo|One placebo pill before bed-time
45404780|NCT04790812|Drug|Celecoxib|Single, preemptive oral dose 200mg of celecoxib. A cyclooxygenase-2 (COX-2) selective inhibitor for pain management. A COX-2 selective nonsteroidal anti-inflammatory drug (NSAID).
45404781|NCT04790812|Drug|Acetaminophen|Single, preemptive oral dose 1000mg of acetaminophen. An over-the-counter medication for pain management.
45513744|NCT03533270|Procedure|Urethroplasty|Surgical repair of Urethral injury
45699119|NCT01107730|Drug|L-Carnitine|L-Carnitine intravenously (2 gr/day [1grX2] for 2 days prior to surgery, and postoperatively for 4 days
45699120|NCT01107730|Drug|Placebo|Placebo
45699121|NCT03463122|Device|field of regard-focused visual exploration therapy|field of regard-focused visual exploration therapy in addition to conventional therapy
45699122|NCT03463122|Other|conventional therapy|conventional therapy for stroke rehabilitation
45404782|NCT04790812|Drug|Placebo|A capsule with no active ingredients designed to mimic the appearance of the acetaminophen capsule to ensure blinding of patients and care providers.
45513745|NCT03671499|Behavioral|Social Cognitive Theory based text messages|Participants receive daily text messages and bi-weekly newsletters with information about reducing sitting behavior and increasing physical activity.
45513746|NCT02070432|Drug|LUZ11|LUZ11 i.v. administration followed by laser light irradiation
45513747|NCT02208752|Other|Exercises|exercise program on strengthening the rotator cuff muscles and motor control of the scapula
45513748|NCT02067312|Other|Thai massage|
45513749|NCT02200406|Drug|Desvenlafaxine|All subjects will receive 50 mg of the medication during week 1 and 2, then 50-100 mg (based on the psychiatrist judgment) for the following 6 weeks. Subjects who experience significant adverse reactions with the 100mg dose during weeks 2 to 4 could return to the lower dose of 50 mg if judged clinically appropriate by the study psychiatrist.
45513750|NCT03782298|Device|Spyromite, Dynomite, Raptomite, Footprint Ultra PK SL|Observational, post-market, clinical follow-up study
45513751|NCT02204852|Drug|Iloprost+eptifibatide|
45513752|NCT02204852|Drug|Placebo|
45513753|NCT02071836|Behavioral|Right Turns web application|
45513754|NCT02071836|Behavioral|Treatment as usual|
45513755|NCT02204930|Drug|PeproStat|A solution of PeproStat containing up to 9.25mg protein soaked immediately prior to use onto a Gelita-Spon® gelatin sponge.
45513756|NCT02200484|Behavioral|Combined parent training and obesity prevention program|
45513757|NCT02200484|Behavioral|Wellness program (active contact control)|
45513758|NCT02070510|Drug|semaglutide|For oral administration once daily. Doses of 5 mg and 10 mg, respectively, will be given for 7 days followed by 20 mg administered on days 43-84.
45513759|NCT02070510|Drug|lisinopril|For oral administration. A single dose of 20 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 1, 15 and 71).
45513760|NCT02070510|Drug|warfarin|For oral administration. A single dose of 5 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 8, 22 and 78).
45513761|NCT02070510|Drug|placebo|A single dose of SNAC is administered conconmitantly with victim compounds (days 15 and 22).
45404783|NCT03754504|Dietary Supplement|Cranberry powder|3 capsules /day of whole cranberry powder (500mg/each)
45404784|NCT03754504|Dietary Supplement|Placebo|3 capsules/day of a placebo comparator
45513762|NCT02258126|Other|Multidisciplinary intervention program|"Exercise group:~The intervention program includes an education program promoting healthy dietary habits and physical activity (nutritionist), supportive therapy and behavioral advice for the family to improve nutrition and physical activity (psychologist) (2 times/month, for children and parents) and supervised exercise (3 times/week, 90 mins) program for 6 months."
45513763|NCT02070666|Behavioral|Protective mechanical ventilation|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode; a minimum of 5 cmH2O level of support should be used; in case the resulting tidal volume exceeds 6 mL/kg PBW this is accepted. This is not a reason to use more sedation and/or muscle relaxants, or to switch the ventilator to a controlled mode of ventilation).~Tidal volume: 6 mL/Kg PBW, decreasing 1 mL/kg PBW each step if necessary (steps of 5 minutes), to maintain plateau pressure < 25 cmH2O until a minimum tidal volume of 4 mL/Kg PBW, unless the patient suffers from severe dyspnea or unacceptable acidosis.~Fraction of inspired oxygen inspired oxygen fraction (FiO2) > 0.21 to maintain oxygen saturation 90-92%.~PEEP ≥ 5 cmH2O, and optimized to maintain Oxygen saturation (SpO2) 90-92% (left to the discretion of the attending physician).~Plateau pressure ≤ 25 cmH2O"
45513764|NCT02070666|Behavioral|Control group|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode, with the level of support adjusted to reach tidal volumes minimum of 8 mL/kg predicted body weight PBW; if it is not possible, the data collection should be continue and an intention-to-treat analysis will be done).~Tidal volume: minimum 8 mL/kg PBW. It is possible to increase until 10 mL/kg PBW unless plateau pressure increases above 25 cmH2O.~· FiO2 > 0.21 to maintain oxygen saturation 90-92%.~PEEP ≥ 5 cmH2O, and optimized to maintain SpO2 90-92% (left to the discretion of the attending physician).~Plateau pressure ≤ 25 cm H2O."
45513765|NCT02070666|Other|Dead space|Volumetric capnography will be used. Dead space (Vd/Vt) measurements will be taken at baseline and daily after initiation of mechanical ventilation. Nursing and respiratory care activities (including changes to ventilator settings) will be suspended for at least 5 minutes prior to all Vd/Vt measurements.
45513766|NCT02200562|Drug|ipilimumab and dabrafenib|
45513767|NCT02205008|Procedure|surgery|Total or subtotal gastrectomy with D2
45513768|NCT02205008|Drug|adjuvant systemic chemotherapy|adjuvant systemic chemotherapy with S-1 (<1.25m2:40mg, 1.25-1.5m2:50mg, >1.5m2:60mg, bid)
45513769|NCT02205008|Drug|Early postoperative intraperitoneal chemothgerapy|"operation day: 0.9％ saline solution 1L plus mitomycin C 10 mg/m2~1 - 4 postoprative day: 0.9％ saline solution 1L plus 5-FU 700 mg/m2 plus sodium bicarbonate 50 mEq"
45513770|NCT02067546|Device|Experimental toilet seat|
45513771|NCT02067546|Device|Standard toilet seat|
45513772|NCT02067624|Other|Thai massage|
45513773|NCT02208908|Other|Evaluation of the oral conditionand proper care|An accurate assessment of the oral condition and proper care will be carried out on day 2 (J2) of hospitalization and repeated on the day of hospital discharge by the nurse detached service, regardless of caregivers.
45513774|NCT02072070|Biological|TissueGene-C|TissueGene-C at 1.8 x 10^7 cells
45513775|NCT02072070|Drug|Placebo|Placebo control(Normal Saline)
45513776|NCT02205086|Other|Diagnosis|"Unaided: The testers will record a differential diagnosis consisting of a list of diseases and their ranking and a prioritized list of test orders, as well as the most appropriate referral for further evaluation and treatment of the patient.~Aided: Then testers will enter the case into diagnostic decision support software and after getting advice from the software, the testers will record the same information as in Unaided, but allowing for the possibility that responses could differ as a result of using the software."
45513777|NCT02200640|Drug|High dose of Micardis®, once daily|
45513778|NCT02200640|Drug|Low dose of Micardis®, once daily|
45513779|NCT02200640|Drug|Low dose of COZAAR®, once daily|
45513780|NCT02200640|Drug|High dose of COZAAR®, once daily|
45513781|NCT02200640|Drug|Placebo|
45513782|NCT02067702|Procedure|Limb Cooling Assessment of ET|The non-pharmacological treatment assessments of limb cooling will take place for the subjects which will include the upper limbs. Both clinical and physiological recordings will be measured for a difference in tremors at three different temperatures. 1)baseline assessment maintaining a normal body temperature (96-98°F). 2) at a temperature of 59°F and 3) at a temperature of 80°F for a period of 10 minutes. The clinical assessments will include the Tremor Rating Scale (TRS), Handwriting Assessment Battery (HAB) and the Functional Dexterity Test (FDT). In addition, the Bagnoli and Trigno EMG systems to record surface EMG signals from muscles and accelerometer readings.
45513783|NCT02200718|Biological|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA BV5S2, BV6S5 BV13S1
45513784|NCT02200718|Biological|IFA Incomplete Freund's Adjuvant|IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion
45851364|NCT02992002|Other|Fluid Challenge|Infusion of a standardized amount of crystalloid solution (500 ml) to assess fluid responsiveness by means of changes in cardiac output, assessed by transpulmonary thermodilution.
45404785|NCT03697252|Drug|Xanomeline and Trospium Chloride Capsules|Xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-34 unless the subject is experiencing adverse events from the xanomeline 100 mg/trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/trospium 20 mg depending on clinical response and tolerability. Dosing must not change after Visit 7 of the study (at 21 ± 2 days of dosing) and may be decreased for tolerability reasons no more than once during the study.
45404786|NCT03697252|Drug|Placebo Capsules|Placebo Capsules
45404787|NCT03701074|Drug|Ibuprofen and acetaminophen|Intravenous ibuprofen given concomitantly with oral acetaminophen
45513785|NCT02070900|Device|POC CD4|Point of Care device for CD4 count testing (to be used as a clinical monitoring tool)
45513786|NCT02070900|Other|Programmatic Mentoring|Programmatic Mentoring aimed at messaging around CD4 count to encourage retention on lifelong ART for PMTCT patients, administered by trained clinical mentors
45513787|NCT02208986|Drug|Triptorelin|Triptorelin is given by s.c injection for ovulation triggering.
45513788|NCT02200796|Other|Control Meal|High carbohydrate meal
45513789|NCT02200796|Other|Low Protein Meal|Omelet with 15 g of protein
45513790|NCT02200796|Other|Moderate Protein Meal|Omelet with 30 g of protein
45513791|NCT02200796|Other|High Protein Meal|Omelet with 45 g of protein
45513792|NCT02067780|Drug|Levofloxacin 500mg|One tablet per day for 7days.
45513793|NCT02205164|Drug|Palonosetron + Aprepitant|Aloxi 0.25mg Emend 125/80/80 mg
45513794|NCT02205164|Drug|Palonosetron|Aloxi 0.25mg
45513795|NCT02072304|Behavioral|web-based CBT|A cognitive behavioral program in 8 weeks that will provide participants with the following: online interactive tools to do their homeworks and guidance on using cognitive and behavioral strategies to help reduce depressive symptoms, information about the depressive symptoms and cognitive behavioral therapy
45513796|NCT02072304|Behavioral|supportive care|supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks with the following: psychoeducation about depression, stigma of mental illness, distraction technique, emotional regulation, active scheduling.
45513797|NCT02257814|Behavioral|Incredible Years Teacher Training|
45513798|NCT02257814|Behavioral|Preschool PATHS|
45513799|NCT02257814|Behavioral|Tools of the Mind|
45513800|NCT03559998|Other|lecture|"Empathy (1 hour)~Doctor- patient relationship (1, 5 hour)"
45513801|NCT03559998|Other|Simulation using Role play|"serious illness announcement~abuse demand management~reticent patient management"
45513802|NCT03559998|Other|Discussion group|Share about clinical work experience and elaboration about psychoaffective and relational challenge
45513803|NCT03559998|Other|Simulation using Simulated patient|"HIV announcement~Refuse of antibiotic prescription"
45404788|NCT03701074|Drug|Ibuprofen and placebo|Intravenous ibuprofen given concomitantly with oral placebo
45513804|NCT02076282|Other|1 MRI scan|"For healthy volunteers: 1 MRI scan without contrast~For patients: 1 MRI scan with contrast"
45513805|NCT02200952|Drug|recombinant LH|recombinant LH twice/day for 10 days from pick up
45851365|NCT02992158|Behavioral|behavioral activation|
45513806|NCT02071212|Drug|Ticagrelor|Loading dose 180 mg . Maintainance dose 90 mg BID
45851366|NCT02992158|Behavioral|treatment-as-usual|psychotherapy (and potentially medication) as part of treatment-as-usual provided in a community mental health center
45851367|NCT02991768|Drug|Entocort|A corticosteroid that decreases levels of inflammatory cytokines.
45851368|NCT02991768|Drug|Placebos|Placebo is matched to the study drug.
45513807|NCT03396770|Procedure|Standard clinical routine|Patient management is carried out according to the usual service protocol
45513808|NCT03396770|Procedure|Nephrocheck test|"Nephrocheck® test is realized 4 hours after the end of the cardiopulmonary bypass~If the test is positive, hemodynamic evaluation is carried out and adapted therapy to result of this evaluation is initiated.~If the test is negative, patient management is carried out according to the usual protocol.~A second test is realized 6 hours after the first test whatever the result of it."
45404789|NCT03757468|Device|orthodontic - maxillary expansion|After appliance placement, the screw (hyrax or leaf type) will be activated until overcorrection. Expansion will be considered adequate when the occlusal surface of the first maxillary palatal cusp contact the occlusal surface of the mandibular first molar facial cusp. When will be achieved, the expander will stay in place for 10 months.
45404790|NCT03754348|Radiation|PET scan with tracer injection [18F] DPA-714|the subject will receive a dose of 3.5MBq / kg intravenous (in bolus) more or less 20%, knowing that the minimum dose injected is unchanged at 150MBq and the maximum dose at 370 MBq. Irradiation will remain below 10 mSv
45404791|NCT01322620|Other|No treatment given|No treatment given. Participants are to complete a questionnarie in the study.
45513809|NCT02072382|Drug|Metformin|metformin 850mg twice a day for eight weeks
45513810|NCT02072382|Drug|Placebo|
45513811|NCT02209220|Device|Positive airway pressure for the treatment of OSA|
45513812|NCT02072460|Other|electromyography|
45513813|NCT02072460|Other|electroencephalography|
45513814|NCT02072460|Other|approaches from psychophysics|
45513815|NCT02205242|Drug|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
45513816|NCT02205242|Device|Dynaport®|Registering physical activity during 7 days post discharge from hospital (0 months), 3 months and 9 months
46057341|NCT02592733|Device|CYDAR|CYDAR is an automated image mask that is cloud based adn delivered to operating theatres over a secure network. It fuses preoperative images with intraoperative images to provide more accurate image guidance for the surgeon.
45513817|NCT02205242|Drug|Placebo|
45513818|NCT02071368|Drug|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
45513819|NCT02071368|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
46057342|NCT04457973|Device|Active tDCS|tDCS with a constant current intensity of 2 milliampere (mA) will be applied for 20 minutes per session daily for 5 days via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and 5x7 cm saline-soaked surface sponge electrodes.
45404792|NCT03754192|Radiation|perfusion Computed Tomography|Will be carried before liver surgery
45404793|NCT03757390|Drug|Exforge® tab 5/160mg, Crestor® tab 10mg|co-administration of Amlodipine 5mg/Valsartan 160mg(combination drug) and Rosuvastation 10mg
45513820|NCT02071368|Drug|CANA/MET XR FDC, Formulation 1, 150 mg/500|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, to be taken orally.
45513821|NCT02071368|Drug|CANA/MET XR FDC, Formulation 2, 150 mg/500 mg|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, to be taken orally.
45513822|NCT02205320|Biological|DRL_PG|
45513823|NCT02205320|Biological|Pegfilgrastim Form A|
45513824|NCT02205320|Biological|Pegfilgrastim Form B|
45699123|NCT03011164|Procedure|Walk and Run|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk or run on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk or run on the treadmill in barefoot at selected gait speed.
46057343|NCT04457973|Device|Sham tDCS|The electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
45404794|NCT03757390|Drug|CJ-30060 5/160/10mg|Fixed-dose combination drug containing Amlodipine 5mg and Valsartan 160mg and Rosuvastatin 10mg
45404795|NCT01322698|Biological|Tests for candidiasis|Tests include (1) anti-candida antibody ELISA kit; (2) candida antigen ELISA kit; (3) detection of circulating Candida DNA via SYBR Breen qPCR Master mix; (4) colonization index based on mycological examination of five out of the following: urine, oral swab, bronchial aspirate, anal swab, swab of a central venous line, gastric liquid.
45513825|NCT02076360|Behavioral|Preoperative Video|Patients will watch preoperative instructional video
45513826|NCT03402841|Drug|Olaparib|300 mg twice daily - oral
45513827|NCT02209298|Device|CoreValve Transcatheter Valve|Patients should be accepted for TAVI by a multidisciplinary team. The procedure should use the Medtronic CoreValve SystemTM and point of enrolment is the day of the procedure. The choice of prosthesis size and access route (transfemoral, subclavian or direct aortic access) is to be left to the discretion of the operating team. Equally the intraprocedural details (anaesthetic, imaging etc.) will proceed as per usual practice.
45513828|NCT02072616|Other|Pancreatic adenocarcinoma diagnosis|
45513829|NCT02209376|Biological|CART-EGFRvIII T cells|
45513830|NCT02072694|Other|75 grams of glucose plus water solution|"A solution composed by 75 grams of glucose and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~300 mL final volume of the solution.~Time of oral ingestion inferior than 2 minutes.~30 minutes before the radiopharmaceutical injection.~12 hours fasting minimum."
45699124|NCT03463044|Drug|nangibotide|Continous i.v. infusion
45404796|NCT03753958|Procedure|Conventional treatment|The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.
45513831|NCT02072694|Other|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~300 mL final volume of the solution.~Time of oral ingestion inferior than 2 minutes.~30 minutes before the radiopharmaceutical injection.~12 hours fasting minimum."
45513832|NCT02205398|Drug|INC280|
45513833|NCT02205398|Drug|cetuximab|
45513834|NCT04130659|Device|Marial® + PPI (generic omeprazole)|Marial®: 1 stick of Marial® twice a day after meals from day 1 to 28 Omeprazole 20 mg cps: once a day from day 1 to 28
45513835|NCT04130659|Other|PPI alone (generic omeprazole)|Omeprazole 20 mg cps: once a day from day 1 to 28
45513836|NCT02071524|Drug|Group Colloid|Group Colloid: cristalloid 1:2 (gelofusine: ringer lactate)
45513837|NCT02071524|Drug|Cristalloid administration|Only Ringer Lactate administration
45513838|NCT02220608|Biological|Bortezomib|
45513839|NCT02220608|Drug|G-CSF|
45513840|NCT02076438|Dietary Supplement|Probiotics|Randomized to receive probiotics or placebo
45513841|NCT02209688|Drug|ESR 1150 CL|
45513842|NCT02209688|Drug|Placebo|
45513843|NCT02076516|Device|Drug-eluting stent: CORACTO®|
45513844|NCT02220686|Behavioral|Offer and Report Protocol|Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.
45513845|NCT03630367|Drug|Dexamethasone|Intramuscular injection 8 mg
45513846|NCT03630367|Drug|L-Carnitine 1G/5mL Injection|slow intravenous injection
45513847|NCT02258282|Drug|Etanercept|
45513848|NCT02258282|Drug|Control|
45513849|NCT01376869|Dietary Supplement|Hops Extract|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers will be used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
45513850|NCT01376869|Other|Placebo (silica)|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers were used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
45513851|NCT02076594|Drug|Docetaxel|Powder for solution for infusion
45513852|NCT02076594|Drug|Epirubicin|Solution for infusion
45513853|NCT02076594|Drug|Oxaliplatin|Powder for solution for infusion
45513854|NCT02076594|Drug|Capecitabine|Film coated tablets
45513855|NCT02258360|Other|Therapeutic hypothermia|Therapeutic hypothermia with a target temperature between 32-34°C.
45513856|NCT04175509|Drug|Rectal acetaminophen|Rectal 1300mg
45513857|NCT04175509|Drug|Intravenous acetaminophen|Intravenous 1000mg
45513858|NCT02220842|Drug|Atezolizumab|During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage.
45513859|NCT02220842|Drug|Obinutuzumab|During safety evaluation stage, obinutuzumab will be administered as 1000 mg IV infusion. During expansion stage, obinutuzumab will be administered as either 1000 mg IV infusion or at dose decided from safety evaluation stage.
45513860|NCT02220842|Drug|Tazemetostat|Tazemetostat 800 mg will be administered orally, twice daily, on Days 1 to 21.
45513861|NCT02072850|Device|Coronary pressure wire|Guidewire-based coronary pressure- and temperature recordings (coronary thermodilution) with and without hyperaemia induced by intravenous administration of adenosine (140 ug/kg/min) in patients with acute ST-elevation myocardial infarction treated by emergency PCI.
45513862|NCT02072850|Other|Magnetic resonance imaging of the heart|Cardiac magnetic resonance imaging (MRI) with gadolinium contrast imaging at baseline (~ day 2) and 6 months (all participants) and in 30 subjects at 4 time-points (< 12 hours, days 2, 7-10 and at 6 months).
45699125|NCT03463044|Drug|Placebo|Placebo
45513863|NCT02205554|Drug|Omnitram|Nine 20 mg doses administered every 6 hours
45513864|NCT02205554|Drug|Tramadol|Nine 50 mg doses administered every 6 hours.
45513865|NCT02205554|Drug|Placebo|Nine doses administered every 6 hours.
45513866|NCT02076672|Drug|Artichoke WPC|Artichoke WPC 500 mg capsules. Dose = 1000 mg (2 - 500 mg capsules) just before breakfast and 1000 mg (2 - 500 mg capsules) before dinner. Duration: daily for a period of 90 days.
45513867|NCT02076750|Dietary Supplement|Vitamin D3 (cholecalciferol)|
45513868|NCT05162599|Device|Diagnostic study, experimental evaluative cross-sectional study|This is a cross-sectional diagnostic study with collection of information from the gold standard (or reference test) and the new device
45513869|NCT05262608|Drug|Olaparib|Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily
45513870|NCT02073006|Dietary Supplement|Natural Fibre Supplement|Natural Fibre Supplement 2 doses per day for 4 weeks
45513871|NCT02205632|Device|MPS II|
45513872|NCT01380457|Drug|Dronabinol|Capsules, 10 mg, single dose, fasting conditions
45513873|NCT01380457|Drug|Marinol|Capsules, 10 mg, single-dose, fasting conditions
45513874|NCT02071602|Drug|CD-NP|Randomized 1:1:1
45851369|NCT02991612|Drug|Rifaximin|Patients receive Rifaximin 400mg bid for 2 months
45851370|NCT02991534|Behavioral|CV Toolkit Components|"Patient completes a CV self screener.~Patient discusses CV risks factors with primary care providers and CV risks are documented and discussed for action steps and referrals.~Patient will be recommended to attend a gender tailored facilitated workgroup - Gateways to Healthy Living to make specific SMART goals and commit to patient preferred services or program"
45513875|NCT02205710|Other|Computerized cognitive training|
45513876|NCT02205710|Other|Computerized games|
45513877|NCT05159089|Behavioral|Socioecological model apply to reduce physical activity drop out in type 2 diabetes patients|"To implement this model this intervention aims to address three key elements: 1) prepare the user; 2) structure the action; and 3) design the context.~These goals will be worked in each session of Nordic Walking during the warm-up and cool-down and, if necessary, during the session (as long as it's non-stop or slowing down)."
45513878|NCT05159089|Behavioral|Nordic Walking|Sessions will be progressive: the first month will long 30 minutes, the second month 35 minutes, and the third month 40 minutes (without 10 minutes warm-up and 10 minutes cool-down each session). The track will not have more than 100 accumulate high and will allow doing 5 kilometers without stopping. The meeting point will be between the Biomedical Research Park (Barcelona) and Hospital del Mar (nearby CAP Sant Joan). All sessions will be conducted by an instructor of nordic walking physiotherapists.
45513879|NCT02071680|Other|Iodine-123 Meta-iodobenzylguanidine|"A single injection of the 123I-mIBG will be given. Imaging will be done twice following injection: at 0120 minutes and 3-5 hours. The timing is dependent on the specific participant and imaging characteristics.~The imaging is done for approximately 24 minutes at each time point."
45513880|NCT05239052|Other|computer task intervention|subject received programs for upper arm movement training with providing computer screen task activities
45513881|NCT05239052|Other|conventional long-term care services|stroke subjects with wheelchair users receive conventional long-term care services
45513882|NCT05138107|Other|Synochi Scar Spray Cosmetic|Application of the cosmetic on each skin graft in a blinded fashion in different sections for a 9 month duration.
45513883|NCT05138107|Other|Synochi Scar Spray Placebo|Application of the placebo on each skin graft in a blinded fashion in different sections for a 9 month duration.
45513884|NCT02071758|Biological|LEISH-F3 + SLA-SE|
45513885|NCT02071758|Biological|LEISH-F3 + GLA-SE|
45513886|NCT01380301|Drug|Miltefosine and antimony|Short course (half of each drug) administered simultaneously
45513887|NCT01380301|Drug|Miltefosine alone|short course (half)
45513888|NCT02205866|Other|Endometrial Receptivity Array analysis of endometrial biopsy|A biopsy of endometrium is peformed and Endometrial Receptivity Array analysis is carried out, as well as analysis of fat distribution and risk factors of Metabolic Syndrome.
45513889|NCT02076828|Drug|Ferro Sanol® sp|The children with IDA that included in Fe-S (Ferro Sanol® sp.)(Group I) were treated with a therapeutic dose Ferro Sanol® sp as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
45513890|NCT02076828|Drug|Santafer® sp.|The children with IDA that included in Fe-OH-PM (Santafer® sp.)(Group II) were treated with a therapeutic dose Santafer® as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
45513891|NCT02076828|Drug|Ferro Zinc® sp|The children with IDA that included in Fe-Zn (Ferro Zinc® sp.)(Group III) were treated with a therapeutic dose Ferro Zinc® sp. as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
45699126|NCT02522208|Drug|BiDil XR|fixed combination capsule
45851371|NCT02991378|Behavioral|Children's emotional and stress coping program|Giving the children lessons about the emotional self-regulation skills and stress coping skills, with the psychoeducation books and lectures for the teachers and parents.
45851372|NCT02991222|Drug|SPARC001 type I|Treatment type I
45851373|NCT02991222|Drug|SPARC001 type II|Treatment type II
45513892|NCT02221076|Device|Confocal Laser Endomicroscopy (CLE)|Real-time microscopic imaging of living tissue during the standard procedure
45513893|NCT02076984|Procedure|Laparoscopic incisional or ventral hernia repair|
45513894|NCT05078359|Diagnostic Test|Prostate Magnetic resonance Imaging|Magnetic resonance imaging (MRI) uses a magnetic field, radiofrequency pulses, and a computer to produce detailed pictures of the organ. Prostate MRI evaluate the presence and extent of prostate cancer and determine whether it has spread around the organ
45513895|NCT02221154|Dietary Supplement|Inofolic®|
45513896|NCT02221154|Other|Gonadotropins; Folic Acid|standard ovarian stimulation
45513897|NCT02079870|Drug|semaglutide|Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks followed by 1.0 mg semaglutide once weekly for five weeks
45513898|NCT02079870|Drug|placebo|Solution for subcutaneous (s.c. - under the skin) injection
45513899|NCT01378897|Device|MedSignals®pillbox,Omron pedometer,VitalSignals®weight scale|Participants will use three home monitoring devices (i.e., weight scale, pedometer, pillbox) for two months. In addition, participants will receive weekly phone calls from the study's bariatric dietician during weeks 1-4 of the study and then receive biweekly calls during the second month. The structured phone calls (approximately 10-15 minutes each call) will focus on discussing the patient's adherence data, discussing any barriers to adherence, and providing tailored patient education.
45513900|NCT02209844|Drug|BI 44847|
45513901|NCT02209844|Drug|Placebo|
45513902|NCT02073084|Drug|K-877 Low Dose|K-877 Low Dose
45404797|NCT03753958|Radiation|aPDT|aPDT will be performed after conventional treatment, in sites with pockets greater than or equal to 5 mm. The PapaMblue® photosensitizer with 100 μM methylene blue will be deposited in the pockets with a syringe, with the bottom of the pouch in the coronal direction, and a pre-irradiation time of 1 min will be adopted, so that the PS may stain the entire bacterial biofilm. Then, the laser emitting an wavelength of 660 nm, with power of 100 mW, will be applied. The laser will be applied to the mucosa on the oral epithelium with an optical fiber (apparatus of DMC Therapy EC, São Carlos, Brazil). Irradiation will be performed until the entire peri-implanted pouch is illuminated for 2 minutes at each point. The 6 points around the implant will be irradiated and each irradiation point will present an area of 0.4 cm2, which will result in radiant exposure of 30 J/cm2 following 2 min of irradiation per point. The irradiation will have a constant power density of 250 mW/cm2.
45404798|NCT03753880|Device|HEMOPATCH Sealing Hemostat|Hemopatch sealing hemostat used after LR to cover the resection surface
45513903|NCT02073084|Drug|Moxifloxacin|
45513904|NCT02073084|Other|Placebo|
45513905|NCT02073084|Drug|K-877 High Dose|K-877 High Dose
45513906|NCT03899701|Procedure|PEC I and PEC II blocks|Participants will get a PEC I block with 10ml of 0.375% ropivacaine and a PEC II block with 20ml of 0.375% ropivacaine using ultrasound guidance.
45513907|NCT02221388|Drug|BI 671800 HEA, 200 mg tablets|
46057344|NCT02593279|Genetic|asthma with proximal airways obstruction phenotype profile description with clinical, biological, morphologic and genetic elements.|symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, igE analysis, tomodensitometric test.
45513908|NCT02221388|Drug|BI 671800 HEA EC, 200 mg tablets|
45513909|NCT02221388|Drug|BI 671800 HEA, 50 mg tablets|
45513910|NCT02221388|Drug|BI 671800 ED, 100 mg capsules|
45513911|NCT02221388|Other|Standard meal|
45513912|NCT03787849|Drug|Sevoflurane|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction. After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
45513913|NCT03787849|Drug|Propofol|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
45513914|NCT02073240|Behavioral|Enhanced TB IC Package|"Facilities randomized to the intervention group will receive:~Skills-based training addressing the hierarchy of TB IC measures, how to conduct a facility TB IC /risk assessment; and development, implementation, and monitoring of an operational TB IC plan for the facility~Audits and Feedback of performance~A TB IC collaborative membership~A standardized unit-level daily checklist of critical IC activities"
45513915|NCT05262218|Drug|PBF-680 10mg|PBF-680 10mg administered orally once a day
45513916|NCT05262218|Drug|Placebo|Placebo administered orally once a day
45513917|NCT03669705|Procedure|Omitting axillary surgery in early breast cancer|Before the Sentinel Node era all invasive breast cancer was recommended to have axillary dissection but after the introduction of national breast cancer screening this guideline statement was challenged by this national Swedish cohort.
45699127|NCT02522208|Drug|BiDil Immediate Release (IR)|fixed combination tablet
45699128|NCT01107964|Drug|Oral Omega-3-acid ethyl esters|1 gram capsule by mouth four times daily for 45 days
45699129|NCT01107964|Drug|Placebo corn oil capsule|1 gram by mouth 4 times daily for 45 days
45851374|NCT02991222|Drug|Reference001 type I|Hydrocodone-Acetaminophen
45513918|NCT03671343|Behavioral|Physical rehabilitation|It will benefit from an initial and final geriatric assessment, an initial dietary balance and a personalized treatment in physical activities adapted for 3 months by an Educator in Adapted Physical Activities.
45513919|NCT03777319|Drug|Spironolactone|Spironolactone will be prescribed for 6 months, after which the family and primary care physician will determine to either remain on spironolactone or transfer to prednisolone.
45513920|NCT03777319|Drug|Prednisolone|Prednisolone will be prescribed for 6 months as the clinical standard of care.
45513921|NCT02205944|Other|Progressive Handgrip Exercise|"Group 1 (Normal Exercise Group): Daily, at home for 20 minutes using an adjustable handgrip trainer up to 8 weeks prior to a scheduled surgery for fistula creation. The exercise intensity is tailored using the Borg CR100 scale (Borg & Borg, 2001).~Group 2 (Restricted Blood Flow Exercise Group): Same as the exercise performed by Group 1 with controlled tourniquet."
45513922|NCT03671265|Drug|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
45513923|NCT03671265|Radiation|IMRT or VMAT|The IMRT or VMAT technique was used in our study.
45513924|NCT03671265|Drug|Apatinib|Apatinib is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2.
45513925|NCT02077218|Procedure|computed tomography|Undergo cardiac CT
45513926|NCT02077218|Other|cytology specimen collection procedure|Undergo collection of blood samples
45513927|NCT02077218|Other|laboratory biomarker analysis|Correlative studies
45513928|NCT02077218|Other|questionnaire administration|Ancillary studies
45404799|NCT05458804|Device|VR training|A musical game called Beat Saber was used to conduct training sessions. The participant's task was to cut through the blocks of various colors in his direction to the rhythm of music, using two virtual swords. The swords were controlled by the player with controllers of different colors. Blocks had to be cut with a sword whose color matches the block and in the right direction which is indicated by an arrow on the block. The training session consisted of 4 music tracks with different paces and intensities of objects. In addition, during the song, the participant had to avoid objects-objects that randomly appeared in the game scenario - forcing the whole body to move.
45513929|NCT05262062|Other|Strain Counter Strain Technique|"When general or local pain began to diminish, upper trapezius , levator scapulae and SCM was placed in a position of ease and was held for approximately 20 to 30 seconds.~2. Moderate digital pressure was applied to the identified MTrP as participants rated their level of pain on a scale ranging from 1 to 10.~3. Ease was defined as the point at which a reduction in pain of at least 70% was achieved.~4. Once the position of ease was identified, it was held for 20 to 30 seconds."
45513930|NCT05262062|Other|Muscle Energy Technique,|"After the ease position was maintained for 20 to 30sec an isometric contraction focused on the muscle fibers around the MTrP was performed.~2. Each isometric contraction was held for 7 to 10 sec and was followed by a soft-tissue stretch for 15 seconds and then relax for 30 seconds. Each stretch was held for 30 seconds, and it was repeated 3 times during the treatment session.~3. Treatment was performed on the 3 most painful areas between the upper border of the upper trapezius muscle, the SCM, the levator scapulae, and the SC muscle."
45513931|NCT05262062|Other|Integrated Neuromuscular Inhibition Technique|"Group c will receive Combination of exercise (strain counter strain , muscle energy & ischemic compression. In ischemic compression patient will receive compression,~After MTrPs identification,~Ischemic compression was applied in an intermittent manner for up to 2 minutes for each MTrP.~The pincer grasp (for the trapezius muscle and SCM) or direct digital pressure (for the levator scapulae and SC muscle) was used with the patients in either the supine position or sitting upright"
45513932|NCT03729427|Procedure|Erector Spinae Plane Block|Erector Spinae Plane block for patents undergoing rib cartilage grafting surgeries
45513933|NCT03671187|Other|Exercise|8 week exercise program
45513934|NCT02073318|Other|Task-oriented balance training|4 weeks individualized task-oriented balance training, twice a week and 1 hour each session
45513935|NCT02073318|Other|Upper extremities exercise|"4 weeks upper extremities exercise in sitting position, twice a week and 1 hour each session~weeks"
45513936|NCT02209922|Device|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
45513937|NCT02209922|Device|Sham|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation then and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
45851375|NCT02991222|Drug|Reference001 type II|Hydrocodone-Acetaminophen
45404800|NCT05457244|Device|single-port robotic surgery|Colorectal surgery using the da Vinci SP System will be performed via the umbilicus, McBurney's site or the reverse McBurney's site depending on the sites of lesion. All of these patients will undergo a standard minimally invasive resection in the same fashion as would be carried out with multiport laparoscopic or robotic surgery.
45513938|NCT03671031|Procedure|isolated roux loop|Isolated roux loop reconstruction following pancreaticoduodenectomy
45513939|NCT03671031|Procedure|single loop|Conventional single loop reconstruction following pancreaticoduodenectomy
45513940|NCT02881957|Drug|Cholecalciferol|
45404801|NCT03753802|Other|Chest Physiotherapy|During sessions, the child is lying on the back, he should not have eaten within two hours prior to the sessions. An extended slow expiration handling is performed on 3 respiratory cycles consecutive, this session is repeated for 10 minutes. Breaks are made regularly during the treatment to have approximately 5 to 6 minutes of handling and 4-5 minutes of rest on the total 10 minutes of treatment. Induced cough handlings will be conducted at five minutes and at ten minutes if the child has not coughed during the movements of chest physiotherapy. These are performed by a brief pressure above the jugular (suprasternal) notch of the patient. Only two consecutive trials of the induced cough handling are allowed, even if the handlings are unsuccessful the physiotherapist does not insist. The following 5 minutes of the session are 5 minutes of rest. During the sessions the physiotherapist wears a mask and respects the usual rules of hygiene.
45404802|NCT03753802|Other|Surveillance|The session is only a surveillance session with the physiotherapist. The physiotherapist is only watching over the child. The parents of the child wait in the waiting room during the physiotherapy session. They don't know which treatment (chest physiotherapy or no treatment) is applied to their child.
45404803|NCT03757156|Other|Withdrawal of aspirin|People who are taking aspirin stop to taking aspirin.
45404804|NCT05420662|Procedure|Manipulation of vagina during abdominal hysterectomy operation|The manipulator applied vaginally prevents unnecessary vaginal length loss by ensuring that the vaginal cuff is cut from the top point.
45404805|NCT05420662|Procedure|Classical conventional abdominal hysterectomy operation|Classical conventional abdominal hysterectomy operation without any manipulation from the vagina.
45404806|NCT05401240|Behavioral|information reveal|the experimental group will be informed that there will be an important examination about his/her cardiopulmonary fitness condition at the outpatient department (OPD)
45404807|NCT04728802|Drug|Proxalutamide|Proxalutamide 300mg q.d
45404808|NCT04728802|Drug|Placebo|Placebo pill
45513941|NCT02881957|Other|Placebo|Oral syrup placebo
45513942|NCT02073396|Diagnostic Test|Blood test|Patients will undergo the tests of thrombosis, before and after stabilisation of their cardiac condition. Cardiac stabilisation will be provided by clinical cardiac teams, outside and independently from the study.
45513943|NCT02206022|Drug|Remifentanil|Pain's evaluation for Remifentanil Group
45513944|NCT02206022|Drug|Placebo|CVC pain's evaluation after local anesthesia + placebo infusion
45513945|NCT02073552|Drug|Polyethylene glycol 4000|- Polyethylene glycol 4000: 16 envelopes (70 g of powder each). It includes electrolytes and sodium sulfate. These substances make PEG metabolically inert, achieving a suitable osmotic balance, despite having a high molecular weight. The preparation passes along the gastrointestinal tract without causing net absorption of fluid or electrolytes. It is routinely used in clinical practice for bowel cleansing, before abdominal surgery, barium enema and other colorectal and genitourinary tract tests. Participants will divide the whole doses in 4 liters of water taking half the day before the examination starting at 20.00 h and the other half at 6.00 pm on the day of the examination.
45513946|NCT02073552|Drug|Macrogol 3350 plus ascorbic acid|- Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid. The properties of the polyethylene glycol are the same as those mentioned previously, while ascorbic acid generates an osmotic gradient potentiating the effect of polyethylene glycol. It is used routinely as a bowel prep. Participants will divide the doses in 2 liters of water taking half the day before (112 g of PEG and an 11 g of ascorbic acid) the examination at 20.00 h and the other half at 6.00 pm on the day of the examination
45513947|NCT03022461|Other|Long term follow-up|
45404809|NCT03757078|Drug|Relief Pro cream|Relief Pro cream:1.0 mg/gm Fluocortolone + 20 mg/gm Lidocaine; Administration according to clinical practice.
45404810|NCT03757078|Drug|Relief Pro rectal suppositories|Relief Pro rectal suppositories: 1.0 mg Fluocortolone + 40 mg Lidocaine; Administration according to clinical practice
45404811|NCT03750916|Drug|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
45404812|NCT05322148|Drug|Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free|A number of studies have shown the benefit of both cyclosporine and steroids in managing dry eye. However, existing formulations of these products are challenged by either limited tolerability, a high out-of-pocket cost or both. Combination therapy with these agents in an advanced, more tolerable formulation have the potential to improve both tolerability and cost. However, the available formulation of preservative free Klarity CL (cyclosporine 0.1% and loteprednol 0.2% in a chondroitin sulfate vehicle) has not been studied rigorously.
45404813|NCT03750760|Drug|Alirocumab|PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor antibody
45513948|NCT03686683|Biological|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
45699130|NCT05684172|Drug|Tenecteplase|If patients are randomized and assigned to receive intra-arterial tenecteplase thrombolysis, tenecteplase will be injected according to protocol, proceeding to inject TNK through a distal access catheter or microcatheter located proximal to the residual thrombus (if still present) and distally to the origin of the lenticulostriates branches.
45404814|NCT03750760|Drug|Atorvastatin 80mg|3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statin)
45699131|NCT05684172|Other|endovascular thrombectomy alone|Patients will receive randomization if the eTICI score on cerebral angiography is 2b-3 and will stop the procedure if they have been assigned to the control group.
45851376|NCT02990832|Device|Exciton|"Exsalt® Wound Dressings will be applied by the physician/nursing staff.~The test product, exsalt® Wound Dressings (0.4 mg Ag/cm2) will be applied after wound cleansing or debridement if required.~Dressings will be changed weekly, either at the out-patient facility or at home with provided dressings. At regular intervals throughout the study, as per the existing Diabetes Foot Care Clinical Care Pathway, wound assessment including size determination, Exsalt Wound Assessment Form, any adverse events will be reported, with tracing and/or photography included where available.~Maximum treatment course will be 28 days (end of study) or until wound closure."
45851377|NCT02990754|Behavioral|Physical activity education|Instruction in suitable physical activity options and education about physical activity with CHD.
45851378|NCT02990676|Behavioral|Computerised cognitive training|Computerised cognitive training regime
45404815|NCT03750760|Drug|Ezetimibe 10mg|Cholesterol absorption inhibitor
45513949|NCT02210156|Dietary Supplement|Omniplus Supreme|Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
45699132|NCT01200160|Drug|Niacin|
45699133|NCT04771650|Other|CAMI|The CAMI is a culturally adapted motivational interview. It is a single 75 minute session that focuses on promoting motivation to change drinking and drug use behavior.
45699134|NCT04908228|Drug|Ibrutinib and obinutuzumab|Patients will receive fixed-duration treatment with ibrutinib and obinutuzumab.
45699135|NCT04452786|Procedure|Endoscopic sleeve gastroplasty|Four-hour solid mixed meal test
45699136|NCT04452786|Procedure|Laparoscopic sleeve gastrectomy|Four-hour solid mixed meal test
45699137|NCT01153672|Drug|vorinostat|Given PO
45699138|NCT01153672|Other|laboratory biomarker analysis|Correlative studies
45699139|NCT01153672|Procedure|biopsy|Optional correlative studies
45851379|NCT02990442|Device|rTMS|repetitive transcranial magnetic stimulation, 1Hz protocol to right dorsolateral pre frontal cortex (R_DLPFC)
45851380|NCT02990286|Drug|Rituximab|Rituximab 500mg concentrate for solution for infusion. One course of IV rituximab consisting of a first infusion of 1000 mg (500 ml solution) rituximab (day 1 infusion), and a second infusion of 1000 mg (500 ml solution) rituximab two weeks later (day 15 infusion)
45851381|NCT02990286|Drug|Placebo of Rituximab|500 ml of saline (0.9% sodium chloride) for infusion One course of intravenous placebo of rituximab consisting of a first infusion of 500 ml of saline (0.9% sodium chloride) infusion (day 1 infusion), and a second infusion of 500 ml of saline infusion two weeks later (day 15 infusion)
45851382|NCT02990286|Drug|Mycophenolate Mofetil|"Mycophenolate Mofetil 500mg film-coated tablets~1 gram twice daily on oral route of MMF (= 2 grams daily) for 6 months."
46057345|NCT02593279|Genetic|asthma with small airways dysfunction phenotype profile description with clinical, biological, morphologic and genetic elements.|symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, IgE analysis, tomodensitometric test.
45404816|NCT01076894|Procedure|epidural anesthesia|In the epidural group prior to the induction of general anesthesia, a thoracic epidural catheter will be was placed at the level of the TH6-TH8. 8 ml ropivacaine 1% were administered through the epidural catheter. EDA is aimed at a sensory block level from TH2 to TH10.
45404817|NCT01076894|Procedure|intercostal anesthesia|In the intercostal group, before chest closure, each 4 ml ropivacaine 0.75 % will be injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and two spaces above and below as well as 5 ml ropivacaine 0,75 % at the thoracic drainage tube exits
45699140|NCT01153672|Radiation|F-18 16 alpha-fluoroestradiol|Correlative studies
45699141|NCT01153672|Procedure|positron emission tomography|Correlative studies
45699142|NCT01153672|Drug|anastrozole|Given PO
45699143|NCT01153672|Drug|letrozole|Given PO
46057346|NCT02592889|Device|MITRACLIP|MITRAL VALVE REPAIR WITH THE MITRACLIP SYSTEM
45699144|NCT01153672|Drug|exemestane|Given PO
45699145|NCT01153672|Genetic|gene expression analysis|Correlative studies
45513950|NCT02210156|Other|Placebo|A product with maltodextrins, flavors and colorants without vitamins, minerals and plant extracts. Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
45513951|NCT02080026|Biological|CPS-immunization|Subjects will receive four 'immunizations' with bites from 15 Plasmodium infected mosquitoes during each immunization, while taking chloroquine prophylaxis.
45513952|NCT02080026|Biological|Controlled Human Malaria Infection|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum, NF54 strain.
45513953|NCT02080026|Drug|chloroquine|Registered for prophylaxis against infection with Plasmodium falciparum and the treatment of acute infections.
45513954|NCT02080026|Drug|atovaquone/proguanil|"Registered for use as an antimalarial agent for the treatment of acute infections with Plasmodium falciparum.~One tablet contains: atovaquone 250 mg, proguanil(hydrochloride) 100 mg"
45513955|NCT02206178|Drug|N-acetylcysteine combination with acetaminophen|
45513956|NCT02206178|Drug|Placebo|
45513957|NCT02080104|Drug|intarvenous and intramusculer 10 IU oxytocin|intarvenous and intramusculer 10 IU oxytocin
45513958|NCT03463057|Drug|Atezolizumab|Intervention Atezolizumab starts after 6 - 8 R-CHOP induction cycles (Rituximab, Cyclophosphamide, Hydroxo-doxorubicin, Vincristine and Prednisone (R-CHOP)); 18 cycles Atezolizumab followed by 12 months of observation
45513959|NCT02211326|Behavioral|Genotype-guided dosing algorithm for warfarin|Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by IWPC( International Warfarin Pharmacogenetics Consortium) algorithm (PG-1),a second dose adjustment will be made after 3 doses of warfarin using a dose revision algorithm (PG-2) that combined INR values,the dose will be adjusted depending on the measurements of INR values after 7 days.The overall follow-up period is 12 weeks.
45513960|NCT02211326|Behavioral|Standard initiation dose for warfarin|Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by standard initiation dose. Following this initiation dose of warfarin,the dose will be adjusted depending on the measurements of INR values after 3 days.The overall follow-up period is 12 weeks.
45513961|NCT02077452|Drug|HMS5552|
45513962|NCT02077452|Drug|Placebo|
45513963|NCT03462979|Device|Immunochromatographic lateral flow test|The immunochromatographic lateral flow test (Gluten Detective) is an at-home test that detects gluten immunogenic peptides excreted in stool or urine. This test can detect gluten exposures which occurred either during the last 24 hours (urine) or within up to a 7 day window (stool). Minimum intake amounts of gluten for successful detection using these test are 50mg (stool) to 500mg (urine)
45513964|NCT02073630|Other|active cerebellar stimulation|
45699146|NCT05321628|Behavioral|Internet-based Cognitive Behavioural Therapy (iCBT) with Decision Support Tool|Cognitive Behavioural Therapy för depression, panic disorder and social anxiety delivered thru texts and home works assignments via an internet platform with therapist weekly support through text messages. Therapist use a traditional, detailed therapist manual with the additions of a Clinical Decision Support Tool (DST) that identifies patients at risk of treatment failure and give suggestions to the therapist on how to act in relation to the specific patient.
45404818|NCT04715932|Drug|Hesperidin|Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
45404819|NCT04715932|Drug|Placebo|Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
45699147|NCT05321628|Behavioral|Internet-based Cognitive Behavioural Therapy (iCBT)|iCBT, as described above, using only the traditional, detailed therapist manual.
45699148|NCT03010072|Drug|low-dose sucroferric oxyhydroxide|250 mg suroferric oxyhydroxide
45699149|NCT03010072|Drug|high-dose sucroferric oxyhydroxide|2000 mg suroferric oxyhydroxide
45851383|NCT02990208|Behavioral|Diaphragmatic breathing|Patients trained in the technique of diaphragmatic breathing were instructed to take a breath by contracting the diaphragm and were trained to maintain their respiration frequency. They were told to inhale through the nose for four seconds and exhale through the mouth for six seconds (six cycles per minute). Patients then had five minutes to practice by following verbal breathing instructions provided over headphones. During VR exposure breathing instructions were provided via headphones. Diaphragmatic is thought to reduce arousal on the physiological level (Hazlett-Stevens & Craske, 2009) but at the same time not to divert attention from the feared situation to the same extent as other coping strategies
45404820|NCT00130832|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|Three doses of rotavirus vaccine, live, oral, pentavalent. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
45404821|NCT00130832|Biological|Comparator: Oral Poliovirus Vaccine (OPV)|Three doses OPV. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
45404822|NCT00130832|Biological|Comparator: Oral Poliovirus Vaccine (OPV) (staggered)|Three doses OPV. Dose 1 was given 14 to 28 days post Dose 1 of RotaTeq, Dose 2 was given 14 to 28 days post Dose 2 of RotaTeq, and Dose 3 was given 14 to 28 days post Dose 3 of RotaTeq.
45404823|NCT00096018|Drug|fludarabine phosphate|Given IV
45404824|NCT00096018|Drug|thalidomide|Orally
45513965|NCT02073630|Other|sham cerebellar stimulation|
45513966|NCT02206256|Drug|Omega-3 fatty acid capsules|2 times a day 1 capsule for 4 weeks before gastric bypass surgery
45513967|NCT02206256|Behavioral|Low calorie diet|A low calorie diet of 600 kcal/day during 2 weeks, using Modifast or an adjusted normal diet.
45513968|NCT04749290|Other|Study Formula|Study infant formula for term infants containing OPO and CPP
45513969|NCT02691793|Drug|Sunitinib|sunitinib 37.5mg QD
45513970|NCT05764603|Drug|MRI|MR ARTHROGRAPHY AND CT ARTHROGRAPHY IN PATIENT WITH KNEE OSTEOARTHRITIS
45513971|NCT02073786|Device|Conventional lightwand intubation|Conventional lightwand intubation technique will perform during intubation
45404825|NCT04713748|Device|Tasso-SST on Demand|Participants will collect a small blood sample using the Tasso-SST OnDemand device during a serology blood draw visit already scheduled for the MURDOCK C3PI Study (Pro00105703). Participants will be provided a kit that includes written, step-by-step instructions that include pictures. Participants will also have the option to watch a brief video on using the device, available online, prior to collection. Both blood samples will be spun and processed for serum. Serum will be frozen and shipped to the lab at Duke for antibody testing. Antibody results will be compared between the two methods.
45404826|NCT04713748|Other|Regular Phlebotomy|Participants will have a small blood sample collected via regular venipuncture.
45513972|NCT02073786|Device|Rigid video stylet|Rigid video stylet will inserted through endotracheal tube before induction. After induction with propofol and remifentanil using TIVA infusion pump, rocuronium 0.6mg/kg were used to facilitate intubation. After 2minutes, board-certificated anesthesiologist perform intubation using Optiscope.
45404827|NCT01079754|Drug|Spinal morphine 0.05 mg|Patient received spinal morphine 0.05 mg
45404828|NCT01079754|Drug|Spinal morphine 0.1 mg|Patient received spinal morphine 0.1 mg
45404829|NCT03757000|Drug|YY-20394|YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
45513973|NCT04747886|Behavioral|WW Only|WW is a structured behavioral weight management program that focuses on diet, physical activity and mindset skills. The dietary approach is based on creating an energy deficit diet to produce weight loss while also being attentive to the quality of the calories. Specifically, the WW program assigns SmartPoints values to foods based on calories, sugar, saturated fat and protein. In addition, particular foods are assigned a points value of zero (0) to encourage a healthier eating pattern (e.g. fruits, vegetables, non-fat yogurt, fish).
45513974|NCT04747886|Behavioral|WW + PolyRules!|In addition to WW, participants will be asked to engage in daily cognitive training using the PolyRules! app for three months. They will be instructed to start with 20-min of daily cognitive training and to progressively increase their training time to 30-min.
45513975|NCT03132415|Behavioral|Get Connected|The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics, HIV/STI testing history and testing motivations, and recent sexual behaviors.
45513976|NCT03132415|Behavioral|HIV Test Locator|The investigators will use a HIV/STI testing locator as the attention-control condition. The test locator provides a list of HIV testing sites in a city or zipcode.
45513977|NCT02221544|Device|Low-frequency repetitive Transcranial Magnetic Stimulation|"Participants will receive treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions). In each session patient will receive repetitive Transcranial Magnetic Stimulation using a stimulation frequency of 10 Hz for half an hour.~The treatment is done by attaching an electromagnetic coil to the scalp using a special hat. Each patient has a personal hat which serves him throughout the entire process. The treatment is performed without anesthesia and patient fully conscious. During the treatment he sits comfortably on a chair, meanwhile the magnetic field passes through the skull into the brain."
45513978|NCT02221544|Device|rTMS maintenance|Same treatment as in rTMS treatment intervention, but only once a week for a month
45513979|NCT02221544|Device|Sham|Participants will receive sham treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions total) for half an hour each session. The treatment is done by attaching an electromagnetic coil to the scalp but without turning on the magnetic field.
45513980|NCT02221544|Device|Sham maintenance|The same as Sham stimuli intervention, but once a week for a month
45513981|NCT01378819|Procedure|3-midline-ports laparoscopic cholecystectomy|The laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
45513982|NCT01378819|Procedure|3-midline-ports laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
45513983|NCT02221622|Drug|Allopregnanolone injection (intravenous solution)|Allopregnanolone intravenous infusion
45513984|NCT02221622|Drug|Placebo injection (intravenous solution)|Placebo intravenous infusion
46057347|NCT00727909|Device|Hearing Aid Treatments|"Hearing aid treatments:~Traditional Custom (TC), Receiver-in-the Aid (RITA) and Receiver-in-the-Ear (RITE)"
46057348|NCT03911973|Drug|Gedatolisib|Gedatolisib, 150-180MG IV
46057349|NCT03911973|Drug|Talazoparib|.75-1.00mg
46057350|NCT02708043|Other|Flexible-Laryngeal Mask Airway|
46057351|NCT00726895|Drug|Quinine Sulfate Capsules 324 mg|1 x 324 mg capsule
45513985|NCT02077686|Behavioral|Education - Diabetes and Travel|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Travel was created. The module covers specific and detailed aspects of the topic travel such as insulin adaption to intercontinental flights, dealing with exotic food, and treatment goals during vacation. With this module, a more comprehensive education of patients with specific interest is possible."
45513986|NCT01380223|Drug|placebo|I.V. infusion of placebo for 8 hr
45513987|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.005 mg/kg/hr
45513988|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.015 mg/kg/hr
45513989|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.025 mg/kg/hr
45513990|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.0625 mg/kg/hr
45513991|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.125 mg/kg/hr
45513992|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.25 mg/kg/hr
45513993|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.5 mg/kg/hr
45513994|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 1.0 mg/kg/hr
45513995|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.75 mg/kg/hr (dose reduced)
45513996|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.625 mg/kg/hr (dose reduced)
46057352|NCT00726895|Drug|Quinine Sulfate Capsules 324 mg|2 x 324 mg capsules
46057353|NCT02707887|Behavioral|LETS ACT|The Life Enhancement Treatment for Substance Use (LETS ACT)
45404830|NCT03750604|Diagnostic Test|visceral fat obesity (surface area and function)|"WC is evaluated at the midpoint between the lower border of the rib cage and the iliac crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels.~Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ [36.58 + (1.89 × BMI)] × TG/0.81 × 1.52/HDL.~And in males:~VAI: WC / [39.68 + (1.88 x BMI)] x TG/ 1.03 x 1.31/ HDL WC: waist circumference, BMI: body mass index, TG: triglyceride, HDL: high-density lipoprotein"
45404831|NCT04702984|Device|LID021201 contact lenses|Investigational silicone hydrogel sphere contact lenses for frequent replacement daily wear
45404832|NCT04702984|Device|OPTI-FREE multipurpose solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
45513997|NCT02221700|Procedure|Massage Therapy|Undergo massage therapy
45513998|NCT02221700|Other|Quality-of-Life Assessment|Ancillary studies
45513999|NCT02221700|Other|Questionnaire Administration|Ancillary studies
45514000|NCT02074020|Drug|Blisibimod|Administered via subcutaneous injection once per week
45514001|NCT02074020|Drug|Placebo|Administered via subcutaneous injection once per week
45514002|NCT05764525|Drug|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
45514003|NCT05764525|Drug|Placebo|IV infusion of 0 mg of VVZ-149
45514004|NCT02213276|Other|Oral Glucose Tolerance Test (OGTT)|At baseline participants are asked to drink a glucose solution consisting of 75 grams of glucose dissolved in 250 ml of water. Meanwhile and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from an intravenous access, in order to asses primary and secondary outcomes.
45514005|NCT02213276|Other|Intravenous Glucose Tolerance Test (IVGTT)|In this intervention, the participant needs to have two intravenous accesses. In one we infuse an adjustable 20% glucose solution, and try to mimic the glucose profile found in the oral glucose tolerance test. In order to do this, blood glucose is measured every 5 minutes. At baseline and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from another intravenous access, in order to asses primary and secondary outcomes.
45514006|NCT02074098|Device|Macintosh laryngoscope|Direct Laryngoscope
45514007|NCT02074098|Device|Glidescope|Videolaryngoscope-1
45514008|NCT02074098|Device|Airwayscope|Videolaryngoscope-2
45596810|NCT05791825|Behavioral|Cultivating Healthy Intentional Mindful Educators|The 8-week, manualized, CHIME intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Each CHIME session focuses on a specific mindfulness technique, such as mindful breathing, mindful listening and bringing attention to current states and surroundings to support optimal responsiveness, emotion regulation, and compassion. Social emotional learning is promoted by focusing on five broad competencies: self-awareness, social awareness, responsible decision-making, self-management, and relationship skills and these competencies are practiced and developed through small group discussions, storytelling, journal reflections, modeling, and guided awareness (e.g., meditations), and implementation activities (e.g., gratitude necklace).
45514009|NCT05764447|Behavioral|Combined qigong Baduanjin and self-administered acupressure|The intervention will combine Baduanjin (BQ) and acupressure. The general design of the combination intervention is for BQ to be performed first (20 min), followed by self-administered acupressure (10 min). BQ comprises eight simple standardized movements. The combination of these simple body movements, breath control, and mindful meditation is designed to improve qi function.The acupressure protocol comprises six acupoints, i.e., Hegu, Quchi, Zusanli, Sanyinjiao, Qihai, and Taichong, which are the most commonly used acupoints in acupuncture trials for relieving CIPN according to previous reviews. These acupoints, based on TCM theory, are beneficial for strengthening the origin of qi and directing its flow to the upper and lower extremities. A massage pen will be used to stimulate the acupoints because participants with CIPN may have difficulty applying pressure with their hands/fingers.
45514010|NCT05764447|Behavioral|Wait-list Control|The participants will receive usual care alone during the study period and will be offered the training after the last follow-up.
45514011|NCT02221856|Procedure|Motion View|Motion View, a software we are using to place brackets virtually on a 3D rendition of a patients teeth, will be used to indirectly bond brackets onto patient's teeth with a 3D printed plastic transfer JIG in which the brackets will be precisely placed on the patients teeth according to the computer-guided software.
45514012|NCT02221856|Procedure|Conventional Orthodontic Treatment|orthodontic treatment using non-customized brackets and stock wires
45514013|NCT02080182|Drug|Acetylcysteine|
45514014|NCT02080182|Drug|placebo acetylcysteine|
45514015|NCT02224898|Behavioral|Mobile Mindfulness Therapy|Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
45514016|NCT02080338|Device|Orthodontic bracket slot system|Orthodontic treatment using different orthodontic bracket slot systems
45514017|NCT02750930|Drug|Albiglutide|Albiglutide liquid drug product is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid drug product (50 mg). Subjects will receive albiglutide 50 mg through subcutaneous injection in the abdomen, thigh or upper arm region via auto-injector. Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist).
45514018|NCT02750930|Device|Auto-injector|The auto-injector delivers the albiglutide liquid drug product in an injection volume of 1.0 mL for the 50 mg dose.
45514019|NCT02080416|Drug|Nelfinavir|Nelfinavir will be given 3000 mg orally twice daily on days 1-14 of a 14-day cycle. NFV will be continued in patients tolerating therapy for 4 cycles (8 weeks).
45514020|NCT05462665|Behavioral|theory training|theory training
45514021|NCT05462665|Behavioral|theory and simulation training|theory and simulation training
45514022|NCT02080494|Drug|Tranexamic Acid|
45514023|NCT02224976|Behavioral|Intensified Training|Volunteers will increase exercise training by 30% from baseline
45514024|NCT05764369|Behavioral|Parenting Wisely Residential Treatment (PWRT)|PWRT experimental intervention
46057354|NCT02707887|Behavioral|LETS ACT-SE|Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
45404833|NCT04701658|Drug|Bamlanivimab|Administered intravenously.
45404834|NCT03750526|Behavioral|rTMS and AR|rTMS performs 1Hz,15 minutes real rTMS. AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.
45404835|NCT03750526|Behavioral|Sham rTMS and AR|Sham rTMS applies 1Hz, 15 minutes sham rTMS. AR intervention includes weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.
45404836|NCT03750526|Behavioral|AR|AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 60 minutes.
45404837|NCT03750526|Behavioral|Conventional physiotherapy|Conventional physiotherapy includes rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on for 60 minutes.
45404838|NCT03756922|Drug|FDL169|CFTR corrector
45404839|NCT03756922|Drug|FDL176|CFTR potentiator
45404840|NCT01322776|Drug|Combination of Bortezomib, Fludarabine and Cyclophosphamide|bortezomib 1.3mg/m^2 i.v. on days 1, 4, 8 and 11 of each 28-day cycle fludarabine 25mg/m^2 i.v. on days 1~3 of each 28-day cycle cyclophosphamide i.v. on days 1~2 of each 28-day cycle
45404841|NCT03756844|Behavioral|Just Right Challenge Food Club|Systematic desensitization, positive reinforcement and escape extinction at a level of just right challenge.
45514025|NCT05764369|Behavioral|TAU|The TAU condition is the standard of care offered to parents in RT settings.
45514026|NCT02213744|Drug|MM-302|
45514027|NCT02213744|Drug|Gemcitabine|
45514028|NCT02213744|Drug|Capecitabine|
45514029|NCT02213744|Drug|Vinorelbine|
45514030|NCT02213744|Drug|Trastuzumab|
45514031|NCT02077764|Procedure|OCT and coronary angiography|
45514032|NCT02077764|Procedure|Right heart cat.|
45514033|NCT02077764|Radiation|PET|
45514034|NCT02077764|Procedure|Echocardiography|
45514035|NCT02077764|Procedure|exercise test|
45514036|NCT02077764|Other|blood samples|
45514037|NCT01378741|Drug|Propofol|Upon arrival to ICU patients will receive a propofol 2-6mg/kg infusion until tracheal extubation
45514038|NCT01378741|Drug|Dexmedetomidine|Upon arrival to ICU patients will receive dexmedetomidine bolus of 0.4mcg/kg followed by an infusion of 0.2-0.7mcg/kg per hour for a maximum period of 24 hours.
45514039|NCT02080650|Device|Mesenchymal-marker based ferrofluid (c-MET)|
45514040|NCT02080650|Device|Epithelial cell adhesion molecule (EpCAM) ferrofluid|
45514041|NCT02077842|Device|Nasal Continuous Positive Airway Pressure|Nasal continuous positive airway pressure at 10 cmH2O
45514042|NCT02077842|Device|Low Flow Oxygen|Low flow oxygen delivered via face mask at 8 litres per minute
45514043|NCT02461849|Drug|Imatinib|Imatinib 400mg qd daily
45514044|NCT02225054|Drug|Dexmedetomidine|0.5 u/kg Dexmedetomidine diluted in saline to 1 mL (single interscalene injection) Dexmedetomidine 0.5 u/kg as a single IV bolus over 30 minutes following GA induction
45514045|NCT02225054|Drug|Ropivacaine|15 ml 0.5%
45514046|NCT02225054|Drug|Normal Saline|1 mL 0.9%
45514047|NCT02080728|Drug|Ropivacaine 500mg/100ml Naropeine|
45514048|NCT02080728|Drug|0.9% sodium chloride BAXTER|
45514049|NCT05136794|Other|Data collection|complications: cardiac, neurological, renal, respiratory, red blood transfusion Hospital stays: ICU stays and hospital stay
45514050|NCT05095298|Drug|Vaccine, COVID19|It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group. Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention. Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.
45514051|NCT02222012|Device|"single channel Multiway Coil®"|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks).
45514052|NCT02222012|Device|"Two channels Multiway stimulator coil® (Brainsway Ltd.)"|"During the two channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)."
45514053|NCT02214758|Other|Nutrition and oral health interventions|On the basis of a blood test, Mini Nutritional Assessment, and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the participant and her/his nurse or family members. If the participants seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. After the dental hygienist interview and oral health examination, the participants in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions. Both the intervention and control groups had the same examinations as with the exception of the nutritional and oral health intervention.
45514054|NCT03078907|Drug|Selexipag|Film-coated tablets for oral use; one tablet (200 mcg) to eight tablets (1600 mcg) are administered depending on the individual tolerability.
45514055|NCT03078907|Drug|Placebo|Matching film coated tablets
45514056|NCT02225210|Drug|Dexmedetomidine|Loading dose:0.4μg.kg-1 Maintenance dose :0.2~0.7µg.kg-1 Sedation-Agitation Scale: maintain between 3 and 4.
45514057|NCT02225210|Drug|Midazolam|Loading dose of midazolam:0.1mg.kg-1 . Maintenance dose of midazolam :0.05~0.1mg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
45514058|NCT02225210|Drug|Fentanyl|Loading dose of fentanyl:1 μg.kg-1 . Maintenance dose of fentanyl: 0.5~1μg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
45514059|NCT02216942|Drug|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
45514060|NCT02216942|Drug|Endodontic treatment using Guedes Pinto|Endodontic treatment using Guedes Pinto paste
45514061|NCT02225288|Drug|E2022|transdermal E2022 tape formulation (8.1 cm x 8.1 cm)
45514062|NCT05462275|Device|Intubation using 3-cuffed double lumen endotracheal tube|After patient's position, 3-cuffed double lumen endotracheal tube is intubated without fiberoptic bronchoscopy guidance
45514063|NCT02225444|Other|OsteoAMP|OsteoAMP in posterolateral fusion procedure of the lumbosacral spine
45514064|NCT05462197|Behavioral|Qigong Wuqinxi|Wuqinxi is an exercise method developed by the ancient Chinese physician Hua Tuo by combining the ancient guide, breathing, and imitating the shapes of five animals, such as tiger, deer, bear, ape, and bird, combined with the zang-fu and meridian theory of traditional Chinese medicine. There have been studies in the past proven that this exercise can achieve health-promoting effects
45514065|NCT02077621|Drug|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline
45514066|NCT02077621|Drug|Placebo|500 mL normal saline
45514067|NCT02217020|Drug|FOLFOXIRI|irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
45514068|NCT03249714|Drug|Ofatumumab|Provided in pre-filled syringes for subcutaneous injection (s.c.) administration containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content)
45514069|NCT03249714|Drug|Matching placebo of ofatumumab|Matching placebo in pre-filled syringes
45596811|NCT05791799|Drug|Etonogestrel|Etongestrel implant will be implanted subcutaneously in the participant's non-dominant arm for one year
45404842|NCT03750214|Device|Biop Colposcopy System|"The procedure stages:~Scanning of the cervix - the cervix is scanned using the micro colposcope probe unit, to produce a total of 51 micro-images and one macro image from the panoramic camera.~Colposcopy exam - during the standard colposcopy exam, the doctor acquires a panoramic image of the cervix with the digital colposcope.~A questionnaire completed by the subject after the Biop procedure, with regards to any unusual sensations or events experienced during the procedure.~A questionnaire completed by the user after the Biop procedure, with regards to system usage~Image Registration analysis"
45851384|NCT02990208|Behavioral|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facilitates the practice of exposure-based treatments especially for situations or places difficult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been conducted or only in a limited manner (Mühlberger & Pauli, 2011)
45404843|NCT04877470|Other|Consultation at spine-centre|All patients who visited the spine-centre for the first time in 2019 are included in this group.
45404844|NCT00128102|Drug|Vorinostat|Vorinostat 100 mg oral capsules
45404845|NCT00128102|Drug|Placebo|Vorinostat-matching placebo oral capsules
45404846|NCT03965858|Drug|Esketamine DPI - low dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
45404847|NCT03965858|Drug|Esketamine DPI - medium dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
45404848|NCT03965858|Drug|Esketamine DPI - high dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
45404849|NCT03965858|Drug|Placebo DPI|Placebo DPI is to be administered via dry powder inhaler.
45404850|NCT03965780|Other|SPIN-SSLED Program|"The SPIN-SSLED Program is a 3-month-long (13 sessions) group training program designed to be delivered via videoconferencing to provide information and skills to improve leader support group leaders' confidence and self-efficacy to carry out their leadership roles and reduce the burden on them of leading a support group. Each session is about 90 minutes long and covers one of the 13 modules of the program.~Module topics includes: (1) The Leader's Role; (2) Starting a Support Group; (3) Structuring a Support Group Meeting; (4) Scleroderma 101; (5) Successful Support Group Culture; (6) Managing Support Group Dynamics; (7) Loss and Grief: The support group leader; (8) Loss and Grief in Scleroderma: Supporting group members; (9) Advertising and Recruitment for the Support Group; (10) The Continuity of the Group; (11) Supporting Yourself as a Leader; (12) Remote Support Groups; and (13) Transitions in Support Groups."
45404851|NCT04668274|Drug|200 mg resveratrol as JOTROL|Low (first) dose of single ascending dose study
45404852|NCT04668274|Drug|500 mg resveratrol as JOTROL|Second (intermediate) dose of single ascending dose study
45404853|NCT04668274|Drug|700 mg resveratrol as JOTROL|Third (highest) dose of single ascending dose study
45404854|NCT04668274|Drug|500 mg resveratrol as JOTROL administered to assess influence of food|500 mg resveratrol as JOTROL administered to assess influence of food
45404855|NCT01077908|Biological|Adoptive Cellular Therapy|CMV-specific T-cells, single infusion at 27 days post-HSCT
45404856|NCT01077908|Drug|Best available antiviral drug therapy|"Intravenous ganciclovir 5mg/kg twice daily~Oral valganciclovir 900mg twice daily~Intravenous foscarnet 90 mg/kg twice daily"
45404857|NCT03750058|Device|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
45404858|NCT04406194|Drug|FAVICOVIR 200 mg Film Tablet|FAVICOVIR 200 MG FT is containing 200 mg favipiravir manufactured by Atabay, Turkey.
45404859|NCT04406194|Drug|AVIGAN 200 mg Film Tablets|AVIGAN 200 mg FT is containing 200 mg favipiravir manufactured by Toyama, Japan.
45404860|NCT03822884|Drug|Epoetin Alfa 40000 UNT/ML|40.000 UI subcutaneous single dose
45404861|NCT03822416|Drug|Nicotine patch|Nicotine patch (dose based on number of cigarettes per day) (4-week, 8-week, or 12-week supply) depending on participant preference and how much they are smoking based on FDA guidelines for use
45404862|NCT03822416|Drug|Nicotine lozenge|Nicotine lozenge (2 or 4 mg if less or greater than 30 minutes to first cigarette in the morning respectively) (4-week, 8-week, or 12-week supply) depending on participant preference and how much they are smoking based on FDA guidelines for use
45404863|NCT03822416|Behavioral|Therapy|In-person meeting at baseline, 6 phone counseling sessions with participants over 8 weeks after initial in-person meeting, possible additional phone counseling (3 phone calls) from 8 weeks to 6 months after initial in-person meeting, and possible text messages when agreed to by participants during the 8 week to 6 month phase
45404864|NCT03822416|Other|Information|Information about smoking and mental illness and referrals to both the QUITPLAN helpline and additional resources in the community
45404865|NCT04405570|Drug|Molnupiravir 200 mg|Oral capsule of molnupiravir
45404866|NCT04405570|Drug|Molnupiravir 400 mg|Oral capsule of molnupiravir
45851385|NCT02990052|Procedure|Volar plating|Open reduction and volar fixed-angle plate fixation of distal radius fracture
45851386|NCT02990052|Procedure|Conservative treatment|Closed reduction & casting of distal radius fracture
45514070|NCT05764291|Behavioral|FIT-TEENS|FIT-TEENS is a digital behaviour change intervention which provides information on physical activity and behaviour change support towards physical activity, presented in multimedia format through an online learning platform (EdApp). The contents is developed in Malay language and consist of 10 self-paced modules and activities. The objectives of FIT-TEENS are for the participants to be able to 1) review the definitions and health benefits of physical activity 2) provide an overview of physical activity guidelines 3) write a SMART goal about physical activity 4) be aware of barriers to physical activity and how to overcome them.
45514071|NCT02217098|Procedure|GIC Restorations|Restorations using Glass Ionomer Cement
45514072|NCT02217098|Procedure|Carbomer Restorations|Restorations using Glass Carbomer
45404867|NCT04405570|Drug|Molnupiravir 800 mg|Oral capsule of molnupiravir
45514073|NCT02217098|Procedure|Compomer Restorations|Restorations using Compomer
45514074|NCT02218502|Other|Ultrasound by general gynaecologist|All patients will undergo an ultrasound by a general gynaecologist at the moment of inclusion. Based on this ultrasound, the gynaecologist will use both the RMI and the simple rules to predict the chance of malignancy.
45514075|NCT02218502|Other|Ultrasound by an expert ultrasonographist|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a second ultrasound scan. This scan is performed by an expert in gynaecological ultrasound.
45514076|NCT02218502|Other|DW-MRI|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a diffusion weighted MRI.
45514077|NCT02218502|Other|Give blood sample|Patients in which the simple rules yield an inconclusive result (about 20% of the patients) will be asked for an extra blood sample. We will use these materials to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
45851387|NCT02991300|Device|BioPoly RS Partial Resurfacing Patella Implant|
45851388|NCT02999958|Biological|Antioxidants|In the Treatment Arm, the G-Series culture media system will be used with antioxidants
45851389|NCT02995746|Drug|Dexamethasone|"On study visit #1 all patients will have a SD-OCT scan and measurement of baseline visual acuity. All patients will receive the 0.7mg dexamethasone intravitreal implant~Subsequent follow-up visits will be at 1 month, 2 months, 3 months, 4 months, 5 months, and 6 months after intravitreal injection of dexamethasone implant~Each visit will consist of measurement of visual acuity, intraocular pressure, dilated fundoscopic examination, and SD-OCT scan~Anticipated duration of the study: 6 months"
45404868|NCT04405570|Drug|Placebo (PBO)|placebo oral capsule
45514078|NCT05461651|Procedure|Knee arthroplasty|total or unilateral knee arthroplasty
45514079|NCT02080806|Device|Mechanical Insufflation Exsufflation|Mechanical Insufflation Exsufflation -Each patient received daily treatments by means of a light-weight, elastic oronasal mask. Treatments were divided between morning and afternoon and were carried out 5 times a week. A total of 20 sessions were carried out by a a trained respiratory therapist.
45514080|NCT02225522|Other|Rapid whole genome sequencing (StatSeq)|Patients in this arm will received standard genetic testing, the Perkins Elmer StepOne expanded newborn screen and the rapid whole genome sequencing (StatSeq). the receipt of the StatSeq testing is the different factor between arms. the standard genetic testing includes any testing that is clinically available to the attending physician that would normally be ordered for the patient if not enrolled in this study.
45514081|NCT04749589|Diagnostic Test|iron deficiency|Its not an intervention. Its an observational study. The groups are defined based on their iron status
45514082|NCT02222168|Drug|BI 409306|medium dose, oral administration
45514083|NCT02222168|Drug|BI 409306|medium dose, oral administration
45514084|NCT02222168|Drug|BI 409306|medium dose, oral administration
45404869|NCT01080092|Behavioral|breathing technique|breathing technique as a stress management technique, reinforced by biofeedback
45404870|NCT01080092|Behavioral|behavioral strategies|the control group reads a paper on the properties and components of tobacco and on behavioural strategies to cope with craving
45404871|NCT00127712|Drug|Amiodarone|
45404872|NCT01322854|Radiation|IMRT with an simultaneous integrated boost|IMRT in 28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed
45404873|NCT01082744|Drug|Ropivacaine + Sufentanil|Sufentanil at 0.25 µg/ml added to ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
45404874|NCT01082744|Drug|Ropivacaine|Ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
45404875|NCT04404010|Other|Immersive Virtual Reality|Participants randomized to the iVR simulator utilizes a head-mounted display producing 3D visuals with haptic controllers for an immersive operating room experience. The module produced consists of the key steps in performing a reverse shoulder arthroplasty using virtual versions of the equipment used in the real procedure. Prior to initiation, participants will be provided with a safety and training demonstration on the use of the VR module by study personnel. Participants will be provided as much time as they require to watch the video, including repetition if desired, which they will be timed for completion.
45404876|NCT04404010|Other|Surgical Technical Instructional Video|Participants will be provided as much time as they require to watch the instructional video, including repetition if desired, which they will be timed for completion.
45404877|NCT03748030|Radiation|Confirmed Left-Sided Breast Cancer|Left-Sided Patients will receive standard radiation therapy, including 42.5 Gy in 16 fractions or 50 Gy in 25 fractions.
45404878|NCT03749824|Dietary Supplement|Omega-3|Omega-3 supplement is a highly concentrated fish oil brain booster supplement that helps compensate for the neurocognitive and brain dysfunction which acts as a predisposition to antisocial and violent behaviour. Individuals with antisocial personality disorder have been found to show an 11% reduction in gray matter in the prefrontal cortex (Raine et al. 2001), and structural prefrontal impairments are hypothesised to result in disinhibition of limbic subcortical structures that give rise to aggressive behaviour. Omega-3 (specifically DHA) is known to play a key role in neuronal structure and function.
45514085|NCT04748731|Behavioral|Internet mentalization-based video feedback intervention to improve parental sensitivity in mother-infant dyads with maternal depressive symptoms|a weekly online brief intervention using video-feedback and psycho-educational materials on early parenting
45514086|NCT04748731|Behavioral|Psycho-Educational Intervention|Reception of psycho-educational materials
45514087|NCT03283722|Device|Profile 3D™ and CG Future® annuloplasty system|Patients suffering from mitral valve disease and indicated for a mitral valve repair procedure with Profile 3D™ and CG Future® annuloplasty system as part of standard of care, in accordance with the product label indications (instructions for use), contraindications, and warnings
45514088|NCT05236478|Other|CoviMouv' program|"An initiation to physical rehabilitation at the hospital center the first week, 3 sessions of 1 hour.~A tele-rehabilitation program led by an Adapted Physical Activity (APA) teacher for 3 weeks with 3 sessions of 1 hour per week.~All the sessions are led by a professional of adapted physical activity and will be personalized and adapted to the functional tests carried out during the initial evaluation.~Therapeutic education video-workshops weekly: about (i) the pathophysiology of fatigue in COVID-19, (ii) returning to work, (iii) lifestyle: sleep, physical activity and diet.~The medical follow-up will be carried out remotely with 1 weekly teleconsultation with a physiologist.~Psychological and / or dietetic follow-up, if necessary, during the program: 1 weekly teleconsultation At the end of the program, each participant is invited to contact the sport-health platform in order to continue the Adapted Physical Activity (APA) practice near home for 2 months."
45514089|NCT05236478|Other|Control|The CoviMouv' program is not presented to theses patients They have support for the resumption of an adapted physical activity in autonomy, according to the results of the aerobic and anaerobic tests carried out during the initial evaluation (delivery of a training booklet).
45514090|NCT02925117|Drug|Upadacitinib|Tablet for oral use
45514091|NCT02925117|Drug|Placebo|Tablet
45851390|NCT02990364|Drug|Sucrose|Sucrose was given to three out of the 4 intervention groups, to assess its effectiveness in managing pain during circumcision.
45851391|NCT02990364|Drug|Lidocaine|Lidocaine was given as a local anesthetic via Ring and Dorsal Penile Block to two of the intervention groups, in combination with the topical cream EMLA and sucking on sucrose.
45514092|NCT05235308|Procedure|Percutaneous adhesiolysis|Percutaneous adhesiolysis is a minimally invasive technique which involves the use of a spring-wound catheter, ideally placed in the ventrolateral aspect of the epidural space for the lysis of adhesions.
45514093|NCT04634149|Drug|BMS-986036|Specified dose on specified days
45851392|NCT02990364|Drug|EMLA Topical Product|EMLA cream will be applied 70 minutes to the circumcision to all participants of the study.
45851393|NCT01270074|Drug|Azithromycin|azithromycin will be given as a liquid preparation at a dose of 10 mg/kg three times per week from three months of age until three years of age
45851394|NCT01270074|Drug|Placebo control|inert liquid preparation will be given three times per week from three months of age to three years of age
46057355|NCT02707887|Behavioral|Treatment as Usual|Participants will receive the treatment typically provided to patients at the substance use treatment facility.
45514094|NCT05056298|Other|Custom made insole|Custom made arch support insole with semi-rigid arch support will be made using the casting method, plaster cast of both feet in a subtalar neutral position will be taken from each subject by highly specialized orthotist. The negative casts will be placed in calcaneal vertical position and custommolded orthosis will be fabricated to positive molds obtained from the negative casts with the goal to control the pronation movement of the foot
46057356|NCT02593201|Drug|Extended antibiotics (cefazolin or ceftazidime)|To continue with the existing effective antibiotic therapy for one extra week
46057357|NCT02593201|Drug|Usual antibiotics (cefazolin or ceftazidime)|Usual duration of effective antibiotic therapy therapy
46057358|NCT02707809|Drug|Dexmedetomidine|Dexmedetomidine infusion
45514095|NCT05056298|Other|Strengthening exercises of extrinsic foot muscles|Participants will perform extrinsic foot muscles strengthening exercises with both ankles 3 times per week, 20 minutes for 8 weeks. they will be trained using a progressive resistance protocol using Thera-Band elasticated bands. Subjects will be progressed weekly throughout the training period according to progressive resistance protocol for dorsiflexors, planterflexors, evertors and investors muscles.
45514096|NCT05056298|Other|Strengthening exercises of intrinsic foot muscles|The patient will assume the same position as in intrinsic foot muscle assessment, then he will be instructed to hold the position for a count of 10 seconds and attempt to maintain the MLA as steady as possible during the entire time without any compensatory extrinsic foot muscle activity. Following the 10-seconds, slowly and with eccentric control allow the foot to pronate and the MLA to lower to a relaxed state .
45514097|NCT05056298|Other|Standard insole|Patient will be instructed to wear a standard prefabricated flat insole as a placepo treatment iniside his shoes for 2 months (8 weeks), 6 to 8 hours per day, and adhere to wearing the orthoses during outdoor walking and during extrinsic foot muscle training.
45514098|NCT02074332|Behavioral|Physical activity guidance|Physical education class amelioration Additional physical activities for overweight&obese students Family physical activities Parent involvement
45514099|NCT02074332|Behavioral|Health education|Knowledge of obesity prevention and control
45404879|NCT03749824|Dietary Supplement|Placebo Capsules|Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months.
45404880|NCT04401202|Dietary Supplement|Nigella sativa oil|Nigella sativa oil 500mg softgel capsules in oral twice daily dose for 10 days
45404881|NCT00096356|Dietary Supplement|CoQ10 & Vitamin E|
45514100|NCT04102735|Device|Under-the-nose facemask|Patients with acute hypercapnic respiratory failure that need noninvasive ventilation and are randomized in the experimental group will receive the AF541 facemask used with the under-the-nose cushion.
45404882|NCT00096356|Dietary Supplement|Placebo & Vitamin E|
45404883|NCT03747952|Procedure|Tibiotalocalcaneal arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
45404884|NCT03747952|Device|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
45404885|NCT03747874|Diagnostic Test|ventilatory polygraphy|we put a ventilatory polygraphy device on the patient in the evening, they come back home to sleep while the device is recording ventilatory parameters and they come back the morrow to give the device back
45514101|NCT04102735|Device|Over-the-nose facemask|Patients with acute hypercapnic respiratory failure that need non-invasive ventilation and are randomized in the comparator group will receive the AF541 facemask used with the over-the-nose cushion.
45514102|NCT02080962|Radiation|30 Gy in 5 fractions|5 fractions of 600 cGy, once a day, five times a week - TDF: 89
45514103|NCT02080962|Radiation|40 Gy in 10 fractions|tumors > 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96
45514104|NCT01379911|Other|Yogurt|
45514105|NCT05235152|Other|Usual individual physiotherapy care|"Usual and individual physiotherapy care guidelines were developed through a round-table discussion involving experts in musculoskeletal health. From the round-table discussion, the consensus as reflecting best-practices for the rehabilitation of musculoskeletal rehabilitation supported an active exercise rehabilitation approach which includes strengthening and neuromuscular training exercises. Furthermore, the following treatments are considered in addition to active exercises:~Range of motion: active, active-assisted, passive, repeated movements (Mulligan or McKenzie);~Stretching / manual therapy: mobilizations, manipulation, neural mobility, active release therapy;~Individual proprioceptive training."
45514106|NCT05235152|Other|Group-supervised physiotherapy training programs|Three group-supervised physiotherapy training programs (The lumbar, the upper extremity and the lower extremity training programs) were developed for military members with musculoskeletal conditions. They are composed of stations that each include several exercises of varying levels of difficulty. Group size will vary between 5 to 20 participants for one physiotherapist, and each military member performs his/her own exercises. During a typical session, the participant and therapist will choose one exercise to perform per station according to two main criteria: severity of the condition and the ability to perform the exercises optimally. The level of supervision is adapted to the participant's needs and performance. Progression in the programs leads to the execution of exercises that simulate functional and occupational tasks.
46057359|NCT00585325|Drug|Instilled 1% Lidocaine|5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
45404886|NCT03749590|Drug|Magnesium Sulfate|Patients receive 2 infusions (10 ml magnesium sulfate added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
45404887|NCT03749590|Drug|Placebo (NaCl 0,9%)|Patients receive 2 infusions (10 ml NaCl 0.9% added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
45404888|NCT03749512|Diagnostic Test|Complete blood count|During routine preoperative blood test complete blood count is taken.
45404889|NCT03749512|Other|Histopathological examination|Routine postoperative histopathological examination of lung tumor.
46057360|NCT00585325|Other|Placebo (0.9% Normal Saline)|.9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
46057361|NCT02717325|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation- SR16-08)
45514107|NCT02077920|Drug|Chlorhexidine|"SFDA Approval No. H21020748; Jinzhou Jiu Tai Pharmaceutical Co., Ltd., Liaoning, China~Drug administration and preparation:~Drug administration: oropharyngeal rinsing and suctioning of subglottic secretions~Drug preparation: 0.12% chlorhexidine solution prepared with distilled water that has been sterilized by autoclaving"
45514108|NCT02077920|Drug|0.9% sodium chloride injection|SFDA Approval No. H20045252; Shenyang Zhiying Pharmaceutical Co., Ltd., Liaoning, China
45514109|NCT02077920|Device|Endotracheal tube|Type 5-10115; size 7.0 mm, 7.5 mm, or 8.0 mm; purchased from Teleflex Medical (USA).
45514110|NCT02077920|Device|Fiber bronchoscope|For suctioning of subglottic secretions. BF-P30 (Olympus, Japan); BF-1T20 (Olympus, Japan); or FB-18BS (Pentax, Japan).
45514111|NCT03630133|Device|Intracept System Ablation|Radiofrequency ablation using Intracept System
45514112|NCT05232890|Other|Datterino tomato purée from hydroponic technology|Daily intake of minimum 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from hydroponic technology (soilless), contained in a 720ml bottle.
45514113|NCT05232890|Other|Datterino tomato puree from conventional cultivation|Daily intake of at least 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from conventional cultivation, contained in a 720 ml bottle.
45514114|NCT02081040|Other|Not applicable (observational study with no active intervention)|
45514115|NCT03630523|Biological|Influvac Tetra|Tetravalent seasonal flu vaccination 2018/2019
45514116|NCT02225756|Drug|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 1
45514117|NCT02225756|Drug|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 2
45514118|NCT02225756|Drug|Placebo|Oral administration for a short time of placebo
45514119|NCT02074488|Other|Balancing Act exercise curriculum|"Balance improvement exercise curriculum titled Balancing Act"
45514120|NCT02074488|Other|Informational Brochure|Informational Brochure on falls prevention
45514121|NCT02220062|Procedure|EUS-CPN|After initially identifying the celiac trunk on endoscopic ultrasound, each injection of 5~10cc ethanol would be performed as bilateral injections at the celiac trunk.
45514122|NCT02220062|Procedure|EUS-CGN|First, identify celiac ganglia. If the celiac ganglia are visualized under linear EUS, the injection of 2~3cc ethanol are applied directly into the each ganglia. If the ganglia are not identified by EUS, bilateral EUS-CPN would be performed
45514123|NCT02074566|Other|Cryoballoon ablation|PVI using cryoballoon
45514124|NCT02225834|Drug|Atorvastatin|treatment with atorvastatin 80 mg (once-daily) from admission day until discharge
45514125|NCT02077998|Radiation|carbon C 14 oxaliplatin|Given IV
45514126|NCT02077998|Drug|oxaliplatin|Given IV
45514127|NCT02077998|Other|laboratory biomarker analysis|Correlative studies
46057362|NCT02717169|Device|Biometrical tracker|35 participants are wearing a activity, sleep and heart rate tracker day and night time over a period of 5 month. The wrist watch is equipped with accelerometer, heart rate monitor using oximetry sensor, 3 led lights and vibrating alarm. The tracker is connected over Bluetooth with a smartphone App displaying the measured values and permitting to show different statistics related to amount of steps, sleep duration and heart rate over days, weeks and months.
45514128|NCT05461183|Other|Retrospective database analysis|This study will review data provided by the BCPDR from April 1, 2008 to March 31, 2021.
45514129|NCT02225912|Other|PrevinC|
45514130|NCT02225912|Drug|placebo|
45514131|NCT02074644|Procedure|Prostatic Arterial Embolization|"The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. Bead Block 300-500 or PVA 100+200 micra particles are slowly injected under fluoroscopic control until the end point is reached. Embolization is considered finished when there is near stasis in the prostatic vessels with interruption of the arterial flow and prostatic gland opacification checked in both oblique and AP views. Upon finishing the embolization of the left prostatic arteries, the right prostatic arteries are embolized in the same way."
45514132|NCT02074644|Procedure|Sham procedure|The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. The catheter is removed and no particles are injected.
45514133|NCT01325233|Drug|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
45514134|NCT01325233|Drug|Placebo|500 ml normal saline, tiw, 2 weeks
45514135|NCT02222324|Drug|Placebo|8 placebo tablets matching E2609
45514136|NCT02222324|Drug|E2609|E2609 will be administered as 8 tablets
46057363|NCT02717247|Device|Active tRNS|"The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsolateral prefrontal cortex (F4).~100Hz-650Hz, 2mA, 30min, twice daily, 5 days"
45404891|NCT04567732|Combination Product|injection of Filtered Autologous Adipose Tissue|Single injection of Filtered Autologous Adipose Tissue
45404892|NCT04567732|Drug|Placebo|Single injection of Placebo
45404893|NCT01076816|Drug|dexmedetomidine|"dexmedetomidine will be given max 48h. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.~Additional drugs are given to every inadequately sedated patient (assessed by regular Comfort scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed."
45404894|NCT01076816|Procedure|Vital signs|systolic and diastolic blood pressure, heart rate, respiratory rate,oxygen saturation, temperature are assessed baseline and at least per hour reassessed after starting the dexmedetomidine.
45514137|NCT02222324|Drug|Moxifloxacin|Administered as 1 tablet with 7 tablets of placebo matching E2609
45514138|NCT02220140|Behavioral|The Resilience Program|See the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'.
45514139|NCT02074800|Drug|CNTO 328 (Sp2/0-derived)|Participants will receive a single-dose of Sp2/0-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
45514140|NCT02074800|Drug|CNTO 328 (CHO-derived)|Participants will receive a single-dose of CHO-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
45404895|NCT01076816|Procedure|blood sampling|Blood sampling for pharmacokinetic modelling is limited to a maximum of 1,8 ml/kg (in line with the EMEA guidelines on maximum blood sampling in children). Pharmacokinetic parameters and influence of covariates on these parameters will be assessed by a population pharmacokinetic approach.
45404896|NCT03777982|Drug|Prednisone|Taking advantage of the anti-inflammatory properties of the medication, corticosteroids are used to decrease the swelling around tumors.
45404897|NCT03777982|Drug|Apalutamide|Apalutamide also prevents the androgens from working within the prostate cancer cells, and can ultimately lead to cancer cell death.
45404898|NCT03777982|Drug|Abiraterone Acetate|Abiraterone acetate interferes with an enzyme that is expressed in testicular, adrenal, and prostatic tumor tissues and is required as part of the body's androgen producing process. Because of this interference the amount of androgens produced are decreased. Abiraterone acetate, blocks androgen production at three sources; the testes, the adrenal glands, as well as from the tumor itself
45404899|NCT03777982|Drug|LHRH Agonist or Antagonist|Luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or GnRH agonists) are drugs that lower the amount of testosterone made by the testicles
45404900|NCT03718156|Other|PREPARED Trial Intervention|Nursing staff members will be trained to adjust the therapeutic nursing plans (TNP) for residents enrolled in the study, as follows: 1) by providing optimal stimulation (surveying the use of eyeglasses and hearing aids, the room lighting and space organization; orienting the resident to time and space; and stimulating the resident using familiar objects, photos, and life histories); and 2) by assessing the presence of 4 modifiable delirium risk factors (antipsychotic use, sensory impairment, restraint use, and dehydration) and taking specific actions once a given risk factor is identified. For instance, if physical restraints are used, the TNP will require that they are to be removed during care when a caregiver is present (nail care, feeding, and wound care).
45404901|NCT03747796|Other|Supine position|The children will be placed in the supine position after ingestion of a standard volume of clear fluid
45404902|NCT03747796|Other|Semi-sitting position|The children will be placed in the semi-sitting position after ingestion of a standard volume of clear fluid
45404903|NCT04384822|Behavioral|Tai Chi Group|Mind-body exercise intervention
45404904|NCT04384822|Behavioral|CBT-I Group|First-line clinically recommended non-pharmacological treatment of insomnia
45404905|NCT03749356|Drug|TacroBell SR cap.|"Orally, once-daily in the morning~After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3~12ng/ml for 0 to 3months and then at 3~8ng/ml for 3 to 6months of study treatment."
45514141|NCT02074800|Drug|Placebo|Participants will receive a single-dose of matching placebo intravenously in Part 1.
45514142|NCT04504045|Drug|Metformin|500 mg tablet
45514143|NCT04504045|Drug|Caffeine|As part of a 6-drug cocktail caffeine 100 mg tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP1A2 activity.
45514144|NCT04504045|Drug|Efavirenz|As part of a 6-drug cocktail efavirenz 50 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2B6 activity.
45514145|NCT04504045|Drug|Losartan|As part of a 6-drug cocktail losartan 12.5 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C9 activity.
45514146|NCT04504045|Drug|Omeprazol|As part of a 6-drug cocktail Omeprazol 10 mg enteric-coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C19 activity.
46057364|NCT02717247|Device|Sham tRNS|The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
46057365|NCT02514525|Device|CryoBalloon Ablation System|CryoBalloon Ablation System, a balloon-based cryotherapy device, provides controlled ablation for the treatment of BE. Deployed through the working channel of an endoscope, the Balloon is simultaneously inflated and cooled with an inert cryogen (nitrous oxide) delivered from the handle that ablates the BE cells upon contact with the esophagus.
45404906|NCT03622528|Radiation|Chest CT scan|Standard dose chest CT scan
45404907|NCT01562470|Other|Cellulite reduction cream|1/8 tsp cellulite cream will be applied to the thigh twice daily - in the morning and at night, for a period of 16 weeks.
45404908|NCT01562158|Procedure|standard therapy|Standard treatment of bleeding
45404909|NCT01562158|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
45404910|NCT01562158|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - medium dose administered i.v. (into the vein)
45404911|NCT01562158|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
45404912|NCT01562158|Drug|placebo|Placebo
45404913|NCT03749200|Other|Obemat2.0 therapy|
45404914|NCT03749200|Other|Regular practise in primary care|
45404915|NCT03612232|Drug|Cabozantinib-s-malate|oral cabozantinib-S-malate 60 mg as a daily single oral dose continuously
45404916|NCT05297110|Drug|atherolive|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
45404917|NCT04315246|Biological|radiolabeled DPTA-omburtamab|Biological, radiolabeled DPTA-omburtamab
45404918|NCT04358068|Drug|Hydroxychloroquine (HCQ)|Administered orally
45404919|NCT04358068|Drug|Azithromycin (Azithro)|Administered orally
45514147|NCT04504045|Drug|Metoprolol|As part of a 6-drug cocktail metoprolol 12.5 mg release tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2D6 activity.
45404920|NCT04358068|Drug|Placebo for Hydroxychloroquine|Administered orally
45514148|NCT04504045|Drug|Midazolam|As part of a 6-drug cocktail midazolam 2 mg oral solution will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP3A4 activity.
45514149|NCT02225990|Other|Experimental Group, Sub-Acute|For the sub-acute experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
45514150|NCT02225990|Other|Experimental Group, Chronic|For the chronic experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
45514151|NCT02225990|Other|Standard of Care, Sub-Acute|This group will receive standard of care stroke rehabilitation therapy.
45514152|NCT02225990|Other|Standard of Care, Chronic|This group will receive standard of care stroke rehabilitation therapy.
45514153|NCT03283488|Drug|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
45404921|NCT04358068|Drug|Placebo for Azithromycin|Administered orally
45404922|NCT03694210|Device|EndoRotor Therapy|To evaluate the EndoRotor's ability to safely remove non-viable/necrotic tissue for direct endoscopic necrosectomy in patients with walled off pancreatic necrosis.
45404923|NCT04339972|Device|LIFUP|Low Intensity Focused Ultrasound Pulsation (LIFUP) is an interesting new form of brain stimulation that may be possible to stimulate non-invasively, safely, deep in the brain with focal precision.
45404924|NCT04339972|Device|Sham LIFUP|The same as LIFUP but the device is not turned on and the subject does not receive any ultrasound.
45404925|NCT04172038|Behavioral|Physical Therapy|Physical therapy will be delivered using a guideline-concordant approach based off the Department of Defense -Veterans Affairs Low Back Pain Guidelines, focusing on risk-stratified care deliver (using the STarT Back tool as an adjunct).
45404926|NCT04172038|Behavioral|Move 2 Health (M2H)|"Participants will receive education for self-management (video and written materials) to introduce the key domains of holistic health in the Move to Health (M2H) model and their relationship to chronic LBP. Next, the participant will complete a Personal Health Inventory. The Inventory will be reviewed by the health coach and patient in order to identify specific domains for priority based on patient preference:~Sleep~Physical Activity~Nutrition~Intrinsic Well-Being (Personal Development, Spiritual Well-Being, Emotional Well-Being)~Extrinsic Well-Being (Family/Social Relationships, Surroundings)~Care may range from guided self-management with the researcher to a specialist referral (e.g., sleep specialist, dietician, behavioral health provider, etc.)."
45514154|NCT03283488|Drug|Megestrol|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
45514155|NCT02258204|Drug|Ketamine|Co-administration of subanesthetic dose of ketamine with tPA for thrombolysis in acute ischemic stroke.
45514156|NCT02258204|Drug|Placebo|
45514157|NCT04448743|Other|Blood sample|20 Ml blood sample
45404927|NCT04172038|Behavioral|MORE Mindfulness|"Throughout the intervention, three core areas are emphasized. Activities include exercises and at-home work for participants to reinforce these core areas.~Mindfulness~Cognitive reappraisal~Savoring of positive experiences"
45404928|NCT00096278|Biological|Bevacizumab|Given IV
45514158|NCT02226068|Drug|Cyclosporine A (CsA)|3 mg/kg/day for 4 month
45514159|NCT02226068|Other|Extracorporeal photopheresis (ECP)|Administered two consecutive days twice a month for 4 month
45514160|NCT02081274|Procedure|Surgery for congenital heart disease|
45514161|NCT05424991|Behavioral|comedy movie group|The patients watched the collage videos of Turkish cinema Yeşilçam comedy films created by the researchers for 25 minutes. The videos were created by making collages from videos on youtube.
45514162|NCT02081352|Other|DermaPure™|"A minimally manipulated human tissue regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps)"
45514163|NCT02081352|Other|Standard care|
45514164|NCT02222402|Behavioral|INTRA-DIALYTIC EXERCISE TRAINING|
45514165|NCT01378585|Drug|DLBS1033|3 x 490 mg DLBS1033 daily
45514166|NCT01378585|Drug|Placebo|3 x 1 tablet daily
45514167|NCT02220218|Drug|Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)|Canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
45514168|NCT02220218|Drug|Canagliflozin|Canagliflozin tablet 50 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
45514169|NCT02220218|Drug|Metformin IR|Metformin IR tablet 500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
45514170|NCT03559452|Procedure|Eccentric exercise|300 eccentric contractions of the knee extensors
45404929|NCT00096278|Drug|Fluorouracil|Given IV
45404930|NCT00096278|Drug|Leucovorin Calcium|Given IV
45514171|NCT02081430|Procedure|CT Manipulation|
45404931|NCT00096278|Drug|Oxaliplatin|Given IV
45514172|NCT02081430|Procedure|Upper trapezius stretch|
45514173|NCT02222480|Drug|Fimasartan|
45514174|NCT02222480|Drug|Hydrochlorothiazide|
45514175|NCT02222480|Drug|Placebo|
45514176|NCT03669471|Other|Testing of performance|"The cross-sectional evaluation will involve assessment of:~Hip muscle function~Single leg jump performance~Self-reported hip and groin function~Evaluation of return to sport~Evaluation of satisfaction regarding usual-care post-operative rehabilitation~The exercise-based treatment will involve criteria-based physiotherapy aiming at improving muscle function around the hip and trunk."
45514177|NCT02081508|Behavioral|Interference onset|Temporal duration of interference onset.
45514178|NCT02258438|Behavioral|Uninterrupted sitting|Subjects will be asked to refrain for two days from any structured activity and to reduce any daily life activity (walking, taking the stairs, biking, etc.) in their daily life. On day 3, subjects will remain seated all day in the room calorimeter, except to rise from the chair to void.
46057366|NCT02717013|Dietary Supplement|Placebo|Placebo capsules containing calcium lactate similar to the HMB capsules.
45514179|NCT02258438|Behavioral|Sitting + 1 bout of activity|Subjects will be asked to perform 45 minutes of moderate-exercise in the morning once per day for two days in their daily life. On day 3 they will remain seated all day in the room calorimeter, except to rise from the chair to void, and to perform one bout of 45-min moderate-intensity (defined below) walking on a treadmill at 1000.
45514180|NCT02258438|Behavioral|Sitting + microbursts of activity|Subjects will be asked to refrain from any structured exercise for two days but to walk for 5 minutes each hour between 1000 and 1800 in daily life. On day 3, subjects will rise from the seated position every hour for 9 hours from 1000 to 1800 to complete 5min moderate-intensity (defined below) walking on a treadmill, which represents a total of 45min.
45514181|NCT03670875|Dietary Supplement|Agave inulin|Will be provided in dehydrated apple cubes
45514182|NCT03670875|Dietary Supplement|Curcumin|Will be provided in capsules
45514183|NCT03670875|Dietary Supplement|O3FA|Will be provided in capsules
45514184|NCT03670875|Behavioral|Control|Dietary recommendations to ingest 1600 calories per day. Exercise: 30 minutes each day, al least 5 days a week (caloric consumption 150-200 kcal per day)
45404932|NCT03748732|Procedure|sclerectomy|scleral flap
45404933|NCT03748654|Diagnostic Test|Visual Field Testing|Visual field test using the protocol 24-2 Threshold Test
45404934|NCT00095940|Drug|lapatinib ditosylate|Given orally
45404935|NCT00095940|Procedure|therapeutic conventional surgery|Undergo surgery
45404936|NCT00095940|Other|laboratory biomarker analysis|Correlative studies
45404937|NCT00095940|Other|pharmacological study|Correlative studies
45404938|NCT00095940|Procedure|positron emission tomography|Correlative studies
45404939|NCT00095940|Procedure|magnetic resonance imaging|Correlative studies
45404940|NCT00114218|Drug|Gemcitabine Hydrochloride|Given IV
45404941|NCT00114218|Drug|Docetaxel|Given IV
45404942|NCT00095628|Drug|ispinesib|Given IV
45404943|NCT00095628|Other|laboratory biomarker analysis|Correlative studies
45404944|NCT00095628|Other|pharmacological study|Correlative studies
45514185|NCT02078076|Device|Magnetic Resonance Cardiac Imaging (with Gadolinium)|
45514186|NCT02226146|Biological|Bertilimumab|
45514187|NCT01379677|Drug|Rubidium-82|Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use
45514188|NCT01379677|Drug|Sestamibi. reconstitution with sodium pertechnetate (99mTc)|Maximum dose allowed per injection: 1000 MBq Intravenous Use
45514189|NCT02220296|Drug|Insulin 338|Healthy subjects will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
45514190|NCT02220296|Drug|placebo|Healthy subjects will receive a single dose of placebo. Injected subcutaneously (under the skin).
45514191|NCT02220296|Drug|Insulin 338|Subjects with type 1 DM will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
46057367|NCT02717013|Dietary Supplement|HMB|HMB capsules supplying 3 grams per day of calcium beta-hydroxyl-beta-methylbutyrate.
45404945|NCT01077986|Drug|Capecitabine|Capecitabine will be administered for 14 days in a 3 weekly cycle, starting on day 8.
45404946|NCT01077986|Drug|Cetuximab|Cetuximab will be administered weekly, starting at day 8.
45404947|NCT01077986|Drug|Everolimus|Everolimus will be administered daily, starting on day 1.
45404948|NCT01082562|Drug|BMS-844421|"Ready-to-use stock solution for SC and IV, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days"
45404949|NCT01082562|Drug|0.9% sodium chloride injection solution|"Injection solution, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days"
45404950|NCT01086930|Device|ReJoyce Workstation|The device has two parts. A muscle-stimulator garment that incorporates a wireless-triggered stimulator cuff and an earpiece, similar to a hearing aid, that sends a radio signal to the stimulator cuff. As well as a specialised workstation known as ReJoyce, which connects to a standard computer via a USB port. This work station will allow the user to play specialised computer games focusing on hand function. The stimulator system and the ReJoyce workstation were developed by Professor Arthur Prochazka, University of Alberta, Canada and has been approved by the Canadian Standards Association.
45404951|NCT01086930|Other|Standard Care|All participants will continue to receive the same standard care for the hand and upper limb as typically provided by their rehabilitation units.
45404952|NCT03748576|Behavioral|telemedicine: management through WeChat group chat|Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care
45404953|NCT03963180|Other|coffee|All patients were asked to drink the entire 150-mL amounts within 20 minutes under the supervision of a nurse or doctor. Patients were free to drink any amount of water but no more coffee, black tea, or other forms of caffeine, such as soda. Coffee and hot water were prepared with a conventional coffee machine (Nescafe Alegria; 100 g caffeine; Nestlé. Gatwick, United Kingdom).
45404954|NCT03963024|Drug|"Conditioning treatment Treosulfan-TMI"|Treosulfan i.v.: 14 g/m²/d (day -6 to -4) Fludarabine i.v.: 30 mg/m²/d (day -6 to -2) Antithymocyte globulin (ATG)-Fresenius i.v.: 5/0 mg/kg (day -4 to -2) Mabthera i.v.: 200/0* mg/m2 (day -1) TMI: (10 Gy) 2 Gy bis in die (BID) (day -2 to -1) or TMI: (12 Gy) 2 Gy BID (day -3 to -1) or TMI: (14 Gy) 2 Gy BID (day -3 to -1)
45404955|NCT03963024|Procedure|SCT|Stem Cell Transplant
45404956|NCT03963024|Drug|GvHD prophylaxis|Rapamycin p.o.: 4 mg/d, (target 8-15 ng/ml) (starting day -7) Mycofenolate mofetile: 10 mg/kg tid, (Maximum dose 720 mg/tid) (starting from day 0)
45404957|NCT01082718|Drug|Mefloquine Artesunate|Mefloquine-artesunate fixed dose combination (Farmanguinhos): Artesuanto 100 mg and Mefloquine 220mg per tablet, dosed once daily for 3 days such that mefloquine dose is approximately 8mg/kg/day.
45404958|NCT02531100|Device|BonyPid 500TM implantation concomitantly to SOC treatment|BonyPid 500TM implantation concomitantly to SOC treatment
45404959|NCT02531100|Other|SOC treatment only|Standard of care treatment (Manual and ultrasonic debridement, and surface decontamination)
45514192|NCT02220296|Drug|insulin glargine|Subjects with type 1 DM will receive 0.4 U/kg insulin glargine once daily for 4 days. Injected subcutaneously (under the skin).
45514193|NCT03670719|Other|Manual Therapy and Exercise|Combination of physiotherapy (manual therapy) techniques and exercises for the cervical spine
45514194|NCT03670719|Other|Exercise|Exercises for the cervical spine
45514195|NCT02074878|Drug|Crixotinib 200 mg and Sunitinib Cohort 1|Crizotinib 200 mg, twice daily with Sunitinib 25.0 mg once a day
45514196|NCT02074878|Drug|Crixotinib 250 mg and Sunitinib Cohort 2|Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
45514197|NCT02074878|Drug|Crizotinib & Sunitinib 37.5 mg Cohort 3|Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
45514198|NCT02258672|Other|Prehabilitation program|Progressive and individualized physical training aimed at improving core muscles strength and endurance as well as spinal stability.
45514199|NCT01379599|Behavioral|brief motivation intervention|Brief motivation intervention consisting of brief psychosocial counseling (20 minutes at the time of an ER visit)
45514200|NCT02220374|Other|Supportive Finger Tape|Dorsally applied elasticated tape may or may not improve the kinetics of the PIPJ and therefore reduce pain as well as improve function
45514201|NCT02081664|Behavioral|lifestyle intervention|
46057368|NCT02716857|Drug|Oxycodone extended-release|
46057369|NCT02716857|Drug|Placebo of oxycodone extended-release|
46057370|NCT04164303|Other|Physical Therapist management|Physical Therapist management included joint manipulation, mobilization with movement, strengthening exercises, and grip proprioception training.
45514202|NCT03075163|Procedure|Acupressure|"Specifically trained personnel will apply pressure on the wrists bilaterally at the P6 point for up to 3 minutes. The P6 point is located three fingerbreadths from the wrist crease on the volar surface of the arm between the palmaris longus and flexor carpi radialis.~In the event of failure in the acupressure group, further treatments will be identical to the control group. Since Ondansetron is the standard Post Anesthetic Care Unit treatment, it will be first line rescue therapy except in the case that the patient has received 8mg in the past 6 hours. If needed, further antiemetic pharmacologic treatments may include, but are not limited to, phenergan, metoclopramide, haloperidol, diphenhydramine or propofol at the clinical discretion of the patient's anesthesiology care team."
45514203|NCT03075163|Drug|Ondansetron|Ondansetron is a medication that belongs to the drug class known as antiemetic and selective 5-HT3 receptor antagonist. Ondansetron is prescribed for the treatment of nausea and vomiting due to cancer chemotherapy and also used to prevent and treat nausea and vomiting after surgery.
45404960|NCT01583010|Device|ANV(R)|"Device: Advanced Needle Visualization Technology ®~Software update for SonoSites M-Turbo® and S-series™ ultrasound systems with enhanced 15-20Mhz ultrasound probe.~Arms: ANV ® Group"
45514204|NCT02628405|Drug|Carboplatin|Given IV
45514205|NCT02628405|Drug|Etoposide|Given IV
45514206|NCT02628405|Drug|Ifosfamide|Given IV
45514207|NCT02628405|Other|Laboratory Biomarker Analysis|Correlative studies
45514208|NCT02628405|Drug|Lenalidomide|Given PO
45514209|NCT02628405|Biological|Rituximab|Given IV
45514210|NCT02258750|Dietary Supplement|Polydextrose|High fibre polydextrose enriched tomato soup (matched for sensory and nutritional characteristics to control) and eaten one hour before an ad-libitum lunch on study days. A 410g pre-packaged portion will be provided which contains 6% polydextrose compared to control.
45514211|NCT02258750|Other|Control|Tomato soup (matched for sensory and nutritional characteristics to control) served in a 410g portion and eaten one hour before an ad-libitum lunch on study days.
45514212|NCT02220530|Drug|Conscious sedation with iv midazolam and fentanyl.|Sedation group: Conscious sedation with iv midazolam and fentanyl dosed according to age, weight and baseline conditions of the patients.
45514213|NCT02078232|Device|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle"
45514214|NCT02078232|Device|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle"
45514215|NCT02075034|Drug|rigosertib|Rigosertib will be supplied as soft gel capsules in strengths of 280 mg and 70 mg.
45514216|NCT03670563|Other|Short foot exercise protocol|Exercises that target intrinsic foot muscles
45514217|NCT03670563|Other|Short foot exercise plus NMES|Exercises that target intrinsic foot muscles supplemented by NMES for muscle re-education
45514218|NCT02567175|Drug|Domperidone|
46057371|NCT02716935|Dietary Supplement|Fortified lipid based nutrient supplement|6 months intervention: participant will take a daily dose of 20g supplement. The product contains 3 g of a mixture (1:1) of inulin and fructan-oligosaccharide
46057372|NCT02716935|Dietary Supplement|lipid based nutrient supplement|Dietary Supplement: lipid based nutrient supplement (Nutributter) 6 months intervention: participant will take a daily dose of 20g supplement.
45404961|NCT04380142|Drug|ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
45404962|NCT04380142|Drug|Placebo for Levodopa/Carbidopa (LD/CD)|Oral capsule
45404963|NCT04380142|Drug|Levodopa/Carbidopa (LD/CD)|Oral encapsulated tablet
45404964|NCT04380142|Drug|Placebo for ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
45404965|NCT04375696|Drug|Polyglucosamine L112|Polyglucosamine; Ascorbic Acid; Tartaric Acid
45514219|NCT02226380|Drug|mFOLFOX6 regimen|oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
45514220|NCT02078388|Drug|Doxorubicin|
45514221|NCT02222636|Drug|Normal saline,1 milliliter|Normal saline,1 milliliter, 20 minutes before anaesthetic induction
45514222|NCT02222636|Drug|Dexmedetomidine 1 μg.kg-1,1 milliliter|Dexmedetomidine 1 μg.kg-1,1 milliliter,20 minutes before anesthesia induction
46057373|NCT02716623|Other|CR diet|Diet consists of meals lower in carbohydrates but does not restrict the number of calories that participants can consume.
45404966|NCT04375696|Other|Placebo|Dicalcium Phosphate; Microcrystalline Cellulose; Iron Oxide (yellow, brown, and black); Magnesium Stearate; Silicon Dioxide
45404967|NCT04045132|Behavioral|Social Media-Based Parenting Program|Participants in the intervention group will be enrolled in Facebook secret user groups, administered by a trained facilitator, in order to permit participants to view and comment on posted materials. Content and user identity are restricted to invited participants to maintain privacy. For each topic, we organize educational materials into video vignettes, narrated PowerPoint presentations, and written materials. The facilitator reviews and comments on postings daily, provides feedback to participants, and removes inappropriate postings if they occur. Facebook analytics for the secret groups are available to group administrators and will provide information on any sessions viewed (engagement) and counts of sessions viewed and comments posted (dosage). Women in the intervention group will also be enrolled in the online depression treatment program, MoodGym.
45514223|NCT02222636|Drug|Dexmedetomidine 2μg.kg-1,1 milliliter|Dexmedetomidine 2μg.kg-1,1 milliliter,20 minutes before anesthesia induction
45404968|NCT04045132|Behavioral|MoodGym|Participants in the control group will be enrolled in MoodGym, an evidence-based online Cognitive Behavioral Therapy (CBT) program for depression. Through the MoodGym program, participants will have access to interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files. We will supplement Moodgym with a facilitator contact by texting or email to check-in and encourage completion of intervention. MoodGym will provide information on the number of sessions completed by participants (engagement and dosage).
45404969|NCT03748498|Device|laser|Application of the laser was performed through root canal and to the buccal mucosa over the apices of the target tooth
45404970|NCT04336228|Drug|Escitalopram|20mg daily for 3-4 weeks.
45404971|NCT04336228|Drug|Placebo oral tablet|20mg placebo tablet daily for 3-4 weeks.
45404972|NCT03937180|Behavioral|Blended care|An interactive e-learning programme delivered through a secured web-based platform for patients and general practitioners (GPs), blended with face-to-face contacts between the involved GP and patient.
45404973|NCT03937180|Behavioral|Usual care|"General practitioners offering usual care are expected to follow the Belgian guidelines as described in the most recent online version of Anxiety, stress and sleeping problems A toolbox for general practitioners. or Sleeping pills and sedatives. How to assist your patients in the search for other solutions? which are both available in French and Dutch."
45404974|NCT03917446|Drug|Propofol bolus|Each patient gets propofol bolus in three doses. 0.25 mg/kg, 0.5 mg/kg and 1 mg/kg. After each dose patient's blood pressure, heart rate and haemodynamic values calibrated with PICCO device (cardiac output, cardiac index, stroke index, stroke volume, stroke volume variation, dPmax) are recorded in 15 seconds intervals for 10 minutes.
45404975|NCT04335136|Drug|RhACE2 APN01|Patients will be treated with APN01 intravenously twice daily (BID).
45514224|NCT02222636|Drug|Anesthesia induction, 8% sevoflurane|Inhalation induction with 8% sevoflurane
45514225|NCT02222636|Drug|Anesthesia maintenance, 2%~3% sevoflurane,fentanyl|2%~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion
45514226|NCT04058223|Device|Hemorrhoidopexy|stapled hemorrhoidopexy
45514227|NCT03559374|Other|Vanadis NIPT system|A novel cost effective not NGS (next-generation sequencing) test, based on imaging single DNA molecules for high precision NIPT (non-invasive prenatal testing)
45851395|NCT01270230|Behavioral|Bruthas Project|The Bruthas Project HIV prevention intervention is a four-session, semi-structured individual risk reduction counseling program based on the Information-Motivation-Behavior (IMB) theoretical model. The counseling sessions are designed to complement standardized HIV-Counseling and Testing, and are delivered every 2-3 weeks over the course of 3 months. Each session lasts for approximately one hour, and is facilitated by a trained African American male counselor. The counselors engage with participants using open-ended questions and a non-judgmental, conversational style designed to elicit feedback on an individual's current level of HIV-related risk. The counselor then provides information and strengthens the participant's prevention skills.
45404976|NCT04335136|Drug|Physiological saline solution|Patients will be treated with placebo intravenously twice daily (BID).
45514228|NCT04058145|Drug|AMD3100|AMD3100 is a drug that inhibits a chemokine CXCR4 which promotes cancer cell growth, spread, and survival and controls immune cell trafficking. Inhibiting CXCR4 expels the immune-suppressive cells out of the tumor and attract the cancer-killing immune cells into the tumor environment so that the body's immune system may be able to better attack the cancer cells.
45514229|NCT04058145|Drug|Pembrolizumab|"Pembrolizumab is thought to block a receptor called PD-1. This receptor usually acts as a brake to prevent the body's immune system from attacking cancer cells. The antibody removes the brake to allow parts of the body's immune system (usually T cells) to attack the tumor."
45514230|NCT02230982|Drug|nintedanib|soft gelatin capsule
45514231|NCT02075112|Drug|Soy isoflavone|Patients will receive genistein 150 mg daily for the duration of radiation treatment. If a patient is experiencing significant side effects attributable to genistein, the treating physician has the option to reduce genistein to 150 mg every other day.
45514232|NCT02075112|Radiation|Radiation|All patients will undergo computed tomography (CT) simulation with intravenous (IV) contrast unless medical contraindications to IV contrast exist. Gross disease will be treated to 70 Gy in 2 Gy/day.
46057374|NCT02716623|Behavioral|Exercise|Participants will be asked to undergo specific exercise schedule. Exercise will be tracked using a fitness device.
45404977|NCT04332874|Procedure|Isolated Limb Infusion|ILI will be performed within 18 days of initiation of pembrolizumab. ILI (infusion of melphalan and dactinomycin into the affected limb via arterial catheter) will be performed in the interventional radiology suite under anesthesia. In pediatric patients, the pediatric pharmacist w ill be consulted prior to the procedure, and an appropriate prophylactic anti-emetic therapy and dose will be selected for the individual patient.
45514233|NCT02075112|Drug|Cisplatin|Cisplatin chemotherapy 100 mg/m² on days 1, 22, and 43 of radiation treatment.
45404978|NCT04332874|Drug|Pembrolizumab|Pembrolizumab at a dose of 200 mg will be administered intravenously on Day 1 and every 3 weeks(+/= 3 days) thereafter. In adolescent patients, the dosing of pembrolizumab w ill be 2 mg/kg up to a maximum of 200 mg.
45404979|NCT04332874|Drug|infusion of melphalan and dactinomycin|infusion of melphalan and dactinomycin
45404980|NCT03748108|Drug|lidocaine|a bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.
45404981|NCT03748108|Drug|Placebo|a bolus intravenous dose of 1.5 mg/ kg a saline placebo over 15 s just before the induction of general anesthesia.
45404982|NCT04171414|Biological|CT-P17 SC AI (adalimumab)|Subcutaneous Injection of Adalimumab 40mg once every two weeks
45404983|NCT04167670|Drug|Vonoprazan|Over-encapsulated tablets administered orally.
45404984|NCT04167670|Drug|Amoxicillin|Capsules administered orally.
45404985|NCT04167670|Drug|Clarithromycin|Tablets administered orally.
45404986|NCT04167670|Drug|Lansoprazole|Over-encapsulated capsules administered orally.
45514234|NCT03078751|Drug|Ribociclib|"Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Ribociclib was supplied in the form of 200 mg film-coated tablets taken by mouth."
45514235|NCT03078751|Drug|Adjuvant endocrine therapy|Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months. In premenopausal women, a GnRH agonist administered every 28 days.
45514236|NCT03078751|Drug|Placebo|"Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Placebo was supplied in the form of 200 mg film-coated tablets taken by mouth."
45514237|NCT02223026|Drug|Linagliptin/metformin FDC|
45514238|NCT02223026|Other|high-fat, high caloric meal|
45514239|NCT02075190|Other|Therapeutic Computerized intervention|Remediation training intervention
45514240|NCT02075190|Other|Nontherapeutic computerized intervention|Online gaming intervention
45404987|NCT03747406|Procedure|Erector spinae plane block|the level between T9 and T10 will be identified using ultrasound as well as transverse processes depth. An array probe will be applied longitudinal orientation 3 cm lateral midline. The erector spinae and the psoas muscle will be identified. A skin wheal will be made using lidocaine 1% at each level and then a 22-gauge Tuohy needle will be advanced inplane until it made contact with the transverse process. The needle will be withdrawn slightly and 30cc of bupivacaine 0.25 % (15ml for each side) will be injected slowly after negative aspiration was confirmed. The same procedure will be repeated in the contralateral side.
45404988|NCT03747406|Procedure|TAP block|a linear array transducer 5-12 MHz will be positioned inferior and parallel to the costal margin in a medio-lateral orientation. The external oblique, internal oblique and transverse abdominis muscles will be identified immediately lateral to the linea semilunaris. A a 22-gauge needle will be advanced medially and in-plane to the US beam until the tip lies between the fascia of the internal oblique muscle and the transverse abdominis muscle layers. 30 ml of 0.25 % bupivacaine will be injected in each side and the spread will be observed between the two muscles layers.
45404989|NCT03747250|Device|Videolaryngoscopy|In experimental group (interventional group), patients will be intubated with the videolaryngoscope
45404990|NCT03747250|Device|Direct laryngoscopy|In control group (active comparator group), patients will be intubated with the direct laryngoscope
45514241|NCT02226614|Device|University of Edinburgh head cooling device|head cooling
45404991|NCT00113516|Drug|carboplatin|AUC of 6 mg*min/mL via IV infusion every 21 days for 4 cycles as per institutional practices.
45404992|NCT00113516|Drug|paclitaxel|175-225 mg/m2 via IV infusion every 21 days for 4 cycles as per institutional practices.
45404993|NCT00113516|Drug|sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment up to 1 year (after completing 1 year of treatment, pts deriving clinical benefit may continue to receive sunitinib in a separate continuation protocol).
45514242|NCT02075268|Drug|prasugrel|prausugrel 10 or 30 mg will be administrated as single dose under overnight fast.
45514243|NCT01378507|Behavioral|endoscopic submucosal dissection|ESD was carried out by using a single-channel upper gastrointestinal endoscope with a water-jet system (Q260J; Olympus Optical Co, Tokyo, Japan) and a high-frequency generator with an automatically controlled system (ENDOCUT mode) (Erbotom ICC 200; ERBE Elektromedizin GmbH, Tübingen, Germany). The transparent attachment was fitted on the tip of the endoscope mainly to obtain a constant endoscopic view and to create tension on the connective tissue for the submucosal dissection.
45514244|NCT02078466|Other|Assessment of functional ability and follow-up at home|Assessment of functional ability and follow-up at home
45514245|NCT01378351|Other|Questionnaire survey|Mailed questionnaire investigating response to empiric treatment trials, further investigations by otolarygology and possible alternative diagnoses.
45514246|NCT02223104|Device|Flexima Active|
45514247|NCT02223104|Device|Sensura|
45514248|NCT01379443|Other|CTN model of care for children and their families|Parental reports on the quality of life of their children and service needs
45404994|NCT04142242|Biological|Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form: Solution for injection; Route of administration: Intramuscular
45404995|NCT04142242|Other|Blood sample|Blood sample for assessment of antibody persistence.
45404996|NCT03251326|Drug|Nabilone|Nabilone capsules (4 mg)
45404997|NCT03251326|Drug|Cannabis|Cigarettes (0.0 and 5.6% THC)
45404998|NCT03251326|Drug|Propranolol|Propranolol capsules (40mg)
45404999|NCT03251326|Drug|Placebo|Placebo capsules
45405000|NCT04140292|Drug|Photodynamic therapy (PDT)|"PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells~Noninvasive fluorescence dosimetry may be performed on up to 6 lesions. Levulan Kerastick will be applied to each lesion and left to incubate for 30 minutes. Blue light (Blu-U device, 20 J/cm2, 33 minutes) will be administered."
45405001|NCT04140292|Drug|Vitamin D3|"D3 pills (10,000 IU each) to be taken daily at home, beginning at either day -5 or day -14, as per their assignment~Participants will receive a 5-day or 14-day supplementation of Vitamin D10,000 IU depending on their baseline Vitamin D 25 Hydroxy result"
45405002|NCT04138810|Other|VCE|Videoconference conducted according to a standard script which reviews the following key aspects of post-operative care: bowel functions, voiding functions, presence of vaginal bleeding, pain control, diet status, ambulatory status and any additional concerns. Standard post-operative instructions and precautions are reviewed as well.
45405003|NCT04138810|Other|Survey|Measure of satisfaction regarding post-op visit.
45405004|NCT00127166|Drug|Montelukast sodium|Montelukast 5 mg chewable tablet once daily
45405005|NCT00127166|Drug|Salmeterol xinafoate|Salmeterol 50 mcg dry powder per actuation inhaled twice daily
45405006|NCT00127166|Drug|Fluticasone propionate|Fluticasone (50 mcg per actuation) 100 mcg inhaled twice daily
45405007|NCT00127166|Drug|Montelukast matching placebo|Matching placebo to montelukast oral tablet administered once daily.
45405008|NCT00127166|Drug|Salmeterol matching placebo|Matching placebo to salmeterol dry powder for inhalation administered twice daily
45405009|NCT00125138|Drug|Melperone HCl|20 mg/day. Strength of melperone syrup is 5 mg/mL
45405010|NCT00125138|Drug|Melperone HCl|40 mg/day. Strength of melperone syrup is 5 mg/mL
45514249|NCT02231138|Drug|Abelmoschus manihot (AM)|Abelmoschus manihot (AM): Huanghui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
45699150|NCT02734212|Behavioral|Ending Self Stigma for PTSD|Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
45699151|NCT02734212|Other|Enhanced Treatment as Usual|The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
45699152|NCT01202578|Device|tympanostomy tube|tympanostomy tube delivery system
45699153|NCT04701450|Other|digital consent|the patient's medical history is taken in a digital survey, information about the anaesthetic procedure is aided by video material
45405011|NCT00125138|Drug|Melperone HCl|60 mg/day. Strength of melperone syrup is 5 mg/mL
45405012|NCT00125138|Drug|Placebo|Syrup formulation
45405013|NCT04132336|Drug|Naproxen sodium/Caffeine (BAY2880376)|Tablet, oral, single dose
45405014|NCT04132336|Drug|Naproxen sodium (Aleve)|Tablet, oral, single dose
45405015|NCT04132336|Drug|Caffeine|Tablet, oral, single dose
45405016|NCT04132336|Drug|Placebo|Tablet, oral, single dose
45405017|NCT04131556|Drug|Maribavir|Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.
45405018|NCT04315636|Drug|Surfactant nebulisation|200 mg/kg body weight nebulised surfactant (Poractant alfa, Chiesi Farmaceutici SpA, Parma, Italy) via a customised vibrating membrane nebuliser (eFlow neonatal nebuliser system, PARI Pharma, Starnberg).
45699154|NCT03462810|Drug|cabotegravir, CAB|open label investigational product
45699155|NCT01202656|Drug|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
45405019|NCT04295356|Biological|CT-P17|subjects will receive a single dose (40 mg) of CT-P17 via AI on Day 1 followed by 10 weeks
45405020|NCT04295356|Biological|CT-P17|subjects will receive a single dose (40 mg) of CT-P17 via PFS on Day 1 followed by 10 weeks
45405021|NCT03691948|Other|Responsible Opioid Prescriber Education (ROPES)|The ROPEs intervention is a self-guided, web-based continuing dental education intervention. Consistent with ADA recommendations, ROPEs consists of seven modules of active content: (1) Overview; (2) Background on the Opioid Epidemic; (3) Dental Pain Management and the Role of Opioids; (4) Universal Precautions Approach; (5) Screening, Monitoring, and PDMP use; (6) Providing Patient Education; and, (7) Case Vignettes. All key intervention content is delivered via video-based platform and includes downloadable practice aides and resources.
45405022|NCT03691948|Other|Active Comparator Control|An online PDF version of the Center for Disease Control Guideline for Prescribing Opioids for Chronic Pain.
45405023|NCT04126174|Device|femtosecond laser system arcuate corneal incision|Corneal arcuate incision made either with a blade (manual) or femtosecond laser system.
45405024|NCT04126174|Other|Manual LRI|Manual LRI
45851396|NCT01270230|Behavioral|Standard HIV Testing and Counseling|This arm represents those receiving the standard HIV testing and counseling. We ultimately settled on the standard-of-care comparison group because our primary research question is whether the implementation of the intervention cast against the backdrop of usual care, in this case, HIV testing and counseling as mandated by the CDC, is efficacious. Thus, participants randomized to the comparison group will receive the current standard intervention which involves HIV testing, pre- and post-test counseling, plus linkage to case management. Individuals who test HIV-positive will be referred to post-test services including counseling for treatment options, HIV-positive support groups, and harm reduction workshops.
45405025|NCT04124926|Drug|Vonoprazan|Over-encapsulated tablet administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
45405026|NCT04124926|Drug|Lansoprazole|Over-encapsulated capsule administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
45851397|NCT01270308|Drug|Lansoprazole|Lansoprazole DR Capsules 30 mg
45851398|NCT01270386|Drug|apatinib|Apatinib 750 mg p.o. once daily
45851399|NCT01270386|Drug|placebo|placebo p.o. once daily
45851400|NCT01270698|Drug|IMMU-130|IMMU-130 will be administered intravenously every 2 weeks for up to 6 months or longer.
45851401|NCT01270854|Other|Plasmalyte A|Intravenous fluid
45405027|NCT03746158|Dietary Supplement|curcumin|subjects will be assigned to consume one capsule of curcumin (330 mg of curcumin per capsule) three times a day (one capsule with each meal).
45405028|NCT05321056|Device|masks (surgical mask, respirator)|The mask (surgical mask, respirator) will be worn on the face of the in vitro bionic model in the procedure room for measuring droplet exposure.
45699156|NCT01202656|Drug|Saline|intrauterine saline infusion 1 cc
45405029|NCT03753100|Other|Dual-energy X-ray absorbtiometry to evaluate periprosthetic bone mineral density around an uncemented stem implanted using either lateral or anterolateral approach to the hip joint|The measurement will start in the area about 2 cm proximal to the greater trochanter and will stop slightly below the tip of the prosthesis. This is the baseline scan and will be carried out twice with the patient lying on the table, but with movement between each scan. This is done to calculate the CV, Coefficient of Variation. We will use the formula from Wilkinson and associates, where delta is standard deviations (SD) of the difference between the two BMD measurements for each patient. BMD has been measured at baseline, 3 and 12 months. A DXA scan is now planned at 60 months. Changes in BMD related to the 7 Gruen zones will be registered.
45405030|NCT03747094|Drug|Fentanyl|0.5 mic/kg fentanyl will be given immediately before the procedure
45405031|NCT03747094|Drug|Ketamine|0.25 mg ketamine will be administered immediately before the procedure
45699157|NCT03462732|Device|Endotracheal tube|Nasotracheal intubation will be done with endotracheal tube
45699158|NCT03462732|Device|Nelaton catheter|plus nelaton catheter
45699159|NCT01219738|Drug|Budesonide 360ug|A single inhaled dose of 360ug budesonide from a DPI.
45699160|NCT01219738|Drug|Budesonide 720ug|A single inhaled dose of 720ug budesonide from a DPI.
45699161|NCT01219738|Drug|Budesonide 1440ug|A single dose of 1440ug of the budesonide from DPI.
45699162|NCT01219738|Drug|Budesonide720ug 4 times|720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.
45699163|NCT01219738|Drug|Placebo|A single inhaled dose of placebo from a DPI.
45699164|NCT04639752|Behavioral|Mom´s Supporting Mom|A preventive peer consultation intervention for Postpartum Depression.
45699165|NCT04639752|Behavioral|Enhanced Treatment As Usual|Referral to treatment in the community, clinical monitoring
45699166|NCT03848754|Drug|Gemtuzumab Ozogamicin 3 mg/m^2|"GO 3 mg/m^2 on Day 1, 4, and 7~Maintenance: 2mg/m2 intravenous administration on day 1, in a 28-day cycle."
45851402|NCT01270854|Other|Normal Saline|Intravenous fluid
45851403|NCT01270932|Drug|Lenalidomide and Dexamethasone|Lenalidomide:Daily for 21 days of a 28 day cycle Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4.
45851404|NCT01271088|Drug|N-acetylcysteine|N-acetylcysteine 600 mg twice a day,one week after administration of antibiotics
45851405|NCT01271166|Drug|Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab|
45851406|NCT01271556|Drug|Salmeterol|50 mcg MDI (inhalatory), once on days A and C at t=0,
45851407|NCT01271556|Procedure|saline infusion (0.9 per cent sodium chloride)|rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment on day A and B
45851408|NCT01271556|Other|Placebo|placebo, inhalatory (MDI) once
45851409|NCT01272024|Behavioral|Symptom Education|Participants are given a Symptom Education Toolkit at baseline and at each visit thereafter (1 month and 3 month) are encouraged to use the Toolkit for symptoms they are experiencing. They are also encouraged to use resources available to them.
45851410|NCT01272024|Behavioral|Intervention|Participants are visited/contacted by an intervention nurse ten times over a 12-week period for the purpose of helping them to manage uncertainty and distress,to boost their problem-solving skills, and to transition to treatment.
45405032|NCT04274686|Device|Tegaderm placement|Placement of perforated Tegaderm bandage over lower face, with diamond-shaped hole aligned with the patient's mouth, for use during bag-mask ventilation
45405033|NCT04274686|Other|No Tegaderm|Bag-mask ventilation performed in ordinary fashion, without use of Tegaderm bandage
45405034|NCT03753022|Other|Group G5|Submitted to peep 5
45514250|NCT02075424|Other|salivary sampling by a biomnis swab|"Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.~Only one sampling will occur to doctors who are assigned to a single workstation.~Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call.~To improve interpretation of the results, a series of control-samples will be taken among the call operators and doctors during a day off and not during a security break.~There will be 4x8 samples taken for each call operator and 2x8 samples per doctor.~They will also be frozen at a temperature of -4°C and sent to the laboratory of the CHR Metz Thionville."
45514251|NCT05226637|Device|ESWT (extra-corporeal shock wave therapy)|The ESWT device (Storz Medical Duolith SD1),
45405035|NCT03753022|Other|Group G10|Submitted to peep 10
45514252|NCT05226637|Device|Sham : The ESWT device (Storz Medical Duolith SD1),|In doing so, the sham head still actuates and makes the same sounds but produces no shockwave. Because the patients receiving this intervention are naïve to ESWT, they will not be biased by the sensation it produces. Communication during treatment will be limited to avoid inadvertent bias.
45514253|NCT05111119|Behavioral|Making PrEP Smart|"The Making PrEP Smart intervention is a mobile-based application with the following components:~Notification-based PrEP Reminders and Adherence Self-Monitoring~HIV self-testing facilitation, interpretation of results, and testing support~HIV partner testing facilitation, interpretation of results, and testing support~Nearby HIV clinic contact information"
45514254|NCT02075502|Behavioral|Exercise therapy|The exercise therapy program with training, monitoring and coaching enhanced by community-based participatory research (CBPR) (TMC+) is a comprehensive approach to community-based walking exercise for improving PAD patient outcomes. The components of TMC+ are optimal training guidelines for patients (i.e., T), monitoring from both investigators and patient self-monitoring (i.e., M), coaching from investigators on how to improve patients' walking ability (i.e., C), and finally enhancements from CBPR practices (+).
45514255|NCT02075502|Procedure|lower extremity ET|catheter-based revascularization of peripheral arteries (background treatment part of standard clinical care at hospital)
45514256|NCT02075502|Procedure|peripheral open intervention|revascularization of lower extremities with open bypass surgery (background treatment part of standard clinical care at hospital)
45514257|NCT02477384|Procedure|8mm-TIPS|
45514258|NCT02477384|Procedure|Endoscopic variceal ligation|
45514259|NCT02477384|Drug|Propranolol|
45514260|NCT02477384|Device|8mm ePTFE-covered stent|
45514261|NCT03709771|Diagnostic Test|Ambulatory Blood Pressure Measurement|"Baseline: Subjects will undergo an abbreviated physical exam, review changes in medical history since last oncology visit, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic digital velocity time interval (VTI) using pulse amplitude tonometry, cubital vein endothelial cell harvest, and ambulatory 24 blood pressure measurement.~Follow-up Visit (approx 1 month after starting treatment): Review changes in medications and any medical events that happened since the last visit, an abbreviated physical exam, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic velocity time interval (VTI), digital pulse amplitude tonometry, endothelial cell harvest, and ambulatory 24 blood pressure."
45514262|NCT02075580|Behavioral|psychological support (interactive/cognitive strategies)|"cognitive/behavioural intervention (6 times starting from hospital admission, in 90 days; for arm of intervention)~metacognitive techniques (6 times starting from hospital admission, in 90 days; for arm of intervention)~psychoeducational intervention (6 times starting from hospital admission; for arm of intervention)~questionnaires: EORTC questionnaires and a written structured interview (3 times: hospital admission,15 days after surgical intervention, 90 days after intervention; in both arms)"
45514263|NCT05001295|Procedure|Physical Activity|Following the guidelines of NICE, the program to be followed by the IG is designed so that the intervention lasts 5 weeks, divided into 4 levels of progressive intensity, in which sessions of 30 to 45 minutes of aerobic exercise will be carried out 2 days a week. week.
45514264|NCT02075736|Procedure|KTP laser|
45514265|NCT02075736|Procedure|TUR-P|device
45514266|NCT02226770|Device|Implantable Cardioverter Defibrillator (ICD)|
45514267|NCT04335253|Drug|EOS884448|Multiple Ascending Dose
45699167|NCT03848754|Drug|Gemtuzumab Ozogamicin 2 mg/m^2|GO 2 mg/m^2 on Day 1 of a 28-day cycle.
45851411|NCT01272258|Drug|PRO 140|SC injection
45405036|NCT03753022|Other|Group G15|Submitted to peep 15
45405037|NCT03752944|Procedure|lefort I osteotomy for maxillary advancement|fixation of lefort I osteotomy in patients with retruded maxilla with two prebent plates versus four miniplates.
45405038|NCT03752788|Behavioral|Dual-task Training Fixed Priority|"Dual-task training fixed priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~Attention was focused on both postural and cognitive tasks throughout this session. In postural tasks, subjects were instructed to perform the following: walk narrow base of support with a cognitive task of counting backward by three walk narrow base of support with cognitive task of count forward by three, walk narrow base of support, step, sideways, backward avoiding the obstacles (holding a basket) with cognitive task to remember words."
45514268|NCT02231216|Procedure|Rhinoseptoplasty|Rhinoseptoplasty without turbinectomy procedure
45405039|NCT03752788|Behavioral|Dual-task Training Variable Priority|"Dual-task training variable priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~During the first half of the training session, attention was focused on postural tasks, while during the remaining half of the session, attention was focused on cognitive tasks."
45405040|NCT04113694|Device|Extended Infusion Set|Each subject is asked to wear each Extended Wear Infusion Set for at least 174 hours.
45405041|NCT03745846|Biological|Composite Gel Containing Black Raspberry|Composite Gel Containing Black Raspberry 3,000/preparation
45405042|NCT03745846|Biological|placebo|Composite Gel Containing Black Raspberry-placebo
45405043|NCT04105972|Drug|ELX/TEZ/IVA|FDC tablet for oral administration.
45405044|NCT04105972|Drug|TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
45405045|NCT04105972|Drug|IVA|Mono tablet for oral administration.
45405046|NCT04102540|Other|Infographic intervention|Information visualizations (infographics) will be used to teach participants about HIV during study visits immediately following their normal clinic visits.
45405047|NCT00124982|Drug|Abatacept|IV solution, IV infusion, between 500mg and 1gram based on body weight, monthly, 6 months.
45514269|NCT02231216|Procedure|Partial turbinectomy|After medial dislocation of the inferior turbinate, proceed partial resection of the inferior turbinate in all its inferior extension in range. Possible bleeding is cauterized.
45405048|NCT00124982|Drug|Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)|During the study, subjects continued to receive 1 or more background non-biologic DMARDs (e.g. methotrexate, leflunomide) at the dose level(s) and regimen(s) administered at the time of abatacept treatment onset (Day 1).
45405049|NCT00124982|Drug|Anti-Tumor Necrosing Factor (TNF) Therapy|Any of the anti-TNF therapies (Infliximab, Adalimumab, Etanercept, etc.)administered at the approved label dose for at least 3 months
45405050|NCT04263142|Drug|GSK3640254 Tablet|GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
45405051|NCT04263142|Drug|GSK3640254 Capsule|GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
45405052|NCT04095286|Drug|AMB new formulation (1 mg)|AMB tablets will be available at a unit dose strength of 1 mg. Participants will orally administer 5 tablets of 1 mg unit dose.
45514270|NCT02231216|Procedure|Endoscopic partial turbinectomy|Endoscopy to medial dislocation of the inferior turbinate with instrument
45514271|NCT03633721|Drug|Cannabis|7% delta9-THC cigarettes will be smoked by 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
45699168|NCT03848754|Drug|Pracinostat - 45 mg|Induction: 45mg administered orally 3 days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by 1 week of rest, in 28-day cycles.
45851412|NCT01272258|Drug|Placebo|SC injection
45699169|NCT03848754|Drug|Pracinostat - 60 mg|Escalation: 60 mg administered orally three days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by one week of rest, in 28-day cycles.
45699170|NCT01155154|Drug|cephalexin|500 mg (two 250 mg capsules) every 6 hours for 7 days
45851413|NCT01272336|Drug|Acute Intermittent Hypoxia (AIH)|Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia) air for 15 minutes.Participants will receive treatment for up to seven visits.
45405053|NCT04095286|Drug|Reference AMB (5 mg)|AMB reference tablet will be available as film-coated tablet at unit dose strength of 5 mg. Participants will orally administer 1 tablet of 5 mg unit dose
45405054|NCT04093414|Device|Select Secure pacing lead|A Select Secure pacing lead is placed in the bundle of His or Left bundle branch area based upon randomization
45405055|NCT04093258|Device|Dailies Total 1® Multifocal Contact Lenses|TEST
45405056|NCT04093258|Device|Air Optix® Multifocal Contact Lenses Plus HydraGlyde®|CONTROL
45514272|NCT03633721|Other|Placebo|0% THC cigarettes will be administered to HIV negative women. Participants will be instructed to 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
45699171|NCT01155154|Drug|clindamycin|300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days
45699172|NCT01155154|Drug|placebo|Two placebo capsules every 6 hours for 7 days
45699173|NCT02521896|Device|Steerable Sheath System|The Vado™ Steerable Sheath consists of a dilator and steerable sheath which are designed to provide intracardiac access and flexible catheter positioning in the cardiac anatomy.
45699174|NCT03786432|Device|Spira-C Interbody Device|40 subjects undergoing anterior cervical discectomy and fusion surgery using Spira-C titanium interbody device
45699175|NCT04614714|Drug|Nicotinamide riboside chloride|Nicotinamide riboside chloride 250 mg capsules, administered once per day (Day 1-7 or Day 11-17)
45514273|NCT02081898|Dietary Supplement|LCD|approximate 100 kcal/d caloric deficit
45514274|NCT02226848|Drug|Erythropoeitin|
45514275|NCT02081976|Behavioral|Integrated Care Group|The group (TG) consisted of periodontal treatment comprising one session of supragingival scaling and personalized oral hygiene instructions, followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days. Individuals were be followed monthly during the first 6 months. In the follow-up sessions, professional plaque removal, oral hygiene instructions, cardiac support along with counseling reinforcement were be provided.
45514276|NCT02081976|Other|Standard Care Group|The group (TG) comprising one session of supragingival scaling followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days.
45514277|NCT03575611|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45514278|NCT02231294|Drug|Sifrol®|
45405057|NCT04090528|Biological|pTVG-HP|pTVG-HP is a plasmid DNA, produced in E. coli, that encodes the complementary deoxyribonucleic acid (cDNA) for human prostatic acid phosphatase (PAP).
45405058|NCT04090528|Biological|pTVG-AR|pTVG-AR is a plasmid DNA
45405059|NCT04090528|Drug|Pembrolizumab|Pembrolizumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
45405060|NCT04253236|Drug|RVT-1401 680 mg/weekly|Non-randomized subjects will receive subcutaneous injection of 680 mg weekly for 12 weeks of RVT-1401
45405061|NCT04253236|Drug|RVT-1401 340 mg/weekly|Non-randomized subjects will receive subcutaneous injection of 340 mg weekly for 12 weeks of RVT-1401
45405062|NCT03433456|Behavioral|Home visitation + HABITS program|The HABITS program will target 5 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, decreasing fried foods, and encouraging regular self-monitoring and self-weighing) aimed at reducing obesity risk in mothers or primary caregivers and children.
45405063|NCT03433456|Behavioral|Standard home visitation program|Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on promoting caregiver and child health by providing screenings and referrals, encouraging smoking cessation, promoting safe sleep practices, and strengthening children's school readiness and achievement, social/emotional and physical development.
45405064|NCT04087720|Biological|Pegloticase|intravenous (IV) infusion
45405065|NCT03747016|Dietary Supplement|high-energy digestible food E2|The women undergoing Cesarean section are given high energy digestible food 300ml before surgery
45405066|NCT03747016|Dietary Supplement|glucose injection G2|The women undergoing Cesarean section are given glucose injection 300ml before surgery
45405067|NCT03747016|Dietary Supplement|normal saline N2|The women undergoing Cesarean section are given normal saline 300ml before surgery
45405068|NCT03747016|Dietary Supplement|high-energy digestible food E1|The women in delivery room are given high energy digestible food 300ml.
45405069|NCT03747016|Dietary Supplement|glucose injection G1|The women in delivery room are given glucose injection 300ml.
45405070|NCT03747016|Dietary Supplement|normal saline N1|The women in delivery room are given normal saline 300ml.
45405071|NCT04086472|Biological|Clesrovimab|Single dose of clesrovimab administered via IV infusion.
45514279|NCT02078544|Other|Integrated Molecular Analysis|
45514280|NCT04962139|Drug|ON101 Cream|Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
45514281|NCT04962139|Other|Vehicle Cream|ON101 Cream Placebo
45514282|NCT02223416|Drug|RGB-10|
45514283|NCT02223416|Drug|Teriparatide|
45514284|NCT02082054|Drug|PSE 120 mg, CM 8 mg, Atr 0.36 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with M27 on scored side and plain on the other side"
45514285|NCT02082054|Drug|PSE 120 mg, CM 8 mg, Atr 0.24 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
45514286|NCT02082054|Drug|PSE 120 mg, CM 8 mg, Atr 0.12 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 mg white, scored, tablets with M27 on scored side and plain on the other side"
45514287|NCT02082054|Drug|PSE 120 mg, CM 8 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg tablets dosed BID
45514288|NCT02082054|Drug|Atropine 0.24 mg|"Atropine sulfate 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
45699176|NCT04614714|Drug|Placebo|Maltodextrin placebo, administered once per day (Day 1-7 or Day 11-17)
45699177|NCT01221298|Drug|ABT-450|tablets
45514289|NCT02231372|Drug|Berodual® Respimat® solution for inhalation|
45514290|NCT04923529|Drug|TAS 102|"Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5.~Days 6 through 7: Recovery Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Recovery"
45699178|NCT01221298|Drug|ABT-072|tablets
45699179|NCT01221298|Drug|Ribavirin|tablets
45699180|NCT01221298|Drug|Ritonavir|capsules
45405072|NCT04086472|Other|Placebo|Placebo (0.9% sodium chloride, USP sterile saline) administered via IV infusion.
45405073|NCT04086472|Biological|RSV-A Memphis 37b|Approximately 4Log10 plaque-forming units (PFU)/mL RSV-A virus inoculation strain Memphis 37b administered via intranasal inoculation.
45405074|NCT03752632|Device|Veinplicity with tourniquet|Veinplicity will be used with a tourniquet
45405075|NCT03752632|Device|Tourniquet|A tourniquet alone will be used.
45405076|NCT03752554|Procedure|segmental resection|All cases will undergo surgery under general anesthesia. The mandibular lesion will be segmentally resected. The cuts will be performed with the aid of the prefabricated digital template. The neurovascular bundle will be separated and protected. Then reconstruction will be performed
45405077|NCT04249336|Drug|Fluoro-Calcium-Phospho-Silicate based dentifrices|Bio-Active glass based formulation
45405078|NCT04249336|Drug|8% Arginine based dentifrices|Tubular occluding formulation
45405079|NCT04249336|Drug|8% Strontium Acetate|Tubular occluding formulation
45405080|NCT04249336|Drug|Sodium Fluoride|No claim of relieving Dentin Hypersensitivity
45405081|NCT03752476|Procedure|number of Beta lactam class prescription for the same infection|Each number of Beta lactam prescription without interruption are compared
45405082|NCT04245202|Device|HFNCOT|The patient will receive a high flow nasal of humidified oxygen, set between 2 to 25 l/min. The inspired fraction of oxygen (FiO2) will be adjusted to obtain the oxygen saturation >92%.
45405083|NCT04245202|Other|St-FMOT|The inspired fraction of oxygen (FiO2) will be adjusted to obtain the oxygen saturation >92%.
45514291|NCT03559296|Diagnostic Test|Ultrasonographic assessment of postmastectomy lymphedema|Qualitative assessment of postmastectomy lymphedema via ultrasound (Subcutaneous echogenicity (SEG) and subcutaneous echo-free space (SEFS) grade systems for postmastectomy lymphedema) and circumferential tape measures ( The circumferential measurement of affected arm at MCP joint, wrist joint, 15 below elbow joint, elbow joint 15cm above elbow point) to assess upper extremity volume
45514292|NCT02884544|Drug|HLD100|Treatment
45514293|NCT04916977|Other|FD patients|Patients with Fabry disease diagnosis
45405084|NCT03979924|Behavioral|Trismus rehabilitation|"The patient will be followed-up by a physiotherapist during all the whole radiotherapy treatment, with short 15-min sessions, twice a week. He/she will be trained to perform regularly and by him/herself the preventive/rehabilitation exercises than the patient will do twice a day until the end of the radiotherapy treatment. The patient will then continue, in an autonomous manner, with his/her rehabilitation.~In case of trismus occurrence, the physiotherapist will advise the patient to add a passive tool to the active exercises (Jaw Trainer, Therabite, tongue depressors,…) in order to strengthen the stretching."
45405085|NCT03752242|Drug|BMX-010|Safety and efficacy of BMX-010 in topical treatment of acne.
45405086|NCT03752164|Behavioral|Yoga and Mindfulness Skills|Single brief session in which children are taught yoga and skills in mindfulness
45405087|NCT04079842|Device|INVSENSOR00029|Noninvasive pulse oximeter sensor
45405088|NCT03745534|Other|eABR|eABR
45405089|NCT04078126|Combination Product|BFF|Treatment with budesonide and formoterol furmate MDI (metered-dose inhaler)
45405090|NCT04078126|Combination Product|Symbicort Turbuhaler|Treatment with budesonide and formoterol furmate DPI (dry-powder inhaler)
45405091|NCT04073368|Dietary Supplement|AXA1957|Amino acids, food study
45405092|NCT04073368|Dietary Supplement|AXA1125|Amino acids, food study
45405093|NCT04073368|Dietary Supplement|Placebo|Amino acids, food study
45405094|NCT03745456|Diagnostic Test|Blood samples for ROTEM and platelet function.|Thormoboelastometry is based on the measurement of elasticity of blood by continuous graphical logging of the firmness of a blood clot during clot formation and subsequent fibrinolysis
45405095|NCT04380688|Drug|Acalabrutinib|Acalabrutinib administered orally
45405096|NCT00124748|Drug|Imatinib mesylate|Imatinib is packaged in bottles as 100mg and 400mg tablets
45405097|NCT04070326|Drug|Lanadelumab|Participants will receive 150 mg dose of lanadelumab every 2 or 4 weeks, depending on the participants age, over the 52-week treatment period.
45405098|NCT01078142|Drug|Temsirolimus, Rituximab, Bendamustin|"Phase I:~Temsirolimus 25 - 50 - 75mg, day 1,8,15 Bendamustin 90/m2, day 1,2 Rituximab 375/m2, day 1 Phase II at established dose, repeat day 28-42 (max)"
45405099|NCT03689452|Device|Platelet Rich Plasma|Platelet Rich Plasma (PRP) is defined as an autologous concentration of human platelets that is 3 to 5 times greater than physiologic concentration of platelets in whole blood. Using the Eclipse PRP system, the participants PRP will be attained. The PRP will then be used as described in the arm/group description section.
45405100|NCT03689452|Drug|Normal saline|Preservative-free normal saline will be used as described in arm/group description section.
45514294|NCT02226926|Drug|Aggrenox|
45514295|NCT02226926|Drug|Persantin Retard|
45514296|NCT02226926|Drug|Acetylsalicylic acid|
45405101|NCT04067050|Device|comfilcon A asphere|Contact Lens
45405102|NCT04067050|Device|Spectacles|Habitual spectacles
45405103|NCT04060654|Drug|Sublocade|SUBLOCADE to be administered approximately every 4 weeks per local standard of care
45405104|NCT00096200|Drug|Carboplatin|Given IV
45405105|NCT00096200|Drug|Paclitaxel|Given IV
45405106|NCT00096200|Drug|Sorafenib Tosylate|Given orally
45405107|NCT04059094|Drug|BI 1265162|Inhalation solution
45405108|NCT04059094|Drug|Placebo|Inhalation solution
45405109|NCT03745378|Other|JAK2V617F mutation|JAK2 V617F is attached to the cytosolic juxtamembrane region of dimeric cytokine receptors, such as EpoR or MPL (TpoR); The JAK2V617F mutation results from a guanine to thymine change at nucleotide 1849 of the cDNA, in exon 14 of the gene. This valine is located at one of the predicted interfaces between JH1 and JH2 domains,
45405110|NCT00096044|Biological|rituximab|IV
45405111|NCT00096044|Drug|lenalidomide|Oral
45514297|NCT02075892|Dietary Supplement|Mushroom Blend|Scivation
45514298|NCT02075892|Dietary Supplement|Placebo|
45699181|NCT03783624|Behavioral|Hypnosis|A 6 session course of individual hypnosis therapy will be offered.
45699182|NCT03783624|Behavioral|Open label placebo|Ritual intake of 2 placebo capsules twice a day
45699183|NCT05321004|Other|Semi-structured interviews will be conducted - there will be no intervention.|The use of semi structured interviews and questionnaires
45405112|NCT01082822|Biological|cell sheet pellets and cell sheet fragment|the denuded root surface area was calculated to determine the size of the transplanted cell sheet in the of proportion of the 2cm X 2cm cell sheet to the 1cm X 1cm denuded area
45405113|NCT03963128|Dietary Supplement|Supplementation Vitamin D3|Supplementation of vitamin D3 at a dose of 50.000 IU administered every two months (equivalent of 800 IU per day)
45405114|NCT03963128|Dietary Supplement|Placebo|Placebo administred every two months
45405115|NCT01082900|Other|Prophylactic CPAP Administration|"EXPERIMENTAL GROUP: Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the Delivery Room via T piece (Neopuff)~CONTROL GROUP: Provision of standard care in the Delivery Room"
45405116|NCT01082978|Device|Electronic (USB) Portable Health File|Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
45405117|NCT01082978|Device|Paper Portable Health File|Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
45405118|NCT03963050|Other|Exercise Training|The ET program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.
45405119|NCT03963050|Other|Exercise Training + Cognitive Training|"ET: The intervention program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.~CT: The intervention program will be configured as a cognitive rehabilitation and mainly memory rehabilitation: the participants will be trained in practicing restorative and compensatory mnemonic techniques, such as visual imagery, face-name association, calendar, notes and prompts."
46057375|NCT02709993|Biological|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
45405120|NCT03963050|Other|Control|NO changes in lifestyle
45405121|NCT02531048|Device|laser stimulations on lower limbs|20 laser stimulations for each site : back foot, outer face of the legs, and anterior thigh
45405122|NCT02531048|Device|laser stimulations cervical|15 laser stimulations cervical areas below the ears.
45405123|NCT02531048|Device|20 laser stimulations for each site on the upper limbs|20 laser stimulations for each site : back of the hands and arms front face
45514299|NCT04898413|Behavioral|Group-based acceptance and commitment therapy (ACT)|Group-based ACT intervention by professional psychotherapist consists of four modules: (a) psychoeducation about dementia and experiential avoidance in caregiving, (b)mindfulness and acceptance of aversive emotions, sensations, and thoughts, (c) behavior management for care recipients' BPSD, and (d) clarifying and choosing one's value, and taking actions toward the chosen values. Each session lasts about 90 minutes and will be held every two weeks. Group-based reminiscence therapy for care recipients will be conducted by a professional psychotherapist other than the one conducting group-based ACT intervention.
45699184|NCT01222234|Drug|Cholecalciferol - CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
45405124|NCT02531048|Device|laser stimulations on face and neck|15 lasers stimulations for each site : mandibular areas and areas below the ears.
45405125|NCT03962660|Other|HaRTS-TRENDS|"HaRTS-TRENDS comprises 4, individual sessions delivered in the context of the interventionist's pragmatic harm-reduction mindset paired with a compassionate, advocacy-oriented heart-set or style. It comprises the delivery of 4 manualized components, including a) participant-led tracking of preferred smoking outcomes, b) elicitation of participants' harm-reduction goals and their progress toward achieving them, c) discussion of the relative risks of various nicotine delivery systems, and d) instruction in using ENDS. Additionally, HaRTS-TRENDS entails provision of commercially available ENDS."
45699185|NCT01222234|Device|Calcitriol - CKD|Calcitriol 0.25 mcg once daily for 8 weeks
45405126|NCT03962660|Other|Standard Care (SC)|The 4-session, individual standard care control condition entails the well-documented and evidence-based 5 As intervention (i.e., Ask about nicotine use, Assess use, Advise to quit smoking, Assist with exploring current smoking/planning smoking cessation, Arrange follow-up). Part of arranging follow-up is the recommendation to call the smoking quit line, which can supply additional counseling and nicotine replacement therapy.
45405127|NCT03962582|Device|Matrix back|The Matrix back will replace the individual's back and the measures will be taken.
45405128|NCT01083212|Drug|AZD1656|Single dose,oral tablet
45405129|NCT01083212|Drug|Gemfibrozil|Oral tablet bid on day 1 - 5.
45405130|NCT01083212|Drug|Placebo|Oral tablet bid on day 1-5
45405131|NCT01083290|Drug|Spironolactone|single dose of one tablet; 25 mg tablet
45405132|NCT01083290|Drug|Spironolactone|single dose of one tablet; 50 mg tablet
45405133|NCT01083290|Drug|Spironolactone|single dose of one tablet; 100 mg tablet
45405134|NCT01326650|Drug|Vitamin D|daily oral vitamin D supplement of 100 micrograms for three years
45405135|NCT01326650|Drug|placebo|daily oral placebo supplement for three years
45405136|NCT03689374|Drug|Semaglutide|Subjects will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly (OW) with a dose of 0.25 mg. The dose should be increased after four weeks to 0.5 mg semaglutide. After 4 more weeks the dose can be increased to 1.0 mg semaglutide if the study doctor decides and further dose adjusted throughout the study.
45405137|NCT03689374|Drug|Insulin aspart|Subjects should initiate treatment with 4U of Insulin aspart (s.c. injections) before each main meal, three times daily (TID). The dose will be adjusted individually based on pre-prandial and bedtime self measured plasma glucose (SMPG) from the preceding 3 days
45405138|NCT03689374|Drug|Insulin glargine U100|Run-in period: Subjects will receive s.c. injections of IGlar U100 OD in accordance with the approved local label of IGlar U100. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.0-6.9 mmol/L)
45405139|NCT00113360|Drug|RAD001|Starting dose of 5 or 10 mg by mouth daily.
45405140|NCT00113360|Drug|Octreotide Depot|30 mg injection into the muscle of either buttock once every 28 (±7) days.
45405141|NCT01083446|Other|Nutritional Intervention|Cognitive and executive functions before and after standard israeli breakfast (30% of caloric value and 21 gram protein)
45405142|NCT01083446|Other|Nutritional Intervention|Cognitive and executive functions during fast
45405143|NCT00123734|Drug|ThromboView|
45405144|NCT03745300|Drug|ATORVASTATIN|Scaling and Root Planing (SRP) followed by placement of atorvastatin gel
45405145|NCT03745300|Drug|SIMVASTATIN|Scaling and Root Planing (SRP) followed by placement of simvastatin gel
45405146|NCT03745300|Drug|PLACEBO|Scaling and Root Planing (SRP) followed by placement of placebo gel
45405147|NCT00112736|Drug|erlotinib|Given orally
45405148|NCT00112736|Drug|temsirolimus|Given IV
45405149|NCT00112736|Procedure|therapeutic conventional surgery|Undergo surgical resection
45514300|NCT04898413|Behavioral|Group-based cognitive behavioral therapy (CBT)|Group-based CBT intervention by professional psychotherapist consists of four modules: (a) psychoeducation about dementia and distress in caregiving, (b) cognitive restructuring and relaxation, (c) behavior management for care recipients' BPSD, and (d) increasing pleasant activities. Each session lasts about 90 minutes and will be held every two weeks. Group-based reminiscence therapy for care recipients will be conducted by a professional psychotherapist other than the one conducting group-based CBT intervention.
45851414|NCT01272336|Other|SHAM-Intermittent Room Air|This is a sham intervention to the AIH intervention. Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia). Participants will receive treatment for up to seven visits.
45851415|NCT01272414|Drug|Botulinum Toxin Type A|2-12 units in weekly 2u doses to effect
45851416|NCT01272414|Drug|Saline injection|Injection of 0.4cc 0.9% normal saline
45405150|NCT00112736|Other|laboratory biomarker analysis|Correlative studies
45405151|NCT00112736|Other|pharmacological study|Correlative studies
45514301|NCT02227004|Diagnostic Test|Perform MRI in patients with pacemaker or ICD|Perform MRI in patients with pacemaker or ICD
45514302|NCT02924883|Drug|Atezolizumab|Atezolizumab 1200 mg IV infusion
45851417|NCT01272492|Other|Computer Use|Participants use the computer with the 5 modules on infant/toddler feeding/nutrition
45851418|NCT01272648|Behavioral|RePCa A|"Intervention patients receives two consultations with a specialist oncology nurse three and six month after ended radiotherapy. The focus are on what is important for the patients at the specific time. The patient can bring his spouse.~Furthermore the patients have two physiotherapy consultations with guidance in pelvic floor exercises and an individual home-program of pelvic and functional training exercises"
45405152|NCT00123422|Behavioral|Breathing retraining|exercise training with computerized training program
45405153|NCT00123422|Behavioral|Heliox|exercise training with a helium oxygen combination
45405154|NCT00123422|Behavioral|Exercise|exercise training
45405155|NCT04052620|Drug|Diclofenac diethylamine 2.32% gel|Participants will apply DDEA 2.32% gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm^2 two times daily for 7 days.
45405156|NCT04052620|Drug|Diclofenac diethylamine 1.16% gel|Participants will apply DDEA 1.16 % gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm^2 four times daily for 7 days.
45405157|NCT04052620|Other|Placebo|Participants will apply Placebo gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm^2 two times daily for 7 days.
45405158|NCT01083524|Drug|Dichloroacetate Sodium|3 mg po bid for 28 weeks
45405159|NCT01083524|Drug|Dichloroacetate Sodium|6.25 mg po bid
45405160|NCT01083524|Drug|Dichloroacetate Sodium|12.5 mg po bid
45405161|NCT05018260|Behavioral|Attention Bias Modification|Feedback according to participants' viewing patterns, in order to modify their attention bias to threat
45405162|NCT05018260|Behavioral|Attention Control|Feedback according to participants' viewing patterns, in order to strengthen their attention control
45405163|NCT03752086|Procedure|greater omentum binding|Bind pancreatic stump using greater omentum after distal pancreatectomy
45405164|NCT03752086|Procedure|Pancreatic stump exposed without omentum binding|Pancreatic stump exposed without greater omentum binding after distal pancreatectomy
45405165|NCT04244032|Behavioral|Working Memory Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in a working memory task designed to utilize individually-adapted difficulty levels.
45405166|NCT04244032|Behavioral|Inhibitory Control Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in an inhibitory control task designed to utilize individually-adapted difficulty levels.
45405167|NCT04244032|Behavioral|Bias Modification Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in a bias modification task designed to utilize individually-adapted difficulty levels.
45405168|NCT00112580|Biological|ipilimumab|
45405169|NCT04238650|Drug|MB02 (Bevacizumab Biosimilar)|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
45405170|NCT04238650|Drug|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
45405171|NCT03752008|Behavioral|Active Play (AP)|This intervention focused on promoting PA in preschoolers through structured, teacher-led activities that could be incorporated into daily curriculum. Teachers attended a 3-hour workshop that included presentation and discussion of 1) the importance of daily physical activity for children's health and development, 2) teachers' beliefs and barriers to promoting PA, and 3) the Active Play! Intervention materials. Teachers were introduced to and given the Active Play! Fun Physical Activities for Young Children Book and Digital Video Disk (DVD), which promotes PA and fundamental movement skills in young children. Clips of the DVD demonstrating various activities were shown and activities were modeled. Examples of activities include jumping on bubble wrap, hula hoop limbo and an indoor obstacle course. The end of the book has a suggested curriculum that teachers could follow. Centers in the Active Play! intervention also received a set of portable toys needed for the suggested activities.
45405172|NCT03752008|Behavioral|Outdoor Play (OP)|This intervention focused on promoting outdoor time in preschoolers as a means to increasing their PA, using both child initiated and teacher-led activities. The training and materials were designed to emphasize the teacher's own connection with nature, the benefits of outdoor time for children and adults, and problem solving around barriers encountered. Teachers at participating centers attended one 3-hour workshop (delivered at the childcare center) that focused on having participants recognize their own connection with the natural world and how to transmit that to the next generation. Teachers were given hats and gloves for themselves, a set of rain jackets and boots for the preschoolers, and ideas on what children could do outdoors to be active.
45405173|NCT03751930|Other|Samples|Urinary and faecal samples
45405174|NCT00095576|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)|"Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 adenovirus genomes [ad-vg]/dose).~This dose is equivalent to 3x10^10 vp/dose used in study V520-016."
45405175|NCT00095576|Drug|Comparator: placebo|Placebo to Trivalent MRKAd5 HIV-1 gag/pol/nef in three 1 mL doses at Day 1, Week 4, and Week 26 administered intramuscularly.
45405176|NCT04049578|Drug|Balovaptan|Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.
45699186|NCT01222234|Drug|Cholecalciferol - non-CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
46057376|NCT02709915|Other|Breakfast Diet (Bdiet)|The Breakfast Ddiet consist of high-energy breakfast, medium-sized lunch and reduced in energy dinner, with distribution of calories: breakfast 50%, lunch 33% and dinner 17%. In this diet, the investigators will evaluate at baseline and at the end of 12 weeks of diet intervention, the diet efficacy on reducing HbA1c, the total daily insulin dose requirements (TDID), the efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion assessed with continuous monitoring system. The investigators will assess also the Clock Genes mRNA expression in white blood cells. at baseline and after 12 weeks of diet intervention
45405177|NCT04044352|Biological|Influenza A/Bethesda/MM2/H1N1 Challenge|Reverse-genetics derived live A/California/04/2009/H1N1-like influenza virus passaged six times in Vero cells.
45405178|NCT04043962|Behavioral|Web-based CBT (Web-MAP)|see arm description
45405179|NCT04043728|Behavioral|Unified Protocol adapted for smoking cessation|Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module. All participants will be provided with the American Lung Association Freedom from Smoking guide to aid in their quit attempt.
45405180|NCT04043416|Other|Motivating reminiscence technology|The jDome BikeAround uses Google Street View, a stationary bike and a domed screen. Residents are seated in front of the screen; their destination is typed into the computer and when loaded the image appears on the screen. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.
45405181|NCT00095498|Drug|placebo|placebo subcutaneous injection
45405182|NCT00095498|Drug|denosumab|For subcutaneous injection
45405183|NCT04237792|Drug|dexmedetomidine|dexmedetomidine low, middle and high doses are provided as an intravenous bolus loading dose followed by an intravenous maintenance dose infusion throughout the MRI scan
45405184|NCT04237792|Drug|propofol|propofol IV administration will be given if needed to maintain sedation
45405185|NCT04233580|Device|Amnio Excel + weekly|Amnio Excel + weekly
45405186|NCT04233580|Device|Amnio Excel + max every 2 weeks|Amnio Excel + max every 2 weeks
45405187|NCT00122954|Drug|Fish oil concentrate|fish oil concentrate at a daily dose of 6 grams (2.1 gram EPA and 1.5 gram DHA).
45405188|NCT00122954|Drug|Placebo|soybean oil with 1% fish oil at a daily dose of 6 grams
45405189|NCT04491994|Drug|HCQ|Tab HCQ 400mg 12 hourly day 0 followed by tab HCQ 200mg 12 hrly for next 5 days
45514303|NCT02924883|Drug|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion
45514304|NCT02924883|Other|Placebo|Placebo matched to atezolizumab
45699187|NCT01203046|Drug|Ertapenem|Ertapenem 1 gr endovenous 3 or 7 days
45699188|NCT04604184|Drug|BI 764198|BI 764198
45699189|NCT04604184|Drug|Placebo|Placebo
45699190|NCT04604106|Diagnostic Test|Eyetracker|Eye-tracking is an objective, non-invasive method and particularly suited to assess neurodevelopmental outcome in infants.
45699191|NCT04604106|Diagnostic Test|Ages & Stages questionnaire|The Ages & Stages Questionnaire is a conventional instrument used to measure developmental outcome in infants.
45851419|NCT01273116|Other|CWS in Hospital|"Every patient aged ≥70 years will be screened for frailty. (For) every frail patient:~will have a comprehensive (geriatric) assessment using an adapted version of the EasyCare instrument;~a geriatric consultation team will propose/recommend a tailored care and welfare plan, which will be updated at the moment of discharge;~will be discussed at least once in a multidisciplinary meeting;~a structured medication review will be carried out by a geriatrician;~is offered an activation programme by volunteers focusing on improvement of orientation, mobility, social activities or nutrition;~may receive a consult of a geriatrician, if judged necessary;~will receive extra attention on discharge arrangements.~Hospital staff will be educated, disease-specific guidelines will be adapted to frail older patients."
45405190|NCT04041700|Device|Osia 2 system|System includes the OSI200 implant surgically placed under the skin behind the ear, the BI300 implant osseointegrated in the bone and the external Osia 2 sound processor.
45405191|NCT03225430|Behavioral|Cognitive behavioural treatment for tics|Mainly based on the habit reversal treatment (HRT) and in addition to HRT components, they learn awareness training, relaxation, competing response, contingency management, and generalization training.
45405192|NCT03225430|Behavioral|Cognitive psychophysiological|Focus on the processes influencing thoughts and behaviors underlying tics.
45405193|NCT03746938|Device|VB-C01|Surgical implant of VB-C01 (Collagen membrane seeded with allogeneic stem cells isolated from adipose tissue, ADSC).
45405194|NCT04036630|Device|Transcranial alternating current stimulation (tACS)|"The main study intervention is tACS stimulation. TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The aim of the tACS stimulation is to enhance degraded speech comprehension in healthy individuals.~TACS stimulation will be applied over the left ventral motor cortex, with a current intensity of 2mA (peak-to-peak)~The arm will be compared to the tACS sham stimulation condition."
45405195|NCT04036630|Device|Transcranial magnetic stimulation (TMS) induced motor-evoked potentials (MEPs)|"TMS is a technique where a transient magnetic field (or pulse) is used to cause an electric current to flow in a targeted brain area via electromagnetic induction. The pulse causes the rapid and above-threshold depolarisation of cell membranes affected by the current. Therefore, TMS induces a current that elicits action potentials in neurons.~MEPs are electrical potentials recorded from a target muscle after TMS stimulation. In experiment 1, so-called articulatory MEPs will be recorded from participants' lip muscle (orbicularis oris). Articulatory MEPs will be recorded by placing two recording electrodes on the right part of orbicularis oris and a reference electrode on the right temple."
45405196|NCT03751852|Behavioral|Exercise Coaching|28 classes in 16 weeks
45514305|NCT02075970|Drug|Epoetin Alpha|"Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.~Infant study 2:~Dosing algorithm will be determined by results of Infant Study 1."
45405197|NCT03751852|Behavioral|Psychoeducation|28 classes in 16 weeks
45405198|NCT04227340|Device|Photobiomodulation Therapy (PBM)|The PBM will be delivered through application of the LED Cluster Probe externally to the right external buccal, left external buccal, mid face with mouth open and submandibular and left/right cervical. Patients who develop an oral lesion, intra-oral directed therapy will be administered with the dental light probe. For patients that can tolerate, an intraoral probe will deliver light directly onto the oral mucosa, this will then replace the mid face application with mouth open. Each laser application will be timed at 60 seconds.
45405199|NCT04227340|Other|Pain and Oral Function Assessment|After the 6-minute laser/ treatment session the child and parent will complete the mucositis evaluation scale on paper or ipad which includes self-report oral function specific to ability to swallow, eat and drink, as well as the patient's self-reported need for medication specific to mouth pain.
45405200|NCT04227340|Other|Parent-Reported Satisfaction Survey|A parent-reported satisfaction survey will be administered via paper questionnaire after the initial LLLT treatment. Parent satisfaction will be reported by parents on a 5-point Likert scale to questions adapted from a parent satisfaction survey used in a study regarding child life services in pediatric imaging.
45405201|NCT04489732|Biological|Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells|"Single dose, starting at~Dose Level 0: 10 x 10^6 injected into one submandibular gland on Day 1"
45405202|NCT03746860|Drug|Tablet, Dispersible|1 tablet/day with 12 SQ-HDM per lyo-tablet
45405203|NCT03744988|Diagnostic Test|serum androgen levels|measurement of serum free and total testosterone
45405204|NCT04033432|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
45514306|NCT02075970|Drug|Biotinylated Red Blood Cells|Biotinylated red blood cells will be transfused to infants to determine red blood cell lifespan.
45405205|NCT04223830|Device|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care endoscopic retrograde cholangiopancreatography (ERCP) or other duodenoscope-based procedure performed with the Exalt single use duodenoscope study device.
45405206|NCT04032652|Procedure|Rectal dialysis|Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
45405207|NCT04032652|Drug|Rectal dialysis|Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
45405208|NCT04031404|Device|Single-pulse TMS|Single-pulse transcranial magnetic stimulation (TMS) on the motor cortex will lead to a twitch in the target muscle and evoke a motor-evoked potential (MEP) measured by electromyography (EMG).
45405209|NCT05256628|Other|Early Weightbearing|Patients randomized to undergo this study intervention will bear weight, as tolerated, on the affected side straight after surgery, with crutches for additional support and stability. They will be allowed to stop using crutches in the weeks after surgery as they feel more comfortable and stable on their surgical leg.
45405210|NCT05256628|Other|Protected Weightbearing|Patients randomized to undergo this study intervention will be instructed to be touch weightbearing for 6 weeks after surgery. They will use crutches and put no more weight on the surgical side than what it takes to crack an egg. After the 6-week mark, they will be able to bear weight.
45405211|NCT03746782|Diagnostic Test|Flow Cytrometry; Thrombin Generation Assay|Apixaban combined with blood specimens (in vitro) of study participants
45405212|NCT03746626|Behavioral|Chaplain visit|The patients will all see a chaplain routinely during 8-week stay according to their personal preference. The chaplain records the 'depth' and frequency of these encounters.
45405213|NCT03751696|Behavioral|Group Coaching|4 sessions of 1-1.5-hour group coaching intervention within 8 weeks
45405214|NCT03751696|Behavioral|SMS self-help tips|4 mental well-being tips through sms within 8 weeks
45405215|NCT04476784|Device|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
45405216|NCT04476784|Device|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
45405217|NCT04476784|Device|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
45405218|NCT04026568|Drug|4-Aminopyridine|Single drug test for nerve continuity
45514307|NCT03432325|Device|Neural Enabled Prosthesis|Surgically implanted neural enabled prosthesis
45514308|NCT02231450|Drug|Lu AE58054 encapsulated film-coated tablets|
45514309|NCT02078622|Other|Respiratory Therapist Education and Case Management|Respiratory Therapists will conduct home care visits over a period of one-year at two-week intervals
45514310|NCT05764057|Drug|Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)|"Dapagliflozin (10 mg per day; per os) on top of standard of care as recommended in current guidelines* for 6 months (experimental group)~*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended."
45405219|NCT04026568|Drug|Placebo oral tablet|Placebo arm
45405220|NCT04025632|Drug|zilucoplan|Daily subcutaneous (SC) inection
45405221|NCT04025632|Other|Placebo|Daily subcutaneous (SC) inection
45405222|NCT04024228|Biological|Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
45405223|NCT04024228|Biological|High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
45405224|NCT04023994|Drug|RO7126209|Participants will be administered single-ascending intravenous doses of RO7126209 with at least 2 weeks between each dose level. After the starting dose, the subsequent doses will be selected in an adaptive design. Sentinel dosing will be employed.
45405225|NCT04023994|Drug|Placebo|Participants will be administered a single intravenous dose of matching placebo.
45405226|NCT04023682|Drug|Provodine Hand Sanitizer|Intervention with Provodine
45405227|NCT04018612|Drug|Acetaminophen|Acetaminophen is an analgesic and antipyretic
45405228|NCT04018612|Other|Placebo|Saline
45514311|NCT05764057|Drug|Placebo comparator|"Placebo daily on top of standard of care as recommended in current guidelines* for 6 months (control group)~*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended."
45405229|NCT04018066|Dietary Supplement|GP-SPI|grape polyphenol-soy protein isolate complex (GP-SPI)
45405230|NCT03751618|Procedure|Hip arthroscopy|"Suture will be realized with two simple suture knots (non resorbable suture material). These suture knots will be performed at the end of hip arthroscopy. Correct capsular suture will be controlled under arthroscopy video.~Patients randomized in control arm will not received capsular suture at the end of the procedure."
45405231|NCT04209400|Biological|Sci-B-Vac®|Sci-B-Vac® vaccine-10 μg of HBsAg, intramuscular injection of 10 μg/ml
45405232|NCT04209400|Biological|Engerix-B®|Engerix-B® vaccine-20 μg of HBsAg, intramuscular injection of 20 μg/ml
45405233|NCT03751540|Procedure|ostap|this block is performed under general anesthesia in this patients for postoperative analgesia.
45851420|NCT01273272|Behavioral|Comprehensive, CBT-based, multi-component treatment|It includes eight modules: diagnosis and goal setting; psychoeducation; engagement in pleasant activities; cognitive restructuring; live review; training caregiver in behavior man-agement techniques; interventions for the caregiver; and couples counselling. It consists of 20 weekly sessions (plus appr. 5 single session with caregiver).
45851421|NCT01273272|Behavioral|Treatment as usual|Each patient/caregiver must receive at least three out of six interventions: (1) psychoeducation on dementia and treatment of dementia (oral and written); (2) appropriate medical treatment; (3) social counseling by specialized staff; (4) memory training in group setting; (5) self-help group for the patient; (6) self-help group for the caregiver.
46057377|NCT02709915|Other|6Meal Diet (6Mdiet|The 6meal diet (6Mdiet) will consist in the traditional antidiabetic diet, consuming 6 small meals: breakfast, lunch and dinner and 3 snacks, with caloric distribution: breakfast 20%, lunch 25%, dinner 25% and 10% each of the 3 snacks. In this diet, the investigators will evaluate at the beginning and at the end of the study (12 weeks), the diet effects on reducing HbA1c, total daily insulin dose requirements (TDID), and the diet efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion, using continuous monitoring system, The investigators will assess also at baseline and at the end of the diet intervention the Clock Genes mRNA expression in white blood cells.
45514312|NCT02259062|Other|Music with brief mindfulness intervention|Music listening with mindfulness therapy
45405234|NCT03751540|Procedure|SIPB plus rectus sheath block|this block is performed under general anesthesia in this patients for postoperative analgesia.
45405235|NCT05346094|Other|No intervention|No intervention
45405236|NCT04207840|Combination Product|Epinephrine (0.125 mg/inhalation)|Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.
45405237|NCT04207840|Combination Product|Epinephrine Injection Auto-Injector (0.3mg/0.3mL)|Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.
45405238|NCT04207840|Combination Product|Albuterol Sulfate (0.09 mg/inhalation)|Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.
45514313|NCT02259062|Other|Music listening alone|
45514314|NCT02259062|Other|Audiobook listening|
45699192|NCT04604106|Diagnostic Test|Bayley Scale of Infant Development|The Bayley Scale of Infant Development is a conventional instrument used to measure developmental outcome in infants.
45699193|NCT04549272|Other|No interventions|No interventions - observational study
45405239|NCT03746548|Device|Adhear|Patients are wearing the Adhesive bone conduction hearing device (Adhear) for 2 weeks
45405240|NCT03746548|Device|Contact Mini (CM)|Patients are wearing the Conventional bone conduction hearing device (Contact Mini) for 2 weeks
45514315|NCT02078700|Other|The early palliative care programme|The intervention consists of an early integration of a palliative care programme with the standard care performed by the oncologists-pneumologists that are following the cancer patients. The intervention will be delivered by the specialised Palliative Care Unit (PCU) of the hospital. Each patient meets the professionals of the PCU by 30 days by cancer diagnosis and at least monthly thereafter in the outpatint settings.
45699194|NCT04542720|Procedure|Randomized: Decompression|Patients will undergo decompression alone of the supradjacent level. The surgical technique will be surgeon dependent. All surgeons will be encouraged to avoid damaging facet joints above the fusion mass, retaining 50% of the pars of the decompressed level and performing as minimal of a medial facetectomy as necessary.
45699195|NCT04542720|Procedure|Randomized: Extension Fusion|Patients will undergo decompression and extension of posterior instrumentation and fusion. This may or may not include exchange of pre-existing instrumentation. The use of interbody cages will be left to the discretion of the treating surgeon. The purpose of introducing this heterogeneity is to increase the generalizability of the trial results. The fusion cohort will not utilize bone morphogenetic protein products.
45699196|NCT04542720|Procedure|Observational: Decompression|This intervention is identical to the Randomized: Decompression intervention. Patients will undergo decompression alone of the supradjacent level. The surgical technique will be surgeon dependent. All surgeons will be encouraged to avoid damaging facet joints above the fusion mass, retaining 50% of the pars of the decompressed level and performing as minimal of a medial facetectomy as necessary.
45405241|NCT05226520|Dietary Supplement|Experimental probiotic product|Probiotic supplementation
45405242|NCT05226520|Other|Placebo comparator|Placebo
45405243|NCT04195828|Drug|Camrelizumab|Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg.
45405244|NCT04195828|Drug|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday。
45405245|NCT04195828|Drug|nab-paclitaxel|nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2.
45405246|NCT04195828|Drug|S1|S-1 was calculated according to body surface area , P.O., bid, d1-d14。And the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time
45405247|NCT04006366|Behavioral|Time restricted feeding|We propose a pilot and feasibility trial of a 10 hour time restricted eating intervention among post-bariatric surgery patients.
45405248|NCT03744520|Procedure|Erector spinae plane block|Local anesthetic infiltration is applied between the erector spinae muscle fascia and transverse process.
45405249|NCT03744442|Procedure|Dignity Therapy (DT) module|psychotherapeutic intervention asking patients about their most important achievements, roles and other important aspects of life; two structured sessions of 60 minutes conducted by a trained therapist
45405250|NCT03744442|Procedure|CALM Therapy module|supportive-expressive psychotherapy aiming to help (1) manage the disease, symptom and treatment, and communicate with healthcare providers, to (2) adjust to changes in self-concept, personal relationships, and support needs, to (3) find a sense of meaning and purpose in life, and to (4) prepare for the future, sustain hope, and face the end of life; two structured sessions of 60 minutes conducted by a trained therapist
45405251|NCT03744442|Procedure|Mindfulness-based interventions module|Mind-body techniques reducing existential and spiritual distress and dealing with common experiences related to life-limiting diseases, including loss of control, uncertainty about the future; two structured sessions of 60 minutes conducted by a trained therapist
45405252|NCT04191148|Drug|LBP-EC01|crPhage cocktail: at approximately 1.5 x 10^10 to 3.0 x 10^10 PFU/vial dosed BID by intraurethral administration
45405253|NCT04191148|Drug|Placebo|Lactated Ringers Solution for Injection dosed BID by intraurethral administration
45405254|NCT04004260|Behavioral|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
45405255|NCT03744364|Drug|Misoprostol 25 mcg|To determine efficacy and safety of vaginal 'Misoprostol 25 mcg' every 4 hours with a maximum of 6 doses for induction of labor.
45405256|NCT03744364|Drug|Dinoprostone 10mg|To determine efficacy and safety of 'Dinoprostone 10mg' vaginal insert for induction of labor.
45405257|NCT03744208|Drug|Anti-EGFR monoclonal antibody|DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression
45405258|NCT05069896|Drug|Mirikizumab Prefilled Syringe|Administered SC by prefilled syringe
45405259|NCT05069896|Drug|Mirikizumab Autoinjector|Administered SC by autoinjector
45405260|NCT01562626|Drug|APS001F|APS001F infusion on Days 1,2,3 of each 28 day cycle.
45405261|NCT01562626|Drug|Flucytosine (5-FC)|oral doses on Days 11-15 and 18-22, each 28 day cycle
45514316|NCT05763277|Diagnostic Test|Early response evaluation|Atezolizumab and bevacizumab are administered every three weeks, and before to the second treatment cycle, blood tests and imaging tests are conducted (week 5). This precedes the standard response evaluation (week 9-12).
45405262|NCT01562626|Drug|10% maltose|10% maltose infusion will be administered on Days 1-5, 8-12, and 15-19, each 28 day cycle.
45405263|NCT04470622|Drug|Aprepitant injectable emulsion|Aprepitant injectable emulsion, once daily (QD) for 14 days.
45405264|NCT04470622|Drug|Saline Placebo|Saline Placebo, once daily (QD) for 14 days.
45405265|NCT04466566|Other|Saline|Saline will serve as the control
45405266|NCT04466566|Biological|Exendin-9,39|Exendin-9,39 will block the GLP-1 receptor
45405267|NCT04465630|Device|OMNI® Surgical System|Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System
45405268|NCT04182880|Drug|CPL-01|CPL-01 will be administered
45405269|NCT04182880|Drug|Placebo|Placebo will be administered
45405270|NCT04465396|Drug|Teduglutide|Participants received 3 mg or 4 mg of Teduglutide SC syringe injection followed by pen injector or vice versa depending upon the treatment sequence AB or BA on Day 1 of Treatment Periods 1 and 2.
45405271|NCT04465396|Device|Syringe Injection|Teduglutide was administered using syringe.
45405272|NCT04465396|Device|Pen injector|Teduglutide was administered using pen injector.
45405273|NCT03751462|Device|Purkinjemeter|The Purkinjemeter will be used for assessment of IOL wobbling, tilt and decentration in patients with pseudoexfoliation syndrome or traumatic cataract
45405274|NCT03744130|Diagnostic Test|Contrast-enhanced Ultrasound|"administration of drotaverine hydrochloride (No-Spa ®) to reduse excessive peristaltic movement~visualization of the previously chosen affected bowel segment with the use of DCE-US (Dynamic Contrast-Enhanced Ultrasound) technology~administration of 2.4 ml SonoVue® intravenously with a bolus injection through a peripheric venous line (left antecubital vein), followed by a 10ml 0.9% Natrium Chloride bolus~the video-loop is acquired during contrast agent administration and wash-out (preferable loop duration - 3 min)~the original DICOM loop is sent to a work station"
45514317|NCT02227082|Radiation|radiotherapy|The whole breast and regional lymph nodes will receive 23 x 2.03 Gy per fraction (total 46.69 Gy) At the macroscopic tumor a added SIB will be given of 23 x 0.63Gy . Total dose: 61.18 Gy
45405275|NCT03999892|Behavioral|ACHIEVE|The investigators will test two modules of the adapted video-assisted curriculum format of 45 to 60-minute multipurpose classes, which will include a segment on group weight management (~20-30 minutes) and group exercise (~20-30 minutes). Within each module, the group weight management topic varies by week, and within each week the content of the three weight management groups builds gradually and is purposely repeated. Within each module, the group exercise classes will focus on mild to moderate intensity aerobic exercise using an exercise video. In this pilot study, a trained study interventionist will deliver the ACHIEVE-D curriculum.
45405276|NCT03996694|Drug|Belbuca 300 µg|Belbuca 300 µg buccal film
45405277|NCT03996694|Drug|Belbuca 600 µg|Belbuca 600 µg buccal film
45405278|NCT03996694|Drug|Belbuca 900 µg|Belbuca 900 µg buccal film
45405279|NCT03996694|Drug|Oxycodone 30 mg|Oxycodone 30 mg capsule
45405280|NCT03996694|Drug|Oxycodone 60 mg|Oxycodone 60 mg capsule
45405281|NCT03996694|Drug|Placebo|placebo buccal film and oral placebo
45405282|NCT04179838|Behavioral|Sleep-Deprived|Sleep for 4 hours at home.
45405283|NCT04179838|Behavioral|Non-Sleep Deprived|Sleep for 8 hours at home.
45405284|NCT03744052|Other|Motivational Messages|Messages regarding physical activity will be texted to participants.
45514318|NCT02227082|Drug|olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, 300 and 400 mg BID
46057378|NCT02716545|Device|balloon assisted enteroscopy|Patients with recurrent bleeding (>2 times for one year) will undergo balloon assisted enteroscopy and be treated with endoscopic therapy if necessary. Currently available endoscopic modalities are argon laser, bipolar electrocoagulation (BiCAP), band ligation, cryotherapy, radiofrequency ablation and argon plasma coagulation (APC). Among these options, APC is the most promising.
45405285|NCT03994120|Other|RTMS|Altering the connectivity of trans-synaptic pathways
45405286|NCT04178590|Drug|SRP + Injectable Platelet-Rich Fibrin|Injectable Platelet-Rich Fibrin application as adjunct to scaling and root planing
45405287|NCT04178590|Drug|SRP + placebo|Saline application during scaling and root planing
45405288|NCT03743974|Procedure|arthroscopic shoulder surgery of rotary cuff (ISB)|ISB were performed in the same manner by one of the two anesthesiologists in our team: (i) patients were monitored, after sedation with sublingual midazolam (0.1 mg/kg) + a single bolus of intravenous (IV) ketamine (0.2 mg/kg); (ii) ultrasound-guidance was carried out using a Kontron® or General Electric® ultrasound machine; (iii) neurostimulation was performed with a Stimuplex HNS® 12 set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; (iv) a single perineural injection was performed with a 50 mm Vygon® needle containing a mixture of 100 mg levobupivacaine (20 mL, 0.5%) and clonidine (1 µg/kg patient) as is the local common protocol and in the absence of contraindications.
45405289|NCT03743974|Procedure|arthroscopic shoulder surgery of rotary cuff (CSB)|SCB were performed in the same manner by one of the two anesthesiologists in our team: (i) patients were monitored, after sedation with sublingual midazolam (0.1 mg/kg) + a single bolus of intravenous (IV) ketamine (0.2 mg/kg); (ii) ultrasound-guidance was carried out using a Kontron® or General Electric® ultrasound machine; (iii) neurostimulation was performed with a Stimuplex HNS® 12 set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; (iv) a single perineural injection was performed with a 50 mm Vygon® needle containing a mixture of 100 mg levobupivacaine (20 mL, 0.5%) and clonidine (1 µg/kg patient) as is the local common protocol and in the absence of contraindications.
45405290|NCT03751384|Dietary Supplement|Möllers Omega-3 Ekstra Sterk|
45405291|NCT03751384|Dietary Supplement|Nutrifriend Cachexia|
45514319|NCT03670485|Device|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
45514320|NCT02227160|Behavioral|10 weekly group meetings|10 weekly group meetings with up to five other men and women at Grady Health System
45514321|NCT02227160|Behavioral|Outpatient counseling and support groups|Usual mental health care
45514322|NCT02223494|Drug|Terbogrel|
45514323|NCT03373435|Drug|exendin 9-39|Exendin 9-39 is a competitive antagonist of GLP-1 at its receptor.
45851422|NCT01273350|Device|Carotid PTA and stenting|Percutaneous interventional treatment of carotid artery stenosis using XACT carotid artery stent and emboshield protection system with bivalirudin as the procedural anticoagulant
46057379|NCT02709837|Other|Nutritional|
45514324|NCT03373435|Other|Placebo|Placebo solution is identical to the active drug product except for the absence of the active ingredient, Exendin 9-39.
45851423|NCT01273428|Drug|HP011-101|
45851424|NCT01273428|Device|HP-828-101|
45851425|NCT01273428|Other|Standard Care|
45405292|NCT03746392|Behavioral|Jumpstart Intervention|"The intervention has 4 steps: use electronic medical record (EHR) to identify seriously ill, hospitalized patients with no documentation of a goals-of-care (GOC) discussion during their current admission; the enrolled patient or his/her surrogate completes a survey assessing preferences for discussions about GOC, barriers to having such discussions, and current GOC which is used to create a Jumpstart form designed to prompt and guide a GOC discussion between the patient or surrogate and the clinicians caring for the patient; use natural language processing/machine learning (NLP/ML) approach to identify GOC discussions or advance directives in the EHR that occurred prior to admission and include this information on the Jumpstart form; and, deliver the Jumpstart form to the primary clinician team. The patient or surrogate is also provided with a version of the form."
45405293|NCT03743896|Drug|Transdermal Glucosamine Cream|
45405294|NCT01562860|Procedure|Pronator Teres Release|Surgical release of median nerve compression
45405295|NCT01562860|Procedure|dual compression release|Both the carpal tunnel compression and the pronator teres compression will be released on the same day.
45699197|NCT04542720|Procedure|Observational: Extension Fusion|This intervention is identical to the Randomized: Extension Fusion intervention. Patients will undergo decompression and extension of posterior instrumentation and fusion. This may or may not include exchange of pre-existing instrumentation. The use of interbody cages will be left to the discretion of the treating surgeon. The purpose of introducing this heterogeneity is to increase the generalizability of the trial results. The fusion cohort will not utilize bone morphogenetic protein products.
45405296|NCT01562860|Procedure|dual compression release|both procedures will be done on the same day
45405297|NCT01562860|Procedure|median nerve release only|only the carpal tunnel compression is released
45405298|NCT04175392|Drug|Align Probiotic Supplement Capsule|Align Probiotic 1 billion units, 1 capsule once daily
45405299|NCT04175392|Drug|Placebos|Placebos capsule 1 capsule Once daily
45405300|NCT01562938|Drug|Placebo|Placebo
45405301|NCT01562938|Drug|MEDI-557|MEDI-557 low-dose
45405302|NCT01562938|Drug|MEDI-557|MEDI-557 high-dose
45851426|NCT01273506|Drug|tapentadol (CG5503) ER 25-mg TRF|50 mg TRF single oral dose
45851427|NCT01273506|Drug|tapentadol (CG5503) ER 50-mg TRF|50 mg TRF single oral dose
45851428|NCT01273662|Drug|AG-013736|All enrolled patients will receive axitinib, 5 mg orally twice daily with food, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
45405303|NCT03737422|Dietary Supplement|hesperidin and flaxseed|2 capsuls hesperidin and 30 g flaxseed
45405304|NCT03737422|Other|control|no supplementation
45405305|NCT03743818|Device|dry needling|dry needling on the trigger point of the vastus medialis of the quadriceps
45405306|NCT03743818|Other|ultrasound|aply ultrasound on the knee
45405307|NCT03743818|Device|hyauluronic acid|aply hyaluronic acid on the knee
45405308|NCT03986866|Other|Video|A 5 minute video on the risks and benefits of opioids, alternative methods to reduce pain, and the proper handling and storage of opioids will be shown.
45405309|NCT03743740|Other|Spinal stabilization exercise|The effects of spinal stabilization exercise in patients with myasthenia gravis will be investigated.There is no study in the literature that previously applied spinal stabilization exercises in patients with myasthenia gravis. The benefits of spinal stabilization exercises in other diseases are shown.
45405310|NCT03751306|Procedure|Transcranial Photobiomodulation|"Photobiomodulation Rehabilitation:~Diode laser, λ infrared = 810 nm, 0.028 cm2 beam area, 100 mW power, 3.5 W / cm2 power density, 3 Joules / dot and Energy Density of 107.1 J / cm2). Each point will be radiated for 30 seconds. The regions of irradiation will be in the middle cerebral arteries (points F7 and F8 will be used as reference point according to the International System 10-20 of the electroencephalogram) and anterior cerebral artery (AFz point according to the International System 10-20 of the electroencephalogram) ."
45405311|NCT03751306|Procedure|Transcranial Photobiomodulation (Placebo)|"Photobiomodulation Placebo Therapy:~The same apparatus of the transcranial group photobiomodulation and the same irradiation points will be used. However, during the procedure, with the laser off."
45405312|NCT03751306|Procedure|Cardiorespiratory Rehabilitation|"Cardiorespiratory Rehabilitation:~Aerobic training on the treadmill will be reliated for 30 minutes using the support of the Rehabilitation and Physical Activity Station BrainMov® (equipment with 4 pillars condition that favors the suspension and stabilization of people with neuromuscular dysfunctions of mild to severe impairment. For monitoring, the training heart rate equation - Karvonen equation, effort perception scale - BORG, systemic arterial pressure, peripheral oxygen saturation, and patient signs and symptoms will be used. Subsequently, respiratory exercises and muscle strengthening of lower limbs, final relaxation and general guidelines will be performed for research volunteer and his / her relatives."
45405313|NCT01562002|Procedure|Stem Cell with Amniotic Membrane Transplant|Single stem cell expansion in amniotic membrane transplant
45405314|NCT03737344|Drug|IL-1Ra Kineret®|Kineret® 100 mg in 0.67 ml Prefilled Syringe
45405315|NCT03737344|Other|IL-1Ra Placebo|Placebo identical to Kineret® 100 mg in 0.67 ml Prefilled Syringe
45405316|NCT03751228|Drug|BMS-986165|Swish and expectorate after tasting
45405317|NCT03751228|Drug|Active Pharmaceutical Ingredient|Swish and expectorate after tasting
45851429|NCT01273740|Procedure|External support|Bypass surgery with externally supported graft
45851430|NCT01273974|Biological|intradermal influenza vaccine|0.25ml ,intradermal
45405318|NCT05006248|Device|Conventional robotic continuous passive movement training|The participants will be single-blinded and wear the M1 robotic device on their affected/weaker foot, and complete up to 30 minutes of continuous passive movement per training session. The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session.
45405319|NCT05006248|Device|Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in transparency mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The transparency mode of the robotic device compensates for its weight and friction so that the participant does not feel weight while moving the device.
45405320|NCT05006248|Device|Haptic and Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in assistance mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The assistance mode of the robotic device applies assistive/resistive torque based on muscle activity.
45405321|NCT05668546|Device|isokinetic testing CSMI HUMAC NORM instrument|The strength (PT) of the bilateral knee flexors and extensors were tested with isokinetic test. Tests were performed under the guidance of a rehabilitation medicine specialist, and the system was calibrated prior to their commencement. The patients were seated in upright position and were fixed with pelvic and thigh belts. Concentric extension (PT_E) and concentric flexion (PT_F) were measured between the 0° and 90° knee ranges at angular velocities of 60°/s and 180°/s (60 PT_E, 60 PT_F, 180 PT_E, and 180 PT_F, respectively) The tests were repeated five times at each velocity, and the highest PTs were selected for statistical analysis. The participants performed repeated trials before sets, while a 20-second rest was provided between sets.
45405322|NCT03980938|Drug|neflamapimod|40 mg neflamapimod capsule
45514325|NCT03670407|Procedure|Ovarian tissue fragmentation|Unilateral ovariectomy, ovarian tissue in vitro fragmentation and reimplantation.
45514326|NCT01369680|Drug|Ketamine|Drug will be given orally three times a day at doses escalating from 0.25mg/kg/dose to 1.5mg/kg/dose in cohorts of 3. Each subject will be administered study drug for 2 weeks.
45514327|NCT03670329|Device|URGO2875|Dressing
45514328|NCT04780321|Biological|Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg)|use dose 1/2/3 60 patients receipt JS016 intravenous infusion on day 1
45514329|NCT04780321|Drug|Placebo|30 patients receipt placebo intravenous infusion on day 1
45851431|NCT01273974|Biological|intramuscular influenza vaccine|0.5ml,intramuscular
45851432|NCT01274130|Drug|Metformin|Diavex 1000mg on Day1 and 750mg on Day2
45514330|NCT02078778|Device|CPAP|3 months of CPAP treatment
45514331|NCT03669393|Drug|THR-317 8mg|3 intravitreal injections of THR-317 8mg, approximately 1 month apart
45514332|NCT03670173|Drug|Osalmid|Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year.
45851433|NCT01274364|Other|JADE|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
45851434|NCT01274364|Other|DIAMOND|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
45851435|NCT01274598|Biological|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|1x10^10 CFU by mouth twice daily for 28 days
45851436|NCT01274676|Device|carotid stenting with MOMA|The MOMA system is an endovascular catheter for proximal protection during carotid stenting. The system allows a concomitant balloon occlusion of both external and common carotid arteries leading to blood flow reversal within the internal carotid artery.
45405323|NCT03980938|Other|Placebo|matching placebo capsule
45405324|NCT03737188|Device|Blood glucose monitoring systems for self-testing|Capillary blood samples will be used for the evaluation of system accuracy.
45405325|NCT03743584|Procedure|Targeted temperature management|Target temperature management at 33°C
45405326|NCT03743584|Procedure|Standard care, early treatment of fever|Standard of care with early treatment of fever
45405327|NCT03108352|Drug|Conbercept ophthalmic injection|Conbercept ophthalmic injection at a dose of 0.5 mg every month(day0-month 5); If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)
45405328|NCT03108352|Other|sham/Conbercept ophthalmic injection|Sham injection every month (Day 0 - Month 5); 0.5 mg Conbercept ophthalmic injection in month 6; If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 7 ~ 11)
45405329|NCT03108196|Procedure|sigmoid|The serosal layer with smooth muscle was detached from a 15 cm sigmoid segment submucosal layer and removed continuously. Only the mucosal and submucosal layers were preserved. Approximately 2 cm of the taeniae and serosal layer were preserved to strengthen the urethra-neobladder anastomosis at the central portion of the isolated sigmoid and at the two ends for the ureter-neobladder anastomosis. The ureters were subsequently implanted in antirefluxing fashion in a submucosal tunnel. The ureter-neobladder anastomoses were protected with a 6Fr Single J® stent. The two ends of the sigmoid were closed with the embedded seromuscular layer. The neobladder was anastomosed to the urethra after that.
45405330|NCT03108196|Procedure|ileal|The isolated 70 cm terminal ileum segment is arranged in either an M or W shape and is opened along the antimesenteric border except for a 5 cm section where the incision is curved to make a U-shaped ﬂap. The four limbs of the M or W are then sutured to one another with a running absorbable suture. A small full-thickness segment of bowel is excised for the urethral anastomosis. Once the ileal neobladder is situated and the urethral sutures are tied, the ureters are implanted from inside the neobladder through a small incision in the ileum. The remaining portion of the anterior wall is then closed with a running absorbable suture. Ureteroileal anastomosis were performed with a freely refluxing, open end-to-side method at each end of the W.
45405331|NCT03751150|Other|Exercise program|The runners will be asked to perform the training program twice a week. The intervention consist of muscle control and foam rolling exercises for the lower extremities.
45405332|NCT03656692|Drug|Acthar Gel|Acthar gel for subcutaneous injection 80 units per mL (40 units per 0.5 mL)
45405333|NCT04439266|Drug|Crizotinib|Given PO
45405334|NCT03682120|Biological|A/H7N9|"Monovalent inactivated, subunit influenza virus vaccine containing the HA and NA from influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS genes from A/Puerto Rico/8/1934 (H1N1)."
45405335|NCT03682120|Drug|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
45514333|NCT04111939|Other|Communities That HEAL|The Communities That HEAL (CTH) intervention is a community-engaged intervention designed to increase the adoption of an integrated set of evidence-based practices delivered across healthcare, behavioral health, justice, and other community-based settings. It includes 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder.
45851437|NCT01274676|Device|Carotid stenting with filter wire EZ|The filter wire EZ a distal protection system that is placed in he distal internal carotid artery before carotid stenting. The filter should entrap almost all the debries that are generated during endovascular procedure. At the end of the procedure the filter is retrieved throught a dedicated retrieval catheter.
45405336|NCT03682120|Other|Phosphate Buffered Saline (PBS) diluent|Diluent for Influenza Virus Vaccine.
45405337|NCT03736642|Biological|blood sampling|12 ml sample
45405338|NCT03736642|Other|stool sampling|20 g sample
45405339|NCT03736642|Other|urine sampling|18 ml sample
45405340|NCT03736642|Diagnostic Test|neuropsychological tests|"Go-nogo~flexibility~food stroop~implicit and explicit evaluation~Child Depression Inventory~Hamilton Depression Rating Scale"
45405341|NCT01329796|Drug|Lignocaine|Intrauterine flushing, pertubation, three treatments given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
45405342|NCT01329796|Drug|Ringers Solution|Intrauterine flushing, pertubation, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
45405343|NCT04428502|Drug|Enbrel|As provided in real world practice
45405344|NCT03736330|Biological|Combinations treatment|Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5*10^10 cells)were incubated with low dose anti-PD-1 antibody（pembrolizumab, Merck & Co., Inc.） and were transferred to participants via intravenous infusion .
45405345|NCT04428424|Drug|Enbrel|As provided in real world practice
45405346|NCT01562080|Dietary Supplement|Armolipid Plus|one tablet per day during 12 weeks
45405347|NCT01562080|Dietary Supplement|placebo|one tablet per day during 12 weeks
45405348|NCT03655756|Biological|IFx-Hu2.0|Subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at a single time point (28-day follow-up post last injection).
45405349|NCT03735784|Behavioral|AWARE|AWARE consists of four group sessions. The AWARE curriculum involves sharing basic information on sexually transmitted diseases; providing condom use skills training; providing normative feedback on substance use and sexual risk behavior among young adults; discussing unrealistic beliefs about substance use and sexual risk; discussing potential benefits of both cutting down and stopping risky behaviors; and discussing risky situations and coping strategies.
45405350|NCT00095238|Drug|Irbesartan|Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
45405351|NCT00095238|Drug|Placebo|Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
45405352|NCT01083888|Drug|roxadustat|oral
45405353|NCT03962478|Device|biliary stent and high-intensity focused ultrasound ablation system|Self-expandable biliary nitinol alloys stent and YDME FEP-BY02 high-intensity focused ultrasound equipment
45514334|NCT04111939|Other|Wait-list control|Communities in the wait-list control condition will continue usual care during the first 30 months of the trial. At month 31, Wave 2 communities will begin receiving the CTH intervention.
45851438|NCT01274910|Dietary Supplement|EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)|"Patient will receive Fish Oil capsules (EPAX 6000 EE) .~Treatment: 5 capsules per day"
45405354|NCT03962478|Device|biliary stent|Self-expandable biliary nitinol alloys stent
45405355|NCT01087008|Drug|zoledronic acid|Zoledronic acid 4 mg every 4 weeks for a total of 12 treatments
45699198|NCT04507464|Behavioral|Ecological Momentary Intervention|Participants will wear a Fitbit that has been programmed to deliver a notification (a buzz) when activity has ceased for more than 10 minutes. They will receive suggestions on their Illumivu mEMA smartphone app on how to replace sitting time with PA such as standing up 5 times or taking 20 steps, or even performing a short (20 seconds) preferred dance routine. Fitbit data will be captured in real-time via the iCardia platform. Participants will receive reminders from their smartphones to enter real-time feedback on activity options selected and how successful they were in adopting the option. These data will allow tracking of underlying preferences for behaviors and to tailor the program accordingly.
45699199|NCT04504266|Behavioral|POWER|This intervention consists of a motivational interview and a mobile-app based coaching program to encourage patients to exercise and adopt a Mediterranean diet in the 3+ weeks prior to surgery.
45851439|NCT01274910|Dietary Supplement|Capsules (Placebo)|"Patient will receive capsules which not contain fish oil.~Treatment: 5 capsules per day"
45851440|NCT01275378|Behavioral|Collaborative Care Plus|Traditional collaborative care + systematic addressing of ADHD comorbidities, parental mental health issues, and adherence to treatment plans
45851441|NCT01275378|Behavioral|Traditional Collaborative Care|Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
45405356|NCT01087008|Other|No treatment control|Patients doesn't receive treatment
45405357|NCT01087086|Behavioral|Crononutrition|"After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support."
45405358|NCT01087086|Behavioral|American Heart Association|"After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support."
45851442|NCT01275456|Procedure|Exposure to house dust mite|0 SQE/qm for 4 hours 250 SQE/qm for 4 hours 500 SQE/qm for 4 hours 1000 SQE/qm for 4 hours
46057380|NCT02709759|Behavioral|Motivational intervention|Involves 60 minutes of counseling delivered by videoconferencing. Provides feedback on drinking and HIV and related behaviors.
46057381|NCT02709759|Behavioral|Brief Advice|Involves 5-10 minutes of brief counseling to reduce drinking
45405359|NCT01084044|Drug|ulinastatin, saline solution|the ulinastatin group receiving ulinastatin (300,000 unit after anesthesia induction and another 300,000 unit during Y- graft anastomosis, n = 40), the control group receiving the same volume of saline solution(n = 40)
45405360|NCT01090440|Drug|GSK1144814|This study is an open label, randomised, three-way cross-over study to evaluate the pharmacokinetics, effect of food, safety and tolerability of a new tablet formulation of GSK1144814 in healthy male and female (non-child bearing potential) subjects. Sixteen subjects will be enrolled to provide a minimum number of 12 evaluable subjects. The doses to be administered will be 100 mg and 200mg in the fasted state, and 100mg following a high fat breakfast.
45405361|NCT01090518|Behavioral|Prolonged Exposure therapy|10 weekly sessions
45405362|NCT01090518|Drug|Hydrocortisone|30mg 20 minutes prior to each PE session including imaginal exposure (8 total)
45405363|NCT01090518|Behavioral|Prolonged Exposure therapy|10 weekly sessions
45405364|NCT00082368|Drug|Tariquidar|3 days after initial PET patients will receive tariquidar and repeat imaging.
45405365|NCT00082368|Drug|Tc-94m Sestamibi|Patients over 18 years of age, who are eligible for, or have completed enrollment in an active NCI (National Cancer Institute) protocol for treatment of cancer will undergo a PET sestamibi scan
45405366|NCT03960216|Procedure|Scaling and root planning|Patients received non-surgical periodontal therapy in the form of full-mouth scaling and root planing (SRP), in two sessions, 1 week apart, with the use of an ultrasonic scaler (Minipiezon Electromedical Systems EMS, Nyon, Switzerland) and hand instruments, under local anaesthesia.
45514335|NCT02076204|Behavioral|Home visiting|MIHOPE-Strong Start will examine local programs that use either of two home visiting service models that have shown previous evidence of improving birth outcomes: Healthy Families America (HFA) and Nurse-Family Partnership (NFP). HFA and NFP provide disadvantaged expectant mothers with individualized in-home services, including assessment of prenatal and postnatal risks to child well-being; referrals to needed health care or social services; and direct education of parents by home visitors on such topics as healthy prenatal behaviors, parenting, and child development.
45514336|NCT03670095|Drug|Lactose-free memantine|Lactose-free memantine tablet, 10 mg; orally as a single dose
45405367|NCT03960216|Procedure|Supragingival Prophylaxis|Supragingival removal of all deposits (plaque and calculus) with an ultrasonic scaler in two sessions, 1 week apart.
45405368|NCT03958032|Other|No intervention|No intervention is planned for the participants for the treatment of gastric cancer. Treatment decision will be in line with clinical practice guidelines. Surgical team will be blind to the participant's sarcopenia status.
45405369|NCT01090596|Drug|Naproxen|500mg naproxen, twice daily for 7 days
45514337|NCT03670095|Drug|Memantine|Lactose-containing memantine tablet, 10 mg, orally as a single dose
45514338|NCT01378039|Drug|comparison of treatment effect on different markers|inhaled budesonide (400 µg BD) or placebo BD
45514339|NCT02078856|Drug|A3384|
45514340|NCT02473341|Drug|Bovine Colostrum|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.~+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated"
45514341|NCT02473341|Drug|Placebo|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks~+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated."
45514342|NCT03240679|Device|Acell MatriStem® Surgical Matrix|Extracellular matrix (ECM) product that is composed of collagen and natural proteins that provide a re-absorbable scaffold for tissue remodeling to facilitate constructive healing following endoscopic submucosal resection (EMR). Covers the defect site following mucosal resection using endoscopy clips or X-tac. The device will remain attached to the esophagus and integrate with native tissue over time.
45514343|NCT01377961|Drug|Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks|"After the screening and OGTT, the treatment group each subject will be in is decided by randomization. Neither subject nor the researchers will be allowed to choose which group a subject is assigned to. A single patient/subject cannot be assigned more than 1 allocation number. Each subject will be assigned randomly (like drawing straws) to receive either on the pills containing the combination of 6mg lycopene and 50mg isoflavones or placebo. Each subject has a 1 in 2 chance of receiving one of these treatments.~The subject are advised to take one capsule of Laflavon/Placebo by mouth daily for 12 weeks."
46057382|NCT02709759|Behavioral|Interactive text messaging|Involves receiving daily text messages that enable participants to track their drinking and related consequences. Provides feedback on drinking and allow setting of goals.
45514344|NCT01377961|Other|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
45514345|NCT01377961|Other|OGTT|OGTT will be done after the screening at Baseline and at the completion of the 12 weeks of taking the supplements by the subject.
45514346|NCT01377961|Other|Anthropometrics and Blood pressure|Measurements of height, weight, hip, waist and Blood Pressure are done before and after 12 weeks of taking the supplements.
46057383|NCT04170309|Drug|Ceftobiprole medocaril|Participants in whom treatment with Ceftobiprole medocaril has been completed
46057384|NCT02709681|Other|Physician standard-of-care in SCD patients|
46057385|NCT00917761|Drug|Entecavir and peginterferon (Pegasys) (52 weeks)|Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
46057386|NCT00917761|Drug|Peginterferon (Pegasys) (96 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-96
45405370|NCT01090596|Drug|Placebo|1 tab,twice a day for a seven days
45405371|NCT01084122|Drug|Iron sucrose|Iron sucrose FERIV® (20 mg/ml). Dilution: 10 ml in 100 ml SF 0.9%. 25 ml in 15 minutes and the rest in others 15 minutes.
45405372|NCT01084200|Drug|Propofol for maintenance|Propofol 6-8mg/kg/h + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
45405373|NCT01084200|Drug|Sevoflurane|Sevoflurane 0.7-1.3MAC + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
45405374|NCT01084200|Drug|Sevoflurane+Propofol|Sevoflurane 0.7-1.3MAC + Remifentanil 0.1-0.2ug/kg/min + Propofol 2mg/kg/h for anesthesia maintenance
45405375|NCT03957798|Behavioral|RecoveryWarrior 2.0|"RecoveryWarrior 2.0 was developed for use with Microsoft Kinect running on a Windows personal computer. All games made use of whole-body motion detection and the same voice-recognition feature. Body motions included a variety of arm, leg, and whole-body movements to physically enact the motions of destroying or evading images of drugs and drug paraphernalia. Voice features consisted of recognition of the refusal phrase I'm Clean Players could say or shout I'm Clean in order to gain additional strength for their game play avatar. All game art was created in a hyperrealistic, idealized, heroic style."
45405376|NCT01087164|Behavioral|Compliance|Parent will either receive a high or no compliance condition where each is asked to endorse the importance of prevention cervical cancer or genital warts depending on their teen's gender.
45405377|NCT01087164|Behavioral|Message sidedness|Parent will receive either a one-sided or two-sided message about the HPV vaccine
45405378|NCT01084434|Dietary Supplement|probiotic|Bifidobacterium lactis HN019 10^9 CFU/day 1 sachet once a day for 7 weeks
45405379|NCT01084434|Dietary Supplement|prebiotic|Galactooligosaccharide 5.5 g/day 1 sachet once a day for 7 weeks
45405380|NCT01084434|Dietary Supplement|Synbiotic|(Bifidobacterium lactis 10^9 CFU + Galactooligosaccharide 5.5g) / day - 1 sachet once a day for 7 weeks
45405381|NCT01084434|Dietary Supplement|Placebo|Maltodextrin 5.5g/day - 1 sachet once a day for 7 weeks
45405382|NCT01087242|Drug|Tang-min Lin pill|Tang-min Lin pill 6g,tid,treat 12 weeks.
45405383|NCT00094770|Drug|sitagliptin (MK0431)|Sitagliptin 100 mg oral tablets of sitagliptin once daily.
45405384|NCT00094770|Drug|Comparator: glipizide|Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.
45405385|NCT00069576|Behavioral|nutritional counseling|
45405386|NCT00069576|Behavioral|self blood glucose monitoring|
45405387|NCT01090674|Other|No intervention|We perform in all patients respiratory functional tests, thoracic x-ray, SNIF test and diaphragmatic magnetic resonance imaging.
45405388|NCT01087398|Drug|Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)|"For sibling full match:~Busulfan 16 mg/kg >5year - 20 mg/kg <5year po~Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~Busulfan 16 mg/kg >5year - 20 mg/kg <5year po~Cyclophosphamide 200 mg/kg iv~ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~Busulfan 16 mg/kg >5year - 20 mg/kg <5year po~Cyclophosphamide 200 mg/kg iv~Fludarabine 160 mg/m^2"
45405389|NCT01087398|Procedure|Stem Cell Transplantation|"Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~Sibling full match~Other related full match~Sibling or other related with 1 mismatch antigen~Cord Blood~Haploidentical"
45405390|NCT01087398|Drug|Cyclosporin, Methotrexate (GVHD prophylaxis)|"Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in PBSCT and +11 in BMT or UCBT) then 9 mg/kg/day po~10 mg/m^2 iv day +1 then 6 mg/m^ iv day +3 and +6 (Not for UCBT)"
45405391|NCT01087476|Drug|Doxycycline hyclate|Sub-microbial dose of Doxycycline hyclate or placebo (50 mg per day), immediately before the initiation of induction chemotherapy and daily during the following 21 days after chemotherapy.
46057387|NCT00917761|Drug|Peginterferon (Pegasys) (48 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-48
46057388|NCT02709603|Drug|hyoscine butyl bromide|oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
45405392|NCT00069264|Drug|E7389|E7389 Dose-escalation starting at 0.25 mg/m^2 intravenous on Days 1, 8, and 15 of a 28 day cycle.
45405393|NCT00069108|Drug|5 FU|As prescribed, in 2 week cycles
45405394|NCT00069108|Drug|Leucovorin|As prescribed, in 2 week cycles
45405395|NCT00069108|Drug|Oxaliplatin|As prescribed, in 3 week cycles
46057389|NCT02709603|Drug|placebo|oral placebo; 2 tablets 30 minutes before the procedure
45405396|NCT00069108|Drug|Oxaliplatin|As prescribed, in 2 week cycles
45405397|NCT00069108|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-15 of each 3 week cycle
45405398|NCT03962712|Other|Increase Minimum Wage to $15-an-hour|Increase in minimum wage to $15-an-hour
45405399|NCT03962712|Other|No Increase in Minimum Wage|No increase in minimum wage
45405400|NCT03961776|Device|MRI-guided radiotherapy by on-board DWI sequences|The radiotherapy treatment will be delivered on the MRI-guided radiotherapy platform. The on-board DWI sequences will be performed every three fractions in addition to the treatment session and will last approximately 3-4 minutes.
45405401|NCT00094536|Device|Extended treatment regimen using Her Option Cryotherapy|Extended treatment regimens using the Her Option Endometrial Cryotherapy System to more effectively ablate the endometrial lining, reducing menstrual levels to normal or less.
45405402|NCT00405587|Drug|PLX4032|Oral capsules administered BID
45405403|NCT01040429|Drug|Clonidine|"Day 1-56 (week 1-8): 25 microgram (1 capsula) x 2/day for patients < 35 kg; 50 microgram (2 capsula) x 2/day for patients > 35 kg.~Day 57-63 (week 9): 25 microgram (1 capsula) x 1/day for patients < 35 kg; 25 microgram (2 capsula) x 2/day for patients > 35 kg."
45405404|NCT01040429|Drug|Lactose capsula|"Day 1-56 (week 1-8): 1 capsula x 2/day for patients < 35 kg; 2 capsula x 2/day for patients > 35 kg.~Day 57-63 (week 9): 1 capsula x 1/day for patients < 35 kg; 1 capsula x 2/day for patients > 35 kg"
45405405|NCT00581243|Drug|SLV-313 SR|sustained relase tablets taken once daily for 14 days
45405406|NCT01039883|Drug|Albaconazole tablet 400mg|Albaconazole tablet 400mg single dose, then four albaconazole capsule 100mg single dose
45405407|NCT01039883|Drug|Albaconazole 100mg capsules, then albaconazole 400mg tablet|Four albaconazole capsule 100mg single dose, then albaconazole tablet 400mg single dose
45405408|NCT00405275|Drug|Etanercept|etanercept, subcutaneous injection
45405409|NCT00405275|Drug|methotrexate|baseline methotrexate is maintained throughout the study and is not provided by the sponsor
45405410|NCT00405275|Drug|Sulfasalazine|sulfasalazine, oral
45405411|NCT00405275|Drug|Hydroxychloroquine|hydroxychloroquine, oral
45405412|NCT00405275|Drug|Placebo, triple|Participants in Etanercept arm (Arm 1) were given placebo hydroxychloroquine and sulfasalazine pills.
45405413|NCT00405275|Drug|Placebo, etanercept|Participants in triple arm (Arm 2) were given placebo etanercept injections.
45405414|NCT00404651|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
45405415|NCT00404651|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, IM
45514347|NCT01377961|Other|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
45514348|NCT01377961|Other|Blood Drawing|The blood will be drawn at the baseline and at the completion of the 12 weeks of taking the capsules of laflavon /placebo.
45514349|NCT02074956|Biological|AERAS-404|AERAS-404 is comprised of the H4 antigen, a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4; and IC31 adjuvant, a combination of a leucine-rich peptide and a synthetic oligonucleotide.
45514350|NCT02074956|Biological|Placebo|Sterile buffer containing 10 mmol Tris and 169 mmol of NaCl in 0.8 mL of aqueous solution. This is the identical buffer solution in which H4 and IC31 are formulated.
45514351|NCT03558750|Biological|Nivolumab|Given by IV
45514352|NCT03558750|Biological|Rituximab|Given by IV
45514353|NCT03558750|Drug|Lenalidomide|Given by mouth
45514354|NCT02083302|Behavioral|SCREAM Theater Dose 1|Intervention 1: A three part program: a skit acted out by peer educators that depicts a sexual assault; an in-character question and answer session; and an out-of-character information session.
45514355|NCT02083302|Behavioral|SCREAM Theater Doses 2 & SCREAM Theater Dose 3|"Dose 2: Scenes from the skit from Session 1 are re-created with small groups of students, but stop at certain points to allow audience members to explore different bystander intervention possibilities.~Dose 3: The six scenes outlined in Session 2 are presented individually to small groups of student participants; specifically outlining potential points of bystander intervention."
45514356|NCT02083302|Behavioral|SCREAM Theater Dose 4|Booster Session
45405416|NCT00404651|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, IM
45405417|NCT00404651|Biological|DTaP-HBV-IPV vaccine|0.5 mL, IM
45405418|NCT03908021|Diagnostic Test|Microbiome analysis and 16S rRNA gene-based analysis|microbial DNA is extracted from the saliva and 16s library is prepared for sequencing.
45405419|NCT00404495|Drug|Irinotecan|Irinotecan 10 mg/m^2 per day on days 1-5 and days 8-12 in repeated 3 week cycles
45405420|NCT00404495|Drug|Temozolomide|Temozolomide 100-125 mg/m^2 daily on days 1-5 in repeated 3 week cycles
45405421|NCT01039961|Drug|losmapimod 1 mg|IV infusion
45514357|NCT04701385|Diagnostic Test|Optical Coherence Tomography (OCT)|Optical Coherence Tomography (OCT) can undertake detailed characterisation of plaque morphology in patients with myocardial infarction at the time of percutaneous treatment. This allows plaque rupture, erosion and other mechanisms of myocardial infarction to be differentiated
45514358|NCT03559140|Procedure|Applied saline solution at 2.5 oC (Cryotherapy group)|Patients assigned to this group will receive a final irrigation (application of cryotherapy) with 5 mL cold (8oC) 17% EDTA followed with 20 mL cold (8oC) sterile saline solution delivered to the WL using a cold (8oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
45405422|NCT01039961|Drug|losmapimod|IV infusion (dose to be determined based on PK from first dose)
45405423|NCT01039961|Drug|losmapimod 15 mg|oral, two 7.5 mg tablets
45405424|NCT00409409|Drug|300 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
45405425|NCT00409409|Drug|Placebo tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
45405426|NCT00409331|Drug|Amifostine|500 mg in two divided doses subcutaneously given 30-60 minutes prior to IMRT.
45405427|NCT00409331|Procedure|Intensity- Modulated Radiation Therapy|2.0 to 2.2 Gy delivered in 30 fractions
45405428|NCT00409175|Drug|Fx-1006A|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
45405429|NCT00409175|Drug|Placebo|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
45405430|NCT00362219|Other|Placebo|Gel with no active ingredient.
45405431|NCT00362219|Drug|Morphine - .25 mg|gel with 0.25 mg morphine per 100cm2 square of wound.
45405432|NCT00362219|Drug|Morphine|Gel with 0.75 mg morphine per 100cm2 square of wound.
45405433|NCT00362219|Drug|Morphine|Gel with 1.25 mg morphine per 100cm2 square of wound.
45405434|NCT01040585|Drug|Linezolid|Treatment for VAP as indication approved and as physician criterium.
45405435|NCT01040117|Procedure|Sensory-motor Integration Training|Exercises will be divided into 3 levels. 1 Starting from the patient's most stable and comfortable standing position. 2 Patient will perform a single-step simulation, shifting his/her weight from one foot to the other in a frontal direction. 3 Patient will perform rapid movements, alternating feet in many directions, progressively increasing weight shifting and decreasing the support base amplitude. In the first five sessions exercises will be performed on a stable surface. During the remaining sessions patients will perform exercises on a compliant surface. During the two training periods the patient's visual condition will be progressively changed.
45514359|NCT03559140|Procedure|Applied saline solution at 8oC (Cryotherapy )|Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
45514360|NCT03559140|Procedure|Applied saline solution at room temperature (No cryotherapy)|Patients assigned to this control group were treated identically to the experimental groups, except that they will receive a final irrigation ( application of irrigant at room temperature) with 5 mL (room temperature) 17% EDTA followed with 20 mL (room temperature) sterile saline solution delivered to the WL using a sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
45405436|NCT01040117|Procedure|Conventional neurorehabilitation treatment|"The treatment will be consist in active joint mobilization, muscle stretching and strengthen and motor coordination exercises. In the first part of each session the active joint mobilization will be carried out while the patient was lying on a carpet in supine, prone. The training will continue with muscle stretching and strengthen exercises performed while patient will be in supine, prone (when possible) and standing.~Motor coordination exercises will be carried out in supine position while sitting on a bench and in the standing position with a front support or with against a wall. The patient will be required to performed a total of 10 exercises with the following sequence: 6 exercises in supine position, 2 exercises in sitting position and 2 in standing position."
45405437|NCT01040663|Other|Dietary intervention|Subjects will be randomly assigned to receive 1 of 3 diets for 4 weeks.
45405438|NCT01040741|Other|Non-intervention observational study|Non-intervention observational study
45405439|NCT01040897|Behavioral|Health Communication and Obesity Prevention|Pediatric residents will be training in effective health communication skills and given a literacy/numeracy sensitive toolkit (GreenLight) to use with parents during all well child visits from 2 months to 18 months.
45405440|NCT01040897|Behavioral|Injury Prevention Arm|Pediatric residents will be trained to address injury prevention using the American Academy of Pediatrics (AAP) TIPP materials.
45405441|NCT01040195|Drug|Methotrexate, Hydroxychloroquine|Methotrexate will be prepared as unmarked tablets of 2.5 mg strength each and Hydroxychloroquine as unmarked tablet of 200 mg strength. Patients will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day or placebo.
45405442|NCT01040195|Drug|Placebo|Identical placebos (for methotrexate and hydroxychloroquine)will be prepared and prescribed in identical fashion as the methotrexate and hydroxychloroquine in the combination DMARD arm.
45405443|NCT01040975|Behavioral|Web-based intervention targeting MD communication; Summary Report|Web-based intervention targeting MD communication; Summary Report detailing 6 risk factors for adolescent overweight/obesity developed by study team
45405444|NCT01040273|Drug|Bupivacaine|
45405445|NCT01040273|Drug|Placebo|
45851443|NCT01275612|Biological|Mesenchymal stromal cell infusion|The first 3 patients will receive a single i.v infusion of donor ex-vivo expanded MSC (1 x 106 MSC/kg). If the efficacy outcome of cell treatment is negligible or partial and the procedure is safe, a second group of additional 3 patients will be enrolled. They will be given MSC i.v infusion at higher dose (2 x 106 MSC/kg).Should the therapeutic efficacy of this treatment again negligible or marginal, but still safe, a third group of 3 patients will be enrolled in the study. The dose of cells to be infused will be up-titrated to 5 x 106 MSC/kg.
46057390|NCT05162469|Drug|SHR-1909 injection|SHR-1909 for intravenous injection;Strength:6ml:0.3g/vial. Dose escalation (non randomized, 6 dose-levels); Dose-expansion and efficacy-expansion(non-randomized,1-3 dose-level(s)).
46057391|NCT02593045|Biological|IPH4102|
45405446|NCT00408629|Biological|adalimumab|Prefilled syringe, 40 mg, 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week between Weeks 4 and 50.
45405447|NCT00408629|Biological|placebo|Matching Placebo for prefilled syringe, 40 mg,
45405448|NCT00408317|Drug|Ultrase® MT20|Ultrase® MT 20 capsules containing enteric-coated minitablets orally daily at a dose stabilized during the first stabilization period (4 days), as per investigator's discretion, for 6 to 7 days in either first intervention period or second intervention period.
45405449|NCT00408317|Drug|Placebo|Placebo matched to Ultrase® MT 20 capsules orally daily for 6 to 7 days in either first intervention period or second intervention period.
45405450|NCT00112502|Drug|Celecoxib|400 mg orally twice a day continuous dosing
45405451|NCT00112502|Drug|Isotretinoin|40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.
45405452|NCT00112502|Drug|Temozolomide|150 mg/m2 orally daily, 7 days on treatment, 7 days off.
45514361|NCT02082366|Device|TCD monitoring of microembolic signal during procedure|monitoring of microembolic signal during procedure
45514362|NCT02082444|Other|Skipping lunch|
45514363|NCT02082600|Other|Sleep deprivation|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and than will keep awake for 60 hours (2 nights), followed by 1 night of sleep, all inside the lab. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
45405453|NCT00112502|Drug|Thalidomide|400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved)
45405454|NCT03965546|Combination Product|Sorafenib combined with ET140202-T cell|"Sorafenib starting dose of 400mg b.i.d. a.c.~Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct by intravenous (IV) infusion"
45405455|NCT03965546|Combination Product|TAE combined with ET140202-T cell|"Transarterial embolization(TAE) treatment~Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct -intravenous (i.v.)"
45405456|NCT03965546|Biological|ET140202-T cell|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) - expression construct -intravenous (i.v.)
45405457|NCT01080404|Procedure|Bariatric surgery|A standardized laparoscopic gastric bypass using Roux-en-Y technique
45405458|NCT01080404|Device|Continuous positive airway pressure|The patients are given standardized CPAP treatment according to current clinical guidelines.
45405459|NCT01083992|Drug|Galvus (vitagliptin)|Galvus (vitagliptin)
45405460|NCT01083992|Drug|Galvus + vitamin D|Galvus + vitamin D
45405461|NCT01084070|Other|Early oral feeding|"Within 6-24 hours after surgery the nasogastric tube will be removed and liquids and soft diet at will indicated."
45405462|NCT01084070|Other|Traditional Care|They will have nasogastric tube and restriction of oral intake until the first sign of restoration of intestinal transit (first flatus or stool, whichever comes first). Since then withdrew nasogastric tube and liquid diet starts within 24 hours, then continues with soft diet.
45405463|NCT01084226|Dietary Supplement|Rye-2008|
45405464|NCT01078532|Other|SMART PHR|Patient receives an active PHR
45699200|NCT03462420|Other|Physical Therapy program|The physical therapy program will be chosen by the treating therapist. However, the most common physiotherapy interventions include therapeutic exercises, joint mobilization techniques and electrotherapy.
45699201|NCT03449394|Other|Metacognitive Training|4 sessions of Metacognitive Training using 4 treatment modules each targeting different cognitive biases
45699202|NCT05320848|Behavioral|cardiac rehabilitation|Cardiac rehabilitation is a valuable treatment for patients with a broad spectrum of cardiac disease.
45699203|NCT03449316|Behavioral|Inhaler technique education|Teaching of inhalers use with placebo devices in real training
45405465|NCT01078532|Other|usual care|Usual passive PHR
45405466|NCT03822182|Drug|liposomal bupivicaine|"The medication administered in the interscalene block is the intervention in this study. There are three different types of interscalene blocks that will be administered in order to compare the independent effectiveness of LB with the effectiveness of LB plus dexamethasone. Study participants will be randomized into one of three groups. The treatment groups are listed below:~Group 1 (Control): 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone Group 2: 15ml 0.5% bupivacaine and 10ml (133mg) of LB (Exparel) and 5.4ml normal saline Group 3: 5ml 0.5% bupivacaine and 10ml LB (Exparel) and 0.4ml (4 mg) dexamethasone and 5ml normal saline"
45405467|NCT03822182|Drug|Dexamethasone|steroid that will be used in control as well as in group 3 to see if effect with liposomal bupivicaine is prolonged as has been shown with standard bupivicaine.
45405468|NCT01078610|Biological|adalimumab (Humira)|40 mg adalimumab (Humira) every other week.
45405469|NCT03741296|Procedure|Single stage revision|One-stage exchange hip joint replacement surgery
45405470|NCT03741296|Procedure|Two-stage revision|Two-stage exchange hip joint replacement surgery
45405471|NCT03964766|Device|Rotary instrumentation|using pedo rotary files in cleaning and shaping the root canals of infected primary molars
45405472|NCT03964766|Device|Hand instrumentation|using conventional hand files in cleaning and shaping the root canals of infected primary molars
45405473|NCT01080482|Drug|Tacrolimus 5 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
45405474|NCT03965624|Drug|Ninlaro|Oral ixazomib will be given on days 1, 8, 15 of a 28-day cycle, the investigator will start with first test dose levels of ixazomib of 3 mg and process with dose escalation, in case of non-response and no severe adverse events at cycle 1 (see above) or de-escalation in case of response and severe adverse events.
45405475|NCT00111800|Drug|Placebo|Placebo capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
45405476|NCT00111800|Drug|DEN 2.5 mg|DEN 2.5 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
45405477|NCT00111800|Drug|DEN 7.5 mg|DEN 7.5 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
45405478|NCT00111800|Drug|DEN 15 mg|DEN 15 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
45699204|NCT05320536|Drug|Guilingji Capsule|This medicine is capsule medicine, take method is oral.
45699205|NCT05320536|Drug|Placebo|This medicine is capsule medicine（Placebo）, take method is oral.
45699206|NCT02460588|Drug|Cyclophosphamide|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2"
45699207|NCT02460588|Drug|Placebo|Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
45699208|NCT02460588|Drug|Corticosteroid (prednisolone)|All patients will receive non experimental medication with high dose of corticosteroid.
45514364|NCT02082600|Other|Normal sleep|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and and will be able to sleep the 3 nights. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
45514365|NCT02078934|Procedure|Endoscopic Gastric Plication|Evaluate the efficacy of endoscopic suturing for weight loss
45514366|NCT03558594|Behavioral|Hypnosis|Behavioral Condition
45405479|NCT00111800|Drug|DEN 30 mg|DEN 30 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
45405480|NCT00111800|Drug|DEN 45 mg|DEN 45 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
45405481|NCT01326806|Behavioral|Families Talking Together|The intervention will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth fora non-acute care visit. A mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. The healthcare provider will endorse the intervention separately for mothers and adolescents. There will be one follow-up booster session administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
45514367|NCT03558594|Behavioral|Mindfulness|Behavioral Condition
45514368|NCT02751320|Drug|0.425 % w/w phytate,1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
45514369|NCT02751320|Drug|0.85 % w/w phytate,1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
45514370|NCT02751320|Drug|0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
45514371|NCT02751320|Other|0 ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
45514372|NCT02751320|Drug|1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
45514373|NCT02751320|Drug|0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
45514374|NCT02079012|Behavioral|10-week walking program|
45514375|NCT02082756|Drug|Bifidobacterium viable pharmaceutics|
45699209|NCT03641430|Other|Supportive care with OCT product|Participants will apply over-the-counter product for a certain period with or without light challenge. We will perform clinical assessments of the skin associated with product application as well as assess these changes with and without light challenge. Skin biopsies will be obtained following standard medical practice and will be used to analyze skin markers related to photoaging, pigmentation, oxidative stress, and other dermatologic conditions.
45405482|NCT01326806|Behavioral|Active Control on Hygiene & Nutrition|The active control group will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth for a non-acute care visit. The mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the active control on hygiene and nutrition will be delivered to the mother.
45405483|NCT02530892|Procedure|EmbryoHug|"An oocyte or embryo will be gently held by a micropipette, and a small inward pressure will be applied to the edge of the oocyte or embryo. The response of the embryo to this pulling force will allow the investigators to measure its stiffness and viscosity. The term micropipette aspiration refers to the pressure applied to the edge of the embryo -- this procedure is not invasive and does not involve any sort of puncture or removal of material from the oocyte or embryo."
45405484|NCT01080560|Drug|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
45405485|NCT00094328|Drug|Bicalutamide|oral
45405486|NCT00094328|Drug|Anastrozole|oral
45405487|NCT00094172|Drug|Atorvastatin|atorvastatin at the dose of 80 mg/day. Participants will be allowed to decrease the daily dose to 40 mg/day if the higher dose is not well-tolerated
45405488|NCT00094172|Drug|Placebo|tablet form
45405489|NCT00094094|Drug|axitinib|Axitinib (AG-013736) tablet administered orally at a dose of 5 milligrams (mg) twice daily (BID) in cycles of 4 weeks.
45514376|NCT02082756|Drug|Berberine Hydrochloride|
45514377|NCT04093219|Drug|IV acetaminophen|use of IV tylenol for pain
45514378|NCT04093219|Other|Placebo|Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl
45514379|NCT02223572|Radiation|hip Xray|
45514380|NCT04615845|Biological|Cellgram-DC-PC|Patients will receive 3 times every 2 weeks injection of Cellgram-DC-PC(Autologous dendritic cell) subcutaneously near the inguinal lymph nodes
45514381|NCT02259140|Procedure|Proximal Femoral Resection Arthroplasty|Drains will be placed at the surgeon's discretion. Patients will be placed in skin traction on the operative side. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
45514382|NCT02259140|Procedure|Subtrochanteric Valgus Osteotomy|Drains will be placed at the surgeon's discretion. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
45405490|NCT01078766|Other|CIMT+HABIT|The daily schedule included one hour of constraining the functional arm with intensive activation of the hemi-paretic arm and then 5 hours of various structured, intensive bimanual functional activities,
45405491|NCT03962816|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
45405492|NCT03962816|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 20 µg per dose
45514383|NCT03559764|Biological|Anti-BCMA CAR T cells|Transparent colorless or slightly yellow liquid
45514384|NCT02082834|Other|abdominal MDCT examination|
45514385|NCT02259218|Other|laboratory biomarker analysis|Correlative studies
45405493|NCT03962816|Biological|60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 60 µg per dose
45514386|NCT01377883|Other|standard|"Preparation and information regarding the BTX procedure: placing EMG electrodes, wiping the area with an alcohol swab, cooling with ethyl chloride, needle insertion into the muscle and the importance of EMG noise.~Injection performed under EMG guidance. Two sites of injection per muscle were used to enhance diffusion. The child could often see the procedure when the upper limb was treated but not during lower limb injections.~Memory change and positive reinforcement: Following the BTX injection, the medical staff present spoke to the child positively and offered prizes Volunteer attendance: In the daycare unit there are young volunteers routinely present, assisting with technical aspects of the procedure."
45514387|NCT01377883|Behavioral|clown care|Cognitive coping Imagery Empowerment Reflecting emotions
45514388|NCT02083458|Procedure|Catheterization of the axillary vein.|
45514389|NCT02231528|Device|Use of ultrasound with active GPS|CVC insertion with ultrasound with active GPS function and appropriate needles
45514390|NCT02231528|Device|Use of ultrasound with inactive GPS|CVC insertion with ultrasound with inactive GPS function and conventional needles
45514391|NCT02079090|Drug|Ketofol|0.5 mg/kg Ketamine IV, and 2 minutes later receive 1 mg/kg Propofol (Diprivan).
45514392|NCT02079090|Drug|Fentofol|1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol (Diprivan)
45514393|NCT04931641|Dietary Supplement|Galacto-oligosaccharides|Prebiotic galacto-oligosaccharides (GOS)
45514394|NCT04931641|Other|Maltodextrin|Maltodextrin (placebo)
45405494|NCT01080638|Drug|glycoprotein IIb/IIIa inhibitor (abciximab)|patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg body weight,continus 12hrs-0.125ug/kg per minute(maximum: 10ug/min)
45405495|NCT01084928|Behavioral|Lifestyle Intervention Classes|The intervention will be based on the Diabetes Prevention Program but tailored to the needs of the community based on feedback gathered in focus groups. Classes will be group-based and will use a variety of teaching techniques and group-based work to teach participants about behavior change, diet, and physical activity. Participant will be required to attend one group exercise class per week based on traditional Indian dances and other culturally appropriate activities. In order to reach their weekly exercise goal of 150 minutes or more per week, participants will also be able to attend an additional group exercise class, an organized group walk, do a culturally-tailored work out video created by the study staff, and/or exercise on their own.
45514395|NCT04931641|Dietary Supplement|Ferrous fumarate|50 mg iron as ferrous fumarate
45514396|NCT04937270|Device|High frequency therapy (5 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 5 minutes using a 500 kHz resistive electric transfer (RET).
45514397|NCT04937270|Device|High frequency therapy (7 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 7 minutes using a 500 kHz resistive electric transfer (RET).
45514398|NCT04937270|Device|High frequency therapy (9 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 9 minutes using a 500 kHz resistive electric transfer (RET).
45514399|NCT04937270|Device|Superficial heat therapy|In the physical therapy used in this study, it was applied for 20 minutes using conventionally used superficial heat therapy.
45514400|NCT02079168|Drug|RXI-109|
45514401|NCT02079168|Drug|Placebo|
45514402|NCT04898959|Other|Filling out Questionaire|Filling out the Arabic Activity Specific Balance Confidence (A-ABC) and the Arabic Prosthetic Mobility Questionnaire twice at 2-3 week intervals
45514403|NCT02227472|Other|Evaluation of cognitive and pre-academic skills|Participants will complete testing to evaluate fluid reasoning, knowledge, quantitative reasoning, visual-spatial processing, verbal and non-verbal working memory, and knowledge of pre-academic skills (such as colors, letters, numbers, counting, sizes, comparisons, and shapes).
45514404|NCT02227472|Other|Parent questionnaires|Parents will complete questionnaires to assess behavioral manifestation of executive functions, functional independence and adaptive functioning, child and parent characteristics, situational/demographic life stress, demographics, education level, and household income.
45699210|NCT04369638|Device|3D NAM|"After consent and birth of the child, a face MRI will be taken of the newborn before discharge from the hospital utilizing the feed and swaddle technique. The MRI will be sent to the dental team to convert into a format compatible with 3D software. With the image, a NAM appliance will be digitally fabricated and 3D printed. The 3D printed model will be tested for fit on stone model made from traditional impression. Both traditional NAM and 3D printed NAM will be inserted at delivery appointment. Fit will be assessed of both appliances by applying a try-in paste to the intaglio surface and counting the number of spots needing adjustment."
45405496|NCT01079000|Behavioral|Opinion Leader letter|The patients' PCP will be notified by fax about the ED visit and management. The Opinion Leader letter will contain a summary of the current asthma guidelines for ambulatory care (including: asthma education, long-term recommendations, smoking cessation, and action plan) signed by a local opinion leader. A review of the patient's management within a week of the ED visit will be recommended. The patient will also receive information regarding their acute exacerbation and will be told to review the current management of their disease with their PCP.
45405497|NCT01079000|Behavioral|Involvement of a care manager|The involvement of a care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged
45405498|NCT01079000|Behavioral|Usual care|Usual care provided to asthma patients when discharged from the ED
45405499|NCT03965312|Device|Continuous temperature monitor|Temperature will be measured using a novel temperature monitor continuously for up to 72 hours. Accuracy (as compared to a commercially available patient monitor) will be evaluated.
45405500|NCT03965312|Device|Neonatal Incubator|Infants at risk for hypothermia will be placed in a neonatal incubator. Their temperature will be monitored as they are treated. The infant will be treated until the infant is transitioned to skin-to-skin care, discharged, or no longer at risk for hypothermia.
45405501|NCT03965312|Device|Patient monitor|Temperature will be measured using a commercially available patient monitor.
45405502|NCT00110396|Biological|Interferon-beta-1a FBS-free/HSA-free|Pre-filled syringes 44mcg/injected subcutaneous 3x per week. Total study period is 96 weeks.
45405503|NCT03819218|Drug|MC2-01 cream|MC2-01 cream (Calcipotriene/betamethasone dipropionate, w/w 0.005%/ 0.064%)
45405504|NCT00093470|Procedure|Clinical Observation|Undergo observation
45405505|NCT00093470|Drug|Tipifarnib|Given PO
45405506|NCT00407537|Drug|Amlodipine besylate/atorvastatin calcium single pill combination|Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion
45405507|NCT00094458|Biological|infliximab infusion; AZA placebo caps|Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
45405508|NCT00094458|Other|infliximab (IFX) infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
45405509|NCT00094458|Drug|infliximab (IFX) placebo infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
45405510|NCT00406367|Drug|incobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, up to 50 Units per eye; Mode of administration: intramuscular injection"
45405511|NCT00406367|Drug|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
45405512|NCT01041443|Drug|5-fluoro-2-deoxycytidine|Given IV
45405513|NCT01041443|Drug|tetrahydrouridine|Given IV
45405514|NCT01041443|Other|laboratory biomarker analysis|Correlative studies
45405515|NCT01041443|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
45405516|NCT01041443|Genetic|DNA methylation analysis|Correlative studies
45405517|NCT03961464|Drug|d-cycloserine|Single dose
45405518|NCT03961464|Drug|Placebo|Single dose
45405519|NCT01087554|Drug|Sirolimus|"Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.~Expansion Phase starting dose: MTD from Escalation Phase."
45405520|NCT01087554|Drug|Vorinostat|"Arm A - Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Arm B + Arm C - Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28."
45405521|NCT01087554|Drug|Everolimus|"Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.~Expansion Phase: MTD from Escalation Phase."
45405522|NCT01087554|Drug|Temsirolimus|"Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.~Expansion Phase: MTD from Escalation Phase."
45405523|NCT01087632|Dietary Supplement|Armolipid Plus|Armolipid Plus 1 tablet QD for 18 weeks
45405524|NCT00394589|Drug|Infliximab Increased Frequency|Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks for 24 weeks
45405525|NCT00394589|Drug|Infliximab Increased Dose|3 mg/kg infliximab + 1 extra vial (100 mg) infliximab every 8 weeks for 24 weeks
45405526|NCT00394589|Drug|Infliximab Control|Continuation of infliximab 3 mg/kg every 8 weeks for 24 weeks
45405527|NCT00068406|Radiation|3-Dimensional Conformal Radiation Therapy|
45405528|NCT00068406|Drug|Cisplatin|Given IV
45405529|NCT00068406|Procedure|Conventional Surgery|
45405530|NCT00403559|Drug|Elidel|
45405531|NCT00403559|Drug|Ketoconazole Cream|
45405532|NCT01087710|Other|medical food with EPA and GLA, vitamins and minerals|1 8oz serving per day for 12 weeks
45405533|NCT01087710|Other|medical food minus EPA and GLA, antioxidant vitamins/minerals|1 8oz serving a day for 12 weeks
45405534|NCT00403481|Drug|olmesartan medoxomil|Olmesartan medoxomil tablets, once daily
45405535|NCT00403481|Drug|Olmesartan medoxomil plus Hydrochlorothiazide|Olmesartan medoxomil and hydrochlorothiazide combination tablets, once daily, if necessary
45405536|NCT03759275|Other|pMDT(Baseline Investigation)|The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
45405537|NCT01043783|Other|Dietary Adherence|Subjects consumed a specified healthy, balanced, reduced calorie diet and provided timed breath samples.
45405538|NCT00402779|Drug|Erlotinib|150 mg by mouth daily
45405539|NCT00402779|Drug|Placebo|Tablet by mouth daily
45405540|NCT00394433|Drug|Bevacizumab|
45405541|NCT00394433|Drug|Docetaxel|
45405542|NCT00394433|Drug|Cisplatin|
45405543|NCT00394433|Drug|Irinotecan|
45405544|NCT00092534|Biological|Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine|A 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study.
45405545|NCT00092534|Biological|Matching Placebo|A placebo 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study.
45405546|NCT01324193|Dietary Supplement|Pomegranate extracts|a 1000mg capsule of a purified pomegranate polyphenol supplement (POMx™, POM Wonderful, Inc. Los Angeles, CA)7 days a week for 12 months.
45405547|NCT00068250|Drug|rituximab|375 mg/m2, intravenously three days prior to the first cycle of methotrexate
45405548|NCT00068250|Drug|methotrexate|Five cycles of methotrexate (MTX) at 3.5 gm/m2 administered every two weeks on weeks 1, 3, 5, 7, and 9 via intravenous infusion over four hours once per cycle. Calcium leucovorin 25 mg orally or intravenously every six hours initiated exactly 24 hours following the start of the MTX infusion. Methotrexate levels to be monitored daily, and calcium leucovorin discontinued when the MTX level is less than 10 micromolar.
45405549|NCT00068250|Drug|temozolomide 100 mg/m^2|Temozolomide 100 mg/m^2 by mouth per day for five days on weeks 4 and 8.
45405550|NCT00068250|Drug|temozolomide 150 mg/m^2|Temozolomide 150 mg/m^2 by mouth per day for five days on weeks 4 and 8.
45405551|NCT00068250|Drug|temozolomide 200 mg/m^2|Temozolomide 200 mg/m^2 per day by mouth for five days on weeks 4 and 8.
45405552|NCT00068250|Radiation|radiation therapy|Whole brain irradiation (WBRT) during weeks 11, 12, and 13, five days per week (excluding weekends). A daily dose of 2.4 Gy delivered in two fractions of 1.2 Gy each with a minimum inter-fraction interval of 6 hours, with a total dose to brain and meninges of 36 Gy.
45405553|NCT00068250|Drug|post-radiation therapy temozolomide|Temozolomide (TMZ) 200 mg/m^2 by mouth per day for 5 days on weeks 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50 for a total of 10 cycles.
45405554|NCT01080872|Device|CFR|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
45405555|NCT00393887|Device|Biodesign IHM|Biodesign IHM is placed to reinforce the hernia repair
45405556|NCT00393887|Device|Polypropylene mesh|Polypropylene mesh is used to reinforce the hernia repair.
45405557|NCT03957720|Drug|DMPS|Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;
45405558|NCT03957720|Drug|Penicillamine|Dosage Form: Penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years;
45405559|NCT03957720|Drug|DMSA|Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
45405560|NCT03957720|Drug|Zinc gluconate|Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:BID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:TID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 210mg per time,Zinc Frequency:TID,Zinc Duration: 5 years;
45405561|NCT00393029|Biological|anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes|Peripheral blood lymphocytes are harvested by lymphapheresis and engineered to express a T cell receptor that binds to P53.
45405562|NCT00393029|Biological|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days
45405563|NCT00393029|Biological|filgrastim|Beginning on day 1 or 2, administered subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day); continue daily until neutrophil count > 1.0 x 10^9/L x 3 days or > 5.0 x 10^9/L.
45405564|NCT00393029|Drug|cyclophosphamide|60 mg/kg/day x 2 days intravenously in 250ml dextrose 5% in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour.
45405565|NCT00393029|Drug|fludarabine phosphate|25 mg/m2/day intravenously piggyback (IVPB) daily over 30 minutes for 5 days.
45405566|NCT00402233|Drug|Pramipexole|
45405567|NCT00402233|Drug|Placebo|
45405568|NCT03993431|Drug|Bio-active cement|A cement used for crown cementation, specially recommended for pediatric esthetic crowns
45405569|NCT03993431|Drug|Packable glass ionomer|Glass ionomer cement with improved mechanical properties usually used for restoration of simple small cavities and in Atraumatic Restorative Treatment
45405570|NCT01044017|Drug|Placebo|single oral dose
45405571|NCT01044017|Drug|RO4998452|single oral doses
45405572|NCT00092456|Biological|rotavirus vaccine, live, oral, pentavalent|Three oral doses (~8.81 X 10^7 IU/Dose for Lot 1; ~8.01 X 10^7 IU/Dose for Lot 2; and ~6.91 X 10^7 IU/Dose for Lot 3) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination
45405573|NCT00092456|Biological|Placebo|"Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10~weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination"
45405574|NCT00067470|Drug|Placebo|
45405575|NCT00067470|Drug|N-acetylgalactosamine 4-sulfatase|
45405576|NCT00401843|Biological|Siltuximab|Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during cycle 1 in Part 1. Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during 42-day Treatment Phase and 35-day Maintenance Phase in Part 2.
45405577|NCT00401843|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus once every 2 weeks during cycle 1 in Part 1. Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period during 42-day treatment phase in Part 2. Bortezomib 1.3 mg/m2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) during 35-day Maintenance Phase in Part 2.
45405578|NCT00401843|Drug|Placebo|Matching placebo will be administered as intravenous infusion once every 2 weeks during 42-day treatment phase and 35-day maintenance phase in Part 2.
45405579|NCT00401843|Drug|Dexamethasone|Dexamethasone tablet will be administered in this study at the first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles in treatment phase and maintenance phase of Part 2.
45405580|NCT00401531|Biological|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|0.5 mL, IM
45405581|NCT00401531|Biological|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|0.5 mL, IM
45405582|NCT00401375|Drug|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
45405583|NCT00401375|Drug|Placebo|Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arm.
45405584|NCT00400985|Device|Implantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool.|SENSE-HF is non randomized trial. Study divided in 3 phases among which the first phase is blinded towards device diagnostic data.
45405585|NCT00400517|Biological|sargramostim|administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day
45405586|NCT00400517|Drug|thalidomide|doses up to 400 mg/day
45405587|NCT00400517|Procedure|conventional surgery|SOC care surgery
45405588|NCT00400517|Procedure|neoadjuvant therapy|post radical prostatectomy
45405589|NCT01044095|Biological|FluMist® live, attenuated, intranasal seasonal influenza vaccine|FluMist® live, attenuated, intranasal seasonal influenza vaccine 0.2mL (0.1mL per nostril)
45405590|NCT01044095|Biological|Fluzone® inactivated influenza virus vaccine|Fluzone® inactivated influenza virus vaccine 0.5mL intramuscularly
45405591|NCT01044173|Device|MR scan|axial and coronal free breathing HASTE sequences 3D T1 weighted gradient echo breathhold
45405592|NCT01324427|Behavioral|virtual medical visit|"At the pre-set time, the Mobile Telehealth Cart will be set up in the exam room or the clinic office, and a connection with the doctor will be made through their computer. The telemedicine visit will be conducted at the same time as the regular clinic visit. During the visit, the nurse will evaluate the physical symptoms, vital signs, past medical history, present medical history, and any side effects from the autologous or allogeneic transplant. The nurse will place a digital stethoscope on the chest to listen to the heart and lungs. The virtual medical visit will take about 25 minutes. At the end of the Virtual Medical Visit, the patient will evaluate the event using a survey to assess the acceptance of the virtual visit. The surveys will be written and should take around 15 minutes to complete. The answers provided will be shared with the MD and nurses after the patient has completed all their virtual medical visits."
45405593|NCT00392171|Drug|Temozolomide|Subjects will receive temozolomide 50 mg/m^2 for cycles of 28 days for 12 months or until progression
45405594|NCT00392015|Biological|NMRC-M3V-Ad-PfCA|Malaria Vaccine
45405595|NCT00392015|Biological|NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA|Malaria Vaccines
45405596|NCT00391625|Drug|GA-GCB|15-60 U/kg every other week via intravenous infusion
45514405|NCT02083536|Radiation|Low Dose Fractionated Whole Abdominal Radiation Therapy|A single fraction of LDFWART will be given 6-8 hours after the start of morning administration of Docetaxel for 6 cycles (the time of the start Docetaxel will be counted as the frame of reference for when the LDFWART can be given).
45405597|NCT03993275|Device|MindMotion GO|Patients will train trunk control and balance using the MindMotion GO device 2-3 times a week. They will perform exergames in sitting or standing, according to their balance level.
45405598|NCT00091832|Biological|Denosumab|Denosumab administered by subcutaneous injection
45405599|NCT00091832|Drug|IV Bisphosphonates|Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid
45514406|NCT02083536|Drug|Docetaxel|Chemotherapy will consist of 6 cycles of Docetaxel. Each cycle will follow standard of care and will be scheduled every 3 weeks ± 3 days. Chemotherapy should be administered in the morning to allow 6-8 hours before Radiation Therapy. On Day 1 of each cycle, chemotherapy will consist of Docetaxel 60 mg/m² infused intravenously over 30-60 minutes (with premedication of dexamethasone 10 mg given IV 30-60 minutes prior to docetaxel administration).
45405600|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (infant dose)
45405601|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (children dose)
45405602|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (infant dose)
45851444|NCT01275768|Procedure|Endoscopic radio-frequency ablation|Endobiliary radiofrequency catheter is 8Fr in diameter and can easily be passed over a 0.035 guide wire through the biopsy channel of a duodenoscope at the time of endoscopic retrograde cholangiography (ERC). Its use in the biliary system was heralded by animal experiments following which power settings of 7-10 Watts for 2 minutes were found to provide adequate ablation. The ablation results in charring of the tumor and this is expected to enhance the patency of SEMS
45405603|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (children dose)
45405604|NCT01085162|Drug|BMS747158|BMS747158 is a novel PET MPI agent labeled with Fluorine-18.
45405605|NCT01044251|Drug|Frovatriptan|2.5 mg po bid for 10 days
45405606|NCT01044251|Drug|Placebo|1 tab po bid for 10 days
45405607|NCT01044329|Drug|Bevacizumab|Intravitreal, 1.25 mg, 3 times, one month apart.
45405608|NCT01044329|Drug|Triamcinolone Acetonide|Intravitreal, 2 mg, 2 times, two months apart.
45514407|NCT03629899|Device|RETINA IMPLANT Alpha AMS|Implantation of the subretinal RETINA IMPLANT Alpha AMS
45851445|NCT01275924|Device|Tightrope Syndesmosis Repair Kit|Tightrope Syndesmosis Repair Kit
45405609|NCT01044407|Device|Pacemaker manipulation|Alternation of cardiac output by modulation of heart rate, atrioventricular delay and modulation from biventricular pacing to right ventricular pacing (where applicable)via a cardiac pacemaker
45405610|NCT01018589|Other|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the epidermic burns or post surgical scars by administration fo the patients twice a day during two months to a dose of 0,1 ml of cream for each cm of surface, being controlled by the specialist in biweekly consultations.~To the patient will be explained the technique of the application."
45405611|NCT00091442|Drug|Docetaxel|Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
45405612|NCT00091442|Drug|DOXIL|DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
45405613|NCT00390689|Drug|Pramipexole 0.125 mg tablet|
45405614|NCT00390689|Drug|Pramipexole 0.5 mg tablet|
45405615|NCT01085240|Other|Mission Possible|The intervention focuses on leisure education, exercise and community re-integration.
45405616|NCT01079078|Drug|Acetaminophen|
45514408|NCT02231606|Other|Free Glasses|Provide free glasses
45514409|NCT02231606|Other|Upgrade Glasses 1|Provide optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
45514410|NCT02231606|Other|Upgrade Glasses 2|Provide optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
45514411|NCT02083614|Procedure|to clamp or release the catheter for 2 days before removal|
45514412|NCT04629937|Other|SPECT acquisitions|All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.
45514413|NCT02231684|Drug|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).
45405617|NCT03965156|Procedure|1) Ultrasound guided Erector spinae block|In the lateral position, after skin sterilization, erector spinae plane block will be performed at the level of T9. Counting down from the spine of seventh cervical vertebrae, the spine of the nine thoracic vertebrae (T9). A linear low frequency ultrasound transducer (US) (3-5 MHz) will placed sagittal 3cm lateral to midline to visualize the muscles of the back, transverse process and simmering pleura in between transverse processes. A 22-gauge short bevel needle will be inserted in cranial-caudal direction towards transverse process (TP) in plane to the US transducer until needle touched the TP crossing all the muscles. The location of the needle tip will be confirmed by visible normal saline fluid separating erector spinae muscle off the bony shadow of the transverse process on ultrasound imaging. Then 20 ml of bupivacaine 0.375% plus plus 5ug/ml adrenaline (1:200000) will be injected. The procedure will be repeated following the same steps on the other side of the back.
45405618|NCT03965156|Procedure|Ultrasound guided transversus abdominis plane block|in supine position and after skin sterilization. The linear high frequency transducer (6-13 MHz) will be placed in the transverse plane to the the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest. The three abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) are visualized. The needle inserted in plane and advanced anterior to posterior under continual visualization until the tip between the internal oblique and the transversus abdominis muscle. After negative aspiration, a 20 ml of bupivacaine 0.375% plus 5ug/ml adrenaline (1:200000) will be injected. The success of the injection will be confirmed by separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in between. The procedure will be repeated following the same steps on the other side.
45699211|NCT04369638|Device|Traditional NAM|The patient will be seen for visit at the clinic for traditional intraoral impression and a dental stone model will be poured. An acrylic NAM will be fabricated on the stone model. The 3D printed model will be tested for fit on stone model made from traditional impression. Both traditional NAM and 3D printed NAM will be inserted at delivery appointment. Fit will be assessed of both appliances by applying a try-in paste to the intaglio surface and counting the number of spots needing adjustment.
45405619|NCT00121238|Drug|cilengitide|Given IV
45699212|NCT05320458|Other|Pulmonary Rehabilitation|1-Pulmonary Rehabilitation: Pulmonary rehabilitation program was applied at 40-60% of submaximal heart rate, 3 days a week for a total of 8 weeks. Diaphragmatic breathing, pursed lip breathing and segmental breathing exercises were practiced with the patients in the company of a physiotherapist. Walking and aerobic exercise training was given.
45699213|NCT05320224|Other|Patient-Oriented Music Intervention (POMI)|The brief name given to this intervention is POMI (Patient-Oriented Music Intervention). In POMI, music is delivered to adult patients either via headphones (Bose) or by music pillow (MusiCure). Adults admitted to the intensive care unit (ICU) will choose the mode of delivery. ICU adult patients who are unable to self-report will hear music via music pillow. Individualized playlists will be created based on the patient music preferences, as self-reported. For patients unable to self-report, a person significant to the patient such as a family member will be asked about the patient music preferences. Questions about preferences will include music genre, track, artist, instrumentalness, acousticness, energy, and valence, as defined by the streaming service Spotify. A POMI web-based tool (https://pomi.glitch.me) will use these preferences to create personalized playlists on Spotify, with a tempo restriction of 60-80 bpm. Music will play for at least 20 minutes, via smart device (iPad).
45699214|NCT03449160|Device|UPRIGHT|A small externally wearable device that is placed on the back, which gently vibrates when correct posture is not maintained. The device is removable, and used for only portions of the day
45699215|NCT03449160|Other|physical therapy|routine physical therapy
45699216|NCT03449082|Biological|High concentration of Allo-ASC|10 million cells of Allo-ASC 0.5cc
45699217|NCT03449082|Biological|Low concentration of Allo-ASC|1 million cells of Allo-ASC 0.5cc
45699218|NCT03449082|Drug|Fibrin glue|Fibrin glue 0.5cc
45699219|NCT03449082|Drug|Normal saline|Normal saline 0.5cc
45699220|NCT05308134|Other|Standard fortification|Standard fortification assumes that the nutrient content of human milk is constant and involves use of a standard fixed dose of multi-nutrient fortifier and as appropriate nutrient modulars.
45699221|NCT05308134|Other|Target fortification|Target fortification involves use of a multi-nutrient fortifier as well as weekly analysis of energy and macronutrients of human milk and subsequent addition of fat and protein modulars if needed.
45699222|NCT05308134|Other|BUN adjustable fortification|BUN (blood urea nitrogen) adjustable fortification involves use of a multi-nutrient fortifier as well as weekly BUN tests and subsequent addition of a protein modular according to a prescribed algorithm.
45405620|NCT00390455|Drug|Fulvestrant|Given IM
45405621|NCT00390455|Other|Laboratory Biomarker Analysis|Correlative studies
45405622|NCT00390455|Drug|Lapatinib Ditosylate|Given PO
45405623|NCT00390455|Other|Placebo Administration|Given PO
45514414|NCT02231684|Drug|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL) or intravenously (i.v.) (1mg/mL).
45514415|NCT02083692|Drug|Metformin|
45405624|NCT03812510|Drug|A-101|hydrogen peroxide topical solution 45%
45405625|NCT01583114|Drug|perindopril|form:1 tablet contained 5 mg of perindopril; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
45405626|NCT01583114|Drug|placebo|form:1 tablet contained 5 mg placebo; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
45405627|NCT01085474|Other|1|In the pilot study the objective is to compare 2 different pharmaceutical interventions (A and B) and to assess which one improves disease control, patient adherence and patient knowledge of the medication.
45405628|NCT01085474|Other|2|The best intervention used in the pilot study will be chosen and included in the main study.
45405629|NCT01079312|Device|infusion pump|anaesthesiologist´s managed infusion of propofol 10 mg/ml at rate of 10-60ml/h during ERCP targeting to moderate sedation level
45405630|NCT01079312|Device|infusion pump for patient-controlled sedation|self-administration of propofol and remifentanil mixture with zero lockout time and without dose limit and background infusion via Arcomed,Syramed AG,Switzerland self-administration pump.
45405631|NCT01079312|Drug|propofol|Propofol 10 mg/ml solution is a short-acting, intravenously administered hypnotic agent.In propofol infusion group moderate sedation was initiated with propofol 40 mg bolus,thereafter propofol infusion was started at rate of 0.5 mg/kg/h.If the performance of ERCP become difficult infusion rate was increased gradually ad maximum rate of 9 mg/kg/h.Additional propofol boluses of 20-40 mg were available in both groups due to an anaesthesiollogist´s ´desigion.In patient-controlled sedation group propofol was used for preparation of sedative mixture.
45405632|NCT01079312|Drug|fentanyl|Fentanyl citrate 50 mcg/ml,solution for injection,is a narcotic analgesic.In propofol infusion group 0.05 mg of fentanyl was administered intravenously before initiation of sedation. Additional 0.05 mg boluses of fentanyl were given if nociceptive stimulus was anticipated.
45405633|NCT01079312|Drug|sedative mixture|Sedative mixture was prepared by adding 5 ml of remifentanil hydrochlorid solution (50 mcg/ml)to 20 ml of propofol (10 mg/ml)
45405634|NCT01079312|Drug|remifentanil hydrochlorid|Solution of remifentanil hydrochlorid (50 mcg/ml) was used for preparation of sedative mixture(see sedative mixture for details)
45405635|NCT00390299|Biological|Carcinoembryonic Antigen-Expressing Measles Virus|Given via injection into resection cavity or around tumor bed and/or IT
45405636|NCT00390299|Other|Laboratory Biomarker Analysis|Correlative studies
45405637|NCT00390299|Procedure|Therapeutic Conventional Surgery|Undergo en bloc resection
45405638|NCT01044485|Drug|lapatinib|escalation dose from 1250 to 1500 mg in association with docetaxel
45405639|NCT01044485|Drug|docetaxel|escalation dose from 75 mg/m2 to 100 mg/m2 in association with lapatinib
45514416|NCT04573699|Device|CNT-HF|A modified CNT, will be delivered as a pacing sequence able to acutely influence sympathetic tone.
45514417|NCT02227550|Drug|Vitamin K antagonist|any locally used VKA, INR 2-3, min. 30 days according to aplicable medical guidelines and local clinical routin
45699223|NCT03449004|Other|Validation of the OPSI questionnaire|A questionnaire to measure satisfaction with online information for patients with low back pain
45405640|NCT00119678|Drug|Abatacept|Injectable, intravenous, 10 mg/kg, abatacept every 28 days, 12 months
45405641|NCT00119678|Drug|Placebo|Injectable, intravenous, 0 mg, every 28 days, 12 months
45405642|NCT00119678|Drug|Prednisone|Tablets, oral, 30 mg, daily for 28 days then taper off, 12 months
45405643|NCT00119678|Drug|Abatacept|Injectable, intravenous, 10 mg/kg, every 28 days
45405644|NCT00110084|Drug|Gemcitabine|1000 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
45405645|NCT00110084|Drug|Paclitaxel protein-bound particles for injectable suspension (albumin-bound)|125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
45405646|NCT00390221|Biological|BIIB019 (Daclizumab High Yield Process)|SC injection
45514418|NCT02227550|Drug|Apixaban|factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose) dose reduction Apixaban 2,5 mg twice daily in patients who fulfill tow of the following criteria at the time of randomisation: chronic kidney disease (serum creatine >= 1.5 mg/dl (133mM), <= 60 kg body weight or age >= 80 years.
45405647|NCT00390221|Drug|Placebo|Placebo SC injection
45514419|NCT02206035|Drug|Tacrolimus|Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant.
45699224|NCT03129672|Procedure|allograft arthrodesis of ankle|patients that underwent trought a block resection of a malignant tumor of the distal tibia and reconstruction with allograft arthrodesis
45405648|NCT00389831|Drug|Rotigotine Nasal Spray|Daily single dose of 62µg, 124µg, and 247µg rotigotine delivered as single puff of nasal spray solution
45514420|NCT02206035|Drug|Methotrexate|Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m^2 Days +3, +6 and +11.
45699225|NCT03130062|Other|Exercise|The following muscular clusters were exerted: latissimus dorsi, deltoid, pectoralis major , triceps brachialis, biceps brachialis, quadriceps, hamstring, thigh adductor muscles, thigh abductor muscles and gastrocnemius.
45405649|NCT00389831|Other|Placebo Nasal Spray|Daily single dose of placebo delivered as single puff of nasal spray solution
45405650|NCT00389597|Device|Cervical Artificial Disc|Cervical artificial disc mechanical device
45405651|NCT00389519|Drug|ramipril|once a day oral ramipril capsules given for 4 weeks
45405652|NCT00389519|Drug|placebo|once a day oral placebo capsule for 4 weeks
45405653|NCT00389441|Drug|AG-013736|AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity
45405654|NCT00118898|Drug|Abacavir/Lamivudine|600 mg abacavir/300 mg lamivudine tablet taken orally daily
45405655|NCT00118898|Drug|Atazanavir|300 mg tablet taken orally daily
45405656|NCT00118898|Drug|Efavirenz|600 mg tablet taken orally daily
45405657|NCT00118898|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate tablet taken orally daily
45405658|NCT00118898|Drug|Ritonavir|100 mg tablet taken orally daily
45405659|NCT00118898|Drug|Abacavir/Lamivudine placebo|Placebo tablet taken orally daily
45405660|NCT00118898|Drug|Emtricitabine/Tenofovir disoproxil fumarate placebo|Placebo tablet taken orally daily
45405661|NCT00118430|Behavioral|Stepped Care|Stepped care will consist of 12 weeks of antidepressant therapy, followed by a pain self-management program (PSMP) in those who fail to achieve both a good pain and global clinical response to antidepressant therapy. Treatment will be delivered by a nurse depression-pain clinical specialist (DPCS) who will be trained in providing both components of the stepped care treatment. The DPCS will meet weekly to review cases with a physician-investigator who will also be available to discuss any management issues that arise between the weekly case meetings. All participants will have six clinical contacts with the DPCS during the acute treatment phase and two clinical contacts during the continuation phase to assess medication adherence, adverse effects, and depression response.
45405662|NCT00118430|Drug|Antidepressants|Participants will be assigned to one of the following antidepressant regimens: venlafaxine (37.5 mg, increased to 75, 150, 225 mg); duloxetine (60 mg, increased to 120 mg); fluoxetine (20 mg, increased to 30 to 40 mg); sertraline (50 mg, increased to 100 to 150 mg); citalopram (20 mg, increased to 30 to 40 mg); paroxetine (20 mg, increased to 30 to 40 mg); or nortriptyline (25 mg, increased to 50 to 75 mg).
45405663|NCT00118430|Drug|Usual Care|This group will receive care as usual from their providers and completes the same outcome assessments as the stepped care group.
45405664|NCT01085552|Drug|Epoetin Beta|Epoetin Beta. A single subcutaneous dose of 50IU/kg on Day 1. The body weight recording on day -1 will be used to calculate the dosage
45699226|NCT03449238|Drug|Pembrolizumab|pembrolizumab will be infused the day before SRS, at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
45699227|NCT03413202|Drug|butylphthalide(NBP)|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 25mg butylphthalide(NBP) injection, and 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, butylphthalide(NBP) capsule for 76 days.
45851446|NCT01275924|Device|Syndesmotic screw|Quadricortical syndesmotic screw
45851447|NCT01276080|Drug|Donepezil|10 mg tablets
45851448|NCT01276158|Procedure|Ultrasound|Ultrasound used to place arterial line
45405665|NCT03962426|Device|SocialVille Social Cognitive Training|"SocialVille exercises in this study include 4 exercises:~Recognition: a speeded face matching task~Face to Face: a speeded facial emotion matching task~Gaze Match: a speeded gaze matching task~Face Poke: a continuous performance task with facial expressions"
45405666|NCT01085708|Drug|rabeprazole|10 mg normal tablet
45405667|NCT01085708|Drug|rabeprazole|Type 1 granule containing rabeprazole 10 mg
45851449|NCT01276158|Procedure|Doppler|Doppler used to place arterial line
45405668|NCT01085708|Drug|rabeprazole|Type 2 granules containing rabeprazole 10 mg
45405669|NCT01085708|Drug|rabeprazole|Type 3 granules containing rabeprazole 10 mg
45405670|NCT01081106|Procedure|Low-Level Laser Therapy|"A LLLT device at 670 nm will be used for light application using lasers affixed in a rotating helmet apparatus. Treatment will be given twice weekly prior to commencing chemotherapy and will be administered once a week until one week after the last chemotherapy.~administration."
45405671|NCT00090584|Drug|Tolterodine|4mg/d for 10 weeks. Could be reduced to 2mg/d for managing side effects.
45405672|NCT00090584|Behavioral|Behavioral training|Training in pelvic floor muscle control and exercises; behavioral strategies to diminish urgency, suppress bladder contractions and prevent incontinence; delayed voiding; and individualized fluid management.
45405673|NCT01326884|Device|ZLP|ZLP Graft
45405674|NCT03965000|Other|Mixed-meal-tolerance-test|To assess the dynamics of the glucagon-incretin axis we need to perform the MMTT. Thereby the patients need to consume a body weight adjusted, standardized meal and we draw blood at fixed time points over 4 hours.
45405675|NCT01081184|Biological|blood sample|blood sample for determination of seric and lymphocytic NT profile will be added to a standard biological analysis done for pSS follow- up
45405676|NCT03964922|Biological|blood sample|20 ml at inclusion, and 20ml at 1, 3, 6 and 12 months after allo HSCT
45405677|NCT03964922|Biological|bone marrow sample|3 ml at inclusion, and 3 ml at 1, 3, 6 and 12 months after allo HSCT
45405678|NCT01079624|Other|Glucose-insulinotropic peptide, Glucagon-like peptide-1|GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min
45514421|NCT02206035|Drug|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1.
45851450|NCT01276548|Drug|Genexol®-PM 260mg/m2 plus Carboplatin 5 AUC|
45851451|NCT01276548|Drug|Genexol® 175mg/m2 plus Carboplatin 5 AUC|
45514422|NCT02227628|Dietary Supplement|Acai polyphenolics|Acai beverage was obtained from the Sambazon (San Clemente, CA).
45514423|NCT02227628|Dietary Supplement|Sugary Beverage|An equal amount of placebo juice comprised of artificially colored water containing sugar (5%), citric acid (0.01% to adjust the pH 3.8), and artificial colors (FD&C Red 40 and Blue 1, Tetra Pak, Denten, TX) that was identical to the acai beverage.
45699228|NCT03413202|Drug|placebo|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, starch capsule for 76 days.
45699229|NCT02521818|Other|Modified Atkins Diet|
45699230|NCT02521818|Other|NIA Diet for Seniors|
45699231|NCT04169100|Drug|Prednisone|We propose to test whether QT prolongation is reversible with moderate doses of prednisone in patients with QT interval greater than 500 msec.
45405679|NCT01086020|Drug|atorvastatin|Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 10mg/d for two years
45405680|NCT01086020|Drug|atorvastatin plus ezetimibe|Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d for two years
45405681|NCT03670810|Drug|Lasmiditan|Administered orally.
45699232|NCT03698448|Drug|OligoG Dry powder for inhalation|10 capsules Dry Powder for Inhalation, BID
45699233|NCT04155996|Device|data collection|Patients will receive a full data acquisition set with CGM sensors, an activity tracker and a smartphone application in which they can log daily events.
45405682|NCT03670810|Drug|Placebo|Administered orally.
45405683|NCT03962192|Other|Attitudinal measures|A collection of 3 distinct attitudinal instruments comprise this survey.
45405684|NCT01086176|Device|NMT (a device that can do neurostimulation and can record the response on the stimulation by Datex)|on one side, we do a post-tetanic count, on the other side we don't, after, we do train-of-four on both sides and check the difference
45405685|NCT01086254|Drug|Iniparib|"Pharmaceutical form: solution for infusion~Route of administration: 60-minute IV infusion"
45405686|NCT01086254|Drug|gemcitabine|"Pharmaceutical form: solution for infusion~Route of administration: 30-minute IV infusion"
45405687|NCT01086254|Drug|cisplatin|"Pharmaceutical form: solution for infusion~Route of administration: 1- to 4-hour IV infusion, according to the local standard"
45405688|NCT01081340|Behavioral|Social network building intervention|Group support and health education sessions weekly during third trimester and once every two weeks until 6 months postpartum
45405689|NCT01081340|Behavioral|Home visit|Three home visits during third trimester and three during postpartum period until 6 months postpartum
45405690|NCT01086332|Drug|Nelfinavir|1250 mg twice daily
45405691|NCT01086332|Drug|Gemcitabine|Escalating doses of gemcitabine during concurrent radiation and nelfinavir therapy.
45514424|NCT02082990|Behavioral|Face-to-Face Brief Intervention|One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
45514425|NCT02082990|Behavioral|Online Brief Intervention|Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
45514426|NCT02079324|Biological|GX-051|intratumoral injection
45699234|NCT05239806|Biological|SCTV01C|Day 0; intramuscular injection
45699235|NCT05239806|Biological|SCTV01E|Day 0; intramuscular injection
45699236|NCT05239806|Biological|Sinopharm inactivated COVID-19 vaccine|Day 0; intramuscular injection
45699237|NCT05239806|Biological|Comirnaty|Day 0; intramuscular injection
45405692|NCT03962270|Device|shock wave device|The experimental group (group ESWT) guided by ultrasound: conventional rehabilitation training is given priority to with strength training, application of pain when necessary, under the guidance of ultrasound ESWT treatment control group (routine rehabilitation group) : conventional rehabilitation training is given priority to with strength training, oral pain when necessary, under the guidance of ultrasound ESWT treatment (shock energy flow density of 0)
45405693|NCT01811368|Biological|rituximab|Given IV
45405694|NCT01811368|Biological|ibritumomab tiuxetan|Given IV
45405695|NCT01811368|Biological|anti-thymocyte globulin|Given IV
45405696|NCT01811368|Radiation|total nodal irradiation|Undergo TLI
45405697|NCT01811368|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
45405698|NCT01811368|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
45514427|NCT02258828|Drug|Memantine|Subjects initially received memantine 5 mg once daily, which was increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day
45405699|NCT01811368|Drug|cyclosporine|Given PO or IV
45405700|NCT01811368|Drug|mycophenolate mofetil|Given PO or IV
45405701|NCT00089648|Drug|Sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment for approximately 1 year or until disease progression/unacceptable toxicity; after completion of 1 year, pts with clinical benefit can continue the study treatment in a separate continuation protocol
45514428|NCT02258828|Drug|Placebo|Matched placebo
45514429|NCT02746471|Device|Reveal LINQ|
45514430|NCT02083068|Biological|Vaccine PvCS N+C+R|Vaccine PvCS N+C+R 60 mcg, freeze dried powder, Batch n°P0RGB, Exp: 18.10.2015 At month 2 and 6
45514431|NCT02083068|Biological|Vaccine PvCS N+C|Vaccine PvCS N+C 60 mcg, freeze dried powder, Batch n°P0RGA, Exp: 18.10.2015, at month 0
45514432|NCT02083068|Biological|SSN Montanide ISA-51|SSN Montanide ISA-51 1 mL
45514433|NCT02228018|Device|CT-scan|CT-Scan will be taken at visit 1 on FRC and TLC breathing levels
45514434|NCT02133183|Other|Laboratory Biomarker Analysis|Correlative studies
45514435|NCT02133183|Other|Pharmacological Study|Correlative studies
45699238|NCT05239806|Biological|SCTV01E|Day 180; intramuscular injection
45699239|NCT01155778|Biological|Recombinant human heparan N-sulfatase (rhHNS)|
45699240|NCT04155840|Drug|Copanlisib|Given IV
45699241|NCT04155840|Biological|Rituximab|Given IV
45699242|NCT04155840|Drug|Bendamustine|Given IV
45405702|NCT01086488|Drug|FOSCAN|Patients will be randomised to one of two treatment groups. The first group of 26 patients will receive 0.1 mg/kg Foscan® at a drug-light interval of 48 hours (2 days). A single surface illumination light dose of 20 J/cm2 fluence rate of 50 mW at 652 nm will be used. The second reference group of 26 patients will be treated by intracavitary brachytherapy
45405703|NCT01079702|Drug|Everolimus|Everolimus, administrated twice daily at a fixed total dose of 10 mg continuously.
45405704|NCT01079702|Drug|Capecitabine|Capecitabine administered bid for 14 days followed by 7 days rest. In this study, capecitabine will be dose escalated. The first dose level of capecitabine is 500 mg/m2 twice daily.
45405705|NCT00118040|Drug|Genistein|Given orally
45405706|NCT00118040|Other|Laboratory Biomarker Analysis|Correlative studies
45405707|NCT00118040|Other|Pharmacological Study|Correlative studies
45405708|NCT00118040|Other|Placebo Administration|Given orally
45405709|NCT00118040|Procedure|Therapeutic Conventional Surgery|Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
45514436|NCT02133183|Drug|Sapanisertib|Given PO
45405710|NCT03961958|Drug|Propofol reduction|Reduction of propofol target concentration
45405711|NCT01081418|Behavioral|Assertive Community Treatment (ACT)|ACT was structured and implemented according to guidelines of the Assertive Community Treatment Association (ACTA). Team members were highly educated psychosis experts consisting of a consultant psychiatrist, a psychiatrist, two psychologists, and a nurse, all of which received training in cognitive behavioral (CBT), dynamic, and/or family psychotherapy. Study participants could use all treatment options within the integrated care program such as psychoeducation groups, social skills training, family groups, motivational addiction therapy, meta-cognitive training etc.
45405712|NCT00389207|Drug|nevirapine bid|nevirapine twice daily
45405713|NCT00389207|Drug|nevirapine qd|nevirapine once daily
45405714|NCT00389207|Drug|atazanavir|atazanavir once daily
45405715|NCT00388973|Drug|Quetiapine|
45405716|NCT01018745|Drug|BMS-907351 (XL184)|Capsules, Oral, 25, 50, 75, 100, 125 and 175 mg, Once daily, Until disease progression or unacceptable toxicity became apparent
45405717|NCT00085202|Biological|filgrastim|Given subcutaneously
45405718|NCT00085202|Drug|cisplatin|Given IV
45405719|NCT00085202|Drug|cyclophosphamide|Given IV
45405720|NCT00085202|Drug|vincristine|Given IV
45699243|NCT03448848|Drug|BCAA preparation Intravenous infusion|BCAA IVi in a dose 0.5-1 gm/Kg/day for 2-5 days post liver surgery versus sterile normal saline in a volume equal to the study drug
45405721|NCT00085202|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
45851452|NCT01276626|Dietary Supplement|Bifidobacterium longum|Powder containing Bifidobacterium longum in maltodextrin.
45405722|NCT00085202|Radiation|radiation therapy|Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks.
45405723|NCT00388583|Biological|Split, Inactivated, Trivalent Influenza Vaccine|0.1 mL, Intradermal
45405724|NCT00388583|Biological|Split, Inactivated, Trivalent Influenza Vaccine|0.5 mL, Intramuscular
45514437|NCT02133183|Procedure|Therapeutic Conventional Surgery|Undergo surgery
45514438|NCT02228252|Other|Whey protein|
45514439|NCT02228252|Other|Casein|
45514440|NCT02228252|Other|Gluten protein|
45514441|NCT04525573|Device|LLLT Combination Red/Gold/IR Therapy|Three LLLT combination treatments per week over the course of two consecutive weeks, and a final follow up on day-15 (total of 7 treatments).
45405725|NCT00117572|Drug|docetaxel|75 mg/m2 on day 1 (induction phase); 25 mg/m2 on day 1 (chemoradiotherapy phase)
45405726|NCT00117572|Drug|cisplatin|75 mg/m2 on day 1
45405727|NCT00117572|Drug|hydroxyurea|Each cycle: 500 mg PO q 12 hours x 6 days (11 doses)
45405728|NCT00117572|Drug|fluorouracil|750 mg/m2/day on days 1-5 (induction phase); 600 mg/m2/day, day 0-4 (chemoradiotherapy phase)
45405729|NCT00117572|Procedure|chemotherapy|See protocol for details
45405730|NCT00117572|Procedure|radiotherapy|See protocol for details
45405731|NCT00388505|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder (TIP) capsules for inhalation.
45514442|NCT02083770|Behavioral|Cancer Clinical Trials Education Program|Hispanic Americans are underrepresented in cancer clinical trials. The purpose of this study is to develop and test programs designed to reduce barriers and increase facilitators associated with cancer clinical trials participation for Hispanic Americans.
45514443|NCT02228330|Procedure|obturator nerve block|a uni-lateral obturator nerve block will be performed under ultrasound guidance- using 2% lidocaine for obtaining a short term block.
45514444|NCT04524715|Device|Non-invasive red LLLT treatment to chest of patient.|Expose patient to LLLT light while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.
45699244|NCT03448848|Drug|sterile normal saline|sterile normal saline in a volume equal to the study drug
45851453|NCT01276626|Other|Maltodextrin|Powder containing only maltodextrin
45405732|NCT00388505|Drug|Tobramycin Solution for Inhalation|Tobramycin solution for inhalation (TOBI), supplied as 300 mg/5mL ampoules administered with a nebulizer
45405733|NCT00388349|Drug|Gemcitabine|
45405734|NCT00388349|Drug|Vinorelbine|
45405735|NCT00388349|Drug|Carmustine|
45405736|NCT00388349|Drug|Etoposide|
45405737|NCT00388349|Drug|Cyclophosphamide|
45405738|NCT00388349|Procedure|Autologous HCT|
45405739|NCT00117338|Drug|montelukast sodium|Montelukast IV 5.25 mg lyophilized (reconstituted in 20 mL of 3.3% dextrose/0.3% sodium chloride) for a study approximately 120 minutes in duration
45405740|NCT00117338|Drug|Comparator: placebo (unspecified)|Pbo for a study approximately 120 minutes in duration
45405741|NCT00388037|Drug|sunitinib malate|Given PO
45405742|NCT00388037|Other|laboratory biomarker analysis|Correlative studies
45405743|NCT00387881|Drug|sumatriptan succinate / naproxen sodium|sumatriptan 85mg / naproxen sodium 500mg
45405744|NCT00387881|Drug|Placebo|Placebo to match Treximet tablets
45851454|NCT01276704|Drug|Placebo|The placebo contains same filler materials as commercially available Brevail® but without active SDG.
45405745|NCT00084656|Biological|ipilimumab|IV over 90 mins on day 1, wks 1,9,17,25,33,41,53 Dose: 3 mg/kg (Part I), 10 mg/kg (Part II)
45405746|NCT00084656|Biological|Tyrosinase/gp100/MART-1 Peptides|(All subjects in Part I and HLA-A*0201 positive subjects only in Part II): SC, day 1 of wks 1,3,5,7,9,11,17, 21,25,33,41,53 Dose: 1 mg peptide emulsified in 1 mL Montanide ISA 51 VG.)
45405747|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
45405748|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
45405749|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
45405750|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
45405751|NCT01086566|Biological|Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005|Inactivated monovalent subvirion H5N1 vaccine (HA of A/Indonesia/05/05) provided in unit-dose vials containing 0.5 mL of either 30 mcg/mL A/H5N1 HA or 180 mcg/mL A/H5N1 HA. Subjects will receive 1 of 2 dose levels of vaccine, 15 or 90 mcg.
45405752|NCT01045811|Behavioral|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
45405753|NCT01045811|Behavioral|Stress management|Cognitive reconstructive strategies for stress management
45405754|NCT00102596|Drug|1-Octanol|1-Octanol is an long-chain alcohol with potential therapeutic benefits in treating alcohol-responsive tremors based on unknown mechanisms. The intervention consisted of either 1) 1-octanol adsorbed to microcrystalline cellulose, NF (Avicel PH 102, FMC Corp., Philadelphia, PA), and fine particle silica (Sipernat 50S, Evonik Degussa Corp., Parsippany, NJ) and encapsulated in 50 mg and 250 mg dosages; or 2) a soft-gel capsule containing 1-octanol embedded in soybean oil at 50 mg and 800 mg dosages (Best Formulations Inc, City of Industry, CA).
45405755|NCT00387647|Drug|Azacitidine|Azacitidine given subcutaneously as outlined in treatment arm.
45405756|NCT01086722|Drug|"karolinska cocktail"|"The karolinska cocktail contains dextrometorphan, caffeine, losartan and omeprazol"
45405757|NCT01086800|Other|Healthy Lifestyles and Sleep Education plus PAP|Participants randomized to this arm will be educated on PAP and then use PAP for 3 months. They will also receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
45405758|NCT01086800|Other|Healthy Lifestyles and Sleep Education plus Supplemental Oxygen|Participants randomized to this arm will be educated on nocturnal supplemental oxygen and then use oxygen for 3 months. They also will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
45405759|NCT01086800|Other|Healthy Lifestyles and Sleep Education|Participants randomized to this arm will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
45405760|NCT00386009|Drug|Tadalafil|20 mg tadalafil tablet taken by mouth once a day for 12 weeks.
45405761|NCT00386009|Drug|Placebo|Placebo tablet taken by mouth once a day for 12 weeks.
45405762|NCT01045889|Other|Rituximab and CHOP regimen + PBSCT|
45405763|NCT00373685|Drug|Celecoxib|open-label
45405764|NCT00373685|Drug|Any commercially available NSAID with the indication for osteoarthritis|dosing as per USPI label related to the chosen commercially marketed NSAID
45405765|NCT00373529|Drug|clofarabine|"Induction cycle 1: cycle 1 of clofarabine 30 mg/m^2/day as a 1-hour intravenous infusion for 5 consecutive days.~Reinduction (cycle 2) and/or Consolidation cycles (cycles 2-6): cycles repeated minimally every 28 days, of clofarabine 20 mg/m^2/day as a 1-hour intravenous infusion for 5 consecutive days."
45405766|NCT00373295|Drug|Baclofen|Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
45405767|NCT00373295|Drug|Marijuana|Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.
45405768|NCT00373295|Drug|Placebo|
45405769|NCT03395795|Device|NAVA|"The study has 3 phases:~Phase 1:~The patient is connected to the SERVOi® ventilator in classic VNI mode, which is parameterized according to the patient's needs and then maintained for 30min for measurements.~Phase 2:~Switch to NAVA mode (1h).~Definition of NAVA parameters: The positive expiratory pressure will not be modified. The NAVA level (the proportionality factor that converts the EADi (microV) to the pressure level in cmH2O was first adjusted according to the actual assisted pressure in the patient in the normal VNI mode.~NAVA period: The ventilatory pressure, as well as the EADI is recorded continuously for 30min after a NAVA adaptation period of about 30min.~Phase 3:~The patient returns to classic VNI mode with Phase 1 ventilatory settings for a 30 minute recording."
45405770|NCT01044563|Behavioral|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
45405771|NCT01044563|Behavioral|Stress management|Cognitive reconstructive strategies for stress management
45405772|NCT00385541|Drug|Morphine PCA|Morphine 1mg/mL, dose 1mL, lockout 6 minutes, max 10mL
45405773|NCT00385541|Drug|Hydromorphone PCA|hydromorphone PCA 0.2mg/lml, dose 1ml, lockout 6min, max 10ml
45405774|NCT01046045|Drug|everolimus|everolimus at an initial daily loading dose between 1 and 4 mg dose of everolimus will be adjusted to maintain a trough everolimus level between 5 and 12 ng/mL
45405775|NCT01046123|Radiation|whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy|Patients will be treated with WBRT/SIB using VMAT, delivering a total of 20 Gy in 5 fractions to the whole brain and 50Gy in 5 fractions to the brain metastases, delivered once daily on working days.
45405776|NCT01044719|Drug|Ceftazidime|Ceftazidime 2g TDS IV
45405777|NCT01044719|Drug|Tobramycin|Tobramycin 7mg/kg/day OD IV
45405778|NCT01044719|Drug|Meropenem|Meropenem 2g TDS IV
45405779|NCT01044875|Procedure|Pan retinal photocoagulation laser treatment|Eyes with PDR are randomised to treatment with either the green laser 532 nm or 577 nm yellow laser.
45405780|NCT01044953|Other|shortened winter break|winter break shortened by 3 weeks (from 6.5 to 3.5) within the German Professional Soccer League in season 2009/2010
45851455|NCT01276704|Drug|secoisolariciresinol|1 capsule daily of secoisolariciresinol diglycoside (SDG)50mg
45405781|NCT01045109|Dietary Supplement|cholecalciferol|4,000 I.U. softgel daily orally for 48 weeks
45405782|NCT01045109|Dietary Supplement|cholecalciferol|cholecalciferol or vitamin D3 4,000 IU daily for 48 weeks
45405783|NCT01045343|Other|Integrated diagnositic system|Heart failure will be managed using the integrated diagnostic system which consists of patient tools and a new Heart Failure Clinician's website which displays a new Heart Failure Risk score. This Heart Failure Clinician's website will be reviewed every 2 weeks in addition to scheduled in-office visits every three months.
45405784|NCT01045343|Other|Routine in office visits|Heart failure will be managed with scheduled in-office visits every three months.
45405785|NCT00094302|Drug|Spironolactone|Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
45405786|NCT00094302|Drug|Placebo|Placebo of spironolactone
45405787|NCT00372905|Drug|rituximab|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
45405788|NCT00372905|Drug|bortezomib|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
45405789|NCT00372905|Drug|Ibritumomab tiuxetan|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
45405790|NCT00384839|Drug|azacitidine for injectable suspension|Vidaza: 75 mg/m2 for 5 consecutive days (Days 1-5) of each 28 day cycle. A cycle will equal to 28 days. Patient will receive a maximum of 12 cycles.
45405791|NCT01046279|Drug|Bevacizumab|Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV) assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons
45514445|NCT04524715|Device|Sham Device Treatment|Expose patient to sham device while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.
45514446|NCT02083848|Other|7T MRI|Ultra high field magnetic resonance imaging
45514447|NCT04933370|Other|Stimulation parameters|Different device stimulation parameters
45514448|NCT02070549|Drug|Trametinib|Given PO
45514449|NCT02223728|Behavioral|Lifestyle|
45514450|NCT02223728|Behavioral|Health Education|
45514451|NCT02079402|Drug|Isotonic crystalloids|
45699245|NCT05086770|Device|Gelatin microsphere (Nexsphere™)|Gelatin microsphere (Nexsphere™) is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications for gelatin microsphere are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.
45851456|NCT01276782|Drug|Levothyroxine|It is FDA approved drug for thyroid disease
45405792|NCT01084590|Behavioral|Healthy Eating/Physical Activity|This intervention arm will include brief pediatrician counseling regarding the child's current BMI percentile status, recommendations for home environmental changes to achieve a healthy weight gain trajectory, and home safety and injury risk reduction environmental recommendations paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the obesity prevention home environmental strategies.
45699246|NCT05086770|Device|Embosphere|Tris-acryl gelatin microspheres (Embosphere Microspheres) are biocompatible and nonresorbable with cell adhesion properties for complete and durable mechanical occlusion.
45405793|NCT01084590|Behavioral|Safety/Injury Prevention|This intervention arm will include the same brief counseling from the pediatrician paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
45405794|NCT00384293|Drug|Comparator: niacin (+) laropiprant (MK0524A)|niacin (+) laropiprant (2 g) po qd.
45405795|NCT00384293|Drug|Comparator: placebo|niacin (+) laropiprant (2 g) placebo po qd.
45405796|NCT01087866|Drug|Metformin|
45405797|NCT01087866|Drug|Insulin|
45405798|NCT01046357|Drug|AZD7687|Single oral dose
45405799|NCT01046357|Drug|Placebo|Single oral dose
45405800|NCT01084746|Behavioral|PC-based tailored intervention|Patients will receive a tailored interactive PC-based intervention at a freestanding kiosk.
45514452|NCT02591953|Procedure|Ultrasound-guidance|Using ultrasound-guidance to perform a corticosteroid injection
45514453|NCT02591953|Procedure|Landmark-guidance|Using landmark-guidance to perform a corticosteroid injection
45514454|NCT02591953|Drug|Methylprednisolone|Corticosteroid used in injection (40 mg)
45514455|NCT02591953|Drug|Lidocaine 1%|Anesthesic used in injection
45699247|NCT03448770|Drug|PEG- 17 gm sachet|PEG- 17 gm sachet 3-4 times per day
45851457|NCT01276938|Radiation|21 Gy radiation|21 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
45851458|NCT01276938|Radiation|18 Gy radiation|18 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
45851459|NCT01277094|Drug|Placebo|Oral daily doses for 12 weeks
45851460|NCT01277094|Drug|RO5093151|Oral daily doses for 12 weeks
45699248|NCT03448770|Drug|Lactulose : 20-30gm|Lactulose : 20-30gm
45699249|NCT03443778|Drug|Bupivacaine 0.5%|Marcaine 0.5% Injectable Solution
45699250|NCT03443778|Drug|Bupivacaine 0.5% , Dexamethasone|Bupivacaine 0.5% , Dexamethasone
45699251|NCT03443778|Drug|Nacl 0,9 %|Injectable Solution
45851461|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
45851462|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
45514456|NCT01938495|Device|NeuRx® Diaphragm Pacing System™ (DPS)|The NeuRx® Diaphragm Pacing System™ (DPS) is a four channel, implanted percutaneous diaphragm muscle stimulation system. Pictures of the device are provided in the Clinician's Manual for the NeuRx® DPS procedure and technique guide from the manufacture Synapse Biomedical, Inc. Under general anesthesia, the intramuscular electrodes are laparoscopically implanted in the diaphragm. The ends of the implanted electrodes are tunneled subcutaneously to an exit site on the chest or abdominal wall and connected to an external stimulator.
45514457|NCT02223806|Behavioral|Uterine Tonus Assessment by Midwife|Uterine tonus assessment every 15 minutes for 2 hours.
45405801|NCT01084746|Behavioral|Printed educational materials|Patients will receive generic printed educational materials about CRCS in the PEC when they arrive at the Main Campus for their appointment.
45405802|NCT01090830|Drug|Belinostat, carboplatin, paclitaxel and bevacizumab|"Induction therapy will include 6 cycles of 5-days of medication administration followed by a 16 day rest period. Belinostat will be given once a day for 5 days total. Three dose levels will be evaluated (600mg/kg, 800 mg/kg, and 1000 mg/kg). In addition, participants will receive fixed doses of intravenous carboplatin (AUC 6), Paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg) once on day 3 of each cycle. Serial disease status evaluations will be done throughout the study.~In the absence of significant toxicity or disease progression, participants may continue with a maintenance regimen of bevacizumab and Belinostat for an additional 6 cycles. The dose of Belinostat received during maintenance will be that tolerated in the initial 6 cycles."
45405803|NCT01084824|Drug|Liquid nitrogen and cantharidin|Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterward.
45405804|NCT01084824|Drug|Liquid nitrogen and topical placebo|Liquid nitrogen applied to wart(s), then placebo vehicle applied thereafter.
45405805|NCT01088022|Drug|Aprepitant, Palonosetron, Dexamethasone|Aprepitant 125-mg capsule 80-mg capsule 80-mg capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
45514458|NCT02223806|Behavioral|Patient self-assessment of uterine tonus|Uterine tonus assessment by patient every 15 minutes for 2 hours.
45514459|NCT02084004|Drug|Bifidobacterium viable pharmaceutics|
45851463|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
45405806|NCT01088022|Drug|Placebo, Palonosetron, Dexamethasone|Aprepitant 125-mg placebo capsule 80-mg placebo capsule 80-mg placebo capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
45405807|NCT00067002|Procedure|Expanded allogeneic cord blood (CB)|Transplantation of Two Unmanipulated Cord Blood Units.
45405808|NCT00067002|Procedure|One Unmanipulated and One Expanded Cord Blood Unit|Transplantation of One Unmanipulated and One Expanded Cord Blood Unit.
45405809|NCT00067002|Drug|Rituxan|375 mg/m2 by vein on Day - 9 for patients with CD20 + malignancies.
45405810|NCT00067002|Drug|Melphalan|140 mg/m2 by vein on Day -8.
45514460|NCT02084004|Drug|Berberine Hydrochloride|
45514461|NCT02223884|Drug|docetaxel 35mg/m2|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
45514462|NCT02223884|Drug|Carboplatin AUC3|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
45514463|NCT04446559|Procedure|Sitting in chair position|For patients randomized in the chair group, we will perform the transfer to the chair immediately after the morning arterial blood gas. The chair position will be maintained for 3 hours, if the patient shows no clinical signs of discomfort or intolerance.
45514464|NCT02079480|Drug|BMS-986090|
45514465|NCT02079480|Drug|Placebo matching with BMS-986090|
45514466|NCT02079480|Drug|Keyhole limpet hemocyanin|
45514467|NCT02569489|Drug|HBI-8000|
45514468|NCT02569489|Drug|Trastuzumab|
45514469|NCT02569489|Drug|Paclitaxel|
45851464|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 14 days for 6 cycles
45851465|NCT01277406|Drug|4SC-201(Resminostat)|oral administration
45851466|NCT01277406|Drug|FOLFIRI|i.v. administration
45851467|NCT01277640|Drug|dapivirine|"dosage form: gel 0.05%~dosage: 2.5g~frequency: once daily~duration: 7 days"
45405811|NCT00067002|Drug|Thiotepa|5 mg/Kg by vein on Day -7.
45405812|NCT00067002|Drug|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
45405813|NCT00067002|Drug|Cyclophosphamide|50 mg/kg by vein on Day -6.
45405814|NCT00067002|Drug|Mesna|10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg).
45405815|NCT00067002|Radiation|Total body irradiation (TBI)|Total body irradiation (TBI) given on Day -1 at 2 Gy.
45405816|NCT03961698|Drug|IPI-549 (eganelisib)|IPI-549 is an oral, selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma). It is an orally-administered capsule that will be dosed at either 20mg/day, 30mg/day, or 40mg/day to patients in both cohorts A and B depending on the results of the safety run-in phase for each cohort.
45405817|NCT03961698|Drug|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). 840 mg of the drug will be administered intravenously (IV) on days 1 and 15 in combination of each 28-day cycle for patients with TNBC. 1200mg will be administered IV on day 1 of each 21-day cycle to patients with RCC.
45405818|NCT03961698|Drug|nab-paclitaxel|Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel (Taxol), a mitotic inhibitor chemotherapy, with less toxicity than solvent-based (sb) paclitaxel and achieves a 33% higher tumor uptake in preclinical models. Nab-paclitaxel will be administered intravenously (IV) at 100 mg/m2 on days 1, 8 and 15 of each 28-day cycle for patients with TNBC.
45514470|NCT02079558|Drug|Carbetocin|Carbetocin with single 100 microg IV dosage was used in this investigation
45514471|NCT02079558|Drug|Oxytocin|Oxytocin with 30 international units (IU) IV infusion was used in this investigation
45514472|NCT03629821|Other|Ballet|The classic ballet classes will respect biological limits of children. The sessions will be 75 minutes long, twice a week during 8 weeks. The class sequence will be: warm-up, follow by exercises about upper and lower limbs ballet positions and sequences of ballet jumps, and at the end a cool-down.
45514473|NCT04058379|Radiation|CT scan|3 ct scans : D0, D1 and D3
45514474|NCT04057755|Drug|botulinum toxin A|
45514475|NCT04057755|Drug|NaCl|
45514476|NCT02139709|Dietary Supplement|Ganglioside|
45514477|NCT02139709|Dietary Supplement|Placebo|
45851468|NCT01277640|Drug|matched placebo|"dosage form: gel, no api~dosage: 2.5g~frequency: once daily~duration: 7 days"
45405819|NCT03961698|Drug|Bevacizumab|Bevacizumab is an anti-vascular endothelial growth factor (anti-VEGF) recombinant monoclonal antibody that is approved by the FDA for the treatment of multiple solid tumors in combination with chemotherapy. It will be administered at 15 mg/kg IV on day 1 of each 21-day cycle to patients with RCC.
45405820|NCT01090908|Drug|Antibiotic|
45514478|NCT03669315|Device|Transcranial Magnetic stimulation|Neuromodulation tool
45514479|NCT04527367|Procedure|Innovative medical technologies in invasive cardiology and cardiac surgery|A follow-up study included the analysis of medical documentation of the Cardiosurgery and the Invasive Cardiology Departments to provided information on the duration and type of procedure performed.
45514480|NCT03669003|Biological|Gelfoam slurry|Approximately 1-2cc of Gelfoam slurry will be used to lace the needle track.
45514481|NCT03669003|Procedure|CT-guided percutaneous lung biopsy|Biopsy of a lung nodule under CT guidance.
45514482|NCT04429399|Other|decrease the positive end expiratory pressure (PEEP)|decrease the PEEP going from high (according to ExPress Trial) to low level
45514483|NCT04429399|Other|mechanical features assessment|evaluation of the mechanical features of respiratory system
45514484|NCT04429399|Other|shunt assessment|evaluation of the pulmonary shunt during two different ventilation setting
45514485|NCT05763745|Diagnostic Test|Point of Care Ultrasound|Use Point of Care Ultrasound to evaluate the gastric content/bleed prior to upper endoscopy
45514486|NCT04313959|Drug|Ropivacaine 0.2% Injectable Solution|Single-shot ultrasound-guided erector spine plane block of 0.2% ropivacaine
45514487|NCT04313959|Drug|Ropivacaine 0.2% + Dexamethasone|Addiction of 5 mg/ml dexamethasone in 0.2% ropivacaine solution
45514488|NCT03073213|Drug|Ixekizumab|Administered as subcutaneous (SC) injection
45405821|NCT03962556|Other|bimanual palpation|bimanual palpation....i..
45405822|NCT01084902|Drug|Latanoprost|once daily
45405823|NCT01084902|Drug|Brinzolamide|Two times daily
45405824|NCT01084980|Drug|Tacrolimus|tacrolimus 0.05mg/kg bid for 12 weeks corticosteroid 0.3 - 0.5mg/kg qd
45514489|NCT03070483|Drug|Cholecalciferol|5000 IU cholecalciferol with 1000 mg calcium citrate daily
45514490|NCT05763667|Drug|Liposomal bupivacaine|"Liposomal bupivacaine is FDA-approved for use single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle."
45851469|NCT01277640|Drug|universal placebo|"dosage form: gel, HEC-based~dosage: 2.5g~frequency: once daily~duration: 7 days"
45405825|NCT01088100|Genetic|Genotyping|Determination of 3 types of clock gene genotypes (HPER 4/4, 5/4, 5/5) on all blood samples
45405826|NCT01085058|Drug|lenograstim|
45514491|NCT05763667|Drug|Bupivacain|"Bupivacaine is FDA-approved for use as a local or regional anesthetic for surgery. It is widely used in TAP blocks.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle."
45514492|NCT03892993|Other|Decision Aid|Use decision aid
45514493|NCT03892993|Other|Questionnaire Administration|Ancillary studies
45514494|NCT04386187|Other|GSH Foods|The intervention consists of customized foods/small meals that have been designed to be high in a single nutrient called glutathione (GSH).
45514495|NCT04386187|Other|Nutrition education about glutathione sources in the diet|Four videos will outline food sources of glutathione, cooking methods to reduce systemic requirements for glutathione, food sources of nutrient cofactors for glutathione production and other related content.
45514496|NCT04386187|Other|Standard of care nutrition education for type 2 diabetes|The educational control is provided with information on standard dietary interventions for diabetes as electronic handouts and web links.
45514497|NCT01208389|Biological|voretigene neparvovec-rzyl|One time, subretinal administration of 1.5E11 vg AAV2-hRPE65v2 vector in 300 microliters to the contralateral, previously uninjected eye.
45405827|NCT03961542|Other|Chewing|Eligible patients are randomized to receive either routine care (control group) or routine care in addition to a chewing gum intervention for five days (beginning with the second study day, i.e. the day after baseline examination): sugar-free, fruit or mint flavoured gum chewed three times daily for 20 minutes before each meal. Routine care includes standard dietary and lifestyle advice for 30 minutes following our local recommendations as well as an advice on capillary blood glucose measurement (fasting as well as 1h after starting each meal). Capillary blood glucose profiles are reevaluated seven days after starting the blood glucose monitoring. Study visits will be scheduled at screening (visit 1, where eligible patients were randomized) as well as seven days later (visit 2).
45405828|NCT01088178|Device|Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)|Placement of Mirena at given intervals during the postpartum period
45514498|NCT04107727|Drug|Quizartinib|"Induction: oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
45514499|NCT04107727|Drug|Placebo oral tablet|"Induction: oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
45405829|NCT01091064|Other|Randomization early depart|Patients will be randomized to either an early depart or for being seen by a physician.
45405830|NCT01091142|Drug|NP001|Cohort 1: 0.3 mg/kg NP001(6:2 active:placebo) Cohort 2: 1.1 mg/kg NP001(6:2 active:placebo) Cohort 3: 2.1 mg/kg NP001(6:2 active:placebo) Cohort 4: 4.3 mg/kg NP001(6:2 active:placebo)
45405831|NCT01091142|Drug|Placebo|Cohort 1: placebo Cohort 2: placebo Cohort 3: placebo Cohort 4: placebo
45514500|NCT04107727|Drug|Cytarabine|"Induction: Cytarabine continuous IV infusion, 200 mg/m2 (days 1-7), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion, 1,5-3 g/m2 (days 1, 3, 5), up to 4 cycles of 35 days."
45405832|NCT01088256|Drug|Etoricoxib|the patients get etoricoxib 90mg for 8 days. They get one pill with 90mg per day
45405833|NCT01088256|Drug|placebo|patients get one pill of placebo (sugar-pill) per day for 8 days.
45514501|NCT04107727|Drug|Idarubicin|Induction: Idarubicin IV infusion 12 mg/m2 (days 1-3), up to 2 cycles of 35 days.
45514502|NCT05763433|Other|upper extremity bone surgery|any ambulatory upper limb bone surgery carried out under axillary PNB
45514503|NCT01074151|Drug|duloxetine|any exposure to duloxetine that occurred during pregnancy
45699252|NCT03443622|Drug|SC-43 Oral Solution|SC-43 Oral Solution has drug substance of 1-[4-chloro-3(trifluoromethyl)phenyl-3-[3-(4-cyanophenoxy)] urea, or SC-43. SC-43 inhibits tumor growth through the activation of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and the repression of p-STAT3 signalings. As a result of STAT3 inhibition by SC-43 treatment, decreased cell viability and enhanced apoptosis have been observed in cancer cells. The anti-tumor activity of SC-43 was also investigated in a variety of xenograft tumor models. Administration of SC-43 provides the tumor-bearing animals survival benefits, including the reduction of tumor volume and prolonged lifespan. SC-43 has been proposed to be evaluated as an anticancer therapeutic in in subjects with refractory solid tumors in the phase I trial.
45851470|NCT01277796|Device|Heat pack conduction-heat therapy|Hand warmer heat pack with reliable (and monitored) temperature (50-52 degrees Celsius) will be applied to lesion borders for 3 minutes (fractionated to 90 second intervals or less) every day, for 7 consecutive days.
45851471|NCT01277874|Device|Nasal CPAP|NCPAP is delivered via nasal prongs placed into infant's nares. It may be delivered via ventilator or by bubble.
45851472|NCT01277874|Device|Oscillatory NCPAP|Bird Industries pneumatic diaphragm is attached to NCPAP patient circuit to provide oscillations.
45405834|NCT03957486|Other|arterila cannulation on same arm|arterila cannulation on same arm receiving continous hemoglobin monitoring
45405835|NCT03957486|Other|arterila cannulation on different arm|arterila cannulation different arm receiving continous hemoglobin monitoring
45405836|NCT03957408|Device|Visual Stimuli|Subjects will be presented various visual stimuli and may be asked to perform tasks. Their accommodative response will be measured.
45405837|NCT01326858|Drug|Olopatadine hydrochloride ophthalmic solution, 0.7%|Treatment A
45405838|NCT01326858|Drug|Olopatadine hydrochloride ophthalmic solution vehicle|Treatment B, inactive ingredients used as placebo
45405839|NCT01326858|Drug|Ketotifen fumarate ophthalmic solution, 0.025%|Treatment C
45405840|NCT01088334|Other|screening|CT-Chest/abdomen and mammography in women
45405841|NCT00091572|Drug|Temozolomide|"oral capsule; 150 mg/m2/day PO (by mouth), on 7 consecutive days every 14 days (7 days on / 7 days off continuously); one cycle of temozolomide is defined as a 6-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop."
45405842|NCT00091572|Drug|Dacarbazine|intravenous solution; dacarbazine 1000 mg/m2 IV (in the vein), on Day 1 +/- 3 days every 3 weeks; one cycle of dacarbazine is defined as a 3-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.
45699253|NCT01872312|Device|treatment with valves (The Spiration® IBV Valve System)|treat BPF
45405843|NCT01091220|Biological|Certolizumab pegol|400 mg certolizumab pegol in 2 x 200 mg/mL, prefilled syringes, administered once, subcutaneously
45405844|NCT01091220|Biological|Placebo|2 x prefilled syringes containing 0.9% saline, administered once, subcutaneously
45405845|NCT03961386|Behavioral|FallsTalk-C|The FT-C experimental intervention involves two face-to-face visits including Initial and Follow-up Interviews, CG training, daily interaction with the PwD using a computer with FT-C software, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.
45851473|NCT01277952|Device|Deep Brain Stimulation|Brain pace maker, implanted in the brain
45851474|NCT01278108|Drug|GLPG0778|single ascending doses, oral solution (10 to 800 mg/dose) and capsules (100 mg/dose)
45851475|NCT01278108|Drug|placebo|single dose, oral solution or capsule (matching corresponding study medication)
45851476|NCT01278108|Drug|GLPG0778|multiple dose, capsule, 7 days
46057392|NCT05156775|Other|Serratus Plane Block (SPB)|While the patient is in the supine position, the arm will be abducted, the ultrasound probe will be placed over the mid-clavicular region of the thoracic cage in sagittal plane. Ribs will be counted until the fifth rib will be identified in the midaxillary line. the latissimus dorsi (superficial and posterior ), teres major (superior), and serratus muscle (deep and inferior)will be identified overlying the fifth rib. As an extra reference point, thoracodorsal artery will be used, this aids in the identification of the plane superficial to the serratus muscle, 30 ml 0.25 %bupivacaine will be injected between latissimus dorsi and serratus anterior muscles at the level of the 5th rib in the mid axillary line.
45405846|NCT03961386|Behavioral|FallsTalk|The FallsTalk intervention involves two face-to-face visits including Initial and Follow-up Interviews,CG training, daily interaction with the PwD, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.
45405847|NCT00084266|Drug|linezolid (Zyvox)|Subjects to receive either linezolid 600 mg IV (Intravenous) or PO (orally) q 12 h (every 12 hours) for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
45405848|NCT00084266|Drug|vancomycin|Subjects to receive vancomycin 15mg/kg IV (Intravenous) q12h (every 12 hours), adjusted for renal function, for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
45514504|NCT05762809|Diagnostic Test|Tampa Scale of Kinesiophobia (TSK-17)|The Tampa Scale of Kinesiophobia (TSK-17) was developed as a self-reported checklist to measure fear of pain during movement and fear of reinjury. The TSK-17 consists of 17 questions. Standardized answer options are given as a 4-point Likert scale, and each question is assigned a score from 1 to 4. A normalized score between 17 and 68 points is calculated. A score of 37 or over indicates kinesiophobia.
45699254|NCT03035448|Behavioral|Questionnaires|"Participants complete 3 assessment questionnaires during an already-scheduled office visit. These questionnaires should take about 9 minutes to complete.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services. These questionnaires should take about 4 minutes to complete."
45699255|NCT03035448|Other|Video Presentation|Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.
45699256|NCT03443544|Procedure|Aggressive debridement|Aggressive debridement of the tissues undergoing fascitis
45405849|NCT01091298|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine (BRV-TV)|Single dose (0.5 mL) of the vaccine administered orally
45405850|NCT01091298|Other|Placebo|Single dose (0.5 mL) of the placebo administered orally
45699257|NCT02958462|Other|follow up|
45699258|NCT02948712|Behavioral|Distress Screening Thermometer|Screening took with an overall distress ranging from 0-10 and additional stress items in the areas of practical problems, family problems, emotional problems, spiritual or religious concerns, and physical problems
45699259|NCT02948712|Behavioral|NCCN Guidelines: Distress management|Based on the NCCN Guidelines Version 1.0.2016 which recommend brief screening, evaluation, and treatment of distress
45699260|NCT04114656|Drug|Placebo|Placebo will be available as intravenous (IV) infusion of normal saline (0.9 percent [%] sodium chloride solution).
45851477|NCT01278108|Drug|placebo|multiple dose, capsule, 7 days
45851478|NCT01278420|Device|Tecnis MF|30 subjects will be implanted with the Tecnis MF
45851479|NCT01278420|Device|ReSTOR|30 subjects will be implanted with ReSTOR
45851480|NCT01278576|Drug|BOTOX-A®|200 units, single treatment only
45851481|NCT01278654|Behavioral|Incentive to exercise|Participants who attain their walkstation goal will be entered into a draw every two weeks. We are testing the effect of different prizes on walkstation usage.
45851482|NCT01278810|Drug|Icaritin|50mg,100mg,200mg,300mg,400mg,500mg ascending-multiple oral dose, Qd, single dose and continuing dose 28 days, to assess the safety,tolerance and pharmacokinetics of icaritin
45514505|NCT05762809|Diagnostic Test|Knee injury and Osteoarthritis Outcome Score (KOOS)|The KOOS consists of five subscales - Symptoms (S), Pain (P), Functional activities of daily living (ADL), Sport and Recreation Function (Sport/Rec) and Knee-Related Quality of life (QOL) - and total KOOS Outcome (O) scores. Standardized answer options are provided (5 Likert boxes), and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.
45514506|NCT05762809|Diagnostic Test|Oxford Knee Score (OKS) scoring|OKS consists of 12 questions. Standardized answer options are provided (5 Likert boxes), and each question is assigned a score from 0 to 4. A score of 40-48 indicates no symptoms or satisfactory joint function, 30-39 moderate knee arthritis, 20-29 moderate to severe knee arthritis, and 0-19 severe knee arthritis.
45405851|NCT03957564|Drug|Neoadjuvant chemotherapy with PSOX regimen.|"Resectable gastric or gastro-oesophageal junction cancer patients receiving neoadjuvant chemotherapy with PSOX（Paclitaxel+Oxaliplatin+S1）regimen.~The details are as follows:~Paclitaxel 135mg/m2 d1, Oxaliplatin 85mg/m2 d1, S1 40-60mg/m2 twice daily, d1-14 , 21 days is one cycle."
45405852|NCT03957564|Other|Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma.|Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in 3 time points：Before neoadjuvant chemotherapy, After 2-3 cycles of neoadjuvant chemotherapy, 10 days after operation.
45405853|NCT03957564|Other|Detect the tumor related DNA in pathological tissues after operation.|Detect the tumor related DNA in pathological tissues after operation.
45514507|NCT05762809|Diagnostic Test|Quadriceps and hamstring muscle isokinetic strength|Quadriceps and hamstring muscle strength at 60˚/s and 180˚/s were measured with an isokinetic dynamometer. For 180˚/s, five trial and fifteen testing repetitions were used, and for 60˚/s, three trial and three testing repetitions were used. The resting time between trial and testing was two minutes, between different speeds one minute, and between legs two minutes. The maximum peak torques were used in the statistical analysis.
45514508|NCT05762809|Diagnostic Test|Single-leg hop test|The single-leg hop test (SLHT) for distance was used for lower limb functional testing. The test started with the participant standing on one leg, toes behind a marked line, and hands on hips throughout to avoid aiding the jump by swinging the arms. The participant was instructed to jump as far as possible and land on the same leg without losing balance. If the patient made contact with the ground with the contralateral limb, lost balance, or made additional hops after landing, the distance was not measured and the jump void. The distance was measured from the starting line to the heel of the leg being tested. For both legs, three trials and three jumps for maximal effort were allowed. The longest distance for both the left leg and the right leg were used in the statistical analysis.
45405854|NCT03957564|Other|Follow-up of DFS and OS in patients with gastric cancer after operation.|Follow-up of DFS and OS in patients with locally advanced or resectable gastric or gastro-oesophageal Junction cancer.
45514509|NCT05762809|Diagnostic Test|Y-balance test|The Y-balance test (YBT) (Move2Perform, United States) for anterior reach was used to measure dynamic balance. Participants performed three trials to familiarize themselves with the test, and then undertook three tests. The test started with the participant standing barefoot on the testing kit. The patients had to push a wooden box with the contralateral leg as far as possible with continuous movement and return to their starting position without losing balance. The longest distance achieved was used in the statistical analysis.
45514510|NCT05762809|Diagnostic Test|Anthropometric measurements|Body mass (kg) and height (cm) were measured, and the body mass index (BMI) was calculated as kg/m2.
45514511|NCT05761405|Combination Product|mannitol-enhanced aminoglycoside|"Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics (± mannitol) will be delivered in a single infusion that will be administered within 30 minutes."
45514512|NCT05761405|Drug|Ceftriaxon|"Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics will be delivered in a single infusion that will be administered within 30 minutes."
45699261|NCT04114656|Drug|GSK3858279|GSK3858279 will be available as IV infusion and the dose level to be administered is 3 milligrams (mg) per kilogram (kg).
45405855|NCT01086878|Drug|cotrimoxazole|"Daily oral cotrimoxazole suspension from 1 to 6 months of age at the following weight-based doses:~less than 5kg: 100mg sulfamethoxazole, 20mg trimethoprim~greater than 5kg: 200mg sulfamethoxazole, 40mg trimethoprim"
45405856|NCT01086956|Drug|epidural infusion of saline, ropivecaine, or ropivacaine and sufentanil|
45405857|NCT00091026|Biological|cetuximab|Given IV
45405858|NCT00091026|Drug|gemcitabine hydrochloride|Given IV
45405859|NCT00091026|Biological|bevacizumab|Given IV
45405860|NCT00091026|Drug|erlotinib hydrochloride|Given orally
45405861|NCT01087034|Device|Acoustic reflection method evaluation|Evaluation of airways by acoustic relection method, with and without the bracing device
45405862|NCT01087034|Radiation|EOS™|Scoliosis and thoracic penetration index evaluation by EOS™ acquisition, with and without the bracing device
45405863|NCT01087034|Other|Non invasive respiratory muscle assessment|Non invasive respiratory muscles assessment, with and without the bracing device.
45405864|NCT03961074|Other|Iron deficiency anemia in Chinese pregnant women|Iron deficiency anemia exists in Chinese pregnant women during pregnancy
45405865|NCT01583634|Device|Mespere Oximeter|Mespere oximeter provides non-invasive venous blood oxygen saturation.
45405866|NCT01583634|Device|Radiometer OSM-3 Co-Oximeter|OSM-3, a Radiometer manufactured hemoximeter, is intended for the photometric determination of hemoglobin.
45405867|NCT01091376|Drug|Erlotinib|Erlotinib 150mg/day
45405868|NCT01091376|Radiation|Thoracic radiotherapy|60-70Gy/30-35f
45405869|NCT00116558|Device|Early NIPPV|Early intervention with non-invasive positive pressure ventilation (NIPPV) at 80% forced vital capacity (FVC).
45405870|NCT00116558|Device|Standard NIPPV|Standard of care non-invasive positive pressure ventilation (NIPPV) at 50% forced vital capacity (FVC).
45405871|NCT01085292|Drug|NOX-E36|Multiple dose 0.25 mg/kg or placebo i.v. to healthy volunteers; dosing frequency q2d
45405872|NCT01085292|Drug|NOX-E36|Multiple dose of 0.0625 mg/kg, 0.125 mg/kg, 0.25 mg/kg or placebo i.v. to patients with type 2 diabetes mellitus (ratio 3:1); dosing frequency q2d
45405873|NCT01085370|Other|Early psychological intervention|3 modules: psychoeducation, reconstruction of the trauma, coping skills
45405874|NCT00116168|Biological|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
45405875|NCT00116168|Biological|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, SC dose
45405876|NCT00116168|Biological|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, SC dose
45405877|NCT00116168|Biological|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, SC dose
45405878|NCT00115934|Procedure|Blalock-Taussig pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
45405879|NCT00115934|Procedure|Right ventricular to pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
45514513|NCT05761405|Drug|Amikacin|Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.
45514514|NCT05203783|Other|McKenzie Exercises|"McKenzie exercises: The McKenzie set consists of 5 exercises.~Prone-lying~Prone-extension~Prone press ups~Progressive extension with pillows~Standing extension"
45514515|NCT05203783|Other|Kinesio Tape Application|Kinesio Tape (KT) application: Participants in the experimental group received additional taping using KT by an experience therapist with prior training in KT application. The tape was applied using the method proposed for the sacrospinalis muscle (Kase, 1996). Y-shaped tape was applied as shown in Figure 1. While the participant was in standing position, the origin of the Y-shaped tape was attached over the centre of the sacrum without stretching the tape and afterward subjects gradually bent forward. A 5-degree angle was maintained within the valley of the Y tape. The tape was changed on the fourth day
45514516|NCT03979885|Behavioral|Smoking cessation counseling (Quitline)|Quitline offers community-based counseling session with a cessation counselor.
45514517|NCT03979885|Behavioral|Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)|Participants will be encouraged to speak to their doctors about using highly effective pharmacotherapies for smoking cessation.
45514518|NCT03979885|Behavioral|Financial incentives for smoking cessation|Participants will receive financial incentives for bioconfirmed smoking cessation.
45514519|NCT03979885|Behavioral|Financial incentives for use of evidence-based smoking cessation therapies|Participants will receive financial incentives for the use of evidence-based smoking cessation therapies including Quitline counseling, community-based smoking cessation programs and pharmacotherapies
45514520|NCT02786329|Drug|TIVA+lidocaine|Patients will be subjected to total intravenous anesthesia with propofol-fentanyl+i.v. lidocaine infusion for the first 48 h postoperatively
45514521|NCT02786329|Drug|Sevoflurane+lidocaine|Patients will be subjected to anesthesia with sevoflurane- fentanyl + lidocaine infusion for the first 48 h postoperatively.
45514522|NCT02786329|Drug|TIVA+placebo|Patients will be subjected to TIVA with propofol-fentanyl + saline infusion for the first 48 h postoperatively
45514523|NCT02786329|Drug|Sevoflurane+placebo|Patients will be subjected to anesthesia with sevoflurane-fentanyl + saline infusion for the first 48 h postoperatively
45514524|NCT04025905|Behavioral|Social Cognition Training|Evaluate the impact of the social cognition training on employment maintaining in transitional Workforce Assistance Facilities and Services.
45514525|NCT04025905|Behavioral|Informations|informations about work environment, social environment, stress management, sleep management, treatments
45405880|NCT00115778|Drug|IVIG|10% Caprylate/Chromatography Purified Intravenous Immunoglobulin 400 mg/kg IV every 4 weeks
45405881|NCT00115778|Other|Placebo|0.1% Albumin in an equal volume to the investigational product
45405882|NCT01081574|Drug|Bilastine|10 mg/qd/ 7 days.Oral dispersible tablets
45405883|NCT00100178|Drug|Mycophenolate mofeteil (MMF)|
45405884|NCT00100178|Drug|Daclizumab (DZB)|
45405885|NCT00100178|Drug|Placebo control for Mycophenolate mofeteil (MMF)|Placebo pills taken orally
45405886|NCT00100178|Drug|Placebo control for Daclizumab (DZB)|saline intravenous infusions
45405887|NCT01087112|Behavioral|Mother-Infant Psychoanalytic tmt|Psychoanalytic sessions with mother and infant, at a median of 23 sessions 2 times weekly.
45405888|NCT01087112|Behavioral|Child Health Centre care|Nurse calls at Child Health Centres (CHC), with regular paediatric checkups. The nurse was encouraged to promote attachment and to detect postnatal depressions. Appointments with a psychiatrist or therapist or child psychiatric psychologist was initiated in 1/3 of the cases. This was registered at the end-point interview.
45405889|NCT00099632|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate|200mg/300mg as one tablet taken orally once daily
45405890|NCT00099632|Drug|Lamivudine/Zidovudine|150mg/300mg as one tablet taken orally twice daily
45514526|NCT05761951|Drug|DKN-01|Given by IV (vein)
45405891|NCT00099632|Drug|Lopinavir/Ritonavir|133.3mg/33.3mg as three capsules taken orally twice daily
45405892|NCT00099632|Drug|single dose Nevirapine|one 200 mg tablet taken orally
45405893|NCT03961802|Other|sessions of shoulder rehabilitation|3 sessions of shoulder rehabilitation per week for 3 months (36 sessions)
45514527|NCT05761951|Drug|Pembrolizumab|Given by IV (vein)
45514528|NCT05761327|Other|Mediterranean Diet|In the Mediterranean diet; The frequency of consumption of foods such as olive oil, olives, nuts, fish, vegetables and fruits will be given in accordance with the Mediterranean diet pyramid. During the study, it is planned to develop new recipes suitable for the nutritional habits of the individual. The researcher will be able to reach the researcher 7/24 in case of any problem experienced by the individual, and the participant's questions will be answered. Nutrition counseling to this group will be supported by an oral explanation given by the dietitian.
45405894|NCT01087190|Drug|Isoniazid treatment|isoniazid 300 mg po qd for 9 months
45514529|NCT05761327|Dietary Supplement|Curcumin Supplementation|Participants will take a daily supplement of 1600 mg of curcumin. It is planned that the participants will use 120 capsules of curcumin supplement during the research.
45514530|NCT05761327|Dietary Supplement|Resveratrol Supplementation|Participants will take a 500mg resveratrol supplement daily. Participants are planned to use 120 capsules of resveratrol supplement during the study.
45514531|NCT05203549|Procedure|Tumor biopsy|Patients with gastric cancer will undergo tumor biopsy before receiving neoadjuvant therapy, conversion therapy, or palliative therapy
45514532|NCT05202925|Other|Musical Training Program|a weekly 45-minute lesson, one-to-one musical training
45514533|NCT02231762|Drug|Lanreotide Autogel 120 mg|Lanreotide Autogel 120 mg subcutaneous (s.c) - injection, every 28 days (+/-2 days).
45514534|NCT02231762|Drug|Temozolomide (TMZ)|Temozolomide capsule (variable dose). 150 mg/m2 per day for 5 days in the first month. 200 mg/m2 per day for 5 days in months 2, 3, 4, 5 and 6.
45514535|NCT04540484|Other|Screening|Blood test screening for covid
45514536|NCT01687335|Other|answering questionnare in differents time of the treatment|
45405895|NCT01090466|Drug|cisplatin|
45405896|NCT01090466|Drug|gemcitabine hydrochloride|
45405897|NCT01090466|Drug|temsirolimus|
45405898|NCT01090466|Other|pharmacological study|
45405899|NCT04116398|Drug|Dexamethasone with 2 loading doses followed by PRN regimen.|"Loading dose with 2 systematic intravitreal injections (IVI) of ozurdex at the baseline and 12 weeks.Followed by a PRN regimen with strict retreatment criteria (already used and published in the Prediamex study, Bellocq,Kodjikian et al Ophthalmology Retina 2017)~Retreatment criteria: Reduction in VA ≥ 5 ETDRS Letters; and/or CSMT ≥ 275 microns by OCT-Cirrus® or ≥ 285 microns by OCT Spectralis®; and/or increase of CSMT > 50 microns; and/or onset of recurrent retinal cysts; and/or residual edema considered by the practitioner to be clinically significant.~Minimal time limit between two IVI : 12 weeks~Visits: monthly during 1 year (to check efficacy and safety) and then for the 2nd-year only at Month18 (M18) and Month 24 (M24)"
45405900|NCT01090544|Device|Nasal Insufflation|Breathing therapy
45405901|NCT00098774|Biological|filgrastim|5 mcg/kg subQ injection daily Day 14 until ANC > or = 500 uL for 2 days or 1500 uL for 1 day (Cycle 6)
45405902|NCT00098774|Biological|rituximab|375 mg/sq m IV infusion (max rate of 400 mg/hr) on Days 3, 10, 17, & 24 of Cycle 1 nad Days 3 & 10 of Cycle 2
45405903|NCT00098774|Drug|cytarabine|2 g/sq m IV infusion over 2 hours q 12 hrs x 8 doses Days 1-4 of Cycle 6
45405904|NCT00098774|Drug|etoposide|5 mg/kg IV infusion over 12 hrs q 12 hrs x 8 doses Days 1-4 of Cycle 6
45405905|NCT00098774|Drug|leucovorin calcium|100 mg/sq m IV infusion q 6 hrs starting 24 hrs after ea MTX dose until serum MTX < or = 0.05uM Cycles 1-5.
45514537|NCT01676181|Procedure|Adenotonsillectomy|Total removal of tonsils and adenoid tissue with cold-steel
45514538|NCT01676181|Procedure|Adenotonsillotomy|Partial removal of tonsils with coblation and total removal of adenoids with cold steel
45514539|NCT04614051|Biological|Cellgram-DC|Patients will receive 3 times every 2 weeks injection of Cellgram-DC(Autologous dendritic cell) subcutaneous injection near the upper arm lymph nodes
45514540|NCT03623217|Behavioral|Qualitative interviews with participants|For the development and validation of a questionnaire.
45699262|NCT03129516|Behavioral|Determining Imaginary levels|Determining the motor imaginary: internal visual, external visual and kinesthetic imagery
45514541|NCT03668145|Procedure|mesenchymal stem cell transplantation or placebo infusion via peripheral vein|0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
45405906|NCT00098774|Drug|methotrexate|8 g/sq m IV infusion over 4 hrs Days 1 & 15 Cycles 1, 2, & 3; Day 15 Cycle 4 and Day 1 Cycle 5.
45514542|NCT02228486|Device|tDCS|2 mA (verum group) over the left dorsolateral prefrontal cortex (F3, anodal), 15 min; 10 seconds ramp in verum and sham group (see also above)
45405907|NCT00098774|Drug|temozolomide|150 mg/sq m PO Days 7-11 Cycles 1-5.
45514543|NCT02228486|Behavioral|Cue Exposure Therapy|5 weeks (9 sessions) of cue-exposure therapy with preferred alcoholic beverage (see also above)
45405908|NCT01087268|Other|questionnaire administration|
45405909|NCT01087268|Procedure|gastrointestinal complications management/prevention|
45514544|NCT04057209|Radiation|Single Vocal Cord Irradiation (SVCI)|The following planning aim will be pursued: full coverage of the PTV with at least 95% of the prescribed dose and a maximum (0.03 cc) PTV dose of <107%: 16 x 3.63 = 58.08 Gy in 5 fractions per week using 5 to 9 static IMRT or VMAT.
45514545|NCT04057209|Procedure|Arm A: Transoral CO2-Laser Microsurgical Cordectomy (TLM)|"The TLM has to be performed using a CO2 laser, coupled to an operative microscope, at 4-8W in ultrapulse mode. The type of cordectomy performed must be mentioned using the following classification according the classification of the European Laryngological Society.~The type of resection chosen should provide complete removal of the primary lesion with negative margins.~Surgery will generally be performed within 3 weeks after randomization and not more than 6 weeks after panendoscopy.~The extent of the cordectomy must include a complete anterior, posterior, inferior and supero-lateral mucosal and deep soft tissue margin."
45514546|NCT04507178|Drug|Nadroparin Injectable Product|high dose LMWH compared to prophylactic dose LMWH
45405910|NCT01087268|Procedure|quality-of-life assessment|
45405911|NCT01081652|Drug|Micronised Progesterone|Micronised progesterone administered intravaginally once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
45405912|NCT01081652|Drug|Progesterone|Progesterone 60 mg administered intramuscular once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
45514547|NCT03668925|Radiation|magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement|magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement
45514548|NCT01191957|Drug|Busulphan plus Cyclophosphamide|"I.V. Bu (Busilvex), 12.8 mg/kg:~Day -9: 0.8 mg/kg/dose x 4 doses Day -8: 0.8 mg/kg/dose x 4 doses Day -7: 0.8 mg/kg/dose x 4 doses Day -6: 0.8 mg/kg/dose x 4 doses Day -5: Rest~Followed by:~Cyclophosphamide, 120 mg/kg iv:~Day -4: 60 mg/kg Day -3: 60 mg/kg"
45405913|NCT01087424|Drug|R mini CHOP|Prednisone 40 mg/m2 D1 D2 D3 D4 D5 Rituximab 375 mg/m2 D1 Doxorubicine 25 mg/m2 D1 Cyclophosphamide 400 mg/m2 D1 Vincristine 1 mg/m2 D1
45405914|NCT01087580|Drug|Docetaxel and Prednisone|A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
45405915|NCT01087580|Drug|Docetaxel and Prednisone|A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
45405916|NCT01087580|Drug|Radiation Therapy|"GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.~GROUPS 2 Bone metastasis (bone scan index < 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.~GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week."
45514549|NCT01191957|Drug|Busulphan plus Fludarabine|"I.V. Bu (Busilvex), 12.8 mg/kg:~Day -6: 0.8 mg/kg/dose x 4 doses Day -5: 0.8 mg/kg/dose x 4 doses Day -4: 0.8 mg/kg/dose x 4 doses Day -3: 0.8 mg/kg/dose x 4 doses plus:~Fludarabine, 4 x 40 mg/m² iv:~Day -6: 40 mg/m² Day -5: 40 mg/m² Day -4: 40 mg/m² Day -3: 40 mg/m²"
45514550|NCT01913912|Drug|LDX.|"In this study 3 different doses of LDX will be used:~30 mg capsules: 30 mg LDX, equivalent to 8.9 mg of dexamphetamine~50 mg capsules: 50 mg LDX, equivalent to 14.8 mg of dexamphetamine~70 mg capsules: 70 mg LDX, equivalent to 20.8 mg of dexamphetamine"
45514551|NCT01913912|Drug|sugar pill|Children will take once only a placebo capsule during the DBPC phase (phase 4) the morning of the testing. For blinding purpose we will blindfold the children when taking placebo.
45405917|NCT03961412|Behavioral|family-based intervention|The participants will identify their accompanying influential person(s) (e.g., spouse, partners, parents, children, friends) with whom they will be attending the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
45405918|NCT03961412|Behavioral|Participant only intervention|Only participant will attend the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
45405919|NCT01087658|Drug|Glutamine|Per os
45405920|NCT01087658|Drug|Calcium and Magnesium|Intravenous
45405921|NCT03958058|Drug|Anti-borrelial antibiotic therapy|Beside symptomatic therapy, patients received oral doxycycline 100 mg (Doxy®) twice daily or ceftriaxone 2 g (Lendacin®) once daily for 14 days. Antibiotic therapy was left to the discretion of treating physicians. Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
45405922|NCT03958058|Other|No antibiotic.|Patients who received symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
45405923|NCT01090622|Drug|XPF-001|Oral capsule
45405924|NCT01090622|Drug|Placebo|Oral capsule
45405925|NCT01081730|Biological|anti-TNF biologics|as prescribed
45405926|NCT01081730|Other|general population|non-treated cohort
45514552|NCT01913912|Device|computer task (Go/No-Go task)|
45405927|NCT01081730|Biological|non-anti-TNF biologics|as prescribed
45514553|NCT01913912|Device|EEG|event-related potentials (ERP) and heart rate measurements
45514554|NCT01913912|Device|pupil size measurements (by using eye tracking)|
45514555|NCT02232230|Drug|Provenge|
45514556|NCT02276066|Other|Iohexol|Both groups of sepsis participants will receive a normal saline dilution of Iohexol 0.5-1 ml given by IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year.
45514557|NCT02276066|Other|Urine Collection|Both groups of sepsis participants will have urine collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine and urea concentration.
45514558|NCT02276066|Other|Blood samples|Both groups of sepsis participants will provide peripheral blood samples to the research staff. The samples will be sent to the laboratory for serum creatinine and cystatin C results.
45514559|NCT01050855|Drug|RIC: Distal Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
45514560|NCT01050855|Drug|RIC:Intermediate Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
45405928|NCT01081730|Biological|ustekinumab|as prescribed
45405929|NCT01081730|Drug|systemic non-biological treatments|as prescribed
45405930|NCT01090700|Drug|TMC435|TMC435 150 mg daily for 7 days
45405931|NCT01090700|Drug|Escitalopram|Escitalopram 10 mg daily for 7 days
45405932|NCT01090700|Drug|TMC435 + Escitalopram|TMC435 150 mg + escitalopram 10 mg daily for 7 days
45514561|NCT01050855|Drug|RIC: Mini Busulfan|Campath, Fludarabine, Busulfan, Cyclosporine, Cellcept (MMF)
45514562|NCT04459286|Drug|Nitazoxanide and atazanavir/ritonavir|1000 mg nitazoxanide tablets twice daily and 300/100 mg atazanavir/ritonavir tablets once daily with meal
45514563|NCT04459286|Other|Standard of Care|SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
45514564|NCT00744081|Drug|Glivec|
45514565|NCT00744081|Drug|Mitoxantrone|
45514566|NCT00744081|Drug|Topotecan|
45514567|NCT00744081|Drug|AraC|
45699263|NCT03443466|Device|Epidural electrical stimulation (EES)|Using loss of resistance technique and electrical stimulation
45699264|NCT03443466|Device|Loss of resistance (LOR)|Using loss of resistance technique only
45851483|NCT01278966|Other|The Modified Atkins Diet|The Modified Atkins Diet; 10 g carbohydrate per day and a high fat intake
45405933|NCT03957980|Other|Occupational therapy|Child/caregiver dyads in this group will participate in telehealth-based intervention sessions in their home environment. Each child/caregiver dyad will participate in up to 9 interventions sessions. All intervention sessions will last 30-60 minutes. The intervention sessions will focus on task analysis, caregiver coaching, parent education and recommendations for task and home/environmental modifications to promote the child's functional vision.
45405934|NCT01087892|Dietary Supplement|Probiotic drink containing the live strain|Probiotic drink contains no strain
45405935|NCT01087892|Dietary Supplement|placebo probiotic|Placebo product is a sweetened flavoured, non fermented, acidified dairy drink
45405936|NCT03957902|Drug|acetylsalicylic acid|Different dosage effect over platelet COX enzymes, non- neoplastic and neoplastic colonic tissues used as biomarkers of clinical efficacy in CRC chemoprevention
45405937|NCT00384059|Biological|13-valent Pneumococcal Conjugate Vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age
45514568|NCT03669939|Other|Communication Strategy|Communication Strategy The intervention consists of a handbook that refers to the CDC Guidelines with tools and communication strategies that the PCP can use when assessing their patients who are on opioids. The Handbook will have a description of the Ohm-app and the information the PCP can retrieve from the dashboard in their medical record. They will also be provided a template to use when seeing the patient to use as guide and as documentation.
45514569|NCT03669939|Other|Standard of Care|The standard information about the CDC Guidelines and no other information that is available through the study.
45514570|NCT02229110|Other|Signal|Automatic signal in the electronic medical record
45514571|NCT03023397|Biological|Der f|Nasal administration of Dermatophagoides farinae with 100 allergen units (AU), 500 AU, and finally 1000 AU
45514572|NCT02229188|Behavioral|Problem Solving Therapy|Problem solving therapy is an evidence based behavioral intervention for late life depression. It consist of 8 weekly session of talk therapy, whereby the therapist helps the patient solve problems that are thought to be causing depressive symptoms.
45514573|NCT02229188|Behavioral|Evolution|Evo is a video game that has therapeutic elements targeting the cognitive control network. Impairment in this neural network is associated with a specific subtype of late life depression that puts people at risk for poor response to SSRIs. Evo is built from a research grade training paradigm that has shown to induce improvements in this network in healthy older adults
45405938|NCT00384059|Biological|7vPnC|Single 0.5 mL dose given at 2, 3, 4 and 12 months of age
45405939|NCT00384059|Biological|Pediacel|concommitant vaccine, both at arm 1 and at arm 2, at 2 months, 3 months and 4 months of age
45405940|NCT00384059|Biological|NeisVac-C|concomittant vaccine, both at arm 1 and at arm 2, at 2 months and 4 months of age
45405941|NCT00384059|Biological|Menitorix|concomitant vaccine, both at arm 1 and at arm 2, at 12 months of age
45405942|NCT00383123|Biological|Fluarix™|"Subjects were administered 1 or 2 doses* intramuscularly, into the non-dominant upper arm for children > 12 months of age, in the anterolateral thigh for children < 12 months.~*Only those subjects between the age of 6 months and < 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 & 1."
45405943|NCT00383123|Biological|Fluzone|"Subjects were administered 1 or 2 doses* intramuscularly, into the non-dominant upper arm for children > 12 months of age, in the anterolateral thigh for children < 12 months.~*Only those subjects between the age of 6 months and < 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 & 1."
45405944|NCT01046435|Procedure|metronidazole and amoxicillin|Metronidazole 250 mg three times a day per 7 days
45405945|NCT01046435|Procedure|Two placebos|Two placebos 3 times a day for 7 days
45514574|NCT02229188|Behavioral|Words|Words is a cognitively challenging crossword/word search type of video game that will serve as the control condition for the second phase of this project
45514575|NCT02223962|Behavioral|Physical activity|Counseling about physical activity will only be provided in the intervention group by 3 weekly telephone contacts. Based on the information the physiotherapist receives, he or she will adapt the goal (in agreement with the patient) and motivate the patient to reach the individual goal.
45514576|NCT04453202|Biological|RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.
45514577|NCT04453202|Other|Placebo|Participants will receive a single IM injection of placebo on Day 1.
45405946|NCT00382967|Procedure|DaTSCAN SPECT imaging|A single intravenous injection of DaTSCAN with a total activity of 111-185 MBq (volume of 2.5 or 5.0 mL). SPECT scanning to be performed 3 to 6 hours after DaTSCAN injection.
45405947|NCT01046591|Procedure|Polysomnography|Overnight sleep studies will be performed on all children.
45405948|NCT00858364|Drug|Darbepoetin alfa|Administered subcutaneously once every 3 weeks
45405949|NCT00858364|Drug|Placebo|Administered subcutaneously once every 3 weeks
45405950|NCT00382733|Drug|Oral Topotecan|Topotecan will be received in one of the five dose levels:0.25mg/day,0.5mg/day, 0.75mg/day, 1.0mg/day, and 1.25mg/day.
45405951|NCT01045577|Drug|Masitinib|6 mg/kg/day
45405952|NCT01045577|Drug|Masitinib|3 mg/kg/day
45405953|NCT01045577|Drug|Placebo|Placebo matching masitinib (3 mg/kg/day and 6 mg/kg/day)
45405954|NCT03992885|Drug|Icotinib|"Intervention: Drug: Icotinib Ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally~Intervention: Drug: Carboplatin/ Cisplatin Pemetrexed 500mg/m2, intravenous infusion, day 1;Carboplatin AUC6/ Cisplatin 75mg/m2,intravenous infusion, day 1,21 days for a cycle"
45405955|NCT05668702|Other|crossover design|The researcher took venous blood sample in a tube from each patient and according to the list of order determined via randomization scheme formed on the computer, the patients' glucose levels were measured by taking a capillary blood sample from the side of the middle fingertip and palm of the dominant hand with the glucometer. Before the study, the patient's pain assessment at the end of each measurement was carried out by a nurse who was trained by the researcher about the use of Visual Analog Scale.
45405956|NCT03739294|Drug|Fluticasone Furoate/ Vilanterol Trifenatate|Asthma inhalation medication
45405957|NCT03739216|Device|ClariFix|The ClariFix device is a handheld cryosurgical device which provides focal, controlled freezing to the target tissue.
45405958|NCT03739060|Device|Transcutaneous electric nerve stimulation|Conventional transcutaneous electric nerve stimulation
45405959|NCT03631732|Drug|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily without regard to food
45405960|NCT03631732|Drug|NRTIs|"The following NRTIs will be administered as prescribed until Week 24 without regard to food:~abacavir (ABC), emtricitabine (FTC), lamivudine (3TC), tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), zidovudine (ZDV or AZT)"
45514578|NCT02229266|Biological|NK cells|
45514579|NCT02229266|Drug|Cytarabine|1 cycle of consolidation chemotherapy with high-dose cytarabine
45514580|NCT01944566|Biological|Microbial transplant|Every subject has 2 armpits; 1 armpit is treated, the other one is not treated. There is a microbial transplant from armpit bacteria.
45514581|NCT02224040|Drug|ceftriaxone|
45514582|NCT02224040|Drug|ceftriaxone and azithromycin|
45514583|NCT02224040|Drug|azithromycin|
45514584|NCT02224040|Drug|azithromycin and cefixime|
45514585|NCT04448834|Drug|Blinatumomab|liposomal vincristine 2.25 mg/m2 weekly x 3 per cycle (weeks 3-5 in cycle 1 and 2-4 in subsequent cycles)
45514586|NCT04447820|Drug|K-877-ER (Dose A)|Dose A Oral Administration
45514587|NCT04447820|Drug|K-877-ER (Dose B)|Dose B Oral Administration
45514588|NCT04447820|Drug|K-877-IR|K-877-IR Oral Administration
45514589|NCT04429178|Other|ultrasound|portal vein pulsatility fraction (percent) measured with ultrasound
45514590|NCT02224118|Drug|CNTO 3649 10 mcg/kg|A single dose of 10 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
45514591|NCT02224118|Drug|CNT0 3649 30 mcg/kg|A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 30 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
45514592|NCT02224118|Drug|CNTO 3649 100 mcg/kg|A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 100 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
45514593|NCT02224118|Drug|CNTO 3649 300 mcg/kg|A single dose of 300 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
45405961|NCT03631732|Drug|Third Agent|"Any one of the following third agents will be administered as prescribed. Protease inhibitors and EVG will be administered with the appropriate pharmacologic booster cobicistat or ritonavir. :~Non-nucleoside reverse transcriptase inhibitors (NNRTIs)~delavirdine (DLV)~efavirenz (EFV)~nevirapine (NVP)~rilpivirine (RPV)~doravirine (DOR)~Integrase inhibitors~dolutegravir (DTG)~elvitegravir (EVG)~raltegravir (RAL)~Protease inhibitors (PIs)~atazanavir (ATV)~darunavir (DRV)~lopinavir (LPV)~nelfinavir NFV)~saquinavir (SQV)~tipranavir (TPV)~Chemokine co-recptor 5 (CCR5) antagonist --maraviroc (MVC)"
45405962|NCT03732508|Drug|Irinotecan liposome|Irinotecan liposome intravenous infusion will be administered during the first day of treatment.
45405963|NCT03732508|Drug|SHR-1316|SHR-1316 intravenous infusion will be administered during the first day of treatment.
45405964|NCT03732508|Drug|Fluorouracil|Fluorouracil intravenous infusion will be administered during the first day of treatment.
45405965|NCT03732430|Drug|IBI308|A humanized anti-PD-1 monoclonal antibody
45514594|NCT02224118|Drug|Placebo|Matching Placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
45514595|NCT04415684|Device|Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)|For the right/test eye, a defocused image is projected onto the peripheral retina while the subject views a distant, in-focus image
45514596|NCT04415684|Device|No Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)|For the left/control eye, no image is projected onto the peripheral retina. The subject views a distant, in-focus image.
45514597|NCT02229422|Drug|GA101/HDMP|"All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:~On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.~On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.~On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.~On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.~All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:~•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered."
45514598|NCT02232308|Drug|Nizatidine|Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
45514599|NCT02232308|Drug|Lisinopril|Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
45405966|NCT03630016|Diagnostic Test|Pulse oximetry with Owlet BabySat v1.0 sensor|A comparative, single-center, non-randomized study to evaluate the SpO2 accuracy guidelines for pulse oximetry over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison with Owlet BabySat v1.0 and Owlet Smart Sock 2 sensors
45405967|NCT03628924|Drug|Guselkumab dose 1|Participants will receive guselkumab dose 1 IV.
45405968|NCT03628924|Drug|Guselkumab dose 2|Participants will receive guselkumab dose 2 SC in Group 1, 2 and Group 3.
45405969|NCT03628924|Drug|Guselkumab dose 3|Participants will receive guselkumab dose 3 SC in Group 3.
45405970|NCT03628924|Drug|Placebo|Participants will receive matched placebo SC and IV in group 1, 2 and 3 with an additional placebo SC dose in Group 3.
45405971|NCT03738982|Device|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
45405972|NCT03735706|Radiation|Radiation dose reduction|The radiation dose is is different between groups
45514600|NCT02232308|Drug|Placebo|Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
45514601|NCT02232386|Drug|Ibrutinib|Ibrutinib (PCI-32765) 420 mg (3 x 140 mg capsules) will be administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis.
45514602|NCT02232386|Drug|Rituximab|Rituximab 375 mg/m2 iv. Month 1: day 1 of weeks 1, 2, 3, 4; months 2-6: day 1of week 1.
45514603|NCT02229500|Dietary Supplement|Inulin|
45851484|NCT01279122|Device|Nanoflex IOL|Patients who were implanted with the Nanoflex IOL
45405973|NCT03735706|Other|Contrast media volume reduction|Contrast media volume is different between groups
45405974|NCT03735706|Radiation|Unenhanced slice|One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.
45405975|NCT03735706|Diagnostic Test|Weight|A weighing scale is used to measure a patients body weight right before the scan.
45405976|NCT03735550|Device|Contact thermographic breast examination device|A class 2a medical device being an active non-invasive multiple-use thermographic contact tester that uses a technology of passive liquid crystal matrices placed in the head of the device that records a thermographic image of breast glands with application of these matrices to the examined organ. The examination is non-invasive.
45405977|NCT03738748|Other|Ultrasound- guided Percutaneous Neuromulation|The experimental group will be treated with percutaneous neuromodulation using a needle with Physio Invasive® device, in its modality of percutaneous electrostimulation for 15 minutes, and guided by ultrasound equipment in the multifidus muscles of L-3, once a week for 4 weeks.
45405978|NCT03738748|Other|TENS Therapy|The control group will apply a transcutaneous treatment with surface electrodes with TENS current at 170 Hz for 15 minutes in the L-3 region, once a week for 4 weeks.
45405979|NCT03627832|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, & Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
45405980|NCT03627832|Behavioral|Sleep Hygiene|All participants will receive a one-page handout on sleep hygiene. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
45514604|NCT02229500|Dietary Supplement|2.5 g of propionate|This system delivers approximately 2.5 g of propionate to the colon in a 10g dose.
45514605|NCT02229500|Dietary Supplement|5 g of propionate|This delivers approximately 5g of propionate to the colon per 10g dose
45514606|NCT02229734|Radiation|Radiation|Radiation: Radiotherapy 7 gray (Gy) per week over 5 weeks (35Gy)
46057393|NCT05156775|Other|Rhomboid intercostal nerve block (RIB)|In the rhomboid intercostal nerve block (RIB) group, the patient will be placed in a lateral position with the affected breast at the top. The ipsilateral arm will be extended to the same level as the ipsilateral chest and breast, and the scapula will be moved outward. On the oblique sagittal plane, a high frequency (6-12MHz) linear ultrasound probe will be placed on the medial edge of the scapula. The US landmarks, trapezius muscle, rhomboid muscle, intercostal muscles, pleura, and lung will be identified. Under the aseptic condition, a 22-gauge needle will be inserted in the plan to the US probe at T5 to T6 levels. Then, 0.25% bupivacaine (30 mL) will be injected into the inter-fascial plane between the rhomboid major muscle and the intercostal muscle, the diffusion of bupivacaine in the fascia between the rhomboid muscle and the intercostal muscle will be visualized. Then, the patient will be positioned in supine position.
45405981|NCT00112437|Drug|Odanacatib|Odanacatib 3 mg, once weekly for 24 months
45405982|NCT00112437|Drug|Odanacatib|Odanacatib 10 mg, once weekly for 24 months
45405983|NCT00112437|Drug|Odanacatib|Odanacatib 25 mg, once weekly for 24 months
45405984|NCT00112437|Drug|Odanacatib|Odanacatib 50 mg, once weekly for 24 months
45405985|NCT00112437|Dietary Supplement|Vitamin D3|Vitamin D3, two 2800 IU weekly throughout the study
45405986|NCT00112437|Dietary Supplement|Calcium Carbonate|Participants who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.
45405987|NCT00112437|Drug|Placebo|Placebo to Odanacatib 3 mg, 10 mg, 25 mg, or 50 once weekly for 24 months
45405988|NCT03735472|Device|Thoraflex™ Hybrid|"The Thoraflex™ Hybrid device is particularly suited to the treatment of extended lesions of the ascending aorta, the aortic arch and the descending aorta, which constitute a major challenge in cardiovascular surgery.~It enables, during a single surgical operation, combination of the Frozen Elephant Trunk technique and a 4-branch prosthesis of the aortic arch, thus enhancing the arsenal of the surgeon in the treatment of complex diseases of the aortic arch."
45514607|NCT02229734|Drug|Androgen Suppression|Leuprolide 45mg every 6 months for a total of 18 months
45514608|NCT02224196|Other|manual ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
45514609|NCT02224196|Other|pressure-controlled ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
45514610|NCT02258516|Behavioral|CHIME 3-M|behavioral intervention for self-management in heart failure
45405989|NCT03738592|Other|behavioral exploration of spatial hearing performances|"Normal hearing children and cochlear implant children will have to localize a sound source in three dimensional space by using a virtual reality system (Neuro immersion platform). The experiment will last thirty minutes.~For normal hearing children, this experience will be performed at the inclusion visit.~For cochlear implant children, this experience will be performed 28 days (+/- 2 days) after inclusion."
45405990|NCT03738592|Other|The Speech, Spatial and Qualities of Hearing Scale (SSQ) questionnaire (for cochlear implant children and their parents)|"For cochlear implant children and their parents, a SSQ questionnaire will be given and completed during the first visit (at the inclusion).~This questionnaire offers a version for parents of children with hearing loss (SSQ Parents CI) and a version for the children themselves (SSQ Children CI)."
45405991|NCT03738592|Other|The Speech, Spatial and Qualities of Hearing Scale (SSQ) questionnaire (for parents of CI children)|"The SSQ questionnaire for Parents of CI children is composed of three distinct sections (A, B and C).~Each section will be filled separately by parents of CI children with one of the study collaborators during 3 telephone calls spaced 1 week apart. Thus, section A will be completed 7 days (+/- 2 days) after inclusion , section B 14 days (+/- 2 days) after inclusion, and section C 21 days (+/- 2 days) after inclusion."
45405992|NCT03653416|Device|Ipack|IPACK block - local anesthesia injected safely under ultrasound guidance in the interspace between the popliteal artery and capsule of the knee.
45405993|NCT03653416|Drug|Bupivacaine|20 cc of bupivacaine(o.25%) injection
45405994|NCT03653416|Procedure|Peri Articular Infiltration|Adductor Canal Catheter and Peri Articular Infiltration
45405995|NCT03738514|Other|5% fluorocalcium phosphosilicate dentifrice|dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks
45514611|NCT02258516|Behavioral|attention control|patients will receive phone calls regarding health-related topics not associated with heart failure
45514612|NCT04333160|Drug|JTA-004|Patients will undergo a single intra-articular injection of JTA-004 into the knee joint
45405996|NCT03738514|Other|5% potassium nitrate dentifrice|5% potassium nitrate dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.
45405997|NCT03738514|Other|Placebo dentrifice|placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks
45405998|NCT01076673|Biological|Peripheral blood stem cells and hyaluronic acid injections|Peripheral blood stem cells and hyaluronic acid injections
45699265|NCT03448380|Device|FreeStyle Libre Flash Glucose Monitoring System|Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
45405999|NCT01076673|Drug|Hyaluronic Acid|Hyaluronic acid injections
45406000|NCT00112359|Drug|AZLI 75 mg three times a day (TID)|
45406001|NCT00112359|Drug|Placebo three times a day (TID)|
45406002|NCT01080183|Other|Patient feedback form|patients receive a report that feeds back their patient reported measures to them prior to their clinical visit
45406003|NCT00119379|Drug|NucleomaxX|NucleomaxX 36 grams TID every other day
45406004|NCT00119379|Drug|Tenofovir Disoproxil Fumarate|Switch of thymidine nucleoside reverse transcriptase inhibitors to Tenofovir Disoproxil Fumarate
45406005|NCT00118911|Behavioral|Cognitive behavioral therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
45406006|NCT00118911|Other|Relaxation techniques and education about ADHD|Participants are provided with education about ADHD, instruction in relaxation techniques, and support in applying relaxation techniques to ADHD symptoms.
45406007|NCT01076829|Other|Spice polyphenols|spice
45406008|NCT01080417|Drug|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
45406009|NCT01079481|Drug|taxol plus everolimus|taxol 175mg/m2 every 3 weeks plus everolimus every day. The dose of everolimus will be started from 2.5mg per day, and increasing to 5mg per day and to 10mg per day.
45406010|NCT01076907|Other|Warm water|Warm water loading of sigmoid colon when spasms occur and waiting for them to subside.
45514613|NCT04333160|Device|Hylan G-F 20|Patients will undergo a single intra-articular injection of Hylan G-F 20 into the knee joint
45406011|NCT01076907|Other|Control|Air will be used instead of warm water for unsedated colonoscopy.
45406012|NCT03965169|Procedure|Prone spinal surgery|spinal surgery in prone position under general anesthesia
45514614|NCT04333160|Other|placebo|Patients will undergo a single intra-articular injection of placebo into the knee joint
45514615|NCT02224352|Device|Functional neuromuscular electrical stimulation|
45514616|NCT04778774|Procedure|Nerve block|Two different nerve block types, Adductor canal block group and Femoral nerve block group
45514617|NCT02224430|Device|schizophrenia/schizoaffective disorder.|Participants with schizophrenia/schizoaffective disorder will be observed remotely and at weekly/biweekly laboratory visits over a period of 16 weeks or until relapse occurs.
45514618|NCT02258906|Drug|ulinastatin|
45514619|NCT02258906|Drug|normal saline|
45514620|NCT02258984|Device|Mespere Venus 1000 Non-Invasive CVP System|The Venus 1000 CVP System is a non-invasive central venous pressure measurement system that utilizes the proven science of NIRS. Approved by FDA, received Health Canada Medical Device Licence and CE Marked, the Venus 1000 has been proven to be clinically equivalent to measurements made via right heart catheterization.
45514621|NCT04325906|Device|high flow nasal cannula (HFNC)|HFNC will be initiated at 50 L/min (AIRVO2 or Optiflow, Fisher &Paykel Health care Limited., Auckland, New Zealand) with temperature set at 37 oC. Nasal cannula size will be determined by the patient's nostril size (≤ 50%). FIO2 will be adjusted to maintain SpO2 at 92% to 95%. Flow and temperature will be adjusted based on patient's comfort and clinical response.
45699266|NCT03443388|Device|Hövding inflatable helmet|The Hövding inflatable helmet is designed for cyclists as a collar with a deployable airbag that inflates when a sensor detects rapid changes in acceleration. The inflated helmet wraps the back and sides of the user's head in inflated nylon fabric which then slowly deflates after deploying.
45851485|NCT01279278|Other|Co-signed letter|Patients receive a personalized letter co-signed by their general practitioner and the medical coordinator of ADECA.
45851486|NCT01279278|Other|Classical Letter|Patients receive classical letter signed by the coordinator doctor of ADECA
45406013|NCT03964779|Diagnostic Test|Hormonal assay|Measurement of Thyroid stimulating hormone
45406014|NCT03964779|Diagnostic Test|Antibody assay|antithyroglobulin and antithyroid peroxidase
45406015|NCT00131937|Drug|sorafenib tosylate|Given orally
45406016|NCT03964701|Other|no intervention|no interventional study
45406017|NCT01079559|Device|Simplex™ P with Tobramycin|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
45406018|NCT01079559|Device|Simplex™ P|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
45406019|NCT01079637|Procedure|Surgery with Midfoot Fusion Bolt|Surgery with Midfoot Fusion Bolt
45514622|NCT04325906|Procedure|Prone positioning (PP)|PP will be performed before or 1 hour after meal. Before PP, all the I.V. lines and nasal cannula will be checked by clinicians. PP will be performed by patient under the supervision of clinicians. Assistance will be offered if needed. If tolerated, PP will be maintained for at least 30 minutes, until the patients feel tired to keep that position. PP will be performed twice a day for the first 3 days after the patient's enrollment. FIO2 will be adjusted to maintain SpO2 at 92-95%.
45514623|NCT02229812|Drug|alteplase|
45514624|NCT04222712|Drug|TRS01 eye drops|Dosed four times a day (QID)
45514625|NCT04222712|Drug|TRS01 eye drops|Dosed four times a day (QID)
45514626|NCT02229890|Drug|alteplase|
45514627|NCT02230046|Drug|Abiraterone acetate (Treatment A)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
45514628|NCT02230046|Drug|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
45514629|NCT02230046|Drug|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
45514630|NCT02230202|Other|Flow-mediated dilation|Flow-mediated dilation used to measure vascular function. The test is minimally invasive, with only a slight discomfort due to the inflation of the arm cuff.
45514631|NCT02230202|Other|single blood draw|single blood draw of approximately 45 mL.
45514632|NCT02224586|Device|light treatment|clinical routine treatment according to the doctor's advice
45514633|NCT02224742|Device|LeucoPatch|LeucoPatch® is prepared by centrifuging one or more 18mL aliquots of the participant's venous blood in the LeucoPatch device and bench-top centrifuge. The centrifugation yields a tough layer of fibrin, with viable white cells and platelets, and this is applied directly to the wound surface using sterile forceps. The wound is then covered with an inert primary dressing, secondary protective dressing and the ulcerated area protected with appropriate off-loading. The patch is prepared and applied each week for up to 20 weeks or until the wound is judged healed.
45514634|NCT02224742|Other|Usual care|"Usual wound care provided in a multidisciplinary foot care clinic , in accordance with international guidelines.~Components of usual wound care include:~Formal assessment of ulcer and surrounding skin~Provision of any necessary off-loading~Debridement (i) sharp, (ii) other as appropriate (but excluding the use of larvae)~Appropriate dressing products~Appropriate antibiotic therapy~Nutrition and self care~Optimal glycaemic control~Revascularisation if deemed clinically necessary~Continued close observation"
45514635|NCT03068455|Biological|nivolumab|Specified Dose on Specified Days
45514636|NCT03068455|Biological|ipilimumab|Specified Dose on Specified Days
45514637|NCT03646994|Drug|Crizotinib|Crizotinib Cap 250 mg po bid
45514638|NCT02810444|Biological|IgG Next Generation (BT595)|
45851487|NCT01279434|Drug|Vitamin E plus Pentoxiphyllin|Both drugs will be administered daily Vit E (400 mg BD) and pentoxiphyllin (400 mg TDS) for 12 months
45406020|NCT01079637|Procedure|Cast treatment|Cast treatment
45406021|NCT01080495|Procedure|TEE (transesophageal echocardiography)|a TEE is performed in all study objects and all parameters (radial strain, fractional shortening and fractional area change) are analysed
45406022|NCT00131469|Drug|Teriparatide (FORTEO)|Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily
45406023|NCT00131469|Drug|Placebos|
45406024|NCT00372593|Drug|asparaginase|Given intramuscularly
45406025|NCT00372593|Drug|cytarabine|Given IV
45406026|NCT00372593|Drug|daunorubicin hydrochloride|Given IV over 6 hours
45406027|NCT00372593|Drug|etoposide|Given IV over 1-4 hours
45406028|NCT00372593|Drug|gemtuzumab ozogamicin|Given IV over 2 hours
45406029|NCT00372593|Drug|mitoxantrone hydrochloride|Given IV over 1 hour
45406030|NCT01324583|Drug|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution~Route of administration: intravenous"
45406031|NCT01324583|Drug|prednisolone|"Pharmaceutical form:tablet~Route of administration: oral"
45406032|NCT03992807|Other|A patient decision aid|Potential participants receive a printed decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
45851488|NCT01279434|Drug|Vitamin E|Vitamin E 400 mg BD daily for 12 months
45406033|NCT03992807|Other|A usual education booklet|Potential participants receive a usual booklet about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
45406034|NCT03666988|Drug|GSK3368715|GSK3368715 will be available with dosing strengths of 25 mg, 100 mg and 250 mg to be administered once daily as an oral capsule.
45406035|NCT03666988|Drug|GSK3368715|GSK3368715 will be available in Immediate release (IR) white film coated tablet with dosing strengths of 50 mg, 100 mg and 250 mg to be administered orally once daily .
45406036|NCT00382109|Drug|thiotepa|Given IV
45406037|NCT00382109|Drug|cyclophosphamide|Given IV
45406038|NCT00382109|Drug|tacrolimus|Given IV or orally
45406039|NCT00382109|Drug|methotrexate|Given IV
45514639|NCT02230280|Other|Strengthening Community-Based Stroke Care: A Pilot Study of a Community Navigation and Rehabilitation Intervention that Includes a Mobile Health Solution|Participants will be offered regular in-home visits over the 6-month study period in addition to usual outpatient rehabilitation services. The health care providers will have access to a mobile health application (MYST) to share real-time information and access community resources and best practice guidelines.
45406040|NCT00382109|Drug|sirolimus|Given orally
45406041|NCT00382109|Radiation|total body irradiation|Part of the transplant preparatory regimen
45514640|NCT04209296|Drug|Ketamine Hydrochloride|Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.
45514641|NCT03067987|Device|Low Intensity Linear Shockwave Device for the Treatment of Erectile Dysfunction.|"This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)~."
45514642|NCT02259296|Procedure|Lower eGFR for AVF construction|Lower eGFR patients (eGFR<10ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR<15ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
45699267|NCT03448302|Radiation|Computed tomography perfusion|Pre-contrast images will be obtained to identify the colorectal tumor location. Then Fifty milliliters of iopromide (Ultravist ) will be injected intra-venously at rate of 5 milliliter per second via an automatic pump injector for computed tomography perfusion scans. Computed tomography perfusion scans will be performed at the mid-portion of the tumor for 60seconds beginning 5 seconds after contrast injection. Then arterial input will be defined by using the mouse to place a circular region of interest and the tumor region of interest will be placed on the most enhanced area of the tumor. Tumor blood flow, blood volume, mean transient time & permeability surface measurements will be obtained.
45406042|NCT03640000|Diagnostic Test|Impedance measurements in Cardiac Resynchronization therapy|Bioimpedance measurements
45699268|NCT03443310|Procedure|Ultrasound assessment of DVT|Using Ultrasound in assessing DVT in high-risk patients following hip fracture and major arthroplasty before the patients become symptomatic.
45406043|NCT05665972|Other|Mandala coloring|Each participant will be given 12 colored felt-tip pen paint sets and 12 mandala coloring pages by the researchers. Participants will be asked to dye for 3 menstrual cycles, 14 days before the start of menstruation, 1 day a week, at any time of the day and for an average of 20-30 minutes each time.
45406044|NCT03735394|Diagnostic Test|ultrasonic probe|apply the head of the ultrasonic probe on the keratinized tissue of the most protruded upper and lower central incisor in order to measure tissue thickness.
45406045|NCT03738358|Dietary Supplement|Trehalose|80 mL pouch/day for 12 weeks, containing trehalose 5 g, water 74.92 g and scent additive 0.08 g
45514643|NCT02259296|Procedure|Higher eGFR for AVF construction|Higher eGFR patients (eGFR 10-15ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR 15-20ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
45699269|NCT03955614|Other|pedal-controlled GoSurgeryTM|"Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are controlled by the surgical staff using pedals.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention."
45406046|NCT03738358|Other|Placebo|80 mL pouch/day for 12 weeks, containing water 79.92 g and scent additive 0.08 g
45406047|NCT03651622|Behavioral|Hypocaloric, low carbohydrate diet|Participants will be advised on use of a hypocaloric, low carbohydrate diet using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
45406048|NCT03651622|Behavioral|Hypocaloric, moderate low fat diet|Participants will be advised on use of a hypocaloric, moderate low fat diet using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
45406049|NCT03651622|Behavioral|Mediterranean diet, no caloric restriction|Participants will be advised on use of a healthy Mediterranean-based eating plan using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
45406050|NCT00381797|Biological|Bevacizumab|Given IV
45406051|NCT00381797|Radiation|Fludeoxyglucose F-18|Undergo fludeoxyglucose F18 PET
45851489|NCT01279512|Drug|Metformin|The metformin dose will be 500 mg/ day in the first week, 1000 mg/ day in the second week and 1500 mg/ day for the next 10 weeks.
45406052|NCT00381797|Drug|Irinotecan Hydrochloride|Given IV
45406053|NCT03738124|Device|Valiant Mona LSA Thoracic Stent Graft System|The Valiant Mona LSA device is a modular two-component system consisting of a main stent graft (MSG) and a branch stent graft (BSG), delivered separately, designed to maintain LSA perfusion. Briefly, under general anesthesia and after heparin injection, a MSG access is achieved via a femoral artery. A Through-and-through wire access for delivery of the BSG is achieved via a brachial artery. After the placement of the main aortic stent graft in the arch with the cuff at the level of the ostium of the LSA, the BSG is placed through a femoral access.
45406054|NCT03738046|Behavioral|Cognitive Behavioral Therapy|Group therapy will occur once weekly (60-90-minute sessions) at the HOPE TEAM offices for 24 weeks. The group sessions with consist of 4 skill modules, each of which last 6 sessions. Three of these--the Cognitive, Social Skills, and Problem-Solving Modules-will be modules taken from Cognitive and Behavioral Social Skills Training (CBSST; Granholm McQuaid, & Holden, 2016) and modified for use with CHR adolescents. The fourth module-Stress Coping-will be adapted for this sample from an established group CBT treatment for psychosis (Lecomte, Leclerc, & Wykes, 2016).
45406055|NCT03665038|Drug|Brexanolone|Administered as IV infusion.
45406056|NCT03664024|Drug|Pembrolizumab|Pembrolizumab, 200 mg, Day 1 of each 21-day cycle (Q3W), intravenous infusion (IV), standard of care in most countries
45406057|NCT03664024|Drug|Pemetrexed|Pemetrexed, 500 mg/m^2 infusion, standard of care, Q3W, IV
45406058|NCT03664024|Drug|Carboplatin|Carboplatin AUC 5 mg/mL/min, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
45514644|NCT02232854|Behavioral|Depression training/supervision program|"The intervention will be composed of:~Training of Primary Health Care teams to ensure compliance to the Clinical Guidelines of the Ministry of Health for the Treatment of Depression. Primary Health Care teams will undergo an Objective Structured Clinical Examination (OSCE) for evaluation.~After the training, a focus group between Primary Health Care teams and study researchers will be held in order to address barriers to clinical guidelines implementation.~Primary Health Care clinics' trained administrative staff will contact patients from a call-center to support treatment adherence.~Psychiatrists, using a web-based platform, will supervise the course of the program, the allocated treatments, the patients' progress, and their response to treatment."
45406059|NCT03664024|Drug|Cisplatin|Cisplatin, 75 mg/m^2, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
45406060|NCT03737890|Other|Inspiratory Muscle Training|"Participants in the experimental group were given Inspiratory Muscle Training by using an IMT device. For this training, the inspiratory load for each participant was set at 30 cmH2O.~In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks."
45406061|NCT03737890|Other|Hold Relax Pectoral Stretch|"In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks."
45406062|NCT00381641|Other|Laboratory Biomarker Analysis|Optional correlative studies
45406063|NCT00381641|Other|Pharmacogenomic Study|Optional correlative studies
45406064|NCT00381641|Drug|Sunitinib|Given PO
45514645|NCT04207736|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed in the Environmental Exposure Chamber.
45514646|NCT04207736|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed in the Environmental Exposure Chamber.
45514647|NCT02232932|Procedure|CAPECITABINE-Radiotherapy -Liver Transplantation|CAPECITABINE (800 mg/m2 twice a day during 5 weeks) + External Radiotherapy (50 grays during 5 weeks) then Liver transplantation
45514648|NCT02232932|Procedure|RESECTION|Intent-to-treat R0 liver resection
45514649|NCT02230358|Procedure|Regional anesthesia|Regional anesthesia
45851490|NCT01279512|Drug|Acarbose|Acarbose group will be treated by acarbose (its dose will be 100 mg/day in the first week, 200 mg/ day in the second week and 300 mg/ day for the next 10 weeks).
45406065|NCT00381641|Drug|Sunitinib Malate|Given PO
45406066|NCT00381563|Device|Patellofemoral realigning knee brace|Knee brace that changes the tracking of the patella over the femur bone
45406067|NCT00381563|Device|Non-aligning knee brace|Knee brace that does not change the tracking of the patella over the femur bone
45406068|NCT01045655|Behavioral|MOMCare|8 sessions of brief interpersonal psychotherapy or medication management; maintenance sessions through 12 months postpartum.
45406069|NCT04516733|Other|supportive care|visit with supportiv unit and neuropsychologue every 3 months
45406070|NCT03624946|Biological|Zika Virus Immune Globulin (ZIKV-IG)|Zika Virus Immune Globulin (ZIKV-IG) is a human immune globulin preparation containing neutralizing antibodies to Zika virus.
45406071|NCT03624946|Other|Placebo|Placebo is a normal saline solution (0.9% sodium chloride).
45406072|NCT03735160|Device|pressure sensor|Pressure sensor at the angle of intratracheal tube and nasal alar
45406073|NCT01310218|Other|extended postoperative dressing|2 weeks of bulky dressing
45406074|NCT01310218|Other|short postoperative dressing|2 days bulky dressing followed by bandaid
45406075|NCT03732274|Drug|TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) at the same time in the morning and evening (BID) approximately 12 hours apart. Durvalumab will be administered as a dose of 1500 mg every 4weeks.
45406076|NCT03735082|Drug|Apatinib|apatinib 250mg,qd,d1-14,14day/cycle
45406077|NCT03735082|Drug|Paclitaxel|paclitaxel 175mg/m2,d1,14day/cycle+carboplatin AUC=4,d1,14day/cycle
45406078|NCT03735082|Drug|Carboplatin|carboplatin AUC=4,d1,14day/cycle;
45514650|NCT02230358|Procedure|General anesthesia|General anesthesia
45514651|NCT02230358|Device|Transcranial Doppler ultrasonography|6x for 4 hours
45514652|NCT02230358|Procedure|blood gas analysis|6 x 3 ml blood withdrawal (18 ml) within 4 hours
45514653|NCT02230358|Procedure|invasive arterial blood pressure measurement|before operation, 8 hours, as done in clinical routine
45514654|NCT02230358|Procedure|arterial blood gas measurement|perioperative, 4-6 times within 8 hours, as done in clinical routine
45514655|NCT02230358|Behavioral|Neurological Control|perioperative, 2-3 days, as done in clinical routine
45514656|NCT02230358|Behavioral|NIRS monitoring|perioperative, for 5 hours, as done in clinical routine
45514657|NCT02230358|Device|oxygen supply (not invasive 'Vigileo')|perioperative for 5 hours, as done in clinical routine
45851491|NCT01279668|Drug|Montelukast|10mg tablets, once per day for 28 days.
45406079|NCT00381095|Drug|Pregabalin|Capsule, Flexible-dosing, Double-blind. Treatment duration is 28 days at 100-600 mg/day administered BID+ taper (6 days).
45406080|NCT00381095|Drug|Placebo|Placebo
45514658|NCT02230436|Other|Early drain removal|Removing drain(s) on postoperative day 3
45514659|NCT02230436|Other|Late drain removal|Removing drain(s) on postoperative day 4 or later
45514660|NCT02230514|Drug|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue in association with open surgery"
45514661|NCT02230514|Other|autologous iliac crest|Autologous iliac crest in association with surgery
45514662|NCT02230514|Procedure|Surgery|Standard surgery for non-union fractures
45514663|NCT04132466|Device|Defibrillation using the ASSURE wearable cardioverter defibrillator therapy delivered via a waveform delivery test system|defibrillation using a 170 joule biphasic truncated exponential waveform designed for the ASSURE wearable cardioverter defibrillator
45514664|NCT02233010|Other|The level of NGAL after pre op,post op 4hr, post op 12hr|
45514665|NCT04098848|Other|Cycling exercise|Intradialytic cycling exercise for 30 minutes a time
46057394|NCT00611793|Drug|PTK787/ZK222584 and Bevacizumab|PTK787/ZK222584 will be administered as a single agent orally on days 1-14 of cycle 1. The day 14 dose of PTK787/ZK222584 will be administered in the outpatient clinic and PK samples will be obtained. On Day 15 the patient will receive the initial dose of IV bevacizumab and PTK787/ZK222584. Bevacizumab will be repeated at 2 week intervals in patients with stable disease or better for four cycles of treatment (16 weeks). After four treatment cycles, only patients with a PR or CR will continue treatment with PTK787/ZK222584 and bevacizumab. Patients with stable disease may continue single agent PTK787/ZK22258 from cycle 5 onward. Protocol treatment will continue until disease progression or intolerable toxicity warrants drug discontinuation.
46057395|NCT02709213|Diagnostic Test|Diagnostic|Determination of pathogens and faecal calprotectin in the stools
45514668|NCT03518138|Drug|Q-122|oral capsule of Q-122
45514669|NCT03518138|Drug|Placebo|oral capsule of placebo
45514670|NCT04066634|Device|Vivio System|The Vivio Analysis Software is an analysis software that assists in identifying suspected systolic murmurs associated with aortic stenosis. The Vivio Analysis Software is used with the Vivio System, a non-invasive device used for the detection and amplification of sounds from the heart and arteries.
45514671|NCT03494504|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered once.
45514672|NCT03494504|Drug|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) administered once.
45514673|NCT03494504|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered once.
45514674|NCT04049864|Biological|DNA vaccine|conjugate of plasmid DNA with linear polyethylenimine 20 kDa (PEI) One dose includes 400 µg of DNA and 500 µg of PEI.
45514675|NCT04049864|Biological|Salmonella oral vaccine|suspension 10^10 CFU of an attenuated Salmonella enterica serovar typhimurium strain (SS2017) containing the plasmid of the corresponding DNA vaccine.
45514676|NCT04049864|Drug|Lenalidomide|Lenalidomide is prescribed in a dose of 25 mg / day in a course of three weeks starting 7 days before the first vaccination course and ending on the day of the last vaccination course.
45514677|NCT03475706|Drug|Solabegron immediate release tablets, low dose|twice daily for 12 weeks.
46057396|NCT03821337|Device|repetitive Trans Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that is able to alter cortical excitability and is FDA-approved to treat Major Depressive Disorder. Magnetic fields pass unimpeded through the scalp, skull and meninges, and can directly excite cortical areas.
45514678|NCT03475706|Drug|Solabegron immediate release tablets, high dose|twice daily for 12 weeks.
45514679|NCT03475706|Drug|Matching Placebo|twice daily for 12 weeks.
45514680|NCT04035200|Drug|V117957 tablets|V117957 tablets taken orally at bedtime
45514681|NCT04035200|Drug|Placebo|Tablets to match V117957
45514682|NCT03997838|Drug|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
45514683|NCT03997838|Drug|Placebo|IV infusion of 0 mg of VVZ-149
45514684|NCT05003180|Procedure|Surgical stabilization|The surgical stabilization can be either open or minimally invasive. The recommended procedure is posterior fixation with pedicle screws and rods. Both short and long segment fixation are allowed in the study. It is up to the treating surgeon to decide on fusion or decompression. If feasible, pedicle screws are inserted in the fractured vertebra.
45514685|NCT03986138|Drug|gadopiclenol|Single intravenous bolus injection
45514686|NCT03986138|Drug|Gadobutrol 1 MMOLE/ML Intravenous Solution|Single intravenous bolus injection
45514687|NCT02234336|Procedure|Noncontrast echocardiography|
45514688|NCT02234336|Procedure|Contrast Echocardiography|
45514689|NCT02234336|Procedure|Cardiac magnetic resonance imaging|
45514690|NCT02234492|Drug|Rosuvastatin|Comparison of rosuvastatin to no rosuvastatin
45514691|NCT01529996|Procedure|Pulse Dye Laser/YAG laser|This study involves treatments with two types of lasers, Pulsed dye lasers (PDL) and the 1064 nm Nd: YAG. Both lasers are FDA approved to treat vascularities in the skin.
45514692|NCT03933410|Drug|KB195|KB195 is a novel glycan
45514693|NCT04950842|Biological|JB-101|induced T cell with suppressive function
45514694|NCT03303170|Device|Sebacia Microparticles|Topical microparticle suspension
45514695|NCT03303170|Device|Nd:Yag Laser|Laser delivering 1064 nm wavelength light
45514696|NCT03290534|Device|CivaSheet|implanting CivaSheet for localized radiation dose delivery
45514697|NCT03928184|Drug|Lorecivivint|Healthcare professional-administered intra-articular injection; performed on Day 1
45514698|NCT03928184|Drug|Placebo|Healthcare professional-administered intra-articular injection; performed on Day 1
45514699|NCT02259374|Procedure|TAP BLOCK 0.2% ROPIVACAINE|Patients randomised to this group will receive 20 ml 0.2% Ropivacaine for bilateral TAP block after hysterectomy
45514700|NCT02259374|Procedure|TAP BLOCK 0.4% ROPIVACAINE|Patients randomised to this group will receive 20 ml 0.4% Ropivacaine for bilateral TAP block after hysterectomy
45514701|NCT03204422|Other|No intervention|no any other intervention
45514704|NCT03197870|Drug|AKB-9778|Subcutaneous AKB-9778 15mg
45514705|NCT03197870|Drug|Placebo|Subcutaneous Placebo
45406081|NCT03619174|Device|Viveve Treatment|The Viveve system is a monopolar radiofrequency system that uses surface cooling and radiofrequency (RF) energy delivery to provide a non-surgical and minimally-invasive approach to generate heat within the submucosal layers of vaginal tissue while keeping the surface cool.
45514706|NCT04921982|Drug|Propranolol|Oral administration of Propranolol, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse once a week for six consecutive weeks.
45406082|NCT05665894|Device|Hematoma Vaacum Assisted Biopsy|The patient was placed supine and meticulous aseptic measures were applied. Prior procedure local anesthesia (lidocaine 1%) was administered following disinfection. A 5 mm skin incision is performed to guarantee appropriate access for the needle insertion in the hematomas. The evacuation was achieved using a Mammotome® vacuum-assisted system (Devicor Medical Products, Inc., Cincinnati, OH, USA), with an 8-G needle, under the guidance of the same high-resolution US equipment (MyLabTM 9 XP; Esaote SpA, Genoa) for preoperative assessment. Empty-needle function and the tissue-biopsy option is preferred to fragment the fibrotic tissue until the hematoma empties and its walls collapsed. Once VAEv is performed, the postoperative US is carried out and VAEv is repeated until more than 90% evacuations of hematoma volume if no complication occurs.
45406083|NCT03737656|Drug|Progesterone vaginal ring|Vaginal ring with 2.0 g progesterone (sustained-release over 90-days)
45514707|NCT04921982|Drug|Placebo|Oral administration of Placebo, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse, once a week for six consecutive weeks.
45406084|NCT00112047|Drug|Emtricitabine (FTC)|Capsule containing 200 mg FTC, taken once daily, for 96 weeks
45406085|NCT00112047|Drug|Tenofovir Disoproxil Fumarate (TDF)|Tablet containing 300 mg TDF, taken once daily, for 96 weeks
45406086|NCT00112047|Drug|Efavirenz (EFV)|Tablet containing 600 mg EFV, taken once daily, for 96 weeks
45406087|NCT00112047|Drug|FTC/TDF|Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg, once daily, from Week 96 to 144
45406088|NCT00112047|Drug|FTC/TDF/EFV|Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg, taken once daily, from Week 144 to 240
45406089|NCT00112047|Drug|Lamivudine/zidovudine|Fixed-dose combination tablet containing lamivudine 150 mg/zidovudine 300 mg, taken twice daily, for 240 weeks
45406090|NCT03737578|Other|Delivery of a connected pedometer / accelerometer|"Delivery of a connected pedometer / accelerometer that the patient will be asked to wear at least 7 consecutive days / month.~Quality of life and leg restless syndrome questionnaires (auto questionnaire) completed by the patients every 3 months"
45514708|NCT04889222|Device|INVSENSOR00050|Noninvasive pulse oximeter sensor
45514709|NCT04889222|Device|RD SET SpO2|Noninvasive pulse oximeter sensor
45514710|NCT04874324|Drug|WCK 2349 Oral|1 dose given orally twice daily at 12 hourly interval for five days.
45514711|NCT04874324|Other|Placebo Oral|Subjects will receive matching placebo
45514712|NCT04866056|Drug|Jaktinib|Jaktinib PO BID
45514713|NCT04866056|Drug|azacitidine|Azacytidine SC
45514714|NCT03911102|Biological|DaxibotulinumtoxinA for injection|Intramuscular injection
45514715|NCT04789148|Drug|Oxytocin nasal spray|4 IU intranasal oxytocin, 24 IU intranasal oxytocin or placebo
45514716|NCT03892772|Drug|SAS0421a|treatment will be given for 3 days
45406091|NCT03658876|Drug|Iron Sucrose Solution for Injection|200mg iron sucrose given on 5 successive haemodialysis sessions
45406092|NCT03658876|Drug|Epoetin Beta|Uptitration of epoetin beta dose. Scale as follows (in units /session): 0-1000-2000-3000-4000-6000-8000-12000
45406093|NCT03618628|Device|Carbon Fiber Off Loading Orthosis (CFO)|A finite element (FE) model will be created to determine properties that will improve CFO strength while maintaining reduction of peak plantar pressures of the CFO and plantarflexor power. A new CFO will then be fabricated for the participant. Participants will be tested in while walking barefoot, wearing their current CFO, and wearing the FE model driven CFO.
45406094|NCT03734926|Drug|ZSP1241|ZSP1241 tablets for oral administration.
45406095|NCT03617770|Behavioral|Sleep Opt-In|8-week intervention that includes a wearable sleep tracker, didactic content, smartphone application and counseling
45406096|NCT03617770|Behavioral|Healthy Living|8-week intervention that includes weekly telephone counseling on healthy living.
45406097|NCT03734848|Drug|Bilateral Ultrasound Guided Pectoralis Nerve Block.|Using a 20-gauge 5 cm needle. Injection bupivacaine 0.25% used as a local anesthetic. The block was performed in a supine position with the arm slightly abducted. The ultrasound probe was placed at the midclavicular level infero-laterally to locate the axillary artery and vein and then moved laterally toward the axilla until pectoralis major, pectoralis minor, and serratus anterior muscles were identified at the level of the fourth rib. The needle was inserted in-plane with respect to the ultrasound probe. A volume of 20 ml of local anesthetic solution was deposited in the fascial plane between pectoralis minor and serratus anterior muscle, followed by withdrawal of the needle to the fascial plane between the pectoralis major and pectoralis minor muscle, where a volume of 10 ml was deposited. The block was performed similarly on the opposite side. Care was taken not to cross the toxic dose of bupivacaine (3 mg/kg).
45406098|NCT03639922|Drug|Imatinib 400mg|2 tablets of Imatinib 400mg per day for 6 days
45406099|NCT03639922|Drug|Placebo Oral Tablet|2 tablets of placebo per day for 6 days
45514717|NCT03892772|Drug|SAS0421b|treatment will be given for 3 days
45514718|NCT03892772|Drug|SAS0421c|treatment will be given for 3 days
45514719|NCT03892772|Drug|placebo|placebo will be given for 3 days
45514720|NCT03172910|Drug|Ciraparantag|Ciraparantag (administered over 10 minutes)
45514721|NCT03172910|Drug|Placebo|Saline for injection
45406100|NCT03616600|Other|Breath-O-Correct Lens|Breath-O correct lenses are new designed ready-made orthokeratology lenses which are made of new material with more elasticity as compared traditional lens material
45406101|NCT03734614|Drug|Low dose of aspirin|Low dose of aspirin, 100 mg daily for longer than one year
45406102|NCT00380393|Biological|GSK malaria vaccine 257049 Vaccine|3 dose intramuscular injection
45406103|NCT00380393|Biological|Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine|3 dose intramuscular injection
45406104|NCT01046747|Procedure|Placement of external fixation pins|The fractures will be treated according to standard of care. If the external fixation is to be used as a staging procedure, then this will be removed and an internal fixation procedure will be performed. The pin sites will be checked daily according to standard of care. All individuals involved in the examination of the pin sites will receive a standardized training in the grading of pin tract infection and loosening. Each pin site will be graded individually by three persons to evaluate internal accuracy of our grading. Pin tract infections will be first graded as yes or no, and then graded according to the Modified Joglekar Classification (Grade 0-4, Grade 0: no erythema, no drainage; Grade 1: erythema, no drainage OR no erythema with serous drainage; Grade 2: erythema, serous drainage; Grade 3: erythema, purulent drainage; Grade 4: gross pin loosening). Pin loosening will be evaluated at the time of pin removal and graded as either yes or no.
45514722|NCT03172910|Drug|Rivaroxaban|Rivaroxaban 20 mg given once per day (QD) in the morning
45406105|NCT00380081|Drug|zolpidem tartrate sublingual tablet 3.5mg|Zolpidem tartrate sublingual tablet 3.5 milligram administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
45406106|NCT00380081|Drug|zolpidem tartrate sublingual tablet 1.75mg|Zolpidem tartrate sublingual tablet 1.75 milligram administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
45406107|NCT00380081|Drug|Placebo|Placebo sublingual tablet administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
45514723|NCT04684940|Biological|Valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
45514724|NCT03881852|Drug|AXS-12 (Reboxetine)|Dosed orally, twice daily for up to 3 weeks
45406108|NCT03579940|Drug|Lasmiditan|Administered orally.
45514725|NCT03881852|Drug|Placebo|Dosed orally, twice daily for up to 3 weeks
45406109|NCT03579940|Drug|Placebo|Administered orally.
45406110|NCT03729934|Dietary Supplement|Ketone Ester|This arm receives 25 g ketone ester.
45406111|NCT03729934|Dietary Supplement|Ketone Salt|This arm receives 25 g ketone salt.
45406112|NCT03732040|Other|miswak stick|miswak stick use as preventive hygiene measures
45514726|NCT03818828|Biological|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B.
45514727|NCT03818828|Other|Profore Compression Therapy|Subjects will utilize the compression system for the duration of the trial, with weekly re-applications of the compression system during study visits
45514728|NCT03818828|Other|Cadexomer Iodine dressing|During the 2-week Screening Run-in period, subjects should be applied cadexomer iodine on the VLU.
45514729|NCT03124862|Device|ARM sensor|Acoustic Monitoring sensor that monitors respiratory rate
45514730|NCT02804282|Combination Product|sc2Wear Furosemide|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
45514731|NCT03789656|Drug|Paltusotine|Paltusotine, capsules, once daily by mouth
45406113|NCT03732040|Other|Miswak plus tooth brushing and tooth paste|use of miswak stick with tooth brushing and fluoride toothpaste for oral hygiene measures
45406114|NCT03732040|Other|Standard preventive measures (tooth brushing , interdental cleaning and mouth rinse use containing CHX and Fluoride)|use toothbrush with fluoride toothpaste and interdental cleaning by dental flossing and use mouth wash containing chlorohexadine
45406115|NCT00098306|Drug|Maraviroc (UK-427,857)|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
45406116|NCT00098306|Drug|Optimized Background Therapy|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
45514732|NCT00974870|Procedure|needling treatment|Needling treatment applied to half of the face at each study visit
45514733|NCT02233244|Drug|CTX-4430|
45406117|NCT00098306|Drug|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy [OBT (3-6 drugs based on treatment history and resistance testing)] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
45406118|NCT00098306|Drug|Placebo|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy [OBT (3-6 drugs based on treatment history and resistance testing)] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
45406119|NCT00098306|Drug|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy [OBT (3-6 drugs based on treatment history and resistance testing)] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment.
45406120|NCT03615040|Drug|MSTT1041A|"MSTT1041A (RO7187807; formerly made by Amgen [AMG] and referred to as AMG 282) is a novel biopharmaceutical that blocks signaling of interleukin (IL)-33, an inflammatory cytokine of the IL-1 family and member of the newly discovered alarmin class of molecules. IL-33 is released from airway epithelial cells in response to allergens, irritants, and infection. IL-33 release can trigger acute exacerbations in both asthma and COPD. MSTT1041A has the ability to block inflammation,prevent exacerbations, and improve lung function and quality of life.~Anti-ST2 is presented as sterile, clear, and colourless to slightly yellow liquid. Each sterile vial is filled with a 1 mL deliverable volume of 70 mg/mL. It is formulated with 15 mM sodium acetate, 9.0% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 5.2."
45406121|NCT03615040|Drug|Placebo|Placebo for Anti-ST2 (MSTT1041A) is formulated with 10 mM sodium acetate, 9.0% (w/v) sucrose, 0.004% (w/v) polysorbate 20, pH 5.2, and is supplied in an identical vial configuration.
46057397|NCT03821337|Device|Sham TMS|Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of TMS, combined with a TENS device which produces a small electric shock mimicking the feeling of real rTMS. This type of sham has been demonstrated to be indistinguishable from real rTMS, has been well tolerated (George et al., 2010; George et al., 2014) and successfully used in other clinical trials (Borckardt et al., 2008; Arana et al., 2008). During each session of rTMS the investigators will present a series of opioid related images, including those utilized in previous studies (Garland et al., 2015; Garland & Howard, 2014).
46057398|NCT00611871|Drug|Propranolol|40mg propranolol, followed 2 hrs after with 60mg propranolol, immediately following memory recollection
46057399|NCT00611871|Drug|Placebo|40mg placebo, followed 2 hrs after with 60mg placebo
46057400|NCT02709447|Behavioral|Date SMART|Skills-based, group prevention program targeting emotion regulation and interpersonal skills using a cognitive-behavioral framework.
46057401|NCT02709447|Behavioral|Health Promotion|Psycho-educational group prevention program targeting knowledge and skills only
45406122|NCT02531204|Drug|ASP1585|oral
45406123|NCT00068822|Device|Percutaneous vertebroplasty|Placement of polymethylmethacrylate (PMMA) into vertebral compression fracture
45851492|NCT01279668|Drug|Placebo|tablets, once per day for 28 days.
45406124|NCT00068822|Procedure|Sham vertebroplasty|Participants, following local anesthesia with lidocaine and bupivacaine, were given verbal and physical cues such as pressure on the back, but the needle was not placed.
45406125|NCT03964064|Radiation|Stereotactic Radiotherapy|"GTV: Combining localization and fusion images to delineate the tumors seen PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 80-100 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 60-80 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).~Normal Tissue Limit: Reference to TG101 Report"
45406126|NCT03964064|Radiation|3D-printing Template-assisted CT-guided I125 Seed Implantation|CT-guided radioactive 125I particle therapy with 3D printing template for pancreatic cancer Preoperative planning Design and fabrication of 3D-PNCT Particle implantation Postoperative dose assessment: CT scan was performed after operation, and the image was transmitted to BTPS for dose verification . The dosimetric parameters included tumor volume, D90, mPD, V100, V150 and V200.
45514734|NCT02233244|Drug|Midazolam|
45514735|NCT02259530|Behavioral|Integrated Psychotherapeutic Intervention|Evidence-based standard tools for the treatment of PTSD and comorbid khat dependence: Community Reinforcement Approach, Relapse Prevention, Narrative Exposure Therapy
45851493|NCT01279746|Device|Ultrasound compression of femoral and popliteal veins|Bedside ultrasound compression of femoral and popliteal veins.
45851494|NCT01279902|Drug|Rituximab plus CHOP Immunochemotherapy|The R-CHOP treatment will continue up to 3 cycles with interval of 21 days: Each cycle consists of rituximab 375mg/m2 (iv, on day 1), cyclophosphamide 750 mg/m2 (iv, on day 1), doxorubicin 50mg/m2 (iv, on day 1), vincristine 1.4mg/m2 (iv, on day 1), and prednisolone 100mg (po, on day 1-5).
45851495|NCT01279044|Behavioral|Adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)|The individualized, cognitive counseling intervention was designed to help participants address the self-justifications-beliefs, thoughts, and attitudes-that they employed in the setting of high-risk sexual behavior, in the company of an empathic counselor.
46057402|NCT02709291|Behavioral|behavioral parent training|Parents receive up to 6 sessions of the Family Check-Up program
46057403|NCT02709291|Behavioral|interventionist training|Interventionists are trained in the delivery of the Family Check-Up program and deliver sessions to families in their community
45851496|NCT01279044|Behavioral|Standard HIV testing with information only|Standard HIV testing with information only
45851497|NCT01278342|Drug|Sandostatin LAR|40 mg intramuscular (i.m.) every 28 days for 3 months
46057404|NCT02693301|Other|Exercise program|
45514736|NCT02234648|Dietary Supplement|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
45514737|NCT02234648|Other|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
45514738|NCT02234726|Behavioral|Early Childhood Development Program|"A cadre of community-based health workers, Child Development Agents (CDAs), have four main tasks and responsibilities: 1) biweekly screening and management (including referral) of acute malnutrition in children; 2) encouragement of caregivers to utilize routine care services for children; 3) screening for symptoms of acute diseases and referral for diagnosis and treatment; and 4) organization and mentoring of weekly meetings for caregivers to discuss parenting issues and promote early childhood cognitive stimulation.~Amendment: during second year extension, CDAs are responsible for organizing and mentoring biweekly (i.e., fortnightly) caregiver meetings. They no longer conduct household visits."
45406127|NCT01090778|Drug|Norditropin SimpleXx (growth hormone)|3mg/subject/day over two consecutive days
45406128|NCT00068588|Biological|GTI-2040|Given IV
45406129|NCT00068588|Drug|capecitabine|Given orally
45406130|NCT01088126|Procedure|radiofrequency catheter ablation|radiofrequency catheter ablation, NavX system
45406131|NCT01088204|Procedure|laparoscopy assisted distal gastrectomy|laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
45406132|NCT01088204|Procedure|open distal gastrectomy|open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
45406133|NCT01088282|Procedure|Cataract surgery|Implantation of multifocal or monofocal IOL
45406134|NCT03963752|Drug|Ziyinxiehuo Granules Herbs|1 pack of Ziyinxiehuo granules Herbs is administered after dissolved, 2 times per day after a meal.
45406135|NCT03963752|Drug|Megestrol Acetate Tablet|the dose is 6-8mg/d, three times per day after meals.
45406136|NCT03963752|Drug|Leuprorelin Acetate 3.75mg Injection|Usage： 80μg/kg by subcutaneous injection, every 4 weeks
45406137|NCT01081808|Biological|EGFRBi-armed autologous activated T cells|EGFRBi-armed autologous activated T cells infused twice a week for 4 weeks for a total of 8 infusions. The doses of the armed ATC will be escalated at the dose levels of 5, 10, 20, and 40 billion armed ATC per infusion. Subcutaneous aldesleukin (300,000IU/m2/day) and Sargramostim (250 ug/m2 twice per week) both starting 3 days before the 1st infusion and ending 7 days after the last dose of armed ATC.
45406138|NCT03650452|Drug|TAK-935|TAK-935 tablets or mini-tablets.
45406139|NCT03650452|Drug|Placebo|TAK-935 placebo-matching tablets or mini-tablets.
45514739|NCT02234804|Device|Xience Prime Stent|
45406140|NCT03729856|Behavioral|intervention|The adapted physical activity (APA) intervention is a theory-based physical activity (PA) promotion intervention. The APA model is comprised of 4 steps: 1) pre-participation evaluation of physiological, personal and environmental factors that influence PA adoption and maintenance; 2) application of individualised, evidence based strategies associated with increased PA participation tailored to the participant's motivational readiness; 3) development of structured exercise and/or lifestyle PA program; and 4) tailored relapse prevention strategies to maintain physical activity beyond the duration of the program. The intervention will be conducted in the participant's home environment.
45406141|NCT03729856|Other|B|Participants will undertake their usual activities during the baseline period. An extended pre-intervention time frame is needed to establish a stable control phase and enhance internal validity.
45406142|NCT03729856|Other|Follow-up|Participants will have no contact with intervention personnel during the 5 week follow-up, withdrawal period. The withdrawal phase enables initial assessment of physical activity behavior change.
45406143|NCT03734458|Other|Group A - PRF plus AFG with a CAF|Group A - PRF plus AFG with a CAF will be used surgically to cover the exposed roots.
45406144|NCT03734458|Other|Group B - PRF only with a CAF|Group B - PRF only with a CAF will be used surgically to cover the exposed roots.
45406145|NCT03734458|Other|Group C - CTG with a CAF|Group C - CTG with a CAF will be used surgically to cover the exposed roots.
45406146|NCT03731962|Procedure|Coronary Angiography|All patients received approximately 60 mL of intra arterial iodinated contrast material that was administered via computer-controlled automated power injector at 4 mL per second.
45406147|NCT03734380|Behavioral|Laboratory-based gait retraining (LGR)|Subjects in the LGR group will be encouraged to modify the gait pattern (e.g. adjusting foot progression angle, performing medial knee thrust, and/or lateral trunk lean) to lower their KAM to 80% of respective average baseline KAM obtained during normal unmodified gait. Real-time auditory feedback will be delivered using stereo speakers from both sides of the staircase. A middle C (261.6 Hz) tone and a high-pitched C (4186.0 Hz) of equal intensity will be generated at a footfall below and above the targeted 80% value, respectively. They will be advised to maintain their new gait pattern during their daily living after training.
45514740|NCT02234804|Device|Medtronic Resolute Integrity stent|
45514741|NCT02234804|Procedure|Angiography|
45514742|NCT02234804|Procedure|OCT|
45514743|NCT02234882|Drug|Rosuvastatin|
45514744|NCT02234882|Drug|BMS-663068|
45514745|NCT05627726|Device|PelviSense-assisted pelvic floor muscle training group|The PelviSense consists of a high-precision, oval-shaped, wearable EMG sensor that displays electrical activity measured in PFMs on the user's mobile device. The reusable, wearable EMG sensor is non-invasive and can be attached to the user's perineal region. The mobile app provides real-time muscular feedback, displayed as EMG waveforms in microvolts. The mobile app can store data for up to 7 days, allowing participants to monitor their progress over the last 7 days in a graphical format.
45514746|NCT05627726|Other|Active comparator|Pelvic floor muscle training (PFMT) alone group: Women allocated to the PFMT alone group will perform unassisted PFMT. Exercise parameters, technique, and progression will be similar to those for the PelviSense-assisted PFMT group, but exercises will be performed without the PelviSense.
45514747|NCT03729362|Drug|AT2221|Participants received ATB200 co-administered with AT2221 (Miglustat)
45514748|NCT03729362|Biological|alglucosidase alfa|alglucosidase alfa via intravenous infusion as prescribed by the participant's treating physician and in accordance with the approved prescribing information via intravenous infusion as prescribed by the participant's treating physician and in accordance with the approved prescribing information
45514749|NCT03729362|Biological|ATB200|Enzyme Replacement Therapy via intravenous infusion
46057405|NCT02709525|Drug|hyaluronic acid|
45514750|NCT02234960|Drug|Tocilizumab|Tocilizumab will be given according to summary of product characteristics as per clinical practice.
45514751|NCT02235038|Behavioral|Low carbohydrate diet|Composition (by proportion of calories) : 15% carbohydrate, 65% fat, 20% protein
45406148|NCT03734380|Behavioral|Sensor-based gait retraining (SGR)|Subjects in the SGR group will receive training similar to LGR, except the KAM measurement is based solely on inputs from IMUs embedded in the shoes. In addition, the auditory feedback will be delivered through a pair of earphones connected to a smartphone, which has been pre-installed with an app for KAM measurement. They will be advised to maintain their new gait pattern during their daily living after training.
45406149|NCT03734380|Behavioral|Walking exercise control (Ctrl)|Subjects in the Ctrl group will walk on the same instrumented staircase at a self-selected pace without any guidance on gait modification. The training period and training time per session will be identical to the other two groups. They will not be given any instructions for out-of-lab activities.
45406150|NCT03734302|Drug|Brexpiprazole|Brexpiprazole , mutiple dose /oral/empty stomach
45514752|NCT02235038|Behavioral|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
45514753|NCT02235038|Behavioral|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
45514754|NCT02235116|Other|Survey|
45514755|NCT03727334|Behavioral|Online Spatial Navigation Training|Participants complete training tasks that test their spatial navigational abilities, cognitive map formation, and pattern separation. These training tasks involve map drawing, vector mapping, proximity judgments, and navigating with blocked routes.
45514756|NCT03727022|Drug|Placebo|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
45851498|NCT01278342|Drug|pegvisomant|Weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for 4 months given with Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months
45406151|NCT03729700|Other|Almond|The almond dose will be provided as 20% of total energy (20% E) in the diet.
45406152|NCT01310296|Drug|Lofexidine hydrochloride|Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
45406153|NCT01310296|Drug|Lofexidine hydrochloride|Single Dose = 200 μg lofexidine in phosphate-buffered saline administered intravenously via infusion pump at a rate of 1 μg/min for 200 min
45406154|NCT03734146|Behavioral|Aerobic Exercise|180 minutes of moderate-vigorous intensity aerobic exercise per week
45406155|NCT03734146|Behavioral|Resistance Exercise|180 minutes of resistance exercise per week
45699270|NCT03955614|Other|ML-controlled GoSurgeryTM|"Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are projected onto screen based on the machine learning algorithm's determination of current operative step.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention."
45851499|NCT01278342|Drug|cabergoline|"Weekly cabergoline for 4 months, with weekly doses of Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months. Cabergoline doses as follows:~st week: 0.25 mg twice a week (0.50 mg/week)~nd week: 0.50 mg/week twice a week (1 mg/week)~rd week: 0.50 mg four times a week (2 mg/week)~th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)"
45406156|NCT03734146|Behavioral|Combined aerobic and resistance exercise|180 minutes of exercise per week with 90 minutes per week coming from moderate-vigorous intensity aerobic exercise and 90 minutes per week coming from resistance exercise
45514757|NCT03727022|Drug|SM04690|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
45514758|NCT02259452|Procedure|SPECT Lung Perfusion Scan|
45514759|NCT02259452|Procedure|SPECT Heart Perfusion Scan|
45514760|NCT02259452|Procedure|Pulmonary Function Tests|
45514761|NCT02259686|Drug|Apelin 1mg subcutaneous|single subcutaneous injection of Apelin 1mg subcutaneous
45514762|NCT02259686|Drug|Apelin 1mg intravenous|15 minute intravenous bolus of Apelin 1mg intravenous
45514763|NCT02259686|Drug|Apelin 5mg subcutaneous|single subcutaneous injection of Apelin 5mg subcutaneous
45514764|NCT02259686|Drug|Apelin 5mg intravenous|15 minute intravenous infusion of Apelin 5mg intravenous
45514765|NCT02259686|Drug|Apelin 10 mg subcutaneous|24 hour continuous subcutaneous infusion of Apelin 10 mg subcutaneous
45514766|NCT02259764|Drug|KUC 7483 CL - single rising dose|
45699271|NCT03955614|Other|NoGo|The operating theatre environment is recorded to observe baseline teamwork.
45699272|NCT01203826|Biological|Asfotase Alfa|
46057406|NCT02709525|Other|Placebo|
45699273|NCT03943836|Behavioral|Music|Patients in the music group will listen to classical music during their dental procedure.
45406157|NCT05665816|Device|Stent PULSAR® -18 T3,|"Post-authorization, prospective and multicenter registry to evaluate the clinical results of the PULSAR® -18 T3 stent, in the treatment of de novo or restenotic lesions of the superficial femoral and/or popliteal artery, primarily as salvage, in a population of patients residing in Spain and in real life conditions."
45406158|NCT03731884|Other|Time from the onset of symptoms to PCI|Patients will be divided in two groups according to the time from the onset of symptoms to PCI
45406159|NCT03729622|Other|Low FODMAP Diet|Both arms will receive the intervention but at different time points.
45406160|NCT03729466|Other|clinical pilates|The intervention group will be performed in clinical pilates 45 to 60 minutes twice a week for 8 weeks.
45406161|NCT03734068|Device|Chemoembolization Using LifePearl|Chemoembolization Using LifePearl
45406162|NCT03734068|Drug|Doxorubicin|Doxorubicin is loaded to LIfePearl
45406163|NCT03575806|Combination Product|TACE plus autologous Tcm immunotherapy|"TACE:transcatheter arterial chemoembolization.~Autologous Tcm immunotherapy: to collect patient's own immune cells and then given back to the patient after amplified in vitro."
45406164|NCT03575806|Procedure|TACE|TACE:transcatheter arterial chemoembolization.
45514767|NCT02259764|Drug|Placebo|
45406165|NCT03610048|Drug|ALKS 5461|samidorphan + buprenorphine administered sublingually
45514768|NCT02259764|Other|standardized high fat meal|
45514769|NCT02233322|Dietary Supplement|Iron|All subjects will receive iron supplementation based on iron levels in the blood
45406166|NCT03733912|Other|Phthalate metabolites measurement|To measure phthalate metabolites of urine and house dust in Pregnancy and Non-pregnancy groups
45699274|NCT03448146|Drug|Para-Toluenesulfonamide|
45699275|NCT03011008|Drug|Liraglutide|Dose escalation of liraglutide starts from 0.6 mg up to 1.2 mg per day.
45699276|NCT03011008|Drug|Insulin|Receive insulin following clinician's instruction.
45699277|NCT03443232|Procedure|Cryoballoon ablation|Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice. According to the objective condition, the operator determine whether or not to carry out an additional cryoablation. Then we will applicate electrophysiological substrate mapping for guiding ablation of atrial fibrillation,If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
45699278|NCT03443232|Procedure|Radiofrequency ablation|Each patient randomly allocated into the radiofrequency ablation group receives circumferential pulmonary vein isolation(CPVI),The default strategy is to create a circle surrounding the two ipsilateral pulmonary veins.We will mapping the left atrial subtrate. If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
45406167|NCT03608254|Other|100% watermelon juice|Participants consumed a one-time dose of 100% watermelon juice. Blood was sampled before and 2 hours after ingestion. Blood pressure and brachial artery flow-mediated dilation were measured before and 2 hours after ingestion.
45514770|NCT02233400|Drug|Acetaminophen|Group 1 (treatment) will receive IV acetaminophen (intervention drug) (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
45514771|NCT03067441|Drug|bempedoic acid|bempedoic acid 180 mg tablets taken orally, once per day.
45514772|NCT03687632|Biological|ST266|1X ST266 applied in a dose of one drop (30-50 µL) in the study eye for 28 days (112 doses total will be administered).
45514773|NCT02235194|Dietary Supplement|Amino Acid and chromium-picolinate containing drink|Amino Acid and chromium - picolinate containg water ist taken with a test meal to study efects on glucose and insulin response.
45514774|NCT02235194|Dietary Supplement|Placebo Drink|Placebo drink ist taken with a test meal to study efects on glucose and insulin response.
45514775|NCT03684278|Drug|Infusion of 5 mg/kg Infliximab|Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
45514776|NCT03684278|Drug|Infusion of 10 mg/kg Infliximab|Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
45514777|NCT03684278|Other|0.9% Sodium Chloride (Placebo)|250 ml (500 ml if patient weighs over 100 kg) of 0.9% Sodium Chloride
45514778|NCT02726659|Drug|Celecoxib|Adjunct celecoxib
45514779|NCT02726659|Drug|Placebo|Adjunct placebo
45514780|NCT03660878|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered four times a day and an additional four times a day on an as needed basis.
45699279|NCT04983732|Drug|FL-101-Intravenous|150 mg administered via the IV route
45699280|NCT04983732|Drug|FL-101-Subcutaneous|150 mg administered via the SC route
46057407|NCT05087589|Drug|Tofacitinib|Tofacitinib 5mg was taken orally twice a day for 6 months
45514781|NCT03660878|Drug|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) administered four times a day and an additional four times a day on an as needed basis.
45514782|NCT03660878|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered four times a day and an additional four times a day on an as needed basis.
45406168|NCT03733756|Procedure|POEM preserving longitudinal muscle|participants are operated POEM only involving circular muscle, leaving longitudinal muscle intact
45406169|NCT03733756|Procedure|POEM involving longitudinal muscle|participants are operated POEM involving both circular and longitudinal muscle
45406170|NCT03731728|Behavioral|Group CBT|"All therapists will use a manualized Cognitive-Behavior Therapy (CBT) protocol with the same handouts and schedule developed based on the book Mind Over Mood. Group CBT will be provided to a group of maximum 10 participants. Each session will be 2 hours long and will be provided by certified therapists with special training to deliver group CBT. The structure of the session will be agenda setting, check-in, review of homework, new concepts/skills, homework assignment, and feedback."
45406171|NCT03731728|Behavioral|Group exercise|Participants enrolled in the group exercise plus TAU arm of the study will be wait-listed for TAU and will receive 50 minutes of scheduled and facilitated exercises three times a week for 14 weeks.
45406172|NCT03606460|Drug|Ocrelizumab Dose 1|300 mg infusion administered to ocrelizumab-naive participants per approved protocol (over approximately 2.5 hours or longer) as per standard of care followed by a second 300 mg shorter infusion over approximately 1.5 hours.
45406173|NCT03606460|Drug|Ocrelizumab Dose 2 and Dose 3|600 mg infusion of ocrelizumab administered at a shorter rate (i.e. over the course of approximately 2 hours) at Week 24 and at Week 48
45699281|NCT04452396|Device|use of continuous glucose monitoring|Patients will wear a CGM device whilst undergoing diagnostic testing for reactive/spontaneous hypoglycaemia and then optimisation of anti-hypoglycaemic medication.
45406174|NCT03729310|Device|Propel 'implant'|The Propel 'implant' is composed of small, flexible tubes which dissolve while releasing Mometasone which is one type of steroid. This application has been approved for use by the FDA.
45514783|NCT05197543|Diagnostic Test|Biomechanical rupture risk assessment|3D computational model is created from CT angiographic images available during standard AAA diagnostic process. Vascular wall stress is assessed based on the 3D model using Finite element method to identify highly stressed parts of AAA and results are compared to populational wall strength information (gathered from previous large histological study), thus rupture risk (stress/strength ratio) of each particular AAA is estimated. Other relevant factors such as gender, blood pressure, presence of intraluminal thrombus etc. are used during the calculation as well.
45514784|NCT04452578|Procedure|Procedure: Heart Transplantation|A HCV negative or previously successfully treated recipient who recieves a HCV positive graft will be monitored. Patients who recieve an HCV graft will be treated for HCV according to accepted protocols.
45514785|NCT05190211|Other|Telerehabilitation exercise program|TGr will be given online exercises, synchronized 2 days a week, and a home program for 1 day, accompanied by a physiotherapist, via videoconference on the group smartphone.
45699282|NCT04452552|Other|healthy diet|balanced diet program which ranged from 1600 kcal to 2000 kcal/day, which was calculated in an individual basis for each woman according to her basal metabolic rate (BMR) for 8 weeks
45699283|NCT01157416|Drug|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
45699284|NCT01157416|Drug|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of the 12-session CBT protocol.
45699285|NCT01157416|Behavioral|CBT|12-session CBT protocol, called Youth PTSD Treatment.
45699286|NCT03443154|Diagnostic Test|VF-Test|A vaginal fluid test of interleukin-6 (IL-6) and alphafetoprotein (AFP).
45699287|NCT01206478|Drug|Amitriptyline|Amitriptyline 1 mg/kg once daily at bedtime.
45851500|NCT01278030|Procedure|3D echo-guided LV lead placement|Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on RT3DE will be available to the physician from the core lab analysis. This location will be used as the target for optimal LV lead placement.
45699288|NCT01206478|Drug|Placebo|Placebo (looks like study drug but has no active ingredients) once daily at bedtime.
45699289|NCT01206478|Drug|Megestrol|At Visit 2, after participating in the study for ten weeks, children will receive a prescription for the appetite stimulant megestrol. The dose each child will receive depends on their age and weight. The dose of megestrol is 6 mg/kg divided into two doses per day.
45406175|NCT03729310|Drug|Triamcinolone|Triamcinolone has been approved for use topically elsewhere on the body, although the specific use of Triamcinolone in the sinuses has not been approved by the FDA.
45406176|NCT03729310|Device|Nasopore|"This packing' is a sponge-like material which dissolves while releasing triamcinolone."
45699290|NCT04963530|Procedure|Treatment with monolithic zirconia restorations|Treatment with monolithic zirconia restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
45406177|NCT05666440|Procedure|Visco-Circumferential-Suture-Trabeculotomy in Primary Open Angle Glaucoma.|A superior limbal-based conjunctival flap and a paracentesis. A superficial rectangular scleral flap 4×4 mm was fashioned and dissected forward toward the limbus. A deep sceral flap (2×2 mm) was then created toward the limbus underneath the superficial flap exposing the scleral spur and deroofing SC. Viscoelastic (Healon GV, Pfizer, NY) was injected (using a standard 30 G viscocanalostomy cannula) into the ostia of SC Then, the 5/0 polypropylene suture tip was cauterized into a blunt tip (to ensure atraumatic probing of SC). The tip was inserted into the left ostium of SC using a microsurgical forceps and advanced through the whole circumference of the canal. When the tip presented to the right ostium the AC was filled with a viscoelastic through the paracentesis and traction was applied to approximate both ends of the 5/0 polypropylene suture, thus creating a visco-360-degree trabeculotomy.
45406178|NCT05666440|Procedure|Rigid probe Viscotrabeculotomy in Primary Open Angle Glaucoma.|A fornixbased conjunctival incision followed by creation of a partial thickness (about 50% thickness) triangular (4×4×4 mm) scleral fap, followed by localization of Schlemm's canal by radial incisions straddling the limbus. High viscosity sodium hyaluronate (Healon GV, Pfzer) was then slowly injected into both ends of Schlemm's canal. Trabeculotomy was completed using the standard Harm's trabeculotome (Geuder Instruments), the scleral fap was then secured tightly with interrupted 10/0 Nylon sutures and conjunctival closure ensued.
45514786|NCT05190211|Other|Videobased exercise program|After 1 session of online simultaneous exercise training in the company of a physiotherapist via videoconference on the smart phone, an exercise video including the exercises will be sent to them and the patients will be asked to do their exercises 3 days a week. The subjects will be asked to keep an exercise diary and the status of the diaries will be followed by calling them once a week.
45406179|NCT03729076|Other|Crystalloid|Patients will receive the rapid co-loading with plasma solution A (PSA) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.
45406180|NCT03729076|Other|Colloid|Patients will receive the rapid co-loading with 6% volulyte (HES in acetated electrolyte) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.
45406181|NCT03728998|Other|Passive leg raise (PLR)|"A PLR will simulate an autotransfusion of 250-300 cc.~1. Starting in semi-succumbed position (45 degree head-up)~2. PLR is performed by lowering head-end and putting a for this purpose designed device of 45 degrees under the patients legs. The PLR is non-invasive."
45406182|NCT03728998|Other|Clearsight non-invasive hemodynamic monitoring system|3 baseline readings will be done for CO, CI, SV and SVR, separated by one minute intervals. Subsequently, the standardized passive leg-raise test will be performed and measurements of CO, CI, SV and SVR will be repeated at 30, 60, 90 and 120 seconds. Then the patient is repositioned to his original position, and after two minutes another reading of CO, CI, SV and SVR is done. Then all patients will receive a fluid challenge of 500cc natriumchloride 0.9% IV, considered as normal treatment/ common practice in our ED. 120 seconds after finishing the fluid challenge the final reading of CO, CI, SV and SVR is done.
45514787|NCT04446962|Drug|Lenalidomide|Patients will receive 4 cycles of induction chemotherapy with R-MPV + Lenalidomide using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
45514788|NCT04446962|Drug|Ibrutinib|Patients will receive 4 cycles of induction chemotherapy with R-MPV + Ibrutinib, using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
45514789|NCT03951961|Drug|Midostaurin|50mg Midostaurin bid for 12 months
45699291|NCT04963530|Procedure|Treatment with lithium disilicate restorations|Treatment with lithium disilicate restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
45406183|NCT03733522|Procedure|Rubber dam isolation|Local anesthesia, use of dental clamp and rubber dam, followed by restoration using universal adhesive system and bulkfill composite restoration
45406184|NCT03733522|Procedure|Relative isolation|No local anesthesia, use of cotton rollers and saliva ejector, followed by restoration using universal adhesive system and bulkfill composite restoration
45406185|NCT03731650|Procedure|maxillary sinus lift|non grafted maxillary sinus floor augmentation with simultaneous implant placement
45406186|NCT03605836|Drug|Centanafadine SR|100 mg, BID, oral tablets
45406187|NCT03605836|Other|Placebo|BID, oral tablet
45406188|NCT03605836|Drug|Centanafadine SR|200 mg, BID, oral tablets
45406189|NCT03605680|Drug|Centanafadine SR|100 mg, BID, oral tablets
45514790|NCT03940105|Behavioral|Packout|Each packout provided during 3 of the 4 snack patterns will contain a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. There are 3 different packouts that will be provided for 3 nonconsecutive weekdays (for a total of 9 packouts). Each packout contains the same calories and types of foods. However, they differ in packaging size and variety.
45514791|NCT02232542|Drug|Duloxetine - low dose|
45514792|NCT02232542|Drug|Duloxetine - high dose|
45514793|NCT02232542|Drug|Placebo|
45514794|NCT02620033|Behavioral|Yoga therapy|
45514795|NCT02235350|Other|Action Observation Treatment (AOT)|Participants will be asked to carefully observe at a computer screen videos depicting different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes. As a whole, therefore, each video will be 12 minutes long. At the end of each motor act presentation, participants will be required to execute with the affected hand the observed motor sequence for 2 minutes. Each single rehabilitation session based on AOT will last 20 minutes. We will record ten daily actions for a total of ten video-clips. Participants will be presented with each video clips, twice a day, in order of complexity as judged by the experimenter. Participants will undergo 10 sessions a week, each lasting 20 minutes for 2 weeks.
45699292|NCT04963530|Procedure|Treatment with metal ceramic restorations|Treatment with metal ceramic restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
45699293|NCT04963530|Procedure|No intervention|No intervention.
45699294|NCT01158820|Drug|Dexmedetomidine load|Dexmedetomidine 1 µg/kg prior to bronchoscopy
45699295|NCT01158820|Drug|Ketamine load|Ketamine 30 mg bolus prior to bronchoscopy
45699296|NCT01158820|Drug|Midazolam load|2 mg bolus prior to bronchoscopy
45699297|NCT01158820|Drug|Fentanyl load|50 µg bolus prior to bronchoscopy
45514796|NCT02235350|Other|Observation of videos with no motor content (MNO)|Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
45406190|NCT03605680|Other|Placebo|BID, oral tablet.
45406191|NCT03605680|Drug|Centanafadine SR|200 mg, BID, oral tablets
45406192|NCT03728764|Other|Preterm infant formula|Preterm infants will receive Stage 1 investigative product as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive stage 2 preterm formula from when 1.8 kg of body weight is achieved until 1 month after hospital discharge.
45406193|NCT03733288|Behavioral|Education and training sessions|Agents will be invited to attend sessions in intervention week 1, 3, 9, and month 6. Sessions will introduce (week 1) and reinforce (week 3, 9, month 6) the intervention aims, benefits of and ways to move more and sit less, with emphasis on active breaks. Feedback from baseline assessment will be provided and discussed in week 3 (health data) and 9 (activity data) and month 6 (health and activity data from the 12-week assessment). Each session will include discussion of daily standing/walking goals set by the research team, with timers and a goal log provided to participants in week 1 to enable self-monitoring. The Stand Up champions, and their role to encourage daily movement and sitting reduction through modelling and verbal support, will be communicated and reinforced in each session.
45406194|NCT03733288|Behavioral|Support emails|Agents will receive support emails weekly (weeks 1-12) then monthly (months 4-9) across the intervention. Each email includes an infographic that encourages moving more and sitting less at work.
45406195|NCT03733288|Behavioral|Team leader training|Team leaders in the participating organisation will be invited to attend a training session before the intervention starts. The training aims to enhance team leader's capabilities to demonstrate positive movement and sitting behaviours at work and promote call agents to sit less and move more at work. Team leaders will be asked to include the intervention as an agenda item in their weekly team meetings with their call agents and their 1:1 sessions with call agents. Team leaders will be encouraged to incorporate walking into their 1:1 meetings with call agents.
45406196|NCT03733288|Device|Height-adjustable workstation|After baseline, agents in the SLAMM+ arm will have a height-adjustable workstation installed on their existing workplace desk. This will enable work in a seated or standing position, with flexibility to alternate between postures. Desk installation will occur with support from the onsite organisation health and safety team. The research team will brief participants on safe and effective workstation use. A laminated sheet will be fixed to each workstation to remind participants of safe and effective use.
45406197|NCT03728686|Other|Different given time|Fentanyl 2mcg/kg (F) was given at either 1,2,3 minutes before intubation
46057408|NCT00741091|Device|Carotid WALLSTENT Monorail Endoprosthesis|A carotid artery stent for use in subjects at high risk for adverse events from Carotid endarterectomy (CEA) due to either anatomic or comorbid conditions who require carotid revascularization in the treatment of ipsilateral or bilateral carotid artery disease.
46057409|NCT00741091|Device|FilterWire EZ™ System™|Embolic protection device used in conjunction with the Carotid WALLSTENT Endoprosthesis.
45514797|NCT05181787|Diagnostic Test|Proteomics|Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
45514798|NCT05181787|Diagnostic Test|Metabolomics|Metabolomic data were obtained by UPLC-QTOF/MS platform.
45514799|NCT04348136|Drug|JR-141|IV infusion, 2.0 mg/kg/week
45699298|NCT01158820|Drug|Dexmedetomidine maintenance|0.5 µg/kg/hour for the duration of bronchoscopy (58.5 minutes average)
46057410|NCT02708979|Other|University exam-period|This visit takes place one week prior to an exam at the university assuming that students will be stressed in this period.
45514800|NCT04318886|Behavioral|ENABLE Cornerstone|The ENABLE (Educate, Nurture, Advise, Before Life Ends) Cornerstone intervention is led by a specially-trained lay coach who is overseen by an interdisciplinary outpatient palliative care team, who employs health coaching techniques and caregiver distress assessment to behaviorally activate and reinforce psychoeducation on managing stress and coping, getting and asking for help, improving caregiving skills, and decision-making/advance care planning over 6 brief in-person/telephonic sessions plus monthly follow-up from diagnosis through early bereavement.
45699299|NCT01158820|Drug|Ketamine maintenance|8 µg/kg/min for the duration of bronchoscopy (58.5 minutes average)
45699300|NCT01158820|Drug|Midazolam demand|0.5 mg demand bolus at discretion of pulmonologist
45699301|NCT01158820|Drug|Fentanyl demand|12.5 µg demand bolus at discretion of pulmonologist
46057411|NCT02708979|Other|University non-exam-period|This visit takes place several weeks post and prior to an exam at the university assuming that students will not be stressed in this period.
46057412|NCT00611949|Other|Geranium oil|2 applications of topical oil per week for 2 weeks
45406200|NCT03728530|Other|Deep Breathing exercises|"In pursed lip exercise subject was guided to inhale through nose with mouth closed and exhale through pressed lips (pursed lips).~In Diaphragmatic breathing subject was instructed to place his one hand below the rib cage and the other hand on chest. The patient inhaled slowly so that stomach moves out against the hand. Tighten the stomach muscle while exhaling through pursed lip.~In powered breathing subject was to inhale and exhale forcefully with some movements like subject was instructed to inhale forcefully while moving his hands upward and exhale forcefully while moving hands downward.~These three exercise techniques were advised to each subject of experimental group. They have to practice these exercises 3-4 times a day with 10 repetitions each. These exercises can be performed in sitting position or in supine lying position. Subject can adopt any position in which he feels comfortable."
45406201|NCT03728452|Procedure|Trophic Nutrition|"According to previously published studies of Trophic Nutritions in critically ill patients, an energy goal of 20-30% estimated caloric needs of 20-30 kcal / kg and a protein intake of 1.2 to 2.0 g / kg / day of proteins will be established. at most 72 hours after the start of nutritional therapy.~The rhythm of initiation and increase of enteral contributions will be at the discretion of each participating ICU. Prokinetic or parenteral nutrition (PN) complementary will not be used routinely, leaving its indication at the discretion of the responsible physician.~A hyperproteic nutritional formula (10 g / 100 ml) will be used, with a caloric intake of 1.2 kcal / ml and a non-protein kcal / nitrogen ratio of 52: 1. TN will be administered over 23 hours each day by continuous infusion pump. The head of the patient's bed will rise above 30° as much as possible to reduce the risk of aspiration. The Gastric Residue Volume (GRV) will be measured every 24 hours."
45406202|NCT03728374|Drug|Anlotinib|Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle)
45514801|NCT04310462|Other|New e-prescribing interface|The goal of this study is to conduct a pragmatic trial to assess the utility of a new e-prescribing (eRX) interface for prescriptions of hydroxychloroquine (HCQ). Through randomization of clinicians to the new interface, the investigators will measure the effectiveness of the system in reducing the number of individuals prescribed HCQ over current guidelines.
45514802|NCT04306250|Procedure|Apical prolapse fixation - anterior access|The surgery is done in anterior access
45514803|NCT04306250|Procedure|Apical prolapse fixation - posterior access|The surgery is done in posterior access
45514804|NCT02600923|Drug|Palbociclib|Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1).
45514805|NCT02600923|Drug|Letrozole|Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
45514806|NCT05539196|Device|Exablate Pallidotomy, Unilateral|Unilateral pallidotomy using focused ultrasound for the treatment of Parkinson's Disease with medication-refractory moderate to severe motor complications.
45514807|NCT05761171|Procedure|Biospecimen Collection|Undergo collection of blood and bone marrow samples
45514808|NCT05761171|Drug|Calaspargase Pegol-mknl|Given IV
45514809|NCT05761171|Drug|Cytarabine|Given IV and IT
45514810|NCT05761171|Procedure|Echocardiography|Undergo ECHO
45514811|NCT05761171|Drug|Fludarabine Phosphate|Given IV
45514812|NCT05761171|Drug|Hydrocortisone Sodium Succinate|Given IT
45514813|NCT05761171|Drug|Methotrexate|Given IT
45514814|NCT05761171|Procedure|Multigated Acquisition Scan|Undergo MUGA scan
45514815|NCT05761171|Drug|Pegaspargase|Given IV
45699302|NCT01158820|Drug|Benadryl demand|25 mg bolus after 6th and 13th demand midazolam/fentanyl bolus
45406203|NCT03728296|Biological|islet body|Transplanting islet bodies under the diaphragm
45514816|NCT05761171|Drug|Prednisolone|Given PO or via NG, NJ, ND or G-tube
45514817|NCT05761171|Drug|Prednisone|Given PO or via NG, NJ, ND or G-tube
45514818|NCT05761171|Drug|Revumenib|Given PO or via NG, NJ, ND or G-tube
45514819|NCT05761171|Drug|Vincristine Sulfate|Given IV
45514820|NCT02232776|Drug|Losartan|Dose of Losartan : 0.7mg/kg once daily.
45514821|NCT05496140|Behavioral|CLS-R-FUERTE|The CLS-R-FUERTE program is a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). It contains the same evidence-based service components to improve youth attention/behavior as the in-person CLS-FUERTE program; specifically, it features school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
45514822|NCT03847519|Drug|ADXS-503|A live attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit T cell responses against shared tumor antigens commonly found in patients with squamous and non-squamous NSCLC.
45514823|NCT03847519|Drug|Pembrolizumab|a programmed death receptor-1 (PD-1)- blocking antibody.
45699303|NCT03707028|Drug|Rivoceranib|Film-coated tablet
45406204|NCT03572218|Behavioral|BWL|The BWL sessions will be based on the Diabetes Prevention Program (DPP) manual. A diet of 1200-1499 calories per day will be prescribed for participants < 250 lb, and 1500-1800 for those ≥ 250 lb. Participants will be instructed to eat a balanced deficit diet. Session topics during the first 12 weeks will include self-monitoring, stimulus control, slowing eating, social support, cognitive restructuring, portion sizes, and goal-setting. Those during weeks 13-26 will focus on continued self-monitoring and skills required for weight loss maintenance and relapse prevention. Physical activity will be prescribed at a level consistent with data showing that >250 min/wk is associated with improved long-term weight loss. BWL sessions will last 60 minutes.
45406205|NCT03572218|Behavioral|BIAS|Following 60 minutes of BWL treatment, the BIAS intervention will devote 30 minutes to stigma-related content. Session topics will include: psychoeducation about weight and weight stigma; challenging myths and cognitive distortions related to weight; strategies for coping with instances of stigma; and increasing empowerment and body esteem. The effects of weight stigma on health behaviors will be discussed, and sessions will focus specifically on helping participants overcome stigma-related barriers to weight management. In the every-other-week and monthly weight loss maintenance sessions from weeks 13-26, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies in the context of weight management.
45514824|NCT02221687|Dietary Supplement|Synbiotic formula|Standard milk formula enriched with a prebiotic fiber and a probiotic strain
45406206|NCT03728218|Device|Contact lenses (Orthokeratology)|Contact lenses
45406207|NCT03728218|Device|Contact lenses (Soft Multifocal)|Contact lenses
45406208|NCT03731494|Biological|Nickel oral hyposensitization treatment|Nickel oral hyposensitization treatment (NiOHT) was performed with hard gelatin capsules containing Nickel sulphate (NiSO4) at different dosages (0.1 ng, 1 ng, 10 ng, 0.1 μg, 0.5 μg) and microcrystalline cellulose as excipient (TIO Nickel, Lofarma SpA, Milan, Italy). Treatment was given 3 times a week increasing progressively the dose from 0.1 ng to 3 μg in 10 weeks with a maintenance phase of 1,5 μg a week for a period of 12 months. After 6 months, patients were allowed to gradually reintroduce nickel-rich foods, starting with those with a maximum of 100 mcg of nickel content. For all the treatment period, information on the appearance of side effects or more severe adverse reactions and the need for antiallergic drugs (corticosteroids, antihistamine drugs) were collected.
45406209|NCT00111813|Drug|vorinostat|Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
45514825|NCT02221687|Dietary Supplement|Control formula|Standard milk formula without pre and probiotic
45514826|NCT02235428|Drug|Ipratropium bromide|
45514827|NCT02235428|Drug|Placebo|
45514828|NCT02235428|Drug|Salbutamol|
45514829|NCT02235506|Procedure|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
45514830|NCT02235506|Procedure|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
45514831|NCT02235506|Device|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
45514832|NCT02235506|Device|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
45514833|NCT03070171|Drug|dabigatran etexilate|single dose
45514834|NCT02262572|Drug|Telmisartan /HCTZ - compression tablet (DC)|
45514835|NCT02262572|Drug|Telmisartan /HCTZ - dry granulation tablet (DG)|
45514836|NCT02262572|Drug|Telmisartan /HCTZ - present commercial formulation|
45514837|NCT02235584|Drug|Dexamethasone|Dexamethasone are given dexamethasone tablets of 2mg twice daily.
45514838|NCT05174377|Diagnostic Test|CT-scan algorithm|CADx model was developed with a Support Vector Machine (SVM) algorithm and trained using five-fold cross-validation
45514839|NCT02235662|Drug|TFV IVR|
45514840|NCT02235662|Drug|TFV/LNG IVR|
45514841|NCT02235662|Other|Placebo IVR|
45514842|NCT05167981|Other|RETAINWORKS|The experimental group is eligible to receive the full set of RETAINWORKS intervention activities. The program includes a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Participants receive intensive case management and care coordination by health and employment services RTW navigators. Financial incentives are offered to participants and medical providers for milestone attainment and training achievement.
45514843|NCT02262650|Drug|Telmisartan|
45514844|NCT02262650|Drug|Clopidogrel|
45514845|NCT02235740|Drug|Afuresertib|Afuresertib will be dosed orally in morning, and will be sourced as opaque, white, size 4, 25 mg capsule and size 1, 100 mg capsules.
45514846|NCT02235740|Drug|Carfilzomib|Intravenous (IV) Carfilzomib will be sourced in the US from commercial stock. It will be a single-use 60 mg vial as a sterile, white to off-white lyophilized cake or powder
45514847|NCT03629431|Procedure|Prophylactic non-invasive ventilation|"The sessions of NIV last 1 hour and are repeated every 2 to 3 hours with a goal of a daily assistance period of 6 to 8 hours for a minimum of 24 hours.~The sessions are spaced by periods of unassisted ventilation of 2 hours allowing the patient to rest, feed, receive care including physiotherapy sessions."
45514848|NCT03629431|Procedure|postoperative standard care|Standard care received postoperatively
45406210|NCT00111813|Drug|bortezomib|Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.
45406211|NCT00118287|Drug|azacitidine|Given SC or IV
45406212|NCT00118287|Biological|etanercept|Given SC
45406213|NCT03965247|Drug|Lithium|
45406214|NCT03965247|Other|Placebo - Rayotabs|
45406215|NCT01079715|Drug|Propranolol|"Dosage of 0.5mg/Kg oral, every 6 hours. The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).~In case such events occur in any of the 3 groups of gestational age, the study could start again with half dose (0.25mg/Kg oral, every 6 hours) after notification to the Ethics Committee.~In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.~In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:~Atropine.~Isoproterenol hydrochloride (isoprenaline.~Terlipressin.~Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular)."
45514849|NCT05163925|Device|Eurosets ECMO Life System|"ECMOLIFE System in combination with ECMOLIFE Centrifugal Pump and ECC (extra-corporeal-circulation) Tubing Set is intended to pump blood through the extracorporeal circuit to provide extracorporeal circulation.~ECMOLIFE System must be used only in combination with ECMOLIFE Centrifugal Pump.~ECMOLIFE System is intended to operate in the following hospital environments: Operating Room, Catheter Laboratory, Emergency Room, Intensive Care Unit and during intra-hospital patient transportation from one to another Unit.~ECMOLIFE System is intended to be used by qualified healthcare professionals specifically trained in the field of extracorporeal circulation: Perfusionists (Thoracic Cardiovascular Surgery - OR), Intensivists, ICU Nurses (ICU), Emergency physicians / Intensivists (ER), Cardiologist (CathLab)."
45406216|NCT00130689|Drug|Cetuximab|
45406217|NCT01326585|Drug|Dexamethasone Sodium Phosphate Injection|8mg (2cc of 4mg/mL solution), IV solution, 1-time dose during surgery
45406218|NCT01326585|Drug|Saline Injection|2cc of 0.9% normal saline, IV injection, 1-time dose during surgery
45406219|NCT03964935|Drug|Lycopene|"Prepared by solving lycopene powder in a solvent (ethanol: propylene glycol: water in the ratio of 50:30:20). The solution was then gelled by adding 8% hydroxypropyl cellulose (HPC). The concentration of the prepared gel equals to 2%.~After SRP, the gel delivered into periodontal pocket using insulin syringes, the therapeutic dose is about 2mg/0.1 ml."
45514850|NCT04476836|Other|Animal-Assisted Therapy|Animal-Assisted Therapy is when animals are used in goal-directed treatment sessions. These goals can be physical, mental, emotional or social.
45406220|NCT03964935|Drug|Minocycline HCl 1mg Oral Powder|Minocycline HCl Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.
45406221|NCT03964935|Other|Distilled water|Used to irrigate periodontal pockets after SRP
45514851|NCT05410730|Drug|SHR-1501|SHR-1501 single agent dose escalation will consist of 3 dose groups: 200 μ g、400 μ g and 600 μ g, and in combination of BCG. The administration method is intravesical instillation.
45514852|NCT02604680|Drug|BLI1100-1|BLI1100-1 Topical gel
45406222|NCT03605212|Drug|Febuxostat|Intervention is orally administered to patients in this arm.
45514853|NCT02604680|Drug|BLI1100-2|BLI1100-2 Topical gel
45514854|NCT02604680|Drug|BLI1100-3|BLI1100-3 Topical gel
45514855|NCT02604680|Drug|BLI1100-4|BLI1100-4 Topical gel
45514856|NCT02604680|Drug|Placebo|Placebo - Topical gel
45514857|NCT03629353|Procedure|endotracheal intubation|After preoxygenation with FiO2 1.0 and flow rate of 8 L/min for 3 minutes, the enrolled patients will be intubated with endotracheal tube and maintained oxygenation during surgery.
45851501|NCT01277718|Drug|Cobimetinib|One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast or approximately 30 minutes after starting the standardized FDA high-fat meal.
45514858|NCT03629353|Procedure|high flow nasal cannula|After preoxygenation with 100% oxygen through high flow nasal cannula for 3 minutes, the enrolled patients will be maintained intubationless oxygenation with flow rate of 70 L/min during surgery.
45514859|NCT01084252|Drug|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45851502|NCT01277718|Drug|Rabeprazole|Rabeprazole 20 mg will be administered orally once daily for 4 days starting on Day -4 and on Day 1 of the treatment period.
46057413|NCT05066451|Other|%5 dextrose prolotherapy|"Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 5% dextrose at the beginning(0.) 3rd week and 6th week.~Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact."
45406223|NCT03603652|Device|Microwave Ablation|Ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon. Prior to the ablation, the treating physician will perform an endobronchial ultrasound to confirm disease staging.
45406224|NCT00117507|Drug|Deferasirox|
45406225|NCT03731416|Procedure|GBR by xenograft and autogenous bone|Ridge augmentation by native collagen membrane and mix of anorganic bovine bone derived mineral with particulated autogenous bone chips (ratio 1:1).
45514860|NCT01084252|Drug|Dexamethasone|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
45514861|NCT01084252|Drug|Dexamethasone|"Pharmaceutical form: tablet~Route of administration: oral"
45514862|NCT05762731|Diagnostic Test|Low dose CT thorax|A multi-detector row CT scanner with minimum section collimation of ≤1 mm and minimum number of data acquisition channels ≥ 16will be employed.
45699304|NCT03707028|Drug|Paclitaxel|Solution administered intravenously
45699305|NCT03447756|Drug|ABX-1431|Capsules of either 2mg, 10mg, or 50mg
45699306|NCT03447756|Drug|Placebo oral capsule|placebo to match
45851503|NCT01276236|Drug|Maraviroc|"FDA Recommended dosing will be used in this study. Subjects on an efavirenz or etravirine-based regimen will be dosed at 600 mg orally, twice per day, for 96 weeks.~Subjects on a ritonavir-boosted protease inhibitor based regimen (except for tipranavir/ritonavir) will be dosed at 150 mg orally, twice per day, for 96 weeks.~Subjects that are on regimens that do not include etravirine, efavirenz, or ritonavir will be dosed at 300mg orally, twice per day, for 96 weeks. These doses are based on the recommendations from the company based on drug-drug interactions."
45406226|NCT03621046|Drug|Zolpidem|Zolpidem is a non-benzodiazepine sedative/hypnotic agent usually prescribed for insomnia.
45406227|NCT03621046|Other|Placebo|Placebo
45406228|NCT03965013|Drug|NNC0268-0965|2 to 3 dose levels will be tested in Part 1. 3 to 5 dose levels will be tested in Part 2
45514863|NCT05762731|Diagnostic Test|Low dose CT thorax|Control subjects will also proceed to CT thorax, and outcome measures be compared to subjects
45514864|NCT05496686|Drug|4.7 microCi 225Ac-MTI-201|4.7 microCi intravenous solution
45851504|NCT01275222|Drug|RAD001|RAD001 was in tablets of 0.5 mg, 1.0 mg, 2.5 mg and 5.0 mg strength and was taken by mouth, once a week or once a day depending upon the treatment group the patient was enrolled into.
45851505|NCT01275222|Drug|Imatinib 600mg/day (Glevec is the brand name for imatinib)|Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth, at a dose of 300 mg twice a day. The Glivec/Gleevec regimen was changed from 600 mg once a day to 300 mg BID, by an amendment since taking too many tablets at once was difficult for patients with gastro-intestinal disease. In the phase II part of the study all patients received Glivec 600 mg/day.
45514865|NCT05496686|Drug|9.5 microCi of 225Ac-MTI-201|9.5 microCi intravenous solution
45514866|NCT05496686|Drug|19 microCi of 225Ac-MTI-201|19 microCi intravenous solution
45514867|NCT05496686|Drug|38 microCi of 225Ac-MTI-201|38 microCi intravenous solution
45514868|NCT05496686|Drug|76 microCi of 225Ac-MTI-201|76 microCi intravenous solution
45514869|NCT05496686|Drug|152 microCi of 225Ac-MTI-201|152 microCi intravenous solution
45514870|NCT05496686|Drug|254 microCi of 225Ac-MTI-201|254 microCi intravenous solution
45514871|NCT05496686|Drug|424 microCi of 225Ac-MTI-201|424 microCi intravenous solution
45406229|NCT03965013|Drug|Placebo|A single dose of placebo given in Part 1
45406230|NCT03965013|Drug|insulin glargine|Insulin glargine given at a fixed dose level of 0.5 U/kg
45514872|NCT05496686|Drug|564 microCi of 225Ac-MTI-201|564 microCi intravenous solution
45514873|NCT05496686|Drug|750 microCi of 225Ac-MTI-201|750 microCi intravenous solution
45514874|NCT05496686|Drug|998 microCi of 225Ac-MTI-201|998 microCi intravenous solution
45514875|NCT05496686|Drug|1327 microCi of 225Ac-MTI-201|1327 microCi intravenous solution
45514876|NCT02235818|Device|Kinesiotape|Pre-cut kinesiotape for tennis elbow, spidertech.com, applied on wrist extensors starting above elbow and ending at distal one third of forearm
45514877|NCT02235818|Device|Counterforce elbow brace|Applied over the wrist extensor muscle mass, had velcro for adjustment, comfortable grip as reported by patient was used to adjust the brace
45514878|NCT03135704|Device|"Re Spine"|A new mattress design made of special materials and built in a specially shaped structure that allows the brain to relax the body and dissipate tension accumulated on the lumbar spine.
45514879|NCT03135704|Other|Physiotherapy|Usual protocol for treatment of low back pain
45514880|NCT03644017|Device|WRAPSODY Stent Graft Placement|The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein
45699307|NCT01207570|Procedure|Endermotherapy|The subjects will receive a single session of endermotherapy applied to the gastrocnemius/soleus muscle on the more affected side for 5 minutes. The treatment will be conducted by a qualified physiotherapist.
45699308|NCT01207570|Procedure|Passive manual stretching|The subjects will receive a single session of passive manual stretching of the gastrocnemius/soleus muscle on the more affected side. The treatment will be given by a qualified physiotherapist.
45699309|NCT03447678|Drug|Pembrolizumab|humanized antibody used in cancer immunotherapy
45699310|NCT01207648|Drug|Rebif®|This is an retrospective cohort study in Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events (Dose regimen as per investigator's decision)
45514881|NCT00158054|Behavioral|Enhanced depression care|Initial patient preference for problem-solving therapy and/or pharmacotherapy, then a stepped-care approach.
45514882|NCT00158054|Behavioral|Referred depression care|Physician notified of depression symptoms, usual care followed.
45514883|NCT04162184|Behavioral|Sexual Health Initiative for Navigation and Education (SHINE) Health Educator Intervention|a brief health educator-led behavioral intervention focused on educating, identifying reproductive health needs, and linking to services if desired
45514884|NCT04476524|Other|Quality improvement|All patients with AF as primary problem treated with study protocol would be compared with historical cohort of AF patients who were treated with routine care in the ER. Patients will be followed up and outcomes will be compared between two groups at 1, 3, 6 and 12 months.
45514885|NCT05075044|Biological|Inactivated COVID-19 vaccine|three doses of inactivated COVID-19 vaccine
45514886|NCT05078125|Device|Holter monitoring|24 hours Holter monitoring
45514887|NCT04504396|Drug|GLP-1 receptor agonist|PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
45514888|NCT04504396|Drug|Placebo|PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
45851506|NCT01275222|Drug|Imatinib 800mg/day (Glevec is the brand name for imatinib)|Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth. In the phase II part of the study all patients received Glivec 600 mg/day, except for 2 patients who received Glivec at a dose of 800 mg/day. This dose was permitted in Phase II as it was found to be safe in Phase I.
45851507|NCT01275144|Drug|LY2216684|Administered orally
45851508|NCT01275144|Drug|Placebo|Administered orally
45851509|NCT01275144|Drug|Lorazepam|Administered orally
45406231|NCT03603496|Behavioral|Transitional Tobacco Care Management (TTCM)|PTCM will provide sustained care after discharge by offering (1) 8 weeks of nicotine replacement therapy at no cost provided at hospital discharge and (2) up to 7 proactive contacts over 3 months delivered by automated IVR call, supplemented by text messaging and email (patient choice). At each contact the patient is offered a return call from the hospital-based tobacco coach who offer counseling, medication advice, and coordination of care with the patient's outpatient health care team.
45406232|NCT03603496|Behavioral|eReferral to State Tobacco Quitline (QL)|Referral from hospital to the state Quitline will be made by the research team on behalf of each enrolled patient. Feedback from the Quitline will be included in the patient's medical chart.
45406233|NCT03603496|Drug|Nicotine replacement therapy|Up to 8 weeks of nicotine replacement therapy provided at no cost to the patient.
45514889|NCT04106414|Drug|Nivolumab|Nivolumab 480 mg every 4 weeks.
45514890|NCT04106414|Drug|BMS- 986205|BMS-986205 100 mg every 4 weeks.
45514891|NCT05307068|Other|No intervention was applied to the groups the samples will be collected in terms of the diagnosis ( periodontitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
45514892|NCT03135964|Device|filler dressing of NPWT|a dressing or filler material is used to fit to the contours of a wound (which is covered with a non-adherent dressing film) .
45514893|NCT05762653|Diagnostic Test|Endoscopic ultrasound|Evaluation of pancreatic fibrosis by endoscopic ultrasound and elastography. Evaluation of exocrine pancreatic function by fecal elastase-test and nutritional evaluation.
45699311|NCT04945278|Other|Double mirror device ALTER-EGO|"The patient and his matched healthy volunteer will be placed on each side of the double mirror device ALTER-EGO. Both sides will be lightened alternatively or at the same time by lights, so according to the light intensity, the subject will see himself in a mirror or the other person throw a classic window. The light intensity will vary from 0 to 100% and to 100% to 0% alternatively from each side of the mirror. At each 10% variation of one side, both patient and volunteer will have to answer that question : who do you see more : him/her or yourself ?"
45699312|NCT04945278|Other|EASE test|The patient will have to answer the EASE test which is a specific test to detect patient with high risk of psychosis or schizophrenia
45699313|NCT01225354|Drug|Calcium hydroxylapatite|Subjects will be treated to full correction at visit 1 and, if needed, a touch-up injection at 2 weeks.
45699314|NCT04937790|Behavioral|Core stabilization group(CSG)|Exercises training of this group occurs from 3 stages. In the stage 1 covering the first two weeks, core stabilization exercises are going to be applied 3 sets of 10 repetitions except side plank. Side plank is going to be performed 3 sets of 10 seconds. Stage 2 is going to include from 3 to 5 weeks. In this stage, exercises are going to be performed 3 sets of 12 repetitions except bride dog, plank and side plank. These exercises are going to be applied 3 sets of 15 seconds. Patients are going to perform exercises of stage 3 from 6 to 8 weeks. Exercises of stage 3 are going to be practiced 3 sets of 15 repetitions except bride dog, side plank and plank exercises which are going to be applied 3 set of 20 second. All stages include the same exercises except modified push-up exercise includes instead of plank exercise in stage 1. All of the exercises are going to practiced 3 days a week for 8 weeks. One of the sessions is estimated to take approximately 45-60 minutes.
45851510|NCT01275066|Drug|BMN 110 Weekly|BMN 110 Weekly: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
45851511|NCT01275066|Drug|Placebo|Intravenous infusion of placebo solution at a volume equivalent to that needed for 2.0 mg/kg dose of BMN 110 administered over a period of approximately 4 hours once a week.
45406234|NCT03964389|Other|Therapeutic Neuroscience Education (TNE)|A talk on Neuroscience Education (EN). This intervention aims to provide information in a clear and simple way to the participants so that through it the patients may be able to modify their attitude towards pain, inviting them to take a more active and less contemplative role. Neuroscience has shown that it is possible to have persistent pain without damage to the tissues or with damage that justifies the perceived disproportion of pain.
45406235|NCT03639844|Biological|rivogenlecleucel|BPX-501 T cells are genetically modified with a suicide safety switch. The cells are infused after T cell-depleted HSCT to potentially enhance immune reconstitution while reducing severity and duration of GVHD.
45406236|NCT03639844|Drug|rimiducid|Rimiducid induces activation of the Caspase 9 suicide gene in BPX-501 T cells inducing apoptosis of the modified T cells in case of GVHD
45406237|NCT03603028|Device|Exergaming|Mixed Reality Gaming for Chronic Low Back Pain
45406238|NCT03602482|Behavioral|Standing|Participants will stand and complete cognitive tests.
45406239|NCT03602482|Behavioral|Supine|Participants will complete cognitive tests while supine.
45406240|NCT00096135|Biological|filgrastim|given subcutaneously (SC)
46057414|NCT05066451|Other|%15 dextrose prolotherapy|"Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 15% dextrose at the beginning(0.) 3rd week and 6th week.~Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact."
45514894|NCT01413529|Behavioral|HEART to HAART|The HEART to HAART intervention is designed to enhance ongoing adherence counseling by providing (1) real time information about medication adherence (using Wisepill device); (2) periodic assessment of medication side effects, depressive symptoms and drug use frequency (as these are linked to poor adherence among drug users) using ecological momentary assessment and (3) tailored education, recommendation and encouragement based on assessments. The participant (using their phone) and their adherence team (using a clinician interface) can jointly track real time changes in adherence increasing the potential for shared decision-making.
45406241|NCT00096135|Drug|cyclophosphamide|IV over 15-30 minutes
45514895|NCT01413529|Behavioral|adherence counseling with the addition of smartphone control|Participants will receive adherence counseling with the addition of smartphone control.
45514896|NCT01337960|Behavioral|Seated Robot Training (SRT)|Participants at least 6 mos. post-stroke will use the ankle robot in a seated visuo-motor training paradigm. They will train on the robot 3x weekly for 6-weeks (18 sessions) by playing videogames with the paretic ankle. They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
45514897|NCT01337960|Behavioral|Treadmill Locomotor-based Training (TMR)|Treadmill training with ankle robot group. Participants at least 6 mos. post-stroke will wear the ankle robot during treadmill locomotor training. They will walk on a treadmill with the ankle robot adjusted to promote paretic ankle engagement during 3 x weekly training sessions over 6 weeks (18 sessions). They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
45406242|NCT00096135|Drug|cytarabine|IV over 3 hours twice daily
45406243|NCT00096135|Drug|daunorubicin hydrochloride|IV over 15 minutes
45406244|NCT00096135|Drug|dexamethasone|oral twice daily
45699315|NCT04937790|Behavioral|Wobble board group (WBG)|Patients in this group are going to perform exercise on computerized wobble board. This device is going to provide unstable surface to patient and offer visual feedback about their movement qualities. The 8 weeks program consists of 3 stages and each stage includes six exercises. In the first stage covering the first two weeks, repetitive exercises are going to be practiced 3 sets of 10 repetitions; time controlled exercises are going to be practiced 3 sets of 20 seconds. Stage 2 is going to include from 3 to 5 weeks. In this stage, repetitive exercises are going to be performed 3 sets of 12 repetition and time controlled exercises are going to be performed 3 sets of 25 seconds. Stage 3 is going to last from 6 to 8 weeks. In this stage, repetitive exercises are going to be practiced 3 sets of 15 repetitions and time controlled exercises are going to be practiced 3 sets of 30 seconds. One of the sessions is estimated to take approximately 45-60 minutes.
46057415|NCT05043051|Device|Vagal stimulation|Vagal stimulation
46057416|NCT05043051|Device|Sham stimulation|Sham vagal stimulation
45406245|NCT00096135|Drug|etoposide|IV over 1 hour
45406246|NCT00096135|Drug|leucovorin calcium|rescue IV over 24 hours
45406247|NCT00096135|Drug|mercaptopurine|oral
45406248|NCT00096135|Drug|methotrexate|intramuscularly (IM)
45406249|NCT00096135|Drug|pegaspargase|intramuscularly (IM)
45406250|NCT00096135|Drug|therapeutic hydrocortisone|
45406251|NCT00096135|Drug|vincristine sulfate|given IV
45406252|NCT00096135|Radiation|radiation therapy|Patients with isolated testicular relapse will start Induction with a single dose of high-dose methotrexate (HDMTX) and will not receive either testicular or cranial radiation. Patients with isolated CNS relapse will NOT receive the initial dose of HDMTX prior to Induction, but will receive 1200 cGy of cranial radiation after completing the initial 12 months of intensive systemic chemotherapy.
45406253|NCT00116805|Drug|TDF|300 mg tablet administered orally once daily
45406254|NCT00116805|Drug|ADV|10 mg tablet administered orally once daily
45406255|NCT00116805|Drug|TDF placebo|Tablet administered orally once daily
45406256|NCT00116805|Drug|ADV placebo|Tablet administered orally once daily
45406257|NCT00116805|Drug|FTC/TDF|200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
45406258|NCT00116649|Drug|imiquimod cream|imiquimod 5% cream applied in doses ranging from one packet (12.5 mg) to 6 packets (75 mg) to either single or multiple body regions for up to 3 cycles
45699316|NCT02521662|Drug|Nicotine patch|A transdermal patch that slowly releases nicotine into the body through the skin.
45851512|NCT01275066|Drug|BMN 110 Every Other Week|BMN 110 Every Other Week: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and infusions of placebo on alternating weeks.
45406259|NCT01080651|Drug|Voriconazole|Day1: voriconazole 200 mg x 2, oral administration, Day2-7: rifampin 600 mg, once a day oral administration, Day8: voriconazole 200 mg x 2 + rifampin 600 mg, oral co-administration
45406260|NCT01082913|Device|SSE|Use of SSE or not use of SSE
45406261|NCT01086891|Device|Oxygen conserving devices|Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated.
45406262|NCT01086891|Device|Oxygen conserving devices|Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated
45406263|NCT01082991|Other|Preemptive Rapid Response Team intervention|Non-ICU inpatients will be randomized on admission to an RRT surveillance group or standard of care. Daily risk prediction scores will be collected for all non-ICU inpatients. Those with high scores, who have been randomized to the surveillance arm, will be included on a list of patients, updated daily, that the Rapid Response Team will receive, with instructions to evaluate and intervene, if required, without waiting for formal activation by the usual channels.
45406264|NCT02531061|Device|HR-pQCT|"The Xtrem CT scanco device is a HR-pQCT. It was initially used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to measure changes in erosion at the 2nd or 3rd metacarpal head. Only the patient's hand will be in contact with the medical device, the acquisition time will be 3 minutes."
45699317|NCT02521662|Device|e-cigarette|A electronically powered device that delivers to the user an aerosol of propylene glycol and/or glycerine, with or without flavourings and nicotine.
45699318|NCT02521662|Drug|Nicotine|Nicotine contained in e-liquid (e-juice) used in e-cigarettes
45851513|NCT01273038|Device|Morfeus|The new ostomy bag filter (called Morfeus) will be tested for a period of 14 days
45406265|NCT01087047|Device|Acoustic reflection method|An acoustic reflection device gives the longitudinal cross-sectional area profile along airways. It is based on the analysis of a planar acoustic wave propagating in a rigid duct connected to airway.
45406266|NCT01080729|Drug|Recombinant-follicle stimulating hormone (r-FSH)|"The dosage and administration of r-FSH will be in accordance with the PFS and current clinical practice in the centers (300 IU/0.5 ml [22 micrograms/0.5 ml]; 450 IU/0.75 ml [33 micrograms/0.75 ml]; or 900 IU/1.5 ml [66 micrograms/1.5 ml].~The dosage and administration of recombinant-hCG (r-hCG; 250 micrograms/0.5 ml), injectable solution in a pre-filled syringe will also be in accordance with the PFS and current clinical practice in the centers (only if the doctor decides to start treatment with r-hCG)."
45406267|NCT01080885|Behavioral|Busy Bodies/Better Bites|This intervention will include brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the healthy eating and physical activity home environmental strategies.
45406268|NCT01080885|Behavioral|Healthy Spots/Safe Tots|This intervention will include the same brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
45406269|NCT03962907|Drug|Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun|5 - day decolonization procedure prior elective surgery. In carriers with Chlorhexidine daily showers and Mupirocin twice a day nasal ointment. In non-carriers Chlorhexidine showers will be used.
45406270|NCT03962907|Drug|BACTROBAN® Nasal ong|Mupirocin, BACTROBAN® Nasal ong, 3g, GSK
45699319|NCT02521662|Behavioral|Behavioural support|Withdrawal-oriented behavioural support
45699320|NCT01226914|Drug|EVICEL|EVICEL
45699321|NCT03499704|Drug|Pioglitazone + Alogliptin|Pioglitazone and Alogliptin FDC tablets
45699322|NCT03499704|Drug|Alogliptin|Alogliptin tablets.
45699323|NCT03499704|Drug|Metformin|Metformin tablets.
45699324|NCT03499704|Drug|Dapagliflozin|Dapagliflozin tablets.
45699325|NCT01158976|Dietary Supplement|Docosahexanoic Acid|450 mg DHA daily beginning at 16-21 weeks gestation and continuing up to time of delivery
45699326|NCT01158976|Other|Placebo|soybean oils with strawberry flavoring
45851514|NCT01273038|Device|SenSura|The CE marked ostomy bag filter will be tested for a period of 14 days
45406271|NCT00083889|Drug|Interferon-alfa|3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity
45406272|NCT00083889|Drug|SU011248|50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity
45514898|NCT01337960|Behavioral|Treadmill Only (TMO)|Treadmill only group. This group will consist of participants at least 6 mos. post-stroke who engage in treadmill training 3x weekly for 6 weeks without robotic support. They will be volunteers from another treadmill training study and evaluated on outcomes at baseline and post-6 weeks training. They will not receive retention testing at 12 weeks because they will be continuing with regular treadmill training beyond the 6-week period.
45514899|NCT03136042|Other|physiotherapy techniques|oscillating positive expiratory pressure during nonstop 5 minutes. After that more five minutes to a forced expiratory technique
45406273|NCT03572062|Biological|Formulation A|RSV vaccine
45514900|NCT03136042|Other|hypertonic saline 3%|four nebulizations with 3% hypertonic saline, the aerosol was generated by an ultrasonic nebulizer
45514901|NCT03136042|Other|saline + physiotherapy maneuvers|sputum induction by hypertonic saline at 3% for seven minutes. And more five minutes under physiotherapists maneuvers
45514902|NCT05040295|Drug|ritlecitinib|30 mg intact adult capsule
45514903|NCT05040295|Drug|ritlecitinib|10 mg pediatric capsule
45514904|NCT05040295|Drug|ritlecitinib|30 mg spray congealed beads
45514905|NCT02571998|Drug|Omiganan (CLS001) Topical Gel|
45699327|NCT04937556|Dietary Supplement|Probiotic: Lactobacillus salivarius + Vit D + Zinc|A mixture of 1*10E9 colony forming unit (CFU) of Lactobacillus salivarius + Vit D + Zinc citrate in 1 capsule will be daily administrated during 28 days.
45514906|NCT02571998|Drug|Vehicle Topical Gel|
45514907|NCT05031949|Combination Product|hyperbaric oxygen therapy plus Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody
45514908|NCT04379986|Device|Senbiosys|The patients will undergo blood pressure estimation as per clinical routine and will simultaneously wear the device.
45514909|NCT05202691|Other|Group 1 (Physical Therapy+Magnetic Field Therapy)|A Physical Therapy Protocol (including manual therapy, stretching and exercise for low back pain) adding a Magnetic Field Therapy using the Zimmer EmfieldPro device (Zimmer MedizinSysteme, Germany)
45514910|NCT05202691|Other|Group 2 (Physical Therapy)|A Physical Therapy Protocol (including manual therapy, stretching and exercise for low back pain)
45514911|NCT02784002|Drug|Ridinilazole|
45406274|NCT03572062|Biological|Formulation B|Adjuvanted RSV vaccine
45406275|NCT03572062|Biological|Formulation C|RSV vaccine
45406276|NCT03572062|Biological|Placebo|Placebo
45406277|NCT03728062|Behavioral|Mindfulness meditation|Guided mindfulness meditation focused on breath sensations, thoughts and emotions.
45406278|NCT03728062|Behavioral|Physical exercise|Cardio exercise at gym like rowing, eliptical, cycling, or running outside.
45406279|NCT03639532|Procedure|COC THA|standard total hip arthroplasty is done, with ceramic on ceramic for the bearing.
45406280|NCT03639532|Procedure|COP THA|standard total hip arthroplasty is done, with ceramic on highly cross linked polyethylene for the bearing.
45406281|NCT03727828|Diagnostic Test|Patients with heart failure|Participants will have serial blood collection on medical therapy for heart failure
45406282|NCT03571516|Drug|Teduglutide|SC injection of 0.05 mg/kg teduglutide will be administered QD into abdomen or into either the thigh or arm for 24 weeks.
45406283|NCT03571516|Other|Standard Medical Therapy|Standard medical therapy will be administered for 24 weeks.
45406284|NCT03571516|Device|Syringe|Teduglutide will be administered using syringe (510k number: K980987).
45406285|NCT03571516|Device|Needle|Teduglutide will be administered using needle (510k number: K021475).
45406286|NCT03600376|Drug|Ryanodex and Standard of Care|Ryanodex to be administered as a rapid IV push
45514912|NCT02784002|Drug|Fidaxomicin|
45514913|NCT04362046|Procedure|Hysteroscopic uterine resection|"Hysteroscopic Resection will be evaluated as a fertility-sparing treatment for patients with early Endometrial Cancer or Endometrial Hyperplasia (atypical or persisting typical) who fail progestin therapy. Failure of progesterone therapy is defined as: (a) Unsuccessful eradication of hyperplasia or cancer in the uterus or (b) Intolerance to the side effects of th hormone therapy.~HR is a common gynecologic procedure that is offered to women for treatment of several benign gynecologic conditions. The conduct, risks, and complications of it are well-understood. In relation to this protocol, it is the indication for HR that constitutes the experimental intervention including the assessment of it's outcome. Patients deemed appropriate for hysteroscopic endomyometrial resection will be counselled on the nature of the procedure along with its risks and complications."
45514914|NCT05202613|Drug|Doravirine|Doravirine, both as single drug and as fixed combination with lamivudine and tenofovir disoproxil fumarate
45699328|NCT04937556|Dietary Supplement|Placebo|Placebo in 1 capsule will be daily administrated during 28 days.
45699329|NCT01227382|Procedure|ERCP with cholangiopancreatoscopy|Endoscopic Retrograde Cholangiopancreatography (ERCP)with cholangiopancreatoscopy and sampling of stricture with SpyBite biopsy forceps, cytology brush and RJ3biopsy forceps
45406287|NCT03600376|Other|Standard of Care|Body cooling measures and supportive measures
45406288|NCT03961659|Drug|Liraglutid|Liraglutid will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study.
45406289|NCT03961659|Drug|Dapagliflozin|Dapagliflozin will be initiated and maintained at 10mg/day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
45514915|NCT02233556|Drug|Memantine|"Taking 20mg(2 capsules) of memantine, followed by Event related potential assessments as below:~Mismatch negativity(MMN)~P50"
45514916|NCT04932733|Other|Exercises|The elderly participants in the experimental group underwent a single session of 5-minute quadriceps isometric exercise. The participant was asked to take a rest of 10 minutes before performing the exercise. After that, the exercise was performed from a long-sitting position.
45406290|NCT03961659|Drug|Acarbose|Acarbose will be initiated at 50mg three times daily for the first week, and then titrated to 100mg three times daily if appropriate.All patients will also continue on their existing dose and regimen of metformin throughout the study.
45406291|NCT03599362|Drug|Nivolumab + Cabiralizumab|Will be administered on Day 1 and Day 14; Subjects will continue treatment every 2 weeks with subsequent imaging every 8 weeks.
45406292|NCT03599362|Radiation|Stereotactic Body Radiotherapy (SBRT)|Patients will be simulated supine with the addition of a 4D C T if appropriate. A stereotactic immobilization device with abdominal compression will be used.
45406293|NCT03741309|Other|5% fluorocalcium phosphosilicate dentifrice|dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks.
45406294|NCT03741309|Other|Calcium sodium phosphosilicate|Calcium sodium phosphosilicatand VAS score assessed at Baseline, 2weeks, 6 weeks.
45406295|NCT03741309|Other|Placebo dentrifice|placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.
45406296|NCT01083147|Device|FORESEE HOME|Home Monitoring
45406297|NCT03598036|Drug|Voclosporin|"Voclosporin softgel capsules. Up to 10 subjects will be enrolled into Cohort 1 and take up to 3 capsules twice daily (BID).~The dose of voclosporin for Cohort 2 (at least 10 subjects) will be determined by analysis of efficacy and safety data at Week 12 from the first 5 or 6 subjects in Cohort 1."
45406298|NCT00082407|Drug|exenatide|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks
45406299|NCT00082407|Drug|biphasic insulin aspart|subcutaneous injection, twice daily; titration to target blood glucose level
45406300|NCT03643432|Behavioral|Exercise adherence intervention|Before their physiotherapy appointment participants will be given four short questions to answer. Following this the participant will be assessed as normal. As part of the treatment they will be given an exercise programme as standard within physiotherapy. Following this participants will be asked to answer a further seven short questions; depending on the answers to both sets of questions, and on any discussion based on the answers, the physiotherapist will suggest one or more adherence approaches from a list of suggestions. These are; Review of exercise programme; Review of method of delivery; Cues or prompts; Discussion of barriers and problem solving; Motivational interviewing, Decision balance sheets; Behavioural contract; Goal setting review; Monitoring telephone call; Reminders.
45514917|NCT04932733|Other|Young isometric exercise|The young participants in the experimental group underwent a single session of 5-minute quadriceps isometric exercise. The participant was asked to take a rest of 10 minutes before performing the exercise. After that, the exercise was performed from a long-sitting position.
45514918|NCT00881920|Biological|Kappa CD28 T cells|"T cells will be given in a lymphopenic environment utilizing (as needed) lymphodepleting chemotherapy (Cy/Flu) prior to T cell infusion as outlined below:~Patients who are not lymphopenic may receive 3 daily doses of cyclophosphamide (500mg/m2/day) together with fludarabine (30mg/m2) to induce lymphopenia, finishing at least 24 hours before T cell infusion.~Patients with lymphopenia due to current drug therapy may be infused at any time starting at least 24 hours after finishing their current cycle of chemotherapy.~ASCT recipients (relapsed/refractory intermediate grade lymphoma) may be infused 14-60 days after the date of transplant.~T cell dosing is as follows:~Group 1: 2x10^7 cells/m^2 CAR-Kappa~Group 2: 1x10^8 cells/m^2 CAR-Kappa~Group 3: 2x10^8 cells/m^2 CAR-Kappa"
45699330|NCT05183880|Dietary Supplement|Phosphatidylcholine-lipid encapsulated vitamin C|Ingesting 1000 mg of vitamin C in phosphatidylcholine-lipid encapsulated form
46057417|NCT02709057|Behavioral|Lifestyle intervention|Life-style intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
45406301|NCT03643432|Behavioral|Usual Care|Participants in usual care will attend physiotherapy sessions as they would have had they not been in the trial.These sessions will include assessment and treatment approaches as given as part of routine care, without including the intervention described above for the 'exercise adherence intervention' arm
45406302|NCT03732976|Other|Modified ramped position|This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.
45406303|NCT03732976|Other|Ramped position|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
45406304|NCT01083225|Behavioral|Client feedback|Client feedback during consultations using ORS (Outcome rating scale) and SRS (Session rating scale).
45406305|NCT01083225|Behavioral|Treatment as usual|Treatment as usual, consultations
45406306|NCT01080963|Drug|Daptomycin|one infusion of 350 mg intraoperatively after disconnection from the heart-lung machine as an add-on to standard antibiotic prophylaxis
45406307|NCT01080963|Drug|Cefuroxime|1500 mg intravenous 30min preoperatively during anesthesia and 1500 mg intravenous intraoperatively after disconnection from the heart-lung machine
45514919|NCT05228132|Device|Pristine™ Long-Term Hemodialysis Catheter|Placement of the Pristine™ Long-Term Hemodialysis Catheter Placement.
45406308|NCT01083303|Behavioral|Weaning Preterm Infants from an incubator|Eligible infants are to be randomized by computer generated random numbers to either the study group weaned at 1500 gr. or the control group weaned at 1600 gr. Both groups were weaned to a warming bassinet.
45406309|NCT01083381|Drug|MS14|MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months
45406310|NCT01083381|Drug|Risperidone|The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months.
45406311|NCT03810183|Drug|QAW039|QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet + Standard of Care
45406312|NCT03810183|Drug|Placebo|Placebo once daily for 6 weeks administered orally as a tablet + Standard of Care
45406313|NCT01087359|Drug|Melatonin|100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo
45406314|NCT03962517|Device|with Gait Enhancing and Motivating System-Hip (GEMS-H)|"The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.~Assessments consist of gait function, cardiopulmonary metabolic energy cost, physical performance, balance, physical level, pain, fall efficacy, depression, quality of life and activities of daily living."
45514920|NCT04914637|Procedure|Cervical interlaminar epidural steroid injection|Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. The injection area is cleaned 3 times with an antiseptic solution and covered with a sterile cloth. Local anesthesia with 2 cc 3% prilocaine will be applied to the skin and subcutaneous tissues in the area of interest. Under fluoroscopy guidance, the needle is advanced into the C7-T1 intervertebral disc level. With the help of the loss of resistance technique, it is understood that the needle is in the epidural space, and second control is provided by administering contrast material. After the confirmation of needle place is done, a mixture of 12 mg dexamethasone, 1 cc 2% lidocaine, 1 cc saline is injected. The patient is taken to the rest room after the procedure and followed up for any complications.
45514921|NCT04914637|Procedure|Dry needling|Dry needling will be applied to the active trigger points for the patients in this group. After cleaning the area of interest with an antiseptic solution, dry needling will be applied with the fast-in/fast-out technique for the active trigger point. During needle maneuvers, local contractions (local twitch response-LTR) are obtained and rapid needle movements are continued until the contractions end. Afterwards, the needle is removed and compression is applied to ensure hemostasis in the relevant area.
45406315|NCT03962517|Other|without Gait Enhancing and Motivating System-Hip (GEMS-H)|The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.
45406316|NCT01087437|Dietary Supplement|gastrolith calcium|
45406317|NCT01083537|Drug|Cisplatin|"1) Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.~Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn~Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour"
45406318|NCT01083537|Drug|Paclitaxel|"2) Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.~Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo~Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn~Hydration: Infuse Paclitaxel in 250cc NS over 1 hour"
45406319|NCT03597022|Drug|Befovacimab (BAY1093884)|Once weekly doses until premature termination of the study, subcutaneous injection
45699331|NCT05183880|Dietary Supplement|Crystalline vitamin C|Ingesting 1000 mg of vitamin C in crystalline form
45699332|NCT04451850|Other|Noninvasive actigraphy monitor|Noninvasive chest-mounted actigraphic device to be worn for 2 hour intervals two times per week during the six month study participation.
45851515|NCT01272180|Biological|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus OMV.
45406320|NCT01087515|Other|Blood donation|"In experimental part 1 to generate preclinical data 250 ml of blood will be donated at day 1 by 10 subjects to induce allergen presenting cells (APCs).~In experimental part 2 to transfer the isolation of pDC or TREGs to a GMP (good manufacturing Practice) compliant clinical grade isolation system, leukapheresis will be performed with the blood from 5 subjects.~In experimental part 3 for potency testing of the clinical grade isolation system of pDC or TREGs, 250 ml of blood will be collected at day 1 from 3 subjects."
45406321|NCT03571204|Biological|3BNC117 and 10-1074|Both 3BNC117 and 10-1074 administered intravenously at 30 mg/kg dose level in 250 ml normal saline for 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The two antibodies will be mixed in separate bags of saline for sequential administration.
45406322|NCT03571204|Biological|Placebo|Placebo is two separate bags of 250 ml normal saline administered intravenously for 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The two separate bags of placebo are administered sequentially.
45406323|NCT03569098|Biological|Botulinum toxin type A|Investigators will inject the reconstituted solution into foot muscles.
45406324|NCT03569098|Drug|Placebo|Investigators will inject the reconstituted solution into foot muscles.
45406325|NCT03727282|Procedure|adjust dobutamine according to the ejection volume index|adjust dobutamine dose
45406326|NCT03727282|Procedure|adjust dobutamine according to the attending physician|adjust dobutamine dose
45406327|NCT03568942|Drug|Gepotidacin|Gepotidacin tablets will be available at a dose strength of 750 mg. Tablets will be administered BID with water after consumption of food.
45406328|NCT00110019|Drug|Carboplatin|Given IV
45514922|NCT04914637|Procedure|Sham dry needling|Although the method of intervention is like dry needling, the only difference is that the blunt end of the needle is used and it does not penetrate the skin.
45514923|NCT02235896|Behavioral|Education/Behavior Modification|Education, lifestyle counseling, experiential cooking, exercise classes.
45406329|NCT00110019|Other|Laboratory Biomarker Analysis|Correlative studies
45406330|NCT00110019|Drug|Paclitaxel|Given IV
45406331|NCT00110019|Other|Pharmacological Study|Correlative studies
45514924|NCT04905433|Behavioral|Cardiac rehabilitation with breathing retraining|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling), with a breathing retraining (using breathing calisthenics, and inspiratory muscle training)
45514925|NCT04905433|Behavioral|Cardiac rehabilitation|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling) only
45514926|NCT04264390|Behavioral|Movement-to-music|Movement-to-music is a physical activity program that was developed onsite at a state-of-the-art adapted fitness facility. The program includes movements that are coupled with music to enhance muscular strength, cardiorespiratory capacity, flexibility, and balance. For this study, the program will be packaged into playlists of exercise videos that will be given to participants. Participants will be instructed to complete the prescribed videos 3 times per week. Participants will also be asked to attend 4 behavioral coaching calls with a telecoach. The goals of the behavioral coaching calls will be to address issues with the technology components of the program and promote physical activity participation within the community and adherence to the movement-to-music videos.
45514927|NCT02235974|Behavioral|Early Intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 30 days of stroke onset.
45514928|NCT02235974|Behavioral|Sub-acute intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 2 to 3 months post stroke.
45514929|NCT02235974|Behavioral|Chronic intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 6 to 9 months post stroke.
45406332|NCT00110019|Other|Placebo|Given PO
45406333|NCT00110019|Drug|Sorafenib Tosylate|Given PO
45406334|NCT03595618|Drug|GLPG1972|Film-coated tablets of GLPG1972 for oral use.
45406335|NCT03595618|Drug|Placebo|Film-coated tablets of matching placebo for oral use.
45406336|NCT02954848|Drug|Placebo|TAK-438 placebo-matching tablets
45406337|NCT02954848|Drug|TAK-438 10 mg|TAK-438 tablets
45514930|NCT02235974|Behavioral|Control|Usual and Customary Care only. No additional therapy will be given during the 1-year study.
45851516|NCT01272180|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.|Two injections of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.
45851517|NCT01272180|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.|One injection of saline solution placebo and one of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
45699333|NCT01159054|Drug|Extended Release Nicotinic Acid (Niaspan)|Subjects will start on 500 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1000 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1500 mg of Niaspan per day for 4 weeks, after this subjects with weight of less than 60 kg will continue at 1500 mg per day of Niaspan for another 12 weeks whereas in subjects with weight of more than 60 kg the dose will be increased to 2000 mg of Niaspan per day which will be continued for 12 weeks.
45851518|NCT01272180|Biological|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus a quarter dose of OMV.
45851519|NCT01271712|Drug|Regorafenib (Stivarga, BAY73-4506)|160 mg po once daily (od), 3 weeks on/1 week off. Route of administration: oral
45851520|NCT01271712|Drug|Placebo|once daily (od), 3 weeks on/1 week off. Route of administration: oral
45514931|NCT05760937|Drug|BMS-986447|Specified dose on specified days
45514932|NCT05760937|Drug|Placebo|Specified dose on specified days
45851521|NCT01271712|Drug|Best supportive care|Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.
45514933|NCT04240288|Other|Procalcitonin-guided antibiotic treatment|Antibiotics will be administered based on the procalcitonin lab results.
45514934|NCT04240288|Other|Standard of Care Antibiotic Treatment|Antibiotics will be administered based on standard of care treatment. The treating physicians will determine the treatment course.
45514935|NCT02236052|Biological|Non-adjuvanted low dose of quadrivalent VLP vaccine|A single non-adjuvanted low dose of quadrivalent VLP vaccine
45699334|NCT04451694|Other|nutritional intervention|nutritional evaluation and intervention and orientation towards adapted care establishment
45699335|NCT01209442|Drug|Bevacizumab|Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, patients will receive 6 cycles of Bevacizumab.
45699336|NCT01209442|Drug|Temozolomide|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily temozolomide at 75 mg/m2 qd concurrent with IMRT. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, temozolomide will be given at 150-200 mg/m2 qd on days 1-5 of each cycle.
45699337|NCT01209442|Radiation|RT (Radiation Therapy)|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx)
45699338|NCT04451928|Diagnostic Test|Serum sample analysis|Analysis of the levels of ischemia-modified albumin, biglycan and decorin levels
45699339|NCT04452006|Drug|ACT-541478 10 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
45699340|NCT04452006|Drug|ACT-541478 30 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
45699341|NCT04452006|Drug|ACT-541478 100 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 50 mg.
45699342|NCT04452006|Drug|ACT-541478 300 mg|ACT-541478 will be provided in HPMC capsules for oral administration at dose strengths of 50 mg and 250 mg.
45699343|NCT04452006|Drug|ACT-541478 1000 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 250 mg.
45851522|NCT01271010|Drug|Cyclophosphamide|Participants received cyclophosphamide 250 mg/m^2 IV or 250 mg/m^2 orally on Days 1-3 of each cycle.
45514936|NCT02236052|Biological|Non-adjuvanted medium dose of quadrivalent VLP vaccine|A single non-adjuvanted medium dose of quadrivalent VLP vaccine
45699344|NCT04452006|Drug|ACT-541478 high or low dose (or placebo)|Cross-over design: ACT-541478 will be provided in HPMC capsules for oral administration at high or low dose strengths (to be defined after completion of Part A).
45699345|NCT04452006|Drug|ACT-541478 dose E1|E1 is a dose level that has been investigated and well tolerated in the adult dose level groups C1 to C3. ACT-541478 will be provided in HPMC capsules for oral administration at dose strengths of 10, 50, and 250 mg.
45699346|NCT04452006|Drug|Matching placebo|Matching placebo will be provided in HPMC capsules for oral administration.
45699347|NCT01160380|Drug|armodafinil|Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.
45699348|NCT01160380|Drug|Placebo|Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.
45851523|NCT01271010|Drug|Fludarabine|Participants received fludarabine 25 mg/m^2 IV or 40 mg/m^2 orally on Days 1-3 of each cycle.
45851524|NCT01271010|Drug|Rituximab|Participants received 375 mg/m^2 IV on Day 1 of Cycle 1, then 500 mg/m^2 IV on Day 1 of each subsequent cycle.
45851525|NCT01270620|Drug|propofol|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
45851526|NCT01270620|Drug|Desflurane|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
45851527|NCT01270464|Drug|Reslizumab|3.0 mg/kg or 0.3 mg/kg doses administered intravenously (iv) by qualified site personnel once every 4 weeks, for a total of 4 doses.
45851528|NCT01270464|Drug|Placebo|Placebo administered by iv infusion by qualified study personnel every 4 weeks for a total of 4 doses.
45851529|NCT01279590|Drug|PPD10558|"PPD10558 40 mg capsule and matching placebo capsule twice a day for 4 weeks, then~PPD10558 80 mg (two 40 mg capsules) twice a day for 8 weeks"
45851530|NCT01279590|Drug|Atorvastatin|"Atorvastatin 40 mg capsule and matching placebo capsule in the morning and 2 placebo capsules in the evening for 4 weeks, then~Atorvastatin 80 mg (two 40 mg capsules) in the morning and 2 placebo capsules in the evening for 8 weeks"
45406338|NCT03642262|Drug|Mucinex®|Mucinex® 600 mg single dose ER bi-layer tablet
45406339|NCT03731104|Device|Near InfraRed Spectroscopy assessment|"Regional Cerebral Oxygen saturation (rScO2 ) values will be collected for all patients during the procedure using a 2-wavelength (730-810 nm) cerebral oxymeter (monitor INVOS 5100C®, Medtronics). Two transducers will be placed on both fronto-parietal sides of the patient's head.~To assess the balance between oxygen delivery and consumption, the Fractional cerebral Tissue Oxygen Extraction (FTOE) will be calculated as this ratio: FTOE=[SpO2-rScO2]/SpO2.~Data will be collected for a period of 3 hours starting from the beginning of catecholamine treatment."
45406340|NCT03731104|Device|Transcranial Doppler Ultrasound assessment|"Transcranial Doppler ultrasound will be performed for all patients during the procedure using a VIVID S-5 (General Electric®) echograph. All examinations will be performed by a single trained operator. A 3 MHz probe will be placed on left and right temporal window to detect signal from the middle cerebral artery. 2 measures will be performed for each side to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
45514937|NCT02236052|Biological|Non-adjuvanted high dose of quadrivalent VLP vaccine|A single non-adjuvanted high dose of quadrivalent VLP vaccine
45514938|NCT02236052|Biological|Adjuvanted low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®
45406341|NCT03731104|Device|Cardiac output assessment|"Transthoracic echocardiography will be realized for all patients during the procedure using a transthoracic ultrasound device (VIVID S-5, General Electric®) with a 3 to 6 MHz probe. All examinations will be performed by a single trained operator.~Two echocardiographic views will be examined to assess cardiac output : the two-chamber long-axis view to measure sub-aortic diameter (d), and the four-chamber view to measure the Left ventricular outflow tract velocity time integral (LVOT VTI). Cardiac output (Qc) will then be calculated taking account these parameters and heart rate with this formula : Qc = [π x d2 x VTI x HR] / 4 2 measures will be performed to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
45406342|NCT03727204|Procedure|On-pump cardiac surgery|All participants will undergo on-pump cardiac surgery
45406343|NCT03727126|Procedure|Robotic esophagectomy|Removal of the esophagus and its draining lymph nodes using robotic surgical instruments
45514939|NCT02236052|Biological|Adjuvanted high dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®
45514940|NCT02236052|Biological|Placebo|A single dose of placebo
45514941|NCT04238494|Diagnostic Test|Nuclear magnetic resonance (NMR)|Muscle architecture, lipid and active tissue muscle content should be measured. Proton NMR imaging (MRI)
45514942|NCT04034888|Behavioral|HEX|HEX is a customized exercise program with components including: 1) controlled flexibility movements; 2) progressive ADL training focusing on bed mobility, bed to chair transfers, and indoor walking; 3) task-specific seated resistance training to improve ability to get out of bed and; 4) and balance exercises. Participants will be expected to perform their HEX program at least 2 times/week in their home and all individualized exercise sessions will be supervised by an Exercise Physiologist. Each exercise has four levels of difficulty, which will be progressed as tolerated throughout the 12-weeks. Seated resistance exercises were designed to target all the major muscle groups and will include the following: arm curls, shoulder raises (lateral/front), overhead arm raise, wrist curls, leg extensions, hip flexion, hip ab/adduction, sit-to-stands, torso rotation, and marching.
45514943|NCT03077737|Behavioral|Choose to Change|Population-based letter outreach automated via the electronic health record system and text messaging targeted to low-income smokers. Paired with automated electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy).
45514944|NCT03077737|Behavioral|Enhanced usual care|Enhanced usual care based on Ask, Advise and Refer in which an electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy) is made during a clinic visit.
45406344|NCT03727126|Procedure|Thoracolaparoscopic esophagectomy|Removal of the esophagus and its draining lymph nodes using conventional thoracoscopic and laparoscopic techniques
45406345|NCT03727048|Drug|Ketorolac|the investigators aimed to evaluate the effect of postoperative ketorolac after ankle fracture surgery on postoperative opioid consumption, pain control, an patient satisfaction.
45406346|NCT03727048|Other|No ketorolac|standard of care post operative pain management protocol
45514945|NCT03062449|Drug|L-Serine|Gummy containing L serine dose
45514946|NCT03062449|Other|Placebo Gummy|Gummy with no dosing of L Serine
45851531|NCT01279590|Drug|Placebo|2 placebo capsules twice daily for 12 weeks
45406347|NCT03732742|Procedure|TOF repair with trans-annular patch VS preservation of PV|One group study
45851532|NCT01271790|Drug|Tegobuvir (GS-9190)|Tegobuvir (GS-9190) capsule, 30 mg BID
45699349|NCT03071328|Drug|Isovue-M 200|Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, soft tissue, or liver metastases in subjects with metastatic castrate resistant prostate cancer, metastatic urothelial carcinoma or metastatic renal cell carcinoma and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site will be obtained at the time of contrast injection and will be stained for CD155 expression.
45699350|NCT03447600|Behavioral|Alternate Day Fasting|25% daily energy requirements every other day until study completion at >/=5% weight loss which is an average of 12 weeks.
45406348|NCT00109707|Drug|Nilotinib|
45406349|NCT00095979|Drug|ixabepilone|Given IV
45406350|NCT01087593|Drug|17β-estradiol|Transdermal administration(50 ug daily)for a period of ten weeks with additional treatment of medroxyprogesterone (10mg daily) for the last two weeks
45851533|NCT01271790|Drug|GS-9451|GS-9451 tablet, 200 mg once daily (QD)
45406351|NCT01087671|Drug|tafluprost|prostaglandin analogue
45514947|NCT04233268|Diagnostic Test|Rapid Pathogen Detection|Rapid assays for pathogen detection on bronchoalveolar lavage fluid
45406352|NCT00082173|Drug|Moxifloxacin|400mg daily for 8 weeks
45406353|NCT01087749|Drug|Propranolol|Propranolol 40mg PO will be given with 6oz of water.Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
45406354|NCT01087749|Drug|Losartan|Losartan 50mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
45406355|NCT01087749|Drug|Eprosartan|Erythromycin 125mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
45514948|NCT04139200|Behavioral|Type 1 physical activity tele coaching intervention|A) Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed. B) Step counter providing direct feedback. C) A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards. D) Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data, failure to progress or change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
45699351|NCT03447600|Behavioral|Continuous dietary restriction|25% daily energy requirements every other day until study completion at >/=5% weight loss which is an average of 12 weeks.
45699352|NCT03447444|Other|music and physical activity|This feasibility study focus on promoting a combination of music therapy and physical activity with the primary goal to describe the influence on restlessness, irritability, and aggression in persons with severe stage of dementia with a mixture of symptoms including frontal lobe problems in institutional care. A secondary goal is to investigate the treatment fidelity.
45699353|NCT04956042|Drug|Fosciclopirox|Fosciclopirox, 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle
45699354|NCT04956042|Drug|Fosciclopirox + Cytarabine|"Fosciclopirox - 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle~Cytarabine - 1g/m2 once daily on D1-D5 of each 21-day treatment cycle"
45851534|NCT01271790|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
45406359|NCT00108069|Drug|Tamoxifen citrate|oral dose 120 mg twice a day, every day
45406360|NCT00108069|Drug|Bortezomib|intravenous (IV) injection 1.3 mg/m^2 days 3, 6, 10, 13, 24, 27,31,34 on every 6 week cycle
45406361|NCT01081119|Behavioral|Project CHOICE|Voluntary after school program offered 1 day per week for 30 minutes
45406362|NCT00079274|Drug|irinotecan hydrochloride|Given IV
45699355|NCT03442998|Other|Suburban walk|Each subject is tested under the 'suburban' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
45699356|NCT03442998|Other|Nature walk|Each subject is tested under the 'nature' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
45851535|NCT01271790|Drug|Copegus®|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
45851536|NCT01271790|Drug|GS-9451|GS-9451 tablet, 200 mg QD
45851537|NCT01271790|Drug|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
45851538|NCT01271790|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
45851539|NCT01271790|Drug|Copegus®|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
45406363|NCT00079274|Drug|oxaliplatin|Given IV
45406364|NCT00079274|Drug|leucovorin calcium|Given IV
45406365|NCT00079274|Drug|fluorouracil|Given IV
45406366|NCT00079274|Biological|cetuximab|Given IV
45406367|NCT00079274|Drug|Locally Directed Therapy|Patients determined to have mutated KRAS (or KRAS not evaluable) will be assigned to an event monitoring arm in which adjuvant therapy will be determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification will be the responsibility of the treating oncologists.
45851540|NCT01271790|Drug|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
45851541|NCT01271790|Drug|GS-9451 placebo|placebo matching GS-9451 tablet QD
45851542|NCT01271790|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
45851543|NCT01271790|Drug|Copegus®|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
45851544|NCT01270152|Drug|Ascorbic Acid|comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes
45514949|NCT04139200|Behavioral|Type 2 physical activity tele coaching intervention|A) Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity. B) A step counter providing direct feedback. C) A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period). D) Telephone contacts triggered in the case of change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
45514950|NCT04122196|Drug|Pregabalin 300mg|Patient will receive a compounded version of 300mg pregabalin PO approximately one hour before surgery.
45406368|NCT01081964|Drug|Zabofloxacin|Zabofloxacin 400mg capsule once daily for 3 days
45406369|NCT01081964|Drug|Levofloxacin 500mg|Levofloxacin 500mg orally for 7 days
45514951|NCT04122196|Drug|Placebo oral tablet|Patient will receive a compounded version of inactive placebo PO approximately one hour before surgery.
45514952|NCT05202457|Procedure|Elective surgery|Patient undergoing elective or urgent surgery
45406370|NCT01081964|Drug|Zabofloxacin 400mg|Zabofloxacin 400mg orally for 5 days
45406371|NCT03960944|Other|Yoga|30 Min Yoga session included of Physical posture, Breathing exercise, Yoga games and Relaxation.
45406372|NCT00079040|Drug|cisplatin|Given IV
45406373|NCT00079040|Drug|etoposide|Given IV
45406374|NCT00079040|Biological|bevacizumab|Given IV
45406375|NCT00079040|Other|laboratory biomarker analysis|Correlative studies
45514953|NCT04085146|Procedure|Individualized optimal positive end-expiratory pressure|Optimal PEEP will be determined by the automated procedure of step-wised decrease in the amount of PEEP of the anesthesia ventilator Aisys Care Station (GE Healthcare, Madison, Wisconsin, USA).
45514954|NCT04085146|Procedure|Conventional positive end-expiratory pressure|A same amount of PEEP of 7 centimeter hydrogen dioxide will be provided during the laparoscopic period of surgery.
45699357|NCT01228084|Drug|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
45699358|NCT01228084|Other|Laboratory biomarker analysis|Correlative studies
45699359|NCT01228084|Other|Pharmacological study|Correlative studies
45699360|NCT03009994|Procedure|Repair of uterine incision|
45514955|NCT02800915|Other|Service innovation with focus on multidisciplinary collaboration|The follow-up is performed via telemedicine (videoconference) to the patient in his or her own home, and in cooperation with the district nurses.
45406376|NCT01088516|Drug|Lopinavir/Ritonavir (200/50 mg) Tablets + Zidovudine + 3TC|Zidovudine 300mg PO BID + 3TC 150 mg PO BID + Lopinavir/Ritonavir (200/50 mg) two tablets PO BID
45406377|NCT03961022|Dietary Supplement|Polyherbal supplement: ReWin(d) vs Placebo|Supplementation during 4 weeks + 72 hours post acute exercice
45406378|NCT00078806|Drug|Etanercept|Administered by subcutaneous injection twice a week
45406379|NCT00078806|Drug|Placebo|Administered by subcutaneous injection twice a week
45406380|NCT01090856|Procedure|Pre-dilation side branch|Balloon pre-dilation of the side branch to facilitate the ulterior wire access.
45406381|NCT00078338|Drug|Rebif®|Subjects will be administered with Rebif® (Recombinant interferon beta-1a) as subcutaneous (SC) injection at a dose of 44 microgram (mcg) three times weekly (tiw).
45406382|NCT00078338|Drug|Copaxone®|Subjects will be administered with Copaxone® (Glatiramer acetate) as subcutaneous (SC) injection at a dose of 20 milligram (mg) once daily (qd).
45406383|NCT01088594|Drug|pioglitazone/rosiglitazone/placebo|single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg +single oral dose of placebo
45406384|NCT01088594|Drug|rosiglitazone/pioglitazone/placebo|single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg + single oral dose of placebo
45406385|NCT01088594|Drug|placebo/pioglitazone/rosiglitazone|single oral dose of placebo + single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg
45406386|NCT01088594|Drug|pioglitazone/placebo/rosiglitazone|single oral dose of pioglitazone 45mg +single oral dose of placebo + single oral dose of rosiglitazone 8mg
45406387|NCT01088594|Drug|rosiglitazone/placebo/pioglitazone|single oral dose of rosiglitazone 8mg + single oral dose of placebo + single oral dose of pioglitazone 45mg
45406388|NCT01088594|Drug|placebo/rosiglitazone/pioglitazone|single oral dose of placebo + single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg
45514956|NCT04908592|Drug|Dexamethasone|Patients will receive dexamethasone 8 mg diluted in 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
45514957|NCT04908592|Other|Placebo|Patients will receive 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
45699361|NCT03009994|Procedure|Exteriorization of the uterus|
45699362|NCT03009994|Procedure|Non exteriorization of the uterus|
45699363|NCT03442920|Other|Exercise|This group made exercise for 12 week/3 times a week.
45699364|NCT03010696|Other|No interventions, questionnaire, collect specimen|
45699365|NCT04923984|Procedure|Embolization of the middle meningeal artery|embolization of the middle meningeal artery with an embolic agent.
45699366|NCT03447366|Diagnostic Test|mitral doppler|Mitral doppler before and after vascular filling
45699367|NCT01229410|Drug|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
45406389|NCT01583192|Procedure|skin preparation|skin preparation while be done either with chloride-hexidine 0,5% soluted in alcohol 70% or povidine-jodine 1% soluted in alcohol 70%
45406390|NCT01090934|Device|High Resolution EEG|High Resolution EEG
45406391|NCT01090934|Device|Stereo-electroencephalography|SEEG
45406392|NCT01082120|Drug|AZD1656|Tablets orally, twice daily for 10 days
45406393|NCT01082120|Drug|Pioglitazone|Tablet oral single dose for 10 days
45406394|NCT03808688|Drug|Netarsudil Ophthalmic Solution 0.02%|1 drop in each eye once daily in the evening
45406395|NCT03808298|Drug|Balovaptan therapeutic dose Treatment A|Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days
45406396|NCT03808298|Drug|Balovaptan supra-therapeutic dose Treatment B|Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.
45406397|NCT03808298|Drug|Active control [moxifloxacin] on Day 2 Treatment C|Day 2: A single oral dose of 400 mg moxifloxacin capsule.
45406398|NCT03808298|Drug|Active control [Moxifloxacin] on Day 15 Treatment D|Day 15: A single oral dose of 400 mg moxifloxacin capsule.
45406399|NCT03808298|Drug|Placebo for Balovaptan Treatment C|Days 1-14: Matching placebo for balovaptan for 14 days.
45406400|NCT03808298|Drug|Placebo for Balovaptan Treatment D|Days 1-14: Matching placebo for balovaptan for 14 days.
45406401|NCT03808298|Drug|Placebo for Moxifloxacin Treatment A|Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.
45406402|NCT03808298|Drug|Placebo for Moxifloxacin Treatment B|Days 2 and 15: Single oral dose of a matching placebo capsule of moxifloxacin.
45406403|NCT03808298|Drug|Moxifloxacin Treatment C|Day 2: A single oral dose of 400 mg moxifloxacin capsule.
45699368|NCT01229410|Drug|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
46057418|NCT04999371|Behavioral|Brief Alcohol Intervention|"The participants in the treatment group received free three-time counsel and constant multi-media messages about the topic of alcohol consumption for three months. One-to-one counseling services will be provided via a telephone call, which is based on World Health Organization (WHO) recommendations. A total of three counsels are conducted, which are set on the second week, sixth and tenth week after the baseline survey.~Brief intervention counselors are from the team of this study and trained by Hongkong University. All counselors are required to attend a full-day workshop before participant recruitment. The contents of the workshop include (1) knowledge of excessive drinking harms and benefits of controlling drinking; (2) overview of AUDIT; (3) alcohol reduction advice; (4) a standard procedure of brief intervention."
45699369|NCT02521740|Other|Research questionnaires, blood sample|assessment of health (frailty, nutrition, physical performance, depression, burden, sense of coherence, caregiver reaction)
45699370|NCT02841930|Other|ActionHealth NYC|care coordination, covered preventive services, and standardized costs for ambulatory care
45699371|NCT01212172|Device|Soprano/SHR|For the Soprano, the constant motion technique will be used with a fluence ranging between 6 J/cm2 and 10 J/cm2, 10 Hz, 20 ms pulse duration. The constant motion technique involves treating 100 cm2 areas with multiple passes until reaching the cumulative energy dose of 8 kJ. Thus, the hand piece is kept in constant motion to deliver continuous low fluence that will build up energy over time.
45699372|NCT01212172|Device|LightSheer|The LightSheer/Duet will be used with conventional single pass (stamping) of the handpiece using settings of single pulse fluence of up to 14 J/cm2 and low vacuum settings.
45699373|NCT04901208|Drug|Nicotine pod|Nicotine pods administered to individuals who use Juul
45406404|NCT03808298|Drug|Placebo for Moxifloxacin Treatment C|Day 15: A single oral dose of a matching placebo capsule for moxifloxacin.
45406405|NCT03808298|Drug|Placebo for Moxifloxacin Treatment D|Day 2: A single oral dose of a matching placebo capsule for moxifloxacin.
45406406|NCT03808298|Drug|Moxifloxacin Treatment D|Day 15: A single oral dose of 400 mg moxifloxacin capsule.
45406407|NCT03961178|Diagnostic Test|High-risk HPV|High-risk HPV testing for the cytology of lower genital tract
45406408|NCT03961178|Diagnostic Test|TCT|Thin prep liquid-based cytology test for the cytology of lower genital tract
45406409|NCT03961334|Drug|Dabigatran|150mg 2x/d
45406410|NCT03961334|Drug|Apixaban|5mg 2x/d
45406411|NCT03961334|Drug|Edoxaban|60mg 1x/d
45406412|NCT03961334|Drug|Aspirin|100mg 1x/d
45406413|NCT03961334|Drug|Clopidogrel|75mg 1x/d
45406414|NCT00077636|Drug|Copegus|400mg po bid for 16 weeks
45406415|NCT00077636|Drug|Copegus|400mg po bid for 24 weeks
45406416|NCT00077636|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 16 weeks
45406417|NCT00077636|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks
45406418|NCT03963674|Other|Diacutaneous fibrolysis|Diacutaneous fibrolysis over the gastrocnemious muscles
45406419|NCT01082198|Biological|HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine|
45406420|NCT01082198|Biological|HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine|
45406421|NCT01082198|Biological|autologous melanoma lysate-pulsed autologous dendritic cell vaccine|
45406422|NCT01082198|Biological|autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine|
45406423|NCT01082198|Biological|dendritic cell-idiotype-keyhole limpet hemocyanin vaccine|
45406424|NCT01082198|Other|flow cytometry|
45406425|NCT01082198|Procedure|adjuvant therapy|
45406426|NCT01088750|Drug|cyclophosphamide|
45406427|NCT01088750|Drug|prednisolone|
45406428|NCT01088750|Drug|vinblastine sulfate|
45406429|NCT01088750|Other|watchful waiting|
45406430|NCT01088750|Procedure|therapeutic conventional surgery|
45406431|NCT01088828|Other|Magnetic Resonance Imaging (MRI) of calf and foot|Detailed 3-D comparison of MRI scans of children with clubfoot and controls without clubfoot in utero, in untreated infants and in older children who have been treated.
45406432|NCT03957746|Other|Resistance training|3, 6 or 9 sets of biceps curl with elastic bands at 20 repetition-maximum (RM)
45406433|NCT01091012|Drug|Sildenafil 20mg oral vs Sildenafil 10mg intravenous|2 arms to comparation: Sildenafil 20mg oral vs intravenous Sildenafil 10mg
45406434|NCT01583582|Dietary Supplement|Marealis Refined Peptide Concentrate|1200 mg per os, once a day, 8 weeks
45406435|NCT01583582|Dietary Supplement|Marealis Refined Peptide Concentrate|600 mg per os, twice a day, 8 weeks
45406436|NCT01583582|Dietary Supplement|Marealis Refined Peptide Concentrate|0 mg per os, daily, 8 weeks
45406437|NCT01082276|Drug|Lurasidone HCl|40mg, Single-dose of lurasidone 40 mg (one 40 mg tablet) on Day 1. Daily dosing of rifampin 600 mg (two 300 mg capsules) on Days 1-8. On Day 8, subjects will also receive a single-dose of lurasidone 40 mg (one 40 mg tablet).
45514958|NCT02761603|Behavioral|Healthy Aging Practice-centered Instruction (HAPI)|"Sessions will include interactive activities derived from the CDC's Program to Encourage Active and Rewarding LiveS (PEARLS) and will include lectures based on health-related topics from presentations given by experts as part of the UC San Diego Stein Institute of Aging's Successful Aging project. The PEARLS Problem Solving Treatment (PST) group discussions will be facilitated by a trained instructor in order for participants to identify problems or barriers they have in engaging in healthy behaviors relevant to each of 12 topic areas (e.g. sleep, nutrition, mental health, social support, bone health, diabetes prevention, cognitive wellness, and resilience). Each session will be composed of: Successful Aging video (45 min), discussion (40 min), and identifying problem solving strategies (25 min) with a homework assignment each week, for a total of 24 hours of in-class instruction and discussion."
45514959|NCT02761603|Behavioral|Tai Chi (CHI)|Sessions will include expert instruction in the brief Yang-style 8-form Tai Chi meditative movements. Each class will include a 10-minute warm-up and cool-down plus 40 minutes of Tai Chi instruction and or practice, for a total of 24 hours of in-class instruction
45406438|NCT01088906|Drug|Pemetrexed/Cisplatin|Pemetrexed 500 mg/m2 IV followed by cisplatin 75 mg/m2 IV every 21 days. A cycle is 21 day.
45406439|NCT01082354|Drug|recombinant somatropin|as per standard practice
45406440|NCT01091090|Behavioral|Cognitive behavioral|Cognitive behavioral intervention for smoking cessation
45406441|NCT01091090|Behavioral|Control|Treatment as usual
45406442|NCT01082432|Other|electrically induced muscle activation|30 Hz frequency, 200 µs pulse duration, and 40% duty cycle (4 sec on, 6 sec off)
45406443|NCT00095199|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
45406444|NCT00095199|Biological|Cetuximab|Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity.
45406445|NCT00095199|Drug|Docetaxel|Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
45406446|NCT00075764|Drug|anastrozole|Given orally
45406447|NCT00075764|Drug|fulvestrant|Given intramuscularly
45514960|NCT01567033|Behavioral|PAT Curriculum + Health Information|Participants in the intervention group will receive the standard PAT curriculum plus information about healthy eating and an active lifestyle. This curriculum will be taught during up to 36 home visits in two years. Months 1-3 the visits are weekly; months 4-6 visits are biweekly; months 7-24 visits are monthly
45514961|NCT04783948|Other|Brace Treatment|Compliance to brace compression used for the correction of pectus carinatum will be evaluated.
45514962|NCT04812067|Drug|TTHX1114|engineered FGF-1
45514963|NCT04783987|Other|Walking asessments|Gait parameters will be evaluated in single and dual task conditions with 10 Meter Walk Test and wireless digital miniature portable walking and movement analyzer.
45514964|NCT05762497|Other|Moldable adhesive|Patients were provided with the new adhesives and a short questionnaire on current ASV use. After a week, they were contacted by telephone to verify any doubts/problems. At the end of the two weeks, the patient was again administered a questionnaire to evaluate the new moldable adhesive (while using the ASV).
45514965|NCT04759768|Drug|Nalmefene Hydrochloride|3mg nasal spray
45514966|NCT04759768|Drug|Nalmefene|1mg intramuscular injection
45514967|NCT04754113|Other|prone position|patient was helped into the prone position, patient received instructions of end expiratory occlusion lasting at least 10 seconds and, 1 seconds after the start, a bolus of 10 mL of 5% NaCl solution was injected via the central venous catheter
45514968|NCT04721392|Other|Mental fatigue (Stroop task)|"A modified Stroop task of approximately 60 min will be used in order to induce mental fatigue (MF). This will be based on their performance during the max test that was conducted during the familiarization session. In this task, which will be partitioned in 4 blocks of 468 stimuli, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself."
45406448|NCT03568162|Drug|ISB 830 - Part 1 Group 1|Subcutaneous injection (SC) every 2 weeks
45406449|NCT03568162|Drug|ISB 830 - Part 1 Group 2|Subcutaneous injection (SC) every 2 weeks
45514969|NCT04721392|Other|Control (documentary)|In the control task subjects will have to watch a documentary of 60 min on the same computer screen as the one used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several documentaries as proposed by the research team.
45406450|NCT03568162|Drug|ISB 830 - Part 1 Group 3|Subcutaneous injection (SC) every 2 weeks
45406451|NCT03568162|Drug|Placebo - Part 1 Group 4|Subcutaneous injection (SC) every 2 weeks
45406452|NCT03568162|Drug|ISB 830 - Part 2 Group 5|Subcutaneous injection (SC) every 2 weeks
45406453|NCT03568162|Drug|Placebo - Part 2 Group 6|Subcutaneous injection (SC) every 2 weeks
45406454|NCT03726970|Radiation|CBCT radiation|CBCT scanning
45406455|NCT03567616|Drug|Venetoclax|Tablet; oral
45406456|NCT03567616|Drug|Pomalidomide|Capsule; oral
45406457|NCT03567616|Drug|Dexamethasone|Administered orally; for participants over 75 years of age, dexamethasone could have been administered at a 20 mg dose [qw]
45406458|NCT03567382|Drug|Tenofovir Disoproxil Fumarate|300 mg tablet of TDF once daily from 28-32 weeks gestation through 12 weeks postpartum.
45406459|NCT03567382|Biological|Monovalent HBV vaccine|Infants born to HBsAg-positive women will be given a single dose of monovalent HBV vaccine within 24 hours of life.
45406460|NCT03595384|Behavioral|Soccer-based adaptation to the DPP|"Participants will complete online education modules during an initial 12 week conditioning phase where they will participate in soccer drills and other fitness routines (two 1-hour sessions per week). At the 12 week mark participants will transition onto a soccer league team for the following 12 weeks where they will continue to complete online modules and meet with the soccer coach monthly.~During the soccer sessions and games participants will be fitted with a wearable soccer-specific device to measure how much they move and their heart rate. In addition, they will also be asked to wear a Garmin fitness tracker for the duration of the study to measure steps and moderate and vigorous activity.~The online education will be a version of the Diabetes Prevention Program and can be completed on a phone or computer with internet access."
45406461|NCT05666128|Drug|HD-6277|HD-6277 Oral tablet 100mg
45406462|NCT05666128|Drug|HD-6277|HD-6277 Oral tablet 50mg
45406463|NCT05666128|Drug|Placebo|Oral tablet
45406464|NCT03731026|Combination Product|LightPath® Imaging System and 68Ga-RM2|"Imaging System:The LightPath® Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post-marketing study).~Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical."
45406465|NCT03731026|Drug|68Ga-RM2|Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
45699374|NCT04901208|Drug|Placebo pod|Nicotine-free pods administered to individuals who use Juul
45699375|NCT03442686|Behavioral|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
45699376|NCT02768766|Drug|Selumetinib|"100mg, 125mg, 150mg, 175mg, 200mg or 225mg of oral capsules~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
45699377|NCT03447054|Behavioral|Combined TDCS active and ICT active|Five 20-minute long sessions including TDCS (2 MicroAmperes during 20 minutes) and ICT, 5 consecutive days
45406466|NCT03730870|Diagnostic Test|Pharmacogenomics report|Intervention is the performance of a pharmacogenomics laboratory-developed test (LDT) performed by high-throughput sequencing of 38 genes involved in drug pharmacokinetics or pharmacodynamics. The clinician reviews the report results for each subject.
45406467|NCT03591874|Drug|Brimonidine Tartrate|Brimonidine Tartrate Nanoemulsion Eye Drops given 2 times a day for 12 weeks.
45699378|NCT03447054|Behavioral|Combined TDCS sham and ICT active|Five 20-minute long sessions including TDCS sham (non active) and ICT, 5 consecutive days
45699379|NCT03447054|Behavioral|Combined TDCS active and ICT inactive|Five 20-minute long sessions including TDCS sham and no-cue inhibition training, 5 consecutive days
45699380|NCT03447054|Behavioral|Combined Sham TDCS and inactive ICT|Five 20-minute long sessions including TDCS and no-cue inhibition training, 5 consecutive days
45699381|NCT01160458|Drug|IMC-A12|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
45851545|NCT01274988|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
45851546|NCT01274988|Other|methadone maintenance treatment|methadone maintenance treatment
45851547|NCT01278498|Drug|Escitalopram|first week:5mg 2nd week~12 week:10mg
45851548|NCT01278498|Drug|sugar pill|first week:5mg 2nd week~12 weeks:10mg
46057419|NCT04999371|Behavioral|Financial Incentive Intervention|The participants in financial Incentive intervention group were conducted by deducting money. Firstly, a certain amount of vouchers were given to the participants, which was equivalent to the reward for passing seven tests. Then, the voucher would be deducted according to every test result. Finally, the participants will receive cash according to the vouchers.
46057420|NCT04087447|Procedure|Thyroidectomy|Thyroidectomy
45406468|NCT03591874|Drug|Placebos|Opthalmic buffered saline solution Eye Drops given 2 times a day for 12 weeks.
45406469|NCT03730714|Drug|"Local Anesthetic, Epinephrine and Morphine"|local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
45406470|NCT03730714|Drug|"Local Anesthetic, Epinephrine, Morphine and Surgicel"|Surgicel soaked with mixture of: local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
45406471|NCT03730714|Drug|"Normal Saline"|normal saline 0.9% to soak the surgicel according to the planned technique
45406472|NCT03726892|Device|PCI|Coronary Intervention
45514970|NCT04745455|Other|Infant formula containing prebiotics, probiotics and postbiotics|Infant formula containing prebiotics, probiotics and postbiotics
45406473|NCT03566680|Device|Orthokeratology|Orthokeratology is a type of contact lens that is worn over night to reduce refractive error, so patients do not need to wear vision correction during the day.
45514971|NCT05738200|Other|Nordic Hamstring Exercise|A 4-week (10 session), progressive, NHE protocol will be used for this study. Immediately following the completion of study visit 1, patients will be informed about the nature of the NHE protocol. Those available and willing to participate will be randomized to an intervention group (NHE, control). Patients randomized to NHE will receive formal instruction about how to correctly perform the exercise, and will be asked to perform several repetitions to familiarize themselves with the exercise and verify proper technique. At this time, patients will be dismissed from study visit 1, and return visits 2-11 will be scheduled to complete the NHE protocol. Patients will return for a final study visit (12) to record post-intervention measurements within 7 days of completing the NHE protocol. A minimum of 48 hours will be used to separate study visits. To accurately assess patients' ability to perform the NHE, all exercise will be performed on a NordBord Hamstring Testing System.
45406474|NCT00106353|Drug|Torisel|60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors. Part 1 is an ascending-dose study to evaluate the safety of IV temsirolimus given once weekly to subjects ages 1 to 21 years with advanced solid tumors disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available. (enrollment completed) Part 2 will be conducted in three groups of children with refractory or relapsed pediatric solid tumors. Subjects with the following tumor types will be enrolled: neuroblastoma, rhabdomyosarcoma, and high-grade gliomas. Subjects will receive IV temsirolimus once weekly until disease progression or unacceptable toxicity.
45406475|NCT01087983|Drug|Lapatinib|Starting oral dose of 500 mg daily for 21 day cycle.
45851549|NCT01279980|Other|Epidural|Epidural analgesia inserted prior to surgery to stay in until at least the second postoperative day
45514972|NCT04676737|Drug|TTHX1114(NM141)|TTHX1114
45514973|NCT05738122|Other|60-Day self-guided Emotion Regulation Journal|A 60-day self guided journal with activities designed to be completed daily to improve an individual's emotion regulation abilities and habits
45514974|NCT05201677|Procedure|Supplement of perfusion fluid through the subiris suspensory ligament space from the lateral incision|After the capsule is filled with viscoelastic material, if the IOP is less than 10 mmHg, the investigators will supply the perfusion fluid through the subiris suspensory ligament space from the lateral incision.
45699382|NCT03109704|Procedure|Supine upper thoracic spine thrust manipulation|The supine thrust manipulation will target the upper thoracic spine and will be performed as previously described. The patient will be asked to lace his or her fingers behind the neck and bring his or her elbows close together in front of the chest. The therapist will place one hand just below the targeted upper thoracic region (at either the T3 or T4 level) using a pistol grip or loose fist to make contact with both transverse processes of the T3 or T4 vertebrae. The therapist will then use his or her body to push down through the patient's upper arms to provide a high-velocity, low-amplitude thrust in the anterior-to-posterior direction.
45406476|NCT01087983|Drug|Sirolimus|Starting oral dose 1 mg daily.
45514975|NCT05738044|Other|No intervention|No intervention
45514976|NCT04676191|Device|Sleepiz One+|Simultaneous sleep study with polysomnography and Sleepiz One+
45514977|NCT04676191|Device|Polysomnography|Simultaneous sleep study with polysomnography and Sleepiz One+
45514978|NCT05737966|Other|evaluation of professional practices|Evaluation of professional practices : evaluation of the case management carried out in a program for early psychosis in France using a checklist according good practices guidelines
45514979|NCT02570282|Drug|Placebo|Approximately 50% of the cream is to be applied externally to the clitoris and labia minora and approximately 50% is to be applied intravaginally.
45514980|NCT02570282|Drug|SST-6007|SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
45514981|NCT05737888|Other|fMRI Neurofeedback|15 intervention sessions on a 3T MRI scanner.
45514982|NCT05737888|Other|EEG Neurofeedback|15 intervention sessions with a standard EEG-cap with 64 active electrodes.
45851550|NCT01279980|Other|Local anaesthetic wound catheter|The catheter will be used to infuse the wound with local anaesthetic for 48 hours post op.
45851551|NCT00249834|Drug|Gonal-f|GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.
46057421|NCT02708901|Dietary Supplement|Vivomixx®|Two packets (900 billions bacteria) per os (P.O.) daily x 1 month and one packet (450 billions bacteria) P.O. daily x 5 months
45406477|NCT01087983|Drug|Metformin|Starting oral dose 1000 mg daily.
45406478|NCT00080301|Drug|Ixabepilone + Capecitabine|"Ixabepilone - Intravenous Solution, IV 40mg/m², Day 1 every 21 days, Until progression/unacceptable toxicity~Capecitabine (Active Comparator) - Tablet, Oral, 2000 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity"
45406479|NCT00080301|Drug|Capecitabine|Tablet, Oral, 2500 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
45406480|NCT01083927|Procedure|Rotational Narrow Strip Conjunctival Graft|Surgical technique
45406481|NCT01083927|Procedure|Full Conjunctival Graft|Surgical technique
45514983|NCT05737888|Behavioral|Cognitive Behavioral Therapy|10 intervention sessions of CBT group therapy, as per local university hospital standard of care.
45514984|NCT02564744|Drug|Debio 1562|Safety run in: Debio 1562 will be given on the same day as rituximab, once every three weeks (Q3W) intravenously (IV) at the dose of 0.7 mg/kg on Day 1 of a 21-day cycle. Parts 2 and 3: Cohort A- Debio 1562 will be given on the same day as rituximab, once every three weeks (Q3W) intravenously (IV) at the dose of 0.7 mg/kg on Day 1 of a 21-day cycle. Cohort B- Debio 1562 weekly (QW) will be given at a total dose of 0.8 milligram per kilogram (mg/kg) IV over a 21-day cycle. Participants receiving QW regimen will be allowed to switch to Q3W regimen during Coronavirus Disease 2019 (COVID-19) pandemic.
45514985|NCT02564744|Drug|Rituximab|Rituximab will be given on the same day as Debio 1562, Q3W IV at a dose of 375 mg/m^2 on Day 1 of a 21-day cycle in all participants.
45514986|NCT05201599|Device|Flexible ureteroscope with intelligent control of renal pelvic pressure|After adjusting the UAS in suitable position, the pressure sensory and suctioning channels are connected to the irrigation and suctioning platform. After being injected with water, a zero calibration is performed for the pressure sensory system. A fully automatic mode is selected on the platform. The perfusion flow is set between 50 to 150 mL/min. The RPP control value is set between -15 to -5 mmHg. The renal pelvic pressure alarm value is set between 20 to 30mmHg. During the operation, a holmium laser is used to break stones into powder (fiber diameter 200 µm), and the flexible ureteroscopy is moved back and forward slightly to suck out the stone particles inside the sheath gap. Particles larger than the sheath gap but smaller than the UAS is sucked out by intermittently withdrawing the flexible ureteroscope without basket.
45406482|NCT03961503|Drug|Daptomycin (DAP) treatment|Group DAP : Daptomycin was administered at a dose of 8 mg/kg in thirty-minutes intravenous infusion every 24 hours in patients without severe impairment of kidney function or every 48 hours in case of GFR below 30 ml/min/m2. The creatine-kinase (CK) level was measured before the initiation of DAP and at least once a week to assess the occurrence of muscular toxicity defined by an increase of CK up to 3-fold the upper superior limit without any evidence of member ischaemia.
45514987|NCT03110536|Diagnostic Test|Copenhagen Burnout Inventory|"A questionnaire based on Copenhagen Burnout Inventory will be completed by each participant to the study, at the beginning of the triage shift and after 2, 4 or 6 hours.~The questionnaire also contains clinical cases that require triage coding."
45514988|NCT03110536|Other|Triage scoring efficacy|The triage scores of the first 5 and the last 5 cases assessed by the investigated nurse will be compared with the triage codes of an expert evaluator (nurse involved in designing The National triage Protocol).
45514989|NCT02564588|Drug|Dasotraline|Dasotraline 4, 6, 8mg flexibly dosed once daily
45514990|NCT02564588|Drug|Placebo|Placebo once daily
45514991|NCT03110302|Behavioral|Prolonged exposure|PE is a manualized treatment developed by Dr. Edna Foa and her colleagues. In all three treatment modalities, 7-15 weekly, 90 minute individual sessions of PE will be provided. PE is based on emotional processing theory, which proposes that avoidance and negative thoughts about the self and the world maintain PTSD symptoms over time. According to emotional processing theory, effective treatment requires repeated activation of the trauma memory (as through memory and in vivo exposure) and incorporation of corrective information into the trauma fear structure. PE has several primary components: (1) psychoeducation about PTSD and avoidance; (2) imaginal exposure with processing, wherein the participant describes the traumatic memory aloud many times and discusses it with the therapist afterward; and (3) in-vivo exposure, wherein the participant engages in feared, but safe, activities that have been avoided since the traumatic event (e.g., crowded places, driving).
45514992|NCT04665817|Diagnostic Test|CT-QFR|CT-QFR is a novel method for evaluating the functional significance of coronary stenosis. It is calculated by coronary computed tomographic angiography images.
45514993|NCT04665817|Diagnostic Test|QFR|QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two. angiographic projections.
45514994|NCT04665817|Diagnostic Test|FFR|FFR measured by pressure wire is the gold standard for evaluating the functional significance of coronary stenosis.
45851552|NCT00249834|Drug|Recombinant human chorionic gonadotrophin (r-hCG)|When at least 1 follicle greater than or equal to (>=) 18 millimeter (mm) and 2 follicles >=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.
46057422|NCT02708901|Dietary Supplement|Placebo|Two packets (4,4 grams of maltose and silicon dioxide x 2) P.O. daily x 1 month and one packet (4,4 grams of maltose and silicon dioxide) P.O. daily x 5 months
45514995|NCT04049500|Other|Digital Diabetes Prevention Program (dDPP)|dDPP tool suite to integrate with the EHR and clinical workflows
45514996|NCT05759767|Drug|Tamsulosin|Children in this group will receive medical expulsive therapy in the form of (tamsulosin at a dose of 0.01 mg/kg once daily for 3 weeks after ESWL session.
45851553|NCT00249444|Drug|Mirtazapine|Mirtazapine
45851554|NCT00249444|Drug|Placebo|placebo
45851555|NCT00249288|Drug|Folate|Folic acid taken as 2, 1mg capsule daily for 12 weeks
45851556|NCT00249288|Drug|Placebo|Placebo taken as 2, 1mg capsule daily for 12 weeks
46057423|NCT04087525|Drug|HIP1701|Vildagliptin
46057424|NCT04087525|Drug|HGP1809|Vildagliptin
45406483|NCT03961503|Drug|Vancomycin (VAN) treatment|Group VAN : Vancomycin intravenous treatment was initiated by a loading dose of 30 mg/kg in 1 hour and followed by a continuous maintenance infusion dosing between 15 and 30 mg/kg/d. The VAN dose was adapted to achieve a target serum vancomycin steady-state concentration of 20-30 mg/L assessed by a daily pharmacologic monitoring (therapeutic drug monitoring).
45406484|NCT01084317|Other|medical documentation and telephone interview|medical documentation analysis supplemented by telephone interview conducted with parents of the child
45406485|NCT00079677|Drug|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
45514997|NCT05759767|Drug|Placebo|Children in this group will receive placebo once daily for 3 weeks after ESWL session.
45514998|NCT02561234|Drug|Co-ArgI-PEG|Administered IV
45514999|NCT03949036|Other|Crystalloid fluid administration with the target of stroke volume variation ≤ 12%|The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 12%
45515000|NCT03949036|Other|Crystalloid fluid administration with the target of stroke volume variation ≤ 6%|The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 6%
45515001|NCT04606693|Other|Treatment of SAHS|Patients diagnosed with SAHS will be treated in the Pneumology Service according to usual practice (dietary hygienic measures, CPAP, etc.).
45515002|NCT03136900|Dietary Supplement|Nutrilon without lactose® fortified by concentration|enteral diet with cow milk protein-based infant formula without lactose 20% in place of 14%
45699383|NCT03109704|Procedure|Seated upper thoracic spine thrust manipulation|The seated thrust manipulation will target the cervicothoracic junction with the patient sitting with fingers laced behind the neck. The therapist will stand behind the patient and thread his or her arms through the patient's arms and clasp his or her hands near the C7-T1 level. The therapist will make contact with his or her chest against the patient's upper thoracic region to serve as a fulcrum. The patient will then be instructed to take a deep breath, and upon exhalation the therapist will apply a high-velocity, low-amplitude distraction thrust in a cephalad direction.
45699384|NCT03109704|Procedure|Sham manipulation|"The sham manipulation will be performed with the patient and the examiner positioned in the same manner as for the seated manipulation, however the examiner will apply only minimal pressure to maintain physical contact and skin lock with the patient. The examiner will then move the patient through the same range of motion but deliver no manipulative thrust."
45851557|NCT00248040|Drug|Reparixin continuous infusion|The Investigational Product was administered as an intravenous infusion into a (high flow) central vein or through an arterio-venous fistula, by an infusion pump adequate to provide reliable infusion rates, as per treatment schedule. Total infusion volume did not exceed 500 mL/24 hours. A dose of 2.772 mg/kg body weight/hour was to be administered for 12 hours. Placebo was volume/schedule matched saline.
45851558|NCT00248040|Drug|reparixin intermittent infusion|A dose of 2.244 mg/kg body weight was to be administered over a 30-minute period, followed by a 1.5-hour interval. Twelve doses were to be administered over a total period of 22.5 hours. Placebo was volume/schedule matched saline.
45851559|NCT00248040|Other|placebo infusion|placebo was volume/schedule matched saline
45851560|NCT00247962|Drug|etanercept|50 mg
45851561|NCT00247962|Drug|sulphasalazine (SSZ)|Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.
45406486|NCT00079677|Drug|Placebo|Matching placebo tablets once daily
45406487|NCT03961425|Behavioral|NO CO2|Traditional mechanical Deairing
45406488|NCT03961425|Device|CO2 Cannula|NON specific, low cost delivery system
45406489|NCT03961425|Device|CO2 Cardia|Specific Commercial CO2 Diffuser
45406490|NCT01088139|Dietary Supplement|Protein supplementation|Ready made protein supplement drinks with approximate protein content of 18-24g per 500ml per day. Caloric content is 490 to 530Kcal depending on the brand of drink.
45406491|NCT03964155|Biological|Sample|After an exposure duration of at least 12 hours, a sample of directly-aspirated, undiluted pulmonary edema fluid will be collected concurrently with AnaConDa-S® filter collection.
45406492|NCT01081275|Behavioral|CI Therapy|CI Therapy will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
45406493|NCT01081275|Behavioral|CAM treatments|CAM treatments will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
45406494|NCT01081353|Drug|Acetylsalicylic Acid (Aspirin BAY1019036)|One tablet of new formula Aspirin under fasting conditions
45406495|NCT01081353|Drug|Alka Seltzer Extra Strength|One effervescent tablet under fasting conditions
45406496|NCT01081353|Drug|Aspirin Migraine|One effervescent tablet under fasting conditions
45406497|NCT01081353|Drug|Aspirin Aspro|One effervescent tablet under fasting conditions
45515003|NCT03136900|Dietary Supplement|Nutrilon without lactose® fortified by Maltodextrin and oil supplementation|enteral diet with cow milk protein-based infant formula without lactose 14%
45515004|NCT02750306|Drug|Suvorexant|10 mg tablet (may be increased to 20 mg tablet)
45515005|NCT02750306|Drug|Placebo|Placebo to suvorexant
45515006|NCT03941704|Dietary Supplement|Pulse-based diet|Low Glycemic Index
45515007|NCT03941704|Dietary Supplement|Regular diet|Moderate Glycemic Index
45851562|NCT00247416|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 intravenously over 30 minutes on days 5 and 12.
45851563|NCT00247416|Drug|Dexamethasone|16 mg bid for 4 days prior to each chemotherapy start.
45851564|NCT00247416|Drug|Carboplatin|AUC 6.0 intravenously over 30 minutes on day 5.
45851565|NCT00246090|Drug|E7389|E7389 1.4 mg/m^2 intravenous bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
45406498|NCT01084395|Behavioral|Adolescent Safer Sex Intervention|Adolescents are randomly assigned to the HIV risk-reduction intervention condition. Adolescents receive a theory-based intervention designed to reduce HIV risk-associated behavior. The intervention consists of six 50-minute modules implemented over the course of two days. The intervention is highly interactive and includes games, videos, discussion, and role-plays.
45406499|NCT01084395|Behavioral|Parent Safer Sex Communication Intervention|Parents are randomly assigned to the Safer Sex Communication Intervention. Parents learn about HIV and other consequences of unprotected sexual behavior. The intervention contains content that focuses on enhancing parent-adolescent communication.
45406500|NCT01084395|Other|Adolescent Health Promotion Control Condition|Adolescents are randomly assigned to the Health Promotion control condition. Adolescents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Adolescents are taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use.
45406501|NCT01084395|Other|Parent Health Promotion Control Condition|Parents are randomly assigned to the Health Promotion control condition. Parents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Parents will be taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use. The intervention also provides content that emphasizes the importance of families.
45406502|NCT00095121|Drug|Placebo (PLB)|Matching placebo
45406503|NCT00095121|Drug|Adefovir Dipivoxil (ADV)|10-mg tablet or 2-mg/mL oral suspension
45515008|NCT03845140|Drug|L-PZQ ODT|Participants will receive single oral dose of L-PZQ ODT 50 mg/Kg on Day 1.
45515009|NCT03845140|Drug|Biltricide®|Participants will receive single oral dose of Biltricide® 40 mg/kg crushed tablet on Day 1.
45515010|NCT03845140|Drug|L-PZQ ODT|Participant will receive single oral dose of L-PZQ ODT 60 mg/kg as decided by the IDMC.
45515011|NCT00238862|Procedure|Amniotic membrane transplantation|
45515012|NCT00238862|Drug|Autologous serum/BSS 20%|
45515013|NCT01816165|Drug|Acipimox|Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.
45515014|NCT01816165|Drug|Placebo|Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day
45515015|NCT03136822|Other|Standard Dressing|Standard dressing is applied for treatment of diabetic foot ulcers
45515016|NCT03136822|Device|DERMALIX|DERMALIX, a class III Medical Device will be applied in addition to standard dressing
45515017|NCT04476680|Dietary Supplement|Vitamin D|Pure Encapsulations' manufacturing facility is a US Food and Drug Administration (FDA) inspected and NSF International Good Manufacturing Practices registered company.
45515018|NCT04952350|Drug|Atorvastatin 40 Mg Oral Tablet|Patients will receive Atorvastatin 40 mg orally within 24 hrs after hospital admission after evaluation of the clinical and laboratory inclusion criteria.
45515019|NCT04952350|Other|Placebo|A formulary similar to the drug tablets and labels but without the active ingredients (Atorvastatin).
45515020|NCT05376202|Drug|Cetuximab-IRDye800CW|Patients will receive 75mg Cetuximab followed by 15mg Cetuximab-IRDye800CW two days prior to surgery
45515021|NCT03890588|Other|CKD enhanced clinical decision support|The CKD-CDS intervention provides clinical recommendations at any primary care visit for patients with a deficit in any of 5 key elements of CKD care.
45515022|NCT04812808|Drug|Bazedoxifene 20 mg|"Bazedoxifene will be administered during the duration of the study in the experimental arm together with chemotherapy.~Prophylactic rivaroxaban (Xarelto®) 10 mg per day orally will be added to avoid thromboembolic events."
45699385|NCT01212484|Drug|Carbidopa|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
45699386|NCT01212484|Drug|Placebo|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
45515023|NCT01780675|Radiation|Radiation Prophylactic Cranial Irradiation|
45515024|NCT01780675|Radiation|Radiation Hippocampal Avoidance PCI|
45515025|NCT04797442|Drug|WST01 strain product|orally given WST01 strain product, added onto lifestyle. The specific ingredients are the optimized Akkermansia muciniphila WST01 strain powder with maximum live bacteria of 5*10^10 CFU/g (1 g/pack, 3 packs QD, 20-30 min after breakfast)
45515026|NCT04797442|Drug|placebo powder|orally given placebo powder (the specific ingrdients are the excipients of the WST01 strain powder), added onto lifestyle. (3 packs of placebo powder QD, 20-30 min after breakfast)
45699387|NCT03446976|Biological|CT-P13 SC Auto-injector|Each subject may receive single dose by subcutaneous administration using Auto-Injector
45699388|NCT03446976|Biological|CT-P13 SC Pre-filled Syringe|Each subject may receive single dose by subcutaneous administration using Pre-filled Syringe
45515027|NCT02262884|Device|SurgiQuest AirSeal Insufflation System (AIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
45515028|NCT02262884|Device|Conventional Insufflation System (CIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
45699389|NCT03109548|Other|Standard care initiated by the general practitioner|Patients are treated based on their symptoms and the research group does not interfere with this.
45406504|NCT00095121|Drug|Lamivudine|100-mg tablet administered according to package labeling. Lamivudine was to be added to the open-label ADV regimen of subjects with a serum HBV DNA concentration >= 1000 copies/mL at 2 consecutive study visits at or after Study Week 96. If the HBV DNA concentration remained >= 1000 copies/mL at 2 consecutive study visits after the addition of lamivudine, the investigator was required to discontinue all study drugs, perform the early termination ssessments, and have the subject return every 4 weeks for 16 weeks of posttreatment evaluations.
45406505|NCT01081431|Drug|Lenalidomide|10 mg d1-d21 of a 28-day cycle
45406506|NCT03962829|Drug|mCPP|Healthy participants administrate one capsule of mCPP (30mg)
45406507|NCT03962829|Drug|Placebo oral tablet|Healthy participants administrate one capsule of placebo (containing lactose)
45406508|NCT00094809|Drug|Placebo|Subjects randomized to placebo will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
45406509|NCT00094809|Drug|Pegfilgrastim|Subjects randomized to pegfilgrastim will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
45406510|NCT03962751|Behavioral|Simultaneous Post Feedback Intervention Delivery|Simultaneous PFI delivery after baseline survey
45699390|NCT01212874|Drug|nitroglycerin|nitroglycerin administered as an infusion following a step up/step down protocol to treat hypertension in patients undergoing cardiac surgery.
45406511|NCT03962751|Behavioral|Sequential Post Feedback Intervention Delivery|Sequential PFI delivery over 3 weeks after baseline survey
45406512|NCT03962751|Behavioral|Text Message Boosters|Text message boosters on PFI content during week of high risk drinking event
45406513|NCT01084473|Drug|Dexmedetomidine|The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
45406514|NCT01084473|Drug|Morphine|The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
45406515|NCT01084473|Drug|Placebo|0.9 % NaCl will be infused.
45406516|NCT01088373|Drug|Azacitidine combined to Lenalidomide|Azacitidine: 75mg/m2/d for 5 days per cycle of 28 days. Lenalidomide: 5mg/day during 14 days for cohort 1. Lenalidomide: 5mg/day during 21 days for cohort 2. Lenalidomide: 10mg/day during 21 days for cohort 3.
45515029|NCT03888872|Device|High tone power therapy|"1- High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort. Duration: 60 min (Each one electrode to both thighs to the knee, each one electrode to both thighs to the groin). Position: lying / setting, Number of sessions: 10, Frequency of sessions: 3 times per week."
45406517|NCT01088451|Drug|Combined prandial insulin therapy (CPIT)|Combined prandial insulin therapy (CPIT) applies individual combination of rapid insulin analogue and human insulin according subject's individual estimation of the type of carbohydrates in concrete mixed-meal, based on thorough education. In this study subjects use two applicators, giving two injections before main meals as per basal-bolus therapy. Insulin aspart (Novorapid, Novo Nordisk) and human insulin (Actrapid, Novo Nordisk) are used.
45515030|NCT03888872|Other|Selected Physical Therapy Program|"Selected physical therapy program: (For both groups).~Wobble board training:~Active range of motion exercises (AROM):~Gentle manual stretching exercises for both UL & LL:~Graduated gait training:"
45515031|NCT04788550|Combination Product|Fluoridated toothpaste|Group 1 will act as control group. Participants will be advised to brush twice daily using fluoridated toothpaste during the follow up periods. No other fluorides supplements will be allowed to use.
45699391|NCT01212874|Drug|esmolol|esmolol will be administered by infusion following a step up / step down protocol to control hypertension.
45406518|NCT00075218|Drug|Placebo|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
45406519|NCT00075218|Drug|SU011248|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
45515032|NCT04788550|Combination Product|fluoride varnish (5% sodium fluoride)|Approximately 0.5-1.0ml fluoride varnish will be applied on the tooth surface (labially) with the paint-on method fom canines to canines. No other fluorides supplements will be allowed to use.
45515033|NCT04788550|Combination Product|CPP-ACP plus crème group|Pea size CPP-ACP plus crème on the tooth surfaces using a clean fingers twice daily after brushing their teeth with fluoridated toothpaste. No other fluorides supplements will be allowed to use.
45406520|NCT03963440|Other|Exercise Adherence Rating Scale (EARS)|"Inclusion and first questionnaires period (10 questionnaires), after geting consent, during normal patient consultation schedule for functional restoration program of the lumbar spine (1 to 3 weeks hospital in day care).~Second questionnaire period at 48h (Only EARS questionnaire) Third questionnaires period (10 questionnaires) at the end of the restoration program hospital care.~Fourth and last questionnaires period (10 questionnaires) at 3 months during a normal patient follow-up consultation No additional appointments."
45406521|NCT01089140|Drug|Tranexamic acid 10mg/kg/hr|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator
45406522|NCT01089140|Drug|Tranexamic acid 100 mg/kg/h infusion|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator.
45406523|NCT01089140|Drug|Saline solution|Saline placebo
45406524|NCT00094653|Drug|MDX-010 (anti-CTLA4) monoclonal antibody|3mg/kg (intravenous [iv] infusion over 90 minutes), every 3 weeks for 4 doses
45406525|NCT00094653|Biological|MDX-1379 (gp100) Melanoma Peptide Vaccine|2mL (2 subcutaneous injections of 2 mL each, 1 to each thigh), every 3 weeks for 4 doses.
45406526|NCT00104247|Drug|sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin|
45406527|NCT03565900|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose.
45406528|NCT03565900|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose
45406529|NCT03565900|Biological|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
45406530|NCT03564184|Behavioral|MT during NICU|Music therapy (MT) by trained music therapist, 3 times/week for 30-40 minutes/session during NICU hospitalization. Involves primary caregiver and infant in musical communication matched to infant post-menstrual age, family/cultural preferences, and infant readiness for stimulation. Music therapist assesses infant´s needs and behavior state, supports caregiver in using basic touch (e.g., hand lightly and statically on infant´s chest or back to perceive breathing pattern) and caregiver´s hummed/sung voice matched to infant behavioral responses, to promote infant state regulation and bonding. Music includes input from music therapist as needed, and multimodal aspects such as gentle dynamic touch when infant demonstrates readiness. MT may occur while infant is held in a static manner by caregiver or is resting in his/her isolette or basinet. MT may occur during skin-to-skin care, if such care is part of standard care.
45515034|NCT01677988|Drug|Neo-adjuvant Chemotherapy|"Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles, for three (3) cycles with growth factor support.~Restaging # 1. (CT or MRI; use same modality as baseline staging unless otherwise indicated by Study Team)~Progressive Disease (PD) → Off study. Subsequent treatment per patient's primary MD.~Stable Disease (SD) or Tumor Response → Continue to Registration #2 for Chemoradiation."
45515035|NCT01677988|Radiation|Chemoradiation|"Chemoradiation may be administered at selected approved CTN sites.~Determination of resectability as reviewed and documented by MUSC-HCC GI Tumor Board.~Unresectable → Off study. Subsequent treatment per patient's primary MD.~Resectable → Continue to Registration #3 for Surgical Resection"
45515036|NCT01677988|Procedure|Surgical Resection|"Meets criteria for resectable* →pancreaticoduodenectomy (POD)~At time of resection, snap frozen tumor specimen sent for correlative biomarker studies"
45515037|NCT05761795|Drug|IVMED 85|Eye drop
45515038|NCT05761795|Drug|Placebo|Placebo eye drop
45515039|NCT03864536|Behavioral|Cognitive Prescriptions|Personalized information on their risk factor profile across five CogRx domains (physical activity, cognitive activity, diet, sleep, social activity) and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
45515040|NCT04538599|Drug|RD13-01 cell infusion|Universal CAR-T cells targeting CD7
45515041|NCT02233634|Drug|Oxygen|Oxygen is provided with a standard medical oxygen mask with reservoir (12L/min) for 3-5 min, assigned to both groups
45699392|NCT03446898|Other|Chronic hypoxic environment|Chronic hypoxic environment. Since the partial pressure of oxygen in inspired air falls with increasing terrestrial elevation above sea level, many physiological variables in adults would be affected by the chronic hypoxia environment.
45699393|NCT03442608|Procedure|Zoll 2000 and/or CureWrap 3500 cooling system|Device(Zoll 2000 and/or CureWrap 3500 cooling system),lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.
45515042|NCT02233634|Other|Hyperventilation Breath-hold (HVBH)|1 Minute of Hyperventilation (25/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
45515043|NCT02233634|Other|HVBH with Oxygen|1 Minute of Hyperventilation (25/min) with an oxygen mask mounted (12L/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
45515044|NCT04692220|Other|Detection of Adverse Drug Events or Drug-Related Problems|Detection of Adverse Drug Events or Drug-Related Problems
45515045|NCT04508413|Other|KB295|KB295 is a novel glycan
45515046|NCT02233712|Biological|G17DT|
45515047|NCT04689490|Diagnostic Test|Cardiopulmonary exercise test|Only diagnostic tests
45515048|NCT04506853|Device|MED-EL Cochlear Implant System|Cochlear implant and audio processor
45699394|NCT03446820|Other|hygro cotton sheets|hygro cotton sheets will be utilized to impact microclimate
45754189|NCT03590353|Device|Dual Chamber Pacemaker|1. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.
45406531|NCT03564184|Behavioral|MT after NICU|Music therapy offered by trained music therapist, 7 times for approximately 45 minutes/session across first 6 months following discharge from initial NICU hospitalization. Sessions include infant and caregiver, and siblings, if desired, and occur at home or in municipal settings. MT after NICU consists of a consult-to-parent model with each session including a brief verbal check-in regarding infant´s progress, musical interactions with music therapist modelling musical engagement, discussion of current challenges and strategies for using musical interactions to address needs in areas such as infant self-regulation, parent/infant interaction, and challenges with bonding. Caregivers will demonstrate techniques discussed during session, and form a brief plan for use of musical interaction in the interim before next session. Sessions will be adapted to infant developmental level and ongoing needs.
45515049|NCT02262962|Other|Redesigned Well-Child Care|The Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and HealthyTxt Messaging service.
45515050|NCT02233790|Drug|Ticagrelor|a loading dose of 180mg pre-PCI, and then 90 mg twice daily for 1 Month within the study. Thereafter, the patients will take clopidogrel if Ticagrelor is not available on the market.
45515051|NCT02233790|Drug|Clopidogrel|Clopidogrel 75 mg once daily after a loading dose of 300 mg pre-PCI.
45515052|NCT02547818|Drug|ALZT-OP1a|1) Mast cell stabilizer, 2) Neuroinflammatory microglial modulator, 3) A-beta oligomerization inhibitor, and 4) anti-inflammatory
45515053|NCT02547818|Drug|ALZT-OP1b|Anti-inflammatory
45515054|NCT02547818|Other|Placebo ALZT-OP1a|Non-active capsules
45699395|NCT03446742|Other|Cardiovascular rehabilitation|The cardiovascular rehabilitation program is performed three times weekly on alternate days and each session lasts approximately 60 minutes divided as follows: 5 minutes to the initial rest where blood pressure (BP), heart rate (HR) and signs and symptoms are assessed; 15 minutes of warm-up, composed by global stretches, lower and upper limb exercises, and exercises combining the two modes; then, patients go to the resistance phase (30 minutes), where are performed an individualized aerobic protocol according to their HR reserve values using bicycle and treadmill (at the 4th and 10th minute of both ergometers at HR is evaluated, and in the bicycle is also evaluated the BP of all the patients). The end of the protocol is composed of 10-minute relaxation, during which the patients perform a small cardiovascular deceleration (a few laps around the room, with free speed) and, finally, lie down at rest. The presence of signs and symptoms is assessed at all stages of the program.
45699396|NCT03129438|Diagnostic Test|continuous EEG (cEEG)|differential use of continuous versus routine EEG
45515055|NCT02547818|Other|Placebo ALZT-OP1b|Non-active tablets
45851566|NCT00246012|Drug|Intetumumab|Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.
45515056|NCT04539808|Drug|Capecitabine|Given PO
45515057|NCT04539808|Drug|Fluorouracil|Given IV
45515058|NCT04539808|Drug|Irinotecan Hydrochloride|Given IV
45515059|NCT04539808|Drug|Leucovorin Calcium|Given IV
45515060|NCT04539808|Drug|Losartan Potassium|Given PO
45515061|NCT04539808|Drug|Oxaliplatin|Given IV
45515062|NCT04539808|Radiation|Radiation Therapy|Undergo short-course or long-course RT
45515063|NCT04539808|Procedure|Resection|Undergo surgical resection
45515064|NCT04457440|Behavioral|Intensive Lifestyle Intervention|This intervention is an abbreviated version of the Diabetes Prevention Program, which has been shown to be effective in reducing the risk of developing type 2 diabetes.
45515065|NCT04457440|Behavioral|Intensive Lifestyle Intervention enhanced with Cognitive Behavioral Sleep Intervention|This intervention will consist of the same 8 sessions of ILI with additions of sleep components in each session. The additional sleep components will include (a) psychoeducation about the importance of sleep in weight control and glycemic control, (b) sleep hygiene, (c) stimulus control, (d) modifying maladaptive beliefs about sleep, (e) and, setting individualized sleep schedule and reviewing sleep schedule.
45406532|NCT03564184|Other|Standard care|Includes necessary medical care and standard supportive interventions offered as part of care during hospitalization, and standard follow-up procedures post-hospitalization.
45406533|NCT05665348|Drug|Ipilimumab Injection|Administration of a combine treatment by atezolizumab and bevacizumab, with addition of ipilimumab for patients enrolled in the experimental arm
45406534|NCT05665348|Drug|Atezolizumab Injection|One of the standard treatment's product for HCC management
45406535|NCT05665348|Drug|Bevacizumab|One of the standard treatment's product for HCC management
45406536|NCT03726814|Biological|EPC treatment group|Brain injection EPC
45406537|NCT03726736|Drug|Anlotinib combined Docetaxel|Anlotinib ( dose base on phase I study, QD PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2 IV, d1, 21 days per cycle)
45406538|NCT03726736|Drug|Docetaxel|Docetaxel (60mg/m2 IV, d1, 21 days per cycle)
45406539|NCT03591406|Drug|Ferric carboxymaltose|Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection Strength: 10 mL vials containing 500 mg iron per vial Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening) Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline) Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.
45406540|NCT03591406|Drug|Iron sucrose|Dosage Form: Sterile solution for injection containing 2% w/v iron Strength: 5 mL ampoules containing 100 mg iron per ampoule Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given Route of administration: IV injection or drip infusion Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.
45406541|NCT03560986|Drug|Neridronic acid 100 mg|100 mg neridronic acid supplied in glass vials in 8 mL of excipients.
45515066|NCT02234024|Dietary Supplement|Supplementation of dairy-derived concentrated gangliosides.|
45406542|NCT03560986|Drug|Placebo|Glass vials with matching placebo.
45406543|NCT03560518|Drug|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration)
45406544|NCT03560518|Drug|Placebo|Placebo (prefilled syringe, weekly IV administration)
45406545|NCT03726580|Drug|Sevoflurane|Assess the effect of isoflurane, sevoflurane, propofol and regional anesthesia on the olfactory threshold, olfactory identification and endocrine regulation of associative memory in the postoperative period in old age group.
45406546|NCT03726502|Procedure|ureteroscopy with safety guide-wire|ureteroscopy with use of safety guide-wire in treatment of ureteral stone
45515067|NCT02520076|Drug|Alpha-1 Antitrypsin|"Subjects will receive their islets treated with Aralast NP during islet isolation process.~Subjects will receive Aralast NP at a dose of 120 mg/kg (at an infusion rate of 0.2 mL/kg/min or less), dependent on patient tolerance, based on Day -1 admission weight and dose rounded to the nearest 20 mg) at the following time points:~Pre-transplant Day -1~Post-transplant Day 3~Post-transplant Day 7~Post-transplant Day 14"
45515068|NCT03752918|Drug|MDMA|A single dose of 1.5mg/kg will be administered once orally.
45515069|NCT03752918|Drug|Niacin|A single dose of 250mg will be administered once orally.
45515070|NCT04259320|Device|Beeswax containing barrier|Use beeswax containing barrier on each nipple after each breastfeeding.
45515071|NCT04259320|Biological|Breast milk|Apply breast milk on each nipple and areola after each breastfeeding.
45406547|NCT03726502|Procedure|ureteroscopy alone|ureteroscopy without use of safety guide-wire in treatment of ureteral stone
45406548|NCT03726502|Procedure|without safety guide-wire|ureteroscopy without use of safety guide-wire in treatment of ureteral stone
45406549|NCT03726502|Procedure|with safety guide-wire|ureteroscopy with use of safety guide-wire in treatment of ureteral stone
45406550|NCT03560206|Behavioral|Family SWaP intervention|The Family Sodium Watcher Program (Family SWaP) proposed in this study incorporates the use of a unique electronic salt monitoring device that easily measures salt content in food-the major source of sodium. The intervention is designed to improve adherence to a sodium restricted diet by both patients and family caregivers through education and strategies for gradual taste adaptation to low salt foods. The Family SWaP intervention (6 weekly 45-minute sessions followed by 5 bi-weekly booster sessions) will be delivered remotely using a video-conferencing program on an iPad tablet.
45406551|NCT03560206|Behavioral|usual care|The usual care group will receive their routine medical and nursing care for heart failure that consists of a recommendation to follow a sodium restricted diet without explicit skills training to do so.
45406552|NCT02892760|Device|C-Brace|C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
45515072|NCT04058158|Drug|SB12 (proposed eculizumab biosimilar)|600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
45406553|NCT03730558|Combination Product|aflibercept + FOLFIRI|aflibercept + FOLFIRI
45406554|NCT03635086|Biological|MV-CHIK lyophilised formulation, low dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, lyophilized low dose (powder for suspension in water for intramuscular [IM] injection): 5x10^4 ±0.5 log tissue culture infectious dose 50 (TCID50)/dose.
45515073|NCT04058158|Drug|Soliris (eculizumab)|600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
45515074|NCT02546960|Biological|ExPEC4V (4 : 4 : 4 : 4)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in microgram [mcg]) from the ExPEC serotypes O1A, O2, O6A, and O25B.
45515075|NCT02546960|Biological|ExPEC4V (4 : 4 : 4 : 8)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
45515076|NCT02546960|Biological|ExPEC4V (8 : 8 : 8 : 8)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
45406555|NCT03635086|Biological|MV-CHIK liquid frozen formulation, low dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid frozen low dose (suspension for IM injection): 1x10^5 ±0.5 log TCID50/dose.
45406556|NCT03635086|Biological|MV-CHIK SPS® formulation, low dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid SPS® low dose (suspension for IM injection): 1x10^5 ±0.5 log TCID50/dose.
45406557|NCT03635086|Biological|MV-CHIK liquid frozen formulation, high dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid frozen high dose (suspension for IM injection): 1x10^6 ±0.5 log TCID50/dose.
45406558|NCT03635086|Other|Placebo|Sterile physiological saline solution (0.9% sodium chloride [NaCl]), administered by IM injection.
45406559|NCT03588910|Drug|Acetaminophen|50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed)
45406560|NCT03588910|Drug|Ibuprofen 600 mg|25 tablets ibuprofen 600mg (1tablet every 6 hours as needed)
45406561|NCT03588910|Drug|Oxycodone|The number of tablets of oxycodone prescribed is the only difference between the two arms.
45406562|NCT05666050|Behavioral|Mobile health intervention|Pregnant women with 26-28 weeks of gestation(based on world health organization eligibility criteria) will be recruited and baseline data will be collected at selected clusters. Women who will provide informed consent will be asked to complete a post-consent eligibility assessment including access to a mobile phone, and willingness to receive health messages on their mobile phone. Women who meet these eligibility criteria will be enrolled in the study and administered the baseline interview. Intervention will be started among randomly selected clustered pregnant women at 30 weeks of gestation and will be continued up to 6 weeks of post partum period for 4 months.
45406563|NCT03726190|Procedure|Oblique Lateral Lumbar Fusion|Oblique lateral lumbar interbody fusion (OLLIF) is a lumbar spinal fusion. OLLIF is performed with the patient in the prone position and employs an oblique lateral approach that enables the instrumentation to pass through Kambin's triangle which is defined as the space between the exiting nerve, the superior border of the caudal vertebra, and the superior articulating process of the inferior facet. This approach may be performed without direct visualization, guided by electrophysiological monitoring and biplanar fluoroscopy. During the approach, a blunt probe is used to make contact with the disc, followed by a series of gentle dilations. Discectomy is performed through a 10-mm access portal. The cage is inserted under continued electrophysiological monitoring and fluoroscopy.
45406564|NCT03726112|Device|SpotOn Specs|SpotOn Balance glasses consists of unique visual stimuli (SpotOn's Neuro Balance Active Spots) applied to specific zones in the peripheral visual field
45406565|NCT03726112|Device|Sham Specs|Sham device
45406566|NCT03726034|Behavioral|Life Story Book|The protocol of life story book creation is validated in Hong Kong. The life story book would contain two elements: (1) the development of the older adults over the course of his/her lifetime (i.e. from childhood to old age); and (2) the psychosocial development and ways of life of the older adults (e.g. education, marriage, career, and hobbies). The product of the intervention will be a written story with pictures or other memorabilia that are meaningful to the older adults. There is no limitation on the number of words, pages, and pictures. Four to six 60-minute scheduled sessions will be needed for the older adult and the live-in migrant caregivers to discuss and produce the lifestory book at home.
45406567|NCT03726034|Behavioral|Self-selected social activities|To control the possible social interaction effects on the dyadic relationship and wellbeing, the caregivers of the control group will conduct self-selected social activities with older adult at home individually for four times weekly.
45406568|NCT03587974|Behavioral|REACH-VIETNAM|Family caregiver education, stress-reduction, and skill-training related to providing care for a person with Alzheimer's disease
45406569|NCT03730402|Drug|Bupivacaine|utilizing local anesthetic to perform a regional block under laparoscopic guidance
45406570|NCT03730402|Drug|Exparel 266 milligram Per 20 ML Injection|utilizing local anesthetic to perform a regional block under laparoscopic guidance
45406571|NCT03730402|Drug|Saline|placebo injection of saline
45406572|NCT00103857|Drug|Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily)|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take MK0431 50 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
45699397|NCT03129438|Diagnostic Test|routine EEG (rEEG)|differential use of continuous versus routine EEG
45699398|NCT03442530|Behavioral|ToPIC|Expanded tobacco cessation counseling for pregnant women.
46059158|NCT02874755|Other|Tuberculosis Program|The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free digital chest X-ray, free sputum microscopy, free or subsidized drug-susceptibility testing, free first-line anti-TB treatment) within the PPIA network, and (2) training or certified medical education (CME) sessions for the providers from the PPIA. Meanwhile, program marketing, CMEs, and other advocacy efforts are aimed to raise awareness in the communities.
45515077|NCT02546960|Biological|ExPEC4V (8 : 8 : 8 : 16)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
45406573|NCT00103857|Drug|Comparator: MK0431 100 mg q.d. (q.d. = once daily)|MK0431 oral tablets will be started on Day 1 as two 50 mg tablets (100 mg q.d.) (q.d. = once daily) and continued at this dose throughout the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
45406574|NCT00103857|Drug|Comparator: Placebo (Phase A)/Metformin (Phase B)|During the placebo-controlled period (Day 1 through Week 24/Phase A), metformin and MK0431 matching placebos will be dispensed as oral tablets. At the beginning of the 30-week active-controlled period (Phase B), metformin will be started as 500 mg q.d. (q.d. = once daily) and up-titrated in 500 mg weekly increments to a stable dose of 1000 mg b.i.d. Patients who complete the 54-week base study and who enter the 50-week extension study will continue to take metformin 1000 mg b.i.d. (b.i.d. = twice daily) for a total placebo/metformin treatment duration of up to 104 weeks.
45515078|NCT02546960|Biological|ExPEC4V (16 : 16 : 16 : 16)|Participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
45515079|NCT02546960|Drug|Placebo|Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.
45699399|NCT03442530|Behavioral|Tobacco Treatment As Usual (TTAU)|Standard of care tobacco cessation counseling for pregnant women
45699400|NCT03442452|Other|Electronic Decision Aid Tool|The AML Decision Aid tool consists of ten video modules, approximately 3 minutes each, containing content regarding key areas such as an explanation of what AML is, treatment choices, and things to consider when determining a treatment path.
45406575|NCT00103857|Drug|Comparator: Metformin 500 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased after 1 week to a stable dose of 500 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 500 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
45406576|NCT00103857|Drug|Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Metformin oral tablets will be started on Day 1 at 500 mg q.d. and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. The open-label treatment period is 24 weeks.
45406577|NCT00103857|Drug|Comparator: Metformin 1000 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 1000 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
45515080|NCT03629990|Behavioral|Approach Bias Modification (ABM)|Approach bias modification (ABM) is a novel treatment that involves retraining the implicit action tendency to approach a drug cue by manipulating contingencies in a stimulus-response paradigm.
45515081|NCT03629990|Behavioral|Sham ABM|"Sham ABM involves similar computerized procedures that mimic the active experimental condition, but do not involve manipulation of response contingencies and thus it does not contain any active intervention."
45515082|NCT03629990|Behavioral|Psychosocial therapy for cannabis use disorder.|All participants will receive psychosocial therapy for cannabis use disorder.
45515083|NCT02234102|Device|Endoscopically guided laser ablation HeartLight system|
45515084|NCT02263196|Other|Alcohol and povidone iodine|using from Alcohol and povidone iodine for prevention of inflammation
45515085|NCT02263196|Other|combination of alcohol and betadin|using from combination Alcohol and povidone iodine for prevention of inflammation
45699401|NCT04900584|Other|Checklist|Checklist of guideline-based treatment before discharge
45699402|NCT04900584|Other|Education|Heart failure education before discharge
45699403|NCT04900584|Other|Telephone monitoring|Telephone monitoring after discharge
45699404|NCT03442218|Drug|Clorhexidine|Vaginal wash with clorhexidine solution previous to cesarean section in patients with premature rupture of membranes.
46059159|NCT00790582|Drug|lithium carbonate|The dosage of lithium carbonate will be adjusted for each individual. The maximum dose is 450mg/day.
45699405|NCT03442218|Drug|Saline solution|Vaginal wash with saline solution previous to cesarean section in patients with premature rupture of membranes.
45699406|NCT01859741|Drug|OMP-59R5|OMP-59R5 administered intravenously
46059160|NCT04078087|Drug|Non obese|After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
45515086|NCT03343834|Biological|biological collection|"At D0:~blood samples~saliva sample~At D8: blood sample~the results will be compared to the analysis of EBV transcripts that are specific for the latent or replicative phase of the virus by reverse transcription-quantitative PCR (RT-qPCR), and to the detection of free virus in the saliva, which is associated with viral reactivation"
45515087|NCT05160506|Drug|Hydrocortisone|Hydrocortisone is a steroid (corticosteroid) medication.
45515088|NCT05160506|Drug|Placebo|50ml of 0.9% NACL will serve as the placebo
45515089|NCT02236286|Behavioral|Exercise|Agility Boot Camp (ABC) exercise intervention consisting of 18 sessions of group exercise led by an exercise trainer.
45515090|NCT05094778|Procedure|a single-portal palm approach|a single-portal palm approach that passes superficially to palmar aponeurosis, and cut the full transverse carpal ligament.
45699407|NCT01859741|Drug|Etoposide|administered intravenously
45699408|NCT01859741|Drug|Placebo|administered IV
45406578|NCT03587584|Drug|liposomal bupivacaine|Experimental
45406579|NCT03587584|Drug|Bupivacaine|Active Comparator
45406580|NCT03586726|Drug|Balovaptan|"In Period 1, balovaptan was administered alone as a once daily (qd) dose on Days 1 to 10.~In Period 2, balovaptan was administered as a qd dose on Days 7 to 16."
45406581|NCT03586726|Drug|Rifampicin|In Period 2, 600 mg of rifampicin will be administered alone as a qd dose from Day 1 to Day 6, and as a qd dose on Days 7 to 16.
45851567|NCT00246012|Drug|Dacarbazine|Commercially available dacarbazine will be administered intravenously over a 60-minute period (+30 minutes/-30 minutes) and prior to the intetumumab/placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue on intetumumab alone.
45851568|NCT00246012|Drug|Placebo|Placebo will be administered intravenously over a period of 2 hours (+15 minutes/-15 minutes).
45851569|NCT00245856|Drug|Dalteparin sodium injection|200units/kg subcutaneous daily for one month, followed by 150units/kg subcutaneous daily for two additional months or 200 units/kg subcutaneously daily for 5 days followed by warfarin.
45406582|NCT03725878|Procedure|Standard tertiary interventions of birth defects|Couples eligible for reproductive policy are entitled to routine health cares including general health cares (health education, medical history inquiry, physical examinations, consulting guidance and pregnancy outcome follow-up) and medical examinations (laboratory examinations, virus screenings and image examinations). But nutrients status are not included in these examinations, such as folate, vitamin B12, and macroelements, et al. Regular antenatal cares are required, such as deformity screening by ultrasound. Routine neonatal screenings are conducted to diagnose infant with birth defect timely.
45515091|NCT02509598|Drug|Tc99m tilmanocept|A single dose of 0.5 mCi and 50 ug of Tc99m tilmanocept administered intradermally, peritumorally approximately 15 minutes to 8 hours before surgery
45515092|NCT02509598|Drug|Vital Blue Dye (optional)|A single dose 1-3 mL of vital blue dye (1%) administered intradermally at the start of or during surgery (optional, per institution's standard of care).
45515093|NCT02509598|Procedure|Lymph Node Mapping|Intraoperative lymph node mapping will occur 15 minutes to 8 hours after Tc99m tilmanocept injection
45515094|NCT02926573|Drug|Gabapentin|
45515095|NCT02926573|Drug|Placebo|
45515096|NCT04477018|Dietary Supplement|Iron bis-glycinate chelate and vitamin C|28 mg iron; 240 mg vitamin C
45515097|NCT04477018|Dietary Supplement|Iron bis-glycinate chelate|28 mg iron only
45515098|NCT04477018|Dietary Supplement|Placebo|Matched placebo
45699409|NCT01859741|Drug|Cisplatin or Carboplatin|administered intravenously
45699410|NCT01212952|Drug|pomalidomide|Given orally
45699411|NCT01212952|Drug|bortezomib|Given IV
45699412|NCT01212952|Drug|dexamethasone|Given orally
45699413|NCT01212952|Other|laboratory biomarker analysis|Optional correlative studies
45699414|NCT01212952|Other|gene expression analysis|Optional correlative studies
45699415|NCT05161182|Other|High fat, low carbohydrate diet|Throughout the 5-day intervention, participants are provided with a high fat, low carbohydrate (HF-LC) diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25%, respectively.
45699416|NCT05161182|Other|Low fat, high carbohydrate diet|Throughout the 5-day intervention, participants are provided with a low fat, high carbohydrate (LF-HC) diet in which the percentage of fat, protein and carbohydrate is 10%, 15% and 75%, respectively.
45699417|NCT04609865|Drug|Lidocaine 2%|the lidocaine infusion protocol is a bolus of 1 mg/kg (ideal weight), followed by 3mg/kg/h for the first hour, 1.5 mg/kg/h for the second hour, 0.72 mg/kg/h for the next 22 hours, and then 0.6mg/kg/h for 14 days or until extubation.
45699418|NCT04609865|Drug|Control|The NaCl 0,9% infusion protocol is a bolus of 0.05 ml/kg (ideal weight), followed by 0.15 ml/kg/h for the first hour, 0.075 ml/kg/h for the second hour, 0.36 ml/kg/h for the next 22 hours, and then 0.03 ml/kg/h for 14 days or until extubation.
45851570|NCT00245856|Drug|Warfarin|Titrated to INR 2-3 through study month 3
45851571|NCT00245466|Drug|Degarelix|Given as a subcutaneous injection once every 4 weeks.
45851572|NCT00245466|Drug|Degarelix|Given as a subcutaneous injection once every 4 weeks.
45406583|NCT03725878|Procedure|Additional preconception health care|Various studies have revealed that folate is essential in early embryo development, whereas folate level evaluation in periconception women is not included in routine health cares. Therefore, we evaluate subject's folate level by serum and red blood cell folate examination. By combination of folate supplement obtained by questionnaire,folate level evaluated by examinations and folate metabolism ability evaluated by genotyping key enzymes in folate metabolism, an individualized folic acid supplementary guide is given to subjects. Red blood cell folate concentration >400 ng/ml before pregnancy is recommended.
45406584|NCT03725878|Procedure|Additional health care procedures during and after pregnancy|Fetus with birth defect will be referred to a tertiary hospital to receive genetic assessments and prenatal diagnosis to reduce unnecessary abortions. A 6-months follow up will be conducted to follow children's birth outcomes. It also helps clinical team to give early diagnosis and treatment for children with birth defect to reduce disability and improve life quality of defect children.
45406585|NCT03586648|Device|senofilcon A Multifocal|TEST Lens
45406586|NCT03586648|Device|senofilcon A Sphere|TEST Lens Sphere
45406587|NCT03586648|Device|etafilcon A Multifocal|CONTROL Lens
45406588|NCT03586648|Device|etafilcon A Sphere|CONTROL Lens Sphere
45406589|NCT02892448|Other|Cardiac magnetic resonance imaging (CMR)|Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.
45406590|NCT03725644|Behavioral|parent-training program|Parents in the treatment group received the training program from the registered pediatric occupational therapist in six hours over three weeks. The occupational therapist provided suggestions and gave feedback. The parents were encouraged to interact with their children for at least 15 hours per week. Between the fourth and 14th weeks, the parents implemented the intervention programs at home and recorded the daily intensity. The occupational therapist met with the parents and children at monthly intervals (the seventh and 11th weeks) at the laboratory to discuss any difficulties they encountered and to practice the child-initiated activities.
45406591|NCT03725644|Behavioral|traditional program|Parents in the control group also conducted a 14-week program. They received six hours of training over three weeks.Between the fourth and 14th weeks, the parents implemented parent-led activities at home and recorded the daily intensity. The parents were encouraged to do activities with their children for at least 15 hours per week. The occupational therapist met with the parents at monthly intervals (the seventh and 11th weeks) at the laboratory to discuss any difficulties they encountered while practicing the parent-led activities.
45406592|NCT03722134|Procedure|MOCA|Great saphenous vein occlusion with a mechanochemical chateter which cause mechanical injury to vessel intima and gives sclerosant to the intima.
45406593|NCT03722134|Procedure|EVLA|Great saphenous vein occlusion with a thermal laser chateter
45406594|NCT03722134|Procedure|RFA|Great saphenous vein occlusion with a thermal radiofrequency chateter
45515099|NCT02236442|Other|Recommendation to use global headache treatment protocol|"The global treatment protocol is :~Put the patient in a quiet spot, ideally an individual room. Avoid waiting in the corridor~Lay down the patient on the stretcher. Avoid waiting on a seat or a chair.~Provide a sound-proof helmet to the patient.~Provide a light-blocking google to the patient.~If judged necessary by the physician in charge of the patient, administer oxygen therapy, 15 liter per minute, during 15 minutes.~If judged necessary by the physician in charge of the patient, administer analgesic treatment adapted to the etiology of the cephalalgia as described :~Migraine : acetylsalicilyc acid + metoclopramide or nonsteroidal anti inflammatory or paracetamol or triptan.~Tension headache : nonsteroidal anti inflammatory or paracetamol. Avoid methylmorphine or tramadol if possible.~Cluster headache : Intravenous or nasal spray sumatriptan and oxygen therapy.~Other etiology : Treatment left at the discretion of the physician in charge of the patient."
45515100|NCT05737654|Other|Exercise with augmented reality glasses|Two days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
45699419|NCT04608695|Procedure|Ovarian puncture|One side ovary of each patient included in the study, will be punctured 10 times under trans-vaginal ultrasound guidance with 17 gauge ovarian pick up needle, 1 month before the scheduled IVF cycle. Control group will be the other side ovary for each patient. Number of ≥ 14 mm follicle and collected oocytes will be compared.
45699420|NCT01229722|Device|Beeper|Beepers are handheld portable devices which can be attached to a belt. At regular intervals corresponding to the participant's preferred reminder time, they buzz for a few minutes or until the participant presses a button to stop the buzzing.
45851573|NCT00245466|Drug|Degarelix|Given as a subcutaneous injection once every 4 weeks.
45406595|NCT03722056|Procedure|Laparoscopic resection|all patients with suspected Gastric GIST undergoes laparoscopic resection. Tumour location decides the approach used for resection. Therefore, a variety of options such as local resections, wedge resections, transgastric resections, intragastric resection and partial gastrectomies were performed.
45406596|NCT03721900|Drug|SHX-001 Active low dose|ketamine transdermal patch
45406597|NCT03721900|Drug|Placebo|transdermal patch
45406598|NCT03721900|Drug|SHX-001 Active High dose|ketamine transdermal patch
45406599|NCT03585712|Drug|Norgestrel 0.075 mg|Subjects will take norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for 1 specific day during treatment period 2 and treatment period 3
45851574|NCT00244764|Drug|GW786034|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
45851575|NCT00244764|Drug|Placebo|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
45406600|NCT03585244|Other|weekly weight|weekly weight data collection for six months
45515101|NCT02261402|Other|Medisinstart|"Medisinstart is a newly developed pharmacy service for patients about to start a new medicine for a chronic or long-term condition. It consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine."
45515102|NCT03629275|Combination Product|CTX0E03 Drug Product and delivery device|Includes stereotactic surgery and a burr hole drilled through the skull to allow for a one time intracerebral injection of 20 million CTX0E03 Drug Product stem cells into an area of the brain adjacent to the area affected by the stroke.
45699421|NCT01229722|Device|ARemind|ARemind will personalize reminder messages based on adherence levels and facilitate patient phone calls with social workers/adherence counselors when appropriate. It will also consist of a text-messaging or interactive voice response (IVR) or phone-based pill count remote adherence assessment module.
45699422|NCT01859507|Drug|Botox|In the first session, proper history taking and proper counseling of the couple including the description of the new modality (BOTOX injection) of treatment and subsequent dilatation sessions. During examination, all our maneuvers are gentle to gain trust of the patient. Following sterilization, we used surface (Xylocaine gel 2% ASTRA ZENECA) anesthesia before the injection. In addition we used finger like ice packs pre-prepared in a surgical latex glove, on the perineum. We made sure to check that the tip of the needle is not in a vessel by aspirating before proceeding with the injection of each bolus of BOTOX.
45851576|NCT00244374|Biological|Hepatitis A & B vaccine|Each subject will receive a total of 4 immunizations over 6 months on a 0-1-2-6 month schedule. At the initial visit, subjects>18 years of age will receive the Twinrix vaccine and subjects<18 years of age will receive the Engerix-B vaccine. Cohort subjects>18 years found to have HAV antibody at screening will receive Engerix-B for their remaining 3 immunizations. All subjects will receive: an immunization record with the first vaccine dose entered and the dates the next doses are due; helpful hints for remembering vaccine appointments; and written instructions on where and how to get immunized outside of SF.
45851577|NCT00244374|Behavioral|Outreach|Outreach worker vaccine adherence support: Half of cohort subjects will be assigned to outreach worker vaccine adherence support and will meet with their outreach workers from Haight Ashbury Youth Outreach Team (HAYOT) and Glide Health Services on the day of vaccine cohort study enrollment. Intensive vaccination tracking and in-person outreach support will begin one week before the second and third vaccine doses are due, and again two weeks before the fourth dose is due.
45851578|NCT00244374|Behavioral|AIC|The Adult Immunization Clinic (AIC) is a public low-cost vaccine clinic located centrally at 101 Grove Street in the lobby of the San Francisco Department of Public Health (SFDPH). The clinic is open from Monday-Friday 9 a.m. to 4 p.m. Nurses at the AIC will be available 40 hours/week to administer free immunizations to study subjects.
45406601|NCT03730246|Procedure|cesarean sectio|consecutive parturients due for cesarean sectio
45515103|NCT03629275|Drug|Placebo|Sham surgical comparator includes stereotactic surgery and a partial thickness burr hole drilled into the skull. No injection of any kind is made into the brain, and no other intervention is given.
45515104|NCT05737498|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation will use to deliver a constant direct current through two surface electrodes, Anodal stimulation was applied according to the 10-20 international system for EEG electrode placement, over F3 of the dorsolateral prefrontal cortex (DLPFC), while the cathode was placed over the contralateral supraorbital area for 20 min, on alternate days for 2 weeks 6 sessions with working memory training task. the anode (positive) and the cathode (negative). To reduce resistance and minimize discomfort during application (the electrodes were covered in 35 cm2, saline-soaked sponges
45515105|NCT05201131|Procedure|Rezum|Rezum
45406602|NCT00074984|Biological|Fabrazyme (agalsidase beta)|1mg/kg Fabrazyme (agalsidase beta) every 2 weeks
45406603|NCT00074984|Biological|Placebo|1 mg/kg placebo intravenously every 2 weeks
45515106|NCT02261480|Other|Blood draw|When possible, blood will be drawn as an extra aliquot utilizing the same needle stick procedure performed for standard of care.
45699423|NCT01140594|Procedure|Photorefractive keratectomy|One eye undergoes wavefront-guided PRK with the Visx S4 CustomVue excimer laser.
45406604|NCT01082510|Drug|Bacille Calmette-Guerin|The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for the BCG maintenance therapy will be the same as that used for BCG induction therapy.
45515107|NCT02261480|Other|Nasopharyngeal wash|Nasopharyngeal washes are optional for Group A and Group B participants. Nasopharyngeal washes will be performed on all subjects in Group C. The technique used will be the same as used for regular standard of care per St. Jude guidelines.
45406605|NCT01082510|Drug|uracil-tegafur|The UFT maintenance therapy arm patients will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.
45406606|NCT03583606|Biological|ChAd3-EBO-Z|Zaire ebolavirus vaccine administered by an IM injection into the deltoid as a single dose of 2 x 10^11 virus particles (vp)).
45406607|NCT03583606|Biological|MVA Multi-Filo Ebola Vaccine|A booster vaccination of replication defective MVA-BN-Filo administered by an IM injection into the deltoid as a single dose of 1 x 10^8 Infectious Units (IU).
45515108|NCT04506775|Device|ViTrack|ViTrack is a continuous non-invasive wearable blood pressure cuff.
45515109|NCT04506775|Procedure|Radial artery catheterization|Radial artery catheterization is the standard of care for measuring blood pressure continuously throughout surgery.
45515110|NCT05759611|Other|Standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises|Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises lasting about 20 minutes per session
45515111|NCT05759611|Other|Standard integrated metabolic rehabilitation protocol + specific respiratory muscle training program|Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + a specific respiratory muscle training program according to the protocol recently proposed by Spengler et al. (Wuthrich et al., 2015; Schaer et al., 2018), adapted according to the baseline characteristics of the respiratory function of the subjects.
45515112|NCT00158860|Drug|Valaciclovir|1g once daily
45515113|NCT00158860|Drug|Placebo|placebo
45515114|NCT02234258|Behavioral|Cognitive behavioral social skills|
45699424|NCT01140594|Procedure|Laser in-situ keratomileusis|One eye undergoes wavefront-guided LASIK using the Visx S4 excimer laser.
45699425|NCT03442140|Other|Harmonica playing|Patients will play the harmonica for up to 6 months
45699426|NCT04608227|Device|Clearsight monitoring|Non invasive hemodynamic monitoring using a finger cuff Cardiac ultrasound performed to calculate Velocity - Time - integral (VTI) Both intervention are performed before and after a passive leg raising challenge.
45699427|NCT03442062|Other|Assessment Feedback Incentives and eXchange|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
45699428|NCT03442062|Other|Physician-to-physician engagement|Physician-to-physician engagement is a quality improvement strategy in which trained physician educators deliver a 60 minute consultation via interactive webinar. The consultations will be delivered to providers in primary care clinics and will include didactic instruction on HPV-related cancers, HPV vaccination, communication training, and assessment and feedback about each clinics' vaccination coverage.
45699429|NCT03442062|Other|Active Intervention Control|Active Intervention Control will be a remotely delivered quality improvement strategy on a clinical topic other than HPV vaccination.
45406608|NCT03583606|Other|Placebo|0.5 mL normal saline administered via IM injection into the deltoid.
45406609|NCT03730168|Other|circuit weight training program|30 male diabetic patients performed circuit weight training for 12 weeks
45406610|NCT03583450|Device|Perioperative virtual reality headset with mobile app|Perioperative virtual reality headset with mobile app (Samsung Gear VR headset, ChariotVR software)
45406611|NCT03583372|Drug|Vibegron|single daily dose 75 mg
45406612|NCT03583372|Drug|placebos|placebo to match vibegron (experimental drug) and tolterodine (active comparator)
45406613|NCT03583372|Drug|Tolterodine Tartrate ER|single daily dose of 4 mg
45406614|NCT03725566|Drug|Experimental|Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
45406615|NCT03582826|Behavioral|Nutritional counselling|Behavioral nutritional counselling delivered via the Internet.
45515115|NCT02234258|Behavioral|Psychoeducation|
45515116|NCT05201053|Diagnostic Test|Exploratory for different markers|Test biomarkers for development of mild, moderat or severe disease
45406616|NCT03582826|Behavioral|Stress-reduction counseling|The psycho-behavioral intervention includes administering questionnaires and monthly maintenance psychological support delivered via the Internet.
45406617|NCT01582958|Procedure|Osteopathic Manipulative Treatment (OMT)|Osteopathic Manipulative Treatment (OMT) is the therapeutic application of manually guided forces by an Osteopathic physician to improve physiologic function.
45515117|NCT03629665|Behavioral|Intensive Language-Action Therapy (ILAT)|ILAT includes communicative language games played in an interactive small-group setting. Three persons with aphasia and one therapist sit around a table and have picture cards in front of them. The card sets include two items of each object or action picture. All participants take turns in making verbal requests. There will be 5 daily sessions (3 hours per session) for two weeks.
45515118|NCT03629665|Device|Repetitive navigated Transcranial Magnetic Stimulation during naming training|Magnetic stimulation will delivered with a figure-of-eight cooled coil of Navigated Brain Stimulation System during picture naming training. The primary targeted area is the right pars triangularis. In each session, rTMS will be applied at 1-Hz for 20 minutes, 5 daily sessions per week for four weeks.
45515119|NCT02490488|Drug|Masitinib|
45851579|NCT00244374|Behavioral|SEP|Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6. Research nurses will provide 16 hours/week of vaccine administration services at SEPs well attended by young IDU. The San Francisco Needle Exchange (SFNE) serves primarily youth and young adults on Mondays, Wednesdays, and Fridays from 5-7 p.m. in an indoor location in the Haight-Ashbury district. A study nurse will be at SFNE for a total of 6 hours per week. HIV Prevention Project (HPP) sites also operate for 2 hrs each (Tues, Thu, Fri, Sat). Medical services are provided either in a clinic setting at indoor sites (6th Street) or at outdoor sites (Hemlock Alley, Duboce). A study nurse will attend each of these 5 weekly sites for a total of 10 hours/week.
45851580|NCT00242658|Behavioral|Tailored Physical Activity Intervention|Tailored physical activity computer reports will be provided to patients and physicians.
45406618|NCT01582958|Other|sham omt|Hands are placed on subjects the same as omt arm but no omt is provided.
45406619|NCT03518008|Device|verofilcon A contact lenses|Investigational daily disposable soft contact lenses
45851581|NCT00242580|Drug|Verteporfin photodynamic therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, verteporfin was activated by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of infusion.
45406620|NCT03518008|Device|somofilcon A contact lenses|Commercially available daily disposable soft contact lenses
45406621|NCT01091324|Drug|Dextromethorphan|60 mg, bid
45851582|NCT00242580|Drug|Pegaptanib|Pegaptanib sodium 0.3 mg administered by intravitreal injection.
45406622|NCT01091324|Drug|Silymarin|150 mg , tid
45851583|NCT00242580|Drug|Triamcinolone acetonide|Triamcinolone acetonide administered by intravitreal injection.
45406623|NCT01091324|Drug|sugar pill|placebo
45406624|NCT03725488|Other|Questionnaire|"students were involved in the pre-clinical prosthodontic lab. Participation in these labs were mandatory and it involved crown and bridge preparations on typodont models. There were 2 sessions of these labs per week, one for each gender. Each session lasted for 3 hours.~The study was conducted in 2 phases. At the beginning of the first phase of the study, the labs were conducted without any BM for 4 weeks. PSS(perceived stress scale), a standardized and validated, self-reporting international test was used for measuring the level of psychological stress were administered to all participants."
45406625|NCT03810014|Other|Conditional ACT subsidy, Arm 1 levels|The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).
45406626|NCT03810014|Other|Conditional ACT subsidy, Arm 2 levels|The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).
45406627|NCT03810014|Other|Conditional ACT subsidy, Arm 3 levels|The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).
45406628|NCT03810014|Other|Conditional ACT subsidy, Arm 4 levels|The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)
45406629|NCT05782725|Other|Comparison of laboratory test results in women in the 4 study arms|Comparison of AMH, FSH, LH, estradiol, AFC/ ovarian volume on ultrasound in women in the 4 study arms
45515120|NCT02490488|Drug|Gemcitabine|
45515121|NCT02490488|Drug|Placebo|
45515122|NCT02261558|Other|Clinical Improvisation Instrumental Music Therapy|Select an instrument of choice (and instruments for caregiver/s if applicable) Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Closure through verbal reflection and sharing (5 minutes)
45515123|NCT02261558|Other|Clinical Vocal Improvisation|* 5 minutes of warm up. Select a few favorite songs of choice. Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Identify themes and issues addressed and/or paralleled in the song and/or within the self Closure through verbal reflection and sharing (5 minutes)
45515124|NCT02654990|Drug|panobinostat capsules|20mg, 10mg or 15mg (for dose reductions only)
45515125|NCT02654990|Drug|bortezomib injection|1.3mg/m2 sub-cutaneous administration; Cycle 1-4: 2 weeks on/1 week off twice a week for patients <=75 years at time of screening; once a week for patient > 75 years Cycle 5+: once a week for all patients
45515126|NCT02654990|Drug|dexamethasone tablets|pre and 24h after BTZ administration; patients <= 75 years at time of screening: 20mg/dose patients > 75 years: 10mg/dose
45406630|NCT05782686|Procedure|Margin shaving|In both cohorts, an intraoperative study of the margins will be carried out, and enlargement of those margins that are affected will be carried out as indicated by the pathologist. Subsequently, shaving is performed in case of being randomized to the study group or surgery is completed in the control group.
45515127|NCT02471222|Drug|ADS-5102|Oral capsules to be administered once daily at bedtime for 4 weeks
45515128|NCT02471222|Other|Placebo|Oral capsules to be administered once daily at bedtime for 4 weeks
45699430|NCT01876043|Drug|plitidepsin|"Patients received plitidepsin as an i.v. 3-h infusion of 5 mg/m2/day on days 1 and 15 every 4 weeks. Patients discontinued plitidepsin if one of the following occurred: consent withdrawal, unacceptable toxicity, disease progression (RECIST v1.1), intercurrent illness or investigator's decision.~Single-arm phase II clinical trial based on a two-stage optimal Simon's design with 37 evaluable patients (first stage: 17 patients) used to distinguish a favorable true non-progression rate of 40% from a null rate of 20% (90% power and 10% type I error).~Stage 1(17 participants): if <=3 non-progressions at 3 months, the study was stopped early. Otherwise, the second group of 20 participants was recruited.~Stage 2 (37 participants): if >= 11 non-progressions, Aplidin was considered promising."
45699431|NCT05128032|Device|Standard microcatheter|Small device used for mapping as part of radioembolization procedure
45699432|NCT05128032|Device|PEDD device|Pressure enabled small device used for mapping as part of radioembolization procedure
45699433|NCT01875731|Behavioral|BPS|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
45699434|NCT01875731|Behavioral|Guideline|Strategy based on enforced guideline guided antibiotic use
45699435|NCT03129204|Behavioral|SAF-T|The Rosenzweig Center for Rapid Recovery has recently developed an adaptation of their Accelerated Resolution Therapy (ART) for psychological trauma and depression, called Sensation Awareness Focused Training (SĀF-T), as an approach to rapidly eliminate negative biological sensations of stress. SĀF-T is designed to elicit a calming response; interrupt negative thoughts, negative feelings, and negative behaviors; and ultimately serve as a self-management stress reduction tool for individuals.
45699436|NCT03441828|Procedure|Quality of surgical field conditions|evaluation of the intraoperative surgical conditions assessed by the surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point) given by deep vs moderate neuromuscular block
45699437|NCT03441828|Drug|Deep Neuromuscular Block|maintenance of a deep neuromuscular block by infusion of rocuronium
45699438|NCT03441828|Drug|Moderate Neuromuscular Block|maintenance of a moderate neuromuscular block.
45699439|NCT03446430|Device|PWV measurement by LDV|PWV measurement by LDV : carotid-femoral, carotid and chest-carotid
45699440|NCT04891614|Device|PRISM|Subjects will complete 15 neurofeedback training sessions delivered twice per week, on non-consecutive days, over 8 consecutive weeks.
46059161|NCT04078087|Drug|Obese.|After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
45699441|NCT01873859|Drug|Metformin|Incidence of lactic acidosis in diabetic patients receiving contrast media in the presence of metformin.
45406631|NCT05782621|Other|Acupoint focused ultrasound|An ultrasound beam is normally pulsed in the ratio of 1:5. For perfect transmission of power from the treatment head to the body, the head will be applied perpendicularly to the skin surface. A stationary technique pulsed ultrasound (1 w/cm2) will be used. The application will be two minutes for each acupuncture point and the head will be glided to the next point in the same side; then to the other side for no more than 10 points, then the device will be turned off
45406632|NCT05782621|Other|Laserpuncture|"The laser tip (0.03 cm2 of beam area) will be positioned with the probe head directly on the acupuncture point, in a perpendicular position and in direct contact with the skin, and every point will be treated for 2 min, totaling 16 min of treatment, plus 4 min of rest, to standardize with the traditional acupuncture time, which is 20 min"
45406633|NCT05782621|Other|conventional treatment|the patients will receive selective neck strengthening ex for (extension, flexion, sidebending, lateral rotation) and selective neck stretching ex for (extension, flexion, sidebending, lateral rotation)
45406634|NCT05782608|Drug|IV ibuprofen|Group 1 will receive IV ibuprofen 400mg \ 6 hours the first dose will be administrated immediately post operative.
45406635|NCT05782608|Drug|IV ketorolac|Group 2 will receive 20 mg IV ketorolac\ 6 hours the first dose will be administrated immediately post operative
45515129|NCT05094310|Device|Acupuncture|Patients with breast cancer who experienced fatigue were measured by the Brief Fatigue Inventory(BFI) scale and other Fatigue related questionnaire. Breast cancer patients diagnosed with cancer related fatigue are included in our clinical study，and those patients will receive acupuncture treatment. The position of acupuncture refers to the principle of acupuncture treatment of traditional Chinese medicine. According to ICD-10-CD code R53.0, the diagnosis of CRF is determined by the experience of diminished energy or other physical and psychological symptoms every day or almost every day for two consecutive weeks in the past month. We collected patients' blood to detect fatigue related SNP.
45515130|NCT02649062|Biological|NGM282|
45699442|NCT03446274|Drug|Evenamide|This is an orally available small molecule that potently blocks voltage-gated sodium channels (VGSCs) in vitro and is indicated for the treatment of patients with schizophrenia, mania, and bipolar disorder.
45699443|NCT00493896|Drug|Fondaparinux|The dose for Arixtra is 2.5 mg once daily, subcutaneously.
45699444|NCT00493896|Drug|Enoxaparin|The dose for Lovenox is 40 mg once daily, subcutaneously.
45406636|NCT05782595|Other|Aquatic therapy|"• Each session was divided into three phases:~Aquatic environment adaptation phase~stretching phase~a phase of static and dynamic exercises for balance"
45515131|NCT02649062|Other|Placebo|
45515132|NCT05094076|Radiation|chest x ray|The chest radiographs obtained will be classiﬁed according to the International Labor Organization (ILO) System for Classiﬁcation of Radiographs for Pneumoconiosis [ILO, 1980]. Film quality, profusion, and shape and size of opacities will be evaluated by this method. Radiographic evidence of silicosis was deﬁned as a profusion score of 1/0 or greater
45515133|NCT05093998|Drug|AV5080|oral hard gelatin capsules
45406637|NCT05782556|Device|Implantation of a transjugular intrahepatic portosystemic shunt (TIPS)|For TIPS implantation, a transjugular approach is used in all patients and a puncture needle was advanced into a hepatic vein. Puncture of the portal vein is performed using ultrasound guidance followed by portography after successful puncture of the portal vein. Further, the parenchymal tract isdilated and the stent graft is placed. Before and after TIPS implantation, portal venous and central venous pressures are measured to calculate the porto-systemic pressure gradient
45406638|NCT05782543|Procedure|Normothermic machine perfusion|To determine whether a 4-6 hour period of normothermic machine perfusion, following standard hypothermic machine perfusion, results in better graft function after transplantation, compared to hypothermic machine perfusion preservation alone of kidneys recovered from deceased donors aged 50 years or older
45406639|NCT05782517|Device|Supraglottic Airway Device|Placement of an I-gel Supraglottic Airway Device.
45515134|NCT05093998|Other|Placebo|Hard gelatin capsules with a white body
45515135|NCT02264756|Other|ASP review|patients admitted to hospital with a diagnosis of community-acquired pneumonia will be reviewed by team members of antimicrobial stewardship program and subsequently feedback to attending physicians will be offered in the form of recommendations for antibiotic management
45699445|NCT04597619|Other|Novel Nonopioid Pathway|The novel nonopioid pathway consists of preoperative counseling, postoperative standardized orders and standard of care adjunctive and analgesic medications, specialized discharge instructions and written patient instructions regarding medications and activity.
45699446|NCT00388908|Behavioral|Reminders and opinion leader generated guidelines +/- leaflets and counselling|
45699447|NCT00388908|Other|Usual Care|
45699448|NCT04288674|Other|Retrospective data collection of demographics|Retrospective data collection of demographics from patients with leptospirosis and matching control group patients.
45699449|NCT04288674|Other|Retrospective data collection of underlying diseases|Retrospective data collection of underlying diseases from patients with leptospirosis and matching control group patients.
45515136|NCT03067129|Drug|Glecaprevir/Pibrentasvir Adult Formulation|Co-formulated film-coated tablet (100 mg/40 mg)
45699450|NCT04288674|Other|Retrospective data collection of duration of hospitalization|Retrospective data collection of duration of hospitalization from patients with leptospirosis and matching control group patients.
45699451|NCT04884438|Behavioral|Psychological intervention for the promotion of gratitude|"A brief intervention protocol has been developed for the promotion of gratitude. The protocol is manualized and the content will be explained to each participant in the videoconference sessions, and a copy of the manual will be given (or sent) to the patients at the end of the therapy sessions.~The structure and contents of the intervention are summarized below:~Psychoeducation about gratitude and its effects on health (both physical and psychological).~Gratitude towards life:~Gratitude walk~Three positive things~Sharing gratitude~Social gratitude:~Daily thanks to others~Gratitude letter~Proof of gratitude~Self-gratitude: this part includes an exercise aimed at fostering self-gratitude in three different areas:~Gratitude for the things I do to take care of my physical health.~Gratitude for what I do to take care of my mental health, my self-esteem and my personal development.~Gratitude for what I do to take care of others."
45699452|NCT03450486|Other|exercise|one 30 minute bout of mild exercise
45699453|NCT03441672|Behavioral|Meaning of Screening|Interactive technology game providing education about prenatal screening and what the results may mean.
45406640|NCT05782517|Device|Endotracheal Tube|Placement of an Endotracheal Tube.
45515137|NCT03067129|Drug|Glecaprevir + Pibrentasvir Pediatric Formulation|Film-coated pellets/granules (15.67%/8.25%) administered by mixing with a small amount (1-2 teaspoons) of a soft food vehicle, such as hazelnut spread, Greek yogurt, or peanut butter.
45515138|NCT03136120|Drug|Ipratropium Bromide|Single dose of 500 mcg Ipratropium nebulizer solution will be administered to all subjects via inhalation route using nebulizer for 10 minutes. Ipratropium bromide is a clear, colorless nebulizer solution available in white plastic ampoules.
45515139|NCT03136120|Procedure|Flexible Bronchoscopy/Biopsy|After biopsy samples required for diagnosis have been collected, additional one to two TBCB samples will be taken for this study. 3-5 endobronchial biopsy samples will be taken from up to 5 subjects to compare drug distribution in proximal and distal lung.
45699454|NCT03449940|Procedure|Immediate repair|
45699455|NCT03449940|Procedure|Delayed repair|
45851584|NCT00241644|Biological|Rotarix™|Two or Three doses, oral administration
45515140|NCT01625390|Drug|BAY86-6150|Four dose levels (6.5 µg/kg, 20 µg/kg, 50 µg/kg and 90 µg/kg) of BAY86-6150 will be studied.
45515141|NCT01625390|Drug|eptacog alfa [activated]|comparative PK/PD (pharmacokinetics/pharmacodynamics) evaluation
45406641|NCT05782504|Behavioral|Patient-centered teleprehabilitation|"Education about the consequences of stress and low physical activity levels with examples of how improving stress tolerance and physical activity can influence QoL and oncological treatment outcomes.~Exercise therapy based on shared-decision making and using a patient-centered approach. The goal will be to strive for 150-220 min. of moderate physical activity/week, including a home exercise program (at least 1 session/week) of 30-45 min. moderate aerobic exercise, 20 min. of strength training and 10 min. cool down. The latter is guided by Physitrack software.~Stress management, including questioning personal stress experiences and perceptions, relevant stressors, and stress coping strategies. Next, 3 different relaxation strategies will be explained. Also, cognitive-emotional approaches to stress management and identification of uplifts will be introduced.~Motivational interviewing will be used during the whole intervention."
45406642|NCT05782478|Diagnostic Test|Point of care Ultrasound according to study protocol|An emergency medicine specialist or resident will according to a structured protocol perform a structured ultrasound examination of the heart, the inferior vena cava and the lungs.
45406643|NCT05782465|Procedure|Blood Collection, processing and analyses|20ml of blood will be drawn from study participant at the baseline visit for molecular analyses.
45406644|NCT05782465|Procedure|Gastroscopy and biopsies collection|Study participant will undergo gastroscopy with collection of gastric mucosal biopsies at the baseline visit to ascertain OLGIM status and for molecular analyses. Study participant will undergo surveillance gastroscopy for gastric cancer at years 2 and 4 to assess whether they have reached endpoint.
45406645|NCT05782465|Diagnostic Test|Urea Breath Test|Study participant will fast for 6 hours or overnight before undergoing the Urea Breath Test (UBT) to test for current H. pylori infection. Breath collection will be performed before ingestion of 13C urea, and at specified time intervals after ingestion.
45515142|NCT01625390|Drug|BAY86-6150|Confirmation of recommended dose of BAY86-6150 to be evaluated further as determined in Part A.
45406646|NCT05782452|Procedure|Ophthalmic examination|Facial photographs of the participants were obtained at the time of enrolment. Pre- and post-operative anterior eye segment photographs were obtained under diffuse, direct focal and retro illumination. Clinical data, including basic information, family history, and comprehensive pre- and post-operative ophthalmic examination findings, were recorded.
45406647|NCT05782452|Genetic|Whole-exome sequencing|Performing whole-exome sequencing and bioinformatics analysis.
45699456|NCT03449940|Drug|Lidocaine|10cc of Lidocaine 1% is used to inject at the base of the penis for a dorsal penile nerve block for the localized repair.
45406648|NCT05782439|Other|Manual evaluation of ITB tension|There will be a double evaluation for each sampling session: 1) if there is a uniformity of the tension between the two sides, or if there is a prevalence on one side; 2) quantification of the difference, if present, with a graduation in 3 levels.
45699457|NCT03449940|Drug|Ceftriaxone|Pre-operative antibiotic given to all patients. Ceftriaxone 1g is administered intravenously.
45515143|NCT01679236|Behavioral|Mindfulness Training for Smokers|The provides the Mindfulness Training for Smokers intervention (7 weeks long).
45699458|NCT03449940|Drug|Diclofenac Sodium|Oral Diclofenac Sodium 50mg tablet is prescribed to be taken as needed up to a maximum of three times daily until the penis is repaired.
45699459|NCT03449862|Other|Simulation-based clinical decision on brain CT ordering|Clinicians asked to make decision on medical imaging for their simulated patient after presentation of clinical case then additional information. At each presentation of new information the clinician may modify their image order.
45699460|NCT04452240|Device|thoracic endovascular repair|Repair of thoracic aorta lesions with the application of a dedicatet stent-graft by endovascular way.
45699461|NCT03446196|Device|Fluid replacement based on MOSTCARE up|Clinician will be able to read MOSTCARE parameters and to choose the best treatment to adequate hemodynamics considering that current literature suggests a fluid IV expansion only if PPV > 12%
45515144|NCT01679236|Behavioral|Interactive Learning for Smokers|This provides the Interactive Learning for Smokers intervention (7 weeks long).
45515145|NCT01625234|Drug|Phase I: X-396 (ensartinib)|Oral, ALK inhibitor
45515146|NCT01625234|Drug|Phase II: X-396 (ensartinib)|Expanded Cohort
45515147|NCT02264834|Drug|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml
45515148|NCT02264834|Drug|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
45515149|NCT02264834|Procedure|Lumbar epidural analgesia|Introduction of a catheter in lumbar epidural space
45515150|NCT05762419|Drug|Etoposide; Oral, 50 Mg|Subjects will receive focused ultrasound sonication followed by once daily oral etoposide (50mg/m^2/dose). Oral etoposide will be taken every day for 21 days, followed by one week of rest. For the first cycle, etoposide will be administered immediately following confirming of the blood brain barrier opening through contrast magnetic resonance imaging (MRI) which will occur within 4 hours of the focused ultrasound procedure. For subsequent cycles, etoposide will be administered immediately following the focused ultrasound procedure. Subjects may continue for a maximum of 4 cycles.
45515151|NCT05762419|Device|Focused ultrasound with neuro-navigator-controlled sonication|Focused ultrasound sonication will be performed a maximum of three times a week for two weeks with two weeks of rest.
45515152|NCT04568408|Device|Xiaomi MiBand 5|Comparison of sleep-monitoring device against polysomnography (PSG)
45515153|NCT04458103|Device|Percutaneous RVAD|ProtekDuo or Impella RP
45515154|NCT02264912|Drug|antiplatelet drugs - P2Y12 antagonists|
45515155|NCT01437722|Drug|1% SPL7013 Gel|vaginal gel
45515156|NCT01437722|Drug|3% SPL7013 Gel|vaginal gel
45515157|NCT01437722|Drug|placebo gel|vaginal gel
45515158|NCT02263352|Drug|Lycored soft gels Jagsonpal Pharma, Systemic 8mgms/day|Lycopene 8mgms taken orally ,one per day for two months.
45515159|NCT02263352|Device|Scaling and root planing|Scaling and root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus
45406649|NCT05782426|Drug|paclitaxel polymeric micelles for injection|Patients will be treated with paclitaxel polymeric micelles for injection, platinum (cisplatin/carboplatin) in combination with sindilizumab for 4-6 cycles. If patient assessment is of clinical benefit, maintenance therapy with sindilizumab plus paclitaxel polymeric micelles for injection(≤230mg/m^2) can be continued based on investor's evaluation and patient's own choice until disease progression (PD), unacceptable toxicity, withdrawal of consent, initiation of additional antineoplastic therapy, death, or other protocol-specified conditions for discontinuation of treatment, whichever comes first.
45515160|NCT01435226|Drug|GS-5885|"Drug: GS-5885 tablet~GS-5885 tablet, 90 mg, QD"
45406650|NCT05782413|Other|mechanical vestibular stimulation|Device produces mechanical vestibular stimulation. The child was placed in a sitting position on the swing and his hands grasping the ropes at the sides then the therapist stood behind him and begin pushing the platform in fast and jerky movements in back and front, side to side, and in spinning directions with the child trying to maintain his balance in all different directions.
45515161|NCT01435226|Drug|GS-9451|"Drug: GS-9451 tablet~GS-9451 tablet, 200 mg QD"
45515162|NCT01435226|Drug|tegobuvir|tegobuvir 30 mg BID
45515163|NCT01435226|Drug|placebo to match tegobuvir|tegobuvir placebo BID
45515164|NCT01435226|Drug|placebo to match RBV|Ribovirin placebo BID
45515165|NCT01435226|Drug|Ribavirin|Ribavirin (Copegus®) BID (1000 mg for subjects weighing < 75 kg and 1200 mg for subjects weighing ≥ 75 kg) divided BID
45515166|NCT01679002|Drug|BIA 2-093|
45406651|NCT05782413|Other|The design exercise program|"A selected therapeutic exercises program was based on the principles of NDTBobath neurodevelopmental therapy, which is effective in controlling spasticity in children with cerebral palsy and improving motor function.~i. Preparation of structures and mobilizations of the scapula, shoulder joint, and chest according to the NDT-Bobath concept ii. Exercises to increase shoulder mobility and elbow joint extension. iii. Fine motor skill exercises, wrist, and hand"
45515167|NCT01679002|Drug|Oxcarbazepine|
45515168|NCT01428362|Drug|VI-1121|
45515169|NCT01428362|Drug|Placebo|
45515170|NCT02261870|Device|MRI T2 quantification|MRI acquisitions will be performed according to the already described method based on conventional Fast Spin Echo sequences and with an additional calibration pad positioned on the patient thorax (dedicated pad made by the Nancy CIC-IT with stable and adapted T2). MRI will be performed if possible before the biopsy and otherwise the radiologist will be kept blinded of the biopsy results.
45515171|NCT04409509|Biological|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously
45515172|NCT04409509|Drug|Placebo|CSL312 diluent administered intravenously
45699462|NCT03441516|Drug|Alfoatirin® Tab. + Aripezil® Tab.|Choline Alphoscerate 400 mg Oral Tablet bid + Donepezil 10 mg Oral Tablet qd for 24 weeks
45515173|NCT02262104|Behavioral|Intensive exercise|Arm 1: Intervention group. Intensive strength exercise (12RM) for lower limb and balance exercises twice a week for 1 hour. Groups of max 3 participants lead by physiotherapist
45515174|NCT02262104|Behavioral|Control|Arm 2: control. Social activity group with light exercise, reading, and games. Lead by occupational therapist or nursing staff
45515175|NCT02263430|Device|Deep Brain Stimulation|
45699463|NCT03441516|Drug|Aripezil® Tab.|Donepezil 10 mg Oral Tablet qd for 24 weeks
45515176|NCT02610296|Drug|QPI-1002|IV injection
45699464|NCT03445962|Diagnostic Test|Assessment of OSAS predictive factors|"All subjects of the two groups realized the same assessment:~Anthropometric evaluation~biological examination (hormonal, inflammatory and complete blood count, and lipidic profile)~rest electrocardiogram~motor assessment (strenght, flexibility and balance)~actigraphy~Autonomic nervous system assessment during sleep~Autonomic nervous system assessment during head up tilt test before and after physical exercise~maximal treadmill test (VO2 max measure)~polysomnography~seismocardiography~questionnaires :sleep and physical activity"
45515177|NCT02610296|Other|Placebo|isotonic saline
45515178|NCT04401865|Combination Product|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
45515179|NCT05206903|Other|Questionnaires|Questionnaires about pandemia process
45515180|NCT02263586|Behavioral|Education in nutrition|Athletes were given a 45 min lesson on the proper diet and fluid intake to prevent hyponatremia in long-distance triathlon.
45515181|NCT02609048|Drug|Placebo Comparator|Placebo Capsule (2 taken once daily)
45515182|NCT02609048|Drug|Experimental: Seladelpar / MBX-8025 50 mg|MBX-8025 50 mg capsule (1 taken once daily)
45515183|NCT02609048|Drug|Experimental: Seladelpar / MBX-8025 200 mg|MBX-8025 100 mg capsules (2 taken once daily)
45515184|NCT02262182|Other|KP group|
45515185|NCT02262182|Other|KM group|
45515186|NCT02265068|Drug|Ticagrelor|Treatment of ACS patients with Ticagrelor
45515187|NCT02262338|Drug|AGT-182|Recombinant HIRMAb-IDS
45515188|NCT01678924|Drug|AGN-214868|AGN-214868 given as injections into the area of pain on Day 1.
45515189|NCT01678924|Drug|AGN-214868 Placebo (Vehicle)|AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
45515190|NCT02265302|Drug|BIIL 284 oral solution|
45515191|NCT02265302|Drug|BIIL 284 wetability improved formulation (WIF) tablets|
45515192|NCT02265302|Drug|Placebo|
45515193|NCT02263742|Behavioral|Peer whole health intervention|Provide wraparound peer support, education, and navigation to individuals
45406652|NCT05782400|Radiation|CT scan|CT scan at baseline and then every three months as per clinical practice. The standardization of the procedure of images' collection through a CT- acquisition's protocol has been planned to control bias.
45406653|NCT05782400|Biological|Plasma collection|● Blood samples will be collected at baseline, at 1 month and at the first PD. Sixteen ml of blood will be collected in EDTA tubes and centrifuged at 1900×g for 10 min at 4 °C within 2 h after drawing to collect plasma, which will be stored at -80°C until analysis. Plasma samples will be sent to the Laboratory of Pharmacogenetics - Unit of Clinical Pharmacology and Pharmacogenetics - University Hospital of Pisa. Plasma samples will be used to isolate cell free DNA (cfDNA) and microvesicles-derived RNA for molecular analysis.
45406654|NCT05782374|Drug|Ibrutinib|ibrutinib alone or in combination with R-CHOP or R-CHOP like
45406655|NCT05782348|Behavioral|Cognitive behavioral intervention|A six-session CBI Intervention component will be used with the TEST GROUP I. This will examine a cognitive behavioral intervention designed to improve tooth brushing and oral hygiene. The components include oral health education, values-based activities, motivational interviewing, goal setting, problem solving skills, cognitive restructuring, verbal reinforcement and stress management.
45406656|NCT05782348|Other|Colgate smart toothbrush|A Colgate smart toothbrush that provides the user with details on toothbrushing habits and frequency
45515194|NCT02263742|Behavioral|EBPs at Wellness Center|four EBPs: a) on-site primary care; b) screening of clients for modifiable risk factors and medical conditions; c) care coordination; and d) peer health navigation
45515195|NCT02265380|Device|Placement of IV catheter|
45515196|NCT02262416|Drug|leuprolide|normal saline
45699465|NCT03445884|Drug|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV.
45699466|NCT03449550|Other|Home Respiratory Polygraphy (HRP)|Randomizing to start with home respiratory polygraphy
45699467|NCT03449550|Other|Standard Polysomnography (PSG)|Randomizing to start with Standard Polysomnography (PSG)
45699468|NCT03449550|Other|Home Respiratory Polygraphy (HRP)|Randomizing for therapeutic decision taken with home respiratory polygraphy (HRP)
45699469|NCT03449550|Other|Standard Polysomnography (PSG)|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
45699470|NCT03441438|Dietary Supplement|Water|Serum and urine markers will be obtained after drinking 5 oz of water
45699471|NCT03441438|Dietary Supplement|Red wine|Serum and urine markers will be obtained after drinking 5 oz of water
45699472|NCT03441438|Dietary Supplement|Polyphenolic Compounds|Serum and urine markers will be obtained after consuming 100 mg of provinols powder
45699473|NCT01857869|Biological|GSK257049 Dosage 1|RTS,S/AS01B administered as 0.5 mL dose at 0 and 1 months and 0.1 mL dose at 7 months for 0,1,7 M Group (delayed fractional dose group). In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
45406657|NCT05782322|Behavioral|Upper-limb training involving RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to listen to the RAS sound, use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They should keep their movements consistent with the sound of the RAS, with one RAS sound corresponding to one pick-up movement.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 7 days."
45515197|NCT01577654|Drug|EC145|2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks)
45515198|NCT01577654|Drug|EC145 + Docetaxel|"EC145 2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks) +~Docetaxel 75 mg/m2 IV Day 1 q 3 weeks"
45515199|NCT01577654|Drug|Docetaxel|75 mg/m2 IV Day 1 q 3 weeks
45515200|NCT01577654|Drug|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
45515201|NCT02608502|Biological|RSV-F Vaccine|
45515202|NCT02608502|Biological|Phosphate Buffer Placebo|
45515203|NCT02262494|Procedure|portable venous compression ultrasonography|venous compression ultrasonography performed using an ultra-portable ultrasound device (by emergency physician)
45515204|NCT02262494|Procedure|venous compress ultrasonography|venous compression ultrasonography performed using a classic ultrasound device (by exploratory specialist)
45515205|NCT02262494|Procedure|Doppler ultrasound of the lower limbs|Doppler ultrasound of the lower limbs (gold standard; by exploratory specialist)
45515206|NCT03278548|Drug|Volulyte 6%|Solution for infusion
45515207|NCT03278548|Drug|Ionolyte|Solution for infusion
45515208|NCT02265458|Behavioral|Musical intervention and sensory isolation|30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
45851585|NCT00241644|Biological|Placebo|One or three doses, oral administration.
45851586|NCT00245622|Biological|Tovaxin Autologous T cell vaccine|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
45406658|NCT05782322|Behavioral|Upper-limb training without the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They are asked to execute the task as fast as possible.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 7 days."
45515209|NCT01423058|Drug|Momelotinib|"In the Part I dose-escalation phase of the study, subjects will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 200 mg BID (twice daily with doses taken approximately 12 hours apart. Doses will be escalated by 50 mg BID in successive cohorts of 3 subjects per dose level. Subjects will be evaluated weekly for the first cycle, every 2 weeks during cycle 2, then monthly for 4 cycles for a total of 6 cycles.~In the dose confirmation phase of the study (Part 2), subjects will be evaluated every 2 weeks during the first treatment cycle, and then monthly for 5 cycles for a total of 6 cycles."
45406659|NCT05782309|Drug|Flavanol|Assessement, supplementation for 30 days with either Placebo or Flavanols, Re-assessment
45406660|NCT05782309|Drug|Placebo|Assessement, supplementation placebo for 30 days with either Placebo or Flavanols, Re-assessment
45406661|NCT05782296|Device|TrueLabor|Non invasive monitoring device
45406662|NCT05782257|Dietary Supplement|Zinc Supplementation|Take one 25mg Zn gluconate tablet daily
45406663|NCT05782257|Other|Zn-Optimized Diet|Consume 11 mg/day of zinc-rich foods for females and 14 mg/day in males.
45699474|NCT01857869|Biological|GSK257049 Dosage 2|RTS,S/AS01B administered as three doses of 0.5mL given one month apart (0, 1, 2 M group) in the challenge model. In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
45406664|NCT05782231|Behavioral|GetActive+|This is a 10-week group mind body program focused on improving self- report, performance based and ambulatory step count by combining mind body skills tailored for individuals with chronic pain, with gradual increased in walking using quota based pacing and goal setting, adapted specifically for older adults from a medically underserved location.
45406665|NCT05782205|Procedure|Severe complications following radical gastrectomy|The respondents are limited to surgeons who had previously experienced severe complications following radical gastrectomy as chief surgeons.
45406666|NCT05782192|Drug|SAL067|SAL067 6mg(2 tablet) and placebo 25mg (1 tablet)
45406667|NCT05782192|Drug|Alogliptin|Alogliptin 25mg(1 tablet) and placebo 6mg (2 tablet)
45406668|NCT05782192|Drug|Placebo|placebo 6mg (2 tablet) and placebo 25mg (1 tablet)
45406669|NCT05782166|Behavioral|Betel Quid Educational Booklet|"Eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained.~Participants will be given an educational booklet containing general information regarding betel quid and areca nut, risk associated with betel quid chewing behaviour, cessation strategies that are modeled after tobacco cessation and some relevant researcher's contact details.~Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour."
45406670|NCT05782166|Behavioral|Betel Quid Cessation Intervention Module|"All eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained.~An interactive, educational talk will be given regarding the content of the educational booklet.~Participants will undergo a 5-intervention sessions cessation program (M-BENIT) and will be given topical worksheets on every session to monitor their triggers, lifestyle changes, social support system and others.~Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour."
45515210|NCT01575470|Biological|autologous bone marrow mononuclear cells|bone marrow harvest (5ml/kg of body weight) performed within 36 hours of injury, followed by single intravenous infusion of bone marrow mononuclear cells.
45515211|NCT02236364|Device|Contour, Bayer Healthcare, LLC|Blood glucose measurement
45851587|NCT00245622|Biological|Placebo|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
45851588|NCT03800784|Drug|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
45851589|NCT03804060|Device|Thermogard XP3|Cooling with the ZOLL® Circulation catheter and the ZOLL® Intravascular Temperature Management system to initiate and maintain hypothermia for 6 hours as an adjunct to endovascular Recanalization.
45851590|NCT03804060|Procedure|Recanalization only|Standard of Care for recanalization
45406671|NCT05782153|Device|Intervention A (hearing aid self-fitting with direct adjustment)|The intervention offered is a hearing aid fitting with the Lexie B2 Powered by Bose receiver-in-the-canal hearing aids using a self-fitting strategy with direct adjustment. The hearing aids will be accompanied and operated with the Lexie smartphone application. Participants will complete a hearing screening (at 500, 1000, 2000 and 4000 Hz) called Hearing Check on the Lexie smartphone application, which will be used to tune the hearing aids according to frequency and loudness level. Participants will be able to use two wheels to change the loudness and fine-tune the hearing aids. Participants will wear the hearing aids for four weeks.
45406672|NCT05782153|Device|Intervention B (hearing aid self-fitting with in-situ fitting)|The intervention offered is a hearing aid fitting with the Lexie B2 Powered by Bose receiver-in-the-canal hearing aids using the in-situ audiometry fitting strategy. The hearing aids will be accompanied and operated with the Lexie smartphone application. Participants will complete an in-situ audiogram on the Lexie app, which enables the measurement of hearing thresholds through the hearing aids (at 500, 1000, 2000 and 4000 Hz). The hearing aids will then be self-programmed according to the participant's in-situ audiogram with a proprietary fitting algorithm that is based on NAL-NL2. Participants will wear the hearing aids for four weeks.
45515212|NCT05735782|Diagnostic Test|Clinical, mental health and psychosocial profile of Post-COVID-19 syndrome|Evaluation of persistent symptoms of COVID-19 and its association with psychological, cognitive and social status in comparison to a healthy control group
45406673|NCT05782140|Device|Mayo Clinic Watch Device|Mayo Clinic remote monitoring platform (Omni) that utilizes a wearable device with integrated physiological monitoring capabilities.
45406674|NCT05782114|Other|Extracorporeal Shockwave therapy|The shockwave will be applied for the experimental group (Group A). The patients will be positioned on a chair, and the hand with the disorder will be placed on a surface with the radio ulnar joint will be in mid position and the thumb will be directed up. will be 1000 impulses with 2 bar pressure at a frequency of 15 Hz on the radial head and focused on the tissue surrounding the maximal pain point.
45406675|NCT05782114|Other|Traditional physical therapy program|"Instruction to wear Thumb Spica splint:~The Thumb Spica splint will be used for 4 weeks for both groups of patients.~Ultrasound Therapy:~Therapeutic Ultrasound parameters will be mode: continuous, duration: 5 minutes, intensity: 1.2watt/cm2 and frequency: 1MHZ.~Stretching exercise:~1. Self-stretch of the thenar eminence: 2. Opposition stretches: 3. Wrist stretch:~4) Strengthening exercise:~Resisted exercise for thumb extension:~Resisted exercise for thumb abduction:~Resisted exercise for thumb opposition:~Wrist radial deviation strengthening:~Grip strengthening:~Finger spring:"
45406676|NCT05782101|Diagnostic Test|Integrated proteomic HPLC-ESI-MS analysis of salivary peptides|A targeted ESI mass spectrometry investigation, based on a top-down analysis of the intact salivary proteome will be performed.
45406677|NCT05782075|Other|Remote biological monitoring by a heart failure nurse|Review of biological results by a nurse (IDE) trained in heart failure monitoring, alongside the cardiologist, at S1, S2, M1, M2 and M3.
45406678|NCT05782049|Other|Ultrasound of the salivary glands|"Salivary gland ultrasound is, a non-invasive, non-irradiating and easily accessible examination, offers promising results for the diagnosis of primary SS. It allows the identification of changes in the homogeneity of the echostructure of the main salivary glands in the parotid and submandibular region.The patient lies on the examination table with the head slightly turned to the side opposite the gland being examined. The examination will be done on the parotid and submandibular glands on both sides.The parotid glands will be measured in length and width.The surface of the gland will be calculated: (length x width)/2.The sub-maxillary glands will be measured in length and surface.~The exam will be performed in 10 minutes."
45406679|NCT05782049|Other|Measurement of salivary flow|Saliva flow measurement, which consists of measuring the quantity of saliva that the patient can emit in 15 minutes
45406680|NCT05782049|Other|A Schirmer test|A strip of blotting paper graduated from five to five millimeters is placed in the eye for 5 minutes, avoiding any corneal contact.
45515213|NCT05735782|Diagnostic Test|Diagnostic performance of echocardiographic and biological markers in Post-COVID-19 syndrome|Determine the inflammatory, immune profile and ventricular function in post-COVID-19 participants compared to a control group
45515214|NCT03135392|Procedure|Breast Reconstruction with Artificial Implant|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with artificial implants
45515215|NCT03135392|Procedure|Autologous Breast Reconstruction|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with the patient's own tissue
45515216|NCT03135392|Procedure|Neurotization|Nerve will be reconstructed during autologous breast tissue reconstruction
45515217|NCT02265536|Drug|LY3022855|Administered IV
45515218|NCT04413292|Diagnostic Test|ELISA assays and Westren blot analysis of survivin and fibulin-3 expression|expression analysis of biomarkers
45515219|NCT01418222|Drug|5-FU|Intravenous repeating dose
45515220|NCT01418222|Drug|FOLFOX regimen|Intravenous repeating dose
45515221|NCT01418222|Drug|Placebo|Intravenous repeating dose
45515222|NCT01418222|Drug|bevacizumab [Avastin]|Intravenous repeating dose
45515223|NCT01418222|Drug|leucovorin|Intravenous repeating dose
45515224|NCT01418222|Drug|onartuzumab [MetMAb]|Intravenous repeating dose
45851591|NCT03808584|Other|Physiotherapy|4 specific core muscle exercises, targeting abdominal muscles, to be performed daily from postoperative day one to 2 months postsurgery.
45851592|NCT03809754|Procedure|Percutaneous Coronary Intervention under OCT|After randomization, subjects receive primary PCI under the guiding of OCT
45406681|NCT05782023|Behavioral|Digital empowerment|The intervention will consist of a minimal interaction face-to-face before hospital discharge for risk factors profiling followed by actions for health empowerment, delivered through an ad-hoc developed web platform, which include: a) periodic delivery of email messages with links to educational, motivational and supportive materials for secondary prevention, b) access to a message box for questions and answers and c) possibility of video-calls with the preventive team.
45406682|NCT05782010|Device|PexyEazy|PexyEazy procedure on patients with hemorrhoidal disease grade II and III. The study is descriptive and non-comparable to evaluate the safety and performance of PexyEazy.
45515225|NCT05377606|Procedure|Pars plana vitrectomy with silicone oil|Silicone oil will be used at the end of primary vitrectomy. OCT, OCTA and microperimetry will be done 2 months later. Silicone oil will be removed at 3 months. Finally, the OCT, OCTA, and microperimetry will be repeated once more after 4 months from the vitrectomy.
45515226|NCT05377606|Procedure|Pars plana vitrectomy with SF6|Sulfur hexafluoride (SF6) will be used at the end of primary vitrectomy. OCT, OCTA, and microperimetry will be done 2 months and 4 months after surgery.
45515227|NCT05092906|Other|LP with complementary hypnoanalgesia|The lumbar puncture technique will be identical to that of the group standard of care. Hypnosis will be performed by a health professional trained in this practice, in addition to the standard analgesic management.
45515228|NCT05092906|Other|LP with standard of care|"The LP will be carried out according to the usual techniques without hypnosis.~Standard analgesic treatments will be used (except contraindications):~EMLA (Lidocain+Prilocain) Cream/Patch~Local anesthesia with lidocain chlorhydrate monohydrate 1% injectable~Nitrous oxide"
45699475|NCT01857869|Procedure|Sporozoite-infected mosquitoes challenge|"Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the volunteers. For each volunteer, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored.~The challenge is scheduled to occur approximately 21 days (3 weeks) after the last vaccination visit (Study Day 196). Volunteers who reconsent for the boost/rechallenge phase will be rechallenged with sporozoite-infected mosquitoes, scheduled to occur approximately 21 days (3 weeks) after the booster dose (Booster Phase Study Day 21)."
45699476|NCT01230424|Drug|Triamcinolone Acetonide|40 mg into the study knee joint every 12 weeks for a total of 8 injections.
45699477|NCT01230424|Drug|0.9% Sodium Chloride Injection as Placebo|Sodium chloride injection will be given into the study knee once every 12 weeks for a total of 8 injections.
45851593|NCT03809754|Procedure|Percutaneous Coronary Intervention under Angiography|After randomization, subjects receive primary PCI under the guiding of angiography
45851594|NCT03809676|Other|periodontal examination|clinical measurements were recorded
45851595|NCT03809832|Diagnostic Test|Microbiological sampling|An microbiological sampling of the ventilator humidifier will be performed.
45851596|NCT03808974|Other|Educational video|Short educational video describing the mid-urethral sling procedure
45851597|NCT03808974|Other|Educational leaflet|Standard educational leaflet describing the mid-urethral sling procedure
45851598|NCT03808896|Procedure|stylet-assisted epiglottic lifting|use stylet-equipped enodtracheal tube to lift the epiglottis and pass the endotracheal tube
45851599|NCT03808896|Device|bougie-assisted intubation|use bougie as a introducer. Pass the bougie to the trachea and pass the tube via bougie guide.
45851600|NCT03809130|Other|Internet-Based Intervention|Use Untire application after baseline up to 6 months
45851601|NCT03809130|Other|Internet-Based Intervention|Use Untire application after 3 months up to 6 months
45406683|NCT05781997|Diagnostic Test|cycloplegic refraction|Cycloplegic autorefraction will be attempted on all children using a table-mounted autorefractor . Cycloplegia will be achieved with three drops of 1% cyclopentolate administered 5 min apart and autorefractive measurements will be performed 30 min after the instillation of the last drop. Auto refraction readings of three consecutive measurements will be obtained and the average will be computed automatically in each eye. Each child will be reexamined until three measurements fell within 0.50 diopters (D) if any two measurements varied by >0.50D.
45406684|NCT05781984|Procedure|Microsugical Excsosion|Microsurgical excision of pineal region tumor or endoscopic biopsy
45515229|NCT01413932|Drug|HT-2157|QD oral dosing
45406685|NCT05781958|Drug|Cadonilimab+Gem/Cis|Cadonilimab (500mg, iv, Q3W, Day1)+Gemcitabine (1000mg/m2, iv, Q3W, Day1and Day8)+Cisplatin (25mg/m2, iv, Q3W, Day1and Day8) Cadonilimab: up to 12months Gem/Cis: 6-8cycles
45515230|NCT01413932|Drug|Placebo|QD oral dosing
45515231|NCT02925793|Drug|DS107|
45515232|NCT02925793|Other|Vehicle cream|
45515233|NCT01256762|Drug|Imetelstat sodium|Imetelstat is administered at a dose of 300 mg/m2 on day one of a 21 day cycle.
45515234|NCT01256762|Drug|Bevacizumab|Bevacizumab is administered at 15 mg/kg on day one of a 21 day cycle
45515235|NCT01256762|Drug|Paclitaxel|Paclitaxel is administered at 90 mg/m2 on days one and eight of a 21 day cycle
45699478|NCT02521428|Other|retrospective analysis|Approximately 200 patients will be enrolled in the study. They are followed up until their death on the ICU. In clinical routine end-of-life decisions are documented for decision-makers and procedures in the patients´ records. Patients´ characteristics and therapeutic approaches are documented in the electronic patient data management system.
45851602|NCT03809130|Other|Quality-of-Life Assessment|Ancillary studies
45851603|NCT03809130|Other|Questionnaire Administration|Ancillary studies
45851604|NCT03808428|Device|Ankle Group|Provide sensory feedback to help subjects relearn how to walk in correct gait pattern.
45851605|NCT03808116|Device|SmartBx|"he SmartBx device is intended for the retention of a biopsy specimen and for preservation of the specimen's in-needle location and orientation.~The SmartBx is used as an aiding tool in biopsy procedures. When operated in conjunction with the standard equipment in a prostate biopsy procedure, the SmartBx may be used for the following:~To preserve sample unity, including core fragments in their original location along the needle notch.~Avoid sample damaging during sample removal from the needle and the following pathology process."
45851606|NCT03808038|Other|None- Observational Study|None- Observational Study
45851607|NCT03807960|Other|written form|The written form which include PCA usage information.
45851608|NCT03807960|Other|video|The video about PCA usage
45851609|NCT03807960|Other|routine care|The routine description about PCA usage
45515236|NCT03135158|Other|Exposure to vaginal delivery|Women who have vaginal births are observed for a minimum of 1 hour postpartum
45515237|NCT05759299|Procedure|Tracheal intubation|Advanced airway management with tracheal intubation performed after induction with hypnotic and/or opioid drugs and laryngoscopy
45515238|NCT02268188|Other|education|Attend classes as part of Harvesting Health program
45515239|NCT02268188|Other|nutrition intervention|Learn how to incorporate nutrition guidelines into daily meal plans as part of Harvesting Health program
45406686|NCT05781945|Dietary Supplement|probiotics|supplementation with Bifidobacterium lactis LA 304, Lactobacillus salivarius LA 302,andLactobacillus acidophilus LA 201+ standard theraph for sars-cov-2
45406687|NCT05781945|Other|standard therapy|standard therapy for sars-cov-2
45515240|NCT02268188|Behavioral|exercise intervention|Use FitBit to log daily steps as part of Harvesting Health program
45515241|NCT02268188|Other|questionnaire administration|Ancillary studies
45515242|NCT02268188|Other|laboratory biomarker analysis|Correlative studies
45406688|NCT05781932|Procedure|Dermal barb suture combined with medical glue|In the experimental group, after tension reduction and suture were completed, the wound and surrounding skin were wiped clean with normal saline and clean gauze, and the blood accumulated in the wound was squeezed out. Histoacryl medical tissue glue (specification:0.5 ml/piece, main components: n-butyl 2-cyanoacrylate (embutate), pigment (1-hydroxy-4[(toluene)amino]-9,10-anthraquinone), and stabilizers (p-diphenol, sulfur dioxide, phosphoric acid)) were evenly spread on the surgical incision and kept in the butt state for 4 to 6 seconds. After it got solidify and dry, a sterile gauze covered the surgical incision. There was no need to disinfect and change the dressings after the operation. Patients can shower normally on the day after the operation by just avoiding rubbing the incision covered with glue. Patients can move normally 1-2 days after the operation, and the glue film falls off on its own within 5-10 days.
45515243|NCT02268188|Other|quality-of-life assessment|Ancillary studies
45515244|NCT04351945|Procedure|Blood test|Hormone levels will be measured just before transplantation, and three day after the transplantation. In case of the donors hormone levels will be defined during the explantation.
45515245|NCT05761717|Drug|Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection|Subcutaneous Injection
45515246|NCT01252628|Drug|PX-866 (SCCHN)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
45515247|NCT01252628|Drug|Cetuximab (SCCHN)|Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.
45515248|NCT01252628|Drug|PX-866 (CRC)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
45406689|NCT05781906|Drug|HMPL-523|D1-D7: HMPL-523 Tablet 300 mg QD
45406690|NCT05781906|Drug|150 µCi [14C]HMPL-523|D8: [14C] HMPL-523 Suspension 300 mg/150 μCi Single dose
45406691|NCT05781867|Other|Manual therapy and conventional physical therapy treatment|manual therapy (chest mobilization, diaphragmatic myofascial release, myofascial release for pectoralis minor, pectoralis major, scaleni ),pursed lip breathing, diaphragmatic breathing and active range of motion exercises of upper limbs
45406692|NCT05781854|Drug|Epidural analgesia with bupivacaine and dexmedetomidine|Epidural analgesia with bupivacaine and dexmedetomidine
45406693|NCT05781841|Diagnostic Test|Detection of expression of SOCS3 gene|Detection of expression of SOCS3, in each samples using Real-Time PCR
45406694|NCT05781841|Diagnostic Test|Detection of expression of IFN-α gene|Detection of expression of IFN-α gene in each samples using Real-Time PCR
45406695|NCT05781841|Diagnostic Test|Detection of expression of IFN-β gene|Detection of expression of IFN-β gene in each samples using Real-Time PCR
45515249|NCT01252628|Drug|Cetuximab (CRC)|Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.
45515250|NCT05206669|Behavioral|Health Messages|Brief messages providing information about the effectiveness of HPV vaccines. Messages included embedded links where participants could find more information.
45515251|NCT01239758|Biological|ACE-031 (Extension of cohort 1 from core study, A031-03)|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
45515252|NCT01239758|Biological|ACE-031 (Extension of cohort 2 from core study, A031-03)|Up to 1.0 mg/kg subcutaneously once every 2 weeks for 24 weeks.
45515253|NCT01239758|Biological|ACE-031 (Extension of cohort 3 from core study, A031-03)|Up to 2.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
45515254|NCT05206045|Other|Standard of care|Standard of care for patients with Sezary Syndrome
45515255|NCT01236638|Drug|Momelotinib|Patients will continue receiving the same doses as assigned during the CCL09101 protocol; up to 400 mg once per day (QD). CYT387 will be administered orally as a single daily dose (at least 20 and no more than 28 hours apart, preferably in a fasted state at least two hours before and one hour after a meal), except for patients on the twice daily (BID) dosing regime (150 mg BID).
45515256|NCT04349371|Drug|Chloroquine|Subjects will take two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration.
45515257|NCT04349371|Drug|Placebo oral tablet|Subjects will take two tabs of placebo for every day for one week and then two tabs of placebo for 1 day a week thereafter for study duration of 3 months).
45515258|NCT01410188|Drug|OPA-6566|OPA-6566, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
45515259|NCT01410188|Drug|Placebo|Placebo, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
45515260|NCT01410188|Drug|Latanoprost|Latanoprost (one drop once per day for 4 weeks)
46059162|NCT01048541|Device|Test Catheter - SpeediCath Compact Male|Compact catheter for intermittent catheterisation
46059163|NCT01048541|Device|SpeediCath|Catheter for intermittent catheterisation
45406696|NCT05781828|Diagnostic Test|Detailed abdominal ultrasound|size of the liver and architecture, size of the spleen, presence or absence of ascites
45406697|NCT05781815|Procedure|dynamic hip screw|using dynamic hip screw in treatment of trochanteric fracture and dynamic hip screw with trochanteric stabilizing plate
45406698|NCT05781789|Other|Telehealth for preoperative evaluation|Conduct of preoperative evaluation remotely using Zoom application
45406699|NCT05781763|Behavioral|High intensity interval training (HIIT)|"2 HIIT sessions/week in self-selected activity and type of interval-session with in total 15 minutes interval time (85-90% of MHR) with active rest (50-70% of MHR) between intervals for 12 weeks~1 self-selected session at moderate or high-intensity/week for 12 weeks Standardized physical and digital coaching by a physiotherapist"
45406700|NCT05781763|Other|Control group|Continuing with exercise as usual during 12 months
45515261|NCT01408082|Drug|ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined)|Azithromycin and Dexamethasone twice daily for 2 weeks
45515262|NCT01408082|Drug|Azasite|Azasite twice daily for 2 weeks
45515263|NCT01408082|Drug|Dexamethasone|Dexamethasone twice daily for 2 weeks
45515264|NCT01408082|Other|Vehicle|Vehicle twice daily for 2 weeks
45515265|NCT03071263|Drug|Patiromer|2 packets/day starting dose, administered orally
45515266|NCT03071263|Drug|Placebo|2 packets/day starting dose, administered orally
45515267|NCT03071263|Drug|Spironolactone|25 mg tablet/day starting dose, administered orally
45515268|NCT04462484|Behavioral|videoconference|The intervention is a person-directed, individual, primary occupational intervention. It will be carried out via videoconference in six sessions of 45 minutes (on a weekly basis). Through guided dialogue, individual difficulties and opportunities of each subject will be examined in order to gain self-awareness of personal characteristics (strengths, limitations, maximum workload capacity) in their particular set of job demands and resources. Participants are encouraged to adopt the set of self-care strategies in each dimension, adapting them to their specific context. Activities will be carried out in Spanish by the researcher.
45515269|NCT02268266|Device|Erigo|The control of cardiovascular parameters within suitable ranges for healthy and neurological patients using verticalization, leg mobilization and electrical stimulation
45515270|NCT01546532|Drug|RLX030|RLX030 as intravenous infusion for 24 hours.
45515271|NCT01546532|Drug|Placebo|Intravenous infusion of Placebo over 24 hours
45515272|NCT04314115|Other|Mindfulness|Brief intervention in mindfulness, of individual type, of four sessions of sixty minutes per week, in addition to individual tasks, according to protocol of brief intervention in developed mindfulness.
45515273|NCT04314115|Other|Systemic therapy|Brief systemic therapy intervention, of four weekly sessions of sixty minutes, with individual tasks and assignments, according to the protocol designed.
45851610|NCT03807726|Behavioral|Simulation breastfeeding education|The integrated interventions are consisted of 1) four sessions of simulation breastfeeding education to build up the participants' performance accomplishment and vicarious learning including breastfeeding knowledge, skill, and self-efficacy; 2) two sessions of breastfeeding mindfulness training to equip women and their partners with stress reduction skills for their emotional arousal during breastfeeding; 3) a series of postpartum professional support to offer verbal persuasion in enhancing their breastfeeding skills and levels of self-efficacy.
45515274|NCT04314115|Other|Cognitive behavioral therapy and positive psychology|Brief intervention of traditional cognitive behavioral therapy with elements of positive psychology, of four weekly sessions of sixty minutes, with individual assignments and assignments, according to the protocol designed.
45515275|NCT02265614|Genetic|PGS|
45515276|NCT02263898|Drug|Raf kinase inhibitor LGX818|Given PO
45515277|NCT02263898|Drug|binimetinib|Given PO
45851611|NCT03807804|Biological|HLCM051|HLCM051 is the stem cell product that can be mass-produced, being derived from adult adhesive stem cells that were taken from bone marrow of healthy unrelated donors from whom the informed consent was obtained, and proliferated ex vivo.
46059164|NCT05405569|Other|CPR Arms Angle 90º|Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 90º.
46059165|NCT05405569|Other|CPR Arms Angle 60º|Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 60º.
46059166|NCT04077931|Other|exercises|Walking on treadmill with fixed 0% grade inclination
45406701|NCT05781685|Drug|Testosterone|Sublingual testosterone was administered to participants. Participants would self-administer the testosterone to themselves.
45406702|NCT05781685|Other|Placebo Syrup|Oil-based sublingual product.
45406703|NCT05781659|Procedure|Ultrasound elastography guided pleural biopsy|The patients will undergo ultrasound elastography (Aixplorer V, SuperSonic Imagine, FRA) guided pleural biopsy.
45515278|NCT02263898|Other|laboratory biomarker analysis|Correlative studies
45515279|NCT04310839|Procedure|Colectomy|colectomy due to neoplastic (stage 1) or diverticulosis
45515280|NCT01403636|Drug|SAR245409|Pharmaceutical form:capsule Route of administration: oral
45515281|NCT03629509|Behavioral|BEFORE decision aid|Implementation of the BEFORE decision aid in clinical practice
45515282|NCT03629509|Behavioral|BEFORE decision aid|Implementation of the BEFORE decision aid on RUBY communication portals
45515283|NCT03629509|Behavioral|BEFORE decision aid|Review impact of BEFORE decision aid implementation in clinical practice
45515284|NCT05200663|Drug|Tab Tamoxifen 10 mg|Tablet tamoxifen 10mg twice a day for 6 months.
45515285|NCT05200663|Drug|Tab Tamoxifen 10mg,Cap vitamin E 400mg|Tab tamoxifen 10 mg is given twice a day and cap vit E 400mg is given once a day for 6 months
45515286|NCT02268344|Device|Grass SD9 Stimulator|Electrical stimulation will be applied to the nerve using the Grass SD9 Stimulator at a frequency of 20Hz, 10-15V, for 60 minutes during the surgery. This will occur after the neck dissection has been completed, and the remainder of the surgery will continue during stimulation. The stimulation will be applied using the Grass SD9 Stimulator and the current will be conducted to the nerve using a sterile wire electrode that will be encircled around the nerve at its most proximally-exposed portion (skull base). The wire will be removed after 60 minutes of stimulation has been applied.
45515287|NCT05758519|Drug|QLS1128|QLS1128
45515288|NCT05758519|Drug|Placebo|Placebo
45515289|NCT02268422|Drug|Buprenorphine|7 day patch
45515290|NCT05758363|Dietary Supplement|Consumption of dietary supplement.|Consumption of a dietary supplement rich in glutathione, selenium, zinc, vitamin D and EPA/DHA. 1 capsule per day of the dietary supplement with breakfast.
45515291|NCT05758363|Other|Consumption of control product|Consumption of 1 capsule per day of control product of identical appearance with breakfast.
45515292|NCT01522196|Drug|Varespladib|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
45406704|NCT05781659|Procedure|Traditional ultrasound guided pleural biopsy|The patients will undergo traditional ultrasound (Aixplorer V, SuperSonic Imagine, FRA) guided pleural biopsy.
45406705|NCT05781646|Diagnostic Test|Xpert MTB/RIF|CSF samples was centrifuged at 3,000 - 4,000 X g for 15 minutes. Supernatant was removed to leave a 1-ml precipitate, which was then used for Ziehl-Neelsen AFB staining (100 μl), inoculation of MGIT culture (100 μl), and Xpert MTB/RIF testing (800 μl).
45515293|NCT01522196|Other|Placebo (Normal Saline)|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
45515294|NCT05762263|Behavioral|Dietary|Depending on the allocation arm, participants will be advised to follow a particular dietary plan (either flexitarian eating, time-restricted eating or both combined).
45515295|NCT01236404|Drug|Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)|
45406706|NCT05781633|Drug|eutidrone etoposide bevacizumab|Eligible patients received a regimen of eutidrone(30mg/m2/d,iv,d1-5,21d/cycle), etoposide(30mg/m2/d,iv,d1-3,21d/cycle), and bevacizumab (10mg/kg,d1,21d/cycle).At least 4 to 6 cycles were administered, and if patients had a response or stable disease, bevacizumab was used as maintenance therapy until disease progression or intolerable toxicity.MRI of the brain with contrast enhancement was performed at baseline and every 6 weeks after enrollment; thereafter, patients with stable disease or a response could be assessed at a reduced frequency to every 9 weeks; central nervous system and noncentral nervous system lesions were assessed according to RANO-BM criteria and RECIST v1.1 criteria until disease progression, respectively.
45406707|NCT05781620|Dietary Supplement|Vitamin D|Participants received 5,000 IU of vitamin D orally twice daily for 4 weeks. If the serum 25(OH)D concentration exceeds 48 ng/mL, the intervention remains the same. However, if the serum 25(OH)D concentration is under 48 ng/mL, the dosage would increase by 2,500 IU. The principle remains the same at week 6.
45406708|NCT05781620|Dietary Supplement|Medium-chain triglycerides|Participants received the same amount of placebo matching vitamin D orally twice daily.
45515296|NCT01236404|Drug|Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)|Once weekly injections for up to four weeks
45515297|NCT05758285|Other|AI-Based Prediction of Treatment Engagement and Outcomes|AI-based algorithms and prediction models of treatment engagement and outcomes based on data from the Online Therapy Unit by Prof. Heather Hadjistavropoulos will be trained to predict symptom improvement of patients from pre- to post-digital psychotherapy intervention and to predict patients' engagement with the digital psychotherapy intervention and to predict patient drop out probability. For prediction model estimation, state of the art AI-based algorithms, such as XGBoost, is used . XGBoost is a machine learning method developed by refining previously established decision-tree-based methodologies. Data is split into training and testing sets (e.g., 80/20 split).
45515298|NCT02268578|Device|Transcranial Direct Current Stimulation|2mA tDCS
45515299|NCT02268578|Procedure|Sham Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is administered but at 0mA
45515300|NCT04220671|Biological|measles vaccine|Measles vaccine, Edmonston-Zagreb strain, 0.5 ml administered as a subcutaneous injection
45515301|NCT04220671|Other|Saline|0.9% NaCl
45515302|NCT01400594|Drug|HTU-520 Patch|Terbinafine hydrochloride patch
45515303|NCT01400594|Other|Placebo Patch|Treatment with Placebo Patch
45515304|NCT05049343|Drug|SAGE-904|SAGE-904 oral solution.
45515305|NCT05049343|Drug|Placebo|Placebo oral solution.
45515306|NCT05049343|Drug|Ketamine|Ketamine intravenous (IV) infusion.
45515307|NCT01569919|Biological|TroVax®|Dose of 1 x 10^9 TCID 50/ml, in 1ml, given on day 1 of weeks 1, 3, 6, 9, 12, 15, 18, 21, 24.
45515308|NCT01569919|Drug|Pemetrexed|500 mg/m^2 over 10 mins, given on day 3 of weeks 4, 7, 10, 13.
45515309|NCT01569919|Drug|Cisplatin|75mg/m^2 over 1 hour, given on day 3 of weeks 4, 7, 10, 13
45515310|NCT01569919|Dietary Supplement|Vitamin B12|1000μg intramuscular, Day 2 of weeks 3 and 12
45515311|NCT01569919|Dietary Supplement|Folic Acid|400μg oral daily from Day 2 of week 3 to Day 2 of week 16
45515312|NCT01569919|Drug|Dexamethasone|4mg BD, Days 2-6 of weeks 4, 7, 10, 13
45515313|NCT05205187|Procedure|Healthy control specimen collection|Collecting blood and feces from healthy population.
45515314|NCT05205187|Procedure|Non-Borrmann IV patient specimen collection|Collecting blood, feces and gastric cancer tissues from Non-Borrmann IV patients.
45515315|NCT05205187|Procedure|Borrmann IV patient specimen collection|Collecting blood, feces and gastric cancer tissues from Borrmann IV patients.
45515316|NCT01399580|Drug|Atrasentan|Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 8 weeks during the treatment period.
45515317|NCT01399580|Drug|Placebo|Subjects will take two tablets daily of placebo QD for 8 weeks during the treatment period.
45406709|NCT05781607|Combination Product|Patient education combined with drug therapy|Receive a health education by a specialist therapist, including explaining the anatomy and function of TMJ; Explain the etiology, prognosis, treatment plan and prognosis of TMD; Correct the patients' daily oral habits, such as unilateral chewing, habitual clenching, eating too much hard food, etc; Instruct the patient to understand the rest position of the temporomandibular joint and correct the bad posture of the neck and shoulder. At the same time, corresponding medication should be given, and NSAIDS should be taken orally or externally for patients with pain.
45406710|NCT05781607|Combination Product|Individualized comprehensive physical therapy|Physical factor therapy and/or manual therapy
45406711|NCT05781581|Other|no intervention|no intervention
45515318|NCT04069585|Device|RHA® Redensity with new anesthetic agent|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.
45515319|NCT04069585|Device|RHA® Redensity with lidocaine|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
45515320|NCT04064671|Other|Implantation of the Zephyr ZSI 475 FTM erectile implant|Until recently, all penile implants were manufactured for erectile dysfunction in biological males and thus presumed the presence of two corpora cavernosa. In 2016 however, the Swiss company, Zephyr Surgical Implants (ZSI), created a 3-piece inflatable erectile device specifically for female-to-male transsexuals: the Zephyr ZSI 475 FTM. This prosthesis has a realistic gland shape, only one cylinder, and a specific anchorage device made of titanium and silicone to anchor the system to the pubic bone of the patient. These specific features could potentially address the aforementioned issues with implanting erectile devices in the neophallus and hopefully lead to better surgical outcomes in these particular patients.
45515321|NCT03969433|Device|TMSi Porti|Data collections
45515322|NCT03969433|Device|Bloomlife sensor|Data collections
45515323|NCT00157196|Biological|Tecemotide (L-BLP25)|After receiving single low-dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide [L-BLP25]) at 6-week intervals, commencing at Week 13, until disease progression is documented.
45515324|NCT00157196|Drug|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
45851612|NCT03807570|Dietary Supplement|Morus Alba L. Extract|Morus Alba L. Extract 30 ml/day for 12 weeks.
46059167|NCT00916240|Behavioral|Multisystemic Therapy|Treatment will consist of a home- and community-based intensive intervention. Psychological treatment sessions will be provided in participants' homes, at a time designated by the participant and will last about 1 hour.
45406712|NCT05781529|Procedure|Alveolar ridge augmentation with injectable platelets rich fibrin|Injectable platelets rich fibrin is added to xenograft for alveolar ridge augmentation in order to preserve bone and decrease bone resorption
45406713|NCT05781529|Procedure|Alveolar ridge augmentation with hyaluronic acid|Hyaluronic is added to xenograft for alveolar ridge augmentation in order to preserve bone and decrease bone resorption
45406714|NCT05781529|Procedure|Alveolar ridge augmentation with xenograft|Xenograft is added alone as a active compatator
45406715|NCT05781490|Drug|Lumentin® 44 Powder for oral foam|Lumentin® 44 is a foam for oral use.
45515325|NCT00157196|Other|Best standard of care (BSC)|The BSC will be provided at the investigator's discretion, and may include but not be limited to psychosocial support, nutritional support and other supportive therapies.
45515326|NCT02265770|Drug|16 weeks of VEC + CDDP|Days 1-36-71-106: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-36-38-71-73-106-108: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-36-71-106: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 22-57-92: Cisplatin: 80 mg/m² over 4 hours + Vincristine:1.5 mg/m² (maximal dose 2 mg) i.v.
45851613|NCT03807570|Dietary Supplement|Placebo|Placebo 30 ml/day for 12 weeks.
45851614|NCT03807258|Other|Transcranial magnetic stimulation (TMS)|Evaluations by TMS
45851615|NCT03807180|Other|Tai Chi (exercise)|Tai Chi exercise method, which is composed of combination of physical exercise and relaxation techniques for patients with rheumatic diseases.
45851616|NCT03807102|Biological|Tumor Vaccine|NeoAntigen Tumor Vaccine (5 injections for each 3 days and then 1 injection for each 3 months till recurrence or up to 2 years).
45851617|NCT03806712|Other|multi method questionary (developped by De Rosa, in 1995 and 2014)|questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)
46059168|NCT00916240|Behavioral|Home-based, Non-Directive Family Support|Treatment will consist of Rogerian, client-centered, non-directive counseling. Participants will receive weekly home-based, supportive family counseling, with sessions lasting about 45 minutes.
46059169|NCT02583217|Drug|Ketamine|To compare ketamine+propofol versus remifentanyl+propofol to maintain good laryngeal mask insertion conditions
46059170|NCT02583217|Drug|remifentanyl|
46059171|NCT02583217|Drug|propofol|
45406716|NCT05781477|Behavioral|Bmum supportive system|Bmum is a web-based online tracking system that aims to improve positive attitude about breastfeeding
45406717|NCT05781464|Procedure|Traditional chest physiotherapy|"Postural drainage: the patient is positioned in postural drainage so that gravity had the maximum effect on the lung segment that needed to be drained, all lung zones are emphasised in positional initiatives for babies.~Percussion is the rhythmic striking of the chest wall with cupped hands for 1 to 2 minutes at a time.~Vibration is performed by placing fingers on the chest wall over the segment being drained and isometrically contracting the forearm and hand muscles to produce a vibratory motion.~Vibration is accomplished either through manual vibratory motion of the therapist's fingers on the infant's chest wall or through the use of a mechanical vibrator ( Foreo vibrator)."
45406718|NCT05781464|Procedure|Prolonged slow expiration technique|The therapist places one hand on the thorax below the suprasternal notch and the other hand over the upper abdomen while the neonate is supine. Both hands will have hypothenar contact with the thorax and abdomen. At the end of the expiratory phase, the therapist places a compression force with both hands. Compression at the end of expiration with hypothenar eminence is kept for 2 or 3 breathing cycles. This technique is repeated several times, with a rest time between applications of about 5 or 10 spontaneous breaths.
45406719|NCT05781451|Drug|LY3361237|All patients will receive LY3361237 450mg subcutaneously every 2 weeks for a total of 12 weeks.
45406720|NCT05781386|Drug|SIM1811-03|SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumor
45406721|NCT05781373|Procedure|Peep individualization|Intraoperative Peep individualization in order to achieve the lowest driving pressure
45406722|NCT05781360|Drug|SIM0237|SIM0237 should be administered intravenously at recommended dose qw or other dosing regimens
45406723|NCT05781347|Procedure|Radiofrequency Energy to the LES (Stretta Procedure)|The Stretta procedure is performed endoscopically under general anesthesia which uses radiofrequency (RF) energy delivered to the lower esophageal sphincter and cardia.
45406724|NCT05781347|Device|Stretta|Stretta is a FDA approved device for the management of GERD.
45406725|NCT05781334|Other|Virtual Consult Intervention|The intervention will consist of a quality improvement (QI)-based virtual consult designed by a multi-disciplinary team that will aim to address provider-level, patient-level, and system-level barriers to cardio-renal-metabolic disease medications
45406726|NCT05781295|Device|TaurolockTM|The patient will be followed up to a maximum of 6 months after randomization after have a TaurolockTM injected each time catheter will be used.
45406727|NCT05781295|Device|Physiological serum|The patient will be followed up to a maximum of 6 months after randomization after have a Physiological serum injected each time catheter will be used.
45406728|NCT05781269|Other|VLCKD|VLCKD diet treatment with medical food
45406729|NCT05781269|Other|r-MedDiet|Mediterranean diet treatment
45406730|NCT05781230|Behavioral|High Intensity Exercises Program|HIE program consisted of ankle pump exercise, Quadriceps isometric exercise, Terminal extension exercise, Passive-active assistive-active range of motion exercise, Heel sliding exercise, Straight leg raise exercise. All exercises were performed for 3 sets of 15 repetitions.
45406731|NCT05781230|Behavioral|Low Intensity Exercises Program|LIE program: LIE program was similar to the HIE program. Main differences from the HIE program was repetitions of exercises. All exercises were performed by the patients for 2 sets of 8 repetitions and CPM sessions lasted each exercises session. LIE program took thirty minutes while HIE program lasted sixty minutes. Exercise intensity was monitored using the rating of perceived exertion (RPE) scale, maintaining a range between 6 and 20 RPE (16). PRE< 8 indicates low intensity, PRE>14 indicates high intensity
45406732|NCT05781204|Other|Survey|Each participant completed an anonymous 62-item online survey.
45406733|NCT05781555|Device|Experimental: DaRT seeds|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. The study objectives are to collect data on the general safety and efficacy of DaRT among patients who do not fit the entry criteria of existing investigational trials.
45515327|NCT02265770|Drug|VEC + HD-MTX|Days 1-22-43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-22-24-43-45: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-22-43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 15-36-57: Administer methotrexate at 8000 mg/m² as a 24 hour IV infusion on days 15-36-57. 10% of the dose should be given over the first hour and 90% over the remaining 23 hours. The infusion must finish at 24 hours even if it has not been completed.
45851618|NCT03807024|Diagnostic Test|Bladder diary|3-day bladder diary: The classification of OAB-wet or OAB-dry is based on the record of the three-day bladder diary of each patient. The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet, otherwise, OAB-dry
46059172|NCT02583217|Device|laryngeal mask|
46059173|NCT00774046|Drug|Ara-C|"Induction: 3000mg/m2 IV infusion for day 1 and day 5~Mobilization: within 2 weeks of end of induction therapy - 2000mg/m2 as 2 hour IV infusion once every 12 hours for 3 days (6 doses total)"
46059174|NCT00774046|Drug|Mitoxantrone|Induction: 30mg/m2 after the end of HiDAC day 1 and day 5
46059175|NCT00774046|Drug|Etoposide|Mobilization: 30mg/kg over 6 doses given once every 12 hours for 3 days
45406734|NCT05781191|Biological|COMIRNATY|Booster (3rd) dose of COMIRNATY Seasonal dose of influenza vaccination based on patient's individual risk factors
45406735|NCT05781178|Dietary Supplement|Oral nutritional supplement rich in omega-3 and olive oil polyphenols|Nutritional intervention with an oral nutrition supplement with anti-inflammatory effect and a programme of physical exercise
45406736|NCT05781139|Diagnostic Test|levels of Neurofilaments (NfL) in serum|the levels Neurofilaments (NfL) (Abcam, USA), C-X-C motif chemokine 13 (CXCL13) and Chitinase 3-like Protein 1 (Sigma-aldrich, Germany) will be determined in the serum and CSF (if available) in the different participant groups.
45406737|NCT05781126|Diagnostic Test|The Spatial Hearing Questionnaire, MINI-MENTAL STATE EXAMINATION, International Outcome Inventory - Hearing Aid, Glasgow Hearing Aid Benefit Profile, BECK-II and STAI questionnaires|a) medical history record, b) ENT examination, c) pure tone audiogram and speech audiometry (with and without the hearing amplification) d) listening effort evaluation (with and without the hearing amplification) Self-report and behavioral methods will be used: Evaluation of subjective performance (Spatial Hearing Questionnaire (SHQ) Evaluation of time response in auditory message Evaluation of speech comprehension with background noise or a competitive speaker e) cognitive function evaluation by using the Greek version of Mini-Mental State Examination, f) evaluation of hearing-aid satisfaction, by using the Glasgow Hearing Aid Benefit Profile (GHABP), and International Outcome Inventory - Hearing Aid (IOI-HA), questionnaires and g) evaluation of stress level and depression by using BECK-II and STAI questionnaires.
45515328|NCT02265770|Drug|Chemotherapy + Valproate|"Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.~Valproate: initial dose 30 mg/kg/day for two weeks in 2 divided doses (BID 15 mg/kg). Increasing weekly up to 40 - 50 - 60 mg/kg/day in 2 divided doses."
45515329|NCT02265770|Radiation|Conformal radiotherapy|Conformal radiotherapy: 59.4Gy (children <18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.
45515330|NCT02265770|Drug|VEC|D1: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D1-D3: Etoposide: 100 mg/m² infused over 60 minutes; D1: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D22: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D22-D24: Etoposide: 100 mg/m² infused over 60 minutes; D22: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D43-D45: Etoposide: 100 mg/m² infused over 60 minutes; D43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes
45515331|NCT02265770|Drug|Chemotherapy|Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.
45515332|NCT02265770|Radiation|conformal radiotherapy +/- boost|"Conformal radiotherapy: 59.4Gy (children <18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.~In case of persistent residue : Boost of radiation 8 Gy in 2 equivalent fractions"
45515333|NCT03066193|Drug|Dronabinol and Palmitoylethanolamide|Participants will receive Dronabinol which will be slowly titrated in the first week of the study. They will be followed for a total of 12 weeks; in addition, participants will receive the PEA in a standing dose of 400mg. They will be followed for a total of 12 weeks.
45515334|NCT02265926|Device|N95 mask|N95 mask material used to cover aperture of Hans Rudolph mask
45515335|NCT03922321|Drug|RVT-1401|RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
45515336|NCT02263976|Drug|BEA 2180 BR|
45699479|NCT01230502|Drug|Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy|"Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy~Mycophenolate sodium : Myfortic therapy will be maintained at a target dose of 720mg BID.~Tacrolimus doses will be lowered to achieve levels of 3-5 ng/ml. 6 months later, immunological monitoring will be repeated and tacrolimus will be completely discontinued if the subject remains DSR + without development of donor specific antibodies (DSA). Those who become DSR- or develop DSA will remain on a tacrolimus dose achieving levels of 3-5 ng/ml, and will not undergone any additional reduction.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples."
45699480|NCT01230502|Other|data and sample collection|"Group 2 : Donor specific regulation (DSR) + standard of care:~These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples"
45851619|NCT03806868|Other|voucher for ordering foods (ONLY omega-3 rich foods)|A voucher will be provided weekly (4 times) for ordering only omega-3 rich foods. Groceries will be delivered to participants' home weekly.
45851620|NCT03806868|Other|voucher for ordering foods in general (any type of foods)|A voucher will be provided weekly (4 times) for ordering any type of food. Groceries will be delivered to participants' home weekly.
45515337|NCT02263976|Drug|Placebo|
45515338|NCT02263976|Device|Respimat® A 4|
45515339|NCT02263976|Drug|Methacholine Chloride|methacholine challenge test
45515340|NCT02263976|Drug|Spiriva|
45515341|NCT02264054|Drug|[14C]talsaclidine, oral|
45515342|NCT02264054|Drug|[14C]talsaclidine, iv|
45515343|NCT01503944|Drug|18F-AV-133|185 MBq
45515344|NCT01503944|Drug|18F-AV-45|185-370 MBq
45515345|NCT01382654|Drug|epinastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
45406738|NCT05781100|Behavioral|Technology Use during Feeding Conditions|At 1 month and 4 months, mother-infant dyads will be observed during 3 different feeding conditions counterbalanced across 3 days, with a 1-day wash-out period between conditions: TV Use condition: mothers will be asked to watch a 22-minute long TV show on a large tablet while they feed their infants. Mothers will choose from four preselected episodes of popular sitcoms. Mobile Device Use condition: mothers will be asked to use their mobile device in a way they find relaxing and pleasurable. Control condition: mothers will be asked to feed their infant in a room free of all potential technological distractions. During all conditions, mothers will feed their infants their typical milk (breast milk or formula) from their typical mode (breast or bottle).
45406739|NCT05781100|Behavioral|Naturalistic Feeding Observation|Mother-infant dyads will be observed during a typical (unmanipulated) feeding interaction to objectively assess maternal technology use during feeding and mother-infant interactions during a typical, home-based feeding interaction. The mother will be instructed to feed her infant as she normally would at home and the research assistants will wait in another room to minimize any possible influence on the mother's or infant's feeding behaviors. The dyad will be observed during breast- or bottle-feeding at 1 month, 4 months, and 6 months. At 9 months and 12 months, the dyad will be observed during solid-food feeding.
45406740|NCT05781100|Behavioral|Still Face Paradigm|At 6 and 12 months, mother-infant dyads will participate in the Still Face Paradigm, which includes 3 phases. During the Free Play Phase (2 minutes), the mother and infant sit face-to-face with the infant in a secure high chair and no toys present, and the mother is instructed to play with the infant as they normally would. During the Still Face Phase (2 minutes), the mother is instructed to turn away from the infant, then turn back holding her face still and unresponsive. During the Reunion Phase (2 minutes), the mother is instructed to turn away again, then turn back and play with the infant (reunion; 2 minutes). Throughout the Still Face Paradigm, 2 video cameras focused on the mother's and infant's faces will record behavioral responses to the 3 Still Face Paradigm Phases.
45515346|NCT01382654|Drug|epinastine 0.1% with taste masking agent|nasal spray 2 sprays to each nostril for a total for a 3 doses
45515347|NCT01382654|Drug|epinastine 0.2%|nasal spray 2 sprays to each nostril for a total of 3 doses
45515348|NCT01382654|Drug|epinastine 0.2% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
45515349|NCT01382654|Drug|azelastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
45515350|NCT01378676|Drug|Placebo (Part A)|Placebo tablets once daily for 14 days (Part A)
45515351|NCT01378676|Drug|CK-2017357 (Part A)|One 125 mg CK-2017357 tablet once daily for 14 days (Part A)
45515352|NCT01378676|Drug|CK-2017357 (Part A)|Two 125 mg CK-2017357 tablets once daily for 14 days (Part A)
45515353|NCT01378676|Drug|CK-2017357 (Part A)|Three 125 mg CK-2017357 tablets once daily for 14 days (Part A)
45515354|NCT01378676|Drug|Riluzole 50 MG (Part B)|One 50 mg tablet once daily for 14 days (Part B)
45515355|NCT01378676|Drug|Placebo (Part B)|Placebo tablets once daily for 14 days (Part B)
45515356|NCT01378676|Drug|CK-2017357 (Part B)|One 125 mg tablet once daily for 14 days (Part B)
45515357|NCT01378676|Drug|CK-2017357 (Part B)|Two 125 mg tablets once daily for 14 days (Part B)
45515358|NCT01378676|Drug|CK-2017357 (Part B)|Three 125 mg tablets once daily for 14 days (Part B)
45515359|NCT01377662|Drug|OND-PR002 and MPh-IR|"Drug: OND-PR002~Single daily oral doses of 8 mg Ond-PR002~Drug: MPh-IR~Single daily oral doses of 20 mg MPh-IR"
45515360|NCT01377662|Other|Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR|Single daily oral doses
45515361|NCT01371578|Drug|GS-5885 tablet|30 mg active tablet
45515362|NCT01371578|Drug|GS-9451 tablet|two active 100 mg tablets
45515363|NCT01371578|Biological|peginterferon alfa-2a|peginterferon alfa-2a (solution for injection) 180 µg/week
45515364|NCT01371578|Drug|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
45515365|NCT01225640|Drug|PNU-100480|600 mg twice daily (BID) for 14 days
45515366|NCT01225640|Drug|PNU-100480|1200 mg once daily (QD) for 14 days
45851621|NCT03806478|Drug|APH-1105|The investigational drug product, APH-1105 is a sterile, pyrogen-free lyophilized powder intended for intranasal administration.
45851622|NCT03806478|Other|Placebo|The placebo is a sterile, pyrogen free lyophilized powder identical in appearance to the experimental drug
45851623|NCT03806010|Procedure|Quantitative sensory testing|Quantitative sensory testing
45406741|NCT05781100|Behavioral|Regulation of Milk Intake Behavioral Protocol|At the 1, 4, 6, and 12-month assessments, mother-infant dyads will engage in a 2-day behavioral protocol to assess infant regulation of milk intake. During one day (Standard Feeding Frequency), the mother will be asked to feed her infant as she normally would and weigh her infant before and after each feeding on an infant scale. During the other day (Increased Feeding Frequency), the mother will be asked to offer her infant a feed hourly and weigh her infant before and after each feeding, regardless of whether the infant accepted the feeding. Caloric compensation is defined as the infants' propensity to maintain his/her caloric intake during the Increased day compared to the Standard day, as indicated by a small percent difference score, calculated as: [(kcal_increased - kcal_standard)/(kcal_increased)]x100 where kcal_increased is energy intake on the Increased day and kcal_standard is energy intake on the Standard day.
45406742|NCT05781100|Behavioral|Regulation of Solid Food Intake Behavioral Protocol|At 12 months, mother-infant dyads will engage in a 2-day behavioral protocol. Infants will be given cherry-flavored preload beverages of low energy density (ED; 3kcal/serving) vs high ED (150kcal/serving). Presentation of low- vs high-ED preloads will be counterbalanced. Thirty minutes following preload consumption, the infant will be served a standardized meal and intake will be measured. The Compensation Index (COMPX) is defined as the infants' propensity to decrease his/her caloric intake of the meal after the higher-ED preload compared to after the lower-ED preload, calculated as: [(LowEDkcal_meal - HighEDkcal_meal) / (HighEDkcal_preload - LowEDkcal_preload)] x 100 where LowEDkcal_meal represents kcal consumed after the low ED pre-load; HighEDkcal_meal represents kcal consumed after the high ED pre-load; LowEDkcal_preload represents kcal of low ED pre-load consumed, and HighEDkcal_preload represents kcal of high ED pre-load consumed.
45406743|NCT05781087|Diagnostic Test|Optical coherence tomography and pressure wire assessment|Non-culprit coronary arteries
45699481|NCT01230502|Other|data and sample collection|"Group 3 : Donor specific regulation (DSR) - standard of care:~These subjects are those who were DSR negative and/or DSA positive at enrollment and therefore are not eligible for the withdrawal aspect of the study. These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment. These subjects will be asked to provide heath information and donate blood, exclusively for research testing, at the same 6 month intervals as those in the other two arms of the study, and will be followed for 24 months."
45699482|NCT03438240|Drug|Bupivacaine|patients will receive combined general anesthesia / epidural analgesia with 15 ml bupivacaine 0.20%
45406744|NCT05781087|Diagnostic Test|Cardiac magnetic resonance angiogram|1.5T
45406745|NCT05781061|Other|Screening for Eligibility|Asynchronous Screening for MA Eligibility
45406746|NCT05781048|Drug|HRS-6209|HRS-6209
45406747|NCT05781022|Procedure|endoscopic repair of iatrogenic esophageal perforation|"For patients in EG, we began with assessment of the site & size of perforation . In this study, In this study, we used a fully covered stent (Mega stent, Taewoong Medical Industries, Gyeonggi-do, South Korea) ultra large and long (length: 24 cm, diameter: 36 mm) stent. We did not experience any complication with Mega stent, particularly migration, thanks to the design of Mega stent that fits well for the post-sleeve anatomy with reduction of migration.~Concurrently, the interventional radiology team subcutaneously drained the intraperitoneal free fluid using 2 intra-peritoneal tubes that were placed under US guidance in the sub-hepatic region and in the pelvis"
45406748|NCT05781009|Drug|Pregnenolone|300mg
45406749|NCT05781009|Drug|Placebo|placebo
45406750|NCT05780996|Device|QMODE +|Atrial fibrillation radiofrequency ablation of the anterior and posterior wall with 90W (vHPSD)
45406751|NCT05780996|Device|QMODE|Atrial fibrillation radiofrequency ablation of the anterior wall with 50W (HPSD). Ablation of the posterior wall with 90 W (vHPSD)
45406752|NCT05780970|Other|No intervention|Non-treated children and caregivers complete assessments only. The primary (treated) parent / adolescent dyad participate in family based weight management treatment through the main trial. In the main trial, families are randomized to either TEENS+Parents as Coaches (parent skills training) or TEENS+Parent Weight Loss (parent behavioral weight loss).
45406753|NCT05780944|Behavioral|Paced Bottle-Feeding Education|Participants will be asked to review an educational handout that outlines how to implement PBF during bottle-feeding interactions. Participants will then be asked to watch a video that further describes PBF and illustrates how to implement it with a live infant. A trained research assistant will then answer questions, further explain PBF, and demonstrate PBF with a baby doll, using a standardized script
45406754|NCT05780931|Behavioral|Study-specific rehabilitation (SSR) procedures|Study-specific rehabilitation procedures will systematically manipulated the spatial or temporal synchrony (or coordination) of visual vs. haptic inputs that the subjects receive.
45515367|NCT01225640|Drug|RHZE|Combination tablet (RHZE) dosed by weight. Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)
45515368|NCT01208168|Drug|NAB001|nail lacquer, once daily, 52 weeks
45515369|NCT01208168|Drug|Vehicle alone|nail lacquer, once daily, 52 weeks
45515370|NCT01677910|Drug|Telotristat etiprate|Telotristat etiprate tablets.
45515371|NCT01677910|Drug|Placebo-matching telotristat etiprate|Placebo-matching telotristat etiprate tablets.
45515372|NCT01205048|Device|Emervel Classic Lidocaine|20 mg/ml + 0.3% lidocaine
45699483|NCT03438240|Drug|Fentanyl|Plus 50 µg fentanyl
45699484|NCT03438240|Drug|Dexmedetomidine|Plus 50 µg dexmedetomidine
45699485|NCT01160848|Drug|Area cleaned with saline water and occluded with Tegaderm|
45699486|NCT01160848|Drug|Area cleaned with saline water|
45699487|NCT01160848|Drug|Area cleaned with Ethyl alcohol solution|
45699488|NCT01160848|Drug|Visonac left on the skin for 24 hours in facial area one|
45699489|NCT01160848|Drug|Visonac wiped off after one hour|
45406755|NCT05780918|Other|Best Case/Worst Case-ICU Communication Tool|"This intervention uses scenario planning and a daily report of the interplay between major events and prognosis to illustrate a range of long-term outcomes and treatment experiences. By using a graphic aid to illustrate what we are hoping for, what we are worried about, and the evolution of the patient's story over time, the tool aims to facilitate dialogue among older adult trauma patients, their families, and the trauma team. Because the tool delivers critical prognostic information over the longitudinal course of care, subsequent treatment decisions can be made within the context of the patient's overall health status. This information alerts patients and families to the life-limiting nature of serious injury and provides an entrée for them to consider how comfort-focused strategies might better align with patients' end-of-life goals.~All clinicians will be trained to create, use, and/or reference the graphic aids with patients depending on their roles in the trauma ICU."
45406756|NCT05780905|Drug|Semaglutide Auto-Injector|"Subjects have an equal chance of receiving semaglutide or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects, Study Site personnel nor image reviewers will know which treatment subjects are assigned to. The study drug must be taken weekly. The subject's other medications may be changed by the study's un-blinded Endocrinologist.~At baseline subject will receive and take home 0.25mg injector for use 3 more times. They will be given a 0.5mg injector and a 1mg injector for use beginning 5 and 9 weeks from baseline respectively.~The target dose for subjects is 1mg per week up to the 52 week treatment duration."
45406757|NCT05780905|Other|Placebo|Placebo
45515373|NCT01205048|Device|Juvederm® Ultra|24mg/ml
45699490|NCT01160848|Drug|Visonac left on the skin 24 hours in facial area two|
45699491|NCT03445572|Other|Best Practice|Receive standard supportive care
45406758|NCT05780866|Other|Video and Activity Tracker|"At enrollment, the participants will complete a baseline survey, PDQ-39 (Parkinson's disease questionnaire), and the Unified Parkinson's Disease Rating Scale (UPDRS) assessment. The researchers will provide the participant with a camera, small tripod, and a set of written directions about how to record the UPDRS motor self-assessment video.~After completing the baseline assessments, the research team will provide the participant with a Fitbit Inspire 3 activity tracker watch. The participant will wear the activity tracker for 24 hours a day for the next 14 days except for if the device needs charging and when bathing.~At 14 days, the research team will send participants a link to complete a web-based exit survey about their experience with the activity tracker during the study."
45406759|NCT05780853|Diagnostic Test|Tablet Game-based Assessment|Tablet game-based assessment to assess neurodevelopmental profile.
45406760|NCT05780853|Diagnostic Test|Adaptive Behavior Assessment System, Third Edition (ABAS-3)|A parent-reported child behavioural assessment questionnaire used to diagnose and classify various developmental, learning and behavioural disabilities and disorders.
45406761|NCT05780853|Other|Demographic questionnaire|Parent/carer and child's demographic data such as age, ethnicity, employment status, household income, medical history and education status.
45406762|NCT05780840|Other|Dihydroxyacetone|Application of 10% dihydroxyacetone (2 mg per square cm skin)
45406763|NCT05780840|Other|Placebo|Application of lotion to the skin (2 mg per square cm skin)
45406764|NCT05780814|Behavioral|Cognitive-Behavioral Therapy for Insomnia (CBT-I)|The CBT-I intervention is a 6-session intervention spread out over 8 weeks that combines education and behavioral techniques to reduce insomnia.
45406765|NCT05780814|Behavioral|Sleep Education Control (EDU)|Subjects will be instructed to read and review select publications from the American Academy of Sleep Medicine
45406766|NCT05780775|Other|HDL2|to perform additional blood samples during acute phase of complications (realized between Day 1 and Day 3) in SCD patients hospitalized for vasoocclusive crisis or priapism.
45406767|NCT05780749|Dietary Supplement|DDI-IBS-001|The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 1.5 g/day. The product is a powder for oral administration 1x/day.
45406768|NCT05780749|Other|DDDI-IBS-001 placebo|The placebo product has the same composition in excipient, same form and same posology as DDI-IBS-001.
45699492|NCT03445572|Procedure|Meditation Therapy|Perform MSB
45406769|NCT05780593|Other|Manual Therapy|After the baseline assessment, each intervention group will be given physical therapy treatment. The group A will receive Manual Mobilization of the Lumbosacral Spine using Sustained Anterior Glide at facet joints and Sustained Medial Glide followed by passive stretching of the hip abductors of both sides of the body. The patient then will be asked to stand on the inclined board for 01 minute with feet 3 to 4 inches apart hands placed on the wall at the level of shoulder joints. After 01-minute patient will be asked to leave the inclined board. The patient will be advised to do this 01-minute inclined board standing for three times a day at home. All the patients in Group A will receive this treatment regime for two weeks.
45515374|NCT01499420|Biological|CSL112 (reconstituted high density lipoprotein)|Single escalating intravenous doses of CSL112
45699493|NCT03445572|Procedure|Meditation Therapy|Perform IK meditation
45699494|NCT03445572|Other|Questionnaire Administration|Ancillary studies
45699495|NCT01213576|Drug|Albendazole 400mg and ivermectin 200mcg/kg|400 mg orally given annually
45699496|NCT01213576|Drug|Albendazole and ivermectin|albendazole 800 mg and ivermectin 400mg orally given annually
45515375|NCT01499420|Biological|Placebo|Single intravenous doses of normal saline (0.9%)
45515376|NCT01498328|Drug|Bevacizumab|A vascular endothelial growth factor (VEGF)-specific humanized monoclonal antibody angiogenesis inhibitor. Infusions of 10 mg/kg of bevacizumab will begin on day 1 and will be administered every two weeks until progression of disease or intolerance during the treatment period.
45515377|NCT01498328|Drug|Rindopepimut (CDX-110) with GM-CSF|Rindopepimut/GM-CSF will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM-CSF.
45699497|NCT01213576|Drug|Albendazole 400mg and ivermectin 200mcg/kg|Albendazole 400mg and ivermectin 200mcg/kg given twice a year
45699498|NCT01213576|Drug|albendazole 800mg and ivermectin 400mcg/kg bi-annually|albendazole 800mg and ivermectin 400mcg/kg given twice a year
45699499|NCT03445416|Behavioral|POL arm|A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
45851624|NCT03805776|Other|Fasting (diet restruction for specific period)|12-14 hours fasting
45406770|NCT05780593|Other|Inclined Board Standing|The patients in Group B will be asked to stick to their medications if advised and stand for one minute on the inclined board for 01 minute. All the patients will be provided advised to follow this inclined standing for 01 minute three times a day at home for two weeks. After two weeks at the completion of intervention, they will be assessed through self-reporting questionnaires of the study.
45406771|NCT05780554|Drug|Cyclophosphamide|Post transplant cyclophosphamide 25 mg/kg on day +3 and +4
45406772|NCT05780554|Drug|Cyclophosphamide|Post transplant cyclophosphamide 50 mg/kg on day +3 and +4
45515378|NCT01498328|Drug|KLH|KLH will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 100 mcg of KLH.
45515379|NCT04537936|Behavioral|Meaning Centered Psychotherapy for Latinos|MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span of 7-14 weeks.
45406773|NCT05779709|Other|exercise|Reformer pilates is a specific type that provides resistance exercise at certain weights with the pulley system relying basically on the same principles. Pilates exercises provide breathing and activation of the deep stabilizing muscles of the trunk in coordination with the PFMs. It includes exercises that focus on pelvic stability, mobility and body alignment. PFMs activation is carried out simultaneously with the trunk muscles in various positions in coordination with breathing.
45406774|NCT05779709|Other|Urotherapy|Urotherapy includes education of the child and family, diet (adequate fiber and fluid consumption), regular optimal voiding, daily physical activity, teaching normal toilet use, pelvic floor muscle training and relaxation
45406775|NCT05778851|Device|EsoGuard result|Education slide-set EsoGuard and patient cases including EsoGuard result
45406776|NCT05777811|Procedure|Vertically coronally advanced flap combined with connective tissue graft.|The exposed root surfaces are planed with Gracey 1-2 curettes. An intrasulcular incision is made with a blade on the buccal aspects of the involved teeth. The incision is extended horizontally to the adjacent papilla. Then, slightly divergent vertical releasing incisions are carried 2 mm beyond the mucogingival junction. A full-thickness flap is raised with a periosteal elevator towards the mucogingival junction. After that, a partial-thickness dissection is carried out in the apical direction to release muscle tension and provide coronal advancement of the flap. The adjacent papillae are de-epithelialized. The connective tissue graft (CTG) is harvested from the lateral palate using the de-epithelialized gingival graft technique. After harvesting, the connective tissue graft is sutured to the recipient bed. Finally, the flap is positioned 2 mm over the cementoenamel junction and sutured with 6-0 polypropylene sutures. No periodontal dressing is applied.
45406777|NCT05777811|Procedure|Free gingival graft|A partial-thickness flap is elevated (using a blade #15c) with horizontal incisions at the cemento-enamel junction (CEJ) level of the adjacent teeth. Then, two vertical incisions extending to the apical are made from the two ends of the horizontal incision. The epithelium in the framed region is removed with a scalpel, and the underlying connective tissue is exposed. To achieve the best vascularization of the free gingival graft from the recipient site, bed preparation is completed with a split-thickness horizontal incision that joins the vertical incisions in the apical region. The free gingival graft is stabilized using interrupted sutures and a sling suture.
45406778|NCT05776992|Device|Xbox virtual reality games|X-box balance evaluation was implemented in a completely dark and isolated room specially prepared for this treatment and evaluation
45406779|NCT05776992|Device|Biodex balance training|the Biodex Balance System SD has been designed to meet the needs of everyone looking to improve balance, increase agility, develop muscle tone and treat a wide variety of pathologies.
45406780|NCT05774925|Diagnostic Test|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
45406781|NCT05774652|Behavioral|Lifestyle intervention Dietary advise and/or advise on physical activity|Lifestyle intervention Dietary advise and/or advise on physical activity
45406782|NCT05769543|Procedure|WATSU application|20-minute application of WATSU
45406783|NCT05769543|Other|Lecture|20-minute lecture on WATSU technique
45406784|NCT05766722|Device|DORA AI|Dora will phone patients on the day of cataract surgery (2 to 4 hours after discharge home) and again at postoperative week three. Dora calls made on the day of surgery will evaluate if the patient has any acute post-operative concerns like pain, and will prompt a postoperative day 1 visit if necessary. Calls to Dora at postoperative week three will result in either a follow-up to check refractive difficulties and/or confirmation of second eye surgery.
45515380|NCT04537936|Behavioral|Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale|Determines the degree of spiritual well-being
45515381|NCT04537936|Behavioral|Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients|Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
45515382|NCT04537936|Behavioral|Pre-assessment questionnaire|Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
45515383|NCT02266082|Other|No intervention|There is no intervention in this study.
45515384|NCT04537000|Diagnostic Test|clinical condition score|A score is firstly identified using a clinical condition scale including the concentration of inspired oxygen to maintain the percutaneous oxygen saturation (SPO2)≧95%, the fusion rate of catecholamine drugs to maintain normal blood pressure, the nasopharyngeal temperature and the oxygen saturation of central venous blood. The score was graded as 0, 1 and 2 points according to the patient's clinical condition. The score identified from the scale plus 7 finally makes the clinical condition score. If the score is higher than 10, it will be replaced with 10. That is to say, the highest clinical condition score is 10. If the clinical condition score≦Hb, blood red cell transfusion will not be started. If the clinical condition score>Hb, blood red cell transfusion will be started, and the volume will be calculated using the following formulation, transfusion volume(ml)=(clinical condition score - Hb)*body weight *5.
45515385|NCT01497704|Drug|YN968D1|Daily dosing of YN968D1 for treatment of solid tumors
45406785|NCT05763758|Other|No intervention|No intervention involved in this study
45515386|NCT05732740|Behavioral|Empower@Home:Connected|Cognitive behavioral therapy
45406786|NCT05755763|Other|Anal incontinence patients with St. Mark's Incontinence Score|The scale was applied to the patients who applied to our clinic with the diagnosis of anal incontinence.
45406787|NCT05869942|Diagnostic Test|Light microscopic studies|Under complete sterile precautions, Skin biopsy will be taken from healthy volunteers of the control group via 3 mm disposable punches and two biopsies will be taken from patients with vitiligo, one from vitiligenous lesion and another from normal skin then will be rinsed in physiological saline and fixed in formalin for 24 hours. The preserved tissues will be trimmed for processing, then undergo dehydration with ethyl alcohol, clearing with xylene, infiltration and embedding with paraffin wax. Paraffin wax blocks will be sectioned at 5μ then mounted on glass slides. Sectioned slides will be stained with hematoxylin and eosin and other histological stains and mounted with (DPX). And examined by light microscope. The pathological changes in vitiligenous skin will be detected
45406788|NCT05869942|Diagnostic Test|Immunohistochemical studies|Monoclonal HMGB1 and active caspase 3 antibodies
45406789|NCT05869916|Behavioral|psychological first aid|The effect of psychological first aid on earthquake victims was measured using the resilience scale and the secondary traumatic stress scale.
45406790|NCT05869903|Drug|Orforglipron|Administered orally.
45406791|NCT05869903|Drug|Placebo|Administered orally.
45406792|NCT05869890|Device|MOSES laser system|A holmium laser technology widely used as the gold standard for laser lithotripsy for ureteroscopy treatment of renal calculi,
45515387|NCT03135626|Drug|Biodentine|
45515388|NCT03135626|Drug|ProRoot (Aggregate)|
45515389|NCT03135626|Drug|MTA Plus|
45515390|NCT03135626|Drug|Ferric Sulfate 20 % Dental Gel|
45515391|NCT05732116|Other|PTSD|Series scales, including GHQ-12, PCL-6, and CAPS-5 will be used to screen and diagnose the development of PTSD in surgeons and anesthesiologists at 3 time points, baseline (time 0), 3 m, and 6 m.
45515392|NCT02266160|Drug|EMLA cream 5%|"the interventional group will spread 2 grams (2 ml) of EMLA cream over the post auricular area. after 4 hours the patient will wash away the cream. the treatment will last 4 days."
45515393|NCT02266160|Other|cetomacrogol cream (lotion cream)|lotion cream that does not contain active drug. has no contraindications
45515394|NCT05731570|Behavioral|Cognitive rehabilitation|Set of restorative and compensatory strategies to rehabilitate cognitive function combined with emotional regulation techniques.
45515395|NCT01491932|Drug|AFQ056|AFQ056 will be supplied as oral capsules.
45515396|NCT05731102|Diagnostic Test|Electronic version of the Composite International Diagnostic Interview 5th version (E-CIDI 5.0)|Observational study assessing prevalence of mental and substance use disorders among college and university students
45515397|NCT03911713|Drug|VX-561|VX-561 tablets for oral administration.
45515398|NCT03911713|Drug|IVA|150-mg film-coated tablet for oral administration.
45515399|NCT03911713|Drug|Placebo|Placebo matched to IVA.
45699500|NCT03445416|Behavioral|Comparison arm|A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
45851625|NCT03805620|Other|Combined physical-cognitive training|combined physical-cognitive training
45406793|NCT05869877|Device|Bundled|An peripheral intravenous catheter will be inserted by an RN specially trained in PIVC placement, with or without ultrasound. Using best of class medical products, will evaluate dwell time and complications of the PIVC inserted using a bundled approach versus one inserted with the bundle
45406794|NCT05869838|Device|Colonoscopy|Screening or surveillance colonoscopy
45406795|NCT05869825|Procedure|High Flow Nasal Canula following extubation|Participants in this group will be randomized to receive High Flow Nasal Cannula support after extubation. The patient will be clinically monitored and respiratory support will be escalated per a specific flow sheet. The patient will remain on this assigned air support method until they are either removed entirely from air support or need to be re-intubated with oxygen.
45515400|NCT03911713|Drug|Placebo|Placebos matched to VX-561.
45515401|NCT05730244|Drug|Cassia alata extract|1 ml Cassia alata extract
45515402|NCT05730244|Drug|Placebo|1 ml placebo solution
45515403|NCT02264132|Drug|Pramipexole ER tablet|
45515404|NCT02264132|Drug|Pramipexole IR tablet|
45515405|NCT01366820|Drug|NNZ-2566|"Solution for intravenous infusion.~Intravenous bolus infusion over 10 minutes followed by a continuous intravenous maintenance infusion for a total of 72 consecutive hours."
45515406|NCT01366820|Drug|Placebo|Sodium Chloride 0.9% Injection
45515407|NCT05728762|Device|Novel LEDs|LEDs with a continuous spectrum of 430-780 nm.
45515408|NCT03910153|Dietary Supplement|MSPrebiotic|MSPrebiotic digestion resistant starch from potatoes (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the potato resistant starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
45515409|NCT03910153|Other|Placebo|Corn starch (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the corn starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
45406796|NCT05869825|Procedure|Non-Invasive Positive Pressure Ventilation following extubation|Participants in this group will be randomized to receive NIPPV respiratory support following extubation. The patient will be clinically monitored and respiratory support will be escalated per a specific flow sheet. The patient will remain on this assigned air support method until they are either removed entirely from air support or need to be re-intubated with oxygen.
45406797|NCT05869812|Drug|CaHMB (Dietary supplement, not Drug)|The investigators will focus our effort, for the purposes of this study, on determining if adding an HMB supplement will stimulate positive outcomes and recovery of the quadriceps and hamstrings muscle architecture and function in females with ACL injury requiring surgical repair, more so than a placebo control.
45406798|NCT05869812|Dietary Supplement|CaLa|Comparative placebo
45515410|NCT01192880|Drug|Placebo|Participants will receive bitopertin matching placebo once daily for 56 weeks.
45406799|NCT05869799|Dietary Supplement|Vigiis 101 Lactobacillus Capsules|Product ingredients: microcrystalline cellulose, corn starch, NTU 101 lactic acid bacteria powder (1.0 x 10^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
45406800|NCT05869799|Dietary Supplement|Placebo Capsules|Maltodextrin was used as a placebo
45851626|NCT03805620|Other|Physical training|Multi-component physical exercise
45515411|NCT01192880|Drug|Bitopertin|Participants will receive 10 mg or 20 mg of bitopertin.
45515412|NCT01192880|Drug|Antipsychotics|Participants will continue to receive their stable antipsychotic regiment throughout the study. Study protocol does not specify any particular antipsychotic drug and regimen.
45515413|NCT03629197|Behavioral|Communication skills training|Intervention components include an 8-10 minute instructional video, a pocket card and pamphlet, and 2 standardized patient visits with role-play and feedback by the standardized patient
45515414|NCT03629197|Other|Attention control|Physician will review materials based on CDC opioid prescribing guidelines.
45515415|NCT04540744|Drug|FDC of macitentan/tadalafil (10 mg/20 mg)|FDC of macitentan/tadalafil (10 mg/20 mg) tablet will be administered orally as per assigned treatment sequence.
45515416|NCT04540744|Drug|Macitentan 10 mg|Macitentan 10 mg tablet will be administered orally as a free combination as per assigned treatment sequence.
45515417|NCT04540744|Drug|Tadalafil 20 mg|Tadalafil 20 mg tablet will be administered orally as a free combination as per assigned treatment sequence.
45515418|NCT05375734|Drug|Tislelizumab in combination with anlotinib|Tislelizumab：200 mg，ivgtt，d1，Q3W anlotinib： 10mg P.O d1-d14, Q3W
45515419|NCT01489046|Drug|BMS-986001|Capsules, Oral, 100 mg, Once daily, At least 48 weeks
45515420|NCT01489046|Drug|BMS-986001|Capsules, Oral, 200 mg, Once daily, At least 48 weeks
45406801|NCT05869760|Other|Carotenoid Intake|Carotenoid intake calculated from food diary records reported by guardians.
45406802|NCT05869760|Other|Serum carotenoid concentrations|Serum carotenoid concentrations measured by HPLC.
45406803|NCT05869747|Behavioral|Blood Donation|Participants asked to donate whole blood at a donation facility from a list provided by the study.
45851627|NCT03805620|Other|Cognitive training|cognitive training
45851628|NCT03805542|Combination Product|0.5% Iodophors|Before lithotripsy, 0.5% iodophor 40 ml(depending on the degree of hydronephrosis) was used to perfuse the calculous side pelvis under low pressure for 5 minutes.
45406804|NCT05869747|Behavioral|Plasma Donation|Participants asked to donate plasma at a donation facility from a list provided by the study.
45406805|NCT05869747|Behavioral|Zone 2 Training|Participants asked to work out in their custom Zone 2 heart range 4 times a week for 45 to 60 minutes.
45406806|NCT05869747|Behavioral|Intermittent Fasting|Participants asked to engage in an intermittent fasting routine of a 16 hour fast followed by an 8 hour eating period at least 4 times a week.
45406807|NCT05869747|Behavioral|Surveys|Participants were asked to complete surveys throughout the study to monitor intervention progress and to collect baseline and end-of-study data.
45406808|NCT05869734|Behavioral|Sleep health promotion|We will provide sleep hygiene related adjustments in the intervention group A; and brief behavioral treatment for insomnia (BBTI) in the intervention group B.
45406809|NCT05869734|Behavioral|Urologic health promotion|We will provide information related to urologic health promotion in three groups (2 experimental groups and 1 comparison group).
45406810|NCT05869734|Behavioral|Pelvic floor muscle training|We will provide information related to pelvic floor muscle training in three groups (2 experimental groups and 1 comparison group).
45515421|NCT01489046|Drug|BMS-986001|Capsules, Oral, 400 mg, Once daily, At least 48 weeks
45515422|NCT01489046|Drug|Placebo matching with BMS-986001|Capsules, Oral, 0 mg, Once daily, At least 48 weeks
45515423|NCT01489046|Drug|Efavirenz|Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
45515424|NCT01489046|Drug|Lamivudine|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
45515425|NCT01489046|Drug|Tenofovir|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
45515426|NCT04540432|Other|Stool collection at the patient's home.|Stool samples will be taken from each patient to look for changes in intestinal microbiota. These collections will be made on Day 0 +24h, 24 hours before the 1st follow-up visit after 1 month of treatment with non-steroidal anti-inflammatory drugs, 24 hours after the second follow-up visit (between months 3 and 4) and finally, at the end of treatment.
45515427|NCT04540432|Diagnostic Test|Blood test|7 ml of blood will be taken from each patient before treatment i.e. at the inclusion visit and at the end of treatment.
45515428|NCT05017948|Other|Risk score based intervention|Targeted interventions based off of risk score software
45851629|NCT03805152|Drug|Neuronox(R)|Injection botulinum toxin intramuscular for affected neck muscle
45851630|NCT03805152|Drug|Dysport (R)|Intramuscular injection
45515429|NCT02266238|Device|DSA guided percutaneous balloon dilatation|Under the guidance of DSA, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
45406811|NCT05869721|Other|Yoga|The yoga forms are designed from the modified traditional Hatha yoga style consisting of pranayama, asana, meditation with additional relaxation elements. The selected postures will engage core and upper limb muscle and which proposed to strengthen the whole body, increase flexibility of shoulder and limbs, particularly, improve upper limb mobility and functions; also, the progression of the yoga therapy is targeted to reach the variations of postures. The combined relaxation elements reinforced to achieve restoration of the body so as to improve sleep.
45515430|NCT02266238|Device|Ultrasound guided percutaneous balloon dilatation|Under the guidance of ultrasound, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
45515431|NCT02266238|Procedure|Surgical reconstruction|Direct surgery to reconstruction the AVF lumen.
45515432|NCT05012488|Other|Comparison of gait and foot pressure|The spatio temporal gait parameters of the patients will be evaluated with Zebris (Zebris Medical Limited , Germany) FDM (Force Distribution Measurement ) treadmill system. The system has production of 3D motion analysis and force measurement technologies for biomechanics. When the treadmill is in static and dynamic condition, strong pressure distribution measurement will be taken.
45515433|NCT02264210|Drug|Icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months.
45515434|NCT01423396|Other|optimal care of VRF|VRF of AD patients will be treated optimally in strict compliance with the French HAS guidelines concerning targets for blood pressure, glycaemia and blood lipid levels, in accordance with standardized therapeutic regimens.
45515435|NCT01423396|Other|standard care|AD patients will be followed with the city doctor and the letter t will be send for remember French HAS guidelines
45515436|NCT02264288|Biological|3 x 10^6 cells|3 x 10^6 cells administered on Study Days 1 and 8
45515437|NCT02264288|Biological|10 x 10^6 cells|10 x 10^6 Human Placenta Derived cells (PDA-002) administered on Study Days 1 and 8
45515438|NCT02264288|Biological|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
45515439|NCT02264288|Other|Placebo|Identical matching placebo administered IM on Study Days 1 and 8
45515440|NCT01401556|Other|case management|
45515441|NCT01401556|Other|Multifaceted quality improvement intervention|
45515442|NCT01180634|Drug|MP-376 (Levofloxacin solution for Inhalation)|240 mg of MP-376 administered BID for 28 days
45515443|NCT01180634|Drug|Placebo|same volume and frequency as study drug
45515444|NCT05697250|Other|Laser power settings (Thulium Fiber Laser)|Ureteroscopic lithotripsy using low power laser settings (0.4 - 0.6 J at 10 Hz corresponding to 2.4 - 6.0 Watts) or high power laser settings (0.4 J at 40 Hz, 0.6 J at 30 Hz or 0.8 J at 20 Hz corresponding to 16 - 18 Watts).
45515445|NCT02264366|Behavioral|Motivational Communication for Health Behavior management|"An appropriate and evidence-informed model of motivational counselling, health coaching and chronic disease self-management will be integrated into the delivery of all aspects of the ACCELERATION program. The focus will be on 4 health behaviors that include healthy eating, exercise, smoking cessation and moderation of alcohol consumption. This will include engagement techniques such as motivational interviewing, identification of stage of change, visioning of best self, goal setting and action planning, expressing empathy, developing discrepancy, decisional balance, rolling with resistance, and supporting self-efficacy. (Rubak 2005, Knight 2006)."
45515446|NCT05693506|Other|Cooking workshops|Cooking workshop in classic form, i.e. with recipes imposed by the dietician on the participants, or cooking workshops in the form of culinary challenges, i.e. without imposed recipes but according to the creativity of the participants
45515447|NCT02268890|Drug|Bortezomib|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.
45515448|NCT04918108|Biological|inflammatory response|laboratory data (leukocyte, neutrophils, monocyte, lymphocytes, platelet, fibrinogen, D-dimer, neutrophils-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio)
45515449|NCT02268968|Drug|Lidocaine 2% Gel|Lidocaine 2% gel will be applied to nostrils and nasal CPAP prong 5 minutes prior to application of nasal CPAP
45515450|NCT04480294|Drug|HRS5091|"Single dose in group 1-5~Multiple doses in group 6-9"
45515451|NCT01359566|Drug|Arbaclofen placarbil 15 mg BID|arbaclofen placarbil 15 mg BID
45515452|NCT01359566|Drug|Placebo|Placebo for arbaclofen placarbil 15, 30 and 45 mg BID
45515453|NCT01359566|Drug|Arbaclofen placarbil 30 mg BID|arbaclofen placarbil 30 mg BID
45515454|NCT01359566|Drug|Arbaclofen placarbil 45 mg BID|arbaclofen placarbil 45 mg BID
45515455|NCT04904770|Device|Scoop stretcher|Already included in arm/group description
45515456|NCT04904770|Device|Vacuum mattress|Already included in arm/group description
45515457|NCT04379284|Other|Biospecimen collection|"Maternal blood, vaginal swab, and anorectal swab will be obtained at the time of enrollment prior to delivery. A sample of breastmilk before hospital discharge and again at six weeks postpartum will be obtained if the mother is lactating.~Neonatal specimens collected following delivery will include placental tissue, fetal membrane roll, umbilical cord tissue, umbilical cord blood, and an anorectal swab."
45406812|NCT05869708|Device|Active RS-EFP|15 (+/- 3) active NF Prism training sessions, aimed to train for upregulating the RS activity. Sessions will occur twice a week, on nonconsecutive days, over 8 consecutive weeks. Subjects will also receive two single booster sessions, one month and two months after their last training session.
45515458|NCT01356914|Drug|BMS-914392|Tablets, Oral, 10 mg, Every Day (QD), 20 days
45406813|NCT05869708|Device|Sham RS-EFP|15 (+/- 3) sham NF Prism training sessions, aimed to train for upregulating the RS activity. Sessions will occur twice a week, on nonconsecutive days, over 8 consecutive weeks. Subjects will also receive two single sham booster sessions, one month and two months after their last training session.
45406814|NCT05869695|Other|OSPRO-ROS Questionnaire|Completion of questionnaires
45406815|NCT05869695|Other|OSPRO-YF Questionnaire|Completion of questionnaires
45406816|NCT05869669|Drug|Neflamapimod|Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40mg capsules
45406817|NCT05869669|Drug|Placebo|Placebo is a capsule that looks just like neflamapimod but without the active ingredients
45851631|NCT03804840|Drug|Dronabinol|THC (Marinol® [dronabinol]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication (Broyd et al, 2016; Hartman and Huestis, 2013).
45406818|NCT05869656|Behavioral|Fluid restriction|Oral fluid restriction of 1000ml per day
45406819|NCT05869656|Behavioral|Free fluids|Continue care without any oral fluid restriction
45406820|NCT05869617|Other|Aquatic exercise|"Participants in the aquatic therapy group will receive aquatic therapy in a HydroWorx aquatic therapy pool at Hydrathletics.~In the aquatic therapy group the 20 minutes of aerobic exercise at each visit will involve walking on an underwater treadmill. The intensity of the walking will be determined by the participant at self-selected intensities that are not perceived to cause a lasting increase in pain for one hour after the exercise session.~The 20 minutes of strengthening exercise will focus on movement patterns that simulate common daily functional activities. Initial intensity of exercises will be determined in collaboration between the health professional and patient by testing the intensity of the exercise that allows the participant to perform 8 repetitions without experiencing a lasting increased in pain. Exercise intensity will be increased weekly by either increasing the number of repetitions or increasing resistance."
45406821|NCT05869617|Other|Land-based Exercise|"Traditional land-based training will take place the Hydrathletics gym with similar exercises provided to the aquatic therapy group.~The aerobic exercise for the land-based therapy group will be 20 minutes of treadmill walking. The intensity will be determined by the participant at self-selected intensities that are not perceived to cause a lasting increase in pain for one hour after the exercise session.~The 20 minutes of strengthening exercise will focus on similar movement patterns to the aquatic therapy group to simulate common daily functional activities. Initial intensity of exercises will be determined in collaboration between the health professional and patient by testing the intensity of the exercise that allows the participant to perform 8 repetitions without experiencing a lasting increased in pain. Exercise intensity will be increased weekly by either increasing the number of repetitions or the resistance used for the exercise."
45406822|NCT05869604|Behavioral|HEALTHY AYA|8-session health lifestyle behavior intervention combining behavioral symptom management strategies with strategies to improve diet and increase physical activity.
45515459|NCT01356914|Drug|BMS-914392|Tablets, Oral, 10 mg, Three Times Daily (TID), 20 days
45515460|NCT01356914|Drug|BMS-914392|Tablets, Oral, 20 mg, Three Times Daily (TID), 20 days
45851632|NCT03804840|Drug|Placebo|Placebo
46059176|NCT01046903|Drug|Fragmin® (Dalteparin Sodium)|Administered per prescribing physician
45406823|NCT05869604|Other|Education Control|Participants will receive paper materials on topics of relevance to adolescent and young adult cancer survivors.
45515461|NCT01356914|Drug|Placebo|Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days
45515462|NCT04885816|Device|Drug Eluting Balloon (DEB)|"Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DEB, and the diameter and pressure used aims a balloon to artery ratio of 1. In case of significant recoil (more than 30% for main vessels and 50% for side vessels), coronary perforation or flow limiting dissection, provisional stent will be implanted with a stent to artery ratio of 1.1 with stent post-dilatation when indicated. Device will be used in accordance with the CE mark instructions.~DAPT will be given for a month with aspirin and a P2Y12 inhibitor (clopidogrel will be favored). Single anti-platelet therapy (SAPT) with aspirin will be continued thereafter."
45515463|NCT04885816|Device|Drug Eluting Stents (DES)|"Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Devices will be used in accordance with the CE mark instructions.~DAPT will be indicated according to actual international guidelines."
45515464|NCT03135314|Dietary Supplement|cocoa flavanol|7 days intake of cocoa flavanol supplement (naturex)
45515465|NCT03135314|Dietary Supplement|placebo|7 days of placebo intake
45406824|NCT05869591|Drug|Apixaban 5 MG [Eliquis]|Pharmacokinetics and pharmacodynamics assessment of apixaban in patients with Child B liver cirrhosis
45406825|NCT05869591|Drug|Edoxaban 60 MG [Lixiana]|Pharmacokinetics and pharmacodynamics assessment of edoxaban in patients with Child B liver cirrhosis
45406826|NCT05869578|Procedure|Anesthesia Intervention|Patients exposed to any anesthesia intervention will be assessed to whether the exposure to anesthesia confers a risk for perioperative outcomes
45406827|NCT05869565|Drug|Sodium Chloride 0.9% infusion alone or in combination with Sodim acetate with normal saline in a ratio 1;1, 2;1 and 3;1|Patients will be enrolled in the study and randomized into one of four arms
45406828|NCT05869539|Drug|Combination of Tumor-infiltrating lymphocyte transfer with ANV419|"The study uses a personalized IMP (investigational medicinal product), i.e. TIL product in combination with ANV419.~Day 0: Autologous TIL: (minimum 5 x 10^9 and up to 2x 10^11 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Intravenous treatment with ANV419 at 243 μg/kg 2 hours after the TIL infusion. Actual body weight will be used to calculate the dose of ANV419.~Day14: Intravenous treatment with ANV419 at 243 μg/kg. Actual body weight will be used to calculate the dose of ANV419."
45406829|NCT05869500|Device|Left Bundle Branch Area Pacemaker|Implantation of Medtronic 3830 lead for left bundle branch area pacing
45406830|NCT05869500|Device|Right Ventricular Pacemaker|Implantation of a conventional right ventricular pacemaker lead
45406831|NCT05869487|Radiation|Dual-energy X-ray absorptiometry|Whole body x-ray absorptiometry
45406832|NCT05869474|Procedure|Iodine125-Seeds implantation|Endoscopic ultrasound-guided intratumoral iodine125-Seeds implantation
45406833|NCT05869474|Drug|Gem/nab-P Chemotherapy|nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8 every 3 weeks
45515466|NCT04865614|Drug|Etomidate|Use of etomidate
45515467|NCT04865614|Drug|Sevoflurane|Use of sevoflurane
45515468|NCT01483898|Biological|Ixmyelocel-T|On Day 14, 20 intramuscular injections of ixmyelocel-T on pre-identified index leg.
45515469|NCT01483898|Other|Placebo|On Day 14, 20 intramuscular injections of vehicle control on pre-identified index leg.
45515470|NCT04847908|Other|Single high-intensity interval exercise intervention|Study participants perform a single bout of exercise on a cycle ergometer (high-intensity interval exercise intervention) within the first and third cycle of chemotherapy. Following a 2 minute warm-up, the interval protocol comprises 10 intervals à 15 seconds with high intensity and 60 seconds low intensity in-between. Blood samples are taken at t0 pre-exercise (after a 10 minute rest) and at t1 immediately post-exercise via central catheter (Hickman/port).
45515471|NCT05377918|Other|Diary|spiritual diary group and diary gruop will write a diary
45851633|NCT03804762|Procedure|the third space robotic and endoscopic cooperative surgery|This technique combines the endoscopic techniques and the merits of Da Vinci surgical robot, such as flexible and precise instruments, tremors filtering system and a 3-D surgical view, and take full advantage of the methodology of the third space to dissect gastric submucosal tumors.
45851634|NCT03804450|Procedure|Regenerative endodontic procedures (REPs)|Instrumentation using rotary Pro-Taper Next, disinfection using sodium hypochlorite and calcium hydroxide as intracanal medication followed by induction of blood and application of Biodentine as a cervical plug.
45406834|NCT05869461|Behavioral|KP Specific Wellness Sessions|The sessions will include content on yoga, nutrition, legal issues, medical information, and community resources from the original Chetana intervention (further described below). They will also include expanded content informed by our previous studies and focus group discussions with MSM and TGW that addresses the needs for sessions on mental health, financial literacy, substance use, legal rights for key populations and coping skills for interacting with the legal system, and community resources for MSM and TGW. Sessions will include specifically tailored content related to the needs of MSM or TGW.
45515472|NCT02269046|Other|acupuncture and moxibustion|Warm needling acupuncture on Fenglong (ST40, bilateral), Zusanli (ST36, bilateral), Sanyinjiao (SP6, bilateral) and Cake-seperated moxibustion on Juque (RN14), Tianshu (ST25, bilateral), Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)
45515473|NCT02269046|Drug|Simvastatin|10mg/d,p.o,12 weeks.
45406835|NCT05869461|Behavioral|Peer Navigation|Participants will be assigned to a peer navigator (PN) who will be their principal point of contact for the intervention. Within a week, the navigator will set up an initial introductory meeting, either in person or via video chat. This will serve as the first monthly check-in to monitor a participant's progress. During these in-person digital meetings, the navigator will work with a participant to identify their unique barriers that currently affect engagement in care and train participants to identify and break down solutions into manageable steps. Special attention will be paid to barriers associated with intersectional stigma and PNs will draw on their own experiences as members of stigmatized groups in identifying and brainstorming successful coping strategies. While this is not a structural intervention, PNs will work with their clients to develop ways of coping with structural barriers, including transportation and referrals to social services.
45406836|NCT05869435|Device|FastWire System Device - Peripheral|The Investigator can use the FastWire System during the procedure to cross CTO Caps and/or to cross multiple lesions.
45406837|NCT05869409|Behavioral|Physical activity and sedentary behavior education|Enrolled patients will participate in an individual face-to-face education session, addressing: definitions and examples of sedentary and physical activity behaviors; physical health-related and mental health-related consequences of these behaviors; ways to break sedentary behaviors; age-adjusted physical activity recommendations (based on the guidelines of the World Health Organization).
45406838|NCT05869396|Diagnostic Test|echocardiography|Bedside echocardiography
45406839|NCT05869383|Drug|Ophiochepalus striatus extract|Ophiochepalus striatus extract 2x5 grams
45515474|NCT02269046|Other|Therapeutic Lifestyle Change|"Reduced intakes of saturated fats (<7% of total calories) and cholesterol (<200 mg per day)~Therapeutic options for enhancing LDL lowering~Weight reduction~Increased physical activity"
45406840|NCT05869383|Drug|Placebo|Placebo 2x5 grams
45406841|NCT05869370|Other|High intensity resistance training|Twelve weeks of resistance training twice a week.
45515475|NCT01483742|Drug|RO5024048|1000 mg orally bid, 24 weeks
45515476|NCT01483742|Drug|danoprevir|100 mg orally bid, 24 weeks
46059177|NCT02581423|Drug|Capecitabine|Participants will receive oral capecitabine, 1250 miligrams per meter-squared (mg/m^2) twice daily, in 3-week treatment cycles for up to 8 cycles. Treatment will be administered for 2 weeks followed by 1 week of rest without medication.
45406842|NCT05869370|Other|Low intensity resistance training combined with blood flow restriction|Twelve weeks of resistance training with blood flow restriction twice a week.
45406843|NCT05869344|Dietary Supplement|Black bean protein hydrolysates (BPH)|Participants were blinded to treatment and received BPH (5 g powder) dissolved in 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of BPH.
45406844|NCT05869344|Other|Commercial non-caloric beverage|Participants were blinded to treatment and received 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of placebo.
45515477|NCT01483742|Drug|peginterferon alfa-2a [Pegasys]|180 mcg weekly, 24 weeks
45515478|NCT01483742|Drug|ribavirin|1000-1200 mg/kg/day orally in two divided doses, 24 weeks
45515479|NCT01483742|Drug|ritonavir|100 mg orally bid, 24 weeks
45515480|NCT03065023|Drug|MK-4621|IT/IL injection Fixed concentration of 0.2 mg/mL Starting dose: 0.2 mg
45515481|NCT04720066|Diagnostic Test|Ultrasound test|point of care ultrasound performed by PEM physicians to limping children presenting to the PED compared to radiologist performed ultrasound test.
45515482|NCT04691128|Drug|Desflurane|After induction, anesthesia will be maintained with 0.8-1.3 MAC desflurane and 0.05-0.2 μg/kg/min remifentanil.
45515483|NCT04691128|Drug|Propofol|After induction, anesthesia will be maintained with 6-8 mg/kg/h propofol and 0.05- 0.2 μg/kg/min remifentanil
45515484|NCT04207918|Radiation|Radiotherapy|44.94Gy and 37.8Gy in 21 fractions to PGTV and PTV for neoadjuvant treatment. 59.92Gy and 50.4Gy in 28 fractions to PGTV and PTV for definitive treatment.
45515485|NCT04207918|Drug|Nimotuzumab|400mg, by intravenous infusion once a week in 4-6 weeks.
45515486|NCT04207918|Drug|S-1|40-60mg/m2/d，orally twice a day concurrently with radiotherapy.
45515487|NCT02269202|Drug|Midazolam, tablet|
45515488|NCT02269202|Drug|Crobenetine, i.v. infusion|
45515489|NCT02269202|Drug|Placebo|
45515490|NCT02266316|Device|Air warming mask|Mask that warms air at the mouth
45851635|NCT03804372|Drug|Rituximab|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
45851636|NCT03804372|Drug|Chemotherapy|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
45406845|NCT05869292|Device|Immediate implant loading|"Implants will be received immediately prosthetic restoration following surgical procedure.~For the provisional restoration, an open tray impression technique will be used. Plaster models with scan bodies will be digitized by the laboratory scanner (3Shape E1, 3Shape, Kopenhagen, Denmark), and the virtual design of provisional restoration will be performed with 3D designing software (Exocad-Matera 2.3, Exocad, Darmstadt, Germany). Provisional restorations will be then created using polymethyl methacrylate (PMMA) (Telio®CAD, Ivoclar Vivadent, Schaan, Lichtenstein) and were drilled from PMMA blocks using the 5-axis milling machine (Zenotec Select, Wieland, Pforzheim, Germany). Screw-retained abutments for the prosthetic bridge will be chosen according to implant angulation and surrounding soft tissue height.~At the end of the six-week healing period, definitive prosthetic restorations will be manufactured and delivered to the patients."
45515491|NCT04655638|Device|High Flow Nasal Therapy|High flow nasal therapy will be delivered by any device (standalone machine or ventilators able to deliver it). The initial flow rate will be set at 40 L/min and potentially increased up to 60 L/min, according to patient tolerance. Large-bore nasal prongs will be selected according to the size of patients' nostrils (i.e. 2/3 of the diameter of the patient's nostril). A surgical mask will be placed on top of the HFNT interface. The temperature will be set at 37°C or 34 °C according to the patient's comfort. The FiO2 will be adjusted to maintain SpO2 between 92-96%.
45406846|NCT05869292|Device|Early implant loading|"Implants won't receive immediately prosthetic restoration following surgical procedure and will be left only healing caps.~At the end of the six-week healing period, definitive prosthetic restorations will be manufactured and delivered to the patients."
45406847|NCT05869279|Biological|CARCIK-CD19|allogeneic cytokine induced killer cells transduced with a transposon CD19-chimeric antigen receptor (CARCIK-CD19) gene
45515492|NCT04655638|Device|Conventional Oxygen Therapy|Conventional Oxygen therapy will be delivered by any device or combination of devices used for delivering oxygen such as nasal cannula, Venturi Mask or Mask with or without a reservoir bag as per usual local practice. Oxygen flow will be titrated to achieve SpO2 between 92-96%.
45515493|NCT02266394|Drug|Mesenchymal stem cell|Intra-arterial infusion of the single-dose MSC
45515494|NCT02266394|Procedure|Mesenchymal stem cell delivery with stent placement|Intra-arterial stent placement after Mesenchymal stem cell infusion
45406848|NCT05869227|Drug|Capecitabine/Placebo combined with treprizumab|Combined
45406849|NCT05869201|Biological|Influenza vaccine [inactivated]|Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine
45406850|NCT05869201|Biological|Influenza vaccine [inactivated]|Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine
45406851|NCT05869201|Biological|Influenza vaccine [inactivated]|Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine
45406852|NCT05869162|Drug|SY-3505|A Third-generation ALK TKI
45406853|NCT05869136|Procedure|microneedling and hyaluronic acid for increasing gingival thickness in thin gingival phenotype|"All the participants will undergo phase-I therapy. Oral hygiene instructions will be imparted and will be reinforced at each appointment.~Local anaesthesia in the form of xylocaine spray will be administered.~Hyaluronic acid:~HA will be injected in the attached gingiva and MN will be carried out 1mm below the gingival margin on the keratinized gingiva of the tooth to be treated with thirty-gauge (0.255 mm) lancet needles in the test group."
45406854|NCT05869136|Procedure|microneedling for increasing gingival thickness in thin gingival phenotype|"All the participants will undergo phase-I therapy. Oral hygiene instructions will be imparted and will be reinforced at each appointment.~Local anaesthesia in the form of xylocaine spray will be administered and microneedling alone will be performed in control group"
45406855|NCT05869110|Other|Effects of odours on calorie intake, food choice and metabolic parameters|"Evaluation of the effects of olfactory stimulation compared to placebo on calorie intake and preference of food during a test-buffet.~Odours will be assigned in a randomized order. Each participant will receive both odours, in between there will be a wash-out period of 1 week."
45406856|NCT05869097|Drug|Trifluridine/Tipiracil|TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
45515495|NCT03614923|Biological|Etokimab|Administered by subcutaneous injection
45515496|NCT03614923|Biological|Placebo|Administered by subcutaneous injection
45515497|NCT03614923|Drug|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray (MFNS) was used from 4 weeks prior to Day 1 (Run-in period) through the end of the study. Participants used 2 actuations (50 μg/actuation) in each nostril BID, total daily dose of 400 μg. Participants intolerant to BID intranasal corticosteroids (INCS) could use the lower dose regimen of 1 actuation in each nostril BID, total daily dose of 200 μg.
45515498|NCT01353248|Drug|GS-5885|tablet, 30 mg QD
45515499|NCT01353248|Drug|Tegobuvir|capsule, 30 mg BID
45515500|NCT01353248|Drug|GS-9451|tablet, 200 mg QD
45515501|NCT01353248|Drug|ribavirin tablet|(weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
45515502|NCT01353248|Drug|GS-5885|tablet, 90 mg QD
45515503|NCT05095636|Drug|Apatinib Mesylate|oral Apatinib once everyday
45515504|NCT05095636|Drug|Camrelizumab|intravenous camrelizumab 200mg once every two weeks
46059178|NCT04102072|Diagnostic Test|Trendelenburg Maneuver|In the Trendelenburg position, the body is laid supine with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
45515505|NCT05756959|Device|PBM|PBM, is a low intensity red light at wavelength of 650nm; Peripheral defocus spectacels is a peripheral design glasseses for correct myopia and control myopia
45515506|NCT05756959|Device|Peripheral defocus spectacles|plus power design of many peripheral small lenses to achieve myopic defocus of the retina in the peripheral retina
45515507|NCT05756959|Device|Single vision spectacles|Distance vision correction with the single vision spectacles for the myopia correction methods (glasseses for myopia correction)
45515508|NCT02264444|Other|Cholecystectomy visualization|Patients undergo a standard removal of the gallbladder through a single incision at the umbilicus will have their operation recorded and graded according to a scale that is established for this study.
45406857|NCT05869097|Drug|Bevacizumab|Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days
45406858|NCT05869084|Diagnostic Test|pulmonary function tests|pulmonary function tests
45515509|NCT05095558|Biological|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
45515510|NCT01343966|Drug|MABT5102A|Repeating subcutaneous injection
45515511|NCT01343966|Drug|MABT5102A|Repeating intravenous infusion
45515512|NCT01343966|Drug|placebo|Repeating subcutaneous injection
45515513|NCT01343966|Drug|placebo|Repeating intravenous infusion
45406859|NCT05869045|Other|Diaphragm shortening fraction measurement by point-of-care ultrasound.|A noninvasive and feasible method to assess diaphragmatic function and predict the prognosis of patients with respiratory failure presenting to the emergency department. The method consists of measuring the diaphragmatic thickness at the end of inspiration and expiration using a linear probe placed in the subcostal region and calculating the percentage of change using the formula: diaphragmatic thickness at the end of inspiration - diaphragmatic thickness at the end of expiration/diaphragmatic thickness at the end of expiration×100. A value lower than 10% indicates diaphragmatic dysfunction and a higher risk of adverse outcomes.
45406860|NCT05869019|Other|education|Premature baby care training will be provided.
45406861|NCT05868993|Drug|Dose of 0.5% Ropivacaine|Dose varied by 5mL of 0.5% Ropivacaine
45406862|NCT05868980|Other|vital signs by postpartum position|Evaluation of vital signs and NIRS values in 4 different positions after birth
45406863|NCT05868967|Drug|[14C]DWP14012|Each subject will receive a single oral dose of [14C]DWP14012 suspension (containing approximately 40 mg/80 μCi [14C]DWP14012) under fasting conditions.
45406864|NCT05868954|Behavioral|MedDiet Program|Subjects allocated to the MedDiet Program group will receive counseling based on the principles of the traditional MedDiet with a focus on a general change in diet instead of micronutrients or macronutrients. Diet adherence will be assessed using a questionnaire. Participants will receive 6, free traditional MedDiet meals every 3 weeks between enrollment and until the subject is approximately 38 weeks pregnant. In addition, participants will receive olive oil and nuts during their enrollment visit and during their routine 26-30 week prenatal visit.
45406865|NCT05868954|Behavioral|ACOG-based Dietary Program|Following ACOG recommendation, subjects allocated to the ACOG-based Dietary Program group, will receive routine counseling on healthy eating. This will include advice on the consumption of grains, fruits, vegetables, protein, and dairy foods recommended during pregnancy. Diet adherence will be assessed using a questionnaire. Participants will receive 6, free traditional healthy meals every 3 weeks between enrollment and until the subject is approximately 38 weeks pregnant. In addition, participants will receive canola oil and healthy snacks during their enrollment visit and during their routine 26-30 week prenatal visit.
45515514|NCT03540277|Behavioral|"Experimental: Prevention Program young In Favor of Myself, active parents"|"Prevention program: young In Favor of Myself, with parent participation"
45515515|NCT03540277|Behavioral|"Experimental: Prevention Program young In Favor of Myself, no parental involvement"|"Prevention program: young In Favor of Myself, without parent participation"
45515516|NCT05095480|Drug|Red Yeast Rice Pill|Taking Lesstat
45515517|NCT05095480|Drug|Placebo|Placebo receiving group
45515518|NCT04438408|Other|questionaires|patients will answer to questionnaires on the quality of life and the control of the asthmatic disease as well as the therapeutic observance.
45515519|NCT02915016|Biological|DNA-HIV-PT123 vaccine|Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.
45515520|NCT02915016|Biological|Bivalent Subtype C gp120/MF59 vaccine|Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.
45515521|NCT02915016|Biological|Bivalent Subtype C gp120/AS01B vaccine|"Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.~Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose."
45515522|NCT02915016|Biological|Placebo|Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.
45515523|NCT03859414|Drug|Therapeutic Dose 1|CHF 5993 100/6/12.5 µg pMDI, fixed combination of BDP 100 µg + FF 6 µg + GB 12.5 µg.
45515524|NCT03859414|Drug|Therapeutic Dose 2|CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
45515525|NCT03859414|Drug|Supra-therapeutic Dose|CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
45515526|NCT03859414|Drug|Placebo|CHF 5993 placebo pMDI
45515527|NCT02269280|Drug|Azacitidine (AZA) Days 1 - 3|Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days.
45406866|NCT05868941|Device|Broncho Muco Cleaner|"The endotracheal tube will be passed with a bronchoscope. During the procedure, the product is connected to the oxygen jack in the hospital, inflated and deflated, turning the thickened goblet cell layer that causes sputum production to foamy liquid. For the procedure, it will be entered through the intubation tube with a fiberoptic bronchoscope, and the airways with a diameter of 3 to 8 mm, primarily the airways, and all the respiratory tract mucosa that can be reached will be treated with a balloon in a total of 3 sessions. For these procedures, balloons selected in accordance with the diameter of the bronchi will be used in the respiratory tract.~In patients who meet the patient selection criteria, intervention will be made with a balloon that inflates and deflates at the determined frequency and pressure from the subsegment level that can be reached with the bronchoscope to the inner surface of the airways proximally."
45406867|NCT05868928|Diagnostic Test|Magnetic resonance imaging (MRI)|Pre-and post-contrast enhanced T1-weighted image, T2-weighted image, fluid-attenuated inversion recovery image
45406868|NCT05868928|Diagnostic Test|Diffusion-weighted MRI|Diffusion-weighted MRI
45406869|NCT05868928|Diagnostic Test|Arterial spin labeling (ASL)|Cerebral blood flow imaging parameter
45406870|NCT05868928|Diagnostic Test|Dynamic susceptibility contrast-MRI (DSC-MRI)|Cerebral blood volume and vessel architectural imaging parameters
45406871|NCT05868915|Biological|HV-101|"Biological: HV-101~HV-101 is autologous tumor-infiltrating lymphocyte cells without genetic modification.~Drug: IL-2~Following cell infusion, the patient receives intravenous IL-2.~Drug: Fludarabine~Part of the non-myeloablative lymphocyte-depleting preparative regimen.~Drug: Cyclophosphamide~Part of the non-myeloablative lymphocyte-depleting preparative regimen."
45406872|NCT05868902|Device|CardioFlux Magnetocardiography|The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)
45515528|NCT02269280|Drug|Decitabine (DAC)|Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days.
45515529|NCT02269280|Other|Best Supportive Care (BSC)|Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only.
45515530|NCT02269280|Drug|Azacitidine (AZA) Days 1 - 5|Azacitidine 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days.
45851637|NCT03804372|Drug|Tenofovir alafenamide|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
45851638|NCT03803982|Procedure|Deep Neuromuscular Blockade|The proposed intervention in this study is delivery of an anesthetic with Deep Neuromuscular Blockage (NMB), which will be defined as a TOF of 0 and 2-3 twitches in the post-tetanic count.
45851639|NCT03803982|Drug|Sugammadex|Sugammadex will be used to reverse the deep neuromuscular blockade in the experimental group.
45406873|NCT05868876|Drug|AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion|AK127 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages.AK104 is administered intravenously according to the frequency and dosage 10mg/kg Q3W.
45406874|NCT05868863|Other|datas of medical record.|"Analysis datas of medical record:~Feasibility of the technique~Safety of the technique with evaluation by Cardiovascular and Interventional Radiological Society of Europe (CIRSE) scale~Analgesic intake before and after the procedure~Functional criteria: early rising, walking"
45406875|NCT05868824|Other|Blood sample|A blood sample for assessing cytokines will be performed at baseline and at follow-up visit 3 months after initiation of treatment. The blood sample will be performed as part of blood tests done for standard AD follow up.
45515531|NCT01170650|Drug|EC145|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
45406876|NCT05868811|Behavioral|Music Together|The intervention consists of 45-minute weekly classes for 16 weeks. Each class is delivered by a trained Music Together facilitator and includes music activities such as singing, dancing, moving and playing musical instruments. At the start of the program, participants receive materials for home use that consist of a song book and online access code for song recordings used in the class.
45406877|NCT05868811|Behavioral|Play Group|The play group consists of 45-minute weekly classes for 16 weeks. During each class parents are encouraged to play with their child and interact with other participants using the provided age appropriate toys. At the start of the program participants receive an age appropriate toy for use at home.
45406878|NCT05868798|Drug|Ammonia Inhalant|For all AI trials, a capsule containing 0.3 mL of AI (composed of 15% of ammonia and 35% of alcohol) was used according to the manufacturer's instructions (Dynarex Corporation, Orangeburg, NY). When the ammonia fumes were released, researcher immediately held the capsule under the participant's nose to inhale until a voluntary withdrawal reflex was observed.
45406879|NCT05868759|Radiation|Roentgen Stereophotogrammetric Analysis (RSA)|"Roentgenstereophotogrammetric analysis (RSA) is a radiographic technique, highly accurate both to evaluate the primary stability of the implant, then the micromovements between bone and implant prosthetic, both for the evaluation of the kinematics of the prosthetic components. The RSA technique in dynamics is able to obtain, with patient in motion, a series of radiographic frames in sequence in two projections, which are captured simultaneously. Each pair of orthogonal projections corresponds to a specific moment of the movement carried out by the patient and will be used to obtain, through dedicated software, a reconstruction three-dimensional instant defined RSA scenes."
45406880|NCT05868759|Device|Delos Postural Proprioceptive System (computerized oscillating platform)|The Delos Postural Proprioceptive System uses electronic tilting tables (on a single axis or three axes) with high frequency that allows very short stop and reversal times that allow both to study the proprioception and the patient's response to the modification of movement of the inclined plane
45406881|NCT05868759|Diagnostic Test|Modified Star Excursional Balance Tests|The Star Excursional Balance Test (SEBT) is a clinical test designed for the evaluation of dynamic physical performance of the tibiotarsica. The first literary references date back to 1998 and the test, remaining in balance with the ankle in the studio, the achievement of the maximum possible distance with the contralateral foot along well-defined axes.
45406882|NCT05868759|Device|Inertial sensors Xsens MVN|"The inertial motion acquisition system Xsens MVN is easy to use and economic to detect the movement of different anatomical districts. MVN is based on inertial sensors in miniature through communication solutions combined with advanced fusion algorithms sensors, using hypotheses of biomechanical models.~This MVN system is a system of inertial kinematic measurement of the whole body, which incorporates synchronized data. Instant graphic output is provided, including angles of motion articular."
45406883|NCT05868759|Other|American Orthopaedic Foot and Ankle Score (AOFAs)|American Orthopaedic Foot and Ankle Score (AOFAs) is a clinical trial commonly used in scientific literature which serves to assess, in terms of value from 0 to 100, the autonomy, pain, stability, ankle alignment and back foot of the patient.
45406884|NCT05868759|Other|Visual Analogue Scale (VAS)|The Visual Analogue Scale (VAS) is a visual representation of the extent of pain that the patient subjectively warns. The VAS is represented by a 10 cm long line in the original version validated, with or without notches at each centimeter. One end indicates the absence of pain and corresponds to 0, the other end indicates the worst pain imaginable and corresponds to 10.
45406885|NCT05868759|Other|12-Item Short Form Survey (SF-12)|The 12-Item Short Form Survey (SF-12) is a self-reported outcome measure assessing the impact of health on an individual's everyday life.
45406886|NCT05868733|Drug|Day 1 Lower Dose (2×106 pfu)|rVSV∆G-LASV-GPC
45406887|NCT05868733|Drug|Day 1 Higher Dose (1×107 pfu)|rVSV∆G-LASV-GPC
45406888|NCT05868733|Drug|Placebo|Placebo
45515532|NCT01170650|Drug|Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)|50 mg/m2 (calculated on the basis of ideal body weight) every 4 weeks. Dose reductions permitted for toxicity.
45515533|NCT01170650|Drug|placebo|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
45515534|NCT01170650|Drug|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
45515535|NCT04533646|Drug|Insulin|Participants will be asked to dose insulin during the first week using fixed doses. During the second week of the study, participants will dose insulin based on carbohydrate counting. Blood sugar control will be compared between the 2 weeks to determine the outcomes of the study.
45515536|NCT04533646|Device|Continuous glucose monitor (CGM)|Participants will be required to wear a CGM to measure glucose trends
45515537|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
45515538|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
45515539|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
45515540|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
45515541|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
45515542|NCT01168310|Drug|Formoterol Fumarate|Inhalation Solution
45406889|NCT05868720|Drug|Risperidone, Aripiprazole|The patients who are randomized to Risperidone group will receive Risperidone at a dose of 1mg/day during the study period that is for 6 weeks. The patients who are randomized to Aripiprazole group will receive Aripiprazole at a dose of 2mg/day during the study period that is for 6 weeks.
45406890|NCT05868707|Drug|OH2|Oncolytic Type 2 Herpes Simplex Virus
45406891|NCT05868707|Drug|Salvage chemotherapy or best supportive care|single or combined, including but not limited to dacarbazine, temozolomide, taxoid, or platinum
45406892|NCT05868681|Device|Delos instrument (computerized balance board)|"Proprioceptive training using Delos instrument (computerized balance board).~Static and dynamic evaluation through Delos with the Riva method; Physiatric visit; Clinical scores (AOFAs); Functional scores (SPPB); SF12 satisfaction."
46059179|NCT04102072|Diagnostic Test|dobutamine stress test|Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. Echocardiography was performed after 5-10 minutes of continuous infusion, and hemodynamic data were recorded.
46059180|NCT02875457|Drug|apatinib;etoposide and cisplatin|
45406896|NCT05868655|Other|Exercise with supervisor|A program of stability and balance exercises will be provided. Participants will be asked to take the final measurements after the exercises have been monitored by a physical therapist for eight weeks.
45406897|NCT05868655|Other|Standart exercise|Participants will be asked to take the final measurements after the exercises have been monitored by a physical therapist for eight weeks.
45406898|NCT05868642|Procedure|subarachnoid block|subarachnoid block with levobupivacaine at different dosage for pation undergoing total hip arthroplasty
45406899|NCT05868629|Other|Non-investigational|Participants obtaining commercial (non-investigational) dabrafenib plus trametinib (i.e. solid formulation or liquid formulation, if approved and commercially available locally) per local guidance or patient access program
45406900|NCT05868616|Device|Cardiac Resynchronization Therapy (CRT)|Cardiac resynchronization therapy (CRT) is a modality of cardiac pacing used in patients with left ventricular (LV) systolic dysfunction and dyssynchronous ventricular activation that provides simultaneous or nearly simultaneous electrical activation of the LV and right ventricle (RV) via stimulation of the LV and RV (biventricular pacing) or LV alone.
45406901|NCT05868603|Other|Remineralization gel|Remineralization gel
45515543|NCT01168310|Drug|Placebo|Inhalation Solution
45406902|NCT05868590|Other|Toothpaste|Using two different toothpastes for removal of the dental plaque in children.
45406903|NCT05868577|Drug|Corticosteroid injection (CSI) with local anesthetic (LA)|The PI will then administer the injection using an infracalcaneal needle peppering
45406904|NCT05868577|Drug|Local anesthetic (LA) with Saline injection|The PI will then administer the injection using an infracalcaneal needle peppering
45406905|NCT05868564|Device|Atherectomy+Drug-coated balloon|Patients in experimental group will undergo endovascular treatment for femoropopliteal lesions. The lesion will be treated by atherectomy+drug-coated balloon in the experimental group
45406906|NCT05868564|Device|Drug-coated balloon|drug-coated balloon only in the active comparator group.
45406907|NCT05868551|Procedure|nodulectomy|incision in an onchocerciasis nodule to extract adult worms
45406908|NCT05868538|Diagnostic Test|Serum calprotectin and IMA concentrations|Serum calprotectin and IMA concentrations were compared among active BD cases, inactive BD cases and control subjects.
45406909|NCT05868525|Drug|Aspirin 325Mg Tab, Aspirin 81Mg Tab|Patients will be administrated daily oral Aspirin 81 mg or oral Aspirin 325 mg according to their assigned group after randomization.
45406910|NCT05868512|Diagnostic Test|Dry needling|Dry Needling Along With Routine Physical Therapy for Chronic Neck Pain
45406911|NCT05868512|Diagnostic Test|Therapeutic ultrasound|Therapeutic ultrasound Along With Routine Physical Therapy for Chronic Neck Pain
45406912|NCT05868499|Biological|EXG34217|Single infusion
45406913|NCT05868486|Procedure|Biospecimen Collection|Undergo blood sample collection
45406914|NCT05868486|Genetic|Genetic Testing for Cancer Risk|Undergo germline testing
45515544|NCT04464928|Other|Facebook Advertisements|Counties will receive advertisements to VoicesForPFD.org's webpage on urinary incontinence on Facebook Ads when triggered by user characteristics indicating elevated risk of female urinary incontinence.
45515545|NCT04464928|Other|Google Advertisements|Counties will receive advertisements to VoicesForPFD.org's webpage on urinary incontinence on Google Ads when triggered by keywords relevant to female urinary incontinence.
45515546|NCT01472198|Drug|Simtuzumab|Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
45515547|NCT01472198|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle
45515548|NCT01472198|Drug|Placebo to match simtuzumab|Placebo to match simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
45515549|NCT04444492|Drug|Ranibizumab Injection|initial three injections of Ranibizumab - afterwards pro re nata monthly
45406915|NCT05868486|Procedure|Liquid Biopsy|Undergo liquid biopsy testing
45406916|NCT05868486|Procedure|Magnetic Resonance Imaging of the Whole Body without Contrast|Undergo whole body MRI without contrast
45406917|NCT05868486|Other|Survey Administration|Complete surveys
45515550|NCT04444492|Device|Laser photocoagulation|Areas of capillary non-perfusion will be treated with photocoagulation upto 4 times
45515551|NCT04575610|Drug|PF-06650833|Subjects randomized to the PF-06650833 arm of the study will receive 200 mg IR suspension formulation every 6 hours (via nasogastric [NG] tube, orogastric [OG] tube, or equivalent) if unable to take tablets by mouth (PO). Subjects for whom concomitant administration of a strong inhibitor of cytochrome P450 (CYP) 3A4 will have the dose of the IR formulation to 200 mg once daily (QD). Subjects who can take tablets PO will receive 400 mg PF-06650833 (2-200 mg tablets) of the MR formulation QD under fasted conditions (preferably at least 4 hours after and 1.5 hours before a meal). No dose adjustment is needed for subjects taking the MR tablet preparation, except if co-administered with ritonavir in which case the dose should be reduced to 200 mg MR QD. All dosing of PF-06650833 will be in addition to current hospital SOC therapy.
45406918|NCT05868473|Diagnostic Test|Mobilization With Movement|Mobilization With Movement Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
45406919|NCT05868473|Diagnostic Test|Kinesotaping|Kinesotaping Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
45406920|NCT05868447|Procedure|Stabilization surgery|"hourly blood gas analysis and hemoglobin and hematocrit control and blood transfusion will be performed when necessary~If a low pO2 value is observed in the blood gas, the fi02 values or fresh gas flow will be increased."
45515552|NCT04575610|Drug|Placebo|Matching placebo tablets will be administered.
45406921|NCT05868434|Procedure|Medial Patellofemoral Ligament Reconstruction (MPFLR) With Fascia Lata Allograft, Based on Isometry Assessment Combined With Elmslie-Trillat Tibial Tuberosity Osteotomy.|Medial Patellofemoral Ligament Reconstruction (MPFLR) With Fascia Lata Allograft, Based on Isometry Assessment Combined With Elmslie-Trillat Tibial Tuberosity Osteotomy. Management of any accompanying patellofemoral lesions will be performed as well.
45515553|NCT02269358|Drug|METHOTREXATE|Infliximab therapy after escalation. SC methotrexate at 15 mg/m2 , not to exceed 25 mg/m2 per week for 4 weeks. Patients in remission after 4 weeks reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
45406922|NCT05868408|Other|Control Formula|Infant formula made with intact protein - minimum 1.8g protein/100kcal
45515554|NCT04504240|Drug|Famotidine 20 MG|Famotidine; tablet Famotac 20mg oral form.
45515555|NCT02266550|Drug|[14C] BILL 284 BS|
45515556|NCT02088060|Drug|Cannabidiol|Cannabidiol capsules
45851640|NCT03804216|Other|Multimodal Imaging Analysis|The patients are seen in consultation ophthalmological before and the 1 hour after their session of dialysis. THE OCT angiography and other not invasive ophthalmological examinations will be realized during the follow-up
45406923|NCT05868408|Other|Experimental Formula 1|Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
45406924|NCT05868408|Other|Experimental Formula 2|Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
45406925|NCT05868395|Drug|Polatuzumab, bendamustin und rituximab|"Polatuzumab vedotin 1.8 mg/kg i.v. on day 2 of cycle 1, then on day 1 of each subsequent cycle~Bendamustine 90 mg/m2 i.v. day 2 & 3 of cycle 1, then on day 1 & 2 of each subsequent cycle~Rituximab 375 mg/m2 i.v. on day 1 of each cycle~Each cycle is 21 days long~Up to 6 cycles per patients planned"
45515557|NCT02088060|Drug|Olanzapine|Olanzapine capsules
45515558|NCT02088060|Drug|Placebo Cannabidiol|Placebo cannabidiol capsules
45515559|NCT02088060|Drug|Placebo Olanzapine|Placebo olanzapine capsules
45515560|NCT04464304|Device|Smartphone|Patients will participate in a similar game to the VR cohort, but will use a smartphone device.
45515561|NCT04464304|Device|Virtual Reality (Oculus Quest)|Patients will participate in a game using VR.
45515562|NCT02269436|Drug|sNN0029 infusion solution|4 µg/day, continuous i.c.v administration
45515563|NCT01202344|Other|Additional x-ray images|Approximately 3 additional x-ray images following angioplasty (within 1 hour)
45515564|NCT02264522|Other|Place dialysis chair into position 3.|Upon device notification event 1, place patient in dialysis chair position 3.
45851641|NCT03803904|Other|Spin|The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
45851642|NCT03803670|Diagnostic Test|evaluation of cerebrospinal fluid of ALL|We evaluated cerebrospinal fluids of patients with ALL by conventional cytology and by flow cytometry
45851643|NCT03803514|Drug|Recombinant EPO|Beta-epoetin (Recormon, Roche). Dosage was performed according to current recommendations.
46059181|NCT02875457|Drug|placebo;etoposide and cisplatin|
45406926|NCT05868369|Device|iVR Group|"On the day of surgery, the iVR group will receive a 30-minute sessions or dose of iVR therapy in the ambulatory post-anesthesia care unit (PACU) during their stay. The three distraction-based or skills-based iVR modules will consist of either 1) Mindful Escape; 2) Empowered Breathing; or 3) Relaxation videos. The iVR group will be sub-randomized into receiving only one of the three types of modules. The modules will start approximately 30 minutes upon arriving in PACU and will last approximately 30 minutes."
45406927|NCT05868369|Drug|Standard pain management regimen|In the ambulatory post-anesthesia care unit (PACU) during their stay with have standard postoperative pain protocol (including a pre-operative local field block).
45406928|NCT05868356|Drug|Treatment A|Oral adagrasib 200 mg twice daily (BID) for 8 days (Days 1 to 8). Predose PK blood samples for the measurement of adagrasib concentration will be collected on Days 2 to 7. Serial PK blood samples for adagrasib will be collected up to 12 hours postdose on Days 1 and 8.
45406929|NCT05868356|Drug|Treatment B|Oral adagrasib 200 mg BID and gemfibrozil 600 mg BID for 10 days (Days 9 to 18), with no evening dose of adagrasib or gemfibrozil on Day 18. Predose PK blood samples for the measurement of adagrasib concentration will be collected on Days 9 to 17 before the morning dose of adagrasib. Predose PK blood samples for the measurement of gemfibrozil trough concentration will be collected on Days 15 to 18 before the morning dose of gemfibrozil. Serial PK blood samples for adagrasib will be collected up to 12 hours postdose on Day 18.
45406930|NCT05868343|Other|Center-based Cardiac Rehabilitation Intervention|The center-based cardiac rehabilitation program is 12 weeks in length. Participants will travel to the center twice a week for the duration of the program. Participants receive an individualized exercise program to be completed at the center according to Canadian recommendations. Twelve pre-recorded educational vignettes on various health topics and two group educational sessions on nutrition are offered to participants in person during the first twelve sessions at the center. In addition, at the beginning of the CR program, participants watch a motivational vignette from one of our patient partners about the importance and benefits of following the CR program. Depending on the needs of each participant, they may be referred to various external clinics within the Vitalité network, such as the Nutrition Service.
45406931|NCT05868343|Other|Hybrid Cardiac Rehabilitation Intervention|The center-based cardiac rehabilitation program is 12 weeks in length. For the first six weeks, participants are required to attend the hospital twice a week. After that, there will be a gradual increase in home sessions for the remaining six weeks. When a patient has a home session, health professionals follow up with a phone call.Twelve pre-recorded educational vignettes on various health topics and two group educational sessions on nutrition are offered to participants in person during the first twelve sessions at the center. In addition, at the beginning of the CR program, participants watch a motivational vignette from one of our patient partners about the importance and benefits of following the CR program. Depending on the needs of each participant, they may be referred to various external clinics within the Vitalité network, such as the Nutrition Service.
45406932|NCT05868330|Procedure|Interscalene Catheter|Pre-operatively the patient will have a interscalene catheter placed by a regional skilled anesthesiologist. The initial block will be with 20 cc of 0.5% Bupivacaine and maintained on an infusion post-operatively at 8cc/hr of 0.2% ropivacaine as is our intuitions protocol
45406933|NCT05868330|Procedure|Exparel Single Shot Interscalene Block|Pre-operatively the patient will have a interscalene single shot block with 133 mg Liposomal Bupivacaine and 10 ccs 0.5% Bupivacaine placed by a regional skilled anesthesiologist.
45699501|NCT05088408|Dietary Supplement|Resource® Energy Apricot|"Bowel preparation as usual plus two bottles of Resource® Energy Apricot (one day before the colonoscopy with no ingestion of solid foods, possibly with ingestion of clear liquids with or without sugar (such as tea or other transparent beverages without pulp, but not milk, yogurt, broth or gelatine), with ingestion of one bottle of 200 mL of the dietary supplement at 08:00 and the other at 12:00, and with ingestion of 275,84 g (4 sachets) of polyethylene glycol 3350 (Klean-Prep®) in 4 litres of water in 3 to 4 hours (250 mL every 15 minutes), starting at 18:00; in the day of the exam the patients can drink the same clear liquids with or without sugar until 4 hours before the colonoscopy, which will be carried out in the morning).~Colonoscopy."
45515565|NCT02264522|Other|Decrease dialysate temperature.|Upon device notification event 2, decrease dialysate temperature by 0.5 degree centigrade.
45851644|NCT03803358|Other|exercise training with non-invasive ventilation|In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.
45406934|NCT05868317|Drug|Chemotherapy With FOLFIRINOX ( 5 Fluorouracil, Oxaliplatine and Irinotecan)|"Induction chemotherapy with six cycles of modified 5 fluorouracil,oxaliplatin and irinotecan followed by short course radiotherapy (RT) (5x5 Gy), then two cycles of 5 fluorouracil and oxaliplatin based chemotherapy and surgery will be performed 6 to 8 weeks after completion of RT.~After surgery , continuation of chemotherapy with 4 cycles of 5 fluorouracil and oxaliplatin regardless of pathological response"
45515566|NCT02264522|Other|Decrease ultrafiltration rate by 25%.|Upon device notification event 3, decrease ultrafiltration rate by 25% from baseline ultrafiltration rate.
45515567|NCT02264522|Other|Decrease ultrafiltration rate by 50%.|Upon device notification event 4, decrease ultrafiltration rate by 50% from baseline ultrafiltration rate.
45515568|NCT02084316|Behavioral|One4All|Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
45515569|NCT02084316|Behavioral|Standard of Care|"The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.~After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.~Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling."
45515570|NCT02269514|Other|Own Brand Cigarette|combustible cigarette brand style smoked most frequently by subject
45515571|NCT02269514|Other|Electronic Cigarette #1|VUSE® Digital Vapor Cigarette (original flavor, 14mg nicotine)
45515572|NCT02269514|Other|Electronic Cigarette #2|VUSE® Digital Vapor Cigarette (original flavor, 29mg nicotine)
45515573|NCT02269514|Other|Electronic Cigarette #3|VUSE® Digital Vapor Cigarette (original flavor, 36mg nicotine)
45515574|NCT02269514|Other|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
45515575|NCT03465982|Procedure|Surgery after 8 weeks from chemoradiation treatment|Minimally invasive surgery after 8 weeks from chemoradiation treatment
45515576|NCT03465982|Procedure|Surgery after 12 weeks from chemoradiation treatment|Minimally invasive surgery after 12 weeks from chemoradiation treatment
45515577|NCT01332812|Drug|Dexamethasone|a dose of 8 mg of dexamethasone will be administered intravenously before induction of general anesthesia
45515578|NCT01332812|Other|control group|General anesthesia, without additional interventions
45851645|NCT03803358|Other|standard exercise training without NIV|In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
45851646|NCT03803124|Drug|Tolvaptan|1 tablet before renography
45851647|NCT03803124|Drug|Placebo|1 tablet before renography
45406935|NCT05868317|Radiation|Radiotherapy|Short Course Radiotherapy
45406936|NCT05868304|Device|BFR|Exercises may involve warm up on a stationary bike for 5 minutes, application of a BFR cuff (a cuff that often uses air to inflate around a limb) on the selected extremity, and exercise sets (e.g. banded squats, step ups, Romanian dead lifts). We will record metrics on an iPad. Testing will be done with ForceDecks and ForceFrames (system for measuring muscle strength and imbalance).
45406937|NCT05868304|Other|Stanard strengthening program.|"The exercise program will be completed 3 times per week Participants will warm up on a stationary bike for 5 minutes~The program will consist of the following exercises using a 30,15,15,15 rep scheme:~Banded squats Step ups (8 inch) Romanian dead lifts (RDL)"
45851648|NCT03802734|Device|Mindful meditation phone app|Participants in the intervention group will be given a free 6-month subscription to a mindful meditation phone app (Headspace). They will also be given an actigraph and a general pregnancy and sleep information leaflet.
46059182|NCT00773968|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|120, 200 or 360 micrograms every 4 weeks by subcutaneous injection.
46059183|NCT05527210|Dietary Supplement|Prebiotic|Prebiotin® is a fine, white to slightly yellow powder, which is mixed into water and has a slightly sweet taste.
46059184|NCT05527210|Dietary Supplement|Placebo Prebiotic|Placebo prebiotic mixed into water
45515579|NCT02079792|Procedure|Lying Head Back Position|Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort.
45515580|NCT02079792|Procedure|Head Down and Forward Position|Subjects randomized to the HDF position will be instructed to kneel down, placing the top of their head on the ground and forehead close to the knees with the nostrils facing upwards.
45515581|NCT03408652|Drug|denosumab|Single subcutaneous injection of denosumab 120 mg every 4 weeks One intravenous infusion of zoledronic acid 4 mg every 4 weeks, according to labelled use.
45515582|NCT01332656|Drug|Ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
45515583|NCT01332656|Drug|Placebo|"Pharmaceutical form:solution~Route of administration: intravenous"
45515584|NCT01332656|Drug|Paclitaxel|"Pharmaceutical form:solution~Route of administration: intravenous"
45515585|NCT01332656|Drug|Carboplatin|"Pharmaceutical form:solution~Route of administration: intravenous"
45515586|NCT02084472|Other|Baby oil|patient in study 1, arm B washed unscented liquid paraffin (baby oil) in place of aqueous cream
45515587|NCT02084472|Other|petroleum jelly|patients in this arm, use petroleum jelly (vaseline), replacing emulsifying ointment as a moisturiser
45515588|NCT02084472|Other|Glycerine:petroleum jelly 2:1|patients in this arm use glycerine and petroleum jelly mixed at a ratio of 2:1 in place of cetomacrogol as a moisturiser
46059185|NCT04078867|Procedure|tricuspid valve repair|Tricuspid valve repair during mitral valve replacement for rheumatic heart disease using suture (DeVega) repair or ring annuloplasty
45406938|NCT05868278|Other|Training method intervention|Traditional learning method will be used in the control group. In the experimental group, interactive learning method will be used.
45406939|NCT05868213|Drug|Cannabis (smoked flower)|Self-Directed Use (ad-libitum)
45406940|NCT05868200|Drug|Capitano zenzero toothpaste|"Filming toothpate formulation, enriched with 3%ginger as active ingredient and Zinc coco sulfate as surfactant, cleansing and emulsifying agent.~Subjectswill then be given the test intervention, Capitano zenzero toothpaste, and will be asked to brush with it for two minute twice per day and will be instructed torefrain from eating and drinking for 30 min after brushing. participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months ."
45406941|NCT05868200|Drug|Colgate total toothpaste|Subjects will then be given Colgate total toothpaste, as an active comparator, and will be asked to brush with it for two minutes twice per day and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles . participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months .
45406942|NCT05868187|Behavioral|Exercise, Problem-Solving Session and Education|Complete assigned exercises three times a week Complete Action plan co-developed Complete part or all of one of the four interactive educational modules
45406943|NCT05868161|Device|Pounce Thrombectomy System|Non-surgical removal of thrombi and emboli from the peripheral arterial vasculature with the Pounce Thrombectomy System.
45515589|NCT02266784|Behavioral|Contingency Management (CM)|
45515590|NCT02266784|Drug|Transdermal nicotine skin patches (i.e. Habitrol)|
45515591|NCT02266784|Other|Supportive Counseling|
45515592|NCT02090790|Drug|iv dexamethasone|2 ml 8 mg iv dexamethasone
45515593|NCT02090790|Drug|femoral dexamethasone|2ml 8mg dexamethasone administration added 30 ml 0,5 % bupivacain
45515594|NCT02090790|Drug|serum physiologic|2 ml iv serum physiologic
45515595|NCT04959916|Behavioral|Group Metacognitive Therapy|Group Meta-Cognitive Therapy (Group-MCT) will consist of six weekly sessions delivered by two trained trainee clinical psychologists over 1-1.5 hours. The aims of the intervention are to help participants develop knowledge that can facilitate control of worry, rumination and attention, and to modify the metacognitive beliefs that maintain these unhelpful patterns of thinking. The treatment follows a manual that has been previously evaluated in the treatment of cardiac patients suffering from anxiety and depression. Sessions include group discussions, experiential learning and homework tasks that participants will be expected to complete between sessions.
45515596|NCT02084550|Dietary Supplement|Vaminolac|Vaminolac with an amino acid content corresponding humane breast milk.
45515597|NCT02084550|Other|Saline|Intravenous isotonic saline with a sodium chloride content of 9mg/ml.
45515598|NCT04946110|Device|Electromagnetic stimulation|Electromagnetic stimulation of the phrenic nerve
45515599|NCT01443728|Drug|Experimental: Vitamin D3 100,000 IU|Oral vitamin D3, 100,000 IU [2.5 mg] given once a month
45515600|NCT01443728|Drug|Active Comparator: Vitamin D3 12,000 IU|Standard dose oral vitamin D3 12,000 IU [0.3 mg] given once a month
45515601|NCT02088138|Device|Functional Electrical Stimulation|Functional electrical stimulation twice per week for eight weeks totaling sixteen sessions.
45515602|NCT02088138|Device|Functional Electrical Stimulation placebo|Functional electrical stimulation in the sensory threshold level, twice a week for eight weeks, totaling sixteen sessions.
45515603|NCT05092048|Other|questionnaire|PHQ-9 and GAD-7 questionnaire
45515604|NCT01324466|Drug|NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
45515605|NCT01324466|Drug|Vehicle|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
45515606|NCT04740346|Diagnostic Test|Computed tomography, Chest X-ray, and blood test|CT will be performed every 3 months after gastrectomy in the 3-months follow-up group. CT will be performed every 6 months after gastrectomy in the 6 months follow-up group.
45515607|NCT05479188|Device|Cerebral oximetry|Cerebral oximetry monitoring with near-infrared spectroscopy.
45406944|NCT05868148|Device|Shoulder iD™ Primary Reversed Glenoid|Device implant via reversed total shoulder arthroplasty
45406945|NCT05868135|Behavioral|eMeistring|Initial face-to-face visit, eight/nine sessions/modules of therapist guided ICBT, final face-to-face visit
45515608|NCT05479188|Device|Peripheral oximetry|Tissue perfusion monitoring with somatic near-infrared spectroscopy.
45515609|NCT05479188|Device|Cerebral autoregulation|Cerebral autoregulation monitoring with COx.
45515610|NCT05479188|Device|Sublingual microscopy|Evaluation of microcirculation with sublingual microscopy.
45515611|NCT02090868|Other|Oral Intake Screening Tool|A screening tool developed from a literature review and expert opinion. It will be used by nurses to assess patients receiving non-invasive ventilation ability to eat and drink orally and suggest what actions should be taken if they are unable to do so
45851649|NCT03802500|Diagnostic Test|Nerve conduction study|"Physical examination of muscle strength is conducted using the Medical Research Council (MRC) scale in 6 muscles bilaterally.~Patients with an MRC score of less than 48 of 60 are diagnosed with critical illness polyneuromyopathy (CIPNM).~The evaluation is completed by a routine neurological examination. In patients meeting the inclusion criteria, the screening Peroneal nerve test (PENT test) is performed on the day of study enrollment and subsequently in 1 week intervals until pathologic findings are detected or patient is discharged from the ICU.~PENT measures the peroneal nerve Compound muscle action potential (CMAP) amplitude in one leg. If the PENT is normal, the contra-lateral peroneal nerve is measured. An abnormal condition is identified if the peroneal nerve CMAP amplitude is reduced below the normal limits of the participating centre in at least one leg. In Lausanne, the abnormal response is < 2,5 mV."
45406946|NCT05868122|Drug|Acetaminophen/Naproxen Sodium Fixed Combination|Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
45406947|NCT05868122|Drug|Placebo|Placebo will be administered orally.
45406948|NCT05868109|Drug|inhaled nitric oxide (iNO)|In patients randomized to the this arm, iNO will be delivered into the ventilator circuit through the endotracheal tube or tracheostomy. The dose will be 80 ppm during chest compressions and reduced to 20 ppm immediately following ROC. If the patient is enrolled following ROC, the dose will be 20 ppm. Dose modifications will occur if there is toxicity or if there is a clinical concern. The iNO or sham will be continued for 72 hours or until extubation.
45406949|NCT05868109|Drug|Sham|In patients randomized to sham, the iNO delivery device will be connected to the ventilator circuit or manual ventilation bag but flow of iNO will not be turned on. For the purposes of patient safety and to maintain blinding, the respiratory therapists (RTs) will continue checks of gas flow, flow adjustments and change iNO gas tanks at rates like routine clinical procedures on patients treated with iNO or sham.
45406950|NCT05868096|Other|Structured holistic thinking course(2 hr)|The holistic thinking curriculum was designed as a structured program using mind maps, case-based discussions, and clinical observations to integrate physical, psychological, social, and spiritual aspects.
45406951|NCT05868096|Other|Clinical practice training|there is no holistic thinking curriculum.Using the holistic thinking case study form - introductory version self-study
45406952|NCT05868083|Drug|SNC-109 CAR-T Cells|SNC-109 CAR-T Cells, first dose from 2×104 CAR+ T Cells, treatment follows the operation and the next dose would be deiced by SRC
45406953|NCT05868070|Device|Conventional rehabilitation plus multimodal exercise|Depending on the patient's condition, the intervention gradually progressed to passive, active assistive, active, and resistive exercise modes and the frequency of exercise interventions is gradually increased, and the application time of cycling/stepping is 20 minutes per session, and up to 3 times if there is no serious problem corresponding to the safety standards.
45406954|NCT05868044|Device|PRIMUS|Peripheral Nerve Stimulator System
45515612|NCT01312454|Drug|AL-59412C injectable solution|Concentration 1 and Concentration 2
45515613|NCT01312454|Drug|Travoprost injectable solution|
45699502|NCT05088408|Other|Bowel preparation as usual.|"Bowel preparation as usual (one day before the colonoscopy with no ingestion of solid foods, possibly with ingestion of clear liquids with or without sugar (such as tea or other transparent beverages without pulp, but not milk, yogurt, broth or gelatine), and with ingestion of 275,84 g (4 sachets) of polyethylene glycol 3350 (Klean-Prep®) in 4 litres of water in 3 to 4 hours (250 mL every 15 minutes), starting at 18:00; in the day of the exam the patients can drink the same clear liquids with or without sugar until 4 hours before the colonoscopy, which will be carried out in the morning).~Colonoscopy."
45515614|NCT01312454|Drug|AL-59412C Vehicle|Inactive ingredients used as placebo
45515615|NCT01310114|Biological|Human Placenta-Derived Cells PDA001- (cenplacel-L)|240 mL of intravenous infusion
45515616|NCT01310114|Drug|Placebo|Thawed placebo
45515617|NCT04090918|Diagnostic Test|Cardiac examination programme 3 months after abdominal surgery|Blood- and urine sampling, electrocardiogram, wavECG (Myovista), transthoracic echocardiography, Finapres, cardiac magnetic resonance imaging
45515618|NCT02088294|Behavioral|Lifestyle Education (LS)|See arm description
45515619|NCT02088294|Behavioral|LS + Stress Reduction Guided Imagery|See Arm Description
45515620|NCT02088294|Behavioral|LS + Activity/Eating Guided Imagery|See arm description
45515621|NCT01305824|Drug|PRT-201|PRT-201 10 micrograms administered at the time of AVF creation.
45406955|NCT05868031|Other|alternative teaching methods|This study aimed to explore the potential benefits of alternative teaching methods in anatomy education, as well as to investigate the effectiveness of traditional lecture-based education in comparison. By examining the outcomes of these different approaches, we hope to understand better how students can best learn and retain knowledge in this field.
45406956|NCT05868018|Behavioral|Education|This was an observational study of changes in evidence based confidence and behavior across 4 physical therapy programs. Students received their typical physical therapy education and we measured changes in evidence based practice confidence and behaviors across programs throughout the curriculum.
45406957|NCT05868005|Other|Clinical decision support system for screening of migrants using the ISMiHealth software tool.|"The implementation of the screening programme will be facilitated using a simple and user-friendly software tool (ISMiHealth).~When an individual attends the PCC for any reason, the tool will generate an alert for health professionals in the EPR system, with recommendations on the conditions that should be considered for screening, based on this patient's characteristics (country of birth, age and sex). Health professionals will decide what diseases/conditions should be screened for, supported by the recommendations of the digital software (intervention centres) or based on their knowledge on the epidemiological background of the diseases (control centres). In any case, health professionals will be responsible for requesting serology tests, chest radiographies and/or referrals to specialists."
45406958|NCT05867992|Other|Type of trauma|Patients in case group have the severe traumatic brain injury, while patients in control group have the traumatic bone fracture without brain injury.
45406959|NCT05867979|Diagnostic Test|Identify structural variants by Optical Genome Mapping of DNA extracted from blood leukocytes|The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.
45406960|NCT05867966|Behavioral|psychoeduc/self-care/self-hypnosis group|See arm description.
45406961|NCT05867953|Device|Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging|Biopsy with the Robotic- Navigational Bronchoscopy System with Adjunct Real-time Imaging
45851650|NCT03802032|Drug|Lidocaine Gel|topical lidocaine gel
45515622|NCT01305824|Drug|Placebo|Placebo administered at the time of AVF creation.
45515623|NCT01305824|Drug|PRT-201|PRT-201 30 micrograms administered at the time of AVF creation.
45515624|NCT03323749|Combination Product|elamipretide|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
45515625|NCT03323749|Combination Product|placebo comparator|40 mg of placebo administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
45515626|NCT03323749|Combination Product|elamipretide open label treatment|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for up to 144 weeks using the elamipretide delivery system
45515627|NCT02084784|Drug|Indocyanine green|Subcutaneous injection around the areola with 2-4 points Indocyanine green with 1ml of 0.5%
45515628|NCT02084784|Drug|methylene blue|Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1%
45515629|NCT02266862|Radiation|Study group|Patients will receive an additional CT sequence (end-expiration) at the time of their standard CT imaging before and after the repair.
45515630|NCT03267589|Drug|Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562|Three different combination are being tested. Each cohort has different combination
45515631|NCT02091024|Dietary Supplement|ECE (Ecklonia cava extract)|ECE 200mg, twice a day
45515632|NCT02091024|Dietary Supplement|Placebo|Placebo 200mg, twice a day
45515633|NCT03135236|Behavioral|Parent training|Participants will attend 3 trainings. There will be a pre-test before training 1 and an initial post-test after training 3. There will be a final post-test 1 month after the final training.
45515634|NCT02084862|Device|Ultrasound guided percutaneous tracheostomy|Ultrasound guided percutaneous tracheostomy
45515635|NCT02084862|Device|Bronchoscopy guided percutaneous tracheostomy|Bronchoscopy guided percutaneous tracheostomy
45851651|NCT03802032|Drug|KY jelly|topical KY jelly
45851652|NCT03802266|Device|Electromagnetic Navigation guided transthoracic needle aspiration|Patients in this group will receive electromagnetic navigation guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
45515636|NCT03240601|Device|Transcutaneous spinal stimulation|For TSS, a transcutaneous electrical nerve stimulation (TENS) unit is used. A 2 inch diameter round electrode is placed on the skin over T11/T12 (cathode), and a large butterfly electrode is placed on the skin over the umbilicus (anode). Pulse width is set to 400 microseconds at 50 Hz.
45515637|NCT03135080|Other|Long-Term HEAD START Training|The Human Eyelid Analogue Device for Surgical Training And skill Reinforcement in Trachoma (HEAD START) is a surgical simulation device used to bridge the gap between classroom and live-surgery training specifically for trichiasis surgery. Long-term HEAD START practice will involve the following components, after completion of standard training (as described in the standard of care arm). Each week the participant will complete 2 surgeries on the HEAD START device. Monthly, the participant will send the accumulated cartridges to Addis Ababa for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his impression of the surgeries with the participant during a regular monthly call and note the findings. Practice will continue for 4-6 months, depending on the length of the rainy season and time of enrollment. At the end of the rainy season, an external examiner will evaluate the first 2 surgeries that the participant completes.
45515638|NCT03135080|Other|Standard of Care|All participants will receive trichiasis surgery training following Orbis' standard training approach, with the inclusion of HEAD START training between classroom and live surgery training. At the end of the surgical training session, an independent examiner will evaluate all trainees using the World Health Organization's Final Assessment of Surgeons form, as part of standard practice. The examiner also will complete a standard questionnaire focusing on the specific skill level achieved for each of the critical aspects of TT surgery. This form will be completed for all trainees undergoing training this spring, regardless of whether they are part of the long-term HEAD START assessment program.
45515639|NCT02091180|Drug|Mannitol|0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
45406962|NCT05867940|Behavioral|Physical activity on prescription|"Physical activity on prescription (PAP) is a well-established method to enhance physical activity in adults in primary care. The prescribed activity should lead to moderate increase of the pulse, such as walking, cycling, swimming, or gardening, and should be performed over a longer period of time in order to achieve a change towards a more active lifestyle. The activity may be prescribed by a physiotherapist, physician, nurse, or other health professional. PAP has shown to be feasible to increase participation in physical activity and to reduce sedentary behaviour in children with cerebral palsy.~Motivational interviewing is used for our PAP with participants with disabilities. During PAP-period, the participants are asked to fill in an activity logbook."
45515640|NCT02091180|Drug|Control|Saline infusion
45515641|NCT03949738|Diagnostic Test|Near-infrared spectroscopy-based assessement of cerebral autoregulation.|"Cerebral autoregulation is assessed using a software that calculates correlation coefficients based on the values of cerebral oxygenation (detected by near-infrared spectroscopy) and invasively measured arterial blood pressure.~Correlation coefficients are calculated at 10-second intervals and averaged over a period of 300 seconds, resulting in an autoregulation index (cerebral oxygenation index, COx). The index can range between -1 and +1. It provides information about cerebral autoregulation capacity, with a value below 0.3 indicating intact cerebral autoregulation."
45515642|NCT03134924|Behavioral|Women's and Sexual Health [WASH]|The WASH was a group-based, 45-minute group session on vaginal health and healthy vaginal practices led by two trained facilitators. The sessions covered topics related to vaginal practices and the potential harm of vaginal practices.
45515643|NCT03134924|Behavioral|Enhanced Standard of Care|"The enhanced standard of care (SOC+) condition received a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV, and medication as needed. At baseline participants received an individual education session on the risk of engaging in IVP and tips on discontinuing IVP."
45515644|NCT02084940|Drug|GnRH antagonist depot Degarelix|Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
45515645|NCT05755321|Other|Skin biopsy|Skin biopsy performed during surgery.
45851653|NCT03802266|Device|CT-guided Transthoracic Needle Aspiration|Patients in this group will receive CT guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
45406963|NCT05867927|Device|Robotic-assisted surgery (da Vinci)|Robotic-assisted surgery (da Vinci)
45406964|NCT05867927|Device|Non-da Vinci Surgery|Non-da Vinci Surgery
45406965|NCT05867888|Other|conventional therapy|conventional therapy ( instructions, ice application, deep tissue massage, stretching exercises, joint mobilization and isometric exercises )
45406966|NCT05867888|Other|shock wave therapy|Acoustic waves (shock waves) that can carry energy and can propagate through tissues promote healing effects.
45406967|NCT05867888|Other|low level laser therapy|The application of light to a biologic system to promote tissue regeneration, reduce inflammation and relieve pain.
45406968|NCT05867862|Other|Test|"A dental consultation of 30 to 45 minutes will be added to the annual visit with a dentist.~If dental treatments are needed, they will be done at the same time, or they will be programmed for another time at the center of dental care (CSD).~Due to the fact that most patient live far away from Nantes and the hospital, teleconsultation for patient in the test groups will happen every 2 months"
45515646|NCT02269748|Procedure|Tunnel technique with subepithelial connective tissue|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival tunnel prepared over the donor site.
45515647|NCT02269748|Procedure|Coronally advanced flap|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival flap which is repositioned coronally
45515648|NCT02269748|Drug|Analgesic Therapy|Ibuprofen 600 mg TID
45406969|NCT05867823|Behavioral|OcuApp|The participants will have instaled a mobile aplication (OcuApp) by a member of the researchs team who will teach them how to use it. The person must register the activities they carry out throughout a week and mark each one of them with a punctuation (from 1 to 5) related to the meaning of the following dimensions: identity, pleasure, competence, importance and value of the activity by other people.The application also allows to collect other information such as where the activity takes place, its duration, and the people with whom it is carried out. Also, at the end of the week, the application will ask users about their perceived occupational balance. All the information registered in the mobile application will be returned to the person in a dynamic and understandable way. Based on this, the person can establish two goals to accomplish. In this sense, OcupApp will offer personalized recommendations based on the objectives to be achieved related to the dimensions of meaning.
45406970|NCT05867823|Behavioral|Three-part work|The intervention on the control group will focus on offering to the participants an informative three-part work on the positive effects of performing activities to control anxiety and depression. After providing this information, any doubts in this regard will be answered.
45406971|NCT05867771|Drug|PM1022|PM1022 Injection
45406972|NCT05867758|Other|Psychosocial group intervention|"The psychosocial group intervention is composed of 8 weekly sessions of 90 minutes each and the receiving of self-help digital materials. Both organized as following: 2 on isolation, loneliness and social connection, 2 on well-being, 2 on the use of digital tools, 2 on the fostering of socialization with peers.~To evaluate the effects of the blended intervention and of the two conditions we will ask participants to fulfill the following clinical questionnaires: ULS-6 (Russell et al. 1980), MSPSS (Zimet et al., 1988), GAD-7 (Spitzer et al., 2006), PHQ-9 (Kroenke, Spitzer & Williams, 2001), SWLS (Diener et al., 1985), MLQ (Steger et al., 2006) before starting the intervention in presence and online (T0), at the end of that period (T1) and 2 months after (T2)."
45406973|NCT05867745|Other|Interview|As previously specified
45406974|NCT05867745|Other|Survey|As previously specified
45406975|NCT05867745|Other|Letter to a friend (autoethnography)|As previously specified
45406976|NCT05867693|Dietary Supplement|palmithoylethanolamide/polydatin|"Palmitoyl-ethanolamide, a saturated fatty acid amide of palmitic acid commonly found in egg yolk and peanuts, is chemically related to anandamide but exhibit low affinity for cannabinoid receptors, and participate in the control of inflammation and nociception mainly via down-regulation of mast cell activity. In addition, palmitoylethanolamide is able to reduce human colonic permeability both in vitro and in vivo. Interestingly, palmithoylethanolamide may act as mast cell modulator as a possible agonist for cannabinoid 2-like receptors; and as agonist for PPAR-α, transient receptor potential vanilloid type 1 (TRPV1), and 'orphan' G protein-coupled receptor 55.~For these reasons, palmithoylethanolamide has emerged as potential regulators of nociception. Polydatin, a resveratrol glucoside, is a common dietary component derived from grapes which may act synergistically with palmithoylethanolamide in reducing mast cell activation and local oxidative stress."
45406977|NCT05867693|Dietary Supplement|placebo|After the screening phase, eligible patients will be randomly assigned to equivalent placebo
45515649|NCT03149809|Drug|solifenacin|Antimuscarinic bladder relaxant, antagonizes bladder muscarinic receptors
45515650|NCT03149809|Behavioral|Pelvic floor muscle exercise-based behavioral therapy|Multicomponent intervention including fluid management, constipation management and behavioral techniques incorporating pelvic floor muscle-exercise based urge suppression and self-monitoring to reduce overactive bladder symptoms
45515651|NCT02269826|Device|Vagisan® Moisturising Cream|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
45515652|NCT02269826|Device|Gynomunal® vaginal gel|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
45515653|NCT04533880|Device|DBM|Demineralized bone matrix (Allosync, CDMB Putty, Arthrex, Naples, FL)
45515654|NCT04533880|Device|Calcium phosphate cement|Quickset, Arthrex, Naples, FL
45515655|NCT04533880|Other|Autologous bone graft|Autologous bone grafting involves utilizing bone obtained from the same individual receiving the graft
45515656|NCT02269904|Drug|Fluorouracil Implants|Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.
45515657|NCT02269904|Drug|Xelox regimes|Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
45515658|NCT04540198|Behavioral|GamePlan4Care|GamePlan4Care; Experimental
45515659|NCT04540198|Behavioral|Resources4Care|R4C; Active Comparator
45515660|NCT03557112|Drug|Nimotuzumab|TPF Regimen Induction Chemotherapy combined with nimotuzumab concurrent radiotherapy concurrent chemoradiotherapy
45515661|NCT03557112|Drug|Cisplatin|TPF Regimen Induction Chemotherapy combined with cisplatin concurrent radiotherapy concurrent chemoradiotherapy
45406978|NCT05867680|Behavioral|Online Mothers and Babies Course (eMB)|The eMB is an online, asynchronous, self-administered intervention modeled after the efficacious and in-person Mothers and Babies Course. (4) The eight-week course includes psychoeducational modules containing YouTube videos, vignettes, interactive quizzes, homework, guided meditations, and downloadable resources that teach strategies to promote a healthy outcome for mothers and their newborns: 1) overview, 2) thoughts and my mood, 3) fighting harmful and increasing helpful thoughts, 4) activities and my mood, 5) pleasant activities help make a healthy reality, 6) contact with others and my mood, 7) planning for the future and graduation, 8) relaxation exercises.
45406979|NCT05867667|Other|Cardiac Rehab|Cardiac Rehab 2x per week and home exercise 1x per week: weeks 1-4 Cardiac Rehab 1x per week and home exercise 2x per week: weeks 5-8, Home exercise 3x per week: weeks 9-12
45515662|NCT01300208|Drug|CC-11050|Cohort 1: 50 milligrams twice per day for 4 weeks Cohort 2: 100 milligrams twice per day for 8 weeks Cohort 3: 200 milligrams twice per day for 12 week
45406980|NCT05867641|Behavioral|Immersive VR Therapy in Head-Mounted Device (HMD)|"Caregivers will be trained to administer VR&R therapy to their loved ones with dementia, in their private home/residence. Participants with dementia will view immersive VR experiences using a commercially-available VR head-mounted device for up to 30 minutes a time, approximately every other day (or as desired), for three weeks. The caregiver will use the custom VR&R web-based application on their personal device (laptop, tablet, or mobile phone) to select and monitor what their loved one sees in VR.~Staying nearby to monitor for safety and assistance, the caregiver may choose to use the time when their loved one is engaged to take some respite time for themselves (e.g., make a cup of coffee, have an uninterrupted phone call)."
45406981|NCT05867628|Other|Activities-based locomotor training (physical therapy)|AB-LT is implemented through a combination of partial body weight supported treadmill training, overground walking, and play-based activities.
45406982|NCT05867615|Drug|[177Lu]Lu-PSMA I&T|177Lu activity to be administered to single patient (range 5.5-7.4 GBq), every 8 weeks (±2 weeks) will be measured in a dose calibrator, properly calibrated for the radionuclide. The radiopharmaceutical will be slowly infused intravenously over 15-30' in a dedicated room using a dedicated pump system.
45406983|NCT05867602|Drug|Albumin|intravenous human albumin at a dose of (1g/kg), with a minimum dose of 50g and a maximum dose of 100g
45406984|NCT05867589|Drug|68Ga/18F-FAPI-04|Subjects will receive one injection of 68Ga/18F-FAPI-04 (0.1~0.15mCi/Kg), a PET radiopharmaceutical selective for fibroblast activation protein. 68Ga/18F-FAPI-04 injection will be followed by a 10 ml saline flush.
45406985|NCT05867576|Behavioral|Acceptance and Commitment Therapy (ACT)|"Acceptance and commitment therapy (ACT) is an evidence-based psychological therapy that has been successfully used to improve physical and mental health among children and adults with chronic conditions. It is a third wave cognitive behavioural therapy that encourages openness to and awareness of the present moment in order to help participants maintain behaviours consistent with their life goals. ACT fosters engagement with, rather than avoidance of, painful experiences to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing difficulties. This gives ACT strong face validity for application to TCS patients where there can be permanent cognitive impairment and unavoidable ongoing physical symptoms and functional limitations."
45406986|NCT05867563|Drug|TQB2103 for injection|TQB2103 for injection is an antibody-drug conjugate targeting CLDN18.2. The drug structure mainly includes anti-humanized CLDN 18.2 antibody, linker and cytotoxic DDDXD, with Drug antibody Ratio (DAR) of 8.
45406987|NCT05867550|Drug|Rifaximin 550 MG|Rifaximin 550 MG Oral Thrice Daily for 2 weeks will be included in all three treatment regimes i.e A, B and C
45515663|NCT01300208|Other|Placebo|
45515664|NCT02085018|Drug|Omeprazole|Drug
45515665|NCT02085018|Drug|Matched placebo|Matched placebo
45515666|NCT05091814|Radiation|radiotherapy|patients who recieved radiotherapy after surgical removal of the tumor
45515667|NCT02091336|Drug|Metformin|patients treatment
45515668|NCT02091336|Drug|Glyburide|patients treatment
45515669|NCT03805204|Procedure|Open reduction and internal fixation (ORIF)|ORIF with a forearm plate
45515670|NCT01442090|Drug|Everolimus|Everolimus will be administered orally at a 10 mg daily dose.
45515671|NCT01442090|Drug|GDC-0980|GDC-0980 will be administered orally at a 40 mg daily dose.
45515672|NCT02085096|Behavioral|Problem-Solving Therapy|Problem-solving therapy programs have been shown to be effective among parents of children diagnosed with cancer. Efforts have been made to apply this same strategy to spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.
45515673|NCT03738904|Combination Product|ERAS|Gabapentin Acetaminophen Ketoroloac IV (intraop) and PO Dexamethasone (included with benzocaine in local anesthesia) Oxycodone PO Polyethylene glycol
45515674|NCT03738904|Combination Product|Standard of care|Oxcodone PO Ketorolac IV only (intraop)
45515675|NCT04475042|Drug|Dapagliflozin|10mg od
45406988|NCT05867550|Drug|Mebeverine 135 MG|Mebeverine 135 MG Oral Twice Daily for 2 weeks will be included in Group A Treatment Regimes
45406989|NCT05867550|Drug|Psyllium Husk|Psyllium Husk 15-35 MG Oral Once Daily for 2 weeks will be included in Group C Treatment Regimes
45406990|NCT05867550|Drug|Amitriptyline Hydrochloride 25 MG|Amitriptyline Hydrochloride 25 MG Oral Once Daily for 2 weeks will be included in Group B Treatment Regimes
45406991|NCT05867537|Dietary Supplement|Gluten-free diet|Implementation a 78-week dietary intervention to patients with ulcerative colitis, crohn´s disease and UC patients with associated PSC (PSC-IBD).
45406992|NCT05867524|Other|Oral Glucose Tolerance Test|75g oral glucose tolerance test, sampled over three hours
45406993|NCT05867524|Other|Cycling test|2 hours of moderate activity level cycling
45515676|NCT04475042|Drug|Placebo|Placebo
45699503|NCT03010774|Behavioral|Risk Stratification|Every night, subjects will be risk stratified into low-risk or medium- to high-risk using a physiologic risk score, eCART. Subjects who meet the low-risk criteria will not be woken up for routine nighttime vitals (typically at midnight and at 4 am). However, subjects will continue to be woken up for laboratory draws, procedures, or treatments as per usual. Subjects who are medium- to high-risk will continue to be woken up at night for routine nighttime vitals. Alarms for all subjects, including low-risk subjects, will continue to alert nurses in real-time. If the primary nurse of a low-risk subject is alerted of an alarm, the nurse will have to go into the subject's room to turn off the alarm and therefore check on the patient.
45406994|NCT05867511|Behavioral|iPAL App|"The intervention will have a duration of eight weeks. It is theory-based, will be delivered to participants' smartphones via the study app (except components 5 and 6), and comprises the following components:~Theory-based individualized feedback.~Self-generated motivational messages.~Motivation for habit formation through push messages.~Motivational images and videos that participants handed in or selected will be sent to them through the app.~Study-specific social media groups. Participants will be offered the option to participate in study-specific social media groups.~Posting motivational stories. A story of a person, who successfully changed his or her lifestyle to be more physically active and/or less sedentary, will be posted once a week in the study-specific social media groups."
45406995|NCT05867485|Other|COVID-19 Discharge Education|"A discharge education brochure has been developed based on information from the literature to complement the verbal information provided to patients. The content of the education brochure includes the following:~Information about the spread of the virus and precautions to be taken.~Guidelines for cleanliness and disinfection of the environment.~Precautions regarding personal and wearable items.~Information about food and beverages.~Guidelines for personal hygiene practices.~Information about quarantine and isolation.~Guidelines for maintaining health and care (e.g., respiratory hygiene, cough etiquette, movement, range of motion exercises) (CDC, 2019; Ministry of Health of Turkey, 2020; CDC 2019 A-B-C-D)."
45406996|NCT05867472|Drug|Isoflurane Inhalant Product|Isoflurane will be administered using an inhalation device
45406997|NCT05867472|Drug|Sevoflurane inhalant product|Sevoflurane will be administered using an inhalation device
45406998|NCT05867459|Diagnostic Test|Serum creatinine|The test wil be measured for all pt in study to detect of their grade of CKD
45406999|NCT05867459|Diagnostic Test|Alb /creat ratio or 24h urine protein|Test will be measured to detect type and sevirity of proteinuria
45407000|NCT05867459|Diagnostic Test|Serum electrolyte|The test will be measured in all pt to detect renal tubular state
45515677|NCT02088450|Drug|Active treatment with nitrendipine (10-40 mg/day).|If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
45699504|NCT03010774|Behavioral|Usual Care|The subject will continue to receive routine vital sign measurements and charting, standard for the ward or according to the physician orders, including routine spot-check vital signs, regardless of risk level.
45699505|NCT05086068|Device|Arthrosamid|Intra-articular hydrogel injection comprising of water and cross-linked polyacrylamide.
45851654|NCT03801798|Drug|GC1102|NAs antivirals+GC1102 180,000 IU
45407001|NCT05867459|Diagnostic Test|Urine analysis|It is mirror of kidney
45407002|NCT05867459|Diagnostic Test|Abdominal ultrasound|To detect the anatomy and any structural abnormality in kidneys
45407003|NCT05867459|Diagnostic Test|Renal biobsy|Is done but not for all pt but for pt that can do it and agree for it .the test is used for detection of type of CKD or type of glomerionephritis
45407004|NCT05867459|Other|Clinical assesment|"Clinical assessment:~age, kidney disease history, history of DM or HTN ,history of pregnancy during study, therapy in early pregnancy , body weight, body height, and . Mean arterial pressure (MAP) . Body mass index (BMI). According to age and Scr level, the estimated glomerular filtration rate (eGFR) was calculated by CKD-EPI Creatinine Equation (2021)~Evaluation of pregnancy outcomes :Adverse pregnancy outcomes included maternal death, severe preeclampsia ,eclampsia ,duration of hospital stay and type of care need, mode of delivery ,need of blood transfusion , gestational age during delivary for detet preterm birth early preterm or late preterm from or extremely preterm > 28W, birth weigh for low birthweight ,very low birth weight , extremely low birth weight,NICU admission,IUGR, still birth ,abortion, and neonatal death."
45515678|NCT03688828|Drug|Saccharomyces boulardii|500mg bid
45515679|NCT03688828|Drug|Esomeprazole|20mg bid
45515680|NCT03688828|Drug|Amoxicillin|1.0g bid
45515681|NCT03688828|Drug|Clarithromycin|0.5g bid
45515682|NCT03688828|Drug|Bismuth potassium citrate|0.22g bid
45515683|NCT03960476|Behavioral|PlanYourLifespan.org|The study intervention is a web-based planning tool, PlanYourLifespan.org
45851655|NCT03801798|Other|GC1102 Placebo|NAs antivirals+GC1102 Placebo
45407005|NCT05867433|Behavioral|STHS Intervention|"STHS program~The intervention group (10 schools) will participate in the STHS program. During the fall semester (September to December), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that provide education on civic engagement, healthy eating, and physical activity. During the spring semester (February to May), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that focus on implementing the school health environmental change project and receive support for maintaining individual-level healthy eating and physical activity behaviors."
45407006|NCT05867433|Behavioral|Usual Care|"No STHS program~The usual care group will be offered the same activities as the intervention group after the conclusion of the research study."
45407007|NCT05867420|Biological|ASKG915|ASKG915 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle.
45407008|NCT05867407|Device|Anumana Low EF AI-ECG Algorithm|Clinician will have access to the Anumana Low EF AI-ECG algorithm via a link in the patient's electronic health record which will display results applied to patients' ECGs, as well as supporting information. Using the results of the algorithm, combined with the clinician's knowledge of patient-specific risk factors, the clinician will determine whether further evaluation is warranted.
45407009|NCT05867407|Other|Care-as-Usual|Clinicians will not have access to the Anumana Low EF AI-ECG algorithm and will provide care-as-usual.
45407010|NCT05867394|Other|Stress ball|Stress ball squeeze
45407011|NCT05867368|Behavioral|HABIT-VR|HABIT-VR is a suite of video games designed on the principals of HABIT treatments. The games are delivered in virtual reality, because these systems provide a way to track the movements of both hands and build software that requires both hands to succeed.
45407012|NCT05867368|Behavioral|Standard HABIT|HABIT is a camp where children play self-select activities that require both hands to succeed.
45407013|NCT05867355|Procedure|surgical fixation|compare implant removal rates between surgical fixation techniques.
45407014|NCT05867342|Drug|Epinephrin|Topical application of 2 pieces of Epinephrin (1:1,000)-soaked cottonoid in nasal cavity
45407015|NCT05867342|Drug|1% lidocaine with epinephrin 1:100,000|4 ml intranasal infiltration of 1% lidocaine with epinephrine (1:100,000) at 2 sites (2 ml infiltration at each site)
45407016|NCT05867342|Drug|Saline|4 ml intranasal infiltration of saline at 2 sites (2 ml infiltration at each site)
45407017|NCT05866692|Drug|TY-2699a|"TY-2699a PO, BID~Escalation stage: increased dose cohorts from low dose to MTD~Expansion stage: The dose for the Expansion stage will be determined based on results"
45407018|NCT05866432|Drug|Datopotamab deruxtecan|Will be given until PD or withdraw
45515684|NCT02091492|Drug|Teriparatide|Teriparatide 20 µg sc (subcutaneous injection) each day for 12 weeks
45407019|NCT05865275|Device|Low-level laser treatment|a single preliminary treatment for a few seconds for each tooth using low level diode laser before of tooth bleaching could reduce risk to arise of tooth sensitivity
45515685|NCT02091492|Drug|Placebo|Placebo teriparatide sc (subcutaneous injection) each day for 12 weeks
45515686|NCT02266940|Drug|DS-1971a suspension|DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.
45515687|NCT02266940|Drug|DS-1971a tablet|A 200 mg DS 1971a tablet for oral administration
45515688|NCT04011358|Other|Sleeping Monitor|to evaluate obstructive sleep apnea
45515689|NCT03981952|Biological|Trivalent Invasive Salmonella Disease Vaccine (6.25 µg)|6.25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
45515690|NCT03981952|Biological|Trivalent Invasive Salmonella Disease Vaccine (12 µg)|12 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
45515691|NCT03981952|Biological|Trivalent Invasive Salmonella Disease Vaccine (25 µg)|25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
45515692|NCT03981952|Biological|Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C)|The highest, well-tolerated dose of the conjugate vaccine among Cohorts A-C is administered via one or two intramuscular injection(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
45515693|NCT03981952|Other|Placebo|0.5 mL of buffer and preservative is administered via one or two intramuscular injections(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
45515694|NCT02269982|Device|AR-v7 assays|
45515695|NCT02091570|Other|Nutrition Bar|Intervention involves consumption of one nutrition bar of approximately 50 g in the beginning of each visit of the crossover sequence
45699506|NCT04452630|Other|Infectious Disease and Cardiology Clinical Consultations|Infectious Diseases and Cardiology Clinical Consultations at 1 month and 12 months of recovery from an episode of Covid-19
45515696|NCT03838120|Other|Procedure/Surgery: bupivakain % 0,5|In this study, 5 patients were included in each volume group and at least 3 applications out of 5 had to be successful to consider the volume to be sufficient. After a successful group, the volume was reduced by 2 ml's and the same procedure was followed until a final group with unsuccessful anesthesia was found (≤2 successful blockades). The study was ended at this point and MEV was determined as the volume used in the last successful group. The researcher which determined the success of blockade was blinded to the study protocol. BMI, ASA Score, Successful blockade onset time Regression time of sensorial blockade Regression time of motor blockade Time of first additional analgesic requirement
45407020|NCT05865275|Other|tooth bleaching procedure|The gingival tissues of the teeth to be bleached were isolated from the bleaching gel using a light-cured resin dam (OpalDam Kit, Ultradent; Milan, Italy). A 38 % ready-to-use Hydrogen peroxide-containing gel (The Smile® Strong, Italy) was applied from the first premolar right to the first premolar left of both jaws for a total period of 20 minutes for a 1 single whitening session.
45407021|NCT05865080|Drug|Ketamine|0.3 mg/kg of ketamine IV diluted to 10 ml followed by infusion 0.1 mg/kg/hr. as 20 ml solution before spinal anesthesia
45407022|NCT05865080|Drug|Placebo|Normal saline
45407023|NCT05864105|Biological|PM8002|PM8002 20mg/kg Q2W
45407024|NCT05864105|Drug|FOLFOX regimen|day 1: oxaliplatin [85 mg/m2, 2-h infusion] plus leucovorin [200 mg/m2, 2-h infusion], followed by 5-fluorouracil [400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion]; day 2: leucovorin [200 mg/m2, 2-h infusion], followed by 5-fluorouracil [400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion]
45407025|NCT05864040|Device|Bitrack System-assisted laparoscopic radical/simple nephrectomy|Robot-Assisted Laparoscopic Transperitoneal Radical/Simple Nephrectomy is performed under general anesthesia. Using blunt dissection, the inferior pole of the kidney is lifted, and ureter and gonadal veins released from fat and connective tissue. The ureter is dissected caudally and sectioned after being sealed with a distal endoscopic clip. Dissection proceeds along the psoas muscle with anterior elevation of the ureter and lower renal pole towards the hilium. Main hilar are circumferentially dissected and sectioned and the kidney is entirely mobilized and released. Gerota´s capsule and suprarenal gland may be preserved if oncologically safe. Once the specimen is completely released, a laparoscopic bag is introduced by the assistant and the specimen entrapped. The robot is undocked, gas evacuated from the abdomen and specimen retrieved. Abdominal wall incisions over 10mm are closed using a continuous suture. Skin incisions are closed using skin staplers.
45515697|NCT04475198|Drug|ST-2427|Investigational drug
45515698|NCT04475198|Drug|Placebo|5% Dextrose Injection
45699507|NCT04452318|Drug|REGN10933 + REGN10987|Subcutaneous (SC) or Intramuscular (IM) injections
45699508|NCT04452318|Drug|Placebo|SC or IM injections
45699509|NCT01161160|Biological|GSK Biologicals' GSK2340274A (two different formulations)|Intramuscular injection
45407026|NCT05863286|Drug|Botulinum toxin type A|"Botulinum toxin is produced by the gram-positive, anaerobic, spore-forming bacterium Clostridium botulinum, and is one of the most lethal biological toxins known to man.~Botulinum toxin has seven antigenically different serotypes and exerts a paralytic action by rapidly and strongly binding to presynaptic cholinergic nerve terminals. It is then internalized and ultimately inhibits the exocytosis of acetylcholine by decreasing the frequency of acetylcholine release. Without its nerve supply, the muscle fiber will deteriorate; however, the muscle will regain its strength as the nerves regenerate."
45407027|NCT05857228|Procedure|Endoscopic sinus surgery (ESS)|Endoscopic sinus surgery for removal of nasal polyps and sinus tissue.
45407028|NCT05855408|Biological|Intramuscularly administered Ad5-nCoV vaccine|This vaccine is produced by CanSino Biologics Inc.
45407029|NCT05855408|Biological|Aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc.
45407030|NCT05855408|Biological|DelNS1-2019-nCoV-RBD-OPT1|This vaccine is produced by Wantai Biopharmaceutical Company.
45407031|NCT05855408|Biological|SYS6006|This vaccine is produced by CSPC Pharmaceutical Group Co., Ltd.
45699510|NCT01161160|Biological|GSK Biologicals' - GSK2340272A|Intramuscular injection
45699511|NCT04621578|Device|HANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China)|"Stimulation sites: Mastoid area on the contralateral side of the operation, Fengchi acupoint on the contralateral side of the operation, and Neiguan acupoints on both sides.~Timing of stimulation: In postanesthesia care unit (PACU) after extubation, 6 hours, 24 hours, 48 hours, and 72 hours after returning to the ward. 30-minutes treatment for each time-point."
45407032|NCT05851768|Drug|Bupivacaine|Bupivacaine 0.25%
45699512|NCT04573764|Dietary Supplement|D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester|"The intervention is D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester and will be bought commercially. As an example: One bottle of KetoneAid KE4 PRO with 60 ml contains 30 g D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester. For more information please refer to: https://shop.ketoneaid.com/collections/all/products/ke4-pro. Placebo will be a taste-matched water solution provided by the company. The placebo solution and the active solution will be prepared in identic bottles and investigators will be blinded."
45699513|NCT04573764|Dietary Supplement|Placebo|Taste-matched water
45407033|NCT05851768|Drug|Bupivacaine + Magnesium|Bupivacaine 0.25% + Magnesium
45407034|NCT05851768|Drug|Bupivacaine + Dexmedetomidine|Bupivacaine 0.25% + Dexmedetomidine
45407035|NCT05846633|Device|C mell treadmill|C Mell treadmill provides Virtual Reality environment for rehabilitation with obstacles and motivational assistance
45407036|NCT05842733|Drug|Naldebain|Oral Placebo A 650 mg + Naldebain 37.5 mg (0.5 mL oil solution) + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
45407037|NCT05842733|Drug|SafeTynadol|Oral SafeTynadol 650 mg + Placebo B (0.5 mL oil solution) +Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
45515699|NCT02091648|Behavioral|I Can Cope Intervention|"Participants randomized to the I Can Cope condition will receive 6 face-to-face individualized sessions over a 2-month period. Each session will last 50 minutes and take place at the child's school either during approved times during the school day or as part of the after-school program. Sessions are psychoeducational and experiential and include opportunities for the child with asthma to: (1) learn about the pathophysiology of asthma; (2) understand the biological impact of stress on the body; (3) learn the relationship among thoughts, feelings, actions, and asthma; (4) acquire a set of coping skills to help deal with asthma-related and day-to-day stressors in their lives, and (5) receive training in biofeedback-assisted relaxation techniques."
45407038|NCT05842733|Drug|Naldebain + SafeTynadol|Oral Naldebain 37.5 mg (0.5 mL oil solution) + SafeTynadol 650 mg + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
45699514|NCT04571190|Behavioral|Prenatal MBSR|Prenatal MBSR is an adaptation to the original MBSR program. The essential program elements characterizing MBSR is maintained and integrated with the particular context and specific needs of this group of pregnant women. Adaptations to the MBSR program draw upon both empirical data as well as existing research and theory.
45407039|NCT05840237|Other|"Anhydrous Enol-Oxaloacetate, a Medical Food"|"Treatment with the medical food Oxaloacetate CFS, 2 - 500 mg capsules BID with food"
45407040|NCT05840237|Other|White Rice Flour|"Treatment with the food White Rice Flour, 2- 500 mg capsules BID with food"
45699515|NCT03010618|Other|Hall technique stainless steel crowns|Primary carious tooth will be treated with stainless steel crowns without local anesthesia or caries removal and the increase in the occlusal vertical dimension will be monitored in two subsequent appointments with measuring canine overbite.
45407041|NCT05834725|Behavioral|Promoting Resilience in Stress Management|Resilience coaching program.
45407042|NCT05834725|Other|Usual Care|Combination of physical therapy, occupational therapy, and psychological counseling as recommended by the treating provider.
45407043|NCT05831748|Other|Classic Exercise|Classic exercise group consists of straight leg raising, back extensor strengthening, and abdominal strengthening exercises.
45407044|NCT05831748|Other|Clinical Pilates|In the Clinical pilates group, pilates exercises will be given. Clinical pilates exercises improve back extensors, trunk flexors, and pelvis stabilization. These exercises will be applied along with breathing exercises.
45407045|NCT05828368|Procedure|Non surgical periodontal therapy|"Scaling and root planing is a deep cleaning below the gumline used to treat gum disease.~Gum disease is caused by a sticky film of bacteria called plaque. Plaque is always forming on your teeth, but if they aren't cleaned well, the bacteria in plaque can cause your gums to become inflamed."
45407046|NCT05825885|Drug|E2|micronized E2 at a daily dose of 4-6mg,
45407047|NCT05814549|Diagnostic Test|NavDx|"Evaluation of HPV presence via NavDx (v1) at two (or three) timepoints~o If one of the two blood samples is positive, the subject will have a third NavDx (v1) test approximately 1 month after the second timepoint. If the test is positive, the subject will move to surveillance phase."
45407048|NCT05807724|Other|Phone-based fall-prevention strategy|Written education material and Phone-Based Fall-Prevention Strategy
45407049|NCT05807724|Other|Home-visit fall prevention strategy|Written education material and Home visit-Based Fall-Prevention Strategy
45407050|NCT05768373|Device|3M™ Clinpro™ Fluoride Aqueous Solution|Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
45699516|NCT03438162|Behavioral|Education|Patients randomized in the intervention group received pre-discharge pharmacotherapeutic education. The education was conducted by a qualified physician.
45407051|NCT05768373|Device|3M™ Vanish™|Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
45407052|NCT05761886|Other|telehealth-based clinical pharmacy intervention|The pharmacist will perform an initial comprehensive review of the medication regimen, make any adjustments, document those in the patient's electronic health record (EHR) and communicate with the patient's T2D care team as needed. They will also call (using an EHR-based software) the patient using phone/video to educate them about T2D self-management and identify any medication-related unmet needs. Periodic reviews of the medication regimen and roughly biweekly follow-up patient calls will occur with frequency based on need (as judged by the pharmacist). Patient intervention calls will be personalized depending on HbA1c levels, comorbidities, and medication complexity
45407053|NCT05756088|Diagnostic Test|Blood draw to measure the levels of dd-cf DNA|Blood draw to measure the levels of dd-cf DNA.
45407054|NCT05753683|Behavioral|mHealth-Women's CoOp|The mHealth-Women's CoOp, was developed and tested in a previous randomized trial, is a gender-specific human immunodeficiency virus (HIV) risk-reduction intervention that addresses the intersection of substance use, sexual risk and gender-based violence through education, skills-building, and role-play and rehearsal via a mobile app. The mHealth-Women's CoOp app is also used to help participants monitor progress toward their goals throughout the study period. Specifically, the app is programmed to prompt the user, to visit the app and participate in several activities, including health and behavior check-in and revisiting aspects of the mHealth-Women's CoOp educational content to sustain risk reduction.
45407055|NCT05753683|Behavioral|Virtual Group|The enhanced online group component will be available to be accessed using the mHealth-Women's CoOp platform for participants in the enhanced arm. The purpose of this component is to allow for young women who use alcohol to interact with young women like them and also discuss issues related to substance use and sexual risk-taking via a guided conversation to allow for motivational and informational support. The virtual group component will include online live discussions moderated and monitored by a trained online facilitator.
45407056|NCT05748730|Behavioral|iCHART|"The Safety Planning App will guide primary care providers or mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.~The Mental Health Screener is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.~The Text Messages is a personalized text messaging intervention for patients and parents that targets engagement with the safety plan to increase the likelihood that a depressed or suicidal patient will maintain or initiate recommended services.~Participants will receive usual care at their pediatric primary care practice following screening including information, psychoeducation, and referral to a mental health treatment provider."
45515700|NCT02091648|Behavioral|Standard Education Intervention|"This group will receive the standard American Lung Association (ALA)Open Airways for Schools program. This program includes six 40-minute sessions covering the National Heart Lung and Blood Institute's recommendations for asthma education."
45699517|NCT03010852|Behavioral|Focused incentive spirometer education and monitoring|
45699518|NCT03438084|Dietary Supplement|Interesterified fat|50 g fat provided as commercially available interesterified fat.
45699519|NCT03438084|Dietary Supplement|Non- interesterified fat|50 g fat provided as commercially available non-interesterified fat.
45699520|NCT03438084|Dietary Supplement|Rapeseed oil|50 g fat provided as commercially available rapeseed oil.
45407057|NCT05748730|Behavioral|Treatment As Usual|Participants in this group will receive usual care from their primary care provider or mental health care provider which may include development of a paper safety plan.
45407058|NCT05743959|Procedure|No intervention|No intervention
45407059|NCT05737693|Drug|Ketamine|Week-long exposure therapy with ketamine infusion on day 2 and 4 of the psychotherapy
45407060|NCT05737693|Drug|Midazolam|Week-long exposure therapy with midazolam infusion on day 2 and 4 of the psychotherapy
45407061|NCT05737108|Dietary Supplement|Bilberry capsule product|A specific bilberry capsule product, containing bilberry dried extracts at 23.2 mg and bilberry powder at 3.2 mg will be given to participants for oral intake for 30 days. 30 days of Bilberry capsule product or placebo with crossover to the other.
45407062|NCT05737108|Dietary Supplement|Placebo(starch)|30 days of placebo or Bilberry capsule product with crossover to the other.
45515701|NCT05091190|Other|Blood draws|"Blood draws will be realized at the following time points:~C1T1: at the baseline, before treatment administration. C1T2: cycle 1, after treatment administration. C2T1: the day of the 2nd cycle, before treatment administration. C2T2: the day of 2nd cycle, after treatment administration. C3T1: the day of the 3rd cycle, before treatment administration. C3T2: the day of 3rd cycle, after treatment administration."
45515702|NCT04475120|Drug|liposomal lactoferrin|oral and intra-nasal formulation
45515703|NCT04475120|Drug|SOC therapy|oral administration
45515704|NCT02252250|Procedure|conventional laparoscopic total mesentery excision|conventional laparoscopic total mesentery excision
45699521|NCT03438084|Dietary Supplement|Butter|50g fat provided as commercially available spreadable butter
45699522|NCT04807764|Combination Product|Standing transspinal stimulation followed by robotic gait training|Fifteen people with spinal cord injury will receive 40 daily sessions of 30 minutes of non-invasive high frequency (e.g. 30 Hz) transcutaneous transspinal stimulation during standing followed by 30 minutes of assisted stepping robotic gait training. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
45851656|NCT03801486|Other|Experimental: Sprouted Chickpea Flour|255g of pasta with 40% sprouted chickpea flour and 60% semolina flour (SCF40) with butter.
45851657|NCT03801486|Other|Control: Semolina Flour|255g of pasta with 100% semolina flour (SEM100) with butter.
45851658|NCT03801720|Other|Ultrasound|Using ultrasound stimulation to induce micturition.
45515705|NCT02252250|Procedure|transanal hybrid-laparoscopic total mesentery excision|transanal laparoscopic total mesentery excision for rectal cancer. Mobilize the rectum from down- to-up. Then, set a single incision laparoscopic surgery (SILS) port at the right-low abdomen to resect the lymph nodes of IMA.
45699523|NCT04807764|Combination Product|Lying transspinal stimulation followed by robotic gait training|Fifteen people with spinal cord injury will receive 40 daily sessions of 30 minutes of non-invasive high frequency (e.g. 30 Hz) transcutaneous transspinal stimulation while lying supine on a therapy table followed by 30 minutes of assisted stepping robotic gait training. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
45851659|NCT03801252|Drug|Cefazolin|intravenous drugs used as prophylactic antibiotics
45851660|NCT03801252|Drug|Placebo|Intravenous saline
45851661|NCT03801252|Drug|Azithromycin|prophylactic antibiotic
45699524|NCT04807764|Other|Standing sham transspinal stimulation followed by robotic gait training|Fifteen people with spinal cord injury will receive 40 daily sessions of 30 minutes of sham transspinal stimulation during standing at an intensity where sensation is absent followed by 30 minutes of robotic gait training. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
45699525|NCT01161862|Device|Bi-hormonal (insulin and glucagon) artificial pancreas|Subjects wore a bionic pancreas consisting of a continuous glucose monitor, an insulin pump and a glucagon pump
45851662|NCT03801018|Other|Questionnary and Interviews|"An internet platform dedicated to the anonymous survey will be set up by the communication department and the digital System Department of the promoter Public assistance hospitals in Marseille, the data Processing manager. It would deplore anonymous questionnaires accessible from a dedicated web page. People will therefore respond to a national survey on the basis of volunteering and anonymity.~Interviews, lasting one to two hours, will be fully transcribed and processed anonymously.~The interviews will seek to collect data on the modalities, conditions and effects of the circulation (or retention) of information on the use of donation, throughout the lives of individuals and families, in a cross-analysis of Viewpoints of parents and people born of donation."
45699526|NCT01214356|Dietary Supplement|Vitamin D3|Patients receive vitamin D 400 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
45699527|NCT01214356|Dietary Supplement|Vitamin D3|Patients receive vitamin D 4000 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
45699528|NCT04542018|Other|a low FODMAP diet for 4 weeks|low FODMAP diet for 4 weeks
45851663|NCT03801096|Behavioral|Narrative Based Therapuetic Assessment (NbTa)|The NbTa interventiom will guide participants through an exploration of their human experience through stories and narratives. The interventionist will facilitate a collaborative process by which participants will explore the unique themes and meanings of their personal narrative (Parry & Doan, 1994) with respect to alcohol and drug use. In addition, participants will also be guided towards considering the re-authorship of personal narratives. The techniques utilized in NbTa aim to dislodge problem saturated narratives and derive more complete personal narratives and meanings (White & Epston, 1990).
45851664|NCT03801096|Behavioral|Health Education Control Condition (HE)|The Health Education session is a didactic 45-minute session that focusses on three health-related topics: 1) Sleep, 2) Physical Activity, and 3) Nutrition. The goal of the session is to present health-related information to participants through videos and dydadic presentation.
45851665|NCT03800706|Drug|TQB2450|TQB2450 is injectived (IV) every-3-weeks (Q3W) and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent, the longest use time of experimental drugs is 96 weeks.
45851666|NCT03800628|Other|qualitative study|semi-structured interviews
45851667|NCT03800550|Drug|Bedaquiline|Bedaquiline tablet will be administered, orally.
45851668|NCT03800550|Drug|Clarithromycin|Clarithromycin tablet will be administered, orally.
45407063|NCT05734690|Drug|SGLT2i, beta blocker, ARNI, MRA, MTD|"Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention."
45407064|NCT05734690|Behavioral|Education-First|For the first 3-months of their participation, patients in this arm will receive curated patient education, an alert to providers, provider education, and then after 3 months, be invited to participate in the remote heart failure clinic. The patient education would consist of curated video content and informational worksheets provided by email or secure patient messaging. Provider alerts would happen through notifying of a patient's eligibility for heart failure therapy. Provider education will also consist of the program's medical algorithm and a summary sheet on indications, outcomes, prescribing, and monitoring information
45407065|NCT05733624|Drug|SCAI-001 0.01% eyedrop|BID for 12weeks
45515706|NCT03821038|Biological|CYT107|IV twice a week at 10µg/kg for 3 weeks
45515707|NCT03821038|Drug|Placebos|IV twice a week at the same volume for 3 weeks
45515708|NCT02208024|Radiation|Stereotactic Body Radiation Therapy|
45699529|NCT01214824|Device|FreeStyle Navigator Continuous Glucose Monitoring System|Six x 5 day wears of the continuous glucose monitoring device. Two of the 6 wears will be using a masked device (1 at the start and 1 at the end of the study).
45851669|NCT03800472|Drug|GLPG3312 IR|GLPG3312 IR tablets, up to 4 single ascending oral doses (A, B, C, D).
45851670|NCT03800472|Drug|Placebo|Placebo tablets
45851671|NCT03800472|Drug|GLPG3312 MR|GLPG3312 MR film-coated tablets, up to 4 single ascending oral doses (H, I, J, K).
45851672|NCT03800472|Drug|GLPG3312 FE MR|GLPG3312 MR film-coated tablets, single oral dose (N) on 2 occasions, i.e. in fed state after a high-fat high-calorie breakfast, and in fasted state.
45851673|NCT03800472|Drug|GLPG3312 MR|GLPG3312 MR film-coated tablets, up to 2 multiple ascending oral doses (O, P).
45515709|NCT03664804|Other|No Study Drug was Administered in this Study|No study drug was administered in this study
45515710|NCT01155362|Biological|Human Placenta-Derived Cells PDA001 Intravenous Infusion|
45515711|NCT01155362|Drug|Vehice Control|
45515712|NCT03279718|Procedure|Periodontal Treatment|Scaling and root planing
45407066|NCT05733624|Drug|SCAI-001 0.02% eyedrop|BID for 12weeks
45407067|NCT05733624|Drug|Restasis 0.05% eyedrop|BID for 12weeks
45515713|NCT02088528|Device|Aurolab glaucoma drainage device|Patients undergoing surgery will receive an implant
45407068|NCT05732142|Other|Postpartum Integration of Vaccines and Contraception Through Gender-Transformative Programming(PIVoT)|The PIVoT intervention is a 30-minute focused information exchange that supports shared contraceptive decision making. The program includes a gender-equity and family planning curriculum covering basic family planning information as well as gender norms and son preference and interactive family planning method index cards (detailing method characteristics, use, duration of action, efficacy, side effects, and contraindications for each method). The program is designed to support person-centered contraceptive choice and encourages women to consider joint family planning decision-making with male partners. If a contraceptive method is desired, it will be provided by nurses who are trained to provide comprehensive family planning care.
45515714|NCT02088528|Procedure|Trabeculectomy with mitomycin-c|Trabeculectomy surgery augmented by application of mitomycin C (0.4 mg/ml) to the sclera in the region of the trabeculectomy site for a period of exactly 3 minutes.
45515715|NCT02272010|Other|Experimental Diet|Altered n-6 (linoleic acid) and n-3 (eicosapentaenic acid (EPA) + docosahexaenoic acid (DHA)) diet.
45515716|NCT02272010|Other|Comparator Diet|Diet standardized to the usual American distribution of n-6 (7%) and n-3 EPA+DHA (150 mg per day).
45515717|NCT02091804|Behavioral|Immediate Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
45407069|NCT05721781|Behavioral|Oral Hygiene instruction|Participants will be instructed on the Modified Bass technique for toothbrushing: brushing with a soft bristled toothbrush held at a 45 degree angle to the gums and brushed in a circular motion. Participants will also be instructed to floss at least once per day using floss or another inter-dental device (e.g., floss pick).
45407070|NCT05721781|Procedure|Dental Cleaning|Participants will receive a dental cleaning according to the current standard of care for routine dental cleanings.
45407071|NCT05717049|Drug|Theophylline Tablets|12 week oral treatment
45407072|NCT05708014|Behavioral|Intervention LuvHub|From day 1 to day 487 (i.e., entire 16-month duration, post baseline) of the trial, participants randomized to the intervention arm will have access to use the five modules as directed. The LuvHub intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
45407073|NCT05708014|Behavioral|Waitlist Control LuvHub|From day 243 to day 487 (i.e., starting after 8-month assessment) of the trial, participants randomized to the waitlist control condition will have access to use the five modules as directed. The LuvHub intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
45407074|NCT05702268|Drug|ICP-332|Tablet, 40 mg
45515718|NCT02091804|Behavioral|Wait-List group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
45515719|NCT03634150|Biological|Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.|Once weekly treatment, with IV doses of Nerofe (96mg\m2) and low dose (20 mg/m2) Doxorubicin 5 or 24 hours from one another) .
45515720|NCT02085330|Device|Hyperbaric oxygen therapy|100%, 2 ATA, 90 minutes
45515721|NCT01148498|Drug|solanezumab|400mg administered once intravenously
45515722|NCT05090956|Other|mri|
45515723|NCT02092038|Drug|Temozolomide|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
45515724|NCT02092038|Radiation|partial brain irradiation|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
45515725|NCT02092038|Procedure|stereotactic biopsy of brain tumor|will be assessed for tumor type and tumor markers
45515726|NCT02092038|Procedure|craniotomy and tumor resection|maximal safe resection
45515727|NCT02272166|Drug|propofol|
45515728|NCT02272166|Drug|Sevoflurane|
45407075|NCT05702268|Drug|ICP-332 Placebo|Tablets, in appearance, size, color, dosage form, packaging, instructions, labels and other aspects of the corresponding specifications of ICP-332.
45407076|NCT05695131|Device|GlenXRose Virtual Reality Speech Therapies|Speech therapies for vocal cord disorders have been developed for virtual reality implementation. These include various games to interact with in a virtual environment while conducting rehabilitation therapy, in addition to educational visualizations
45407077|NCT05684575|Other|Phone satisfaction questionnaire|Evaluation of the outcome of Covid-19 patients discharged home on oxygen therapy
45407078|NCT05674370|Device|GRIP Electronic Diagnostic Chip|Graphene-based point-of-care device for detection of respiratory viruses (e.g., COVID-19 and influenza) from a nasal swab
45407079|NCT05674370|Diagnostic Test|Labor